cancer_type qtl_type tag_SNP LD SNP_id gene_id gene_symbol t-stat p-value FDR beta r Traits SNP_position Gene_position LIHC cis rs9326248 0.954 rs8521 ENSG00000254851.1 RP11-109L13.1 -23.59 9.95e-74 9.11e-68 -1 -0.79 Blood protein levels; chr11:117196983 chr11:117135528~117138582:+ LIHC cis rs9326248 0.911 rs11216284 ENSG00000254851.1 RP11-109L13.1 -23.56 1.28e-73 1.02e-67 -0.98 -0.79 Blood protein levels; chr11:117132344 chr11:117135528~117138582:+ LIHC cis rs9326248 0.954 rs4938349 ENSG00000254851.1 RP11-109L13.1 -23.46 3.13e-73 2.21e-67 -0.98 -0.79 Blood protein levels; chr11:117151207 chr11:117135528~117138582:+ LIHC cis rs9326248 0.954 rs521171 ENSG00000254851.1 RP11-109L13.1 -23.35 9.1e-73 6.08e-67 -0.99 -0.78 Blood protein levels; chr11:117193977 chr11:117135528~117138582:+ LIHC cis rs9326248 0.911 rs474339 ENSG00000254851.1 RP11-109L13.1 -23.33 1.05e-72 6.64e-67 -0.99 -0.78 Blood protein levels; chr11:117188836 chr11:117135528~117138582:+ LIHC cis rs9326248 0.953 rs488962 ENSG00000254851.1 RP11-109L13.1 23.29 1.51e-72 9.09e-67 0.99 0.78 Blood protein levels; chr11:117201809 chr11:117135528~117138582:+ LIHC cis rs9326248 0.953 rs634960 ENSG00000254851.1 RP11-109L13.1 23.29 1.51e-72 9.09e-67 0.99 0.78 Blood protein levels; chr11:117202247 chr11:117135528~117138582:+ LIHC cis rs9326248 0.954 rs10790177 ENSG00000254851.1 RP11-109L13.1 -23.26 1.91e-72 1.1e-66 -0.98 -0.78 Blood protein levels; chr11:117177701 chr11:117135528~117138582:+ LIHC cis rs9326248 1 rs664082 ENSG00000254851.1 RP11-109L13.1 -23.23 2.7e-72 1.48e-66 -0.99 -0.78 Blood protein levels; chr11:117200354 chr11:117135528~117138582:+ LIHC cis rs9326248 1 rs664922 ENSG00000254851.1 RP11-109L13.1 -23.22 2.84e-72 1.5e-66 -0.99 -0.78 Blood protein levels; chr11:117200179 chr11:117135528~117138582:+ LIHC cis rs9326248 0.906 rs171052 ENSG00000254851.1 RP11-109L13.1 23.1 8.2e-72 4.14e-66 0.99 0.78 Blood protein levels; chr11:117211047 chr11:117135528~117138582:+ LIHC cis rs9326248 1 rs585849 ENSG00000254851.1 RP11-109L13.1 -23.09 9.27e-72 4.58e-66 -0.99 -0.78 Blood protein levels; chr11:117198345 chr11:117135528~117138582:+ LIHC cis rs1577917 0.655 rs1059307 ENSG00000203875.9 SNHG5 22.97 2.68e-71 1.25e-65 0.85 0.78 Response to antipsychotic treatment; chr6:85678170 chr6:85660950~85678736:- LIHC cis rs9326248 1 rs664971 ENSG00000254851.1 RP11-109L13.1 22.74 2.21e-70 9.12e-65 0.99 0.78 Blood protein levels; chr11:117200141 chr11:117135528~117138582:+ LIHC cis rs9326248 1 rs3736120 ENSG00000254851.1 RP11-109L13.1 -22.36 7.21e-69 2.74e-63 -0.99 -0.77 Blood protein levels; chr11:117161409 chr11:117135528~117138582:+ LIHC cis rs9326248 1 rs10790175 ENSG00000254851.1 RP11-109L13.1 -22.34 8.44e-69 3.16e-63 -0.97 -0.77 Blood protein levels; chr11:117164013 chr11:117135528~117138582:+ LIHC cis rs9326248 1 rs7946257 ENSG00000254851.1 RP11-109L13.1 -22.33 8.87e-69 3.27e-63 -0.97 -0.77 Blood protein levels; chr11:117182449 chr11:117135528~117138582:+ LIHC cis rs1577917 0.559 rs1173418 ENSG00000203875.9 SNHG5 22.27 1.53e-68 5.41e-63 0.82 0.77 Response to antipsychotic treatment; chr6:85693198 chr6:85660950~85678736:- LIHC cis rs9326248 1 rs4938354 ENSG00000254851.1 RP11-109L13.1 -22.23 2.28e-68 7.72e-63 -0.98 -0.77 Blood protein levels; chr11:117180449 chr11:117135528~117138582:+ LIHC cis rs1577917 0.561 rs3087978 ENSG00000203875.9 SNHG5 22.03 1.36e-67 4.22e-62 0.82 0.77 Response to antipsychotic treatment; chr6:85678505 chr6:85660950~85678736:- LIHC cis rs9326248 0.817 rs1242127 ENSG00000254851.1 RP11-109L13.1 21.92 3.9e-67 1.15e-61 0.95 0.76 Blood protein levels; chr11:117205848 chr11:117135528~117138582:+ LIHC cis rs9326248 1 rs9326248 ENSG00000254851.1 RP11-109L13.1 -21.77 1.51e-66 3.85e-61 -0.96 -0.76 Blood protein levels; chr11:117128509 chr11:117135528~117138582:+ LIHC cis rs9326248 0.798 rs10892079 ENSG00000254851.1 RP11-109L13.1 -21.73 2.26e-66 5.59e-61 -0.96 -0.76 Blood protein levels; chr11:117146108 chr11:117135528~117138582:+ LIHC cis rs9326248 1 rs4938344 ENSG00000254851.1 RP11-109L13.1 -21.66 4.17e-66 1.02e-60 -0.96 -0.76 Blood protein levels; chr11:117133033 chr11:117135528~117138582:+ LIHC cis rs9326248 1 rs7107152 ENSG00000254851.1 RP11-109L13.1 20.29 1.2e-60 1.73e-55 0.93 0.74 Blood protein levels; chr11:117185364 chr11:117135528~117138582:+ LIHC cis rs2739330 0.892 rs5751776 ENSG00000273295.1 AP000350.5 20.19 3.09e-60 4.2e-55 0.77 0.74 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23901432~23907068:- LIHC cis rs1577917 0.655 rs9450311 ENSG00000203875.9 SNHG5 19.78 1.34e-58 1.45e-53 0.79 0.73 Response to antipsychotic treatment; chr6:85666868 chr6:85660950~85678736:- LIHC cis rs1577917 0.727 rs9344539 ENSG00000203875.9 SNHG5 -19.75 1.76e-58 1.81e-53 -0.78 -0.73 Response to antipsychotic treatment; chr6:85643903 chr6:85660950~85678736:- LIHC cis rs1577917 0.771 rs9362232 ENSG00000203875.9 SNHG5 -19.75 1.76e-58 1.81e-53 -0.78 -0.73 Response to antipsychotic treatment; chr6:85643904 chr6:85660950~85678736:- LIHC cis rs1577917 0.655 rs2842605 ENSG00000203875.9 SNHG5 -19.68 3.47e-58 3.45e-53 -0.79 -0.73 Response to antipsychotic treatment; chr6:85625432 chr6:85660950~85678736:- LIHC cis rs1577917 0.655 rs2758848 ENSG00000203875.9 SNHG5 -19.68 3.5e-58 3.45e-53 -0.79 -0.73 Response to antipsychotic treatment; chr6:85637887 chr6:85660950~85678736:- LIHC cis rs1577917 0.655 rs2758849 ENSG00000203875.9 SNHG5 -19.67 3.81e-58 3.74e-53 -0.79 -0.73 Response to antipsychotic treatment; chr6:85634578 chr6:85660950~85678736:- LIHC cis rs1577917 0.655 rs9444354 ENSG00000203875.9 SNHG5 19.61 6.22e-58 5.94e-53 0.79 0.73 Response to antipsychotic treatment; chr6:85582217 chr6:85660950~85678736:- LIHC cis rs1577917 0.56 rs12193777 ENSG00000203875.9 SNHG5 19.55 1.11e-57 9.52e-53 0.78 0.73 Response to antipsychotic treatment; chr6:85536991 chr6:85660950~85678736:- LIHC cis rs1577917 0.655 rs9444351 ENSG00000203875.9 SNHG5 19.55 1.11e-57 9.52e-53 0.78 0.73 Response to antipsychotic treatment; chr6:85538081 chr6:85660950~85678736:- LIHC cis rs1577917 0.655 rs7766485 ENSG00000203875.9 SNHG5 19.55 1.11e-57 9.52e-53 0.78 0.73 Response to antipsychotic treatment; chr6:85553837 chr6:85660950~85678736:- LIHC cis rs2739330 0.929 rs5751775 ENSG00000273295.1 AP000350.5 19.38 5.27e-57 4.43e-52 0.76 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23901432~23907068:- LIHC cis rs1577917 0.566 rs2842611 ENSG00000203875.9 SNHG5 -19.21 2.76e-56 2.28e-51 -0.78 -0.72 Response to antipsychotic treatment; chr6:85592316 chr6:85660950~85678736:- LIHC cis rs1577917 0.681 rs4707211 ENSG00000203875.9 SNHG5 19.18 3.48e-56 2.86e-51 0.78 0.72 Response to antipsychotic treatment; chr6:85522992 chr6:85660950~85678736:- LIHC cis rs1577917 0.681 rs4348284 ENSG00000203875.9 SNHG5 -19.12 6.04e-56 4.94e-51 -0.78 -0.72 Response to antipsychotic treatment; chr6:85640676 chr6:85660950~85678736:- LIHC cis rs1577917 0.655 rs12203963 ENSG00000203875.9 SNHG5 19.1 7.51e-56 6.11e-51 0.78 0.72 Response to antipsychotic treatment; chr6:85513598 chr6:85660950~85678736:- LIHC cis rs2739330 0.892 rs5751776 ENSG00000218537.1 MIF-AS1 19.06 1.02e-55 8.21e-51 0.93 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23894426~23898930:- LIHC cis rs1577917 0.629 rs6927475 ENSG00000203875.9 SNHG5 19 1.77e-55 1.41e-50 0.78 0.72 Response to antipsychotic treatment; chr6:85497055 chr6:85660950~85678736:- LIHC cis rs1577917 0.629 rs9450285 ENSG00000203875.9 SNHG5 19 1.87e-55 1.48e-50 0.78 0.72 Response to antipsychotic treatment; chr6:85498378 chr6:85660950~85678736:- LIHC cis rs1577917 0.61 rs11752795 ENSG00000203875.9 SNHG5 18.9 4.76e-55 3.75e-50 0.78 0.71 Response to antipsychotic treatment; chr6:85577411 chr6:85660950~85678736:- LIHC cis rs1577917 0.655 rs2842600 ENSG00000203875.9 SNHG5 -18.8 1.14e-54 8.85e-50 -0.77 -0.71 Response to antipsychotic treatment; chr6:85615914 chr6:85660950~85678736:- LIHC cis rs1577917 0.655 rs9342045 ENSG00000203875.9 SNHG5 18.73 2.36e-54 1.83e-49 0.77 0.71 Response to antipsychotic treatment; chr6:85715430 chr6:85660950~85678736:- LIHC cis rs1577917 0.883 rs2166664 ENSG00000203875.9 SNHG5 -18.71 2.61e-54 2e-49 -0.77 -0.71 Response to antipsychotic treatment; chr6:85886904 chr6:85660950~85678736:- LIHC cis rs1577917 0.883 rs9450348 ENSG00000203875.9 SNHG5 -18.71 2.61e-54 2e-49 -0.77 -0.71 Response to antipsychotic treatment; chr6:85888318 chr6:85660950~85678736:- LIHC cis rs1577917 0.883 rs1415749 ENSG00000203875.9 SNHG5 18.71 2.68e-54 2.05e-49 0.78 0.71 Response to antipsychotic treatment; chr6:86069366 chr6:85660950~85678736:- LIHC cis rs1577917 0.816 rs1838952 ENSG00000203875.9 SNHG5 -18.68 3.65e-54 2.78e-49 -0.77 -0.71 Response to antipsychotic treatment; chr6:85891426 chr6:85660950~85678736:- LIHC cis rs1577917 0.839 rs12664634 ENSG00000203875.9 SNHG5 -18.66 4.33e-54 3.28e-49 -0.78 -0.71 Response to antipsychotic treatment; chr6:85869696 chr6:85660950~85678736:- LIHC cis rs1577917 0.839 rs6454504 ENSG00000203875.9 SNHG5 -18.63 5.76e-54 4.35e-49 -0.78 -0.71 Response to antipsychotic treatment; chr6:85870612 chr6:85660950~85678736:- LIHC cis rs1577917 0.655 rs6454472 ENSG00000203875.9 SNHG5 18.58 8.96e-54 6.75e-49 0.78 0.71 Response to antipsychotic treatment; chr6:85514335 chr6:85660950~85678736:- LIHC cis rs1577917 0.839 rs6454492 ENSG00000203875.9 SNHG5 -18.58 9.11e-54 6.85e-49 -0.79 -0.71 Response to antipsychotic treatment; chr6:85773496 chr6:85660950~85678736:- LIHC cis rs2739330 0.892 rs5751776 ENSG00000272787.1 KB-226F1.2 -18.56 1.13e-53 8.39e-49 -0.88 -0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23969211~23969873:+ LIHC cis rs1577917 0.839 rs1596990 ENSG00000203875.9 SNHG5 -18.53 1.48e-53 1.07e-48 -0.78 -0.71 Response to antipsychotic treatment; chr6:85840974 chr6:85660950~85678736:- LIHC cis rs1577917 0.916 rs12661611 ENSG00000203875.9 SNHG5 -18.53 1.48e-53 1.07e-48 -0.78 -0.71 Response to antipsychotic treatment; chr6:85844117 chr6:85660950~85678736:- LIHC cis rs1577917 0.637 rs1838957 ENSG00000203875.9 SNHG5 -18.53 1.48e-53 1.07e-48 -0.78 -0.71 Response to antipsychotic treatment; chr6:85855338 chr6:85660950~85678736:- LIHC cis rs1577917 0.839 rs1838956 ENSG00000203875.9 SNHG5 -18.53 1.48e-53 1.07e-48 -0.78 -0.71 Response to antipsychotic treatment; chr6:85855545 chr6:85660950~85678736:- LIHC cis rs1577917 0.839 rs12216103 ENSG00000203875.9 SNHG5 -18.53 1.48e-53 1.07e-48 -0.78 -0.71 Response to antipsychotic treatment; chr6:85861410 chr6:85660950~85678736:- LIHC cis rs1577917 0.655 rs9444352 ENSG00000203875.9 SNHG5 18.53 1.49e-53 1.07e-48 0.77 0.71 Response to antipsychotic treatment; chr6:85547817 chr6:85660950~85678736:- LIHC cis rs1577917 0.839 rs12055653 ENSG00000203875.9 SNHG5 -18.48 2.4e-53 1.7e-48 -0.77 -0.71 Response to antipsychotic treatment; chr6:85836945 chr6:85660950~85678736:- LIHC cis rs2739330 0.929 rs5751775 ENSG00000218537.1 MIF-AS1 18.44 3.39e-53 2.4e-48 0.92 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23894426~23898930:- LIHC cis rs1577917 0.883 rs6454505 ENSG00000203875.9 SNHG5 -18.41 4.55e-53 3.21e-48 -0.78 -0.71 Response to antipsychotic treatment; chr6:85882644 chr6:85660950~85678736:- LIHC cis rs62445005 1 rs62445005 ENSG00000211697.3 TRGV5 18.3 1.19e-52 8.31e-48 0.93 0.7 Shingles; chr7:38346957 chr7:38343894~38350022:- LIHC cis rs2739330 0.929 rs5751777 ENSG00000273295.1 AP000350.5 18.29 1.28e-52 8.91e-48 0.73 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23901432~23907068:- LIHC cis rs2882667 0.69 rs288014 ENSG00000253404.1 AC034243.1 -18.23 2.34e-52 1.61e-47 -1.08 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138860104 chr5:138744434~138753309:- LIHC cis rs2882667 0.587 rs288015 ENSG00000253404.1 AC034243.1 -18.22 2.51e-52 1.7e-47 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138859528 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs495638 ENSG00000253404.1 AC034243.1 -18.22 2.51e-52 1.7e-47 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138865253 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288042 ENSG00000253404.1 AC034243.1 18.22 2.51e-52 1.7e-47 1.07 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138867345 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs4835708 ENSG00000253404.1 AC034243.1 -18.16 4.36e-52 2.91e-47 -1.08 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138844204 chr5:138744434~138753309:- LIHC cis rs2882667 0.587 rs1848506 ENSG00000253404.1 AC034243.1 -18.16 4.36e-52 2.91e-47 -1.08 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138846768 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs1848505 ENSG00000253404.1 AC034243.1 -18.16 4.36e-52 2.91e-47 -1.08 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138846841 chr5:138744434~138753309:- LIHC cis rs2739330 0.929 rs5751775 ENSG00000272787.1 KB-226F1.2 -18.13 5.8e-52 3.84e-47 -0.88 -0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23969211~23969873:+ LIHC cis rs2882667 0.69 rs10043478 ENSG00000253404.1 AC034243.1 18.12 6.36e-52 4.19e-47 1.08 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138853022 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs1651032 ENSG00000253404.1 AC034243.1 -18.11 7.35e-52 4.78e-47 -1.06 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138743151 chr5:138744434~138753309:- LIHC cis rs2739330 0.929 rs5751777 ENSG00000272787.1 KB-226F1.2 -18.1 8.09e-52 5.25e-47 -0.87 -0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23969211~23969873:+ LIHC cis rs2882667 0.69 rs6877187 ENSG00000253404.1 AC034243.1 -18.09 8.22e-52 5.29e-47 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138823655 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs3804199 ENSG00000253404.1 AC034243.1 -18.09 8.22e-52 5.29e-47 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138826440 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs6863054 ENSG00000253404.1 AC034243.1 -18.06 1.1e-51 6.98e-47 -1.08 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138853166 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288030 ENSG00000253404.1 AC034243.1 18.05 1.23e-51 7.77e-47 1.07 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138880594 chr5:138744434~138753309:- LIHC cis rs1577917 0.793 rs9362245 ENSG00000203875.9 SNHG5 -18.04 1.3e-51 8.24e-47 -0.77 -0.7 Response to antipsychotic treatment; chr6:85786602 chr6:85660950~85678736:- LIHC cis rs1577917 0.959 rs2816822 ENSG00000203875.9 SNHG5 -18 1.92e-51 1.2e-46 -0.77 -0.7 Response to antipsychotic treatment; chr6:85948574 chr6:85660950~85678736:- LIHC cis rs1577917 0.883 rs13212415 ENSG00000203875.9 SNHG5 -17.99 2.16e-51 1.35e-46 -0.76 -0.7 Response to antipsychotic treatment; chr6:85898365 chr6:85660950~85678736:- LIHC cis rs1577917 0.839 rs1447159 ENSG00000203875.9 SNHG5 -17.99 2.16e-51 1.35e-46 -0.76 -0.7 Response to antipsychotic treatment; chr6:85899531 chr6:85660950~85678736:- LIHC cis rs2882667 0.654 rs288019 ENSG00000253404.1 AC034243.1 -17.98 2.35e-51 1.43e-46 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138855704 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288013 ENSG00000253404.1 AC034243.1 -17.98 2.35e-51 1.43e-46 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138860128 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs176381 ENSG00000253404.1 AC034243.1 -17.98 2.35e-51 1.43e-46 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138861042 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288011 ENSG00000253404.1 AC034243.1 -17.98 2.35e-51 1.43e-46 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138864250 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288010 ENSG00000253404.1 AC034243.1 -17.98 2.35e-51 1.43e-46 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138864340 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288041 ENSG00000253404.1 AC034243.1 17.98 2.35e-51 1.43e-46 1.07 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138868322 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288039 ENSG00000253404.1 AC034243.1 17.98 2.35e-51 1.43e-46 1.07 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138870511 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288038 ENSG00000253404.1 AC034243.1 17.98 2.35e-51 1.43e-46 1.07 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138871844 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs1095374 ENSG00000253404.1 AC034243.1 -17.97 2.5e-51 1.51e-46 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138759517 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs700620 ENSG00000253404.1 AC034243.1 -17.97 2.5e-51 1.51e-46 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138762247 chr5:138744434~138753309:- LIHC cis rs2882667 0.659 rs700621 ENSG00000253404.1 AC034243.1 -17.97 2.5e-51 1.51e-46 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138762741 chr5:138744434~138753309:- LIHC cis rs2739330 0.796 rs5760106 ENSG00000272787.1 KB-226F1.2 17.97 2.6e-51 1.52e-46 0.85 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23969211~23969873:+ LIHC cis rs2882667 0.69 rs1627698 ENSG00000253404.1 AC034243.1 -17.97 2.61e-51 1.52e-46 -1.06 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138741777 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs700616 ENSG00000253404.1 AC034243.1 -17.97 2.61e-51 1.52e-46 -1.06 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138752184 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs700617 ENSG00000253404.1 AC034243.1 -17.97 2.61e-51 1.52e-46 -1.06 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138752290 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs700618 ENSG00000253404.1 AC034243.1 -17.97 2.61e-51 1.52e-46 -1.06 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138752429 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs700625 ENSG00000253404.1 AC034243.1 -17.97 2.61e-51 1.52e-46 -1.06 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138763908 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs2940595 ENSG00000253404.1 AC034243.1 -17.97 2.61e-51 1.52e-46 -1.06 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138765348 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs851278 ENSG00000253404.1 AC034243.1 -17.97 2.61e-51 1.52e-46 -1.06 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138767577 chr5:138744434~138753309:- LIHC cis rs2882667 0.589 rs825770 ENSG00000253404.1 AC034243.1 -17.97 2.61e-51 1.52e-46 -1.06 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138779530 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs825769 ENSG00000253404.1 AC034243.1 -17.97 2.61e-51 1.52e-46 -1.06 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138779666 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs700627 ENSG00000253404.1 AC034243.1 -17.97 2.61e-51 1.52e-46 -1.06 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138783711 chr5:138744434~138753309:- LIHC cis rs1577917 0.839 rs6929514 ENSG00000203875.9 SNHG5 -17.96 2.86e-51 1.65e-46 -0.77 -0.7 Response to antipsychotic treatment; chr6:85816050 chr6:85660950~85678736:- LIHC cis rs2882667 0.69 rs7710288 ENSG00000253404.1 AC034243.1 -17.96 2.98e-51 1.71e-46 -1.08 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138844049 chr5:138744434~138753309:- LIHC cis rs1577917 0.796 rs12661231 ENSG00000203875.9 SNHG5 -17.94 3.34e-51 1.91e-46 -0.77 -0.7 Response to antipsychotic treatment; chr6:85834753 chr6:85660950~85678736:- LIHC cis rs2882667 0.62 rs3789151 ENSG00000253404.1 AC034243.1 -17.88 6.04e-51 3.38e-46 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138809771 chr5:138744434~138753309:- LIHC cis rs2882667 0.587 rs6596450 ENSG00000253404.1 AC034243.1 -17.88 6.04e-51 3.38e-46 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138810831 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs1972072 ENSG00000253404.1 AC034243.1 -17.88 6.11e-51 3.41e-46 -1.07 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138849604 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs1828187 ENSG00000253404.1 AC034243.1 17.87 6.76e-51 3.73e-46 1.07 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138836531 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs1039789 ENSG00000253404.1 AC034243.1 -17.87 6.76e-51 3.73e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138835734 chr5:138744434~138753309:- LIHC cis rs2882667 0.591 rs56322405 ENSG00000253404.1 AC034243.1 -17.87 6.76e-51 3.73e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138837693 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs6887841 ENSG00000253404.1 AC034243.1 -17.87 6.76e-51 3.73e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138840221 chr5:138744434~138753309:- LIHC cis rs2882667 0.72 rs56044552 ENSG00000253404.1 AC034243.1 -17.87 6.76e-51 3.73e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138841265 chr5:138744434~138753309:- LIHC cis rs2882667 0.659 rs12719515 ENSG00000253404.1 AC034243.1 17.86 7.31e-51 4.01e-46 1.05 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138905629 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs160406 ENSG00000253404.1 AC034243.1 -17.85 7.82e-51 4.29e-46 -1.06 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138748032 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs884470 ENSG00000253404.1 AC034243.1 -17.85 7.87e-51 4.29e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138820236 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs4835705 ENSG00000253404.1 AC034243.1 -17.85 7.87e-51 4.29e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138827887 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs17207772 ENSG00000253404.1 AC034243.1 17.84 8.69e-51 4.7e-46 1.04 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138906131 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs10038162 ENSG00000253404.1 AC034243.1 -17.84 8.69e-51 4.7e-46 -1.04 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138901066 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs6421921 ENSG00000253404.1 AC034243.1 -17.84 8.85e-51 4.78e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138831581 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs7446631 ENSG00000253404.1 AC034243.1 17.82 1e-50 5.41e-46 1.06 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138891376 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288031 ENSG00000253404.1 AC034243.1 17.81 1.18e-50 6.34e-46 1.07 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138880377 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs1039788 ENSG00000253404.1 AC034243.1 -17.8 1.26e-50 6.66e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138835812 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs1828188 ENSG00000253404.1 AC034243.1 -17.8 1.26e-50 6.66e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138836307 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs4835707 ENSG00000253404.1 AC034243.1 -17.8 1.26e-50 6.66e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138838831 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs12656942 ENSG00000253404.1 AC034243.1 -17.8 1.26e-50 6.66e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138840769 chr5:138744434~138753309:- LIHC cis rs2882667 0.686 rs62381196 ENSG00000253404.1 AC034243.1 -17.8 1.26e-50 6.66e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138841000 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs1976568 ENSG00000253404.1 AC034243.1 -17.8 1.26e-50 6.66e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138844627 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs6880786 ENSG00000253404.1 AC034243.1 -17.8 1.26e-50 6.66e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138845874 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs9327826 ENSG00000253404.1 AC034243.1 -17.8 1.26e-50 6.66e-46 -1.07 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138846318 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs6873425 ENSG00000253404.1 AC034243.1 -17.78 1.52e-50 7.9e-46 -1.06 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138819556 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs6860780 ENSG00000253404.1 AC034243.1 -17.78 1.52e-50 7.9e-46 -1.06 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138824367 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs6884198 ENSG00000253404.1 AC034243.1 -17.78 1.52e-50 7.9e-46 -1.06 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138828618 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs4835706 ENSG00000253404.1 AC034243.1 -17.78 1.52e-50 7.9e-46 -1.06 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138829037 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288033 ENSG00000253404.1 AC034243.1 17.78 1.54e-50 7.99e-46 1.05 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138878405 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs12517514 ENSG00000253404.1 AC034243.1 -17.76 1.74e-50 9.02e-46 -1.06 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138814430 chr5:138744434~138753309:- LIHC cis rs2739330 0.929 rs5751777 ENSG00000218537.1 MIF-AS1 17.76 1.84e-50 9.51e-46 0.9 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23894426~23898930:- LIHC cis rs2882667 0.69 rs700624 ENSG00000253404.1 AC034243.1 -17.73 2.34e-50 1.19e-45 -1.06 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138763332 chr5:138744434~138753309:- LIHC cis rs2882667 0.587 rs2174972 ENSG00000253404.1 AC034243.1 -17.73 2.34e-50 1.19e-45 -1.06 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138766229 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs2693963 ENSG00000253404.1 AC034243.1 -17.73 2.34e-50 1.19e-45 -1.06 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138770637 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs1567313 ENSG00000253404.1 AC034243.1 -17.73 2.34e-50 1.19e-45 -1.06 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138775013 chr5:138744434~138753309:- LIHC cis rs2882667 0.621 rs55901834 ENSG00000253404.1 AC034243.1 -17.71 2.93e-50 1.48e-45 -1.06 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138844094 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288022 ENSG00000253404.1 AC034243.1 17.71 3e-50 1.5e-45 1.06 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138888586 chr5:138744434~138753309:- LIHC cis rs2882667 0.598 rs288020 ENSG00000253404.1 AC034243.1 17.71 3e-50 1.5e-45 1.06 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138888609 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs176382 ENSG00000253404.1 AC034243.1 17.7 3.13e-50 1.56e-45 1.06 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138891078 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs825748 ENSG00000253404.1 AC034243.1 -17.68 3.82e-50 1.89e-45 -1.05 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138800378 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs825746 ENSG00000253404.1 AC034243.1 -17.68 3.82e-50 1.89e-45 -1.05 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138800930 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs825762 ENSG00000253404.1 AC034243.1 -17.68 3.82e-50 1.89e-45 -1.05 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138801981 chr5:138744434~138753309:- LIHC cis rs507080 0.885 rs693037 ENSG00000255239.1 AP002954.6 17.67 4.23e-50 2.09e-45 0.82 0.69 Serum metabolite levels; chr11:118682617 chr11:118688039~118690600:- LIHC cis rs2882667 0.69 rs825754 ENSG00000253404.1 AC034243.1 -17.65 5.09e-50 2.5e-45 -1.05 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138796200 chr5:138744434~138753309:- LIHC cis rs2882667 0.722 rs825751 ENSG00000253404.1 AC034243.1 -17.65 5.09e-50 2.5e-45 -1.05 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138798180 chr5:138744434~138753309:- LIHC cis rs2882667 0.722 rs4835649 ENSG00000253404.1 AC034243.1 -17.65 5.09e-50 2.5e-45 -1.05 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138810534 chr5:138744434~138753309:- LIHC cis rs1577917 0.633 rs7770835 ENSG00000203875.9 SNHG5 -17.63 5.86e-50 2.88e-45 -0.75 -0.69 Response to antipsychotic treatment; chr6:85899189 chr6:85660950~85678736:- LIHC cis rs2882667 0.69 rs2662543 ENSG00000253404.1 AC034243.1 17.63 5.97e-50 2.93e-45 1.04 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138898441 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs7714455 ENSG00000253404.1 AC034243.1 -17.62 6.5e-50 3.18e-45 -1.06 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138818281 chr5:138744434~138753309:- LIHC cis rs1577917 0.92 rs1337842 ENSG00000203875.9 SNHG5 -17.6 7.76e-50 3.77e-45 -0.76 -0.69 Response to antipsychotic treatment; chr6:85965379 chr6:85660950~85678736:- LIHC cis rs2882667 0.69 rs13172507 ENSG00000253404.1 AC034243.1 17.6 7.98e-50 3.86e-45 1.04 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138907409 chr5:138744434~138753309:- LIHC cis rs507080 0.845 rs613377 ENSG00000255239.1 AP002954.6 17.6 8.06e-50 3.89e-45 0.82 0.69 Serum metabolite levels; chr11:118685375 chr11:118688039~118690600:- LIHC cis rs1577917 0.804 rs2786854 ENSG00000203875.9 SNHG5 -17.6 8.22e-50 3.96e-45 -0.76 -0.69 Response to antipsychotic treatment; chr6:85959022 chr6:85660950~85678736:- LIHC cis rs2882667 0.69 rs825761 ENSG00000253404.1 AC034243.1 -17.59 8.84e-50 4.25e-45 -1.04 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138802318 chr5:138744434~138753309:- LIHC cis rs507080 0.922 rs546890 ENSG00000255239.1 AP002954.6 17.59 9.07e-50 4.25e-45 0.82 0.69 Serum metabolite levels; chr11:118686489 chr11:118688039~118690600:- LIHC cis rs507080 0.883 rs693306 ENSG00000255239.1 AP002954.6 17.59 9.07e-50 4.25e-45 0.82 0.69 Serum metabolite levels; chr11:118687624 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs561845 ENSG00000255239.1 AP002954.6 17.59 9.07e-50 4.25e-45 0.82 0.69 Serum metabolite levels; chr11:118688118 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs638805 ENSG00000255239.1 AP002954.6 17.59 9.07e-50 4.25e-45 0.82 0.69 Serum metabolite levels; chr11:118688180 chr11:118688039~118690600:- LIHC cis rs507080 0.845 rs510408 ENSG00000255239.1 AP002954.6 17.59 9.07e-50 4.25e-45 0.82 0.69 Serum metabolite levels; chr11:118688192 chr11:118688039~118690600:- LIHC cis rs507080 0.845 rs509641 ENSG00000255239.1 AP002954.6 17.59 9.07e-50 4.25e-45 0.82 0.69 Serum metabolite levels; chr11:118688243 chr11:118688039~118690600:- LIHC cis rs507080 0.883 rs563549 ENSG00000255239.1 AP002954.6 17.59 9.07e-50 4.25e-45 0.82 0.69 Serum metabolite levels; chr11:118688244 chr11:118688039~118690600:- LIHC cis rs2739330 0.828 rs4820572 ENSG00000272787.1 KB-226F1.2 -17.56 1.12e-49 5.22e-45 -0.85 -0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23969211~23969873:+ LIHC cis rs2739330 0.828 rs5760099 ENSG00000272787.1 KB-226F1.2 -17.53 1.48e-49 6.87e-45 -0.87 -0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23969211~23969873:+ LIHC cis rs2739330 0.828 rs2186366 ENSG00000272787.1 KB-226F1.2 17.53 1.51e-49 7.02e-45 0.88 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23969211~23969873:+ LIHC cis rs2882667 0.69 rs160405 ENSG00000253404.1 AC034243.1 17.52 1.68e-49 7.78e-45 1.05 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138748387 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288016 ENSG00000253404.1 AC034243.1 -17.51 1.78e-49 8.26e-45 -1.05 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138859299 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs825758 ENSG00000253404.1 AC034243.1 -17.51 1.79e-49 8.27e-45 -1.05 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138791288 chr5:138744434~138753309:- LIHC cis rs2739330 0.828 rs4822454 ENSG00000272787.1 KB-226F1.2 -17.5 1.97e-49 9.07e-45 -0.89 -0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23969211~23969873:+ LIHC cis rs507080 0.885 rs533144 ENSG00000255239.1 AP002954.6 17.49 2.15e-49 9.87e-45 0.81 0.69 Serum metabolite levels; chr11:118688538 chr11:118688039~118690600:- LIHC cis rs507080 0.883 rs12798453 ENSG00000255239.1 AP002954.6 17.49 2.15e-49 9.87e-45 0.81 0.69 Serum metabolite levels; chr11:118690701 chr11:118688039~118690600:- LIHC cis rs1577917 0.816 rs12664099 ENSG00000203875.9 SNHG5 -17.48 2.35e-49 1.08e-44 -0.75 -0.69 Response to antipsychotic treatment; chr6:85938854 chr6:85660950~85678736:- LIHC cis rs507080 0.922 rs625513 ENSG00000255239.1 AP002954.6 17.47 2.58e-49 1.18e-44 0.81 0.69 Serum metabolite levels; chr11:118685010 chr11:118688039~118690600:- LIHC cis rs2739330 0.753 rs4822452 ENSG00000272787.1 KB-226F1.2 -17.43 3.71e-49 1.68e-44 -0.88 -0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23969211~23969873:+ LIHC cis rs1577917 0.883 rs9450375 ENSG00000203875.9 SNHG5 17.43 3.82e-49 1.71e-44 0.75 0.69 Response to antipsychotic treatment; chr6:86046911 chr6:85660950~85678736:- LIHC cis rs2739330 0.796 rs2154594 ENSG00000272787.1 KB-226F1.2 17.4 4.93e-49 2.21e-44 0.89 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23969211~23969873:+ LIHC cis rs2882667 0.599 rs288008 ENSG00000253404.1 AC034243.1 17.4 5.09e-49 2.27e-44 1.04 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138893632 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288004 ENSG00000253404.1 AC034243.1 17.4 5.09e-49 2.27e-44 1.04 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138895956 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs160398 ENSG00000253404.1 AC034243.1 17.4 5.21e-49 2.32e-44 1.05 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138727750 chr5:138744434~138753309:- LIHC cis rs1577917 0.883 rs2660575 ENSG00000203875.9 SNHG5 -17.39 5.84e-49 2.6e-44 -0.75 -0.68 Response to antipsychotic treatment; chr6:85975277 chr6:85660950~85678736:- LIHC cis rs507080 0.922 rs558907 ENSG00000255239.1 AP002954.6 17.37 6.52e-49 2.9e-44 0.81 0.68 Serum metabolite levels; chr11:118687746 chr11:118688039~118690600:- LIHC cis rs1577917 0.883 rs1337854 ENSG00000203875.9 SNHG5 17.37 6.84e-49 3.03e-44 0.75 0.68 Response to antipsychotic treatment; chr6:86014297 chr6:85660950~85678736:- LIHC cis rs2739330 0.828 rs5760102 ENSG00000272787.1 KB-226F1.2 -17.36 7.23e-49 3.19e-44 -0.87 -0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23969211~23969873:+ LIHC cis rs507080 0.663 rs7926970 ENSG00000255239.1 AP002954.6 17.35 7.91e-49 3.48e-44 0.81 0.68 Serum metabolite levels; chr11:118689172 chr11:118688039~118690600:- LIHC cis rs2882667 0.654 rs700626 ENSG00000253404.1 AC034243.1 -17.34 9.01e-49 3.95e-44 -1.05 -0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138782249 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288023 ENSG00000253404.1 AC034243.1 17.33 9.48e-49 4.13e-44 1.05 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138888359 chr5:138744434~138753309:- LIHC cis rs507080 0.885 rs4938530 ENSG00000255239.1 AP002954.6 17.28 1.5e-48 6.51e-44 0.81 0.68 Serum metabolite levels; chr11:118689861 chr11:118688039~118690600:- LIHC cis rs507080 0.883 rs527475 ENSG00000255239.1 AP002954.6 17.28 1.53e-48 6.62e-44 0.81 0.68 Serum metabolite levels; chr11:118692530 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs585039 ENSG00000255239.1 AP002954.6 17.26 1.79e-48 7.74e-44 0.81 0.68 Serum metabolite levels; chr11:118692672 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs514143 ENSG00000255239.1 AP002954.6 17.26 1.84e-48 7.94e-44 0.81 0.68 Serum metabolite levels; chr11:118687740 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs7114458 ENSG00000255239.1 AP002954.6 17.25 2.03e-48 8.67e-44 0.83 0.68 Serum metabolite levels; chr11:118695466 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs7114216 ENSG00000255239.1 AP002954.6 17.25 2.03e-48 8.67e-44 0.83 0.68 Serum metabolite levels; chr11:118695525 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs555356 ENSG00000255239.1 AP002954.6 17.24 2.24e-48 9.55e-44 0.81 0.68 Serum metabolite levels; chr11:118687369 chr11:118688039~118690600:- LIHC cis rs2739330 0.892 rs4822455 ENSG00000272787.1 KB-226F1.2 -17.24 2.29e-48 9.75e-44 -0.87 -0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23969211~23969873:+ LIHC cis rs507080 0.922 rs533646 ENSG00000255239.1 AP002954.6 17.23 2.46e-48 1.05e-43 0.83 0.68 Serum metabolite levels; chr11:118696037 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs582630 ENSG00000255239.1 AP002954.6 17.22 2.6e-48 1.1e-43 0.81 0.68 Serum metabolite levels; chr11:118692090 chr11:118688039~118690600:- LIHC cis rs507080 0.807 rs7926944 ENSG00000255239.1 AP002954.6 17.18 3.78e-48 1.6e-43 0.8 0.68 Serum metabolite levels; chr11:118689119 chr11:118688039~118690600:- LIHC cis rs507080 0.883 rs558593 ENSG00000255239.1 AP002954.6 17.18 3.82e-48 1.61e-43 0.81 0.68 Serum metabolite levels; chr11:118691811 chr11:118688039~118690600:- LIHC cis rs2882667 0.69 rs10515504 ENSG00000253404.1 AC034243.1 -17.18 3.86e-48 1.63e-43 -1.04 -0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138887305 chr5:138744434~138753309:- LIHC cis rs2739330 0.828 rs2877178 ENSG00000272787.1 KB-226F1.2 -17.18 3.9e-48 1.64e-43 -0.85 -0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23969211~23969873:+ LIHC cis rs507080 0.885 rs7926959 ENSG00000255239.1 AP002954.6 17.17 4.13e-48 1.73e-43 0.81 0.68 Serum metabolite levels; chr11:118689157 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs508640 ENSG00000255239.1 AP002954.6 17.17 4.41e-48 1.84e-43 0.81 0.68 Serum metabolite levels; chr11:118693704 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs471227 ENSG00000255239.1 AP002954.6 17.17 4.41e-48 1.84e-43 0.81 0.68 Serum metabolite levels; chr11:118693892 chr11:118688039~118690600:- LIHC cis rs2739330 0.828 rs4822451 ENSG00000272787.1 KB-226F1.2 -17.16 4.71e-48 1.97e-43 -0.86 -0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23969211~23969873:+ LIHC cis rs507080 0.922 rs558781 ENSG00000255239.1 AP002954.6 17.15 5.29e-48 2.2e-43 0.81 0.68 Serum metabolite levels; chr11:118693688 chr11:118688039~118690600:- LIHC cis rs2882667 0.69 rs288025 ENSG00000253404.1 AC034243.1 17.12 6.94e-48 2.88e-43 1.03 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138887944 chr5:138744434~138753309:- LIHC cis rs2739330 0.828 rs5760108 ENSG00000272787.1 KB-226F1.2 -17.11 7.66e-48 3.17e-43 -0.84 -0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23969211~23969873:+ LIHC cis rs2739330 0.828 rs2154593 ENSG00000272787.1 KB-226F1.2 -17.1 8.05e-48 3.32e-43 -0.84 -0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23969211~23969873:+ LIHC cis rs507080 0.961 rs34413584 ENSG00000255239.1 AP002954.6 17.09 8.64e-48 3.56e-43 0.8 0.68 Serum metabolite levels; chr11:118675072 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs502601 ENSG00000255239.1 AP002954.6 17.07 1.07e-47 4.4e-43 0.81 0.68 Serum metabolite levels; chr11:118694970 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs516153 ENSG00000255239.1 AP002954.6 17.05 1.25e-47 5.1e-43 0.81 0.68 Serum metabolite levels; chr11:118694053 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs518028 ENSG00000255239.1 AP002954.6 17.05 1.25e-47 5.1e-43 0.81 0.68 Serum metabolite levels; chr11:118694273 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs519982 ENSG00000255239.1 AP002954.6 17.05 1.25e-47 5.1e-43 0.81 0.68 Serum metabolite levels; chr11:118694522 chr11:118688039~118690600:- LIHC cis rs1577917 0.883 rs12214536 ENSG00000203875.9 SNHG5 -17.05 1.3e-47 5.3e-43 -0.76 -0.68 Response to antipsychotic treatment; chr6:86080592 chr6:85660950~85678736:- LIHC cis rs2739330 0.828 rs5760098 ENSG00000272787.1 KB-226F1.2 -17 2.06e-47 8.37e-43 -0.86 -0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23969211~23969873:+ LIHC cis rs2739330 0.796 rs5760097 ENSG00000272787.1 KB-226F1.2 -16.98 2.48e-47 1e-42 -0.86 -0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23969211~23969873:+ LIHC cis rs1577917 0.839 rs9450333 ENSG00000203875.9 SNHG5 -16.97 2.75e-47 1.11e-42 -0.75 -0.68 Response to antipsychotic treatment; chr6:85810037 chr6:85660950~85678736:- LIHC cis rs507080 0.922 rs525485 ENSG00000255239.1 AP002954.6 16.96 3.1e-47 1.24e-42 0.8 0.68 Serum metabolite levels; chr11:118685045 chr11:118688039~118690600:- LIHC cis rs2739330 0.828 rs5760107 ENSG00000272787.1 KB-226F1.2 -16.92 4.14e-47 1.64e-42 -0.85 -0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23969211~23969873:+ LIHC cis rs2739330 0.828 rs2330635 ENSG00000272787.1 KB-226F1.2 -16.91 4.61e-47 1.82e-42 -0.85 -0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23969211~23969873:+ LIHC cis rs2882667 0.69 rs311596 ENSG00000253404.1 AC034243.1 -16.86 7.56e-47 2.98e-42 -1.04 -0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138736393 chr5:138744434~138753309:- LIHC cis rs507080 0.922 rs478371 ENSG00000255239.1 AP002954.6 16.86 7.86e-47 3.1e-42 0.81 0.67 Serum metabolite levels; chr11:118694627 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs493834 ENSG00000255239.1 AP002954.6 16.86 7.9e-47 3.11e-42 0.81 0.67 Serum metabolite levels; chr11:118696735 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs644498 ENSG00000255239.1 AP002954.6 16.86 7.9e-47 3.11e-42 0.81 0.67 Serum metabolite levels; chr11:118696777 chr11:118688039~118690600:- LIHC cis rs2739330 0.789 rs5760109 ENSG00000272787.1 KB-226F1.2 -16.77 1.69e-46 6.58e-42 -0.85 -0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23969211~23969873:+ LIHC cis rs2739330 0.828 rs5751770 ENSG00000272787.1 KB-226F1.2 -16.74 2.25e-46 8.74e-42 -0.83 -0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23969211~23969873:+ LIHC cis rs1577917 0.56 rs9450288 ENSG00000203875.9 SNHG5 16.73 2.45e-46 9.54e-42 0.74 0.67 Response to antipsychotic treatment; chr6:85511868 chr6:85660950~85678736:- LIHC cis rs7188445 0.556 rs7203910 ENSG00000261390.4 RP11-345M22.2 -16.73 2.61e-46 1.01e-41 -0.76 -0.67 Urate levels; chr16:79711722 chr16:79715232~79770563:- LIHC cis rs507080 0.922 rs4938524 ENSG00000255239.1 AP002954.6 16.72 2.7e-46 1.05e-41 0.79 0.67 Serum metabolite levels; chr11:118681365 chr11:118688039~118690600:- LIHC cis rs2882667 0.658 rs311592 ENSG00000253404.1 AC034243.1 16.71 2.91e-46 1.12e-41 1.04 0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138734506 chr5:138744434~138753309:- LIHC cis rs507080 0.922 rs644867 ENSG00000255239.1 AP002954.6 16.71 3e-46 1.16e-41 0.8 0.67 Serum metabolite levels; chr11:118696836 chr11:118688039~118690600:- LIHC cis rs2739330 0.627 rs9608219 ENSG00000273295.1 AP000350.5 16.69 3.61e-46 1.39e-41 0.7 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23901432~23907068:- LIHC cis rs507080 0.922 rs4589335 ENSG00000255239.1 AP002954.6 16.69 3.78e-46 1.45e-41 0.79 0.67 Serum metabolite levels; chr11:118668431 chr11:118688039~118690600:- LIHC cis rs2882667 0.69 rs311597 ENSG00000253404.1 AC034243.1 16.58 9.69e-46 3.7e-41 1.03 0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138720212 chr5:138744434~138753309:- LIHC cis rs507080 0.922 rs592280 ENSG00000255239.1 AP002954.6 16.58 9.75e-46 3.72e-41 0.78 0.67 Serum metabolite levels; chr11:118682509 chr11:118688039~118690600:- LIHC cis rs507080 0.883 rs692750 ENSG00000255239.1 AP002954.6 16.55 1.31e-45 4.97e-41 0.78 0.67 Serum metabolite levels; chr11:118667599 chr11:118688039~118690600:- LIHC cis rs507080 0.961 rs4457789 ENSG00000255239.1 AP002954.6 16.51 1.94e-45 7.35e-41 0.79 0.67 Serum metabolite levels; chr11:118668461 chr11:118688039~118690600:- LIHC cis rs2739330 0.685 rs4822453 ENSG00000272787.1 KB-226F1.2 -16.5 2.02e-45 7.62e-41 -0.85 -0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23969211~23969873:+ LIHC cis rs507080 0.961 rs642497 ENSG00000255239.1 AP002954.6 16.48 2.63e-45 9.81e-41 0.77 0.67 Serum metabolite levels; chr11:118680075 chr11:118688039~118690600:- LIHC cis rs2882667 0.69 rs700629 ENSG00000253404.1 AC034243.1 -16.44 3.73e-45 1.38e-40 -0.99 -0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138788305 chr5:138744434~138753309:- LIHC cis rs507080 0.961 rs520543 ENSG00000255239.1 AP002954.6 16.41 4.65e-45 1.71e-40 0.78 0.66 Serum metabolite levels; chr11:118667448 chr11:118688039~118690600:- LIHC cis rs2739330 0.791 rs9612520 ENSG00000273295.1 AP000350.5 16.41 4.79e-45 1.76e-40 0.7 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23901432~23907068:- LIHC cis rs2882667 0.69 rs160402 ENSG00000253404.1 AC034243.1 16.41 4.98e-45 1.82e-40 1.04 0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138723599 chr5:138744434~138753309:- LIHC cis rs507080 0.922 rs519848 ENSG00000255239.1 AP002954.6 16.4 5.4e-45 1.98e-40 0.78 0.66 Serum metabolite levels; chr11:118682006 chr11:118688039~118690600:- LIHC cis rs507080 0.961 rs642530 ENSG00000255239.1 AP002954.6 16.36 7.49e-45 2.73e-40 0.77 0.66 Serum metabolite levels; chr11:118680047 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs12788848 ENSG00000255239.1 AP002954.6 16.36 7.61e-45 2.75e-40 0.77 0.66 Serum metabolite levels; chr11:118683079 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs4474473 ENSG00000255239.1 AP002954.6 16.36 7.61e-45 2.75e-40 0.77 0.66 Serum metabolite levels; chr11:118683180 chr11:118688039~118690600:- LIHC cis rs507080 0.922 rs12796373 ENSG00000255239.1 AP002954.6 16.36 7.61e-45 2.75e-40 0.77 0.66 Serum metabolite levels; chr11:118684230 chr11:118688039~118690600:- LIHC cis rs9326248 0.817 rs6589598 ENSG00000254851.1 RP11-109L13.1 -16.33 9.6e-45 3.46e-40 -0.83 -0.66 Blood protein levels; chr11:117131687 chr11:117135528~117138582:+ LIHC cis rs2882667 0.69 rs288012 ENSG00000253404.1 AC034243.1 -16.33 1.04e-44 3.75e-40 -0.98 -0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138860584 chr5:138744434~138753309:- LIHC cis rs2882667 0.722 rs2011462 ENSG00000253404.1 AC034243.1 -16.31 1.24e-44 4.46e-40 -0.98 -0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138827083 chr5:138744434~138753309:- LIHC cis rs2739330 0.752 rs2330634 ENSG00000272787.1 KB-226F1.2 -16.29 1.43e-44 5.1e-40 -0.84 -0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908608 chr22:23969211~23969873:+ LIHC cis rs2882667 0.69 rs274119 ENSG00000253404.1 AC034243.1 16.29 1.49e-44 5.33e-40 0.98 0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138728530 chr5:138744434~138753309:- LIHC cis rs4853012 0.838 rs4563249 ENSG00000217702.2 RP11-287D1.4 16.27 1.7e-44 6.04e-40 0.86 0.66 Gestational age at birth (maternal effect); chr2:74126889 chr2:74130583~74135395:+ LIHC cis rs858239 0.6 rs10256361 ENSG00000230658.1 KLHL7-AS1 16.27 1.71e-44 6.07e-40 0.78 0.66 Cerebrospinal fluid biomarker levels; chr7:23084266 chr7:23101228~23105703:- LIHC cis rs4853012 0.838 rs12619982 ENSG00000217702.2 RP11-287D1.4 16.27 1.78e-44 6.3e-40 0.87 0.66 Gestational age at birth (maternal effect); chr2:74128895 chr2:74130583~74135395:+ LIHC cis rs507080 0.961 rs600969 ENSG00000255239.1 AP002954.6 16.26 1.89e-44 6.68e-40 0.77 0.66 Serum metabolite levels; chr11:118675087 chr11:118688039~118690600:- LIHC cis rs507080 0.961 rs673770 ENSG00000255239.1 AP002954.6 16.26 1.89e-44 6.68e-40 0.77 0.66 Serum metabolite levels; chr11:118679892 chr11:118688039~118690600:- LIHC cis rs2882667 0.69 rs311599 ENSG00000253404.1 AC034243.1 16.25 2.03e-44 7.15e-40 1.04 0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138718994 chr5:138744434~138753309:- LIHC cis rs507080 0.883 rs656575 ENSG00000255239.1 AP002954.6 16.24 2.3e-44 8.06e-40 0.77 0.66 Serum metabolite levels; chr11:118679199 chr11:118688039~118690600:- LIHC cis rs2882667 0.69 rs1703212 ENSG00000253404.1 AC034243.1 -16.23 2.62e-44 9.14e-40 -0.98 -0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138742863 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs700623 ENSG00000253404.1 AC034243.1 -16.23 2.62e-44 9.14e-40 -0.98 -0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138762993 chr5:138744434~138753309:- LIHC cis rs858239 0.6 rs7787110 ENSG00000230658.1 KLHL7-AS1 16.22 2.76e-44 9.6e-40 0.77 0.66 Cerebrospinal fluid biomarker levels; chr7:23098855 chr7:23101228~23105703:- LIHC cis rs507080 0.845 rs667982 ENSG00000255239.1 AP002954.6 16.21 3.05e-44 1.06e-39 0.78 0.66 Serum metabolite levels; chr11:118692058 chr11:118688039~118690600:- LIHC cis rs9326248 0.861 rs4938353 ENSG00000254851.1 RP11-109L13.1 -16.21 3.06e-44 1.06e-39 -0.84 -0.66 Blood protein levels; chr11:117175481 chr11:117135528~117138582:+ LIHC cis rs2882667 0.69 rs160404 ENSG00000253404.1 AC034243.1 16.21 3.09e-44 1.07e-39 1.01 0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138748580 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs884469 ENSG00000253404.1 AC034243.1 -16.2 3.23e-44 1.11e-39 -0.98 -0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138820270 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs825749 ENSG00000253404.1 AC034243.1 -16.16 4.7e-44 1.61e-39 -0.98 -0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138800232 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs160399 ENSG00000253404.1 AC034243.1 16.15 5.24e-44 1.79e-39 0.96 0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138727552 chr5:138744434~138753309:- LIHC cis rs858239 0.6 rs28646184 ENSG00000230658.1 KLHL7-AS1 16.15 5.27e-44 1.79e-39 0.77 0.66 Cerebrospinal fluid biomarker levels; chr7:23099976 chr7:23101228~23105703:- LIHC cis rs2882667 0.69 rs274118 ENSG00000253404.1 AC034243.1 16.14 5.63e-44 1.91e-39 0.97 0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138729198 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs274117 ENSG00000253404.1 AC034243.1 16.14 5.63e-44 1.91e-39 0.97 0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138729359 chr5:138744434~138753309:- LIHC cis rs7188445 0.592 rs4404082 ENSG00000261390.4 RP11-345M22.2 16.14 5.82e-44 1.97e-39 0.77 0.66 Urate levels; chr16:79716615 chr16:79715232~79770563:- LIHC cis rs7188445 0.556 rs7194711 ENSG00000261390.4 RP11-345M22.2 -16.14 6e-44 2.03e-39 -0.75 -0.66 Urate levels; chr16:79715134 chr16:79715232~79770563:- LIHC cis rs2882667 0.69 rs6596456 ENSG00000253404.1 AC034243.1 -16.13 6.27e-44 2.12e-39 -0.98 -0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138831808 chr5:138744434~138753309:- LIHC cis rs507080 0.961 rs1784298 ENSG00000255239.1 AP002954.6 16.11 7.95e-44 2.65e-39 0.77 0.66 Serum metabolite levels; chr11:118677956 chr11:118688039~118690600:- LIHC cis rs507080 0.961 rs4938522 ENSG00000255239.1 AP002954.6 16.11 7.95e-44 2.65e-39 0.77 0.66 Serum metabolite levels; chr11:118677962 chr11:118688039~118690600:- LIHC cis rs507080 0.961 rs4938523 ENSG00000255239.1 AP002954.6 16.11 7.95e-44 2.65e-39 0.77 0.66 Serum metabolite levels; chr11:118678129 chr11:118688039~118690600:- LIHC cis rs507080 1 rs659969 ENSG00000255239.1 AP002954.6 16.11 7.95e-44 2.65e-39 0.77 0.66 Serum metabolite levels; chr11:118679094 chr11:118688039~118690600:- LIHC cis rs507080 0.961 rs656505 ENSG00000255239.1 AP002954.6 16.11 7.95e-44 2.65e-39 0.77 0.66 Serum metabolite levels; chr11:118679245 chr11:118688039~118690600:- LIHC cis rs507080 0.961 rs660489 ENSG00000255239.1 AP002954.6 16.11 7.95e-44 2.65e-39 0.77 0.66 Serum metabolite levels; chr11:118679255 chr11:118688039~118690600:- LIHC cis rs507080 0.961 rs543327 ENSG00000255239.1 AP002954.6 16.11 7.95e-44 2.65e-39 0.77 0.66 Serum metabolite levels; chr11:118679276 chr11:118688039~118690600:- LIHC cis rs507080 0.961 rs543413 ENSG00000255239.1 AP002954.6 16.11 7.95e-44 2.65e-39 0.77 0.66 Serum metabolite levels; chr11:118679308 chr11:118688039~118690600:- LIHC cis rs2882667 0.69 rs906695 ENSG00000253404.1 AC034243.1 16.1 8.66e-44 2.88e-39 1.01 0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138803588 chr5:138744434~138753309:- LIHC cis rs2739330 0.892 rs4822455 ENSG00000273295.1 AP000350.5 16.07 1.06e-43 3.51e-39 0.7 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23901432~23907068:- LIHC cis rs916888 0.773 rs199448 ENSG00000214401.4 KANSL1-AS1 16.06 1.17e-43 3.85e-39 1.21 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46193576~46196723:+ LIHC cis rs4853012 0.941 rs4852329 ENSG00000217702.2 RP11-287D1.4 16.05 1.32e-43 4.33e-39 0.87 0.66 Gestational age at birth (maternal effect); chr2:74127417 chr2:74130583~74135395:+ LIHC cis rs2739330 0.752 rs2330634 ENSG00000273295.1 AP000350.5 16.04 1.49e-43 4.9e-39 0.69 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908608 chr22:23901432~23907068:- LIHC cis rs4853012 0.838 rs72915068 ENSG00000217702.2 RP11-287D1.4 16.03 1.53e-43 5e-39 0.86 0.66 Gestational age at birth (maternal effect); chr2:74129058 chr2:74130583~74135395:+ LIHC cis rs858239 0.6 rs10256359 ENSG00000230658.1 KLHL7-AS1 16.03 1.58e-43 5.18e-39 0.77 0.65 Cerebrospinal fluid biomarker levels; chr7:23084258 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs2014768 ENSG00000230658.1 KLHL7-AS1 16.02 1.78e-43 5.8e-39 0.77 0.65 Cerebrospinal fluid biomarker levels; chr7:23082821 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs7790157 ENSG00000230658.1 KLHL7-AS1 16.02 1.78e-43 5.8e-39 0.77 0.65 Cerebrospinal fluid biomarker levels; chr7:23087379 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs6961131 ENSG00000230658.1 KLHL7-AS1 16.02 1.78e-43 5.8e-39 0.77 0.65 Cerebrospinal fluid biomarker levels; chr7:23095171 chr7:23101228~23105703:- LIHC cis rs2882667 0.69 rs6872423 ENSG00000253404.1 AC034243.1 16 2.04e-43 6.63e-39 1.11 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138911089 chr5:138744434~138753309:- LIHC cis rs858239 0.6 rs6960001 ENSG00000230658.1 KLHL7-AS1 16 2.12e-43 6.86e-39 0.77 0.65 Cerebrospinal fluid biomarker levels; chr7:23091257 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs10237755 ENSG00000230658.1 KLHL7-AS1 16 2.12e-43 6.86e-39 0.77 0.65 Cerebrospinal fluid biomarker levels; chr7:23091945 chr7:23101228~23105703:- LIHC cis rs507080 1 rs507080 ENSG00000255239.1 AP002954.6 15.99 2.28e-43 7.38e-39 0.76 0.65 Serum metabolite levels; chr11:118678873 chr11:118688039~118690600:- LIHC cis rs858239 0.6 rs1115941 ENSG00000230658.1 KLHL7-AS1 15.98 2.6e-43 8.38e-39 0.77 0.65 Cerebrospinal fluid biomarker levels; chr7:23097569 chr7:23101228~23105703:- LIHC cis rs1577917 0.74 rs9344542 ENSG00000203875.9 SNHG5 15.93 4.04e-43 1.29e-38 0.69 0.65 Response to antipsychotic treatment; chr6:85684187 chr6:85660950~85678736:- LIHC cis rs2882667 0.69 rs6890932 ENSG00000253404.1 AC034243.1 15.92 4.25e-43 1.36e-38 1.11 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138910639 chr5:138744434~138753309:- LIHC cis rs2882667 0.659 rs10056014 ENSG00000253404.1 AC034243.1 15.92 4.25e-43 1.36e-38 1.11 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138920329 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs423469 ENSG00000253404.1 AC034243.1 15.91 4.94e-43 1.58e-38 0.96 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138898427 chr5:138744434~138753309:- LIHC cis rs858239 0.6 rs10256524 ENSG00000230658.1 KLHL7-AS1 15.89 5.54e-43 1.76e-38 0.76 0.65 Cerebrospinal fluid biomarker levels; chr7:23105328 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs7785842 ENSG00000230658.1 KLHL7-AS1 15.88 6.03e-43 1.91e-38 0.76 0.65 Cerebrospinal fluid biomarker levels; chr7:23102087 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs7456915 ENSG00000230658.1 KLHL7-AS1 15.88 6.03e-43 1.91e-38 0.76 0.65 Cerebrospinal fluid biomarker levels; chr7:23103430 chr7:23101228~23105703:- LIHC cis rs2882667 0.69 rs1725335 ENSG00000253404.1 AC034243.1 -15.87 6.96e-43 2.2e-38 -1.14 -0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138745541 chr5:138744434~138753309:- LIHC cis rs2739330 0.892 rs4822455 ENSG00000218537.1 MIF-AS1 15.87 7.06e-43 2.23e-38 0.86 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23894426~23898930:- LIHC cis rs9326248 0.813 rs7115562 ENSG00000254851.1 RP11-109L13.1 -15.87 7.2e-43 2.27e-38 -0.83 -0.65 Blood protein levels; chr11:117149754 chr11:117135528~117138582:+ LIHC cis rs858239 0.6 rs13438179 ENSG00000230658.1 KLHL7-AS1 15.86 7.47e-43 2.35e-38 0.76 0.65 Cerebrospinal fluid biomarker levels; chr7:23104232 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs6967419 ENSG00000230658.1 KLHL7-AS1 15.84 9.36e-43 2.93e-38 0.75 0.65 Cerebrospinal fluid biomarker levels; chr7:23096691 chr7:23101228~23105703:- LIHC cis rs2739330 0.791 rs4822458 ENSG00000273295.1 AP000350.5 15.82 1.12e-42 3.5e-38 0.67 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23901432~23907068:- LIHC cis rs507080 0.922 rs12577485 ENSG00000255239.1 AP002954.6 15.81 1.16e-42 3.61e-38 0.76 0.65 Serum metabolite levels; chr11:118676793 chr11:118688039~118690600:- LIHC cis rs2882667 0.659 rs311595 ENSG00000253404.1 AC034243.1 15.81 1.24e-42 3.86e-38 0.96 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138736183 chr5:138744434~138753309:- LIHC cis rs858239 0.6 rs2072369 ENSG00000230658.1 KLHL7-AS1 15.8 1.33e-42 4.11e-38 0.76 0.65 Cerebrospinal fluid biomarker levels; chr7:23106570 chr7:23101228~23105703:- LIHC cis rs916888 0.773 rs199451 ENSG00000214401.4 KANSL1-AS1 15.8 1.34e-42 4.13e-38 1.2 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:46193576~46196723:+ LIHC cis rs2882667 0.69 rs7709789 ENSG00000253404.1 AC034243.1 15.79 1.4e-42 4.32e-38 1.13 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138938762 chr5:138744434~138753309:- LIHC cis rs858239 0.6 rs2003555 ENSG00000230658.1 KLHL7-AS1 15.79 1.41e-42 4.35e-38 0.76 0.65 Cerebrospinal fluid biomarker levels; chr7:23083296 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs7784929 ENSG00000230658.1 KLHL7-AS1 15.79 1.41e-42 4.35e-38 0.76 0.65 Cerebrospinal fluid biomarker levels; chr7:23084658 chr7:23101228~23105703:- LIHC cis rs9326248 0.768 rs4936366 ENSG00000254851.1 RP11-109L13.1 -15.79 1.46e-42 4.49e-38 -0.82 -0.65 Blood protein levels; chr11:117156169 chr11:117135528~117138582:+ LIHC cis rs9326248 0.861 rs4938352 ENSG00000254851.1 RP11-109L13.1 -15.79 1.46e-42 4.49e-38 -0.82 -0.65 Blood protein levels; chr11:117156765 chr11:117135528~117138582:+ LIHC cis rs858239 0.6 rs7776649 ENSG00000230658.1 KLHL7-AS1 15.79 1.49e-42 4.57e-38 0.77 0.65 Cerebrospinal fluid biomarker levels; chr7:23079698 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs6978827 ENSG00000230658.1 KLHL7-AS1 15.78 1.51e-42 4.63e-38 0.76 0.65 Cerebrospinal fluid biomarker levels; chr7:23085925 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs28483572 ENSG00000230658.1 KLHL7-AS1 15.78 1.55e-42 4.74e-38 0.75 0.65 Cerebrospinal fluid biomarker levels; chr7:23092166 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs6961406 ENSG00000230658.1 KLHL7-AS1 15.78 1.55e-42 4.74e-38 0.75 0.65 Cerebrospinal fluid biomarker levels; chr7:23095272 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs6461690 ENSG00000230658.1 KLHL7-AS1 15.78 1.55e-42 4.74e-38 0.75 0.65 Cerebrospinal fluid biomarker levels; chr7:23095915 chr7:23101228~23105703:- LIHC cis rs858239 0.632 rs7811903 ENSG00000230658.1 KLHL7-AS1 15.78 1.57e-42 4.79e-38 0.77 0.65 Cerebrospinal fluid biomarker levels; chr7:23079437 chr7:23101228~23105703:- LIHC cis rs7188445 0.615 rs4340340 ENSG00000261390.4 RP11-345M22.2 -15.78 1.59e-42 4.85e-38 -0.75 -0.65 Urate levels; chr16:79716720 chr16:79715232~79770563:- LIHC cis rs858239 0.6 rs7799422 ENSG00000230658.1 KLHL7-AS1 15.77 1.74e-42 5.3e-38 0.76 0.65 Cerebrospinal fluid biomarker levels; chr7:23088794 chr7:23101228~23105703:- LIHC cis rs2882667 0.69 rs160401 ENSG00000253404.1 AC034243.1 -15.76 1.81e-42 5.49e-38 -0.89 -0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138725652 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs13177415 ENSG00000253404.1 AC034243.1 15.76 1.88e-42 5.67e-38 1.11 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138914251 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs13181762 ENSG00000253404.1 AC034243.1 15.76 1.88e-42 5.67e-38 1.11 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138914417 chr5:138744434~138753309:- LIHC cis rs7188445 0.592 rs17767281 ENSG00000261390.4 RP11-345M22.2 -15.75 2.02e-42 6.07e-38 -0.73 -0.65 Urate levels; chr16:79708544 chr16:79715232~79770563:- LIHC cis rs1577917 0.74 rs9353327 ENSG00000203875.9 SNHG5 -15.74 2.17e-42 6.52e-38 -0.69 -0.65 Response to antipsychotic treatment; chr6:85684348 chr6:85660950~85678736:- LIHC cis rs858239 0.601 rs1034963 ENSG00000230658.1 KLHL7-AS1 15.74 2.18e-42 6.54e-38 0.75 0.65 Cerebrospinal fluid biomarker levels; chr7:23108854 chr7:23101228~23105703:- LIHC cis rs4853012 0.838 rs4452177 ENSG00000217702.2 RP11-287D1.4 15.74 2.36e-42 7.05e-38 0.84 0.65 Gestational age at birth (maternal effect); chr2:74118079 chr2:74130583~74135395:+ LIHC cis rs858239 0.6 rs7789237 ENSG00000230658.1 KLHL7-AS1 15.73 2.42e-42 7.22e-38 0.75 0.65 Cerebrospinal fluid biomarker levels; chr7:23085094 chr7:23101228~23105703:- LIHC cis rs916888 0.773 rs199457 ENSG00000214401.4 KANSL1-AS1 15.73 2.56e-42 7.63e-38 1.2 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:46193576~46196723:+ LIHC cis rs916888 0.687 rs199456 ENSG00000214401.4 KANSL1-AS1 15.73 2.56e-42 7.63e-38 1.2 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:46193576~46196723:+ LIHC cis rs2882667 0.69 rs160400 ENSG00000253404.1 AC034243.1 -15.73 2.56e-42 7.63e-38 -0.96 -0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138727330 chr5:138744434~138753309:- LIHC cis rs916888 0.773 rs199447 ENSG00000214401.4 KANSL1-AS1 15.72 2.78e-42 8.26e-38 1.2 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:46193576~46196723:+ LIHC cis rs9326248 0.652 rs7128382 ENSG00000254851.1 RP11-109L13.1 -15.72 2.8e-42 8.31e-38 -0.82 -0.65 Blood protein levels; chr11:117152771 chr11:117135528~117138582:+ LIHC cis rs9326248 0.861 rs7120309 ENSG00000254851.1 RP11-109L13.1 -15.71 2.92e-42 8.64e-38 -0.83 -0.65 Blood protein levels; chr11:117172100 chr11:117135528~117138582:+ LIHC cis rs9326248 0.861 rs7120449 ENSG00000254851.1 RP11-109L13.1 -15.71 2.92e-42 8.64e-38 -0.83 -0.65 Blood protein levels; chr11:117172183 chr11:117135528~117138582:+ LIHC cis rs2882667 0.598 rs10078179 ENSG00000253404.1 AC034243.1 15.7 3.36e-42 9.89e-38 1.11 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138920410 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs13178601 ENSG00000253404.1 AC034243.1 15.69 3.59e-42 1.06e-37 1.11 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138931688 chr5:138744434~138753309:- LIHC cis rs858239 0.6 rs1468592 ENSG00000230658.1 KLHL7-AS1 -15.69 3.7e-42 1.09e-37 -0.75 -0.65 Cerebrospinal fluid biomarker levels; chr7:23101028 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs28499396 ENSG00000230658.1 KLHL7-AS1 15.68 3.91e-42 1.15e-37 0.75 0.65 Cerebrospinal fluid biomarker levels; chr7:23084479 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs10255228 ENSG00000230658.1 KLHL7-AS1 15.68 3.92e-42 1.15e-37 0.75 0.65 Cerebrospinal fluid biomarker levels; chr7:23119244 chr7:23101228~23105703:- LIHC cis rs916888 0.773 rs1378358 ENSG00000214401.4 KANSL1-AS1 15.68 3.99e-42 1.17e-37 1.2 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:46193576~46196723:+ LIHC cis rs2260433 0.693 rs11225355 ENSG00000281655.1 RP11-817J15.3 15.68 4.08e-42 1.19e-37 0.98 0.65 Cleft palate; chr11:102640430 chr11:102681310~102683913:+ LIHC cis rs2882667 0.654 rs1703211 ENSG00000253404.1 AC034243.1 -15.68 4.08e-42 1.19e-37 -0.96 -0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138740587 chr5:138744434~138753309:- LIHC cis rs858239 0.6 rs9691762 ENSG00000230658.1 KLHL7-AS1 15.67 4.12e-42 1.2e-37 0.75 0.65 Cerebrospinal fluid biomarker levels; chr7:23086303 chr7:23101228~23105703:- LIHC cis rs9326248 0.861 rs7931335 ENSG00000254851.1 RP11-109L13.1 -15.66 4.73e-42 1.37e-37 -0.82 -0.65 Blood protein levels; chr11:117166089 chr11:117135528~117138582:+ LIHC cis rs801193 1 rs2707850 ENSG00000226824.5 RP4-756H11.3 -15.66 4.76e-42 1.37e-37 -0.81 -0.65 Aortic root size; chr7:66738883 chr7:66654538~66669855:+ LIHC cis rs801193 0.967 rs1110414 ENSG00000226824.5 RP4-756H11.3 -15.66 4.76e-42 1.37e-37 -0.81 -0.65 Aortic root size; chr7:66740595 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs7783924 ENSG00000226824.5 RP4-756H11.3 -15.66 4.76e-42 1.37e-37 -0.81 -0.65 Aortic root size; chr7:66744070 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs7789184 ENSG00000226824.5 RP4-756H11.3 -15.66 4.76e-42 1.37e-37 -0.81 -0.65 Aortic root size; chr7:66745208 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs2707854 ENSG00000226824.5 RP4-756H11.3 -15.66 4.76e-42 1.37e-37 -0.81 -0.65 Aortic root size; chr7:66747610 chr7:66654538~66669855:+ LIHC cis rs916888 0.773 rs199439 ENSG00000214401.4 KANSL1-AS1 15.66 4.84e-42 1.39e-37 1.2 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:46193576~46196723:+ LIHC cis rs9326248 0.861 rs4938343 ENSG00000254851.1 RP11-109L13.1 -15.65 5e-42 1.43e-37 -0.84 -0.65 Blood protein levels; chr11:117132812 chr11:117135528~117138582:+ LIHC cis rs2739330 0.791 rs4822458 ENSG00000218537.1 MIF-AS1 15.65 5.13e-42 1.47e-37 0.83 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23894426~23898930:- LIHC cis rs916888 0.773 rs169201 ENSG00000214401.4 KANSL1-AS1 15.65 5.23e-42 1.49e-37 1.2 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:46193576~46196723:+ LIHC cis rs916888 0.773 rs538628 ENSG00000214401.4 KANSL1-AS1 15.65 5.34e-42 1.52e-37 1.2 0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:46193576~46196723:+ LIHC cis rs858239 0.601 rs73272048 ENSG00000230658.1 KLHL7-AS1 15.65 5.35e-42 1.52e-37 0.75 0.65 Cerebrospinal fluid biomarker levels; chr7:23113034 chr7:23101228~23105703:- LIHC cis rs9326248 0.727 rs4938347 ENSG00000254851.1 RP11-109L13.1 -15.64 5.44e-42 1.54e-37 -0.82 -0.65 Blood protein levels; chr11:117151043 chr11:117135528~117138582:+ LIHC cis rs9326248 0.861 rs4938348 ENSG00000254851.1 RP11-109L13.1 -15.64 5.44e-42 1.54e-37 -0.82 -0.65 Blood protein levels; chr11:117151161 chr11:117135528~117138582:+ LIHC cis rs9326248 0.813 rs4938350 ENSG00000254851.1 RP11-109L13.1 -15.64 5.44e-42 1.54e-37 -0.82 -0.65 Blood protein levels; chr11:117151560 chr11:117135528~117138582:+ LIHC cis rs2882667 0.69 rs1651358 ENSG00000253404.1 AC034243.1 -15.64 5.87e-42 1.66e-37 -1.11 -0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138745318 chr5:138744434~138753309:- LIHC cis rs9326248 0.773 rs1060211 ENSG00000254851.1 RP11-109L13.1 -15.63 6.15e-42 1.73e-37 -0.82 -0.65 Blood protein levels; chr11:117169081 chr11:117135528~117138582:+ LIHC cis rs801193 1 rs62466793 ENSG00000226824.5 RP4-756H11.3 -15.62 6.8e-42 1.91e-37 -0.81 -0.65 Aortic root size; chr7:66726530 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs1553610 ENSG00000226824.5 RP4-756H11.3 -15.62 6.8e-42 1.91e-37 -0.81 -0.65 Aortic root size; chr7:66732246 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs2707845 ENSG00000226824.5 RP4-756H11.3 -15.62 6.8e-42 1.91e-37 -0.81 -0.65 Aortic root size; chr7:66733811 chr7:66654538~66669855:+ LIHC cis rs507080 0.961 rs607527 ENSG00000255239.1 AP002954.6 -15.61 7.52e-42 2.11e-37 -0.75 -0.65 Serum metabolite levels; chr11:118667478 chr11:118688039~118690600:- LIHC cis rs916888 0.773 rs199534 ENSG00000214401.4 KANSL1-AS1 15.6 8.3e-42 2.32e-37 1.2 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:46193576~46196723:+ LIHC cis rs801193 1 rs3800812 ENSG00000226824.5 RP4-756H11.3 -15.59 8.8e-42 2.44e-37 -0.81 -0.64 Aortic root size; chr7:66758474 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs4279493 ENSG00000226824.5 RP4-756H11.3 -15.59 8.8e-42 2.44e-37 -0.81 -0.64 Aortic root size; chr7:66761633 chr7:66654538~66669855:+ LIHC cis rs801193 0.761 rs2659888 ENSG00000226824.5 RP4-756H11.3 -15.59 8.8e-42 2.44e-37 -0.81 -0.64 Aortic root size; chr7:66765184 chr7:66654538~66669855:+ LIHC cis rs2882667 0.658 rs172664 ENSG00000253404.1 AC034243.1 15.59 8.92e-42 2.47e-37 0.96 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138720617 chr5:138744434~138753309:- LIHC cis rs5769707 0.967 rs9616701 ENSG00000188511.11 C22orf34 15.59 9.06e-42 2.51e-37 0.74 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49631898 chr22:49414524~49657542:- LIHC cis rs9326248 0.861 rs1871757 ENSG00000254851.1 RP11-109L13.1 -15.59 9.2e-42 2.54e-37 -0.82 -0.64 Blood protein levels; chr11:117159865 chr11:117135528~117138582:+ LIHC cis rs801193 1 rs4717319 ENSG00000226824.5 RP4-756H11.3 -15.58 9.93e-42 2.74e-37 -0.81 -0.64 Aortic root size; chr7:66777606 chr7:66654538~66669855:+ LIHC cis rs801193 0.904 rs4718403 ENSG00000226824.5 RP4-756H11.3 -15.58 9.93e-42 2.74e-37 -0.81 -0.64 Aortic root size; chr7:66777742 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs3778909 ENSG00000226824.5 RP4-756H11.3 -15.58 9.93e-42 2.74e-37 -0.81 -0.64 Aortic root size; chr7:66790659 chr7:66654538~66669855:+ LIHC cis rs2882667 0.69 rs2016720 ENSG00000253404.1 AC034243.1 15.57 1.11e-41 3.06e-37 1.11 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138928369 chr5:138744434~138753309:- LIHC cis rs858239 0.6 rs7776644 ENSG00000230658.1 KLHL7-AS1 15.56 1.14e-41 3.13e-37 0.75 0.64 Cerebrospinal fluid biomarker levels; chr7:23079688 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs10233039 ENSG00000230658.1 KLHL7-AS1 15.56 1.18e-41 3.24e-37 0.81 0.64 Cerebrospinal fluid biomarker levels; chr7:23103494 chr7:23101228~23105703:- LIHC cis rs4853012 0.838 rs60964317 ENSG00000217702.2 RP11-287D1.4 15.55 1.28e-41 3.51e-37 0.85 0.64 Gestational age at birth (maternal effect); chr2:74116296 chr2:74130583~74135395:+ LIHC cis rs858239 0.6 rs10235786 ENSG00000230658.1 KLHL7-AS1 15.55 1.34e-41 3.65e-37 0.81 0.64 Cerebrospinal fluid biomarker levels; chr7:23100321 chr7:23101228~23105703:- LIHC cis rs801193 0.935 rs2659899 ENSG00000226824.5 RP4-756H11.3 -15.54 1.4e-41 3.8e-37 -0.8 -0.64 Aortic root size; chr7:66721734 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs62466794 ENSG00000226824.5 RP4-756H11.3 -15.54 1.4e-41 3.8e-37 -0.8 -0.64 Aortic root size; chr7:66726592 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs1553609 ENSG00000226824.5 RP4-756H11.3 -15.54 1.4e-41 3.8e-37 -0.8 -0.64 Aortic root size; chr7:66732152 chr7:66654538~66669855:+ LIHC cis rs1577917 0.74 rs7752502 ENSG00000203875.9 SNHG5 15.54 1.44e-41 3.91e-37 0.69 0.64 Response to antipsychotic treatment; chr6:85700933 chr6:85660950~85678736:- LIHC cis rs801193 0.904 rs4718405 ENSG00000226824.5 RP4-756H11.3 -15.53 1.56e-41 4.23e-37 -0.82 -0.64 Aortic root size; chr7:66789659 chr7:66654538~66669855:+ LIHC cis rs858239 0.632 rs1985769 ENSG00000230658.1 KLHL7-AS1 15.53 1.58e-41 4.26e-37 0.75 0.64 Cerebrospinal fluid biomarker levels; chr7:23082887 chr7:23101228~23105703:- LIHC cis rs5769707 0.967 rs739248 ENSG00000188511.11 C22orf34 15.51 1.81e-41 4.87e-37 0.73 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49631557 chr22:49414524~49657542:- LIHC cis rs1577917 0.682 rs1173419 ENSG00000203875.9 SNHG5 -15.5 1.95e-41 5.26e-37 -0.68 -0.64 Response to antipsychotic treatment; chr6:85692445 chr6:85660950~85678736:- LIHC cis rs916888 0.773 rs199533 ENSG00000214401.4 KANSL1-AS1 15.49 2.26e-41 6.06e-37 1.19 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:46193576~46196723:+ LIHC cis rs2882667 0.69 rs1059110 ENSG00000253404.1 AC034243.1 15.47 2.61e-41 6.98e-37 1.11 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138930857 chr5:138744434~138753309:- LIHC cis rs801193 0.967 rs2707853 ENSG00000226824.5 RP4-756H11.3 -15.47 2.79e-41 7.44e-37 -0.8 -0.64 Aortic root size; chr7:66749023 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs2659889 ENSG00000226824.5 RP4-756H11.3 -15.47 2.79e-41 7.44e-37 -0.8 -0.64 Aortic root size; chr7:66752125 chr7:66654538~66669855:+ LIHC cis rs916888 0.821 rs70600 ENSG00000214401.4 KANSL1-AS1 15.46 2.97e-41 7.9e-37 1.2 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:46193576~46196723:+ LIHC cis rs2882667 0.728 rs10068766 ENSG00000253404.1 AC034243.1 15.45 3.15e-41 8.36e-37 1.12 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138941095 chr5:138744434~138753309:- LIHC cis rs1577917 0.74 rs2475792 ENSG00000203875.9 SNHG5 15.44 3.43e-41 9.07e-37 0.69 0.64 Response to antipsychotic treatment; chr6:85682384 chr6:85660950~85678736:- LIHC cis rs4853012 0.838 rs72911122 ENSG00000217702.2 RP11-287D1.4 15.43 3.92e-41 1.01e-36 0.84 0.64 Gestational age at birth (maternal effect); chr2:74116992 chr2:74130583~74135395:+ LIHC cis rs4853012 0.838 rs59570457 ENSG00000217702.2 RP11-287D1.4 15.43 3.92e-41 1.01e-36 0.84 0.64 Gestational age at birth (maternal effect); chr2:74117155 chr2:74130583~74135395:+ LIHC cis rs916888 0.779 rs199528 ENSG00000214401.4 KANSL1-AS1 15.43 3.95e-41 1.01e-36 1.21 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:46193576~46196723:+ LIHC cis rs916888 0.821 rs199525 ENSG00000214401.4 KANSL1-AS1 15.43 3.95e-41 1.01e-36 1.21 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:46193576~46196723:+ LIHC cis rs801193 1 rs2420824 ENSG00000226824.5 RP4-756H11.3 15.43 3.99e-41 1.02e-36 0.81 0.64 Aortic root size; chr7:66666129 chr7:66654538~66669855:+ LIHC cis rs858239 0.6 rs13438188 ENSG00000230658.1 KLHL7-AS1 -15.42 4.35e-41 1.11e-36 -0.74 -0.64 Cerebrospinal fluid biomarker levels; chr7:23104578 chr7:23101228~23105703:- LIHC cis rs1577917 0.682 rs1173417 ENSG00000203875.9 SNHG5 15.42 4.41e-41 1.12e-36 0.68 0.64 Response to antipsychotic treatment; chr6:85694223 chr6:85660950~85678736:- LIHC cis rs4853012 0.838 rs6707729 ENSG00000217702.2 RP11-287D1.4 15.41 4.44e-41 1.13e-36 0.84 0.64 Gestational age at birth (maternal effect); chr2:74117558 chr2:74130583~74135395:+ LIHC cis rs5769707 0.967 rs763127 ENSG00000188511.11 C22orf34 15.41 4.7e-41 1.19e-36 0.72 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49612430 chr22:49414524~49657542:- LIHC cis rs858239 0.632 rs13438452 ENSG00000230658.1 KLHL7-AS1 15.41 4.76e-41 1.21e-36 0.75 0.64 Cerebrospinal fluid biomarker levels; chr7:23134563 chr7:23101228~23105703:- LIHC cis rs4853012 0.838 rs60705299 ENSG00000217702.2 RP11-287D1.4 15.41 4.85e-41 1.23e-36 0.83 0.64 Gestational age at birth (maternal effect); chr2:74118243 chr2:74130583~74135395:+ LIHC cis rs2882667 0.654 rs7709770 ENSG00000253404.1 AC034243.1 -15.4 5.11e-41 1.29e-36 -1.15 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138813650 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs9327827 ENSG00000253404.1 AC034243.1 15.4 5.26e-41 1.33e-36 0.98 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138846639 chr5:138744434~138753309:- LIHC cis rs858239 0.601 rs4140959 ENSG00000230658.1 KLHL7-AS1 15.39 5.41e-41 1.36e-36 0.76 0.64 Cerebrospinal fluid biomarker levels; chr7:23131157 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs15775 ENSG00000230658.1 KLHL7-AS1 15.39 5.49e-41 1.38e-36 0.75 0.64 Cerebrospinal fluid biomarker levels; chr7:23125082 chr7:23101228~23105703:- LIHC cis rs2882667 0.622 rs34645817 ENSG00000253404.1 AC034243.1 -15.39 5.72e-41 1.43e-36 -1.15 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138816944 chr5:138744434~138753309:- LIHC cis rs916888 0.773 rs199445 ENSG00000214401.4 KANSL1-AS1 15.38 5.85e-41 1.46e-36 1.18 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:46193576~46196723:+ LIHC cis rs916888 0.773 rs199443 ENSG00000214401.4 KANSL1-AS1 15.38 5.85e-41 1.46e-36 1.18 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:46193576~46196723:+ LIHC cis rs858239 0.6 rs4409314 ENSG00000230658.1 KLHL7-AS1 15.37 6.48e-41 1.61e-36 0.76 0.64 Cerebrospinal fluid biomarker levels; chr7:23088333 chr7:23101228~23105703:- LIHC cis rs801193 1 rs17566701 ENSG00000226824.5 RP4-756H11.3 -15.37 6.75e-41 1.68e-36 -0.8 -0.64 Aortic root size; chr7:66728196 chr7:66654538~66669855:+ LIHC cis rs4853012 0.941 rs7571083 ENSG00000217702.2 RP11-287D1.4 15.37 6.87e-41 1.68e-36 0.84 0.64 Gestational age at birth (maternal effect); chr2:74115133 chr2:74130583~74135395:+ LIHC cis rs4853012 0.793 rs6707619 ENSG00000217702.2 RP11-287D1.4 15.36 7.1e-41 1.73e-36 0.84 0.64 Gestational age at birth (maternal effect); chr2:74117529 chr2:74130583~74135395:+ LIHC cis rs801193 0.967 rs34356500 ENSG00000226824.5 RP4-756H11.3 -15.35 8.04e-41 1.94e-36 -0.81 -0.64 Aortic root size; chr7:66771620 chr7:66654538~66669855:+ LIHC cis rs1577917 0.771 rs7762321 ENSG00000203875.9 SNHG5 15.35 8.23e-41 1.98e-36 0.68 0.64 Response to antipsychotic treatment; chr6:85702428 chr6:85660950~85678736:- LIHC cis rs2739330 0.627 rs9608219 ENSG00000218537.1 MIF-AS1 15.35 8.23e-41 1.98e-36 0.83 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23894426~23898930:- LIHC cis rs4853012 0.941 rs2421752 ENSG00000217702.2 RP11-287D1.4 15.33 9.22e-41 2.2e-36 0.85 0.64 Gestational age at birth (maternal effect); chr2:74114488 chr2:74130583~74135395:+ LIHC cis rs801193 1 rs2659909 ENSG00000226824.5 RP4-756H11.3 -15.32 1.02e-40 2.42e-36 -0.8 -0.64 Aortic root size; chr7:66695292 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs2707856 ENSG00000226824.5 RP4-756H11.3 -15.32 1.07e-40 2.53e-36 -0.8 -0.64 Aortic root size; chr7:66746023 chr7:66654538~66669855:+ LIHC cis rs2739330 0.752 rs2330634 ENSG00000218537.1 MIF-AS1 15.32 1.09e-40 2.57e-36 0.84 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908608 chr22:23894426~23898930:- LIHC cis rs2739330 0.76 rs1002286 ENSG00000272787.1 KB-226F1.2 15.32 1.1e-40 2.6e-36 0.8 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23969211~23969873:+ LIHC cis rs2739330 0.627 rs9608219 ENSG00000272787.1 KB-226F1.2 -15.31 1.19e-40 2.79e-36 -0.8 -0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23969211~23969873:+ LIHC cis rs858239 0.57 rs10271613 ENSG00000230658.1 KLHL7-AS1 15.31 1.19e-40 2.8e-36 0.75 0.64 Cerebrospinal fluid biomarker levels; chr7:23122967 chr7:23101228~23105703:- LIHC cis rs858239 0.57 rs10242166 ENSG00000230658.1 KLHL7-AS1 15.31 1.19e-40 2.8e-36 0.75 0.64 Cerebrospinal fluid biomarker levels; chr7:23123180 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs3735228 ENSG00000230658.1 KLHL7-AS1 15.3 1.27e-40 2.96e-36 0.75 0.64 Cerebrospinal fluid biomarker levels; chr7:23130808 chr7:23101228~23105703:- LIHC cis rs4853012 0.941 rs60291089 ENSG00000217702.2 RP11-287D1.4 15.3 1.27e-40 2.97e-36 0.84 0.64 Gestational age at birth (maternal effect); chr2:74117763 chr2:74130583~74135395:+ LIHC cis rs4853012 0.838 rs58759652 ENSG00000217702.2 RP11-287D1.4 15.3 1.27e-40 2.97e-36 0.84 0.64 Gestational age at birth (maternal effect); chr2:74117775 chr2:74130583~74135395:+ LIHC cis rs801193 1 rs2055682 ENSG00000226824.5 RP4-756H11.3 -15.28 1.46e-40 3.4e-36 -0.8 -0.64 Aortic root size; chr7:66795302 chr7:66654538~66669855:+ LIHC cis rs858239 0.6 rs7341483 ENSG00000230658.1 KLHL7-AS1 -15.28 1.53e-40 3.55e-36 -0.74 -0.64 Cerebrospinal fluid biomarker levels; chr7:23088038 chr7:23101228~23105703:- LIHC cis rs2882667 0.654 rs825760 ENSG00000253404.1 AC034243.1 -15.28 1.58e-40 3.64e-36 -1.14 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138804285 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs160403 ENSG00000253404.1 AC034243.1 15.27 1.72e-40 3.97e-36 0.9 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138722793 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288029 ENSG00000253404.1 AC034243.1 15.27 1.74e-40 4e-36 1.13 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138881616 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288028 ENSG00000253404.1 AC034243.1 15.26 1.87e-40 4.29e-36 1.14 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138886300 chr5:138744434~138753309:- LIHC cis rs4853012 0.838 rs2177707 ENSG00000217702.2 RP11-287D1.4 15.25 1.97e-40 4.52e-36 0.84 0.64 Gestational age at birth (maternal effect); chr2:74129723 chr2:74130583~74135395:+ LIHC cis rs2882667 0.69 rs288021 ENSG00000253404.1 AC034243.1 15.25 2.03e-40 4.59e-36 1.15 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138888594 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288040 ENSG00000253404.1 AC034243.1 15.25 2.03e-40 4.59e-36 1.15 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138869205 chr5:138744434~138753309:- LIHC cis rs2882667 0.659 rs288037 ENSG00000253404.1 AC034243.1 15.25 2.03e-40 4.59e-36 1.15 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138872752 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288035 ENSG00000253404.1 AC034243.1 15.25 2.03e-40 4.59e-36 1.15 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138876728 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288032 ENSG00000253404.1 AC034243.1 15.25 2.03e-40 4.59e-36 1.15 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138879639 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288026 ENSG00000253404.1 AC034243.1 15.25 2.03e-40 4.59e-36 1.15 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138886905 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs6596455 ENSG00000253404.1 AC034243.1 -15.25 2.03e-40 4.59e-36 -1.15 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138831416 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs995177 ENSG00000253404.1 AC034243.1 -15.25 2.03e-40 4.59e-36 -1.15 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138833874 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs7710300 ENSG00000253404.1 AC034243.1 -15.25 2.03e-40 4.59e-36 -1.15 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138834793 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs2351247 ENSG00000253404.1 AC034243.1 -15.25 2.03e-40 4.59e-36 -1.15 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138849456 chr5:138744434~138753309:- LIHC cis rs2882667 0.619 rs6861556 ENSG00000253404.1 AC034243.1 -15.25 2.03e-40 4.59e-36 -1.15 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138852351 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288018 ENSG00000253404.1 AC034243.1 -15.25 2.03e-40 4.59e-36 -1.15 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138856727 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288017 ENSG00000253404.1 AC034243.1 -15.25 2.03e-40 4.59e-36 -1.15 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138857826 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs167009 ENSG00000253404.1 AC034243.1 -15.25 2.03e-40 4.59e-36 -1.15 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138864768 chr5:138744434~138753309:- LIHC cis rs4853012 0.838 rs6715351 ENSG00000217702.2 RP11-287D1.4 15.25 2.05e-40 4.63e-36 0.85 0.64 Gestational age at birth (maternal effect); chr2:74118992 chr2:74130583~74135395:+ LIHC cis rs2739330 0.791 rs9612520 ENSG00000272787.1 KB-226F1.2 -15.24 2.13e-40 4.79e-36 -0.81 -0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23969211~23969873:+ LIHC cis rs2882667 0.69 rs12186373 ENSG00000253404.1 AC034243.1 15.24 2.27e-40 5.11e-36 1.12 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138912885 chr5:138744434~138753309:- LIHC cis rs858239 0.601 rs929507 ENSG00000230658.1 KLHL7-AS1 15.23 2.37e-40 5.21e-36 0.75 0.64 Cerebrospinal fluid biomarker levels; chr7:23127045 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs929508 ENSG00000230658.1 KLHL7-AS1 15.23 2.37e-40 5.21e-36 0.75 0.64 Cerebrospinal fluid biomarker levels; chr7:23127090 chr7:23101228~23105703:- LIHC cis rs858239 0.57 rs6968242 ENSG00000230658.1 KLHL7-AS1 15.23 2.37e-40 5.21e-36 0.75 0.64 Cerebrospinal fluid biomarker levels; chr7:23127792 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs1981665 ENSG00000230658.1 KLHL7-AS1 15.23 2.37e-40 5.21e-36 0.75 0.64 Cerebrospinal fluid biomarker levels; chr7:23128350 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs4599714 ENSG00000230658.1 KLHL7-AS1 15.23 2.37e-40 5.21e-36 0.75 0.64 Cerebrospinal fluid biomarker levels; chr7:23129182 chr7:23101228~23105703:- LIHC cis rs2882667 0.69 rs7736925 ENSG00000253404.1 AC034243.1 -15.23 2.41e-40 5.3e-36 -1.14 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138818841 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs883333 ENSG00000253404.1 AC034243.1 -15.23 2.41e-40 5.3e-36 -1.14 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138819781 chr5:138744434~138753309:- LIHC cis rs5769707 1 rs5769707 ENSG00000188511.11 C22orf34 15.23 2.47e-40 5.41e-36 0.73 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49619754 chr22:49414524~49657542:- LIHC cis rs5769707 0.904 rs7288869 ENSG00000188511.11 C22orf34 15.23 2.47e-40 5.41e-36 0.73 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49621679 chr22:49414524~49657542:- LIHC cis rs801193 1 rs7788576 ENSG00000226824.5 RP4-756H11.3 15.23 2.49e-40 5.43e-36 0.8 0.64 Aortic root size; chr7:66683315 chr7:66654538~66669855:+ LIHC cis rs801193 0.935 rs2659916 ENSG00000226824.5 RP4-756H11.3 -15.23 2.49e-40 5.43e-36 -0.8 -0.64 Aortic root size; chr7:66686365 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs6958520 ENSG00000226824.5 RP4-756H11.3 -15.23 2.49e-40 5.43e-36 -0.8 -0.64 Aortic root size; chr7:66686466 chr7:66654538~66669855:+ LIHC cis rs801193 0.967 rs2707849 ENSG00000226824.5 RP4-756H11.3 -15.23 2.49e-40 5.43e-36 -0.8 -0.64 Aortic root size; chr7:66687725 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs2659912 ENSG00000226824.5 RP4-756H11.3 -15.23 2.49e-40 5.43e-36 -0.8 -0.64 Aortic root size; chr7:66693012 chr7:66654538~66669855:+ LIHC cis rs2882667 0.69 rs10044401 ENSG00000253404.1 AC034243.1 15.22 2.58e-40 5.58e-36 1.12 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138901868 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs10067361 ENSG00000253404.1 AC034243.1 15.22 2.58e-40 5.58e-36 1.12 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138905185 chr5:138744434~138753309:- LIHC cis rs2882667 0.628 rs10076629 ENSG00000253404.1 AC034243.1 15.22 2.58e-40 5.58e-36 1.12 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138920272 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs10078079 ENSG00000253404.1 AC034243.1 15.22 2.58e-40 5.58e-36 1.12 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138920450 chr5:138744434~138753309:- LIHC cis rs2882667 0.659 rs11750067 ENSG00000253404.1 AC034243.1 15.22 2.58e-40 5.58e-36 1.12 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138920589 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs10054682 ENSG00000253404.1 AC034243.1 15.22 2.58e-40 5.58e-36 1.12 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138923754 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs11953339 ENSG00000253404.1 AC034243.1 15.22 2.58e-40 5.58e-36 1.12 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138923853 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs9327828 ENSG00000253404.1 AC034243.1 15.22 2.58e-40 5.58e-36 1.12 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:138925859 chr5:138744434~138753309:- LIHC cis rs875971 0.638 rs7793569 ENSG00000226824.5 RP4-756H11.3 15.22 2.7e-40 5.8e-36 0.8 0.64 Aortic root size; chr7:66651646 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs6975195 ENSG00000226824.5 RP4-756H11.3 15.22 2.7e-40 5.8e-36 0.8 0.64 Aortic root size; chr7:66659787 chr7:66654538~66669855:+ LIHC cis rs2882667 0.654 rs10044432 ENSG00000253404.1 AC034243.1 15.19 3.59e-40 7.69e-36 1.14 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138939207 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs9327829 ENSG00000253404.1 AC034243.1 -15.18 3.66e-40 7.83e-36 -1.09 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138925982 chr5:138744434~138753309:- LIHC cis rs5769707 0.935 rs5770594 ENSG00000188511.11 C22orf34 15.18 3.72e-40 7.95e-36 0.73 0.63 Monocyte percentage of white cells;Monocyte count; chr22:49624849 chr22:49414524~49657542:- LIHC cis rs5769707 0.967 rs4524218 ENSG00000188511.11 C22orf34 15.18 3.73e-40 7.95e-36 0.73 0.63 Monocyte percentage of white cells;Monocyte count; chr22:49624991 chr22:49414524~49657542:- LIHC cis rs5758659 0.714 rs5758574 ENSG00000237037.8 NDUFA6-AS1 -15.18 3.77e-40 8.03e-36 -0.74 -0.63 Cognitive function; chr22:42085396 chr22:42090931~42137742:+ LIHC cis rs801193 1 rs3857688 ENSG00000226824.5 RP4-756H11.3 15.18 3.82e-40 8.1e-36 0.8 0.63 Aortic root size; chr7:66662819 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs2286684 ENSG00000226824.5 RP4-756H11.3 15.18 3.82e-40 8.1e-36 0.8 0.63 Aortic root size; chr7:66664843 chr7:66654538~66669855:+ LIHC cis rs801193 0.935 rs2286683 ENSG00000226824.5 RP4-756H11.3 15.18 3.82e-40 8.1e-36 0.8 0.63 Aortic root size; chr7:66664856 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs10274773 ENSG00000226824.5 RP4-756H11.3 15.18 3.82e-40 8.1e-36 0.8 0.63 Aortic root size; chr7:66668591 chr7:66654538~66669855:+ LIHC cis rs858239 0.601 rs6980224 ENSG00000230658.1 KLHL7-AS1 15.18 3.83e-40 8.12e-36 0.74 0.63 Cerebrospinal fluid biomarker levels; chr7:23109518 chr7:23101228~23105703:- LIHC cis rs2739330 0.828 rs5751770 ENSG00000273295.1 AP000350.5 15.17 4.1e-40 8.68e-36 0.65 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23901432~23907068:- LIHC cis rs2882667 0.69 rs825669 ENSG00000253404.1 AC034243.1 -15.16 4.59e-40 9.69e-36 -0.93 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138731258 chr5:138744434~138753309:- LIHC cis rs5769707 0.967 rs9616327 ENSG00000188511.11 C22orf34 15.15 4.9e-40 1.03e-35 0.72 0.63 Monocyte percentage of white cells;Monocyte count; chr22:49617243 chr22:49414524~49657542:- LIHC cis rs801193 1 rs2003301 ENSG00000226824.5 RP4-756H11.3 15.15 4.99e-40 1.05e-35 0.79 0.63 Aortic root size; chr7:66682669 chr7:66654538~66669855:+ LIHC cis rs801193 0.967 rs2707841 ENSG00000226824.5 RP4-756H11.3 -15.15 4.99e-40 1.05e-35 -0.79 -0.63 Aortic root size; chr7:66692033 chr7:66654538~66669855:+ LIHC cis rs801193 0.935 rs3800820 ENSG00000226824.5 RP4-756H11.3 15.14 5.24e-40 1.1e-35 0.79 0.63 Aortic root size; chr7:66682191 chr7:66654538~66669855:+ LIHC cis rs2882667 0.69 rs10155636 ENSG00000253404.1 AC034243.1 15.14 5.43e-40 1.14e-35 1.11 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138926301 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs10463975 ENSG00000253404.1 AC034243.1 15.14 5.43e-40 1.14e-35 1.11 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138927560 chr5:138744434~138753309:- LIHC cis rs858239 0.6 rs10266123 ENSG00000230658.1 KLHL7-AS1 15.14 5.47e-40 1.15e-35 0.8 0.63 Cerebrospinal fluid biomarker levels; chr7:23096868 chr7:23101228~23105703:- LIHC cis rs2882667 0.69 rs288036 ENSG00000253404.1 AC034243.1 15.14 5.53e-40 1.16e-35 1.14 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138875206 chr5:138744434~138753309:- LIHC cis rs858239 0.601 rs7805206 ENSG00000230658.1 KLHL7-AS1 15.13 5.88e-40 1.23e-35 0.76 0.63 Cerebrospinal fluid biomarker levels; chr7:23120591 chr7:23101228~23105703:- LIHC cis rs4853012 0.838 rs61521879 ENSG00000217702.2 RP11-287D1.4 15.13 5.91e-40 1.23e-35 0.84 0.63 Gestational age at birth (maternal effect); chr2:74119081 chr2:74130583~74135395:+ LIHC cis rs2882667 0.69 rs311601 ENSG00000253404.1 AC034243.1 15.13 6.07e-40 1.27e-35 1.14 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138717697 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs10045605 ENSG00000253404.1 AC034243.1 15.13 6.12e-40 1.27e-35 1.13 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138936458 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs311602 ENSG00000253404.1 AC034243.1 15.12 6.73e-40 1.4e-35 0.96 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138717370 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs930063 ENSG00000253404.1 AC034243.1 15.12 6.73e-40 1.4e-35 0.96 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138717929 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs930062 ENSG00000253404.1 AC034243.1 15.12 6.73e-40 1.4e-35 0.96 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138717934 chr5:138744434~138753309:- LIHC cis rs4853012 0.793 rs6723185 ENSG00000217702.2 RP11-287D1.4 15.11 6.92e-40 1.43e-35 0.83 0.63 Gestational age at birth (maternal effect); chr2:74117757 chr2:74130583~74135395:+ LIHC cis rs858239 0.601 rs987257 ENSG00000230658.1 KLHL7-AS1 15.11 7.12e-40 1.47e-35 0.74 0.63 Cerebrospinal fluid biomarker levels; chr7:23108221 chr7:23101228~23105703:- LIHC cis rs5758659 0.714 rs2413668 ENSG00000237037.8 NDUFA6-AS1 -15.11 7.18e-40 1.48e-35 -0.73 -0.63 Cognitive function; chr22:42109837 chr22:42090931~42137742:+ LIHC cis rs801193 1 rs7785213 ENSG00000226824.5 RP4-756H11.3 15.1 7.56e-40 1.56e-35 0.79 0.63 Aortic root size; chr7:66673991 chr7:66654538~66669855:+ LIHC cis rs4853012 0.838 rs4429500 ENSG00000217702.2 RP11-287D1.4 15.1 8.06e-40 1.66e-35 0.83 0.63 Gestational age at birth (maternal effect); chr2:74118209 chr2:74130583~74135395:+ LIHC cis rs2882667 0.69 rs700619 ENSG00000253404.1 AC034243.1 -15.09 8.32e-40 1.69e-35 -1.13 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138753060 chr5:138744434~138753309:- LIHC cis rs2882667 0.652 rs700622 ENSG00000253404.1 AC034243.1 -15.09 8.32e-40 1.69e-35 -1.13 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138762862 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs7722965 ENSG00000253404.1 AC034243.1 -15.09 8.32e-40 1.69e-35 -1.13 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138764766 chr5:138744434~138753309:- LIHC cis rs2882667 0.587 rs825674 ENSG00000253404.1 AC034243.1 -15.09 8.32e-40 1.69e-35 -1.13 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138767031 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs1976562 ENSG00000253404.1 AC034243.1 -15.09 8.32e-40 1.69e-35 -1.13 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138774905 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs825759 ENSG00000253404.1 AC034243.1 -15.09 8.32e-40 1.69e-35 -1.13 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138790250 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288024 ENSG00000253404.1 AC034243.1 15.09 8.37e-40 1.7e-35 1.14 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138888103 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs4835703 ENSG00000253404.1 AC034243.1 -15.09 8.39e-40 1.7e-35 -1.14 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138815048 chr5:138744434~138753309:- LIHC cis rs2882667 0.654 rs4835704 ENSG00000253404.1 AC034243.1 -15.09 8.39e-40 1.7e-35 -1.14 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138815636 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs6596453 ENSG00000253404.1 AC034243.1 -15.09 8.39e-40 1.7e-35 -1.14 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138816202 chr5:138744434~138753309:- LIHC cis rs2260433 0.624 rs10895331 ENSG00000281655.1 RP11-817J15.3 15.09 8.56e-40 1.73e-35 0.98 0.63 Cleft palate; chr11:102641005 chr11:102681310~102683913:+ LIHC cis rs9326248 0.813 rs474488 ENSG00000254851.1 RP11-109L13.1 -15.09 8.62e-40 1.74e-35 -0.81 -0.63 Blood protein levels; chr11:117198261 chr11:117135528~117138582:+ LIHC cis rs916888 0.697 rs199516 ENSG00000214401.4 KANSL1-AS1 -15.09 8.68e-40 1.74e-35 -1.16 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:46193576~46196723:+ LIHC cis rs916888 0.821 rs199514 ENSG00000214401.4 KANSL1-AS1 -15.09 8.68e-40 1.74e-35 -1.16 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:46193576~46196723:+ LIHC cis rs916888 0.821 rs199512 ENSG00000214401.4 KANSL1-AS1 -15.09 8.68e-40 1.74e-35 -1.16 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:46193576~46196723:+ LIHC cis rs916888 0.821 rs199509 ENSG00000214401.4 KANSL1-AS1 -15.09 8.68e-40 1.74e-35 -1.16 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:46193576~46196723:+ LIHC cis rs916888 0.821 rs199507 ENSG00000214401.4 KANSL1-AS1 -15.09 8.68e-40 1.74e-35 -1.16 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:46193576~46196723:+ LIHC cis rs916888 0.821 rs415430 ENSG00000214401.4 KANSL1-AS1 -15.09 8.68e-40 1.74e-35 -1.16 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:46193576~46196723:+ LIHC cis rs916888 0.779 rs430685 ENSG00000214401.4 KANSL1-AS1 -15.09 8.68e-40 1.74e-35 -1.16 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:46193576~46196723:+ LIHC cis rs916888 0.821 rs199505 ENSG00000214401.4 KANSL1-AS1 -15.09 8.68e-40 1.74e-35 -1.16 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:46193576~46196723:+ LIHC cis rs916888 0.821 rs70602 ENSG00000214401.4 KANSL1-AS1 -15.09 8.68e-40 1.74e-35 -1.16 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:46193576~46196723:+ LIHC cis rs5758659 0.714 rs133373 ENSG00000237037.8 NDUFA6-AS1 15.08 9.01e-40 1.8e-35 0.73 0.63 Cognitive function; chr22:42069784 chr22:42090931~42137742:+ LIHC cis rs801193 1 rs2707836 ENSG00000226824.5 RP4-756H11.3 -15.08 9.1e-40 1.81e-35 -0.8 -0.63 Aortic root size; chr7:66695448 chr7:66654538~66669855:+ LIHC cis rs801193 0.844 rs7779971 ENSG00000226824.5 RP4-756H11.3 -15.08 9.1e-40 1.81e-35 -0.8 -0.63 Aortic root size; chr7:66696803 chr7:66654538~66669855:+ LIHC cis rs801193 1 rs2659906 ENSG00000226824.5 RP4-756H11.3 -15.08 9.1e-40 1.81e-35 -0.8 -0.63 Aortic root size; chr7:66700323 chr7:66654538~66669855:+ LIHC cis rs2739330 0.753 rs4822452 ENSG00000218537.1 MIF-AS1 15.08 9.61e-40 1.91e-35 0.84 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23894426~23898930:- LIHC cis rs858239 0.632 rs6952947 ENSG00000230658.1 KLHL7-AS1 -15.06 1.08e-39 2.14e-35 -0.73 -0.63 Cerebrospinal fluid biomarker levels; chr7:23081423 chr7:23101228~23105703:- LIHC cis rs2882667 0.69 rs11954103 ENSG00000253404.1 AC034243.1 15.06 1.1e-39 2.17e-35 1.13 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138933459 chr5:138744434~138753309:- LIHC cis rs801193 0.935 rs11772264 ENSG00000226824.5 RP4-756H11.3 -15.06 1.11e-39 2.19e-35 -0.8 -0.63 Aortic root size; chr7:66711400 chr7:66654538~66669855:+ LIHC cis rs858239 0.6 rs61292332 ENSG00000230658.1 KLHL7-AS1 15.05 1.2e-39 2.36e-35 0.74 0.63 Cerebrospinal fluid biomarker levels; chr7:23092243 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs59073109 ENSG00000230658.1 KLHL7-AS1 15.05 1.2e-39 2.36e-35 0.74 0.63 Cerebrospinal fluid biomarker levels; chr7:23093607 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs7788821 ENSG00000230658.1 KLHL7-AS1 15.05 1.2e-39 2.36e-35 0.74 0.63 Cerebrospinal fluid biomarker levels; chr7:23094026 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs6956595 ENSG00000230658.1 KLHL7-AS1 15.05 1.2e-39 2.36e-35 0.74 0.63 Cerebrospinal fluid biomarker levels; chr7:23094637 chr7:23101228~23105703:- LIHC cis rs801193 0.967 rs2420827 ENSG00000226824.5 RP4-756H11.3 15.05 1.22e-39 2.41e-35 0.79 0.63 Aortic root size; chr7:66682114 chr7:66654538~66669855:+ LIHC cis rs4853012 0.887 rs77148265 ENSG00000217702.2 RP11-287D1.4 15.05 1.24e-39 2.43e-35 0.85 0.63 Gestational age at birth (maternal effect); chr2:74112392 chr2:74130583~74135395:+ LIHC cis rs858239 0.6 rs2072368 ENSG00000230658.1 KLHL7-AS1 15.05 1.25e-39 2.46e-35 0.74 0.63 Cerebrospinal fluid biomarker levels; chr7:23106493 chr7:23101228~23105703:- LIHC cis rs9326248 0.813 rs588534 ENSG00000254851.1 RP11-109L13.1 -15.05 1.26e-39 2.46e-35 -0.8 -0.63 Blood protein levels; chr11:117197788 chr11:117135528~117138582:+ LIHC cis rs2260433 0.693 rs1940061 ENSG00000281655.1 RP11-817J15.3 15.04 1.35e-39 2.64e-35 0.95 0.63 Cleft palate; chr11:102639722 chr11:102681310~102683913:+ LIHC cis rs858239 0.6 rs4321896 ENSG00000230658.1 KLHL7-AS1 15.04 1.38e-39 2.7e-35 0.74 0.63 Cerebrospinal fluid biomarker levels; chr7:23088437 chr7:23101228~23105703:- LIHC cis rs858239 0.57 rs10235467 ENSG00000230658.1 KLHL7-AS1 15.03 1.44e-39 2.81e-35 0.73 0.63 Cerebrospinal fluid biomarker levels; chr7:23109189 chr7:23101228~23105703:- LIHC cis rs801193 1 rs11773829 ENSG00000226824.5 RP4-756H11.3 15.03 1.49e-39 2.9e-35 0.79 0.63 Aortic root size; chr7:66676087 chr7:66654538~66669855:+ LIHC cis rs916888 0.821 rs199504 ENSG00000214401.4 KANSL1-AS1 -15.02 1.57e-39 3.05e-35 -1.17 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:46193576~46196723:+ LIHC cis rs2882667 0.628 rs311605 ENSG00000253404.1 AC034243.1 15.02 1.58e-39 3.06e-35 0.92 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138710150 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288009 ENSG00000253404.1 AC034243.1 15.02 1.68e-39 3.26e-35 1.12 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138892973 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs185956 ENSG00000253404.1 AC034243.1 15.02 1.68e-39 3.26e-35 1.12 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138894574 chr5:138744434~138753309:- LIHC cis rs2882667 0.658 rs288003 ENSG00000253404.1 AC034243.1 15.02 1.68e-39 3.26e-35 1.12 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138896266 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs288002 ENSG00000253404.1 AC034243.1 15.02 1.68e-39 3.26e-35 1.12 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138896398 chr5:138744434~138753309:- LIHC cis rs801193 1 rs4717310 ENSG00000226824.5 RP4-756H11.3 -15.01 1.75e-39 3.38e-35 -0.79 -0.63 Aortic root size; chr7:66696020 chr7:66654538~66669855:+ LIHC cis rs2739330 0.791 rs9612520 ENSG00000218537.1 MIF-AS1 15.01 1.79e-39 3.46e-35 0.83 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23894426~23898930:- LIHC cis rs4853012 0.887 rs6737314 ENSG00000217702.2 RP11-287D1.4 15.01 1.81e-39 3.5e-35 0.85 0.63 Gestational age at birth (maternal effect); chr2:74112459 chr2:74130583~74135395:+ LIHC cis rs801193 0.967 rs3800823 ENSG00000226824.5 RP4-756H11.3 15 1.86e-39 3.59e-35 0.79 0.63 Aortic root size; chr7:66682123 chr7:66654538~66669855:+ LIHC cis rs858239 0.6 rs6461692 ENSG00000230658.1 KLHL7-AS1 15 1.88e-39 3.61e-35 0.73 0.63 Cerebrospinal fluid biomarker levels; chr7:23100076 chr7:23101228~23105703:- LIHC cis rs2882667 0.728 rs10068786 ENSG00000253404.1 AC034243.1 15 1.93e-39 3.72e-35 1.12 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138941255 chr5:138744434~138753309:- LIHC cis rs801193 1 rs7782320 ENSG00000226824.5 RP4-756H11.3 -14.99 2.1e-39 4.04e-35 -0.79 -0.63 Aortic root size; chr7:66712111 chr7:66654538~66669855:+ LIHC cis rs2260433 0.624 rs11225353 ENSG00000281655.1 RP11-817J15.3 14.99 2.16e-39 4.15e-35 1 0.63 Cleft palate; chr11:102639104 chr11:102681310~102683913:+ LIHC cis rs5769707 0.967 rs5770585 ENSG00000188511.11 C22orf34 14.98 2.27e-39 4.35e-35 0.72 0.63 Monocyte percentage of white cells;Monocyte count; chr22:49614226 chr22:49414524~49657542:- LIHC cis rs858239 0.6 rs10241208 ENSG00000230658.1 KLHL7-AS1 14.98 2.31e-39 4.42e-35 0.8 0.63 Cerebrospinal fluid biomarker levels; chr7:23105295 chr7:23101228~23105703:- LIHC cis rs5769707 0.967 rs2071904 ENSG00000188511.11 C22orf34 14.97 2.47e-39 4.72e-35 0.73 0.63 Monocyte percentage of white cells;Monocyte count; chr22:49640829 chr22:49414524~49657542:- LIHC cis rs875971 0.66 rs2013222 ENSG00000226824.5 RP4-756H11.3 14.97 2.59e-39 4.93e-35 0.78 0.63 Aortic root size; chr7:66570949 chr7:66654538~66669855:+ LIHC cis rs5758659 0.714 rs2284087 ENSG00000237037.8 NDUFA6-AS1 -14.96 2.74e-39 5.22e-35 -0.73 -0.63 Cognitive function; chr22:42089667 chr22:42090931~42137742:+ LIHC cis rs6597981 0.592 rs10902218 ENSG00000279672.1 CMB9-55F22.1 -14.96 2.84e-39 5.39e-35 -0.66 -0.63 Breast cancer; chr11:743813 chr11:779617~780755:+ LIHC cis rs858239 0.539 rs6971673 ENSG00000230658.1 KLHL7-AS1 14.96 2.9e-39 5.5e-35 0.73 0.63 Cerebrospinal fluid biomarker levels; chr7:23119904 chr7:23101228~23105703:- LIHC cis rs9326248 0.581 rs10892076 ENSG00000254851.1 RP11-109L13.1 -14.95 3e-39 5.67e-35 -0.79 -0.63 Blood protein levels; chr11:117118220 chr11:117135528~117138582:+ LIHC cis rs5758659 0.657 rs5758587 ENSG00000237037.8 NDUFA6-AS1 -14.95 3.07e-39 5.8e-35 -0.73 -0.63 Cognitive function; chr22:42121632 chr22:42090931~42137742:+ LIHC cis rs507080 0.769 rs7389 ENSG00000255239.1 AP002954.6 -14.94 3.21e-39 6.06e-35 -0.74 -0.63 Serum metabolite levels; chr11:118657756 chr11:118688039~118690600:- LIHC cis rs858239 0.6 rs4628176 ENSG00000230658.1 KLHL7-AS1 14.94 3.39e-39 6.39e-35 0.8 0.63 Cerebrospinal fluid biomarker levels; chr7:23102947 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs10488077 ENSG00000230658.1 KLHL7-AS1 14.94 3.39e-39 6.39e-35 0.8 0.63 Cerebrospinal fluid biomarker levels; chr7:23104563 chr7:23101228~23105703:- LIHC cis rs5769707 0.846 rs5770610 ENSG00000188511.11 C22orf34 14.94 3.48e-39 6.55e-35 0.73 0.63 Monocyte percentage of white cells;Monocyte count; chr22:49643249 chr22:49414524~49657542:- LIHC cis rs2260433 0.693 rs10895329 ENSG00000281655.1 RP11-817J15.3 14.93 3.54e-39 6.64e-35 0.95 0.63 Cleft palate; chr11:102638497 chr11:102681310~102683913:+ LIHC cis rs2260433 0.693 rs10895330 ENSG00000281655.1 RP11-817J15.3 14.93 3.54e-39 6.64e-35 0.95 0.63 Cleft palate; chr11:102638544 chr11:102681310~102683913:+ LIHC cis rs2882667 0.69 rs825677 ENSG00000253404.1 AC034243.1 -14.93 3.82e-39 7.16e-35 -1.11 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138769081 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs11749163 ENSG00000253404.1 AC034243.1 14.9 4.66e-39 8.71e-35 1.1 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138926981 chr5:138744434~138753309:- LIHC cis rs858239 0.601 rs1558313 ENSG00000230658.1 KLHL7-AS1 14.89 5.07e-39 9.43e-35 0.73 0.63 Cerebrospinal fluid biomarker levels; chr7:23116460 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs6962526 ENSG00000230658.1 KLHL7-AS1 14.89 5.07e-39 9.43e-35 0.73 0.63 Cerebrospinal fluid biomarker levels; chr7:23118614 chr7:23101228~23105703:- LIHC cis rs2260433 0.693 rs12363883 ENSG00000281655.1 RP11-817J15.3 14.88 5.61e-39 1.04e-34 0.94 0.63 Cleft palate; chr11:102638621 chr11:102681310~102683913:+ LIHC cis rs2260433 0.693 rs12363884 ENSG00000281655.1 RP11-817J15.3 14.88 5.61e-39 1.04e-34 0.94 0.63 Cleft palate; chr11:102638629 chr11:102681310~102683913:+ LIHC cis rs2739330 0.753 rs4822452 ENSG00000273295.1 AP000350.5 14.87 6.19e-39 1.14e-34 0.67 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23901432~23907068:- LIHC cis rs858239 0.601 rs11984129 ENSG00000230658.1 KLHL7-AS1 14.86 7.12e-39 1.31e-34 0.73 0.63 Cerebrospinal fluid biomarker levels; chr7:23113058 chr7:23101228~23105703:- LIHC cis rs5758659 0.714 rs5758578 ENSG00000237037.8 NDUFA6-AS1 -14.84 8e-39 1.46e-34 -0.72 -0.63 Cognitive function; chr22:42094288 chr22:42090931~42137742:+ LIHC cis rs858239 0.601 rs10278776 ENSG00000230658.1 KLHL7-AS1 14.83 8.72e-39 1.59e-34 0.74 0.63 Cerebrospinal fluid biomarker levels; chr7:23130140 chr7:23101228~23105703:- LIHC cis rs858239 0.6 rs6461691 ENSG00000230658.1 KLHL7-AS1 14.83 8.89e-39 1.62e-34 0.79 0.63 Cerebrospinal fluid biomarker levels; chr7:23099726 chr7:23101228~23105703:- LIHC cis rs5769707 0.967 rs8141807 ENSG00000188511.11 C22orf34 14.83 8.96e-39 1.63e-34 0.73 0.63 Monocyte percentage of white cells;Monocyte count; chr22:49650090 chr22:49414524~49657542:- LIHC cis rs2882667 0.69 rs825672 ENSG00000253404.1 AC034243.1 -14.82 9.54e-39 1.73e-34 -1.1 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138759954 chr5:138744434~138753309:- LIHC cis rs2882667 0.628 rs311607 ENSG00000253404.1 AC034243.1 14.82 1.03e-38 1.87e-34 0.91 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138709231 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs17031 ENSG00000253404.1 AC034243.1 14.82 1.03e-38 1.87e-34 1.11 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138934853 chr5:138744434~138753309:- LIHC cis rs5769707 0.967 rs1018812 ENSG00000188511.11 C22orf34 14.81 1.12e-38 2.03e-34 0.71 0.63 Monocyte percentage of white cells;Monocyte count; chr22:49616425 chr22:49414524~49657542:- LIHC cis rs7188445 0.614 rs62043313 ENSG00000261390.4 RP11-345M22.2 -14.8 1.14e-38 2.07e-34 -0.71 -0.62 Urate levels; chr16:79710237 chr16:79715232~79770563:- LIHC cis rs507080 0.769 rs745663 ENSG00000255239.1 AP002954.6 14.8 1.19e-38 2.15e-34 0.74 0.62 Serum metabolite levels; chr11:118658886 chr11:118688039~118690600:- LIHC cis rs2739330 0.828 rs2877178 ENSG00000273295.1 AP000350.5 14.8 1.19e-38 2.15e-34 0.65 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23901432~23907068:- LIHC cis rs5769707 0.967 rs2051626 ENSG00000188511.11 C22orf34 14.79 1.34e-38 2.41e-34 0.71 0.62 Monocyte percentage of white cells;Monocyte count; chr22:49615325 chr22:49414524~49657542:- LIHC cis rs858239 0.601 rs764533 ENSG00000230658.1 KLHL7-AS1 14.79 1.35e-38 2.43e-34 0.73 0.62 Cerebrospinal fluid biomarker levels; chr7:23114256 chr7:23101228~23105703:- LIHC cis rs2739330 0.828 rs5760108 ENSG00000273295.1 AP000350.5 14.78 1.4e-38 2.53e-34 0.65 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23901432~23907068:- LIHC cis rs2260433 0.693 rs11225351 ENSG00000281655.1 RP11-817J15.3 -14.78 1.42e-38 2.54e-34 -0.93 -0.62 Cleft palate; chr11:102637740 chr11:102681310~102683913:+ LIHC cis rs2739330 0.828 rs2154593 ENSG00000273295.1 AP000350.5 14.78 1.43e-38 2.57e-34 0.65 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23901432~23907068:- LIHC cis rs916888 0.821 rs199506 ENSG00000214401.4 KANSL1-AS1 -14.78 1.44e-38 2.57e-34 -1.15 -0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:46193576~46196723:+ LIHC cis rs2260433 0.693 rs11225352 ENSG00000281655.1 RP11-817J15.3 14.78 1.47e-38 2.63e-34 0.94 0.62 Cleft palate; chr11:102637990 chr11:102681310~102683913:+ LIHC cis rs1577917 0.883 rs2782263 ENSG00000203875.9 SNHG5 -14.77 1.6e-38 2.87e-34 -0.7 -0.62 Response to antipsychotic treatment; chr6:86081589 chr6:85660950~85678736:- LIHC cis rs858239 0.601 rs6461693 ENSG00000230658.1 KLHL7-AS1 -14.77 1.63e-38 2.91e-34 -0.73 -0.62 Cerebrospinal fluid biomarker levels; chr7:23120514 chr7:23101228~23105703:- LIHC cis rs4853012 0.775 rs12465641 ENSG00000217702.2 RP11-287D1.4 -14.76 1.67e-38 2.99e-34 -0.83 -0.62 Gestational age at birth (maternal effect); chr2:74110588 chr2:74130583~74135395:+ LIHC cis rs875971 0.66 rs12698534 ENSG00000226824.5 RP4-756H11.3 -14.76 1.72e-38 3.04e-34 -0.77 -0.62 Aortic root size; chr7:66521858 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs62465434 ENSG00000226824.5 RP4-756H11.3 -14.76 1.72e-38 3.04e-34 -0.77 -0.62 Aortic root size; chr7:66540165 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs13224319 ENSG00000226824.5 RP4-756H11.3 -14.76 1.72e-38 3.04e-34 -0.77 -0.62 Aortic root size; chr7:66542376 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs801217 ENSG00000226824.5 RP4-756H11.3 14.76 1.72e-38 3.04e-34 0.77 0.62 Aortic root size; chr7:66545590 chr7:66654538~66669855:+ LIHC cis rs875971 0.638 rs801216 ENSG00000226824.5 RP4-756H11.3 14.76 1.72e-38 3.04e-34 0.77 0.62 Aortic root size; chr7:66546680 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs801211 ENSG00000226824.5 RP4-756H11.3 14.76 1.72e-38 3.04e-34 0.77 0.62 Aortic root size; chr7:66550702 chr7:66654538~66669855:+ LIHC cis rs875971 0.638 rs801205 ENSG00000226824.5 RP4-756H11.3 14.76 1.72e-38 3.04e-34 0.77 0.62 Aortic root size; chr7:66557157 chr7:66654538~66669855:+ LIHC cis rs875971 0.617 rs810400 ENSG00000226824.5 RP4-756H11.3 14.76 1.72e-38 3.04e-34 0.77 0.62 Aortic root size; chr7:66557902 chr7:66654538~66669855:+ LIHC cis rs875971 0.638 rs3898855 ENSG00000226824.5 RP4-756H11.3 14.76 1.72e-38 3.04e-34 0.77 0.62 Aortic root size; chr7:66571411 chr7:66654538~66669855:+ LIHC cis rs875971 0.638 rs10278816 ENSG00000226824.5 RP4-756H11.3 14.76 1.72e-38 3.04e-34 0.77 0.62 Aortic root size; chr7:66572000 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs10281080 ENSG00000226824.5 RP4-756H11.3 14.76 1.72e-38 3.04e-34 0.77 0.62 Aortic root size; chr7:66577454 chr7:66654538~66669855:+ LIHC cis rs2260433 0.693 rs11225350 ENSG00000281655.1 RP11-817J15.3 14.76 1.75e-38 3.09e-34 0.94 0.62 Cleft palate; chr11:102637649 chr11:102681310~102683913:+ LIHC cis rs2739330 0.828 rs2186366 ENSG00000218537.1 MIF-AS1 -14.74 2.11e-38 3.71e-34 -0.83 -0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23894426~23898930:- LIHC cis rs5769707 0.967 rs9616713 ENSG00000188511.11 C22orf34 14.72 2.45e-38 4.29e-34 0.73 0.62 Monocyte percentage of white cells;Monocyte count; chr22:49655461 chr22:49414524~49657542:- LIHC cis rs875971 0.619 rs2302918 ENSG00000226824.5 RP4-756H11.3 -14.72 2.56e-38 4.49e-34 -0.77 -0.62 Aortic root size; chr7:66535945 chr7:66654538~66669855:+ LIHC cis rs858239 0.601 rs10239760 ENSG00000230658.1 KLHL7-AS1 14.71 2.6e-38 4.54e-34 0.79 0.62 Cerebrospinal fluid biomarker levels; chr7:23110331 chr7:23101228~23105703:- LIHC cis rs875971 0.619 rs12533585 ENSG00000226824.5 RP4-756H11.3 -14.71 2.65e-38 4.62e-34 -0.77 -0.62 Aortic root size; chr7:66519618 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs28698552 ENSG00000226824.5 RP4-756H11.3 -14.71 2.65e-38 4.62e-34 -0.77 -0.62 Aortic root size; chr7:66540031 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs801192 ENSG00000226824.5 RP4-756H11.3 14.71 2.65e-38 4.62e-34 0.77 0.62 Aortic root size; chr7:66566965 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs801190 ENSG00000226824.5 RP4-756H11.3 14.71 2.65e-38 4.62e-34 0.77 0.62 Aortic root size; chr7:66568046 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs3857686 ENSG00000226824.5 RP4-756H11.3 14.71 2.65e-38 4.62e-34 0.77 0.62 Aortic root size; chr7:66571204 chr7:66654538~66669855:+ LIHC cis rs2882667 0.69 rs288007 ENSG00000253404.1 AC034243.1 14.71 2.72e-38 4.73e-34 1.11 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:138894939 chr5:138744434~138753309:- LIHC cis rs5758659 0.714 rs5758589 ENSG00000237037.8 NDUFA6-AS1 -14.7 2.85e-38 4.92e-34 -0.72 -0.62 Cognitive function; chr22:42122378 chr22:42090931~42137742:+ LIHC cis rs5769707 0.935 rs9616332 ENSG00000188511.11 C22orf34 14.7 3.03e-38 5.22e-34 0.72 0.62 Monocyte percentage of white cells;Monocyte count; chr22:49654030 chr22:49414524~49657542:- LIHC cis rs2739330 0.76 rs1002286 ENSG00000273295.1 AP000350.5 -14.69 3.13e-38 5.37e-34 -0.65 -0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23901432~23907068:- LIHC cis rs5758659 0.714 rs133376 ENSG00000237037.8 NDUFA6-AS1 14.66 4.41e-38 7.52e-34 0.73 0.62 Cognitive function; chr22:42070901 chr22:42090931~42137742:+ LIHC cis rs858239 0.601 rs10278700 ENSG00000230658.1 KLHL7-AS1 14.65 4.44e-38 7.57e-34 0.73 0.62 Cerebrospinal fluid biomarker levels; chr7:23120910 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs10263110 ENSG00000230658.1 KLHL7-AS1 14.65 4.44e-38 7.57e-34 0.73 0.62 Cerebrospinal fluid biomarker levels; chr7:23120932 chr7:23101228~23105703:- LIHC cis rs875971 0.638 rs6960778 ENSG00000226824.5 RP4-756H11.3 14.65 4.71e-38 8e-34 0.78 0.62 Aortic root size; chr7:66606610 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs7807930 ENSG00000226824.5 RP4-756H11.3 14.65 4.71e-38 8e-34 0.78 0.62 Aortic root size; chr7:66622178 chr7:66654538~66669855:+ LIHC cis rs1577917 0.958 rs12192033 ENSG00000203875.9 SNHG5 -14.63 5.5e-38 9.31e-34 -0.67 -0.62 Response to antipsychotic treatment; chr6:85762841 chr6:85660950~85678736:- LIHC cis rs858239 0.601 rs6948469 ENSG00000230658.1 KLHL7-AS1 14.61 6.66e-38 1.12e-33 0.73 0.62 Cerebrospinal fluid biomarker levels; chr7:23135147 chr7:23101228~23105703:- LIHC cis rs2882667 0.628 rs13171173 ENSG00000253404.1 AC034243.1 -14.6 7.54e-38 1.27e-33 -1.1 -0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:138706775 chr5:138744434~138753309:- LIHC cis rs858239 0.601 rs2068459 ENSG00000230658.1 KLHL7-AS1 14.59 7.66e-38 1.28e-33 0.8 0.62 Cerebrospinal fluid biomarker levels; chr7:23114694 chr7:23101228~23105703:- LIHC cis rs4853012 0.941 rs78128123 ENSG00000217702.2 RP11-287D1.4 14.59 7.93e-38 1.33e-33 0.84 0.62 Gestational age at birth (maternal effect); chr2:74120398 chr2:74130583~74135395:+ LIHC cis rs858239 0.601 rs11982002 ENSG00000230658.1 KLHL7-AS1 14.58 8.39e-38 1.4e-33 0.73 0.62 Cerebrospinal fluid biomarker levels; chr7:23123651 chr7:23101228~23105703:- LIHC cis rs875971 0.66 rs79009421 ENSG00000226824.5 RP4-756H11.3 14.58 9.03e-38 1.5e-33 0.77 0.62 Aortic root size; chr7:66603522 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs6460308 ENSG00000226824.5 RP4-756H11.3 14.58 9.03e-38 1.5e-33 0.77 0.62 Aortic root size; chr7:66619753 chr7:66654538~66669855:+ LIHC cis rs916888 0.773 rs199535 ENSG00000214401.4 KANSL1-AS1 14.57 9.74e-38 1.61e-33 1.16 0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:46193576~46196723:+ LIHC cis rs5758659 0.714 rs5751216 ENSG00000237037.8 NDUFA6-AS1 -14.57 9.88e-38 1.63e-33 -0.72 -0.62 Cognitive function; chr22:42112933 chr22:42090931~42137742:+ LIHC cis rs1577917 0.958 rs13207173 ENSG00000203875.9 SNHG5 -14.56 1.04e-37 1.72e-33 -0.67 -0.62 Response to antipsychotic treatment; chr6:85747804 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs34795473 ENSG00000203875.9 SNHG5 -14.56 1.04e-37 1.72e-33 -0.67 -0.62 Response to antipsychotic treatment; chr6:85752081 chr6:85660950~85678736:- LIHC cis rs858239 0.669 rs12539467 ENSG00000230658.1 KLHL7-AS1 14.54 1.24e-37 2.03e-33 0.79 0.62 Cerebrospinal fluid biomarker levels; chr7:23076240 chr7:23101228~23105703:- LIHC cis rs858239 0.571 rs6953020 ENSG00000230658.1 KLHL7-AS1 14.54 1.3e-37 2.13e-33 0.72 0.62 Cerebrospinal fluid biomarker levels; chr7:23132513 chr7:23101228~23105703:- LIHC cis rs875971 0.66 rs7807944 ENSG00000226824.5 RP4-756H11.3 14.53 1.34e-37 2.19e-33 0.77 0.62 Aortic root size; chr7:66622208 chr7:66654538~66669855:+ LIHC cis rs858239 0.541 rs4624924 ENSG00000230658.1 KLHL7-AS1 14.52 1.57e-37 2.56e-33 0.72 0.62 Cerebrospinal fluid biomarker levels; chr7:23129224 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs12539331 ENSG00000230658.1 KLHL7-AS1 14.51 1.64e-37 2.67e-33 0.79 0.62 Cerebrospinal fluid biomarker levels; chr7:23111711 chr7:23101228~23105703:- LIHC cis rs875971 0.66 rs3764903 ENSG00000226824.5 RP4-756H11.3 14.51 1.67e-37 2.72e-33 0.77 0.62 Aortic root size; chr7:66633495 chr7:66654538~66669855:+ LIHC cis rs2739330 0.734 rs2000467 ENSG00000272787.1 KB-226F1.2 14.51 1.7e-37 2.77e-33 0.79 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23969211~23969873:+ LIHC cis rs2882667 0.628 rs311606 ENSG00000253404.1 AC034243.1 14.5 1.72e-37 2.81e-33 0.94 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:138709551 chr5:138744434~138753309:- LIHC cis rs2739330 0.828 rs4822454 ENSG00000218537.1 MIF-AS1 14.5 1.87e-37 3.04e-33 0.83 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23894426~23898930:- LIHC cis rs2739330 0.828 rs4822451 ENSG00000273295.1 AP000350.5 14.49 1.89e-37 3.07e-33 0.65 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23901432~23907068:- LIHC cis rs2739330 0.828 rs5760099 ENSG00000273295.1 AP000350.5 14.49 1.9e-37 3.09e-33 0.65 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23901432~23907068:- LIHC cis rs507080 0.769 rs483283 ENSG00000255239.1 AP002954.6 14.49 1.93e-37 3.13e-33 0.73 0.62 Serum metabolite levels; chr11:118635684 chr11:118688039~118690600:- LIHC cis rs875971 0.638 rs35986979 ENSG00000226824.5 RP4-756H11.3 14.48 2.23e-37 3.61e-33 0.77 0.62 Aortic root size; chr7:66624003 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs1860470 ENSG00000226824.5 RP4-756H11.3 14.47 2.36e-37 3.81e-33 0.77 0.62 Aortic root size; chr7:66638707 chr7:66654538~66669855:+ LIHC cis rs875971 0.642 rs35526611 ENSG00000226824.5 RP4-756H11.3 14.46 2.64e-37 4.25e-33 0.77 0.62 Aortic root size; chr7:66629021 chr7:66654538~66669855:+ LIHC cis rs858239 0.601 rs6971002 ENSG00000230658.1 KLHL7-AS1 14.45 2.72e-37 4.38e-33 0.72 0.62 Cerebrospinal fluid biomarker levels; chr7:23132685 chr7:23101228~23105703:- LIHC cis rs1577917 0.958 rs10944136 ENSG00000203875.9 SNHG5 -14.45 2.72e-37 4.38e-33 -0.67 -0.62 Response to antipsychotic treatment; chr6:85738781 chr6:85660950~85678736:- LIHC cis rs916888 0.821 rs199513 ENSG00000214401.4 KANSL1-AS1 -14.45 2.79e-37 4.49e-33 -1.09 -0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:46193576~46196723:+ LIHC cis rs858239 0.601 rs764534 ENSG00000230658.1 KLHL7-AS1 14.44 3.01e-37 4.82e-33 0.79 0.62 Cerebrospinal fluid biomarker levels; chr7:23114316 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs73272053 ENSG00000230658.1 KLHL7-AS1 14.44 3.01e-37 4.82e-33 0.79 0.62 Cerebrospinal fluid biomarker levels; chr7:23115906 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs6969733 ENSG00000230658.1 KLHL7-AS1 14.42 3.86e-37 6.17e-33 0.72 0.61 Cerebrospinal fluid biomarker levels; chr7:23128758 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs4440529 ENSG00000230658.1 KLHL7-AS1 14.42 3.86e-37 6.17e-33 0.72 0.61 Cerebrospinal fluid biomarker levels; chr7:23129132 chr7:23101228~23105703:- LIHC cis rs2739330 0.828 rs2877178 ENSG00000218537.1 MIF-AS1 14.41 3.97e-37 6.34e-33 0.79 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23894426~23898930:- LIHC cis rs5758659 0.653 rs133383 ENSG00000237037.8 NDUFA6-AS1 14.41 4.08e-37 6.51e-33 0.73 0.61 Cognitive function; chr22:42077599 chr22:42090931~42137742:+ LIHC cis rs858239 0.602 rs6953996 ENSG00000230658.1 KLHL7-AS1 14.41 4.23e-37 6.75e-33 0.79 0.61 Cerebrospinal fluid biomarker levels; chr7:23136327 chr7:23101228~23105703:- LIHC cis rs5758659 0.714 rs6002607 ENSG00000237037.8 NDUFA6-AS1 -14.38 5.12e-37 8.14e-33 -0.73 -0.61 Cognitive function; chr22:42100502 chr22:42090931~42137742:+ LIHC cis rs2739330 0.828 rs5760108 ENSG00000218537.1 MIF-AS1 14.37 5.71e-37 9.07e-33 0.79 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23894426~23898930:- LIHC cis rs9326248 0.581 rs7120515 ENSG00000254851.1 RP11-109L13.1 -14.36 6.12e-37 9.71e-33 -0.78 -0.61 Blood protein levels; chr11:117121210 chr11:117135528~117138582:+ LIHC cis rs507080 0.769 rs11603616 ENSG00000255239.1 AP002954.6 14.36 6.23e-37 9.86e-33 0.73 0.61 Serum metabolite levels; chr11:118625350 chr11:118688039~118690600:- LIHC cis rs2739330 0.828 rs2154593 ENSG00000218537.1 MIF-AS1 14.36 6.23e-37 9.86e-33 0.79 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23894426~23898930:- LIHC cis rs2739330 0.796 rs1006771 ENSG00000273295.1 AP000350.5 14.33 8.18e-37 1.29e-32 0.62 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23901432~23907068:- LIHC cis rs875971 0.638 rs6460305 ENSG00000226824.5 RP4-756H11.3 14.33 8.62e-37 1.35e-32 0.76 0.61 Aortic root size; chr7:66595421 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs10272357 ENSG00000226824.5 RP4-756H11.3 14.33 8.62e-37 1.35e-32 0.76 0.61 Aortic root size; chr7:66598087 chr7:66654538~66669855:+ LIHC cis rs2739330 0.731 rs5751792 ENSG00000231271.1 AP000350.8 14.31 9.85e-37 1.54e-32 0.73 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23949918~23954042:+ LIHC cis rs507080 0.769 rs570952 ENSG00000255239.1 AP002954.6 14.31 9.98e-37 1.56e-32 0.73 0.61 Serum metabolite levels; chr11:118629477 chr11:118688039~118690600:- LIHC cis rs5758659 0.714 rs5751220 ENSG00000237037.8 NDUFA6-AS1 -14.31 1.01e-36 1.58e-32 -0.73 -0.61 Cognitive function; chr22:42120201 chr22:42090931~42137742:+ LIHC cis rs801193 1 rs10234018 ENSG00000226824.5 RP4-756H11.3 14.31 1.02e-36 1.59e-32 0.77 0.61 Aortic root size; chr7:66681297 chr7:66654538~66669855:+ LIHC cis rs858239 0.539 rs870476 ENSG00000230658.1 KLHL7-AS1 14.29 1.17e-36 1.83e-32 0.7 0.61 Cerebrospinal fluid biomarker levels; chr7:23153652 chr7:23101228~23105703:- LIHC cis rs875971 0.66 rs1860468 ENSG00000226824.5 RP4-756H11.3 14.29 1.21e-36 1.89e-32 0.76 0.61 Aortic root size; chr7:66642265 chr7:66654538~66669855:+ LIHC cis rs507080 0.922 rs4936433 ENSG00000255239.1 AP002954.6 -14.28 1.28e-36 1.99e-32 -0.73 -0.61 Serum metabolite levels; chr11:118681711 chr11:118688039~118690600:- LIHC cis rs875971 0.66 rs10950044 ENSG00000226824.5 RP4-756H11.3 14.26 1.54e-36 2.38e-32 0.76 0.61 Aortic root size; chr7:66577989 chr7:66654538~66669855:+ LIHC cis rs1577917 0.696 rs2842617 ENSG00000203875.9 SNHG5 -14.26 1.54e-36 2.39e-32 -0.65 -0.61 Response to antipsychotic treatment; chr6:85599980 chr6:85660950~85678736:- LIHC cis rs1577917 0.917 rs4098044 ENSG00000203875.9 SNHG5 -14.26 1.61e-36 2.49e-32 -0.66 -0.61 Response to antipsychotic treatment; chr6:85752348 chr6:85660950~85678736:- LIHC cis rs875971 0.638 rs10249404 ENSG00000226824.5 RP4-756H11.3 14.26 1.63e-36 2.51e-32 0.76 0.61 Aortic root size; chr7:66581737 chr7:66654538~66669855:+ LIHC cis rs2739330 0.761 rs5760176 ENSG00000231271.1 AP000350.8 -14.25 1.67e-36 2.59e-32 -0.72 -0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23949918~23954042:+ LIHC cis rs875971 0.522 rs1968127 ENSG00000226824.5 RP4-756H11.3 14.25 1.68e-36 2.6e-32 0.76 0.61 Aortic root size; chr7:66591816 chr7:66654538~66669855:+ LIHC cis rs2739330 0.828 rs5751770 ENSG00000218537.1 MIF-AS1 14.24 1.79e-36 2.76e-32 0.78 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23894426~23898930:- LIHC cis rs875971 0.66 rs10215132 ENSG00000226824.5 RP4-756H11.3 14.24 1.81e-36 2.79e-32 0.76 0.61 Aortic root size; chr7:66589419 chr7:66654538~66669855:+ LIHC cis rs5769707 0.967 rs2187891 ENSG00000188511.11 C22orf34 14.24 1.82e-36 2.8e-32 0.71 0.61 Monocyte percentage of white cells;Monocyte count; chr22:49600446 chr22:49414524~49657542:- LIHC cis rs1577917 0.958 rs12213343 ENSG00000203875.9 SNHG5 -14.19 2.95e-36 4.46e-32 -0.66 -0.61 Response to antipsychotic treatment; chr6:85733301 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12215265 ENSG00000203875.9 SNHG5 -14.19 2.95e-36 4.46e-32 -0.66 -0.61 Response to antipsychotic treatment; chr6:85734251 chr6:85660950~85678736:- LIHC cis rs5758659 0.714 rs6002626 ENSG00000237037.8 NDUFA6-AS1 -14.18 3.12e-36 4.71e-32 -0.72 -0.61 Cognitive function; chr22:42121985 chr22:42090931~42137742:+ LIHC cis rs1577917 0.518 rs2475787 ENSG00000203875.9 SNHG5 14.16 3.84e-36 5.77e-32 0.64 0.61 Response to antipsychotic treatment; chr6:85705518 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs16876529 ENSG00000203875.9 SNHG5 -14.15 4.17e-36 6.26e-32 -0.65 -0.61 Response to antipsychotic treatment; chr6:85881484 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12204015 ENSG00000203875.9 SNHG5 -14.15 4.17e-36 6.26e-32 -0.65 -0.61 Response to antipsychotic treatment; chr6:85888616 chr6:85660950~85678736:- LIHC cis rs5769707 0.837 rs5769709 ENSG00000188511.11 C22orf34 14.14 4.46e-36 6.67e-32 0.71 0.61 Monocyte percentage of white cells;Monocyte count; chr22:49628109 chr22:49414524~49657542:- LIHC cis rs507080 0.769 rs527290 ENSG00000255239.1 AP002954.6 14.14 4.64e-36 6.93e-32 0.73 0.61 Serum metabolite levels; chr11:118644898 chr11:118688039~118690600:- LIHC cis rs2739330 0.828 rs4822451 ENSG00000218537.1 MIF-AS1 14.14 4.75e-36 7.08e-32 0.8 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23894426~23898930:- LIHC cis rs2739330 0.828 rs5760099 ENSG00000218537.1 MIF-AS1 14.13 4.81e-36 7.17e-32 0.79 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23894426~23898930:- LIHC cis rs1577917 0.958 rs12197463 ENSG00000203875.9 SNHG5 -14.13 5.06e-36 7.53e-32 -0.66 -0.61 Response to antipsychotic treatment; chr6:85735524 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs66807489 ENSG00000203875.9 SNHG5 -14.12 5.5e-36 8.16e-32 -0.66 -0.61 Response to antipsychotic treatment; chr6:85730984 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs7453105 ENSG00000203875.9 SNHG5 -14.12 5.71e-36 8.45e-32 -0.66 -0.61 Response to antipsychotic treatment; chr6:85791043 chr6:85660950~85678736:- LIHC cis rs801193 1 rs2659915 ENSG00000226824.5 RP4-756H11.3 -14.11 5.96e-36 8.82e-32 -0.75 -0.61 Aortic root size; chr7:66688114 chr7:66654538~66669855:+ LIHC cis rs2739330 0.828 rs5760107 ENSG00000273295.1 AP000350.5 14.1 6.41e-36 9.46e-32 0.63 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23901432~23907068:- LIHC cis rs5769707 0.967 rs5769698 ENSG00000188511.11 C22orf34 14.1 6.57e-36 9.7e-32 0.69 0.61 Monocyte percentage of white cells;Monocyte count; chr22:49604058 chr22:49414524~49657542:- LIHC cis rs858239 0.539 rs6949363 ENSG00000230658.1 KLHL7-AS1 14.09 6.88e-36 1.01e-31 0.71 0.61 Cerebrospinal fluid biomarker levels; chr7:23152775 chr7:23101228~23105703:- LIHC cis rs5769707 0.933 rs2157444 ENSG00000188511.11 C22orf34 14.09 6.92e-36 1.02e-31 0.71 0.61 Monocyte percentage of white cells;Monocyte count; chr22:49600644 chr22:49414524~49657542:- LIHC cis rs2739330 0.791 rs4822458 ENSG00000272787.1 KB-226F1.2 -14.09 7.24e-36 1.06e-31 -0.75 -0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23969211~23969873:+ LIHC cis rs5769707 0.837 rs1573726 ENSG00000188511.11 C22orf34 14.08 7.92e-36 1.16e-31 0.71 0.61 Monocyte percentage of white cells;Monocyte count; chr22:49639224 chr22:49414524~49657542:- LIHC cis rs507080 0.769 rs570836 ENSG00000255239.1 AP002954.6 14.07 8.54e-36 1.25e-31 0.72 0.61 Serum metabolite levels; chr11:118641444 chr11:118688039~118690600:- LIHC cis rs2739330 0.892 rs5751776 ENSG00000225282.1 AP000350.6 14.07 8.68e-36 1.27e-31 0.73 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23926900~23929574:+ LIHC cis rs2739330 0.731 rs4822450 ENSG00000273295.1 AP000350.5 14.07 8.85e-36 1.29e-31 0.64 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23901432~23907068:- LIHC cis rs916888 0.61 rs199529 ENSG00000214401.4 KANSL1-AS1 14.07 8.95e-36 1.3e-31 1.09 0.61 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:46193576~46196723:+ LIHC cis rs5769707 0.837 rs5770599 ENSG00000188511.11 C22orf34 14.06 9.13e-36 1.33e-31 0.7 0.61 Monocyte percentage of white cells;Monocyte count; chr22:49626333 chr22:49414524~49657542:- LIHC cis rs2739330 0.828 rs2330635 ENSG00000273295.1 AP000350.5 14.06 9.21e-36 1.34e-31 0.63 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23901432~23907068:- LIHC cis rs858239 0.571 rs2390755 ENSG00000230658.1 KLHL7-AS1 14.06 9.37e-36 1.36e-31 0.72 0.61 Cerebrospinal fluid biomarker levels; chr7:23151097 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs4365988 ENSG00000230658.1 KLHL7-AS1 14.06 9.37e-36 1.36e-31 0.72 0.61 Cerebrospinal fluid biomarker levels; chr7:23151252 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs10279194 ENSG00000230658.1 KLHL7-AS1 14.06 9.37e-36 1.36e-31 0.72 0.61 Cerebrospinal fluid biomarker levels; chr7:23151464 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs3950345 ENSG00000230658.1 KLHL7-AS1 14.06 9.37e-36 1.36e-31 0.72 0.61 Cerebrospinal fluid biomarker levels; chr7:23151495 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs2178139 ENSG00000230658.1 KLHL7-AS1 14.06 9.37e-36 1.36e-31 0.72 0.61 Cerebrospinal fluid biomarker levels; chr7:23152017 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs2141306 ENSG00000230658.1 KLHL7-AS1 14.06 9.37e-36 1.36e-31 0.72 0.61 Cerebrospinal fluid biomarker levels; chr7:23152045 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs2141305 ENSG00000230658.1 KLHL7-AS1 14.06 9.37e-36 1.36e-31 0.72 0.61 Cerebrospinal fluid biomarker levels; chr7:23152280 chr7:23101228~23105703:- LIHC cis rs1577917 0.916 rs4142546 ENSG00000203875.9 SNHG5 -14.06 9.66e-36 1.4e-31 -0.66 -0.61 Response to antipsychotic treatment; chr6:85795593 chr6:85660950~85678736:- LIHC cis rs858239 0.539 rs2178140 ENSG00000230658.1 KLHL7-AS1 14.05 1.01e-35 1.42e-31 0.72 0.61 Cerebrospinal fluid biomarker levels; chr7:23152006 chr7:23101228~23105703:- LIHC cis rs9326248 0.52 rs236919 ENSG00000254851.1 RP11-109L13.1 -14.05 1.03e-35 1.45e-31 -0.75 -0.6 Blood protein levels; chr11:117224645 chr11:117135528~117138582:+ LIHC cis rs858239 0.539 rs57864591 ENSG00000230658.1 KLHL7-AS1 14.04 1.09e-35 1.52e-31 0.71 0.6 Cerebrospinal fluid biomarker levels; chr7:23144805 chr7:23101228~23105703:- LIHC cis rs1577917 0.74 rs7771612 ENSG00000203875.9 SNHG5 14.04 1.11e-35 1.55e-31 0.65 0.6 Response to antipsychotic treatment; chr6:85554656 chr6:85660950~85678736:- LIHC cis rs858239 0.511 rs10256996 ENSG00000230658.1 KLHL7-AS1 -14.03 1.23e-35 1.71e-31 -0.77 -0.6 Cerebrospinal fluid biomarker levels; chr7:23105676 chr7:23101228~23105703:- LIHC cis rs2739330 0.828 rs2186366 ENSG00000273295.1 AP000350.5 -14.03 1.27e-35 1.75e-31 -0.65 -0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23901432~23907068:- LIHC cis rs2739330 0.828 rs4822454 ENSG00000273295.1 AP000350.5 14.03 1.27e-35 1.77e-31 0.65 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23901432~23907068:- LIHC cis rs5758659 0.967 rs5758670 ENSG00000237037.8 NDUFA6-AS1 14.03 1.28e-35 1.78e-31 0.7 0.6 Cognitive function; chr22:42240681 chr22:42090931~42137742:+ LIHC cis rs2882667 0.628 rs13162420 ENSG00000253404.1 AC034243.1 14.01 1.46e-35 2.01e-31 1.11 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:138839070 chr5:138744434~138753309:- LIHC cis rs2882667 0.628 rs13167462 ENSG00000253404.1 AC034243.1 14.01 1.46e-35 2.01e-31 1.11 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:138841572 chr5:138744434~138753309:- LIHC cis rs1577917 0.958 rs12209259 ENSG00000203875.9 SNHG5 -14 1.63e-35 2.24e-31 -0.65 -0.6 Response to antipsychotic treatment; chr6:85792630 chr6:85660950~85678736:- LIHC cis rs2882667 0.69 rs13158360 ENSG00000253404.1 AC034243.1 14 1.64e-35 2.25e-31 0.97 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:138922488 chr5:138744434~138753309:- LIHC cis rs1577917 0.74 rs9344533 ENSG00000203875.9 SNHG5 13.99 1.82e-35 2.49e-31 0.64 0.6 Response to antipsychotic treatment; chr6:85526470 chr6:85660950~85678736:- LIHC cis rs1577917 0.74 rs9353320 ENSG00000203875.9 SNHG5 13.99 1.82e-35 2.49e-31 0.64 0.6 Response to antipsychotic treatment; chr6:85535130 chr6:85660950~85678736:- LIHC cis rs1577917 0.74 rs7775864 ENSG00000203875.9 SNHG5 13.99 1.82e-35 2.49e-31 0.64 0.6 Response to antipsychotic treatment; chr6:85538041 chr6:85660950~85678736:- LIHC cis rs858239 0.539 rs6945510 ENSG00000230658.1 KLHL7-AS1 13.98 1.88e-35 2.56e-31 0.71 0.6 Cerebrospinal fluid biomarker levels; chr7:23152621 chr7:23101228~23105703:- LIHC cis rs2739330 0.796 rs5760097 ENSG00000273295.1 AP000350.5 13.98 1.88e-35 2.56e-31 0.64 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23901432~23907068:- LIHC cis rs5758659 0.714 rs7245 ENSG00000237037.8 NDUFA6-AS1 -13.98 1.98e-35 2.69e-31 -0.73 -0.6 Cognitive function; chr22:42085845 chr22:42090931~42137742:+ LIHC cis rs2739330 0.76 rs5760095 ENSG00000272787.1 KB-226F1.2 -13.97 2.14e-35 2.91e-31 -0.77 -0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23969211~23969873:+ LIHC cis rs507080 0.769 rs2077173 ENSG00000255239.1 AP002954.6 13.97 2.15e-35 2.92e-31 0.72 0.6 Serum metabolite levels; chr11:118621876 chr11:118688039~118690600:- LIHC cis rs5758659 0.967 rs5751250 ENSG00000237037.8 NDUFA6-AS1 13.97 2.19e-35 2.94e-31 0.7 0.6 Cognitive function; chr22:42243639 chr22:42090931~42137742:+ LIHC cis rs1577917 0.917 rs1838959 ENSG00000203875.9 SNHG5 -13.97 2.19e-35 2.94e-31 -0.66 -0.6 Response to antipsychotic treatment; chr6:85847086 chr6:85660950~85678736:- LIHC cis rs1577917 0.917 rs1579886 ENSG00000203875.9 SNHG5 -13.97 2.19e-35 2.94e-31 -0.66 -0.6 Response to antipsychotic treatment; chr6:85847473 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs1816937 ENSG00000203875.9 SNHG5 -13.97 2.19e-35 2.94e-31 -0.66 -0.6 Response to antipsychotic treatment; chr6:85847533 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs7382798 ENSG00000203875.9 SNHG5 -13.97 2.19e-35 2.94e-31 -0.66 -0.6 Response to antipsychotic treatment; chr6:85850116 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs1838958 ENSG00000203875.9 SNHG5 -13.97 2.19e-35 2.94e-31 -0.66 -0.6 Response to antipsychotic treatment; chr6:85854250 chr6:85660950~85678736:- LIHC cis rs1577917 0.917 rs12665464 ENSG00000203875.9 SNHG5 -13.97 2.19e-35 2.94e-31 -0.66 -0.6 Response to antipsychotic treatment; chr6:85864415 chr6:85660950~85678736:- LIHC cis rs1577917 0.682 rs6909767 ENSG00000203875.9 SNHG5 13.96 2.4e-35 3.22e-31 0.65 0.6 Response to antipsychotic treatment; chr6:85518391 chr6:85660950~85678736:- LIHC cis rs5769707 0.967 rs17182154 ENSG00000188511.11 C22orf34 13.95 2.43e-35 3.26e-31 0.7 0.6 Monocyte percentage of white cells;Monocyte count; chr22:49596822 chr22:49414524~49657542:- LIHC cis rs1577917 0.917 rs1414201 ENSG00000203875.9 SNHG5 -13.95 2.46e-35 3.3e-31 -0.66 -0.6 Response to antipsychotic treatment; chr6:85790598 chr6:85660950~85678736:- LIHC cis rs507080 0.769 rs571001 ENSG00000255239.1 AP002954.6 13.95 2.46e-35 3.3e-31 0.72 0.6 Serum metabolite levels; chr11:118629457 chr11:118688039~118690600:- LIHC cis rs5769707 0.935 rs1109320 ENSG00000188511.11 C22orf34 13.95 2.47e-35 3.31e-31 0.69 0.6 Monocyte percentage of white cells;Monocyte count; chr22:49595458 chr22:49414524~49657542:- LIHC cis rs5769707 0.839 rs73176988 ENSG00000188511.11 C22orf34 13.95 2.47e-35 3.31e-31 0.69 0.6 Monocyte percentage of white cells;Monocyte count; chr22:49596001 chr22:49414524~49657542:- LIHC cis rs5769707 0.872 rs5770604 ENSG00000188511.11 C22orf34 13.94 2.73e-35 3.65e-31 0.7 0.6 Monocyte percentage of white cells;Monocyte count; chr22:49637024 chr22:49414524~49657542:- LIHC cis rs5758659 1 rs5758677 ENSG00000237037.8 NDUFA6-AS1 13.94 2.8e-35 3.74e-31 0.7 0.6 Cognitive function; chr22:42247033 chr22:42090931~42137742:+ LIHC cis rs858239 0.539 rs10280815 ENSG00000230658.1 KLHL7-AS1 13.93 3.08e-35 4.09e-31 0.71 0.6 Cerebrospinal fluid biomarker levels; chr7:23148751 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs10225608 ENSG00000230658.1 KLHL7-AS1 13.93 3.08e-35 4.09e-31 0.71 0.6 Cerebrospinal fluid biomarker levels; chr7:23149289 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs28624974 ENSG00000230658.1 KLHL7-AS1 13.93 3.08e-35 4.09e-31 0.71 0.6 Cerebrospinal fluid biomarker levels; chr7:23149317 chr7:23101228~23105703:- LIHC cis rs5850 0.557 rs10270788 ENSG00000230658.1 KLHL7-AS1 13.93 3.08e-35 4.09e-31 0.71 0.6 Blood protein levels; chr7:23149381 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs28716381 ENSG00000230658.1 KLHL7-AS1 13.93 3.08e-35 4.09e-31 0.71 0.6 Cerebrospinal fluid biomarker levels; chr7:23149396 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs1358442 ENSG00000230658.1 KLHL7-AS1 13.93 3.08e-35 4.09e-31 0.71 0.6 Cerebrospinal fluid biomarker levels; chr7:23150120 chr7:23101228~23105703:- LIHC cis rs2882667 0.628 rs13173618 ENSG00000253404.1 AC034243.1 13.93 3.14e-35 4.17e-31 1.1 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:138804091 chr5:138744434~138753309:- LIHC cis rs2739330 0.828 rs5760107 ENSG00000218537.1 MIF-AS1 13.92 3.18e-35 4.22e-31 0.78 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23894426~23898930:- LIHC cis rs1577917 0.958 rs12195776 ENSG00000203875.9 SNHG5 -13.91 3.63e-35 4.79e-31 -0.66 -0.6 Response to antipsychotic treatment; chr6:85778881 chr6:85660950~85678736:- LIHC cis rs916888 0.773 rs9896243 ENSG00000214401.4 KANSL1-AS1 13.91 3.68e-35 4.85e-31 1.08 0.6 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:46193576~46196723:+ LIHC cis rs5769707 0.749 rs7286706 ENSG00000188511.11 C22orf34 13.91 3.73e-35 4.92e-31 0.71 0.6 Monocyte percentage of white cells;Monocyte count; chr22:49664698 chr22:49414524~49657542:- LIHC cis rs858239 0.6 rs6967475 ENSG00000230658.1 KLHL7-AS1 13.9 3.76e-35 4.96e-31 0.69 0.6 Cerebrospinal fluid biomarker levels; chr7:23089363 chr7:23101228~23105703:- LIHC cis rs2882667 0.728 rs7722413 ENSG00000253404.1 AC034243.1 13.9 3.78e-35 4.98e-31 0.98 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:138942562 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs13174008 ENSG00000253404.1 AC034243.1 13.9 3.83e-35 5.04e-31 0.97 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:138922220 chr5:138744434~138753309:- LIHC cis rs507080 0.733 rs601318 ENSG00000255239.1 AP002954.6 13.9 3.88e-35 5.11e-31 0.72 0.6 Serum metabolite levels; chr11:118648845 chr11:118688039~118690600:- LIHC cis rs2739330 0.828 rs2330635 ENSG00000218537.1 MIF-AS1 13.9 3.92e-35 5.16e-31 0.78 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23894426~23898930:- LIHC cis rs2739330 0.789 rs5760109 ENSG00000273295.1 AP000350.5 13.9 4e-35 5.26e-31 0.63 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23901432~23907068:- LIHC cis rs507080 0.769 rs645637 ENSG00000255239.1 AP002954.6 13.89 4.13e-35 5.42e-31 0.72 0.6 Serum metabolite levels; chr11:118634373 chr11:118688039~118690600:- LIHC cis rs5758659 1 rs134873 ENSG00000237037.8 NDUFA6-AS1 13.88 4.64e-35 6.08e-31 0.69 0.6 Cognitive function; chr22:42261560 chr22:42090931~42137742:+ LIHC cis rs2739330 0.796 rs5760097 ENSG00000218537.1 MIF-AS1 13.88 4.69e-35 6.13e-31 0.79 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23894426~23898930:- LIHC cis rs507080 0.769 rs12290522 ENSG00000255239.1 AP002954.6 13.88 4.86e-35 6.35e-31 0.72 0.6 Serum metabolite levels; chr11:118615610 chr11:118688039~118690600:- LIHC cis rs2882667 0.728 rs10037071 ENSG00000253404.1 AC034243.1 13.88 4.89e-35 6.38e-31 0.98 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:138942158 chr5:138744434~138753309:- LIHC cis rs4423214 1 rs2002063 ENSG00000254682.1 RP11-660L16.2 13.87 5.07e-35 6.59e-31 0.77 0.6 Vitamin D levels; chr11:71452430 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs11600860 ENSG00000254682.1 RP11-660L16.2 13.87 5.07e-35 6.59e-31 0.77 0.6 Vitamin D levels; chr11:71452973 chr11:71448674~71452157:+ LIHC cis rs4423214 0.959 rs11606611 ENSG00000254682.1 RP11-660L16.2 13.87 5.07e-35 6.59e-31 0.77 0.6 Vitamin D levels; chr11:71453000 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs11606612 ENSG00000254682.1 RP11-660L16.2 13.87 5.07e-35 6.59e-31 0.77 0.6 Vitamin D levels; chr11:71453001 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs11606631 ENSG00000254682.1 RP11-660L16.2 13.87 5.07e-35 6.59e-31 0.77 0.6 Vitamin D levels; chr11:71453075 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs12789751 ENSG00000254682.1 RP11-660L16.2 13.87 5.07e-35 6.59e-31 0.77 0.6 Vitamin D levels; chr11:71453425 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs12791871 ENSG00000254682.1 RP11-660L16.2 13.87 5.07e-35 6.59e-31 0.77 0.6 Vitamin D levels; chr11:71453498 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs7944926 ENSG00000254682.1 RP11-660L16.2 13.87 5.07e-35 6.59e-31 0.77 0.6 Vitamin D levels; chr11:71454579 chr11:71448674~71452157:+ LIHC cis rs2739330 0.796 rs2154594 ENSG00000218537.1 MIF-AS1 -13.87 5.08e-35 6.6e-31 -0.81 -0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23894426~23898930:- LIHC cis rs1577917 0.958 rs2324840 ENSG00000203875.9 SNHG5 -13.87 5.29e-35 6.86e-31 -0.65 -0.6 Response to antipsychotic treatment; chr6:85847902 chr6:85660950~85678736:- LIHC cis rs875971 0.66 rs801193 ENSG00000226824.5 RP4-756H11.3 13.86 5.72e-35 7.39e-31 0.73 0.6 Aortic root size; chr7:66565625 chr7:66654538~66669855:+ LIHC cis rs2882667 0.69 rs9327830 ENSG00000253404.1 AC034243.1 13.84 6.71e-35 8.63e-31 0.98 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:138936560 chr5:138744434~138753309:- LIHC cis rs2739330 0.929 rs5751775 ENSG00000225282.1 AP000350.6 13.84 6.78e-35 8.71e-31 0.72 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23926900~23929574:+ LIHC cis rs858239 0.539 rs6976957 ENSG00000230658.1 KLHL7-AS1 13.84 6.88e-35 8.84e-31 0.7 0.6 Cerebrospinal fluid biomarker levels; chr7:23147714 chr7:23101228~23105703:- LIHC cis rs875971 0.577 rs35072105 ENSG00000226824.5 RP4-756H11.3 13.83 7.13e-35 9.14e-31 0.78 0.6 Aortic root size; chr7:66144830 chr7:66654538~66669855:+ LIHC cis rs507080 0.697 rs653008 ENSG00000255239.1 AP002954.6 13.83 7.37e-35 9.44e-31 0.72 0.6 Serum metabolite levels; chr11:118649775 chr11:118688039~118690600:- LIHC cis rs1577917 0.916 rs12206726 ENSG00000203875.9 SNHG5 -13.83 7.44e-35 9.52e-31 -0.65 -0.6 Response to antipsychotic treatment; chr6:85789998 chr6:85660950~85678736:- LIHC cis rs2882667 0.69 rs2351463 ENSG00000253404.1 AC034243.1 13.82 7.72e-35 9.87e-31 0.97 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:138923113 chr5:138744434~138753309:- LIHC cis rs5758659 1 rs5758660 ENSG00000237037.8 NDUFA6-AS1 13.82 7.8e-35 9.96e-31 0.7 0.6 Cognitive function; chr22:42227712 chr22:42090931~42137742:+ LIHC cis rs5758659 1 rs134869 ENSG00000237037.8 NDUFA6-AS1 13.82 8.19e-35 1.05e-30 0.69 0.6 Cognitive function; chr22:42256068 chr22:42090931~42137742:+ LIHC cis rs1577917 0.687 rs1470531 ENSG00000203875.9 SNHG5 -13.82 8.28e-35 1.06e-30 -0.65 -0.6 Response to antipsychotic treatment; chr6:85797651 chr6:85660950~85678736:- LIHC cis rs916888 0.738 rs199515 ENSG00000214401.4 KANSL1-AS1 -13.81 8.51e-35 1.08e-30 -1.05 -0.6 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:46193576~46196723:+ LIHC cis rs2739330 0.828 rs4820572 ENSG00000273295.1 AP000350.5 13.81 8.58e-35 1.09e-30 0.62 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23901432~23907068:- LIHC cis rs875971 0.619 rs10278371 ENSG00000226824.5 RP4-756H11.3 13.81 8.67e-35 1.1e-30 0.77 0.6 Aortic root size; chr7:66586553 chr7:66654538~66669855:+ LIHC cis rs858239 0.601 rs2141307 ENSG00000230658.1 KLHL7-AS1 13.8 9.44e-35 1.2e-30 0.77 0.6 Cerebrospinal fluid biomarker levels; chr7:23151805 chr7:23101228~23105703:- LIHC cis rs1577917 0.538 rs6454483 ENSG00000203875.9 SNHG5 13.8 9.78e-35 1.24e-30 0.63 0.6 Response to antipsychotic treatment; chr6:85708565 chr6:85660950~85678736:- LIHC cis rs1577917 0.74 rs2758843 ENSG00000203875.9 SNHG5 -13.8 9.83e-35 1.25e-30 -0.63 -0.6 Response to antipsychotic treatment; chr6:85618713 chr6:85660950~85678736:- LIHC cis rs1577917 0.74 rs2842614 ENSG00000203875.9 SNHG5 -13.79 1.02e-34 1.29e-30 -0.63 -0.6 Response to antipsychotic treatment; chr6:85596351 chr6:85660950~85678736:- LIHC cis rs858239 0.539 rs7791200 ENSG00000230658.1 KLHL7-AS1 13.79 1.03e-34 1.31e-30 0.71 0.6 Cerebrospinal fluid biomarker levels; chr7:23142502 chr7:23101228~23105703:- LIHC cis rs1577917 0.876 rs4618490 ENSG00000203875.9 SNHG5 -13.79 1.06e-34 1.34e-30 -0.66 -0.6 Response to antipsychotic treatment; chr6:85808685 chr6:85660950~85678736:- LIHC cis rs507080 0.733 rs4486664 ENSG00000255239.1 AP002954.6 13.78 1.1e-34 1.38e-30 0.71 0.6 Serum metabolite levels; chr11:118698358 chr11:118688039~118690600:- LIHC cis rs1577917 0.655 rs9359658 ENSG00000203875.9 SNHG5 13.78 1.11e-34 1.39e-30 0.63 0.6 Response to antipsychotic treatment; chr6:85596051 chr6:85660950~85678736:- LIHC cis rs858239 0.509 rs6975524 ENSG00000230658.1 KLHL7-AS1 13.78 1.11e-34 1.39e-30 0.7 0.6 Cerebrospinal fluid biomarker levels; chr7:23146833 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs6955726 ENSG00000230658.1 KLHL7-AS1 13.78 1.11e-34 1.39e-30 0.7 0.6 Cerebrospinal fluid biomarker levels; chr7:23147072 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs6956828 ENSG00000230658.1 KLHL7-AS1 13.78 1.11e-34 1.39e-30 0.7 0.6 Cerebrospinal fluid biomarker levels; chr7:23147728 chr7:23101228~23105703:- LIHC cis rs507080 0.663 rs523793 ENSG00000255239.1 AP002954.6 13.78 1.15e-34 1.43e-30 0.71 0.6 Serum metabolite levels; chr11:118699988 chr11:118688039~118690600:- LIHC cis rs507080 0.736 rs659564 ENSG00000255239.1 AP002954.6 13.78 1.15e-34 1.43e-30 0.71 0.6 Serum metabolite levels; chr11:118700205 chr11:118688039~118690600:- LIHC cis rs507080 0.736 rs642224 ENSG00000255239.1 AP002954.6 13.78 1.15e-34 1.43e-30 0.71 0.6 Serum metabolite levels; chr11:118700210 chr11:118688039~118690600:- LIHC cis rs507080 0.733 rs541631 ENSG00000255239.1 AP002954.6 13.78 1.15e-34 1.43e-30 0.71 0.6 Serum metabolite levels; chr11:118700314 chr11:118688039~118690600:- LIHC cis rs507080 0.736 rs658676 ENSG00000255239.1 AP002954.6 13.78 1.15e-34 1.43e-30 0.71 0.6 Serum metabolite levels; chr11:118700414 chr11:118688039~118690600:- LIHC cis rs507080 0.733 rs488141 ENSG00000255239.1 AP002954.6 13.78 1.15e-34 1.43e-30 0.71 0.6 Serum metabolite levels; chr11:118700459 chr11:118688039~118690600:- LIHC cis rs507080 0.733 rs657769 ENSG00000255239.1 AP002954.6 13.78 1.15e-34 1.43e-30 0.71 0.6 Serum metabolite levels; chr11:118700607 chr11:118688039~118690600:- LIHC cis rs507080 0.733 rs544452 ENSG00000255239.1 AP002954.6 13.78 1.15e-34 1.43e-30 0.71 0.6 Serum metabolite levels; chr11:118700648 chr11:118688039~118690600:- LIHC cis rs507080 0.697 rs656287 ENSG00000255239.1 AP002954.6 13.78 1.15e-34 1.43e-30 0.71 0.6 Serum metabolite levels; chr11:118701081 chr11:118688039~118690600:- LIHC cis rs507080 0.733 rs570949 ENSG00000255239.1 AP002954.6 13.78 1.15e-34 1.43e-30 0.71 0.6 Serum metabolite levels; chr11:118701202 chr11:118688039~118690600:- LIHC cis rs5758659 0.904 rs5758653 ENSG00000237037.8 NDUFA6-AS1 13.78 1.15e-34 1.43e-30 0.7 0.6 Cognitive function; chr22:42217479 chr22:42090931~42137742:+ LIHC cis rs2739330 0.685 rs4822453 ENSG00000273295.1 AP000350.5 13.78 1.15e-34 1.43e-30 0.64 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23901432~23907068:- LIHC cis rs5758659 0.935 rs134879 ENSG00000237037.8 NDUFA6-AS1 13.78 1.17e-34 1.45e-30 0.69 0.6 Cognitive function; chr22:42268195 chr22:42090931~42137742:+ LIHC cis rs1577917 0.74 rs2758842 ENSG00000203875.9 SNHG5 -13.78 1.17e-34 1.45e-30 -0.63 -0.6 Response to antipsychotic treatment; chr6:85599013 chr6:85660950~85678736:- LIHC cis rs1577917 0.572 rs911927 ENSG00000203875.9 SNHG5 -13.78 1.17e-34 1.45e-30 -0.63 -0.6 Response to antipsychotic treatment; chr6:85618142 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs6900436 ENSG00000203875.9 SNHG5 -13.77 1.2e-34 1.49e-30 -0.65 -0.6 Response to antipsychotic treatment; chr6:85796570 chr6:85660950~85678736:- LIHC cis rs2739330 0.789 rs5760109 ENSG00000218537.1 MIF-AS1 13.77 1.24e-34 1.53e-30 0.78 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23894426~23898930:- LIHC cis rs1577917 0.958 rs6921315 ENSG00000203875.9 SNHG5 -13.77 1.26e-34 1.56e-30 -0.64 -0.6 Response to antipsychotic treatment; chr6:85761950 chr6:85660950~85678736:- LIHC cis rs507080 0.733 rs4393358 ENSG00000255239.1 AP002954.6 13.77 1.28e-34 1.58e-30 0.71 0.6 Serum metabolite levels; chr11:118698388 chr11:118688039~118690600:- LIHC cis rs858239 0.539 rs4295546 ENSG00000230658.1 KLHL7-AS1 13.77 1.29e-34 1.59e-30 0.7 0.6 Cerebrospinal fluid biomarker levels; chr7:23151402 chr7:23101228~23105703:- LIHC cis rs2739330 0.76 rs1002286 ENSG00000218537.1 MIF-AS1 -13.76 1.32e-34 1.63e-30 -0.77 -0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23894426~23898930:- LIHC cis rs1577917 0.958 rs2324817 ENSG00000203875.9 SNHG5 -13.76 1.35e-34 1.66e-30 -0.64 -0.6 Response to antipsychotic treatment; chr6:85752936 chr6:85660950~85678736:- LIHC cis rs1577917 0.74 rs9450302 ENSG00000203875.9 SNHG5 13.76 1.37e-34 1.69e-30 0.64 0.6 Response to antipsychotic treatment; chr6:85579955 chr6:85660950~85678736:- LIHC cis rs858239 0.539 rs4294098 ENSG00000230658.1 KLHL7-AS1 13.76 1.42e-34 1.74e-30 0.7 0.6 Cerebrospinal fluid biomarker levels; chr7:23146376 chr7:23101228~23105703:- LIHC cis rs1577917 0.837 rs806529 ENSG00000203875.9 SNHG5 -13.75 1.44e-34 1.77e-30 -0.64 -0.6 Response to antipsychotic treatment; chr6:85757403 chr6:85660950~85678736:- LIHC cis rs507080 0.733 rs7108144 ENSG00000255239.1 AP002954.6 13.75 1.53e-34 1.87e-30 0.71 0.6 Serum metabolite levels; chr11:118698985 chr11:118688039~118690600:- LIHC cis rs5758659 0.904 rs134877 ENSG00000237037.8 NDUFA6-AS1 13.75 1.54e-34 1.88e-30 0.69 0.6 Cognitive function; chr22:42266365 chr22:42090931~42137742:+ LIHC cis rs2882667 0.628 rs13154573 ENSG00000253404.1 AC034243.1 13.75 1.55e-34 1.9e-30 1.09 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:138812375 chr5:138744434~138753309:- LIHC cis rs2739330 0.828 rs5760102 ENSG00000273295.1 AP000350.5 13.74 1.65e-34 2.01e-30 0.63 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23901432~23907068:- LIHC cis rs2739330 0.828 rs5760098 ENSG00000273295.1 AP000350.5 13.73 1.8e-34 2.19e-30 0.63 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23901432~23907068:- LIHC cis rs858239 0.539 rs6965833 ENSG00000230658.1 KLHL7-AS1 13.73 1.82e-34 2.21e-30 0.7 0.6 Cerebrospinal fluid biomarker levels; chr7:23152747 chr7:23101228~23105703:- LIHC cis rs1577917 0.518 rs6454482 ENSG00000203875.9 SNHG5 13.73 1.85e-34 2.24e-30 0.62 0.6 Response to antipsychotic treatment; chr6:85708470 chr6:85660950~85678736:- LIHC cis rs2882667 0.69 rs9327831 ENSG00000253404.1 AC034243.1 13.72 1.92e-34 2.32e-30 0.98 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:138936597 chr5:138744434~138753309:- LIHC cis rs507080 0.733 rs552079 ENSG00000255239.1 AP002954.6 13.71 2.06e-34 2.48e-30 0.71 0.6 Serum metabolite levels; chr11:118702313 chr11:118688039~118690600:- LIHC cis rs507080 0.733 rs673547 ENSG00000255239.1 AP002954.6 13.71 2.06e-34 2.48e-30 0.71 0.6 Serum metabolite levels; chr11:118702630 chr11:118688039~118690600:- LIHC cis rs507080 0.733 rs517445 ENSG00000255239.1 AP002954.6 13.71 2.06e-34 2.48e-30 0.71 0.6 Serum metabolite levels; chr11:118702826 chr11:118688039~118690600:- LIHC cis rs507080 0.771 rs687664 ENSG00000255239.1 AP002954.6 13.71 2.06e-34 2.48e-30 0.71 0.6 Serum metabolite levels; chr11:118703476 chr11:118688039~118690600:- LIHC cis rs507080 0.771 rs523715 ENSG00000255239.1 AP002954.6 13.71 2.06e-34 2.48e-30 0.71 0.6 Serum metabolite levels; chr11:118703479 chr11:118688039~118690600:- LIHC cis rs2882667 0.554 rs1368425 ENSG00000253404.1 AC034243.1 13.71 2.14e-34 2.58e-30 0.98 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:138944528 chr5:138744434~138753309:- LIHC cis rs1577917 0.74 rs12212560 ENSG00000203875.9 SNHG5 -13.71 2.16e-34 2.61e-30 -0.64 -0.6 Response to antipsychotic treatment; chr6:85632961 chr6:85660950~85678736:- LIHC cis rs5758659 1 rs5758659 ENSG00000237037.8 NDUFA6-AS1 13.71 2.18e-34 2.62e-30 0.7 0.6 Cognitive function; chr22:42225997 chr22:42090931~42137742:+ LIHC cis rs1577917 0.958 rs6454488 ENSG00000203875.9 SNHG5 -13.71 2.21e-34 2.66e-30 -0.64 -0.6 Response to antipsychotic treatment; chr6:85741124 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12191340 ENSG00000203875.9 SNHG5 -13.7 2.24e-34 2.69e-30 -0.65 -0.6 Response to antipsychotic treatment; chr6:85811682 chr6:85660950~85678736:- LIHC cis rs2739330 0.828 rs5760102 ENSG00000218537.1 MIF-AS1 13.7 2.28e-34 2.74e-30 0.78 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23894426~23898930:- LIHC cis rs1577917 0.958 rs9647601 ENSG00000203875.9 SNHG5 -13.7 2.31e-34 2.78e-30 -0.64 -0.6 Response to antipsychotic treatment; chr6:85740109 chr6:85660950~85678736:- LIHC cis rs4423214 1 rs4944958 ENSG00000254682.1 RP11-660L16.2 13.7 2.41e-34 2.89e-30 0.76 0.6 Vitamin D levels; chr11:71457027 chr11:71448674~71452157:+ LIHC cis rs1577917 0.57 rs114854865 ENSG00000203875.9 SNHG5 -13.69 2.47e-34 2.96e-30 -0.65 -0.6 Response to antipsychotic treatment; chr6:85844518 chr6:85660950~85678736:- LIHC cis rs2739330 0.828 rs5760098 ENSG00000218537.1 MIF-AS1 13.69 2.5e-34 3e-30 0.79 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23894426~23898930:- LIHC cis rs1577917 0.74 rs2758845 ENSG00000203875.9 SNHG5 -13.69 2.55e-34 3.05e-30 -0.64 -0.59 Response to antipsychotic treatment; chr6:85625130 chr6:85660950~85678736:- LIHC cis rs1577917 0.696 rs2842603 ENSG00000203875.9 SNHG5 -13.69 2.55e-34 3.05e-30 -0.64 -0.59 Response to antipsychotic treatment; chr6:85626619 chr6:85660950~85678736:- LIHC cis rs5769707 0.777 rs739243 ENSG00000188511.11 C22orf34 13.69 2.55e-34 3.05e-30 0.69 0.59 Monocyte percentage of white cells;Monocyte count; chr22:49663563 chr22:49414524~49657542:- LIHC cis rs858239 0.509 rs6962213 ENSG00000230658.1 KLHL7-AS1 13.69 2.59e-34 3.1e-30 0.69 0.59 Cerebrospinal fluid biomarker levels; chr7:23148490 chr7:23101228~23105703:- LIHC cis rs5758659 0.845 rs5758645 ENSG00000237037.8 NDUFA6-AS1 13.69 2.63e-34 3.15e-30 0.71 0.59 Cognitive function; chr22:42202945 chr22:42090931~42137742:+ LIHC cis rs7188445 0.592 rs7199794 ENSG00000261390.4 RP11-345M22.2 13.69 2.66e-34 3.17e-30 0.71 0.59 Urate levels; chr16:79708296 chr16:79715232~79770563:- LIHC cis rs858239 0.539 rs6955969 ENSG00000230658.1 KLHL7-AS1 13.68 2.67e-34 3.19e-30 0.69 0.59 Cerebrospinal fluid biomarker levels; chr7:23147080 chr7:23101228~23105703:- LIHC cis rs2739330 0.828 rs4820572 ENSG00000218537.1 MIF-AS1 13.68 2.68e-34 3.2e-30 0.77 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23894426~23898930:- LIHC cis rs507080 0.733 rs611733 ENSG00000255239.1 AP002954.6 13.68 2.73e-34 3.26e-30 0.71 0.59 Serum metabolite levels; chr11:118702051 chr11:118688039~118690600:- LIHC cis rs4423214 0.959 rs12793224 ENSG00000254682.1 RP11-660L16.2 13.68 2.77e-34 3.3e-30 0.76 0.59 Vitamin D levels; chr11:71457664 chr11:71448674~71452157:+ LIHC cis rs4423214 0.959 rs12794668 ENSG00000254682.1 RP11-660L16.2 13.68 2.77e-34 3.3e-30 0.76 0.59 Vitamin D levels; chr11:71457669 chr11:71448674~71452157:+ LIHC cis rs858239 0.665 rs6964665 ENSG00000230658.1 KLHL7-AS1 13.68 2.83e-34 3.37e-30 0.78 0.59 Cerebrospinal fluid biomarker levels; chr7:23171733 chr7:23101228~23105703:- LIHC cis rs4423214 1 rs12790010 ENSG00000254682.1 RP11-660L16.2 13.68 2.91e-34 3.45e-30 0.76 0.59 Vitamin D levels; chr11:71459607 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs12806844 ENSG00000254682.1 RP11-660L16.2 13.68 2.91e-34 3.45e-30 0.76 0.59 Vitamin D levels; chr11:71459724 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs12808368 ENSG00000254682.1 RP11-660L16.2 13.68 2.91e-34 3.45e-30 0.76 0.59 Vitamin D levels; chr11:71459771 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs12790558 ENSG00000254682.1 RP11-660L16.2 13.68 2.91e-34 3.45e-30 0.76 0.59 Vitamin D levels; chr11:71459859 chr11:71448674~71452157:+ LIHC cis rs4423214 0.959 rs11233747 ENSG00000254682.1 RP11-660L16.2 13.68 2.91e-34 3.45e-30 0.76 0.59 Vitamin D levels; chr11:71460596 chr11:71448674~71452157:+ LIHC cis rs875971 0.54 rs35510581 ENSG00000226824.5 RP4-756H11.3 13.67 2.94e-34 3.48e-30 0.78 0.59 Aortic root size; chr7:66113790 chr7:66654538~66669855:+ LIHC cis rs2882667 0.69 rs10068280 ENSG00000253404.1 AC034243.1 13.67 3.04e-34 3.6e-30 0.97 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138931394 chr5:138744434~138753309:- LIHC cis rs4423214 1 rs4944959 ENSG00000254682.1 RP11-660L16.2 -13.67 3.05e-34 3.61e-30 -0.75 -0.59 Vitamin D levels; chr11:71457188 chr11:71448674~71452157:+ LIHC cis rs1577917 0.916 rs4706252 ENSG00000203875.9 SNHG5 -13.66 3.23e-34 3.79e-30 -0.65 -0.59 Response to antipsychotic treatment; chr6:85845462 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12202188 ENSG00000203875.9 SNHG5 -13.66 3.23e-34 3.79e-30 -0.65 -0.59 Response to antipsychotic treatment; chr6:85852982 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs36035797 ENSG00000203875.9 SNHG5 -13.66 3.23e-34 3.79e-30 -0.65 -0.59 Response to antipsychotic treatment; chr6:85853162 chr6:85660950~85678736:- LIHC cis rs1577917 0.917 rs2084293 ENSG00000203875.9 SNHG5 -13.66 3.23e-34 3.79e-30 -0.65 -0.59 Response to antipsychotic treatment; chr6:85856284 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12209668 ENSG00000203875.9 SNHG5 -13.66 3.23e-34 3.79e-30 -0.65 -0.59 Response to antipsychotic treatment; chr6:85856799 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs11752180 ENSG00000203875.9 SNHG5 -13.66 3.23e-34 3.79e-30 -0.65 -0.59 Response to antipsychotic treatment; chr6:85863447 chr6:85660950~85678736:- LIHC cis rs2882667 0.628 rs3749663 ENSG00000253404.1 AC034243.1 13.65 3.63e-34 4.26e-30 0.97 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138935498 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs3749664 ENSG00000253404.1 AC034243.1 13.65 3.63e-34 4.26e-30 0.97 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138935732 chr5:138744434~138753309:- LIHC cis rs2739330 0.76 rs5751760 ENSG00000273295.1 AP000350.5 13.65 3.68e-34 4.31e-30 0.64 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23901432~23907068:- LIHC cis rs858239 0.699 rs858260 ENSG00000230658.1 KLHL7-AS1 13.65 3.8e-34 4.45e-30 0.79 0.59 Cerebrospinal fluid biomarker levels; chr7:23173315 chr7:23101228~23105703:- LIHC cis rs1577917 0.696 rs10806334 ENSG00000203875.9 SNHG5 -13.63 4.18e-34 4.88e-30 -0.64 -0.59 Response to antipsychotic treatment; chr6:85729611 chr6:85660950~85678736:- LIHC cis rs2882667 0.654 rs6862845 ENSG00000253404.1 AC034243.1 13.63 4.22e-34 4.92e-30 0.98 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138937456 chr5:138744434~138753309:- LIHC cis rs2882667 0.69 rs10071381 ENSG00000253404.1 AC034243.1 13.63 4.35e-34 5.07e-30 0.99 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138937159 chr5:138744434~138753309:- LIHC cis rs1577917 0.655 rs7742691 ENSG00000203875.9 SNHG5 13.63 4.39e-34 5.11e-30 0.63 0.59 Response to antipsychotic treatment; chr6:85568973 chr6:85660950~85678736:- LIHC cis rs2739330 0.796 rs2154594 ENSG00000273295.1 AP000350.5 -13.63 4.44e-34 5.17e-30 -0.64 -0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23901432~23907068:- LIHC cis rs2739330 0.731 rs4822450 ENSG00000272787.1 KB-226F1.2 -13.63 4.5e-34 5.23e-30 -0.76 -0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23969211~23969873:+ LIHC cis rs1577917 0.71 rs9342041 ENSG00000203875.9 SNHG5 13.61 5.1e-34 5.91e-30 0.63 0.59 Response to antipsychotic treatment; chr6:85571157 chr6:85660950~85678736:- LIHC cis rs2882667 0.69 rs9942422 ENSG00000253404.1 AC034243.1 13.61 5.16e-34 5.98e-30 0.95 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138936847 chr5:138744434~138753309:- LIHC cis rs1577917 0.958 rs12190603 ENSG00000203875.9 SNHG5 -13.59 6.04e-34 6.99e-30 -0.64 -0.59 Response to antipsychotic treatment; chr6:85766000 chr6:85660950~85678736:- LIHC cis rs858239 0.539 rs4504540 ENSG00000230658.1 KLHL7-AS1 13.59 6.04e-34 6.99e-30 0.69 0.59 Cerebrospinal fluid biomarker levels; chr7:23146579 chr7:23101228~23105703:- LIHC cis rs1577917 0.958 rs4707223 ENSG00000203875.9 SNHG5 -13.58 7.08e-34 8.16e-30 -0.65 -0.59 Response to antipsychotic treatment; chr6:85800084 chr6:85660950~85678736:- LIHC cis rs1577917 0.771 rs9450319 ENSG00000203875.9 SNHG5 13.56 7.87e-34 9.07e-30 0.64 0.59 Response to antipsychotic treatment; chr6:85717607 chr6:85660950~85678736:- LIHC cis rs2882667 0.69 rs3763016 ENSG00000253404.1 AC034243.1 13.56 8.36e-34 9.62e-30 0.96 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138935043 chr5:138744434~138753309:- LIHC cis rs801193 0.844 rs2244022 ENSG00000226824.5 RP4-756H11.3 -13.55 8.6e-34 9.89e-30 -0.72 -0.59 Aortic root size; chr7:66737443 chr7:66654538~66669855:+ LIHC cis rs2739330 0.76 rs1007888 ENSG00000272787.1 KB-226F1.2 -13.55 9e-34 1.04e-29 -0.75 -0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23969211~23969873:+ LIHC cis rs1577917 0.682 rs6935918 ENSG00000203875.9 SNHG5 13.55 9.07e-34 1.04e-29 0.63 0.59 Response to antipsychotic treatment; chr6:85573857 chr6:85660950~85678736:- LIHC cis rs5758659 1 rs5751255 ENSG00000237037.8 NDUFA6-AS1 13.53 1.03e-33 1.18e-29 0.69 0.59 Cognitive function; chr22:42252402 chr22:42090931~42137742:+ LIHC cis rs2739330 0.76 rs5751760 ENSG00000272787.1 KB-226F1.2 -13.53 1.08e-33 1.24e-29 -0.76 -0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23969211~23969873:+ LIHC cis rs2882667 0.69 rs891996 ENSG00000253404.1 AC034243.1 13.51 1.22e-33 1.4e-29 0.97 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138932127 chr5:138744434~138753309:- LIHC cis rs1577917 0.958 rs1545376 ENSG00000203875.9 SNHG5 13.51 1.25e-33 1.43e-29 0.64 0.59 Response to antipsychotic treatment; chr6:85794864 chr6:85660950~85678736:- LIHC cis rs2739330 0.685 rs4822453 ENSG00000218537.1 MIF-AS1 13.5 1.41e-33 1.61e-29 0.78 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23894426~23898930:- LIHC cis rs2882667 0.658 rs10076442 ENSG00000253404.1 AC034243.1 13.49 1.5e-33 1.71e-29 0.96 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138941090 chr5:138744434~138753309:- LIHC cis rs2739330 0.652 rs2000469 ENSG00000272787.1 KB-226F1.2 -13.49 1.51e-33 1.72e-29 -0.77 -0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23969211~23969873:+ LIHC cis rs1577917 0.958 rs16876530 ENSG00000203875.9 SNHG5 -13.49 1.52e-33 1.73e-29 -0.63 -0.59 Response to antipsychotic treatment; chr6:85885923 chr6:85660950~85678736:- LIHC cis rs1577917 0.771 rs4383777 ENSG00000203875.9 SNHG5 13.49 1.56e-33 1.77e-29 0.64 0.59 Response to antipsychotic treatment; chr6:85726242 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs6454487 ENSG00000203875.9 SNHG5 13.48 1.64e-33 1.86e-29 0.64 0.59 Response to antipsychotic treatment; chr6:85737150 chr6:85660950~85678736:- LIHC cis rs2739330 0.76 rs1007888 ENSG00000273295.1 AP000350.5 13.47 1.73e-33 1.95e-29 0.63 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23901432~23907068:- LIHC cis rs9326248 0.861 rs494356 ENSG00000254851.1 RP11-109L13.1 -13.47 1.83e-33 2.05e-29 -0.78 -0.59 Blood protein levels; chr11:117201254 chr11:117135528~117138582:+ LIHC cis rs2739330 0.796 rs5760106 ENSG00000218537.1 MIF-AS1 -13.47 1.84e-33 2.06e-29 -0.75 -0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23894426~23898930:- LIHC cis rs875971 0.66 rs10263935 ENSG00000226824.5 RP4-756H11.3 -13.47 1.86e-33 2.08e-29 -0.73 -0.59 Aortic root size; chr7:66631041 chr7:66654538~66669855:+ LIHC cis rs1577917 1 rs2166663 ENSG00000203875.9 SNHG5 -13.47 1.88e-33 2.1e-29 -0.63 -0.59 Response to antipsychotic treatment; chr6:85884178 chr6:85660950~85678736:- LIHC cis rs2739330 0.731 rs2000468 ENSG00000273295.1 AP000350.5 13.45 2.1e-33 2.35e-29 0.62 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23901432~23907068:- LIHC cis rs9326248 0.52 rs2735183 ENSG00000254851.1 RP11-109L13.1 -13.44 2.24e-33 2.5e-29 -0.74 -0.59 Blood protein levels; chr11:117144479 chr11:117135528~117138582:+ LIHC cis rs801193 1 rs10252765 ENSG00000226824.5 RP4-756H11.3 -13.44 2.35e-33 2.62e-29 -0.74 -0.59 Aortic root size; chr7:66763745 chr7:66654538~66669855:+ LIHC cis rs1577917 0.771 rs9362239 ENSG00000203875.9 SNHG5 13.43 2.64e-33 2.93e-29 0.62 0.59 Response to antipsychotic treatment; chr6:85719545 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs1414199 ENSG00000203875.9 SNHG5 -13.42 2.75e-33 3.04e-29 -0.65 -0.59 Response to antipsychotic treatment; chr6:85812652 chr6:85660950~85678736:- LIHC cis rs4423214 1 rs11600569 ENSG00000254682.1 RP11-660L16.2 13.42 2.83e-33 3.14e-29 0.75 0.59 Vitamin D levels; chr11:71462701 chr11:71448674~71452157:+ LIHC cis rs9326248 0.501 rs4938351 ENSG00000254851.1 RP11-109L13.1 -13.42 2.89e-33 3.2e-29 -0.74 -0.59 Blood protein levels; chr11:117151636 chr11:117135528~117138582:+ LIHC cis rs1577917 0.958 rs4707229 ENSG00000203875.9 SNHG5 -13.4 3.31e-33 3.62e-29 -0.64 -0.59 Response to antipsychotic treatment; chr6:85836519 chr6:85660950~85678736:- LIHC cis rs2882667 0.728 rs13181830 ENSG00000253404.1 AC034243.1 -13.38 3.83e-33 4.16e-29 -0.95 -0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138944727 chr5:138744434~138753309:- LIHC cis rs1577917 0.958 rs4707236 ENSG00000203875.9 SNHG5 -13.37 4.32e-33 4.68e-29 -0.63 -0.59 Response to antipsychotic treatment; chr6:85874249 chr6:85660950~85678736:- LIHC cis rs858239 0.669 rs10950940 ENSG00000230658.1 KLHL7-AS1 -13.37 4.35e-33 4.7e-29 -0.68 -0.59 Cerebrospinal fluid biomarker levels; chr7:23157197 chr7:23101228~23105703:- LIHC cis rs2739330 0.627 rs9608219 ENSG00000225282.1 AP000350.6 13.34 5.76e-33 6.2e-29 0.71 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23926900~23929574:+ LIHC cis rs875971 0.706 rs1643374 ENSG00000226824.5 RP4-756H11.3 -13.33 6.33e-33 6.8e-29 -0.77 -0.58 Aortic root size; chr7:66407695 chr7:66654538~66669855:+ LIHC cis rs9326248 0.52 rs74830 ENSG00000254851.1 RP11-109L13.1 13.32 6.82e-33 7.31e-29 0.74 0.58 Blood protein levels; chr11:117219842 chr11:117135528~117138582:+ LIHC cis rs2739330 0.796 rs5760106 ENSG00000273295.1 AP000350.5 -13.32 7.06e-33 7.56e-29 -0.6 -0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23901432~23907068:- LIHC cis rs9326248 0.52 rs6589602 ENSG00000254851.1 RP11-109L13.1 -13.31 7.41e-33 7.92e-29 -0.74 -0.58 Blood protein levels; chr11:117166349 chr11:117135528~117138582:+ LIHC cis rs9326248 0.539 rs7120565 ENSG00000254851.1 RP11-109L13.1 -13.31 7.41e-33 7.92e-29 -0.74 -0.58 Blood protein levels; chr11:117172233 chr11:117135528~117138582:+ LIHC cis rs5758659 1 rs134882 ENSG00000237037.8 NDUFA6-AS1 13.3 7.72e-33 8.22e-29 0.68 0.58 Cognitive function; chr22:42274959 chr22:42090931~42137742:+ LIHC cis rs5769707 0.967 rs763126 ENSG00000188511.11 C22orf34 -13.3 8.16e-33 8.68e-29 -0.67 -0.58 Monocyte percentage of white cells;Monocyte count; chr22:49594926 chr22:49414524~49657542:- LIHC cis rs1577917 0.816 rs9353349 ENSG00000203875.9 SNHG5 13.3 8.27e-33 8.79e-29 0.64 0.58 Response to antipsychotic treatment; chr6:85998007 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs10455448 ENSG00000203875.9 SNHG5 -13.28 9.61e-33 1.01e-28 -0.64 -0.58 Response to antipsychotic treatment; chr6:85823893 chr6:85660950~85678736:- LIHC cis rs1577917 0.917 rs13196576 ENSG00000203875.9 SNHG5 -13.28 9.61e-33 1.01e-28 -0.64 -0.58 Response to antipsychotic treatment; chr6:85824348 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs3857480 ENSG00000203875.9 SNHG5 -13.28 9.61e-33 1.01e-28 -0.64 -0.58 Response to antipsychotic treatment; chr6:85825431 chr6:85660950~85678736:- LIHC cis rs858239 0.509 rs57611130 ENSG00000230658.1 KLHL7-AS1 13.28 9.9e-33 1.04e-28 0.7 0.58 Cerebrospinal fluid biomarker levels; chr7:23144933 chr7:23101228~23105703:- LIHC cis rs2739330 0.731 rs4822450 ENSG00000218537.1 MIF-AS1 13.28 9.97e-33 1.05e-28 0.77 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23894426~23898930:- LIHC cis rs2882667 0.69 rs11750163 ENSG00000253404.1 AC034243.1 13.27 1.09e-32 1.15e-28 0.96 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:138705920 chr5:138744434~138753309:- LIHC cis rs1577917 1 rs7747824 ENSG00000203875.9 SNHG5 -13.26 1.13e-32 1.19e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85937388 chr6:85660950~85678736:- LIHC cis rs10256972 0.577 rs6962809 ENSG00000229043.2 AC091729.9 -13.26 1.19e-32 1.25e-28 -0.64 -0.58 Endometriosis;Longevity; chr7:1169253 chr7:1160374~1165267:+ LIHC cis rs2260433 0.556 rs11606477 ENSG00000281655.1 RP11-817J15.3 -13.25 1.24e-32 1.29e-28 -0.89 -0.58 Cleft palate; chr11:102633548 chr11:102681310~102683913:+ LIHC cis rs875971 0.666 rs13242072 ENSG00000226824.5 RP4-756H11.3 13.25 1.25e-32 1.3e-28 0.76 0.58 Aortic root size; chr7:66301001 chr7:66654538~66669855:+ LIHC cis rs10256972 0.552 rs6978842 ENSG00000229043.2 AC091729.9 -13.25 1.27e-32 1.32e-28 -0.64 -0.58 Endometriosis;Longevity; chr7:1164963 chr7:1160374~1165267:+ LIHC cis rs2739330 0.76 rs5760095 ENSG00000273295.1 AP000350.5 13.22 1.61e-32 1.67e-28 0.62 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23901432~23907068:- LIHC cis rs2882667 0.69 rs311608 ENSG00000253404.1 AC034243.1 13.22 1.67e-32 1.73e-28 0.97 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:138708000 chr5:138744434~138753309:- LIHC cis rs8013143 1 rs11846575 ENSG00000279656.1 RP11-298I3.6 -13.22 1.67e-32 1.73e-28 -0.85 -0.58 Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width; chr14:23022075 chr14:23023083~23024217:- LIHC cis rs801193 0.773 rs801207 ENSG00000226824.5 RP4-756H11.3 13.21 1.71e-32 1.77e-28 0.7 0.58 Aortic root size; chr7:66555603 chr7:66654538~66669855:+ LIHC cis rs875971 0.543 rs801191 ENSG00000226824.5 RP4-756H11.3 13.21 1.71e-32 1.77e-28 0.7 0.58 Aortic root size; chr7:66567968 chr7:66654538~66669855:+ LIHC cis rs1577917 1 rs7766645 ENSG00000203875.9 SNHG5 -13.2 2.01e-32 2.07e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85912520 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs1911552 ENSG00000203875.9 SNHG5 -13.2 2.01e-32 2.07e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85928306 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs9647603 ENSG00000203875.9 SNHG5 -13.2 2.01e-32 2.07e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85929623 chr6:85660950~85678736:- LIHC cis rs858239 0.669 rs1618339 ENSG00000230658.1 KLHL7-AS1 13.19 2.04e-32 2.1e-28 0.69 0.58 Cerebrospinal fluid biomarker levels; chr7:23190155 chr7:23101228~23105703:- LIHC cis rs7188445 0.787 rs7189954 ENSG00000261390.4 RP11-345M22.2 13.19 2.06e-32 2.13e-28 0.67 0.58 Urate levels; chr16:79701150 chr16:79715232~79770563:- LIHC cis rs1577917 0.958 rs12216074 ENSG00000203875.9 SNHG5 -13.19 2.16e-32 2.23e-28 -0.64 -0.58 Response to antipsychotic treatment; chr6:85810284 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs13199006 ENSG00000203875.9 SNHG5 -13.19 2.2e-32 2.26e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85898990 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs4707239 ENSG00000203875.9 SNHG5 -13.19 2.2e-32 2.26e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85900999 chr6:85660950~85678736:- LIHC cis rs8013143 1 rs941718 ENSG00000279656.1 RP11-298I3.6 -13.18 2.23e-32 2.3e-28 -0.86 -0.58 Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width; chr14:23025839 chr14:23023083~23024217:- LIHC cis rs875971 0.628 rs6974355 ENSG00000226824.5 RP4-756H11.3 -13.18 2.36e-32 2.42e-28 -0.76 -0.58 Aortic root size; chr7:66376994 chr7:66654538~66669855:+ LIHC cis rs8013143 1 rs8013143 ENSG00000279656.1 RP11-298I3.6 -13.17 2.58e-32 2.65e-28 -0.86 -0.58 Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width; chr14:23025068 chr14:23023083~23024217:- LIHC cis rs2739330 0.796 rs1006771 ENSG00000218537.1 MIF-AS1 13.17 2.59e-32 2.66e-28 0.73 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23894426~23898930:- LIHC cis rs1577917 1 rs791856 ENSG00000203875.9 SNHG5 13.15 2.91e-32 2.97e-28 0.62 0.58 Response to antipsychotic treatment; chr6:85972123 chr6:85660950~85678736:- LIHC cis rs2739330 0.791 rs9612520 ENSG00000225282.1 AP000350.6 13.15 3e-32 3.06e-28 0.71 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23926900~23929574:+ LIHC cis rs858239 0.669 rs1990365 ENSG00000230658.1 KLHL7-AS1 13.15 3.02e-32 3.08e-28 0.68 0.58 Cerebrospinal fluid biomarker levels; chr7:23076347 chr7:23101228~23105703:- LIHC cis rs1577917 0.958 rs7739241 ENSG00000203875.9 SNHG5 -13.15 3.15e-32 3.21e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85866078 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12202712 ENSG00000203875.9 SNHG5 -13.15 3.15e-32 3.21e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85868823 chr6:85660950~85678736:- LIHC cis rs1577917 0.739 rs9450318 ENSG00000203875.9 SNHG5 13.14 3.32e-32 3.38e-28 0.62 0.58 Response to antipsychotic treatment; chr6:85717459 chr6:85660950~85678736:- LIHC cis rs875971 0.577 rs34888281 ENSG00000226824.5 RP4-756H11.3 13.14 3.38e-32 3.44e-28 0.8 0.58 Aortic root size; chr7:66120784 chr7:66654538~66669855:+ LIHC cis rs10256972 0.552 rs2960830 ENSG00000229043.2 AC091729.9 -13.14 3.39e-32 3.44e-28 -0.64 -0.58 Endometriosis;Longevity; chr7:1161005 chr7:1160374~1165267:+ LIHC cis rs10256972 0.552 rs2960831 ENSG00000229043.2 AC091729.9 -13.14 3.39e-32 3.44e-28 -0.64 -0.58 Endometriosis;Longevity; chr7:1161556 chr7:1160374~1165267:+ LIHC cis rs1577917 1 rs6914463 ENSG00000203875.9 SNHG5 -13.13 3.69e-32 3.73e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85943697 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs2816821 ENSG00000203875.9 SNHG5 -13.13 3.69e-32 3.73e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85947366 chr6:85660950~85678736:- LIHC cis rs10256972 0.577 rs2949179 ENSG00000229043.2 AC091729.9 -13.12 4.03e-32 4.03e-28 -0.64 -0.58 Endometriosis;Longevity; chr7:1170249 chr7:1160374~1165267:+ LIHC cis rs10256972 0.504 rs2949178 ENSG00000229043.2 AC091729.9 -13.12 4.03e-32 4.03e-28 -0.64 -0.58 Endometriosis;Longevity; chr7:1170289 chr7:1160374~1165267:+ LIHC cis rs801193 0.844 rs732465 ENSG00000226824.5 RP4-756H11.3 -13.11 4.2e-32 4.19e-28 -0.7 -0.58 Aortic root size; chr7:66533463 chr7:66654538~66669855:+ LIHC cis rs4423214 1 rs12785878 ENSG00000254682.1 RP11-660L16.2 13.1 4.76e-32 4.73e-28 0.72 0.58 Vitamin D levels; chr11:71456403 chr11:71448674~71452157:+ LIHC cis rs2260433 0.556 rs11225348 ENSG00000281655.1 RP11-817J15.3 13.1 4.79e-32 4.75e-28 0.89 0.58 Cleft palate; chr11:102633740 chr11:102681310~102683913:+ LIHC cis rs1577917 1 rs35385043 ENSG00000203875.9 SNHG5 -13.09 4.94e-32 4.89e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85938828 chr6:85660950~85678736:- LIHC cis rs801193 1 rs13239306 ENSG00000226824.5 RP4-756H11.3 13.09 4.96e-32 4.92e-28 0.72 0.58 Aortic root size; chr7:66671030 chr7:66654538~66669855:+ LIHC cis rs801193 0.901 rs4273746 ENSG00000226824.5 RP4-756H11.3 13.06 6.39e-32 6.29e-28 0.78 0.58 Aortic root size; chr7:66836124 chr7:66654538~66669855:+ LIHC cis rs875971 0.66 rs10229345 ENSG00000226824.5 RP4-756H11.3 -13.05 7.17e-32 7.02e-28 -0.75 -0.58 Aortic root size; chr7:66517181 chr7:66654538~66669855:+ LIHC cis rs1577917 0.958 rs1447160 ENSG00000203875.9 SNHG5 -13.04 7.88e-32 7.66e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85836405 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12198061 ENSG00000203875.9 SNHG5 -13.04 7.88e-32 7.66e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85841267 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs1838955 ENSG00000203875.9 SNHG5 -13.04 7.88e-32 7.66e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85855731 chr6:85660950~85678736:- LIHC cis rs1577917 0.874 rs1838954 ENSG00000203875.9 SNHG5 -13.04 7.88e-32 7.66e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85855760 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs2084294 ENSG00000203875.9 SNHG5 -13.04 7.88e-32 7.66e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85856225 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12660846 ENSG00000203875.9 SNHG5 -13.04 7.88e-32 7.66e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85864091 chr6:85660950~85678736:- LIHC cis rs858239 0.669 rs1006709 ENSG00000230658.1 KLHL7-AS1 13.03 8.44e-32 8.19e-28 0.66 0.58 Cerebrospinal fluid biomarker levels; chr7:23100480 chr7:23101228~23105703:- LIHC cis rs858239 0.699 rs955187 ENSG00000230658.1 KLHL7-AS1 -13.03 9.02e-32 8.74e-28 -0.66 -0.58 Cerebrospinal fluid biomarker levels; chr7:23154986 chr7:23101228~23105703:- LIHC cis rs1577917 0.958 rs12213431 ENSG00000203875.9 SNHG5 -13.02 9.09e-32 8.8e-28 -0.63 -0.58 Response to antipsychotic treatment; chr6:85791238 chr6:85660950~85678736:- LIHC cis rs801193 0.839 rs12534943 ENSG00000226824.5 RP4-756H11.3 13.02 9.78e-32 9.41e-28 0.7 0.58 Aortic root size; chr7:66605533 chr7:66654538~66669855:+ LIHC cis rs875971 0.508 rs10950045 ENSG00000226824.5 RP4-756H11.3 13.02 9.83e-32 9.41e-28 0.69 0.58 Aortic root size; chr7:66601386 chr7:66654538~66669855:+ LIHC cis rs801193 0.839 rs6968619 ENSG00000226824.5 RP4-756H11.3 13.02 9.83e-32 9.41e-28 0.69 0.58 Aortic root size; chr7:66603880 chr7:66654538~66669855:+ LIHC cis rs801193 0.805 rs12532355 ENSG00000226824.5 RP4-756H11.3 13.01 9.94e-32 9.51e-28 0.69 0.58 Aortic root size; chr7:66605597 chr7:66654538~66669855:+ LIHC cis rs2739330 0.929 rs5751777 ENSG00000225282.1 AP000350.6 13.01 1.04e-31 9.98e-28 0.69 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23926900~23929574:+ LIHC cis rs1577917 0.916 rs7759727 ENSG00000203875.9 SNHG5 -13 1.17e-31 1.11e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85809160 chr6:85660950~85678736:- LIHC cis rs875971 0.508 rs10258739 ENSG00000226824.5 RP4-756H11.3 12.99 1.23e-31 1.17e-27 0.69 0.57 Aortic root size; chr7:66597948 chr7:66654538~66669855:+ LIHC cis rs1577917 1 rs4706254 ENSG00000203875.9 SNHG5 -12.99 1.24e-31 1.18e-27 -0.62 -0.57 Response to antipsychotic treatment; chr6:85893095 chr6:85660950~85678736:- LIHC cis rs875971 0.558 rs4433015 ENSG00000226824.5 RP4-756H11.3 12.97 1.47e-31 1.39e-27 0.77 0.57 Aortic root size; chr7:66174736 chr7:66654538~66669855:+ LIHC cis rs1577917 0.538 rs7755996 ENSG00000203875.9 SNHG5 12.96 1.57e-31 1.49e-27 0.6 0.57 Response to antipsychotic treatment; chr6:85714002 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12196230 ENSG00000203875.9 SNHG5 -12.95 1.76e-31 1.65e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85810242 chr6:85660950~85678736:- LIHC cis rs858239 0.539 rs2103281 ENSG00000230658.1 KLHL7-AS1 12.94 1.85e-31 1.74e-27 0.75 0.57 Cerebrospinal fluid biomarker levels; chr7:23154612 chr7:23101228~23105703:- LIHC cis rs4423214 1 rs12792306 ENSG00000254682.1 RP11-660L16.2 12.94 1.87e-31 1.75e-27 0.72 0.57 Vitamin D levels; chr11:71455946 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs4944955 ENSG00000254682.1 RP11-660L16.2 12.94 1.87e-31 1.75e-27 0.72 0.57 Vitamin D levels; chr11:71456631 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs4944956 ENSG00000254682.1 RP11-660L16.2 12.94 1.87e-31 1.75e-27 0.72 0.57 Vitamin D levels; chr11:71456719 chr11:71448674~71452157:+ LIHC cis rs1577917 0.958 rs2660576 ENSG00000203875.9 SNHG5 -12.94 1.89e-31 1.78e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85941885 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs34994386 ENSG00000203875.9 SNHG5 -12.92 2.27e-31 2.12e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85814417 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs36042496 ENSG00000203875.9 SNHG5 -12.92 2.27e-31 2.12e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85814496 chr6:85660950~85678736:- LIHC cis rs1577917 0.917 rs1584273 ENSG00000203875.9 SNHG5 -12.92 2.27e-31 2.12e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85814859 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12198971 ENSG00000203875.9 SNHG5 -12.92 2.27e-31 2.12e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85815727 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs34230196 ENSG00000203875.9 SNHG5 -12.92 2.27e-31 2.12e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85816304 chr6:85660950~85678736:- LIHC cis rs1577917 0.917 rs4707226 ENSG00000203875.9 SNHG5 -12.92 2.27e-31 2.12e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85818110 chr6:85660950~85678736:- LIHC cis rs1577917 0.876 rs12212808 ENSG00000203875.9 SNHG5 -12.92 2.27e-31 2.12e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85824254 chr6:85660950~85678736:- LIHC cis rs1577917 0.917 rs13213603 ENSG00000203875.9 SNHG5 -12.92 2.27e-31 2.12e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85825040 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs2324839 ENSG00000203875.9 SNHG5 -12.92 2.27e-31 2.12e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85827224 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs3900313 ENSG00000203875.9 SNHG5 -12.92 2.27e-31 2.12e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85827436 chr6:85660950~85678736:- LIHC cis rs858239 0.539 rs2390757 ENSG00000230658.1 KLHL7-AS1 12.92 2.3e-31 2.14e-27 0.74 0.57 Cerebrospinal fluid biomarker levels; chr7:23151873 chr7:23101228~23105703:- LIHC cis rs1577917 0.958 rs1337843 ENSG00000203875.9 SNHG5 -12.92 2.32e-31 2.16e-27 -0.62 -0.57 Response to antipsychotic treatment; chr6:85965827 chr6:85660950~85678736:- LIHC cis rs6952407 1 rs6952407 ENSG00000226824.5 RP4-756H11.3 12.91 2.38e-31 2.22e-27 0.75 0.57 Cotinine glucuronidation; chr7:66580525 chr7:66654538~66669855:+ LIHC cis rs1577917 1 rs2812972 ENSG00000203875.9 SNHG5 -12.91 2.51e-31 2.33e-27 -0.62 -0.57 Response to antipsychotic treatment; chr6:85960162 chr6:85660950~85678736:- LIHC cis rs2739330 0.731 rs2000468 ENSG00000272787.1 KB-226F1.2 -12.9 2.78e-31 2.57e-27 -0.73 -0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23969211~23969873:+ LIHC cis rs10256972 0.552 rs2960837 ENSG00000229043.2 AC091729.9 -12.9 2.78e-31 2.58e-27 -0.64 -0.57 Endometriosis;Longevity; chr7:1164321 chr7:1160374~1165267:+ LIHC cis rs4423214 1 rs7928249 ENSG00000254682.1 RP11-660L16.2 12.9 2.8e-31 2.6e-27 0.72 0.57 Vitamin D levels; chr11:71450017 chr11:71448674~71452157:+ LIHC cis rs1577917 0.917 rs2218594 ENSG00000203875.9 SNHG5 -12.87 3.39e-31 3.11e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85834048 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs2197648 ENSG00000203875.9 SNHG5 -12.87 3.39e-31 3.11e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85834169 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs2100109 ENSG00000203875.9 SNHG5 -12.87 3.39e-31 3.11e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85835208 chr6:85660950~85678736:- LIHC cis rs16828019 0.852 rs12759050 ENSG00000235358.1 RP11-399E6.1 12.87 3.39e-31 3.11e-27 0.86 0.57 Intelligence (multi-trait analysis); chr1:41198532 chr1:41242373~41284861:+ LIHC cis rs16828019 0.789 rs34216154 ENSG00000235358.1 RP11-399E6.1 12.87 3.39e-31 3.11e-27 0.86 0.57 Intelligence (multi-trait analysis); chr1:41205235 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs12044539 ENSG00000235358.1 RP11-399E6.1 12.87 3.53e-31 3.22e-27 0.86 0.57 Intelligence (multi-trait analysis); chr1:41196060 chr1:41242373~41284861:+ LIHC cis rs1577917 1 rs35760725 ENSG00000203875.9 SNHG5 -12.85 4.07e-31 3.7e-27 -0.63 -0.57 Response to antipsychotic treatment; chr6:85939267 chr6:85660950~85678736:- LIHC cis rs4423214 1 rs2276360 ENSG00000254682.1 RP11-660L16.2 12.85 4.17e-31 3.78e-27 0.73 0.57 Vitamin D levels; chr11:71458501 chr11:71448674~71452157:+ LIHC cis rs858239 0.508 rs2390754 ENSG00000230658.1 KLHL7-AS1 12.85 4.2e-31 3.81e-27 0.73 0.57 Cerebrospinal fluid biomarker levels; chr7:23150875 chr7:23101228~23105703:- LIHC cis rs4423214 1 rs12797951 ENSG00000254682.1 RP11-660L16.2 -12.85 4.27e-31 3.87e-27 -0.71 -0.57 Vitamin D levels; chr11:71432220 chr11:71448674~71452157:+ LIHC cis rs16828019 0.852 rs12742803 ENSG00000235358.1 RP11-399E6.1 12.84 4.73e-31 4.27e-27 0.87 0.57 Intelligence (multi-trait analysis); chr1:41182459 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs12408956 ENSG00000235358.1 RP11-399E6.1 12.84 4.73e-31 4.27e-27 0.87 0.57 Intelligence (multi-trait analysis); chr1:41186280 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs35992757 ENSG00000235358.1 RP11-399E6.1 12.84 4.73e-31 4.27e-27 0.87 0.57 Intelligence (multi-trait analysis); chr1:41187190 chr1:41242373~41284861:+ LIHC cis rs858239 0.539 rs10247268 ENSG00000230658.1 KLHL7-AS1 12.83 5.04e-31 4.54e-27 0.73 0.57 Cerebrospinal fluid biomarker levels; chr7:23147560 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs6461694 ENSG00000230658.1 KLHL7-AS1 12.83 5.04e-31 4.54e-27 0.73 0.57 Cerebrospinal fluid biomarker levels; chr7:23148160 chr7:23101228~23105703:- LIHC cis rs858239 0.508 rs7805071 ENSG00000230658.1 KLHL7-AS1 12.83 5.04e-31 4.54e-27 0.73 0.57 Cerebrospinal fluid biomarker levels; chr7:23150593 chr7:23101228~23105703:- LIHC cis rs858239 0.508 rs7805085 ENSG00000230658.1 KLHL7-AS1 12.83 5.04e-31 4.54e-27 0.73 0.57 Cerebrospinal fluid biomarker levels; chr7:23150624 chr7:23101228~23105703:- LIHC cis rs2739330 0.76 rs5751760 ENSG00000218537.1 MIF-AS1 12.83 5.04e-31 4.54e-27 0.76 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23894426~23898930:- LIHC cis rs4423214 1 rs2276361 ENSG00000254682.1 RP11-660L16.2 12.82 5.34e-31 4.81e-27 0.72 0.57 Vitamin D levels; chr11:71458602 chr11:71448674~71452157:+ LIHC cis rs875971 0.508 rs10242423 ENSG00000226824.5 RP4-756H11.3 12.82 5.4e-31 4.86e-27 0.69 0.57 Aortic root size; chr7:66594188 chr7:66654538~66669855:+ LIHC cis rs875971 0.508 rs10253883 ENSG00000226824.5 RP4-756H11.3 12.82 5.4e-31 4.86e-27 0.69 0.57 Aortic root size; chr7:66596151 chr7:66654538~66669855:+ LIHC cis rs1577917 0.876 rs11752223 ENSG00000203875.9 SNHG5 -12.82 5.56e-31 5e-27 -0.62 -0.57 Response to antipsychotic treatment; chr6:85863676 chr6:85660950~85678736:- LIHC cis rs2739330 0.791 rs4822458 ENSG00000225282.1 AP000350.6 12.81 6.03e-31 5.41e-27 0.68 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23926900~23929574:+ LIHC cis rs16828019 0.929 rs1032728 ENSG00000235358.1 RP11-399E6.1 12.8 6.2e-31 5.56e-27 0.85 0.57 Intelligence (multi-trait analysis); chr1:41213894 chr1:41242373~41284861:+ LIHC cis rs1577917 1 rs2816815 ENSG00000203875.9 SNHG5 -12.8 6.29e-31 5.64e-27 -0.62 -0.57 Response to antipsychotic treatment; chr6:85981938 chr6:85660950~85678736:- LIHC cis rs875971 0.508 rs6947808 ENSG00000226824.5 RP4-756H11.3 12.8 6.62e-31 5.93e-27 0.69 0.57 Aortic root size; chr7:66580095 chr7:66654538~66669855:+ LIHC cis rs916888 0.821 rs199499 ENSG00000214401.4 KANSL1-AS1 12.79 6.83e-31 6.11e-27 1.23 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788132 chr17:46193576~46196723:+ LIHC cis rs2260433 0.556 rs61893868 ENSG00000281655.1 RP11-817J15.3 12.79 7.3e-31 6.52e-27 0.87 0.57 Cleft palate; chr11:102633068 chr11:102681310~102683913:+ LIHC cis rs2260433 0.556 rs61893869 ENSG00000281655.1 RP11-817J15.3 12.79 7.3e-31 6.52e-27 0.87 0.57 Cleft palate; chr11:102633373 chr11:102681310~102683913:+ LIHC cis rs16828019 0.929 rs12029321 ENSG00000235358.1 RP11-399E6.1 12.78 7.74e-31 6.89e-27 0.84 0.57 Intelligence (multi-trait analysis); chr1:41216858 chr1:41242373~41284861:+ LIHC cis rs16828019 0.929 rs35286837 ENSG00000235358.1 RP11-399E6.1 12.78 7.74e-31 6.89e-27 0.84 0.57 Intelligence (multi-trait analysis); chr1:41217326 chr1:41242373~41284861:+ LIHC cis rs16828019 0.929 rs11209734 ENSG00000235358.1 RP11-399E6.1 12.78 7.74e-31 6.89e-27 0.84 0.57 Intelligence (multi-trait analysis); chr1:41232402 chr1:41242373~41284861:+ LIHC cis rs16828019 0.929 rs12037037 ENSG00000235358.1 RP11-399E6.1 12.78 7.74e-31 6.89e-27 0.84 0.57 Intelligence (multi-trait analysis); chr1:41232584 chr1:41242373~41284861:+ LIHC cis rs858239 0.539 rs4559148 ENSG00000230658.1 KLHL7-AS1 12.78 7.89e-31 7.01e-27 0.73 0.57 Cerebrospinal fluid biomarker levels; chr7:23146348 chr7:23101228~23105703:- LIHC cis rs858239 0.539 rs4377861 ENSG00000230658.1 KLHL7-AS1 12.78 7.89e-31 7.01e-27 0.73 0.57 Cerebrospinal fluid biomarker levels; chr7:23146350 chr7:23101228~23105703:- LIHC cis rs16828019 0.852 rs12759023 ENSG00000235358.1 RP11-399E6.1 12.78 7.93e-31 7.03e-27 0.87 0.57 Intelligence (multi-trait analysis); chr1:41138306 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs34286980 ENSG00000235358.1 RP11-399E6.1 12.78 7.93e-31 7.03e-27 0.87 0.57 Intelligence (multi-trait analysis); chr1:41142717 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs71648534 ENSG00000235358.1 RP11-399E6.1 12.78 7.93e-31 7.03e-27 0.87 0.57 Intelligence (multi-trait analysis); chr1:41148075 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs71648535 ENSG00000235358.1 RP11-399E6.1 12.78 7.93e-31 7.03e-27 0.87 0.57 Intelligence (multi-trait analysis); chr1:41148078 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs12048187 ENSG00000235358.1 RP11-399E6.1 12.78 7.93e-31 7.03e-27 0.87 0.57 Intelligence (multi-trait analysis); chr1:41150511 chr1:41242373~41284861:+ LIHC cis rs858239 0.539 rs6461695 ENSG00000230658.1 KLHL7-AS1 12.77 8.46e-31 7.5e-27 0.75 0.57 Cerebrospinal fluid biomarker levels; chr7:23158165 chr7:23101228~23105703:- LIHC cis rs4423214 1 rs2852853 ENSG00000254682.1 RP11-660L16.2 12.76 9.25e-31 8.19e-27 0.71 0.57 Vitamin D levels; chr11:71439171 chr11:71448674~71452157:+ LIHC cis rs858239 0.67 rs6967526 ENSG00000230658.1 KLHL7-AS1 12.75 1e-30 8.86e-27 0.65 0.57 Cerebrospinal fluid biomarker levels; chr7:23119622 chr7:23101228~23105703:- LIHC cis rs1577917 1 rs6454513 ENSG00000203875.9 SNHG5 12.74 1.08e-30 9.51e-27 0.61 0.57 Response to antipsychotic treatment; chr6:86010331 chr6:85660950~85678736:- LIHC cis rs858239 0.669 rs6461687 ENSG00000230658.1 KLHL7-AS1 12.74 1.08e-30 9.53e-27 0.67 0.57 Cerebrospinal fluid biomarker levels; chr7:23076961 chr7:23101228~23105703:- LIHC cis rs4423214 1 rs4944957 ENSG00000254682.1 RP11-660L16.2 -12.73 1.2e-30 1.06e-26 -0.71 -0.57 Vitamin D levels; chr11:71456989 chr11:71448674~71452157:+ LIHC cis rs4423214 0.819 rs7938885 ENSG00000254682.1 RP11-660L16.2 12.72 1.29e-30 1.14e-26 0.72 0.57 Vitamin D levels; chr11:71458997 chr11:71448674~71452157:+ LIHC cis rs4423214 0.959 rs12800438 ENSG00000254682.1 RP11-660L16.2 12.72 1.29e-30 1.14e-26 0.72 0.57 Vitamin D levels; chr11:71459957 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs12807718 ENSG00000254682.1 RP11-660L16.2 12.72 1.29e-30 1.14e-26 0.72 0.57 Vitamin D levels; chr11:71460124 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs4423214 ENSG00000254682.1 RP11-660L16.2 12.72 1.29e-30 1.14e-26 0.72 0.57 Vitamin D levels; chr11:71462208 chr11:71448674~71452157:+ LIHC cis rs1577917 1 rs6923148 ENSG00000203875.9 SNHG5 12.72 1.31e-30 1.15e-26 0.62 0.57 Response to antipsychotic treatment; chr6:86058068 chr6:85660950~85678736:- LIHC cis rs2739330 0.76 rs5751761 ENSG00000273295.1 AP000350.5 -12.72 1.35e-30 1.18e-26 -0.62 -0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23901432~23907068:- LIHC cis rs507080 0.733 rs489126 ENSG00000255239.1 AP002954.6 12.72 1.35e-30 1.18e-26 0.68 0.57 Serum metabolite levels; chr11:118702038 chr11:118688039~118690600:- LIHC cis rs858239 0.539 rs6975852 ENSG00000230658.1 KLHL7-AS1 12.71 1.47e-30 1.28e-26 0.73 0.57 Cerebrospinal fluid biomarker levels; chr7:23147035 chr7:23101228~23105703:- LIHC cis rs2882667 0.69 rs825747 ENSG00000253404.1 AC034243.1 -12.7 1.56e-30 1.36e-26 -1 -0.57 Age-related hearing impairment (SNP x SNP interaction); chr5:138800896 chr5:138744434~138753309:- LIHC cis rs858239 0.539 rs10254544 ENSG00000230658.1 KLHL7-AS1 12.7 1.56e-30 1.36e-26 0.75 0.57 Cerebrospinal fluid biomarker levels; chr7:23180616 chr7:23101228~23105703:- LIHC cis rs858239 0.537 rs10279691 ENSG00000230658.1 KLHL7-AS1 12.7 1.6e-30 1.39e-26 0.74 0.57 Cerebrospinal fluid biomarker levels; chr7:23188768 chr7:23101228~23105703:- LIHC cis rs2739330 0.731 rs5751792 ENSG00000272787.1 KB-226F1.2 -12.68 1.88e-30 1.63e-26 -0.72 -0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23969211~23969873:+ LIHC cis rs2739330 0.761 rs5760176 ENSG00000272787.1 KB-226F1.2 12.67 1.93e-30 1.67e-26 0.72 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23969211~23969873:+ LIHC cis rs4423214 0.918 rs11233789 ENSG00000254682.1 RP11-660L16.2 12.66 2.2e-30 1.9e-26 0.71 0.56 Vitamin D levels; chr11:71470039 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs11233746 ENSG00000254682.1 RP11-660L16.2 12.66 2.26e-30 1.95e-26 0.71 0.56 Vitamin D levels; chr11:71460394 chr11:71448674~71452157:+ LIHC cis rs5769707 0.732 rs135865 ENSG00000188511.11 C22orf34 12.65 2.4e-30 2.06e-26 0.65 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49611181 chr22:49414524~49657542:- LIHC cis rs4423214 1 rs7935125 ENSG00000254682.1 RP11-660L16.2 12.64 2.56e-30 2.19e-26 0.73 0.56 Vitamin D levels; chr11:71473144 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs3794060 ENSG00000254682.1 RP11-660L16.2 12.64 2.56e-30 2.19e-26 0.73 0.56 Vitamin D levels; chr11:71476633 chr11:71448674~71452157:+ LIHC cis rs2739330 0.76 rs1007888 ENSG00000218537.1 MIF-AS1 12.64 2.7e-30 2.31e-26 0.75 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23894426~23898930:- LIHC cis rs4423214 1 rs4944946 ENSG00000254682.1 RP11-660L16.2 12.63 2.74e-30 2.34e-26 0.73 0.56 Vitamin D levels; chr11:71448383 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs28364617 ENSG00000254682.1 RP11-660L16.2 12.63 2.74e-30 2.34e-26 0.73 0.56 Vitamin D levels; chr11:71448718 chr11:71448674~71452157:+ LIHC cis rs16828019 0.929 rs8179465 ENSG00000235358.1 RP11-399E6.1 12.63 2.86e-30 2.44e-26 0.84 0.56 Intelligence (multi-trait analysis); chr1:41236075 chr1:41242373~41284861:+ LIHC cis rs9326248 0.689 rs4516002 ENSG00000254851.1 RP11-109L13.1 -12.62 3.19e-30 2.71e-26 -0.74 -0.56 Blood protein levels; chr11:117128343 chr11:117135528~117138582:+ LIHC cis rs4423214 1 rs2276362 ENSG00000254682.1 RP11-660L16.2 12.61 3.33e-30 2.82e-26 0.72 0.56 Vitamin D levels; chr11:71463406 chr11:71448674~71452157:+ LIHC cis rs858239 0.537 rs2286272 ENSG00000230658.1 KLHL7-AS1 12.59 4.11e-30 3.44e-26 0.74 0.56 Cerebrospinal fluid biomarker levels; chr7:23184748 chr7:23101228~23105703:- LIHC cis rs858239 0.537 rs6955115 ENSG00000230658.1 KLHL7-AS1 12.59 4.11e-30 3.44e-26 0.74 0.56 Cerebrospinal fluid biomarker levels; chr7:23187525 chr7:23101228~23105703:- LIHC cis rs977987 0.735 rs11149831 ENSG00000261783.1 RP11-252K23.2 -12.58 4.35e-30 3.63e-26 -0.67 -0.56 Dupuytren's disease; chr16:75417563 chr16:75379818~75381260:- LIHC cis rs5758659 0.737 rs10854749 ENSG00000237037.8 NDUFA6-AS1 12.58 4.45e-30 3.71e-26 0.68 0.56 Cognitive function; chr22:42051337 chr22:42090931~42137742:+ LIHC cis rs4423214 1 rs909217 ENSG00000254682.1 RP11-660L16.2 12.57 4.66e-30 3.88e-26 0.72 0.56 Vitamin D levels; chr11:71435531 chr11:71448674~71452157:+ LIHC cis rs5769707 0.632 rs6009782 ENSG00000188511.11 C22orf34 12.56 5.14e-30 4.28e-26 0.67 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49617164 chr22:49414524~49657542:- LIHC cis rs2739330 0.731 rs2000468 ENSG00000218537.1 MIF-AS1 12.56 5.18e-30 4.31e-26 0.74 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23894426~23898930:- LIHC cis rs2739330 0.796 rs1006771 ENSG00000272787.1 KB-226F1.2 -12.54 6.23e-30 5.17e-26 -0.68 -0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23969211~23969873:+ LIHC cis rs4423214 1 rs732934 ENSG00000254682.1 RP11-660L16.2 12.54 6.37e-30 5.29e-26 0.72 0.56 Vitamin D levels; chr11:71475430 chr11:71448674~71452157:+ LIHC cis rs16828019 0.852 rs71648536 ENSG00000235358.1 RP11-399E6.1 12.51 7.73e-30 6.39e-26 0.83 0.56 Intelligence (multi-trait analysis); chr1:41166336 chr1:41242373~41284861:+ LIHC cis rs858239 0.508 rs10242104 ENSG00000230658.1 KLHL7-AS1 12.51 7.76e-30 6.42e-26 0.75 0.56 Cerebrospinal fluid biomarker levels; chr7:23180831 chr7:23101228~23105703:- LIHC cis rs858239 0.537 rs6942981 ENSG00000230658.1 KLHL7-AS1 12.51 8.31e-30 6.85e-26 0.75 0.56 Cerebrospinal fluid biomarker levels; chr7:23191929 chr7:23101228~23105703:- LIHC cis rs858239 0.636 rs28706766 ENSG00000230658.1 KLHL7-AS1 12.49 9.1e-30 7.48e-26 0.65 0.56 Cerebrospinal fluid biomarker levels; chr7:23130215 chr7:23101228~23105703:- LIHC cis rs858239 0.568 rs6970694 ENSG00000230658.1 KLHL7-AS1 12.49 9.12e-30 7.5e-26 0.75 0.56 Cerebrospinal fluid biomarker levels; chr7:23211209 chr7:23101228~23105703:- LIHC cis rs858239 0.601 rs28673077 ENSG00000230658.1 KLHL7-AS1 12.49 9.22e-30 7.57e-26 0.75 0.56 Cerebrospinal fluid biomarker levels; chr7:23211235 chr7:23101228~23105703:- LIHC cis rs2739330 0.76 rs1002286 ENSG00000225282.1 AP000350.6 -12.48 9.94e-30 8.16e-26 -0.67 -0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23926900~23929574:+ LIHC cis rs10256972 0.552 rs2949192 ENSG00000229043.2 AC091729.9 -12.45 1.34e-29 1.09e-25 -0.61 -0.56 Endometriosis;Longevity; chr7:1164205 chr7:1160374~1165267:+ LIHC cis rs16828019 0.929 rs35883594 ENSG00000235358.1 RP11-399E6.1 12.44 1.47e-29 1.19e-25 0.86 0.56 Intelligence (multi-trait analysis); chr1:41278421 chr1:41242373~41284861:+ LIHC cis rs2739330 0.731 rs5751792 ENSG00000250470.1 AP000351.3 12.43 1.59e-29 1.29e-25 0.68 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23976904~23977585:- LIHC cis rs16828019 0.789 rs36084778 ENSG00000235358.1 RP11-399E6.1 12.43 1.6e-29 1.3e-25 0.84 0.56 Intelligence (multi-trait analysis); chr1:41013866 chr1:41242373~41284861:+ LIHC cis rs16828019 0.777 rs11209363 ENSG00000235358.1 RP11-399E6.1 12.43 1.6e-29 1.3e-25 0.84 0.56 Intelligence (multi-trait analysis); chr1:41019405 chr1:41242373~41284861:+ LIHC cis rs4423214 1 rs12422045 ENSG00000254682.1 RP11-660L16.2 12.41 1.87e-29 1.51e-25 0.7 0.56 Vitamin D levels; chr11:71443774 chr11:71448674~71452157:+ LIHC cis rs16828019 0.929 rs35813191 ENSG00000235358.1 RP11-399E6.1 12.41 1.88e-29 1.52e-25 0.84 0.56 Intelligence (multi-trait analysis); chr1:41277128 chr1:41242373~41284861:+ LIHC cis rs10256972 0.567 rs2949185 ENSG00000229043.2 AC091729.9 -12.4 1.98e-29 1.6e-25 -0.62 -0.56 Endometriosis;Longevity; chr7:1169377 chr7:1160374~1165267:+ LIHC cis rs4423214 1 rs1981412 ENSG00000254682.1 RP11-660L16.2 12.4 2.07e-29 1.67e-25 0.7 0.56 Vitamin D levels; chr11:71427664 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs12419279 ENSG00000254682.1 RP11-660L16.2 12.4 2.07e-29 1.67e-25 0.7 0.56 Vitamin D levels; chr11:71428015 chr11:71448674~71452157:+ LIHC cis rs2739330 0.761 rs5760176 ENSG00000250470.1 AP000351.3 -12.39 2.19e-29 1.76e-25 -0.68 -0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23976904~23977585:- LIHC cis rs1577917 0.837 rs10944157 ENSG00000203875.9 SNHG5 -12.38 2.41e-29 1.93e-25 -0.62 -0.56 Response to antipsychotic treatment; chr6:85867481 chr6:85660950~85678736:- LIHC cis rs16828019 0.929 rs4131949 ENSG00000235358.1 RP11-399E6.1 12.36 2.8e-29 2.24e-25 0.83 0.56 Intelligence (multi-trait analysis); chr1:41272965 chr1:41242373~41284861:+ LIHC cis rs5769707 0.609 rs2007024 ENSG00000188511.11 C22orf34 12.36 3.02e-29 2.41e-25 0.67 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49595167 chr22:49414524~49657542:- LIHC cis rs10256972 0.552 rs2949195 ENSG00000229043.2 AC091729.9 -12.35 3.14e-29 2.5e-25 -0.62 -0.56 Endometriosis;Longevity; chr7:1163069 chr7:1160374~1165267:+ LIHC cis rs12022452 0.591 rs1001400 ENSG00000238287.1 RP11-656D10.3 -12.35 3.26e-29 2.6e-25 -0.72 -0.56 Age-related hearing impairment (SNP x SNP interaction); chr1:40533230 chr1:40493157~40508661:- LIHC cis rs12022452 0.591 rs61781641 ENSG00000238287.1 RP11-656D10.3 -12.34 3.41e-29 2.71e-25 -0.72 -0.56 Age-related hearing impairment (SNP x SNP interaction); chr1:40517412 chr1:40493157~40508661:- LIHC cis rs12022452 0.591 rs11208315 ENSG00000238287.1 RP11-656D10.3 -12.34 3.41e-29 2.71e-25 -0.72 -0.56 Age-related hearing impairment (SNP x SNP interaction); chr1:40519730 chr1:40493157~40508661:- LIHC cis rs12022452 0.591 rs12049435 ENSG00000238287.1 RP11-656D10.3 -12.34 3.41e-29 2.71e-25 -0.72 -0.56 Age-related hearing impairment (SNP x SNP interaction); chr1:40524888 chr1:40493157~40508661:- LIHC cis rs5769707 0.749 rs8137251 ENSG00000188511.11 C22orf34 12.34 3.42e-29 2.72e-25 0.65 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49643021 chr22:49414524~49657542:- LIHC cis rs16828019 0.852 rs3766324 ENSG00000235358.1 RP11-399E6.1 12.34 3.46e-29 2.75e-25 0.83 0.56 Intelligence (multi-trait analysis); chr1:41122981 chr1:41242373~41284861:+ LIHC cis rs4423214 1 rs12419334 ENSG00000254682.1 RP11-660L16.2 12.34 3.49e-29 2.77e-25 0.69 0.56 Vitamin D levels; chr11:71428426 chr11:71448674~71452157:+ LIHC cis rs5758659 1 rs134900 ENSG00000237037.8 NDUFA6-AS1 12.34 3.52e-29 2.8e-25 0.64 0.55 Cognitive function; chr22:42287337 chr22:42090931~42137742:+ LIHC cis rs2739330 0.76 rs5760095 ENSG00000218537.1 MIF-AS1 12.33 3.74e-29 2.96e-25 0.74 0.55 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23894426~23898930:- LIHC cis rs5769707 0.592 rs6009783 ENSG00000188511.11 C22orf34 12.33 3.86e-29 3.06e-25 0.66 0.55 Monocyte percentage of white cells;Monocyte count; chr22:49617353 chr22:49414524~49657542:- LIHC cis rs1930961 1 rs6004672 ENSG00000100058.11 CRYBB2P1 12.33 3.89e-29 3.08e-25 0.85 0.55 Bipolar disorder with mood-incongruent psychosis; chr22:25485046 chr22:25448105~25520854:+ LIHC cis rs4423214 0.879 rs4945008 ENSG00000254682.1 RP11-660L16.2 12.32 4.12e-29 3.26e-25 0.71 0.55 Vitamin D levels; chr11:71510202 chr11:71448674~71452157:+ LIHC cis rs16828019 0.929 rs111309254 ENSG00000235358.1 RP11-399E6.1 12.32 4.14e-29 3.27e-25 0.83 0.55 Intelligence (multi-trait analysis); chr1:41270328 chr1:41242373~41284861:+ LIHC cis rs5769707 0.609 rs2071890 ENSG00000188511.11 C22orf34 12.32 4.26e-29 3.37e-25 0.66 0.55 Monocyte percentage of white cells;Monocyte count; chr22:49607643 chr22:49414524~49657542:- LIHC cis rs12022452 0.822 rs7545012 ENSG00000238287.1 RP11-656D10.3 12.3 4.66e-29 3.68e-25 0.7 0.55 Age-related hearing impairment (SNP x SNP interaction); chr1:40562178 chr1:40493157~40508661:- LIHC cis rs5769707 0.616 rs6009786 ENSG00000188511.11 C22orf34 12.3 4.76e-29 3.75e-25 0.66 0.55 Monocyte percentage of white cells;Monocyte count; chr22:49621497 chr22:49414524~49657542:- LIHC cis rs977987 0.735 rs166013 ENSG00000261783.1 RP11-252K23.2 12.3 4.89e-29 3.86e-25 0.67 0.55 Dupuytren's disease; chr16:75400248 chr16:75379818~75381260:- LIHC cis rs858239 0.539 rs10270695 ENSG00000230658.1 KLHL7-AS1 -12.29 5.32e-29 4.18e-25 -0.64 -0.55 Cerebrospinal fluid biomarker levels; chr7:23149369 chr7:23101228~23105703:- LIHC cis rs1930961 1 rs997873 ENSG00000100058.11 CRYBB2P1 12.29 5.34e-29 4.2e-25 0.85 0.55 Bipolar disorder with mood-incongruent psychosis; chr22:25482315 chr22:25448105~25520854:+ LIHC cis rs1930961 1 rs997872 ENSG00000100058.11 CRYBB2P1 12.29 5.34e-29 4.2e-25 0.85 0.55 Bipolar disorder with mood-incongruent psychosis; chr22:25482647 chr22:25448105~25520854:+ LIHC cis rs1930961 1 rs6004671 ENSG00000100058.11 CRYBB2P1 12.29 5.34e-29 4.2e-25 0.85 0.55 Bipolar disorder with mood-incongruent psychosis; chr22:25483507 chr22:25448105~25520854:+ LIHC cis rs858239 0.601 rs6461702 ENSG00000230658.1 KLHL7-AS1 12.29 5.36e-29 4.21e-25 0.73 0.55 Cerebrospinal fluid biomarker levels; chr7:23209654 chr7:23101228~23105703:- LIHC cis rs10256972 0.567 rs2960835 ENSG00000229043.2 AC091729.9 -12.28 5.68e-29 4.45e-25 -0.62 -0.55 Endometriosis;Longevity; chr7:1163327 chr7:1160374~1165267:+ LIHC cis rs10256972 0.552 rs7805591 ENSG00000229043.2 AC091729.9 -12.27 6.46e-29 5.06e-25 -0.62 -0.55 Endometriosis;Longevity; chr7:1171109 chr7:1160374~1165267:+ LIHC cis rs5850 0.602 rs1005786 ENSG00000230658.1 KLHL7-AS1 12.27 6.48e-29 5.07e-25 0.65 0.55 Blood protein levels; chr7:23106218 chr7:23101228~23105703:- LIHC cis rs16828019 0.929 rs2363805 ENSG00000235358.1 RP11-399E6.1 12.26 6.69e-29 5.22e-25 0.83 0.55 Intelligence (multi-trait analysis); chr1:41253762 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs71648540 ENSG00000235358.1 RP11-399E6.1 12.26 6.69e-29 5.22e-25 0.83 0.55 Intelligence (multi-trait analysis); chr1:41256623 chr1:41242373~41284861:+ LIHC cis rs875971 0.522 rs1880556 ENSG00000226824.5 RP4-756H11.3 -12.26 6.71e-29 5.24e-25 -0.74 -0.55 Aortic root size; chr7:65967557 chr7:66654538~66669855:+ LIHC cis rs16828019 0.852 rs16827876 ENSG00000235358.1 RP11-399E6.1 12.26 6.81e-29 5.31e-25 0.82 0.55 Intelligence (multi-trait analysis); chr1:41073864 chr1:41242373~41284861:+ LIHC cis rs12022452 0.822 rs6600343 ENSG00000238287.1 RP11-656D10.3 -12.25 7.43e-29 5.78e-25 -0.72 -0.55 Age-related hearing impairment (SNP x SNP interaction); chr1:40562538 chr1:40493157~40508661:- LIHC cis rs16828019 0.64 rs1140227 ENSG00000235358.1 RP11-399E6.1 12.23 9.07e-29 7.04e-25 0.83 0.55 Intelligence (multi-trait analysis); chr1:41028139 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs3904243 ENSG00000235358.1 RP11-399E6.1 12.22 9.5e-29 7.36e-25 0.82 0.55 Intelligence (multi-trait analysis); chr1:41109180 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs11209545 ENSG00000235358.1 RP11-399E6.1 12.22 9.5e-29 7.36e-25 0.82 0.55 Intelligence (multi-trait analysis); chr1:41110685 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs11209576 ENSG00000235358.1 RP11-399E6.1 12.22 9.5e-29 7.36e-25 0.82 0.55 Intelligence (multi-trait analysis); chr1:41120357 chr1:41242373~41284861:+ LIHC cis rs16828019 0.929 rs10524 ENSG00000235358.1 RP11-399E6.1 12.22 9.58e-29 7.42e-25 0.83 0.55 Intelligence (multi-trait analysis); chr1:41260801 chr1:41242373~41284861:+ LIHC cis rs875971 1 rs709597 ENSG00000226824.5 RP4-756H11.3 12.22 9.72e-29 7.52e-25 0.65 0.55 Aortic root size; chr7:66360996 chr7:66654538~66669855:+ LIHC cis rs16828019 0.852 rs12742379 ENSG00000235358.1 RP11-399E6.1 12.22 9.78e-29 7.56e-25 0.81 0.55 Intelligence (multi-trait analysis); chr1:41060709 chr1:41242373~41284861:+ LIHC cis rs5769707 0.632 rs135871 ENSG00000188511.11 C22orf34 12.22 9.96e-29 7.7e-25 0.66 0.55 Monocyte percentage of white cells;Monocyte count; chr22:49615321 chr22:49414524~49657542:- LIHC cis rs5758659 1 rs134902 ENSG00000237037.8 NDUFA6-AS1 12.21 1.02e-28 7.87e-25 0.63 0.55 Cognitive function; chr22:42287991 chr22:42090931~42137742:+ LIHC cis rs875971 0.522 rs781144 ENSG00000226824.5 RP4-756H11.3 -12.21 1.03e-28 7.94e-25 -0.74 -0.55 Aortic root size; chr7:65975357 chr7:66654538~66669855:+ LIHC cis rs4423214 0.921 rs11603330 ENSG00000254682.1 RP11-660L16.2 12.21 1.04e-28 8.01e-25 0.7 0.55 Vitamin D levels; chr11:71442413 chr11:71448674~71452157:+ LIHC cis rs858239 0.699 rs1881201 ENSG00000230658.1 KLHL7-AS1 -12.21 1.08e-28 8.29e-25 -0.7 -0.55 Cerebrospinal fluid biomarker levels; chr7:23154394 chr7:23101228~23105703:- LIHC cis rs12022452 0.591 rs4660415 ENSG00000238287.1 RP11-656D10.3 -12.2 1.13e-28 8.68e-25 -0.71 -0.55 Age-related hearing impairment (SNP x SNP interaction); chr1:40512819 chr1:40493157~40508661:- LIHC cis rs12022452 0.556 rs11208298 ENSG00000238287.1 RP11-656D10.3 -12.2 1.13e-28 8.68e-25 -0.71 -0.55 Age-related hearing impairment (SNP x SNP interaction); chr1:40513206 chr1:40493157~40508661:- LIHC cis rs4423214 1 rs4944062 ENSG00000254682.1 RP11-660L16.2 12.2 1.18e-28 9.05e-25 0.71 0.55 Vitamin D levels; chr11:71476248 chr11:71448674~71452157:+ LIHC cis rs12022452 0.556 rs12037288 ENSG00000238287.1 RP11-656D10.3 -12.2 1.18e-28 9.08e-25 -0.72 -0.55 Age-related hearing impairment (SNP x SNP interaction); chr1:40530625 chr1:40493157~40508661:- LIHC cis rs16828019 0.852 rs3820090 ENSG00000235358.1 RP11-399E6.1 12.19 1.2e-28 9.21e-25 0.82 0.55 Intelligence (multi-trait analysis); chr1:41107980 chr1:41242373~41284861:+ LIHC cis rs875971 1 rs6956179 ENSG00000226824.5 RP4-756H11.3 12.19 1.26e-28 9.65e-25 0.66 0.55 Aortic root size; chr7:66341672 chr7:66654538~66669855:+ LIHC cis rs1577917 0.771 rs6454486 ENSG00000203875.9 SNHG5 12.19 1.27e-28 9.75e-25 0.6 0.55 Response to antipsychotic treatment; chr6:85723869 chr6:85660950~85678736:- LIHC cis rs5769707 0.656 rs135875 ENSG00000188511.11 C22orf34 12.19 1.29e-28 9.92e-25 0.66 0.55 Monocyte percentage of white cells;Monocyte count; chr22:49618771 chr22:49414524~49657542:- LIHC cis rs16828019 0.852 rs34979067 ENSG00000235358.1 RP11-399E6.1 12.18 1.33e-28 1.01e-24 0.82 0.55 Intelligence (multi-trait analysis); chr1:41077412 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs35190461 ENSG00000235358.1 RP11-399E6.1 12.18 1.33e-28 1.01e-24 0.82 0.55 Intelligence (multi-trait analysis); chr1:41077463 chr1:41242373~41284861:+ LIHC cis rs12022452 0.63 rs3795346 ENSG00000238287.1 RP11-656D10.3 -12.15 1.75e-28 1.33e-24 -0.71 -0.55 Age-related hearing impairment (SNP x SNP interaction); chr1:40508753 chr1:40493157~40508661:- LIHC cis rs16828019 0.852 rs12729586 ENSG00000235358.1 RP11-399E6.1 12.12 2.25e-28 1.7e-24 0.82 0.55 Intelligence (multi-trait analysis); chr1:41056705 chr1:41242373~41284861:+ LIHC cis rs16828019 0.704 rs34486565 ENSG00000235358.1 RP11-399E6.1 12.12 2.25e-28 1.7e-24 0.82 0.55 Intelligence (multi-trait analysis); chr1:41056838 chr1:41242373~41284861:+ LIHC cis rs858239 0.536 rs6961109 ENSG00000230658.1 KLHL7-AS1 12.11 2.4e-28 1.81e-24 0.73 0.55 Cerebrospinal fluid biomarker levels; chr7:23212794 chr7:23101228~23105703:- LIHC cis rs2739330 0.892 rs4822455 ENSG00000225282.1 AP000350.6 12.11 2.51e-28 1.89e-24 0.67 0.55 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23926900~23929574:+ LIHC cis rs858239 0.636 rs7808488 ENSG00000230658.1 KLHL7-AS1 12.11 2.55e-28 1.92e-24 0.7 0.55 Cerebrospinal fluid biomarker levels; chr7:23182251 chr7:23101228~23105703:- LIHC cis rs16828019 0.852 rs12022978 ENSG00000235358.1 RP11-399E6.1 12.1 2.62e-28 1.96e-24 0.81 0.55 Intelligence (multi-trait analysis); chr1:41088416 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs2300649 ENSG00000235358.1 RP11-399E6.1 12.1 2.62e-28 1.96e-24 0.81 0.55 Intelligence (multi-trait analysis); chr1:41103531 chr1:41242373~41284861:+ LIHC cis rs1930961 1 rs6004667 ENSG00000100058.11 CRYBB2P1 -12.1 2.63e-28 1.97e-24 -0.85 -0.55 Bipolar disorder with mood-incongruent psychosis; chr22:25478497 chr22:25448105~25520854:+ LIHC cis rs4853012 0.539 rs9789534 ENSG00000217702.2 RP11-287D1.4 12.1 2.7e-28 2.02e-24 0.71 0.55 Gestational age at birth (maternal effect); chr2:74135863 chr2:74130583~74135395:+ LIHC cis rs9828933 0.832 rs2292662 ENSG00000280620.1 SCAANT1 12.1 2.75e-28 2.05e-24 0.76 0.55 Type 2 diabetes; chr3:63911539 chr3:63911518~63911772:- LIHC cis rs5769707 0.632 rs135877 ENSG00000188511.11 C22orf34 12.1 2.77e-28 2.07e-24 0.66 0.55 Monocyte percentage of white cells;Monocyte count; chr22:49620354 chr22:49414524~49657542:- LIHC cis rs16828019 0.704 rs4996176 ENSG00000235358.1 RP11-399E6.1 12.09 2.81e-28 2.1e-24 0.84 0.55 Intelligence (multi-trait analysis); chr1:41022496 chr1:41242373~41284861:+ LIHC cis rs16828019 0.777 rs35496942 ENSG00000235358.1 RP11-399E6.1 12.09 2.81e-28 2.1e-24 0.84 0.55 Intelligence (multi-trait analysis); chr1:41023232 chr1:41242373~41284861:+ LIHC cis rs16828019 0.704 rs12031277 ENSG00000235358.1 RP11-399E6.1 12.09 2.81e-28 2.1e-24 0.84 0.55 Intelligence (multi-trait analysis); chr1:41026129 chr1:41242373~41284861:+ LIHC cis rs858239 0.699 rs1881200 ENSG00000230658.1 KLHL7-AS1 -12.09 2.89e-28 2.16e-24 -0.71 -0.55 Cerebrospinal fluid biomarker levels; chr7:23162018 chr7:23101228~23105703:- LIHC cis rs12022452 0.591 rs16827359 ENSG00000238287.1 RP11-656D10.3 12.07 3.49e-28 2.6e-24 0.71 0.55 Age-related hearing impairment (SNP x SNP interaction); chr1:40535766 chr1:40493157~40508661:- LIHC cis rs16828019 0.777 rs16911 ENSG00000235358.1 RP11-399E6.1 12.07 3.53e-28 2.61e-24 0.83 0.55 Intelligence (multi-trait analysis); chr1:41032349 chr1:41242373~41284861:+ LIHC cis rs16828019 0.777 rs2300658 ENSG00000235358.1 RP11-399E6.1 12.07 3.53e-28 2.61e-24 0.83 0.55 Intelligence (multi-trait analysis); chr1:41039350 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs12729448 ENSG00000235358.1 RP11-399E6.1 12.07 3.53e-28 2.61e-24 0.83 0.55 Intelligence (multi-trait analysis); chr1:41044162 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs2268678 ENSG00000235358.1 RP11-399E6.1 12.07 3.53e-28 2.61e-24 0.83 0.55 Intelligence (multi-trait analysis); chr1:41045381 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs10489520 ENSG00000235358.1 RP11-399E6.1 12.07 3.53e-28 2.61e-24 0.83 0.55 Intelligence (multi-trait analysis); chr1:41046083 chr1:41242373~41284861:+ LIHC cis rs16828019 0.852 rs12406620 ENSG00000235358.1 RP11-399E6.1 12.07 3.53e-28 2.61e-24 0.83 0.55 Intelligence (multi-trait analysis); chr1:41046992 chr1:41242373~41284861:+ LIHC cis rs4423214 1 rs2040323 ENSG00000254682.1 RP11-660L16.2 12.07 3.58e-28 2.65e-24 0.69 0.55 Vitamin D levels; chr11:71461737 chr11:71448674~71452157:+ LIHC cis rs875971 1 rs7783613 ENSG00000226824.5 RP4-756H11.3 12.06 3.88e-28 2.87e-24 0.65 0.55 Aortic root size; chr7:66340274 chr7:66654538~66669855:+ LIHC cis rs5769707 0.632 rs135876 ENSG00000188511.11 C22orf34 12.05 4.15e-28 3.06e-24 0.66 0.55 Monocyte percentage of white cells;Monocyte count; chr22:49619925 chr22:49414524~49657542:- LIHC cis rs4423214 0.921 rs12807827 ENSG00000254682.1 RP11-660L16.2 12.05 4.27e-28 3.15e-24 0.69 0.55 Vitamin D levels; chr11:71492744 chr11:71448674~71452157:+ LIHC cis rs875971 0.965 rs7794930 ENSG00000226824.5 RP4-756H11.3 12.05 4.29e-28 3.16e-24 0.65 0.55 Aortic root size; chr7:66313559 chr7:66654538~66669855:+ LIHC cis rs9326248 0.603 rs7396061 ENSG00000254851.1 RP11-109L13.1 -12.04 4.47e-28 3.29e-24 -0.69 -0.55 Blood protein levels; chr11:116880158 chr11:117135528~117138582:+ LIHC cis rs858239 0.512 rs55788996 ENSG00000230658.1 KLHL7-AS1 12.03 4.81e-28 3.53e-24 0.7 0.55 Cerebrospinal fluid biomarker levels; chr7:23153230 chr7:23101228~23105703:- LIHC cis rs875971 0.83 rs4718358 ENSG00000226824.5 RP4-756H11.3 -12.03 5.05e-28 3.7e-24 -0.65 -0.55 Aortic root size; chr7:66508681 chr7:66654538~66669855:+ LIHC cis rs5769707 0.609 rs135861 ENSG00000188511.11 C22orf34 12.02 5.13e-28 3.75e-24 0.65 0.55 Monocyte percentage of white cells;Monocyte count; chr22:49604470 chr22:49414524~49657542:- LIHC cis rs5769707 0.609 rs739247 ENSG00000188511.11 C22orf34 12.01 5.82e-28 4.25e-24 0.66 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49603009 chr22:49414524~49657542:- LIHC cis rs875971 0.505 rs2462573 ENSG00000226824.5 RP4-756H11.3 12.01 5.92e-28 4.32e-24 0.72 0.54 Aortic root size; chr7:66042405 chr7:66654538~66669855:+ LIHC cis rs875971 0.505 rs1167386 ENSG00000226824.5 RP4-756H11.3 12.01 6.02e-28 4.38e-24 0.72 0.54 Aortic root size; chr7:66048109 chr7:66654538~66669855:+ LIHC cis rs875971 0.505 rs1167385 ENSG00000226824.5 RP4-756H11.3 12.01 6.02e-28 4.38e-24 0.72 0.54 Aortic root size; chr7:66048321 chr7:66654538~66669855:+ LIHC cis rs4423214 1 rs12278461 ENSG00000254682.1 RP11-660L16.2 12 6.04e-28 4.4e-24 0.68 0.54 Vitamin D levels; chr11:71471139 chr11:71448674~71452157:+ LIHC cis rs977987 0.705 rs4888377 ENSG00000261783.1 RP11-252K23.2 -12 6.13e-28 4.46e-24 -0.66 -0.54 Dupuytren's disease; chr16:75291788 chr16:75379818~75381260:- LIHC cis rs858239 0.536 rs6956974 ENSG00000230658.1 KLHL7-AS1 -12 6.37e-28 4.62e-24 -0.7 -0.54 Cerebrospinal fluid biomarker levels; chr7:23212699 chr7:23101228~23105703:- LIHC cis rs4423214 1 rs2282621 ENSG00000254682.1 RP11-660L16.2 11.99 7.12e-28 5.15e-24 0.68 0.54 Vitamin D levels; chr11:71472428 chr11:71448674~71452157:+ LIHC cis rs4423214 1 rs2282620 ENSG00000254682.1 RP11-660L16.2 11.99 7.12e-28 5.15e-24 0.68 0.54 Vitamin D levels; chr11:71472431 chr11:71448674~71452157:+ LIHC cis rs12022452 0.591 rs11208356 ENSG00000238287.1 RP11-656D10.3 -11.97 7.97e-28 5.74e-24 -0.71 -0.54 Age-related hearing impairment (SNP x SNP interaction); chr1:40541259 chr1:40493157~40508661:- LIHC cis rs16828019 0.852 rs34386859 ENSG00000235358.1 RP11-399E6.1 11.96 8.73e-28 6.26e-24 0.8 0.54 Intelligence (multi-trait analysis); chr1:41098352 chr1:41242373~41284861:+ LIHC cis rs9828933 0.701 rs7621544 ENSG00000280620.1 SCAANT1 11.96 8.86e-28 6.34e-24 0.75 0.54 Type 2 diabetes; chr3:63943005 chr3:63911518~63911772:- LIHC cis rs1930961 0.867 rs6423498 ENSG00000100058.11 CRYBB2P1 11.96 8.98e-28 6.42e-24 0.83 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25457401 chr22:25448105~25520854:+ LIHC cis rs875971 1 rs937495 ENSG00000226824.5 RP4-756H11.3 11.96 9.1e-28 6.5e-24 0.65 0.54 Aortic root size; chr7:66314811 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs2036264 ENSG00000226824.5 RP4-756H11.3 11.96 9.1e-28 6.5e-24 0.65 0.54 Aortic root size; chr7:66334917 chr7:66654538~66669855:+ LIHC cis rs875971 0.838 rs2173570 ENSG00000226824.5 RP4-756H11.3 11.95 9.25e-28 6.6e-24 0.65 0.54 Aortic root size; chr7:66297976 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs778735 ENSG00000226824.5 RP4-756H11.3 -11.95 9.53e-28 6.8e-24 -0.65 -0.54 Aortic root size; chr7:66349822 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs12698523 ENSG00000226824.5 RP4-756H11.3 -11.95 9.67e-28 6.89e-24 -0.64 -0.54 Aortic root size; chr7:66503126 chr7:66654538~66669855:+ LIHC cis rs16828019 0.777 rs3738369 ENSG00000235358.1 RP11-399E6.1 11.95 9.83e-28 7e-24 0.83 0.54 Intelligence (multi-trait analysis); chr1:41020736 chr1:41242373~41284861:+ LIHC cis rs875971 0.964 rs6978429 ENSG00000226824.5 RP4-756H11.3 -11.95 1e-27 7.12e-24 -0.64 -0.54 Aortic root size; chr7:66494889 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs4718357 ENSG00000226824.5 RP4-756H11.3 -11.95 1e-27 7.12e-24 -0.64 -0.54 Aortic root size; chr7:66495891 chr7:66654538~66669855:+ LIHC cis rs875971 0.929 rs12535036 ENSG00000226824.5 RP4-756H11.3 -11.95 1e-27 7.12e-24 -0.64 -0.54 Aortic root size; chr7:66499076 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs12532998 ENSG00000226824.5 RP4-756H11.3 -11.95 1e-27 7.12e-24 -0.64 -0.54 Aortic root size; chr7:66502472 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs6970030 ENSG00000226824.5 RP4-756H11.3 -11.95 1e-27 7.12e-24 -0.64 -0.54 Aortic root size; chr7:66503692 chr7:66654538~66669855:+ LIHC cis rs875971 0.928 rs6970357 ENSG00000226824.5 RP4-756H11.3 -11.95 1e-27 7.12e-24 -0.64 -0.54 Aortic root size; chr7:66503891 chr7:66654538~66669855:+ LIHC cis rs5769707 0.681 rs9616329 ENSG00000188511.11 C22orf34 11.94 1.01e-27 7.14e-24 0.64 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49632666 chr22:49414524~49657542:- LIHC cis rs5769707 0.632 rs135872 ENSG00000188511.11 C22orf34 11.94 1.01e-27 7.14e-24 0.65 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49615652 chr22:49414524~49657542:- LIHC cis rs16828019 0.777 rs35044078 ENSG00000235358.1 RP11-399E6.1 11.94 1.03e-27 7.3e-24 0.83 0.54 Intelligence (multi-trait analysis); chr1:41008728 chr1:41242373~41284861:+ LIHC cis rs5769707 0.554 rs10854876 ENSG00000188511.11 C22orf34 11.94 1.03e-27 7.34e-24 0.65 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49616922 chr22:49414524~49657542:- LIHC cis rs507080 0.922 rs654792 ENSG00000255239.1 AP002954.6 -11.94 1.05e-27 7.43e-24 -0.62 -0.54 Serum metabolite levels; chr11:118682287 chr11:118688039~118690600:- LIHC cis rs875971 0.929 rs6970860 ENSG00000226824.5 RP4-756H11.3 -11.93 1.12e-27 7.91e-24 -0.64 -0.54 Aortic root size; chr7:66511647 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs6957199 ENSG00000226824.5 RP4-756H11.3 -11.93 1.12e-27 7.91e-24 -0.64 -0.54 Aortic root size; chr7:66513532 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs3735148 ENSG00000226824.5 RP4-756H11.3 -11.93 1.15e-27 8.05e-24 -0.64 -0.54 Aortic root size; chr7:66506022 chr7:66654538~66669855:+ LIHC cis rs1930961 1 rs6004657 ENSG00000100058.11 CRYBB2P1 11.93 1.17e-27 8.19e-24 0.84 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25459747 chr22:25448105~25520854:+ LIHC cis rs12022452 0.544 rs11208423 ENSG00000238287.1 RP11-656D10.3 -11.93 1.19e-27 8.31e-24 -0.7 -0.54 Age-related hearing impairment (SNP x SNP interaction); chr1:40563942 chr1:40493157~40508661:- LIHC cis rs875971 1 rs6958271 ENSG00000226824.5 RP4-756H11.3 -11.92 1.27e-27 8.83e-24 -0.64 -0.54 Aortic root size; chr7:66514344 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs6958277 ENSG00000226824.5 RP4-756H11.3 -11.92 1.27e-27 8.83e-24 -0.64 -0.54 Aortic root size; chr7:66514362 chr7:66654538~66669855:+ LIHC cis rs1930961 1 rs9624834 ENSG00000100058.11 CRYBB2P1 11.92 1.29e-27 8.96e-24 0.83 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25450048 chr22:25448105~25520854:+ LIHC cis rs1930961 1 rs9624835 ENSG00000100058.11 CRYBB2P1 11.92 1.29e-27 8.96e-24 0.83 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25450054 chr22:25448105~25520854:+ LIHC cis rs1930961 1 rs9624836 ENSG00000100058.11 CRYBB2P1 11.92 1.29e-27 8.96e-24 0.83 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25450120 chr22:25448105~25520854:+ LIHC cis rs1930961 1 rs6004654 ENSG00000100058.11 CRYBB2P1 11.91 1.31e-27 9.12e-24 0.84 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25459237 chr22:25448105~25520854:+ LIHC cis rs1930961 1 rs6519611 ENSG00000100058.11 CRYBB2P1 11.91 1.33e-27 9.26e-24 0.84 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25449888 chr22:25448105~25520854:+ LIHC cis rs1930961 1 rs6004658 ENSG00000100058.11 CRYBB2P1 11.91 1.33e-27 9.26e-24 0.84 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25460264 chr22:25448105~25520854:+ LIHC cis rs1930961 1 rs6004659 ENSG00000100058.11 CRYBB2P1 11.91 1.33e-27 9.26e-24 0.84 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25460444 chr22:25448105~25520854:+ LIHC cis rs858239 1 rs156407 ENSG00000230658.1 KLHL7-AS1 11.91 1.37e-27 9.53e-24 0.66 0.54 Cerebrospinal fluid biomarker levels; chr7:23276020 chr7:23101228~23105703:- LIHC cis rs1799949 1 rs8176126 ENSG00000198496.9 NBR2 11.9 1.42e-27 9.87e-24 0.61 0.54 Menopause (age at onset); chr17:43107032 chr17:43125610~43153671:+ LIHC cis rs17711722 0.727 rs781151 ENSG00000226824.5 RP4-756H11.3 -11.9 1.44e-27 1e-23 -0.74 -0.54 Calcium levels; chr7:66014891 chr7:66654538~66669855:+ LIHC cis rs2260433 0.867 rs1940477 ENSG00000281655.1 RP11-817J15.3 11.9 1.48e-27 1.03e-23 0.68 0.54 Cleft palate; chr11:102637049 chr11:102681310~102683913:+ LIHC cis rs875971 1 rs6979382 ENSG00000226824.5 RP4-756H11.3 -11.9 1.49e-27 1.03e-23 -0.64 -0.54 Aortic root size; chr7:66421388 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs6961990 ENSG00000226824.5 RP4-756H11.3 -11.9 1.49e-27 1.03e-23 -0.64 -0.54 Aortic root size; chr7:66423583 chr7:66654538~66669855:+ LIHC cis rs875971 0.965 rs9969301 ENSG00000226824.5 RP4-756H11.3 11.89 1.57e-27 1.09e-23 0.64 0.54 Aortic root size; chr7:66316668 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs6460292 ENSG00000226824.5 RP4-756H11.3 11.89 1.57e-27 1.09e-23 0.64 0.54 Aortic root size; chr7:66345088 chr7:66654538~66669855:+ LIHC cis rs875971 0.965 rs10267430 ENSG00000226824.5 RP4-756H11.3 11.89 1.6e-27 1.1e-23 0.64 0.54 Aortic root size; chr7:66278036 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs10257427 ENSG00000226824.5 RP4-756H11.3 11.89 1.6e-27 1.1e-23 0.64 0.54 Aortic root size; chr7:66278221 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs55748098 ENSG00000226824.5 RP4-756H11.3 11.89 1.6e-27 1.1e-23 0.64 0.54 Aortic root size; chr7:66298631 chr7:66654538~66669855:+ LIHC cis rs875971 0.54 rs781152 ENSG00000226824.5 RP4-756H11.3 -11.89 1.61e-27 1.11e-23 -0.74 -0.54 Aortic root size; chr7:66014585 chr7:66654538~66669855:+ LIHC cis rs16828019 0.777 rs67460888 ENSG00000235358.1 RP11-399E6.1 11.89 1.67e-27 1.14e-23 0.86 0.54 Intelligence (multi-trait analysis); chr1:41003665 chr1:41242373~41284861:+ LIHC cis rs16828019 0.777 rs12023079 ENSG00000235358.1 RP11-399E6.1 11.89 1.67e-27 1.14e-23 0.86 0.54 Intelligence (multi-trait analysis); chr1:41004439 chr1:41242373~41284861:+ LIHC cis rs1930961 1 rs760554 ENSG00000100058.11 CRYBB2P1 11.88 1.74e-27 1.19e-23 0.85 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25476625 chr22:25448105~25520854:+ LIHC cis rs875971 1 rs6945843 ENSG00000226824.5 RP4-756H11.3 11.88 1.75e-27 1.2e-23 0.64 0.54 Aortic root size; chr7:66269796 chr7:66654538~66669855:+ LIHC cis rs1930961 1 rs6004662 ENSG00000100058.11 CRYBB2P1 11.87 1.83e-27 1.25e-23 0.84 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25466157 chr22:25448105~25520854:+ LIHC cis rs875971 0.505 rs1723275 ENSG00000226824.5 RP4-756H11.3 11.87 1.88e-27 1.28e-23 0.71 0.54 Aortic root size; chr7:66039646 chr7:66654538~66669855:+ LIHC cis rs875971 0.895 rs3857684 ENSG00000226824.5 RP4-756H11.3 -11.87 1.91e-27 1.31e-23 -0.64 -0.54 Aortic root size; chr7:66473171 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs12533997 ENSG00000226824.5 RP4-756H11.3 -11.87 1.91e-27 1.31e-23 -0.64 -0.54 Aortic root size; chr7:66500390 chr7:66654538~66669855:+ LIHC cis rs875971 0.522 rs34973832 ENSG00000226824.5 RP4-756H11.3 -11.87 1.96e-27 1.33e-23 -0.72 -0.54 Aortic root size; chr7:65931217 chr7:66654538~66669855:+ LIHC cis rs858239 0.698 rs858295 ENSG00000230658.1 KLHL7-AS1 11.86 2.02e-27 1.38e-23 0.69 0.54 Cerebrospinal fluid biomarker levels; chr7:23205950 chr7:23101228~23105703:- LIHC cis rs875971 1 rs778726 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66363744 chr7:66654538~66669855:+ LIHC cis rs875971 0.767 rs1695815 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66366357 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs778685 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66371189 chr7:66654538~66669855:+ LIHC cis rs875971 0.929 rs778682 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66372947 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs11765965 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66377234 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs1643388 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66379575 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs778722 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66379841 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs778721 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66380410 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs778706 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66395437 chr7:66654538~66669855:+ LIHC cis rs875971 0.895 rs778700 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66401463 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs778699 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66403303 chr7:66654538~66669855:+ LIHC cis rs875971 0.929 rs778692 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66407462 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs4718343 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66409301 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs1968225 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66409786 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs6460295 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66417741 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs6978721 ENSG00000226824.5 RP4-756H11.3 -11.86 2.06e-27 1.4e-23 -0.64 -0.54 Aortic root size; chr7:66418217 chr7:66654538~66669855:+ LIHC cis rs17711722 0.74 rs7809991 ENSG00000226824.5 RP4-756H11.3 -11.86 2.09e-27 1.42e-23 -0.72 -0.54 Calcium levels; chr7:65941231 chr7:66654538~66669855:+ LIHC cis rs875971 0.929 rs10950041 ENSG00000226824.5 RP4-756H11.3 -11.86 2.15e-27 1.45e-23 -0.64 -0.54 Aortic root size; chr7:66508888 chr7:66654538~66669855:+ LIHC cis rs2260433 0.782 rs7109663 ENSG00000281655.1 RP11-817J15.3 11.85 2.25e-27 1.52e-23 0.66 0.54 Cleft palate; chr11:102641030 chr11:102681310~102683913:+ LIHC cis rs5769707 0.616 rs135869 ENSG00000188511.11 C22orf34 11.85 2.34e-27 1.57e-23 0.65 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49614718 chr22:49414524~49657542:- LIHC cis rs9326248 0.731 rs90192 ENSG00000254851.1 RP11-109L13.1 -11.84 2.4e-27 1.61e-23 -0.7 -0.54 Blood protein levels; chr11:117188631 chr11:117135528~117138582:+ LIHC cis rs17711722 1 rs17711722 ENSG00000226824.5 RP4-756H11.3 11.84 2.44e-27 1.63e-23 0.72 0.54 Calcium levels; chr7:65806210 chr7:66654538~66669855:+ LIHC cis rs17711722 0.675 rs6947132 ENSG00000226824.5 RP4-756H11.3 11.84 2.44e-27 1.63e-23 0.72 0.54 Calcium levels; chr7:65808508 chr7:66654538~66669855:+ LIHC cis rs17711722 0.701 rs781143 ENSG00000226824.5 RP4-756H11.3 -11.84 2.45e-27 1.64e-23 -0.72 -0.54 Calcium levels; chr7:65974892 chr7:66654538~66669855:+ LIHC cis rs875971 0.522 rs4718285 ENSG00000226824.5 RP4-756H11.3 -11.84 2.53e-27 1.69e-23 -0.72 -0.54 Aortic root size; chr7:65827018 chr7:66654538~66669855:+ LIHC cis rs17711722 0.64 rs13237956 ENSG00000226824.5 RP4-756H11.3 -11.84 2.53e-27 1.69e-23 -0.72 -0.54 Calcium levels; chr7:65853042 chr7:66654538~66669855:+ LIHC cis rs875971 0.516 rs6945322 ENSG00000226824.5 RP4-756H11.3 -11.84 2.53e-27 1.69e-23 -0.72 -0.54 Aortic root size; chr7:65871069 chr7:66654538~66669855:+ LIHC cis rs17711722 0.701 rs4467826 ENSG00000226824.5 RP4-756H11.3 -11.84 2.53e-27 1.69e-23 -0.72 -0.54 Calcium levels; chr7:65903721 chr7:66654538~66669855:+ LIHC cis rs17711722 0.727 rs1880555 ENSG00000226824.5 RP4-756H11.3 -11.83 2.61e-27 1.74e-23 -0.72 -0.54 Calcium levels; chr7:65967580 chr7:66654538~66669855:+ LIHC cis rs4820294 0.669 rs1894532 ENSG00000233360.4 Z83844.1 11.83 2.69e-27 1.79e-23 0.6 0.54 Fat distribution (HIV); chr22:37663743 chr22:37641832~37658377:- LIHC cis rs875971 0.522 rs4502988 ENSG00000226824.5 RP4-756H11.3 -11.83 2.71e-27 1.8e-23 -0.72 -0.54 Aortic root size; chr7:65832759 chr7:66654538~66669855:+ LIHC cis rs875971 0.522 rs2008188 ENSG00000226824.5 RP4-756H11.3 -11.83 2.71e-27 1.8e-23 -0.72 -0.54 Aortic root size; chr7:65964026 chr7:66654538~66669855:+ LIHC cis rs875971 0.522 rs709604 ENSG00000226824.5 RP4-756H11.3 11.81 3.12e-27 2.06e-23 0.72 0.54 Aortic root size; chr7:66032447 chr7:66654538~66669855:+ LIHC cis rs1930961 1 rs6004668 ENSG00000272977.1 CTA-390C10.10 11.81 3.18e-27 2.1e-23 0.87 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25478535 chr22:25476218~25479971:+ LIHC cis rs875971 0.54 rs1723268 ENSG00000226824.5 RP4-756H11.3 -11.81 3.28e-27 2.16e-23 -0.72 -0.54 Aortic root size; chr7:66008093 chr7:66654538~66669855:+ LIHC cis rs875971 0.522 rs7784623 ENSG00000226824.5 RP4-756H11.3 -11.8 3.42e-27 2.25e-23 -0.71 -0.54 Aortic root size; chr7:65930047 chr7:66654538~66669855:+ LIHC cis rs875971 0.522 rs10807697 ENSG00000226824.5 RP4-756H11.3 -11.8 3.47e-27 2.28e-23 -0.72 -0.54 Aortic root size; chr7:65951183 chr7:66654538~66669855:+ LIHC cis rs858239 0.665 rs858306 ENSG00000230658.1 KLHL7-AS1 11.8 3.54e-27 2.32e-23 0.69 0.54 Cerebrospinal fluid biomarker levels; chr7:23203135 chr7:23101228~23105703:- LIHC cis rs875971 0.505 rs6955582 ENSG00000226824.5 RP4-756H11.3 -11.79 3.69e-27 2.43e-23 -0.72 -0.54 Aortic root size; chr7:65966699 chr7:66654538~66669855:+ LIHC cis rs5769707 0.706 rs763128 ENSG00000188511.11 C22orf34 11.79 3.72e-27 2.44e-23 0.65 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49624397 chr22:49414524~49657542:- LIHC cis rs875971 1 rs709595 ENSG00000226824.5 RP4-756H11.3 -11.79 3.84e-27 2.51e-23 -0.64 -0.54 Aortic root size; chr7:66352346 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs811880 ENSG00000226824.5 RP4-756H11.3 -11.79 3.84e-27 2.51e-23 -0.64 -0.54 Aortic root size; chr7:66353659 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs778723 ENSG00000226824.5 RP4-756H11.3 -11.79 3.84e-27 2.51e-23 -0.64 -0.54 Aortic root size; chr7:66364510 chr7:66654538~66669855:+ LIHC cis rs875971 0.929 rs778712 ENSG00000226824.5 RP4-756H11.3 -11.79 3.84e-27 2.51e-23 -0.64 -0.54 Aortic root size; chr7:66384991 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs778710 ENSG00000226824.5 RP4-756H11.3 -11.79 3.84e-27 2.51e-23 -0.64 -0.54 Aortic root size; chr7:66389847 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs778708 ENSG00000226824.5 RP4-756H11.3 -11.79 3.84e-27 2.51e-23 -0.64 -0.54 Aortic root size; chr7:66391332 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs778696 ENSG00000226824.5 RP4-756H11.3 -11.79 3.84e-27 2.51e-23 -0.64 -0.54 Aortic root size; chr7:66405826 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs778694 ENSG00000226824.5 RP4-756H11.3 -11.79 3.84e-27 2.51e-23 -0.64 -0.54 Aortic root size; chr7:66406571 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs4718344 ENSG00000226824.5 RP4-756H11.3 -11.79 3.84e-27 2.51e-23 -0.64 -0.54 Aortic root size; chr7:66409394 chr7:66654538~66669855:+ LIHC cis rs875971 0.737 rs7803424 ENSG00000226824.5 RP4-756H11.3 -11.79 3.84e-27 2.51e-23 -0.64 -0.54 Aortic root size; chr7:66415618 chr7:66654538~66669855:+ LIHC cis rs875971 0.83 rs7799834 ENSG00000226824.5 RP4-756H11.3 -11.79 3.84e-27 2.51e-23 -0.64 -0.54 Aortic root size; chr7:66415707 chr7:66654538~66669855:+ LIHC cis rs7104764 1 rs7104764 ENSG00000277290.1 RP11-326C3.16 -11.78 3.93e-27 2.57e-23 -0.52 -0.54 Menarche (age at onset); chr11:229977 chr11:243099~243483:- LIHC cis rs7104764 0.957 rs3829998 ENSG00000277290.1 RP11-326C3.16 -11.78 3.93e-27 2.57e-23 -0.52 -0.54 Menarche (age at onset); chr11:230751 chr11:243099~243483:- LIHC cis rs875971 0.522 rs6960048 ENSG00000226824.5 RP4-756H11.3 -11.78 3.99e-27 2.61e-23 -0.71 -0.54 Aortic root size; chr7:65943052 chr7:66654538~66669855:+ LIHC cis rs17711722 0.701 rs781145 ENSG00000226824.5 RP4-756H11.3 -11.77 4.26e-27 2.78e-23 -0.71 -0.54 Calcium levels; chr7:65975383 chr7:66654538~66669855:+ LIHC cis rs875971 0.522 rs4718286 ENSG00000226824.5 RP4-756H11.3 -11.77 4.41e-27 2.86e-23 -0.71 -0.54 Aortic root size; chr7:65827777 chr7:66654538~66669855:+ LIHC cis rs17711722 0.585 rs6942660 ENSG00000226824.5 RP4-756H11.3 -11.77 4.41e-27 2.86e-23 -0.71 -0.54 Calcium levels; chr7:65837419 chr7:66654538~66669855:+ LIHC cis rs17711722 0.701 rs55773927 ENSG00000226824.5 RP4-756H11.3 -11.77 4.41e-27 2.86e-23 -0.71 -0.54 Calcium levels; chr7:65872915 chr7:66654538~66669855:+ LIHC cis rs17711722 0.727 rs35850374 ENSG00000226824.5 RP4-756H11.3 -11.77 4.41e-27 2.86e-23 -0.71 -0.54 Calcium levels; chr7:65892789 chr7:66654538~66669855:+ LIHC cis rs1930961 1 rs760555 ENSG00000100058.11 CRYBB2P1 11.77 4.48e-27 2.91e-23 0.85 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25476870 chr22:25448105~25520854:+ LIHC cis rs2260433 0.782 rs7109522 ENSG00000281655.1 RP11-817J15.3 11.76 4.66e-27 3.02e-23 0.66 0.54 Cleft palate; chr11:102640944 chr11:102681310~102683913:+ LIHC cis rs875971 0.597 rs11771318 ENSG00000226824.5 RP4-756H11.3 11.76 4.7e-27 3.04e-23 0.75 0.54 Aortic root size; chr7:66597493 chr7:66654538~66669855:+ LIHC cis rs7104764 1 rs7483951 ENSG00000277290.1 RP11-326C3.16 -11.76 4.72e-27 3.06e-23 -0.52 -0.54 Menarche (age at onset); chr11:231758 chr11:243099~243483:- LIHC cis rs7104764 1 rs9795476 ENSG00000277290.1 RP11-326C3.16 -11.76 4.72e-27 3.06e-23 -0.52 -0.54 Menarche (age at onset); chr11:235894 chr11:243099~243483:- LIHC cis rs5769707 0.656 rs135878 ENSG00000188511.11 C22orf34 11.76 4.73e-27 3.06e-23 0.65 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49620721 chr22:49414524~49657542:- LIHC cis rs875971 0.54 rs736270 ENSG00000226824.5 RP4-756H11.3 -11.76 4.78e-27 3.09e-23 -0.72 -0.54 Aortic root size; chr7:65963835 chr7:66654538~66669855:+ LIHC cis rs1930961 1 rs7285549 ENSG00000272977.1 CTA-390C10.10 -11.76 4.89e-27 3.15e-23 -0.87 -0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25478613 chr22:25476218~25479971:+ LIHC cis rs507080 0.733 rs4393358 ENSG00000255422.1 AP002954.4 -11.76 4.89e-27 3.15e-23 -0.62 -0.54 Serum metabolite levels; chr11:118698388 chr11:118704607~118750263:+ LIHC cis rs5769707 0.568 rs2011097 ENSG00000188511.11 C22orf34 11.76 4.99e-27 3.21e-23 0.64 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49624421 chr22:49414524~49657542:- LIHC cis rs875971 1 rs10215948 ENSG00000226824.5 RP4-756H11.3 11.75 5.38e-27 3.45e-23 0.64 0.54 Aortic root size; chr7:66282799 chr7:66654538~66669855:+ LIHC cis rs858239 0.73 rs858290 ENSG00000230658.1 KLHL7-AS1 11.75 5.38e-27 3.45e-23 0.69 0.54 Cerebrospinal fluid biomarker levels; chr7:23208417 chr7:23101228~23105703:- LIHC cis rs5769707 0.681 rs4824068 ENSG00000188511.11 C22orf34 11.74 5.77e-27 3.69e-23 0.65 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49631153 chr22:49414524~49657542:- LIHC cis rs4820294 0.646 rs9622675 ENSG00000233360.4 Z83844.1 11.74 5.84e-27 3.73e-23 0.59 0.54 Fat distribution (HIV); chr22:37657658 chr22:37641832~37658377:- LIHC cis rs5769707 0.605 rs6009791 ENSG00000188511.11 C22orf34 11.73 5.97e-27 3.81e-23 0.65 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49631617 chr22:49414524~49657542:- LIHC cis rs17711722 0.727 rs2658585 ENSG00000226824.5 RP4-756H11.3 -11.73 6.06e-27 3.85e-23 -0.71 -0.54 Calcium levels; chr7:65996954 chr7:66654538~66669855:+ LIHC cis rs5769707 0.681 rs2319346 ENSG00000188511.11 C22orf34 11.73 6.16e-27 3.9e-23 0.65 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49635992 chr22:49414524~49657542:- LIHC cis rs9326248 0.574 rs1263173 ENSG00000254851.1 RP11-109L13.1 -11.73 6.27e-27 3.97e-23 -0.66 -0.54 Blood protein levels; chr11:116810292 chr11:117135528~117138582:+ LIHC cis rs12022452 0.506 rs12569328 ENSG00000238287.1 RP11-656D10.3 -11.73 6.43e-27 4.06e-23 -0.71 -0.54 Age-related hearing impairment (SNP x SNP interaction); chr1:40553549 chr1:40493157~40508661:- LIHC cis rs507080 0.663 rs523793 ENSG00000255422.1 AP002954.4 -11.73 6.43e-27 4.06e-23 -0.62 -0.54 Serum metabolite levels; chr11:118699988 chr11:118704607~118750263:+ LIHC cis rs507080 0.736 rs659564 ENSG00000255422.1 AP002954.4 -11.73 6.43e-27 4.06e-23 -0.62 -0.54 Serum metabolite levels; chr11:118700205 chr11:118704607~118750263:+ LIHC cis rs507080 0.736 rs642224 ENSG00000255422.1 AP002954.4 -11.73 6.43e-27 4.06e-23 -0.62 -0.54 Serum metabolite levels; chr11:118700210 chr11:118704607~118750263:+ LIHC cis rs507080 0.733 rs541631 ENSG00000255422.1 AP002954.4 -11.73 6.43e-27 4.06e-23 -0.62 -0.54 Serum metabolite levels; chr11:118700314 chr11:118704607~118750263:+ LIHC cis rs507080 0.736 rs658676 ENSG00000255422.1 AP002954.4 -11.73 6.43e-27 4.06e-23 -0.62 -0.54 Serum metabolite levels; chr11:118700414 chr11:118704607~118750263:+ LIHC cis rs507080 0.733 rs488141 ENSG00000255422.1 AP002954.4 -11.73 6.43e-27 4.06e-23 -0.62 -0.54 Serum metabolite levels; chr11:118700459 chr11:118704607~118750263:+ LIHC cis rs507080 0.733 rs657769 ENSG00000255422.1 AP002954.4 -11.73 6.43e-27 4.06e-23 -0.62 -0.54 Serum metabolite levels; chr11:118700607 chr11:118704607~118750263:+ LIHC cis rs507080 0.733 rs544452 ENSG00000255422.1 AP002954.4 -11.73 6.43e-27 4.06e-23 -0.62 -0.54 Serum metabolite levels; chr11:118700648 chr11:118704607~118750263:+ LIHC cis rs507080 0.697 rs656287 ENSG00000255422.1 AP002954.4 -11.73 6.43e-27 4.06e-23 -0.62 -0.54 Serum metabolite levels; chr11:118701081 chr11:118704607~118750263:+ LIHC cis rs507080 0.733 rs570949 ENSG00000255422.1 AP002954.4 -11.73 6.43e-27 4.06e-23 -0.62 -0.54 Serum metabolite levels; chr11:118701202 chr11:118704607~118750263:+ LIHC cis rs1930961 0.85 rs5996945 ENSG00000272977.1 CTA-390C10.10 11.73 6.45e-27 4.06e-23 0.84 0.54 Bipolar disorder with mood-incongruent psychosis; chr22:25479606 chr22:25476218~25479971:+ LIHC cis rs858239 0.633 rs858300 ENSG00000230658.1 KLHL7-AS1 11.72 6.49e-27 4.09e-23 0.69 0.54 Cerebrospinal fluid biomarker levels; chr7:23205012 chr7:23101228~23105703:- LIHC cis rs977987 0.671 rs9922008 ENSG00000261783.1 RP11-252K23.2 -11.72 6.65e-27 4.18e-23 -0.65 -0.54 Dupuytren's disease; chr16:75301508 chr16:75379818~75381260:- LIHC cis rs4820294 0.669 rs9622677 ENSG00000233360.4 Z83844.1 11.71 7.17e-27 4.48e-23 0.59 0.54 Fat distribution (HIV); chr22:37658255 chr22:37641832~37658377:- LIHC cis rs4820294 0.669 rs7287340 ENSG00000233360.4 Z83844.1 11.71 7.17e-27 4.48e-23 0.59 0.54 Fat distribution (HIV); chr22:37658318 chr22:37641832~37658377:- LIHC cis rs4820294 0.669 rs7287358 ENSG00000233360.4 Z83844.1 11.71 7.17e-27 4.48e-23 0.59 0.54 Fat distribution (HIV); chr22:37658396 chr22:37641832~37658377:- LIHC cis rs7104764 1 rs6598074 ENSG00000277290.1 RP11-326C3.16 -11.71 7.29e-27 4.55e-23 -0.53 -0.53 Menarche (age at onset); chr11:219398 chr11:243099~243483:- LIHC cis rs875971 0.964 rs60193905 ENSG00000226824.5 RP4-756H11.3 -11.71 7.44e-27 4.64e-23 -0.64 -0.53 Aortic root size; chr7:66506273 chr7:66654538~66669855:+ LIHC cis rs875971 0.522 rs2949690 ENSG00000226824.5 RP4-756H11.3 11.71 7.5e-27 4.68e-23 0.71 0.53 Aortic root size; chr7:66018255 chr7:66654538~66669855:+ LIHC cis rs7104764 1 rs2272563 ENSG00000277290.1 RP11-326C3.16 -11.7 7.75e-27 4.82e-23 -0.52 -0.53 Menarche (age at onset); chr11:236871 chr11:243099~243483:- LIHC cis rs7104764 0.917 rs1045288 ENSG00000277290.1 RP11-326C3.16 -11.7 7.75e-27 4.82e-23 -0.52 -0.53 Menarche (age at onset); chr11:237087 chr11:243099~243483:- LIHC cis rs7104764 0.957 rs3817629 ENSG00000277290.1 RP11-326C3.16 -11.7 7.75e-27 4.82e-23 -0.52 -0.53 Menarche (age at onset); chr11:237312 chr11:243099~243483:- LIHC cis rs7104764 1 rs10902110 ENSG00000277290.1 RP11-326C3.16 -11.7 7.75e-27 4.82e-23 -0.52 -0.53 Menarche (age at onset); chr11:237648 chr11:243099~243483:- LIHC cis rs7104764 1 rs7481993 ENSG00000277290.1 RP11-326C3.16 -11.7 7.75e-27 4.82e-23 -0.52 -0.53 Menarche (age at onset); chr11:237875 chr11:243099~243483:- LIHC cis rs7104764 1 rs6598069 ENSG00000277290.1 RP11-326C3.16 -11.7 7.75e-27 4.82e-23 -0.52 -0.53 Menarche (age at onset); chr11:240664 chr11:243099~243483:- LIHC cis rs7104764 1 rs7395328 ENSG00000277290.1 RP11-326C3.16 -11.7 8.01e-27 4.97e-23 -0.52 -0.53 Menarche (age at onset); chr11:242624 chr11:243099~243483:- LIHC cis rs5769707 0.681 rs135879 ENSG00000188511.11 C22orf34 11.69 8.38e-27 5.18e-23 0.64 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49625003 chr22:49414524~49657542:- LIHC cis rs5769707 0.642 rs135880 ENSG00000188511.11 C22orf34 11.69 8.38e-27 5.18e-23 0.64 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49625006 chr22:49414524~49657542:- LIHC cis rs11763147 1 rs11763147 ENSG00000226824.5 RP4-756H11.3 11.69 8.64e-27 5.33e-23 0.72 0.53 Corneal structure; chr7:65861834 chr7:66654538~66669855:+ LIHC cis rs858239 0.73 rs858289 ENSG00000230658.1 KLHL7-AS1 11.69 8.68e-27 5.35e-23 0.69 0.53 Cerebrospinal fluid biomarker levels; chr7:23208539 chr7:23101228~23105703:- LIHC cis rs5769707 0.777 rs8141219 ENSG00000188511.11 C22orf34 11.69 8.78e-27 5.41e-23 0.64 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49650898 chr22:49414524~49657542:- LIHC cis rs16828019 0.852 rs12045171 ENSG00000235358.1 RP11-399E6.1 11.68 9.73e-27 5.97e-23 0.77 0.53 Intelligence (multi-trait analysis); chr1:41063133 chr1:41242373~41284861:+ LIHC cis rs5769707 0.605 rs9616702 ENSG00000188511.11 C22orf34 11.67 1e-26 6.16e-23 0.65 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49632290 chr22:49414524~49657542:- LIHC cis rs507080 0.733 rs7108144 ENSG00000255422.1 AP002954.4 -11.67 1.02e-26 6.25e-23 -0.62 -0.53 Serum metabolite levels; chr11:118698985 chr11:118704607~118750263:+ LIHC cis rs1930961 1 rs6004675 ENSG00000100058.11 CRYBB2P1 11.67 1.02e-26 6.26e-23 0.82 0.53 Bipolar disorder with mood-incongruent psychosis; chr22:25493418 chr22:25448105~25520854:+ LIHC cis rs507080 0.733 rs4486664 ENSG00000255422.1 AP002954.4 -11.67 1.03e-26 6.3e-23 -0.62 -0.53 Serum metabolite levels; chr11:118698358 chr11:118704607~118750263:+ LIHC cis rs507080 0.733 rs611733 ENSG00000255422.1 AP002954.4 -11.67 1.05e-26 6.38e-23 -0.62 -0.53 Serum metabolite levels; chr11:118702051 chr11:118704607~118750263:+ LIHC cis rs16828019 0.852 rs11209531 ENSG00000235358.1 RP11-399E6.1 11.67 1.05e-26 6.43e-23 0.79 0.53 Intelligence (multi-trait analysis); chr1:41105349 chr1:41242373~41284861:+ LIHC cis rs5769707 0.667 rs4824069 ENSG00000188511.11 C22orf34 11.66 1.07e-26 6.51e-23 0.65 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49636677 chr22:49414524~49657542:- LIHC cis rs7104764 1 rs10400248 ENSG00000277290.1 RP11-326C3.16 -11.66 1.1e-26 6.7e-23 -0.52 -0.53 Menarche (age at onset); chr11:247029 chr11:243099~243483:- LIHC cis rs858239 0.67 rs3807452 ENSG00000230658.1 KLHL7-AS1 -11.65 1.22e-26 7.39e-23 -0.61 -0.53 Cerebrospinal fluid biomarker levels; chr7:23122462 chr7:23101228~23105703:- LIHC cis rs6597981 0.675 rs4963120 ENSG00000279672.1 CMB9-55F22.1 -11.65 1.25e-26 7.54e-23 -0.55 -0.53 Breast cancer; chr11:825777 chr11:779617~780755:+ LIHC cis rs2260433 0.556 rs61895694 ENSG00000281655.1 RP11-817J15.3 11.64 1.33e-26 8e-23 0.83 0.53 Cleft palate; chr11:102632269 chr11:102681310~102683913:+ LIHC cis rs7104764 0.879 rs6598070 ENSG00000277290.1 RP11-326C3.16 -11.64 1.33e-26 8.01e-23 -0.52 -0.53 Menarche (age at onset); chr11:225466 chr11:243099~243483:- LIHC cis rs7188445 0.932 rs17767419 ENSG00000261390.4 RP11-345M22.2 -11.64 1.35e-26 8.1e-23 -0.64 -0.53 Urate levels; chr16:79710651 chr16:79715232~79770563:- LIHC cis rs875971 0.867 rs1002053 ENSG00000226824.5 RP4-756H11.3 11.63 1.43e-26 8.58e-23 0.63 0.53 Aortic root size; chr7:66333558 chr7:66654538~66669855:+ LIHC cis rs5769707 0.681 rs4622843 ENSG00000188511.11 C22orf34 11.62 1.52e-26 9.06e-23 0.64 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49643268 chr22:49414524~49657542:- LIHC cis rs7104764 1 rs6598061 ENSG00000277290.1 RP11-326C3.16 -11.62 1.56e-26 9.24e-23 -0.51 -0.53 Menarche (age at onset); chr11:243853 chr11:243099~243483:- LIHC cis rs7104764 1 rs10902112 ENSG00000277290.1 RP11-326C3.16 -11.62 1.56e-26 9.24e-23 -0.51 -0.53 Menarche (age at onset); chr11:244106 chr11:243099~243483:- LIHC cis rs7104764 0.917 rs7107362 ENSG00000277290.1 RP11-326C3.16 -11.62 1.56e-26 9.24e-23 -0.51 -0.53 Menarche (age at onset); chr11:244108 chr11:243099~243483:- LIHC cis rs7104764 1 rs7128044 ENSG00000277290.1 RP11-326C3.16 -11.62 1.56e-26 9.24e-23 -0.51 -0.53 Menarche (age at onset); chr11:244115 chr11:243099~243483:- LIHC cis rs7104764 0.957 rs7116130 ENSG00000277290.1 RP11-326C3.16 -11.62 1.56e-26 9.24e-23 -0.51 -0.53 Menarche (age at onset); chr11:244129 chr11:243099~243483:- LIHC cis rs7104764 1 rs7128029 ENSG00000277290.1 RP11-326C3.16 -11.62 1.56e-26 9.24e-23 -0.51 -0.53 Menarche (age at onset); chr11:244141 chr11:243099~243483:- LIHC cis rs7104764 1 rs1128320 ENSG00000277290.1 RP11-326C3.16 -11.62 1.56e-26 9.24e-23 -0.51 -0.53 Menarche (age at onset); chr11:244167 chr11:243099~243483:- LIHC cis rs7104764 1 rs2272565 ENSG00000277290.1 RP11-326C3.16 -11.62 1.56e-26 9.24e-23 -0.51 -0.53 Menarche (age at onset); chr11:244414 chr11:243099~243483:- LIHC cis rs7104764 1 rs10902113 ENSG00000277290.1 RP11-326C3.16 -11.62 1.56e-26 9.24e-23 -0.51 -0.53 Menarche (age at onset); chr11:245523 chr11:243099~243483:- LIHC cis rs7104764 1 rs7482591 ENSG00000277290.1 RP11-326C3.16 -11.62 1.56e-26 9.24e-23 -0.51 -0.53 Menarche (age at onset); chr11:245861 chr11:243099~243483:- LIHC cis rs7104764 1 rs6598066 ENSG00000277290.1 RP11-326C3.16 -11.62 1.59e-26 9.44e-23 -0.52 -0.53 Menarche (age at onset); chr11:243185 chr11:243099~243483:- LIHC cis rs7188445 0.932 rs7203756 ENSG00000261390.4 RP11-345M22.2 11.61 1.7e-26 1.01e-22 0.64 0.53 Urate levels; chr16:79711709 chr16:79715232~79770563:- LIHC cis rs1799949 1 rs67060599 ENSG00000198496.9 NBR2 -11.61 1.75e-26 1.04e-22 -0.6 -0.53 Menopause (age at onset); chr17:43103085 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176133 ENSG00000198496.9 NBR2 -11.61 1.75e-26 1.04e-22 -0.6 -0.53 Menopause (age at onset); chr17:43105441 chr17:43125610~43153671:+ LIHC cis rs2260433 0.744 rs7109815 ENSG00000281655.1 RP11-817J15.3 11.61 1.75e-26 1.04e-22 0.65 0.53 Cleft palate; chr11:102641173 chr11:102681310~102683913:+ LIHC cis rs5769707 0.681 rs739236 ENSG00000188511.11 C22orf34 11.6 1.87e-26 1.1e-22 0.65 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49647954 chr22:49414524~49657542:- LIHC cis rs17711722 0.583 rs11768292 ENSG00000226824.5 RP4-756H11.3 11.6 1.89e-26 1.11e-22 0.77 0.53 Calcium levels; chr7:66009814 chr7:66654538~66669855:+ LIHC cis rs7104764 0.879 rs6598072 ENSG00000277290.1 RP11-326C3.16 -11.6 1.89e-26 1.11e-22 -0.52 -0.53 Menarche (age at onset); chr11:219793 chr11:243099~243483:- LIHC cis rs7104764 0.957 rs6598071 ENSG00000277290.1 RP11-326C3.16 -11.6 1.89e-26 1.11e-22 -0.52 -0.53 Menarche (age at onset); chr11:219800 chr11:243099~243483:- LIHC cis rs7104764 0.957 rs10794301 ENSG00000277290.1 RP11-326C3.16 -11.6 1.89e-26 1.11e-22 -0.52 -0.53 Menarche (age at onset); chr11:220401 chr11:243099~243483:- LIHC cis rs1799949 1 rs16941 ENSG00000198496.9 NBR2 -11.6 1.92e-26 1.13e-22 -0.6 -0.53 Menopause (age at onset); chr17:43092418 chr17:43125610~43153671:+ LIHC cis rs7104764 0.917 rs6598068 ENSG00000277290.1 RP11-326C3.16 -11.59 1.94e-26 1.14e-22 -0.51 -0.53 Menarche (age at onset); chr11:243092 chr11:243099~243483:- LIHC cis rs7104764 0.917 rs6598067 ENSG00000277290.1 RP11-326C3.16 -11.59 1.94e-26 1.14e-22 -0.51 -0.53 Menarche (age at onset); chr11:243093 chr11:243099~243483:- LIHC cis rs7104764 1 rs6598065 ENSG00000277290.1 RP11-326C3.16 -11.59 1.94e-26 1.14e-22 -0.51 -0.53 Menarche (age at onset); chr11:243211 chr11:243099~243483:- LIHC cis rs7104764 0.957 rs6598064 ENSG00000277290.1 RP11-326C3.16 -11.59 1.94e-26 1.14e-22 -0.51 -0.53 Menarche (age at onset); chr11:243557 chr11:243099~243483:- LIHC cis rs7104764 1 rs6598063 ENSG00000277290.1 RP11-326C3.16 -11.59 1.94e-26 1.14e-22 -0.51 -0.53 Menarche (age at onset); chr11:243672 chr11:243099~243483:- LIHC cis rs7104764 1 rs6598062 ENSG00000277290.1 RP11-326C3.16 -11.59 1.94e-26 1.14e-22 -0.51 -0.53 Menarche (age at onset); chr11:243712 chr11:243099~243483:- LIHC cis rs5760092 0.755 rs4585126 ENSG00000272787.1 KB-226F1.2 11.59 2.03e-26 1.19e-22 0.73 0.53 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23969211~23969873:+ LIHC cis rs7104764 1 rs10902114 ENSG00000277290.1 RP11-326C3.16 -11.58 2.11e-26 1.23e-22 -0.51 -0.53 Menarche (age at onset); chr11:246234 chr11:243099~243483:- LIHC cis rs1930961 1 rs5996946 ENSG00000272977.1 CTA-390C10.10 -11.58 2.16e-26 1.26e-22 -0.87 -0.53 Bipolar disorder with mood-incongruent psychosis; chr22:25480021 chr22:25476218~25479971:+ LIHC cis rs7188445 0.932 rs73575076 ENSG00000261390.4 RP11-345M22.2 -11.58 2.24e-26 1.3e-22 -0.64 -0.53 Urate levels; chr16:79710251 chr16:79715232~79770563:- LIHC cis rs1930961 1 rs6004669 ENSG00000272977.1 CTA-390C10.10 -11.57 2.28e-26 1.33e-22 -0.88 -0.53 Bipolar disorder with mood-incongruent psychosis; chr22:25479836 chr22:25476218~25479971:+ LIHC cis rs1930961 1 rs1930961 ENSG00000272977.1 CTA-390C10.10 -11.57 2.33e-26 1.34e-22 -0.86 -0.53 Bipolar disorder with mood-incongruent psychosis; chr22:25479298 chr22:25476218~25479971:+ LIHC cis rs507080 0.733 rs552079 ENSG00000255422.1 AP002954.4 -11.57 2.36e-26 1.36e-22 -0.62 -0.53 Serum metabolite levels; chr11:118702313 chr11:118704607~118750263:+ LIHC cis rs507080 0.733 rs673547 ENSG00000255422.1 AP002954.4 -11.57 2.36e-26 1.36e-22 -0.62 -0.53 Serum metabolite levels; chr11:118702630 chr11:118704607~118750263:+ LIHC cis rs507080 0.733 rs517445 ENSG00000255422.1 AP002954.4 -11.57 2.36e-26 1.36e-22 -0.62 -0.53 Serum metabolite levels; chr11:118702826 chr11:118704607~118750263:+ LIHC cis rs507080 0.771 rs687664 ENSG00000255422.1 AP002954.4 -11.57 2.36e-26 1.36e-22 -0.62 -0.53 Serum metabolite levels; chr11:118703476 chr11:118704607~118750263:+ LIHC cis rs507080 0.771 rs523715 ENSG00000255422.1 AP002954.4 -11.57 2.36e-26 1.36e-22 -0.62 -0.53 Serum metabolite levels; chr11:118703479 chr11:118704607~118750263:+ LIHC cis rs1799949 1 rs11652332 ENSG00000198496.9 NBR2 -11.56 2.55e-26 1.47e-22 -0.6 -0.53 Menopause (age at onset); chr17:43143472 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs8176087 ENSG00000198496.9 NBR2 -11.55 2.83e-26 1.61e-22 -0.6 -0.53 Menopause (age at onset); chr17:43118649 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176083 ENSG00000198496.9 NBR2 -11.55 2.83e-26 1.61e-22 -0.6 -0.53 Menopause (age at onset); chr17:43123134 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11657835 ENSG00000198496.9 NBR2 -11.55 2.83e-26 1.61e-22 -0.6 -0.53 Menopause (age at onset); chr17:43139936 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs1135214 ENSG00000198496.9 NBR2 -11.55 2.83e-26 1.61e-22 -0.6 -0.53 Menopause (age at onset); chr17:43140306 chr17:43125610~43153671:+ LIHC cis rs2260433 0.556 rs61895692 ENSG00000281655.1 RP11-817J15.3 11.55 2.87e-26 1.63e-22 0.83 0.53 Cleft palate; chr11:102632135 chr11:102681310~102683913:+ LIHC cis rs2739330 0.685 rs4822453 ENSG00000225282.1 AP000350.6 11.54 3.03e-26 1.72e-22 0.65 0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23926900~23929574:+ LIHC cis rs2260433 0.556 rs61895693 ENSG00000281655.1 RP11-817J15.3 11.54 3.13e-26 1.78e-22 0.83 0.53 Cleft palate; chr11:102632144 chr11:102681310~102683913:+ LIHC cis rs7104764 0.879 rs6421986 ENSG00000277290.1 RP11-326C3.16 -11.53 3.25e-26 1.84e-22 -0.51 -0.53 Menarche (age at onset); chr11:221659 chr11:243099~243483:- LIHC cis rs5769707 0.632 rs5770601 ENSG00000188511.11 C22orf34 11.53 3.3e-26 1.87e-22 0.65 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49628255 chr22:49414524~49657542:- LIHC cis rs7188445 0.932 rs73575083 ENSG00000261390.4 RP11-345M22.2 -11.53 3.35e-26 1.9e-22 -0.63 -0.53 Urate levels; chr16:79713958 chr16:79715232~79770563:- LIHC cis rs7188445 0.932 rs73575085 ENSG00000261390.4 RP11-345M22.2 -11.53 3.35e-26 1.9e-22 -0.63 -0.53 Urate levels; chr16:79714179 chr16:79715232~79770563:- LIHC cis rs5769707 0.632 rs1476037 ENSG00000188511.11 C22orf34 11.53 3.42e-26 1.93e-22 0.63 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49597729 chr22:49414524~49657542:- LIHC cis rs2260433 0.867 rs7927404 ENSG00000281655.1 RP11-817J15.3 11.52 3.58e-26 2.02e-22 0.66 0.53 Cleft palate; chr11:102639459 chr11:102681310~102683913:+ LIHC cis rs1799949 1 rs34942571 ENSG00000198496.9 NBR2 -11.51 3.85e-26 2.17e-22 -0.6 -0.53 Menopause (age at onset); chr17:43121362 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs4793215 ENSG00000198496.9 NBR2 -11.51 3.89e-26 2.19e-22 -0.6 -0.53 Menopause (age at onset); chr17:43166915 chr17:43125610~43153671:+ LIHC cis rs7188445 0.932 rs17767383 ENSG00000261390.4 RP11-345M22.2 -11.5 4.38e-26 2.44e-22 -0.63 -0.53 Urate levels; chr16:79710504 chr16:79715232~79770563:- LIHC cis rs1799949 1 rs35668327 ENSG00000198496.9 NBR2 -11.49 4.55e-26 2.52e-22 -0.6 -0.53 Menopause (age at onset); chr17:43121078 chr17:43125610~43153671:+ LIHC cis rs2260433 0.556 rs78769223 ENSG00000281655.1 RP11-817J15.3 11.49 4.55e-26 2.52e-22 0.82 0.53 Cleft palate; chr11:102632067 chr11:102681310~102683913:+ LIHC cis rs16828019 0.704 rs12024115 ENSG00000235358.1 RP11-399E6.1 11.49 4.63e-26 2.56e-22 0.79 0.53 Intelligence (multi-trait analysis); chr1:41068685 chr1:41242373~41284861:+ LIHC cis rs7188445 0.932 rs73575079 ENSG00000261390.4 RP11-345M22.2 -11.49 4.69e-26 2.59e-22 -0.63 -0.53 Urate levels; chr16:79711344 chr16:79715232~79770563:- LIHC cis rs1799949 0.965 rs33961729 ENSG00000198496.9 NBR2 -11.49 4.73e-26 2.61e-22 -0.6 -0.53 Menopause (age at onset); chr17:43135907 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs4793212 ENSG00000198496.9 NBR2 -11.49 4.79e-26 2.64e-22 -0.59 -0.53 Menopause (age at onset); chr17:43150733 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs34534709 ENSG00000198496.9 NBR2 -11.49 4.79e-26 2.64e-22 -0.59 -0.53 Menopause (age at onset); chr17:43150923 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs34059614 ENSG00000198496.9 NBR2 -11.49 4.79e-26 2.64e-22 -0.59 -0.53 Menopause (age at onset); chr17:43151054 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs1973646 ENSG00000198496.9 NBR2 -11.49 4.79e-26 2.64e-22 -0.59 -0.53 Menopause (age at onset); chr17:43158478 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11653460 ENSG00000198496.9 NBR2 -11.48 4.98e-26 2.74e-22 -0.59 -0.53 Menopause (age at onset); chr17:43179289 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs11650913 ENSG00000198496.9 NBR2 -11.48 4.98e-26 2.74e-22 -0.59 -0.53 Menopause (age at onset); chr17:43179580 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs12936831 ENSG00000198496.9 NBR2 -11.48 4.98e-26 2.74e-22 -0.59 -0.53 Menopause (age at onset); chr17:43179799 chr17:43125610~43153671:+ LIHC cis rs1799949 0.93 rs35292991 ENSG00000198496.9 NBR2 -11.48 4.98e-26 2.74e-22 -0.59 -0.53 Menopause (age at onset); chr17:43181999 chr17:43125610~43153671:+ LIHC cis rs1799949 0.896 rs35908185 ENSG00000198496.9 NBR2 -11.48 5.18e-26 2.85e-22 -0.59 -0.53 Menopause (age at onset); chr17:43103094 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs8176130 ENSG00000198496.9 NBR2 -11.48 5.18e-26 2.85e-22 -0.59 -0.53 Menopause (age at onset); chr17:43106026 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176120 ENSG00000198496.9 NBR2 -11.48 5.18e-26 2.85e-22 -0.59 -0.53 Menopause (age at onset); chr17:43109216 chr17:43125610~43153671:+ LIHC cis rs7188445 0.932 rs17689159 ENSG00000261390.4 RP11-345M22.2 -11.48 5.21e-26 2.86e-22 -0.64 -0.53 Urate levels; chr16:79708493 chr16:79715232~79770563:- LIHC cis rs7188445 0.899 rs17689024 ENSG00000261390.4 RP11-345M22.2 -11.47 5.55e-26 3.04e-22 -0.65 -0.53 Urate levels; chr16:79706081 chr16:79715232~79770563:- LIHC cis rs1799949 0.965 rs8176161 ENSG00000198496.9 NBR2 -11.47 5.65e-26 3.09e-22 -0.59 -0.53 Menopause (age at onset); chr17:43089373 chr17:43125610~43153671:+ LIHC cis rs1799949 0.894 rs8176160 ENSG00000198496.9 NBR2 -11.47 5.65e-26 3.09e-22 -0.59 -0.53 Menopause (age at onset); chr17:43089486 chr17:43125610~43153671:+ LIHC cis rs7188445 0.932 rs17689455 ENSG00000261390.4 RP11-345M22.2 -11.46 5.74e-26 3.14e-22 -0.63 -0.53 Urate levels; chr16:79712438 chr16:79715232~79770563:- LIHC cis rs4820294 0.669 rs9622678 ENSG00000233360.4 Z83844.1 11.46 5.78e-26 3.16e-22 0.58 0.53 Fat distribution (HIV); chr22:37661331 chr22:37641832~37658377:- LIHC cis rs5769707 0.681 rs916360 ENSG00000188511.11 C22orf34 11.46 6.08e-26 3.32e-22 0.64 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49648324 chr22:49414524~49657542:- LIHC cis rs2739330 0.76 rs5751761 ENSG00000272787.1 KB-226F1.2 11.45 6.23e-26 3.4e-22 0.69 0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23969211~23969873:+ LIHC cis rs7188445 0.932 rs73575086 ENSG00000261390.4 RP11-345M22.2 -11.45 6.23e-26 3.4e-22 -0.63 -0.53 Urate levels; chr16:79714588 chr16:79715232~79770563:- LIHC cis rs7104764 1 rs6598060 ENSG00000277290.1 RP11-326C3.16 -11.45 6.37e-26 3.48e-22 -0.5 -0.53 Menarche (age at onset); chr11:243987 chr11:243099~243483:- LIHC cis rs1930961 1 rs760554 ENSG00000272977.1 CTA-390C10.10 -11.45 6.55e-26 3.57e-22 -0.87 -0.53 Bipolar disorder with mood-incongruent psychosis; chr22:25476625 chr22:25476218~25479971:+ LIHC cis rs5769707 0.706 rs2071903 ENSG00000188511.11 C22orf34 11.45 6.73e-26 3.66e-22 0.65 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49640869 chr22:49414524~49657542:- LIHC cis rs16828019 0.777 rs12047657 ENSG00000235358.1 RP11-399E6.1 11.45 6.73e-26 3.66e-22 0.85 0.53 Intelligence (multi-trait analysis); chr1:40995841 chr1:41242373~41284861:+ LIHC cis rs16828019 0.85 rs12027691 ENSG00000235358.1 RP11-399E6.1 11.45 6.73e-26 3.66e-22 0.85 0.53 Intelligence (multi-trait analysis); chr1:40996360 chr1:41242373~41284861:+ LIHC cis rs16828019 0.777 rs12739052 ENSG00000235358.1 RP11-399E6.1 11.45 6.73e-26 3.66e-22 0.85 0.53 Intelligence (multi-trait analysis); chr1:40998783 chr1:41242373~41284861:+ LIHC cis rs16828019 0.777 rs12748235 ENSG00000235358.1 RP11-399E6.1 11.45 6.73e-26 3.66e-22 0.85 0.53 Intelligence (multi-trait analysis); chr1:41000549 chr1:41242373~41284861:+ LIHC cis rs7104764 0.957 rs1128321 ENSG00000277290.1 RP11-326C3.16 -11.44 6.85e-26 3.72e-22 -0.51 -0.53 Menarche (age at onset); chr11:244171 chr11:243099~243483:- LIHC cis rs7104764 1 rs10794302 ENSG00000277290.1 RP11-326C3.16 -11.44 6.98e-26 3.79e-22 -0.52 -0.53 Menarche (age at onset); chr11:234102 chr11:243099~243483:- LIHC cis rs4820294 0.669 rs12628135 ENSG00000233360.4 Z83844.1 11.44 7.12e-26 3.86e-22 0.58 0.53 Fat distribution (HIV); chr22:37669648 chr22:37641832~37658377:- LIHC cis rs1799949 1 rs33946455 ENSG00000198496.9 NBR2 -11.43 7.37e-26 4e-22 -0.6 -0.53 Menopause (age at onset); chr17:43169829 chr17:43125610~43153671:+ LIHC cis rs12022452 0.822 rs11208390 ENSG00000238287.1 RP11-656D10.3 -11.43 7.49e-26 4.06e-22 -0.7 -0.53 Age-related hearing impairment (SNP x SNP interaction); chr1:40556342 chr1:40493157~40508661:- LIHC cis rs380904 0.926 rs7842979 ENSG00000254859.1 RP11-661A12.5 -11.43 7.55e-26 4.09e-22 -0.81 -0.53 Venous thromboembolism (SNP x SNP interaction); chr8:143519726 chr8:143541973~143549729:- LIHC cis rs1799949 0.965 rs11651623 ENSG00000198496.9 NBR2 -11.43 7.6e-26 4.11e-22 -0.59 -0.53 Menopause (age at onset); chr17:43177830 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs11657883 ENSG00000198496.9 NBR2 -11.43 7.6e-26 4.11e-22 -0.59 -0.53 Menopause (age at onset); chr17:43178007 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs11656945 ENSG00000198496.9 NBR2 -11.43 7.6e-26 4.11e-22 -0.59 -0.53 Menopause (age at onset); chr17:43178248 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs11658499 ENSG00000198496.9 NBR2 -11.43 7.6e-26 4.11e-22 -0.59 -0.53 Menopause (age at onset); chr17:43182732 chr17:43125610~43153671:+ LIHC cis rs801193 0.66 rs1962050 ENSG00000226824.5 RP4-756H11.3 11.43 7.68e-26 4.15e-22 0.61 0.53 Aortic root size; chr7:66775021 chr7:66654538~66669855:+ LIHC cis rs4820294 0.669 rs35662099 ENSG00000233360.4 Z83844.1 11.43 7.82e-26 4.22e-22 0.58 0.53 Fat distribution (HIV); chr22:37657902 chr22:37641832~37658377:- LIHC cis rs7847628 0.587 rs1060817 ENSG00000226752.6 PSMD5-AS1 -11.43 7.96e-26 4.3e-22 -0.53 -0.53 Birth weight; chr9:120820914 chr9:120824828~120854385:+ LIHC cis rs1799949 1 rs8176109 ENSG00000198496.9 NBR2 -11.42 8.3e-26 4.47e-22 -0.59 -0.53 Menopause (age at onset); chr17:43113759 chr17:43125610~43153671:+ LIHC cis rs1799949 0.896 rs8176098 ENSG00000198496.9 NBR2 -11.42 8.3e-26 4.47e-22 -0.59 -0.53 Menopause (age at onset); chr17:43116189 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11656097 ENSG00000198496.9 NBR2 -11.42 8.3e-26 4.47e-22 -0.59 -0.53 Menopause (age at onset); chr17:43138596 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs2292595 ENSG00000198496.9 NBR2 -11.42 8.3e-26 4.47e-22 -0.59 -0.53 Menopause (age at onset); chr17:43138657 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11658754 ENSG00000198496.9 NBR2 -11.42 8.3e-26 4.47e-22 -0.59 -0.53 Menopause (age at onset); chr17:43140722 chr17:43125610~43153671:+ LIHC cis rs5769707 0.681 rs1107514 ENSG00000188511.11 C22orf34 11.42 8.57e-26 4.61e-22 0.64 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49648735 chr22:49414524~49657542:- LIHC cis rs5769707 0.681 rs2071902 ENSG00000188511.11 C22orf34 11.41 8.7e-26 4.68e-22 0.64 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49640890 chr22:49414524~49657542:- LIHC cis rs1799949 1 rs11651341 ENSG00000198496.9 NBR2 -11.41 9.06e-26 4.86e-22 -0.6 -0.53 Menopause (age at onset); chr17:43350693 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs34572725 ENSG00000198496.9 NBR2 -11.41 9.06e-26 4.86e-22 -0.6 -0.53 Menopause (age at onset); chr17:43351298 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs4534897 ENSG00000198496.9 NBR2 -11.41 9.06e-26 4.86e-22 -0.6 -0.53 Menopause (age at onset); chr17:43354440 chr17:43125610~43153671:+ LIHC cis rs2260433 0.867 rs11225349 ENSG00000281655.1 RP11-817J15.3 11.41 9.19e-26 4.93e-22 0.66 0.53 Cleft palate; chr11:102637462 chr11:102681310~102683913:+ LIHC cis rs9326248 0.59 rs2542063 ENSG00000254851.1 RP11-109L13.1 -11.41 9.31e-26 4.99e-22 -0.66 -0.52 Blood protein levels; chr11:116814051 chr11:117135528~117138582:+ LIHC cis rs7188445 0.932 rs17767491 ENSG00000261390.4 RP11-345M22.2 -11.41 9.36e-26 5.01e-22 -0.63 -0.52 Urate levels; chr16:79711590 chr16:79715232~79770563:- LIHC cis rs1799949 0.965 rs11650132 ENSG00000198496.9 NBR2 -11.4 9.57e-26 5.12e-22 -0.59 -0.52 Menopause (age at onset); chr17:43174070 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11654731 ENSG00000198496.9 NBR2 -11.4 9.57e-26 5.12e-22 -0.59 -0.52 Menopause (age at onset); chr17:43174923 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176202 ENSG00000198496.9 NBR2 -11.4 9.63e-26 5.15e-22 -0.59 -0.52 Menopause (age at onset); chr17:43078211 chr17:43125610~43153671:+ LIHC cis rs1930961 1 rs7285549 ENSG00000100058.11 CRYBB2P1 11.4 9.9e-26 5.29e-22 0.82 0.52 Bipolar disorder with mood-incongruent psychosis; chr22:25478613 chr22:25448105~25520854:+ LIHC cis rs5769707 0.604 rs1018814 ENSG00000188511.11 C22orf34 11.4 1e-25 5.35e-22 0.64 0.52 Monocyte percentage of white cells;Monocyte count; chr22:49643252 chr22:49414524~49657542:- LIHC cis rs1799949 1 rs2037075 ENSG00000198496.9 NBR2 -11.4 1.02e-25 5.43e-22 -0.59 -0.52 Menopause (age at onset); chr17:43153809 chr17:43125610~43153671:+ LIHC cis rs801193 0.66 rs2659897 ENSG00000226824.5 RP4-756H11.3 11.39 1.06e-25 5.67e-22 0.62 0.52 Aortic root size; chr7:66722728 chr7:66654538~66669855:+ LIHC cis rs1930961 1 rs997873 ENSG00000272977.1 CTA-390C10.10 -11.39 1.09e-25 5.78e-22 -0.84 -0.52 Bipolar disorder with mood-incongruent psychosis; chr22:25482315 chr22:25476218~25479971:+ LIHC cis rs1930961 1 rs997872 ENSG00000272977.1 CTA-390C10.10 -11.39 1.09e-25 5.78e-22 -0.84 -0.52 Bipolar disorder with mood-incongruent psychosis; chr22:25482647 chr22:25476218~25479971:+ LIHC cis rs1930961 1 rs6004671 ENSG00000272977.1 CTA-390C10.10 -11.39 1.09e-25 5.78e-22 -0.84 -0.52 Bipolar disorder with mood-incongruent psychosis; chr22:25483507 chr22:25476218~25479971:+ LIHC cis rs1799949 0.93 rs33968979 ENSG00000198496.9 NBR2 -11.38 1.13e-25 5.98e-22 -0.59 -0.52 Menopause (age at onset); chr17:43145975 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs12952790 ENSG00000198496.9 NBR2 -11.38 1.13e-25 5.98e-22 -0.59 -0.52 Menopause (age at onset); chr17:43147590 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs12950607 ENSG00000198496.9 NBR2 -11.38 1.13e-25 5.98e-22 -0.59 -0.52 Menopause (age at onset); chr17:43147911 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11079056 ENSG00000198496.9 NBR2 -11.38 1.13e-25 5.98e-22 -0.59 -0.52 Menopause (age at onset); chr17:43148782 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs12936816 ENSG00000198496.9 NBR2 -11.38 1.13e-25 5.98e-22 -0.59 -0.52 Menopause (age at onset); chr17:43149692 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs35521261 ENSG00000198496.9 NBR2 -11.38 1.13e-25 5.98e-22 -0.59 -0.52 Menopause (age at onset); chr17:43161595 chr17:43125610~43153671:+ LIHC cis rs1799949 0.896 rs33933393 ENSG00000198496.9 NBR2 -11.38 1.13e-25 5.98e-22 -0.59 -0.52 Menopause (age at onset); chr17:43165415 chr17:43125610~43153671:+ LIHC cis rs4423214 0.959 rs11606033 ENSG00000254682.1 RP11-660L16.2 11.38 1.14e-25 6.03e-22 0.65 0.52 Vitamin D levels; chr11:71443158 chr11:71448674~71452157:+ LIHC cis rs801193 0.66 rs1016265 ENSG00000226824.5 RP4-756H11.3 -11.38 1.15e-25 6.11e-22 -0.62 -0.52 Aortic root size; chr7:66749580 chr7:66654538~66669855:+ LIHC cis rs801193 0.591 rs2707839 ENSG00000226824.5 RP4-756H11.3 -11.38 1.17e-25 6.2e-22 -0.62 -0.52 Aortic root size; chr7:66728097 chr7:66654538~66669855:+ LIHC cis rs801193 0.636 rs2659895 ENSG00000226824.5 RP4-756H11.3 -11.38 1.17e-25 6.2e-22 -0.62 -0.52 Aortic root size; chr7:66731484 chr7:66654538~66669855:+ LIHC cis rs1799949 0.896 rs8176086 ENSG00000198496.9 NBR2 -11.38 1.18e-25 6.25e-22 -0.59 -0.52 Menopause (age at onset); chr17:43122761 chr17:43125610~43153671:+ LIHC cis rs801193 0.66 rs4610622 ENSG00000226824.5 RP4-756H11.3 -11.38 1.19e-25 6.29e-22 -0.62 -0.52 Aortic root size; chr7:66759510 chr7:66654538~66669855:+ LIHC cis rs801193 0.66 rs10950049 ENSG00000226824.5 RP4-756H11.3 -11.38 1.19e-25 6.29e-22 -0.62 -0.52 Aortic root size; chr7:66765873 chr7:66654538~66669855:+ LIHC cis rs2188561 0.697 rs6947099 ENSG00000241764.3 AC002467.7 11.37 1.24e-25 6.56e-22 0.69 0.52 Alcohol consumption; chr7:107720471 chr7:107742817~107744581:- LIHC cis rs1799949 1 rs4793197 ENSG00000198496.9 NBR2 -11.37 1.24e-25 6.57e-22 -0.59 -0.52 Menopause (age at onset); chr17:43079885 chr17:43125610~43153671:+ LIHC cis rs1799949 0.55 rs2343818 ENSG00000198496.9 NBR2 -11.37 1.27e-25 6.71e-22 -0.59 -0.52 Menopause (age at onset); chr17:43332406 chr17:43125610~43153671:+ LIHC cis rs1799949 0.526 rs4352088 ENSG00000198496.9 NBR2 -11.37 1.27e-25 6.71e-22 -0.59 -0.52 Menopause (age at onset); chr17:43337311 chr17:43125610~43153671:+ LIHC cis rs2739330 0.753 rs4822452 ENSG00000225282.1 AP000350.6 11.37 1.3e-25 6.86e-22 0.64 0.52 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23926900~23929574:+ LIHC cis rs1799949 0.965 rs34633610 ENSG00000198496.9 NBR2 -11.36 1.37e-25 7.18e-22 -0.59 -0.52 Menopause (age at onset); chr17:43342017 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs11654051 ENSG00000198496.9 NBR2 -11.36 1.37e-25 7.18e-22 -0.59 -0.52 Menopause (age at onset); chr17:43342288 chr17:43125610~43153671:+ LIHC cis rs1799949 0.93 rs56729776 ENSG00000198496.9 NBR2 -11.36 1.37e-25 7.18e-22 -0.59 -0.52 Menopause (age at onset); chr17:43344763 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs9646417 ENSG00000198496.9 NBR2 -11.36 1.37e-25 7.18e-22 -0.59 -0.52 Menopause (age at onset); chr17:43346885 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs1545764 ENSG00000198496.9 NBR2 -11.36 1.37e-25 7.18e-22 -0.59 -0.52 Menopause (age at onset); chr17:43347197 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs9646412 ENSG00000198496.9 NBR2 -11.36 1.37e-25 7.18e-22 -0.59 -0.52 Menopause (age at onset); chr17:43348525 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs4793231 ENSG00000198496.9 NBR2 -11.36 1.37e-25 7.18e-22 -0.59 -0.52 Menopause (age at onset); chr17:43350101 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs2298862 ENSG00000198496.9 NBR2 -11.36 1.37e-25 7.2e-22 -0.59 -0.52 Menopause (age at onset); chr17:43024671 chr17:43125610~43153671:+ LIHC cis rs1799949 0.93 rs2298861 ENSG00000198496.9 NBR2 -11.36 1.37e-25 7.2e-22 -0.59 -0.52 Menopause (age at onset); chr17:43024814 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs33926631 ENSG00000198496.9 NBR2 -11.36 1.38e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43152446 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs1960605 ENSG00000198496.9 NBR2 -11.36 1.38e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43153380 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs2037076 ENSG00000198496.9 NBR2 -11.36 1.38e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43153866 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs12950779 ENSG00000198496.9 NBR2 -11.36 1.38e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43154506 chr17:43125610~43153671:+ LIHC cis rs1799949 0.929 rs12937015 ENSG00000198496.9 NBR2 -11.36 1.38e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43155456 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs4340367 ENSG00000198496.9 NBR2 -11.36 1.38e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43155755 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs4792981 ENSG00000198496.9 NBR2 -11.36 1.38e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43156257 chr17:43125610~43153671:+ LIHC cis rs1799949 0.93 rs3765640 ENSG00000198496.9 NBR2 -11.36 1.39e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43124230 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176077 ENSG00000198496.9 NBR2 -11.36 1.39e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43124331 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11655505 ENSG00000198496.9 NBR2 -11.36 1.39e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43126360 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs4793204 ENSG00000198496.9 NBR2 -11.36 1.39e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43127281 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs12947782 ENSG00000198496.9 NBR2 -11.36 1.39e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43127865 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs33945274 ENSG00000198496.9 NBR2 -11.36 1.39e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43128056 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11653069 ENSG00000198496.9 NBR2 -11.36 1.39e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43131360 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs2175957 ENSG00000198496.9 NBR2 -11.36 1.39e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43134805 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs33988650 ENSG00000198496.9 NBR2 -11.36 1.39e-25 7.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43135863 chr17:43125610~43153671:+ LIHC cis rs9326248 0.515 rs2727793 ENSG00000254851.1 RP11-109L13.1 -11.36 1.39e-25 7.27e-22 -0.65 -0.52 Blood protein levels; chr11:116812658 chr11:117135528~117138582:+ LIHC cis rs5769707 0.681 rs8137111 ENSG00000188511.11 C22orf34 11.36 1.4e-25 7.31e-22 0.64 0.52 Monocyte percentage of white cells;Monocyte count; chr22:49650102 chr22:49414524~49657542:- LIHC cis rs875971 0.522 rs1701760 ENSG00000226824.5 RP4-756H11.3 -11.35 1.53e-25 7.95e-22 -0.7 -0.52 Aortic root size; chr7:66008701 chr7:66654538~66669855:+ LIHC cis rs1799949 0.93 rs8176194 ENSG00000198496.9 NBR2 -11.34 1.59e-25 8.24e-22 -0.59 -0.52 Menopause (age at onset); chr17:43079204 chr17:43125610~43153671:+ LIHC cis rs977987 0.868 rs10871313 ENSG00000261783.1 RP11-252K23.2 -11.34 1.66e-25 8.58e-22 -0.63 -0.52 Dupuytren's disease; chr16:75473196 chr16:75379818~75381260:- LIHC cis rs1799949 0.93 rs3092987 ENSG00000198496.9 NBR2 -11.33 1.71e-25 8.85e-22 -0.59 -0.52 Menopause (age at onset); chr17:43070706 chr17:43125610~43153671:+ LIHC cis rs7188445 0.932 rs3813582 ENSG00000261390.4 RP11-345M22.2 -11.33 1.76e-25 9.07e-22 -0.62 -0.52 Urate levels; chr16:79715456 chr16:79715232~79770563:- LIHC cis rs5769707 0.681 rs8140095 ENSG00000188511.11 C22orf34 11.33 1.78e-25 9.15e-22 0.64 0.52 Monocyte percentage of white cells;Monocyte count; chr22:49650147 chr22:49414524~49657542:- LIHC cis rs1799949 1 rs3092994 ENSG00000198496.9 NBR2 -11.33 1.78e-25 9.16e-22 -0.59 -0.52 Menopause (age at onset); chr17:43063808 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176234 ENSG00000198496.9 NBR2 -11.32 1.88e-25 9.63e-22 -0.59 -0.52 Menopause (age at onset); chr17:43067763 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176233 ENSG00000198496.9 NBR2 -11.32 1.88e-25 9.63e-22 -0.59 -0.52 Menopause (age at onset); chr17:43067787 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176242 ENSG00000198496.9 NBR2 -11.32 1.97e-25 1.01e-21 -0.59 -0.52 Menopause (age at onset); chr17:43065857 chr17:43125610~43153671:+ LIHC cis rs1930961 1 rs6004672 ENSG00000272977.1 CTA-390C10.10 -11.31 2e-25 1.02e-21 -0.83 -0.52 Bipolar disorder with mood-incongruent psychosis; chr22:25485046 chr22:25476218~25479971:+ LIHC cis rs1799949 1 rs915945 ENSG00000198496.9 NBR2 -11.31 2.08e-25 1.06e-21 -0.59 -0.52 Menopause (age at onset); chr17:43027847 chr17:43125610~43153671:+ LIHC cis rs858239 1 rs199351 ENSG00000230658.1 KLHL7-AS1 11.31 2.14e-25 1.09e-21 0.63 0.52 Cerebrospinal fluid biomarker levels; chr7:23260430 chr7:23101228~23105703:- LIHC cis rs1799949 1 rs33994002 ENSG00000198496.9 NBR2 -11.31 2.16e-25 1.1e-21 -0.59 -0.52 Menopause (age at onset); chr17:43176801 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs33920795 ENSG00000198496.9 NBR2 -11.31 2.16e-25 1.1e-21 -0.59 -0.52 Menopause (age at onset); chr17:43176993 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs33918839 ENSG00000198496.9 NBR2 -11.31 2.16e-25 1.1e-21 -0.59 -0.52 Menopause (age at onset); chr17:43177155 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11653231 ENSG00000198496.9 NBR2 -11.31 2.16e-25 1.1e-21 -0.59 -0.52 Menopause (age at onset); chr17:43179443 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs1399323 ENSG00000198496.9 NBR2 -11.31 2.16e-25 1.1e-21 -0.59 -0.52 Menopause (age at onset); chr17:43180313 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs35954893 ENSG00000198496.9 NBR2 -11.31 2.16e-25 1.1e-21 -0.59 -0.52 Menopause (age at onset); chr17:43181769 chr17:43125610~43153671:+ LIHC cis rs1799949 0.93 rs4445938 ENSG00000198496.9 NBR2 -11.31 2.16e-25 1.1e-21 -0.59 -0.52 Menopause (age at onset); chr17:43185883 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs4793194 ENSG00000198496.9 NBR2 -11.3 2.16e-25 1.1e-21 -0.59 -0.52 Menopause (age at onset); chr17:43066316 chr17:43125610~43153671:+ LIHC cis rs1930961 1 rs6004662 ENSG00000272977.1 CTA-390C10.10 -11.3 2.19e-25 1.11e-21 -0.85 -0.52 Bipolar disorder with mood-incongruent psychosis; chr22:25466157 chr22:25476218~25479971:+ LIHC cis rs1799949 0.93 rs66499067 ENSG00000198496.9 NBR2 -11.3 2.26e-25 1.14e-21 -0.59 -0.52 Menopause (age at onset); chr17:43096467 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs35956818 ENSG00000198496.9 NBR2 -11.3 2.3e-25 1.17e-21 -0.59 -0.52 Menopause (age at onset); chr17:43345617 chr17:43125610~43153671:+ LIHC cis rs1799949 0.93 rs4584865 ENSG00000198496.9 NBR2 -11.3 2.3e-25 1.17e-21 -0.59 -0.52 Menopause (age at onset); chr17:43347551 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs2271573 ENSG00000198496.9 NBR2 -11.29 2.36e-25 1.19e-21 -0.6 -0.52 Menopause (age at onset); chr17:43175604 chr17:43125610~43153671:+ LIHC cis rs875971 0.867 rs13227219 ENSG00000226824.5 RP4-756H11.3 -11.29 2.36e-25 1.2e-21 -0.62 -0.52 Aortic root size; chr7:66379075 chr7:66654538~66669855:+ LIHC cis rs801193 0.66 rs974239 ENSG00000226824.5 RP4-756H11.3 -11.29 2.42e-25 1.23e-21 -0.62 -0.52 Aortic root size; chr7:66748504 chr7:66654538~66669855:+ LIHC cis rs1799949 1 rs16940 ENSG00000198496.9 NBR2 -11.29 2.46e-25 1.24e-21 -0.59 -0.52 Menopause (age at onset); chr17:43093220 chr17:43125610~43153671:+ LIHC cis rs7104764 1 rs1128322 ENSG00000277290.1 RP11-326C3.16 11.28 2.58e-25 1.3e-21 0.49 0.52 Menarche (age at onset); chr11:244197 chr11:243099~243483:- LIHC cis rs4423214 1 rs1044482 ENSG00000254682.1 RP11-660L16.2 11.28 2.67e-25 1.35e-21 0.65 0.52 Vitamin D levels; chr11:71444125 chr11:71448674~71452157:+ LIHC cis rs1799949 1 rs2271574 ENSG00000198496.9 NBR2 -11.28 2.69e-25 1.36e-21 -0.59 -0.52 Menopause (age at onset); chr17:43175631 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs33925201 ENSG00000198496.9 NBR2 -11.27 2.82e-25 1.42e-21 -0.59 -0.52 Menopause (age at onset); chr17:43128665 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176220 ENSG00000198496.9 NBR2 -11.27 2.87e-25 1.44e-21 -0.59 -0.52 Menopause (age at onset); chr17:43070445 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs1799966 ENSG00000198496.9 NBR2 -11.27 2.87e-25 1.44e-21 -0.59 -0.52 Menopause (age at onset); chr17:43071077 chr17:43125610~43153671:+ LIHC cis rs12022452 0.822 rs7514623 ENSG00000238287.1 RP11-656D10.3 -11.27 2.95e-25 1.49e-21 -0.69 -0.52 Age-related hearing impairment (SNP x SNP interaction); chr1:40559330 chr1:40493157~40508661:- LIHC cis rs12022452 0.822 rs11811369 ENSG00000238287.1 RP11-656D10.3 -11.27 2.95e-25 1.49e-21 -0.69 -0.52 Age-related hearing impairment (SNP x SNP interaction); chr1:40560611 chr1:40493157~40508661:- LIHC cis rs875971 0.798 rs57739047 ENSG00000226824.5 RP4-756H11.3 -11.27 3e-25 1.51e-21 -0.62 -0.52 Aortic root size; chr7:66507579 chr7:66654538~66669855:+ LIHC cis rs875971 0.83 rs6950137 ENSG00000226824.5 RP4-756H11.3 -11.27 3.01e-25 1.51e-21 -0.62 -0.52 Aortic root size; chr7:66511623 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs4236208 ENSG00000226824.5 RP4-756H11.3 11.26 3.03e-25 1.53e-21 0.62 0.52 Aortic root size; chr7:66284091 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs1544549 ENSG00000226824.5 RP4-756H11.3 11.26 3.04e-25 1.53e-21 0.62 0.52 Aortic root size; chr7:66625676 chr7:66654538~66669855:+ LIHC cis rs10256972 0.528 rs7784607 ENSG00000229043.2 AC091729.9 -11.26 3.06e-25 1.54e-21 -0.6 -0.52 Endometriosis;Longevity; chr7:1139058 chr7:1160374~1165267:+ LIHC cis rs875971 0.798 rs6460304 ENSG00000226824.5 RP4-756H11.3 -11.26 3.06e-25 1.54e-21 -0.62 -0.52 Aortic root size; chr7:66499741 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6945775 ENSG00000226824.5 RP4-756H11.3 -11.26 3.06e-25 1.54e-21 -0.62 -0.52 Aortic root size; chr7:66503987 chr7:66654538~66669855:+ LIHC cis rs1799949 1 rs1060915 ENSG00000198496.9 NBR2 -11.26 3.08e-25 1.55e-21 -0.59 -0.52 Menopause (age at onset); chr17:43082453 chr17:43125610~43153671:+ LIHC cis rs7847628 0.587 rs3793638 ENSG00000226752.6 PSMD5-AS1 -11.26 3.11e-25 1.56e-21 -0.53 -0.52 Birth weight; chr9:120820419 chr9:120824828~120854385:+ LIHC cis rs858239 0.932 rs858272 ENSG00000230658.1 KLHL7-AS1 11.26 3.14e-25 1.58e-21 0.62 0.52 Cerebrospinal fluid biomarker levels; chr7:23237166 chr7:23101228~23105703:- LIHC cis rs2739330 0.652 rs2000469 ENSG00000218537.1 MIF-AS1 11.25 3.37e-25 1.69e-21 0.7 0.52 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23894426~23898930:- LIHC cis rs1799949 0.501 rs2343819 ENSG00000198496.9 NBR2 -11.25 3.53e-25 1.76e-21 -0.59 -0.52 Menopause (age at onset); chr17:43332285 chr17:43125610~43153671:+ LIHC cis rs1799949 0.501 rs35399157 ENSG00000198496.9 NBR2 -11.25 3.53e-25 1.76e-21 -0.59 -0.52 Menopause (age at onset); chr17:43334234 chr17:43125610~43153671:+ LIHC cis rs1799949 0.602 rs4600503 ENSG00000198496.9 NBR2 -11.25 3.53e-25 1.76e-21 -0.59 -0.52 Menopause (age at onset); chr17:43336956 chr17:43125610~43153671:+ LIHC cis rs1799949 0.501 rs9675035 ENSG00000198496.9 NBR2 -11.25 3.53e-25 1.76e-21 -0.59 -0.52 Menopause (age at onset); chr17:43337648 chr17:43125610~43153671:+ LIHC cis rs875971 0.862 rs778724 ENSG00000226824.5 RP4-756H11.3 -11.25 3.53e-25 1.76e-21 -0.62 -0.52 Aortic root size; chr7:66364304 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs778686 ENSG00000226824.5 RP4-756H11.3 -11.25 3.53e-25 1.76e-21 -0.62 -0.52 Aortic root size; chr7:66370923 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs778684 ENSG00000226824.5 RP4-756H11.3 -11.25 3.53e-25 1.76e-21 -0.62 -0.52 Aortic root size; chr7:66371416 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs778680 ENSG00000226824.5 RP4-756H11.3 -11.25 3.53e-25 1.76e-21 -0.62 -0.52 Aortic root size; chr7:66375427 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs11769079 ENSG00000226824.5 RP4-756H11.3 -11.25 3.53e-25 1.76e-21 -0.62 -0.52 Aortic root size; chr7:66377141 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs1695820 ENSG00000226824.5 RP4-756H11.3 -11.25 3.53e-25 1.76e-21 -0.62 -0.52 Aortic root size; chr7:66379576 chr7:66654538~66669855:+ LIHC cis rs875971 0.83 rs778715 ENSG00000226824.5 RP4-756H11.3 -11.25 3.53e-25 1.76e-21 -0.62 -0.52 Aortic root size; chr7:66384222 chr7:66654538~66669855:+ LIHC cis rs875971 0.83 rs809025 ENSG00000226824.5 RP4-756H11.3 -11.25 3.53e-25 1.76e-21 -0.62 -0.52 Aortic root size; chr7:66384832 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs778702 ENSG00000226824.5 RP4-756H11.3 -11.25 3.53e-25 1.76e-21 -0.62 -0.52 Aortic root size; chr7:66399848 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs1643375 ENSG00000226824.5 RP4-756H11.3 -11.25 3.53e-25 1.76e-21 -0.62 -0.52 Aortic root size; chr7:66407690 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6962717 ENSG00000226824.5 RP4-756H11.3 -11.25 3.53e-25 1.76e-21 -0.62 -0.52 Aortic root size; chr7:66418748 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs2420820 ENSG00000226824.5 RP4-756H11.3 11.25 3.55e-25 1.76e-21 0.62 0.52 Aortic root size; chr7:66626920 chr7:66654538~66669855:+ LIHC cis rs1799949 0.931 rs34410138 ENSG00000198496.9 NBR2 -11.24 3.6e-25 1.79e-21 -0.59 -0.52 Menopause (age at onset); chr17:43127753 chr17:43125610~43153671:+ LIHC cis rs1930961 1 rs760555 ENSG00000272977.1 CTA-390C10.10 -11.24 3.63e-25 1.8e-21 -0.85 -0.52 Bipolar disorder with mood-incongruent psychosis; chr22:25476870 chr22:25476218~25479971:+ LIHC cis rs1799949 1 rs11649954 ENSG00000198496.9 NBR2 -11.24 3.79e-25 1.88e-21 -0.59 -0.52 Menopause (age at onset); chr17:43342667 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs1824889 ENSG00000198496.9 NBR2 -11.24 3.79e-25 1.88e-21 -0.59 -0.52 Menopause (age at onset); chr17:43344508 chr17:43125610~43153671:+ LIHC cis rs2188561 0.697 rs6956243 ENSG00000241764.3 AC002467.7 11.23 3.88e-25 1.92e-21 0.68 0.52 Alcohol consumption; chr7:107748466 chr7:107742817~107744581:- LIHC cis rs2188561 0.697 rs12539555 ENSG00000241764.3 AC002467.7 11.23 3.88e-25 1.92e-21 0.68 0.52 Alcohol consumption; chr7:107764028 chr7:107742817~107744581:- LIHC cis rs7847628 0.587 rs12684934 ENSG00000226752.6 PSMD5-AS1 -11.23 3.93e-25 1.94e-21 -0.53 -0.52 Birth weight; chr9:120830881 chr9:120824828~120854385:+ LIHC cis rs12439619 0.846 rs62011975 ENSG00000278603.1 RP13-608F4.5 11.23 4.05e-25 2e-21 1 0.52 Intelligence (multi-trait analysis); chr15:82159213 chr15:82472203~82472426:+ LIHC cis rs2188561 0.708 rs9718496 ENSG00000241764.3 AC002467.7 11.23 4.18e-25 2.06e-21 0.69 0.52 Alcohol consumption; chr7:107730187 chr7:107742817~107744581:- LIHC cis rs296381 0.641 rs17272617 ENSG00000259108.2 CTD-3098H1.2 -11.22 4.2e-25 2.06e-21 -0.91 -0.52 Blood metabolite levels; chr19:47854103 chr19:47863483~47865341:- LIHC cis rs7847628 0.587 rs4837796 ENSG00000226752.6 PSMD5-AS1 11.22 4.34e-25 2.13e-21 0.51 0.52 Birth weight; chr9:120848010 chr9:120824828~120854385:+ LIHC cis rs1799949 1 rs12944430 ENSG00000198496.9 NBR2 -11.22 4.34e-25 2.14e-21 -0.59 -0.52 Menopause (age at onset); chr17:43178803 chr17:43125610~43153671:+ LIHC cis rs2188561 0.697 rs10808154 ENSG00000241764.3 AC002467.7 11.22 4.51e-25 2.21e-21 0.68 0.52 Alcohol consumption; chr7:107745951 chr7:107742817~107744581:- LIHC cis rs9322193 0.923 rs4869750 ENSG00000231760.4 RP11-350J20.5 11.22 4.51e-25 2.21e-21 0.71 0.52 Lung cancer; chr6:149855996 chr6:149796151~149826294:- LIHC cis rs12439619 0.846 rs62012056 ENSG00000278603.1 RP13-608F4.5 11.21 4.56e-25 2.24e-21 0.98 0.52 Intelligence (multi-trait analysis); chr15:82247278 chr15:82472203~82472426:+ LIHC cis rs1799949 0.965 rs8176193 ENSG00000198496.9 NBR2 -11.21 4.61e-25 2.26e-21 -0.58 -0.52 Menopause (age at onset); chr17:43079499 chr17:43125610~43153671:+ LIHC cis rs2188561 0.697 rs3735607 ENSG00000241764.3 AC002467.7 11.21 4.61e-25 2.26e-21 0.68 0.52 Alcohol consumption; chr7:107743833 chr7:107742817~107744581:- LIHC cis rs5758659 0.504 rs133367 ENSG00000237037.8 NDUFA6-AS1 -11.21 4.75e-25 2.32e-21 -0.6 -0.52 Cognitive function; chr22:42067362 chr22:42090931~42137742:+ LIHC cis rs1799949 1 rs8074136 ENSG00000198496.9 NBR2 -11.21 4.78e-25 2.34e-21 -0.58 -0.52 Menopause (age at onset); chr17:43190296 chr17:43125610~43153671:+ LIHC cis rs875971 0.929 rs34406470 ENSG00000226824.5 RP4-756H11.3 -11.21 4.88e-25 2.38e-21 -0.62 -0.52 Aortic root size; chr7:66464969 chr7:66654538~66669855:+ LIHC cis rs875971 0.895 rs7788984 ENSG00000226824.5 RP4-756H11.3 -11.2 4.97e-25 2.43e-21 -0.62 -0.52 Aortic root size; chr7:66450629 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs1981798 ENSG00000226824.5 RP4-756H11.3 -11.2 4.97e-25 2.43e-21 -0.62 -0.52 Aortic root size; chr7:66489916 chr7:66654538~66669855:+ LIHC cis rs7104764 0.957 rs6598075 ENSG00000277290.1 RP11-326C3.16 11.2 5.16e-25 2.52e-21 0.49 0.52 Menarche (age at onset); chr11:207275 chr11:243099~243483:- LIHC cis rs7104764 0.957 rs58692051 ENSG00000277290.1 RP11-326C3.16 11.2 5.16e-25 2.52e-21 0.49 0.52 Menarche (age at onset); chr11:207410 chr11:243099~243483:- LIHC cis rs2188561 0.638 rs3735609 ENSG00000241764.3 AC002467.7 11.2 5.34e-25 2.6e-21 0.68 0.52 Alcohol consumption; chr7:107743299 chr7:107742817~107744581:- LIHC cis rs875971 0.54 rs4717275 ENSG00000226824.5 RP4-756H11.3 11.19 5.38e-25 2.62e-21 0.69 0.52 Aortic root size; chr7:65800193 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs7781698 ENSG00000226824.5 RP4-756H11.3 -11.19 5.47e-25 2.66e-21 -0.62 -0.52 Aortic root size; chr7:66431325 chr7:66654538~66669855:+ LIHC cis rs1799949 1 rs8070085 ENSG00000198496.9 NBR2 11.19 5.54e-25 2.69e-21 0.58 0.52 Menopause (age at onset); chr17:43189967 chr17:43125610~43153671:+ LIHC cis rs2739330 0.652 rs2000469 ENSG00000273295.1 AP000350.5 11.19 5.65e-25 2.75e-21 0.56 0.52 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23901432~23907068:- LIHC cis rs12439619 0.846 rs62012059 ENSG00000278603.1 RP13-608F4.5 11.19 5.75e-25 2.79e-21 0.98 0.52 Intelligence (multi-trait analysis); chr15:82251669 chr15:82472203~82472426:+ LIHC cis rs12439619 0.846 rs62010071 ENSG00000278603.1 RP13-608F4.5 11.19 5.75e-25 2.79e-21 0.98 0.52 Intelligence (multi-trait analysis); chr15:82289442 chr15:82472203~82472426:+ LIHC cis rs1930961 1 rs6004668 ENSG00000100058.11 CRYBB2P1 -11.19 5.8e-25 2.82e-21 -0.8 -0.52 Bipolar disorder with mood-incongruent psychosis; chr22:25478535 chr22:25448105~25520854:+ LIHC cis rs875971 0.862 rs4149461 ENSG00000226824.5 RP4-756H11.3 11.18 5.87e-25 2.85e-21 0.62 0.52 Aortic root size; chr7:66279745 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs10261398 ENSG00000226824.5 RP4-756H11.3 11.18 5.87e-25 2.85e-21 0.62 0.52 Aortic root size; chr7:66285177 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs10224872 ENSG00000226824.5 RP4-756H11.3 11.18 5.87e-25 2.85e-21 0.62 0.52 Aortic root size; chr7:66294786 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs949930 ENSG00000226824.5 RP4-756H11.3 11.18 5.89e-25 2.85e-21 0.62 0.52 Aortic root size; chr7:66301835 chr7:66654538~66669855:+ LIHC cis rs875971 0.928 rs2036263 ENSG00000226824.5 RP4-756H11.3 11.18 5.89e-25 2.85e-21 0.62 0.52 Aortic root size; chr7:66335210 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs10240949 ENSG00000226824.5 RP4-756H11.3 11.18 5.89e-25 2.85e-21 0.62 0.52 Aortic root size; chr7:66339430 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs7782704 ENSG00000226824.5 RP4-756H11.3 11.18 5.89e-25 2.85e-21 0.62 0.52 Aortic root size; chr7:66340379 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6959268 ENSG00000226824.5 RP4-756H11.3 11.18 5.89e-25 2.85e-21 0.62 0.52 Aortic root size; chr7:66347979 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs778734 ENSG00000226824.5 RP4-756H11.3 -11.18 5.89e-25 2.85e-21 -0.62 -0.52 Aortic root size; chr7:66349862 chr7:66654538~66669855:+ LIHC cis rs1799949 1 rs8176145 ENSG00000198496.9 NBR2 -11.17 6.37e-25 3.07e-21 -0.58 -0.52 Menopause (age at onset); chr17:43097077 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs8176140 ENSG00000198496.9 NBR2 -11.17 6.37e-25 3.07e-21 -0.58 -0.52 Menopause (age at onset); chr17:43099629 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs12944458 ENSG00000198496.9 NBR2 -11.17 6.49e-25 3.13e-21 -0.58 -0.52 Menopause (age at onset); chr17:43028755 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs36036395 ENSG00000198496.9 NBR2 -11.17 6.49e-25 3.13e-21 -0.58 -0.52 Menopause (age at onset); chr17:43029280 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs72829113 ENSG00000198496.9 NBR2 -11.17 6.49e-25 3.13e-21 -0.58 -0.52 Menopause (age at onset); chr17:43029818 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11653253 ENSG00000198496.9 NBR2 -11.17 6.49e-25 3.13e-21 -0.58 -0.52 Menopause (age at onset); chr17:43030645 chr17:43125610~43153671:+ LIHC cis rs7188445 0.932 rs17767904 ENSG00000261390.4 RP11-345M22.2 -11.17 6.52e-25 3.14e-21 -0.63 -0.52 Urate levels; chr16:79716078 chr16:79715232~79770563:- LIHC cis rs5758659 0.819 rs134871 ENSG00000237037.8 NDUFA6-AS1 11.17 6.55e-25 3.15e-21 0.57 0.52 Cognitive function; chr22:42256710 chr22:42090931~42137742:+ LIHC cis rs875971 0.862 rs6460290 ENSG00000226824.5 RP4-756H11.3 11.17 6.68e-25 3.22e-21 0.61 0.52 Aortic root size; chr7:66344119 chr7:66654538~66669855:+ LIHC cis rs875971 0.825 rs1000464 ENSG00000226824.5 RP4-756H11.3 11.17 6.87e-25 3.3e-21 0.62 0.52 Aortic root size; chr7:66312922 chr7:66654538~66669855:+ LIHC cis rs1799949 1 rs3950989 ENSG00000198496.9 NBR2 -11.16 6.92e-25 3.32e-21 -0.58 -0.52 Menopause (age at onset); chr17:43085936 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs2070834 ENSG00000198496.9 NBR2 -11.16 6.92e-25 3.32e-21 -0.58 -0.52 Menopause (age at onset); chr17:43090268 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs16942 ENSG00000198496.9 NBR2 -11.16 6.92e-25 3.32e-21 -0.58 -0.52 Menopause (age at onset); chr17:43091983 chr17:43125610~43153671:+ LIHC cis rs7188445 0.932 rs17767742 ENSG00000261390.4 RP11-345M22.2 -11.16 7.1e-25 3.41e-21 -0.64 -0.52 Urate levels; chr16:79715108 chr16:79715232~79770563:- LIHC cis rs7104764 0.957 rs56357554 ENSG00000277290.1 RP11-326C3.16 11.16 7.16e-25 3.44e-21 0.5 0.52 Menarche (age at onset); chr11:204715 chr11:243099~243483:- LIHC cis rs1799949 1 rs8176103 ENSG00000198496.9 NBR2 -11.16 7.26e-25 3.48e-21 -0.58 -0.52 Menopause (age at onset); chr17:43115033 chr17:43125610~43153671:+ LIHC cis rs875971 0.767 rs1643394 ENSG00000226824.5 RP4-756H11.3 -11.16 7.39e-25 3.54e-21 -0.61 -0.52 Aortic root size; chr7:66371107 chr7:66654538~66669855:+ LIHC cis rs7188445 0.836 rs3813580 ENSG00000261390.4 RP11-345M22.2 -11.16 7.39e-25 3.54e-21 -0.63 -0.52 Urate levels; chr16:79715383 chr16:79715232~79770563:- LIHC cis rs875971 1 rs1167612 ENSG00000226824.5 RP4-756H11.3 11.16 7.43e-25 3.56e-21 0.63 0.52 Aortic root size; chr7:66102989 chr7:66654538~66669855:+ LIHC cis rs12439619 0.846 rs62012004 ENSG00000278603.1 RP13-608F4.5 11.15 7.63e-25 3.65e-21 0.98 0.52 Intelligence (multi-trait analysis); chr15:82183924 chr15:82472203~82472426:+ LIHC cis rs1799949 1 rs35070007 ENSG00000198496.9 NBR2 11.15 7.74e-25 3.7e-21 0.58 0.52 Menopause (age at onset); chr17:43164730 chr17:43125610~43153671:+ LIHC cis rs2739330 0.76 rs5751761 ENSG00000218537.1 MIF-AS1 -11.15 7.82e-25 3.74e-21 -0.7 -0.52 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23894426~23898930:- LIHC cis rs1799949 0.773 rs2137990 ENSG00000198496.9 NBR2 11.15 8.03e-25 3.84e-21 0.58 0.52 Menopause (age at onset); chr17:43165879 chr17:43125610~43153671:+ LIHC cis rs1930961 1 rs6004669 ENSG00000100058.11 CRYBB2P1 11.14 8.16e-25 3.9e-21 0.82 0.52 Bipolar disorder with mood-incongruent psychosis; chr22:25479836 chr22:25448105~25520854:+ LIHC cis rs2188561 0.697 rs34986332 ENSG00000241764.3 AC002467.7 11.14 8.33e-25 3.98e-21 0.68 0.52 Alcohol consumption; chr7:107739010 chr7:107742817~107744581:- LIHC cis rs1799949 1 rs8176273 ENSG00000198496.9 NBR2 -11.14 8.39e-25 4.01e-21 -0.58 -0.52 Menopause (age at onset); chr17:43059636 chr17:43125610~43153671:+ LIHC cis rs858239 0.896 rs1637193 ENSG00000230658.1 KLHL7-AS1 11.14 8.44e-25 4.03e-21 0.66 0.52 Cerebrospinal fluid biomarker levels; chr7:23220632 chr7:23101228~23105703:- LIHC cis rs7188445 0.932 rs17689625 ENSG00000261390.4 RP11-345M22.2 -11.14 8.54e-25 4.07e-21 -0.62 -0.52 Urate levels; chr16:79715065 chr16:79715232~79770563:- LIHC cis rs875971 0.862 rs12537823 ENSG00000226824.5 RP4-756H11.3 -11.13 9.02e-25 4.3e-21 -0.61 -0.52 Aortic root size; chr7:66255897 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs10282433 ENSG00000226824.5 RP4-756H11.3 11.13 9.02e-25 4.3e-21 0.61 0.52 Aortic root size; chr7:66256452 chr7:66654538~66669855:+ LIHC cis rs1799949 1 rs35330014 ENSG00000198496.9 NBR2 -11.13 9.29e-25 4.42e-21 -0.58 -0.52 Menopause (age at onset); chr17:43060530 chr17:43125610~43153671:+ LIHC cis rs875971 0.895 rs12698520 ENSG00000226824.5 RP4-756H11.3 -11.13 9.31e-25 4.43e-21 -0.62 -0.52 Aortic root size; chr7:66453720 chr7:66654538~66669855:+ LIHC cis rs1930961 1 rs1930961 ENSG00000100058.11 CRYBB2P1 11.13 9.44e-25 4.49e-21 0.8 0.52 Bipolar disorder with mood-incongruent psychosis; chr22:25479298 chr22:25448105~25520854:+ LIHC cis rs875971 1 rs4717292 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66430611 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs2420591 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66447394 chr7:66654538~66669855:+ LIHC cis rs875971 0.895 rs10755833 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66448930 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs12668936 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66449417 chr7:66654538~66669855:+ LIHC cis rs875971 0.895 rs1833495 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66456608 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs6945032 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66457499 chr7:66654538~66669855:+ LIHC cis rs875971 0.929 rs12673810 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66458866 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs35149210 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66464938 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs6961155 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66468308 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs7789768 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66473993 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs1363055 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66478288 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs9691480 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66479319 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs7789554 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66481051 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs4717300 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66482393 chr7:66654538~66669855:+ LIHC cis rs875971 0.895 rs1974769 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66485627 chr7:66654538~66669855:+ LIHC cis rs875971 0.895 rs6460300 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66487937 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs7803416 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66489212 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs1981799 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66490572 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs2277911 ENSG00000226824.5 RP4-756H11.3 -11.12 9.59e-25 4.54e-21 -0.62 -0.52 Aortic root size; chr7:66493638 chr7:66654538~66669855:+ LIHC cis rs1799949 1 rs8176269 ENSG00000198496.9 NBR2 -11.12 9.62e-25 4.55e-21 -0.58 -0.52 Menopause (age at onset); chr17:43061609 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176265 ENSG00000198496.9 NBR2 -11.12 9.62e-25 4.55e-21 -0.58 -0.52 Menopause (age at onset); chr17:43061979 chr17:43125610~43153671:+ LIHC cis rs875971 1 rs2077593 ENSG00000226824.5 RP4-756H11.3 -11.12 9.92e-25 4.69e-21 -0.62 -0.52 Aortic root size; chr7:66427543 chr7:66654538~66669855:+ LIHC cis rs1799949 1 rs12951869 ENSG00000198496.9 NBR2 -11.12 1.02e-24 4.82e-21 -0.58 -0.52 Menopause (age at onset); chr17:43035550 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11654452 ENSG00000198496.9 NBR2 -11.12 1.02e-24 4.82e-21 -0.58 -0.52 Menopause (age at onset); chr17:43037366 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs4793189 ENSG00000198496.9 NBR2 -11.12 1.02e-24 4.82e-21 -0.58 -0.52 Menopause (age at onset); chr17:43038698 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11657053 ENSG00000198496.9 NBR2 -11.12 1.02e-24 4.82e-21 -0.58 -0.52 Menopause (age at onset); chr17:43039112 chr17:43125610~43153671:+ LIHC cis rs12439619 0.739 rs62012046 ENSG00000278603.1 RP13-608F4.5 11.12 1.03e-24 4.87e-21 0.98 0.52 Intelligence (multi-trait analysis); chr15:82236824 chr15:82472203~82472426:+ LIHC cis rs12439619 0.774 rs62012047 ENSG00000278603.1 RP13-608F4.5 11.12 1.03e-24 4.87e-21 0.98 0.52 Intelligence (multi-trait analysis); chr15:82236852 chr15:82472203~82472426:+ LIHC cis rs12439619 0.81 rs62012049 ENSG00000278603.1 RP13-608F4.5 11.12 1.03e-24 4.87e-21 0.98 0.52 Intelligence (multi-trait analysis); chr15:82237722 chr15:82472203~82472426:+ LIHC cis rs1799949 0.929 rs799906 ENSG00000198496.9 NBR2 -11.11 1.06e-24 4.98e-21 -0.58 -0.52 Menopause (age at onset); chr17:43126099 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs799908 ENSG00000198496.9 NBR2 -11.11 1.06e-24 4.98e-21 -0.58 -0.52 Menopause (age at onset); chr17:43126899 chr17:43125610~43153671:+ LIHC cis rs1799949 0.93 rs1554063 ENSG00000198496.9 NBR2 -11.11 1.06e-24 4.98e-21 -0.58 -0.52 Menopause (age at onset); chr17:43135128 chr17:43125610~43153671:+ LIHC cis rs875971 1 rs2087647 ENSG00000226824.5 RP4-756H11.3 11.1 1.15e-24 5.43e-21 0.62 0.51 Aortic root size; chr7:66128201 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs6958484 ENSG00000226824.5 RP4-756H11.3 11.1 1.15e-24 5.43e-21 0.62 0.51 Aortic root size; chr7:66134459 chr7:66654538~66669855:+ LIHC cis rs801193 0.613 rs2016325 ENSG00000226824.5 RP4-756H11.3 11.1 1.2e-24 5.62e-21 0.71 0.51 Aortic root size; chr7:66858513 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs709596 ENSG00000226824.5 RP4-756H11.3 -11.1 1.21e-24 5.7e-21 -0.61 -0.51 Aortic root size; chr7:66360926 chr7:66654538~66669855:+ LIHC cis rs4423214 0.879 rs12803256 ENSG00000254682.1 RP11-660L16.2 11.09 1.26e-24 5.9e-21 0.65 0.51 Vitamin D levels; chr11:71421822 chr11:71448674~71452157:+ LIHC cis rs875971 0.522 rs1917563 ENSG00000226824.5 RP4-756H11.3 11.09 1.33e-24 6.21e-21 0.69 0.51 Aortic root size; chr7:65950660 chr7:66654538~66669855:+ LIHC cis rs801193 0.66 rs2659914 ENSG00000226824.5 RP4-756H11.3 -11.08 1.36e-24 6.38e-21 -0.61 -0.51 Aortic root size; chr7:66691927 chr7:66654538~66669855:+ LIHC cis rs7188445 0.932 rs4575545 ENSG00000261390.4 RP11-345M22.2 -11.08 1.36e-24 6.38e-21 -0.63 -0.51 Urate levels; chr16:79721549 chr16:79715232~79770563:- LIHC cis rs875971 0.964 rs6945019 ENSG00000226824.5 RP4-756H11.3 -11.08 1.37e-24 6.41e-21 -0.62 -0.51 Aortic root size; chr7:66457471 chr7:66654538~66669855:+ LIHC cis rs1799949 1 rs4793236 ENSG00000198496.9 NBR2 -11.08 1.38e-24 6.43e-21 -0.59 -0.51 Menopause (age at onset); chr17:43359072 chr17:43125610~43153671:+ LIHC cis rs875971 0.862 rs10276077 ENSG00000226824.5 RP4-756H11.3 11.08 1.4e-24 6.56e-21 0.61 0.51 Aortic root size; chr7:66263424 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs11773628 ENSG00000226824.5 RP4-756H11.3 11.08 1.44e-24 6.7e-21 0.61 0.51 Aortic root size; chr7:66517644 chr7:66654538~66669855:+ LIHC cis rs801193 0.613 rs2659900 ENSG00000226824.5 RP4-756H11.3 -11.07 1.45e-24 6.76e-21 -0.61 -0.51 Aortic root size; chr7:66719456 chr7:66654538~66669855:+ LIHC cis rs8062405 0.965 rs8049439 ENSG00000259982.1 CDC37P1 11.07 1.45e-24 6.79e-21 0.56 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28826194 chr16:28700294~28701540:- LIHC cis rs1930961 1 rs5996946 ENSG00000100058.11 CRYBB2P1 11.07 1.46e-24 6.81e-21 0.81 0.51 Bipolar disorder with mood-incongruent psychosis; chr22:25480021 chr22:25448105~25520854:+ LIHC cis rs977987 0.832 rs37597 ENSG00000261783.1 RP11-252K23.2 11.07 1.46e-24 6.84e-21 0.62 0.51 Dupuytren's disease; chr16:75466377 chr16:75379818~75381260:- LIHC cis rs1799949 1 rs8077486 ENSG00000198496.9 NBR2 -11.07 1.47e-24 6.87e-21 -0.58 -0.51 Menopause (age at onset); chr17:43060788 chr17:43125610~43153671:+ LIHC cis rs9326248 0.53 rs2471884 ENSG00000254851.1 RP11-109L13.1 -11.07 1.5e-24 6.98e-21 -0.71 -0.51 Blood protein levels; chr11:117139604 chr11:117135528~117138582:+ LIHC cis rs2188561 0.697 rs66560125 ENSG00000241764.3 AC002467.7 11.07 1.5e-24 7e-21 0.69 0.51 Alcohol consumption; chr7:107729589 chr7:107742817~107744581:- LIHC cis rs2188561 0.697 rs13242107 ENSG00000241764.3 AC002467.7 11.07 1.5e-24 7e-21 0.69 0.51 Alcohol consumption; chr7:107734800 chr7:107742817~107744581:- LIHC cis rs1799949 0.794 rs116409325 ENSG00000198496.9 NBR2 -11.07 1.54e-24 7.17e-21 -0.59 -0.51 Menopause (age at onset); chr17:43368092 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs12944597 ENSG00000198496.9 NBR2 -11.07 1.54e-24 7.18e-21 -0.58 -0.51 Menopause (age at onset); chr17:43035667 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs12942277 ENSG00000198496.9 NBR2 -11.07 1.54e-24 7.18e-21 -0.58 -0.51 Menopause (age at onset); chr17:43035957 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs34616041 ENSG00000198496.9 NBR2 -11.07 1.54e-24 7.18e-21 -0.58 -0.51 Menopause (age at onset); chr17:43036769 chr17:43125610~43153671:+ LIHC cis rs875971 0.862 rs11763189 ENSG00000226824.5 RP4-756H11.3 -11.07 1.55e-24 7.21e-21 -0.61 -0.51 Aortic root size; chr7:66518542 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6460302 ENSG00000226824.5 RP4-756H11.3 -11.07 1.56e-24 7.26e-21 -0.61 -0.51 Aortic root size; chr7:66495270 chr7:66654538~66669855:+ LIHC cis rs1799949 0.894 rs36062488 ENSG00000198496.9 NBR2 11.06 1.57e-24 7.31e-21 0.58 0.51 Menopause (age at onset); chr17:43185455 chr17:43125610~43153671:+ LIHC cis rs1930961 0.702 rs1930966 ENSG00000100058.11 CRYBB2P1 11.06 1.6e-24 7.44e-21 0.79 0.51 Bipolar disorder with mood-incongruent psychosis; chr22:25489737 chr22:25448105~25520854:+ LIHC cis rs507080 0.501 rs626645 ENSG00000255239.1 AP002954.6 11.06 1.61e-24 7.47e-21 0.59 0.51 Serum metabolite levels; chr11:118704471 chr11:118688039~118690600:- LIHC cis rs1891275 0.513 rs1539041 ENSG00000228701.1 TNKS2-AS1 -11.06 1.62e-24 7.53e-21 -0.76 -0.51 Intelligence (multi-trait analysis); chr10:91817384 chr10:91782839~91798291:- LIHC cis rs875971 0.825 rs4587224 ENSG00000226824.5 RP4-756H11.3 11.06 1.64e-24 7.61e-21 0.61 0.51 Aortic root size; chr7:66271195 chr7:66654538~66669855:+ LIHC cis rs875971 0.792 rs6971752 ENSG00000226824.5 RP4-756H11.3 11.06 1.64e-24 7.61e-21 0.61 0.51 Aortic root size; chr7:66272999 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs10950033 ENSG00000226824.5 RP4-756H11.3 11.06 1.64e-24 7.61e-21 0.61 0.51 Aortic root size; chr7:66274686 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs11760844 ENSG00000226824.5 RP4-756H11.3 11.06 1.64e-24 7.61e-21 0.61 0.51 Aortic root size; chr7:66274896 chr7:66654538~66669855:+ LIHC cis rs801193 0.636 rs10233806 ENSG00000226824.5 RP4-756H11.3 11.05 1.71e-24 7.9e-21 0.61 0.51 Aortic root size; chr7:66653261 chr7:66654538~66669855:+ LIHC cis rs1799949 0.965 rs9897425 ENSG00000198496.9 NBR2 -11.05 1.71e-24 7.93e-21 -0.58 -0.51 Menopause (age at onset); chr17:43352811 chr17:43125610~43153671:+ LIHC cis rs875971 0.895 rs4718349 ENSG00000226824.5 RP4-756H11.3 -11.05 1.76e-24 8.14e-21 -0.62 -0.51 Aortic root size; chr7:66444024 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs2042133 ENSG00000226824.5 RP4-756H11.3 -11.05 1.76e-24 8.14e-21 -0.62 -0.51 Aortic root size; chr7:66466935 chr7:66654538~66669855:+ LIHC cis rs875971 0.964 rs2161065 ENSG00000226824.5 RP4-756H11.3 -11.05 1.76e-24 8.14e-21 -0.62 -0.51 Aortic root size; chr7:66467918 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs12698521 ENSG00000226824.5 RP4-756H11.3 -11.05 1.76e-24 8.14e-21 -0.62 -0.51 Aortic root size; chr7:66474502 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs3981131 ENSG00000226824.5 RP4-756H11.3 -11.05 1.78e-24 8.24e-21 -0.62 -0.51 Aortic root size; chr7:66486690 chr7:66654538~66669855:+ LIHC cis rs1930961 1 rs6519611 ENSG00000272977.1 CTA-390C10.10 -11.05 1.79e-24 8.26e-21 -0.83 -0.51 Bipolar disorder with mood-incongruent psychosis; chr22:25449888 chr22:25476218~25479971:+ LIHC cis rs1930961 1 rs6004658 ENSG00000272977.1 CTA-390C10.10 -11.05 1.79e-24 8.26e-21 -0.83 -0.51 Bipolar disorder with mood-incongruent psychosis; chr22:25460264 chr22:25476218~25479971:+ LIHC cis rs1930961 1 rs6004659 ENSG00000272977.1 CTA-390C10.10 -11.05 1.79e-24 8.26e-21 -0.83 -0.51 Bipolar disorder with mood-incongruent psychosis; chr22:25460444 chr22:25476218~25479971:+ LIHC cis rs9326248 0.53 rs11216316 ENSG00000254851.1 RP11-109L13.1 11.05 1.8e-24 8.31e-21 0.74 0.51 Blood protein levels; chr11:117210784 chr11:117135528~117138582:+ LIHC cis rs7188445 0.932 rs73575095 ENSG00000261390.4 RP11-345M22.2 -11.05 1.81e-24 8.35e-21 -0.63 -0.51 Urate levels; chr16:79716435 chr16:79715232~79770563:- LIHC cis rs875971 1 rs6460296 ENSG00000226824.5 RP4-756H11.3 -11.05 1.82e-24 8.4e-21 -0.61 -0.51 Aortic root size; chr7:66430152 chr7:66654538~66669855:+ LIHC cis rs977987 0.902 rs34539062 ENSG00000261783.1 RP11-252K23.2 -11.05 1.83e-24 8.44e-21 -0.6 -0.51 Dupuytren's disease; chr16:75459381 chr16:75379818~75381260:- LIHC cis rs977987 0.866 rs17696831 ENSG00000261783.1 RP11-252K23.2 -11.05 1.83e-24 8.44e-21 -0.6 -0.51 Dupuytren's disease; chr16:75459400 chr16:75379818~75381260:- LIHC cis rs977987 0.898 rs12918797 ENSG00000261783.1 RP11-252K23.2 -11.05 1.83e-24 8.44e-21 -0.6 -0.51 Dupuytren's disease; chr16:75459912 chr16:75379818~75381260:- LIHC cis rs977987 0.898 rs12918974 ENSG00000261783.1 RP11-252K23.2 -11.05 1.83e-24 8.44e-21 -0.6 -0.51 Dupuytren's disease; chr16:75460045 chr16:75379818~75381260:- LIHC cis rs977987 0.866 rs12932606 ENSG00000261783.1 RP11-252K23.2 -11.05 1.83e-24 8.44e-21 -0.6 -0.51 Dupuytren's disease; chr16:75460046 chr16:75379818~75381260:- LIHC cis rs875971 0.862 rs778720 ENSG00000226824.5 RP4-756H11.3 11.05 1.83e-24 8.44e-21 0.61 0.51 Aortic root size; chr7:66381288 chr7:66654538~66669855:+ LIHC cis rs7188445 0.899 rs57652769 ENSG00000261390.4 RP11-345M22.2 -11.04 1.91e-24 8.8e-21 -0.63 -0.51 Urate levels; chr16:79720079 chr16:79715232~79770563:- LIHC cis rs1799949 0.965 rs2236762 ENSG00000198496.9 NBR2 -11.04 1.96e-24 9e-21 -0.58 -0.51 Menopause (age at onset); chr17:43074658 chr17:43125610~43153671:+ LIHC cis rs1930961 1 rs6004654 ENSG00000272977.1 CTA-390C10.10 -11.04 1.97e-24 9.06e-21 -0.83 -0.51 Bipolar disorder with mood-incongruent psychosis; chr22:25459237 chr22:25476218~25479971:+ LIHC cis rs7188445 0.932 rs56738967 ENSG00000261390.4 RP11-345M22.2 -11.04 1.97e-24 9.06e-21 -0.63 -0.51 Urate levels; chr16:79706644 chr16:79715232~79770563:- LIHC cis rs7188445 0.899 rs58722186 ENSG00000261390.4 RP11-345M22.2 -11.03 2.02e-24 9.29e-21 -0.63 -0.51 Urate levels; chr16:79717694 chr16:79715232~79770563:- LIHC cis rs10256972 0.527 rs28671326 ENSG00000229043.2 AC091729.9 -11.03 2.04e-24 9.36e-21 -0.59 -0.51 Endometriosis;Longevity; chr7:1135337 chr7:1160374~1165267:+ LIHC cis rs1799949 1 rs4793190 ENSG00000198496.9 NBR2 -11.03 2.05e-24 9.39e-21 -0.57 -0.51 Menopause (age at onset); chr17:43048092 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176297 ENSG00000198496.9 NBR2 -11.03 2.05e-24 9.39e-21 -0.57 -0.51 Menopause (age at onset); chr17:43051308 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176296 ENSG00000198496.9 NBR2 -11.03 2.05e-24 9.39e-21 -0.57 -0.51 Menopause (age at onset); chr17:43051574 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs4793191 ENSG00000198496.9 NBR2 -11.03 2.05e-24 9.39e-21 -0.57 -0.51 Menopause (age at onset); chr17:43052360 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs4793192 ENSG00000198496.9 NBR2 -11.03 2.05e-24 9.39e-21 -0.57 -0.51 Menopause (age at onset); chr17:43052373 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs8176289 ENSG00000198496.9 NBR2 -11.03 2.05e-24 9.39e-21 -0.57 -0.51 Menopause (age at onset); chr17:43054039 chr17:43125610~43153671:+ LIHC cis rs10256972 0.591 rs6968988 ENSG00000229043.2 AC091729.9 -11.03 2.06e-24 9.44e-21 -0.59 -0.51 Endometriosis;Longevity; chr7:1129983 chr7:1160374~1165267:+ LIHC cis rs7104764 1 rs2293167 ENSG00000277290.1 RP11-326C3.16 11.03 2.1e-24 9.63e-21 0.49 0.51 Menarche (age at onset); chr11:211644 chr11:243099~243483:- LIHC cis rs7847628 0.587 rs10760117 ENSG00000226752.6 PSMD5-AS1 -11.02 2.21e-24 1.01e-20 -0.52 -0.51 Birth weight; chr9:120824459 chr9:120824828~120854385:+ LIHC cis rs1799949 0.894 rs71367985 ENSG00000198496.9 NBR2 -11.02 2.36e-24 1.08e-20 -0.58 -0.51 Menopause (age at onset); chr17:43222443 chr17:43125610~43153671:+ LIHC cis rs875971 1 rs6961717 ENSG00000226824.5 RP4-756H11.3 11.01 2.39e-24 1.09e-20 0.62 0.51 Aortic root size; chr7:66122550 chr7:66654538~66669855:+ LIHC cis rs2739330 0.587 rs4820571 ENSG00000272787.1 KB-226F1.2 -11.01 2.39e-24 1.09e-20 -0.67 -0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23969211~23969873:+ LIHC cis rs7104764 0.957 rs1045454 ENSG00000277290.1 RP11-326C3.16 11 2.62e-24 1.19e-20 0.49 0.51 Menarche (age at onset); chr11:204228 chr11:243099~243483:- LIHC cis rs977987 0.654 rs8054194 ENSG00000261783.1 RP11-252K23.2 -11 2.65e-24 1.21e-20 -0.62 -0.51 Dupuytren's disease; chr16:75463262 chr16:75379818~75381260:- LIHC cis rs977987 0.581 rs8056141 ENSG00000261783.1 RP11-252K23.2 -11 2.65e-24 1.21e-20 -0.62 -0.51 Dupuytren's disease; chr16:75463264 chr16:75379818~75381260:- LIHC cis rs875971 0.522 rs1617484 ENSG00000226824.5 RP4-756H11.3 -11 2.66e-24 1.21e-20 -0.66 -0.51 Aortic root size; chr7:65998108 chr7:66654538~66669855:+ LIHC cis rs1930961 1 rs6004657 ENSG00000272977.1 CTA-390C10.10 -10.99 2.82e-24 1.28e-20 -0.82 -0.51 Bipolar disorder with mood-incongruent psychosis; chr22:25459747 chr22:25476218~25479971:+ LIHC cis rs8062405 1 rs7187776 ENSG00000259982.1 CDC37P1 10.99 2.88e-24 1.31e-20 0.55 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28846324 chr16:28700294~28701540:- LIHC cis rs2739330 0.752 rs2330634 ENSG00000225282.1 AP000350.6 10.99 2.99e-24 1.36e-20 0.62 0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908608 chr22:23926900~23929574:+ LIHC cis rs2739330 0.731 rs4822450 ENSG00000225282.1 AP000350.6 10.98 3.08e-24 1.4e-20 0.63 0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23926900~23929574:+ LIHC cis rs1799949 0.864 rs60309406 ENSG00000198496.9 NBR2 -10.98 3.1e-24 1.4e-20 -0.59 -0.51 Menopause (age at onset); chr17:43358297 chr17:43125610~43153671:+ LIHC cis rs1577917 1 rs1962716 ENSG00000203875.9 SNHG5 -10.98 3.12e-24 1.41e-20 -0.6 -0.51 Response to antipsychotic treatment; chr6:85938718 chr6:85660950~85678736:- LIHC cis rs2188561 0.638 rs28690459 ENSG00000241764.3 AC002467.7 10.98 3.15e-24 1.43e-20 0.68 0.51 Alcohol consumption; chr7:107740258 chr7:107742817~107744581:- LIHC cis rs875971 1 rs11971949 ENSG00000226824.5 RP4-756H11.3 10.98 3.2e-24 1.45e-20 0.62 0.51 Aortic root size; chr7:66161027 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs11974264 ENSG00000226824.5 RP4-756H11.3 10.98 3.2e-24 1.45e-20 0.62 0.51 Aortic root size; chr7:66182595 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs1540651 ENSG00000226824.5 RP4-756H11.3 10.98 3.2e-24 1.45e-20 0.62 0.51 Aortic root size; chr7:66185134 chr7:66654538~66669855:+ LIHC cis rs875971 0.898 rs6977501 ENSG00000226824.5 RP4-756H11.3 10.98 3.2e-24 1.45e-20 0.62 0.51 Aortic root size; chr7:66228355 chr7:66654538~66669855:+ LIHC cis rs875971 0.965 rs6971509 ENSG00000226824.5 RP4-756H11.3 10.98 3.2e-24 1.45e-20 0.62 0.51 Aortic root size; chr7:66249983 chr7:66654538~66669855:+ LIHC cis rs1577917 0.654 rs9450284 ENSG00000203875.9 SNHG5 10.98 3.25e-24 1.47e-20 0.56 0.51 Response to antipsychotic treatment; chr6:85489611 chr6:85660950~85678736:- LIHC cis rs4820294 0.77 rs7285699 ENSG00000233360.4 Z83844.1 10.98 3.26e-24 1.48e-20 0.57 0.51 Fat distribution (HIV); chr22:37670549 chr22:37641832~37658377:- LIHC cis rs1799949 0.965 rs4793233 ENSG00000198496.9 NBR2 -10.98 3.27e-24 1.48e-20 -0.59 -0.51 Menopause (age at onset); chr17:43358069 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs4793234 ENSG00000198496.9 NBR2 -10.98 3.27e-24 1.48e-20 -0.59 -0.51 Menopause (age at onset); chr17:43358815 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs7212284 ENSG00000198496.9 NBR2 -10.97 3.41e-24 1.54e-20 -0.57 -0.51 Menopause (age at onset); chr17:43053924 chr17:43125610~43153671:+ LIHC cis rs1930961 1 rs6004673 ENSG00000272977.1 CTA-390C10.10 -10.96 3.68e-24 1.66e-20 -0.78 -0.51 Bipolar disorder with mood-incongruent psychosis; chr22:25489386 chr22:25476218~25479971:+ LIHC cis rs2188561 0.697 rs2237679 ENSG00000241764.3 AC002467.7 10.96 3.84e-24 1.73e-20 0.67 0.51 Alcohol consumption; chr7:107693581 chr7:107742817~107744581:- LIHC cis rs2188561 0.697 rs2072064 ENSG00000241764.3 AC002467.7 10.96 3.84e-24 1.73e-20 0.67 0.51 Alcohol consumption; chr7:107694068 chr7:107742817~107744581:- LIHC cis rs875971 1 rs4718307 ENSG00000226824.5 RP4-756H11.3 10.95 3.99e-24 1.79e-20 0.62 0.51 Aortic root size; chr7:66146001 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs7801282 ENSG00000226824.5 RP4-756H11.3 10.95 3.99e-24 1.79e-20 0.62 0.51 Aortic root size; chr7:66148700 chr7:66654538~66669855:+ LIHC cis rs7115242 0.8 rs7131536 ENSG00000254851.1 RP11-109L13.1 -10.95 4.07e-24 1.83e-20 -0.7 -0.51 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117128730 chr11:117135528~117138582:+ LIHC cis rs7104764 0.957 rs3782120 ENSG00000277290.1 RP11-326C3.16 10.94 4.23e-24 1.9e-20 0.49 0.51 Menarche (age at onset); chr11:206089 chr11:243099~243483:- LIHC cis rs507080 0.501 rs625735 ENSG00000255239.1 AP002954.6 10.94 4.25e-24 1.91e-20 0.59 0.51 Serum metabolite levels; chr11:118704710 chr11:118688039~118690600:- LIHC cis rs1799949 1 rs4793229 ENSG00000198496.9 NBR2 10.94 4.37e-24 1.96e-20 0.57 0.51 Menopause (age at onset); chr17:43340966 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs11659028 ENSG00000198496.9 NBR2 -10.94 4.4e-24 1.97e-20 -0.58 -0.51 Menopause (age at onset); chr17:43043008 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs3092988 ENSG00000198496.9 NBR2 -10.94 4.42e-24 1.98e-20 -0.57 -0.51 Menopause (age at onset); chr17:43049685 chr17:43125610~43153671:+ LIHC cis rs9326248 0.53 rs7112513 ENSG00000254851.1 RP11-109L13.1 -10.94 4.45e-24 1.99e-20 -0.71 -0.51 Blood protein levels; chr11:117166645 chr11:117135528~117138582:+ LIHC cis rs801193 0.548 rs2659904 ENSG00000226824.5 RP4-756H11.3 -10.94 4.45e-24 1.99e-20 -0.61 -0.51 Aortic root size; chr7:66713615 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs875971 ENSG00000226824.5 RP4-756H11.3 10.94 4.47e-24 2e-20 0.62 0.51 Aortic root size; chr7:66152608 chr7:66654538~66669855:+ LIHC cis rs507080 0.501 rs516503 ENSG00000255239.1 AP002954.6 10.93 4.66e-24 2.09e-20 0.59 0.51 Serum metabolite levels; chr11:118709639 chr11:118688039~118690600:- LIHC cis rs875971 1 rs55962648 ENSG00000226824.5 RP4-756H11.3 10.92 4.95e-24 2.2e-20 0.61 0.51 Aortic root size; chr7:66160764 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs2420168 ENSG00000226824.5 RP4-756H11.3 10.92 4.95e-24 2.2e-20 0.61 0.51 Aortic root size; chr7:66165644 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs11974219 ENSG00000226824.5 RP4-756H11.3 10.92 4.95e-24 2.2e-20 0.61 0.51 Aortic root size; chr7:66182423 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs1565531 ENSG00000226824.5 RP4-756H11.3 10.92 4.95e-24 2.2e-20 0.61 0.51 Aortic root size; chr7:66198126 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs6963646 ENSG00000226824.5 RP4-756H11.3 10.92 4.95e-24 2.2e-20 0.61 0.51 Aortic root size; chr7:66220780 chr7:66654538~66669855:+ LIHC cis rs875971 0.965 rs28682868 ENSG00000226824.5 RP4-756H11.3 10.92 4.95e-24 2.2e-20 0.61 0.51 Aortic root size; chr7:66224822 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs9986696 ENSG00000226824.5 RP4-756H11.3 10.92 4.95e-24 2.2e-20 0.61 0.51 Aortic root size; chr7:66239589 chr7:66654538~66669855:+ LIHC cis rs2739330 0.76 rs5751760 ENSG00000225282.1 AP000350.6 10.92 4.99e-24 2.22e-20 0.63 0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23926900~23929574:+ LIHC cis rs5769707 0.542 rs739242 ENSG00000188511.11 C22orf34 10.92 5.02e-24 2.23e-20 0.61 0.51 Monocyte percentage of white cells;Monocyte count; chr22:49663468 chr22:49414524~49657542:- LIHC cis rs5769707 0.521 rs7285764 ENSG00000188511.11 C22orf34 10.92 5.02e-24 2.23e-20 0.61 0.51 Monocyte percentage of white cells;Monocyte count; chr22:49664913 chr22:49414524~49657542:- LIHC cis rs5769707 0.521 rs9616715 ENSG00000188511.11 C22orf34 10.92 5.02e-24 2.23e-20 0.61 0.51 Monocyte percentage of white cells;Monocyte count; chr22:49664934 chr22:49414524~49657542:- LIHC cis rs5769707 0.521 rs6009805 ENSG00000188511.11 C22orf34 10.92 5.02e-24 2.23e-20 0.61 0.51 Monocyte percentage of white cells;Monocyte count; chr22:49665067 chr22:49414524~49657542:- LIHC cis rs5769707 0.521 rs6009807 ENSG00000188511.11 C22orf34 10.92 5.02e-24 2.23e-20 0.61 0.51 Monocyte percentage of white cells;Monocyte count; chr22:49665274 chr22:49414524~49657542:- LIHC cis rs7104764 1 rs76552490 ENSG00000277290.1 RP11-326C3.16 10.92 5.14e-24 2.29e-20 0.49 0.51 Menarche (age at onset); chr11:212015 chr11:243099~243483:- LIHC cis rs7104764 1 rs1533825 ENSG00000277290.1 RP11-326C3.16 10.92 5.14e-24 2.29e-20 0.49 0.51 Menarche (age at onset); chr11:214163 chr11:243099~243483:- LIHC cis rs1799949 0.965 rs1842147 ENSG00000198496.9 NBR2 -10.92 5.26e-24 2.34e-20 -0.58 -0.51 Menopause (age at onset); chr17:43357824 chr17:43125610~43153671:+ LIHC cis rs7174755 0.924 rs8035431 ENSG00000260657.2 RP11-315D16.4 10.91 5.59e-24 2.48e-20 0.74 0.51 Major depressive disorder; chr15:68305012 chr15:68267792~68277994:- LIHC cis rs858239 1 rs156421 ENSG00000230658.1 KLHL7-AS1 10.91 5.69e-24 2.53e-20 0.61 0.51 Cerebrospinal fluid biomarker levels; chr7:23272868 chr7:23101228~23105703:- LIHC cis rs2260433 0.867 rs10895328 ENSG00000281655.1 RP11-817J15.3 10.9 5.83e-24 2.59e-20 0.64 0.51 Cleft palate; chr11:102637617 chr11:102681310~102683913:+ LIHC cis rs875971 1 rs7792762 ENSG00000226824.5 RP4-756H11.3 -10.9 5.91e-24 2.62e-20 -0.6 -0.51 Aortic root size; chr7:66539151 chr7:66654538~66669855:+ LIHC cis rs507080 0.501 rs637563 ENSG00000255239.1 AP002954.6 10.9 5.94e-24 2.63e-20 0.58 0.51 Serum metabolite levels; chr11:118704770 chr11:118688039~118690600:- LIHC cis rs1799949 0.536 rs4793227 ENSG00000198496.9 NBR2 -10.9 5.99e-24 2.65e-20 -0.58 -0.51 Menopause (age at onset); chr17:43334882 chr17:43125610~43153671:+ LIHC cis rs9326248 0.53 rs7122944 ENSG00000254851.1 RP11-109L13.1 -10.9 6.02e-24 2.67e-20 -0.71 -0.51 Blood protein levels; chr11:117163903 chr11:117135528~117138582:+ LIHC cis rs9326248 0.53 rs236918 ENSG00000254851.1 RP11-109L13.1 10.9 6.07e-24 2.69e-20 0.73 0.51 Blood protein levels; chr11:117220893 chr11:117135528~117138582:+ LIHC cis rs977987 0.902 rs4888430 ENSG00000261783.1 RP11-252K23.2 -10.89 6.62e-24 2.93e-20 -0.61 -0.51 Dupuytren's disease; chr16:75460526 chr16:75379818~75381260:- LIHC cis rs1799949 0.86 rs8176279 ENSG00000198496.9 NBR2 -10.88 6.93e-24 3.06e-20 -0.58 -0.51 Menopause (age at onset); chr17:43058379 chr17:43125610~43153671:+ LIHC cis rs9326248 0.53 rs1242229 ENSG00000254851.1 RP11-109L13.1 -10.88 6.96e-24 3.07e-20 -0.71 -0.51 Blood protein levels; chr11:117191654 chr11:117135528~117138582:+ LIHC cis rs9326248 0.53 rs2127905 ENSG00000254851.1 RP11-109L13.1 -10.88 7.35e-24 3.25e-20 -0.71 -0.51 Blood protein levels; chr11:117155658 chr11:117135528~117138582:+ LIHC cis rs7115242 0.514 rs4936367 ENSG00000254851.1 RP11-109L13.1 -10.88 7.35e-24 3.25e-20 -0.71 -0.51 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117171661 chr11:117135528~117138582:+ LIHC cis rs9326248 0.53 rs4604928 ENSG00000254851.1 RP11-109L13.1 -10.88 7.35e-24 3.25e-20 -0.71 -0.51 Blood protein levels; chr11:117173487 chr11:117135528~117138582:+ LIHC cis rs5758659 0.729 rs134866 ENSG00000237037.8 NDUFA6-AS1 10.88 7.41e-24 3.27e-20 0.57 0.51 Cognitive function; chr22:42254657 chr22:42090931~42137742:+ LIHC cis rs1799949 0.965 rs8176323 ENSG00000198496.9 NBR2 -10.87 7.53e-24 3.32e-20 -0.57 -0.51 Menopause (age at onset); chr17:43043694 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs8176322 ENSG00000198496.9 NBR2 -10.87 7.53e-24 3.32e-20 -0.57 -0.51 Menopause (age at onset); chr17:43043756 chr17:43125610~43153671:+ LIHC cis rs1799949 1 rs12516 ENSG00000198496.9 NBR2 -10.87 7.53e-24 3.32e-20 -0.57 -0.51 Menopause (age at onset); chr17:43044391 chr17:43125610~43153671:+ LIHC cis rs2739330 0.828 rs4822454 ENSG00000225282.1 AP000350.6 10.87 7.82e-24 3.45e-20 0.63 0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23926900~23929574:+ LIHC cis rs977987 0.966 rs6564261 ENSG00000261783.1 RP11-252K23.2 -10.87 7.91e-24 3.49e-20 -0.6 -0.51 Dupuytren's disease; chr16:75458344 chr16:75379818~75381260:- LIHC cis rs9326248 0.53 rs7940310 ENSG00000254851.1 RP11-109L13.1 -10.86 8.49e-24 3.74e-20 -0.7 -0.51 Blood protein levels; chr11:117153765 chr11:117135528~117138582:+ LIHC cis rs875971 0.929 rs4122249 ENSG00000226824.5 RP4-756H11.3 -10.86 8.69e-24 3.82e-20 -0.6 -0.51 Aortic root size; chr7:66455949 chr7:66654538~66669855:+ LIHC cis rs1930961 1 rs9624834 ENSG00000272977.1 CTA-390C10.10 -10.85 8.84e-24 3.88e-20 -0.81 -0.51 Bipolar disorder with mood-incongruent psychosis; chr22:25450048 chr22:25476218~25479971:+ LIHC cis rs1930961 1 rs9624835 ENSG00000272977.1 CTA-390C10.10 -10.85 8.84e-24 3.88e-20 -0.81 -0.51 Bipolar disorder with mood-incongruent psychosis; chr22:25450054 chr22:25476218~25479971:+ LIHC cis rs1930961 1 rs9624836 ENSG00000272977.1 CTA-390C10.10 -10.85 8.84e-24 3.88e-20 -0.81 -0.51 Bipolar disorder with mood-incongruent psychosis; chr22:25450120 chr22:25476218~25479971:+ LIHC cis rs17711722 0.565 rs73372653 ENSG00000164669.11 INTS4P1 -10.85 9.1e-24 4e-20 -0.64 -0.51 Calcium levels; chr7:65977808 chr7:65141225~65234216:+ LIHC cis rs875971 1 rs10244498 ENSG00000226824.5 RP4-756H11.3 -10.85 9.2e-24 4.04e-20 -0.6 -0.51 Aortic root size; chr7:66651069 chr7:66654538~66669855:+ LIHC cis rs1930961 0.867 rs6423498 ENSG00000272977.1 CTA-390C10.10 -10.85 9.24e-24 4.06e-20 -0.81 -0.51 Bipolar disorder with mood-incongruent psychosis; chr22:25457401 chr22:25476218~25479971:+ LIHC cis rs1577917 0.629 rs7761762 ENSG00000203875.9 SNHG5 10.85 9.34e-24 4.1e-20 0.57 0.51 Response to antipsychotic treatment; chr6:85496250 chr6:85660950~85678736:- LIHC cis rs494459 0.964 rs576283 ENSG00000255239.1 AP002954.6 10.84 9.76e-24 4.28e-20 0.58 0.51 Height; chr11:118703185 chr11:118688039~118690600:- LIHC cis rs494459 0.929 rs627391 ENSG00000255239.1 AP002954.6 10.84 9.76e-24 4.28e-20 0.58 0.51 Height; chr11:118703207 chr11:118688039~118690600:- LIHC cis rs507080 0.524 rs524409 ENSG00000255239.1 AP002954.6 10.84 9.76e-24 4.28e-20 0.58 0.51 Serum metabolite levels; chr11:118703602 chr11:118688039~118690600:- LIHC cis rs12439619 0.774 rs2867649 ENSG00000278603.1 RP13-608F4.5 10.84 9.96e-24 4.36e-20 0.95 0.51 Intelligence (multi-trait analysis); chr15:82262331 chr15:82472203~82472426:+ LIHC cis rs12439619 0.846 rs28697264 ENSG00000278603.1 RP13-608F4.5 10.84 9.96e-24 4.36e-20 0.95 0.51 Intelligence (multi-trait analysis); chr15:82265559 chr15:82472203~82472426:+ LIHC cis rs12439619 0.846 rs62013464 ENSG00000278603.1 RP13-608F4.5 10.84 9.96e-24 4.36e-20 0.95 0.51 Intelligence (multi-trait analysis); chr15:82288250 chr15:82472203~82472426:+ LIHC cis rs1577917 0.785 rs1885607 ENSG00000203875.9 SNHG5 10.83 1.06e-23 4.64e-20 0.59 0.51 Response to antipsychotic treatment; chr6:85685187 chr6:85660950~85678736:- LIHC cis rs2455601 0.638 rs2742485 ENSG00000254860.4 TMEM9B-AS1 10.83 1.11e-23 4.86e-20 0.59 0.51 Schizophrenia; chr11:8965240 chr11:8964675~8977527:+ LIHC cis rs858239 1 rs156425 ENSG00000230658.1 KLHL7-AS1 -10.82 1.14e-23 4.98e-20 -0.6 -0.51 Cerebrospinal fluid biomarker levels; chr7:23269500 chr7:23101228~23105703:- LIHC cis rs10256972 0.553 rs4236381 ENSG00000229043.2 AC091729.9 -10.82 1.15e-23 5.04e-20 -0.58 -0.51 Endometriosis;Longevity; chr7:1126087 chr7:1160374~1165267:+ LIHC cis rs977987 0.864 rs40446 ENSG00000261783.1 RP11-252K23.2 10.82 1.2e-23 5.24e-20 0.62 0.5 Dupuytren's disease; chr16:75462760 chr16:75379818~75381260:- LIHC cis rs977987 0.864 rs37592 ENSG00000261783.1 RP11-252K23.2 10.82 1.2e-23 5.24e-20 0.62 0.5 Dupuytren's disease; chr16:75462893 chr16:75379818~75381260:- LIHC cis rs977987 0.864 rs37593 ENSG00000261783.1 RP11-252K23.2 10.82 1.2e-23 5.24e-20 0.62 0.5 Dupuytren's disease; chr16:75463009 chr16:75379818~75381260:- LIHC cis rs858239 0.738 rs13225593 ENSG00000230658.1 KLHL7-AS1 10.82 1.21e-23 5.26e-20 0.65 0.5 Cerebrospinal fluid biomarker levels; chr7:23220688 chr7:23101228~23105703:- LIHC cis rs5760092 0.755 rs4585126 ENSG00000273295.1 AP000350.5 -10.81 1.23e-23 5.36e-20 -0.58 -0.5 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23901432~23907068:- LIHC cis rs977987 0.864 rs37594 ENSG00000261783.1 RP11-252K23.2 10.81 1.29e-23 5.63e-20 0.62 0.5 Dupuytren's disease; chr16:75463045 chr16:75379818~75381260:- LIHC cis rs977987 0.864 rs37595 ENSG00000261783.1 RP11-252K23.2 10.81 1.29e-23 5.63e-20 0.62 0.5 Dupuytren's disease; chr16:75463065 chr16:75379818~75381260:- LIHC cis rs1799949 0.683 rs55737636 ENSG00000198496.9 NBR2 -10.81 1.3e-23 5.65e-20 -0.58 -0.5 Menopause (age at onset); chr17:43112722 chr17:43125610~43153671:+ LIHC cis rs12439619 0.846 rs62012003 ENSG00000278603.1 RP13-608F4.5 10.8 1.34e-23 5.81e-20 0.95 0.5 Intelligence (multi-trait analysis); chr15:82183236 chr15:82472203~82472426:+ LIHC cis rs1799949 0.965 rs9911630 ENSG00000198496.9 NBR2 -10.8 1.39e-23 6.03e-20 -0.57 -0.5 Menopause (age at onset); chr17:43036325 chr17:43125610~43153671:+ LIHC cis rs7174755 0.961 rs12148843 ENSG00000260657.2 RP11-315D16.4 10.8 1.39e-23 6.04e-20 0.77 0.5 Major depressive disorder; chr15:68302184 chr15:68267792~68277994:- LIHC cis rs7174755 0.961 rs1122247 ENSG00000260657.2 RP11-315D16.4 10.8 1.39e-23 6.04e-20 0.77 0.5 Major depressive disorder; chr15:68302523 chr15:68267792~68277994:- LIHC cis rs7174755 0.961 rs11631030 ENSG00000260657.2 RP11-315D16.4 10.8 1.39e-23 6.04e-20 0.77 0.5 Major depressive disorder; chr15:68303463 chr15:68267792~68277994:- LIHC cis rs12022452 0.591 rs12042242 ENSG00000238287.1 RP11-656D10.3 10.79 1.45e-23 6.28e-20 0.66 0.5 Age-related hearing impairment (SNP x SNP interaction); chr1:40528201 chr1:40493157~40508661:- LIHC cis rs4718428 1 rs4718428 ENSG00000226824.5 RP4-756H11.3 -10.78 1.57e-23 6.8e-20 -0.65 -0.5 Corneal structure; chr7:66956459 chr7:66654538~66669855:+ LIHC cis rs12439619 0.81 rs28876157 ENSG00000278603.1 RP13-608F4.5 10.78 1.57e-23 6.81e-20 0.95 0.5 Intelligence (multi-trait analysis); chr15:82216708 chr15:82472203~82472426:+ LIHC cis rs12439619 0.846 rs7496227 ENSG00000278603.1 RP13-608F4.5 10.78 1.61e-23 6.97e-20 0.95 0.5 Intelligence (multi-trait analysis); chr15:82275241 chr15:82472203~82472426:+ LIHC cis rs9326248 0.53 rs7123517 ENSG00000254851.1 RP11-109L13.1 -10.78 1.64e-23 7.08e-20 -0.7 -0.5 Blood protein levels; chr11:117157039 chr11:117135528~117138582:+ LIHC cis rs977987 0.931 rs1424013 ENSG00000261783.1 RP11-252K23.2 -10.78 1.65e-23 7.12e-20 -0.59 -0.5 Dupuytren's disease; chr16:75462088 chr16:75379818~75381260:- LIHC cis rs9828933 0.752 rs28675788 ENSG00000280620.1 SCAANT1 10.78 1.66e-23 7.17e-20 0.73 0.5 Type 2 diabetes; chr3:63956512 chr3:63911518~63911772:- LIHC cis rs507080 0.501 rs494459 ENSG00000255239.1 AP002954.6 -10.77 1.68e-23 7.28e-20 -0.58 -0.5 Serum metabolite levels; chr11:118703966 chr11:118688039~118690600:- LIHC cis rs7104764 0.957 rs519592 ENSG00000277290.1 RP11-326C3.16 -10.77 1.76e-23 7.6e-20 -0.48 -0.5 Menarche (age at onset); chr11:236811 chr11:243099~243483:- LIHC cis rs977987 0.931 rs11641430 ENSG00000261783.1 RP11-252K23.2 -10.77 1.79e-23 7.72e-20 -0.59 -0.5 Dupuytren's disease; chr16:75461378 chr16:75379818~75381260:- LIHC cis rs977987 0.931 rs7195161 ENSG00000261783.1 RP11-252K23.2 -10.77 1.79e-23 7.72e-20 -0.59 -0.5 Dupuytren's disease; chr16:75461674 chr16:75379818~75381260:- LIHC cis rs12439619 0.768 rs28694364 ENSG00000278603.1 RP13-608F4.5 10.77 1.79e-23 7.75e-20 0.95 0.5 Intelligence (multi-trait analysis); chr15:82208119 chr15:82472203~82472426:+ LIHC cis rs1799949 0.965 rs9646413 ENSG00000198496.9 NBR2 -10.77 1.8e-23 7.78e-20 -0.58 -0.5 Menopause (age at onset); chr17:43348789 chr17:43125610~43153671:+ LIHC cis rs9828933 0.832 rs3774723 ENSG00000280620.1 SCAANT1 10.76 1.84e-23 7.95e-20 0.72 0.5 Type 2 diabetes; chr3:63976663 chr3:63911518~63911772:- LIHC cis rs5758659 0.692 rs5751251 ENSG00000237037.8 NDUFA6-AS1 10.76 1.88e-23 8.09e-20 0.58 0.5 Cognitive function; chr22:42244600 chr22:42090931~42137742:+ LIHC cis rs67383717 0.777 rs591486 ENSG00000175611.10 LINC00476 -10.75 1.97e-23 8.51e-20 -0.58 -0.5 Parkinson's disease (pesticide exposure interaction); chr9:95887764 chr9:95759231~95875977:- LIHC cis rs2188561 0.697 rs12705421 ENSG00000241764.3 AC002467.7 10.75 2e-23 8.62e-20 0.67 0.5 Alcohol consumption; chr7:107760984 chr7:107742817~107744581:- LIHC cis rs1930961 1 rs6004673 ENSG00000100058.11 CRYBB2P1 10.75 2.12e-23 9.14e-20 0.74 0.5 Bipolar disorder with mood-incongruent psychosis; chr22:25489386 chr22:25448105~25520854:+ LIHC cis rs1799949 0.931 rs9912203 ENSG00000198496.9 NBR2 10.74 2.15e-23 9.24e-20 0.57 0.5 Menopause (age at onset); chr17:43367777 chr17:43125610~43153671:+ LIHC cis rs1577917 0.727 rs9444361 ENSG00000203875.9 SNHG5 10.74 2.2e-23 9.46e-20 0.59 0.5 Response to antipsychotic treatment; chr6:85691182 chr6:85660950~85678736:- LIHC cis rs10256972 0.567 rs7782651 ENSG00000229043.2 AC091729.9 -10.74 2.21e-23 9.51e-20 -0.58 -0.5 Endometriosis;Longevity; chr7:1120259 chr7:1160374~1165267:+ LIHC cis rs2455601 0.671 rs2568091 ENSG00000254860.4 TMEM9B-AS1 10.74 2.29e-23 9.83e-20 0.58 0.5 Schizophrenia; chr11:8964501 chr11:8964675~8977527:+ LIHC cis rs2188561 0.615 rs13226711 ENSG00000241764.3 AC002467.7 10.74 2.3e-23 9.85e-20 0.67 0.5 Alcohol consumption; chr7:107754897 chr7:107742817~107744581:- LIHC cis rs858239 0.932 rs1637190 ENSG00000230658.1 KLHL7-AS1 10.74 2.3e-23 9.88e-20 0.63 0.5 Cerebrospinal fluid biomarker levels; chr7:23229446 chr7:23101228~23105703:- LIHC cis rs858239 0.932 rs1728313 ENSG00000230658.1 KLHL7-AS1 10.74 2.31e-23 9.89e-20 0.61 0.5 Cerebrospinal fluid biomarker levels; chr7:23231412 chr7:23101228~23105703:- LIHC cis rs2188561 0.666 rs13231387 ENSG00000241764.3 AC002467.7 10.73 2.35e-23 1.01e-19 0.67 0.5 Alcohol consumption; chr7:107749534 chr7:107742817~107744581:- LIHC cis rs2455601 0.574 rs2568094 ENSG00000254860.4 TMEM9B-AS1 10.73 2.43e-23 1.04e-19 0.58 0.5 Schizophrenia; chr11:8970671 chr11:8964675~8977527:+ LIHC cis rs2455601 0.638 rs2742478 ENSG00000254860.4 TMEM9B-AS1 10.73 2.43e-23 1.04e-19 0.58 0.5 Schizophrenia; chr11:8974552 chr11:8964675~8977527:+ LIHC cis rs2739330 0.828 rs2877178 ENSG00000225282.1 AP000350.6 10.73 2.44e-23 1.04e-19 0.6 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23926900~23929574:+ LIHC cis rs10256972 0.591 rs11766651 ENSG00000229043.2 AC091729.9 -10.72 2.54e-23 1.09e-19 -0.58 -0.5 Endometriosis;Longevity; chr7:1122010 chr7:1160374~1165267:+ LIHC cis rs380904 1 rs12543128 ENSG00000254859.1 RP11-661A12.5 -10.72 2.66e-23 1.13e-19 -0.73 -0.5 Venous thromboembolism (SNP x SNP interaction); chr8:143512872 chr8:143541973~143549729:- LIHC cis rs7208859 0.673 rs9911989 ENSG00000263531.1 RP13-753N3.1 -10.71 2.74e-23 1.17e-19 -0.89 -0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910684 chr17:30863921~30864940:- LIHC cis rs7847628 0.55 rs12343516 ENSG00000226752.6 PSMD5-AS1 -10.71 2.81e-23 1.2e-19 -0.51 -0.5 Birth weight; chr9:120841191 chr9:120824828~120854385:+ LIHC cis rs7188445 0.899 rs7195321 ENSG00000261390.4 RP11-345M22.2 -10.71 2.89e-23 1.23e-19 -0.62 -0.5 Urate levels; chr16:79701065 chr16:79715232~79770563:- LIHC cis rs7208859 0.673 rs17826219 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834827 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs61223749 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30836729 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs3764420 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30837136 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs3764421 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30840635 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11651858 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30843700 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs36056619 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30845266 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9909497 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30846210 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs11080135 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30849463 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9894876 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30855002 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs60020217 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30858036 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs73277974 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862851 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs73277978 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30864431 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11657391 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30867269 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs58089675 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869746 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs73263755 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30871954 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9899349 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30873104 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11652358 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30878462 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9891179 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881142 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9891413 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881191 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs73263776 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30884313 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11650271 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30886925 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9889968 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30893110 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs61348930 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30894745 chr17:30863921~30864940:- LIHC cis rs7208859 0.614 rs28758251 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896294 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9899943 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896907 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs11080138 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30897524 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs73265612 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30898965 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs11658435 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30901543 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs73265624 ENSG00000263531.1 RP13-753N3.1 10.71 2.94e-23 1.24e-19 0.91 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905048 chr17:30863921~30864940:- LIHC cis rs2739330 0.734 rs2000467 ENSG00000218537.1 MIF-AS1 -10.7 3.01e-23 1.27e-19 -0.66 -0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23894426~23898930:- LIHC cis rs2455601 0.638 rs2742484 ENSG00000254860.4 TMEM9B-AS1 10.7 3.09e-23 1.3e-19 0.58 0.5 Schizophrenia; chr11:8966536 chr11:8964675~8977527:+ LIHC cis rs2455601 0.638 rs2248245 ENSG00000254860.4 TMEM9B-AS1 10.7 3.09e-23 1.3e-19 0.58 0.5 Schizophrenia; chr11:8966803 chr11:8964675~8977527:+ LIHC cis rs858239 0.899 rs2268745 ENSG00000230658.1 KLHL7-AS1 10.69 3.24e-23 1.36e-19 0.65 0.5 Cerebrospinal fluid biomarker levels; chr7:23277981 chr7:23101228~23105703:- LIHC cis rs10256972 0.568 rs1133043 ENSG00000229043.2 AC091729.9 -10.68 3.69e-23 1.55e-19 -0.57 -0.5 Endometriosis;Longevity; chr7:1093669 chr7:1160374~1165267:+ LIHC cis rs858239 0.899 rs7794684 ENSG00000230658.1 KLHL7-AS1 10.68 3.72e-23 1.57e-19 0.65 0.5 Cerebrospinal fluid biomarker levels; chr7:23271186 chr7:23101228~23105703:- LIHC cis rs2739330 0.828 rs5760108 ENSG00000225282.1 AP000350.6 10.67 3.94e-23 1.65e-19 0.6 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23926900~23929574:+ LIHC cis rs5758659 0.716 rs5758661 ENSG00000237037.8 NDUFA6-AS1 10.67 4.01e-23 1.68e-19 0.57 0.5 Cognitive function; chr22:42228439 chr22:42090931~42137742:+ LIHC cis rs9828933 0.766 rs864975 ENSG00000280620.1 SCAANT1 -10.67 4.02e-23 1.69e-19 -0.74 -0.5 Type 2 diabetes; chr3:63899939 chr3:63911518~63911772:- LIHC cis rs2188561 0.697 rs739518 ENSG00000241764.3 AC002467.7 10.67 4.03e-23 1.69e-19 0.65 0.5 Alcohol consumption; chr7:107743682 chr7:107742817~107744581:- LIHC cis rs2739330 0.828 rs2154593 ENSG00000225282.1 AP000350.6 10.66 4.08e-23 1.71e-19 0.6 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23926900~23929574:+ LIHC cis rs1799949 0.965 rs9646418 ENSG00000198496.9 NBR2 -10.66 4.31e-23 1.81e-19 -0.57 -0.5 Menopause (age at onset); chr17:43348533 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs7223952 ENSG00000198496.9 NBR2 -10.66 4.4e-23 1.84e-19 -0.57 -0.5 Menopause (age at onset); chr17:43042868 chr17:43125610~43153671:+ LIHC cis rs17826219 0.706 rs9905827 ENSG00000263531.1 RP13-753N3.1 10.65 4.61e-23 1.93e-19 0.9 0.5 Body mass index; chr17:30865150 chr17:30863921~30864940:- LIHC cis rs1930961 1 rs6004667 ENSG00000272977.1 CTA-390C10.10 10.65 4.64e-23 1.94e-19 0.81 0.5 Bipolar disorder with mood-incongruent psychosis; chr22:25478497 chr22:25476218~25479971:+ LIHC cis rs2739330 0.734 rs2000467 ENSG00000273295.1 AP000350.5 -10.64 5.08e-23 2.12e-19 -0.53 -0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23901432~23907068:- LIHC cis rs2739330 0.587 rs4820571 ENSG00000218537.1 MIF-AS1 10.64 5.13e-23 2.14e-19 0.67 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23894426~23898930:- LIHC cis rs1799949 0.827 rs74252763 ENSG00000198496.9 NBR2 -10.64 5.16e-23 2.15e-19 -0.58 -0.5 Menopause (age at onset); chr17:43324652 chr17:43125610~43153671:+ LIHC cis rs10256972 0.516 rs12702081 ENSG00000229043.2 AC091729.9 -10.63 5.41e-23 2.26e-19 -0.57 -0.5 Endometriosis;Longevity; chr7:1101892 chr7:1160374~1165267:+ LIHC cis rs977987 0.931 rs1834013 ENSG00000261783.1 RP11-252K23.2 -10.63 5.49e-23 2.29e-19 -0.6 -0.5 Dupuytren's disease; chr16:75462265 chr16:75379818~75381260:- LIHC cis rs7208859 0.673 rs2433 ENSG00000263531.1 RP13-753N3.1 10.62 5.65e-23 2.36e-19 0.9 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30899210 chr17:30863921~30864940:- LIHC cis rs7174755 1 rs7174755 ENSG00000260657.2 RP11-315D16.4 -10.62 5.68e-23 2.37e-19 -0.72 -0.5 Major depressive disorder; chr15:68304789 chr15:68267792~68277994:- LIHC cis rs1799949 0.965 rs799912 ENSG00000198496.9 NBR2 -10.62 5.69e-23 2.37e-19 -0.57 -0.5 Menopause (age at onset); chr17:43105117 chr17:43125610~43153671:+ LIHC cis rs977987 1 rs977985 ENSG00000261783.1 RP11-252K23.2 -10.62 5.72e-23 2.38e-19 -0.6 -0.5 Dupuytren's disease; chr16:75473049 chr16:75379818~75381260:- LIHC cis rs977987 1 rs977987 ENSG00000261783.1 RP11-252K23.2 -10.62 5.76e-23 2.4e-19 -0.6 -0.5 Dupuytren's disease; chr16:75472695 chr16:75379818~75381260:- LIHC cis rs10256972 0.591 rs10229680 ENSG00000229043.2 AC091729.9 -10.62 5.78e-23 2.4e-19 -0.57 -0.5 Endometriosis;Longevity; chr7:1118929 chr7:1160374~1165267:+ LIHC cis rs977987 0.933 rs4888431 ENSG00000261783.1 RP11-252K23.2 -10.62 5.9e-23 2.45e-19 -0.6 -0.5 Dupuytren's disease; chr16:75466801 chr16:75379818~75381260:- LIHC cis rs977987 1 rs62060550 ENSG00000261783.1 RP11-252K23.2 -10.62 5.9e-23 2.45e-19 -0.6 -0.5 Dupuytren's disease; chr16:75468354 chr16:75379818~75381260:- LIHC cis rs977987 0.966 rs62060551 ENSG00000261783.1 RP11-252K23.2 -10.62 5.9e-23 2.45e-19 -0.6 -0.5 Dupuytren's disease; chr16:75468414 chr16:75379818~75381260:- LIHC cis rs1577917 0.771 rs7742201 ENSG00000203875.9 SNHG5 -10.62 5.99e-23 2.49e-19 -0.59 -0.5 Response to antipsychotic treatment; chr6:85723212 chr6:85660950~85678736:- LIHC cis rs7208859 0.673 rs79541516 ENSG00000263531.1 RP13-753N3.1 10.61 6.19e-23 2.56e-19 0.9 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913565 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9895684 ENSG00000263531.1 RP13-753N3.1 10.61 6.22e-23 2.57e-19 0.9 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30915582 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs73277967 ENSG00000263531.1 RP13-753N3.1 10.61 6.3e-23 2.6e-19 0.9 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30857148 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs2269915 ENSG00000263531.1 RP13-753N3.1 10.61 6.3e-23 2.6e-19 0.9 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906326 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs2269916 ENSG00000263531.1 RP13-753N3.1 10.61 6.3e-23 2.6e-19 0.9 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906745 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs11649765 ENSG00000263531.1 RP13-753N3.1 10.61 6.3e-23 2.6e-19 0.9 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906870 chr17:30863921~30864940:- LIHC cis rs4718428 1 rs1830070 ENSG00000226824.5 RP4-756H11.3 -10.61 6.35e-23 2.62e-19 -0.65 -0.5 Corneal structure; chr7:66884684 chr7:66654538~66669855:+ LIHC cis rs1799949 0.859 rs11657004 ENSG00000198496.9 NBR2 -10.61 6.41e-23 2.64e-19 -0.57 -0.5 Menopause (age at onset); chr17:43365383 chr17:43125610~43153671:+ LIHC cis rs1799949 0.931 rs34474989 ENSG00000198496.9 NBR2 -10.61 6.41e-23 2.64e-19 -0.57 -0.5 Menopause (age at onset); chr17:43368042 chr17:43125610~43153671:+ LIHC cis rs977987 0.966 rs11643207 ENSG00000261783.1 RP11-252K23.2 -10.61 6.42e-23 2.65e-19 -0.6 -0.5 Dupuytren's disease; chr16:75464895 chr16:75379818~75381260:- LIHC cis rs5758659 0.716 rs2143138 ENSG00000237037.8 NDUFA6-AS1 10.6 6.63e-23 2.73e-19 0.57 0.5 Cognitive function; chr22:42222334 chr22:42090931~42137742:+ LIHC cis rs7208859 0.673 rs73263785 ENSG00000263531.1 RP13-753N3.1 10.59 7.53e-23 3.09e-19 0.9 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887790 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs55904046 ENSG00000263531.1 RP13-753N3.1 10.59 7.53e-23 3.09e-19 0.9 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888373 chr17:30863921~30864940:- LIHC cis rs2739330 0.828 rs5751770 ENSG00000225282.1 AP000350.6 10.58 7.81e-23 3.2e-19 0.59 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23926900~23929574:+ LIHC cis rs2188561 0.697 rs13224313 ENSG00000241764.3 AC002467.7 10.58 7.86e-23 3.22e-19 0.64 0.5 Alcohol consumption; chr7:107741907 chr7:107742817~107744581:- LIHC cis rs2739330 0.828 rs2186366 ENSG00000225282.1 AP000350.6 -10.58 7.97e-23 3.27e-19 -0.61 -0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23926900~23929574:+ LIHC cis rs9828933 0.752 rs832192 ENSG00000280620.1 SCAANT1 -10.57 8.51e-23 3.48e-19 -0.73 -0.5 Type 2 diabetes; chr3:63867747 chr3:63911518~63911772:- LIHC cis rs1930961 1 rs6004675 ENSG00000272977.1 CTA-390C10.10 -10.56 9.16e-23 3.74e-19 -0.79 -0.5 Bipolar disorder with mood-incongruent psychosis; chr22:25493418 chr22:25476218~25479971:+ LIHC cis rs1577917 0.71 rs1059306 ENSG00000203875.9 SNHG5 10.56 9.2e-23 3.75e-19 0.58 0.5 Response to antipsychotic treatment; chr6:85678391 chr6:85660950~85678736:- LIHC cis rs10256972 0.641 rs12702017 ENSG00000229043.2 AC091729.9 -10.56 9.35e-23 3.81e-19 -0.56 -0.5 Endometriosis;Longevity; chr7:1089777 chr7:1160374~1165267:+ LIHC cis rs801193 0.569 rs2707824 ENSG00000226824.5 RP4-756H11.3 -10.56 9.72e-23 3.96e-19 -0.58 -0.5 Aortic root size; chr7:66724256 chr7:66654538~66669855:+ LIHC cis rs977987 0.736 rs11865296 ENSG00000261783.1 RP11-252K23.2 -10.55 1.01e-22 4.12e-19 -0.57 -0.5 Dupuytren's disease; chr16:75439795 chr16:75379818~75381260:- LIHC cis rs10256972 0.616 rs4585652 ENSG00000229043.2 AC091729.9 -10.55 1.03e-22 4.18e-19 -0.57 -0.5 Endometriosis;Longevity; chr7:1105760 chr7:1160374~1165267:+ LIHC cis rs7188445 1 rs11150189 ENSG00000261390.4 RP11-345M22.2 -10.55 1.05e-22 4.25e-19 -0.63 -0.5 Urate levels; chr16:79700330 chr16:79715232~79770563:- LIHC cis rs507080 0.733 rs489126 ENSG00000255422.1 AP002954.4 -10.55 1.06e-22 4.3e-19 -0.58 -0.5 Serum metabolite levels; chr11:118702038 chr11:118704607~118750263:+ LIHC cis rs7208859 0.673 rs11656845 ENSG00000263531.1 RP13-753N3.1 10.54 1.08e-22 4.36e-19 0.9 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30879146 chr17:30863921~30864940:- LIHC cis rs2739330 0.76 rs5760095 ENSG00000225282.1 AP000350.6 10.54 1.11e-22 4.48e-19 0.61 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23926900~23929574:+ LIHC cis rs7174755 1 rs68069953 ENSG00000260657.2 RP11-315D16.4 10.54 1.11e-22 4.5e-19 0.73 0.5 Major depressive disorder; chr15:68304235 chr15:68267792~68277994:- LIHC cis rs9828933 0.766 rs704361 ENSG00000280620.1 SCAANT1 -10.53 1.16e-22 4.71e-19 -0.72 -0.49 Type 2 diabetes; chr3:63897995 chr3:63911518~63911772:- LIHC cis rs2019137 0.56 rs6707386 ENSG00000189223.12 PAX8-AS1 -10.53 1.21e-22 4.91e-19 -0.66 -0.49 Lymphocyte counts; chr2:113223445 chr2:113211522~113276581:+ LIHC cis rs875971 0.862 rs6971059 ENSG00000226824.5 RP4-756H11.3 10.53 1.23e-22 4.97e-19 0.58 0.49 Aortic root size; chr7:66602045 chr7:66654538~66669855:+ LIHC cis rs875971 0.789 rs7808013 ENSG00000226824.5 RP4-756H11.3 10.53 1.23e-22 4.97e-19 0.58 0.49 Aortic root size; chr7:66606209 chr7:66654538~66669855:+ LIHC cis rs875971 0.825 rs7384021 ENSG00000226824.5 RP4-756H11.3 10.53 1.23e-22 4.97e-19 0.58 0.49 Aortic root size; chr7:66612917 chr7:66654538~66669855:+ LIHC cis rs875971 0.825 rs66981195 ENSG00000226824.5 RP4-756H11.3 10.53 1.23e-22 4.97e-19 0.58 0.49 Aortic root size; chr7:66614048 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs3926380 ENSG00000226824.5 RP4-756H11.3 10.53 1.23e-22 4.97e-19 0.58 0.49 Aortic root size; chr7:66615658 chr7:66654538~66669855:+ LIHC cis rs875971 0.825 rs1860472 ENSG00000226824.5 RP4-756H11.3 10.53 1.23e-22 4.97e-19 0.58 0.49 Aortic root size; chr7:66617736 chr7:66654538~66669855:+ LIHC cis rs5760092 0.755 rs4585126 ENSG00000218537.1 MIF-AS1 -10.53 1.23e-22 4.97e-19 -0.7 -0.49 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23894426~23898930:- LIHC cis rs4423214 0.57 rs7118246 ENSG00000254682.1 RP11-660L16.2 10.52 1.29e-22 5.19e-19 0.62 0.49 Vitamin D levels; chr11:71520078 chr11:71448674~71452157:+ LIHC cis rs7208859 0.673 rs12103759 ENSG00000263531.1 RP13-753N3.1 10.52 1.31e-22 5.24e-19 0.9 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908669 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs59029591 ENSG00000263531.1 RP13-753N3.1 10.52 1.31e-22 5.24e-19 0.9 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908728 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs73265633 ENSG00000263531.1 RP13-753N3.1 10.52 1.31e-22 5.24e-19 0.9 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30909288 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9913782 ENSG00000263531.1 RP13-753N3.1 10.52 1.31e-22 5.24e-19 0.9 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910366 chr17:30863921~30864940:- LIHC cis rs1577917 0.771 rs9362237 ENSG00000203875.9 SNHG5 10.52 1.35e-22 5.4e-19 0.58 0.49 Response to antipsychotic treatment; chr6:85699346 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs2225754 ENSG00000203875.9 SNHG5 -10.51 1.37e-22 5.47e-19 -0.59 -0.49 Response to antipsychotic treatment; chr6:85739980 chr6:85660950~85678736:- LIHC cis rs10256972 0.63 rs13235747 ENSG00000229043.2 AC091729.9 -10.51 1.37e-22 5.48e-19 -0.57 -0.49 Endometriosis;Longevity; chr7:1089487 chr7:1160374~1165267:+ LIHC cis rs1577917 0.958 rs1335442 ENSG00000203875.9 SNHG5 -10.51 1.39e-22 5.55e-19 -0.59 -0.49 Response to antipsychotic treatment; chr6:85756974 chr6:85660950~85678736:- LIHC cis rs875971 0.893 rs62465470 ENSG00000226824.5 RP4-756H11.3 10.51 1.41e-22 5.63e-19 0.6 0.49 Aortic root size; chr7:66136231 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs4368860 ENSG00000226824.5 RP4-756H11.3 10.51 1.41e-22 5.63e-19 0.6 0.49 Aortic root size; chr7:66143495 chr7:66654538~66669855:+ LIHC cis rs2455601 0.529 rs2653569 ENSG00000254860.4 TMEM9B-AS1 10.51 1.45e-22 5.75e-19 0.57 0.49 Schizophrenia; chr11:8965431 chr11:8964675~8977527:+ LIHC cis rs875971 0.895 rs4145009 ENSG00000226824.5 RP4-756H11.3 10.51 1.45e-22 5.77e-19 0.6 0.49 Aortic root size; chr7:66261628 chr7:66654538~66669855:+ LIHC cis rs10256972 0.681 rs12702016 ENSG00000229043.2 AC091729.9 -10.5 1.49e-22 5.91e-19 -0.56 -0.49 Endometriosis;Longevity; chr7:1089756 chr7:1160374~1165267:+ LIHC cis rs875971 0.83 rs6976714 ENSG00000226824.5 RP4-756H11.3 -10.5 1.56e-22 6.18e-19 -0.59 -0.49 Aortic root size; chr7:66426474 chr7:66654538~66669855:+ LIHC cis rs875971 0.651 rs2420596 ENSG00000226824.5 RP4-756H11.3 -10.5 1.56e-22 6.18e-19 -0.59 -0.49 Aortic root size; chr7:66450996 chr7:66654538~66669855:+ LIHC cis rs875971 0.52 rs2420597 ENSG00000226824.5 RP4-756H11.3 -10.5 1.56e-22 6.18e-19 -0.59 -0.49 Aortic root size; chr7:66450999 chr7:66654538~66669855:+ LIHC cis rs2739330 0.76 rs1007888 ENSG00000225282.1 AP000350.6 10.5 1.57e-22 6.23e-19 0.6 0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23926900~23929574:+ LIHC cis rs9828933 0.752 rs73117082 ENSG00000280620.1 SCAANT1 10.5 1.59e-22 6.31e-19 0.72 0.49 Type 2 diabetes; chr3:63961889 chr3:63911518~63911772:- LIHC cis rs5758659 0.679 rs134870 ENSG00000237037.8 NDUFA6-AS1 10.49 1.6e-22 6.34e-19 0.56 0.49 Cognitive function; chr22:42256311 chr22:42090931~42137742:+ LIHC cis rs1799949 0.929 rs799905 ENSG00000198496.9 NBR2 -10.49 1.64e-22 6.49e-19 -0.56 -0.49 Menopause (age at onset); chr17:43125170 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs799910 ENSG00000198496.9 NBR2 -10.49 1.64e-22 6.49e-19 -0.56 -0.49 Menopause (age at onset); chr17:43127544 chr17:43125610~43153671:+ LIHC cis rs875971 0.862 rs28470208 ENSG00000226824.5 RP4-756H11.3 10.49 1.71e-22 6.76e-19 0.6 0.49 Aortic root size; chr7:66119713 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs7796162 ENSG00000226824.5 RP4-756H11.3 10.48 1.75e-22 6.91e-19 0.58 0.49 Aortic root size; chr7:66280771 chr7:66654538~66669855:+ LIHC cis rs10256972 0.591 rs6950319 ENSG00000229043.2 AC091729.9 -10.48 1.81e-22 7.14e-19 -0.56 -0.49 Endometriosis;Longevity; chr7:1121688 chr7:1160374~1165267:+ LIHC cis rs801193 0.569 rs7800620 ENSG00000226824.5 RP4-756H11.3 -10.48 1.83e-22 7.19e-19 -0.58 -0.49 Aortic root size; chr7:66758701 chr7:66654538~66669855:+ LIHC cis rs7188445 1 rs7190187 ENSG00000261390.4 RP11-345M22.2 -10.48 1.83e-22 7.19e-19 -0.6 -0.49 Urate levels; chr16:79701281 chr16:79715232~79770563:- LIHC cis rs1577917 0.771 rs2484355 ENSG00000203875.9 SNHG5 -10.47 1.94e-22 7.64e-19 -0.58 -0.49 Response to antipsychotic treatment; chr6:85684685 chr6:85660950~85678736:- LIHC cis rs2739330 0.731 rs2000468 ENSG00000225282.1 AP000350.6 10.47 1.95e-22 7.65e-19 0.6 0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23926900~23929574:+ LIHC cis rs875971 0.755 rs76288834 ENSG00000226824.5 RP4-756H11.3 10.47 1.95e-22 7.67e-19 0.58 0.49 Aortic root size; chr7:66604815 chr7:66654538~66669855:+ LIHC cis rs1577917 0.958 rs13213899 ENSG00000203875.9 SNHG5 -10.46 2.06e-22 8.07e-19 -0.59 -0.49 Response to antipsychotic treatment; chr6:85763422 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs10806337 ENSG00000203875.9 SNHG5 -10.46 2.06e-22 8.07e-19 -0.59 -0.49 Response to antipsychotic treatment; chr6:85764531 chr6:85660950~85678736:- LIHC cis rs875971 0.862 rs4718330 ENSG00000226824.5 RP4-756H11.3 10.46 2.07e-22 8.1e-19 0.59 0.49 Aortic root size; chr7:66250256 chr7:66654538~66669855:+ LIHC cis rs858239 0.899 rs2268747 ENSG00000230658.1 KLHL7-AS1 10.46 2.08e-22 8.14e-19 0.64 0.49 Cerebrospinal fluid biomarker levels; chr7:23273843 chr7:23101228~23105703:- LIHC cis rs9828933 0.766 rs3774725 ENSG00000280620.1 SCAANT1 10.46 2.08e-22 8.15e-19 0.69 0.49 Type 2 diabetes; chr3:63988582 chr3:63911518~63911772:- LIHC cis rs801193 0.569 rs11772819 ENSG00000226824.5 RP4-756H11.3 -10.46 2.1e-22 8.22e-19 -0.58 -0.49 Aortic root size; chr7:66752983 chr7:66654538~66669855:+ LIHC cis rs7104764 0.673 rs3782118 ENSG00000277290.1 RP11-326C3.16 -10.46 2.12e-22 8.29e-19 -0.42 -0.49 Menarche (age at onset); chr11:222620 chr11:243099~243483:- LIHC cis rs1799949 0.965 rs8176310 ENSG00000198496.9 NBR2 -10.46 2.12e-22 8.29e-19 -0.57 -0.49 Menopause (age at onset); chr17:43047896 chr17:43125610~43153671:+ LIHC cis rs1799949 0.965 rs8070179 ENSG00000198496.9 NBR2 -10.46 2.12e-22 8.29e-19 -0.57 -0.49 Menopause (age at onset); chr17:43050671 chr17:43125610~43153671:+ LIHC cis rs12022452 0.908 rs4660423 ENSG00000238287.1 RP11-656D10.3 -10.46 2.15e-22 8.37e-19 -0.69 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40554632 chr1:40493157~40508661:- LIHC cis rs801193 0.569 rs13226966 ENSG00000226824.5 RP4-756H11.3 -10.45 2.26e-22 8.79e-19 -0.58 -0.49 Aortic root size; chr7:66768636 chr7:66654538~66669855:+ LIHC cis rs2455601 0.573 rs2653573 ENSG00000254860.4 TMEM9B-AS1 10.45 2.28e-22 8.88e-19 0.57 0.49 Schizophrenia; chr11:8968327 chr11:8964675~8977527:+ LIHC cis rs2188561 0.673 rs2712218 ENSG00000241764.3 AC002467.7 10.45 2.3e-22 8.94e-19 0.68 0.49 Alcohol consumption; chr7:107716314 chr7:107742817~107744581:- LIHC cis rs12022452 0.818 rs11810978 ENSG00000238287.1 RP11-656D10.3 -10.45 2.31e-22 8.98e-19 -0.68 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40554175 chr1:40493157~40508661:- LIHC cis rs12022452 0.908 rs11811487 ENSG00000238287.1 RP11-656D10.3 -10.45 2.31e-22 8.98e-19 -0.68 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40555398 chr1:40493157~40508661:- LIHC cis rs977987 0.806 rs1109342 ENSG00000261783.1 RP11-252K23.2 10.45 2.33e-22 9.04e-19 0.57 0.49 Dupuytren's disease; chr16:75411777 chr16:75379818~75381260:- LIHC cis rs4423214 1 rs3750997 ENSG00000254682.1 RP11-660L16.2 10.44 2.48e-22 9.6e-19 0.62 0.49 Vitamin D levels; chr11:71447795 chr11:71448674~71452157:+ LIHC cis rs7208859 0.673 rs11657270 ENSG00000263531.1 RP13-753N3.1 10.44 2.53e-22 9.8e-19 0.89 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887369 chr17:30863921~30864940:- LIHC cis rs2739330 0.587 rs4820571 ENSG00000273295.1 AP000350.5 10.43 2.64e-22 1.02e-18 0.53 0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23901432~23907068:- LIHC cis rs7208859 0.673 rs11651802 ENSG00000263531.1 RP13-753N3.1 10.43 2.69e-22 1.04e-18 0.89 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832642 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9914242 ENSG00000263531.1 RP13-753N3.1 10.43 2.7e-22 1.04e-18 0.88 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889227 chr17:30863921~30864940:- LIHC cis rs7188445 0.932 rs11150191 ENSG00000261390.4 RP11-345M22.2 -10.43 2.71e-22 1.05e-18 -0.62 -0.49 Urate levels; chr16:79700390 chr16:79715232~79770563:- LIHC cis rs8062405 0.823 rs7202948 ENSG00000259982.1 CDC37P1 10.43 2.72e-22 1.05e-18 0.53 0.49 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28546968 chr16:28700294~28701540:- LIHC cis rs2188561 0.697 rs3735606 ENSG00000241764.3 AC002467.7 10.43 2.75e-22 1.06e-18 0.64 0.49 Alcohol consumption; chr7:107743864 chr7:107742817~107744581:- LIHC cis rs875971 0.862 rs1612452 ENSG00000226824.5 RP4-756H11.3 10.42 2.85e-22 1.1e-18 0.6 0.49 Aortic root size; chr7:66108909 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs1167390 ENSG00000226824.5 RP4-756H11.3 10.42 2.85e-22 1.1e-18 0.6 0.49 Aortic root size; chr7:66110906 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs35034167 ENSG00000226824.5 RP4-756H11.3 10.42 2.85e-22 1.1e-18 0.6 0.49 Aortic root size; chr7:66115179 chr7:66654538~66669855:+ LIHC cis rs858239 0.863 rs274054 ENSG00000230658.1 KLHL7-AS1 10.42 2.89e-22 1.11e-18 0.6 0.49 Cerebrospinal fluid biomarker levels; chr7:23350848 chr7:23101228~23105703:- LIHC cis rs977987 0.645 rs34904236 ENSG00000261783.1 RP11-252K23.2 -10.42 2.95e-22 1.13e-18 -0.59 -0.49 Dupuytren's disease; chr16:75464355 chr16:75379818~75381260:- LIHC cis rs2019137 0.539 rs6755040 ENSG00000189223.12 PAX8-AS1 -10.42 2.97e-22 1.14e-18 -0.65 -0.49 Lymphocyte counts; chr2:113223560 chr2:113211522~113276581:+ LIHC cis rs2188561 0.697 rs4730258 ENSG00000241764.3 AC002467.7 10.42 3.01e-22 1.16e-18 0.64 0.49 Alcohol consumption; chr7:107755787 chr7:107742817~107744581:- LIHC cis rs1799949 0.965 rs4793230 ENSG00000198496.9 NBR2 -10.42 3.02e-22 1.16e-18 -0.56 -0.49 Menopause (age at onset); chr17:43350035 chr17:43125610~43153671:+ LIHC cis rs977987 0.843 rs10431974 ENSG00000261783.1 RP11-252K23.2 -10.41 3.04e-22 1.17e-18 -0.57 -0.49 Dupuytren's disease; chr16:75401563 chr16:75379818~75381260:- LIHC cis rs9828933 0.752 rs13433909 ENSG00000280620.1 SCAANT1 10.41 3.12e-22 1.2e-18 0.7 0.49 Type 2 diabetes; chr3:63962933 chr3:63911518~63911772:- LIHC cis rs801193 0.569 rs2659893 ENSG00000226824.5 RP4-756H11.3 -10.41 3.13e-22 1.2e-18 -0.58 -0.49 Aortic root size; chr7:66735006 chr7:66654538~66669855:+ LIHC cis rs801193 0.569 rs2659892 ENSG00000226824.5 RP4-756H11.3 -10.41 3.13e-22 1.2e-18 -0.58 -0.49 Aortic root size; chr7:66735318 chr7:66654538~66669855:+ LIHC cis rs801193 0.548 rs2659891 ENSG00000226824.5 RP4-756H11.3 -10.41 3.13e-22 1.2e-18 -0.58 -0.49 Aortic root size; chr7:66736127 chr7:66654538~66669855:+ LIHC cis rs801193 0.569 rs2707847 ENSG00000226824.5 RP4-756H11.3 -10.41 3.13e-22 1.2e-18 -0.58 -0.49 Aortic root size; chr7:66737884 chr7:66654538~66669855:+ LIHC cis rs801193 0.548 rs7805152 ENSG00000226824.5 RP4-756H11.3 -10.41 3.13e-22 1.2e-18 -0.58 -0.49 Aortic root size; chr7:66744266 chr7:66654538~66669855:+ LIHC cis rs801193 0.569 rs11761542 ENSG00000226824.5 RP4-756H11.3 -10.41 3.13e-22 1.2e-18 -0.58 -0.49 Aortic root size; chr7:66753209 chr7:66654538~66669855:+ LIHC cis rs1799949 0.965 rs8176198 ENSG00000198496.9 NBR2 -10.41 3.15e-22 1.21e-18 -0.54 -0.49 Menopause (age at onset); chr17:43078520 chr17:43125610~43153671:+ LIHC cis rs5758659 0.716 rs86669 ENSG00000237037.8 NDUFA6-AS1 10.41 3.16e-22 1.21e-18 0.55 0.49 Cognitive function; chr22:42284794 chr22:42090931~42137742:+ LIHC cis rs2739330 0.627 rs9608219 ENSG00000231271.1 AP000350.8 10.41 3.16e-22 1.21e-18 0.57 0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23949918~23954042:+ LIHC cis rs5769707 0.521 rs6009810 ENSG00000188511.11 C22orf34 10.41 3.17e-22 1.22e-18 0.59 0.49 Monocyte percentage of white cells;Monocyte count; chr22:49665892 chr22:49414524~49657542:- LIHC cis rs2188561 0.697 rs7787927 ENSG00000241764.3 AC002467.7 10.41 3.17e-22 1.22e-18 0.64 0.49 Alcohol consumption; chr7:107763915 chr7:107742817~107744581:- LIHC cis rs2019137 0.539 rs4849177 ENSG00000189223.12 PAX8-AS1 -10.41 3.23e-22 1.24e-18 -0.65 -0.49 Lymphocyte counts; chr2:113225007 chr2:113211522~113276581:+ LIHC cis rs1799949 0.965 rs4239149 ENSG00000198496.9 NBR2 10.4 3.3e-22 1.26e-18 0.56 0.49 Menopause (age at onset); chr17:43176078 chr17:43125610~43153671:+ LIHC cis rs8062405 0.824 rs4788083 ENSG00000259982.1 CDC37P1 10.4 3.31e-22 1.27e-18 0.53 0.49 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28534128 chr16:28700294~28701540:- LIHC cis rs5758659 0.633 rs762995 ENSG00000237037.8 NDUFA6-AS1 10.4 3.37e-22 1.29e-18 0.56 0.49 Cognitive function; chr22:42276118 chr22:42090931~42137742:+ LIHC cis rs977987 0.806 rs1364077 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75363093 chr16:75379818~75381260:- LIHC cis rs977987 0.843 rs4887820 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75363389 chr16:75379818~75381260:- LIHC cis rs977987 0.778 rs34222958 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75364354 chr16:75379818~75381260:- LIHC cis rs977987 0.778 rs4887821 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75364676 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs4888390 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75366422 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs4888391 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75366848 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs8054769 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75367215 chr16:75379818~75381260:- LIHC cis rs977987 0.778 rs35415181 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75369226 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs11640473 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75369391 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs8057203 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75371076 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs35552529 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75371981 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs56343285 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75375899 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs1544810 ENSG00000261783.1 RP11-252K23.2 -10.4 3.44e-22 1.31e-18 -0.56 -0.49 Dupuytren's disease; chr16:75377265 chr16:75379818~75381260:- LIHC cis rs7208859 0.673 rs78799101 ENSG00000263531.1 RP13-753N3.1 10.4 3.46e-22 1.32e-18 0.89 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888142 chr17:30863921~30864940:- LIHC cis rs977987 0.806 rs4888411 ENSG00000261783.1 RP11-252K23.2 -10.4 3.47e-22 1.32e-18 -0.56 -0.49 Dupuytren's disease; chr16:75409285 chr16:75379818~75381260:- LIHC cis rs1577917 0.958 rs12212480 ENSG00000203875.9 SNHG5 -10.4 3.48e-22 1.33e-18 -0.59 -0.49 Response to antipsychotic treatment; chr6:85749059 chr6:85660950~85678736:- LIHC cis rs977987 0.806 rs1030262 ENSG00000261783.1 RP11-252K23.2 -10.4 3.55e-22 1.35e-18 -0.58 -0.49 Dupuytren's disease; chr16:75457429 chr16:75379818~75381260:- LIHC cis rs2019137 0.539 rs11123170 ENSG00000189223.12 PAX8-AS1 -10.39 3.57e-22 1.36e-18 -0.66 -0.49 Lymphocyte counts; chr2:113221363 chr2:113211522~113276581:+ LIHC cis rs977987 0.806 rs4888388 ENSG00000261783.1 RP11-252K23.2 -10.39 3.57e-22 1.36e-18 -0.56 -0.49 Dupuytren's disease; chr16:75360250 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs7185640 ENSG00000261783.1 RP11-252K23.2 -10.39 3.57e-22 1.36e-18 -0.56 -0.49 Dupuytren's disease; chr16:75360501 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs11640674 ENSG00000261783.1 RP11-252K23.2 -10.39 3.57e-22 1.36e-18 -0.56 -0.49 Dupuytren's disease; chr16:75361046 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs4888389 ENSG00000261783.1 RP11-252K23.2 -10.39 3.57e-22 1.36e-18 -0.56 -0.49 Dupuytren's disease; chr16:75361330 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs11865004 ENSG00000261783.1 RP11-252K23.2 -10.39 3.57e-22 1.36e-18 -0.56 -0.49 Dupuytren's disease; chr16:75361879 chr16:75379818~75381260:- LIHC cis rs2455601 0.638 rs2568092 ENSG00000254860.4 TMEM9B-AS1 -10.39 3.58e-22 1.36e-18 -0.56 -0.49 Schizophrenia; chr11:8965891 chr11:8964675~8977527:+ LIHC cis rs8062405 0.824 rs7191618 ENSG00000259982.1 CDC37P1 10.39 3.65e-22 1.38e-18 0.53 0.49 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554346 chr16:28700294~28701540:- LIHC cis rs8062405 0.754 rs3859172 ENSG00000259982.1 CDC37P1 10.39 3.65e-22 1.38e-18 0.53 0.49 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554837 chr16:28700294~28701540:- LIHC cis rs875971 0.862 rs7786892 ENSG00000226824.5 RP4-756H11.3 10.39 3.65e-22 1.38e-18 0.6 0.49 Aortic root size; chr7:66163889 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs2420174 ENSG00000226824.5 RP4-756H11.3 10.39 3.65e-22 1.38e-18 0.6 0.49 Aortic root size; chr7:66180374 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs2420173 ENSG00000226824.5 RP4-756H11.3 10.39 3.65e-22 1.38e-18 0.6 0.49 Aortic root size; chr7:66180412 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs4718319 ENSG00000226824.5 RP4-756H11.3 10.39 3.65e-22 1.38e-18 0.6 0.49 Aortic root size; chr7:66187797 chr7:66654538~66669855:+ LIHC cis rs875971 0.723 rs28391294 ENSG00000226824.5 RP4-756H11.3 10.39 3.65e-22 1.38e-18 0.6 0.49 Aortic root size; chr7:66189328 chr7:66654538~66669855:+ LIHC cis rs875971 0.83 rs6967708 ENSG00000226824.5 RP4-756H11.3 10.39 3.65e-22 1.38e-18 0.6 0.49 Aortic root size; chr7:66192326 chr7:66654538~66669855:+ LIHC cis rs875971 0.895 rs7782806 ENSG00000226824.5 RP4-756H11.3 10.39 3.65e-22 1.38e-18 0.6 0.49 Aortic root size; chr7:66192910 chr7:66654538~66669855:+ LIHC cis rs2188561 0.697 rs7782475 ENSG00000241764.3 AC002467.7 -10.39 3.74e-22 1.41e-18 -0.64 -0.49 Alcohol consumption; chr7:107745806 chr7:107742817~107744581:- LIHC cis rs7580658 0.864 rs3088374 ENSG00000236682.1 AC068282.3 -10.39 3.81e-22 1.44e-18 -0.62 -0.49 Protein C levels; chr2:127304472 chr2:127389130~127400580:+ LIHC cis rs977987 0.806 rs2865531 ENSG00000261783.1 RP11-252K23.2 -10.38 3.9e-22 1.47e-18 -0.56 -0.49 Dupuytren's disease; chr16:75356418 chr16:75379818~75381260:- LIHC cis rs2019137 0.56 rs7578633 ENSG00000189223.12 PAX8-AS1 -10.38 3.91e-22 1.48e-18 -0.66 -0.49 Lymphocyte counts; chr2:113221073 chr2:113211522~113276581:+ LIHC cis rs977987 0.778 rs2113232 ENSG00000261783.1 RP11-252K23.2 -10.38 4.04e-22 1.52e-18 -0.56 -0.49 Dupuytren's disease; chr16:75357287 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs35263058 ENSG00000261783.1 RP11-252K23.2 -10.38 4.04e-22 1.52e-18 -0.56 -0.49 Dupuytren's disease; chr16:75358039 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs1895490 ENSG00000261783.1 RP11-252K23.2 -10.38 4.04e-22 1.52e-18 -0.56 -0.49 Dupuytren's disease; chr16:75358908 chr16:75379818~75381260:- LIHC cis rs977987 0.736 rs4888392 ENSG00000261783.1 RP11-252K23.2 -10.38 4.04e-22 1.52e-18 -0.56 -0.49 Dupuytren's disease; chr16:75378364 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs11860284 ENSG00000261783.1 RP11-252K23.2 -10.38 4.13e-22 1.56e-18 -0.56 -0.49 Dupuytren's disease; chr16:75379009 chr16:75379818~75381260:- LIHC cis rs8062405 0.72 rs9926245 ENSG00000259982.1 CDC37P1 10.36 4.66e-22 1.75e-18 0.53 0.49 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28544385 chr16:28700294~28701540:- LIHC cis rs2019137 0.56 rs11123172 ENSG00000189223.12 PAX8-AS1 10.36 4.7e-22 1.77e-18 0.65 0.49 Lymphocyte counts; chr2:113226726 chr2:113211522~113276581:+ LIHC cis rs1799949 0.965 rs6503727 ENSG00000198496.9 NBR2 -10.36 4.73e-22 1.78e-18 -0.56 -0.49 Menopause (age at onset); chr17:43160842 chr17:43125610~43153671:+ LIHC cis rs875971 0.862 rs778736 ENSG00000226824.5 RP4-756H11.3 -10.36 4.74e-22 1.78e-18 -0.57 -0.49 Aortic root size; chr7:66348861 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs2901152 ENSG00000226824.5 RP4-756H11.3 10.36 4.74e-22 1.78e-18 0.57 0.49 Aortic root size; chr7:66300017 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs10263690 ENSG00000226824.5 RP4-756H11.3 10.36 4.74e-22 1.78e-18 0.57 0.49 Aortic root size; chr7:66301466 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs10250544 ENSG00000226824.5 RP4-756H11.3 10.36 4.74e-22 1.78e-18 0.57 0.49 Aortic root size; chr7:66301574 chr7:66654538~66669855:+ LIHC cis rs875971 0.895 rs12531677 ENSG00000226824.5 RP4-756H11.3 10.36 4.74e-22 1.78e-18 0.57 0.49 Aortic root size; chr7:66304099 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs7798630 ENSG00000226824.5 RP4-756H11.3 10.36 4.74e-22 1.78e-18 0.57 0.49 Aortic root size; chr7:66306492 chr7:66654538~66669855:+ LIHC cis rs875971 0.755 rs10228885 ENSG00000226824.5 RP4-756H11.3 10.36 4.74e-22 1.78e-18 0.57 0.49 Aortic root size; chr7:66315542 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs3893216 ENSG00000226824.5 RP4-756H11.3 10.36 4.74e-22 1.78e-18 0.57 0.49 Aortic root size; chr7:66325720 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6958294 ENSG00000226824.5 RP4-756H11.3 10.36 4.74e-22 1.78e-18 0.57 0.49 Aortic root size; chr7:66329809 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs2088655 ENSG00000226824.5 RP4-756H11.3 10.36 4.74e-22 1.78e-18 0.57 0.49 Aortic root size; chr7:66330724 chr7:66654538~66669855:+ LIHC cis rs875971 0.895 rs10447522 ENSG00000226824.5 RP4-756H11.3 10.36 4.74e-22 1.78e-18 0.57 0.49 Aortic root size; chr7:66331087 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs2088653 ENSG00000226824.5 RP4-756H11.3 10.36 4.74e-22 1.78e-18 0.57 0.49 Aortic root size; chr7:66343621 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6460293 ENSG00000226824.5 RP4-756H11.3 10.36 4.74e-22 1.78e-18 0.57 0.49 Aortic root size; chr7:66345205 chr7:66654538~66669855:+ LIHC cis rs2019137 0.56 rs4849179 ENSG00000189223.12 PAX8-AS1 -10.36 4.84e-22 1.81e-18 -0.65 -0.49 Lymphocyte counts; chr2:113227593 chr2:113211522~113276581:+ LIHC cis rs977987 0.778 rs11858992 ENSG00000261783.1 RP11-252K23.2 -10.36 4.86e-22 1.82e-18 -0.56 -0.49 Dupuytren's disease; chr16:75377547 chr16:75379818~75381260:- LIHC cis rs1577917 0.958 rs72907388 ENSG00000203875.9 SNHG5 -10.35 4.97e-22 1.86e-18 -0.59 -0.49 Response to antipsychotic treatment; chr6:85730489 chr6:85660950~85678736:- LIHC cis rs2283792 0.812 rs240066 ENSG00000224086.5 LL22NC03-86G7.1 10.35 5.2e-22 1.95e-18 0.46 0.49 Multiple sclerosis; chr22:21938623 chr22:21938293~21977632:+ LIHC cis rs12022452 1 rs2184877 ENSG00000238287.1 RP11-656D10.3 -10.34 5.37e-22 2.01e-18 -0.68 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40531260 chr1:40493157~40508661:- LIHC cis rs1577917 0.958 rs11758508 ENSG00000203875.9 SNHG5 10.34 5.54e-22 2.07e-18 0.58 0.49 Response to antipsychotic treatment; chr6:85797160 chr6:85660950~85678736:- LIHC cis rs875971 0.862 rs7809814 ENSG00000226824.5 RP4-756H11.3 10.34 5.64e-22 2.11e-18 0.6 0.49 Aortic root size; chr7:66150410 chr7:66654538~66669855:+ LIHC cis rs7208859 0.673 rs4131618 ENSG00000263531.1 RP13-753N3.1 10.34 5.67e-22 2.12e-18 0.89 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30877783 chr17:30863921~30864940:- LIHC cis rs4718428 1 rs12534637 ENSG00000226824.5 RP4-756H11.3 -10.33 5.76e-22 2.15e-18 -0.64 -0.49 Corneal structure; chr7:66862667 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs1968126 ENSG00000226824.5 RP4-756H11.3 10.33 5.8e-22 2.16e-18 0.57 0.49 Aortic root size; chr7:66592017 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6460306 ENSG00000226824.5 RP4-756H11.3 10.33 5.8e-22 2.16e-18 0.57 0.49 Aortic root size; chr7:66595806 chr7:66654538~66669855:+ LIHC cis rs12022452 1 rs12022452 ENSG00000238287.1 RP11-656D10.3 -10.33 5.8e-22 2.16e-18 -0.7 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40487628 chr1:40493157~40508661:- LIHC cis rs977987 0.806 rs4993970 ENSG00000261783.1 RP11-252K23.2 -10.33 5.83e-22 2.17e-18 -0.56 -0.49 Dupuytren's disease; chr16:75377721 chr16:75379818~75381260:- LIHC cis rs875971 0.862 rs2024192 ENSG00000226824.5 RP4-756H11.3 10.33 5.87e-22 2.19e-18 0.57 0.49 Aortic root size; chr7:66576460 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6955837 ENSG00000226824.5 RP4-756H11.3 10.33 5.87e-22 2.19e-18 0.57 0.49 Aortic root size; chr7:66578155 chr7:66654538~66669855:+ LIHC cis rs875971 0.825 rs10281499 ENSG00000226824.5 RP4-756H11.3 10.33 5.87e-22 2.19e-18 0.57 0.49 Aortic root size; chr7:66583979 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs4718377 ENSG00000226824.5 RP4-756H11.3 10.33 5.87e-22 2.19e-18 0.57 0.49 Aortic root size; chr7:66584691 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs10278014 ENSG00000226824.5 RP4-756H11.3 10.33 5.87e-22 2.19e-18 0.57 0.49 Aortic root size; chr7:66586277 chr7:66654538~66669855:+ LIHC cis rs977987 0.806 rs7202596 ENSG00000261783.1 RP11-252K23.2 -10.33 5.89e-22 2.19e-18 -0.58 -0.49 Dupuytren's disease; chr16:75457174 chr16:75379818~75381260:- LIHC cis rs1799949 0.965 rs799917 ENSG00000198496.9 NBR2 -10.33 5.9e-22 2.2e-18 -0.56 -0.49 Menopause (age at onset); chr17:43092919 chr17:43125610~43153671:+ LIHC cis rs1577917 0.958 rs10944137 ENSG00000203875.9 SNHG5 -10.33 5.93e-22 2.21e-18 -0.59 -0.49 Response to antipsychotic treatment; chr6:85744596 chr6:85660950~85678736:- LIHC cis rs7208859 0.673 rs9898858 ENSG00000263531.1 RP13-753N3.1 10.33 6.01e-22 2.24e-18 0.88 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829193 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs55658077 ENSG00000263531.1 RP13-753N3.1 10.33 6.01e-22 2.24e-18 0.88 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829501 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9899692 ENSG00000263531.1 RP13-753N3.1 10.33 6.01e-22 2.24e-18 0.88 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829921 chr17:30863921~30864940:- LIHC cis rs9326248 0.569 rs10892082 ENSG00000254851.1 RP11-109L13.1 -10.33 6.06e-22 2.25e-18 -0.67 -0.49 Blood protein levels; chr11:117168609 chr11:117135528~117138582:+ LIHC cis rs875971 0.862 rs2909688 ENSG00000226824.5 RP4-756H11.3 -10.33 6.11e-22 2.27e-18 -0.57 -0.49 Aortic root size; chr7:66376625 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs908915 ENSG00000226824.5 RP4-756H11.3 10.33 6.16e-22 2.28e-18 0.6 0.49 Aortic root size; chr7:66149664 chr7:66654538~66669855:+ LIHC cis rs875971 0.83 rs778711 ENSG00000226824.5 RP4-756H11.3 -10.32 6.28e-22 2.31e-18 -0.57 -0.49 Aortic root size; chr7:66386670 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs1083554 ENSG00000226824.5 RP4-756H11.3 -10.32 6.28e-22 2.31e-18 -0.57 -0.49 Aortic root size; chr7:66387354 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs778707 ENSG00000226824.5 RP4-756H11.3 -10.32 6.28e-22 2.31e-18 -0.57 -0.49 Aortic root size; chr7:66392040 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs778705 ENSG00000226824.5 RP4-756H11.3 -10.32 6.28e-22 2.31e-18 -0.57 -0.49 Aortic root size; chr7:66396128 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs778697 ENSG00000226824.5 RP4-756H11.3 -10.32 6.28e-22 2.31e-18 -0.57 -0.49 Aortic root size; chr7:66405439 chr7:66654538~66669855:+ LIHC cis rs875971 0.798 rs7789615 ENSG00000226824.5 RP4-756H11.3 -10.32 6.28e-22 2.31e-18 -0.57 -0.49 Aortic root size; chr7:66413674 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6978028 ENSG00000226824.5 RP4-756H11.3 -10.32 6.28e-22 2.31e-18 -0.57 -0.49 Aortic root size; chr7:66421313 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6947339 ENSG00000226824.5 RP4-756H11.3 -10.32 6.28e-22 2.31e-18 -0.57 -0.49 Aortic root size; chr7:66423483 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs880166 ENSG00000226824.5 RP4-756H11.3 10.32 6.38e-22 2.35e-18 0.59 0.49 Aortic root size; chr7:66205775 chr7:66654538~66669855:+ LIHC cis rs4423214 0.65 rs2186777 ENSG00000254682.1 RP11-660L16.2 10.32 6.41e-22 2.36e-18 0.61 0.49 Vitamin D levels; chr11:71508757 chr11:71448674~71452157:+ LIHC cis rs875971 0.756 rs4718328 ENSG00000226824.5 RP4-756H11.3 10.32 6.44e-22 2.37e-18 0.59 0.49 Aortic root size; chr7:66228350 chr7:66654538~66669855:+ LIHC cis rs7208859 0.623 rs58908911 ENSG00000263531.1 RP13-753N3.1 10.31 6.96e-22 2.56e-18 0.86 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917540 chr17:30863921~30864940:- LIHC cis rs1023500 0.573 rs133380 ENSG00000237037.8 NDUFA6-AS1 10.31 7.03e-22 2.58e-18 0.56 0.49 Schizophrenia; chr22:42072906 chr22:42090931~42137742:+ LIHC cis rs977987 0.778 rs4888412 ENSG00000261783.1 RP11-252K23.2 -10.31 7.16e-22 2.63e-18 -0.56 -0.49 Dupuytren's disease; chr16:75409298 chr16:75379818~75381260:- LIHC cis rs977987 0.778 rs4888413 ENSG00000261783.1 RP11-252K23.2 -10.31 7.16e-22 2.63e-18 -0.56 -0.49 Dupuytren's disease; chr16:75409325 chr16:75379818~75381260:- LIHC cis rs9828933 0.626 rs73119018 ENSG00000280620.1 SCAANT1 10.3 7.27e-22 2.67e-18 0.72 0.49 Type 2 diabetes; chr3:63989652 chr3:63911518~63911772:- LIHC cis rs977987 0.806 rs2865530 ENSG00000261783.1 RP11-252K23.2 -10.3 7.34e-22 2.7e-18 -0.56 -0.49 Dupuytren's disease; chr16:75380478 chr16:75379818~75381260:- LIHC cis rs12022452 1 rs12034162 ENSG00000238287.1 RP11-656D10.3 -10.3 7.86e-22 2.89e-18 -0.68 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40498933 chr1:40493157~40508661:- LIHC cis rs7208859 0.623 rs9906957 ENSG00000263531.1 RP13-753N3.1 10.29 8e-22 2.94e-18 0.88 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30830737 chr17:30863921~30864940:- LIHC cis rs977987 0.806 rs17696696 ENSG00000261783.1 RP11-252K23.2 10.29 8.04e-22 2.95e-18 0.56 0.49 Dupuytren's disease; chr16:75359454 chr16:75379818~75381260:- LIHC cis rs858239 0.72 rs10227559 ENSG00000230658.1 KLHL7-AS1 10.29 8.13e-22 2.98e-18 0.64 0.49 Cerebrospinal fluid biomarker levels; chr7:23232525 chr7:23101228~23105703:- LIHC cis rs801193 0.527 rs2707837 ENSG00000226824.5 RP4-756H11.3 -10.29 8.34e-22 3.05e-18 -0.57 -0.49 Aortic root size; chr7:66716086 chr7:66654538~66669855:+ LIHC cis rs977987 0.778 rs8057849 ENSG00000261783.1 RP11-252K23.2 -10.29 8.41e-22 3.08e-18 -0.56 -0.49 Dupuytren's disease; chr16:75409918 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs72787160 ENSG00000261783.1 RP11-252K23.2 -10.29 8.41e-22 3.08e-18 -0.56 -0.49 Dupuytren's disease; chr16:75411264 chr16:75379818~75381260:- LIHC cis rs977987 0.778 rs1109341 ENSG00000261783.1 RP11-252K23.2 -10.29 8.41e-22 3.08e-18 -0.56 -0.49 Dupuytren's disease; chr16:75411707 chr16:75379818~75381260:- LIHC cis rs7174755 0.923 rs4777033 ENSG00000260657.2 RP11-315D16.4 -10.29 8.5e-22 3.11e-18 -0.7 -0.49 Major depressive disorder; chr15:68308010 chr15:68267792~68277994:- LIHC cis rs977987 0.933 rs1834014 ENSG00000261783.1 RP11-252K23.2 -10.28 8.53e-22 3.12e-18 -0.59 -0.49 Dupuytren's disease; chr16:75467376 chr16:75379818~75381260:- LIHC cis rs1577917 1 rs955196 ENSG00000203875.9 SNHG5 10.28 8.61e-22 3.15e-18 0.58 0.49 Response to antipsychotic treatment; chr6:86020233 chr6:85660950~85678736:- LIHC cis rs801193 0.569 rs2659908 ENSG00000226824.5 RP4-756H11.3 -10.28 8.62e-22 3.15e-18 -0.57 -0.49 Aortic root size; chr7:66695835 chr7:66654538~66669855:+ LIHC cis rs801193 0.569 rs7782587 ENSG00000226824.5 RP4-756H11.3 -10.28 8.62e-22 3.15e-18 -0.57 -0.49 Aortic root size; chr7:66701485 chr7:66654538~66669855:+ LIHC cis rs801193 0.569 rs4717315 ENSG00000226824.5 RP4-756H11.3 -10.28 8.62e-22 3.15e-18 -0.57 -0.49 Aortic root size; chr7:66713338 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs801206 ENSG00000226824.5 RP4-756H11.3 10.28 8.72e-22 3.18e-18 0.57 0.49 Aortic root size; chr7:66556979 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs801204 ENSG00000226824.5 RP4-756H11.3 10.28 8.72e-22 3.18e-18 0.57 0.49 Aortic root size; chr7:66557934 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs801203 ENSG00000226824.5 RP4-756H11.3 10.28 8.72e-22 3.18e-18 0.57 0.49 Aortic root size; chr7:66558025 chr7:66654538~66669855:+ LIHC cis rs875971 0.825 rs801202 ENSG00000226824.5 RP4-756H11.3 10.28 8.72e-22 3.18e-18 0.57 0.49 Aortic root size; chr7:66558942 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs801194 ENSG00000226824.5 RP4-756H11.3 10.28 8.72e-22 3.18e-18 0.57 0.49 Aortic root size; chr7:66563508 chr7:66654538~66669855:+ LIHC cis rs1577917 0.958 rs34622605 ENSG00000203875.9 SNHG5 -10.28 8.72e-22 3.18e-18 -0.58 -0.49 Response to antipsychotic treatment; chr6:85746801 chr6:85660950~85678736:- LIHC cis rs875971 0.862 rs801195 ENSG00000226824.5 RP4-756H11.3 10.28 8.75e-22 3.19e-18 0.57 0.49 Aortic root size; chr7:66561128 chr7:66654538~66669855:+ LIHC cis rs1577917 0.917 rs2197651 ENSG00000203875.9 SNHG5 -10.28 8.8e-22 3.21e-18 -0.6 -0.49 Response to antipsychotic treatment; chr6:85785724 chr6:85660950~85678736:- LIHC cis rs875971 0.798 rs12698522 ENSG00000226824.5 RP4-756H11.3 -10.28 8.83e-22 3.22e-18 -0.57 -0.49 Aortic root size; chr7:66502354 chr7:66654538~66669855:+ LIHC cis rs875971 0.83 rs28714531 ENSG00000226824.5 RP4-756H11.3 -10.28 8.83e-22 3.22e-18 -0.57 -0.49 Aortic root size; chr7:66503250 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs12698526 ENSG00000226824.5 RP4-756H11.3 -10.28 8.83e-22 3.22e-18 -0.57 -0.49 Aortic root size; chr7:66504118 chr7:66654538~66669855:+ LIHC cis rs2019137 0.56 rs7421852 ENSG00000189223.12 PAX8-AS1 -10.28 8.86e-22 3.23e-18 -0.65 -0.49 Lymphocyte counts; chr2:113232684 chr2:113211522~113276581:+ LIHC cis rs2019137 0.56 rs10206269 ENSG00000189223.12 PAX8-AS1 -10.28 8.86e-22 3.23e-18 -0.65 -0.49 Lymphocyte counts; chr2:113232816 chr2:113211522~113276581:+ LIHC cis rs9828933 0.678 rs704366 ENSG00000280620.1 SCAANT1 -10.28 9.07e-22 3.3e-18 -0.7 -0.49 Type 2 diabetes; chr3:63885972 chr3:63911518~63911772:- LIHC cis rs2739330 0.76 rs5760095 ENSG00000231271.1 AP000350.8 10.28 9.14e-22 3.33e-18 0.58 0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23949918~23954042:+ LIHC cis rs858239 1 rs166663 ENSG00000230658.1 KLHL7-AS1 10.27 9.33e-22 3.4e-18 0.62 0.49 Cerebrospinal fluid biomarker levels; chr7:23277123 chr7:23101228~23105703:- LIHC cis rs875971 0.825 rs6951503 ENSG00000226824.5 RP4-756H11.3 10.26 1e-21 3.63e-18 0.57 0.49 Aortic root size; chr7:66253949 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs1983372 ENSG00000226824.5 RP4-756H11.3 10.26 1.04e-21 3.77e-18 0.59 0.49 Aortic root size; chr7:66146364 chr7:66654538~66669855:+ LIHC cis rs1577917 0.958 rs12205492 ENSG00000203875.9 SNHG5 -10.26 1.04e-21 3.78e-18 -0.58 -0.49 Response to antipsychotic treatment; chr6:85766258 chr6:85660950~85678736:- LIHC cis rs977987 0.806 rs34021527 ENSG00000261783.1 RP11-252K23.2 -10.25 1.11e-21 4.01e-18 -0.55 -0.48 Dupuytren's disease; chr16:75440192 chr16:75379818~75381260:- LIHC cis rs977987 0.751 rs56004344 ENSG00000261783.1 RP11-252K23.2 -10.25 1.11e-21 4.01e-18 -0.55 -0.48 Dupuytren's disease; chr16:75440291 chr16:75379818~75381260:- LIHC cis rs12439619 0.705 rs4778665 ENSG00000278603.1 RP13-608F4.5 10.25 1.13e-21 4.08e-18 0.93 0.48 Intelligence (multi-trait analysis); chr15:82144163 chr15:82472203~82472426:+ LIHC cis rs2739330 0.76 rs1002286 ENSG00000231271.1 AP000350.8 -10.25 1.14e-21 4.13e-18 -0.56 -0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23949918~23954042:+ LIHC cis rs2455601 0.507 rs2568044 ENSG00000254860.4 TMEM9B-AS1 -10.25 1.15e-21 4.16e-18 -0.55 -0.48 Schizophrenia; chr11:8980930 chr11:8964675~8977527:+ LIHC cis rs801193 0.591 rs4506088 ENSG00000226824.5 RP4-756H11.3 10.24 1.19e-21 4.29e-18 0.57 0.48 Aortic root size; chr7:66670470 chr7:66654538~66669855:+ LIHC cis rs875971 1 rs6946143 ENSG00000226824.5 RP4-756H11.3 -10.24 1.21e-21 4.36e-18 -0.57 -0.48 Aortic root size; chr7:66114735 chr7:66654538~66669855:+ LIHC cis rs7208859 0.614 rs73265646 ENSG00000263531.1 RP13-753N3.1 10.24 1.23e-21 4.42e-18 0.85 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917005 chr17:30863921~30864940:- LIHC cis rs4820294 0.669 rs732857 ENSG00000233360.4 Z83844.1 10.24 1.24e-21 4.46e-18 0.54 0.48 Fat distribution (HIV); chr22:37664843 chr22:37641832~37658377:- LIHC cis rs875971 0.862 rs1875057 ENSG00000226824.5 RP4-756H11.3 10.24 1.24e-21 4.47e-18 0.57 0.48 Aortic root size; chr7:66266868 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6960446 ENSG00000226824.5 RP4-756H11.3 10.24 1.24e-21 4.47e-18 0.57 0.48 Aortic root size; chr7:66268272 chr7:66654538~66669855:+ LIHC cis rs875971 0.789 rs10260426 ENSG00000226824.5 RP4-756H11.3 10.24 1.24e-21 4.47e-18 0.57 0.48 Aortic root size; chr7:66271055 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs7783779 ENSG00000226824.5 RP4-756H11.3 10.24 1.24e-21 4.47e-18 0.57 0.48 Aortic root size; chr7:66331639 chr7:66654538~66669855:+ LIHC cis rs12022452 1 rs12031278 ENSG00000238287.1 RP11-656D10.3 -10.23 1.33e-21 4.78e-18 -0.68 -0.48 Age-related hearing impairment (SNP x SNP interaction); chr1:40511246 chr1:40493157~40508661:- LIHC cis rs801193 0.569 rs2659907 ENSG00000226824.5 RP4-756H11.3 -10.22 1.4e-21 5.02e-18 -0.57 -0.48 Aortic root size; chr7:66699045 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs10274883 ENSG00000226824.5 RP4-756H11.3 10.22 1.41e-21 5.06e-18 0.57 0.48 Aortic root size; chr7:66651104 chr7:66654538~66669855:+ LIHC cis rs801193 0.569 rs881285 ENSG00000226824.5 RP4-756H11.3 10.22 1.41e-21 5.06e-18 0.57 0.48 Aortic root size; chr7:66654433 chr7:66654538~66669855:+ LIHC cis rs801193 0.569 rs3846973 ENSG00000226824.5 RP4-756H11.3 10.22 1.41e-21 5.06e-18 0.57 0.48 Aortic root size; chr7:66655048 chr7:66654538~66669855:+ LIHC cis rs801193 0.569 rs2013908 ENSG00000226824.5 RP4-756H11.3 10.22 1.41e-21 5.06e-18 0.57 0.48 Aortic root size; chr7:66656082 chr7:66654538~66669855:+ LIHC cis rs801193 0.548 rs2109297 ENSG00000226824.5 RP4-756H11.3 10.22 1.41e-21 5.06e-18 0.57 0.48 Aortic root size; chr7:66657397 chr7:66654538~66669855:+ LIHC cis rs801193 0.569 rs6978178 ENSG00000226824.5 RP4-756H11.3 10.22 1.41e-21 5.06e-18 0.57 0.48 Aortic root size; chr7:66658097 chr7:66654538~66669855:+ LIHC cis rs801193 0.591 rs721717 ENSG00000226824.5 RP4-756H11.3 10.22 1.41e-21 5.06e-18 0.57 0.48 Aortic root size; chr7:66665305 chr7:66654538~66669855:+ LIHC cis rs801193 0.569 rs6951302 ENSG00000226824.5 RP4-756H11.3 10.22 1.41e-21 5.06e-18 0.57 0.48 Aortic root size; chr7:66667525 chr7:66654538~66669855:+ LIHC cis rs1799949 0.965 rs8071278 ENSG00000198496.9 NBR2 -10.22 1.44e-21 5.14e-18 -0.56 -0.48 Menopause (age at onset); chr17:43041893 chr17:43125610~43153671:+ LIHC cis rs507080 0.922 rs644867 ENSG00000255422.1 AP002954.4 -10.22 1.44e-21 5.16e-18 -0.57 -0.48 Serum metabolite levels; chr11:118696836 chr11:118704607~118750263:+ LIHC cis rs977987 0.778 rs4888409 ENSG00000261783.1 RP11-252K23.2 -10.22 1.47e-21 5.26e-18 -0.55 -0.48 Dupuytren's disease; chr16:75402333 chr16:75379818~75381260:- LIHC cis rs858239 0.806 rs10268610 ENSG00000230658.1 KLHL7-AS1 10.22 1.47e-21 5.26e-18 0.62 0.48 Cerebrospinal fluid biomarker levels; chr7:23235145 chr7:23101228~23105703:- LIHC cis rs977987 0.806 rs4146809 ENSG00000261783.1 RP11-252K23.2 10.22 1.47e-21 5.26e-18 0.55 0.48 Dupuytren's disease; chr16:75381877 chr16:75379818~75381260:- LIHC cis rs1577917 0.958 rs12193904 ENSG00000203875.9 SNHG5 -10.22 1.48e-21 5.27e-18 -0.58 -0.48 Response to antipsychotic treatment; chr6:85742985 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs11754330 ENSG00000203875.9 SNHG5 -10.22 1.48e-21 5.27e-18 -0.58 -0.48 Response to antipsychotic treatment; chr6:85745352 chr6:85660950~85678736:- LIHC cis rs875971 0.862 rs11984115 ENSG00000226824.5 RP4-756H11.3 10.21 1.48e-21 5.3e-18 0.57 0.48 Aortic root size; chr7:66308872 chr7:66654538~66669855:+ LIHC cis rs875971 0.825 rs1129531 ENSG00000226824.5 RP4-756H11.3 10.21 1.53e-21 5.47e-18 0.59 0.48 Aortic root size; chr7:66154117 chr7:66654538~66669855:+ LIHC cis rs5769707 0.521 rs5769719 ENSG00000188511.11 C22orf34 10.21 1.55e-21 5.54e-18 0.58 0.48 Monocyte percentage of white cells;Monocyte count; chr22:49668453 chr22:49414524~49657542:- LIHC cis rs5769707 0.521 rs5769720 ENSG00000188511.11 C22orf34 10.21 1.55e-21 5.54e-18 0.58 0.48 Monocyte percentage of white cells;Monocyte count; chr22:49668485 chr22:49414524~49657542:- LIHC cis rs5769707 0.521 rs5770633 ENSG00000188511.11 C22orf34 10.21 1.55e-21 5.54e-18 0.58 0.48 Monocyte percentage of white cells;Monocyte count; chr22:49668779 chr22:49414524~49657542:- LIHC cis rs1939012 0.565 rs2846707 ENSG00000281655.1 RP11-817J15.3 -10.21 1.6e-21 5.7e-18 -0.73 -0.48 Epilepsy; chr11:102705627 chr11:102681310~102683913:+ LIHC cis rs977987 0.806 rs12051136 ENSG00000261783.1 RP11-252K23.2 -10.2 1.64e-21 5.85e-18 -0.55 -0.48 Dupuytren's disease; chr16:75401833 chr16:75379818~75381260:- LIHC cis rs7115242 0.8 rs6589597 ENSG00000254851.1 RP11-109L13.1 10.2 1.66e-21 5.93e-18 0.66 0.48 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117127082 chr11:117135528~117138582:+ LIHC cis rs2455601 0.744 rs2163626 ENSG00000254860.4 TMEM9B-AS1 10.2 1.67e-21 5.93e-18 0.57 0.48 Schizophrenia; chr11:8962000 chr11:8964675~8977527:+ LIHC cis rs801193 0.548 rs6975044 ENSG00000226824.5 RP4-756H11.3 -10.2 1.69e-21 6.02e-18 -0.57 -0.48 Aortic root size; chr7:66762495 chr7:66654538~66669855:+ LIHC cis rs507080 0.922 rs493834 ENSG00000255422.1 AP002954.4 -10.2 1.71e-21 6.09e-18 -0.57 -0.48 Serum metabolite levels; chr11:118696735 chr11:118704607~118750263:+ LIHC cis rs507080 0.922 rs644498 ENSG00000255422.1 AP002954.4 -10.2 1.71e-21 6.09e-18 -0.57 -0.48 Serum metabolite levels; chr11:118696777 chr11:118704607~118750263:+ LIHC cis rs7208859 0.673 rs73271887 ENSG00000263531.1 RP13-753N3.1 10.19 1.74e-21 6.2e-18 0.87 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827917 chr17:30863921~30864940:- LIHC cis rs858239 0.665 rs858305 ENSG00000230658.1 KLHL7-AS1 -10.19 1.77e-21 6.29e-18 -0.61 -0.48 Cerebrospinal fluid biomarker levels; chr7:23203211 chr7:23101228~23105703:- LIHC cis rs7174755 0.961 rs58175526 ENSG00000260657.2 RP11-315D16.4 10.19 1.77e-21 6.31e-18 0.76 0.48 Major depressive disorder; chr15:68300789 chr15:68267792~68277994:- LIHC cis rs977987 0.806 rs12051326 ENSG00000261783.1 RP11-252K23.2 -10.19 1.79e-21 6.35e-18 -0.55 -0.48 Dupuytren's disease; chr16:75403989 chr16:75379818~75381260:- LIHC cis rs1939012 0.544 rs947875 ENSG00000281655.1 RP11-817J15.3 -10.19 1.84e-21 6.52e-18 -0.73 -0.48 Epilepsy; chr11:102706938 chr11:102681310~102683913:+ LIHC cis rs1939012 0.565 rs1276284 ENSG00000281655.1 RP11-817J15.3 -10.19 1.84e-21 6.52e-18 -0.73 -0.48 Epilepsy; chr11:102711137 chr11:102681310~102683913:+ LIHC cis rs1939012 0.544 rs1276283 ENSG00000281655.1 RP11-817J15.3 -10.19 1.84e-21 6.52e-18 -0.73 -0.48 Epilepsy; chr11:102711187 chr11:102681310~102683913:+ LIHC cis rs977987 0.966 rs8055490 ENSG00000261783.1 RP11-252K23.2 -10.19 1.84e-21 6.54e-18 -0.58 -0.48 Dupuytren's disease; chr16:75463237 chr16:75379818~75381260:- LIHC cis rs2019137 0.56 rs10175462 ENSG00000189223.12 PAX8-AS1 -10.18 1.9e-21 6.74e-18 -0.64 -0.48 Lymphocyte counts; chr2:113230915 chr2:113211522~113276581:+ LIHC cis rs977987 0.771 rs4888387 ENSG00000261783.1 RP11-252K23.2 -10.18 1.96e-21 6.94e-18 -0.55 -0.48 Dupuytren's disease; chr16:75355857 chr16:75379818~75381260:- LIHC cis rs977987 0.778 rs7206541 ENSG00000261783.1 RP11-252K23.2 -10.17 2.03e-21 7.18e-18 -0.55 -0.48 Dupuytren's disease; chr16:75402815 chr16:75379818~75381260:- LIHC cis rs977987 0.788 rs7184525 ENSG00000261783.1 RP11-252K23.2 -10.17 2.03e-21 7.18e-18 -0.55 -0.48 Dupuytren's disease; chr16:75403288 chr16:75379818~75381260:- LIHC cis rs977987 0.843 rs12443834 ENSG00000261783.1 RP11-252K23.2 -10.17 2.03e-21 7.18e-18 -0.55 -0.48 Dupuytren's disease; chr16:75404571 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs12924920 ENSG00000261783.1 RP11-252K23.2 -10.17 2.03e-21 7.18e-18 -0.55 -0.48 Dupuytren's disease; chr16:75406235 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs7204984 ENSG00000261783.1 RP11-252K23.2 -10.17 2.04e-21 7.2e-18 -0.57 -0.48 Dupuytren's disease; chr16:75441622 chr16:75379818~75381260:- LIHC cis rs977987 0.778 rs35214308 ENSG00000261783.1 RP11-252K23.2 -10.17 2.09e-21 7.38e-18 -0.57 -0.48 Dupuytren's disease; chr16:75442190 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs4888425 ENSG00000261783.1 RP11-252K23.2 -10.17 2.09e-21 7.38e-18 -0.57 -0.48 Dupuytren's disease; chr16:75442465 chr16:75379818~75381260:- LIHC cis rs977987 0.778 rs4888426 ENSG00000261783.1 RP11-252K23.2 -10.17 2.09e-21 7.38e-18 -0.57 -0.48 Dupuytren's disease; chr16:75442553 chr16:75379818~75381260:- LIHC cis rs2019137 0.539 rs4849181 ENSG00000189223.12 PAX8-AS1 -10.17 2.1e-21 7.4e-18 -0.65 -0.48 Lymphocyte counts; chr2:113234393 chr2:113211522~113276581:+ LIHC cis rs801193 0.569 rs35070132 ENSG00000226824.5 RP4-756H11.3 -10.17 2.11e-21 7.46e-18 -0.57 -0.48 Aortic root size; chr7:66773096 chr7:66654538~66669855:+ LIHC cis rs977987 0.806 rs2285225 ENSG00000261783.1 RP11-252K23.2 -10.17 2.13e-21 7.5e-18 -0.55 -0.48 Dupuytren's disease; chr16:75395354 chr16:75379818~75381260:- LIHC cis rs2739330 0.791 rs9612520 ENSG00000231271.1 AP000350.8 10.17 2.19e-21 7.71e-18 0.57 0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23949918~23954042:+ LIHC cis rs977987 0.836 rs7200053 ENSG00000261783.1 RP11-252K23.2 -10.16 2.23e-21 7.86e-18 -0.57 -0.48 Dupuytren's disease; chr16:75440720 chr16:75379818~75381260:- LIHC cis rs7208859 0.623 rs3752019 ENSG00000263531.1 RP13-753N3.1 10.16 2.26e-21 7.97e-18 0.87 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824687 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs73271869 ENSG00000263531.1 RP13-753N3.1 10.16 2.26e-21 7.97e-18 0.87 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30825203 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs73271872 ENSG00000263531.1 RP13-753N3.1 10.16 2.26e-21 7.97e-18 0.87 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30825210 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs56146117 ENSG00000263531.1 RP13-753N3.1 10.16 2.26e-21 7.97e-18 0.87 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30826307 chr17:30863921~30864940:- LIHC cis rs17826219 0.568 rs9907834 ENSG00000263531.1 RP13-753N3.1 10.16 2.26e-21 7.97e-18 0.87 0.48 Body mass index; chr17:30826995 chr17:30863921~30864940:- LIHC cis rs12022452 1 rs12048678 ENSG00000238287.1 RP11-656D10.3 -10.16 2.27e-21 7.98e-18 -0.7 -0.48 Age-related hearing impairment (SNP x SNP interaction); chr1:40482096 chr1:40493157~40508661:- LIHC cis rs10935480 1 rs10935480 ENSG00000239445.4 ST3GAL6-AS1 -10.16 2.33e-21 8.19e-18 -0.58 -0.48 Blood protein levels; chr3:98713142 chr3:98714330~98732651:- LIHC cis rs858239 0.704 rs199657 ENSG00000230658.1 KLHL7-AS1 -10.15 2.39e-21 8.41e-18 -0.64 -0.48 Cerebrospinal fluid biomarker levels; chr7:23297888 chr7:23101228~23105703:- LIHC cis rs858239 0.704 rs199656 ENSG00000230658.1 KLHL7-AS1 -10.15 2.39e-21 8.41e-18 -0.64 -0.48 Cerebrospinal fluid biomarker levels; chr7:23297996 chr7:23101228~23105703:- LIHC cis rs801193 0.569 rs13242290 ENSG00000226824.5 RP4-756H11.3 10.15 2.47e-21 8.68e-18 0.56 0.48 Aortic root size; chr7:66656898 chr7:66654538~66669855:+ LIHC cis rs7208859 0.673 rs11654331 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30837999 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs73277964 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30852183 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs11652409 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30855689 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9896095 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30860479 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs58920731 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30864728 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs73277984 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869115 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs73277986 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869179 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs12103588 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30870442 chr17:30863921~30864940:- LIHC cis rs7208859 0.614 rs9914534 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30875646 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs11658344 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30880727 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9900144 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881371 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs11656121 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887025 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11650973 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887027 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs56085216 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30890216 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs11650305 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902343 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs11654914 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902406 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9914271 ENSG00000263531.1 RP13-753N3.1 10.15 2.48e-21 8.68e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905607 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs28588622 ENSG00000263531.1 RP13-753N3.1 10.15 2.56e-21 8.95e-18 0.84 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30918681 chr17:30863921~30864940:- LIHC cis rs977987 0.778 rs7203157 ENSG00000261783.1 RP11-252K23.2 -10.14 2.58e-21 9e-18 -0.55 -0.48 Dupuytren's disease; chr16:75384022 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs4887824 ENSG00000261783.1 RP11-252K23.2 -10.14 2.59e-21 9.06e-18 -0.55 -0.48 Dupuytren's disease; chr16:75407715 chr16:75379818~75381260:- LIHC cis rs977987 0.931 rs8057084 ENSG00000261783.1 RP11-252K23.2 10.14 2.66e-21 9.26e-18 0.57 0.48 Dupuytren's disease; chr16:75458808 chr16:75379818~75381260:- LIHC cis rs875971 0.79 rs10257911 ENSG00000226824.5 RP4-756H11.3 10.14 2.69e-21 9.35e-18 0.57 0.48 Aortic root size; chr7:66278783 chr7:66654538~66669855:+ LIHC cis rs7208859 0.673 rs75142521 ENSG00000263531.1 RP13-753N3.1 10.14 2.69e-21 9.35e-18 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913519 chr17:30863921~30864940:- LIHC cis rs2739330 0.796 rs2154594 ENSG00000225282.1 AP000350.6 -10.14 2.69e-21 9.36e-18 -0.6 -0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23926900~23929574:+ LIHC cis rs2188561 1 rs2712207 ENSG00000241764.3 AC002467.7 10.13 2.93e-21 1.02e-17 0.66 0.48 Alcohol consumption; chr7:107711672 chr7:107742817~107744581:- LIHC cis rs977987 0.778 rs11149825 ENSG00000261783.1 RP11-252K23.2 -10.13 2.97e-21 1.03e-17 -0.55 -0.48 Dupuytren's disease; chr16:75400980 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs11864102 ENSG00000261783.1 RP11-252K23.2 -10.13 3e-21 1.04e-17 -0.55 -0.48 Dupuytren's disease; chr16:75408462 chr16:75379818~75381260:- LIHC cis rs977987 0.585 rs62059845 ENSG00000261783.1 RP11-252K23.2 -10.12 3.2e-21 1.11e-17 -0.55 -0.48 Dupuytren's disease; chr16:75396815 chr16:75379818~75381260:- LIHC cis rs977987 0.843 rs11149824 ENSG00000261783.1 RP11-252K23.2 -10.12 3.2e-21 1.11e-17 -0.55 -0.48 Dupuytren's disease; chr16:75397932 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs4887823 ENSG00000261783.1 RP11-252K23.2 -10.12 3.2e-21 1.11e-17 -0.55 -0.48 Dupuytren's disease; chr16:75399176 chr16:75379818~75381260:- LIHC cis rs7188445 1 rs7188445 ENSG00000261390.4 RP11-345M22.2 -10.12 3.23e-21 1.12e-17 -0.6 -0.48 Urate levels; chr16:79701090 chr16:79715232~79770563:- LIHC cis rs2739330 0.828 rs2330635 ENSG00000225282.1 AP000350.6 10.11 3.3e-21 1.14e-17 0.58 0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23926900~23929574:+ LIHC cis rs875971 0.83 rs12673450 ENSG00000226824.5 RP4-756H11.3 -10.11 3.42e-21 1.18e-17 -0.57 -0.48 Aortic root size; chr7:66544233 chr7:66654538~66669855:+ LIHC cis rs296381 0.561 rs62128816 ENSG00000259108.2 CTD-3098H1.2 10.11 3.47e-21 1.2e-17 0.88 0.48 Blood metabolite levels; chr19:47846773 chr19:47863483~47865341:- LIHC cis rs296381 0.561 rs62128818 ENSG00000259108.2 CTD-3098H1.2 10.11 3.47e-21 1.2e-17 0.88 0.48 Blood metabolite levels; chr19:47847835 chr19:47863483~47865341:- LIHC cis rs977987 0.806 rs2903033 ENSG00000261783.1 RP11-252K23.2 -10.1 3.6e-21 1.25e-17 -0.54 -0.48 Dupuytren's disease; chr16:75355708 chr16:75379818~75381260:- LIHC cis rs7208859 0.673 rs999797 ENSG00000263531.1 RP13-753N3.1 10.1 3.64e-21 1.26e-17 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832311 chr17:30863921~30864940:- LIHC cis rs977987 0.527 rs62059844 ENSG00000261783.1 RP11-252K23.2 -10.1 3.66e-21 1.26e-17 -0.55 -0.48 Dupuytren's disease; chr16:75395839 chr16:75379818~75381260:- LIHC cis rs296381 0.598 rs10426277 ENSG00000259108.2 CTD-3098H1.2 10.1 3.75e-21 1.3e-17 0.87 0.48 Blood metabolite levels; chr19:47850904 chr19:47863483~47865341:- LIHC cis rs2739330 0.828 rs5760107 ENSG00000225282.1 AP000350.6 10.09 3.84e-21 1.32e-17 0.58 0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23926900~23929574:+ LIHC cis rs977987 0.75 rs4888407 ENSG00000261783.1 RP11-252K23.2 -10.09 3.92e-21 1.35e-17 -0.55 -0.48 Dupuytren's disease; chr16:75398492 chr16:75379818~75381260:- LIHC cis rs875971 0.862 rs13226170 ENSG00000226824.5 RP4-756H11.3 -10.09 3.96e-21 1.36e-17 -0.56 -0.48 Aortic root size; chr7:66534311 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs2420611 ENSG00000226824.5 RP4-756H11.3 -10.09 3.96e-21 1.36e-17 -0.56 -0.48 Aortic root size; chr7:66534333 chr7:66654538~66669855:+ LIHC cis rs296381 0.598 rs76234461 ENSG00000259108.2 CTD-3098H1.2 10.09 4.03e-21 1.39e-17 0.87 0.48 Blood metabolite levels; chr19:47850161 chr19:47863483~47865341:- LIHC cis rs977987 0.836 rs7198873 ENSG00000261783.1 RP11-252K23.2 -10.09 4.1e-21 1.41e-17 -0.57 -0.48 Dupuytren's disease; chr16:75440856 chr16:75379818~75381260:- LIHC cis rs7208859 0.673 rs11656462 ENSG00000263531.1 RP13-753N3.1 10.08 4.18e-21 1.44e-17 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30833682 chr17:30863921~30864940:- LIHC cis rs1577917 0.958 rs34765423 ENSG00000203875.9 SNHG5 -10.08 4.19e-21 1.44e-17 -0.59 -0.48 Response to antipsychotic treatment; chr6:85774730 chr6:85660950~85678736:- LIHC cis rs875971 0.862 rs13232191 ENSG00000226824.5 RP4-756H11.3 -10.08 4.21e-21 1.44e-17 -0.56 -0.48 Aortic root size; chr7:66521661 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs35378740 ENSG00000226824.5 RP4-756H11.3 -10.08 4.21e-21 1.44e-17 -0.56 -0.48 Aortic root size; chr7:66522725 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs10950043 ENSG00000226824.5 RP4-756H11.3 -10.08 4.21e-21 1.44e-17 -0.56 -0.48 Aortic root size; chr7:66523623 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs17747530 ENSG00000226824.5 RP4-756H11.3 -10.08 4.21e-21 1.44e-17 -0.56 -0.48 Aortic root size; chr7:66529742 chr7:66654538~66669855:+ LIHC cis rs875971 0.767 rs61348003 ENSG00000226824.5 RP4-756H11.3 -10.08 4.21e-21 1.44e-17 -0.56 -0.48 Aortic root size; chr7:66540947 chr7:66654538~66669855:+ LIHC cis rs10935480 0.935 rs4857414 ENSG00000239445.4 ST3GAL6-AS1 -10.08 4.32e-21 1.48e-17 -0.57 -0.48 Blood protein levels; chr3:98713715 chr3:98714330~98732651:- LIHC cis rs1577917 0.917 rs12202170 ENSG00000203875.9 SNHG5 -10.08 4.32e-21 1.48e-17 -0.58 -0.48 Response to antipsychotic treatment; chr6:85880668 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs10455449 ENSG00000203875.9 SNHG5 -10.08 4.32e-21 1.48e-17 -0.58 -0.48 Response to antipsychotic treatment; chr6:85882508 chr6:85660950~85678736:- LIHC cis rs875971 0.861 rs801215 ENSG00000226824.5 RP4-756H11.3 10.08 4.37e-21 1.5e-17 0.56 0.48 Aortic root size; chr7:66546951 chr7:66654538~66669855:+ LIHC cis rs875971 0.756 rs2901210 ENSG00000226824.5 RP4-756H11.3 10.08 4.4e-21 1.51e-17 0.56 0.48 Aortic root size; chr7:66552518 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs13536 ENSG00000226824.5 RP4-756H11.3 10.08 4.4e-21 1.51e-17 0.56 0.48 Aortic root size; chr7:66554203 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs801209 ENSG00000226824.5 RP4-756H11.3 10.08 4.4e-21 1.51e-17 0.56 0.48 Aortic root size; chr7:66554403 chr7:66654538~66669855:+ LIHC cis rs1577917 1 rs1577917 ENSG00000203875.9 SNHG5 -10.07 4.53e-21 1.55e-17 -0.57 -0.48 Response to antipsychotic treatment; chr6:85982222 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs2324843 ENSG00000203875.9 SNHG5 -10.06 4.83e-21 1.65e-17 -0.58 -0.48 Response to antipsychotic treatment; chr6:85907783 chr6:85660950~85678736:- LIHC cis rs1799949 0.965 rs11080034 ENSG00000198496.9 NBR2 -10.06 5.11e-21 1.75e-17 -0.56 -0.48 Menopause (age at onset); chr17:43365646 chr17:43125610~43153671:+ LIHC cis rs977987 0.806 rs8050059 ENSG00000261783.1 RP11-252K23.2 -10.06 5.17e-21 1.77e-17 -0.55 -0.48 Dupuytren's disease; chr16:75354833 chr16:75379818~75381260:- LIHC cis rs7847628 0.765 rs10985024 ENSG00000226752.6 PSMD5-AS1 -10.05 5.42e-21 1.85e-17 -0.5 -0.48 Birth weight; chr9:120754534 chr9:120824828~120854385:+ LIHC cis rs2739330 0.828 rs5760099 ENSG00000225282.1 AP000350.6 10.04 5.79e-21 1.97e-17 0.58 0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23926900~23929574:+ LIHC cis rs1577917 0.917 rs35738006 ENSG00000203875.9 SNHG5 -10.04 5.83e-21 1.98e-17 -0.58 -0.48 Response to antipsychotic treatment; chr6:85936591 chr6:85660950~85678736:- LIHC cis rs977987 0.806 rs4888386 ENSG00000261783.1 RP11-252K23.2 -10.04 5.91e-21 2.01e-17 -0.55 -0.48 Dupuytren's disease; chr16:75355842 chr16:75379818~75381260:- LIHC cis rs1799949 0.931 rs9891977 ENSG00000198496.9 NBR2 -10.04 5.92e-21 2.01e-17 -0.55 -0.48 Menopause (age at onset); chr17:43360030 chr17:43125610~43153671:+ LIHC cis rs7208859 0.673 rs9915139 ENSG00000263531.1 RP13-753N3.1 10.04 5.94e-21 2.02e-17 0.85 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831497 chr17:30863921~30864940:- LIHC cis rs2739330 0.828 rs4820572 ENSG00000225282.1 AP000350.6 10.03 6.27e-21 2.13e-17 0.57 0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23926900~23929574:+ LIHC cis rs977987 0.806 rs8050769 ENSG00000261783.1 RP11-252K23.2 -10.03 6.32e-21 2.15e-17 -0.54 -0.48 Dupuytren's disease; chr16:75354536 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs6564252 ENSG00000261783.1 RP11-252K23.2 -10.03 6.32e-21 2.15e-17 -0.54 -0.48 Dupuytren's disease; chr16:75355042 chr16:75379818~75381260:- LIHC cis rs12022452 1 rs3738471 ENSG00000238287.1 RP11-656D10.3 -10.03 6.43e-21 2.18e-17 -0.68 -0.48 Age-related hearing impairment (SNP x SNP interaction); chr1:40540873 chr1:40493157~40508661:- LIHC cis rs977987 0.806 rs4888383 ENSG00000261783.1 RP11-252K23.2 -10.03 6.46e-21 2.19e-17 -0.54 -0.48 Dupuytren's disease; chr16:75352451 chr16:75379818~75381260:- LIHC cis rs7174755 0.962 rs4777034 ENSG00000260657.2 RP11-315D16.4 -10.03 6.48e-21 2.2e-17 -0.68 -0.48 Major depressive disorder; chr15:68309546 chr15:68267792~68277994:- LIHC cis rs1577917 1 rs12192992 ENSG00000203875.9 SNHG5 -10.02 6.66e-21 2.26e-17 -0.58 -0.48 Response to antipsychotic treatment; chr6:85900197 chr6:85660950~85678736:- LIHC cis rs977987 0.806 rs4888404 ENSG00000261783.1 RP11-252K23.2 -10.02 6.79e-21 2.3e-17 -0.54 -0.48 Dupuytren's disease; chr16:75394199 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs1549306 ENSG00000261783.1 RP11-252K23.2 -10.01 7.14e-21 2.41e-17 -0.55 -0.48 Dupuytren's disease; chr16:75381443 chr16:75379818~75381260:- LIHC cis rs296381 0.598 rs10408997 ENSG00000259108.2 CTD-3098H1.2 10.01 7.15e-21 2.42e-17 0.85 0.48 Blood metabolite levels; chr19:47852502 chr19:47863483~47865341:- LIHC cis rs977987 0.806 rs11643410 ENSG00000261783.1 RP11-252K23.2 -10.01 7.17e-21 2.42e-17 -0.54 -0.48 Dupuytren's disease; chr16:75394408 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs4888405 ENSG00000261783.1 RP11-252K23.2 -10.01 7.35e-21 2.48e-17 -0.55 -0.48 Dupuytren's disease; chr16:75394298 chr16:75379818~75381260:- LIHC cis rs977987 0.778 rs4888400 ENSG00000261783.1 RP11-252K23.2 -10 7.73e-21 2.61e-17 -0.54 -0.48 Dupuytren's disease; chr16:75391698 chr16:75379818~75381260:- LIHC cis rs7174755 0.923 rs898590 ENSG00000260657.2 RP11-315D16.4 -10 7.75e-21 2.61e-17 -0.69 -0.48 Major depressive disorder; chr15:68311837 chr15:68267792~68277994:- LIHC cis rs858239 0.965 rs156429 ENSG00000230658.1 KLHL7-AS1 10 7.99e-21 2.69e-17 0.57 0.48 Cerebrospinal fluid biomarker levels; chr7:23266401 chr7:23101228~23105703:- LIHC cis rs9828933 0.577 rs832193 ENSG00000280620.1 SCAANT1 -10 8.05e-21 2.71e-17 -0.68 -0.48 Type 2 diabetes; chr3:63868769 chr3:63911518~63911772:- LIHC cis rs1150668 0.835 rs203869 ENSG00000216901.1 AL022393.7 10 8.23e-21 2.77e-17 0.53 0.48 Pubertal anthropometrics; chr6:28073041 chr6:28176188~28176674:+ LIHC cis rs7174755 0.962 rs1020842 ENSG00000260657.2 RP11-315D16.4 -10 8.33e-21 2.81e-17 -0.68 -0.48 Major depressive disorder; chr15:68309840 chr15:68267792~68277994:- LIHC cis rs2739330 0.731 rs4822450 ENSG00000231271.1 AP000350.8 9.99 8.47e-21 2.85e-17 0.56 0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23949918~23954042:+ LIHC cis rs977987 0.806 rs12599361 ENSG00000261783.1 RP11-252K23.2 -9.99 8.52e-21 2.87e-17 -0.54 -0.48 Dupuytren's disease; chr16:75401075 chr16:75379818~75381260:- LIHC cis rs8062405 0.964 rs78613234 ENSG00000259982.1 CDC37P1 9.99 8.58e-21 2.89e-17 0.55 0.48 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828104 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs62036624 ENSG00000259982.1 CDC37P1 9.99 8.58e-21 2.89e-17 0.55 0.48 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828609 chr16:28700294~28701540:- LIHC cis rs2739330 0.828 rs4822451 ENSG00000225282.1 AP000350.6 9.99 8.65e-21 2.91e-17 0.58 0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23926900~23929574:+ LIHC cis rs858239 1 rs858239 ENSG00000230658.1 KLHL7-AS1 9.99 8.75e-21 2.94e-17 0.58 0.48 Cerebrospinal fluid biomarker levels; chr7:23246696 chr7:23101228~23105703:- LIHC cis rs7104764 0.719 rs3782116 ENSG00000277290.1 RP11-326C3.16 -9.99 8.85e-21 2.98e-17 -0.41 -0.48 Menarche (age at onset); chr11:223119 chr11:243099~243483:- LIHC cis rs172166 0.516 rs1225618 ENSG00000216901.1 AL022393.7 9.99 8.88e-21 2.99e-17 0.53 0.48 Cardiac Troponin-T levels; chr6:28161935 chr6:28176188~28176674:+ LIHC cis rs7208859 0.623 rs55724095 ENSG00000263531.1 RP13-753N3.1 9.99 8.91e-21 3e-17 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30826040 chr17:30863921~30864940:- LIHC cis rs17826219 0.568 rs9903854 ENSG00000263531.1 RP13-753N3.1 9.99 8.91e-21 3e-17 0.86 0.48 Body mass index; chr17:30826980 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs80355557 ENSG00000263531.1 RP13-753N3.1 9.99 8.91e-21 3e-17 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827403 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9911173 ENSG00000263531.1 RP13-753N3.1 9.99 8.91e-21 3e-17 0.86 0.48 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827732 chr17:30863921~30864940:- LIHC cis rs8062405 1 rs8062405 ENSG00000259982.1 CDC37P1 -9.98 9.55e-21 3.21e-17 -0.54 -0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28826585 chr16:28700294~28701540:- LIHC cis rs9660180 0.967 rs9660106 ENSG00000231050.1 RP1-140A9.1 9.98 9.59e-21 3.22e-17 0.44 0.47 Body mass index; chr1:1866508 chr1:1891471~1892658:+ LIHC cis rs977987 0.806 rs4638613 ENSG00000261783.1 RP11-252K23.2 -9.97 9.82e-21 3.29e-17 -0.54 -0.47 Dupuytren's disease; chr16:75391655 chr16:75379818~75381260:- LIHC cis rs12022452 0.73 rs2297755 ENSG00000238287.1 RP11-656D10.3 -9.97 9.89e-21 3.32e-17 -0.67 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr1:40547343 chr1:40493157~40508661:- LIHC cis rs2739330 0.789 rs5760109 ENSG00000225282.1 AP000350.6 9.97 9.95e-21 3.34e-17 0.58 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23926900~23929574:+ LIHC cis rs12022452 1 rs75936657 ENSG00000238287.1 RP11-656D10.3 -9.96 1.09e-20 3.64e-17 -0.68 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr1:40536017 chr1:40493157~40508661:- LIHC cis rs8062405 1 rs62037365 ENSG00000259982.1 CDC37P1 9.96 1.13e-20 3.77e-17 0.55 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28857641 chr16:28700294~28701540:- LIHC cis rs1577917 0.959 rs16876540 ENSG00000203875.9 SNHG5 -9.94 1.24e-20 4.14e-17 -0.58 -0.47 Response to antipsychotic treatment; chr6:85902801 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs35761942 ENSG00000203875.9 SNHG5 -9.94 1.24e-20 4.14e-17 -0.58 -0.47 Response to antipsychotic treatment; chr6:85919786 chr6:85660950~85678736:- LIHC cis rs1930961 0.702 rs8141065 ENSG00000272977.1 CTA-390C10.10 9.94 1.29e-20 4.3e-17 0.8 0.47 Bipolar disorder with mood-incongruent psychosis; chr22:25489221 chr22:25476218~25479971:+ LIHC cis rs507080 0.501 rs494459 ENSG00000255422.1 AP002954.4 9.93 1.34e-20 4.46e-17 0.53 0.47 Serum metabolite levels; chr11:118703966 chr11:118704607~118750263:+ LIHC cis rs858239 0.931 rs9690941 ENSG00000230658.1 KLHL7-AS1 9.93 1.37e-20 4.57e-17 0.6 0.47 Cerebrospinal fluid biomarker levels; chr7:23242134 chr7:23101228~23105703:- LIHC cis rs9828933 0.577 rs704374 ENSG00000280620.1 SCAANT1 -9.93 1.39e-20 4.62e-17 -0.67 -0.47 Type 2 diabetes; chr3:63880271 chr3:63911518~63911772:- LIHC cis rs7208859 0.673 rs11655623 ENSG00000263531.1 RP13-753N3.1 9.93 1.4e-20 4.65e-17 0.84 0.47 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30835155 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs73277960 ENSG00000263531.1 RP13-753N3.1 9.93 1.4e-20 4.65e-17 0.84 0.47 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30850423 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs73263788 ENSG00000263531.1 RP13-753N3.1 9.93 1.4e-20 4.65e-17 0.84 0.47 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889472 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs12949860 ENSG00000263531.1 RP13-753N3.1 9.93 1.4e-20 4.65e-17 0.84 0.47 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896014 chr17:30863921~30864940:- LIHC cis rs8062405 1 rs55991577 ENSG00000259982.1 CDC37P1 9.93 1.42e-20 4.71e-17 0.55 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28831704 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs56358680 ENSG00000259982.1 CDC37P1 9.93 1.42e-20 4.71e-17 0.55 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28831797 chr16:28700294~28701540:- LIHC cis rs2739330 0.828 rs4820572 ENSG00000231271.1 AP000350.8 9.91 1.6e-20 5.28e-17 0.54 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23949918~23954042:+ LIHC cis rs8062405 1 rs62036626 ENSG00000259982.1 CDC37P1 9.91 1.62e-20 5.36e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28832963 chr16:28700294~28701540:- LIHC cis rs1799949 0.965 rs799916 ENSG00000198496.9 NBR2 9.91 1.63e-20 5.39e-17 0.51 0.47 Menopause (age at onset); chr17:43091173 chr17:43125610~43153671:+ LIHC cis rs17711722 0.522 rs6957759 ENSG00000164669.11 INTS4P1 -9.91 1.64e-20 5.43e-17 -0.6 -0.47 Calcium levels; chr7:65806798 chr7:65141225~65234216:+ LIHC cis rs977987 0.843 rs62062564 ENSG00000261783.1 RP11-252K23.2 -9.91 1.65e-20 5.47e-17 -0.55 -0.47 Dupuytren's disease; chr16:75408724 chr16:75379818~75381260:- LIHC cis rs977987 0.843 rs62062568 ENSG00000261783.1 RP11-252K23.2 -9.91 1.65e-20 5.47e-17 -0.55 -0.47 Dupuytren's disease; chr16:75411426 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs4993969 ENSG00000261783.1 RP11-252K23.2 -9.91 1.66e-20 5.49e-17 -0.54 -0.47 Dupuytren's disease; chr16:75377623 chr16:75379818~75381260:- LIHC cis rs17711722 0.522 rs62469933 ENSG00000164669.11 INTS4P1 -9.91 1.68e-20 5.54e-17 -0.6 -0.47 Calcium levels; chr7:65800652 chr7:65141225~65234216:+ LIHC cis rs2260433 0.503 rs10750652 ENSG00000281655.1 RP11-817J15.3 9.9 1.76e-20 5.81e-17 0.61 0.47 Cleft palate; chr11:102646775 chr11:102681310~102683913:+ LIHC cis rs977987 0.815 rs1364078 ENSG00000261783.1 RP11-252K23.2 -9.9 1.81e-20 5.96e-17 -0.55 -0.47 Dupuytren's disease; chr16:75362983 chr16:75379818~75381260:- LIHC cis rs977987 0.815 rs11646677 ENSG00000261783.1 RP11-252K23.2 -9.9 1.81e-20 5.96e-17 -0.55 -0.47 Dupuytren's disease; chr16:75375083 chr16:75379818~75381260:- LIHC cis rs977987 0.843 rs8056080 ENSG00000261783.1 RP11-252K23.2 -9.9 1.81e-20 5.96e-17 -0.55 -0.47 Dupuytren's disease; chr16:75376900 chr16:75379818~75381260:- LIHC cis rs977987 0.843 rs2059256 ENSG00000261783.1 RP11-252K23.2 -9.89 1.83e-20 6.03e-17 -0.55 -0.47 Dupuytren's disease; chr16:75361937 chr16:75379818~75381260:- LIHC cis rs7174755 0.923 rs9672310 ENSG00000260657.2 RP11-315D16.4 9.89 1.83e-20 6.03e-17 0.69 0.47 Major depressive disorder; chr15:68306578 chr15:68267792~68277994:- LIHC cis rs977987 0.778 rs11862719 ENSG00000261783.1 RP11-252K23.2 -9.89 1.85e-20 6.09e-17 -0.54 -0.47 Dupuytren's disease; chr16:75397810 chr16:75379818~75381260:- LIHC cis rs977987 0.806 rs11862582 ENSG00000261783.1 RP11-252K23.2 -9.89 1.9e-20 6.26e-17 -0.54 -0.47 Dupuytren's disease; chr16:75397397 chr16:75379818~75381260:- LIHC cis rs5758659 0.512 rs4822072 ENSG00000237037.8 NDUFA6-AS1 9.89 1.95e-20 6.41e-17 0.57 0.47 Cognitive function; chr22:41964829 chr22:42090931~42137742:+ LIHC cis rs858239 0.799 rs10279941 ENSG00000230658.1 KLHL7-AS1 9.89 1.96e-20 6.46e-17 0.62 0.47 Cerebrospinal fluid biomarker levels; chr7:23330889 chr7:23101228~23105703:- LIHC cis rs8062405 1 rs62036657 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28833044 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs12444171 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28833930 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs56404918 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835519 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs55719896 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835545 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs55830740 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835828 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs3088215 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28842675 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs28403629 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28843448 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs61737565 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28844201 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs4788099 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28844406 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs9972693 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28848481 chr16:28700294~28701540:- LIHC cis rs8062405 0.964 rs9972768 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28850413 chr16:28700294~28701540:- LIHC cis rs8062405 0.965 rs62037363 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28853721 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs7205323 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28854571 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs4788101 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28856483 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs62037364 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28857374 chr16:28700294~28701540:- LIHC cis rs8062405 0.929 rs11150609 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859275 chr16:28700294~28701540:- LIHC cis rs8062405 0.737 rs11861132 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28860539 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs11861174 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28860668 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs4788102 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28862077 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs62037367 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863226 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs7198606 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863801 chr16:28700294~28701540:- LIHC cis rs8062405 0.929 rs11864750 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863883 chr16:28700294~28701540:- LIHC cis rs8062405 0.964 rs7193733 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28864161 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs8055982 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28869881 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs7498665 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28871920 chr16:28700294~28701540:- LIHC cis rs8062405 0.964 rs11864107 ENSG00000259982.1 CDC37P1 9.88 1.99e-20 6.53e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28874610 chr16:28700294~28701540:- LIHC cis rs977987 0.806 rs11862095 ENSG00000261783.1 RP11-252K23.2 -9.88 2.02e-20 6.6e-17 -0.54 -0.47 Dupuytren's disease; chr16:75351520 chr16:75379818~75381260:- LIHC cis rs2455601 0.786 rs2568068 ENSG00000254860.4 TMEM9B-AS1 9.88 2.02e-20 6.62e-17 0.55 0.47 Schizophrenia; chr11:8956283 chr11:8964675~8977527:+ LIHC cis rs172166 0.516 rs2791333 ENSG00000216901.1 AL022393.7 9.88 2.03e-20 6.64e-17 0.53 0.47 Cardiac Troponin-T levels; chr6:28143336 chr6:28176188~28176674:+ LIHC cis rs8062405 1 rs62037371 ENSG00000259982.1 CDC37P1 9.88 2.04e-20 6.67e-17 0.55 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28878810 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs8055138 ENSG00000259982.1 CDC37P1 9.88 2.04e-20 6.67e-17 0.55 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28880144 chr16:28700294~28701540:- LIHC cis rs2882667 0.964 rs2288824 ENSG00000253404.1 AC034243.1 9.88 2.09e-20 6.84e-17 0.67 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:138962707 chr5:138744434~138753309:- LIHC cis rs9660180 0.967 rs11260623 ENSG00000231050.1 RP1-140A9.1 9.88 2.11e-20 6.89e-17 0.44 0.47 Body mass index; chr1:1850017 chr1:1891471~1892658:+ LIHC cis rs2739330 0.828 rs2330635 ENSG00000231271.1 AP000350.8 9.87 2.18e-20 7.11e-17 0.55 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23949918~23954042:+ LIHC cis rs977987 0.806 rs766521 ENSG00000261783.1 RP11-252K23.2 9.87 2.2e-20 7.18e-17 0.53 0.47 Dupuytren's disease; chr16:75390256 chr16:75379818~75381260:- LIHC cis rs9660180 0.967 rs6603802 ENSG00000231050.1 RP1-140A9.1 9.87 2.21e-20 7.2e-17 0.44 0.47 Body mass index; chr1:1881082 chr1:1891471~1892658:+ LIHC cis rs9828933 1 rs1060897 ENSG00000280620.1 SCAANT1 -9.87 2.22e-20 7.24e-17 -0.66 -0.47 Type 2 diabetes; chr3:64012196 chr3:63911518~63911772:- LIHC cis rs801193 0.569 rs10950050 ENSG00000226824.5 RP4-756H11.3 -9.87 2.24e-20 7.29e-17 -0.55 -0.47 Aortic root size; chr7:66774601 chr7:66654538~66669855:+ LIHC cis rs977987 0.778 rs62059846 ENSG00000261783.1 RP11-252K23.2 -9.87 2.24e-20 7.31e-17 -0.54 -0.47 Dupuytren's disease; chr16:75396911 chr16:75379818~75381260:- LIHC cis rs8062405 0.964 rs11860513 ENSG00000259982.1 CDC37P1 9.87 2.27e-20 7.4e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814099 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs1987472 ENSG00000259982.1 CDC37P1 9.87 2.27e-20 7.4e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814456 chr16:28700294~28701540:- LIHC cis rs8062405 0.895 rs56186137 ENSG00000259982.1 CDC37P1 9.87 2.27e-20 7.4e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814632 chr16:28700294~28701540:- LIHC cis rs858239 0.932 rs1624451 ENSG00000230658.1 KLHL7-AS1 -9.87 2.28e-20 7.43e-17 -0.62 -0.47 Cerebrospinal fluid biomarker levels; chr7:23222816 chr7:23101228~23105703:- LIHC cis rs17711722 0.522 rs4642526 ENSG00000164669.11 INTS4P1 -9.86 2.3e-20 7.49e-17 -0.59 -0.47 Calcium levels; chr7:65751755 chr7:65141225~65234216:+ LIHC cis rs150992 1 rs150992 ENSG00000248489.1 CTD-2007H13.3 9.86 2.31e-20 7.53e-17 0.7 0.47 Body mass index; chr5:98939493 chr5:98929171~98995013:+ LIHC cis rs507080 0.922 rs7114458 ENSG00000255422.1 AP002954.4 -9.86 2.33e-20 7.57e-17 -0.56 -0.47 Serum metabolite levels; chr11:118695466 chr11:118704607~118750263:+ LIHC cis rs507080 0.922 rs7114216 ENSG00000255422.1 AP002954.4 -9.86 2.33e-20 7.57e-17 -0.56 -0.47 Serum metabolite levels; chr11:118695525 chr11:118704607~118750263:+ LIHC cis rs875971 0.862 rs10256544 ENSG00000226824.5 RP4-756H11.3 -9.86 2.39e-20 7.78e-17 -0.57 -0.47 Aortic root size; chr7:66210141 chr7:66654538~66669855:+ LIHC cis rs8062405 0.679 rs72793818 ENSG00000259982.1 CDC37P1 9.86 2.42e-20 7.86e-17 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28881816 chr16:28700294~28701540:- LIHC cis rs1577917 1 rs13196930 ENSG00000203875.9 SNHG5 -9.86 2.45e-20 7.97e-17 -0.58 -0.47 Response to antipsychotic treatment; chr6:85942527 chr6:85660950~85678736:- LIHC cis rs875971 0.862 rs9791712 ENSG00000226824.5 RP4-756H11.3 9.86 2.47e-20 8e-17 0.56 0.47 Aortic root size; chr7:66640176 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs9791713 ENSG00000226824.5 RP4-756H11.3 9.86 2.47e-20 8e-17 0.56 0.47 Aortic root size; chr7:66640211 chr7:66654538~66669855:+ LIHC cis rs858239 0.863 rs466225 ENSG00000230658.1 KLHL7-AS1 9.85 2.54e-20 8.24e-17 0.61 0.47 Cerebrospinal fluid biomarker levels; chr7:23292784 chr7:23101228~23105703:- LIHC cis rs875971 0.825 rs28480509 ENSG00000226824.5 RP4-756H11.3 9.85 2.56e-20 8.31e-17 0.55 0.47 Aortic root size; chr7:66634237 chr7:66654538~66669855:+ LIHC cis rs9660180 0.934 rs12729990 ENSG00000231050.1 RP1-140A9.1 9.85 2.65e-20 8.58e-17 0.44 0.47 Body mass index; chr1:1880596 chr1:1891471~1892658:+ LIHC cis rs9660180 0.837 rs915292 ENSG00000231050.1 RP1-140A9.1 9.85 2.65e-20 8.58e-17 0.44 0.47 Body mass index; chr1:1860718 chr1:1891471~1892658:+ LIHC cis rs17711722 0.565 rs4717276 ENSG00000164669.11 INTS4P1 -9.84 2.69e-20 8.7e-17 -0.59 -0.47 Calcium levels; chr7:65829754 chr7:65141225~65234216:+ LIHC cis rs9660180 0.967 rs6687065 ENSG00000231050.1 RP1-140A9.1 9.84 2.82e-20 9.12e-17 0.44 0.47 Body mass index; chr1:1847030 chr1:1891471~1892658:+ LIHC cis rs2739330 0.796 rs1006771 ENSG00000225282.1 AP000350.6 9.83 2.9e-20 9.37e-17 0.55 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23926900~23929574:+ LIHC cis rs1799949 1 rs8176318 ENSG00000198496.9 NBR2 -9.83 2.95e-20 9.53e-17 -0.51 -0.47 Menopause (age at onset); chr17:43045257 chr17:43125610~43153671:+ LIHC cis rs10935480 0.904 rs13065271 ENSG00000239445.4 ST3GAL6-AS1 -9.83 3e-20 9.7e-17 -0.55 -0.47 Blood protein levels; chr3:98715649 chr3:98714330~98732651:- LIHC cis rs8062405 1 rs3888190 ENSG00000259982.1 CDC37P1 9.83 3.12e-20 1.01e-16 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28878165 chr16:28700294~28701540:- LIHC cis rs7104764 0.778 rs7930823 ENSG00000277290.1 RP11-326C3.16 9.82 3.13e-20 1.01e-16 0.39 0.47 Menarche (age at onset); chr11:206767 chr11:243099~243483:- LIHC cis rs7847628 0.666 rs2031974 ENSG00000226752.6 PSMD5-AS1 -9.82 3.2e-20 1.03e-16 -0.49 -0.47 Birth weight; chr9:120765243 chr9:120824828~120854385:+ LIHC cis rs7617773 0.817 rs6796490 ENSG00000229759.1 MRPS18AP1 9.82 3.21e-20 1.03e-16 0.5 0.47 Coronary artery disease; chr3:48195614 chr3:48256350~48256938:- LIHC cis rs7208859 0.623 rs56325146 ENSG00000263531.1 RP13-753N3.1 9.82 3.21e-20 1.04e-16 0.84 0.47 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824006 chr17:30863921~30864940:- LIHC cis rs12439619 0.846 rs28470877 ENSG00000278603.1 RP13-608F4.5 9.82 3.21e-20 1.04e-16 0.91 0.47 Intelligence (multi-trait analysis); chr15:82245797 chr15:82472203~82472426:+ LIHC cis rs977987 0.872 rs7206665 ENSG00000261783.1 RP11-252K23.2 -9.82 3.22e-20 1.04e-16 -0.57 -0.47 Dupuytren's disease; chr16:75441389 chr16:75379818~75381260:- LIHC cis rs2739330 0.828 rs5760107 ENSG00000231271.1 AP000350.8 9.82 3.33e-20 1.07e-16 0.55 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23949918~23954042:+ LIHC cis rs2739330 0.796 rs5760097 ENSG00000225282.1 AP000350.6 9.82 3.34e-20 1.07e-16 0.57 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23926900~23929574:+ LIHC cis rs1577917 0.958 rs11755642 ENSG00000203875.9 SNHG5 -9.82 3.35e-20 1.08e-16 -0.56 -0.47 Response to antipsychotic treatment; chr6:85740348 chr6:85660950~85678736:- LIHC cis rs2739330 0.892 rs5751776 ENSG00000231271.1 AP000350.8 9.82 3.37e-20 1.08e-16 0.54 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23949918~23954042:+ LIHC cis rs8062405 1 rs4788095 ENSG00000259982.1 CDC37P1 9.81 3.42e-20 1.1e-16 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28820038 chr16:28700294~28701540:- LIHC cis rs8062405 0.964 rs72793809 ENSG00000259982.1 CDC37P1 9.81 3.42e-20 1.1e-16 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821061 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs62036620 ENSG00000259982.1 CDC37P1 9.81 3.42e-20 1.1e-16 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821776 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs62036621 ENSG00000259982.1 CDC37P1 9.81 3.42e-20 1.1e-16 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821978 chr16:28700294~28701540:- LIHC cis rs9326248 0.569 rs4938315 ENSG00000254851.1 RP11-109L13.1 -9.81 3.5e-20 1.13e-16 -0.63 -0.47 Blood protein levels; chr11:116860489 chr11:117135528~117138582:+ LIHC cis rs2455601 0.786 rs2568070 ENSG00000254860.4 TMEM9B-AS1 9.81 3.57e-20 1.15e-16 0.55 0.47 Schizophrenia; chr11:8955346 chr11:8964675~8977527:+ LIHC cis rs1577917 0.958 rs13219504 ENSG00000203875.9 SNHG5 -9.81 3.58e-20 1.15e-16 -0.58 -0.47 Response to antipsychotic treatment; chr6:85847199 chr6:85660950~85678736:- LIHC cis rs2739330 0.789 rs5760109 ENSG00000231271.1 AP000350.8 9.8 3.68e-20 1.18e-16 0.55 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23949918~23954042:+ LIHC cis rs2739330 0.796 rs5760106 ENSG00000225282.1 AP000350.6 -9.8 3.72e-20 1.19e-16 -0.55 -0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23926900~23929574:+ LIHC cis rs858239 0.899 rs28458177 ENSG00000230658.1 KLHL7-AS1 9.8 3.78e-20 1.21e-16 0.63 0.47 Cerebrospinal fluid biomarker levels; chr7:23255253 chr7:23101228~23105703:- LIHC cis rs9828933 0.752 rs13434089 ENSG00000280620.1 SCAANT1 -9.8 3.85e-20 1.23e-16 -0.67 -0.47 Type 2 diabetes; chr3:63962890 chr3:63911518~63911772:- LIHC cis rs977987 0.806 rs7188231 ENSG00000261783.1 RP11-252K23.2 -9.8 3.86e-20 1.24e-16 -0.55 -0.47 Dupuytren's disease; chr16:75402663 chr16:75379818~75381260:- LIHC cis rs977987 0.843 rs12443904 ENSG00000261783.1 RP11-252K23.2 -9.8 3.86e-20 1.24e-16 -0.55 -0.47 Dupuytren's disease; chr16:75404872 chr16:75379818~75381260:- LIHC cis rs977987 0.843 rs35737321 ENSG00000261783.1 RP11-252K23.2 -9.8 3.86e-20 1.24e-16 -0.55 -0.47 Dupuytren's disease; chr16:75405287 chr16:75379818~75381260:- LIHC cis rs7617773 0.817 rs6806112 ENSG00000229759.1 MRPS18AP1 9.8 3.94e-20 1.26e-16 0.5 0.47 Coronary artery disease; chr3:48234587 chr3:48256350~48256938:- LIHC cis rs7617773 0.817 rs11720622 ENSG00000229759.1 MRPS18AP1 9.79 3.97e-20 1.27e-16 0.5 0.47 Coronary artery disease; chr3:48205189 chr3:48256350~48256938:- LIHC cis rs2260433 0.503 rs6590981 ENSG00000281655.1 RP11-817J15.3 9.79 4.04e-20 1.29e-16 0.6 0.47 Cleft palate; chr11:102643876 chr11:102681310~102683913:+ LIHC cis rs2260433 0.503 rs4631843 ENSG00000281655.1 RP11-817J15.3 9.79 4.04e-20 1.29e-16 0.6 0.47 Cleft palate; chr11:102644465 chr11:102681310~102683913:+ LIHC cis rs2260433 0.503 rs10750649 ENSG00000281655.1 RP11-817J15.3 9.79 4.04e-20 1.29e-16 0.6 0.47 Cleft palate; chr11:102645284 chr11:102681310~102683913:+ LIHC cis rs2260433 0.503 rs10791582 ENSG00000281655.1 RP11-817J15.3 9.79 4.04e-20 1.29e-16 0.6 0.47 Cleft palate; chr11:102645453 chr11:102681310~102683913:+ LIHC cis rs2260433 0.503 rs10895333 ENSG00000281655.1 RP11-817J15.3 9.79 4.04e-20 1.29e-16 0.6 0.47 Cleft palate; chr11:102645949 chr11:102681310~102683913:+ LIHC cis rs2260433 0.503 rs10791584 ENSG00000281655.1 RP11-817J15.3 9.79 4.04e-20 1.29e-16 0.6 0.47 Cleft palate; chr11:102646272 chr11:102681310~102683913:+ LIHC cis rs2260433 0.503 rs10791585 ENSG00000281655.1 RP11-817J15.3 9.79 4.04e-20 1.29e-16 0.6 0.47 Cleft palate; chr11:102646454 chr11:102681310~102683913:+ LIHC cis rs2260433 0.503 rs10895335 ENSG00000281655.1 RP11-817J15.3 9.79 4.04e-20 1.29e-16 0.6 0.47 Cleft palate; chr11:102646565 chr11:102681310~102683913:+ LIHC cis rs2260433 0.535 rs10791587 ENSG00000281655.1 RP11-817J15.3 9.79 4.04e-20 1.29e-16 0.6 0.47 Cleft palate; chr11:102646902 chr11:102681310~102683913:+ LIHC cis rs2260433 0.503 rs10736624 ENSG00000281655.1 RP11-817J15.3 9.79 4.04e-20 1.29e-16 0.6 0.47 Cleft palate; chr11:102647066 chr11:102681310~102683913:+ LIHC cis rs4713118 0.505 rs156740 ENSG00000216901.1 AL022393.7 9.79 4.06e-20 1.29e-16 0.54 0.47 Parkinson's disease; chr6:27992657 chr6:28176188~28176674:+ LIHC cis rs1577917 0.958 rs10944147 ENSG00000203875.9 SNHG5 -9.78 4.4e-20 1.4e-16 -0.57 -0.47 Response to antipsychotic treatment; chr6:85841068 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs13201730 ENSG00000203875.9 SNHG5 -9.78 4.4e-20 1.4e-16 -0.57 -0.47 Response to antipsychotic treatment; chr6:85846929 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12196377 ENSG00000203875.9 SNHG5 -9.78 4.4e-20 1.4e-16 -0.57 -0.47 Response to antipsychotic treatment; chr6:85857057 chr6:85660950~85678736:- LIHC cis rs977987 0.806 rs12444589 ENSG00000261783.1 RP11-252K23.2 9.78 4.45e-20 1.42e-16 0.53 0.47 Dupuytren's disease; chr16:75420506 chr16:75379818~75381260:- LIHC cis rs858239 1 rs199347 ENSG00000230658.1 KLHL7-AS1 9.78 4.49e-20 1.43e-16 0.56 0.47 Cerebrospinal fluid biomarker levels; chr7:23254127 chr7:23101228~23105703:- LIHC cis rs172166 0.516 rs1225710 ENSG00000216901.1 AL022393.7 -9.78 4.55e-20 1.45e-16 -0.53 -0.47 Cardiac Troponin-T levels; chr6:28132862 chr6:28176188~28176674:+ LIHC cis rs1577917 1 rs955227 ENSG00000203875.9 SNHG5 -9.77 4.61e-20 1.47e-16 -0.58 -0.47 Response to antipsychotic treatment; chr6:85941314 chr6:85660950~85678736:- LIHC cis rs296381 0.561 rs58784223 ENSG00000259108.2 CTD-3098H1.2 9.77 4.8e-20 1.52e-16 0.82 0.47 Blood metabolite levels; chr19:47847236 chr19:47863483~47865341:- LIHC cis rs858239 0.676 rs274032 ENSG00000230658.1 KLHL7-AS1 9.76 5.03e-20 1.6e-16 0.58 0.47 Cerebrospinal fluid biomarker levels; chr7:23334940 chr7:23101228~23105703:- LIHC cis rs507080 0.922 rs533646 ENSG00000255422.1 AP002954.4 -9.76 5.06e-20 1.61e-16 -0.55 -0.47 Serum metabolite levels; chr11:118696037 chr11:118704607~118750263:+ LIHC cis rs8062405 1 rs4451951 ENSG00000259982.1 CDC37P1 9.76 5.16e-20 1.64e-16 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28824884 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs62036617 ENSG00000259982.1 CDC37P1 9.76 5.2e-20 1.65e-16 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28816177 chr16:28700294~28701540:- LIHC cis rs2260433 0.503 rs4433535 ENSG00000281655.1 RP11-817J15.3 9.76 5.25e-20 1.67e-16 0.6 0.47 Cleft palate; chr11:102644130 chr11:102681310~102683913:+ LIHC cis rs977987 0.843 rs11149820 ENSG00000261783.1 RP11-252K23.2 -9.75 5.41e-20 1.71e-16 -0.54 -0.47 Dupuytren's disease; chr16:75388862 chr16:75379818~75381260:- LIHC cis rs1577917 0.916 rs12198730 ENSG00000203875.9 SNHG5 -9.75 5.44e-20 1.73e-16 -0.57 -0.47 Response to antipsychotic treatment; chr6:85845420 chr6:85660950~85678736:- LIHC cis rs875971 0.862 rs1860469 ENSG00000226824.5 RP4-756H11.3 9.75 5.52e-20 1.75e-16 0.55 0.47 Aortic root size; chr7:66641888 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs4718383 ENSG00000226824.5 RP4-756H11.3 9.75 5.52e-20 1.75e-16 0.55 0.47 Aortic root size; chr7:66643422 chr7:66654538~66669855:+ LIHC cis rs172166 0.538 rs1150686 ENSG00000216901.1 AL022393.7 9.75 5.56e-20 1.76e-16 0.52 0.47 Cardiac Troponin-T levels; chr6:28193493 chr6:28176188~28176674:+ LIHC cis rs1150688 1 rs1150688 ENSG00000216901.1 AL022393.7 9.75 5.56e-20 1.76e-16 0.52 0.47 Autism spectrum disorder or schizophrenia; chr6:28195002 chr6:28176188~28176674:+ LIHC cis rs8062405 0.965 rs56040780 ENSG00000259982.1 CDC37P1 9.75 5.61e-20 1.78e-16 0.54 0.47 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28850560 chr16:28700294~28701540:- LIHC cis rs1577917 1 rs10498958 ENSG00000203875.9 SNHG5 9.75 5.77e-20 1.83e-16 0.57 0.47 Response to antipsychotic treatment; chr6:85939987 chr6:85660950~85678736:- LIHC cis rs977987 0.843 rs60730309 ENSG00000261783.1 RP11-252K23.2 -9.74 5.83e-20 1.84e-16 -0.54 -0.47 Dupuytren's disease; chr16:75397871 chr16:75379818~75381260:- LIHC cis rs977987 0.75 rs4888406 ENSG00000261783.1 RP11-252K23.2 -9.74 5.83e-20 1.84e-16 -0.54 -0.47 Dupuytren's disease; chr16:75398436 chr16:75379818~75381260:- LIHC cis rs977987 0.843 rs10514396 ENSG00000261783.1 RP11-252K23.2 -9.74 5.86e-20 1.85e-16 -0.54 -0.47 Dupuytren's disease; chr16:75389005 chr16:75379818~75381260:- LIHC cis rs1577917 0.958 rs36053156 ENSG00000203875.9 SNHG5 -9.74 5.87e-20 1.86e-16 -0.57 -0.47 Response to antipsychotic treatment; chr6:85865791 chr6:85660950~85678736:- LIHC cis rs172166 0.56 rs203878 ENSG00000216901.1 AL022393.7 9.74 5.9e-20 1.86e-16 0.52 0.47 Cardiac Troponin-T levels; chr6:28081218 chr6:28176188~28176674:+ LIHC cis rs977987 0.836 rs7199062 ENSG00000261783.1 RP11-252K23.2 -9.74 5.93e-20 1.87e-16 -0.56 -0.47 Dupuytren's disease; chr16:75440929 chr16:75379818~75381260:- LIHC cis rs858239 0.738 rs7807879 ENSG00000230658.1 KLHL7-AS1 9.74 6e-20 1.89e-16 0.62 0.47 Cerebrospinal fluid biomarker levels; chr7:23220969 chr7:23101228~23105703:- LIHC cis rs1577917 0.958 rs12213331 ENSG00000203875.9 SNHG5 -9.74 6.07e-20 1.92e-16 -0.56 -0.47 Response to antipsychotic treatment; chr6:85795079 chr6:85660950~85678736:- LIHC cis rs494459 0.838 rs1784543 ENSG00000255239.1 AP002954.6 9.74 6.12e-20 1.93e-16 0.54 0.47 Height; chr11:118760944 chr11:118688039~118690600:- LIHC cis rs858239 0.899 rs858271 ENSG00000230658.1 KLHL7-AS1 9.74 6.2e-20 1.95e-16 0.57 0.47 Cerebrospinal fluid biomarker levels; chr7:23238664 chr7:23101228~23105703:- LIHC cis rs2739330 0.731 rs5751792 ENSG00000273295.1 AP000350.5 9.73 6.3e-20 1.98e-16 0.5 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23901432~23907068:- LIHC cis rs17507216 1 rs17507216 ENSG00000278603.1 RP13-608F4.5 -9.73 6.46e-20 2.03e-16 -0.86 -0.47 Excessive daytime sleepiness; chr15:82558175 chr15:82472203~82472426:+ LIHC cis rs1577917 1 rs13194429 ENSG00000203875.9 SNHG5 -9.73 6.47e-20 2.03e-16 -0.56 -0.47 Response to antipsychotic treatment; chr6:85936987 chr6:85660950~85678736:- LIHC cis rs5760092 0.755 rs4585126 ENSG00000231271.1 AP000350.8 -9.73 6.57e-20 2.07e-16 -0.59 -0.47 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23949918~23954042:+ LIHC cis rs17711722 0.565 rs4275112 ENSG00000164669.11 INTS4P1 9.73 6.62e-20 2.08e-16 0.59 0.47 Calcium levels; chr7:65733651 chr7:65141225~65234216:+ LIHC cis rs1577917 0.958 rs1591438 ENSG00000203875.9 SNHG5 -9.73 6.63e-20 2.08e-16 -0.57 -0.47 Response to antipsychotic treatment; chr6:85815496 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs1591437 ENSG00000203875.9 SNHG5 -9.73 6.63e-20 2.08e-16 -0.57 -0.47 Response to antipsychotic treatment; chr6:85815587 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs67024565 ENSG00000203875.9 SNHG5 -9.73 6.66e-20 2.09e-16 -0.57 -0.47 Response to antipsychotic treatment; chr6:85844279 chr6:85660950~85678736:- LIHC cis rs494459 0.964 rs576283 ENSG00000255422.1 AP002954.4 -9.73 6.73e-20 2.11e-16 -0.52 -0.47 Height; chr11:118703185 chr11:118704607~118750263:+ LIHC cis rs494459 0.929 rs627391 ENSG00000255422.1 AP002954.4 -9.73 6.73e-20 2.11e-16 -0.52 -0.47 Height; chr11:118703207 chr11:118704607~118750263:+ LIHC cis rs507080 0.524 rs524409 ENSG00000255422.1 AP002954.4 -9.73 6.73e-20 2.11e-16 -0.52 -0.47 Serum metabolite levels; chr11:118703602 chr11:118704607~118750263:+ LIHC cis rs2739330 0.76 rs5751760 ENSG00000231271.1 AP000350.8 9.72 6.96e-20 2.18e-16 0.55 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23949918~23954042:+ LIHC cis rs1150668 0.835 rs1233696 ENSG00000216901.1 AL022393.7 9.72 7.08e-20 2.22e-16 0.52 0.47 Pubertal anthropometrics; chr6:28175232 chr6:28176188~28176674:+ LIHC cis rs172166 0.516 rs1150670 ENSG00000216901.1 AL022393.7 9.72 7.08e-20 2.22e-16 0.52 0.47 Cardiac Troponin-T levels; chr6:28162781 chr6:28176188~28176674:+ LIHC cis rs172166 0.516 rs2021826 ENSG00000216901.1 AL022393.7 9.72 7.08e-20 2.22e-16 0.52 0.47 Cardiac Troponin-T levels; chr6:28164978 chr6:28176188~28176674:+ LIHC cis rs1577917 1 rs12201571 ENSG00000203875.9 SNHG5 -9.72 7.19e-20 2.25e-16 -0.56 -0.47 Response to antipsychotic treatment; chr6:85900032 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs11759855 ENSG00000203875.9 SNHG5 -9.72 7.19e-20 2.25e-16 -0.56 -0.47 Response to antipsychotic treatment; chr6:85901123 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs1857964 ENSG00000203875.9 SNHG5 -9.72 7.19e-20 2.25e-16 -0.56 -0.47 Response to antipsychotic treatment; chr6:85926276 chr6:85660950~85678736:- LIHC cis rs1577917 0.798 rs7772384 ENSG00000203875.9 SNHG5 -9.72 7.19e-20 2.25e-16 -0.56 -0.47 Response to antipsychotic treatment; chr6:85929962 chr6:85660950~85678736:- LIHC cis rs858239 0.896 rs1637192 ENSG00000230658.1 KLHL7-AS1 9.72 7.2e-20 2.25e-16 0.61 0.47 Cerebrospinal fluid biomarker levels; chr7:23220895 chr7:23101228~23105703:- LIHC cis rs507080 0.501 rs625735 ENSG00000255422.1 AP002954.4 -9.71 7.45e-20 2.33e-16 -0.52 -0.46 Serum metabolite levels; chr11:118704710 chr11:118704607~118750263:+ LIHC cis rs1577917 1 rs12200330 ENSG00000203875.9 SNHG5 -9.71 7.47e-20 2.34e-16 -0.57 -0.46 Response to antipsychotic treatment; chr6:85946935 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs2875456 ENSG00000203875.9 SNHG5 -9.71 7.55e-20 2.36e-16 -0.57 -0.46 Response to antipsychotic treatment; chr6:85892566 chr6:85660950~85678736:- LIHC cis rs7617773 0.817 rs11130163 ENSG00000229759.1 MRPS18AP1 9.71 7.63e-20 2.38e-16 0.5 0.46 Coronary artery disease; chr3:48271168 chr3:48256350~48256938:- LIHC cis rs10256972 0.681 rs6979076 ENSG00000229043.2 AC091729.9 9.7 8e-20 2.5e-16 0.52 0.46 Endometriosis;Longevity; chr7:1076611 chr7:1160374~1165267:+ LIHC cis rs507080 0.501 rs626645 ENSG00000255422.1 AP002954.4 -9.7 8.13e-20 2.54e-16 -0.52 -0.46 Serum metabolite levels; chr11:118704471 chr11:118704607~118750263:+ LIHC cis rs858239 1 rs858240 ENSG00000230658.1 KLHL7-AS1 9.7 8.15e-20 2.54e-16 0.57 0.46 Cerebrospinal fluid biomarker levels; chr7:23244618 chr7:23101228~23105703:- LIHC cis rs17711722 0.523 rs365896 ENSG00000164669.11 INTS4P1 9.7 8.15e-20 2.54e-16 0.57 0.46 Calcium levels; chr7:66045710 chr7:65141225~65234216:+ LIHC cis rs977987 0.843 rs17696749 ENSG00000261783.1 RP11-252K23.2 -9.7 8.16e-20 2.54e-16 -0.54 -0.46 Dupuytren's disease; chr16:75369164 chr16:75379818~75381260:- LIHC cis rs977987 0.762 rs1364079 ENSG00000261783.1 RP11-252K23.2 -9.7 8.16e-20 2.54e-16 -0.54 -0.46 Dupuytren's disease; chr16:75359233 chr16:75379818~75381260:- LIHC cis rs977987 0.843 rs4146810 ENSG00000261783.1 RP11-252K23.2 -9.7 8.28e-20 2.58e-16 -0.54 -0.46 Dupuytren's disease; chr16:75381933 chr16:75379818~75381260:- LIHC cis rs296381 0.561 rs62128815 ENSG00000259108.2 CTD-3098H1.2 9.69 8.56e-20 2.67e-16 0.82 0.46 Blood metabolite levels; chr19:47846001 chr19:47863483~47865341:- LIHC cis rs507080 0.922 rs582630 ENSG00000255422.1 AP002954.4 -9.69 8.7e-20 2.71e-16 -0.54 -0.46 Serum metabolite levels; chr11:118692090 chr11:118704607~118750263:+ LIHC cis rs17711722 0.653 rs2460421 ENSG00000226824.5 RP4-756H11.3 9.69 8.85e-20 2.75e-16 0.58 0.46 Calcium levels; chr7:66026136 chr7:66654538~66669855:+ LIHC cis rs507080 0.769 rs7389 ENSG00000255422.1 AP002954.4 9.69 9e-20 2.8e-16 0.54 0.46 Serum metabolite levels; chr11:118657756 chr11:118704607~118750263:+ LIHC cis rs17711722 0.523 rs313812 ENSG00000164669.11 INTS4P1 9.69 9.04e-20 2.81e-16 0.57 0.46 Calcium levels; chr7:66040056 chr7:65141225~65234216:+ LIHC cis rs9828933 0.577 rs832194 ENSG00000280620.1 SCAANT1 -9.68 9.32e-20 2.89e-16 -0.67 -0.46 Type 2 diabetes; chr3:63871395 chr3:63911518~63911772:- LIHC cis rs2739330 0.929 rs5751775 ENSG00000231271.1 AP000350.8 9.68 9.36e-20 2.9e-16 0.54 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23949918~23954042:+ LIHC cis rs10256972 0.706 rs12701969 ENSG00000229043.2 AC091729.9 -9.68 9.45e-20 2.93e-16 -0.53 -0.46 Endometriosis;Longevity; chr7:1082213 chr7:1160374~1165267:+ LIHC cis rs507080 0.501 rs637563 ENSG00000255422.1 AP002954.4 -9.68 9.57e-20 2.96e-16 -0.52 -0.46 Serum metabolite levels; chr11:118704770 chr11:118704607~118750263:+ LIHC cis rs1577917 1 rs12208493 ENSG00000203875.9 SNHG5 -9.68 9.7e-20 3e-16 -0.56 -0.46 Response to antipsychotic treatment; chr6:85952549 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12213149 ENSG00000203875.9 SNHG5 -9.68 9.7e-20 3e-16 -0.56 -0.46 Response to antipsychotic treatment; chr6:85958926 chr6:85660950~85678736:- LIHC cis rs2455601 0.744 rs2568085 ENSG00000254860.4 TMEM9B-AS1 -9.68 9.71e-20 3.01e-16 -0.54 -0.46 Schizophrenia; chr11:8954201 chr11:8964675~8977527:+ LIHC cis rs1577917 0.958 rs12198876 ENSG00000203875.9 SNHG5 -9.68 9.79e-20 3.03e-16 -0.57 -0.46 Response to antipsychotic treatment; chr6:85815758 chr6:85660950~85678736:- LIHC cis rs1729407 0.647 rs2727791 ENSG00000254851.1 RP11-109L13.1 -9.68 9.91e-20 3.06e-16 -0.56 -0.46 Apolipoprotein A-IV levels; chr11:116813846 chr11:117135528~117138582:+ LIHC cis rs1577917 0.876 rs66986937 ENSG00000203875.9 SNHG5 -9.68 9.92e-20 3.07e-16 -0.57 -0.46 Response to antipsychotic treatment; chr6:85822473 chr6:85660950~85678736:- LIHC cis rs507080 0.922 rs508640 ENSG00000255422.1 AP002954.4 -9.67 9.96e-20 3.08e-16 -0.54 -0.46 Serum metabolite levels; chr11:118693704 chr11:118704607~118750263:+ LIHC cis rs507080 0.922 rs471227 ENSG00000255422.1 AP002954.4 -9.67 9.96e-20 3.08e-16 -0.54 -0.46 Serum metabolite levels; chr11:118693892 chr11:118704607~118750263:+ LIHC cis rs4423214 0.65 rs4245442 ENSG00000254682.1 RP11-660L16.2 9.67 1.05e-19 3.23e-16 0.57 0.46 Vitamin D levels; chr11:71509863 chr11:71448674~71452157:+ LIHC cis rs494459 0.838 rs581045 ENSG00000255239.1 AP002954.6 9.66 1.07e-19 3.31e-16 0.53 0.46 Height; chr11:118761813 chr11:118688039~118690600:- LIHC cis rs1577917 0.958 rs12665542 ENSG00000203875.9 SNHG5 -9.66 1.13e-19 3.48e-16 -0.57 -0.46 Response to antipsychotic treatment; chr6:85834725 chr6:85660950~85678736:- LIHC cis rs858239 0.676 rs3807459 ENSG00000230658.1 KLHL7-AS1 9.66 1.16e-19 3.56e-16 0.58 0.46 Cerebrospinal fluid biomarker levels; chr7:23350132 chr7:23101228~23105703:- LIHC cis rs494459 0.838 rs2510897 ENSG00000255239.1 AP002954.6 9.65 1.17e-19 3.58e-16 0.53 0.46 Height; chr11:118773873 chr11:118688039~118690600:- LIHC cis rs2739330 0.761 rs5760176 ENSG00000273295.1 AP000350.5 -9.65 1.17e-19 3.59e-16 -0.49 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23901432~23907068:- LIHC cis rs7617773 0.817 rs6787500 ENSG00000229759.1 MRPS18AP1 9.65 1.18e-19 3.63e-16 0.49 0.46 Coronary artery disease; chr3:48257949 chr3:48256350~48256938:- LIHC cis rs507080 0.922 rs558781 ENSG00000255422.1 AP002954.4 -9.65 1.22e-19 3.75e-16 -0.54 -0.46 Serum metabolite levels; chr11:118693688 chr11:118704607~118750263:+ LIHC cis rs507080 0.769 rs745663 ENSG00000255422.1 AP002954.4 -9.65 1.24e-19 3.81e-16 -0.54 -0.46 Serum metabolite levels; chr11:118658886 chr11:118704607~118750263:+ LIHC cis rs1577917 1 rs10455455 ENSG00000203875.9 SNHG5 -9.64 1.27e-19 3.88e-16 -0.56 -0.46 Response to antipsychotic treatment; chr6:85960496 chr6:85660950~85678736:- LIHC cis rs172166 0.538 rs149956 ENSG00000216901.1 AL022393.7 9.64 1.29e-19 3.96e-16 0.52 0.46 Cardiac Troponin-T levels; chr6:28068473 chr6:28176188~28176674:+ LIHC cis rs507080 0.883 rs527475 ENSG00000255422.1 AP002954.4 -9.64 1.3e-19 3.98e-16 -0.54 -0.46 Serum metabolite levels; chr11:118692530 chr11:118704607~118750263:+ LIHC cis rs1150668 1 rs1150668 ENSG00000216901.1 AL022393.7 9.64 1.32e-19 4.05e-16 0.53 0.46 Pubertal anthropometrics; chr6:28162011 chr6:28176188~28176674:+ LIHC cis rs2739330 0.828 rs5760102 ENSG00000225282.1 AP000350.6 9.63 1.35e-19 4.14e-16 0.56 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23926900~23929574:+ LIHC cis rs977987 0.843 rs7499872 ENSG00000261783.1 RP11-252K23.2 -9.63 1.36e-19 4.15e-16 -0.54 -0.46 Dupuytren's disease; chr16:75392631 chr16:75379818~75381260:- LIHC cis rs858239 0.867 rs10250602 ENSG00000230658.1 KLHL7-AS1 9.63 1.38e-19 4.2e-16 0.62 0.46 Cerebrospinal fluid biomarker levels; chr7:23264082 chr7:23101228~23105703:- LIHC cis rs7174755 0.923 rs9672383 ENSG00000260657.2 RP11-315D16.4 9.63 1.38e-19 4.21e-16 0.67 0.46 Major depressive disorder; chr15:68306731 chr15:68267792~68277994:- LIHC cis rs977987 0.843 rs10459859 ENSG00000261783.1 RP11-252K23.2 -9.63 1.41e-19 4.3e-16 -0.54 -0.46 Dupuytren's disease; chr16:75348052 chr16:75379818~75381260:- LIHC cis rs977987 0.872 rs4887816 ENSG00000261783.1 RP11-252K23.2 -9.63 1.43e-19 4.35e-16 -0.53 -0.46 Dupuytren's disease; chr16:75285818 chr16:75379818~75381260:- LIHC cis rs7115242 0.748 rs1035237 ENSG00000254851.1 RP11-109L13.1 -9.62 1.46e-19 4.45e-16 -0.63 -0.46 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116857134 chr11:117135528~117138582:+ LIHC cis rs10256972 0.706 rs12701970 ENSG00000229043.2 AC091729.9 -9.62 1.51e-19 4.61e-16 -0.52 -0.46 Endometriosis;Longevity; chr7:1082322 chr7:1160374~1165267:+ LIHC cis rs1577917 0.958 rs2121594 ENSG00000203875.9 SNHG5 -9.62 1.54e-19 4.68e-16 -0.56 -0.46 Response to antipsychotic treatment; chr6:85867136 chr6:85660950~85678736:- LIHC cis rs1799949 0.602 rs8176235 ENSG00000198496.9 NBR2 -9.62 1.57e-19 4.77e-16 -0.54 -0.46 Menopause (age at onset); chr17:43067543 chr17:43125610~43153671:+ LIHC cis rs977987 0.586 rs12920883 ENSG00000261783.1 RP11-252K23.2 -9.62 1.57e-19 4.77e-16 -0.54 -0.46 Dupuytren's disease; chr16:75398783 chr16:75379818~75381260:- LIHC cis rs977987 0.624 rs59867374 ENSG00000261783.1 RP11-252K23.2 -9.62 1.57e-19 4.77e-16 -0.54 -0.46 Dupuytren's disease; chr16:75398784 chr16:75379818~75381260:- LIHC cis rs7617773 0.817 rs11130162 ENSG00000229759.1 MRPS18AP1 9.61 1.62e-19 4.92e-16 0.49 0.46 Coronary artery disease; chr3:48256121 chr3:48256350~48256938:- LIHC cis rs2260433 0.503 rs10895338 ENSG00000281655.1 RP11-817J15.3 9.61 1.63e-19 4.96e-16 0.59 0.46 Cleft palate; chr11:102647462 chr11:102681310~102683913:+ LIHC cis rs977987 0.835 rs7200616 ENSG00000261783.1 RP11-252K23.2 -9.61 1.65e-19 5.01e-16 -0.54 -0.46 Dupuytren's disease; chr16:75332191 chr16:75379818~75381260:- LIHC cis rs6504950 0.83 rs12936860 ENSG00000275710.1 RP11-257O5.4 9.61 1.66e-19 5.03e-16 0.64 0.46 Breast cancer; chr17:54952865 chr17:54964474~54964679:+ LIHC cis rs1577917 0.958 rs10944144 ENSG00000203875.9 SNHG5 -9.61 1.66e-19 5.05e-16 -0.57 -0.46 Response to antipsychotic treatment; chr6:85828037 chr6:85660950~85678736:- LIHC cis rs9326248 0.53 rs2075292 ENSG00000254851.1 RP11-109L13.1 -9.61 1.67e-19 5.07e-16 -0.63 -0.46 Blood protein levels; chr11:116861796 chr11:117135528~117138582:+ LIHC cis rs875971 0.767 rs12668005 ENSG00000226824.5 RP4-756H11.3 -9.61 1.69e-19 5.11e-16 -0.55 -0.46 Aortic root size; chr7:66444034 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs11765791 ENSG00000226824.5 RP4-756H11.3 -9.61 1.69e-19 5.11e-16 -0.55 -0.46 Aortic root size; chr7:66471587 chr7:66654538~66669855:+ LIHC cis rs507080 0.922 rs585039 ENSG00000255422.1 AP002954.4 -9.61 1.7e-19 5.14e-16 -0.54 -0.46 Serum metabolite levels; chr11:118692672 chr11:118704607~118750263:+ LIHC cis rs172166 0.516 rs2622322 ENSG00000216901.1 AL022393.7 9.6 1.71e-19 5.19e-16 0.52 0.46 Cardiac Troponin-T levels; chr6:28149665 chr6:28176188~28176674:+ LIHC cis rs8062405 1 rs2008514 ENSG00000259982.1 CDC37P1 -9.6 1.75e-19 5.29e-16 -0.53 -0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814284 chr16:28700294~28701540:- LIHC cis rs858239 0.899 rs28635122 ENSG00000230658.1 KLHL7-AS1 9.6 1.76e-19 5.31e-16 0.62 0.46 Cerebrospinal fluid biomarker levels; chr7:23270562 chr7:23101228~23105703:- LIHC cis rs2739330 0.796 rs5760106 ENSG00000231271.1 AP000350.8 -9.6 1.77e-19 5.34e-16 -0.52 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23949918~23954042:+ LIHC cis rs9326248 0.53 rs6589575 ENSG00000254851.1 RP11-109L13.1 -9.6 1.77e-19 5.34e-16 -0.63 -0.46 Blood protein levels; chr11:116862594 chr11:117135528~117138582:+ LIHC cis rs9326248 0.53 rs718847 ENSG00000254851.1 RP11-109L13.1 -9.6 1.77e-19 5.34e-16 -0.63 -0.46 Blood protein levels; chr11:116863430 chr11:117135528~117138582:+ LIHC cis rs1577917 1 rs10944163 ENSG00000203875.9 SNHG5 -9.6 1.8e-19 5.42e-16 -0.56 -0.46 Response to antipsychotic treatment; chr6:85948975 chr6:85660950~85678736:- LIHC cis rs977987 0.806 rs35937717 ENSG00000261783.1 RP11-252K23.2 -9.6 1.8e-19 5.43e-16 -0.53 -0.46 Dupuytren's disease; chr16:75297669 chr16:75379818~75381260:- LIHC cis rs494459 0.657 rs614554 ENSG00000255239.1 AP002954.6 9.6 1.81e-19 5.47e-16 0.53 0.46 Height; chr11:118764443 chr11:118688039~118690600:- LIHC cis rs2188561 1 rs2188561 ENSG00000241764.3 AC002467.7 9.6 1.83e-19 5.52e-16 0.62 0.46 Alcohol consumption; chr7:107695613 chr7:107742817~107744581:- LIHC cis rs172166 0.561 rs149973 ENSG00000216901.1 AL022393.7 9.59 1.94e-19 5.84e-16 0.52 0.46 Cardiac Troponin-T levels; chr6:28015835 chr6:28176188~28176674:+ LIHC cis rs172166 0.561 rs149974 ENSG00000216901.1 AL022393.7 9.59 1.94e-19 5.84e-16 0.52 0.46 Cardiac Troponin-T levels; chr6:28017318 chr6:28176188~28176674:+ LIHC cis rs4423214 0.65 rs7940244 ENSG00000254682.1 RP11-660L16.2 -9.59 1.96e-19 5.89e-16 -0.56 -0.46 Vitamin D levels; chr11:71510528 chr11:71448674~71452157:+ LIHC cis rs1799949 0.602 rs8176257 ENSG00000198496.9 NBR2 -9.59 1.96e-19 5.92e-16 -0.54 -0.46 Menopause (age at onset); chr17:43064188 chr17:43125610~43153671:+ LIHC cis rs2188561 1 rs2712208 ENSG00000241764.3 AC002467.7 9.59 1.97e-19 5.94e-16 0.62 0.46 Alcohol consumption; chr7:107703317 chr7:107742817~107744581:- LIHC cis rs2739330 0.828 rs5760098 ENSG00000225282.1 AP000350.6 9.58 2.05e-19 6.17e-16 0.56 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23926900~23929574:+ LIHC cis rs977987 0.806 rs4887818 ENSG00000261783.1 RP11-252K23.2 -9.58 2.1e-19 6.33e-16 -0.54 -0.46 Dupuytren's disease; chr16:75328097 chr16:75379818~75381260:- LIHC cis rs296381 0.561 rs58914460 ENSG00000259108.2 CTD-3098H1.2 9.58 2.11e-19 6.35e-16 0.83 0.46 Blood metabolite levels; chr19:47847590 chr19:47863483~47865341:- LIHC cis rs507080 0.885 rs4938530 ENSG00000255422.1 AP002954.4 -9.58 2.12e-19 6.36e-16 -0.53 -0.46 Serum metabolite levels; chr11:118689861 chr11:118704607~118750263:+ LIHC cis rs494459 0.838 rs607125 ENSG00000255239.1 AP002954.6 9.56 2.4e-19 7.2e-16 0.53 0.46 Height; chr11:118746590 chr11:118688039~118690600:- LIHC cis rs2487048 0.761 rs1800976 ENSG00000226334.1 RP11-217B7.2 -9.56 2.42e-19 7.25e-16 -0.58 -0.46 Intraocular pressure; chr9:104928428 chr9:104927553~104928892:+ LIHC cis rs507080 0.769 rs527290 ENSG00000255422.1 AP002954.4 -9.56 2.46e-19 7.38e-16 -0.54 -0.46 Serum metabolite levels; chr11:118644898 chr11:118704607~118750263:+ LIHC cis rs1150668 0.965 rs1654774 ENSG00000216901.1 AL022393.7 9.55 2.57e-19 7.71e-16 0.53 0.46 Pubertal anthropometrics; chr6:28128502 chr6:28176188~28176674:+ LIHC cis rs1930961 0.702 rs1930966 ENSG00000272977.1 CTA-390C10.10 -9.55 2.62e-19 7.83e-16 -0.73 -0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25489737 chr22:25476218~25479971:+ LIHC cis rs2739330 0.929 rs5751777 ENSG00000231271.1 AP000350.8 9.54 2.73e-19 8.16e-16 0.53 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23949918~23954042:+ LIHC cis rs2739330 0.828 rs4822454 ENSG00000231271.1 AP000350.8 9.54 2.78e-19 8.31e-16 0.55 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23949918~23954042:+ LIHC cis rs150992 0.711 rs1069182 ENSG00000248489.1 CTD-2007H13.3 -9.54 2.87e-19 8.56e-16 -0.7 -0.46 Body mass index; chr5:98806512 chr5:98929171~98995013:+ LIHC cis rs150992 0.673 rs992773 ENSG00000248489.1 CTD-2007H13.3 -9.54 2.87e-19 8.56e-16 -0.7 -0.46 Body mass index; chr5:98808169 chr5:98929171~98995013:+ LIHC cis rs1799949 0.93 rs34210004 ENSG00000198496.9 NBR2 -9.53 3.02e-19 8.99e-16 -0.53 -0.46 Menopause (age at onset); chr17:43218318 chr17:43125610~43153671:+ LIHC cis rs494459 0.838 rs632124 ENSG00000255239.1 AP002954.6 9.53 3.04e-19 9.05e-16 0.53 0.46 Height; chr11:118742526 chr11:118688039~118690600:- LIHC cis rs5769707 0.521 rs739244 ENSG00000188511.11 C22orf34 9.52 3.27e-19 9.72e-16 0.55 0.46 Monocyte percentage of white cells;Monocyte count; chr22:49666510 chr22:49414524~49657542:- LIHC cis rs4423214 0.61 rs12793607 ENSG00000254682.1 RP11-660L16.2 -9.51 3.41e-19 1.01e-15 -0.54 -0.46 Vitamin D levels; chr11:71418270 chr11:71448674~71452157:+ LIHC cis rs10256972 0.706 rs4285396 ENSG00000229043.2 AC091729.9 -9.51 3.41e-19 1.01e-15 -0.51 -0.46 Endometriosis;Longevity; chr7:1084102 chr7:1160374~1165267:+ LIHC cis rs1577917 1 rs955197 ENSG00000203875.9 SNHG5 -9.51 3.46e-19 1.03e-15 -0.55 -0.46 Response to antipsychotic treatment; chr6:86019957 chr6:85660950~85678736:- LIHC cis rs875971 0.862 rs6460307 ENSG00000226824.5 RP4-756H11.3 -9.51 3.5e-19 1.04e-15 -0.53 -0.46 Aortic root size; chr7:66595884 chr7:66654538~66669855:+ LIHC cis rs494459 0.688 rs1048040 ENSG00000255239.1 AP002954.6 9.51 3.51e-19 1.04e-15 0.53 0.46 Height; chr11:118747911 chr11:118688039~118690600:- LIHC cis rs10256972 0.721 rs4720249 ENSG00000229043.2 AC091729.9 -9.51 3.54e-19 1.05e-15 -0.53 -0.46 Endometriosis;Longevity; chr7:1032927 chr7:1160374~1165267:+ LIHC cis rs875971 0.895 rs6460278 ENSG00000226824.5 RP4-756H11.3 9.5 3.65e-19 1.08e-15 0.55 0.46 Aortic root size; chr7:66197749 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6460279 ENSG00000226824.5 RP4-756H11.3 9.5 3.65e-19 1.08e-15 0.55 0.46 Aortic root size; chr7:66197774 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs28491091 ENSG00000226824.5 RP4-756H11.3 9.5 3.65e-19 1.08e-15 0.55 0.46 Aortic root size; chr7:66204077 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6952182 ENSG00000226824.5 RP4-756H11.3 9.5 3.65e-19 1.08e-15 0.55 0.46 Aortic root size; chr7:66218330 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6964437 ENSG00000226824.5 RP4-756H11.3 9.5 3.65e-19 1.08e-15 0.55 0.46 Aortic root size; chr7:66221457 chr7:66654538~66669855:+ LIHC cis rs3762637 1 rs10049131 ENSG00000272758.4 RP11-299J3.8 -9.5 3.68e-19 1.09e-15 -0.59 -0.46 LDL cholesterol levels; chr3:122483255 chr3:122416207~122443180:+ LIHC cis rs507080 0.885 rs533144 ENSG00000255422.1 AP002954.4 -9.5 3.68e-19 1.09e-15 -0.53 -0.46 Serum metabolite levels; chr11:118688538 chr11:118704607~118750263:+ LIHC cis rs507080 0.883 rs12798453 ENSG00000255422.1 AP002954.4 -9.5 3.68e-19 1.09e-15 -0.53 -0.46 Serum metabolite levels; chr11:118690701 chr11:118704607~118750263:+ LIHC cis rs1577917 1 rs12661204 ENSG00000203875.9 SNHG5 -9.5 3.87e-19 1.14e-15 -0.56 -0.46 Response to antipsychotic treatment; chr6:85968868 chr6:85660950~85678736:- LIHC cis rs1729407 0.933 rs1729405 ENSG00000254851.1 RP11-109L13.1 -9.5 3.92e-19 1.16e-15 -0.56 -0.46 Apolipoprotein A-IV levels; chr11:116808044 chr11:117135528~117138582:+ LIHC cis rs1577917 0.958 rs10944168 ENSG00000203875.9 SNHG5 -9.49 3.94e-19 1.16e-15 -0.56 -0.46 Response to antipsychotic treatment; chr6:85970438 chr6:85660950~85678736:- LIHC cis rs507080 0.922 rs516153 ENSG00000255422.1 AP002954.4 -9.49 4.02e-19 1.19e-15 -0.53 -0.46 Serum metabolite levels; chr11:118694053 chr11:118704607~118750263:+ LIHC cis rs507080 0.922 rs518028 ENSG00000255422.1 AP002954.4 -9.49 4.02e-19 1.19e-15 -0.53 -0.46 Serum metabolite levels; chr11:118694273 chr11:118704607~118750263:+ LIHC cis rs507080 0.922 rs519982 ENSG00000255422.1 AP002954.4 -9.49 4.02e-19 1.19e-15 -0.53 -0.46 Serum metabolite levels; chr11:118694522 chr11:118704607~118750263:+ LIHC cis rs875971 0.662 rs448725 ENSG00000226824.5 RP4-756H11.3 -9.49 4.11e-19 1.21e-15 -0.56 -0.46 Aortic root size; chr7:66049641 chr7:66654538~66669855:+ LIHC cis rs875971 0.658 rs432667 ENSG00000226824.5 RP4-756H11.3 -9.49 4.11e-19 1.21e-15 -0.56 -0.46 Aortic root size; chr7:66049646 chr7:66654538~66669855:+ LIHC cis rs8062405 0.755 rs12447461 ENSG00000259982.1 CDC37P1 9.49 4.12e-19 1.21e-15 0.57 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28571620 chr16:28700294~28701540:- LIHC cis rs172166 0.585 rs149963 ENSG00000216901.1 AL022393.7 9.49 4.14e-19 1.22e-15 0.52 0.46 Cardiac Troponin-T levels; chr6:28049354 chr6:28176188~28176674:+ LIHC cis rs494459 0.838 rs488219 ENSG00000255239.1 AP002954.6 9.49 4.19e-19 1.23e-15 0.52 0.46 Height; chr11:118749988 chr11:118688039~118690600:- LIHC cis rs1799949 0.965 rs4793237 ENSG00000198496.9 NBR2 -9.49 4.2e-19 1.24e-15 -0.53 -0.46 Menopause (age at onset); chr17:43359227 chr17:43125610~43153671:+ LIHC cis rs507080 0.922 rs478371 ENSG00000255422.1 AP002954.4 -9.49 4.21e-19 1.24e-15 -0.53 -0.46 Serum metabolite levels; chr11:118694627 chr11:118704607~118750263:+ LIHC cis rs172166 0.516 rs1225715 ENSG00000216901.1 AL022393.7 -9.49 4.21e-19 1.24e-15 -0.5 -0.46 Cardiac Troponin-T levels; chr6:28145595 chr6:28176188~28176674:+ LIHC cis rs858239 0.614 rs10229956 ENSG00000230658.1 KLHL7-AS1 -9.49 4.23e-19 1.24e-15 -0.55 -0.46 Cerebrospinal fluid biomarker levels; chr7:23363317 chr7:23101228~23105703:- LIHC cis rs858239 0.899 rs5850 ENSG00000230658.1 KLHL7-AS1 9.48 4.29e-19 1.26e-15 0.61 0.46 Cerebrospinal fluid biomarker levels; chr7:23274928 chr7:23101228~23105703:- LIHC cis rs1577917 0.958 rs11756615 ENSG00000203875.9 SNHG5 -9.48 4.34e-19 1.28e-15 -0.56 -0.46 Response to antipsychotic treatment; chr6:85970117 chr6:85660950~85678736:- LIHC cis rs10256972 0.721 rs2030959 ENSG00000229043.2 AC091729.9 -9.48 4.43e-19 1.3e-15 -0.53 -0.46 Endometriosis;Longevity; chr7:1036270 chr7:1160374~1165267:+ LIHC cis rs1577917 1 rs12205336 ENSG00000203875.9 SNHG5 -9.48 4.47e-19 1.31e-15 -0.55 -0.46 Response to antipsychotic treatment; chr6:86012649 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12209127 ENSG00000203875.9 SNHG5 -9.48 4.47e-19 1.31e-15 -0.55 -0.46 Response to antipsychotic treatment; chr6:86014709 chr6:85660950~85678736:- LIHC cis rs2739330 0.76 rs1007888 ENSG00000231271.1 AP000350.8 9.48 4.51e-19 1.33e-15 0.54 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23949918~23954042:+ LIHC cis rs977987 0.835 rs4888380 ENSG00000261783.1 RP11-252K23.2 -9.48 4.55e-19 1.34e-15 -0.54 -0.46 Dupuytren's disease; chr16:75313792 chr16:75379818~75381260:- LIHC cis rs977987 0.835 rs8057535 ENSG00000261783.1 RP11-252K23.2 -9.48 4.55e-19 1.34e-15 -0.54 -0.46 Dupuytren's disease; chr16:75314043 chr16:75379818~75381260:- LIHC cis rs977987 0.872 rs4243111 ENSG00000261783.1 RP11-252K23.2 -9.47 4.62e-19 1.35e-15 -0.53 -0.46 Dupuytren's disease; chr16:75286929 chr16:75379818~75381260:- LIHC cis rs858239 0.899 rs10262243 ENSG00000230658.1 KLHL7-AS1 9.47 4.63e-19 1.36e-15 0.6 0.46 Cerebrospinal fluid biomarker levels; chr7:23251368 chr7:23101228~23105703:- LIHC cis rs2739330 0.76 rs5751761 ENSG00000225282.1 AP000350.6 -9.47 4.64e-19 1.36e-15 -0.57 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23926900~23929574:+ LIHC cis rs494459 0.838 rs555639 ENSG00000255239.1 AP002954.6 -9.47 4.71e-19 1.38e-15 -0.53 -0.46 Height; chr11:118758322 chr11:118688039~118690600:- LIHC cis rs977987 0.835 rs4888379 ENSG00000261783.1 RP11-252K23.2 -9.47 4.8e-19 1.41e-15 -0.53 -0.46 Dupuytren's disease; chr16:75306333 chr16:75379818~75381260:- LIHC cis rs997154 0.579 rs12889177 ENSG00000279656.1 RP11-298I3.6 -9.47 4.81e-19 1.41e-15 -0.7 -0.46 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:23022120 chr14:23023083~23024217:- LIHC cis rs2739330 0.731 rs5751792 ENSG00000218537.1 MIF-AS1 9.46 5.13e-19 1.5e-15 0.6 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23894426~23898930:- LIHC cis rs2487048 0.725 rs2246293 ENSG00000226334.1 RP11-217B7.2 9.46 5.2e-19 1.52e-15 0.57 0.46 Intraocular pressure; chr9:104928557 chr9:104927553~104928892:+ LIHC cis rs7208859 0.673 rs3816780 ENSG00000263531.1 RP13-753N3.1 9.46 5.21e-19 1.52e-15 0.81 0.46 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834340 chr17:30863921~30864940:- LIHC cis rs507080 0.922 rs502601 ENSG00000255422.1 AP002954.4 -9.46 5.21e-19 1.52e-15 -0.53 -0.46 Serum metabolite levels; chr11:118694970 chr11:118704607~118750263:+ LIHC cis rs9326248 0.53 rs6589576 ENSG00000254851.1 RP11-109L13.1 9.46 5.25e-19 1.53e-15 0.63 0.46 Blood protein levels; chr11:116865072 chr11:117135528~117138582:+ LIHC cis rs977987 0.8 rs12922951 ENSG00000261783.1 RP11-252K23.2 -9.46 5.28e-19 1.54e-15 -0.54 -0.46 Dupuytren's disease; chr16:75321198 chr16:75379818~75381260:- LIHC cis rs977987 0.815 rs11149818 ENSG00000261783.1 RP11-252K23.2 -9.45 5.42e-19 1.58e-15 -0.53 -0.46 Dupuytren's disease; chr16:75385475 chr16:75379818~75381260:- LIHC cis rs1799949 0.628 rs4474733 ENSG00000198496.9 NBR2 -9.45 5.45e-19 1.59e-15 -0.53 -0.46 Menopause (age at onset); chr17:43356292 chr17:43125610~43153671:+ LIHC cis rs977987 0.835 rs8046109 ENSG00000261783.1 RP11-252K23.2 -9.45 5.61e-19 1.64e-15 -0.54 -0.45 Dupuytren's disease; chr16:75326198 chr16:75379818~75381260:- LIHC cis rs507080 0.922 rs558907 ENSG00000255422.1 AP002954.4 -9.45 5.72e-19 1.67e-15 -0.53 -0.45 Serum metabolite levels; chr11:118687746 chr11:118704607~118750263:+ LIHC cis rs977987 0.872 rs2161648 ENSG00000261783.1 RP11-252K23.2 -9.44 6.02e-19 1.75e-15 -0.54 -0.45 Dupuytren's disease; chr16:75280731 chr16:75379818~75381260:- LIHC cis rs858239 0.899 rs10085838 ENSG00000230658.1 KLHL7-AS1 9.44 6.05e-19 1.76e-15 0.61 0.45 Cerebrospinal fluid biomarker levels; chr7:23258796 chr7:23101228~23105703:- LIHC cis rs3762637 1 rs7626861 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122436349 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs9833415 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122440993 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs9842736 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122442254 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs13321097 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122443160 chr3:122416207~122443180:+ LIHC cis rs3762637 0.941 rs112768052 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122450537 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs9882100 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122451061 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs9968189 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122456289 chr3:122416207~122443180:+ LIHC cis rs3762637 0.941 rs77599736 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122460662 chr3:122416207~122443180:+ LIHC cis rs3762637 0.941 rs60222267 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122460785 chr3:122416207~122443180:+ LIHC cis rs3762637 0.882 rs56074178 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122461164 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs72958458 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122466702 chr3:122416207~122443180:+ LIHC cis rs3762637 0.943 rs10439995 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122470313 chr3:122416207~122443180:+ LIHC cis rs3762637 0.882 rs7630833 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122471577 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs7642869 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122471939 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs7617042 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122472138 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs6790051 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122473999 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs9878699 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122475384 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs12638866 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122475535 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs7644540 ENSG00000272758.4 RP11-299J3.8 -9.43 6.37e-19 1.84e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122491205 chr3:122416207~122443180:+ LIHC cis rs7208859 0.673 rs9903862 ENSG00000263531.1 RP13-753N3.1 9.43 6.5e-19 1.88e-15 0.86 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30879415 chr17:30863921~30864940:- LIHC cis rs507080 0.663 rs7926970 ENSG00000255422.1 AP002954.4 -9.43 6.6e-19 1.91e-15 -0.53 -0.45 Serum metabolite levels; chr11:118689172 chr11:118704607~118750263:+ LIHC cis rs1577917 0.771 rs2842613 ENSG00000203875.9 SNHG5 9.42 6.75e-19 1.95e-15 0.52 0.45 Response to antipsychotic treatment; chr6:85595984 chr6:85660950~85678736:- LIHC cis rs7208859 0.725 rs7210904 ENSG00000263531.1 RP13-753N3.1 9.41 7.23e-19 2.08e-15 0.78 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30843187 chr17:30863921~30864940:- LIHC cis rs7208859 0.725 rs9915802 ENSG00000263531.1 RP13-753N3.1 9.41 7.23e-19 2.08e-15 0.78 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30846040 chr17:30863921~30864940:- LIHC cis rs7208859 0.725 rs7342938 ENSG00000263531.1 RP13-753N3.1 9.41 7.23e-19 2.08e-15 0.78 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862812 chr17:30863921~30864940:- LIHC cis rs7208859 0.725 rs6505215 ENSG00000263531.1 RP13-753N3.1 9.41 7.23e-19 2.08e-15 0.78 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862885 chr17:30863921~30864940:- LIHC cis rs150992 0.711 rs331918 ENSG00000248489.1 CTD-2007H13.3 9.41 7.3e-19 2.1e-15 0.69 0.45 Body mass index; chr5:98823040 chr5:98929171~98995013:+ LIHC cis rs2739330 0.761 rs5760176 ENSG00000218537.1 MIF-AS1 -9.41 7.39e-19 2.13e-15 -0.6 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23894426~23898930:- LIHC cis rs8062405 0.755 rs7186573 ENSG00000259982.1 CDC37P1 9.4 7.84e-19 2.25e-15 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576068 chr16:28700294~28701540:- LIHC cis rs10256972 0.758 rs4723649 ENSG00000229043.2 AC091729.9 -9.4 7.86e-19 2.26e-15 -0.53 -0.45 Endometriosis;Longevity; chr7:1032269 chr7:1160374~1165267:+ LIHC cis rs3762637 1 rs12633461 ENSG00000272758.4 RP11-299J3.8 -9.4 8.1e-19 2.33e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122417050 chr3:122416207~122443180:+ LIHC cis rs17507216 0.958 rs72751643 ENSG00000278603.1 RP13-608F4.5 9.4 8.14e-19 2.34e-15 0.86 0.45 Excessive daytime sleepiness; chr15:82559444 chr15:82472203~82472426:+ LIHC cis rs67383717 0.689 rs62559007 ENSG00000175611.10 LINC00476 -9.4 8.14e-19 2.34e-15 -0.53 -0.45 Parkinson's disease (pesticide exposure interaction); chr9:95790981 chr9:95759231~95875977:- LIHC cis rs9828933 0.938 rs9809432 ENSG00000280620.1 SCAANT1 9.4 8.2e-19 2.35e-15 0.68 0.45 Type 2 diabetes; chr3:64017277 chr3:63911518~63911772:- LIHC cis rs1577917 1 rs12215037 ENSG00000203875.9 SNHG5 -9.39 8.51e-19 2.44e-15 -0.55 -0.45 Response to antipsychotic treatment; chr6:86017913 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs1337850 ENSG00000203875.9 SNHG5 -9.39 8.51e-19 2.44e-15 -0.55 -0.45 Response to antipsychotic treatment; chr6:86019385 chr6:85660950~85678736:- LIHC cis rs10256972 0.758 rs2280724 ENSG00000229043.2 AC091729.9 -9.39 8.55e-19 2.45e-15 -0.52 -0.45 Endometriosis;Longevity; chr7:1025084 chr7:1160374~1165267:+ LIHC cis rs858239 0.932 rs858275 ENSG00000230658.1 KLHL7-AS1 9.39 8.87e-19 2.54e-15 0.55 0.45 Cerebrospinal fluid biomarker levels; chr7:23254525 chr7:23101228~23105703:- LIHC cis rs494459 0.838 rs566733 ENSG00000255239.1 AP002954.6 9.39 8.98e-19 2.57e-15 0.52 0.45 Height; chr11:118737916 chr11:118688039~118690600:- LIHC cis rs507080 0.883 rs558593 ENSG00000255422.1 AP002954.4 -9.38 9.06e-19 2.59e-15 -0.52 -0.45 Serum metabolite levels; chr11:118691811 chr11:118704607~118750263:+ LIHC cis rs875971 0.8 rs427557 ENSG00000226824.5 RP4-756H11.3 -9.38 9.08e-19 2.6e-15 -0.55 -0.45 Aortic root size; chr7:66054263 chr7:66654538~66669855:+ LIHC cis rs8062405 0.755 rs111693583 ENSG00000259982.1 CDC37P1 9.38 9.34e-19 2.67e-15 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28572289 chr16:28700294~28701540:- LIHC cis rs150992 0.711 rs170734 ENSG00000248489.1 CTD-2007H13.3 9.38 9.43e-19 2.7e-15 0.69 0.45 Body mass index; chr5:98811337 chr5:98929171~98995013:+ LIHC cis rs8062405 0.755 rs55792032 ENSG00000259982.1 CDC37P1 9.38 9.58e-19 2.74e-15 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28588090 chr16:28700294~28701540:- LIHC cis rs3762637 1 rs9843165 ENSG00000272758.4 RP11-299J3.8 -9.37 9.8e-19 2.79e-15 -0.58 -0.45 LDL cholesterol levels; chr3:122412264 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs9836309 ENSG00000272758.4 RP11-299J3.8 -9.37 9.8e-19 2.79e-15 -0.58 -0.45 LDL cholesterol levels; chr3:122416348 chr3:122416207~122443180:+ LIHC cis rs3762637 0.941 rs9873842 ENSG00000272758.4 RP11-299J3.8 -9.37 9.8e-19 2.79e-15 -0.58 -0.45 LDL cholesterol levels; chr3:122416484 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs9879508 ENSG00000272758.4 RP11-299J3.8 -9.37 9.8e-19 2.79e-15 -0.58 -0.45 LDL cholesterol levels; chr3:122417633 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs12630576 ENSG00000272758.4 RP11-299J3.8 -9.37 9.8e-19 2.79e-15 -0.58 -0.45 LDL cholesterol levels; chr3:122420670 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs9858558 ENSG00000272758.4 RP11-299J3.8 -9.37 9.8e-19 2.79e-15 -0.58 -0.45 LDL cholesterol levels; chr3:122420895 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs55853677 ENSG00000272758.4 RP11-299J3.8 -9.37 9.8e-19 2.79e-15 -0.58 -0.45 LDL cholesterol levels; chr3:122421769 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs3762637 ENSG00000272758.4 RP11-299J3.8 -9.37 9.8e-19 2.79e-15 -0.58 -0.45 LDL cholesterol levels; chr3:122426477 chr3:122416207~122443180:+ LIHC cis rs507080 0.922 rs546890 ENSG00000255422.1 AP002954.4 -9.37 9.83e-19 2.8e-15 -0.53 -0.45 Serum metabolite levels; chr11:118686489 chr11:118704607~118750263:+ LIHC cis rs507080 0.883 rs693306 ENSG00000255422.1 AP002954.4 -9.37 9.83e-19 2.8e-15 -0.53 -0.45 Serum metabolite levels; chr11:118687624 chr11:118704607~118750263:+ LIHC cis rs507080 0.922 rs561845 ENSG00000255422.1 AP002954.4 -9.37 9.83e-19 2.8e-15 -0.53 -0.45 Serum metabolite levels; chr11:118688118 chr11:118704607~118750263:+ LIHC cis rs507080 0.922 rs638805 ENSG00000255422.1 AP002954.4 -9.37 9.83e-19 2.8e-15 -0.53 -0.45 Serum metabolite levels; chr11:118688180 chr11:118704607~118750263:+ LIHC cis rs507080 0.845 rs510408 ENSG00000255422.1 AP002954.4 -9.37 9.83e-19 2.8e-15 -0.53 -0.45 Serum metabolite levels; chr11:118688192 chr11:118704607~118750263:+ LIHC cis rs507080 0.845 rs509641 ENSG00000255422.1 AP002954.4 -9.37 9.83e-19 2.8e-15 -0.53 -0.45 Serum metabolite levels; chr11:118688243 chr11:118704607~118750263:+ LIHC cis rs507080 0.883 rs563549 ENSG00000255422.1 AP002954.4 -9.37 9.83e-19 2.8e-15 -0.53 -0.45 Serum metabolite levels; chr11:118688244 chr11:118704607~118750263:+ LIHC cis rs67383717 0.713 rs1369156 ENSG00000175611.10 LINC00476 -9.37 1e-18 2.86e-15 -0.53 -0.45 Parkinson's disease (pesticide exposure interaction); chr9:95794612 chr9:95759231~95875977:- LIHC cis rs9843304 0.868 rs4681516 ENSG00000244503.1 RP11-278L15.6 -9.37 1.02e-18 2.9e-15 -0.42 -0.45 Gallstone disease; chr3:149494338 chr3:149494660~149495995:+ LIHC cis rs875971 0.83 rs587360 ENSG00000226824.5 RP4-756H11.3 -9.37 1.05e-18 2.98e-15 -0.55 -0.45 Aortic root size; chr7:66057711 chr7:66654538~66669855:+ LIHC cis rs8062405 0.723 rs12445744 ENSG00000259982.1 CDC37P1 9.37 1.05e-18 2.98e-15 0.57 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28577074 chr16:28700294~28701540:- LIHC cis rs8062405 0.755 rs4787455 ENSG00000259982.1 CDC37P1 9.37 1.05e-18 2.98e-15 0.57 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28578134 chr16:28700294~28701540:- LIHC cis rs3762637 1 rs6777596 ENSG00000272758.4 RP11-299J3.8 -9.36 1.06e-18 3.02e-15 -0.59 -0.45 LDL cholesterol levels; chr3:122414474 chr3:122416207~122443180:+ LIHC cis rs507080 0.922 rs4589335 ENSG00000255422.1 AP002954.4 -9.36 1.07e-18 3.04e-15 -0.52 -0.45 Serum metabolite levels; chr11:118668431 chr11:118704607~118750263:+ LIHC cis rs507080 0.922 rs555356 ENSG00000255422.1 AP002954.4 -9.36 1.08e-18 3.06e-15 -0.53 -0.45 Serum metabolite levels; chr11:118687369 chr11:118704607~118750263:+ LIHC cis rs977987 0.835 rs11641532 ENSG00000261783.1 RP11-252K23.2 -9.36 1.1e-18 3.12e-15 -0.53 -0.45 Dupuytren's disease; chr16:75295582 chr16:75379818~75381260:- LIHC cis rs507080 0.807 rs7926944 ENSG00000255422.1 AP002954.4 -9.36 1.11e-18 3.15e-15 -0.52 -0.45 Serum metabolite levels; chr11:118689119 chr11:118704607~118750263:+ LIHC cis rs507080 0.922 rs514143 ENSG00000255422.1 AP002954.4 -9.35 1.14e-18 3.22e-15 -0.52 -0.45 Serum metabolite levels; chr11:118687740 chr11:118704607~118750263:+ LIHC cis rs858239 0.698 rs4265084 ENSG00000230658.1 KLHL7-AS1 9.35 1.14e-18 3.22e-15 0.61 0.45 Cerebrospinal fluid biomarker levels; chr7:23367621 chr7:23101228~23105703:- LIHC cis rs507080 0.883 rs692750 ENSG00000255422.1 AP002954.4 -9.35 1.15e-18 3.26e-15 -0.52 -0.45 Serum metabolite levels; chr11:118667599 chr11:118704607~118750263:+ LIHC cis rs2739330 0.685 rs4822453 ENSG00000231271.1 AP000350.8 9.35 1.15e-18 3.26e-15 0.53 0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23949918~23954042:+ LIHC cis rs10256972 0.758 rs11979275 ENSG00000229043.2 AC091729.9 -9.35 1.21e-18 3.43e-15 -0.53 -0.45 Endometriosis;Longevity; chr7:1029699 chr7:1160374~1165267:+ LIHC cis rs10256972 0.758 rs11980081 ENSG00000229043.2 AC091729.9 -9.35 1.21e-18 3.43e-15 -0.53 -0.45 Endometriosis;Longevity; chr7:1029736 chr7:1160374~1165267:+ LIHC cis rs1577917 1 rs1018184 ENSG00000203875.9 SNHG5 9.34 1.25e-18 3.54e-15 0.53 0.45 Response to antipsychotic treatment; chr6:85938757 chr6:85660950~85678736:- LIHC cis rs507080 0.501 rs516503 ENSG00000255422.1 AP002954.4 -9.33 1.35e-18 3.8e-15 -0.51 -0.45 Serum metabolite levels; chr11:118709639 chr11:118704607~118750263:+ LIHC cis rs9660180 0.967 rs12034740 ENSG00000231050.1 RP1-140A9.1 9.33 1.35e-18 3.82e-15 0.42 0.45 Body mass index; chr1:1797530 chr1:1891471~1892658:+ LIHC cis rs507080 0.845 rs613377 ENSG00000255422.1 AP002954.4 -9.33 1.38e-18 3.88e-15 -0.52 -0.45 Serum metabolite levels; chr11:118685375 chr11:118704607~118750263:+ LIHC cis rs8062405 0.755 rs4788073 ENSG00000259982.1 CDC37P1 9.33 1.39e-18 3.93e-15 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28583228 chr16:28700294~28701540:- LIHC cis rs507080 0.961 rs520543 ENSG00000255422.1 AP002954.4 -9.32 1.45e-18 4.1e-15 -0.52 -0.45 Serum metabolite levels; chr11:118667448 chr11:118704607~118750263:+ LIHC cis rs172166 0.561 rs149971 ENSG00000216901.1 AL022393.7 9.32 1.46e-18 4.12e-15 0.52 0.45 Cardiac Troponin-T levels; chr6:28014374 chr6:28176188~28176674:+ LIHC cis rs507080 0.961 rs34413584 ENSG00000255422.1 AP002954.4 -9.32 1.48e-18 4.18e-15 -0.52 -0.45 Serum metabolite levels; chr11:118675072 chr11:118704607~118750263:+ LIHC cis rs8062405 0.755 rs62034358 ENSG00000259982.1 CDC37P1 9.31 1.55e-18 4.36e-15 0.57 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576276 chr16:28700294~28701540:- LIHC cis rs8062405 0.755 rs12445823 ENSG00000259982.1 CDC37P1 9.31 1.55e-18 4.36e-15 0.57 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576728 chr16:28700294~28701540:- LIHC cis rs2487048 0.725 rs2422493 ENSG00000226334.1 RP11-217B7.2 -9.31 1.56e-18 4.38e-15 -0.57 -0.45 Intraocular pressure; chr9:104928714 chr9:104927553~104928892:+ LIHC cis rs950027 0.62 rs1145077 ENSG00000259520.4 CTD-2651B20.3 9.31 1.57e-18 4.41e-15 0.61 0.45 Response to fenofibrate (adiponectin levels); chr15:45391597 chr15:45251580~45279251:- LIHC cis rs507080 0.885 rs7926959 ENSG00000255422.1 AP002954.4 -9.31 1.64e-18 4.6e-15 -0.52 -0.45 Serum metabolite levels; chr11:118689157 chr11:118704607~118750263:+ LIHC cis rs6860806 0.507 rs2631369 ENSG00000233006.5 AC034220.3 -9.3 1.67e-18 4.69e-15 -0.45 -0.45 Breast cancer; chr5:132369574 chr5:132311285~132369916:- LIHC cis rs274567 0.501 rs2631368 ENSG00000233006.5 AC034220.3 -9.3 1.67e-18 4.69e-15 -0.45 -0.45 Blood metabolite levels; chr5:132369605 chr5:132311285~132369916:- LIHC cis rs507080 0.769 rs570952 ENSG00000255422.1 AP002954.4 -9.3 1.77e-18 4.96e-15 -0.52 -0.45 Serum metabolite levels; chr11:118629477 chr11:118704607~118750263:+ LIHC cis rs2739330 0.731 rs2000468 ENSG00000231271.1 AP000350.8 9.29 1.84e-18 5.13e-15 0.53 0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23949918~23954042:+ LIHC cis rs11317778 1 rs11317778 ENSG00000248489.1 CTD-2007H13.3 9.29 1.84e-18 5.15e-15 0.67 0.45 Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr5:98905525 chr5:98929171~98995013:+ LIHC cis rs150992 0.711 rs2617507 ENSG00000248489.1 CTD-2007H13.3 9.29 1.84e-18 5.15e-15 0.67 0.45 Body mass index; chr5:98912548 chr5:98929171~98995013:+ LIHC cis rs8062405 1 rs72793811 ENSG00000259982.1 CDC37P1 9.29 1.85e-18 5.17e-15 0.53 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828071 chr16:28700294~28701540:- LIHC cis rs8062405 0.723 rs4788079 ENSG00000259982.1 CDC37P1 9.29 1.87e-18 5.22e-15 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548042 chr16:28700294~28701540:- LIHC cis rs12439619 0.693 rs9944185 ENSG00000278603.1 RP13-608F4.5 9.29 1.89e-18 5.28e-15 0.78 0.45 Intelligence (multi-trait analysis); chr15:82157927 chr15:82472203~82472426:+ LIHC cis rs507080 0.922 rs625513 ENSG00000255422.1 AP002954.4 -9.28 1.92e-18 5.36e-15 -0.52 -0.45 Serum metabolite levels; chr11:118685010 chr11:118704607~118750263:+ LIHC cis rs6860806 0.507 rs272878 ENSG00000233006.5 AC034220.3 -9.28 1.96e-18 5.46e-15 -0.46 -0.45 Breast cancer; chr5:132336076 chr5:132311285~132369916:- LIHC cis rs1577917 1 rs12216203 ENSG00000203875.9 SNHG5 -9.28 1.97e-18 5.49e-15 -0.54 -0.45 Response to antipsychotic treatment; chr6:85965583 chr6:85660950~85678736:- LIHC cis rs7208859 0.725 rs9910051 ENSG00000263531.1 RP13-753N3.1 9.28 1.98e-18 5.5e-15 0.77 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834184 chr17:30863921~30864940:- LIHC cis rs507080 0.961 rs4457789 ENSG00000255422.1 AP002954.4 -9.28 1.99e-18 5.53e-15 -0.52 -0.45 Serum metabolite levels; chr11:118668461 chr11:118704607~118750263:+ LIHC cis rs1577917 1 rs68171315 ENSG00000203875.9 SNHG5 -9.27 2.13e-18 5.92e-15 -0.54 -0.45 Response to antipsychotic treatment; chr6:85997682 chr6:85660950~85678736:- LIHC cis rs10256972 0.713 rs10435026 ENSG00000229043.2 AC091729.9 -9.27 2.16e-18 5.99e-15 -0.52 -0.45 Endometriosis;Longevity; chr7:1026312 chr7:1160374~1165267:+ LIHC cis rs1577917 0.874 rs11756621 ENSG00000203875.9 SNHG5 -9.27 2.21e-18 6.11e-15 -0.55 -0.45 Response to antipsychotic treatment; chr6:86030345 chr6:85660950~85678736:- LIHC cis rs296381 0.866 rs2637115 ENSG00000259108.2 CTD-3098H1.2 -9.26 2.24e-18 6.2e-15 -0.76 -0.45 Blood metabolite levels; chr19:47882370 chr19:47863483~47865341:- LIHC cis rs6860806 0.507 rs273917 ENSG00000233006.5 AC034220.3 9.26 2.27e-18 6.28e-15 0.45 0.45 Breast cancer; chr5:132323925 chr5:132311285~132369916:- LIHC cis rs270601 0.913 rs273916 ENSG00000233006.5 AC034220.3 9.26 2.27e-18 6.28e-15 0.45 0.45 Acylcarnitine levels; chr5:132324137 chr5:132311285~132369916:- LIHC cis rs6860806 0.507 rs273915 ENSG00000233006.5 AC034220.3 9.26 2.27e-18 6.28e-15 0.45 0.45 Breast cancer; chr5:132324426 chr5:132311285~132369916:- LIHC cis rs270601 0.955 rs273911 ENSG00000233006.5 AC034220.3 9.26 2.27e-18 6.28e-15 0.45 0.45 Acylcarnitine levels; chr5:132325833 chr5:132311285~132369916:- LIHC cis rs858239 0.899 rs1881203 ENSG00000230658.1 KLHL7-AS1 9.26 2.36e-18 6.52e-15 0.59 0.45 Cerebrospinal fluid biomarker levels; chr7:23253189 chr7:23101228~23105703:- LIHC cis rs150992 0.711 rs326489 ENSG00000248489.1 CTD-2007H13.3 9.26 2.37e-18 6.55e-15 0.67 0.45 Body mass index; chr5:98841105 chr5:98929171~98995013:+ LIHC cis rs6860806 0.531 rs272887 ENSG00000233006.5 AC034220.3 9.26 2.38e-18 6.58e-15 0.45 0.45 Breast cancer; chr5:132330020 chr5:132311285~132369916:- LIHC cis rs274567 0.55 rs272885 ENSG00000233006.5 AC034220.3 9.26 2.38e-18 6.58e-15 0.45 0.45 Blood metabolite levels; chr5:132332043 chr5:132311285~132369916:- LIHC cis rs6860806 0.507 rs272883 ENSG00000233006.5 AC034220.3 9.26 2.38e-18 6.58e-15 0.45 0.45 Breast cancer; chr5:132333005 chr5:132311285~132369916:- LIHC cis rs6860806 0.507 rs272882 ENSG00000233006.5 AC034220.3 9.26 2.38e-18 6.58e-15 0.45 0.45 Breast cancer; chr5:132333468 chr5:132311285~132369916:- LIHC cis rs6860806 0.507 rs272880 ENSG00000233006.5 AC034220.3 9.26 2.38e-18 6.58e-15 0.45 0.45 Breast cancer; chr5:132334485 chr5:132311285~132369916:- LIHC cis rs1577917 1 rs1415753 ENSG00000203875.9 SNHG5 -9.26 2.39e-18 6.61e-15 -0.55 -0.45 Response to antipsychotic treatment; chr6:86043356 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs1577919 ENSG00000203875.9 SNHG5 -9.26 2.39e-18 6.61e-15 -0.55 -0.45 Response to antipsychotic treatment; chr6:86047578 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12203493 ENSG00000203875.9 SNHG5 -9.26 2.39e-18 6.61e-15 -0.55 -0.45 Response to antipsychotic treatment; chr6:86048924 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12665321 ENSG00000203875.9 SNHG5 -9.26 2.39e-18 6.61e-15 -0.55 -0.45 Response to antipsychotic treatment; chr6:86059571 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12203924 ENSG00000203875.9 SNHG5 -9.26 2.39e-18 6.61e-15 -0.55 -0.45 Response to antipsychotic treatment; chr6:86066694 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12196175 ENSG00000203875.9 SNHG5 -9.26 2.39e-18 6.61e-15 -0.55 -0.45 Response to antipsychotic treatment; chr6:86069652 chr6:85660950~85678736:- LIHC cis rs12439619 0.693 rs4778989 ENSG00000278603.1 RP13-608F4.5 9.26 2.4e-18 6.62e-15 0.77 0.45 Intelligence (multi-trait analysis); chr15:82276963 chr15:82472203~82472426:+ LIHC cis rs12439619 0.705 rs17354185 ENSG00000278603.1 RP13-608F4.5 -9.25 2.41e-18 6.64e-15 -0.83 -0.45 Intelligence (multi-trait analysis); chr15:82133829 chr15:82472203~82472426:+ LIHC cis rs507080 0.769 rs11603616 ENSG00000255422.1 AP002954.4 -9.25 2.45e-18 6.76e-15 -0.52 -0.45 Serum metabolite levels; chr11:118625350 chr11:118704607~118750263:+ LIHC cis rs12439619 0.883 rs62012045 ENSG00000278603.1 RP13-608F4.5 9.25 2.47e-18 6.82e-15 0.76 0.45 Intelligence (multi-trait analysis); chr15:82229366 chr15:82472203~82472426:+ LIHC cis rs9843304 0.772 rs4681515 ENSG00000244503.1 RP11-278L15.6 -9.25 2.51e-18 6.87e-15 -0.41 -0.45 Gallstone disease; chr3:149494289 chr3:149494660~149495995:+ LIHC cis rs67383717 0.689 rs1836404 ENSG00000175611.10 LINC00476 -9.25 2.52e-18 6.89e-15 -0.53 -0.45 Parkinson's disease (pesticide exposure interaction); chr9:95787982 chr9:95759231~95875977:- LIHC cis rs6860806 0.507 rs272892 ENSG00000233006.5 AC034220.3 9.25 2.54e-18 6.96e-15 0.45 0.45 Breast cancer; chr5:132328656 chr5:132311285~132369916:- LIHC cis rs6860806 0.507 rs272891 ENSG00000233006.5 AC034220.3 9.25 2.54e-18 6.96e-15 0.45 0.45 Breast cancer; chr5:132328701 chr5:132311285~132369916:- LIHC cis rs6860806 0.531 rs272888 ENSG00000233006.5 AC034220.3 9.25 2.54e-18 6.96e-15 0.45 0.45 Breast cancer; chr5:132329730 chr5:132311285~132369916:- LIHC cis rs17711722 0.528 rs73138179 ENSG00000164669.11 INTS4P1 -9.24 2.63e-18 7.2e-15 -0.56 -0.45 Calcium levels; chr7:65829495 chr7:65141225~65234216:+ LIHC cis rs6844153 0.752 rs58968032 ENSG00000240005.4 RP11-293A21.1 -9.24 2.69e-18 7.34e-15 -0.53 -0.45 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26884674 chr4:26859806~26860599:- LIHC cis rs507080 0.769 rs645637 ENSG00000255422.1 AP002954.4 -9.24 2.7e-18 7.37e-15 -0.52 -0.45 Serum metabolite levels; chr11:118634373 chr11:118704607~118750263:+ LIHC cis rs8062405 0.964 rs62036614 ENSG00000259982.1 CDC37P1 9.24 2.72e-18 7.44e-15 0.53 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28813364 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs62036616 ENSG00000259982.1 CDC37P1 9.24 2.72e-18 7.44e-15 0.53 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814986 chr16:28700294~28701540:- LIHC cis rs12439619 0.921 rs4778672 ENSG00000278603.1 RP13-608F4.5 -9.24 2.73e-18 7.44e-15 -0.76 -0.45 Intelligence (multi-trait analysis); chr15:82245013 chr15:82472203~82472426:+ LIHC cis rs9843304 0.9 rs6774253 ENSG00000244503.1 RP11-278L15.6 -9.24 2.74e-18 7.49e-15 -0.41 -0.45 Gallstone disease; chr3:149494110 chr3:149494660~149495995:+ LIHC cis rs8062405 0.755 rs4787457 ENSG00000259982.1 CDC37P1 9.23 2.82e-18 7.69e-15 0.55 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28544079 chr16:28700294~28701540:- LIHC cis rs8062405 0.755 rs4788080 ENSG00000259982.1 CDC37P1 9.23 2.82e-18 7.69e-15 0.55 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28546760 chr16:28700294~28701540:- LIHC cis rs8062405 0.755 rs4787456 ENSG00000259982.1 CDC37P1 9.23 2.82e-18 7.69e-15 0.55 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548252 chr16:28700294~28701540:- LIHC cis rs8062405 0.755 rs4788078 ENSG00000259982.1 CDC37P1 9.23 2.82e-18 7.69e-15 0.55 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548660 chr16:28700294~28701540:- LIHC cis rs8062405 0.755 rs62034350 ENSG00000259982.1 CDC37P1 9.23 2.82e-18 7.69e-15 0.55 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28550935 chr16:28700294~28701540:- LIHC cis rs8062405 0.755 rs4149398 ENSG00000259982.1 CDC37P1 9.23 2.85e-18 7.75e-15 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597617 chr16:28700294~28701540:- LIHC cis rs8062405 0.755 rs17640009 ENSG00000259982.1 CDC37P1 9.23 2.85e-18 7.77e-15 0.56 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28584379 chr16:28700294~28701540:- LIHC cis rs2739330 0.76 rs5751761 ENSG00000231271.1 AP000350.8 -9.23 2.87e-18 7.8e-15 -0.54 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23949918~23954042:+ LIHC cis rs4889009 0.533 rs12596569 ENSG00000261390.4 RP11-345M22.2 9.23 2.87e-18 7.81e-15 0.53 0.45 Thyroid peroxidase antibody positivity; chr16:79701354 chr16:79715232~79770563:- LIHC cis rs12439619 0.693 rs17269819 ENSG00000278603.1 RP13-608F4.5 9.23 2.94e-18 7.98e-15 0.77 0.45 Intelligence (multi-trait analysis); chr15:82174660 chr15:82472203~82472426:+ LIHC cis rs507080 0.885 rs693037 ENSG00000255422.1 AP002954.4 -9.23 2.94e-18 7.98e-15 -0.52 -0.45 Serum metabolite levels; chr11:118682617 chr11:118704607~118750263:+ LIHC cis rs2882667 0.893 rs10054796 ENSG00000253404.1 AC034243.1 9.23 2.97e-18 8.08e-15 0.61 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:138958655 chr5:138744434~138753309:- LIHC cis rs2882667 0.893 rs10069961 ENSG00000253404.1 AC034243.1 9.23 2.97e-18 8.08e-15 0.61 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:138958879 chr5:138744434~138753309:- LIHC cis rs977987 0.741 rs10514393 ENSG00000261783.1 RP11-252K23.2 -9.23 3e-18 8.14e-15 -0.52 -0.45 Dupuytren's disease; chr16:75310578 chr16:75379818~75381260:- LIHC cis rs150992 0.678 rs161950 ENSG00000248489.1 CTD-2007H13.3 -9.22 3.01e-18 8.17e-15 -0.66 -0.45 Body mass index; chr5:98924533 chr5:98929171~98995013:+ LIHC cis rs1577917 1 rs12196411 ENSG00000203875.9 SNHG5 -9.22 3.02e-18 8.21e-15 -0.55 -0.45 Response to antipsychotic treatment; chr6:86070044 chr6:85660950~85678736:- LIHC cis rs507080 0.769 rs2077173 ENSG00000255422.1 AP002954.4 -9.22 3.05e-18 8.28e-15 -0.52 -0.45 Serum metabolite levels; chr11:118621876 chr11:118704607~118750263:+ LIHC cis rs8062405 1 rs72793812 ENSG00000259982.1 CDC37P1 9.22 3.06e-18 8.3e-15 0.53 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28829060 chr16:28700294~28701540:- LIHC cis rs12439619 0.921 rs56042848 ENSG00000278603.1 RP13-608F4.5 9.22 3.07e-18 8.32e-15 0.76 0.45 Intelligence (multi-trait analysis); chr15:82235244 chr15:82472203~82472426:+ LIHC cis rs8062405 1 rs12443881 ENSG00000259982.1 CDC37P1 9.22 3.07e-18 8.32e-15 0.53 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28830456 chr16:28700294~28701540:- LIHC cis rs1577917 0.739 rs2758846 ENSG00000203875.9 SNHG5 -9.22 3.09e-18 8.36e-15 -0.52 -0.45 Response to antipsychotic treatment; chr6:85639852 chr6:85660950~85678736:- LIHC cis rs2882667 0.893 rs10044672 ENSG00000253404.1 AC034243.1 9.22 3.09e-18 8.36e-15 0.61 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:138954790 chr5:138744434~138753309:- LIHC cis rs8062405 1 rs12325113 ENSG00000259982.1 CDC37P1 9.22 3.09e-18 8.36e-15 0.53 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28837347 chr16:28700294~28701540:- LIHC cis rs56163509 1 rs56163509 ENSG00000259982.1 CDC37P1 9.22 3.09e-18 8.36e-15 0.53 0.45 Tonsillectomy;Mean corpuscular volume; chr16:28853150 chr16:28700294~28701540:- LIHC cis rs8062405 0.964 rs7187333 ENSG00000259982.1 CDC37P1 9.22 3.09e-18 8.36e-15 0.53 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28854595 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs62037369 ENSG00000259982.1 CDC37P1 9.22 3.09e-18 8.36e-15 0.53 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28872520 chr16:28700294~28701540:- LIHC cis rs8062405 0.965 rs7359397 ENSG00000259982.1 CDC37P1 9.22 3.09e-18 8.36e-15 0.53 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28874338 chr16:28700294~28701540:- LIHC cis rs11723261 0.621 rs11733385 ENSG00000275426.1 CH17-262A2.1 9.22 3.11e-18 8.42e-15 0.55 0.45 Immune response to smallpox vaccine (IL-6); chr4:146677 chr4:149738~150317:+ LIHC cis rs11723261 0.546 rs4315728 ENSG00000275426.1 CH17-262A2.1 9.22 3.11e-18 8.42e-15 0.55 0.45 Immune response to smallpox vaccine (IL-6); chr4:147237 chr4:149738~150317:+ LIHC cis rs977987 0.872 rs1559339 ENSG00000261783.1 RP11-252K23.2 -9.22 3.16e-18 8.56e-15 -0.52 -0.45 Dupuytren's disease; chr16:75284748 chr16:75379818~75381260:- LIHC cis rs7208859 0.725 rs9897673 ENSG00000263531.1 RP13-753N3.1 9.22 3.18e-18 8.6e-15 0.75 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916348 chr17:30863921~30864940:- LIHC cis rs1577917 0.771 rs2842601 ENSG00000203875.9 SNHG5 -9.22 3.22e-18 8.71e-15 -0.52 -0.45 Response to antipsychotic treatment; chr6:85620415 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12192546 ENSG00000203875.9 SNHG5 9.22 3.23e-18 8.73e-15 0.55 0.45 Response to antipsychotic treatment; chr6:85766766 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs6940458 ENSG00000203875.9 SNHG5 -9.21 3.24e-18 8.77e-15 -0.54 -0.45 Response to antipsychotic treatment; chr6:85935274 chr6:85660950~85678736:- LIHC cis rs10256972 0.786 rs3735686 ENSG00000229043.2 AC091729.9 -9.21 3.27e-18 8.84e-15 -0.51 -0.45 Endometriosis;Longevity; chr7:1022891 chr7:1160374~1165267:+ LIHC cis rs17608059 0.524 rs9897978 ENSG00000141028.6 CDRT15P1 9.21 3.29e-18 8.89e-15 0.53 0.45 Temperament; chr17:13996939 chr17:14024514~14025488:+ LIHC cis rs11723261 0.621 rs57013142 ENSG00000275426.1 CH17-262A2.1 9.21 3.37e-18 9.09e-15 0.55 0.45 Immune response to smallpox vaccine (IL-6); chr4:141956 chr4:149738~150317:+ LIHC cis rs858239 0.796 rs433395 ENSG00000230658.1 KLHL7-AS1 9.21 3.38e-18 9.11e-15 0.56 0.45 Cerebrospinal fluid biomarker levels; chr7:23362336 chr7:23101228~23105703:- LIHC cis rs296381 0.808 rs10426201 ENSG00000259108.2 CTD-3098H1.2 -9.21 3.43e-18 9.25e-15 -0.76 -0.45 Blood metabolite levels; chr19:47881492 chr19:47863483~47865341:- LIHC cis rs1577917 0.74 rs9450302 ENSG00000234155.1 RP11-30P6.6 -9.21 3.46e-18 9.33e-15 -0.52 -0.45 Response to antipsychotic treatment; chr6:85579955 chr6:85387219~85390186:- LIHC cis rs12439619 0.693 rs7165536 ENSG00000278603.1 RP13-608F4.5 9.2 3.63e-18 9.76e-15 0.77 0.45 Intelligence (multi-trait analysis); chr15:82273743 chr15:82472203~82472426:+ LIHC cis rs8062405 1 rs7498555 ENSG00000259982.1 CDC37P1 9.2 3.65e-18 9.82e-15 0.53 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28882250 chr16:28700294~28701540:- LIHC cis rs507080 0.769 rs571001 ENSG00000255422.1 AP002954.4 -9.2 3.69e-18 9.93e-15 -0.52 -0.45 Serum metabolite levels; chr11:118629457 chr11:118704607~118750263:+ LIHC cis rs8062405 0.755 rs4788074 ENSG00000259982.1 CDC37P1 -9.2 3.75e-18 1.01e-14 -0.55 -0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28582276 chr16:28700294~28701540:- LIHC cis rs1577917 0.771 rs2783171 ENSG00000203875.9 SNHG5 9.2 3.75e-18 1.01e-14 0.51 0.45 Response to antipsychotic treatment; chr6:85673047 chr6:85660950~85678736:- LIHC cis rs1577917 0.771 rs2842612 ENSG00000203875.9 SNHG5 -9.19 3.78e-18 1.02e-14 -0.51 -0.45 Response to antipsychotic treatment; chr6:85593373 chr6:85660950~85678736:- LIHC cis rs2882667 0.893 rs7717375 ENSG00000253404.1 AC034243.1 9.19 3.79e-18 1.02e-14 0.61 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:138955716 chr5:138744434~138753309:- LIHC cis rs1577917 0.727 rs2758840 ENSG00000203875.9 SNHG5 -9.19 3.83e-18 1.03e-14 -0.51 -0.45 Response to antipsychotic treatment; chr6:85594907 chr6:85660950~85678736:- LIHC cis rs1577917 0.771 rs9362230 ENSG00000203875.9 SNHG5 -9.19 3.83e-18 1.03e-14 -0.51 -0.45 Response to antipsychotic treatment; chr6:85595295 chr6:85660950~85678736:- LIHC cis rs2882667 0.893 rs13180851 ENSG00000253404.1 AC034243.1 9.19 3.85e-18 1.03e-14 0.61 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:138954918 chr5:138744434~138753309:- LIHC cis rs12439619 0.693 rs8034801 ENSG00000278603.1 RP13-608F4.5 9.19 3.85e-18 1.03e-14 0.77 0.45 Intelligence (multi-trait analysis); chr15:82183996 chr15:82472203~82472426:+ LIHC cis rs2739330 0.828 rs2877178 ENSG00000231271.1 AP000350.8 9.19 3.89e-18 1.04e-14 0.51 0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23949918~23954042:+ LIHC cis rs1577917 0.958 rs11755048 ENSG00000203875.9 SNHG5 -9.19 3.92e-18 1.05e-14 -0.56 -0.45 Response to antipsychotic treatment; chr6:85804616 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12212733 ENSG00000203875.9 SNHG5 -9.19 3.92e-18 1.05e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:86016295 chr6:85660950~85678736:- LIHC cis rs8062405 0.755 rs2077031 ENSG00000259982.1 CDC37P1 9.19 4.03e-18 1.08e-14 0.56 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28591847 chr16:28700294~28701540:- LIHC cis rs9660180 1 rs3737628 ENSG00000231050.1 RP1-140A9.1 9.18 4.08e-18 1.09e-14 0.41 0.44 Body mass index; chr1:1791493 chr1:1891471~1892658:+ LIHC cis rs6860806 0.507 rs2631362 ENSG00000233006.5 AC034220.3 -9.18 4.33e-18 1.16e-14 -0.45 -0.44 Breast cancer; chr5:132371601 chr5:132311285~132369916:- LIHC cis rs1577917 0.771 rs2842602 ENSG00000203875.9 SNHG5 -9.18 4.34e-18 1.16e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85622169 chr6:85660950~85678736:- LIHC cis rs7684253 0.526 rs34112167 ENSG00000269949.1 RP11-738E22.3 -9.17 4.38e-18 1.17e-14 -0.62 -0.44 Migraine; chr4:56853383 chr4:56960927~56961373:- LIHC cis rs2739330 0.828 rs5751770 ENSG00000231271.1 AP000350.8 9.17 4.4e-18 1.18e-14 0.51 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23949918~23954042:+ LIHC cis rs2455601 0.638 rs11042148 ENSG00000254860.4 TMEM9B-AS1 9.17 4.41e-18 1.18e-14 0.52 0.44 Schizophrenia; chr11:8987127 chr11:8964675~8977527:+ LIHC cis rs8062405 0.755 rs7193402 ENSG00000259982.1 CDC37P1 9.17 4.43e-18 1.18e-14 0.55 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28574806 chr16:28700294~28701540:- LIHC cis rs1577917 0.771 rs12199873 ENSG00000203875.9 SNHG5 -9.17 4.52e-18 1.2e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85585229 chr6:85660950~85678736:- LIHC cis rs1577917 0.771 rs2842609 ENSG00000203875.9 SNHG5 -9.17 4.52e-18 1.2e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85587070 chr6:85660950~85678736:- LIHC cis rs875971 0.83 rs427575 ENSG00000226824.5 RP4-756H11.3 -9.17 4.53e-18 1.21e-14 -0.55 -0.44 Aortic root size; chr7:66054232 chr7:66654538~66669855:+ LIHC cis rs8062405 0.723 rs113208333 ENSG00000259982.1 CDC37P1 9.17 4.56e-18 1.22e-14 0.56 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28594839 chr16:28700294~28701540:- LIHC cis rs1577917 0.727 rs9351065 ENSG00000203875.9 SNHG5 -9.17 4.59e-18 1.22e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85650710 chr6:85660950~85678736:- LIHC cis rs8062405 0.691 rs743590 ENSG00000259982.1 CDC37P1 9.17 4.63e-18 1.23e-14 0.56 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28596909 chr16:28700294~28701540:- LIHC cis rs8062405 1 rs62036622 ENSG00000259982.1 CDC37P1 9.16 4.77e-18 1.27e-14 0.53 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28825882 chr16:28700294~28701540:- LIHC cis rs12439619 0.693 rs28689861 ENSG00000278603.1 RP13-608F4.5 9.16 4.95e-18 1.32e-14 0.76 0.44 Intelligence (multi-trait analysis); chr15:82206369 chr15:82472203~82472426:+ LIHC cis rs11723261 0.564 rs61792258 ENSG00000275426.1 CH17-262A2.1 9.16 4.99e-18 1.33e-14 0.54 0.44 Immune response to smallpox vaccine (IL-6); chr4:143482 chr4:149738~150317:+ LIHC cis rs858239 0.829 rs2268744 ENSG00000230658.1 KLHL7-AS1 9.15 5.09e-18 1.35e-14 0.62 0.44 Cerebrospinal fluid biomarker levels; chr7:23292661 chr7:23101228~23105703:- LIHC cis rs1577917 0.958 rs13213551 ENSG00000203875.9 SNHG5 -9.15 5.26e-18 1.39e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85898983 chr6:85660950~85678736:- LIHC cis rs1577917 0.876 rs12201992 ENSG00000203875.9 SNHG5 -9.15 5.26e-18 1.39e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85908501 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12201880 ENSG00000203875.9 SNHG5 -9.15 5.26e-18 1.39e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85917289 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs7756203 ENSG00000203875.9 SNHG5 -9.15 5.26e-18 1.39e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85917989 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs10944161 ENSG00000203875.9 SNHG5 -9.15 5.26e-18 1.39e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85920658 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs1857965 ENSG00000203875.9 SNHG5 -9.15 5.26e-18 1.39e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85921058 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs34622557 ENSG00000203875.9 SNHG5 -9.15 5.26e-18 1.39e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85921134 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs1911553 ENSG00000203875.9 SNHG5 -9.15 5.26e-18 1.39e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85921174 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs7771342 ENSG00000203875.9 SNHG5 -9.15 5.26e-18 1.39e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85922218 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs1995688 ENSG00000203875.9 SNHG5 -9.15 5.26e-18 1.39e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85922601 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12154056 ENSG00000203875.9 SNHG5 -9.15 5.26e-18 1.39e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85924376 chr6:85660950~85678736:- LIHC cis rs150992 0.673 rs331929 ENSG00000248489.1 CTD-2007H13.3 9.15 5.27e-18 1.4e-14 0.67 0.44 Body mass index; chr5:98830528 chr5:98929171~98995013:+ LIHC cis rs1577917 0.771 rs4441928 ENSG00000203875.9 SNHG5 9.15 5.3e-18 1.4e-14 0.5 0.44 Response to antipsychotic treatment; chr6:85532176 chr6:85660950~85678736:- LIHC cis rs7208859 0.673 rs57432042 ENSG00000263531.1 RP13-753N3.1 9.15 5.32e-18 1.41e-14 0.82 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30914020 chr17:30863921~30864940:- LIHC cis rs1799949 0.965 rs8067269 ENSG00000198496.9 NBR2 -9.15 5.35e-18 1.42e-14 -0.5 -0.44 Menopause (age at onset); chr17:43083782 chr17:43125610~43153671:+ LIHC cis rs17711722 0.51 rs11767457 ENSG00000164669.11 INTS4P1 -9.15 5.36e-18 1.42e-14 -0.55 -0.44 Calcium levels; chr7:65825628 chr7:65141225~65234216:+ LIHC cis rs8062405 0.755 rs17707300 ENSG00000259982.1 CDC37P1 9.15 5.44e-18 1.44e-14 0.56 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28582026 chr16:28700294~28701540:- LIHC cis rs1577917 0.958 rs12215232 ENSG00000203875.9 SNHG5 -9.14 5.45e-18 1.44e-14 -0.56 -0.44 Response to antipsychotic treatment; chr6:86075712 chr6:85660950~85678736:- LIHC cis rs9660180 0.934 rs34849348 ENSG00000231050.1 RP1-140A9.1 9.14 5.51e-18 1.45e-14 0.42 0.44 Body mass index; chr1:1831318 chr1:1891471~1892658:+ LIHC cis rs1577917 0.771 rs2475790 ENSG00000203875.9 SNHG5 -9.14 5.56e-18 1.47e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85658350 chr6:85660950~85678736:- LIHC cis rs1577917 0.771 rs9362233 ENSG00000203875.9 SNHG5 -9.14 5.57e-18 1.47e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85648529 chr6:85660950~85678736:- LIHC cis rs9660180 1 rs9660180 ENSG00000231050.1 RP1-140A9.1 9.14 5.59e-18 1.47e-14 0.41 0.44 Body mass index; chr1:1791592 chr1:1891471~1892658:+ LIHC cis rs7684253 0.548 rs922570 ENSG00000269949.1 RP11-738E22.3 -9.14 5.68e-18 1.5e-14 -0.61 -0.44 Migraine; chr4:56851192 chr4:56960927~56961373:- LIHC cis rs7684253 0.548 rs13108002 ENSG00000269949.1 RP11-738E22.3 -9.14 5.68e-18 1.5e-14 -0.61 -0.44 Migraine; chr4:56852087 chr4:56960927~56961373:- LIHC cis rs3762637 0.882 rs9856011 ENSG00000272758.4 RP11-299J3.8 -9.14 5.72e-18 1.51e-14 -0.57 -0.44 LDL cholesterol levels; chr3:122374723 chr3:122416207~122443180:+ LIHC cis rs6860806 0.507 rs272854 ENSG00000233006.5 AC034220.3 9.14 5.82e-18 1.53e-14 0.44 0.44 Breast cancer; chr5:132352324 chr5:132311285~132369916:- LIHC cis rs150992 0.585 rs331931 ENSG00000248489.1 CTD-2007H13.3 9.13 5.9e-18 1.55e-14 0.67 0.44 Body mass index; chr5:98834012 chr5:98929171~98995013:+ LIHC cis rs8062405 1 rs12446589 ENSG00000259982.1 CDC37P1 9.13 5.91e-18 1.55e-14 0.53 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859641 chr16:28700294~28701540:- LIHC cis rs3762637 0.941 rs9863712 ENSG00000272758.4 RP11-299J3.8 -9.13 5.94e-18 1.56e-14 -0.57 -0.44 LDL cholesterol levels; chr3:122381059 chr3:122416207~122443180:+ LIHC cis rs3762637 0.941 rs28679619 ENSG00000272758.4 RP11-299J3.8 -9.13 5.94e-18 1.56e-14 -0.57 -0.44 LDL cholesterol levels; chr3:122381502 chr3:122416207~122443180:+ LIHC cis rs9660180 0.935 rs9786942 ENSG00000231050.1 RP1-140A9.1 9.13 5.98e-18 1.57e-14 0.42 0.44 Body mass index; chr1:1827774 chr1:1891471~1892658:+ LIHC cis rs4718428 0.96 rs6460317 ENSG00000226824.5 RP4-756H11.3 -9.13 6.11e-18 1.6e-14 -0.6 -0.44 Corneal structure; chr7:66925268 chr7:66654538~66669855:+ LIHC cis rs8062405 0.723 rs62031562 ENSG00000259982.1 CDC37P1 9.13 6.18e-18 1.62e-14 0.56 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28598008 chr16:28700294~28701540:- LIHC cis rs1577917 0.771 rs10944133 ENSG00000203875.9 SNHG5 -9.13 6.24e-18 1.64e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85649266 chr6:85660950~85678736:- LIHC cis rs7208859 0.623 rs7220999 ENSG00000263531.1 RP13-753N3.1 9.12 6.35e-18 1.66e-14 0.79 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822280 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs55638872 ENSG00000263531.1 RP13-753N3.1 9.12 6.35e-18 1.66e-14 0.79 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822534 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9899268 ENSG00000263531.1 RP13-753N3.1 9.12 6.35e-18 1.66e-14 0.79 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30823237 chr17:30863921~30864940:- LIHC cis rs2739330 0.828 rs5760102 ENSG00000231271.1 AP000350.8 9.12 6.38e-18 1.67e-14 0.52 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23949918~23954042:+ LIHC cis rs1577917 0.771 rs2475791 ENSG00000203875.9 SNHG5 -9.12 6.52e-18 1.71e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85658446 chr6:85660950~85678736:- LIHC cis rs2739330 0.828 rs2154593 ENSG00000231271.1 AP000350.8 9.12 6.69e-18 1.75e-14 0.51 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23949918~23954042:+ LIHC cis rs8062405 0.722 rs3785354 ENSG00000259982.1 CDC37P1 9.12 6.76e-18 1.77e-14 0.55 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28539346 chr16:28700294~28701540:- LIHC cis rs2739330 0.791 rs4822458 ENSG00000231271.1 AP000350.8 9.12 6.78e-18 1.77e-14 0.51 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23949918~23954042:+ LIHC cis rs3762637 0.943 rs9841897 ENSG00000272758.4 RP11-299J3.8 -9.12 6.79e-18 1.78e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122563722 chr3:122416207~122443180:+ LIHC cis rs3762637 0.943 rs28372690 ENSG00000272758.4 RP11-299J3.8 -9.12 6.79e-18 1.78e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122564248 chr3:122416207~122443180:+ LIHC cis rs1577917 1 rs11758849 ENSG00000203875.9 SNHG5 -9.12 6.8e-18 1.78e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85998544 chr6:85660950~85678736:- LIHC cis rs1577917 0.74 rs2842604 ENSG00000203875.9 SNHG5 -9.11 6.82e-18 1.78e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85626582 chr6:85660950~85678736:- LIHC cis rs1577917 0.771 rs2842607 ENSG00000203875.9 SNHG5 -9.11 6.82e-18 1.78e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85635321 chr6:85660950~85678736:- LIHC cis rs1577917 0.771 rs2758847 ENSG00000203875.9 SNHG5 -9.11 6.82e-18 1.78e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85639385 chr6:85660950~85678736:- LIHC cis rs10916248 0.559 rs56023673 ENSG00000232628.4 RP11-365O16.3 9.11 6.84e-18 1.79e-14 0.67 0.44 QT interval (drug interaction); chr1:224180821 chr1:224208747~224213279:- LIHC cis rs1577917 0.958 rs7747897 ENSG00000203875.9 SNHG5 -9.11 6.89e-18 1.8e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85937631 chr6:85660950~85678736:- LIHC cis rs2739330 0.828 rs5760108 ENSG00000231271.1 AP000350.8 9.11 7.01e-18 1.83e-14 0.51 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23949918~23954042:+ LIHC cis rs8062405 0.895 rs62036658 ENSG00000259982.1 CDC37P1 9.11 7.04e-18 1.83e-14 0.53 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28839050 chr16:28700294~28701540:- LIHC cis rs2739330 0.828 rs2186366 ENSG00000231271.1 AP000350.8 -9.11 7.08e-18 1.85e-14 -0.53 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23949918~23954042:+ LIHC cis rs8062405 0.69 rs7187604 ENSG00000259982.1 CDC37P1 9.11 7.12e-18 1.86e-14 0.55 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554632 chr16:28700294~28701540:- LIHC cis rs507080 0.769 rs483283 ENSG00000255422.1 AP002954.4 -9.11 7.19e-18 1.87e-14 -0.51 -0.44 Serum metabolite levels; chr11:118635684 chr11:118704607~118750263:+ LIHC cis rs1577917 0.655 rs9359658 ENSG00000234155.1 RP11-30P6.6 -9.11 7.21e-18 1.88e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85596051 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs11756510 ENSG00000203875.9 SNHG5 -9.11 7.29e-18 1.9e-14 -0.54 -0.44 Response to antipsychotic treatment; chr6:85990076 chr6:85660950~85678736:- LIHC cis rs6504950 0.83 rs12949538 ENSG00000275710.1 RP11-257O5.4 -9.1 7.36e-18 1.92e-14 -0.65 -0.44 Breast cancer; chr17:54933309 chr17:54964474~54964679:+ LIHC cis rs1577917 0.652 rs75593931 ENSG00000203875.9 SNHG5 -9.1 7.37e-18 1.92e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:86009821 chr6:85660950~85678736:- LIHC cis rs1577917 0.959 rs12201739 ENSG00000203875.9 SNHG5 -9.1 7.37e-18 1.92e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:86011021 chr6:85660950~85678736:- LIHC cis rs8062405 0.721 rs151181 ENSG00000259982.1 CDC37P1 9.1 7.39e-18 1.92e-14 0.52 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28479196 chr16:28700294~28701540:- LIHC cis rs1577917 0.74 rs9344533 ENSG00000234155.1 RP11-30P6.6 -9.1 7.47e-18 1.94e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85526470 chr6:85387219~85390186:- LIHC cis rs1577917 0.74 rs9353320 ENSG00000234155.1 RP11-30P6.6 -9.1 7.47e-18 1.94e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85535130 chr6:85387219~85390186:- LIHC cis rs1577917 0.74 rs7775864 ENSG00000234155.1 RP11-30P6.6 -9.1 7.47e-18 1.94e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85538041 chr6:85387219~85390186:- LIHC cis rs1577917 0.655 rs7742691 ENSG00000234155.1 RP11-30P6.6 -9.1 7.48e-18 1.94e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85568973 chr6:85387219~85390186:- LIHC cis rs8062405 0.755 rs56209193 ENSG00000259982.1 CDC37P1 9.1 7.6e-18 1.97e-14 0.56 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28574315 chr16:28700294~28701540:- LIHC cis rs3762637 0.943 rs9289198 ENSG00000272758.4 RP11-299J3.8 -9.1 7.7e-18 2e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122558313 chr3:122416207~122443180:+ LIHC cis rs3762637 0.943 rs9289199 ENSG00000272758.4 RP11-299J3.8 -9.1 7.7e-18 2e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122558325 chr3:122416207~122443180:+ LIHC cis rs10256972 0.626 rs62433138 ENSG00000229043.2 AC091729.9 -9.1 7.72e-18 2e-14 -0.51 -0.44 Endometriosis;Longevity; chr7:1011241 chr7:1160374~1165267:+ LIHC cis rs172166 0.61 rs156737 ENSG00000216901.1 AL022393.7 9.1 7.85e-18 2.04e-14 0.5 0.44 Cardiac Troponin-T levels; chr6:27927435 chr6:28176188~28176674:+ LIHC cis rs1577917 0.71 rs9342041 ENSG00000234155.1 RP11-30P6.6 -9.09 7.97e-18 2.06e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85571157 chr6:85387219~85390186:- LIHC cis rs150992 0.547 rs325217 ENSG00000248489.1 CTD-2007H13.3 9.09 8e-18 2.07e-14 0.66 0.44 Body mass index; chr5:98844109 chr5:98929171~98995013:+ LIHC cis rs1729407 0.774 rs2849167 ENSG00000254851.1 RP11-109L13.1 9.09 8.09e-18 2.09e-14 0.54 0.44 Apolipoprotein A-IV levels; chr11:116814028 chr11:117135528~117138582:+ LIHC cis rs1577917 1 rs10944169 ENSG00000203875.9 SNHG5 -9.09 8.1e-18 2.1e-14 -0.52 -0.44 Response to antipsychotic treatment; chr6:85973318 chr6:85660950~85678736:- LIHC cis rs1577917 0.917 rs35283633 ENSG00000203875.9 SNHG5 -9.09 8.23e-18 2.13e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85981069 chr6:85660950~85678736:- LIHC cis rs6844153 0.68 rs6833053 ENSG00000240005.4 RP11-293A21.1 -9.09 8.35e-18 2.16e-14 -0.51 -0.44 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26870838 chr4:26859806~26860599:- LIHC cis rs875971 0.862 rs6944374 ENSG00000226824.5 RP4-756H11.3 9.09 8.41e-18 2.17e-14 0.52 0.44 Aortic root size; chr7:66221942 chr7:66654538~66669855:+ LIHC cis rs1577917 0.771 rs4351223 ENSG00000203875.9 SNHG5 9.09 8.43e-18 2.18e-14 0.5 0.44 Response to antipsychotic treatment; chr6:85528079 chr6:85660950~85678736:- LIHC cis rs1577917 0.771 rs7452605 ENSG00000203875.9 SNHG5 9.09 8.43e-18 2.18e-14 0.5 0.44 Response to antipsychotic treatment; chr6:85531233 chr6:85660950~85678736:- LIHC cis rs1577917 0.771 rs9294337 ENSG00000203875.9 SNHG5 9.09 8.43e-18 2.18e-14 0.5 0.44 Response to antipsychotic treatment; chr6:85538742 chr6:85660950~85678736:- LIHC cis rs977987 0.836 rs11646044 ENSG00000261783.1 RP11-252K23.2 -9.08 8.56e-18 2.21e-14 -0.52 -0.44 Dupuytren's disease; chr16:75278650 chr16:75379818~75381260:- LIHC cis rs1577917 1 rs12664335 ENSG00000203875.9 SNHG5 9.08 8.57e-18 2.21e-14 0.52 0.44 Response to antipsychotic treatment; chr6:85888056 chr6:85660950~85678736:- LIHC cis rs3762637 0.823 rs59569049 ENSG00000272758.4 RP11-299J3.8 -9.08 8.66e-18 2.23e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122519941 chr3:122416207~122443180:+ LIHC cis rs3762637 0.943 rs9822345 ENSG00000272758.4 RP11-299J3.8 -9.08 8.66e-18 2.23e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122526751 chr3:122416207~122443180:+ LIHC cis rs3762637 0.823 rs9849013 ENSG00000272758.4 RP11-299J3.8 -9.08 8.66e-18 2.23e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122531758 chr3:122416207~122443180:+ LIHC cis rs1577917 0.74 rs6926049 ENSG00000203875.9 SNHG5 9.08 8.71e-18 2.25e-14 0.51 0.44 Response to antipsychotic treatment; chr6:85556415 chr6:85660950~85678736:- LIHC cis rs2487048 0.761 rs2980083 ENSG00000226334.1 RP11-217B7.2 -9.08 8.78e-18 2.26e-14 -0.56 -0.44 Intraocular pressure; chr9:104929081 chr9:104927553~104928892:+ LIHC cis rs1577917 0.771 rs2842608 ENSG00000203875.9 SNHG5 -9.08 8.8e-18 2.27e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85586140 chr6:85660950~85678736:- LIHC cis rs10256972 0.669 rs10229964 ENSG00000229043.2 AC091729.9 -9.08 8.81e-18 2.27e-14 -0.51 -0.44 Endometriosis;Longevity; chr7:1012140 chr7:1160374~1165267:+ LIHC cis rs2739330 0.828 rs5760099 ENSG00000231271.1 AP000350.8 9.08 8.87e-18 2.28e-14 0.51 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23949918~23954042:+ LIHC cis rs858239 0.73 rs10255155 ENSG00000230658.1 KLHL7-AS1 -9.08 8.98e-18 2.31e-14 -0.57 -0.44 Cerebrospinal fluid biomarker levels; chr7:23362528 chr7:23101228~23105703:- LIHC cis rs2283792 0.812 rs5995269 ENSG00000224086.5 LL22NC03-86G7.1 -9.08 9e-18 2.32e-14 -0.41 -0.44 Multiple sclerosis; chr22:21935025 chr22:21938293~21977632:+ LIHC cis rs10256972 0.647 rs10233430 ENSG00000229043.2 AC091729.9 -9.07 9.38e-18 2.41e-14 -0.5 -0.44 Endometriosis;Longevity; chr7:1012028 chr7:1160374~1165267:+ LIHC cis rs3762637 0.943 rs78429050 ENSG00000272758.4 RP11-299J3.8 -9.07 9.43e-18 2.42e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122533581 chr3:122416207~122443180:+ LIHC cis rs6860806 0.507 rs272868 ENSG00000233006.5 AC034220.3 9.07 9.46e-18 2.42e-14 0.44 0.44 Breast cancer; chr5:132345058 chr5:132311285~132369916:- LIHC cis rs6504950 0.83 rs12937006 ENSG00000275710.1 RP11-257O5.4 9.07 9.46e-18 2.42e-14 0.62 0.44 Breast cancer; chr17:54953100 chr17:54964474~54964679:+ LIHC cis rs6504950 0.79 rs8076984 ENSG00000275710.1 RP11-257O5.4 9.07 9.46e-18 2.42e-14 0.62 0.44 Breast cancer; chr17:54958067 chr17:54964474~54964679:+ LIHC cis rs6504950 0.83 rs17745231 ENSG00000275710.1 RP11-257O5.4 9.07 9.46e-18 2.42e-14 0.62 0.44 Breast cancer; chr17:54959168 chr17:54964474~54964679:+ LIHC cis rs6504950 0.83 rs12938118 ENSG00000275710.1 RP11-257O5.4 9.07 9.46e-18 2.42e-14 0.62 0.44 Breast cancer; chr17:54959998 chr17:54964474~54964679:+ LIHC cis rs6504950 0.83 rs1802212 ENSG00000275710.1 RP11-257O5.4 9.07 9.46e-18 2.42e-14 0.62 0.44 Breast cancer; chr17:54961293 chr17:54964474~54964679:+ LIHC cis rs6504950 0.83 rs17817901 ENSG00000275710.1 RP11-257O5.4 9.07 9.46e-18 2.42e-14 0.62 0.44 Breast cancer; chr17:54961384 chr17:54964474~54964679:+ LIHC cis rs6504950 0.83 rs12150038 ENSG00000275710.1 RP11-257O5.4 9.07 9.46e-18 2.42e-14 0.62 0.44 Breast cancer; chr17:54964159 chr17:54964474~54964679:+ LIHC cis rs6504950 0.83 rs12951542 ENSG00000275710.1 RP11-257O5.4 9.07 9.46e-18 2.42e-14 0.62 0.44 Breast cancer; chr17:54964604 chr17:54964474~54964679:+ LIHC cis rs6504950 0.83 rs72831295 ENSG00000275710.1 RP11-257O5.4 9.07 9.46e-18 2.42e-14 0.62 0.44 Breast cancer; chr17:54966443 chr17:54964474~54964679:+ LIHC cis rs1577917 1 rs12205548 ENSG00000203875.9 SNHG5 -9.07 9.57e-18 2.45e-14 -0.55 -0.44 Response to antipsychotic treatment; chr6:86050052 chr6:85660950~85678736:- LIHC cis rs10256972 0.758 rs7799391 ENSG00000229043.2 AC091729.9 -9.07 9.73e-18 2.49e-14 -0.51 -0.44 Endometriosis;Longevity; chr7:1042930 chr7:1160374~1165267:+ LIHC cis rs6597981 0.604 rs7945912 ENSG00000279672.1 CMB9-55F22.1 9.07 9.87e-18 2.52e-14 0.43 0.44 Breast cancer; chr11:750849 chr11:779617~780755:+ LIHC cis rs10256972 0.758 rs9801444 ENSG00000229043.2 AC091729.9 9.06 1.01e-17 2.57e-14 0.52 0.44 Endometriosis;Longevity; chr7:1040808 chr7:1160374~1165267:+ LIHC cis rs2882667 0.964 rs12719517 ENSG00000253404.1 AC034243.1 9.06 1.01e-17 2.58e-14 0.62 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:138969813 chr5:138744434~138753309:- LIHC cis rs2739330 0.753 rs4822452 ENSG00000231271.1 AP000350.8 9.06 1.01e-17 2.58e-14 0.52 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23949918~23954042:+ LIHC cis rs6860806 0.507 rs273901 ENSG00000233006.5 AC034220.3 9.06 1.02e-17 2.6e-14 0.44 0.44 Breast cancer; chr5:132358667 chr5:132311285~132369916:- LIHC cis rs270601 0.913 rs273899 ENSG00000233006.5 AC034220.3 9.06 1.02e-17 2.6e-14 0.44 0.44 Acylcarnitine levels; chr5:132359485 chr5:132311285~132369916:- LIHC cis rs1577917 0.74 rs2758843 ENSG00000234155.1 RP11-30P6.6 9.06 1.02e-17 2.6e-14 0.51 0.44 Response to antipsychotic treatment; chr6:85618713 chr6:85387219~85390186:- LIHC cis rs3762637 0.941 rs79493664 ENSG00000272758.4 RP11-299J3.8 -9.06 1.02e-17 2.6e-14 -0.57 -0.44 LDL cholesterol levels; chr3:122390699 chr3:122416207~122443180:+ LIHC cis rs1577917 1 rs12196037 ENSG00000203875.9 SNHG5 -9.06 1.04e-17 2.66e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:85984913 chr6:85660950~85678736:- LIHC cis rs2739330 0.828 rs5760098 ENSG00000231271.1 AP000350.8 9.06 1.06e-17 2.69e-14 0.52 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23949918~23954042:+ LIHC cis rs17608059 0.545 rs736261 ENSG00000141028.6 CDRT15P1 -9.06 1.06e-17 2.69e-14 -0.46 -0.44 Temperament; chr17:14033087 chr17:14024514~14025488:+ LIHC cis rs6504950 0.83 rs35097996 ENSG00000275710.1 RP11-257O5.4 9.05 1.06e-17 2.71e-14 0.63 0.44 Breast cancer; chr17:54944562 chr17:54964474~54964679:+ LIHC cis rs6504950 0.79 rs8066833 ENSG00000275710.1 RP11-257O5.4 9.05 1.06e-17 2.71e-14 0.63 0.44 Breast cancer; chr17:54948114 chr17:54964474~54964679:+ LIHC cis rs6504950 0.821 rs8066588 ENSG00000275710.1 RP11-257O5.4 9.05 1.06e-17 2.71e-14 0.63 0.44 Breast cancer; chr17:54948328 chr17:54964474~54964679:+ LIHC cis rs1577917 0.74 rs2842614 ENSG00000234155.1 RP11-30P6.6 9.05 1.06e-17 2.71e-14 0.51 0.44 Response to antipsychotic treatment; chr6:85596351 chr6:85387219~85390186:- LIHC cis rs9828933 0.938 rs3816157 ENSG00000280620.1 SCAANT1 9.05 1.08e-17 2.75e-14 0.67 0.44 Type 2 diabetes; chr3:64013646 chr3:63911518~63911772:- LIHC cis rs4718428 0.924 rs6971897 ENSG00000226824.5 RP4-756H11.3 -9.05 1.08e-17 2.75e-14 -0.6 -0.44 Corneal structure; chr7:66947787 chr7:66654538~66669855:+ LIHC cis rs1577917 0.74 rs2758842 ENSG00000234155.1 RP11-30P6.6 9.05 1.08e-17 2.75e-14 0.51 0.44 Response to antipsychotic treatment; chr6:85599013 chr6:85387219~85390186:- LIHC cis rs1577917 0.572 rs911927 ENSG00000234155.1 RP11-30P6.6 9.05 1.08e-17 2.75e-14 0.51 0.44 Response to antipsychotic treatment; chr6:85618142 chr6:85387219~85390186:- LIHC cis rs8062405 0.723 rs35175818 ENSG00000259982.1 CDC37P1 9.05 1.12e-17 2.85e-14 0.56 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597425 chr16:28700294~28701540:- LIHC cis rs7208859 0.673 rs999796 ENSG00000263531.1 RP13-753N3.1 9.04 1.15e-17 2.91e-14 0.75 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832386 chr17:30863921~30864940:- LIHC cis rs3762637 0.882 rs72958418 ENSG00000272758.4 RP11-299J3.8 -9.04 1.16e-17 2.93e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122441526 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs7609972 ENSG00000272758.4 RP11-299J3.8 -9.04 1.16e-17 2.93e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122480579 chr3:122416207~122443180:+ LIHC cis rs9660180 0.967 rs12044597 ENSG00000231050.1 RP1-140A9.1 9.04 1.19e-17 3.01e-14 0.41 0.44 Body mass index; chr1:1777362 chr1:1891471~1892658:+ LIHC cis rs1577917 0.771 rs2758844 ENSG00000203875.9 SNHG5 -9.04 1.2e-17 3.04e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85620397 chr6:85660950~85678736:- LIHC cis rs3762637 1 rs28497203 ENSG00000272758.4 RP11-299J3.8 -9.03 1.24e-17 3.14e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122512972 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs9867429 ENSG00000272758.4 RP11-299J3.8 -9.03 1.24e-17 3.14e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122513821 chr3:122416207~122443180:+ LIHC cis rs172166 0.561 rs149976 ENSG00000216901.1 AL022393.7 -9.03 1.27e-17 3.22e-14 -0.5 -0.44 Cardiac Troponin-T levels; chr6:28019998 chr6:28176188~28176674:+ LIHC cis rs2739330 0.752 rs2330634 ENSG00000231271.1 AP000350.8 9.03 1.28e-17 3.22e-14 0.52 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908608 chr22:23949918~23954042:+ LIHC cis rs7617773 0.694 rs13099560 ENSG00000229759.1 MRPS18AP1 -9.03 1.28e-17 3.23e-14 -0.47 -0.44 Coronary artery disease; chr3:48163278 chr3:48256350~48256938:- LIHC cis rs6504950 0.83 rs3087650 ENSG00000275710.1 RP11-257O5.4 9.03 1.28e-17 3.23e-14 0.62 0.44 Breast cancer; chr17:54951967 chr17:54964474~54964679:+ LIHC cis rs1577917 1 rs12207305 ENSG00000203875.9 SNHG5 -9.03 1.28e-17 3.24e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:86013784 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12199784 ENSG00000203875.9 SNHG5 -9.03 1.28e-17 3.24e-14 -0.53 -0.44 Response to antipsychotic treatment; chr6:86017090 chr6:85660950~85678736:- LIHC cis rs8062405 0.755 rs1074631 ENSG00000259982.1 CDC37P1 -9.03 1.29e-17 3.26e-14 -0.56 -0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28542787 chr16:28700294~28701540:- LIHC cis rs6504950 0.76 rs7214573 ENSG00000275710.1 RP11-257O5.4 9.03 1.3e-17 3.27e-14 0.65 0.44 Breast cancer; chr17:54929293 chr17:54964474~54964679:+ LIHC cis rs11723261 0.621 rs3829 ENSG00000275426.1 CH17-262A2.1 9.03 1.3e-17 3.28e-14 0.54 0.44 Immune response to smallpox vaccine (IL-6); chr4:141070 chr4:149738~150317:+ LIHC cis rs8062405 0.728 rs11642449 ENSG00000259982.1 CDC37P1 9.03 1.31e-17 3.29e-14 0.53 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28884694 chr16:28700294~28701540:- LIHC cis rs8062405 0.728 rs8056890 ENSG00000259982.1 CDC37P1 9.03 1.31e-17 3.29e-14 0.53 0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28886131 chr16:28700294~28701540:- LIHC cis rs1577917 0.958 rs11755864 ENSG00000203875.9 SNHG5 -9.03 1.31e-17 3.31e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85982073 chr6:85660950~85678736:- LIHC cis rs7208859 0.623 rs7214570 ENSG00000263531.1 RP13-753N3.1 9.03 1.32e-17 3.33e-14 0.75 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30820146 chr17:30863921~30864940:- LIHC cis rs11723261 0.582 rs61792238 ENSG00000275426.1 CH17-262A2.1 9.02 1.34e-17 3.37e-14 0.54 0.44 Immune response to smallpox vaccine (IL-6); chr4:112398 chr4:149738~150317:+ LIHC cis rs7684253 0.548 rs62308071 ENSG00000269949.1 RP11-738E22.3 -9.02 1.36e-17 3.42e-14 -0.61 -0.44 Migraine; chr4:56850720 chr4:56960927~56961373:- LIHC cis rs6860806 0.507 rs273912 ENSG00000233006.5 AC034220.3 -9.02 1.39e-17 3.49e-14 -0.44 -0.44 Breast cancer; chr5:132325656 chr5:132311285~132369916:- LIHC cis rs6860806 0.507 rs270608 ENSG00000233006.5 AC034220.3 9.02 1.41e-17 3.54e-14 0.44 0.44 Breast cancer; chr5:132312713 chr5:132311285~132369916:- LIHC cis rs6504950 0.83 rs8073158 ENSG00000275710.1 RP11-257O5.4 9.02 1.41e-17 3.54e-14 0.62 0.44 Breast cancer; chr17:54951254 chr17:54964474~54964679:+ LIHC cis rs507080 0.769 rs570836 ENSG00000255422.1 AP002954.4 -9.01 1.44e-17 3.63e-14 -0.51 -0.44 Serum metabolite levels; chr11:118641444 chr11:118704607~118750263:+ LIHC cis rs2739330 0.828 rs4822451 ENSG00000231271.1 AP000350.8 9.01 1.5e-17 3.77e-14 0.51 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23949918~23954042:+ LIHC cis rs6860806 0.507 rs270606 ENSG00000233006.5 AC034220.3 9.01 1.51e-17 3.78e-14 0.44 0.44 Breast cancer; chr5:132315174 chr5:132311285~132369916:- LIHC cis rs3762637 1 rs78381804 ENSG00000272758.4 RP11-299J3.8 -9.01 1.53e-17 3.83e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122503415 chr3:122416207~122443180:+ LIHC cis rs858239 0.863 rs274058 ENSG00000230658.1 KLHL7-AS1 9 1.56e-17 3.92e-14 0.55 0.44 Cerebrospinal fluid biomarker levels; chr7:23351890 chr7:23101228~23105703:- LIHC cis rs858239 1 rs199348 ENSG00000230658.1 KLHL7-AS1 9 1.64e-17 4.1e-14 0.57 0.44 Cerebrospinal fluid biomarker levels; chr7:23253479 chr7:23101228~23105703:- LIHC cis rs3762637 1 rs76599189 ENSG00000272758.4 RP11-299J3.8 -9 1.64e-17 4.11e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122405229 chr3:122416207~122443180:+ LIHC cis rs2283792 0.812 rs94194 ENSG00000224086.5 LL22NC03-86G7.1 -9 1.65e-17 4.12e-14 -0.41 -0.44 Multiple sclerosis; chr22:21933937 chr22:21938293~21977632:+ LIHC cis rs1577917 1 rs34581302 ENSG00000203875.9 SNHG5 -8.99 1.69e-17 4.23e-14 -0.52 -0.44 Response to antipsychotic treatment; chr6:85996230 chr6:85660950~85678736:- LIHC cis rs150992 0.742 rs34495 ENSG00000248489.1 CTD-2007H13.3 8.99 1.7e-17 4.25e-14 0.63 0.44 Body mass index; chr5:98930103 chr5:98929171~98995013:+ LIHC cis rs1577917 0.771 rs4145082 ENSG00000203875.9 SNHG5 -8.99 1.73e-17 4.31e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85642298 chr6:85660950~85678736:- LIHC cis rs3762637 1 rs16845530 ENSG00000272758.4 RP11-299J3.8 -8.99 1.73e-17 4.32e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122423600 chr3:122416207~122443180:+ LIHC cis rs1577917 0.771 rs12205013 ENSG00000203875.9 SNHG5 -8.99 1.74e-17 4.34e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85623311 chr6:85660950~85678736:- LIHC cis rs3762637 0.941 rs6788746 ENSG00000272758.4 RP11-299J3.8 -8.99 1.76e-17 4.4e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122387896 chr3:122416207~122443180:+ LIHC cis rs296381 0.866 rs296360 ENSG00000259108.2 CTD-3098H1.2 8.99 1.77e-17 4.41e-14 0.8 0.44 Blood metabolite levels; chr19:47885401 chr19:47863483~47865341:- LIHC cis rs10510102 0.608 rs4486560 ENSG00000226864.1 ATE1-AS1 8.99 1.77e-17 4.42e-14 0.58 0.44 Breast cancer; chr10:121844840 chr10:121928312~121951965:+ LIHC cis rs6860806 0.507 rs2631364 ENSG00000233006.5 AC034220.3 -8.98 1.78e-17 4.44e-14 -0.43 -0.44 Breast cancer; chr5:132371222 chr5:132311285~132369916:- LIHC cis rs1577917 0.917 rs35038582 ENSG00000203875.9 SNHG5 -8.98 1.78e-17 4.44e-14 -0.52 -0.44 Response to antipsychotic treatment; chr6:86011587 chr6:85660950~85678736:- LIHC cis rs2882667 0.929 rs17207828 ENSG00000253404.1 AC034243.1 8.98 1.79e-17 4.47e-14 0.61 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:138964146 chr5:138744434~138753309:- LIHC cis rs17608059 0.504 rs11656981 ENSG00000141028.6 CDRT15P1 -8.98 1.8e-17 4.49e-14 -0.46 -0.44 Temperament; chr17:14075460 chr17:14024514~14025488:+ LIHC cis rs1799949 0.965 rs6503726 ENSG00000198496.9 NBR2 -8.98 1.82e-17 4.52e-14 -0.5 -0.44 Menopause (age at onset); chr17:43132725 chr17:43125610~43153671:+ LIHC cis rs7195287 0.826 rs9925824 ENSG00000276791.1 CTD-2270P14.5 -8.98 1.87e-17 4.65e-14 -0.44 -0.44 Eosinophil counts; chr16:2777972 chr16:2777319~2780568:+ LIHC cis rs12594515 0.967 rs11070465 ENSG00000273972.1 CTD-2306A12.1 -8.98 1.88e-17 4.67e-14 -0.5 -0.44 Weight;Waist circumference; chr15:45692701 chr15:45702640~45703183:+ LIHC cis rs12594515 0.967 rs11070466 ENSG00000273972.1 CTD-2306A12.1 -8.98 1.88e-17 4.67e-14 -0.5 -0.44 Weight;Waist circumference; chr15:45692757 chr15:45702640~45703183:+ LIHC cis rs858239 0.862 rs1728292 ENSG00000230658.1 KLHL7-AS1 8.98 1.9e-17 4.71e-14 0.53 0.44 Cerebrospinal fluid biomarker levels; chr7:23223855 chr7:23101228~23105703:- LIHC cis rs1577917 0.74 rs7771612 ENSG00000234155.1 RP11-30P6.6 -8.98 1.9e-17 4.71e-14 -0.51 -0.44 Response to antipsychotic treatment; chr6:85554656 chr6:85387219~85390186:- LIHC cis rs172166 0.61 rs276369 ENSG00000216901.1 AL022393.7 8.98 1.9e-17 4.71e-14 0.49 0.44 Cardiac Troponin-T levels; chr6:27951465 chr6:28176188~28176674:+ LIHC cis rs7208859 0.623 rs9912440 ENSG00000263531.1 RP13-753N3.1 8.97 1.92e-17 4.76e-14 0.75 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30821754 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs79505916 ENSG00000263531.1 RP13-753N3.1 8.97 1.99e-17 4.93e-14 0.77 0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30735308 chr17:30863921~30864940:- LIHC cis rs11723261 0.621 rs11721745 ENSG00000275426.1 CH17-262A2.1 8.97 2e-17 4.95e-14 0.54 0.44 Immune response to smallpox vaccine (IL-6); chr4:115052 chr4:149738~150317:+ LIHC cis rs12594515 1 rs12906442 ENSG00000273972.1 CTD-2306A12.1 -8.97 2.02e-17 5e-14 -0.5 -0.44 Weight;Waist circumference; chr15:45693056 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs12911309 ENSG00000273972.1 CTD-2306A12.1 -8.97 2.02e-17 5e-14 -0.5 -0.44 Weight;Waist circumference; chr15:45693521 chr15:45702640~45703183:+ LIHC cis rs1577917 1 rs12663690 ENSG00000203875.9 SNHG5 8.96 2.15e-17 5.3e-14 0.52 0.44 Response to antipsychotic treatment; chr6:85930444 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs7760207 ENSG00000203875.9 SNHG5 -8.96 2.21e-17 5.43e-14 -0.52 -0.44 Response to antipsychotic treatment; chr6:86011982 chr6:85660950~85678736:- LIHC cis rs12594515 1 rs58368732 ENSG00000273972.1 CTD-2306A12.1 -8.95 2.24e-17 5.5e-14 -0.51 -0.44 Weight;Waist circumference; chr15:45698333 chr15:45702640~45703183:+ LIHC cis rs1577917 1 rs12199516 ENSG00000203875.9 SNHG5 -8.95 2.24e-17 5.51e-14 -0.52 -0.44 Response to antipsychotic treatment; chr6:86016503 chr6:85660950~85678736:- LIHC cis rs12594515 0.967 rs11856523 ENSG00000273972.1 CTD-2306A12.1 -8.95 2.25e-17 5.52e-14 -0.51 -0.44 Weight;Waist circumference; chr15:45697297 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs6493175 ENSG00000273972.1 CTD-2306A12.1 -8.95 2.25e-17 5.52e-14 -0.51 -0.44 Weight;Waist circumference; chr15:45697700 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs6493176 ENSG00000273972.1 CTD-2306A12.1 -8.95 2.25e-17 5.52e-14 -0.51 -0.44 Weight;Waist circumference; chr15:45697828 chr15:45702640~45703183:+ LIHC cis rs12594515 0.967 rs8039088 ENSG00000273972.1 CTD-2306A12.1 -8.95 2.25e-17 5.52e-14 -0.51 -0.44 Weight;Waist circumference; chr15:45697980 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs8038320 ENSG00000273972.1 CTD-2306A12.1 -8.95 2.25e-17 5.52e-14 -0.51 -0.44 Weight;Waist circumference; chr15:45698069 chr15:45702640~45703183:+ LIHC cis rs12594515 0.967 rs67854274 ENSG00000273972.1 CTD-2306A12.1 -8.95 2.25e-17 5.52e-14 -0.51 -0.44 Weight;Waist circumference; chr15:45698320 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs7172161 ENSG00000273972.1 CTD-2306A12.1 -8.95 2.25e-17 5.52e-14 -0.51 -0.44 Weight;Waist circumference; chr15:45698582 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs7173144 ENSG00000273972.1 CTD-2306A12.1 -8.95 2.25e-17 5.52e-14 -0.51 -0.44 Weight;Waist circumference; chr15:45698998 chr15:45702640~45703183:+ LIHC cis rs17608059 1 rs17608059 ENSG00000141028.6 CDRT15P1 -8.95 2.27e-17 5.56e-14 -0.45 -0.44 Temperament; chr17:14007232 chr17:14024514~14025488:+ LIHC cis rs2739330 0.731 rs5751792 ENSG00000206090.4 AP000350.7 8.95 2.38e-17 5.83e-14 0.52 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23939998~23942798:+ LIHC cis rs507080 0.922 rs525485 ENSG00000255422.1 AP002954.4 -8.94 2.42e-17 5.92e-14 -0.51 -0.44 Serum metabolite levels; chr11:118685045 chr11:118704607~118750263:+ LIHC cis rs1577917 0.739 rs9344532 ENSG00000203875.9 SNHG5 8.94 2.43e-17 5.96e-14 0.5 0.44 Response to antipsychotic treatment; chr6:85524352 chr6:85660950~85678736:- LIHC cis rs1577917 0.876 rs1582126 ENSG00000203875.9 SNHG5 -8.94 2.45e-17 6e-14 -0.54 -0.44 Response to antipsychotic treatment; chr6:85987487 chr6:85660950~85678736:- LIHC cis rs3762637 0.941 rs74467988 ENSG00000272758.4 RP11-299J3.8 -8.94 2.47e-17 6.03e-14 -0.56 -0.44 LDL cholesterol levels; chr3:122364293 chr3:122416207~122443180:+ LIHC cis rs8062405 0.698 rs7188071 ENSG00000259982.1 CDC37P1 -8.94 2.47e-17 6.03e-14 -0.52 -0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28906323 chr16:28700294~28701540:- LIHC cis rs7208859 0.673 rs9889755 ENSG00000263531.1 RP13-753N3.1 -8.94 2.53e-17 6.15e-14 -0.73 -0.44 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30907487 chr17:30863921~30864940:- LIHC cis rs274567 0.501 rs272856 ENSG00000233006.5 AC034220.3 8.93 2.58e-17 6.27e-14 0.43 0.44 Blood metabolite levels; chr5:132351388 chr5:132311285~132369916:- LIHC cis rs6844153 0.938 rs12646473 ENSG00000240005.4 RP11-293A21.1 -8.93 2.62e-17 6.36e-14 -0.54 -0.43 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26873833 chr4:26859806~26860599:- LIHC cis rs2455601 0.638 rs3815991 ENSG00000254860.4 TMEM9B-AS1 -8.93 2.64e-17 6.4e-14 -0.52 -0.43 Schizophrenia; chr11:8986122 chr11:8964675~8977527:+ LIHC cis rs11723261 0.509 rs61792240 ENSG00000275426.1 CH17-262A2.1 8.93 2.64e-17 6.41e-14 0.54 0.43 Immune response to smallpox vaccine (IL-6); chr4:134876 chr4:149738~150317:+ LIHC cis rs17711722 0.503 rs453835 ENSG00000164669.11 INTS4P1 8.93 2.66e-17 6.44e-14 0.54 0.43 Calcium levels; chr7:66046172 chr7:65141225~65234216:+ LIHC cis rs8062405 0.691 rs11646653 ENSG00000259982.1 CDC37P1 -8.93 2.69e-17 6.5e-14 -0.5 -0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28910828 chr16:28700294~28701540:- LIHC cis rs6860806 0.507 rs270601 ENSG00000233006.5 AC034220.3 8.93 2.76e-17 6.67e-14 0.44 0.43 Breast cancer; chr5:132321304 chr5:132311285~132369916:- LIHC cis rs7684253 0.548 rs13106200 ENSG00000269949.1 RP11-738E22.3 -8.92 2.77e-17 6.69e-14 -0.6 -0.43 Migraine; chr4:56852029 chr4:56960927~56961373:- LIHC cis rs10256972 0.621 rs2280725 ENSG00000229043.2 AC091729.9 -8.92 2.78e-17 6.71e-14 -0.51 -0.43 Endometriosis;Longevity; chr7:1047790 chr7:1160374~1165267:+ LIHC cis rs6860806 0.507 rs156322 ENSG00000233006.5 AC034220.3 8.92 2.78e-17 6.72e-14 0.44 0.43 Breast cancer; chr5:132318232 chr5:132311285~132369916:- LIHC cis rs7208859 0.623 rs59447372 ENSG00000263531.1 RP13-753N3.1 8.92 2.88e-17 6.95e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30730567 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs8079891 ENSG00000263531.1 RP13-753N3.1 8.92 2.88e-17 6.95e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30731845 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs73267858 ENSG00000263531.1 RP13-753N3.1 8.92 2.88e-17 6.95e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732719 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs56095789 ENSG00000263531.1 RP13-753N3.1 8.92 2.88e-17 6.95e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733152 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11656844 ENSG00000263531.1 RP13-753N3.1 8.92 2.88e-17 6.95e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733579 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11652533 ENSG00000263531.1 RP13-753N3.1 8.92 2.88e-17 6.95e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733583 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11652631 ENSG00000263531.1 RP13-753N3.1 8.92 2.88e-17 6.95e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733748 chr17:30863921~30864940:- LIHC cis rs2487048 1 rs2487046 ENSG00000226334.1 RP11-217B7.2 -8.92 2.91e-17 7.01e-14 -0.59 -0.43 Intraocular pressure; chr9:104929948 chr9:104927553~104928892:+ LIHC cis rs2739330 0.761 rs5760176 ENSG00000206090.4 AP000350.7 -8.92 2.93e-17 7.07e-14 -0.51 -0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23939998~23942798:+ LIHC cis rs10256972 0.621 rs10951594 ENSG00000229043.2 AC091729.9 -8.91 3e-17 7.22e-14 -0.51 -0.43 Endometriosis;Longevity; chr7:1048971 chr7:1160374~1165267:+ LIHC cis rs9660180 0.839 rs12040826 ENSG00000231050.1 RP1-140A9.1 8.91 3.01e-17 7.26e-14 0.4 0.43 Body mass index; chr1:1773848 chr1:1891471~1892658:+ LIHC cis rs1577917 0.682 rs6935918 ENSG00000234155.1 RP11-30P6.6 -8.91 3.04e-17 7.3e-14 -0.51 -0.43 Response to antipsychotic treatment; chr6:85573857 chr6:85387219~85390186:- LIHC cis rs6860806 0.507 rs2631371 ENSG00000233006.5 AC034220.3 -8.91 3.1e-17 7.43e-14 -0.43 -0.43 Breast cancer; chr5:132367999 chr5:132311285~132369916:- LIHC cis rs7208859 0.673 rs999798 ENSG00000263531.1 RP13-753N3.1 8.91 3.1e-17 7.45e-14 0.74 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831822 chr17:30863921~30864940:- LIHC cis rs507080 0.733 rs601318 ENSG00000255422.1 AP002954.4 -8.91 3.11e-17 7.45e-14 -0.51 -0.43 Serum metabolite levels; chr11:118648845 chr11:118704607~118750263:+ LIHC cis rs12594515 1 rs6493170 ENSG00000273972.1 CTD-2306A12.1 -8.91 3.14e-17 7.53e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45694821 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs8039622 ENSG00000273972.1 CTD-2306A12.1 -8.91 3.15e-17 7.56e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45694233 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs6493167 ENSG00000273972.1 CTD-2306A12.1 -8.91 3.15e-17 7.56e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45694611 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs6493168 ENSG00000273972.1 CTD-2306A12.1 -8.91 3.15e-17 7.56e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45694613 chr15:45702640~45703183:+ LIHC cis rs2455601 0.786 rs3763914 ENSG00000254860.4 TMEM9B-AS1 8.9 3.23e-17 7.72e-14 0.53 0.43 Schizophrenia; chr11:8919156 chr11:8964675~8977527:+ LIHC cis rs6504950 0.83 rs56175787 ENSG00000275710.1 RP11-257O5.4 8.9 3.3e-17 7.88e-14 0.63 0.43 Breast cancer; chr17:54940386 chr17:54964474~54964679:+ LIHC cis rs6504950 0.83 rs17817847 ENSG00000275710.1 RP11-257O5.4 8.9 3.3e-17 7.88e-14 0.63 0.43 Breast cancer; chr17:54940920 chr17:54964474~54964679:+ LIHC cis rs6860806 0.507 rs272872 ENSG00000233006.5 AC034220.3 -8.9 3.3e-17 7.89e-14 -0.43 -0.43 Breast cancer; chr5:132340171 chr5:132311285~132369916:- LIHC cis rs875971 0.862 rs6460282 ENSG00000226824.5 RP4-756H11.3 8.9 3.31e-17 7.92e-14 0.53 0.43 Aortic root size; chr7:66226259 chr7:66654538~66669855:+ LIHC cis rs11647589 0.834 rs6497491 ENSG00000260762.1 ACSM5P1 8.9 3.33e-17 7.95e-14 0.44 0.43 Blood metabolite levels; chr16:20468691 chr16:20586550~20607107:- LIHC cis rs12594515 1 rs8025258 ENSG00000273972.1 CTD-2306A12.1 -8.9 3.38e-17 8.08e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45695356 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs8027000 ENSG00000273972.1 CTD-2306A12.1 -8.9 3.38e-17 8.08e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45695597 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs6493172 ENSG00000273972.1 CTD-2306A12.1 -8.9 3.39e-17 8.09e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45695015 chr15:45702640~45703183:+ LIHC cis rs7208859 0.623 rs7219361 ENSG00000263531.1 RP13-753N3.1 8.9 3.4e-17 8.13e-14 0.75 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753375 chr17:30863921~30864940:- LIHC cis rs12594515 1 rs8026221 ENSG00000273972.1 CTD-2306A12.1 -8.9 3.41e-17 8.15e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45695712 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs8031128 ENSG00000273972.1 CTD-2306A12.1 -8.9 3.41e-17 8.15e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45696330 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs8032361 ENSG00000273972.1 CTD-2306A12.1 -8.9 3.41e-17 8.15e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45696355 chr15:45702640~45703183:+ LIHC cis rs12594515 0.967 rs71405295 ENSG00000273972.1 CTD-2306A12.1 -8.9 3.41e-17 8.15e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45696723 chr15:45702640~45703183:+ LIHC cis rs12594515 0.506 rs74199860 ENSG00000273972.1 CTD-2306A12.1 -8.89 3.5e-17 8.36e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45696992 chr15:45702640~45703183:+ LIHC cis rs3762637 0.941 rs7653592 ENSG00000272758.4 RP11-299J3.8 -8.89 3.54e-17 8.45e-14 -0.55 -0.43 LDL cholesterol levels; chr3:122499524 chr3:122416207~122443180:+ LIHC cis rs2260433 0.66 rs7129790 ENSG00000281655.1 RP11-817J15.3 8.89 3.56e-17 8.5e-14 0.51 0.43 Cleft palate; chr11:102641383 chr11:102681310~102683913:+ LIHC cis rs1577917 0.771 rs9450290 ENSG00000203875.9 SNHG5 8.89 3.57e-17 8.52e-14 0.49 0.43 Response to antipsychotic treatment; chr6:85523679 chr6:85660950~85678736:- LIHC cis rs7208859 0.524 rs77498725 ENSG00000263531.1 RP13-753N3.1 8.89 3.6e-17 8.55e-14 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30736968 chr17:30863921~30864940:- LIHC cis rs7208859 0.524 rs59923796 ENSG00000263531.1 RP13-753N3.1 8.89 3.6e-17 8.55e-14 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737901 chr17:30863921~30864940:- LIHC cis rs17826219 0.5 rs57005940 ENSG00000263531.1 RP13-753N3.1 8.89 3.6e-17 8.55e-14 0.76 0.43 Body mass index; chr17:30739311 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs73267872 ENSG00000263531.1 RP13-753N3.1 8.89 3.6e-17 8.55e-14 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30740189 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs56812022 ENSG00000263531.1 RP13-753N3.1 8.89 3.6e-17 8.55e-14 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741715 chr17:30863921~30864940:- LIHC cis rs7208859 0.524 rs57670615 ENSG00000263531.1 RP13-753N3.1 8.89 3.6e-17 8.55e-14 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30742480 chr17:30863921~30864940:- LIHC cis rs17826219 0.5 rs2874724 ENSG00000263531.1 RP13-753N3.1 8.89 3.6e-17 8.55e-14 0.76 0.43 Body mass index; chr17:30745415 chr17:30863921~30864940:- LIHC cis rs17826219 0.568 rs9898097 ENSG00000263531.1 RP13-753N3.1 8.89 3.6e-17 8.55e-14 0.76 0.43 Body mass index; chr17:30745654 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9911490 ENSG00000263531.1 RP13-753N3.1 8.89 3.6e-17 8.55e-14 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30745995 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs7503542 ENSG00000263531.1 RP13-753N3.1 8.89 3.6e-17 8.55e-14 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746812 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs11656278 ENSG00000263531.1 RP13-753N3.1 8.89 3.6e-17 8.55e-14 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748170 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs6505207 ENSG00000263531.1 RP13-753N3.1 8.89 3.6e-17 8.55e-14 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749553 chr17:30863921~30864940:- LIHC cis rs150992 0.673 rs331934 ENSG00000248489.1 CTD-2007H13.3 -8.89 3.6e-17 8.55e-14 -0.65 -0.43 Body mass index; chr5:98804016 chr5:98929171~98995013:+ LIHC cis rs150992 0.673 rs331549 ENSG00000248489.1 CTD-2007H13.3 -8.89 3.6e-17 8.55e-14 -0.65 -0.43 Body mass index; chr5:98805731 chr5:98929171~98995013:+ LIHC cis rs150992 0.673 rs992775 ENSG00000248489.1 CTD-2007H13.3 -8.89 3.6e-17 8.55e-14 -0.65 -0.43 Body mass index; chr5:98807754 chr5:98929171~98995013:+ LIHC cis rs150992 0.673 rs331545 ENSG00000248489.1 CTD-2007H13.3 -8.89 3.6e-17 8.55e-14 -0.65 -0.43 Body mass index; chr5:98810402 chr5:98929171~98995013:+ LIHC cis rs8062405 0.728 rs9931989 ENSG00000259982.1 CDC37P1 -8.89 3.68e-17 8.72e-14 -0.52 -0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28894763 chr16:28700294~28701540:- LIHC cis rs274567 0.501 rs272855 ENSG00000233006.5 AC034220.3 8.89 3.68e-17 8.74e-14 0.43 0.43 Blood metabolite levels; chr5:132351482 chr5:132311285~132369916:- LIHC cis rs200367988 1 rs200367988 ENSG00000271670.1 RP11-95I16.4 -8.88 3.73e-17 8.83e-14 -0.43 -0.43 Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels; chr10:120915337 chr10:120879256~120880667:- LIHC cis rs17826219 0.5 rs28452421 ENSG00000263531.1 RP13-753N3.1 8.88 3.74e-17 8.83e-14 0.77 0.43 Body mass index; chr17:30756962 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs28779471 ENSG00000263531.1 RP13-753N3.1 8.88 3.74e-17 8.83e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757351 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11658022 ENSG00000263531.1 RP13-753N3.1 8.88 3.74e-17 8.83e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758341 chr17:30863921~30864940:- LIHC cis rs17826219 0.5 rs61685770 ENSG00000263531.1 RP13-753N3.1 8.88 3.74e-17 8.83e-14 0.77 0.43 Body mass index; chr17:30758695 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs57486336 ENSG00000263531.1 RP13-753N3.1 8.88 3.74e-17 8.83e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758713 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs12103440 ENSG00000263531.1 RP13-753N3.1 8.88 3.74e-17 8.83e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759639 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11657777 ENSG00000263531.1 RP13-753N3.1 8.88 3.74e-17 8.83e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30764767 chr17:30863921~30864940:- LIHC cis rs3762637 0.882 rs9818537 ENSG00000272758.4 RP11-299J3.8 -8.88 3.91e-17 9.2e-14 -0.56 -0.43 LDL cholesterol levels; chr3:122367610 chr3:122416207~122443180:+ LIHC cis rs11723261 0.621 rs7440274 ENSG00000275426.1 CH17-262A2.1 -8.88 3.91e-17 9.22e-14 -0.54 -0.43 Immune response to smallpox vaccine (IL-6); chr4:161923 chr4:149738~150317:+ LIHC cis rs3762637 1 rs7615673 ENSG00000272758.4 RP11-299J3.8 -8.88 3.99e-17 9.38e-14 -0.55 -0.43 LDL cholesterol levels; chr3:122406697 chr3:122416207~122443180:+ LIHC cis rs10256972 1 rs10256972 ENSG00000229043.2 AC091729.9 8.87 4e-17 9.4e-14 0.48 0.43 Endometriosis;Longevity; chr7:999367 chr7:1160374~1165267:+ LIHC cis rs12594515 1 rs8039974 ENSG00000273972.1 CTD-2306A12.1 -8.87 4.06e-17 9.52e-14 -0.5 -0.43 Weight;Waist circumference; chr15:45694467 chr15:45702640~45703183:+ LIHC cis rs1577917 1 rs12216328 ENSG00000203875.9 SNHG5 -8.87 4.12e-17 9.59e-14 -0.52 -0.43 Response to antipsychotic treatment; chr6:85993700 chr6:85660950~85678736:- LIHC cis rs7208859 0.623 rs8075163 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779292 chr17:30863921~30864940:- LIHC cis rs17826219 0.706 rs8075107 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Body mass index; chr17:30779631 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs7223209 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780202 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs7223404 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780345 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9916725 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780453 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9916727 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780454 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs73269945 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781741 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9897728 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781786 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs1054400 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30782936 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs1054397 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783178 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9890558 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783337 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9912283 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783355 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs3752020 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784107 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9890855 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784689 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9893422 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784697 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9891166 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784884 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs73269974 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785366 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs34756112 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785998 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs60724269 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786255 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs76633166 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786347 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs1061346 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787211 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs1061343 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787258 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs73269988 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30791127 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9899525 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793278 chr17:30863921~30864940:- LIHC cis rs7208859 0.524 rs11653098 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795483 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9911784 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797562 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9911997 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797630 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9890862 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30798432 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs78071511 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30801136 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs2035494 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803375 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs3794796 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803862 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9915566 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805140 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11657369 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809450 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs8075341 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809547 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs73271842 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30810137 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs8077116 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813144 chr17:30863921~30864940:- LIHC cis rs7208859 0.524 rs28760584 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813999 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs7212991 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816731 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs28627615 ENSG00000263531.1 RP13-753N3.1 8.87 4.12e-17 9.59e-14 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30818799 chr17:30863921~30864940:- LIHC cis rs2882667 0.964 rs12108892 ENSG00000253404.1 AC034243.1 8.87 4.2e-17 9.76e-14 0.58 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:138963941 chr5:138744434~138753309:- LIHC cis rs2019137 0.868 rs3748916 ENSG00000189223.12 PAX8-AS1 8.87 4.23e-17 9.84e-14 0.56 0.43 Lymphocyte counts; chr2:113226456 chr2:113211522~113276581:+ LIHC cis rs7617773 0.962 rs6797587 ENSG00000229759.1 MRPS18AP1 -8.87 4.26e-17 9.9e-14 -0.48 -0.43 Coronary artery disease; chr3:48156124 chr3:48256350~48256938:- LIHC cis rs1577917 1 rs12201741 ENSG00000203875.9 SNHG5 -8.86 4.34e-17 1.01e-13 -0.52 -0.43 Response to antipsychotic treatment; chr6:85892901 chr6:85660950~85678736:- LIHC cis rs3762637 0.943 rs3817040 ENSG00000272758.4 RP11-299J3.8 -8.86 4.34e-17 1.01e-13 -0.55 -0.43 LDL cholesterol levels; chr3:122535922 chr3:122416207~122443180:+ LIHC cis rs10256972 0.9 rs7812072 ENSG00000229043.2 AC091729.9 -8.86 4.41e-17 1.02e-13 -0.49 -0.43 Endometriosis;Longevity; chr7:1014226 chr7:1160374~1165267:+ LIHC cis rs9660180 0.935 rs2180311 ENSG00000231050.1 RP1-140A9.1 8.86 4.46e-17 1.03e-13 0.41 0.43 Body mass index; chr1:1817295 chr1:1891471~1892658:+ LIHC cis rs9660180 0.967 rs6664664 ENSG00000231050.1 RP1-140A9.1 8.86 4.46e-17 1.03e-13 0.41 0.43 Body mass index; chr1:1819825 chr1:1891471~1892658:+ LIHC cis rs6844153 0.887 rs62302535 ENSG00000240005.4 RP11-293A21.1 -8.86 4.49e-17 1.04e-13 -0.53 -0.43 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26957254 chr4:26859806~26860599:- LIHC cis rs9828933 0.938 rs2578011 ENSG00000280620.1 SCAANT1 8.86 4.54e-17 1.05e-13 0.63 0.43 Type 2 diabetes; chr3:64019143 chr3:63911518~63911772:- LIHC cis rs1577917 0.958 rs12199832 ENSG00000203875.9 SNHG5 -8.85 4.73e-17 1.09e-13 -0.52 -0.43 Response to antipsychotic treatment; chr6:85943030 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12207374 ENSG00000203875.9 SNHG5 -8.85 4.73e-17 1.09e-13 -0.52 -0.43 Response to antipsychotic treatment; chr6:85946927 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12213740 ENSG00000203875.9 SNHG5 -8.85 4.73e-17 1.09e-13 -0.52 -0.43 Response to antipsychotic treatment; chr6:85947015 chr6:85660950~85678736:- LIHC cis rs7208859 0.623 rs73269913 ENSG00000263531.1 RP13-753N3.1 8.85 4.73e-17 1.09e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765165 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs7217984 ENSG00000263531.1 RP13-753N3.1 8.85 4.73e-17 1.09e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765748 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs73267865 ENSG00000263531.1 RP13-753N3.1 8.85 4.76e-17 1.1e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737186 chr17:30863921~30864940:- LIHC cis rs8062405 0.656 rs7189927 ENSG00000259982.1 CDC37P1 -8.85 4.76e-17 1.1e-13 -0.52 -0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28902466 chr16:28700294~28701540:- LIHC cis rs8062405 0.755 rs4788076 ENSG00000259982.1 CDC37P1 8.85 4.77e-17 1.1e-13 0.53 0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28558684 chr16:28700294~28701540:- LIHC cis rs12594515 1 rs11070467 ENSG00000273972.1 CTD-2306A12.1 8.85 4.79e-17 1.11e-13 0.5 0.43 Weight;Waist circumference; chr15:45692803 chr15:45702640~45703183:+ LIHC cis rs11647589 0.678 rs7198521 ENSG00000260762.1 ACSM5P1 8.85 4.91e-17 1.13e-13 0.42 0.43 Blood metabolite levels; chr16:20441382 chr16:20586550~20607107:- LIHC cis rs1577917 0.74 rs12212560 ENSG00000234155.1 RP11-30P6.6 8.85 4.93e-17 1.14e-13 0.5 0.43 Response to antipsychotic treatment; chr6:85632961 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs1999852 ENSG00000203875.9 SNHG5 -8.85 4.94e-17 1.14e-13 -0.52 -0.43 Response to antipsychotic treatment; chr6:85996020 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs35797755 ENSG00000203875.9 SNHG5 -8.85 4.94e-17 1.14e-13 -0.52 -0.43 Response to antipsychotic treatment; chr6:85996836 chr6:85660950~85678736:- LIHC cis rs12594515 1 rs12594515 ENSG00000273972.1 CTD-2306A12.1 8.85 4.95e-17 1.14e-13 0.51 0.43 Weight;Waist circumference; chr15:45692873 chr15:45702640~45703183:+ LIHC cis rs1577917 0.74 rs2758845 ENSG00000234155.1 RP11-30P6.6 8.84 5.04e-17 1.16e-13 0.5 0.43 Response to antipsychotic treatment; chr6:85625130 chr6:85387219~85390186:- LIHC cis rs1577917 0.696 rs2842603 ENSG00000234155.1 RP11-30P6.6 8.84 5.04e-17 1.16e-13 0.5 0.43 Response to antipsychotic treatment; chr6:85626619 chr6:85387219~85390186:- LIHC cis rs12594515 1 rs12595137 ENSG00000273972.1 CTD-2306A12.1 -8.84 5.16e-17 1.19e-13 -0.5 -0.43 Weight;Waist circumference; chr15:45693907 chr15:45702640~45703183:+ LIHC cis rs12594515 0.967 rs12595138 ENSG00000273972.1 CTD-2306A12.1 -8.84 5.16e-17 1.19e-13 -0.5 -0.43 Weight;Waist circumference; chr15:45693910 chr15:45702640~45703183:+ LIHC cis rs11723261 0.621 rs6599306 ENSG00000275426.1 CH17-262A2.1 -8.84 5.2e-17 1.19e-13 -0.52 -0.43 Immune response to smallpox vaccine (IL-6); chr4:149655 chr4:149738~150317:+ LIHC cis rs1577917 1 rs12190604 ENSG00000203875.9 SNHG5 -8.83 5.44e-17 1.25e-13 -0.52 -0.43 Response to antipsychotic treatment; chr6:86006497 chr6:85660950~85678736:- LIHC cis rs1577917 0.916 rs12203358 ENSG00000203875.9 SNHG5 -8.83 5.47e-17 1.26e-13 -0.52 -0.43 Response to antipsychotic treatment; chr6:85893506 chr6:85660950~85678736:- LIHC cis rs10256972 0.732 rs12701856 ENSG00000229043.2 AC091729.9 -8.83 5.48e-17 1.26e-13 -0.49 -0.43 Endometriosis;Longevity; chr7:1068071 chr7:1160374~1165267:+ LIHC cis rs6844153 1 rs4557251 ENSG00000240005.4 RP11-293A21.1 -8.83 5.49e-17 1.26e-13 -0.54 -0.43 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26848285 chr4:26859806~26860599:- LIHC cis rs1577917 1 rs34281561 ENSG00000203875.9 SNHG5 -8.83 5.51e-17 1.26e-13 -0.52 -0.43 Response to antipsychotic treatment; chr6:85992154 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs35419329 ENSG00000203875.9 SNHG5 -8.83 5.51e-17 1.26e-13 -0.52 -0.43 Response to antipsychotic treatment; chr6:85992573 chr6:85660950~85678736:- LIHC cis rs1577917 0.682 rs6909767 ENSG00000234155.1 RP11-30P6.6 -8.83 5.51e-17 1.26e-13 -0.5 -0.43 Response to antipsychotic treatment; chr6:85518391 chr6:85387219~85390186:- LIHC cis rs977987 0.872 rs10781976 ENSG00000261783.1 RP11-252K23.2 -8.83 5.54e-17 1.27e-13 -0.52 -0.43 Dupuytren's disease; chr16:75280940 chr16:75379818~75381260:- LIHC cis rs1577917 1 rs12201735 ENSG00000203875.9 SNHG5 -8.83 5.63e-17 1.29e-13 -0.52 -0.43 Response to antipsychotic treatment; chr6:85947221 chr6:85660950~85678736:- LIHC cis rs12594515 1 rs11854554 ENSG00000273972.1 CTD-2306A12.1 -8.83 5.69e-17 1.3e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45702348 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs35182335 ENSG00000273972.1 CTD-2306A12.1 -8.83 5.69e-17 1.3e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45702986 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs11855509 ENSG00000273972.1 CTD-2306A12.1 -8.83 5.69e-17 1.3e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45703276 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs11855562 ENSG00000273972.1 CTD-2306A12.1 -8.83 5.69e-17 1.3e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45703461 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs8043291 ENSG00000273972.1 CTD-2306A12.1 -8.83 5.69e-17 1.3e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45704049 chr15:45702640~45703183:+ LIHC cis rs12594515 0.935 rs8042519 ENSG00000273972.1 CTD-2306A12.1 -8.83 5.69e-17 1.3e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45704143 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs56412446 ENSG00000273972.1 CTD-2306A12.1 -8.83 5.69e-17 1.3e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45704226 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs57299255 ENSG00000273972.1 CTD-2306A12.1 -8.83 5.69e-17 1.3e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45704334 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs56220882 ENSG00000273972.1 CTD-2306A12.1 -8.83 5.69e-17 1.3e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45704877 chr15:45702640~45703183:+ LIHC cis rs6504950 0.72 rs9914836 ENSG00000275710.1 RP11-257O5.4 8.83 5.71e-17 1.31e-13 0.67 0.43 Breast cancer; chr17:54920514 chr17:54964474~54964679:+ LIHC cis rs10256972 0.967 rs7799110 ENSG00000229043.2 AC091729.9 -8.82 5.93e-17 1.35e-13 -0.48 -0.43 Endometriosis;Longevity; chr7:999429 chr7:1160374~1165267:+ LIHC cis rs6504950 0.83 rs17817877 ENSG00000275710.1 RP11-257O5.4 8.82 5.98e-17 1.36e-13 0.63 0.43 Breast cancer; chr17:54957267 chr17:54964474~54964679:+ LIHC cis rs10256972 0.732 rs1574108 ENSG00000229043.2 AC091729.9 -8.82 6.03e-17 1.37e-13 -0.49 -0.43 Endometriosis;Longevity; chr7:1066169 chr7:1160374~1165267:+ LIHC cis rs10256972 0.869 rs4720158 ENSG00000229043.2 AC091729.9 -8.82 6.08e-17 1.38e-13 -0.48 -0.43 Endometriosis;Longevity; chr7:1000689 chr7:1160374~1165267:+ LIHC cis rs296381 0.866 rs212099 ENSG00000259108.2 CTD-3098H1.2 8.82 6.17e-17 1.4e-13 0.82 0.43 Blood metabolite levels; chr19:47885745 chr19:47863483~47865341:- LIHC cis rs7208859 0.623 rs56018041 ENSG00000263531.1 RP13-753N3.1 8.81 6.21e-17 1.41e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732967 chr17:30863921~30864940:- LIHC cis rs10256972 0.684 rs2363279 ENSG00000229043.2 AC091729.9 -8.81 6.3e-17 1.43e-13 -0.5 -0.43 Endometriosis;Longevity; chr7:1056507 chr7:1160374~1165267:+ LIHC cis rs3762637 1 rs10934602 ENSG00000272758.4 RP11-299J3.8 8.81 6.36e-17 1.44e-13 0.54 0.43 LDL cholesterol levels; chr3:122504335 chr3:122416207~122443180:+ LIHC cis rs17826219 0.706 rs61643715 ENSG00000263531.1 RP13-753N3.1 8.81 6.62e-17 1.5e-13 0.76 0.43 Body mass index; chr17:30730744 chr17:30863921~30864940:- LIHC cis rs6860806 0.531 rs270607 ENSG00000233006.5 AC034220.3 8.8 6.67e-17 1.51e-13 0.44 0.43 Breast cancer; chr5:132313493 chr5:132311285~132369916:- LIHC cis rs12594515 1 rs12185095 ENSG00000273972.1 CTD-2306A12.1 -8.8 6.69e-17 1.52e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45702437 chr15:45702640~45703183:+ LIHC cis rs858239 1 rs199357 ENSG00000230658.1 KLHL7-AS1 -8.8 6.8e-17 1.54e-13 -0.55 -0.43 Cerebrospinal fluid biomarker levels; chr7:23248690 chr7:23101228~23105703:- LIHC cis rs6844153 0.887 rs3792685 ENSG00000240005.4 RP11-293A21.1 -8.8 6.82e-17 1.54e-13 -0.52 -0.43 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26957585 chr4:26859806~26860599:- LIHC cis rs6504950 0.8 rs35647022 ENSG00000275710.1 RP11-257O5.4 8.8 6.83e-17 1.55e-13 0.66 0.43 Breast cancer; chr17:54930710 chr17:54964474~54964679:+ LIHC cis rs12594515 1 rs11070464 ENSG00000273972.1 CTD-2306A12.1 -8.8 6.9e-17 1.56e-13 -0.5 -0.43 Weight;Waist circumference; chr15:45692578 chr15:45702640~45703183:+ LIHC cis rs6844153 1 rs6844153 ENSG00000240005.4 RP11-293A21.1 -8.8 6.98e-17 1.58e-13 -0.54 -0.43 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26942692 chr4:26859806~26860599:- LIHC cis rs7188445 0.871 rs8048928 ENSG00000261390.4 RP11-345M22.2 -8.8 7e-17 1.58e-13 -0.48 -0.43 Urate levels; chr16:79671039 chr16:79715232~79770563:- LIHC cis rs17826219 0.706 rs8075357 ENSG00000263531.1 RP13-753N3.1 8.8 7.06e-17 1.59e-13 0.76 0.43 Body mass index; chr17:30730179 chr17:30863921~30864940:- LIHC cis rs7208859 0.725 rs9891656 ENSG00000263531.1 RP13-753N3.1 8.79 7.14e-17 1.61e-13 0.71 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916337 chr17:30863921~30864940:- LIHC cis rs73086581 0.947 rs73084523 ENSG00000229539.1 RP11-119B16.2 8.79 7.14e-17 1.61e-13 0.79 0.43 Response to antidepressants in depression; chr20:3894979 chr20:3888239~3888868:- LIHC cis rs6844153 1 rs80197589 ENSG00000240005.4 RP11-293A21.1 -8.79 7.25e-17 1.64e-13 -0.53 -0.43 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26887030 chr4:26859806~26860599:- LIHC cis rs1577917 1 rs10455456 ENSG00000203875.9 SNHG5 -8.79 7.35e-17 1.66e-13 -0.51 -0.43 Response to antipsychotic treatment; chr6:85960604 chr6:85660950~85678736:- LIHC cis rs7208859 0.623 rs1061342 ENSG00000263531.1 RP13-753N3.1 8.79 7.41e-17 1.67e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787445 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs7223803 ENSG00000263531.1 RP13-753N3.1 8.79 7.52e-17 1.69e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750175 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs55814012 ENSG00000263531.1 RP13-753N3.1 8.79 7.52e-17 1.69e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750679 chr17:30863921~30864940:- LIHC cis rs17826219 0.5 rs2449749 ENSG00000263531.1 RP13-753N3.1 8.79 7.52e-17 1.69e-13 0.76 0.43 Body mass index; chr17:30751280 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9894709 ENSG00000263531.1 RP13-753N3.1 8.79 7.52e-17 1.69e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751436 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9896603 ENSG00000263531.1 RP13-753N3.1 8.79 7.52e-17 1.69e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751494 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs8080882 ENSG00000263531.1 RP13-753N3.1 8.79 7.52e-17 1.69e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30754128 chr17:30863921~30864940:- LIHC cis rs6504950 0.76 rs17745189 ENSG00000275710.1 RP11-257O5.4 8.79 7.55e-17 1.7e-13 0.64 0.43 Breast cancer; chr17:54936619 chr17:54964474~54964679:+ LIHC cis rs17826219 0.706 rs57698184 ENSG00000263531.1 RP13-753N3.1 8.78 7.74e-17 1.74e-13 0.75 0.43 Body mass index; chr17:30737900 chr17:30863921~30864940:- LIHC cis rs17826219 0.706 rs9893922 ENSG00000263531.1 RP13-753N3.1 8.78 7.74e-17 1.74e-13 0.75 0.43 Body mass index; chr17:30741407 chr17:30863921~30864940:- LIHC cis rs17826219 0.5 rs9891256 ENSG00000263531.1 RP13-753N3.1 8.78 7.74e-17 1.74e-13 0.75 0.43 Body mass index; chr17:30745674 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs7503335 ENSG00000263531.1 RP13-753N3.1 8.78 7.74e-17 1.74e-13 0.75 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746944 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs28556733 ENSG00000263531.1 RP13-753N3.1 8.78 7.93e-17 1.78e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30756927 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs28433704 ENSG00000263531.1 RP13-753N3.1 8.78 7.93e-17 1.78e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757267 chr17:30863921~30864940:- LIHC cis rs17826219 0.706 rs55764512 ENSG00000263531.1 RP13-753N3.1 8.78 7.93e-17 1.78e-13 0.76 0.43 Body mass index; chr17:30758740 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs12103508 ENSG00000263531.1 RP13-753N3.1 8.78 7.93e-17 1.78e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759763 chr17:30863921~30864940:- LIHC cis rs7208859 0.524 rs11653605 ENSG00000263531.1 RP13-753N3.1 8.78 7.93e-17 1.78e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30761367 chr17:30863921~30864940:- LIHC cis rs11723261 0.582 rs11248006 ENSG00000275426.1 CH17-262A2.1 8.78 8.09e-17 1.81e-13 0.54 0.43 Immune response to smallpox vaccine (IL-6); chr4:172914 chr4:149738~150317:+ LIHC cis rs6844153 0.887 rs60890366 ENSG00000240005.4 RP11-293A21.1 -8.78 8.12e-17 1.82e-13 -0.53 -0.43 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26938615 chr4:26859806~26860599:- LIHC cis rs2882667 0.931 rs10077896 ENSG00000253404.1 AC034243.1 8.78 8.22e-17 1.84e-13 0.58 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:139021067 chr5:138744434~138753309:- LIHC cis rs7208859 0.562 rs8078897 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779239 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9914499 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780570 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs12006 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783634 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs3752021 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784025 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs55938328 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30789992 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs55961983 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792268 chr17:30863921~30864940:- LIHC cis rs17826219 0.568 rs7213925 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Body mass index; chr17:30794616 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11658945 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795491 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11650982 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30802937 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9915546 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805126 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9895815 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811015 chr17:30863921~30864940:- LIHC cis rs17826219 0.706 rs73271850 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Body mass index; chr17:30815122 chr17:30863921~30864940:- LIHC cis rs17826219 0.636 rs79565452 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Body mass index; chr17:30815823 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs7208088 ENSG00000263531.1 RP13-753N3.1 8.77 8.26e-17 1.84e-13 0.77 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816649 chr17:30863921~30864940:- LIHC cis rs17826219 0.568 rs11658027 ENSG00000263531.1 RP13-753N3.1 -8.77 8.3e-17 1.85e-13 -0.76 -0.43 Body mass index; chr17:30767864 chr17:30863921~30864940:- LIHC cis rs10256972 0.933 rs35696159 ENSG00000229043.2 AC091729.9 -8.76 9.1e-17 2.01e-13 -0.48 -0.43 Endometriosis;Longevity; chr7:1007558 chr7:1160374~1165267:+ LIHC cis rs7208859 0.623 rs11657662 ENSG00000263531.1 RP13-753N3.1 -8.76 9.16e-17 2.02e-13 -0.74 -0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749329 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs11654035 ENSG00000263531.1 RP13-753N3.1 8.76 9.18e-17 2.02e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809408 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs7208441 ENSG00000263531.1 RP13-753N3.1 8.76 9.18e-17 2.02e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816845 chr17:30863921~30864940:- LIHC cis rs12594515 1 rs7162201 ENSG00000273972.1 CTD-2306A12.1 -8.76 9.2e-17 2.03e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45700460 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs8029209 ENSG00000273972.1 CTD-2306A12.1 -8.76 9.2e-17 2.03e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45701291 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs12592190 ENSG00000273972.1 CTD-2306A12.1 -8.76 9.2e-17 2.03e-13 -0.51 -0.43 Weight;Waist circumference; chr15:45701830 chr15:45702640~45703183:+ LIHC cis rs6844153 0.715 rs73813220 ENSG00000240005.4 RP11-293A21.1 -8.76 9.25e-17 2.04e-13 -0.5 -0.43 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26920224 chr4:26859806~26860599:- LIHC cis rs507080 0.697 rs653008 ENSG00000255422.1 AP002954.4 -8.76 9.41e-17 2.07e-13 -0.5 -0.43 Serum metabolite levels; chr11:118649775 chr11:118704607~118750263:+ LIHC cis rs12594515 1 rs6493169 ENSG00000273972.1 CTD-2306A12.1 8.76 9.51e-17 2.09e-13 0.5 0.43 Weight;Waist circumference; chr15:45694796 chr15:45702640~45703183:+ LIHC cis rs6860806 0.531 rs274556 ENSG00000233006.5 AC034220.3 -8.75 9.65e-17 2.12e-13 -0.43 -0.43 Breast cancer; chr5:132386383 chr5:132311285~132369916:- LIHC cis rs1153858 1 rs4775911 ENSG00000259520.4 CTD-2651B20.3 8.75 9.9e-17 2.17e-13 0.53 0.43 Homoarginine levels; chr15:45357589 chr15:45251580~45279251:- LIHC cis rs2487048 0.905 rs2437812 ENSG00000226334.1 RP11-217B7.2 -8.75 1.01e-16 2.21e-13 -0.57 -0.43 Intraocular pressure; chr9:104930920 chr9:104927553~104928892:+ LIHC cis rs2882667 1 rs2060222 ENSG00000253404.1 AC034243.1 8.75 1.01e-16 2.22e-13 0.59 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:138972777 chr5:138744434~138753309:- LIHC cis rs9399135 0.967 rs12661423 ENSG00000232876.1 CTA-212D2.2 -8.74 1.03e-16 2.25e-13 -0.51 -0.43 Red blood cell count; chr6:135028432 chr6:135055033~135060550:+ LIHC cis rs6860806 0.531 rs2631359 ENSG00000233006.5 AC034220.3 -8.74 1.04e-16 2.26e-13 -0.42 -0.43 Breast cancer; chr5:132372200 chr5:132311285~132369916:- LIHC cis rs6860806 0.507 rs582490 ENSG00000233006.5 AC034220.3 -8.74 1.04e-16 2.26e-13 -0.42 -0.43 Breast cancer; chr5:132374403 chr5:132311285~132369916:- LIHC cis rs274567 0.501 rs581968 ENSG00000233006.5 AC034220.3 -8.74 1.04e-16 2.26e-13 -0.42 -0.43 Blood metabolite levels; chr5:132374510 chr5:132311285~132369916:- LIHC cis rs6860806 0.507 rs274572 ENSG00000233006.5 AC034220.3 -8.74 1.04e-16 2.26e-13 -0.42 -0.43 Breast cancer; chr5:132375225 chr5:132311285~132369916:- LIHC cis rs274567 0.501 rs274571 ENSG00000233006.5 AC034220.3 -8.74 1.04e-16 2.26e-13 -0.42 -0.43 Blood metabolite levels; chr5:132376433 chr5:132311285~132369916:- LIHC cis rs3762637 1 rs7645862 ENSG00000272758.4 RP11-299J3.8 -8.74 1.04e-16 2.27e-13 -0.54 -0.43 LDL cholesterol levels; chr3:122502292 chr3:122416207~122443180:+ LIHC cis rs2739330 0.796 rs5760097 ENSG00000231271.1 AP000350.8 8.74 1.05e-16 2.28e-13 0.5 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23949918~23954042:+ LIHC cis rs832187 0.629 rs59971314 ENSG00000280620.1 SCAANT1 8.74 1.08e-16 2.36e-13 0.55 0.43 Schizophrenia; chr3:63928942 chr3:63911518~63911772:- LIHC cis rs2882667 0.898 rs2351465 ENSG00000253404.1 AC034243.1 8.73 1.1e-16 2.41e-13 0.57 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:139028162 chr5:138744434~138753309:- LIHC cis rs2882667 0.964 rs12055237 ENSG00000253404.1 AC034243.1 8.73 1.12e-16 2.45e-13 0.59 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:138971617 chr5:138744434~138753309:- LIHC cis rs1263173 0.696 rs1263172 ENSG00000254851.1 RP11-109L13.1 -8.73 1.13e-16 2.47e-13 -0.5 -0.43 HDL cholesterol; chr11:116810202 chr11:117135528~117138582:+ LIHC cis rs1577917 1 rs10455158 ENSG00000203875.9 SNHG5 -8.73 1.16e-16 2.52e-13 -0.51 -0.43 Response to antipsychotic treatment; chr6:85963107 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs34106666 ENSG00000203875.9 SNHG5 -8.73 1.16e-16 2.52e-13 -0.51 -0.43 Response to antipsychotic treatment; chr6:85966540 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs1337844 ENSG00000203875.9 SNHG5 -8.73 1.16e-16 2.52e-13 -0.51 -0.43 Response to antipsychotic treatment; chr6:85967555 chr6:85660950~85678736:- LIHC cis rs12594515 1 rs8038058 ENSG00000273972.1 CTD-2306A12.1 -8.73 1.16e-16 2.53e-13 -0.5 -0.43 Weight;Waist circumference; chr15:45698074 chr15:45702640~45703183:+ LIHC cis rs7208859 0.573 rs56031503 ENSG00000263531.1 RP13-753N3.1 8.73 1.16e-16 2.53e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748647 chr17:30863921~30864940:- LIHC cis rs9399135 0.967 rs1041480 ENSG00000232876.1 CTA-212D2.2 -8.73 1.18e-16 2.56e-13 -0.49 -0.43 Red blood cell count; chr6:135051938 chr6:135055033~135060550:+ LIHC cis rs2882667 0.931 rs13153618 ENSG00000253404.1 AC034243.1 8.73 1.18e-16 2.57e-13 0.57 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:139017087 chr5:138744434~138753309:- LIHC cis rs6844153 0.68 rs11729927 ENSG00000240005.4 RP11-293A21.1 -8.72 1.21e-16 2.62e-13 -0.5 -0.43 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26922178 chr4:26859806~26860599:- LIHC cis rs2882667 0.894 rs1433008 ENSG00000253404.1 AC034243.1 8.72 1.22e-16 2.64e-13 0.57 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:138997975 chr5:138744434~138753309:- LIHC cis rs7208859 0.623 rs9898084 ENSG00000263531.1 RP13-753N3.1 8.72 1.22e-16 2.66e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30755316 chr17:30863921~30864940:- LIHC cis rs4423214 0.61 rs3763856 ENSG00000254682.1 RP11-660L16.2 8.72 1.24e-16 2.69e-13 0.51 0.43 Vitamin D levels; chr11:71414299 chr11:71448674~71452157:+ LIHC cis rs4423214 0.61 rs12789253 ENSG00000254682.1 RP11-660L16.2 8.72 1.24e-16 2.69e-13 0.51 0.43 Vitamin D levels; chr11:71414719 chr11:71448674~71452157:+ LIHC cis rs2882667 0.898 rs3828600 ENSG00000253404.1 AC034243.1 8.72 1.25e-16 2.71e-13 0.57 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:139051170 chr5:138744434~138753309:- LIHC cis rs3762637 0.943 rs10222564 ENSG00000272758.4 RP11-299J3.8 -8.72 1.25e-16 2.72e-13 -0.53 -0.43 LDL cholesterol levels; chr3:122547489 chr3:122416207~122443180:+ LIHC cis rs12594515 1 rs8032835 ENSG00000273972.1 CTD-2306A12.1 -8.72 1.26e-16 2.72e-13 -0.5 -0.43 Weight;Waist circumference; chr15:45705699 chr15:45702640~45703183:+ LIHC cis rs12594515 1 rs8033148 ENSG00000273972.1 CTD-2306A12.1 -8.72 1.26e-16 2.72e-13 -0.5 -0.43 Weight;Waist circumference; chr15:45705731 chr15:45702640~45703183:+ LIHC cis rs12594515 0.904 rs8032875 ENSG00000273972.1 CTD-2306A12.1 -8.72 1.26e-16 2.72e-13 -0.5 -0.43 Weight;Waist circumference; chr15:45705812 chr15:45702640~45703183:+ LIHC cis rs12594515 0.874 rs8032878 ENSG00000273972.1 CTD-2306A12.1 -8.72 1.26e-16 2.72e-13 -0.5 -0.43 Weight;Waist circumference; chr15:45705817 chr15:45702640~45703183:+ LIHC cis rs977987 0.843 rs4888372 ENSG00000261783.1 RP11-252K23.2 -8.72 1.27e-16 2.74e-13 -0.51 -0.43 Dupuytren's disease; chr16:75279587 chr16:75379818~75381260:- LIHC cis rs8062405 0.69 rs62034351 ENSG00000259982.1 CDC37P1 8.72 1.27e-16 2.75e-13 0.54 0.43 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554168 chr16:28700294~28701540:- LIHC cis rs858239 0.712 rs199650 ENSG00000230658.1 KLHL7-AS1 -8.71 1.28e-16 2.77e-13 -0.53 -0.43 Cerebrospinal fluid biomarker levels; chr7:23327570 chr7:23101228~23105703:- LIHC cis rs150992 0.962 rs327811 ENSG00000248489.1 CTD-2007H13.3 8.71 1.29e-16 2.8e-13 0.62 0.43 Body mass index; chr5:98935471 chr5:98929171~98995013:+ LIHC cis rs3762637 0.943 rs72960447 ENSG00000272758.4 RP11-299J3.8 -8.71 1.3e-16 2.81e-13 -0.53 -0.43 LDL cholesterol levels; chr3:122516258 chr3:122416207~122443180:+ LIHC cis rs3762637 0.943 rs6762156 ENSG00000272758.4 RP11-299J3.8 -8.71 1.3e-16 2.81e-13 -0.53 -0.43 LDL cholesterol levels; chr3:122517178 chr3:122416207~122443180:+ LIHC cis rs3762637 0.943 rs9872708 ENSG00000272758.4 RP11-299J3.8 -8.71 1.3e-16 2.81e-13 -0.53 -0.43 LDL cholesterol levels; chr3:122523960 chr3:122416207~122443180:+ LIHC cis rs3762637 0.943 rs28403550 ENSG00000272758.4 RP11-299J3.8 -8.71 1.3e-16 2.81e-13 -0.53 -0.43 LDL cholesterol levels; chr3:122532991 chr3:122416207~122443180:+ LIHC cis rs4718428 0.705 rs4717331 ENSG00000273142.1 RP11-458F8.4 -8.71 1.32e-16 2.85e-13 -0.42 -0.43 Corneal structure; chr7:66913899 chr7:66902857~66906297:+ LIHC cis rs2882667 0.964 rs67296915 ENSG00000253404.1 AC034243.1 8.71 1.33e-16 2.86e-13 0.57 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:138965910 chr5:138744434~138753309:- LIHC cis rs7208859 0.524 rs8065744 ENSG00000263531.1 RP13-753N3.1 8.71 1.33e-16 2.88e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30772431 chr17:30863921~30864940:- LIHC cis rs17826219 0.706 rs8071236 ENSG00000263531.1 RP13-753N3.1 8.71 1.33e-16 2.88e-13 0.76 0.43 Body mass index; chr17:30772984 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs56163556 ENSG00000263531.1 RP13-753N3.1 8.71 1.33e-16 2.88e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774850 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs73269923 ENSG00000263531.1 RP13-753N3.1 8.71 1.33e-16 2.88e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775553 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs8064686 ENSG00000263531.1 RP13-753N3.1 8.71 1.33e-16 2.88e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30807821 chr17:30863921~30864940:- LIHC cis rs2882667 0.931 rs12719518 ENSG00000253404.1 AC034243.1 8.71 1.34e-16 2.89e-13 0.57 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:139005287 chr5:138744434~138753309:- LIHC cis rs10256972 0.967 rs4723338 ENSG00000229043.2 AC091729.9 -8.71 1.35e-16 2.91e-13 -0.48 -0.43 Endometriosis;Longevity; chr7:996605 chr7:1160374~1165267:+ LIHC cis rs2019137 0.936 rs2241978 ENSG00000189223.12 PAX8-AS1 8.71 1.36e-16 2.93e-13 0.55 0.43 Lymphocyte counts; chr2:113196429 chr2:113211522~113276581:+ LIHC cis rs2019137 0.936 rs3828188 ENSG00000189223.12 PAX8-AS1 8.71 1.36e-16 2.93e-13 0.55 0.43 Lymphocyte counts; chr2:113196670 chr2:113211522~113276581:+ LIHC cis rs2019137 0.936 rs4849169 ENSG00000189223.12 PAX8-AS1 8.71 1.37e-16 2.94e-13 0.55 0.43 Lymphocyte counts; chr2:113196080 chr2:113211522~113276581:+ LIHC cis rs2019137 0.836 rs4848318 ENSG00000189223.12 PAX8-AS1 8.71 1.37e-16 2.94e-13 0.55 0.43 Lymphocyte counts; chr2:113196375 chr2:113211522~113276581:+ LIHC cis rs17826219 0.636 rs4055314 ENSG00000263531.1 RP13-753N3.1 8.7 1.38e-16 2.96e-13 0.76 0.43 Body mass index; chr17:30752751 chr17:30863921~30864940:- LIHC cis rs11647589 0.688 rs28556968 ENSG00000260762.1 ACSM5P1 8.7 1.39e-16 2.98e-13 0.41 0.43 Blood metabolite levels; chr16:20469357 chr16:20586550~20607107:- LIHC cis rs494459 0.756 rs570806 ENSG00000255239.1 AP002954.6 8.7 1.41e-16 3.04e-13 0.49 0.43 Height; chr11:118786602 chr11:118688039~118690600:- LIHC cis rs2019137 0.868 rs6755639 ENSG00000189223.12 PAX8-AS1 -8.7 1.42e-16 3.04e-13 -0.54 -0.43 Lymphocyte counts; chr2:113224233 chr2:113211522~113276581:+ LIHC cis rs2283792 0.687 rs381849 ENSG00000224086.5 LL22NC03-86G7.1 -8.7 1.44e-16 3.09e-13 -0.39 -0.43 Multiple sclerosis; chr22:21951341 chr22:21938293~21977632:+ LIHC cis rs6860806 0.507 rs183898 ENSG00000233006.5 AC034220.3 -8.7 1.45e-16 3.12e-13 -0.42 -0.43 Breast cancer; chr5:132381210 chr5:132311285~132369916:- LIHC cis rs73086581 0.947 rs56123574 ENSG00000229539.1 RP11-119B16.2 8.7 1.45e-16 3.12e-13 0.8 0.43 Response to antidepressants in depression; chr20:3897434 chr20:3888239~3888868:- LIHC cis rs10256972 0.616 rs7806746 ENSG00000229043.2 AC091729.9 -8.7 1.46e-16 3.13e-13 -0.48 -0.43 Endometriosis;Longevity; chr7:1035937 chr7:1160374~1165267:+ LIHC cis rs9828933 0.882 rs3816156 ENSG00000280620.1 SCAANT1 8.7 1.47e-16 3.16e-13 0.62 0.43 Type 2 diabetes; chr3:64014036 chr3:63911518~63911772:- LIHC cis rs6844153 0.887 rs62302532 ENSG00000240005.4 RP11-293A21.1 -8.69 1.49e-16 3.2e-13 -0.51 -0.43 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26947150 chr4:26859806~26860599:- LIHC cis rs6844153 0.887 rs6448488 ENSG00000240005.4 RP11-293A21.1 -8.69 1.49e-16 3.2e-13 -0.51 -0.43 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26949365 chr4:26859806~26860599:- LIHC cis rs7208859 0.524 rs60114476 ENSG00000263531.1 RP13-753N3.1 8.69 1.5e-16 3.22e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770649 chr17:30863921~30864940:- LIHC cis rs6844153 1 rs7655686 ENSG00000240005.4 RP11-293A21.1 -8.69 1.55e-16 3.31e-13 -0.54 -0.43 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26897955 chr4:26859806~26860599:- LIHC cis rs17826219 0.568 rs2626985 ENSG00000263531.1 RP13-753N3.1 8.69 1.55e-16 3.32e-13 0.76 0.43 Body mass index; chr17:30750419 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs8078656 ENSG00000263531.1 RP13-753N3.1 8.69 1.55e-16 3.32e-13 0.76 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753953 chr17:30863921~30864940:- LIHC cis rs2019137 0.936 rs2305133 ENSG00000189223.12 PAX8-AS1 8.69 1.56e-16 3.33e-13 0.55 0.43 Lymphocyte counts; chr2:113199244 chr2:113211522~113276581:+ LIHC cis rs2019137 0.936 rs12612729 ENSG00000189223.12 PAX8-AS1 8.69 1.56e-16 3.33e-13 0.55 0.43 Lymphocyte counts; chr2:113199471 chr2:113211522~113276581:+ LIHC cis rs2019137 0.936 rs731834 ENSG00000189223.12 PAX8-AS1 8.69 1.56e-16 3.33e-13 0.55 0.43 Lymphocyte counts; chr2:113199621 chr2:113211522~113276581:+ LIHC cis rs1577917 1 rs13217384 ENSG00000203875.9 SNHG5 -8.69 1.57e-16 3.36e-13 -0.52 -0.43 Response to antipsychotic treatment; chr6:86010282 chr6:85660950~85678736:- LIHC cis rs9399135 0.967 rs2183709 ENSG00000232876.1 CTA-212D2.2 -8.69 1.57e-16 3.36e-13 -0.49 -0.43 Red blood cell count; chr6:135055953 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs4142299 ENSG00000232876.1 CTA-212D2.2 -8.69 1.57e-16 3.36e-13 -0.49 -0.43 Red blood cell count; chr6:135056048 chr6:135055033~135060550:+ LIHC cis rs7178615 1 rs7178615 ENSG00000259471.1 LINC01169 8.69 1.58e-16 3.38e-13 0.57 0.43 Diastolic blood pressure; chr15:66576734 chr15:66582190~66685794:+ LIHC cis rs1577917 0.771 rs4419647 ENSG00000203875.9 SNHG5 8.68 1.59e-16 3.4e-13 0.49 0.43 Response to antipsychotic treatment; chr6:85516021 chr6:85660950~85678736:- LIHC cis rs1577917 0.771 rs9353318 ENSG00000203875.9 SNHG5 8.68 1.59e-16 3.4e-13 0.49 0.43 Response to antipsychotic treatment; chr6:85522003 chr6:85660950~85678736:- LIHC cis rs2739330 0.892 rs4822455 ENSG00000231271.1 AP000350.8 8.68 1.62e-16 3.46e-13 0.5 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23949918~23954042:+ LIHC cis rs10256972 0.967 rs1881122 ENSG00000229043.2 AC091729.9 -8.68 1.62e-16 3.46e-13 -0.48 -0.42 Endometriosis;Longevity; chr7:1001310 chr7:1160374~1165267:+ LIHC cis rs2019137 0.905 rs2276561 ENSG00000189223.12 PAX8-AS1 8.68 1.64e-16 3.5e-13 0.55 0.42 Lymphocyte counts; chr2:113198794 chr2:113211522~113276581:+ LIHC cis rs9660180 0.967 rs2272908 ENSG00000231050.1 RP1-140A9.1 -8.68 1.66e-16 3.55e-13 -0.39 -0.42 Body mass index; chr1:1790040 chr1:1891471~1892658:+ LIHC cis rs2019137 0.936 rs3828189 ENSG00000189223.12 PAX8-AS1 8.68 1.68e-16 3.59e-13 0.55 0.42 Lymphocyte counts; chr2:113196919 chr2:113211522~113276581:+ LIHC cis rs11723261 0.621 rs61794960 ENSG00000275426.1 CH17-262A2.1 8.67 1.71e-16 3.64e-13 0.53 0.42 Immune response to smallpox vaccine (IL-6); chr4:156661 chr4:149738~150317:+ LIHC cis rs10256972 0.684 rs4724039 ENSG00000229043.2 AC091729.9 -8.67 1.72e-16 3.67e-13 -0.48 -0.42 Endometriosis;Longevity; chr7:1071997 chr7:1160374~1165267:+ LIHC cis rs17826219 0.636 rs8080829 ENSG00000263531.1 RP13-753N3.1 8.67 1.73e-16 3.68e-13 0.76 0.42 Body mass index; chr17:30731712 chr17:30863921~30864940:- LIHC cis rs1577917 0.666 rs6454471 ENSG00000203875.9 SNHG5 8.67 1.76e-16 3.73e-13 0.48 0.42 Response to antipsychotic treatment; chr6:85504738 chr6:85660950~85678736:- LIHC cis rs1577917 0.665 rs4304137 ENSG00000203875.9 SNHG5 8.67 1.76e-16 3.73e-13 0.48 0.42 Response to antipsychotic treatment; chr6:85507730 chr6:85660950~85678736:- LIHC cis rs270601 0.909 rs2569265 ENSG00000233006.5 AC034220.3 -8.67 1.76e-16 3.74e-13 -0.42 -0.42 Acylcarnitine levels; chr5:132368827 chr5:132311285~132369916:- LIHC cis rs7195287 0.591 rs63744561 ENSG00000276791.1 CTD-2270P14.5 8.67 1.76e-16 3.74e-13 0.44 0.42 Eosinophil counts; chr16:2778171 chr16:2777319~2780568:+ LIHC cis rs1577917 0.696 rs2842617 ENSG00000234155.1 RP11-30P6.6 8.67 1.77e-16 3.76e-13 0.49 0.42 Response to antipsychotic treatment; chr6:85599980 chr6:85387219~85390186:- LIHC cis rs7208859 0.623 rs11657990 ENSG00000263531.1 RP13-753N3.1 8.67 1.79e-16 3.81e-13 0.76 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797182 chr17:30863921~30864940:- LIHC cis rs6844153 1 rs57663175 ENSG00000240005.4 RP11-293A21.1 -8.67 1.8e-16 3.82e-13 -0.53 -0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26917770 chr4:26859806~26860599:- LIHC cis rs2283792 0.812 rs240064 ENSG00000224086.5 LL22NC03-86G7.1 8.67 1.81e-16 3.84e-13 0.39 0.42 Multiple sclerosis; chr22:21927265 chr22:21938293~21977632:+ LIHC cis rs3762637 1 rs72960431 ENSG00000272758.4 RP11-299J3.8 -8.67 1.81e-16 3.85e-13 -0.54 -0.42 LDL cholesterol levels; chr3:122509814 chr3:122416207~122443180:+ LIHC cis rs3762637 1 rs28434553 ENSG00000272758.4 RP11-299J3.8 -8.67 1.81e-16 3.85e-13 -0.54 -0.42 LDL cholesterol levels; chr3:122510668 chr3:122416207~122443180:+ LIHC cis rs3762637 0.941 rs9837149 ENSG00000272758.4 RP11-299J3.8 -8.67 1.81e-16 3.85e-13 -0.54 -0.42 LDL cholesterol levels; chr3:122511998 chr3:122416207~122443180:+ LIHC cis rs296381 0.866 rs2547231 ENSG00000259108.2 CTD-3098H1.2 8.67 1.82e-16 3.87e-13 0.7 0.42 Blood metabolite levels; chr19:47881800 chr19:47863483~47865341:- LIHC cis rs6844153 0.627 rs11730235 ENSG00000240005.4 RP11-293A21.1 -8.66 1.87e-16 3.97e-13 -0.51 -0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26922822 chr4:26859806~26860599:- LIHC cis rs6860806 0.507 rs635620 ENSG00000233006.5 AC034220.3 -8.66 1.89e-16 3.99e-13 -0.42 -0.42 Breast cancer; chr5:132384571 chr5:132311285~132369916:- LIHC cis rs6860806 0.507 rs635619 ENSG00000233006.5 AC034220.3 -8.66 1.89e-16 3.99e-13 -0.42 -0.42 Breast cancer; chr5:132384573 chr5:132311285~132369916:- LIHC cis rs7208859 0.623 rs55811708 ENSG00000263531.1 RP13-753N3.1 8.66 1.89e-16 4.01e-13 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777713 chr17:30863921~30864940:- LIHC cis rs7044106 0.791 rs10985004 ENSG00000226752.6 PSMD5-AS1 -8.66 1.93e-16 4.07e-13 -0.44 -0.42 Hip circumference adjusted for BMI; chr9:120722659 chr9:120824828~120854385:+ LIHC cis rs11647589 0.735 rs2221448 ENSG00000260762.1 ACSM5P1 8.66 1.93e-16 4.08e-13 0.41 0.42 Blood metabolite levels; chr16:20473548 chr16:20586550~20607107:- LIHC cis rs274567 0.602 rs272853 ENSG00000233006.5 AC034220.3 8.65 2.02e-16 4.26e-13 0.42 0.42 Blood metabolite levels; chr5:132352868 chr5:132311285~132369916:- LIHC cis rs2487048 1 rs2487048 ENSG00000226334.1 RP11-217B7.2 -8.65 2.07e-16 4.36e-13 -0.58 -0.42 Intraocular pressure; chr9:104929542 chr9:104927553~104928892:+ LIHC cis rs2335455 1 rs2335455 ENSG00000276791.1 CTD-2270P14.5 8.65 2.09e-16 4.41e-13 0.44 0.42 Sum eosinophil basophil counts; chr16:2778172 chr16:2777319~2780568:+ LIHC cis rs1150668 0.799 rs1736891 ENSG00000216901.1 AL022393.7 8.65 2.11e-16 4.44e-13 0.48 0.42 Pubertal anthropometrics; chr6:28219323 chr6:28176188~28176674:+ LIHC cis rs2019137 0.967 rs902695 ENSG00000189223.12 PAX8-AS1 8.64 2.12e-16 4.47e-13 0.55 0.42 Lymphocyte counts; chr2:113197497 chr2:113211522~113276581:+ LIHC cis rs858239 0.712 rs200717 ENSG00000230658.1 KLHL7-AS1 8.64 2.16e-16 4.55e-13 0.52 0.42 Cerebrospinal fluid biomarker levels; chr7:23352652 chr7:23101228~23105703:- LIHC cis rs1577917 0.959 rs34258068 ENSG00000203875.9 SNHG5 -8.64 2.16e-16 4.55e-13 -0.51 -0.42 Response to antipsychotic treatment; chr6:85969731 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs884841 ENSG00000203875.9 SNHG5 -8.64 2.16e-16 4.55e-13 -0.51 -0.42 Response to antipsychotic treatment; chr6:85970582 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs884842 ENSG00000203875.9 SNHG5 -8.64 2.16e-16 4.55e-13 -0.51 -0.42 Response to antipsychotic treatment; chr6:85970679 chr6:85660950~85678736:- LIHC cis rs6504950 0.751 rs12937760 ENSG00000275710.1 RP11-257O5.4 8.64 2.18e-16 4.59e-13 0.62 0.42 Breast cancer; chr17:54938769 chr17:54964474~54964679:+ LIHC cis rs8062405 0.723 rs4788077 ENSG00000259982.1 CDC37P1 8.64 2.2e-16 4.63e-13 0.54 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28558443 chr16:28700294~28701540:- LIHC cis rs6844153 0.887 rs62302533 ENSG00000240005.4 RP11-293A21.1 -8.63 2.27e-16 4.76e-13 -0.5 -0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26955309 chr4:26859806~26860599:- LIHC cis rs7208859 0.623 rs73269916 ENSG00000263531.1 RP13-753N3.1 8.63 2.29e-16 4.81e-13 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30769308 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs9895785 ENSG00000263531.1 RP13-753N3.1 -8.63 2.29e-16 4.81e-13 -0.74 -0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780690 chr17:30863921~30864940:- LIHC cis rs2882667 0.931 rs7720150 ENSG00000253404.1 AC034243.1 8.63 2.36e-16 4.94e-13 0.57 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:138998380 chr5:138744434~138753309:- LIHC cis rs17507216 1 rs3850610 ENSG00000278603.1 RP13-608F4.5 -8.63 2.37e-16 4.95e-13 -0.75 -0.42 Excessive daytime sleepiness; chr15:82552642 chr15:82472203~82472426:+ LIHC cis rs150992 0.673 rs330419 ENSG00000248489.1 CTD-2007H13.3 -8.63 2.37e-16 4.96e-13 -0.62 -0.42 Body mass index; chr5:98857460 chr5:98929171~98995013:+ LIHC cis rs2260433 0.66 rs7109950 ENSG00000281655.1 RP11-817J15.3 8.63 2.39e-16 5e-13 0.49 0.42 Cleft palate; chr11:102641320 chr11:102681310~102683913:+ LIHC cis rs6860806 0.507 rs274570 ENSG00000233006.5 AC034220.3 -8.63 2.41e-16 5.04e-13 -0.42 -0.42 Breast cancer; chr5:132377534 chr5:132311285~132369916:- LIHC cis rs4423214 0.569 rs12806918 ENSG00000254682.1 RP11-660L16.2 8.62 2.45e-16 5.12e-13 0.51 0.42 Vitamin D levels; chr11:71407972 chr11:71448674~71452157:+ LIHC cis rs6504950 1 rs9902718 ENSG00000275710.1 RP11-257O5.4 8.62 2.49e-16 5.2e-13 0.6 0.42 Breast cancer; chr17:54984261 chr17:54964474~54964679:+ LIHC cis rs494459 0.838 rs12796102 ENSG00000255239.1 AP002954.6 8.62 2.51e-16 5.24e-13 0.49 0.42 Height; chr11:118791319 chr11:118688039~118690600:- LIHC cis rs2882667 0.931 rs1433009 ENSG00000253404.1 AC034243.1 8.62 2.54e-16 5.29e-13 0.57 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:138998095 chr5:138744434~138753309:- LIHC cis rs494459 0.691 rs607472 ENSG00000255239.1 AP002954.6 8.62 2.57e-16 5.35e-13 0.49 0.42 Height; chr11:118809363 chr11:118688039~118690600:- LIHC cis rs17826219 0.706 rs28469200 ENSG00000263531.1 RP13-753N3.1 8.62 2.59e-16 5.4e-13 0.75 0.42 Body mass index; chr17:30806554 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs7214313 ENSG00000263531.1 RP13-753N3.1 8.62 2.59e-16 5.4e-13 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811578 chr17:30863921~30864940:- LIHC cis rs1150668 0.768 rs1233713 ENSG00000216901.1 AL022393.7 8.62 2.59e-16 5.4e-13 0.48 0.42 Pubertal anthropometrics; chr6:28230503 chr6:28176188~28176674:+ LIHC cis rs17826219 0.636 rs2449770 ENSG00000263531.1 RP13-753N3.1 8.62 2.62e-16 5.44e-13 0.76 0.42 Body mass index; chr17:30774046 chr17:30863921~30864940:- LIHC cis rs7208859 0.524 rs59913838 ENSG00000263531.1 RP13-753N3.1 8.62 2.62e-16 5.44e-13 0.76 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774545 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs8067338 ENSG00000263531.1 RP13-753N3.1 8.62 2.62e-16 5.44e-13 0.76 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775327 chr17:30863921~30864940:- LIHC cis rs2882667 0.931 rs10075893 ENSG00000253404.1 AC034243.1 -8.61 2.68e-16 5.57e-13 -0.56 -0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139020182 chr5:138744434~138753309:- LIHC cis rs853679 0.506 rs1150711 ENSG00000216901.1 AL022393.7 8.61 2.72e-16 5.65e-13 0.49 0.42 Depression; chr6:28240757 chr6:28176188~28176674:+ LIHC cis rs1577917 0.958 rs12208227 ENSG00000203875.9 SNHG5 -8.61 2.75e-16 5.7e-13 -0.51 -0.42 Response to antipsychotic treatment; chr6:85961226 chr6:85660950~85678736:- LIHC cis rs6504950 1 rs17818028 ENSG00000275710.1 RP11-257O5.4 -8.61 2.78e-16 5.78e-13 -0.6 -0.42 Breast cancer; chr17:54985394 chr17:54964474~54964679:+ LIHC cis rs1153858 1 rs9783731 ENSG00000259520.4 CTD-2651B20.3 8.61 2.79e-16 5.78e-13 0.53 0.42 Homoarginine levels; chr15:45350686 chr15:45251580~45279251:- LIHC cis rs7208859 0.524 rs73988172 ENSG00000263531.1 RP13-753N3.1 8.61 2.8e-16 5.81e-13 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759314 chr17:30863921~30864940:- LIHC cis rs3762637 0.943 rs7629285 ENSG00000272758.4 RP11-299J3.8 8.61 2.8e-16 5.81e-13 0.51 0.42 LDL cholesterol levels; chr3:122546892 chr3:122416207~122443180:+ LIHC cis rs2245008 0.671 rs907036 ENSG00000260932.1 RP11-483P21.6 -8.61 2.81e-16 5.83e-13 -0.6 -0.42 Pursuit maintenance gain; chr16:83956245 chr16:83929796~83931223:- LIHC cis rs2260433 0.683 rs11225360 ENSG00000281655.1 RP11-817J15.3 8.6 2.86e-16 5.93e-13 0.49 0.42 Cleft palate; chr11:102642685 chr11:102681310~102683913:+ LIHC cis rs9399135 0.967 rs2327580 ENSG00000232876.1 CTA-212D2.2 -8.6 2.87e-16 5.94e-13 -0.48 -0.42 Red blood cell count; chr6:135043279 chr6:135055033~135060550:+ LIHC cis rs9399135 0.844 rs13209789 ENSG00000232876.1 CTA-212D2.2 -8.6 2.87e-16 5.94e-13 -0.48 -0.42 Red blood cell count; chr6:135046778 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs6915770 ENSG00000232876.1 CTA-212D2.2 -8.6 2.87e-16 5.94e-13 -0.48 -0.42 Red blood cell count; chr6:135048076 chr6:135055033~135060550:+ LIHC cis rs9399135 0.935 rs9376086 ENSG00000232876.1 CTA-212D2.2 -8.6 2.87e-16 5.94e-13 -0.48 -0.42 Red blood cell count; chr6:135050191 chr6:135055033~135060550:+ LIHC cis rs2882667 1 rs10064130 ENSG00000253404.1 AC034243.1 8.6 2.88e-16 5.95e-13 0.58 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:138973618 chr5:138744434~138753309:- LIHC cis rs2882667 0.931 rs10069528 ENSG00000253404.1 AC034243.1 8.6 2.95e-16 6.08e-13 0.57 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139018338 chr5:138744434~138753309:- LIHC cis rs6844153 1 rs57686546 ENSG00000240005.4 RP11-293A21.1 -8.6 2.99e-16 6.15e-13 -0.53 -0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26915162 chr4:26859806~26860599:- LIHC cis rs7208859 0.573 rs4055105 ENSG00000263531.1 RP13-753N3.1 8.6 3.01e-16 6.19e-13 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775532 chr17:30863921~30864940:- LIHC cis rs2882667 0.898 rs6882330 ENSG00000253404.1 AC034243.1 8.59 3.04e-16 6.25e-13 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139046493 chr5:138744434~138753309:- LIHC cis rs2882667 0.898 rs6882526 ENSG00000253404.1 AC034243.1 8.59 3.04e-16 6.25e-13 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139046679 chr5:138744434~138753309:- LIHC cis rs494459 0.726 rs1784300 ENSG00000255239.1 AP002954.6 8.59 3.07e-16 6.32e-13 0.49 0.42 Height; chr11:118808920 chr11:118688039~118690600:- LIHC cis rs12594515 0.967 rs11854477 ENSG00000273972.1 CTD-2306A12.1 -8.59 3.1e-16 6.37e-13 -0.5 -0.42 Weight;Waist circumference; chr15:45706147 chr15:45702640~45703183:+ LIHC cis rs4423214 0.569 rs4944044 ENSG00000254682.1 RP11-660L16.2 8.59 3.11e-16 6.39e-13 0.51 0.42 Vitamin D levels; chr11:71409167 chr11:71448674~71452157:+ LIHC cis rs6844153 1 rs74356465 ENSG00000240005.4 RP11-293A21.1 -8.59 3.14e-16 6.45e-13 -0.53 -0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26902405 chr4:26859806~26860599:- LIHC cis rs3762637 0.941 rs9289192 ENSG00000272758.4 RP11-299J3.8 -8.59 3.2e-16 6.57e-13 -0.54 -0.42 LDL cholesterol levels; chr3:122357268 chr3:122416207~122443180:+ LIHC cis rs2019137 0.901 rs4849176 ENSG00000189223.12 PAX8-AS1 8.58 3.26e-16 6.7e-13 0.54 0.42 Lymphocyte counts; chr2:113220359 chr2:113211522~113276581:+ LIHC cis rs2882667 0.861 rs10043676 ENSG00000253404.1 AC034243.1 8.58 3.27e-16 6.71e-13 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139053872 chr5:138744434~138753309:- LIHC cis rs2882667 0.898 rs10038121 ENSG00000253404.1 AC034243.1 8.58 3.27e-16 6.71e-13 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139053913 chr5:138744434~138753309:- LIHC cis rs2882667 0.861 rs10075541 ENSG00000253404.1 AC034243.1 8.58 3.27e-16 6.71e-13 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139054629 chr5:138744434~138753309:- LIHC cis rs270601 0.837 rs367805 ENSG00000233006.5 AC034220.3 8.58 3.28e-16 6.74e-13 0.42 0.42 Acylcarnitine levels; chr5:132365587 chr5:132311285~132369916:- LIHC cis rs2882667 0.931 rs10044736 ENSG00000253404.1 AC034243.1 -8.58 3.34e-16 6.85e-13 -0.56 -0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:138985120 chr5:138744434~138753309:- LIHC cis rs8062405 0.755 rs56272201 ENSG00000259982.1 CDC37P1 8.58 3.43e-16 7.03e-13 0.54 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28569364 chr16:28700294~28701540:- LIHC cis rs8062405 0.755 rs62034355 ENSG00000259982.1 CDC37P1 8.58 3.43e-16 7.03e-13 0.54 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28569717 chr16:28700294~28701540:- LIHC cis rs2882667 0.898 rs2043272 ENSG00000253404.1 AC034243.1 8.58 3.44e-16 7.06e-13 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139054942 chr5:138744434~138753309:- LIHC cis rs6844153 0.887 rs6835631 ENSG00000240005.4 RP11-293A21.1 8.58 3.49e-16 7.14e-13 0.51 0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26946864 chr4:26859806~26860599:- LIHC cis rs7208859 0.573 rs7222803 ENSG00000263531.1 RP13-753N3.1 8.57 3.49e-16 7.16e-13 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792879 chr17:30863921~30864940:- LIHC cis rs12922040 1 rs12922040 ENSG00000263335.1 AF001548.5 -8.57 3.5e-16 7.16e-13 -0.48 -0.42 Serum uric acid levels in response to allopurinol in gout; chr16:15775609 chr16:15726674~15732993:+ LIHC cis rs7208859 0.573 rs55661352 ENSG00000263531.1 RP13-753N3.1 8.57 3.57e-16 7.3e-13 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30718610 chr17:30863921~30864940:- LIHC cis rs2882667 1 rs10064201 ENSG00000253404.1 AC034243.1 8.57 3.61e-16 7.39e-13 0.58 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:138973716 chr5:138744434~138753309:- LIHC cis rs6844153 1 rs74895929 ENSG00000240005.4 RP11-293A21.1 -8.57 3.66e-16 7.48e-13 -0.52 -0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26846035 chr4:26859806~26860599:- LIHC cis rs73086581 0.787 rs67633417 ENSG00000229539.1 RP11-119B16.2 8.57 3.7e-16 7.54e-13 0.81 0.42 Response to antidepressants in depression; chr20:3887610 chr20:3888239~3888868:- LIHC cis rs73086581 0.787 rs68127408 ENSG00000229539.1 RP11-119B16.2 8.57 3.7e-16 7.54e-13 0.81 0.42 Response to antidepressants in depression; chr20:3887800 chr20:3888239~3888868:- LIHC cis rs73086581 0.787 rs67724338 ENSG00000229539.1 RP11-119B16.2 8.57 3.7e-16 7.54e-13 0.81 0.42 Response to antidepressants in depression; chr20:3888410 chr20:3888239~3888868:- LIHC cis rs73086581 0.787 rs67202952 ENSG00000229539.1 RP11-119B16.2 8.57 3.7e-16 7.54e-13 0.81 0.42 Response to antidepressants in depression; chr20:3888452 chr20:3888239~3888868:- LIHC cis rs1891275 0.551 rs2000177 ENSG00000228701.1 TNKS2-AS1 -8.56 3.82e-16 7.77e-13 -0.63 -0.42 Intelligence (multi-trait analysis); chr10:91653237 chr10:91782839~91798291:- LIHC cis rs1891275 0.576 rs2000178 ENSG00000228701.1 TNKS2-AS1 -8.56 3.82e-16 7.77e-13 -0.63 -0.42 Intelligence (multi-trait analysis); chr10:91653287 chr10:91782839~91798291:- LIHC cis rs9399135 0.967 rs9389258 ENSG00000232876.1 CTA-212D2.2 -8.56 3.82e-16 7.77e-13 -0.48 -0.42 Red blood cell count; chr6:135040002 chr6:135055033~135060550:+ LIHC cis rs2019137 0.936 rs3811059 ENSG00000189223.12 PAX8-AS1 8.56 3.9e-16 7.94e-13 0.54 0.42 Lymphocyte counts; chr2:113204494 chr2:113211522~113276581:+ LIHC cis rs2019137 0.936 rs12620738 ENSG00000189223.12 PAX8-AS1 8.56 3.9e-16 7.94e-13 0.54 0.42 Lymphocyte counts; chr2:113206162 chr2:113211522~113276581:+ LIHC cis rs6504950 1 rs12940106 ENSG00000275710.1 RP11-257O5.4 8.56 3.94e-16 8e-13 0.64 0.42 Breast cancer; chr17:54990322 chr17:54964474~54964679:+ LIHC cis rs2882667 0.931 rs10075951 ENSG00000253404.1 AC034243.1 8.56 3.98e-16 8.09e-13 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139020274 chr5:138744434~138753309:- LIHC cis rs3762637 0.941 rs9810996 ENSG00000272758.4 RP11-299J3.8 -8.56 3.99e-16 8.11e-13 -0.54 -0.42 LDL cholesterol levels; chr3:122355540 chr3:122416207~122443180:+ LIHC cis rs3762637 0.941 rs9810999 ENSG00000272758.4 RP11-299J3.8 -8.56 3.99e-16 8.11e-13 -0.54 -0.42 LDL cholesterol levels; chr3:122355544 chr3:122416207~122443180:+ LIHC cis rs150992 0.673 rs692832 ENSG00000248489.1 CTD-2007H13.3 8.56 4e-16 8.13e-13 0.61 0.42 Body mass index; chr5:98856761 chr5:98929171~98995013:+ LIHC cis rs7208859 0.524 rs8069400 ENSG00000263531.1 RP13-753N3.1 8.56 4.01e-16 8.16e-13 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748949 chr17:30863921~30864940:- LIHC cis rs1577917 1 rs10944170 ENSG00000203875.9 SNHG5 -8.55 4.06e-16 8.25e-13 -0.5 -0.42 Response to antipsychotic treatment; chr6:85975751 chr6:85660950~85678736:- LIHC cis rs9399135 0.967 rs2297338 ENSG00000232876.1 CTA-212D2.2 -8.55 4.14e-16 8.39e-13 -0.48 -0.42 Red blood cell count; chr6:135054624 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs2297340 ENSG00000232876.1 CTA-212D2.2 -8.55 4.14e-16 8.39e-13 -0.48 -0.42 Red blood cell count; chr6:135054920 chr6:135055033~135060550:+ LIHC cis rs1891275 0.551 rs7088831 ENSG00000228701.1 TNKS2-AS1 -8.55 4.14e-16 8.4e-13 -0.63 -0.42 Intelligence (multi-trait analysis); chr10:91652695 chr10:91782839~91798291:- LIHC cis rs6860806 0.507 rs200837 ENSG00000233006.5 AC034220.3 8.55 4.15e-16 8.43e-13 0.42 0.42 Breast cancer; chr5:132364266 chr5:132311285~132369916:- LIHC cis rs3762637 0.941 rs75344200 ENSG00000272758.4 RP11-299J3.8 -8.55 4.21e-16 8.55e-13 -0.54 -0.42 LDL cholesterol levels; chr3:122354574 chr3:122416207~122443180:+ LIHC cis rs9807368 1 rs9807368 ENSG00000263627.1 PPP4R1-AS1 -8.55 4.22e-16 8.56e-13 -0.69 -0.42 Platelet distribution width; chr18:9620161 chr18:9615264~9619363:+ LIHC cis rs1577917 0.545 rs9294338 ENSG00000203875.9 SNHG5 8.55 4.24e-16 8.6e-13 0.45 0.42 Response to antipsychotic treatment; chr6:85764650 chr6:85660950~85678736:- LIHC cis rs1891275 0.551 rs4933687 ENSG00000228701.1 TNKS2-AS1 -8.55 4.26e-16 8.63e-13 -0.62 -0.42 Intelligence (multi-trait analysis); chr10:91650642 chr10:91782839~91798291:- LIHC cis rs7688540 0.511 rs61794965 ENSG00000275426.1 CH17-262A2.1 8.55 4.27e-16 8.65e-13 0.54 0.42 Facial morphology (factor 6, height of vermillion lower lip); chr4:177880 chr4:149738~150317:+ LIHC cis rs7688540 0.511 rs11731927 ENSG00000275426.1 CH17-262A2.1 8.55 4.27e-16 8.65e-13 0.54 0.42 Facial morphology (factor 6, height of vermillion lower lip); chr4:180316 chr4:149738~150317:+ LIHC cis rs1577917 1 rs12207610 ENSG00000203875.9 SNHG5 -8.54 4.33e-16 8.76e-13 -0.5 -0.42 Response to antipsychotic treatment; chr6:85978298 chr6:85660950~85678736:- LIHC cis rs1577917 0.958 rs12203457 ENSG00000203875.9 SNHG5 -8.54 4.33e-16 8.76e-13 -0.5 -0.42 Response to antipsychotic treatment; chr6:85979559 chr6:85660950~85678736:- LIHC cis rs7174755 0.923 rs4777036 ENSG00000260657.2 RP11-315D16.4 -8.54 4.34e-16 8.79e-13 -0.66 -0.42 Major depressive disorder; chr15:68313230 chr15:68267792~68277994:- LIHC cis rs1577917 0.545 rs1335443 ENSG00000203875.9 SNHG5 -8.54 4.35e-16 8.82e-13 -0.44 -0.42 Response to antipsychotic treatment; chr6:85769019 chr6:85660950~85678736:- LIHC cis rs6504950 0.615 rs66898273 ENSG00000275710.1 RP11-257O5.4 8.54 4.44e-16 8.97e-13 0.62 0.42 Breast cancer; chr17:54916595 chr17:54964474~54964679:+ LIHC cis rs6504950 0.745 rs1962045 ENSG00000275710.1 RP11-257O5.4 8.54 4.44e-16 8.97e-13 0.62 0.42 Breast cancer; chr17:54918789 chr17:54964474~54964679:+ LIHC cis rs6504950 0.72 rs9914596 ENSG00000275710.1 RP11-257O5.4 8.54 4.44e-16 8.97e-13 0.62 0.42 Breast cancer; chr17:54919190 chr17:54964474~54964679:+ LIHC cis rs2019137 0.56 rs4849179 ENSG00000274877.1 RP11-65I12.1 -8.54 4.47e-16 9.04e-13 -0.52 -0.42 Lymphocyte counts; chr2:113227593 chr2:113237595~113240825:+ LIHC cis rs150992 0.638 rs466340 ENSG00000248489.1 CTD-2007H13.3 8.54 4.5e-16 9.08e-13 0.61 0.42 Body mass index; chr5:98904318 chr5:98929171~98995013:+ LIHC cis rs150992 0.673 rs326463 ENSG00000248489.1 CTD-2007H13.3 8.54 4.5e-16 9.08e-13 0.61 0.42 Body mass index; chr5:98905785 chr5:98929171~98995013:+ LIHC cis rs150992 0.673 rs327792 ENSG00000248489.1 CTD-2007H13.3 8.54 4.5e-16 9.08e-13 0.61 0.42 Body mass index; chr5:98909802 chr5:98929171~98995013:+ LIHC cis rs150992 0.678 rs327793 ENSG00000248489.1 CTD-2007H13.3 8.54 4.5e-16 9.08e-13 0.61 0.42 Body mass index; chr5:98913717 chr5:98929171~98995013:+ LIHC cis rs150992 0.673 rs161953 ENSG00000248489.1 CTD-2007H13.3 8.54 4.5e-16 9.08e-13 0.61 0.42 Body mass index; chr5:98921201 chr5:98929171~98995013:+ LIHC cis rs150992 0.673 rs161952 ENSG00000248489.1 CTD-2007H13.3 8.54 4.5e-16 9.08e-13 0.61 0.42 Body mass index; chr5:98921665 chr5:98929171~98995013:+ LIHC cis rs9399135 0.967 rs2150681 ENSG00000232876.1 CTA-212D2.2 8.54 4.5e-16 9.1e-13 0.48 0.42 Red blood cell count; chr6:135054094 chr6:135055033~135060550:+ LIHC cis rs2260433 0.66 rs4754861 ENSG00000281655.1 RP11-817J15.3 8.54 4.5e-16 9.1e-13 0.49 0.42 Cleft palate; chr11:102643155 chr11:102681310~102683913:+ LIHC cis rs8062405 0.69 rs762634 ENSG00000259982.1 CDC37P1 8.54 4.52e-16 9.13e-13 0.54 0.42 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28592014 chr16:28700294~28701540:- LIHC cis rs62034325 0.697 rs710410 ENSG00000259982.1 CDC37P1 8.54 4.52e-16 9.13e-13 0.54 0.42 Body mass index; chr16:28592021 chr16:28700294~28701540:- LIHC cis rs12594515 0.967 rs11857628 ENSG00000273972.1 CTD-2306A12.1 -8.54 4.57e-16 9.23e-13 -0.5 -0.42 Weight;Waist circumference; chr15:45706008 chr15:45702640~45703183:+ LIHC cis rs4718428 0.705 rs28648401 ENSG00000273142.1 RP11-458F8.4 -8.54 4.58e-16 9.24e-13 -0.41 -0.42 Corneal structure; chr7:66902145 chr7:66902857~66906297:+ LIHC cis rs4718428 0.607 rs66954441 ENSG00000273142.1 RP11-458F8.4 -8.54 4.58e-16 9.24e-13 -0.41 -0.42 Corneal structure; chr7:66904222 chr7:66902857~66906297:+ LIHC cis rs4718428 0.705 rs4718424 ENSG00000273142.1 RP11-458F8.4 -8.54 4.58e-16 9.24e-13 -0.41 -0.42 Corneal structure; chr7:66911108 chr7:66902857~66906297:+ LIHC cis rs2455601 0.766 rs1109304 ENSG00000254860.4 TMEM9B-AS1 8.54 4.62e-16 9.31e-13 0.51 0.42 Schizophrenia; chr11:8933908 chr11:8964675~8977527:+ LIHC cis rs2882667 0.931 rs10075039 ENSG00000253404.1 AC034243.1 8.53 4.72e-16 9.52e-13 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139002165 chr5:138744434~138753309:- LIHC cis rs6991838 0.584 rs1053088 ENSG00000272010.1 CTD-3025N20.3 8.53 4.76e-16 9.58e-13 0.46 0.42 Intelligence (multi-trait analysis); chr8:65603548 chr8:65591850~65592472:- LIHC cis rs17826219 0.636 rs7221463 ENSG00000263531.1 RP13-753N3.1 8.53 4.77e-16 9.61e-13 0.75 0.42 Body mass index; chr17:30753533 chr17:30863921~30864940:- LIHC cis rs2260433 0.66 rs10160697 ENSG00000281655.1 RP11-817J15.3 8.53 4.79e-16 9.63e-13 0.49 0.42 Cleft palate; chr11:102641623 chr11:102681310~102683913:+ LIHC cis rs2260433 0.66 rs10160700 ENSG00000281655.1 RP11-817J15.3 8.53 4.79e-16 9.63e-13 0.49 0.42 Cleft palate; chr11:102641687 chr11:102681310~102683913:+ LIHC cis rs2260433 0.66 rs11225358 ENSG00000281655.1 RP11-817J15.3 8.53 4.79e-16 9.63e-13 0.49 0.42 Cleft palate; chr11:102642149 chr11:102681310~102683913:+ LIHC cis rs858239 0.831 rs7796541 ENSG00000230658.1 KLHL7-AS1 8.53 4.82e-16 9.7e-13 0.56 0.42 Cerebrospinal fluid biomarker levels; chr7:23349454 chr7:23101228~23105703:- LIHC cis rs2882667 0.898 rs12719519 ENSG00000253404.1 AC034243.1 8.53 4.83e-16 9.72e-13 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139039998 chr5:138744434~138753309:- LIHC cis rs2260433 0.66 rs11225359 ENSG00000281655.1 RP11-817J15.3 8.53 4.85e-16 9.75e-13 0.49 0.42 Cleft palate; chr11:102642254 chr11:102681310~102683913:+ LIHC cis rs6844153 0.752 rs7681462 ENSG00000240005.4 RP11-293A21.1 -8.53 4.89e-16 9.83e-13 -0.48 -0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26894272 chr4:26859806~26860599:- LIHC cis rs9399135 0.935 rs11759999 ENSG00000232876.1 CTA-212D2.2 -8.53 4.89e-16 9.84e-13 -0.48 -0.42 Red blood cell count; chr6:135049357 chr6:135055033~135060550:+ LIHC cis rs9399135 0.935 rs11760000 ENSG00000232876.1 CTA-212D2.2 -8.53 4.89e-16 9.84e-13 -0.48 -0.42 Red blood cell count; chr6:135049358 chr6:135055033~135060550:+ LIHC cis rs6844153 0.752 rs73811400 ENSG00000240005.4 RP11-293A21.1 -8.53 4.91e-16 9.87e-13 -0.48 -0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26887701 chr4:26859806~26860599:- LIHC cis rs8072100 0.967 rs12452315 ENSG00000228782.6 CTD-2026D20.3 -8.53 4.98e-16 1e-12 -0.47 -0.42 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402080 chr17:47450568~47492492:- LIHC cis rs1577917 0.682 rs1173419 ENSG00000234155.1 RP11-30P6.6 8.52 5.09e-16 1.02e-12 0.48 0.42 Response to antipsychotic treatment; chr6:85692445 chr6:85387219~85390186:- LIHC cis rs17826219 0.706 rs2322197 ENSG00000263531.1 RP13-753N3.1 8.52 5.1e-16 1.02e-12 0.75 0.42 Body mass index; chr17:30778787 chr17:30863921~30864940:- LIHC cis rs11647589 0.553 rs6497484 ENSG00000260762.1 ACSM5P1 8.52 5.14e-16 1.03e-12 0.4 0.42 Blood metabolite levels; chr16:20428396 chr16:20586550~20607107:- LIHC cis rs2260433 0.66 rs4754862 ENSG00000281655.1 RP11-817J15.3 8.52 5.23e-16 1.05e-12 0.49 0.42 Cleft palate; chr11:102643427 chr11:102681310~102683913:+ LIHC cis rs4713118 0.505 rs276371 ENSG00000216901.1 AL022393.7 8.51 5.53e-16 1.11e-12 0.46 0.42 Parkinson's disease; chr6:27942930 chr6:28176188~28176674:+ LIHC cis rs7188445 0.871 rs11150187 ENSG00000261390.4 RP11-345M22.2 8.51 5.55e-16 1.11e-12 0.47 0.42 Urate levels; chr16:79670515 chr16:79715232~79770563:- LIHC cis rs7208859 0.623 rs7219712 ENSG00000263531.1 RP13-753N3.1 8.51 5.57e-16 1.11e-12 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753552 chr17:30863921~30864940:- LIHC cis rs9399135 0.967 rs7763836 ENSG00000232876.1 CTA-212D2.2 -8.51 5.58e-16 1.12e-12 -0.48 -0.42 Red blood cell count; chr6:135041240 chr6:135055033~135060550:+ LIHC cis rs2882667 0.931 rs11955952 ENSG00000253404.1 AC034243.1 8.51 5.62e-16 1.12e-12 0.55 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:138993430 chr5:138744434~138753309:- LIHC cis rs2929278 0.617 rs12908467 ENSG00000205771.5 CATSPER2P1 8.51 5.7e-16 1.14e-12 0.53 0.42 Schizophrenia; chr15:43755232 chr15:43726918~43747094:- LIHC cis rs2019137 0.56 rs6707386 ENSG00000274877.1 RP11-65I12.1 -8.51 5.73e-16 1.15e-12 -0.53 -0.42 Lymphocyte counts; chr2:113223445 chr2:113237595~113240825:+ LIHC cis rs7208859 0.623 rs7220289 ENSG00000263531.1 RP13-753N3.1 8.5 5.93e-16 1.18e-12 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30776744 chr17:30863921~30864940:- LIHC cis rs73086581 0.947 rs73084531 ENSG00000229539.1 RP11-119B16.2 8.5 5.97e-16 1.19e-12 0.79 0.42 Response to antidepressants in depression; chr20:3897782 chr20:3888239~3888868:- LIHC cis rs2882667 0.931 rs10068237 ENSG00000253404.1 AC034243.1 8.5 6.02e-16 1.2e-12 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139002271 chr5:138744434~138753309:- LIHC cis rs7617773 1 rs7617773 ENSG00000229759.1 MRPS18AP1 -8.5 6.09e-16 1.21e-12 -0.46 -0.42 Coronary artery disease; chr3:48152025 chr3:48256350~48256938:- LIHC cis rs2882667 0.898 rs11950819 ENSG00000253404.1 AC034243.1 8.5 6.14e-16 1.23e-12 0.55 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139061411 chr5:138744434~138753309:- LIHC cis rs2739330 0.587 rs4820571 ENSG00000225282.1 AP000350.6 8.49 6.2e-16 1.24e-12 0.52 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23926900~23929574:+ LIHC cis rs12922040 0.651 rs35288467 ENSG00000263335.1 AF001548.5 -8.49 6.43e-16 1.28e-12 -0.48 -0.42 Serum uric acid levels in response to allopurinol in gout; chr16:15773097 chr16:15726674~15732993:+ LIHC cis rs6504950 1 rs7219874 ENSG00000275710.1 RP11-257O5.4 8.49 6.47e-16 1.29e-12 0.62 0.42 Breast cancer; chr17:54988446 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs8082471 ENSG00000275710.1 RP11-257O5.4 8.49 6.47e-16 1.29e-12 0.62 0.42 Breast cancer; chr17:54990632 chr17:54964474~54964679:+ LIHC cis rs6844153 0.941 rs75656258 ENSG00000240005.4 RP11-293A21.1 -8.49 6.52e-16 1.3e-12 -0.52 -0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26843577 chr4:26859806~26860599:- LIHC cis rs2882667 0.898 rs6862393 ENSG00000253404.1 AC034243.1 8.49 6.53e-16 1.3e-12 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139029009 chr5:138744434~138753309:- LIHC cis rs2455601 0.786 rs3763913 ENSG00000254860.4 TMEM9B-AS1 8.49 6.62e-16 1.32e-12 0.5 0.42 Schizophrenia; chr11:8929683 chr11:8964675~8977527:+ LIHC cis rs1577917 0.739 rs6922 ENSG00000203875.9 SNHG5 8.48 6.62e-16 1.32e-12 0.48 0.42 Response to antipsychotic treatment; chr6:85495605 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12215903 ENSG00000203875.9 SNHG5 -8.48 6.67e-16 1.33e-12 -0.5 -0.42 Response to antipsychotic treatment; chr6:85965310 chr6:85660950~85678736:- LIHC cis rs2882667 0.898 rs6882583 ENSG00000253404.1 AC034243.1 8.48 6.72e-16 1.34e-12 0.55 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139050107 chr5:138744434~138753309:- LIHC cis rs2882667 0.898 rs13182437 ENSG00000253404.1 AC034243.1 8.48 6.72e-16 1.34e-12 0.55 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139051460 chr5:138744434~138753309:- LIHC cis rs17826219 0.636 rs12946563 ENSG00000263531.1 RP13-753N3.1 8.48 6.72e-16 1.34e-12 0.75 0.42 Body mass index; chr17:30776148 chr17:30863921~30864940:- LIHC cis rs6504950 0.745 rs35079296 ENSG00000275710.1 RP11-257O5.4 8.48 6.75e-16 1.34e-12 0.61 0.42 Breast cancer; chr17:54916849 chr17:54964474~54964679:+ LIHC cis rs7188445 0.871 rs8047723 ENSG00000261390.4 RP11-345M22.2 8.48 6.77e-16 1.34e-12 0.47 0.42 Urate levels; chr16:79671018 chr16:79715232~79770563:- LIHC cis rs4718428 0.705 rs10267335 ENSG00000273142.1 RP11-458F8.4 -8.48 6.82e-16 1.35e-12 -0.41 -0.42 Corneal structure; chr7:66938233 chr7:66902857~66906297:+ LIHC cis rs6844153 0.752 rs11737218 ENSG00000240005.4 RP11-293A21.1 8.48 6.88e-16 1.37e-12 0.47 0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26884151 chr4:26859806~26860599:- LIHC cis rs9399135 0.967 rs34546690 ENSG00000232876.1 CTA-212D2.2 -8.48 6.93e-16 1.37e-12 -0.47 -0.42 Red blood cell count; chr6:135048571 chr6:135055033~135060550:+ LIHC cis rs6844153 0.752 rs12650172 ENSG00000240005.4 RP11-293A21.1 -8.48 7.03e-16 1.39e-12 -0.48 -0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26872784 chr4:26859806~26860599:- LIHC cis rs6844153 0.752 rs12641261 ENSG00000240005.4 RP11-293A21.1 -8.48 7.03e-16 1.39e-12 -0.48 -0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26872814 chr4:26859806~26860599:- LIHC cis rs6844153 0.752 rs6815719 ENSG00000240005.4 RP11-293A21.1 -8.48 7.03e-16 1.39e-12 -0.48 -0.42 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26880232 chr4:26859806~26860599:- LIHC cis rs9399135 0.967 rs9373122 ENSG00000232876.1 CTA-212D2.2 -8.48 7.04e-16 1.4e-12 -0.47 -0.42 Red blood cell count; chr6:135052396 chr6:135055033~135060550:+ LIHC cis rs2260433 0.621 rs10160727 ENSG00000281655.1 RP11-817J15.3 8.47 7.14e-16 1.41e-12 0.49 0.42 Cleft palate; chr11:102641640 chr11:102681310~102683913:+ LIHC cis rs2739330 0.796 rs2154594 ENSG00000231271.1 AP000350.8 -8.47 7.22e-16 1.43e-12 -0.5 -0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23949918~23954042:+ LIHC cis rs2283792 0.718 rs239918 ENSG00000224086.5 LL22NC03-86G7.1 -8.47 7.31e-16 1.45e-12 -0.38 -0.42 Multiple sclerosis; chr22:21959457 chr22:21938293~21977632:+ LIHC cis rs2882667 0.861 rs13176902 ENSG00000253404.1 AC034243.1 8.47 7.33e-16 1.45e-12 0.55 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139057640 chr5:138744434~138753309:- LIHC cis rs11647589 0.687 rs12598584 ENSG00000260762.1 ACSM5P1 -8.47 7.34e-16 1.45e-12 -0.41 -0.42 Blood metabolite levels; chr16:20476785 chr16:20586550~20607107:- LIHC cis rs4423214 0.535 rs1540129 ENSG00000254682.1 RP11-660L16.2 8.47 7.48e-16 1.48e-12 0.51 0.42 Vitamin D levels; chr11:71418477 chr11:71448674~71452157:+ LIHC cis rs2019137 0.539 rs11123170 ENSG00000274877.1 RP11-65I12.1 -8.47 7.55e-16 1.49e-12 -0.53 -0.42 Lymphocyte counts; chr2:113221363 chr2:113237595~113240825:+ LIHC cis rs1577917 1 rs12190598 ENSG00000203875.9 SNHG5 -8.47 7.63e-16 1.5e-12 -0.51 -0.42 Response to antipsychotic treatment; chr6:85976356 chr6:85660950~85678736:- LIHC cis rs2882667 0.898 rs3925110 ENSG00000253404.1 AC034243.1 8.46 7.68e-16 1.51e-12 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139035676 chr5:138744434~138753309:- LIHC cis rs2455601 0.786 rs11042127 ENSG00000254860.4 TMEM9B-AS1 8.46 7.75e-16 1.52e-12 0.51 0.42 Schizophrenia; chr11:8926039 chr11:8964675~8977527:+ LIHC cis rs7208859 0.623 rs60890550 ENSG00000263531.1 RP13-753N3.1 8.46 7.77e-16 1.53e-12 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30703843 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs11653955 ENSG00000263531.1 RP13-753N3.1 8.46 7.77e-16 1.53e-12 0.75 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30706274 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs8067035 ENSG00000263531.1 RP13-753N3.1 8.46 7.82e-16 1.54e-12 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775170 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs216423 ENSG00000263531.1 RP13-753N3.1 8.46 7.88e-16 1.55e-12 0.69 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30615091 chr17:30863921~30864940:- LIHC cis rs7208859 0.573 rs8070182 ENSG00000263531.1 RP13-753N3.1 8.46 7.91e-16 1.55e-12 0.74 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30808576 chr17:30863921~30864940:- LIHC cis rs17507216 1 rs17356118 ENSG00000278603.1 RP13-608F4.5 8.46 7.92e-16 1.56e-12 0.77 0.42 Excessive daytime sleepiness; chr15:82569149 chr15:82472203~82472426:+ LIHC cis rs4718428 0.705 rs13227468 ENSG00000273142.1 RP11-458F8.4 -8.46 7.93e-16 1.56e-12 -0.41 -0.42 Corneal structure; chr7:66968576 chr7:66902857~66906297:+ LIHC cis rs1891275 0.551 rs2027486 ENSG00000228701.1 TNKS2-AS1 -8.46 7.95e-16 1.56e-12 -0.63 -0.42 Intelligence (multi-trait analysis); chr10:91654229 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs2421623 ENSG00000228701.1 TNKS2-AS1 -8.46 7.95e-16 1.56e-12 -0.63 -0.42 Intelligence (multi-trait analysis); chr10:91654700 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs10881941 ENSG00000228701.1 TNKS2-AS1 -8.46 7.95e-16 1.56e-12 -0.63 -0.42 Intelligence (multi-trait analysis); chr10:91655154 chr10:91782839~91798291:- LIHC cis rs1891275 0.576 rs10881942 ENSG00000228701.1 TNKS2-AS1 -8.46 7.95e-16 1.56e-12 -0.63 -0.42 Intelligence (multi-trait analysis); chr10:91655263 chr10:91782839~91798291:- LIHC cis rs1891275 0.516 rs10881943 ENSG00000228701.1 TNKS2-AS1 -8.46 7.95e-16 1.56e-12 -0.63 -0.42 Intelligence (multi-trait analysis); chr10:91655373 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs7087959 ENSG00000228701.1 TNKS2-AS1 -8.46 7.95e-16 1.56e-12 -0.63 -0.42 Intelligence (multi-trait analysis); chr10:91656160 chr10:91782839~91798291:- LIHC cis rs2019137 0.539 rs6755040 ENSG00000274877.1 RP11-65I12.1 -8.46 8.03e-16 1.57e-12 -0.52 -0.42 Lymphocyte counts; chr2:113223560 chr2:113237595~113240825:+ LIHC cis rs507080 0.961 rs600969 ENSG00000255422.1 AP002954.4 -8.46 8.13e-16 1.59e-12 -0.47 -0.42 Serum metabolite levels; chr11:118675087 chr11:118704607~118750263:+ LIHC cis rs507080 0.961 rs673770 ENSG00000255422.1 AP002954.4 -8.46 8.13e-16 1.59e-12 -0.47 -0.42 Serum metabolite levels; chr11:118679892 chr11:118704607~118750263:+ LIHC cis rs7727544 0.684 rs272889 ENSG00000233006.5 AC034220.3 8.45 8.23e-16 1.61e-12 0.41 0.42 Blood metabolite levels; chr5:132329685 chr5:132311285~132369916:- LIHC cis rs2882667 0.894 rs10054478 ENSG00000253404.1 AC034243.1 8.45 8.25e-16 1.61e-12 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139018386 chr5:138744434~138753309:- LIHC cis rs2882667 0.931 rs10070021 ENSG00000253404.1 AC034243.1 8.45 8.26e-16 1.62e-12 0.56 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:138989017 chr5:138744434~138753309:- LIHC cis rs7688540 0.511 rs10003260 ENSG00000275426.1 CH17-262A2.1 8.45 8.27e-16 1.62e-12 0.54 0.42 Facial morphology (factor 6, height of vermillion lower lip); chr4:191053 chr4:149738~150317:+ LIHC cis rs507080 0.769 rs12290522 ENSG00000255422.1 AP002954.4 -8.45 8.41e-16 1.64e-12 -0.49 -0.42 Serum metabolite levels; chr11:118615610 chr11:118704607~118750263:+ LIHC cis rs2739330 0.731 rs5751792 ENSG00000225282.1 AP000350.6 8.45 8.42e-16 1.65e-12 0.51 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23926900~23929574:+ LIHC cis rs2882667 0.898 rs2882792 ENSG00000253404.1 AC034243.1 8.45 8.53e-16 1.67e-12 0.55 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139044791 chr5:138744434~138753309:- LIHC cis rs2019137 0.56 rs11123172 ENSG00000274877.1 RP11-65I12.1 8.45 8.61e-16 1.68e-12 0.52 0.42 Lymphocyte counts; chr2:113226726 chr2:113237595~113240825:+ LIHC cis rs1153858 1 rs1554521 ENSG00000259520.4 CTD-2651B20.3 8.45 8.7e-16 1.7e-12 0.53 0.42 Homoarginine levels; chr15:45371991 chr15:45251580~45279251:- LIHC cis rs3096299 0.685 rs2911244 ENSG00000274627.1 RP11-104N10.2 8.44 8.82e-16 1.72e-12 0.43 0.42 Multiple myeloma (IgH translocation); chr16:89455452 chr16:89516797~89522217:+ LIHC cis rs2019137 0.539 rs4849177 ENSG00000274877.1 RP11-65I12.1 -8.44 8.93e-16 1.74e-12 -0.52 -0.42 Lymphocyte counts; chr2:113225007 chr2:113237595~113240825:+ LIHC cis rs7208859 0.673 rs216418 ENSG00000263531.1 RP13-753N3.1 8.44 8.96e-16 1.74e-12 0.68 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30609519 chr17:30863921~30864940:- LIHC cis rs10510102 0.608 rs4077606 ENSG00000226864.1 ATE1-AS1 -8.44 8.96e-16 1.74e-12 -0.56 -0.42 Breast cancer; chr10:121849907 chr10:121928312~121951965:+ LIHC cis rs2019137 0.56 rs7578633 ENSG00000274877.1 RP11-65I12.1 -8.44 8.96e-16 1.74e-12 -0.53 -0.42 Lymphocyte counts; chr2:113221073 chr2:113237595~113240825:+ LIHC cis rs4718428 0.672 rs12530806 ENSG00000273142.1 RP11-458F8.4 -8.44 8.98e-16 1.74e-12 -0.41 -0.42 Corneal structure; chr7:66925737 chr7:66902857~66906297:+ LIHC cis rs7208859 0.573 rs73267873 ENSG00000263531.1 RP13-753N3.1 8.44 9e-16 1.75e-12 0.71 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741439 chr17:30863921~30864940:- LIHC cis rs17826219 0.561 rs4085382 ENSG00000263531.1 RP13-753N3.1 8.44 9e-16 1.75e-12 0.71 0.42 Body mass index; chr17:30744184 chr17:30863921~30864940:- LIHC cis rs1891275 0.527 rs35812291 ENSG00000228701.1 TNKS2-AS1 -8.44 9.03e-16 1.75e-12 -0.62 -0.42 Intelligence (multi-trait analysis); chr10:91642584 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs4933681 ENSG00000228701.1 TNKS2-AS1 -8.44 9.03e-16 1.75e-12 -0.62 -0.42 Intelligence (multi-trait analysis); chr10:91643365 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs7071844 ENSG00000228701.1 TNKS2-AS1 -8.44 9.03e-16 1.75e-12 -0.62 -0.42 Intelligence (multi-trait analysis); chr10:91644092 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs4933684 ENSG00000228701.1 TNKS2-AS1 -8.44 9.03e-16 1.75e-12 -0.62 -0.42 Intelligence (multi-trait analysis); chr10:91647805 chr10:91782839~91798291:- LIHC cis rs7688540 0.511 rs75433628 ENSG00000275426.1 CH17-262A2.1 8.44 9.09e-16 1.76e-12 0.54 0.42 Facial morphology (factor 6, height of vermillion lower lip); chr4:184563 chr4:149738~150317:+ LIHC cis rs7688540 0.511 rs4522818 ENSG00000275426.1 CH17-262A2.1 8.44 9.09e-16 1.76e-12 0.54 0.42 Facial morphology (factor 6, height of vermillion lower lip); chr4:187973 chr4:149738~150317:+ LIHC cis rs7688540 0.511 rs61794969 ENSG00000275426.1 CH17-262A2.1 8.44 9.09e-16 1.76e-12 0.54 0.42 Facial morphology (factor 6, height of vermillion lower lip); chr4:194242 chr4:149738~150317:+ LIHC cis rs11723261 0.582 rs11732336 ENSG00000275426.1 CH17-262A2.1 8.44 9.2e-16 1.78e-12 0.49 0.42 Immune response to smallpox vaccine (IL-6); chr4:146728 chr4:149738~150317:+ LIHC cis rs2019137 1 rs2019137 ENSG00000189223.12 PAX8-AS1 8.44 9.31e-16 1.8e-12 0.53 0.42 Lymphocyte counts; chr2:113216055 chr2:113211522~113276581:+ LIHC cis rs6504950 0.889 rs1156287 ENSG00000275710.1 RP11-257O5.4 -8.44 9.32e-16 1.8e-12 -0.63 -0.42 Breast cancer; chr17:54999438 chr17:54964474~54964679:+ LIHC cis rs507080 0.845 rs667982 ENSG00000255422.1 AP002954.4 -8.43 9.77e-16 1.89e-12 -0.48 -0.41 Serum metabolite levels; chr11:118692058 chr11:118704607~118750263:+ LIHC cis rs507080 0.961 rs607527 ENSG00000255422.1 AP002954.4 8.43 9.79e-16 1.89e-12 0.47 0.41 Serum metabolite levels; chr11:118667478 chr11:118704607~118750263:+ LIHC cis rs2882667 0.898 rs6890272 ENSG00000253404.1 AC034243.1 8.43 9.88e-16 1.91e-12 0.56 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139035427 chr5:138744434~138753309:- LIHC cis rs9399135 0.933 rs41294852 ENSG00000232876.1 CTA-212D2.2 -8.43 1e-15 1.94e-12 -0.47 -0.41 Red blood cell count; chr6:135055241 chr6:135055033~135060550:+ LIHC cis rs2019137 0.967 rs895412 ENSG00000189223.12 PAX8-AS1 8.43 1e-15 1.94e-12 0.53 0.41 Lymphocyte counts; chr2:113216387 chr2:113211522~113276581:+ LIHC cis rs4356975 0.83 rs7438033 ENSG00000249956.3 RP11-790I12.2 -8.42 1.03e-15 1.98e-12 -0.46 -0.41 Obesity-related traits; chr4:69059343 chr4:69408836~69423164:+ LIHC cis rs507080 0.922 rs12788848 ENSG00000255422.1 AP002954.4 -8.42 1.03e-15 1.98e-12 -0.47 -0.41 Serum metabolite levels; chr11:118683079 chr11:118704607~118750263:+ LIHC cis rs507080 0.922 rs4474473 ENSG00000255422.1 AP002954.4 -8.42 1.03e-15 1.98e-12 -0.47 -0.41 Serum metabolite levels; chr11:118683180 chr11:118704607~118750263:+ LIHC cis rs507080 0.922 rs12796373 ENSG00000255422.1 AP002954.4 -8.42 1.03e-15 1.98e-12 -0.47 -0.41 Serum metabolite levels; chr11:118684230 chr11:118704607~118750263:+ LIHC cis rs2455601 0.786 rs56680262 ENSG00000254860.4 TMEM9B-AS1 8.42 1.04e-15 2e-12 0.5 0.41 Schizophrenia; chr11:8950008 chr11:8964675~8977527:+ LIHC cis rs8062405 0.698 rs8046545 ENSG00000259982.1 CDC37P1 -8.42 1.04e-15 2e-12 -0.51 -0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28903896 chr16:28700294~28701540:- LIHC cis rs8062405 0.698 rs10499 ENSG00000259982.1 CDC37P1 -8.42 1.04e-15 2e-12 -0.51 -0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28904206 chr16:28700294~28701540:- LIHC cis rs2260433 0.548 rs4754860 ENSG00000281655.1 RP11-817J15.3 8.42 1.06e-15 2.04e-12 0.48 0.41 Cleft palate; chr11:102642942 chr11:102681310~102683913:+ LIHC cis rs17608059 0.545 rs9915045 ENSG00000141028.6 CDRT15P1 -8.42 1.06e-15 2.04e-12 -0.44 -0.41 Temperament; chr17:13999319 chr17:14024514~14025488:+ LIHC cis rs2882667 0.931 rs6596457 ENSG00000253404.1 AC034243.1 8.42 1.07e-15 2.06e-12 0.55 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:138987690 chr5:138744434~138753309:- LIHC cis rs10256972 0.63 rs10282584 ENSG00000229043.2 AC091729.9 -8.42 1.08e-15 2.07e-12 -0.48 -0.41 Endometriosis;Longevity; chr7:1041806 chr7:1160374~1165267:+ LIHC cis rs6844153 0.752 rs12644073 ENSG00000240005.4 RP11-293A21.1 -8.41 1.1e-15 2.12e-12 -0.48 -0.41 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26895436 chr4:26859806~26860599:- LIHC cis rs3096299 0.719 rs2353581 ENSG00000274627.1 RP11-104N10.2 8.41 1.13e-15 2.17e-12 0.43 0.41 Multiple myeloma (IgH translocation); chr16:89452500 chr16:89516797~89522217:+ LIHC cis rs7208859 0.623 rs8081299 ENSG00000263531.1 RP13-753N3.1 8.41 1.14e-15 2.19e-12 0.74 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777278 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs8068645 ENSG00000263531.1 RP13-753N3.1 8.41 1.14e-15 2.19e-12 0.74 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777324 chr17:30863921~30864940:- LIHC cis rs2882667 0.898 rs10058347 ENSG00000253404.1 AC034243.1 8.4 1.17e-15 2.25e-12 0.55 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139025669 chr5:138744434~138753309:- LIHC cis rs2882667 0.931 rs10038799 ENSG00000253404.1 AC034243.1 8.4 1.18e-15 2.26e-12 0.55 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139026594 chr5:138744434~138753309:- LIHC cis rs494459 0.838 rs555649 ENSG00000255239.1 AP002954.6 8.4 1.2e-15 2.29e-12 0.48 0.41 Height; chr11:118781100 chr11:118688039~118690600:- LIHC cis rs1150668 0.799 rs1150707 ENSG00000216901.1 AL022393.7 8.4 1.21e-15 2.31e-12 0.47 0.41 Pubertal anthropometrics; chr6:28229827 chr6:28176188~28176674:+ LIHC cis rs1150668 0.799 rs7206 ENSG00000216901.1 AL022393.7 8.4 1.21e-15 2.31e-12 0.47 0.41 Pubertal anthropometrics; chr6:28233360 chr6:28176188~28176674:+ LIHC cis rs507080 0.961 rs1784298 ENSG00000255422.1 AP002954.4 -8.4 1.21e-15 2.32e-12 -0.47 -0.41 Serum metabolite levels; chr11:118677956 chr11:118704607~118750263:+ LIHC cis rs507080 0.961 rs4938522 ENSG00000255422.1 AP002954.4 -8.4 1.21e-15 2.32e-12 -0.47 -0.41 Serum metabolite levels; chr11:118677962 chr11:118704607~118750263:+ LIHC cis rs507080 0.961 rs4938523 ENSG00000255422.1 AP002954.4 -8.4 1.21e-15 2.32e-12 -0.47 -0.41 Serum metabolite levels; chr11:118678129 chr11:118704607~118750263:+ LIHC cis rs507080 1 rs659969 ENSG00000255422.1 AP002954.4 -8.4 1.21e-15 2.32e-12 -0.47 -0.41 Serum metabolite levels; chr11:118679094 chr11:118704607~118750263:+ LIHC cis rs507080 0.961 rs656505 ENSG00000255422.1 AP002954.4 -8.4 1.21e-15 2.32e-12 -0.47 -0.41 Serum metabolite levels; chr11:118679245 chr11:118704607~118750263:+ LIHC cis rs507080 0.961 rs660489 ENSG00000255422.1 AP002954.4 -8.4 1.21e-15 2.32e-12 -0.47 -0.41 Serum metabolite levels; chr11:118679255 chr11:118704607~118750263:+ LIHC cis rs507080 0.961 rs543327 ENSG00000255422.1 AP002954.4 -8.4 1.21e-15 2.32e-12 -0.47 -0.41 Serum metabolite levels; chr11:118679276 chr11:118704607~118750263:+ LIHC cis rs507080 0.961 rs543413 ENSG00000255422.1 AP002954.4 -8.4 1.21e-15 2.32e-12 -0.47 -0.41 Serum metabolite levels; chr11:118679308 chr11:118704607~118750263:+ LIHC cis rs507080 0.922 rs519848 ENSG00000255422.1 AP002954.4 -8.4 1.24e-15 2.36e-12 -0.47 -0.41 Serum metabolite levels; chr11:118682006 chr11:118704607~118750263:+ LIHC cis rs1577917 0.771 rs7762321 ENSG00000234155.1 RP11-30P6.6 -8.4 1.24e-15 2.38e-12 -0.48 -0.41 Response to antipsychotic treatment; chr6:85702428 chr6:85387219~85390186:- LIHC cis rs7208859 0.673 rs1347359 ENSG00000263531.1 RP13-753N3.1 8.4 1.25e-15 2.39e-12 0.68 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587511 chr17:30863921~30864940:- LIHC cis rs507080 0.883 rs656575 ENSG00000255422.1 AP002954.4 -8.39 1.26e-15 2.41e-12 -0.47 -0.41 Serum metabolite levels; chr11:118679199 chr11:118704607~118750263:+ LIHC cis rs2019137 0.539 rs4849181 ENSG00000274877.1 RP11-65I12.1 -8.39 1.26e-15 2.41e-12 -0.52 -0.41 Lymphocyte counts; chr2:113234393 chr2:113237595~113240825:+ LIHC cis rs11723261 0.546 rs57839456 ENSG00000275426.1 CH17-262A2.1 8.39 1.27e-15 2.42e-12 0.49 0.41 Immune response to smallpox vaccine (IL-6); chr4:154494 chr4:149738~150317:+ LIHC cis rs507080 0.961 rs642530 ENSG00000255422.1 AP002954.4 -8.39 1.27e-15 2.42e-12 -0.47 -0.41 Serum metabolite levels; chr11:118680047 chr11:118704607~118750263:+ LIHC cis rs7688540 0.511 rs77815676 ENSG00000275426.1 CH17-262A2.1 8.39 1.28e-15 2.44e-12 0.53 0.41 Facial morphology (factor 6, height of vermillion lower lip); chr4:196080 chr4:149738~150317:+ LIHC cis rs7688540 0.547 rs11728864 ENSG00000275426.1 CH17-262A2.1 8.39 1.28e-15 2.44e-12 0.53 0.41 Facial morphology (factor 6, height of vermillion lower lip); chr4:197518 chr4:149738~150317:+ LIHC cis rs9399135 0.967 rs7766189 ENSG00000232876.1 CTA-212D2.2 -8.39 1.29e-15 2.47e-12 -0.46 -0.41 Red blood cell count; chr6:135032713 chr6:135055033~135060550:+ LIHC cis rs2739330 0.761 rs5760176 ENSG00000225282.1 AP000350.6 -8.39 1.32e-15 2.51e-12 -0.51 -0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23926900~23929574:+ LIHC cis rs7396835 0.537 rs10892035 ENSG00000254851.1 RP11-109L13.1 -8.39 1.32e-15 2.51e-12 -0.55 -0.41 Quantitative traits; chr11:116824222 chr11:117135528~117138582:+ LIHC cis rs3096299 0.658 rs34590044 ENSG00000274627.1 RP11-104N10.2 8.39 1.33e-15 2.53e-12 0.42 0.41 Multiple myeloma (IgH translocation); chr16:89476749 chr16:89516797~89522217:+ LIHC cis rs12022452 0.591 rs6672398 ENSG00000238287.1 RP11-656D10.3 -8.39 1.33e-15 2.53e-12 -0.52 -0.41 Age-related hearing impairment (SNP x SNP interaction); chr1:40536505 chr1:40493157~40508661:- LIHC cis rs7044106 0.791 rs12554440 ENSG00000226752.6 PSMD5-AS1 -8.38 1.35e-15 2.57e-12 -0.42 -0.41 Hip circumference adjusted for BMI; chr9:120723055 chr9:120824828~120854385:+ LIHC cis rs17507216 0.958 rs28648832 ENSG00000278603.1 RP13-608F4.5 8.38 1.36e-15 2.59e-12 0.75 0.41 Excessive daytime sleepiness; chr15:82567642 chr15:82472203~82472426:+ LIHC cis rs7208859 0.673 rs73263981 ENSG00000263531.1 RP13-753N3.1 8.38 1.37e-15 2.6e-12 0.69 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30593484 chr17:30863921~30864940:- LIHC cis rs507080 0.922 rs592280 ENSG00000255422.1 AP002954.4 -8.38 1.37e-15 2.6e-12 -0.47 -0.41 Serum metabolite levels; chr11:118682509 chr11:118704607~118750263:+ LIHC cis rs7617773 0.823 rs9839446 ENSG00000229759.1 MRPS18AP1 -8.38 1.39e-15 2.64e-12 -0.47 -0.41 Coronary artery disease; chr3:48153176 chr3:48256350~48256938:- LIHC cis rs7617773 0.823 rs9839447 ENSG00000229759.1 MRPS18AP1 -8.38 1.39e-15 2.64e-12 -0.47 -0.41 Coronary artery disease; chr3:48153177 chr3:48256350~48256938:- LIHC cis rs3762637 1 rs11932 ENSG00000272758.4 RP11-299J3.8 8.38 1.39e-15 2.65e-12 0.52 0.41 LDL cholesterol levels; chr3:122422288 chr3:122416207~122443180:+ LIHC cis rs507080 0.961 rs642497 ENSG00000255422.1 AP002954.4 -8.38 1.4e-15 2.65e-12 -0.47 -0.41 Serum metabolite levels; chr11:118680075 chr11:118704607~118750263:+ LIHC cis rs1155848 0.892 rs1023293 ENSG00000227354.5 RBM26-AS1 8.38 1.4e-15 2.66e-12 0.75 0.41 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79480285 chr13:79406309~79424328:+ LIHC cis rs2882667 0.861 rs10037106 ENSG00000253404.1 AC034243.1 8.38 1.41e-15 2.67e-12 0.55 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139029801 chr5:138744434~138753309:- LIHC cis rs6991838 0.584 rs14213 ENSG00000272010.1 CTD-3025N20.3 8.38 1.42e-15 2.7e-12 0.44 0.41 Intelligence (multi-trait analysis); chr8:65602719 chr8:65591850~65592472:- LIHC cis rs2882667 0.931 rs7706391 ENSG00000253404.1 AC034243.1 8.38 1.43e-15 2.71e-12 0.55 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139013475 chr5:138744434~138753309:- LIHC cis rs12744310 1 rs56381773 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41305046 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs56096486 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41305558 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs57529969 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41306011 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs60825180 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41306072 chr1:41242373~41284861:+ LIHC cis rs12744310 0.778 rs61477144 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41306121 chr1:41242373~41284861:+ LIHC cis rs12744310 0.943 rs7521544 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41306454 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs7513682 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41306495 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs56409354 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41307299 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs34008156 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41307510 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12744310 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41307830 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs56077539 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41308270 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs55892603 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41308322 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs55929643 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41308540 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs34759578 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41308678 chr1:41242373~41284861:+ LIHC cis rs12744310 0.945 rs72665690 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41309564 chr1:41242373~41284861:+ LIHC cis rs12744310 0.945 rs72665691 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41309573 chr1:41242373~41284861:+ LIHC cis rs12744310 0.945 rs72665692 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41309707 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs72665694 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41309712 chr1:41242373~41284861:+ LIHC cis rs12744310 0.945 rs72665696 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41309757 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs72665698 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41309917 chr1:41242373~41284861:+ LIHC cis rs12744310 0.943 rs12751511 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41310731 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs34073585 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41311527 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12756822 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41311655 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12036554 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41312317 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12036555 ENSG00000235358.1 RP11-399E6.1 8.38 1.43e-15 2.72e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41312318 chr1:41242373~41284861:+ LIHC cis rs12922040 0.701 rs12149912 ENSG00000263335.1 AF001548.5 -8.37 1.45e-15 2.75e-12 -0.48 -0.41 Serum uric acid levels in response to allopurinol in gout; chr16:15774798 chr16:15726674~15732993:+ LIHC cis rs4718428 0.672 rs4718412 ENSG00000273142.1 RP11-458F8.4 8.37 1.51e-15 2.86e-12 0.41 0.41 Corneal structure; chr7:66821880 chr7:66902857~66906297:+ LIHC cis rs1891275 0.551 rs2421621 ENSG00000228701.1 TNKS2-AS1 -8.36 1.55e-15 2.92e-12 -0.62 -0.41 Intelligence (multi-trait analysis); chr10:91640344 chr10:91782839~91798291:- LIHC cis rs7617773 0.963 rs6771787 ENSG00000229759.1 MRPS18AP1 -8.36 1.55e-15 2.94e-12 -0.47 -0.41 Coronary artery disease; chr3:48152752 chr3:48256350~48256938:- LIHC cis rs7617773 1 rs6771889 ENSG00000229759.1 MRPS18AP1 -8.36 1.55e-15 2.94e-12 -0.47 -0.41 Coronary artery disease; chr3:48152836 chr3:48256350~48256938:- LIHC cis rs2455601 0.786 rs3751064 ENSG00000254860.4 TMEM9B-AS1 8.36 1.56e-15 2.94e-12 0.5 0.41 Schizophrenia; chr11:8937356 chr11:8964675~8977527:+ LIHC cis rs6991838 0.584 rs7459944 ENSG00000272010.1 CTD-3025N20.3 -8.36 1.56e-15 2.95e-12 -0.45 -0.41 Intelligence (multi-trait analysis); chr8:65566040 chr8:65591850~65592472:- LIHC cis rs11723261 0.582 rs4634177 ENSG00000275426.1 CH17-262A2.1 8.36 1.57e-15 2.97e-12 0.49 0.41 Immune response to smallpox vaccine (IL-6); chr4:143055 chr4:149738~150317:+ LIHC cis rs2882667 0.931 rs10074461 ENSG00000253404.1 AC034243.1 8.36 1.58e-15 2.98e-12 0.55 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:138984126 chr5:138744434~138753309:- LIHC cis rs12022452 0.506 rs11208363 ENSG00000238287.1 RP11-656D10.3 -8.36 1.59e-15 2.99e-12 -0.52 -0.41 Age-related hearing impairment (SNP x SNP interaction); chr1:40544782 chr1:40493157~40508661:- LIHC cis rs1891275 0.516 rs10881935 ENSG00000228701.1 TNKS2-AS1 -8.36 1.6e-15 3.02e-12 -0.62 -0.41 Intelligence (multi-trait analysis); chr10:91637944 chr10:91782839~91798291:- LIHC cis rs2882667 0.898 rs13163536 ENSG00000253404.1 AC034243.1 8.36 1.61e-15 3.03e-12 0.55 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139041530 chr5:138744434~138753309:- LIHC cis rs7208859 0.673 rs216424 ENSG00000263531.1 RP13-753N3.1 8.36 1.62e-15 3.05e-12 0.69 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30616046 chr17:30863921~30864940:- LIHC cis rs8072100 0.84 rs9893901 ENSG00000228782.6 CTD-2026D20.3 8.35 1.66e-15 3.13e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47429316 chr17:47450568~47492492:- LIHC cis rs2882667 0.898 rs2116789 ENSG00000253404.1 AC034243.1 8.35 1.69e-15 3.17e-12 0.54 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139058573 chr5:138744434~138753309:- LIHC cis rs73086581 0.741 rs17212649 ENSG00000229539.1 RP11-119B16.2 8.35 1.71e-15 3.22e-12 0.79 0.41 Response to antidepressants in depression; chr20:3872446 chr20:3888239~3888868:- LIHC cis rs4423214 0.55 rs4944885 ENSG00000254682.1 RP11-660L16.2 8.35 1.73e-15 3.26e-12 0.49 0.41 Vitamin D levels; chr11:71403029 chr11:71448674~71452157:+ LIHC cis rs8072100 0.84 rs2136751 ENSG00000228782.6 CTD-2026D20.3 8.35 1.74e-15 3.27e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47378727 chr17:47450568~47492492:- LIHC cis rs7208859 0.573 rs8078182 ENSG00000263531.1 RP13-753N3.1 8.35 1.74e-15 3.27e-12 0.71 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822646 chr17:30863921~30864940:- LIHC cis rs1577917 1 rs36096931 ENSG00000203875.9 SNHG5 -8.35 1.78e-15 3.33e-12 -0.49 -0.41 Response to antipsychotic treatment; chr6:85983416 chr6:85660950~85678736:- LIHC cis rs2019137 0.56 rs10175462 ENSG00000274877.1 RP11-65I12.1 -8.34 1.78e-15 3.35e-12 -0.52 -0.41 Lymphocyte counts; chr2:113230915 chr2:113237595~113240825:+ LIHC cis rs2882667 0.898 rs6867343 ENSG00000253404.1 AC034243.1 8.34 1.81e-15 3.38e-12 0.55 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139038739 chr5:138744434~138753309:- LIHC cis rs8072100 0.744 rs34537623 ENSG00000228782.6 CTD-2026D20.3 8.34 1.82e-15 3.41e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47452837 chr17:47450568~47492492:- LIHC cis rs8072100 0.777 rs9914653 ENSG00000228782.6 CTD-2026D20.3 8.34 1.82e-15 3.41e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47460029 chr17:47450568~47492492:- LIHC cis rs9543976 1 rs9573592 ENSG00000261553.4 RP11-29G8.3 -8.34 1.83e-15 3.43e-12 -0.6 -0.41 Diabetic retinopathy; chr13:75623707 chr13:75549773~75807120:+ LIHC cis rs34779708 0.931 rs11596502 ENSG00000230534.5 RP11-297A16.2 8.34 1.87e-15 3.5e-12 0.53 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35098259 chr10:35098006~35127020:- LIHC cis rs7617773 0.746 rs7619865 ENSG00000229759.1 MRPS18AP1 8.34 1.89e-15 3.53e-12 0.43 0.41 Coronary artery disease; chr3:48329090 chr3:48256350~48256938:- LIHC cis rs17608059 0.566 rs17676459 ENSG00000141028.6 CDRT15P1 -8.34 1.9e-15 3.55e-12 -0.43 -0.41 Temperament; chr17:14007198 chr17:14024514~14025488:+ LIHC cis rs17608059 0.566 rs5005684 ENSG00000141028.6 CDRT15P1 -8.34 1.9e-15 3.55e-12 -0.43 -0.41 Temperament; chr17:14007316 chr17:14024514~14025488:+ LIHC cis rs8072100 0.84 rs9895746 ENSG00000228782.6 CTD-2026D20.3 8.33 1.91e-15 3.57e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47401733 chr17:47450568~47492492:- LIHC cis rs8072100 0.84 rs11079774 ENSG00000228782.6 CTD-2026D20.3 8.33 1.91e-15 3.57e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402340 chr17:47450568~47492492:- LIHC cis rs8072100 0.84 rs12452796 ENSG00000228782.6 CTD-2026D20.3 -8.33 1.91e-15 3.57e-12 -0.46 -0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402367 chr17:47450568~47492492:- LIHC cis rs8072100 0.807 rs2175290 ENSG00000228782.6 CTD-2026D20.3 8.33 1.91e-15 3.57e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402551 chr17:47450568~47492492:- LIHC cis rs17301013 0.606 rs72711443 ENSG00000227373.4 RP11-160H22.5 8.33 1.92e-15 3.58e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174090876 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs10912728 ENSG00000227373.4 RP11-160H22.5 8.33 1.92e-15 3.58e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174093234 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs4652168 ENSG00000227373.4 RP11-160H22.5 8.33 1.92e-15 3.58e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174095077 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs28831202 ENSG00000227373.4 RP11-160H22.5 8.33 1.92e-15 3.58e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174099231 chr1:174115300~174160004:- LIHC cis rs9828933 1 rs9828933 ENSG00000280620.1 SCAANT1 8.33 1.95e-15 3.65e-12 0.6 0.41 Type 2 diabetes; chr3:64017221 chr3:63911518~63911772:- LIHC cis rs9828933 0.938 rs7617036 ENSG00000280620.1 SCAANT1 8.33 1.95e-15 3.65e-12 0.6 0.41 Type 2 diabetes; chr3:64017319 chr3:63911518~63911772:- LIHC cis rs8072100 0.84 rs9900360 ENSG00000228782.6 CTD-2026D20.3 8.33 1.96e-15 3.65e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47414613 chr17:47450568~47492492:- LIHC cis rs8072100 0.84 rs56952963 ENSG00000228782.6 CTD-2026D20.3 8.33 1.96e-15 3.65e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47416460 chr17:47450568~47492492:- LIHC cis rs7208859 0.673 rs216420 ENSG00000263531.1 RP13-753N3.1 8.33 2e-15 3.72e-12 0.68 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30611490 chr17:30863921~30864940:- LIHC cis rs2019137 0.936 rs902696 ENSG00000189223.12 PAX8-AS1 -8.33 2e-15 3.74e-12 -0.53 -0.41 Lymphocyte counts; chr2:113197302 chr2:113211522~113276581:+ LIHC cis rs3096299 0.632 rs8051537 ENSG00000274627.1 RP11-104N10.2 8.33 2.03e-15 3.78e-12 0.42 0.41 Multiple myeloma (IgH translocation); chr16:89477976 chr16:89516797~89522217:+ LIHC cis rs507080 0.922 rs12577485 ENSG00000255422.1 AP002954.4 -8.32 2.07e-15 3.85e-12 -0.47 -0.41 Serum metabolite levels; chr11:118676793 chr11:118704607~118750263:+ LIHC cis rs1930961 0.702 rs8141065 ENSG00000100058.11 CRYBB2P1 -8.32 2.09e-15 3.88e-12 -0.66 -0.41 Bipolar disorder with mood-incongruent psychosis; chr22:25489221 chr22:25448105~25520854:+ LIHC cis rs8062405 0.625 rs8060365 ENSG00000259982.1 CDC37P1 -8.32 2.1e-15 3.91e-12 -0.51 -0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28899988 chr16:28700294~28701540:- LIHC cis rs2019137 0.56 rs7421852 ENSG00000274877.1 RP11-65I12.1 -8.32 2.11e-15 3.93e-12 -0.52 -0.41 Lymphocyte counts; chr2:113232684 chr2:113237595~113240825:+ LIHC cis rs2019137 0.56 rs10206269 ENSG00000274877.1 RP11-65I12.1 -8.32 2.11e-15 3.93e-12 -0.52 -0.41 Lymphocyte counts; chr2:113232816 chr2:113237595~113240825:+ LIHC cis rs6504950 0.85 rs11079143 ENSG00000275710.1 RP11-257O5.4 -8.32 2.12e-15 3.93e-12 -0.62 -0.41 Breast cancer; chr17:55005761 chr17:54964474~54964679:+ LIHC cis rs17301013 0.606 rs4650939 ENSG00000227373.4 RP11-160H22.5 8.32 2.12e-15 3.93e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174096823 chr1:174115300~174160004:- LIHC cis rs7208859 0.623 rs426434 ENSG00000263531.1 RP13-753N3.1 8.32 2.14e-15 3.97e-12 0.73 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30598335 chr17:30863921~30864940:- LIHC cis rs1577917 0.958 rs13207354 ENSG00000203875.9 SNHG5 -8.32 2.15e-15 3.99e-12 -0.49 -0.41 Response to antipsychotic treatment; chr6:85990545 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12204365 ENSG00000203875.9 SNHG5 -8.32 2.15e-15 3.99e-12 -0.49 -0.41 Response to antipsychotic treatment; chr6:85990814 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs12663651 ENSG00000203875.9 SNHG5 -8.32 2.15e-15 3.99e-12 -0.49 -0.41 Response to antipsychotic treatment; chr6:85991937 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs34852683 ENSG00000203875.9 SNHG5 -8.32 2.15e-15 3.99e-12 -0.49 -0.41 Response to antipsychotic treatment; chr6:85992612 chr6:85660950~85678736:- LIHC cis rs1577917 1 rs6936048 ENSG00000203875.9 SNHG5 -8.32 2.15e-15 3.99e-12 -0.49 -0.41 Response to antipsychotic treatment; chr6:85992890 chr6:85660950~85678736:- LIHC cis rs7208859 0.524 rs73263982 ENSG00000263531.1 RP13-753N3.1 8.32 2.19e-15 4.06e-12 0.69 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30593606 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs216433 ENSG00000263531.1 RP13-753N3.1 8.32 2.19e-15 4.06e-12 0.69 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30594842 chr17:30863921~30864940:- LIHC cis rs10256972 0.621 rs2363285 ENSG00000229043.2 AC091729.9 -8.31 2.2e-15 4.08e-12 -0.45 -0.41 Endometriosis;Longevity; chr7:1052008 chr7:1160374~1165267:+ LIHC cis rs8072100 0.967 rs4338849 ENSG00000228782.6 CTD-2026D20.3 8.31 2.28e-15 4.22e-12 0.47 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47435117 chr17:47450568~47492492:- LIHC cis rs4718428 0.672 rs36038499 ENSG00000273142.1 RP11-458F8.4 -8.31 2.29e-15 4.24e-12 -0.41 -0.41 Corneal structure; chr7:66824628 chr7:66902857~66906297:+ LIHC cis rs507080 1 rs507080 ENSG00000255422.1 AP002954.4 -8.31 2.33e-15 4.3e-12 -0.47 -0.41 Serum metabolite levels; chr11:118678873 chr11:118704607~118750263:+ LIHC cis rs2455601 0.744 rs11042133 ENSG00000254860.4 TMEM9B-AS1 8.31 2.33e-15 4.31e-12 0.49 0.41 Schizophrenia; chr11:8944964 chr11:8964675~8977527:+ LIHC cis rs1150668 0.799 rs1150705 ENSG00000216901.1 AL022393.7 8.3 2.36e-15 4.36e-12 0.46 0.41 Pubertal anthropometrics; chr6:28226008 chr6:28176188~28176674:+ LIHC cis rs3762637 0.943 rs9289196 ENSG00000272758.4 RP11-299J3.8 -8.3 2.37e-15 4.38e-12 -0.49 -0.41 LDL cholesterol levels; chr3:122549659 chr3:122416207~122443180:+ LIHC cis rs6504950 1 rs7221223 ENSG00000275710.1 RP11-257O5.4 8.3 2.38e-15 4.4e-12 0.62 0.41 Breast cancer; chr17:54981646 chr17:54964474~54964679:+ LIHC cis rs9399135 0.967 rs9402676 ENSG00000232876.1 CTA-212D2.2 -8.3 2.4e-15 4.43e-12 -0.46 -0.41 Red blood cell count; chr6:135034369 chr6:135055033~135060550:+ LIHC cis rs34779708 0.966 rs12769484 ENSG00000230534.5 RP11-297A16.2 8.3 2.4e-15 4.43e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35176818 chr10:35098006~35127020:- LIHC cis rs7208859 0.673 rs216435 ENSG00000263531.1 RP13-753N3.1 8.3 2.4e-15 4.44e-12 0.69 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595719 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs11651857 ENSG00000263531.1 RP13-753N3.1 8.3 2.45e-15 4.52e-12 0.73 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30599344 chr17:30863921~30864940:- LIHC cis rs8072100 0.905 rs9895274 ENSG00000228782.6 CTD-2026D20.3 8.3 2.46e-15 4.53e-12 0.47 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47461751 chr17:47450568~47492492:- LIHC cis rs1155848 0.892 rs9565509 ENSG00000227354.5 RBM26-AS1 8.3 2.49e-15 4.6e-12 0.75 0.41 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79483696 chr13:79406309~79424328:+ LIHC cis rs9399135 0.933 rs9389262 ENSG00000232876.1 CTA-212D2.2 -8.3 2.5e-15 4.6e-12 -0.47 -0.41 Red blood cell count; chr6:135055271 chr6:135055033~135060550:+ LIHC cis rs3096299 0.685 rs12935112 ENSG00000274627.1 RP11-104N10.2 -8.29 2.54e-15 4.69e-12 -0.41 -0.41 Multiple myeloma (IgH translocation); chr16:89476450 chr16:89516797~89522217:+ LIHC cis rs34779708 0.897 rs34481177 ENSG00000230534.5 RP11-297A16.2 8.29 2.55e-15 4.69e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35091985 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs11593858 ENSG00000230534.5 RP11-297A16.2 8.29 2.55e-15 4.69e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35092445 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs72789690 ENSG00000230534.5 RP11-297A16.2 8.29 2.55e-15 4.69e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35093889 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs68039650 ENSG00000230534.5 RP11-297A16.2 8.29 2.55e-15 4.69e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35096571 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs35136660 ENSG00000230534.5 RP11-297A16.2 8.29 2.55e-15 4.69e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35097045 chr10:35098006~35127020:- LIHC cis rs34779708 0.897 rs12764820 ENSG00000230534.5 RP11-297A16.2 8.29 2.55e-15 4.69e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35097393 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs67261877 ENSG00000230534.5 RP11-297A16.2 8.29 2.55e-15 4.69e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35097412 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs12768019 ENSG00000230534.5 RP11-297A16.2 8.29 2.55e-15 4.69e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35100915 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs4934724 ENSG00000230534.5 RP11-297A16.2 8.29 2.55e-15 4.69e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35104741 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs4294520 ENSG00000230534.5 RP11-297A16.2 8.29 2.55e-15 4.69e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35133578 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs34876468 ENSG00000230534.5 RP11-297A16.2 8.29 2.55e-15 4.69e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35135522 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs35814343 ENSG00000230534.5 RP11-297A16.2 8.29 2.55e-15 4.69e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35138786 chr10:35098006~35127020:- LIHC cis rs7208859 0.623 rs170051 ENSG00000263531.1 RP13-753N3.1 8.29 2.58e-15 4.76e-12 0.73 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587135 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs216436 ENSG00000263531.1 RP13-753N3.1 8.29 2.66e-15 4.89e-12 0.73 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595882 chr17:30863921~30864940:- LIHC cis rs6504950 0.85 rs11658717 ENSG00000275710.1 RP11-257O5.4 -8.29 2.69e-15 4.94e-12 -0.62 -0.41 Breast cancer; chr17:54999625 chr17:54964474~54964679:+ LIHC cis rs7727544 0.684 rs272893 ENSG00000233006.5 AC034220.3 8.29 2.69e-15 4.95e-12 0.41 0.41 Blood metabolite levels; chr5:132327369 chr5:132311285~132369916:- LIHC cis rs172166 0.543 rs1150691 ENSG00000216901.1 AL022393.7 8.29 2.69e-15 4.95e-12 0.46 0.41 Cardiac Troponin-T levels; chr6:28200255 chr6:28176188~28176674:+ LIHC cis rs2882667 0.858 rs4643949 ENSG00000253404.1 AC034243.1 8.29 2.7e-15 4.97e-12 0.55 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139036656 chr5:138744434~138753309:- LIHC cis rs2487048 0.773 rs2472494 ENSG00000226334.1 RP11-217B7.2 -8.28 2.71e-15 4.99e-12 -0.53 -0.41 Intraocular pressure; chr9:104933258 chr9:104927553~104928892:+ LIHC cis rs1577917 0.682 rs1173417 ENSG00000234155.1 RP11-30P6.6 -8.28 2.72e-15 4.99e-12 -0.48 -0.41 Response to antipsychotic treatment; chr6:85694223 chr6:85387219~85390186:- LIHC cis rs832187 0.665 rs7627690 ENSG00000280620.1 SCAANT1 8.28 2.74e-15 5.03e-12 0.51 0.41 Schizophrenia; chr3:63914801 chr3:63911518~63911772:- LIHC cis rs10510102 0.608 rs4486560 ENSG00000276742.1 RP11-500G22.4 8.28 2.74e-15 5.04e-12 0.52 0.41 Breast cancer; chr10:121844840 chr10:121956782~121957098:+ LIHC cis rs150992 0.711 rs161735 ENSG00000248489.1 CTD-2007H13.3 8.28 2.83e-15 5.19e-12 0.64 0.41 Body mass index; chr5:98862026 chr5:98929171~98995013:+ LIHC cis rs2929278 0.589 rs11638972 ENSG00000205771.5 CATSPER2P1 8.28 2.84e-15 5.21e-12 0.49 0.41 Schizophrenia; chr15:43782493 chr15:43726918~43747094:- LIHC cis rs6504950 1 rs17745344 ENSG00000275710.1 RP11-257O5.4 8.28 2.84e-15 5.21e-12 0.62 0.41 Breast cancer; chr17:54970958 chr17:54964474~54964679:+ LIHC cis rs9399135 0.967 rs59329760 ENSG00000232876.1 CTA-212D2.2 -8.28 2.85e-15 5.23e-12 -0.46 -0.41 Red blood cell count; chr6:135021299 chr6:135055033~135060550:+ LIHC cis rs11723261 0.582 rs11735742 ENSG00000275426.1 CH17-262A2.1 -8.28 2.89e-15 5.29e-12 -0.48 -0.41 Immune response to smallpox vaccine (IL-6); chr4:148766 chr4:149738~150317:+ LIHC cis rs12744310 1 rs68132196 ENSG00000235358.1 RP11-399E6.1 8.28 2.9e-15 5.32e-12 0.54 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41304948 chr1:41242373~41284861:+ LIHC cis rs7617773 0.78 rs9846818 ENSG00000229759.1 MRPS18AP1 8.27 2.93e-15 5.36e-12 0.44 0.41 Coronary artery disease; chr3:48334195 chr3:48256350~48256938:- LIHC cis rs3096299 0.685 rs3803682 ENSG00000274627.1 RP11-104N10.2 8.27 2.93e-15 5.36e-12 0.42 0.41 Multiple myeloma (IgH translocation); chr16:89478228 chr16:89516797~89522217:+ LIHC cis rs3096299 0.685 rs3803681 ENSG00000274627.1 RP11-104N10.2 8.27 2.93e-15 5.36e-12 0.42 0.41 Multiple myeloma (IgH translocation); chr16:89478348 chr16:89516797~89522217:+ LIHC cis rs8072100 0.811 rs1912483 ENSG00000228782.6 CTD-2026D20.3 8.27 2.94e-15 5.38e-12 0.47 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47366128 chr17:47450568~47492492:- LIHC cis rs8072100 0.811 rs9889709 ENSG00000228782.6 CTD-2026D20.3 8.27 2.94e-15 5.38e-12 0.47 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47367863 chr17:47450568~47492492:- LIHC cis rs2882667 0.838 rs11958529 ENSG00000253404.1 AC034243.1 8.27 2.94e-15 5.38e-12 0.54 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139059379 chr5:138744434~138753309:- LIHC cis rs4356975 0.83 rs3922514 ENSG00000249956.3 RP11-790I12.2 8.27 2.96e-15 5.42e-12 0.45 0.41 Obesity-related traits; chr4:69060905 chr4:69408836~69423164:+ LIHC cis rs4356975 0.83 rs28775401 ENSG00000249956.3 RP11-790I12.2 8.27 2.96e-15 5.42e-12 0.45 0.41 Obesity-related traits; chr4:69060999 chr4:69408836~69423164:+ LIHC cis rs6504950 1 rs10468513 ENSG00000275710.1 RP11-257O5.4 8.27 2.99e-15 5.46e-12 0.61 0.41 Breast cancer; chr17:54985542 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs56348638 ENSG00000275710.1 RP11-257O5.4 8.27 2.99e-15 5.46e-12 0.61 0.41 Breast cancer; chr17:54987189 chr17:54964474~54964679:+ LIHC cis rs3096299 0.642 rs12934829 ENSG00000274627.1 RP11-104N10.2 8.27 3.03e-15 5.53e-12 0.42 0.41 Multiple myeloma (IgH translocation); chr16:89456941 chr16:89516797~89522217:+ LIHC cis rs34779708 0.931 rs17591135 ENSG00000230534.5 RP11-297A16.2 8.27 3.04e-15 5.55e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35176262 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs55724039 ENSG00000230534.5 RP11-297A16.2 8.27 3.04e-15 5.55e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35176469 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs12784482 ENSG00000230534.5 RP11-297A16.2 8.27 3.07e-15 5.6e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35157937 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs34630580 ENSG00000230534.5 RP11-297A16.2 8.27 3.07e-15 5.6e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35160300 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs17499811 ENSG00000230534.5 RP11-297A16.2 8.27 3.07e-15 5.6e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35167287 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs35146199 ENSG00000230534.5 RP11-297A16.2 8.27 3.07e-15 5.6e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35172011 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs4934538 ENSG00000230534.5 RP11-297A16.2 8.27 3.07e-15 5.6e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35183222 chr10:35098006~35127020:- LIHC cis rs34779708 0.833 rs12777517 ENSG00000230534.5 RP11-297A16.2 8.27 3.07e-15 5.6e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35184999 chr10:35098006~35127020:- LIHC cis rs2739330 0.587 rs4820571 ENSG00000231271.1 AP000350.8 8.27 3.08e-15 5.61e-12 0.49 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23949918~23954042:+ LIHC cis rs2882667 0.898 rs11952020 ENSG00000253404.1 AC034243.1 8.27 3.1e-15 5.66e-12 0.54 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139059467 chr5:138744434~138753309:- LIHC cis rs4356975 1 rs4356975 ENSG00000249956.3 RP11-790I12.2 8.26 3.16e-15 5.75e-12 0.46 0.41 Obesity-related traits; chr4:69106745 chr4:69408836~69423164:+ LIHC cis rs4356975 0.83 rs4413468 ENSG00000249956.3 RP11-790I12.2 8.26 3.16e-15 5.76e-12 0.45 0.41 Obesity-related traits; chr4:69061845 chr4:69408836~69423164:+ LIHC cis rs9399135 0.935 rs987690 ENSG00000232876.1 CTA-212D2.2 -8.26 3.19e-15 5.81e-12 -0.46 -0.41 Red blood cell count; chr6:135029241 chr6:135055033~135060550:+ LIHC cis rs17507216 1 rs17158413 ENSG00000278603.1 RP13-608F4.5 8.26 3.22e-15 5.86e-12 0.78 0.41 Excessive daytime sleepiness; chr15:82566658 chr15:82472203~82472426:+ LIHC cis rs4718428 0.705 rs12698547 ENSG00000273142.1 RP11-458F8.4 -8.26 3.22e-15 5.87e-12 -0.4 -0.41 Corneal structure; chr7:66813271 chr7:66902857~66906297:+ LIHC cis rs5760092 0.755 rs4585126 ENSG00000250470.1 AP000351.3 -8.26 3.26e-15 5.94e-12 -0.54 -0.41 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23976904~23977585:- LIHC cis rs6844153 0.752 rs10029307 ENSG00000240005.4 RP11-293A21.1 -8.26 3.31e-15 6.03e-12 -0.47 -0.41 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26902591 chr4:26859806~26860599:- LIHC cis rs9399135 0.967 rs4896125 ENSG00000232876.1 CTA-212D2.2 -8.25 3.43e-15 6.22e-12 -0.46 -0.41 Red blood cell count; chr6:135021431 chr6:135055033~135060550:+ LIHC cis rs9399135 0.935 rs949547 ENSG00000232876.1 CTA-212D2.2 -8.25 3.43e-15 6.22e-12 -0.46 -0.41 Red blood cell count; chr6:135022361 chr6:135055033~135060550:+ LIHC cis rs9399135 0.935 rs2150680 ENSG00000232876.1 CTA-212D2.2 -8.25 3.43e-15 6.22e-12 -0.46 -0.41 Red blood cell count; chr6:135025993 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs11756988 ENSG00000232876.1 CTA-212D2.2 -8.25 3.43e-15 6.22e-12 -0.46 -0.41 Red blood cell count; chr6:135026457 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs11754783 ENSG00000232876.1 CTA-212D2.2 -8.25 3.43e-15 6.22e-12 -0.46 -0.41 Red blood cell count; chr6:135026523 chr6:135055033~135060550:+ LIHC cis rs2487048 0.773 rs2472493 ENSG00000226334.1 RP11-217B7.2 -8.25 3.48e-15 6.3e-12 -0.54 -0.41 Intraocular pressure; chr9:104933567 chr9:104927553~104928892:+ LIHC cis rs34779708 0.733 rs11597184 ENSG00000230534.5 RP11-297A16.2 8.25 3.5e-15 6.33e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35108468 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs34087268 ENSG00000230534.5 RP11-297A16.2 8.25 3.51e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35057796 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs58159560 ENSG00000230534.5 RP11-297A16.2 8.25 3.51e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35062321 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs4934725 ENSG00000230534.5 RP11-297A16.2 8.25 3.52e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35109308 chr10:35098006~35127020:- LIHC cis rs34779708 1 rs12769189 ENSG00000230534.5 RP11-297A16.2 8.25 3.52e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35110740 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs12774834 ENSG00000230534.5 RP11-297A16.2 8.25 3.52e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35111142 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs12775759 ENSG00000230534.5 RP11-297A16.2 8.25 3.52e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35111255 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs34296409 ENSG00000230534.5 RP11-297A16.2 8.25 3.52e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35115685 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs11599606 ENSG00000230534.5 RP11-297A16.2 8.25 3.52e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35117698 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs35777088 ENSG00000230534.5 RP11-297A16.2 8.25 3.52e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35120120 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs11592567 ENSG00000230534.5 RP11-297A16.2 8.25 3.52e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35120441 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs34605125 ENSG00000230534.5 RP11-297A16.2 8.25 3.52e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35122318 chr10:35098006~35127020:- LIHC cis rs34779708 0.897 rs16935880 ENSG00000230534.5 RP11-297A16.2 8.25 3.52e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35126540 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs4934730 ENSG00000230534.5 RP11-297A16.2 8.25 3.52e-15 6.36e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35126627 chr10:35098006~35127020:- LIHC cis rs6504950 1 rs9903146 ENSG00000275710.1 RP11-257O5.4 8.25 3.53e-15 6.37e-12 0.6 0.41 Breast cancer; chr17:54980386 chr17:54964474~54964679:+ LIHC cis rs6504950 0.962 rs9902950 ENSG00000275710.1 RP11-257O5.4 8.25 3.53e-15 6.37e-12 0.6 0.41 Breast cancer; chr17:54980403 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9903220 ENSG00000275710.1 RP11-257O5.4 8.25 3.53e-15 6.37e-12 0.6 0.41 Breast cancer; chr17:54980504 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9903444 ENSG00000275710.1 RP11-257O5.4 8.25 3.53e-15 6.37e-12 0.6 0.41 Breast cancer; chr17:54980532 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9903825 ENSG00000275710.1 RP11-257O5.4 8.25 3.53e-15 6.37e-12 0.6 0.41 Breast cancer; chr17:54980553 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs16955471 ENSG00000275710.1 RP11-257O5.4 8.25 3.53e-15 6.37e-12 0.6 0.41 Breast cancer; chr17:54981446 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9891865 ENSG00000275710.1 RP11-257O5.4 8.25 3.53e-15 6.37e-12 0.6 0.41 Breast cancer; chr17:54982672 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9892173 ENSG00000275710.1 RP11-257O5.4 8.25 3.53e-15 6.37e-12 0.6 0.41 Breast cancer; chr17:54982853 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs1990674 ENSG00000275710.1 RP11-257O5.4 8.25 3.53e-15 6.37e-12 0.6 0.41 Breast cancer; chr17:54983714 chr17:54964474~54964679:+ LIHC cis rs12744310 0.83 rs12028010 ENSG00000235358.1 RP11-399E6.1 8.25 3.53e-15 6.38e-12 0.53 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41298799 chr1:41242373~41284861:+ LIHC cis rs3096299 0.658 rs4291902 ENSG00000274627.1 RP11-104N10.2 8.25 3.53e-15 6.39e-12 0.41 0.41 Multiple myeloma (IgH translocation); chr16:89493907 chr16:89516797~89522217:+ LIHC cis rs17301013 0.606 rs4233169 ENSG00000227373.4 RP11-160H22.5 8.24 3.59e-15 6.49e-12 0.63 0.41 Systemic lupus erythematosus; chr1:174118986 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs1853321 ENSG00000227373.4 RP11-160H22.5 8.24 3.59e-15 6.49e-12 0.63 0.41 Systemic lupus erythematosus; chr1:174125295 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs6694208 ENSG00000227373.4 RP11-160H22.5 8.24 3.59e-15 6.49e-12 0.63 0.41 Systemic lupus erythematosus; chr1:174127631 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs727912 ENSG00000227373.4 RP11-160H22.5 8.24 3.59e-15 6.49e-12 0.63 0.41 Systemic lupus erythematosus; chr1:174132729 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs4650950 ENSG00000227373.4 RP11-160H22.5 8.24 3.59e-15 6.49e-12 0.63 0.41 Systemic lupus erythematosus; chr1:174134264 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs4650951 ENSG00000227373.4 RP11-160H22.5 8.24 3.59e-15 6.49e-12 0.63 0.41 Systemic lupus erythematosus; chr1:174134368 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs4652191 ENSG00000227373.4 RP11-160H22.5 8.24 3.59e-15 6.49e-12 0.63 0.41 Systemic lupus erythematosus; chr1:174135473 chr1:174115300~174160004:- LIHC cis rs2487048 0.804 rs2472496 ENSG00000226334.1 RP11-217B7.2 -8.24 3.61e-15 6.52e-12 -0.52 -0.41 Intraocular pressure; chr9:104933072 chr9:104927553~104928892:+ LIHC cis rs8072100 0.967 rs9894905 ENSG00000228782.6 CTD-2026D20.3 8.24 3.66e-15 6.61e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47408616 chr17:47450568~47492492:- LIHC cis rs7208859 0.51 rs216402 ENSG00000263531.1 RP13-753N3.1 8.24 3.7e-15 6.68e-12 0.72 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30590108 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs216434 ENSG00000263531.1 RP13-753N3.1 8.24 3.7e-15 6.68e-12 0.72 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595317 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs216439 ENSG00000263531.1 RP13-753N3.1 8.24 3.7e-15 6.68e-12 0.72 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30600866 chr17:30863921~30864940:- LIHC cis rs7727544 0.735 rs272884 ENSG00000233006.5 AC034220.3 8.24 3.71e-15 6.69e-12 0.41 0.41 Blood metabolite levels; chr5:132332961 chr5:132311285~132369916:- LIHC cis rs7727544 0.735 rs272881 ENSG00000233006.5 AC034220.3 8.24 3.71e-15 6.69e-12 0.41 0.41 Blood metabolite levels; chr5:132333571 chr5:132311285~132369916:- LIHC cis rs7727544 0.735 rs272879 ENSG00000233006.5 AC034220.3 8.24 3.71e-15 6.69e-12 0.41 0.41 Blood metabolite levels; chr5:132334853 chr5:132311285~132369916:- LIHC cis rs6844153 0.68 rs61047003 ENSG00000240005.4 RP11-293A21.1 -8.24 3.73e-15 6.72e-12 -0.47 -0.41 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26937139 chr4:26859806~26860599:- LIHC cis rs17301013 0.606 rs6670425 ENSG00000227373.4 RP11-160H22.5 8.24 3.76e-15 6.76e-12 0.63 0.41 Systemic lupus erythematosus; chr1:174144204 chr1:174115300~174160004:- LIHC cis rs7044106 0.791 rs10739572 ENSG00000226752.6 PSMD5-AS1 -8.23 3.86e-15 6.93e-12 -0.42 -0.41 Hip circumference adjusted for BMI; chr9:120727537 chr9:120824828~120854385:+ LIHC cis rs9402673 0.558 rs9688342 ENSG00000232876.1 CTA-212D2.2 -8.23 3.87e-15 6.96e-12 -0.45 -0.41 High light scatter reticulocyte count;Reticulocyte count; chr6:135001888 chr6:135055033~135060550:+ LIHC cis rs34779708 0.931 rs34375045 ENSG00000230534.5 RP11-297A16.2 8.23 3.92e-15 7.04e-12 0.51 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35073428 chr10:35098006~35127020:- LIHC cis rs73086581 0.891 rs11907503 ENSG00000229539.1 RP11-119B16.2 8.23 3.93e-15 7.05e-12 0.72 0.41 Response to antidepressants in depression; chr20:3906943 chr20:3888239~3888868:- LIHC cis rs3762637 1 rs7615930 ENSG00000272758.4 RP11-299J3.8 -8.23 3.93e-15 7.06e-12 -0.52 -0.41 LDL cholesterol levels; chr3:122406903 chr3:122416207~122443180:+ LIHC cis rs3096299 0.667 rs2965947 ENSG00000274627.1 RP11-104N10.2 8.23 3.99e-15 7.16e-12 0.41 0.41 Multiple myeloma (IgH translocation); chr16:89452262 chr16:89516797~89522217:+ LIHC cis rs6991838 0.584 rs4737221 ENSG00000272010.1 CTD-3025N20.3 -8.23 4.03e-15 7.23e-12 -0.45 -0.41 Intelligence (multi-trait analysis); chr8:65569075 chr8:65591850~65592472:- LIHC cis rs8072100 0.84 rs9912311 ENSG00000228782.6 CTD-2026D20.3 8.23 4.04e-15 7.25e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469766 chr17:47450568~47492492:- LIHC cis rs2882667 0.898 rs11749944 ENSG00000253404.1 AC034243.1 8.23 4.04e-15 7.25e-12 0.55 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139077090 chr5:138744434~138753309:- LIHC cis rs12022452 0.506 rs61779163 ENSG00000238287.1 RP11-656D10.3 -8.23 4.04e-15 7.25e-12 -0.52 -0.41 Age-related hearing impairment (SNP x SNP interaction); chr1:40549751 chr1:40493157~40508661:- LIHC cis rs9399135 0.967 rs10872427 ENSG00000232876.1 CTA-212D2.2 -8.23 4.04e-15 7.25e-12 -0.45 -0.41 Red blood cell count; chr6:135032314 chr6:135055033~135060550:+ LIHC cis rs17301013 0.606 rs7535987 ENSG00000227373.4 RP11-160H22.5 8.23 4.05e-15 7.27e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174240840 chr1:174115300~174160004:- LIHC cis rs6504950 1 rs9915183 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54969776 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9895808 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54971081 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9897447 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54971108 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9896044 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54971181 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9902687 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54971563 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs8080491 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54972508 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs6504948 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54972626 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs6504949 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54972772 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs8078550 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54976018 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9914732 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54977006 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9916642 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54977136 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9915832 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54977336 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9893306 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54977388 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9894529 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54977885 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs6504950 ENSG00000275710.1 RP11-257O5.4 8.23 4.08e-15 7.3e-12 0.6 0.41 Breast cancer; chr17:54979110 chr17:54964474~54964679:+ LIHC cis rs8072100 0.84 rs12453233 ENSG00000228782.6 CTD-2026D20.3 8.22 4.13e-15 7.39e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47377204 chr17:47450568~47492492:- LIHC cis rs8072100 0.84 rs1912482 ENSG00000228782.6 CTD-2026D20.3 8.22 4.13e-15 7.39e-12 0.46 0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47377517 chr17:47450568~47492492:- LIHC cis rs8072100 1 rs8072100 ENSG00000228782.6 CTD-2026D20.3 -8.22 4.16e-15 7.45e-12 -0.47 -0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47597321 chr17:47450568~47492492:- LIHC cis rs17301013 0.581 rs12081445 ENSG00000227373.4 RP11-160H22.5 8.22 4.18e-15 7.48e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174226923 chr1:174115300~174160004:- LIHC cis rs3096299 0.685 rs8050512 ENSG00000274627.1 RP11-104N10.2 8.22 4.24e-15 7.59e-12 0.42 0.41 Multiple myeloma (IgH translocation); chr16:89485912 chr16:89516797~89522217:+ LIHC cis rs6504950 1 rs6504951 ENSG00000275710.1 RP11-257O5.4 8.22 4.26e-15 7.62e-12 0.6 0.41 Breast cancer; chr17:54979614 chr17:54964474~54964679:+ LIHC cis rs7115242 0.925 rs7925256 ENSG00000254851.1 RP11-109L13.1 -8.22 4.28e-15 7.65e-12 -0.71 -0.41 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117174619 chr11:117135528~117138582:+ LIHC cis rs1150668 0.699 rs2394049 ENSG00000216901.1 AL022393.7 8.22 4.37e-15 7.81e-12 0.45 0.41 Pubertal anthropometrics; chr6:28271903 chr6:28176188~28176674:+ LIHC cis rs4718428 0.705 rs62465692 ENSG00000273142.1 RP11-458F8.4 -8.22 4.39e-15 7.85e-12 -0.4 -0.41 Corneal structure; chr7:66830758 chr7:66902857~66906297:+ LIHC cis rs4718428 0.662 rs34577323 ENSG00000273142.1 RP11-458F8.4 -8.22 4.39e-15 7.85e-12 -0.4 -0.41 Corneal structure; chr7:66845054 chr7:66902857~66906297:+ LIHC cis rs4718428 0.705 rs4717328 ENSG00000273142.1 RP11-458F8.4 -8.22 4.39e-15 7.85e-12 -0.4 -0.41 Corneal structure; chr7:66887678 chr7:66902857~66906297:+ LIHC cis rs4718428 0.705 rs4718422 ENSG00000273142.1 RP11-458F8.4 -8.22 4.39e-15 7.85e-12 -0.4 -0.41 Corneal structure; chr7:66894282 chr7:66902857~66906297:+ LIHC cis rs4718428 0.705 rs13231140 ENSG00000273142.1 RP11-458F8.4 -8.22 4.39e-15 7.85e-12 -0.4 -0.41 Corneal structure; chr7:66896631 chr7:66902857~66906297:+ LIHC cis rs7044106 0.5 rs56725168 ENSG00000226752.6 PSMD5-AS1 -8.22 4.41e-15 7.87e-12 -0.41 -0.41 Hip circumference adjusted for BMI; chr9:120730298 chr9:120824828~120854385:+ LIHC cis rs12744310 1 rs12029950 ENSG00000235358.1 RP11-399E6.1 8.21 4.5e-15 8.02e-12 0.53 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41287493 chr1:41242373~41284861:+ LIHC cis rs12744310 0.943 rs12027685 ENSG00000235358.1 RP11-399E6.1 8.21 4.5e-15 8.02e-12 0.53 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41290626 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12024413 ENSG00000235358.1 RP11-399E6.1 8.21 4.5e-15 8.02e-12 0.53 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41290744 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs34027267 ENSG00000235358.1 RP11-399E6.1 8.21 4.5e-15 8.02e-12 0.53 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41291005 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12722758 ENSG00000235358.1 RP11-399E6.1 8.21 4.5e-15 8.02e-12 0.53 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41291343 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12723893 ENSG00000235358.1 RP11-399E6.1 8.21 4.5e-15 8.02e-12 0.53 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41291368 chr1:41242373~41284861:+ LIHC cis rs2882667 0.861 rs11959727 ENSG00000253404.1 AC034243.1 8.21 4.51e-15 8.04e-12 0.54 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139061276 chr5:138744434~138753309:- LIHC cis rs8072100 0.688 rs12602134 ENSG00000228782.6 CTD-2026D20.3 -8.21 4.52e-15 8.05e-12 -0.46 -0.41 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47504770 chr17:47450568~47492492:- LIHC cis rs7044106 0.791 rs10985008 ENSG00000226752.6 PSMD5-AS1 -8.21 4.53e-15 8.06e-12 -0.41 -0.41 Hip circumference adjusted for BMI; chr9:120730682 chr9:120824828~120854385:+ LIHC cis rs17301013 0.606 rs11802158 ENSG00000227373.4 RP11-160H22.5 8.21 4.53e-15 8.07e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174223973 chr1:174115300~174160004:- LIHC cis rs10256972 0.869 rs1007766 ENSG00000229043.2 AC091729.9 -8.21 4.73e-15 8.41e-12 -0.47 -0.41 Endometriosis;Longevity; chr7:995267 chr7:1160374~1165267:+ LIHC cis rs11723261 0.582 rs3747693 ENSG00000275426.1 CH17-262A2.1 8.2 4.75e-15 8.45e-12 0.49 0.41 Immune response to smallpox vaccine (IL-6); chr4:124493 chr4:149738~150317:+ LIHC cis rs2260433 0.66 rs7129777 ENSG00000281655.1 RP11-817J15.3 8.2 4.78e-15 8.5e-12 0.47 0.41 Cleft palate; chr11:102641355 chr11:102681310~102683913:+ LIHC cis rs2882667 0.898 rs4380651 ENSG00000253404.1 AC034243.1 8.2 4.79e-15 8.51e-12 0.55 0.41 Age-related hearing impairment (SNP x SNP interaction); chr5:139055383 chr5:138744434~138753309:- LIHC cis rs6844153 0.752 rs28497454 ENSG00000240005.4 RP11-293A21.1 -8.2 4.8e-15 8.52e-12 -0.47 -0.41 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26906230 chr4:26859806~26860599:- LIHC cis rs3096299 0.685 rs4785568 ENSG00000274627.1 RP11-104N10.2 8.2 4.84e-15 8.58e-12 0.41 0.41 Multiple myeloma (IgH translocation); chr16:89487299 chr16:89516797~89522217:+ LIHC cis rs17301013 0.606 rs12079689 ENSG00000227373.4 RP11-160H22.5 8.2 4.84e-15 8.58e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174240514 chr1:174115300~174160004:- LIHC cis rs17301013 0.581 rs7551605 ENSG00000227373.4 RP11-160H22.5 8.2 4.84e-15 8.58e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174245718 chr1:174115300~174160004:- LIHC cis rs17301013 0.581 rs12080977 ENSG00000227373.4 RP11-160H22.5 8.2 4.84e-15 8.58e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174247026 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs72713503 ENSG00000227373.4 RP11-160H22.5 8.2 4.84e-15 8.58e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174247553 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs16846816 ENSG00000227373.4 RP11-160H22.5 8.2 4.84e-15 8.58e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174251602 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs10912750 ENSG00000227373.4 RP11-160H22.5 8.2 4.84e-15 8.58e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174253637 chr1:174115300~174160004:- LIHC cis rs17301013 0.581 rs12083540 ENSG00000227373.4 RP11-160H22.5 8.2 4.84e-15 8.58e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174254096 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs12085311 ENSG00000227373.4 RP11-160H22.5 8.2 4.84e-15 8.58e-12 0.64 0.41 Systemic lupus erythematosus; chr1:174256097 chr1:174115300~174160004:- LIHC cis rs7397814 0.558 rs4764447 ENSG00000256673.1 RP11-599J14.2 8.2 4.85e-15 8.61e-12 0.42 0.41 IgG glycosylation; chr12:9426513 chr12:9398355~9414851:- LIHC cis rs507080 0.922 rs4938524 ENSG00000255422.1 AP002954.4 -8.2 4.87e-15 8.63e-12 -0.47 -0.41 Serum metabolite levels; chr11:118681365 chr11:118704607~118750263:+ LIHC cis rs150992 0.512 rs161954 ENSG00000248489.1 CTD-2007H13.3 8.2 4.9e-15 8.69e-12 0.59 0.41 Body mass index; chr5:98920833 chr5:98929171~98995013:+ LIHC cis rs34779708 0.966 rs17591163 ENSG00000230534.5 RP11-297A16.2 8.2 4.91e-15 8.71e-12 0.52 0.41 Inflammatory bowel disease;Crohn's disease; chr10:35176351 chr10:35098006~35127020:- LIHC cis rs6504950 1 rs28558726 ENSG00000275710.1 RP11-257O5.4 8.2 4.93e-15 8.74e-12 0.6 0.41 Breast cancer; chr17:54981315 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9892976 ENSG00000275710.1 RP11-257O5.4 8.2 4.93e-15 8.74e-12 0.6 0.41 Breast cancer; chr17:54982968 chr17:54964474~54964679:+ LIHC cis rs893363 0.517 rs6445606 ENSG00000271916.1 RP11-884K10.6 -8.2 4.94e-15 8.75e-12 -0.78 -0.41 Axial length; chr3:53822023 chr3:53797764~53798019:- LIHC cis rs7208859 0.562 rs216408 ENSG00000263531.1 RP13-753N3.1 -8.2 5.02e-15 8.9e-12 -0.68 -0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30580739 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs450585 ENSG00000263531.1 RP13-753N3.1 8.2 5.07e-15 8.98e-12 0.68 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30624021 chr17:30863921~30864940:- LIHC cis rs17826219 0.706 rs609472 ENSG00000263531.1 RP13-753N3.1 8.19 5.12e-15 9.07e-12 0.7 0.41 Body mass index; chr17:30624409 chr17:30863921~30864940:- LIHC cis rs12744310 0.945 rs1343776 ENSG00000235358.1 RP11-399E6.1 8.19 5.19e-15 9.19e-12 0.53 0.41 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41292046 chr1:41242373~41284861:+ LIHC cis rs7617773 0.746 rs4130995 ENSG00000229759.1 MRPS18AP1 8.19 5.2e-15 9.19e-12 0.43 0.41 Coronary artery disease; chr3:48316765 chr3:48256350~48256938:- LIHC cis rs9527 0.637 rs12219247 ENSG00000236937.2 PTGES3P4 8.19 5.32e-15 9.41e-12 0.49 0.4 Arsenic metabolism; chr10:102853604 chr10:102845595~102845950:+ LIHC cis rs17826219 0.561 rs562840 ENSG00000263531.1 RP13-753N3.1 8.19 5.33e-15 9.42e-12 0.68 0.4 Body mass index; chr17:30622372 chr17:30863921~30864940:- LIHC cis rs1577917 0.876 rs12190735 ENSG00000203875.9 SNHG5 -8.19 5.33e-15 9.43e-12 -0.49 -0.4 Response to antipsychotic treatment; chr6:85976749 chr6:85660950~85678736:- LIHC cis rs17301013 0.581 rs6685499 ENSG00000227373.4 RP11-160H22.5 8.19 5.35e-15 9.46e-12 0.63 0.4 Systemic lupus erythematosus; chr1:174144237 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs4652193 ENSG00000227373.4 RP11-160H22.5 8.19 5.35e-15 9.46e-12 0.63 0.4 Systemic lupus erythematosus; chr1:174144554 chr1:174115300~174160004:- LIHC cis rs17301013 0.632 rs12079214 ENSG00000227373.4 RP11-160H22.5 8.19 5.35e-15 9.46e-12 0.63 0.4 Systemic lupus erythematosus; chr1:174149572 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs12065785 ENSG00000227373.4 RP11-160H22.5 8.19 5.35e-15 9.46e-12 0.63 0.4 Systemic lupus erythematosus; chr1:174151296 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs16846717 ENSG00000227373.4 RP11-160H22.5 8.19 5.35e-15 9.46e-12 0.63 0.4 Systemic lupus erythematosus; chr1:174152180 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs16846718 ENSG00000227373.4 RP11-160H22.5 8.19 5.35e-15 9.46e-12 0.63 0.4 Systemic lupus erythematosus; chr1:174152782 chr1:174115300~174160004:- LIHC cis rs34779708 0.931 rs67976880 ENSG00000230534.5 RP11-297A16.2 8.19 5.36e-15 9.46e-12 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35083333 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs72789687 ENSG00000230534.5 RP11-297A16.2 8.19 5.36e-15 9.46e-12 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35083561 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs35997236 ENSG00000230534.5 RP11-297A16.2 8.19 5.36e-15 9.46e-12 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35087762 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs4934719 ENSG00000230534.5 RP11-297A16.2 8.19 5.36e-15 9.46e-12 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35087841 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs4934720 ENSG00000230534.5 RP11-297A16.2 8.19 5.36e-15 9.46e-12 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35087872 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs4934535 ENSG00000230534.5 RP11-297A16.2 8.19 5.36e-15 9.46e-12 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35143793 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs4934734 ENSG00000230534.5 RP11-297A16.2 8.19 5.36e-15 9.46e-12 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35145445 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs12769575 ENSG00000230534.5 RP11-297A16.2 8.19 5.36e-15 9.46e-12 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35146999 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs4934536 ENSG00000230534.5 RP11-297A16.2 8.19 5.36e-15 9.46e-12 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35152241 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs4934537 ENSG00000230534.5 RP11-297A16.2 8.19 5.36e-15 9.46e-12 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35152584 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs1545757 ENSG00000230534.5 RP11-297A16.2 8.19 5.36e-15 9.46e-12 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35156660 chr10:35098006~35127020:- LIHC cis rs17301013 0.606 rs2103640 ENSG00000227373.4 RP11-160H22.5 8.19 5.41e-15 9.55e-12 0.64 0.4 Systemic lupus erythematosus; chr1:174219147 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs56338048 ENSG00000227373.4 RP11-160H22.5 8.19 5.41e-15 9.55e-12 0.64 0.4 Systemic lupus erythematosus; chr1:174220266 chr1:174115300~174160004:- LIHC cis rs4356975 0.83 rs7435274 ENSG00000249956.3 RP11-790I12.2 8.18 5.57e-15 9.82e-12 0.45 0.4 Obesity-related traits; chr4:69050281 chr4:69408836~69423164:+ LIHC cis rs4356975 0.83 rs7438808 ENSG00000249956.3 RP11-790I12.2 8.18 5.57e-15 9.82e-12 0.45 0.4 Obesity-related traits; chr4:69050666 chr4:69408836~69423164:+ LIHC cis rs9399135 0.967 rs12527683 ENSG00000232876.1 CTA-212D2.2 -8.18 5.58e-15 9.84e-12 -0.45 -0.4 Red blood cell count; chr6:135003396 chr6:135055033~135060550:+ LIHC cis rs6504950 1 rs9892848 ENSG00000275710.1 RP11-257O5.4 8.18 5.62e-15 9.9e-12 0.63 0.4 Breast cancer; chr17:54982414 chr17:54964474~54964679:+ LIHC cis rs6504950 1 rs9890971 ENSG00000275710.1 RP11-257O5.4 8.18 5.62e-15 9.9e-12 0.63 0.4 Breast cancer; chr17:54982415 chr17:54964474~54964679:+ LIHC cis rs9543976 1 rs73223984 ENSG00000261553.4 RP11-29G8.3 -8.18 5.71e-15 1e-11 -0.59 -0.4 Diabetic retinopathy; chr13:75607005 chr13:75549773~75807120:+ LIHC cis rs7208859 0.673 rs56846352 ENSG00000263531.1 RP13-753N3.1 8.18 5.74e-15 1.01e-11 0.7 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792170 chr17:30863921~30864940:- LIHC cis rs1165205 0.558 rs531750 ENSG00000242387.1 HIST1H2APS2 8.17 5.84e-15 1.03e-11 0.52 0.4 Urate levels; chr6:25882414 chr6:25882026~25882395:- LIHC cis rs11723261 0.582 rs6814287 ENSG00000275426.1 CH17-262A2.1 8.17 5.86e-15 1.03e-11 0.49 0.4 Immune response to smallpox vaccine (IL-6); chr4:122443 chr4:149738~150317:+ LIHC cis rs8062405 0.54 rs151226 ENSG00000259982.1 CDC37P1 8.17 5.9e-15 1.04e-11 0.43 0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28538502 chr16:28700294~28701540:- LIHC cis rs9389248 0.5 rs116273677 ENSG00000232876.1 CTA-212D2.2 -8.17 5.91e-15 1.04e-11 -0.46 -0.4 High light scatter reticulocyte percentage of red cells; chr6:135017997 chr6:135055033~135060550:+ LIHC cis rs34779708 0.931 rs4934723 ENSG00000230534.5 RP11-297A16.2 8.17 5.96e-15 1.04e-11 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35092835 chr10:35098006~35127020:- LIHC cis rs7727544 0.735 rs273914 ENSG00000233006.5 AC034220.3 8.17 6.01e-15 1.05e-11 0.41 0.4 Blood metabolite levels; chr5:132324738 chr5:132311285~132369916:- LIHC cis rs4356975 0.83 rs10012607 ENSG00000249956.3 RP11-790I12.2 8.17 6.02e-15 1.05e-11 0.45 0.4 Obesity-related traits; chr4:69048866 chr4:69408836~69423164:+ LIHC cis rs12022452 0.506 rs6673386 ENSG00000238287.1 RP11-656D10.3 -8.17 6.04e-15 1.06e-11 -0.51 -0.4 Age-related hearing impairment (SNP x SNP interaction); chr1:40546207 chr1:40493157~40508661:- LIHC cis rs7208859 0.673 rs216440 ENSG00000263531.1 RP13-753N3.1 8.17 6.04e-15 1.06e-11 0.67 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30601291 chr17:30863921~30864940:- LIHC cis rs11723261 0.621 rs7692530 ENSG00000275426.1 CH17-262A2.1 8.17 6.06e-15 1.06e-11 0.49 0.4 Immune response to smallpox vaccine (IL-6); chr4:123563 chr4:149738~150317:+ LIHC cis rs5758659 0.504 rs133367 ENSG00000227370.1 RP4-669P10.19 8.17 6.17e-15 1.08e-11 0.45 0.4 Cognitive function; chr22:42067362 chr22:42132543~42132998:+ LIHC cis rs9399135 0.967 rs6919862 ENSG00000232876.1 CTA-212D2.2 -8.17 6.18e-15 1.08e-11 -0.45 -0.4 Red blood cell count; chr6:135031305 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs3756799 ENSG00000232876.1 CTA-212D2.2 -8.17 6.24e-15 1.09e-11 -0.46 -0.4 Red blood cell count; chr6:135019873 chr6:135055033~135060550:+ LIHC cis rs9399135 0.838 rs4896126 ENSG00000232876.1 CTA-212D2.2 -8.17 6.24e-15 1.09e-11 -0.46 -0.4 Red blood cell count; chr6:135021648 chr6:135055033~135060550:+ LIHC cis rs9402673 0.517 rs978036 ENSG00000232876.1 CTA-212D2.2 -8.17 6.24e-15 1.09e-11 -0.46 -0.4 High light scatter reticulocyte count;Reticulocyte count; chr6:135021765 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs1023179 ENSG00000232876.1 CTA-212D2.2 -8.17 6.24e-15 1.09e-11 -0.46 -0.4 Red blood cell count; chr6:135022691 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs952674 ENSG00000232876.1 CTA-212D2.2 -8.17 6.24e-15 1.09e-11 -0.46 -0.4 Red blood cell count; chr6:135028019 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs6902438 ENSG00000232876.1 CTA-212D2.2 -8.16 6.28e-15 1.09e-11 -0.46 -0.4 Red blood cell count; chr6:135015449 chr6:135055033~135060550:+ LIHC cis rs9399135 0.935 rs6908681 ENSG00000232876.1 CTA-212D2.2 -8.16 6.28e-15 1.09e-11 -0.46 -0.4 Red blood cell count; chr6:135016595 chr6:135055033~135060550:+ LIHC cis rs7044106 0.734 rs12553070 ENSG00000226752.6 PSMD5-AS1 -8.16 6.3e-15 1.1e-11 -0.41 -0.4 Hip circumference adjusted for BMI; chr9:120722988 chr9:120824828~120854385:+ LIHC cis rs4718428 0.705 rs11028 ENSG00000273142.1 RP11-458F8.4 -8.16 6.32e-15 1.1e-11 -0.4 -0.4 Corneal structure; chr7:66811230 chr7:66902857~66906297:+ LIHC cis rs12744310 1 rs12035913 ENSG00000235358.1 RP11-399E6.1 -8.16 6.34e-15 1.1e-11 -0.52 -0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41291385 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs67483852 ENSG00000235358.1 RP11-399E6.1 8.16 6.38e-15 1.11e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41318793 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs36015391 ENSG00000235358.1 RP11-399E6.1 8.16 6.38e-15 1.11e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41319133 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs28399806 ENSG00000235358.1 RP11-399E6.1 8.16 6.38e-15 1.11e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41319299 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs12047875 ENSG00000235358.1 RP11-399E6.1 8.16 6.38e-15 1.11e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41319504 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs35932978 ENSG00000235358.1 RP11-399E6.1 8.16 6.38e-15 1.11e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41319773 chr1:41242373~41284861:+ LIHC cis rs2882667 0.964 rs11739351 ENSG00000253404.1 AC034243.1 8.16 6.48e-15 1.13e-11 0.54 0.4 Age-related hearing impairment (SNP x SNP interaction); chr5:138976053 chr5:138744434~138753309:- LIHC cis rs7727544 0.735 rs272894 ENSG00000233006.5 AC034220.3 8.16 6.51e-15 1.13e-11 0.41 0.4 Blood metabolite levels; chr5:132326767 chr5:132311285~132369916:- LIHC cis rs2882667 0.898 rs10045761 ENSG00000253404.1 AC034243.1 8.16 6.57e-15 1.14e-11 0.53 0.4 Age-related hearing impairment (SNP x SNP interaction); chr5:139061600 chr5:138744434~138753309:- LIHC cis rs9399135 0.684 rs1135205 ENSG00000232876.1 CTA-212D2.2 -8.16 6.69e-15 1.16e-11 -0.45 -0.4 Red blood cell count; chr6:134960657 chr6:135055033~135060550:+ LIHC cis rs4356975 0.932 rs4694159 ENSG00000249956.3 RP11-790I12.2 8.16 6.69e-15 1.16e-11 0.45 0.4 Obesity-related traits; chr4:69068460 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs4694597 ENSG00000249956.3 RP11-790I12.2 8.16 6.69e-15 1.16e-11 0.45 0.4 Obesity-related traits; chr4:69068643 chr4:69408836~69423164:+ LIHC cis rs4356975 0.899 rs4694160 ENSG00000249956.3 RP11-790I12.2 8.16 6.69e-15 1.16e-11 0.45 0.4 Obesity-related traits; chr4:69068755 chr4:69408836~69423164:+ LIHC cis rs4356975 0.899 rs7439419 ENSG00000249956.3 RP11-790I12.2 8.16 6.69e-15 1.16e-11 0.45 0.4 Obesity-related traits; chr4:69069090 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs7658748 ENSG00000249956.3 RP11-790I12.2 8.16 6.69e-15 1.16e-11 0.45 0.4 Obesity-related traits; chr4:69069219 chr4:69408836~69423164:+ LIHC cis rs4356975 0.899 rs7687336 ENSG00000249956.3 RP11-790I12.2 8.16 6.69e-15 1.16e-11 0.45 0.4 Obesity-related traits; chr4:69069397 chr4:69408836~69423164:+ LIHC cis rs4356975 0.899 rs7659138 ENSG00000249956.3 RP11-790I12.2 8.16 6.69e-15 1.16e-11 0.45 0.4 Obesity-related traits; chr4:69069420 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs7674600 ENSG00000249956.3 RP11-790I12.2 8.16 6.69e-15 1.16e-11 0.45 0.4 Obesity-related traits; chr4:69069614 chr4:69408836~69423164:+ LIHC cis rs3096299 0.563 rs4600467 ENSG00000274627.1 RP11-104N10.2 8.15 6.72e-15 1.17e-11 0.41 0.4 Multiple myeloma (IgH translocation); chr16:89496108 chr16:89516797~89522217:+ LIHC cis rs17301013 0.606 rs7530265 ENSG00000227373.4 RP11-160H22.5 8.15 6.78e-15 1.18e-11 0.61 0.4 Systemic lupus erythematosus; chr1:174564603 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs12080535 ENSG00000227373.4 RP11-160H22.5 8.15 6.78e-15 1.18e-11 0.61 0.4 Systemic lupus erythematosus; chr1:174569832 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs12083628 ENSG00000227373.4 RP11-160H22.5 8.15 6.78e-15 1.18e-11 0.61 0.4 Systemic lupus erythematosus; chr1:174572097 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs6691118 ENSG00000227373.4 RP11-160H22.5 8.15 6.78e-15 1.18e-11 0.61 0.4 Systemic lupus erythematosus; chr1:174577798 chr1:174115300~174160004:- LIHC cis rs17301013 0.54 rs61624206 ENSG00000227373.4 RP11-160H22.5 8.15 6.78e-15 1.18e-11 0.61 0.4 Systemic lupus erythematosus; chr1:174578374 chr1:174115300~174160004:- LIHC cis rs9399135 0.66 rs4646868 ENSG00000232876.1 CTA-212D2.2 -8.15 6.94e-15 1.21e-11 -0.46 -0.4 Red blood cell count; chr6:134950808 chr6:135055033~135060550:+ LIHC cis rs17301013 0.606 rs10912735 ENSG00000227373.4 RP11-160H22.5 8.15 6.94e-15 1.21e-11 0.63 0.4 Systemic lupus erythematosus; chr1:174159002 chr1:174115300~174160004:- LIHC cis rs8072100 0.934 rs6504872 ENSG00000228782.6 CTD-2026D20.3 8.15 6.94e-15 1.21e-11 0.46 0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47361586 chr17:47450568~47492492:- LIHC cis rs73086581 1 rs6052220 ENSG00000229539.1 RP11-119B16.2 8.15 7.02e-15 1.22e-11 0.73 0.4 Response to antidepressants in depression; chr20:3989947 chr20:3888239~3888868:- LIHC cis rs3096299 0.685 rs4785675 ENSG00000274627.1 RP11-104N10.2 8.15 7.04e-15 1.22e-11 0.42 0.4 Multiple myeloma (IgH translocation); chr16:89473566 chr16:89516797~89522217:+ LIHC cis rs3096299 0.685 rs4238830 ENSG00000274627.1 RP11-104N10.2 8.15 7.04e-15 1.22e-11 0.42 0.4 Multiple myeloma (IgH translocation); chr16:89473833 chr16:89516797~89522217:+ LIHC cis rs12744310 1 rs12035012 ENSG00000235358.1 RP11-399E6.1 8.15 7.07e-15 1.23e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41284976 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs35318047 ENSG00000235358.1 RP11-399E6.1 8.15 7.07e-15 1.23e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41289494 chr1:41242373~41284861:+ LIHC cis rs12744310 0.943 rs35493284 ENSG00000235358.1 RP11-399E6.1 8.15 7.07e-15 1.23e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41289517 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12025254 ENSG00000235358.1 RP11-399E6.1 8.15 7.07e-15 1.23e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41291234 chr1:41242373~41284861:+ LIHC cis rs7727544 0.66 rs272886 ENSG00000233006.5 AC034220.3 8.15 7.07e-15 1.23e-11 0.4 0.4 Blood metabolite levels; chr5:132330147 chr5:132311285~132369916:- LIHC cis rs12744310 1 rs60552457 ENSG00000235358.1 RP11-399E6.1 8.14 7.23e-15 1.25e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41293827 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12739950 ENSG00000235358.1 RP11-399E6.1 8.14 7.23e-15 1.25e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41294219 chr1:41242373~41284861:+ LIHC cis rs12744310 0.945 rs12740093 ENSG00000235358.1 RP11-399E6.1 8.14 7.23e-15 1.25e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41294329 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12038894 ENSG00000235358.1 RP11-399E6.1 8.14 7.23e-15 1.25e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41294535 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12038924 ENSG00000235358.1 RP11-399E6.1 8.14 7.23e-15 1.25e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41294645 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12032514 ENSG00000235358.1 RP11-399E6.1 8.14 7.23e-15 1.25e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41294890 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12039767 ENSG00000235358.1 RP11-399E6.1 8.14 7.23e-15 1.25e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41295188 chr1:41242373~41284861:+ LIHC cis rs4718428 0.705 rs3800817 ENSG00000273142.1 RP11-458F8.4 -8.14 7.31e-15 1.27e-11 -0.4 -0.4 Corneal structure; chr7:66798563 chr7:66902857~66906297:+ LIHC cis rs34779708 0.931 rs4934721 ENSG00000230534.5 RP11-297A16.2 8.14 7.32e-15 1.27e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35088787 chr10:35098006~35127020:- LIHC cis rs7727544 0.684 rs272869 ENSG00000233006.5 AC034220.3 8.14 7.45e-15 1.29e-11 0.4 0.4 Blood metabolite levels; chr5:132342304 chr5:132311285~132369916:- LIHC cis rs34779708 0.966 rs35079558 ENSG00000230534.5 RP11-297A16.2 8.14 7.49e-15 1.29e-11 0.52 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35190958 chr10:35098006~35127020:- LIHC cis rs1155848 0.892 rs9574424 ENSG00000227354.5 RBM26-AS1 -8.14 7.64e-15 1.32e-11 -0.67 -0.4 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79448541 chr13:79406309~79424328:+ LIHC cis rs17301013 0.606 rs5015737 ENSG00000227373.4 RP11-160H22.5 8.13 7.74e-15 1.34e-11 0.61 0.4 Systemic lupus erythematosus; chr1:174452857 chr1:174115300~174160004:- LIHC cis rs7727544 0.684 rs270602 ENSG00000233006.5 AC034220.3 8.13 7.75e-15 1.34e-11 0.4 0.4 Blood metabolite levels; chr5:132321007 chr5:132311285~132369916:- LIHC cis rs529413 0.543 rs12915134 ENSG00000259237.1 RP11-209E8.1 8.13 7.81e-15 1.35e-11 0.51 0.4 Itch intensity from mosquito bite adjusted by bite size; chr15:53159314 chr15:53116365~53129698:+ LIHC cis rs9399135 0.967 rs6923765 ENSG00000232876.1 CTA-212D2.2 8.13 7.89e-15 1.36e-11 0.47 0.4 Red blood cell count; chr6:135014038 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs6902954 ENSG00000232876.1 CTA-212D2.2 -8.13 7.95e-15 1.37e-11 -0.45 -0.4 Red blood cell count; chr6:134992856 chr6:135055033~135060550:+ LIHC cis rs8072100 1 rs11650372 ENSG00000228782.6 CTD-2026D20.3 8.13 8e-15 1.38e-11 0.46 0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47644429 chr17:47450568~47492492:- LIHC cis rs8072100 1 rs8065669 ENSG00000228782.6 CTD-2026D20.3 8.13 8e-15 1.38e-11 0.46 0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47647630 chr17:47450568~47492492:- LIHC cis rs11647589 0.784 rs1700804 ENSG00000260762.1 ACSM5P1 -8.13 8.01e-15 1.38e-11 -0.41 -0.4 Blood metabolite levels; chr16:20477047 chr16:20586550~20607107:- LIHC cis rs9543976 0.858 rs9530447 ENSG00000261553.4 RP11-29G8.3 8.13 8.08e-15 1.39e-11 0.57 0.4 Diabetic retinopathy; chr13:75592666 chr13:75549773~75807120:+ LIHC cis rs4718428 0.672 rs13241598 ENSG00000273142.1 RP11-458F8.4 -8.12 8.31e-15 1.43e-11 -0.4 -0.4 Corneal structure; chr7:66835665 chr7:66902857~66906297:+ LIHC cis rs9399135 0.967 rs6929661 ENSG00000232876.1 CTA-212D2.2 -8.12 8.48e-15 1.46e-11 -0.45 -0.4 Red blood cell count; chr6:135007654 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs2327578 ENSG00000232876.1 CTA-212D2.2 -8.12 8.48e-15 1.46e-11 -0.45 -0.4 Red blood cell count; chr6:135008831 chr6:135055033~135060550:+ LIHC cis rs858239 0.932 rs199355 ENSG00000230658.1 KLHL7-AS1 8.12 8.49e-15 1.46e-11 0.52 0.4 Cerebrospinal fluid biomarker levels; chr7:23256914 chr7:23101228~23105703:- LIHC cis rs1577917 0.876 rs1582127 ENSG00000203875.9 SNHG5 -8.12 8.51e-15 1.46e-11 -0.49 -0.4 Response to antipsychotic treatment; chr6:85987486 chr6:85660950~85678736:- LIHC cis rs2302464 1 rs57326588 ENSG00000214846.4 RP11-115L11.1 8.12 8.59e-15 1.47e-11 0.64 0.4 Cerebrospinal fluid biomarker levels; chr4:15723813 chr4:15730962~15731627:- LIHC cis rs17301013 0.531 rs6678286 ENSG00000227373.4 RP11-160H22.5 8.12 8.6e-15 1.48e-11 0.63 0.4 Systemic lupus erythematosus; chr1:174200481 chr1:174115300~174160004:- LIHC cis rs7617773 1 rs6442108 ENSG00000229759.1 MRPS18AP1 -8.12 8.63e-15 1.48e-11 -0.46 -0.4 Coronary artery disease; chr3:48151469 chr3:48256350~48256938:- LIHC cis rs7617773 1 rs6442109 ENSG00000229759.1 MRPS18AP1 -8.12 8.63e-15 1.48e-11 -0.46 -0.4 Coronary artery disease; chr3:48151491 chr3:48256350~48256938:- LIHC cis rs73086581 0.947 rs67356712 ENSG00000229539.1 RP11-119B16.2 8.12 8.65e-15 1.48e-11 0.74 0.4 Response to antidepressants in depression; chr20:3912239 chr20:3888239~3888868:- LIHC cis rs7044106 0.791 rs747819 ENSG00000226752.6 PSMD5-AS1 -8.12 8.73e-15 1.5e-11 -0.41 -0.4 Hip circumference adjusted for BMI; chr9:120726163 chr9:120824828~120854385:+ LIHC cis rs7044106 0.791 rs735110 ENSG00000226752.6 PSMD5-AS1 -8.12 8.73e-15 1.5e-11 -0.41 -0.4 Hip circumference adjusted for BMI; chr9:120726662 chr9:120824828~120854385:+ LIHC cis rs34779708 0.966 rs113170867 ENSG00000230534.5 RP11-297A16.2 8.12 8.75e-15 1.5e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35161219 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs35126129 ENSG00000230534.5 RP11-297A16.2 8.12 8.75e-15 1.5e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35163213 chr10:35098006~35127020:- LIHC cis rs4423214 0.515 rs4944042 ENSG00000254682.1 RP11-660L16.2 8.12 8.79e-15 1.51e-11 0.48 0.4 Vitamin D levels; chr11:71407742 chr11:71448674~71452157:+ LIHC cis rs17301013 0.606 rs12354141 ENSG00000227373.4 RP11-160H22.5 8.11 8.94e-15 1.53e-11 0.62 0.4 Systemic lupus erythematosus; chr1:174166078 chr1:174115300~174160004:- LIHC cis rs2929278 0.617 rs4617832 ENSG00000205771.5 CATSPER2P1 8.11 8.96e-15 1.53e-11 0.51 0.4 Schizophrenia; chr15:43738381 chr15:43726918~43747094:- LIHC cis rs6844153 0.752 rs28520489 ENSG00000240005.4 RP11-293A21.1 -8.11 8.98e-15 1.54e-11 -0.47 -0.4 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26896082 chr4:26859806~26860599:- LIHC cis rs11723261 0.582 rs6599293 ENSG00000275426.1 CH17-262A2.1 8.11 9.06e-15 1.55e-11 0.48 0.4 Immune response to smallpox vaccine (IL-6); chr4:139246 chr4:149738~150317:+ LIHC cis rs2524005 1 rs2524005 ENSG00000204625.9 HCG9 8.11 9.13e-15 1.56e-11 0.56 0.4 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29975112~29978410:+ LIHC cis rs8062405 0.54 rs193628 ENSG00000259982.1 CDC37P1 -8.11 9.18e-15 1.57e-11 -0.44 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28570821 chr16:28700294~28701540:- LIHC cis rs6991838 0.584 rs4737747 ENSG00000272010.1 CTD-3025N20.3 -8.11 9.23e-15 1.58e-11 -0.44 -0.4 Intelligence (multi-trait analysis); chr8:65607024 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs73236948 ENSG00000272010.1 CTD-3025N20.3 -8.11 9.23e-15 1.58e-11 -0.44 -0.4 Intelligence (multi-trait analysis); chr8:65609176 chr8:65591850~65592472:- LIHC cis rs9399135 0.967 rs6925424 ENSG00000232876.1 CTA-212D2.2 -8.11 9.32e-15 1.59e-11 -0.45 -0.4 Red blood cell count; chr6:134992810 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs17638970 ENSG00000232876.1 CTA-212D2.2 -8.11 9.32e-15 1.59e-11 -0.45 -0.4 Red blood cell count; chr6:134998925 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs45544135 ENSG00000232876.1 CTA-212D2.2 -8.11 9.32e-15 1.59e-11 -0.45 -0.4 Red blood cell count; chr6:135002913 chr6:135055033~135060550:+ LIHC cis rs9399135 0.933 rs4559100 ENSG00000232876.1 CTA-212D2.2 -8.11 9.32e-15 1.59e-11 -0.45 -0.4 Red blood cell count; chr6:135002947 chr6:135055033~135060550:+ LIHC cis rs6991838 0.584 rs7463649 ENSG00000272010.1 CTD-3025N20.3 -8.11 9.33e-15 1.59e-11 -0.44 -0.4 Intelligence (multi-trait analysis); chr8:65573760 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs66467166 ENSG00000272010.1 CTD-3025N20.3 -8.11 9.33e-15 1.59e-11 -0.44 -0.4 Intelligence (multi-trait analysis); chr8:65574165 chr8:65591850~65592472:- LIHC cis rs10935480 0.634 rs1585488 ENSG00000239445.4 ST3GAL6-AS1 -8.11 9.36e-15 1.6e-11 -0.47 -0.4 Blood protein levels; chr3:98640819 chr3:98714330~98732651:- LIHC cis rs7617773 1 rs11711766 ENSG00000229759.1 MRPS18AP1 -8.11 9.42e-15 1.61e-11 -0.45 -0.4 Coronary artery disease; chr3:48151680 chr3:48256350~48256938:- LIHC cis rs3096299 0.685 rs4329923 ENSG00000274627.1 RP11-104N10.2 8.1 9.55e-15 1.63e-11 0.42 0.4 Multiple myeloma (IgH translocation); chr16:89493770 chr16:89516797~89522217:+ LIHC cis rs2882667 1 rs10515505 ENSG00000253404.1 AC034243.1 8.1 9.6e-15 1.64e-11 0.53 0.4 Age-related hearing impairment (SNP x SNP interaction); chr5:138977457 chr5:138744434~138753309:- LIHC cis rs34779708 0.931 rs12771399 ENSG00000230534.5 RP11-297A16.2 8.1 9.65e-15 1.65e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35163449 chr10:35098006~35127020:- LIHC cis rs8072100 0.934 rs8067286 ENSG00000228782.6 CTD-2026D20.3 -8.1 9.66e-15 1.65e-11 -0.46 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47517224 chr17:47450568~47492492:- LIHC cis rs8072100 0.875 rs62073966 ENSG00000228782.6 CTD-2026D20.3 -8.1 9.66e-15 1.65e-11 -0.46 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47522647 chr17:47450568~47492492:- LIHC cis rs8072100 0.935 rs78551919 ENSG00000228782.6 CTD-2026D20.3 -8.1 9.66e-15 1.65e-11 -0.46 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47548636 chr17:47450568~47492492:- LIHC cis rs6991838 0.584 rs1053085 ENSG00000272010.1 CTD-3025N20.3 -8.1 9.79e-15 1.67e-11 -0.44 -0.4 Intelligence (multi-trait analysis); chr8:65603753 chr8:65591850~65592472:- LIHC cis rs9543976 1 rs9543976 ENSG00000261553.4 RP11-29G8.3 8.1 9.79e-15 1.67e-11 0.56 0.4 Diabetic retinopathy; chr13:75562512 chr13:75549773~75807120:+ LIHC cis rs2524005 1 rs2524005 ENSG00000227766.1 HCG4P5 -8.1 9.85e-15 1.68e-11 -0.59 -0.4 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29942075~29943067:- LIHC cis rs4356975 0.932 rs4694602 ENSG00000249956.3 RP11-790I12.2 8.1 9.91e-15 1.69e-11 0.44 0.4 Obesity-related traits; chr4:69070955 chr4:69408836~69423164:+ LIHC cis rs34779708 0.966 rs7913615 ENSG00000230534.5 RP11-297A16.2 8.1 9.92e-15 1.69e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35134029 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs1926556 ENSG00000230534.5 RP11-297A16.2 8.1 9.93e-15 1.69e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35055979 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs1926554 ENSG00000230534.5 RP11-297A16.2 8.1 9.93e-15 1.69e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35056041 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs4934710 ENSG00000230534.5 RP11-297A16.2 8.1 9.93e-15 1.69e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35061488 chr10:35098006~35127020:- LIHC cis rs34779708 0.897 rs35784065 ENSG00000230534.5 RP11-297A16.2 8.1 9.93e-15 1.69e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35064646 chr10:35098006~35127020:- LIHC cis rs12744310 0.895 rs1892417 ENSG00000235358.1 RP11-399E6.1 8.1 1e-14 1.7e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41314001 chr1:41242373~41284861:+ LIHC cis rs17301013 0.606 rs6692437 ENSG00000227373.4 RP11-160H22.5 8.09 1.02e-14 1.74e-11 0.63 0.4 Systemic lupus erythematosus; chr1:174213771 chr1:174115300~174160004:- LIHC cis rs8072100 0.539 rs36043200 ENSG00000228782.6 CTD-2026D20.3 -8.09 1.03e-14 1.75e-11 -0.46 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47552040 chr17:47450568~47492492:- LIHC cis rs17301013 0.606 rs6676161 ENSG00000227373.4 RP11-160H22.5 8.09 1.03e-14 1.75e-11 0.63 0.4 Systemic lupus erythematosus; chr1:174138555 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs10912746 ENSG00000227373.4 RP11-160H22.5 8.09 1.04e-14 1.76e-11 0.63 0.4 Systemic lupus erythematosus; chr1:174210205 chr1:174115300~174160004:- LIHC cis rs4356975 0.83 rs6600865 ENSG00000249956.3 RP11-790I12.2 8.09 1.05e-14 1.78e-11 0.45 0.4 Obesity-related traits; chr4:69057904 chr4:69408836~69423164:+ LIHC cis rs6991838 0.584 rs6993876 ENSG00000272010.1 CTD-3025N20.3 8.09 1.05e-14 1.78e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65601240 chr8:65591850~65592472:- LIHC cis rs6903823 0.508 rs1778484 ENSG00000216901.1 AL022393.7 8.09 1.08e-14 1.83e-11 0.45 0.4 Pulmonary function; chr6:28273021 chr6:28176188~28176674:+ LIHC cis rs8072100 1 rs4375701 ENSG00000228782.6 CTD-2026D20.3 8.09 1.08e-14 1.83e-11 0.46 0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47634852 chr17:47450568~47492492:- LIHC cis rs8072100 1 rs8065437 ENSG00000228782.6 CTD-2026D20.3 8.09 1.08e-14 1.83e-11 0.46 0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47644287 chr17:47450568~47492492:- LIHC cis rs4356975 0.83 rs4481286 ENSG00000249956.3 RP11-790I12.2 8.09 1.08e-14 1.83e-11 0.45 0.4 Obesity-related traits; chr4:69056631 chr4:69408836~69423164:+ LIHC cis rs4356975 0.83 rs4583828 ENSG00000249956.3 RP11-790I12.2 8.09 1.08e-14 1.83e-11 0.45 0.4 Obesity-related traits; chr4:69056669 chr4:69408836~69423164:+ LIHC cis rs6844153 0.713 rs11734308 ENSG00000240005.4 RP11-293A21.1 -8.08 1.09e-14 1.85e-11 -0.47 -0.4 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26934877 chr4:26859806~26860599:- LIHC cis rs6991838 0.584 rs7463740 ENSG00000272010.1 CTD-3025N20.3 -8.08 1.11e-14 1.88e-11 -0.44 -0.4 Intelligence (multi-trait analysis); chr8:65573950 chr8:65591850~65592472:- LIHC cis rs11191419 1 rs11191419 ENSG00000236937.2 PTGES3P4 8.08 1.12e-14 1.9e-11 0.48 0.4 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:102852578 chr10:102845595~102845950:+ LIHC cis rs12744310 1 rs1343775 ENSG00000235358.1 RP11-399E6.1 8.08 1.13e-14 1.9e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41292321 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12731400 ENSG00000235358.1 RP11-399E6.1 8.08 1.13e-14 1.9e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41295680 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12032756 ENSG00000235358.1 RP11-399E6.1 8.08 1.13e-14 1.9e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41295757 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs55859000 ENSG00000235358.1 RP11-399E6.1 8.08 1.13e-14 1.9e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41295769 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12030372 ENSG00000235358.1 RP11-399E6.1 8.08 1.13e-14 1.9e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41296357 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12032162 ENSG00000235358.1 RP11-399E6.1 8.08 1.13e-14 1.9e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41297263 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12031417 ENSG00000235358.1 RP11-399E6.1 8.08 1.13e-14 1.9e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41297356 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12037588 ENSG00000235358.1 RP11-399E6.1 8.08 1.13e-14 1.9e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41298283 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12037657 ENSG00000235358.1 RP11-399E6.1 8.08 1.13e-14 1.9e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41298503 chr1:41242373~41284861:+ LIHC cis rs12744310 0.832 rs12027990 ENSG00000235358.1 RP11-399E6.1 8.08 1.13e-14 1.9e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41298765 chr1:41242373~41284861:+ LIHC cis rs6991838 0.584 rs13268343 ENSG00000272010.1 CTD-3025N20.3 8.08 1.13e-14 1.92e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65631742 chr8:65591850~65592472:- LIHC cis rs8062405 0.558 rs151228 ENSG00000259982.1 CDC37P1 8.08 1.14e-14 1.92e-11 0.43 0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28551705 chr16:28700294~28701540:- LIHC cis rs1150668 0.699 rs12214383 ENSG00000216901.1 AL022393.7 -8.08 1.15e-14 1.94e-11 -0.44 -0.4 Pubertal anthropometrics; chr6:28255953 chr6:28176188~28176674:+ LIHC cis rs4356975 0.83 rs4235113 ENSG00000249956.3 RP11-790I12.2 8.08 1.15e-14 1.94e-11 0.45 0.4 Obesity-related traits; chr4:69056739 chr4:69408836~69423164:+ LIHC cis rs529413 0.516 rs1396092 ENSG00000259237.1 RP11-209E8.1 8.08 1.15e-14 1.94e-11 0.51 0.4 Itch intensity from mosquito bite adjusted by bite size; chr15:53160017 chr15:53116365~53129698:+ LIHC cis rs6991838 0.584 rs7841652 ENSG00000272010.1 CTD-3025N20.3 -8.08 1.15e-14 1.94e-11 -0.43 -0.4 Intelligence (multi-trait analysis); chr8:65606392 chr8:65591850~65592472:- LIHC cis rs6991838 0.53 rs35038843 ENSG00000272010.1 CTD-3025N20.3 -8.08 1.15e-14 1.94e-11 -0.43 -0.4 Intelligence (multi-trait analysis); chr8:65610263 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs4737748 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65613630 chr8:65591850~65592472:- LIHC cis rs6991838 0.55 rs12335006 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65619394 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs10957361 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65619626 chr8:65591850~65592472:- LIHC cis rs6991838 0.612 rs12335276 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65619668 chr8:65591850~65592472:- LIHC cis rs6991838 0.612 rs7832407 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65621071 chr8:65591850~65592472:- LIHC cis rs6991838 0.551 rs7007505 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65621719 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs7012856 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65622740 chr8:65591850~65592472:- LIHC cis rs6991838 0.55 rs7817112 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65624885 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs2048650 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65625664 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs4737749 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65627672 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs10092109 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65627683 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs6997959 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65628247 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs7814841 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65629328 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs11985628 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65630504 chr8:65591850~65592472:- LIHC cis rs6991838 0.557 rs13266834 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65631303 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs7835313 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65633891 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs3812412 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65634857 chr8:65591850~65592472:- LIHC cis rs6991838 0.53 rs6472217 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65635496 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs6472218 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65635502 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs1533285 ENSG00000272010.1 CTD-3025N20.3 8.08 1.15e-14 1.94e-11 0.43 0.4 Intelligence (multi-trait analysis); chr8:65637129 chr8:65591850~65592472:- LIHC cis rs17301013 0.606 rs10798307 ENSG00000227373.4 RP11-160H22.5 8.08 1.16e-14 1.95e-11 0.62 0.4 Systemic lupus erythematosus; chr1:174264172 chr1:174115300~174160004:- LIHC cis rs12744310 0.887 rs12045979 ENSG00000235358.1 RP11-399E6.1 8.07 1.17e-14 1.96e-11 0.54 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41343805 chr1:41242373~41284861:+ LIHC cis rs7044106 0.791 rs10985009 ENSG00000226752.6 PSMD5-AS1 8.07 1.18e-14 1.99e-11 0.4 0.4 Hip circumference adjusted for BMI; chr9:120730761 chr9:120824828~120854385:+ LIHC cis rs2929278 0.589 rs2411284 ENSG00000205771.5 CATSPER2P1 8.07 1.18e-14 1.99e-11 0.51 0.4 Schizophrenia; chr15:43746701 chr15:43726918~43747094:- LIHC cis rs12922040 1 rs2075516 ENSG00000263335.1 AF001548.5 8.07 1.19e-14 1.99e-11 0.47 0.4 Serum uric acid levels in response to allopurinol in gout; chr16:15775668 chr16:15726674~15732993:+ LIHC cis rs4356975 0.83 rs6422322 ENSG00000249956.3 RP11-790I12.2 8.07 1.19e-14 2e-11 0.45 0.4 Obesity-related traits; chr4:69055571 chr4:69408836~69423164:+ LIHC cis rs9399135 0.967 rs12527707 ENSG00000232876.1 CTA-212D2.2 -8.07 1.2e-14 2.02e-11 -0.44 -0.4 Red blood cell count; chr6:135003373 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs9389251 ENSG00000232876.1 CTA-212D2.2 -8.07 1.2e-14 2.02e-11 -0.44 -0.4 Red blood cell count; chr6:135004579 chr6:135055033~135060550:+ LIHC cis rs8062405 0.54 rs480400 ENSG00000259982.1 CDC37P1 8.07 1.2e-14 2.02e-11 0.43 0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28563294 chr16:28700294~28701540:- LIHC cis rs4356975 0.83 rs4235114 ENSG00000249956.3 RP11-790I12.2 8.07 1.2e-14 2.02e-11 0.45 0.4 Obesity-related traits; chr4:69056953 chr4:69408836~69423164:+ LIHC cis rs8072100 0.905 rs8077106 ENSG00000228782.6 CTD-2026D20.3 -8.07 1.21e-14 2.03e-11 -0.46 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47575925 chr17:47450568~47492492:- LIHC cis rs34779708 0.931 rs4934700 ENSG00000230534.5 RP11-297A16.2 8.07 1.22e-14 2.04e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35021914 chr10:35098006~35127020:- LIHC cis rs6991838 0.584 rs3765205 ENSG00000272010.1 CTD-3025N20.3 -8.07 1.22e-14 2.04e-11 -0.43 -0.4 Intelligence (multi-trait analysis); chr8:65605251 chr8:65591850~65592472:- LIHC cis rs1062177 1 rs1062177 ENSG00000213433.5 RPLP1P6 -8.07 1.23e-14 2.06e-11 -0.46 -0.4 Preschool internalizing problems; chr5:151805140 chr5:151765859~151766378:- LIHC cis rs17301013 0.606 rs12082461 ENSG00000227373.4 RP11-160H22.5 8.07 1.24e-14 2.07e-11 0.62 0.4 Systemic lupus erythematosus; chr1:174169876 chr1:174115300~174160004:- LIHC cis rs507080 0.922 rs4936433 ENSG00000255422.1 AP002954.4 8.07 1.24e-14 2.07e-11 0.47 0.4 Serum metabolite levels; chr11:118681711 chr11:118704607~118750263:+ LIHC cis rs1155848 0.892 rs28546558 ENSG00000227354.5 RBM26-AS1 8.06 1.26e-14 2.1e-11 0.73 0.4 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79516024 chr13:79406309~79424328:+ LIHC cis rs3096299 0.632 rs4399533 ENSG00000274627.1 RP11-104N10.2 8.06 1.27e-14 2.12e-11 0.41 0.4 Multiple myeloma (IgH translocation); chr16:89472974 chr16:89516797~89522217:+ LIHC cis rs2739330 0.76 rs5760095 ENSG00000250470.1 AP000351.3 8.06 1.29e-14 2.15e-11 0.49 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23976904~23977585:- LIHC cis rs8072100 0.846 rs4264433 ENSG00000228782.6 CTD-2026D20.3 -8.06 1.29e-14 2.15e-11 -0.46 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47659909 chr17:47450568~47492492:- LIHC cis rs17301013 0.606 rs724888 ENSG00000227373.4 RP11-160H22.5 8.05 1.34e-14 2.24e-11 0.63 0.4 Systemic lupus erythematosus; chr1:174180403 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs72711487 ENSG00000227373.4 RP11-160H22.5 8.05 1.34e-14 2.24e-11 0.63 0.4 Systemic lupus erythematosus; chr1:174189002 chr1:174115300~174160004:- LIHC cis rs2882667 0.858 rs7724108 ENSG00000253404.1 AC034243.1 -8.05 1.35e-14 2.24e-11 -0.53 -0.4 Age-related hearing impairment (SNP x SNP interaction); chr5:139075233 chr5:138744434~138753309:- LIHC cis rs34779708 0.931 rs2148482 ENSG00000230534.5 RP11-297A16.2 8.05 1.36e-14 2.26e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35059982 chr10:35098006~35127020:- LIHC cis rs4356975 0.932 rs4400061 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69071281 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs4446390 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69071328 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs7434389 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69071698 chr4:69408836~69423164:+ LIHC cis rs4356975 0.896 rs58496756 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69072070 chr4:69408836~69423164:+ LIHC cis rs4356975 0.599 rs7660019 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69072135 chr4:69408836~69423164:+ LIHC cis rs4356975 0.574 rs7660021 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69072143 chr4:69408836~69423164:+ LIHC cis rs4356975 0.549 rs7687692 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69072154 chr4:69408836~69423164:+ LIHC cis rs4356975 0.899 rs7687725 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69072229 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs4516791 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69072402 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs4694605 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69072777 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs4694607 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69073025 chr4:69408836~69423164:+ LIHC cis rs4356975 0.899 rs4410590 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69073381 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs4611997 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69073429 chr4:69408836~69423164:+ LIHC cis rs4356975 0.899 rs4412058 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69073715 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs7436912 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69074077 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs72852416 ENSG00000249956.3 RP11-790I12.2 8.05 1.36e-14 2.26e-11 0.44 0.4 Obesity-related traits; chr4:69075085 chr4:69408836~69423164:+ LIHC cis rs9399135 0.967 rs1041481 ENSG00000232876.1 CTA-212D2.2 -8.05 1.38e-14 2.29e-11 -0.45 -0.4 Red blood cell count; chr6:135013925 chr6:135055033~135060550:+ LIHC cis rs62229266 0.654 rs62230787 ENSG00000231106.2 LINC01436 8.05 1.38e-14 2.3e-11 0.45 0.4 Mitral valve prolapse; chr21:36004182 chr21:36005338~36007838:+ LIHC cis rs8062405 0.655 rs7184597 ENSG00000259982.1 CDC37P1 -8.05 1.39e-14 2.31e-11 -0.49 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28910488 chr16:28700294~28701540:- LIHC cis rs1150668 0.699 rs1736895 ENSG00000216901.1 AL022393.7 8.05 1.4e-14 2.32e-11 0.44 0.4 Pubertal anthropometrics; chr6:28252048 chr6:28176188~28176674:+ LIHC cis rs9399135 1 rs11754265 ENSG00000232876.1 CTA-212D2.2 -8.05 1.4e-14 2.33e-11 -0.44 -0.4 Red blood cell count; chr6:135035078 chr6:135055033~135060550:+ LIHC cis rs34779708 0.897 rs7897827 ENSG00000230534.5 RP11-297A16.2 8.05 1.41e-14 2.34e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35097309 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs12776390 ENSG00000230534.5 RP11-297A16.2 8.05 1.41e-14 2.34e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35102607 chr10:35098006~35127020:- LIHC cis rs12744310 1 rs34190295 ENSG00000235358.1 RP11-399E6.1 8.05 1.43e-14 2.37e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41300207 chr1:41242373~41284861:+ LIHC cis rs12744310 0.945 rs34961305 ENSG00000235358.1 RP11-399E6.1 8.05 1.43e-14 2.37e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41300272 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12030762 ENSG00000235358.1 RP11-399E6.1 8.05 1.43e-14 2.37e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41301089 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs35529558 ENSG00000235358.1 RP11-399E6.1 8.05 1.43e-14 2.37e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41301350 chr1:41242373~41284861:+ LIHC cis rs4356975 0.932 rs4400060 ENSG00000249956.3 RP11-790I12.2 8.05 1.43e-14 2.37e-11 0.44 0.4 Obesity-related traits; chr4:69071215 chr4:69408836~69423164:+ LIHC cis rs7727544 0.636 rs2631365 ENSG00000233006.5 AC034220.3 -8.04 1.44e-14 2.38e-11 -0.4 -0.4 Blood metabolite levels; chr5:132370257 chr5:132311285~132369916:- LIHC cis rs4718428 0.705 rs12536410 ENSG00000273142.1 RP11-458F8.4 -8.04 1.44e-14 2.39e-11 -0.4 -0.4 Corneal structure; chr7:66789303 chr7:66902857~66906297:+ LIHC cis rs4718428 0.705 rs68168107 ENSG00000273142.1 RP11-458F8.4 -8.04 1.44e-14 2.39e-11 -0.4 -0.4 Corneal structure; chr7:66790251 chr7:66902857~66906297:+ LIHC cis rs4356975 0.806 rs12648808 ENSG00000249956.3 RP11-790I12.2 8.04 1.45e-14 2.4e-11 0.44 0.4 Obesity-related traits; chr4:69075351 chr4:69408836~69423164:+ LIHC cis rs17301013 0.606 rs2860907 ENSG00000227373.4 RP11-160H22.5 8.04 1.46e-14 2.42e-11 0.61 0.4 Systemic lupus erythematosus; chr1:174203246 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs4607949 ENSG00000227373.4 RP11-160H22.5 8.04 1.46e-14 2.42e-11 0.61 0.4 Systemic lupus erythematosus; chr1:174212218 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs6668096 ENSG00000227373.4 RP11-160H22.5 8.04 1.46e-14 2.42e-11 0.59 0.4 Systemic lupus erythematosus; chr1:174537343 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs6692173 ENSG00000227373.4 RP11-160H22.5 8.04 1.46e-14 2.42e-11 0.59 0.4 Systemic lupus erythematosus; chr1:174544474 chr1:174115300~174160004:- LIHC cis rs9399135 0.967 rs13191501 ENSG00000232876.1 CTA-212D2.2 -8.04 1.46e-14 2.42e-11 -0.45 -0.4 Red blood cell count; chr6:135045742 chr6:135055033~135060550:+ LIHC cis rs4423214 0.84 rs1792229 ENSG00000254682.1 RP11-660L16.2 -8.04 1.47e-14 2.43e-11 -0.51 -0.4 Vitamin D levels; chr11:71468349 chr11:71448674~71452157:+ LIHC cis rs3096299 0.692 rs4785565 ENSG00000274627.1 RP11-104N10.2 8.04 1.47e-14 2.43e-11 0.41 0.4 Multiple myeloma (IgH translocation); chr16:89449351 chr16:89516797~89522217:+ LIHC cis rs1891275 0.515 rs10881945 ENSG00000228701.1 TNKS2-AS1 -8.04 1.48e-14 2.44e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91663826 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs2421629 ENSG00000228701.1 TNKS2-AS1 -8.04 1.48e-14 2.44e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91664018 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs4933692 ENSG00000228701.1 TNKS2-AS1 -8.04 1.48e-14 2.44e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91664876 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs7900863 ENSG00000228701.1 TNKS2-AS1 -8.04 1.48e-14 2.44e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91665737 chr10:91782839~91798291:- LIHC cis rs1891275 0.588 rs6583782 ENSG00000228701.1 TNKS2-AS1 -8.04 1.48e-14 2.44e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91666022 chr10:91782839~91798291:- LIHC cis rs1891275 0.576 rs1891272 ENSG00000228701.1 TNKS2-AS1 -8.04 1.48e-14 2.44e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91666306 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs1891271 ENSG00000228701.1 TNKS2-AS1 -8.04 1.48e-14 2.44e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91666566 chr10:91782839~91798291:- LIHC cis rs34779708 0.931 rs34304999 ENSG00000230534.5 RP11-297A16.2 8.04 1.49e-14 2.46e-11 0.5 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35076777 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs12773647 ENSG00000230534.5 RP11-297A16.2 8.04 1.49e-14 2.46e-11 0.5 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35151399 chr10:35098006~35127020:- LIHC cis rs4356975 0.83 rs10012215 ENSG00000249956.3 RP11-790I12.2 8.04 1.49e-14 2.46e-11 0.45 0.4 Obesity-related traits; chr4:69048448 chr4:69408836~69423164:+ LIHC cis rs4356975 0.83 rs10012240 ENSG00000249956.3 RP11-790I12.2 8.04 1.49e-14 2.46e-11 0.45 0.4 Obesity-related traits; chr4:69048519 chr4:69408836~69423164:+ LIHC cis rs7208859 0.673 rs1347360 ENSG00000263531.1 RP13-753N3.1 8.04 1.49e-14 2.47e-11 0.69 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587514 chr17:30863921~30864940:- LIHC cis rs1891275 0.54 rs10732773 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91656468 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs2421624 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91656659 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs2421625 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91656744 chr10:91782839~91798291:- LIHC cis rs1891275 0.576 rs7900117 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91657530 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs4933213 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91657947 chr10:91782839~91798291:- LIHC cis rs1891275 0.506 rs4933214 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91658004 chr10:91782839~91798291:- LIHC cis rs1891275 0.515 rs7358148 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91658775 chr10:91782839~91798291:- LIHC cis rs1891275 0.601 rs7358034 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91659007 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs7908547 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91659230 chr10:91782839~91798291:- LIHC cis rs1891275 0.515 rs7908980 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91659545 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs4933690 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91659810 chr10:91782839~91798291:- LIHC cis rs1891275 0.576 rs4933216 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91659825 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs4933691 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91660200 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs2421626 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91661177 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs2421627 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91662226 chr10:91782839~91798291:- LIHC cis rs1891275 0.551 rs2421628 ENSG00000228701.1 TNKS2-AS1 -8.04 1.5e-14 2.47e-11 -0.59 -0.4 Intelligence (multi-trait analysis); chr10:91662412 chr10:91782839~91798291:- LIHC cis rs7847628 0.765 rs7026635 ENSG00000226752.6 PSMD5-AS1 8.04 1.5e-14 2.48e-11 0.43 0.4 Birth weight; chr9:120787749 chr9:120824828~120854385:+ LIHC cis rs7727544 0.735 rs4705933 ENSG00000233006.5 AC034220.3 8.04 1.51e-14 2.49e-11 0.4 0.4 Blood metabolite levels; chr5:132342719 chr5:132311285~132369916:- LIHC cis rs7727544 0.735 rs272867 ENSG00000233006.5 AC034220.3 8.04 1.51e-14 2.49e-11 0.4 0.4 Blood metabolite levels; chr5:132345364 chr5:132311285~132369916:- LIHC cis rs2929278 0.617 rs3087657 ENSG00000205771.5 CATSPER2P1 -8.04 1.52e-14 2.51e-11 -0.47 -0.4 Schizophrenia; chr15:43771661 chr15:43726918~43747094:- LIHC cis rs6991838 0.584 rs1053087 ENSG00000272010.1 CTD-3025N20.3 -8.04 1.52e-14 2.51e-11 -0.43 -0.4 Intelligence (multi-trait analysis); chr8:65603630 chr8:65591850~65592472:- LIHC cis rs9399135 0.967 rs9389253 ENSG00000232876.1 CTA-212D2.2 -8.04 1.53e-14 2.52e-11 -0.45 -0.4 Red blood cell count; chr6:135008617 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs9389254 ENSG00000232876.1 CTA-212D2.2 -8.04 1.53e-14 2.52e-11 -0.45 -0.4 Red blood cell count; chr6:135009571 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs1014020 ENSG00000232876.1 CTA-212D2.2 -8.03 1.54e-14 2.53e-11 -0.45 -0.4 Red blood cell count; chr6:135013288 chr6:135055033~135060550:+ LIHC cis rs8072100 0.935 rs12150231 ENSG00000228782.6 CTD-2026D20.3 -8.03 1.54e-14 2.54e-11 -0.46 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47639725 chr17:47450568~47492492:- LIHC cis rs4356975 0.795 rs4694599 ENSG00000249956.3 RP11-790I12.2 8.03 1.55e-14 2.55e-11 0.44 0.4 Obesity-related traits; chr4:69070858 chr4:69408836~69423164:+ LIHC cis rs17301013 0.606 rs12064743 ENSG00000227373.4 RP11-160H22.5 8.03 1.56e-14 2.56e-11 0.6 0.4 Systemic lupus erythematosus; chr1:174496646 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs7536102 ENSG00000227373.4 RP11-160H22.5 8.03 1.56e-14 2.56e-11 0.6 0.4 Systemic lupus erythematosus; chr1:174496801 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs7522253 ENSG00000227373.4 RP11-160H22.5 8.03 1.56e-14 2.56e-11 0.6 0.4 Systemic lupus erythematosus; chr1:174496980 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs4652500 ENSG00000227373.4 RP11-160H22.5 8.03 1.56e-14 2.56e-11 0.6 0.4 Systemic lupus erythematosus; chr1:174500656 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12071794 ENSG00000227373.4 RP11-160H22.5 8.03 1.56e-14 2.56e-11 0.6 0.4 Systemic lupus erythematosus; chr1:174500767 chr1:174115300~174160004:- LIHC cis rs17301013 0.556 rs7535845 ENSG00000227373.4 RP11-160H22.5 8.03 1.56e-14 2.56e-11 0.6 0.4 Systemic lupus erythematosus; chr1:174502672 chr1:174115300~174160004:- LIHC cis rs17301013 0.581 rs1591944 ENSG00000227373.4 RP11-160H22.5 8.03 1.57e-14 2.59e-11 0.63 0.4 Systemic lupus erythematosus; chr1:174204917 chr1:174115300~174160004:- LIHC cis rs55665837 1 rs2305305 ENSG00000251991.1 RNU7-49P 8.03 1.58e-14 2.6e-11 0.42 0.4 Vitamin D levels; chr11:14519396 chr11:14478892~14478953:+ LIHC cis rs4356975 0.932 rs60814050 ENSG00000249956.3 RP11-790I12.2 8.03 1.58e-14 2.6e-11 0.44 0.4 Obesity-related traits; chr4:69063770 chr4:69408836~69423164:+ LIHC cis rs4423214 0.798 rs12224205 ENSG00000254682.1 RP11-660L16.2 -8.03 1.59e-14 2.61e-11 -0.51 -0.4 Vitamin D levels; chr11:71469946 chr11:71448674~71452157:+ LIHC cis rs34779708 0.931 rs11592404 ENSG00000230534.5 RP11-297A16.2 8.03 1.61e-14 2.64e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:34984548 chr10:35098006~35127020:- LIHC cis rs12744310 0.887 rs16828067 ENSG00000235358.1 RP11-399E6.1 8.03 1.61e-14 2.65e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41317880 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs16828071 ENSG00000235358.1 RP11-399E6.1 8.03 1.61e-14 2.65e-11 0.53 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41317931 chr1:41242373~41284861:+ LIHC cis rs8072100 0.754 rs8081717 ENSG00000228782.6 CTD-2026D20.3 -8.03 1.61e-14 2.65e-11 -0.46 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47576555 chr17:47450568~47492492:- LIHC cis rs34779708 0.966 rs2045918 ENSG00000230534.5 RP11-297A16.2 8.03 1.62e-14 2.66e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35129589 chr10:35098006~35127020:- LIHC cis rs9399135 0.967 rs4896121 ENSG00000232876.1 CTA-212D2.2 -8.03 1.62e-14 2.66e-11 -0.45 -0.4 Red blood cell count; chr6:134972507 chr6:135055033~135060550:+ LIHC cis rs7044106 0.791 rs7043969 ENSG00000226752.6 PSMD5-AS1 -8.03 1.62e-14 2.67e-11 -0.41 -0.4 Hip circumference adjusted for BMI; chr9:120731711 chr9:120824828~120854385:+ LIHC cis rs7657257 1 rs11931532 ENSG00000214846.4 RP11-115L11.1 8.03 1.63e-14 2.67e-11 0.63 0.4 Blood protein levels; chr4:15724143 chr4:15730962~15731627:- LIHC cis rs12744310 0.943 rs35502198 ENSG00000235358.1 RP11-399E6.1 8.03 1.63e-14 2.67e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41302869 chr1:41242373~41284861:+ LIHC cis rs12744310 0.943 rs34862272 ENSG00000235358.1 RP11-399E6.1 8.03 1.63e-14 2.67e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41302981 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs34796305 ENSG00000235358.1 RP11-399E6.1 8.03 1.63e-14 2.67e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41303373 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs55707527 ENSG00000235358.1 RP11-399E6.1 8.03 1.63e-14 2.67e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41303441 chr1:41242373~41284861:+ LIHC cis rs12744310 0.943 rs35972058 ENSG00000235358.1 RP11-399E6.1 8.03 1.63e-14 2.67e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41303474 chr1:41242373~41284861:+ LIHC cis rs12744310 0.943 rs12032906 ENSG00000235358.1 RP11-399E6.1 8.03 1.63e-14 2.67e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41303486 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs34315814 ENSG00000235358.1 RP11-399E6.1 8.03 1.63e-14 2.67e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41303500 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12032191 ENSG00000235358.1 RP11-399E6.1 8.03 1.63e-14 2.67e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41303546 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12032215 ENSG00000235358.1 RP11-399E6.1 8.03 1.63e-14 2.67e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41303662 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12035353 ENSG00000235358.1 RP11-399E6.1 8.03 1.63e-14 2.67e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41303665 chr1:41242373~41284861:+ LIHC cis rs2739330 0.731 rs4822450 ENSG00000250470.1 AP000351.3 8.03 1.63e-14 2.68e-11 0.49 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23976904~23977585:- LIHC cis rs7044106 0.791 rs735109 ENSG00000226752.6 PSMD5-AS1 -8.03 1.64e-14 2.68e-11 -0.41 -0.4 Hip circumference adjusted for BMI; chr9:120726601 chr9:120824828~120854385:+ LIHC cis rs1062177 1 rs2964612 ENSG00000213433.5 RPLP1P6 -8.02 1.66e-14 2.72e-11 -0.46 -0.4 Preschool internalizing problems; chr5:151819189 chr5:151765859~151766378:- LIHC cis rs17301013 0.606 rs6425277 ENSG00000227373.4 RP11-160H22.5 8.02 1.66e-14 2.72e-11 0.61 0.4 Systemic lupus erythematosus; chr1:174296153 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs12074276 ENSG00000227373.4 RP11-160H22.5 8.02 1.66e-14 2.72e-11 0.61 0.4 Systemic lupus erythematosus; chr1:174302167 chr1:174115300~174160004:- LIHC cis rs1577917 0.74 rs2475792 ENSG00000234155.1 RP11-30P6.6 -8.02 1.67e-14 2.73e-11 -0.47 -0.4 Response to antipsychotic treatment; chr6:85682384 chr6:85387219~85390186:- LIHC cis rs9399135 0.967 rs7741626 ENSG00000232876.1 CTA-212D2.2 -8.02 1.69e-14 2.76e-11 -0.45 -0.4 Red blood cell count; chr6:134993044 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs4895439 ENSG00000232876.1 CTA-212D2.2 -8.02 1.69e-14 2.76e-11 -0.45 -0.4 Red blood cell count; chr6:134997716 chr6:135055033~135060550:+ LIHC cis rs9399135 0.935 rs11754504 ENSG00000232876.1 CTA-212D2.2 -8.02 1.69e-14 2.76e-11 -0.45 -0.4 Red blood cell count; chr6:135000371 chr6:135055033~135060550:+ LIHC cis rs34779708 0.966 rs10827493 ENSG00000230534.5 RP11-297A16.2 8.02 1.7e-14 2.78e-11 0.5 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35166048 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs12260130 ENSG00000230534.5 RP11-297A16.2 8.02 1.7e-14 2.78e-11 0.5 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35178743 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs4934539 ENSG00000230534.5 RP11-297A16.2 8.02 1.7e-14 2.78e-11 0.5 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35183271 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs1478463 ENSG00000230534.5 RP11-297A16.2 8.02 1.7e-14 2.78e-11 0.5 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35184107 chr10:35098006~35127020:- LIHC cis rs1062177 0.95 rs892005 ENSG00000213433.5 RPLP1P6 -8.02 1.7e-14 2.79e-11 -0.45 -0.4 Preschool internalizing problems; chr5:151801060 chr5:151765859~151766378:- LIHC cis rs73086581 0.787 rs73084505 ENSG00000229539.1 RP11-119B16.2 8.02 1.71e-14 2.8e-11 0.73 0.4 Response to antidepressants in depression; chr20:3876227 chr20:3888239~3888868:- LIHC cis rs12744310 1 rs35812095 ENSG00000235358.1 RP11-399E6.1 8.02 1.72e-14 2.81e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41300402 chr1:41242373~41284861:+ LIHC cis rs17301013 0.606 rs10912740 ENSG00000227373.4 RP11-160H22.5 8.02 1.72e-14 2.81e-11 0.62 0.4 Systemic lupus erythematosus; chr1:174180224 chr1:174115300~174160004:- LIHC cis rs4423214 0.84 rs1792224 ENSG00000254682.1 RP11-660L16.2 -8.02 1.74e-14 2.84e-11 -0.51 -0.4 Vitamin D levels; chr11:71465095 chr11:71448674~71452157:+ LIHC cis rs4423214 0.84 rs1792226 ENSG00000254682.1 RP11-660L16.2 -8.02 1.74e-14 2.84e-11 -0.51 -0.4 Vitamin D levels; chr11:71465528 chr11:71448674~71452157:+ LIHC cis rs4423214 0.84 rs1790344 ENSG00000254682.1 RP11-660L16.2 -8.02 1.74e-14 2.84e-11 -0.51 -0.4 Vitamin D levels; chr11:71465851 chr11:71448674~71452157:+ LIHC cis rs4423214 0.84 rs1790343 ENSG00000254682.1 RP11-660L16.2 -8.02 1.74e-14 2.84e-11 -0.51 -0.4 Vitamin D levels; chr11:71466161 chr11:71448674~71452157:+ LIHC cis rs4423214 0.84 rs1792227 ENSG00000254682.1 RP11-660L16.2 -8.02 1.74e-14 2.84e-11 -0.51 -0.4 Vitamin D levels; chr11:71466366 chr11:71448674~71452157:+ LIHC cis rs4423214 0.84 rs1790341 ENSG00000254682.1 RP11-660L16.2 -8.02 1.74e-14 2.84e-11 -0.51 -0.4 Vitamin D levels; chr11:71466532 chr11:71448674~71452157:+ LIHC cis rs4423214 0.84 rs1540127 ENSG00000254682.1 RP11-660L16.2 -8.02 1.74e-14 2.84e-11 -0.51 -0.4 Vitamin D levels; chr11:71467992 chr11:71448674~71452157:+ LIHC cis rs4423214 0.84 rs1792235 ENSG00000254682.1 RP11-660L16.2 -8.02 1.74e-14 2.84e-11 -0.51 -0.4 Vitamin D levels; chr11:71470427 chr11:71448674~71452157:+ LIHC cis rs17301013 0.507 rs10912757 ENSG00000227373.4 RP11-160H22.5 8.01 1.8e-14 2.94e-11 0.66 0.4 Systemic lupus erythematosus; chr1:174299064 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10912758 ENSG00000227373.4 RP11-160H22.5 8.01 1.8e-14 2.94e-11 0.66 0.4 Systemic lupus erythematosus; chr1:174300822 chr1:174115300~174160004:- LIHC cis rs7208859 0.673 rs7211776 ENSG00000263531.1 RP13-753N3.1 8.01 1.81e-14 2.94e-11 0.69 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793178 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9912122 ENSG00000263531.1 RP13-753N3.1 8.01 1.81e-14 2.94e-11 0.69 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813698 chr17:30863921~30864940:- LIHC cis rs2283792 0.633 rs240068 ENSG00000224086.5 LL22NC03-86G7.1 -8.01 1.81e-14 2.95e-11 -0.38 -0.4 Multiple sclerosis; chr22:21936031 chr22:21938293~21977632:+ LIHC cis rs150992 0.517 rs326464 ENSG00000248489.1 CTD-2007H13.3 8.01 1.82e-14 2.95e-11 0.57 0.4 Body mass index; chr5:98906499 chr5:98929171~98995013:+ LIHC cis rs1501911 0.53 rs162149 ENSG00000248489.1 CTD-2007H13.3 8.01 1.82e-14 2.95e-11 0.57 0.4 Lung function (FEV1/FVC); chr5:98913851 chr5:98929171~98995013:+ LIHC cis rs1501911 0.53 rs162150 ENSG00000248489.1 CTD-2007H13.3 8.01 1.82e-14 2.95e-11 0.57 0.4 Lung function (FEV1/FVC); chr5:98913909 chr5:98929171~98995013:+ LIHC cis rs17301013 0.606 rs10912798 ENSG00000227373.4 RP11-160H22.5 8.01 1.86e-14 3.02e-11 0.6 0.4 Systemic lupus erythematosus; chr1:174511420 chr1:174115300~174160004:- LIHC cis rs17301013 0.581 rs10912799 ENSG00000227373.4 RP11-160H22.5 8.01 1.86e-14 3.02e-11 0.6 0.4 Systemic lupus erythematosus; chr1:174511422 chr1:174115300~174160004:- LIHC cis rs17301013 0.556 rs10912800 ENSG00000227373.4 RP11-160H22.5 8.01 1.86e-14 3.02e-11 0.6 0.4 Systemic lupus erythematosus; chr1:174513939 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs56213002 ENSG00000227373.4 RP11-160H22.5 8.01 1.86e-14 3.02e-11 0.6 0.4 Systemic lupus erythematosus; chr1:174516512 chr1:174115300~174160004:- LIHC cis rs17301013 0.541 rs10798319 ENSG00000227373.4 RP11-160H22.5 8.01 1.86e-14 3.02e-11 0.6 0.4 Systemic lupus erythematosus; chr1:174516983 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs9730220 ENSG00000227373.4 RP11-160H22.5 8.01 1.86e-14 3.02e-11 0.6 0.4 Systemic lupus erythematosus; chr1:174519092 chr1:174115300~174160004:- LIHC cis rs4423214 0.84 rs1619577 ENSG00000254682.1 RP11-660L16.2 -8.01 1.86e-14 3.03e-11 -0.51 -0.4 Vitamin D levels; chr11:71470439 chr11:71448674~71452157:+ LIHC cis rs1972460 0.506 rs62012050 ENSG00000278603.1 RP13-608F4.5 8.01 1.88e-14 3.05e-11 0.66 0.4 Intelligence (multi-trait analysis); chr15:82239933 chr15:82472203~82472426:+ LIHC cis rs2455601 0.786 rs10279 ENSG00000254860.4 TMEM9B-AS1 8 1.89e-14 3.07e-11 0.47 0.4 Schizophrenia; chr11:8947762 chr11:8964675~8977527:+ LIHC cis rs9399135 0.967 rs4388304 ENSG00000232876.1 CTA-212D2.2 -8 1.89e-14 3.07e-11 -0.45 -0.4 Red blood cell count; chr6:134988459 chr6:135055033~135060550:+ LIHC cis rs34779708 0.966 rs10827487 ENSG00000230534.5 RP11-297A16.2 8 1.93e-14 3.13e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35117950 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs11010101 ENSG00000230534.5 RP11-297A16.2 8 1.93e-14 3.13e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35122117 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs11010102 ENSG00000230534.5 RP11-297A16.2 8 1.93e-14 3.13e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35122138 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs12765038 ENSG00000230534.5 RP11-297A16.2 8 1.93e-14 3.13e-11 0.51 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35127585 chr10:35098006~35127020:- LIHC cis rs7727544 0.735 rs274559 ENSG00000233006.5 AC034220.3 -8 1.94e-14 3.15e-11 -0.4 -0.4 Blood metabolite levels; chr5:132384378 chr5:132311285~132369916:- LIHC cis rs9399135 0.967 rs13218642 ENSG00000232876.1 CTA-212D2.2 -8 1.95e-14 3.15e-11 -0.44 -0.4 Red blood cell count; chr6:134988802 chr6:135055033~135060550:+ LIHC cis rs1062177 0.826 rs1549920 ENSG00000213433.5 RPLP1P6 -8 1.96e-14 3.17e-11 -0.46 -0.4 Preschool internalizing problems; chr5:151761283 chr5:151765859~151766378:- LIHC cis rs3096299 0.658 rs4785679 ENSG00000274627.1 RP11-104N10.2 8 1.98e-14 3.2e-11 0.4 0.4 Multiple myeloma (IgH translocation); chr16:89499705 chr16:89516797~89522217:+ LIHC cis rs1062177 1 rs72802204 ENSG00000213433.5 RPLP1P6 -8 2e-14 3.24e-11 -0.45 -0.4 Preschool internalizing problems; chr5:151803622 chr5:151765859~151766378:- LIHC cis rs7208859 0.673 rs216409 ENSG00000263531.1 RP13-753N3.1 -8 2.01e-14 3.26e-11 -0.66 -0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30579251 chr17:30863921~30864940:- LIHC cis rs17301013 0.507 rs1121537 ENSG00000227373.4 RP11-160H22.5 7.99 2.02e-14 3.27e-11 0.64 0.4 Systemic lupus erythematosus; chr1:174307568 chr1:174115300~174160004:- LIHC cis rs8072100 0.745 rs7214410 ENSG00000228782.6 CTD-2026D20.3 7.99 2.04e-14 3.29e-11 0.45 0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47345262 chr17:47450568~47492492:- LIHC cis rs62229266 0.659 rs2026259 ENSG00000231106.2 LINC01436 7.99 2.04e-14 3.3e-11 0.44 0.4 Mitral valve prolapse; chr21:36058329 chr21:36005338~36007838:+ LIHC cis rs34779708 0.931 rs4934524 ENSG00000230534.5 RP11-297A16.2 7.99 2.05e-14 3.31e-11 0.5 0.4 Inflammatory bowel disease;Crohn's disease; chr10:34981993 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs4934693 ENSG00000230534.5 RP11-297A16.2 7.99 2.05e-14 3.31e-11 0.5 0.4 Inflammatory bowel disease;Crohn's disease; chr10:34982916 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs66887762 ENSG00000230534.5 RP11-297A16.2 7.99 2.06e-14 3.33e-11 0.5 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35041649 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs12775548 ENSG00000230534.5 RP11-297A16.2 7.99 2.08e-14 3.36e-11 0.5 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35190576 chr10:35098006~35127020:- LIHC cis rs34779708 0.658 rs4934715 ENSG00000230534.5 RP11-297A16.2 7.99 2.09e-14 3.38e-11 0.5 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35076064 chr10:35098006~35127020:- LIHC cis rs4356975 0.899 rs72501227 ENSG00000249956.3 RP11-790I12.2 7.99 2.09e-14 3.38e-11 0.44 0.4 Obesity-related traits; chr4:69069866 chr4:69408836~69423164:+ LIHC cis rs7727544 0.709 rs272852 ENSG00000233006.5 AC034220.3 7.99 2.13e-14 3.44e-11 0.39 0.4 Blood metabolite levels; chr5:132353074 chr5:132311285~132369916:- LIHC cis rs7727544 0.661 rs273900 ENSG00000233006.5 AC034220.3 7.99 2.13e-14 3.44e-11 0.39 0.4 Blood metabolite levels; chr5:132358913 chr5:132311285~132369916:- LIHC cis rs1577917 0.518 rs2475787 ENSG00000234155.1 RP11-30P6.6 -7.99 2.13e-14 3.44e-11 -0.45 -0.4 Response to antipsychotic treatment; chr6:85705518 chr6:85387219~85390186:- LIHC cis rs34779708 0.931 rs2384283 ENSG00000230534.5 RP11-297A16.2 7.99 2.14e-14 3.45e-11 0.5 0.4 Inflammatory bowel disease;Crohn's disease; chr10:35037861 chr10:35098006~35127020:- LIHC cis rs9399135 0.636 rs7749106 ENSG00000232876.1 CTA-212D2.2 -7.99 2.15e-14 3.47e-11 -0.45 -0.4 Red blood cell count; chr6:134947004 chr6:135055033~135060550:+ LIHC cis rs9399135 0.869 rs9402675 ENSG00000232876.1 CTA-212D2.2 -7.99 2.15e-14 3.47e-11 -0.44 -0.4 Red blood cell count; chr6:135004656 chr6:135055033~135060550:+ LIHC cis rs8072100 0.967 rs4580230 ENSG00000228782.6 CTD-2026D20.3 7.99 2.16e-14 3.47e-11 0.45 0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47661495 chr17:47450568~47492492:- LIHC cis rs4356975 0.932 rs4694604 ENSG00000249956.3 RP11-790I12.2 7.99 2.16e-14 3.47e-11 0.44 0.4 Obesity-related traits; chr4:69072745 chr4:69408836~69423164:+ LIHC cis rs9399135 0.636 rs4646871 ENSG00000232876.1 CTA-212D2.2 7.98 2.16e-14 3.49e-11 0.45 0.4 Red blood cell count; chr6:134944479 chr6:135055033~135060550:+ LIHC cis rs11723261 0.582 rs4582104 ENSG00000275426.1 CH17-262A2.1 7.98 2.17e-14 3.5e-11 0.46 0.4 Immune response to smallpox vaccine (IL-6); chr4:143160 chr4:149738~150317:+ LIHC cis rs12744310 1 rs12041533 ENSG00000235358.1 RP11-399E6.1 7.98 2.22e-14 3.56e-11 0.52 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41302599 chr1:41242373~41284861:+ LIHC cis rs9543976 0.623 rs7317250 ENSG00000261553.4 RP11-29G8.3 7.98 2.22e-14 3.58e-11 0.5 0.4 Diabetic retinopathy; chr13:75593005 chr13:75549773~75807120:+ LIHC cis rs11723261 0.582 rs6830247 ENSG00000275426.1 CH17-262A2.1 7.98 2.25e-14 3.62e-11 0.48 0.4 Immune response to smallpox vaccine (IL-6); chr4:156885 chr4:149738~150317:+ LIHC cis rs1062177 1 rs973529 ENSG00000213433.5 RPLP1P6 -7.98 2.25e-14 3.62e-11 -0.45 -0.4 Preschool internalizing problems; chr5:151808597 chr5:151765859~151766378:- LIHC cis rs17826219 0.568 rs59858012 ENSG00000263531.1 RP13-753N3.1 7.98 2.27e-14 3.64e-11 0.74 0.4 Body mass index; chr17:30751564 chr17:30863921~30864940:- LIHC cis rs7085104 0.7 rs10786712 ENSG00000236937.2 PTGES3P4 -7.97 2.33e-14 3.73e-11 -0.47 -0.4 Immature fraction of reticulocytes;Schizophrenia; chr10:102836639 chr10:102845595~102845950:+ LIHC cis rs7684253 0.565 rs7697176 ENSG00000269949.1 RP11-738E22.3 -7.97 2.33e-14 3.74e-11 -0.48 -0.4 Migraine; chr4:56956882 chr4:56960927~56961373:- LIHC cis rs7684253 0.565 rs7680140 ENSG00000269949.1 RP11-738E22.3 -7.97 2.33e-14 3.74e-11 -0.48 -0.4 Migraine; chr4:56957291 chr4:56960927~56961373:- LIHC cis rs12439619 1 rs35152457 ENSG00000278603.1 RP13-608F4.5 7.97 2.33e-14 3.74e-11 0.64 0.4 Intelligence (multi-trait analysis); chr15:82254207 chr15:82472203~82472426:+ LIHC cis rs4356975 0.932 rs7662632 ENSG00000249956.3 RP11-790I12.2 7.97 2.34e-14 3.75e-11 0.44 0.4 Obesity-related traits; chr4:69062256 chr4:69408836~69423164:+ LIHC cis rs2929278 0.617 rs663214 ENSG00000205771.5 CATSPER2P1 7.97 2.34e-14 3.75e-11 0.48 0.4 Schizophrenia; chr15:43821584 chr15:43726918~43747094:- LIHC cis rs2455601 0.744 rs7938995 ENSG00000254860.4 TMEM9B-AS1 7.97 2.37e-14 3.79e-11 0.47 0.4 Schizophrenia; chr11:8954128 chr11:8964675~8977527:+ LIHC cis rs11723261 0.582 rs11248005 ENSG00000275426.1 CH17-262A2.1 7.97 2.38e-14 3.82e-11 0.48 0.4 Immune response to smallpox vaccine (IL-6); chr4:172826 chr4:149738~150317:+ LIHC cis rs11723261 0.582 rs11733927 ENSG00000275426.1 CH17-262A2.1 7.97 2.38e-14 3.82e-11 0.48 0.4 Immune response to smallpox vaccine (IL-6); chr4:173039 chr4:149738~150317:+ LIHC cis rs7208859 0.573 rs216442 ENSG00000263531.1 RP13-753N3.1 7.97 2.4e-14 3.84e-11 0.69 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604179 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs216445 ENSG00000263531.1 RP13-753N3.1 7.97 2.4e-14 3.84e-11 0.69 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30606558 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs216446 ENSG00000263531.1 RP13-753N3.1 7.97 2.4e-14 3.84e-11 0.69 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30606700 chr17:30863921~30864940:- LIHC cis rs17301013 0.606 rs7547766 ENSG00000227373.4 RP11-160H22.5 7.97 2.41e-14 3.85e-11 0.63 0.4 Systemic lupus erythematosus; chr1:174180977 chr1:174115300~174160004:- LIHC cis rs4423214 0.84 rs1792231 ENSG00000254682.1 RP11-660L16.2 -7.97 2.41e-14 3.85e-11 -0.51 -0.4 Vitamin D levels; chr11:71471635 chr11:71448674~71452157:+ LIHC cis rs2739330 0.652 rs2000469 ENSG00000225282.1 AP000350.6 7.97 2.43e-14 3.88e-11 0.5 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23926900~23929574:+ LIHC cis rs8072100 1 rs4794048 ENSG00000228782.6 CTD-2026D20.3 7.97 2.44e-14 3.91e-11 0.45 0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47685707 chr17:47450568~47492492:- LIHC cis rs1062177 0.826 rs2053063 ENSG00000213433.5 RPLP1P6 -7.97 2.46e-14 3.93e-11 -0.45 -0.4 Preschool internalizing problems; chr5:151787203 chr5:151765859~151766378:- LIHC cis rs1062177 1 rs2964571 ENSG00000213433.5 RPLP1P6 -7.97 2.46e-14 3.93e-11 -0.45 -0.4 Preschool internalizing problems; chr5:151791695 chr5:151765859~151766378:- LIHC cis rs1062177 1 rs2915869 ENSG00000213433.5 RPLP1P6 -7.97 2.46e-14 3.93e-11 -0.45 -0.4 Preschool internalizing problems; chr5:151791948 chr5:151765859~151766378:- LIHC cis rs1062177 1 rs2347596 ENSG00000213433.5 RPLP1P6 -7.97 2.46e-14 3.93e-11 -0.45 -0.4 Preschool internalizing problems; chr5:151799638 chr5:151765859~151766378:- LIHC cis rs3096299 0.685 rs12446145 ENSG00000274627.1 RP11-104N10.2 7.97 2.47e-14 3.95e-11 0.41 0.4 Multiple myeloma (IgH translocation); chr16:89476287 chr16:89516797~89522217:+ LIHC cis rs1062177 0.826 rs2915873 ENSG00000213433.5 RPLP1P6 -7.96 2.48e-14 3.96e-11 -0.45 -0.4 Preschool internalizing problems; chr5:151777097 chr5:151765859~151766378:- LIHC cis rs9399135 0.935 rs4273704 ENSG00000232876.1 CTA-212D2.2 -7.96 2.49e-14 3.97e-11 -0.44 -0.4 Red blood cell count; chr6:134976382 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs4637662 ENSG00000232876.1 CTA-212D2.2 -7.96 2.49e-14 3.97e-11 -0.44 -0.4 Red blood cell count; chr6:134977020 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs4895436 ENSG00000232876.1 CTA-212D2.2 -7.96 2.5e-14 4e-11 -0.44 -0.4 Red blood cell count; chr6:134973863 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs4896122 ENSG00000232876.1 CTA-212D2.2 -7.96 2.5e-14 4e-11 -0.44 -0.4 Red blood cell count; chr6:134973943 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs9376075 ENSG00000232876.1 CTA-212D2.2 -7.96 2.5e-14 4e-11 -0.44 -0.4 Red blood cell count; chr6:134975825 chr6:135055033~135060550:+ LIHC cis rs7208859 0.673 rs11652370 ENSG00000263531.1 RP13-753N3.1 7.96 2.56e-14 4.08e-11 0.68 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770205 chr17:30863921~30864940:- LIHC cis rs2739330 0.828 rs4820572 ENSG00000250470.1 AP000351.3 7.96 2.57e-14 4.1e-11 0.47 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23976904~23977585:- LIHC cis rs6504950 0.925 rs2787497 ENSG00000275710.1 RP11-257O5.4 -7.96 2.57e-14 4.1e-11 -0.59 -0.4 Breast cancer; chr17:55098850 chr17:54964474~54964679:+ LIHC cis rs6504950 0.925 rs181727 ENSG00000275710.1 RP11-257O5.4 7.96 2.57e-14 4.1e-11 0.59 0.4 Breast cancer; chr17:55113634 chr17:54964474~54964679:+ LIHC cis rs6504950 0.925 rs244358 ENSG00000275710.1 RP11-257O5.4 7.96 2.57e-14 4.1e-11 0.59 0.4 Breast cancer; chr17:55114870 chr17:54964474~54964679:+ LIHC cis rs8072100 0.967 rs2317826 ENSG00000228782.6 CTD-2026D20.3 7.96 2.59e-14 4.12e-11 0.45 0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47653533 chr17:47450568~47492492:- LIHC cis rs1577917 0.545 rs7755958 ENSG00000203875.9 SNHG5 7.96 2.6e-14 4.14e-11 0.42 0.4 Response to antipsychotic treatment; chr6:85778793 chr6:85660950~85678736:- LIHC cis rs4356975 0.932 rs7654272 ENSG00000249956.3 RP11-790I12.2 7.96 2.61e-14 4.15e-11 0.44 0.4 Obesity-related traits; chr4:69074144 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs6600867 ENSG00000249956.3 RP11-790I12.2 7.96 2.61e-14 4.15e-11 0.44 0.4 Obesity-related traits; chr4:69074157 chr4:69408836~69423164:+ LIHC cis rs4853012 0.941 rs78128123 ENSG00000257800.1 FNBP1P1 7.96 2.63e-14 4.2e-11 0.46 0.4 Gestational age at birth (maternal effect); chr2:74120398 chr2:74120680~74123218:+ LIHC cis rs12594515 0.694 rs2068295 ENSG00000273972.1 CTD-2306A12.1 -7.95 2.69e-14 4.28e-11 -0.47 -0.4 Weight;Waist circumference; chr15:45693348 chr15:45702640~45703183:+ LIHC cis rs2442825 0.693 rs2728924 ENSG00000206573.7 THUMPD3-AS1 7.95 2.71e-14 4.31e-11 0.35 0.4 Cerebrospinal fluid clusterin levels; chr3:9381294 chr3:9349689~9398579:- LIHC cis rs12744310 1 rs12034357 ENSG00000235358.1 RP11-399E6.1 7.95 2.71e-14 4.31e-11 0.51 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41302557 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs7553908 ENSG00000235358.1 RP11-399E6.1 7.95 2.71e-14 4.31e-11 0.51 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41302569 chr1:41242373~41284861:+ LIHC cis rs12744310 1 rs12031169 ENSG00000235358.1 RP11-399E6.1 7.95 2.71e-14 4.31e-11 0.51 0.4 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41302579 chr1:41242373~41284861:+ LIHC cis rs2882667 0.898 rs6863347 ENSG00000253404.1 AC034243.1 7.95 2.72e-14 4.33e-11 0.52 0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139025446 chr5:138744434~138753309:- LIHC cis rs6903823 0.508 rs1150726 ENSG00000216901.1 AL022393.7 7.95 2.77e-14 4.41e-11 0.44 0.39 Pulmonary function; chr6:28275265 chr6:28176188~28176674:+ LIHC cis rs4356975 0.932 rs7692377 ENSG00000249956.3 RP11-790I12.2 7.95 2.78e-14 4.41e-11 0.44 0.39 Obesity-related traits; chr4:69078113 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs61612343 ENSG00000249956.3 RP11-790I12.2 7.95 2.78e-14 4.41e-11 0.44 0.39 Obesity-related traits; chr4:69078247 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs7679418 ENSG00000249956.3 RP11-790I12.2 7.95 2.78e-14 4.41e-11 0.44 0.39 Obesity-related traits; chr4:69078533 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs7680156 ENSG00000249956.3 RP11-790I12.2 7.95 2.78e-14 4.41e-11 0.44 0.39 Obesity-related traits; chr4:69078868 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs7698430 ENSG00000249956.3 RP11-790I12.2 7.95 2.78e-14 4.41e-11 0.44 0.39 Obesity-related traits; chr4:69078897 chr4:69408836~69423164:+ LIHC cis rs17301013 0.606 rs12086693 ENSG00000227373.4 RP11-160H22.5 7.95 2.8e-14 4.44e-11 0.6 0.39 Systemic lupus erythematosus; chr1:174527651 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs12062170 ENSG00000227373.4 RP11-160H22.5 7.95 2.8e-14 4.44e-11 0.6 0.39 Systemic lupus erythematosus; chr1:174528420 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs12062483 ENSG00000227373.4 RP11-160H22.5 7.95 2.8e-14 4.44e-11 0.6 0.39 Systemic lupus erythematosus; chr1:174529089 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs6681970 ENSG00000227373.4 RP11-160H22.5 7.95 2.8e-14 4.44e-11 0.6 0.39 Systemic lupus erythematosus; chr1:174532698 chr1:174115300~174160004:- LIHC cis rs9399135 0.967 rs6910530 ENSG00000232876.1 CTA-212D2.2 -7.95 2.8e-14 4.45e-11 -0.44 -0.39 Red blood cell count; chr6:135011632 chr6:135055033~135060550:+ LIHC cis rs9399135 0.66 rs4267967 ENSG00000232876.1 CTA-212D2.2 -7.95 2.8e-14 4.45e-11 -0.45 -0.39 Red blood cell count; chr6:134951339 chr6:135055033~135060550:+ LIHC cis rs977987 0.872 rs4888422 ENSG00000261783.1 RP11-252K23.2 -7.95 2.84e-14 4.5e-11 -0.48 -0.39 Dupuytren's disease; chr16:75436678 chr16:75379818~75381260:- LIHC cis rs8062405 0.558 rs231976 ENSG00000259982.1 CDC37P1 7.94 2.84e-14 4.5e-11 0.42 0.39 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28534266 chr16:28700294~28701540:- LIHC cis rs7208859 0.673 rs2470251 ENSG00000263531.1 RP13-753N3.1 7.94 2.84e-14 4.51e-11 0.68 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30768043 chr17:30863921~30864940:- LIHC cis rs17301013 0.659 rs59649440 ENSG00000227373.4 RP11-160H22.5 7.94 2.86e-14 4.53e-11 0.6 0.39 Systemic lupus erythematosus; chr1:174332024 chr1:174115300~174160004:- LIHC cis rs8062405 0.688 rs3924376 ENSG00000259982.1 CDC37P1 -7.94 2.92e-14 4.62e-11 -0.48 -0.39 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28914657 chr16:28700294~28701540:- LIHC cis rs5760092 0.755 rs4585126 ENSG00000225282.1 AP000350.6 -7.94 2.95e-14 4.67e-11 -0.52 -0.39 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23926900~23929574:+ LIHC cis rs9399135 0.933 rs7755680 ENSG00000232876.1 CTA-212D2.2 -7.94 2.95e-14 4.68e-11 -0.44 -0.39 Red blood cell count; chr6:134973121 chr6:135055033~135060550:+ LIHC cis rs7174755 0.772 rs80187654 ENSG00000260657.2 RP11-315D16.4 7.94 2.96e-14 4.68e-11 0.64 0.39 Major depressive disorder; chr15:68082833 chr15:68267792~68277994:- LIHC cis rs7727544 0.735 rs270605 ENSG00000233006.5 AC034220.3 7.94 2.96e-14 4.68e-11 0.4 0.39 Blood metabolite levels; chr5:132316118 chr5:132311285~132369916:- LIHC cis rs9399135 0.967 rs4896119 ENSG00000232876.1 CTA-212D2.2 -7.94 2.96e-14 4.68e-11 -0.44 -0.39 Red blood cell count; chr6:134972253 chr6:135055033~135060550:+ LIHC cis rs10510102 0.608 rs4077606 ENSG00000276742.1 RP11-500G22.4 -7.94 2.96e-14 4.68e-11 -0.51 -0.39 Breast cancer; chr10:121849907 chr10:121956782~121957098:+ LIHC cis rs6504950 0.85 rs2541242 ENSG00000275710.1 RP11-257O5.4 -7.94 2.96e-14 4.69e-11 -0.59 -0.39 Breast cancer; chr17:55012326 chr17:54964474~54964679:+ LIHC cis rs6504950 0.889 rs2541245 ENSG00000275710.1 RP11-257O5.4 -7.94 2.96e-14 4.69e-11 -0.59 -0.39 Breast cancer; chr17:55023839 chr17:54964474~54964679:+ LIHC cis rs6504950 0.889 rs2787505 ENSG00000275710.1 RP11-257O5.4 -7.94 2.96e-14 4.69e-11 -0.59 -0.39 Breast cancer; chr17:55030071 chr17:54964474~54964679:+ LIHC cis rs7174755 0.772 rs75395345 ENSG00000260657.2 RP11-315D16.4 7.94 2.97e-14 4.69e-11 0.62 0.39 Major depressive disorder; chr15:68081380 chr15:68267792~68277994:- LIHC cis rs10510102 0.608 rs4752607 ENSG00000226864.1 ATE1-AS1 -7.94 2.97e-14 4.7e-11 -0.54 -0.39 Breast cancer; chr10:121835426 chr10:121928312~121951965:+ LIHC cis rs55665837 1 rs10766182 ENSG00000251991.1 RNU7-49P 7.94 3e-14 4.75e-11 0.41 0.39 Vitamin D levels; chr11:14477990 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs10832278 ENSG00000251991.1 RNU7-49P 7.94 3.02e-14 4.77e-11 0.41 0.39 Vitamin D levels; chr11:14475073 chr11:14478892~14478953:+ LIHC cis rs55665837 0.961 rs11023237 ENSG00000251991.1 RNU7-49P 7.94 3.02e-14 4.77e-11 0.41 0.39 Vitamin D levels; chr11:14478788 chr11:14478892~14478953:+ LIHC cis rs34779708 0.931 rs4934711 ENSG00000230534.5 RP11-297A16.2 7.94 3.02e-14 4.77e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35071382 chr10:35098006~35127020:- LIHC cis rs8072100 1 rs11870935 ENSG00000228782.6 CTD-2026D20.3 -7.93 3.09e-14 4.88e-11 -0.45 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47655239 chr17:47450568~47492492:- LIHC cis rs73086581 0.947 rs11906612 ENSG00000229539.1 RP11-119B16.2 7.93 3.1e-14 4.89e-11 0.72 0.39 Response to antidepressants in depression; chr20:3922987 chr20:3888239~3888868:- LIHC cis rs7727544 0.735 rs2631370 ENSG00000233006.5 AC034220.3 -7.93 3.16e-14 4.98e-11 -0.39 -0.39 Blood metabolite levels; chr5:132368084 chr5:132311285~132369916:- LIHC cis rs9399135 0.967 rs6569990 ENSG00000232876.1 CTA-212D2.2 -7.93 3.17e-14 4.99e-11 -0.45 -0.39 Red blood cell count; chr6:135044680 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs6908512 ENSG00000232876.1 CTA-212D2.2 -7.93 3.17e-14 4.99e-11 -0.45 -0.39 Red blood cell count; chr6:135046619 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs11755229 ENSG00000232876.1 CTA-212D2.2 -7.93 3.17e-14 4.99e-11 -0.45 -0.39 Red blood cell count; chr6:135048775 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs9389261 ENSG00000232876.1 CTA-212D2.2 -7.93 3.17e-14 4.99e-11 -0.45 -0.39 Red blood cell count; chr6:135050010 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs9376085 ENSG00000232876.1 CTA-212D2.2 -7.93 3.17e-14 4.99e-11 -0.45 -0.39 Red blood cell count; chr6:135050086 chr6:135055033~135060550:+ LIHC cis rs17301013 0.507 rs6697959 ENSG00000227373.4 RP11-160H22.5 7.93 3.17e-14 4.99e-11 0.66 0.39 Systemic lupus erythematosus; chr1:174285450 chr1:174115300~174160004:- LIHC cis rs7684253 0.565 rs13108570 ENSG00000269949.1 RP11-738E22.3 -7.93 3.19e-14 5.02e-11 -0.49 -0.39 Migraine; chr4:56940917 chr4:56960927~56961373:- LIHC cis rs55665837 1 rs34980103 ENSG00000251991.1 RNU7-49P 7.93 3.2e-14 5.04e-11 0.41 0.39 Vitamin D levels; chr11:14491339 chr11:14478892~14478953:+ LIHC cis rs6504950 0.925 rs2787483 ENSG00000275710.1 RP11-257O5.4 7.93 3.23e-14 5.08e-11 0.59 0.39 Breast cancer; chr17:55132953 chr17:54964474~54964679:+ LIHC cis rs6504950 0.925 rs2628317 ENSG00000275710.1 RP11-257O5.4 7.93 3.23e-14 5.08e-11 0.59 0.39 Breast cancer; chr17:55135212 chr17:54964474~54964679:+ LIHC cis rs7727544 0.645 rs272857 ENSG00000233006.5 AC034220.3 7.93 3.25e-14 5.11e-11 0.39 0.39 Blood metabolite levels; chr5:132349604 chr5:132311285~132369916:- LIHC cis rs17301013 0.507 rs6678209 ENSG00000227373.4 RP11-160H22.5 -7.92 3.25e-14 5.12e-11 -0.62 -0.39 Systemic lupus erythematosus; chr1:174325607 chr1:174115300~174160004:- LIHC cis rs3096299 0.504 rs4785574 ENSG00000274627.1 RP11-104N10.2 7.92 3.31e-14 5.2e-11 0.41 0.39 Multiple myeloma (IgH translocation); chr16:89502467 chr16:89516797~89522217:+ LIHC cis rs34779708 0.931 rs7908573 ENSG00000230534.5 RP11-297A16.2 7.92 3.31e-14 5.2e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35020585 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs17583009 ENSG00000230534.5 RP11-297A16.2 7.92 3.31e-14 5.2e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35031987 chr10:35098006~35127020:- LIHC cis rs6991838 0.584 rs7823840 ENSG00000272010.1 CTD-3025N20.3 -7.92 3.31e-14 5.21e-11 -0.43 -0.39 Intelligence (multi-trait analysis); chr8:65606766 chr8:65591850~65592472:- LIHC cis rs1891275 0.551 rs7908678 ENSG00000228701.1 TNKS2-AS1 7.92 3.31e-14 5.21e-11 0.58 0.39 Intelligence (multi-trait analysis); chr10:91659253 chr10:91782839~91798291:- LIHC cis rs17301013 0.606 rs1407127 ENSG00000227373.4 RP11-160H22.5 -7.92 3.39e-14 5.33e-11 -0.58 -0.39 Systemic lupus erythematosus; chr1:174119548 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12067852 ENSG00000227373.4 RP11-160H22.5 -7.92 3.42e-14 5.37e-11 -0.63 -0.39 Systemic lupus erythematosus; chr1:174302481 chr1:174115300~174160004:- LIHC cis rs4423214 0.765 rs2002064 ENSG00000254682.1 RP11-660L16.2 -7.92 3.44e-14 5.4e-11 -0.5 -0.39 Vitamin D levels; chr11:71452374 chr11:71448674~71452157:+ LIHC cis rs4423214 0.84 rs1792315 ENSG00000254682.1 RP11-660L16.2 -7.92 3.44e-14 5.4e-11 -0.5 -0.39 Vitamin D levels; chr11:71454501 chr11:71448674~71452157:+ LIHC cis rs2739330 0.734 rs2000467 ENSG00000231271.1 AP000350.8 -7.92 3.45e-14 5.41e-11 -0.47 -0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23949918~23954042:+ LIHC cis rs9543976 1 rs7989568 ENSG00000261553.4 RP11-29G8.3 7.92 3.47e-14 5.44e-11 0.56 0.39 Diabetic retinopathy; chr13:75581428 chr13:75549773~75807120:+ LIHC cis rs34779708 0.931 rs59418206 ENSG00000230534.5 RP11-297A16.2 7.92 3.47e-14 5.44e-11 0.51 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35042696 chr10:35098006~35127020:- LIHC cis rs2882667 0.898 rs10079634 ENSG00000253404.1 AC034243.1 7.92 3.47e-14 5.45e-11 0.51 0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139077364 chr5:138744434~138753309:- LIHC cis rs55665837 1 rs12364959 ENSG00000251991.1 RNU7-49P 7.91 3.5e-14 5.48e-11 0.41 0.39 Vitamin D levels; chr11:14485889 chr11:14478892~14478953:+ LIHC cis rs6504950 0.925 rs244348 ENSG00000275710.1 RP11-257O5.4 7.91 3.51e-14 5.5e-11 0.57 0.39 Breast cancer; chr17:55118930 chr17:54964474~54964679:+ LIHC cis rs55665837 1 rs10466412 ENSG00000251991.1 RNU7-49P 7.91 3.51e-14 5.5e-11 0.41 0.39 Vitamin D levels; chr11:14483643 chr11:14478892~14478953:+ LIHC cis rs1062177 0.774 rs2964574 ENSG00000213433.5 RPLP1P6 -7.91 3.52e-14 5.51e-11 -0.45 -0.39 Preschool internalizing problems; chr5:151776150 chr5:151765859~151766378:- LIHC cis rs1062177 0.906 rs2964573 ENSG00000213433.5 RPLP1P6 -7.91 3.52e-14 5.51e-11 -0.45 -0.39 Preschool internalizing problems; chr5:151780561 chr5:151765859~151766378:- LIHC cis rs12744310 0.887 rs12724625 ENSG00000235358.1 RP11-399E6.1 7.91 3.52e-14 5.51e-11 0.52 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41316598 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs12041352 ENSG00000235358.1 RP11-399E6.1 7.91 3.52e-14 5.51e-11 0.52 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41317109 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs28566545 ENSG00000235358.1 RP11-399E6.1 7.91 3.52e-14 5.51e-11 0.52 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41317561 chr1:41242373~41284861:+ LIHC cis rs34779708 0.931 rs7897457 ENSG00000230534.5 RP11-297A16.2 7.91 3.55e-14 5.55e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35097112 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs34776628 ENSG00000230534.5 RP11-297A16.2 7.91 3.55e-14 5.55e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35137396 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs17499247 ENSG00000230534.5 RP11-297A16.2 7.91 3.55e-14 5.55e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35137827 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs10827491 ENSG00000230534.5 RP11-297A16.2 7.91 3.55e-14 5.55e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35138467 chr10:35098006~35127020:- LIHC cis rs7727544 0.735 rs2569266 ENSG00000233006.5 AC034220.3 -7.91 3.55e-14 5.56e-11 -0.39 -0.39 Blood metabolite levels; chr5:132371099 chr5:132311285~132369916:- LIHC cis rs9399135 0.967 rs4376365 ENSG00000232876.1 CTA-212D2.2 -7.91 3.56e-14 5.56e-11 -0.44 -0.39 Red blood cell count; chr6:134986602 chr6:135055033~135060550:+ LIHC cis rs6504950 0.925 rs8082622 ENSG00000275710.1 RP11-257O5.4 -7.91 3.57e-14 5.58e-11 -0.58 -0.39 Breast cancer; chr17:55100206 chr17:54964474~54964679:+ LIHC cis rs6504950 0.925 rs244377 ENSG00000275710.1 RP11-257O5.4 -7.91 3.57e-14 5.58e-11 -0.58 -0.39 Breast cancer; chr17:55105718 chr17:54964474~54964679:+ LIHC cis rs6991838 0.55 rs4737750 ENSG00000272010.1 CTD-3025N20.3 7.91 3.57e-14 5.59e-11 0.43 0.39 Intelligence (multi-trait analysis); chr8:65638724 chr8:65591850~65592472:- LIHC cis rs6504950 1 rs7222197 ENSG00000275710.1 RP11-257O5.4 -7.91 3.57e-14 5.59e-11 -0.57 -0.39 Breast cancer; chr17:54970138 chr17:54964474~54964679:+ LIHC cis rs1577917 0.518 rs6454482 ENSG00000234155.1 RP11-30P6.6 -7.91 3.59e-14 5.61e-11 -0.45 -0.39 Response to antipsychotic treatment; chr6:85708470 chr6:85387219~85390186:- LIHC cis rs7684253 0.565 rs13130605 ENSG00000269949.1 RP11-738E22.3 -7.91 3.59e-14 5.62e-11 -0.49 -0.39 Migraine; chr4:56943905 chr4:56960927~56961373:- LIHC cis rs9399135 0.967 rs4451151 ENSG00000232876.1 CTA-212D2.2 -7.91 3.6e-14 5.63e-11 -0.44 -0.39 Red blood cell count; chr6:134989408 chr6:135055033~135060550:+ LIHC cis rs6504950 0.925 rs244315 ENSG00000275710.1 RP11-257O5.4 7.91 3.6e-14 5.63e-11 0.59 0.39 Breast cancer; chr17:55137293 chr17:54964474~54964679:+ LIHC cis rs2019137 0.868 rs3748916 ENSG00000274877.1 RP11-65I12.1 7.91 3.62e-14 5.65e-11 0.48 0.39 Lymphocyte counts; chr2:113226456 chr2:113237595~113240825:+ LIHC cis rs11723261 0.582 rs7679573 ENSG00000275426.1 CH17-262A2.1 7.91 3.62e-14 5.66e-11 0.48 0.39 Immune response to smallpox vaccine (IL-6); chr4:157810 chr4:149738~150317:+ LIHC cis rs7727544 0.735 rs272875 ENSG00000233006.5 AC034220.3 7.91 3.63e-14 5.66e-11 0.4 0.39 Blood metabolite levels; chr5:132339195 chr5:132311285~132369916:- LIHC cis rs55665837 1 rs11023246 ENSG00000251991.1 RNU7-49P 7.91 3.66e-14 5.71e-11 0.41 0.39 Vitamin D levels; chr11:14515410 chr11:14478892~14478953:+ LIHC cis rs9543976 1 rs3818355 ENSG00000261553.4 RP11-29G8.3 7.91 3.7e-14 5.78e-11 0.57 0.39 Diabetic retinopathy; chr13:75622731 chr13:75549773~75807120:+ LIHC cis rs8072100 0.871 rs7206971 ENSG00000228782.6 CTD-2026D20.3 -7.91 3.71e-14 5.78e-11 -0.45 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47347749 chr17:47450568~47492492:- LIHC cis rs7727544 0.684 rs272849 ENSG00000233006.5 AC034220.3 7.91 3.71e-14 5.78e-11 0.39 0.39 Blood metabolite levels; chr5:132354548 chr5:132311285~132369916:- LIHC cis rs4423214 0.84 rs1629220 ENSG00000254682.1 RP11-660L16.2 -7.9 3.72e-14 5.81e-11 -0.51 -0.39 Vitamin D levels; chr11:71463507 chr11:71448674~71452157:+ LIHC cis rs4356975 0.932 rs4694610 ENSG00000249956.3 RP11-790I12.2 7.9 3.82e-14 5.95e-11 0.44 0.39 Obesity-related traits; chr4:69079224 chr4:69408836~69423164:+ LIHC cis rs8072100 0.84 rs4968319 ENSG00000228782.6 CTD-2026D20.3 7.9 3.88e-14 6.04e-11 0.44 0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47387601 chr17:47450568~47492492:- LIHC cis rs17301013 0.606 rs3086 ENSG00000227373.4 RP11-160H22.5 7.9 3.89e-14 6.06e-11 0.61 0.39 Systemic lupus erythematosus; chr1:174167236 chr1:174115300~174160004:- LIHC cis rs1062177 1 rs12654573 ENSG00000213433.5 RPLP1P6 -7.9 3.91e-14 6.09e-11 -0.45 -0.39 Preschool internalizing problems; chr5:151827912 chr5:151765859~151766378:- LIHC cis rs9399135 0.967 rs7750300 ENSG00000232876.1 CTA-212D2.2 -7.9 3.94e-14 6.13e-11 -0.45 -0.39 Red blood cell count; chr6:135029812 chr6:135055033~135060550:+ LIHC cis rs1155848 0.892 rs9565508 ENSG00000227354.5 RBM26-AS1 7.9 3.94e-14 6.13e-11 0.69 0.39 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79482451 chr13:79406309~79424328:+ LIHC cis rs17301013 0.54 rs72713601 ENSG00000227373.4 RP11-160H22.5 7.9 3.97e-14 6.15e-11 0.6 0.39 Systemic lupus erythematosus; chr1:174482987 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs9729907 ENSG00000227373.4 RP11-160H22.5 7.9 3.97e-14 6.15e-11 0.6 0.39 Systemic lupus erythematosus; chr1:174483607 chr1:174115300~174160004:- LIHC cis rs17301013 0.581 rs2901818 ENSG00000227373.4 RP11-160H22.5 7.9 3.97e-14 6.15e-11 0.6 0.39 Systemic lupus erythematosus; chr1:174486239 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs6658315 ENSG00000227373.4 RP11-160H22.5 7.9 3.97e-14 6.15e-11 0.6 0.39 Systemic lupus erythematosus; chr1:174489961 chr1:174115300~174160004:- LIHC cis rs4356975 0.83 rs7666894 ENSG00000249956.3 RP11-790I12.2 7.9 3.97e-14 6.15e-11 0.43 0.39 Obesity-related traits; chr4:69078780 chr4:69408836~69423164:+ LIHC cis rs3096299 0.685 rs4785676 ENSG00000274627.1 RP11-104N10.2 7.89 4e-14 6.18e-11 0.41 0.39 Multiple myeloma (IgH translocation); chr16:89487216 chr16:89516797~89522217:+ LIHC cis rs12594515 0.694 rs2068294 ENSG00000273972.1 CTD-2306A12.1 -7.89 4.01e-14 6.19e-11 -0.46 -0.39 Weight;Waist circumference; chr15:45693350 chr15:45702640~45703183:+ LIHC cis rs34779708 0.966 rs4934540 ENSG00000230534.5 RP11-297A16.2 7.89 4.02e-14 6.22e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35185771 chr10:35098006~35127020:- LIHC cis rs8072100 0.875 rs4794047 ENSG00000228782.6 CTD-2026D20.3 -7.89 4.06e-14 6.28e-11 -0.45 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47685639 chr17:47450568~47492492:- LIHC cis rs3096299 0.658 rs12443705 ENSG00000274627.1 RP11-104N10.2 7.89 4.07e-14 6.28e-11 0.41 0.39 Multiple myeloma (IgH translocation); chr16:89480646 chr16:89516797~89522217:+ LIHC cis rs2739330 0.627 rs9608219 ENSG00000250470.1 AP000351.3 7.89 4.09e-14 6.31e-11 0.47 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23976904~23977585:- LIHC cis rs62229266 0.682 rs2835224 ENSG00000231106.2 LINC01436 7.89 4.11e-14 6.35e-11 0.44 0.39 Mitral valve prolapse; chr21:35997732 chr21:36005338~36007838:+ LIHC cis rs2283792 0.745 rs5756306 ENSG00000224086.5 LL22NC03-86G7.1 7.89 4.13e-14 6.36e-11 0.36 0.39 Multiple sclerosis; chr22:21978846 chr22:21938293~21977632:+ LIHC cis rs831571 0.774 rs40610 ENSG00000280620.1 SCAANT1 7.89 4.13e-14 6.37e-11 0.51 0.39 Type 2 diabetes; chr3:64023832 chr3:63911518~63911772:- LIHC cis rs34779708 0.931 rs4934697 ENSG00000230534.5 RP11-297A16.2 7.89 4.17e-14 6.42e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:34998264 chr10:35098006~35127020:- LIHC cis rs17301013 0.531 rs12079687 ENSG00000227373.4 RP11-160H22.5 7.89 4.17e-14 6.42e-11 0.62 0.39 Systemic lupus erythematosus; chr1:174175545 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs12087808 ENSG00000227373.4 RP11-160H22.5 7.89 4.17e-14 6.42e-11 0.62 0.39 Systemic lupus erythematosus; chr1:174178848 chr1:174115300~174160004:- LIHC cis rs9399135 0.66 rs9376072 ENSG00000232876.1 CTA-212D2.2 -7.89 4.19e-14 6.45e-11 -0.43 -0.39 Red blood cell count; chr6:134959381 chr6:135055033~135060550:+ LIHC cis rs4356975 0.768 rs4518318 ENSG00000249956.3 RP11-790I12.2 -7.89 4.2e-14 6.47e-11 -0.44 -0.39 Obesity-related traits; chr4:69045479 chr4:69408836~69423164:+ LIHC cis rs4356975 0.83 rs4351079 ENSG00000249956.3 RP11-790I12.2 -7.89 4.2e-14 6.47e-11 -0.44 -0.39 Obesity-related traits; chr4:69045631 chr4:69408836~69423164:+ LIHC cis rs4356975 0.798 rs4607293 ENSG00000249956.3 RP11-790I12.2 -7.89 4.2e-14 6.47e-11 -0.44 -0.39 Obesity-related traits; chr4:69045714 chr4:69408836~69423164:+ LIHC cis rs1891275 0.515 rs1592051 ENSG00000228701.1 TNKS2-AS1 7.89 4.21e-14 6.48e-11 0.48 0.39 Intelligence (multi-trait analysis); chr10:91782429 chr10:91782839~91798291:- LIHC cis rs34779708 0.897 rs9665538 ENSG00000230534.5 RP11-297A16.2 7.89 4.25e-14 6.55e-11 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35172110 chr10:35098006~35127020:- LIHC cis rs3096299 0.719 rs2965945 ENSG00000274627.1 RP11-104N10.2 7.88 4.28e-14 6.59e-11 0.39 0.39 Multiple myeloma (IgH translocation); chr16:89447609 chr16:89516797~89522217:+ LIHC cis rs17301013 0.606 rs11487399 ENSG00000227373.4 RP11-160H22.5 7.88 4.29e-14 6.61e-11 0.59 0.39 Systemic lupus erythematosus; chr1:174527129 chr1:174115300~174160004:- LIHC cis rs62229266 0.682 rs11700546 ENSG00000231106.2 LINC01436 7.88 4.32e-14 6.65e-11 0.44 0.39 Mitral valve prolapse; chr21:35998841 chr21:36005338~36007838:+ LIHC cis rs3096299 0.658 rs3934737 ENSG00000274627.1 RP11-104N10.2 7.88 4.4e-14 6.76e-11 0.4 0.39 Multiple myeloma (IgH translocation); chr16:89493801 chr16:89516797~89522217:+ LIHC cis rs17301013 0.606 rs10912751 ENSG00000227373.4 RP11-160H22.5 7.88 4.41e-14 6.77e-11 0.61 0.39 Systemic lupus erythematosus; chr1:174262992 chr1:174115300~174160004:- LIHC cis rs2929278 0.546 rs686666 ENSG00000205771.5 CATSPER2P1 -7.88 4.42e-14 6.79e-11 -0.5 -0.39 Schizophrenia; chr15:43869352 chr15:43726918~43747094:- LIHC cis rs4356975 0.867 rs6600869 ENSG00000249956.3 RP11-790I12.2 7.88 4.43e-14 6.8e-11 0.43 0.39 Obesity-related traits; chr4:69075937 chr4:69408836~69423164:+ LIHC cis rs4356975 0.836 rs6600870 ENSG00000249956.3 RP11-790I12.2 7.88 4.43e-14 6.8e-11 0.43 0.39 Obesity-related traits; chr4:69075944 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs7442394 ENSG00000249956.3 RP11-790I12.2 7.88 4.43e-14 6.8e-11 0.43 0.39 Obesity-related traits; chr4:69076309 chr4:69408836~69423164:+ LIHC cis rs7727544 0.735 rs273913 ENSG00000233006.5 AC034220.3 7.88 4.44e-14 6.82e-11 0.39 0.39 Blood metabolite levels; chr5:132325463 chr5:132311285~132369916:- LIHC cis rs893363 0.61 rs893362 ENSG00000271916.1 RP11-884K10.6 -7.88 4.48e-14 6.87e-11 -0.72 -0.39 Axial length; chr3:53813767 chr3:53797764~53798019:- LIHC cis rs6504950 0.85 rs2787507 ENSG00000275710.1 RP11-257O5.4 -7.88 4.49e-14 6.88e-11 -0.59 -0.39 Breast cancer; chr17:55050563 chr17:54964474~54964679:+ LIHC cis rs6504950 0.813 rs9889687 ENSG00000275710.1 RP11-257O5.4 -7.88 4.49e-14 6.88e-11 -0.59 -0.39 Breast cancer; chr17:55055050 chr17:54964474~54964679:+ LIHC cis rs6504950 0.85 rs17745534 ENSG00000275710.1 RP11-257O5.4 -7.88 4.49e-14 6.88e-11 -0.59 -0.39 Breast cancer; chr17:55060145 chr17:54964474~54964679:+ LIHC cis rs6504950 0.889 rs9303363 ENSG00000275710.1 RP11-257O5.4 -7.88 4.49e-14 6.88e-11 -0.59 -0.39 Breast cancer; chr17:55060613 chr17:54964474~54964679:+ LIHC cis rs9543976 0.858 rs8192763 ENSG00000261553.4 RP11-29G8.3 7.88 4.49e-14 6.89e-11 0.56 0.39 Diabetic retinopathy; chr13:75605034 chr13:75549773~75807120:+ LIHC cis rs9543976 1 rs1535724 ENSG00000261553.4 RP11-29G8.3 7.88 4.49e-14 6.89e-11 0.56 0.39 Diabetic retinopathy; chr13:75609137 chr13:75549773~75807120:+ LIHC cis rs9543976 0.925 rs2876706 ENSG00000261553.4 RP11-29G8.3 7.88 4.49e-14 6.89e-11 0.56 0.39 Diabetic retinopathy; chr13:75612169 chr13:75549773~75807120:+ LIHC cis rs1577917 0.74 rs7752502 ENSG00000234155.1 RP11-30P6.6 -7.88 4.49e-14 6.89e-11 -0.46 -0.39 Response to antipsychotic treatment; chr6:85700933 chr6:85387219~85390186:- LIHC cis rs34779708 0.966 rs11010129 ENSG00000230534.5 RP11-297A16.2 7.88 4.56e-14 6.98e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35221894 chr10:35098006~35127020:- LIHC cis rs9543976 1 rs2031236 ENSG00000261553.4 RP11-29G8.3 -7.87 4.56e-14 6.99e-11 -0.56 -0.39 Diabetic retinopathy; chr13:75595641 chr13:75549773~75807120:+ LIHC cis rs4718428 0.705 rs13220977 ENSG00000273142.1 RP11-458F8.4 7.87 4.57e-14 6.99e-11 0.39 0.39 Corneal structure; chr7:66872661 chr7:66902857~66906297:+ LIHC cis rs9543976 1 rs4885324 ENSG00000261553.4 RP11-29G8.3 7.87 4.58e-14 7.01e-11 0.56 0.39 Diabetic retinopathy; chr13:75599611 chr13:75549773~75807120:+ LIHC cis rs9326248 0.515 rs2727793 ENSG00000236267.1 AP006216.5 7.87 4.58e-14 7.01e-11 0.39 0.39 Blood protein levels; chr11:116812658 chr11:116813204~116814003:- LIHC cis rs7847628 0.566 rs10739575 ENSG00000226752.6 PSMD5-AS1 7.87 4.58e-14 7.02e-11 0.45 0.39 Birth weight; chr9:120843823 chr9:120824828~120854385:+ LIHC cis rs34779708 0.966 rs12782948 ENSG00000230534.5 RP11-297A16.2 7.87 4.64e-14 7.09e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35161679 chr10:35098006~35127020:- LIHC cis rs7617773 1 rs9832957 ENSG00000229759.1 MRPS18AP1 -7.87 4.64e-14 7.09e-11 -0.44 -0.39 Coronary artery disease; chr3:48143776 chr3:48256350~48256938:- LIHC cis rs9399135 0.933 rs28384512 ENSG00000232876.1 CTA-212D2.2 -7.87 4.65e-14 7.1e-11 -0.45 -0.39 Red blood cell count; chr6:135055094 chr6:135055033~135060550:+ LIHC cis rs3096299 0.503 rs9940093 ENSG00000274627.1 RP11-104N10.2 7.87 4.66e-14 7.12e-11 0.4 0.39 Multiple myeloma (IgH translocation); chr16:89492297 chr16:89516797~89522217:+ LIHC cis rs7727544 0.684 rs2631363 ENSG00000233006.5 AC034220.3 -7.87 4.69e-14 7.17e-11 -0.39 -0.39 Blood metabolite levels; chr5:132371403 chr5:132311285~132369916:- LIHC cis rs6504950 0.925 rs2787481 ENSG00000275710.1 RP11-257O5.4 -7.87 4.71e-14 7.19e-11 -0.57 -0.39 Breast cancer; chr17:55133749 chr17:54964474~54964679:+ LIHC cis rs9399135 1 rs4896130 ENSG00000232876.1 CTA-212D2.2 -7.87 4.71e-14 7.19e-11 -0.43 -0.39 Red blood cell count; chr6:135033980 chr6:135055033~135060550:+ LIHC cis rs6504950 0.925 rs244317 ENSG00000275710.1 RP11-257O5.4 -7.87 4.71e-14 7.2e-11 -0.59 -0.39 Breast cancer; chr17:55139624 chr17:54964474~54964679:+ LIHC cis rs9543976 0.92 rs9543992 ENSG00000261553.4 RP11-29G8.3 7.87 4.77e-14 7.29e-11 0.56 0.39 Diabetic retinopathy; chr13:75600938 chr13:75549773~75807120:+ LIHC cis rs9543976 1 rs8192762 ENSG00000261553.4 RP11-29G8.3 7.87 4.77e-14 7.29e-11 0.56 0.39 Diabetic retinopathy; chr13:75602544 chr13:75549773~75807120:+ LIHC cis rs6686842 0.689 rs2885697 ENSG00000235358.1 RP11-399E6.1 -7.87 4.78e-14 7.29e-11 -0.47 -0.39 Height; chr1:41078607 chr1:41242373~41284861:+ LIHC cis rs7580658 0.637 rs9636235 ENSG00000236682.1 AC068282.3 -7.87 4.79e-14 7.31e-11 -0.49 -0.39 Protein C levels; chr2:127223975 chr2:127389130~127400580:+ LIHC cis rs7580658 0.637 rs9636236 ENSG00000236682.1 AC068282.3 -7.87 4.79e-14 7.31e-11 -0.49 -0.39 Protein C levels; chr2:127225365 chr2:127389130~127400580:+ LIHC cis rs34779708 0.931 rs11010130 ENSG00000230534.5 RP11-297A16.2 7.87 4.8e-14 7.32e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35224379 chr10:35098006~35127020:- LIHC cis rs34779708 0.897 rs11010131 ENSG00000230534.5 RP11-297A16.2 7.87 4.8e-14 7.32e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35224388 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs7099036 ENSG00000230534.5 RP11-297A16.2 7.87 4.8e-14 7.32e-11 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35060646 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs11010083 ENSG00000230534.5 RP11-297A16.2 7.87 4.8e-14 7.32e-11 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35062603 chr10:35098006~35127020:- LIHC cis rs2470135 1 rs2470135 ENSG00000205771.5 CATSPER2P1 -7.87 4.81e-14 7.34e-11 -0.48 -0.39 Diastolic blood pressure; chr15:43703591 chr15:43726918~43747094:- LIHC cis rs34779708 0.931 rs34954932 ENSG00000230534.5 RP11-297A16.2 7.87 4.81e-14 7.34e-11 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35121879 chr10:35098006~35127020:- LIHC cis rs4356975 0.798 rs4694588 ENSG00000249956.3 RP11-790I12.2 -7.87 4.81e-14 7.34e-11 -0.44 -0.39 Obesity-related traits; chr4:69044664 chr4:69408836~69423164:+ LIHC cis rs4356975 0.83 rs7693166 ENSG00000249956.3 RP11-790I12.2 -7.87 4.81e-14 7.34e-11 -0.44 -0.39 Obesity-related traits; chr4:69044866 chr4:69408836~69423164:+ LIHC cis rs4356975 0.83 rs6422321 ENSG00000249956.3 RP11-790I12.2 -7.87 4.81e-14 7.34e-11 -0.44 -0.39 Obesity-related traits; chr4:69044911 chr4:69408836~69423164:+ LIHC cis rs11723261 0.664 rs4627799 ENSG00000275426.1 CH17-262A2.1 7.87 4.86e-14 7.4e-11 0.46 0.39 Immune response to smallpox vaccine (IL-6); chr4:138608 chr4:149738~150317:+ LIHC cis rs34779708 0.931 rs7079498 ENSG00000230534.5 RP11-297A16.2 7.87 4.88e-14 7.43e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35086416 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs13376871 ENSG00000230534.5 RP11-297A16.2 7.86 4.91e-14 7.48e-11 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35080128 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs12761675 ENSG00000230534.5 RP11-297A16.2 -7.86 4.96e-14 7.55e-11 -0.49 -0.39 Inflammatory bowel disease;Crohn's disease; chr10:35149409 chr10:35098006~35127020:- LIHC cis rs6504950 0.8 rs12952253 ENSG00000275710.1 RP11-257O5.4 7.86 4.99e-14 7.59e-11 0.48 0.39 Breast cancer; chr17:54928355 chr17:54964474~54964679:+ LIHC cis rs6504950 0.8 rs7208123 ENSG00000275710.1 RP11-257O5.4 7.86 4.99e-14 7.59e-11 0.48 0.39 Breast cancer; chr17:54928978 chr17:54964474~54964679:+ LIHC cis rs6504950 0.8 rs72829484 ENSG00000275710.1 RP11-257O5.4 7.86 4.99e-14 7.59e-11 0.48 0.39 Breast cancer; chr17:54931919 chr17:54964474~54964679:+ LIHC cis rs6504950 0.8 rs9916547 ENSG00000275710.1 RP11-257O5.4 7.86 5e-14 7.59e-11 0.48 0.39 Breast cancer; chr17:54929529 chr17:54964474~54964679:+ LIHC cis rs6504950 0.8 rs8065361 ENSG00000275710.1 RP11-257O5.4 7.86 5e-14 7.59e-11 0.48 0.39 Breast cancer; chr17:54931492 chr17:54964474~54964679:+ LIHC cis rs6504950 0.745 rs12603899 ENSG00000275710.1 RP11-257O5.4 7.86 5e-14 7.59e-11 0.48 0.39 Breast cancer; chr17:54932737 chr17:54964474~54964679:+ LIHC cis rs6504950 0.8 rs9891704 ENSG00000275710.1 RP11-257O5.4 7.86 5e-14 7.59e-11 0.48 0.39 Breast cancer; chr17:54933394 chr17:54964474~54964679:+ LIHC cis rs6504950 0.8 rs9900816 ENSG00000275710.1 RP11-257O5.4 7.86 5e-14 7.59e-11 0.48 0.39 Breast cancer; chr17:54934696 chr17:54964474~54964679:+ LIHC cis rs6504950 0.8 rs9907961 ENSG00000275710.1 RP11-257O5.4 7.86 5e-14 7.59e-11 0.48 0.39 Breast cancer; chr17:54935566 chr17:54964474~54964679:+ LIHC cis rs1150668 0.699 rs1531681 ENSG00000216901.1 AL022393.7 7.86 5.05e-14 7.67e-11 0.43 0.39 Pubertal anthropometrics; chr6:28259100 chr6:28176188~28176674:+ LIHC cis rs1891275 0.515 rs7475294 ENSG00000228701.1 TNKS2-AS1 -7.86 5.06e-14 7.68e-11 -0.48 -0.39 Intelligence (multi-trait analysis); chr10:91748442 chr10:91782839~91798291:- LIHC cis rs7727544 0.735 rs272860 ENSG00000233006.5 AC034220.3 7.86 5.11e-14 7.75e-11 0.39 0.39 Blood metabolite levels; chr5:132348482 chr5:132311285~132369916:- LIHC cis rs9399135 0.967 rs9376082 ENSG00000232876.1 CTA-212D2.2 -7.86 5.15e-14 7.8e-11 -0.44 -0.39 Red blood cell count; chr6:135025251 chr6:135055033~135060550:+ LIHC cis rs1577917 0.545 rs9450325 ENSG00000203875.9 SNHG5 7.86 5.15e-14 7.8e-11 0.42 0.39 Response to antipsychotic treatment; chr6:85766096 chr6:85660950~85678736:- LIHC cis rs831571 0.955 rs35837 ENSG00000280620.1 SCAANT1 7.86 5.17e-14 7.83e-11 0.55 0.39 Type 2 diabetes; chr3:64027573 chr3:63911518~63911772:- LIHC cis rs7580658 0.637 rs1566822 ENSG00000236682.1 AC068282.3 -7.86 5.19e-14 7.86e-11 -0.49 -0.39 Protein C levels; chr2:127229815 chr2:127389130~127400580:+ LIHC cis rs150992 0.714 rs76798907 ENSG00000248489.1 CTD-2007H13.3 7.85 5.25e-14 7.93e-11 0.57 0.39 Body mass index; chr5:98990780 chr5:98929171~98995013:+ LIHC cis rs2442825 0.693 rs2728928 ENSG00000206573.7 THUMPD3-AS1 -7.85 5.33e-14 8.05e-11 -0.34 -0.39 Cerebrospinal fluid clusterin levels; chr3:9388275 chr3:9349689~9398579:- LIHC cis rs4718428 0.576 rs12698546 ENSG00000273142.1 RP11-458F8.4 -7.85 5.33e-14 8.05e-11 -0.4 -0.39 Corneal structure; chr7:66801919 chr7:66902857~66906297:+ LIHC cis rs147858478 1 rs147858478 ENSG00000233006.5 AC034220.3 7.85 5.36e-14 8.09e-11 0.39 0.39 High light scatter reticulocyte percentage of red cells; chr5:132347099 chr5:132311285~132369916:- LIHC cis rs1062177 1 rs62377945 ENSG00000213433.5 RPLP1P6 -7.85 5.39e-14 8.13e-11 -0.45 -0.39 Preschool internalizing problems; chr5:151828443 chr5:151765859~151766378:- LIHC cis rs1062177 1 rs12515762 ENSG00000213433.5 RPLP1P6 -7.85 5.39e-14 8.13e-11 -0.45 -0.39 Preschool internalizing problems; chr5:151830361 chr5:151765859~151766378:- LIHC cis rs17301013 0.606 rs16846938 ENSG00000227373.4 RP11-160H22.5 7.85 5.43e-14 8.19e-11 0.61 0.39 Systemic lupus erythematosus; chr1:174400537 chr1:174115300~174160004:- LIHC cis rs6991838 0.557 rs67685675 ENSG00000272010.1 CTD-3025N20.3 -7.85 5.43e-14 8.19e-11 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65574371 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs66486920 ENSG00000272010.1 CTD-3025N20.3 -7.85 5.43e-14 8.19e-11 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65574458 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs60023200 ENSG00000272010.1 CTD-3025N20.3 -7.85 5.43e-14 8.19e-11 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65574547 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs61083799 ENSG00000272010.1 CTD-3025N20.3 -7.85 5.43e-14 8.19e-11 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65574868 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs4449837 ENSG00000272010.1 CTD-3025N20.3 -7.85 5.43e-14 8.19e-11 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65575917 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs57042777 ENSG00000272010.1 CTD-3025N20.3 -7.85 5.43e-14 8.19e-11 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65576855 chr8:65591850~65592472:- LIHC cis rs6991838 0.557 rs67046768 ENSG00000272010.1 CTD-3025N20.3 -7.85 5.43e-14 8.19e-11 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65577486 chr8:65591850~65592472:- LIHC cis rs4423214 0.84 rs1790339 ENSG00000254682.1 RP11-660L16.2 -7.85 5.45e-14 8.21e-11 -0.5 -0.39 Vitamin D levels; chr11:71471715 chr11:71448674~71452157:+ LIHC cis rs34779708 0.898 rs11595898 ENSG00000230534.5 RP11-297A16.2 7.85 5.49e-14 8.27e-11 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35037335 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs35886556 ENSG00000230534.5 RP11-297A16.2 7.85 5.49e-14 8.27e-11 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35046057 chr10:35098006~35127020:- LIHC cis rs10935480 0.551 rs34070949 ENSG00000239445.4 ST3GAL6-AS1 -7.85 5.5e-14 8.29e-11 -0.46 -0.39 Blood protein levels; chr3:98635347 chr3:98714330~98732651:- LIHC cis rs17301013 0.531 rs4650958 ENSG00000227373.4 RP11-160H22.5 7.85 5.54e-14 8.33e-11 0.6 0.39 Systemic lupus erythematosus; chr1:174178378 chr1:174115300~174160004:- LIHC cis rs6504950 0.889 rs2628301 ENSG00000275710.1 RP11-257O5.4 -7.85 5.56e-14 8.37e-11 -0.59 -0.39 Breast cancer; chr17:55081912 chr17:54964474~54964679:+ LIHC cis rs150992 0.574 rs2927655 ENSG00000248489.1 CTD-2007H13.3 7.84 5.62e-14 8.45e-11 0.58 0.39 Body mass index; chr5:98839049 chr5:98929171~98995013:+ LIHC cis rs34779708 1 rs34779708 ENSG00000230534.5 RP11-297A16.2 7.84 5.65e-14 8.5e-11 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35177257 chr10:35098006~35127020:- LIHC cis rs2739330 0.734 rs2000467 ENSG00000225282.1 AP000350.6 -7.84 5.67e-14 8.53e-11 -0.48 -0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23926900~23929574:+ LIHC cis rs17301013 0.507 rs12066504 ENSG00000227373.4 RP11-160H22.5 7.84 5.7e-14 8.57e-11 0.66 0.39 Systemic lupus erythematosus; chr1:174288695 chr1:174115300~174160004:- LIHC cis rs4423214 0.84 rs4435028 ENSG00000254682.1 RP11-660L16.2 -7.84 5.71e-14 8.59e-11 -0.51 -0.39 Vitamin D levels; chr11:71472644 chr11:71448674~71452157:+ LIHC cis rs4423214 0.802 rs4616066 ENSG00000254682.1 RP11-660L16.2 -7.84 5.71e-14 8.59e-11 -0.51 -0.39 Vitamin D levels; chr11:71472800 chr11:71448674~71452157:+ LIHC cis rs4423214 0.802 rs4402322 ENSG00000254682.1 RP11-660L16.2 -7.84 5.71e-14 8.59e-11 -0.51 -0.39 Vitamin D levels; chr11:71472969 chr11:71448674~71452157:+ LIHC cis rs4423214 0.84 rs1123007 ENSG00000254682.1 RP11-660L16.2 -7.84 5.71e-14 8.59e-11 -0.51 -0.39 Vitamin D levels; chr11:71474311 chr11:71448674~71452157:+ LIHC cis rs4423214 0.84 rs3794057 ENSG00000254682.1 RP11-660L16.2 -7.84 5.71e-14 8.59e-11 -0.51 -0.39 Vitamin D levels; chr11:71475698 chr11:71448674~71452157:+ LIHC cis rs4423214 0.84 rs2017686 ENSG00000254682.1 RP11-660L16.2 -7.84 5.71e-14 8.59e-11 -0.51 -0.39 Vitamin D levels; chr11:71476015 chr11:71448674~71452157:+ LIHC cis rs34779708 0.931 rs79749947 ENSG00000230534.5 RP11-297A16.2 7.84 5.77e-14 8.66e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:34988153 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs9663401 ENSG00000230534.5 RP11-297A16.2 7.84 5.77e-14 8.66e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:34989921 chr10:35098006~35127020:- LIHC cis rs34779708 0.897 rs9787566 ENSG00000230534.5 RP11-297A16.2 7.84 5.77e-14 8.66e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:34990527 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs4351760 ENSG00000230534.5 RP11-297A16.2 7.84 5.77e-14 8.66e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:34991326 chr10:35098006~35127020:- LIHC cis rs34779708 0.898 rs4934695 ENSG00000230534.5 RP11-297A16.2 7.84 5.77e-14 8.66e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:34991677 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs11597483 ENSG00000230534.5 RP11-297A16.2 7.84 5.77e-14 8.66e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:34996189 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs35317849 ENSG00000230534.5 RP11-297A16.2 7.84 5.77e-14 8.66e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:34996793 chr10:35098006~35127020:- LIHC cis rs9399135 0.816 rs4134030 ENSG00000232876.1 CTA-212D2.2 -7.84 5.85e-14 8.78e-11 -0.44 -0.39 Red blood cell count; chr6:135032956 chr6:135055033~135060550:+ LIHC cis rs10793273 1 rs10793273 ENSG00000246174.6 KCTD21-AS1 -7.84 5.93e-14 8.89e-11 -0.42 -0.39 Pelvic organ prolapse; chr11:78031549 chr11:78139771~78175323:+ LIHC cis rs6844153 0.941 rs73116683 ENSG00000240005.4 RP11-293A21.1 -7.84 5.93e-14 8.89e-11 -0.46 -0.39 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26955376 chr4:26859806~26860599:- LIHC cis rs3096299 0.719 rs2965817 ENSG00000274627.1 RP11-104N10.2 7.84 5.97e-14 8.94e-11 0.39 0.39 Multiple myeloma (IgH translocation); chr16:89446826 chr16:89516797~89522217:+ LIHC cis rs2739330 0.828 rs5760107 ENSG00000250470.1 AP000351.3 7.83 6.03e-14 9.02e-11 0.47 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23976904~23977585:- LIHC cis rs17301013 0.606 rs12089182 ENSG00000227373.4 RP11-160H22.5 7.83 6.06e-14 9.08e-11 0.59 0.39 Systemic lupus erythematosus; chr1:174463816 chr1:174115300~174160004:- LIHC cis rs1891275 0.515 rs7092884 ENSG00000228701.1 TNKS2-AS1 7.83 6.07e-14 9.08e-11 0.46 0.39 Intelligence (multi-trait analysis); chr10:91724115 chr10:91782839~91798291:- LIHC cis rs6504950 0.8 rs17745183 ENSG00000275710.1 RP11-257O5.4 7.83 6.08e-14 9.1e-11 0.48 0.39 Breast cancer; chr17:54936234 chr17:54964474~54964679:+ LIHC cis rs2935183 1 rs2935183 ENSG00000228782.6 CTD-2026D20.3 -7.83 6.12e-14 9.15e-11 -0.45 -0.39 Multiple sclerosis or amyotrophic lateral sclerosis; chr17:47530206 chr17:47450568~47492492:- LIHC cis rs6504950 0.85 rs2628309 ENSG00000275710.1 RP11-257O5.4 -7.83 6.13e-14 9.17e-11 -0.59 -0.39 Breast cancer; chr17:55038058 chr17:54964474~54964679:+ LIHC cis rs4423214 0.84 rs1792234 ENSG00000254682.1 RP11-660L16.2 -7.83 6.16e-14 9.21e-11 -0.5 -0.39 Vitamin D levels; chr11:71470972 chr11:71448674~71452157:+ LIHC cis rs17301013 0.606 rs7536987 ENSG00000227373.4 RP11-160H22.5 7.83 6.17e-14 9.22e-11 0.61 0.39 Systemic lupus erythematosus; chr1:174367978 chr1:174115300~174160004:- LIHC cis rs17301013 0.556 rs10912774 ENSG00000227373.4 RP11-160H22.5 7.83 6.17e-14 9.22e-11 0.61 0.39 Systemic lupus erythematosus; chr1:174387706 chr1:174115300~174160004:- LIHC cis rs34779708 0.966 rs4934736 ENSG00000230534.5 RP11-297A16.2 7.83 6.23e-14 9.31e-11 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35207940 chr10:35098006~35127020:- LIHC cis rs7208859 0.673 rs216411 ENSG00000263531.1 RP13-753N3.1 -7.83 6.27e-14 9.36e-11 -0.66 -0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576475 chr17:30863921~30864940:- LIHC cis rs7085104 0.66 rs3781286 ENSG00000236937.2 PTGES3P4 7.83 6.3e-14 9.4e-11 0.46 0.39 Immature fraction of reticulocytes;Schizophrenia; chr10:102835962 chr10:102845595~102845950:+ LIHC cis rs4853012 0.941 rs4852329 ENSG00000257800.1 FNBP1P1 7.82 6.47e-14 9.64e-11 0.44 0.39 Gestational age at birth (maternal effect); chr2:74127417 chr2:74120680~74123218:+ LIHC cis rs7208859 0.673 rs216410 ENSG00000263531.1 RP13-753N3.1 -7.82 6.56e-14 9.77e-11 -0.66 -0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576813 chr17:30863921~30864940:- LIHC cis rs2882667 0.858 rs10900856 ENSG00000253404.1 AC034243.1 -7.82 6.6e-14 9.82e-11 -0.53 -0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139082057 chr5:138744434~138753309:- LIHC cis rs12744310 0.887 rs2363810 ENSG00000235358.1 RP11-399E6.1 7.82 6.63e-14 9.86e-11 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41318201 chr1:41242373~41284861:+ LIHC cis rs2739330 0.76 rs1002286 ENSG00000250470.1 AP000351.3 -7.82 6.67e-14 9.91e-11 -0.47 -0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23976904~23977585:- LIHC cis rs9543976 0.623 rs7986566 ENSG00000261553.4 RP11-29G8.3 7.82 6.75e-14 1e-10 0.53 0.39 Diabetic retinopathy; chr13:75623795 chr13:75549773~75807120:+ LIHC cis rs12744310 0.887 rs35410722 ENSG00000235358.1 RP11-399E6.1 7.82 6.83e-14 1.01e-10 0.52 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41330592 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs34539673 ENSG00000235358.1 RP11-399E6.1 7.82 6.83e-14 1.01e-10 0.52 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41331145 chr1:41242373~41284861:+ LIHC cis rs2739330 0.828 rs2330635 ENSG00000250470.1 AP000351.3 7.82 6.83e-14 1.01e-10 0.47 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23976904~23977585:- LIHC cis rs2882667 0.861 rs7703288 ENSG00000253404.1 AC034243.1 7.81 6.87e-14 1.02e-10 0.51 0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139030850 chr5:138744434~138753309:- LIHC cis rs7208859 0.623 rs79607958 ENSG00000263531.1 RP13-753N3.1 7.81 6.9e-14 1.02e-10 0.69 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607530 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs75136574 ENSG00000263531.1 RP13-753N3.1 7.81 6.9e-14 1.02e-10 0.69 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607531 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs77544470 ENSG00000263531.1 RP13-753N3.1 7.81 6.9e-14 1.02e-10 0.69 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607532 chr17:30863921~30864940:- LIHC cis rs9918079 0.56 rs4698406 ENSG00000273133.1 RP11-799M12.2 -7.81 6.97e-14 1.03e-10 -0.56 -0.39 Obesity-related traits; chr4:15638994 chr4:15563698~15564253:- LIHC cis rs6504950 0.925 rs244336 ENSG00000275710.1 RP11-257O5.4 7.81 6.98e-14 1.03e-10 0.58 0.39 Breast cancer; chr17:55124141 chr17:54964474~54964679:+ LIHC cis rs67180937 0.885 rs2133187 ENSG00000272750.1 RP11-378J18.8 -7.81 7.02e-14 1.04e-10 -0.4 -0.39 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222640383 chr1:222658867~222661512:- LIHC cis rs34779708 0.931 rs12773169 ENSG00000230534.5 RP11-297A16.2 7.81 7.09e-14 1.05e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35077534 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs7099593 ENSG00000230534.5 RP11-297A16.2 7.81 7.09e-14 1.05e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35077950 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs7084196 ENSG00000230534.5 RP11-297A16.2 7.81 7.09e-14 1.05e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35078233 chr10:35098006~35127020:- LIHC cis rs34779708 0.897 rs4934716 ENSG00000230534.5 RP11-297A16.2 7.81 7.09e-14 1.05e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35080371 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs13376801 ENSG00000230534.5 RP11-297A16.2 7.81 7.09e-14 1.05e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35081515 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs4934732 ENSG00000230534.5 RP11-297A16.2 7.81 7.09e-14 1.05e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35142756 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs878264 ENSG00000230534.5 RP11-297A16.2 7.81 7.09e-14 1.05e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35151653 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs13377158 ENSG00000230534.5 RP11-297A16.2 -7.81 7.09e-14 1.05e-10 -0.49 -0.39 Inflammatory bowel disease;Crohn's disease; chr10:35081537 chr10:35098006~35127020:- LIHC cis rs10899021 0.915 rs11236198 ENSG00000279353.1 RP11-864N7.4 7.81 7.14e-14 1.05e-10 0.98 0.39 Response to metformin (IC50); chr11:74661155 chr11:74698231~74699658:- LIHC cis rs1891275 0.515 rs1418161 ENSG00000228701.1 TNKS2-AS1 -7.81 7.15e-14 1.06e-10 -0.47 -0.39 Intelligence (multi-trait analysis); chr10:91724898 chr10:91782839~91798291:- LIHC cis rs7208859 0.573 rs216443 ENSG00000263531.1 RP13-753N3.1 7.81 7.28e-14 1.07e-10 0.65 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604853 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs609063 ENSG00000263531.1 RP13-753N3.1 7.8 7.35e-14 1.08e-10 0.68 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30624495 chr17:30863921~30864940:- LIHC cis rs9543976 0.623 rs8192756 ENSG00000261553.4 RP11-29G8.3 7.8 7.37e-14 1.09e-10 0.53 0.39 Diabetic retinopathy; chr13:75590802 chr13:75549773~75807120:+ LIHC cis rs9543976 0.623 rs3783028 ENSG00000261553.4 RP11-29G8.3 7.8 7.37e-14 1.09e-10 0.53 0.39 Diabetic retinopathy; chr13:75591146 chr13:75549773~75807120:+ LIHC cis rs9543976 0.623 rs7139740 ENSG00000261553.4 RP11-29G8.3 7.8 7.37e-14 1.09e-10 0.53 0.39 Diabetic retinopathy; chr13:75592806 chr13:75549773~75807120:+ LIHC cis rs4356975 0.83 rs6600868 ENSG00000249956.3 RP11-790I12.2 7.8 7.47e-14 1.1e-10 0.43 0.39 Obesity-related traits; chr4:69075923 chr4:69408836~69423164:+ LIHC cis rs7684253 0.565 rs12641030 ENSG00000269949.1 RP11-738E22.3 -7.8 7.52e-14 1.11e-10 -0.48 -0.39 Migraine; chr4:56937339 chr4:56960927~56961373:- LIHC cis rs17301013 0.606 rs10912737 ENSG00000227373.4 RP11-160H22.5 7.8 7.55e-14 1.11e-10 0.61 0.39 Systemic lupus erythematosus; chr1:174172999 chr1:174115300~174160004:- LIHC cis rs9543976 1 rs7339146 ENSG00000261553.4 RP11-29G8.3 -7.8 7.62e-14 1.12e-10 -0.56 -0.39 Diabetic retinopathy; chr13:75599583 chr13:75549773~75807120:+ LIHC cis rs9399135 1 rs1014021 ENSG00000232876.1 CTA-212D2.2 7.8 7.64e-14 1.12e-10 0.43 0.39 Red blood cell count; chr6:135013462 chr6:135055033~135060550:+ LIHC cis rs12744310 1 rs36143444 ENSG00000235358.1 RP11-399E6.1 7.8 7.65e-14 1.12e-10 0.5 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41298638 chr1:41242373~41284861:+ LIHC cis rs1577917 0.74 rs9344542 ENSG00000234155.1 RP11-30P6.6 -7.8 7.76e-14 1.14e-10 -0.45 -0.39 Response to antipsychotic treatment; chr6:85684187 chr6:85387219~85390186:- LIHC cis rs1891275 0.515 rs7092745 ENSG00000228701.1 TNKS2-AS1 -7.79 7.88e-14 1.15e-10 -0.46 -0.39 Intelligence (multi-trait analysis); chr10:91724063 chr10:91782839~91798291:- LIHC cis rs34779708 0.966 rs1057108 ENSG00000230534.5 RP11-297A16.2 7.79 7.89e-14 1.16e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35196021 chr10:35098006~35127020:- LIHC cis rs2929278 0.561 rs62018952 ENSG00000205771.5 CATSPER2P1 7.79 7.93e-14 1.16e-10 0.49 0.39 Schizophrenia; chr15:43788539 chr15:43726918~43747094:- LIHC cis rs9399135 1 rs9399135 ENSG00000232876.1 CTA-212D2.2 -7.79 7.98e-14 1.17e-10 -0.44 -0.39 Red blood cell count; chr6:135047176 chr6:135055033~135060550:+ LIHC cis rs11723261 0.621 rs6599307 ENSG00000275426.1 CH17-262A2.1 7.79 8.03e-14 1.18e-10 0.45 0.39 Immune response to smallpox vaccine (IL-6); chr4:149993 chr4:149738~150317:+ LIHC cis rs1062177 1 rs2964585 ENSG00000213433.5 RPLP1P6 -7.79 8.05e-14 1.18e-10 -0.45 -0.39 Preschool internalizing problems; chr5:151762334 chr5:151765859~151766378:- LIHC cis rs1062177 1 rs2964578 ENSG00000213433.5 RPLP1P6 -7.79 8.05e-14 1.18e-10 -0.45 -0.39 Preschool internalizing problems; chr5:151767637 chr5:151765859~151766378:- LIHC cis rs2882667 0.858 rs13176497 ENSG00000253404.1 AC034243.1 7.79 8.06e-14 1.18e-10 0.54 0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139110385 chr5:138744434~138753309:- LIHC cis rs4423214 0.802 rs2276358 ENSG00000254682.1 RP11-660L16.2 -7.79 8.11e-14 1.19e-10 -0.51 -0.39 Vitamin D levels; chr11:71473452 chr11:71448674~71452157:+ LIHC cis rs55665837 1 rs2305306 ENSG00000251991.1 RNU7-49P 7.79 8.12e-14 1.19e-10 0.41 0.39 Vitamin D levels; chr11:14513453 chr11:14478892~14478953:+ LIHC cis rs7208859 0.614 rs216412 ENSG00000263531.1 RP13-753N3.1 -7.79 8.13e-14 1.19e-10 -0.63 -0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576376 chr17:30863921~30864940:- LIHC cis rs2739330 0.76 rs5751760 ENSG00000250470.1 AP000351.3 7.79 8.13e-14 1.19e-10 0.48 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23976904~23977585:- LIHC cis rs6991838 0.584 rs2175810 ENSG00000272010.1 CTD-3025N20.3 -7.79 8.17e-14 1.19e-10 -0.41 -0.39 Intelligence (multi-trait analysis); chr8:65643583 chr8:65591850~65592472:- LIHC cis rs4356975 0.692 rs7691361 ENSG00000249956.3 RP11-790I12.2 7.79 8.21e-14 1.2e-10 0.43 0.39 Obesity-related traits; chr4:69077628 chr4:69408836~69423164:+ LIHC cis rs4356975 0.72 rs7691362 ENSG00000249956.3 RP11-790I12.2 7.79 8.21e-14 1.2e-10 0.43 0.39 Obesity-related traits; chr4:69077631 chr4:69408836~69423164:+ LIHC cis rs7684253 0.565 rs6830774 ENSG00000269949.1 RP11-738E22.3 -7.79 8.23e-14 1.2e-10 -0.48 -0.39 Migraine; chr4:56950140 chr4:56960927~56961373:- LIHC cis rs7617773 1 rs12496784 ENSG00000229759.1 MRPS18AP1 -7.79 8.24e-14 1.2e-10 -0.41 -0.39 Coronary artery disease; chr3:48144777 chr3:48256350~48256938:- LIHC cis rs8072100 1 rs4794016 ENSG00000228782.6 CTD-2026D20.3 -7.79 8.28e-14 1.21e-10 -0.44 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47648565 chr17:47450568~47492492:- LIHC cis rs2882667 0.931 rs10077796 ENSG00000253404.1 AC034243.1 -7.79 8.3e-14 1.21e-10 -0.51 -0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139021086 chr5:138744434~138753309:- LIHC cis rs1577917 0.771 rs9450319 ENSG00000234155.1 RP11-30P6.6 -7.79 8.31e-14 1.21e-10 -0.45 -0.39 Response to antipsychotic treatment; chr6:85717607 chr6:85387219~85390186:- LIHC cis rs8072100 0.934 rs9905583 ENSG00000228782.6 CTD-2026D20.3 7.78 8.41e-14 1.23e-10 0.45 0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47663650 chr17:47450568~47492492:- LIHC cis rs34779708 0.966 rs2045917 ENSG00000230534.5 RP11-297A16.2 7.78 8.46e-14 1.23e-10 0.5 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35129598 chr10:35098006~35127020:- LIHC cis rs3096299 0.719 rs2911265 ENSG00000274627.1 RP11-104N10.2 7.78 8.48e-14 1.24e-10 0.39 0.39 Multiple myeloma (IgH translocation); chr16:89444920 chr16:89516797~89522217:+ LIHC cis rs9399135 0.66 rs9389248 ENSG00000232876.1 CTA-212D2.2 -7.78 8.49e-14 1.24e-10 -0.43 -0.39 Red blood cell count; chr6:134961518 chr6:135055033~135060550:+ LIHC cis rs4356975 0.932 rs72852450 ENSG00000249956.3 RP11-790I12.2 7.78 8.54e-14 1.25e-10 0.43 0.39 Obesity-related traits; chr4:69079704 chr4:69408836~69423164:+ LIHC cis rs12744310 0.887 rs1892419 ENSG00000235358.1 RP11-399E6.1 7.78 8.65e-14 1.26e-10 0.52 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41315479 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs1892420 ENSG00000235358.1 RP11-399E6.1 7.78 8.65e-14 1.26e-10 0.52 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41315738 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs28541673 ENSG00000235358.1 RP11-399E6.1 7.78 8.65e-14 1.26e-10 0.52 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41316322 chr1:41242373~41284861:+ LIHC cis rs6991838 0.584 rs10089708 ENSG00000272010.1 CTD-3025N20.3 7.78 8.73e-14 1.27e-10 0.43 0.39 Intelligence (multi-trait analysis); chr8:65642927 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs6991731 ENSG00000272010.1 CTD-3025N20.3 7.78 8.73e-14 1.27e-10 0.43 0.39 Intelligence (multi-trait analysis); chr8:65643232 chr8:65591850~65592472:- LIHC cis rs6504950 0.889 rs1484776 ENSG00000275710.1 RP11-257O5.4 -7.78 8.76e-14 1.27e-10 -0.58 -0.39 Breast cancer; chr17:55034022 chr17:54964474~54964679:+ LIHC cis rs2019137 0.936 rs2241978 ENSG00000274877.1 RP11-65I12.1 7.78 8.84e-14 1.28e-10 0.47 0.39 Lymphocyte counts; chr2:113196429 chr2:113237595~113240825:+ LIHC cis rs2019137 0.936 rs3828188 ENSG00000274877.1 RP11-65I12.1 7.78 8.84e-14 1.28e-10 0.47 0.39 Lymphocyte counts; chr2:113196670 chr2:113237595~113240825:+ LIHC cis rs7727544 0.709 rs441969 ENSG00000233006.5 AC034220.3 7.78 8.94e-14 1.3e-10 0.39 0.39 Blood metabolite levels; chr5:132366428 chr5:132311285~132369916:- LIHC cis rs12744310 0.887 rs72667608 ENSG00000235358.1 RP11-399E6.1 7.78 8.95e-14 1.3e-10 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41329101 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs72667610 ENSG00000235358.1 RP11-399E6.1 7.78 8.95e-14 1.3e-10 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41329138 chr1:41242373~41284861:+ LIHC cis rs17301013 0.507 rs10912762 ENSG00000227373.4 RP11-160H22.5 7.77 8.96e-14 1.3e-10 0.64 0.39 Systemic lupus erythematosus; chr1:174312477 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10912763 ENSG00000227373.4 RP11-160H22.5 7.77 8.96e-14 1.3e-10 0.64 0.39 Systemic lupus erythematosus; chr1:174316083 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10912764 ENSG00000227373.4 RP11-160H22.5 7.77 8.96e-14 1.3e-10 0.64 0.39 Systemic lupus erythematosus; chr1:174316085 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12097252 ENSG00000227373.4 RP11-160H22.5 7.77 8.96e-14 1.3e-10 0.64 0.39 Systemic lupus erythematosus; chr1:174318374 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10912765 ENSG00000227373.4 RP11-160H22.5 7.77 8.96e-14 1.3e-10 0.64 0.39 Systemic lupus erythematosus; chr1:174322812 chr1:174115300~174160004:- LIHC cis rs9527 0.637 rs7096169 ENSG00000236937.2 PTGES3P4 7.77 8.97e-14 1.3e-10 0.47 0.39 Arsenic metabolism; chr10:102858938 chr10:102845595~102845950:+ LIHC cis rs2019137 0.936 rs4849169 ENSG00000274877.1 RP11-65I12.1 7.77 9e-14 1.31e-10 0.47 0.39 Lymphocyte counts; chr2:113196080 chr2:113237595~113240825:+ LIHC cis rs2019137 0.836 rs4848318 ENSG00000274877.1 RP11-65I12.1 7.77 9e-14 1.31e-10 0.47 0.39 Lymphocyte counts; chr2:113196375 chr2:113237595~113240825:+ LIHC cis rs2442825 0.693 rs2600194 ENSG00000206573.7 THUMPD3-AS1 7.77 9.09e-14 1.32e-10 0.34 0.39 Cerebrospinal fluid clusterin levels; chr3:9382941 chr3:9349689~9398579:- LIHC cis rs4853012 0.838 rs4563249 ENSG00000257800.1 FNBP1P1 7.77 9.17e-14 1.33e-10 0.43 0.39 Gestational age at birth (maternal effect); chr2:74126889 chr2:74120680~74123218:+ LIHC cis rs17301013 0.507 rs12065326 ENSG00000227373.4 RP11-160H22.5 7.77 9.25e-14 1.34e-10 0.62 0.39 Systemic lupus erythematosus; chr1:174426892 chr1:174115300~174160004:- LIHC cis rs7617773 0.925 rs6442105 ENSG00000229759.1 MRPS18AP1 -7.77 9.37e-14 1.36e-10 -0.44 -0.39 Coronary artery disease; chr3:48140836 chr3:48256350~48256938:- LIHC cis rs2882667 0.858 rs66839813 ENSG00000253404.1 AC034243.1 7.77 9.37e-14 1.36e-10 0.53 0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139106633 chr5:138744434~138753309:- LIHC cis rs12744310 0.887 rs12047161 ENSG00000235358.1 RP11-399E6.1 7.77 9.51e-14 1.38e-10 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41341856 chr1:41242373~41284861:+ LIHC cis rs4356975 0.932 rs4694612 ENSG00000249956.3 RP11-790I12.2 7.76 9.58e-14 1.39e-10 0.43 0.39 Obesity-related traits; chr4:69079446 chr4:69408836~69423164:+ LIHC cis rs4356975 0.932 rs56879009 ENSG00000249956.3 RP11-790I12.2 7.76 9.58e-14 1.39e-10 0.43 0.39 Obesity-related traits; chr4:69079589 chr4:69408836~69423164:+ LIHC cis rs2739330 0.789 rs5760109 ENSG00000250470.1 AP000351.3 7.76 9.71e-14 1.4e-10 0.47 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23976904~23977585:- LIHC cis rs17301013 0.606 rs913687 ENSG00000227373.4 RP11-160H22.5 7.76 9.78e-14 1.41e-10 0.6 0.39 Systemic lupus erythematosus; chr1:174805993 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs1793315 ENSG00000227373.4 RP11-160H22.5 -7.76 9.78e-14 1.41e-10 -0.6 -0.39 Systemic lupus erythematosus; chr1:174808923 chr1:174115300~174160004:- LIHC cis rs6504950 0.85 rs2628308 ENSG00000275710.1 RP11-257O5.4 -7.76 9.87e-14 1.42e-10 -0.58 -0.39 Breast cancer; chr17:55046212 chr17:54964474~54964679:+ LIHC cis rs34779708 0.931 rs2384287 ENSG00000230534.5 RP11-297A16.2 7.76 9.91e-14 1.43e-10 0.48 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35051631 chr10:35098006~35127020:- LIHC cis rs9399135 1 rs35123050 ENSG00000232876.1 CTA-212D2.2 -7.76 1e-13 1.44e-10 -0.43 -0.39 Red blood cell count; chr6:134981602 chr6:135055033~135060550:+ LIHC cis rs73086581 1 rs73086505 ENSG00000229539.1 RP11-119B16.2 7.76 1e-13 1.45e-10 0.71 0.39 Response to antidepressants in depression; chr20:3940924 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs73086508 ENSG00000229539.1 RP11-119B16.2 7.76 1e-13 1.45e-10 0.71 0.39 Response to antidepressants in depression; chr20:3941068 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs73086510 ENSG00000229539.1 RP11-119B16.2 7.76 1e-13 1.45e-10 0.71 0.39 Response to antidepressants in depression; chr20:3941484 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs17286768 ENSG00000229539.1 RP11-119B16.2 7.76 1e-13 1.45e-10 0.71 0.39 Response to antidepressants in depression; chr20:3943922 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs17214621 ENSG00000229539.1 RP11-119B16.2 7.76 1e-13 1.45e-10 0.71 0.39 Response to antidepressants in depression; chr20:3945277 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs73086581 ENSG00000229539.1 RP11-119B16.2 7.76 1e-13 1.45e-10 0.71 0.39 Response to antidepressants in depression; chr20:3996678 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs14047 ENSG00000229539.1 RP11-119B16.2 7.76 1e-13 1.45e-10 0.71 0.39 Response to antidepressants in depression; chr20:3933568 chr20:3888239~3888868:- LIHC cis rs17301013 0.606 rs10912754 ENSG00000227373.4 RP11-160H22.5 7.76 1e-13 1.45e-10 0.6 0.39 Systemic lupus erythematosus; chr1:174273667 chr1:174115300~174160004:- LIHC cis rs7208859 0.623 rs8082537 ENSG00000263531.1 RP13-753N3.1 7.76 1.01e-13 1.46e-10 0.65 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30688914 chr17:30863921~30864940:- LIHC cis rs2882667 0.931 rs3749665 ENSG00000253404.1 AC034243.1 7.76 1.02e-13 1.47e-10 0.5 0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139021522 chr5:138744434~138753309:- LIHC cis rs9399135 0.967 rs4896120 ENSG00000232876.1 CTA-212D2.2 -7.76 1.02e-13 1.47e-10 -0.43 -0.39 Red blood cell count; chr6:134972374 chr6:135055033~135060550:+ LIHC cis rs7085104 0.7 rs10883785 ENSG00000236937.2 PTGES3P4 7.75 1.03e-13 1.48e-10 0.46 0.39 Immature fraction of reticulocytes;Schizophrenia; chr10:102843831 chr10:102845595~102845950:+ LIHC cis rs7396835 0.5 rs5092 ENSG00000254851.1 RP11-109L13.1 -7.75 1.05e-13 1.52e-10 -0.52 -0.39 Quantitative traits; chr11:116822748 chr11:117135528~117138582:+ LIHC cis rs34779708 0.931 rs11597392 ENSG00000230534.5 RP11-297A16.2 7.75 1.06e-13 1.52e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:34999647 chr10:35098006~35127020:- LIHC cis rs138857 0.515 rs9616373 ENSG00000278869.1 CITF22-49E9.3 7.75 1.07e-13 1.54e-10 0.81 0.39 Mean platelet volume; chr22:49914949 chr22:49933198~49934074:- LIHC cis rs2882667 0.858 rs13174479 ENSG00000253404.1 AC034243.1 7.75 1.07e-13 1.54e-10 0.53 0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139108481 chr5:138744434~138753309:- LIHC cis rs2882667 0.929 rs34846849 ENSG00000253404.1 AC034243.1 7.75 1.08e-13 1.55e-10 0.53 0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139024889 chr5:138744434~138753309:- LIHC cis rs17301013 0.507 rs4651008 ENSG00000227373.4 RP11-160H22.5 7.75 1.08e-13 1.55e-10 0.64 0.39 Systemic lupus erythematosus; chr1:174342681 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs7517516 ENSG00000227373.4 RP11-160H22.5 7.75 1.08e-13 1.55e-10 0.64 0.39 Systemic lupus erythematosus; chr1:174346187 chr1:174115300~174160004:- LIHC cis rs34779708 0.771 rs12098283 ENSG00000230534.5 RP11-297A16.2 7.75 1.08e-13 1.56e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35189187 chr10:35098006~35127020:- LIHC cis rs2442825 0.693 rs2596916 ENSG00000206573.7 THUMPD3-AS1 7.74 1.1e-13 1.58e-10 0.33 0.39 Cerebrospinal fluid clusterin levels; chr3:9380526 chr3:9349689~9398579:- LIHC cis rs17301013 0.507 rs61528155 ENSG00000227373.4 RP11-160H22.5 7.74 1.1e-13 1.58e-10 0.65 0.39 Systemic lupus erythematosus; chr1:174276140 chr1:174115300~174160004:- LIHC cis rs2882667 0.861 rs11242445 ENSG00000253404.1 AC034243.1 7.74 1.1e-13 1.58e-10 0.5 0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139081365 chr5:138744434~138753309:- LIHC cis rs2019137 0.967 rs902695 ENSG00000274877.1 RP11-65I12.1 7.74 1.1e-13 1.59e-10 0.47 0.39 Lymphocyte counts; chr2:113197497 chr2:113237595~113240825:+ LIHC cis rs34779708 0.931 rs11010125 ENSG00000230534.5 RP11-297A16.2 7.74 1.11e-13 1.59e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35214025 chr10:35098006~35127020:- LIHC cis rs7580658 0.637 rs4662710 ENSG00000236682.1 AC068282.3 -7.74 1.12e-13 1.6e-10 -0.48 -0.39 Protein C levels; chr2:127219241 chr2:127389130~127400580:+ LIHC cis rs7044106 0.762 rs13291660 ENSG00000226752.6 PSMD5-AS1 -7.74 1.13e-13 1.62e-10 -0.4 -0.39 Hip circumference adjusted for BMI; chr9:120630470 chr9:120824828~120854385:+ LIHC cis rs17301013 0.581 rs11801385 ENSG00000227373.4 RP11-160H22.5 7.74 1.13e-13 1.62e-10 0.61 0.39 Systemic lupus erythematosus; chr1:174089454 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs17350956 ENSG00000227373.4 RP11-160H22.5 7.74 1.13e-13 1.62e-10 0.61 0.39 Systemic lupus erythematosus; chr1:174093863 chr1:174115300~174160004:- LIHC cis rs12744310 0.887 rs12046670 ENSG00000235358.1 RP11-399E6.1 7.74 1.14e-13 1.63e-10 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41343640 chr1:41242373~41284861:+ LIHC cis rs34779708 0.966 rs10827492 ENSG00000230534.5 RP11-297A16.2 -7.74 1.14e-13 1.63e-10 -0.49 -0.39 Inflammatory bowel disease;Crohn's disease; chr10:35140897 chr10:35098006~35127020:- LIHC cis rs17301013 0.507 rs12072050 ENSG00000227373.4 RP11-160H22.5 7.74 1.14e-13 1.64e-10 0.65 0.39 Systemic lupus erythematosus; chr1:174269648 chr1:174115300~174160004:- LIHC cis rs1062177 1 rs2915882 ENSG00000213433.5 RPLP1P6 -7.74 1.15e-13 1.64e-10 -0.44 -0.39 Preschool internalizing problems; chr5:151765875 chr5:151765859~151766378:- LIHC cis rs1062177 1 rs2915880 ENSG00000213433.5 RPLP1P6 -7.74 1.15e-13 1.64e-10 -0.44 -0.39 Preschool internalizing problems; chr5:151767773 chr5:151765859~151766378:- LIHC cis rs1062177 0.826 rs2915879 ENSG00000213433.5 RPLP1P6 -7.74 1.15e-13 1.64e-10 -0.44 -0.39 Preschool internalizing problems; chr5:151767881 chr5:151765859~151766378:- LIHC cis rs7580658 0.637 rs4580338 ENSG00000236682.1 AC068282.3 -7.74 1.15e-13 1.64e-10 -0.48 -0.39 Protein C levels; chr2:127217361 chr2:127389130~127400580:+ LIHC cis rs6504950 0.886 rs2541236 ENSG00000275710.1 RP11-257O5.4 -7.74 1.16e-13 1.66e-10 -0.58 -0.39 Breast cancer; chr17:55082471 chr17:54964474~54964679:+ LIHC cis rs6991838 0.584 rs7812446 ENSG00000272010.1 CTD-3025N20.3 -7.74 1.16e-13 1.66e-10 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65593753 chr8:65591850~65592472:- LIHC cis rs6991838 0.557 rs7812390 ENSG00000272010.1 CTD-3025N20.3 -7.74 1.16e-13 1.66e-10 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65593982 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs16932245 ENSG00000272010.1 CTD-3025N20.3 -7.74 1.16e-13 1.66e-10 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65597810 chr8:65591850~65592472:- LIHC cis rs6991838 0.557 rs57419568 ENSG00000272010.1 CTD-3025N20.3 -7.74 1.16e-13 1.66e-10 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65598633 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs16932250 ENSG00000272010.1 CTD-3025N20.3 -7.74 1.16e-13 1.66e-10 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65598779 chr8:65591850~65592472:- LIHC cis rs2442825 0.693 rs2728949 ENSG00000206573.7 THUMPD3-AS1 7.74 1.16e-13 1.67e-10 0.34 0.39 Cerebrospinal fluid clusterin levels; chr3:9364977 chr3:9349689~9398579:- LIHC cis rs832187 0.704 rs832195 ENSG00000280620.1 SCAANT1 -7.74 1.17e-13 1.67e-10 -0.48 -0.39 Schizophrenia; chr3:63878936 chr3:63911518~63911772:- LIHC cis rs4356975 0.932 rs4694611 ENSG00000249956.3 RP11-790I12.2 7.73 1.17e-13 1.68e-10 0.42 0.39 Obesity-related traits; chr4:69079387 chr4:69408836~69423164:+ LIHC cis rs73086581 1 rs17214949 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3960305 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs73086535 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3963503 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs17215054 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3964132 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs17287486 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3965620 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs73086540 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3970203 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs73086544 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3970281 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs2326289 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3971653 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs73086549 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3974015 chr20:3888239~3888868:- LIHC cis rs73086581 0.947 rs55794220 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3975755 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs113812453 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3982546 chr20:3888239~3888868:- LIHC cis rs73086581 0.891 rs55871214 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3985059 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs56069856 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3985062 chr20:3888239~3888868:- LIHC cis rs73086581 0.947 rs17287577 ENSG00000229539.1 RP11-119B16.2 7.73 1.17e-13 1.68e-10 0.71 0.39 Response to antidepressants in depression; chr20:3985607 chr20:3888239~3888868:- LIHC cis rs8072100 0.905 rs8078686 ENSG00000228782.6 CTD-2026D20.3 -7.73 1.17e-13 1.68e-10 -0.45 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47658340 chr17:47450568~47492492:- LIHC cis rs7580658 0.676 rs4150407 ENSG00000236682.1 AC068282.3 7.73 1.18e-13 1.68e-10 0.48 0.39 Protein C levels; chr2:127292055 chr2:127389130~127400580:+ LIHC cis rs9828933 0.752 rs17069507 ENSG00000280620.1 SCAANT1 7.73 1.18e-13 1.69e-10 0.63 0.39 Type 2 diabetes; chr3:63939280 chr3:63911518~63911772:- LIHC cis rs8072100 1 rs3809868 ENSG00000228782.6 CTD-2026D20.3 -7.73 1.19e-13 1.69e-10 -0.45 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47673230 chr17:47450568~47492492:- LIHC cis rs8072100 1 rs7210738 ENSG00000228782.6 CTD-2026D20.3 -7.73 1.19e-13 1.69e-10 -0.45 -0.39 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47680232 chr17:47450568~47492492:- LIHC cis rs6991838 0.584 rs34494846 ENSG00000272010.1 CTD-3025N20.3 -7.73 1.19e-13 1.7e-10 -0.42 -0.39 Intelligence (multi-trait analysis); chr8:65602397 chr8:65591850~65592472:- LIHC cis rs9399135 0.967 rs6909975 ENSG00000232876.1 CTA-212D2.2 -7.73 1.19e-13 1.7e-10 -0.43 -0.39 Red blood cell count; chr6:134994432 chr6:135055033~135060550:+ LIHC cis rs9399135 0.967 rs7773126 ENSG00000232876.1 CTA-212D2.2 -7.73 1.19e-13 1.7e-10 -0.43 -0.39 Red blood cell count; chr6:134997252 chr6:135055033~135060550:+ LIHC cis rs9543976 0.623 rs9544004 ENSG00000261553.4 RP11-29G8.3 7.73 1.2e-13 1.71e-10 0.52 0.39 Diabetic retinopathy; chr13:75617748 chr13:75549773~75807120:+ LIHC cis rs9543976 0.588 rs7324195 ENSG00000261553.4 RP11-29G8.3 7.73 1.2e-13 1.71e-10 0.52 0.39 Diabetic retinopathy; chr13:75618386 chr13:75549773~75807120:+ LIHC cis rs67180937 0.844 rs35626308 ENSG00000272750.1 RP11-378J18.8 -7.73 1.2e-13 1.71e-10 -0.4 -0.39 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222643014 chr1:222658867~222661512:- LIHC cis rs17301013 0.507 rs6677243 ENSG00000227373.4 RP11-160H22.5 7.73 1.21e-13 1.72e-10 0.62 0.39 Systemic lupus erythematosus; chr1:174339471 chr1:174115300~174160004:- LIHC cis rs2188561 0.806 rs2712210 ENSG00000241764.3 AC002467.7 7.73 1.21e-13 1.73e-10 0.5 0.39 Alcohol consumption; chr7:107687407 chr7:107742817~107744581:- LIHC cis rs494459 0.838 rs2510897 ENSG00000255422.1 AP002954.4 -7.73 1.23e-13 1.75e-10 -0.43 -0.39 Height; chr11:118773873 chr11:118704607~118750263:+ LIHC cis rs1165205 0.558 rs793144 ENSG00000242387.1 HIST1H2APS2 7.73 1.24e-13 1.76e-10 0.48 0.39 Urate levels; chr6:25879093 chr6:25882026~25882395:- LIHC cis rs1165205 0.5 rs629835 ENSG00000242387.1 HIST1H2APS2 7.73 1.24e-13 1.76e-10 0.48 0.39 Urate levels; chr6:25879102 chr6:25882026~25882395:- LIHC cis rs17826219 0.561 rs11655876 ENSG00000263531.1 RP13-753N3.1 7.73 1.25e-13 1.78e-10 0.63 0.39 Body mass index; chr17:30690132 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9907197 ENSG00000263531.1 RP13-753N3.1 7.73 1.25e-13 1.78e-10 0.63 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30691245 chr17:30863921~30864940:- LIHC cis rs7208859 0.673 rs9915963 ENSG00000263531.1 RP13-753N3.1 7.73 1.25e-13 1.78e-10 0.63 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30692625 chr17:30863921~30864940:- LIHC cis rs2929278 0.588 rs1975364 ENSG00000205771.5 CATSPER2P1 -7.73 1.25e-13 1.78e-10 -0.49 -0.39 Schizophrenia; chr15:43857991 chr15:43726918~43747094:- LIHC cis rs9399135 0.967 rs6923827 ENSG00000232876.1 CTA-212D2.2 -7.72 1.25e-13 1.78e-10 -0.43 -0.39 Red blood cell count; chr6:135014244 chr6:135055033~135060550:+ LIHC cis rs12744310 0.83 rs12045184 ENSG00000235358.1 RP11-399E6.1 7.72 1.25e-13 1.78e-10 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41333939 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs12724690 ENSG00000235358.1 RP11-399E6.1 7.72 1.25e-13 1.78e-10 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41334585 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs35464028 ENSG00000235358.1 RP11-399E6.1 7.72 1.25e-13 1.78e-10 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41334802 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs34152153 ENSG00000235358.1 RP11-399E6.1 7.72 1.25e-13 1.78e-10 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41335736 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs36040148 ENSG00000235358.1 RP11-399E6.1 7.72 1.25e-13 1.78e-10 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41335776 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs35807669 ENSG00000235358.1 RP11-399E6.1 7.72 1.25e-13 1.78e-10 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41335980 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs12026404 ENSG00000235358.1 RP11-399E6.1 7.72 1.25e-13 1.78e-10 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41336240 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs12047272 ENSG00000235358.1 RP11-399E6.1 7.72 1.25e-13 1.78e-10 0.51 0.39 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41336271 chr1:41242373~41284861:+ LIHC cis rs62355901 0.505 rs62356565 ENSG00000271828.1 CTD-2310F14.1 7.72 1.26e-13 1.78e-10 0.59 0.39 Breast cancer; chr5:56948139 chr5:56927874~56929573:+ LIHC cis rs34779708 0.897 rs4934529 ENSG00000230534.5 RP11-297A16.2 7.72 1.27e-13 1.8e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35013448 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs7920095 ENSG00000230534.5 RP11-297A16.2 7.72 1.27e-13 1.8e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35014406 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs35848945 ENSG00000230534.5 RP11-297A16.2 7.72 1.27e-13 1.8e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:34998633 chr10:35098006~35127020:- LIHC cis rs4728142 0.604 rs2272347 ENSG00000275106.1 RP11-309L24.10 7.72 1.28e-13 1.81e-10 0.47 0.39 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128979361 chr7:128952527~128953316:- LIHC cis rs151227923 1 rs151227923 ENSG00000273117.1 AC144652.1 7.72 1.28e-13 1.82e-10 0.41 0.39 Stem cell growth factor beta levels; chr7:155314854 chr7:155295918~155297541:- LIHC cis rs140365914 1 rs140365914 ENSG00000273117.1 AC144652.1 7.72 1.28e-13 1.82e-10 0.41 0.39 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr7:155314860 chr7:155295918~155297541:- LIHC cis rs1577917 0.771 rs4383777 ENSG00000234155.1 RP11-30P6.6 -7.72 1.29e-13 1.82e-10 -0.45 -0.39 Response to antipsychotic treatment; chr6:85726242 chr6:85387219~85390186:- LIHC cis rs4356975 0.932 rs12648830 ENSG00000249956.3 RP11-790I12.2 -7.72 1.29e-13 1.83e-10 -0.43 -0.39 Obesity-related traits; chr4:69075436 chr4:69408836~69423164:+ LIHC cis rs2019137 0.936 rs3828189 ENSG00000274877.1 RP11-65I12.1 7.72 1.29e-13 1.83e-10 0.47 0.39 Lymphocyte counts; chr2:113196919 chr2:113237595~113240825:+ LIHC cis rs2019137 0.936 rs2305133 ENSG00000274877.1 RP11-65I12.1 7.72 1.3e-13 1.83e-10 0.47 0.39 Lymphocyte counts; chr2:113199244 chr2:113237595~113240825:+ LIHC cis rs2019137 0.936 rs12612729 ENSG00000274877.1 RP11-65I12.1 7.72 1.3e-13 1.83e-10 0.47 0.39 Lymphocyte counts; chr2:113199471 chr2:113237595~113240825:+ LIHC cis rs2019137 0.936 rs731834 ENSG00000274877.1 RP11-65I12.1 7.72 1.3e-13 1.83e-10 0.47 0.39 Lymphocyte counts; chr2:113199621 chr2:113237595~113240825:+ LIHC cis rs9543976 1 rs2328964 ENSG00000261553.4 RP11-29G8.3 7.72 1.3e-13 1.84e-10 0.56 0.39 Diabetic retinopathy; chr13:75564694 chr13:75549773~75807120:+ LIHC cis rs34779708 0.868 rs2384352 ENSG00000230534.5 RP11-297A16.2 7.72 1.31e-13 1.85e-10 0.49 0.39 Inflammatory bowel disease;Crohn's disease; chr10:35203904 chr10:35098006~35127020:- LIHC cis rs7727544 0.684 rs274567 ENSG00000233006.5 AC034220.3 -7.72 1.31e-13 1.85e-10 -0.38 -0.39 Blood metabolite levels; chr5:132378717 chr5:132311285~132369916:- LIHC cis rs2739330 0.76 rs1007888 ENSG00000250470.1 AP000351.3 7.72 1.31e-13 1.86e-10 0.47 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23976904~23977585:- LIHC cis rs1891275 0.515 rs7911755 ENSG00000228701.1 TNKS2-AS1 -7.72 1.32e-13 1.86e-10 -0.47 -0.39 Intelligence (multi-trait analysis); chr10:91730060 chr10:91782839~91798291:- LIHC cis rs494459 0.838 rs488219 ENSG00000255422.1 AP002954.4 -7.72 1.32e-13 1.87e-10 -0.43 -0.39 Height; chr11:118749988 chr11:118704607~118750263:+ LIHC cis rs2019137 0.905 rs2276561 ENSG00000274877.1 RP11-65I12.1 7.72 1.32e-13 1.87e-10 0.47 0.39 Lymphocyte counts; chr2:113198794 chr2:113237595~113240825:+ LIHC cis rs1577917 0.538 rs7755996 ENSG00000234155.1 RP11-30P6.6 -7.72 1.32e-13 1.87e-10 -0.44 -0.39 Response to antipsychotic treatment; chr6:85714002 chr6:85387219~85390186:- LIHC cis rs9543976 1 rs55927305 ENSG00000261553.4 RP11-29G8.3 -7.71 1.34e-13 1.89e-10 -0.57 -0.38 Diabetic retinopathy; chr13:75561213 chr13:75549773~75807120:+ LIHC cis rs67180937 0.921 rs35700460 ENSG00000272750.1 RP11-378J18.8 -7.71 1.35e-13 1.9e-10 -0.4 -0.38 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222638065 chr1:222658867~222661512:- LIHC cis rs12744310 0.887 rs35021924 ENSG00000235358.1 RP11-399E6.1 7.71 1.38e-13 1.94e-10 0.5 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41321235 chr1:41242373~41284861:+ LIHC cis rs34779708 0.966 rs7070427 ENSG00000230534.5 RP11-297A16.2 7.71 1.39e-13 1.95e-10 0.49 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35196761 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs12775799 ENSG00000230534.5 RP11-297A16.2 7.71 1.39e-13 1.95e-10 0.49 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35199336 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs11010122 ENSG00000230534.5 RP11-297A16.2 7.71 1.39e-13 1.95e-10 0.49 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35204590 chr10:35098006~35127020:- LIHC cis rs34779708 0.9 rs73262807 ENSG00000230534.5 RP11-297A16.2 7.71 1.39e-13 1.95e-10 0.49 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35207458 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs17591781 ENSG00000230534.5 RP11-297A16.2 7.71 1.39e-13 1.95e-10 0.49 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35209610 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs17500582 ENSG00000230534.5 RP11-297A16.2 7.71 1.39e-13 1.95e-10 0.49 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35209860 chr10:35098006~35127020:- LIHC cis rs9543976 1 rs73223968 ENSG00000261553.4 RP11-29G8.3 -7.71 1.4e-13 1.97e-10 -0.56 -0.38 Diabetic retinopathy; chr13:75567585 chr13:75549773~75807120:+ LIHC cis rs9543976 1 rs2296146 ENSG00000261553.4 RP11-29G8.3 -7.71 1.4e-13 1.97e-10 -0.56 -0.38 Diabetic retinopathy; chr13:75569436 chr13:75549773~75807120:+ LIHC cis rs1501911 0.509 rs330422 ENSG00000248489.1 CTD-2007H13.3 7.71 1.43e-13 2.01e-10 0.56 0.38 Lung function (FEV1/FVC); chr5:98859184 chr5:98929171~98995013:+ LIHC cis rs7727544 0.735 rs274566 ENSG00000233006.5 AC034220.3 -7.7 1.43e-13 2.01e-10 -0.39 -0.38 Blood metabolite levels; chr5:132379319 chr5:132311285~132369916:- LIHC cis rs34779708 0.931 rs4934709 ENSG00000230534.5 RP11-297A16.2 -7.7 1.44e-13 2.01e-10 -0.48 -0.38 Inflammatory bowel disease;Crohn's disease; chr10:35050396 chr10:35098006~35127020:- LIHC cis rs296381 0.932 rs296391 ENSG00000259108.2 CTD-3098H1.2 7.7 1.44e-13 2.02e-10 0.57 0.38 Blood metabolite levels; chr19:47865277 chr19:47863483~47865341:- LIHC cis rs1577917 0.739 rs9450318 ENSG00000234155.1 RP11-30P6.6 -7.7 1.45e-13 2.03e-10 -0.45 -0.38 Response to antipsychotic treatment; chr6:85717459 chr6:85387219~85390186:- LIHC cis rs1062177 0.951 rs2915876 ENSG00000213433.5 RPLP1P6 -7.7 1.45e-13 2.03e-10 -0.44 -0.38 Preschool internalizing problems; chr5:151771184 chr5:151765859~151766378:- LIHC cis rs1062177 1 rs17741826 ENSG00000213433.5 RPLP1P6 7.7 1.45e-13 2.03e-10 0.44 0.38 Preschool internalizing problems; chr5:151769701 chr5:151765859~151766378:- LIHC cis rs6991838 0.584 rs34226237 ENSG00000272010.1 CTD-3025N20.3 -7.7 1.45e-13 2.04e-10 -0.41 -0.38 Intelligence (multi-trait analysis); chr8:65600930 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs6994213 ENSG00000272010.1 CTD-3025N20.3 -7.7 1.45e-13 2.04e-10 -0.41 -0.38 Intelligence (multi-trait analysis); chr8:65601497 chr8:65591850~65592472:- LIHC cis rs7044106 0.718 rs1981021 ENSG00000226752.6 PSMD5-AS1 -7.7 1.46e-13 2.05e-10 -0.4 -0.38 Hip circumference adjusted for BMI; chr9:120626115 chr9:120824828~120854385:+ LIHC cis rs7044106 0.734 rs1981020 ENSG00000226752.6 PSMD5-AS1 -7.7 1.46e-13 2.05e-10 -0.4 -0.38 Hip circumference adjusted for BMI; chr9:120626186 chr9:120824828~120854385:+ LIHC cis rs34779708 0.897 rs12830 ENSG00000230534.5 RP11-297A16.2 7.7 1.47e-13 2.05e-10 0.49 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35013777 chr10:35098006~35127020:- LIHC cis rs12439619 1 rs12439619 ENSG00000278603.1 RP13-608F4.5 7.7 1.47e-13 2.06e-10 0.63 0.38 Intelligence (multi-trait analysis); chr15:82254605 chr15:82472203~82472426:+ LIHC cis rs1891275 0.515 rs4244930 ENSG00000228701.1 TNKS2-AS1 -7.7 1.47e-13 2.06e-10 -0.46 -0.38 Intelligence (multi-trait analysis); chr10:91707092 chr10:91782839~91798291:- LIHC cis rs1891275 0.515 rs11186666 ENSG00000228701.1 TNKS2-AS1 -7.7 1.47e-13 2.06e-10 -0.46 -0.38 Intelligence (multi-trait analysis); chr10:91718162 chr10:91782839~91798291:- LIHC cis rs17301013 0.606 rs12077529 ENSG00000227373.4 RP11-160H22.5 7.7 1.49e-13 2.08e-10 0.57 0.38 Systemic lupus erythematosus; chr1:174549874 chr1:174115300~174160004:- LIHC cis rs893363 0.61 rs920252 ENSG00000271916.1 RP11-884K10.6 -7.7 1.49e-13 2.08e-10 -0.73 -0.38 Axial length; chr3:53814645 chr3:53797764~53798019:- LIHC cis rs7727544 0.735 rs274568 ENSG00000233006.5 AC034220.3 -7.7 1.5e-13 2.09e-10 -0.39 -0.38 Blood metabolite levels; chr5:132377886 chr5:132311285~132369916:- LIHC cis rs6991838 0.584 rs35790435 ENSG00000272010.1 CTD-3025N20.3 -7.7 1.5e-13 2.1e-10 -0.41 -0.38 Intelligence (multi-trait analysis); chr8:65590288 chr8:65591850~65592472:- LIHC cis rs34779708 0.966 rs17591857 ENSG00000230534.5 RP11-297A16.2 -7.7 1.5e-13 2.1e-10 -0.49 -0.38 Inflammatory bowel disease;Crohn's disease; chr10:35210115 chr10:35098006~35127020:- LIHC cis rs9543976 0.623 rs6562915 ENSG00000261553.4 RP11-29G8.3 7.7 1.5e-13 2.1e-10 0.52 0.38 Diabetic retinopathy; chr13:75596750 chr13:75549773~75807120:+ LIHC cis rs9399135 1 rs4475342 ENSG00000232876.1 CTA-212D2.2 -7.7 1.51e-13 2.11e-10 -0.43 -0.38 Red blood cell count; chr6:134962210 chr6:135055033~135060550:+ LIHC cis rs9543976 0.623 rs6562913 ENSG00000261553.4 RP11-29G8.3 7.7 1.51e-13 2.11e-10 0.52 0.38 Diabetic retinopathy; chr13:75593297 chr13:75549773~75807120:+ LIHC cis rs9543976 0.623 rs6562914 ENSG00000261553.4 RP11-29G8.3 7.7 1.52e-13 2.13e-10 0.51 0.38 Diabetic retinopathy; chr13:75593401 chr13:75549773~75807120:+ LIHC cis rs1577917 0.696 rs10806334 ENSG00000234155.1 RP11-30P6.6 7.69 1.53e-13 2.13e-10 0.45 0.38 Response to antipsychotic treatment; chr6:85729611 chr6:85387219~85390186:- LIHC cis rs1062177 1 rs2964584 ENSG00000213433.5 RPLP1P6 -7.69 1.54e-13 2.14e-10 -0.44 -0.38 Preschool internalizing problems; chr5:151763317 chr5:151765859~151766378:- LIHC cis rs34779708 0.931 rs7923172 ENSG00000230534.5 RP11-297A16.2 7.69 1.54e-13 2.16e-10 0.48 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35020439 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs3740083 ENSG00000230534.5 RP11-297A16.2 7.69 1.54e-13 2.16e-10 0.48 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35031455 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs12261654 ENSG00000230534.5 RP11-297A16.2 7.69 1.54e-13 2.16e-10 0.48 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35033096 chr10:35098006~35127020:- LIHC cis rs2283792 0.622 rs381523 ENSG00000224086.5 LL22NC03-86G7.1 -7.69 1.55e-13 2.16e-10 -0.36 -0.38 Multiple sclerosis; chr22:21951257 chr22:21938293~21977632:+ LIHC cis rs2882667 0.858 rs11242448 ENSG00000253404.1 AC034243.1 7.69 1.56e-13 2.17e-10 0.53 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139107465 chr5:138744434~138753309:- LIHC cis rs6890270 0.634 rs62356569 ENSG00000271828.1 CTD-2310F14.1 7.69 1.58e-13 2.2e-10 0.55 0.38 Breast cancer; chr5:56963908 chr5:56927874~56929573:+ LIHC cis rs17301013 0.507 rs10912753 ENSG00000227373.4 RP11-160H22.5 7.69 1.59e-13 2.21e-10 0.64 0.38 Systemic lupus erythematosus; chr1:174265226 chr1:174115300~174160004:- LIHC cis rs8062405 0.755 rs62031607 ENSG00000259982.1 CDC37P1 7.69 1.59e-13 2.21e-10 0.5 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620209 chr16:28700294~28701540:- LIHC cis rs494459 0.838 rs581045 ENSG00000255422.1 AP002954.4 -7.69 1.59e-13 2.22e-10 -0.43 -0.38 Height; chr11:118761813 chr11:118704607~118750263:+ LIHC cis rs9918079 0.524 rs4235379 ENSG00000273133.1 RP11-799M12.2 -7.69 1.59e-13 2.22e-10 -0.54 -0.38 Obesity-related traits; chr4:15657655 chr4:15563698~15564253:- LIHC cis rs6991838 0.557 rs7012578 ENSG00000272010.1 CTD-3025N20.3 -7.69 1.59e-13 2.22e-10 -0.41 -0.38 Intelligence (multi-trait analysis); chr8:65592592 chr8:65591850~65592472:- LIHC cis rs17301013 0.581 rs12082139 ENSG00000227373.4 RP11-160H22.5 7.69 1.6e-13 2.23e-10 0.59 0.38 Systemic lupus erythematosus; chr1:174589043 chr1:174115300~174160004:- LIHC cis rs17301013 0.62 rs1793310 ENSG00000227373.4 RP11-160H22.5 -7.69 1.61e-13 2.24e-10 -0.59 -0.38 Systemic lupus erythematosus; chr1:174770786 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs1618408 ENSG00000227373.4 RP11-160H22.5 -7.69 1.61e-13 2.24e-10 -0.59 -0.38 Systemic lupus erythematosus; chr1:174777402 chr1:174115300~174160004:- LIHC cis rs2019137 0.868 rs6755639 ENSG00000274877.1 RP11-65I12.1 -7.69 1.61e-13 2.24e-10 -0.46 -0.38 Lymphocyte counts; chr2:113224233 chr2:113237595~113240825:+ LIHC cis rs17301013 0.507 rs6693198 ENSG00000227373.4 RP11-160H22.5 7.69 1.61e-13 2.24e-10 0.63 0.38 Systemic lupus erythematosus; chr1:174304301 chr1:174115300~174160004:- LIHC cis rs1150668 0.83 rs213240 ENSG00000216901.1 AL022393.7 7.69 1.62e-13 2.26e-10 0.44 0.38 Pubertal anthropometrics; chr6:28348098 chr6:28176188~28176674:+ LIHC cis rs494459 0.838 rs555639 ENSG00000255422.1 AP002954.4 7.68 1.64e-13 2.27e-10 0.44 0.38 Height; chr11:118758322 chr11:118704607~118750263:+ LIHC cis rs7727544 0.684 rs274546 ENSG00000233006.5 AC034220.3 7.68 1.64e-13 2.28e-10 0.38 0.38 Blood metabolite levels; chr5:132364175 chr5:132311285~132369916:- LIHC cis rs992157 1 rs6736362 ENSG00000261338.2 RP11-378A13.1 7.68 1.64e-13 2.28e-10 0.4 0.38 Colorectal cancer; chr2:218250385 chr2:218255319~218257366:+ LIHC cis rs9399135 0.967 rs9389256 ENSG00000232876.1 CTA-212D2.2 -7.68 1.66e-13 2.3e-10 -0.43 -0.38 Red blood cell count; chr6:135010116 chr6:135055033~135060550:+ LIHC cis rs3096299 0.728 rs1011749 ENSG00000274627.1 RP11-104N10.2 7.68 1.67e-13 2.32e-10 0.39 0.38 Multiple myeloma (IgH translocation); chr16:89444461 chr16:89516797~89522217:+ LIHC cis rs11098499 1 rs1011054 ENSG00000245958.5 RP11-33B1.1 7.68 1.68e-13 2.33e-10 0.42 0.38 Corneal astigmatism; chr4:119281232 chr4:119454791~119552025:+ LIHC cis rs17301013 0.502 rs6703836 ENSG00000227373.4 RP11-160H22.5 7.68 1.69e-13 2.35e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174099675 chr1:174115300~174160004:- LIHC cis rs12744310 1 rs2364535 ENSG00000235358.1 RP11-399E6.1 7.68 1.69e-13 2.35e-10 0.49 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41300564 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs12043581 ENSG00000235358.1 RP11-399E6.1 7.68 1.72e-13 2.39e-10 0.49 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41322593 chr1:41242373~41284861:+ LIHC cis rs7727544 0.66 rs2631361 ENSG00000233006.5 AC034220.3 -7.68 1.73e-13 2.39e-10 -0.38 -0.38 Blood metabolite levels; chr5:132371688 chr5:132311285~132369916:- LIHC cis rs9399135 0.967 rs9321481 ENSG00000232876.1 CTA-212D2.2 7.68 1.74e-13 2.4e-10 0.44 0.38 Red blood cell count; chr6:135031510 chr6:135055033~135060550:+ LIHC cis rs12744310 0.887 rs12757611 ENSG00000235358.1 RP11-399E6.1 7.67 1.75e-13 2.42e-10 0.5 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41343300 chr1:41242373~41284861:+ LIHC cis rs7727544 0.735 rs272842 ENSG00000233006.5 AC034220.3 7.67 1.75e-13 2.42e-10 0.38 0.38 Blood metabolite levels; chr5:132320824 chr5:132311285~132369916:- LIHC cis rs2739330 0.796 rs5760106 ENSG00000250470.1 AP000351.3 -7.67 1.76e-13 2.43e-10 -0.45 -0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23976904~23977585:- LIHC cis rs17301013 0.507 rs16828481 ENSG00000227373.4 RP11-160H22.5 7.67 1.77e-13 2.45e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174415979 chr1:174115300~174160004:- LIHC cis rs3096299 0.503 rs4785677 ENSG00000274627.1 RP11-104N10.2 7.67 1.77e-13 2.45e-10 0.4 0.38 Multiple myeloma (IgH translocation); chr16:89488693 chr16:89516797~89522217:+ LIHC cis rs7727544 0.684 rs2516788 ENSG00000233006.5 AC034220.3 -7.67 1.82e-13 2.52e-10 -0.38 -0.38 Blood metabolite levels; chr5:132379873 chr5:132311285~132369916:- LIHC cis rs7727544 0.66 rs274563 ENSG00000233006.5 AC034220.3 -7.67 1.82e-13 2.52e-10 -0.38 -0.38 Blood metabolite levels; chr5:132382167 chr5:132311285~132369916:- LIHC cis rs7044106 0.762 rs10739570 ENSG00000226752.6 PSMD5-AS1 -7.67 1.83e-13 2.52e-10 -0.39 -0.38 Hip circumference adjusted for BMI; chr9:120618944 chr9:120824828~120854385:+ LIHC cis rs9543976 1 rs9565177 ENSG00000261553.4 RP11-29G8.3 -7.67 1.84e-13 2.54e-10 -0.56 -0.38 Diabetic retinopathy; chr13:75621267 chr13:75549773~75807120:+ LIHC cis rs62229266 0.633 rs743420 ENSG00000231106.2 LINC01436 7.67 1.85e-13 2.55e-10 0.43 0.38 Mitral valve prolapse; chr21:36015104 chr21:36005338~36007838:+ LIHC cis rs7085104 0.7 rs6163 ENSG00000236937.2 PTGES3P4 7.67 1.86e-13 2.56e-10 0.45 0.38 Immature fraction of reticulocytes;Schizophrenia; chr10:102837167 chr10:102845595~102845950:+ LIHC cis rs9399135 0.904 rs4895438 ENSG00000232876.1 CTA-212D2.2 -7.67 1.86e-13 2.56e-10 -0.43 -0.38 Red blood cell count; chr6:134996527 chr6:135055033~135060550:+ LIHC cis rs17301013 0.507 rs12066700 ENSG00000227373.4 RP11-160H22.5 7.66 1.88e-13 2.59e-10 0.65 0.38 Systemic lupus erythematosus; chr1:174282054 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12060460 ENSG00000227373.4 RP11-160H22.5 7.66 1.88e-13 2.59e-10 0.65 0.38 Systemic lupus erythematosus; chr1:174284513 chr1:174115300~174160004:- LIHC cis rs6991838 0.612 rs7842162 ENSG00000272010.1 CTD-3025N20.3 7.66 1.89e-13 2.6e-10 0.42 0.38 Intelligence (multi-trait analysis); chr8:65644057 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs7459944 ENSG00000200714.1 Y_RNA -7.66 1.89e-13 2.61e-10 -0.41 -0.38 Intelligence (multi-trait analysis); chr8:65566040 chr8:65592731~65592820:+ LIHC cis rs17301013 0.507 rs12083814 ENSG00000227373.4 RP11-160H22.5 7.66 1.9e-13 2.61e-10 0.63 0.38 Systemic lupus erythematosus; chr1:174319917 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs56152378 ENSG00000227373.4 RP11-160H22.5 7.66 1.9e-13 2.62e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174106480 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs4652179 ENSG00000227373.4 RP11-160H22.5 7.66 1.9e-13 2.62e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174107185 chr1:174115300~174160004:- LIHC cis rs17301013 0.581 rs17353198 ENSG00000227373.4 RP11-160H22.5 7.66 1.9e-13 2.62e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174107439 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs17350991 ENSG00000227373.4 RP11-160H22.5 7.66 1.9e-13 2.62e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174114330 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs57407575 ENSG00000227373.4 RP11-160H22.5 7.66 1.9e-13 2.62e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174115504 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs6656491 ENSG00000227373.4 RP11-160H22.5 7.66 1.9e-13 2.62e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174127524 chr1:174115300~174160004:- LIHC cis rs17301013 0.581 rs72711457 ENSG00000227373.4 RP11-160H22.5 7.66 1.9e-13 2.62e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174135385 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs6668008 ENSG00000227373.4 RP11-160H22.5 7.66 1.9e-13 2.62e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174138752 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10912786 ENSG00000227373.4 RP11-160H22.5 7.66 1.95e-13 2.68e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174427609 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12074416 ENSG00000227373.4 RP11-160H22.5 7.66 1.95e-13 2.68e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174430109 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12069134 ENSG00000227373.4 RP11-160H22.5 7.66 1.95e-13 2.68e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174434287 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs6677262 ENSG00000227373.4 RP11-160H22.5 7.66 1.95e-13 2.68e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174434539 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs60409344 ENSG00000227373.4 RP11-160H22.5 7.66 1.95e-13 2.68e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174438724 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs72713584 ENSG00000227373.4 RP11-160H22.5 7.66 1.95e-13 2.68e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174439129 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12077381 ENSG00000227373.4 RP11-160H22.5 7.66 1.95e-13 2.68e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174439566 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs74126805 ENSG00000227373.4 RP11-160H22.5 7.66 1.95e-13 2.68e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174440226 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12078960 ENSG00000227373.4 RP11-160H22.5 7.66 1.95e-13 2.68e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174440891 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12080407 ENSG00000227373.4 RP11-160H22.5 7.66 1.95e-13 2.68e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174441964 chr1:174115300~174160004:- LIHC cis rs7688540 0.511 rs76125013 ENSG00000275426.1 CH17-262A2.1 7.66 1.96e-13 2.69e-10 0.49 0.38 Facial morphology (factor 6, height of vermillion lower lip); chr4:201493 chr4:149738~150317:+ LIHC cis rs4423214 0.84 rs1792233 ENSG00000254682.1 RP11-660L16.2 -7.66 1.97e-13 2.7e-10 -0.49 -0.38 Vitamin D levels; chr11:71471133 chr11:71448674~71452157:+ LIHC cis rs1891275 0.515 rs1361552 ENSG00000228701.1 TNKS2-AS1 -7.65 2e-13 2.74e-10 -0.47 -0.38 Intelligence (multi-trait analysis); chr10:91774867 chr10:91782839~91798291:- LIHC cis rs10899021 1 rs11236193 ENSG00000279353.1 RP11-864N7.4 7.65 2.01e-13 2.76e-10 0.97 0.38 Response to metformin (IC50); chr11:74657262 chr11:74698231~74699658:- LIHC cis rs17301013 0.507 rs16846861 ENSG00000227373.4 RP11-160H22.5 7.65 2.01e-13 2.76e-10 0.63 0.38 Systemic lupus erythematosus; chr1:174338731 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs12067463 ENSG00000227373.4 RP11-160H22.5 7.65 2.04e-13 2.8e-10 0.59 0.38 Systemic lupus erythematosus; chr1:174625437 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs10912823 ENSG00000227373.4 RP11-160H22.5 7.65 2.04e-13 2.8e-10 0.59 0.38 Systemic lupus erythematosus; chr1:174625602 chr1:174115300~174160004:- LIHC cis rs62229266 0.771 rs62230790 ENSG00000231106.2 LINC01436 7.65 2.05e-13 2.81e-10 0.42 0.38 Mitral valve prolapse; chr21:36016613 chr21:36005338~36007838:+ LIHC cis rs1062177 1 rs2915878 ENSG00000213433.5 RPLP1P6 -7.65 2.05e-13 2.81e-10 -0.44 -0.38 Preschool internalizing problems; chr5:151770101 chr5:151765859~151766378:- LIHC cis rs1062177 1 rs2915877 ENSG00000213433.5 RPLP1P6 -7.65 2.05e-13 2.81e-10 -0.44 -0.38 Preschool internalizing problems; chr5:151771040 chr5:151765859~151766378:- LIHC cis rs1062177 1 rs2964576 ENSG00000213433.5 RPLP1P6 -7.65 2.05e-13 2.81e-10 -0.44 -0.38 Preschool internalizing problems; chr5:151771041 chr5:151765859~151766378:- LIHC cis rs1062177 1 rs6890099 ENSG00000213433.5 RPLP1P6 -7.65 2.05e-13 2.81e-10 -0.44 -0.38 Preschool internalizing problems; chr5:151772401 chr5:151765859~151766378:- LIHC cis rs8072100 0.676 rs7221345 ENSG00000228782.6 CTD-2026D20.3 7.65 2.06e-13 2.81e-10 0.43 0.38 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47327778 chr17:47450568~47492492:- LIHC cis rs17301013 0.507 rs3920486 ENSG00000227373.4 RP11-160H22.5 7.65 2.06e-13 2.81e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174567714 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12079118 ENSG00000227373.4 RP11-160H22.5 7.65 2.06e-13 2.81e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174568885 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs7414200 ENSG00000227373.4 RP11-160H22.5 7.65 2.06e-13 2.81e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174569820 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12079879 ENSG00000227373.4 RP11-160H22.5 7.65 2.06e-13 2.81e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174571877 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2092084 ENSG00000227373.4 RP11-160H22.5 7.65 2.06e-13 2.81e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174581547 chr1:174115300~174160004:- LIHC cis rs9549367 0.789 rs9549695 ENSG00000269125.1 RP11-98F14.11 7.65 2.06e-13 2.82e-10 0.47 0.38 Platelet distribution width; chr13:113220500 chr13:113165002~113165183:- LIHC cis rs2019137 0.901 rs4849176 ENSG00000274877.1 RP11-65I12.1 7.65 2.06e-13 2.82e-10 0.47 0.38 Lymphocyte counts; chr2:113220359 chr2:113237595~113240825:+ LIHC cis rs7201929 1 rs12920514 ENSG00000259982.1 CDC37P1 -7.65 2.07e-13 2.83e-10 -0.42 -0.38 QT interval; chr16:28824579 chr16:28700294~28701540:- LIHC cis rs2882667 0.858 rs17207870 ENSG00000253404.1 AC034243.1 7.65 2.08e-13 2.85e-10 0.52 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139052048 chr5:138744434~138753309:- LIHC cis rs3096299 0.933 rs28608022 ENSG00000274627.1 RP11-104N10.2 7.65 2.11e-13 2.88e-10 0.39 0.38 Multiple myeloma (IgH translocation); chr16:89387884 chr16:89516797~89522217:+ LIHC cis rs494459 0.838 rs607125 ENSG00000255422.1 AP002954.4 -7.65 2.12e-13 2.88e-10 -0.43 -0.38 Height; chr11:118746590 chr11:118704607~118750263:+ LIHC cis rs62229266 0.804 rs2835231 ENSG00000231106.2 LINC01436 7.64 2.14e-13 2.91e-10 0.42 0.38 Mitral valve prolapse; chr21:36018300 chr21:36005338~36007838:+ LIHC cis rs494459 0.838 rs1784543 ENSG00000255422.1 AP002954.4 -7.64 2.14e-13 2.92e-10 -0.43 -0.38 Height; chr11:118760944 chr11:118704607~118750263:+ LIHC cis rs11723261 0.545 rs6812799 ENSG00000275426.1 CH17-262A2.1 7.64 2.18e-13 2.96e-10 0.49 0.38 Immune response to smallpox vaccine (IL-6); chr4:203545 chr4:149738~150317:+ LIHC cis rs7688540 0.511 rs6841415 ENSG00000275426.1 CH17-262A2.1 7.64 2.18e-13 2.96e-10 0.49 0.38 Facial morphology (factor 6, height of vermillion lower lip); chr4:203594 chr4:149738~150317:+ LIHC cis rs12744310 0.887 rs35592291 ENSG00000235358.1 RP11-399E6.1 7.64 2.19e-13 2.97e-10 0.5 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41325599 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs2363811 ENSG00000235358.1 RP11-399E6.1 7.64 2.19e-13 2.97e-10 0.5 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41326193 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs12026778 ENSG00000235358.1 RP11-399E6.1 7.64 2.19e-13 2.97e-10 0.5 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41326602 chr1:41242373~41284861:+ LIHC cis rs7044106 0.791 rs10818473 ENSG00000226752.6 PSMD5-AS1 -7.64 2.19e-13 2.98e-10 -0.39 -0.38 Hip circumference adjusted for BMI; chr9:120721877 chr9:120824828~120854385:+ LIHC cis rs7688540 0.511 rs61794991 ENSG00000275426.1 CH17-262A2.1 7.64 2.21e-13 3.01e-10 0.49 0.38 Facial morphology (factor 6, height of vermillion lower lip); chr4:204418 chr4:149738~150317:+ LIHC cis rs1150668 0.799 rs2142730 ENSG00000216901.1 AL022393.7 7.64 2.21e-13 3.01e-10 0.42 0.38 Pubertal anthropometrics; chr6:28298372 chr6:28176188~28176674:+ LIHC cis rs12744310 0.887 rs12028244 ENSG00000235358.1 RP11-399E6.1 7.64 2.24e-13 3.04e-10 0.5 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41343490 chr1:41242373~41284861:+ LIHC cis rs34779708 0.931 rs12767414 ENSG00000230534.5 RP11-297A16.2 7.64 2.25e-13 3.06e-10 0.48 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35101265 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs11010095 ENSG00000230534.5 RP11-297A16.2 7.64 2.25e-13 3.06e-10 0.48 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35107020 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs2045915 ENSG00000230534.5 RP11-297A16.2 7.64 2.25e-13 3.06e-10 0.48 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35129688 chr10:35098006~35127020:- LIHC cis rs17301013 0.606 rs4650968 ENSG00000227373.4 RP11-160H22.5 7.64 2.26e-13 3.07e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174223322 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs4650969 ENSG00000227373.4 RP11-160H22.5 7.64 2.26e-13 3.07e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174229622 chr1:174115300~174160004:- LIHC cis rs17301013 0.581 rs72711501 ENSG00000227373.4 RP11-160H22.5 7.64 2.26e-13 3.07e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174233081 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs72713504 ENSG00000227373.4 RP11-160H22.5 7.64 2.26e-13 3.07e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174251916 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs72713505 ENSG00000227373.4 RP11-160H22.5 7.64 2.26e-13 3.07e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174255911 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs55698100 ENSG00000227373.4 RP11-160H22.5 7.64 2.26e-13 3.07e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174258295 chr1:174115300~174160004:- LIHC cis rs150992 0.721 rs2937706 ENSG00000248489.1 CTD-2007H13.3 7.63 2.29e-13 3.1e-10 0.56 0.38 Body mass index; chr5:98990434 chr5:98929171~98995013:+ LIHC cis rs2882667 0.858 rs11957633 ENSG00000253404.1 AC034243.1 7.63 2.3e-13 3.12e-10 0.53 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139028705 chr5:138744434~138753309:- LIHC cis rs9326248 0.59 rs2542063 ENSG00000236267.1 AP006216.5 7.63 2.33e-13 3.16e-10 0.38 0.38 Blood protein levels; chr11:116814051 chr11:116813204~116814003:- LIHC cis rs7044106 0.708 rs959558 ENSG00000226752.6 PSMD5-AS1 -7.63 2.34e-13 3.17e-10 -0.39 -0.38 Hip circumference adjusted for BMI; chr9:120606633 chr9:120824828~120854385:+ LIHC cis rs10899021 1 rs7102084 ENSG00000279353.1 RP11-864N7.4 7.63 2.35e-13 3.18e-10 0.87 0.38 Response to metformin (IC50); chr11:74647087 chr11:74698231~74699658:- LIHC cis rs6991838 0.584 rs4388482 ENSG00000272010.1 CTD-3025N20.3 -7.63 2.35e-13 3.18e-10 -0.41 -0.38 Intelligence (multi-trait analysis); chr8:65583968 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs4637885 ENSG00000272010.1 CTD-3025N20.3 -7.63 2.35e-13 3.18e-10 -0.41 -0.38 Intelligence (multi-trait analysis); chr8:65584849 chr8:65591850~65592472:- LIHC cis rs6991838 0.556 rs7846527 ENSG00000272010.1 CTD-3025N20.3 -7.63 2.35e-13 3.18e-10 -0.41 -0.38 Intelligence (multi-trait analysis); chr8:65586522 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs4320587 ENSG00000272010.1 CTD-3025N20.3 -7.63 2.35e-13 3.18e-10 -0.41 -0.38 Intelligence (multi-trait analysis); chr8:65586991 chr8:65591850~65592472:- LIHC cis rs6991838 0.584 rs35941313 ENSG00000272010.1 CTD-3025N20.3 -7.63 2.35e-13 3.18e-10 -0.41 -0.38 Intelligence (multi-trait analysis); chr8:65587498 chr8:65591850~65592472:- LIHC cis rs3096299 0.754 rs2965816 ENSG00000274627.1 RP11-104N10.2 -7.63 2.35e-13 3.19e-10 -0.38 -0.38 Multiple myeloma (IgH translocation); chr16:89447775 chr16:89516797~89522217:+ LIHC cis rs9543976 0.623 rs4611344 ENSG00000261553.4 RP11-29G8.3 7.63 2.36e-13 3.19e-10 0.52 0.38 Diabetic retinopathy; chr13:75601192 chr13:75549773~75807120:+ LIHC cis rs9543976 0.545 rs2328963 ENSG00000261553.4 RP11-29G8.3 7.63 2.36e-13 3.19e-10 0.52 0.38 Diabetic retinopathy; chr13:75601390 chr13:75549773~75807120:+ LIHC cis rs2882667 0.858 rs11242442 ENSG00000253404.1 AC034243.1 7.63 2.37e-13 3.2e-10 0.52 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139044800 chr5:138744434~138753309:- LIHC cis rs1150668 0.745 rs213238 ENSG00000216901.1 AL022393.7 7.63 2.39e-13 3.23e-10 0.43 0.38 Pubertal anthropometrics; chr6:28354216 chr6:28176188~28176674:+ LIHC cis rs9399135 0.967 rs1854865 ENSG00000232876.1 CTA-212D2.2 -7.63 2.4e-13 3.24e-10 -0.43 -0.38 Red blood cell count; chr6:135039162 chr6:135055033~135060550:+ LIHC cis rs7580658 0.724 rs7568261 ENSG00000236682.1 AC068282.3 -7.63 2.4e-13 3.25e-10 -0.48 -0.38 Protein C levels; chr2:127359748 chr2:127389130~127400580:+ LIHC cis rs7727544 0.684 rs611084 ENSG00000233006.5 AC034220.3 -7.63 2.41e-13 3.26e-10 -0.38 -0.38 Blood metabolite levels; chr5:132374047 chr5:132311285~132369916:- LIHC cis rs1577917 0.958 rs12197463 ENSG00000234155.1 RP11-30P6.6 7.63 2.42e-13 3.27e-10 0.45 0.38 Response to antipsychotic treatment; chr6:85735524 chr6:85387219~85390186:- LIHC cis rs9549367 0.713 rs2146750 ENSG00000269125.1 RP11-98F14.11 7.62 2.44e-13 3.29e-10 0.46 0.38 Platelet distribution width; chr13:113168216 chr13:113165002~113165183:- LIHC cis rs2739330 0.791 rs9612520 ENSG00000250470.1 AP000351.3 7.62 2.47e-13 3.33e-10 0.46 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23976904~23977585:- LIHC cis rs17301013 0.606 rs332764 ENSG00000227373.4 RP11-160H22.5 7.62 2.48e-13 3.35e-10 0.59 0.38 Systemic lupus erythematosus; chr1:174693056 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs332763 ENSG00000227373.4 RP11-160H22.5 7.62 2.48e-13 3.35e-10 0.59 0.38 Systemic lupus erythematosus; chr1:174693482 chr1:174115300~174160004:- LIHC cis rs17301013 0.581 rs332772 ENSG00000227373.4 RP11-160H22.5 7.62 2.48e-13 3.35e-10 0.59 0.38 Systemic lupus erythematosus; chr1:174695740 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs333471 ENSG00000227373.4 RP11-160H22.5 7.62 2.48e-13 3.35e-10 0.59 0.38 Systemic lupus erythematosus; chr1:174705062 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs332784 ENSG00000227373.4 RP11-160H22.5 7.62 2.48e-13 3.35e-10 0.59 0.38 Systemic lupus erythematosus; chr1:174719927 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs332798 ENSG00000227373.4 RP11-160H22.5 7.62 2.48e-13 3.35e-10 0.59 0.38 Systemic lupus erythematosus; chr1:174729096 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs1793307 ENSG00000227373.4 RP11-160H22.5 -7.62 2.48e-13 3.35e-10 -0.59 -0.38 Systemic lupus erythematosus; chr1:174758716 chr1:174115300~174160004:- LIHC cis rs739496 0.579 rs7294902 ENSG00000226469.1 ADAM1B 7.62 2.48e-13 3.35e-10 0.48 0.38 Platelet count; chr12:111916727 chr12:111927018~111929017:+ LIHC cis rs6504950 0.8 rs7209926 ENSG00000275710.1 RP11-257O5.4 -7.62 2.49e-13 3.35e-10 -0.46 -0.38 Breast cancer; chr17:54928963 chr17:54964474~54964679:+ LIHC cis rs198426 0.506 rs198465 ENSG00000124915.9 DKFZP434K028 7.62 2.49e-13 3.36e-10 0.42 0.38 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr11:61753846 chr11:61746493~61757655:- LIHC cis rs34779708 0.931 rs4934704 ENSG00000230534.5 RP11-297A16.2 7.62 2.5e-13 3.37e-10 0.48 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35043236 chr10:35098006~35127020:- LIHC cis rs17301013 0.507 rs10912759 ENSG00000227373.4 RP11-160H22.5 7.62 2.51e-13 3.38e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174312178 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs6425278 ENSG00000227373.4 RP11-160H22.5 7.62 2.51e-13 3.38e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174313148 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12083548 ENSG00000227373.4 RP11-160H22.5 7.62 2.51e-13 3.38e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174319134 chr1:174115300~174160004:- LIHC cis rs832187 0.704 rs704364 ENSG00000280620.1 SCAANT1 -7.62 2.52e-13 3.4e-10 -0.47 -0.38 Schizophrenia; chr3:63889058 chr3:63911518~63911772:- LIHC cis rs7044106 0.762 rs10818471 ENSG00000226752.6 PSMD5-AS1 -7.62 2.52e-13 3.4e-10 -0.39 -0.38 Hip circumference adjusted for BMI; chr9:120631767 chr9:120824828~120854385:+ LIHC cis rs12744310 0.887 rs4453028 ENSG00000235358.1 RP11-399E6.1 7.62 2.54e-13 3.42e-10 0.5 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41326851 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs12040046 ENSG00000235358.1 RP11-399E6.1 -7.62 2.54e-13 3.42e-10 -0.5 -0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41331911 chr1:41242373~41284861:+ LIHC cis rs17301013 0.606 rs6666588 ENSG00000227373.4 RP11-160H22.5 7.62 2.56e-13 3.44e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174248972 chr1:174115300~174160004:- LIHC cis rs7044106 0.762 rs10760107 ENSG00000226752.6 PSMD5-AS1 -7.62 2.56e-13 3.44e-10 -0.39 -0.38 Hip circumference adjusted for BMI; chr9:120621352 chr9:120824828~120854385:+ LIHC cis rs17301013 0.507 rs10912766 ENSG00000227373.4 RP11-160H22.5 7.62 2.56e-13 3.44e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174341129 chr1:174115300~174160004:- LIHC cis rs1891275 0.508 rs7099557 ENSG00000228701.1 TNKS2-AS1 -7.62 2.56e-13 3.44e-10 -0.45 -0.38 Intelligence (multi-trait analysis); chr10:91685607 chr10:91782839~91798291:- LIHC cis rs17301013 0.507 rs72713532 ENSG00000227373.4 RP11-160H22.5 7.62 2.57e-13 3.46e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174337826 chr1:174115300~174160004:- LIHC cis rs7617773 0.746 rs11713476 ENSG00000229759.1 MRPS18AP1 7.62 2.57e-13 3.46e-10 0.43 0.38 Coronary artery disease; chr3:48333944 chr3:48256350~48256938:- LIHC cis rs7580658 0.75 rs4497825 ENSG00000236682.1 AC068282.3 -7.62 2.58e-13 3.46e-10 -0.48 -0.38 Protein C levels; chr2:127303477 chr2:127389130~127400580:+ LIHC cis rs7044106 0.537 rs10739573 ENSG00000226752.6 PSMD5-AS1 -7.61 2.62e-13 3.51e-10 -0.4 -0.38 Hip circumference adjusted for BMI; chr9:120727540 chr9:120824828~120854385:+ LIHC cis rs7617773 0.963 rs9822496 ENSG00000229759.1 MRPS18AP1 7.61 2.62e-13 3.52e-10 0.39 0.38 Coronary artery disease; chr3:48139843 chr3:48256350~48256938:- LIHC cis rs17301013 0.606 rs6677874 ENSG00000227373.4 RP11-160H22.5 7.61 2.62e-13 3.52e-10 0.59 0.38 Systemic lupus erythematosus; chr1:174628410 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2860955 ENSG00000227373.4 RP11-160H22.5 -7.61 2.63e-13 3.53e-10 -0.61 -0.38 Systemic lupus erythematosus; chr1:174391380 chr1:174115300~174160004:- LIHC cis rs10899021 1 rs11236186 ENSG00000279353.1 RP11-864N7.4 7.61 2.64e-13 3.55e-10 0.88 0.38 Response to metformin (IC50); chr11:74651820 chr11:74698231~74699658:- LIHC cis rs10899021 1 rs7935426 ENSG00000279353.1 RP11-864N7.4 7.61 2.64e-13 3.55e-10 0.88 0.38 Response to metformin (IC50); chr11:74652845 chr11:74698231~74699658:- LIHC cis rs2442825 0.659 rs1129170 ENSG00000206573.7 THUMPD3-AS1 7.61 2.64e-13 3.55e-10 0.33 0.38 Cerebrospinal fluid clusterin levels; chr3:9384227 chr3:9349689~9398579:- LIHC cis rs34779708 0.966 rs4934737 ENSG00000230534.5 RP11-297A16.2 7.61 2.65e-13 3.56e-10 0.49 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35223871 chr10:35098006~35127020:- LIHC cis rs55665837 1 rs10832276 ENSG00000251991.1 RNU7-49P 7.61 2.66e-13 3.57e-10 0.4 0.38 Vitamin D levels; chr11:14461728 chr11:14478892~14478953:+ LIHC cis rs11098499 0.954 rs13145352 ENSG00000245958.5 RP11-33B1.1 7.61 2.69e-13 3.59e-10 0.41 0.38 Corneal astigmatism; chr4:119488808 chr4:119454791~119552025:+ LIHC cis rs1062177 1 rs17804178 ENSG00000213433.5 RPLP1P6 -7.61 2.69e-13 3.59e-10 -0.44 -0.38 Preschool internalizing problems; chr5:151818168 chr5:151765859~151766378:- LIHC cis rs6142102 0.602 rs2268086 ENSG00000276073.1 RP5-1125A11.7 7.61 2.71e-13 3.61e-10 0.39 0.38 Skin pigmentation; chr20:34060932 chr20:33985617~33988989:- LIHC cis rs2882667 0.822 rs13187096 ENSG00000253404.1 AC034243.1 7.61 2.71e-13 3.62e-10 0.52 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139068399 chr5:138744434~138753309:- LIHC cis rs34779708 0.931 rs4007289 ENSG00000230534.5 RP11-297A16.2 7.61 2.72e-13 3.62e-10 0.48 0.38 Inflammatory bowel disease;Crohn's disease; chr10:34980862 chr10:35098006~35127020:- LIHC cis rs11723261 0.527 rs11731581 ENSG00000275426.1 CH17-262A2.1 7.61 2.73e-13 3.64e-10 0.45 0.38 Immune response to smallpox vaccine (IL-6); chr4:88044 chr4:149738~150317:+ LIHC cis rs893363 0.621 rs14165 ENSG00000271916.1 RP11-884K10.6 -7.61 2.73e-13 3.64e-10 -0.72 -0.38 Axial length; chr3:53813381 chr3:53797764~53798019:- LIHC cis rs739496 0.546 rs11066055 ENSG00000226469.1 ADAM1B 7.61 2.75e-13 3.66e-10 0.48 0.38 Platelet count; chr12:111875412 chr12:111927018~111929017:+ LIHC cis rs7727544 0.684 rs274560 ENSG00000233006.5 AC034220.3 -7.61 2.76e-13 3.67e-10 -0.38 -0.38 Blood metabolite levels; chr5:132383758 chr5:132311285~132369916:- LIHC cis rs34779708 0.966 rs10508816 ENSG00000230534.5 RP11-297A16.2 7.61 2.77e-13 3.69e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35171048 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs12762493 ENSG00000230534.5 RP11-297A16.2 7.61 2.77e-13 3.69e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35182945 chr10:35098006~35127020:- LIHC cis rs17301013 0.581 rs4652204 ENSG00000227373.4 RP11-160H22.5 7.6 2.79e-13 3.71e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174150682 chr1:174115300~174160004:- LIHC cis rs9543976 0.623 rs7982517 ENSG00000261553.4 RP11-29G8.3 7.6 2.8e-13 3.72e-10 0.52 0.38 Diabetic retinopathy; chr13:75587903 chr13:75549773~75807120:+ LIHC cis rs9543976 0.557 rs6562916 ENSG00000261553.4 RP11-29G8.3 7.6 2.8e-13 3.72e-10 0.52 0.38 Diabetic retinopathy; chr13:75597086 chr13:75549773~75807120:+ LIHC cis rs9543976 0.623 rs4885322 ENSG00000261553.4 RP11-29G8.3 7.6 2.8e-13 3.72e-10 0.52 0.38 Diabetic retinopathy; chr13:75597195 chr13:75549773~75807120:+ LIHC cis rs739496 0.579 rs57046217 ENSG00000226469.1 ADAM1B 7.6 2.84e-13 3.78e-10 0.48 0.38 Platelet count; chr12:111847312 chr12:111927018~111929017:+ LIHC cis rs10262624 0.528 rs722294 ENSG00000234286.1 AC006026.13 7.6 2.88e-13 3.83e-10 0.41 0.38 Schizophrenia; chr7:23706966 chr7:23680195~23680786:- LIHC cis rs12744310 0.887 rs12728217 ENSG00000235358.1 RP11-399E6.1 7.6 2.89e-13 3.84e-10 0.5 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41332597 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs12732820 ENSG00000235358.1 RP11-399E6.1 7.6 2.89e-13 3.84e-10 0.5 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41333101 chr1:41242373~41284861:+ LIHC cis rs893363 0.636 rs4687587 ENSG00000271916.1 RP11-884K10.6 7.6 2.9e-13 3.85e-10 0.72 0.38 Axial length; chr3:53815483 chr3:53797764~53798019:- LIHC cis rs9660180 0.967 rs6603802 ENSG00000268575.1 RP1-283E3.8 -7.6 2.91e-13 3.86e-10 -0.35 -0.38 Body mass index; chr1:1881082 chr1:1702736~1737688:- LIHC cis rs2019137 0.936 rs902696 ENSG00000274877.1 RP11-65I12.1 -7.6 2.93e-13 3.88e-10 -0.46 -0.38 Lymphocyte counts; chr2:113197302 chr2:113237595~113240825:+ LIHC cis rs10899021 1 rs11236201 ENSG00000279353.1 RP11-864N7.4 7.6 2.93e-13 3.89e-10 1.01 0.38 Response to metformin (IC50); chr11:74664588 chr11:74698231~74699658:- LIHC cis rs10899021 1 rs11236202 ENSG00000279353.1 RP11-864N7.4 7.6 2.93e-13 3.89e-10 1.01 0.38 Response to metformin (IC50); chr11:74665647 chr11:74698231~74699658:- LIHC cis rs7580658 0.895 rs62157549 ENSG00000236682.1 AC068282.3 -7.6 2.94e-13 3.89e-10 -0.48 -0.38 Protein C levels; chr2:127308431 chr2:127389130~127400580:+ LIHC cis rs73086581 1 rs73088416 ENSG00000229539.1 RP11-119B16.2 7.6 2.94e-13 3.89e-10 0.71 0.38 Response to antidepressants in depression; chr20:4014629 chr20:3888239~3888868:- LIHC cis rs3096299 0.503 rs9925045 ENSG00000274627.1 RP11-104N10.2 7.6 2.96e-13 3.92e-10 0.39 0.38 Multiple myeloma (IgH translocation); chr16:89490068 chr16:89516797~89522217:+ LIHC cis rs6504950 0.889 rs2628305 ENSG00000275710.1 RP11-257O5.4 7.6 2.97e-13 3.93e-10 0.56 0.38 Breast cancer; chr17:55063066 chr17:54964474~54964679:+ LIHC cis rs494459 0.838 rs632124 ENSG00000255422.1 AP002954.4 -7.59 2.98e-13 3.94e-10 -0.43 -0.38 Height; chr11:118742526 chr11:118704607~118750263:+ LIHC cis rs1577917 0.74 rs9353327 ENSG00000234155.1 RP11-30P6.6 7.59 3.04e-13 4.02e-10 0.44 0.38 Response to antipsychotic treatment; chr6:85684348 chr6:85387219~85390186:- LIHC cis rs2882667 0.898 rs11956089 ENSG00000253404.1 AC034243.1 -7.59 3.04e-13 4.02e-10 -0.49 -0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139058915 chr5:138744434~138753309:- LIHC cis rs34779708 0.931 rs2384289 ENSG00000230534.5 RP11-297A16.2 7.59 3.08e-13 4.07e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35054597 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs10466072 ENSG00000230534.5 RP11-297A16.2 7.59 3.12e-13 4.11e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35113828 chr10:35098006~35127020:- LIHC cis rs853679 0.527 rs853683 ENSG00000216901.1 AL022393.7 7.59 3.12e-13 4.12e-10 0.43 0.38 Depression; chr6:28327262 chr6:28176188~28176674:+ LIHC cis rs2929278 0.589 rs7174732 ENSG00000205771.5 CATSPER2P1 7.59 3.14e-13 4.14e-10 0.48 0.38 Schizophrenia; chr15:43746265 chr15:43726918~43747094:- LIHC cis rs3096299 0.685 rs4785571 ENSG00000274627.1 RP11-104N10.2 7.59 3.15e-13 4.15e-10 0.37 0.38 Multiple myeloma (IgH translocation); chr16:89498761 chr16:89516797~89522217:+ LIHC cis rs34779708 0.931 rs11010082 ENSG00000230534.5 RP11-297A16.2 7.59 3.15e-13 4.15e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35062227 chr10:35098006~35127020:- LIHC cis rs150992 0.751 rs172874 ENSG00000248489.1 CTD-2007H13.3 7.59 3.15e-13 4.16e-10 0.55 0.38 Body mass index; chr5:98969402 chr5:98929171~98995013:+ LIHC cis rs12744310 0.83 rs4406620 ENSG00000235358.1 RP11-399E6.1 7.59 3.16e-13 4.17e-10 0.5 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41327093 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs35436312 ENSG00000235358.1 RP11-399E6.1 7.59 3.16e-13 4.17e-10 0.5 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41327686 chr1:41242373~41284861:+ LIHC cis rs12744310 0.887 rs1316274 ENSG00000235358.1 RP11-399E6.1 7.59 3.16e-13 4.17e-10 0.5 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41327986 chr1:41242373~41284861:+ LIHC cis rs17301013 0.507 rs12059307 ENSG00000227373.4 RP11-160H22.5 7.58 3.18e-13 4.2e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174342105 chr1:174115300~174160004:- LIHC cis rs9399135 0.967 rs9399129 ENSG00000232876.1 CTA-212D2.2 -7.58 3.19e-13 4.21e-10 -0.43 -0.38 Red blood cell count; chr6:134964010 chr6:135055033~135060550:+ LIHC cis rs34779708 0.931 rs72789609 ENSG00000230534.5 RP11-297A16.2 7.58 3.2e-13 4.22e-10 0.48 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35017278 chr10:35098006~35127020:- LIHC cis rs6991838 0.557 rs4737222 ENSG00000272010.1 CTD-3025N20.3 -7.58 3.21e-13 4.23e-10 -0.41 -0.38 Intelligence (multi-trait analysis); chr8:65587878 chr8:65591850~65592472:- LIHC cis rs739496 0.579 rs75080921 ENSG00000226469.1 ADAM1B 7.58 3.23e-13 4.25e-10 0.48 0.38 Platelet count; chr12:111861168 chr12:111927018~111929017:+ LIHC cis rs739496 0.615 rs7312260 ENSG00000226469.1 ADAM1B 7.58 3.23e-13 4.25e-10 0.48 0.38 Platelet count; chr12:111920859 chr12:111927018~111929017:+ LIHC cis rs9543976 0.623 rs974373 ENSG00000261553.4 RP11-29G8.3 7.58 3.26e-13 4.29e-10 0.53 0.38 Diabetic retinopathy; chr13:75589660 chr13:75549773~75807120:+ LIHC cis rs17301013 0.507 rs34409674 ENSG00000227373.4 RP11-160H22.5 -7.58 3.26e-13 4.3e-10 -0.62 -0.38 Systemic lupus erythematosus; chr1:174560246 chr1:174115300~174160004:- LIHC cis rs1555322 0.53 rs932562 ENSG00000126005.14 MMP24-AS1 -7.58 3.27e-13 4.3e-10 -0.56 -0.38 Attention deficit hyperactivity disorder; chr20:35283507 chr20:35216462~35278131:- LIHC cis rs1555322 0.53 rs2275275 ENSG00000126005.14 MMP24-AS1 -7.58 3.27e-13 4.3e-10 -0.56 -0.38 Attention deficit hyperactivity disorder; chr20:35284508 chr20:35216462~35278131:- LIHC cis rs10716631 1 rs10716631 ENSG00000261338.2 RP11-378A13.1 7.58 3.28e-13 4.31e-10 0.39 0.38 Plateletcrit;High light scatter reticulocyte percentage of red cells; chr2:218273447 chr2:218255319~218257366:+ LIHC cis rs62229266 0.771 rs2835232 ENSG00000231106.2 LINC01436 7.58 3.3e-13 4.34e-10 0.42 0.38 Mitral valve prolapse; chr21:36021129 chr21:36005338~36007838:+ LIHC cis rs62229266 0.74 rs2835233 ENSG00000231106.2 LINC01436 7.58 3.3e-13 4.34e-10 0.42 0.38 Mitral valve prolapse; chr21:36021284 chr21:36005338~36007838:+ LIHC cis rs150992 0.79 rs325220 ENSG00000248489.1 CTD-2007H13.3 7.58 3.32e-13 4.36e-10 0.55 0.38 Body mass index; chr5:98968860 chr5:98929171~98995013:+ LIHC cis rs853679 0.527 rs707907 ENSG00000216901.1 AL022393.7 7.58 3.32e-13 4.36e-10 0.43 0.38 Depression; chr6:28323463 chr6:28176188~28176674:+ LIHC cis rs10262624 0.504 rs59865844 ENSG00000234286.1 AC006026.13 7.58 3.33e-13 4.38e-10 0.4 0.38 Schizophrenia; chr7:23693421 chr7:23680195~23680786:- LIHC cis rs7044106 1 rs7044106 ENSG00000226752.6 PSMD5-AS1 -7.58 3.33e-13 4.38e-10 -0.43 -0.38 Hip circumference adjusted for BMI; chr9:120731784 chr9:120824828~120854385:+ LIHC cis rs9543976 0.623 rs4885323 ENSG00000261553.4 RP11-29G8.3 7.58 3.34e-13 4.4e-10 0.52 0.38 Diabetic retinopathy; chr13:75598278 chr13:75549773~75807120:+ LIHC cis rs9326248 1 rs9326248 ENSG00000280143.1 AP000892.6 7.58 3.36e-13 4.42e-10 0.43 0.38 Blood protein levels; chr11:117128509 chr11:117204967~117210292:+ LIHC cis rs1062177 1 rs892006 ENSG00000213433.5 RPLP1P6 -7.58 3.38e-13 4.44e-10 -0.42 -0.38 Preschool internalizing problems; chr5:151801329 chr5:151765859~151766378:- LIHC cis rs7580658 0.711 rs12469035 ENSG00000236682.1 AC068282.3 -7.58 3.38e-13 4.44e-10 -0.47 -0.38 Protein C levels; chr2:127227341 chr2:127389130~127400580:+ LIHC cis rs2442825 0.693 rs2596913 ENSG00000206573.7 THUMPD3-AS1 7.57 3.4e-13 4.46e-10 0.33 0.38 Cerebrospinal fluid clusterin levels; chr3:9394788 chr3:9349689~9398579:- LIHC cis rs7085104 0.684 rs7092690 ENSG00000236937.2 PTGES3P4 7.57 3.4e-13 4.47e-10 0.45 0.38 Immature fraction of reticulocytes;Schizophrenia; chr10:102849608 chr10:102845595~102845950:+ LIHC cis rs17301013 0.507 rs57953555 ENSG00000227373.4 RP11-160H22.5 7.57 3.48e-13 4.57e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174384958 chr1:174115300~174160004:- LIHC cis rs1577917 0.958 rs66807489 ENSG00000234155.1 RP11-30P6.6 7.57 3.55e-13 4.65e-10 0.45 0.38 Response to antipsychotic treatment; chr6:85730984 chr6:85387219~85390186:- LIHC cis rs7085104 0.7 rs7096183 ENSG00000236937.2 PTGES3P4 7.57 3.56e-13 4.66e-10 0.45 0.38 Immature fraction of reticulocytes;Schizophrenia; chr10:102849709 chr10:102845595~102845950:+ LIHC cis rs17301013 0.507 rs6701911 ENSG00000227373.4 RP11-160H22.5 7.57 3.57e-13 4.67e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174364755 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs61218633 ENSG00000227373.4 RP11-160H22.5 7.57 3.57e-13 4.67e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174375955 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs56148594 ENSG00000227373.4 RP11-160H22.5 7.57 3.57e-13 4.67e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174383932 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12091056 ENSG00000227373.4 RP11-160H22.5 7.57 3.57e-13 4.67e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174384470 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs4651019 ENSG00000227373.4 RP11-160H22.5 7.57 3.57e-13 4.67e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174385079 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10912775 ENSG00000227373.4 RP11-160H22.5 7.57 3.57e-13 4.67e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174388034 chr1:174115300~174160004:- LIHC cis rs1061377 1 rs7685468 ENSG00000249207.1 RP11-360F5.1 -7.57 3.59e-13 4.69e-10 -0.38 -0.38 Uric acid levels; chr4:39116649 chr4:39112677~39126818:- LIHC cis rs1150668 0.768 rs1150716 ENSG00000216901.1 AL022393.7 7.56 3.63e-13 4.75e-10 0.42 0.38 Pubertal anthropometrics; chr6:28294921 chr6:28176188~28176674:+ LIHC cis rs7688540 0.511 rs6845131 ENSG00000275426.1 CH17-262A2.1 7.56 3.63e-13 4.75e-10 0.49 0.38 Facial morphology (factor 6, height of vermillion lower lip); chr4:206358 chr4:149738~150317:+ LIHC cis rs7688540 0.511 rs11731623 ENSG00000275426.1 CH17-262A2.1 7.56 3.63e-13 4.75e-10 0.49 0.38 Facial morphology (factor 6, height of vermillion lower lip); chr4:207221 chr4:149738~150317:+ LIHC cis rs73086581 1 rs73088421 ENSG00000229539.1 RP11-119B16.2 7.56 3.63e-13 4.75e-10 0.7 0.38 Response to antidepressants in depression; chr20:4017224 chr20:3888239~3888868:- LIHC cis rs34779708 0.931 rs11010077 ENSG00000230534.5 RP11-297A16.2 -7.56 3.63e-13 4.75e-10 -0.47 -0.38 Inflammatory bowel disease;Crohn's disease; chr10:35039160 chr10:35098006~35127020:- LIHC cis rs67180937 0.961 rs17465637 ENSG00000272750.1 RP11-378J18.8 7.56 3.64e-13 4.76e-10 0.39 0.38 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222650187 chr1:222658867~222661512:- LIHC cis rs17301013 0.507 rs6701534 ENSG00000227373.4 RP11-160H22.5 7.56 3.66e-13 4.78e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174418612 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10798312 ENSG00000227373.4 RP11-160H22.5 7.56 3.66e-13 4.78e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174419089 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs4652422 ENSG00000227373.4 RP11-160H22.5 7.56 3.66e-13 4.78e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174419501 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs4233181 ENSG00000227373.4 RP11-160H22.5 7.56 3.66e-13 4.78e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174419697 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10489258 ENSG00000227373.4 RP11-160H22.5 7.56 3.66e-13 4.78e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174420447 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10798313 ENSG00000227373.4 RP11-160H22.5 7.56 3.66e-13 4.78e-10 0.6 0.38 Systemic lupus erythematosus; chr1:174420995 chr1:174115300~174160004:- LIHC cis rs10899021 0.79 rs59958321 ENSG00000279353.1 RP11-864N7.4 7.56 3.72e-13 4.86e-10 0.84 0.38 Response to metformin (IC50); chr11:74643569 chr11:74698231~74699658:- LIHC cis rs2882667 0.858 rs11959803 ENSG00000253404.1 AC034243.1 7.56 3.72e-13 4.86e-10 0.52 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139115626 chr5:138744434~138753309:- LIHC cis rs17301013 0.507 rs12063545 ENSG00000227373.4 RP11-160H22.5 7.56 3.75e-13 4.89e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174552863 chr1:174115300~174160004:- LIHC cis rs8072100 0.512 rs3809863 ENSG00000228782.6 CTD-2026D20.3 7.56 3.75e-13 4.9e-10 0.44 0.38 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47307646 chr17:47450568~47492492:- LIHC cis rs9543976 0.623 rs7996884 ENSG00000261553.4 RP11-29G8.3 7.56 3.76e-13 4.91e-10 0.52 0.38 Diabetic retinopathy; chr13:75598608 chr13:75549773~75807120:+ LIHC cis rs3096299 0.933 rs2965823 ENSG00000274627.1 RP11-104N10.2 7.56 3.76e-13 4.91e-10 0.39 0.38 Multiple myeloma (IgH translocation); chr16:89388516 chr16:89516797~89522217:+ LIHC cis rs17301013 0.507 rs12076548 ENSG00000227373.4 RP11-160H22.5 -7.56 3.79e-13 4.95e-10 -0.61 -0.38 Systemic lupus erythematosus; chr1:174479005 chr1:174115300~174160004:- LIHC cis rs6142102 0.602 rs4911395 ENSG00000276073.1 RP5-1125A11.7 -7.56 3.8e-13 4.96e-10 -0.39 -0.38 Skin pigmentation; chr20:33992095 chr20:33985617~33988989:- LIHC cis rs9543976 0.623 rs6562918 ENSG00000261553.4 RP11-29G8.3 7.56 3.81e-13 4.97e-10 0.52 0.38 Diabetic retinopathy; chr13:75600441 chr13:75549773~75807120:+ LIHC cis rs62229266 0.804 rs11088331 ENSG00000231106.2 LINC01436 7.56 3.82e-13 4.98e-10 0.41 0.38 Mitral valve prolapse; chr21:36049574 chr21:36005338~36007838:+ LIHC cis rs9527 0.571 rs4917985 ENSG00000236937.2 PTGES3P4 7.56 3.83e-13 5e-10 0.44 0.38 Arsenic metabolism; chr10:102864315 chr10:102845595~102845950:+ LIHC cis rs7174755 0.608 rs62004789 ENSG00000260657.2 RP11-315D16.4 7.56 3.84e-13 5.01e-10 0.58 0.38 Major depressive disorder; chr15:68148268 chr15:68267792~68277994:- LIHC cis rs17301013 0.606 rs333423 ENSG00000227373.4 RP11-160H22.5 7.56 3.84e-13 5.01e-10 0.58 0.38 Systemic lupus erythematosus; chr1:174666557 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs333437 ENSG00000227373.4 RP11-160H22.5 7.56 3.84e-13 5.01e-10 0.58 0.38 Systemic lupus erythematosus; chr1:174672224 chr1:174115300~174160004:- LIHC cis rs6490294 0.571 rs12425329 ENSG00000226469.1 ADAM1B 7.56 3.85e-13 5.01e-10 0.52 0.38 Mean platelet volume; chr12:112004628 chr12:111927018~111929017:+ LIHC cis rs6504950 0.705 rs17745123 ENSG00000275710.1 RP11-257O5.4 7.56 3.86e-13 5.03e-10 0.54 0.38 Breast cancer; chr17:54910871 chr17:54964474~54964679:+ LIHC cis rs2882667 0.858 rs6882112 ENSG00000253404.1 AC034243.1 -7.56 3.86e-13 5.03e-10 -0.5 -0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139078046 chr5:138744434~138753309:- LIHC cis rs4853012 0.838 rs12619982 ENSG00000257800.1 FNBP1P1 7.55 3.88e-13 5.06e-10 0.43 0.38 Gestational age at birth (maternal effect); chr2:74128895 chr2:74120680~74123218:+ LIHC cis rs7044106 0.537 rs4434680 ENSG00000226752.6 PSMD5-AS1 -7.55 3.91e-13 5.09e-10 -0.4 -0.38 Hip circumference adjusted for BMI; chr9:120727410 chr9:120824828~120854385:+ LIHC cis rs12744310 0.887 rs35690915 ENSG00000235358.1 RP11-399E6.1 7.55 3.91e-13 5.09e-10 0.49 0.38 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41332327 chr1:41242373~41284861:+ LIHC cis rs1555322 0.53 rs6060347 ENSG00000126005.14 MMP24-AS1 -7.55 3.92e-13 5.11e-10 -0.55 -0.38 Attention deficit hyperactivity disorder; chr20:35286348 chr20:35216462~35278131:- LIHC cis rs2929278 0.562 rs8033846 ENSG00000205771.5 CATSPER2P1 7.55 3.98e-13 5.18e-10 0.48 0.38 Schizophrenia; chr15:43743165 chr15:43726918~43747094:- LIHC cis rs62229266 0.659 rs7275820 ENSG00000231106.2 LINC01436 7.55 3.99e-13 5.19e-10 0.42 0.38 Mitral valve prolapse; chr21:36037116 chr21:36005338~36007838:+ LIHC cis rs6142102 0.602 rs4911396 ENSG00000276073.1 RP5-1125A11.7 -7.55 4.01e-13 5.21e-10 -0.39 -0.38 Skin pigmentation; chr20:33992139 chr20:33985617~33988989:- LIHC cis rs8040855 0.559 rs6496801 ENSG00000259295.5 CSPG4P12 -7.55 4.01e-13 5.22e-10 -0.57 -0.38 Bulimia nervosa; chr15:85185168 chr15:85191438~85213905:+ LIHC cis rs494459 0.657 rs614554 ENSG00000255422.1 AP002954.4 -7.55 4.04e-13 5.25e-10 -0.43 -0.38 Height; chr11:118764443 chr11:118704607~118750263:+ LIHC cis rs2739330 0.652 rs2000469 ENSG00000231271.1 AP000350.8 7.55 4.04e-13 5.25e-10 0.46 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23949918~23954042:+ LIHC cis rs6142102 0.602 rs10485503 ENSG00000276073.1 RP5-1125A11.7 -7.55 4.08e-13 5.3e-10 -0.39 -0.38 Skin pigmentation; chr20:33970036 chr20:33985617~33988989:- LIHC cis rs34779708 0.966 rs998658 ENSG00000230534.5 RP11-297A16.2 7.54 4.17e-13 5.41e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35119726 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs4934731 ENSG00000230534.5 RP11-297A16.2 7.54 4.19e-13 5.42e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35142708 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs6481941 ENSG00000230534.5 RP11-297A16.2 7.54 4.19e-13 5.42e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35151213 chr10:35098006~35127020:- LIHC cis rs494459 0.838 rs566733 ENSG00000255422.1 AP002954.4 -7.54 4.24e-13 5.46e-10 -0.43 -0.38 Height; chr11:118737916 chr11:118704607~118750263:+ LIHC cis rs8072100 0.676 rs9905308 ENSG00000228782.6 CTD-2026D20.3 7.54 4.25e-13 5.47e-10 0.42 0.38 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47332020 chr17:47450568~47492492:- LIHC cis rs1062177 0.826 rs2915822 ENSG00000213433.5 RPLP1P6 7.54 4.28e-13 5.51e-10 0.43 0.38 Preschool internalizing problems; chr5:151751340 chr5:151765859~151766378:- LIHC cis rs831571 0.519 rs13059603 ENSG00000280620.1 SCAANT1 -7.54 4.29e-13 5.52e-10 -0.49 -0.38 Type 2 diabetes; chr3:63841705 chr3:63911518~63911772:- LIHC cis rs7044106 0.791 rs4617229 ENSG00000226752.6 PSMD5-AS1 -7.54 4.33e-13 5.58e-10 -0.39 -0.38 Hip circumference adjusted for BMI; chr9:120718418 chr9:120824828~120854385:+ LIHC cis rs2882667 0.822 rs11738376 ENSG00000253404.1 AC034243.1 7.54 4.37e-13 5.62e-10 0.52 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139062483 chr5:138744434~138753309:- LIHC cis rs2739330 0.76 rs5751761 ENSG00000250470.1 AP000351.3 -7.54 4.38e-13 5.63e-10 -0.47 -0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23976904~23977585:- LIHC cis rs9399135 0.967 rs9376077 ENSG00000232876.1 CTA-212D2.2 -7.54 4.39e-13 5.64e-10 -0.42 -0.38 Red blood cell count; chr6:134978575 chr6:135055033~135060550:+ LIHC cis rs17301013 0.507 rs1474575 ENSG00000227373.4 RP11-160H22.5 -7.54 4.4e-13 5.65e-10 -0.6 -0.38 Systemic lupus erythematosus; chr1:174569563 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2142864 ENSG00000227373.4 RP11-160H22.5 7.54 4.41e-13 5.66e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174304924 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2860909 ENSG00000227373.4 RP11-160H22.5 7.54 4.41e-13 5.66e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174305211 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs7553317 ENSG00000227373.4 RP11-160H22.5 7.54 4.41e-13 5.66e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174307182 chr1:174115300~174160004:- LIHC cis rs7044106 0.791 rs4836830 ENSG00000226752.6 PSMD5-AS1 -7.53 4.42e-13 5.67e-10 -0.39 -0.38 Hip circumference adjusted for BMI; chr9:120721390 chr9:120824828~120854385:+ LIHC cis rs17301013 0.507 rs12091076 ENSG00000227373.4 RP11-160H22.5 7.53 4.43e-13 5.69e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174321545 chr1:174115300~174160004:- LIHC cis rs73086581 0.945 rs6037715 ENSG00000229539.1 RP11-119B16.2 7.53 4.43e-13 5.69e-10 0.68 0.38 Response to antidepressants in depression; chr20:3991519 chr20:3888239~3888868:- LIHC cis rs73086581 0.945 rs6052222 ENSG00000229539.1 RP11-119B16.2 7.53 4.43e-13 5.69e-10 0.68 0.38 Response to antidepressants in depression; chr20:3992146 chr20:3888239~3888868:- LIHC cis rs7044106 0.718 rs1960421 ENSG00000226752.6 PSMD5-AS1 -7.53 4.47e-13 5.74e-10 -0.39 -0.38 Hip circumference adjusted for BMI; chr9:120632616 chr9:120824828~120854385:+ LIHC cis rs992157 1 rs992157 ENSG00000261338.2 RP11-378A13.1 -7.53 4.47e-13 5.74e-10 -0.38 -0.38 Colorectal cancer; chr2:218290058 chr2:218255319~218257366:+ LIHC cis rs6504950 0.785 rs2628304 ENSG00000275710.1 RP11-257O5.4 -7.53 4.49e-13 5.76e-10 -0.56 -0.38 Breast cancer; chr17:55079828 chr17:54964474~54964679:+ LIHC cis rs150992 0.673 rs161747 ENSG00000248489.1 CTD-2007H13.3 -7.53 4.54e-13 5.83e-10 -0.55 -0.38 Body mass index; chr5:98920433 chr5:98929171~98995013:+ LIHC cis rs17301013 0.507 rs72713591 ENSG00000227373.4 RP11-160H22.5 7.53 4.54e-13 5.83e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174442956 chr1:174115300~174160004:- LIHC cis rs1891275 0.515 rs6583784 ENSG00000228701.1 TNKS2-AS1 7.53 4.55e-13 5.84e-10 0.45 0.38 Intelligence (multi-trait analysis); chr10:91731819 chr10:91782839~91798291:- LIHC cis rs1555322 0.53 rs6060341 ENSG00000126005.14 MMP24-AS1 7.53 4.58e-13 5.87e-10 0.56 0.38 Attention deficit hyperactivity disorder; chr20:35275830 chr20:35216462~35278131:- LIHC cis rs17301013 0.581 rs56158362 ENSG00000227373.4 RP11-160H22.5 7.53 4.6e-13 5.9e-10 0.59 0.38 Systemic lupus erythematosus; chr1:174166437 chr1:174115300~174160004:- LIHC cis rs34779708 0.75 rs35032841 ENSG00000230534.5 RP11-297A16.2 7.53 4.62e-13 5.91e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35023759 chr10:35098006~35127020:- LIHC cis rs34779708 0.742 rs35912711 ENSG00000230534.5 RP11-297A16.2 7.53 4.62e-13 5.91e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35024068 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs4934702 ENSG00000230534.5 RP11-297A16.2 7.53 4.62e-13 5.91e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35034146 chr10:35098006~35127020:- LIHC cis rs494459 0.691 rs607472 ENSG00000255422.1 AP002954.4 -7.53 4.68e-13 5.99e-10 -0.42 -0.38 Height; chr11:118809363 chr11:118704607~118750263:+ LIHC cis rs7617773 0.925 rs7374376 ENSG00000229759.1 MRPS18AP1 -7.53 4.7e-13 6.02e-10 -0.4 -0.38 Coronary artery disease; chr3:48131197 chr3:48256350~48256938:- LIHC cis rs3096299 1 rs3096299 ENSG00000274627.1 RP11-104N10.2 7.52 4.71e-13 6.03e-10 0.4 0.38 Multiple myeloma (IgH translocation); chr16:89382255 chr16:89516797~89522217:+ LIHC cis rs7044106 0.791 rs4837793 ENSG00000226752.6 PSMD5-AS1 -7.52 4.73e-13 6.04e-10 -0.39 -0.38 Hip circumference adjusted for BMI; chr9:120721343 chr9:120824828~120854385:+ LIHC cis rs1891275 0.508 rs2096079 ENSG00000228701.1 TNKS2-AS1 -7.52 4.76e-13 6.07e-10 -0.46 -0.38 Intelligence (multi-trait analysis); chr10:91736910 chr10:91782839~91798291:- LIHC cis rs17301013 0.507 rs72713586 ENSG00000227373.4 RP11-160H22.5 7.52 4.77e-13 6.09e-10 0.63 0.38 Systemic lupus erythematosus; chr1:174441265 chr1:174115300~174160004:- LIHC cis rs7580658 0.724 rs71414745 ENSG00000236682.1 AC068282.3 -7.52 4.8e-13 6.13e-10 -0.46 -0.38 Protein C levels; chr2:127235012 chr2:127389130~127400580:+ LIHC cis rs17301013 0.507 rs11799535 ENSG00000227373.4 RP11-160H22.5 7.52 4.81e-13 6.14e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174415790 chr1:174115300~174160004:- LIHC cis rs2882667 0.858 rs35812969 ENSG00000253404.1 AC034243.1 7.52 4.86e-13 6.2e-10 0.52 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139041861 chr5:138744434~138753309:- LIHC cis rs9399135 0.967 rs13199205 ENSG00000232876.1 CTA-212D2.2 -7.52 4.87e-13 6.21e-10 -0.42 -0.38 Red blood cell count; chr6:134965367 chr6:135055033~135060550:+ LIHC cis rs992157 1 rs2168704 ENSG00000261338.2 RP11-378A13.1 7.52 4.88e-13 6.22e-10 0.38 0.38 Colorectal cancer; chr2:218277769 chr2:218255319~218257366:+ LIHC cis rs2882667 0.858 rs11242444 ENSG00000253404.1 AC034243.1 7.52 4.92e-13 6.27e-10 0.52 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139070690 chr5:138744434~138753309:- LIHC cis rs7201929 1 rs11644151 ENSG00000259982.1 CDC37P1 -7.52 4.93e-13 6.28e-10 -0.41 -0.38 QT interval; chr16:28884339 chr16:28700294~28701540:- LIHC cis rs7044106 0.762 rs7044226 ENSG00000226752.6 PSMD5-AS1 -7.52 4.93e-13 6.29e-10 -0.38 -0.38 Hip circumference adjusted for BMI; chr9:120704050 chr9:120824828~120854385:+ LIHC cis rs1023500 0.573 rs133380 ENSG00000227370.1 RP4-669P10.19 -7.52 4.97e-13 6.33e-10 -0.42 -0.38 Schizophrenia; chr22:42072906 chr22:42132543~42132998:+ LIHC cis rs62229266 0.652 rs7280551 ENSG00000231106.2 LINC01436 7.52 4.98e-13 6.34e-10 0.41 0.38 Mitral valve prolapse; chr21:36037311 chr21:36005338~36007838:+ LIHC cis rs17301013 0.606 rs459078 ENSG00000227373.4 RP11-160H22.5 7.52 5e-13 6.37e-10 0.58 0.38 Systemic lupus erythematosus; chr1:174733772 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs162815 ENSG00000227373.4 RP11-160H22.5 7.52 5e-13 6.37e-10 0.58 0.38 Systemic lupus erythematosus; chr1:174738792 chr1:174115300~174160004:- LIHC cis rs7044106 0.762 rs12003646 ENSG00000226752.6 PSMD5-AS1 -7.51 5.07e-13 6.45e-10 -0.39 -0.38 Hip circumference adjusted for BMI; chr9:120708343 chr9:120824828~120854385:+ LIHC cis rs73086581 1 rs11906274 ENSG00000229539.1 RP11-119B16.2 7.51 5.07e-13 6.45e-10 0.68 0.38 Response to antidepressants in depression; chr20:3964889 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs6052196 ENSG00000229539.1 RP11-119B16.2 7.51 5.07e-13 6.45e-10 0.68 0.38 Response to antidepressants in depression; chr20:3965177 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs6116130 ENSG00000229539.1 RP11-119B16.2 7.51 5.07e-13 6.45e-10 0.68 0.38 Response to antidepressants in depression; chr20:3966379 chr20:3888239~3888868:- LIHC cis rs73086581 0.786 rs6037705 ENSG00000229539.1 RP11-119B16.2 7.51 5.07e-13 6.45e-10 0.68 0.38 Response to antidepressants in depression; chr20:3972183 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs6037708 ENSG00000229539.1 RP11-119B16.2 7.51 5.07e-13 6.45e-10 0.68 0.38 Response to antidepressants in depression; chr20:3980606 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs6052209 ENSG00000229539.1 RP11-119B16.2 7.51 5.07e-13 6.45e-10 0.68 0.38 Response to antidepressants in depression; chr20:3981100 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs6052217 ENSG00000229539.1 RP11-119B16.2 7.51 5.07e-13 6.45e-10 0.68 0.38 Response to antidepressants in depression; chr20:3989564 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs6052218 ENSG00000229539.1 RP11-119B16.2 7.51 5.07e-13 6.45e-10 0.68 0.38 Response to antidepressants in depression; chr20:3989565 chr20:3888239~3888868:- LIHC cis rs73086581 0.945 rs6052219 ENSG00000229539.1 RP11-119B16.2 7.51 5.07e-13 6.45e-10 0.68 0.38 Response to antidepressants in depression; chr20:3989660 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs6107386 ENSG00000229539.1 RP11-119B16.2 7.51 5.07e-13 6.45e-10 0.68 0.38 Response to antidepressants in depression; chr20:3992109 chr20:3888239~3888868:- LIHC cis rs62229266 0.74 rs4817759 ENSG00000231106.2 LINC01436 7.51 5.08e-13 6.45e-10 0.41 0.38 Mitral valve prolapse; chr21:36017261 chr21:36005338~36007838:+ LIHC cis rs17301013 0.507 rs11805578 ENSG00000227373.4 RP11-160H22.5 7.51 5.08e-13 6.46e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174573174 chr1:174115300~174160004:- LIHC cis rs34779708 0.931 rs6481935 ENSG00000230534.5 RP11-297A16.2 7.51 5.08e-13 6.46e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35054031 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs12242882 ENSG00000230534.5 RP11-297A16.2 7.51 5.08e-13 6.46e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35058932 chr10:35098006~35127020:- LIHC cis rs992157 1 rs736730 ENSG00000261338.2 RP11-378A13.1 7.51 5.08e-13 6.46e-10 0.39 0.38 Colorectal cancer; chr2:218255532 chr2:218255319~218257366:+ LIHC cis rs992157 1 rs736731 ENSG00000261338.2 RP11-378A13.1 7.51 5.08e-13 6.46e-10 0.39 0.38 Colorectal cancer; chr2:218255865 chr2:218255319~218257366:+ LIHC cis rs992157 1 rs3731859 ENSG00000261338.2 RP11-378A13.1 7.51 5.08e-13 6.46e-10 0.39 0.38 Colorectal cancer; chr2:218259499 chr2:218255319~218257366:+ LIHC cis rs992157 1 rs13003334 ENSG00000261338.2 RP11-378A13.1 7.51 5.08e-13 6.46e-10 0.39 0.38 Colorectal cancer; chr2:218260198 chr2:218255319~218257366:+ LIHC cis rs992157 1 rs11554825 ENSG00000261338.2 RP11-378A13.1 7.51 5.08e-13 6.46e-10 0.39 0.38 Colorectal cancer; chr2:218261086 chr2:218255319~218257366:+ LIHC cis rs55665837 1 rs4412729 ENSG00000251991.1 RNU7-49P 7.51 5.16e-13 6.56e-10 0.39 0.38 Vitamin D levels; chr11:14417454 chr11:14478892~14478953:+ LIHC cis rs1577917 0.538 rs6454483 ENSG00000234155.1 RP11-30P6.6 -7.51 5.17e-13 6.56e-10 -0.43 -0.38 Response to antipsychotic treatment; chr6:85708565 chr6:85387219~85390186:- LIHC cis rs7044106 0.762 rs7357638 ENSG00000226752.6 PSMD5-AS1 -7.51 5.25e-13 6.66e-10 -0.39 -0.38 Hip circumference adjusted for BMI; chr9:120626926 chr9:120824828~120854385:+ LIHC cis rs198426 0.506 rs198462 ENSG00000124915.9 DKFZP434K028 7.51 5.27e-13 6.68e-10 0.42 0.38 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr11:61756647 chr11:61746493~61757655:- LIHC cis rs2032447 0.507 rs478349 ENSG00000242387.1 HIST1H2APS2 7.51 5.28e-13 6.69e-10 0.53 0.38 Intelligence (multi-trait analysis); chr6:25893829 chr6:25882026~25882395:- LIHC cis rs1183201 0.505 rs1165201 ENSG00000242387.1 HIST1H2APS2 7.51 5.29e-13 6.7e-10 0.47 0.38 Uric acid levels; chr6:25874595 chr6:25882026~25882395:- LIHC cis rs7617773 0.963 rs12495221 ENSG00000229759.1 MRPS18AP1 -7.51 5.36e-13 6.79e-10 -0.39 -0.38 Coronary artery disease; chr3:48137688 chr3:48256350~48256938:- LIHC cis rs17301013 0.507 rs2860954 ENSG00000227373.4 RP11-160H22.5 7.5 5.38e-13 6.81e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174344313 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs60864659 ENSG00000227373.4 RP11-160H22.5 7.5 5.38e-13 6.81e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174344641 chr1:174115300~174160004:- LIHC cis rs6991838 0.584 rs4737221 ENSG00000200714.1 Y_RNA -7.5 5.39e-13 6.83e-10 -0.4 -0.38 Intelligence (multi-trait analysis); chr8:65569075 chr8:65592731~65592820:+ LIHC cis rs4820294 1 rs41280035 ENSG00000233360.4 Z83844.1 7.5 5.39e-13 6.83e-10 0.47 0.38 Fat distribution (HIV); chr22:37658031 chr22:37641832~37658377:- LIHC cis rs17301013 0.507 rs2568098 ENSG00000227373.4 RP11-160H22.5 7.5 5.4e-13 6.84e-10 0.62 0.38 Systemic lupus erythematosus; chr1:174732183 chr1:174115300~174160004:- LIHC cis rs34779708 0.931 rs12240347 ENSG00000230534.5 RP11-297A16.2 7.5 5.41e-13 6.86e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35070547 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs4934533 ENSG00000230534.5 RP11-297A16.2 7.5 5.41e-13 6.86e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35070691 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs12248333 ENSG00000230534.5 RP11-297A16.2 7.5 5.41e-13 6.86e-10 0.47 0.38 Inflammatory bowel disease;Crohn's disease; chr10:35074049 chr10:35098006~35127020:- LIHC cis rs62229266 0.804 rs62230822 ENSG00000231106.2 LINC01436 7.5 5.42e-13 6.86e-10 0.42 0.38 Mitral valve prolapse; chr21:36057647 chr21:36005338~36007838:+ LIHC cis rs9399135 0.967 rs4895434 ENSG00000232876.1 CTA-212D2.2 -7.5 5.42e-13 6.87e-10 -0.42 -0.38 Red blood cell count; chr6:134972227 chr6:135055033~135060550:+ LIHC cis rs9399135 1 rs4895435 ENSG00000232876.1 CTA-212D2.2 -7.5 5.42e-13 6.87e-10 -0.42 -0.38 Red blood cell count; chr6:134972325 chr6:135055033~135060550:+ LIHC cis rs10899021 0.92 rs7112384 ENSG00000279353.1 RP11-864N7.4 7.5 5.43e-13 6.87e-10 0.83 0.38 Response to metformin (IC50); chr11:74637160 chr11:74698231~74699658:- LIHC cis rs10899021 0.92 rs7112664 ENSG00000279353.1 RP11-864N7.4 7.5 5.43e-13 6.87e-10 0.83 0.38 Response to metformin (IC50); chr11:74637381 chr11:74698231~74699658:- LIHC cis rs17301013 0.507 rs72715224 ENSG00000227373.4 RP11-160H22.5 7.5 5.43e-13 6.87e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174534256 chr1:174115300~174160004:- LIHC cis rs62355901 0.545 rs16886256 ENSG00000271828.1 CTD-2310F14.1 -7.5 5.49e-13 6.95e-10 -0.58 -0.38 Breast cancer; chr5:56765737 chr5:56927874~56929573:+ LIHC cis rs9399135 0.967 rs4896123 ENSG00000232876.1 CTA-212D2.2 -7.5 5.53e-13 7e-10 -0.42 -0.38 Red blood cell count; chr6:134974272 chr6:135055033~135060550:+ LIHC cis rs9543976 0.92 rs9543972 ENSG00000261553.4 RP11-29G8.3 7.5 5.57e-13 7.05e-10 0.55 0.38 Diabetic retinopathy; chr13:75547539 chr13:75549773~75807120:+ LIHC cis rs7657257 1 rs16892283 ENSG00000214846.4 RP11-115L11.1 7.5 5.61e-13 7.09e-10 0.61 0.38 Blood protein levels; chr4:15729911 chr4:15730962~15731627:- LIHC cis rs2882667 0.858 rs6596460 ENSG00000253404.1 AC034243.1 7.5 5.67e-13 7.16e-10 0.51 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139078491 chr5:138744434~138753309:- LIHC cis rs7115242 0.858 rs6589592 ENSG00000254851.1 RP11-109L13.1 -7.5 5.7e-13 7.2e-10 -0.63 -0.38 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117087191 chr11:117135528~117138582:+ LIHC cis rs7727544 0.735 rs274558 ENSG00000233006.5 AC034220.3 -7.5 5.72e-13 7.23e-10 -0.38 -0.38 Blood metabolite levels; chr5:132385482 chr5:132311285~132369916:- LIHC cis rs7727544 0.735 rs274557 ENSG00000233006.5 AC034220.3 -7.5 5.72e-13 7.23e-10 -0.38 -0.38 Blood metabolite levels; chr5:132385512 chr5:132311285~132369916:- LIHC cis rs56091001 0.528 rs9616387 ENSG00000278869.1 CITF22-49E9.3 7.5 5.73e-13 7.23e-10 0.85 0.38 Acne (severe); chr22:49919571 chr22:49933198~49934074:- LIHC cis rs1789 0.903 rs6850422 ENSG00000273133.1 RP11-799M12.2 -7.49 5.74e-13 7.25e-10 -0.49 -0.38 Blood protein levels; chr4:15680814 chr4:15563698~15564253:- LIHC cis rs198426 0.506 rs198464 ENSG00000124915.9 DKFZP434K028 7.49 5.75e-13 7.26e-10 0.41 0.38 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr11:61754149 chr11:61746493~61757655:- LIHC cis rs55665837 1 rs10832268 ENSG00000251991.1 RNU7-49P 7.49 5.78e-13 7.29e-10 0.39 0.38 Vitamin D levels; chr11:14443522 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs10832269 ENSG00000251991.1 RNU7-49P 7.49 5.78e-13 7.29e-10 0.39 0.38 Vitamin D levels; chr11:14443523 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs10832271 ENSG00000251991.1 RNU7-49P 7.49 5.78e-13 7.29e-10 0.39 0.38 Vitamin D levels; chr11:14445373 chr11:14478892~14478953:+ LIHC cis rs55665837 0.961 rs12576926 ENSG00000251991.1 RNU7-49P 7.49 5.78e-13 7.29e-10 0.39 0.38 Vitamin D levels; chr11:14458746 chr11:14478892~14478953:+ LIHC cis rs7580658 0.676 rs4662717 ENSG00000236682.1 AC068282.3 -7.49 5.81e-13 7.33e-10 -0.46 -0.38 Protein C levels; chr2:127255928 chr2:127389130~127400580:+ LIHC cis rs6991838 0.584 rs7836349 ENSG00000272010.1 CTD-3025N20.3 -7.49 5.84e-13 7.36e-10 -0.4 -0.38 Intelligence (multi-trait analysis); chr8:65591328 chr8:65591850~65592472:- LIHC cis rs55665837 1 rs12792120 ENSG00000251991.1 RNU7-49P 7.49 5.85e-13 7.38e-10 0.39 0.38 Vitamin D levels; chr11:14447897 chr11:14478892~14478953:+ LIHC cis rs6490294 0.528 rs11066126 ENSG00000226469.1 ADAM1B 7.49 5.87e-13 7.39e-10 0.52 0.38 Mean platelet volume; chr12:112007087 chr12:111927018~111929017:+ LIHC cis rs7617773 0.963 rs6766754 ENSG00000229759.1 MRPS18AP1 -7.49 5.9e-13 7.44e-10 -0.4 -0.38 Coronary artery disease; chr3:48141099 chr3:48256350~48256938:- LIHC cis rs7617773 0.832 rs6775114 ENSG00000229759.1 MRPS18AP1 -7.49 5.9e-13 7.44e-10 -0.4 -0.38 Coronary artery disease; chr3:48141130 chr3:48256350~48256938:- LIHC cis rs4423214 0.879 rs10898144 ENSG00000254682.1 RP11-660L16.2 -7.49 5.9e-13 7.44e-10 -0.46 -0.38 Vitamin D levels; chr11:71440494 chr11:71448674~71452157:+ LIHC cis rs2980436 1 rs2980436 ENSG00000173295.6 FAM86B3P -7.49 5.94e-13 7.48e-10 -0.51 -0.38 Schizophrenia; chr8:8234503 chr8:8228595~8244865:+ LIHC cis rs2739330 0.892 rs5751776 ENSG00000250470.1 AP000351.3 7.49 6.03e-13 7.59e-10 0.45 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23976904~23977585:- LIHC cis rs17301013 0.507 rs7537823 ENSG00000227373.4 RP11-160H22.5 7.49 6.04e-13 7.59e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174502222 chr1:174115300~174160004:- LIHC cis rs2882667 0.858 rs11741150 ENSG00000253404.1 AC034243.1 7.49 6.1e-13 7.66e-10 0.53 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139095768 chr5:138744434~138753309:- LIHC cis rs17301013 0.606 rs77379897 ENSG00000227373.4 RP11-160H22.5 7.49 6.11e-13 7.68e-10 0.59 0.38 Systemic lupus erythematosus; chr1:174169373 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs392307 ENSG00000227373.4 RP11-160H22.5 7.49 6.11e-13 7.68e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174744243 chr1:174115300~174160004:- LIHC cis rs7174755 0.743 rs4777035 ENSG00000260657.2 RP11-315D16.4 -7.48 6.18e-13 7.77e-10 -0.51 -0.38 Major depressive disorder; chr15:68312831 chr15:68267792~68277994:- LIHC cis rs9399135 1 rs6569988 ENSG00000232876.1 CTA-212D2.2 -7.48 6.19e-13 7.78e-10 -0.41 -0.38 Red blood cell count; chr6:135031165 chr6:135055033~135060550:+ LIHC cis rs7044106 0.708 rs10760113 ENSG00000226752.6 PSMD5-AS1 -7.48 6.19e-13 7.78e-10 -0.38 -0.38 Hip circumference adjusted for BMI; chr9:120711772 chr9:120824828~120854385:+ LIHC cis rs2019137 0.936 rs3811059 ENSG00000274877.1 RP11-65I12.1 7.48 6.21e-13 7.8e-10 0.45 0.38 Lymphocyte counts; chr2:113204494 chr2:113237595~113240825:+ LIHC cis rs2019137 0.936 rs12620738 ENSG00000274877.1 RP11-65I12.1 7.48 6.21e-13 7.8e-10 0.45 0.38 Lymphocyte counts; chr2:113206162 chr2:113237595~113240825:+ LIHC cis rs73086581 1 rs17215529 ENSG00000229539.1 RP11-119B16.2 7.48 6.23e-13 7.81e-10 0.68 0.38 Response to antidepressants in depression; chr20:3994755 chr20:3888239~3888868:- LIHC cis rs6490294 0.571 rs35662477 ENSG00000226469.1 ADAM1B 7.48 6.25e-13 7.85e-10 0.53 0.38 Mean platelet volume; chr12:111875404 chr12:111927018~111929017:+ LIHC cis rs17301013 0.507 rs6665535 ENSG00000227373.4 RP11-160H22.5 7.48 6.25e-13 7.85e-10 0.61 0.38 Systemic lupus erythematosus; chr1:174522480 chr1:174115300~174160004:- LIHC cis rs55665837 1 rs10832254 ENSG00000251991.1 RNU7-49P 7.48 6.28e-13 7.87e-10 0.39 0.38 Vitamin D levels; chr11:14413152 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs11023214 ENSG00000251991.1 RNU7-49P 7.48 6.28e-13 7.87e-10 0.39 0.38 Vitamin D levels; chr11:14414713 chr11:14478892~14478953:+ LIHC cis rs6142102 0.625 rs2050208 ENSG00000276073.1 RP5-1125A11.7 -7.48 6.3e-13 7.89e-10 -0.39 -0.37 Skin pigmentation; chr20:33955767 chr20:33985617~33988989:- LIHC cis rs62229266 0.804 rs12483151 ENSG00000231106.2 LINC01436 7.48 6.33e-13 7.94e-10 0.41 0.37 Mitral valve prolapse; chr21:36047280 chr21:36005338~36007838:+ LIHC cis rs2739330 0.828 rs5751770 ENSG00000250470.1 AP000351.3 7.48 6.44e-13 8.06e-10 0.44 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23976904~23977585:- LIHC cis rs17301013 0.507 rs12065454 ENSG00000227373.4 RP11-160H22.5 7.48 6.45e-13 8.07e-10 0.61 0.37 Systemic lupus erythematosus; chr1:174492226 chr1:174115300~174160004:- LIHC cis rs55665837 1 rs55665837 ENSG00000251991.1 RNU7-49P 7.48 6.47e-13 8.1e-10 0.39 0.37 Vitamin D levels; chr11:14473503 chr11:14478892~14478953:+ LIHC cis rs9326248 0.574 rs1263173 ENSG00000236267.1 AP006216.5 7.47 6.62e-13 8.29e-10 0.37 0.37 Blood protein levels; chr11:116810292 chr11:116813204~116814003:- LIHC cis rs10916248 0.511 rs1060386 ENSG00000232628.4 RP11-365O16.3 7.47 6.64e-13 8.31e-10 0.53 0.37 QT interval (drug interaction); chr1:224192776 chr1:224208747~224213279:- LIHC cis rs62355901 0.505 rs62356561 ENSG00000271828.1 CTD-2310F14.1 7.47 6.65e-13 8.32e-10 0.58 0.37 Breast cancer; chr5:56933826 chr5:56927874~56929573:+ LIHC cis rs2929278 0.617 rs575082 ENSG00000205771.5 CATSPER2P1 7.47 6.66e-13 8.33e-10 0.47 0.37 Schizophrenia; chr15:43817944 chr15:43726918~43747094:- LIHC cis rs2929278 0.617 rs2955969 ENSG00000205771.5 CATSPER2P1 7.47 6.66e-13 8.33e-10 0.47 0.37 Schizophrenia; chr15:43822329 chr15:43726918~43747094:- LIHC cis rs6860806 0.507 rs2631372 ENSG00000233006.5 AC034220.3 7.47 6.69e-13 8.37e-10 0.37 0.37 Breast cancer; chr5:132367886 chr5:132311285~132369916:- LIHC cis rs10899021 0.92 rs61901540 ENSG00000279353.1 RP11-864N7.4 7.47 6.7e-13 8.38e-10 0.83 0.37 Response to metformin (IC50); chr11:74603820 chr11:74698231~74699658:- LIHC cis rs10899021 0.92 rs61901541 ENSG00000279353.1 RP11-864N7.4 7.47 6.7e-13 8.38e-10 0.83 0.37 Response to metformin (IC50); chr11:74606940 chr11:74698231~74699658:- LIHC cis rs10899021 0.92 rs7122710 ENSG00000279353.1 RP11-864N7.4 7.47 6.7e-13 8.38e-10 0.83 0.37 Response to metformin (IC50); chr11:74612130 chr11:74698231~74699658:- LIHC cis rs10899021 0.92 rs10899014 ENSG00000279353.1 RP11-864N7.4 7.47 6.7e-13 8.38e-10 0.83 0.37 Response to metformin (IC50); chr11:74614064 chr11:74698231~74699658:- LIHC cis rs7044106 0.791 rs7036196 ENSG00000226752.6 PSMD5-AS1 -7.47 6.74e-13 8.42e-10 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120717179 chr9:120824828~120854385:+ LIHC cis rs7044106 0.791 rs3904196 ENSG00000226752.6 PSMD5-AS1 -7.47 6.74e-13 8.42e-10 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120718091 chr9:120824828~120854385:+ LIHC cis rs9326248 1 rs4938344 ENSG00000280143.1 AP000892.6 7.47 6.74e-13 8.43e-10 0.43 0.37 Blood protein levels; chr11:117133033 chr11:117204967~117210292:+ LIHC cis rs3096299 0.933 rs3114848 ENSG00000274627.1 RP11-104N10.2 7.47 6.79e-13 8.48e-10 0.39 0.37 Multiple myeloma (IgH translocation); chr16:89386363 chr16:89516797~89522217:+ LIHC cis rs1155848 0.892 rs953005 ENSG00000227354.5 RBM26-AS1 7.47 6.81e-13 8.5e-10 0.67 0.37 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79480544 chr13:79406309~79424328:+ LIHC cis rs9399135 0.935 rs4445070 ENSG00000232876.1 CTA-212D2.2 -7.47 6.82e-13 8.52e-10 -0.42 -0.37 Red blood cell count; chr6:134988074 chr6:135055033~135060550:+ LIHC cis rs17301013 0.606 rs17300775 ENSG00000227373.4 RP11-160H22.5 7.47 6.83e-13 8.53e-10 0.6 0.37 Systemic lupus erythematosus; chr1:174191901 chr1:174115300~174160004:- LIHC cis rs17301013 0.566 rs72711492 ENSG00000227373.4 RP11-160H22.5 7.47 6.83e-13 8.53e-10 0.6 0.37 Systemic lupus erythematosus; chr1:174195464 chr1:174115300~174160004:- LIHC cis rs7201929 1 rs7201929 ENSG00000259982.1 CDC37P1 7.47 6.9e-13 8.61e-10 0.4 0.37 QT interval; chr16:28860645 chr16:28700294~28701540:- LIHC cis rs6991838 0.584 rs4275254 ENSG00000272010.1 CTD-3025N20.3 -7.47 6.91e-13 8.62e-10 -0.4 -0.37 Intelligence (multi-trait analysis); chr8:65589129 chr8:65591850~65592472:- LIHC cis rs2739330 0.587 rs4820571 ENSG00000250470.1 AP000351.3 7.47 6.92e-13 8.63e-10 0.47 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23976904~23977585:- LIHC cis rs73086581 1 rs73084594 ENSG00000229539.1 RP11-119B16.2 7.47 6.94e-13 8.66e-10 0.69 0.37 Response to antidepressants in depression; chr20:3935733 chr20:3888239~3888868:- LIHC cis rs7044106 0.718 rs10616 ENSG00000226752.6 PSMD5-AS1 -7.47 6.96e-13 8.67e-10 -0.39 -0.37 Hip circumference adjusted for BMI; chr9:120601255 chr9:120824828~120854385:+ LIHC cis rs1061377 1 rs7664078 ENSG00000249207.1 RP11-360F5.1 -7.47 6.96e-13 8.68e-10 -0.38 -0.37 Uric acid levels; chr4:39116583 chr4:39112677~39126818:- LIHC cis rs17301013 0.507 rs2281011 ENSG00000227373.4 RP11-160H22.5 7.46 7.01e-13 8.73e-10 0.6 0.37 Systemic lupus erythematosus; chr1:174509890 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2072759 ENSG00000227373.4 RP11-160H22.5 7.46 7.01e-13 8.73e-10 0.6 0.37 Systemic lupus erythematosus; chr1:174510189 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs4652511 ENSG00000227373.4 RP11-160H22.5 7.46 7.01e-13 8.73e-10 0.6 0.37 Systemic lupus erythematosus; chr1:174515500 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs4652513 ENSG00000227373.4 RP11-160H22.5 7.46 7.01e-13 8.73e-10 0.6 0.37 Systemic lupus erythematosus; chr1:174515794 chr1:174115300~174160004:- LIHC cis rs9549367 0.707 rs9549353 ENSG00000269125.1 RP11-98F14.11 -7.46 7.02e-13 8.75e-10 -0.48 -0.37 Platelet distribution width; chr13:113189113 chr13:113165002~113165183:- LIHC cis rs6142102 0.602 rs2268079 ENSG00000276073.1 RP5-1125A11.7 -7.46 7.06e-13 8.79e-10 -0.39 -0.37 Skin pigmentation; chr20:34008944 chr20:33985617~33988989:- LIHC cis rs55665837 1 rs10832275 ENSG00000251991.1 RNU7-49P 7.46 7.08e-13 8.82e-10 0.39 0.37 Vitamin D levels; chr11:14456678 chr11:14478892~14478953:+ LIHC cis rs7580658 0.864 rs4150441 ENSG00000236682.1 AC068282.3 -7.46 7.11e-13 8.86e-10 -0.47 -0.37 Protein C levels; chr2:127283339 chr2:127389130~127400580:+ LIHC cis rs12744310 0.887 rs12042464 ENSG00000235358.1 RP11-399E6.1 -7.46 7.16e-13 8.92e-10 -0.49 -0.37 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41321182 chr1:41242373~41284861:+ LIHC cis rs34779708 0.897 rs4934527 ENSG00000230534.5 RP11-297A16.2 7.46 7.17e-13 8.92e-10 0.47 0.37 Inflammatory bowel disease;Crohn's disease; chr10:34992190 chr10:35098006~35127020:- LIHC cis rs17301013 0.507 rs10798310 ENSG00000227373.4 RP11-160H22.5 7.46 7.18e-13 8.93e-10 0.6 0.37 Systemic lupus erythematosus; chr1:174408581 chr1:174115300~174160004:- LIHC cis rs992157 1 rs2292553 ENSG00000261338.2 RP11-378A13.1 7.46 7.18e-13 8.93e-10 0.38 0.37 Colorectal cancer; chr2:218282080 chr2:218255319~218257366:+ LIHC cis rs150992 0.609 rs78254063 ENSG00000248489.1 CTD-2007H13.3 7.46 7.28e-13 9.05e-10 0.55 0.37 Body mass index; chr5:98990803 chr5:98929171~98995013:+ LIHC cis rs55665837 1 rs11023216 ENSG00000251991.1 RNU7-49P 7.46 7.28e-13 9.05e-10 0.39 0.37 Vitamin D levels; chr11:14415607 chr11:14478892~14478953:+ LIHC cis rs7044106 0.762 rs3903886 ENSG00000226752.6 PSMD5-AS1 7.46 7.35e-13 9.12e-10 0.38 0.37 Hip circumference adjusted for BMI; chr9:120621368 chr9:120824828~120854385:+ LIHC cis rs6142102 0.625 rs4911381 ENSG00000276073.1 RP5-1125A11.7 7.46 7.42e-13 9.21e-10 0.38 0.37 Skin pigmentation; chr20:33962539 chr20:33985617~33988989:- LIHC cis rs10262624 0.528 rs5029444 ENSG00000234286.1 AC006026.13 7.45 7.53e-13 9.34e-10 0.4 0.37 Schizophrenia; chr7:23698176 chr7:23680195~23680786:- LIHC cis rs7727544 0.684 rs274561 ENSG00000233006.5 AC034220.3 7.45 7.54e-13 9.35e-10 0.37 0.37 Blood metabolite levels; chr5:132383536 chr5:132311285~132369916:- LIHC cis rs1577917 0.958 rs12213343 ENSG00000234155.1 RP11-30P6.6 7.45 7.55e-13 9.36e-10 0.44 0.37 Response to antipsychotic treatment; chr6:85733301 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs12215265 ENSG00000234155.1 RP11-30P6.6 7.45 7.55e-13 9.36e-10 0.44 0.37 Response to antipsychotic treatment; chr6:85734251 chr6:85387219~85390186:- LIHC cis rs17301013 0.507 rs12097931 ENSG00000227373.4 RP11-160H22.5 7.45 7.6e-13 9.42e-10 0.59 0.37 Systemic lupus erythematosus; chr1:174454841 chr1:174115300~174160004:- LIHC cis rs55665837 1 rs10047429 ENSG00000251991.1 RNU7-49P 7.45 7.61e-13 9.43e-10 0.39 0.37 Vitamin D levels; chr11:14417486 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs10047457 ENSG00000251991.1 RNU7-49P 7.45 7.61e-13 9.43e-10 0.39 0.37 Vitamin D levels; chr11:14417913 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs3923294 ENSG00000251991.1 RNU7-49P 7.45 7.61e-13 9.43e-10 0.39 0.37 Vitamin D levels; chr11:14419856 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs12283797 ENSG00000251991.1 RNU7-49P 7.45 7.61e-13 9.43e-10 0.39 0.37 Vitamin D levels; chr11:14420716 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs10832256 ENSG00000251991.1 RNU7-49P 7.45 7.61e-13 9.43e-10 0.39 0.37 Vitamin D levels; chr11:14421329 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs10832257 ENSG00000251991.1 RNU7-49P 7.45 7.61e-13 9.43e-10 0.39 0.37 Vitamin D levels; chr11:14421770 chr11:14478892~14478953:+ LIHC cis rs55665837 0.961 rs12795972 ENSG00000251991.1 RNU7-49P 7.45 7.61e-13 9.43e-10 0.39 0.37 Vitamin D levels; chr11:14422229 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs12287715 ENSG00000251991.1 RNU7-49P 7.45 7.61e-13 9.43e-10 0.39 0.37 Vitamin D levels; chr11:14423029 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs12295723 ENSG00000251991.1 RNU7-49P 7.45 7.61e-13 9.43e-10 0.39 0.37 Vitamin D levels; chr11:14428655 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs12288873 ENSG00000251991.1 RNU7-49P 7.45 7.61e-13 9.43e-10 0.39 0.37 Vitamin D levels; chr11:14428919 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs12295888 ENSG00000251991.1 RNU7-49P 7.45 7.61e-13 9.43e-10 0.39 0.37 Vitamin D levels; chr11:14428985 chr11:14478892~14478953:+ LIHC cis rs62229266 0.609 rs12482541 ENSG00000231106.2 LINC01436 7.45 7.66e-13 9.48e-10 0.41 0.37 Mitral valve prolapse; chr21:36047445 chr21:36005338~36007838:+ LIHC cis rs62229266 0.609 rs2835253 ENSG00000231106.2 LINC01436 7.45 7.66e-13 9.48e-10 0.41 0.37 Mitral valve prolapse; chr21:36047447 chr21:36005338~36007838:+ LIHC cis rs17301013 0.507 rs7550472 ENSG00000227373.4 RP11-160H22.5 7.45 7.67e-13 9.49e-10 0.59 0.37 Systemic lupus erythematosus; chr1:174536442 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs11484645 ENSG00000227373.4 RP11-160H22.5 7.45 7.67e-13 9.49e-10 0.59 0.37 Systemic lupus erythematosus; chr1:174542993 chr1:174115300~174160004:- LIHC cis rs832187 0.593 rs3774713 ENSG00000280620.1 SCAANT1 7.45 7.69e-13 9.52e-10 0.46 0.37 Schizophrenia; chr3:63932016 chr3:63911518~63911772:- LIHC cis rs7617773 0.963 rs12493256 ENSG00000229759.1 MRPS18AP1 -7.45 7.7e-13 9.52e-10 -0.39 -0.37 Coronary artery disease; chr3:48135257 chr3:48256350~48256938:- LIHC cis rs832187 0.64 rs56293138 ENSG00000280620.1 SCAANT1 7.45 7.77e-13 9.6e-10 0.46 0.37 Schizophrenia; chr3:63903259 chr3:63911518~63911772:- LIHC cis rs7044106 0.791 rs2416799 ENSG00000226752.6 PSMD5-AS1 -7.45 7.77e-13 9.61e-10 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120718588 chr9:120824828~120854385:+ LIHC cis rs7044106 0.791 rs10984998 ENSG00000226752.6 PSMD5-AS1 -7.45 7.77e-13 9.61e-10 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120719238 chr9:120824828~120854385:+ LIHC cis rs17301013 0.507 rs72713537 ENSG00000227373.4 RP11-160H22.5 7.45 7.8e-13 9.64e-10 0.61 0.37 Systemic lupus erythematosus; chr1:174354189 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs6684688 ENSG00000227373.4 RP11-160H22.5 7.45 7.8e-13 9.64e-10 0.61 0.37 Systemic lupus erythematosus; chr1:174357180 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs926349 ENSG00000227373.4 RP11-160H22.5 7.45 7.8e-13 9.64e-10 0.61 0.37 Systemic lupus erythematosus; chr1:174368408 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs28628056 ENSG00000227373.4 RP11-160H22.5 7.45 7.8e-13 9.64e-10 0.61 0.37 Systemic lupus erythematosus; chr1:174369545 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10912772 ENSG00000227373.4 RP11-160H22.5 7.45 7.8e-13 9.64e-10 0.61 0.37 Systemic lupus erythematosus; chr1:174370832 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12073751 ENSG00000227373.4 RP11-160H22.5 7.45 7.8e-13 9.64e-10 0.61 0.37 Systemic lupus erythematosus; chr1:174373177 chr1:174115300~174160004:- LIHC cis rs9399135 0.967 rs12526055 ENSG00000232876.1 CTA-212D2.2 -7.45 7.81e-13 9.65e-10 -0.42 -0.37 Red blood cell count; chr6:135004780 chr6:135055033~135060550:+ LIHC cis rs6903823 0.508 rs1150721 ENSG00000216901.1 AL022393.7 7.45 7.86e-13 9.72e-10 0.42 0.37 Pulmonary function; chr6:28287263 chr6:28176188~28176674:+ LIHC cis rs34779708 0.966 rs57081218 ENSG00000230534.5 RP11-297A16.2 7.45 7.86e-13 9.72e-10 0.46 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35145680 chr10:35098006~35127020:- LIHC cis rs1891275 0.515 rs2153653 ENSG00000228701.1 TNKS2-AS1 -7.45 7.88e-13 9.74e-10 -0.46 -0.37 Intelligence (multi-trait analysis); chr10:91736169 chr10:91782839~91798291:- LIHC cis rs62229266 0.804 rs2835241 ENSG00000231106.2 LINC01436 -7.45 7.9e-13 9.76e-10 -0.42 -0.37 Mitral valve prolapse; chr21:36039082 chr21:36005338~36007838:+ LIHC cis rs2882667 0.858 rs11949916 ENSG00000253404.1 AC034243.1 7.44 7.98e-13 9.85e-10 0.51 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139060588 chr5:138744434~138753309:- LIHC cis rs9918079 0.56 rs7438356 ENSG00000273133.1 RP11-799M12.2 -7.44 8.02e-13 9.89e-10 -0.47 -0.37 Obesity-related traits; chr4:15623147 chr4:15563698~15564253:- LIHC cis rs9399135 0.967 rs1590975 ENSG00000232876.1 CTA-212D2.2 -7.44 8.03e-13 9.9e-10 -0.41 -0.37 Red blood cell count; chr6:135030950 chr6:135055033~135060550:+ LIHC cis rs992157 1 rs10932766 ENSG00000261338.2 RP11-378A13.1 7.44 8.04e-13 9.91e-10 0.39 0.37 Colorectal cancer; chr2:218257367 chr2:218255319~218257366:+ LIHC cis rs67180937 0.961 rs2133189 ENSG00000272750.1 RP11-378J18.8 -7.44 8.1e-13 9.98e-10 -0.38 -0.37 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222641100 chr1:222658867~222661512:- LIHC cis rs2283792 0.622 rs239917 ENSG00000224086.5 LL22NC03-86G7.1 -7.44 8.18e-13 1.01e-09 -0.35 -0.37 Multiple sclerosis; chr22:21960091 chr22:21938293~21977632:+ LIHC cis rs7201929 1 rs7499878 ENSG00000259982.1 CDC37P1 -7.44 8.21e-13 1.01e-09 -0.4 -0.37 QT interval; chr16:28857143 chr16:28700294~28701540:- LIHC cis rs1185460 0.565 rs538478 ENSG00000271751.1 RP11-110I1.14 7.44 8.34e-13 1.03e-09 0.48 0.37 Coronary artery disease; chr11:119054629 chr11:119065263~119065677:- LIHC cis rs6504950 0.705 rs9899545 ENSG00000275710.1 RP11-257O5.4 7.43 8.49e-13 1.04e-09 0.54 0.37 Breast cancer; chr17:54909484 chr17:54964474~54964679:+ LIHC cis rs17301013 0.507 rs12082012 ENSG00000227373.4 RP11-160H22.5 7.43 8.51e-13 1.05e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174588729 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12085652 ENSG00000227373.4 RP11-160H22.5 7.43 8.51e-13 1.05e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174588864 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs11802092 ENSG00000227373.4 RP11-160H22.5 7.43 8.51e-13 1.05e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174601773 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs4451598 ENSG00000227373.4 RP11-160H22.5 7.43 8.51e-13 1.05e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174606576 chr1:174115300~174160004:- LIHC cis rs1577917 0.655 rs2842600 ENSG00000234155.1 RP11-30P6.6 7.43 8.58e-13 1.05e-09 0.44 0.37 Response to antipsychotic treatment; chr6:85615914 chr6:85387219~85390186:- LIHC cis rs17301013 0.507 rs1793292 ENSG00000227373.4 RP11-160H22.5 -7.43 8.58e-13 1.05e-09 -0.61 -0.37 Systemic lupus erythematosus; chr1:174778185 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs1793298 ENSG00000227373.4 RP11-160H22.5 -7.43 8.58e-13 1.05e-09 -0.61 -0.37 Systemic lupus erythematosus; chr1:174784601 chr1:174115300~174160004:- LIHC cis rs2882667 0.858 rs11956159 ENSG00000253404.1 AC034243.1 7.43 8.59e-13 1.05e-09 0.51 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139072879 chr5:138744434~138753309:- LIHC cis rs62229266 0.804 rs880221 ENSG00000231106.2 LINC01436 7.43 8.63e-13 1.06e-09 0.41 0.37 Mitral valve prolapse; chr21:36048487 chr21:36005338~36007838:+ LIHC cis rs17301013 0.632 rs1653636 ENSG00000227373.4 RP11-160H22.5 -7.43 8.76e-13 1.07e-09 -0.58 -0.37 Systemic lupus erythematosus; chr1:174767739 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs1754360 ENSG00000227373.4 RP11-160H22.5 -7.43 8.76e-13 1.07e-09 -0.58 -0.37 Systemic lupus erythematosus; chr1:174775825 chr1:174115300~174160004:- LIHC cis rs2260433 0.73 rs1940476 ENSG00000281655.1 RP11-817J15.3 -7.43 8.83e-13 1.08e-09 -0.44 -0.37 Cleft palate; chr11:102637088 chr11:102681310~102683913:+ LIHC cis rs5758659 0.652 rs4822084 ENSG00000237037.8 NDUFA6-AS1 -7.43 8.83e-13 1.08e-09 -0.44 -0.37 Cognitive function; chr22:42039864 chr22:42090931~42137742:+ LIHC cis rs494459 0.756 rs570806 ENSG00000255422.1 AP002954.4 -7.43 8.88e-13 1.09e-09 -0.42 -0.37 Height; chr11:118786602 chr11:118704607~118750263:+ LIHC cis rs1062177 1 rs2016409 ENSG00000213433.5 RPLP1P6 7.43 8.89e-13 1.09e-09 0.43 0.37 Preschool internalizing problems; chr5:151746763 chr5:151765859~151766378:- LIHC cis rs67180937 0.774 rs3748626 ENSG00000272750.1 RP11-378J18.8 -7.43 8.91e-13 1.09e-09 -0.38 -0.37 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222629461 chr1:222658867~222661512:- LIHC cis rs853679 0.527 rs1997660 ENSG00000216901.1 AL022393.7 7.43 8.93e-13 1.09e-09 0.42 0.37 Depression; chr6:28301886 chr6:28176188~28176674:+ LIHC cis rs853679 0.527 rs9468333 ENSG00000216901.1 AL022393.7 7.43 8.93e-13 1.09e-09 0.42 0.37 Depression; chr6:28303421 chr6:28176188~28176674:+ LIHC cis rs7580658 0.864 rs4150454 ENSG00000236682.1 AC068282.3 -7.43 9e-13 1.1e-09 -0.47 -0.37 Protein C levels; chr2:127280968 chr2:127389130~127400580:+ LIHC cis rs6142102 0.602 rs6142069 ENSG00000276073.1 RP5-1125A11.7 -7.42 9.06e-13 1.11e-09 -0.39 -0.37 Skin pigmentation; chr20:33972736 chr20:33985617~33988989:- LIHC cis rs992157 0.965 rs13419763 ENSG00000261338.2 RP11-378A13.1 7.42 9.11e-13 1.11e-09 0.38 0.37 Colorectal cancer; chr2:218270227 chr2:218255319~218257366:+ LIHC cis rs7085104 0.7 rs743572 ENSG00000236937.2 PTGES3P4 7.42 9.18e-13 1.12e-09 0.45 0.37 Immature fraction of reticulocytes;Schizophrenia; chr10:102837395 chr10:102845595~102845950:+ LIHC cis rs62229266 0.618 rs11088334 ENSG00000231106.2 LINC01436 7.42 9.3e-13 1.13e-09 0.41 0.37 Mitral valve prolapse; chr21:36094531 chr21:36005338~36007838:+ LIHC cis rs17301013 0.507 rs10912817 ENSG00000227373.4 RP11-160H22.5 7.42 9.32e-13 1.14e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174615581 chr1:174115300~174160004:- LIHC cis rs55665837 0.922 rs12287212 ENSG00000251991.1 RNU7-49P 7.42 9.33e-13 1.14e-09 0.39 0.37 Vitamin D levels; chr11:14428315 chr11:14478892~14478953:+ LIHC cis rs1062177 0.724 rs2915828 ENSG00000213433.5 RPLP1P6 7.42 9.36e-13 1.14e-09 0.43 0.37 Preschool internalizing problems; chr5:151738560 chr5:151765859~151766378:- LIHC cis rs1062177 0.724 rs2964590 ENSG00000213433.5 RPLP1P6 7.42 9.36e-13 1.14e-09 0.43 0.37 Preschool internalizing problems; chr5:151738585 chr5:151765859~151766378:- LIHC cis rs17301013 0.507 rs10912777 ENSG00000227373.4 RP11-160H22.5 7.42 9.36e-13 1.14e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174393764 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10912778 ENSG00000227373.4 RP11-160H22.5 7.42 9.36e-13 1.14e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174393827 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2205937 ENSG00000227373.4 RP11-160H22.5 7.42 9.36e-13 1.14e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174394440 chr1:174115300~174160004:- LIHC cis rs6142102 0.58 rs761233 ENSG00000276073.1 RP5-1125A11.7 -7.42 9.36e-13 1.14e-09 -0.39 -0.37 Skin pigmentation; chr20:33981080 chr20:33985617~33988989:- LIHC cis rs6504950 0.72 rs28564882 ENSG00000275710.1 RP11-257O5.4 7.42 9.38e-13 1.14e-09 0.53 0.37 Breast cancer; chr17:54912237 chr17:54964474~54964679:+ LIHC cis rs1891275 0.515 rs7093728 ENSG00000228701.1 TNKS2-AS1 -7.42 9.38e-13 1.14e-09 -0.44 -0.37 Intelligence (multi-trait analysis); chr10:91683860 chr10:91782839~91798291:- LIHC cis rs1891275 0.515 rs10786010 ENSG00000228701.1 TNKS2-AS1 -7.42 9.38e-13 1.14e-09 -0.44 -0.37 Intelligence (multi-trait analysis); chr10:91684016 chr10:91782839~91798291:- LIHC cis rs1891275 0.515 rs1986941 ENSG00000228701.1 TNKS2-AS1 -7.42 9.38e-13 1.14e-09 -0.44 -0.37 Intelligence (multi-trait analysis); chr10:91684586 chr10:91782839~91798291:- LIHC cis rs1891275 0.515 rs7098763 ENSG00000228701.1 TNKS2-AS1 -7.42 9.38e-13 1.14e-09 -0.44 -0.37 Intelligence (multi-trait analysis); chr10:91685070 chr10:91782839~91798291:- LIHC cis rs12220777 1 rs12220777 ENSG00000230091.5 TMEM254-AS1 -7.42 9.39e-13 1.14e-09 -0.48 -0.37 Chronic obstructive pulmonary disease-related biomarkers; chr10:80028348 chr10:80046860~80078912:- LIHC cis rs1061377 1 rs35116118 ENSG00000249207.1 RP11-360F5.1 -7.42 9.43e-13 1.15e-09 -0.37 -0.37 Uric acid levels; chr4:39127293 chr4:39112677~39126818:- LIHC cis rs6504950 0.889 rs2541237 ENSG00000275710.1 RP11-257O5.4 -7.42 9.46e-13 1.15e-09 -0.56 -0.37 Breast cancer; chr17:55086676 chr17:54964474~54964679:+ LIHC cis rs4853012 0.838 rs2177707 ENSG00000257800.1 FNBP1P1 7.42 9.53e-13 1.16e-09 0.42 0.37 Gestational age at birth (maternal effect); chr2:74129723 chr2:74120680~74123218:+ LIHC cis rs1062177 0.756 rs2915826 ENSG00000213433.5 RPLP1P6 7.42 9.56e-13 1.16e-09 0.43 0.37 Preschool internalizing problems; chr5:151740402 chr5:151765859~151766378:- LIHC cis rs1062177 0.756 rs2964587 ENSG00000213433.5 RPLP1P6 7.42 9.56e-13 1.16e-09 0.43 0.37 Preschool internalizing problems; chr5:151740411 chr5:151765859~151766378:- LIHC cis rs6142102 0.538 rs6142058 ENSG00000276073.1 RP5-1125A11.7 -7.42 9.56e-13 1.16e-09 -0.38 -0.37 Skin pigmentation; chr20:33954995 chr20:33985617~33988989:- LIHC cis rs6142102 0.502 rs58393429 ENSG00000276073.1 RP5-1125A11.7 -7.42 9.56e-13 1.16e-09 -0.38 -0.37 Skin pigmentation; chr20:33957996 chr20:33985617~33988989:- LIHC cis rs6142102 0.602 rs4911380 ENSG00000276073.1 RP5-1125A11.7 -7.42 9.56e-13 1.16e-09 -0.38 -0.37 Skin pigmentation; chr20:33958418 chr20:33985617~33988989:- LIHC cis rs6142102 0.625 rs4911138 ENSG00000276073.1 RP5-1125A11.7 -7.42 9.56e-13 1.16e-09 -0.38 -0.37 Skin pigmentation; chr20:33959893 chr20:33985617~33988989:- LIHC cis rs6142102 0.625 rs4243974 ENSG00000276073.1 RP5-1125A11.7 -7.42 9.56e-13 1.16e-09 -0.38 -0.37 Skin pigmentation; chr20:33960062 chr20:33985617~33988989:- LIHC cis rs34779708 0.966 rs2126984 ENSG00000230534.5 RP11-297A16.2 7.42 9.61e-13 1.17e-09 0.46 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35121363 chr10:35098006~35127020:- LIHC cis rs6142102 0.602 rs2300209 ENSG00000276073.1 RP5-1125A11.7 -7.42 9.66e-13 1.17e-09 -0.39 -0.37 Skin pigmentation; chr20:34055294 chr20:33985617~33988989:- LIHC cis rs17301013 0.507 rs72715240 ENSG00000227373.4 RP11-160H22.5 7.41 9.68e-13 1.18e-09 0.62 0.37 Systemic lupus erythematosus; chr1:174560838 chr1:174115300~174160004:- LIHC cis rs2882667 0.858 rs11750382 ENSG00000253404.1 AC034243.1 -7.41 9.76e-13 1.19e-09 -0.51 -0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139121305 chr5:138744434~138753309:- LIHC cis rs9660180 0.967 rs12044597 ENSG00000268575.1 RP1-283E3.8 -7.41 9.8e-13 1.19e-09 -0.34 -0.37 Body mass index; chr1:1777362 chr1:1702736~1737688:- LIHC cis rs34779708 0.931 rs7923217 ENSG00000230534.5 RP11-297A16.2 7.41 9.88e-13 1.2e-09 0.46 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35020661 chr10:35098006~35127020:- LIHC cis rs17301013 0.507 rs74128393 ENSG00000227373.4 RP11-160H22.5 7.41 9.92e-13 1.2e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174407961 chr1:174115300~174160004:- LIHC cis rs2882667 0.858 rs11948429 ENSG00000253404.1 AC034243.1 7.41 9.92e-13 1.2e-09 0.52 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139122895 chr5:138744434~138753309:- LIHC cis rs2882667 0.858 rs2043271 ENSG00000253404.1 AC034243.1 7.41 9.92e-13 1.2e-09 0.52 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139123419 chr5:138744434~138753309:- LIHC cis rs1577917 0.56 rs12193777 ENSG00000234155.1 RP11-30P6.6 -7.41 1e-12 1.21e-09 -0.44 -0.37 Response to antipsychotic treatment; chr6:85536991 chr6:85387219~85390186:- LIHC cis rs1577917 0.655 rs9444351 ENSG00000234155.1 RP11-30P6.6 -7.41 1e-12 1.21e-09 -0.44 -0.37 Response to antipsychotic treatment; chr6:85538081 chr6:85387219~85390186:- LIHC cis rs1577917 0.655 rs7766485 ENSG00000234155.1 RP11-30P6.6 -7.41 1e-12 1.21e-09 -0.44 -0.37 Response to antipsychotic treatment; chr6:85553837 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs10944136 ENSG00000234155.1 RP11-30P6.6 7.41 1.02e-12 1.23e-09 0.44 0.37 Response to antipsychotic treatment; chr6:85738781 chr6:85387219~85390186:- LIHC cis rs1555322 0.505 rs591590 ENSG00000126005.14 MMP24-AS1 7.41 1.02e-12 1.24e-09 0.56 0.37 Attention deficit hyperactivity disorder; chr20:35278225 chr20:35216462~35278131:- LIHC cis rs1061377 1 rs1982009 ENSG00000249207.1 RP11-360F5.1 -7.4 1.03e-12 1.25e-09 -0.37 -0.37 Uric acid levels; chr4:39123253 chr4:39112677~39126818:- LIHC cis rs1061377 0.965 rs1138494 ENSG00000249207.1 RP11-360F5.1 -7.4 1.03e-12 1.25e-09 -0.37 -0.37 Uric acid levels; chr4:39123315 chr4:39112677~39126818:- LIHC cis rs1061377 0.965 rs1046655 ENSG00000249207.1 RP11-360F5.1 -7.4 1.03e-12 1.25e-09 -0.37 -0.37 Uric acid levels; chr4:39126127 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs7694760 ENSG00000249207.1 RP11-360F5.1 -7.4 1.03e-12 1.25e-09 -0.37 -0.37 Uric acid levels; chr4:39126481 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs34771104 ENSG00000249207.1 RP11-360F5.1 -7.4 1.03e-12 1.25e-09 -0.37 -0.37 Uric acid levels; chr4:39127432 chr4:39112677~39126818:- LIHC cis rs1061377 0.965 rs11728058 ENSG00000249207.1 RP11-360F5.1 -7.4 1.03e-12 1.25e-09 -0.37 -0.37 Uric acid levels; chr4:39128224 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs17508864 ENSG00000249207.1 RP11-360F5.1 -7.4 1.03e-12 1.25e-09 -0.37 -0.37 Uric acid levels; chr4:39129025 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs1897136 ENSG00000249207.1 RP11-360F5.1 -7.4 1.03e-12 1.25e-09 -0.37 -0.37 Uric acid levels; chr4:39131242 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs1897137 ENSG00000249207.1 RP11-360F5.1 -7.4 1.03e-12 1.25e-09 -0.37 -0.37 Uric acid levels; chr4:39131387 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs7681116 ENSG00000249207.1 RP11-360F5.1 -7.4 1.03e-12 1.25e-09 -0.37 -0.37 Uric acid levels; chr4:39133015 chr4:39112677~39126818:- LIHC cis rs1061377 0.965 rs10018622 ENSG00000249207.1 RP11-360F5.1 -7.4 1.03e-12 1.25e-09 -0.37 -0.37 Uric acid levels; chr4:39133944 chr4:39112677~39126818:- LIHC cis rs932287 0.666 rs10840161 ENSG00000254860.4 TMEM9B-AS1 -7.4 1.03e-12 1.25e-09 -0.38 -0.37 Colonoscopy-negative controls vs population controls; chr11:9032277 chr11:8964675~8977527:+ LIHC cis rs1555322 0.53 rs2425043 ENSG00000126005.14 MMP24-AS1 -7.4 1.03e-12 1.25e-09 -0.55 -0.37 Attention deficit hyperactivity disorder; chr20:35280899 chr20:35216462~35278131:- LIHC cis rs7044106 0.762 rs10984972 ENSG00000226752.6 PSMD5-AS1 -7.4 1.04e-12 1.25e-09 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120647586 chr9:120824828~120854385:+ LIHC cis rs992157 1 rs4674280 ENSG00000261338.2 RP11-378A13.1 -7.4 1.04e-12 1.26e-09 -0.38 -0.37 Colorectal cancer; chr2:218276735 chr2:218255319~218257366:+ LIHC cis rs2882667 0.964 rs11958050 ENSG00000253404.1 AC034243.1 7.4 1.04e-12 1.26e-09 0.48 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:138966139 chr5:138744434~138753309:- LIHC cis rs1062177 1 rs2915887 ENSG00000213433.5 RPLP1P6 -7.4 1.04e-12 1.26e-09 -0.43 -0.37 Preschool internalizing problems; chr5:151825943 chr5:151765859~151766378:- LIHC cis rs992157 1 rs13429408 ENSG00000261338.2 RP11-378A13.1 7.4 1.05e-12 1.27e-09 0.38 0.37 Colorectal cancer; chr2:218278137 chr2:218255319~218257366:+ LIHC cis rs3096299 0.874 rs3102342 ENSG00000274627.1 RP11-104N10.2 7.4 1.06e-12 1.28e-09 0.39 0.37 Multiple myeloma (IgH translocation); chr16:89385167 chr16:89516797~89522217:+ LIHC cis rs8070463 0.515 rs11655943 ENSG00000228782.6 CTD-2026D20.3 7.4 1.06e-12 1.28e-09 0.44 0.37 Multiple sclerosis;Ankylosing spondylitis; chr17:47308274 chr17:47450568~47492492:- LIHC cis rs17301013 0.507 rs913688 ENSG00000227373.4 RP11-160H22.5 -7.4 1.08e-12 1.3e-09 -0.62 -0.37 Systemic lupus erythematosus; chr1:174805080 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2860725 ENSG00000227373.4 RP11-160H22.5 -7.4 1.08e-12 1.3e-09 -0.62 -0.37 Systemic lupus erythematosus; chr1:174815447 chr1:174115300~174160004:- LIHC cis rs1062177 1 rs41494545 ENSG00000213433.5 RPLP1P6 7.4 1.08e-12 1.31e-09 0.43 0.37 Preschool internalizing problems; chr5:151855533 chr5:151765859~151766378:- LIHC cis rs6504950 0.705 rs9899602 ENSG00000275710.1 RP11-257O5.4 -7.4 1.08e-12 1.31e-09 -0.54 -0.37 Breast cancer; chr17:54909547 chr17:54964474~54964679:+ LIHC cis rs2929278 0.617 rs11070410 ENSG00000205771.5 CATSPER2P1 7.4 1.08e-12 1.31e-09 0.47 0.37 Schizophrenia; chr15:43764847 chr15:43726918~43747094:- LIHC cis rs17301013 0.507 rs10912822 ENSG00000227373.4 RP11-160H22.5 7.4 1.09e-12 1.31e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174624490 chr1:174115300~174160004:- LIHC cis rs9660180 0.839 rs12040826 ENSG00000268575.1 RP1-283E3.8 -7.4 1.1e-12 1.32e-09 -0.34 -0.37 Body mass index; chr1:1773848 chr1:1702736~1737688:- LIHC cis rs7580658 0.817 rs6761447 ENSG00000236682.1 AC068282.3 -7.39 1.1e-12 1.33e-09 -0.47 -0.37 Protein C levels; chr2:127316997 chr2:127389130~127400580:+ LIHC cis rs7580658 0.857 rs11890187 ENSG00000236682.1 AC068282.3 -7.39 1.1e-12 1.33e-09 -0.47 -0.37 Protein C levels; chr2:127326162 chr2:127389130~127400580:+ LIHC cis rs9549367 0.664 rs9549689 ENSG00000269125.1 RP11-98F14.11 -7.39 1.1e-12 1.33e-09 -0.48 -0.37 Platelet distribution width; chr13:113194073 chr13:113165002~113165183:- LIHC cis rs9549367 0.713 rs9549356 ENSG00000269125.1 RP11-98F14.11 -7.39 1.1e-12 1.33e-09 -0.48 -0.37 Platelet distribution width; chr13:113197319 chr13:113165002~113165183:- LIHC cis rs17301013 0.507 rs332800 ENSG00000227373.4 RP11-160H22.5 7.39 1.11e-12 1.34e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174753467 chr1:174115300~174160004:- LIHC cis rs1577917 0.545 rs9344548 ENSG00000203875.9 SNHG5 7.39 1.12e-12 1.34e-09 0.39 0.37 Response to antipsychotic treatment; chr6:85777619 chr6:85660950~85678736:- LIHC cis rs7044106 0.791 rs7036766 ENSG00000226752.6 PSMD5-AS1 -7.39 1.12e-12 1.35e-09 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120717343 chr9:120824828~120854385:+ LIHC cis rs62355901 0.505 rs12655082 ENSG00000271828.1 CTD-2310F14.1 7.39 1.12e-12 1.35e-09 0.58 0.37 Breast cancer; chr5:56930384 chr5:56927874~56929573:+ LIHC cis rs62355901 0.505 rs12657396 ENSG00000271828.1 CTD-2310F14.1 7.39 1.12e-12 1.35e-09 0.58 0.37 Breast cancer; chr5:56930778 chr5:56927874~56929573:+ LIHC cis rs73086581 0.838 rs73088426 ENSG00000229539.1 RP11-119B16.2 7.39 1.12e-12 1.35e-09 0.7 0.37 Response to antidepressants in depression; chr20:4022636 chr20:3888239~3888868:- LIHC cis rs1061377 0.965 rs7677729 ENSG00000249207.1 RP11-360F5.1 -7.39 1.13e-12 1.36e-09 -0.37 -0.37 Uric acid levels; chr4:39120370 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs3796511 ENSG00000249207.1 RP11-360F5.1 -7.39 1.13e-12 1.36e-09 -0.37 -0.37 Uric acid levels; chr4:39120586 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs3733274 ENSG00000249207.1 RP11-360F5.1 -7.39 1.13e-12 1.36e-09 -0.37 -0.37 Uric acid levels; chr4:39120957 chr4:39112677~39126818:- LIHC cis rs62229266 0.659 rs2835242 ENSG00000231106.2 LINC01436 7.39 1.13e-12 1.36e-09 0.41 0.37 Mitral valve prolapse; chr21:36041234 chr21:36005338~36007838:+ LIHC cis rs62229266 0.659 rs2835243 ENSG00000231106.2 LINC01436 7.39 1.13e-12 1.36e-09 0.41 0.37 Mitral valve prolapse; chr21:36041648 chr21:36005338~36007838:+ LIHC cis rs1577917 0.566 rs2842611 ENSG00000234155.1 RP11-30P6.6 7.39 1.13e-12 1.36e-09 0.44 0.37 Response to antipsychotic treatment; chr6:85592316 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs13207173 ENSG00000234155.1 RP11-30P6.6 7.39 1.13e-12 1.36e-09 0.44 0.37 Response to antipsychotic treatment; chr6:85747804 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs34795473 ENSG00000234155.1 RP11-30P6.6 7.39 1.13e-12 1.36e-09 0.44 0.37 Response to antipsychotic treatment; chr6:85752081 chr6:85387219~85390186:- LIHC cis rs62229266 0.659 rs62230814 ENSG00000231106.2 LINC01436 7.39 1.14e-12 1.37e-09 0.41 0.37 Mitral valve prolapse; chr21:36031248 chr21:36005338~36007838:+ LIHC cis rs1577917 0.655 rs9444352 ENSG00000234155.1 RP11-30P6.6 -7.39 1.14e-12 1.37e-09 -0.44 -0.37 Response to antipsychotic treatment; chr6:85547817 chr6:85387219~85390186:- LIHC cis rs6142102 0.602 rs6141435 ENSG00000276073.1 RP5-1125A11.7 -7.39 1.15e-12 1.38e-09 -0.39 -0.37 Skin pigmentation; chr20:33963473 chr20:33985617~33988989:- LIHC cis rs4356975 0.932 rs7657426 ENSG00000249956.3 RP11-790I12.2 7.39 1.15e-12 1.39e-09 0.41 0.37 Obesity-related traits; chr4:69079291 chr4:69408836~69423164:+ LIHC cis rs2882667 0.858 rs11957527 ENSG00000253404.1 AC034243.1 7.39 1.16e-12 1.4e-09 0.51 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139069206 chr5:138744434~138753309:- LIHC cis rs7617773 0.963 rs12494304 ENSG00000229759.1 MRPS18AP1 -7.39 1.17e-12 1.4e-09 -0.39 -0.37 Coronary artery disease; chr3:48136539 chr3:48256350~48256938:- LIHC cis rs6490294 0.528 rs57502306 ENSG00000226469.1 ADAM1B 7.39 1.17e-12 1.4e-09 0.52 0.37 Mean platelet volume; chr12:111852639 chr12:111927018~111929017:+ LIHC cis rs9660180 0.967 rs2272908 ENSG00000268575.1 RP1-283E3.8 7.39 1.17e-12 1.41e-09 0.34 0.37 Body mass index; chr1:1790040 chr1:1702736~1737688:- LIHC cis rs9549367 0.713 rs9549352 ENSG00000269125.1 RP11-98F14.11 -7.38 1.18e-12 1.41e-09 -0.48 -0.37 Platelet distribution width; chr13:113178907 chr13:113165002~113165183:- LIHC cis rs9543976 0.623 rs8192764 ENSG00000261553.4 RP11-29G8.3 7.38 1.18e-12 1.41e-09 0.51 0.37 Diabetic retinopathy; chr13:75605079 chr13:75549773~75807120:+ LIHC cis rs10256972 0.64 rs10271082 ENSG00000229043.2 AC091729.9 -7.38 1.18e-12 1.42e-09 -0.43 -0.37 Endometriosis;Longevity; chr7:1041926 chr7:1160374~1165267:+ LIHC cis rs7044106 0.537 rs10818474 ENSG00000226752.6 PSMD5-AS1 -7.38 1.2e-12 1.43e-09 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120727686 chr9:120824828~120854385:+ LIHC cis rs150992 0.79 rs40075 ENSG00000248489.1 CTD-2007H13.3 7.38 1.2e-12 1.44e-09 0.55 0.37 Body mass index; chr5:98976743 chr5:98929171~98995013:+ LIHC cis rs150992 0.79 rs45931 ENSG00000248489.1 CTD-2007H13.3 7.38 1.2e-12 1.44e-09 0.55 0.37 Body mass index; chr5:98978344 chr5:98929171~98995013:+ LIHC cis rs150992 0.79 rs161731 ENSG00000248489.1 CTD-2007H13.3 7.38 1.2e-12 1.44e-09 0.55 0.37 Body mass index; chr5:98984339 chr5:98929171~98995013:+ LIHC cis rs1577917 0.545 rs1832070 ENSG00000203875.9 SNHG5 7.38 1.21e-12 1.45e-09 0.39 0.37 Response to antipsychotic treatment; chr6:85773454 chr6:85660950~85678736:- LIHC cis rs2455601 0.882 rs11042115 ENSG00000254860.4 TMEM9B-AS1 7.38 1.21e-12 1.45e-09 0.46 0.37 Schizophrenia; chr11:8905132 chr11:8964675~8977527:+ LIHC cis rs2455601 0.882 rs11042116 ENSG00000254860.4 TMEM9B-AS1 7.38 1.21e-12 1.45e-09 0.46 0.37 Schizophrenia; chr11:8906925 chr11:8964675~8977527:+ LIHC cis rs2455601 0.882 rs11042118 ENSG00000254860.4 TMEM9B-AS1 7.38 1.21e-12 1.45e-09 0.46 0.37 Schizophrenia; chr11:8907244 chr11:8964675~8977527:+ LIHC cis rs6142102 0.625 rs6142061 ENSG00000276073.1 RP5-1125A11.7 -7.38 1.22e-12 1.46e-09 -0.38 -0.37 Skin pigmentation; chr20:33960529 chr20:33985617~33988989:- LIHC cis rs62229266 0.659 rs2835245 ENSG00000231106.2 LINC01436 7.38 1.22e-12 1.46e-09 0.41 0.37 Mitral valve prolapse; chr21:36044410 chr21:36005338~36007838:+ LIHC cis rs17301013 0.507 rs398350 ENSG00000227373.4 RP11-160H22.5 7.38 1.22e-12 1.46e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174706168 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs3117843 ENSG00000227373.4 RP11-160H22.5 7.38 1.22e-12 1.46e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174711581 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs332786 ENSG00000227373.4 RP11-160H22.5 7.38 1.22e-12 1.46e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174713584 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs332779 ENSG00000227373.4 RP11-160H22.5 7.38 1.22e-12 1.46e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174716623 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs332781 ENSG00000227373.4 RP11-160H22.5 7.38 1.22e-12 1.46e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174718483 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs193082 ENSG00000227373.4 RP11-160H22.5 7.38 1.22e-12 1.46e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174725439 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs460878 ENSG00000227373.4 RP11-160H22.5 7.38 1.22e-12 1.46e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174732645 chr1:174115300~174160004:- LIHC cis rs6142102 0.625 rs9753690 ENSG00000276073.1 RP5-1125A11.7 -7.38 1.23e-12 1.47e-09 -0.38 -0.37 Skin pigmentation; chr20:33952995 chr20:33985617~33988989:- LIHC cis rs6142102 0.625 rs7263727 ENSG00000276073.1 RP5-1125A11.7 -7.38 1.23e-12 1.47e-09 -0.38 -0.37 Skin pigmentation; chr20:33953133 chr20:33985617~33988989:- LIHC cis rs6142102 0.625 rs6142056 ENSG00000276073.1 RP5-1125A11.7 -7.38 1.23e-12 1.47e-09 -0.38 -0.37 Skin pigmentation; chr20:33953349 chr20:33985617~33988989:- LIHC cis rs7208859 0.673 rs423151 ENSG00000263531.1 RP13-753N3.1 7.38 1.24e-12 1.47e-09 0.61 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30625268 chr17:30863921~30864940:- LIHC cis rs1061377 1 rs28607301 ENSG00000249207.1 RP11-360F5.1 -7.38 1.24e-12 1.48e-09 -0.37 -0.37 Uric acid levels; chr4:39136460 chr4:39112677~39126818:- LIHC cis rs17301013 0.606 rs724889 ENSG00000227373.4 RP11-160H22.5 -7.38 1.24e-12 1.48e-09 -0.6 -0.37 Systemic lupus erythematosus; chr1:174180326 chr1:174115300~174160004:- LIHC cis rs67180937 0.921 rs17163360 ENSG00000272750.1 RP11-378J18.8 -7.38 1.25e-12 1.49e-09 -0.38 -0.37 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222647448 chr1:222658867~222661512:- LIHC cis rs9543976 0.623 rs9318361 ENSG00000261553.4 RP11-29G8.3 7.38 1.25e-12 1.49e-09 0.51 0.37 Diabetic retinopathy; chr13:75602944 chr13:75549773~75807120:+ LIHC cis rs7580658 0.637 rs4560059 ENSG00000236682.1 AC068282.3 -7.37 1.26e-12 1.5e-09 -0.46 -0.37 Protein C levels; chr2:127214652 chr2:127389130~127400580:+ LIHC cis rs6142102 0.625 rs1883707 ENSG00000276073.1 RP5-1125A11.7 7.37 1.26e-12 1.5e-09 0.38 0.37 Skin pigmentation; chr20:33964781 chr20:33985617~33988989:- LIHC cis rs6142102 0.625 rs6142062 ENSG00000276073.1 RP5-1125A11.7 -7.37 1.26e-12 1.5e-09 -0.38 -0.37 Skin pigmentation; chr20:33960706 chr20:33985617~33988989:- LIHC cis rs6142102 0.625 rs6141432 ENSG00000276073.1 RP5-1125A11.7 -7.37 1.26e-12 1.5e-09 -0.38 -0.37 Skin pigmentation; chr20:33960791 chr20:33985617~33988989:- LIHC cis rs6142102 0.602 rs6141433 ENSG00000276073.1 RP5-1125A11.7 -7.37 1.26e-12 1.5e-09 -0.38 -0.37 Skin pigmentation; chr20:33961056 chr20:33985617~33988989:- LIHC cis rs6142102 0.58 rs4911139 ENSG00000276073.1 RP5-1125A11.7 -7.37 1.26e-12 1.5e-09 -0.38 -0.37 Skin pigmentation; chr20:33963729 chr20:33985617~33988989:- LIHC cis rs6142102 0.625 rs1883706 ENSG00000276073.1 RP5-1125A11.7 -7.37 1.26e-12 1.5e-09 -0.38 -0.37 Skin pigmentation; chr20:33965071 chr20:33985617~33988989:- LIHC cis rs6142102 0.625 rs1883705 ENSG00000276073.1 RP5-1125A11.7 -7.37 1.26e-12 1.5e-09 -0.38 -0.37 Skin pigmentation; chr20:33965072 chr20:33985617~33988989:- LIHC cis rs2032447 0.531 rs428469 ENSG00000242387.1 HIST1H2APS2 7.37 1.28e-12 1.53e-09 0.53 0.37 Intelligence (multi-trait analysis); chr6:25898396 chr6:25882026~25882395:- LIHC cis rs7044106 0.791 rs4836829 ENSG00000226752.6 PSMD5-AS1 -7.37 1.29e-12 1.53e-09 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120720469 chr9:120824828~120854385:+ LIHC cis rs494459 0.726 rs1784300 ENSG00000255422.1 AP002954.4 -7.37 1.31e-12 1.55e-09 -0.42 -0.37 Height; chr11:118808920 chr11:118704607~118750263:+ LIHC cis rs893363 0.594 rs12676 ENSG00000271916.1 RP11-884K10.6 -7.37 1.31e-12 1.56e-09 -0.76 -0.37 Axial length; chr3:53823776 chr3:53797764~53798019:- LIHC cis rs2739330 0.828 rs2154593 ENSG00000250470.1 AP000351.3 7.37 1.31e-12 1.56e-09 0.44 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23976904~23977585:- LIHC cis rs34779708 0.966 rs7077242 ENSG00000230534.5 RP11-297A16.2 -7.37 1.31e-12 1.56e-09 -0.47 -0.37 Inflammatory bowel disease;Crohn's disease; chr10:35193037 chr10:35098006~35127020:- LIHC cis rs853679 0.527 rs853690 ENSG00000216901.1 AL022393.7 7.37 1.32e-12 1.56e-09 0.42 0.37 Depression; chr6:28317705 chr6:28176188~28176674:+ LIHC cis rs9527 0.637 rs7085104 ENSG00000236937.2 PTGES3P4 7.37 1.32e-12 1.56e-09 0.44 0.37 Arsenic metabolism; chr10:102869116 chr10:102845595~102845950:+ LIHC cis rs67180937 0.961 rs17011681 ENSG00000272750.1 RP11-378J18.8 -7.37 1.32e-12 1.56e-09 -0.38 -0.37 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222651746 chr1:222658867~222661512:- LIHC cis rs1061377 1 rs10026775 ENSG00000249207.1 RP11-360F5.1 -7.37 1.33e-12 1.58e-09 -0.37 -0.37 Uric acid levels; chr4:39115155 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs3733276 ENSG00000249207.1 RP11-360F5.1 -7.37 1.33e-12 1.58e-09 -0.37 -0.37 Uric acid levels; chr4:39115291 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs3733277 ENSG00000249207.1 RP11-360F5.1 -7.37 1.33e-12 1.58e-09 -0.37 -0.37 Uric acid levels; chr4:39115483 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs3733278 ENSG00000249207.1 RP11-360F5.1 -7.37 1.33e-12 1.58e-09 -0.37 -0.37 Uric acid levels; chr4:39115615 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs3733279 ENSG00000249207.1 RP11-360F5.1 -7.37 1.33e-12 1.58e-09 -0.37 -0.37 Uric acid levels; chr4:39115625 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs10018049 ENSG00000249207.1 RP11-360F5.1 -7.37 1.33e-12 1.58e-09 -0.37 -0.37 Uric acid levels; chr4:39115781 chr4:39112677~39126818:- LIHC cis rs7580658 0.895 rs7589451 ENSG00000236682.1 AC068282.3 -7.37 1.33e-12 1.58e-09 -0.47 -0.37 Protein C levels; chr2:127371199 chr2:127389130~127400580:+ LIHC cis rs2739330 0.828 rs2877178 ENSG00000250470.1 AP000351.3 7.37 1.33e-12 1.58e-09 0.44 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23976904~23977585:- LIHC cis rs2739330 0.828 rs5760108 ENSG00000250470.1 AP000351.3 7.36 1.34e-12 1.59e-09 0.44 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23976904~23977585:- LIHC cis rs34779708 0.966 rs1148245 ENSG00000230534.5 RP11-297A16.2 7.36 1.34e-12 1.59e-09 0.46 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35222966 chr10:35098006~35127020:- LIHC cis rs17301013 0.507 rs10912828 ENSG00000227373.4 RP11-160H22.5 7.36 1.34e-12 1.59e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174635701 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10912829 ENSG00000227373.4 RP11-160H22.5 7.36 1.34e-12 1.59e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174635894 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs395109 ENSG00000227373.4 RP11-160H22.5 7.36 1.34e-12 1.59e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174641233 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2760058 ENSG00000227373.4 RP11-160H22.5 7.36 1.34e-12 1.59e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174641320 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs333454 ENSG00000227373.4 RP11-160H22.5 7.36 1.34e-12 1.59e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174653939 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs333452 ENSG00000227373.4 RP11-160H22.5 7.36 1.34e-12 1.59e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174654718 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs411665 ENSG00000227373.4 RP11-160H22.5 7.36 1.34e-12 1.59e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174656563 chr1:174115300~174160004:- LIHC cis rs8062405 0.789 rs1968752 ENSG00000259982.1 CDC37P1 7.36 1.34e-12 1.59e-09 0.47 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620264 chr16:28700294~28701540:- LIHC cis rs17301013 0.606 rs1894198 ENSG00000227373.4 RP11-160H22.5 -7.36 1.36e-12 1.61e-09 -0.57 -0.37 Systemic lupus erythematosus; chr1:174835393 chr1:174115300~174160004:- LIHC cis rs17301013 0.659 rs1894199 ENSG00000227373.4 RP11-160H22.5 -7.36 1.36e-12 1.61e-09 -0.57 -0.37 Systemic lupus erythematosus; chr1:174835545 chr1:174115300~174160004:- LIHC cis rs7201929 0.801 rs9933198 ENSG00000259982.1 CDC37P1 -7.36 1.36e-12 1.61e-09 -0.39 -0.37 QT interval; chr16:28877088 chr16:28700294~28701540:- LIHC cis rs17301013 0.507 rs12084948 ENSG00000227373.4 RP11-160H22.5 7.36 1.36e-12 1.61e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174525776 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs11809482 ENSG00000227373.4 RP11-160H22.5 7.36 1.36e-12 1.61e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174530269 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs909533 ENSG00000227373.4 RP11-160H22.5 7.36 1.36e-12 1.61e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174531428 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12093966 ENSG00000227373.4 RP11-160H22.5 7.36 1.36e-12 1.61e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174535120 chr1:174115300~174160004:- LIHC cis rs1061377 1 rs7685082 ENSG00000249207.1 RP11-360F5.1 -7.36 1.37e-12 1.62e-09 -0.37 -0.37 Uric acid levels; chr4:39116472 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs9998481 ENSG00000249207.1 RP11-360F5.1 -7.36 1.37e-12 1.62e-09 -0.37 -0.37 Uric acid levels; chr4:39117215 chr4:39112677~39126818:- LIHC cis rs34779708 0.931 rs12268745 ENSG00000230534.5 RP11-297A16.2 7.36 1.37e-12 1.62e-09 0.46 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35017061 chr10:35098006~35127020:- LIHC cis rs7208859 0.623 rs383436 ENSG00000263531.1 RP13-753N3.1 7.36 1.38e-12 1.63e-09 0.67 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30632161 chr17:30863921~30864940:- LIHC cis rs62229266 0.804 rs62230821 ENSG00000231106.2 LINC01436 7.36 1.38e-12 1.63e-09 0.4 0.37 Mitral valve prolapse; chr21:36052818 chr21:36005338~36007838:+ LIHC cis rs62229266 0.804 rs2835259 ENSG00000231106.2 LINC01436 7.36 1.38e-12 1.63e-09 0.4 0.37 Mitral valve prolapse; chr21:36053004 chr21:36005338~36007838:+ LIHC cis rs6142102 0.602 rs4911399 ENSG00000276073.1 RP5-1125A11.7 -7.36 1.4e-12 1.65e-09 -0.38 -0.37 Skin pigmentation; chr20:34035612 chr20:33985617~33988989:- LIHC cis rs7580658 0.857 rs2896980 ENSG00000236682.1 AC068282.3 -7.36 1.4e-12 1.65e-09 -0.47 -0.37 Protein C levels; chr2:127382383 chr2:127389130~127400580:+ LIHC cis rs3096299 0.967 rs28575874 ENSG00000274627.1 RP11-104N10.2 7.36 1.41e-12 1.66e-09 0.38 0.37 Multiple myeloma (IgH translocation); chr16:89403482 chr16:89516797~89522217:+ LIHC cis rs3096299 0.933 rs3096297 ENSG00000274627.1 RP11-104N10.2 7.36 1.41e-12 1.67e-09 0.39 0.37 Multiple myeloma (IgH translocation); chr16:89386747 chr16:89516797~89522217:+ LIHC cis rs2442825 0.693 rs2255558 ENSG00000206573.7 THUMPD3-AS1 7.36 1.41e-12 1.67e-09 0.33 0.37 Cerebrospinal fluid clusterin levels; chr3:9375148 chr3:9349689~9398579:- LIHC cis rs17301013 0.507 rs12065527 ENSG00000227373.4 RP11-160H22.5 7.36 1.41e-12 1.67e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174627066 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12064403 ENSG00000227373.4 RP11-160H22.5 7.36 1.41e-12 1.67e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174627067 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12065825 ENSG00000227373.4 RP11-160H22.5 7.36 1.41e-12 1.67e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174627902 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs6667107 ENSG00000227373.4 RP11-160H22.5 7.36 1.41e-12 1.67e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174628667 chr1:174115300~174160004:- LIHC cis rs1062177 0.756 rs2915827 ENSG00000213433.5 RPLP1P6 7.36 1.41e-12 1.67e-09 0.43 0.37 Preschool internalizing problems; chr5:151740144 chr5:151765859~151766378:- LIHC cis rs1789 0.903 rs4470622 ENSG00000273133.1 RP11-799M12.2 -7.36 1.42e-12 1.67e-09 -0.48 -0.37 Blood protein levels; chr4:15672552 chr4:15563698~15564253:- LIHC cis rs7580658 0.75 rs6731176 ENSG00000236682.1 AC068282.3 -7.36 1.42e-12 1.67e-09 -0.46 -0.37 Protein C levels; chr2:127313427 chr2:127389130~127400580:+ LIHC cis rs7044106 0.762 rs1324473 ENSG00000226752.6 PSMD5-AS1 7.36 1.42e-12 1.68e-09 0.37 0.37 Hip circumference adjusted for BMI; chr9:120642332 chr9:120824828~120854385:+ LIHC cis rs992157 0.965 rs62182826 ENSG00000261338.2 RP11-378A13.1 7.36 1.42e-12 1.68e-09 0.38 0.37 Colorectal cancer; chr2:218284000 chr2:218255319~218257366:+ LIHC cis rs10262624 0.504 rs4722255 ENSG00000234286.1 AC006026.13 -7.35 1.43e-12 1.68e-09 -0.4 -0.37 Schizophrenia; chr7:23706453 chr7:23680195~23680786:- LIHC cis rs62229266 0.804 rs2835263 ENSG00000231106.2 LINC01436 -7.35 1.44e-12 1.69e-09 -0.4 -0.37 Mitral valve prolapse; chr21:36057947 chr21:36005338~36007838:+ LIHC cis rs17301013 0.507 rs333438 ENSG00000227373.4 RP11-160H22.5 7.35 1.44e-12 1.69e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174672782 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2771401 ENSG00000227373.4 RP11-160H22.5 7.35 1.44e-12 1.69e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174678302 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs464540 ENSG00000227373.4 RP11-160H22.5 7.35 1.44e-12 1.69e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174679250 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs467437 ENSG00000227373.4 RP11-160H22.5 7.35 1.44e-12 1.69e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174679861 chr1:174115300~174160004:- LIHC cis rs2442825 0.72 rs2648561 ENSG00000206573.7 THUMPD3-AS1 7.35 1.44e-12 1.69e-09 0.33 0.37 Cerebrospinal fluid clusterin levels; chr3:9376399 chr3:9349689~9398579:- LIHC cis rs17301013 0.507 rs3117838 ENSG00000227373.4 RP11-160H22.5 7.35 1.44e-12 1.69e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174749205 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs1923818 ENSG00000227373.4 RP11-160H22.5 7.35 1.44e-12 1.69e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174749737 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs332801 ENSG00000227373.4 RP11-160H22.5 7.35 1.44e-12 1.69e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174753192 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2901820 ENSG00000227373.4 RP11-160H22.5 7.35 1.44e-12 1.69e-09 0.62 0.37 Systemic lupus erythematosus; chr1:174505201 chr1:174115300~174160004:- LIHC cis rs55665837 1 rs7121171 ENSG00000251991.1 RNU7-49P 7.35 1.44e-12 1.7e-09 0.38 0.37 Vitamin D levels; chr11:14424874 chr11:14478892~14478953:+ LIHC cis rs832187 0.603 rs7615475 ENSG00000280620.1 SCAANT1 7.35 1.45e-12 1.7e-09 0.46 0.37 Schizophrenia; chr3:63940985 chr3:63911518~63911772:- LIHC cis rs3096299 0.935 rs3114890 ENSG00000274627.1 RP11-104N10.2 7.35 1.45e-12 1.71e-09 0.39 0.37 Multiple myeloma (IgH translocation); chr16:89383138 chr16:89516797~89522217:+ LIHC cis rs9326248 1 rs7946257 ENSG00000280143.1 AP000892.6 7.35 1.45e-12 1.71e-09 0.42 0.37 Blood protein levels; chr11:117182449 chr11:117204967~117210292:+ LIHC cis rs34779708 0.931 rs10437420 ENSG00000230534.5 RP11-297A16.2 -7.35 1.45e-12 1.71e-09 -0.46 -0.37 Inflammatory bowel disease;Crohn's disease; chr10:35046116 chr10:35098006~35127020:- LIHC cis rs2739330 0.929 rs5751775 ENSG00000250470.1 AP000351.3 7.35 1.45e-12 1.71e-09 0.44 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23976904~23977585:- LIHC cis rs9527 0.571 rs7096249 ENSG00000236937.2 PTGES3P4 7.35 1.46e-12 1.72e-09 0.44 0.37 Arsenic metabolism; chr10:102858767 chr10:102845595~102845950:+ LIHC cis rs9527 0.571 rs10786715 ENSG00000236937.2 PTGES3P4 7.35 1.46e-12 1.72e-09 0.44 0.37 Arsenic metabolism; chr10:102860978 chr10:102845595~102845950:+ LIHC cis rs1061377 1 rs2890659 ENSG00000249207.1 RP11-360F5.1 -7.35 1.47e-12 1.72e-09 -0.37 -0.37 Uric acid levels; chr4:39125401 chr4:39112677~39126818:- LIHC cis rs1061377 0.932 rs35464499 ENSG00000249207.1 RP11-360F5.1 -7.35 1.47e-12 1.72e-09 -0.37 -0.37 Uric acid levels; chr4:39127670 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs35437629 ENSG00000249207.1 RP11-360F5.1 -7.35 1.47e-12 1.72e-09 -0.37 -0.37 Uric acid levels; chr4:39131712 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs7657926 ENSG00000249207.1 RP11-360F5.1 -7.35 1.47e-12 1.72e-09 -0.37 -0.37 Uric acid levels; chr4:39132443 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs11096982 ENSG00000249207.1 RP11-360F5.1 -7.35 1.47e-12 1.72e-09 -0.37 -0.37 Uric acid levels; chr4:39133247 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs11727875 ENSG00000249207.1 RP11-360F5.1 -7.35 1.47e-12 1.72e-09 -0.37 -0.37 Uric acid levels; chr4:39133699 chr4:39112677~39126818:- LIHC cis rs7044106 0.708 rs2416760 ENSG00000226752.6 PSMD5-AS1 -7.35 1.48e-12 1.73e-09 -0.37 -0.37 Hip circumference adjusted for BMI; chr9:120612361 chr9:120824828~120854385:+ LIHC cis rs17301013 0.507 rs10912791 ENSG00000227373.4 RP11-160H22.5 7.35 1.48e-12 1.74e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174479298 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12079334 ENSG00000227373.4 RP11-160H22.5 7.35 1.48e-12 1.74e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174480815 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12084291 ENSG00000227373.4 RP11-160H22.5 7.35 1.49e-12 1.75e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174395721 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2901815 ENSG00000227373.4 RP11-160H22.5 7.35 1.49e-12 1.75e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174397404 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs1883262 ENSG00000227373.4 RP11-160H22.5 7.35 1.49e-12 1.75e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174401104 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2860959 ENSG00000227373.4 RP11-160H22.5 7.35 1.49e-12 1.75e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174403704 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10912779 ENSG00000227373.4 RP11-160H22.5 7.35 1.49e-12 1.75e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174404311 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12090860 ENSG00000227373.4 RP11-160H22.5 7.35 1.49e-12 1.75e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174405166 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12064126 ENSG00000227373.4 RP11-160H22.5 7.35 1.49e-12 1.75e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174405312 chr1:174115300~174160004:- LIHC cis rs2929278 0.617 rs693919 ENSG00000205771.5 CATSPER2P1 7.35 1.5e-12 1.76e-09 0.46 0.37 Schizophrenia; chr15:43810130 chr15:43726918~43747094:- LIHC cis rs496547 0.686 rs540180 ENSG00000255239.1 AP002954.6 7.35 1.51e-12 1.77e-09 0.43 0.37 Hip minimal joint space width; chr11:118782920 chr11:118688039~118690600:- LIHC cis rs496547 0.686 rs2508916 ENSG00000255239.1 AP002954.6 7.35 1.51e-12 1.77e-09 0.43 0.37 Hip minimal joint space width; chr11:118783942 chr11:118688039~118690600:- LIHC cis rs7044106 0.708 rs10984992 ENSG00000226752.6 PSMD5-AS1 -7.35 1.51e-12 1.77e-09 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120711138 chr9:120824828~120854385:+ LIHC cis rs6142102 0.625 rs4012234 ENSG00000276073.1 RP5-1125A11.7 -7.35 1.52e-12 1.78e-09 -0.38 -0.37 Skin pigmentation; chr20:33965241 chr20:33985617~33988989:- LIHC cis rs6142102 0.649 rs4911382 ENSG00000276073.1 RP5-1125A11.7 -7.35 1.52e-12 1.78e-09 -0.38 -0.37 Skin pigmentation; chr20:33965289 chr20:33985617~33988989:- LIHC cis rs6142102 0.625 rs6141436 ENSG00000276073.1 RP5-1125A11.7 -7.35 1.52e-12 1.78e-09 -0.38 -0.37 Skin pigmentation; chr20:33966765 chr20:33985617~33988989:- LIHC cis rs9543976 0.623 rs9543990 ENSG00000261553.4 RP11-29G8.3 7.35 1.52e-12 1.78e-09 0.51 0.37 Diabetic retinopathy; chr13:75598298 chr13:75549773~75807120:+ LIHC cis rs1789 0.903 rs4453929 ENSG00000273133.1 RP11-799M12.2 -7.34 1.53e-12 1.79e-09 -0.48 -0.37 Blood protein levels; chr4:15670550 chr4:15563698~15564253:- LIHC cis rs1789 0.903 rs4616746 ENSG00000273133.1 RP11-799M12.2 -7.34 1.53e-12 1.79e-09 -0.48 -0.37 Blood protein levels; chr4:15671475 chr4:15563698~15564253:- LIHC cis rs1789 0.868 rs4631041 ENSG00000273133.1 RP11-799M12.2 -7.34 1.53e-12 1.79e-09 -0.48 -0.37 Blood protein levels; chr4:15671772 chr4:15563698~15564253:- LIHC cis rs6085948 0.861 rs6085947 ENSG00000238102.1 RP11-19D2.1 7.34 1.54e-12 1.79e-09 0.69 0.37 Interleukin-10 levels; chr20:7252181 chr20:7256580~7258214:- LIHC cis rs17301013 0.606 rs1417186 ENSG00000227373.4 RP11-160H22.5 -7.34 1.54e-12 1.8e-09 -0.57 -0.37 Systemic lupus erythematosus; chr1:174171090 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs969472 ENSG00000227373.4 RP11-160H22.5 7.34 1.55e-12 1.81e-09 0.58 0.37 Systemic lupus erythematosus; chr1:174458562 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs10798314 ENSG00000227373.4 RP11-160H22.5 7.34 1.55e-12 1.81e-09 0.58 0.37 Systemic lupus erythematosus; chr1:174458958 chr1:174115300~174160004:- LIHC cis rs62229266 0.804 rs2255858 ENSG00000231106.2 LINC01436 7.34 1.56e-12 1.82e-09 0.41 0.37 Mitral valve prolapse; chr21:36040454 chr21:36005338~36007838:+ LIHC cis rs9660180 0.934 rs12729990 ENSG00000268575.1 RP1-283E3.8 -7.34 1.57e-12 1.83e-09 -0.34 -0.37 Body mass index; chr1:1880596 chr1:1702736~1737688:- LIHC cis rs6142102 0.602 rs1054534 ENSG00000276073.1 RP5-1125A11.7 -7.34 1.57e-12 1.83e-09 -0.38 -0.37 Skin pigmentation; chr20:34017521 chr20:33985617~33988989:- LIHC cis rs9399135 0.967 rs7741515 ENSG00000232876.1 CTA-212D2.2 7.34 1.58e-12 1.85e-09 0.43 0.37 Red blood cell count; chr6:135053230 chr6:135055033~135060550:+ LIHC cis rs7044106 0.762 rs1470307 ENSG00000226752.6 PSMD5-AS1 -7.34 1.58e-12 1.85e-09 -0.37 -0.37 Hip circumference adjusted for BMI; chr9:120670761 chr9:120824828~120854385:+ LIHC cis rs1062177 1 rs12518722 ENSG00000213433.5 RPLP1P6 -7.34 1.59e-12 1.85e-09 -0.43 -0.37 Preschool internalizing problems; chr5:151851899 chr5:151765859~151766378:- LIHC cis rs1577917 0.771 rs9362239 ENSG00000234155.1 RP11-30P6.6 -7.34 1.59e-12 1.86e-09 -0.43 -0.37 Response to antipsychotic treatment; chr6:85719545 chr6:85387219~85390186:- LIHC cis rs9527 0.571 rs12219246 ENSG00000236937.2 PTGES3P4 7.34 1.6e-12 1.86e-09 0.44 0.37 Arsenic metabolism; chr10:102853598 chr10:102845595~102845950:+ LIHC cis rs1061377 1 rs9997089 ENSG00000249207.1 RP11-360F5.1 -7.34 1.61e-12 1.87e-09 -0.37 -0.37 Uric acid levels; chr4:39119263 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs28465556 ENSG00000249207.1 RP11-360F5.1 -7.34 1.61e-12 1.87e-09 -0.37 -0.37 Uric acid levels; chr4:39119569 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs10027813 ENSG00000249207.1 RP11-360F5.1 -7.34 1.61e-12 1.87e-09 -0.37 -0.37 Uric acid levels; chr4:39119818 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs9990755 ENSG00000249207.1 RP11-360F5.1 -7.34 1.61e-12 1.87e-09 -0.37 -0.37 Uric acid levels; chr4:39119819 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs7676008 ENSG00000249207.1 RP11-360F5.1 -7.34 1.61e-12 1.87e-09 -0.37 -0.37 Uric acid levels; chr4:39120154 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs7655122 ENSG00000249207.1 RP11-360F5.1 -7.34 1.61e-12 1.87e-09 -0.37 -0.37 Uric acid levels; chr4:39120396 chr4:39112677~39126818:- LIHC cis rs1061377 0.965 rs3733275 ENSG00000249207.1 RP11-360F5.1 -7.34 1.61e-12 1.87e-09 -0.37 -0.37 Uric acid levels; chr4:39121077 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs13182 ENSG00000249207.1 RP11-360F5.1 -7.34 1.61e-12 1.87e-09 -0.37 -0.37 Uric acid levels; chr4:39121293 chr4:39112677~39126818:- LIHC cis rs62229266 0.633 rs34259635 ENSG00000231106.2 LINC01436 7.33 1.62e-12 1.89e-09 0.41 0.37 Mitral valve prolapse; chr21:36031272 chr21:36005338~36007838:+ LIHC cis rs17301013 0.507 rs4652512 ENSG00000227373.4 RP11-160H22.5 7.33 1.62e-12 1.89e-09 0.62 0.37 Systemic lupus erythematosus; chr1:174515519 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs57512497 ENSG00000227373.4 RP11-160H22.5 7.33 1.62e-12 1.89e-09 0.62 0.37 Systemic lupus erythematosus; chr1:174518346 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs11807229 ENSG00000227373.4 RP11-160H22.5 7.33 1.62e-12 1.89e-09 0.62 0.37 Systemic lupus erythematosus; chr1:174519456 chr1:174115300~174160004:- LIHC cis rs6142102 0.58 rs9753679 ENSG00000276073.1 RP5-1125A11.7 -7.33 1.62e-12 1.89e-09 -0.38 -0.37 Skin pigmentation; chr20:33953054 chr20:33985617~33988989:- LIHC cis rs17301013 0.507 rs6700482 ENSG00000227373.4 RP11-160H22.5 7.33 1.64e-12 1.9e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174306699 chr1:174115300~174160004:- LIHC cis rs992157 1 rs4791 ENSG00000261338.2 RP11-378A13.1 7.33 1.64e-12 1.91e-09 0.38 0.37 Colorectal cancer; chr2:218274217 chr2:218255319~218257366:+ LIHC cis rs10899021 1 rs61900635 ENSG00000279353.1 RP11-864N7.4 7.33 1.66e-12 1.92e-09 0.85 0.37 Response to metformin (IC50); chr11:74647965 chr11:74698231~74699658:- LIHC cis rs1061377 0.87 rs73238544 ENSG00000249207.1 RP11-360F5.1 -7.33 1.66e-12 1.93e-09 -0.37 -0.37 Uric acid levels; chr4:39137343 chr4:39112677~39126818:- LIHC cis rs496547 0.719 rs1790189 ENSG00000255239.1 AP002954.6 7.33 1.67e-12 1.94e-09 0.43 0.37 Hip minimal joint space width; chr11:118781617 chr11:118688039~118690600:- LIHC cis rs2019137 1 rs2019137 ENSG00000274877.1 RP11-65I12.1 7.33 1.68e-12 1.94e-09 0.44 0.37 Lymphocyte counts; chr2:113216055 chr2:113237595~113240825:+ LIHC cis rs1062177 0.756 rs2964588 ENSG00000213433.5 RPLP1P6 7.33 1.69e-12 1.96e-09 0.42 0.37 Preschool internalizing problems; chr5:151738825 chr5:151765859~151766378:- LIHC cis rs2929278 0.617 rs694461 ENSG00000205771.5 CATSPER2P1 7.33 1.7e-12 1.97e-09 0.47 0.37 Schizophrenia; chr15:43803865 chr15:43726918~43747094:- LIHC cis rs62229266 0.659 rs2835258 ENSG00000231106.2 LINC01436 7.33 1.7e-12 1.97e-09 0.4 0.37 Mitral valve prolapse; chr21:36052067 chr21:36005338~36007838:+ LIHC cis rs17301013 0.507 rs1653630 ENSG00000227373.4 RP11-160H22.5 -7.33 1.7e-12 1.97e-09 -0.61 -0.37 Systemic lupus erythematosus; chr1:174791810 chr1:174115300~174160004:- LIHC cis rs62229266 0.804 rs56279140 ENSG00000231106.2 LINC01436 7.33 1.7e-12 1.97e-09 0.4 0.37 Mitral valve prolapse; chr21:36052063 chr21:36005338~36007838:+ LIHC cis rs17301013 0.507 rs6689153 ENSG00000227373.4 RP11-160H22.5 7.33 1.72e-12 1.99e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174639550 chr1:174115300~174160004:- LIHC cis rs6504950 0.889 rs2628296 ENSG00000275710.1 RP11-257O5.4 -7.32 1.73e-12 2e-09 -0.55 -0.37 Breast cancer; chr17:55089134 chr17:54964474~54964679:+ LIHC cis rs67180937 0.645 rs2270707 ENSG00000272750.1 RP11-378J18.8 7.32 1.74e-12 2.01e-09 0.38 0.37 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222664252 chr1:222658867~222661512:- LIHC cis rs17301013 0.507 rs12074107 ENSG00000227373.4 RP11-160H22.5 -7.32 1.74e-12 2.02e-09 -0.56 -0.37 Systemic lupus erythematosus; chr1:174307926 chr1:174115300~174160004:- LIHC cis rs1061377 1 rs1061377 ENSG00000249207.1 RP11-360F5.1 -7.32 1.75e-12 2.02e-09 -0.37 -0.37 Uric acid levels; chr4:39123130 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs13109200 ENSG00000249207.1 RP11-360F5.1 -7.32 1.75e-12 2.02e-09 -0.37 -0.37 Uric acid levels; chr4:39124396 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs13144374 ENSG00000249207.1 RP11-360F5.1 -7.32 1.75e-12 2.02e-09 -0.37 -0.37 Uric acid levels; chr4:39128859 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs36090629 ENSG00000249207.1 RP11-360F5.1 -7.32 1.75e-12 2.02e-09 -0.37 -0.37 Uric acid levels; chr4:39137195 chr4:39112677~39126818:- LIHC cis rs7044106 0.762 rs10760115 ENSG00000226752.6 PSMD5-AS1 -7.32 1.75e-12 2.03e-09 -0.37 -0.37 Hip circumference adjusted for BMI; chr9:120714674 chr9:120824828~120854385:+ LIHC cis rs11603023 0.805 rs687190 ENSG00000255239.1 AP002954.6 7.32 1.76e-12 2.03e-09 0.42 0.37 Cholesterol, total; chr11:118671674 chr11:118688039~118690600:- LIHC cis rs17301013 0.507 rs10489264 ENSG00000227373.4 RP11-160H22.5 7.32 1.76e-12 2.04e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174584310 chr1:174115300~174160004:- LIHC cis rs8072100 0.512 rs9674670 ENSG00000228782.6 CTD-2026D20.3 7.32 1.78e-12 2.05e-09 0.43 0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47308791 chr17:47450568~47492492:- LIHC cis rs9326248 0.798 rs10892079 ENSG00000280143.1 AP000892.6 7.32 1.78e-12 2.06e-09 0.42 0.37 Blood protein levels; chr11:117146108 chr11:117204967~117210292:+ LIHC cis rs2882667 0.858 rs11242447 ENSG00000253404.1 AC034243.1 7.32 1.78e-12 2.06e-09 0.51 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139090484 chr5:138744434~138753309:- LIHC cis rs6903823 0.508 rs1150718 ENSG00000216901.1 AL022393.7 7.32 1.81e-12 2.08e-09 0.41 0.37 Pulmonary function; chr6:28289170 chr6:28176188~28176674:+ LIHC cis rs6903823 0.508 rs1233660 ENSG00000216901.1 AL022393.7 7.32 1.81e-12 2.08e-09 0.41 0.37 Pulmonary function; chr6:28292472 chr6:28176188~28176674:+ LIHC cis rs7208859 0.623 rs56378576 ENSG00000263531.1 RP13-753N3.1 7.32 1.81e-12 2.08e-09 0.65 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30683102 chr17:30863921~30864940:- LIHC cis rs7208859 0.623 rs35916850 ENSG00000263531.1 RP13-753N3.1 7.32 1.81e-12 2.08e-09 0.65 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30684155 chr17:30863921~30864940:- LIHC cis rs2882667 0.754 rs11746434 ENSG00000253404.1 AC034243.1 7.32 1.82e-12 2.09e-09 0.51 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139099614 chr5:138744434~138753309:- LIHC cis rs4853012 0.838 rs72915068 ENSG00000257800.1 FNBP1P1 7.32 1.82e-12 2.1e-09 0.41 0.37 Gestational age at birth (maternal effect); chr2:74129058 chr2:74120680~74123218:+ LIHC cis rs1577917 0.958 rs12192033 ENSG00000234155.1 RP11-30P6.6 7.32 1.82e-12 2.1e-09 0.43 0.37 Response to antipsychotic treatment; chr6:85762841 chr6:85387219~85390186:- LIHC cis rs7044106 0.791 rs10985001 ENSG00000226752.6 PSMD5-AS1 -7.32 1.82e-12 2.1e-09 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120721954 chr9:120824828~120854385:+ LIHC cis rs1577917 0.958 rs12195776 ENSG00000234155.1 RP11-30P6.6 7.32 1.83e-12 2.11e-09 0.44 0.37 Response to antipsychotic treatment; chr6:85778881 chr6:85387219~85390186:- LIHC cis rs1061377 1 rs2381284 ENSG00000249207.1 RP11-360F5.1 -7.32 1.83e-12 2.11e-09 -0.37 -0.37 Uric acid levels; chr4:39117976 chr4:39112677~39126818:- LIHC cis rs494459 0.688 rs1048040 ENSG00000255422.1 AP002954.4 -7.31 1.85e-12 2.13e-09 -0.42 -0.37 Height; chr11:118747911 chr11:118704607~118750263:+ LIHC cis rs7044106 0.708 rs991121 ENSG00000226752.6 PSMD5-AS1 -7.31 1.85e-12 2.13e-09 -0.37 -0.37 Hip circumference adjusted for BMI; chr9:120608067 chr9:120824828~120854385:+ LIHC cis rs7044106 0.762 rs1547268 ENSG00000226752.6 PSMD5-AS1 -7.31 1.85e-12 2.13e-09 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120646410 chr9:120824828~120854385:+ LIHC cis rs7044106 0.762 rs1547267 ENSG00000226752.6 PSMD5-AS1 -7.31 1.85e-12 2.13e-09 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120646458 chr9:120824828~120854385:+ LIHC cis rs7044106 0.762 rs4142158 ENSG00000226752.6 PSMD5-AS1 -7.31 1.85e-12 2.13e-09 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120648541 chr9:120824828~120854385:+ LIHC cis rs1061377 0.76 rs7678457 ENSG00000249207.1 RP11-360F5.1 -7.31 1.85e-12 2.13e-09 -0.37 -0.37 Uric acid levels; chr4:39136041 chr4:39112677~39126818:- LIHC cis rs17301013 0.507 rs55748748 ENSG00000227373.4 RP11-160H22.5 7.31 1.86e-12 2.13e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174546252 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs41266050 ENSG00000227373.4 RP11-160H22.5 7.31 1.86e-12 2.13e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174547861 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs72715237 ENSG00000227373.4 RP11-160H22.5 7.31 1.86e-12 2.13e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174550527 chr1:174115300~174160004:- LIHC cis rs9527 0.637 rs11191424 ENSG00000236937.2 PTGES3P4 7.31 1.86e-12 2.14e-09 0.44 0.37 Arsenic metabolism; chr10:102866129 chr10:102845595~102845950:+ LIHC cis rs1150668 0.799 rs853684 ENSG00000216901.1 AL022393.7 7.31 1.86e-12 2.14e-09 0.41 0.37 Pubertal anthropometrics; chr6:28326773 chr6:28176188~28176674:+ LIHC cis rs2739330 0.828 rs5760102 ENSG00000250470.1 AP000351.3 7.31 1.86e-12 2.14e-09 0.45 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23976904~23977585:- LIHC cis rs1061377 1 rs7675782 ENSG00000249207.1 RP11-360F5.1 -7.31 1.87e-12 2.15e-09 -0.37 -0.37 Uric acid levels; chr4:39120048 chr4:39112677~39126818:- LIHC cis rs1150668 0.799 rs9301 ENSG00000216901.1 AL022393.7 7.31 1.87e-12 2.15e-09 0.41 0.37 Pubertal anthropometrics; chr6:28324929 chr6:28176188~28176674:+ LIHC cis rs12744310 0.887 rs12032040 ENSG00000235358.1 RP11-399E6.1 7.31 1.88e-12 2.16e-09 0.49 0.37 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41352635 chr1:41242373~41284861:+ LIHC cis rs7396835 0.537 rs10892035 ENSG00000236267.1 AP006216.5 7.31 1.89e-12 2.17e-09 0.39 0.37 Quantitative traits; chr11:116824222 chr11:116813204~116814003:- LIHC cis rs2019137 0.967 rs895412 ENSG00000274877.1 RP11-65I12.1 7.31 1.89e-12 2.17e-09 0.44 0.37 Lymphocyte counts; chr2:113216387 chr2:113237595~113240825:+ LIHC cis rs7615952 0.611 rs9681518 ENSG00000171084.14 FAM86JP 7.31 1.9e-12 2.19e-09 0.77 0.37 Blood pressure (smoking interaction); chr3:125896287 chr3:125916620~125930024:+ LIHC cis rs6085948 0.861 rs8121934 ENSG00000238102.1 RP11-19D2.1 -7.31 1.92e-12 2.2e-09 -0.69 -0.37 Interleukin-10 levels; chr20:7263706 chr20:7256580~7258214:- LIHC cis rs17301013 0.507 rs10912789 ENSG00000227373.4 RP11-160H22.5 7.31 1.92e-12 2.2e-09 0.58 0.37 Systemic lupus erythematosus; chr1:174465616 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs6684141 ENSG00000227373.4 RP11-160H22.5 7.31 1.92e-12 2.2e-09 0.58 0.37 Systemic lupus erythematosus; chr1:174467305 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs12058377 ENSG00000227373.4 RP11-160H22.5 7.31 1.92e-12 2.2e-09 0.58 0.37 Systemic lupus erythematosus; chr1:174470971 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs6656925 ENSG00000227373.4 RP11-160H22.5 7.31 1.92e-12 2.2e-09 0.58 0.37 Systemic lupus erythematosus; chr1:174474161 chr1:174115300~174160004:- LIHC cis rs1061377 1 rs10030904 ENSG00000249207.1 RP11-360F5.1 -7.31 1.92e-12 2.21e-09 -0.37 -0.37 Uric acid levels; chr4:39113603 chr4:39112677~39126818:- LIHC cis rs62229266 0.659 rs2255734 ENSG00000231106.2 LINC01436 7.31 1.93e-12 2.21e-09 0.4 0.37 Mitral valve prolapse; chr21:36039611 chr21:36005338~36007838:+ LIHC cis rs67180937 1 rs67180937 ENSG00000272750.1 RP11-378J18.8 -7.31 1.94e-12 2.23e-09 -0.38 -0.37 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222650401 chr1:222658867~222661512:- LIHC cis rs1061377 1 rs9998867 ENSG00000249207.1 RP11-360F5.1 -7.31 1.95e-12 2.24e-09 -0.37 -0.37 Uric acid levels; chr4:39117542 chr4:39112677~39126818:- LIHC cis rs17301013 0.507 rs2142863 ENSG00000227373.4 RP11-160H22.5 7.31 1.96e-12 2.24e-09 0.61 0.37 Systemic lupus erythematosus; chr1:174301582 chr1:174115300~174160004:- LIHC cis rs1061377 1 rs12499266 ENSG00000249207.1 RP11-360F5.1 7.3 1.97e-12 2.25e-09 0.37 0.37 Uric acid levels; chr4:39118133 chr4:39112677~39126818:- LIHC cis rs4853012 0.941 rs7571083 ENSG00000257800.1 FNBP1P1 7.3 1.97e-12 2.26e-09 0.42 0.37 Gestational age at birth (maternal effect); chr2:74115133 chr2:74120680~74123218:+ LIHC cis rs4853012 0.793 rs6707619 ENSG00000257800.1 FNBP1P1 7.3 1.97e-12 2.26e-09 0.41 0.37 Gestational age at birth (maternal effect); chr2:74117529 chr2:74120680~74123218:+ LIHC cis rs2739330 0.828 rs5760099 ENSG00000250470.1 AP000351.3 7.3 1.98e-12 2.26e-09 0.44 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23976904~23977585:- LIHC cis rs7174755 0.608 rs10162905 ENSG00000260657.2 RP11-315D16.4 7.3 1.98e-12 2.26e-09 0.56 0.37 Major depressive disorder; chr15:68103709 chr15:68267792~68277994:- LIHC cis rs17301013 0.507 rs12079011 ENSG00000227373.4 RP11-160H22.5 7.3 2.01e-12 2.29e-09 0.59 0.37 Systemic lupus erythematosus; chr1:174441055 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs56375942 ENSG00000227373.4 RP11-160H22.5 7.3 2.02e-12 2.3e-09 0.59 0.37 Systemic lupus erythematosus; chr1:174176206 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs56404641 ENSG00000227373.4 RP11-160H22.5 7.3 2.02e-12 2.3e-09 0.59 0.37 Systemic lupus erythematosus; chr1:174176323 chr1:174115300~174160004:- LIHC cis rs17301013 0.606 rs56239105 ENSG00000227373.4 RP11-160H22.5 7.3 2.02e-12 2.3e-09 0.59 0.37 Systemic lupus erythematosus; chr1:174179346 chr1:174115300~174160004:- LIHC cis rs1555322 0.53 rs2425044 ENSG00000126005.14 MMP24-AS1 -7.3 2.02e-12 2.31e-09 -0.55 -0.37 Attention deficit hyperactivity disorder; chr20:35281932 chr20:35216462~35278131:- LIHC cis rs6085948 0.861 rs6085955 ENSG00000238102.1 RP11-19D2.1 -7.3 2.02e-12 2.31e-09 -0.68 -0.37 Interleukin-10 levels; chr20:7258347 chr20:7256580~7258214:- LIHC cis rs17301013 0.531 rs332806 ENSG00000227373.4 RP11-160H22.5 7.3 2.02e-12 2.31e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174653645 chr1:174115300~174160004:- LIHC cis rs1061377 0.803 rs6857761 ENSG00000249207.1 RP11-360F5.1 -7.3 2.04e-12 2.32e-09 -0.37 -0.37 Uric acid levels; chr4:39118353 chr4:39112677~39126818:- LIHC cis rs992157 0.932 rs56109829 ENSG00000261338.2 RP11-378A13.1 7.3 2.04e-12 2.33e-09 0.38 0.37 Colorectal cancer; chr2:218285017 chr2:218255319~218257366:+ LIHC cis rs10899021 0.92 rs11236171 ENSG00000279353.1 RP11-864N7.4 7.3 2.04e-12 2.33e-09 0.81 0.37 Response to metformin (IC50); chr11:74606473 chr11:74698231~74699658:- LIHC cis rs7085104 0.552 rs11191414 ENSG00000236937.2 PTGES3P4 7.3 2.06e-12 2.35e-09 0.43 0.37 Immature fraction of reticulocytes;Schizophrenia; chr10:102841808 chr10:102845595~102845950:+ LIHC cis rs7580658 0.857 rs17015199 ENSG00000236682.1 AC068282.3 -7.3 2.07e-12 2.36e-09 -0.47 -0.37 Protein C levels; chr2:127336477 chr2:127389130~127400580:+ LIHC cis rs7580658 0.895 rs4662722 ENSG00000236682.1 AC068282.3 -7.3 2.07e-12 2.36e-09 -0.47 -0.37 Protein C levels; chr2:127344993 chr2:127389130~127400580:+ LIHC cis rs7580658 0.895 rs4662580 ENSG00000236682.1 AC068282.3 -7.3 2.07e-12 2.36e-09 -0.47 -0.37 Protein C levels; chr2:127345230 chr2:127389130~127400580:+ LIHC cis rs7580658 0.864 rs34832797 ENSG00000236682.1 AC068282.3 -7.3 2.07e-12 2.36e-09 -0.47 -0.37 Protein C levels; chr2:127361865 chr2:127389130~127400580:+ LIHC cis rs7580658 0.895 rs9636237 ENSG00000236682.1 AC068282.3 -7.3 2.07e-12 2.36e-09 -0.47 -0.37 Protein C levels; chr2:127318446 chr2:127389130~127400580:+ LIHC cis rs55665837 1 rs11023215 ENSG00000251991.1 RNU7-49P 7.3 2.08e-12 2.37e-09 0.38 0.37 Vitamin D levels; chr11:14415424 chr11:14478892~14478953:+ LIHC cis rs9918079 0.506 rs10214 ENSG00000273133.1 RP11-799M12.2 7.29 2.1e-12 2.38e-09 0.47 0.37 Obesity-related traits; chr4:15604808 chr4:15563698~15564253:- LIHC cis rs7131987 0.65 rs6487808 ENSG00000257176.2 RP11-996F15.2 7.29 2.1e-12 2.39e-09 0.42 0.37 QT interval; chr12:29310426 chr12:29280418~29317848:- LIHC cis rs9326248 1 rs7107152 ENSG00000280143.1 AP000892.6 -7.29 2.15e-12 2.44e-09 -0.42 -0.37 Blood protein levels; chr11:117185364 chr11:117204967~117210292:+ LIHC cis rs10899021 0.79 rs7932194 ENSG00000279353.1 RP11-864N7.4 7.29 2.15e-12 2.44e-09 0.8 0.37 Response to metformin (IC50); chr11:74616333 chr11:74698231~74699658:- LIHC cis rs6903823 0.527 rs4713158 ENSG00000216901.1 AL022393.7 7.29 2.2e-12 2.49e-09 0.42 0.37 Pulmonary function; chr6:28309994 chr6:28176188~28176674:+ LIHC cis rs9549367 0.713 rs3024757 ENSG00000269125.1 RP11-98F14.11 -7.29 2.2e-12 2.49e-09 -0.47 -0.37 Platelet distribution width; chr13:113168872 chr13:113165002~113165183:- LIHC cis rs9918079 0.542 rs7688984 ENSG00000273133.1 RP11-799M12.2 -7.29 2.21e-12 2.5e-09 -0.51 -0.37 Obesity-related traits; chr4:15655630 chr4:15563698~15564253:- LIHC cis rs2929278 0.588 rs688009 ENSG00000205771.5 CATSPER2P1 -7.29 2.21e-12 2.51e-09 -0.47 -0.37 Schizophrenia; chr15:43864104 chr15:43726918~43747094:- LIHC cis rs150992 0.609 rs393697 ENSG00000248489.1 CTD-2007H13.3 7.29 2.21e-12 2.51e-09 0.54 0.37 Body mass index; chr5:98991357 chr5:98929171~98995013:+ LIHC cis rs4853012 0.838 rs6707729 ENSG00000257800.1 FNBP1P1 7.29 2.21e-12 2.51e-09 0.41 0.37 Gestational age at birth (maternal effect); chr2:74117558 chr2:74120680~74123218:+ LIHC cis rs7208859 0.562 rs11650923 ENSG00000263531.1 RP13-753N3.1 7.29 2.22e-12 2.51e-09 0.65 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30681149 chr17:30863921~30864940:- LIHC cis rs9918079 0.56 rs4270584 ENSG00000273133.1 RP11-799M12.2 7.28 2.24e-12 2.53e-09 0.47 0.37 Obesity-related traits; chr4:15599176 chr4:15563698~15564253:- LIHC cis rs496547 0.686 rs524590 ENSG00000255239.1 AP002954.6 7.28 2.24e-12 2.54e-09 0.43 0.37 Hip minimal joint space width; chr11:118769354 chr11:118688039~118690600:- LIHC cis rs55665837 1 rs11023224 ENSG00000251991.1 RNU7-49P 7.28 2.27e-12 2.57e-09 0.39 0.37 Vitamin D levels; chr11:14436193 chr11:14478892~14478953:+ LIHC cis rs55665837 0.961 rs11023226 ENSG00000251991.1 RNU7-49P 7.28 2.27e-12 2.57e-09 0.39 0.37 Vitamin D levels; chr11:14437271 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs11023227 ENSG00000251991.1 RNU7-49P 7.28 2.27e-12 2.57e-09 0.39 0.37 Vitamin D levels; chr11:14437541 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs10832264 ENSG00000251991.1 RNU7-49P 7.28 2.27e-12 2.57e-09 0.39 0.37 Vitamin D levels; chr11:14438436 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs11023229 ENSG00000251991.1 RNU7-49P 7.28 2.27e-12 2.57e-09 0.39 0.37 Vitamin D levels; chr11:14439455 chr11:14478892~14478953:+ LIHC cis rs11673344 0.642 rs73025481 ENSG00000226686.6 LINC01535 7.28 2.29e-12 2.59e-09 0.45 0.37 Obesity-related traits; chr19:37346437 chr19:37251912~37265535:+ LIHC cis rs1891275 0.515 rs1080496 ENSG00000228701.1 TNKS2-AS1 7.28 2.29e-12 2.59e-09 0.43 0.37 Intelligence (multi-trait analysis); chr10:91684505 chr10:91782839~91798291:- LIHC cis rs9399135 0.66 rs4440481 ENSG00000232876.1 CTA-212D2.2 -7.28 2.3e-12 2.6e-09 -0.41 -0.37 Red blood cell count; chr6:134955558 chr6:135055033~135060550:+ LIHC cis rs7396835 0.5 rs5092 ENSG00000236267.1 AP006216.5 7.28 2.3e-12 2.61e-09 0.39 0.37 Quantitative traits; chr11:116822748 chr11:116813204~116814003:- LIHC cis rs1577917 0.958 rs6454488 ENSG00000234155.1 RP11-30P6.6 7.28 2.31e-12 2.61e-09 0.43 0.37 Response to antipsychotic treatment; chr6:85741124 chr6:85387219~85390186:- LIHC cis rs34779708 0.931 rs10508815 ENSG00000230534.5 RP11-297A16.2 7.28 2.31e-12 2.61e-09 0.45 0.37 Inflammatory bowel disease;Crohn's disease; chr10:35043693 chr10:35098006~35127020:- LIHC cis rs7044106 0.791 rs10984994 ENSG00000226752.6 PSMD5-AS1 7.28 2.32e-12 2.62e-09 0.37 0.37 Hip circumference adjusted for BMI; chr9:120716491 chr9:120824828~120854385:+ LIHC cis rs6490294 0.808 rs7137270 ENSG00000226469.1 ADAM1B 7.28 2.32e-12 2.62e-09 0.47 0.37 Mean platelet volume; chr12:111825598 chr12:111927018~111929017:+ LIHC cis rs739496 0.652 rs10849974 ENSG00000226469.1 ADAM1B 7.28 2.32e-12 2.62e-09 0.47 0.37 Platelet count; chr12:111826354 chr12:111927018~111929017:+ LIHC cis rs6142102 0.625 rs4911384 ENSG00000276073.1 RP5-1125A11.7 -7.28 2.32e-12 2.62e-09 -0.38 -0.37 Skin pigmentation; chr20:33968001 chr20:33985617~33988989:- LIHC cis rs11673344 0.642 rs55755939 ENSG00000226686.6 LINC01535 7.28 2.33e-12 2.63e-09 0.45 0.37 Obesity-related traits; chr19:37353723 chr19:37251912~37265535:+ LIHC cis rs1061377 1 rs9999327 ENSG00000249207.1 RP11-360F5.1 -7.28 2.34e-12 2.64e-09 -0.37 -0.37 Uric acid levels; chr4:39110111 chr4:39112677~39126818:- LIHC cis rs10899021 0.92 rs12287097 ENSG00000279353.1 RP11-864N7.4 7.28 2.34e-12 2.64e-09 0.79 0.37 Response to metformin (IC50); chr11:74621619 chr11:74698231~74699658:- LIHC cis rs10899021 0.92 rs11236174 ENSG00000279353.1 RP11-864N7.4 7.28 2.34e-12 2.64e-09 0.79 0.37 Response to metformin (IC50); chr11:74623156 chr11:74698231~74699658:- LIHC cis rs7044106 0.791 rs2416797 ENSG00000226752.6 PSMD5-AS1 -7.28 2.35e-12 2.66e-09 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120718322 chr9:120824828~120854385:+ LIHC cis rs7044106 0.791 rs2416798 ENSG00000226752.6 PSMD5-AS1 -7.28 2.35e-12 2.66e-09 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120718325 chr9:120824828~120854385:+ LIHC cis rs7044106 0.791 rs4837792 ENSG00000226752.6 PSMD5-AS1 -7.28 2.37e-12 2.68e-09 -0.37 -0.37 Hip circumference adjusted for BMI; chr9:120721281 chr9:120824828~120854385:+ LIHC cis rs7044106 0.791 rs10985000 ENSG00000226752.6 PSMD5-AS1 -7.28 2.37e-12 2.68e-09 -0.37 -0.37 Hip circumference adjusted for BMI; chr9:120721837 chr9:120824828~120854385:+ LIHC cis rs2739330 0.828 rs5760098 ENSG00000250470.1 AP000351.3 7.28 2.38e-12 2.69e-09 0.45 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23976904~23977585:- LIHC cis rs3096299 0.933 rs2965824 ENSG00000274627.1 RP11-104N10.2 7.28 2.38e-12 2.69e-09 0.38 0.37 Multiple myeloma (IgH translocation); chr16:89388898 chr16:89516797~89522217:+ LIHC cis rs9326248 0.954 rs4938349 ENSG00000280143.1 AP000892.6 7.27 2.39e-12 2.7e-09 0.42 0.37 Blood protein levels; chr11:117151207 chr11:117204967~117210292:+ LIHC cis rs1061377 1 rs9990742 ENSG00000249207.1 RP11-360F5.1 -7.27 2.4e-12 2.7e-09 -0.37 -0.37 Uric acid levels; chr4:39119794 chr4:39112677~39126818:- LIHC cis rs2882667 0.858 rs13170388 ENSG00000253404.1 AC034243.1 7.27 2.42e-12 2.72e-09 0.51 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139101176 chr5:138744434~138753309:- LIHC cis rs832187 0.629 rs6798742 ENSG00000280620.1 SCAANT1 7.27 2.44e-12 2.75e-09 0.44 0.37 Schizophrenia; chr3:63918083 chr3:63911518~63911772:- LIHC cis rs17826219 0.714 rs11650821 ENSG00000263531.1 RP13-753N3.1 7.27 2.46e-12 2.77e-09 0.66 0.37 Body mass index; chr17:30641132 chr17:30863921~30864940:- LIHC cis rs1061377 0.965 rs6833654 ENSG00000249207.1 RP11-360F5.1 -7.27 2.47e-12 2.78e-09 -0.37 -0.37 Uric acid levels; chr4:39110701 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs1036038 ENSG00000249207.1 RP11-360F5.1 -7.27 2.47e-12 2.78e-09 -0.37 -0.37 Uric acid levels; chr4:39111383 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs1560396 ENSG00000249207.1 RP11-360F5.1 -7.27 2.47e-12 2.78e-09 -0.37 -0.37 Uric acid levels; chr4:39112092 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs1560397 ENSG00000249207.1 RP11-360F5.1 -7.27 2.47e-12 2.78e-09 -0.37 -0.37 Uric acid levels; chr4:39112265 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs2381285 ENSG00000249207.1 RP11-360F5.1 -7.27 2.47e-12 2.78e-09 -0.37 -0.37 Uric acid levels; chr4:39112775 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs2163272 ENSG00000249207.1 RP11-360F5.1 -7.27 2.47e-12 2.78e-09 -0.37 -0.37 Uric acid levels; chr4:39112790 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs2163273 ENSG00000249207.1 RP11-360F5.1 -7.27 2.47e-12 2.78e-09 -0.37 -0.37 Uric acid levels; chr4:39112835 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs62310332 ENSG00000249207.1 RP11-360F5.1 -7.27 2.47e-12 2.78e-09 -0.37 -0.37 Uric acid levels; chr4:39112939 chr4:39112677~39126818:- LIHC cis rs1061377 0.965 rs3796510 ENSG00000249207.1 RP11-360F5.1 -7.27 2.47e-12 2.78e-09 -0.37 -0.37 Uric acid levels; chr4:39113309 chr4:39112677~39126818:- LIHC cis rs1061377 0.932 rs6855118 ENSG00000249207.1 RP11-360F5.1 -7.27 2.47e-12 2.78e-09 -0.37 -0.37 Uric acid levels; chr4:39114322 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs6829234 ENSG00000249207.1 RP11-360F5.1 -7.27 2.47e-12 2.78e-09 -0.37 -0.37 Uric acid levels; chr4:39114586 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs6812540 ENSG00000249207.1 RP11-360F5.1 -7.27 2.47e-12 2.78e-09 -0.37 -0.37 Uric acid levels; chr4:39114803 chr4:39112677~39126818:- LIHC cis rs7688540 0.511 rs11735723 ENSG00000275426.1 CH17-262A2.1 7.27 2.48e-12 2.79e-09 0.48 0.37 Facial morphology (factor 6, height of vermillion lower lip); chr4:205848 chr4:149738~150317:+ LIHC cis rs1577917 0.916 rs4142546 ENSG00000234155.1 RP11-30P6.6 7.27 2.49e-12 2.79e-09 0.43 0.37 Response to antipsychotic treatment; chr6:85795593 chr6:85387219~85390186:- LIHC cis rs739496 0.579 rs3213628 ENSG00000226469.1 ADAM1B 7.27 2.49e-12 2.79e-09 0.47 0.37 Platelet count; chr12:111842969 chr12:111927018~111929017:+ LIHC cis rs7044106 0.791 rs10984995 ENSG00000226752.6 PSMD5-AS1 -7.27 2.49e-12 2.8e-09 -0.37 -0.37 Hip circumference adjusted for BMI; chr9:120716932 chr9:120824828~120854385:+ LIHC cis rs496547 0.686 rs477014 ENSG00000255239.1 AP002954.6 7.27 2.49e-12 2.8e-09 0.42 0.37 Hip minimal joint space width; chr11:118808277 chr11:118688039~118690600:- LIHC cis rs496547 0.557 rs516719 ENSG00000255239.1 AP002954.6 7.27 2.49e-12 2.8e-09 0.42 0.37 Hip minimal joint space width; chr11:118808736 chr11:118688039~118690600:- LIHC cis rs7208859 0.623 rs122898 ENSG00000263531.1 RP13-753N3.1 -7.27 2.5e-12 2.8e-09 -0.63 -0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30578236 chr17:30863921~30864940:- LIHC cis rs7115242 1 rs7115242 ENSG00000254851.1 RP11-109L13.1 7.27 2.51e-12 2.82e-09 0.57 0.37 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117037567 chr11:117135528~117138582:+ LIHC cis rs3096299 0.719 rs2911262 ENSG00000274627.1 RP11-104N10.2 7.26 2.55e-12 2.86e-09 0.38 0.37 Multiple myeloma (IgH translocation); chr16:89448633 chr16:89516797~89522217:+ LIHC cis rs7044106 0.708 rs920745 ENSG00000226752.6 PSMD5-AS1 -7.26 2.56e-12 2.87e-09 -0.37 -0.37 Hip circumference adjusted for BMI; chr9:120667665 chr9:120824828~120854385:+ LIHC cis rs7044106 0.734 rs10491784 ENSG00000226752.6 PSMD5-AS1 -7.26 2.56e-12 2.87e-09 -0.37 -0.37 Hip circumference adjusted for BMI; chr9:120670011 chr9:120824828~120854385:+ LIHC cis rs17301013 0.507 rs2568096 ENSG00000227373.4 RP11-160H22.5 7.26 2.59e-12 2.9e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174735463 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs333436 ENSG00000227373.4 RP11-160H22.5 7.26 2.59e-12 2.9e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174739069 chr1:174115300~174160004:- LIHC cis rs739496 0.527 rs12427012 ENSG00000226469.1 ADAM1B 7.26 2.6e-12 2.91e-09 0.47 0.37 Platelet count; chr12:111905570 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs12316525 ENSG00000226469.1 ADAM1B 7.26 2.6e-12 2.91e-09 0.47 0.37 Platelet count; chr12:111906315 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs73426314 ENSG00000226469.1 ADAM1B 7.26 2.6e-12 2.91e-09 0.47 0.37 Platelet count; chr12:111907252 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs12582302 ENSG00000226469.1 ADAM1B 7.26 2.6e-12 2.91e-09 0.47 0.37 Platelet count; chr12:111907830 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs11066077 ENSG00000226469.1 ADAM1B 7.26 2.6e-12 2.91e-09 0.47 0.37 Platelet count; chr12:111908857 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs10849984 ENSG00000226469.1 ADAM1B 7.26 2.6e-12 2.91e-09 0.47 0.37 Platelet count; chr12:111909924 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs10849985 ENSG00000226469.1 ADAM1B 7.26 2.6e-12 2.91e-09 0.47 0.37 Platelet count; chr12:111909950 chr12:111927018~111929017:+ LIHC cis rs739496 0.527 rs7136469 ENSG00000226469.1 ADAM1B 7.26 2.6e-12 2.91e-09 0.47 0.37 Platelet count; chr12:111910387 chr12:111927018~111929017:+ LIHC cis rs6490294 0.799 rs11066082 ENSG00000226469.1 ADAM1B 7.26 2.6e-12 2.91e-09 0.47 0.37 Mean platelet volume; chr12:111913544 chr12:111927018~111929017:+ LIHC cis rs739496 0.615 rs57303367 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111827279 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7488629 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111835696 chr12:111927018~111929017:+ LIHC cis rs6490294 0.748 rs73422316 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Mean platelet volume; chr12:111835870 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs73422318 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111838169 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7314870 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111838660 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7980569 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111843580 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7970847 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111843689 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs3782885 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111844779 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs11066046 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111846077 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs2158030 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111847787 chr12:111927018~111929017:+ LIHC cis rs6490294 0.799 rs7315642 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Mean platelet volume; chr12:111848992 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs12302040 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111850375 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs12322899 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111850398 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs12307192 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111852542 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs12307365 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111852847 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs6489817 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111853438 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7296199 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111854040 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs12313385 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111854343 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7310605 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111854666 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7956495 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111857889 chr12:111927018~111929017:+ LIHC cis rs6490294 0.748 rs111752063 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Mean platelet volume; chr12:111859646 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7976557 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111862976 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs11066054 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111868361 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7297760 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111875884 chr12:111927018~111929017:+ LIHC cis rs6490294 0.799 rs12426566 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Mean platelet volume; chr12:111877368 chr12:111927018~111929017:+ LIHC cis rs739496 0.527 rs2097701 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111878970 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7294623 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111879292 chr12:111927018~111929017:+ LIHC cis rs739496 0.527 rs16941703 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111880930 chr12:111927018~111929017:+ LIHC cis rs739496 0.527 rs61440627 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111881193 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs3741998 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111902039 chr12:111927018~111929017:+ LIHC cis rs739496 0.527 rs12319165 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111902930 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs73426310 ENSG00000226469.1 ADAM1B 7.26 2.63e-12 2.93e-09 0.46 0.37 Platelet count; chr12:111904606 chr12:111927018~111929017:+ LIHC cis rs992157 0.835 rs2271543 ENSG00000261338.2 RP11-378A13.1 -7.26 2.63e-12 2.93e-09 -0.37 -0.37 Colorectal cancer; chr2:218277768 chr2:218255319~218257366:+ LIHC cis rs7044106 0.762 rs1886337 ENSG00000226752.6 PSMD5-AS1 -7.26 2.64e-12 2.94e-09 -0.37 -0.37 Hip circumference adjusted for BMI; chr9:120681498 chr9:120824828~120854385:+ LIHC cis rs9660180 0.967 rs9660106 ENSG00000268575.1 RP1-283E3.8 -7.26 2.65e-12 2.95e-09 -0.34 -0.37 Body mass index; chr1:1866508 chr1:1702736~1737688:- LIHC cis rs4728142 0.604 rs4731541 ENSG00000275106.1 RP11-309L24.10 -7.26 2.66e-12 2.96e-09 -0.45 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129038182 chr7:128952527~128953316:- LIHC cis rs10899021 1 rs61900636 ENSG00000279353.1 RP11-864N7.4 7.26 2.66e-12 2.96e-09 0.85 0.37 Response to metformin (IC50); chr11:74648546 chr11:74698231~74699658:- LIHC cis rs17301013 0.507 rs1754352 ENSG00000227373.4 RP11-160H22.5 7.26 2.66e-12 2.96e-09 0.6 0.37 Systemic lupus erythematosus; chr1:174835984 chr1:174115300~174160004:- LIHC cis rs7044106 0.762 rs1530370 ENSG00000226752.6 PSMD5-AS1 -7.26 2.66e-12 2.97e-09 -0.38 -0.37 Hip circumference adjusted for BMI; chr9:120662274 chr9:120824828~120854385:+ LIHC cis rs2739330 0.828 rs4822451 ENSG00000250470.1 AP000351.3 7.26 2.67e-12 2.97e-09 0.44 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23976904~23977585:- LIHC cis rs7617773 0.817 rs34225441 ENSG00000229759.1 MRPS18AP1 7.26 2.68e-12 2.98e-09 0.46 0.37 Coronary artery disease; chr3:48267401 chr3:48256350~48256938:- LIHC cis rs4853012 0.941 rs2421752 ENSG00000257800.1 FNBP1P1 7.26 2.68e-12 2.98e-09 0.42 0.37 Gestational age at birth (maternal effect); chr2:74114488 chr2:74120680~74123218:+ LIHC cis rs1061377 1 rs1036037 ENSG00000249207.1 RP11-360F5.1 -7.26 2.68e-12 2.98e-09 -0.37 -0.37 Uric acid levels; chr4:39111272 chr4:39112677~39126818:- LIHC cis rs9918079 0.56 rs6449153 ENSG00000273133.1 RP11-799M12.2 -7.26 2.7e-12 3e-09 -0.51 -0.37 Obesity-related traits; chr4:15629593 chr4:15563698~15564253:- LIHC cis rs992157 0.835 rs10932768 ENSG00000261338.2 RP11-378A13.1 -7.26 2.71e-12 3.01e-09 -0.37 -0.37 Colorectal cancer; chr2:218281476 chr2:218255319~218257366:+ LIHC cis rs1185460 0.565 rs10892325 ENSG00000271751.1 RP11-110I1.14 7.25 2.77e-12 3.06e-09 0.47 0.37 Coronary artery disease; chr11:119041992 chr11:119065263~119065677:- LIHC cis rs1150668 0.83 rs2531831 ENSG00000216901.1 AL022393.7 7.25 2.79e-12 3.08e-09 0.41 0.37 Pubertal anthropometrics; chr6:28420988 chr6:28176188~28176674:+ LIHC cis rs7044106 0.762 rs966396 ENSG00000226752.6 PSMD5-AS1 -7.25 2.79e-12 3.09e-09 -0.37 -0.37 Hip circumference adjusted for BMI; chr9:120691003 chr9:120824828~120854385:+ LIHC cis rs7580658 0.676 rs58475809 ENSG00000236682.1 AC068282.3 -7.25 2.8e-12 3.09e-09 -0.45 -0.36 Protein C levels; chr2:127245074 chr2:127389130~127400580:+ LIHC cis rs4853012 0.838 rs72911122 ENSG00000257800.1 FNBP1P1 7.25 2.81e-12 3.11e-09 0.41 0.36 Gestational age at birth (maternal effect); chr2:74116992 chr2:74120680~74123218:+ LIHC cis rs4853012 0.838 rs59570457 ENSG00000257800.1 FNBP1P1 7.25 2.81e-12 3.11e-09 0.41 0.36 Gestational age at birth (maternal effect); chr2:74117155 chr2:74120680~74123218:+ LIHC cis rs496547 0.719 rs472641 ENSG00000255239.1 AP002954.6 7.25 2.82e-12 3.11e-09 0.42 0.36 Hip minimal joint space width; chr11:118746835 chr11:118688039~118690600:- LIHC cis rs496547 0.588 rs473298 ENSG00000255239.1 AP002954.6 7.25 2.83e-12 3.12e-09 0.42 0.36 Hip minimal joint space width; chr11:118808678 chr11:118688039~118690600:- LIHC cis rs7615952 1 rs7616044 ENSG00000171084.14 FAM86JP 7.25 2.83e-12 3.12e-09 0.66 0.36 Blood pressure (smoking interaction); chr3:125930511 chr3:125916620~125930024:+ LIHC cis rs4853012 0.838 rs60964317 ENSG00000257800.1 FNBP1P1 7.25 2.85e-12 3.14e-09 0.41 0.36 Gestational age at birth (maternal effect); chr2:74116296 chr2:74120680~74123218:+ LIHC cis rs9326248 1 rs4938354 ENSG00000280143.1 AP000892.6 7.25 2.85e-12 3.15e-09 0.42 0.36 Blood protein levels; chr11:117180449 chr11:117204967~117210292:+ LIHC cis rs1555322 0.53 rs7004 ENSG00000126005.14 MMP24-AS1 -7.25 2.86e-12 3.16e-09 -0.55 -0.36 Attention deficit hyperactivity disorder; chr20:35278950 chr20:35216462~35278131:- LIHC cis rs11673344 0.555 rs502546 ENSG00000226686.6 LINC01535 -7.25 2.89e-12 3.19e-09 -0.45 -0.36 Obesity-related traits; chr19:37361788 chr19:37251912~37265535:+ LIHC cis rs12744310 0.887 rs12048805 ENSG00000235358.1 RP11-399E6.1 7.24 2.9e-12 3.2e-09 0.48 0.36 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41348604 chr1:41242373~41284861:+ LIHC cis rs739496 0.579 rs2879603 ENSG00000226469.1 ADAM1B 7.24 2.9e-12 3.2e-09 0.46 0.36 Platelet count; chr12:111840221 chr12:111927018~111929017:+ LIHC cis rs992157 0.717 rs3817266 ENSG00000261338.2 RP11-378A13.1 -7.24 2.91e-12 3.21e-09 -0.37 -0.36 Colorectal cancer; chr2:218277871 chr2:218255319~218257366:+ LIHC cis rs992157 0.835 rs2292551 ENSG00000261338.2 RP11-378A13.1 -7.24 2.91e-12 3.21e-09 -0.37 -0.36 Colorectal cancer; chr2:218278506 chr2:218255319~218257366:+ LIHC cis rs992157 0.835 rs12987180 ENSG00000261338.2 RP11-378A13.1 -7.24 2.91e-12 3.21e-09 -0.37 -0.36 Colorectal cancer; chr2:218279366 chr2:218255319~218257366:+ LIHC cis rs992157 0.835 rs12987219 ENSG00000261338.2 RP11-378A13.1 -7.24 2.91e-12 3.21e-09 -0.37 -0.36 Colorectal cancer; chr2:218279426 chr2:218255319~218257366:+ LIHC cis rs992157 0.835 rs4674283 ENSG00000261338.2 RP11-378A13.1 -7.24 2.91e-12 3.21e-09 -0.37 -0.36 Colorectal cancer; chr2:218279531 chr2:218255319~218257366:+ LIHC cis rs992157 0.835 rs2045434 ENSG00000261338.2 RP11-378A13.1 -7.24 2.91e-12 3.21e-09 -0.37 -0.36 Colorectal cancer; chr2:218279775 chr2:218255319~218257366:+ LIHC cis rs11673344 0.642 rs12462487 ENSG00000226686.6 LINC01535 7.24 2.92e-12 3.22e-09 0.44 0.36 Obesity-related traits; chr19:37311211 chr19:37251912~37265535:+ LIHC cis rs67180937 0.921 rs2291834 ENSG00000272750.1 RP11-378J18.8 -7.24 2.93e-12 3.23e-09 -0.37 -0.36 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222658953 chr1:222658867~222661512:- LIHC cis rs67180937 0.882 rs17163345 ENSG00000272750.1 RP11-378J18.8 -7.24 2.96e-12 3.26e-09 -0.37 -0.36 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222632876 chr1:222658867~222661512:- LIHC cis rs12744310 0.887 rs12022655 ENSG00000235358.1 RP11-399E6.1 7.24 2.97e-12 3.27e-09 0.48 0.36 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41350647 chr1:41242373~41284861:+ LIHC cis rs62229266 0.563 rs6517325 ENSG00000231106.2 LINC01436 7.24 2.98e-12 3.27e-09 0.4 0.36 Mitral valve prolapse; chr21:36062680 chr21:36005338~36007838:+ LIHC cis rs1061377 1 rs1036036 ENSG00000249207.1 RP11-360F5.1 -7.24 2.98e-12 3.28e-09 -0.37 -0.36 Uric acid levels; chr4:39111104 chr4:39112677~39126818:- LIHC cis rs55665837 1 rs12276938 ENSG00000251991.1 RNU7-49P 7.24 3e-12 3.3e-09 0.38 0.36 Vitamin D levels; chr11:14441942 chr11:14478892~14478953:+ LIHC cis rs7174755 0.637 rs10152713 ENSG00000260657.2 RP11-315D16.4 -7.24 3.03e-12 3.33e-09 -0.55 -0.36 Major depressive disorder; chr15:68179553 chr15:68267792~68277994:- LIHC cis rs1140227 0.502 rs10789304 ENSG00000235358.1 RP11-399E6.1 7.24 3.04e-12 3.35e-09 0.43 0.36 Intelligence (multi-trait analysis); chr1:41121740 chr1:41242373~41284861:+ LIHC cis rs6490294 0.571 rs57168159 ENSG00000226469.1 ADAM1B 7.24 3.06e-12 3.36e-09 0.51 0.36 Mean platelet volume; chr12:112189041 chr12:111927018~111929017:+ LIHC cis rs62229266 0.693 rs2835264 ENSG00000231106.2 LINC01436 7.24 3.07e-12 3.37e-09 0.4 0.36 Mitral valve prolapse; chr21:36063667 chr21:36005338~36007838:+ LIHC cis rs853679 0.527 rs853693 ENSG00000216901.1 AL022393.7 7.23 3.09e-12 3.39e-09 0.41 0.36 Depression; chr6:28314871 chr6:28176188~28176674:+ LIHC cis rs6490294 0.528 rs7970181 ENSG00000226469.1 ADAM1B 7.23 3.09e-12 3.39e-09 0.5 0.36 Mean platelet volume; chr12:112172194 chr12:111927018~111929017:+ LIHC cis rs67180937 0.849 rs4575092 ENSG00000272750.1 RP11-378J18.8 -7.23 3.1e-12 3.4e-09 -0.37 -0.36 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222661161 chr1:222658867~222661512:- LIHC cis rs150992 0.609 rs2927648 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98990273 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs116183885 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98990735 chr5:98929171~98995013:+ LIHC cis rs150992 0.534 rs115121903 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98990736 chr5:98929171~98995013:+ LIHC cis rs150992 0.592 rs2455423 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98990844 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs559574 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98991122 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs443726 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98991163 chr5:98929171~98995013:+ LIHC cis rs150992 0.57 rs398436 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98991352 chr5:98929171~98995013:+ LIHC cis rs150992 0.592 rs407562 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98991512 chr5:98929171~98995013:+ LIHC cis rs150992 0.632 rs395668 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98991611 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs449204 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98991775 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs378089 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98991818 chr5:98929171~98995013:+ LIHC cis rs150992 0.587 rs422127 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98991984 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs113423144 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98992055 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs380156 ENSG00000248489.1 CTD-2007H13.3 7.23 3.13e-12 3.44e-09 0.53 0.36 Body mass index; chr5:98992386 chr5:98929171~98995013:+ LIHC cis rs67180937 0.884 rs2291832 ENSG00000272750.1 RP11-378J18.8 -7.23 3.14e-12 3.44e-09 -0.37 -0.36 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222653139 chr1:222658867~222661512:- LIHC cis rs7615952 0.932 rs7629977 ENSG00000171084.14 FAM86JP 7.23 3.18e-12 3.48e-09 0.67 0.36 Blood pressure (smoking interaction); chr3:125930730 chr3:125916620~125930024:+ LIHC cis rs7615952 0.932 rs7630077 ENSG00000171084.14 FAM86JP 7.23 3.18e-12 3.48e-09 0.67 0.36 Blood pressure (smoking interaction); chr3:125930833 chr3:125916620~125930024:+ LIHC cis rs739496 0.579 rs57427612 ENSG00000226469.1 ADAM1B 7.23 3.19e-12 3.49e-09 0.46 0.36 Platelet count; chr12:111856192 chr12:111927018~111929017:+ LIHC cis rs7044106 0.762 rs1411158 ENSG00000226752.6 PSMD5-AS1 -7.23 3.2e-12 3.51e-09 -0.37 -0.36 Hip circumference adjusted for BMI; chr9:120702526 chr9:120824828~120854385:+ LIHC cis rs1061377 1 rs6829450 ENSG00000249207.1 RP11-360F5.1 -7.23 3.23e-12 3.53e-09 -0.37 -0.36 Uric acid levels; chr4:39114721 chr4:39112677~39126818:- LIHC cis rs11146838 1 rs11146838 ENSG00000263064.2 RP11-291L22.7 7.23 3.24e-12 3.55e-09 0.39 0.36 Breast cancer; chr10:38856846 chr10:38448689~38448949:+ LIHC cis rs12744310 0.887 rs12047439 ENSG00000235358.1 RP11-399E6.1 7.23 3.24e-12 3.55e-09 0.47 0.36 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41343968 chr1:41242373~41284861:+ LIHC cis rs6991838 0.584 rs14213 ENSG00000200714.1 Y_RNA 7.23 3.26e-12 3.56e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65602719 chr8:65592731~65592820:+ LIHC cis rs7085104 0.632 rs4290163 ENSG00000236937.2 PTGES3P4 7.23 3.27e-12 3.58e-09 0.44 0.36 Immature fraction of reticulocytes;Schizophrenia; chr10:102851169 chr10:102845595~102845950:+ LIHC cis rs992157 0.835 rs10932769 ENSG00000261338.2 RP11-378A13.1 -7.23 3.28e-12 3.58e-09 -0.37 -0.36 Colorectal cancer; chr2:218282522 chr2:218255319~218257366:+ LIHC cis rs6490294 0.571 rs58368428 ENSG00000226469.1 ADAM1B 7.23 3.28e-12 3.58e-09 0.51 0.36 Mean platelet volume; chr12:112024471 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs6489824 ENSG00000226469.1 ADAM1B 7.23 3.28e-12 3.58e-09 0.51 0.36 Mean platelet volume; chr12:112030613 chr12:111927018~111929017:+ LIHC cis rs1061377 0.722 rs34803689 ENSG00000249207.1 RP11-360F5.1 -7.22 3.29e-12 3.59e-09 -0.37 -0.36 Uric acid levels; chr4:39116665 chr4:39112677~39126818:- LIHC cis rs739496 0.579 rs3177647 ENSG00000226469.1 ADAM1B 7.22 3.29e-12 3.59e-09 0.47 0.36 Platelet count; chr12:111839772 chr12:111927018~111929017:+ LIHC cis rs17270561 0.609 rs7746502 ENSG00000216436.2 HIST1H2APS1 7.22 3.3e-12 3.6e-09 0.46 0.36 Iron status biomarkers; chr6:25718534 chr6:25732497~25732827:+ LIHC cis rs10899021 1 rs10899025 ENSG00000279353.1 RP11-864N7.4 7.22 3.3e-12 3.6e-09 0.91 0.36 Response to metformin (IC50); chr11:74655995 chr11:74698231~74699658:- LIHC cis rs1577917 0.958 rs9647601 ENSG00000234155.1 RP11-30P6.6 7.22 3.3e-12 3.61e-09 0.43 0.36 Response to antipsychotic treatment; chr6:85740109 chr6:85387219~85390186:- LIHC cis rs4853012 0.941 rs60291089 ENSG00000257800.1 FNBP1P1 7.22 3.3e-12 3.61e-09 0.41 0.36 Gestational age at birth (maternal effect); chr2:74117763 chr2:74120680~74123218:+ LIHC cis rs4853012 0.838 rs58759652 ENSG00000257800.1 FNBP1P1 7.22 3.3e-12 3.61e-09 0.41 0.36 Gestational age at birth (maternal effect); chr2:74117775 chr2:74120680~74123218:+ LIHC cis rs6490294 0.571 rs7973898 ENSG00000226469.1 ADAM1B 7.22 3.31e-12 3.62e-09 0.5 0.36 Mean platelet volume; chr12:112178363 chr12:111927018~111929017:+ LIHC cis rs739496 0.527 rs61612992 ENSG00000226469.1 ADAM1B 7.22 3.31e-12 3.62e-09 0.47 0.36 Platelet count; chr12:111920260 chr12:111927018~111929017:+ LIHC cis rs739496 0.527 rs7300320 ENSG00000226469.1 ADAM1B 7.22 3.31e-12 3.62e-09 0.47 0.36 Platelet count; chr12:111922364 chr12:111927018~111929017:+ LIHC cis rs739496 0.527 rs11066089 ENSG00000226469.1 ADAM1B 7.22 3.31e-12 3.62e-09 0.47 0.36 Platelet count; chr12:111925463 chr12:111927018~111929017:+ LIHC cis rs1061377 1 rs4974931 ENSG00000249207.1 RP11-360F5.1 -7.22 3.32e-12 3.62e-09 -0.37 -0.36 Uric acid levels; chr4:39108896 chr4:39112677~39126818:- LIHC cis rs34779708 0.931 rs35388511 ENSG00000230534.5 RP11-297A16.2 7.22 3.33e-12 3.63e-09 0.45 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35007688 chr10:35098006~35127020:- LIHC cis rs34779708 0.931 rs34815241 ENSG00000230534.5 RP11-297A16.2 7.22 3.33e-12 3.63e-09 0.45 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35007748 chr10:35098006~35127020:- LIHC cis rs17301013 0.507 rs72715218 ENSG00000227373.4 RP11-160H22.5 7.22 3.33e-12 3.63e-09 0.61 0.36 Systemic lupus erythematosus; chr1:174529056 chr1:174115300~174160004:- LIHC cis rs2739330 0.828 rs4822454 ENSG00000250470.1 AP000351.3 7.22 3.33e-12 3.64e-09 0.45 0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23976904~23977585:- LIHC cis rs992157 0.735 rs13392177 ENSG00000261338.2 RP11-378A13.1 -7.22 3.34e-12 3.64e-09 -0.36 -0.36 Colorectal cancer; chr2:218248233 chr2:218255319~218257366:+ LIHC cis rs6490294 0.528 rs60690688 ENSG00000226469.1 ADAM1B 7.22 3.35e-12 3.66e-09 0.5 0.36 Mean platelet volume; chr12:112104179 chr12:111927018~111929017:+ LIHC cis rs494459 0.838 rs12796102 ENSG00000255422.1 AP002954.4 -7.22 3.36e-12 3.66e-09 -0.41 -0.36 Height; chr11:118791319 chr11:118704607~118750263:+ LIHC cis rs6490294 0.571 rs7295294 ENSG00000226469.1 ADAM1B 7.22 3.36e-12 3.66e-09 0.5 0.36 Mean platelet volume; chr12:112027089 chr12:111927018~111929017:+ LIHC cis rs4853012 0.838 rs60705299 ENSG00000257800.1 FNBP1P1 7.22 3.36e-12 3.67e-09 0.41 0.36 Gestational age at birth (maternal effect); chr2:74118243 chr2:74120680~74123218:+ LIHC cis rs4266144 1 rs4266144 ENSG00000244515.1 KRT18P34 -7.22 3.37e-12 3.68e-09 -0.36 -0.36 Coronary artery disease; chr3:157134803 chr3:157162663~157163932:- LIHC cis rs35158675 1 rs35158675 ENSG00000272750.1 RP11-378J18.8 -7.22 3.38e-12 3.68e-09 -0.37 -0.36 Coronary artery disease; chr1:222656208 chr1:222658867~222661512:- LIHC cis rs1555322 0.53 rs2425042 ENSG00000126005.14 MMP24-AS1 -7.22 3.39e-12 3.69e-09 -0.55 -0.36 Attention deficit hyperactivity disorder; chr20:35278092 chr20:35216462~35278131:- LIHC cis rs1577917 0.958 rs7453105 ENSG00000234155.1 RP11-30P6.6 7.22 3.41e-12 3.71e-09 0.43 0.36 Response to antipsychotic treatment; chr6:85791043 chr6:85387219~85390186:- LIHC cis rs739496 0.579 rs12321677 ENSG00000226469.1 ADAM1B -7.22 3.41e-12 3.71e-09 -0.47 -0.36 Platelet count; chr12:111901211 chr12:111927018~111929017:+ LIHC cis rs1577917 0.61 rs11752795 ENSG00000234155.1 RP11-30P6.6 -7.22 3.43e-12 3.74e-09 -0.43 -0.36 Response to antipsychotic treatment; chr6:85577411 chr6:85387219~85390186:- LIHC cis rs7743045 0.643 rs114000233 ENSG00000253194.1 RP11-351A11.1 7.22 3.44e-12 3.75e-09 0.49 0.36 Mean platelet volume; chr6:118935167 chr6:118934785~119031541:+ LIHC cis rs7085104 0.591 rs4919683 ENSG00000236937.2 PTGES3P4 7.22 3.49e-12 3.79e-09 0.43 0.36 Immature fraction of reticulocytes;Schizophrenia; chr10:102825368 chr10:102845595~102845950:+ LIHC cis rs73086581 0.838 rs41398349 ENSG00000229539.1 RP11-119B16.2 -7.21 3.51e-12 3.82e-09 -0.68 -0.36 Response to antidepressants in depression; chr20:4043792 chr20:3888239~3888868:- LIHC cis rs7085104 0.632 rs6162 ENSG00000236937.2 PTGES3P4 7.21 3.51e-12 3.82e-09 0.43 0.36 Immature fraction of reticulocytes;Schizophrenia; chr10:102837224 chr10:102845595~102845950:+ LIHC cis rs7615952 1 rs9289275 ENSG00000171084.14 FAM86JP 7.21 3.52e-12 3.83e-09 0.67 0.36 Blood pressure (smoking interaction); chr3:125929816 chr3:125916620~125930024:+ LIHC cis rs11673344 0.642 rs55926714 ENSG00000226686.6 LINC01535 7.21 3.53e-12 3.84e-09 0.44 0.36 Obesity-related traits; chr19:37307974 chr19:37251912~37265535:+ LIHC cis rs7743045 0.711 rs4946371 ENSG00000253194.1 RP11-351A11.1 7.21 3.53e-12 3.84e-09 0.49 0.36 Mean platelet volume; chr6:118935483 chr6:118934785~119031541:+ LIHC cis rs2882667 0.858 rs11951899 ENSG00000253404.1 AC034243.1 7.21 3.53e-12 3.84e-09 0.5 0.36 Age-related hearing impairment (SNP x SNP interaction); chr5:139038621 chr5:138744434~138753309:- LIHC cis rs992157 0.835 rs7585702 ENSG00000261338.2 RP11-378A13.1 -7.21 3.54e-12 3.85e-09 -0.37 -0.36 Colorectal cancer; chr2:218281884 chr2:218255319~218257366:+ LIHC cis rs992157 0.866 rs2292554 ENSG00000261338.2 RP11-378A13.1 -7.21 3.54e-12 3.85e-09 -0.37 -0.36 Colorectal cancer; chr2:218282145 chr2:218255319~218257366:+ LIHC cis rs11920570 0.526 rs3828362 ENSG00000272758.4 RP11-299J3.8 7.21 3.54e-12 3.85e-09 0.39 0.36 Resting heart rate; chr3:122412930 chr3:122416207~122443180:+ LIHC cis rs67180937 0.961 rs17163363 ENSG00000272750.1 RP11-378J18.8 -7.21 3.55e-12 3.86e-09 -0.37 -0.36 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222655362 chr1:222658867~222661512:- LIHC cis rs1061377 1 rs3796509 ENSG00000249207.1 RP11-360F5.1 -7.21 3.55e-12 3.86e-09 -0.37 -0.36 Uric acid levels; chr4:39108566 chr4:39112677~39126818:- LIHC cis rs6903823 0.508 rs1150724 ENSG00000216901.1 AL022393.7 7.21 3.57e-12 3.87e-09 0.41 0.36 Pulmonary function; chr6:28282459 chr6:28176188~28176674:+ LIHC cis rs7044106 0.762 rs10760112 ENSG00000226752.6 PSMD5-AS1 -7.21 3.58e-12 3.89e-09 -0.37 -0.36 Hip circumference adjusted for BMI; chr9:120705292 chr9:120824828~120854385:+ LIHC cis rs992157 0.835 rs6707559 ENSG00000261338.2 RP11-378A13.1 7.21 3.6e-12 3.91e-09 0.37 0.36 Colorectal cancer; chr2:218278050 chr2:218255319~218257366:+ LIHC cis rs739496 0.579 rs12296574 ENSG00000226469.1 ADAM1B 7.21 3.63e-12 3.94e-09 0.46 0.36 Platelet count; chr12:111884973 chr12:111927018~111929017:+ LIHC cis rs34779708 0.931 rs11010067 ENSG00000230534.5 RP11-297A16.2 -7.21 3.64e-12 3.95e-09 -0.45 -0.36 Inflammatory bowel disease;Crohn's disease; chr10:35006503 chr10:35098006~35127020:- LIHC cis rs739496 0.563 rs61547643 ENSG00000226469.1 ADAM1B 7.21 3.68e-12 3.99e-09 0.46 0.36 Platelet count; chr12:111828820 chr12:111927018~111929017:+ LIHC cis rs150992 0.609 rs1093794 ENSG00000248489.1 CTD-2007H13.3 -7.21 3.69e-12 4e-09 -0.53 -0.36 Body mass index; chr5:98993334 chr5:98929171~98995013:+ LIHC cis rs17301013 0.507 rs72715204 ENSG00000227373.4 RP11-160H22.5 7.21 3.7e-12 4.01e-09 0.62 0.36 Systemic lupus erythematosus; chr1:174492787 chr1:174115300~174160004:- LIHC cis rs11673344 0.58 rs320881 ENSG00000226686.6 LINC01535 7.21 3.72e-12 4.02e-09 0.44 0.36 Obesity-related traits; chr19:37246948 chr19:37251912~37265535:+ LIHC cis rs6504950 0.72 rs12602751 ENSG00000275710.1 RP11-257O5.4 7.21 3.72e-12 4.03e-09 0.46 0.36 Breast cancer; chr17:54916813 chr17:54964474~54964679:+ LIHC cis rs6504950 0.72 rs7216138 ENSG00000275710.1 RP11-257O5.4 7.21 3.72e-12 4.03e-09 0.46 0.36 Breast cancer; chr17:54918303 chr17:54964474~54964679:+ LIHC cis rs6504950 0.72 rs9910653 ENSG00000275710.1 RP11-257O5.4 7.2 3.74e-12 4.05e-09 0.46 0.36 Breast cancer; chr17:54914907 chr17:54964474~54964679:+ LIHC cis rs7044106 0.791 rs10984997 ENSG00000226752.6 PSMD5-AS1 -7.2 3.75e-12 4.06e-09 -0.37 -0.36 Hip circumference adjusted for BMI; chr9:120718928 chr9:120824828~120854385:+ LIHC cis rs2882667 0.867 rs6868085 ENSG00000253404.1 AC034243.1 7.2 3.76e-12 4.07e-09 0.48 0.36 Age-related hearing impairment (SNP x SNP interaction); chr5:139096757 chr5:138744434~138753309:- LIHC cis rs4853012 0.838 rs4452177 ENSG00000257800.1 FNBP1P1 7.2 3.76e-12 4.07e-09 0.4 0.36 Gestational age at birth (maternal effect); chr2:74118079 chr2:74120680~74123218:+ LIHC cis rs2739330 0.796 rs5760097 ENSG00000250470.1 AP000351.3 7.2 3.77e-12 4.07e-09 0.44 0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23976904~23977585:- LIHC cis rs4853012 0.838 rs61521879 ENSG00000257800.1 FNBP1P1 7.2 3.77e-12 4.07e-09 0.41 0.36 Gestational age at birth (maternal effect); chr2:74119081 chr2:74120680~74123218:+ LIHC cis rs62355901 0.505 rs55698001 ENSG00000271828.1 CTD-2310F14.1 7.2 3.78e-12 4.09e-09 0.57 0.36 Breast cancer; chr5:56949313 chr5:56927874~56929573:+ LIHC cis rs4423214 0.879 rs1792283 ENSG00000254682.1 RP11-660L16.2 -7.2 3.79e-12 4.09e-09 -0.46 -0.36 Vitamin D levels; chr11:71424090 chr11:71448674~71452157:+ LIHC cis rs62229266 0.839 rs11088335 ENSG00000231106.2 LINC01436 7.2 3.79e-12 4.09e-09 0.41 0.36 Mitral valve prolapse; chr21:36098037 chr21:36005338~36007838:+ LIHC cis rs5769707 0.521 rs74351010 ENSG00000188511.11 C22orf34 -7.2 3.85e-12 4.15e-09 -0.66 -0.36 Monocyte percentage of white cells;Monocyte count; chr22:49643172 chr22:49414524~49657542:- LIHC cis rs55665837 1 rs34382046 ENSG00000251991.1 RNU7-49P 7.2 3.87e-12 4.17e-09 0.38 0.36 Vitamin D levels; chr11:14429772 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs7945167 ENSG00000251991.1 RNU7-49P 7.2 3.87e-12 4.17e-09 0.38 0.36 Vitamin D levels; chr11:14430274 chr11:14478892~14478953:+ LIHC cis rs55665837 0.961 rs60622588 ENSG00000251991.1 RNU7-49P 7.2 3.87e-12 4.17e-09 0.38 0.36 Vitamin D levels; chr11:14435452 chr11:14478892~14478953:+ LIHC cis rs55665837 1 rs11023223 ENSG00000251991.1 RNU7-49P 7.2 3.87e-12 4.17e-09 0.38 0.36 Vitamin D levels; chr11:14435566 chr11:14478892~14478953:+ LIHC cis rs10899021 0.92 rs11236172 ENSG00000279353.1 RP11-864N7.4 7.2 3.87e-12 4.18e-09 0.81 0.36 Response to metformin (IC50); chr11:74619843 chr11:74698231~74699658:- LIHC cis rs1789 0.839 rs9997068 ENSG00000273133.1 RP11-799M12.2 -7.2 3.88e-12 4.18e-09 -0.47 -0.36 Blood protein levels; chr4:15649367 chr4:15563698~15564253:- LIHC cis rs9918079 0.56 rs6414767 ENSG00000273133.1 RP11-799M12.2 -7.2 3.88e-12 4.18e-09 -0.47 -0.36 Obesity-related traits; chr4:15654098 chr4:15563698~15564253:- LIHC cis rs739496 0.579 rs9971746 ENSG00000226469.1 ADAM1B -7.2 3.88e-12 4.18e-09 -0.46 -0.36 Platelet count; chr12:111899558 chr12:111927018~111929017:+ LIHC cis rs9399135 0.66 rs4472368 ENSG00000232876.1 CTA-212D2.2 -7.2 3.89e-12 4.2e-09 -0.41 -0.36 Red blood cell count; chr6:134953094 chr6:135055033~135060550:+ LIHC cis rs2033711 0.783 rs11671113 ENSG00000269473.1 CTD-2619J13.19 7.2 3.9e-12 4.21e-09 0.42 0.36 Uric acid clearance; chr19:58446720 chr19:58440448~58445849:+ LIHC cis rs9660180 1 rs9660180 ENSG00000268575.1 RP1-283E3.8 -7.2 3.91e-12 4.21e-09 -0.34 -0.36 Body mass index; chr1:1791592 chr1:1702736~1737688:- LIHC cis rs739496 0.512 rs73422315 ENSG00000226469.1 ADAM1B 7.2 3.92e-12 4.23e-09 0.46 0.36 Platelet count; chr12:111830495 chr12:111927018~111929017:+ LIHC cis rs1577917 0.917 rs4098044 ENSG00000234155.1 RP11-30P6.6 7.2 3.92e-12 4.23e-09 0.43 0.36 Response to antipsychotic treatment; chr6:85752348 chr6:85387219~85390186:- LIHC cis rs739496 0.579 rs1981517 ENSG00000226469.1 ADAM1B 7.2 3.92e-12 4.23e-09 0.46 0.36 Platelet count; chr12:111885778 chr12:111927018~111929017:+ LIHC cis rs739496 0.527 rs2269801 ENSG00000226469.1 ADAM1B 7.2 3.92e-12 4.23e-09 0.46 0.36 Platelet count; chr12:111888319 chr12:111927018~111929017:+ LIHC cis rs6490294 0.748 rs2269802 ENSG00000226469.1 ADAM1B 7.2 3.92e-12 4.23e-09 0.46 0.36 Mean platelet volume; chr12:111888334 chr12:111927018~111929017:+ LIHC cis rs6490294 0.799 rs73424286 ENSG00000226469.1 ADAM1B 7.2 3.92e-12 4.23e-09 0.46 0.36 Mean platelet volume; chr12:111889338 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7974772 ENSG00000226469.1 ADAM1B 7.2 3.92e-12 4.23e-09 0.46 0.36 Platelet count; chr12:111894479 chr12:111927018~111929017:+ LIHC cis rs739496 0.527 rs10849981 ENSG00000226469.1 ADAM1B 7.2 3.92e-12 4.23e-09 0.46 0.36 Platelet count; chr12:111897413 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs10849982 ENSG00000226469.1 ADAM1B 7.2 3.92e-12 4.23e-09 0.46 0.36 Platelet count; chr12:111897735 chr12:111927018~111929017:+ LIHC cis rs17301013 0.507 rs4652494 ENSG00000227373.4 RP11-160H22.5 7.2 3.95e-12 4.25e-09 0.59 0.36 Systemic lupus erythematosus; chr1:174495861 chr1:174115300~174160004:- LIHC cis rs150992 0.609 rs366000 ENSG00000248489.1 CTD-2007H13.3 -7.2 3.95e-12 4.25e-09 -0.53 -0.36 Body mass index; chr5:98991705 chr5:98929171~98995013:+ LIHC cis rs4853012 0.838 rs6715351 ENSG00000257800.1 FNBP1P1 7.2 3.97e-12 4.28e-09 0.41 0.36 Gestational age at birth (maternal effect); chr2:74118992 chr2:74120680~74123218:+ LIHC cis rs1061377 1 rs4974997 ENSG00000249207.1 RP11-360F5.1 -7.19 3.98e-12 4.28e-09 -0.37 -0.36 Uric acid levels; chr4:39109151 chr4:39112677~39126818:- LIHC cis rs1065852 0.51 rs5751247 ENSG00000237037.8 NDUFA6-AS1 -7.19 3.98e-12 4.29e-09 -0.42 -0.36 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42237048 chr22:42090931~42137742:+ LIHC cis rs2739330 0.731 rs2000468 ENSG00000250470.1 AP000351.3 7.19 3.99e-12 4.29e-09 0.44 0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23976904~23977585:- LIHC cis rs7085104 0.513 rs619824 ENSG00000236937.2 PTGES3P4 7.19 3.99e-12 4.3e-09 0.44 0.36 Immature fraction of reticulocytes;Schizophrenia; chr10:102821531 chr10:102845595~102845950:+ LIHC cis rs9322193 0.607 rs9322229 ENSG00000231760.4 RP11-350J20.5 7.19 4e-12 4.3e-09 0.46 0.36 Lung cancer; chr6:149908949 chr6:149796151~149826294:- LIHC cis rs7044106 0.762 rs10491783 ENSG00000226752.6 PSMD5-AS1 -7.19 4.01e-12 4.31e-09 -0.36 -0.36 Hip circumference adjusted for BMI; chr9:120687877 chr9:120824828~120854385:+ LIHC cis rs7044106 0.762 rs966397 ENSG00000226752.6 PSMD5-AS1 -7.19 4.01e-12 4.31e-09 -0.36 -0.36 Hip circumference adjusted for BMI; chr9:120691034 chr9:120824828~120854385:+ LIHC cis rs17301013 0.507 rs332767 ENSG00000227373.4 RP11-160H22.5 7.19 4.07e-12 4.37e-09 0.59 0.36 Systemic lupus erythematosus; chr1:174686386 chr1:174115300~174160004:- LIHC cis rs9326248 0.954 rs10790177 ENSG00000280143.1 AP000892.6 7.19 4.08e-12 4.38e-09 0.41 0.36 Blood protein levels; chr11:117177701 chr11:117204967~117210292:+ LIHC cis rs496547 0.721 rs2508570 ENSG00000255239.1 AP002954.6 7.19 4.09e-12 4.39e-09 0.42 0.36 Hip minimal joint space width; chr11:118807900 chr11:118688039~118690600:- LIHC cis rs496547 0.686 rs591756 ENSG00000255239.1 AP002954.6 7.19 4.09e-12 4.39e-09 0.42 0.36 Hip minimal joint space width; chr11:118808172 chr11:118688039~118690600:- LIHC cis rs9918079 0.56 rs12651550 ENSG00000273133.1 RP11-799M12.2 -7.19 4.1e-12 4.4e-09 -0.46 -0.36 Obesity-related traits; chr4:15639395 chr4:15563698~15564253:- LIHC cis rs9918079 0.506 rs7696127 ENSG00000273133.1 RP11-799M12.2 -7.19 4.1e-12 4.4e-09 -0.46 -0.36 Obesity-related traits; chr4:15641330 chr4:15563698~15564253:- LIHC cis rs9595066 0.715 rs9567366 ENSG00000227258.4 SMIM2-AS1 -7.19 4.11e-12 4.41e-09 -0.42 -0.36 Schizophrenia; chr13:44108837 chr13:44110451~44240517:+ LIHC cis rs2882667 0.858 rs13177503 ENSG00000253404.1 AC034243.1 7.19 4.13e-12 4.43e-09 0.5 0.36 Age-related hearing impairment (SNP x SNP interaction); chr5:139097070 chr5:138744434~138753309:- LIHC cis rs9660180 0.935 rs2180311 ENSG00000268575.1 RP1-283E3.8 -7.19 4.15e-12 4.45e-09 -0.34 -0.36 Body mass index; chr1:1817295 chr1:1702736~1737688:- LIHC cis rs9660180 0.967 rs6664664 ENSG00000268575.1 RP1-283E3.8 -7.19 4.15e-12 4.45e-09 -0.34 -0.36 Body mass index; chr1:1819825 chr1:1702736~1737688:- LIHC cis rs73086581 1 rs3746666 ENSG00000229539.1 RP11-119B16.2 7.19 4.18e-12 4.48e-09 0.6 0.36 Response to antidepressants in depression; chr20:3930214 chr20:3888239~3888868:- LIHC cis rs67180937 0.922 rs1133220 ENSG00000272750.1 RP11-378J18.8 -7.19 4.19e-12 4.49e-09 -0.37 -0.36 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222661461 chr1:222658867~222661512:- LIHC cis rs9918079 0.6 rs12500587 ENSG00000273133.1 RP11-799M12.2 7.19 4.2e-12 4.5e-09 0.52 0.36 Obesity-related traits; chr4:15579131 chr4:15563698~15564253:- LIHC cis rs150992 0.688 rs161947 ENSG00000248489.1 CTD-2007H13.3 7.19 4.23e-12 4.53e-09 0.63 0.36 Body mass index; chr5:98932868 chr5:98929171~98995013:+ LIHC cis rs67180937 0.961 rs17163358 ENSG00000272750.1 RP11-378J18.8 -7.19 4.23e-12 4.53e-09 -0.37 -0.36 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222647297 chr1:222658867~222661512:- LIHC cis rs1577917 0.655 rs9444354 ENSG00000234155.1 RP11-30P6.6 -7.19 4.23e-12 4.53e-09 -0.43 -0.36 Response to antipsychotic treatment; chr6:85582217 chr6:85387219~85390186:- LIHC cis rs73086581 0.68 rs11908158 ENSG00000229539.1 RP11-119B16.2 7.19 4.24e-12 4.54e-09 0.65 0.36 Response to antidepressants in depression; chr20:3956025 chr20:3888239~3888868:- LIHC cis rs7044106 0.762 rs3904197 ENSG00000226752.6 PSMD5-AS1 -7.18 4.27e-12 4.57e-09 -0.37 -0.36 Hip circumference adjusted for BMI; chr9:120718100 chr9:120824828~120854385:+ LIHC cis rs1062177 0.756 rs2915817 ENSG00000213433.5 RPLP1P6 7.18 4.28e-12 4.58e-09 0.42 0.36 Preschool internalizing problems; chr5:151735956 chr5:151765859~151766378:- LIHC cis rs1555322 0.53 rs2425047 ENSG00000126005.14 MMP24-AS1 7.18 4.28e-12 4.59e-09 0.52 0.36 Attention deficit hyperactivity disorder; chr20:35283872 chr20:35216462~35278131:- LIHC cis rs7044106 0.762 rs4837790 ENSG00000226752.6 PSMD5-AS1 -7.18 4.32e-12 4.62e-09 -0.36 -0.36 Hip circumference adjusted for BMI; chr9:120684047 chr9:120824828~120854385:+ LIHC cis rs916888 0.773 rs169201 ENSG00000262881.1 RP11-669E14.4 -7.18 4.33e-12 4.63e-09 -0.58 -0.36 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45907670~45910779:- LIHC cis rs4853012 0.793 rs6723185 ENSG00000257800.1 FNBP1P1 7.18 4.37e-12 4.68e-09 0.41 0.36 Gestational age at birth (maternal effect); chr2:74117757 chr2:74120680~74123218:+ LIHC cis rs7044106 0.762 rs10760110 ENSG00000226752.6 PSMD5-AS1 7.18 4.38e-12 4.68e-09 0.37 0.36 Hip circumference adjusted for BMI; chr9:120650285 chr9:120824828~120854385:+ LIHC cis rs739496 0.579 rs12319315 ENSG00000226469.1 ADAM1B 7.18 4.39e-12 4.69e-09 0.47 0.36 Platelet count; chr12:111903215 chr12:111927018~111929017:+ LIHC cis rs4728142 0.604 rs10239340 ENSG00000275106.1 RP11-309L24.10 -7.18 4.39e-12 4.69e-09 -0.45 -0.36 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129028456 chr7:128952527~128953316:- LIHC cis rs6490294 0.571 rs73421065 ENSG00000226469.1 ADAM1B 7.18 4.4e-12 4.7e-09 0.51 0.36 Mean platelet volume; chr12:112121575 chr12:111927018~111929017:+ LIHC cis rs6490294 0.528 rs58047810 ENSG00000226469.1 ADAM1B 7.18 4.4e-12 4.7e-09 0.51 0.36 Mean platelet volume; chr12:112124682 chr12:111927018~111929017:+ LIHC cis rs7397814 0.558 rs4764447 ENSG00000278635.1 CTD-2318O12.1 7.18 4.41e-12 4.71e-09 0.39 0.36 IgG glycosylation; chr12:9426513 chr12:9415641~9416718:+ LIHC cis rs992157 0.835 rs6729058 ENSG00000261338.2 RP11-378A13.1 -7.18 4.42e-12 4.73e-09 -0.37 -0.36 Colorectal cancer; chr2:218283646 chr2:218255319~218257366:+ LIHC cis rs916888 0.773 rs1378358 ENSG00000262881.1 RP11-669E14.4 -7.18 4.43e-12 4.73e-09 -0.58 -0.36 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45907670~45910779:- LIHC cis rs9660180 0.62 rs3817856 ENSG00000268575.1 RP1-283E3.8 7.18 4.46e-12 4.76e-09 0.39 0.36 Body mass index; chr1:1732392 chr1:1702736~1737688:- LIHC cis rs10916248 0.511 rs10916515 ENSG00000232628.4 RP11-365O16.3 7.18 4.48e-12 4.78e-09 0.48 0.36 QT interval (drug interaction); chr1:224222121 chr1:224208747~224213279:- LIHC cis rs6490294 0.571 rs11066120 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:111998391 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs7312472 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112000966 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs57439171 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112001483 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs7316650 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112001860 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs7313773 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112003884 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs12423960 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112004612 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs10849992 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112005213 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs7310545 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112006156 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs7296841 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112006305 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs11066127 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112008551 chr12:111927018~111929017:+ LIHC cis rs6490294 0.528 rs7980579 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112009556 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs7952986 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112010358 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs7132863 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112011079 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs12300496 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112012629 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs11066128 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112012950 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs7316563 ENSG00000226469.1 ADAM1B 7.18 4.48e-12 4.78e-09 0.5 0.36 Mean platelet volume; chr12:112015831 chr12:111927018~111929017:+ LIHC cis rs1577917 0.681 rs4348284 ENSG00000234155.1 RP11-30P6.6 7.18 4.49e-12 4.78e-09 0.43 0.36 Response to antipsychotic treatment; chr6:85640676 chr6:85387219~85390186:- LIHC cis rs1577917 0.655 rs12203963 ENSG00000234155.1 RP11-30P6.6 -7.17 4.54e-12 4.83e-09 -0.43 -0.36 Response to antipsychotic treatment; chr6:85513598 chr6:85387219~85390186:- LIHC cis rs4853012 0.838 rs4429500 ENSG00000257800.1 FNBP1P1 7.17 4.57e-12 4.86e-09 0.41 0.36 Gestational age at birth (maternal effect); chr2:74118209 chr2:74120680~74123218:+ LIHC cis rs7396835 1 rs7396835 ENSG00000236267.1 AP006216.5 7.17 4.59e-12 4.88e-09 0.41 0.36 Quantitative traits; chr11:116813312 chr11:116813204~116814003:- LIHC cis rs9549367 0.713 rs3024745 ENSG00000269125.1 RP11-98F14.11 -7.17 4.61e-12 4.9e-09 -0.46 -0.36 Platelet distribution width; chr13:113167284 chr13:113165002~113165183:- LIHC cis rs67180937 0.961 rs17465940 ENSG00000272750.1 RP11-378J18.8 -7.17 4.62e-12 4.91e-09 -0.37 -0.36 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222663654 chr1:222658867~222661512:- LIHC cis rs7131987 0.683 rs12366505 ENSG00000257176.2 RP11-996F15.2 -7.17 4.63e-12 4.92e-09 -0.42 -0.36 QT interval; chr12:29321177 chr12:29280418~29317848:- LIHC cis rs7131987 0.65 rs12366527 ENSG00000257176.2 RP11-996F15.2 -7.17 4.63e-12 4.92e-09 -0.42 -0.36 QT interval; chr12:29321323 chr12:29280418~29317848:- LIHC cis rs7131987 0.65 rs7311912 ENSG00000257176.2 RP11-996F15.2 -7.17 4.63e-12 4.92e-09 -0.42 -0.36 QT interval; chr12:29322770 chr12:29280418~29317848:- LIHC cis rs2739330 0.892 rs5751776 ENSG00000099984.9 GSTT2 -7.17 4.63e-12 4.92e-09 -0.42 -0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23980123~23983911:+ LIHC cis rs17301013 0.507 rs72713528 ENSG00000227373.4 RP11-160H22.5 7.17 4.64e-12 4.93e-09 0.6 0.36 Systemic lupus erythematosus; chr1:174319862 chr1:174115300~174160004:- LIHC cis rs7044106 0.762 rs1867254 ENSG00000226752.6 PSMD5-AS1 -7.17 4.65e-12 4.94e-09 -0.37 -0.36 Hip circumference adjusted for BMI; chr9:120666800 chr9:120824828~120854385:+ LIHC cis rs1061377 0.965 rs7669376 ENSG00000249207.1 RP11-360F5.1 -7.17 4.65e-12 4.94e-09 -0.36 -0.36 Uric acid levels; chr4:39116717 chr4:39112677~39126818:- LIHC cis rs17301013 0.507 rs1793320 ENSG00000227373.4 RP11-160H22.5 7.17 4.66e-12 4.95e-09 0.59 0.36 Systemic lupus erythematosus; chr1:174796308 chr1:174115300~174160004:- LIHC cis rs2283792 0.622 rs5756323 ENSG00000224086.5 LL22NC03-86G7.1 7.17 4.66e-12 4.95e-09 0.33 0.36 Multiple sclerosis; chr22:21980398 chr22:21938293~21977632:+ LIHC cis rs7580658 0.676 rs2174270 ENSG00000236682.1 AC068282.3 -7.17 4.66e-12 4.95e-09 -0.45 -0.36 Protein C levels; chr2:127248502 chr2:127389130~127400580:+ LIHC cis rs6991838 0.584 rs4737747 ENSG00000200714.1 Y_RNA -7.17 4.67e-12 4.95e-09 -0.38 -0.36 Intelligence (multi-trait analysis); chr8:65607024 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs73236948 ENSG00000200714.1 Y_RNA -7.17 4.67e-12 4.95e-09 -0.38 -0.36 Intelligence (multi-trait analysis); chr8:65609176 chr8:65592731~65592820:+ LIHC cis rs6142102 0.602 rs932388 ENSG00000276073.1 RP5-1125A11.7 -7.17 4.68e-12 4.97e-09 -0.38 -0.36 Skin pigmentation; chr20:34069572 chr20:33985617~33988989:- LIHC cis rs6991838 0.55 rs4737750 ENSG00000200714.1 Y_RNA 7.17 4.69e-12 4.98e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65638724 chr8:65592731~65592820:+ LIHC cis rs916888 0.773 rs538628 ENSG00000262881.1 RP11-669E14.4 -7.17 4.76e-12 5.05e-09 -0.58 -0.36 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45907670~45910779:- LIHC cis rs1577917 0.958 rs2324817 ENSG00000234155.1 RP11-30P6.6 7.17 4.76e-12 5.05e-09 0.42 0.36 Response to antipsychotic treatment; chr6:85752936 chr6:85387219~85390186:- LIHC cis rs2455601 0.882 rs11042106 ENSG00000254860.4 TMEM9B-AS1 -7.17 4.77e-12 5.05e-09 -0.44 -0.36 Schizophrenia; chr11:8874536 chr11:8964675~8977527:+ LIHC cis rs9918079 0.56 rs4557256 ENSG00000273133.1 RP11-799M12.2 -7.17 4.78e-12 5.07e-09 -0.46 -0.36 Obesity-related traits; chr4:15625024 chr4:15563698~15564253:- LIHC cis rs7085104 0.514 rs284855 ENSG00000236937.2 PTGES3P4 -7.17 4.8e-12 5.09e-09 -0.44 -0.36 Immature fraction of reticulocytes;Schizophrenia; chr10:102814665 chr10:102845595~102845950:+ LIHC cis rs2929278 0.617 rs524908 ENSG00000205771.5 CATSPER2P1 7.16 4.83e-12 5.12e-09 0.46 0.36 Schizophrenia; chr15:43895793 chr15:43726918~43747094:- LIHC cis rs1891275 0.55 rs4933694 ENSG00000228701.1 TNKS2-AS1 -7.16 4.84e-12 5.13e-09 -0.44 -0.36 Intelligence (multi-trait analysis); chr10:91739456 chr10:91782839~91798291:- LIHC cis rs2739330 0.929 rs5751777 ENSG00000250470.1 AP000351.3 7.16 4.84e-12 5.13e-09 0.43 0.36 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23976904~23977585:- LIHC cis rs3096299 0.967 rs11648663 ENSG00000274627.1 RP11-104N10.2 7.16 4.85e-12 5.13e-09 0.38 0.36 Multiple myeloma (IgH translocation); chr16:89399899 chr16:89516797~89522217:+ LIHC cis rs1577917 0.958 rs12209259 ENSG00000234155.1 RP11-30P6.6 7.16 4.85e-12 5.14e-09 0.43 0.36 Response to antipsychotic treatment; chr6:85792630 chr6:85387219~85390186:- LIHC cis rs6142102 0.581 rs4911148 ENSG00000276073.1 RP5-1125A11.7 -7.16 4.85e-12 5.14e-09 -0.38 -0.36 Skin pigmentation; chr20:34080438 chr20:33985617~33988989:- LIHC cis rs992157 0.835 rs2292555 ENSG00000261338.2 RP11-378A13.1 -7.16 4.86e-12 5.15e-09 -0.37 -0.36 Colorectal cancer; chr2:218282159 chr2:218255319~218257366:+ LIHC cis rs496547 0.719 rs598373 ENSG00000255239.1 AP002954.6 7.16 4.87e-12 5.15e-09 0.42 0.36 Hip minimal joint space width; chr11:118793668 chr11:118688039~118690600:- LIHC cis rs1577917 0.958 rs4707223 ENSG00000234155.1 RP11-30P6.6 7.16 4.89e-12 5.18e-09 0.43 0.36 Response to antipsychotic treatment; chr6:85800084 chr6:85387219~85390186:- LIHC cis rs916888 0.773 rs199445 ENSG00000262881.1 RP11-669E14.4 -7.16 4.92e-12 5.21e-09 -0.57 -0.36 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45907670~45910779:- LIHC cis rs916888 0.773 rs199443 ENSG00000262881.1 RP11-669E14.4 -7.16 4.92e-12 5.21e-09 -0.57 -0.36 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45907670~45910779:- LIHC cis rs1062177 0.756 rs2964589 ENSG00000213433.5 RPLP1P6 7.16 4.94e-12 5.22e-09 0.42 0.36 Preschool internalizing problems; chr5:151738628 chr5:151765859~151766378:- LIHC cis rs9918079 0.56 rs7662032 ENSG00000273133.1 RP11-799M12.2 -7.16 4.94e-12 5.22e-09 -0.46 -0.36 Obesity-related traits; chr4:15633791 chr4:15563698~15564253:- LIHC cis rs6991838 0.584 rs1053085 ENSG00000200714.1 Y_RNA -7.16 4.95e-12 5.24e-09 -0.38 -0.36 Intelligence (multi-trait analysis); chr8:65603753 chr8:65592731~65592820:+ LIHC cis rs496547 0.686 rs487728 ENSG00000255239.1 AP002954.6 7.16 4.97e-12 5.26e-09 0.42 0.36 Hip minimal joint space width; chr11:118750785 chr11:118688039~118690600:- LIHC cis rs10510102 0.608 rs4752607 ENSG00000276742.1 RP11-500G22.4 -7.16 4.99e-12 5.27e-09 -0.48 -0.36 Breast cancer; chr10:121835426 chr10:121956782~121957098:+ LIHC cis rs1061377 0.861 rs35739603 ENSG00000249207.1 RP11-360F5.1 -7.16 5.01e-12 5.3e-09 -0.37 -0.36 Uric acid levels; chr4:39107938 chr4:39112677~39126818:- LIHC cis rs9918079 0.56 rs10008975 ENSG00000273133.1 RP11-799M12.2 -7.16 5.03e-12 5.31e-09 -0.46 -0.36 Obesity-related traits; chr4:15622948 chr4:15563698~15564253:- LIHC cis rs1061377 1 rs4974998 ENSG00000249207.1 RP11-360F5.1 -7.16 5.04e-12 5.32e-09 -0.37 -0.36 Uric acid levels; chr4:39109129 chr4:39112677~39126818:- LIHC cis rs1061377 1 rs7673299 ENSG00000249207.1 RP11-360F5.1 -7.16 5.04e-12 5.32e-09 -0.37 -0.36 Uric acid levels; chr4:39109138 chr4:39112677~39126818:- LIHC cis rs6142102 0.646 rs2223553 ENSG00000276073.1 RP5-1125A11.7 -7.16 5.08e-12 5.37e-09 -0.38 -0.36 Skin pigmentation; chr20:34121638 chr20:33985617~33988989:- LIHC cis rs6490294 0.571 rs2272308 ENSG00000226469.1 ADAM1B 7.16 5.1e-12 5.38e-09 0.5 0.36 Mean platelet volume; chr12:112163446 chr12:111927018~111929017:+ LIHC cis rs6490294 0.904 rs73426401 ENSG00000226469.1 ADAM1B 7.16 5.1e-12 5.39e-09 0.48 0.36 Mean platelet volume; chr12:111985482 chr12:111927018~111929017:+ LIHC cis rs4423214 0.879 rs1792282 ENSG00000254682.1 RP11-660L16.2 -7.16 5.11e-12 5.4e-09 -0.45 -0.36 Vitamin D levels; chr11:71424120 chr11:71448674~71452157:+ LIHC cis rs150992 0.609 rs113868271 ENSG00000248489.1 CTD-2007H13.3 7.15 5.15e-12 5.43e-09 0.53 0.36 Body mass index; chr5:98992741 chr5:98929171~98995013:+ LIHC cis rs150992 0.631 rs112393710 ENSG00000248489.1 CTD-2007H13.3 7.15 5.15e-12 5.43e-09 0.53 0.36 Body mass index; chr5:98992761 chr5:98929171~98995013:+ LIHC cis rs150992 0.631 rs111871078 ENSG00000248489.1 CTD-2007H13.3 7.15 5.15e-12 5.43e-09 0.53 0.36 Body mass index; chr5:98992766 chr5:98929171~98995013:+ LIHC cis rs9660180 1 rs3737628 ENSG00000268575.1 RP1-283E3.8 -7.15 5.16e-12 5.44e-09 -0.33 -0.36 Body mass index; chr1:1791493 chr1:1702736~1737688:- LIHC cis rs34779708 0.966 rs4934735 ENSG00000230534.5 RP11-297A16.2 -7.15 5.17e-12 5.45e-09 -0.45 -0.36 Inflammatory bowel disease;Crohn's disease; chr10:35207802 chr10:35098006~35127020:- LIHC cis rs1185460 0.547 rs667584 ENSG00000271751.1 RP11-110I1.14 7.15 5.18e-12 5.46e-09 0.46 0.36 Coronary artery disease; chr11:119040834 chr11:119065263~119065677:- LIHC cis rs1185460 0.565 rs657685 ENSG00000271751.1 RP11-110I1.14 7.15 5.18e-12 5.46e-09 0.46 0.36 Coronary artery disease; chr11:119042272 chr11:119065263~119065677:- LIHC cis rs992157 0.965 rs13427681 ENSG00000261338.2 RP11-378A13.1 7.15 5.2e-12 5.48e-09 0.37 0.36 Colorectal cancer; chr2:218302840 chr2:218255319~218257366:+ LIHC cis rs7580658 0.676 rs12465955 ENSG00000236682.1 AC068282.3 -7.15 5.28e-12 5.56e-09 -0.45 -0.36 Protein C levels; chr2:127249498 chr2:127389130~127400580:+ LIHC cis rs6490294 0.571 rs7965087 ENSG00000226469.1 ADAM1B 7.15 5.28e-12 5.56e-09 0.5 0.36 Mean platelet volume; chr12:112110758 chr12:111927018~111929017:+ LIHC cis rs138880 0.542 rs9616393 ENSG00000278869.1 CITF22-49E9.3 -7.15 5.29e-12 5.57e-09 -0.74 -0.36 Schizophrenia; chr22:49921161 chr22:49933198~49934074:- LIHC cis rs6142102 0.602 rs4911402 ENSG00000276073.1 RP5-1125A11.7 -7.15 5.31e-12 5.59e-09 -0.38 -0.36 Skin pigmentation; chr20:34079839 chr20:33985617~33988989:- LIHC cis rs7314031 1 rs7314031 ENSG00000226469.1 ADAM1B 7.15 5.32e-12 5.6e-09 0.5 0.36 Reticulocyte count;Reticulocyte fraction of red cells; chr12:112392775 chr12:111927018~111929017:+ LIHC cis rs17301013 0.507 rs1329281 ENSG00000227373.4 RP11-160H22.5 -7.15 5.33e-12 5.6e-09 -0.59 -0.36 Systemic lupus erythematosus; chr1:174766432 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs6696465 ENSG00000227373.4 RP11-160H22.5 -7.15 5.33e-12 5.6e-09 -0.59 -0.36 Systemic lupus erythematosus; chr1:174769700 chr1:174115300~174160004:- LIHC cis rs17301013 0.531 rs1653634 ENSG00000227373.4 RP11-160H22.5 -7.15 5.33e-12 5.6e-09 -0.59 -0.36 Systemic lupus erythematosus; chr1:174783348 chr1:174115300~174160004:- LIHC cis rs11673344 0.563 rs256744 ENSG00000226686.6 LINC01535 -7.15 5.34e-12 5.62e-09 -0.44 -0.36 Obesity-related traits; chr19:37364586 chr19:37251912~37265535:+ LIHC cis rs1577917 0.687 rs1470531 ENSG00000234155.1 RP11-30P6.6 7.15 5.36e-12 5.64e-09 0.43 0.36 Response to antipsychotic treatment; chr6:85797651 chr6:85387219~85390186:- LIHC cis rs6991838 0.584 rs7841652 ENSG00000200714.1 Y_RNA -7.15 5.46e-12 5.73e-09 -0.38 -0.36 Intelligence (multi-trait analysis); chr8:65606392 chr8:65592731~65592820:+ LIHC cis rs6991838 0.53 rs35038843 ENSG00000200714.1 Y_RNA -7.15 5.46e-12 5.73e-09 -0.38 -0.36 Intelligence (multi-trait analysis); chr8:65610263 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs4737748 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65613630 chr8:65592731~65592820:+ LIHC cis rs6991838 0.55 rs12335006 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65619394 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs10957361 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65619626 chr8:65592731~65592820:+ LIHC cis rs6991838 0.612 rs12335276 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65619668 chr8:65592731~65592820:+ LIHC cis rs6991838 0.612 rs7832407 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65621071 chr8:65592731~65592820:+ LIHC cis rs6991838 0.551 rs7007505 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65621719 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs7012856 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65622740 chr8:65592731~65592820:+ LIHC cis rs6991838 0.55 rs7817112 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65624885 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs2048650 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65625664 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs4737749 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65627672 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs10092109 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65627683 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs6997959 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65628247 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs7814841 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65629328 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs11985628 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65630504 chr8:65592731~65592820:+ LIHC cis rs6991838 0.557 rs13266834 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65631303 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs7835313 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65633891 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs3812412 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65634857 chr8:65592731~65592820:+ LIHC cis rs6991838 0.53 rs6472217 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65635496 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs6472218 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65635502 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs1533285 ENSG00000200714.1 Y_RNA 7.15 5.46e-12 5.73e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65637129 chr8:65592731~65592820:+ LIHC cis rs1577917 0.958 rs6900436 ENSG00000234155.1 RP11-30P6.6 7.14 5.5e-12 5.77e-09 0.43 0.36 Response to antipsychotic treatment; chr6:85796570 chr6:85387219~85390186:- LIHC cis rs6991838 0.584 rs13268343 ENSG00000200714.1 Y_RNA 7.14 5.5e-12 5.77e-09 0.38 0.36 Intelligence (multi-trait analysis); chr8:65631742 chr8:65592731~65592820:+ LIHC cis rs9918079 0.56 rs7685083 ENSG00000273133.1 RP11-799M12.2 7.14 5.52e-12 5.79e-09 0.46 0.36 Obesity-related traits; chr4:15609148 chr4:15563698~15564253:- LIHC cis rs1930961 0.85 rs5996945 ENSG00000100058.11 CRYBB2P1 -7.14 5.56e-12 5.82e-09 -0.54 -0.36 Bipolar disorder with mood-incongruent psychosis; chr22:25479606 chr22:25448105~25520854:+ LIHC cis rs9918079 0.542 rs1789 ENSG00000273133.1 RP11-799M12.2 -7.14 5.58e-12 5.85e-09 -0.46 -0.36 Obesity-related traits; chr4:15662912 chr4:15563698~15564253:- LIHC cis rs1577917 0.917 rs1414201 ENSG00000234155.1 RP11-30P6.6 7.14 5.64e-12 5.9e-09 0.43 0.36 Response to antipsychotic treatment; chr6:85790598 chr6:85387219~85390186:- LIHC cis rs12744310 0.887 rs12024263 ENSG00000235358.1 RP11-399E6.1 7.14 5.64e-12 5.91e-09 0.48 0.36 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41355277 chr1:41242373~41284861:+ LIHC cis rs9326248 1 rs3736120 ENSG00000280143.1 AP000892.6 7.14 5.75e-12 6.01e-09 0.42 0.36 Blood protein levels; chr11:117161409 chr11:117204967~117210292:+ LIHC cis rs6991838 0.584 rs3765205 ENSG00000200714.1 Y_RNA -7.14 5.78e-12 6.03e-09 -0.38 -0.36 Intelligence (multi-trait analysis); chr8:65605251 chr8:65592731~65592820:+ LIHC cis rs34779708 0.931 rs2244100 ENSG00000230534.5 RP11-297A16.2 -7.14 5.79e-12 6.04e-09 -0.44 -0.36 Inflammatory bowel disease;Crohn's disease; chr10:35034708 chr10:35098006~35127020:- LIHC cis rs9660180 0.62 rs34298494 ENSG00000268575.1 RP1-283E3.8 7.14 5.79e-12 6.05e-09 0.39 0.36 Body mass index; chr1:1731963 chr1:1702736~1737688:- LIHC cis rs7923609 0.578 rs10740138 ENSG00000232075.1 MRPL35P2 -7.14 5.79e-12 6.05e-09 -0.37 -0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63635373 chr10:63634317~63634827:- LIHC cis rs10899021 0.92 rs11236181 ENSG00000279353.1 RP11-864N7.4 7.14 5.82e-12 6.08e-09 0.78 0.36 Response to metformin (IC50); chr11:74634778 chr11:74698231~74699658:- LIHC cis rs6490294 0.571 rs12312538 ENSG00000226469.1 ADAM1B 7.13 5.83e-12 6.08e-09 0.5 0.36 Mean platelet volume; chr12:112051717 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs7959011 ENSG00000226469.1 ADAM1B 7.13 5.83e-12 6.08e-09 0.5 0.36 Mean platelet volume; chr12:112063433 chr12:111927018~111929017:+ LIHC cis rs7580658 0.637 rs12463909 ENSG00000236682.1 AC068282.3 7.13 5.85e-12 6.11e-09 0.45 0.36 Protein C levels; chr2:127214162 chr2:127389130~127400580:+ LIHC cis rs2455601 1 rs72632952 ENSG00000254860.4 TMEM9B-AS1 7.13 5.89e-12 6.14e-09 0.45 0.36 Schizophrenia; chr11:8896429 chr11:8964675~8977527:+ LIHC cis rs2882667 0.867 rs11749045 ENSG00000253404.1 AC034243.1 7.13 5.91e-12 6.16e-09 0.47 0.36 Age-related hearing impairment (SNP x SNP interaction); chr5:139085271 chr5:138744434~138753309:- LIHC cis rs992157 0.798 rs7557709 ENSG00000261338.2 RP11-378A13.1 7.13 5.91e-12 6.16e-09 0.37 0.36 Colorectal cancer; chr2:218302806 chr2:218255319~218257366:+ LIHC cis rs7174755 0.637 rs113002386 ENSG00000260657.2 RP11-315D16.4 7.13 5.93e-12 6.18e-09 0.55 0.36 Major depressive disorder; chr15:68172375 chr15:68267792~68277994:- LIHC cis rs2455601 0.882 rs10840139 ENSG00000254860.4 TMEM9B-AS1 7.13 5.96e-12 6.21e-09 0.44 0.36 Schizophrenia; chr11:8873291 chr11:8964675~8977527:+ LIHC cis rs6142102 0.625 rs6141431 ENSG00000276073.1 RP5-1125A11.7 -7.13 5.96e-12 6.21e-09 -0.38 -0.36 Skin pigmentation; chr20:33952508 chr20:33985617~33988989:- LIHC cis rs6142102 0.602 rs4911145 ENSG00000276073.1 RP5-1125A11.7 7.13 5.99e-12 6.24e-09 0.37 0.36 Skin pigmentation; chr20:34027417 chr20:33985617~33988989:- LIHC cis rs7085104 0.632 rs3781287 ENSG00000236937.2 PTGES3P4 7.13 6e-12 6.25e-09 0.42 0.36 Immature fraction of reticulocytes;Schizophrenia; chr10:102835663 chr10:102845595~102845950:+ LIHC cis rs17301013 0.507 rs1622802 ENSG00000227373.4 RP11-160H22.5 -7.13 6e-12 6.25e-09 -0.59 -0.36 Systemic lupus erythematosus; chr1:174766066 chr1:174115300~174160004:- LIHC cis rs7044106 0.762 rs10984974 ENSG00000226752.6 PSMD5-AS1 -7.13 6.01e-12 6.26e-09 -0.36 -0.36 Hip circumference adjusted for BMI; chr9:120659278 chr9:120824828~120854385:+ LIHC cis rs7131987 0.65 rs11050187 ENSG00000257176.2 RP11-996F15.2 -7.13 6.02e-12 6.26e-09 -0.42 -0.36 QT interval; chr12:29319943 chr12:29280418~29317848:- LIHC cis rs7131987 0.65 rs16934135 ENSG00000257176.2 RP11-996F15.2 -7.13 6.02e-12 6.26e-09 -0.42 -0.36 QT interval; chr12:29331030 chr12:29280418~29317848:- LIHC cis rs17301013 0.507 rs1793316 ENSG00000227373.4 RP11-160H22.5 7.13 6.06e-12 6.31e-09 0.58 0.36 Systemic lupus erythematosus; chr1:174825006 chr1:174115300~174160004:- LIHC cis rs10899021 0.79 rs12288525 ENSG00000279353.1 RP11-864N7.4 7.13 6.06e-12 6.31e-09 0.74 0.36 Response to metformin (IC50); chr11:74621544 chr11:74698231~74699658:- LIHC cis rs73086581 1 rs73084575 ENSG00000229539.1 RP11-119B16.2 7.13 6.07e-12 6.31e-09 0.61 0.36 Response to antidepressants in depression; chr20:3926121 chr20:3888239~3888868:- LIHC cis rs1789 0.786 rs6414768 ENSG00000273133.1 RP11-799M12.2 -7.13 6.08e-12 6.33e-09 -0.48 -0.36 Blood protein levels; chr4:15693740 chr4:15563698~15564253:- LIHC cis rs929843 1 rs929843 ENSG00000226232.7 RP11-419C5.2 -7.13 6.15e-12 6.4e-09 -0.55 -0.36 Menarche (age at onset); chr16:70011845 chr16:69976388~69996188:- LIHC cis rs7085104 0.632 rs7097872 ENSG00000236937.2 PTGES3P4 7.13 6.18e-12 6.43e-09 0.43 0.36 Immature fraction of reticulocytes;Schizophrenia; chr10:102846879 chr10:102845595~102845950:+ LIHC cis rs916888 0.773 rs199448 ENSG00000262881.1 RP11-669E14.4 -7.12 6.25e-12 6.5e-09 -0.57 -0.36 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45907670~45910779:- LIHC cis rs7131987 0.621 rs11050181 ENSG00000257176.2 RP11-996F15.2 -7.12 6.27e-12 6.52e-09 -0.42 -0.36 QT interval; chr12:29314736 chr12:29280418~29317848:- LIHC cis rs3813579 0.654 rs4480821 ENSG00000261390.4 RP11-345M22.2 -7.12 6.27e-12 6.52e-09 -0.46 -0.36 Thyroid volume; chr16:79711416 chr16:79715232~79770563:- LIHC cis rs73086581 0.898 rs11906452 ENSG00000229539.1 RP11-119B16.2 7.12 6.29e-12 6.53e-09 0.63 0.36 Response to antidepressants in depression; chr20:4000912 chr20:3888239~3888868:- LIHC cis rs11603023 0.772 rs540800 ENSG00000255239.1 AP002954.6 7.12 6.29e-12 6.53e-09 0.41 0.36 Cholesterol, total; chr11:118694942 chr11:118688039~118690600:- LIHC cis rs1062177 0.756 rs2915815 ENSG00000213433.5 RPLP1P6 7.12 6.33e-12 6.57e-09 0.41 0.36 Preschool internalizing problems; chr5:151736322 chr5:151765859~151766378:- LIHC cis rs5758511 0.514 rs5751211 ENSG00000237037.8 NDUFA6-AS1 -7.12 6.34e-12 6.59e-09 -0.45 -0.36 Birth weight; chr22:42090052 chr22:42090931~42137742:+ LIHC cis rs5758511 0.514 rs3985938 ENSG00000237037.8 NDUFA6-AS1 -7.12 6.34e-12 6.59e-09 -0.45 -0.36 Birth weight; chr22:42115723 chr22:42090931~42137742:+ LIHC cis rs5758511 0.514 rs5758586 ENSG00000237037.8 NDUFA6-AS1 -7.12 6.34e-12 6.59e-09 -0.45 -0.36 Birth weight; chr22:42121467 chr22:42090931~42137742:+ LIHC cis rs5758511 0.514 rs5751222 ENSG00000237037.8 NDUFA6-AS1 -7.12 6.34e-12 6.59e-09 -0.45 -0.36 Birth weight; chr22:42121918 chr22:42090931~42137742:+ LIHC cis rs1577917 0.958 rs6921315 ENSG00000234155.1 RP11-30P6.6 7.12 6.35e-12 6.59e-09 0.42 0.36 Response to antipsychotic treatment; chr6:85761950 chr6:85387219~85390186:- LIHC cis rs7044106 0.708 rs1324472 ENSG00000226752.6 PSMD5-AS1 -7.12 6.35e-12 6.6e-09 -0.36 -0.36 Hip circumference adjusted for BMI; chr9:120612832 chr9:120824828~120854385:+ LIHC cis rs67180937 0.922 rs10495198 ENSG00000272750.1 RP11-378J18.8 -7.12 6.39e-12 6.63e-09 -0.37 -0.36 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222652375 chr1:222658867~222661512:- LIHC cis rs1577917 0.681 rs4707211 ENSG00000234155.1 RP11-30P6.6 -7.12 6.41e-12 6.65e-09 -0.43 -0.36 Response to antipsychotic treatment; chr6:85522992 chr6:85387219~85390186:- LIHC cis rs7131987 0.65 rs10843384 ENSG00000257176.2 RP11-996F15.2 -7.12 6.43e-12 6.68e-09 -0.42 -0.36 QT interval; chr12:29319476 chr12:29280418~29317848:- LIHC cis rs17301013 0.507 rs464635 ENSG00000227373.4 RP11-160H22.5 7.12 6.44e-12 6.68e-09 0.57 0.36 Systemic lupus erythematosus; chr1:174732730 chr1:174115300~174160004:- LIHC cis rs73086581 0.838 rs11907416 ENSG00000229539.1 RP11-119B16.2 7.12 6.49e-12 6.73e-09 0.67 0.36 Response to antidepressants in depression; chr20:4024972 chr20:3888239~3888868:- LIHC cis rs7208859 0.573 rs73267829 ENSG00000263531.1 RP13-753N3.1 7.12 6.52e-12 6.76e-09 0.64 0.36 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30676921 chr17:30863921~30864940:- LIHC cis rs6490294 0.95 rs7313892 ENSG00000226469.1 ADAM1B 7.11 6.63e-12 6.86e-09 0.48 0.36 Mean platelet volume; chr12:111983548 chr12:111927018~111929017:+ LIHC cis rs6490294 0.904 rs7956483 ENSG00000226469.1 ADAM1B 7.11 6.63e-12 6.86e-09 0.48 0.36 Mean platelet volume; chr12:111986766 chr12:111927018~111929017:+ LIHC cis rs7580658 0.963 rs12463451 ENSG00000236682.1 AC068282.3 -7.11 6.71e-12 6.94e-09 -0.46 -0.36 Protein C levels; chr2:127296307 chr2:127389130~127400580:+ LIHC cis rs7580658 0.963 rs4233583 ENSG00000236682.1 AC068282.3 -7.11 6.71e-12 6.94e-09 -0.46 -0.36 Protein C levels; chr2:127302492 chr2:127389130~127400580:+ LIHC cis rs7580658 0.963 rs4233584 ENSG00000236682.1 AC068282.3 -7.11 6.71e-12 6.94e-09 -0.46 -0.36 Protein C levels; chr2:127302587 chr2:127389130~127400580:+ LIHC cis rs992157 0.804 rs6758540 ENSG00000261338.2 RP11-378A13.1 -7.11 6.73e-12 6.95e-09 -0.37 -0.36 Colorectal cancer; chr2:218273902 chr2:218255319~218257366:+ LIHC cis rs992157 0.835 rs2292550 ENSG00000261338.2 RP11-378A13.1 -7.11 6.73e-12 6.95e-09 -0.37 -0.36 Colorectal cancer; chr2:218275565 chr2:218255319~218257366:+ LIHC cis rs73086581 1 rs56141565 ENSG00000229539.1 RP11-119B16.2 7.11 6.74e-12 6.96e-09 0.67 0.36 Response to antidepressants in depression; chr20:4017956 chr20:3888239~3888868:- LIHC cis rs7044106 0.615 rs10818470 ENSG00000226752.6 PSMD5-AS1 -7.11 6.74e-12 6.97e-09 -0.38 -0.36 Hip circumference adjusted for BMI; chr9:120596926 chr9:120824828~120854385:+ LIHC cis rs6991838 0.584 rs7463649 ENSG00000200714.1 Y_RNA -7.11 6.74e-12 6.97e-09 -0.38 -0.36 Intelligence (multi-trait analysis); chr8:65573760 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs66467166 ENSG00000200714.1 Y_RNA -7.11 6.74e-12 6.97e-09 -0.38 -0.36 Intelligence (multi-trait analysis); chr8:65574165 chr8:65592731~65592820:+ LIHC cis rs4423214 0.524 rs4944046 ENSG00000254682.1 RP11-660L16.2 7.11 6.74e-12 6.97e-09 0.42 0.36 Vitamin D levels; chr11:71412748 chr11:71448674~71452157:+ LIHC cis rs1065852 0.51 rs5758666 ENSG00000237037.8 NDUFA6-AS1 -7.11 6.81e-12 7.03e-09 -0.42 -0.36 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42236827 chr22:42090931~42137742:+ LIHC cis rs17301013 0.507 rs10489256 ENSG00000227373.4 RP11-160H22.5 7.11 6.82e-12 7.03e-09 0.6 0.36 Systemic lupus erythematosus; chr1:174359663 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs4651016 ENSG00000227373.4 RP11-160H22.5 7.11 6.82e-12 7.03e-09 0.6 0.36 Systemic lupus erythematosus; chr1:174375146 chr1:174115300~174160004:- LIHC cis rs1577917 0.837 rs806529 ENSG00000234155.1 RP11-30P6.6 7.11 6.83e-12 7.04e-09 0.42 0.36 Response to antipsychotic treatment; chr6:85757403 chr6:85387219~85390186:- LIHC cis rs1061377 1 rs9996285 ENSG00000249207.1 RP11-360F5.1 -7.11 6.89e-12 7.1e-09 -0.36 -0.36 Uric acid levels; chr4:39130556 chr4:39112677~39126818:- LIHC cis rs10875746 0.81 rs10875732 ENSG00000240399.1 RP1-228P16.1 -7.11 6.9e-12 7.1e-09 -0.4 -0.36 Longevity (90 years and older); chr12:48048322 chr12:48054813~48055591:- LIHC cis rs7131987 0.622 rs7294598 ENSG00000257176.2 RP11-996F15.2 7.11 6.9e-12 7.11e-09 0.42 0.36 QT interval; chr12:29379056 chr12:29280418~29317848:- LIHC cis rs5758511 0.514 rs5758580 ENSG00000237037.8 NDUFA6-AS1 -7.11 6.94e-12 7.14e-09 -0.45 -0.36 Birth weight; chr22:42097871 chr22:42090931~42137742:+ LIHC cis rs55665837 0.778 rs11023212 ENSG00000251991.1 RNU7-49P 7.11 6.97e-12 7.17e-09 0.39 0.36 Vitamin D levels; chr11:14410163 chr11:14478892~14478953:+ LIHC cis rs1185460 0.547 rs34150933 ENSG00000271751.1 RP11-110I1.14 7.11 6.99e-12 7.19e-09 0.45 0.36 Coronary artery disease; chr11:119040329 chr11:119065263~119065677:- LIHC cis rs916888 0.773 rs199439 ENSG00000262881.1 RP11-669E14.4 -7.1 7.05e-12 7.25e-09 -0.57 -0.36 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45907670~45910779:- LIHC cis rs6490294 0.904 rs11066098 ENSG00000226469.1 ADAM1B 7.1 7.08e-12 7.28e-09 0.46 0.36 Mean platelet volume; chr12:111950324 chr12:111927018~111929017:+ LIHC cis rs765787 0.53 rs2554454 ENSG00000259520.4 CTD-2651B20.3 7.1 7.12e-12 7.32e-09 0.42 0.36 Uric acid levels; chr15:45229338 chr15:45251580~45279251:- LIHC cis rs17301013 0.507 rs2064150 ENSG00000227373.4 RP11-160H22.5 -7.1 7.15e-12 7.34e-09 -0.57 -0.36 Systemic lupus erythematosus; chr1:174339289 chr1:174115300~174160004:- LIHC cis rs9918079 0.56 rs4698409 ENSG00000273133.1 RP11-799M12.2 -7.1 7.16e-12 7.36e-09 -0.46 -0.36 Obesity-related traits; chr4:15658143 chr4:15563698~15564253:- LIHC cis rs1789 0.786 rs6449161 ENSG00000273133.1 RP11-799M12.2 -7.1 7.18e-12 7.38e-09 -0.47 -0.36 Blood protein levels; chr4:15691331 chr4:15563698~15564253:- LIHC cis rs7044106 0.762 rs7024046 ENSG00000226752.6 PSMD5-AS1 -7.1 7.19e-12 7.39e-09 -0.36 -0.36 Hip circumference adjusted for BMI; chr9:120656900 chr9:120824828~120854385:+ LIHC cis rs9918079 0.542 rs12499412 ENSG00000273133.1 RP11-799M12.2 7.1 7.27e-12 7.47e-09 0.46 0.36 Obesity-related traits; chr4:15600629 chr4:15563698~15564253:- LIHC cis rs9918079 0.58 rs13120905 ENSG00000273133.1 RP11-799M12.2 7.1 7.27e-12 7.47e-09 0.46 0.36 Obesity-related traits; chr4:15610665 chr4:15563698~15564253:- LIHC cis rs17301013 0.507 rs72715259 ENSG00000227373.4 RP11-160H22.5 7.1 7.3e-12 7.5e-09 0.61 0.36 Systemic lupus erythematosus; chr1:174604590 chr1:174115300~174160004:- LIHC cis rs7044106 0.762 rs4837789 ENSG00000226752.6 PSMD5-AS1 -7.1 7.31e-12 7.5e-09 -0.36 -0.36 Hip circumference adjusted for BMI; chr9:120663978 chr9:120824828~120854385:+ LIHC cis rs150992 0.609 rs2937709 ENSG00000248489.1 CTD-2007H13.3 7.1 7.36e-12 7.55e-09 0.53 0.36 Body mass index; chr5:98993120 chr5:98929171~98995013:+ LIHC cis rs150992 0.632 rs1104262 ENSG00000248489.1 CTD-2007H13.3 7.1 7.36e-12 7.55e-09 0.53 0.36 Body mass index; chr5:98993145 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs2927654 ENSG00000248489.1 CTD-2007H13.3 7.1 7.36e-12 7.55e-09 0.53 0.36 Body mass index; chr5:98993195 chr5:98929171~98995013:+ LIHC cis rs7580658 0.864 rs1566823 ENSG00000236682.1 AC068282.3 -7.1 7.37e-12 7.56e-09 -0.45 -0.36 Protein C levels; chr2:127260616 chr2:127389130~127400580:+ LIHC cis rs5758511 0.514 rs5751221 ENSG00000237037.8 NDUFA6-AS1 -7.1 7.4e-12 7.59e-09 -0.45 -0.36 Birth weight; chr22:42120362 chr22:42090931~42137742:+ LIHC cis rs17301013 0.507 rs333422 ENSG00000227373.4 RP11-160H22.5 -7.1 7.42e-12 7.61e-09 -0.58 -0.36 Systemic lupus erythematosus; chr1:174664167 chr1:174115300~174160004:- LIHC cis rs1185460 0.547 rs666741 ENSG00000271751.1 RP11-110I1.14 7.1 7.47e-12 7.66e-09 0.46 0.36 Coronary artery disease; chr11:119040640 chr11:119065263~119065677:- LIHC cis rs6991838 0.584 rs1053087 ENSG00000200714.1 Y_RNA -7.09 7.52e-12 7.71e-09 -0.38 -0.36 Intelligence (multi-trait analysis); chr8:65603630 chr8:65592731~65592820:+ LIHC cis rs3096299 0.967 rs28644774 ENSG00000274627.1 RP11-104N10.2 7.09 7.53e-12 7.72e-09 0.37 0.36 Multiple myeloma (IgH translocation); chr16:89405773 chr16:89516797~89522217:+ LIHC cis rs1577917 0.916 rs12206726 ENSG00000234155.1 RP11-30P6.6 7.09 7.54e-12 7.73e-09 0.43 0.36 Response to antipsychotic treatment; chr6:85789998 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs6454487 ENSG00000234155.1 RP11-30P6.6 -7.09 7.59e-12 7.78e-09 -0.42 -0.36 Response to antipsychotic treatment; chr6:85737150 chr6:85387219~85390186:- LIHC cis rs1150668 0.796 rs1124132 ENSG00000216901.1 AL022393.7 7.09 7.64e-12 7.83e-09 0.41 0.36 Pubertal anthropometrics; chr6:28412544 chr6:28176188~28176674:+ LIHC cis rs1789 0.872 rs4333182 ENSG00000273133.1 RP11-799M12.2 -7.09 7.65e-12 7.84e-09 -0.47 -0.36 Blood protein levels; chr4:15683089 chr4:15563698~15564253:- LIHC cis rs34779708 0.931 rs2384275 ENSG00000230534.5 RP11-297A16.2 7.09 7.65e-12 7.84e-09 0.44 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35008214 chr10:35098006~35127020:- LIHC cis rs916888 0.773 rs199451 ENSG00000262881.1 RP11-669E14.4 -7.09 7.71e-12 7.9e-09 -0.57 -0.36 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45907670~45910779:- LIHC cis rs138880 0.505 rs56248708 ENSG00000278869.1 CITF22-49E9.3 7.09 7.74e-12 7.92e-09 0.77 0.36 Schizophrenia; chr22:49913321 chr22:49933198~49934074:- LIHC cis rs6700559 1 rs6700559 ENSG00000260088.1 RP11-92G12.3 7.09 7.74e-12 7.93e-09 0.46 0.36 Coronary artery disease; chr1:200676945 chr1:200669507~200694250:+ LIHC cis rs7615952 0.673 rs3811677 ENSG00000171084.14 FAM86JP 7.09 7.78e-12 7.96e-09 0.66 0.36 Blood pressure (smoking interaction); chr3:125929237 chr3:125916620~125930024:+ LIHC cis rs4660456 0.913 rs656230 ENSG00000237899.1 RP4-739H11.3 7.09 7.79e-12 7.97e-09 0.47 0.36 Platelet count; chr1:40692701 chr1:40669089~40687588:- LIHC cis rs7131987 0.65 rs11050188 ENSG00000257176.2 RP11-996F15.2 -7.09 7.79e-12 7.97e-09 -0.42 -0.36 QT interval; chr12:29320175 chr12:29280418~29317848:- LIHC cis rs832187 0.704 rs3774720 ENSG00000280620.1 SCAANT1 7.09 7.87e-12 8.06e-09 0.45 0.36 Schizophrenia; chr3:63966089 chr3:63911518~63911772:- LIHC cis rs10899021 0.79 rs12280434 ENSG00000279353.1 RP11-864N7.4 7.08 8e-12 8.18e-09 0.76 0.36 Response to metformin (IC50); chr11:74621782 chr11:74698231~74699658:- LIHC cis rs10899021 0.79 rs10899019 ENSG00000279353.1 RP11-864N7.4 7.08 8e-12 8.18e-09 0.76 0.36 Response to metformin (IC50); chr11:74624117 chr11:74698231~74699658:- LIHC cis rs1577917 0.958 rs1545376 ENSG00000234155.1 RP11-30P6.6 -7.08 8.03e-12 8.21e-09 -0.43 -0.36 Response to antipsychotic treatment; chr6:85794864 chr6:85387219~85390186:- LIHC cis rs6142102 0.625 rs6142068 ENSG00000276073.1 RP5-1125A11.7 7.08 8.11e-12 8.28e-09 0.37 0.36 Skin pigmentation; chr20:33969366 chr20:33985617~33988989:- LIHC cis rs992157 0.717 rs11692780 ENSG00000261338.2 RP11-378A13.1 -7.08 8.17e-12 8.34e-09 -0.37 -0.36 Colorectal cancer; chr2:218284440 chr2:218255319~218257366:+ LIHC cis rs6142102 0.625 rs4911137 ENSG00000276073.1 RP5-1125A11.7 -7.08 8.18e-12 8.35e-09 -0.37 -0.36 Skin pigmentation; chr20:33947657 chr20:33985617~33988989:- LIHC cis rs992157 0.835 rs7559416 ENSG00000261338.2 RP11-378A13.1 -7.08 8.2e-12 8.37e-09 -0.37 -0.36 Colorectal cancer; chr2:218285488 chr2:218255319~218257366:+ LIHC cis rs10875746 0.859 rs11168371 ENSG00000240399.1 RP1-228P16.1 -7.08 8.2e-12 8.37e-09 -0.39 -0.36 Longevity (90 years and older); chr12:48043903 chr12:48054813~48055591:- LIHC cis rs7617773 0.963 rs6800730 ENSG00000229759.1 MRPS18AP1 7.08 8.25e-12 8.42e-09 0.37 0.36 Coronary artery disease; chr3:48132720 chr3:48256350~48256938:- LIHC cis rs62355901 0.505 rs62356567 ENSG00000271828.1 CTD-2310F14.1 7.08 8.25e-12 8.42e-09 0.57 0.36 Breast cancer; chr5:56953442 chr5:56927874~56929573:+ LIHC cis rs11673344 0.642 rs11083420 ENSG00000226686.6 LINC01535 7.08 8.35e-12 8.51e-09 0.44 0.36 Obesity-related traits; chr19:37317901 chr19:37251912~37265535:+ LIHC cis rs4356975 0.697 rs66666893 ENSG00000249956.3 RP11-790I12.2 7.08 8.35e-12 8.51e-09 0.42 0.36 Obesity-related traits; chr4:69133393 chr4:69408836~69423164:+ LIHC cis rs4423214 0.879 rs1792264 ENSG00000254682.1 RP11-660L16.2 -7.08 8.37e-12 8.53e-09 -0.45 -0.36 Vitamin D levels; chr11:71439201 chr11:71448674~71452157:+ LIHC cis rs2283792 0.622 rs2266979 ENSG00000224086.5 LL22NC03-86G7.1 -7.08 8.43e-12 8.59e-09 -0.33 -0.36 Multiple sclerosis; chr22:21977447 chr22:21938293~21977632:+ LIHC cis rs4660456 0.913 rs2744808 ENSG00000237899.1 RP4-739H11.3 -7.08 8.47e-12 8.63e-09 -0.47 -0.36 Platelet count; chr1:40712271 chr1:40669089~40687588:- LIHC cis rs17301013 0.507 rs1613634 ENSG00000227373.4 RP11-160H22.5 -7.08 8.48e-12 8.64e-09 -0.58 -0.36 Systemic lupus erythematosus; chr1:174803184 chr1:174115300~174160004:- LIHC cis rs8072100 0.512 rs9303533 ENSG00000228782.6 CTD-2026D20.3 7.07 8.51e-12 8.67e-09 0.42 0.36 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47309174 chr17:47450568~47492492:- LIHC cis rs3020736 0.5 rs11090076 ENSG00000227370.1 RP4-669P10.19 7.07 8.55e-12 8.71e-09 0.42 0.36 Autism spectrum disorder or schizophrenia; chr22:42118186 chr22:42132543~42132998:+ LIHC cis rs2882667 0.858 rs11744972 ENSG00000253404.1 AC034243.1 7.07 8.56e-12 8.71e-09 0.49 0.36 Age-related hearing impairment (SNP x SNP interaction); chr5:139093100 chr5:138744434~138753309:- LIHC cis rs67180937 0.922 rs17465982 ENSG00000272750.1 RP11-378J18.8 -7.07 8.58e-12 8.73e-09 -0.37 -0.36 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222664597 chr1:222658867~222661512:- LIHC cis rs62355900 0.627 rs9292123 ENSG00000271828.1 CTD-2310F14.1 7.07 8.6e-12 8.75e-09 0.55 0.36 Endometriosis; chr5:56807982 chr5:56927874~56929573:+ LIHC cis rs17301013 0.507 rs10489255 ENSG00000227373.4 RP11-160H22.5 7.07 8.69e-12 8.84e-09 0.58 0.36 Systemic lupus erythematosus; chr1:174341985 chr1:174115300~174160004:- LIHC cis rs34779708 0.897 rs7900480 ENSG00000230534.5 RP11-297A16.2 -7.07 8.7e-12 8.84e-09 -0.45 -0.36 Inflammatory bowel disease;Crohn's disease; chr10:35049771 chr10:35098006~35127020:- LIHC cis rs4728142 0.604 rs6467222 ENSG00000275106.1 RP11-309L24.10 -7.07 8.7e-12 8.85e-09 -0.44 -0.36 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129034365 chr7:128952527~128953316:- LIHC cis rs3096299 0.967 rs2965830 ENSG00000274627.1 RP11-104N10.2 7.07 8.71e-12 8.85e-09 0.37 0.36 Multiple myeloma (IgH translocation); chr16:89393882 chr16:89516797~89522217:+ LIHC cis rs10875746 0.903 rs2158516 ENSG00000240399.1 RP1-228P16.1 -7.07 8.71e-12 8.86e-09 -0.39 -0.36 Longevity (90 years and older); chr12:48097051 chr12:48054813~48055591:- LIHC cis rs10875746 0.855 rs73102065 ENSG00000240399.1 RP1-228P16.1 -7.07 8.71e-12 8.86e-09 -0.39 -0.36 Longevity (90 years and older); chr12:48098824 chr12:48054813~48055591:- LIHC cis rs10875746 0.855 rs73102067 ENSG00000240399.1 RP1-228P16.1 -7.07 8.71e-12 8.86e-09 -0.39 -0.36 Longevity (90 years and older); chr12:48100643 chr12:48054813~48055591:- LIHC cis rs4853012 0.887 rs6737314 ENSG00000257800.1 FNBP1P1 7.07 8.73e-12 8.88e-09 0.41 0.36 Gestational age at birth (maternal effect); chr2:74112459 chr2:74120680~74123218:+ LIHC cis rs7085104 0.572 rs284856 ENSG00000236937.2 PTGES3P4 -7.07 8.75e-12 8.9e-09 -0.44 -0.36 Immature fraction of reticulocytes;Schizophrenia; chr10:102814572 chr10:102845595~102845950:+ LIHC cis rs916888 0.773 rs199457 ENSG00000262881.1 RP11-669E14.4 -7.07 8.8e-12 8.94e-09 -0.57 -0.36 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45907670~45910779:- LIHC cis rs916888 0.687 rs199456 ENSG00000262881.1 RP11-669E14.4 -7.07 8.8e-12 8.94e-09 -0.57 -0.36 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45907670~45910779:- LIHC cis rs992157 0.775 rs1877714 ENSG00000261338.2 RP11-378A13.1 -7.07 8.89e-12 9.02e-09 -0.37 -0.36 Colorectal cancer; chr2:218270205 chr2:218255319~218257366:+ LIHC cis rs7044106 0.762 rs1158554 ENSG00000226752.6 PSMD5-AS1 -7.07 8.93e-12 9.06e-09 -0.36 -0.36 Hip circumference adjusted for BMI; chr9:120638620 chr9:120824828~120854385:+ LIHC cis rs6700559 1 rs6656619 ENSG00000260088.1 RP11-92G12.3 7.07 8.96e-12 9.09e-09 0.45 0.36 Coronary artery disease; chr1:200671664 chr1:200669507~200694250:+ LIHC cis rs9918079 0.56 rs10008376 ENSG00000273133.1 RP11-799M12.2 7.07 8.96e-12 9.1e-09 0.46 0.36 Obesity-related traits; chr4:15622332 chr4:15563698~15564253:- LIHC cis rs10875746 0.903 rs3782911 ENSG00000240399.1 RP1-228P16.1 -7.07 8.99e-12 9.12e-09 -0.39 -0.36 Longevity (90 years and older); chr12:48089709 chr12:48054813~48055591:- LIHC cis rs6061231 1 rs11908473 ENSG00000273619.1 RP5-908M14.9 -7.07 9e-12 9.13e-09 -0.31 -0.36 Colorectal cancer; chr20:62382714 chr20:62386303~62386970:- LIHC cis rs6061231 1 rs67941642 ENSG00000273619.1 RP5-908M14.9 -7.07 9e-12 9.13e-09 -0.31 -0.36 Colorectal cancer; chr20:62383052 chr20:62386303~62386970:- LIHC cis rs17301013 0.507 rs2987872 ENSG00000227373.4 RP11-160H22.5 -7.06 9.13e-12 9.25e-09 -0.59 -0.36 Systemic lupus erythematosus; chr1:174840935 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs1793305 ENSG00000227373.4 RP11-160H22.5 -7.06 9.13e-12 9.25e-09 -0.59 -0.36 Systemic lupus erythematosus; chr1:174841124 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs1894201 ENSG00000227373.4 RP11-160H22.5 -7.06 9.13e-12 9.25e-09 -0.59 -0.36 Systemic lupus erythematosus; chr1:174841452 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2281010 ENSG00000227373.4 RP11-160H22.5 7.06 9.14e-12 9.26e-09 0.59 0.36 Systemic lupus erythematosus; chr1:174509917 chr1:174115300~174160004:- LIHC cis rs10899021 0.704 rs11236177 ENSG00000279353.1 RP11-864N7.4 7.06 9.15e-12 9.27e-09 0.76 0.36 Response to metformin (IC50); chr11:74628022 chr11:74698231~74699658:- LIHC cis rs10899021 0.79 rs10899022 ENSG00000279353.1 RP11-864N7.4 7.06 9.15e-12 9.27e-09 0.76 0.36 Response to metformin (IC50); chr11:74628341 chr11:74698231~74699658:- LIHC cis rs10899021 0.79 rs11236180 ENSG00000279353.1 RP11-864N7.4 7.06 9.15e-12 9.27e-09 0.76 0.36 Response to metformin (IC50); chr11:74631883 chr11:74698231~74699658:- LIHC cis rs73086581 1 rs17286349 ENSG00000229539.1 RP11-119B16.2 7.06 9.21e-12 9.33e-09 0.59 0.36 Response to antidepressants in depression; chr20:3933655 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs73086512 ENSG00000229539.1 RP11-119B16.2 7.06 9.22e-12 9.34e-09 0.59 0.36 Response to antidepressants in depression; chr20:3942125 chr20:3888239~3888868:- LIHC cis rs2455601 0.935 rs12049908 ENSG00000254860.4 TMEM9B-AS1 7.06 9.35e-12 9.46e-09 0.44 0.36 Schizophrenia; chr11:8897762 chr11:8964675~8977527:+ LIHC cis rs2455601 1 rs11042114 ENSG00000254860.4 TMEM9B-AS1 7.06 9.35e-12 9.46e-09 0.44 0.36 Schizophrenia; chr11:8898342 chr11:8964675~8977527:+ LIHC cis rs9326248 1 rs10790175 ENSG00000280143.1 AP000892.6 7.06 9.37e-12 9.48e-09 0.41 0.36 Blood protein levels; chr11:117164013 chr11:117204967~117210292:+ LIHC cis rs6142102 0.625 rs6142067 ENSG00000276073.1 RP5-1125A11.7 -7.06 9.39e-12 9.51e-09 -0.37 -0.36 Skin pigmentation; chr20:33968766 chr20:33985617~33988989:- LIHC cis rs4423214 0.879 rs1630498 ENSG00000254682.1 RP11-660L16.2 -7.06 9.4e-12 9.51e-09 -0.45 -0.36 Vitamin D levels; chr11:71439739 chr11:71448674~71452157:+ LIHC cis rs113835537 0.529 rs2305535 ENSG00000255517.5 CTD-3074O7.5 7.06 9.46e-12 9.57e-09 0.39 0.36 Airway imaging phenotypes; chr11:66504766 chr11:66473490~66480233:- LIHC cis rs1555322 0.53 rs2425049 ENSG00000126005.14 MMP24-AS1 -7.06 9.5e-12 9.61e-09 -0.52 -0.36 Attention deficit hyperactivity disorder; chr20:35286917 chr20:35216462~35278131:- LIHC cis rs4660456 0.956 rs4660457 ENSG00000237899.1 RP4-739H11.3 -7.06 9.56e-12 9.66e-09 -0.47 -0.36 Platelet count; chr1:40774121 chr1:40669089~40687588:- LIHC cis rs6061231 1 rs13043313 ENSG00000273619.1 RP5-908M14.9 -7.06 9.58e-12 9.68e-09 -0.31 -0.36 Colorectal cancer; chr20:62383213 chr20:62386303~62386970:- LIHC cis rs1577917 1 rs791856 ENSG00000234155.1 RP11-30P6.6 -7.06 9.63e-12 9.73e-09 -0.42 -0.36 Response to antipsychotic treatment; chr6:85972123 chr6:85387219~85390186:- LIHC cis rs138880 0.542 rs9616371 ENSG00000278869.1 CITF22-49E9.3 7.05 9.76e-12 9.86e-09 0.77 0.36 Schizophrenia; chr22:49912690 chr22:49933198~49934074:- LIHC cis rs7615952 0.932 rs13086087 ENSG00000171084.14 FAM86JP 7.05 9.81e-12 9.91e-09 0.66 0.36 Blood pressure (smoking interaction); chr3:125927438 chr3:125916620~125930024:+ LIHC cis rs1150668 0.796 rs213237 ENSG00000216901.1 AL022393.7 7.05 9.87e-12 9.96e-09 0.4 0.36 Pubertal anthropometrics; chr6:28356161 chr6:28176188~28176674:+ LIHC cis rs34779708 0.966 rs2505639 ENSG00000230534.5 RP11-297A16.2 -7.05 9.88e-12 9.98e-09 -0.44 -0.36 Inflammatory bowel disease;Crohn's disease; chr10:35185493 chr10:35098006~35127020:- LIHC cis rs6991838 0.584 rs7823840 ENSG00000200714.1 Y_RNA -7.05 9.96e-12 1e-08 -0.38 -0.36 Intelligence (multi-trait analysis); chr8:65606766 chr8:65592731~65592820:+ LIHC cis rs7044106 0.762 rs1158553 ENSG00000226752.6 PSMD5-AS1 -7.05 1e-11 1.01e-08 -0.36 -0.36 Hip circumference adjusted for BMI; chr9:120638696 chr9:120824828~120854385:+ LIHC cis rs1023500 0.596 rs133352 ENSG00000227370.1 RP4-669P10.19 -7.05 1e-11 1.01e-08 -0.42 -0.36 Schizophrenia; chr22:42038018 chr22:42132543~42132998:+ LIHC cis rs55665837 1 rs12804549 ENSG00000251991.1 RNU7-49P 7.05 1e-11 1.01e-08 0.36 0.36 Vitamin D levels; chr11:14416212 chr11:14478892~14478953:+ LIHC cis rs3823536 0.583 rs10156169 ENSG00000275106.1 RP11-309L24.10 -7.05 1.01e-11 1.02e-08 -0.45 -0.36 Sjögren's syndrome; chr7:129044517 chr7:128952527~128953316:- LIHC cis rs10875746 0.903 rs58952582 ENSG00000240399.1 RP1-228P16.1 -7.05 1.01e-11 1.02e-08 -0.39 -0.36 Longevity (90 years and older); chr12:48064665 chr12:48054813~48055591:- LIHC cis rs2032447 0.507 rs199748 ENSG00000242387.1 HIST1H2APS2 7.05 1.02e-11 1.02e-08 0.49 0.36 Intelligence (multi-trait analysis); chr6:25908817 chr6:25882026~25882395:- LIHC cis rs3096299 0.967 rs2965827 ENSG00000274627.1 RP11-104N10.2 -7.05 1.02e-11 1.03e-08 -0.37 -0.36 Multiple myeloma (IgH translocation); chr16:89390942 chr16:89516797~89522217:+ LIHC cis rs3823536 0.583 rs3778750 ENSG00000275106.1 RP11-309L24.10 -7.04 1.03e-11 1.04e-08 -0.44 -0.36 Sjögren's syndrome; chr7:128977035 chr7:128952527~128953316:- LIHC cis rs4728142 0.604 rs10954215 ENSG00000275106.1 RP11-309L24.10 -7.04 1.04e-11 1.05e-08 -0.44 -0.36 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129005459 chr7:128952527~128953316:- LIHC cis rs6085948 0.861 rs11907461 ENSG00000238102.1 RP11-19D2.1 -7.04 1.05e-11 1.05e-08 -0.67 -0.36 Interleukin-10 levels; chr20:7251766 chr20:7256580~7258214:- LIHC cis rs4660456 0.871 rs7549789 ENSG00000237899.1 RP4-739H11.3 -7.04 1.06e-11 1.07e-08 -0.46 -0.36 Platelet count; chr1:40759362 chr1:40669089~40687588:- LIHC cis rs3823536 0.583 rs10279821 ENSG00000275106.1 RP11-309L24.10 -7.04 1.07e-11 1.07e-08 -0.44 -0.36 Sjögren's syndrome; chr7:129043493 chr7:128952527~128953316:- LIHC cis rs992157 0.804 rs7559525 ENSG00000261338.2 RP11-378A13.1 -7.04 1.07e-11 1.08e-08 -0.36 -0.36 Colorectal cancer; chr2:218285584 chr2:218255319~218257366:+ LIHC cis rs992157 0.835 rs13005100 ENSG00000261338.2 RP11-378A13.1 -7.04 1.07e-11 1.08e-08 -0.36 -0.36 Colorectal cancer; chr2:218287044 chr2:218255319~218257366:+ LIHC cis rs992157 0.835 rs13031757 ENSG00000261338.2 RP11-378A13.1 -7.04 1.07e-11 1.08e-08 -0.36 -0.36 Colorectal cancer; chr2:218287203 chr2:218255319~218257366:+ LIHC cis rs11603023 0.804 rs527619 ENSG00000255239.1 AP002954.6 -7.04 1.07e-11 1.08e-08 -0.41 -0.36 Cholesterol, total; chr11:118692577 chr11:118688039~118690600:- LIHC cis rs34779708 0.931 rs2001893 ENSG00000230534.5 RP11-297A16.2 7.04 1.09e-11 1.09e-08 0.44 0.36 Inflammatory bowel disease;Crohn's disease; chr10:35011695 chr10:35098006~35127020:- LIHC cis rs2033711 0.87 rs11084545 ENSG00000269473.1 CTD-2619J13.19 7.03 1.09e-11 1.1e-08 0.41 0.36 Uric acid clearance; chr19:58440326 chr19:58440448~58445849:+ LIHC cis rs1023500 0.573 rs1807494 ENSG00000227370.1 RP4-669P10.19 7.03 1.09e-11 1.1e-08 0.41 0.36 Schizophrenia; chr22:42078134 chr22:42132543~42132998:+ LIHC cis rs1023500 0.573 rs133370 ENSG00000227370.1 RP4-669P10.19 -7.03 1.09e-11 1.1e-08 -0.41 -0.36 Schizophrenia; chr22:42069256 chr22:42132543~42132998:+ LIHC cis rs1185460 0.967 rs1784461 ENSG00000271751.1 RP11-110I1.14 -7.03 1.1e-11 1.1e-08 -0.48 -0.36 Coronary artery disease; chr11:119067274 chr11:119065263~119065677:- LIHC cis rs1185460 0.967 rs1784459 ENSG00000271751.1 RP11-110I1.14 -7.03 1.1e-11 1.1e-08 -0.48 -0.36 Coronary artery disease; chr11:119067677 chr11:119065263~119065677:- LIHC cis rs2033711 0.87 rs6510152 ENSG00000269473.1 CTD-2619J13.19 7.03 1.1e-11 1.11e-08 0.41 0.36 Uric acid clearance; chr19:58441952 chr19:58440448~58445849:+ LIHC cis rs2033711 0.902 rs4801589 ENSG00000269473.1 CTD-2619J13.19 7.03 1.11e-11 1.11e-08 0.41 0.36 Uric acid clearance; chr19:58442031 chr19:58440448~58445849:+ LIHC cis rs150992 0.821 rs326480 ENSG00000248489.1 CTD-2007H13.3 7.03 1.12e-11 1.12e-08 0.52 0.36 Body mass index; chr5:98949263 chr5:98929171~98995013:+ LIHC cis rs150992 0.861 rs428836 ENSG00000248489.1 CTD-2007H13.3 7.03 1.12e-11 1.12e-08 0.52 0.36 Body mass index; chr5:98951673 chr5:98929171~98995013:+ LIHC cis rs7104764 0.507 rs6598056 ENSG00000277290.1 RP11-326C3.16 7.03 1.13e-11 1.13e-08 0.38 0.36 Menarche (age at onset); chr11:252283 chr11:243099~243483:- LIHC cis rs7044106 0.648 rs2031369 ENSG00000226752.6 PSMD5-AS1 -7.03 1.13e-11 1.13e-08 -0.37 -0.36 Hip circumference adjusted for BMI; chr9:120598016 chr9:120824828~120854385:+ LIHC cis rs6061231 1 rs6061231 ENSG00000273619.1 RP5-908M14.9 -7.03 1.14e-11 1.14e-08 -0.31 -0.36 Colorectal cancer; chr20:62381861 chr20:62386303~62386970:- LIHC cis rs7615952 0.932 rs1976458 ENSG00000171084.14 FAM86JP 7.03 1.14e-11 1.14e-08 0.65 0.36 Blood pressure (smoking interaction); chr3:125928669 chr3:125916620~125930024:+ LIHC cis rs3096299 0.967 rs28689480 ENSG00000274627.1 RP11-104N10.2 7.03 1.14e-11 1.14e-08 0.37 0.36 Multiple myeloma (IgH translocation); chr16:89393685 chr16:89516797~89522217:+ LIHC cis rs992157 0.835 rs11677953 ENSG00000261338.2 RP11-378A13.1 -7.03 1.15e-11 1.16e-08 -0.37 -0.36 Colorectal cancer; chr2:218256940 chr2:218255319~218257366:+ LIHC cis rs1185460 0.565 rs584115 ENSG00000271751.1 RP11-110I1.14 7.02 1.17e-11 1.17e-08 0.46 0.36 Coronary artery disease; chr11:119068169 chr11:119065263~119065677:- LIHC cis rs150992 0.631 rs112047336 ENSG00000248489.1 CTD-2007H13.3 7.02 1.17e-11 1.17e-08 0.52 0.36 Body mass index; chr5:98990041 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs112042355 ENSG00000248489.1 CTD-2007H13.3 7.02 1.17e-11 1.17e-08 0.52 0.36 Body mass index; chr5:98990046 chr5:98929171~98995013:+ LIHC cis rs150992 0.587 rs75001231 ENSG00000248489.1 CTD-2007H13.3 7.02 1.17e-11 1.17e-08 0.52 0.36 Body mass index; chr5:98990085 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs2927647 ENSG00000248489.1 CTD-2007H13.3 7.02 1.17e-11 1.17e-08 0.52 0.36 Body mass index; chr5:98990161 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs77892628 ENSG00000248489.1 CTD-2007H13.3 7.02 1.17e-11 1.17e-08 0.52 0.36 Body mass index; chr5:98990624 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs77231989 ENSG00000248489.1 CTD-2007H13.3 7.02 1.17e-11 1.17e-08 0.52 0.36 Body mass index; chr5:98990650 chr5:98929171~98995013:+ LIHC cis rs150992 0.631 rs79191251 ENSG00000248489.1 CTD-2007H13.3 7.02 1.17e-11 1.17e-08 0.52 0.36 Body mass index; chr5:98990680 chr5:98929171~98995013:+ LIHC cis rs2117029 0.586 rs10783308 ENSG00000258017.1 RP11-386G11.10 -7.02 1.17e-11 1.17e-08 -0.43 -0.36 Intelligence (multi-trait analysis); chr12:49137675 chr12:49127782~49147869:+ LIHC cis rs6991838 0.584 rs1053088 ENSG00000200714.1 Y_RNA 7.02 1.17e-11 1.17e-08 0.38 0.36 Intelligence (multi-trait analysis); chr8:65603548 chr8:65592731~65592820:+ LIHC cis rs7615952 0.8 rs13086460 ENSG00000171084.14 FAM86JP 7.02 1.18e-11 1.18e-08 0.65 0.36 Blood pressure (smoking interaction); chr3:125927574 chr3:125916620~125930024:+ LIHC cis rs7615952 0.866 rs1976459 ENSG00000171084.14 FAM86JP 7.02 1.18e-11 1.18e-08 0.65 0.36 Blood pressure (smoking interaction); chr3:125928643 chr3:125916620~125930024:+ LIHC cis rs1577917 0.958 rs12190603 ENSG00000234155.1 RP11-30P6.6 7.02 1.18e-11 1.18e-08 0.42 0.35 Response to antipsychotic treatment; chr6:85766000 chr6:85387219~85390186:- LIHC cis rs7085104 0.572 rs284858 ENSG00000236937.2 PTGES3P4 -7.02 1.19e-11 1.19e-08 -0.44 -0.35 Immature fraction of reticulocytes;Schizophrenia; chr10:102814179 chr10:102845595~102845950:+ LIHC cis rs992157 0.735 rs13430006 ENSG00000261338.2 RP11-378A13.1 -7.02 1.19e-11 1.19e-08 -0.35 -0.35 Colorectal cancer; chr2:218248366 chr2:218255319~218257366:+ LIHC cis rs62229266 0.625 rs62230813 ENSG00000231106.2 LINC01436 7.02 1.19e-11 1.19e-08 0.39 0.35 Mitral valve prolapse; chr21:36031134 chr21:36005338~36007838:+ LIHC cis rs150992 0.861 rs151102 ENSG00000248489.1 CTD-2007H13.3 -7.02 1.19e-11 1.19e-08 -0.52 -0.35 Body mass index; chr5:98947626 chr5:98929171~98995013:+ LIHC cis rs6490294 0.904 rs60217649 ENSG00000226469.1 ADAM1B 7.02 1.2e-11 1.2e-08 0.46 0.35 Mean platelet volume; chr12:111973116 chr12:111927018~111929017:+ LIHC cis rs2117029 0.523 rs12227296 ENSG00000258017.1 RP11-386G11.10 -7.02 1.2e-11 1.2e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49136712 chr12:49127782~49147869:+ LIHC cis rs1577917 1 rs7766645 ENSG00000234155.1 RP11-30P6.6 7.02 1.21e-11 1.2e-08 0.42 0.35 Response to antipsychotic treatment; chr6:85912520 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs1911552 ENSG00000234155.1 RP11-30P6.6 7.02 1.21e-11 1.2e-08 0.42 0.35 Response to antipsychotic treatment; chr6:85928306 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs9647603 ENSG00000234155.1 RP11-30P6.6 7.02 1.21e-11 1.2e-08 0.42 0.35 Response to antipsychotic treatment; chr6:85929623 chr6:85387219~85390186:- LIHC cis rs73086581 1 rs73086597 ENSG00000229539.1 RP11-119B16.2 7.02 1.22e-11 1.21e-08 0.59 0.35 Response to antidepressants in depression; chr20:4002924 chr20:3888239~3888868:- LIHC cis rs11168854 0.656 rs7969963 ENSG00000258017.1 RP11-386G11.10 -7.02 1.22e-11 1.22e-08 -0.42 -0.35 Body mass index; chr12:49118222 chr12:49127782~49147869:+ LIHC cis rs6700559 0.804 rs11588318 ENSG00000260088.1 RP11-92G12.3 -7.02 1.23e-11 1.23e-08 -0.46 -0.35 Coronary artery disease; chr1:200669534 chr1:200669507~200694250:+ LIHC cis rs2117029 0.521 rs10875925 ENSG00000258017.1 RP11-386G11.10 -7.02 1.23e-11 1.23e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49142575 chr12:49127782~49147869:+ LIHC cis rs2117029 0.586 rs11168882 ENSG00000258017.1 RP11-386G11.10 -7.02 1.23e-11 1.23e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49143560 chr12:49127782~49147869:+ LIHC cis rs2117029 0.521 rs12227610 ENSG00000258017.1 RP11-386G11.10 -7.02 1.23e-11 1.23e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49146153 chr12:49127782~49147869:+ LIHC cis rs6142102 0.625 rs6142051 ENSG00000276073.1 RP5-1125A11.7 -7.02 1.23e-11 1.23e-08 -0.36 -0.35 Skin pigmentation; chr20:33945212 chr20:33985617~33988989:- LIHC cis rs7615952 0.932 rs3811679 ENSG00000171084.14 FAM86JP 7.02 1.24e-11 1.23e-08 0.64 0.35 Blood pressure (smoking interaction); chr3:125929440 chr3:125916620~125930024:+ LIHC cis rs10875746 0.855 rs12296244 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48047696 chr12:48054813~48055591:- LIHC cis rs10875746 0.855 rs12310999 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48053875 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs61918774 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48054351 chr12:48054813~48055591:- LIHC cis rs10875746 0.807 rs12297004 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48060037 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs10875735 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48070023 chr12:48054813~48055591:- LIHC cis rs10875746 0.855 rs17122620 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48070692 chr12:48054813~48055591:- LIHC cis rs10875746 0.859 rs4760680 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48072914 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs11168386 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48074194 chr12:48054813~48055591:- LIHC cis rs10875746 0.807 rs12313300 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48076934 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs12315625 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48078670 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs10875738 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48079956 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs12301339 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48081450 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs886588 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48083639 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs11168401 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48087736 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs12304476 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48088370 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs12306451 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48089458 chr12:48054813~48055591:- LIHC cis rs10875746 0.859 rs3782910 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48089724 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs989144 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48090190 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs61918806 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48090650 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs11168403 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48091175 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs10875740 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48095334 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs12313404 ENSG00000240399.1 RP1-228P16.1 -7.02 1.24e-11 1.23e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48098265 chr12:48054813~48055591:- LIHC cis rs2032447 0.507 rs199741 ENSG00000242387.1 HIST1H2APS2 7.01 1.24e-11 1.24e-08 0.51 0.35 Intelligence (multi-trait analysis); chr6:25931349 chr6:25882026~25882395:- LIHC cis rs2117029 0.586 rs2114846 ENSG00000258017.1 RP11-386G11.10 -7.01 1.25e-11 1.24e-08 -0.43 -0.35 Intelligence (multi-trait analysis); chr12:49154493 chr12:49127782~49147869:+ LIHC cis rs1577917 0.655 rs6454472 ENSG00000234155.1 RP11-30P6.6 -7.01 1.26e-11 1.25e-08 -0.42 -0.35 Response to antipsychotic treatment; chr6:85514335 chr6:85387219~85390186:- LIHC cis rs7085104 0.632 rs7096475 ENSG00000236937.2 PTGES3P4 7.01 1.27e-11 1.26e-08 0.41 0.35 Immature fraction of reticulocytes;Schizophrenia; chr10:102849919 chr10:102845595~102845950:+ LIHC cis rs1185460 0.565 rs540261 ENSG00000271751.1 RP11-110I1.14 7.01 1.27e-11 1.26e-08 0.47 0.35 Coronary artery disease; chr11:119076924 chr11:119065263~119065677:- LIHC cis rs6142102 0.602 rs11696338 ENSG00000276073.1 RP5-1125A11.7 -7.01 1.29e-11 1.28e-08 -0.37 -0.35 Skin pigmentation; chr20:34099805 chr20:33985617~33988989:- LIHC cis rs6142102 0.58 rs6142101 ENSG00000276073.1 RP5-1125A11.7 -7.01 1.29e-11 1.28e-08 -0.37 -0.35 Skin pigmentation; chr20:34110039 chr20:33985617~33988989:- LIHC cis rs7615952 0.932 rs13314869 ENSG00000171084.14 FAM86JP 7.01 1.3e-11 1.28e-08 0.66 0.35 Blood pressure (smoking interaction); chr3:125925826 chr3:125916620~125930024:+ LIHC cis rs17301013 0.507 rs1754354 ENSG00000227373.4 RP11-160H22.5 -7.01 1.3e-11 1.29e-08 -0.59 -0.35 Systemic lupus erythematosus; chr1:174817196 chr1:174115300~174160004:- LIHC cis rs3020736 0.5 rs1801311 ENSG00000227370.1 RP4-669P10.19 7.01 1.3e-11 1.29e-08 0.42 0.35 Autism spectrum disorder or schizophrenia; chr22:42090719 chr22:42132543~42132998:+ LIHC cis rs496547 0.654 rs688161 ENSG00000255239.1 AP002954.6 7.01 1.3e-11 1.29e-08 0.41 0.35 Hip minimal joint space width; chr11:118807001 chr11:118688039~118690600:- LIHC cis rs916888 0.773 rs199534 ENSG00000262881.1 RP11-669E14.4 -7.01 1.31e-11 1.29e-08 -0.56 -0.35 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45907670~45910779:- LIHC cis rs17301013 0.507 rs16846949 ENSG00000227373.4 RP11-160H22.5 7.01 1.31e-11 1.3e-08 0.59 0.35 Systemic lupus erythematosus; chr1:174402071 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs7413513 ENSG00000227373.4 RP11-160H22.5 7.01 1.31e-11 1.3e-08 0.59 0.35 Systemic lupus erythematosus; chr1:174403163 chr1:174115300~174160004:- LIHC cis rs992157 0.798 rs10193383 ENSG00000261338.2 RP11-378A13.1 7.01 1.31e-11 1.3e-08 0.36 0.35 Colorectal cancer; chr2:218292969 chr2:218255319~218257366:+ LIHC cis rs992157 0.798 rs10206064 ENSG00000261338.2 RP11-378A13.1 7.01 1.31e-11 1.3e-08 0.36 0.35 Colorectal cancer; chr2:218293236 chr2:218255319~218257366:+ LIHC cis rs992157 0.7 rs10165153 ENSG00000261338.2 RP11-378A13.1 7.01 1.31e-11 1.3e-08 0.36 0.35 Colorectal cancer; chr2:218294906 chr2:218255319~218257366:+ LIHC cis rs9660180 0.837 rs915292 ENSG00000268575.1 RP1-283E3.8 -7.01 1.31e-11 1.3e-08 -0.33 -0.35 Body mass index; chr1:1860718 chr1:1702736~1737688:- LIHC cis rs3823536 0.544 rs12532542 ENSG00000275106.1 RP11-309L24.10 -7.01 1.32e-11 1.3e-08 -0.44 -0.35 Sjögren's syndrome; chr7:129027358 chr7:128952527~128953316:- LIHC cis rs3823536 0.583 rs4731540 ENSG00000275106.1 RP11-309L24.10 -7.01 1.32e-11 1.3e-08 -0.44 -0.35 Sjögren's syndrome; chr7:129028196 chr7:128952527~128953316:- LIHC cis rs1023500 0.573 rs133377 ENSG00000227370.1 RP4-669P10.19 -7.01 1.32e-11 1.3e-08 -0.41 -0.35 Schizophrenia; chr22:42070946 chr22:42132543~42132998:+ LIHC cis rs6061231 1 rs11696991 ENSG00000273619.1 RP5-908M14.9 -7 1.32e-11 1.3e-08 -0.31 -0.35 Colorectal cancer; chr20:62384638 chr20:62386303~62386970:- LIHC cis rs10916248 0.511 rs10916489 ENSG00000232628.4 RP11-365O16.3 -7 1.33e-11 1.32e-08 -0.46 -0.35 QT interval (drug interaction); chr1:224215164 chr1:224208747~224213279:- LIHC cis rs6490294 0.904 rs11066111 ENSG00000226469.1 ADAM1B 7 1.33e-11 1.32e-08 0.46 0.35 Mean platelet volume; chr12:111977375 chr12:111927018~111929017:+ LIHC cis rs6490294 0.904 rs11066112 ENSG00000226469.1 ADAM1B 7 1.33e-11 1.32e-08 0.46 0.35 Mean platelet volume; chr12:111978782 chr12:111927018~111929017:+ LIHC cis rs17301013 0.507 rs4652652 ENSG00000227373.4 RP11-160H22.5 7 1.33e-11 1.32e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174596582 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs4651103 ENSG00000227373.4 RP11-160H22.5 7 1.33e-11 1.32e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174596750 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs72715262 ENSG00000227373.4 RP11-160H22.5 7 1.33e-11 1.32e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174607088 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs4615901 ENSG00000227373.4 RP11-160H22.5 7 1.33e-11 1.32e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174609432 chr1:174115300~174160004:- LIHC cis rs1023500 0.552 rs5758566 ENSG00000227370.1 RP4-669P10.19 -7 1.33e-11 1.32e-08 -0.42 -0.35 Schizophrenia; chr22:42058350 chr22:42132543~42132998:+ LIHC cis rs4728142 0.604 rs7783384 ENSG00000275106.1 RP11-309L24.10 -7 1.35e-11 1.34e-08 -0.43 -0.35 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129041243 chr7:128952527~128953316:- LIHC cis rs1577917 0.739 rs6922 ENSG00000234155.1 RP11-30P6.6 -7 1.36e-11 1.34e-08 -0.44 -0.35 Response to antipsychotic treatment; chr6:85495605 chr6:85387219~85390186:- LIHC cis rs2033711 0.87 rs7259841 ENSG00000269473.1 CTD-2619J13.19 7 1.37e-11 1.35e-08 0.41 0.35 Uric acid clearance; chr19:58439756 chr19:58440448~58445849:+ LIHC cis rs150992 0.504 rs152036 ENSG00000248489.1 CTD-2007H13.3 7 1.37e-11 1.36e-08 0.63 0.35 Body mass index; chr5:98981729 chr5:98929171~98995013:+ LIHC cis rs1023500 0.551 rs133355 ENSG00000227370.1 RP4-669P10.19 -7 1.38e-11 1.36e-08 -0.41 -0.35 Schizophrenia; chr22:42044281 chr22:42132543~42132998:+ LIHC cis rs2117029 0.521 rs7953169 ENSG00000258017.1 RP11-386G11.10 -7 1.38e-11 1.36e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49184389 chr12:49127782~49147869:+ LIHC cis rs6490294 0.571 rs7309841 ENSG00000226469.1 ADAM1B 7 1.39e-11 1.38e-08 0.49 0.35 Mean platelet volume; chr12:112127249 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs7294753 ENSG00000226469.1 ADAM1B 7 1.39e-11 1.38e-08 0.49 0.35 Mean platelet volume; chr12:112129646 chr12:111927018~111929017:+ LIHC cis rs7044106 0.664 rs7861679 ENSG00000226752.6 PSMD5-AS1 6.99 1.4e-11 1.38e-08 0.36 0.35 Hip circumference adjusted for BMI; chr9:120613311 chr9:120824828~120854385:+ LIHC cis rs3823536 0.583 rs11760442 ENSG00000275106.1 RP11-309L24.10 -6.99 1.4e-11 1.38e-08 -0.44 -0.35 Sjögren's syndrome; chr7:129016066 chr7:128952527~128953316:- LIHC cis rs3823536 0.583 rs3847099 ENSG00000275106.1 RP11-309L24.10 -6.99 1.4e-11 1.38e-08 -0.44 -0.35 Sjögren's syndrome; chr7:129016777 chr7:128952527~128953316:- LIHC cis rs3823536 0.604 rs3857852 ENSG00000275106.1 RP11-309L24.10 -6.99 1.4e-11 1.38e-08 -0.44 -0.35 Sjögren's syndrome; chr7:129017223 chr7:128952527~128953316:- LIHC cis rs916888 0.773 rs199447 ENSG00000262881.1 RP11-669E14.4 -6.99 1.41e-11 1.39e-08 -0.56 -0.35 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45907670~45910779:- LIHC cis rs1577917 1 rs7747824 ENSG00000234155.1 RP11-30P6.6 6.99 1.42e-11 1.4e-08 0.42 0.35 Response to antipsychotic treatment; chr6:85937388 chr6:85387219~85390186:- LIHC cis rs2117029 0.586 rs10783307 ENSG00000258017.1 RP11-386G11.10 -6.99 1.42e-11 1.4e-08 -0.43 -0.35 Intelligence (multi-trait analysis); chr12:49135822 chr12:49127782~49147869:+ LIHC cis rs2117029 0.554 rs12306494 ENSG00000258017.1 RP11-386G11.10 -6.99 1.42e-11 1.4e-08 -0.43 -0.35 Intelligence (multi-trait analysis); chr12:49136998 chr12:49127782~49147869:+ LIHC cis rs7615952 0.736 rs11921945 ENSG00000171084.14 FAM86JP 6.99 1.42e-11 1.4e-08 0.65 0.35 Blood pressure (smoking interaction); chr3:125924876 chr3:125916620~125930024:+ LIHC cis rs7617773 0.817 rs3731497 ENSG00000229759.1 MRPS18AP1 6.99 1.42e-11 1.4e-08 0.44 0.35 Coronary artery disease; chr3:48185063 chr3:48256350~48256938:- LIHC cis rs7174755 0.558 rs11071975 ENSG00000260657.2 RP11-315D16.4 -6.99 1.44e-11 1.41e-08 -0.58 -0.35 Major depressive disorder; chr15:68037106 chr15:68267792~68277994:- LIHC cis rs3823536 0.583 rs7789423 ENSG00000275106.1 RP11-309L24.10 -6.99 1.44e-11 1.41e-08 -0.44 -0.35 Sjögren's syndrome; chr7:128981150 chr7:128952527~128953316:- LIHC cis rs3823536 0.583 rs6948928 ENSG00000275106.1 RP11-309L24.10 -6.99 1.44e-11 1.41e-08 -0.44 -0.35 Sjögren's syndrome; chr7:128983043 chr7:128952527~128953316:- LIHC cis rs1023500 0.552 rs133368 ENSG00000227370.1 RP4-669P10.19 -6.99 1.45e-11 1.42e-08 -0.41 -0.35 Schizophrenia; chr22:42067685 chr22:42132543~42132998:+ LIHC cis rs739496 0.579 rs7975437 ENSG00000226469.1 ADAM1B 6.99 1.45e-11 1.43e-08 0.46 0.35 Platelet count; chr12:111939145 chr12:111927018~111929017:+ LIHC cis rs2739330 0.752 rs2330634 ENSG00000250470.1 AP000351.3 6.99 1.46e-11 1.43e-08 0.43 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908608 chr22:23976904~23977585:- LIHC cis rs992157 0.835 rs34353396 ENSG00000261338.2 RP11-378A13.1 -6.99 1.46e-11 1.43e-08 -0.36 -0.35 Colorectal cancer; chr2:218289259 chr2:218255319~218257366:+ LIHC cis rs2739330 0.929 rs5751775 ENSG00000099984.9 GSTT2 -6.99 1.46e-11 1.44e-08 -0.41 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23980123~23983911:+ LIHC cis rs11603023 0.874 rs483598 ENSG00000255239.1 AP002954.6 6.99 1.46e-11 1.44e-08 0.4 0.35 Cholesterol, total; chr11:118638950 chr11:118688039~118690600:- LIHC cis rs6991838 0.584 rs7463740 ENSG00000200714.1 Y_RNA -6.99 1.47e-11 1.45e-08 -0.38 -0.35 Intelligence (multi-trait analysis); chr8:65573950 chr8:65592731~65592820:+ LIHC cis rs150992 0.861 rs467728 ENSG00000248489.1 CTD-2007H13.3 6.99 1.48e-11 1.45e-08 0.52 0.35 Body mass index; chr5:98953863 chr5:98929171~98995013:+ LIHC cis rs6085948 0.861 rs17394617 ENSG00000238102.1 RP11-19D2.1 -6.99 1.48e-11 1.45e-08 -0.73 -0.35 Interleukin-10 levels; chr20:7249043 chr20:7256580~7258214:- LIHC cis rs9543976 0.614 rs4885308 ENSG00000261553.4 RP11-29G8.3 -6.99 1.48e-11 1.46e-08 -0.58 -0.35 Diabetic retinopathy; chr13:75532357 chr13:75549773~75807120:+ LIHC cis rs854624 1 rs854626 ENSG00000278690.1 RP11-104J23.2 6.99 1.49e-11 1.46e-08 0.49 0.35 Blood protein levels; chr17:36002489 chr17:36012504~36012891:+ LIHC cis rs916888 0.773 rs199533 ENSG00000262881.1 RP11-669E14.4 -6.99 1.49e-11 1.47e-08 -0.56 -0.35 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45907670~45910779:- LIHC cis rs2117029 0.586 rs11168884 ENSG00000258017.1 RP11-386G11.10 -6.98 1.5e-11 1.48e-08 -0.43 -0.35 Intelligence (multi-trait analysis); chr12:49146109 chr12:49127782~49147869:+ LIHC cis rs11168854 0.719 rs11168890 ENSG00000258017.1 RP11-386G11.10 -6.98 1.5e-11 1.48e-08 -0.43 -0.35 Body mass index; chr12:49150130 chr12:49127782~49147869:+ LIHC cis rs2117029 0.586 rs7954521 ENSG00000258017.1 RP11-386G11.10 -6.98 1.5e-11 1.48e-08 -0.43 -0.35 Intelligence (multi-trait analysis); chr12:49151857 chr12:49127782~49147869:+ LIHC cis rs2117029 0.553 rs2162644 ENSG00000258017.1 RP11-386G11.10 -6.98 1.5e-11 1.48e-08 -0.43 -0.35 Intelligence (multi-trait analysis); chr12:49154407 chr12:49127782~49147869:+ LIHC cis rs6163 0.727 rs284854 ENSG00000236937.2 PTGES3P4 -6.98 1.51e-11 1.48e-08 -0.43 -0.35 Waist circumference;Hip circumference; chr10:102814805 chr10:102845595~102845950:+ LIHC cis rs2919917 0.688 rs6993386 ENSG00000254352.1 RP11-578O24.2 -6.98 1.51e-11 1.49e-08 -0.41 -0.35 Lymphocyte counts; chr8:78741910 chr8:78723796~78724136:- LIHC cis rs992157 0.798 rs2382817 ENSG00000261338.2 RP11-378A13.1 6.98 1.52e-11 1.49e-08 0.36 0.35 Colorectal cancer; chr2:218286495 chr2:218255319~218257366:+ LIHC cis rs73086581 1 rs73086588 ENSG00000229539.1 RP11-119B16.2 6.98 1.52e-11 1.49e-08 0.59 0.35 Response to antidepressants in depression; chr20:4001577 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs73086595 ENSG00000229539.1 RP11-119B16.2 6.98 1.52e-11 1.49e-08 0.59 0.35 Response to antidepressants in depression; chr20:4002801 chr20:3888239~3888868:- LIHC cis rs12744310 0.887 rs6660265 ENSG00000235358.1 RP11-399E6.1 -6.98 1.53e-11 1.5e-08 -0.47 -0.35 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41353004 chr1:41242373~41284861:+ LIHC cis rs992157 0.56 rs1514132 ENSG00000261338.2 RP11-378A13.1 -6.98 1.54e-11 1.51e-08 -0.35 -0.35 Colorectal cancer; chr2:218219359 chr2:218255319~218257366:+ LIHC cis rs138857 0.515 rs9616375 ENSG00000278869.1 CITF22-49E9.3 6.98 1.55e-11 1.52e-08 0.76 0.35 Mean platelet volume; chr22:49916952 chr22:49933198~49934074:- LIHC cis rs6490294 0.904 rs2339908 ENSG00000226469.1 ADAM1B 6.98 1.56e-11 1.53e-08 0.46 0.35 Mean platelet volume; chr12:111980692 chr12:111927018~111929017:+ LIHC cis rs9543976 0.688 rs56084319 ENSG00000261553.4 RP11-29G8.3 -6.98 1.56e-11 1.53e-08 -0.57 -0.35 Diabetic retinopathy; chr13:75536543 chr13:75549773~75807120:+ LIHC cis rs9399137 0.507 rs4896128 ENSG00000232876.1 CTA-212D2.2 6.98 1.57e-11 1.54e-08 0.4 0.35 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135028618 chr6:135055033~135060550:+ LIHC cis rs73086581 1 rs34640283 ENSG00000229539.1 RP11-119B16.2 6.98 1.57e-11 1.54e-08 0.59 0.35 Response to antidepressants in depression; chr20:4008929 chr20:3888239~3888868:- LIHC cis rs3096299 0.933 rs747485 ENSG00000274627.1 RP11-104N10.2 6.98 1.57e-11 1.54e-08 0.37 0.35 Multiple myeloma (IgH translocation); chr16:89407686 chr16:89516797~89522217:+ LIHC cis rs748404 0.56 rs689797 ENSG00000205771.5 CATSPER2P1 -6.98 1.57e-11 1.54e-08 -0.43 -0.35 Lung cancer; chr15:43534359 chr15:43726918~43747094:- LIHC cis rs6490294 0.904 rs1016078 ENSG00000226469.1 ADAM1B 6.98 1.58e-11 1.55e-08 0.45 0.35 Mean platelet volume; chr12:111972273 chr12:111927018~111929017:+ LIHC cis rs992157 0.798 rs10932772 ENSG00000261338.2 RP11-378A13.1 6.98 1.58e-11 1.55e-08 0.36 0.35 Colorectal cancer; chr2:218312425 chr2:218255319~218257366:+ LIHC cis rs6142102 0.517 rs8119076 ENSG00000276073.1 RP5-1125A11.7 -6.98 1.59e-11 1.55e-08 -0.36 -0.35 Skin pigmentation; chr20:33937909 chr20:33985617~33988989:- LIHC cis rs2117029 0.554 rs2334931 ENSG00000258017.1 RP11-386G11.10 -6.97 1.59e-11 1.56e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49174130 chr12:49127782~49147869:+ LIHC cis rs2117029 0.586 rs10875929 ENSG00000258017.1 RP11-386G11.10 -6.97 1.59e-11 1.56e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49174605 chr12:49127782~49147869:+ LIHC cis rs2117029 0.554 rs2334930 ENSG00000258017.1 RP11-386G11.10 -6.97 1.59e-11 1.56e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49175528 chr12:49127782~49147869:+ LIHC cis rs2117029 0.586 rs11168904 ENSG00000258017.1 RP11-386G11.10 -6.97 1.59e-11 1.56e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49177234 chr12:49127782~49147869:+ LIHC cis rs2117029 0.586 rs10875931 ENSG00000258017.1 RP11-386G11.10 -6.97 1.59e-11 1.56e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49179513 chr12:49127782~49147869:+ LIHC cis rs2117029 0.554 rs7954530 ENSG00000258017.1 RP11-386G11.10 -6.97 1.59e-11 1.56e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49179742 chr12:49127782~49147869:+ LIHC cis rs2117029 0.586 rs7957998 ENSG00000258017.1 RP11-386G11.10 -6.97 1.59e-11 1.56e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49180240 chr12:49127782~49147869:+ LIHC cis rs7580658 0.864 rs10928761 ENSG00000236682.1 AC068282.3 -6.97 1.6e-11 1.57e-08 -0.45 -0.35 Protein C levels; chr2:127245671 chr2:127389130~127400580:+ LIHC cis rs6700559 0.683 rs4915450 ENSG00000260088.1 RP11-92G12.3 -6.97 1.61e-11 1.57e-08 -0.45 -0.35 Coronary artery disease; chr1:200672461 chr1:200669507~200694250:+ LIHC cis rs7615952 0.741 rs13314845 ENSG00000171084.14 FAM86JP 6.97 1.61e-11 1.57e-08 0.65 0.35 Blood pressure (smoking interaction); chr3:125925939 chr3:125916620~125930024:+ LIHC cis rs7615952 0.733 rs13314847 ENSG00000171084.14 FAM86JP 6.97 1.61e-11 1.57e-08 0.65 0.35 Blood pressure (smoking interaction); chr3:125925945 chr3:125916620~125930024:+ LIHC cis rs2739330 0.796 rs2154594 ENSG00000250470.1 AP000351.3 -6.97 1.61e-11 1.57e-08 -0.44 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23976904~23977585:- LIHC cis rs1023500 0.573 rs8135801 ENSG00000227370.1 RP4-669P10.19 6.97 1.61e-11 1.57e-08 0.41 0.35 Schizophrenia; chr22:42079564 chr22:42132543~42132998:+ LIHC cis rs748404 0.56 rs570933 ENSG00000205771.5 CATSPER2P1 -6.97 1.61e-11 1.58e-08 -0.42 -0.35 Lung cancer; chr15:43531832 chr15:43726918~43747094:- LIHC cis rs1061377 0.965 rs7690465 ENSG00000249207.1 RP11-360F5.1 -6.97 1.62e-11 1.58e-08 -0.36 -0.35 Uric acid levels; chr4:39147015 chr4:39112677~39126818:- LIHC cis rs2117029 0.553 rs11168909 ENSG00000258017.1 RP11-386G11.10 -6.97 1.62e-11 1.59e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49183092 chr12:49127782~49147869:+ LIHC cis rs10875746 0.855 rs11168369 ENSG00000240399.1 RP1-228P16.1 -6.97 1.62e-11 1.59e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48037385 chr12:48054813~48055591:- LIHC cis rs10875746 0.855 rs10875731 ENSG00000240399.1 RP1-228P16.1 -6.97 1.62e-11 1.59e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48038960 chr12:48054813~48055591:- LIHC cis rs62229266 0.625 rs2051395 ENSG00000231106.2 LINC01436 -6.97 1.63e-11 1.59e-08 -0.38 -0.35 Mitral valve prolapse; chr21:36058967 chr21:36005338~36007838:+ LIHC cis rs1577917 1 rs35385043 ENSG00000234155.1 RP11-30P6.6 6.97 1.63e-11 1.59e-08 0.42 0.35 Response to antipsychotic treatment; chr6:85938828 chr6:85387219~85390186:- LIHC cis rs17301013 0.507 rs7521109 ENSG00000227373.4 RP11-160H22.5 6.97 1.64e-11 1.6e-08 0.61 0.35 Systemic lupus erythematosus; chr1:174802629 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs72717616 ENSG00000227373.4 RP11-160H22.5 6.97 1.64e-11 1.6e-08 0.61 0.35 Systemic lupus erythematosus; chr1:174812711 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2183202 ENSG00000227373.4 RP11-160H22.5 6.97 1.64e-11 1.6e-08 0.61 0.35 Systemic lupus erythematosus; chr1:174824553 chr1:174115300~174160004:- LIHC cis rs11673344 0.562 rs256740 ENSG00000226686.6 LINC01535 -6.97 1.65e-11 1.61e-08 -0.43 -0.35 Obesity-related traits; chr19:37365451 chr19:37251912~37265535:+ LIHC cis rs7396835 0.741 rs7396851 ENSG00000236267.1 AP006216.5 -6.97 1.66e-11 1.62e-08 -0.4 -0.35 Quantitative traits; chr11:116813448 chr11:116813204~116814003:- LIHC cis rs6700559 1 rs4311922 ENSG00000260088.1 RP11-92G12.3 -6.97 1.66e-11 1.62e-08 -0.45 -0.35 Coronary artery disease; chr1:200674257 chr1:200669507~200694250:+ LIHC cis rs6700559 0.967 rs4447009 ENSG00000260088.1 RP11-92G12.3 -6.97 1.66e-11 1.62e-08 -0.45 -0.35 Coronary artery disease; chr1:200674278 chr1:200669507~200694250:+ LIHC cis rs6700559 1 rs4265457 ENSG00000260088.1 RP11-92G12.3 -6.97 1.66e-11 1.62e-08 -0.45 -0.35 Coronary artery disease; chr1:200674326 chr1:200669507~200694250:+ LIHC cis rs6700559 0.903 rs6661240 ENSG00000260088.1 RP11-92G12.3 -6.97 1.66e-11 1.62e-08 -0.45 -0.35 Coronary artery disease; chr1:200669719 chr1:200669507~200694250:+ LIHC cis rs6700559 0.967 rs6688581 ENSG00000260088.1 RP11-92G12.3 -6.97 1.66e-11 1.62e-08 -0.45 -0.35 Coronary artery disease; chr1:200670028 chr1:200669507~200694250:+ LIHC cis rs6700559 1 rs3806358 ENSG00000260088.1 RP11-92G12.3 -6.97 1.66e-11 1.62e-08 -0.45 -0.35 Coronary artery disease; chr1:200670555 chr1:200669507~200694250:+ LIHC cis rs3020736 0.5 rs2413669 ENSG00000227370.1 RP4-669P10.19 6.97 1.66e-11 1.62e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42111744 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs6002618 ENSG00000227370.1 RP4-669P10.19 6.97 1.66e-11 1.62e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42111855 chr22:42132543~42132998:+ LIHC cis rs1023500 0.551 rs61665536 ENSG00000227370.1 RP4-669P10.19 6.97 1.66e-11 1.62e-08 0.41 0.35 Schizophrenia; chr22:42116609 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs2413672 ENSG00000227370.1 RP4-669P10.19 6.97 1.66e-11 1.62e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42117257 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs6002623 ENSG00000227370.1 RP4-669P10.19 6.97 1.66e-11 1.62e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42117757 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs764481 ENSG00000227370.1 RP4-669P10.19 6.97 1.66e-11 1.62e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42122422 chr22:42132543~42132998:+ LIHC cis rs1891275 0.509 rs34190234 ENSG00000228701.1 TNKS2-AS1 -6.97 1.67e-11 1.62e-08 -0.43 -0.35 Intelligence (multi-trait analysis); chr10:91683317 chr10:91782839~91798291:- LIHC cis rs1891275 0.509 rs76313529 ENSG00000228701.1 TNKS2-AS1 -6.97 1.67e-11 1.62e-08 -0.43 -0.35 Intelligence (multi-trait analysis); chr10:91683319 chr10:91782839~91798291:- LIHC cis rs1062177 0.756 rs2964591 ENSG00000213433.5 RPLP1P6 6.97 1.67e-11 1.62e-08 0.4 0.35 Preschool internalizing problems; chr5:151737836 chr5:151765859~151766378:- LIHC cis rs6700559 1 rs10494821 ENSG00000260088.1 RP11-92G12.3 -6.97 1.67e-11 1.62e-08 -0.45 -0.35 Coronary artery disease; chr1:200673357 chr1:200669507~200694250:+ LIHC cis rs6700559 1 rs6667172 ENSG00000260088.1 RP11-92G12.3 -6.97 1.67e-11 1.62e-08 -0.45 -0.35 Coronary artery disease; chr1:200674710 chr1:200669507~200694250:+ LIHC cis rs6700559 1 rs7527499 ENSG00000260088.1 RP11-92G12.3 -6.97 1.67e-11 1.62e-08 -0.45 -0.35 Coronary artery disease; chr1:200676217 chr1:200669507~200694250:+ LIHC cis rs6700559 1 rs6427838 ENSG00000260088.1 RP11-92G12.3 -6.97 1.67e-11 1.62e-08 -0.45 -0.35 Coronary artery disease; chr1:200676519 chr1:200669507~200694250:+ LIHC cis rs7085104 0.572 rs284857 ENSG00000236937.2 PTGES3P4 -6.97 1.67e-11 1.63e-08 -0.43 -0.35 Immature fraction of reticulocytes;Schizophrenia; chr10:102814306 chr10:102845595~102845950:+ LIHC cis rs138880 0.58 rs28562884 ENSG00000278869.1 CITF22-49E9.3 6.96 1.71e-11 1.66e-08 0.76 0.35 Schizophrenia; chr22:49919221 chr22:49933198~49934074:- LIHC cis rs2455601 0.882 rs11042105 ENSG00000254860.4 TMEM9B-AS1 6.96 1.71e-11 1.66e-08 0.44 0.35 Schizophrenia; chr11:8872963 chr11:8964675~8977527:+ LIHC cis rs2739330 0.791 rs4822458 ENSG00000250470.1 AP000351.3 6.96 1.72e-11 1.67e-08 0.42 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23976904~23977585:- LIHC cis rs992157 0.767 rs2014615 ENSG00000261338.2 RP11-378A13.1 6.96 1.73e-11 1.68e-08 0.35 0.35 Colorectal cancer; chr2:218306468 chr2:218255319~218257366:+ LIHC cis rs992157 0.798 rs12053514 ENSG00000261338.2 RP11-378A13.1 -6.96 1.74e-11 1.69e-08 -0.36 -0.35 Colorectal cancer; chr2:218303242 chr2:218255319~218257366:+ LIHC cis rs9595066 0.627 rs4942287 ENSG00000227258.4 SMIM2-AS1 -6.96 1.74e-11 1.7e-08 -0.42 -0.35 Schizophrenia; chr13:44160560 chr13:44110451~44240517:+ LIHC cis rs9326248 0.911 rs11216284 ENSG00000280143.1 AP000892.6 6.96 1.74e-11 1.7e-08 0.4 0.35 Blood protein levels; chr11:117132344 chr11:117204967~117210292:+ LIHC cis rs9326248 0.813 rs7115562 ENSG00000280143.1 AP000892.6 6.96 1.75e-11 1.7e-08 0.41 0.35 Blood protein levels; chr11:117149754 chr11:117204967~117210292:+ LIHC cis rs4356975 0.899 rs7677996 ENSG00000249956.3 RP11-790I12.2 6.96 1.76e-11 1.71e-08 0.4 0.35 Obesity-related traits; chr4:69075473 chr4:69408836~69423164:+ LIHC cis rs6700559 1 rs12061346 ENSG00000260088.1 RP11-92G12.3 -6.96 1.77e-11 1.72e-08 -0.45 -0.35 Coronary artery disease; chr1:200677648 chr1:200669507~200694250:+ LIHC cis rs6700559 1 rs7533971 ENSG00000260088.1 RP11-92G12.3 -6.96 1.77e-11 1.72e-08 -0.45 -0.35 Coronary artery disease; chr1:200678243 chr1:200669507~200694250:+ LIHC cis rs6700559 1 rs10919998 ENSG00000260088.1 RP11-92G12.3 -6.96 1.77e-11 1.72e-08 -0.45 -0.35 Coronary artery disease; chr1:200679182 chr1:200669507~200694250:+ LIHC cis rs6700559 0.967 rs4072552 ENSG00000260088.1 RP11-92G12.3 -6.96 1.77e-11 1.72e-08 -0.45 -0.35 Coronary artery disease; chr1:200680003 chr1:200669507~200694250:+ LIHC cis rs17301013 0.507 rs3118990 ENSG00000227373.4 RP11-160H22.5 -6.96 1.77e-11 1.72e-08 -0.58 -0.35 Systemic lupus erythematosus; chr1:174818586 chr1:174115300~174160004:- LIHC cis rs4728142 0.604 rs6969930 ENSG00000275106.1 RP11-309L24.10 -6.96 1.77e-11 1.72e-08 -0.44 -0.35 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128990259 chr7:128952527~128953316:- LIHC cis rs4728142 0.604 rs4731536 ENSG00000275106.1 RP11-309L24.10 -6.96 1.77e-11 1.72e-08 -0.44 -0.35 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129000239 chr7:128952527~128953316:- LIHC cis rs2882667 0.858 rs11959851 ENSG00000253404.1 AC034243.1 6.96 1.77e-11 1.72e-08 0.47 0.35 Age-related hearing impairment (SNP x SNP interaction); chr5:139085716 chr5:138744434~138753309:- LIHC cis rs2117029 0.521 rs2114845 ENSG00000258017.1 RP11-386G11.10 -6.96 1.78e-11 1.73e-08 -0.41 -0.35 Intelligence (multi-trait analysis); chr12:49164750 chr12:49127782~49147869:+ LIHC cis rs1023500 0.551 rs133371 ENSG00000227370.1 RP4-669P10.19 -6.96 1.78e-11 1.73e-08 -0.41 -0.35 Schizophrenia; chr22:42069570 chr22:42132543~42132998:+ LIHC cis rs1023500 0.573 rs133374 ENSG00000227370.1 RP4-669P10.19 -6.96 1.78e-11 1.73e-08 -0.41 -0.35 Schizophrenia; chr22:42069937 chr22:42132543~42132998:+ LIHC cis rs1023500 0.573 rs133378 ENSG00000227370.1 RP4-669P10.19 -6.96 1.78e-11 1.73e-08 -0.41 -0.35 Schizophrenia; chr22:42071691 chr22:42132543~42132998:+ LIHC cis rs1023500 0.573 rs133382 ENSG00000227370.1 RP4-669P10.19 -6.96 1.78e-11 1.73e-08 -0.41 -0.35 Schizophrenia; chr22:42075770 chr22:42132543~42132998:+ LIHC cis rs4853012 0.887 rs77148265 ENSG00000257800.1 FNBP1P1 6.96 1.79e-11 1.73e-08 0.41 0.35 Gestational age at birth (maternal effect); chr2:74112392 chr2:74120680~74123218:+ LIHC cis rs17301013 0.531 rs1793318 ENSG00000227373.4 RP11-160H22.5 -6.96 1.79e-11 1.74e-08 -0.58 -0.35 Systemic lupus erythematosus; chr1:174824678 chr1:174115300~174160004:- LIHC cis rs9595066 0.627 rs4394973 ENSG00000227258.4 SMIM2-AS1 -6.96 1.79e-11 1.74e-08 -0.41 -0.35 Schizophrenia; chr13:44179173 chr13:44110451~44240517:+ LIHC cis rs6085948 0.817 rs17394645 ENSG00000238102.1 RP11-19D2.1 -6.96 1.8e-11 1.75e-08 -0.72 -0.35 Interleukin-10 levels; chr20:7250193 chr20:7256580~7258214:- LIHC cis rs6991838 0.557 rs67685675 ENSG00000200714.1 Y_RNA -6.95 1.81e-11 1.75e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65574371 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs66486920 ENSG00000200714.1 Y_RNA -6.95 1.81e-11 1.75e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65574458 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs60023200 ENSG00000200714.1 Y_RNA -6.95 1.81e-11 1.75e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65574547 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs61083799 ENSG00000200714.1 Y_RNA -6.95 1.81e-11 1.75e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65574868 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs4449837 ENSG00000200714.1 Y_RNA -6.95 1.81e-11 1.75e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65575917 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs57042777 ENSG00000200714.1 Y_RNA -6.95 1.81e-11 1.75e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65576855 chr8:65592731~65592820:+ LIHC cis rs6991838 0.557 rs67046768 ENSG00000200714.1 Y_RNA -6.95 1.81e-11 1.75e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65577486 chr8:65592731~65592820:+ LIHC cis rs17301013 0.507 rs16847335 ENSG00000227373.4 RP11-160H22.5 6.95 1.81e-11 1.76e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174682746 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs3862941 ENSG00000227373.4 RP11-160H22.5 6.95 1.81e-11 1.76e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174689418 chr1:174115300~174160004:- LIHC cis rs17301013 0.531 rs55688014 ENSG00000227373.4 RP11-160H22.5 6.95 1.81e-11 1.76e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174693321 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs55667039 ENSG00000227373.4 RP11-160H22.5 6.95 1.81e-11 1.76e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174698699 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs72715281 ENSG00000227373.4 RP11-160H22.5 6.95 1.81e-11 1.76e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174711533 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2861005 ENSG00000227373.4 RP11-160H22.5 6.95 1.81e-11 1.76e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174711832 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs2146564 ENSG00000227373.4 RP11-160H22.5 6.95 1.81e-11 1.76e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174716214 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs17842157 ENSG00000227373.4 RP11-160H22.5 6.95 1.81e-11 1.76e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174719442 chr1:174115300~174160004:- LIHC cis rs4660456 0.826 rs2744802 ENSG00000237899.1 RP4-739H11.3 6.95 1.81e-11 1.76e-08 0.47 0.35 Platelet count; chr1:40687577 chr1:40669089~40687588:- LIHC cis rs7044106 0.762 rs7849566 ENSG00000226752.6 PSMD5-AS1 -6.95 1.82e-11 1.76e-08 -0.36 -0.35 Hip circumference adjusted for BMI; chr9:120698491 chr9:120824828~120854385:+ LIHC cis rs1150668 0.796 rs9468372 ENSG00000216901.1 AL022393.7 6.95 1.82e-11 1.76e-08 0.4 0.35 Pubertal anthropometrics; chr6:28411584 chr6:28176188~28176674:+ LIHC cis rs4660456 0.913 rs2780952 ENSG00000237899.1 RP4-739H11.3 6.95 1.82e-11 1.76e-08 0.47 0.35 Platelet count; chr1:40689711 chr1:40669089~40687588:- LIHC cis rs1577917 0.629 rs6927475 ENSG00000234155.1 RP11-30P6.6 -6.95 1.82e-11 1.76e-08 -0.41 -0.35 Response to antipsychotic treatment; chr6:85497055 chr6:85387219~85390186:- LIHC cis rs2117029 0.586 rs11168874 ENSG00000258017.1 RP11-386G11.10 -6.95 1.83e-11 1.77e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49133753 chr12:49127782~49147869:+ LIHC cis rs138880 0.542 rs9616210 ENSG00000278869.1 CITF22-49E9.3 6.95 1.83e-11 1.78e-08 0.74 0.35 Schizophrenia; chr22:49923698 chr22:49933198~49934074:- LIHC cis rs17301013 0.507 rs72715260 ENSG00000227373.4 RP11-160H22.5 6.95 1.84e-11 1.78e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174604995 chr1:174115300~174160004:- LIHC cis rs916888 0.773 rs199535 ENSG00000262881.1 RP11-669E14.4 -6.95 1.84e-11 1.78e-08 -0.57 -0.35 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45907670~45910779:- LIHC cis rs6142102 0.517 rs6059577 ENSG00000276073.1 RP5-1125A11.7 -6.95 1.86e-11 1.8e-08 -0.36 -0.35 Skin pigmentation; chr20:33939880 chr20:33985617~33988989:- LIHC cis rs10875746 0.855 rs10875730 ENSG00000240399.1 RP1-228P16.1 -6.95 1.86e-11 1.8e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48034092 chr12:48054813~48055591:- LIHC cis rs2117029 0.521 rs11168885 ENSG00000258017.1 RP11-386G11.10 -6.95 1.87e-11 1.81e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49146204 chr12:49127782~49147869:+ LIHC cis rs17301013 0.507 rs41472847 ENSG00000227373.4 RP11-160H22.5 -6.95 1.87e-11 1.81e-08 -0.58 -0.35 Systemic lupus erythematosus; chr1:174475342 chr1:174115300~174160004:- LIHC cis rs4660456 0.913 rs34212676 ENSG00000237899.1 RP4-739H11.3 -6.95 1.88e-11 1.82e-08 -0.46 -0.35 Platelet count; chr1:40766522 chr1:40669089~40687588:- LIHC cis rs2260433 0.505 rs1298740 ENSG00000281655.1 RP11-817J15.3 6.95 1.88e-11 1.82e-08 0.4 0.35 Cleft palate; chr11:102682048 chr11:102681310~102683913:+ LIHC cis rs7615952 1 rs7615952 ENSG00000171084.14 FAM86JP -6.95 1.88e-11 1.82e-08 -0.62 -0.35 Blood pressure (smoking interaction); chr3:125930560 chr3:125916620~125930024:+ LIHC cis rs4728142 0.525 rs4731534 ENSG00000275106.1 RP11-309L24.10 -6.95 1.88e-11 1.82e-08 -0.44 -0.35 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128965540 chr7:128952527~128953316:- LIHC cis rs4660456 0.564 rs34320811 ENSG00000237899.1 RP4-739H11.3 -6.95 1.89e-11 1.83e-08 -0.46 -0.35 Platelet count; chr1:40763288 chr1:40669089~40687588:- LIHC cis rs992157 0.775 rs7559428 ENSG00000261338.2 RP11-378A13.1 -6.95 1.9e-11 1.83e-08 -0.36 -0.35 Colorectal cancer; chr2:218285515 chr2:218255319~218257366:+ LIHC cis rs11168854 0.651 rs12227770 ENSG00000258017.1 RP11-386G11.10 -6.95 1.9e-11 1.84e-08 -0.42 -0.35 Body mass index; chr12:49183065 chr12:49127782~49147869:+ LIHC cis rs2439831 0.702 rs8033995 ENSG00000205771.5 CATSPER2P1 -6.94 1.92e-11 1.85e-08 -0.51 -0.35 Lung cancer in ever smokers; chr15:43721311 chr15:43726918~43747094:- LIHC cis rs4660456 0.913 rs3767951 ENSG00000237899.1 RP4-739H11.3 -6.94 1.92e-11 1.86e-08 -0.46 -0.35 Platelet count; chr1:40767359 chr1:40669089~40687588:- LIHC cis rs1185460 0.967 rs1784302 ENSG00000271751.1 RP11-110I1.14 -6.94 1.92e-11 1.86e-08 -0.48 -0.35 Coronary artery disease; chr11:119070247 chr11:119065263~119065677:- LIHC cis rs6490294 0.904 rs12423126 ENSG00000226469.1 ADAM1B 6.94 1.92e-11 1.86e-08 0.46 0.35 Mean platelet volume; chr12:111991665 chr12:111927018~111929017:+ LIHC cis rs9326248 0.652 rs7128382 ENSG00000280143.1 AP000892.6 6.94 1.94e-11 1.87e-08 0.41 0.35 Blood protein levels; chr11:117152771 chr11:117204967~117210292:+ LIHC cis rs2033711 0.84 rs4801590 ENSG00000269473.1 CTD-2619J13.19 6.94 1.95e-11 1.89e-08 0.4 0.35 Uric acid clearance; chr19:58450446 chr19:58440448~58445849:+ LIHC cis rs67180937 0.645 rs1909197 ENSG00000272750.1 RP11-378J18.8 -6.94 1.96e-11 1.89e-08 -0.38 -0.35 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222645879 chr1:222658867~222661512:- LIHC cis rs10899021 0.92 rs76121309 ENSG00000279353.1 RP11-864N7.4 6.94 1.96e-11 1.9e-08 0.87 0.35 Response to metformin (IC50); chr11:74632876 chr11:74698231~74699658:- LIHC cis rs7617773 0.784 rs11715799 ENSG00000229759.1 MRPS18AP1 6.94 1.98e-11 1.92e-08 0.44 0.35 Coronary artery disease; chr3:48213730 chr3:48256350~48256938:- LIHC cis rs7617773 0.817 rs34728236 ENSG00000229759.1 MRPS18AP1 6.94 1.98e-11 1.92e-08 0.44 0.35 Coronary artery disease; chr3:48217618 chr3:48256350~48256938:- LIHC cis rs7617773 0.817 rs79310258 ENSG00000229759.1 MRPS18AP1 6.94 1.98e-11 1.92e-08 0.44 0.35 Coronary artery disease; chr3:48218177 chr3:48256350~48256938:- LIHC cis rs992157 0.687 rs35271699 ENSG00000261338.2 RP11-378A13.1 6.94 1.99e-11 1.92e-08 0.34 0.35 Colorectal cancer; chr2:218252759 chr2:218255319~218257366:+ LIHC cis rs3020736 0.5 rs8138678 ENSG00000227370.1 RP4-669P10.19 6.94 2.02e-11 1.95e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42120225 chr22:42132543~42132998:+ LIHC cis rs7617773 0.817 rs11709691 ENSG00000229759.1 MRPS18AP1 6.94 2.02e-11 1.95e-08 0.44 0.35 Coronary artery disease; chr3:48262179 chr3:48256350~48256938:- LIHC cis rs765787 0.53 rs4774542 ENSG00000259520.4 CTD-2651B20.3 -6.94 2.03e-11 1.95e-08 -0.42 -0.35 Uric acid levels; chr15:45233828 chr15:45251580~45279251:- LIHC cis rs1577917 0.629 rs9450285 ENSG00000234155.1 RP11-30P6.6 -6.94 2.04e-11 1.96e-08 -0.41 -0.35 Response to antipsychotic treatment; chr6:85498378 chr6:85387219~85390186:- LIHC cis rs34779708 0.966 rs11010135 ENSG00000230534.5 RP11-297A16.2 6.93 2.04e-11 1.96e-08 0.46 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35229135 chr10:35098006~35127020:- LIHC cis rs10875746 0.855 rs2269936 ENSG00000240399.1 RP1-228P16.1 -6.93 2.04e-11 1.97e-08 -0.38 -0.35 Longevity (90 years and older); chr12:48031452 chr12:48054813~48055591:- LIHC cis rs3020736 0.519 rs5996116 ENSG00000227370.1 RP4-669P10.19 6.93 2.05e-11 1.97e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42121488 chr22:42132543~42132998:+ LIHC cis rs11023332 0.641 rs4281505 ENSG00000251991.1 RNU7-49P 6.93 2.05e-11 1.97e-08 0.37 0.35 Vitamin D levels;Adiponectin levels; chr11:14779114 chr11:14478892~14478953:+ LIHC cis rs11023332 0.65 rs2122942 ENSG00000251991.1 RNU7-49P 6.93 2.05e-11 1.97e-08 0.37 0.35 Vitamin D levels;Adiponectin levels; chr11:14785829 chr11:14478892~14478953:+ LIHC cis rs6142102 0.602 rs68051854 ENSG00000276073.1 RP5-1125A11.7 -6.93 2.05e-11 1.97e-08 -0.37 -0.35 Skin pigmentation; chr20:34114150 chr20:33985617~33988989:- LIHC cis rs1185460 0.565 rs1043314 ENSG00000271751.1 RP11-110I1.14 6.93 2.05e-11 1.97e-08 0.45 0.35 Coronary artery disease; chr11:119045232 chr11:119065263~119065677:- LIHC cis rs11023332 0.617 rs1451678 ENSG00000251991.1 RNU7-49P 6.93 2.05e-11 1.98e-08 0.37 0.35 Vitamin D levels;Adiponectin levels; chr11:14760075 chr11:14478892~14478953:+ LIHC cis rs7615952 0.8 rs11915699 ENSG00000171084.14 FAM86JP 6.93 2.05e-11 1.98e-08 0.64 0.35 Blood pressure (smoking interaction); chr3:125913841 chr3:125916620~125930024:+ LIHC cis rs739496 0.579 rs16941759 ENSG00000226469.1 ADAM1B -6.93 2.05e-11 1.98e-08 -0.46 -0.35 Platelet count; chr12:111930117 chr12:111927018~111929017:+ LIHC cis rs11603023 0.874 rs577396 ENSG00000255239.1 AP002954.6 6.93 2.06e-11 1.98e-08 0.39 0.35 Cholesterol, total; chr11:118628753 chr11:118688039~118690600:- LIHC cis rs11603023 0.874 rs11216934 ENSG00000255239.1 AP002954.6 6.93 2.06e-11 1.98e-08 0.39 0.35 Cholesterol, total; chr11:118630742 chr11:118688039~118690600:- LIHC cis rs1577917 1 rs13199006 ENSG00000234155.1 RP11-30P6.6 6.93 2.07e-11 1.99e-08 0.41 0.35 Response to antipsychotic treatment; chr6:85898990 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs4707239 ENSG00000234155.1 RP11-30P6.6 6.93 2.07e-11 1.99e-08 0.41 0.35 Response to antipsychotic treatment; chr6:85900999 chr6:85387219~85390186:- LIHC cis rs4660456 0.913 rs2780953 ENSG00000237899.1 RP4-739H11.3 6.93 2.07e-11 1.99e-08 0.46 0.35 Platelet count; chr1:40694105 chr1:40669089~40687588:- LIHC cis rs992157 0.735 rs10932765 ENSG00000261338.2 RP11-378A13.1 6.93 2.07e-11 2e-08 0.35 0.35 Colorectal cancer; chr2:218234761 chr2:218255319~218257366:+ LIHC cis rs9549367 0.789 rs12584813 ENSG00000269125.1 RP11-98F14.11 -6.93 2.07e-11 2e-08 -0.43 -0.35 Platelet distribution width; chr13:113241129 chr13:113165002~113165183:- LIHC cis rs9595066 0.627 rs4432167 ENSG00000227258.4 SMIM2-AS1 -6.93 2.08e-11 2.01e-08 -0.42 -0.35 Schizophrenia; chr13:44178225 chr13:44110451~44240517:+ LIHC cis rs8062405 0.754 rs28410083 ENSG00000259982.1 CDC37P1 -6.93 2.09e-11 2.01e-08 -0.46 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620039 chr16:28700294~28701540:- LIHC cis rs8062405 0.789 rs1968751 ENSG00000259982.1 CDC37P1 -6.93 2.09e-11 2.01e-08 -0.46 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620438 chr16:28700294~28701540:- LIHC cis rs2929278 0.561 rs3099045 ENSG00000205771.5 CATSPER2P1 -6.93 2.09e-11 2.01e-08 -0.44 -0.35 Schizophrenia; chr15:43631757 chr15:43726918~43747094:- LIHC cis rs9660180 0.967 rs12034740 ENSG00000268575.1 RP1-283E3.8 -6.93 2.09e-11 2.02e-08 -0.33 -0.35 Body mass index; chr1:1797530 chr1:1702736~1737688:- LIHC cis rs17301013 0.507 rs11806996 ENSG00000227373.4 RP11-160H22.5 6.93 2.1e-11 2.02e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174654784 chr1:174115300~174160004:- LIHC cis rs10875746 0.951 rs2286021 ENSG00000240399.1 RP1-228P16.1 -6.93 2.11e-11 2.03e-08 -0.4 -0.35 Longevity (90 years and older); chr12:48134437 chr12:48054813~48055591:- LIHC cis rs2117029 0.521 rs1056875 ENSG00000258017.1 RP11-386G11.10 -6.93 2.11e-11 2.03e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49186397 chr12:49127782~49147869:+ LIHC cis rs7684253 1 rs7684253 ENSG00000269949.1 RP11-738E22.3 6.93 2.13e-11 2.05e-08 0.43 0.35 Migraine; chr4:56861145 chr4:56960927~56961373:- LIHC cis rs748404 0.56 rs2255663 ENSG00000205771.5 CATSPER2P1 6.93 2.14e-11 2.06e-08 0.42 0.35 Lung cancer; chr15:43536810 chr15:43726918~43747094:- LIHC cis rs17301013 0.556 rs1754353 ENSG00000227373.4 RP11-160H22.5 -6.93 2.15e-11 2.06e-08 -0.59 -0.35 Systemic lupus erythematosus; chr1:174822229 chr1:174115300~174160004:- LIHC cis rs10875746 0.904 rs11168422 ENSG00000240399.1 RP1-228P16.1 -6.93 2.15e-11 2.07e-08 -0.4 -0.35 Longevity (90 years and older); chr12:48125722 chr12:48054813~48055591:- LIHC cis rs73086581 0.687 rs73082600 ENSG00000229539.1 RP11-119B16.2 6.93 2.16e-11 2.07e-08 0.64 0.35 Response to antidepressants in depression; chr20:3863718 chr20:3888239~3888868:- LIHC cis rs17301013 0.507 rs10798324 ENSG00000227373.4 RP11-160H22.5 -6.92 2.17e-11 2.08e-08 -0.58 -0.35 Systemic lupus erythematosus; chr1:174787485 chr1:174115300~174160004:- LIHC cis rs739496 0.579 rs12423041 ENSG00000226469.1 ADAM1B 6.92 2.18e-11 2.09e-08 0.44 0.35 Platelet count; chr12:111887042 chr12:111927018~111929017:+ LIHC cis rs832187 0.629 rs7624403 ENSG00000280620.1 SCAANT1 6.92 2.18e-11 2.09e-08 0.43 0.35 Schizophrenia; chr3:63984401 chr3:63911518~63911772:- LIHC cis rs765787 0.53 rs2433229 ENSG00000259520.4 CTD-2651B20.3 6.92 2.18e-11 2.09e-08 0.41 0.35 Uric acid levels; chr15:45223037 chr15:45251580~45279251:- LIHC cis rs916888 0.821 rs70600 ENSG00000262881.1 RP11-669E14.4 -6.92 2.18e-11 2.09e-08 -0.56 -0.35 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45907670~45910779:- LIHC cis rs1150668 0.796 rs2531832 ENSG00000216901.1 AL022393.7 6.92 2.18e-11 2.1e-08 0.4 0.35 Pubertal anthropometrics; chr6:28421445 chr6:28176188~28176674:+ LIHC cis rs1577917 0.771 rs6454486 ENSG00000234155.1 RP11-30P6.6 -6.92 2.19e-11 2.1e-08 -0.42 -0.35 Response to antipsychotic treatment; chr6:85723869 chr6:85387219~85390186:- LIHC cis rs17301013 0.507 rs2060158 ENSG00000227373.4 RP11-160H22.5 6.92 2.19e-11 2.1e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174667379 chr1:174115300~174160004:- LIHC cis rs5760092 0.572 rs738806 ENSG00000272787.1 KB-226F1.2 -6.92 2.19e-11 2.1e-08 -0.5 -0.35 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23969211~23969873:+ LIHC cis rs6490294 0.571 rs7970397 ENSG00000226469.1 ADAM1B 6.92 2.19e-11 2.11e-08 0.49 0.35 Mean platelet volume; chr12:112142267 chr12:111927018~111929017:+ LIHC cis rs6991838 0.584 rs6993876 ENSG00000200714.1 Y_RNA 6.92 2.2e-11 2.11e-08 0.37 0.35 Intelligence (multi-trait analysis); chr8:65601240 chr8:65592731~65592820:+ LIHC cis rs7580658 0.929 rs4150477 ENSG00000236682.1 AC068282.3 6.92 2.2e-11 2.11e-08 0.44 0.35 Protein C levels; chr2:127274970 chr2:127389130~127400580:+ LIHC cis rs7580658 0.891 rs55998967 ENSG00000236682.1 AC068282.3 -6.92 2.2e-11 2.11e-08 -0.44 -0.35 Protein C levels; chr2:127291098 chr2:127389130~127400580:+ LIHC cis rs11168854 0.656 rs7969967 ENSG00000258017.1 RP11-386G11.10 6.92 2.2e-11 2.11e-08 0.42 0.35 Body mass index; chr12:49118234 chr12:49127782~49147869:+ LIHC cis rs7580658 0.891 rs3768866 ENSG00000236682.1 AC068282.3 -6.92 2.2e-11 2.11e-08 -0.44 -0.35 Protein C levels; chr2:127287839 chr2:127389130~127400580:+ LIHC cis rs2117029 0.586 rs1874908 ENSG00000258017.1 RP11-386G11.10 -6.92 2.23e-11 2.13e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49190247 chr12:49127782~49147869:+ LIHC cis rs9918079 0.56 rs4698402 ENSG00000273133.1 RP11-799M12.2 -6.92 2.24e-11 2.15e-08 -0.45 -0.35 Obesity-related traits; chr4:15628180 chr4:15563698~15564253:- LIHC cis rs765787 0.53 rs4774550 ENSG00000259520.4 CTD-2651B20.3 6.92 2.24e-11 2.15e-08 0.41 0.35 Uric acid levels; chr15:45250114 chr15:45251580~45279251:- LIHC cis rs4660456 0.913 rs16827552 ENSG00000237899.1 RP4-739H11.3 -6.92 2.25e-11 2.15e-08 -0.45 -0.35 Platelet count; chr1:40758336 chr1:40669089~40687588:- LIHC cis rs7617773 0.817 rs13100815 ENSG00000229759.1 MRPS18AP1 6.92 2.25e-11 2.16e-08 0.44 0.35 Coronary artery disease; chr3:48245959 chr3:48256350~48256938:- LIHC cis rs7615952 0.673 rs9821905 ENSG00000171084.14 FAM86JP -6.92 2.26e-11 2.16e-08 -0.75 -0.35 Blood pressure (smoking interaction); chr3:125902007 chr3:125916620~125930024:+ LIHC cis rs1061377 1 rs12646251 ENSG00000249207.1 RP11-360F5.1 -6.92 2.27e-11 2.18e-08 -0.36 -0.35 Uric acid levels; chr4:39132751 chr4:39112677~39126818:- LIHC cis rs3823536 0.583 rs1072767 ENSG00000275106.1 RP11-309L24.10 -6.92 2.28e-11 2.18e-08 -0.44 -0.35 Sjögren's syndrome; chr7:129033151 chr7:128952527~128953316:- LIHC cis rs3823536 0.583 rs3807302 ENSG00000275106.1 RP11-309L24.10 -6.92 2.28e-11 2.19e-08 -0.43 -0.35 Sjögren's syndrome; chr7:129004803 chr7:128952527~128953316:- LIHC cis rs6490294 0.528 rs79761579 ENSG00000226469.1 ADAM1B 6.92 2.29e-11 2.19e-08 0.53 0.35 Mean platelet volume; chr12:112021081 chr12:111927018~111929017:+ LIHC cis rs7615952 0.673 rs34209763 ENSG00000171084.14 FAM86JP 6.92 2.29e-11 2.19e-08 0.71 0.35 Blood pressure (smoking interaction); chr3:125880752 chr3:125916620~125930024:+ LIHC cis rs7615952 0.8 rs35390120 ENSG00000171084.14 FAM86JP 6.92 2.29e-11 2.19e-08 0.71 0.35 Blood pressure (smoking interaction); chr3:125880966 chr3:125916620~125930024:+ LIHC cis rs7615952 0.611 rs35321002 ENSG00000171084.14 FAM86JP 6.92 2.29e-11 2.19e-08 0.71 0.35 Blood pressure (smoking interaction); chr3:125893222 chr3:125916620~125930024:+ LIHC cis rs7580658 0.963 rs867304 ENSG00000236682.1 AC068282.3 -6.92 2.3e-11 2.2e-08 -0.45 -0.35 Protein C levels; chr2:127320912 chr2:127389130~127400580:+ LIHC cis rs7580658 0.963 rs12622436 ENSG00000236682.1 AC068282.3 -6.92 2.3e-11 2.2e-08 -0.45 -0.35 Protein C levels; chr2:127324106 chr2:127389130~127400580:+ LIHC cis rs2929278 0.617 rs533143 ENSG00000205771.5 CATSPER2P1 -6.91 2.31e-11 2.21e-08 -0.44 -0.35 Schizophrenia; chr15:43896656 chr15:43726918~43747094:- LIHC cis rs7396835 0.866 rs7927820 ENSG00000236267.1 AP006216.5 6.91 2.32e-11 2.22e-08 0.41 0.35 Quantitative traits; chr11:116811440 chr11:116813204~116814003:- LIHC cis rs6991838 0.557 rs4737222 ENSG00000200714.1 Y_RNA -6.91 2.32e-11 2.22e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65587878 chr8:65592731~65592820:+ LIHC cis rs7617773 0.817 rs17647717 ENSG00000229759.1 MRPS18AP1 6.91 2.33e-11 2.23e-08 0.45 0.35 Coronary artery disease; chr3:48263966 chr3:48256350~48256938:- LIHC cis rs8028182 0.583 rs9944207 ENSG00000260269.4 CTD-2323K18.1 -6.91 2.35e-11 2.25e-08 -0.46 -0.35 Sudden cardiac arrest; chr15:75620548 chr15:75527150~75601205:- LIHC cis rs7615952 0.673 rs35001498 ENSG00000171084.14 FAM86JP 6.91 2.36e-11 2.26e-08 0.73 0.35 Blood pressure (smoking interaction); chr3:125909801 chr3:125916620~125930024:+ LIHC cis rs1577917 0.655 rs2758849 ENSG00000234155.1 RP11-30P6.6 6.91 2.37e-11 2.26e-08 0.41 0.35 Response to antipsychotic treatment; chr6:85634578 chr6:85387219~85390186:- LIHC cis rs494459 0.536 rs11217063 ENSG00000255239.1 AP002954.6 6.91 2.37e-11 2.27e-08 0.4 0.35 Height; chr11:118855233 chr11:118688039~118690600:- LIHC cis rs494459 0.536 rs11217065 ENSG00000255239.1 AP002954.6 6.91 2.37e-11 2.27e-08 0.4 0.35 Height; chr11:118855938 chr11:118688039~118690600:- LIHC cis rs1577917 0.655 rs2758848 ENSG00000234155.1 RP11-30P6.6 6.91 2.38e-11 2.27e-08 0.41 0.35 Response to antipsychotic treatment; chr6:85637887 chr6:85387219~85390186:- LIHC cis rs4423214 0.592 rs10898186 ENSG00000254682.1 RP11-660L16.2 -6.91 2.39e-11 2.28e-08 -0.47 -0.35 Vitamin D levels; chr11:71477754 chr11:71448674~71452157:+ LIHC cis rs11603023 0.874 rs613243 ENSG00000255239.1 AP002954.6 6.91 2.39e-11 2.28e-08 0.39 0.35 Cholesterol, total; chr11:118643304 chr11:118688039~118690600:- LIHC cis rs17301013 0.507 rs72715294 ENSG00000227373.4 RP11-160H22.5 6.91 2.39e-11 2.28e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174754922 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs1813136 ENSG00000227373.4 RP11-160H22.5 6.91 2.39e-11 2.28e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174756656 chr1:174115300~174160004:- LIHC cis rs34779708 0.832 rs12764283 ENSG00000230534.5 RP11-297A16.2 6.91 2.4e-11 2.29e-08 0.45 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35241532 chr10:35098006~35127020:- LIHC cis rs7615952 0.673 rs115942855 ENSG00000171084.14 FAM86JP 6.91 2.4e-11 2.29e-08 0.78 0.35 Blood pressure (smoking interaction); chr3:125883117 chr3:125916620~125930024:+ LIHC cis rs1577917 0.655 rs2842605 ENSG00000234155.1 RP11-30P6.6 6.91 2.41e-11 2.3e-08 0.41 0.35 Response to antipsychotic treatment; chr6:85625432 chr6:85387219~85390186:- LIHC cis rs7617773 0.817 rs17786132 ENSG00000229759.1 MRPS18AP1 6.91 2.41e-11 2.3e-08 0.43 0.35 Coronary artery disease; chr3:48207930 chr3:48256350~48256938:- LIHC cis rs7617773 0.817 rs35456569 ENSG00000229759.1 MRPS18AP1 6.91 2.41e-11 2.3e-08 0.43 0.35 Coronary artery disease; chr3:48209409 chr3:48256350~48256938:- LIHC cis rs2487032 0.573 rs2164560 ENSG00000226334.1 RP11-217B7.2 -6.91 2.41e-11 2.3e-08 -0.48 -0.35 Glaucoma (high intraocular pressure); chr9:104945072 chr9:104927553~104928892:+ LIHC cis rs3823536 0.604 rs13221560 ENSG00000275106.1 RP11-309L24.10 -6.91 2.42e-11 2.31e-08 -0.43 -0.35 Sjögren's syndrome; chr7:129023121 chr7:128952527~128953316:- LIHC cis rs832187 0.64 rs704367 ENSG00000280620.1 SCAANT1 -6.91 2.43e-11 2.32e-08 -0.43 -0.35 Schizophrenia; chr3:63883101 chr3:63911518~63911772:- LIHC cis rs1062177 1 rs62394155 ENSG00000213433.5 RPLP1P6 -6.91 2.45e-11 2.33e-08 -0.41 -0.35 Preschool internalizing problems; chr5:151868508 chr5:151765859~151766378:- LIHC cis rs1062177 1 rs12653926 ENSG00000213433.5 RPLP1P6 -6.91 2.45e-11 2.33e-08 -0.41 -0.35 Preschool internalizing problems; chr5:151870687 chr5:151765859~151766378:- LIHC cis rs7617773 0.746 rs6796343 ENSG00000229759.1 MRPS18AP1 6.91 2.45e-11 2.33e-08 0.44 0.35 Coronary artery disease; chr3:48240531 chr3:48256350~48256938:- LIHC cis rs7615952 0.8 rs2062773 ENSG00000171084.14 FAM86JP 6.91 2.45e-11 2.33e-08 0.63 0.35 Blood pressure (smoking interaction); chr3:125920805 chr3:125916620~125930024:+ LIHC cis rs7615952 0.799 rs13315434 ENSG00000171084.14 FAM86JP 6.91 2.45e-11 2.33e-08 0.63 0.35 Blood pressure (smoking interaction); chr3:125922551 chr3:125916620~125930024:+ LIHC cis rs2836950 0.545 rs11700813 ENSG00000255568.3 BRWD1-AS2 -6.9 2.47e-11 2.35e-08 -0.29 -0.35 Menarche (age at onset); chr21:39145543 chr21:39313935~39314962:+ LIHC cis rs992157 0.731 rs1399132 ENSG00000261338.2 RP11-378A13.1 6.9 2.48e-11 2.36e-08 0.36 0.35 Colorectal cancer; chr2:218295047 chr2:218255319~218257366:+ LIHC cis rs992157 0.796 rs55680399 ENSG00000261338.2 RP11-378A13.1 6.9 2.48e-11 2.36e-08 0.36 0.35 Colorectal cancer; chr2:218295898 chr2:218255319~218257366:+ LIHC cis rs3823536 0.583 rs921403 ENSG00000275106.1 RP11-309L24.10 -6.9 2.48e-11 2.36e-08 -0.43 -0.35 Sjögren's syndrome; chr7:129036670 chr7:128952527~128953316:- LIHC cis rs3823536 0.583 rs6973975 ENSG00000275106.1 RP11-309L24.10 -6.9 2.49e-11 2.37e-08 -0.43 -0.35 Sjögren's syndrome; chr7:129035495 chr7:128952527~128953316:- LIHC cis rs2117029 0.556 rs1057725 ENSG00000258017.1 RP11-386G11.10 -6.9 2.52e-11 2.39e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49128795 chr12:49127782~49147869:+ LIHC cis rs62355901 0.505 rs56984944 ENSG00000271828.1 CTD-2310F14.1 6.9 2.53e-11 2.4e-08 0.56 0.35 Breast cancer; chr5:56927671 chr5:56927874~56929573:+ LIHC cis rs138880 0.542 rs9616215 ENSG00000278869.1 CITF22-49E9.3 6.9 2.56e-11 2.43e-08 0.74 0.35 Schizophrenia; chr22:49925186 chr22:49933198~49934074:- LIHC cis rs11603023 0.967 rs4245184 ENSG00000255239.1 AP002954.6 -6.9 2.57e-11 2.44e-08 -0.39 -0.35 Cholesterol, total; chr11:118639844 chr11:118688039~118690600:- LIHC cis rs4728142 0.584 rs6965542 ENSG00000275106.1 RP11-309L24.10 -6.9 2.57e-11 2.44e-08 -0.43 -0.35 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129015864 chr7:128952527~128953316:- LIHC cis rs34779708 0.931 rs2505631 ENSG00000230534.5 RP11-297A16.2 -6.9 2.57e-11 2.44e-08 -0.43 -0.35 Inflammatory bowel disease;Crohn's disease; chr10:35079457 chr10:35098006~35127020:- LIHC cis rs34779708 0.966 rs1213392 ENSG00000230534.5 RP11-297A16.2 6.9 2.57e-11 2.44e-08 0.43 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35141357 chr10:35098006~35127020:- LIHC cis rs9326248 0.861 rs7120309 ENSG00000280143.1 AP000892.6 6.9 2.58e-11 2.45e-08 0.4 0.35 Blood protein levels; chr11:117172100 chr11:117204967~117210292:+ LIHC cis rs9326248 0.861 rs7120449 ENSG00000280143.1 AP000892.6 6.9 2.58e-11 2.45e-08 0.4 0.35 Blood protein levels; chr11:117172183 chr11:117204967~117210292:+ LIHC cis rs4660456 0.913 rs556875 ENSG00000237899.1 RP4-739H11.3 -6.9 2.58e-11 2.45e-08 -0.46 -0.35 Platelet count; chr1:40688571 chr1:40669089~40687588:- LIHC cis rs7131987 0.718 rs7976961 ENSG00000257176.2 RP11-996F15.2 -6.9 2.58e-11 2.45e-08 -0.4 -0.35 QT interval; chr12:29310155 chr12:29280418~29317848:- LIHC cis rs17301013 0.507 rs4652797 ENSG00000227373.4 RP11-160H22.5 6.9 2.58e-11 2.45e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174791236 chr1:174115300~174160004:- LIHC cis rs9918079 0.542 rs6414765 ENSG00000273133.1 RP11-799M12.2 -6.9 2.59e-11 2.45e-08 -0.45 -0.35 Obesity-related traits; chr4:15624870 chr4:15563698~15564253:- LIHC cis rs6991838 0.584 rs10089708 ENSG00000200714.1 Y_RNA 6.9 2.6e-11 2.46e-08 0.37 0.35 Intelligence (multi-trait analysis); chr8:65642927 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs6991731 ENSG00000200714.1 Y_RNA 6.9 2.6e-11 2.46e-08 0.37 0.35 Intelligence (multi-trait analysis); chr8:65643232 chr8:65592731~65592820:+ LIHC cis rs7615952 0.604 rs9837847 ENSG00000171084.14 FAM86JP 6.89 2.61e-11 2.48e-08 0.73 0.35 Blood pressure (smoking interaction); chr3:125905076 chr3:125916620~125930024:+ LIHC cis rs11023332 0.617 rs1879888 ENSG00000251991.1 RNU7-49P 6.89 2.62e-11 2.48e-08 0.36 0.35 Vitamin D levels;Adiponectin levels; chr11:14657701 chr11:14478892~14478953:+ LIHC cis rs9549367 0.789 rs12866090 ENSG00000269125.1 RP11-98F14.11 -6.89 2.63e-11 2.49e-08 -0.43 -0.35 Platelet distribution width; chr13:113215096 chr13:113165002~113165183:- LIHC cis rs1023500 0.573 rs2269524 ENSG00000227370.1 RP4-669P10.19 6.89 2.63e-11 2.49e-08 0.41 0.35 Schizophrenia; chr22:42079699 chr22:42132543~42132998:+ LIHC cis rs62229266 0.557 rs4817760 ENSG00000231106.2 LINC01436 6.89 2.66e-11 2.52e-08 0.4 0.35 Mitral valve prolapse; chr21:36023003 chr21:36005338~36007838:+ LIHC cis rs2117029 0.521 rs58336603 ENSG00000258017.1 RP11-386G11.10 -6.89 2.67e-11 2.53e-08 -0.41 -0.35 Intelligence (multi-trait analysis); chr12:49163105 chr12:49127782~49147869:+ LIHC cis rs2117029 0.553 rs1991427 ENSG00000258017.1 RP11-386G11.10 -6.89 2.67e-11 2.53e-08 -0.41 -0.35 Intelligence (multi-trait analysis); chr12:49164175 chr12:49127782~49147869:+ LIHC cis rs2117029 0.521 rs6580702 ENSG00000258017.1 RP11-386G11.10 -6.89 2.67e-11 2.53e-08 -0.41 -0.35 Intelligence (multi-trait analysis); chr12:49169483 chr12:49127782~49147869:+ LIHC cis rs17301013 0.507 rs17842156 ENSG00000227373.4 RP11-160H22.5 6.89 2.68e-11 2.53e-08 0.59 0.35 Systemic lupus erythematosus; chr1:174715050 chr1:174115300~174160004:- LIHC cis rs2117029 0.619 rs9325145 ENSG00000258017.1 RP11-386G11.10 -6.89 2.68e-11 2.54e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49132101 chr12:49127782~49147869:+ LIHC cis rs2739330 0.828 rs2186366 ENSG00000250470.1 AP000351.3 -6.89 2.69e-11 2.54e-08 -0.43 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23976904~23977585:- LIHC cis rs1577917 0.666 rs6454471 ENSG00000234155.1 RP11-30P6.6 -6.89 2.69e-11 2.54e-08 -0.43 -0.35 Response to antipsychotic treatment; chr6:85504738 chr6:85387219~85390186:- LIHC cis rs1577917 0.665 rs4304137 ENSG00000234155.1 RP11-30P6.6 -6.89 2.69e-11 2.54e-08 -0.43 -0.35 Response to antipsychotic treatment; chr6:85507730 chr6:85387219~85390186:- LIHC cis rs3096299 0.559 rs9931073 ENSG00000274627.1 RP11-104N10.2 6.89 2.72e-11 2.57e-08 0.35 0.35 Multiple myeloma (IgH translocation); chr16:89502105 chr16:89516797~89522217:+ LIHC cis rs1939012 0.967 rs1940475 ENSG00000281655.1 RP11-817J15.3 -6.89 2.73e-11 2.58e-08 -0.41 -0.35 Epilepsy; chr11:102722517 chr11:102681310~102683913:+ LIHC cis rs1577917 0.876 rs4618490 ENSG00000234155.1 RP11-30P6.6 6.89 2.73e-11 2.58e-08 0.42 0.35 Response to antipsychotic treatment; chr6:85808685 chr6:85387219~85390186:- LIHC cis rs6991838 0.584 rs4388482 ENSG00000200714.1 Y_RNA -6.89 2.74e-11 2.59e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65583968 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs4637885 ENSG00000200714.1 Y_RNA -6.89 2.74e-11 2.59e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65584849 chr8:65592731~65592820:+ LIHC cis rs6991838 0.556 rs7846527 ENSG00000200714.1 Y_RNA -6.89 2.74e-11 2.59e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65586522 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs4320587 ENSG00000200714.1 Y_RNA -6.89 2.74e-11 2.59e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65586991 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs35941313 ENSG00000200714.1 Y_RNA -6.89 2.74e-11 2.59e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65587498 chr8:65592731~65592820:+ LIHC cis rs3096299 0.967 rs16965692 ENSG00000274627.1 RP11-104N10.2 6.89 2.75e-11 2.59e-08 0.37 0.35 Multiple myeloma (IgH translocation); chr16:89405074 chr16:89516797~89522217:+ LIHC cis rs4660456 0.913 rs2361650 ENSG00000237899.1 RP4-739H11.3 -6.89 2.75e-11 2.6e-08 -0.46 -0.35 Platelet count; chr1:40764678 chr1:40669089~40687588:- LIHC cis rs7131987 0.65 rs11050208 ENSG00000257176.2 RP11-996F15.2 -6.89 2.75e-11 2.6e-08 -0.42 -0.35 QT interval; chr12:29357436 chr12:29280418~29317848:- LIHC cis rs765787 0.53 rs1648285 ENSG00000259520.4 CTD-2651B20.3 6.88 2.79e-11 2.63e-08 0.41 0.35 Uric acid levels; chr15:45225307 chr15:45251580~45279251:- LIHC cis rs17301013 0.507 rs72717618 ENSG00000227373.4 RP11-160H22.5 6.88 2.79e-11 2.63e-08 0.61 0.35 Systemic lupus erythematosus; chr1:174816839 chr1:174115300~174160004:- LIHC cis rs7615952 0.673 rs35955861 ENSG00000171084.14 FAM86JP 6.88 2.79e-11 2.63e-08 0.73 0.35 Blood pressure (smoking interaction); chr3:125907358 chr3:125916620~125930024:+ LIHC cis rs748404 0.588 rs2255410 ENSG00000205771.5 CATSPER2P1 -6.88 2.79e-11 2.63e-08 -0.42 -0.35 Lung cancer; chr15:43538899 chr15:43726918~43747094:- LIHC cis rs5769765 0.542 rs5769751 ENSG00000278869.1 CITF22-49E9.3 -6.88 2.81e-11 2.65e-08 -0.89 -0.35 Schizophrenia; chr22:49849085 chr22:49933198~49934074:- LIHC cis rs1185460 0.967 rs1786141 ENSG00000271751.1 RP11-110I1.14 -6.88 2.82e-11 2.66e-08 -0.47 -0.35 Coronary artery disease; chr11:119067604 chr11:119065263~119065677:- LIHC cis rs2929278 0.561 rs2927071 ENSG00000205771.5 CATSPER2P1 -6.88 2.83e-11 2.67e-08 -0.44 -0.35 Schizophrenia; chr15:43626883 chr15:43726918~43747094:- LIHC cis rs17301013 0.507 rs6687616 ENSG00000227373.4 RP11-160H22.5 6.88 2.87e-11 2.7e-08 0.6 0.35 Systemic lupus erythematosus; chr1:174840322 chr1:174115300~174160004:- LIHC cis rs2836950 0.52 rs11911087 ENSG00000255568.3 BRWD1-AS2 -6.88 2.88e-11 2.71e-08 -0.29 -0.35 Menarche (age at onset); chr21:39293266 chr21:39313935~39314962:+ LIHC cis rs9660180 0.967 rs11260623 ENSG00000268575.1 RP1-283E3.8 -6.88 2.9e-11 2.73e-08 -0.32 -0.35 Body mass index; chr1:1850017 chr1:1702736~1737688:- LIHC cis rs7580658 0.963 rs12052483 ENSG00000236682.1 AC068282.3 -6.88 2.91e-11 2.74e-08 -0.45 -0.35 Protein C levels; chr2:127379244 chr2:127389130~127400580:+ LIHC cis rs7580658 0.926 rs4662725 ENSG00000236682.1 AC068282.3 -6.88 2.91e-11 2.74e-08 -0.45 -0.35 Protein C levels; chr2:127383744 chr2:127389130~127400580:+ LIHC cis rs6991838 0.557 rs7012578 ENSG00000200714.1 Y_RNA -6.88 2.92e-11 2.75e-08 -0.36 -0.35 Intelligence (multi-trait analysis); chr8:65592592 chr8:65592731~65592820:+ LIHC cis rs10875746 0.951 rs10875747 ENSG00000240399.1 RP1-228P16.1 -6.88 2.93e-11 2.76e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48132078 chr12:48054813~48055591:- LIHC cis rs10875746 0.951 rs10875748 ENSG00000240399.1 RP1-228P16.1 -6.88 2.93e-11 2.76e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48132577 chr12:48054813~48055591:- LIHC cis rs1185460 0.565 rs1182922 ENSG00000271751.1 RP11-110I1.14 6.88 2.94e-11 2.77e-08 0.45 0.35 Coronary artery disease; chr11:119062148 chr11:119065263~119065677:- LIHC cis rs10875746 0.859 rs4760622 ENSG00000240399.1 RP1-228P16.1 -6.88 2.95e-11 2.77e-08 -0.38 -0.35 Longevity (90 years and older); chr12:48198177 chr12:48054813~48055591:- LIHC cis rs3020736 0.5 rs4147641 ENSG00000227370.1 RP4-669P10.19 6.88 2.95e-11 2.77e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42086498 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs4147640 ENSG00000227370.1 RP4-669P10.19 6.88 2.95e-11 2.77e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42089288 chr22:42132543~42132998:+ LIHC cis rs1023500 0.507 rs6002600 ENSG00000227370.1 RP4-669P10.19 6.88 2.95e-11 2.77e-08 0.41 0.35 Schizophrenia; chr22:42092902 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs6002601 ENSG00000227370.1 RP4-669P10.19 6.88 2.95e-11 2.77e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42093054 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs6002604 ENSG00000227370.1 RP4-669P10.19 6.88 2.95e-11 2.77e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42097077 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs5996109 ENSG00000227370.1 RP4-669P10.19 6.88 2.95e-11 2.77e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42097094 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs5996110 ENSG00000227370.1 RP4-669P10.19 6.88 2.95e-11 2.77e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42097763 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs9620026 ENSG00000227370.1 RP4-669P10.19 6.88 2.95e-11 2.77e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42102574 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs28791586 ENSG00000227370.1 RP4-669P10.19 6.88 2.95e-11 2.77e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42104479 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs2839708 ENSG00000227370.1 RP4-669P10.19 6.88 2.95e-11 2.77e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42104741 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs6519306 ENSG00000227370.1 RP4-669P10.19 6.88 2.95e-11 2.77e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42105213 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs6002614 ENSG00000227370.1 RP4-669P10.19 6.88 2.95e-11 2.77e-08 0.41 0.35 Autism spectrum disorder or schizophrenia; chr22:42105798 chr22:42132543~42132998:+ LIHC cis rs10875746 0.903 rs11168414 ENSG00000240399.1 RP1-228P16.1 -6.87 2.95e-11 2.78e-08 -0.39 -0.35 Longevity (90 years and older); chr12:48118548 chr12:48054813~48055591:- LIHC cis rs4718428 0.705 rs10267335 ENSG00000226824.5 RP4-756H11.3 -6.87 2.96e-11 2.78e-08 -0.46 -0.35 Corneal structure; chr7:66938233 chr7:66654538~66669855:+ LIHC cis rs6991838 0.584 rs34494846 ENSG00000200714.1 Y_RNA -6.87 2.96e-11 2.79e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65602397 chr8:65592731~65592820:+ LIHC cis rs1185460 0.967 rs1168568 ENSG00000271751.1 RP11-110I1.14 -6.87 2.96e-11 2.79e-08 -0.48 -0.35 Coronary artery disease; chr11:119079089 chr11:119065263~119065677:- LIHC cis rs1185460 0.967 rs1307145 ENSG00000271751.1 RP11-110I1.14 -6.87 2.96e-11 2.79e-08 -0.48 -0.35 Coronary artery disease; chr11:119079507 chr11:119065263~119065677:- LIHC cis rs1939012 1 rs1939012 ENSG00000281655.1 RP11-817J15.3 -6.87 2.96e-11 2.79e-08 -0.41 -0.35 Epilepsy; chr11:102724404 chr11:102681310~102683913:+ LIHC cis rs7617773 0.817 rs13059037 ENSG00000229759.1 MRPS18AP1 6.87 2.97e-11 2.8e-08 0.43 0.35 Coronary artery disease; chr3:48246389 chr3:48256350~48256938:- LIHC cis rs7617773 0.817 rs35414021 ENSG00000229759.1 MRPS18AP1 6.87 2.97e-11 2.8e-08 0.43 0.35 Coronary artery disease; chr3:48252034 chr3:48256350~48256938:- LIHC cis rs62355900 0.636 rs12654584 ENSG00000271828.1 CTD-2310F14.1 6.87 2.98e-11 2.8e-08 0.57 0.35 Endometriosis; chr5:56762588 chr5:56927874~56929573:+ LIHC cis rs6991838 0.584 rs7812446 ENSG00000200714.1 Y_RNA -6.87 3.02e-11 2.84e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65593753 chr8:65592731~65592820:+ LIHC cis rs6991838 0.557 rs7812390 ENSG00000200714.1 Y_RNA -6.87 3.02e-11 2.84e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65593982 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs16932245 ENSG00000200714.1 Y_RNA -6.87 3.02e-11 2.84e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65597810 chr8:65592731~65592820:+ LIHC cis rs6991838 0.557 rs57419568 ENSG00000200714.1 Y_RNA -6.87 3.02e-11 2.84e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65598633 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs16932250 ENSG00000200714.1 Y_RNA -6.87 3.02e-11 2.84e-08 -0.37 -0.35 Intelligence (multi-trait analysis); chr8:65598779 chr8:65592731~65592820:+ LIHC cis rs1577917 1 rs6914463 ENSG00000234155.1 RP11-30P6.6 6.87 3.03e-11 2.84e-08 0.41 0.35 Response to antipsychotic treatment; chr6:85943697 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs2816821 ENSG00000234155.1 RP11-30P6.6 6.87 3.03e-11 2.84e-08 0.41 0.35 Response to antipsychotic treatment; chr6:85947366 chr6:85387219~85390186:- LIHC cis rs496547 0.719 rs476246 ENSG00000255239.1 AP002954.6 -6.87 3.03e-11 2.85e-08 -0.4 -0.35 Hip minimal joint space width; chr11:118747211 chr11:118688039~118690600:- LIHC cis rs34779708 0.966 rs12257770 ENSG00000230534.5 RP11-297A16.2 6.87 3.04e-11 2.85e-08 0.44 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35228306 chr10:35098006~35127020:- LIHC cis rs9918079 0.56 rs13147590 ENSG00000273133.1 RP11-799M12.2 6.87 3.04e-11 2.85e-08 0.45 0.35 Obesity-related traits; chr4:15619565 chr4:15563698~15564253:- LIHC cis rs765787 0.53 rs1706837 ENSG00000259520.4 CTD-2651B20.3 6.87 3.06e-11 2.87e-08 0.41 0.35 Uric acid levels; chr15:45226838 chr15:45251580~45279251:- LIHC cis rs4718428 0.705 rs28648401 ENSG00000226824.5 RP4-756H11.3 -6.87 3.08e-11 2.89e-08 -0.46 -0.35 Corneal structure; chr7:66902145 chr7:66654538~66669855:+ LIHC cis rs4718428 0.607 rs66954441 ENSG00000226824.5 RP4-756H11.3 -6.87 3.08e-11 2.89e-08 -0.46 -0.35 Corneal structure; chr7:66904222 chr7:66654538~66669855:+ LIHC cis rs4718428 0.705 rs4718424 ENSG00000226824.5 RP4-756H11.3 -6.87 3.08e-11 2.89e-08 -0.46 -0.35 Corneal structure; chr7:66911108 chr7:66654538~66669855:+ LIHC cis rs6991838 0.584 rs35790435 ENSG00000200714.1 Y_RNA -6.87 3.09e-11 2.9e-08 -0.36 -0.35 Intelligence (multi-trait analysis); chr8:65590288 chr8:65592731~65592820:+ LIHC cis rs3096299 0.967 rs7205785 ENSG00000274627.1 RP11-104N10.2 6.87 3.09e-11 2.9e-08 0.36 0.35 Multiple myeloma (IgH translocation); chr16:89392576 chr16:89516797~89522217:+ LIHC cis rs494459 0.536 rs10790267 ENSG00000255239.1 AP002954.6 6.87 3.09e-11 2.9e-08 0.4 0.35 Height; chr11:118856460 chr11:118688039~118690600:- LIHC cis rs494459 0.536 rs11217067 ENSG00000255239.1 AP002954.6 6.87 3.09e-11 2.9e-08 0.4 0.35 Height; chr11:118856623 chr11:118688039~118690600:- LIHC cis rs2510897 0.675 rs4936442 ENSG00000255239.1 AP002954.6 6.87 3.09e-11 2.9e-08 0.4 0.35 Height; chr11:118857611 chr11:118688039~118690600:- LIHC cis rs765787 0.53 rs2554457 ENSG00000259520.4 CTD-2651B20.3 6.87 3.1e-11 2.9e-08 0.41 0.35 Uric acid levels; chr15:45228728 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs2554456 ENSG00000259520.4 CTD-2651B20.3 6.87 3.1e-11 2.9e-08 0.41 0.35 Uric acid levels; chr15:45228940 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs10467979 ENSG00000259520.4 CTD-2651B20.3 6.87 3.1e-11 2.9e-08 0.41 0.35 Uric acid levels; chr15:45229072 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs2554455 ENSG00000259520.4 CTD-2651B20.3 6.87 3.1e-11 2.9e-08 0.41 0.35 Uric acid levels; chr15:45229106 chr15:45251580~45279251:- LIHC cis rs1185460 0.546 rs7114961 ENSG00000271751.1 RP11-110I1.14 6.87 3.1e-11 2.9e-08 0.44 0.35 Coronary artery disease; chr11:119043677 chr11:119065263~119065677:- LIHC cis rs73086581 1 rs56324992 ENSG00000229539.1 RP11-119B16.2 6.87 3.1e-11 2.91e-08 0.58 0.35 Response to antidepressants in depression; chr20:3997506 chr20:3888239~3888868:- LIHC cis rs73086581 1 rs6107393 ENSG00000229539.1 RP11-119B16.2 6.87 3.11e-11 2.92e-08 0.58 0.35 Response to antidepressants in depression; chr20:4007091 chr20:3888239~3888868:- LIHC cis rs11603023 0.967 rs644273 ENSG00000255239.1 AP002954.6 -6.87 3.13e-11 2.93e-08 -0.39 -0.35 Cholesterol, total; chr11:118640634 chr11:118688039~118690600:- LIHC cis rs11603023 0.967 rs654423 ENSG00000255239.1 AP002954.6 -6.87 3.13e-11 2.93e-08 -0.39 -0.35 Cholesterol, total; chr11:118641039 chr11:118688039~118690600:- LIHC cis rs765787 0.53 rs1706835 ENSG00000259520.4 CTD-2651B20.3 6.86 3.16e-11 2.96e-08 0.41 0.35 Uric acid levels; chr15:45225686 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs1631533 ENSG00000259520.4 CTD-2651B20.3 6.86 3.16e-11 2.96e-08 0.41 0.35 Uric acid levels; chr15:45226430 chr15:45251580~45279251:- LIHC cis rs1939012 0.875 rs6590983 ENSG00000281655.1 RP11-817J15.3 -6.86 3.18e-11 2.97e-08 -0.42 -0.35 Epilepsy; chr11:102723645 chr11:102681310~102683913:+ LIHC cis rs1939012 0.846 rs3765620 ENSG00000281655.1 RP11-817J15.3 -6.86 3.18e-11 2.97e-08 -0.42 -0.35 Epilepsy; chr11:102724761 chr11:102681310~102683913:+ LIHC cis rs17301013 0.507 rs7515116 ENSG00000227373.4 RP11-160H22.5 -6.86 3.18e-11 2.98e-08 -0.53 -0.35 Systemic lupus erythematosus; chr1:174474516 chr1:174115300~174160004:- LIHC cis rs2882667 0.66 rs3088052 ENSG00000253404.1 AC034243.1 6.86 3.19e-11 2.99e-08 0.45 0.35 Age-related hearing impairment (SNP x SNP interaction); chr5:139121126 chr5:138744434~138753309:- LIHC cis rs7617773 0.71 rs36064160 ENSG00000229759.1 MRPS18AP1 6.86 3.2e-11 3e-08 0.43 0.35 Coronary artery disease; chr3:48201611 chr3:48256350~48256938:- LIHC cis rs7131987 0.683 rs3782511 ENSG00000257176.2 RP11-996F15.2 -6.86 3.22e-11 3.01e-08 -0.41 -0.35 QT interval; chr12:29343291 chr12:29280418~29317848:- LIHC cis rs7617773 0.851 rs7647817 ENSG00000229759.1 MRPS18AP1 6.86 3.22e-11 3.01e-08 0.43 0.35 Coronary artery disease; chr3:48195017 chr3:48256350~48256938:- LIHC cis rs7617773 0.817 rs11707606 ENSG00000229759.1 MRPS18AP1 6.86 3.22e-11 3.01e-08 0.43 0.35 Coronary artery disease; chr3:48195597 chr3:48256350~48256938:- LIHC cis rs4423214 0.879 rs1792284 ENSG00000254682.1 RP11-660L16.2 6.86 3.22e-11 3.01e-08 0.44 0.35 Vitamin D levels; chr11:71423920 chr11:71448674~71452157:+ LIHC cis rs2739330 0.734 rs2000467 ENSG00000250470.1 AP000351.3 -6.86 3.25e-11 3.04e-08 -0.43 -0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23976904~23977585:- LIHC cis rs34779708 0.931 rs11010132 ENSG00000230534.5 RP11-297A16.2 6.86 3.29e-11 3.08e-08 0.44 0.35 Inflammatory bowel disease;Crohn's disease; chr10:35228337 chr10:35098006~35127020:- LIHC cis rs765787 0.53 rs2668737 ENSG00000259520.4 CTD-2651B20.3 6.86 3.29e-11 3.08e-08 0.41 0.35 Uric acid levels; chr15:45230601 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs1706764 ENSG00000259520.4 CTD-2651B20.3 6.86 3.29e-11 3.08e-08 0.41 0.35 Uric acid levels; chr15:45232058 chr15:45251580~45279251:- LIHC cis rs11673344 0.624 rs862234 ENSG00000226686.6 LINC01535 -6.86 3.31e-11 3.09e-08 -0.42 -0.35 Obesity-related traits; chr19:37237100 chr19:37251912~37265535:+ LIHC cis rs4660456 0.913 rs6664044 ENSG00000237899.1 RP4-739H11.3 -6.86 3.31e-11 3.1e-08 -0.45 -0.35 Platelet count; chr1:40735089 chr1:40669089~40687588:- LIHC cis rs7615952 0.673 rs9289270 ENSG00000171084.14 FAM86JP 6.86 3.32e-11 3.1e-08 0.73 0.35 Blood pressure (smoking interaction); chr3:125918136 chr3:125916620~125930024:+ LIHC cis rs1577917 1 rs2812972 ENSG00000234155.1 RP11-30P6.6 6.86 3.33e-11 3.11e-08 0.41 0.35 Response to antipsychotic treatment; chr6:85960162 chr6:85387219~85390186:- LIHC cis rs73086581 1 rs6107391 ENSG00000229539.1 RP11-119B16.2 6.85 3.36e-11 3.13e-08 0.58 0.35 Response to antidepressants in depression; chr20:4002436 chr20:3888239~3888868:- LIHC cis rs6490294 0.528 rs60998439 ENSG00000226469.1 ADAM1B 6.85 3.36e-11 3.13e-08 0.52 0.35 Mean platelet volume; chr12:112008165 chr12:111927018~111929017:+ LIHC cis rs1577917 0.727 rs9344539 ENSG00000234155.1 RP11-30P6.6 6.85 3.36e-11 3.13e-08 0.41 0.35 Response to antipsychotic treatment; chr6:85643903 chr6:85387219~85390186:- LIHC cis rs1577917 0.771 rs9362232 ENSG00000234155.1 RP11-30P6.6 6.85 3.36e-11 3.13e-08 0.41 0.35 Response to antipsychotic treatment; chr6:85643904 chr6:85387219~85390186:- LIHC cis rs1577917 0.655 rs9450311 ENSG00000234155.1 RP11-30P6.6 -6.85 3.37e-11 3.14e-08 -0.41 -0.35 Response to antipsychotic treatment; chr6:85666868 chr6:85387219~85390186:- LIHC cis rs7044106 0.887 rs1359328 ENSG00000226752.6 PSMD5-AS1 -6.85 3.37e-11 3.14e-08 -0.38 -0.35 Hip circumference adjusted for BMI; chr9:120608544 chr9:120824828~120854385:+ LIHC cis rs6490294 0.571 rs11066117 ENSG00000226469.1 ADAM1B 6.85 3.38e-11 3.16e-08 0.48 0.35 Mean platelet volume; chr12:111994905 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs11066118 ENSG00000226469.1 ADAM1B 6.85 3.38e-11 3.16e-08 0.48 0.35 Mean platelet volume; chr12:111996348 chr12:111927018~111929017:+ LIHC cis rs1150668 0.83 rs2023493 ENSG00000216901.1 AL022393.7 6.85 3.4e-11 3.17e-08 0.4 0.35 Pubertal anthropometrics; chr6:28432385 chr6:28176188~28176674:+ LIHC cis rs6490294 0.528 rs12579851 ENSG00000226469.1 ADAM1B 6.85 3.4e-11 3.17e-08 0.54 0.35 Mean platelet volume; chr12:112230951 chr12:111927018~111929017:+ LIHC cis rs6504950 0.889 rs1484769 ENSG00000275710.1 RP11-257O5.4 -6.85 3.42e-11 3.19e-08 -0.52 -0.35 Breast cancer; chr17:55089290 chr17:54964474~54964679:+ LIHC cis rs6991838 0.584 rs34226237 ENSG00000200714.1 Y_RNA -6.85 3.42e-11 3.19e-08 -0.36 -0.35 Intelligence (multi-trait analysis); chr8:65600930 chr8:65592731~65592820:+ LIHC cis rs6991838 0.584 rs6994213 ENSG00000200714.1 Y_RNA -6.85 3.42e-11 3.19e-08 -0.36 -0.35 Intelligence (multi-trait analysis); chr8:65601497 chr8:65592731~65592820:+ LIHC cis rs7615952 0.611 rs2971298 ENSG00000171084.14 FAM86JP 6.85 3.42e-11 3.19e-08 0.7 0.35 Blood pressure (smoking interaction); chr3:125883870 chr3:125916620~125930024:+ LIHC cis rs2836950 0.501 rs2056844 ENSG00000255568.3 BRWD1-AS2 -6.85 3.42e-11 3.19e-08 -0.29 -0.35 Menarche (age at onset); chr21:39298534 chr21:39313935~39314962:+ LIHC cis rs7131987 0.65 rs7973786 ENSG00000257176.2 RP11-996F15.2 -6.85 3.43e-11 3.2e-08 -0.4 -0.35 QT interval; chr12:29309811 chr12:29280418~29317848:- LIHC cis rs1577917 0.56 rs9450288 ENSG00000234155.1 RP11-30P6.6 -6.85 3.43e-11 3.2e-08 -0.42 -0.35 Response to antipsychotic treatment; chr6:85511868 chr6:85387219~85390186:- LIHC cis rs4423214 0.879 rs1790330 ENSG00000254682.1 RP11-660L16.2 -6.85 3.45e-11 3.21e-08 -0.43 -0.35 Vitamin D levels; chr11:71436779 chr11:71448674~71452157:+ LIHC cis rs4423214 0.84 rs1790328 ENSG00000254682.1 RP11-660L16.2 -6.85 3.45e-11 3.22e-08 -0.43 -0.35 Vitamin D levels; chr11:71436992 chr11:71448674~71452157:+ LIHC cis rs4820294 1 rs732856 ENSG00000233360.4 Z83844.1 -6.85 3.46e-11 3.22e-08 -0.44 -0.35 Fat distribution (HIV); chr22:37664684 chr22:37641832~37658377:- LIHC cis rs6490294 0.571 rs6489830 ENSG00000226469.1 ADAM1B 6.85 3.47e-11 3.23e-08 0.49 0.35 Mean platelet volume; chr12:112144736 chr12:111927018~111929017:+ LIHC cis rs6490294 0.571 rs12422864 ENSG00000226469.1 ADAM1B 6.85 3.47e-11 3.23e-08 0.49 0.35 Mean platelet volume; chr12:112146397 chr12:111927018~111929017:+ LIHC cis rs7085104 0.513 rs192569 ENSG00000236937.2 PTGES3P4 -6.85 3.47e-11 3.23e-08 -0.43 -0.35 Immature fraction of reticulocytes;Schizophrenia; chr10:102818158 chr10:102845595~102845950:+ LIHC cis rs10875746 0.951 rs2228500 ENSG00000240399.1 RP1-228P16.1 6.85 3.49e-11 3.25e-08 0.39 0.35 Longevity (90 years and older); chr12:48132929 chr12:48054813~48055591:- LIHC cis rs4423214 0.879 rs1790345 ENSG00000254682.1 RP11-660L16.2 -6.85 3.5e-11 3.26e-08 -0.43 -0.35 Vitamin D levels; chr11:71434895 chr11:71448674~71452157:+ LIHC cis rs2117029 0.586 rs6580701 ENSG00000258017.1 RP11-386G11.10 -6.85 3.51e-11 3.27e-08 -0.41 -0.35 Intelligence (multi-trait analysis); chr12:49163482 chr12:49127782~49147869:+ LIHC cis rs765787 0.53 rs2668751 ENSG00000259520.4 CTD-2651B20.3 6.85 3.51e-11 3.27e-08 0.41 0.35 Uric acid levels; chr15:45225095 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs1648286 ENSG00000259520.4 CTD-2651B20.3 6.85 3.51e-11 3.27e-08 0.41 0.35 Uric acid levels; chr15:45225188 chr15:45251580~45279251:- LIHC cis rs992157 0.798 rs1017698 ENSG00000261338.2 RP11-378A13.1 -6.85 3.53e-11 3.29e-08 -0.35 -0.35 Colorectal cancer; chr2:218305802 chr2:218255319~218257366:+ LIHC cis rs765787 0.53 rs4331289 ENSG00000259520.4 CTD-2651B20.3 6.85 3.54e-11 3.29e-08 0.41 0.35 Uric acid levels; chr15:45223140 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs2433228 ENSG00000259520.4 CTD-2651B20.3 6.85 3.54e-11 3.29e-08 0.41 0.35 Uric acid levels; chr15:45223173 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs11854690 ENSG00000259520.4 CTD-2651B20.3 6.85 3.54e-11 3.29e-08 0.41 0.35 Uric acid levels; chr15:45223818 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs28733848 ENSG00000259520.4 CTD-2651B20.3 6.85 3.54e-11 3.29e-08 0.41 0.35 Uric acid levels; chr15:45223849 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs11854689 ENSG00000259520.4 CTD-2651B20.3 6.85 3.54e-11 3.29e-08 0.41 0.35 Uric acid levels; chr15:45223854 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs1706830 ENSG00000259520.4 CTD-2651B20.3 6.85 3.54e-11 3.29e-08 0.41 0.35 Uric acid levels; chr15:45224031 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs1706831 ENSG00000259520.4 CTD-2651B20.3 6.85 3.54e-11 3.29e-08 0.41 0.35 Uric acid levels; chr15:45224032 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs2433227 ENSG00000259520.4 CTD-2651B20.3 6.85 3.54e-11 3.29e-08 0.41 0.35 Uric acid levels; chr15:45224921 chr15:45251580~45279251:- LIHC cis rs1023500 0.551 rs2301521 ENSG00000227370.1 RP4-669P10.19 -6.84 3.56e-11 3.31e-08 -0.42 -0.35 Schizophrenia; chr22:42027106 chr22:42132543~42132998:+ LIHC cis rs7615952 0.736 rs13063122 ENSG00000171084.14 FAM86JP 6.84 3.57e-11 3.32e-08 0.64 0.35 Blood pressure (smoking interaction); chr3:125925017 chr3:125916620~125930024:+ LIHC cis rs7131987 0.683 rs7954278 ENSG00000257176.2 RP11-996F15.2 -6.84 3.58e-11 3.33e-08 -0.4 -0.35 QT interval; chr12:29306357 chr12:29280418~29317848:- LIHC cis rs1062753 0.771 rs932376 ENSG00000237037.8 NDUFA6-AS1 -6.84 3.6e-11 3.34e-08 -0.4 -0.35 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42218356 chr22:42090931~42137742:+ LIHC cis rs4660456 1 rs4660456 ENSG00000237899.1 RP4-739H11.3 -6.84 3.6e-11 3.35e-08 -0.45 -0.35 Platelet count; chr1:40773839 chr1:40669089~40687588:- LIHC cis rs7580658 0.963 rs12991768 ENSG00000236682.1 AC068282.3 -6.84 3.62e-11 3.36e-08 -0.45 -0.35 Protein C levels; chr2:127388669 chr2:127389130~127400580:+ LIHC cis rs6490294 0.528 rs74187049 ENSG00000226469.1 ADAM1B 6.84 3.62e-11 3.36e-08 0.53 0.35 Mean platelet volume; chr12:112180114 chr12:111927018~111929017:+ LIHC cis rs6490294 0.528 rs16941909 ENSG00000226469.1 ADAM1B 6.84 3.62e-11 3.36e-08 0.53 0.35 Mean platelet volume; chr12:112188420 chr12:111927018~111929017:+ LIHC cis rs7580658 0.926 rs79789049 ENSG00000236682.1 AC068282.3 -6.84 3.62e-11 3.36e-08 -0.45 -0.35 Protein C levels; chr2:127387896 chr2:127389130~127400580:+ LIHC cis rs494459 0.536 rs57719838 ENSG00000255239.1 AP002954.6 6.84 3.65e-11 3.38e-08 0.4 0.35 Height; chr11:118854014 chr11:118688039~118690600:- LIHC cis rs1005277 0.579 rs1740735 ENSG00000263064.2 RP11-291L22.7 6.84 3.65e-11 3.39e-08 0.36 0.35 Extrinsic epigenetic age acceleration; chr10:38208849 chr10:38448689~38448949:+ LIHC cis rs494459 0.838 rs555649 ENSG00000255422.1 AP002954.4 -6.84 3.65e-11 3.39e-08 -0.39 -0.35 Height; chr11:118781100 chr11:118704607~118750263:+ LIHC cis rs150992 0.632 rs34490 ENSG00000248489.1 CTD-2007H13.3 6.84 3.65e-11 3.39e-08 0.5 0.35 Body mass index; chr5:98974967 chr5:98929171~98995013:+ LIHC cis rs1023500 0.551 rs2859438 ENSG00000227370.1 RP4-669P10.19 -6.84 3.66e-11 3.39e-08 -0.4 -0.35 Schizophrenia; chr22:42070976 chr22:42132543~42132998:+ LIHC cis rs992157 0.767 rs2382822 ENSG00000261338.2 RP11-378A13.1 -6.84 3.67e-11 3.4e-08 -0.35 -0.35 Colorectal cancer; chr2:218308604 chr2:218255319~218257366:+ LIHC cis rs6490294 0.528 rs57866673 ENSG00000226469.1 ADAM1B 6.84 3.67e-11 3.41e-08 0.53 0.35 Mean platelet volume; chr12:112195500 chr12:111927018~111929017:+ LIHC cis rs4660456 0.913 rs2744799 ENSG00000237899.1 RP4-739H11.3 6.84 3.7e-11 3.43e-08 0.45 0.35 Platelet count; chr1:40719862 chr1:40669089~40687588:- LIHC cis rs9326248 0.861 rs4938343 ENSG00000280143.1 AP000892.6 6.84 3.71e-11 3.44e-08 0.41 0.35 Blood protein levels; chr11:117132812 chr11:117204967~117210292:+ LIHC cis rs17301013 0.507 rs10494492 ENSG00000227373.4 RP11-160H22.5 -6.84 3.74e-11 3.47e-08 -0.54 -0.35 Systemic lupus erythematosus; chr1:174723499 chr1:174115300~174160004:- LIHC cis rs2117029 0.554 rs35884657 ENSG00000258017.1 RP11-386G11.10 -6.84 3.75e-11 3.47e-08 -0.41 -0.35 Intelligence (multi-trait analysis); chr12:49137317 chr12:49127782~49147869:+ LIHC cis rs11168854 0.62 rs11168888 ENSG00000258017.1 RP11-386G11.10 -6.84 3.75e-11 3.47e-08 -0.41 -0.35 Body mass index; chr12:49149614 chr12:49127782~49147869:+ LIHC cis rs7684446 1 rs7684446 ENSG00000273133.1 RP11-799M12.2 6.84 3.75e-11 3.48e-08 0.42 0.35 Red blood cell count; chr4:15591241 chr4:15563698~15564253:- LIHC cis rs1789 0.653 rs13142069 ENSG00000273133.1 RP11-799M12.2 6.84 3.75e-11 3.48e-08 0.42 0.35 Blood protein levels; chr4:15592069 chr4:15563698~15564253:- LIHC cis rs7615952 0.932 rs6438948 ENSG00000171084.14 FAM86JP -6.84 3.76e-11 3.48e-08 -0.59 -0.35 Blood pressure (smoking interaction); chr3:125931202 chr3:125916620~125930024:+ LIHC cis rs4820294 1 rs62236665 ENSG00000233360.4 Z83844.1 6.84 3.76e-11 3.48e-08 0.44 0.35 Fat distribution (HIV); chr22:37663840 chr22:37641832~37658377:- LIHC cis rs4820294 1 rs78974622 ENSG00000233360.4 Z83844.1 6.84 3.76e-11 3.48e-08 0.44 0.35 Fat distribution (HIV); chr22:37663918 chr22:37641832~37658377:- LIHC cis rs3823536 0.583 rs10236569 ENSG00000275106.1 RP11-309L24.10 -6.83 3.79e-11 3.51e-08 -0.44 -0.35 Sjögren's syndrome; chr7:128957533 chr7:128952527~128953316:- LIHC cis rs7615952 0.932 rs13325495 ENSG00000171084.14 FAM86JP 6.83 3.83e-11 3.54e-08 0.65 0.35 Blood pressure (smoking interaction); chr3:125918573 chr3:125916620~125930024:+ LIHC cis rs2284378 0.515 rs6059579 ENSG00000276073.1 RP5-1125A11.7 -6.83 3.83e-11 3.55e-08 -0.36 -0.35 Breast cancer; chr20:33940059 chr20:33985617~33988989:- LIHC cis rs992157 0.735 rs2271541 ENSG00000261338.2 RP11-378A13.1 6.83 3.85e-11 3.57e-08 0.34 0.35 Colorectal cancer; chr2:218217396 chr2:218255319~218257366:+ LIHC cis rs4820294 1 rs4820294 ENSG00000233360.4 Z83844.1 6.83 3.87e-11 3.58e-08 0.44 0.35 Fat distribution (HIV); chr22:37675036 chr22:37641832~37658377:- LIHC cis rs3020736 0.5 rs6002616 ENSG00000227370.1 RP4-669P10.19 6.83 3.88e-11 3.59e-08 0.4 0.35 Autism spectrum disorder or schizophrenia; chr22:42108675 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs7364293 ENSG00000227370.1 RP4-669P10.19 6.83 3.88e-11 3.59e-08 0.4 0.35 Autism spectrum disorder or schizophrenia; chr22:42110366 chr22:42132543~42132998:+ LIHC cis rs200895692 1 rs200895692 ENSG00000227533.4 SLC2A1-AS1 6.83 3.91e-11 3.61e-08 0.53 0.35 Monocyte count; chr1:42956299 chr1:42959049~42983358:+ LIHC cis rs1150668 0.764 rs9368565 ENSG00000216901.1 AL022393.7 -6.83 3.92e-11 3.62e-08 -0.4 -0.35 Pubertal anthropometrics; chr6:28377433 chr6:28176188~28176674:+ LIHC cis rs1150668 0.796 rs1052215 ENSG00000216901.1 AL022393.7 -6.83 3.92e-11 3.62e-08 -0.4 -0.35 Pubertal anthropometrics; chr6:28380381 chr6:28176188~28176674:+ LIHC cis rs992157 0.798 rs7587220 ENSG00000261338.2 RP11-378A13.1 -6.83 3.96e-11 3.66e-08 -0.35 -0.35 Colorectal cancer; chr2:218296141 chr2:218255319~218257366:+ LIHC cis rs4820294 0.961 rs62236664 ENSG00000233360.4 Z83844.1 6.83 3.99e-11 3.68e-08 0.44 0.35 Fat distribution (HIV); chr22:37663420 chr22:37641832~37658377:- LIHC cis rs9399135 0.622 rs3817776 ENSG00000232876.1 CTA-212D2.2 6.83 3.99e-11 3.68e-08 0.39 0.35 Red blood cell count; chr6:134935618 chr6:135055033~135060550:+ LIHC cis rs992157 0.56 rs10932763 ENSG00000261338.2 RP11-378A13.1 -6.83 3.99e-11 3.69e-08 -0.34 -0.35 Colorectal cancer; chr2:218221140 chr2:218255319~218257366:+ LIHC cis rs7615952 0.866 rs13063119 ENSG00000171084.14 FAM86JP 6.83 4.01e-11 3.7e-08 0.63 0.35 Blood pressure (smoking interaction); chr3:125925004 chr3:125916620~125930024:+ LIHC cis rs6490294 0.528 rs77211491 ENSG00000226469.1 ADAM1B 6.82 4.02e-11 3.71e-08 0.51 0.35 Mean platelet volume; chr12:111884974 chr12:111927018~111929017:+ LIHC cis rs6490294 0.528 rs77030808 ENSG00000226469.1 ADAM1B 6.82 4.02e-11 3.71e-08 0.51 0.35 Mean platelet volume; chr12:111891224 chr12:111927018~111929017:+ LIHC cis rs6490294 0.528 rs12580246 ENSG00000226469.1 ADAM1B 6.82 4.02e-11 3.71e-08 0.51 0.35 Mean platelet volume; chr12:111893513 chr12:111927018~111929017:+ LIHC cis rs1577917 0.771 rs2842608 ENSG00000234155.1 RP11-30P6.6 6.82 4.03e-11 3.72e-08 0.43 0.35 Response to antipsychotic treatment; chr6:85586140 chr6:85387219~85390186:- LIHC cis rs8072100 0.837 rs62074055 ENSG00000228782.6 CTD-2026D20.3 6.82 4.03e-11 3.72e-08 0.4 0.35 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47694567 chr17:47450568~47492492:- LIHC cis rs2117029 0.619 rs2241727 ENSG00000258017.1 RP11-386G11.10 -6.82 4.04e-11 3.72e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49131225 chr12:49127782~49147869:+ LIHC cis rs1577917 0.958 rs1337843 ENSG00000234155.1 RP11-30P6.6 6.82 4.04e-11 3.72e-08 0.41 0.35 Response to antipsychotic treatment; chr6:85965827 chr6:85387219~85390186:- LIHC cis rs1023500 0.596 rs5751204 ENSG00000227370.1 RP4-669P10.19 -6.82 4.05e-11 3.73e-08 -0.41 -0.35 Schizophrenia; chr22:42037797 chr22:42132543~42132998:+ LIHC cis rs9549367 0.713 rs11620600 ENSG00000269125.1 RP11-98F14.11 -6.82 4.06e-11 3.74e-08 -0.44 -0.35 Platelet distribution width; chr13:113174776 chr13:113165002~113165183:- LIHC cis rs9549367 0.713 rs9549681 ENSG00000269125.1 RP11-98F14.11 -6.82 4.06e-11 3.74e-08 -0.44 -0.35 Platelet distribution width; chr13:113175559 chr13:113165002~113165183:- LIHC cis rs9549367 0.713 rs9549682 ENSG00000269125.1 RP11-98F14.11 -6.82 4.06e-11 3.74e-08 -0.44 -0.35 Platelet distribution width; chr13:113175867 chr13:113165002~113165183:- LIHC cis rs9549367 0.713 rs56002882 ENSG00000269125.1 RP11-98F14.11 -6.82 4.06e-11 3.74e-08 -0.44 -0.35 Platelet distribution width; chr13:113176380 chr13:113165002~113165183:- LIHC cis rs1577917 0.771 rs4419647 ENSG00000234155.1 RP11-30P6.6 -6.82 4.07e-11 3.75e-08 -0.43 -0.35 Response to antipsychotic treatment; chr6:85516021 chr6:85387219~85390186:- LIHC cis rs1577917 0.771 rs9353318 ENSG00000234155.1 RP11-30P6.6 -6.82 4.07e-11 3.75e-08 -0.43 -0.35 Response to antipsychotic treatment; chr6:85522003 chr6:85387219~85390186:- LIHC cis rs6490294 0.528 rs74636821 ENSG00000226469.1 ADAM1B 6.82 4.08e-11 3.76e-08 0.52 0.35 Mean platelet volume; chr12:112078108 chr12:111927018~111929017:+ LIHC cis rs3020736 0.5 rs8143153 ENSG00000227370.1 RP4-669P10.19 6.82 4.09e-11 3.77e-08 0.4 0.35 Autism spectrum disorder or schizophrenia; chr22:42119633 chr22:42132543~42132998:+ LIHC cis rs62355901 0.545 rs6895844 ENSG00000271828.1 CTD-2310F14.1 6.82 4.09e-11 3.77e-08 0.57 0.35 Breast cancer; chr5:56762113 chr5:56927874~56929573:+ LIHC cis rs2739330 0.753 rs4822452 ENSG00000250470.1 AP000351.3 6.82 4.1e-11 3.77e-08 0.42 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23976904~23977585:- LIHC cis rs992157 0.798 rs4674284 ENSG00000261338.2 RP11-378A13.1 -6.82 4.1e-11 3.78e-08 -0.35 -0.35 Colorectal cancer; chr2:218296518 chr2:218255319~218257366:+ LIHC cis rs4820294 1 rs739139 ENSG00000233360.4 Z83844.1 6.82 4.11e-11 3.78e-08 0.44 0.35 Fat distribution (HIV); chr22:37671004 chr22:37641832~37658377:- LIHC cis rs4660456 0.913 rs3754179 ENSG00000237899.1 RP4-739H11.3 -6.82 4.12e-11 3.79e-08 -0.45 -0.35 Platelet count; chr1:40768464 chr1:40669089~40687588:- LIHC cis rs6490294 0.528 rs12423572 ENSG00000226469.1 ADAM1B 6.82 4.12e-11 3.8e-08 0.52 0.35 Mean platelet volume; chr12:112178115 chr12:111927018~111929017:+ LIHC cis rs1023500 0.529 rs133375 ENSG00000227370.1 RP4-669P10.19 -6.82 4.13e-11 3.8e-08 -0.4 -0.35 Schizophrenia; chr22:42070505 chr22:42132543~42132998:+ LIHC cis rs992157 0.798 rs4996257 ENSG00000261338.2 RP11-378A13.1 6.82 4.13e-11 3.8e-08 0.35 0.35 Colorectal cancer; chr2:218298113 chr2:218255319~218257366:+ LIHC cis rs4718428 0.672 rs12530806 ENSG00000226824.5 RP4-756H11.3 -6.82 4.14e-11 3.81e-08 -0.45 -0.35 Corneal structure; chr7:66925737 chr7:66654538~66669855:+ LIHC cis rs7580658 0.963 rs6732279 ENSG00000236682.1 AC068282.3 -6.82 4.15e-11 3.82e-08 -0.44 -0.35 Protein C levels; chr2:127331964 chr2:127389130~127400580:+ LIHC cis rs1150668 0.796 rs1005125 ENSG00000216901.1 AL022393.7 6.82 4.15e-11 3.82e-08 0.39 0.35 Pubertal anthropometrics; chr6:28399578 chr6:28176188~28176674:+ LIHC cis rs6490294 0.571 rs77176084 ENSG00000226469.1 ADAM1B 6.82 4.16e-11 3.83e-08 0.52 0.35 Mean platelet volume; chr12:112077508 chr12:111927018~111929017:+ LIHC cis rs4660456 0.913 rs657149 ENSG00000237899.1 RP4-739H11.3 6.82 4.17e-11 3.83e-08 0.46 0.35 Platelet count; chr1:40692486 chr1:40669089~40687588:- LIHC cis rs2117029 0.555 rs9788139 ENSG00000258017.1 RP11-386G11.10 -6.82 4.17e-11 3.84e-08 -0.41 -0.35 Intelligence (multi-trait analysis); chr12:49126886 chr12:49127782~49147869:+ LIHC cis rs7580658 0.963 rs62157555 ENSG00000236682.1 AC068282.3 -6.82 4.18e-11 3.85e-08 -0.44 -0.35 Protein C levels; chr2:127349600 chr2:127389130~127400580:+ LIHC cis rs7580658 0.963 rs12479003 ENSG00000236682.1 AC068282.3 -6.82 4.18e-11 3.85e-08 -0.44 -0.35 Protein C levels; chr2:127360977 chr2:127389130~127400580:+ LIHC cis rs7580658 0.963 rs10803585 ENSG00000236682.1 AC068282.3 -6.82 4.18e-11 3.85e-08 -0.44 -0.35 Protein C levels; chr2:127372532 chr2:127389130~127400580:+ LIHC cis rs7580658 0.963 rs2090574 ENSG00000236682.1 AC068282.3 -6.82 4.18e-11 3.85e-08 -0.44 -0.35 Protein C levels; chr2:127373815 chr2:127389130~127400580:+ LIHC cis rs7201929 1 rs8061877 ENSG00000259982.1 CDC37P1 -6.82 4.25e-11 3.91e-08 -0.4 -0.35 QT interval; chr16:28845498 chr16:28700294~28701540:- LIHC cis rs9549367 0.789 rs9549361 ENSG00000269125.1 RP11-98F14.11 6.82 4.25e-11 3.91e-08 0.42 0.35 Platelet distribution width; chr13:113244015 chr13:113165002~113165183:- LIHC cis rs62355901 0.545 rs12654176 ENSG00000271828.1 CTD-2310F14.1 6.82 4.26e-11 3.91e-08 0.58 0.35 Breast cancer; chr5:56762660 chr5:56927874~56929573:+ LIHC cis rs1577917 0.771 rs4351223 ENSG00000234155.1 RP11-30P6.6 -6.82 4.27e-11 3.92e-08 -0.43 -0.35 Response to antipsychotic treatment; chr6:85528079 chr6:85387219~85390186:- LIHC cis rs1577917 0.771 rs7452605 ENSG00000234155.1 RP11-30P6.6 -6.82 4.27e-11 3.92e-08 -0.43 -0.35 Response to antipsychotic treatment; chr6:85531233 chr6:85387219~85390186:- LIHC cis rs1577917 0.771 rs9294337 ENSG00000234155.1 RP11-30P6.6 -6.82 4.27e-11 3.92e-08 -0.43 -0.35 Response to antipsychotic treatment; chr6:85538742 chr6:85387219~85390186:- LIHC cis rs10916248 0.511 rs10916512 ENSG00000232628.4 RP11-365O16.3 6.81 4.27e-11 3.92e-08 0.46 0.35 QT interval (drug interaction); chr1:224220968 chr1:224208747~224213279:- LIHC cis rs6490294 0.898 rs57646770 ENSG00000226469.1 ADAM1B 6.81 4.27e-11 3.92e-08 0.45 0.35 Mean platelet volume; chr12:111993408 chr12:111927018~111929017:+ LIHC cis rs1577917 0.958 rs12191340 ENSG00000234155.1 RP11-30P6.6 6.81 4.28e-11 3.93e-08 0.41 0.35 Response to antipsychotic treatment; chr6:85811682 chr6:85387219~85390186:- LIHC cis rs7131987 0.621 rs57803026 ENSG00000257176.2 RP11-996F15.2 -6.81 4.29e-11 3.94e-08 -0.41 -0.35 QT interval; chr12:29344573 chr12:29280418~29317848:- LIHC cis rs748404 0.518 rs480108 ENSG00000205771.5 CATSPER2P1 -6.81 4.29e-11 3.94e-08 -0.42 -0.35 Lung cancer; chr15:43525208 chr15:43726918~43747094:- LIHC cis rs10899021 0.79 rs12296094 ENSG00000279353.1 RP11-864N7.4 6.81 4.31e-11 3.96e-08 0.76 0.35 Response to metformin (IC50); chr11:74610655 chr11:74698231~74699658:- LIHC cis rs4820294 1 rs62236667 ENSG00000233360.4 Z83844.1 6.81 4.31e-11 3.96e-08 0.44 0.35 Fat distribution (HIV); chr22:37665513 chr22:37641832~37658377:- LIHC cis rs4820294 1 rs713835 ENSG00000233360.4 Z83844.1 6.81 4.31e-11 3.96e-08 0.44 0.35 Fat distribution (HIV); chr22:37668643 chr22:37641832~37658377:- LIHC cis rs55665837 0.701 rs12286408 ENSG00000251991.1 RNU7-49P 6.81 4.32e-11 3.97e-08 0.38 0.35 Vitamin D levels; chr11:14557830 chr11:14478892~14478953:+ LIHC cis rs7580658 0.724 rs12623948 ENSG00000236682.1 AC068282.3 -6.81 4.36e-11 4e-08 -0.43 -0.35 Protein C levels; chr2:127243766 chr2:127389130~127400580:+ LIHC cis rs2439831 0.85 rs3825783 ENSG00000205771.5 CATSPER2P1 -6.81 4.38e-11 4.02e-08 -0.52 -0.35 Lung cancer in ever smokers; chr15:43810111 chr15:43726918~43747094:- LIHC cis rs4660456 0.913 rs3767950 ENSG00000237899.1 RP4-739H11.3 -6.81 4.39e-11 4.03e-08 -0.46 -0.35 Platelet count; chr1:40767541 chr1:40669089~40687588:- LIHC cis rs11168854 0.719 rs11168902 ENSG00000258017.1 RP11-386G11.10 -6.81 4.4e-11 4.03e-08 -0.41 -0.35 Body mass index; chr12:49174483 chr12:49127782~49147869:+ LIHC cis rs2117029 0.553 rs11168903 ENSG00000258017.1 RP11-386G11.10 -6.81 4.4e-11 4.03e-08 -0.41 -0.35 Intelligence (multi-trait analysis); chr12:49174883 chr12:49127782~49147869:+ LIHC cis rs1891275 0.515 rs10881957 ENSG00000228701.1 TNKS2-AS1 -6.81 4.42e-11 4.05e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr10:91742119 chr10:91782839~91798291:- LIHC cis rs4728142 0.604 rs12155080 ENSG00000275106.1 RP11-309L24.10 -6.81 4.43e-11 4.06e-08 -0.43 -0.35 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129018685 chr7:128952527~128953316:- LIHC cis rs4728142 0.604 rs10229001 ENSG00000275106.1 RP11-309L24.10 -6.81 4.45e-11 4.08e-08 -0.43 -0.35 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128959343 chr7:128952527~128953316:- LIHC cis rs7615952 0.611 rs7632305 ENSG00000171084.14 FAM86JP 6.81 4.5e-11 4.12e-08 0.73 0.35 Blood pressure (smoking interaction); chr3:125915924 chr3:125916620~125930024:+ LIHC cis rs7615952 0.673 rs9841194 ENSG00000171084.14 FAM86JP 6.81 4.5e-11 4.12e-08 0.73 0.35 Blood pressure (smoking interaction); chr3:125916896 chr3:125916620~125930024:+ LIHC cis rs7617773 0.817 rs3729577 ENSG00000229759.1 MRPS18AP1 6.81 4.5e-11 4.12e-08 0.43 0.35 Coronary artery disease; chr3:48187504 chr3:48256350~48256938:- LIHC cis rs6991838 0.584 rs2175810 ENSG00000200714.1 Y_RNA -6.81 4.53e-11 4.15e-08 -0.36 -0.35 Intelligence (multi-trait analysis); chr8:65643583 chr8:65592731~65592820:+ LIHC cis rs1003645 0.569 rs7222922 ENSG00000278690.1 RP11-104J23.2 6.81 4.53e-11 4.15e-08 0.45 0.35 Blood protein levels; chr17:36008654 chr17:36012504~36012891:+ LIHC cis rs1185460 0.967 rs4454730 ENSG00000271751.1 RP11-110I1.14 -6.8 4.55e-11 4.17e-08 -0.46 -0.35 Coronary artery disease; chr11:119066733 chr11:119065263~119065677:- LIHC cis rs1185460 0.967 rs4545564 ENSG00000271751.1 RP11-110I1.14 -6.8 4.55e-11 4.17e-08 -0.46 -0.35 Coronary artery disease; chr11:119066807 chr11:119065263~119065677:- LIHC cis rs9660180 0.935 rs9786942 ENSG00000268575.1 RP1-283E3.8 -6.8 4.59e-11 4.2e-08 -0.32 -0.35 Body mass index; chr1:1827774 chr1:1702736~1737688:- LIHC cis rs2033711 0.811 rs9304814 ENSG00000269473.1 CTD-2619J13.19 6.8 4.6e-11 4.21e-08 0.4 0.35 Uric acid clearance; chr19:58440444 chr19:58440448~58445849:+ LIHC cis rs2117029 0.619 rs2753 ENSG00000258017.1 RP11-386G11.10 -6.8 4.61e-11 4.22e-08 -0.41 -0.35 Intelligence (multi-trait analysis); chr12:49127889 chr12:49127782~49147869:+ LIHC cis rs831571 0.774 rs254858 ENSG00000280620.1 SCAANT1 -6.8 4.61e-11 4.22e-08 -0.47 -0.35 Type 2 diabetes; chr3:64070579 chr3:63911518~63911772:- LIHC cis rs6142102 0.517 rs6142050 ENSG00000276073.1 RP5-1125A11.7 -6.8 4.62e-11 4.22e-08 -0.35 -0.35 Skin pigmentation; chr20:33939322 chr20:33985617~33988989:- LIHC cis rs2836950 0.52 rs2836966 ENSG00000255568.3 BRWD1-AS2 -6.8 4.65e-11 4.25e-08 -0.28 -0.35 Menarche (age at onset); chr21:39265595 chr21:39313935~39314962:+ LIHC cis rs17270561 0.609 rs7746609 ENSG00000216436.2 HIST1H2APS1 6.8 4.65e-11 4.25e-08 0.42 0.35 Iron status biomarkers; chr6:25727768 chr6:25732497~25732827:+ LIHC cis rs2117029 0.653 rs1476137 ENSG00000258017.1 RP11-386G11.10 -6.8 4.66e-11 4.26e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49129930 chr12:49127782~49147869:+ LIHC cis rs2117029 0.553 rs731350 ENSG00000258017.1 RP11-386G11.10 -6.8 4.66e-11 4.26e-08 -0.42 -0.35 Intelligence (multi-trait analysis); chr12:49130804 chr12:49127782~49147869:+ LIHC cis rs1005277 0.579 rs1621040 ENSG00000263064.2 RP11-291L22.7 6.8 4.67e-11 4.27e-08 0.36 0.35 Extrinsic epigenetic age acceleration; chr10:38208304 chr10:38448689~38448949:+ LIHC cis rs1185460 0.565 rs2276060 ENSG00000271751.1 RP11-110I1.14 6.8 4.67e-11 4.27e-08 0.44 0.35 Coronary artery disease; chr11:119048420 chr11:119065263~119065677:- LIHC cis rs1023500 0.573 rs4822088 ENSG00000227370.1 RP4-669P10.19 -6.8 4.67e-11 4.27e-08 -0.4 -0.35 Schizophrenia; chr22:42074585 chr22:42132543~42132998:+ LIHC cis rs1577917 1 rs6923148 ENSG00000234155.1 RP11-30P6.6 -6.8 4.71e-11 4.3e-08 -0.41 -0.35 Response to antipsychotic treatment; chr6:86058068 chr6:85387219~85390186:- LIHC cis rs2836950 0.502 rs12627205 ENSG00000255568.3 BRWD1-AS2 -6.8 4.71e-11 4.31e-08 -0.28 -0.35 Menarche (age at onset); chr21:39258101 chr21:39313935~39314962:+ LIHC cis rs916888 0.647 rs199449 ENSG00000214401.4 KANSL1-AS1 6.8 4.72e-11 4.31e-08 0.42 0.35 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:46193576~46196723:+ LIHC cis rs2882667 0.755 rs55650316 ENSG00000253404.1 AC034243.1 6.8 4.73e-11 4.32e-08 0.48 0.35 Age-related hearing impairment (SNP x SNP interaction); chr5:139131603 chr5:138744434~138753309:- LIHC cis rs916888 0.61 rs199444 ENSG00000214401.4 KANSL1-AS1 6.8 4.74e-11 4.33e-08 0.42 0.35 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:46193576~46196723:+ LIHC cis rs916888 0.61 rs199442 ENSG00000214401.4 KANSL1-AS1 6.8 4.74e-11 4.33e-08 0.42 0.35 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:46193576~46196723:+ LIHC cis rs801193 0.591 rs9986881 ENSG00000226824.5 RP4-756H11.3 -6.8 4.74e-11 4.33e-08 -0.41 -0.35 Aortic root size; chr7:66708053 chr7:66654538~66669855:+ LIHC cis rs4718428 0.705 rs4717331 ENSG00000226824.5 RP4-756H11.3 -6.8 4.78e-11 4.37e-08 -0.45 -0.34 Corneal structure; chr7:66913899 chr7:66654538~66669855:+ LIHC cis rs1577917 0.917 rs1838959 ENSG00000234155.1 RP11-30P6.6 6.8 4.79e-11 4.37e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85847086 chr6:85387219~85390186:- LIHC cis rs1577917 0.917 rs1579886 ENSG00000234155.1 RP11-30P6.6 6.8 4.79e-11 4.37e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85847473 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs1816937 ENSG00000234155.1 RP11-30P6.6 6.8 4.79e-11 4.37e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85847533 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs7382798 ENSG00000234155.1 RP11-30P6.6 6.8 4.79e-11 4.37e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85850116 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs1838958 ENSG00000234155.1 RP11-30P6.6 6.8 4.79e-11 4.37e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85854250 chr6:85387219~85390186:- LIHC cis rs1577917 0.917 rs12665464 ENSG00000234155.1 RP11-30P6.6 6.8 4.79e-11 4.37e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85864415 chr6:85387219~85390186:- LIHC cis rs992157 0.835 rs4674282 ENSG00000261338.2 RP11-378A13.1 -6.8 4.81e-11 4.39e-08 -0.35 -0.34 Colorectal cancer; chr2:218279507 chr2:218255319~218257366:+ LIHC cis rs2836950 0.545 rs8132424 ENSG00000255568.3 BRWD1-AS2 6.8 4.82e-11 4.4e-08 0.28 0.34 Menarche (age at onset); chr21:39212486 chr21:39313935~39314962:+ LIHC cis rs1577917 0.771 rs9450290 ENSG00000234155.1 RP11-30P6.6 -6.79 4.83e-11 4.41e-08 -0.43 -0.34 Response to antipsychotic treatment; chr6:85523679 chr6:85387219~85390186:- LIHC cis rs1185460 0.967 rs1786684 ENSG00000271751.1 RP11-110I1.14 -6.79 4.85e-11 4.42e-08 -0.46 -0.34 Coronary artery disease; chr11:119067724 chr11:119065263~119065677:- LIHC cis rs10256972 0.524 rs6945202 ENSG00000229043.2 AC091729.9 -6.79 4.87e-11 4.44e-08 -0.4 -0.34 Endometriosis;Longevity; chr7:1076922 chr7:1160374~1165267:+ LIHC cis rs992157 0.71 rs12694432 ENSG00000261338.2 RP11-378A13.1 6.79 4.88e-11 4.45e-08 0.34 0.34 Colorectal cancer; chr2:218217607 chr2:218255319~218257366:+ LIHC cis rs992157 0.698 rs6746089 ENSG00000261338.2 RP11-378A13.1 6.79 4.88e-11 4.45e-08 0.35 0.34 Colorectal cancer; chr2:218305654 chr2:218255319~218257366:+ LIHC cis rs1065852 0.906 rs9611734 ENSG00000237037.8 NDUFA6-AS1 -6.79 4.93e-11 4.49e-08 -0.43 -0.34 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42106066 chr22:42090931~42137742:+ LIHC cis rs7617773 0.817 rs13068265 ENSG00000229759.1 MRPS18AP1 6.79 4.93e-11 4.49e-08 0.43 0.34 Coronary artery disease; chr3:48260124 chr3:48256350~48256938:- LIHC cis rs7615952 0.932 rs11922218 ENSG00000171084.14 FAM86JP 6.79 4.95e-11 4.51e-08 0.63 0.34 Blood pressure (smoking interaction); chr3:125912446 chr3:125916620~125930024:+ LIHC cis rs7615952 0.866 rs11922276 ENSG00000171084.14 FAM86JP 6.79 4.95e-11 4.51e-08 0.63 0.34 Blood pressure (smoking interaction); chr3:125912483 chr3:125916620~125930024:+ LIHC cis rs7615952 0.551 rs6438945 ENSG00000171084.14 FAM86JP 6.79 4.97e-11 4.52e-08 0.64 0.34 Blood pressure (smoking interaction); chr3:125915630 chr3:125916620~125930024:+ LIHC cis rs7615952 0.932 rs9841157 ENSG00000171084.14 FAM86JP 6.79 4.97e-11 4.52e-08 0.64 0.34 Blood pressure (smoking interaction); chr3:125916812 chr3:125916620~125930024:+ LIHC cis rs7615952 0.551 rs12695470 ENSG00000171084.14 FAM86JP 6.79 4.97e-11 4.52e-08 0.64 0.34 Blood pressure (smoking interaction); chr3:125916875 chr3:125916620~125930024:+ LIHC cis rs9326248 0.817 rs1242127 ENSG00000280143.1 AP000892.6 -6.79 4.97e-11 4.52e-08 -0.39 -0.34 Blood protein levels; chr11:117205848 chr11:117204967~117210292:+ LIHC cis rs1185460 0.967 rs1786690 ENSG00000271751.1 RP11-110I1.14 -6.79 4.97e-11 4.53e-08 -0.46 -0.34 Coronary artery disease; chr11:119071357 chr11:119065263~119065677:- LIHC cis rs7131987 0.65 rs7954871 ENSG00000257176.2 RP11-996F15.2 -6.79 4.99e-11 4.54e-08 -0.4 -0.34 QT interval; chr12:29306799 chr12:29280418~29317848:- LIHC cis rs1005277 0.579 rs2103938 ENSG00000263064.2 RP11-291L22.7 6.79 5e-11 4.55e-08 0.36 0.34 Extrinsic epigenetic age acceleration; chr10:38205070 chr10:38448689~38448949:+ LIHC cis rs1939012 0.846 rs3758857 ENSG00000281655.1 RP11-817J15.3 -6.79 5e-11 4.56e-08 -0.4 -0.34 Epilepsy; chr11:102727628 chr11:102681310~102683913:+ LIHC cis rs1939012 0.875 rs3758858 ENSG00000281655.1 RP11-817J15.3 -6.79 5e-11 4.56e-08 -0.4 -0.34 Epilepsy; chr11:102727726 chr11:102681310~102683913:+ LIHC cis rs992157 0.56 rs7578940 ENSG00000261338.2 RP11-378A13.1 -6.79 5.01e-11 4.56e-08 -0.34 -0.34 Colorectal cancer; chr2:218218595 chr2:218255319~218257366:+ LIHC cis rs1577917 0.958 rs2660576 ENSG00000234155.1 RP11-30P6.6 6.79 5.03e-11 4.58e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85941885 chr6:85387219~85390186:- LIHC cis rs1023500 0.596 rs133369 ENSG00000227370.1 RP4-669P10.19 -6.79 5.09e-11 4.63e-08 -0.4 -0.34 Schizophrenia; chr22:42067810 chr22:42132543~42132998:+ LIHC cis rs950027 0.787 rs1153845 ENSG00000259520.4 CTD-2651B20.3 6.79 5.1e-11 4.64e-08 0.43 0.34 Response to fenofibrate (adiponectin levels); chr15:45432531 chr15:45251580~45279251:- LIHC cis rs7617773 0.817 rs936427 ENSG00000229759.1 MRPS18AP1 -6.79 5.11e-11 4.65e-08 -0.43 -0.34 Coronary artery disease; chr3:48259584 chr3:48256350~48256938:- LIHC cis rs17270561 0.609 rs4132072 ENSG00000216436.2 HIST1H2APS1 -6.78 5.15e-11 4.69e-08 -0.42 -0.34 Iron status biomarkers; chr6:25717615 chr6:25732497~25732827:+ LIHC cis rs17270561 0.636 rs7453371 ENSG00000216436.2 HIST1H2APS1 -6.78 5.15e-11 4.69e-08 -0.42 -0.34 Iron status biomarkers; chr6:25719028 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs7450798 ENSG00000216436.2 HIST1H2APS1 -6.78 5.15e-11 4.69e-08 -0.42 -0.34 Iron status biomarkers; chr6:25719052 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4712957 ENSG00000216436.2 HIST1H2APS1 -6.78 5.15e-11 4.69e-08 -0.42 -0.34 Iron status biomarkers; chr6:25719586 chr6:25732497~25732827:+ LIHC cis rs17270561 0.666 rs17320090 ENSG00000216436.2 HIST1H2APS1 -6.78 5.15e-11 4.69e-08 -0.42 -0.34 Iron status biomarkers; chr6:25719987 chr6:25732497~25732827:+ LIHC cis rs7615952 0.932 rs13065725 ENSG00000171084.14 FAM86JP 6.78 5.17e-11 4.7e-08 0.64 0.34 Blood pressure (smoking interaction); chr3:125913446 chr3:125916620~125930024:+ LIHC cis rs1185460 0.546 rs2508948 ENSG00000271751.1 RP11-110I1.14 6.78 5.18e-11 4.71e-08 0.45 0.34 Coronary artery disease; chr11:119080932 chr11:119065263~119065677:- LIHC cis rs1939012 0.846 rs11225395 ENSG00000281655.1 RP11-817J15.3 -6.78 5.21e-11 4.73e-08 -0.41 -0.34 Epilepsy; chr11:102725749 chr11:102681310~102683913:+ LIHC cis rs1185460 0.967 rs1184902 ENSG00000271751.1 RP11-110I1.14 -6.78 5.22e-11 4.75e-08 -0.47 -0.34 Coronary artery disease; chr11:119074627 chr11:119065263~119065677:- LIHC cis rs739496 0.579 rs3752630 ENSG00000226469.1 ADAM1B 6.78 5.24e-11 4.76e-08 0.44 0.34 Platelet count; chr12:111938186 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7973309 ENSG00000226469.1 ADAM1B 6.78 5.24e-11 4.76e-08 0.44 0.34 Platelet count; chr12:111944447 chr12:111927018~111929017:+ LIHC cis rs17270561 0.636 rs9393656 ENSG00000216436.2 HIST1H2APS1 -6.78 5.25e-11 4.76e-08 -0.42 -0.34 Iron status biomarkers; chr6:25721831 chr6:25732497~25732827:+ LIHC cis rs7131987 0.65 rs7957339 ENSG00000257176.2 RP11-996F15.2 -6.78 5.27e-11 4.79e-08 -0.39 -0.34 QT interval; chr12:29303562 chr12:29280418~29317848:- LIHC cis rs7615952 0.673 rs7632557 ENSG00000171084.14 FAM86JP 6.78 5.28e-11 4.8e-08 0.64 0.34 Blood pressure (smoking interaction); chr3:125916038 chr3:125916620~125930024:+ LIHC cis rs2117029 0.521 rs12229524 ENSG00000258017.1 RP11-386G11.10 -6.78 5.3e-11 4.81e-08 -0.41 -0.34 Intelligence (multi-trait analysis); chr12:49191570 chr12:49127782~49147869:+ LIHC cis rs6490294 0.851 rs1016079 ENSG00000226469.1 ADAM1B -6.78 5.31e-11 4.82e-08 -0.44 -0.34 Mean platelet volume; chr12:111972382 chr12:111927018~111929017:+ LIHC cis rs2836950 0.545 rs1888489 ENSG00000255568.3 BRWD1-AS2 -6.78 5.32e-11 4.83e-08 -0.28 -0.34 Menarche (age at onset); chr21:39161238 chr21:39313935~39314962:+ LIHC cis rs524281 0.731 rs11227439 ENSG00000255320.1 RP11-755F10.1 6.78 5.33e-11 4.83e-08 0.47 0.34 Electroencephalogram traits; chr11:66258208 chr11:66244840~66246239:- LIHC cis rs524281 0.773 rs11227448 ENSG00000255320.1 RP11-755F10.1 6.78 5.33e-11 4.83e-08 0.47 0.34 Electroencephalogram traits; chr11:66281020 chr11:66244840~66246239:- LIHC cis rs6490294 0.528 rs12580175 ENSG00000226469.1 ADAM1B 6.78 5.36e-11 4.86e-08 0.51 0.34 Mean platelet volume; chr12:111926708 chr12:111927018~111929017:+ LIHC cis rs7617773 0.78 rs3731489 ENSG00000229759.1 MRPS18AP1 6.78 5.38e-11 4.88e-08 0.43 0.34 Coronary artery disease; chr3:48187416 chr3:48256350~48256938:- LIHC cis rs7617773 0.779 rs3731487 ENSG00000229759.1 MRPS18AP1 6.78 5.38e-11 4.88e-08 0.43 0.34 Coronary artery disease; chr3:48188134 chr3:48256350~48256938:- LIHC cis rs2882667 0.683 rs13188935 ENSG00000253404.1 AC034243.1 6.78 5.39e-11 4.89e-08 0.44 0.34 Age-related hearing impairment (SNP x SNP interaction); chr5:139116536 chr5:138744434~138753309:- LIHC cis rs4660456 0.913 rs4660449 ENSG00000237899.1 RP4-739H11.3 6.78 5.41e-11 4.9e-08 0.45 0.34 Platelet count; chr1:40739780 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs6661855 ENSG00000237899.1 RP4-739H11.3 6.78 5.41e-11 4.91e-08 0.46 0.34 Platelet count; chr1:40703245 chr1:40669089~40687588:- LIHC cis rs7580658 0.724 rs6712213 ENSG00000236682.1 AC068282.3 -6.78 5.42e-11 4.91e-08 -0.43 -0.34 Protein C levels; chr2:127240654 chr2:127389130~127400580:+ LIHC cis rs1577917 0.57 rs114854865 ENSG00000234155.1 RP11-30P6.6 6.78 5.43e-11 4.92e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85844518 chr6:85387219~85390186:- LIHC cis rs2439831 0.85 rs2228368 ENSG00000205771.5 CATSPER2P1 -6.78 5.45e-11 4.94e-08 -0.52 -0.34 Lung cancer in ever smokers; chr15:43809812 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs3097773 ENSG00000205771.5 CATSPER2P1 6.77 5.45e-11 4.94e-08 0.47 0.34 Lung cancer in ever smokers; chr15:43600874 chr15:43726918~43747094:- LIHC cis rs1062753 0.771 rs5751245 ENSG00000237037.8 NDUFA6-AS1 -6.77 5.46e-11 4.95e-08 -0.39 -0.34 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42224934 chr22:42090931~42137742:+ LIHC cis rs6490294 0.528 rs12423268 ENSG00000226469.1 ADAM1B 6.77 5.48e-11 4.96e-08 0.52 0.34 Mean platelet volume; chr12:112203903 chr12:111927018~111929017:+ LIHC cis rs765787 0.556 rs2413778 ENSG00000259520.4 CTD-2651B20.3 6.77 5.49e-11 4.97e-08 0.41 0.34 Uric acid levels; chr15:45247199 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs28756676 ENSG00000259520.4 CTD-2651B20.3 6.77 5.49e-11 4.97e-08 0.41 0.34 Uric acid levels; chr15:45248162 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs55771002 ENSG00000259520.4 CTD-2651B20.3 6.77 5.49e-11 4.97e-08 0.41 0.34 Uric acid levels; chr15:45249368 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs55920042 ENSG00000259520.4 CTD-2651B20.3 6.77 5.49e-11 4.97e-08 0.41 0.34 Uric acid levels; chr15:45249379 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4238376 ENSG00000259520.4 CTD-2651B20.3 6.77 5.49e-11 4.97e-08 0.41 0.34 Uric acid levels; chr15:45249689 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4238377 ENSG00000259520.4 CTD-2651B20.3 6.77 5.49e-11 4.97e-08 0.41 0.34 Uric acid levels; chr15:45249783 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4775844 ENSG00000259520.4 CTD-2651B20.3 6.77 5.49e-11 4.97e-08 0.41 0.34 Uric acid levels; chr15:45249850 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs3759893 ENSG00000259520.4 CTD-2651B20.3 6.77 5.49e-11 4.97e-08 0.41 0.34 Uric acid levels; chr15:45250752 chr15:45251580~45279251:- LIHC cis rs1939012 0.846 rs1939014 ENSG00000281655.1 RP11-817J15.3 -6.77 5.49e-11 4.97e-08 -0.4 -0.34 Epilepsy; chr11:102727181 chr11:102681310~102683913:+ LIHC cis rs10875746 0.859 rs4760695 ENSG00000240399.1 RP1-228P16.1 -6.77 5.51e-11 4.99e-08 -0.37 -0.34 Longevity (90 years and older); chr12:48198065 chr12:48054813~48055591:- LIHC cis rs2882667 0.66 rs11951084 ENSG00000253404.1 AC034243.1 6.77 5.52e-11 5e-08 0.45 0.34 Age-related hearing impairment (SNP x SNP interaction); chr5:139125858 chr5:138744434~138753309:- LIHC cis rs2117029 0.587 rs57853986 ENSG00000258017.1 RP11-386G11.10 -6.77 5.53e-11 5e-08 -0.42 -0.34 Intelligence (multi-trait analysis); chr12:49124612 chr12:49127782~49147869:+ LIHC cis rs9549367 0.826 rs35306827 ENSG00000269125.1 RP11-98F14.11 -6.77 5.56e-11 5.03e-08 -0.42 -0.34 Platelet distribution width; chr13:113214731 chr13:113165002~113165183:- LIHC cis rs4728142 0.625 rs4731533 ENSG00000275106.1 RP11-309L24.10 -6.77 5.56e-11 5.03e-08 -0.43 -0.34 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128962088 chr7:128952527~128953316:- LIHC cis rs67383717 0.527 rs12004422 ENSG00000175611.10 LINC00476 6.77 5.56e-11 5.03e-08 0.44 0.34 Parkinson's disease (pesticide exposure interaction); chr9:95873393 chr9:95759231~95875977:- LIHC cis rs10875746 0.859 rs12305511 ENSG00000240399.1 RP1-228P16.1 6.77 5.57e-11 5.04e-08 0.37 0.34 Longevity (90 years and older); chr12:48188933 chr12:48054813~48055591:- LIHC cis rs10875746 0.859 rs12305647 ENSG00000240399.1 RP1-228P16.1 -6.77 5.58e-11 5.04e-08 -0.37 -0.34 Longevity (90 years and older); chr12:48189178 chr12:48054813~48055591:- LIHC cis rs4728142 0.584 rs7796963 ENSG00000275106.1 RP11-309L24.10 -6.77 5.58e-11 5.05e-08 -0.42 -0.34 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128988947 chr7:128952527~128953316:- LIHC cis rs916888 0.61 rs199446 ENSG00000214401.4 KANSL1-AS1 -6.77 5.6e-11 5.07e-08 -0.42 -0.34 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:46193576~46196723:+ LIHC cis rs916888 0.61 rs199536 ENSG00000214401.4 KANSL1-AS1 -6.77 5.6e-11 5.07e-08 -0.42 -0.34 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:46193576~46196723:+ LIHC cis rs7396835 0.8 rs6589572 ENSG00000236267.1 AP006216.5 6.77 5.61e-11 5.07e-08 0.41 0.34 Quantitative traits; chr11:116810847 chr11:116813204~116814003:- LIHC cis rs4660456 0.913 rs12727412 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40723243 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs4660448 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40724682 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs7532802 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40725528 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs2361648 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40726825 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs6675886 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40727955 chr1:40669089~40687588:- LIHC cis rs4660456 0.83 rs12742219 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40728665 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs6668453 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40733299 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs35881320 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40733893 chr1:40669089~40687588:- LIHC cis rs4660456 0.871 rs34512220 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40733912 chr1:40669089~40687588:- LIHC cis rs4660456 0.871 rs2274957 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40747290 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs4660173 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40747876 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs4660452 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40748519 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs12567925 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40751428 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs12728776 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40751718 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs12567755 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40751813 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs16827532 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40755064 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs12729696 ENSG00000237899.1 RP4-739H11.3 -6.77 5.64e-11 5.09e-08 -0.45 -0.34 Platelet count; chr1:40755099 chr1:40669089~40687588:- LIHC cis rs4660456 0.827 rs10736404 ENSG00000237899.1 RP4-739H11.3 6.77 5.64e-11 5.09e-08 0.45 0.34 Platelet count; chr1:40710331 chr1:40669089~40687588:- LIHC cis rs3096299 0.838 rs4785561 ENSG00000274627.1 RP11-104N10.2 6.77 5.65e-11 5.11e-08 0.4 0.34 Multiple myeloma (IgH translocation); chr16:89362644 chr16:89516797~89522217:+ LIHC cis rs992157 0.735 rs13388024 ENSG00000261338.2 RP11-378A13.1 6.77 5.72e-11 5.16e-08 0.34 0.34 Colorectal cancer; chr2:218233050 chr2:218255319~218257366:+ LIHC cis rs992157 0.735 rs12990082 ENSG00000261338.2 RP11-378A13.1 6.77 5.72e-11 5.16e-08 0.34 0.34 Colorectal cancer; chr2:218237609 chr2:218255319~218257366:+ LIHC cis rs992157 0.661 rs17653757 ENSG00000261338.2 RP11-378A13.1 6.77 5.72e-11 5.16e-08 0.34 0.34 Colorectal cancer; chr2:218244641 chr2:218255319~218257366:+ LIHC cis rs2439831 0.85 rs8032649 ENSG00000205771.5 CATSPER2P1 6.77 5.74e-11 5.18e-08 0.51 0.34 Lung cancer in ever smokers; chr15:43842724 chr15:43726918~43747094:- LIHC cis rs765787 0.53 rs7167389 ENSG00000259520.4 CTD-2651B20.3 6.77 5.74e-11 5.18e-08 0.41 0.34 Uric acid levels; chr15:45243485 chr15:45251580~45279251:- LIHC cis rs2117029 0.555 rs9788140 ENSG00000258017.1 RP11-386G11.10 -6.77 5.75e-11 5.19e-08 -0.41 -0.34 Intelligence (multi-trait analysis); chr12:49126738 chr12:49127782~49147869:+ LIHC cis rs6085948 0.861 rs6117729 ENSG00000238102.1 RP11-19D2.1 -6.77 5.76e-11 5.2e-08 -0.52 -0.34 Interleukin-10 levels; chr20:7267542 chr20:7256580~7258214:- LIHC cis rs6490294 0.528 rs61012856 ENSG00000226469.1 ADAM1B 6.77 5.79e-11 5.22e-08 0.51 0.34 Mean platelet volume; chr12:111927687 chr12:111927018~111929017:+ LIHC cis rs6490294 0.528 rs59131168 ENSG00000226469.1 ADAM1B 6.77 5.79e-11 5.22e-08 0.51 0.34 Mean platelet volume; chr12:111930559 chr12:111927018~111929017:+ LIHC cis rs2439831 0.85 rs60883262 ENSG00000205771.5 CATSPER2P1 -6.76 5.83e-11 5.26e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43784305 chr15:43726918~43747094:- LIHC cis rs7309 0.935 rs1921309 ENSG00000227403.1 AC009299.3 -6.76 5.86e-11 5.28e-08 -0.42 -0.34 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161192464 chr2:161244739~161249050:+ LIHC cis rs7309 0.935 rs11884495 ENSG00000227403.1 AC009299.3 -6.76 5.86e-11 5.28e-08 -0.42 -0.34 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161203458 chr2:161244739~161249050:+ LIHC cis rs7309 0.935 rs10930013 ENSG00000227403.1 AC009299.3 -6.76 5.86e-11 5.28e-08 -0.42 -0.34 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161213814 chr2:161244739~161249050:+ LIHC cis rs2836950 0.565 rs7278297 ENSG00000255568.3 BRWD1-AS2 -6.76 5.88e-11 5.3e-08 -0.29 -0.34 Menarche (age at onset); chr21:39253826 chr21:39313935~39314962:+ LIHC cis rs2439831 0.85 rs7168158 ENSG00000205771.5 CATSPER2P1 -6.76 5.94e-11 5.35e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43758178 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs7174208 ENSG00000205771.5 CATSPER2P1 -6.76 5.94e-11 5.35e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43760484 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs12101756 ENSG00000205771.5 CATSPER2P1 -6.76 5.94e-11 5.35e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43761689 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs3862142 ENSG00000205771.5 CATSPER2P1 -6.76 5.94e-11 5.35e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43772608 chr15:43726918~43747094:- LIHC cis rs2439831 0.702 rs2788 ENSG00000205771.5 CATSPER2P1 -6.76 5.94e-11 5.35e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43772688 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs28891769 ENSG00000205771.5 CATSPER2P1 -6.76 5.94e-11 5.35e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43780662 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs28578398 ENSG00000205771.5 CATSPER2P1 -6.76 5.94e-11 5.35e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43782848 chr15:43726918~43747094:- LIHC cis rs3096299 0.582 rs12935119 ENSG00000274627.1 RP11-104N10.2 6.76 5.95e-11 5.36e-08 0.35 0.34 Multiple myeloma (IgH translocation); chr16:89476466 chr16:89516797~89522217:+ LIHC cis rs7309 0.935 rs6432674 ENSG00000227403.1 AC009299.3 -6.76 5.95e-11 5.36e-08 -0.41 -0.34 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161168811 chr2:161244739~161249050:+ LIHC cis rs7309 0.81 rs11684253 ENSG00000227403.1 AC009299.3 -6.76 5.95e-11 5.36e-08 -0.41 -0.34 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161178025 chr2:161244739~161249050:+ LIHC cis rs9527 0.571 rs3740400 ENSG00000236937.2 PTGES3P4 6.76 5.97e-11 5.37e-08 0.41 0.34 Arsenic metabolism; chr10:102869708 chr10:102845595~102845950:+ LIHC cis rs9527 0.571 rs7904113 ENSG00000236937.2 PTGES3P4 6.76 6e-11 5.4e-08 0.41 0.34 Arsenic metabolism; chr10:102873357 chr10:102845595~102845950:+ LIHC cis rs8028182 0.583 rs4886722 ENSG00000260269.4 CTD-2323K18.1 -6.76 6e-11 5.4e-08 -0.45 -0.34 Sudden cardiac arrest; chr15:75629295 chr15:75527150~75601205:- LIHC cis rs748404 0.56 rs572837 ENSG00000205771.5 CATSPER2P1 -6.76 6e-11 5.4e-08 -0.42 -0.34 Lung cancer; chr15:43531615 chr15:43726918~43747094:- LIHC cis rs9527 0.525 rs12770034 ENSG00000236937.2 PTGES3P4 6.76 6.03e-11 5.43e-08 0.41 0.34 Arsenic metabolism; chr10:102875838 chr10:102845595~102845950:+ LIHC cis rs1577917 0.655 rs1059307 ENSG00000234155.1 RP11-30P6.6 -6.76 6.06e-11 5.45e-08 -0.41 -0.34 Response to antipsychotic treatment; chr6:85678170 chr6:85387219~85390186:- LIHC cis rs10875746 0.903 rs11168427 ENSG00000240399.1 RP1-228P16.1 -6.76 6.11e-11 5.49e-08 -0.39 -0.34 Longevity (90 years and older); chr12:48145196 chr12:48054813~48055591:- LIHC cis rs10875746 0.951 rs61918826 ENSG00000240399.1 RP1-228P16.1 -6.76 6.11e-11 5.49e-08 -0.39 -0.34 Longevity (90 years and older); chr12:48150195 chr12:48054813~48055591:- LIHC cis rs10875746 0.904 rs10875750 ENSG00000240399.1 RP1-228P16.1 -6.76 6.11e-11 5.49e-08 -0.39 -0.34 Longevity (90 years and older); chr12:48151847 chr12:48054813~48055591:- LIHC cis rs10875746 0.951 rs7485355 ENSG00000240399.1 RP1-228P16.1 -6.76 6.11e-11 5.49e-08 -0.39 -0.34 Longevity (90 years and older); chr12:48154559 chr12:48054813~48055591:- LIHC cis rs10899021 1 rs10899021 ENSG00000279353.1 RP11-864N7.4 -6.76 6.14e-11 5.52e-08 -0.72 -0.34 Response to metformin (IC50); chr11:74627009 chr11:74698231~74699658:- LIHC cis rs1939012 0.846 rs10750653 ENSG00000281655.1 RP11-817J15.3 -6.76 6.14e-11 5.52e-08 -0.4 -0.34 Epilepsy; chr11:102729275 chr11:102681310~102683913:+ LIHC cis rs1577917 1 rs35760725 ENSG00000234155.1 RP11-30P6.6 6.76 6.14e-11 5.52e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85939267 chr6:85387219~85390186:- LIHC cis rs10875746 0.951 rs11168433 ENSG00000240399.1 RP1-228P16.1 -6.76 6.15e-11 5.53e-08 -0.39 -0.34 Longevity (90 years and older); chr12:48164281 chr12:48054813~48055591:- LIHC cis rs524281 0.731 rs476551 ENSG00000255320.1 RP11-755F10.1 6.75 6.16e-11 5.54e-08 0.46 0.34 Electroencephalogram traits; chr11:66238852 chr11:66244840~66246239:- LIHC cis rs765787 0.53 rs2554453 ENSG00000259520.4 CTD-2651B20.3 6.75 6.18e-11 5.55e-08 0.4 0.34 Uric acid levels; chr15:45229909 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs11858988 ENSG00000259520.4 CTD-2651B20.3 6.75 6.18e-11 5.55e-08 0.4 0.34 Uric acid levels; chr15:45229916 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs11855435 ENSG00000259520.4 CTD-2651B20.3 6.75 6.18e-11 5.55e-08 0.4 0.34 Uric acid levels; chr15:45229919 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs2458224 ENSG00000259520.4 CTD-2651B20.3 6.75 6.18e-11 5.55e-08 0.4 0.34 Uric acid levels; chr15:45229932 chr15:45251580~45279251:- LIHC cis rs1862618 0.573 rs2034245 ENSG00000271828.1 CTD-2310F14.1 -6.75 6.19e-11 5.56e-08 -0.5 -0.34 Initial pursuit acceleration; chr5:56947858 chr5:56927874~56929573:+ LIHC cis rs150992 0.587 rs10040066 ENSG00000248489.1 CTD-2007H13.3 -6.75 6.2e-11 5.57e-08 -0.51 -0.34 Body mass index; chr5:99001333 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs4565239 ENSG00000248489.1 CTD-2007H13.3 -6.75 6.2e-11 5.57e-08 -0.51 -0.34 Body mass index; chr5:99002144 chr5:98929171~98995013:+ LIHC cis rs524281 0.773 rs10791863 ENSG00000255320.1 RP11-755F10.1 6.75 6.2e-11 5.57e-08 0.46 0.34 Electroencephalogram traits; chr11:66259887 chr11:66244840~66246239:- LIHC cis rs524281 0.773 rs10750781 ENSG00000255320.1 RP11-755F10.1 6.75 6.2e-11 5.57e-08 0.46 0.34 Electroencephalogram traits; chr11:66269799 chr11:66244840~66246239:- LIHC cis rs524281 0.773 rs2017969 ENSG00000255320.1 RP11-755F10.1 6.75 6.2e-11 5.57e-08 0.46 0.34 Electroencephalogram traits; chr11:66271561 chr11:66244840~66246239:- LIHC cis rs1023500 0.573 rs133381 ENSG00000227370.1 RP4-669P10.19 -6.75 6.21e-11 5.57e-08 -0.4 -0.34 Schizophrenia; chr22:42074604 chr22:42132543~42132998:+ LIHC cis rs4660456 0.913 rs954654 ENSG00000237899.1 RP4-739H11.3 -6.75 6.22e-11 5.59e-08 -0.45 -0.34 Platelet count; chr1:40764979 chr1:40669089~40687588:- LIHC cis rs7580658 0.724 rs4662711 ENSG00000236682.1 AC068282.3 -6.75 6.27e-11 5.63e-08 -0.42 -0.34 Protein C levels; chr2:127233264 chr2:127389130~127400580:+ LIHC cis rs7580658 0.929 rs11886231 ENSG00000236682.1 AC068282.3 -6.75 6.27e-11 5.63e-08 -0.43 -0.34 Protein C levels; chr2:127270554 chr2:127389130~127400580:+ LIHC cis rs2117029 0.587 rs1865157 ENSG00000258017.1 RP11-386G11.10 -6.75 6.29e-11 5.64e-08 -0.42 -0.34 Intelligence (multi-trait analysis); chr12:49129003 chr12:49127782~49147869:+ LIHC cis rs1023500 0.551 rs2854837 ENSG00000227370.1 RP4-669P10.19 -6.75 6.35e-11 5.7e-08 -0.4 -0.34 Schizophrenia; chr22:42062477 chr22:42132543~42132998:+ LIHC cis rs2283792 0.73 rs2027790 ENSG00000224086.5 LL22NC03-86G7.1 -6.75 6.46e-11 5.79e-08 -0.37 -0.34 Multiple sclerosis; chr22:21933592 chr22:21938293~21977632:+ LIHC cis rs6085948 0.861 rs6077169 ENSG00000238102.1 RP11-19D2.1 -6.75 6.46e-11 5.79e-08 -0.52 -0.34 Interleukin-10 levels; chr20:7267815 chr20:7256580~7258214:- LIHC cis rs9595066 0.627 rs4941486 ENSG00000227258.4 SMIM2-AS1 6.75 6.48e-11 5.8e-08 0.42 0.34 Schizophrenia; chr13:44175021 chr13:44110451~44240517:+ LIHC cis rs6061231 0.834 rs2427307 ENSG00000273619.1 RP5-908M14.9 -6.75 6.49e-11 5.81e-08 -0.31 -0.34 Colorectal cancer; chr20:62391630 chr20:62386303~62386970:- LIHC cis rs6490294 0.851 rs56814171 ENSG00000226469.1 ADAM1B 6.75 6.49e-11 5.81e-08 0.44 0.34 Mean platelet volume; chr12:111965146 chr12:111927018~111929017:+ LIHC cis rs765787 0.53 rs2413786 ENSG00000259520.4 CTD-2651B20.3 6.75 6.5e-11 5.82e-08 0.4 0.34 Uric acid levels; chr15:45233196 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4775819 ENSG00000259520.4 CTD-2651B20.3 6.75 6.5e-11 5.82e-08 0.4 0.34 Uric acid levels; chr15:45233768 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs28815867 ENSG00000259520.4 CTD-2651B20.3 6.75 6.5e-11 5.82e-08 0.4 0.34 Uric acid levels; chr15:45234607 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4775822 ENSG00000259520.4 CTD-2651B20.3 6.75 6.5e-11 5.82e-08 0.4 0.34 Uric acid levels; chr15:45234929 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs11854294 ENSG00000259520.4 CTD-2651B20.3 6.75 6.5e-11 5.82e-08 0.4 0.34 Uric acid levels; chr15:45235798 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs2899381 ENSG00000259520.4 CTD-2651B20.3 6.75 6.5e-11 5.82e-08 0.4 0.34 Uric acid levels; chr15:45237432 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs2413785 ENSG00000259520.4 CTD-2651B20.3 6.75 6.5e-11 5.82e-08 0.4 0.34 Uric acid levels; chr15:45238183 chr15:45251580~45279251:- LIHC cis rs2439831 0.85 rs10163054 ENSG00000205771.5 CATSPER2P1 -6.75 6.52e-11 5.84e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43755440 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs12442129 ENSG00000205771.5 CATSPER2P1 -6.75 6.52e-11 5.84e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43763658 chr15:43726918~43747094:- LIHC cis rs2439831 0.702 rs7175032 ENSG00000205771.5 CATSPER2P1 -6.75 6.52e-11 5.84e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43768038 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs2277531 ENSG00000205771.5 CATSPER2P1 -6.75 6.52e-11 5.84e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43776871 chr15:43726918~43747094:- LIHC cis rs7131987 0.65 rs10843377 ENSG00000257176.2 RP11-996F15.2 6.74 6.58e-11 5.89e-08 0.4 0.34 QT interval; chr12:29284120 chr12:29280418~29317848:- LIHC cis rs9549367 0.662 rs3818334 ENSG00000269125.1 RP11-98F14.11 -6.74 6.59e-11 5.89e-08 -0.44 -0.34 Platelet distribution width; chr13:113170860 chr13:113165002~113165183:- LIHC cis rs932287 0.58 rs10743098 ENSG00000254860.4 TMEM9B-AS1 -6.74 6.6e-11 5.9e-08 -0.36 -0.34 Colonoscopy-negative controls vs population controls; chr11:9038003 chr11:8964675~8977527:+ LIHC cis rs7923609 0.578 rs10761789 ENSG00000232075.1 MRPL35P2 -6.74 6.6e-11 5.9e-08 -0.36 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63636804 chr10:63634317~63634827:- LIHC cis rs739496 0.579 rs3752631 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Platelet count; chr12:111938353 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7959619 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Platelet count; chr12:111938793 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs11066095 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Platelet count; chr12:111939733 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs7133881 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Platelet count; chr12:111940964 chr12:111927018~111929017:+ LIHC cis rs6490294 0.748 rs7295665 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Mean platelet volume; chr12:111941467 chr12:111927018~111929017:+ LIHC cis rs739496 0.614 rs7137889 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Platelet count; chr12:111941783 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs80017658 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Platelet count; chr12:111942568 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs73426362 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Platelet count; chr12:111942666 chr12:111927018~111929017:+ LIHC cis rs6490294 0.904 rs12579298 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Mean platelet volume; chr12:111956218 chr12:111927018~111929017:+ LIHC cis rs6490294 0.904 rs12306814 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Mean platelet volume; chr12:111966009 chr12:111927018~111929017:+ LIHC cis rs6490294 0.904 rs12423061 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Mean platelet volume; chr12:111967091 chr12:111927018~111929017:+ LIHC cis rs6490294 0.904 rs112426410 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Mean platelet volume; chr12:111969634 chr12:111927018~111929017:+ LIHC cis rs6490294 0.904 rs9971871 ENSG00000226469.1 ADAM1B 6.74 6.61e-11 5.9e-08 0.44 0.34 Mean platelet volume; chr12:111970572 chr12:111927018~111929017:+ LIHC cis rs62355901 0.545 rs6882255 ENSG00000271828.1 CTD-2310F14.1 6.74 6.61e-11 5.9e-08 0.57 0.34 Breast cancer; chr5:56762344 chr5:56927874~56929573:+ LIHC cis rs7615952 0.8 rs12489350 ENSG00000171084.14 FAM86JP 6.74 6.62e-11 5.91e-08 0.62 0.34 Blood pressure (smoking interaction); chr3:125925273 chr3:125916620~125930024:+ LIHC cis rs2836950 0.545 rs2836956 ENSG00000255568.3 BRWD1-AS2 6.74 6.63e-11 5.92e-08 0.28 0.34 Menarche (age at onset); chr21:39251092 chr21:39313935~39314962:+ LIHC cis rs1577917 0.958 rs10455448 ENSG00000234155.1 RP11-30P6.6 6.74 6.64e-11 5.93e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85823893 chr6:85387219~85390186:- LIHC cis rs1577917 0.917 rs13196576 ENSG00000234155.1 RP11-30P6.6 6.74 6.64e-11 5.93e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85824348 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs3857480 ENSG00000234155.1 RP11-30P6.6 6.74 6.64e-11 5.93e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85825431 chr6:85387219~85390186:- LIHC cis rs2882667 0.66 rs6894907 ENSG00000253404.1 AC034243.1 6.74 6.64e-11 5.93e-08 0.43 0.34 Age-related hearing impairment (SNP x SNP interaction); chr5:139106815 chr5:138744434~138753309:- LIHC cis rs34779708 0.931 rs2490663 ENSG00000230534.5 RP11-297A16.2 -6.74 6.65e-11 5.93e-08 -0.42 -0.34 Inflammatory bowel disease;Crohn's disease; chr10:35040807 chr10:35098006~35127020:- LIHC cis rs9326248 0.773 rs1060211 ENSG00000280143.1 AP000892.6 6.74 6.68e-11 5.96e-08 0.4 0.34 Blood protein levels; chr11:117169081 chr11:117204967~117210292:+ LIHC cis rs2117029 0.521 rs1039225 ENSG00000258017.1 RP11-386G11.10 -6.74 6.7e-11 5.98e-08 -0.41 -0.34 Intelligence (multi-trait analysis); chr12:49188909 chr12:49127782~49147869:+ LIHC cis rs2117029 0.521 rs11168910 ENSG00000258017.1 RP11-386G11.10 -6.74 6.7e-11 5.98e-08 -0.41 -0.34 Intelligence (multi-trait analysis); chr12:49192707 chr12:49127782~49147869:+ LIHC cis rs6490294 0.571 rs58886972 ENSG00000226469.1 ADAM1B 6.74 6.74e-11 6.01e-08 0.52 0.34 Mean platelet volume; chr12:112071477 chr12:111927018~111929017:+ LIHC cis rs2734839 0.507 rs2245805 ENSG00000270179.1 RP11-159N11.4 -6.74 6.8e-11 6.06e-08 -0.39 -0.34 Information processing speed; chr11:113419977 chr11:113368478~113369117:+ LIHC cis rs494459 0.504 rs7929520 ENSG00000255239.1 AP002954.6 6.74 6.83e-11 6.09e-08 0.39 0.34 Height; chr11:118859432 chr11:118688039~118690600:- LIHC cis rs4660456 0.83 rs12566786 ENSG00000237899.1 RP4-739H11.3 -6.74 6.89e-11 6.14e-08 -0.45 -0.34 Platelet count; chr1:40742709 chr1:40669089~40687588:- LIHC cis rs992157 0.798 rs2382818 ENSG00000261338.2 RP11-378A13.1 -6.74 6.95e-11 6.19e-08 -0.35 -0.34 Colorectal cancer; chr2:218291184 chr2:218255319~218257366:+ LIHC cis rs992157 0.798 rs2382819 ENSG00000261338.2 RP11-378A13.1 -6.74 6.95e-11 6.19e-08 -0.35 -0.34 Colorectal cancer; chr2:218291186 chr2:218255319~218257366:+ LIHC cis rs4660456 0.913 rs6702983 ENSG00000237899.1 RP4-739H11.3 -6.73 6.96e-11 6.2e-08 -0.45 -0.34 Platelet count; chr1:40735585 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs12566733 ENSG00000237899.1 RP4-739H11.3 -6.73 6.96e-11 6.2e-08 -0.45 -0.34 Platelet count; chr1:40736067 chr1:40669089~40687588:- LIHC cis rs11603023 0.967 rs494560 ENSG00000255239.1 AP002954.6 -6.73 6.99e-11 6.22e-08 -0.38 -0.34 Cholesterol, total; chr11:118650844 chr11:118688039~118690600:- LIHC cis rs1577917 0.958 rs4707229 ENSG00000234155.1 RP11-30P6.6 6.73 7e-11 6.23e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85836519 chr6:85387219~85390186:- LIHC cis rs2243480 0.908 rs4718273 ENSG00000164669.11 INTS4P1 -6.73 7.01e-11 6.24e-08 -0.6 -0.34 Diabetic kidney disease; chr7:65751112 chr7:65141225~65234216:+ LIHC cis rs4820294 1 rs929039 ENSG00000233360.4 Z83844.1 6.73 7.06e-11 6.28e-08 0.44 0.34 Fat distribution (HIV); chr22:37675504 chr22:37641832~37658377:- LIHC cis rs6991838 0.584 rs4275254 ENSG00000200714.1 Y_RNA -6.73 7.09e-11 6.31e-08 -0.36 -0.34 Intelligence (multi-trait analysis); chr8:65589129 chr8:65592731~65592820:+ LIHC cis rs4660456 0.913 rs16827569 ENSG00000237899.1 RP4-739H11.3 -6.73 7.1e-11 6.31e-08 -0.45 -0.34 Platelet count; chr1:40761655 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs552147 ENSG00000237899.1 RP4-739H11.3 -6.73 7.11e-11 6.32e-08 -0.46 -0.34 Platelet count; chr1:40689141 chr1:40669089~40687588:- LIHC cis rs3020736 0.5 rs4147638 ENSG00000227370.1 RP4-669P10.19 6.73 7.13e-11 6.33e-08 0.4 0.34 Autism spectrum disorder or schizophrenia; chr22:42091896 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs6002605 ENSG00000227370.1 RP4-669P10.19 6.73 7.13e-11 6.33e-08 0.4 0.34 Autism spectrum disorder or schizophrenia; chr22:42098331 chr22:42132543~42132998:+ LIHC cis rs17301013 0.507 rs60811893 ENSG00000227373.4 RP11-160H22.5 6.73 7.13e-11 6.34e-08 0.58 0.34 Systemic lupus erythematosus; chr1:174765968 chr1:174115300~174160004:- LIHC cis rs62229266 0.557 rs4817761 ENSG00000231106.2 LINC01436 6.73 7.17e-11 6.37e-08 0.38 0.34 Mitral valve prolapse; chr21:36023258 chr21:36005338~36007838:+ LIHC cis rs494459 0.536 rs7103067 ENSG00000255239.1 AP002954.6 6.73 7.17e-11 6.38e-08 0.4 0.34 Height; chr11:118852670 chr11:118688039~118690600:- LIHC cis rs4660456 0.826 rs3767952 ENSG00000237899.1 RP4-739H11.3 -6.73 7.2e-11 6.39e-08 -0.45 -0.34 Platelet count; chr1:40765360 chr1:40669089~40687588:- LIHC cis rs1023500 0.573 rs2413666 ENSG00000227370.1 RP4-669P10.19 -6.73 7.2e-11 6.4e-08 -0.4 -0.34 Schizophrenia; chr22:42063618 chr22:42132543~42132998:+ LIHC cis rs524281 0.773 rs2298468 ENSG00000255320.1 RP11-755F10.1 6.73 7.24e-11 6.43e-08 0.46 0.34 Electroencephalogram traits; chr11:66275491 chr11:66244840~66246239:- LIHC cis rs494459 0.536 rs34561290 ENSG00000255239.1 AP002954.6 6.73 7.29e-11 6.48e-08 0.39 0.34 Height; chr11:118860890 chr11:118688039~118690600:- LIHC cis rs494459 0.536 rs11217072 ENSG00000255239.1 AP002954.6 6.73 7.29e-11 6.48e-08 0.39 0.34 Height; chr11:118861053 chr11:118688039~118690600:- LIHC cis rs1005277 0.557 rs2983338 ENSG00000263064.2 RP11-291L22.7 6.73 7.31e-11 6.49e-08 0.36 0.34 Extrinsic epigenetic age acceleration; chr10:38261806 chr10:38448689~38448949:+ LIHC cis rs9660180 0.783 rs1107910 ENSG00000268575.1 RP1-283E3.8 -6.73 7.33e-11 6.51e-08 -0.32 -0.34 Body mass index; chr1:1760882 chr1:1702736~1737688:- LIHC cis rs1005277 0.529 rs1780125 ENSG00000263064.2 RP11-291L22.7 6.73 7.35e-11 6.53e-08 0.36 0.34 Extrinsic epigenetic age acceleration; chr10:38242448 chr10:38448689~38448949:+ LIHC cis rs1005277 0.502 rs2800484 ENSG00000263064.2 RP11-291L22.7 6.73 7.35e-11 6.53e-08 0.36 0.34 Extrinsic epigenetic age acceleration; chr10:38253487 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2800485 ENSG00000263064.2 RP11-291L22.7 6.73 7.35e-11 6.53e-08 0.36 0.34 Extrinsic epigenetic age acceleration; chr10:38253660 chr10:38448689~38448949:+ LIHC cis rs55665837 0.701 rs12787709 ENSG00000251991.1 RNU7-49P 6.73 7.36e-11 6.53e-08 0.39 0.34 Vitamin D levels; chr11:14617711 chr11:14478892~14478953:+ LIHC cis rs7580658 0.68 rs2069931 ENSG00000236682.1 AC068282.3 -6.73 7.39e-11 6.55e-08 -0.43 -0.34 Protein C levels; chr2:127427993 chr2:127389130~127400580:+ LIHC cis rs4728142 0.564 rs11767711 ENSG00000275106.1 RP11-309L24.10 -6.72 7.39e-11 6.56e-08 -0.42 -0.34 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129011778 chr7:128952527~128953316:- LIHC cis rs73086581 1 rs3746665 ENSG00000229539.1 RP11-119B16.2 -6.72 7.45e-11 6.61e-08 -0.55 -0.34 Response to antidepressants in depression; chr20:3929759 chr20:3888239~3888868:- LIHC cis rs2836950 0.527 rs2836958 ENSG00000255568.3 BRWD1-AS2 -6.72 7.47e-11 6.62e-08 -0.28 -0.34 Menarche (age at onset); chr21:39251600 chr21:39313935~39314962:+ LIHC cis rs4718428 0.705 rs12536410 ENSG00000226824.5 RP4-756H11.3 -6.72 7.52e-11 6.66e-08 -0.45 -0.34 Corneal structure; chr7:66789303 chr7:66654538~66669855:+ LIHC cis rs4718428 0.705 rs68168107 ENSG00000226824.5 RP4-756H11.3 -6.72 7.52e-11 6.66e-08 -0.45 -0.34 Corneal structure; chr7:66790251 chr7:66654538~66669855:+ LIHC cis rs1023500 0.573 rs6002592 ENSG00000227370.1 RP4-669P10.19 6.72 7.53e-11 6.68e-08 0.39 0.34 Schizophrenia; chr22:42080750 chr22:42132543~42132998:+ LIHC cis rs992157 0.71 rs10169718 ENSG00000261338.2 RP11-378A13.1 -6.72 7.56e-11 6.7e-08 -0.34 -0.34 Colorectal cancer; chr2:218238857 chr2:218255319~218257366:+ LIHC cis rs1150668 0.796 rs213236 ENSG00000216901.1 AL022393.7 6.72 7.59e-11 6.73e-08 0.39 0.34 Pubertal anthropometrics; chr6:28356620 chr6:28176188~28176674:+ LIHC cis rs992157 0.56 rs7605980 ENSG00000261338.2 RP11-378A13.1 6.72 7.6e-11 6.74e-08 0.34 0.34 Colorectal cancer; chr2:218236146 chr2:218255319~218257366:+ LIHC cis rs7580658 0.929 rs4150496 ENSG00000236682.1 AC068282.3 -6.72 7.62e-11 6.75e-08 -0.43 -0.34 Protein C levels; chr2:127271927 chr2:127389130~127400580:+ LIHC cis rs6490294 0.528 rs16941724 ENSG00000226469.1 ADAM1B 6.72 7.66e-11 6.79e-08 0.51 0.34 Mean platelet volume; chr12:111889253 chr12:111927018~111929017:+ LIHC cis rs950027 0.787 rs2433616 ENSG00000259520.4 CTD-2651B20.3 -6.72 7.68e-11 6.8e-08 -0.42 -0.34 Response to fenofibrate (adiponectin levels); chr15:45436401 chr15:45251580~45279251:- LIHC cis rs992157 0.56 rs12992937 ENSG00000261338.2 RP11-378A13.1 -6.72 7.68e-11 6.8e-08 -0.34 -0.34 Colorectal cancer; chr2:218222349 chr2:218255319~218257366:+ LIHC cis rs992157 0.56 rs4674274 ENSG00000261338.2 RP11-378A13.1 -6.72 7.68e-11 6.8e-08 -0.34 -0.34 Colorectal cancer; chr2:218224408 chr2:218255319~218257366:+ LIHC cis rs2382817 0.58 rs6756265 ENSG00000261338.2 RP11-378A13.1 -6.72 7.68e-11 6.8e-08 -0.34 -0.34 Crohn's disease;Ulcerative colitis;Inflammatory bowel disease; chr2:218230831 chr2:218255319~218257366:+ LIHC cis rs992157 0.56 rs4674275 ENSG00000261338.2 RP11-378A13.1 -6.72 7.68e-11 6.8e-08 -0.34 -0.34 Colorectal cancer; chr2:218233015 chr2:218255319~218257366:+ LIHC cis rs992157 0.585 rs62182795 ENSG00000261338.2 RP11-378A13.1 -6.72 7.68e-11 6.8e-08 -0.34 -0.34 Colorectal cancer; chr2:218235479 chr2:218255319~218257366:+ LIHC cis rs2439831 0.85 rs8023458 ENSG00000205771.5 CATSPER2P1 -6.72 7.69e-11 6.81e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43788741 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs16963953 ENSG00000205771.5 CATSPER2P1 -6.72 7.69e-11 6.81e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43789521 chr15:43726918~43747094:- LIHC cis rs992157 0.732 rs10932771 ENSG00000261338.2 RP11-378A13.1 6.72 7.78e-11 6.88e-08 0.34 0.34 Colorectal cancer; chr2:218305513 chr2:218255319~218257366:+ LIHC cis rs4718428 0.576 rs12698546 ENSG00000226824.5 RP4-756H11.3 -6.72 7.82e-11 6.92e-08 -0.46 -0.34 Corneal structure; chr7:66801919 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs4718270 ENSG00000164669.11 INTS4P1 6.72 7.83e-11 6.92e-08 0.59 0.34 Diabetic kidney disease; chr7:65737415 chr7:65141225~65234216:+ LIHC cis rs2243480 0.901 rs2900904 ENSG00000164669.11 INTS4P1 6.72 7.83e-11 6.92e-08 0.59 0.34 Diabetic kidney disease; chr7:65739282 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs6460260 ENSG00000164669.11 INTS4P1 -6.72 7.83e-11 6.92e-08 -0.59 -0.34 Diabetic kidney disease; chr7:65750468 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs6460261 ENSG00000164669.11 INTS4P1 -6.72 7.83e-11 6.92e-08 -0.59 -0.34 Diabetic kidney disease; chr7:65750593 chr7:65141225~65234216:+ LIHC cis rs17301013 0.507 rs72715300 ENSG00000227373.4 RP11-160H22.5 6.71 7.89e-11 6.97e-08 0.58 0.34 Systemic lupus erythematosus; chr1:174768405 chr1:174115300~174160004:- LIHC cis rs17301013 0.507 rs55844798 ENSG00000227373.4 RP11-160H22.5 6.71 7.89e-11 6.97e-08 0.58 0.34 Systemic lupus erythematosus; chr1:174768973 chr1:174115300~174160004:- LIHC cis rs6490294 0.615 rs78729142 ENSG00000226469.1 ADAM1B 6.71 7.91e-11 6.99e-08 0.51 0.34 Mean platelet volume; chr12:111919456 chr12:111927018~111929017:+ LIHC cis rs2455601 0.679 rs2653559 ENSG00000254860.4 TMEM9B-AS1 6.71 7.94e-11 7.02e-08 0.42 0.34 Schizophrenia; chr11:8878847 chr11:8964675~8977527:+ LIHC cis rs7615952 0.932 rs13321217 ENSG00000171084.14 FAM86JP 6.71 7.95e-11 7.02e-08 0.61 0.34 Blood pressure (smoking interaction); chr3:125912928 chr3:125916620~125930024:+ LIHC cis rs2836950 0.52 rs59916147 ENSG00000255568.3 BRWD1-AS2 -6.71 7.96e-11 7.03e-08 -0.28 -0.34 Menarche (age at onset); chr21:39262776 chr21:39313935~39314962:+ LIHC cis rs2739330 0.685 rs4822453 ENSG00000250470.1 AP000351.3 6.71 8.01e-11 7.07e-08 0.42 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23976904~23977585:- LIHC cis rs9341808 0.529 rs2322765 ENSG00000272129.1 RP11-250B2.6 6.71 8.08e-11 7.13e-08 0.34 0.34 Sitting height ratio; chr6:80354879 chr6:80355424~80356859:+ LIHC cis rs6085948 0.861 rs6085954 ENSG00000238102.1 RP11-19D2.1 -6.71 8.1e-11 7.15e-08 -0.65 -0.34 Interleukin-10 levels; chr20:7257602 chr20:7256580~7258214:- LIHC cis rs9843304 0.616 rs34783865 ENSG00000244503.1 RP11-278L15.6 6.71 8.15e-11 7.19e-08 0.37 0.34 Gallstone disease; chr3:149488005 chr3:149494660~149495995:+ LIHC cis rs4718428 0.705 rs12698547 ENSG00000226824.5 RP4-756H11.3 -6.71 8.17e-11 7.21e-08 -0.45 -0.34 Corneal structure; chr7:66813271 chr7:66654538~66669855:+ LIHC cis rs7131987 0.621 rs6487805 ENSG00000257176.2 RP11-996F15.2 6.71 8.19e-11 7.23e-08 0.39 0.34 QT interval; chr12:29304617 chr12:29280418~29317848:- LIHC cis rs67383717 0.672 rs589458 ENSG00000175611.10 LINC00476 6.71 8.2e-11 7.23e-08 0.39 0.34 Parkinson's disease (pesticide exposure interaction); chr9:95878389 chr9:95759231~95875977:- LIHC cis rs17270561 0.609 rs12529272 ENSG00000216436.2 HIST1H2APS1 -6.71 8.21e-11 7.24e-08 -0.42 -0.34 Iron status biomarkers; chr6:25731114 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9393659 ENSG00000216436.2 HIST1H2APS1 -6.71 8.21e-11 7.24e-08 -0.42 -0.34 Iron status biomarkers; chr6:25731130 chr6:25732497~25732827:+ LIHC cis rs2439831 0.85 rs28524541 ENSG00000205771.5 CATSPER2P1 -6.71 8.27e-11 7.29e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43832633 chr15:43726918~43747094:- LIHC cis rs2882667 0.756 rs11957953 ENSG00000253404.1 AC034243.1 6.71 8.27e-11 7.3e-08 0.49 0.34 Age-related hearing impairment (SNP x SNP interaction); chr5:139143688 chr5:138744434~138753309:- LIHC cis rs4660456 0.913 rs7542019 ENSG00000237899.1 RP4-739H11.3 6.71 8.27e-11 7.3e-08 0.45 0.34 Platelet count; chr1:40704039 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs1494 ENSG00000237899.1 RP4-739H11.3 6.71 8.27e-11 7.3e-08 0.45 0.34 Platelet count; chr1:40706176 chr1:40669089~40687588:- LIHC cis rs4660456 0.869 rs7518344 ENSG00000237899.1 RP4-739H11.3 6.71 8.27e-11 7.3e-08 0.45 0.34 Platelet count; chr1:40708327 chr1:40669089~40687588:- LIHC cis rs6991838 0.584 rs7836349 ENSG00000200714.1 Y_RNA -6.71 8.33e-11 7.34e-08 -0.35 -0.34 Intelligence (multi-trait analysis); chr8:65591328 chr8:65592731~65592820:+ LIHC cis rs10170846 1 rs10170846 ENSG00000261428.2 RP11-16P6.1 -6.7 8.35e-11 7.36e-08 -0.36 -0.34 Schizophrenia (inflammation and infection response interaction); chr2:222652986 chr2:222566899~222569719:- LIHC cis rs2439831 0.867 rs3101443 ENSG00000205771.5 CATSPER2P1 -6.7 8.38e-11 7.38e-08 -0.52 -0.34 Lung cancer in ever smokers; chr15:43620174 chr15:43726918~43747094:- LIHC cis rs2836950 0.545 rs11700449 ENSG00000255568.3 BRWD1-AS2 -6.7 8.38e-11 7.39e-08 -0.28 -0.34 Menarche (age at onset); chr21:39150493 chr21:39313935~39314962:+ LIHC cis rs6142102 0.517 rs6142046 ENSG00000276073.1 RP5-1125A11.7 -6.7 8.39e-11 7.4e-08 -0.35 -0.34 Skin pigmentation; chr20:33926255 chr20:33985617~33988989:- LIHC cis rs2283792 0.73 rs894095 ENSG00000224086.5 LL22NC03-86G7.1 -6.7 8.44e-11 7.43e-08 -0.36 -0.34 Multiple sclerosis; chr22:21928404 chr22:21938293~21977632:+ LIHC cis rs2734839 0.507 rs1076562 ENSG00000270179.1 RP11-159N11.4 -6.7 8.49e-11 7.47e-08 -0.38 -0.34 Information processing speed; chr11:113425286 chr11:113368478~113369117:+ LIHC cis rs1005277 0.579 rs1780133 ENSG00000263064.2 RP11-291L22.7 6.7 8.52e-11 7.49e-08 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38210581 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs1780136 ENSG00000263064.2 RP11-291L22.7 6.7 8.52e-11 7.49e-08 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38212525 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs1780138 ENSG00000263064.2 RP11-291L22.7 6.7 8.52e-11 7.49e-08 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38212726 chr10:38448689~38448949:+ LIHC cis rs1005277 0.602 rs1780141 ENSG00000263064.2 RP11-291L22.7 6.7 8.52e-11 7.49e-08 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38215371 chr10:38448689~38448949:+ LIHC cis rs1005277 0.541 rs1740741 ENSG00000263064.2 RP11-291L22.7 6.7 8.52e-11 7.49e-08 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38226406 chr10:38448689~38448949:+ LIHC cis rs1005277 0.528 rs2057228 ENSG00000263064.2 RP11-291L22.7 6.7 8.52e-11 7.49e-08 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38226838 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs1740742 ENSG00000263064.2 RP11-291L22.7 6.7 8.52e-11 7.49e-08 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38229932 chr10:38448689~38448949:+ LIHC cis rs1005277 0.602 rs1740743 ENSG00000263064.2 RP11-291L22.7 6.7 8.52e-11 7.49e-08 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38230294 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs1740745 ENSG00000263064.2 RP11-291L22.7 6.7 8.52e-11 7.49e-08 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38231128 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs1740747 ENSG00000263064.2 RP11-291L22.7 6.7 8.52e-11 7.49e-08 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38231537 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs1740749 ENSG00000263064.2 RP11-291L22.7 6.7 8.52e-11 7.49e-08 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38232718 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs1780115 ENSG00000263064.2 RP11-291L22.7 6.7 8.52e-11 7.49e-08 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38235845 chr10:38448689~38448949:+ LIHC cis rs2735413 0.564 rs1882595 ENSG00000276007.1 RP11-358L22.3 6.7 8.53e-11 7.5e-08 0.46 0.34 Systolic blood pressure (alcohol consumption interaction); chr16:78066787 chr16:78123243~78124332:+ LIHC cis rs7429990 0.932 rs11720151 ENSG00000229759.1 MRPS18AP1 -6.7 8.53e-11 7.5e-08 -0.36 -0.34 Educational attainment (years of education); chr3:48099144 chr3:48256350~48256938:- LIHC cis rs739496 0.653 rs11613713 ENSG00000226469.1 ADAM1B 6.7 8.54e-11 7.51e-08 0.46 0.34 Platelet count; chr12:111779334 chr12:111927018~111929017:+ LIHC cis rs6490294 0.528 rs79976090 ENSG00000226469.1 ADAM1B 6.7 8.54e-11 7.51e-08 0.51 0.34 Mean platelet volume; chr12:111928314 chr12:111927018~111929017:+ LIHC cis rs1005277 0.579 rs1780139 ENSG00000263064.2 RP11-291L22.7 6.7 8.55e-11 7.51e-08 0.36 0.34 Extrinsic epigenetic age acceleration; chr10:38214090 chr10:38448689~38448949:+ LIHC cis rs1023500 0.596 rs5758562 ENSG00000227370.1 RP4-669P10.19 -6.7 8.62e-11 7.57e-08 -0.4 -0.34 Schizophrenia; chr22:42052234 chr22:42132543~42132998:+ LIHC cis rs1023500 0.596 rs5751209 ENSG00000227370.1 RP4-669P10.19 -6.7 8.62e-11 7.57e-08 -0.4 -0.34 Schizophrenia; chr22:42055599 chr22:42132543~42132998:+ LIHC cis rs1862618 0.526 rs2591963 ENSG00000271828.1 CTD-2310F14.1 -6.7 8.68e-11 7.63e-08 -0.5 -0.34 Initial pursuit acceleration; chr5:56941308 chr5:56927874~56929573:+ LIHC cis rs1862618 0.573 rs2591962 ENSG00000271828.1 CTD-2310F14.1 -6.7 8.68e-11 7.63e-08 -0.5 -0.34 Initial pursuit acceleration; chr5:56941328 chr5:56927874~56929573:+ LIHC cis rs4266144 1 rs4561781 ENSG00000244515.1 KRT18P34 6.7 8.7e-11 7.64e-08 0.33 0.34 Coronary artery disease; chr3:157135154 chr3:157162663~157163932:- LIHC cis rs1150668 0.83 rs2859365 ENSG00000216901.1 AL022393.7 -6.7 8.71e-11 7.65e-08 -0.38 -0.34 Pubertal anthropometrics; chr6:28423688 chr6:28176188~28176674:+ LIHC cis rs1577917 0.739 rs9344532 ENSG00000234155.1 RP11-30P6.6 -6.7 8.72e-11 7.66e-08 -0.42 -0.34 Response to antipsychotic treatment; chr6:85524352 chr6:85387219~85390186:- LIHC cis rs11603023 0.967 rs7936556 ENSG00000255239.1 AP002954.6 -6.7 8.73e-11 7.66e-08 -0.39 -0.34 Cholesterol, total; chr11:118630582 chr11:118688039~118690600:- LIHC cis rs3020736 0.5 rs6002597 ENSG00000227370.1 RP4-669P10.19 6.7 8.76e-11 7.69e-08 0.4 0.34 Autism spectrum disorder or schizophrenia; chr22:42092156 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs7292241 ENSG00000227370.1 RP4-669P10.19 6.7 8.76e-11 7.69e-08 0.4 0.34 Autism spectrum disorder or schizophrenia; chr22:42096059 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs6002603 ENSG00000227370.1 RP4-669P10.19 6.7 8.76e-11 7.69e-08 0.4 0.34 Autism spectrum disorder or schizophrenia; chr22:42096358 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs5996111 ENSG00000227370.1 RP4-669P10.19 6.7 8.76e-11 7.69e-08 0.4 0.34 Autism spectrum disorder or schizophrenia; chr22:42097898 chr22:42132543~42132998:+ LIHC cis rs7674212 0.507 rs223331 ENSG00000230069.3 LRRC37A15P -6.7 8.76e-11 7.69e-08 -0.33 -0.34 Type 2 diabetes; chr4:102872408 chr4:102727274~102730721:- LIHC cis rs8040855 0.557 rs9744503 ENSG00000259295.5 CSPG4P12 -6.7 8.78e-11 7.7e-08 -0.43 -0.34 Bulimia nervosa; chr15:85180986 chr15:85191438~85213905:+ LIHC cis rs1939012 0.846 rs6590985 ENSG00000281655.1 RP11-817J15.3 -6.7 8.78e-11 7.71e-08 -0.4 -0.34 Epilepsy; chr11:102727924 chr11:102681310~102683913:+ LIHC cis rs524281 0.731 rs2276036 ENSG00000255320.1 RP11-755F10.1 6.7 8.81e-11 7.73e-08 0.46 0.34 Electroencephalogram traits; chr11:66265959 chr11:66244840~66246239:- LIHC cis rs1577917 1 rs2816815 ENSG00000234155.1 RP11-30P6.6 6.7 8.83e-11 7.75e-08 0.4 0.34 Response to antipsychotic treatment; chr6:85981938 chr6:85387219~85390186:- LIHC cis rs2283792 0.73 rs2083565 ENSG00000224086.5 LL22NC03-86G7.1 -6.69 8.86e-11 7.77e-08 -0.37 -0.34 Multiple sclerosis; chr22:21929985 chr22:21938293~21977632:+ LIHC cis rs10875746 0.903 rs4760681 ENSG00000240399.1 RP1-228P16.1 -6.69 8.9e-11 7.8e-08 -0.38 -0.34 Longevity (90 years and older); chr12:48111447 chr12:48054813~48055591:- LIHC cis rs10875746 0.903 rs11168418 ENSG00000240399.1 RP1-228P16.1 -6.69 8.9e-11 7.8e-08 -0.38 -0.34 Longevity (90 years and older); chr12:48121971 chr12:48054813~48055591:- LIHC cis rs4728142 0.604 rs7807018 ENSG00000275106.1 RP11-309L24.10 -6.69 8.93e-11 7.83e-08 -0.42 -0.34 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129000134 chr7:128952527~128953316:- LIHC cis rs2117029 0.586 rs10875928 ENSG00000258017.1 RP11-386G11.10 -6.69 8.93e-11 7.83e-08 -0.41 -0.34 Intelligence (multi-trait analysis); chr12:49162520 chr12:49127782~49147869:+ LIHC cis rs7131987 0.65 rs3782509 ENSG00000257176.2 RP11-996F15.2 -6.69 8.97e-11 7.87e-08 -0.39 -0.34 QT interval; chr12:29300845 chr12:29280418~29317848:- LIHC cis rs62229266 1 rs62229266 ENSG00000231106.2 LINC01436 6.69 8.99e-11 7.88e-08 0.37 0.34 Mitral valve prolapse; chr21:36087973 chr21:36005338~36007838:+ LIHC cis rs9527 0.571 rs12765337 ENSG00000236937.2 PTGES3P4 6.69 9.02e-11 7.9e-08 0.41 0.34 Arsenic metabolism; chr10:102875587 chr10:102845595~102845950:+ LIHC cis rs2836950 0.545 rs2836959 ENSG00000255568.3 BRWD1-AS2 -6.69 9.04e-11 7.92e-08 -0.28 -0.34 Menarche (age at onset); chr21:39251742 chr21:39313935~39314962:+ LIHC cis rs916888 0.61 rs199436 ENSG00000214401.4 KANSL1-AS1 -6.69 9.07e-11 7.95e-08 -0.42 -0.34 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:46193576~46196723:+ LIHC cis rs7131987 0.617 rs3764953 ENSG00000257176.2 RP11-996F15.2 -6.69 9.08e-11 7.95e-08 -0.4 -0.34 QT interval; chr12:29349303 chr12:29280418~29317848:- LIHC cis rs1939012 0.846 rs948218 ENSG00000281655.1 RP11-817J15.3 -6.69 9.13e-11 7.99e-08 -0.4 -0.34 Epilepsy; chr11:102722311 chr11:102681310~102683913:+ LIHC cis rs831571 1 rs166230 ENSG00000280620.1 SCAANT1 -6.69 9.13e-11 8e-08 -0.48 -0.34 Type 2 diabetes; chr3:64067531 chr3:63911518~63911772:- LIHC cis rs1577917 0.958 rs1414199 ENSG00000234155.1 RP11-30P6.6 6.69 9.15e-11 8.01e-08 0.41 0.34 Response to antipsychotic treatment; chr6:85812652 chr6:85387219~85390186:- LIHC cis rs739496 0.615 rs11609628 ENSG00000226469.1 ADAM1B 6.69 9.15e-11 8.01e-08 0.45 0.34 Platelet count; chr12:111779404 chr12:111927018~111929017:+ LIHC cis rs2439831 0.85 rs3736180 ENSG00000205771.5 CATSPER2P1 -6.69 9.15e-11 8.01e-08 -0.5 -0.34 Lung cancer in ever smokers; chr15:43814426 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs28684672 ENSG00000205771.5 CATSPER2P1 -6.69 9.15e-11 8.01e-08 -0.5 -0.34 Lung cancer in ever smokers; chr15:43815464 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs12440573 ENSG00000205771.5 CATSPER2P1 -6.69 9.15e-11 8.01e-08 -0.5 -0.34 Lung cancer in ever smokers; chr15:43816799 chr15:43726918~43747094:- LIHC cis rs992157 0.71 rs12996912 ENSG00000261338.2 RP11-378A13.1 6.69 9.19e-11 8.05e-08 0.34 0.34 Colorectal cancer; chr2:218245832 chr2:218255319~218257366:+ LIHC cis rs35160687 0.829 rs13017143 ENSG00000273080.1 RP11-301O19.1 -6.69 9.19e-11 8.05e-08 -0.46 -0.34 Night sleep phenotypes; chr2:86239426 chr2:86195590~86196049:+ LIHC cis rs4718428 0.672 rs36038499 ENSG00000226824.5 RP4-756H11.3 -6.69 9.2e-11 8.05e-08 -0.45 -0.34 Corneal structure; chr7:66824628 chr7:66654538~66669855:+ LIHC cis rs2033711 0.837 rs3764535 ENSG00000269473.1 CTD-2619J13.19 6.69 9.21e-11 8.06e-08 0.41 0.34 Uric acid clearance; chr19:58417685 chr19:58440448~58445849:+ LIHC cis rs2033711 0.84 rs3764533 ENSG00000269473.1 CTD-2619J13.19 6.69 9.21e-11 8.06e-08 0.41 0.34 Uric acid clearance; chr19:58417827 chr19:58440448~58445849:+ LIHC cis rs765787 0.53 rs11636018 ENSG00000259520.4 CTD-2651B20.3 6.69 9.23e-11 8.07e-08 0.4 0.34 Uric acid levels; chr15:45246939 chr15:45251580~45279251:- LIHC cis rs2836950 0.585 rs1029004 ENSG00000255568.3 BRWD1-AS2 -6.69 9.24e-11 8.08e-08 -0.28 -0.34 Menarche (age at onset); chr21:39243417 chr21:39313935~39314962:+ LIHC cis rs2439831 0.85 rs7169988 ENSG00000205771.5 CATSPER2P1 -6.69 9.38e-11 8.2e-08 -0.51 -0.34 Lung cancer in ever smokers; chr15:43768237 chr15:43726918~43747094:- LIHC cis rs2836950 0.545 rs2297256 ENSG00000255568.3 BRWD1-AS2 -6.69 9.4e-11 8.22e-08 -0.28 -0.34 Menarche (age at onset); chr21:39186495 chr21:39313935~39314962:+ LIHC cis rs8028182 0.525 rs9920028 ENSG00000260269.4 CTD-2323K18.1 -6.68 9.45e-11 8.26e-08 -0.44 -0.34 Sudden cardiac arrest; chr15:75635376 chr15:75527150~75601205:- LIHC cis rs992157 0.71 rs13026485 ENSG00000261338.2 RP11-378A13.1 -6.68 9.48e-11 8.29e-08 -0.34 -0.34 Colorectal cancer; chr2:218193261 chr2:218255319~218257366:+ LIHC cis rs7580658 0.929 rs4662575 ENSG00000236682.1 AC068282.3 -6.68 9.51e-11 8.31e-08 -0.43 -0.34 Protein C levels; chr2:127264639 chr2:127389130~127400580:+ LIHC cis rs1023500 0.596 rs133350 ENSG00000227370.1 RP4-669P10.19 -6.68 9.56e-11 8.35e-08 -0.4 -0.34 Schizophrenia; chr22:42033045 chr22:42132543~42132998:+ LIHC cis rs4660456 0.711 rs12409109 ENSG00000237899.1 RP4-739H11.3 -6.68 9.58e-11 8.37e-08 -0.44 -0.34 Platelet count; chr1:40727216 chr1:40669089~40687588:- LIHC cis rs2836950 0.501 rs35994303 ENSG00000255568.3 BRWD1-AS2 -6.68 9.61e-11 8.39e-08 -0.28 -0.34 Menarche (age at onset); chr21:39314094 chr21:39313935~39314962:+ LIHC cis rs17301013 0.507 rs72717617 ENSG00000227373.4 RP11-160H22.5 6.68 9.61e-11 8.39e-08 0.58 0.34 Systemic lupus erythematosus; chr1:174815514 chr1:174115300~174160004:- LIHC cis rs524281 0.682 rs4483592 ENSG00000255320.1 RP11-755F10.1 6.68 9.65e-11 8.43e-08 0.46 0.34 Electroencephalogram traits; chr11:66222968 chr11:66244840~66246239:- LIHC cis rs524281 0.773 rs2155201 ENSG00000255320.1 RP11-755F10.1 6.68 9.65e-11 8.43e-08 0.46 0.34 Electroencephalogram traits; chr11:66224873 chr11:66244840~66246239:- LIHC cis rs765787 0.53 rs2413784 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45238318 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs7165889 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45239442 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs11070451 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45241343 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs28897155 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45241776 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4775831 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45242524 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4775832 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45242630 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4442750 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45243130 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4444275 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45243149 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4270107 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45243152 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4544188 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45243195 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs11636367 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45243664 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs11636440 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45243784 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs28396110 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45244711 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4775834 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45245313 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4775835 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45245355 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4775836 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45245466 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs4775837 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45245486 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs12917187 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45246099 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs11639403 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45246152 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs2413782 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45246292 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs2413780 ENSG00000259520.4 CTD-2651B20.3 6.68 9.68e-11 8.44e-08 0.4 0.34 Uric acid levels; chr15:45246668 chr15:45251580~45279251:- LIHC cis rs2735413 0.564 rs78769909 ENSG00000276007.1 RP11-358L22.3 6.68 9.69e-11 8.45e-08 0.48 0.34 Systolic blood pressure (alcohol consumption interaction); chr16:78070105 chr16:78123243~78124332:+ LIHC cis rs9549367 0.713 rs9549357 ENSG00000269125.1 RP11-98F14.11 -6.68 9.7e-11 8.46e-08 -0.39 -0.34 Platelet distribution width; chr13:113205807 chr13:113165002~113165183:- LIHC cis rs2836950 0.545 rs2836922 ENSG00000255568.3 BRWD1-AS2 -6.68 9.7e-11 8.46e-08 -0.28 -0.34 Menarche (age at onset); chr21:39144382 chr21:39313935~39314962:+ LIHC cis rs2283792 0.73 rs2329884 ENSG00000224086.5 LL22NC03-86G7.1 -6.68 9.75e-11 8.5e-08 -0.36 -0.34 Multiple sclerosis; chr22:21927890 chr22:21938293~21977632:+ LIHC cis rs6597981 0.592 rs10902218 ENSG00000255142.1 AP006621.6 -6.68 9.77e-11 8.52e-08 -0.31 -0.34 Breast cancer; chr11:743813 chr11:781645~782105:+ LIHC cis rs8028182 0.501 rs7166281 ENSG00000260269.4 CTD-2323K18.1 6.68 9.78e-11 8.52e-08 0.43 0.34 Sudden cardiac arrest; chr15:75635851 chr15:75527150~75601205:- LIHC cis rs1862618 0.573 rs1550821 ENSG00000271828.1 CTD-2310F14.1 -6.68 9.78e-11 8.53e-08 -0.49 -0.34 Initial pursuit acceleration; chr5:56946496 chr5:56927874~56929573:+ LIHC cis rs1577917 0.74 rs6926049 ENSG00000234155.1 RP11-30P6.6 -6.68 9.85e-11 8.59e-08 -0.43 -0.34 Response to antipsychotic treatment; chr6:85556415 chr6:85387219~85390186:- LIHC cis rs12681287 0.752 rs4427148 ENSG00000250569.1 NTAN1P2 6.68 9.86e-11 8.59e-08 0.41 0.34 Caudate activity during reward; chr8:86238439 chr8:86481754~86483002:- LIHC cis rs7131987 0.65 rs4331146 ENSG00000257176.2 RP11-996F15.2 -6.68 9.87e-11 8.6e-08 -0.39 -0.34 QT interval; chr12:29287150 chr12:29280418~29317848:- LIHC cis rs524281 0.773 rs11227447 ENSG00000255320.1 RP11-755F10.1 6.68 9.9e-11 8.62e-08 0.46 0.34 Electroencephalogram traits; chr11:66280809 chr11:66244840~66246239:- LIHC cis rs9525916 1 rs9525916 ENSG00000227258.4 SMIM2-AS1 6.68 9.92e-11 8.64e-08 0.38 0.34 Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction); chr13:44128733 chr13:44110451~44240517:+ LIHC cis rs7914558 0.752 rs7896519 ENSG00000236937.2 PTGES3P4 6.68 9.92e-11 8.64e-08 0.41 0.34 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103107106 chr10:102845595~102845950:+ LIHC cis rs916888 0.821 rs199504 ENSG00000262881.1 RP11-669E14.4 6.68 9.95e-11 8.66e-08 0.54 0.34 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:45907670~45910779:- LIHC cis rs1939012 0.967 rs3758859 ENSG00000281655.1 RP11-817J15.3 -6.67 1e-10 8.74e-08 -0.39 -0.34 Epilepsy; chr11:102727749 chr11:102681310~102683913:+ LIHC cis rs1185460 1 rs1784305 ENSG00000271751.1 RP11-110I1.14 -6.67 1e-10 8.74e-08 -0.46 -0.34 Coronary artery disease; chr11:119071338 chr11:119065263~119065677:- LIHC cis rs8062405 0.69 rs6498089 ENSG00000259982.1 CDC37P1 -6.67 1.01e-10 8.78e-08 -0.44 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28617979 chr16:28700294~28701540:- LIHC cis rs916888 0.773 rs9896243 ENSG00000262881.1 RP11-669E14.4 -6.67 1.01e-10 8.79e-08 -0.52 -0.34 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45907670~45910779:- LIHC cis rs9326248 0.768 rs4936366 ENSG00000280143.1 AP000892.6 6.67 1.01e-10 8.83e-08 0.39 0.34 Blood protein levels; chr11:117156169 chr11:117204967~117210292:+ LIHC cis rs9326248 0.861 rs4938352 ENSG00000280143.1 AP000892.6 6.67 1.01e-10 8.83e-08 0.39 0.34 Blood protein levels; chr11:117156765 chr11:117204967~117210292:+ LIHC cis rs765787 0.53 rs28414644 ENSG00000259520.4 CTD-2651B20.3 6.67 1.02e-10 8.84e-08 0.4 0.34 Uric acid levels; chr15:45244523 chr15:45251580~45279251:- LIHC cis rs12681287 0.752 rs10104138 ENSG00000250569.1 NTAN1P2 6.67 1.02e-10 8.89e-08 0.41 0.34 Caudate activity during reward; chr8:86235430 chr8:86481754~86483002:- LIHC cis rs6890270 1 rs6890270 ENSG00000271828.1 CTD-2310F14.1 6.67 1.02e-10 8.89e-08 0.48 0.34 Breast cancer; chr5:56964779 chr5:56927874~56929573:+ LIHC cis rs2243480 1 rs56291018 ENSG00000164669.11 INTS4P1 6.67 1.02e-10 8.9e-08 0.6 0.34 Diabetic kidney disease; chr7:65925352 chr7:65141225~65234216:+ LIHC cis rs524281 0.773 rs2155030 ENSG00000255320.1 RP11-755F10.1 6.67 1.03e-10 8.92e-08 0.46 0.34 Electroencephalogram traits; chr11:66263216 chr11:66244840~66246239:- LIHC cis rs524281 0.773 rs2155031 ENSG00000255320.1 RP11-755F10.1 6.67 1.03e-10 8.92e-08 0.46 0.34 Electroencephalogram traits; chr11:66263456 chr11:66244840~66246239:- LIHC cis rs1939012 0.704 rs2186602 ENSG00000281655.1 RP11-817J15.3 -6.67 1.05e-10 9.11e-08 -0.4 -0.34 Epilepsy; chr11:102721214 chr11:102681310~102683913:+ LIHC cis rs1577917 0.916 rs4706252 ENSG00000234155.1 RP11-30P6.6 6.67 1.05e-10 9.12e-08 0.4 0.34 Response to antipsychotic treatment; chr6:85845462 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs12202188 ENSG00000234155.1 RP11-30P6.6 6.67 1.05e-10 9.12e-08 0.4 0.34 Response to antipsychotic treatment; chr6:85852982 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs36035797 ENSG00000234155.1 RP11-30P6.6 6.67 1.05e-10 9.12e-08 0.4 0.34 Response to antipsychotic treatment; chr6:85853162 chr6:85387219~85390186:- LIHC cis rs1577917 0.917 rs2084293 ENSG00000234155.1 RP11-30P6.6 6.67 1.05e-10 9.12e-08 0.4 0.34 Response to antipsychotic treatment; chr6:85856284 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs12209668 ENSG00000234155.1 RP11-30P6.6 6.67 1.05e-10 9.12e-08 0.4 0.34 Response to antipsychotic treatment; chr6:85856799 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs11752180 ENSG00000234155.1 RP11-30P6.6 6.67 1.05e-10 9.12e-08 0.4 0.34 Response to antipsychotic treatment; chr6:85863447 chr6:85387219~85390186:- LIHC cis rs4820294 0.926 rs62236671 ENSG00000233360.4 Z83844.1 6.67 1.05e-10 9.14e-08 0.43 0.34 Fat distribution (HIV); chr22:37673298 chr22:37641832~37658377:- LIHC cis rs7580658 0.929 rs2276583 ENSG00000236682.1 AC068282.3 -6.67 1.06e-10 9.14e-08 -0.43 -0.34 Protein C levels; chr2:127257108 chr2:127389130~127400580:+ LIHC cis rs2734839 0.507 rs2002453 ENSG00000270179.1 RP11-159N11.4 -6.67 1.06e-10 9.14e-08 -0.38 -0.34 Information processing speed; chr11:113418576 chr11:113368478~113369117:+ LIHC cis rs7429990 0.965 rs4599334 ENSG00000229759.1 MRPS18AP1 -6.67 1.06e-10 9.16e-08 -0.37 -0.34 Educational attainment (years of education); chr3:48024910 chr3:48256350~48256938:- LIHC cis rs2243480 1 rs437889 ENSG00000164669.11 INTS4P1 6.67 1.06e-10 9.16e-08 0.58 0.34 Diabetic kidney disease; chr7:66044247 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs402418 ENSG00000164669.11 INTS4P1 6.67 1.06e-10 9.16e-08 0.58 0.34 Diabetic kidney disease; chr7:66044482 chr7:65141225~65234216:+ LIHC cis rs2243480 0.803 rs423187 ENSG00000164669.11 INTS4P1 6.67 1.06e-10 9.16e-08 0.58 0.34 Diabetic kidney disease; chr7:66044512 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs431318 ENSG00000164669.11 INTS4P1 6.67 1.06e-10 9.16e-08 0.58 0.34 Diabetic kidney disease; chr7:66046610 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs73150014 ENSG00000164669.11 INTS4P1 6.67 1.06e-10 9.17e-08 0.59 0.34 Diabetic kidney disease; chr7:65985932 chr7:65141225~65234216:+ LIHC cis rs62229266 0.771 rs7280136 ENSG00000231106.2 LINC01436 -6.67 1.06e-10 9.18e-08 -0.38 -0.34 Mitral valve prolapse; chr21:36060612 chr21:36005338~36007838:+ LIHC cis rs6991838 0.584 rs7842085 ENSG00000272010.1 CTD-3025N20.3 6.66 1.07e-10 9.23e-08 0.38 0.34 Intelligence (multi-trait analysis); chr8:65636787 chr8:65591850~65592472:- LIHC cis rs7131987 0.65 rs7301398 ENSG00000257176.2 RP11-996F15.2 -6.66 1.07e-10 9.23e-08 -0.39 -0.34 QT interval; chr12:29302457 chr12:29280418~29317848:- LIHC cis rs7131987 0.65 rs7301188 ENSG00000257176.2 RP11-996F15.2 -6.66 1.07e-10 9.23e-08 -0.39 -0.34 QT interval; chr12:29302458 chr12:29280418~29317848:- LIHC cis rs2439831 0.702 rs3759791 ENSG00000205771.5 CATSPER2P1 -6.66 1.07e-10 9.28e-08 -0.49 -0.34 Lung cancer in ever smokers; chr15:43798600 chr15:43726918~43747094:- LIHC cis rs7617773 0.817 rs13094727 ENSG00000229759.1 MRPS18AP1 6.66 1.07e-10 9.29e-08 0.42 0.34 Coronary artery disease; chr3:48281999 chr3:48256350~48256938:- LIHC cis rs9843304 0.721 rs4681176 ENSG00000244503.1 RP11-278L15.6 6.66 1.07e-10 9.29e-08 0.35 0.34 Gallstone disease; chr3:149484167 chr3:149494660~149495995:+ LIHC cis rs748404 0.56 rs1060939 ENSG00000205771.5 CATSPER2P1 -6.66 1.07e-10 9.3e-08 -0.41 -0.34 Lung cancer; chr15:43524719 chr15:43726918~43747094:- LIHC cis rs9399137 0.507 rs13209780 ENSG00000232876.1 CTA-212D2.2 -6.66 1.08e-10 9.32e-08 -0.39 -0.34 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135023657 chr6:135055033~135060550:+ LIHC cis rs7617773 0.817 rs13072018 ENSG00000229759.1 MRPS18AP1 6.66 1.1e-10 9.47e-08 0.42 0.34 Coronary artery disease; chr3:48278842 chr3:48256350~48256938:- LIHC cis rs2243480 1 rs3885839 ENSG00000164669.11 INTS4P1 6.66 1.1e-10 9.49e-08 0.6 0.34 Diabetic kidney disease; chr7:65825416 chr7:65141225~65234216:+ LIHC cis rs2243480 0.901 rs3813708 ENSG00000164669.11 INTS4P1 6.66 1.1e-10 9.49e-08 0.6 0.34 Diabetic kidney disease; chr7:65840645 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs73142122 ENSG00000164669.11 INTS4P1 6.66 1.1e-10 9.49e-08 0.6 0.34 Diabetic kidney disease; chr7:65846311 chr7:65141225~65234216:+ LIHC cis rs2243480 0.901 rs73142137 ENSG00000164669.11 INTS4P1 6.66 1.1e-10 9.49e-08 0.6 0.34 Diabetic kidney disease; chr7:65878455 chr7:65141225~65234216:+ LIHC cis rs9843304 0.721 rs13062142 ENSG00000244503.1 RP11-278L15.6 6.66 1.1e-10 9.53e-08 0.35 0.34 Gallstone disease; chr3:149484196 chr3:149494660~149495995:+ LIHC cis rs9326248 0.727 rs4938347 ENSG00000280143.1 AP000892.6 6.66 1.11e-10 9.55e-08 0.39 0.34 Blood protein levels; chr11:117151043 chr11:117204967~117210292:+ LIHC cis rs9326248 0.861 rs4938348 ENSG00000280143.1 AP000892.6 6.66 1.11e-10 9.55e-08 0.39 0.34 Blood protein levels; chr11:117151161 chr11:117204967~117210292:+ LIHC cis rs9326248 0.813 rs4938350 ENSG00000280143.1 AP000892.6 6.66 1.11e-10 9.55e-08 0.39 0.34 Blood protein levels; chr11:117151560 chr11:117204967~117210292:+ LIHC cis rs2439831 0.85 rs28564774 ENSG00000205771.5 CATSPER2P1 -6.66 1.11e-10 9.58e-08 -0.5 -0.34 Lung cancer in ever smokers; chr15:43833277 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs28513374 ENSG00000205771.5 CATSPER2P1 -6.66 1.11e-10 9.58e-08 -0.5 -0.34 Lung cancer in ever smokers; chr15:43833297 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs12441984 ENSG00000205771.5 CATSPER2P1 -6.66 1.11e-10 9.58e-08 -0.5 -0.34 Lung cancer in ever smokers; chr15:43834087 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs7169322 ENSG00000205771.5 CATSPER2P1 -6.66 1.11e-10 9.58e-08 -0.5 -0.34 Lung cancer in ever smokers; chr15:43838816 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs28707214 ENSG00000205771.5 CATSPER2P1 -6.66 1.11e-10 9.58e-08 -0.5 -0.34 Lung cancer in ever smokers; chr15:43839425 chr15:43726918~43747094:- LIHC cis rs9326248 0.954 rs8521 ENSG00000280143.1 AP000892.6 6.66 1.11e-10 9.59e-08 0.39 0.34 Blood protein levels; chr11:117196983 chr11:117204967~117210292:+ LIHC cis rs8062405 0.757 rs2411453 ENSG00000259982.1 CDC37P1 -6.66 1.11e-10 9.6e-08 -0.36 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620700 chr16:28700294~28701540:- LIHC cis rs62355901 0.545 rs12657172 ENSG00000271828.1 CTD-2310F14.1 6.66 1.11e-10 9.6e-08 0.54 0.34 Breast cancer; chr5:56768280 chr5:56927874~56929573:+ LIHC cis rs62355901 0.545 rs16886263 ENSG00000271828.1 CTD-2310F14.1 -6.66 1.11e-10 9.6e-08 -0.54 -0.34 Breast cancer; chr5:56769680 chr5:56927874~56929573:+ LIHC cis rs2882667 0.652 rs6596463 ENSG00000253404.1 AC034243.1 6.66 1.12e-10 9.65e-08 0.44 0.34 Age-related hearing impairment (SNP x SNP interaction); chr5:139109237 chr5:138744434~138753309:- LIHC cis rs6490294 0.651 rs440 ENSG00000226469.1 ADAM1B 6.66 1.12e-10 9.66e-08 0.45 0.34 Mean platelet volume; chr12:111790910 chr12:111927018~111929017:+ LIHC cis rs150992 0.609 rs539024 ENSG00000248489.1 CTD-2007H13.3 6.66 1.12e-10 9.67e-08 0.5 0.34 Body mass index; chr5:98997103 chr5:98929171~98995013:+ LIHC cis rs1577917 0.916 rs7759727 ENSG00000234155.1 RP11-30P6.6 6.66 1.12e-10 9.67e-08 0.4 0.34 Response to antipsychotic treatment; chr6:85809160 chr6:85387219~85390186:- LIHC cis rs9660180 0.934 rs34849348 ENSG00000268575.1 RP1-283E3.8 -6.66 1.12e-10 9.68e-08 -0.32 -0.34 Body mass index; chr1:1831318 chr1:1702736~1737688:- LIHC cis rs1023500 0.551 rs133379 ENSG00000227370.1 RP4-669P10.19 -6.66 1.12e-10 9.7e-08 -0.4 -0.34 Schizophrenia; chr22:42072531 chr22:42132543~42132998:+ LIHC cis rs1185460 0.967 rs2509121 ENSG00000271751.1 RP11-110I1.14 -6.66 1.13e-10 9.71e-08 -0.46 -0.34 Coronary artery disease; chr11:119057542 chr11:119065263~119065677:- LIHC cis rs7580658 0.724 rs6712446 ENSG00000236682.1 AC068282.3 -6.65 1.13e-10 9.78e-08 -0.42 -0.34 Protein C levels; chr2:127240823 chr2:127389130~127400580:+ LIHC cis rs7580658 0.963 rs9789510 ENSG00000236682.1 AC068282.3 -6.65 1.14e-10 9.79e-08 -0.43 -0.34 Protein C levels; chr2:127379436 chr2:127389130~127400580:+ LIHC cis rs875971 0.545 rs4441996 ENSG00000164669.11 INTS4P1 6.65 1.14e-10 9.8e-08 0.46 0.34 Aortic root size; chr7:66123233 chr7:65141225~65234216:+ LIHC cis rs6490294 0.8 rs78783055 ENSG00000226469.1 ADAM1B 6.65 1.14e-10 9.8e-08 0.45 0.34 Mean platelet volume; chr12:111795691 chr12:111927018~111929017:+ LIHC cis rs2739330 0.652 rs2000469 ENSG00000250470.1 AP000351.3 6.65 1.14e-10 9.82e-08 0.42 0.34 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23976904~23977585:- LIHC cis rs73086581 1 rs17287822 ENSG00000229539.1 RP11-119B16.2 6.65 1.14e-10 9.84e-08 0.54 0.34 Response to antidepressants in depression; chr20:3997889 chr20:3888239~3888868:- LIHC cis rs524281 0.773 rs79770412 ENSG00000255320.1 RP11-755F10.1 6.65 1.14e-10 9.85e-08 0.46 0.34 Electroencephalogram traits; chr11:66277873 chr11:66244840~66246239:- LIHC cis rs992157 0.697 rs13384682 ENSG00000261338.2 RP11-378A13.1 6.65 1.14e-10 9.86e-08 0.33 0.34 Colorectal cancer; chr2:218204414 chr2:218255319~218257366:+ LIHC cis rs992157 0.71 rs7569907 ENSG00000261338.2 RP11-378A13.1 6.65 1.14e-10 9.86e-08 0.33 0.34 Colorectal cancer; chr2:218205828 chr2:218255319~218257366:+ LIHC cis rs739496 0.615 rs4646777 ENSG00000226469.1 ADAM1B 6.65 1.15e-10 9.89e-08 0.45 0.34 Platelet count; chr12:111792232 chr12:111927018~111929017:+ LIHC cis rs1062177 0.756 rs2964592 ENSG00000213433.5 RPLP1P6 6.65 1.15e-10 9.91e-08 0.38 0.34 Preschool internalizing problems; chr5:151736127 chr5:151765859~151766378:- LIHC cis rs10875746 0.903 rs725454 ENSG00000240399.1 RP1-228P16.1 -6.65 1.16e-10 1e-07 -0.38 -0.34 Longevity (90 years and older); chr12:48108317 chr12:48054813~48055591:- LIHC cis rs831571 1 rs831571 ENSG00000280620.1 SCAANT1 -6.65 1.17e-10 1.01e-07 -0.47 -0.34 Type 2 diabetes; chr3:64062621 chr3:63911518~63911772:- LIHC cis rs9399137 0.507 rs4896129 ENSG00000232876.1 CTA-212D2.2 -6.65 1.17e-10 1.01e-07 -0.39 -0.34 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135028707 chr6:135055033~135060550:+ LIHC cis rs1023500 0.573 rs13057094 ENSG00000227370.1 RP4-669P10.19 -6.65 1.17e-10 1.01e-07 -0.4 -0.34 Schizophrenia; chr22:42074313 chr22:42132543~42132998:+ LIHC cis rs2243480 1 rs1723269 ENSG00000164669.11 INTS4P1 6.65 1.17e-10 1.01e-07 0.58 0.34 Diabetic kidney disease; chr7:66007799 chr7:65141225~65234216:+ LIHC cis rs1577917 1 rs4706254 ENSG00000234155.1 RP11-30P6.6 6.65 1.17e-10 1.01e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85893095 chr6:85387219~85390186:- LIHC cis rs34779708 0.931 rs7079205 ENSG00000230534.5 RP11-297A16.2 6.65 1.17e-10 1.01e-07 0.44 0.34 Inflammatory bowel disease;Crohn's disease; chr10:35035691 chr10:35098006~35127020:- LIHC cis rs7923609 0.578 rs3858121 ENSG00000232075.1 MRPL35P2 -6.65 1.17e-10 1.01e-07 -0.35 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63640237 chr10:63634317~63634827:- LIHC cis rs4820294 1 rs62236668 ENSG00000233360.4 Z83844.1 6.65 1.17e-10 1.01e-07 0.43 0.34 Fat distribution (HIV); chr22:37667863 chr22:37641832~37658377:- LIHC cis rs2243480 1 rs34970380 ENSG00000164669.11 INTS4P1 6.65 1.18e-10 1.01e-07 0.59 0.34 Diabetic kidney disease; chr7:65966506 chr7:65141225~65234216:+ LIHC cis rs2243480 0.901 rs73148097 ENSG00000164669.11 INTS4P1 6.65 1.18e-10 1.01e-07 0.59 0.34 Diabetic kidney disease; chr7:65966800 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs906134 ENSG00000164669.11 INTS4P1 6.65 1.18e-10 1.01e-07 0.59 0.34 Diabetic kidney disease; chr7:65979301 chr7:65141225~65234216:+ LIHC cis rs1939012 0.811 rs7123658 ENSG00000281655.1 RP11-817J15.3 -6.65 1.18e-10 1.02e-07 -0.41 -0.34 Epilepsy; chr11:102723248 chr11:102681310~102683913:+ LIHC cis rs17270561 0.583 rs7765833 ENSG00000216436.2 HIST1H2APS1 -6.65 1.19e-10 1.02e-07 -0.43 -0.34 Iron status biomarkers; chr6:25712205 chr6:25732497~25732827:+ LIHC cis rs2439831 0.85 rs7179388 ENSG00000205771.5 CATSPER2P1 -6.65 1.19e-10 1.02e-07 -0.51 -0.34 Lung cancer in ever smokers; chr15:43831747 chr15:43726918~43747094:- LIHC cis rs1862618 0.573 rs832532 ENSG00000271828.1 CTD-2310F14.1 6.65 1.19e-10 1.02e-07 0.5 0.34 Initial pursuit acceleration; chr5:56926111 chr5:56927874~56929573:+ LIHC cis rs6490294 0.528 rs12579336 ENSG00000226469.1 ADAM1B 6.64 1.2e-10 1.03e-07 0.51 0.34 Mean platelet volume; chr12:112177734 chr12:111927018~111929017:+ LIHC cis rs8040855 0.599 rs8037195 ENSG00000259295.5 CSPG4P12 -6.64 1.2e-10 1.03e-07 -0.43 -0.34 Bulimia nervosa; chr15:85181455 chr15:85191438~85213905:+ LIHC cis rs2836950 0.565 rs7279497 ENSG00000255568.3 BRWD1-AS2 6.64 1.2e-10 1.03e-07 0.28 0.34 Menarche (age at onset); chr21:39159380 chr21:39313935~39314962:+ LIHC cis rs950027 0.787 rs1547487 ENSG00000259520.4 CTD-2651B20.3 -6.64 1.2e-10 1.03e-07 -0.42 -0.34 Response to fenofibrate (adiponectin levels); chr15:45431785 chr15:45251580~45279251:- LIHC cis rs4423214 0.879 rs1790353 ENSG00000254682.1 RP11-660L16.2 -6.64 1.21e-10 1.04e-07 -0.43 -0.34 Vitamin D levels; chr11:71425684 chr11:71448674~71452157:+ LIHC cis rs9549367 0.713 rs9549691 ENSG00000269125.1 RP11-98F14.11 -6.64 1.22e-10 1.05e-07 -0.44 -0.34 Platelet distribution width; chr13:113207292 chr13:113165002~113165183:- LIHC cis rs17270561 0.609 rs17267614 ENSG00000216436.2 HIST1H2APS1 -6.64 1.23e-10 1.05e-07 -0.42 -0.34 Iron status biomarkers; chr6:25729799 chr6:25732497~25732827:+ LIHC cis rs1185460 0.967 rs1786685 ENSG00000271751.1 RP11-110I1.14 -6.64 1.23e-10 1.05e-07 -0.46 -0.34 Coronary artery disease; chr11:119068246 chr11:119065263~119065677:- LIHC cis rs113835537 0.529 rs17147644 ENSG00000255517.5 CTD-3074O7.5 -6.64 1.23e-10 1.06e-07 -0.38 -0.34 Airway imaging phenotypes; chr11:66489189 chr11:66473490~66480233:- LIHC cis rs524281 0.773 rs2236651 ENSG00000255320.1 RP11-755F10.1 6.64 1.23e-10 1.06e-07 0.46 0.34 Electroencephalogram traits; chr11:66233947 chr11:66244840~66246239:- LIHC cis rs524281 0.773 rs4393319 ENSG00000255320.1 RP11-755F10.1 6.64 1.23e-10 1.06e-07 0.46 0.34 Electroencephalogram traits; chr11:66234407 chr11:66244840~66246239:- LIHC cis rs524281 0.773 rs10896105 ENSG00000255320.1 RP11-755F10.1 6.64 1.23e-10 1.06e-07 0.46 0.34 Electroencephalogram traits; chr11:66234789 chr11:66244840~66246239:- LIHC cis rs524281 0.773 rs2236652 ENSG00000255320.1 RP11-755F10.1 6.64 1.23e-10 1.06e-07 0.46 0.34 Electroencephalogram traits; chr11:66235210 chr11:66244840~66246239:- LIHC cis rs524281 0.731 rs11227433 ENSG00000255320.1 RP11-755F10.1 6.64 1.23e-10 1.06e-07 0.46 0.34 Electroencephalogram traits; chr11:66237222 chr11:66244840~66246239:- LIHC cis rs524281 0.773 rs10791861 ENSG00000255320.1 RP11-755F10.1 6.64 1.23e-10 1.06e-07 0.46 0.34 Electroencephalogram traits; chr11:66240999 chr11:66244840~66246239:- LIHC cis rs524281 0.773 rs10791862 ENSG00000255320.1 RP11-755F10.1 6.64 1.23e-10 1.06e-07 0.46 0.34 Electroencephalogram traits; chr11:66246193 chr11:66244840~66246239:- LIHC cis rs524281 0.773 rs2155198 ENSG00000255320.1 RP11-755F10.1 6.64 1.23e-10 1.06e-07 0.46 0.34 Electroencephalogram traits; chr11:66246829 chr11:66244840~66246239:- LIHC cis rs12681287 0.752 rs4463401 ENSG00000250569.1 NTAN1P2 6.64 1.23e-10 1.06e-07 0.41 0.34 Caudate activity during reward; chr8:86238080 chr8:86481754~86483002:- LIHC cis rs2033711 0.87 rs4801583 ENSG00000269473.1 CTD-2619J13.19 6.64 1.24e-10 1.06e-07 0.4 0.34 Uric acid clearance; chr19:58407038 chr19:58440448~58445849:+ LIHC cis rs7580658 0.724 rs6712551 ENSG00000236682.1 AC068282.3 -6.64 1.24e-10 1.07e-07 -0.42 -0.34 Protein C levels; chr2:127240909 chr2:127389130~127400580:+ LIHC cis rs12681287 0.752 rs10111095 ENSG00000250569.1 NTAN1P2 6.64 1.25e-10 1.07e-07 0.41 0.34 Caudate activity during reward; chr8:86238755 chr8:86481754~86483002:- LIHC cis rs524281 0.725 rs3132851 ENSG00000255320.1 RP11-755F10.1 -6.64 1.26e-10 1.08e-07 -0.45 -0.34 Electroencephalogram traits; chr11:66288671 chr11:66244840~66246239:- LIHC cis rs739496 0.615 rs4648328 ENSG00000226469.1 ADAM1B 6.63 1.28e-10 1.1e-07 0.45 0.34 Platelet count; chr12:111784984 chr12:111927018~111929017:+ LIHC cis rs1577917 0.958 rs7739241 ENSG00000234155.1 RP11-30P6.6 6.63 1.28e-10 1.1e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85866078 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs12202712 ENSG00000234155.1 RP11-30P6.6 6.63 1.28e-10 1.1e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85868823 chr6:85387219~85390186:- LIHC cis rs2243480 1 rs781150 ENSG00000164669.11 INTS4P1 6.63 1.28e-10 1.1e-07 0.58 0.34 Diabetic kidney disease; chr7:66015986 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs313798 ENSG00000164669.11 INTS4P1 6.63 1.28e-10 1.1e-07 0.58 0.34 Diabetic kidney disease; chr7:66028044 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs35396113 ENSG00000164669.11 INTS4P1 6.63 1.28e-10 1.1e-07 0.58 0.34 Diabetic kidney disease; chr7:66030474 chr7:65141225~65234216:+ LIHC cis rs1577917 0.958 rs12213431 ENSG00000234155.1 RP11-30P6.6 6.63 1.29e-10 1.1e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85791238 chr6:85387219~85390186:- LIHC cis rs7914558 0.966 rs10786719 ENSG00000236937.2 PTGES3P4 -6.63 1.29e-10 1.1e-07 -0.4 -0.34 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102878235 chr10:102845595~102845950:+ LIHC cis rs6490294 0.571 rs11066119 ENSG00000226469.1 ADAM1B 6.63 1.3e-10 1.11e-07 0.46 0.34 Mean platelet volume; chr12:111996700 chr12:111927018~111929017:+ LIHC cis rs1134634 1 rs1134634 ENSG00000273133.1 RP11-799M12.2 6.63 1.3e-10 1.11e-07 0.39 0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15601446 chr4:15563698~15564253:- LIHC cis rs2243480 1 rs313814 ENSG00000164669.11 INTS4P1 6.63 1.31e-10 1.12e-07 0.58 0.34 Diabetic kidney disease; chr7:66038306 chr7:65141225~65234216:+ LIHC cis rs4660456 0.871 rs669072 ENSG00000237899.1 RP4-739H11.3 6.63 1.32e-10 1.13e-07 0.46 0.34 Platelet count; chr1:40679946 chr1:40669089~40687588:- LIHC cis rs4660456 0.912 rs658806 ENSG00000237899.1 RP4-739H11.3 6.63 1.32e-10 1.13e-07 0.46 0.34 Platelet count; chr1:40683312 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs489222 ENSG00000237899.1 RP4-739H11.3 6.63 1.32e-10 1.13e-07 0.46 0.34 Platelet count; chr1:40683422 chr1:40669089~40687588:- LIHC cis rs4660456 0.871 rs671704 ENSG00000237899.1 RP4-739H11.3 6.63 1.32e-10 1.13e-07 0.46 0.34 Platelet count; chr1:40683974 chr1:40669089~40687588:- LIHC cis rs62355901 0.545 rs56008823 ENSG00000271828.1 CTD-2310F14.1 6.63 1.32e-10 1.13e-07 0.55 0.34 Breast cancer; chr5:56772187 chr5:56927874~56929573:+ LIHC cis rs2243480 1 rs56016656 ENSG00000164669.11 INTS4P1 6.63 1.32e-10 1.13e-07 0.59 0.34 Diabetic kidney disease; chr7:65918494 chr7:65141225~65234216:+ LIHC cis rs2243480 0.803 rs55700941 ENSG00000164669.11 INTS4P1 6.63 1.32e-10 1.13e-07 0.59 0.34 Diabetic kidney disease; chr7:65924813 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs36033484 ENSG00000164669.11 INTS4P1 6.63 1.32e-10 1.13e-07 0.59 0.34 Diabetic kidney disease; chr7:65925571 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs34193460 ENSG00000164669.11 INTS4P1 6.63 1.32e-10 1.13e-07 0.59 0.34 Diabetic kidney disease; chr7:65928123 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs34560516 ENSG00000164669.11 INTS4P1 6.63 1.32e-10 1.13e-07 0.59 0.34 Diabetic kidney disease; chr7:65939105 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs57057549 ENSG00000164669.11 INTS4P1 6.63 1.32e-10 1.13e-07 0.59 0.34 Diabetic kidney disease; chr7:65940751 chr7:65141225~65234216:+ LIHC cis rs2243480 0.808 rs12698508 ENSG00000164669.11 INTS4P1 6.63 1.32e-10 1.13e-07 0.59 0.34 Diabetic kidney disease; chr7:65946971 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs2961102 ENSG00000164669.11 INTS4P1 6.63 1.32e-10 1.13e-07 0.59 0.34 Diabetic kidney disease; chr7:65959671 chr7:65141225~65234216:+ LIHC cis rs1862618 0.573 rs185220 ENSG00000271828.1 CTD-2310F14.1 6.63 1.32e-10 1.13e-07 0.49 0.34 Initial pursuit acceleration; chr5:56909530 chr5:56927874~56929573:+ LIHC cis rs916888 0.61 rs199438 ENSG00000214401.4 KANSL1-AS1 6.63 1.32e-10 1.13e-07 0.42 0.34 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:46193576~46196723:+ LIHC cis rs3823536 0.583 rs7800687 ENSG00000275106.1 RP11-309L24.10 -6.63 1.33e-10 1.13e-07 -0.43 -0.34 Sjögren's syndrome; chr7:128953665 chr7:128952527~128953316:- LIHC cis rs11098499 0.954 rs13145352 ENSG00000260091.1 RP11-33B1.4 6.63 1.34e-10 1.15e-07 0.25 0.34 Corneal astigmatism; chr4:119488808 chr4:119409333~119410233:+ LIHC cis rs916888 0.531 rs183211 ENSG00000214401.4 KANSL1-AS1 6.63 1.34e-10 1.15e-07 0.41 0.34 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:46193576~46196723:+ LIHC cis rs1939012 0.846 rs1939013 ENSG00000281655.1 RP11-817J15.3 -6.63 1.35e-10 1.15e-07 -0.39 -0.34 Epilepsy; chr11:102727079 chr11:102681310~102683913:+ LIHC cis rs2836950 0.565 rs2836934 ENSG00000255568.3 BRWD1-AS2 -6.63 1.35e-10 1.15e-07 -0.28 -0.34 Menarche (age at onset); chr21:39192959 chr21:39313935~39314962:+ LIHC cis rs4423214 0.592 rs10898191 ENSG00000254682.1 RP11-660L16.2 -6.62 1.36e-10 1.16e-07 -0.46 -0.34 Vitamin D levels; chr11:71483555 chr11:71448674~71452157:+ LIHC cis rs6504950 0.783 rs7211787 ENSG00000275710.1 RP11-257O5.4 6.62 1.36e-10 1.16e-07 0.53 0.34 Breast cancer; chr17:55157551 chr17:54964474~54964679:+ LIHC cis rs6504950 0.783 rs12936639 ENSG00000275710.1 RP11-257O5.4 6.62 1.36e-10 1.16e-07 0.53 0.34 Breast cancer; chr17:55158621 chr17:54964474~54964679:+ LIHC cis rs9549367 0.713 rs2476328 ENSG00000269125.1 RP11-98F14.11 6.62 1.37e-10 1.17e-07 0.41 0.34 Platelet distribution width; chr13:113175036 chr13:113165002~113165183:- LIHC cis rs739496 0.615 rs56884502 ENSG00000226469.1 ADAM1B 6.62 1.37e-10 1.17e-07 0.45 0.34 Platelet count; chr12:111769496 chr12:111927018~111929017:+ LIHC cis rs739496 0.642 rs74849450 ENSG00000226469.1 ADAM1B 6.62 1.37e-10 1.17e-07 0.45 0.34 Platelet count; chr12:111771034 chr12:111927018~111929017:+ LIHC cis rs739496 0.579 rs2238152 ENSG00000226469.1 ADAM1B 6.62 1.37e-10 1.17e-07 0.45 0.34 Platelet count; chr12:111776655 chr12:111927018~111929017:+ LIHC cis rs4423214 0.879 rs1792277 ENSG00000254682.1 RP11-660L16.2 -6.62 1.38e-10 1.18e-07 -0.42 -0.34 Vitamin D levels; chr11:71427872 chr11:71448674~71452157:+ LIHC cis rs62229266 0.835 rs998384 ENSG00000231106.2 LINC01436 6.62 1.39e-10 1.18e-07 0.36 0.34 Mitral valve prolapse; chr21:36073228 chr21:36005338~36007838:+ LIHC cis rs916888 0.61 rs199454 ENSG00000214401.4 KANSL1-AS1 -6.62 1.39e-10 1.19e-07 -0.42 -0.34 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:46193576~46196723:+ LIHC cis rs524281 0.773 rs7945723 ENSG00000255320.1 RP11-755F10.1 6.62 1.4e-10 1.19e-07 0.46 0.34 Electroencephalogram traits; chr11:66288986 chr11:66244840~66246239:- LIHC cis rs12681287 0.752 rs10086569 ENSG00000250569.1 NTAN1P2 6.62 1.41e-10 1.2e-07 0.4 0.34 Caudate activity during reward; chr8:86234980 chr8:86481754~86483002:- LIHC cis rs832187 0.594 rs832197 ENSG00000280620.1 SCAANT1 -6.62 1.41e-10 1.2e-07 -0.41 -0.34 Schizophrenia; chr3:63898616 chr3:63911518~63911772:- LIHC cis rs1862618 0.853 rs252919 ENSG00000271828.1 CTD-2310F14.1 6.62 1.41e-10 1.2e-07 0.48 0.34 Initial pursuit acceleration; chr5:56828284 chr5:56927874~56929573:+ LIHC cis rs4423214 0.879 rs736894 ENSG00000254682.1 RP11-660L16.2 6.62 1.42e-10 1.21e-07 0.43 0.34 Vitamin D levels; chr11:71441212 chr11:71448674~71452157:+ LIHC cis rs4423214 0.879 rs1792281 ENSG00000254682.1 RP11-660L16.2 -6.62 1.42e-10 1.21e-07 -0.42 -0.34 Vitamin D levels; chr11:71424450 chr11:71448674~71452157:+ LIHC cis rs4718428 0.705 rs62465692 ENSG00000226824.5 RP4-756H11.3 -6.62 1.43e-10 1.22e-07 -0.45 -0.34 Corneal structure; chr7:66830758 chr7:66654538~66669855:+ LIHC cis rs4718428 0.662 rs34577323 ENSG00000226824.5 RP4-756H11.3 -6.62 1.43e-10 1.22e-07 -0.45 -0.34 Corneal structure; chr7:66845054 chr7:66654538~66669855:+ LIHC cis rs4718428 0.705 rs4717328 ENSG00000226824.5 RP4-756H11.3 -6.62 1.43e-10 1.22e-07 -0.45 -0.34 Corneal structure; chr7:66887678 chr7:66654538~66669855:+ LIHC cis rs4718428 0.705 rs4718422 ENSG00000226824.5 RP4-756H11.3 -6.62 1.43e-10 1.22e-07 -0.45 -0.34 Corneal structure; chr7:66894282 chr7:66654538~66669855:+ LIHC cis rs4718428 0.705 rs13231140 ENSG00000226824.5 RP4-756H11.3 -6.62 1.43e-10 1.22e-07 -0.45 -0.34 Corneal structure; chr7:66896631 chr7:66654538~66669855:+ LIHC cis rs12744310 0.887 rs17362424 ENSG00000235358.1 RP11-399E6.1 -6.62 1.43e-10 1.22e-07 -0.47 -0.34 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41328731 chr1:41242373~41284861:+ LIHC cis rs3823536 0.583 rs2280714 ENSG00000275106.1 RP11-309L24.10 -6.62 1.43e-10 1.22e-07 -0.43 -0.34 Sjögren's syndrome; chr7:128954671 chr7:128952527~128953316:- LIHC cis rs1862618 0.802 rs7733041 ENSG00000271828.1 CTD-2310F14.1 6.62 1.43e-10 1.22e-07 0.47 0.34 Initial pursuit acceleration; chr5:56811550 chr5:56927874~56929573:+ LIHC cis rs832187 0.813 rs704370 ENSG00000280620.1 SCAANT1 -6.61 1.44e-10 1.22e-07 -0.41 -0.34 Schizophrenia; chr3:63882574 chr3:63911518~63911772:- LIHC cis rs9660180 0.967 rs6687065 ENSG00000268575.1 RP1-283E3.8 -6.61 1.44e-10 1.23e-07 -0.31 -0.34 Body mass index; chr1:1847030 chr1:1702736~1737688:- LIHC cis rs113835537 0.529 rs11227495 ENSG00000255517.5 CTD-3074O7.5 -6.61 1.44e-10 1.23e-07 -0.37 -0.34 Airway imaging phenotypes; chr11:66495772 chr11:66473490~66480233:- LIHC cis rs62229266 0.804 rs998383 ENSG00000231106.2 LINC01436 6.61 1.44e-10 1.23e-07 0.36 0.34 Mitral valve prolapse; chr21:36073441 chr21:36005338~36007838:+ LIHC cis rs150992 0.609 rs709390 ENSG00000248489.1 CTD-2007H13.3 6.61 1.44e-10 1.23e-07 0.5 0.34 Body mass index; chr5:98993771 chr5:98929171~98995013:+ LIHC cis rs992157 0.735 rs13393821 ENSG00000261338.2 RP11-378A13.1 6.61 1.44e-10 1.23e-07 0.33 0.34 Colorectal cancer; chr2:218212019 chr2:218255319~218257366:+ LIHC cis rs7115242 0.844 rs645258 ENSG00000254851.1 RP11-109L13.1 -6.61 1.45e-10 1.23e-07 -0.54 -0.34 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116930485 chr11:117135528~117138582:+ LIHC cis rs35160687 0.64 rs13015186 ENSG00000273080.1 RP11-301O19.1 6.61 1.46e-10 1.24e-07 0.45 0.34 Night sleep phenotypes; chr2:86258455 chr2:86195590~86196049:+ LIHC cis rs2836950 0.545 rs2836940 ENSG00000255568.3 BRWD1-AS2 -6.61 1.48e-10 1.25e-07 -0.28 -0.34 Menarche (age at onset); chr21:39216770 chr21:39313935~39314962:+ LIHC cis rs2836950 0.509 rs4816618 ENSG00000255568.3 BRWD1-AS2 -6.61 1.49e-10 1.26e-07 -0.28 -0.34 Menarche (age at onset); chr21:39227603 chr21:39313935~39314962:+ LIHC cis rs2836950 0.527 rs2836948 ENSG00000255568.3 BRWD1-AS2 -6.61 1.49e-10 1.26e-07 -0.28 -0.34 Menarche (age at onset); chr21:39227751 chr21:39313935~39314962:+ LIHC cis rs17301013 0.507 rs16847337 ENSG00000227373.4 RP11-160H22.5 -6.61 1.49e-10 1.26e-07 -0.58 -0.34 Systemic lupus erythematosus; chr1:174683121 chr1:174115300~174160004:- LIHC cis rs1862618 0.853 rs10051747 ENSG00000271828.1 CTD-2310F14.1 6.61 1.49e-10 1.27e-07 0.48 0.34 Initial pursuit acceleration; chr5:56787462 chr5:56927874~56929573:+ LIHC cis rs524281 0.773 rs7925123 ENSG00000255320.1 RP11-755F10.1 6.61 1.49e-10 1.27e-07 0.45 0.34 Electroencephalogram traits; chr11:66225742 chr11:66244840~66246239:- LIHC cis rs2734839 0.507 rs2005313 ENSG00000270179.1 RP11-159N11.4 -6.61 1.49e-10 1.27e-07 -0.38 -0.34 Information processing speed; chr11:113419327 chr11:113368478~113369117:+ LIHC cis rs765787 0.505 rs1648302 ENSG00000259520.4 CTD-2651B20.3 6.61 1.49e-10 1.27e-07 0.4 0.34 Uric acid levels; chr15:45202040 chr15:45251580~45279251:- LIHC cis rs6504950 0.886 rs4794551 ENSG00000275710.1 RP11-257O5.4 -6.61 1.5e-10 1.27e-07 -0.41 -0.34 Breast cancer; chr17:54998066 chr17:54964474~54964679:+ LIHC cis rs8040855 0.794 rs4843024 ENSG00000259295.5 CSPG4P12 -6.61 1.5e-10 1.27e-07 -0.52 -0.34 Bulimia nervosa; chr15:85162669 chr15:85191438~85213905:+ LIHC cis rs13068223 0.584 rs345985 ENSG00000243926.1 TIPARP-AS1 -6.61 1.5e-10 1.27e-07 -0.33 -0.34 Age-related hearing impairment (SNP x SNP interaction); chr3:156679385 chr3:156671862~156674378:- LIHC cis rs7674212 0.531 rs4698876 ENSG00000230069.3 LRRC37A15P -6.61 1.5e-10 1.27e-07 -0.32 -0.34 Type 2 diabetes; chr4:103012410 chr4:102727274~102730721:- LIHC cis rs7674212 0.531 rs7665026 ENSG00000230069.3 LRRC37A15P -6.61 1.5e-10 1.27e-07 -0.32 -0.34 Type 2 diabetes; chr4:103015491 chr4:102727274~102730721:- LIHC cis rs12681287 0.752 rs10092651 ENSG00000250569.1 NTAN1P2 6.61 1.51e-10 1.28e-07 0.4 0.34 Caudate activity during reward; chr8:86235449 chr8:86481754~86483002:- LIHC cis rs12681287 0.752 rs10104242 ENSG00000250569.1 NTAN1P2 6.61 1.51e-10 1.28e-07 0.4 0.34 Caudate activity during reward; chr8:86235485 chr8:86481754~86483002:- LIHC cis rs7674212 0.507 rs223317 ENSG00000230069.3 LRRC37A15P -6.61 1.51e-10 1.29e-07 -0.33 -0.34 Type 2 diabetes; chr4:102881667 chr4:102727274~102730721:- LIHC cis rs875971 0.545 rs13311962 ENSG00000226824.5 RP4-756H11.3 6.6 1.53e-10 1.3e-07 0.43 0.34 Aortic root size; chr7:66603142 chr7:66654538~66669855:+ LIHC cis rs6061231 0.958 rs2379126 ENSG00000273619.1 RP5-908M14.9 -6.6 1.53e-10 1.3e-07 -0.31 -0.34 Colorectal cancer; chr20:62377949 chr20:62386303~62386970:- LIHC cis rs6061231 0.958 rs2427304 ENSG00000273619.1 RP5-908M14.9 -6.6 1.53e-10 1.3e-07 -0.31 -0.34 Colorectal cancer; chr20:62378528 chr20:62386303~62386970:- LIHC cis rs6061231 0.958 rs2427305 ENSG00000273619.1 RP5-908M14.9 -6.6 1.53e-10 1.3e-07 -0.31 -0.34 Colorectal cancer; chr20:62378693 chr20:62386303~62386970:- LIHC cis rs2117029 0.554 rs12579015 ENSG00000258017.1 RP11-386G11.10 -6.6 1.56e-10 1.32e-07 -0.4 -0.34 Intelligence (multi-trait analysis); chr12:49162648 chr12:49127782~49147869:+ LIHC cis rs739496 0.501 rs441 ENSG00000226469.1 ADAM1B 6.6 1.56e-10 1.32e-07 0.45 0.34 Platelet count; chr12:111791045 chr12:111927018~111929017:+ LIHC cis rs150992 0.532 rs416750 ENSG00000248489.1 CTD-2007H13.3 6.6 1.56e-10 1.32e-07 0.5 0.34 Body mass index; chr5:98999046 chr5:98929171~98995013:+ LIHC cis rs150992 0.609 rs819232 ENSG00000248489.1 CTD-2007H13.3 6.6 1.56e-10 1.32e-07 0.5 0.34 Body mass index; chr5:98999416 chr5:98929171~98995013:+ LIHC cis rs1577917 0.876 rs11752223 ENSG00000234155.1 RP11-30P6.6 6.6 1.56e-10 1.33e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85863676 chr6:85387219~85390186:- LIHC cis rs2243480 1 rs1723270 ENSG00000164669.11 INTS4P1 6.6 1.57e-10 1.33e-07 0.59 0.34 Diabetic kidney disease; chr7:66004843 chr7:65141225~65234216:+ LIHC cis rs2882667 0.824 rs13189485 ENSG00000253404.1 AC034243.1 6.6 1.57e-10 1.33e-07 0.47 0.34 Age-related hearing impairment (SNP x SNP interaction); chr5:139139712 chr5:138744434~138753309:- LIHC cis rs62355901 0.505 rs12657615 ENSG00000271828.1 CTD-2310F14.1 6.6 1.57e-10 1.33e-07 0.56 0.34 Breast cancer; chr5:56768306 chr5:56927874~56929573:+ LIHC cis rs2243480 1 rs313809 ENSG00000164669.11 INTS4P1 6.6 1.58e-10 1.34e-07 0.58 0.34 Diabetic kidney disease; chr7:66034996 chr7:65141225~65234216:+ LIHC cis rs9326248 0.861 rs4938353 ENSG00000280143.1 AP000892.6 6.6 1.58e-10 1.34e-07 0.39 0.34 Blood protein levels; chr11:117175481 chr11:117204967~117210292:+ LIHC cis rs1729407 0.659 rs2542050 ENSG00000254851.1 RP11-109L13.1 -6.6 1.59e-10 1.34e-07 -0.4 -0.34 Apolipoprotein A-IV levels; chr11:116826401 chr11:117135528~117138582:+ LIHC cis rs4423214 0.559 rs7949129 ENSG00000254682.1 RP11-660L16.2 -6.6 1.59e-10 1.35e-07 -0.46 -0.34 Vitamin D levels; chr11:71482089 chr11:71448674~71452157:+ LIHC cis rs9399137 0.507 rs4289677 ENSG00000232876.1 CTA-212D2.2 -6.6 1.6e-10 1.35e-07 -0.38 -0.34 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134954347 chr6:135055033~135060550:+ LIHC cis rs1862618 0.853 rs252909 ENSG00000271828.1 CTD-2310F14.1 6.6 1.6e-10 1.35e-07 0.47 0.34 Initial pursuit acceleration; chr5:56825304 chr5:56927874~56929573:+ LIHC cis rs35160687 0.862 rs13023154 ENSG00000273080.1 RP11-301O19.1 -6.6 1.6e-10 1.35e-07 -0.45 -0.34 Night sleep phenotypes; chr2:86289861 chr2:86195590~86196049:+ LIHC cis rs2033711 0.755 rs4801587 ENSG00000269473.1 CTD-2619J13.19 6.6 1.61e-10 1.36e-07 0.41 0.34 Uric acid clearance; chr19:58425312 chr19:58440448~58445849:+ LIHC cis rs2439831 0.85 rs16965120 ENSG00000205771.5 CATSPER2P1 -6.6 1.61e-10 1.36e-07 -0.51 -0.34 Lung cancer in ever smokers; chr15:43808144 chr15:43726918~43747094:- LIHC cis rs4728142 0.604 rs13242262 ENSG00000275106.1 RP11-309L24.10 -6.6 1.61e-10 1.37e-07 -0.42 -0.34 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128951310 chr7:128952527~128953316:- LIHC cis rs1577917 0.771 rs12199873 ENSG00000234155.1 RP11-30P6.6 6.59 1.63e-10 1.38e-07 0.42 0.34 Response to antipsychotic treatment; chr6:85585229 chr6:85387219~85390186:- LIHC cis rs1577917 0.771 rs2842609 ENSG00000234155.1 RP11-30P6.6 6.59 1.63e-10 1.38e-07 0.42 0.34 Response to antipsychotic treatment; chr6:85587070 chr6:85387219~85390186:- LIHC cis rs62229266 0.839 rs11702763 ENSG00000231106.2 LINC01436 6.59 1.64e-10 1.38e-07 0.38 0.34 Mitral valve prolapse; chr21:36098406 chr21:36005338~36007838:+ LIHC cis rs2243480 1 rs35820085 ENSG00000164669.11 INTS4P1 6.59 1.64e-10 1.39e-07 0.59 0.34 Diabetic kidney disease; chr7:65977771 chr7:65141225~65234216:+ LIHC cis rs2243480 0.908 rs55876148 ENSG00000164669.11 INTS4P1 6.59 1.65e-10 1.39e-07 0.59 0.34 Diabetic kidney disease; chr7:65914813 chr7:65141225~65234216:+ LIHC cis rs4660456 0.913 rs7551747 ENSG00000237899.1 RP4-739H11.3 6.59 1.65e-10 1.39e-07 0.44 0.34 Platelet count; chr1:40699407 chr1:40669089~40687588:- LIHC cis rs1729407 0.565 rs2849173 ENSG00000254851.1 RP11-109L13.1 -6.59 1.65e-10 1.4e-07 -0.4 -0.34 Apolipoprotein A-IV levels; chr11:116826605 chr11:117135528~117138582:+ LIHC cis rs992157 0.56 rs6436047 ENSG00000261338.2 RP11-378A13.1 6.59 1.65e-10 1.4e-07 0.33 0.34 Colorectal cancer; chr2:218244190 chr2:218255319~218257366:+ LIHC cis rs113835537 0.529 rs4930379 ENSG00000255517.5 CTD-3074O7.5 -6.59 1.67e-10 1.41e-07 -0.37 -0.34 Airway imaging phenotypes; chr11:66488203 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs4930183 ENSG00000255517.5 CTD-3074O7.5 -6.59 1.67e-10 1.41e-07 -0.37 -0.34 Airway imaging phenotypes; chr11:66488261 chr11:66473490~66480233:- LIHC cis rs11168854 0.595 rs11168857 ENSG00000258017.1 RP11-386G11.10 -6.59 1.67e-10 1.41e-07 -0.39 -0.34 Body mass index; chr12:49096526 chr12:49127782~49147869:+ LIHC cis rs2033711 0.87 rs7409473 ENSG00000269473.1 CTD-2619J13.19 6.59 1.67e-10 1.41e-07 0.4 0.34 Uric acid clearance; chr19:58427798 chr19:58440448~58445849:+ LIHC cis rs2033711 0.87 rs7408188 ENSG00000269473.1 CTD-2619J13.19 6.59 1.67e-10 1.41e-07 0.4 0.34 Uric acid clearance; chr19:58428022 chr19:58440448~58445849:+ LIHC cis rs2033711 0.87 rs1051500 ENSG00000269473.1 CTD-2619J13.19 6.59 1.67e-10 1.41e-07 0.4 0.34 Uric acid clearance; chr19:58433035 chr19:58440448~58445849:+ LIHC cis rs12439619 0.508 rs8023960 ENSG00000278603.1 RP13-608F4.5 6.59 1.68e-10 1.42e-07 0.43 0.34 Intelligence (multi-trait analysis); chr15:82206704 chr15:82472203~82472426:+ LIHC cis rs1577917 0.816 rs9353349 ENSG00000234155.1 RP11-30P6.6 -6.59 1.68e-10 1.42e-07 -0.4 -0.34 Response to antipsychotic treatment; chr6:85998007 chr6:85387219~85390186:- LIHC cis rs523522 0.962 rs1050187 ENSG00000278344.1 RP11-18C24.8 -6.59 1.69e-10 1.42e-07 -0.4 -0.34 High light scatter reticulocyte count; chr12:120464308 chr12:120500735~120501090:- LIHC cis rs62355901 0.545 rs72756091 ENSG00000271828.1 CTD-2310F14.1 6.59 1.69e-10 1.43e-07 0.55 0.34 Breast cancer; chr5:56765903 chr5:56927874~56929573:+ LIHC cis rs9527 0.501 rs12244388 ENSG00000236937.2 PTGES3P4 6.59 1.69e-10 1.43e-07 0.4 0.34 Arsenic metabolism; chr10:102880295 chr10:102845595~102845950:+ LIHC cis rs739496 0.615 rs59905228 ENSG00000226469.1 ADAM1B 6.59 1.7e-10 1.43e-07 0.43 0.34 Platelet count; chr12:111743422 chr12:111927018~111929017:+ LIHC cis rs12681287 0.752 rs13256500 ENSG00000250569.1 NTAN1P2 6.59 1.7e-10 1.43e-07 0.4 0.34 Caudate activity during reward; chr8:86234834 chr8:86481754~86483002:- LIHC cis rs6504950 0.679 rs9897646 ENSG00000275710.1 RP11-257O5.4 6.59 1.71e-10 1.44e-07 0.49 0.34 Breast cancer; chr17:54907990 chr17:54964474~54964679:+ LIHC cis rs1185460 0.546 rs592190 ENSG00000271751.1 RP11-110I1.14 6.59 1.71e-10 1.44e-07 0.44 0.34 Coronary artery disease; chr11:119084604 chr11:119065263~119065677:- LIHC cis rs2412819 0.599 rs2470120 ENSG00000205771.5 CATSPER2P1 -6.59 1.71e-10 1.44e-07 -0.42 -0.34 Lung cancer; chr15:43636872 chr15:43726918~43747094:- LIHC cis rs6061231 0.916 rs58488796 ENSG00000273619.1 RP5-908M14.9 -6.59 1.71e-10 1.44e-07 -0.31 -0.34 Colorectal cancer; chr20:62373994 chr20:62386303~62386970:- LIHC cis rs1862618 0.853 rs252916 ENSG00000271828.1 CTD-2310F14.1 6.59 1.71e-10 1.44e-07 0.47 0.34 Initial pursuit acceleration; chr5:56825961 chr5:56927874~56929573:+ LIHC cis rs1862618 0.802 rs832560 ENSG00000271828.1 CTD-2310F14.1 6.59 1.71e-10 1.44e-07 0.47 0.34 Initial pursuit acceleration; chr5:56828596 chr5:56927874~56929573:+ LIHC cis rs1577917 0.958 rs34994386 ENSG00000234155.1 RP11-30P6.6 6.58 1.72e-10 1.45e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85814417 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs36042496 ENSG00000234155.1 RP11-30P6.6 6.58 1.72e-10 1.45e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85814496 chr6:85387219~85390186:- LIHC cis rs1577917 0.917 rs1584273 ENSG00000234155.1 RP11-30P6.6 6.58 1.72e-10 1.45e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85814859 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs12198971 ENSG00000234155.1 RP11-30P6.6 6.58 1.72e-10 1.45e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85815727 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs34230196 ENSG00000234155.1 RP11-30P6.6 6.58 1.72e-10 1.45e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85816304 chr6:85387219~85390186:- LIHC cis rs1577917 0.917 rs4707226 ENSG00000234155.1 RP11-30P6.6 6.58 1.72e-10 1.45e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85818110 chr6:85387219~85390186:- LIHC cis rs1577917 0.876 rs12212808 ENSG00000234155.1 RP11-30P6.6 6.58 1.72e-10 1.45e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85824254 chr6:85387219~85390186:- LIHC cis rs1577917 0.917 rs13213603 ENSG00000234155.1 RP11-30P6.6 6.58 1.72e-10 1.45e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85825040 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs2324839 ENSG00000234155.1 RP11-30P6.6 6.58 1.72e-10 1.45e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85827224 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs3900313 ENSG00000234155.1 RP11-30P6.6 6.58 1.72e-10 1.45e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85827436 chr6:85387219~85390186:- LIHC cis rs1862618 0.853 rs252904 ENSG00000271828.1 CTD-2310F14.1 6.58 1.72e-10 1.45e-07 0.48 0.34 Initial pursuit acceleration; chr5:56822906 chr5:56927874~56929573:+ LIHC cis rs113835537 0.529 rs80100524 ENSG00000255517.5 CTD-3074O7.5 -6.58 1.73e-10 1.46e-07 -0.38 -0.34 Airway imaging phenotypes; chr11:66478465 chr11:66473490~66480233:- LIHC cis rs4718428 0.705 rs3800817 ENSG00000226824.5 RP4-756H11.3 -6.58 1.73e-10 1.46e-07 -0.44 -0.34 Corneal structure; chr7:66798563 chr7:66654538~66669855:+ LIHC cis rs6991838 0.612 rs7842162 ENSG00000200714.1 Y_RNA 6.58 1.73e-10 1.46e-07 0.35 0.34 Intelligence (multi-trait analysis); chr8:65644057 chr8:65592731~65592820:+ LIHC cis rs9843304 0.721 rs4681175 ENSG00000244503.1 RP11-278L15.6 6.58 1.74e-10 1.47e-07 0.35 0.34 Gallstone disease; chr3:149484076 chr3:149494660~149495995:+ LIHC cis rs1862618 0.511 rs2591952 ENSG00000271828.1 CTD-2310F14.1 6.58 1.75e-10 1.47e-07 0.47 0.34 Initial pursuit acceleration; chr5:56824942 chr5:56927874~56929573:+ LIHC cis rs71327718 1 rs71327718 ENSG00000171084.14 FAM86JP 6.58 1.75e-10 1.48e-07 0.7 0.34 Metabolite levels (HVA/5-HIAA ratio); chr3:125874014 chr3:125916620~125930024:+ LIHC cis rs1005277 0.579 rs1740732 ENSG00000263064.2 RP11-291L22.7 6.58 1.75e-10 1.48e-07 0.35 0.34 Extrinsic epigenetic age acceleration; chr10:38202457 chr10:38448689~38448949:+ LIHC cis rs6142102 0.517 rs6059580 ENSG00000276073.1 RP5-1125A11.7 -6.58 1.75e-10 1.48e-07 -0.34 -0.34 Skin pigmentation; chr20:33940067 chr20:33985617~33988989:- LIHC cis rs2522056 0.808 rs1016988 ENSG00000233006.5 AC034220.3 -6.58 1.75e-10 1.48e-07 -0.36 -0.34 Fibrinogen;Lymphocyte counts; chr5:132408882 chr5:132311285~132369916:- LIHC cis rs12681287 0.752 rs4288357 ENSG00000250569.1 NTAN1P2 6.58 1.76e-10 1.48e-07 0.4 0.34 Caudate activity during reward; chr8:86239604 chr8:86481754~86483002:- LIHC cis rs12681287 0.752 rs4472493 ENSG00000250569.1 NTAN1P2 6.58 1.76e-10 1.48e-07 0.4 0.34 Caudate activity during reward; chr8:86239685 chr8:86481754~86483002:- LIHC cis rs10875746 0.903 rs17122666 ENSG00000240399.1 RP1-228P16.1 -6.58 1.76e-10 1.48e-07 -0.38 -0.34 Longevity (90 years and older); chr12:48108791 chr12:48054813~48055591:- LIHC cis rs9549367 0.789 rs3764125 ENSG00000269125.1 RP11-98F14.11 6.58 1.77e-10 1.49e-07 0.42 0.34 Platelet distribution width; chr13:113243334 chr13:113165002~113165183:- LIHC cis rs1023500 0.506 rs6002625 ENSG00000227370.1 RP4-669P10.19 6.58 1.77e-10 1.49e-07 0.4 0.34 Schizophrenia; chr22:42121685 chr22:42132543~42132998:+ LIHC cis rs1555322 0.505 rs639763 ENSG00000126005.14 MMP24-AS1 -6.58 1.78e-10 1.49e-07 -0.51 -0.34 Attention deficit hyperactivity disorder; chr20:35274101 chr20:35216462~35278131:- LIHC cis rs55665837 0.701 rs11023278 ENSG00000251991.1 RNU7-49P 6.58 1.78e-10 1.49e-07 0.37 0.34 Vitamin D levels; chr11:14619638 chr11:14478892~14478953:+ LIHC cis rs1862618 0.853 rs252915 ENSG00000271828.1 CTD-2310F14.1 -6.58 1.78e-10 1.5e-07 -0.47 -0.34 Initial pursuit acceleration; chr5:56825927 chr5:56927874~56929573:+ LIHC cis rs3096299 0.9 rs4785663 ENSG00000274627.1 RP11-104N10.2 6.58 1.78e-10 1.5e-07 0.35 0.34 Multiple myeloma (IgH translocation); chr16:89368480 chr16:89516797~89522217:+ LIHC cis rs1555322 0.53 rs2250205 ENSG00000126005.14 MMP24-AS1 -6.58 1.79e-10 1.5e-07 -0.51 -0.34 Attention deficit hyperactivity disorder; chr20:35280121 chr20:35216462~35278131:- LIHC cis rs2439831 0.85 rs28718261 ENSG00000205771.5 CATSPER2P1 -6.58 1.79e-10 1.51e-07 -0.5 -0.34 Lung cancer in ever smokers; chr15:43751595 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs28595038 ENSG00000205771.5 CATSPER2P1 -6.58 1.79e-10 1.51e-07 -0.5 -0.34 Lung cancer in ever smokers; chr15:43752661 chr15:43726918~43747094:- LIHC cis rs1577917 0.958 rs1447160 ENSG00000234155.1 RP11-30P6.6 6.58 1.79e-10 1.51e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85836405 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs12198061 ENSG00000234155.1 RP11-30P6.6 6.58 1.79e-10 1.51e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85841267 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs1838955 ENSG00000234155.1 RP11-30P6.6 6.58 1.79e-10 1.51e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85855731 chr6:85387219~85390186:- LIHC cis rs1577917 0.874 rs1838954 ENSG00000234155.1 RP11-30P6.6 6.58 1.79e-10 1.51e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85855760 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs2084294 ENSG00000234155.1 RP11-30P6.6 6.58 1.79e-10 1.51e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85856225 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs12660846 ENSG00000234155.1 RP11-30P6.6 6.58 1.79e-10 1.51e-07 0.4 0.34 Response to antipsychotic treatment; chr6:85864091 chr6:85387219~85390186:- LIHC cis rs4356975 0.697 rs6849081 ENSG00000249956.3 RP11-790I12.2 6.58 1.8e-10 1.51e-07 0.4 0.34 Obesity-related traits; chr4:69144840 chr4:69408836~69423164:+ LIHC cis rs4356975 0.649 rs59421013 ENSG00000249956.3 RP11-790I12.2 6.58 1.8e-10 1.51e-07 0.4 0.34 Obesity-related traits; chr4:69149131 chr4:69408836~69423164:+ LIHC cis rs4356975 0.697 rs58039330 ENSG00000249956.3 RP11-790I12.2 6.58 1.8e-10 1.51e-07 0.4 0.34 Obesity-related traits; chr4:69149529 chr4:69408836~69423164:+ LIHC cis rs4356975 0.66 rs60567038 ENSG00000249956.3 RP11-790I12.2 6.58 1.8e-10 1.51e-07 0.4 0.34 Obesity-related traits; chr4:69150135 chr4:69408836~69423164:+ LIHC cis rs4356975 0.697 rs58366569 ENSG00000249956.3 RP11-790I12.2 6.58 1.8e-10 1.51e-07 0.4 0.34 Obesity-related traits; chr4:69150626 chr4:69408836~69423164:+ LIHC cis rs2836950 0.545 rs8132143 ENSG00000255568.3 BRWD1-AS2 -6.58 1.8e-10 1.51e-07 -0.28 -0.34 Menarche (age at onset); chr21:39212332 chr21:39313935~39314962:+ LIHC cis rs6504950 0.888 rs244320 ENSG00000275710.1 RP11-257O5.4 6.58 1.8e-10 1.51e-07 0.4 0.34 Breast cancer; chr17:55145559 chr17:54964474~54964679:+ LIHC cis rs2836950 0.545 rs2836952 ENSG00000255568.3 BRWD1-AS2 -6.58 1.8e-10 1.51e-07 -0.28 -0.34 Menarche (age at onset); chr21:39244725 chr21:39313935~39314962:+ LIHC cis rs35160687 0.862 rs12476706 ENSG00000273080.1 RP11-301O19.1 6.58 1.81e-10 1.52e-07 0.45 0.34 Night sleep phenotypes; chr2:86301247 chr2:86195590~86196049:+ LIHC cis rs9322193 0.607 rs9383941 ENSG00000231760.4 RP11-350J20.5 -6.58 1.81e-10 1.52e-07 -0.44 -0.34 Lung cancer; chr6:149912100 chr6:149796151~149826294:- LIHC cis rs73086581 0.838 rs73088424 ENSG00000229539.1 RP11-119B16.2 6.58 1.81e-10 1.52e-07 0.57 0.34 Response to antidepressants in depression; chr20:4020359 chr20:3888239~3888868:- LIHC cis rs2836950 0.565 rs7276046 ENSG00000255568.3 BRWD1-AS2 -6.58 1.82e-10 1.53e-07 -0.28 -0.33 Menarche (age at onset); chr21:39209367 chr21:39313935~39314962:+ LIHC cis rs1062177 0.694 rs2915816 ENSG00000213433.5 RPLP1P6 6.57 1.83e-10 1.53e-07 0.37 0.33 Preschool internalizing problems; chr5:151736296 chr5:151765859~151766378:- LIHC cis rs2882667 0.788 rs11959691 ENSG00000253404.1 AC034243.1 6.57 1.83e-10 1.54e-07 0.48 0.33 Age-related hearing impairment (SNP x SNP interaction); chr5:139145399 chr5:138744434~138753309:- LIHC cis rs10875746 0.951 rs2269935 ENSG00000240399.1 RP1-228P16.1 -6.57 1.83e-10 1.54e-07 -0.39 -0.33 Longevity (90 years and older); chr12:48122681 chr12:48054813~48055591:- LIHC cis rs992157 0.687 rs10206984 ENSG00000261338.2 RP11-378A13.1 6.57 1.85e-10 1.55e-07 0.33 0.33 Colorectal cancer; chr2:218202257 chr2:218255319~218257366:+ LIHC cis rs3823536 0.505 rs3925323 ENSG00000275106.1 RP11-309L24.10 -6.57 1.85e-10 1.55e-07 -0.42 -0.33 Sjögren's syndrome; chr7:128952187 chr7:128952527~128953316:- LIHC cis rs739496 0.615 rs12427276 ENSG00000226469.1 ADAM1B 6.57 1.86e-10 1.55e-07 0.42 0.33 Platelet count; chr12:111675704 chr12:111927018~111929017:+ LIHC cis rs739496 0.615 rs847895 ENSG00000226469.1 ADAM1B 6.57 1.86e-10 1.55e-07 0.42 0.33 Platelet count; chr12:111680772 chr12:111927018~111929017:+ LIHC cis rs2283792 0.73 rs738858 ENSG00000224086.5 LL22NC03-86G7.1 -6.57 1.86e-10 1.56e-07 -0.35 -0.33 Multiple sclerosis; chr22:21926544 chr22:21938293~21977632:+ LIHC cis rs1150668 0.796 rs2247002 ENSG00000216901.1 AL022393.7 6.57 1.86e-10 1.56e-07 0.38 0.33 Pubertal anthropometrics; chr6:28430174 chr6:28176188~28176674:+ LIHC cis rs1150668 0.796 rs728122 ENSG00000216901.1 AL022393.7 6.57 1.86e-10 1.56e-07 0.38 0.33 Pubertal anthropometrics; chr6:28431347 chr6:28176188~28176674:+ LIHC cis rs832187 0.776 rs854622 ENSG00000280620.1 SCAANT1 6.57 1.86e-10 1.56e-07 0.4 0.33 Schizophrenia; chr3:63877166 chr3:63911518~63911772:- LIHC cis rs765787 0.53 rs11636410 ENSG00000259520.4 CTD-2651B20.3 -6.57 1.86e-10 1.56e-07 -0.4 -0.33 Uric acid levels; chr15:45243715 chr15:45251580~45279251:- LIHC cis rs854625 1 rs854625 ENSG00000278690.1 RP11-104J23.2 -6.57 1.87e-10 1.57e-07 -0.49 -0.33 Cerebrospinal fluid biomarker levels; chr17:36001422 chr17:36012504~36012891:+ LIHC cis rs2033711 0.87 rs1465789 ENSG00000269473.1 CTD-2619J13.19 6.57 1.87e-10 1.57e-07 0.41 0.33 Uric acid clearance; chr19:58434689 chr19:58440448~58445849:+ LIHC cis rs3096299 0.9 rs3114867 ENSG00000274627.1 RP11-104N10.2 6.57 1.87e-10 1.57e-07 0.34 0.33 Multiple myeloma (IgH translocation); chr16:89362559 chr16:89516797~89522217:+ LIHC cis rs992157 0.56 rs12987130 ENSG00000261338.2 RP11-378A13.1 -6.57 1.88e-10 1.57e-07 -0.33 -0.33 Colorectal cancer; chr2:218240267 chr2:218255319~218257366:+ LIHC cis rs113835537 0.559 rs11227498 ENSG00000255517.5 CTD-3074O7.5 -6.57 1.88e-10 1.58e-07 -0.36 -0.33 Airway imaging phenotypes; chr11:66502243 chr11:66473490~66480233:- LIHC cis rs1185460 0.546 rs589925 ENSG00000271751.1 RP11-110I1.14 6.57 1.89e-10 1.58e-07 0.44 0.33 Coronary artery disease; chr11:119084969 chr11:119065263~119065677:- LIHC cis rs7674212 0.507 rs223322 ENSG00000230069.3 LRRC37A15P -6.57 1.89e-10 1.58e-07 -0.32 -0.33 Type 2 diabetes; chr4:102879037 chr4:102727274~102730721:- LIHC cis rs10170846 0.924 rs3768973 ENSG00000261428.2 RP11-16P6.1 6.57 1.89e-10 1.58e-07 0.35 0.33 Schizophrenia (inflammation and infection response interaction); chr2:222571683 chr2:222566899~222569719:- LIHC cis rs10875746 0.951 rs4760689 ENSG00000240399.1 RP1-228P16.1 -6.57 1.89e-10 1.58e-07 -0.38 -0.33 Longevity (90 years and older); chr12:48169861 chr12:48054813~48055591:- LIHC cis rs10875746 0.951 rs58865997 ENSG00000240399.1 RP1-228P16.1 -6.57 1.89e-10 1.58e-07 -0.38 -0.33 Longevity (90 years and older); chr12:48173090 chr12:48054813~48055591:- LIHC cis rs12681287 0.752 rs34279109 ENSG00000250569.1 NTAN1P2 6.57 1.89e-10 1.58e-07 0.4 0.33 Caudate activity during reward; chr8:86235715 chr8:86481754~86483002:- LIHC cis rs739496 0.615 rs4646778 ENSG00000226469.1 ADAM1B 6.57 1.9e-10 1.59e-07 0.45 0.33 Platelet count; chr12:111797979 chr12:111927018~111929017:+ LIHC cis rs150992 0.57 rs10050423 ENSG00000248489.1 CTD-2007H13.3 -6.57 1.9e-10 1.59e-07 -0.49 -0.33 Body mass index; chr5:99006312 chr5:98929171~98995013:+ LIHC cis rs9341808 0.559 rs7762895 ENSG00000272129.1 RP11-250B2.6 6.57 1.91e-10 1.6e-07 0.34 0.33 Sitting height ratio; chr6:80351714 chr6:80355424~80356859:+ LIHC cis rs1577917 0.958 rs12196230 ENSG00000234155.1 RP11-30P6.6 6.57 1.92e-10 1.61e-07 0.4 0.33 Response to antipsychotic treatment; chr6:85810242 chr6:85387219~85390186:- LIHC cis rs55665837 0.701 rs2007361 ENSG00000251991.1 RNU7-49P 6.57 1.93e-10 1.61e-07 0.37 0.33 Vitamin D levels; chr11:14641176 chr11:14478892~14478953:+ LIHC cis rs1862618 0.853 rs2432195 ENSG00000271828.1 CTD-2310F14.1 6.56 1.93e-10 1.62e-07 0.47 0.33 Initial pursuit acceleration; chr5:56824586 chr5:56927874~56929573:+ LIHC cis rs1577917 0.771 rs2842612 ENSG00000234155.1 RP11-30P6.6 6.56 1.93e-10 1.62e-07 0.42 0.33 Response to antipsychotic treatment; chr6:85593373 chr6:85387219~85390186:- LIHC cis rs113835537 0.529 rs2279864 ENSG00000255517.5 CTD-3074O7.5 -6.56 1.94e-10 1.62e-07 -0.37 -0.33 Airway imaging phenotypes; chr11:66480373 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs78999944 ENSG00000255517.5 CTD-3074O7.5 -6.56 1.94e-10 1.62e-07 -0.37 -0.33 Airway imaging phenotypes; chr11:66483757 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs11550299 ENSG00000255517.5 CTD-3074O7.5 -6.56 1.94e-10 1.62e-07 -0.37 -0.33 Airway imaging phenotypes; chr11:66486614 chr11:66473490~66480233:- LIHC cis rs12744310 0.836 rs12048808 ENSG00000235358.1 RP11-399E6.1 6.56 1.94e-10 1.62e-07 0.47 0.33 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41348636 chr1:41242373~41284861:+ LIHC cis rs4718428 0.672 rs13241598 ENSG00000226824.5 RP4-756H11.3 -6.56 1.95e-10 1.63e-07 -0.44 -0.33 Corneal structure; chr7:66835665 chr7:66654538~66669855:+ LIHC cis rs4423214 0.592 rs3829251 ENSG00000254682.1 RP11-660L16.2 -6.56 1.95e-10 1.63e-07 -0.46 -0.33 Vitamin D levels; chr11:71483513 chr11:71448674~71452157:+ LIHC cis rs2439831 0.702 rs7171750 ENSG00000205771.5 CATSPER2P1 -6.56 1.97e-10 1.64e-07 -0.5 -0.33 Lung cancer in ever smokers; chr15:43733660 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs11070408 ENSG00000205771.5 CATSPER2P1 -6.56 1.97e-10 1.64e-07 -0.5 -0.33 Lung cancer in ever smokers; chr15:43742590 chr15:43726918~43747094:- LIHC cis rs4423214 0.592 rs11233977 ENSG00000254682.1 RP11-660L16.2 -6.56 1.98e-10 1.65e-07 -0.45 -0.33 Vitamin D levels; chr11:71510559 chr11:71448674~71452157:+ LIHC cis rs1150668 0.796 rs2531825 ENSG00000216901.1 AL022393.7 6.56 1.98e-10 1.65e-07 0.38 0.33 Pubertal anthropometrics; chr6:28381487 chr6:28176188~28176674:+ LIHC cis rs6504950 0.888 rs244319 ENSG00000275710.1 RP11-257O5.4 6.56 1.98e-10 1.65e-07 0.4 0.33 Breast cancer; chr17:55145513 chr17:54964474~54964679:+ LIHC cis rs6504950 0.813 rs244321 ENSG00000275710.1 RP11-257O5.4 6.56 1.98e-10 1.65e-07 0.4 0.33 Breast cancer; chr17:55146637 chr17:54964474~54964679:+ LIHC cis rs6504950 0.854 rs244322 ENSG00000275710.1 RP11-257O5.4 6.56 1.98e-10 1.65e-07 0.4 0.33 Breast cancer; chr17:55147398 chr17:54964474~54964679:+ LIHC cis rs2882667 0.824 rs11748097 ENSG00000253404.1 AC034243.1 6.56 1.98e-10 1.65e-07 0.48 0.33 Age-related hearing impairment (SNP x SNP interaction); chr5:139144198 chr5:138744434~138753309:- LIHC cis rs2882667 0.824 rs12173085 ENSG00000253404.1 AC034243.1 6.56 1.98e-10 1.65e-07 0.48 0.33 Age-related hearing impairment (SNP x SNP interaction); chr5:139144336 chr5:138744434~138753309:- LIHC cis rs113835537 0.597 rs57288351 ENSG00000255517.5 CTD-3074O7.5 -6.56 1.99e-10 1.66e-07 -0.38 -0.33 Airway imaging phenotypes; chr11:66540018 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs11227525 ENSG00000255517.5 CTD-3074O7.5 -6.56 1.99e-10 1.66e-07 -0.38 -0.33 Airway imaging phenotypes; chr11:66540594 chr11:66473490~66480233:- LIHC cis rs7617773 0.817 rs745116 ENSG00000229759.1 MRPS18AP1 6.56 2e-10 1.67e-07 0.4 0.33 Coronary artery disease; chr3:48231046 chr3:48256350~48256938:- LIHC cis rs4660456 0.826 rs507914 ENSG00000237899.1 RP4-739H11.3 6.56 2e-10 1.67e-07 0.46 0.33 Platelet count; chr1:40686529 chr1:40669089~40687588:- LIHC cis rs4660456 0.913 rs2780950 ENSG00000237899.1 RP4-739H11.3 6.56 2e-10 1.67e-07 0.46 0.33 Platelet count; chr1:40686937 chr1:40669089~40687588:- LIHC cis rs8040855 0.599 rs2342123 ENSG00000259295.5 CSPG4P12 6.56 2.01e-10 1.67e-07 0.42 0.33 Bulimia nervosa; chr15:85181918 chr15:85191438~85213905:+ LIHC cis rs150992 0.609 rs7711061 ENSG00000248489.1 CTD-2007H13.3 -6.56 2.02e-10 1.68e-07 -0.49 -0.33 Body mass index; chr5:99003535 chr5:98929171~98995013:+ LIHC cis rs2439831 0.85 rs7183809 ENSG00000205771.5 CATSPER2P1 -6.56 2.03e-10 1.69e-07 -0.49 -0.33 Lung cancer in ever smokers; chr15:43828670 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs3759790 ENSG00000205771.5 CATSPER2P1 -6.56 2.03e-10 1.69e-07 -0.49 -0.33 Lung cancer in ever smokers; chr15:43828832 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs68079546 ENSG00000205771.5 CATSPER2P1 -6.56 2.03e-10 1.69e-07 -0.49 -0.33 Lung cancer in ever smokers; chr15:43844759 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs56909447 ENSG00000205771.5 CATSPER2P1 -6.56 2.03e-10 1.69e-07 -0.49 -0.33 Lung cancer in ever smokers; chr15:43845420 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs28476182 ENSG00000205771.5 CATSPER2P1 -6.56 2.03e-10 1.69e-07 -0.49 -0.33 Lung cancer in ever smokers; chr15:43847445 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs28696802 ENSG00000205771.5 CATSPER2P1 -6.56 2.03e-10 1.69e-07 -0.49 -0.33 Lung cancer in ever smokers; chr15:43848197 chr15:43726918~43747094:- LIHC cis rs55665837 0.701 rs10766188 ENSG00000251991.1 RNU7-49P 6.56 2.03e-10 1.69e-07 0.37 0.33 Vitamin D levels; chr11:14639280 chr11:14478892~14478953:+ LIHC cis rs2739330 0.892 rs4822455 ENSG00000250470.1 AP000351.3 6.56 2.03e-10 1.69e-07 0.41 0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23976904~23977585:- LIHC cis rs832187 0.813 rs704369 ENSG00000280620.1 SCAANT1 -6.56 2.03e-10 1.69e-07 -0.41 -0.33 Schizophrenia; chr3:63882595 chr3:63911518~63911772:- LIHC cis rs832187 0.813 rs704368 ENSG00000280620.1 SCAANT1 -6.56 2.03e-10 1.69e-07 -0.41 -0.33 Schizophrenia; chr3:63882661 chr3:63911518~63911772:- LIHC cis rs2117029 0.555 rs7978448 ENSG00000258017.1 RP11-386G11.10 -6.56 2.03e-10 1.69e-07 -0.4 -0.33 Intelligence (multi-trait analysis); chr12:49113157 chr12:49127782~49147869:+ LIHC cis rs7674212 0.556 rs6533039 ENSG00000230069.3 LRRC37A15P -6.55 2.08e-10 1.73e-07 -0.32 -0.33 Type 2 diabetes; chr4:102938381 chr4:102727274~102730721:- LIHC cis rs4853012 0.775 rs12465641 ENSG00000257800.1 FNBP1P1 -6.55 2.08e-10 1.73e-07 -0.38 -0.33 Gestational age at birth (maternal effect); chr2:74110588 chr2:74120680~74123218:+ LIHC cis rs4820294 1 rs7291867 ENSG00000233360.4 Z83844.1 6.55 2.1e-10 1.74e-07 0.43 0.33 Fat distribution (HIV); chr22:37666105 chr22:37641832~37658377:- LIHC cis rs2439831 0.867 rs2260160 ENSG00000205771.5 CATSPER2P1 -6.55 2.1e-10 1.74e-07 -0.5 -0.33 Lung cancer in ever smokers; chr15:43603445 chr15:43726918~43747094:- LIHC cis rs2882667 0.824 rs1560656 ENSG00000253404.1 AC034243.1 -6.55 2.1e-10 1.74e-07 -0.47 -0.33 Age-related hearing impairment (SNP x SNP interaction); chr5:139135100 chr5:138744434~138753309:- LIHC cis rs916888 0.647 rs199523 ENSG00000214401.4 KANSL1-AS1 -6.55 2.11e-10 1.75e-07 -0.42 -0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:46193576~46196723:+ LIHC cis rs12439619 0.508 rs17354842 ENSG00000278603.1 RP13-608F4.5 -6.55 2.12e-10 1.76e-07 -0.42 -0.33 Intelligence (multi-trait analysis); chr15:82177259 chr15:82472203~82472426:+ LIHC cis rs9389248 0.708 rs7750574 ENSG00000232876.1 CTA-212D2.2 -6.55 2.13e-10 1.76e-07 -0.39 -0.33 High light scatter reticulocyte percentage of red cells; chr6:135029794 chr6:135055033~135060550:+ LIHC cis rs950027 1 rs950027 ENSG00000259520.4 CTD-2651B20.3 6.55 2.13e-10 1.77e-07 0.44 0.33 Response to fenofibrate (adiponectin levels); chr15:45508837 chr15:45251580~45279251:- LIHC cis rs916888 0.61 rs142167 ENSG00000214401.4 KANSL1-AS1 -6.55 2.13e-10 1.77e-07 -0.41 -0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:46193576~46196723:+ LIHC cis rs2243480 1 rs73142162 ENSG00000164669.11 INTS4P1 6.55 2.13e-10 1.77e-07 0.59 0.33 Diabetic kidney disease; chr7:65909309 chr7:65141225~65234216:+ LIHC cis rs3096299 0.935 rs3102387 ENSG00000274627.1 RP11-104N10.2 6.55 2.14e-10 1.78e-07 0.35 0.33 Multiple myeloma (IgH translocation); chr16:89365868 chr16:89516797~89522217:+ LIHC cis rs2836950 0.565 rs2836945 ENSG00000255568.3 BRWD1-AS2 -6.55 2.15e-10 1.78e-07 -0.28 -0.33 Menarche (age at onset); chr21:39224831 chr21:39313935~39314962:+ LIHC cis rs9399137 0.507 rs4451150 ENSG00000232876.1 CTA-212D2.2 -6.55 2.17e-10 1.8e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134957925 chr6:135055033~135060550:+ LIHC cis rs2243480 1 rs73142166 ENSG00000164669.11 INTS4P1 6.55 2.17e-10 1.8e-07 0.59 0.33 Diabetic kidney disease; chr7:65910845 chr7:65141225~65234216:+ LIHC cis rs7684253 0.587 rs2170074 ENSG00000269949.1 RP11-738E22.3 -6.54 2.18e-10 1.81e-07 -0.4 -0.33 Migraine; chr4:56880190 chr4:56960927~56961373:- LIHC cis rs2243480 1 rs13247184 ENSG00000164669.11 INTS4P1 6.54 2.2e-10 1.82e-07 0.59 0.33 Diabetic kidney disease; chr7:65893941 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs35283677 ENSG00000164669.11 INTS4P1 6.54 2.2e-10 1.82e-07 0.59 0.33 Diabetic kidney disease; chr7:65894246 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs35421653 ENSG00000164669.11 INTS4P1 6.54 2.2e-10 1.82e-07 0.59 0.33 Diabetic kidney disease; chr7:65898442 chr7:65141225~65234216:+ LIHC cis rs17270561 0.609 rs9358878 ENSG00000216436.2 HIST1H2APS1 -6.54 2.21e-10 1.83e-07 -0.41 -0.33 Iron status biomarkers; chr6:25740045 chr6:25732497~25732827:+ LIHC cis rs9549367 0.737 rs71446680 ENSG00000269125.1 RP11-98F14.11 -6.54 2.21e-10 1.83e-07 -0.41 -0.33 Platelet distribution width; chr13:113240532 chr13:113165002~113165183:- LIHC cis rs17270561 0.609 rs4131670 ENSG00000216436.2 HIST1H2APS1 -6.54 2.23e-10 1.84e-07 -0.41 -0.33 Iron status biomarkers; chr6:25738391 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4464787 ENSG00000216436.2 HIST1H2APS1 -6.54 2.23e-10 1.85e-07 -0.41 -0.33 Iron status biomarkers; chr6:25733330 chr6:25732497~25732827:+ LIHC cis rs12681287 0.752 rs10085920 ENSG00000250569.1 NTAN1P2 6.54 2.24e-10 1.86e-07 0.4 0.33 Caudate activity during reward; chr8:86240437 chr8:86481754~86483002:- LIHC cis rs1577917 0.727 rs2758840 ENSG00000234155.1 RP11-30P6.6 6.54 2.24e-10 1.86e-07 0.42 0.33 Response to antipsychotic treatment; chr6:85594907 chr6:85387219~85390186:- LIHC cis rs1577917 0.771 rs9362230 ENSG00000234155.1 RP11-30P6.6 6.54 2.24e-10 1.86e-07 0.42 0.33 Response to antipsychotic treatment; chr6:85595295 chr6:85387219~85390186:- LIHC cis rs17270561 0.636 rs12194699 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25729001 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9379786 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25730027 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9393658 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25730210 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs12203927 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25732462 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs12192077 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25732566 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4711098 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25734111 chr6:25732497~25732827:+ LIHC cis rs17270561 0.636 rs4360128 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25734330 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs3922699 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25734741 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs6924782 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25735588 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs6924794 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25735646 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs3922842 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25736336 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9358876 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25738728 chr6:25732497~25732827:+ LIHC cis rs17270561 0.583 rs9393661 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25738852 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9356986 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25738891 chr6:25732497~25732827:+ LIHC cis rs17270561 0.666 rs9356987 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25738959 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9358877 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25739000 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs12663099 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25739290 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9393662 ENSG00000216436.2 HIST1H2APS1 -6.54 2.24e-10 1.86e-07 -0.41 -0.33 Iron status biomarkers; chr6:25739442 chr6:25732497~25732827:+ LIHC cis rs7684253 0.587 rs2170073 ENSG00000269949.1 RP11-738E22.3 -6.54 2.25e-10 1.86e-07 -0.4 -0.33 Migraine; chr4:56880659 chr4:56960927~56961373:- LIHC cis rs2522056 0.808 rs7704457 ENSG00000233006.5 AC034220.3 6.54 2.25e-10 1.86e-07 0.35 0.33 Fibrinogen;Lymphocyte counts; chr5:132409098 chr5:132311285~132369916:- LIHC cis rs7044106 0.69 rs10739569 ENSG00000226752.6 PSMD5-AS1 -6.54 2.25e-10 1.86e-07 -0.34 -0.33 Hip circumference adjusted for BMI; chr9:120598749 chr9:120824828~120854385:+ LIHC cis rs1185460 0.967 rs11217133 ENSG00000271751.1 RP11-110I1.14 -6.54 2.25e-10 1.86e-07 -0.46 -0.33 Coronary artery disease; chr11:119057538 chr11:119065263~119065677:- LIHC cis rs1185460 0.967 rs1784460 ENSG00000271751.1 RP11-110I1.14 6.54 2.26e-10 1.87e-07 0.44 0.33 Coronary artery disease; chr11:119067660 chr11:119065263~119065677:- LIHC cis rs6142102 0.923 rs6059586 ENSG00000276073.1 RP5-1125A11.7 -6.54 2.27e-10 1.87e-07 -0.37 -0.33 Skin pigmentation; chr20:33952695 chr20:33985617~33988989:- LIHC cis rs9399137 0.507 rs12664898 ENSG00000232876.1 CTA-212D2.2 -6.54 2.3e-10 1.9e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134967525 chr6:135055033~135060550:+ LIHC cis rs9549367 0.713 rs3024776 ENSG00000269125.1 RP11-98F14.11 6.53 2.32e-10 1.91e-07 0.42 0.33 Platelet distribution width; chr13:113172761 chr13:113165002~113165183:- LIHC cis rs748404 0.516 rs523156 ENSG00000205771.5 CATSPER2P1 6.53 2.33e-10 1.93e-07 0.41 0.33 Lung cancer; chr15:43519645 chr15:43726918~43747094:- LIHC cis rs2243480 1 rs427044 ENSG00000164669.11 INTS4P1 6.53 2.35e-10 1.94e-07 0.57 0.33 Diabetic kidney disease; chr7:66043558 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs1039664 ENSG00000164669.11 INTS4P1 6.53 2.36e-10 1.95e-07 0.58 0.33 Diabetic kidney disease; chr7:65984729 chr7:65141225~65234216:+ LIHC cis rs9843304 0.568 rs13072639 ENSG00000244503.1 RP11-278L15.6 6.53 2.36e-10 1.95e-07 0.36 0.33 Gallstone disease; chr3:149489241 chr3:149494660~149495995:+ LIHC cis rs3096299 0.591 rs748940 ENSG00000274627.1 RP11-104N10.2 6.53 2.37e-10 1.95e-07 0.35 0.33 Multiple myeloma (IgH translocation); chr16:89374349 chr16:89516797~89522217:+ LIHC cis rs2439831 0.867 rs11856184 ENSG00000205771.5 CATSPER2P1 -6.53 2.37e-10 1.96e-07 -0.5 -0.33 Lung cancer in ever smokers; chr15:43626964 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs2447211 ENSG00000205771.5 CATSPER2P1 -6.53 2.37e-10 1.96e-07 -0.5 -0.33 Lung cancer in ever smokers; chr15:43644153 chr15:43726918~43747094:- LIHC cis rs2439831 0.571 rs2470121 ENSG00000205771.5 CATSPER2P1 -6.53 2.37e-10 1.96e-07 -0.5 -0.33 Lung cancer in ever smokers; chr15:43645420 chr15:43726918~43747094:- LIHC cis rs1862618 0.853 rs190414 ENSG00000271828.1 CTD-2310F14.1 6.53 2.38e-10 1.96e-07 0.47 0.33 Initial pursuit acceleration; chr5:56820945 chr5:56927874~56929573:+ LIHC cis rs10875746 0.768 rs4760676 ENSG00000240399.1 RP1-228P16.1 -6.53 2.38e-10 1.97e-07 -0.36 -0.33 Longevity (90 years and older); chr12:48027880 chr12:48054813~48055591:- LIHC cis rs1939012 0.525 rs17099462 ENSG00000281655.1 RP11-817J15.3 -6.53 2.38e-10 1.97e-07 -0.4 -0.33 Epilepsy; chr11:102729975 chr11:102681310~102683913:+ LIHC cis rs7674212 0.507 rs6843738 ENSG00000230069.3 LRRC37A15P -6.53 2.39e-10 1.97e-07 -0.32 -0.33 Type 2 diabetes; chr4:103014844 chr4:102727274~102730721:- LIHC cis rs1862618 0.853 rs9283717 ENSG00000271828.1 CTD-2310F14.1 6.53 2.4e-10 1.98e-07 0.47 0.33 Initial pursuit acceleration; chr5:56782832 chr5:56927874~56929573:+ LIHC cis rs2836950 0.565 rs8134214 ENSG00000255568.3 BRWD1-AS2 -6.53 2.4e-10 1.98e-07 -0.28 -0.33 Menarche (age at onset); chr21:39170441 chr21:39313935~39314962:+ LIHC cis rs9549367 0.789 rs2316442 ENSG00000269125.1 RP11-98F14.11 -6.53 2.4e-10 1.98e-07 -0.42 -0.33 Platelet distribution width; chr13:113223173 chr13:113165002~113165183:- LIHC cis rs1023500 0.505 rs134878 ENSG00000237037.8 NDUFA6-AS1 6.53 2.41e-10 1.99e-07 0.35 0.33 Schizophrenia; chr22:42267868 chr22:42090931~42137742:+ LIHC cis rs1577917 0.771 rs4441928 ENSG00000234155.1 RP11-30P6.6 -6.53 2.43e-10 2e-07 -0.41 -0.33 Response to antipsychotic treatment; chr6:85532176 chr6:85387219~85390186:- LIHC cis rs5758511 0.817 rs133291 ENSG00000237037.8 NDUFA6-AS1 -6.53 2.44e-10 2e-07 -0.41 -0.33 Birth weight; chr22:41873624 chr22:42090931~42137742:+ LIHC cis rs7617773 0.817 rs9847953 ENSG00000229759.1 MRPS18AP1 6.53 2.44e-10 2.01e-07 0.4 0.33 Coronary artery disease; chr3:48241205 chr3:48256350~48256938:- LIHC cis rs7617773 0.817 rs11710861 ENSG00000229759.1 MRPS18AP1 6.53 2.44e-10 2.01e-07 0.4 0.33 Coronary artery disease; chr3:48256070 chr3:48256350~48256938:- LIHC cis rs739496 0.615 rs617044 ENSG00000226469.1 ADAM1B 6.53 2.44e-10 2.01e-07 0.43 0.33 Platelet count; chr12:111695071 chr12:111927018~111929017:+ LIHC cis rs739496 0.615 rs602276 ENSG00000226469.1 ADAM1B 6.53 2.44e-10 2.01e-07 0.43 0.33 Platelet count; chr12:111696120 chr12:111927018~111929017:+ LIHC cis rs34779708 0.771 rs3867218 ENSG00000230534.5 RP11-297A16.2 6.52 2.46e-10 2.02e-07 0.42 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35238615 chr10:35098006~35127020:- LIHC cis rs9326248 0.954 rs521171 ENSG00000280143.1 AP000892.6 6.52 2.46e-10 2.03e-07 0.38 0.33 Blood protein levels; chr11:117193977 chr11:117204967~117210292:+ LIHC cis rs854624 1 rs854626 ENSG00000275944.1 RP11-104J23.1 6.52 2.48e-10 2.04e-07 0.39 0.33 Blood protein levels; chr17:36002489 chr17:36001419~36011618:+ LIHC cis rs67180937 0.582 rs71524942 ENSG00000272750.1 RP11-378J18.8 -6.52 2.48e-10 2.04e-07 -0.35 -0.33 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222689650 chr1:222658867~222661512:- LIHC cis rs2439831 0.85 rs9944216 ENSG00000205771.5 CATSPER2P1 6.52 2.49e-10 2.05e-07 0.51 0.33 Lung cancer in ever smokers; chr15:43868575 chr15:43726918~43747094:- LIHC cis rs916888 0.61 rs199529 ENSG00000262881.1 RP11-669E14.4 -6.52 2.51e-10 2.06e-07 -0.51 -0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:45907670~45910779:- LIHC cis rs2439831 0.85 rs12441861 ENSG00000205771.5 CATSPER2P1 -6.52 2.51e-10 2.06e-07 -0.5 -0.33 Lung cancer in ever smokers; chr15:43768685 chr15:43726918~43747094:- LIHC cis rs7104764 0.507 rs6598054 ENSG00000277290.1 RP11-326C3.16 6.52 2.51e-10 2.06e-07 0.39 0.33 Menarche (age at onset); chr11:254010 chr11:243099~243483:- LIHC cis rs2739330 0.892 rs4822455 ENSG00000099984.9 GSTT2 -6.52 2.52e-10 2.07e-07 -0.39 -0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23980123~23983911:+ LIHC cis rs7617773 0.817 rs3731513 ENSG00000229759.1 MRPS18AP1 6.52 2.52e-10 2.07e-07 0.41 0.33 Coronary artery disease; chr3:48178047 chr3:48256350~48256938:- LIHC cis rs55665837 0.665 rs11023273 ENSG00000251991.1 RNU7-49P 6.52 2.53e-10 2.08e-07 0.36 0.33 Vitamin D levels; chr11:14609273 chr11:14478892~14478953:+ LIHC cis rs9595066 0.712 rs4391951 ENSG00000227258.4 SMIM2-AS1 -6.52 2.53e-10 2.08e-07 -0.39 -0.33 Schizophrenia; chr13:44180935 chr13:44110451~44240517:+ LIHC cis rs2836950 0.509 rs11088466 ENSG00000255568.3 BRWD1-AS2 -6.52 2.54e-10 2.08e-07 -0.27 -0.33 Menarche (age at onset); chr21:39208091 chr21:39313935~39314962:+ LIHC cis rs3096299 0.781 rs2965819 ENSG00000274627.1 RP11-104N10.2 -6.52 2.56e-10 2.1e-07 -0.34 -0.33 Multiple myeloma (IgH translocation); chr16:89434622 chr16:89516797~89522217:+ LIHC cis rs1501911 0.611 rs56180458 ENSG00000248489.1 CTD-2007H13.3 6.52 2.57e-10 2.11e-07 0.49 0.33 Lung function (FEV1/FVC); chr5:99043633 chr5:98929171~98995013:+ LIHC cis rs2243480 1 rs1723267 ENSG00000164669.11 INTS4P1 6.52 2.58e-10 2.11e-07 0.57 0.33 Diabetic kidney disease; chr7:66008327 chr7:65141225~65234216:+ LIHC cis rs11168854 0.93 rs10783302 ENSG00000258017.1 RP11-386G11.10 6.52 2.58e-10 2.12e-07 0.39 0.33 Body mass index; chr12:49104347 chr12:49127782~49147869:+ LIHC cis rs2033711 0.87 rs11669741 ENSG00000269473.1 CTD-2619J13.19 -6.52 2.58e-10 2.12e-07 -0.38 -0.33 Uric acid clearance; chr19:58449114 chr19:58440448~58445849:+ LIHC cis rs6490294 0.571 rs57929857 ENSG00000226469.1 ADAM1B 6.52 2.59e-10 2.12e-07 0.5 0.33 Mean platelet volume; chr12:111995752 chr12:111927018~111929017:+ LIHC cis rs55665837 0.701 rs11023272 ENSG00000251991.1 RNU7-49P 6.52 2.59e-10 2.12e-07 0.36 0.33 Vitamin D levels; chr11:14608824 chr11:14478892~14478953:+ LIHC cis rs2882667 0.638 rs6895690 ENSG00000253404.1 AC034243.1 6.51 2.61e-10 2.14e-07 0.43 0.33 Age-related hearing impairment (SNP x SNP interaction); chr5:139130162 chr5:138744434~138753309:- LIHC cis rs1023500 0.505 rs134887 ENSG00000237037.8 NDUFA6-AS1 6.51 2.62e-10 2.14e-07 0.36 0.33 Schizophrenia; chr22:42278233 chr22:42090931~42137742:+ LIHC cis rs62355901 0.505 rs72759712 ENSG00000271828.1 CTD-2310F14.1 6.51 2.62e-10 2.15e-07 0.54 0.33 Breast cancer; chr5:56906519 chr5:56927874~56929573:+ LIHC cis rs2439831 0.867 rs2255042 ENSG00000205771.5 CATSPER2P1 6.51 2.63e-10 2.15e-07 0.45 0.33 Lung cancer in ever smokers; chr15:43542120 chr15:43726918~43747094:- LIHC cis rs3096299 0.617 rs2353030 ENSG00000274627.1 RP11-104N10.2 -6.51 2.63e-10 2.15e-07 -0.34 -0.33 Multiple myeloma (IgH translocation); chr16:89339419 chr16:89516797~89522217:+ LIHC cis rs10875746 0.951 rs10875756 ENSG00000240399.1 RP1-228P16.1 -6.51 2.63e-10 2.16e-07 -0.38 -0.33 Longevity (90 years and older); chr12:48168521 chr12:48054813~48055591:- LIHC cis rs10875746 0.951 rs4760690 ENSG00000240399.1 RP1-228P16.1 -6.51 2.63e-10 2.16e-07 -0.38 -0.33 Longevity (90 years and older); chr12:48169870 chr12:48054813~48055591:- LIHC cis rs55665837 0.701 rs10160597 ENSG00000251991.1 RNU7-49P 6.51 2.64e-10 2.16e-07 0.36 0.33 Vitamin D levels; chr11:14582446 chr11:14478892~14478953:+ LIHC cis rs2117029 0.555 rs2047101 ENSG00000258017.1 RP11-386G11.10 -6.51 2.64e-10 2.16e-07 -0.39 -0.33 Intelligence (multi-trait analysis); chr12:49103860 chr12:49127782~49147869:+ LIHC cis rs150992 0.548 rs12109067 ENSG00000248489.1 CTD-2007H13.3 6.51 2.65e-10 2.17e-07 0.49 0.33 Body mass index; chr5:99038928 chr5:98929171~98995013:+ LIHC cis rs9326248 0.861 rs1871757 ENSG00000280143.1 AP000892.6 6.51 2.67e-10 2.19e-07 0.39 0.33 Blood protein levels; chr11:117159865 chr11:117204967~117210292:+ LIHC cis rs854624 1 rs854624 ENSG00000278690.1 RP11-104J23.2 6.51 2.68e-10 2.19e-07 0.47 0.33 Blood protein levels; chr17:36000884 chr17:36012504~36012891:+ LIHC cis rs739496 0.615 rs630616 ENSG00000226469.1 ADAM1B 6.51 2.68e-10 2.19e-07 0.43 0.33 Platelet count; chr12:111721162 chr12:111927018~111929017:+ LIHC cis rs854624 1 rs41508645 ENSG00000278690.1 RP11-104J23.2 -6.51 2.7e-10 2.21e-07 -0.48 -0.33 Blood protein levels; chr17:36001998 chr17:36012504~36012891:+ LIHC cis rs2762353 0.595 rs10498728 ENSG00000242387.1 HIST1H2APS2 6.51 2.7e-10 2.21e-07 0.41 0.33 Blood metabolite levels; chr6:25751092 chr6:25882026~25882395:- LIHC cis rs2243480 1 rs313803 ENSG00000164669.11 INTS4P1 6.51 2.71e-10 2.21e-07 0.57 0.33 Diabetic kidney disease; chr7:66049744 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs313802 ENSG00000164669.11 INTS4P1 6.51 2.71e-10 2.21e-07 0.57 0.33 Diabetic kidney disease; chr7:66051386 chr7:65141225~65234216:+ LIHC cis rs2243480 0.803 rs403089 ENSG00000164669.11 INTS4P1 6.51 2.71e-10 2.21e-07 0.57 0.33 Diabetic kidney disease; chr7:66052736 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs458291 ENSG00000164669.11 INTS4P1 6.51 2.71e-10 2.21e-07 0.57 0.33 Diabetic kidney disease; chr7:66055492 chr7:65141225~65234216:+ LIHC cis rs7617773 0.817 rs3731534 ENSG00000229759.1 MRPS18AP1 6.5 2.76e-10 2.25e-07 0.41 0.33 Coronary artery disease; chr3:48170287 chr3:48256350~48256938:- LIHC cis rs1577917 0.837 rs10944157 ENSG00000234155.1 RP11-30P6.6 6.5 2.76e-10 2.26e-07 0.4 0.33 Response to antipsychotic treatment; chr6:85867481 chr6:85387219~85390186:- LIHC cis rs2836950 0.565 rs2836942 ENSG00000255568.3 BRWD1-AS2 -6.5 2.78e-10 2.27e-07 -0.28 -0.33 Menarche (age at onset); chr21:39219455 chr21:39313935~39314962:+ LIHC cis rs113835537 0.529 rs2305532 ENSG00000255517.5 CTD-3074O7.5 -6.5 2.79e-10 2.28e-07 -0.38 -0.33 Airway imaging phenotypes; chr11:66531123 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs2305533 ENSG00000255517.5 CTD-3074O7.5 -6.5 2.79e-10 2.28e-07 -0.38 -0.33 Airway imaging phenotypes; chr11:66531152 chr11:66473490~66480233:- LIHC cis rs832187 1 rs832187 ENSG00000280620.1 SCAANT1 -6.5 2.8e-10 2.28e-07 -0.4 -0.33 Schizophrenia; chr3:63847374 chr3:63911518~63911772:- LIHC cis rs9326248 0.861 rs7931335 ENSG00000280143.1 AP000892.6 6.5 2.81e-10 2.3e-07 0.38 0.33 Blood protein levels; chr11:117166089 chr11:117204967~117210292:+ LIHC cis rs3096299 0.967 rs2911257 ENSG00000274627.1 RP11-104N10.2 6.5 2.83e-10 2.31e-07 0.35 0.33 Multiple myeloma (IgH translocation); chr16:89417726 chr16:89516797~89522217:+ LIHC cis rs9549367 0.713 rs3024761 ENSG00000269125.1 RP11-98F14.11 6.5 2.83e-10 2.31e-07 0.42 0.33 Platelet distribution width; chr13:113169776 chr13:113165002~113165183:- LIHC cis rs17023223 0.537 rs10923767 ENSG00000231365.4 RP11-418J17.1 -6.5 2.84e-10 2.31e-07 -0.38 -0.33 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119189724 chr1:119140396~119275973:+ LIHC cis rs2033711 0.87 rs3764534 ENSG00000269473.1 CTD-2619J13.19 6.5 2.84e-10 2.32e-07 0.4 0.33 Uric acid clearance; chr19:58417769 chr19:58440448~58445849:+ LIHC cis rs2243480 1 rs781157 ENSG00000164669.11 INTS4P1 6.5 2.84e-10 2.32e-07 0.57 0.33 Diabetic kidney disease; chr7:66013324 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs781156 ENSG00000164669.11 INTS4P1 6.5 2.84e-10 2.32e-07 0.57 0.33 Diabetic kidney disease; chr7:66014154 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs781149 ENSG00000164669.11 INTS4P1 6.5 2.84e-10 2.32e-07 0.57 0.33 Diabetic kidney disease; chr7:66016297 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs451396 ENSG00000164669.11 INTS4P1 6.5 2.84e-10 2.32e-07 0.57 0.33 Diabetic kidney disease; chr7:66019087 chr7:65141225~65234216:+ LIHC cis rs2243480 0.901 rs58207111 ENSG00000164669.11 INTS4P1 6.5 2.84e-10 2.32e-07 0.57 0.33 Diabetic kidney disease; chr7:66021736 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs1167613 ENSG00000164669.11 INTS4P1 6.5 2.84e-10 2.32e-07 0.57 0.33 Diabetic kidney disease; chr7:66022452 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs1715235 ENSG00000164669.11 INTS4P1 6.5 2.84e-10 2.32e-07 0.57 0.33 Diabetic kidney disease; chr7:66023407 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs313799 ENSG00000164669.11 INTS4P1 6.5 2.84e-10 2.32e-07 0.57 0.33 Diabetic kidney disease; chr7:66029343 chr7:65141225~65234216:+ LIHC cis rs875971 0.502 rs1796227 ENSG00000226824.5 RP4-756H11.3 6.5 2.86e-10 2.33e-07 0.42 0.33 Aortic root size; chr7:66622032 chr7:66654538~66669855:+ LIHC cis rs17270561 0.609 rs9379783 ENSG00000216436.2 HIST1H2APS1 -6.5 2.87e-10 2.34e-07 -0.4 -0.33 Iron status biomarkers; chr6:25724979 chr6:25732497~25732827:+ LIHC cis rs10875746 0.768 rs10875724 ENSG00000240399.1 RP1-228P16.1 -6.5 2.87e-10 2.34e-07 -0.36 -0.33 Longevity (90 years and older); chr12:48026470 chr12:48054813~48055591:- LIHC cis rs6085948 0.861 rs6054849 ENSG00000238102.1 RP11-19D2.1 -6.5 2.88e-10 2.34e-07 -0.6 -0.33 Interleukin-10 levels; chr20:7251460 chr20:7256580~7258214:- LIHC cis rs992157 0.71 rs6752254 ENSG00000261338.2 RP11-378A13.1 6.5 2.88e-10 2.35e-07 0.33 0.33 Colorectal cancer; chr2:218194020 chr2:218255319~218257366:+ LIHC cis rs2439831 0.867 rs2614811 ENSG00000205771.5 CATSPER2P1 -6.5 2.89e-10 2.35e-07 -0.5 -0.33 Lung cancer in ever smokers; chr15:43621289 chr15:43726918~43747094:- LIHC cis rs2836950 0.565 rs4816617 ENSG00000255568.3 BRWD1-AS2 -6.5 2.9e-10 2.36e-07 -0.27 -0.33 Menarche (age at onset); chr21:39168764 chr21:39313935~39314962:+ LIHC cis rs7429990 0.901 rs9825114 ENSG00000229759.1 MRPS18AP1 -6.5 2.91e-10 2.37e-07 -0.36 -0.33 Educational attainment (years of education); chr3:48096592 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs6777081 ENSG00000229759.1 MRPS18AP1 -6.5 2.91e-10 2.37e-07 -0.36 -0.33 Educational attainment (years of education); chr3:48114079 chr3:48256350~48256938:- LIHC cis rs9399137 0.507 rs12663810 ENSG00000232876.1 CTA-212D2.2 -6.5 2.92e-10 2.38e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134968644 chr6:135055033~135060550:+ LIHC cis rs113835537 0.529 rs7950790 ENSG00000255517.5 CTD-3074O7.5 -6.49 2.93e-10 2.38e-07 -0.36 -0.33 Airway imaging phenotypes; chr11:66490582 chr11:66473490~66480233:- LIHC cis rs9399137 0.507 rs6940878 ENSG00000232876.1 CTA-212D2.2 -6.49 2.95e-10 2.4e-07 -0.39 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135045171 chr6:135055033~135060550:+ LIHC cis rs2439831 0.717 rs28495368 ENSG00000205771.5 CATSPER2P1 -6.49 2.97e-10 2.41e-07 -0.5 -0.33 Lung cancer in ever smokers; chr15:43603444 chr15:43726918~43747094:- LIHC cis rs73086581 0.838 rs6052265 ENSG00000229539.1 RP11-119B16.2 6.49 2.97e-10 2.41e-07 0.57 0.33 Response to antidepressants in depression; chr20:4046188 chr20:3888239~3888868:- LIHC cis rs507080 0.922 rs654792 ENSG00000255422.1 AP002954.4 6.49 2.98e-10 2.42e-07 0.37 0.33 Serum metabolite levels; chr11:118682287 chr11:118704607~118750263:+ LIHC cis rs523522 0.962 rs12309824 ENSG00000278344.1 RP11-18C24.8 6.49 2.98e-10 2.42e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120552779 chr12:120500735~120501090:- LIHC cis rs1185460 0.546 rs474201 ENSG00000271751.1 RP11-110I1.14 -6.49 2.98e-10 2.42e-07 -0.43 -0.33 Coronary artery disease; chr11:119087519 chr11:119065263~119065677:- LIHC cis rs7580658 0.751 rs2069924 ENSG00000236682.1 AC068282.3 -6.49 2.98e-10 2.42e-07 -0.42 -0.33 Protein C levels; chr2:127425418 chr2:127389130~127400580:+ LIHC cis rs523522 0.962 rs10744752 ENSG00000278344.1 RP11-18C24.8 6.49 3.01e-10 2.44e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120462751 chr12:120500735~120501090:- LIHC cis rs7131987 0.621 rs3782506 ENSG00000257176.2 RP11-996F15.2 6.49 3.02e-10 2.46e-07 0.38 0.33 QT interval; chr12:29292489 chr12:29280418~29317848:- LIHC cis rs7617773 0.817 rs11928691 ENSG00000229759.1 MRPS18AP1 6.49 3.03e-10 2.46e-07 0.4 0.33 Coronary artery disease; chr3:48245275 chr3:48256350~48256938:- LIHC cis rs8040855 0.644 rs4635318 ENSG00000259295.5 CSPG4P12 -6.49 3.03e-10 2.46e-07 -0.46 -0.33 Bulimia nervosa; chr15:85183506 chr15:85191438~85213905:+ LIHC cis rs2439831 0.867 rs12443102 ENSG00000205771.5 CATSPER2P1 -6.49 3.06e-10 2.49e-07 -0.5 -0.33 Lung cancer in ever smokers; chr15:43639905 chr15:43726918~43747094:- LIHC cis rs9399137 0.507 rs6569986 ENSG00000232876.1 CTA-212D2.2 -6.49 3.06e-10 2.49e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134990503 chr6:135055033~135060550:+ LIHC cis rs2735413 0.564 rs74316728 ENSG00000276007.1 RP11-358L22.3 6.49 3.07e-10 2.49e-07 0.48 0.33 Systolic blood pressure (alcohol consumption interaction); chr16:78065756 chr16:78123243~78124332:+ LIHC cis rs17301013 0.507 rs72717608 ENSG00000227373.4 RP11-160H22.5 6.49 3.07e-10 2.49e-07 0.57 0.33 Systemic lupus erythematosus; chr1:174788316 chr1:174115300~174160004:- LIHC cis rs113835537 0.559 rs74933537 ENSG00000255517.5 CTD-3074O7.5 -6.49 3.08e-10 2.5e-07 -0.36 -0.33 Airway imaging phenotypes; chr11:66507487 chr11:66473490~66480233:- LIHC cis rs10875746 0.951 rs8804 ENSG00000240399.1 RP1-228P16.1 -6.49 3.09e-10 2.5e-07 -0.38 -0.33 Longevity (90 years and older); chr12:48147974 chr12:48054813~48055591:- LIHC cis rs2243480 1 rs160634 ENSG00000164669.11 INTS4P1 -6.49 3.09e-10 2.5e-07 -0.54 -0.33 Diabetic kidney disease; chr7:66063677 chr7:65141225~65234216:+ LIHC cis rs1185460 0.967 rs11217137 ENSG00000271751.1 RP11-110I1.14 -6.49 3.1e-10 2.52e-07 -0.45 -0.33 Coronary artery disease; chr11:119060319 chr11:119065263~119065677:- LIHC cis rs7429990 0.932 rs6766641 ENSG00000229759.1 MRPS18AP1 -6.48 3.12e-10 2.53e-07 -0.36 -0.33 Educational attainment (years of education); chr3:48103734 chr3:48256350~48256938:- LIHC cis rs5758659 1 rs134902 ENSG00000227370.1 RP4-669P10.19 -6.48 3.12e-10 2.53e-07 -0.37 -0.33 Cognitive function; chr22:42287991 chr22:42132543~42132998:+ LIHC cis rs2033711 0.783 rs8113810 ENSG00000269473.1 CTD-2619J13.19 6.48 3.13e-10 2.53e-07 0.4 0.33 Uric acid clearance; chr19:58420739 chr19:58440448~58445849:+ LIHC cis rs2033711 0.87 rs4801270 ENSG00000269473.1 CTD-2619J13.19 6.48 3.13e-10 2.53e-07 0.4 0.33 Uric acid clearance; chr19:58421395 chr19:58440448~58445849:+ LIHC cis rs9399137 0.507 rs56164974 ENSG00000232876.1 CTA-212D2.2 -6.48 3.14e-10 2.54e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134967578 chr6:135055033~135060550:+ LIHC cis rs8040855 0.86 rs6496775 ENSG00000259295.5 CSPG4P12 -6.48 3.15e-10 2.55e-07 -0.51 -0.33 Bulimia nervosa; chr15:85164910 chr15:85191438~85213905:+ LIHC cis rs9326248 0.911 rs474339 ENSG00000280143.1 AP000892.6 6.48 3.15e-10 2.55e-07 0.38 0.33 Blood protein levels; chr11:117188836 chr11:117204967~117210292:+ LIHC cis rs765787 0.53 rs2413776 ENSG00000259520.4 CTD-2651B20.3 6.48 3.16e-10 2.56e-07 0.39 0.33 Uric acid levels; chr15:45251972 chr15:45251580~45279251:- LIHC cis rs1577917 0.958 rs2324840 ENSG00000234155.1 RP11-30P6.6 6.48 3.16e-10 2.56e-07 0.39 0.33 Response to antipsychotic treatment; chr6:85847902 chr6:85387219~85390186:- LIHC cis rs6504950 0.924 rs244353 ENSG00000275710.1 RP11-257O5.4 -6.48 3.16e-10 2.56e-07 -0.39 -0.33 Breast cancer; chr17:55117408 chr17:54964474~54964679:+ LIHC cis rs916888 0.821 rs199506 ENSG00000262881.1 RP11-669E14.4 6.48 3.17e-10 2.57e-07 0.52 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45907670~45910779:- LIHC cis rs9399137 0.507 rs13197750 ENSG00000232876.1 CTA-212D2.2 -6.48 3.17e-10 2.57e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134991242 chr6:135055033~135060550:+ LIHC cis rs9399137 0.507 rs7761964 ENSG00000232876.1 CTA-212D2.2 -6.48 3.17e-10 2.57e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134993127 chr6:135055033~135060550:+ LIHC cis rs9399137 0.507 rs11753673 ENSG00000232876.1 CTA-212D2.2 -6.48 3.17e-10 2.57e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134995338 chr6:135055033~135060550:+ LIHC cis rs9399137 0.507 rs12663447 ENSG00000232876.1 CTA-212D2.2 -6.48 3.17e-10 2.57e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134995888 chr6:135055033~135060550:+ LIHC cis rs9399137 0.507 rs4895437 ENSG00000232876.1 CTA-212D2.2 -6.48 3.17e-10 2.57e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134996216 chr6:135055033~135060550:+ LIHC cis rs6504950 0.72 rs2877634 ENSG00000275710.1 RP11-257O5.4 6.48 3.18e-10 2.57e-07 0.42 0.33 Breast cancer; chr17:54910184 chr17:54964474~54964679:+ LIHC cis rs6061231 0.675 rs755726 ENSG00000273619.1 RP5-908M14.9 -6.48 3.18e-10 2.58e-07 -0.28 -0.33 Colorectal cancer; chr20:62387568 chr20:62386303~62386970:- LIHC cis rs523522 0.962 rs2235218 ENSG00000278344.1 RP11-18C24.8 6.48 3.2e-10 2.59e-07 0.4 0.33 High light scatter reticulocyte count; chr12:120450816 chr12:120500735~120501090:- LIHC cis rs55665837 0.701 rs11023265 ENSG00000251991.1 RNU7-49P 6.48 3.2e-10 2.59e-07 0.36 0.33 Vitamin D levels; chr11:14594492 chr11:14478892~14478953:+ LIHC cis rs2033711 0.728 rs4801586 ENSG00000269473.1 CTD-2619J13.19 6.48 3.21e-10 2.6e-07 0.4 0.33 Uric acid clearance; chr19:58423161 chr19:58440448~58445849:+ LIHC cis rs55665837 0.583 rs78843135 ENSG00000251991.1 RNU7-49P 6.48 3.25e-10 2.63e-07 0.35 0.33 Vitamin D levels; chr11:14389708 chr11:14478892~14478953:+ LIHC cis rs2243480 1 rs4718269 ENSG00000164669.11 INTS4P1 -6.48 3.26e-10 2.63e-07 -0.57 -0.33 Diabetic kidney disease; chr7:65735810 chr7:65141225~65234216:+ LIHC cis rs2033711 0.84 rs10423138 ENSG00000269473.1 CTD-2619J13.19 6.48 3.26e-10 2.64e-07 0.4 0.33 Uric acid clearance; chr19:58416935 chr19:58440448~58445849:+ LIHC cis rs12681287 0.604 rs71502657 ENSG00000250569.1 NTAN1P2 6.48 3.28e-10 2.65e-07 0.39 0.33 Caudate activity during reward; chr8:86466552 chr8:86481754~86483002:- LIHC cis rs1577917 0.917 rs2218594 ENSG00000234155.1 RP11-30P6.6 6.48 3.28e-10 2.65e-07 0.39 0.33 Response to antipsychotic treatment; chr6:85834048 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs2197648 ENSG00000234155.1 RP11-30P6.6 6.48 3.28e-10 2.65e-07 0.39 0.33 Response to antipsychotic treatment; chr6:85834169 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs2100109 ENSG00000234155.1 RP11-30P6.6 6.48 3.28e-10 2.65e-07 0.39 0.33 Response to antipsychotic treatment; chr6:85835208 chr6:85387219~85390186:- LIHC cis rs6479891 0.908 rs61853655 ENSG00000232075.1 MRPL35P2 6.48 3.29e-10 2.66e-07 0.39 0.33 Arthritis (juvenile idiopathic); chr10:63570645 chr10:63634317~63634827:- LIHC cis rs992157 0.71 rs56364928 ENSG00000261338.2 RP11-378A13.1 6.47 3.3e-10 2.66e-07 0.33 0.33 Colorectal cancer; chr2:218194335 chr2:218255319~218257366:+ LIHC cis rs150992 0.57 rs7710032 ENSG00000248489.1 CTD-2007H13.3 -6.47 3.3e-10 2.67e-07 -0.49 -0.33 Body mass index; chr5:99007501 chr5:98929171~98995013:+ LIHC cis rs524281 0.773 rs2282568 ENSG00000255320.1 RP11-755F10.1 6.47 3.3e-10 2.67e-07 0.45 0.33 Electroencephalogram traits; chr11:66285361 chr11:66244840~66246239:- LIHC cis rs1939012 1 rs1940474 ENSG00000281655.1 RP11-817J15.3 -6.47 3.35e-10 2.7e-07 -0.38 -0.33 Epilepsy; chr11:102722322 chr11:102681310~102683913:+ LIHC cis rs1023500 0.573 rs8135801 ENSG00000237037.8 NDUFA6-AS1 -6.47 3.39e-10 2.73e-07 -0.4 -0.33 Schizophrenia; chr22:42079564 chr22:42090931~42137742:+ LIHC cis rs854624 1 rs854624 ENSG00000275944.1 RP11-104J23.1 6.47 3.4e-10 2.75e-07 0.39 0.33 Blood protein levels; chr17:36000884 chr17:36001419~36011618:+ LIHC cis rs7684253 0.587 rs2002154 ENSG00000269949.1 RP11-738E22.3 -6.47 3.42e-10 2.76e-07 -0.4 -0.33 Migraine; chr4:56879851 chr4:56960927~56961373:- LIHC cis rs4660456 0.913 rs2223486 ENSG00000237899.1 RP4-739H11.3 -6.47 3.43e-10 2.77e-07 -0.44 -0.33 Platelet count; chr1:40693557 chr1:40669089~40687588:- LIHC cis rs1555322 0.53 rs8122819 ENSG00000126005.14 MMP24-AS1 -6.47 3.43e-10 2.77e-07 -0.5 -0.33 Attention deficit hyperactivity disorder; chr20:35293783 chr20:35216462~35278131:- LIHC cis rs2243480 1 rs1964692 ENSG00000164669.11 INTS4P1 6.47 3.45e-10 2.78e-07 0.58 0.33 Diabetic kidney disease; chr7:65989196 chr7:65141225~65234216:+ LIHC cis rs2243480 0.901 rs2456483 ENSG00000164669.11 INTS4P1 6.47 3.45e-10 2.78e-07 0.58 0.33 Diabetic kidney disease; chr7:65996588 chr7:65141225~65234216:+ LIHC cis rs2243480 0.901 rs2949697 ENSG00000164669.11 INTS4P1 6.47 3.45e-10 2.78e-07 0.58 0.33 Diabetic kidney disease; chr7:65999249 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs1701750 ENSG00000164669.11 INTS4P1 6.47 3.45e-10 2.78e-07 0.58 0.33 Diabetic kidney disease; chr7:66002158 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs1701758 ENSG00000164669.11 INTS4P1 6.47 3.45e-10 2.78e-07 0.58 0.33 Diabetic kidney disease; chr7:66005214 chr7:65141225~65234216:+ LIHC cis rs2243480 0.901 rs1701759 ENSG00000164669.11 INTS4P1 6.47 3.45e-10 2.78e-07 0.58 0.33 Diabetic kidney disease; chr7:66005945 chr7:65141225~65234216:+ LIHC cis rs1577917 0.958 rs4707236 ENSG00000234155.1 RP11-30P6.6 6.47 3.48e-10 2.8e-07 0.39 0.33 Response to antipsychotic treatment; chr6:85874249 chr6:85387219~85390186:- LIHC cis rs2243480 1 rs313807 ENSG00000164669.11 INTS4P1 6.46 3.5e-10 2.82e-07 0.57 0.33 Diabetic kidney disease; chr7:66034494 chr7:65141225~65234216:+ LIHC cis rs2243480 0.901 rs313808 ENSG00000164669.11 INTS4P1 6.46 3.5e-10 2.82e-07 0.57 0.33 Diabetic kidney disease; chr7:66034886 chr7:65141225~65234216:+ LIHC cis rs2522056 1 rs1003533 ENSG00000233006.5 AC034220.3 -6.46 3.51e-10 2.82e-07 -0.35 -0.33 Fibrinogen;Lymphocyte counts; chr5:132419959 chr5:132311285~132369916:- LIHC cis rs916888 0.647 rs199524 ENSG00000214401.4 KANSL1-AS1 -6.46 3.55e-10 2.86e-07 -0.41 -0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:46193576~46196723:+ LIHC cis rs2243480 1 rs59794892 ENSG00000164669.11 INTS4P1 6.46 3.55e-10 2.86e-07 0.57 0.33 Diabetic kidney disease; chr7:65950886 chr7:65141225~65234216:+ LIHC cis rs2243480 0.803 rs36004293 ENSG00000164669.11 INTS4P1 6.46 3.55e-10 2.86e-07 0.57 0.33 Diabetic kidney disease; chr7:65951525 chr7:65141225~65234216:+ LIHC cis rs2243480 0.803 rs35268390 ENSG00000164669.11 INTS4P1 6.46 3.55e-10 2.86e-07 0.57 0.33 Diabetic kidney disease; chr7:65951549 chr7:65141225~65234216:+ LIHC cis rs73086581 0.838 rs56401022 ENSG00000229539.1 RP11-119B16.2 6.46 3.57e-10 2.87e-07 0.57 0.33 Response to antidepressants in depression; chr20:4043634 chr20:3888239~3888868:- LIHC cis rs36093924 0.646 rs5996094 ENSG00000237037.8 NDUFA6-AS1 -6.46 3.59e-10 2.89e-07 -0.41 -0.33 Intelligence; chr22:41951056 chr22:42090931~42137742:+ LIHC cis rs17270561 0.609 rs9348694 ENSG00000216436.2 HIST1H2APS1 -6.46 3.61e-10 2.9e-07 -0.4 -0.33 Iron status biomarkers; chr6:25753412 chr6:25732497~25732827:+ LIHC cis rs9399137 0.507 rs7745289 ENSG00000232876.1 CTA-212D2.2 -6.46 3.62e-10 2.91e-07 -0.39 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135059189 chr6:135055033~135060550:+ LIHC cis rs9399137 0.507 rs11759062 ENSG00000232876.1 CTA-212D2.2 -6.46 3.62e-10 2.91e-07 -0.39 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135060110 chr6:135055033~135060550:+ LIHC cis rs9399137 0.507 rs11759077 ENSG00000232876.1 CTA-212D2.2 -6.46 3.62e-10 2.91e-07 -0.39 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135060213 chr6:135055033~135060550:+ LIHC cis rs4718428 0.705 rs13227468 ENSG00000226824.5 RP4-756H11.3 -6.46 3.62e-10 2.91e-07 -0.44 -0.33 Corneal structure; chr7:66968576 chr7:66654538~66669855:+ LIHC cis rs1862618 0.754 rs252899 ENSG00000271828.1 CTD-2310F14.1 6.46 3.64e-10 2.92e-07 0.48 0.33 Initial pursuit acceleration; chr5:56892742 chr5:56927874~56929573:+ LIHC cis rs2836950 0.502 rs2150411 ENSG00000255568.3 BRWD1-AS2 -6.46 3.64e-10 2.93e-07 -0.27 -0.33 Menarche (age at onset); chr21:39202626 chr21:39313935~39314962:+ LIHC cis rs2836950 0.545 rs4818001 ENSG00000255568.3 BRWD1-AS2 -6.46 3.64e-10 2.93e-07 -0.27 -0.33 Menarche (age at onset); chr21:39203162 chr21:39313935~39314962:+ LIHC cis rs2439831 0.85 rs28590651 ENSG00000205771.5 CATSPER2P1 -6.46 3.66e-10 2.94e-07 -0.5 -0.33 Lung cancer in ever smokers; chr15:43820818 chr15:43726918~43747094:- LIHC cis rs12681287 0.64 rs10086340 ENSG00000250569.1 NTAN1P2 6.46 3.67e-10 2.95e-07 0.38 0.33 Caudate activity during reward; chr8:86434560 chr8:86481754~86483002:- LIHC cis rs6504950 0.72 rs9913784 ENSG00000275710.1 RP11-257O5.4 6.46 3.68e-10 2.95e-07 0.42 0.33 Breast cancer; chr17:54911710 chr17:54964474~54964679:+ LIHC cis rs6061231 0.834 rs2427311 ENSG00000273619.1 RP5-908M14.9 -6.46 3.68e-10 2.95e-07 -0.29 -0.33 Colorectal cancer; chr20:62395067 chr20:62386303~62386970:- LIHC cis rs2117029 0.619 rs11168862 ENSG00000258017.1 RP11-386G11.10 -6.46 3.69e-10 2.96e-07 -0.4 -0.33 Intelligence (multi-trait analysis); chr12:49112175 chr12:49127782~49147869:+ LIHC cis rs7684253 0.587 rs7670313 ENSG00000269949.1 RP11-738E22.3 -6.46 3.69e-10 2.96e-07 -0.4 -0.33 Migraine; chr4:56880007 chr4:56960927~56961373:- LIHC cis rs10875746 0.68 rs4760610 ENSG00000240399.1 RP1-228P16.1 -6.46 3.7e-10 2.97e-07 -0.36 -0.33 Longevity (90 years and older); chr12:48024442 chr12:48054813~48055591:- LIHC cis rs2117029 0.561 rs7957983 ENSG00000258017.1 RP11-386G11.10 -6.45 3.74e-10 3e-07 -0.4 -0.33 Intelligence (multi-trait analysis); chr12:49115204 chr12:49127782~49147869:+ LIHC cis rs2117029 0.587 rs7958572 ENSG00000258017.1 RP11-386G11.10 -6.45 3.74e-10 3e-07 -0.4 -0.33 Intelligence (multi-trait analysis); chr12:49115658 chr12:49127782~49147869:+ LIHC cis rs1003645 0.861 rs6505500 ENSG00000278690.1 RP11-104J23.2 6.45 3.75e-10 3.01e-07 0.43 0.33 Blood protein levels; chr17:36019746 chr17:36012504~36012891:+ LIHC cis rs832187 0.666 rs2241823 ENSG00000280620.1 SCAANT1 6.45 3.76e-10 3.01e-07 0.41 0.33 Schizophrenia; chr3:63979417 chr3:63911518~63911772:- LIHC cis rs10256972 0.804 rs10275585 ENSG00000229043.2 AC091729.9 -6.45 3.76e-10 3.01e-07 -0.39 -0.33 Endometriosis;Longevity; chr7:977703 chr7:1160374~1165267:+ LIHC cis rs1729407 0.709 rs2098453 ENSG00000254851.1 RP11-109L13.1 -6.45 3.77e-10 3.02e-07 -0.39 -0.33 Apolipoprotein A-IV levels; chr11:116825964 chr11:117135528~117138582:+ LIHC cis rs2117029 0.619 rs10747562 ENSG00000258017.1 RP11-386G11.10 -6.45 3.77e-10 3.02e-07 -0.4 -0.33 Intelligence (multi-trait analysis); chr12:49111401 chr12:49127782~49147869:+ LIHC cis rs4423214 0.592 rs10898193 ENSG00000254682.1 RP11-660L16.2 6.45 3.79e-10 3.03e-07 0.44 0.33 Vitamin D levels; chr11:71486037 chr11:71448674~71452157:+ LIHC cis rs9843304 0.616 rs4681177 ENSG00000244503.1 RP11-278L15.6 6.45 3.81e-10 3.05e-07 0.36 0.33 Gallstone disease; chr3:149485213 chr3:149494660~149495995:+ LIHC cis rs7617773 0.784 rs9850672 ENSG00000229759.1 MRPS18AP1 6.45 3.81e-10 3.05e-07 0.39 0.33 Coronary artery disease; chr3:48259682 chr3:48256350~48256938:- LIHC cis rs2439831 0.85 rs10438303 ENSG00000205771.5 CATSPER2P1 -6.45 3.82e-10 3.06e-07 -0.49 -0.33 Lung cancer in ever smokers; chr15:43724219 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs28504496 ENSG00000205771.5 CATSPER2P1 -6.45 3.82e-10 3.06e-07 -0.49 -0.33 Lung cancer in ever smokers; chr15:43724685 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs12441127 ENSG00000205771.5 CATSPER2P1 -6.45 3.82e-10 3.06e-07 -0.49 -0.33 Lung cancer in ever smokers; chr15:43728977 chr15:43726918~43747094:- LIHC cis rs2243480 0.708 rs35825036 ENSG00000273142.1 RP11-458F8.4 -6.45 3.83e-10 3.06e-07 -0.41 -0.33 Diabetic kidney disease; chr7:66521515 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs13237037 ENSG00000273142.1 RP11-458F8.4 -6.45 3.83e-10 3.06e-07 -0.41 -0.33 Diabetic kidney disease; chr7:66532895 chr7:66902857~66906297:+ LIHC cis rs2243480 0.901 rs13237344 ENSG00000273142.1 RP11-458F8.4 -6.45 3.83e-10 3.06e-07 -0.41 -0.33 Diabetic kidney disease; chr7:66557269 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs1796228 ENSG00000273142.1 RP11-458F8.4 -6.45 3.83e-10 3.06e-07 -0.41 -0.33 Diabetic kidney disease; chr7:66568097 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs1267820 ENSG00000273142.1 RP11-458F8.4 -6.45 3.83e-10 3.06e-07 -0.41 -0.33 Diabetic kidney disease; chr7:66585308 chr7:66902857~66906297:+ LIHC cis rs62355900 0.627 rs62355943 ENSG00000271828.1 CTD-2310F14.1 6.45 3.84e-10 3.07e-07 0.52 0.33 Endometriosis; chr5:56814472 chr5:56927874~56929573:+ LIHC cis rs62355900 0.627 rs72758038 ENSG00000271828.1 CTD-2310F14.1 6.45 3.84e-10 3.07e-07 0.52 0.33 Endometriosis; chr5:56814857 chr5:56927874~56929573:+ LIHC cis rs739496 0.615 rs7978737 ENSG00000226469.1 ADAM1B 6.45 3.85e-10 3.08e-07 0.43 0.33 Platelet count; chr12:111758807 chr12:111927018~111929017:+ LIHC cis rs2836950 0.52 rs8130240 ENSG00000255568.3 BRWD1-AS2 -6.45 3.86e-10 3.08e-07 -0.27 -0.33 Menarche (age at onset); chr21:39166182 chr21:39313935~39314962:+ LIHC cis rs9549367 0.789 rs57747440 ENSG00000269125.1 RP11-98F14.11 -6.45 3.88e-10 3.1e-07 -0.4 -0.33 Platelet distribution width; chr13:113240436 chr13:113165002~113165183:- LIHC cis rs9549367 0.789 rs34989271 ENSG00000269125.1 RP11-98F14.11 -6.45 3.88e-10 3.1e-07 -0.4 -0.33 Platelet distribution width; chr13:113240452 chr13:113165002~113165183:- LIHC cis rs9549367 0.789 rs71446679 ENSG00000269125.1 RP11-98F14.11 -6.45 3.88e-10 3.1e-07 -0.4 -0.33 Platelet distribution width; chr13:113240507 chr13:113165002~113165183:- LIHC cis rs9549367 0.789 rs71446682 ENSG00000269125.1 RP11-98F14.11 -6.45 3.88e-10 3.1e-07 -0.4 -0.33 Platelet distribution width; chr13:113240594 chr13:113165002~113165183:- LIHC cis rs150992 0.592 rs10038192 ENSG00000248489.1 CTD-2007H13.3 6.45 3.89e-10 3.11e-07 0.49 0.33 Body mass index; chr5:98989755 chr5:98929171~98995013:+ LIHC cis rs150992 0.571 rs10045959 ENSG00000248489.1 CTD-2007H13.3 6.45 3.89e-10 3.11e-07 0.49 0.33 Body mass index; chr5:98989767 chr5:98929171~98995013:+ LIHC cis rs150992 0.571 rs10037147 ENSG00000248489.1 CTD-2007H13.3 6.45 3.89e-10 3.11e-07 0.49 0.33 Body mass index; chr5:98989768 chr5:98929171~98995013:+ LIHC cis rs4423214 0.625 rs78685409 ENSG00000254682.1 RP11-660L16.2 -6.45 3.92e-10 3.13e-07 -0.42 -0.33 Vitamin D levels; chr11:71426337 chr11:71448674~71452157:+ LIHC cis rs7429990 0.901 rs7431567 ENSG00000229759.1 MRPS18AP1 -6.44 3.94e-10 3.14e-07 -0.37 -0.33 Educational attainment (years of education); chr3:47986342 chr3:48256350~48256938:- LIHC cis rs2980436 1 rs2980436 ENSG00000253981.4 ALG1L13P -6.44 3.94e-10 3.15e-07 -0.41 -0.33 Schizophrenia; chr8:8234503 chr8:8236003~8244667:- LIHC cis rs3829655 0.905 rs4801882 ENSG00000273837.1 LLNLR-470E3.1 -6.44 3.96e-10 3.16e-07 -0.34 -0.33 Cerebrospinal fluid biomarker levels; chr19:51623800 chr19:51639478~51639931:- LIHC cis rs1501911 0.713 rs10479344 ENSG00000248489.1 CTD-2007H13.3 -6.44 3.97e-10 3.17e-07 -0.49 -0.33 Lung function (FEV1/FVC); chr5:99012676 chr5:98929171~98995013:+ LIHC cis rs1862618 0.853 rs832553 ENSG00000271828.1 CTD-2310F14.1 6.44 3.99e-10 3.19e-07 0.47 0.33 Initial pursuit acceleration; chr5:56818959 chr5:56927874~56929573:+ LIHC cis rs6479891 0.908 rs4746201 ENSG00000232075.1 MRPL35P2 6.44 4.01e-10 3.2e-07 0.39 0.33 Arthritis (juvenile idiopathic); chr10:63562621 chr10:63634317~63634827:- LIHC cis rs73086581 0.735 rs6037730 ENSG00000229539.1 RP11-119B16.2 6.44 4.03e-10 3.21e-07 0.57 0.33 Response to antidepressants in depression; chr20:4046171 chr20:3888239~3888868:- LIHC cis rs62355900 0.627 rs1862620 ENSG00000271828.1 CTD-2310F14.1 6.44 4.03e-10 3.21e-07 0.52 0.33 Endometriosis; chr5:56802543 chr5:56927874~56929573:+ LIHC cis rs1729407 0.625 rs2727789 ENSG00000254851.1 RP11-109L13.1 -6.44 4.04e-10 3.22e-07 -0.38 -0.33 Apolipoprotein A-IV levels; chr11:116826171 chr11:117135528~117138582:+ LIHC cis rs2836950 0.565 rs2836926 ENSG00000255568.3 BRWD1-AS2 -6.44 4.05e-10 3.23e-07 -0.27 -0.33 Menarche (age at onset); chr21:39164864 chr21:39313935~39314962:+ LIHC cis rs62355901 0.505 rs62355944 ENSG00000271828.1 CTD-2310F14.1 6.44 4.06e-10 3.23e-07 0.54 0.33 Breast cancer; chr5:56816871 chr5:56927874~56929573:+ LIHC cis rs992157 0.71 rs6719789 ENSG00000261338.2 RP11-378A13.1 -6.44 4.08e-10 3.25e-07 -0.32 -0.33 Colorectal cancer; chr2:218193087 chr2:218255319~218257366:+ LIHC cis rs9326248 0.569 rs10892082 ENSG00000280143.1 AP000892.6 6.44 4.08e-10 3.25e-07 0.41 0.33 Blood protein levels; chr11:117168609 chr11:117204967~117210292:+ LIHC cis rs7684253 0.55 rs4566710 ENSG00000269949.1 RP11-738E22.3 -6.44 4.08e-10 3.25e-07 -0.4 -0.33 Migraine; chr4:56879297 chr4:56960927~56961373:- LIHC cis rs7567389 0.74 rs4536600 ENSG00000236682.1 AC068282.3 -6.44 4.1e-10 3.26e-07 -0.46 -0.33 Self-rated health; chr2:127244996 chr2:127389130~127400580:+ LIHC cis rs2836950 0.501 rs2836980 ENSG00000255568.3 BRWD1-AS2 -6.44 4.11e-10 3.27e-07 -0.27 -0.33 Menarche (age at onset); chr21:39315692 chr21:39313935~39314962:+ LIHC cis rs150992 0.609 rs78721487 ENSG00000248489.1 CTD-2007H13.3 6.44 4.12e-10 3.28e-07 0.47 0.33 Body mass index; chr5:98992926 chr5:98929171~98995013:+ LIHC cis rs6504950 0.886 rs12449538 ENSG00000275710.1 RP11-257O5.4 -6.44 4.13e-10 3.28e-07 -0.4 -0.33 Breast cancer; chr17:55033760 chr17:54964474~54964679:+ LIHC cis rs2836950 0.565 rs8131132 ENSG00000255568.3 BRWD1-AS2 -6.44 4.13e-10 3.29e-07 -0.27 -0.33 Menarche (age at onset); chr21:39166330 chr21:39313935~39314962:+ LIHC cis rs765787 0.53 rs16941017 ENSG00000259520.4 CTD-2651B20.3 6.44 4.13e-10 3.29e-07 0.39 0.33 Uric acid levels; chr15:45251083 chr15:45251580~45279251:- LIHC cis rs2688482 0.512 rs3103954 ENSG00000224769.1 AC069213.1 6.44 4.14e-10 3.3e-07 0.49 0.33 Lung disease severity in cystic fibrosis; chr3:195789759 chr3:195614947~195620233:+ LIHC cis rs1185460 0.967 rs3825061 ENSG00000271751.1 RP11-110I1.14 -6.44 4.14e-10 3.3e-07 -0.46 -0.33 Coronary artery disease; chr11:119073965 chr11:119065263~119065677:- LIHC cis rs1577917 1 rs6454513 ENSG00000234155.1 RP11-30P6.6 -6.44 4.16e-10 3.31e-07 -0.39 -0.33 Response to antipsychotic treatment; chr6:86010331 chr6:85387219~85390186:- LIHC cis rs11672691 0.829 rs8112363 ENSG00000267107.5 PCAT19 6.44 4.16e-10 3.31e-07 0.39 0.33 Prostate cancer; chr19:41483803 chr19:41454169~41500649:- LIHC cis rs2117029 0.555 rs3741621 ENSG00000258017.1 RP11-386G11.10 -6.44 4.16e-10 3.31e-07 -0.39 -0.33 Intelligence (multi-trait analysis); chr12:49100242 chr12:49127782~49147869:+ LIHC cis rs2439831 0.867 rs2255440 ENSG00000205771.5 CATSPER2P1 -6.43 4.18e-10 3.33e-07 -0.45 -0.33 Lung cancer in ever smokers; chr15:43538269 chr15:43726918~43747094:- LIHC cis rs9399137 0.507 rs13196486 ENSG00000232876.1 CTA-212D2.2 -6.43 4.19e-10 3.33e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134962736 chr6:135055033~135060550:+ LIHC cis rs9399137 0.507 rs6918512 ENSG00000232876.1 CTA-212D2.2 -6.43 4.19e-10 3.33e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134963701 chr6:135055033~135060550:+ LIHC cis rs9399137 0.507 rs13064 ENSG00000232876.1 CTA-212D2.2 -6.43 4.19e-10 3.33e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134966395 chr6:135055033~135060550:+ LIHC cis rs9399137 0.507 rs35571217 ENSG00000232876.1 CTA-212D2.2 -6.43 4.19e-10 3.33e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134969217 chr6:135055033~135060550:+ LIHC cis rs9399137 0.507 rs11757723 ENSG00000232876.1 CTA-212D2.2 -6.43 4.19e-10 3.33e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134970155 chr6:135055033~135060550:+ LIHC cis rs17270561 0.609 rs9393655 ENSG00000216436.2 HIST1H2APS1 -6.43 4.2e-10 3.34e-07 -0.4 -0.33 Iron status biomarkers; chr6:25711110 chr6:25732497~25732827:+ LIHC cis rs2243480 0.803 rs13224048 ENSG00000273142.1 RP11-458F8.4 -6.43 4.21e-10 3.34e-07 -0.41 -0.33 Diabetic kidney disease; chr7:66528779 chr7:66902857~66906297:+ LIHC cis rs1577917 0.958 rs12216074 ENSG00000234155.1 RP11-30P6.6 6.43 4.24e-10 3.37e-07 0.39 0.33 Response to antipsychotic treatment; chr6:85810284 chr6:85387219~85390186:- LIHC cis rs1862618 0.853 rs6885541 ENSG00000271828.1 CTD-2310F14.1 6.43 4.25e-10 3.38e-07 0.47 0.33 Initial pursuit acceleration; chr5:56815030 chr5:56927874~56929573:+ LIHC cis rs1862618 0.853 rs11739344 ENSG00000271828.1 CTD-2310F14.1 6.43 4.25e-10 3.38e-07 0.47 0.33 Initial pursuit acceleration; chr5:56815260 chr5:56927874~56929573:+ LIHC cis rs9399137 0.507 rs13214669 ENSG00000232876.1 CTA-212D2.2 -6.43 4.25e-10 3.38e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134978821 chr6:135055033~135060550:+ LIHC cis rs6921919 0.697 rs6942030 ENSG00000216901.1 AL022393.7 6.43 4.25e-10 3.38e-07 0.38 0.33 Autism spectrum disorder or schizophrenia; chr6:28348181 chr6:28176188~28176674:+ LIHC cis rs34779708 0.832 rs6481946 ENSG00000230534.5 RP11-297A16.2 6.43 4.27e-10 3.39e-07 0.42 0.33 Inflammatory bowel disease;Crohn's disease; chr10:35240186 chr10:35098006~35127020:- LIHC cis rs55665837 0.54 rs10832294 ENSG00000251991.1 RNU7-49P 6.43 4.27e-10 3.39e-07 0.35 0.33 Vitamin D levels; chr11:14725881 chr11:14478892~14478953:+ LIHC cis rs1062177 0.901 rs1549622 ENSG00000213433.5 RPLP1P6 -6.43 4.28e-10 3.4e-07 -0.37 -0.33 Preschool internalizing problems; chr5:151886488 chr5:151765859~151766378:- LIHC cis rs1939012 0.819 rs6590986 ENSG00000281655.1 RP11-817J15.3 -6.43 4.33e-10 3.43e-07 -0.39 -0.33 Epilepsy; chr11:102728128 chr11:102681310~102683913:+ LIHC cis rs916888 0.61 rs199453 ENSG00000214401.4 KANSL1-AS1 6.43 4.33e-10 3.44e-07 0.4 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:46193576~46196723:+ LIHC cis rs2243480 0.901 rs778732 ENSG00000273142.1 RP11-458F8.4 -6.43 4.33e-10 3.44e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66357373 chr7:66902857~66906297:+ LIHC cis rs1555322 0.53 rs6058224 ENSG00000126005.14 MMP24-AS1 -6.43 4.35e-10 3.45e-07 -0.49 -0.33 Attention deficit hyperactivity disorder; chr20:35293971 chr20:35216462~35278131:- LIHC cis rs67079557 1 rs67079557 ENSG00000260269.4 CTD-2323K18.1 -6.43 4.41e-10 3.5e-07 -0.43 -0.33 Breast cancer; chr15:75637966 chr15:75527150~75601205:- LIHC cis rs55665837 0.54 rs10832299 ENSG00000251991.1 RNU7-49P 6.43 4.42e-10 3.5e-07 0.35 0.33 Vitamin D levels; chr11:14747846 chr11:14478892~14478953:+ LIHC cis rs55665837 0.523 rs10832301 ENSG00000251991.1 RNU7-49P 6.43 4.42e-10 3.5e-07 0.35 0.33 Vitamin D levels; chr11:14767418 chr11:14478892~14478953:+ LIHC cis rs1005277 0.579 rs1780137 ENSG00000263064.2 RP11-291L22.7 6.42 4.45e-10 3.53e-07 0.34 0.33 Extrinsic epigenetic age acceleration; chr10:38212547 chr10:38448689~38448949:+ LIHC cis rs9399137 0.507 rs6923512 ENSG00000232876.1 CTA-212D2.2 6.42 4.46e-10 3.53e-07 0.38 0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135014130 chr6:135055033~135060550:+ LIHC cis rs9487094 0.744 rs13204787 ENSG00000260273.1 RP11-425D10.10 6.42 4.46e-10 3.54e-07 0.48 0.33 Height; chr6:109618283 chr6:109382795~109383666:+ LIHC cis rs765787 0.53 rs1706834 ENSG00000259520.4 CTD-2651B20.3 6.42 4.48e-10 3.55e-07 0.39 0.33 Uric acid levels; chr15:45225656 chr15:45251580~45279251:- LIHC cis rs2919917 0.662 rs1483572 ENSG00000254352.1 RP11-578O24.2 6.42 4.51e-10 3.57e-07 0.38 0.33 Lymphocyte counts; chr8:78723008 chr8:78723796~78724136:- LIHC cis rs9399137 0.507 rs28384513 ENSG00000232876.1 CTA-212D2.2 -6.42 4.52e-10 3.57e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135055071 chr6:135055033~135060550:+ LIHC cis rs7617773 0.744 rs2125482 ENSG00000229759.1 MRPS18AP1 6.42 4.52e-10 3.58e-07 0.4 0.33 Coronary artery disease; chr3:48281643 chr3:48256350~48256938:- LIHC cis rs2688482 0.512 rs3103953 ENSG00000224769.1 AC069213.1 -6.42 4.52e-10 3.58e-07 -0.49 -0.33 Lung disease severity in cystic fibrosis; chr3:195793726 chr3:195614947~195620233:+ LIHC cis rs2439831 0.85 rs28509275 ENSG00000205771.5 CATSPER2P1 -6.42 4.53e-10 3.58e-07 -0.52 -0.33 Lung cancer in ever smokers; chr15:43805907 chr15:43726918~43747094:- LIHC cis rs2836950 0.565 rs2150413 ENSG00000255568.3 BRWD1-AS2 -6.42 4.53e-10 3.59e-07 -0.27 -0.33 Menarche (age at onset); chr21:39242952 chr21:39313935~39314962:+ LIHC cis rs11603023 0.625 rs633683 ENSG00000255239.1 AP002954.6 6.42 4.54e-10 3.59e-07 0.38 0.33 Cholesterol, total; chr11:118634025 chr11:118688039~118690600:- LIHC cis rs1862618 0.853 rs252898 ENSG00000271828.1 CTD-2310F14.1 6.42 4.55e-10 3.6e-07 0.47 0.33 Initial pursuit acceleration; chr5:56893104 chr5:56927874~56929573:+ LIHC cis rs1862618 0.802 rs194058 ENSG00000271828.1 CTD-2310F14.1 6.42 4.55e-10 3.6e-07 0.47 0.33 Initial pursuit acceleration; chr5:56893150 chr5:56927874~56929573:+ LIHC cis rs9399137 0.507 rs11154791 ENSG00000232876.1 CTA-212D2.2 -6.42 4.55e-10 3.6e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135058010 chr6:135055033~135060550:+ LIHC cis rs150992 0.587 rs11949103 ENSG00000248489.1 CTD-2007H13.3 -6.42 4.55e-10 3.6e-07 -0.48 -0.33 Body mass index; chr5:99011939 chr5:98929171~98995013:+ LIHC cis rs7085104 0.66 rs7902804 ENSG00000236937.2 PTGES3P4 6.42 4.58e-10 3.62e-07 0.4 0.33 Immature fraction of reticulocytes;Schizophrenia; chr10:102825648 chr10:102845595~102845950:+ LIHC cis rs150992 0.587 rs6885458 ENSG00000248489.1 CTD-2007H13.3 6.42 4.58e-10 3.62e-07 0.49 0.33 Body mass index; chr5:99046048 chr5:98929171~98995013:+ LIHC cis rs7617773 0.817 rs6800492 ENSG00000229759.1 MRPS18AP1 6.42 4.59e-10 3.62e-07 0.4 0.33 Coronary artery disease; chr3:48282400 chr3:48256350~48256938:- LIHC cis rs9399137 0.507 rs4580893 ENSG00000232876.1 CTA-212D2.2 -6.42 4.59e-10 3.63e-07 -0.37 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134976524 chr6:135055033~135060550:+ LIHC cis rs9389248 0.737 rs56358308 ENSG00000232876.1 CTA-212D2.2 -6.42 4.59e-10 3.63e-07 -0.37 -0.33 High light scatter reticulocyte percentage of red cells; chr6:134985842 chr6:135055033~135060550:+ LIHC cis rs9399137 0.507 rs11754021 ENSG00000232876.1 CTA-212D2.2 -6.42 4.59e-10 3.63e-07 -0.37 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134987237 chr6:135055033~135060550:+ LIHC cis rs3779195 0.627 rs6950023 ENSG00000272950.1 RP11-307C18.1 6.42 4.59e-10 3.63e-07 0.48 0.33 Sex hormone-binding globulin levels; chr7:98286323 chr7:98322853~98323430:+ LIHC cis rs3779195 0.627 rs6967728 ENSG00000272950.1 RP11-307C18.1 6.42 4.59e-10 3.63e-07 0.48 0.33 Sex hormone-binding globulin levels; chr7:98286325 chr7:98322853~98323430:+ LIHC cis rs62229266 0.626 rs7280896 ENSG00000231106.2 LINC01436 6.42 4.63e-10 3.66e-07 0.37 0.33 Mitral valve prolapse; chr21:36088608 chr21:36005338~36007838:+ LIHC cis rs6921919 0.697 rs12180820 ENSG00000216901.1 AL022393.7 -6.42 4.63e-10 3.66e-07 -0.37 -0.33 Autism spectrum disorder or schizophrenia; chr6:28348701 chr6:28176188~28176674:+ LIHC cis rs7617773 0.78 rs6442111 ENSG00000229759.1 MRPS18AP1 6.42 4.66e-10 3.67e-07 0.39 0.33 Coronary artery disease; chr3:48270570 chr3:48256350~48256938:- LIHC cis rs7617773 0.851 rs6775179 ENSG00000229759.1 MRPS18AP1 6.42 4.66e-10 3.67e-07 0.39 0.33 Coronary artery disease; chr3:48271928 chr3:48256350~48256938:- LIHC cis rs7617773 0.817 rs9311421 ENSG00000229759.1 MRPS18AP1 6.42 4.66e-10 3.68e-07 0.39 0.33 Coronary artery disease; chr3:48251588 chr3:48256350~48256938:- LIHC cis rs55665837 0.54 rs12416696 ENSG00000251991.1 RNU7-49P 6.42 4.68e-10 3.69e-07 0.35 0.33 Vitamin D levels; chr11:14769343 chr11:14478892~14478953:+ LIHC cis rs12458462 0.892 rs3786228 ENSG00000274828.1 RP11-567M16.6 -6.42 4.69e-10 3.7e-07 -0.34 -0.33 Monocyte count; chr18:79704170 chr18:79677287~79679358:- LIHC cis rs2117029 0.555 rs10783304 ENSG00000258017.1 RP11-386G11.10 -6.41 4.69e-10 3.7e-07 -0.39 -0.33 Intelligence (multi-trait analysis); chr12:49106615 chr12:49127782~49147869:+ LIHC cis rs67180937 0.553 rs2133188 ENSG00000272750.1 RP11-378J18.8 6.41 4.72e-10 3.73e-07 0.37 0.33 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222640411 chr1:222658867~222661512:- LIHC cis rs8040855 0.621 rs6496796 ENSG00000259295.5 CSPG4P12 -6.41 4.73e-10 3.73e-07 -0.46 -0.33 Bulimia nervosa; chr15:85183617 chr15:85191438~85213905:+ LIHC cis rs7429990 0.901 rs6442091 ENSG00000229759.1 MRPS18AP1 -6.41 4.73e-10 3.73e-07 -0.37 -0.33 Educational attainment (years of education); chr3:48001568 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs4858810 ENSG00000229759.1 MRPS18AP1 -6.41 4.73e-10 3.73e-07 -0.37 -0.33 Educational attainment (years of education); chr3:48002247 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs4296617 ENSG00000229759.1 MRPS18AP1 -6.41 4.73e-10 3.73e-07 -0.37 -0.33 Educational attainment (years of education); chr3:48026818 chr3:48256350~48256938:- LIHC cis rs4538475 1 rs4538475 ENSG00000214846.4 RP11-115L11.1 6.41 4.74e-10 3.74e-07 0.43 0.33 Parkinson's disease; chr4:15736314 chr4:15730962~15731627:- LIHC cis rs2243480 1 rs160633 ENSG00000164669.11 INTS4P1 6.41 4.76e-10 3.75e-07 0.56 0.33 Diabetic kidney disease; chr7:66063241 chr7:65141225~65234216:+ LIHC cis rs5758659 0.714 rs2413668 ENSG00000227370.1 RP4-669P10.19 6.41 4.77e-10 3.76e-07 0.37 0.33 Cognitive function; chr22:42109837 chr22:42132543~42132998:+ LIHC cis rs6490294 0.528 rs78745958 ENSG00000226469.1 ADAM1B 6.41 4.79e-10 3.78e-07 0.49 0.33 Mean platelet volume; chr12:111990367 chr12:111927018~111929017:+ LIHC cis rs7500321 1 rs7500321 ENSG00000259982.1 CDC37P1 -6.41 4.79e-10 3.78e-07 -0.42 -0.33 Intelligence (multi-trait analysis); chr16:28965699 chr16:28700294~28701540:- LIHC cis rs1003645 0.569 rs7222922 ENSG00000275944.1 RP11-104J23.1 6.41 4.8e-10 3.78e-07 0.36 0.33 Blood protein levels; chr17:36008654 chr17:36001419~36011618:+ LIHC cis rs5758659 0.714 rs6002626 ENSG00000227370.1 RP4-669P10.19 6.41 4.8e-10 3.78e-07 0.38 0.33 Cognitive function; chr22:42121985 chr22:42132543~42132998:+ LIHC cis rs62355901 0.505 rs16886257 ENSG00000271828.1 CTD-2310F14.1 6.41 4.81e-10 3.79e-07 0.55 0.33 Breast cancer; chr5:56766994 chr5:56927874~56929573:+ LIHC cis rs62355900 0.627 rs62355941 ENSG00000271828.1 CTD-2310F14.1 6.41 4.81e-10 3.79e-07 0.52 0.33 Endometriosis; chr5:56807871 chr5:56927874~56929573:+ LIHC cis rs1185460 0.967 rs1177562 ENSG00000271751.1 RP11-110I1.14 -6.41 4.81e-10 3.79e-07 -0.45 -0.33 Coronary artery disease; chr11:119078621 chr11:119065263~119065677:- LIHC cis rs2243480 0.901 rs57126451 ENSG00000164669.11 INTS4P1 6.41 4.85e-10 3.82e-07 0.57 0.33 Diabetic kidney disease; chr7:65951319 chr7:65141225~65234216:+ LIHC cis rs1862618 0.627 rs744023 ENSG00000271828.1 CTD-2310F14.1 6.41 4.86e-10 3.83e-07 0.48 0.33 Initial pursuit acceleration; chr5:56901251 chr5:56927874~56929573:+ LIHC cis rs7684253 0.587 rs4339274 ENSG00000269949.1 RP11-738E22.3 6.41 4.87e-10 3.84e-07 0.4 0.33 Migraine; chr4:56881468 chr4:56960927~56961373:- LIHC cis rs13068223 0.584 rs345986 ENSG00000243926.1 TIPARP-AS1 -6.41 4.88e-10 3.84e-07 -0.36 -0.33 Age-related hearing impairment (SNP x SNP interaction); chr3:156677540 chr3:156671862~156674378:- LIHC cis rs7617773 0.78 rs11706277 ENSG00000229759.1 MRPS18AP1 6.41 4.9e-10 3.86e-07 0.4 0.33 Coronary artery disease; chr3:48318943 chr3:48256350~48256938:- LIHC cis rs765787 0.53 rs1648289 ENSG00000259520.4 CTD-2651B20.3 6.41 4.91e-10 3.86e-07 0.39 0.33 Uric acid levels; chr15:45224296 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs1648287 ENSG00000259520.4 CTD-2651B20.3 6.41 4.91e-10 3.86e-07 0.39 0.33 Uric acid levels; chr15:45224758 chr15:45251580~45279251:- LIHC cis rs1862618 0.802 rs2591949 ENSG00000271828.1 CTD-2310F14.1 6.41 4.93e-10 3.88e-07 0.46 0.33 Initial pursuit acceleration; chr5:56836800 chr5:56927874~56929573:+ LIHC cis rs1862618 0.853 rs2548664 ENSG00000271828.1 CTD-2310F14.1 6.41 4.93e-10 3.88e-07 0.46 0.33 Initial pursuit acceleration; chr5:56837728 chr5:56927874~56929573:+ LIHC cis rs854625 0.661 rs854689 ENSG00000278690.1 RP11-104J23.2 -6.41 4.94e-10 3.89e-07 -0.48 -0.33 Cerebrospinal fluid biomarker levels; chr17:35996083 chr17:36012504~36012891:+ LIHC cis rs9399137 0.507 rs6940258 ENSG00000232876.1 CTA-212D2.2 -6.41 4.97e-10 3.91e-07 -0.38 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135044994 chr6:135055033~135060550:+ LIHC cis rs2439831 0.867 rs2447208 ENSG00000205771.5 CATSPER2P1 -6.41 4.97e-10 3.91e-07 -0.48 -0.33 Lung cancer in ever smokers; chr15:43641697 chr15:43726918~43747094:- LIHC cis rs3096299 0.9 rs744327 ENSG00000274627.1 RP11-104N10.2 6.41 4.97e-10 3.91e-07 0.35 0.33 Multiple myeloma (IgH translocation); chr16:89372862 chr16:89516797~89522217:+ LIHC cis rs62355901 0.609 rs66893416 ENSG00000271828.1 CTD-2310F14.1 6.4 4.99e-10 3.92e-07 0.5 0.33 Breast cancer; chr5:56755769 chr5:56927874~56929573:+ LIHC cis rs1185460 1 rs1614264 ENSG00000271751.1 RP11-110I1.14 -6.4 5.04e-10 3.96e-07 -0.45 -0.33 Coronary artery disease; chr11:119071928 chr11:119065263~119065677:- LIHC cis rs992157 0.56 rs6738394 ENSG00000261338.2 RP11-378A13.1 -6.4 5.05e-10 3.96e-07 -0.32 -0.33 Colorectal cancer; chr2:218245902 chr2:218255319~218257366:+ LIHC cis rs9549367 0.789 rs3794422 ENSG00000269125.1 RP11-98F14.11 -6.4 5.07e-10 3.98e-07 -0.4 -0.33 Platelet distribution width; chr13:113239415 chr13:113165002~113165183:- LIHC cis rs9326248 0.569 rs4938315 ENSG00000236267.1 AP006216.5 6.4 5.07e-10 3.98e-07 0.35 0.33 Blood protein levels; chr11:116860489 chr11:116813204~116814003:- LIHC cis rs7131987 0.65 rs67146951 ENSG00000257176.2 RP11-996F15.2 -6.4 5.07e-10 3.98e-07 -0.38 -0.33 QT interval; chr12:29297620 chr12:29280418~29317848:- LIHC cis rs7131987 0.65 rs10843382 ENSG00000257176.2 RP11-996F15.2 -6.4 5.07e-10 3.98e-07 -0.38 -0.33 QT interval; chr12:29298788 chr12:29280418~29317848:- LIHC cis rs2243480 1 rs1404147 ENSG00000164669.11 INTS4P1 6.4 5.07e-10 3.98e-07 0.56 0.33 Diabetic kidney disease; chr7:65799537 chr7:65141225~65234216:+ LIHC cis rs9341808 0.556 rs10455370 ENSG00000272129.1 RP11-250B2.6 -6.4 5.08e-10 3.98e-07 -0.33 -0.33 Sitting height ratio; chr6:80331150 chr6:80355424~80356859:+ LIHC cis rs875971 0.545 rs1796226 ENSG00000226824.5 RP4-756H11.3 -6.4 5.09e-10 3.99e-07 -0.41 -0.33 Aortic root size; chr7:66622723 chr7:66654538~66669855:+ LIHC cis rs150992 0.593 rs34496 ENSG00000248489.1 CTD-2007H13.3 6.4 5.09e-10 3.99e-07 0.46 0.33 Body mass index; chr5:98963812 chr5:98929171~98995013:+ LIHC cis rs17270561 0.636 rs9379782 ENSG00000216436.2 HIST1H2APS1 -6.4 5.09e-10 4e-07 -0.4 -0.33 Iron status biomarkers; chr6:25714795 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9348692 ENSG00000216436.2 HIST1H2APS1 -6.4 5.09e-10 4e-07 -0.4 -0.33 Iron status biomarkers; chr6:25720584 chr6:25732497~25732827:+ LIHC cis rs1862618 0.802 rs986049 ENSG00000271828.1 CTD-2310F14.1 6.4 5.09e-10 4e-07 0.46 0.33 Initial pursuit acceleration; chr5:56814406 chr5:56927874~56929573:+ LIHC cis rs1862618 0.756 rs13356762 ENSG00000271828.1 CTD-2310F14.1 6.4 5.09e-10 4e-07 0.46 0.33 Initial pursuit acceleration; chr5:56815165 chr5:56927874~56929573:+ LIHC cis rs5758659 0.657 rs5758587 ENSG00000227370.1 RP4-669P10.19 6.4 5.11e-10 4e-07 0.37 0.33 Cognitive function; chr22:42121632 chr22:42132543~42132998:+ LIHC cis rs1577917 1 rs16876529 ENSG00000234155.1 RP11-30P6.6 6.4 5.11e-10 4e-07 0.38 0.33 Response to antipsychotic treatment; chr6:85881484 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs12204015 ENSG00000234155.1 RP11-30P6.6 6.4 5.11e-10 4e-07 0.38 0.33 Response to antipsychotic treatment; chr6:85888616 chr6:85387219~85390186:- LIHC cis rs9322193 0.923 rs4869750 ENSG00000216906.2 RP11-350J20.9 6.4 5.11e-10 4.01e-07 0.37 0.33 Lung cancer; chr6:149855996 chr6:149904243~149906418:+ LIHC cis rs1862618 0.853 rs252902 ENSG00000271828.1 CTD-2310F14.1 6.4 5.12e-10 4.02e-07 0.46 0.33 Initial pursuit acceleration; chr5:56820258 chr5:56927874~56929573:+ LIHC cis rs7674212 0.531 rs6816370 ENSG00000230069.3 LRRC37A15P -6.4 5.13e-10 4.02e-07 -0.31 -0.33 Type 2 diabetes; chr4:103018276 chr4:102727274~102730721:- LIHC cis rs8040855 0.599 rs1964724 ENSG00000259295.5 CSPG4P12 -6.4 5.14e-10 4.03e-07 -0.41 -0.33 Bulimia nervosa; chr15:85183269 chr15:85191438~85213905:+ LIHC cis rs7184046 0.797 rs13737 ENSG00000260269.4 CTD-2323K18.1 -6.4 5.14e-10 4.03e-07 -0.43 -0.33 Height; chr15:75639788 chr15:75527150~75601205:- LIHC cis rs7674212 0.581 rs11946020 ENSG00000230069.3 LRRC37A15P -6.4 5.15e-10 4.03e-07 -0.31 -0.33 Type 2 diabetes; chr4:103023585 chr4:102727274~102730721:- LIHC cis rs523522 0.962 rs3893104 ENSG00000278344.1 RP11-18C24.8 6.4 5.15e-10 4.04e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120466133 chr12:120500735~120501090:- LIHC cis rs7188445 0.736 rs4243177 ENSG00000261390.4 RP11-345M22.2 6.4 5.17e-10 4.05e-07 0.38 0.33 Urate levels; chr16:79669932 chr16:79715232~79770563:- LIHC cis rs875971 0.571 rs160641 ENSG00000164669.11 INTS4P1 6.4 5.2e-10 4.07e-07 0.44 0.33 Aortic root size; chr7:66112359 chr7:65141225~65234216:+ LIHC cis rs9843304 0.568 rs13062027 ENSG00000244503.1 RP11-278L15.6 6.4 5.23e-10 4.1e-07 0.35 0.33 Gallstone disease; chr3:149494892 chr3:149494660~149495995:+ LIHC cis rs150992 0.525 rs331930 ENSG00000248489.1 CTD-2007H13.3 6.4 5.24e-10 4.1e-07 0.44 0.33 Body mass index; chr5:98833559 chr5:98929171~98995013:+ LIHC cis rs2243480 1 rs2533288 ENSG00000273142.1 RP11-458F8.4 -6.4 5.25e-10 4.11e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66591724 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs2707844 ENSG00000273142.1 RP11-458F8.4 -6.4 5.25e-10 4.11e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66594522 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs1796220 ENSG00000273142.1 RP11-458F8.4 -6.4 5.25e-10 4.11e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66597113 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs2707831 ENSG00000273142.1 RP11-458F8.4 -6.4 5.25e-10 4.11e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66597524 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs313813 ENSG00000164669.11 INTS4P1 6.4 5.25e-10 4.11e-07 0.56 0.33 Diabetic kidney disease; chr7:66038513 chr7:65141225~65234216:+ LIHC cis rs150992 0.587 rs10076291 ENSG00000248489.1 CTD-2007H13.3 -6.39 5.27e-10 4.13e-07 -0.48 -0.33 Body mass index; chr5:99012954 chr5:98929171~98995013:+ LIHC cis rs523522 0.962 rs10774549 ENSG00000278344.1 RP11-18C24.8 6.39 5.27e-10 4.13e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120453369 chr12:120500735~120501090:- LIHC cis rs150992 0.504 rs11745405 ENSG00000248489.1 CTD-2007H13.3 -6.39 5.3e-10 4.15e-07 -0.51 -0.33 Body mass index; chr5:99047700 chr5:98929171~98995013:+ LIHC cis rs523522 0.962 rs9040 ENSG00000278344.1 RP11-18C24.8 6.39 5.32e-10 4.16e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120462471 chr12:120500735~120501090:- LIHC cis rs11676348 0.811 rs13027120 ENSG00000261338.2 RP11-378A13.1 6.39 5.34e-10 4.17e-07 0.34 0.33 Ulcerative colitis; chr2:218156191 chr2:218255319~218257366:+ LIHC cis rs2439831 0.85 rs16977798 ENSG00000205771.5 CATSPER2P1 -6.39 5.35e-10 4.18e-07 -0.48 -0.33 Lung cancer in ever smokers; chr15:43859750 chr15:43726918~43747094:- LIHC cis rs12291225 0.535 rs11023203 ENSG00000251991.1 RNU7-49P 6.39 5.35e-10 4.18e-07 0.35 0.33 Sense of smell; chr11:14388269 chr11:14478892~14478953:+ LIHC cis rs12291225 0.535 rs12806025 ENSG00000251991.1 RNU7-49P 6.39 5.35e-10 4.18e-07 0.35 0.33 Sense of smell; chr11:14392271 chr11:14478892~14478953:+ LIHC cis rs832190 1 rs832190 ENSG00000280620.1 SCAANT1 -6.39 5.36e-10 4.19e-07 -0.4 -0.33 Schizophrenia; chr3:63856953 chr3:63911518~63911772:- LIHC cis rs7674212 0.531 rs4698875 ENSG00000230069.3 LRRC37A15P -6.39 5.4e-10 4.21e-07 -0.31 -0.33 Type 2 diabetes; chr4:103012211 chr4:102727274~102730721:- LIHC cis rs5758659 0.714 rs5751216 ENSG00000227370.1 RP4-669P10.19 6.39 5.44e-10 4.25e-07 0.36 0.33 Cognitive function; chr22:42112933 chr22:42132543~42132998:+ LIHC cis rs765787 0.53 rs3759895 ENSG00000259520.4 CTD-2651B20.3 6.39 5.46e-10 4.26e-07 0.39 0.33 Uric acid levels; chr15:45251672 chr15:45251580~45279251:- LIHC cis rs2243480 1 rs34815098 ENSG00000164669.11 INTS4P1 6.39 5.47e-10 4.27e-07 0.57 0.33 Diabetic kidney disease; chr7:65827267 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs4548056 ENSG00000164669.11 INTS4P1 6.39 5.47e-10 4.27e-07 0.57 0.33 Diabetic kidney disease; chr7:65833886 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs7456042 ENSG00000164669.11 INTS4P1 6.39 5.47e-10 4.27e-07 0.57 0.33 Diabetic kidney disease; chr7:65834791 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs35735127 ENSG00000164669.11 INTS4P1 6.39 5.47e-10 4.27e-07 0.57 0.33 Diabetic kidney disease; chr7:65835436 chr7:65141225~65234216:+ LIHC cis rs2243480 0.901 rs35256305 ENSG00000164669.11 INTS4P1 6.39 5.47e-10 4.27e-07 0.57 0.33 Diabetic kidney disease; chr7:65841418 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs73142121 ENSG00000164669.11 INTS4P1 6.39 5.47e-10 4.27e-07 0.57 0.33 Diabetic kidney disease; chr7:65846219 chr7:65141225~65234216:+ LIHC cis rs2243480 0.803 rs34004500 ENSG00000164669.11 INTS4P1 6.39 5.47e-10 4.27e-07 0.57 0.33 Diabetic kidney disease; chr7:65847191 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs35825738 ENSG00000164669.11 INTS4P1 6.39 5.47e-10 4.27e-07 0.57 0.33 Diabetic kidney disease; chr7:65853040 chr7:65141225~65234216:+ LIHC cis rs6061231 0.837 rs6121558 ENSG00000273619.1 RP5-908M14.9 -6.39 5.48e-10 4.27e-07 -0.31 -0.33 Colorectal cancer; chr20:62386309 chr20:62386303~62386970:- LIHC cis rs1862618 0.853 rs2548665 ENSG00000271828.1 CTD-2310F14.1 6.39 5.49e-10 4.28e-07 0.46 0.33 Initial pursuit acceleration; chr5:56835978 chr5:56927874~56929573:+ LIHC cis rs7914558 1 rs11191577 ENSG00000236937.2 PTGES3P4 6.39 5.52e-10 4.3e-07 0.39 0.33 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103142408 chr10:102845595~102845950:+ LIHC cis rs12681287 0.604 rs7017716 ENSG00000250569.1 NTAN1P2 6.39 5.53e-10 4.31e-07 0.38 0.33 Caudate activity during reward; chr8:86416772 chr8:86481754~86483002:- LIHC cis rs55665837 0.54 rs3206554 ENSG00000251991.1 RNU7-49P 6.39 5.55e-10 4.33e-07 0.35 0.33 Vitamin D levels; chr11:14776399 chr11:14478892~14478953:+ LIHC cis rs2243480 1 rs937108 ENSG00000164669.11 INTS4P1 6.38 5.59e-10 4.35e-07 0.56 0.33 Diabetic kidney disease; chr7:65963465 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs35542501 ENSG00000164669.11 INTS4P1 6.38 5.59e-10 4.35e-07 0.56 0.33 Diabetic kidney disease; chr7:65966228 chr7:65141225~65234216:+ LIHC cis rs2243480 0.711 rs1626926 ENSG00000164669.11 INTS4P1 6.38 5.59e-10 4.35e-07 0.56 0.33 Diabetic kidney disease; chr7:65970805 chr7:65141225~65234216:+ LIHC cis rs2243480 0.708 rs781141 ENSG00000164669.11 INTS4P1 6.38 5.59e-10 4.35e-07 0.56 0.33 Diabetic kidney disease; chr7:65973566 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs781142 ENSG00000164669.11 INTS4P1 6.38 5.59e-10 4.35e-07 0.56 0.33 Diabetic kidney disease; chr7:65973791 chr7:65141225~65234216:+ LIHC cis rs523522 0.962 rs7488320 ENSG00000278344.1 RP11-18C24.8 6.38 5.61e-10 4.36e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120543827 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs12814055 ENSG00000278344.1 RP11-18C24.8 6.38 5.61e-10 4.36e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120549588 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs3213565 ENSG00000278344.1 RP11-18C24.8 6.38 5.61e-10 4.36e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120554598 chr12:120500735~120501090:- LIHC cis rs2243480 1 rs778729 ENSG00000273142.1 RP11-458F8.4 -6.38 5.62e-10 4.37e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66359432 chr7:66902857~66906297:+ LIHC cis rs2243480 0.901 rs778687 ENSG00000273142.1 RP11-458F8.4 -6.38 5.62e-10 4.37e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66370832 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs778679 ENSG00000273142.1 RP11-458F8.4 -6.38 5.62e-10 4.37e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66375924 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs778704 ENSG00000273142.1 RP11-458F8.4 -6.38 5.62e-10 4.37e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66398480 chr7:66902857~66906297:+ LIHC cis rs2243480 0.901 rs778693 ENSG00000273142.1 RP11-458F8.4 -6.38 5.62e-10 4.37e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66407358 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs778691 ENSG00000273142.1 RP11-458F8.4 -6.38 5.62e-10 4.37e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66408105 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs13235972 ENSG00000273142.1 RP11-458F8.4 -6.38 5.62e-10 4.37e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66418618 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs34192067 ENSG00000273142.1 RP11-458F8.4 -6.38 5.62e-10 4.37e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66422670 chr7:66902857~66906297:+ LIHC cis rs2243480 0.803 rs160649 ENSG00000164669.11 INTS4P1 6.38 5.64e-10 4.39e-07 0.57 0.33 Diabetic kidney disease; chr7:66078212 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs160648 ENSG00000164669.11 INTS4P1 6.38 5.64e-10 4.39e-07 0.57 0.33 Diabetic kidney disease; chr7:66078397 chr7:65141225~65234216:+ LIHC cis rs55665837 0.54 rs10219313 ENSG00000251991.1 RNU7-49P 6.38 5.65e-10 4.39e-07 0.35 0.33 Vitamin D levels; chr11:14728303 chr11:14478892~14478953:+ LIHC cis rs55665837 0.54 rs4144487 ENSG00000251991.1 RNU7-49P 6.38 5.65e-10 4.39e-07 0.35 0.33 Vitamin D levels; chr11:14728905 chr11:14478892~14478953:+ LIHC cis rs55665837 0.519 rs10832297 ENSG00000251991.1 RNU7-49P 6.38 5.65e-10 4.39e-07 0.35 0.33 Vitamin D levels; chr11:14736191 chr11:14478892~14478953:+ LIHC cis rs55665837 0.54 rs12788030 ENSG00000251991.1 RNU7-49P 6.38 5.65e-10 4.39e-07 0.35 0.33 Vitamin D levels; chr11:14743138 chr11:14478892~14478953:+ LIHC cis rs6061231 0.701 rs6061505 ENSG00000273619.1 RP5-908M14.9 -6.38 5.66e-10 4.4e-07 -0.27 -0.33 Colorectal cancer; chr20:62385155 chr20:62386303~62386970:- LIHC cis rs4660456 0.913 rs2361651 ENSG00000237899.1 RP4-739H11.3 6.38 5.67e-10 4.41e-07 0.44 0.33 Platelet count; chr1:40764542 chr1:40669089~40687588:- LIHC cis rs8062405 0.573 rs8045689 ENSG00000259982.1 CDC37P1 -6.38 5.68e-10 4.41e-07 -0.4 -0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28976948 chr16:28700294~28701540:- LIHC cis rs17270561 0.609 rs9358886 ENSG00000216436.2 HIST1H2APS1 -6.38 5.68e-10 4.41e-07 -0.4 -0.33 Iron status biomarkers; chr6:25758025 chr6:25732497~25732827:+ LIHC cis rs7914558 1 rs7067970 ENSG00000236937.2 PTGES3P4 6.38 5.7e-10 4.43e-07 0.39 0.33 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103154113 chr10:102845595~102845950:+ LIHC cis rs523522 0.962 rs11065145 ENSG00000278344.1 RP11-18C24.8 6.38 5.7e-10 4.43e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120509616 chr12:120500735~120501090:- LIHC cis rs523522 0.923 rs10774553 ENSG00000278344.1 RP11-18C24.8 6.38 5.7e-10 4.43e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120517181 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs11065149 ENSG00000278344.1 RP11-18C24.8 6.38 5.7e-10 4.43e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120519160 chr12:120500735~120501090:- LIHC cis rs523522 0.924 rs11065150 ENSG00000278344.1 RP11-18C24.8 6.38 5.7e-10 4.43e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120521072 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs10849757 ENSG00000278344.1 RP11-18C24.8 6.38 5.7e-10 4.43e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120526211 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs55848094 ENSG00000278344.1 RP11-18C24.8 6.38 5.7e-10 4.43e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120528856 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs3742052 ENSG00000278344.1 RP11-18C24.8 6.38 5.7e-10 4.43e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120529118 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs10849758 ENSG00000278344.1 RP11-18C24.8 6.38 5.7e-10 4.43e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120533346 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs11065154 ENSG00000278344.1 RP11-18C24.8 6.38 5.7e-10 4.43e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120533614 chr12:120500735~120501090:- LIHC cis rs523522 0.926 rs10774555 ENSG00000278344.1 RP11-18C24.8 6.38 5.7e-10 4.43e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120534175 chr12:120500735~120501090:- LIHC cis rs4718428 0.672 rs4718412 ENSG00000226824.5 RP4-756H11.3 6.38 5.72e-10 4.44e-07 0.43 0.33 Corneal structure; chr7:66821880 chr7:66654538~66669855:+ LIHC cis rs62355901 0.545 rs16886260 ENSG00000271828.1 CTD-2310F14.1 -6.38 5.72e-10 4.44e-07 -0.52 -0.33 Breast cancer; chr5:56769629 chr5:56927874~56929573:+ LIHC cis rs4718428 0.705 rs11028 ENSG00000226824.5 RP4-756H11.3 -6.38 5.75e-10 4.46e-07 -0.43 -0.33 Corneal structure; chr7:66811230 chr7:66654538~66669855:+ LIHC cis rs523522 0.923 rs1048830 ENSG00000278344.1 RP11-18C24.8 6.38 5.77e-10 4.47e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120444414 chr12:120500735~120501090:- LIHC cis rs1499614 1 rs1267817 ENSG00000273142.1 RP11-458F8.4 -6.38 5.77e-10 4.47e-07 -0.4 -0.33 Gout; chr7:66645053 chr7:66902857~66906297:+ LIHC cis rs5758659 0.714 rs6002607 ENSG00000227370.1 RP4-669P10.19 6.38 5.8e-10 4.5e-07 0.37 0.33 Cognitive function; chr22:42100502 chr22:42132543~42132998:+ LIHC cis rs2243480 0.901 rs34807232 ENSG00000273142.1 RP11-458F8.4 -6.38 5.82e-10 4.51e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66500146 chr7:66902857~66906297:+ LIHC cis rs2243480 0.901 rs35823062 ENSG00000273142.1 RP11-458F8.4 -6.38 5.82e-10 4.51e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66500834 chr7:66902857~66906297:+ LIHC cis rs3020736 0.5 rs4147641 ENSG00000237037.8 NDUFA6-AS1 -6.38 5.83e-10 4.51e-07 -0.39 -0.33 Autism spectrum disorder or schizophrenia; chr22:42086498 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs4147640 ENSG00000237037.8 NDUFA6-AS1 -6.38 5.83e-10 4.51e-07 -0.39 -0.33 Autism spectrum disorder or schizophrenia; chr22:42089288 chr22:42090931~42137742:+ LIHC cis rs1023500 0.507 rs6002600 ENSG00000237037.8 NDUFA6-AS1 -6.38 5.83e-10 4.51e-07 -0.39 -0.33 Schizophrenia; chr22:42092902 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs6002601 ENSG00000237037.8 NDUFA6-AS1 -6.38 5.83e-10 4.51e-07 -0.39 -0.33 Autism spectrum disorder or schizophrenia; chr22:42093054 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs6002604 ENSG00000237037.8 NDUFA6-AS1 -6.38 5.83e-10 4.51e-07 -0.39 -0.33 Autism spectrum disorder or schizophrenia; chr22:42097077 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs5996109 ENSG00000237037.8 NDUFA6-AS1 -6.38 5.83e-10 4.51e-07 -0.39 -0.33 Autism spectrum disorder or schizophrenia; chr22:42097094 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs5996110 ENSG00000237037.8 NDUFA6-AS1 -6.38 5.83e-10 4.51e-07 -0.39 -0.33 Autism spectrum disorder or schizophrenia; chr22:42097763 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs9620026 ENSG00000237037.8 NDUFA6-AS1 -6.38 5.83e-10 4.51e-07 -0.39 -0.33 Autism spectrum disorder or schizophrenia; chr22:42102574 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs28791586 ENSG00000237037.8 NDUFA6-AS1 -6.38 5.83e-10 4.51e-07 -0.39 -0.33 Autism spectrum disorder or schizophrenia; chr22:42104479 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs2839708 ENSG00000237037.8 NDUFA6-AS1 -6.38 5.83e-10 4.51e-07 -0.39 -0.33 Autism spectrum disorder or schizophrenia; chr22:42104741 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs6519306 ENSG00000237037.8 NDUFA6-AS1 -6.38 5.83e-10 4.51e-07 -0.39 -0.33 Autism spectrum disorder or schizophrenia; chr22:42105213 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs6002614 ENSG00000237037.8 NDUFA6-AS1 -6.38 5.83e-10 4.51e-07 -0.39 -0.33 Autism spectrum disorder or schizophrenia; chr22:42105798 chr22:42090931~42137742:+ LIHC cis rs1862618 0.853 rs3099459 ENSG00000271828.1 CTD-2310F14.1 6.38 5.83e-10 4.52e-07 0.46 0.33 Initial pursuit acceleration; chr5:56841343 chr5:56927874~56929573:+ LIHC cis rs9326248 1 rs585849 ENSG00000280143.1 AP000892.6 6.38 5.85e-10 4.53e-07 0.38 0.33 Blood protein levels; chr11:117198345 chr11:117204967~117210292:+ LIHC cis rs2243480 1 rs4149468 ENSG00000273142.1 RP11-458F8.4 -6.38 5.89e-10 4.56e-07 -0.4 -0.33 Diabetic kidney disease; chr7:66360703 chr7:66902857~66906297:+ LIHC cis rs523522 0.923 rs2235217 ENSG00000278344.1 RP11-18C24.8 6.38 5.9e-10 4.57e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120446525 chr12:120500735~120501090:- LIHC cis rs1729407 0.649 rs2849176 ENSG00000254851.1 RP11-109L13.1 6.38 5.91e-10 4.58e-07 0.38 0.33 Apolipoprotein A-IV levels; chr11:116826205 chr11:117135528~117138582:+ LIHC cis rs1005277 0.579 rs1780121 ENSG00000263064.2 RP11-291L22.7 6.38 5.91e-10 4.58e-07 0.34 0.33 Extrinsic epigenetic age acceleration; chr10:38240509 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs1780122 ENSG00000263064.2 RP11-291L22.7 6.38 5.91e-10 4.58e-07 0.34 0.33 Extrinsic epigenetic age acceleration; chr10:38240581 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs1780145 ENSG00000263064.2 RP11-291L22.7 6.38 5.91e-10 4.58e-07 0.34 0.33 Extrinsic epigenetic age acceleration; chr10:38248142 chr10:38448689~38448949:+ LIHC cis rs17270561 0.609 rs4711095 ENSG00000216436.2 HIST1H2APS1 -6.38 5.91e-10 4.58e-07 -0.4 -0.33 Iron status biomarkers; chr6:25726546 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4712959 ENSG00000216436.2 HIST1H2APS1 -6.38 5.91e-10 4.58e-07 -0.4 -0.33 Iron status biomarkers; chr6:25726829 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4712960 ENSG00000216436.2 HIST1H2APS1 -6.38 5.91e-10 4.58e-07 -0.4 -0.33 Iron status biomarkers; chr6:25727037 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4712961 ENSG00000216436.2 HIST1H2APS1 -6.38 5.91e-10 4.58e-07 -0.4 -0.33 Iron status biomarkers; chr6:25727106 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9358872 ENSG00000216436.2 HIST1H2APS1 -6.38 5.91e-10 4.58e-07 -0.4 -0.33 Iron status biomarkers; chr6:25727289 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9356985 ENSG00000216436.2 HIST1H2APS1 -6.38 5.91e-10 4.58e-07 -0.4 -0.33 Iron status biomarkers; chr6:25727870 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4712964 ENSG00000216436.2 HIST1H2APS1 -6.38 5.92e-10 4.58e-07 -0.4 -0.33 Iron status biomarkers; chr6:25740594 chr6:25732497~25732827:+ LIHC cis rs8040855 0.599 rs6496800 ENSG00000259295.5 CSPG4P12 -6.37 5.93e-10 4.59e-07 -0.41 -0.33 Bulimia nervosa; chr15:85185055 chr15:85191438~85213905:+ LIHC cis rs7617773 0.817 rs3937 ENSG00000229759.1 MRPS18AP1 6.37 5.94e-10 4.59e-07 0.39 0.33 Coronary artery disease; chr3:48270912 chr3:48256350~48256938:- LIHC cis rs524281 0.773 rs7951079 ENSG00000255320.1 RP11-755F10.1 6.37 5.94e-10 4.6e-07 0.45 0.33 Electroencephalogram traits; chr11:66213079 chr11:66244840~66246239:- LIHC cis rs113835537 0.529 rs7950407 ENSG00000255517.5 CTD-3074O7.5 -6.37 5.95e-10 4.6e-07 -0.35 -0.33 Airway imaging phenotypes; chr11:66490535 chr11:66473490~66480233:- LIHC cis rs3858145 0.588 rs61854831 ENSG00000233590.1 RP11-153K11.3 -6.37 5.96e-10 4.61e-07 -0.43 -0.33 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68276080 chr10:68233251~68242379:- LIHC cis rs3858145 0.588 rs55888445 ENSG00000233590.1 RP11-153K11.3 -6.37 5.96e-10 4.61e-07 -0.43 -0.33 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68276699 chr10:68233251~68242379:- LIHC cis rs3858145 0.588 rs76854765 ENSG00000233590.1 RP11-153K11.3 -6.37 5.96e-10 4.61e-07 -0.43 -0.33 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68277699 chr10:68233251~68242379:- LIHC cis rs11023332 1 rs11023332 ENSG00000251991.1 RNU7-49P 6.37 5.96e-10 4.61e-07 0.35 0.33 Vitamin D levels;Adiponectin levels; chr11:14762564 chr11:14478892~14478953:+ LIHC cis rs2439831 0.867 rs2927072 ENSG00000205771.5 CATSPER2P1 -6.37 5.99e-10 4.63e-07 -0.49 -0.33 Lung cancer in ever smokers; chr15:43630200 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs2920781 ENSG00000205771.5 CATSPER2P1 -6.37 5.99e-10 4.63e-07 -0.49 -0.33 Lung cancer in ever smokers; chr15:43632484 chr15:43726918~43747094:- LIHC cis rs2439831 0.764 rs2447193 ENSG00000205771.5 CATSPER2P1 -6.37 5.99e-10 4.63e-07 -0.49 -0.33 Lung cancer in ever smokers; chr15:43637535 chr15:43726918~43747094:- LIHC cis rs523522 0.962 rs12371550 ENSG00000278344.1 RP11-18C24.8 6.37 6e-10 4.64e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120549840 chr12:120500735~120501090:- LIHC cis rs9399137 0.507 rs10484496 ENSG00000232876.1 CTA-212D2.2 -6.37 6.02e-10 4.65e-07 -0.37 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134978544 chr6:135055033~135060550:+ LIHC cis rs4660456 0.913 rs545218 ENSG00000237899.1 RP4-739H11.3 6.37 6.04e-10 4.67e-07 0.47 0.33 Platelet count; chr1:40675313 chr1:40669089~40687588:- LIHC cis rs1185460 0.967 rs1177563 ENSG00000271751.1 RP11-110I1.14 -6.37 6.05e-10 4.67e-07 -0.45 -0.33 Coronary artery disease; chr11:119078373 chr11:119065263~119065677:- LIHC cis rs11089937 0.926 rs5750601 ENSG00000211639.2 IGLV4-60 6.37 6.06e-10 4.68e-07 0.27 0.33 Periodontitis (PAL4Q3); chr22:22144396 chr22:22162199~22162681:+ LIHC cis rs55665837 0.559 rs9667144 ENSG00000251991.1 RNU7-49P -6.37 6.12e-10 4.73e-07 -0.35 -0.33 Vitamin D levels; chr11:14399555 chr11:14478892~14478953:+ LIHC cis rs710216 0.536 rs710222 ENSG00000227533.4 SLC2A1-AS1 6.37 6.12e-10 4.73e-07 0.37 0.33 Red cell distribution width; chr1:42947982 chr1:42959049~42983358:+ LIHC cis rs523522 0.847 rs11065132 ENSG00000278344.1 RP11-18C24.8 6.37 6.13e-10 4.74e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120470656 chr12:120500735~120501090:- LIHC cis rs8062405 0.573 rs6565300 ENSG00000259982.1 CDC37P1 6.37 6.17e-10 4.76e-07 0.41 0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28981728 chr16:28700294~28701540:- LIHC cis rs2439831 0.85 rs11856795 ENSG00000205771.5 CATSPER2P1 -6.37 6.2e-10 4.78e-07 -0.5 -0.33 Lung cancer in ever smokers; chr15:43868384 chr15:43726918~43747094:- LIHC cis rs7580658 0.68 rs6710535 ENSG00000236682.1 AC068282.3 6.37 6.23e-10 4.81e-07 0.42 0.33 Protein C levels; chr2:127433384 chr2:127389130~127400580:+ LIHC cis rs2739330 0.791 rs9612520 ENSG00000099984.9 GSTT2 -6.37 6.26e-10 4.83e-07 -0.38 -0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23980123~23983911:+ LIHC cis rs113835537 0.569 rs17496586 ENSG00000255517.5 CTD-3074O7.5 -6.36 6.3e-10 4.86e-07 -0.42 -0.33 Airway imaging phenotypes; chr11:66548041 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs11824771 ENSG00000255517.5 CTD-3074O7.5 -6.36 6.31e-10 4.86e-07 -0.35 -0.33 Airway imaging phenotypes; chr11:66495079 chr11:66473490~66480233:- LIHC cis rs2243480 0.831 rs7806717 ENSG00000164669.11 INTS4P1 -6.36 6.32e-10 4.86e-07 -0.56 -0.33 Diabetic kidney disease; chr7:65928187 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs78803505 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65917585 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs34933526 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65918212 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs34577383 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65920739 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs6949812 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65922114 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs6970243 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65923503 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs7794661 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65924743 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs7795242 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65925107 chr7:65141225~65234216:+ LIHC cis rs2243480 0.708 rs35310401 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65925372 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs35058610 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65925938 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs2177703 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65926730 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs35432774 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65928032 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs56985706 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65929575 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs60683927 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65929781 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs58062456 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65929865 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs34529418 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65938222 chr7:65141225~65234216:+ LIHC cis rs2243480 0.901 rs35087093 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65940221 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs35046236 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65943626 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs36068983 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65944004 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs68189316 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65944182 chr7:65141225~65234216:+ LIHC cis rs2243480 0.803 rs34804747 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65947955 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs11538349 ENSG00000164669.11 INTS4P1 6.36 6.32e-10 4.86e-07 0.56 0.33 Diabetic kidney disease; chr7:65956884 chr7:65141225~65234216:+ LIHC cis rs992157 0.56 rs6436048 ENSG00000261338.2 RP11-378A13.1 6.36 6.33e-10 4.88e-07 0.32 0.33 Colorectal cancer; chr2:218244310 chr2:218255319~218257366:+ LIHC cis rs55665837 0.524 rs61884009 ENSG00000251991.1 RNU7-49P 6.36 6.36e-10 4.89e-07 0.36 0.33 Vitamin D levels; chr11:14404916 chr11:14478892~14478953:+ LIHC cis rs150992 0.587 rs12189335 ENSG00000248489.1 CTD-2007H13.3 -6.36 6.36e-10 4.9e-07 -0.48 -0.33 Body mass index; chr5:99009311 chr5:98929171~98995013:+ LIHC cis rs12291225 0.535 rs10832248 ENSG00000251991.1 RNU7-49P 6.36 6.39e-10 4.92e-07 0.35 0.33 Sense of smell; chr11:14391541 chr11:14478892~14478953:+ LIHC cis rs1555322 0.53 rs2425053 ENSG00000126005.14 MMP24-AS1 -6.36 6.4e-10 4.92e-07 -0.49 -0.33 Attention deficit hyperactivity disorder; chr20:35294017 chr20:35216462~35278131:- LIHC cis rs2735413 0.711 rs12921476 ENSG00000276007.1 RP11-358L22.3 -6.36 6.4e-10 4.92e-07 -0.36 -0.33 Systolic blood pressure (alcohol consumption interaction); chr16:78045949 chr16:78123243~78124332:+ LIHC cis rs1005277 0.579 rs1614236 ENSG00000263064.2 RP11-291L22.7 6.36 6.41e-10 4.93e-07 0.34 0.33 Extrinsic epigenetic age acceleration; chr10:38214068 chr10:38448689~38448949:+ LIHC cis rs9549367 0.789 rs12869947 ENSG00000269125.1 RP11-98F14.11 -6.36 6.47e-10 4.97e-07 -0.4 -0.33 Platelet distribution width; chr13:113241842 chr13:113165002~113165183:- LIHC cis rs523522 0.962 rs4767905 ENSG00000278344.1 RP11-18C24.8 6.36 6.47e-10 4.98e-07 0.39 0.33 High light scatter reticulocyte count; chr12:120493032 chr12:120500735~120501090:- LIHC cis rs2933343 0.716 rs9867404 ENSG00000231305.3 RP11-723O4.2 -6.36 6.48e-10 4.98e-07 -0.37 -0.33 IgG glycosylation; chr3:128847295 chr3:128861313~128871540:- LIHC cis rs6085948 0.861 rs2224055 ENSG00000238102.1 RP11-19D2.1 -6.36 6.5e-10 5e-07 -0.58 -0.33 Interleukin-10 levels; chr20:7253521 chr20:7256580~7258214:- LIHC cis rs9326248 0.731 rs90192 ENSG00000280143.1 AP000892.6 6.36 6.51e-10 5e-07 0.39 0.33 Blood protein levels; chr11:117188631 chr11:117204967~117210292:+ LIHC cis rs9399137 0.561 rs11753985 ENSG00000232876.1 CTA-212D2.2 -6.36 6.52e-10 5.01e-07 -0.37 -0.33 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134959300 chr6:135055033~135060550:+ LIHC cis rs4356975 0.563 rs7698645 ENSG00000249956.3 RP11-790I12.2 6.36 6.53e-10 5.02e-07 0.36 0.33 Obesity-related traits; chr4:69106192 chr4:69408836~69423164:+ LIHC cis rs1005277 0.579 rs1740737 ENSG00000263064.2 RP11-291L22.7 6.36 6.53e-10 5.02e-07 0.34 0.33 Extrinsic epigenetic age acceleration; chr10:38210437 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2749616 ENSG00000263064.2 RP11-291L22.7 6.36 6.53e-10 5.02e-07 0.34 0.33 Extrinsic epigenetic age acceleration; chr10:38222065 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs1780146 ENSG00000263064.2 RP11-291L22.7 6.36 6.53e-10 5.02e-07 0.34 0.33 Extrinsic epigenetic age acceleration; chr10:38228946 chr10:38448689~38448949:+ LIHC cis rs7743045 0.777 rs6916491 ENSG00000253194.1 RP11-351A11.1 6.36 6.55e-10 5.03e-07 0.44 0.33 Mean platelet volume; chr6:118926569 chr6:118934785~119031541:+ LIHC cis rs4423214 0.879 rs1790324 ENSG00000254682.1 RP11-660L16.2 -6.36 6.57e-10 5.04e-07 -0.4 -0.33 Vitamin D levels; chr11:71439474 chr11:71448674~71452157:+ LIHC cis rs2243480 1 rs34703416 ENSG00000164669.11 INTS4P1 6.36 6.58e-10 5.05e-07 0.57 0.33 Diabetic kidney disease; chr7:65835655 chr7:65141225~65234216:+ LIHC cis rs73086581 0.838 rs11906481 ENSG00000229539.1 RP11-119B16.2 6.36 6.62e-10 5.08e-07 0.56 0.33 Response to antidepressants in depression; chr20:4048059 chr20:3888239~3888868:- LIHC cis rs12439619 0.508 rs11856561 ENSG00000278603.1 RP13-608F4.5 6.36 6.63e-10 5.09e-07 0.42 0.33 Intelligence (multi-trait analysis); chr15:82161415 chr15:82472203~82472426:+ LIHC cis rs765787 0.53 rs1706832 ENSG00000259520.4 CTD-2651B20.3 6.36 6.63e-10 5.09e-07 0.39 0.33 Uric acid levels; chr15:45224975 chr15:45251580~45279251:- LIHC cis rs1577917 0.958 rs16876530 ENSG00000234155.1 RP11-30P6.6 6.36 6.65e-10 5.1e-07 0.38 0.32 Response to antipsychotic treatment; chr6:85885923 chr6:85387219~85390186:- LIHC cis rs9549367 0.789 rs9549699 ENSG00000269125.1 RP11-98F14.11 -6.35 6.66e-10 5.11e-07 -0.4 -0.32 Platelet distribution width; chr13:113223949 chr13:113165002~113165183:- LIHC cis rs8040855 0.599 rs4577058 ENSG00000259295.5 CSPG4P12 -6.35 6.67e-10 5.12e-07 -0.41 -0.32 Bulimia nervosa; chr15:85183227 chr15:85191438~85213905:+ LIHC cis rs1062177 0.547 rs2915818 ENSG00000213433.5 RPLP1P6 6.35 6.68e-10 5.12e-07 0.36 0.32 Preschool internalizing problems; chr5:151735729 chr5:151765859~151766378:- LIHC cis rs9326248 1 rs664082 ENSG00000280143.1 AP000892.6 6.35 6.7e-10 5.14e-07 0.37 0.32 Blood protein levels; chr11:117200354 chr11:117204967~117210292:+ LIHC cis rs62355900 0.636 rs62355907 ENSG00000271828.1 CTD-2310F14.1 6.35 6.71e-10 5.14e-07 0.51 0.32 Endometriosis; chr5:56775503 chr5:56927874~56929573:+ LIHC cis rs2243480 1 rs1638734 ENSG00000273142.1 RP11-458F8.4 -6.35 6.73e-10 5.16e-07 -0.4 -0.32 Diabetic kidney disease; chr7:66632552 chr7:66902857~66906297:+ LIHC cis rs523522 0.962 rs3759394 ENSG00000278344.1 RP11-18C24.8 6.35 6.74e-10 5.17e-07 0.39 0.32 High light scatter reticulocyte count; chr12:120495370 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs2233676 ENSG00000278344.1 RP11-18C24.8 6.35 6.74e-10 5.17e-07 0.39 0.32 High light scatter reticulocyte count; chr12:120495804 chr12:120500735~120501090:- LIHC cis rs523522 0.923 rs3916065 ENSG00000278344.1 RP11-18C24.8 6.35 6.74e-10 5.17e-07 0.39 0.32 High light scatter reticulocyte count; chr12:120496821 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs9788155 ENSG00000278344.1 RP11-18C24.8 6.35 6.74e-10 5.17e-07 0.39 0.32 High light scatter reticulocyte count; chr12:120500605 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs10849754 ENSG00000278344.1 RP11-18C24.8 6.35 6.74e-10 5.17e-07 0.39 0.32 High light scatter reticulocyte count; chr12:120502615 chr12:120500735~120501090:- LIHC cis rs9843304 0.616 rs4131174 ENSG00000244503.1 RP11-278L15.6 6.35 6.74e-10 5.17e-07 0.35 0.32 Gallstone disease; chr3:149486123 chr3:149494660~149495995:+ LIHC cis rs916888 0.779 rs199528 ENSG00000262881.1 RP11-669E14.4 -6.35 6.77e-10 5.19e-07 -0.53 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45907670~45910779:- LIHC cis rs916888 0.821 rs199525 ENSG00000262881.1 RP11-669E14.4 -6.35 6.77e-10 5.19e-07 -0.53 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45907670~45910779:- LIHC cis rs150992 0.593 rs34497 ENSG00000248489.1 CTD-2007H13.3 6.35 6.77e-10 5.19e-07 0.46 0.32 Body mass index; chr5:98962885 chr5:98929171~98995013:+ LIHC cis rs1005277 0.579 rs1780116 ENSG00000263064.2 RP11-291L22.7 6.35 6.77e-10 5.19e-07 0.34 0.32 Extrinsic epigenetic age acceleration; chr10:38237693 chr10:38448689~38448949:+ LIHC cis rs9326248 1 rs664922 ENSG00000280143.1 AP000892.6 6.35 6.77e-10 5.19e-07 0.37 0.32 Blood protein levels; chr11:117200179 chr11:117204967~117210292:+ LIHC cis rs10510102 0.872 rs116521083 ENSG00000276742.1 RP11-500G22.4 6.35 6.79e-10 5.2e-07 0.53 0.32 Breast cancer; chr10:121950611 chr10:121956782~121957098:+ LIHC cis rs10510102 0.748 rs4589226 ENSG00000276742.1 RP11-500G22.4 6.35 6.79e-10 5.2e-07 0.53 0.32 Breast cancer; chr10:121951073 chr10:121956782~121957098:+ LIHC cis rs10510102 0.81 rs34738294 ENSG00000276742.1 RP11-500G22.4 6.35 6.79e-10 5.2e-07 0.53 0.32 Breast cancer; chr10:121951357 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs12258234 ENSG00000276742.1 RP11-500G22.4 6.35 6.79e-10 5.2e-07 0.53 0.32 Breast cancer; chr10:121952828 chr10:121956782~121957098:+ LIHC cis rs10510102 0.515 rs11200285 ENSG00000276742.1 RP11-500G22.4 6.35 6.79e-10 5.2e-07 0.53 0.32 Breast cancer; chr10:121953931 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs75831447 ENSG00000276742.1 RP11-500G22.4 6.35 6.79e-10 5.2e-07 0.53 0.32 Breast cancer; chr10:121953963 chr10:121956782~121957098:+ LIHC cis rs10510102 0.63 rs79960726 ENSG00000276742.1 RP11-500G22.4 6.35 6.79e-10 5.2e-07 0.53 0.32 Breast cancer; chr10:121954358 chr10:121956782~121957098:+ LIHC cis rs1862618 0.715 rs6866779 ENSG00000271828.1 CTD-2310F14.1 6.35 6.81e-10 5.22e-07 0.46 0.32 Initial pursuit acceleration; chr5:56794173 chr5:56927874~56929573:+ LIHC cis rs1023500 0.505 rs134891 ENSG00000237037.8 NDUFA6-AS1 6.35 6.82e-10 5.22e-07 0.35 0.32 Schizophrenia; chr22:42279876 chr22:42090931~42137742:+ LIHC cis rs9326248 0.53 rs2127905 ENSG00000280143.1 AP000892.6 6.35 6.84e-10 5.24e-07 0.41 0.32 Blood protein levels; chr11:117155658 chr11:117204967~117210292:+ LIHC cis rs7115242 0.514 rs4936367 ENSG00000280143.1 AP000892.6 6.35 6.84e-10 5.24e-07 0.41 0.32 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117171661 chr11:117204967~117210292:+ LIHC cis rs9326248 0.53 rs4604928 ENSG00000280143.1 AP000892.6 6.35 6.84e-10 5.24e-07 0.41 0.32 Blood protein levels; chr11:117173487 chr11:117204967~117210292:+ LIHC cis rs523522 0.962 rs2393590 ENSG00000278344.1 RP11-18C24.8 6.35 6.84e-10 5.24e-07 0.39 0.32 High light scatter reticulocyte count; chr12:120476097 chr12:120500735~120501090:- LIHC cis rs12681287 0.752 rs4310184 ENSG00000250569.1 NTAN1P2 6.35 6.86e-10 5.25e-07 0.39 0.32 Caudate activity during reward; chr8:86233024 chr8:86481754~86483002:- LIHC cis rs12681287 0.711 rs28506490 ENSG00000250569.1 NTAN1P2 6.35 6.86e-10 5.25e-07 0.39 0.32 Caudate activity during reward; chr8:86233889 chr8:86481754~86483002:- LIHC cis rs12285276 0.536 rs4411261 ENSG00000205106.4 DKFZp779M0652 6.35 6.89e-10 5.27e-07 0.32 0.32 Visceral fat; chr11:45785530 chr11:45771432~45772358:+ LIHC cis rs4356975 0.697 rs5002700 ENSG00000249956.3 RP11-790I12.2 6.35 6.9e-10 5.28e-07 0.39 0.32 Obesity-related traits; chr4:69155637 chr4:69408836~69423164:+ LIHC cis rs2735413 0.599 rs79414963 ENSG00000276007.1 RP11-358L22.3 6.35 6.9e-10 5.28e-07 0.45 0.32 Systolic blood pressure (alcohol consumption interaction); chr16:78043132 chr16:78123243~78124332:+ LIHC cis rs1862618 0.853 rs6450408 ENSG00000271828.1 CTD-2310F14.1 6.35 6.91e-10 5.29e-07 0.46 0.32 Initial pursuit acceleration; chr5:56802319 chr5:56927874~56929573:+ LIHC cis rs1862618 0.802 rs4389648 ENSG00000271828.1 CTD-2310F14.1 6.35 6.91e-10 5.29e-07 0.46 0.32 Initial pursuit acceleration; chr5:56807775 chr5:56927874~56929573:+ LIHC cis rs7674212 0.507 rs223361 ENSG00000230069.3 LRRC37A15P -6.35 6.98e-10 5.33e-07 -0.32 -0.32 Type 2 diabetes; chr4:102848147 chr4:102727274~102730721:- LIHC cis rs1185460 0.934 rs10892328 ENSG00000271751.1 RP11-110I1.14 -6.35 6.99e-10 5.34e-07 -0.45 -0.32 Coronary artery disease; chr11:119071944 chr11:119065263~119065677:- LIHC cis rs1862618 0.853 rs252922 ENSG00000271828.1 CTD-2310F14.1 6.35 7.01e-10 5.35e-07 0.46 0.32 Initial pursuit acceleration; chr5:56840516 chr5:56927874~56929573:+ LIHC cis rs4356975 0.563 rs6600885 ENSG00000249956.3 RP11-790I12.2 6.35 7.01e-10 5.36e-07 0.36 0.32 Obesity-related traits; chr4:69103949 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs6600886 ENSG00000249956.3 RP11-790I12.2 6.35 7.01e-10 5.36e-07 0.36 0.32 Obesity-related traits; chr4:69104017 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs6600887 ENSG00000249956.3 RP11-790I12.2 6.35 7.01e-10 5.36e-07 0.36 0.32 Obesity-related traits; chr4:69104070 chr4:69408836~69423164:+ LIHC cis rs4356975 0.522 rs6600888 ENSG00000249956.3 RP11-790I12.2 6.35 7.01e-10 5.36e-07 0.36 0.32 Obesity-related traits; chr4:69104141 chr4:69408836~69423164:+ LIHC cis rs2153535 0.58 rs9406169 ENSG00000230939.1 RP11-314C16.1 -6.35 7.02e-10 5.36e-07 -0.38 -0.32 Motion sickness; chr6:8509237 chr6:8784178~8785445:+ LIHC cis rs9322193 0.923 rs4869750 ENSG00000268592.3 RAET1E-AS1 6.35 7.04e-10 5.38e-07 0.45 0.32 Lung cancer; chr6:149855996 chr6:149863494~149919507:+ LIHC cis rs8040855 0.579 rs6496797 ENSG00000259295.5 CSPG4P12 -6.35 7.05e-10 5.38e-07 -0.41 -0.32 Bulimia nervosa; chr15:85183624 chr15:85191438~85213905:+ LIHC cis rs916888 0.61 rs199452 ENSG00000214401.4 KANSL1-AS1 6.34 7.06e-10 5.39e-07 0.4 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:46193576~46196723:+ LIHC cis rs9640161 0.75 rs11538922 ENSG00000261305.1 RP4-584D14.7 6.34 7.07e-10 5.4e-07 0.42 0.32 Blood protein levels;Circulating chemerin levels; chr7:150338094 chr7:150341771~150342607:+ LIHC cis rs2836950 0.565 rs2836943 ENSG00000255568.3 BRWD1-AS2 -6.34 7.07e-10 5.4e-07 -0.27 -0.32 Menarche (age at onset); chr21:39220685 chr21:39313935~39314962:+ LIHC cis rs150992 0.632 rs326493 ENSG00000248489.1 CTD-2007H13.3 6.34 7.12e-10 5.43e-07 0.46 0.32 Body mass index; chr5:98966251 chr5:98929171~98995013:+ LIHC cis rs60065504 1 rs60065504 ENSG00000251022.5 THAP9-AS1 -6.34 7.13e-10 5.44e-07 -0.33 -0.32 Lymphocyte percentage of white cells; chr4:82964057 chr4:82893009~82900960:- LIHC cis rs1005277 0.691 rs2474558 ENSG00000263064.2 RP11-291L22.7 -6.34 7.15e-10 5.46e-07 -0.35 -0.32 Extrinsic epigenetic age acceleration; chr10:38197213 chr10:38448689~38448949:+ LIHC cis rs7916697 0.52 rs12265247 ENSG00000233590.1 RP11-153K11.3 -6.34 7.16e-10 5.47e-07 -0.41 -0.32 Optic disc area; chr10:68278641 chr10:68233251~68242379:- LIHC cis rs7429990 0.93 rs71323371 ENSG00000229759.1 MRPS18AP1 6.34 7.22e-10 5.51e-07 0.35 0.32 Educational attainment (years of education); chr3:47904327 chr3:48256350~48256938:- LIHC cis rs765787 0.53 rs28526629 ENSG00000259520.4 CTD-2651B20.3 6.34 7.23e-10 5.51e-07 0.38 0.32 Uric acid levels; chr15:45248264 chr15:45251580~45279251:- LIHC cis rs6860806 0.507 rs169256 ENSG00000233006.5 AC034220.3 6.34 7.25e-10 5.53e-07 0.38 0.32 Breast cancer; chr5:132352840 chr5:132311285~132369916:- LIHC cis rs2439831 0.85 rs16950562 ENSG00000205771.5 CATSPER2P1 -6.34 7.3e-10 5.57e-07 -0.49 -0.32 Lung cancer in ever smokers; chr15:43744166 chr15:43726918~43747094:- LIHC cis rs17270561 0.609 rs9379785 ENSG00000216436.2 HIST1H2APS1 -6.34 7.32e-10 5.58e-07 -0.39 -0.32 Iron status biomarkers; chr6:25725985 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9358871 ENSG00000216436.2 HIST1H2APS1 -6.34 7.32e-10 5.58e-07 -0.39 -0.32 Iron status biomarkers; chr6:25726447 chr6:25732497~25732827:+ LIHC cis rs55665837 0.502 rs4757269 ENSG00000251991.1 RNU7-49P 6.34 7.32e-10 5.58e-07 0.34 0.32 Vitamin D levels; chr11:14814646 chr11:14478892~14478953:+ LIHC cis rs9326248 0.53 rs7122944 ENSG00000280143.1 AP000892.6 6.34 7.33e-10 5.58e-07 0.41 0.32 Blood protein levels; chr11:117163903 chr11:117204967~117210292:+ LIHC cis rs2243480 1 rs4718317 ENSG00000273142.1 RP11-458F8.4 6.34 7.35e-10 5.6e-07 0.38 0.32 Diabetic kidney disease; chr7:66183914 chr7:66902857~66906297:+ LIHC cis rs2739330 0.753 rs4822452 ENSG00000099984.9 GSTT2 -6.34 7.36e-10 5.61e-07 -0.38 -0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23980123~23983911:+ LIHC cis rs7914558 1 rs1926030 ENSG00000236937.2 PTGES3P4 6.34 7.38e-10 5.62e-07 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103095899 chr10:102845595~102845950:+ LIHC cis rs2836950 0.52 rs1980407 ENSG00000255568.3 BRWD1-AS2 -6.34 7.39e-10 5.63e-07 -0.27 -0.32 Menarche (age at onset); chr21:39172035 chr21:39313935~39314962:+ LIHC cis rs2836950 0.565 rs2836931 ENSG00000255568.3 BRWD1-AS2 -6.34 7.39e-10 5.63e-07 -0.27 -0.32 Menarche (age at onset); chr21:39174643 chr21:39313935~39314962:+ LIHC cis rs1061377 0.748 rs6812316 ENSG00000249207.1 RP11-360F5.1 -6.34 7.41e-10 5.64e-07 -0.33 -0.32 Uric acid levels; chr4:39106617 chr4:39112677~39126818:- LIHC cis rs9399137 0.507 rs4520025 ENSG00000232876.1 CTA-212D2.2 -6.34 7.43e-10 5.66e-07 -0.37 -0.32 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134957481 chr6:135055033~135060550:+ LIHC cis rs7208859 0.615 rs216462 ENSG00000263531.1 RP13-753N3.1 -6.34 7.43e-10 5.66e-07 -0.59 -0.32 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30568879 chr17:30863921~30864940:- LIHC cis rs3020736 0.519 rs5996116 ENSG00000237037.8 NDUFA6-AS1 -6.34 7.47e-10 5.69e-07 -0.39 -0.32 Autism spectrum disorder or schizophrenia; chr22:42121488 chr22:42090931~42137742:+ LIHC cis rs2300206 1 rs2300206 ENSG00000276073.1 RP5-1125A11.7 -6.33 7.48e-10 5.69e-07 -0.37 -0.32 Cancer (pleiotropy);Cancer; chr20:34002002 chr20:33985617~33988989:- LIHC cis rs11672691 0.871 rs2191139 ENSG00000267107.5 PCAT19 6.33 7.48e-10 5.69e-07 0.38 0.32 Prostate cancer; chr19:41495302 chr19:41454169~41500649:- LIHC cis rs2243480 0.706 rs34466769 ENSG00000273142.1 RP11-458F8.4 -6.33 7.52e-10 5.72e-07 -0.36 -0.32 Diabetic kidney disease; chr7:65988305 chr7:66902857~66906297:+ LIHC cis rs10510102 0.872 rs10887032 ENSG00000276742.1 RP11-500G22.4 -6.33 7.56e-10 5.75e-07 -0.52 -0.32 Breast cancer; chr10:121955887 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs12246693 ENSG00000276742.1 RP11-500G22.4 6.33 7.56e-10 5.75e-07 0.52 0.32 Breast cancer; chr10:121957373 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs12248806 ENSG00000276742.1 RP11-500G22.4 6.33 7.56e-10 5.75e-07 0.52 0.32 Breast cancer; chr10:121958638 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs12255832 ENSG00000276742.1 RP11-500G22.4 6.33 7.56e-10 5.75e-07 0.52 0.32 Breast cancer; chr10:121958762 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs12247367 ENSG00000276742.1 RP11-500G22.4 6.33 7.56e-10 5.75e-07 0.52 0.32 Breast cancer; chr10:121961556 chr10:121956782~121957098:+ LIHC cis rs2243480 1 rs1618893 ENSG00000273142.1 RP11-458F8.4 -6.33 7.6e-10 5.78e-07 -0.37 -0.32 Diabetic kidney disease; chr7:66631132 chr7:66902857~66906297:+ LIHC cis rs10875746 0.768 rs12305182 ENSG00000240399.1 RP1-228P16.1 -6.33 7.63e-10 5.8e-07 -0.35 -0.32 Longevity (90 years and older); chr12:48027624 chr12:48054813~48055591:- LIHC cis rs1577917 1 rs2166663 ENSG00000234155.1 RP11-30P6.6 6.33 7.66e-10 5.82e-07 0.37 0.32 Response to antipsychotic treatment; chr6:85884178 chr6:85387219~85390186:- LIHC cis rs9322193 0.607 rs10457852 ENSG00000231760.4 RP11-350J20.5 6.33 7.67e-10 5.83e-07 0.43 0.32 Lung cancer; chr6:149880584 chr6:149796151~149826294:- LIHC cis rs7914558 1 rs7896547 ENSG00000236937.2 PTGES3P4 6.33 7.67e-10 5.83e-07 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103107201 chr10:102845595~102845950:+ LIHC cis rs875971 0.545 rs1796217 ENSG00000226824.5 RP4-756H11.3 6.33 7.68e-10 5.84e-07 0.41 0.32 Aortic root size; chr7:66620931 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs778730 ENSG00000273142.1 RP11-458F8.4 -6.33 7.69e-10 5.84e-07 -0.39 -0.32 Diabetic kidney disease; chr7:66358338 chr7:66902857~66906297:+ LIHC cis rs6921919 0.697 rs758398 ENSG00000216901.1 AL022393.7 6.33 7.7e-10 5.85e-07 0.37 0.32 Autism spectrum disorder or schizophrenia; chr6:28352897 chr6:28176188~28176674:+ LIHC cis rs7826238 0.566 rs2945886 ENSG00000253893.2 FAM85B -6.33 7.71e-10 5.86e-07 -0.38 -0.32 Systolic blood pressure; chr8:8290748 chr8:8167819~8226614:- LIHC cis rs55665837 0.524 rs2882128 ENSG00000251991.1 RNU7-49P 6.33 7.73e-10 5.87e-07 0.34 0.32 Vitamin D levels; chr11:14393088 chr11:14478892~14478953:+ LIHC cis rs916888 0.61 rs199530 ENSG00000214401.4 KANSL1-AS1 -6.33 7.74e-10 5.88e-07 -0.4 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:46193576~46196723:+ LIHC cis rs9341808 0.529 rs9350851 ENSG00000272129.1 RP11-250B2.6 6.33 7.78e-10 5.9e-07 0.33 0.32 Sitting height ratio; chr6:80349471 chr6:80355424~80356859:+ LIHC cis rs9341808 0.529 rs9352826 ENSG00000272129.1 RP11-250B2.6 6.33 7.78e-10 5.9e-07 0.33 0.32 Sitting height ratio; chr6:80349654 chr6:80355424~80356859:+ LIHC cis rs7916697 0.52 rs12246624 ENSG00000233590.1 RP11-153K11.3 -6.33 7.78e-10 5.91e-07 -0.41 -0.32 Optic disc area; chr10:68276805 chr10:68233251~68242379:- LIHC cis rs2243480 1 rs67728539 ENSG00000164669.11 INTS4P1 6.33 7.79e-10 5.91e-07 0.56 0.32 Diabetic kidney disease; chr7:65913137 chr7:65141225~65234216:+ LIHC cis rs3096299 0.967 rs2965935 ENSG00000274627.1 RP11-104N10.2 -6.33 7.79e-10 5.92e-07 -0.33 -0.32 Multiple myeloma (IgH translocation); chr16:89414866 chr16:89516797~89522217:+ LIHC cis rs7617773 0.638 rs7644414 ENSG00000229759.1 MRPS18AP1 6.33 7.8e-10 5.92e-07 0.39 0.32 Coronary artery disease; chr3:48257589 chr3:48256350~48256938:- LIHC cis rs7914558 0.933 rs2066323 ENSG00000236937.2 PTGES3P4 6.33 7.8e-10 5.92e-07 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103111604 chr10:102845595~102845950:+ LIHC cis rs7914558 1 rs7899084 ENSG00000236937.2 PTGES3P4 6.33 7.8e-10 5.92e-07 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103112790 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs10748837 ENSG00000236937.2 PTGES3P4 6.33 7.8e-10 5.92e-07 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103120479 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs12571568 ENSG00000236937.2 PTGES3P4 6.33 7.8e-10 5.92e-07 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103131639 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs12766205 ENSG00000236937.2 PTGES3P4 6.33 7.8e-10 5.92e-07 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103133811 chr10:102845595~102845950:+ LIHC cis rs7914558 1 rs10883837 ENSG00000236937.2 PTGES3P4 6.33 7.8e-10 5.92e-07 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103136729 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs746293 ENSG00000236937.2 PTGES3P4 6.33 7.8e-10 5.92e-07 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103137497 chr10:102845595~102845950:+ LIHC cis rs62355900 0.627 rs16886383 ENSG00000271828.1 CTD-2310F14.1 6.33 7.84e-10 5.94e-07 0.5 0.32 Endometriosis; chr5:56829869 chr5:56927874~56929573:+ LIHC cis rs7580658 0.613 rs12463538 ENSG00000236682.1 AC068282.3 -6.33 7.84e-10 5.95e-07 -0.4 -0.32 Protein C levels; chr2:127439278 chr2:127389130~127400580:+ LIHC cis rs9843304 0.568 rs71304473 ENSG00000244503.1 RP11-278L15.6 6.33 7.84e-10 5.95e-07 0.34 0.32 Gallstone disease; chr3:149499403 chr3:149494660~149495995:+ LIHC cis rs765787 0.53 rs28524974 ENSG00000259520.4 CTD-2651B20.3 6.33 7.91e-10 6e-07 0.38 0.32 Uric acid levels; chr15:45251330 chr15:45251580~45279251:- LIHC cis rs4718428 0.705 rs13220977 ENSG00000226824.5 RP4-756H11.3 6.32 7.93e-10 6.01e-07 0.43 0.32 Corneal structure; chr7:66872661 chr7:66654538~66669855:+ LIHC cis rs6479891 0.908 rs16918603 ENSG00000232075.1 MRPL35P2 6.32 7.96e-10 6.03e-07 0.39 0.32 Arthritis (juvenile idiopathic); chr10:63561712 chr10:63634317~63634827:- LIHC cis rs9389248 0.69 rs6569982 ENSG00000232876.1 CTA-212D2.2 -6.32 7.96e-10 6.03e-07 -0.38 -0.32 High light scatter reticulocyte percentage of red cells; chr6:134935357 chr6:135055033~135060550:+ LIHC cis rs7429990 0.932 rs7630685 ENSG00000229759.1 MRPS18AP1 -6.32 7.97e-10 6.04e-07 -0.36 -0.32 Educational attainment (years of education); chr3:48089680 chr3:48256350~48256938:- LIHC cis rs2735413 0.599 rs77209133 ENSG00000276007.1 RP11-358L22.3 6.32 7.97e-10 6.04e-07 0.45 0.32 Systolic blood pressure (alcohol consumption interaction); chr16:78042827 chr16:78123243~78124332:+ LIHC cis rs765787 0.53 rs11636395 ENSG00000259520.4 CTD-2651B20.3 6.32 8.05e-10 6.09e-07 0.38 0.32 Uric acid levels; chr15:45243486 chr15:45251580~45279251:- LIHC cis rs10875746 0.729 rs11168357 ENSG00000240399.1 RP1-228P16.1 -6.32 8.1e-10 6.13e-07 -0.35 -0.32 Longevity (90 years and older); chr12:48018355 chr12:48054813~48055591:- LIHC cis rs1003645 0.861 rs7222703 ENSG00000278690.1 RP11-104J23.2 6.32 8.11e-10 6.14e-07 0.41 0.32 Blood protein levels; chr17:36014155 chr17:36012504~36012891:+ LIHC cis rs1003645 0.906 rs8065543 ENSG00000278690.1 RP11-104J23.2 6.32 8.11e-10 6.14e-07 0.41 0.32 Blood protein levels; chr17:36014962 chr17:36012504~36012891:+ LIHC cis rs1862618 0.853 rs252921 ENSG00000271828.1 CTD-2310F14.1 6.32 8.11e-10 6.14e-07 0.46 0.32 Initial pursuit acceleration; chr5:56841960 chr5:56927874~56929573:+ LIHC cis rs523522 0.962 rs4766968 ENSG00000278344.1 RP11-18C24.8 6.32 8.12e-10 6.14e-07 0.39 0.32 High light scatter reticulocyte count; chr12:120509985 chr12:120500735~120501090:- LIHC cis rs3096299 0.838 rs3102376 ENSG00000274627.1 RP11-104N10.2 6.32 8.14e-10 6.16e-07 0.34 0.32 Multiple myeloma (IgH translocation); chr16:89336065 chr16:89516797~89522217:+ LIHC cis rs12439619 0.508 rs8032033 ENSG00000278603.1 RP13-608F4.5 6.32 8.22e-10 6.21e-07 0.42 0.32 Intelligence (multi-trait analysis); chr15:82165555 chr15:82472203~82472426:+ LIHC cis rs6142102 0.961 rs8119937 ENSG00000276073.1 RP5-1125A11.7 -6.32 8.31e-10 6.28e-07 -0.35 -0.32 Skin pigmentation; chr20:34057745 chr20:33985617~33988989:- LIHC cis rs2735413 0.564 rs4324138 ENSG00000276007.1 RP11-358L22.3 6.32 8.33e-10 6.29e-07 0.43 0.32 Systolic blood pressure (alcohol consumption interaction); chr16:78067475 chr16:78123243~78124332:+ LIHC cis rs1862618 0.853 rs10461617 ENSG00000271828.1 CTD-2310F14.1 6.32 8.33e-10 6.29e-07 0.46 0.32 Initial pursuit acceleration; chr5:56808481 chr5:56927874~56929573:+ LIHC cis rs523522 0.962 rs4767902 ENSG00000278344.1 RP11-18C24.8 6.32 8.38e-10 6.33e-07 0.39 0.32 High light scatter reticulocyte count; chr12:120472201 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs10849753 ENSG00000278344.1 RP11-18C24.8 6.32 8.38e-10 6.33e-07 0.39 0.32 High light scatter reticulocyte count; chr12:120473010 chr12:120500735~120501090:- LIHC cis rs17270561 0.609 rs9356984 ENSG00000216436.2 HIST1H2APS1 6.31 8.42e-10 6.35e-07 0.39 0.32 Iron status biomarkers; chr6:25725253 chr6:25732497~25732827:+ LIHC cis rs7104764 0.507 rs7111364 ENSG00000277290.1 RP11-326C3.16 -6.31 8.43e-10 6.36e-07 -0.38 -0.32 Menarche (age at onset); chr11:258542 chr11:243099~243483:- LIHC cis rs2243480 1 rs4718333 ENSG00000273142.1 RP11-458F8.4 6.31 8.48e-10 6.4e-07 0.39 0.32 Diabetic kidney disease; chr7:66307771 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs7792391 ENSG00000273142.1 RP11-458F8.4 6.31 8.48e-10 6.4e-07 0.39 0.32 Diabetic kidney disease; chr7:66308442 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs10247526 ENSG00000273142.1 RP11-458F8.4 6.31 8.48e-10 6.4e-07 0.39 0.32 Diabetic kidney disease; chr7:66315709 chr7:66902857~66906297:+ LIHC cis rs2243480 0.908 rs1532573 ENSG00000273142.1 RP11-458F8.4 6.31 8.48e-10 6.4e-07 0.39 0.32 Diabetic kidney disease; chr7:66333815 chr7:66902857~66906297:+ LIHC cis rs2439831 0.85 rs694985 ENSG00000205771.5 CATSPER2P1 -6.31 8.48e-10 6.4e-07 -0.43 -0.32 Lung cancer in ever smokers; chr15:43521189 chr15:43726918~43747094:- LIHC cis rs8100891 0.537 rs10410770 ENSG00000267213.4 AC007773.2 -6.31 8.5e-10 6.41e-07 -0.42 -0.32 Neuroticism; chr19:32411498 chr19:32390050~32405560:- LIHC cis rs9399135 0.527 rs61738492 ENSG00000232876.1 CTA-212D2.2 -6.31 8.55e-10 6.45e-07 -0.37 -0.32 Red blood cell count; chr6:134961633 chr6:135055033~135060550:+ LIHC cis rs10899021 1 rs11236190 ENSG00000279353.1 RP11-864N7.4 6.31 8.57e-10 6.46e-07 0.78 0.32 Response to metformin (IC50); chr11:74655710 chr11:74698231~74699658:- LIHC cis rs12681287 0.752 rs12675974 ENSG00000250569.1 NTAN1P2 6.31 8.59e-10 6.47e-07 0.39 0.32 Caudate activity during reward; chr8:86235616 chr8:86481754~86483002:- LIHC cis rs1862618 0.853 rs832568 ENSG00000271828.1 CTD-2310F14.1 6.31 8.59e-10 6.47e-07 0.46 0.32 Initial pursuit acceleration; chr5:56857949 chr5:56927874~56929573:+ LIHC cis rs1862618 0.853 rs832569 ENSG00000271828.1 CTD-2310F14.1 6.31 8.59e-10 6.47e-07 0.46 0.32 Initial pursuit acceleration; chr5:56858757 chr5:56927874~56929573:+ LIHC cis rs9326248 0.53 rs7123517 ENSG00000280143.1 AP000892.6 6.31 8.6e-10 6.48e-07 0.41 0.32 Blood protein levels; chr11:117157039 chr11:117204967~117210292:+ LIHC cis rs10510102 0.872 rs11200277 ENSG00000276742.1 RP11-500G22.4 6.31 8.62e-10 6.49e-07 0.52 0.32 Breast cancer; chr10:121944295 chr10:121956782~121957098:+ LIHC cis rs1023500 0.573 rs133370 ENSG00000237037.8 NDUFA6-AS1 6.31 8.65e-10 6.51e-07 0.39 0.32 Schizophrenia; chr22:42069256 chr22:42090931~42137742:+ LIHC cis rs1023500 0.573 rs1807494 ENSG00000237037.8 NDUFA6-AS1 -6.31 8.65e-10 6.51e-07 -0.39 -0.32 Schizophrenia; chr22:42078134 chr22:42090931~42137742:+ LIHC cis rs17270561 0.609 rs4712963 ENSG00000216436.2 HIST1H2APS1 -6.31 8.66e-10 6.52e-07 -0.4 -0.32 Iron status biomarkers; chr6:25740274 chr6:25732497~25732827:+ LIHC cis rs7429990 0.965 rs184388 ENSG00000229759.1 MRPS18AP1 6.31 8.68e-10 6.53e-07 0.35 0.32 Educational attainment (years of education); chr3:47898136 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs319696 ENSG00000229759.1 MRPS18AP1 6.31 8.68e-10 6.53e-07 0.35 0.32 Educational attainment (years of education); chr3:47902371 chr3:48256350~48256938:- LIHC cis rs7429990 0.932 rs34025851 ENSG00000229759.1 MRPS18AP1 6.31 8.68e-10 6.53e-07 0.35 0.32 Educational attainment (years of education); chr3:47912243 chr3:48256350~48256938:- LIHC cis rs4356975 0.563 rs7375178 ENSG00000249956.3 RP11-790I12.2 6.31 8.68e-10 6.53e-07 0.36 0.32 Obesity-related traits; chr4:69103961 chr4:69408836~69423164:+ LIHC cis rs8059260 0.544 rs35347079 ENSG00000274038.1 RP11-66H6.4 -6.31 8.7e-10 6.54e-07 -0.53 -0.32 Alcohol consumption over the past year; chr16:11099696 chr16:11056556~11057034:+ LIHC cis rs3858145 0.588 rs78041174 ENSG00000233590.1 RP11-153K11.3 -6.31 8.74e-10 6.57e-07 -0.43 -0.32 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68279014 chr10:68233251~68242379:- LIHC cis rs9326248 1 rs10790175 ENSG00000236267.1 AP006216.5 6.31 8.75e-10 6.57e-07 0.33 0.32 Blood protein levels; chr11:117164013 chr11:116813204~116814003:- LIHC cis rs150992 0.632 rs34489 ENSG00000248489.1 CTD-2007H13.3 -6.31 8.8e-10 6.61e-07 -0.46 -0.32 Body mass index; chr5:98977180 chr5:98929171~98995013:+ LIHC cis rs3020736 0.5 rs1801311 ENSG00000237037.8 NDUFA6-AS1 -6.31 8.82e-10 6.63e-07 -0.39 -0.32 Autism spectrum disorder or schizophrenia; chr22:42090719 chr22:42090931~42137742:+ LIHC cis rs9549367 0.789 rs9549698 ENSG00000269125.1 RP11-98F14.11 -6.31 8.83e-10 6.63e-07 -0.39 -0.32 Platelet distribution width; chr13:113223387 chr13:113165002~113165183:- LIHC cis rs853679 0.517 rs17711344 ENSG00000219392.1 RP1-265C24.5 6.31 8.84e-10 6.64e-07 0.49 0.32 Depression; chr6:28109824 chr6:28115628~28116551:+ LIHC cis rs1862618 0.853 rs43184 ENSG00000271828.1 CTD-2310F14.1 6.31 8.87e-10 6.66e-07 0.46 0.32 Initial pursuit acceleration; chr5:56845950 chr5:56927874~56929573:+ LIHC cis rs1862618 0.853 rs33326 ENSG00000271828.1 CTD-2310F14.1 6.31 8.87e-10 6.66e-07 0.46 0.32 Initial pursuit acceleration; chr5:56846774 chr5:56927874~56929573:+ LIHC cis rs1862618 0.802 rs33327 ENSG00000271828.1 CTD-2310F14.1 6.31 8.87e-10 6.66e-07 0.46 0.32 Initial pursuit acceleration; chr5:56846866 chr5:56927874~56929573:+ LIHC cis rs1862618 0.853 rs832565 ENSG00000271828.1 CTD-2310F14.1 6.31 8.87e-10 6.66e-07 0.46 0.32 Initial pursuit acceleration; chr5:56854976 chr5:56927874~56929573:+ LIHC cis rs2243480 1 rs2462569 ENSG00000164669.11 INTS4P1 -6.31 8.87e-10 6.66e-07 -0.55 -0.32 Diabetic kidney disease; chr7:66009859 chr7:65141225~65234216:+ LIHC cis rs55879323 1 rs55879323 ENSG00000237975.5 FLG-AS1 -6.3 8.93e-10 6.7e-07 -0.41 -0.32 Inflammatory skin disease; chr1:152196264 chr1:152168125~152445456:+ LIHC cis rs2243480 1 rs34136756 ENSG00000164669.11 INTS4P1 6.3 8.93e-10 6.7e-07 0.56 0.32 Diabetic kidney disease; chr7:65916269 chr7:65141225~65234216:+ LIHC cis rs2836950 0.501 rs11088470 ENSG00000255568.3 BRWD1-AS2 -6.3 8.97e-10 6.73e-07 -0.26 -0.32 Menarche (age at onset); chr21:39317236 chr21:39313935~39314962:+ LIHC cis rs2836950 0.501 rs2836983 ENSG00000255568.3 BRWD1-AS2 -6.3 8.97e-10 6.73e-07 -0.26 -0.32 Menarche (age at onset); chr21:39317410 chr21:39313935~39314962:+ LIHC cis rs2836950 0.52 rs8133927 ENSG00000255568.3 BRWD1-AS2 -6.3 8.97e-10 6.73e-07 -0.26 -0.32 Menarche (age at onset); chr21:39318035 chr21:39313935~39314962:+ LIHC cis rs2836950 0.52 rs8133928 ENSG00000255568.3 BRWD1-AS2 -6.3 8.97e-10 6.73e-07 -0.26 -0.32 Menarche (age at onset); chr21:39318037 chr21:39313935~39314962:+ LIHC cis rs113835537 0.597 rs4576 ENSG00000255517.5 CTD-3074O7.5 -6.3 9e-10 6.75e-07 -0.36 -0.32 Airway imaging phenotypes; chr11:66563529 chr11:66473490~66480233:- LIHC cis rs5758659 0.714 rs5751220 ENSG00000227370.1 RP4-669P10.19 6.3 9.02e-10 6.77e-07 0.37 0.32 Cognitive function; chr22:42120201 chr22:42132543~42132998:+ LIHC cis rs4660456 0.913 rs569159 ENSG00000237899.1 RP4-739H11.3 -6.3 9.04e-10 6.77e-07 -0.43 -0.32 Platelet count; chr1:40701862 chr1:40669089~40687588:- LIHC cis rs1061377 0.748 rs11096977 ENSG00000249207.1 RP11-360F5.1 -6.3 9.05e-10 6.78e-07 -0.33 -0.32 Uric acid levels; chr4:39106186 chr4:39112677~39126818:- LIHC cis rs1061377 0.748 rs6810770 ENSG00000249207.1 RP11-360F5.1 -6.3 9.05e-10 6.78e-07 -0.33 -0.32 Uric acid levels; chr4:39106545 chr4:39112677~39126818:- LIHC cis rs7617773 0.779 rs11718329 ENSG00000229759.1 MRPS18AP1 6.3 9.09e-10 6.81e-07 0.39 0.32 Coronary artery disease; chr3:48268338 chr3:48256350~48256938:- LIHC cis rs10510102 0.872 rs12248004 ENSG00000276742.1 RP11-500G22.4 6.3 9.1e-10 6.82e-07 0.56 0.32 Breast cancer; chr10:121972215 chr10:121956782~121957098:+ LIHC cis rs55665837 0.519 rs1451677 ENSG00000251991.1 RNU7-49P 6.3 9.11e-10 6.82e-07 0.35 0.32 Vitamin D levels; chr11:14724466 chr11:14478892~14478953:+ LIHC cis rs2455601 1 rs12418190 ENSG00000254860.4 TMEM9B-AS1 6.3 9.11e-10 6.82e-07 0.41 0.32 Schizophrenia; chr11:8878271 chr11:8964675~8977527:+ LIHC cis rs2455601 1 rs12223690 ENSG00000254860.4 TMEM9B-AS1 6.3 9.11e-10 6.82e-07 0.41 0.32 Schizophrenia; chr11:8880277 chr11:8964675~8977527:+ LIHC cis rs2455601 1 rs7104661 ENSG00000254860.4 TMEM9B-AS1 6.3 9.11e-10 6.82e-07 0.41 0.32 Schizophrenia; chr11:8880954 chr11:8964675~8977527:+ LIHC cis rs10510102 0.872 rs7916008 ENSG00000276742.1 RP11-500G22.4 6.3 9.13e-10 6.83e-07 0.52 0.32 Breast cancer; chr10:121943578 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs7916380 ENSG00000276742.1 RP11-500G22.4 6.3 9.13e-10 6.83e-07 0.52 0.32 Breast cancer; chr10:121943773 chr10:121956782~121957098:+ LIHC cis rs10510102 0.808 rs7920024 ENSG00000276742.1 RP11-500G22.4 6.3 9.13e-10 6.83e-07 0.52 0.32 Breast cancer; chr10:121944063 chr10:121956782~121957098:+ LIHC cis rs523522 0.962 rs4767914 ENSG00000278344.1 RP11-18C24.8 6.3 9.16e-10 6.86e-07 0.39 0.32 High light scatter reticulocyte count; chr12:120556014 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs10849759 ENSG00000278344.1 RP11-18C24.8 6.3 9.16e-10 6.86e-07 0.39 0.32 High light scatter reticulocyte count; chr12:120556685 chr12:120500735~120501090:- LIHC cis rs585510 1 rs585510 ENSG00000278344.1 RP11-18C24.8 6.3 9.16e-10 6.86e-07 0.39 0.32 Reticulocyte fraction of red cells; chr12:120562330 chr12:120500735~120501090:- LIHC cis rs1020064 0.636 rs2679883 ENSG00000235319.1 AC012360.4 -6.3 9.17e-10 6.86e-07 -0.41 -0.32 AIDS; chr2:105333211 chr2:105324210~105330529:+ LIHC cis rs1020064 0.583 rs2576775 ENSG00000235319.1 AC012360.4 -6.3 9.17e-10 6.86e-07 -0.42 -0.32 AIDS; chr2:105356755 chr2:105324210~105330529:+ LIHC cis rs5758659 0.714 rs7245 ENSG00000227370.1 RP4-669P10.19 6.3 9.19e-10 6.87e-07 0.38 0.32 Cognitive function; chr22:42085845 chr22:42132543~42132998:+ LIHC cis rs13068223 0.584 rs344018 ENSG00000243926.1 TIPARP-AS1 -6.3 9.19e-10 6.88e-07 -0.36 -0.32 Age-related hearing impairment (SNP x SNP interaction); chr3:156698204 chr3:156671862~156674378:- LIHC cis rs1185460 0.904 rs1003081 ENSG00000271751.1 RP11-110I1.14 6.3 9.23e-10 6.91e-07 0.4 0.32 Coronary artery disease; chr11:119043282 chr11:119065263~119065677:- LIHC cis rs6504950 0.886 rs2787500 ENSG00000275710.1 RP11-257O5.4 -6.3 9.24e-10 6.91e-07 -0.39 -0.32 Breast cancer; chr17:55092445 chr17:54964474~54964679:+ LIHC cis rs6504950 0.924 rs187242 ENSG00000275710.1 RP11-257O5.4 6.3 9.27e-10 6.93e-07 0.39 0.32 Breast cancer; chr17:55115585 chr17:54964474~54964679:+ LIHC cis rs6504950 0.732 rs244373 ENSG00000275710.1 RP11-257O5.4 -6.3 9.27e-10 6.93e-07 -0.39 -0.32 Breast cancer; chr17:55107588 chr17:54964474~54964679:+ LIHC cis rs9549367 0.789 rs2287253 ENSG00000269125.1 RP11-98F14.11 6.3 9.37e-10 7.01e-07 0.39 0.32 Platelet distribution width; chr13:113236761 chr13:113165002~113165183:- LIHC cis rs3020736 0.5 rs8138678 ENSG00000237037.8 NDUFA6-AS1 -6.3 9.41e-10 7.04e-07 -0.39 -0.32 Autism spectrum disorder or schizophrenia; chr22:42120225 chr22:42090931~42137742:+ LIHC cis rs150992 0.632 rs162341 ENSG00000248489.1 CTD-2007H13.3 6.29 9.46e-10 7.07e-07 0.46 0.32 Body mass index; chr5:98967230 chr5:98929171~98995013:+ LIHC cis rs12439619 0.693 rs28665836 ENSG00000278603.1 RP13-608F4.5 6.29 9.56e-10 7.14e-07 0.42 0.32 Intelligence (multi-trait analysis); chr15:82218955 chr15:82472203~82472426:+ LIHC cis rs7617773 0.817 rs9819094 ENSG00000229759.1 MRPS18AP1 6.29 9.57e-10 7.15e-07 0.37 0.32 Coronary artery disease; chr3:48278068 chr3:48256350~48256938:- LIHC cis rs9843304 0.568 rs11720325 ENSG00000244503.1 RP11-278L15.6 6.29 9.65e-10 7.2e-07 0.34 0.32 Gallstone disease; chr3:149498524 chr3:149494660~149495995:+ LIHC cis rs1729407 0.695 rs1263176 ENSG00000254851.1 RP11-109L13.1 -6.29 9.72e-10 7.26e-07 -0.38 -0.32 Apolipoprotein A-IV levels; chr11:116819407 chr11:117135528~117138582:+ LIHC cis rs5758659 1 rs134900 ENSG00000227370.1 RP4-669P10.19 -6.29 9.76e-10 7.28e-07 -0.36 -0.32 Cognitive function; chr22:42287337 chr22:42132543~42132998:+ LIHC cis rs3858145 0.588 rs61854833 ENSG00000233590.1 RP11-153K11.3 -6.29 9.81e-10 7.31e-07 -0.43 -0.32 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68277570 chr10:68233251~68242379:- LIHC cis rs3020736 0.5 rs2413669 ENSG00000237037.8 NDUFA6-AS1 -6.29 9.84e-10 7.34e-07 -0.39 -0.32 Autism spectrum disorder or schizophrenia; chr22:42111744 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs6002618 ENSG00000237037.8 NDUFA6-AS1 -6.29 9.84e-10 7.34e-07 -0.39 -0.32 Autism spectrum disorder or schizophrenia; chr22:42111855 chr22:42090931~42137742:+ LIHC cis rs1023500 0.551 rs61665536 ENSG00000237037.8 NDUFA6-AS1 -6.29 9.84e-10 7.34e-07 -0.39 -0.32 Schizophrenia; chr22:42116609 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs2413672 ENSG00000237037.8 NDUFA6-AS1 -6.29 9.84e-10 7.34e-07 -0.39 -0.32 Autism spectrum disorder or schizophrenia; chr22:42117257 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs6002623 ENSG00000237037.8 NDUFA6-AS1 -6.29 9.84e-10 7.34e-07 -0.39 -0.32 Autism spectrum disorder or schizophrenia; chr22:42117757 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs764481 ENSG00000237037.8 NDUFA6-AS1 -6.29 9.84e-10 7.34e-07 -0.39 -0.32 Autism spectrum disorder or schizophrenia; chr22:42122422 chr22:42090931~42137742:+ LIHC cis rs9527 0.614 rs4919691 ENSG00000236937.2 PTGES3P4 6.29 9.89e-10 7.37e-07 0.39 0.32 Arsenic metabolism; chr10:102864718 chr10:102845595~102845950:+ LIHC cis rs10875746 0.729 rs11168355 ENSG00000240399.1 RP1-228P16.1 6.29 9.91e-10 7.38e-07 0.34 0.32 Longevity (90 years and older); chr12:48017195 chr12:48054813~48055591:- LIHC cis rs6504950 0.924 rs244342 ENSG00000275710.1 RP11-257O5.4 6.29 9.91e-10 7.38e-07 0.39 0.32 Breast cancer; chr17:55121046 chr17:54964474~54964679:+ LIHC cis rs12681287 0.752 rs4641037 ENSG00000250569.1 NTAN1P2 6.29 9.93e-10 7.4e-07 0.38 0.32 Caudate activity during reward; chr8:86256150 chr8:86481754~86483002:- LIHC cis rs7674212 0.581 rs10516496 ENSG00000230069.3 LRRC37A15P -6.28 1e-09 7.45e-07 -0.3 -0.32 Type 2 diabetes; chr4:103021008 chr4:102727274~102730721:- LIHC cis rs7429990 0.965 rs34750113 ENSG00000229759.1 MRPS18AP1 6.28 1e-09 7.45e-07 0.36 0.32 Educational attainment (years of education); chr3:47944902 chr3:48256350~48256938:- LIHC cis rs5758659 0.714 rs5758589 ENSG00000227370.1 RP4-669P10.19 6.28 1.01e-09 7.52e-07 0.36 0.32 Cognitive function; chr22:42122378 chr22:42132543~42132998:+ LIHC cis rs4356975 0.563 rs7698846 ENSG00000249956.3 RP11-790I12.2 6.28 1.01e-09 7.52e-07 0.36 0.32 Obesity-related traits; chr4:69106278 chr4:69408836~69423164:+ LIHC cis rs2836950 0.501 rs4818018 ENSG00000255568.3 BRWD1-AS2 -6.28 1.02e-09 7.57e-07 -0.26 -0.32 Menarche (age at onset); chr21:39322146 chr21:39313935~39314962:+ LIHC cis rs2836950 0.501 rs4818019 ENSG00000255568.3 BRWD1-AS2 -6.28 1.02e-09 7.57e-07 -0.26 -0.32 Menarche (age at onset); chr21:39322530 chr21:39313935~39314962:+ LIHC cis rs12439619 0.53 rs28883606 ENSG00000278603.1 RP13-608F4.5 6.28 1.02e-09 7.57e-07 0.42 0.32 Intelligence (multi-trait analysis); chr15:82216713 chr15:82472203~82472426:+ LIHC cis rs35160687 0.862 rs17737955 ENSG00000273080.1 RP11-301O19.1 6.28 1.02e-09 7.6e-07 0.43 0.32 Night sleep phenotypes; chr2:86280891 chr2:86195590~86196049:+ LIHC cis rs55665837 0.54 rs10766192 ENSG00000251991.1 RNU7-49P 6.28 1.03e-09 7.62e-07 0.34 0.32 Vitamin D levels; chr11:14790140 chr11:14478892~14478953:+ LIHC cis rs2933343 0.621 rs4927921 ENSG00000231305.3 RP11-723O4.2 -6.28 1.03e-09 7.64e-07 -0.35 -0.32 IgG glycosylation; chr3:128850025 chr3:128861313~128871540:- LIHC cis rs7429990 0.965 rs4858887 ENSG00000229759.1 MRPS18AP1 -6.28 1.03e-09 7.64e-07 -0.36 -0.32 Educational attainment (years of education); chr3:48050527 chr3:48256350~48256938:- LIHC cis rs9399137 0.507 rs61738647 ENSG00000232876.1 CTA-212D2.2 -6.28 1.03e-09 7.66e-07 -0.37 -0.32 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134961597 chr6:135055033~135060550:+ LIHC cis rs4814920 0.818 rs4813376 ENSG00000275142.1 RP5-999L4.2 6.28 1.03e-09 7.68e-07 0.6 0.32 Bipolar disorder (body mass index interaction); chr20:19870811 chr20:19871891~19872284:+ LIHC cis rs7617773 0.78 rs3731550 ENSG00000229759.1 MRPS18AP1 6.28 1.04e-09 7.69e-07 0.4 0.32 Coronary artery disease; chr3:48165093 chr3:48256350~48256938:- LIHC cis rs55665837 0.54 rs1007392 ENSG00000251991.1 RNU7-49P 6.28 1.04e-09 7.72e-07 0.34 0.32 Vitamin D levels; chr11:14753045 chr11:14478892~14478953:+ LIHC cis rs10916248 0.559 rs116083281 ENSG00000232628.4 RP11-365O16.3 6.28 1.04e-09 7.72e-07 0.45 0.32 QT interval (drug interaction); chr1:224199365 chr1:224208747~224213279:- LIHC cis rs853679 0.517 rs9380047 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28070115 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs7755442 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28071237 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs12174753 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28074687 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs55747925 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28076559 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs56310871 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28076704 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs34716816 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28078391 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9380049 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28080757 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9380050 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28080760 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9393885 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28082231 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9393886 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28082261 chr6:28115628~28116551:+ LIHC cis rs4713118 0.515 rs9368549 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Parkinson's disease; chr6:28082269 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs56364346 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28082984 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9357061 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28083994 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9368550 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28084025 chr6:28115628~28116551:+ LIHC cis rs853679 0.542 rs2295594 ENSG00000219392.1 RP1-265C24.5 -6.28 1.04e-09 7.72e-07 -0.49 -0.32 Depression; chr6:28085319 chr6:28115628~28116551:+ LIHC cis rs2243480 1 rs466983 ENSG00000164669.11 INTS4P1 6.28 1.05e-09 7.75e-07 0.55 0.32 Diabetic kidney disease; chr7:66055509 chr7:65141225~65234216:+ LIHC cis rs17270561 0.609 rs9358883 ENSG00000216436.2 HIST1H2APS1 -6.28 1.05e-09 7.75e-07 -0.39 -0.32 Iron status biomarkers; chr6:25755287 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs1937132 ENSG00000216436.2 HIST1H2APS1 -6.28 1.05e-09 7.75e-07 -0.39 -0.32 Iron status biomarkers; chr6:25756789 chr6:25732497~25732827:+ LIHC cis rs2243480 1 rs34702770 ENSG00000164669.11 INTS4P1 6.28 1.05e-09 7.75e-07 0.56 0.32 Diabetic kidney disease; chr7:65879836 chr7:65141225~65234216:+ LIHC cis rs2243480 0.803 rs35480979 ENSG00000164669.11 INTS4P1 6.28 1.05e-09 7.75e-07 0.56 0.32 Diabetic kidney disease; chr7:65892097 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs34637256 ENSG00000164669.11 INTS4P1 6.28 1.05e-09 7.75e-07 0.56 0.32 Diabetic kidney disease; chr7:65895144 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs35391607 ENSG00000164669.11 INTS4P1 6.28 1.05e-09 7.75e-07 0.56 0.32 Diabetic kidney disease; chr7:65895842 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs13220979 ENSG00000164669.11 INTS4P1 6.28 1.05e-09 7.75e-07 0.56 0.32 Diabetic kidney disease; chr7:65898217 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs34974928 ENSG00000164669.11 INTS4P1 6.28 1.05e-09 7.75e-07 0.56 0.32 Diabetic kidney disease; chr7:65899019 chr7:65141225~65234216:+ LIHC cis rs10875746 0.859 rs11558768 ENSG00000240399.1 RP1-228P16.1 -6.28 1.05e-09 7.76e-07 -0.36 -0.32 Longevity (90 years and older); chr12:48184006 chr12:48054813~48055591:- LIHC cis rs9843304 0.616 rs67576825 ENSG00000244503.1 RP11-278L15.6 6.28 1.05e-09 7.8e-07 0.34 0.32 Gallstone disease; chr3:149484896 chr3:149494660~149495995:+ LIHC cis rs9549367 0.789 rs34568744 ENSG00000269125.1 RP11-98F14.11 -6.28 1.06e-09 7.82e-07 -0.39 -0.32 Platelet distribution width; chr13:113240250 chr13:113165002~113165183:- LIHC cis rs853679 0.517 rs4713145 ENSG00000219392.1 RP1-265C24.5 -6.27 1.06e-09 7.82e-07 -0.5 -0.32 Depression; chr6:28139049 chr6:28115628~28116551:+ LIHC cis rs4423214 0.592 rs11233933 ENSG00000254682.1 RP11-660L16.2 -6.27 1.06e-09 7.82e-07 -0.45 -0.32 Vitamin D levels; chr11:71499024 chr11:71448674~71452157:+ LIHC cis rs12439619 0.53 rs7162177 ENSG00000278603.1 RP13-608F4.5 6.27 1.06e-09 7.83e-07 0.41 0.32 Intelligence (multi-trait analysis); chr15:82181728 chr15:82472203~82472426:+ LIHC cis rs3829251 0.786 rs7103591 ENSG00000254682.1 RP11-660L16.2 -6.27 1.06e-09 7.85e-07 -0.44 -0.32 Vitamin D levels; chr11:71526573 chr11:71448674~71452157:+ LIHC cis rs1862618 0.853 rs33325 ENSG00000271828.1 CTD-2310F14.1 6.27 1.07e-09 7.87e-07 0.45 0.32 Initial pursuit acceleration; chr5:56846720 chr5:56927874~56929573:+ LIHC cis rs1862618 0.802 rs42769 ENSG00000271828.1 CTD-2310F14.1 6.27 1.07e-09 7.87e-07 0.45 0.32 Initial pursuit acceleration; chr5:56848325 chr5:56927874~56929573:+ LIHC cis rs9549367 0.789 rs3850451 ENSG00000269125.1 RP11-98F14.11 -6.27 1.07e-09 7.9e-07 -0.4 -0.32 Platelet distribution width; chr13:113251498 chr13:113165002~113165183:- LIHC cis rs2243480 1 rs10807702 ENSG00000273142.1 RP11-458F8.4 -6.27 1.07e-09 7.9e-07 -0.39 -0.32 Diabetic kidney disease; chr7:66302856 chr7:66902857~66906297:+ LIHC cis rs10875746 1 rs10875746 ENSG00000240399.1 RP1-228P16.1 -6.27 1.07e-09 7.92e-07 -0.34 -0.32 Longevity (90 years and older); chr12:48124481 chr12:48054813~48055591:- LIHC cis rs6142102 0.961 rs6059587 ENSG00000276073.1 RP5-1125A11.7 -6.27 1.07e-09 7.93e-07 -0.36 -0.32 Skin pigmentation; chr20:33955120 chr20:33985617~33988989:- LIHC cis rs2836950 0.545 rs11701805 ENSG00000255568.3 BRWD1-AS2 -6.27 1.08e-09 7.94e-07 -0.27 -0.32 Menarche (age at onset); chr21:39246757 chr21:39313935~39314962:+ LIHC cis rs55665837 0.54 rs4757261 ENSG00000251991.1 RNU7-49P 6.27 1.08e-09 7.95e-07 0.34 0.32 Vitamin D levels; chr11:14648256 chr11:14478892~14478953:+ LIHC cis rs55665837 0.54 rs11023302 ENSG00000251991.1 RNU7-49P 6.27 1.08e-09 7.95e-07 0.34 0.32 Vitamin D levels; chr11:14672389 chr11:14478892~14478953:+ LIHC cis rs55665837 0.54 rs10128681 ENSG00000251991.1 RNU7-49P 6.27 1.08e-09 7.95e-07 0.34 0.32 Vitamin D levels; chr11:14680030 chr11:14478892~14478953:+ LIHC cis rs55665837 0.52 rs10766189 ENSG00000251991.1 RNU7-49P 6.27 1.08e-09 7.95e-07 0.34 0.32 Vitamin D levels; chr11:14712377 chr11:14478892~14478953:+ LIHC cis rs6504950 0.886 rs2787501 ENSG00000275710.1 RP11-257O5.4 6.27 1.08e-09 7.96e-07 0.38 0.32 Breast cancer; chr17:55016604 chr17:54964474~54964679:+ LIHC cis rs4356975 0.563 rs6600891 ENSG00000249956.3 RP11-790I12.2 6.27 1.09e-09 8.02e-07 0.36 0.32 Obesity-related traits; chr4:69105878 chr4:69408836~69423164:+ LIHC cis rs4356975 0.522 rs7693957 ENSG00000249956.3 RP11-790I12.2 6.27 1.09e-09 8.02e-07 0.36 0.32 Obesity-related traits; chr4:69106078 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs12513195 ENSG00000249956.3 RP11-790I12.2 6.27 1.09e-09 8.02e-07 0.36 0.32 Obesity-related traits; chr4:69106368 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4541594 ENSG00000249956.3 RP11-790I12.2 6.27 1.09e-09 8.02e-07 0.36 0.32 Obesity-related traits; chr4:69106554 chr4:69408836~69423164:+ LIHC cis rs4356975 0.583 rs4351080 ENSG00000249956.3 RP11-790I12.2 6.27 1.09e-09 8.02e-07 0.36 0.32 Obesity-related traits; chr4:69106601 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs5013211 ENSG00000249956.3 RP11-790I12.2 6.27 1.09e-09 8.02e-07 0.36 0.32 Obesity-related traits; chr4:69107059 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4292394 ENSG00000249956.3 RP11-790I12.2 6.27 1.09e-09 8.02e-07 0.36 0.32 Obesity-related traits; chr4:69107231 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4337789 ENSG00000249956.3 RP11-790I12.2 6.27 1.09e-09 8.02e-07 0.36 0.32 Obesity-related traits; chr4:69107326 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4521414 ENSG00000249956.3 RP11-790I12.2 6.27 1.09e-09 8.02e-07 0.36 0.32 Obesity-related traits; chr4:69107807 chr4:69408836~69423164:+ LIHC cis rs17270561 0.609 rs7754733 ENSG00000216436.2 HIST1H2APS1 -6.27 1.09e-09 8.04e-07 -0.39 -0.32 Iron status biomarkers; chr6:25744821 chr6:25732497~25732827:+ LIHC cis rs17270561 0.636 rs7754814 ENSG00000216436.2 HIST1H2APS1 -6.27 1.09e-09 8.04e-07 -0.39 -0.32 Iron status biomarkers; chr6:25745015 chr6:25732497~25732827:+ LIHC cis rs17270561 0.636 rs7775354 ENSG00000216436.2 HIST1H2APS1 -6.27 1.09e-09 8.04e-07 -0.39 -0.32 Iron status biomarkers; chr6:25745038 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9379789 ENSG00000216436.2 HIST1H2APS1 -6.27 1.09e-09 8.04e-07 -0.39 -0.32 Iron status biomarkers; chr6:25745351 chr6:25732497~25732827:+ LIHC cis rs1577917 0.771 rs12205013 ENSG00000234155.1 RP11-30P6.6 6.27 1.09e-09 8.07e-07 0.41 0.32 Response to antipsychotic treatment; chr6:85623311 chr6:85387219~85390186:- LIHC cis rs8040855 0.599 rs4643289 ENSG00000259295.5 CSPG4P12 -6.27 1.09e-09 8.07e-07 -0.4 -0.32 Bulimia nervosa; chr15:85183483 chr15:85191438~85213905:+ LIHC cis rs4356975 0.563 rs4314345 ENSG00000249956.3 RP11-790I12.2 6.27 1.1e-09 8.07e-07 0.36 0.32 Obesity-related traits; chr4:69107922 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4588522 ENSG00000249956.3 RP11-790I12.2 6.27 1.1e-09 8.07e-07 0.36 0.32 Obesity-related traits; chr4:69107949 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4364327 ENSG00000249956.3 RP11-790I12.2 6.27 1.1e-09 8.07e-07 0.36 0.32 Obesity-related traits; chr4:69107974 chr4:69408836~69423164:+ LIHC cis rs2274273 0.87 rs61210954 ENSG00000258413.1 RP11-665C16.6 -6.27 1.1e-09 8.07e-07 -0.37 -0.32 Protein biomarker; chr14:55298684 chr14:55262767~55272075:- LIHC cis rs9341808 0.529 rs4706840 ENSG00000272129.1 RP11-250B2.6 6.27 1.1e-09 8.07e-07 0.33 0.32 Sitting height ratio; chr6:80348052 chr6:80355424~80356859:+ LIHC cis rs7429990 0.965 rs1550914 ENSG00000229759.1 MRPS18AP1 6.27 1.1e-09 8.08e-07 0.34 0.32 Educational attainment (years of education); chr3:47953678 chr3:48256350~48256938:- LIHC cis rs113835537 0.529 rs11227509 ENSG00000255517.5 CTD-3074O7.5 -6.27 1.1e-09 8.09e-07 -0.35 -0.32 Airway imaging phenotypes; chr11:66513723 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs11227510 ENSG00000255517.5 CTD-3074O7.5 -6.27 1.1e-09 8.09e-07 -0.35 -0.32 Airway imaging phenotypes; chr11:66513749 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs11227512 ENSG00000255517.5 CTD-3074O7.5 -6.27 1.1e-09 8.09e-07 -0.35 -0.32 Airway imaging phenotypes; chr11:66513820 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs2298806 ENSG00000255517.5 CTD-3074O7.5 -6.27 1.1e-09 8.09e-07 -0.35 -0.32 Airway imaging phenotypes; chr11:66514624 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs2276406 ENSG00000255517.5 CTD-3074O7.5 -6.27 1.1e-09 8.09e-07 -0.35 -0.32 Airway imaging phenotypes; chr11:66515786 chr11:66473490~66480233:- LIHC cis rs1185460 0.804 rs13929 ENSG00000271751.1 RP11-110I1.14 -6.27 1.1e-09 8.1e-07 -0.41 -0.32 Coronary artery disease; chr11:119045044 chr11:119065263~119065677:- LIHC cis rs9487094 0.666 rs9480958 ENSG00000260273.1 RP11-425D10.10 -6.27 1.1e-09 8.11e-07 -0.37 -0.32 Height; chr6:109432968 chr6:109382795~109383666:+ LIHC cis rs3096299 0.869 rs748941 ENSG00000274627.1 RP11-104N10.2 6.27 1.1e-09 8.11e-07 0.33 0.32 Multiple myeloma (IgH translocation); chr16:89374346 chr16:89516797~89522217:+ LIHC cis rs3096299 0.748 rs3102339 ENSG00000274627.1 RP11-104N10.2 6.27 1.1e-09 8.13e-07 0.34 0.32 Multiple myeloma (IgH translocation); chr16:89376303 chr16:89516797~89522217:+ LIHC cis rs8100891 0.537 rs738093 ENSG00000267213.4 AC007773.2 -6.27 1.12e-09 8.24e-07 -0.41 -0.32 Neuroticism; chr19:32439601 chr19:32390050~32405560:- LIHC cis rs17270561 0.609 rs4711094 ENSG00000216436.2 HIST1H2APS1 -6.26 1.12e-09 8.25e-07 -0.41 -0.32 Iron status biomarkers; chr6:25705946 chr6:25732497~25732827:+ LIHC cis rs12681287 0.64 rs7833049 ENSG00000250569.1 NTAN1P2 -6.26 1.12e-09 8.25e-07 -0.37 -0.32 Caudate activity during reward; chr8:86433669 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs13253296 ENSG00000250569.1 NTAN1P2 6.26 1.12e-09 8.25e-07 0.37 0.32 Caudate activity during reward; chr8:86436016 chr8:86481754~86483002:- LIHC cis rs12681287 0.604 rs34227066 ENSG00000250569.1 NTAN1P2 6.26 1.12e-09 8.25e-07 0.37 0.32 Caudate activity during reward; chr8:86437137 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs34794500 ENSG00000250569.1 NTAN1P2 6.26 1.12e-09 8.25e-07 0.37 0.32 Caudate activity during reward; chr8:86437766 chr8:86481754~86483002:- LIHC cis rs10461617 0.592 rs6450403 ENSG00000271828.1 CTD-2310F14.1 6.26 1.12e-09 8.26e-07 0.43 0.32 Type 2 diabetes; chr5:56766910 chr5:56927874~56929573:+ LIHC cis rs523522 0.962 rs4766966 ENSG00000278344.1 RP11-18C24.8 6.26 1.13e-09 8.28e-07 0.38 0.32 High light scatter reticulocyte count; chr12:120505108 chr12:120500735~120501090:- LIHC cis rs17270561 0.609 rs6941933 ENSG00000216436.2 HIST1H2APS1 -6.26 1.13e-09 8.33e-07 -0.39 -0.32 Iron status biomarkers; chr6:25745474 chr6:25732497~25732827:+ LIHC cis rs62355901 0.545 rs58774999 ENSG00000271828.1 CTD-2310F14.1 6.26 1.13e-09 8.33e-07 0.5 0.32 Breast cancer; chr5:56798018 chr5:56927874~56929573:+ LIHC cis rs62355901 0.545 rs62355938 ENSG00000271828.1 CTD-2310F14.1 6.26 1.13e-09 8.33e-07 0.5 0.32 Breast cancer; chr5:56798887 chr5:56927874~56929573:+ LIHC cis rs2836950 0.565 rs2836930 ENSG00000255568.3 BRWD1-AS2 -6.26 1.14e-09 8.36e-07 -0.27 -0.32 Menarche (age at onset); chr21:39173730 chr21:39313935~39314962:+ LIHC cis rs9543976 0.614 rs73223948 ENSG00000261553.4 RP11-29G8.3 -6.26 1.14e-09 8.37e-07 -0.52 -0.32 Diabetic retinopathy; chr13:75523889 chr13:75549773~75807120:+ LIHC cis rs10461617 0.531 rs2662033 ENSG00000271828.1 CTD-2310F14.1 6.26 1.14e-09 8.4e-07 0.47 0.32 Type 2 diabetes; chr5:56917583 chr5:56927874~56929573:+ LIHC cis rs853679 0.517 rs3757187 ENSG00000219392.1 RP1-265C24.5 -6.26 1.15e-09 8.43e-07 -0.5 -0.32 Depression; chr6:28139876 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs3757185 ENSG00000219392.1 RP1-265C24.5 -6.26 1.15e-09 8.43e-07 -0.5 -0.32 Depression; chr6:28139998 chr6:28115628~28116551:+ LIHC cis rs7104764 0.507 rs7121085 ENSG00000277290.1 RP11-326C3.16 -6.26 1.15e-09 8.45e-07 -0.38 -0.32 Menarche (age at onset); chr11:258523 chr11:243099~243483:- LIHC cis rs17270561 0.609 rs9366629 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25740988 chr6:25732497~25732827:+ LIHC cis rs17270561 0.553 rs6456696 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25741180 chr6:25732497~25732827:+ LIHC cis rs17270561 0.636 rs6456697 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25741206 chr6:25732497~25732827:+ LIHC cis rs17270561 0.636 rs6456698 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25741436 chr6:25732497~25732827:+ LIHC cis rs17270561 0.666 rs4711099 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25741581 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4711100 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25741726 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4711101 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25741742 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4712965 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25741794 chr6:25732497~25732827:+ LIHC cis rs17270561 0.608 rs4711102 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25741847 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4711103 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25741996 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9379788 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25742531 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9358879 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25742690 chr6:25732497~25732827:+ LIHC cis rs17270561 0.636 rs9358880 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25742933 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4145216 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25743331 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs4145217 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25743769 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs9393665 ENSG00000216436.2 HIST1H2APS1 -6.26 1.15e-09 8.46e-07 -0.39 -0.32 Iron status biomarkers; chr6:25744056 chr6:25732497~25732827:+ LIHC cis rs55665837 0.54 rs7938266 ENSG00000251991.1 RNU7-49P 6.26 1.16e-09 8.47e-07 0.34 0.32 Vitamin D levels; chr11:14687778 chr11:14478892~14478953:+ LIHC cis rs2762353 0.595 rs12207270 ENSG00000242387.1 HIST1H2APS2 6.26 1.16e-09 8.49e-07 0.39 0.32 Blood metabolite levels; chr6:25751493 chr6:25882026~25882395:- LIHC cis rs1577917 0.771 rs3812133 ENSG00000203875.9 SNHG5 -6.26 1.16e-09 8.53e-07 -0.4 -0.32 Response to antipsychotic treatment; chr6:85644693 chr6:85660950~85678736:- LIHC cis rs17270561 0.609 rs7754296 ENSG00000216436.2 HIST1H2APS1 -6.26 1.17e-09 8.54e-07 -0.39 -0.32 Iron status biomarkers; chr6:25744650 chr6:25732497~25732827:+ LIHC cis rs6504950 0.924 rs244338 ENSG00000275710.1 RP11-257O5.4 6.26 1.17e-09 8.56e-07 0.38 0.32 Breast cancer; chr17:55123057 chr17:54964474~54964679:+ LIHC cis rs1862618 0.853 rs33322 ENSG00000271828.1 CTD-2310F14.1 6.26 1.18e-09 8.61e-07 0.45 0.32 Initial pursuit acceleration; chr5:56879399 chr5:56927874~56929573:+ LIHC cis rs35160687 0.862 rs13024964 ENSG00000273080.1 RP11-301O19.1 6.26 1.18e-09 8.63e-07 0.43 0.32 Night sleep phenotypes; chr2:86284745 chr2:86195590~86196049:+ LIHC cis rs7615952 0.688 rs7624806 ENSG00000171084.14 FAM86JP 6.26 1.18e-09 8.63e-07 0.57 0.32 Blood pressure (smoking interaction); chr3:125880231 chr3:125916620~125930024:+ LIHC cis rs8100891 0.537 rs16967141 ENSG00000267213.4 AC007773.2 -6.26 1.18e-09 8.65e-07 -0.41 -0.32 Neuroticism; chr19:32480317 chr19:32390050~32405560:- LIHC cis rs6490294 0.528 rs12422941 ENSG00000226469.1 ADAM1B -6.26 1.18e-09 8.65e-07 -0.48 -0.32 Mean platelet volume; chr12:112099934 chr12:111927018~111929017:+ LIHC cis rs7674212 0.531 rs4699048 ENSG00000230069.3 LRRC37A15P -6.25 1.19e-09 8.69e-07 -0.3 -0.32 Type 2 diabetes; chr4:103005570 chr4:102727274~102730721:- LIHC cis rs875971 0.545 rs1796222 ENSG00000226824.5 RP4-756H11.3 6.25 1.19e-09 8.69e-07 0.4 0.32 Aortic root size; chr7:66592167 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs55895244 ENSG00000164669.11 INTS4P1 6.25 1.19e-09 8.71e-07 0.55 0.32 Diabetic kidney disease; chr7:65922691 chr7:65141225~65234216:+ LIHC cis rs11676348 0.755 rs13410318 ENSG00000261338.2 RP11-378A13.1 6.25 1.19e-09 8.73e-07 0.34 0.32 Ulcerative colitis; chr2:218158187 chr2:218255319~218257366:+ LIHC cis rs17270561 0.636 rs6923839 ENSG00000216436.2 HIST1H2APS1 -6.25 1.2e-09 8.73e-07 -0.39 -0.32 Iron status biomarkers; chr6:25745625 chr6:25732497~25732827:+ LIHC cis rs1789 0.706 rs8180240 ENSG00000273133.1 RP11-799M12.2 -6.25 1.2e-09 8.74e-07 -0.48 -0.32 Blood protein levels; chr4:15699952 chr4:15563698~15564253:- LIHC cis rs17270561 0.636 rs6923367 ENSG00000216436.2 HIST1H2APS1 -6.25 1.2e-09 8.74e-07 -0.39 -0.32 Iron status biomarkers; chr6:25745624 chr6:25732497~25732827:+ LIHC cis rs17270561 0.636 rs4145218 ENSG00000216436.2 HIST1H2APS1 -6.25 1.2e-09 8.74e-07 -0.39 -0.32 Iron status biomarkers; chr6:25745855 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs1892255 ENSG00000216436.2 HIST1H2APS1 -6.25 1.2e-09 8.74e-07 -0.39 -0.32 Iron status biomarkers; chr6:25750126 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs1892254 ENSG00000216436.2 HIST1H2APS1 -6.25 1.2e-09 8.74e-07 -0.39 -0.32 Iron status biomarkers; chr6:25750302 chr6:25732497~25732827:+ LIHC cis rs7617773 0.817 rs3731555 ENSG00000229759.1 MRPS18AP1 6.25 1.2e-09 8.75e-07 0.39 0.32 Coronary artery disease; chr3:48164612 chr3:48256350~48256938:- LIHC cis rs1020064 0.636 rs2576750 ENSG00000235319.1 AC012360.4 -6.25 1.2e-09 8.77e-07 -0.41 -0.32 AIDS; chr2:105300178 chr2:105324210~105330529:+ LIHC cis rs12681287 0.64 rs4961193 ENSG00000250569.1 NTAN1P2 -6.25 1.2e-09 8.78e-07 -0.37 -0.32 Caudate activity during reward; chr8:86473939 chr8:86481754~86483002:- LIHC cis rs748404 0.56 rs1869258 ENSG00000205771.5 CATSPER2P1 -6.25 1.2e-09 8.78e-07 -0.38 -0.32 Lung cancer; chr15:43511423 chr15:43726918~43747094:- LIHC cis rs748404 0.56 rs529611 ENSG00000205771.5 CATSPER2P1 -6.25 1.2e-09 8.78e-07 -0.38 -0.32 Lung cancer; chr15:43513790 chr15:43726918~43747094:- LIHC cis rs1577917 0.771 rs2842602 ENSG00000234155.1 RP11-30P6.6 6.25 1.2e-09 8.78e-07 0.4 0.32 Response to antipsychotic treatment; chr6:85622169 chr6:85387219~85390186:- LIHC cis rs113835537 0.529 rs57634456 ENSG00000255517.5 CTD-3074O7.5 -6.25 1.2e-09 8.79e-07 -0.36 -0.32 Airway imaging phenotypes; chr11:66483367 chr11:66473490~66480233:- LIHC cis rs8059260 0.668 rs75811377 ENSG00000274038.1 RP11-66H6.4 -6.25 1.2e-09 8.79e-07 -0.53 -0.32 Alcohol consumption over the past year; chr16:11023451 chr16:11056556~11057034:+ LIHC cis rs523522 0.962 rs4767912 ENSG00000278344.1 RP11-18C24.8 6.25 1.21e-09 8.85e-07 0.38 0.32 High light scatter reticulocyte count; chr12:120543399 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs4766969 ENSG00000278344.1 RP11-18C24.8 6.25 1.21e-09 8.85e-07 0.38 0.32 High light scatter reticulocyte count; chr12:120550435 chr12:120500735~120501090:- LIHC cis rs853679 0.517 rs6932109 ENSG00000219392.1 RP1-265C24.5 6.25 1.21e-09 8.86e-07 0.49 0.32 Depression; chr6:28110525 chr6:28115628~28116551:+ LIHC cis rs1263173 0.696 rs1263172 ENSG00000236267.1 AP006216.5 6.25 1.22e-09 8.87e-07 0.3 0.32 HDL cholesterol; chr11:116810202 chr11:116813204~116814003:- LIHC cis rs6940638 0.615 rs9393801 ENSG00000216901.1 AL022393.7 6.25 1.22e-09 8.9e-07 0.41 0.32 Intelligence (multi-trait analysis); chr6:27274902 chr6:28176188~28176674:+ LIHC cis rs2739330 0.627 rs9608219 ENSG00000099984.9 GSTT2 -6.25 1.22e-09 8.9e-07 -0.37 -0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23980123~23983911:+ LIHC cis rs6142102 0.961 rs1319363 ENSG00000276073.1 RP5-1125A11.7 -6.25 1.22e-09 8.91e-07 -0.36 -0.32 Skin pigmentation; chr20:33954070 chr20:33985617~33988989:- LIHC cis rs7429990 0.965 rs7642590 ENSG00000229759.1 MRPS18AP1 -6.25 1.23e-09 8.93e-07 -0.36 -0.32 Educational attainment (years of education); chr3:48058260 chr3:48256350~48256938:- LIHC cis rs12458462 0.859 rs35493271 ENSG00000274828.1 RP11-567M16.6 6.25 1.23e-09 8.99e-07 0.32 0.32 Monocyte count; chr18:79688793 chr18:79677287~79679358:- LIHC cis rs17270561 0.585 rs9393663 ENSG00000216436.2 HIST1H2APS1 -6.25 1.24e-09 8.99e-07 -0.39 -0.32 Iron status biomarkers; chr6:25740805 chr6:25732497~25732827:+ LIHC cis rs7674212 0.531 rs10006474 ENSG00000230069.3 LRRC37A15P -6.25 1.24e-09 9.01e-07 -0.3 -0.32 Type 2 diabetes; chr4:103006890 chr4:102727274~102730721:- LIHC cis rs2153535 0.58 rs2327051 ENSG00000230939.1 RP11-314C16.1 6.25 1.24e-09 9.01e-07 0.38 0.32 Motion sickness; chr6:8440917 chr6:8784178~8785445:+ LIHC cis rs3020736 0.5 rs4147638 ENSG00000237037.8 NDUFA6-AS1 -6.25 1.24e-09 9.02e-07 -0.39 -0.32 Autism spectrum disorder or schizophrenia; chr22:42091896 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs6002605 ENSG00000237037.8 NDUFA6-AS1 -6.25 1.24e-09 9.02e-07 -0.39 -0.32 Autism spectrum disorder or schizophrenia; chr22:42098331 chr22:42090931~42137742:+ LIHC cis rs1862618 0.853 rs2113079 ENSG00000271828.1 CTD-2310F14.1 6.25 1.24e-09 9.03e-07 0.45 0.32 Initial pursuit acceleration; chr5:56862124 chr5:56927874~56929573:+ LIHC cis rs9326248 0.953 rs488962 ENSG00000280143.1 AP000892.6 -6.25 1.25e-09 9.06e-07 -0.37 -0.32 Blood protein levels; chr11:117201809 chr11:117204967~117210292:+ LIHC cis rs9326248 0.953 rs634960 ENSG00000280143.1 AP000892.6 -6.25 1.25e-09 9.06e-07 -0.37 -0.32 Blood protein levels; chr11:117202247 chr11:117204967~117210292:+ LIHC cis rs2739330 0.796 rs1006771 ENSG00000231271.1 AP000350.8 6.25 1.25e-09 9.09e-07 0.36 0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23949918~23954042:+ LIHC cis rs765787 0.505 rs11630884 ENSG00000259520.4 CTD-2651B20.3 6.25 1.26e-09 9.13e-07 0.38 0.32 Uric acid levels; chr15:45240048 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs13329228 ENSG00000259520.4 CTD-2651B20.3 6.25 1.26e-09 9.13e-07 0.38 0.32 Uric acid levels; chr15:45240819 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs11634794 ENSG00000259520.4 CTD-2651B20.3 6.25 1.26e-09 9.13e-07 0.38 0.32 Uric acid levels; chr15:45242294 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs11636404 ENSG00000259520.4 CTD-2651B20.3 6.25 1.26e-09 9.13e-07 0.38 0.32 Uric acid levels; chr15:45243663 chr15:45251580~45279251:- LIHC cis rs12130219 0.5 rs1552991 ENSG00000237975.5 FLG-AS1 -6.24 1.26e-09 9.16e-07 -0.4 -0.32 Inflammatory skin disease; chr1:152193402 chr1:152168125~152445456:+ LIHC cis rs1789 0.706 rs7696938 ENSG00000273133.1 RP11-799M12.2 6.24 1.26e-09 9.16e-07 0.47 0.32 Blood protein levels; chr4:15701954 chr4:15563698~15564253:- LIHC cis rs992157 0.71 rs12612347 ENSG00000261338.2 RP11-378A13.1 -6.24 1.26e-09 9.17e-07 -0.32 -0.32 Colorectal cancer; chr2:218192615 chr2:218255319~218257366:+ LIHC cis rs2243480 1 rs313831 ENSG00000164669.11 INTS4P1 6.24 1.27e-09 9.19e-07 0.55 0.32 Diabetic kidney disease; chr7:66086239 chr7:65141225~65234216:+ LIHC cis rs12458462 0.509 rs3786241 ENSG00000274828.1 RP11-567M16.6 6.24 1.27e-09 9.23e-07 0.34 0.32 Monocyte count; chr18:79734328 chr18:79677287~79679358:- LIHC cis rs13068223 0.607 rs184695 ENSG00000243926.1 TIPARP-AS1 -6.24 1.27e-09 9.23e-07 -0.35 -0.32 Age-related hearing impairment (SNP x SNP interaction); chr3:156679600 chr3:156671862~156674378:- LIHC cis rs5758659 0.714 rs133376 ENSG00000227370.1 RP4-669P10.19 -6.24 1.27e-09 9.23e-07 -0.37 -0.32 Cognitive function; chr22:42070901 chr22:42132543~42132998:+ LIHC cis rs7580658 0.613 rs12478656 ENSG00000236682.1 AC068282.3 -6.24 1.27e-09 9.25e-07 -0.4 -0.32 Protein C levels; chr2:127438944 chr2:127389130~127400580:+ LIHC cis rs523522 0.962 rs4767904 ENSG00000278344.1 RP11-18C24.8 6.24 1.28e-09 9.32e-07 0.38 0.32 High light scatter reticulocyte count; chr12:120492995 chr12:120500735~120501090:- LIHC cis rs7429990 0.932 rs6442101 ENSG00000229759.1 MRPS18AP1 -6.24 1.29e-09 9.33e-07 -0.35 -0.32 Educational attainment (years of education); chr3:48089403 chr3:48256350~48256938:- LIHC cis rs6490294 0.528 rs12582100 ENSG00000226469.1 ADAM1B 6.24 1.29e-09 9.36e-07 0.48 0.32 Mean platelet volume; chr12:111941105 chr12:111927018~111929017:+ LIHC cis rs7674212 0.507 rs223413 ENSG00000230069.3 LRRC37A15P 6.24 1.29e-09 9.37e-07 0.3 0.32 Type 2 diabetes; chr4:102811709 chr4:102727274~102730721:- LIHC cis rs523522 0.962 rs2168319 ENSG00000278344.1 RP11-18C24.8 6.24 1.29e-09 9.38e-07 0.38 0.32 High light scatter reticulocyte count; chr12:120495414 chr12:120500735~120501090:- LIHC cis rs9326248 0.689 rs4516002 ENSG00000236267.1 AP006216.5 6.24 1.29e-09 9.38e-07 0.34 0.32 Blood protein levels; chr11:117128343 chr11:116813204~116814003:- LIHC cis rs832187 0.679 rs9879045 ENSG00000280620.1 SCAANT1 6.24 1.3e-09 9.41e-07 0.42 0.32 Schizophrenia; chr3:64016249 chr3:63911518~63911772:- LIHC cis rs853679 0.542 rs6934769 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Depression; chr6:28123153 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs17711801 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Depression; chr6:28124529 chr6:28115628~28116551:+ LIHC cis rs4713118 0.527 rs9461433 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Parkinson's disease; chr6:28127394 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9468292 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Depression; chr6:28127577 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs1947863 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Depression; chr6:28131566 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs4713141 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Depression; chr6:28133900 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9380056 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Depression; chr6:28136698 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9380057 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Depression; chr6:28136856 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs1947862 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Depression; chr6:28137418 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs6941992 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Depression; chr6:28138363 chr6:28115628~28116551:+ LIHC cis rs4713118 0.516 rs4713142 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Parkinson's disease; chr6:28138569 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs4713143 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Depression; chr6:28138981 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs4713144 ENSG00000219392.1 RP1-265C24.5 -6.24 1.3e-09 9.42e-07 -0.49 -0.32 Depression; chr6:28139012 chr6:28115628~28116551:+ LIHC cis rs2455601 1 rs56336128 ENSG00000254860.4 TMEM9B-AS1 6.24 1.3e-09 9.42e-07 0.41 0.32 Schizophrenia; chr11:8886752 chr11:8964675~8977527:+ LIHC cis rs2439831 0.85 rs28858500 ENSG00000205771.5 CATSPER2P1 -6.24 1.3e-09 9.42e-07 -0.48 -0.32 Lung cancer in ever smokers; chr15:43864744 chr15:43726918~43747094:- LIHC cis rs11023332 0.832 rs10832289 ENSG00000251991.1 RNU7-49P -6.24 1.3e-09 9.42e-07 -0.34 -0.32 Vitamin D levels;Adiponectin levels; chr11:14647950 chr11:14478892~14478953:+ LIHC cis rs1862618 0.756 rs9292125 ENSG00000271828.1 CTD-2310F14.1 6.24 1.3e-09 9.45e-07 0.45 0.32 Initial pursuit acceleration; chr5:56811373 chr5:56927874~56929573:+ LIHC cis rs1005277 0.563 rs2505215 ENSG00000263064.2 RP11-291L22.7 6.24 1.3e-09 9.45e-07 0.33 0.32 Extrinsic epigenetic age acceleration; chr10:38192345 chr10:38448689~38448949:+ LIHC cis rs1005277 0.563 rs2505216 ENSG00000263064.2 RP11-291L22.7 6.24 1.3e-09 9.45e-07 0.33 0.32 Extrinsic epigenetic age acceleration; chr10:38193902 chr10:38448689~38448949:+ LIHC cis rs1005277 0.563 rs2800550 ENSG00000263064.2 RP11-291L22.7 6.24 1.3e-09 9.45e-07 0.33 0.32 Extrinsic epigenetic age acceleration; chr10:38194001 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2749612 ENSG00000263064.2 RP11-291L22.7 6.24 1.3e-09 9.45e-07 0.33 0.32 Extrinsic epigenetic age acceleration; chr10:38199682 chr10:38448689~38448949:+ LIHC cis rs1075265 0.584 rs1862122 ENSG00000233266.1 HMGB1P31 -6.24 1.3e-09 9.45e-07 -0.4 -0.32 Chronotype;Morning vs. evening chronotype; chr2:54052992 chr2:54051334~54051760:+ LIHC cis rs523522 0.962 rs4767903 ENSG00000278344.1 RP11-18C24.8 6.24 1.31e-09 9.45e-07 0.38 0.32 High light scatter reticulocyte count; chr12:120492243 chr12:120500735~120501090:- LIHC cis rs62355901 0.505 rs72758017 ENSG00000271828.1 CTD-2310F14.1 6.24 1.31e-09 9.48e-07 0.52 0.32 Breast cancer; chr5:56797732 chr5:56927874~56929573:+ LIHC cis rs7396835 0.741 rs7396851 ENSG00000254851.1 RP11-109L13.1 6.24 1.31e-09 9.51e-07 0.45 0.32 Quantitative traits; chr11:116813448 chr11:117135528~117138582:+ LIHC cis rs853679 0.517 rs16893666 ENSG00000219392.1 RP1-265C24.5 6.24 1.31e-09 9.51e-07 0.49 0.32 Depression; chr6:28086929 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9393884 ENSG00000219392.1 RP1-265C24.5 -6.24 1.31e-09 9.51e-07 -0.49 -0.32 Depression; chr6:28079011 chr6:28115628~28116551:+ LIHC cis rs2243480 1 rs160655 ENSG00000164669.11 INTS4P1 6.24 1.32e-09 9.56e-07 0.55 0.32 Diabetic kidney disease; chr7:66068227 chr7:65141225~65234216:+ LIHC cis rs7617773 0.851 rs13068288 ENSG00000229759.1 MRPS18AP1 6.24 1.33e-09 9.59e-07 0.38 0.32 Coronary artery disease; chr3:48290261 chr3:48256350~48256938:- LIHC cis rs12458462 0.892 rs2242174 ENSG00000274828.1 RP11-567M16.6 6.24 1.33e-09 9.62e-07 0.32 0.32 Monocyte count; chr18:79698037 chr18:79677287~79679358:- LIHC cis rs7914558 0.966 rs1971589 ENSG00000236937.2 PTGES3P4 6.24 1.33e-09 9.63e-07 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102984649 chr10:102845595~102845950:+ LIHC cis rs523522 1 rs1563333 ENSG00000278344.1 RP11-18C24.8 6.23 1.33e-09 9.64e-07 0.38 0.32 High light scatter reticulocyte count; chr12:120496604 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs7136951 ENSG00000278344.1 RP11-18C24.8 6.23 1.33e-09 9.64e-07 0.38 0.32 High light scatter reticulocyte count; chr12:120504124 chr12:120500735~120501090:- LIHC cis rs7914558 0.966 rs10748836 ENSG00000236937.2 PTGES3P4 6.23 1.34e-09 9.66e-07 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102934160 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs10786727 ENSG00000236937.2 PTGES3P4 6.23 1.34e-09 9.66e-07 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102938766 chr10:102845595~102845950:+ LIHC cis rs3020736 0.5 rs11090076 ENSG00000237037.8 NDUFA6-AS1 -6.23 1.34e-09 9.68e-07 -0.39 -0.32 Autism spectrum disorder or schizophrenia; chr22:42118186 chr22:42090931~42137742:+ LIHC cis rs12681287 0.608 rs13273338 ENSG00000250569.1 NTAN1P2 6.23 1.34e-09 9.69e-07 0.37 0.32 Caudate activity during reward; chr8:86441132 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs13258126 ENSG00000250569.1 NTAN1P2 6.23 1.34e-09 9.69e-07 0.37 0.32 Caudate activity during reward; chr8:86441149 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs13256765 ENSG00000250569.1 NTAN1P2 6.23 1.34e-09 9.69e-07 0.37 0.32 Caudate activity during reward; chr8:86445604 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs12678720 ENSG00000250569.1 NTAN1P2 6.23 1.34e-09 9.69e-07 0.37 0.32 Caudate activity during reward; chr8:86445700 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs13253261 ENSG00000250569.1 NTAN1P2 6.23 1.34e-09 9.69e-07 0.37 0.32 Caudate activity during reward; chr8:86446271 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs13253515 ENSG00000250569.1 NTAN1P2 6.23 1.34e-09 9.69e-07 0.37 0.32 Caudate activity during reward; chr8:86446367 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs12541793 ENSG00000250569.1 NTAN1P2 6.23 1.34e-09 9.69e-07 0.37 0.32 Caudate activity during reward; chr8:86450329 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs12679811 ENSG00000250569.1 NTAN1P2 6.23 1.34e-09 9.69e-07 0.37 0.32 Caudate activity during reward; chr8:86453141 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs13264364 ENSG00000250569.1 NTAN1P2 6.23 1.34e-09 9.69e-07 0.37 0.32 Caudate activity during reward; chr8:86454156 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs67123356 ENSG00000250569.1 NTAN1P2 6.23 1.34e-09 9.69e-07 0.37 0.32 Caudate activity during reward; chr8:86441763 chr8:86481754~86483002:- LIHC cis rs10510102 0.688 rs74570569 ENSG00000276742.1 RP11-500G22.4 6.23 1.35e-09 9.72e-07 0.51 0.32 Breast cancer; chr10:121945347 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs7076727 ENSG00000276742.1 RP11-500G22.4 6.23 1.35e-09 9.72e-07 0.51 0.32 Breast cancer; chr10:121947000 chr10:121956782~121957098:+ LIHC cis rs10510102 0.745 rs7076882 ENSG00000276742.1 RP11-500G22.4 6.23 1.35e-09 9.72e-07 0.51 0.32 Breast cancer; chr10:121947039 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs7077035 ENSG00000276742.1 RP11-500G22.4 6.23 1.35e-09 9.72e-07 0.51 0.32 Breast cancer; chr10:121947130 chr10:121956782~121957098:+ LIHC cis rs916888 0.697 rs199516 ENSG00000262881.1 RP11-669E14.4 6.23 1.35e-09 9.72e-07 0.5 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45907670~45910779:- LIHC cis rs916888 0.821 rs199514 ENSG00000262881.1 RP11-669E14.4 6.23 1.35e-09 9.72e-07 0.5 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45907670~45910779:- LIHC cis rs916888 0.821 rs199512 ENSG00000262881.1 RP11-669E14.4 6.23 1.35e-09 9.72e-07 0.5 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45907670~45910779:- LIHC cis rs916888 0.821 rs199509 ENSG00000262881.1 RP11-669E14.4 6.23 1.35e-09 9.72e-07 0.5 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45907670~45910779:- LIHC cis rs916888 0.821 rs199507 ENSG00000262881.1 RP11-669E14.4 6.23 1.35e-09 9.72e-07 0.5 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45907670~45910779:- LIHC cis rs916888 0.821 rs415430 ENSG00000262881.1 RP11-669E14.4 6.23 1.35e-09 9.72e-07 0.5 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45907670~45910779:- LIHC cis rs916888 0.779 rs430685 ENSG00000262881.1 RP11-669E14.4 6.23 1.35e-09 9.72e-07 0.5 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45907670~45910779:- LIHC cis rs916888 0.821 rs199505 ENSG00000262881.1 RP11-669E14.4 6.23 1.35e-09 9.72e-07 0.5 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45907670~45910779:- LIHC cis rs916888 0.821 rs70602 ENSG00000262881.1 RP11-669E14.4 6.23 1.35e-09 9.72e-07 0.5 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45907670~45910779:- LIHC cis rs853679 0.517 rs2273564 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28089816 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs1853097 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28090857 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9393888 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28091439 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs3734573 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28091659 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9357063 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28092227 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs3823180 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28093966 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9368551 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28094014 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9393890 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28096077 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9366715 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28096855 chr6:28115628~28116551:+ LIHC cis rs853679 0.598 rs9380054 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28099759 chr6:28115628~28116551:+ LIHC cis rs4713118 0.547 rs2116981 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Parkinson's disease; chr6:28100173 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9368552 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28100648 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs2281588 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28104824 chr6:28115628~28116551:+ LIHC cis rs853679 0.542 rs34131763 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28107222 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs35193936 ENSG00000219392.1 RP1-265C24.5 -6.23 1.35e-09 9.74e-07 -0.49 -0.32 Depression; chr6:28108492 chr6:28115628~28116551:+ LIHC cis rs8100891 0.537 rs2302773 ENSG00000267213.4 AC007773.2 -6.23 1.36e-09 9.78e-07 -0.41 -0.32 Neuroticism; chr19:32436405 chr19:32390050~32405560:- LIHC cis rs17270561 0.609 rs4711096 ENSG00000216436.2 HIST1H2APS1 -6.23 1.36e-09 9.79e-07 -0.39 -0.32 Iron status biomarkers; chr6:25726826 chr6:25732497~25732827:+ LIHC cis rs8028182 0.501 rs11072553 ENSG00000260269.4 CTD-2323K18.1 -6.23 1.37e-09 9.88e-07 -0.41 -0.32 Sudden cardiac arrest; chr15:75640436 chr15:75527150~75601205:- LIHC cis rs2032447 0.517 rs7767546 ENSG00000242387.1 HIST1H2APS2 6.23 1.37e-09 9.89e-07 0.43 0.32 Intelligence (multi-trait analysis); chr6:25903839 chr6:25882026~25882395:- LIHC cis rs2749592 0.513 rs1208708 ENSG00000263064.2 RP11-291L22.7 6.23 1.38e-09 9.91e-07 0.33 0.32 Age-related hearing impairment (SNP x SNP interaction); chr10:37796648 chr10:38448689~38448949:+ LIHC cis rs9326248 0.53 rs7112513 ENSG00000280143.1 AP000892.6 6.23 1.38e-09 9.93e-07 0.41 0.32 Blood protein levels; chr11:117166645 chr11:117204967~117210292:+ LIHC cis rs113835537 0.529 rs11227501 ENSG00000255517.5 CTD-3074O7.5 -6.23 1.38e-09 9.96e-07 -0.34 -0.32 Airway imaging phenotypes; chr11:66506601 chr11:66473490~66480233:- LIHC cis rs9532669 0.926 rs2039119 ENSG00000176268.5 CYCSP34 -6.23 1.38e-09 9.98e-07 -0.37 -0.32 Cervical cancer; chr13:40872432 chr13:40863599~40863902:- LIHC cis rs6142102 0.812 rs761238 ENSG00000276073.1 RP5-1125A11.7 6.23 1.39e-09 9.98e-07 0.34 0.32 Skin pigmentation; chr20:33932182 chr20:33985617~33988989:- LIHC cis rs1577917 0.771 rs2842613 ENSG00000234155.1 RP11-30P6.6 -6.23 1.39e-09 1e-06 -0.4 -0.32 Response to antipsychotic treatment; chr6:85595984 chr6:85387219~85390186:- LIHC cis rs3858145 0.588 rs731063 ENSG00000233590.1 RP11-153K11.3 6.23 1.39e-09 1e-06 0.42 0.32 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68283433 chr10:68233251~68242379:- LIHC cis rs7085104 0.7 rs3740397 ENSG00000236937.2 PTGES3P4 6.23 1.4e-09 1.01e-06 0.39 0.32 Immature fraction of reticulocytes;Schizophrenia; chr10:102832918 chr10:102845595~102845950:+ LIHC cis rs11673344 0.615 rs2921561 ENSG00000226686.6 LINC01535 6.23 1.4e-09 1.01e-06 0.39 0.32 Obesity-related traits; chr19:37348969 chr19:37251912~37265535:+ LIHC cis rs1862618 0.853 rs832554 ENSG00000271828.1 CTD-2310F14.1 6.23 1.4e-09 1.01e-06 0.45 0.32 Initial pursuit acceleration; chr5:56819209 chr5:56927874~56929573:+ LIHC cis rs113835537 0.627 rs11227534 ENSG00000255517.5 CTD-3074O7.5 -6.23 1.41e-09 1.01e-06 -0.35 -0.32 Airway imaging phenotypes; chr11:66568700 chr11:66473490~66480233:- LIHC cis rs2933343 1 rs1683811 ENSG00000231305.3 RP11-723O4.2 6.22 1.41e-09 1.02e-06 0.36 0.32 IgG glycosylation; chr3:128893270 chr3:128861313~128871540:- LIHC cis rs2933343 1 rs2929859 ENSG00000231305.3 RP11-723O4.2 6.22 1.42e-09 1.02e-06 0.36 0.32 IgG glycosylation; chr3:128889498 chr3:128861313~128871540:- LIHC cis rs4356975 0.509 rs6422323 ENSG00000249956.3 RP11-790I12.2 6.22 1.42e-09 1.02e-06 0.37 0.32 Obesity-related traits; chr4:69087362 chr4:69408836~69423164:+ LIHC cis rs1862618 0.853 rs832578 ENSG00000271828.1 CTD-2310F14.1 6.22 1.42e-09 1.02e-06 0.45 0.32 Initial pursuit acceleration; chr5:56868396 chr5:56927874~56929573:+ LIHC cis rs6504950 0.695 rs9904377 ENSG00000275710.1 RP11-257O5.4 6.22 1.43e-09 1.02e-06 0.4 0.32 Breast cancer; chr17:54908621 chr17:54964474~54964679:+ LIHC cis rs2933343 1 rs789232 ENSG00000231305.3 RP11-723O4.2 6.22 1.43e-09 1.02e-06 0.36 0.32 IgG glycosylation; chr3:128884237 chr3:128861313~128871540:- LIHC cis rs7115242 0.8 rs6589597 ENSG00000280143.1 AP000892.6 -6.22 1.43e-09 1.03e-06 -0.4 -0.32 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117127082 chr11:117204967~117210292:+ LIHC cis rs1862618 0.853 rs252887 ENSG00000271828.1 CTD-2310F14.1 6.22 1.43e-09 1.03e-06 0.45 0.32 Initial pursuit acceleration; chr5:56870361 chr5:56927874~56929573:+ LIHC cis rs9487094 0.67 rs1998811 ENSG00000260273.1 RP11-425D10.10 6.22 1.44e-09 1.03e-06 0.38 0.32 Height; chr6:109490935 chr6:109382795~109383666:+ LIHC cis rs4356975 0.563 rs4356974 ENSG00000249956.3 RP11-790I12.2 6.22 1.44e-09 1.03e-06 0.36 0.32 Obesity-related traits; chr4:69106696 chr4:69408836~69423164:+ LIHC cis rs7826238 0.539 rs2945891 ENSG00000253893.2 FAM85B -6.22 1.44e-09 1.04e-06 -0.38 -0.32 Systolic blood pressure; chr8:8297953 chr8:8167819~8226614:- LIHC cis rs2739330 0.752 rs2330634 ENSG00000099984.9 GSTT2 -6.22 1.45e-09 1.04e-06 -0.37 -0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908608 chr22:23980123~23983911:+ LIHC cis rs9326248 0.53 rs7940310 ENSG00000280143.1 AP000892.6 6.22 1.45e-09 1.04e-06 0.4 0.32 Blood protein levels; chr11:117153765 chr11:117204967~117210292:+ LIHC cis rs2243480 1 rs464895 ENSG00000164669.11 INTS4P1 6.22 1.46e-09 1.05e-06 0.55 0.32 Diabetic kidney disease; chr7:66062119 chr7:65141225~65234216:+ LIHC cis rs6142102 0.961 rs2377957 ENSG00000276073.1 RP5-1125A11.7 -6.22 1.46e-09 1.05e-06 -0.35 -0.32 Skin pigmentation; chr20:33966667 chr20:33985617~33988989:- LIHC cis rs7115242 0.8 rs7131536 ENSG00000280143.1 AP000892.6 6.22 1.46e-09 1.05e-06 0.4 0.32 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117128730 chr11:117204967~117210292:+ LIHC cis rs2439831 0.85 rs8042868 ENSG00000205771.5 CATSPER2P1 -6.22 1.47e-09 1.05e-06 -0.49 -0.32 Lung cancer in ever smokers; chr15:43647444 chr15:43726918~43747094:- LIHC cis rs11673344 0.642 rs12462708 ENSG00000226686.6 LINC01535 -6.22 1.47e-09 1.06e-06 -0.38 -0.32 Obesity-related traits; chr19:37306676 chr19:37251912~37265535:+ LIHC cis rs7674212 0.581 rs13150953 ENSG00000230069.3 LRRC37A15P -6.22 1.47e-09 1.06e-06 -0.3 -0.32 Type 2 diabetes; chr4:103021341 chr4:102727274~102730721:- LIHC cis rs7674212 0.556 rs13151569 ENSG00000230069.3 LRRC37A15P -6.22 1.47e-09 1.06e-06 -0.3 -0.32 Type 2 diabetes; chr4:103021633 chr4:102727274~102730721:- LIHC cis rs853679 0.517 rs36078605 ENSG00000219392.1 RP1-265C24.5 -6.22 1.49e-09 1.07e-06 -0.49 -0.32 Depression; chr6:28110254 chr6:28115628~28116551:+ LIHC cis rs12458462 0.892 rs12456692 ENSG00000274828.1 RP11-567M16.6 6.21 1.49e-09 1.07e-06 0.33 0.32 Monocyte count; chr18:79722189 chr18:79677287~79679358:- LIHC cis rs113835537 0.66 rs7116940 ENSG00000255517.5 CTD-3074O7.5 -6.21 1.49e-09 1.07e-06 -0.36 -0.32 Airway imaging phenotypes; chr11:66536424 chr11:66473490~66480233:- LIHC cis rs8062405 0.573 rs11645306 ENSG00000259982.1 CDC37P1 -6.21 1.5e-09 1.07e-06 -0.41 -0.32 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28972615 chr16:28700294~28701540:- LIHC cis rs1577917 0.561 rs3087978 ENSG00000234155.1 RP11-30P6.6 -6.21 1.5e-09 1.08e-06 -0.37 -0.32 Response to antipsychotic treatment; chr6:85678505 chr6:85387219~85390186:- LIHC cis rs3020736 0.5 rs6002616 ENSG00000237037.8 NDUFA6-AS1 -6.21 1.5e-09 1.08e-06 -0.38 -0.32 Autism spectrum disorder or schizophrenia; chr22:42108675 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs7364293 ENSG00000237037.8 NDUFA6-AS1 -6.21 1.5e-09 1.08e-06 -0.38 -0.32 Autism spectrum disorder or schizophrenia; chr22:42110366 chr22:42090931~42137742:+ LIHC cis rs17270561 0.553 rs9379784 ENSG00000216436.2 HIST1H2APS1 -6.21 1.51e-09 1.08e-06 -0.38 -0.32 Iron status biomarkers; chr6:25725278 chr6:25732497~25732827:+ LIHC cis rs227275 0.554 rs223334 ENSG00000230069.3 LRRC37A15P 6.21 1.51e-09 1.08e-06 0.29 0.32 Allergic disease (asthma, hay fever or eczema); chr4:102867054 chr4:102727274~102730721:- LIHC cis rs1499614 1 rs1267818 ENSG00000273142.1 RP11-458F8.4 -6.21 1.52e-09 1.08e-06 -0.4 -0.32 Gout; chr7:66642037 chr7:66902857~66906297:+ LIHC cis rs9549367 0.774 rs9549696 ENSG00000269125.1 RP11-98F14.11 -6.21 1.52e-09 1.08e-06 -0.4 -0.32 Platelet distribution width; chr13:113220748 chr13:113165002~113165183:- LIHC cis rs4423214 0.592 rs7130829 ENSG00000254682.1 RP11-660L16.2 -6.21 1.52e-09 1.08e-06 -0.44 -0.32 Vitamin D levels; chr11:71526656 chr11:71448674~71452157:+ LIHC cis rs4356975 0.563 rs4327554 ENSG00000249956.3 RP11-790I12.2 -6.21 1.53e-09 1.09e-06 -0.36 -0.32 Obesity-related traits; chr4:69120690 chr4:69408836~69423164:+ LIHC cis rs904251 0.523 rs2797796 ENSG00000204110.6 RP1-153P14.8 -6.21 1.53e-09 1.09e-06 -0.38 -0.32 Cognitive performance; chr6:37513110 chr6:37507348~37535616:+ LIHC cis rs904251 0.523 rs2776870 ENSG00000204110.6 RP1-153P14.8 -6.21 1.53e-09 1.09e-06 -0.38 -0.32 Cognitive performance; chr6:37513588 chr6:37507348~37535616:+ LIHC cis rs7829975 0.54 rs2976909 ENSG00000173295.6 FAM86B3P -6.21 1.53e-09 1.09e-06 -0.46 -0.32 Mood instability; chr8:8489180 chr8:8228595~8244865:+ LIHC cis rs6504950 0.888 rs244294 ENSG00000275710.1 RP11-257O5.4 6.21 1.53e-09 1.09e-06 0.39 0.32 Breast cancer; chr17:55151182 chr17:54964474~54964679:+ LIHC cis rs9326248 0.773 rs1060211 ENSG00000236267.1 AP006216.5 6.21 1.54e-09 1.1e-06 0.33 0.32 Blood protein levels; chr11:117169081 chr11:116813204~116814003:- LIHC cis rs11098499 0.954 rs12510138 ENSG00000245958.5 RP11-33B1.1 -6.21 1.54e-09 1.1e-06 -0.33 -0.32 Corneal astigmatism; chr4:119502780 chr4:119454791~119552025:+ LIHC cis rs1555322 0.53 rs2297789 ENSG00000126005.14 MMP24-AS1 -6.21 1.54e-09 1.1e-06 -0.48 -0.32 Attention deficit hyperactivity disorder; chr20:35279445 chr20:35216462~35278131:- LIHC cis rs2243480 1 rs7804223 ENSG00000273142.1 RP11-458F8.4 6.21 1.54e-09 1.1e-06 0.39 0.32 Diabetic kidney disease; chr7:66199572 chr7:66902857~66906297:+ LIHC cis rs1023500 0.505 rs134885 ENSG00000237037.8 NDUFA6-AS1 6.21 1.55e-09 1.11e-06 0.34 0.32 Schizophrenia; chr22:42277805 chr22:42090931~42137742:+ LIHC cis rs12458462 0.859 rs2242177 ENSG00000274828.1 RP11-567M16.6 6.21 1.56e-09 1.11e-06 0.33 0.32 Monocyte count; chr18:79717379 chr18:79677287~79679358:- LIHC cis rs12681287 0.752 rs9297861 ENSG00000250569.1 NTAN1P2 6.21 1.56e-09 1.11e-06 0.39 0.32 Caudate activity during reward; chr8:86242501 chr8:86481754~86483002:- LIHC cis rs12681287 0.752 rs67615966 ENSG00000250569.1 NTAN1P2 6.21 1.56e-09 1.11e-06 0.39 0.32 Caudate activity during reward; chr8:86242974 chr8:86481754~86483002:- LIHC cis rs1577917 0.771 rs2475790 ENSG00000234155.1 RP11-30P6.6 6.21 1.56e-09 1.12e-06 0.4 0.32 Response to antipsychotic treatment; chr6:85658350 chr6:85387219~85390186:- LIHC cis rs494459 0.536 rs7103067 ENSG00000255422.1 AP002954.4 -6.21 1.57e-09 1.12e-06 -0.36 -0.32 Height; chr11:118852670 chr11:118704607~118750263:+ LIHC cis rs11672691 0.792 rs7248215 ENSG00000267107.5 PCAT19 6.21 1.57e-09 1.12e-06 0.38 0.32 Prostate cancer; chr19:41493212 chr19:41454169~41500649:- LIHC cis rs7188445 0.736 rs4888043 ENSG00000261390.4 RP11-345M22.2 6.21 1.58e-09 1.12e-06 0.37 0.32 Urate levels; chr16:79668744 chr16:79715232~79770563:- LIHC cis rs8072100 0.935 rs12943464 ENSG00000228782.6 CTD-2026D20.3 -6.2 1.58e-09 1.13e-06 -0.34 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47612985 chr17:47450568~47492492:- LIHC cis rs8072100 0.935 rs4793978 ENSG00000228782.6 CTD-2026D20.3 -6.2 1.58e-09 1.13e-06 -0.34 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47620809 chr17:47450568~47492492:- LIHC cis rs2243480 1 rs466983 ENSG00000273142.1 RP11-458F8.4 -6.2 1.58e-09 1.13e-06 -0.39 -0.32 Diabetic kidney disease; chr7:66055509 chr7:66902857~66906297:+ LIHC cis rs13068223 0.607 rs193197 ENSG00000243926.1 TIPARP-AS1 -6.2 1.58e-09 1.13e-06 -0.35 -0.32 Age-related hearing impairment (SNP x SNP interaction); chr3:156693943 chr3:156671862~156674378:- LIHC cis rs2980439 0.556 rs2921059 ENSG00000253893.2 FAM85B -6.2 1.59e-09 1.13e-06 -0.41 -0.32 Neuroticism; chr8:8460377 chr8:8167819~8226614:- LIHC cis rs9532669 0.927 rs9532670 ENSG00000176268.5 CYCSP34 -6.2 1.6e-09 1.14e-06 -0.36 -0.32 Cervical cancer; chr13:40927691 chr13:40863599~40863902:- LIHC cis rs7914558 1 rs4917996 ENSG00000236937.2 PTGES3P4 6.2 1.61e-09 1.15e-06 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103166072 chr10:102845595~102845950:+ LIHC cis rs7914558 1 rs6584540 ENSG00000236937.2 PTGES3P4 6.2 1.61e-09 1.15e-06 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103167877 chr10:102845595~102845950:+ LIHC cis rs7914558 1 rs7081075 ENSG00000236937.2 PTGES3P4 6.2 1.61e-09 1.15e-06 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103169434 chr10:102845595~102845950:+ LIHC cis rs8059260 0.604 rs9652600 ENSG00000274038.1 RP11-66H6.4 -6.2 1.61e-09 1.15e-06 -0.51 -0.32 Alcohol consumption over the past year; chr16:11080157 chr16:11056556~11057034:+ LIHC cis rs7396835 0.8 rs6589572 ENSG00000254851.1 RP11-109L13.1 -6.2 1.61e-09 1.15e-06 -0.47 -0.32 Quantitative traits; chr11:116810847 chr11:117135528~117138582:+ LIHC cis rs7637701 0.517 rs66538320 ENSG00000243926.1 TIPARP-AS1 6.2 1.61e-09 1.15e-06 0.3 0.32 Breast cancer; chr3:156674346 chr3:156671862~156674378:- LIHC cis rs2439831 0.85 rs2957637 ENSG00000205771.5 CATSPER2P1 -6.2 1.62e-09 1.15e-06 -0.48 -0.32 Lung cancer in ever smokers; chr15:43658920 chr15:43726918~43747094:- LIHC cis rs7914558 0.966 rs2065977 ENSG00000236937.2 PTGES3P4 6.2 1.62e-09 1.15e-06 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102969658 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs12569617 ENSG00000236937.2 PTGES3P4 6.2 1.62e-09 1.15e-06 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102970239 chr10:102845595~102845950:+ LIHC cis rs7914558 0.933 rs1538204 ENSG00000236937.2 PTGES3P4 6.2 1.62e-09 1.15e-06 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102974136 chr10:102845595~102845950:+ LIHC cis rs1577917 0.771 rs2842601 ENSG00000234155.1 RP11-30P6.6 6.2 1.62e-09 1.15e-06 0.4 0.32 Response to antipsychotic treatment; chr6:85620415 chr6:85387219~85390186:- LIHC cis rs748404 0.66 rs690367 ENSG00000205771.5 CATSPER2P1 6.2 1.62e-09 1.15e-06 0.38 0.32 Lung cancer; chr15:43456106 chr15:43726918~43747094:- LIHC cis rs5758659 0.714 rs5758574 ENSG00000227370.1 RP4-669P10.19 6.2 1.62e-09 1.15e-06 0.36 0.32 Cognitive function; chr22:42085396 chr22:42132543~42132998:+ LIHC cis rs62355900 0.627 rs60985357 ENSG00000271828.1 CTD-2310F14.1 6.2 1.63e-09 1.16e-06 0.5 0.32 Endometriosis; chr5:56827875 chr5:56927874~56929573:+ LIHC cis rs7914558 1 rs10786740 ENSG00000236937.2 PTGES3P4 6.2 1.63e-09 1.16e-06 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103175836 chr10:102845595~102845950:+ LIHC cis rs17270561 0.609 rs9358873 ENSG00000216436.2 HIST1H2APS1 -6.2 1.64e-09 1.17e-06 -0.39 -0.32 Iron status biomarkers; chr6:25731555 chr6:25732497~25732827:+ LIHC cis rs17270561 0.666 rs3923725 ENSG00000216436.2 HIST1H2APS1 -6.2 1.64e-09 1.17e-06 -0.39 -0.32 Iron status biomarkers; chr6:25734692 chr6:25732497~25732827:+ LIHC cis rs5769765 0.908 rs4058453 ENSG00000278869.1 CITF22-49E9.3 -6.2 1.65e-09 1.18e-06 -0.6 -0.32 Schizophrenia; chr22:49856649 chr22:49933198~49934074:- LIHC cis rs853679 0.517 rs6922063 ENSG00000219392.1 RP1-265C24.5 -6.2 1.66e-09 1.18e-06 -0.49 -0.32 Depression; chr6:28126588 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs2275508 ENSG00000219392.1 RP1-265C24.5 -6.2 1.66e-09 1.18e-06 -0.49 -0.32 Depression; chr6:28126953 chr6:28115628~28116551:+ LIHC cis rs2439831 0.867 rs2245715 ENSG00000205771.5 CATSPER2P1 -6.2 1.66e-09 1.18e-06 -0.44 -0.32 Lung cancer in ever smokers; chr15:43525854 chr15:43726918~43747094:- LIHC cis rs2442825 0.691 rs2600182 ENSG00000206573.7 THUMPD3-AS1 6.2 1.66e-09 1.18e-06 0.29 0.32 Cerebrospinal fluid clusterin levels; chr3:9396376 chr3:9349689~9398579:- LIHC cis rs950027 0.62 rs1145077 ENSG00000259433.2 CTD-2651B20.4 6.2 1.66e-09 1.18e-06 0.46 0.32 Response to fenofibrate (adiponectin levels); chr15:45391597 chr15:45330209~45332634:- LIHC cis rs904251 0.523 rs2797798 ENSG00000204110.6 RP1-153P14.8 -6.2 1.67e-09 1.19e-06 -0.38 -0.32 Cognitive performance; chr6:37513661 chr6:37507348~37535616:+ LIHC cis rs904251 0.523 rs2776871 ENSG00000204110.6 RP1-153P14.8 -6.2 1.67e-09 1.19e-06 -0.38 -0.32 Cognitive performance; chr6:37513983 chr6:37507348~37535616:+ LIHC cis rs12291225 0.535 rs16930126 ENSG00000251991.1 RNU7-49P -6.2 1.67e-09 1.19e-06 -0.34 -0.32 Sense of smell; chr11:14383437 chr11:14478892~14478953:+ LIHC cis rs9549367 0.756 rs2316463 ENSG00000269125.1 RP11-98F14.11 -6.2 1.67e-09 1.19e-06 -0.39 -0.32 Platelet distribution width; chr13:113247092 chr13:113165002~113165183:- LIHC cis rs12681287 0.752 rs12679266 ENSG00000250569.1 NTAN1P2 6.2 1.67e-09 1.19e-06 0.38 0.32 Caudate activity during reward; chr8:86246604 chr8:86481754~86483002:- LIHC cis rs62355901 0.505 rs61193961 ENSG00000271828.1 CTD-2310F14.1 6.2 1.67e-09 1.19e-06 0.52 0.32 Breast cancer; chr5:56792343 chr5:56927874~56929573:+ LIHC cis rs853679 0.517 rs9393891 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Depression; chr6:28111382 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9468286 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Depression; chr6:28111650 chr6:28115628~28116551:+ LIHC cis rs4713118 0.516 rs7739216 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Parkinson's disease; chr6:28112168 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs35512245 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Depression; chr6:28112175 chr6:28115628~28116551:+ LIHC cis rs853679 0.542 rs9393892 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Depression; chr6:28113616 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9380055 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Depression; chr6:28113851 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9368553 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Depression; chr6:28114487 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9368554 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Depression; chr6:28114933 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs4713137 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Depression; chr6:28115743 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9348793 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Depression; chr6:28116411 chr6:28115628~28116551:+ LIHC cis rs4713118 0.586 rs6905516 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Parkinson's disease; chr6:28118700 chr6:28115628~28116551:+ LIHC cis rs4713118 0.586 rs6905522 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Parkinson's disease; chr6:28118701 chr6:28115628~28116551:+ LIHC cis rs4713118 0.586 rs9468290 ENSG00000219392.1 RP1-265C24.5 -6.19 1.68e-09 1.19e-06 -0.49 -0.32 Parkinson's disease; chr6:28119896 chr6:28115628~28116551:+ LIHC cis rs7914558 0.966 rs11191471 ENSG00000236937.2 PTGES3P4 6.19 1.69e-09 1.2e-06 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102942293 chr10:102845595~102845950:+ LIHC cis rs12550612 0.614 rs4268128 ENSG00000253616.4 RP11-875O11.3 6.19 1.69e-09 1.2e-06 0.4 0.32 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23080343 chr8:23071377~23074488:- LIHC cis rs2274273 0.837 rs6573017 ENSG00000258413.1 RP11-665C16.6 -6.19 1.69e-09 1.2e-06 -0.37 -0.32 Protein biomarker; chr14:55335525 chr14:55262767~55272075:- LIHC cis rs2274273 0.714 rs7154889 ENSG00000258413.1 RP11-665C16.6 -6.19 1.69e-09 1.2e-06 -0.37 -0.32 Protein biomarker; chr14:55340167 chr14:55262767~55272075:- LIHC cis rs2933343 0.951 rs789220 ENSG00000231305.3 RP11-723O4.2 -6.19 1.69e-09 1.2e-06 -0.36 -0.32 IgG glycosylation; chr3:128873292 chr3:128861313~128871540:- LIHC cis rs1799810 0.899 rs6753288 ENSG00000236682.1 AC068282.3 -6.19 1.69e-09 1.2e-06 -0.46 -0.32 Self-rated health; chr2:127412323 chr2:127389130~127400580:+ LIHC cis rs1799810 0.899 rs4662726 ENSG00000236682.1 AC068282.3 6.19 1.69e-09 1.2e-06 0.46 0.32 Self-rated health; chr2:127413086 chr2:127389130~127400580:+ LIHC cis rs2297363 1 rs2297363 ENSG00000213073.4 RP11-288H12.3 -6.19 1.69e-09 1.2e-06 -0.36 -0.32 Total cholesterol levels;Blood protein levels; chr6:160085430 chr6:160093082~160096212:+ LIHC cis rs6490294 0.528 rs12578195 ENSG00000226469.1 ADAM1B 6.19 1.7e-09 1.2e-06 0.48 0.32 Mean platelet volume; chr12:111956130 chr12:111927018~111929017:+ LIHC cis rs6490294 0.528 rs12423689 ENSG00000226469.1 ADAM1B 6.19 1.7e-09 1.2e-06 0.48 0.32 Mean platelet volume; chr12:111965331 chr12:111927018~111929017:+ LIHC cis rs6490294 0.528 rs12423699 ENSG00000226469.1 ADAM1B 6.19 1.7e-09 1.2e-06 0.48 0.32 Mean platelet volume; chr12:111965357 chr12:111927018~111929017:+ LIHC cis rs6490294 0.528 rs12426312 ENSG00000226469.1 ADAM1B 6.19 1.7e-09 1.2e-06 0.48 0.32 Mean platelet volume; chr12:111968945 chr12:111927018~111929017:+ LIHC cis rs739496 0.615 rs609230 ENSG00000226469.1 ADAM1B -6.19 1.7e-09 1.2e-06 -0.41 -0.32 Platelet count; chr12:111709107 chr12:111927018~111929017:+ LIHC cis rs853679 0.517 rs9393887 ENSG00000219392.1 RP1-265C24.5 -6.19 1.7e-09 1.21e-06 -0.48 -0.32 Depression; chr6:28091242 chr6:28115628~28116551:+ LIHC cis rs2286503 0.65 rs1990279 ENSG00000228649.7 AC005682.5 6.19 1.71e-09 1.21e-06 0.37 0.32 Fibrinogen; chr7:22851123 chr7:22854178~22861579:+ LIHC cis rs7176527 0.784 rs62021162 ENSG00000189136.7 UBE2Q2P1 -6.19 1.71e-09 1.21e-06 -0.27 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84565602 chr15:84526781~84571216:- LIHC cis rs6504950 0.85 rs2628321 ENSG00000275710.1 RP11-257O5.4 6.19 1.72e-09 1.22e-06 0.38 0.32 Breast cancer; chr17:55128556 chr17:54964474~54964679:+ LIHC cis rs2787486 1 rs2787486 ENSG00000275710.1 RP11-257O5.4 6.19 1.72e-09 1.22e-06 0.38 0.32 Breast cancer; chr17:55132413 chr17:54964474~54964679:+ LIHC cis rs2439831 0.702 rs9989313 ENSG00000205771.5 CATSPER2P1 -6.19 1.72e-09 1.22e-06 -0.47 -0.32 Lung cancer in ever smokers; chr15:43860619 chr15:43726918~43747094:- LIHC cis rs6479891 1 rs12411988 ENSG00000232075.1 MRPL35P2 -6.19 1.72e-09 1.22e-06 -0.38 -0.32 Arthritis (juvenile idiopathic); chr10:63555637 chr10:63634317~63634827:- LIHC cis rs2735413 0.709 rs1319049 ENSG00000276007.1 RP11-358L22.3 6.19 1.74e-09 1.23e-06 0.36 0.32 Systolic blood pressure (alcohol consumption interaction); chr16:78050713 chr16:78123243~78124332:+ LIHC cis rs9487094 0.67 rs7755941 ENSG00000260273.1 RP11-425D10.10 6.19 1.74e-09 1.23e-06 0.38 0.32 Height; chr6:109494148 chr6:109382795~109383666:+ LIHC cis rs7115242 0.748 rs1035237 ENSG00000236267.1 AP006216.5 6.19 1.74e-09 1.23e-06 0.35 0.32 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116857134 chr11:116813204~116814003:- LIHC cis rs7429990 0.965 rs2166770 ENSG00000229759.1 MRPS18AP1 6.19 1.75e-09 1.24e-06 0.34 0.32 Educational attainment (years of education); chr3:47964183 chr3:48256350~48256938:- LIHC cis rs4423214 0.559 rs11234042 ENSG00000254682.1 RP11-660L16.2 -6.19 1.76e-09 1.24e-06 -0.44 -0.32 Vitamin D levels; chr11:71528040 chr11:71448674~71452157:+ LIHC cis rs2033711 0.936 rs7257999 ENSG00000269473.1 CTD-2619J13.19 6.19 1.76e-09 1.24e-06 0.38 0.32 Uric acid clearance; chr19:58453493 chr19:58440448~58445849:+ LIHC cis rs6490294 0.904 rs76300790 ENSG00000226469.1 ADAM1B 6.19 1.76e-09 1.25e-06 0.43 0.32 Mean platelet volume; chr12:111964865 chr12:111927018~111929017:+ LIHC cis rs2243480 1 rs4718334 ENSG00000273142.1 RP11-458F8.4 6.19 1.77e-09 1.25e-06 0.38 0.32 Diabetic kidney disease; chr7:66324467 chr7:66902857~66906297:+ LIHC cis rs7617773 0.817 rs936426 ENSG00000229759.1 MRPS18AP1 6.19 1.77e-09 1.25e-06 0.37 0.32 Coronary artery disease; chr3:48173763 chr3:48256350~48256938:- LIHC cis rs7674212 0.556 rs223401 ENSG00000230069.3 LRRC37A15P -6.19 1.77e-09 1.25e-06 -0.3 -0.32 Type 2 diabetes; chr4:102817815 chr4:102727274~102730721:- LIHC cis rs7429990 0.803 rs11714518 ENSG00000229759.1 MRPS18AP1 -6.19 1.77e-09 1.25e-06 -0.33 -0.32 Educational attainment (years of education); chr3:48115145 chr3:48256350~48256938:- LIHC cis rs4660456 0.913 rs6667368 ENSG00000237899.1 RP4-739H11.3 6.18 1.77e-09 1.25e-06 0.44 0.32 Platelet count; chr1:40694887 chr1:40669089~40687588:- LIHC cis rs4423214 0.592 rs79634040 ENSG00000254682.1 RP11-660L16.2 -6.18 1.77e-09 1.25e-06 -0.43 -0.32 Vitamin D levels; chr11:71519123 chr11:71448674~71452157:+ LIHC cis rs4423214 0.547 rs11234030 ENSG00000254682.1 RP11-660L16.2 -6.18 1.78e-09 1.26e-06 -0.43 -0.32 Vitamin D levels; chr11:71525921 chr11:71448674~71452157:+ LIHC cis rs2933343 1 rs789227 ENSG00000231305.3 RP11-723O4.2 6.18 1.78e-09 1.26e-06 0.36 0.32 IgG glycosylation; chr3:128881742 chr3:128861313~128871540:- LIHC cis rs113835537 0.529 rs3741360 ENSG00000255517.5 CTD-3074O7.5 -6.18 1.78e-09 1.26e-06 -0.36 -0.32 Airway imaging phenotypes; chr11:66532877 chr11:66473490~66480233:- LIHC cis rs5758659 0.714 rs2284087 ENSG00000227370.1 RP4-669P10.19 6.18 1.79e-09 1.26e-06 0.35 0.32 Cognitive function; chr22:42089667 chr22:42132543~42132998:+ LIHC cis rs2735413 0.599 rs76440854 ENSG00000276007.1 RP11-358L22.3 6.18 1.81e-09 1.27e-06 0.46 0.32 Systolic blood pressure (alcohol consumption interaction); chr16:78046986 chr16:78123243~78124332:+ LIHC cis rs17023223 0.537 rs3934789 ENSG00000231365.4 RP11-418J17.1 -6.18 1.81e-09 1.28e-06 -0.39 -0.32 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119140440 chr1:119140396~119275973:+ LIHC cis rs523522 0.962 rs7471 ENSG00000278344.1 RP11-18C24.8 6.18 1.81e-09 1.28e-06 0.38 0.32 High light scatter reticulocyte count; chr12:120503412 chr12:120500735~120501090:- LIHC cis rs1023500 0.573 rs2269524 ENSG00000237037.8 NDUFA6-AS1 -6.18 1.81e-09 1.28e-06 -0.38 -0.32 Schizophrenia; chr22:42079699 chr22:42090931~42137742:+ LIHC cis rs8100891 0.537 rs2012353 ENSG00000267213.4 AC007773.2 -6.18 1.82e-09 1.29e-06 -0.4 -0.32 Neuroticism; chr19:32408387 chr19:32390050~32405560:- LIHC cis rs853679 0.538 rs13199081 ENSG00000204709.4 LINC01556 6.18 1.82e-09 1.29e-06 0.42 0.32 Depression; chr6:28364057 chr6:28943877~28944537:+ LIHC cis rs5769765 0.542 rs761878 ENSG00000278869.1 CITF22-49E9.3 -6.18 1.83e-09 1.29e-06 -0.6 -0.32 Schizophrenia; chr22:49856029 chr22:49933198~49934074:- LIHC cis rs10510102 0.935 rs11200263 ENSG00000276742.1 RP11-500G22.4 6.18 1.83e-09 1.29e-06 0.5 0.32 Breast cancer; chr10:121922836 chr10:121956782~121957098:+ LIHC cis rs765787 0.53 rs4514617 ENSG00000259520.4 CTD-2651B20.3 6.18 1.84e-09 1.3e-06 0.38 0.32 Uric acid levels; chr15:45243241 chr15:45251580~45279251:- LIHC cis rs12681287 0.752 rs12677470 ENSG00000250569.1 NTAN1P2 6.18 1.84e-09 1.3e-06 0.38 0.32 Caudate activity during reward; chr8:86248330 chr8:86481754~86483002:- LIHC cis rs12681287 0.752 rs10435563 ENSG00000250569.1 NTAN1P2 6.18 1.84e-09 1.3e-06 0.38 0.32 Caudate activity during reward; chr8:86253831 chr8:86481754~86483002:- LIHC cis rs12681287 0.752 rs10435564 ENSG00000250569.1 NTAN1P2 6.18 1.84e-09 1.3e-06 0.38 0.32 Caudate activity during reward; chr8:86254010 chr8:86481754~86483002:- LIHC cis rs6991838 0.584 rs7842085 ENSG00000200714.1 Y_RNA 6.18 1.85e-09 1.31e-06 0.34 0.32 Intelligence (multi-trait analysis); chr8:65636787 chr8:65592731~65592820:+ LIHC cis rs8040855 0.579 rs28521166 ENSG00000259295.5 CSPG4P12 -6.18 1.85e-09 1.31e-06 -0.39 -0.32 Bulimia nervosa; chr15:85184801 chr15:85191438~85213905:+ LIHC cis rs2882667 0.537 rs10057545 ENSG00000253404.1 AC034243.1 6.18 1.86e-09 1.31e-06 0.41 0.32 Age-related hearing impairment (SNP x SNP interaction); chr5:139095319 chr5:138744434~138753309:- LIHC cis rs523522 0.962 rs509445 ENSG00000278344.1 RP11-18C24.8 6.18 1.86e-09 1.31e-06 0.38 0.32 High light scatter reticulocyte count; chr12:120579440 chr12:120500735~120501090:- LIHC cis rs11603023 0.569 rs573905 ENSG00000255239.1 AP002954.6 6.18 1.87e-09 1.31e-06 0.37 0.32 Cholesterol, total; chr11:118701558 chr11:118688039~118690600:- LIHC cis rs9525916 0.967 rs9533775 ENSG00000227258.4 SMIM2-AS1 -6.18 1.87e-09 1.32e-06 -0.36 -0.32 Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction); chr13:44123820 chr13:44110451~44240517:+ LIHC cis rs6142102 0.961 rs2300204 ENSG00000276073.1 RP5-1125A11.7 -6.17 1.88e-09 1.32e-06 -0.35 -0.32 Skin pigmentation; chr20:34000967 chr20:33985617~33988989:- LIHC cis rs5758659 0.714 rs5758578 ENSG00000227370.1 RP4-669P10.19 6.17 1.89e-09 1.33e-06 0.35 0.32 Cognitive function; chr22:42094288 chr22:42132543~42132998:+ LIHC cis rs2243480 1 rs313803 ENSG00000273142.1 RP11-458F8.4 -6.17 1.89e-09 1.33e-06 -0.39 -0.32 Diabetic kidney disease; chr7:66049744 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs313802 ENSG00000273142.1 RP11-458F8.4 -6.17 1.89e-09 1.33e-06 -0.39 -0.32 Diabetic kidney disease; chr7:66051386 chr7:66902857~66906297:+ LIHC cis rs2243480 0.803 rs403089 ENSG00000273142.1 RP11-458F8.4 -6.17 1.89e-09 1.33e-06 -0.39 -0.32 Diabetic kidney disease; chr7:66052736 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs458291 ENSG00000273142.1 RP11-458F8.4 -6.17 1.89e-09 1.33e-06 -0.39 -0.32 Diabetic kidney disease; chr7:66055492 chr7:66902857~66906297:+ LIHC cis rs7674212 0.531 rs2866416 ENSG00000230069.3 LRRC37A15P -6.17 1.89e-09 1.33e-06 -0.3 -0.32 Type 2 diabetes; chr4:102959554 chr4:102727274~102730721:- LIHC cis rs7567389 0.511 rs61185143 ENSG00000236682.1 AC068282.3 6.17 1.9e-09 1.34e-06 0.45 0.32 Self-rated health; chr2:127407902 chr2:127389130~127400580:+ LIHC cis rs62355900 0.627 rs62358104 ENSG00000271828.1 CTD-2310F14.1 6.17 1.91e-09 1.34e-06 0.5 0.32 Endometriosis; chr5:56863344 chr5:56927874~56929573:+ LIHC cis rs1023500 0.551 rs133371 ENSG00000237037.8 NDUFA6-AS1 6.17 1.91e-09 1.34e-06 0.38 0.32 Schizophrenia; chr22:42069570 chr22:42090931~42137742:+ LIHC cis rs1023500 0.573 rs133374 ENSG00000237037.8 NDUFA6-AS1 6.17 1.91e-09 1.34e-06 0.38 0.32 Schizophrenia; chr22:42069937 chr22:42090931~42137742:+ LIHC cis rs1023500 0.573 rs133378 ENSG00000237037.8 NDUFA6-AS1 6.17 1.91e-09 1.34e-06 0.38 0.32 Schizophrenia; chr22:42071691 chr22:42090931~42137742:+ LIHC cis rs1023500 0.573 rs133382 ENSG00000237037.8 NDUFA6-AS1 6.17 1.91e-09 1.34e-06 0.38 0.32 Schizophrenia; chr22:42075770 chr22:42090931~42137742:+ LIHC cis rs4814920 0.756 rs6046400 ENSG00000275142.1 RP5-999L4.2 -6.17 1.91e-09 1.34e-06 -0.63 -0.32 Bipolar disorder (body mass index interaction); chr20:19878482 chr20:19871891~19872284:+ LIHC cis rs9640161 0.75 rs73170185 ENSG00000261305.1 RP4-584D14.7 6.17 1.92e-09 1.35e-06 0.41 0.32 Blood protein levels;Circulating chemerin levels; chr7:150333102 chr7:150341771~150342607:+ LIHC cis rs9549367 0.789 rs9549708 ENSG00000269125.1 RP11-98F14.11 -6.17 1.92e-09 1.35e-06 -0.39 -0.32 Platelet distribution width; chr13:113237573 chr13:113165002~113165183:- LIHC cis rs4356975 0.522 rs7679184 ENSG00000249956.3 RP11-790I12.2 6.17 1.93e-09 1.35e-06 0.35 0.32 Obesity-related traits; chr4:69100212 chr4:69408836~69423164:+ LIHC cis rs9487094 0.626 rs12195904 ENSG00000260273.1 RP11-425D10.10 6.17 1.93e-09 1.35e-06 0.38 0.32 Height; chr6:109494760 chr6:109382795~109383666:+ LIHC cis rs4356975 0.509 rs4587017 ENSG00000249956.3 RP11-790I12.2 6.17 1.93e-09 1.35e-06 0.36 0.32 Obesity-related traits; chr4:69081680 chr4:69408836~69423164:+ LIHC cis rs4356975 0.509 rs4458521 ENSG00000249956.3 RP11-790I12.2 6.17 1.93e-09 1.35e-06 0.36 0.32 Obesity-related traits; chr4:69086240 chr4:69408836~69423164:+ LIHC cis rs4356975 0.509 rs4694169 ENSG00000249956.3 RP11-790I12.2 6.17 1.93e-09 1.35e-06 0.36 0.32 Obesity-related traits; chr4:69088433 chr4:69408836~69423164:+ LIHC cis rs7617773 0.743 rs71323397 ENSG00000229759.1 MRPS18AP1 6.17 1.93e-09 1.35e-06 0.39 0.32 Coronary artery disease; chr3:48333384 chr3:48256350~48256938:- LIHC cis rs1185460 0.934 rs1006195 ENSG00000271751.1 RP11-110I1.14 6.17 1.94e-09 1.36e-06 0.43 0.32 Coronary artery disease; chr11:119088159 chr11:119065263~119065677:- LIHC cis rs904251 0.504 rs2797795 ENSG00000204110.6 RP1-153P14.8 -6.17 1.94e-09 1.36e-06 -0.38 -0.32 Cognitive performance; chr6:37512907 chr6:37507348~37535616:+ LIHC cis rs10461617 0.617 rs79742142 ENSG00000271828.1 CTD-2310F14.1 6.17 1.94e-09 1.36e-06 0.45 0.32 Type 2 diabetes; chr5:56808550 chr5:56927874~56929573:+ LIHC cis rs1862618 0.853 rs832582 ENSG00000271828.1 CTD-2310F14.1 6.17 1.95e-09 1.37e-06 0.45 0.32 Initial pursuit acceleration; chr5:56881916 chr5:56927874~56929573:+ LIHC cis rs1862618 0.853 rs832583 ENSG00000271828.1 CTD-2310F14.1 6.17 1.95e-09 1.37e-06 0.45 0.32 Initial pursuit acceleration; chr5:56882390 chr5:56927874~56929573:+ LIHC cis rs1862618 0.713 rs832550 ENSG00000271828.1 CTD-2310F14.1 6.17 1.95e-09 1.37e-06 0.45 0.32 Initial pursuit acceleration; chr5:56886762 chr5:56927874~56929573:+ LIHC cis rs1862618 0.713 rs832549 ENSG00000271828.1 CTD-2310F14.1 6.17 1.95e-09 1.37e-06 0.45 0.32 Initial pursuit acceleration; chr5:56887715 chr5:56927874~56929573:+ LIHC cis rs1862618 0.802 rs832547 ENSG00000271828.1 CTD-2310F14.1 6.17 1.95e-09 1.37e-06 0.45 0.32 Initial pursuit acceleration; chr5:56888114 chr5:56927874~56929573:+ LIHC cis rs1862618 0.853 rs866222 ENSG00000271828.1 CTD-2310F14.1 6.17 1.95e-09 1.37e-06 0.45 0.32 Initial pursuit acceleration; chr5:56888617 chr5:56927874~56929573:+ LIHC cis rs1862618 0.853 rs861283 ENSG00000271828.1 CTD-2310F14.1 6.17 1.95e-09 1.37e-06 0.45 0.32 Initial pursuit acceleration; chr5:56888783 chr5:56927874~56929573:+ LIHC cis rs1862618 0.802 rs252900 ENSG00000271828.1 CTD-2310F14.1 6.17 1.95e-09 1.37e-06 0.45 0.32 Initial pursuit acceleration; chr5:56889454 chr5:56927874~56929573:+ LIHC cis rs2933343 0.716 rs9872706 ENSG00000231305.3 RP11-723O4.2 -6.17 1.96e-09 1.37e-06 -0.37 -0.32 IgG glycosylation; chr3:128848262 chr3:128861313~128871540:- LIHC cis rs10510102 0.872 rs12240306 ENSG00000276742.1 RP11-500G22.4 6.17 1.97e-09 1.38e-06 0.52 0.32 Breast cancer; chr10:121963391 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs12240308 ENSG00000276742.1 RP11-500G22.4 6.17 1.97e-09 1.38e-06 0.52 0.32 Breast cancer; chr10:121963407 chr10:121956782~121957098:+ LIHC cis rs11676348 0.776 rs11690316 ENSG00000261338.2 RP11-378A13.1 -6.17 1.97e-09 1.38e-06 -0.34 -0.32 Ulcerative colitis; chr2:218152739 chr2:218255319~218257366:+ LIHC cis rs13068223 0.562 rs346003 ENSG00000243926.1 TIPARP-AS1 -6.17 1.97e-09 1.38e-06 -0.34 -0.32 Age-related hearing impairment (SNP x SNP interaction); chr3:156705283 chr3:156671862~156674378:- LIHC cis rs523522 0.962 rs603574 ENSG00000278344.1 RP11-18C24.8 6.17 1.98e-09 1.38e-06 0.38 0.32 High light scatter reticulocyte count; chr12:120560640 chr12:120500735~120501090:- LIHC cis rs67180937 0.553 rs3002148 ENSG00000272750.1 RP11-378J18.8 6.17 1.98e-09 1.38e-06 0.37 0.32 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222637575 chr1:222658867~222661512:- LIHC cis rs1862618 0.853 rs863840 ENSG00000271828.1 CTD-2310F14.1 6.17 1.98e-09 1.38e-06 0.44 0.32 Initial pursuit acceleration; chr5:56833172 chr5:56927874~56929573:+ LIHC cis rs12130219 0.5 rs4845743 ENSG00000237975.5 FLG-AS1 -6.17 1.98e-09 1.39e-06 -0.37 -0.32 Inflammatory skin disease; chr1:152211673 chr1:152168125~152445456:+ LIHC cis rs7927592 0.913 rs4316515 ENSG00000212093.1 AP000807.1 -6.17 1.98e-09 1.39e-06 -0.35 -0.32 Total body bone mineral density; chr11:68541372 chr11:68506083~68506166:- LIHC cis rs5760092 0.755 rs4585126 ENSG00000206090.4 AP000350.7 -6.16 1.99e-09 1.39e-06 -0.4 -0.32 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23939998~23942798:+ LIHC cis rs12439619 0.508 rs8042665 ENSG00000278603.1 RP13-608F4.5 6.16 2e-09 1.4e-06 0.41 0.32 Intelligence (multi-trait analysis); chr15:82189008 chr15:82472203~82472426:+ LIHC cis rs12681287 0.64 rs7007855 ENSG00000250569.1 NTAN1P2 -6.16 2e-09 1.4e-06 -0.37 -0.32 Caudate activity during reward; chr8:86417262 chr8:86481754~86483002:- LIHC cis rs12681287 0.57 rs10956830 ENSG00000250569.1 NTAN1P2 -6.16 2e-09 1.4e-06 -0.37 -0.32 Caudate activity during reward; chr8:86418254 chr8:86481754~86483002:- LIHC cis rs12681287 0.604 rs28378899 ENSG00000250569.1 NTAN1P2 -6.16 2e-09 1.4e-06 -0.37 -0.32 Caudate activity during reward; chr8:86422271 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs10098356 ENSG00000250569.1 NTAN1P2 -6.16 2e-09 1.4e-06 -0.37 -0.32 Caudate activity during reward; chr8:86430438 chr8:86481754~86483002:- LIHC cis rs8062405 0.573 rs7187575 ENSG00000259982.1 CDC37P1 -6.16 2.01e-09 1.41e-06 -0.41 -0.32 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28978780 chr16:28700294~28701540:- LIHC cis rs4814920 0.818 rs6046387 ENSG00000275142.1 RP5-999L4.2 -6.16 2.02e-09 1.41e-06 -0.63 -0.32 Bipolar disorder (body mass index interaction); chr20:19869186 chr20:19871891~19872284:+ LIHC cis rs6085948 0.861 rs6054847 ENSG00000238102.1 RP11-19D2.1 -6.16 2.02e-09 1.41e-06 -0.62 -0.32 Interleukin-10 levels; chr20:7249794 chr20:7256580~7258214:- LIHC cis rs6085948 0.861 rs11908494 ENSG00000238102.1 RP11-19D2.1 -6.16 2.02e-09 1.41e-06 -0.62 -0.32 Interleukin-10 levels; chr20:7250266 chr20:7256580~7258214:- LIHC cis rs9549367 0.789 rs912012 ENSG00000269125.1 RP11-98F14.11 -6.16 2.02e-09 1.41e-06 -0.39 -0.32 Platelet distribution width; chr13:113231838 chr13:113165002~113165183:- LIHC cis rs4423214 0.559 rs10898228 ENSG00000254682.1 RP11-660L16.2 -6.16 2.03e-09 1.41e-06 -0.43 -0.32 Vitamin D levels; chr11:71517312 chr11:71448674~71452157:+ LIHC cis rs12681287 0.64 rs7846090 ENSG00000250569.1 NTAN1P2 6.16 2.03e-09 1.42e-06 0.37 0.32 Caudate activity during reward; chr8:86455495 chr8:86481754~86483002:- LIHC cis rs9549367 0.826 rs2287249 ENSG00000269125.1 RP11-98F14.11 -6.16 2.04e-09 1.42e-06 -0.39 -0.32 Platelet distribution width; chr13:113235041 chr13:113165002~113165183:- LIHC cis rs2720460 0.502 rs223374 ENSG00000230069.3 LRRC37A15P -6.16 2.04e-09 1.42e-06 -0.3 -0.32 Testicular germ cell tumor; chr4:102837144 chr4:102727274~102730721:- LIHC cis rs4538475 0.697 rs16892260 ENSG00000214846.4 RP11-115L11.1 6.16 2.04e-09 1.43e-06 0.44 0.32 Parkinson's disease; chr4:15711380 chr4:15730962~15731627:- LIHC cis rs9660180 0.875 rs4648727 ENSG00000231050.1 RP1-140A9.1 -6.16 2.04e-09 1.43e-06 -0.31 -0.32 Body mass index; chr1:1844830 chr1:1891471~1892658:+ LIHC cis rs1577917 0.771 rs2758844 ENSG00000234155.1 RP11-30P6.6 6.16 2.05e-09 1.43e-06 0.4 0.32 Response to antipsychotic treatment; chr6:85620397 chr6:85387219~85390186:- LIHC cis rs2439831 0.867 rs2470134 ENSG00000205771.5 CATSPER2P1 6.16 2.05e-09 1.43e-06 0.48 0.32 Lung cancer in ever smokers; chr15:43557688 chr15:43726918~43747094:- LIHC cis rs7914558 0.899 rs7913682 ENSG00000236937.2 PTGES3P4 6.16 2.05e-09 1.43e-06 0.37 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102924635 chr10:102845595~102845950:+ LIHC cis rs2455601 1 rs11042108 ENSG00000254860.4 TMEM9B-AS1 6.16 2.06e-09 1.44e-06 0.4 0.32 Schizophrenia; chr11:8884474 chr11:8964675~8977527:+ LIHC cis rs2836950 0.565 rs8130320 ENSG00000255568.3 BRWD1-AS2 -6.16 2.07e-09 1.44e-06 -0.26 -0.32 Menarche (age at onset); chr21:39208332 chr21:39313935~39314962:+ LIHC cis rs3020736 0.5 rs8143153 ENSG00000237037.8 NDUFA6-AS1 -6.16 2.07e-09 1.45e-06 -0.38 -0.32 Autism spectrum disorder or schizophrenia; chr22:42119633 chr22:42090931~42137742:+ LIHC cis rs2762353 0.595 rs12200838 ENSG00000242387.1 HIST1H2APS2 -6.16 2.08e-09 1.45e-06 -0.39 -0.32 Blood metabolite levels; chr6:25753375 chr6:25882026~25882395:- LIHC cis rs2762353 0.595 rs1892256 ENSG00000242387.1 HIST1H2APS2 -6.16 2.08e-09 1.45e-06 -0.39 -0.32 Blood metabolite levels; chr6:25754043 chr6:25882026~25882395:- LIHC cis rs2439831 0.571 rs689883 ENSG00000205771.5 CATSPER2P1 -6.16 2.09e-09 1.46e-06 -0.43 -0.32 Lung cancer in ever smokers; chr15:43520398 chr15:43726918~43747094:- LIHC cis rs7914558 0.966 rs4532960 ENSG00000236937.2 PTGES3P4 6.16 2.1e-09 1.46e-06 0.37 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102907649 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs10786724 ENSG00000236937.2 PTGES3P4 6.16 2.1e-09 1.46e-06 0.37 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102909185 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs2297786 ENSG00000236937.2 PTGES3P4 6.16 2.1e-09 1.46e-06 0.37 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102920221 chr10:102845595~102845950:+ LIHC cis rs853679 0.567 rs3799499 ENSG00000204709.4 LINC01556 6.16 2.1e-09 1.46e-06 0.42 0.32 Depression; chr6:28386473 chr6:28943877~28944537:+ LIHC cis rs7208859 0.528 rs3764416 ENSG00000263531.1 RP13-753N3.1 -6.16 2.1e-09 1.46e-06 -0.56 -0.32 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30573690 chr17:30863921~30864940:- LIHC cis rs7119038 0.818 rs73003215 ENSG00000255239.1 AP002954.6 -6.15 2.1e-09 1.46e-06 -0.4 -0.32 Sjögren's syndrome; chr11:118778803 chr11:118688039~118690600:- LIHC cis rs7617773 0.78 rs13082158 ENSG00000229759.1 MRPS18AP1 6.15 2.11e-09 1.47e-06 0.39 0.32 Coronary artery disease; chr3:48330980 chr3:48256350~48256938:- LIHC cis rs7617773 0.676 rs13060020 ENSG00000229759.1 MRPS18AP1 6.15 2.11e-09 1.47e-06 0.39 0.32 Coronary artery disease; chr3:48331156 chr3:48256350~48256938:- LIHC cis rs904251 0.523 rs2797794 ENSG00000204110.6 RP1-153P14.8 -6.15 2.12e-09 1.47e-06 -0.38 -0.32 Cognitive performance; chr6:37512828 chr6:37507348~37535616:+ LIHC cis rs62355900 0.627 rs61141156 ENSG00000271828.1 CTD-2310F14.1 6.15 2.12e-09 1.47e-06 0.49 0.32 Endometriosis; chr5:56842951 chr5:56927874~56929573:+ LIHC cis rs62355900 0.627 rs58151318 ENSG00000271828.1 CTD-2310F14.1 6.15 2.12e-09 1.47e-06 0.49 0.32 Endometriosis; chr5:56843355 chr5:56927874~56929573:+ LIHC cis rs62355900 0.627 rs16886403 ENSG00000271828.1 CTD-2310F14.1 6.15 2.12e-09 1.47e-06 0.49 0.32 Endometriosis; chr5:56843419 chr5:56927874~56929573:+ LIHC cis rs9549367 0.789 rs34448227 ENSG00000269125.1 RP11-98F14.11 -6.15 2.12e-09 1.48e-06 -0.39 -0.32 Platelet distribution width; chr13:113230440 chr13:113165002~113165183:- LIHC cis rs7914558 0.966 rs7096269 ENSG00000236937.2 PTGES3P4 6.15 2.12e-09 1.48e-06 0.37 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102976964 chr10:102845595~102845950:+ LIHC cis rs7914558 0.933 rs10883814 ENSG00000236937.2 PTGES3P4 6.15 2.12e-09 1.48e-06 0.37 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102977647 chr10:102845595~102845950:+ LIHC cis rs6504950 0.888 rs2628315 ENSG00000275710.1 RP11-257O5.4 6.15 2.13e-09 1.48e-06 0.38 0.32 Breast cancer; chr17:55149261 chr17:54964474~54964679:+ LIHC cis rs2243480 1 rs12698509 ENSG00000164669.11 INTS4P1 6.15 2.13e-09 1.48e-06 0.55 0.32 Diabetic kidney disease; chr7:65953889 chr7:65141225~65234216:+ LIHC cis rs8100891 0.537 rs73036023 ENSG00000267213.4 AC007773.2 -6.15 2.13e-09 1.48e-06 -0.41 -0.32 Neuroticism; chr19:32457414 chr19:32390050~32405560:- LIHC cis rs904251 0.523 rs9349039 ENSG00000204110.6 RP1-153P14.8 -6.15 2.13e-09 1.49e-06 -0.38 -0.32 Cognitive performance; chr6:37512616 chr6:37507348~37535616:+ LIHC cis rs904251 0.523 rs9366935 ENSG00000204110.6 RP1-153P14.8 -6.15 2.13e-09 1.49e-06 -0.38 -0.32 Cognitive performance; chr6:37512628 chr6:37507348~37535616:+ LIHC cis rs2565722 0.825 rs1247540 ENSG00000243831.1 RP1-81D8.4 6.15 2.14e-09 1.49e-06 0.49 0.32 Blood protein levels; chr6:160831984 chr6:160666228~160676523:- LIHC cis rs6142102 0.961 rs6088355 ENSG00000276073.1 RP5-1125A11.7 -6.15 2.14e-09 1.49e-06 -0.35 -0.32 Skin pigmentation; chr20:33958081 chr20:33985617~33988989:- LIHC cis rs6142102 0.961 rs6057957 ENSG00000276073.1 RP5-1125A11.7 -6.15 2.14e-09 1.49e-06 -0.35 -0.32 Skin pigmentation; chr20:33962052 chr20:33985617~33988989:- LIHC cis rs853679 0.567 rs2232427 ENSG00000204709.4 LINC01556 6.15 2.15e-09 1.49e-06 0.42 0.32 Depression; chr6:28391932 chr6:28943877~28944537:+ LIHC cis rs9843304 0.616 rs4681174 ENSG00000244503.1 RP11-278L15.6 6.15 2.15e-09 1.5e-06 0.34 0.32 Gallstone disease; chr3:149483839 chr3:149494660~149495995:+ LIHC cis rs9399137 0.507 rs7768278 ENSG00000232876.1 CTA-212D2.2 -6.15 2.16e-09 1.5e-06 -0.36 -0.32 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134953819 chr6:135055033~135060550:+ LIHC cis rs9549367 0.789 rs9549705 ENSG00000269125.1 RP11-98F14.11 -6.15 2.16e-09 1.5e-06 -0.39 -0.32 Platelet distribution width; chr13:113234111 chr13:113165002~113165183:- LIHC cis rs8177376 1 rs598169 ENSG00000254905.1 RP11-712L6.7 6.15 2.17e-09 1.51e-06 0.47 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126219158 chr11:126292922~126294254:- LIHC cis rs1023500 0.505 rs134874 ENSG00000237037.8 NDUFA6-AS1 6.15 2.17e-09 1.51e-06 0.33 0.32 Schizophrenia; chr22:42265138 chr22:42090931~42137742:+ LIHC cis rs4538475 1 rs4273468 ENSG00000214846.4 RP11-115L11.1 -6.15 2.17e-09 1.51e-06 -0.41 -0.32 Parkinson's disease; chr4:15736240 chr4:15730962~15731627:- LIHC cis rs7637701 0.517 rs3851992 ENSG00000243926.1 TIPARP-AS1 6.15 2.17e-09 1.51e-06 0.29 0.32 Breast cancer; chr3:156681391 chr3:156671862~156674378:- LIHC cis rs17826219 0.585 rs8064302 ENSG00000263531.1 RP13-753N3.1 -6.15 2.18e-09 1.51e-06 -0.55 -0.32 Body mass index; chr17:30397920 chr17:30863921~30864940:- LIHC cis rs4423214 0.592 rs7114252 ENSG00000254682.1 RP11-660L16.2 -6.15 2.18e-09 1.51e-06 -0.43 -0.32 Vitamin D levels; chr11:71526560 chr11:71448674~71452157:+ LIHC cis rs1023500 0.573 rs6002592 ENSG00000237037.8 NDUFA6-AS1 -6.15 2.18e-09 1.52e-06 -0.38 -0.32 Schizophrenia; chr22:42080750 chr22:42090931~42137742:+ LIHC cis rs7429990 0.965 rs7426976 ENSG00000229759.1 MRPS18AP1 -6.15 2.19e-09 1.52e-06 -0.33 -0.32 Educational attainment (years of education); chr3:47981083 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs1013431 ENSG00000229759.1 MRPS18AP1 -6.15 2.19e-09 1.52e-06 -0.33 -0.32 Educational attainment (years of education); chr3:47987628 chr3:48256350~48256938:- LIHC cis rs7429990 0.932 rs9862913 ENSG00000229759.1 MRPS18AP1 6.15 2.19e-09 1.52e-06 0.33 0.32 Educational attainment (years of education); chr3:47974682 chr3:48256350~48256938:- LIHC cis rs875971 0.502 rs6460311 ENSG00000226824.5 RP4-756H11.3 6.15 2.2e-09 1.53e-06 0.41 0.32 Aortic root size; chr7:66646886 chr7:66654538~66669855:+ LIHC cis rs1862618 0.756 rs832548 ENSG00000271828.1 CTD-2310F14.1 6.15 2.21e-09 1.53e-06 0.44 0.32 Initial pursuit acceleration; chr5:56887810 chr5:56927874~56929573:+ LIHC cis rs1577917 0.771 rs2783171 ENSG00000234155.1 RP11-30P6.6 -6.15 2.21e-09 1.54e-06 -0.4 -0.32 Response to antipsychotic treatment; chr6:85673047 chr6:85387219~85390186:- LIHC cis rs6801605 0.963 rs6445607 ENSG00000271916.1 RP11-884K10.6 -6.15 2.22e-09 1.54e-06 -0.45 -0.32 Blood protein levels; chr3:53843122 chr3:53797764~53798019:- LIHC cis rs9487094 0.67 rs1406899 ENSG00000260273.1 RP11-425D10.10 6.14 2.23e-09 1.55e-06 0.38 0.32 Height; chr6:109495102 chr6:109382795~109383666:+ LIHC cis rs7914558 0.966 rs10786745 ENSG00000236937.2 PTGES3P4 6.14 2.24e-09 1.55e-06 0.37 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103197070 chr10:102845595~102845950:+ LIHC cis rs8059260 0.736 rs7192695 ENSG00000274038.1 RP11-66H6.4 -6.14 2.24e-09 1.56e-06 -0.51 -0.32 Alcohol consumption over the past year; chr16:11005395 chr16:11056556~11057034:+ LIHC cis rs1577917 0.74 rs2842604 ENSG00000234155.1 RP11-30P6.6 6.14 2.25e-09 1.56e-06 0.4 0.32 Response to antipsychotic treatment; chr6:85626582 chr6:85387219~85390186:- LIHC cis rs1577917 0.771 rs2842607 ENSG00000234155.1 RP11-30P6.6 6.14 2.25e-09 1.56e-06 0.4 0.32 Response to antipsychotic treatment; chr6:85635321 chr6:85387219~85390186:- LIHC cis rs1577917 0.771 rs2758847 ENSG00000234155.1 RP11-30P6.6 6.14 2.25e-09 1.56e-06 0.4 0.32 Response to antipsychotic treatment; chr6:85639385 chr6:85387219~85390186:- LIHC cis rs2439831 0.702 rs16977724 ENSG00000205771.5 CATSPER2P1 -6.14 2.26e-09 1.57e-06 -0.48 -0.32 Lung cancer in ever smokers; chr15:43859101 chr15:43726918~43747094:- LIHC cis rs9640161 0.711 rs3735170 ENSG00000261305.1 RP4-584D14.7 6.14 2.26e-09 1.57e-06 0.41 0.32 Blood protein levels;Circulating chemerin levels; chr7:150337095 chr7:150341771~150342607:+ LIHC cis rs9640161 0.75 rs3735169 ENSG00000261305.1 RP4-584D14.7 6.14 2.26e-09 1.57e-06 0.41 0.32 Blood protein levels;Circulating chemerin levels; chr7:150337289 chr7:150341771~150342607:+ LIHC cis rs17270561 0.609 rs1937131 ENSG00000216436.2 HIST1H2APS1 6.14 2.26e-09 1.57e-06 0.38 0.32 Iron status biomarkers; chr6:25744603 chr6:25732497~25732827:+ LIHC cis rs3096299 0.933 rs2965934 ENSG00000274627.1 RP11-104N10.2 6.14 2.27e-09 1.57e-06 0.33 0.32 Multiple myeloma (IgH translocation); chr16:89414821 chr16:89516797~89522217:+ LIHC cis rs2933343 0.951 rs789251 ENSG00000231305.3 RP11-723O4.2 6.14 2.27e-09 1.57e-06 0.36 0.32 IgG glycosylation; chr3:128857927 chr3:128861313~128871540:- LIHC cis rs9326248 1 rs664971 ENSG00000280143.1 AP000892.6 -6.14 2.28e-09 1.58e-06 -0.36 -0.32 Blood protein levels; chr11:117200141 chr11:117204967~117210292:+ LIHC cis rs8177376 0.953 rs529328 ENSG00000254905.1 RP11-712L6.7 6.14 2.28e-09 1.58e-06 0.47 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126263746 chr11:126292922~126294254:- LIHC cis rs2243480 1 rs73142166 ENSG00000273142.1 RP11-458F8.4 -6.14 2.28e-09 1.58e-06 -0.4 -0.32 Diabetic kidney disease; chr7:65910845 chr7:66902857~66906297:+ LIHC cis rs7617773 0.779 rs77957078 ENSG00000229759.1 MRPS18AP1 6.14 2.28e-09 1.58e-06 0.38 0.32 Coronary artery disease; chr3:48289796 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs35199727 ENSG00000229759.1 MRPS18AP1 6.14 2.29e-09 1.58e-06 0.35 0.32 Educational attainment (years of education); chr3:47905218 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs11707679 ENSG00000229759.1 MRPS18AP1 6.14 2.29e-09 1.58e-06 0.35 0.32 Educational attainment (years of education); chr3:47915016 chr3:48256350~48256938:- LIHC cis rs2749592 0.531 rs1208559 ENSG00000263064.2 RP11-291L22.7 -6.14 2.29e-09 1.59e-06 -0.32 -0.32 Age-related hearing impairment (SNP x SNP interaction); chr10:37932442 chr10:38448689~38448949:+ LIHC cis rs2439831 0.717 rs2470132 ENSG00000205771.5 CATSPER2P1 -6.14 2.3e-09 1.59e-06 -0.43 -0.32 Lung cancer in ever smokers; chr15:43543283 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs2251844 ENSG00000205771.5 CATSPER2P1 -6.14 2.3e-09 1.59e-06 -0.43 -0.32 Lung cancer in ever smokers; chr15:43544280 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs486301 ENSG00000205771.5 CATSPER2P1 -6.14 2.3e-09 1.59e-06 -0.43 -0.32 Lung cancer in ever smokers; chr15:43544751 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs2255051 ENSG00000205771.5 CATSPER2P1 -6.14 2.3e-09 1.59e-06 -0.43 -0.32 Lung cancer in ever smokers; chr15:43553963 chr15:43726918~43747094:- LIHC cis rs12458462 0.892 rs2242175 ENSG00000274828.1 RP11-567M16.6 6.14 2.3e-09 1.59e-06 0.32 0.32 Monocyte count; chr18:79704406 chr18:79677287~79679358:- LIHC cis rs9527 0.551 rs28606370 ENSG00000236937.2 PTGES3P4 6.14 2.31e-09 1.59e-06 0.38 0.32 Arsenic metabolism; chr10:102911075 chr10:102845595~102845950:+ LIHC cis rs7429990 0.932 rs11130155 ENSG00000229759.1 MRPS18AP1 -6.14 2.32e-09 1.6e-06 -0.33 -0.31 Educational attainment (years of education); chr3:48098938 chr3:48256350~48256938:- LIHC cis rs7429990 0.901 rs6442102 ENSG00000229759.1 MRPS18AP1 -6.14 2.32e-09 1.6e-06 -0.33 -0.31 Educational attainment (years of education); chr3:48111072 chr3:48256350~48256938:- LIHC cis rs2836950 0.561 rs34705151 ENSG00000255568.3 BRWD1-AS2 -6.14 2.34e-09 1.61e-06 -0.26 -0.31 Menarche (age at onset); chr21:39181418 chr21:39313935~39314962:+ LIHC cis rs1062177 0.855 rs62395861 ENSG00000213433.5 RPLP1P6 -6.14 2.34e-09 1.62e-06 -0.36 -0.31 Preschool internalizing problems; chr5:151889709 chr5:151765859~151766378:- LIHC cis rs9341808 0.718 rs9352806 ENSG00000272129.1 RP11-250B2.6 6.14 2.34e-09 1.62e-06 0.31 0.31 Sitting height ratio; chr6:80270340 chr6:80355424~80356859:+ LIHC cis rs2439831 0.85 rs61390361 ENSG00000205771.5 CATSPER2P1 -6.14 2.34e-09 1.62e-06 -0.48 -0.31 Lung cancer in ever smokers; chr15:43867644 chr15:43726918~43747094:- LIHC cis rs2117029 0.555 rs7958241 ENSG00000258017.1 RP11-386G11.10 6.14 2.35e-09 1.62e-06 0.38 0.31 Intelligence (multi-trait analysis); chr12:49115479 chr12:49127782~49147869:+ LIHC cis rs2243480 1 rs1039664 ENSG00000273142.1 RP11-458F8.4 -6.13 2.35e-09 1.63e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65984729 chr7:66902857~66906297:+ LIHC cis rs853679 0.567 rs7774981 ENSG00000204709.4 LINC01556 6.13 2.36e-09 1.63e-06 0.42 0.31 Depression; chr6:28379133 chr6:28943877~28944537:+ LIHC cis rs853679 0.567 rs7754960 ENSG00000204709.4 LINC01556 6.13 2.36e-09 1.63e-06 0.42 0.31 Depression; chr6:28379168 chr6:28943877~28944537:+ LIHC cis rs9326248 0.954 rs10790177 ENSG00000236267.1 AP006216.5 6.13 2.36e-09 1.63e-06 0.32 0.31 Blood protein levels; chr11:117177701 chr11:116813204~116814003:- LIHC cis rs1729407 0.632 rs2071523 ENSG00000254851.1 RP11-109L13.1 -6.13 2.37e-09 1.64e-06 -0.37 -0.31 Apolipoprotein A-IV levels; chr11:116826628 chr11:117135528~117138582:+ LIHC cis rs1499614 0.803 rs1796229 ENSG00000273142.1 RP11-458F8.4 -6.13 2.38e-09 1.64e-06 -0.39 -0.31 Gout; chr7:66654674 chr7:66902857~66906297:+ LIHC cis rs1499614 0.901 rs3936 ENSG00000273142.1 RP11-458F8.4 -6.13 2.38e-09 1.64e-06 -0.39 -0.31 Gout; chr7:66661502 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs313832 ENSG00000164669.11 INTS4P1 6.13 2.38e-09 1.64e-06 0.55 0.31 Diabetic kidney disease; chr7:66085904 chr7:65141225~65234216:+ LIHC cis rs34779708 0.801 rs12242110 ENSG00000230534.5 RP11-297A16.2 6.13 2.38e-09 1.65e-06 0.4 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35246767 chr10:35098006~35127020:- LIHC cis rs12285276 0.636 rs7114337 ENSG00000205106.4 DKFZp779M0652 6.13 2.39e-09 1.65e-06 0.33 0.31 Visceral fat; chr11:45779608 chr11:45771432~45772358:+ LIHC cis rs5758659 0.737 rs10854749 ENSG00000227370.1 RP4-669P10.19 -6.13 2.39e-09 1.65e-06 -0.37 -0.31 Cognitive function; chr22:42051337 chr22:42132543~42132998:+ LIHC cis rs7429990 0.896 rs7427648 ENSG00000229759.1 MRPS18AP1 -6.13 2.4e-09 1.65e-06 -0.33 -0.31 Educational attainment (years of education); chr3:48116749 chr3:48256350~48256938:- LIHC cis rs1862618 0.853 rs832551 ENSG00000271828.1 CTD-2310F14.1 6.13 2.4e-09 1.65e-06 0.45 0.31 Initial pursuit acceleration; chr5:56884285 chr5:56927874~56929573:+ LIHC cis rs854624 1 rs41508645 ENSG00000275944.1 RP11-104J23.1 -6.13 2.41e-09 1.66e-06 -0.38 -0.31 Blood protein levels; chr17:36001998 chr17:36001419~36011618:+ LIHC cis rs932287 0.858 rs7109896 ENSG00000254860.4 TMEM9B-AS1 -6.13 2.41e-09 1.66e-06 -0.34 -0.31 Colonoscopy-negative controls vs population controls; chr11:9032975 chr11:8964675~8977527:+ LIHC cis rs5758659 0.653 rs133383 ENSG00000227370.1 RP4-669P10.19 -6.13 2.41e-09 1.66e-06 -0.36 -0.31 Cognitive function; chr22:42077599 chr22:42132543~42132998:+ LIHC cis rs113835537 0.559 rs11227497 ENSG00000255517.5 CTD-3074O7.5 -6.13 2.41e-09 1.66e-06 -0.34 -0.31 Airway imaging phenotypes; chr11:66501993 chr11:66473490~66480233:- LIHC cis rs12285276 0.534 rs57467722 ENSG00000205106.4 DKFZp779M0652 6.13 2.41e-09 1.66e-06 0.31 0.31 Visceral fat; chr11:45773301 chr11:45771432~45772358:+ LIHC cis rs12285276 0.662 rs60923315 ENSG00000205106.4 DKFZp779M0652 6.13 2.41e-09 1.66e-06 0.31 0.31 Visceral fat; chr11:45773302 chr11:45771432~45772358:+ LIHC cis rs7617773 0.78 rs11710257 ENSG00000229759.1 MRPS18AP1 6.13 2.42e-09 1.67e-06 0.39 0.31 Coronary artery disease; chr3:48331724 chr3:48256350~48256938:- LIHC cis rs7617773 0.707 rs13061269 ENSG00000229759.1 MRPS18AP1 6.13 2.42e-09 1.67e-06 0.39 0.31 Coronary artery disease; chr3:48331853 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs71323395 ENSG00000229759.1 MRPS18AP1 6.13 2.42e-09 1.67e-06 0.39 0.31 Coronary artery disease; chr3:48332587 chr3:48256350~48256938:- LIHC cis rs2739330 0.76 rs1002286 ENSG00000099984.9 GSTT2 6.13 2.42e-09 1.67e-06 0.36 0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23980123~23983911:+ LIHC cis rs1005277 0.602 rs1831315 ENSG00000263064.2 RP11-291L22.7 6.13 2.43e-09 1.67e-06 0.33 0.31 Extrinsic epigenetic age acceleration; chr10:38184425 chr10:38448689~38448949:+ LIHC cis rs6085948 0.953 rs6077166 ENSG00000238102.1 RP11-19D2.1 6.13 2.43e-09 1.67e-06 0.46 0.31 Interleukin-10 levels; chr20:7252921 chr20:7256580~7258214:- LIHC cis rs8072100 0.967 rs11079784 ENSG00000228782.6 CTD-2026D20.3 -6.13 2.44e-09 1.68e-06 -0.34 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47624914 chr17:47450568~47492492:- LIHC cis rs8059260 0.668 rs79389789 ENSG00000274038.1 RP11-66H6.4 -6.13 2.44e-09 1.68e-06 -0.53 -0.31 Alcohol consumption over the past year; chr16:11015168 chr16:11056556~11057034:+ LIHC cis rs2274273 0.87 rs10142547 ENSG00000258413.1 RP11-665C16.6 -6.13 2.44e-09 1.68e-06 -0.36 -0.31 Protein biomarker; chr14:55297245 chr14:55262767~55272075:- LIHC cis rs2274273 0.87 rs8023197 ENSG00000258413.1 RP11-665C16.6 -6.13 2.44e-09 1.68e-06 -0.36 -0.31 Protein biomarker; chr14:55300677 chr14:55262767~55272075:- LIHC cis rs2274273 0.837 rs7148171 ENSG00000258413.1 RP11-665C16.6 -6.13 2.44e-09 1.68e-06 -0.36 -0.31 Protein biomarker; chr14:55304026 chr14:55262767~55272075:- LIHC cis rs2274273 0.87 rs1109170 ENSG00000258413.1 RP11-665C16.6 -6.13 2.44e-09 1.68e-06 -0.36 -0.31 Protein biomarker; chr14:55319070 chr14:55262767~55272075:- LIHC cis rs2274273 0.837 rs10141483 ENSG00000258413.1 RP11-665C16.6 -6.13 2.44e-09 1.68e-06 -0.36 -0.31 Protein biomarker; chr14:55320153 chr14:55262767~55272075:- LIHC cis rs2274273 0.837 rs10131913 ENSG00000258413.1 RP11-665C16.6 -6.13 2.44e-09 1.68e-06 -0.36 -0.31 Protein biomarker; chr14:55320702 chr14:55262767~55272075:- LIHC cis rs2274273 0.901 rs112870553 ENSG00000258413.1 RP11-665C16.6 -6.13 2.44e-09 1.68e-06 -0.36 -0.31 Protein biomarker; chr14:55323344 chr14:55262767~55272075:- LIHC cis rs34779708 0.733 rs3936503 ENSG00000230534.5 RP11-297A16.2 -6.13 2.45e-09 1.68e-06 -0.39 -0.31 Inflammatory bowel disease;Crohn's disease; chr10:35260329 chr10:35098006~35127020:- LIHC cis rs10875746 0.537 rs4760625 ENSG00000240399.1 RP1-228P16.1 -6.13 2.45e-09 1.68e-06 -0.34 -0.31 Longevity (90 years and older); chr12:48279960 chr12:48054813~48055591:- LIHC cis rs17270561 0.609 rs4711097 ENSG00000216436.2 HIST1H2APS1 -6.13 2.45e-09 1.69e-06 -0.38 -0.31 Iron status biomarkers; chr6:25732086 chr6:25732497~25732827:+ LIHC cis rs17270561 0.608 rs9358875 ENSG00000216436.2 HIST1H2APS1 -6.13 2.45e-09 1.69e-06 -0.38 -0.31 Iron status biomarkers; chr6:25737780 chr6:25732497~25732827:+ LIHC cis rs2243480 1 rs59794892 ENSG00000273142.1 RP11-458F8.4 -6.13 2.45e-09 1.69e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65950886 chr7:66902857~66906297:+ LIHC cis rs2243480 0.803 rs36004293 ENSG00000273142.1 RP11-458F8.4 -6.13 2.45e-09 1.69e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65951525 chr7:66902857~66906297:+ LIHC cis rs2243480 0.803 rs35268390 ENSG00000273142.1 RP11-458F8.4 -6.13 2.45e-09 1.69e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65951549 chr7:66902857~66906297:+ LIHC cis rs854625 1 rs854625 ENSG00000275944.1 RP11-104J23.1 -6.13 2.45e-09 1.69e-06 -0.38 -0.31 Cerebrospinal fluid biomarker levels; chr17:36001422 chr17:36001419~36011618:+ LIHC cis rs10256972 0.616 rs6957733 ENSG00000229043.2 AC091729.9 -6.13 2.46e-09 1.7e-06 -0.37 -0.31 Endometriosis;Longevity; chr7:1066691 chr7:1160374~1165267:+ LIHC cis rs17826219 0.789 rs4794873 ENSG00000263531.1 RP13-753N3.1 6.13 2.47e-09 1.7e-06 0.53 0.31 Body mass index; chr17:30421334 chr17:30863921~30864940:- LIHC cis rs1023500 0.552 rs133368 ENSG00000237037.8 NDUFA6-AS1 6.13 2.47e-09 1.7e-06 0.38 0.31 Schizophrenia; chr22:42067685 chr22:42090931~42137742:+ LIHC cis rs3096299 0.933 rs889576 ENSG00000274627.1 RP11-104N10.2 -6.13 2.47e-09 1.7e-06 -0.32 -0.31 Multiple myeloma (IgH translocation); chr16:89363245 chr16:89516797~89522217:+ LIHC cis rs2274273 0.84 rs28568813 ENSG00000258413.1 RP11-665C16.6 -6.13 2.48e-09 1.7e-06 -0.36 -0.31 Protein biomarker; chr14:55327396 chr14:55262767~55272075:- LIHC cis rs8100891 0.537 rs10405382 ENSG00000267213.4 AC007773.2 -6.13 2.48e-09 1.7e-06 -0.41 -0.31 Neuroticism; chr19:32405810 chr19:32390050~32405560:- LIHC cis rs9326248 0.53 rs2075292 ENSG00000236267.1 AP006216.5 6.13 2.48e-09 1.71e-06 0.35 0.31 Blood protein levels; chr11:116861796 chr11:116813204~116814003:- LIHC cis rs6921919 1 rs35875412 ENSG00000204709.4 LINC01556 6.13 2.49e-09 1.71e-06 0.48 0.31 Autism spectrum disorder or schizophrenia; chr6:28364041 chr6:28943877~28944537:+ LIHC cis rs7580658 0.613 rs6754999 ENSG00000236682.1 AC068282.3 -6.12 2.49e-09 1.71e-06 -0.4 -0.31 Protein C levels; chr2:127437811 chr2:127389130~127400580:+ LIHC cis rs2243480 1 rs427044 ENSG00000273142.1 RP11-458F8.4 -6.12 2.5e-09 1.72e-06 -0.38 -0.31 Diabetic kidney disease; chr7:66043558 chr7:66902857~66906297:+ LIHC cis rs992157 0.71 rs10167446 ENSG00000261338.2 RP11-378A13.1 6.12 2.5e-09 1.72e-06 0.31 0.31 Colorectal cancer; chr2:218192143 chr2:218255319~218257366:+ LIHC cis rs9549367 0.774 rs2287246 ENSG00000269125.1 RP11-98F14.11 -6.12 2.5e-09 1.72e-06 -0.38 -0.31 Platelet distribution width; chr13:113234813 chr13:113165002~113165183:- LIHC cis rs9549367 0.789 rs2287251 ENSG00000269125.1 RP11-98F14.11 -6.12 2.5e-09 1.72e-06 -0.38 -0.31 Platelet distribution width; chr13:113235185 chr13:113165002~113165183:- LIHC cis rs1005277 0.579 rs1780130 ENSG00000263064.2 RP11-291L22.7 6.12 2.51e-09 1.73e-06 0.33 0.31 Extrinsic epigenetic age acceleration; chr10:38196450 chr10:38448689~38448949:+ LIHC cis rs2439831 0.85 rs28413704 ENSG00000205771.5 CATSPER2P1 -6.12 2.52e-09 1.73e-06 -0.47 -0.31 Lung cancer in ever smokers; chr15:43856229 chr15:43726918~43747094:- LIHC cis rs6479891 1 rs12412012 ENSG00000232075.1 MRPL35P2 6.12 2.53e-09 1.74e-06 0.37 0.31 Arthritis (juvenile idiopathic); chr10:63556003 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs61579729 ENSG00000232075.1 MRPL35P2 6.12 2.53e-09 1.74e-06 0.37 0.31 Arthritis (juvenile idiopathic); chr10:63559553 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs16918599 ENSG00000232075.1 MRPL35P2 6.12 2.53e-09 1.74e-06 0.37 0.31 Arthritis (juvenile idiopathic); chr10:63560319 chr10:63634317~63634827:- LIHC cis rs6479891 0.73 rs16918600 ENSG00000232075.1 MRPL35P2 6.12 2.53e-09 1.74e-06 0.37 0.31 Arthritis (juvenile idiopathic); chr10:63560690 chr10:63634317~63634827:- LIHC cis rs6479891 0.915 rs11812934 ENSG00000232075.1 MRPL35P2 6.12 2.53e-09 1.74e-06 0.37 0.31 Arthritis (juvenile idiopathic); chr10:63560970 chr10:63634317~63634827:- LIHC cis rs6479891 0.915 rs16918601 ENSG00000232075.1 MRPL35P2 6.12 2.53e-09 1.74e-06 0.37 0.31 Arthritis (juvenile idiopathic); chr10:63561291 chr10:63634317~63634827:- LIHC cis rs4356975 0.563 rs35402056 ENSG00000249956.3 RP11-790I12.2 6.12 2.53e-09 1.74e-06 0.35 0.31 Obesity-related traits; chr4:69108549 chr4:69408836~69423164:+ LIHC cis rs7429990 0.932 rs936428 ENSG00000229759.1 MRPS18AP1 -6.12 2.54e-09 1.74e-06 -0.33 -0.31 Educational attainment (years of education); chr3:48125791 chr3:48256350~48256938:- LIHC cis rs7429990 0.901 rs7433678 ENSG00000229759.1 MRPS18AP1 -6.12 2.54e-09 1.75e-06 -0.33 -0.31 Educational attainment (years of education); chr3:47995588 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs4392441 ENSG00000229759.1 MRPS18AP1 -6.12 2.54e-09 1.75e-06 -0.33 -0.31 Educational attainment (years of education); chr3:48036211 chr3:48256350~48256938:- LIHC cis rs4423214 0.592 rs10898223 ENSG00000254682.1 RP11-660L16.2 -6.12 2.55e-09 1.75e-06 -0.43 -0.31 Vitamin D levels; chr11:71508218 chr11:71448674~71452157:+ LIHC cis rs2111504 0.887 rs68013007 ENSG00000267213.4 AC007773.2 -6.12 2.55e-09 1.75e-06 -0.4 -0.31 Bipolar disorder; chr19:32447775 chr19:32390050~32405560:- LIHC cis rs3812049 0.784 rs2250127 ENSG00000245937.6 LINC01184 -6.12 2.55e-09 1.75e-06 -0.42 -0.31 Lymphocyte counts;Red cell distribution width; chr5:128053152 chr5:127940426~128083172:- LIHC cis rs2933343 0.679 rs789254 ENSG00000231305.3 RP11-723O4.2 6.12 2.57e-09 1.76e-06 0.35 0.31 IgG glycosylation; chr3:128855750 chr3:128861313~128871540:- LIHC cis rs2243480 0.522 rs431168 ENSG00000164669.11 INTS4P1 6.12 2.57e-09 1.76e-06 0.58 0.31 Diabetic kidney disease; chr7:66046617 chr7:65141225~65234216:+ LIHC cis rs1577917 0.727 rs9351065 ENSG00000234155.1 RP11-30P6.6 6.12 2.57e-09 1.77e-06 0.39 0.31 Response to antipsychotic treatment; chr6:85650710 chr6:85387219~85390186:- LIHC cis rs10510102 0.872 rs11814703 ENSG00000276742.1 RP11-500G22.4 6.12 2.58e-09 1.77e-06 0.51 0.31 Breast cancer; chr10:121964774 chr10:121956782~121957098:+ LIHC cis rs2933343 0.951 rs796862 ENSG00000231305.3 RP11-723O4.2 6.12 2.59e-09 1.78e-06 0.36 0.31 IgG glycosylation; chr3:128874197 chr3:128861313~128871540:- LIHC cis rs10510102 0.872 rs12259144 ENSG00000276742.1 RP11-500G22.4 6.12 2.6e-09 1.78e-06 0.51 0.31 Breast cancer; chr10:121965433 chr10:121956782~121957098:+ LIHC cis rs1023500 0.505 rs134886 ENSG00000237037.8 NDUFA6-AS1 -6.12 2.6e-09 1.78e-06 -0.34 -0.31 Schizophrenia; chr22:42277850 chr22:42090931~42137742:+ LIHC cis rs1577917 0.739 rs2758846 ENSG00000234155.1 RP11-30P6.6 6.12 2.62e-09 1.8e-06 0.4 0.31 Response to antipsychotic treatment; chr6:85639852 chr6:85387219~85390186:- LIHC cis rs2243480 0.901 rs57126451 ENSG00000273142.1 RP11-458F8.4 -6.12 2.63e-09 1.8e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65951319 chr7:66902857~66906297:+ LIHC cis rs113835537 0.529 rs7943327 ENSG00000255517.5 CTD-3074O7.5 -6.12 2.63e-09 1.8e-06 -0.34 -0.31 Airway imaging phenotypes; chr11:66489110 chr11:66473490~66480233:- LIHC cis rs2243480 0.908 rs55876148 ENSG00000273142.1 RP11-458F8.4 -6.11 2.64e-09 1.81e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65914813 chr7:66902857~66906297:+ LIHC cis rs62355900 0.627 rs16886407 ENSG00000271828.1 CTD-2310F14.1 6.11 2.64e-09 1.81e-06 0.49 0.31 Endometriosis; chr5:56845540 chr5:56927874~56929573:+ LIHC cis rs11089937 0.963 rs5757078 ENSG00000211639.2 IGLV4-60 6.11 2.64e-09 1.81e-06 0.27 0.31 Periodontitis (PAL4Q3); chr22:22145526 chr22:22162199~22162681:+ LIHC cis rs4356975 0.563 rs7439152 ENSG00000249956.3 RP11-790I12.2 6.11 2.65e-09 1.81e-06 0.35 0.31 Obesity-related traits; chr4:69103288 chr4:69408836~69423164:+ LIHC cis rs4423214 0.592 rs10898234 ENSG00000254682.1 RP11-660L16.2 -6.11 2.65e-09 1.82e-06 -0.43 -0.31 Vitamin D levels; chr11:71525638 chr11:71448674~71452157:+ LIHC cis rs11089937 0.929 rs2236727 ENSG00000211639.2 IGLV4-60 6.11 2.65e-09 1.82e-06 0.27 0.31 Periodontitis (PAL4Q3); chr22:22156654 chr22:22162199~22162681:+ LIHC cis rs10256972 0.521 rs7811577 ENSG00000229043.2 AC091729.9 -6.11 2.65e-09 1.82e-06 -0.37 -0.31 Endometriosis;Longevity; chr7:1063193 chr7:1160374~1165267:+ LIHC cis rs4423214 0.592 rs10898211 ENSG00000254682.1 RP11-660L16.2 -6.11 2.66e-09 1.82e-06 -0.43 -0.31 Vitamin D levels; chr11:71499631 chr11:71448674~71452157:+ LIHC cis rs150992 0.593 rs326491 ENSG00000248489.1 CTD-2007H13.3 6.11 2.67e-09 1.83e-06 0.45 0.31 Body mass index; chr5:98972225 chr5:98929171~98995013:+ LIHC cis rs2735413 0.564 rs73574780 ENSG00000276007.1 RP11-358L22.3 6.11 2.67e-09 1.83e-06 0.42 0.31 Systolic blood pressure (alcohol consumption interaction); chr16:78054207 chr16:78123243~78124332:+ LIHC cis rs7914558 1 rs11191541 ENSG00000236937.2 PTGES3P4 6.11 2.67e-09 1.83e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103064442 chr10:102845595~102845950:+ LIHC cis rs904251 0.504 rs9380677 ENSG00000204110.6 RP1-153P14.8 -6.11 2.68e-09 1.83e-06 -0.38 -0.31 Cognitive performance; chr6:37512590 chr6:37507348~37535616:+ LIHC cis rs62355900 0.627 rs16886429 ENSG00000271828.1 CTD-2310F14.1 6.11 2.68e-09 1.83e-06 0.49 0.31 Endometriosis; chr5:56857265 chr5:56927874~56929573:+ LIHC cis rs11098499 0.954 rs9993199 ENSG00000245958.5 RP11-33B1.1 6.11 2.68e-09 1.83e-06 0.32 0.31 Corneal astigmatism; chr4:119471718 chr4:119454791~119552025:+ LIHC cis rs6479891 0.908 rs16918638 ENSG00000232075.1 MRPL35P2 6.11 2.7e-09 1.85e-06 0.37 0.31 Arthritis (juvenile idiopathic); chr10:63583371 chr10:63634317~63634827:- LIHC cis rs3812049 0.784 rs7734927 ENSG00000245937.6 LINC01184 6.11 2.71e-09 1.85e-06 0.42 0.31 Lymphocyte counts;Red cell distribution width; chr5:128118043 chr5:127940426~128083172:- LIHC cis rs9326248 1 rs7946257 ENSG00000236267.1 AP006216.5 6.11 2.71e-09 1.85e-06 0.32 0.31 Blood protein levels; chr11:117182449 chr11:116813204~116814003:- LIHC cis rs1023500 0.573 rs133377 ENSG00000237037.8 NDUFA6-AS1 6.11 2.71e-09 1.85e-06 0.38 0.31 Schizophrenia; chr22:42070946 chr22:42090931~42137742:+ LIHC cis rs1577917 0.559 rs1173418 ENSG00000234155.1 RP11-30P6.6 -6.11 2.71e-09 1.85e-06 -0.37 -0.31 Response to antipsychotic treatment; chr6:85693198 chr6:85387219~85390186:- LIHC cis rs7580658 0.68 rs12468304 ENSG00000236682.1 AC068282.3 6.11 2.71e-09 1.85e-06 0.38 0.31 Protein C levels; chr2:127436236 chr2:127389130~127400580:+ LIHC cis rs13631 0.728 rs10118245 ENSG00000268996.3 MAN1B1-AS1 6.11 2.72e-09 1.86e-06 0.34 0.31 Cerebrospinal fluid biomarker levels; chr9:137085140 chr9:137084946~137086817:- LIHC cis rs7914558 1 rs7094843 ENSG00000236937.2 PTGES3P4 6.11 2.73e-09 1.86e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103046897 chr10:102845595~102845950:+ LIHC cis rs7914558 1 rs4917994 ENSG00000236937.2 PTGES3P4 6.11 2.73e-09 1.86e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103051942 chr10:102845595~102845950:+ LIHC cis rs7914558 1 rs2275271 ENSG00000236937.2 PTGES3P4 6.11 2.73e-09 1.86e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103054405 chr10:102845595~102845950:+ LIHC cis rs7914558 1 rs11191539 ENSG00000236937.2 PTGES3P4 6.11 2.73e-09 1.86e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103060013 chr10:102845595~102845950:+ LIHC cis rs7914558 1 rs943038 ENSG00000236937.2 PTGES3P4 6.11 2.73e-09 1.86e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103066504 chr10:102845595~102845950:+ LIHC cis rs9326248 0.798 rs10892079 ENSG00000236267.1 AP006216.5 6.11 2.73e-09 1.86e-06 0.32 0.31 Blood protein levels; chr11:117146108 chr11:116813204~116814003:- LIHC cis rs8062405 0.573 rs7140 ENSG00000259982.1 CDC37P1 -6.11 2.73e-09 1.87e-06 -0.4 -0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28984436 chr16:28700294~28701540:- LIHC cis rs12285276 0.636 rs7120031 ENSG00000205106.4 DKFZp779M0652 6.11 2.74e-09 1.87e-06 0.33 0.31 Visceral fat; chr11:45794469 chr11:45771432~45772358:+ LIHC cis rs1023500 0.505 rs134889 ENSG00000237037.8 NDUFA6-AS1 6.11 2.74e-09 1.87e-06 0.34 0.31 Schizophrenia; chr22:42278344 chr22:42090931~42137742:+ LIHC cis rs1577917 0.771 rs4145082 ENSG00000234155.1 RP11-30P6.6 6.11 2.74e-09 1.87e-06 0.4 0.31 Response to antipsychotic treatment; chr6:85642298 chr6:85387219~85390186:- LIHC cis rs17270561 0.636 rs6456694 ENSG00000216436.2 HIST1H2APS1 -6.11 2.75e-09 1.88e-06 -0.37 -0.31 Iron status biomarkers; chr6:25712666 chr6:25732497~25732827:+ LIHC cis rs7914558 0.966 rs1591915 ENSG00000236937.2 PTGES3P4 6.11 2.75e-09 1.88e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102887092 chr10:102845595~102845950:+ LIHC cis rs6142102 0.961 rs6119447 ENSG00000276073.1 RP5-1125A11.7 -6.11 2.77e-09 1.89e-06 -0.35 -0.31 Skin pigmentation; chr20:34080770 chr20:33985617~33988989:- LIHC cis rs1023500 0.573 rs2413666 ENSG00000237037.8 NDUFA6-AS1 6.11 2.77e-09 1.89e-06 0.38 0.31 Schizophrenia; chr22:42063618 chr22:42090931~42137742:+ LIHC cis rs6490294 0.747 rs632650 ENSG00000226469.1 ADAM1B 6.11 2.77e-09 1.89e-06 0.42 0.31 Mean platelet volume; chr12:111693894 chr12:111927018~111929017:+ LIHC cis rs7914558 0.966 rs56946876 ENSG00000236937.2 PTGES3P4 6.11 2.78e-09 1.9e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102893788 chr10:102845595~102845950:+ LIHC cis rs7914558 0.933 rs12763665 ENSG00000236937.2 PTGES3P4 6.11 2.78e-09 1.9e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102893960 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs10786721 ENSG00000236937.2 PTGES3P4 6.11 2.78e-09 1.9e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102894626 chr10:102845595~102845950:+ LIHC cis rs9326248 0.768 rs4936366 ENSG00000236267.1 AP006216.5 6.11 2.79e-09 1.9e-06 0.32 0.31 Blood protein levels; chr11:117156169 chr11:116813204~116814003:- LIHC cis rs9326248 0.861 rs4938352 ENSG00000236267.1 AP006216.5 6.11 2.79e-09 1.9e-06 0.32 0.31 Blood protein levels; chr11:117156765 chr11:116813204~116814003:- LIHC cis rs9326248 0.861 rs4938353 ENSG00000236267.1 AP006216.5 6.11 2.79e-09 1.9e-06 0.32 0.31 Blood protein levels; chr11:117175481 chr11:116813204~116814003:- LIHC cis rs4356975 0.563 rs6858558 ENSG00000249956.3 RP11-790I12.2 6.1 2.79e-09 1.9e-06 0.35 0.31 Obesity-related traits; chr4:69103825 chr4:69408836~69423164:+ LIHC cis rs1729407 0.706 rs595049 ENSG00000254851.1 RP11-109L13.1 -6.1 2.8e-09 1.91e-06 -0.38 -0.31 Apolipoprotein A-IV levels; chr11:116828729 chr11:117135528~117138582:+ LIHC cis rs9487094 0.67 rs2024849 ENSG00000260273.1 RP11-425D10.10 6.1 2.81e-09 1.91e-06 0.37 0.31 Height; chr6:109497088 chr6:109382795~109383666:+ LIHC cis rs2836950 0.565 rs3171465 ENSG00000255568.3 BRWD1-AS2 -6.1 2.81e-09 1.91e-06 -0.26 -0.31 Menarche (age at onset); chr21:39180381 chr21:39313935~39314962:+ LIHC cis rs9487094 0.67 rs11754455 ENSG00000260273.1 RP11-425D10.10 6.1 2.81e-09 1.92e-06 0.37 0.31 Height; chr6:109496680 chr6:109382795~109383666:+ LIHC cis rs1577917 0.771 rs10944133 ENSG00000234155.1 RP11-30P6.6 6.1 2.81e-09 1.92e-06 0.39 0.31 Response to antipsychotic treatment; chr6:85649266 chr6:85387219~85390186:- LIHC cis rs1862618 0.525 rs2662021 ENSG00000271828.1 CTD-2310F14.1 -6.1 2.82e-09 1.92e-06 -0.46 -0.31 Initial pursuit acceleration; chr5:56965864 chr5:56927874~56929573:+ LIHC cis rs1023500 0.529 rs133375 ENSG00000237037.8 NDUFA6-AS1 6.1 2.82e-09 1.92e-06 0.38 0.31 Schizophrenia; chr22:42070505 chr22:42090931~42137742:+ LIHC cis rs8177376 1 rs692955 ENSG00000254905.1 RP11-712L6.7 6.1 2.82e-09 1.92e-06 0.46 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126214601 chr11:126292922~126294254:- LIHC cis rs10510102 0.808 rs11200296 ENSG00000276742.1 RP11-500G22.4 6.1 2.84e-09 1.93e-06 0.53 0.31 Breast cancer; chr10:121971956 chr10:121956782~121957098:+ LIHC cis rs2735413 0.709 rs8051521 ENSG00000276007.1 RP11-358L22.3 6.1 2.84e-09 1.94e-06 0.35 0.31 Systolic blood pressure (alcohol consumption interaction); chr16:78054259 chr16:78123243~78124332:+ LIHC cis rs113835537 0.597 rs2075792 ENSG00000255517.5 CTD-3074O7.5 -6.1 2.85e-09 1.94e-06 -0.35 -0.31 Airway imaging phenotypes; chr11:66567085 chr11:66473490~66480233:- LIHC cis rs9399137 0.507 rs7771310 ENSG00000232876.1 CTA-212D2.2 -6.1 2.85e-09 1.94e-06 -0.36 -0.31 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134951397 chr6:135055033~135060550:+ LIHC cis rs9322193 0.607 rs6557165 ENSG00000231760.4 RP11-350J20.5 -6.1 2.85e-09 1.94e-06 -0.39 -0.31 Lung cancer; chr6:149906883 chr6:149796151~149826294:- LIHC cis rs7916697 0.626 rs3858146 ENSG00000233590.1 RP11-153K11.3 -6.1 2.85e-09 1.94e-06 -0.37 -0.31 Optic disc area; chr10:68253493 chr10:68233251~68242379:- LIHC cis rs2243480 1 rs1964692 ENSG00000273142.1 RP11-458F8.4 -6.1 2.86e-09 1.95e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65989196 chr7:66902857~66906297:+ LIHC cis rs2243480 0.901 rs2456483 ENSG00000273142.1 RP11-458F8.4 -6.1 2.86e-09 1.95e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65996588 chr7:66902857~66906297:+ LIHC cis rs2243480 0.901 rs2949697 ENSG00000273142.1 RP11-458F8.4 -6.1 2.86e-09 1.95e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65999249 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs1701750 ENSG00000273142.1 RP11-458F8.4 -6.1 2.86e-09 1.95e-06 -0.39 -0.31 Diabetic kidney disease; chr7:66002158 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs1701758 ENSG00000273142.1 RP11-458F8.4 -6.1 2.86e-09 1.95e-06 -0.39 -0.31 Diabetic kidney disease; chr7:66005214 chr7:66902857~66906297:+ LIHC cis rs2243480 0.901 rs1701759 ENSG00000273142.1 RP11-458F8.4 -6.1 2.86e-09 1.95e-06 -0.39 -0.31 Diabetic kidney disease; chr7:66005945 chr7:66902857~66906297:+ LIHC cis rs3096299 0.967 rs2965932 ENSG00000274627.1 RP11-104N10.2 -6.1 2.86e-09 1.95e-06 -0.33 -0.31 Multiple myeloma (IgH translocation); chr16:89410643 chr16:89516797~89522217:+ LIHC cis rs6142102 0.923 rs4911383 ENSG00000276073.1 RP5-1125A11.7 -6.1 2.87e-09 1.95e-06 -0.36 -0.31 Skin pigmentation; chr20:33967973 chr20:33985617~33988989:- LIHC cis rs9487094 0.67 rs2024850 ENSG00000260273.1 RP11-425D10.10 -6.1 2.87e-09 1.95e-06 -0.38 -0.31 Height; chr6:109497253 chr6:109382795~109383666:+ LIHC cis rs9549367 0.789 rs2287247 ENSG00000269125.1 RP11-98F14.11 -6.1 2.88e-09 1.96e-06 -0.38 -0.31 Platelet distribution width; chr13:113234898 chr13:113165002~113165183:- LIHC cis rs9549367 0.789 rs2287248 ENSG00000269125.1 RP11-98F14.11 -6.1 2.88e-09 1.96e-06 -0.38 -0.31 Platelet distribution width; chr13:113234912 chr13:113165002~113165183:- LIHC cis rs1862618 0.529 rs978406 ENSG00000271828.1 CTD-2310F14.1 -6.1 2.88e-09 1.96e-06 -0.46 -0.31 Initial pursuit acceleration; chr5:56963981 chr5:56927874~56929573:+ LIHC cis rs7914558 1 rs12780843 ENSG00000236937.2 PTGES3P4 6.1 2.88e-09 1.96e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103009578 chr10:102845595~102845950:+ LIHC cis rs111326718 1 rs111326718 ENSG00000236937.2 PTGES3P4 6.1 2.88e-09 1.96e-06 0.37 0.31 Reticulocyte count; chr10:103011454 chr10:102845595~102845950:+ LIHC cis rs9322193 0.607 rs9371228 ENSG00000231760.4 RP11-350J20.5 -6.1 2.89e-09 1.97e-06 -0.43 -0.31 Lung cancer; chr6:149921977 chr6:149796151~149826294:- LIHC cis rs7914558 0.966 rs10748835 ENSG00000236937.2 PTGES3P4 6.1 2.89e-09 1.97e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102900499 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs10450373 ENSG00000236937.2 PTGES3P4 6.1 2.89e-09 1.97e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102968859 chr10:102845595~102845950:+ LIHC cis rs1075265 0.584 rs1833497 ENSG00000233266.1 HMGB1P31 6.1 2.9e-09 1.97e-06 0.39 0.31 Chronotype;Morning vs. evening chronotype; chr2:54052186 chr2:54051334~54051760:+ LIHC cis rs1075265 0.584 rs7558126 ENSG00000233266.1 HMGB1P31 6.1 2.9e-09 1.97e-06 0.39 0.31 Chronotype;Morning vs. evening chronotype; chr2:54053847 chr2:54051334~54051760:+ LIHC cis rs7927592 0.731 rs11228275 ENSG00000212093.1 AP000807.1 -6.1 2.9e-09 1.97e-06 -0.31 -0.31 Total body bone mineral density; chr11:68536512 chr11:68506083~68506166:- LIHC cis rs10510102 0.872 rs12246728 ENSG00000276742.1 RP11-500G22.4 6.1 2.9e-09 1.97e-06 0.51 0.31 Breast cancer; chr10:121966618 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs12261371 ENSG00000276742.1 RP11-500G22.4 6.1 2.9e-09 1.97e-06 0.51 0.31 Breast cancer; chr10:121966686 chr10:121956782~121957098:+ LIHC cis rs10510102 0.808 rs17102804 ENSG00000276742.1 RP11-500G22.4 6.1 2.9e-09 1.97e-06 0.51 0.31 Breast cancer; chr10:121968365 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs12265369 ENSG00000276742.1 RP11-500G22.4 6.1 2.9e-09 1.97e-06 0.51 0.31 Breast cancer; chr10:121968455 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs12265542 ENSG00000276742.1 RP11-500G22.4 6.1 2.9e-09 1.97e-06 0.51 0.31 Breast cancer; chr10:121968740 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs11200293 ENSG00000276742.1 RP11-500G22.4 6.1 2.9e-09 1.97e-06 0.51 0.31 Breast cancer; chr10:121969195 chr10:121956782~121957098:+ LIHC cis rs7914558 0.966 rs11191518 ENSG00000236937.2 PTGES3P4 6.1 2.9e-09 1.97e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103023096 chr10:102845595~102845950:+ LIHC cis rs3858145 0.588 rs61854837 ENSG00000233590.1 RP11-153K11.3 -6.1 2.91e-09 1.98e-06 -0.42 -0.31 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68282613 chr10:68233251~68242379:- LIHC cis rs7396835 1 rs7396835 ENSG00000254851.1 RP11-109L13.1 -6.1 2.92e-09 1.98e-06 -0.44 -0.31 Quantitative traits; chr11:116813312 chr11:117135528~117138582:+ LIHC cis rs6479891 1 rs16918575 ENSG00000232075.1 MRPL35P2 -6.1 2.92e-09 1.98e-06 -0.36 -0.31 Arthritis (juvenile idiopathic); chr10:63541565 chr10:63634317~63634827:- LIHC cis rs8177376 1 rs8177365 ENSG00000254905.1 RP11-712L6.7 6.1 2.92e-09 1.99e-06 0.46 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126289965 chr11:126292922~126294254:- LIHC cis rs8059260 0.668 rs7198089 ENSG00000274038.1 RP11-66H6.4 -6.1 2.92e-09 1.99e-06 -0.51 -0.31 Alcohol consumption over the past year; chr16:11027199 chr16:11056556~11057034:+ LIHC cis rs2033711 0.905 rs1077420 ENSG00000269473.1 CTD-2619J13.19 6.1 2.92e-09 1.99e-06 0.39 0.31 Uric acid clearance; chr19:58457508 chr19:58440448~58445849:+ LIHC cis rs2033711 0.905 rs893186 ENSG00000269473.1 CTD-2619J13.19 6.1 2.92e-09 1.99e-06 0.39 0.31 Uric acid clearance; chr19:58457812 chr19:58440448~58445849:+ LIHC cis rs7914558 1 rs4917380 ENSG00000236937.2 PTGES3P4 6.1 2.93e-09 1.99e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103015578 chr10:102845595~102845950:+ LIHC cis rs7914558 1 rs7914558 ENSG00000236937.2 PTGES3P4 6.1 2.93e-09 1.99e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103016151 chr10:102845595~102845950:+ LIHC cis rs9549367 0.789 rs9549715 ENSG00000269125.1 RP11-98F14.11 -6.09 2.95e-09 2.01e-06 -0.39 -0.31 Platelet distribution width; chr13:113253926 chr13:113165002~113165183:- LIHC cis rs9549367 0.789 rs2302757 ENSG00000269125.1 RP11-98F14.11 -6.09 2.95e-09 2.01e-06 -0.39 -0.31 Platelet distribution width; chr13:113255025 chr13:113165002~113165183:- LIHC cis rs7914558 1 rs7071373 ENSG00000236937.2 PTGES3P4 6.09 2.95e-09 2.01e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103012165 chr10:102845595~102845950:+ LIHC cis rs1799810 0.899 rs7599210 ENSG00000236682.1 AC068282.3 -6.09 2.95e-09 2.01e-06 -0.45 -0.31 Self-rated health; chr2:127406601 chr2:127389130~127400580:+ LIHC cis rs8072100 0.967 rs8078880 ENSG00000228782.6 CTD-2026D20.3 -6.09 2.96e-09 2.01e-06 -0.34 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47599160 chr17:47450568~47492492:- LIHC cis rs8177376 1 rs8177376 ENSG00000254905.1 RP11-712L6.7 6.09 2.97e-09 2.01e-06 0.46 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126293717 chr11:126292922~126294254:- LIHC cis rs2243480 0.522 rs12698511 ENSG00000164669.11 INTS4P1 6.09 2.97e-09 2.02e-06 0.58 0.31 Diabetic kidney disease; chr7:66009932 chr7:65141225~65234216:+ LIHC cis rs8177376 0.953 rs4935964 ENSG00000254905.1 RP11-712L6.7 6.09 2.97e-09 2.02e-06 0.46 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126285289 chr11:126292922~126294254:- LIHC cis rs599083 0.573 rs3018713 ENSG00000212093.1 AP000807.1 6.09 2.97e-09 2.02e-06 0.32 0.31 Bone mineral density (spine); chr11:68623518 chr11:68506083~68506166:- LIHC cis rs7914558 0.901 rs35525740 ENSG00000236937.2 PTGES3P4 6.09 2.98e-09 2.02e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103181355 chr10:102845595~102845950:+ LIHC cis rs7914558 0.869 rs10883842 ENSG00000236937.2 PTGES3P4 6.09 2.98e-09 2.02e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103181832 chr10:102845595~102845950:+ LIHC cis rs1023500 0.551 rs133355 ENSG00000237037.8 NDUFA6-AS1 6.09 2.98e-09 2.02e-06 0.38 0.31 Schizophrenia; chr22:42044281 chr22:42090931~42137742:+ LIHC cis rs7914558 0.966 rs10883805 ENSG00000236937.2 PTGES3P4 6.09 3e-09 2.03e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102948494 chr10:102845595~102845950:+ LIHC cis rs7914558 0.933 rs10786729 ENSG00000236937.2 PTGES3P4 6.09 3e-09 2.03e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102959621 chr10:102845595~102845950:+ LIHC cis rs7914558 1 rs12255047 ENSG00000236937.2 PTGES3P4 6.09 3.02e-09 2.05e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103000995 chr10:102845595~102845950:+ LIHC cis rs2243480 1 rs160652 ENSG00000164669.11 INTS4P1 6.09 3.02e-09 2.05e-06 0.54 0.31 Diabetic kidney disease; chr7:66073444 chr7:65141225~65234216:+ LIHC cis rs2739330 0.828 rs5751770 ENSG00000099984.9 GSTT2 -6.09 3.03e-09 2.06e-06 -0.36 -0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23980123~23983911:+ LIHC cis rs17023223 0.537 rs12065809 ENSG00000231365.4 RP11-418J17.1 -6.09 3.04e-09 2.06e-06 -0.39 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119181912 chr1:119140396~119275973:+ LIHC cis rs17023223 0.553 rs11484962 ENSG00000231365.4 RP11-418J17.1 -6.09 3.04e-09 2.06e-06 -0.39 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119182563 chr1:119140396~119275973:+ LIHC cis rs17023223 0.537 rs55836852 ENSG00000231365.4 RP11-418J17.1 -6.09 3.04e-09 2.06e-06 -0.39 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119182778 chr1:119140396~119275973:+ LIHC cis rs17023223 0.537 rs66715579 ENSG00000231365.4 RP11-418J17.1 -6.09 3.04e-09 2.06e-06 -0.39 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119182809 chr1:119140396~119275973:+ LIHC cis rs17023223 0.537 rs11487668 ENSG00000231365.4 RP11-418J17.1 -6.09 3.04e-09 2.06e-06 -0.39 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119184173 chr1:119140396~119275973:+ LIHC cis rs17023223 0.537 rs10923766 ENSG00000231365.4 RP11-418J17.1 -6.09 3.04e-09 2.06e-06 -0.39 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119184309 chr1:119140396~119275973:+ LIHC cis rs17023223 0.537 rs61806983 ENSG00000231365.4 RP11-418J17.1 -6.09 3.04e-09 2.06e-06 -0.39 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119188901 chr1:119140396~119275973:+ LIHC cis rs17023223 0.537 rs12087987 ENSG00000231365.4 RP11-418J17.1 -6.09 3.04e-09 2.06e-06 -0.39 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119192198 chr1:119140396~119275973:+ LIHC cis rs8177376 1 rs655540 ENSG00000254905.1 RP11-712L6.7 6.09 3.05e-09 2.07e-06 0.46 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126281347 chr11:126292922~126294254:- LIHC cis rs113835537 0.529 rs61561111 ENSG00000255517.5 CTD-3074O7.5 -6.09 3.05e-09 2.07e-06 -0.34 -0.31 Airway imaging phenotypes; chr11:66508452 chr11:66473490~66480233:- LIHC cis rs854625 0.661 rs854689 ENSG00000275944.1 RP11-104J23.1 -6.09 3.05e-09 2.07e-06 -0.39 -0.31 Cerebrospinal fluid biomarker levels; chr17:35996083 chr17:36001419~36011618:+ LIHC cis rs9532669 0.926 rs9532657 ENSG00000176268.5 CYCSP34 -6.09 3.06e-09 2.07e-06 -0.34 -0.31 Cervical cancer; chr13:40918208 chr13:40863599~40863902:- LIHC cis rs1862618 0.525 rs832403 ENSG00000271828.1 CTD-2310F14.1 -6.09 3.08e-09 2.09e-06 -0.46 -0.31 Initial pursuit acceleration; chr5:56970165 chr5:56927874~56929573:+ LIHC cis rs62355901 0.505 rs115495921 ENSG00000271828.1 CTD-2310F14.1 6.09 3.09e-09 2.09e-06 0.5 0.31 Breast cancer; chr5:56833021 chr5:56927874~56929573:+ LIHC cis rs494459 0.504 rs7929520 ENSG00000255422.1 AP002954.4 -6.09 3.1e-09 2.1e-06 -0.35 -0.31 Height; chr11:118859432 chr11:118704607~118750263:+ LIHC cis rs748404 0.646 rs2253268 ENSG00000205771.5 CATSPER2P1 -6.09 3.1e-09 2.1e-06 -0.38 -0.31 Lung cancer; chr15:43508770 chr15:43726918~43747094:- LIHC cis rs1577917 0.771 rs9362233 ENSG00000234155.1 RP11-30P6.6 6.09 3.1e-09 2.1e-06 0.39 0.31 Response to antipsychotic treatment; chr6:85648529 chr6:85387219~85390186:- LIHC cis rs150992 0.632 rs34491 ENSG00000248489.1 CTD-2007H13.3 6.09 3.11e-09 2.1e-06 0.44 0.31 Body mass index; chr5:98974118 chr5:98929171~98995013:+ LIHC cis rs7617773 0.78 rs13066044 ENSG00000229759.1 MRPS18AP1 6.09 3.11e-09 2.1e-06 0.39 0.31 Coronary artery disease; chr3:48335786 chr3:48256350~48256938:- LIHC cis rs7617773 0.778 rs11715776 ENSG00000229759.1 MRPS18AP1 6.09 3.11e-09 2.1e-06 0.39 0.31 Coronary artery disease; chr3:48336121 chr3:48256350~48256938:- LIHC cis rs7617773 0.778 rs11707997 ENSG00000229759.1 MRPS18AP1 6.09 3.11e-09 2.1e-06 0.39 0.31 Coronary artery disease; chr3:48336385 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs11720026 ENSG00000229759.1 MRPS18AP1 6.09 3.11e-09 2.1e-06 0.39 0.31 Coronary artery disease; chr3:48336431 chr3:48256350~48256938:- LIHC cis rs7617773 0.743 rs11715876 ENSG00000229759.1 MRPS18AP1 6.09 3.11e-09 2.1e-06 0.39 0.31 Coronary artery disease; chr3:48336432 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs11716848 ENSG00000229759.1 MRPS18AP1 6.09 3.11e-09 2.1e-06 0.39 0.31 Coronary artery disease; chr3:48337010 chr3:48256350~48256938:- LIHC cis rs150992 0.609 rs161935 ENSG00000248489.1 CTD-2007H13.3 6.09 3.11e-09 2.1e-06 0.45 0.31 Body mass index; chr5:98982733 chr5:98929171~98995013:+ LIHC cis rs150992 0.632 rs161936 ENSG00000248489.1 CTD-2007H13.3 6.09 3.11e-09 2.1e-06 0.45 0.31 Body mass index; chr5:98982953 chr5:98929171~98995013:+ LIHC cis rs4356975 0.509 rs4309908 ENSG00000249956.3 RP11-790I12.2 6.08 3.12e-09 2.11e-06 0.36 0.31 Obesity-related traits; chr4:69086022 chr4:69408836~69423164:+ LIHC cis rs2762353 0.574 rs16890999 ENSG00000242387.1 HIST1H2APS2 -6.08 3.14e-09 2.13e-06 -0.39 -0.31 Blood metabolite levels; chr6:25755355 chr6:25882026~25882395:- LIHC cis rs9388451 0.874 rs13209968 ENSG00000237742.5 RP11-624M8.1 -6.08 3.15e-09 2.13e-06 -0.29 -0.31 Brugada syndrome; chr6:125768139 chr6:125578558~125749190:- LIHC cis rs1020064 0.636 rs1529974 ENSG00000235319.1 AC012360.4 -6.08 3.18e-09 2.15e-06 -0.4 -0.31 AIDS; chr2:105311539 chr2:105324210~105330529:+ LIHC cis rs1020064 0.636 rs2679876 ENSG00000235319.1 AC012360.4 -6.08 3.18e-09 2.15e-06 -0.4 -0.31 AIDS; chr2:105321650 chr2:105324210~105330529:+ LIHC cis rs62355900 0.627 rs16886419 ENSG00000271828.1 CTD-2310F14.1 6.08 3.18e-09 2.15e-06 0.49 0.31 Endometriosis; chr5:56847034 chr5:56927874~56929573:+ LIHC cis rs62355901 0.545 rs1862621 ENSG00000271828.1 CTD-2310F14.1 6.08 3.18e-09 2.15e-06 0.49 0.31 Breast cancer; chr5:56847332 chr5:56927874~56929573:+ LIHC cis rs62355900 0.627 rs62358076 ENSG00000271828.1 CTD-2310F14.1 6.08 3.18e-09 2.15e-06 0.49 0.31 Endometriosis; chr5:56848189 chr5:56927874~56929573:+ LIHC cis rs62355900 0.627 rs16886424 ENSG00000271828.1 CTD-2310F14.1 6.08 3.18e-09 2.15e-06 0.49 0.31 Endometriosis; chr5:56850866 chr5:56927874~56929573:+ LIHC cis rs992157 0.661 rs10171839 ENSG00000261338.2 RP11-378A13.1 6.08 3.18e-09 2.15e-06 0.31 0.31 Colorectal cancer; chr2:218186591 chr2:218255319~218257366:+ LIHC cis rs2243480 1 rs316331 ENSG00000273142.1 RP11-458F8.4 6.08 3.18e-09 2.15e-06 0.38 0.31 Diabetic kidney disease; chr7:66139635 chr7:66902857~66906297:+ LIHC cis rs496547 0.756 rs562059 ENSG00000255239.1 AP002954.6 6.08 3.19e-09 2.15e-06 0.39 0.31 Hip minimal joint space width; chr11:118731349 chr11:118688039~118690600:- LIHC cis rs2274273 0.84 rs11547116 ENSG00000258413.1 RP11-665C16.6 -6.08 3.21e-09 2.17e-06 -0.36 -0.31 Protein biomarker; chr14:55271447 chr14:55262767~55272075:- LIHC cis rs17023223 0.537 rs12083510 ENSG00000231365.4 RP11-418J17.1 -6.08 3.23e-09 2.18e-06 -0.39 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119203997 chr1:119140396~119275973:+ LIHC cis rs6479891 0.908 rs11817901 ENSG00000232075.1 MRPL35P2 6.08 3.24e-09 2.18e-06 0.37 0.31 Arthritis (juvenile idiopathic); chr10:63580123 chr10:63634317~63634827:- LIHC cis rs9326248 1 rs4938354 ENSG00000236267.1 AP006216.5 6.08 3.24e-09 2.19e-06 0.32 0.31 Blood protein levels; chr11:117180449 chr11:116813204~116814003:- LIHC cis rs7916697 0.626 rs3858145 ENSG00000233590.1 RP11-153K11.3 -6.08 3.24e-09 2.19e-06 -0.37 -0.31 Optic disc area; chr10:68252081 chr10:68233251~68242379:- LIHC cis rs6504950 0.924 rs2628316 ENSG00000275710.1 RP11-257O5.4 -6.08 3.24e-09 2.19e-06 -0.37 -0.31 Breast cancer; chr17:55142476 chr17:54964474~54964679:+ LIHC cis rs1729407 0.814 rs2071521 ENSG00000254851.1 RP11-109L13.1 6.08 3.24e-09 2.19e-06 0.37 0.31 Apolipoprotein A-IV levels; chr11:116827132 chr11:117135528~117138582:+ LIHC cis rs748404 0.66 rs690012 ENSG00000205771.5 CATSPER2P1 -6.08 3.24e-09 2.19e-06 -0.37 -0.31 Lung cancer; chr15:43427557 chr15:43726918~43747094:- LIHC cis rs6435862 0.636 rs717548 ENSG00000229267.2 AC072062.1 6.08 3.27e-09 2.2e-06 0.36 0.31 Neuroblastoma (high-risk); chr2:214812181 chr2:214810229~214963274:+ LIHC cis rs6085948 1 rs6077170 ENSG00000238102.1 RP11-19D2.1 6.08 3.28e-09 2.21e-06 0.45 0.31 Interleukin-10 levels; chr20:7268888 chr20:7256580~7258214:- LIHC cis rs8028182 0.636 rs4886715 ENSG00000260269.4 CTD-2323K18.1 -6.08 3.28e-09 2.21e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75539108 chr15:75527150~75601205:- LIHC cis rs11089937 0.963 rs2226943 ENSG00000211639.2 IGLV4-60 6.08 3.29e-09 2.22e-06 0.27 0.31 Periodontitis (PAL4Q3); chr22:22143100 chr22:22162199~22162681:+ LIHC cis rs7617773 0.815 rs9825637 ENSG00000229759.1 MRPS18AP1 6.08 3.29e-09 2.22e-06 0.38 0.31 Coronary artery disease; chr3:48330792 chr3:48256350~48256938:- LIHC cis rs1757171 0.504 rs11969056 ENSG00000204110.6 RP1-153P14.8 -6.08 3.3e-09 2.22e-06 -0.37 -0.31 Cognitive performance; chr6:37516509 chr6:37507348~37535616:+ LIHC cis rs494459 0.536 rs34561290 ENSG00000255422.1 AP002954.4 -6.08 3.3e-09 2.22e-06 -0.35 -0.31 Height; chr11:118860890 chr11:118704607~118750263:+ LIHC cis rs494459 0.536 rs11217072 ENSG00000255422.1 AP002954.4 -6.08 3.3e-09 2.22e-06 -0.35 -0.31 Height; chr11:118861053 chr11:118704607~118750263:+ LIHC cis rs12681287 0.64 rs7460342 ENSG00000250569.1 NTAN1P2 6.08 3.3e-09 2.23e-06 0.36 0.31 Caudate activity during reward; chr8:86462908 chr8:86481754~86483002:- LIHC cis rs17023223 0.537 rs61319010 ENSG00000231365.4 RP11-418J17.1 -6.07 3.31e-09 2.23e-06 -0.39 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119200388 chr1:119140396~119275973:+ LIHC cis rs2243480 1 rs34970380 ENSG00000273142.1 RP11-458F8.4 -6.07 3.31e-09 2.23e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65966506 chr7:66902857~66906297:+ LIHC cis rs2243480 0.901 rs73148097 ENSG00000273142.1 RP11-458F8.4 -6.07 3.31e-09 2.23e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65966800 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs906134 ENSG00000273142.1 RP11-458F8.4 -6.07 3.31e-09 2.23e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65979301 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs56016656 ENSG00000273142.1 RP11-458F8.4 -6.07 3.32e-09 2.24e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65918494 chr7:66902857~66906297:+ LIHC cis rs2243480 0.803 rs55700941 ENSG00000273142.1 RP11-458F8.4 -6.07 3.32e-09 2.24e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65924813 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs36033484 ENSG00000273142.1 RP11-458F8.4 -6.07 3.32e-09 2.24e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65925571 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs34193460 ENSG00000273142.1 RP11-458F8.4 -6.07 3.32e-09 2.24e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65928123 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs34560516 ENSG00000273142.1 RP11-458F8.4 -6.07 3.32e-09 2.24e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65939105 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs57057549 ENSG00000273142.1 RP11-458F8.4 -6.07 3.32e-09 2.24e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65940751 chr7:66902857~66906297:+ LIHC cis rs2243480 0.808 rs12698508 ENSG00000273142.1 RP11-458F8.4 -6.07 3.32e-09 2.24e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65946971 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs2961102 ENSG00000273142.1 RP11-458F8.4 -6.07 3.32e-09 2.24e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65959671 chr7:66902857~66906297:+ LIHC cis rs12681287 0.752 rs9283958 ENSG00000250569.1 NTAN1P2 6.07 3.32e-09 2.24e-06 0.38 0.31 Caudate activity during reward; chr8:86240819 chr8:86481754~86483002:- LIHC cis rs2243480 1 rs67728539 ENSG00000273142.1 RP11-458F8.4 -6.07 3.32e-09 2.24e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65913137 chr7:66902857~66906297:+ LIHC cis rs2274273 0.837 rs7146748 ENSG00000258413.1 RP11-665C16.6 -6.07 3.32e-09 2.24e-06 -0.36 -0.31 Protein biomarker; chr14:55280368 chr14:55262767~55272075:- LIHC cis rs4356975 0.563 rs7657423 ENSG00000249956.3 RP11-790I12.2 -6.07 3.33e-09 2.24e-06 -0.35 -0.31 Obesity-related traits; chr4:69090196 chr4:69408836~69423164:+ LIHC cis rs7914558 0.966 rs10786725 ENSG00000236937.2 PTGES3P4 6.07 3.34e-09 2.25e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102922600 chr10:102845595~102845950:+ LIHC cis rs523522 0.962 rs651627 ENSG00000278344.1 RP11-18C24.8 6.07 3.34e-09 2.25e-06 0.38 0.31 High light scatter reticulocyte count; chr12:120571395 chr12:120500735~120501090:- LIHC cis rs113835537 0.597 rs3737525 ENSG00000255517.5 CTD-3074O7.5 -6.07 3.34e-09 2.25e-06 -0.41 -0.31 Airway imaging phenotypes; chr11:66538884 chr11:66473490~66480233:- LIHC cis rs2243480 1 rs316331 ENSG00000164669.11 INTS4P1 -6.07 3.35e-09 2.25e-06 -0.54 -0.31 Diabetic kidney disease; chr7:66139635 chr7:65141225~65234216:+ LIHC cis rs1799810 1 rs1799810 ENSG00000236682.1 AC068282.3 -6.07 3.35e-09 2.25e-06 -0.44 -0.31 Self-rated health; chr2:127418464 chr2:127389130~127400580:+ LIHC cis rs1499614 1 rs2707832 ENSG00000273142.1 RP11-458F8.4 -6.07 3.35e-09 2.25e-06 -0.37 -0.31 Gout; chr7:66671562 chr7:66902857~66906297:+ LIHC cis rs7429990 0.965 rs9846062 ENSG00000229759.1 MRPS18AP1 6.07 3.35e-09 2.26e-06 0.33 0.31 Educational attainment (years of education); chr3:47957476 chr3:48256350~48256938:- LIHC cis rs7429990 0.93 rs7374516 ENSG00000229759.1 MRPS18AP1 6.07 3.35e-09 2.26e-06 0.33 0.31 Educational attainment (years of education); chr3:47961150 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs7645425 ENSG00000229759.1 MRPS18AP1 6.07 3.37e-09 2.27e-06 0.38 0.31 Coronary artery disease; chr3:48320879 chr3:48256350~48256938:- LIHC cis rs7617773 0.743 rs11716371 ENSG00000229759.1 MRPS18AP1 6.07 3.37e-09 2.27e-06 0.38 0.31 Coronary artery disease; chr3:48321260 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs6793223 ENSG00000229759.1 MRPS18AP1 6.07 3.37e-09 2.27e-06 0.38 0.31 Coronary artery disease; chr3:48322611 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs4541431 ENSG00000229759.1 MRPS18AP1 6.07 3.37e-09 2.27e-06 0.38 0.31 Coronary artery disease; chr3:48323728 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs11714944 ENSG00000229759.1 MRPS18AP1 6.07 3.37e-09 2.27e-06 0.38 0.31 Coronary artery disease; chr3:48325481 chr3:48256350~48256938:- LIHC cis rs7617773 0.743 rs13071960 ENSG00000229759.1 MRPS18AP1 6.07 3.37e-09 2.27e-06 0.38 0.31 Coronary artery disease; chr3:48326047 chr3:48256350~48256938:- LIHC cis rs7617773 0.743 rs4632568 ENSG00000229759.1 MRPS18AP1 6.07 3.37e-09 2.27e-06 0.38 0.31 Coronary artery disease; chr3:48326329 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs11130164 ENSG00000229759.1 MRPS18AP1 6.07 3.37e-09 2.27e-06 0.38 0.31 Coronary artery disease; chr3:48327544 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs7653336 ENSG00000229759.1 MRPS18AP1 6.07 3.37e-09 2.27e-06 0.38 0.31 Coronary artery disease; chr3:48327974 chr3:48256350~48256938:- LIHC cis rs7617773 0.747 rs34076262 ENSG00000229759.1 MRPS18AP1 6.07 3.37e-09 2.27e-06 0.38 0.31 Coronary artery disease; chr3:48328926 chr3:48256350~48256938:- LIHC cis rs4356975 0.563 rs12642938 ENSG00000249956.3 RP11-790I12.2 6.07 3.38e-09 2.27e-06 0.35 0.31 Obesity-related traits; chr4:69110499 chr4:69408836~69423164:+ LIHC cis rs12681287 0.547 rs13261956 ENSG00000250569.1 NTAN1P2 6.07 3.42e-09 2.3e-06 0.37 0.31 Caudate activity during reward; chr8:86466536 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs71502658 ENSG00000250569.1 NTAN1P2 6.07 3.42e-09 2.3e-06 0.37 0.31 Caudate activity during reward; chr8:86466556 chr8:86481754~86483002:- LIHC cis rs9326248 0.569 rs10892082 ENSG00000236267.1 AP006216.5 6.07 3.43e-09 2.3e-06 0.35 0.31 Blood protein levels; chr11:117168609 chr11:116813204~116814003:- LIHC cis rs2439831 0.867 rs496584 ENSG00000205771.5 CATSPER2P1 -6.07 3.44e-09 2.31e-06 -0.43 -0.31 Lung cancer in ever smokers; chr15:43539725 chr15:43726918~43747094:- LIHC cis rs11098499 0.954 rs10034623 ENSG00000245958.5 RP11-33B1.1 -6.07 3.44e-09 2.31e-06 -0.32 -0.31 Corneal astigmatism; chr4:119476674 chr4:119454791~119552025:+ LIHC cis rs2243480 1 rs2257790 ENSG00000164669.11 INTS4P1 6.07 3.44e-09 2.31e-06 0.54 0.31 Diabetic kidney disease; chr7:66135463 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs316332 ENSG00000164669.11 INTS4P1 6.07 3.44e-09 2.31e-06 0.54 0.31 Diabetic kidney disease; chr7:66139312 chr7:65141225~65234216:+ LIHC cis rs6142102 0.961 rs2268089 ENSG00000276073.1 RP5-1125A11.7 -6.07 3.45e-09 2.32e-06 -0.34 -0.31 Skin pigmentation; chr20:34079492 chr20:33985617~33988989:- LIHC cis rs4423214 0.592 rs11234027 ENSG00000254682.1 RP11-660L16.2 -6.07 3.45e-09 2.32e-06 -0.43 -0.31 Vitamin D levels; chr11:71523061 chr11:71448674~71452157:+ LIHC cis rs3812049 0.826 rs6860245 ENSG00000245937.6 LINC01184 -6.07 3.45e-09 2.32e-06 -0.41 -0.31 Lymphocyte counts;Red cell distribution width; chr5:128032306 chr5:127940426~128083172:- LIHC cis rs1023500 0.505 rs134901 ENSG00000237037.8 NDUFA6-AS1 6.07 3.46e-09 2.32e-06 0.34 0.31 Schizophrenia; chr22:42287514 chr22:42090931~42137742:+ LIHC cis rs6142102 0.961 rs973409 ENSG00000276073.1 RP5-1125A11.7 -6.07 3.47e-09 2.33e-06 -0.35 -0.31 Skin pigmentation; chr20:33948558 chr20:33985617~33988989:- LIHC cis rs73219805 1 rs17310286 ENSG00000228451.3 SDAD1P1 6.07 3.48e-09 2.34e-06 0.36 0.31 Schizophrenia; chr8:26411516 chr8:26379259~26382953:- LIHC cis rs2274273 0.84 rs6573013 ENSG00000258413.1 RP11-665C16.6 -6.07 3.49e-09 2.34e-06 -0.36 -0.31 Protein biomarker; chr14:55269155 chr14:55262767~55272075:- LIHC cis rs2243480 1 rs422164 ENSG00000273142.1 RP11-458F8.4 -6.06 3.5e-09 2.35e-06 -0.38 -0.31 Diabetic kidney disease; chr7:66121618 chr7:66902857~66906297:+ LIHC cis rs3779195 0.591 rs77968419 ENSG00000272950.1 RP11-307C18.1 -6.06 3.5e-09 2.35e-06 -0.49 -0.31 Sex hormone-binding globulin levels; chr7:98237168 chr7:98322853~98323430:+ LIHC cis rs7429990 0.932 rs13085054 ENSG00000229759.1 MRPS18AP1 -6.06 3.51e-09 2.35e-06 -0.32 -0.31 Educational attainment (years of education); chr3:48092647 chr3:48256350~48256938:- LIHC cis rs2243480 0.901 rs12530490 ENSG00000273142.1 RP11-458F8.4 6.06 3.51e-09 2.35e-06 0.38 0.31 Diabetic kidney disease; chr7:66226660 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs7778911 ENSG00000273142.1 RP11-458F8.4 6.06 3.51e-09 2.35e-06 0.38 0.31 Diabetic kidney disease; chr7:66229519 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs1979823 ENSG00000273142.1 RP11-458F8.4 6.06 3.51e-09 2.35e-06 0.38 0.31 Diabetic kidney disease; chr7:66239626 chr7:66902857~66906297:+ LIHC cis rs4356975 0.563 rs4694177 ENSG00000249956.3 RP11-790I12.2 6.06 3.52e-09 2.36e-06 0.35 0.31 Obesity-related traits; chr4:69110141 chr4:69408836~69423164:+ LIHC cis rs2243480 1 rs316317 ENSG00000273142.1 RP11-458F8.4 -6.06 3.53e-09 2.36e-06 -0.39 -0.31 Diabetic kidney disease; chr7:66148650 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs316304 ENSG00000273142.1 RP11-458F8.4 -6.06 3.53e-09 2.36e-06 -0.39 -0.31 Diabetic kidney disease; chr7:66151907 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs2465120 ENSG00000273142.1 RP11-458F8.4 -6.06 3.53e-09 2.36e-06 -0.39 -0.31 Diabetic kidney disease; chr7:66155987 chr7:66902857~66906297:+ LIHC cis rs2243480 0.908 rs2460431 ENSG00000273142.1 RP11-458F8.4 6.06 3.53e-09 2.36e-06 0.39 0.31 Diabetic kidney disease; chr7:66157859 chr7:66902857~66906297:+ LIHC cis rs2243480 0.711 rs2460426 ENSG00000273142.1 RP11-458F8.4 6.06 3.53e-09 2.36e-06 0.39 0.31 Diabetic kidney disease; chr7:66158142 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs4718309 ENSG00000273142.1 RP11-458F8.4 6.06 3.53e-09 2.36e-06 0.39 0.31 Diabetic kidney disease; chr7:66162777 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs6460274 ENSG00000273142.1 RP11-458F8.4 6.06 3.53e-09 2.36e-06 0.39 0.31 Diabetic kidney disease; chr7:66163497 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs7787230 ENSG00000273142.1 RP11-458F8.4 6.06 3.53e-09 2.36e-06 0.39 0.31 Diabetic kidney disease; chr7:66164112 chr7:66902857~66906297:+ LIHC cis rs2274273 0.84 rs2341622 ENSG00000258413.1 RP11-665C16.6 -6.06 3.53e-09 2.37e-06 -0.36 -0.31 Protein biomarker; chr14:55270525 chr14:55262767~55272075:- LIHC cis rs8028182 0.636 rs7495610 ENSG00000260269.4 CTD-2323K18.1 -6.06 3.55e-09 2.37e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75492100 chr15:75527150~75601205:- LIHC cis rs8028182 0.636 rs4299117 ENSG00000260269.4 CTD-2323K18.1 -6.06 3.55e-09 2.37e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75497103 chr15:75527150~75601205:- LIHC cis rs8028182 0.636 rs12708519 ENSG00000260269.4 CTD-2323K18.1 -6.06 3.55e-09 2.37e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75510859 chr15:75527150~75601205:- LIHC cis rs8028182 0.636 rs8029112 ENSG00000260269.4 CTD-2323K18.1 -6.06 3.55e-09 2.37e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75516631 chr15:75527150~75601205:- LIHC cis rs8028182 0.636 rs4886712 ENSG00000260269.4 CTD-2323K18.1 -6.06 3.55e-09 2.37e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75520547 chr15:75527150~75601205:- LIHC cis rs8028182 0.636 rs8030802 ENSG00000260269.4 CTD-2323K18.1 -6.06 3.55e-09 2.37e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75520812 chr15:75527150~75601205:- LIHC cis rs8028182 0.577 rs8023268 ENSG00000260269.4 CTD-2323K18.1 -6.06 3.55e-09 2.37e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75522331 chr15:75527150~75601205:- LIHC cis rs8028182 0.636 rs8023815 ENSG00000260269.4 CTD-2323K18.1 -6.06 3.55e-09 2.37e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75522363 chr15:75527150~75601205:- LIHC cis rs8028182 0.636 rs11636031 ENSG00000260269.4 CTD-2323K18.1 -6.06 3.55e-09 2.37e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75523417 chr15:75527150~75601205:- LIHC cis rs6061231 0.724 rs1570027 ENSG00000273619.1 RP5-908M14.9 -6.06 3.56e-09 2.39e-06 -0.31 -0.31 Colorectal cancer; chr20:62393540 chr20:62386303~62386970:- LIHC cis rs2762353 0.595 rs13194155 ENSG00000242387.1 HIST1H2APS2 -6.06 3.58e-09 2.4e-06 -0.39 -0.31 Blood metabolite levels; chr6:25755280 chr6:25882026~25882395:- LIHC cis rs1862618 0.853 rs860580 ENSG00000271828.1 CTD-2310F14.1 -6.06 3.58e-09 2.4e-06 -0.44 -0.31 Initial pursuit acceleration; chr5:56853602 chr5:56927874~56929573:+ LIHC cis rs2734839 0.507 rs4648318 ENSG00000270179.1 RP11-159N11.4 -6.06 3.59e-09 2.4e-06 -0.35 -0.31 Information processing speed; chr11:113442667 chr11:113368478~113369117:+ LIHC cis rs9487094 0.67 rs2024853 ENSG00000260273.1 RP11-425D10.10 6.06 3.6e-09 2.41e-06 0.37 0.31 Height; chr6:109498751 chr6:109382795~109383666:+ LIHC cis rs9487094 0.67 rs12197180 ENSG00000260273.1 RP11-425D10.10 6.06 3.6e-09 2.41e-06 0.37 0.31 Height; chr6:109500687 chr6:109382795~109383666:+ LIHC cis rs2274273 0.806 rs7146752 ENSG00000258413.1 RP11-665C16.6 -6.06 3.62e-09 2.42e-06 -0.36 -0.31 Protein biomarker; chr14:55272189 chr14:55262767~55272075:- LIHC cis rs62355900 0.627 rs61243567 ENSG00000271828.1 CTD-2310F14.1 6.06 3.62e-09 2.42e-06 0.49 0.31 Endometriosis; chr5:56867986 chr5:56927874~56929573:+ LIHC cis rs9549367 0.756 rs2302756 ENSG00000269125.1 RP11-98F14.11 6.06 3.62e-09 2.42e-06 0.37 0.31 Platelet distribution width; chr13:113245883 chr13:113165002~113165183:- LIHC cis rs1577917 0.771 rs2475791 ENSG00000234155.1 RP11-30P6.6 6.06 3.63e-09 2.42e-06 0.39 0.31 Response to antipsychotic treatment; chr6:85658446 chr6:85387219~85390186:- LIHC cis rs10022260 1 rs10022260 ENSG00000251022.5 THAP9-AS1 -6.06 3.66e-09 2.45e-06 -0.35 -0.31 Adult asthma; chr4:82872768 chr4:82893009~82900960:- LIHC cis rs9549367 0.789 rs7338235 ENSG00000269125.1 RP11-98F14.11 -6.06 3.66e-09 2.45e-06 -0.38 -0.31 Platelet distribution width; chr13:113234373 chr13:113165002~113165183:- LIHC cis rs12681287 0.64 rs8635 ENSG00000250569.1 NTAN1P2 6.06 3.67e-09 2.45e-06 0.36 0.31 Caudate activity during reward; chr8:86467581 chr8:86481754~86483002:- LIHC cis rs6142102 0.961 rs1007090 ENSG00000276073.1 RP5-1125A11.7 -6.06 3.67e-09 2.45e-06 -0.35 -0.31 Skin pigmentation; chr20:33995065 chr20:33985617~33988989:- LIHC cis rs6142102 0.923 rs2284377 ENSG00000276073.1 RP5-1125A11.7 -6.06 3.67e-09 2.45e-06 -0.35 -0.31 Skin pigmentation; chr20:33998876 chr20:33985617~33988989:- LIHC cis rs6142102 0.961 rs2284378 ENSG00000276073.1 RP5-1125A11.7 -6.06 3.67e-09 2.45e-06 -0.35 -0.31 Skin pigmentation; chr20:34000289 chr20:33985617~33988989:- LIHC cis rs6142102 0.961 rs2284379 ENSG00000276073.1 RP5-1125A11.7 -6.06 3.67e-09 2.45e-06 -0.35 -0.31 Skin pigmentation; chr20:34006836 chr20:33985617~33988989:- LIHC cis rs6142102 0.961 rs2268080 ENSG00000276073.1 RP5-1125A11.7 -6.06 3.67e-09 2.45e-06 -0.35 -0.31 Skin pigmentation; chr20:34009910 chr20:33985617~33988989:- LIHC cis rs7580658 0.55 rs62160290 ENSG00000236682.1 AC068282.3 -6.06 3.67e-09 2.45e-06 -0.39 -0.31 Protein C levels; chr2:127443119 chr2:127389130~127400580:+ LIHC cis rs6061231 0.798 rs2427308 ENSG00000273619.1 RP5-908M14.9 -6.06 3.67e-09 2.45e-06 -0.31 -0.31 Colorectal cancer; chr20:62394395 chr20:62386303~62386970:- LIHC cis rs7617773 0.78 rs11718350 ENSG00000229759.1 MRPS18AP1 6.06 3.68e-09 2.46e-06 0.38 0.31 Coronary artery disease; chr3:48319502 chr3:48256350~48256938:- LIHC cis rs4814920 0.818 rs6046403 ENSG00000275142.1 RP5-999L4.2 -6.06 3.69e-09 2.46e-06 -0.62 -0.31 Bipolar disorder (body mass index interaction); chr20:19882329 chr20:19871891~19872284:+ LIHC cis rs904251 0.523 rs1776455 ENSG00000204110.6 RP1-153P14.8 -6.06 3.7e-09 2.47e-06 -0.37 -0.31 Cognitive performance; chr6:37515147 chr6:37507348~37535616:+ LIHC cis rs7914558 0.966 rs1890185 ENSG00000236937.2 PTGES3P4 6.05 3.7e-09 2.47e-06 0.36 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102988961 chr10:102845595~102845950:+ LIHC cis rs9326248 1 rs7107152 ENSG00000236267.1 AP006216.5 -6.05 3.72e-09 2.49e-06 -0.31 -0.31 Blood protein levels; chr11:117185364 chr11:116813204~116814003:- LIHC cis rs2739330 0.685 rs4822453 ENSG00000099984.9 GSTT2 -6.05 3.73e-09 2.49e-06 -0.37 -0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23980123~23983911:+ LIHC cis rs12025262 0.934 rs10924961 ENSG00000227671.4 RP11-488L18.4 6.05 3.73e-09 2.49e-06 0.2 0.31 Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50); chr1:247198985 chr1:247189851~247210856:- LIHC cis rs10875746 0.669 rs11168487 ENSG00000240399.1 RP1-228P16.1 -6.05 3.74e-09 2.5e-06 -0.34 -0.31 Longevity (90 years and older); chr12:48246926 chr12:48054813~48055591:- LIHC cis rs2243480 1 rs73150014 ENSG00000273142.1 RP11-458F8.4 -6.05 3.75e-09 2.5e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65985932 chr7:66902857~66906297:+ LIHC cis rs1023500 0.596 rs133352 ENSG00000237037.8 NDUFA6-AS1 6.05 3.75e-09 2.51e-06 0.38 0.31 Schizophrenia; chr22:42038018 chr22:42090931~42137742:+ LIHC cis rs2117029 0.555 rs2279596 ENSG00000258017.1 RP11-386G11.10 -6.05 3.75e-09 2.51e-06 -0.37 -0.31 Intelligence (multi-trait analysis); chr12:49104968 chr12:49127782~49147869:+ LIHC cis rs9549367 0.826 rs9549710 ENSG00000269125.1 RP11-98F14.11 -6.05 3.76e-09 2.51e-06 -0.38 -0.31 Platelet distribution width; chr13:113243750 chr13:113165002~113165183:- LIHC cis rs2243480 1 rs410128 ENSG00000164669.11 INTS4P1 6.05 3.76e-09 2.51e-06 0.56 0.31 Diabetic kidney disease; chr7:66138186 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs56291018 ENSG00000273142.1 RP11-458F8.4 -6.05 3.76e-09 2.51e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65925352 chr7:66902857~66906297:+ LIHC cis rs7429990 0.87 rs13089844 ENSG00000229759.1 MRPS18AP1 -6.05 3.77e-09 2.51e-06 -0.32 -0.31 Educational attainment (years of education); chr3:48098741 chr3:48256350~48256938:- LIHC cis rs7429990 0.932 rs12493348 ENSG00000229759.1 MRPS18AP1 -6.05 3.77e-09 2.51e-06 -0.32 -0.31 Educational attainment (years of education); chr3:48102048 chr3:48256350~48256938:- LIHC cis rs7429990 0.932 rs12486714 ENSG00000229759.1 MRPS18AP1 -6.05 3.77e-09 2.51e-06 -0.32 -0.31 Educational attainment (years of education); chr3:48107210 chr3:48256350~48256938:- LIHC cis rs7429990 0.932 rs2361684 ENSG00000229759.1 MRPS18AP1 -6.05 3.77e-09 2.51e-06 -0.32 -0.31 Educational attainment (years of education); chr3:48111128 chr3:48256350~48256938:- LIHC cis rs7429990 0.901 rs7374482 ENSG00000229759.1 MRPS18AP1 -6.05 3.77e-09 2.51e-06 -0.32 -0.31 Educational attainment (years of education); chr3:48126900 chr3:48256350~48256938:- LIHC cis rs10256972 0.521 rs10280960 ENSG00000229043.2 AC091729.9 -6.05 3.77e-09 2.51e-06 -0.36 -0.31 Endometriosis;Longevity; chr7:1064061 chr7:1160374~1165267:+ LIHC cis rs2243480 0.831 rs57294491 ENSG00000273142.1 RP11-458F8.4 6.05 3.77e-09 2.51e-06 0.38 0.31 Diabetic kidney disease; chr7:66219914 chr7:66902857~66906297:+ LIHC cis rs5769765 0.542 rs1033666 ENSG00000278869.1 CITF22-49E9.3 -6.05 3.78e-09 2.52e-06 -0.57 -0.31 Schizophrenia; chr22:49859135 chr22:49933198~49934074:- LIHC cis rs5769765 0.526 rs5770722 ENSG00000278869.1 CITF22-49E9.3 -6.05 3.78e-09 2.52e-06 -0.57 -0.31 Schizophrenia; chr22:49859572 chr22:49933198~49934074:- LIHC cis rs5769765 0.542 rs5770725 ENSG00000278869.1 CITF22-49E9.3 -6.05 3.78e-09 2.52e-06 -0.57 -0.31 Schizophrenia; chr22:49862661 chr22:49933198~49934074:- LIHC cis rs5769765 0.505 rs4561759 ENSG00000278869.1 CITF22-49E9.3 -6.05 3.78e-09 2.52e-06 -0.57 -0.31 Schizophrenia; chr22:49863038 chr22:49933198~49934074:- LIHC cis rs5769765 0.565 rs8137232 ENSG00000278869.1 CITF22-49E9.3 -6.05 3.78e-09 2.52e-06 -0.57 -0.31 Schizophrenia; chr22:49863237 chr22:49933198~49934074:- LIHC cis rs5769765 0.657 rs8136116 ENSG00000278869.1 CITF22-49E9.3 -6.05 3.78e-09 2.52e-06 -0.57 -0.31 Schizophrenia; chr22:49863238 chr22:49933198~49934074:- LIHC cis rs7927592 0.956 rs2510384 ENSG00000212093.1 AP000807.1 6.05 3.78e-09 2.52e-06 0.34 0.31 Total body bone mineral density; chr11:68624369 chr11:68506083~68506166:- LIHC cis rs7829975 0.54 rs2976909 ENSG00000253981.4 ALG1L13P -6.05 3.8e-09 2.53e-06 -0.41 -0.31 Mood instability; chr8:8489180 chr8:8236003~8244667:- LIHC cis rs5769707 0.681 rs135879 ENSG00000235111.1 RP1-29C18.8 -6.05 3.8e-09 2.53e-06 -0.37 -0.31 Monocyte percentage of white cells;Monocyte count; chr22:49625003 chr22:49612657~49615716:- LIHC cis rs5769707 0.642 rs135880 ENSG00000235111.1 RP1-29C18.8 -6.05 3.8e-09 2.53e-06 -0.37 -0.31 Monocyte percentage of white cells;Monocyte count; chr22:49625006 chr22:49612657~49615716:- LIHC cis rs8059260 0.604 rs78753859 ENSG00000274038.1 RP11-66H6.4 -6.05 3.8e-09 2.53e-06 -0.52 -0.31 Alcohol consumption over the past year; chr16:11052774 chr16:11056556~11057034:+ LIHC cis rs9326248 0.861 rs494356 ENSG00000280143.1 AP000892.6 6.05 3.81e-09 2.54e-06 0.38 0.31 Blood protein levels; chr11:117201254 chr11:117204967~117210292:+ LIHC cis rs9326248 0.53 rs6589575 ENSG00000236267.1 AP006216.5 6.05 3.81e-09 2.54e-06 0.34 0.31 Blood protein levels; chr11:116862594 chr11:116813204~116814003:- LIHC cis rs9326248 0.53 rs718847 ENSG00000236267.1 AP006216.5 6.05 3.81e-09 2.54e-06 0.34 0.31 Blood protein levels; chr11:116863430 chr11:116813204~116814003:- LIHC cis rs7429990 0.932 rs2166772 ENSG00000229759.1 MRPS18AP1 -6.05 3.83e-09 2.55e-06 -0.33 -0.31 Educational attainment (years of education); chr3:48006384 chr3:48256350~48256938:- LIHC cis rs10256972 0.616 rs6463001 ENSG00000229043.2 AC091729.9 -6.05 3.83e-09 2.55e-06 -0.36 -0.31 Endometriosis;Longevity; chr7:1068636 chr7:1160374~1165267:+ LIHC cis rs12681287 0.64 rs13251006 ENSG00000250569.1 NTAN1P2 6.05 3.83e-09 2.55e-06 0.36 0.31 Caudate activity during reward; chr8:86456876 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs13269259 ENSG00000250569.1 NTAN1P2 6.05 3.83e-09 2.55e-06 0.36 0.31 Caudate activity during reward; chr8:86458224 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs7461413 ENSG00000250569.1 NTAN1P2 6.05 3.83e-09 2.55e-06 0.36 0.31 Caudate activity during reward; chr8:86458749 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs12550142 ENSG00000250569.1 NTAN1P2 6.05 3.83e-09 2.55e-06 0.36 0.31 Caudate activity during reward; chr8:86459632 chr8:86481754~86483002:- LIHC cis rs831571 0.636 rs831565 ENSG00000280620.1 SCAANT1 -6.05 3.85e-09 2.57e-06 -0.43 -0.31 Type 2 diabetes; chr3:64090682 chr3:63911518~63911772:- LIHC cis rs7914558 0.966 rs3977751 ENSG00000236937.2 PTGES3P4 6.05 3.86e-09 2.57e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103160475 chr10:102845595~102845950:+ LIHC cis rs2243480 1 rs437889 ENSG00000273142.1 RP11-458F8.4 -6.05 3.86e-09 2.57e-06 -0.38 -0.31 Diabetic kidney disease; chr7:66044247 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs402418 ENSG00000273142.1 RP11-458F8.4 -6.05 3.86e-09 2.57e-06 -0.38 -0.31 Diabetic kidney disease; chr7:66044482 chr7:66902857~66906297:+ LIHC cis rs2243480 0.803 rs423187 ENSG00000273142.1 RP11-458F8.4 -6.05 3.86e-09 2.57e-06 -0.38 -0.31 Diabetic kidney disease; chr7:66044512 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs431318 ENSG00000273142.1 RP11-458F8.4 -6.05 3.86e-09 2.57e-06 -0.38 -0.31 Diabetic kidney disease; chr7:66046610 chr7:66902857~66906297:+ LIHC cis rs6142102 0.961 rs4911392 ENSG00000276073.1 RP5-1125A11.7 -6.05 3.87e-09 2.57e-06 -0.34 -0.31 Skin pigmentation; chr20:33982712 chr20:33985617~33988989:- LIHC cis rs6142102 0.961 rs4911393 ENSG00000276073.1 RP5-1125A11.7 -6.05 3.87e-09 2.57e-06 -0.34 -0.31 Skin pigmentation; chr20:33983120 chr20:33985617~33988989:- LIHC cis rs2243480 1 rs35820085 ENSG00000273142.1 RP11-458F8.4 -6.05 3.89e-09 2.59e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65977771 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs73142162 ENSG00000273142.1 RP11-458F8.4 -6.05 3.9e-09 2.59e-06 -0.39 -0.31 Diabetic kidney disease; chr7:65909309 chr7:66902857~66906297:+ LIHC cis rs3020736 0.5 rs6002597 ENSG00000237037.8 NDUFA6-AS1 -6.05 3.9e-09 2.59e-06 -0.38 -0.31 Autism spectrum disorder or schizophrenia; chr22:42092156 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs7292241 ENSG00000237037.8 NDUFA6-AS1 -6.05 3.9e-09 2.59e-06 -0.38 -0.31 Autism spectrum disorder or schizophrenia; chr22:42096059 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs6002603 ENSG00000237037.8 NDUFA6-AS1 -6.05 3.9e-09 2.59e-06 -0.38 -0.31 Autism spectrum disorder or schizophrenia; chr22:42096358 chr22:42090931~42137742:+ LIHC cis rs3020736 0.5 rs5996111 ENSG00000237037.8 NDUFA6-AS1 -6.05 3.9e-09 2.59e-06 -0.38 -0.31 Autism spectrum disorder or schizophrenia; chr22:42097898 chr22:42090931~42137742:+ LIHC cis rs12681287 0.752 rs13277670 ENSG00000250569.1 NTAN1P2 6.04 3.92e-09 2.61e-06 0.38 0.31 Caudate activity during reward; chr8:86247691 chr8:86481754~86483002:- LIHC cis rs2243480 1 rs387676 ENSG00000164669.11 INTS4P1 6.04 3.95e-09 2.62e-06 0.54 0.31 Diabetic kidney disease; chr7:66133233 chr7:65141225~65234216:+ LIHC cis rs7615952 0.611 rs2947646 ENSG00000171084.14 FAM86JP -6.04 3.95e-09 2.62e-06 -0.65 -0.31 Blood pressure (smoking interaction); chr3:125874759 chr3:125916620~125930024:+ LIHC cis rs7617773 0.78 rs7653152 ENSG00000229759.1 MRPS18AP1 6.04 3.96e-09 2.63e-06 0.38 0.31 Coronary artery disease; chr3:48320607 chr3:48256350~48256938:- LIHC cis rs12681287 0.64 rs6471314 ENSG00000250569.1 NTAN1P2 -6.04 3.96e-09 2.63e-06 -0.37 -0.31 Caudate activity during reward; chr8:86388230 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs7830480 ENSG00000250569.1 NTAN1P2 -6.04 3.96e-09 2.63e-06 -0.37 -0.31 Caudate activity during reward; chr8:86390908 chr8:86481754~86483002:- LIHC cis rs12681287 0.604 rs6471316 ENSG00000250569.1 NTAN1P2 -6.04 3.96e-09 2.63e-06 -0.37 -0.31 Caudate activity during reward; chr8:86391358 chr8:86481754~86483002:- LIHC cis rs7927592 0.731 rs2156463 ENSG00000212093.1 AP000807.1 6.04 3.98e-09 2.64e-06 0.31 0.31 Total body bone mineral density; chr11:68618843 chr11:68506083~68506166:- LIHC cis rs10510102 0.872 rs11200292 ENSG00000276742.1 RP11-500G22.4 6.04 3.99e-09 2.65e-06 0.51 0.31 Breast cancer; chr10:121967383 chr10:121956782~121957098:+ LIHC cis rs4356975 0.509 rs10006452 ENSG00000249956.3 RP11-790I12.2 6.04 3.99e-09 2.65e-06 0.35 0.31 Obesity-related traits; chr4:69112090 chr4:69408836~69423164:+ LIHC cis rs8028182 0.636 rs4322627 ENSG00000260269.4 CTD-2323K18.1 -6.04 4.01e-09 2.66e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75518318 chr15:75527150~75601205:- LIHC cis rs3812049 0.826 rs34576922 ENSG00000245937.6 LINC01184 -6.04 4.02e-09 2.67e-06 -0.41 -0.31 Lymphocyte counts;Red cell distribution width; chr5:128028411 chr5:127940426~128083172:- LIHC cis rs2933343 0.951 rs789217 ENSG00000231305.3 RP11-723O4.2 6.04 4.04e-09 2.68e-06 0.36 0.31 IgG glycosylation; chr3:128874358 chr3:128861313~128871540:- LIHC cis rs7429990 0.965 rs6770467 ENSG00000229759.1 MRPS18AP1 -6.04 4.05e-09 2.68e-06 -0.33 -0.31 Educational attainment (years of education); chr3:47977742 chr3:48256350~48256938:- LIHC cis rs7429990 0.932 rs6770477 ENSG00000229759.1 MRPS18AP1 -6.04 4.05e-09 2.68e-06 -0.33 -0.31 Educational attainment (years of education); chr3:47977768 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs28637561 ENSG00000229759.1 MRPS18AP1 -6.04 4.05e-09 2.68e-06 -0.33 -0.31 Educational attainment (years of education); chr3:47979528 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs7427418 ENSG00000229759.1 MRPS18AP1 -6.04 4.05e-09 2.68e-06 -0.33 -0.31 Educational attainment (years of education); chr3:47981217 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs13075795 ENSG00000229759.1 MRPS18AP1 -6.04 4.05e-09 2.68e-06 -0.33 -0.31 Educational attainment (years of education); chr3:47983139 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs7431572 ENSG00000229759.1 MRPS18AP1 -6.04 4.05e-09 2.68e-06 -0.33 -0.31 Educational attainment (years of education); chr3:47986361 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs13074973 ENSG00000229759.1 MRPS18AP1 -6.04 4.05e-09 2.68e-06 -0.33 -0.31 Educational attainment (years of education); chr3:47986654 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs7649981 ENSG00000229759.1 MRPS18AP1 6.04 4.05e-09 2.68e-06 0.33 0.31 Educational attainment (years of education); chr3:47957847 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs9811277 ENSG00000229759.1 MRPS18AP1 6.04 4.05e-09 2.68e-06 0.33 0.31 Educational attainment (years of education); chr3:47970148 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs9814961 ENSG00000229759.1 MRPS18AP1 6.04 4.05e-09 2.68e-06 0.33 0.31 Educational attainment (years of education); chr3:47976127 chr3:48256350~48256938:- LIHC cis rs8177376 1 rs7932766 ENSG00000254905.1 RP11-712L6.7 6.04 4.05e-09 2.69e-06 0.46 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126292967 chr11:126292922~126294254:- LIHC cis rs8100891 0.537 rs28672356 ENSG00000267213.4 AC007773.2 -6.04 4.05e-09 2.69e-06 -0.39 -0.31 Neuroticism; chr19:32416937 chr19:32390050~32405560:- LIHC cis rs3779195 0.585 rs58699591 ENSG00000272950.1 RP11-307C18.1 -6.04 4.05e-09 2.69e-06 -0.49 -0.31 Sex hormone-binding globulin levels; chr7:98247392 chr7:98322853~98323430:+ LIHC cis rs3813579 0.679 rs4329928 ENSG00000261390.4 RP11-345M22.2 6.04 4.06e-09 2.69e-06 0.37 0.31 Thyroid volume; chr16:79713988 chr16:79715232~79770563:- LIHC cis rs9549367 0.789 rs2302754 ENSG00000269125.1 RP11-98F14.11 6.04 4.07e-09 2.7e-06 0.38 0.31 Platelet distribution width; chr13:113244071 chr13:113165002~113165183:- LIHC cis rs12681287 0.577 rs13257414 ENSG00000250569.1 NTAN1P2 6.04 4.07e-09 2.7e-06 0.37 0.31 Caudate activity during reward; chr8:86481909 chr8:86481754~86483002:- LIHC cis rs12681287 0.609 rs13281414 ENSG00000250569.1 NTAN1P2 6.04 4.07e-09 2.7e-06 0.37 0.31 Caudate activity during reward; chr8:86483025 chr8:86481754~86483002:- LIHC cis rs12681287 0.546 rs12546802 ENSG00000250569.1 NTAN1P2 6.04 4.07e-09 2.7e-06 0.37 0.31 Caudate activity during reward; chr8:86487106 chr8:86481754~86483002:- LIHC cis rs904251 0.504 rs12202664 ENSG00000204110.6 RP1-153P14.8 -6.04 4.07e-09 2.7e-06 -0.37 -0.31 Cognitive performance; chr6:37513422 chr6:37507348~37535616:+ LIHC cis rs9399137 0.507 rs7748708 ENSG00000232876.1 CTA-212D2.2 -6.04 4.07e-09 2.7e-06 -0.35 -0.31 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134954004 chr6:135055033~135060550:+ LIHC cis rs2243480 1 rs1546059 ENSG00000273142.1 RP11-458F8.4 6.04 4.09e-09 2.71e-06 0.38 0.31 Diabetic kidney disease; chr7:66189722 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs6958289 ENSG00000273142.1 RP11-458F8.4 6.04 4.09e-09 2.71e-06 0.38 0.31 Diabetic kidney disease; chr7:66192124 chr7:66902857~66906297:+ LIHC cis rs10510102 0.872 rs11200267 ENSG00000276742.1 RP11-500G22.4 6.04 4.09e-09 2.71e-06 0.52 0.31 Breast cancer; chr10:121929851 chr10:121956782~121957098:+ LIHC cis rs2243480 1 rs937108 ENSG00000273142.1 RP11-458F8.4 -6.04 4.09e-09 2.71e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65963465 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs35542501 ENSG00000273142.1 RP11-458F8.4 -6.04 4.09e-09 2.71e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65966228 chr7:66902857~66906297:+ LIHC cis rs2243480 0.711 rs1626926 ENSG00000273142.1 RP11-458F8.4 -6.04 4.09e-09 2.71e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65970805 chr7:66902857~66906297:+ LIHC cis rs2243480 0.708 rs781141 ENSG00000273142.1 RP11-458F8.4 -6.04 4.09e-09 2.71e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65973566 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs781142 ENSG00000273142.1 RP11-458F8.4 -6.04 4.09e-09 2.71e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65973791 chr7:66902857~66906297:+ LIHC cis rs12285276 0.673 rs12283175 ENSG00000205106.4 DKFZp779M0652 6.04 4.12e-09 2.73e-06 0.32 0.31 Visceral fat; chr11:45781619 chr11:45771432~45772358:+ LIHC cis rs4814920 0.818 rs6035467 ENSG00000275142.1 RP5-999L4.2 -6.04 4.12e-09 2.73e-06 -0.63 -0.31 Bipolar disorder (body mass index interaction); chr20:19879602 chr20:19871891~19872284:+ LIHC cis rs8100891 0.537 rs28729153 ENSG00000267213.4 AC007773.2 -6.04 4.12e-09 2.73e-06 -0.39 -0.31 Neuroticism; chr19:32416672 chr19:32390050~32405560:- LIHC cis rs875971 0.545 rs6969224 ENSG00000226824.5 RP4-756H11.3 -6.04 4.13e-09 2.74e-06 -0.4 -0.31 Aortic root size; chr7:66370011 chr7:66654538~66669855:+ LIHC cis rs9549367 0.789 rs6577035 ENSG00000269125.1 RP11-98F14.11 -6.03 4.14e-09 2.74e-06 -0.38 -0.31 Platelet distribution width; chr13:113225683 chr13:113165002~113165183:- LIHC cis rs62355900 0.627 rs16886400 ENSG00000271828.1 CTD-2310F14.1 6.03 4.15e-09 2.74e-06 0.48 0.31 Endometriosis; chr5:56841605 chr5:56927874~56929573:+ LIHC cis rs2933343 0.859 rs789247 ENSG00000231305.3 RP11-723O4.2 6.03 4.15e-09 2.74e-06 0.35 0.31 IgG glycosylation; chr3:128861742 chr3:128861313~128871540:- LIHC cis rs2933343 0.903 rs2638846 ENSG00000231305.3 RP11-723O4.2 6.03 4.15e-09 2.74e-06 0.35 0.31 IgG glycosylation; chr3:128868320 chr3:128861313~128871540:- LIHC cis rs2933343 0.951 rs1055128 ENSG00000231305.3 RP11-723O4.2 6.03 4.15e-09 2.74e-06 0.35 0.31 IgG glycosylation; chr3:128872205 chr3:128861313~128871540:- LIHC cis rs2243480 1 rs78803505 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65917585 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs34933526 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65918212 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs34577383 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65920739 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs6949812 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65922114 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs6970243 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65923503 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs7794661 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65924743 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs7795242 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65925107 chr7:66902857~66906297:+ LIHC cis rs2243480 0.708 rs35310401 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65925372 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs35058610 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65925938 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs2177703 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65926730 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs35432774 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65928032 chr7:66902857~66906297:+ LIHC cis rs2243480 0.831 rs7806717 ENSG00000273142.1 RP11-458F8.4 6.03 4.15e-09 2.74e-06 0.38 0.31 Diabetic kidney disease; chr7:65928187 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs56985706 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65929575 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs60683927 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65929781 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs58062456 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65929865 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs34529418 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65938222 chr7:66902857~66906297:+ LIHC cis rs2243480 0.901 rs35087093 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65940221 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs35046236 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65943626 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs36068983 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65944004 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs68189316 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65944182 chr7:66902857~66906297:+ LIHC cis rs2243480 0.803 rs34804747 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65947955 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs11538349 ENSG00000273142.1 RP11-458F8.4 -6.03 4.15e-09 2.74e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65956884 chr7:66902857~66906297:+ LIHC cis rs113835537 0.529 rs4930378 ENSG00000255517.5 CTD-3074O7.5 -6.03 4.15e-09 2.74e-06 -0.34 -0.31 Airway imaging phenotypes; chr11:66488044 chr11:66473490~66480233:- LIHC cis rs7927592 0.672 rs10501398 ENSG00000212093.1 AP000807.1 -6.03 4.15e-09 2.75e-06 -0.31 -0.31 Total body bone mineral density; chr11:68564247 chr11:68506083~68506166:- LIHC cis rs9326248 0.906 rs171052 ENSG00000280143.1 AP000892.6 -6.03 4.16e-09 2.75e-06 -0.36 -0.31 Blood protein levels; chr11:117211047 chr11:117204967~117210292:+ LIHC cis rs113835537 0.529 rs74869459 ENSG00000255517.5 CTD-3074O7.5 -6.03 4.16e-09 2.75e-06 -0.35 -0.31 Airway imaging phenotypes; chr11:66529098 chr11:66473490~66480233:- LIHC cis rs7617773 0.78 rs35411187 ENSG00000229759.1 MRPS18AP1 6.03 4.17e-09 2.76e-06 0.38 0.31 Coronary artery disease; chr3:48318527 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs11714176 ENSG00000229759.1 MRPS18AP1 6.03 4.17e-09 2.76e-06 0.38 0.31 Coronary artery disease; chr3:48319372 chr3:48256350~48256938:- LIHC cis rs7927592 0.763 rs11822059 ENSG00000212093.1 AP000807.1 6.03 4.19e-09 2.77e-06 0.31 0.31 Total body bone mineral density; chr11:68533354 chr11:68506083~68506166:- LIHC cis rs2243480 0.764 rs2460423 ENSG00000164669.11 INTS4P1 6.03 4.19e-09 2.77e-06 0.54 0.31 Diabetic kidney disease; chr7:66136229 chr7:65141225~65234216:+ LIHC cis rs17023223 0.537 rs4590715 ENSG00000231365.4 RP11-418J17.1 -6.03 4.22e-09 2.78e-06 -0.38 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119207578 chr1:119140396~119275973:+ LIHC cis rs5758659 0.652 rs4822084 ENSG00000227370.1 RP4-669P10.19 6.03 4.22e-09 2.79e-06 0.36 0.31 Cognitive function; chr22:42039864 chr22:42132543~42132998:+ LIHC cis rs2882667 0.537 rs6887866 ENSG00000253404.1 AC034243.1 6.03 4.23e-09 2.79e-06 0.4 0.31 Age-related hearing impairment (SNP x SNP interaction); chr5:139102007 chr5:138744434~138753309:- LIHC cis rs12681287 0.785 rs13263353 ENSG00000250569.1 NTAN1P2 6.03 4.24e-09 2.8e-06 0.37 0.31 Caudate activity during reward; chr8:86232353 chr8:86481754~86483002:- LIHC cis rs2735413 0.564 rs73578735 ENSG00000276007.1 RP11-358L22.3 6.03 4.24e-09 2.8e-06 0.44 0.31 Systolic blood pressure (alcohol consumption interaction); chr16:78071039 chr16:78123243~78124332:+ LIHC cis rs55665837 0.701 rs1522633 ENSG00000251991.1 RNU7-49P 6.03 4.25e-09 2.81e-06 0.33 0.31 Vitamin D levels; chr11:14623692 chr11:14478892~14478953:+ LIHC cis rs12285276 0.711 rs12274152 ENSG00000205106.4 DKFZp779M0652 6.03 4.26e-09 2.81e-06 0.32 0.31 Visceral fat; chr11:45786272 chr11:45771432~45772358:+ LIHC cis rs12285276 0.75 rs4756024 ENSG00000205106.4 DKFZp779M0652 6.03 4.26e-09 2.81e-06 0.32 0.31 Visceral fat; chr11:45789727 chr11:45771432~45772358:+ LIHC cis rs1023500 0.573 rs4822088 ENSG00000237037.8 NDUFA6-AS1 6.03 4.26e-09 2.81e-06 0.37 0.31 Schizophrenia; chr22:42074585 chr22:42090931~42137742:+ LIHC cis rs2243480 1 rs316313 ENSG00000164669.11 INTS4P1 6.03 4.27e-09 2.82e-06 0.54 0.31 Diabetic kidney disease; chr7:66128561 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs316312 ENSG00000164669.11 INTS4P1 6.03 4.27e-09 2.82e-06 0.54 0.31 Diabetic kidney disease; chr7:66131504 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs419603 ENSG00000164669.11 INTS4P1 6.03 4.27e-09 2.82e-06 0.54 0.31 Diabetic kidney disease; chr7:66132354 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs431076 ENSG00000164669.11 INTS4P1 6.03 4.27e-09 2.82e-06 0.54 0.31 Diabetic kidney disease; chr7:66135333 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs2460422 ENSG00000164669.11 INTS4P1 6.03 4.27e-09 2.82e-06 0.54 0.31 Diabetic kidney disease; chr7:66136518 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs316334 ENSG00000164669.11 INTS4P1 6.03 4.27e-09 2.82e-06 0.54 0.31 Diabetic kidney disease; chr7:66137139 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs316330 ENSG00000164669.11 INTS4P1 6.03 4.27e-09 2.82e-06 0.54 0.31 Diabetic kidney disease; chr7:66140385 chr7:65141225~65234216:+ LIHC cis rs523522 0.962 rs687873 ENSG00000278344.1 RP11-18C24.8 6.03 4.28e-09 2.82e-06 0.37 0.31 High light scatter reticulocyte count; chr12:120581831 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs670568 ENSG00000278344.1 RP11-18C24.8 6.03 4.28e-09 2.82e-06 0.37 0.31 High light scatter reticulocyte count; chr12:120583403 chr12:120500735~120501090:- LIHC cis rs523522 0.885 rs524735 ENSG00000278344.1 RP11-18C24.8 6.03 4.28e-09 2.82e-06 0.37 0.31 High light scatter reticulocyte count; chr12:120584296 chr12:120500735~120501090:- LIHC cis rs523522 0.962 rs655530 ENSG00000278344.1 RP11-18C24.8 6.03 4.28e-09 2.82e-06 0.37 0.31 High light scatter reticulocyte count; chr12:120584472 chr12:120500735~120501090:- LIHC cis rs7927592 0.913 rs11228276 ENSG00000212093.1 AP000807.1 6.03 4.28e-09 2.82e-06 0.34 0.31 Total body bone mineral density; chr11:68540057 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs67005337 ENSG00000212093.1 AP000807.1 6.03 4.28e-09 2.82e-06 0.34 0.31 Total body bone mineral density; chr11:68540290 chr11:68506083~68506166:- LIHC cis rs2243480 1 rs34136756 ENSG00000273142.1 RP11-458F8.4 -6.03 4.29e-09 2.83e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65916269 chr7:66902857~66906297:+ LIHC cis rs8028182 0.636 rs11634863 ENSG00000260269.4 CTD-2323K18.1 -6.03 4.29e-09 2.83e-06 -0.41 -0.31 Sudden cardiac arrest; chr15:75474331 chr15:75527150~75601205:- LIHC cis rs113835537 0.597 rs7116921 ENSG00000255517.5 CTD-3074O7.5 -6.03 4.29e-09 2.83e-06 -0.35 -0.31 Airway imaging phenotypes; chr11:66536383 chr11:66473490~66480233:- LIHC cis rs4934494 0.911 rs34486602 ENSG00000232936.4 RP11-80H5.2 6.03 4.32e-09 2.85e-06 0.39 0.31 Red blood cell count; chr10:89655895 chr10:89645282~89650667:+ LIHC cis rs4934494 0.911 rs6586213 ENSG00000232936.4 RP11-80H5.2 6.03 4.32e-09 2.85e-06 0.39 0.31 Red blood cell count; chr10:89656327 chr10:89645282~89650667:+ LIHC cis rs2243480 1 rs4718317 ENSG00000226824.5 RP4-756H11.3 6.03 4.33e-09 2.85e-06 0.49 0.31 Diabetic kidney disease; chr7:66183914 chr7:66654538~66669855:+ LIHC cis rs55665837 0.559 rs11023210 ENSG00000251991.1 RNU7-49P -6.03 4.33e-09 2.85e-06 -0.34 -0.31 Vitamin D levels; chr11:14401216 chr11:14478892~14478953:+ LIHC cis rs55665837 0.559 rs11023209 ENSG00000251991.1 RNU7-49P 6.03 4.33e-09 2.85e-06 0.34 0.31 Vitamin D levels; chr11:14401054 chr11:14478892~14478953:+ LIHC cis rs17023223 0.553 rs56234947 ENSG00000231365.4 RP11-418J17.1 -6.03 4.34e-09 2.86e-06 -0.38 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119165121 chr1:119140396~119275973:+ LIHC cis rs4535700 0.501 rs10245725 ENSG00000226278.1 PSPHP1 -6.03 4.34e-09 2.86e-06 -0.35 -0.31 Macular telangiectasia type 2; chr7:55908855 chr7:55764797~55773288:+ LIHC cis rs6142102 0.961 rs2284386 ENSG00000276073.1 RP5-1125A11.7 -6.03 4.34e-09 2.86e-06 -0.34 -0.31 Skin pigmentation; chr20:34056590 chr20:33985617~33988989:- LIHC cis rs1062177 0.95 rs59580263 ENSG00000213433.5 RPLP1P6 -6.03 4.34e-09 2.86e-06 -0.35 -0.31 Preschool internalizing problems; chr5:151890016 chr5:151765859~151766378:- LIHC cis rs10875746 0.624 rs11168498 ENSG00000240399.1 RP1-228P16.1 -6.03 4.36e-09 2.87e-06 -0.34 -0.31 Longevity (90 years and older); chr12:48261305 chr12:48054813~48055591:- LIHC cis rs7617773 0.78 rs71323396 ENSG00000229759.1 MRPS18AP1 6.02 4.37e-09 2.88e-06 0.38 0.31 Coronary artery disease; chr3:48333244 chr3:48256350~48256938:- LIHC cis rs9640161 0.673 rs11773351 ENSG00000261305.1 RP4-584D14.7 6.02 4.38e-09 2.89e-06 0.4 0.31 Blood protein levels;Circulating chemerin levels; chr7:150333874 chr7:150341771~150342607:+ LIHC cis rs904251 0.523 rs1776454 ENSG00000204110.6 RP1-153P14.8 -6.02 4.41e-09 2.9e-06 -0.37 -0.31 Cognitive performance; chr6:37514323 chr6:37507348~37535616:+ LIHC cis rs2842992 0.915 rs1967802 ENSG00000237927.1 RP3-393E18.2 -6.02 4.43e-09 2.92e-06 -0.39 -0.31 Age-related macular degeneration (geographic atrophy); chr6:159676759 chr6:159586955~159589169:- LIHC cis rs13631 0.965 rs7853589 ENSG00000268996.3 MAN1B1-AS1 -6.02 4.43e-09 2.92e-06 -0.34 -0.31 Cerebrospinal fluid biomarker levels; chr9:137109392 chr9:137084946~137086817:- LIHC cis rs2243480 1 rs2420170 ENSG00000273142.1 RP11-458F8.4 6.02 4.43e-09 2.92e-06 0.38 0.31 Diabetic kidney disease; chr7:66191066 chr7:66902857~66906297:+ LIHC cis rs875971 0.502 rs11769702 ENSG00000226824.5 RP4-756H11.3 -6.02 4.44e-09 2.92e-06 -0.4 -0.31 Aortic root size; chr7:66255529 chr7:66654538~66669855:+ LIHC cis rs2274273 0.87 rs13379169 ENSG00000258413.1 RP11-665C16.6 -6.02 4.44e-09 2.92e-06 -0.36 -0.31 Protein biomarker; chr14:55274569 chr14:55262767~55272075:- LIHC cis rs7429990 0.965 rs7430879 ENSG00000229759.1 MRPS18AP1 -6.02 4.47e-09 2.94e-06 -0.33 -0.31 Educational attainment (years of education); chr3:47997224 chr3:48256350~48256938:- LIHC cis rs7429990 0.932 rs4293721 ENSG00000229759.1 MRPS18AP1 -6.02 4.47e-09 2.94e-06 -0.33 -0.31 Educational attainment (years of education); chr3:48003647 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs11130154 ENSG00000229759.1 MRPS18AP1 -6.02 4.47e-09 2.94e-06 -0.33 -0.31 Educational attainment (years of education); chr3:48027752 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs5012971 ENSG00000229759.1 MRPS18AP1 -6.02 4.47e-09 2.94e-06 -0.33 -0.31 Educational attainment (years of education); chr3:48033057 chr3:48256350~48256938:- LIHC cis rs7429990 0.813 rs7637622 ENSG00000229759.1 MRPS18AP1 -6.02 4.47e-09 2.94e-06 -0.33 -0.31 Educational attainment (years of education); chr3:48051561 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs7627645 ENSG00000229759.1 MRPS18AP1 -6.02 4.47e-09 2.94e-06 -0.33 -0.31 Educational attainment (years of education); chr3:48051643 chr3:48256350~48256938:- LIHC cis rs9549367 0.789 rs7999579 ENSG00000269125.1 RP11-98F14.11 -6.02 4.47e-09 2.94e-06 -0.38 -0.31 Platelet distribution width; chr13:113225043 chr13:113165002~113165183:- LIHC cis rs113835537 0.529 rs11227500 ENSG00000255517.5 CTD-3074O7.5 -6.02 4.5e-09 2.96e-06 -0.34 -0.31 Airway imaging phenotypes; chr11:66505762 chr11:66473490~66480233:- LIHC cis rs6142102 0.961 rs6120487 ENSG00000276073.1 RP5-1125A11.7 -6.02 4.53e-09 2.98e-06 -0.34 -0.31 Skin pigmentation; chr20:34034802 chr20:33985617~33988989:- LIHC cis rs1211375 0.607 rs1203978 ENSG00000268836.1 LA16c-OS12.2 -6.02 4.53e-09 2.98e-06 -0.33 -0.31 Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin; chr16:207212 chr16:185748~186294:- LIHC cis rs1862618 0.853 rs252910 ENSG00000271828.1 CTD-2310F14.1 6.02 4.53e-09 2.98e-06 0.45 0.31 Initial pursuit acceleration; chr5:56897156 chr5:56927874~56929573:+ LIHC cis rs2243480 1 rs1723270 ENSG00000273142.1 RP11-458F8.4 -6.02 4.54e-09 2.99e-06 -0.39 -0.31 Diabetic kidney disease; chr7:66004843 chr7:66902857~66906297:+ LIHC cis rs7617773 0.78 rs13090538 ENSG00000229759.1 MRPS18AP1 6.02 4.55e-09 2.99e-06 0.38 0.31 Coronary artery disease; chr3:48329279 chr3:48256350~48256938:- LIHC cis rs1061377 0.748 rs12649085 ENSG00000249207.1 RP11-360F5.1 -6.02 4.56e-09 2.99e-06 -0.3 -0.31 Uric acid levels; chr4:39106459 chr4:39112677~39126818:- LIHC cis rs1023500 0.596 rs5751204 ENSG00000237037.8 NDUFA6-AS1 6.02 4.57e-09 3e-06 0.38 0.31 Schizophrenia; chr22:42037797 chr22:42090931~42137742:+ LIHC cis rs8028182 0.636 rs4545784 ENSG00000260269.4 CTD-2323K18.1 -6.02 4.58e-09 3.01e-06 -0.41 -0.31 Sudden cardiac arrest; chr15:75463310 chr15:75527150~75601205:- LIHC cis rs875971 0.545 rs2707851 ENSG00000226824.5 RP4-756H11.3 6.02 4.59e-09 3.01e-06 0.39 0.31 Aortic root size; chr7:66624178 chr7:66654538~66669855:+ LIHC cis rs2297363 0.841 rs13220323 ENSG00000213073.4 RP11-288H12.3 -6.02 4.59e-09 3.01e-06 -0.36 -0.31 Total cholesterol levels;Blood protein levels; chr6:160085723 chr6:160093082~160096212:+ LIHC cis rs8059260 0.668 rs78573173 ENSG00000274038.1 RP11-66H6.4 -6.02 4.59e-09 3.01e-06 -0.52 -0.31 Alcohol consumption over the past year; chr16:11017642 chr16:11056556~11057034:+ LIHC cis rs6142102 0.886 rs6059583 ENSG00000276073.1 RP5-1125A11.7 -6.02 4.59e-09 3.01e-06 -0.35 -0.31 Skin pigmentation; chr20:33944308 chr20:33985617~33988989:- LIHC cis rs3812049 0.737 rs1993878 ENSG00000245937.6 LINC01184 6.02 4.6e-09 3.02e-06 0.41 0.31 Lymphocyte counts;Red cell distribution width; chr5:128141279 chr5:127940426~128083172:- LIHC cis rs113835537 0.529 rs11227502 ENSG00000255517.5 CTD-3074O7.5 -6.02 4.6e-09 3.02e-06 -0.34 -0.31 Airway imaging phenotypes; chr11:66506677 chr11:66473490~66480233:- LIHC cis rs9487094 0.626 rs7773950 ENSG00000260273.1 RP11-425D10.10 6.02 4.61e-09 3.02e-06 0.37 0.31 Height; chr6:109494237 chr6:109382795~109383666:+ LIHC cis rs12681287 0.546 rs11539113 ENSG00000250569.1 NTAN1P2 6.02 4.61e-09 3.03e-06 0.37 0.31 Caudate activity during reward; chr8:86484947 chr8:86481754~86483002:- LIHC cis rs8072100 0.967 rs4794001 ENSG00000228782.6 CTD-2026D20.3 6.01 4.64e-09 3.05e-06 0.33 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47643483 chr17:47450568~47492492:- LIHC cis rs523522 0.673 rs643372 ENSG00000278344.1 RP11-18C24.8 6.01 4.65e-09 3.05e-06 0.37 0.31 High light scatter reticulocyte count; chr12:120584837 chr12:120500735~120501090:- LIHC cis rs4356975 0.563 rs6422324 ENSG00000249956.3 RP11-790I12.2 6.01 4.66e-09 3.06e-06 0.35 0.31 Obesity-related traits; chr4:69087385 chr4:69408836~69423164:+ LIHC cis rs4423214 0.592 rs7120029 ENSG00000254682.1 RP11-660L16.2 -6.01 4.67e-09 3.06e-06 -0.43 -0.31 Vitamin D levels; chr11:71487911 chr11:71448674~71452157:+ LIHC cis rs997154 0.655 rs2008345 ENSG00000279656.1 RP11-298I3.6 6.01 4.67e-09 3.06e-06 0.51 0.31 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22932233 chr14:23023083~23024217:- LIHC cis rs2243480 1 rs55895244 ENSG00000273142.1 RP11-458F8.4 -6.01 4.7e-09 3.08e-06 -0.38 -0.31 Diabetic kidney disease; chr7:65922691 chr7:66902857~66906297:+ LIHC cis rs8072100 0.967 rs4289035 ENSG00000228782.6 CTD-2026D20.3 6.01 4.72e-09 3.09e-06 0.33 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47629845 chr17:47450568~47492492:- LIHC cis rs113835537 0.529 rs11821155 ENSG00000255517.5 CTD-3074O7.5 6.01 4.72e-09 3.1e-06 0.34 0.31 Airway imaging phenotypes; chr11:66478866 chr11:66473490~66480233:- LIHC cis rs4356975 0.503 rs11938761 ENSG00000249956.3 RP11-790I12.2 6.01 4.74e-09 3.1e-06 0.35 0.31 Obesity-related traits; chr4:69083992 chr4:69408836~69423164:+ LIHC cis rs4356975 0.545 rs11935886 ENSG00000249956.3 RP11-790I12.2 6.01 4.74e-09 3.1e-06 0.35 0.31 Obesity-related traits; chr4:69083994 chr4:69408836~69423164:+ LIHC cis rs2933343 1 rs789213 ENSG00000231305.3 RP11-723O4.2 -6.01 4.74e-09 3.1e-06 -0.36 -0.31 IgG glycosylation; chr3:128897516 chr3:128861313~128871540:- LIHC cis rs2439831 0.85 rs3816792 ENSG00000205771.5 CATSPER2P1 6.01 4.74e-09 3.1e-06 0.44 0.31 Lung cancer in ever smokers; chr15:43824788 chr15:43726918~43747094:- LIHC cis rs8028182 0.636 rs28610581 ENSG00000260269.4 CTD-2323K18.1 -6.01 4.76e-09 3.12e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75520133 chr15:75527150~75601205:- LIHC cis rs8028182 0.636 rs8036758 ENSG00000260269.4 CTD-2323K18.1 -6.01 4.76e-09 3.12e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75525221 chr15:75527150~75601205:- LIHC cis rs2243480 1 rs316307 ENSG00000164669.11 INTS4P1 6.01 4.77e-09 3.12e-06 0.53 0.31 Diabetic kidney disease; chr7:66105184 chr7:65141225~65234216:+ LIHC cis rs494459 0.536 rs57719838 ENSG00000255422.1 AP002954.4 -6.01 4.78e-09 3.13e-06 -0.35 -0.31 Height; chr11:118854014 chr11:118704607~118750263:+ LIHC cis rs875971 0.545 rs73146609 ENSG00000226824.5 RP4-756H11.3 -6.01 4.79e-09 3.14e-06 -0.39 -0.31 Aortic root size; chr7:66302477 chr7:66654538~66669855:+ LIHC cis rs12458462 0.892 rs2007483 ENSG00000274828.1 RP11-567M16.6 6.01 4.79e-09 3.14e-06 0.31 0.31 Monocyte count; chr18:79716131 chr18:79677287~79679358:- LIHC cis rs10833905 0.641 rs34946681 ENSG00000246225.5 RP11-17A1.3 -6.01 4.8e-09 3.14e-06 -0.41 -0.31 Sudden cardiac arrest; chr11:22935960 chr11:22829380~22945393:+ LIHC cis rs12291225 0.546 rs11023199 ENSG00000251991.1 RNU7-49P 6.01 4.81e-09 3.15e-06 0.32 0.31 Sense of smell; chr11:14372712 chr11:14478892~14478953:+ LIHC cis rs853679 0.517 rs1340004 ENSG00000219392.1 RP1-265C24.5 -6.01 4.81e-09 3.15e-06 -0.48 -0.31 Depression; chr6:28135913 chr6:28115628~28116551:+ LIHC cis rs748404 0.69 rs2467737 ENSG00000205771.5 CATSPER2P1 -6.01 4.81e-09 3.15e-06 -0.37 -0.31 Lung cancer; chr15:43444990 chr15:43726918~43747094:- LIHC cis rs2243480 1 rs6964245 ENSG00000273142.1 RP11-458F8.4 6.01 4.82e-09 3.15e-06 0.38 0.31 Diabetic kidney disease; chr7:66253730 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs6964530 ENSG00000273142.1 RP11-458F8.4 6.01 4.82e-09 3.15e-06 0.38 0.31 Diabetic kidney disease; chr7:66253864 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs10807701 ENSG00000273142.1 RP11-458F8.4 6.01 4.82e-09 3.15e-06 0.38 0.31 Diabetic kidney disease; chr7:66259699 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs1499613 ENSG00000273142.1 RP11-458F8.4 6.01 4.82e-09 3.15e-06 0.38 0.31 Diabetic kidney disease; chr7:66265873 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs1553174 ENSG00000273142.1 RP11-458F8.4 6.01 4.82e-09 3.15e-06 0.38 0.31 Diabetic kidney disease; chr7:66266207 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs10950032 ENSG00000273142.1 RP11-458F8.4 6.01 4.82e-09 3.15e-06 0.38 0.31 Diabetic kidney disease; chr7:66273604 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs1392104 ENSG00000273142.1 RP11-458F8.4 6.01 4.82e-09 3.15e-06 0.38 0.31 Diabetic kidney disease; chr7:66294120 chr7:66902857~66906297:+ LIHC cis rs7115242 0.8 rs6589597 ENSG00000236267.1 AP006216.5 -6.01 4.82e-09 3.15e-06 -0.34 -0.31 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117127082 chr11:116813204~116814003:- LIHC cis rs1023500 0.573 rs13057094 ENSG00000237037.8 NDUFA6-AS1 6.01 4.82e-09 3.16e-06 0.38 0.31 Schizophrenia; chr22:42074313 chr22:42090931~42137742:+ LIHC cis rs1023500 0.505 rs134899 ENSG00000237037.8 NDUFA6-AS1 6.01 4.82e-09 3.16e-06 0.34 0.31 Schizophrenia; chr22:42287024 chr22:42090931~42137742:+ LIHC cis rs10875746 0.669 rs11168499 ENSG00000240399.1 RP1-228P16.1 -6.01 4.83e-09 3.16e-06 -0.34 -0.31 Longevity (90 years and older); chr12:48268887 chr12:48054813~48055591:- LIHC cis rs1020064 0.636 rs2576726 ENSG00000235319.1 AC012360.4 -6.01 4.84e-09 3.17e-06 -0.4 -0.31 AIDS; chr2:105319955 chr2:105324210~105330529:+ LIHC cis rs875971 0.571 rs78668714 ENSG00000226824.5 RP4-756H11.3 -6.01 4.85e-09 3.17e-06 -0.4 -0.31 Aortic root size; chr7:66474464 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs73150604 ENSG00000226824.5 RP4-756H11.3 -6.01 4.85e-09 3.17e-06 -0.4 -0.31 Aortic root size; chr7:66480545 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs7810213 ENSG00000226824.5 RP4-756H11.3 -6.01 4.85e-09 3.17e-06 -0.4 -0.31 Aortic root size; chr7:66481592 chr7:66654538~66669855:+ LIHC cis rs6142102 0.961 rs1883524 ENSG00000276073.1 RP5-1125A11.7 -6.01 4.86e-09 3.17e-06 -0.34 -0.31 Skin pigmentation; chr20:34038301 chr20:33985617~33988989:- LIHC cis rs5758659 0.714 rs133373 ENSG00000227370.1 RP4-669P10.19 -6.01 4.88e-09 3.19e-06 -0.35 -0.31 Cognitive function; chr22:42069784 chr22:42132543~42132998:+ LIHC cis rs8040855 0.791 rs8042888 ENSG00000259295.5 CSPG4P12 -6.01 4.89e-09 3.19e-06 -0.47 -0.31 Bulimia nervosa; chr15:85152360 chr15:85191438~85213905:+ LIHC cis rs2882667 0.537 rs7701116 ENSG00000253404.1 AC034243.1 6.01 4.89e-09 3.19e-06 0.38 0.31 Age-related hearing impairment (SNP x SNP interaction); chr5:139070389 chr5:138744434~138753309:- LIHC cis rs7429990 0.965 rs2053767 ENSG00000229759.1 MRPS18AP1 6.01 4.89e-09 3.2e-06 0.32 0.31 Educational attainment (years of education); chr3:47958184 chr3:48256350~48256938:- LIHC cis rs7396835 0.866 rs7927820 ENSG00000254851.1 RP11-109L13.1 -6 4.9e-09 3.21e-06 -0.45 -0.31 Quantitative traits; chr11:116811440 chr11:117135528~117138582:+ LIHC cis rs6142102 0.961 rs1055857 ENSG00000276073.1 RP5-1125A11.7 -6 4.91e-09 3.21e-06 -0.34 -0.31 Skin pigmentation; chr20:34026067 chr20:33985617~33988989:- LIHC cis rs9326248 0.813 rs474488 ENSG00000280143.1 AP000892.6 6 4.92e-09 3.21e-06 0.36 0.31 Blood protein levels; chr11:117198261 chr11:117204967~117210292:+ LIHC cis rs748404 0.66 rs2467738 ENSG00000205771.5 CATSPER2P1 -6 4.94e-09 3.23e-06 -0.37 -0.31 Lung cancer; chr15:43447738 chr15:43726918~43747094:- LIHC cis rs7927592 0.673 rs2510392 ENSG00000212093.1 AP000807.1 6 4.96e-09 3.24e-06 0.31 0.31 Total body bone mineral density; chr11:68626989 chr11:68506083~68506166:- LIHC cis rs7176527 0.519 rs12148368 ENSG00000189136.7 UBE2Q2P1 -6 4.97e-09 3.24e-06 -0.25 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84563274 chr15:84526781~84571216:- LIHC cis rs10875746 0.669 rs10875779 ENSG00000240399.1 RP1-228P16.1 -6 4.98e-09 3.25e-06 -0.34 -0.31 Longevity (90 years and older); chr12:48236086 chr12:48054813~48055591:- LIHC cis rs113835537 0.529 rs117112180 ENSG00000255517.5 CTD-3074O7.5 -6 4.98e-09 3.25e-06 -0.4 -0.31 Airway imaging phenotypes; chr11:66525802 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs3816492 ENSG00000255517.5 CTD-3074O7.5 -6 4.98e-09 3.25e-06 -0.4 -0.31 Airway imaging phenotypes; chr11:66529892 chr11:66473490~66480233:- LIHC cis rs12681287 0.64 rs28561640 ENSG00000250569.1 NTAN1P2 -6 5.01e-09 3.27e-06 -0.36 -0.31 Caudate activity during reward; chr8:86413409 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs10095498 ENSG00000250569.1 NTAN1P2 -6 5.01e-09 3.27e-06 -0.36 -0.31 Caudate activity during reward; chr8:86413422 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs6992287 ENSG00000250569.1 NTAN1P2 -6 5.01e-09 3.27e-06 -0.36 -0.31 Caudate activity during reward; chr8:86406731 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs6992944 ENSG00000250569.1 NTAN1P2 -6 5.01e-09 3.27e-06 -0.36 -0.31 Caudate activity during reward; chr8:86407079 chr8:86481754~86483002:- LIHC cis rs9532669 0.89 rs2324738 ENSG00000176268.5 CYCSP34 6 5.04e-09 3.29e-06 0.34 0.31 Cervical cancer; chr13:40925242 chr13:40863599~40863902:- LIHC cis rs9532669 0.963 rs2324739 ENSG00000176268.5 CYCSP34 6 5.04e-09 3.29e-06 0.34 0.31 Cervical cancer; chr13:40925479 chr13:40863599~40863902:- LIHC cis rs12130219 0.5 rs4845737 ENSG00000237975.5 FLG-AS1 -6 5.07e-09 3.31e-06 -0.39 -0.31 Inflammatory skin disease; chr1:152205063 chr1:152168125~152445456:+ LIHC cis rs748404 0.66 rs2467742 ENSG00000205771.5 CATSPER2P1 -6 5.07e-09 3.31e-06 -0.37 -0.31 Lung cancer; chr15:43458039 chr15:43726918~43747094:- LIHC cis rs748404 0.69 rs2244981 ENSG00000205771.5 CATSPER2P1 -6 5.07e-09 3.31e-06 -0.37 -0.31 Lung cancer; chr15:43460553 chr15:43726918~43747094:- LIHC cis rs7396835 0.866 rs6589571 ENSG00000236267.1 AP006216.5 6 5.09e-09 3.32e-06 0.4 0.31 Quantitative traits; chr11:116809702 chr11:116813204~116814003:- LIHC cis rs8028182 0.636 rs11637586 ENSG00000260269.4 CTD-2323K18.1 -6 5.1e-09 3.33e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75498771 chr15:75527150~75601205:- LIHC cis rs7927592 0.913 rs7106010 ENSG00000212093.1 AP000807.1 6 5.11e-09 3.33e-06 0.34 0.31 Total body bone mineral density; chr11:68597744 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs3758643 ENSG00000212093.1 AP000807.1 6 5.11e-09 3.33e-06 0.34 0.31 Total body bone mineral density; chr11:68599725 chr11:68506083~68506166:- LIHC cis rs2297363 1 rs13207901 ENSG00000213073.4 RP11-288H12.3 -6 5.13e-09 3.34e-06 -0.35 -0.31 Total cholesterol levels;Blood protein levels; chr6:160081428 chr6:160093082~160096212:+ LIHC cis rs1023500 0.551 rs2301521 ENSG00000237037.8 NDUFA6-AS1 6 5.13e-09 3.35e-06 0.39 0.31 Schizophrenia; chr22:42027106 chr22:42090931~42137742:+ LIHC cis rs8059260 0.668 rs76212701 ENSG00000274038.1 RP11-66H6.4 -6 5.14e-09 3.35e-06 -0.5 -0.31 Alcohol consumption over the past year; chr16:11023634 chr16:11056556~11057034:+ LIHC cis rs7927592 0.871 rs55953412 ENSG00000212093.1 AP000807.1 6 5.15e-09 3.35e-06 0.34 0.31 Total body bone mineral density; chr11:68560815 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs7102898 ENSG00000212093.1 AP000807.1 6 5.15e-09 3.35e-06 0.34 0.31 Total body bone mineral density; chr11:68561402 chr11:68506083~68506166:- LIHC cis rs2274273 0.84 rs6573014 ENSG00000258413.1 RP11-665C16.6 6 5.16e-09 3.36e-06 0.36 0.31 Protein biomarker; chr14:55269174 chr14:55262767~55272075:- LIHC cis rs2111504 0.583 rs8104714 ENSG00000267213.4 AC007773.2 6 5.16e-09 3.36e-06 0.32 0.31 Bipolar disorder; chr19:32381203 chr19:32390050~32405560:- LIHC cis rs8177376 0.861 rs4937119 ENSG00000254905.1 RP11-712L6.7 6 5.17e-09 3.37e-06 0.46 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126297825 chr11:126292922~126294254:- LIHC cis rs875971 0.545 rs6950988 ENSG00000226824.5 RP4-756H11.3 -5.99 5.17e-09 3.37e-06 -0.39 -0.31 Aortic root size; chr7:66511428 chr7:66654538~66669855:+ LIHC cis rs11690935 0.959 rs6754817 ENSG00000228389.1 AC068039.4 5.99 5.17e-09 3.37e-06 0.42 0.31 Schizophrenia; chr2:171806884 chr2:171773482~171775844:+ LIHC cis rs6142102 0.923 rs3787230 ENSG00000276073.1 RP5-1125A11.7 -5.99 5.18e-09 3.37e-06 -0.34 -0.31 Skin pigmentation; chr20:34052466 chr20:33985617~33988989:- LIHC cis rs7674212 0.507 rs223471 ENSG00000230069.3 LRRC37A15P -5.99 5.19e-09 3.38e-06 -0.29 -0.31 Type 2 diabetes; chr4:102777629 chr4:102727274~102730721:- LIHC cis rs2243480 1 rs6966322 ENSG00000273142.1 RP11-458F8.4 5.99 5.2e-09 3.38e-06 0.38 0.31 Diabetic kidney disease; chr7:66181767 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs4145008 ENSG00000273142.1 RP11-458F8.4 5.99 5.2e-09 3.38e-06 0.38 0.31 Diabetic kidney disease; chr7:66182524 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs4718315 ENSG00000273142.1 RP11-458F8.4 5.99 5.2e-09 3.38e-06 0.38 0.31 Diabetic kidney disease; chr7:66183554 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs4718316 ENSG00000273142.1 RP11-458F8.4 5.99 5.2e-09 3.38e-06 0.38 0.31 Diabetic kidney disease; chr7:66183744 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs1873494 ENSG00000273142.1 RP11-458F8.4 5.99 5.2e-09 3.38e-06 0.38 0.31 Diabetic kidney disease; chr7:66184912 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs6959002 ENSG00000273142.1 RP11-458F8.4 5.99 5.2e-09 3.38e-06 0.38 0.31 Diabetic kidney disease; chr7:66185509 chr7:66902857~66906297:+ LIHC cis rs8100891 0.537 rs73038232 ENSG00000267213.4 AC007773.2 -5.99 5.2e-09 3.38e-06 -0.41 -0.31 Neuroticism; chr19:32496747 chr19:32390050~32405560:- LIHC cis rs853679 0.567 rs1005126 ENSG00000204709.4 LINC01556 5.99 5.2e-09 3.38e-06 0.41 0.31 Depression; chr6:28399846 chr6:28943877~28944537:+ LIHC cis rs875971 0.545 rs2420612 ENSG00000226824.5 RP4-756H11.3 -5.99 5.2e-09 3.39e-06 -0.39 -0.31 Aortic root size; chr7:66536825 chr7:66654538~66669855:+ LIHC cis rs7119038 0.818 rs6589685 ENSG00000255239.1 AP002954.6 -5.99 5.2e-09 3.39e-06 -0.39 -0.31 Sjögren's syndrome; chr11:118741488 chr11:118688039~118690600:- LIHC cis rs2274273 0.84 rs2009291 ENSG00000258413.1 RP11-665C16.6 5.99 5.21e-09 3.39e-06 0.36 0.31 Protein biomarker; chr14:55371512 chr14:55262767~55272075:- LIHC cis rs1023500 0.596 rs133350 ENSG00000237037.8 NDUFA6-AS1 5.99 5.22e-09 3.39e-06 0.38 0.31 Schizophrenia; chr22:42033045 chr22:42090931~42137742:+ LIHC cis rs1862618 0.525 rs2662016 ENSG00000271828.1 CTD-2310F14.1 -5.99 5.22e-09 3.4e-06 -0.45 -0.31 Initial pursuit acceleration; chr5:56973220 chr5:56927874~56929573:+ LIHC cis rs113835537 0.597 rs7939759 ENSG00000255517.5 CTD-3074O7.5 -5.99 5.23e-09 3.4e-06 -0.34 -0.31 Airway imaging phenotypes; chr11:66570493 chr11:66473490~66480233:- LIHC cis rs113835537 0.597 rs10896129 ENSG00000255517.5 CTD-3074O7.5 -5.99 5.23e-09 3.4e-06 -0.34 -0.31 Airway imaging phenotypes; chr11:66570829 chr11:66473490~66480233:- LIHC cis rs113835537 0.559 rs57045447 ENSG00000255517.5 CTD-3074O7.5 -5.99 5.23e-09 3.4e-06 -0.34 -0.31 Airway imaging phenotypes; chr11:66572212 chr11:66473490~66480233:- LIHC cis rs9399137 0.507 rs4594969 ENSG00000232876.1 CTA-212D2.2 -5.99 5.25e-09 3.41e-06 -0.35 -0.31 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134964448 chr6:135055033~135060550:+ LIHC cis rs1023500 0.505 rs2143139 ENSG00000237037.8 NDUFA6-AS1 5.99 5.26e-09 3.42e-06 0.33 0.31 Schizophrenia; chr22:42218395 chr22:42090931~42137742:+ LIHC cis rs9549367 0.789 rs12584981 ENSG00000269125.1 RP11-98F14.11 -5.99 5.26e-09 3.42e-06 -0.38 -0.31 Platelet distribution width; chr13:113226871 chr13:113165002~113165183:- LIHC cis rs9549367 0.789 rs12584008 ENSG00000269125.1 RP11-98F14.11 -5.99 5.26e-09 3.42e-06 -0.38 -0.31 Platelet distribution width; chr13:113226914 chr13:113165002~113165183:- LIHC cis rs9549367 0.789 rs9549701 ENSG00000269125.1 RP11-98F14.11 -5.99 5.26e-09 3.42e-06 -0.38 -0.31 Platelet distribution width; chr13:113227438 chr13:113165002~113165183:- LIHC cis rs2933343 0.818 rs6764681 ENSG00000231305.3 RP11-723O4.2 -5.99 5.26e-09 3.42e-06 -0.35 -0.31 IgG glycosylation; chr3:128849537 chr3:128861313~128871540:- LIHC cis rs875971 0.545 rs2173571 ENSG00000226824.5 RP4-756H11.3 -5.99 5.28e-09 3.43e-06 -0.39 -0.31 Aortic root size; chr7:66305392 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs11770063 ENSG00000226824.5 RP4-756H11.3 -5.99 5.28e-09 3.43e-06 -0.39 -0.31 Aortic root size; chr7:66318029 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs3936065 ENSG00000226824.5 RP4-756H11.3 -5.99 5.28e-09 3.43e-06 -0.39 -0.31 Aortic root size; chr7:66325577 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs4718335 ENSG00000226824.5 RP4-756H11.3 -5.99 5.28e-09 3.43e-06 -0.39 -0.31 Aortic root size; chr7:66339619 chr7:66654538~66669855:+ LIHC cis rs2735413 0.709 rs4395084 ENSG00000276007.1 RP11-358L22.3 -5.99 5.28e-09 3.43e-06 -0.35 -0.31 Systolic blood pressure (alcohol consumption interaction); chr16:78054114 chr16:78123243~78124332:+ LIHC cis rs2688482 0.557 rs3103952 ENSG00000224769.1 AC069213.1 5.99 5.29e-09 3.44e-06 0.45 0.31 Lung disease severity in cystic fibrosis; chr3:195795819 chr3:195614947~195620233:+ LIHC cis rs2762353 0.574 rs11756503 ENSG00000242387.1 HIST1H2APS2 -5.99 5.31e-09 3.45e-06 -0.39 -0.31 Blood metabolite levels; chr6:25710204 chr6:25882026~25882395:- LIHC cis rs875971 0.545 rs1796219 ENSG00000226824.5 RP4-756H11.3 5.99 5.31e-09 3.45e-06 0.4 0.31 Aortic root size; chr7:66645977 chr7:66654538~66669855:+ LIHC cis rs916888 0.821 rs199513 ENSG00000262881.1 RP11-669E14.4 5.99 5.32e-09 3.45e-06 0.47 0.31 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:45907670~45910779:- LIHC cis rs9326248 0.861 rs7931335 ENSG00000236267.1 AP006216.5 5.99 5.32e-09 3.46e-06 0.32 0.31 Blood protein levels; chr11:117166089 chr11:116813204~116814003:- LIHC cis rs1862618 0.853 rs832584 ENSG00000271828.1 CTD-2310F14.1 -5.99 5.34e-09 3.47e-06 -0.43 -0.31 Initial pursuit acceleration; chr5:56883385 chr5:56927874~56929573:+ LIHC cis rs9341808 0.586 rs3805869 ENSG00000272129.1 RP11-250B2.6 5.99 5.36e-09 3.48e-06 0.31 0.31 Sitting height ratio; chr6:80336200 chr6:80355424~80356859:+ LIHC cis rs904251 0.523 rs10947675 ENSG00000204110.6 RP1-153P14.8 -5.99 5.38e-09 3.49e-06 -0.37 -0.31 Cognitive performance; chr6:37512196 chr6:37507348~37535616:+ LIHC cis rs7429990 0.965 rs4858880 ENSG00000229759.1 MRPS18AP1 -5.99 5.41e-09 3.51e-06 -0.32 -0.31 Educational attainment (years of education); chr3:48062959 chr3:48256350~48256938:- LIHC cis rs2243480 1 rs465359 ENSG00000164669.11 INTS4P1 5.99 5.43e-09 3.53e-06 0.52 0.31 Diabetic kidney disease; chr7:66093177 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs462853 ENSG00000164669.11 INTS4P1 5.99 5.43e-09 3.53e-06 0.52 0.31 Diabetic kidney disease; chr7:66093180 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs160644 ENSG00000164669.11 INTS4P1 5.99 5.43e-09 3.53e-06 0.52 0.31 Diabetic kidney disease; chr7:66093199 chr7:65141225~65234216:+ LIHC cis rs7567389 0.704 rs4662714 ENSG00000236682.1 AC068282.3 5.99 5.44e-09 3.53e-06 0.44 0.31 Self-rated health; chr2:127237637 chr2:127389130~127400580:+ LIHC cis rs2882667 0.556 rs6873733 ENSG00000253404.1 AC034243.1 5.99 5.45e-09 3.53e-06 0.38 0.31 Age-related hearing impairment (SNP x SNP interaction); chr5:139067628 chr5:138744434~138753309:- LIHC cis rs9399137 0.529 rs7739722 ENSG00000232876.1 CTA-212D2.2 -5.99 5.45e-09 3.54e-06 -0.35 -0.31 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134961087 chr6:135055033~135060550:+ LIHC cis rs2274273 0.87 rs7158768 ENSG00000258413.1 RP11-665C16.6 -5.99 5.45e-09 3.54e-06 -0.36 -0.31 Protein biomarker; chr14:55296894 chr14:55262767~55272075:- LIHC cis rs875971 0.545 rs2279757 ENSG00000226824.5 RP4-756H11.3 -5.98 5.47e-09 3.54e-06 -0.39 -0.31 Aortic root size; chr7:66363676 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs11766183 ENSG00000226824.5 RP4-756H11.3 -5.98 5.47e-09 3.54e-06 -0.39 -0.31 Aortic root size; chr7:66374173 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs1065265 ENSG00000226824.5 RP4-756H11.3 -5.98 5.47e-09 3.54e-06 -0.39 -0.31 Aortic root size; chr7:66376216 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs7811204 ENSG00000226824.5 RP4-756H11.3 -5.98 5.47e-09 3.54e-06 -0.39 -0.31 Aortic root size; chr7:66387213 chr7:66654538~66669855:+ LIHC cis rs8177376 1 rs657361 ENSG00000254905.1 RP11-712L6.7 5.98 5.47e-09 3.55e-06 0.46 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126241196 chr11:126292922~126294254:- LIHC cis rs11710088 0.626 rs6803863 ENSG00000244503.1 RP11-278L15.6 -5.98 5.48e-09 3.55e-06 -0.32 -0.31 QRS duration; chr3:149507931 chr3:149494660~149495995:+ LIHC cis rs904251 0.523 rs2776920 ENSG00000204110.6 RP1-153P14.8 -5.98 5.48e-09 3.55e-06 -0.37 -0.31 Cognitive performance; chr6:37512829 chr6:37507348~37535616:+ LIHC cis rs1005277 0.522 rs9418276 ENSG00000263064.2 RP11-291L22.7 5.98 5.5e-09 3.56e-06 0.32 0.31 Extrinsic epigenetic age acceleration; chr10:37651188 chr10:38448689~38448949:+ LIHC cis rs1005277 0.522 rs7072977 ENSG00000263064.2 RP11-291L22.7 5.98 5.5e-09 3.56e-06 0.32 0.31 Extrinsic epigenetic age acceleration; chr10:37651512 chr10:38448689~38448949:+ LIHC cis rs9322193 0.566 rs3922947 ENSG00000231760.4 RP11-350J20.5 -5.98 5.5e-09 3.56e-06 -0.42 -0.31 Lung cancer; chr6:149924856 chr6:149796151~149826294:- LIHC cis rs7927592 0.956 rs60212556 ENSG00000212093.1 AP000807.1 5.98 5.51e-09 3.57e-06 0.34 0.31 Total body bone mineral density; chr11:68538026 chr11:68506083~68506166:- LIHC cis rs9640161 0.636 rs3735171 ENSG00000261305.1 RP4-584D14.7 5.98 5.52e-09 3.58e-06 0.4 0.31 Blood protein levels;Circulating chemerin levels; chr7:150336793 chr7:150341771~150342607:+ LIHC cis rs7104764 0.917 rs3825075 ENSG00000277290.1 RP11-326C3.16 5.98 5.53e-09 3.58e-06 0.26 0.31 Menarche (age at onset); chr11:217140 chr11:243099~243483:- LIHC cis rs8072100 0.701 rs10163469 ENSG00000228782.6 CTD-2026D20.3 -5.98 5.55e-09 3.6e-06 -0.33 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47610401 chr17:47450568~47492492:- LIHC cis rs8072100 0.967 rs3760370 ENSG00000228782.6 CTD-2026D20.3 -5.98 5.55e-09 3.6e-06 -0.33 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47618466 chr17:47450568~47492492:- LIHC cis rs6142102 0.961 rs6059596 ENSG00000276073.1 RP5-1125A11.7 -5.98 5.56e-09 3.6e-06 -0.35 -0.31 Skin pigmentation; chr20:33969313 chr20:33985617~33988989:- LIHC cis rs6142102 0.961 rs6088360 ENSG00000276073.1 RP5-1125A11.7 -5.98 5.56e-09 3.6e-06 -0.35 -0.31 Skin pigmentation; chr20:33969383 chr20:33985617~33988989:- LIHC cis rs2739330 0.828 rs2154593 ENSG00000099984.9 GSTT2 -5.98 5.57e-09 3.61e-06 -0.35 -0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23980123~23983911:+ LIHC cis rs6921919 0.945 rs7765989 ENSG00000204709.4 LINC01556 5.98 5.57e-09 3.61e-06 0.47 0.31 Autism spectrum disorder or schizophrenia; chr6:28432518 chr6:28943877~28944537:+ LIHC cis rs4934494 0.911 rs7081788 ENSG00000232936.4 RP11-80H5.2 5.98 5.58e-09 3.61e-06 0.38 0.31 Red blood cell count; chr10:89648999 chr10:89645282~89650667:+ LIHC cis rs6061231 0.793 rs2427320 ENSG00000273619.1 RP5-908M14.9 -5.98 5.6e-09 3.62e-06 -0.3 -0.31 Colorectal cancer; chr20:62401667 chr20:62386303~62386970:- LIHC cis rs6061231 0.793 rs6061512 ENSG00000273619.1 RP5-908M14.9 -5.98 5.6e-09 3.62e-06 -0.3 -0.31 Colorectal cancer; chr20:62401873 chr20:62386303~62386970:- LIHC cis rs6061231 0.837 rs6061235 ENSG00000273619.1 RP5-908M14.9 -5.98 5.6e-09 3.62e-06 -0.3 -0.31 Colorectal cancer; chr20:62403468 chr20:62386303~62386970:- LIHC cis rs8059260 0.736 rs80207136 ENSG00000274038.1 RP11-66H6.4 -5.98 5.61e-09 3.63e-06 -0.52 -0.31 Alcohol consumption over the past year; chr16:11015480 chr16:11056556~11057034:+ LIHC cis rs7916697 0.52 rs10762201 ENSG00000233590.1 RP11-153K11.3 5.98 5.62e-09 3.63e-06 0.38 0.31 Optic disc area; chr10:68280354 chr10:68233251~68242379:- LIHC cis rs7914558 0.966 rs10748839 ENSG00000236937.2 PTGES3P4 5.98 5.62e-09 3.63e-06 0.36 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103193790 chr10:102845595~102845950:+ LIHC cis rs7429990 0.965 rs1060407 ENSG00000229759.1 MRPS18AP1 5.98 5.63e-09 3.64e-06 0.34 0.31 Educational attainment (years of education); chr3:47916547 chr3:48256350~48256938:- LIHC cis rs7119038 0.818 rs10892279 ENSG00000255239.1 AP002954.6 -5.98 5.63e-09 3.64e-06 -0.39 -0.31 Sjögren's syndrome; chr11:118741072 chr11:118688039~118690600:- LIHC cis rs4356975 0.563 rs7658752 ENSG00000249956.3 RP11-790I12.2 5.98 5.64e-09 3.65e-06 0.34 0.31 Obesity-related traits; chr4:69112350 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs12506962 ENSG00000249956.3 RP11-790I12.2 5.98 5.64e-09 3.65e-06 0.34 0.31 Obesity-related traits; chr4:69100306 chr4:69408836~69423164:+ LIHC cis rs9549367 0.789 rs2025247 ENSG00000269125.1 RP11-98F14.11 -5.98 5.65e-09 3.65e-06 -0.38 -0.31 Platelet distribution width; chr13:113228250 chr13:113165002~113165183:- LIHC cis rs12285276 0.75 rs7116816 ENSG00000205106.4 DKFZp779M0652 5.98 5.65e-09 3.65e-06 0.31 0.31 Visceral fat; chr11:45783444 chr11:45771432~45772358:+ LIHC cis rs1577917 0.633 rs7770835 ENSG00000234155.1 RP11-30P6.6 5.98 5.66e-09 3.66e-06 0.37 0.31 Response to antipsychotic treatment; chr6:85899189 chr6:85387219~85390186:- LIHC cis rs904251 0.523 rs2797799 ENSG00000204110.6 RP1-153P14.8 -5.98 5.67e-09 3.66e-06 -0.36 -0.31 Cognitive performance; chr6:37515844 chr6:37507348~37535616:+ LIHC cis rs4356975 0.563 rs4131317 ENSG00000249956.3 RP11-790I12.2 5.98 5.71e-09 3.69e-06 0.35 0.31 Obesity-related traits; chr4:69083280 chr4:69408836~69423164:+ LIHC cis rs12364620 1 rs12364620 ENSG00000212093.1 AP000807.1 5.98 5.72e-09 3.69e-06 0.34 0.31 Total body bone mineral density (age 0-15); chr11:68484655 chr11:68506083~68506166:- LIHC cis rs3812049 0.784 rs1560637 ENSG00000245937.6 LINC01184 5.98 5.73e-09 3.7e-06 0.41 0.31 Lymphocyte counts;Red cell distribution width; chr5:128112374 chr5:127940426~128083172:- LIHC cis rs2933343 0.951 rs7648327 ENSG00000231305.3 RP11-723O4.2 5.98 5.73e-09 3.7e-06 0.35 0.31 IgG glycosylation; chr3:128851865 chr3:128861313~128871540:- LIHC cis rs904251 0.504 rs1757188 ENSG00000204110.6 RP1-153P14.8 -5.98 5.74e-09 3.71e-06 -0.36 -0.31 Cognitive performance; chr6:37516032 chr6:37507348~37535616:+ LIHC cis rs11096990 0.572 rs35040563 ENSG00000249207.1 RP11-360F5.1 -5.98 5.74e-09 3.71e-06 -0.31 -0.31 Cognitive function; chr4:39154262 chr4:39112677~39126818:- LIHC cis rs9326248 0.813 rs474488 ENSG00000236267.1 AP006216.5 5.98 5.76e-09 3.72e-06 0.32 0.31 Blood protein levels; chr11:117198261 chr11:116813204~116814003:- LIHC cis rs2739330 0.828 rs5760108 ENSG00000099984.9 GSTT2 -5.98 5.77e-09 3.73e-06 -0.35 -0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23980123~23983911:+ LIHC cis rs7916697 0.52 rs4745957 ENSG00000233590.1 RP11-153K11.3 5.98 5.78e-09 3.73e-06 0.4 0.31 Optic disc area; chr10:68284945 chr10:68233251~68242379:- LIHC cis rs7115242 0.844 rs645258 ENSG00000236267.1 AP006216.5 5.97 5.78e-09 3.73e-06 0.4 0.31 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116930485 chr11:116813204~116814003:- LIHC cis rs7927592 0.763 rs624003 ENSG00000212093.1 AP000807.1 5.97 5.8e-09 3.74e-06 0.31 0.31 Total body bone mineral density; chr11:68463772 chr11:68506083~68506166:- LIHC cis rs2153535 0.58 rs4365970 ENSG00000230939.1 RP11-314C16.1 5.97 5.81e-09 3.75e-06 0.37 0.31 Motion sickness; chr6:8453580 chr6:8784178~8785445:+ LIHC cis rs6142102 0.961 rs4911146 ENSG00000276073.1 RP5-1125A11.7 -5.97 5.82e-09 3.75e-06 -0.34 -0.31 Skin pigmentation; chr20:34052241 chr20:33985617~33988989:- LIHC cis rs4356975 0.527 rs12643840 ENSG00000249956.3 RP11-790I12.2 5.97 5.82e-09 3.75e-06 0.35 0.31 Obesity-related traits; chr4:69082245 chr4:69408836~69423164:+ LIHC cis rs875971 0.545 rs7783889 ENSG00000226824.5 RP4-756H11.3 -5.97 5.82e-09 3.76e-06 -0.39 -0.31 Aortic root size; chr7:66283366 chr7:66654538~66669855:+ LIHC cis rs3812049 0.667 rs6888037 ENSG00000245937.6 LINC01184 5.97 5.82e-09 3.76e-06 0.41 0.31 Lymphocyte counts;Red cell distribution width; chr5:128070567 chr5:127940426~128083172:- LIHC cis rs3779195 0.524 rs80195155 ENSG00000272950.1 RP11-307C18.1 -5.97 5.83e-09 3.76e-06 -0.48 -0.31 Sex hormone-binding globulin levels; chr7:98248841 chr7:98322853~98323430:+ LIHC cis rs17023223 0.537 rs12097967 ENSG00000231365.4 RP11-418J17.1 -5.97 5.85e-09 3.77e-06 -0.38 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119160290 chr1:119140396~119275973:+ LIHC cis rs17023223 0.537 rs6677107 ENSG00000231365.4 RP11-418J17.1 -5.97 5.85e-09 3.77e-06 -0.38 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119166142 chr1:119140396~119275973:+ LIHC cis rs17023223 0.537 rs12064033 ENSG00000231365.4 RP11-418J17.1 -5.97 5.85e-09 3.77e-06 -0.38 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119166935 chr1:119140396~119275973:+ LIHC cis rs17023223 0.537 rs12064137 ENSG00000231365.4 RP11-418J17.1 -5.97 5.85e-09 3.77e-06 -0.38 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119167126 chr1:119140396~119275973:+ LIHC cis rs17023223 0.509 rs61806978 ENSG00000231365.4 RP11-418J17.1 -5.97 5.85e-09 3.77e-06 -0.38 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119170592 chr1:119140396~119275973:+ LIHC cis rs17023223 0.509 rs56195272 ENSG00000231365.4 RP11-418J17.1 -5.97 5.85e-09 3.77e-06 -0.38 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119171374 chr1:119140396~119275973:+ LIHC cis rs7927592 0.731 rs7108376 ENSG00000212093.1 AP000807.1 -5.97 5.91e-09 3.81e-06 -0.31 -0.31 Total body bone mineral density; chr11:68580402 chr11:68506083~68506166:- LIHC cis rs7927592 0.731 rs11228288 ENSG00000212093.1 AP000807.1 5.97 5.91e-09 3.81e-06 0.31 0.31 Total body bone mineral density; chr11:68586082 chr11:68506083~68506166:- LIHC cis rs9487094 0.601 rs4945831 ENSG00000260273.1 RP11-425D10.10 5.97 5.92e-09 3.82e-06 0.35 0.31 Height; chr6:109440234 chr6:109382795~109383666:+ LIHC cis rs2117029 0.555 rs10747561 ENSG00000258017.1 RP11-386G11.10 -5.97 5.92e-09 3.82e-06 -0.36 -0.31 Intelligence (multi-trait analysis); chr12:49106726 chr12:49127782~49147869:+ LIHC cis rs3096299 0.967 rs2911256 ENSG00000274627.1 RP11-104N10.2 5.97 5.93e-09 3.82e-06 0.32 0.31 Multiple myeloma (IgH translocation); chr16:89418688 chr16:89516797~89522217:+ LIHC cis rs4356975 0.545 rs11249525 ENSG00000249956.3 RP11-790I12.2 5.97 5.93e-09 3.82e-06 0.35 0.31 Obesity-related traits; chr4:69080923 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4443355 ENSG00000249956.3 RP11-790I12.2 5.97 5.93e-09 3.82e-06 0.35 0.31 Obesity-related traits; chr4:69083026 chr4:69408836~69423164:+ LIHC cis rs1499614 1 rs1638731 ENSG00000273142.1 RP11-458F8.4 -5.97 5.93e-09 3.82e-06 -0.38 -0.31 Gout; chr7:66679692 chr7:66902857~66906297:+ LIHC cis rs1499614 1 rs1882655 ENSG00000273142.1 RP11-458F8.4 5.97 5.93e-09 3.82e-06 0.38 0.31 Gout; chr7:66682070 chr7:66902857~66906297:+ LIHC cis rs1499614 0.831 rs3800822 ENSG00000273142.1 RP11-458F8.4 5.97 5.93e-09 3.82e-06 0.38 0.31 Gout; chr7:66682162 chr7:66902857~66906297:+ LIHC cis rs12681287 0.64 rs13267782 ENSG00000250569.1 NTAN1P2 5.97 5.94e-09 3.83e-06 0.36 0.31 Caudate activity during reward; chr8:86469658 chr8:86481754~86483002:- LIHC cis rs7914558 0.966 rs7908280 ENSG00000236937.2 PTGES3P4 5.97 5.95e-09 3.83e-06 0.37 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103057190 chr10:102845595~102845950:+ LIHC cis rs2735413 0.564 rs17776122 ENSG00000276007.1 RP11-358L22.3 5.97 5.96e-09 3.84e-06 0.44 0.31 Systolic blood pressure (alcohol consumption interaction); chr16:78072389 chr16:78123243~78124332:+ LIHC cis rs2735413 0.564 rs7193020 ENSG00000276007.1 RP11-358L22.3 5.97 5.96e-09 3.84e-06 0.44 0.31 Systolic blood pressure (alcohol consumption interaction); chr16:78072543 chr16:78123243~78124332:+ LIHC cis rs10510102 0.748 rs11200297 ENSG00000276742.1 RP11-500G22.4 5.97 5.97e-09 3.84e-06 0.51 0.31 Breast cancer; chr10:121972916 chr10:121956782~121957098:+ LIHC cis rs7617773 0.743 rs6804986 ENSG00000229759.1 MRPS18AP1 5.97 5.97e-09 3.84e-06 0.37 0.31 Coronary artery disease; chr3:48322105 chr3:48256350~48256938:- LIHC cis rs6142102 0.812 rs6059574 ENSG00000276073.1 RP5-1125A11.7 5.97 5.97e-09 3.84e-06 0.33 0.31 Skin pigmentation; chr20:33935366 chr20:33985617~33988989:- LIHC cis rs6142102 1 rs2378078 ENSG00000276073.1 RP5-1125A11.7 -5.97 5.98e-09 3.85e-06 -0.33 -0.31 Skin pigmentation; chr20:34126922 chr20:33985617~33988989:- LIHC cis rs9487094 0.67 rs11153183 ENSG00000260273.1 RP11-425D10.10 5.97 6e-09 3.86e-06 0.37 0.31 Height; chr6:109496073 chr6:109382795~109383666:+ LIHC cis rs4356975 0.527 rs62296943 ENSG00000249956.3 RP11-790I12.2 5.97 6.02e-09 3.87e-06 0.34 0.31 Obesity-related traits; chr4:69093465 chr4:69408836~69423164:+ LIHC cis rs9326248 0.53 rs2471884 ENSG00000280143.1 AP000892.6 5.97 6.04e-09 3.88e-06 0.39 0.31 Blood protein levels; chr11:117139604 chr11:117204967~117210292:+ LIHC cis rs2274273 0.84 rs943590 ENSG00000258413.1 RP11-665C16.6 -5.97 6.04e-09 3.89e-06 -0.35 -0.31 Protein biomarker; chr14:55271878 chr14:55262767~55272075:- LIHC cis rs67180937 0.583 rs2936052 ENSG00000272750.1 RP11-378J18.8 5.97 6.05e-09 3.89e-06 0.36 0.31 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222629034 chr1:222658867~222661512:- LIHC cis rs7914558 0.966 rs11191438 ENSG00000236937.2 PTGES3P4 5.97 6.06e-09 3.9e-06 0.36 0.31 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102878107 chr10:102845595~102845950:+ LIHC cis rs2739330 0.828 rs2877178 ENSG00000099984.9 GSTT2 -5.97 6.06e-09 3.9e-06 -0.35 -0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23980123~23983911:+ LIHC cis rs2522056 1 rs10900807 ENSG00000233006.5 AC034220.3 -5.97 6.07e-09 3.9e-06 -0.33 -0.31 Fibrinogen;Lymphocyte counts; chr5:132421788 chr5:132311285~132369916:- LIHC cis rs875971 0.545 rs1267814 ENSG00000226824.5 RP4-756H11.3 5.97 6.07e-09 3.91e-06 0.39 0.31 Aortic root size; chr7:66579422 chr7:66654538~66669855:+ LIHC cis rs2735413 0.709 rs9938043 ENSG00000276007.1 RP11-358L22.3 -5.97 6.1e-09 3.92e-06 -0.34 -0.31 Systolic blood pressure (alcohol consumption interaction); chr16:78057529 chr16:78123243~78124332:+ LIHC cis rs17023223 0.508 rs12096448 ENSG00000231365.4 RP11-418J17.1 -5.97 6.1e-09 3.92e-06 -0.38 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119140767 chr1:119140396~119275973:+ LIHC cis rs72627509 0.951 rs72627508 ENSG00000269949.1 RP11-738E22.3 5.97 6.1e-09 3.92e-06 0.41 0.31 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56965398 chr4:56960927~56961373:- LIHC cis rs2274273 0.837 rs11625968 ENSG00000258413.1 RP11-665C16.6 -5.96 6.12e-09 3.93e-06 -0.36 -0.31 Protein biomarker; chr14:55334286 chr14:55262767~55272075:- LIHC cis rs13068223 0.716 rs344067 ENSG00000243926.1 TIPARP-AS1 -5.96 6.15e-09 3.95e-06 -0.33 -0.31 Age-related hearing impairment (SNP x SNP interaction); chr3:156723825 chr3:156671862~156674378:- LIHC cis rs6921919 0.583 rs6907950 ENSG00000216901.1 AL022393.7 5.96 6.16e-09 3.95e-06 0.38 0.31 Autism spectrum disorder or schizophrenia; chr6:28402469 chr6:28176188~28176674:+ LIHC cis rs4356975 0.583 rs4632729 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69080286 chr4:69408836~69423164:+ LIHC cis rs4356975 0.545 rs11249524 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69080653 chr4:69408836~69423164:+ LIHC cis rs4356975 0.545 rs11249526 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69080934 chr4:69408836~69423164:+ LIHC cis rs4356975 0.602 rs7674851 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69081113 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs7679550 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69081187 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4478248 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69081498 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs7680709 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69081745 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4540108 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69083614 chr4:69408836~69423164:+ LIHC cis rs4356975 0.545 rs4640729 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69083642 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4522933 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69083780 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs11937683 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69084102 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs7659306 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69084560 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4454000 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69084853 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4273534 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69084927 chr4:69408836~69423164:+ LIHC cis rs4356975 0.522 rs4642304 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69085832 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4446391 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69086364 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs7437174 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69086885 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs6600874 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69087695 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs6843382 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69087884 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4694171 ENSG00000249956.3 RP11-790I12.2 5.96 6.18e-09 3.97e-06 0.35 0.31 Obesity-related traits; chr4:69088579 chr4:69408836~69423164:+ LIHC cis rs17270561 0.583 rs6908713 ENSG00000216436.2 HIST1H2APS1 5.96 6.19e-09 3.98e-06 0.38 0.31 Iron status biomarkers; chr6:25703383 chr6:25732497~25732827:+ LIHC cis rs17270561 0.583 rs6908407 ENSG00000216436.2 HIST1H2APS1 5.96 6.19e-09 3.98e-06 0.38 0.31 Iron status biomarkers; chr6:25703428 chr6:25732497~25732827:+ LIHC cis rs4706831 0.663 rs1984242 ENSG00000272129.1 RP11-250B2.6 5.96 6.19e-09 3.98e-06 0.3 0.31 Joint mobility (Beighton score); chr6:80341528 chr6:80355424~80356859:+ LIHC cis rs7617773 0.817 rs4131361 ENSG00000229759.1 MRPS18AP1 5.96 6.21e-09 3.98e-06 0.36 0.31 Coronary artery disease; chr3:48287322 chr3:48256350~48256938:- LIHC cis rs7617773 0.817 rs6791930 ENSG00000229759.1 MRPS18AP1 5.96 6.21e-09 3.98e-06 0.36 0.31 Coronary artery disease; chr3:48288410 chr3:48256350~48256938:- LIHC cis rs7617773 0.817 rs6794644 ENSG00000229759.1 MRPS18AP1 5.96 6.21e-09 3.98e-06 0.36 0.31 Coronary artery disease; chr3:48288547 chr3:48256350~48256938:- LIHC cis rs4356975 0.509 rs4371688 ENSG00000249956.3 RP11-790I12.2 5.96 6.21e-09 3.99e-06 0.36 0.31 Obesity-related traits; chr4:69124323 chr4:69408836~69423164:+ LIHC cis rs12681287 0.64 rs72606633 ENSG00000250569.1 NTAN1P2 5.96 6.23e-09 3.99e-06 0.36 0.31 Caudate activity during reward; chr8:86464007 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs61106663 ENSG00000250569.1 NTAN1P2 5.96 6.23e-09 3.99e-06 0.36 0.31 Caudate activity during reward; chr8:86464852 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs13252046 ENSG00000250569.1 NTAN1P2 5.96 6.23e-09 3.99e-06 0.36 0.31 Caudate activity during reward; chr8:86465522 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs13261901 ENSG00000250569.1 NTAN1P2 5.96 6.23e-09 3.99e-06 0.36 0.31 Caudate activity during reward; chr8:86466488 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs7017706 ENSG00000250569.1 NTAN1P2 5.96 6.23e-09 3.99e-06 0.36 0.31 Caudate activity during reward; chr8:86468661 chr8:86481754~86483002:- LIHC cis rs12681287 0.608 rs13272148 ENSG00000250569.1 NTAN1P2 5.96 6.23e-09 3.99e-06 0.36 0.31 Caudate activity during reward; chr8:86469624 chr8:86481754~86483002:- LIHC cis rs12681287 0.608 rs1135451 ENSG00000250569.1 NTAN1P2 5.96 6.23e-09 3.99e-06 0.36 0.31 Caudate activity during reward; chr8:86471379 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs13260345 ENSG00000250569.1 NTAN1P2 5.96 6.23e-09 3.99e-06 0.36 0.31 Caudate activity during reward; chr8:86471492 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs13282351 ENSG00000250569.1 NTAN1P2 5.96 6.23e-09 3.99e-06 0.36 0.31 Caudate activity during reward; chr8:86472440 chr8:86481754~86483002:- LIHC cis rs10833905 0.641 rs10833850 ENSG00000246225.5 RP11-17A1.3 -5.96 6.26e-09 4.01e-06 -0.4 -0.31 Sudden cardiac arrest; chr11:22930969 chr11:22829380~22945393:+ LIHC cis rs6921919 0.887 rs16894116 ENSG00000204709.4 LINC01556 5.96 6.27e-09 4.02e-06 0.47 0.31 Autism spectrum disorder or schizophrenia; chr6:28447190 chr6:28943877~28944537:+ LIHC cis rs2153535 0.58 rs9505454 ENSG00000230939.1 RP11-314C16.1 -5.96 6.29e-09 4.03e-06 -0.37 -0.31 Motion sickness; chr6:8478299 chr6:8784178~8785445:+ LIHC cis rs2762353 0.595 rs12207313 ENSG00000242387.1 HIST1H2APS2 -5.96 6.3e-09 4.04e-06 -0.38 -0.31 Blood metabolite levels; chr6:25740799 chr6:25882026~25882395:- LIHC cis rs67180937 0.504 rs3008625 ENSG00000272750.1 RP11-378J18.8 5.96 6.3e-09 4.04e-06 0.36 0.31 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222646680 chr1:222658867~222661512:- LIHC cis rs2735413 0.564 rs2222897 ENSG00000276007.1 RP11-358L22.3 5.96 6.33e-09 4.05e-06 0.43 0.31 Systolic blood pressure (alcohol consumption interaction); chr16:78058138 chr16:78123243~78124332:+ LIHC cis rs5769765 0.913 rs28670284 ENSG00000278869.1 CITF22-49E9.3 5.96 6.33e-09 4.06e-06 0.56 0.31 Schizophrenia; chr22:49828325 chr22:49933198~49934074:- LIHC cis rs3812049 0.784 rs3749748 ENSG00000245937.6 LINC01184 -5.96 6.37e-09 4.08e-06 -0.4 -0.31 Lymphocyte counts;Red cell distribution width; chr5:128014857 chr5:127940426~128083172:- LIHC cis rs202072 0.818 rs405078 ENSG00000215022.6 RP1-257A7.4 -5.96 6.37e-09 4.08e-06 -0.35 -0.31 HIV-1 viral setpoint; chr6:13279635 chr6:13264861~13295586:- LIHC cis rs7927592 0.871 rs17603185 ENSG00000212093.1 AP000807.1 5.96 6.38e-09 4.09e-06 0.34 0.31 Total body bone mineral density; chr11:68608773 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs2236708 ENSG00000212093.1 AP000807.1 5.96 6.38e-09 4.09e-06 0.34 0.31 Total body bone mineral density; chr11:68610577 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs4988291 ENSG00000212093.1 AP000807.1 5.96 6.38e-09 4.09e-06 0.34 0.31 Total body bone mineral density; chr11:68614139 chr11:68506083~68506166:- LIHC cis rs7927592 0.871 rs12941 ENSG00000212093.1 AP000807.1 5.96 6.38e-09 4.09e-06 0.34 0.31 Total body bone mineral density; chr11:68614725 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs11228293 ENSG00000212093.1 AP000807.1 5.96 6.38e-09 4.09e-06 0.34 0.31 Total body bone mineral density; chr11:68617178 chr11:68506083~68506166:- LIHC cis rs9549367 0.789 rs9549711 ENSG00000269125.1 RP11-98F14.11 -5.96 6.39e-09 4.09e-06 -0.38 -0.31 Platelet distribution width; chr13:113246243 chr13:113165002~113165183:- LIHC cis rs9549367 0.737 rs9549712 ENSG00000269125.1 RP11-98F14.11 -5.96 6.39e-09 4.09e-06 -0.38 -0.31 Platelet distribution width; chr13:113248041 chr13:113165002~113165183:- LIHC cis rs9549367 0.774 rs9549364 ENSG00000269125.1 RP11-98F14.11 -5.96 6.39e-09 4.09e-06 -0.38 -0.31 Platelet distribution width; chr13:113249431 chr13:113165002~113165183:- LIHC cis rs9549367 0.737 rs11619691 ENSG00000269125.1 RP11-98F14.11 -5.96 6.39e-09 4.09e-06 -0.38 -0.31 Platelet distribution width; chr13:113250322 chr13:113165002~113165183:- LIHC cis rs9549367 0.826 rs9549713 ENSG00000269125.1 RP11-98F14.11 -5.96 6.39e-09 4.09e-06 -0.38 -0.31 Platelet distribution width; chr13:113250994 chr13:113165002~113165183:- LIHC cis rs9549367 0.789 rs3861720 ENSG00000269125.1 RP11-98F14.11 -5.96 6.39e-09 4.09e-06 -0.38 -0.31 Platelet distribution width; chr13:113251783 chr13:113165002~113165183:- LIHC cis rs9549367 0.865 rs3861721 ENSG00000269125.1 RP11-98F14.11 -5.96 6.39e-09 4.09e-06 -0.38 -0.31 Platelet distribution width; chr13:113251994 chr13:113165002~113165183:- LIHC cis rs7688540 0.771 rs61794997 ENSG00000275426.1 CH17-262A2.1 5.96 6.39e-09 4.09e-06 0.42 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:228314 chr4:149738~150317:+ LIHC cis rs2243480 1 rs313813 ENSG00000273142.1 RP11-458F8.4 -5.96 6.4e-09 4.09e-06 -0.37 -0.31 Diabetic kidney disease; chr7:66038513 chr7:66902857~66906297:+ LIHC cis rs17270561 0.609 rs9467572 ENSG00000216436.2 HIST1H2APS1 5.96 6.4e-09 4.1e-06 0.38 0.31 Iron status biomarkers; chr6:25703898 chr6:25732497~25732827:+ LIHC cis rs9341808 0.718 rs9343978 ENSG00000272129.1 RP11-250B2.6 5.96 6.41e-09 4.1e-06 0.29 0.31 Sitting height ratio; chr6:80262261 chr6:80355424~80356859:+ LIHC cis rs9341808 0.754 rs9341810 ENSG00000272129.1 RP11-250B2.6 5.96 6.41e-09 4.1e-06 0.29 0.31 Sitting height ratio; chr6:80265121 chr6:80355424~80356859:+ LIHC cis rs9341808 0.7 rs12215236 ENSG00000272129.1 RP11-250B2.6 5.96 6.41e-09 4.1e-06 0.29 0.31 Sitting height ratio; chr6:80265341 chr6:80355424~80356859:+ LIHC cis rs8072100 0.935 rs8070759 ENSG00000228782.6 CTD-2026D20.3 -5.96 6.42e-09 4.11e-06 -0.33 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47561394 chr17:47450568~47492492:- LIHC cis rs8072100 0.764 rs2644349 ENSG00000228782.6 CTD-2026D20.3 -5.96 6.42e-09 4.11e-06 -0.33 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47564377 chr17:47450568~47492492:- LIHC cis rs17023223 0.581 rs11811859 ENSG00000231365.4 RP11-418J17.1 -5.96 6.43e-09 4.12e-06 -0.38 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119165057 chr1:119140396~119275973:+ LIHC cis rs10875746 0.669 rs17122812 ENSG00000240399.1 RP1-228P16.1 -5.95 6.47e-09 4.14e-06 -0.34 -0.31 Longevity (90 years and older); chr12:48203270 chr12:48054813~48055591:- LIHC cis rs2284378 0.506 rs6142059 ENSG00000276073.1 RP5-1125A11.7 -5.95 6.48e-09 4.15e-06 -0.31 -0.31 Breast cancer; chr20:33956521 chr20:33985617~33988989:- LIHC cis rs7617773 0.78 rs13079728 ENSG00000229759.1 MRPS18AP1 5.95 6.51e-09 4.16e-06 0.38 0.31 Coronary artery disease; chr3:48297870 chr3:48256350~48256938:- LIHC cis rs2243480 1 rs313832 ENSG00000273142.1 RP11-458F8.4 -5.95 6.51e-09 4.16e-06 -0.38 -0.31 Diabetic kidney disease; chr7:66085904 chr7:66902857~66906297:+ LIHC cis rs12744310 0.697 rs11209802 ENSG00000235358.1 RP11-399E6.1 5.95 6.52e-09 4.17e-06 0.36 0.31 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41291154 chr1:41242373~41284861:+ LIHC cis rs4356975 0.509 rs28375964 ENSG00000249956.3 RP11-790I12.2 5.95 6.52e-09 4.17e-06 0.35 0.31 Obesity-related traits; chr4:69098070 chr4:69408836~69423164:+ LIHC cis rs1789 0.592 rs1558572 ENSG00000273133.1 RP11-799M12.2 -5.95 6.57e-09 4.2e-06 -0.48 -0.31 Blood protein levels; chr4:15537121 chr4:15563698~15564253:- LIHC cis rs6435862 0.517 rs6757091 ENSG00000229267.2 AC072062.1 5.95 6.58e-09 4.2e-06 0.36 0.31 Neuroblastoma (high-risk); chr2:214808069 chr2:214810229~214963274:+ LIHC cis rs6435862 0.5 rs6756902 ENSG00000229267.2 AC072062.1 5.95 6.58e-09 4.2e-06 0.36 0.31 Neuroblastoma (high-risk); chr2:214808103 chr2:214810229~214963274:+ LIHC cis rs6435862 0.5 rs12477063 ENSG00000229267.2 AC072062.1 5.95 6.58e-09 4.2e-06 0.36 0.31 Neuroblastoma (high-risk); chr2:214808940 chr2:214810229~214963274:+ LIHC cis rs853679 0.657 rs1778483 ENSG00000216901.1 AL022393.7 5.95 6.6e-09 4.22e-06 0.36 0.31 Depression; chr6:28273214 chr6:28176188~28176674:+ LIHC cis rs853679 0.657 rs1778482 ENSG00000216901.1 AL022393.7 5.95 6.6e-09 4.22e-06 0.36 0.31 Depression; chr6:28273215 chr6:28176188~28176674:+ LIHC cis rs7927592 0.913 rs10896338 ENSG00000212093.1 AP000807.1 5.95 6.6e-09 4.22e-06 0.34 0.31 Total body bone mineral density; chr11:68531892 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs7115374 ENSG00000212093.1 AP000807.1 5.95 6.6e-09 4.22e-06 0.34 0.31 Total body bone mineral density; chr11:68532608 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs67605986 ENSG00000212093.1 AP000807.1 5.95 6.6e-09 4.22e-06 0.34 0.31 Total body bone mineral density; chr11:68533487 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs12285993 ENSG00000212093.1 AP000807.1 5.95 6.6e-09 4.22e-06 0.34 0.31 Total body bone mineral density; chr11:68535070 chr11:68506083~68506166:- LIHC cis rs875971 0.545 rs801199 ENSG00000226824.5 RP4-756H11.3 5.95 6.62e-09 4.23e-06 0.39 0.31 Aortic root size; chr7:66560286 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs1638724 ENSG00000226824.5 RP4-756H11.3 5.95 6.62e-09 4.23e-06 0.39 0.31 Aortic root size; chr7:66575494 chr7:66654538~66669855:+ LIHC cis rs2243480 0.803 rs36127118 ENSG00000164669.11 INTS4P1 5.95 6.62e-09 4.23e-06 0.52 0.31 Diabetic kidney disease; chr7:66100518 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs383402 ENSG00000273142.1 RP11-458F8.4 5.95 6.63e-09 4.23e-06 0.37 0.31 Diabetic kidney disease; chr7:66121666 chr7:66902857~66906297:+ LIHC cis rs1005277 0.522 rs289643 ENSG00000263064.2 RP11-291L22.7 5.95 6.65e-09 4.24e-06 0.31 0.31 Extrinsic epigenetic age acceleration; chr10:37652566 chr10:38448689~38448949:+ LIHC cis rs8100891 0.537 rs28562777 ENSG00000267213.4 AC007773.2 -5.95 6.65e-09 4.25e-06 -0.39 -0.31 Neuroticism; chr19:32409913 chr19:32390050~32405560:- LIHC cis rs8100891 0.537 rs2302772 ENSG00000267213.4 AC007773.2 -5.95 6.65e-09 4.25e-06 -0.39 -0.31 Neuroticism; chr19:32411144 chr19:32390050~32405560:- LIHC cis rs992157 0.643 rs10191283 ENSG00000261338.2 RP11-378A13.1 5.95 6.66e-09 4.25e-06 0.3 0.31 Colorectal cancer; chr2:218192032 chr2:218255319~218257366:+ LIHC cis rs7829975 0.514 rs2976929 ENSG00000253893.2 FAM85B -5.95 6.66e-09 4.25e-06 -0.36 -0.31 Mood instability; chr8:8401202 chr8:8167819~8226614:- LIHC cis rs6061231 0.631 rs927133 ENSG00000273619.1 RP5-908M14.9 -5.95 6.68e-09 4.26e-06 -0.26 -0.31 Colorectal cancer; chr20:62397053 chr20:62386303~62386970:- LIHC cis rs1023500 0.551 rs133379 ENSG00000237037.8 NDUFA6-AS1 5.95 6.7e-09 4.27e-06 0.37 0.31 Schizophrenia; chr22:42072531 chr22:42090931~42137742:+ LIHC cis rs494459 0.536 rs11217063 ENSG00000255422.1 AP002954.4 -5.95 6.73e-09 4.29e-06 -0.34 -0.31 Height; chr11:118855233 chr11:118704607~118750263:+ LIHC cis rs494459 0.536 rs11217065 ENSG00000255422.1 AP002954.4 -5.95 6.73e-09 4.29e-06 -0.34 -0.31 Height; chr11:118855938 chr11:118704607~118750263:+ LIHC cis rs3812049 0.784 rs2568928 ENSG00000245937.6 LINC01184 -5.95 6.75e-09 4.3e-06 -0.4 -0.31 Lymphocyte counts;Red cell distribution width; chr5:128151911 chr5:127940426~128083172:- LIHC cis rs7119038 0.818 rs2155433 ENSG00000255239.1 AP002954.6 -5.95 6.77e-09 4.32e-06 -0.39 -0.31 Sjögren's syndrome; chr11:118742212 chr11:118688039~118690600:- LIHC cis rs9326248 0.911 rs11216284 ENSG00000236267.1 AP006216.5 5.95 6.79e-09 4.33e-06 0.31 0.31 Blood protein levels; chr11:117132344 chr11:116813204~116814003:- LIHC cis rs10170846 0.8 rs10194743 ENSG00000261428.2 RP11-16P6.1 5.95 6.8e-09 4.33e-06 0.32 0.31 Schizophrenia (inflammation and infection response interaction); chr2:222653432 chr2:222566899~222569719:- LIHC cis rs12681287 0.752 rs10103229 ENSG00000250569.1 NTAN1P2 -5.94 6.83e-09 4.35e-06 -0.38 -0.31 Caudate activity during reward; chr8:86236725 chr8:86481754~86483002:- LIHC cis rs7617773 0.779 rs9833309 ENSG00000229759.1 MRPS18AP1 5.94 6.85e-09 4.36e-06 0.36 0.31 Coronary artery disease; chr3:48285960 chr3:48256350~48256938:- LIHC cis rs7617773 0.817 rs9853804 ENSG00000229759.1 MRPS18AP1 5.94 6.85e-09 4.36e-06 0.36 0.31 Coronary artery disease; chr3:48286239 chr3:48256350~48256938:- LIHC cis rs7617773 0.817 rs9834095 ENSG00000229759.1 MRPS18AP1 5.94 6.85e-09 4.36e-06 0.36 0.31 Coronary artery disease; chr3:48286261 chr3:48256350~48256938:- LIHC cis rs7927592 0.763 rs7129248 ENSG00000212093.1 AP000807.1 5.94 6.86e-09 4.37e-06 0.31 0.31 Total body bone mineral density; chr11:68495808 chr11:68506083~68506166:- LIHC cis rs2688482 0.557 rs2550236 ENSG00000224769.1 AC069213.1 5.94 6.86e-09 4.37e-06 0.45 0.31 Lung disease severity in cystic fibrosis; chr3:195795450 chr3:195614947~195620233:+ LIHC cis rs9399137 0.507 rs6904897 ENSG00000232876.1 CTA-212D2.2 -5.94 6.89e-09 4.39e-06 -0.36 -0.31 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135061842 chr6:135055033~135060550:+ LIHC cis rs9549367 0.789 rs7994324 ENSG00000269125.1 RP11-98F14.11 -5.94 6.93e-09 4.41e-06 -0.38 -0.31 Platelet distribution width; chr13:113252183 chr13:113165002~113165183:- LIHC cis rs7927592 0.763 rs10896326 ENSG00000212093.1 AP000807.1 5.94 6.93e-09 4.41e-06 0.31 0.31 Total body bone mineral density; chr11:68467103 chr11:68506083~68506166:- LIHC cis rs8059260 0.604 rs2160042 ENSG00000274038.1 RP11-66H6.4 -5.94 6.94e-09 4.42e-06 -0.52 -0.31 Alcohol consumption over the past year; chr16:11064375 chr16:11056556~11057034:+ LIHC cis rs2762353 0.574 rs9467573 ENSG00000242387.1 HIST1H2APS2 -5.94 6.95e-09 4.42e-06 -0.39 -0.31 Blood metabolite levels; chr6:25703962 chr6:25882026~25882395:- LIHC cis rs11723261 0.513 rs2353623 ENSG00000275426.1 CH17-262A2.1 5.94 6.95e-09 4.42e-06 0.34 0.31 Immune response to smallpox vaccine (IL-6); chr4:95673 chr4:149738~150317:+ LIHC cis rs12908161 1 rs58416181 ENSG00000259295.5 CSPG4P12 5.94 6.96e-09 4.43e-06 0.42 0.31 Schizophrenia; chr15:84721230 chr15:85191438~85213905:+ LIHC cis rs7688540 0.723 rs1986386 ENSG00000275426.1 CH17-262A2.1 5.94 6.97e-09 4.44e-06 0.42 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:235020 chr4:149738~150317:+ LIHC cis rs7927592 0.913 rs11228292 ENSG00000212093.1 AP000807.1 5.94 6.98e-09 4.44e-06 0.34 0.31 Total body bone mineral density; chr11:68612304 chr11:68506083~68506166:- LIHC cis rs7927592 0.701 rs12226585 ENSG00000212093.1 AP000807.1 -5.94 7e-09 4.45e-06 -0.31 -0.31 Total body bone mineral density; chr11:68490393 chr11:68506083~68506166:- LIHC cis rs10833905 0.641 rs10766981 ENSG00000246225.5 RP11-17A1.3 -5.94 7e-09 4.46e-06 -0.4 -0.31 Sudden cardiac arrest; chr11:22920950 chr11:22829380~22945393:+ LIHC cis rs17826219 0.562 rs719600 ENSG00000263531.1 RP13-753N3.1 -5.94 7.02e-09 4.46e-06 -0.52 -0.31 Body mass index; chr17:30404244 chr17:30863921~30864940:- LIHC cis rs748404 0.587 rs690276 ENSG00000205771.5 CATSPER2P1 -5.94 7.03e-09 4.47e-06 -0.37 -0.31 Lung cancer; chr15:43412360 chr15:43726918~43747094:- LIHC cis rs2882667 0.537 rs13181793 ENSG00000253404.1 AC034243.1 5.94 7.04e-09 4.48e-06 0.38 0.31 Age-related hearing impairment (SNP x SNP interaction); chr5:139073267 chr5:138744434~138753309:- LIHC cis rs2882667 0.537 rs11743534 ENSG00000253404.1 AC034243.1 5.94 7.04e-09 4.48e-06 0.38 0.31 Age-related hearing impairment (SNP x SNP interaction); chr5:139073318 chr5:138744434~138753309:- LIHC cis rs2243480 1 rs464895 ENSG00000273142.1 RP11-458F8.4 -5.94 7.05e-09 4.48e-06 -0.37 -0.31 Diabetic kidney disease; chr7:66062119 chr7:66902857~66906297:+ LIHC cis rs3779195 0.585 rs7777991 ENSG00000272950.1 RP11-307C18.1 -5.94 7.06e-09 4.49e-06 -0.48 -0.31 Sex hormone-binding globulin levels; chr7:98236445 chr7:98322853~98323430:+ LIHC cis rs2243480 1 rs313831 ENSG00000273142.1 RP11-458F8.4 -5.94 7.08e-09 4.5e-06 -0.38 -0.31 Diabetic kidney disease; chr7:66086239 chr7:66902857~66906297:+ LIHC cis rs5758511 0.573 rs1883205 ENSG00000237037.8 NDUFA6-AS1 5.94 7.11e-09 4.52e-06 0.36 0.31 Birth weight; chr22:41847016 chr22:42090931~42137742:+ LIHC cis rs7617773 0.817 rs4131362 ENSG00000229759.1 MRPS18AP1 5.94 7.12e-09 4.52e-06 0.36 0.31 Coronary artery disease; chr3:48287546 chr3:48256350~48256938:- LIHC cis rs34779708 0.733 rs7081597 ENSG00000230534.5 RP11-297A16.2 5.94 7.12e-09 4.52e-06 0.38 0.31 Inflammatory bowel disease;Crohn's disease; chr10:35257403 chr10:35098006~35127020:- LIHC cis rs7567389 0.74 rs1604817 ENSG00000236682.1 AC068282.3 5.94 7.12e-09 4.53e-06 0.44 0.31 Self-rated health; chr2:127242345 chr2:127389130~127400580:+ LIHC cis rs7945705 0.783 rs11042125 ENSG00000254860.4 TMEM9B-AS1 5.94 7.13e-09 4.53e-06 0.3 0.31 Hemoglobin concentration; chr11:8916502 chr11:8964675~8977527:+ LIHC cis rs7927592 0.763 rs7119422 ENSG00000212093.1 AP000807.1 -5.94 7.14e-09 4.54e-06 -0.31 -0.31 Total body bone mineral density; chr11:68563686 chr11:68506083~68506166:- LIHC cis rs2882667 0.537 rs7701338 ENSG00000253404.1 AC034243.1 5.94 7.16e-09 4.55e-06 0.38 0.31 Age-related hearing impairment (SNP x SNP interaction); chr5:139070305 chr5:138744434~138753309:- LIHC cis rs932287 1 rs932287 ENSG00000254860.4 TMEM9B-AS1 5.94 7.16e-09 4.55e-06 0.35 0.31 Colonoscopy-negative controls vs population controls; chr11:9023220 chr11:8964675~8977527:+ LIHC cis rs8028182 0.636 rs4243034 ENSG00000260269.4 CTD-2323K18.1 -5.94 7.17e-09 4.55e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75458628 chr15:75527150~75601205:- LIHC cis rs8028182 0.636 rs6495182 ENSG00000260269.4 CTD-2323K18.1 -5.94 7.2e-09 4.57e-06 -0.4 -0.31 Sudden cardiac arrest; chr15:75522047 chr15:75527150~75601205:- LIHC cis rs17023223 0.537 rs4508058 ENSG00000231365.4 RP11-418J17.1 -5.93 7.22e-09 4.59e-06 -0.38 -0.31 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119141627 chr1:119140396~119275973:+ LIHC cis rs7927592 0.871 rs113020558 ENSG00000212093.1 AP000807.1 5.93 7.26e-09 4.61e-06 0.34 0.31 Total body bone mineral density; chr11:68529364 chr11:68506083~68506166:- LIHC cis rs9326248 0.813 rs588534 ENSG00000280143.1 AP000892.6 5.93 7.27e-09 4.62e-06 0.35 0.31 Blood protein levels; chr11:117197788 chr11:117204967~117210292:+ LIHC cis rs7688540 0.771 rs11724417 ENSG00000275426.1 CH17-262A2.1 5.93 7.28e-09 4.62e-06 0.42 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:229563 chr4:149738~150317:+ LIHC cis rs7688540 0.771 rs11724176 ENSG00000275426.1 CH17-262A2.1 5.93 7.28e-09 4.62e-06 0.42 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:231112 chr4:149738~150317:+ LIHC cis rs3812049 0.784 rs2617617 ENSG00000245937.6 LINC01184 5.93 7.34e-09 4.66e-06 0.41 0.31 Lymphocyte counts;Red cell distribution width; chr5:128119316 chr5:127940426~128083172:- LIHC cis rs4423214 0.559 rs10898201 ENSG00000254682.1 RP11-660L16.2 -5.93 7.34e-09 4.66e-06 -0.42 -0.31 Vitamin D levels; chr11:71490481 chr11:71448674~71452157:+ LIHC cis rs853679 0.517 rs4713135 ENSG00000219392.1 RP1-265C24.5 -5.93 7.34e-09 4.66e-06 -0.47 -0.31 Depression; chr6:28071808 chr6:28115628~28116551:+ LIHC cis rs2243480 1 rs160642 ENSG00000164669.11 INTS4P1 5.93 7.36e-09 4.67e-06 0.52 0.31 Diabetic kidney disease; chr7:66093386 chr7:65141225~65234216:+ LIHC cis rs2243480 0.614 rs34032527 ENSG00000164669.11 INTS4P1 5.93 7.36e-09 4.67e-06 0.52 0.31 Diabetic kidney disease; chr7:66100154 chr7:65141225~65234216:+ LIHC cis rs9326248 0.817 rs6589598 ENSG00000280143.1 AP000892.6 5.93 7.37e-09 4.67e-06 0.35 0.31 Blood protein levels; chr11:117131687 chr11:117204967~117210292:+ LIHC cis rs7617773 0.78 rs13067450 ENSG00000229759.1 MRPS18AP1 5.93 7.37e-09 4.67e-06 0.38 0.31 Coronary artery disease; chr3:48295716 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs4479622 ENSG00000229759.1 MRPS18AP1 5.93 7.37e-09 4.67e-06 0.38 0.31 Coronary artery disease; chr3:48296683 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs34946886 ENSG00000229759.1 MRPS18AP1 5.93 7.37e-09 4.67e-06 0.38 0.31 Coronary artery disease; chr3:48296997 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs34589064 ENSG00000229759.1 MRPS18AP1 5.93 7.37e-09 4.67e-06 0.38 0.31 Coronary artery disease; chr3:48298059 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs2541 ENSG00000229759.1 MRPS18AP1 5.93 7.37e-09 4.67e-06 0.38 0.31 Coronary artery disease; chr3:48298128 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs13085251 ENSG00000229759.1 MRPS18AP1 5.93 7.37e-09 4.67e-06 0.38 0.31 Coronary artery disease; chr3:48298555 chr3:48256350~48256938:- LIHC cis rs4356975 0.563 rs6600893 ENSG00000249956.3 RP11-790I12.2 5.93 7.37e-09 4.68e-06 0.34 0.31 Obesity-related traits; chr4:69113183 chr4:69408836~69423164:+ LIHC cis rs55665837 0.54 rs12290926 ENSG00000251991.1 RNU7-49P 5.93 7.38e-09 4.68e-06 0.33 0.31 Vitamin D levels; chr11:14673500 chr11:14478892~14478953:+ LIHC cis rs113835537 0.529 rs3819247 ENSG00000255517.5 CTD-3074O7.5 -5.93 7.4e-09 4.69e-06 -0.34 -0.31 Airway imaging phenotypes; chr11:66526308 chr11:66473490~66480233:- LIHC cis rs875971 0.545 rs1909508 ENSG00000226824.5 RP4-756H11.3 -5.93 7.42e-09 4.7e-06 -0.39 -0.31 Aortic root size; chr7:66301366 chr7:66654538~66669855:+ LIHC cis rs1023500 0.506 rs6002625 ENSG00000237037.8 NDUFA6-AS1 -5.93 7.44e-09 4.72e-06 -0.37 -0.31 Schizophrenia; chr22:42121685 chr22:42090931~42137742:+ LIHC cis rs3812049 0.693 rs9327468 ENSG00000245937.6 LINC01184 5.93 7.45e-09 4.72e-06 0.41 0.31 Lymphocyte counts;Red cell distribution width; chr5:128106169 chr5:127940426~128083172:- LIHC cis rs7396835 0.551 rs10750098 ENSG00000254851.1 RP11-109L13.1 -5.93 7.47e-09 4.73e-06 -0.44 -0.31 Quantitative traits; chr11:116834852 chr11:117135528~117138582:+ LIHC cis rs6142102 0.961 rs4911390 ENSG00000276073.1 RP5-1125A11.7 -5.93 7.47e-09 4.73e-06 -0.34 -0.31 Skin pigmentation; chr20:33977401 chr20:33985617~33988989:- LIHC cis rs6142102 0.923 rs6057961 ENSG00000276073.1 RP5-1125A11.7 -5.93 7.47e-09 4.73e-06 -0.34 -0.31 Skin pigmentation; chr20:33986005 chr20:33985617~33988989:- LIHC cis rs7615952 0.609 rs13088451 ENSG00000171084.14 FAM86JP 5.93 7.48e-09 4.74e-06 0.44 0.31 Blood pressure (smoking interaction); chr3:125834656 chr3:125916620~125930024:+ LIHC cis rs2439831 0.85 rs3742982 ENSG00000205771.5 CATSPER2P1 -5.93 7.49e-09 4.74e-06 -0.46 -0.31 Lung cancer in ever smokers; chr15:43884483 chr15:43726918~43747094:- LIHC cis rs7208859 0.614 rs216474 ENSG00000263531.1 RP13-753N3.1 -5.93 7.5e-09 4.75e-06 -0.53 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30538073 chr17:30863921~30864940:- LIHC cis rs7927592 0.731 rs2840367 ENSG00000212093.1 AP000807.1 -5.93 7.51e-09 4.76e-06 -0.3 -0.31 Total body bone mineral density; chr11:68534633 chr11:68506083~68506166:- LIHC cis rs6142102 0.961 rs4911385 ENSG00000276073.1 RP5-1125A11.7 -5.93 7.51e-09 4.76e-06 -0.34 -0.31 Skin pigmentation; chr20:33970787 chr20:33985617~33988989:- LIHC cis rs1023500 0.596 rs133369 ENSG00000237037.8 NDUFA6-AS1 5.93 7.54e-09 4.77e-06 0.37 0.31 Schizophrenia; chr22:42067810 chr22:42090931~42137742:+ LIHC cis rs6142102 0.961 rs4911389 ENSG00000276073.1 RP5-1125A11.7 -5.93 7.55e-09 4.78e-06 -0.34 -0.31 Skin pigmentation; chr20:33977235 chr20:33985617~33988989:- LIHC cis rs10510102 0.872 rs28586586 ENSG00000276742.1 RP11-500G22.4 5.93 7.59e-09 4.8e-06 0.5 0.31 Breast cancer; chr10:121950228 chr10:121956782~121957098:+ LIHC cis rs7617773 0.78 rs3197223 ENSG00000229759.1 MRPS18AP1 5.93 7.6e-09 4.81e-06 0.38 0.31 Coronary artery disease; chr3:48294367 chr3:48256350~48256938:- LIHC cis rs9326248 0.954 rs4938349 ENSG00000236267.1 AP006216.5 5.93 7.61e-09 4.81e-06 0.31 0.31 Blood protein levels; chr11:117151207 chr11:116813204~116814003:- LIHC cis rs6142102 0.961 rs1555075 ENSG00000276073.1 RP5-1125A11.7 -5.93 7.61e-09 4.82e-06 -0.34 -0.31 Skin pigmentation; chr20:34022595 chr20:33985617~33988989:- LIHC cis rs62355900 0.627 rs59715006 ENSG00000271828.1 CTD-2310F14.1 5.92 7.64e-09 4.83e-06 0.48 0.31 Endometriosis; chr5:56899820 chr5:56927874~56929573:+ LIHC cis rs62355900 0.627 rs61663138 ENSG00000271828.1 CTD-2310F14.1 5.92 7.64e-09 4.83e-06 0.48 0.31 Endometriosis; chr5:56899946 chr5:56927874~56929573:+ LIHC cis rs904251 0.522 rs882322 ENSG00000204110.6 RP1-153P14.8 -5.92 7.64e-09 4.83e-06 -0.36 -0.31 Cognitive performance; chr6:37516327 chr6:37507348~37535616:+ LIHC cis rs916888 0.738 rs199515 ENSG00000262881.1 RP11-669E14.4 5.92 7.69e-09 4.86e-06 0.46 0.31 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:45907670~45910779:- LIHC cis rs3858145 0.588 rs736535 ENSG00000233590.1 RP11-153K11.3 -5.92 7.72e-09 4.88e-06 -0.42 -0.31 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68284159 chr10:68233251~68242379:- LIHC cis rs150992 0.587 rs4448016 ENSG00000248489.1 CTD-2007H13.3 5.92 7.73e-09 4.89e-06 0.45 0.3 Body mass index; chr5:99037904 chr5:98929171~98995013:+ LIHC cis rs9326248 0.727 rs4938347 ENSG00000236267.1 AP006216.5 5.92 7.75e-09 4.89e-06 0.31 0.3 Blood protein levels; chr11:117151043 chr11:116813204~116814003:- LIHC cis rs9326248 0.861 rs4938348 ENSG00000236267.1 AP006216.5 5.92 7.75e-09 4.89e-06 0.31 0.3 Blood protein levels; chr11:117151161 chr11:116813204~116814003:- LIHC cis rs9326248 0.813 rs4938350 ENSG00000236267.1 AP006216.5 5.92 7.75e-09 4.89e-06 0.31 0.3 Blood protein levels; chr11:117151560 chr11:116813204~116814003:- LIHC cis rs13068223 0.669 rs168247 ENSG00000243926.1 TIPARP-AS1 -5.92 7.76e-09 4.9e-06 -0.33 -0.3 Age-related hearing impairment (SNP x SNP interaction); chr3:156722397 chr3:156671862~156674378:- LIHC cis rs1005277 0.54 rs2474598 ENSG00000263064.2 RP11-291L22.7 -5.92 7.76e-09 4.9e-06 -0.31 -0.3 Extrinsic epigenetic age acceleration; chr10:38141368 chr10:38448689~38448949:+ LIHC cis rs2735413 0.563 rs72800910 ENSG00000276007.1 RP11-358L22.3 5.92 7.76e-09 4.9e-06 0.4 0.3 Systolic blood pressure (alcohol consumption interaction); chr16:78014005 chr16:78123243~78124332:+ LIHC cis rs9326248 0.53 rs7123517 ENSG00000236267.1 AP006216.5 5.92 7.78e-09 4.91e-06 0.34 0.3 Blood protein levels; chr11:117157039 chr11:116813204~116814003:- LIHC cis rs1799810 1 rs1799809 ENSG00000236682.1 AC068282.3 5.92 7.8e-09 4.93e-06 0.43 0.3 Self-rated health; chr2:127418299 chr2:127389130~127400580:+ LIHC cis rs2243480 1 rs160639 ENSG00000164669.11 INTS4P1 5.92 7.81e-09 4.93e-06 0.52 0.3 Diabetic kidney disease; chr7:66115000 chr7:65141225~65234216:+ LIHC cis rs1023500 0.552 rs5758566 ENSG00000237037.8 NDUFA6-AS1 5.92 7.81e-09 4.93e-06 0.37 0.3 Schizophrenia; chr22:42058350 chr22:42090931~42137742:+ LIHC cis rs6061231 0.63 rs62196294 ENSG00000273619.1 RP5-908M14.9 -5.92 7.85e-09 4.96e-06 -0.25 -0.3 Colorectal cancer; chr20:62398376 chr20:62386303~62386970:- LIHC cis rs10875746 0.768 rs4760609 ENSG00000240399.1 RP1-228P16.1 5.92 7.9e-09 4.98e-06 0.32 0.3 Longevity (90 years and older); chr12:48021974 chr12:48054813~48055591:- LIHC cis rs7617773 0.817 rs9818937 ENSG00000229759.1 MRPS18AP1 5.92 7.9e-09 4.99e-06 0.36 0.3 Coronary artery disease; chr3:48283791 chr3:48256350~48256938:- LIHC cis rs7927592 0.913 rs7109294 ENSG00000212093.1 AP000807.1 5.92 7.92e-09 5e-06 0.34 0.3 Total body bone mineral density; chr11:68564625 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs2282563 ENSG00000212093.1 AP000807.1 5.92 7.92e-09 5e-06 0.34 0.3 Total body bone mineral density; chr11:68565732 chr11:68506083~68506166:- LIHC cis rs5758511 0.573 rs2267438 ENSG00000237037.8 NDUFA6-AS1 5.92 7.92e-09 5e-06 0.36 0.3 Birth weight; chr22:41841561 chr22:42090931~42137742:+ LIHC cis rs5758511 0.573 rs2284082 ENSG00000237037.8 NDUFA6-AS1 5.92 7.92e-09 5e-06 0.36 0.3 Birth weight; chr22:41844793 chr22:42090931~42137742:+ LIHC cis rs6490294 0.747 rs659964 ENSG00000226469.1 ADAM1B 5.92 7.94e-09 5.01e-06 0.4 0.3 Mean platelet volume; chr12:111692395 chr12:111927018~111929017:+ LIHC cis rs10510102 0.935 rs11200258 ENSG00000276742.1 RP11-500G22.4 5.92 7.95e-09 5.01e-06 0.47 0.3 Breast cancer; chr10:121918392 chr10:121956782~121957098:+ LIHC cis rs7429990 0.965 rs7430913 ENSG00000229759.1 MRPS18AP1 -5.92 7.95e-09 5.01e-06 -0.32 -0.3 Educational attainment (years of education); chr3:47990867 chr3:48256350~48256938:- LIHC cis rs3812049 0.784 rs6889311 ENSG00000245937.6 LINC01184 5.92 7.97e-09 5.02e-06 0.41 0.3 Lymphocyte counts;Red cell distribution width; chr5:128095593 chr5:127940426~128083172:- LIHC cis rs3812049 0.826 rs2409110 ENSG00000245937.6 LINC01184 5.92 7.97e-09 5.02e-06 0.41 0.3 Lymphocyte counts;Red cell distribution width; chr5:128097355 chr5:127940426~128083172:- LIHC cis rs1005277 0.579 rs2008449 ENSG00000263064.2 RP11-291L22.7 -5.92 7.98e-09 5.03e-06 -0.31 -0.3 Extrinsic epigenetic age acceleration; chr10:38125276 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs932538 ENSG00000263064.2 RP11-291L22.7 5.92 7.98e-09 5.03e-06 0.31 0.3 Extrinsic epigenetic age acceleration; chr10:38092386 chr10:38448689~38448949:+ LIHC cis rs1005277 0.541 rs2472177 ENSG00000263064.2 RP11-291L22.7 5.92 7.98e-09 5.03e-06 0.31 0.3 Extrinsic epigenetic age acceleration; chr10:38095087 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2472178 ENSG00000263064.2 RP11-291L22.7 5.92 7.98e-09 5.03e-06 0.31 0.3 Extrinsic epigenetic age acceleration; chr10:38095822 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474572 ENSG00000263064.2 RP11-291L22.7 5.92 7.98e-09 5.03e-06 0.31 0.3 Extrinsic epigenetic age acceleration; chr10:38096388 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2505198 ENSG00000263064.2 RP11-291L22.7 5.92 7.98e-09 5.03e-06 0.31 0.3 Extrinsic epigenetic age acceleration; chr10:38104255 chr10:38448689~38448949:+ LIHC cis rs853679 0.567 rs13209596 ENSG00000204709.4 LINC01556 5.92 7.98e-09 5.03e-06 0.41 0.3 Depression; chr6:28428413 chr6:28943877~28944537:+ LIHC cis rs853679 0.567 rs9969098 ENSG00000204709.4 LINC01556 5.92 7.98e-09 5.03e-06 0.41 0.3 Depression; chr6:28430971 chr6:28943877~28944537:+ LIHC cis rs853679 0.567 rs7740429 ENSG00000204709.4 LINC01556 5.92 7.98e-09 5.03e-06 0.41 0.3 Depression; chr6:28431469 chr6:28943877~28944537:+ LIHC cis rs853679 0.567 rs16894106 ENSG00000204709.4 LINC01556 5.92 7.98e-09 5.03e-06 0.41 0.3 Depression; chr6:28432562 chr6:28943877~28944537:+ LIHC cis rs17270561 0.609 rs7772382 ENSG00000216436.2 HIST1H2APS1 -5.92 7.99e-09 5.03e-06 -0.38 -0.3 Iron status biomarkers; chr6:25707888 chr6:25732497~25732827:+ LIHC cis rs67180937 0.553 rs1498382 ENSG00000272750.1 RP11-378J18.8 5.92 8.02e-09 5.05e-06 0.35 0.3 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222641495 chr1:222658867~222661512:- LIHC cis rs2842992 0.75 rs2758354 ENSG00000237927.1 RP3-393E18.2 -5.92 8.02e-09 5.05e-06 -0.38 -0.3 Age-related macular degeneration (geographic atrophy); chr6:159704822 chr6:159586955~159589169:- LIHC cis rs8100891 0.537 rs1030094 ENSG00000267213.4 AC007773.2 -5.92 8.05e-09 5.07e-06 -0.38 -0.3 Neuroticism; chr19:32419525 chr19:32390050~32405560:- LIHC cis rs150992 0.587 rs11960896 ENSG00000248489.1 CTD-2007H13.3 -5.91 8.05e-09 5.07e-06 -0.45 -0.3 Body mass index; chr5:99014294 chr5:98929171~98995013:+ LIHC cis rs10510102 0.935 rs12264495 ENSG00000276742.1 RP11-500G22.4 5.91 8.06e-09 5.08e-06 0.47 0.3 Breast cancer; chr10:121919967 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs11200261 ENSG00000276742.1 RP11-500G22.4 5.91 8.06e-09 5.08e-06 0.47 0.3 Breast cancer; chr10:121921133 chr10:121956782~121957098:+ LIHC cis rs12681287 0.752 rs1436628 ENSG00000250569.1 NTAN1P2 -5.91 8.07e-09 5.08e-06 -0.36 -0.3 Caudate activity during reward; chr8:86301116 chr8:86481754~86483002:- LIHC cis rs113835537 0.529 rs57207756 ENSG00000255517.5 CTD-3074O7.5 -5.91 8.08e-09 5.09e-06 -0.38 -0.3 Airway imaging phenotypes; chr11:66502889 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs17496250 ENSG00000255517.5 CTD-3074O7.5 -5.91 8.08e-09 5.09e-06 -0.38 -0.3 Airway imaging phenotypes; chr11:66503303 chr11:66473490~66480233:- LIHC cis rs62355900 0.627 rs58292679 ENSG00000271828.1 CTD-2310F14.1 5.91 8.09e-09 5.09e-06 0.47 0.3 Endometriosis; chr5:56839989 chr5:56927874~56929573:+ LIHC cis rs7927592 0.913 rs6591340 ENSG00000212093.1 AP000807.1 5.91 8.11e-09 5.1e-06 0.34 0.3 Total body bone mineral density; chr11:68530168 chr11:68506083~68506166:- LIHC cis rs9326248 0.813 rs588534 ENSG00000236267.1 AP006216.5 5.91 8.13e-09 5.11e-06 0.31 0.3 Blood protein levels; chr11:117197788 chr11:116813204~116814003:- LIHC cis rs9487094 0.689 rs2884037 ENSG00000260273.1 RP11-425D10.10 5.91 8.14e-09 5.12e-06 0.36 0.3 Height; chr6:109354092 chr6:109382795~109383666:+ LIHC cis rs12701220 0.655 rs10215292 ENSG00000229043.2 AC091729.9 -5.91 8.15e-09 5.13e-06 -0.42 -0.3 Bronchopulmonary dysplasia; chr7:1095627 chr7:1160374~1165267:+ LIHC cis rs7927592 0.626 rs11228279 ENSG00000212093.1 AP000807.1 -5.91 8.15e-09 5.13e-06 -0.3 -0.3 Total body bone mineral density; chr11:68542212 chr11:68506083~68506166:- LIHC cis rs10256972 0.521 rs871019 ENSG00000229043.2 AC091729.9 -5.91 8.16e-09 5.13e-06 -0.36 -0.3 Endometriosis;Longevity; chr7:1065594 chr7:1160374~1165267:+ LIHC cis rs8059260 0.736 rs7200623 ENSG00000274038.1 RP11-66H6.4 -5.91 8.16e-09 5.13e-06 -0.51 -0.3 Alcohol consumption over the past year; chr16:11001188 chr16:11056556~11057034:+ LIHC cis rs7617773 0.817 rs9830016 ENSG00000229759.1 MRPS18AP1 5.91 8.2e-09 5.15e-06 0.35 0.3 Coronary artery disease; chr3:48241004 chr3:48256350~48256938:- LIHC cis rs2739330 0.76 rs5751761 ENSG00000206090.4 AP000350.7 -5.91 8.21e-09 5.16e-06 -0.37 -0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23939998~23942798:+ LIHC cis rs12744310 0.697 rs11209838 ENSG00000235358.1 RP11-399E6.1 5.91 8.23e-09 5.17e-06 0.36 0.3 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41307285 chr1:41242373~41284861:+ LIHC cis rs12744310 0.697 rs11209839 ENSG00000235358.1 RP11-399E6.1 5.91 8.23e-09 5.17e-06 0.36 0.3 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41307332 chr1:41242373~41284861:+ LIHC cis rs12744310 0.731 rs12755632 ENSG00000235358.1 RP11-399E6.1 5.91 8.23e-09 5.17e-06 0.36 0.3 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41310951 chr1:41242373~41284861:+ LIHC cis rs9341808 0.754 rs3805907 ENSG00000272129.1 RP11-250B2.6 -5.91 8.24e-09 5.18e-06 -0.29 -0.3 Sitting height ratio; chr6:80263948 chr6:80355424~80356859:+ LIHC cis rs7927592 0.763 rs7120876 ENSG00000212093.1 AP000807.1 5.91 8.29e-09 5.21e-06 0.3 0.3 Total body bone mineral density; chr11:68493930 chr11:68506083~68506166:- LIHC cis rs6142102 0.961 rs761235 ENSG00000276073.1 RP5-1125A11.7 -5.91 8.3e-09 5.21e-06 -0.34 -0.3 Skin pigmentation; chr20:33946602 chr20:33985617~33988989:- LIHC cis rs11089937 0.929 rs5757155 ENSG00000211639.2 IGLV4-60 5.91 8.3e-09 5.21e-06 0.26 0.3 Periodontitis (PAL4Q3); chr22:22165378 chr22:22162199~22162681:+ LIHC cis rs2243480 1 rs13310597 ENSG00000164669.11 INTS4P1 5.91 8.31e-09 5.22e-06 0.53 0.3 Diabetic kidney disease; chr7:66133553 chr7:65141225~65234216:+ LIHC cis rs2522056 0.935 rs1981524 ENSG00000233006.5 AC034220.3 -5.91 8.31e-09 5.22e-06 -0.33 -0.3 Fibrinogen;Lymphocyte counts; chr5:132420814 chr5:132311285~132369916:- LIHC cis rs7927592 0.913 rs10047412 ENSG00000212093.1 AP000807.1 5.91 8.31e-09 5.22e-06 0.34 0.3 Total body bone mineral density; chr11:68465444 chr11:68506083~68506166:- LIHC cis rs853679 0.517 rs9380052 ENSG00000219392.1 RP1-265C24.5 -5.91 8.32e-09 5.22e-06 -0.46 -0.3 Depression; chr6:28096845 chr6:28115628~28116551:+ LIHC cis rs875971 0.545 rs1909508 ENSG00000237310.1 GS1-124K5.4 5.91 8.34e-09 5.23e-06 0.29 0.3 Aortic root size; chr7:66301366 chr7:66493706~66495474:+ LIHC cis rs2762353 0.574 rs34067542 ENSG00000242387.1 HIST1H2APS2 -5.91 8.36e-09 5.24e-06 -0.4 -0.3 Blood metabolite levels; chr6:25727982 chr6:25882026~25882395:- LIHC cis rs2762353 0.538 rs35670731 ENSG00000242387.1 HIST1H2APS2 -5.91 8.36e-09 5.24e-06 -0.4 -0.3 Blood metabolite levels; chr6:25728007 chr6:25882026~25882395:- LIHC cis rs2735413 0.564 rs73578752 ENSG00000276007.1 RP11-358L22.3 5.91 8.36e-09 5.25e-06 0.43 0.3 Systolic blood pressure (alcohol consumption interaction); chr16:78073657 chr16:78123243~78124332:+ LIHC cis rs7529073 0.545 rs340884 ENSG00000274895.1 RP11-478J18.2 5.91 8.39e-09 5.26e-06 0.32 0.3 Schizophrenia; chr1:213972046 chr1:213983793~213986419:- LIHC cis rs7927592 0.763 rs10791982 ENSG00000212093.1 AP000807.1 -5.91 8.39e-09 5.26e-06 -0.3 -0.3 Total body bone mineral density; chr11:68570196 chr11:68506083~68506166:- LIHC cis rs1577917 0.655 rs9342045 ENSG00000234155.1 RP11-30P6.6 -5.91 8.41e-09 5.27e-06 -0.36 -0.3 Response to antipsychotic treatment; chr6:85715430 chr6:85387219~85390186:- LIHC cis rs1075265 0.584 rs1862121 ENSG00000233266.1 HMGB1P31 5.91 8.42e-09 5.28e-06 0.38 0.3 Chronotype;Morning vs. evening chronotype; chr2:54058102 chr2:54051334~54051760:+ LIHC cis rs2243480 1 rs9769882 ENSG00000273142.1 RP11-458F8.4 5.91 8.43e-09 5.29e-06 0.37 0.3 Diabetic kidney disease; chr7:66177938 chr7:66902857~66906297:+ LIHC cis rs11098499 0.954 rs9998585 ENSG00000245958.5 RP11-33B1.1 -5.91 8.44e-09 5.29e-06 -0.31 -0.3 Corneal astigmatism; chr4:119475647 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs6842762 ENSG00000245958.5 RP11-33B1.1 -5.91 8.44e-09 5.29e-06 -0.31 -0.3 Corneal astigmatism; chr4:119477081 chr4:119454791~119552025:+ LIHC cis rs17023223 0.537 rs12081198 ENSG00000231365.4 RP11-418J17.1 -5.91 8.46e-09 5.3e-06 -0.38 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119143481 chr1:119140396~119275973:+ LIHC cis rs17023223 0.537 rs12081327 ENSG00000231365.4 RP11-418J17.1 -5.91 8.46e-09 5.3e-06 -0.38 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119143735 chr1:119140396~119275973:+ LIHC cis rs2933343 1 rs1680790 ENSG00000231305.3 RP11-723O4.2 5.9 8.51e-09 5.33e-06 0.35 0.3 IgG glycosylation; chr3:128907010 chr3:128861313~128871540:- LIHC cis rs2933343 1 rs876756 ENSG00000231305.3 RP11-723O4.2 5.9 8.51e-09 5.33e-06 0.35 0.3 IgG glycosylation; chr3:128908780 chr3:128861313~128871540:- LIHC cis rs2933343 1 rs876755 ENSG00000231305.3 RP11-723O4.2 5.9 8.51e-09 5.33e-06 0.35 0.3 IgG glycosylation; chr3:128909090 chr3:128861313~128871540:- LIHC cis rs34779708 0.643 rs4275563 ENSG00000230534.5 RP11-297A16.2 5.9 8.53e-09 5.34e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35256358 chr10:35098006~35127020:- LIHC cis rs1023500 0.505 rs134888 ENSG00000237037.8 NDUFA6-AS1 5.9 8.57e-09 5.37e-06 0.33 0.3 Schizophrenia; chr22:42278275 chr22:42090931~42137742:+ LIHC cis rs9843304 0.568 rs10935763 ENSG00000244503.1 RP11-278L15.6 -5.9 8.67e-09 5.43e-06 -0.3 -0.3 Gallstone disease; chr3:149501283 chr3:149494660~149495995:+ LIHC cis rs4356975 0.563 rs7442453 ENSG00000249956.3 RP11-790I12.2 5.9 8.69e-09 5.44e-06 0.35 0.3 Obesity-related traits; chr4:69103462 chr4:69408836~69423164:+ LIHC cis rs3812049 0.826 rs17764730 ENSG00000245937.6 LINC01184 5.9 8.7e-09 5.45e-06 0.39 0.3 Lymphocyte counts;Red cell distribution width; chr5:128021834 chr5:127940426~128083172:- LIHC cis rs4538475 0.556 rs4613561 ENSG00000214846.4 RP11-115L11.1 5.9 8.72e-09 5.46e-06 0.39 0.3 Parkinson's disease; chr4:15736267 chr4:15730962~15731627:- LIHC cis rs7927592 0.913 rs66752716 ENSG00000212093.1 AP000807.1 5.9 8.72e-09 5.46e-06 0.33 0.3 Total body bone mineral density; chr11:68506158 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs11228262 ENSG00000212093.1 AP000807.1 5.9 8.72e-09 5.46e-06 0.33 0.3 Total body bone mineral density; chr11:68507439 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs55883802 ENSG00000212093.1 AP000807.1 5.9 8.72e-09 5.46e-06 0.33 0.3 Total body bone mineral density; chr11:68511361 chr11:68506083~68506166:- LIHC cis rs12458462 0.892 rs58675823 ENSG00000274828.1 RP11-567M16.6 5.9 8.75e-09 5.47e-06 0.31 0.3 Monocyte count; chr18:79703672 chr18:79677287~79679358:- LIHC cis rs8100891 0.537 rs11880569 ENSG00000267213.4 AC007773.2 -5.9 8.78e-09 5.49e-06 -0.39 -0.3 Neuroticism; chr19:32478348 chr19:32390050~32405560:- LIHC cis rs34779708 0.733 rs4007271 ENSG00000230534.5 RP11-297A16.2 5.9 8.79e-09 5.49e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35257683 chr10:35098006~35127020:- LIHC cis rs34779708 0.702 rs4007272 ENSG00000230534.5 RP11-297A16.2 5.9 8.79e-09 5.49e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35257931 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs4934740 ENSG00000230534.5 RP11-297A16.2 5.9 8.79e-09 5.49e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35258213 chr10:35098006~35127020:- LIHC cis rs34779708 0.702 rs4244995 ENSG00000230534.5 RP11-297A16.2 5.9 8.79e-09 5.49e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35258247 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs4244997 ENSG00000230534.5 RP11-297A16.2 5.9 8.79e-09 5.49e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35258326 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs4298846 ENSG00000230534.5 RP11-297A16.2 5.9 8.79e-09 5.49e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35258452 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs4391768 ENSG00000230534.5 RP11-297A16.2 5.9 8.79e-09 5.49e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35258667 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs7914468 ENSG00000230534.5 RP11-297A16.2 5.9 8.79e-09 5.49e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35259143 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs7914560 ENSG00000230534.5 RP11-297A16.2 5.9 8.79e-09 5.49e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35259171 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs4444023 ENSG00000230534.5 RP11-297A16.2 5.9 8.79e-09 5.49e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35259426 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs12243593 ENSG00000230534.5 RP11-297A16.2 5.9 8.79e-09 5.49e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35260117 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs3936502 ENSG00000230534.5 RP11-297A16.2 5.9 8.79e-09 5.49e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35260290 chr10:35098006~35127020:- LIHC cis rs1023500 0.551 rs2854837 ENSG00000237037.8 NDUFA6-AS1 5.9 8.83e-09 5.52e-06 0.37 0.3 Schizophrenia; chr22:42062477 chr22:42090931~42137742:+ LIHC cis rs6061231 0.631 rs2427317 ENSG00000273619.1 RP5-908M14.9 -5.9 8.87e-09 5.54e-06 -0.25 -0.3 Colorectal cancer; chr20:62400669 chr20:62386303~62386970:- LIHC cis rs6061231 0.631 rs2427318 ENSG00000273619.1 RP5-908M14.9 -5.9 8.87e-09 5.54e-06 -0.25 -0.3 Colorectal cancer; chr20:62400671 chr20:62386303~62386970:- LIHC cis rs150992 0.609 rs363929 ENSG00000248489.1 CTD-2007H13.3 5.9 8.88e-09 5.55e-06 0.44 0.3 Body mass index; chr5:98985933 chr5:98929171~98995013:+ LIHC cis rs6921919 0.945 rs16901847 ENSG00000204709.4 LINC01556 5.9 8.91e-09 5.56e-06 0.47 0.3 Autism spectrum disorder or schizophrenia; chr6:28408074 chr6:28943877~28944537:+ LIHC cis rs6142102 0.961 rs6088361 ENSG00000276073.1 RP5-1125A11.7 -5.9 8.96e-09 5.59e-06 -0.34 -0.3 Skin pigmentation; chr20:33969520 chr20:33985617~33988989:- LIHC cis rs1577917 0.727 rs9444361 ENSG00000234155.1 RP11-30P6.6 -5.9 8.97e-09 5.6e-06 -0.39 -0.3 Response to antipsychotic treatment; chr6:85691182 chr6:85387219~85390186:- LIHC cis rs7927592 0.763 rs10896327 ENSG00000212093.1 AP000807.1 5.9 8.98e-09 5.6e-06 0.3 0.3 Total body bone mineral density; chr11:68467807 chr11:68506083~68506166:- LIHC cis rs6435862 0.593 rs34732883 ENSG00000229267.2 AC072062.1 5.89 9.04e-09 5.64e-06 0.35 0.3 Neuroblastoma (high-risk); chr2:214809647 chr2:214810229~214963274:+ LIHC cis rs2739330 0.731 rs4822450 ENSG00000206090.4 AP000350.7 5.89 9.04e-09 5.64e-06 0.36 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23939998~23942798:+ LIHC cis rs8040855 0.894 rs6496770 ENSG00000259295.5 CSPG4P12 -5.89 9.05e-09 5.64e-06 -0.43 -0.3 Bulimia nervosa; chr15:85161890 chr15:85191438~85213905:+ LIHC cis rs875971 0.545 rs6970498 ENSG00000226824.5 RP4-756H11.3 -5.89 9.05e-09 5.65e-06 -0.39 -0.3 Aortic root size; chr7:66275908 chr7:66654538~66669855:+ LIHC cis rs4713118 0.587 rs61471148 ENSG00000219392.1 RP1-265C24.5 -5.89 9.06e-09 5.65e-06 -0.46 -0.3 Parkinson's disease; chr6:28069254 chr6:28115628~28116551:+ LIHC cis rs4713118 0.621 rs4713132 ENSG00000219392.1 RP1-265C24.5 -5.89 9.07e-09 5.66e-06 -0.46 -0.3 Parkinson's disease; chr6:28066257 chr6:28115628~28116551:+ LIHC cis rs4713118 0.621 rs4713133 ENSG00000219392.1 RP1-265C24.5 -5.89 9.07e-09 5.66e-06 -0.46 -0.3 Parkinson's disease; chr6:28066263 chr6:28115628~28116551:+ LIHC cis rs4713118 0.621 rs4713134 ENSG00000219392.1 RP1-265C24.5 -5.89 9.07e-09 5.66e-06 -0.46 -0.3 Parkinson's disease; chr6:28066343 chr6:28115628~28116551:+ LIHC cis rs1020064 0.636 rs1529975 ENSG00000235319.1 AC012360.4 -5.89 9.07e-09 5.66e-06 -0.39 -0.3 AIDS; chr2:105313444 chr2:105324210~105330529:+ LIHC cis rs2153535 0.58 rs6927589 ENSG00000230939.1 RP11-314C16.1 5.89 9.1e-09 5.67e-06 0.37 0.3 Motion sickness; chr6:8456399 chr6:8784178~8785445:+ LIHC cis rs2243480 0.711 rs2420172 ENSG00000273142.1 RP11-458F8.4 5.89 9.11e-09 5.68e-06 0.37 0.3 Diabetic kidney disease; chr7:66170354 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs6974723 ENSG00000273142.1 RP11-458F8.4 5.89 9.11e-09 5.68e-06 0.37 0.3 Diabetic kidney disease; chr7:66172952 chr7:66902857~66906297:+ LIHC cis rs2153535 0.58 rs6941670 ENSG00000230939.1 RP11-314C16.1 -5.89 9.11e-09 5.68e-06 -0.37 -0.3 Motion sickness; chr6:8446113 chr6:8784178~8785445:+ LIHC cis rs4713118 0.621 rs9368548 ENSG00000219392.1 RP1-265C24.5 -5.89 9.13e-09 5.69e-06 -0.46 -0.3 Parkinson's disease; chr6:28066959 chr6:28115628~28116551:+ LIHC cis rs3858145 0.588 rs4142048 ENSG00000233590.1 RP11-153K11.3 -5.89 9.16e-09 5.71e-06 -0.42 -0.3 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68284274 chr10:68233251~68242379:- LIHC cis rs6921919 0.638 rs1416920 ENSG00000216901.1 AL022393.7 5.89 9.17e-09 5.72e-06 0.34 0.3 Autism spectrum disorder or schizophrenia; chr6:28335007 chr6:28176188~28176674:+ LIHC cis rs6921919 0.525 rs1361386 ENSG00000216901.1 AL022393.7 5.89 9.17e-09 5.72e-06 0.34 0.3 Autism spectrum disorder or schizophrenia; chr6:28337827 chr6:28176188~28176674:+ LIHC cis rs6921919 0.638 rs6456815 ENSG00000216901.1 AL022393.7 5.89 9.17e-09 5.72e-06 0.34 0.3 Autism spectrum disorder or schizophrenia; chr6:28338360 chr6:28176188~28176674:+ LIHC cis rs6921919 0.638 rs2108926 ENSG00000216901.1 AL022393.7 5.89 9.17e-09 5.72e-06 0.34 0.3 Autism spectrum disorder or schizophrenia; chr6:28340970 chr6:28176188~28176674:+ LIHC cis rs2274273 0.901 rs8011288 ENSG00000258413.1 RP11-665C16.6 -5.89 9.18e-09 5.72e-06 -0.35 -0.3 Protein biomarker; chr14:55268394 chr14:55262767~55272075:- LIHC cis rs9487094 0.689 rs1476387 ENSG00000260273.1 RP11-425D10.10 5.89 9.23e-09 5.75e-06 0.35 0.3 Height; chr6:109443332 chr6:109382795~109383666:+ LIHC cis rs10875746 0.579 rs10875778 ENSG00000240399.1 RP1-228P16.1 -5.89 9.24e-09 5.75e-06 -0.33 -0.3 Longevity (90 years and older); chr12:48230872 chr12:48054813~48055591:- LIHC cis rs875971 0.545 rs2420456 ENSG00000226824.5 RP4-756H11.3 -5.89 9.24e-09 5.75e-06 -0.39 -0.3 Aortic root size; chr7:66280619 chr7:66654538~66669855:+ LIHC cis rs4356975 0.563 rs12512526 ENSG00000249956.3 RP11-790I12.2 5.89 9.25e-09 5.76e-06 0.34 0.3 Obesity-related traits; chr4:69100700 chr4:69408836~69423164:+ LIHC cis rs4356975 0.522 rs34386959 ENSG00000249956.3 RP11-790I12.2 5.89 9.25e-09 5.76e-06 0.34 0.3 Obesity-related traits; chr4:69100837 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs55834557 ENSG00000249956.3 RP11-790I12.2 5.89 9.25e-09 5.76e-06 0.34 0.3 Obesity-related traits; chr4:69100876 chr4:69408836~69423164:+ LIHC cis rs4356975 0.522 rs56388229 ENSG00000249956.3 RP11-790I12.2 5.89 9.25e-09 5.76e-06 0.34 0.3 Obesity-related traits; chr4:69100940 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs34318523 ENSG00000249956.3 RP11-790I12.2 5.89 9.25e-09 5.76e-06 0.34 0.3 Obesity-related traits; chr4:69101135 chr4:69408836~69423164:+ LIHC cis rs4356975 0.583 rs34630750 ENSG00000249956.3 RP11-790I12.2 5.89 9.25e-09 5.76e-06 0.34 0.3 Obesity-related traits; chr4:69101208 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs12508257 ENSG00000249956.3 RP11-790I12.2 5.89 9.25e-09 5.76e-06 0.34 0.3 Obesity-related traits; chr4:69101921 chr4:69408836~69423164:+ LIHC cis rs12291225 0.585 rs4757250 ENSG00000251991.1 RNU7-49P 5.89 9.25e-09 5.76e-06 0.32 0.3 Sense of smell; chr11:14354137 chr11:14478892~14478953:+ LIHC cis rs6061231 0.631 rs2427310 ENSG00000273619.1 RP5-908M14.9 -5.89 9.28e-09 5.77e-06 -0.25 -0.3 Colorectal cancer; chr20:62394873 chr20:62386303~62386970:- LIHC cis rs7927592 0.913 rs11228268 ENSG00000212093.1 AP000807.1 5.89 9.29e-09 5.78e-06 0.33 0.3 Total body bone mineral density; chr11:68519979 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs4084149 ENSG00000212093.1 AP000807.1 5.89 9.29e-09 5.78e-06 0.33 0.3 Total body bone mineral density; chr11:68521099 chr11:68506083~68506166:- LIHC cis rs3096299 0.838 rs3102384 ENSG00000274627.1 RP11-104N10.2 5.89 9.32e-09 5.8e-06 0.32 0.3 Multiple myeloma (IgH translocation); chr16:89345253 chr16:89516797~89522217:+ LIHC cis rs2439831 0.717 rs2447198 ENSG00000205771.5 CATSPER2P1 -5.89 9.34e-09 5.81e-06 -0.47 -0.3 Lung cancer in ever smokers; chr15:43602920 chr15:43726918~43747094:- LIHC cis rs2522056 1 rs62385693 ENSG00000233006.5 AC034220.3 -5.89 9.34e-09 5.81e-06 -0.32 -0.3 Fibrinogen;Lymphocyte counts; chr5:132437982 chr5:132311285~132369916:- LIHC cis rs4814920 0.818 rs6081790 ENSG00000275142.1 RP5-999L4.2 -5.89 9.38e-09 5.83e-06 -0.62 -0.3 Bipolar disorder (body mass index interaction); chr20:19882273 chr20:19871891~19872284:+ LIHC cis rs3096299 0.9 rs744327 ENSG00000261118.1 RP11-104N10.1 5.89 9.39e-09 5.84e-06 0.31 0.3 Multiple myeloma (IgH translocation); chr16:89372862 chr16:89492017~89504460:- LIHC cis rs12681287 0.64 rs7460650 ENSG00000250569.1 NTAN1P2 5.89 9.41e-09 5.85e-06 0.35 0.3 Caudate activity during reward; chr8:86461856 chr8:86481754~86483002:- LIHC cis rs6142102 0.961 rs2056990 ENSG00000276073.1 RP5-1125A11.7 -5.89 9.42e-09 5.85e-06 -0.34 -0.3 Skin pigmentation; chr20:34035658 chr20:33985617~33988989:- LIHC cis rs11098499 0.954 rs1480931 ENSG00000245958.5 RP11-33B1.1 -5.89 9.43e-09 5.86e-06 -0.31 -0.3 Corneal astigmatism; chr4:119474654 chr4:119454791~119552025:+ LIHC cis rs2933343 0.621 rs883843 ENSG00000231305.3 RP11-723O4.2 -5.89 9.45e-09 5.87e-06 -0.34 -0.3 IgG glycosylation; chr3:128848540 chr3:128861313~128871540:- LIHC cis rs11672691 0.67 rs4802119 ENSG00000267107.5 PCAT19 5.89 9.46e-09 5.88e-06 0.37 0.3 Prostate cancer; chr19:41484417 chr19:41454169~41500649:- LIHC cis rs2836950 0.565 rs2150414 ENSG00000255568.3 BRWD1-AS2 -5.89 9.46e-09 5.88e-06 -0.25 -0.3 Menarche (age at onset); chr21:39243062 chr21:39313935~39314962:+ LIHC cis rs8100891 0.537 rs1001446 ENSG00000267213.4 AC007773.2 -5.89 9.48e-09 5.89e-06 -0.38 -0.3 Neuroticism; chr19:32410051 chr19:32390050~32405560:- LIHC cis rs7688540 0.771 rs7686546 ENSG00000275426.1 CH17-262A2.1 5.89 9.48e-09 5.89e-06 0.42 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:246825 chr4:149738~150317:+ LIHC cis rs7927592 0.913 rs7925275 ENSG00000212093.1 AP000807.1 5.89 9.49e-09 5.89e-06 0.34 0.3 Total body bone mineral density; chr11:68522965 chr11:68506083~68506166:- LIHC cis rs1891275 0.601 rs1970506 ENSG00000228701.1 TNKS2-AS1 -5.89 9.49e-09 5.89e-06 -0.4 -0.3 Intelligence (multi-trait analysis); chr10:91668529 chr10:91782839~91798291:- LIHC cis rs4853012 0.539 rs9789534 ENSG00000257800.1 FNBP1P1 5.88 9.55e-09 5.93e-06 0.34 0.3 Gestational age at birth (maternal effect); chr2:74135863 chr2:74120680~74123218:+ LIHC cis rs9487094 0.67 rs2024852 ENSG00000260273.1 RP11-425D10.10 5.88 9.56e-09 5.94e-06 0.37 0.3 Height; chr6:109498586 chr6:109382795~109383666:+ LIHC cis rs9487094 0.67 rs13203587 ENSG00000260273.1 RP11-425D10.10 5.88 9.56e-09 5.94e-06 0.37 0.3 Height; chr6:109499759 chr6:109382795~109383666:+ LIHC cis rs9326248 0.954 rs8521 ENSG00000236267.1 AP006216.5 5.88 9.58e-09 5.95e-06 0.31 0.3 Blood protein levels; chr11:117196983 chr11:116813204~116814003:- LIHC cis rs113835537 0.529 rs11227514 ENSG00000255517.5 CTD-3074O7.5 -5.88 9.6e-09 5.96e-06 -0.33 -0.3 Airway imaging phenotypes; chr11:66519156 chr11:66473490~66480233:- LIHC cis rs7927592 0.763 rs1193699 ENSG00000212093.1 AP000807.1 5.88 9.63e-09 5.98e-06 0.3 0.3 Total body bone mineral density; chr11:68482012 chr11:68506083~68506166:- LIHC cis rs67180937 0.583 rs2936054 ENSG00000272750.1 RP11-378J18.8 5.88 9.66e-09 5.99e-06 0.36 0.3 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222627290 chr1:222658867~222661512:- LIHC cis rs2243480 0.908 rs313822 ENSG00000164669.11 INTS4P1 5.88 9.68e-09 6e-06 0.51 0.3 Diabetic kidney disease; chr7:66108952 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs313820 ENSG00000164669.11 INTS4P1 5.88 9.68e-09 6e-06 0.51 0.3 Diabetic kidney disease; chr7:66109479 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs313824 ENSG00000164669.11 INTS4P1 5.88 9.68e-09 6e-06 0.51 0.3 Diabetic kidney disease; chr7:66116220 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs186378 ENSG00000164669.11 INTS4P1 5.88 9.68e-09 6e-06 0.51 0.3 Diabetic kidney disease; chr7:66117071 chr7:65141225~65234216:+ LIHC cis rs2243480 1 rs160637 ENSG00000164669.11 INTS4P1 5.88 9.68e-09 6e-06 0.51 0.3 Diabetic kidney disease; chr7:66119331 chr7:65141225~65234216:+ LIHC cis rs1555322 0.556 rs7272884 ENSG00000126005.14 MMP24-AS1 -5.88 9.7e-09 6.01e-06 -0.47 -0.3 Attention deficit hyperactivity disorder; chr20:35295212 chr20:35216462~35278131:- LIHC cis rs1211375 0.628 rs3859141 ENSG00000268836.1 LA16c-OS12.2 5.88 9.71e-09 6.02e-06 0.32 0.3 Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin; chr16:195080 chr16:185748~186294:- LIHC cis rs5758511 0.573 rs5996074 ENSG00000237037.8 NDUFA6-AS1 5.88 9.72e-09 6.02e-06 0.36 0.3 Birth weight; chr22:41840333 chr22:42090931~42137742:+ LIHC cis rs7927592 0.913 rs3740631 ENSG00000212093.1 AP000807.1 5.88 9.8e-09 6.07e-06 0.33 0.3 Total body bone mineral density; chr11:68574254 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs3824850 ENSG00000212093.1 AP000807.1 5.88 9.8e-09 6.07e-06 0.33 0.3 Total body bone mineral density; chr11:68574405 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs3740629 ENSG00000212093.1 AP000807.1 5.88 9.8e-09 6.07e-06 0.33 0.3 Total body bone mineral density; chr11:68576125 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs11228287 ENSG00000212093.1 AP000807.1 5.88 9.8e-09 6.07e-06 0.33 0.3 Total body bone mineral density; chr11:68582286 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs10896346 ENSG00000212093.1 AP000807.1 5.88 9.8e-09 6.07e-06 0.33 0.3 Total body bone mineral density; chr11:68585203 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs10896347 ENSG00000212093.1 AP000807.1 5.88 9.8e-09 6.07e-06 0.33 0.3 Total body bone mineral density; chr11:68585659 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs6591344 ENSG00000212093.1 AP000807.1 5.88 9.8e-09 6.07e-06 0.33 0.3 Total body bone mineral density; chr11:68593405 chr11:68506083~68506166:- LIHC cis rs6142102 0.812 rs6059578 ENSG00000276073.1 RP5-1125A11.7 -5.88 9.81e-09 6.08e-06 -0.34 -0.3 Skin pigmentation; chr20:33939900 chr20:33985617~33988989:- LIHC cis rs6142102 0.961 rs6059649 ENSG00000276073.1 RP5-1125A11.7 -5.88 9.82e-09 6.08e-06 -0.34 -0.3 Skin pigmentation; chr20:34056071 chr20:33985617~33988989:- LIHC cis rs6142102 0.961 rs6059651 ENSG00000276073.1 RP5-1125A11.7 -5.88 9.82e-09 6.08e-06 -0.34 -0.3 Skin pigmentation; chr20:34057246 chr20:33985617~33988989:- LIHC cis rs8040855 0.825 rs4843021 ENSG00000259295.5 CSPG4P12 -5.88 9.82e-09 6.08e-06 -0.47 -0.3 Bulimia nervosa; chr15:85151317 chr15:85191438~85213905:+ LIHC cis rs3829655 0.504 rs7251234 ENSG00000273837.1 LLNLR-470E3.1 5.88 9.82e-09 6.08e-06 0.31 0.3 Cerebrospinal fluid biomarker levels; chr19:51614767 chr19:51639478~51639931:- LIHC cis rs2933343 0.729 rs789228 ENSG00000231305.3 RP11-723O4.2 5.88 9.84e-09 6.09e-06 0.34 0.3 IgG glycosylation; chr3:128882207 chr3:128861313~128871540:- LIHC cis rs8059260 0.542 rs6498148 ENSG00000274038.1 RP11-66H6.4 -5.88 9.84e-09 6.09e-06 -0.51 -0.3 Alcohol consumption over the past year; chr16:11018374 chr16:11056556~11057034:+ LIHC cis rs7927592 0.763 rs10896340 ENSG00000212093.1 AP000807.1 -5.88 9.86e-09 6.1e-06 -0.3 -0.3 Total body bone mineral density; chr11:68545177 chr11:68506083~68506166:- LIHC cis rs4423214 0.559 rs10898203 ENSG00000254682.1 RP11-660L16.2 -5.88 9.86e-09 6.11e-06 -0.42 -0.3 Vitamin D levels; chr11:71492390 chr11:71448674~71452157:+ LIHC cis rs6921919 0.638 rs7772827 ENSG00000216901.1 AL022393.7 5.88 9.89e-09 6.12e-06 0.35 0.3 Autism spectrum disorder or schizophrenia; chr6:28333366 chr6:28176188~28176674:+ LIHC cis rs2243480 1 rs383402 ENSG00000164669.11 INTS4P1 -5.88 9.91e-09 6.13e-06 -0.52 -0.3 Diabetic kidney disease; chr7:66121666 chr7:65141225~65234216:+ LIHC cis rs113835537 0.529 rs11227503 ENSG00000255517.5 CTD-3074O7.5 -5.88 9.91e-09 6.13e-06 -0.33 -0.3 Airway imaging phenotypes; chr11:66507771 chr11:66473490~66480233:- LIHC cis rs6686842 1 rs6686842 ENSG00000235358.1 RP11-399E6.1 5.88 9.92e-09 6.14e-06 0.33 0.3 Height; chr1:41065199 chr1:41242373~41284861:+ LIHC cis rs2243480 1 rs6958420 ENSG00000273142.1 RP11-458F8.4 5.88 9.94e-09 6.15e-06 0.37 0.3 Diabetic kidney disease; chr7:66286184 chr7:66902857~66906297:+ LIHC cis rs7688540 0.723 rs61794999 ENSG00000275426.1 CH17-262A2.1 5.88 9.96e-09 6.16e-06 0.42 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:238578 chr4:149738~150317:+ LIHC cis rs7688540 0.609 rs77700883 ENSG00000275426.1 CH17-262A2.1 5.88 9.96e-09 6.16e-06 0.42 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:238743 chr4:149738~150317:+ LIHC cis rs7688540 0.609 rs78896226 ENSG00000275426.1 CH17-262A2.1 5.88 9.96e-09 6.16e-06 0.42 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:238744 chr4:149738~150317:+ LIHC cis rs875971 0.545 rs11767262 ENSG00000226824.5 RP4-756H11.3 -5.88 9.96e-09 6.16e-06 -0.39 -0.3 Aortic root size; chr7:66302237 chr7:66654538~66669855:+ LIHC cis rs12701220 0.655 rs34696066 ENSG00000229043.2 AC091729.9 -5.88 9.97e-09 6.16e-06 -0.42 -0.3 Bronchopulmonary dysplasia; chr7:1101283 chr7:1160374~1165267:+ LIHC cis rs8072100 0.967 rs8075411 ENSG00000228782.6 CTD-2026D20.3 -5.88 9.97e-09 6.17e-06 -0.33 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47599394 chr17:47450568~47492492:- LIHC cis rs2297363 1 rs3777404 ENSG00000213073.4 RP11-288H12.3 -5.88 1e-08 6.19e-06 -0.36 -0.3 Total cholesterol levels;Blood protein levels; chr6:160077017 chr6:160093082~160096212:+ LIHC cis rs8072100 0.967 rs4793842 ENSG00000228782.6 CTD-2026D20.3 -5.87 1e-08 6.2e-06 -0.33 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47594140 chr17:47450568~47492492:- LIHC cis rs904251 0.523 rs10807184 ENSG00000204110.6 RP1-153P14.8 -5.87 1e-08 6.21e-06 -0.36 -0.3 Cognitive performance; chr6:37515937 chr6:37507348~37535616:+ LIHC cis rs904251 0.561 rs1757189 ENSG00000204110.6 RP1-153P14.8 -5.87 1e-08 6.21e-06 -0.36 -0.3 Cognitive performance; chr6:37515951 chr6:37507348~37535616:+ LIHC cis rs1757171 0.542 rs3818985 ENSG00000204110.6 RP1-153P14.8 -5.87 1e-08 6.21e-06 -0.36 -0.3 Cognitive performance; chr6:37516438 chr6:37507348~37535616:+ LIHC cis rs2739330 0.828 rs2186366 ENSG00000099984.9 GSTT2 5.87 1e-08 6.21e-06 0.36 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23980123~23983911:+ LIHC cis rs3779195 0.929 rs10953259 ENSG00000272950.1 RP11-307C18.1 -5.87 1.01e-08 6.25e-06 -0.43 -0.3 Sex hormone-binding globulin levels; chr7:98383795 chr7:98322853~98323430:+ LIHC cis rs2153535 0.58 rs2327061 ENSG00000230939.1 RP11-314C16.1 -5.87 1.01e-08 6.26e-06 -0.37 -0.3 Motion sickness; chr6:8446998 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7453115 ENSG00000230939.1 RP11-314C16.1 -5.87 1.01e-08 6.26e-06 -0.37 -0.3 Motion sickness; chr6:8447028 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6910742 ENSG00000230939.1 RP11-314C16.1 -5.87 1.01e-08 6.26e-06 -0.37 -0.3 Motion sickness; chr6:8448095 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1832100 ENSG00000230939.1 RP11-314C16.1 -5.87 1.02e-08 6.31e-06 -0.37 -0.3 Motion sickness; chr6:8446723 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2327058 ENSG00000230939.1 RP11-314C16.1 -5.87 1.02e-08 6.31e-06 -0.37 -0.3 Motion sickness; chr6:8446785 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs2327059 ENSG00000230939.1 RP11-314C16.1 -5.87 1.02e-08 6.31e-06 -0.37 -0.3 Motion sickness; chr6:8446838 chr6:8784178~8785445:+ LIHC cis rs7688540 0.771 rs61794996 ENSG00000275426.1 CH17-262A2.1 5.87 1.02e-08 6.32e-06 0.42 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:215539 chr4:149738~150317:+ LIHC cis rs7688540 0.771 rs11248009 ENSG00000275426.1 CH17-262A2.1 5.87 1.03e-08 6.33e-06 0.43 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:226360 chr4:149738~150317:+ LIHC cis rs4356975 0.583 rs6600877 ENSG00000249956.3 RP11-790I12.2 5.87 1.03e-08 6.33e-06 0.34 0.3 Obesity-related traits; chr4:69091505 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs6600878 ENSG00000249956.3 RP11-790I12.2 5.87 1.03e-08 6.33e-06 0.34 0.3 Obesity-related traits; chr4:69092618 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs57216626 ENSG00000249956.3 RP11-790I12.2 5.87 1.03e-08 6.33e-06 0.34 0.3 Obesity-related traits; chr4:69093105 chr4:69408836~69423164:+ LIHC cis rs4356975 0.522 rs59415892 ENSG00000249956.3 RP11-790I12.2 5.87 1.03e-08 6.33e-06 0.34 0.3 Obesity-related traits; chr4:69093191 chr4:69408836~69423164:+ LIHC cis rs4356975 0.522 rs62296942 ENSG00000249956.3 RP11-790I12.2 5.87 1.03e-08 6.33e-06 0.34 0.3 Obesity-related traits; chr4:69093401 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs7437039 ENSG00000249956.3 RP11-790I12.2 5.87 1.03e-08 6.33e-06 0.34 0.3 Obesity-related traits; chr4:69093758 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs7439792 ENSG00000249956.3 RP11-790I12.2 5.87 1.03e-08 6.33e-06 0.34 0.3 Obesity-related traits; chr4:69093881 chr4:69408836~69423164:+ LIHC cis rs4356975 0.545 rs62296944 ENSG00000249956.3 RP11-790I12.2 5.87 1.03e-08 6.33e-06 0.34 0.3 Obesity-related traits; chr4:69094492 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs6600879 ENSG00000249956.3 RP11-790I12.2 5.87 1.03e-08 6.33e-06 0.34 0.3 Obesity-related traits; chr4:69094669 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs6600880 ENSG00000249956.3 RP11-790I12.2 5.87 1.03e-08 6.33e-06 0.34 0.3 Obesity-related traits; chr4:69094762 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4554144 ENSG00000249956.3 RP11-790I12.2 5.87 1.03e-08 6.33e-06 0.34 0.3 Obesity-related traits; chr4:69094837 chr4:69408836~69423164:+ LIHC cis rs12908161 0.92 rs35738019 ENSG00000259295.5 CSPG4P12 5.87 1.03e-08 6.35e-06 0.41 0.3 Schizophrenia; chr15:84736979 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs34570071 ENSG00000259295.5 CSPG4P12 5.87 1.03e-08 6.35e-06 0.41 0.3 Schizophrenia; chr15:84736981 chr15:85191438~85213905:+ LIHC cis rs7927592 0.956 rs7106259 ENSG00000212093.1 AP000807.1 5.87 1.03e-08 6.36e-06 0.33 0.3 Total body bone mineral density; chr11:68531044 chr11:68506083~68506166:- LIHC cis rs6142102 0.961 rs4911144 ENSG00000276073.1 RP5-1125A11.7 -5.87 1.03e-08 6.37e-06 -0.34 -0.3 Skin pigmentation; chr20:34026565 chr20:33985617~33988989:- LIHC cis rs6142102 0.923 rs4911379 ENSG00000276073.1 RP5-1125A11.7 -5.87 1.03e-08 6.38e-06 -0.33 -0.3 Skin pigmentation; chr20:33947499 chr20:33985617~33988989:- LIHC cis rs2153535 0.58 rs6921964 ENSG00000230939.1 RP11-314C16.1 -5.87 1.04e-08 6.38e-06 -0.37 -0.3 Motion sickness; chr6:8446162 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs4637688 ENSG00000230939.1 RP11-314C16.1 -5.87 1.04e-08 6.38e-06 -0.37 -0.3 Motion sickness; chr6:8446268 chr6:8784178~8785445:+ LIHC cis rs748404 0.66 rs694725 ENSG00000205771.5 CATSPER2P1 -5.87 1.04e-08 6.39e-06 -0.36 -0.3 Lung cancer; chr15:43464012 chr15:43726918~43747094:- LIHC cis rs6142102 0.961 rs2284389 ENSG00000276073.1 RP5-1125A11.7 -5.87 1.04e-08 6.39e-06 -0.33 -0.3 Skin pigmentation; chr20:34069035 chr20:33985617~33988989:- LIHC cis rs113835537 0.529 rs4542420 ENSG00000255517.5 CTD-3074O7.5 -5.87 1.04e-08 6.4e-06 -0.33 -0.3 Airway imaging phenotypes; chr11:66510139 chr11:66473490~66480233:- LIHC cis rs4356975 0.563 rs6851533 ENSG00000249956.3 RP11-790I12.2 5.87 1.04e-08 6.41e-06 0.34 0.3 Obesity-related traits; chr4:69113032 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs7666195 ENSG00000249956.3 RP11-790I12.2 5.87 1.04e-08 6.41e-06 0.34 0.3 Obesity-related traits; chr4:69113765 chr4:69408836~69423164:+ LIHC cis rs6142102 0.923 rs4911394 ENSG00000276073.1 RP5-1125A11.7 -5.87 1.04e-08 6.41e-06 -0.34 -0.3 Skin pigmentation; chr20:33989521 chr20:33985617~33988989:- LIHC cis rs12744310 0.731 rs12030420 ENSG00000235358.1 RP11-399E6.1 5.87 1.04e-08 6.42e-06 0.35 0.3 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41296484 chr1:41242373~41284861:+ LIHC cis rs1862618 0.853 rs2113078 ENSG00000271828.1 CTD-2310F14.1 5.87 1.04e-08 6.43e-06 0.42 0.3 Initial pursuit acceleration; chr5:56791363 chr5:56927874~56929573:+ LIHC cis rs7617773 0.78 rs77044321 ENSG00000229759.1 MRPS18AP1 5.87 1.05e-08 6.44e-06 0.37 0.3 Coronary artery disease; chr3:48307824 chr3:48256350~48256938:- LIHC cis rs7617773 0.746 rs4371540 ENSG00000229759.1 MRPS18AP1 5.87 1.05e-08 6.44e-06 0.37 0.3 Coronary artery disease; chr3:48312053 chr3:48256350~48256938:- LIHC cis rs7617773 0.743 rs13081633 ENSG00000229759.1 MRPS18AP1 5.87 1.05e-08 6.44e-06 0.37 0.3 Coronary artery disease; chr3:48315791 chr3:48256350~48256938:- LIHC cis rs4713118 0.621 rs9295756 ENSG00000219392.1 RP1-265C24.5 -5.87 1.05e-08 6.45e-06 -0.46 -0.3 Parkinson's disease; chr6:28065618 chr6:28115628~28116551:+ LIHC cis rs8059260 0.604 rs16958021 ENSG00000274038.1 RP11-66H6.4 -5.87 1.05e-08 6.45e-06 -0.5 -0.3 Alcohol consumption over the past year; chr16:11076190 chr16:11056556~11057034:+ LIHC cis rs9388451 0.839 rs10457469 ENSG00000237742.5 RP11-624M8.1 -5.87 1.05e-08 6.47e-06 -0.28 -0.3 Brugada syndrome; chr6:125762512 chr6:125578558~125749190:- LIHC cis rs4814920 0.818 rs4813377 ENSG00000275142.1 RP5-999L4.2 -5.87 1.05e-08 6.49e-06 -0.55 -0.3 Bipolar disorder (body mass index interaction); chr20:19870822 chr20:19871891~19872284:+ LIHC cis rs1023500 0.596 rs5758562 ENSG00000237037.8 NDUFA6-AS1 5.87 1.06e-08 6.5e-06 0.37 0.3 Schizophrenia; chr22:42052234 chr22:42090931~42137742:+ LIHC cis rs1023500 0.596 rs5751209 ENSG00000237037.8 NDUFA6-AS1 5.87 1.06e-08 6.5e-06 0.37 0.3 Schizophrenia; chr22:42055599 chr22:42090931~42137742:+ LIHC cis rs7927592 0.673 rs498782 ENSG00000212093.1 AP000807.1 5.87 1.06e-08 6.5e-06 0.3 0.3 Total body bone mineral density; chr11:68508383 chr11:68506083~68506166:- LIHC cis rs4356975 0.563 rs6600876 ENSG00000249956.3 RP11-790I12.2 5.86 1.06e-08 6.53e-06 0.34 0.3 Obesity-related traits; chr4:69091212 chr4:69408836~69423164:+ LIHC cis rs62355900 0.627 rs3736430 ENSG00000271828.1 CTD-2310F14.1 5.86 1.06e-08 6.54e-06 0.48 0.3 Endometriosis; chr5:56884653 chr5:56927874~56929573:+ LIHC cis rs4356975 0.509 rs6600884 ENSG00000249956.3 RP11-790I12.2 5.86 1.06e-08 6.55e-06 0.35 0.3 Obesity-related traits; chr4:69102348 chr4:69408836~69423164:+ LIHC cis rs2243480 1 rs709607 ENSG00000273142.1 RP11-458F8.4 5.86 1.06e-08 6.55e-06 0.38 0.3 Diabetic kidney disease; chr7:65984554 chr7:66902857~66906297:+ LIHC cis rs8072100 0.967 rs11656855 ENSG00000228782.6 CTD-2026D20.3 -5.86 1.07e-08 6.56e-06 -0.33 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47637289 chr17:47450568~47492492:- LIHC cis rs6921919 0.583 rs9468370 ENSG00000216901.1 AL022393.7 5.86 1.07e-08 6.56e-06 0.37 0.3 Autism spectrum disorder or schizophrenia; chr6:28401163 chr6:28176188~28176674:+ LIHC cis rs1005277 0.54 rs289638 ENSG00000263064.2 RP11-291L22.7 5.86 1.07e-08 6.56e-06 0.31 0.3 Extrinsic epigenetic age acceleration; chr10:37634803 chr10:38448689~38448949:+ LIHC cis rs1005277 0.54 rs7903942 ENSG00000263064.2 RP11-291L22.7 -5.86 1.07e-08 6.56e-06 -0.31 -0.3 Extrinsic epigenetic age acceleration; chr10:37640348 chr10:38448689~38448949:+ LIHC cis rs2274273 0.773 rs8012380 ENSG00000258413.1 RP11-665C16.6 -5.86 1.07e-08 6.57e-06 -0.35 -0.3 Protein biomarker; chr14:55268292 chr14:55262767~55272075:- LIHC cis rs2243480 1 rs160643 ENSG00000164669.11 INTS4P1 5.86 1.07e-08 6.59e-06 0.49 0.3 Diabetic kidney disease; chr7:66093235 chr7:65141225~65234216:+ LIHC cis rs7927592 0.913 rs59056571 ENSG00000212093.1 AP000807.1 5.86 1.07e-08 6.6e-06 0.33 0.3 Total body bone mineral density; chr11:68505505 chr11:68506083~68506166:- LIHC cis rs9640161 0.75 rs3800780 ENSG00000261305.1 RP4-584D14.7 5.86 1.08e-08 6.61e-06 0.38 0.3 Blood protein levels;Circulating chemerin levels; chr7:150330195 chr7:150341771~150342607:+ LIHC cis rs9640161 0.711 rs3800781 ENSG00000261305.1 RP4-584D14.7 5.86 1.08e-08 6.61e-06 0.38 0.3 Blood protein levels;Circulating chemerin levels; chr7:150330235 chr7:150341771~150342607:+ LIHC cis rs5758659 1 rs134869 ENSG00000227370.1 RP4-669P10.19 -5.86 1.08e-08 6.64e-06 -0.34 -0.3 Cognitive function; chr22:42256068 chr22:42132543~42132998:+ LIHC cis rs2933343 0.679 rs789229 ENSG00000231305.3 RP11-723O4.2 5.86 1.08e-08 6.64e-06 0.33 0.3 IgG glycosylation; chr3:128883683 chr3:128861313~128871540:- LIHC cis rs2933343 0.729 rs789230 ENSG00000231305.3 RP11-723O4.2 5.86 1.08e-08 6.64e-06 0.33 0.3 IgG glycosylation; chr3:128883715 chr3:128861313~128871540:- LIHC cis rs2933343 0.661 rs2630259 ENSG00000231305.3 RP11-723O4.2 5.86 1.08e-08 6.64e-06 0.33 0.3 IgG glycosylation; chr3:128887479 chr3:128861313~128871540:- LIHC cis rs2933343 0.729 rs6790091 ENSG00000231305.3 RP11-723O4.2 5.86 1.08e-08 6.64e-06 0.33 0.3 IgG glycosylation; chr3:128889908 chr3:128861313~128871540:- LIHC cis rs2439831 1 rs7173487 ENSG00000205771.5 CATSPER2P1 -5.86 1.08e-08 6.65e-06 -0.45 -0.3 Lung cancer in ever smokers; chr15:43458041 chr15:43726918~43747094:- LIHC cis rs7916697 0.593 rs3740587 ENSG00000233590.1 RP11-153K11.3 5.86 1.08e-08 6.65e-06 0.36 0.3 Optic disc area; chr10:68261045 chr10:68233251~68242379:- LIHC cis rs7617773 0.817 rs9837228 ENSG00000229759.1 MRPS18AP1 -5.86 1.08e-08 6.65e-06 -0.36 -0.3 Coronary artery disease; chr3:48282976 chr3:48256350~48256938:- LIHC cis rs7927592 0.913 rs12272917 ENSG00000212093.1 AP000807.1 5.86 1.08e-08 6.65e-06 0.33 0.3 Total body bone mineral density; chr11:68495902 chr11:68506083~68506166:- LIHC cis rs2882667 0.522 rs7731574 ENSG00000253404.1 AC034243.1 -5.86 1.08e-08 6.66e-06 -0.38 -0.3 Age-related hearing impairment (SNP x SNP interaction); chr5:139118503 chr5:138744434~138753309:- LIHC cis rs8100891 0.537 rs11883143 ENSG00000267213.4 AC007773.2 -5.86 1.09e-08 6.67e-06 -0.38 -0.3 Neuroticism; chr19:32478350 chr19:32390050~32405560:- LIHC cis rs853679 0.567 rs13196606 ENSG00000216901.1 AL022393.7 5.86 1.09e-08 6.68e-06 0.39 0.3 Depression; chr6:28402301 chr6:28176188~28176674:+ LIHC cis rs62355900 0.627 rs16886463 ENSG00000271828.1 CTD-2310F14.1 5.86 1.09e-08 6.71e-06 0.48 0.3 Endometriosis; chr5:56883514 chr5:56927874~56929573:+ LIHC cis rs62355900 0.627 rs62358106 ENSG00000271828.1 CTD-2310F14.1 5.86 1.09e-08 6.71e-06 0.48 0.3 Endometriosis; chr5:56885542 chr5:56927874~56929573:+ LIHC cis rs62355900 0.627 rs3817119 ENSG00000271828.1 CTD-2310F14.1 5.86 1.09e-08 6.71e-06 0.48 0.3 Endometriosis; chr5:56887916 chr5:56927874~56929573:+ LIHC cis rs8100891 0.537 rs10424665 ENSG00000267213.4 AC007773.2 -5.86 1.1e-08 6.73e-06 -0.4 -0.3 Neuroticism; chr19:32404725 chr19:32390050~32405560:- LIHC cis rs12744310 0.697 rs12030183 ENSG00000235358.1 RP11-399E6.1 5.86 1.1e-08 6.74e-06 0.35 0.3 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41295548 chr1:41242373~41284861:+ LIHC cis rs12744310 0.638 rs12027245 ENSG00000235358.1 RP11-399E6.1 5.86 1.1e-08 6.74e-06 0.35 0.3 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41298791 chr1:41242373~41284861:+ LIHC cis rs10510102 0.688 rs76573813 ENSG00000276742.1 RP11-500G22.4 5.86 1.1e-08 6.76e-06 0.49 0.3 Breast cancer; chr10:121928955 chr10:121956782~121957098:+ LIHC cis rs7945705 0.747 rs2742480 ENSG00000254860.4 TMEM9B-AS1 5.86 1.1e-08 6.76e-06 0.3 0.3 Hemoglobin concentration; chr11:8971583 chr11:8964675~8977527:+ LIHC cis rs12458462 1 rs12458462 ENSG00000274828.1 RP11-567M16.6 5.86 1.1e-08 6.77e-06 0.31 0.3 Monocyte count; chr18:79712436 chr18:79677287~79679358:- LIHC cis rs1023500 0.551 rs2859438 ENSG00000237037.8 NDUFA6-AS1 5.86 1.1e-08 6.78e-06 0.36 0.3 Schizophrenia; chr22:42070976 chr22:42090931~42137742:+ LIHC cis rs748404 0.66 rs2444251 ENSG00000205771.5 CATSPER2P1 -5.86 1.11e-08 6.79e-06 -0.36 -0.3 Lung cancer; chr15:43496397 chr15:43726918~43747094:- LIHC cis rs748404 0.66 rs548704 ENSG00000205771.5 CATSPER2P1 -5.86 1.11e-08 6.79e-06 -0.36 -0.3 Lung cancer; chr15:43499508 chr15:43726918~43747094:- LIHC cis rs5758511 0.573 rs4501042 ENSG00000237037.8 NDUFA6-AS1 5.86 1.11e-08 6.79e-06 0.36 0.3 Birth weight; chr22:41849759 chr22:42090931~42137742:+ LIHC cis rs2019137 0.589 rs7560701 ENSG00000189223.12 PAX8-AS1 -5.86 1.11e-08 6.79e-06 -0.39 -0.3 Lymphocyte counts; chr2:113269305 chr2:113211522~113276581:+ LIHC cis rs4356975 0.583 rs62296935 ENSG00000249956.3 RP11-790I12.2 5.86 1.11e-08 6.8e-06 0.34 0.3 Obesity-related traits; chr4:69082878 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs62296936 ENSG00000249956.3 RP11-790I12.2 5.86 1.11e-08 6.8e-06 0.34 0.3 Obesity-related traits; chr4:69082903 chr4:69408836~69423164:+ LIHC cis rs2153535 0.541 rs9505456 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8478768 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9505458 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8478982 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9379215 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8480992 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2225766 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8481600 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6597326 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8481786 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs1414353 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8485409 chr6:8784178~8785445:+ LIHC cis rs2153535 0.525 rs1335644 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8487808 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9393025 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8490385 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1414340 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8490906 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1335628 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8491509 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6597330 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8491843 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6941771 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8494219 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6937186 ENSG00000230939.1 RP11-314C16.1 -5.86 1.11e-08 6.81e-06 -0.37 -0.3 Motion sickness; chr6:8494260 chr6:8784178~8785445:+ LIHC cis rs7927592 1 rs7927592 ENSG00000212093.1 AP000807.1 5.86 1.11e-08 6.82e-06 0.33 0.3 Total body bone mineral density; chr11:68602492 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs7107622 ENSG00000212093.1 AP000807.1 5.86 1.11e-08 6.82e-06 0.33 0.3 Total body bone mineral density; chr11:68606715 chr11:68506083~68506166:- LIHC cis rs8028182 0.636 rs28783769 ENSG00000260269.4 CTD-2323K18.1 -5.86 1.11e-08 6.82e-06 -0.39 -0.3 Sudden cardiac arrest; chr15:75556668 chr15:75527150~75601205:- LIHC cis rs7617773 0.817 rs6801801 ENSG00000229759.1 MRPS18AP1 5.86 1.11e-08 6.83e-06 0.35 0.3 Coronary artery disease; chr3:48284943 chr3:48256350~48256938:- LIHC cis rs524281 0.861 rs10896086 ENSG00000255320.1 RP11-755F10.1 5.86 1.12e-08 6.84e-06 0.4 0.3 Electroencephalogram traits; chr11:66147293 chr11:66244840~66246239:- LIHC cis rs748404 0.66 rs493377 ENSG00000205771.5 CATSPER2P1 -5.86 1.12e-08 6.85e-06 -0.36 -0.3 Lung cancer; chr15:43481269 chr15:43726918~43747094:- LIHC cis rs4356975 0.563 rs11249527 ENSG00000249956.3 RP11-790I12.2 5.85 1.12e-08 6.86e-06 0.34 0.3 Obesity-related traits; chr4:69089267 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs6846298 ENSG00000249956.3 RP11-790I12.2 5.85 1.12e-08 6.86e-06 0.34 0.3 Obesity-related traits; chr4:69089278 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs11249528 ENSG00000249956.3 RP11-790I12.2 5.85 1.12e-08 6.86e-06 0.34 0.3 Obesity-related traits; chr4:69089337 chr4:69408836~69423164:+ LIHC cis rs4356975 0.545 rs55757747 ENSG00000249956.3 RP11-790I12.2 5.85 1.12e-08 6.86e-06 0.34 0.3 Obesity-related traits; chr4:69089919 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs56217918 ENSG00000249956.3 RP11-790I12.2 5.85 1.12e-08 6.86e-06 0.34 0.3 Obesity-related traits; chr4:69089925 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs7663584 ENSG00000249956.3 RP11-790I12.2 5.85 1.12e-08 6.86e-06 0.34 0.3 Obesity-related traits; chr4:69090392 chr4:69408836~69423164:+ LIHC cis rs7927592 0.956 rs2155730 ENSG00000212093.1 AP000807.1 5.85 1.12e-08 6.87e-06 0.33 0.3 Total body bone mineral density; chr11:68562006 chr11:68506083~68506166:- LIHC cis rs12681287 0.64 rs4587306 ENSG00000250569.1 NTAN1P2 -5.85 1.12e-08 6.87e-06 -0.36 -0.3 Caudate activity during reward; chr8:86373282 chr8:86481754~86483002:- LIHC cis rs3858145 0.588 rs2305083 ENSG00000233590.1 RP11-153K11.3 -5.85 1.13e-08 6.9e-06 -0.42 -0.3 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68285180 chr10:68233251~68242379:- LIHC cis rs8028182 0.636 rs7184046 ENSG00000260269.4 CTD-2323K18.1 -5.85 1.13e-08 6.91e-06 -0.39 -0.3 Sudden cardiac arrest; chr15:75573809 chr15:75527150~75601205:- LIHC cis rs2933343 0.729 rs789231 ENSG00000231305.3 RP11-723O4.2 5.85 1.13e-08 6.91e-06 0.33 0.3 IgG glycosylation; chr3:128884004 chr3:128861313~128871540:- LIHC cis rs2933343 0.621 rs789249 ENSG00000231305.3 RP11-723O4.2 5.85 1.13e-08 6.91e-06 0.34 0.3 IgG glycosylation; chr3:128859610 chr3:128861313~128871540:- LIHC cis rs2933343 0.621 rs789241 ENSG00000231305.3 RP11-723O4.2 5.85 1.13e-08 6.91e-06 0.34 0.3 IgG glycosylation; chr3:128866909 chr3:128861313~128871540:- LIHC cis rs8072100 0.967 rs11871606 ENSG00000228782.6 CTD-2026D20.3 -5.85 1.13e-08 6.93e-06 -0.33 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47655408 chr17:47450568~47492492:- LIHC cis rs5769765 0.542 rs1535189 ENSG00000278869.1 CITF22-49E9.3 -5.85 1.13e-08 6.93e-06 -0.54 -0.3 Schizophrenia; chr22:49855483 chr22:49933198~49934074:- LIHC cis rs5769765 0.542 rs738707 ENSG00000278869.1 CITF22-49E9.3 -5.85 1.13e-08 6.93e-06 -0.54 -0.3 Schizophrenia; chr22:49857179 chr22:49933198~49934074:- LIHC cis rs10510102 0.935 rs11200252 ENSG00000276742.1 RP11-500G22.4 5.85 1.13e-08 6.93e-06 0.47 0.3 Breast cancer; chr10:121914728 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs12254184 ENSG00000276742.1 RP11-500G22.4 5.85 1.13e-08 6.93e-06 0.47 0.3 Breast cancer; chr10:121914971 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200253 ENSG00000276742.1 RP11-500G22.4 5.85 1.13e-08 6.93e-06 0.47 0.3 Breast cancer; chr10:121915114 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200254 ENSG00000276742.1 RP11-500G22.4 5.85 1.13e-08 6.93e-06 0.47 0.3 Breast cancer; chr10:121915241 chr10:121956782~121957098:+ LIHC cis rs7927592 0.731 rs488381 ENSG00000212093.1 AP000807.1 -5.85 1.14e-08 6.96e-06 -0.3 -0.3 Total body bone mineral density; chr11:68524225 chr11:68506083~68506166:- LIHC cis rs7119038 0.686 rs55894437 ENSG00000255239.1 AP002954.6 -5.85 1.14e-08 6.96e-06 -0.39 -0.3 Sjögren's syndrome; chr11:118736708 chr11:118688039~118690600:- LIHC cis rs11146838 1 rs11146838 ENSG00000276805.1 RP11-291L22.6 5.85 1.14e-08 6.96e-06 0.38 0.3 Breast cancer; chr10:38856846 chr10:38451030~38451785:+ LIHC cis rs7927592 0.956 rs7116899 ENSG00000212093.1 AP000807.1 5.85 1.14e-08 6.96e-06 0.33 0.3 Total body bone mineral density; chr11:68618067 chr11:68506083~68506166:- LIHC cis rs7927592 0.956 rs7102273 ENSG00000212093.1 AP000807.1 5.85 1.14e-08 6.96e-06 0.33 0.3 Total body bone mineral density; chr11:68618111 chr11:68506083~68506166:- LIHC cis rs2858942 0.602 rs1211375 ENSG00000268836.1 LA16c-OS12.2 -5.85 1.14e-08 6.98e-06 -0.31 -0.3 Mean corpuscular hemoglobin; chr16:190281 chr16:185748~186294:- LIHC cis rs4713118 0.516 rs6931858 ENSG00000219392.1 RP1-265C24.5 -5.85 1.14e-08 6.98e-06 -0.46 -0.3 Parkinson's disease; chr6:28110633 chr6:28115628~28116551:+ LIHC cis rs2882667 0.638 rs2351905 ENSG00000253404.1 AC034243.1 5.85 1.15e-08 7e-06 0.39 0.3 Age-related hearing impairment (SNP x SNP interaction); chr5:139135641 chr5:138744434~138753309:- LIHC cis rs997154 0.655 rs4981454 ENSG00000279656.1 RP11-298I3.6 5.85 1.15e-08 7.02e-06 0.49 0.3 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22952977 chr14:23023083~23024217:- LIHC cis rs2243480 1 rs316318 ENSG00000273142.1 RP11-458F8.4 -5.85 1.15e-08 7.03e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66147917 chr7:66902857~66906297:+ LIHC cis rs10875746 0.855 rs10875729 ENSG00000240399.1 RP1-228P16.1 -5.85 1.15e-08 7.05e-06 -0.32 -0.3 Longevity (90 years and older); chr12:48032943 chr12:48054813~48055591:- LIHC cis rs1577917 0.883 rs13212415 ENSG00000234155.1 RP11-30P6.6 5.85 1.16e-08 7.06e-06 0.36 0.3 Response to antipsychotic treatment; chr6:85898365 chr6:85387219~85390186:- LIHC cis rs1577917 0.839 rs1447159 ENSG00000234155.1 RP11-30P6.6 5.85 1.16e-08 7.06e-06 0.36 0.3 Response to antipsychotic treatment; chr6:85899531 chr6:85387219~85390186:- LIHC cis rs524281 0.861 rs9645684 ENSG00000255320.1 RP11-755F10.1 5.85 1.16e-08 7.09e-06 0.39 0.3 Electroencephalogram traits; chr11:66140493 chr11:66244840~66246239:- LIHC cis rs9326248 0.689 rs4516002 ENSG00000280143.1 AP000892.6 5.85 1.16e-08 7.09e-06 0.36 0.3 Blood protein levels; chr11:117128343 chr11:117204967~117210292:+ LIHC cis rs6589219 0.866 rs4477469 ENSG00000196167.8 COLCA1 -5.85 1.16e-08 7.09e-06 -0.34 -0.3 Colorectal cancer; chr11:111290028 chr11:111290787~111305045:- LIHC cis rs4356975 0.563 rs7438135 ENSG00000249956.3 RP11-790I12.2 5.85 1.17e-08 7.11e-06 0.34 0.3 Obesity-related traits; chr4:69095621 chr4:69408836~69423164:+ LIHC cis rs274567 0.599 rs11242110 ENSG00000233006.5 AC034220.3 -5.85 1.17e-08 7.11e-06 -0.3 -0.3 Blood metabolite levels; chr5:132408085 chr5:132311285~132369916:- LIHC cis rs2297363 1 rs3777399 ENSG00000213073.4 RP11-288H12.3 -5.85 1.17e-08 7.12e-06 -0.35 -0.3 Total cholesterol levels;Blood protein levels; chr6:160092761 chr6:160093082~160096212:+ LIHC cis rs12681287 0.609 rs13279850 ENSG00000250569.1 NTAN1P2 5.85 1.17e-08 7.14e-06 0.35 0.3 Caudate activity during reward; chr8:86465571 chr8:86481754~86483002:- LIHC cis rs875971 0.545 rs1547529 ENSG00000226824.5 RP4-756H11.3 -5.85 1.17e-08 7.15e-06 -0.39 -0.3 Aortic root size; chr7:66258859 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs2420171 ENSG00000273142.1 RP11-458F8.4 5.85 1.17e-08 7.15e-06 0.37 0.3 Diabetic kidney disease; chr7:66172773 chr7:66902857~66906297:+ LIHC cis rs7396835 0.551 rs10750098 ENSG00000236267.1 AP006216.5 5.85 1.17e-08 7.16e-06 0.35 0.3 Quantitative traits; chr11:116834852 chr11:116813204~116814003:- LIHC cis rs6921919 0.945 rs61289879 ENSG00000204709.4 LINC01556 5.85 1.17e-08 7.17e-06 0.46 0.3 Autism spectrum disorder or schizophrenia; chr6:28451385 chr6:28943877~28944537:+ LIHC cis rs2842992 0.915 rs1322427 ENSG00000237927.1 RP3-393E18.2 -5.85 1.18e-08 7.17e-06 -0.38 -0.3 Age-related macular degeneration (geographic atrophy); chr6:159654422 chr6:159586955~159589169:- LIHC cis rs7617773 0.78 rs35297395 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48301392 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs36075665 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48301597 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs34630841 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48301771 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs35190747 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48301800 chr3:48256350~48256938:- LIHC cis rs7617773 0.743 rs7621785 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48302218 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs4511915 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48302368 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs13066758 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48302387 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs4392440 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48302430 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs13082859 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48303185 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs35778847 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48305495 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs34749846 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48305678 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs7632297 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48306673 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs79089926 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48307074 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs4511916 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48308876 chr3:48256350~48256938:- LIHC cis rs7617773 0.815 rs7624450 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48308885 chr3:48256350~48256938:- LIHC cis rs7617773 0.815 rs6793150 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48310070 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs6793239 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48310128 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs6782166 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48310193 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs4130522 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48310823 chr3:48256350~48256938:- LIHC cis rs7617773 0.674 rs13069029 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48313534 chr3:48256350~48256938:- LIHC cis rs7617773 0.78 rs13081169 ENSG00000229759.1 MRPS18AP1 5.85 1.18e-08 7.18e-06 0.37 0.3 Coronary artery disease; chr3:48315307 chr3:48256350~48256938:- LIHC cis rs7927592 0.956 rs11228269 ENSG00000212093.1 AP000807.1 5.85 1.18e-08 7.18e-06 0.33 0.3 Total body bone mineral density; chr11:68522328 chr11:68506083~68506166:- LIHC cis rs12458462 0.892 rs35928863 ENSG00000274828.1 RP11-567M16.6 5.85 1.18e-08 7.18e-06 0.31 0.3 Monocyte count; chr18:79678956 chr18:79677287~79679358:- LIHC cis rs4356975 0.563 rs7662029 ENSG00000249956.3 RP11-790I12.2 5.85 1.18e-08 7.19e-06 0.34 0.3 Obesity-related traits; chr4:69096194 chr4:69408836~69423164:+ LIHC cis rs11098499 0.954 rs3733524 ENSG00000245958.5 RP11-33B1.1 -5.85 1.18e-08 7.19e-06 -0.31 -0.3 Corneal astigmatism; chr4:119502574 chr4:119454791~119552025:+ LIHC cis rs2522056 1 rs2106854 ENSG00000233006.5 AC034220.3 -5.84 1.18e-08 7.2e-06 -0.31 -0.3 Fibrinogen;Lymphocyte counts; chr5:132433482 chr5:132311285~132369916:- LIHC cis rs9326248 0.53 rs7122944 ENSG00000236267.1 AP006216.5 5.84 1.19e-08 7.22e-06 0.34 0.3 Blood protein levels; chr11:117163903 chr11:116813204~116814003:- LIHC cis rs5769707 0.777 rs8141219 ENSG00000235111.1 RP1-29C18.8 -5.84 1.19e-08 7.24e-06 -0.36 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49650898 chr22:49612657~49615716:- LIHC cis rs6142102 1 rs6059681 ENSG00000276073.1 RP5-1125A11.7 -5.84 1.19e-08 7.27e-06 -0.34 -0.3 Skin pigmentation; chr20:34135535 chr20:33985617~33988989:- LIHC cis rs17023223 0.581 rs10923750 ENSG00000231365.4 RP11-418J17.1 -5.84 1.19e-08 7.27e-06 -0.37 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119108172 chr1:119140396~119275973:+ LIHC cis rs4356975 0.583 rs6819757 ENSG00000249956.3 RP11-790I12.2 5.84 1.19e-08 7.27e-06 0.34 0.3 Obesity-related traits; chr4:69092946 chr4:69408836~69423164:+ LIHC cis rs748404 0.66 rs509306 ENSG00000205771.5 CATSPER2P1 -5.84 1.2e-08 7.3e-06 -0.35 -0.3 Lung cancer; chr15:43422973 chr15:43726918~43747094:- LIHC cis rs12681287 0.64 rs7832493 ENSG00000250569.1 NTAN1P2 -5.84 1.2e-08 7.32e-06 -0.36 -0.3 Caudate activity during reward; chr8:86359304 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs7816275 ENSG00000250569.1 NTAN1P2 -5.84 1.2e-08 7.32e-06 -0.36 -0.3 Caudate activity during reward; chr8:86361175 chr8:86481754~86483002:- LIHC cis rs2439831 0.702 rs2467402 ENSG00000205771.5 CATSPER2P1 5.84 1.2e-08 7.32e-06 0.44 0.3 Lung cancer in ever smokers; chr15:43732292 chr15:43726918~43747094:- LIHC cis rs3096299 0.935 rs3102387 ENSG00000261118.1 RP11-104N10.1 5.84 1.2e-08 7.33e-06 0.31 0.3 Multiple myeloma (IgH translocation); chr16:89365868 chr16:89492017~89504460:- LIHC cis rs2243480 0.708 rs13242216 ENSG00000273142.1 RP11-458F8.4 -5.84 1.21e-08 7.34e-06 -0.38 -0.3 Diabetic kidney disease; chr7:66433290 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs67536397 ENSG00000273142.1 RP11-458F8.4 -5.84 1.21e-08 7.34e-06 -0.38 -0.3 Diabetic kidney disease; chr7:66482930 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs58669269 ENSG00000273142.1 RP11-458F8.4 -5.84 1.21e-08 7.34e-06 -0.38 -0.3 Diabetic kidney disease; chr7:66486966 chr7:66902857~66906297:+ LIHC cis rs1757171 0.542 rs1757186 ENSG00000204110.6 RP1-153P14.8 -5.84 1.21e-08 7.35e-06 -0.36 -0.3 Cognitive performance; chr6:37516335 chr6:37507348~37535616:+ LIHC cis rs748404 0.66 rs693510 ENSG00000205771.5 CATSPER2P1 -5.84 1.21e-08 7.38e-06 -0.36 -0.3 Lung cancer; chr15:43422427 chr15:43726918~43747094:- LIHC cis rs748404 0.66 rs690512 ENSG00000205771.5 CATSPER2P1 -5.84 1.21e-08 7.38e-06 -0.36 -0.3 Lung cancer; chr15:43425480 chr15:43726918~43747094:- LIHC cis rs748404 0.66 rs542898 ENSG00000205771.5 CATSPER2P1 -5.84 1.21e-08 7.38e-06 -0.36 -0.3 Lung cancer; chr15:43427194 chr15:43726918~43747094:- LIHC cis rs748404 0.66 rs2249952 ENSG00000205771.5 CATSPER2P1 -5.84 1.21e-08 7.38e-06 -0.36 -0.3 Lung cancer; chr15:43428335 chr15:43726918~43747094:- LIHC cis rs6686842 0.965 rs1121866 ENSG00000235358.1 RP11-399E6.1 5.84 1.21e-08 7.38e-06 0.33 0.3 Height; chr1:41242427 chr1:41242373~41284861:+ LIHC cis rs3096299 0.869 rs748941 ENSG00000261118.1 RP11-104N10.1 5.84 1.22e-08 7.38e-06 0.3 0.3 Multiple myeloma (IgH translocation); chr16:89374346 chr16:89492017~89504460:- LIHC cis rs6479901 0.947 rs10761780 ENSG00000232075.1 MRPL35P2 -5.84 1.22e-08 7.41e-06 -0.33 -0.3 Intelligence (multi-trait analysis); chr10:63524272 chr10:63634317~63634827:- LIHC cis rs5758511 0.573 rs2267439 ENSG00000237037.8 NDUFA6-AS1 5.84 1.22e-08 7.44e-06 0.36 0.3 Birth weight; chr22:41841765 chr22:42090931~42137742:+ LIHC cis rs4814920 0.756 rs6075586 ENSG00000275142.1 RP5-999L4.2 -5.84 1.23e-08 7.44e-06 -0.59 -0.3 Bipolar disorder (body mass index interaction); chr20:19874650 chr20:19871891~19872284:+ LIHC cis rs4356975 0.563 rs7441750 ENSG00000249956.3 RP11-790I12.2 5.84 1.23e-08 7.45e-06 0.33 0.3 Obesity-related traits; chr4:69098803 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs7441774 ENSG00000249956.3 RP11-790I12.2 5.84 1.23e-08 7.45e-06 0.33 0.3 Obesity-related traits; chr4:69098836 chr4:69408836~69423164:+ LIHC cis rs4356975 0.522 rs7434332 ENSG00000249956.3 RP11-790I12.2 5.84 1.23e-08 7.45e-06 0.33 0.3 Obesity-related traits; chr4:69099141 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs4293848 ENSG00000249956.3 RP11-790I12.2 5.84 1.23e-08 7.45e-06 0.33 0.3 Obesity-related traits; chr4:69099784 chr4:69408836~69423164:+ LIHC cis rs2243480 1 rs313814 ENSG00000273142.1 RP11-458F8.4 -5.84 1.23e-08 7.45e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66038306 chr7:66902857~66906297:+ LIHC cis rs7829975 0.564 rs2921057 ENSG00000253893.2 FAM85B -5.84 1.23e-08 7.49e-06 -0.4 -0.3 Mood instability; chr8:8461157 chr8:8167819~8226614:- LIHC cis rs4356975 0.563 rs4455491 ENSG00000249956.3 RP11-790I12.2 5.84 1.24e-08 7.5e-06 0.33 0.3 Obesity-related traits; chr4:69095215 chr4:69408836~69423164:+ LIHC cis rs4356975 0.522 rs11940220 ENSG00000249956.3 RP11-790I12.2 5.84 1.24e-08 7.5e-06 0.33 0.3 Obesity-related traits; chr4:69095222 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs11940316 ENSG00000249956.3 RP11-790I12.2 5.84 1.24e-08 7.5e-06 0.33 0.3 Obesity-related traits; chr4:69095409 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs7668258 ENSG00000249956.3 RP11-790I12.2 5.84 1.24e-08 7.5e-06 0.33 0.3 Obesity-related traits; chr4:69096360 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs58544196 ENSG00000249956.3 RP11-790I12.2 5.84 1.24e-08 7.5e-06 0.33 0.3 Obesity-related traits; chr4:69097740 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs7439326 ENSG00000249956.3 RP11-790I12.2 5.84 1.24e-08 7.5e-06 0.33 0.3 Obesity-related traits; chr4:69098462 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs7438244 ENSG00000249956.3 RP11-790I12.2 5.84 1.24e-08 7.5e-06 0.33 0.3 Obesity-related traits; chr4:69098491 chr4:69408836~69423164:+ LIHC cis rs2153535 0.58 rs6920779 ENSG00000230939.1 RP11-314C16.1 -5.84 1.24e-08 7.5e-06 -0.37 -0.3 Motion sickness; chr6:8437391 chr6:8784178~8785445:+ LIHC cis rs11098499 0.954 rs10008459 ENSG00000245958.5 RP11-33B1.1 -5.84 1.24e-08 7.5e-06 -0.31 -0.3 Corneal astigmatism; chr4:119473076 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs2127821 ENSG00000245958.5 RP11-33B1.1 -5.84 1.24e-08 7.5e-06 -0.31 -0.3 Corneal astigmatism; chr4:119473380 chr4:119454791~119552025:+ LIHC cis rs2243480 0.908 rs313822 ENSG00000273142.1 RP11-458F8.4 -5.84 1.24e-08 7.52e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66108952 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs313820 ENSG00000273142.1 RP11-458F8.4 -5.84 1.24e-08 7.52e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66109479 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs313824 ENSG00000273142.1 RP11-458F8.4 -5.84 1.24e-08 7.52e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66116220 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs186378 ENSG00000273142.1 RP11-458F8.4 -5.84 1.24e-08 7.52e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66117071 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs160637 ENSG00000273142.1 RP11-458F8.4 -5.84 1.24e-08 7.52e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66119331 chr7:66902857~66906297:+ LIHC cis rs8072100 0.817 rs6505049 ENSG00000228782.6 CTD-2026D20.3 -5.84 1.24e-08 7.52e-06 -0.33 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47598415 chr17:47450568~47492492:- LIHC cis rs2243480 0.615 rs34363376 ENSG00000273142.1 RP11-458F8.4 -5.84 1.24e-08 7.52e-06 -0.38 -0.3 Diabetic kidney disease; chr7:66474549 chr7:66902857~66906297:+ LIHC cis rs12571093 0.656 rs3858147 ENSG00000233590.1 RP11-153K11.3 -5.84 1.24e-08 7.53e-06 -0.46 -0.3 Optic nerve measurement (disc area); chr10:68253507 chr10:68233251~68242379:- LIHC cis rs12681287 0.57 rs4961188 ENSG00000250569.1 NTAN1P2 -5.84 1.24e-08 7.53e-06 -0.36 -0.3 Caudate activity during reward; chr8:86370804 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs4490816 ENSG00000250569.1 NTAN1P2 -5.84 1.24e-08 7.53e-06 -0.36 -0.3 Caudate activity during reward; chr8:86372709 chr8:86481754~86483002:- LIHC cis rs6142102 0.961 rs4911405 ENSG00000276073.1 RP5-1125A11.7 -5.84 1.24e-08 7.53e-06 -0.34 -0.3 Skin pigmentation; chr20:34087161 chr20:33985617~33988989:- LIHC cis rs12908161 1 rs60957376 ENSG00000259295.5 CSPG4P12 5.84 1.24e-08 7.53e-06 0.41 0.3 Schizophrenia; chr15:84737561 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs11632465 ENSG00000259295.5 CSPG4P12 5.84 1.24e-08 7.53e-06 0.41 0.3 Schizophrenia; chr15:84738814 chr15:85191438~85213905:+ LIHC cis rs12908161 0.96 rs17599989 ENSG00000259295.5 CSPG4P12 5.84 1.24e-08 7.53e-06 0.41 0.3 Schizophrenia; chr15:84742305 chr15:85191438~85213905:+ LIHC cis rs2243480 1 rs465359 ENSG00000273142.1 RP11-458F8.4 -5.84 1.24e-08 7.53e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66093177 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs462853 ENSG00000273142.1 RP11-458F8.4 -5.84 1.24e-08 7.53e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66093180 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs160644 ENSG00000273142.1 RP11-458F8.4 -5.84 1.24e-08 7.53e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66093199 chr7:66902857~66906297:+ LIHC cis rs2998286 0.715 rs2993985 ENSG00000254635.4 WAC-AS1 -5.84 1.24e-08 7.53e-06 -0.37 -0.3 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28510311 chr10:28522652~28532743:- LIHC cis rs2153535 0.58 rs4639392 ENSG00000230939.1 RP11-314C16.1 -5.83 1.25e-08 7.57e-06 -0.37 -0.3 Motion sickness; chr6:8446314 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2184582 ENSG00000230939.1 RP11-314C16.1 -5.83 1.25e-08 7.57e-06 -0.37 -0.3 Motion sickness; chr6:8447560 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2184583 ENSG00000230939.1 RP11-314C16.1 -5.83 1.25e-08 7.57e-06 -0.37 -0.3 Motion sickness; chr6:8447575 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9505446 ENSG00000230939.1 RP11-314C16.1 -5.83 1.25e-08 7.57e-06 -0.37 -0.3 Motion sickness; chr6:8448458 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1335633 ENSG00000230939.1 RP11-314C16.1 -5.83 1.25e-08 7.57e-06 -0.37 -0.3 Motion sickness; chr6:8448567 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1115079 ENSG00000230939.1 RP11-314C16.1 -5.83 1.25e-08 7.57e-06 -0.37 -0.3 Motion sickness; chr6:8449382 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1115078 ENSG00000230939.1 RP11-314C16.1 -5.83 1.25e-08 7.57e-06 -0.37 -0.3 Motion sickness; chr6:8449405 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6597322 ENSG00000230939.1 RP11-314C16.1 -5.83 1.25e-08 7.57e-06 -0.37 -0.3 Motion sickness; chr6:8449719 chr6:8784178~8785445:+ LIHC cis rs853679 0.567 rs6905380 ENSG00000204709.4 LINC01556 5.83 1.25e-08 7.57e-06 0.4 0.3 Depression; chr6:28407125 chr6:28943877~28944537:+ LIHC cis rs4713118 0.621 rs10484403 ENSG00000219392.1 RP1-265C24.5 -5.83 1.25e-08 7.59e-06 -0.45 -0.3 Parkinson's disease; chr6:28065745 chr6:28115628~28116551:+ LIHC cis rs12458462 0.812 rs34583578 ENSG00000274828.1 RP11-567M16.6 5.83 1.26e-08 7.61e-06 0.32 0.3 Monocyte count; chr18:79731070 chr18:79677287~79679358:- LIHC cis rs7945705 0.747 rs2653605 ENSG00000254860.4 TMEM9B-AS1 5.83 1.26e-08 7.61e-06 0.3 0.3 Hemoglobin concentration; chr11:8971762 chr11:8964675~8977527:+ LIHC cis rs3779195 0.929 rs2906184 ENSG00000272950.1 RP11-307C18.1 -5.83 1.26e-08 7.63e-06 -0.43 -0.3 Sex hormone-binding globulin levels; chr7:98310675 chr7:98322853~98323430:+ LIHC cis rs7688540 0.771 rs61795002 ENSG00000275426.1 CH17-262A2.1 5.83 1.26e-08 7.63e-06 0.41 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:249008 chr4:149738~150317:+ LIHC cis rs5758659 1 rs5751255 ENSG00000227370.1 RP4-669P10.19 -5.83 1.26e-08 7.65e-06 -0.34 -0.3 Cognitive function; chr22:42252402 chr22:42132543~42132998:+ LIHC cis rs7688540 0.771 rs4129956 ENSG00000275426.1 CH17-262A2.1 5.83 1.27e-08 7.66e-06 0.42 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:308219 chr4:149738~150317:+ LIHC cis rs6142102 0.961 rs2284387 ENSG00000276073.1 RP5-1125A11.7 -5.83 1.27e-08 7.66e-06 -0.34 -0.3 Skin pigmentation; chr20:34056782 chr20:33985617~33988989:- LIHC cis rs13068223 0.663 rs12107178 ENSG00000243926.1 TIPARP-AS1 5.83 1.27e-08 7.67e-06 0.28 0.3 Age-related hearing impairment (SNP x SNP interaction); chr3:156756735 chr3:156671862~156674378:- LIHC cis rs12701220 0.553 rs9639882 ENSG00000229043.2 AC091729.9 -5.83 1.27e-08 7.67e-06 -0.42 -0.3 Bronchopulmonary dysplasia; chr7:1094095 chr7:1160374~1165267:+ LIHC cis rs2882667 0.518 rs10041986 ENSG00000253404.1 AC034243.1 5.83 1.27e-08 7.71e-06 0.37 0.3 Age-related hearing impairment (SNP x SNP interaction); chr5:139088748 chr5:138744434~138753309:- LIHC cis rs6504950 0.679 rs9908752 ENSG00000275710.1 RP11-257O5.4 5.83 1.28e-08 7.72e-06 0.39 0.3 Breast cancer; chr17:54905855 chr17:54964474~54964679:+ LIHC cis rs10875746 0.669 rs61941003 ENSG00000240399.1 RP1-228P16.1 -5.83 1.28e-08 7.74e-06 -0.33 -0.3 Longevity (90 years and older); chr12:48225842 chr12:48054813~48055591:- LIHC cis rs9326248 0.53 rs2127905 ENSG00000236267.1 AP006216.5 5.83 1.28e-08 7.74e-06 0.34 0.3 Blood protein levels; chr11:117155658 chr11:116813204~116814003:- LIHC cis rs7115242 0.514 rs4936367 ENSG00000236267.1 AP006216.5 5.83 1.28e-08 7.74e-06 0.34 0.3 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117171661 chr11:116813204~116814003:- LIHC cis rs9326248 0.53 rs4604928 ENSG00000236267.1 AP006216.5 5.83 1.28e-08 7.74e-06 0.34 0.3 Blood protein levels; chr11:117173487 chr11:116813204~116814003:- LIHC cis rs2524005 1 rs2524005 ENSG00000181126.12 HLA-V 5.83 1.29e-08 7.77e-06 0.41 0.3 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29790954~29797811:+ LIHC cis rs7617773 0.643 rs78159520 ENSG00000229759.1 MRPS18AP1 5.83 1.29e-08 7.77e-06 0.37 0.3 Coronary artery disease; chr3:48307533 chr3:48256350~48256938:- LIHC cis rs4356975 0.522 rs12647681 ENSG00000249956.3 RP11-790I12.2 5.83 1.29e-08 7.78e-06 0.33 0.3 Obesity-related traits; chr4:69097442 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs12647682 ENSG00000249956.3 RP11-790I12.2 5.83 1.29e-08 7.78e-06 0.33 0.3 Obesity-related traits; chr4:69097450 chr4:69408836~69423164:+ LIHC cis rs2274273 0.774 rs17128440 ENSG00000258413.1 RP11-665C16.6 -5.83 1.29e-08 7.79e-06 -0.34 -0.3 Protein biomarker; chr14:55395194 chr14:55262767~55272075:- LIHC cis rs34779708 0.733 rs60616028 ENSG00000230534.5 RP11-297A16.2 5.83 1.29e-08 7.8e-06 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35254874 chr10:35098006~35127020:- LIHC cis rs904251 0.523 rs2776872 ENSG00000204110.6 RP1-153P14.8 -5.83 1.29e-08 7.8e-06 -0.35 -0.3 Cognitive performance; chr6:37515011 chr6:37507348~37535616:+ LIHC cis rs904251 0.523 rs1757191 ENSG00000204110.6 RP1-153P14.8 -5.83 1.29e-08 7.8e-06 -0.35 -0.3 Cognitive performance; chr6:37515095 chr6:37507348~37535616:+ LIHC cis rs7927592 0.731 rs10896350 ENSG00000212093.1 AP000807.1 5.83 1.29e-08 7.8e-06 0.3 0.3 Total body bone mineral density; chr11:68618905 chr11:68506083~68506166:- LIHC cis rs5758659 0.904 rs134877 ENSG00000227370.1 RP4-669P10.19 -5.83 1.29e-08 7.81e-06 -0.33 -0.3 Cognitive function; chr22:42266365 chr22:42132543~42132998:+ LIHC cis rs9527 1 rs4919690 ENSG00000236937.2 PTGES3P4 -5.83 1.3e-08 7.83e-06 -0.43 -0.3 Arsenic metabolism; chr10:102856743 chr10:102845595~102845950:+ LIHC cis rs7927592 0.956 rs7124078 ENSG00000212093.1 AP000807.1 5.83 1.3e-08 7.84e-06 0.33 0.3 Total body bone mineral density; chr11:68531165 chr11:68506083~68506166:- LIHC cis rs6142102 0.847 rs4911413 ENSG00000276073.1 RP5-1125A11.7 -5.83 1.3e-08 7.85e-06 -0.33 -0.3 Skin pigmentation; chr20:34133969 chr20:33985617~33988989:- LIHC cis rs6142102 1 rs2143230 ENSG00000276073.1 RP5-1125A11.7 -5.83 1.3e-08 7.85e-06 -0.33 -0.3 Skin pigmentation; chr20:34136539 chr20:33985617~33988989:- LIHC cis rs7927592 0.731 rs643609 ENSG00000212093.1 AP000807.1 5.83 1.3e-08 7.85e-06 0.3 0.3 Total body bone mineral density; chr11:68474365 chr11:68506083~68506166:- LIHC cis rs7927592 0.763 rs596494 ENSG00000212093.1 AP000807.1 5.83 1.3e-08 7.85e-06 0.3 0.3 Total body bone mineral density; chr11:68483586 chr11:68506083~68506166:- LIHC cis rs7617773 0.78 rs36121690 ENSG00000229759.1 MRPS18AP1 5.83 1.3e-08 7.85e-06 0.37 0.3 Coronary artery disease; chr3:48304021 chr3:48256350~48256938:- LIHC cis rs2836950 0.501 rs2836984 ENSG00000255568.3 BRWD1-AS2 -5.83 1.3e-08 7.86e-06 -0.25 -0.3 Menarche (age at onset); chr21:39329023 chr21:39313935~39314962:+ LIHC cis rs6142102 0.812 rs2377955 ENSG00000276073.1 RP5-1125A11.7 -5.83 1.3e-08 7.87e-06 -0.33 -0.3 Skin pigmentation; chr20:33937564 chr20:33985617~33988989:- LIHC cis rs2153535 0.542 rs6912740 ENSG00000230939.1 RP11-314C16.1 -5.83 1.31e-08 7.91e-06 -0.37 -0.3 Motion sickness; chr6:8439726 chr6:8784178~8785445:+ LIHC cis rs8100891 0.537 rs4805762 ENSG00000267213.4 AC007773.2 -5.83 1.31e-08 7.92e-06 -0.38 -0.3 Neuroticism; chr19:32473048 chr19:32390050~32405560:- LIHC cis rs8100891 0.537 rs7253039 ENSG00000267213.4 AC007773.2 -5.83 1.31e-08 7.92e-06 -0.38 -0.3 Neuroticism; chr19:32482171 chr19:32390050~32405560:- LIHC cis rs8100891 0.537 rs1057395 ENSG00000267213.4 AC007773.2 -5.83 1.31e-08 7.92e-06 -0.38 -0.3 Neuroticism; chr19:32483832 chr19:32390050~32405560:- LIHC cis rs8100891 0.537 rs1057397 ENSG00000267213.4 AC007773.2 -5.83 1.31e-08 7.92e-06 -0.38 -0.3 Neuroticism; chr19:32484007 chr19:32390050~32405560:- LIHC cis rs8100891 0.537 rs737093 ENSG00000267213.4 AC007773.2 -5.83 1.31e-08 7.92e-06 -0.38 -0.3 Neuroticism; chr19:32486500 chr19:32390050~32405560:- LIHC cis rs7916697 0.626 rs3858144 ENSG00000233590.1 RP11-153K11.3 -5.83 1.31e-08 7.92e-06 -0.35 -0.3 Optic disc area; chr10:68251597 chr10:68233251~68242379:- LIHC cis rs4356975 0.563 rs4538548 ENSG00000249956.3 RP11-790I12.2 5.83 1.32e-08 7.93e-06 0.33 0.3 Obesity-related traits; chr4:69094951 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs6600883 ENSG00000249956.3 RP11-790I12.2 5.83 1.32e-08 7.93e-06 0.33 0.3 Obesity-related traits; chr4:69094953 chr4:69408836~69423164:+ LIHC cis rs5758659 0.935 rs134879 ENSG00000227370.1 RP4-669P10.19 -5.82 1.32e-08 7.95e-06 -0.33 -0.3 Cognitive function; chr22:42268195 chr22:42132543~42132998:+ LIHC cis rs4865169 0.791 rs11731868 ENSG00000269949.1 RP11-738E22.3 -5.82 1.33e-08 7.99e-06 -0.37 -0.3 Breast cancer; chr4:57029048 chr4:56960927~56961373:- LIHC cis rs4934494 0.813 rs12775783 ENSG00000232936.4 RP11-80H5.2 5.82 1.33e-08 7.99e-06 0.39 0.3 Red blood cell count; chr10:89646494 chr10:89645282~89650667:+ LIHC cis rs10899021 0.512 rs10219168 ENSG00000279353.1 RP11-864N7.4 -5.82 1.33e-08 8.01e-06 -0.44 -0.3 Response to metformin (IC50); chr11:74663408 chr11:74698231~74699658:- LIHC cis rs9549367 0.789 rs9549718 ENSG00000269125.1 RP11-98F14.11 -5.82 1.33e-08 8.01e-06 -0.37 -0.3 Platelet distribution width; chr13:113255508 chr13:113165002~113165183:- LIHC cis rs6921919 0.515 rs1339898 ENSG00000216901.1 AL022393.7 5.82 1.33e-08 8.03e-06 0.37 0.3 Autism spectrum disorder or schizophrenia; chr6:28427729 chr6:28176188~28176674:+ LIHC cis rs6142102 0.961 rs909884 ENSG00000276073.1 RP5-1125A11.7 -5.82 1.34e-08 8.04e-06 -0.34 -0.3 Skin pigmentation; chr20:34058257 chr20:33985617~33988989:- LIHC cis rs1499614 1 rs2659913 ENSG00000273142.1 RP11-458F8.4 -5.82 1.34e-08 8.04e-06 -0.37 -0.3 Gout; chr7:66692349 chr7:66902857~66906297:+ LIHC cis rs1499614 1 rs2707840 ENSG00000273142.1 RP11-458F8.4 -5.82 1.34e-08 8.04e-06 -0.37 -0.3 Gout; chr7:66693028 chr7:66902857~66906297:+ LIHC cis rs1499614 1 rs2659911 ENSG00000273142.1 RP11-458F8.4 -5.82 1.34e-08 8.04e-06 -0.37 -0.3 Gout; chr7:66693433 chr7:66902857~66906297:+ LIHC cis rs1499614 1 rs2707838 ENSG00000273142.1 RP11-458F8.4 -5.82 1.34e-08 8.04e-06 -0.37 -0.3 Gout; chr7:66694214 chr7:66902857~66906297:+ LIHC cis rs1499614 1 rs60326618 ENSG00000273142.1 RP11-458F8.4 -5.82 1.34e-08 8.04e-06 -0.37 -0.3 Gout; chr7:66701371 chr7:66902857~66906297:+ LIHC cis rs1499614 1 rs2707830 ENSG00000273142.1 RP11-458F8.4 -5.82 1.34e-08 8.04e-06 -0.37 -0.3 Gout; chr7:66702658 chr7:66902857~66906297:+ LIHC cis rs1499614 1 rs2707828 ENSG00000273142.1 RP11-458F8.4 -5.82 1.34e-08 8.04e-06 -0.37 -0.3 Gout; chr7:66706390 chr7:66902857~66906297:+ LIHC cis rs1499614 0.803 rs1922723 ENSG00000273142.1 RP11-458F8.4 -5.82 1.34e-08 8.04e-06 -0.37 -0.3 Gout; chr7:66710076 chr7:66902857~66906297:+ LIHC cis rs1499614 1 rs2659903 ENSG00000273142.1 RP11-458F8.4 -5.82 1.34e-08 8.04e-06 -0.37 -0.3 Gout; chr7:66715944 chr7:66902857~66906297:+ LIHC cis rs1499614 1 rs2141924 ENSG00000273142.1 RP11-458F8.4 -5.82 1.34e-08 8.04e-06 -0.37 -0.3 Gout; chr7:66721259 chr7:66902857~66906297:+ LIHC cis rs11676348 0.755 rs1008562 ENSG00000261338.2 RP11-378A13.1 5.82 1.34e-08 8.04e-06 0.32 0.3 Ulcerative colitis; chr2:218162249 chr2:218255319~218257366:+ LIHC cis rs7617773 0.925 rs35942721 ENSG00000229759.1 MRPS18AP1 5.82 1.34e-08 8.05e-06 0.37 0.3 Coronary artery disease; chr3:48131579 chr3:48256350~48256938:- LIHC cis rs1005277 0.505 rs7099777 ENSG00000263064.2 RP11-291L22.7 -5.82 1.34e-08 8.05e-06 -0.31 -0.3 Extrinsic epigenetic age acceleration; chr10:37894641 chr10:38448689~38448949:+ LIHC cis rs1005277 0.505 rs1208689 ENSG00000263064.2 RP11-291L22.7 5.82 1.34e-08 8.06e-06 0.31 0.3 Extrinsic epigenetic age acceleration; chr10:37808847 chr10:38448689~38448949:+ LIHC cis rs7927592 0.956 rs7113287 ENSG00000212093.1 AP000807.1 5.82 1.34e-08 8.08e-06 0.32 0.3 Total body bone mineral density; chr11:68604718 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs6591346 ENSG00000212093.1 AP000807.1 5.82 1.34e-08 8.08e-06 0.32 0.3 Total body bone mineral density; chr11:68617150 chr11:68506083~68506166:- LIHC cis rs12701220 0.604 rs34904312 ENSG00000229043.2 AC091729.9 -5.82 1.34e-08 8.09e-06 -0.42 -0.3 Bronchopulmonary dysplasia; chr7:1096247 chr7:1160374~1165267:+ LIHC cis rs6504950 0.72 rs9895901 ENSG00000275710.1 RP11-257O5.4 5.82 1.35e-08 8.1e-06 0.39 0.3 Breast cancer; chr17:54907524 chr17:54964474~54964679:+ LIHC cis rs12025262 0.546 rs10754539 ENSG00000227671.4 RP11-488L18.4 -5.82 1.35e-08 8.11e-06 -0.19 -0.3 Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50); chr1:247202128 chr1:247189851~247210856:- LIHC cis rs2274273 0.84 rs7153110 ENSG00000258413.1 RP11-665C16.6 -5.82 1.35e-08 8.11e-06 -0.34 -0.3 Protein biomarker; chr14:55353910 chr14:55262767~55272075:- LIHC cis rs6085948 1 rs1033603 ENSG00000238102.1 RP11-19D2.1 5.82 1.35e-08 8.12e-06 0.43 0.3 Interleukin-10 levels; chr20:7267540 chr20:7256580~7258214:- LIHC cis rs2243480 1 rs422164 ENSG00000226824.5 RP4-756H11.3 -5.82 1.35e-08 8.14e-06 -0.49 -0.3 Diabetic kidney disease; chr7:66121618 chr7:66654538~66669855:+ LIHC cis rs12681287 0.64 rs7841690 ENSG00000250569.1 NTAN1P2 -5.82 1.35e-08 8.14e-06 -0.36 -0.3 Caudate activity during reward; chr8:86353130 chr8:86481754~86483002:- LIHC cis rs150992 0.631 rs79399563 ENSG00000248489.1 CTD-2007H13.3 5.82 1.36e-08 8.15e-06 0.46 0.3 Body mass index; chr5:98993275 chr5:98929171~98995013:+ LIHC cis rs10875746 0.669 rs2279464 ENSG00000240399.1 RP1-228P16.1 -5.82 1.36e-08 8.15e-06 -0.32 -0.3 Longevity (90 years and older); chr12:48296626 chr12:48054813~48055591:- LIHC cis rs67180937 0.553 rs3008629 ENSG00000272750.1 RP11-378J18.8 5.82 1.36e-08 8.15e-06 0.35 0.3 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222662588 chr1:222658867~222661512:- LIHC cis rs2243480 1 rs160639 ENSG00000273142.1 RP11-458F8.4 -5.82 1.36e-08 8.16e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66115000 chr7:66902857~66906297:+ LIHC cis rs6940638 0.662 rs6915678 ENSG00000216901.1 AL022393.7 5.82 1.36e-08 8.16e-06 0.38 0.3 Intelligence (multi-trait analysis); chr6:27268087 chr6:28176188~28176674:+ LIHC cis rs6142102 0.812 rs6059558 ENSG00000276073.1 RP5-1125A11.7 -5.82 1.36e-08 8.18e-06 -0.34 -0.3 Skin pigmentation; chr20:33929024 chr20:33985617~33988989:- LIHC cis rs6142102 0.659 rs6057945 ENSG00000276073.1 RP5-1125A11.7 -5.82 1.36e-08 8.18e-06 -0.34 -0.3 Skin pigmentation; chr20:33929374 chr20:33985617~33988989:- LIHC cis rs6683071 0.501 rs3002146 ENSG00000272750.1 RP11-378J18.8 5.82 1.36e-08 8.18e-06 0.35 0.3 Cognitive performance; chr1:222636066 chr1:222658867~222661512:- LIHC cis rs67180937 0.553 rs1391557 ENSG00000272750.1 RP11-378J18.8 5.82 1.36e-08 8.18e-06 0.35 0.3 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222636274 chr1:222658867~222661512:- LIHC cis rs7927592 0.763 rs10896351 ENSG00000212093.1 AP000807.1 5.82 1.37e-08 8.2e-06 0.3 0.3 Total body bone mineral density; chr11:68619428 chr11:68506083~68506166:- LIHC cis rs1005277 0.505 rs7917943 ENSG00000263064.2 RP11-291L22.7 -5.82 1.37e-08 8.2e-06 -0.31 -0.3 Extrinsic epigenetic age acceleration; chr10:37906883 chr10:38448689~38448949:+ LIHC cis rs9487094 0.67 rs12199154 ENSG00000260273.1 RP11-425D10.10 -5.82 1.37e-08 8.22e-06 -0.35 -0.3 Height; chr6:109501793 chr6:109382795~109383666:+ LIHC cis rs113835537 0.529 rs11227511 ENSG00000255517.5 CTD-3074O7.5 -5.82 1.37e-08 8.24e-06 -0.33 -0.3 Airway imaging phenotypes; chr11:66513773 chr11:66473490~66480233:- LIHC cis rs3858145 0.588 rs4142049 ENSG00000233590.1 RP11-153K11.3 -5.82 1.37e-08 8.24e-06 -0.42 -0.3 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68284695 chr10:68233251~68242379:- LIHC cis rs3858145 0.588 rs7081284 ENSG00000233590.1 RP11-153K11.3 -5.82 1.37e-08 8.24e-06 -0.42 -0.3 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68285035 chr10:68233251~68242379:- LIHC cis rs11673344 0.566 rs185368 ENSG00000226686.6 LINC01535 -5.82 1.37e-08 8.25e-06 -0.37 -0.3 Obesity-related traits; chr19:37381827 chr19:37251912~37265535:+ LIHC cis rs7674212 0.507 rs10516495 ENSG00000230069.3 LRRC37A15P -5.82 1.38e-08 8.28e-06 -0.29 -0.3 Type 2 diabetes; chr4:102978933 chr4:102727274~102730721:- LIHC cis rs2735413 0.632 rs4436790 ENSG00000276007.1 RP11-358L22.3 5.82 1.38e-08 8.29e-06 0.34 0.3 Systolic blood pressure (alcohol consumption interaction); chr16:78063355 chr16:78123243~78124332:+ LIHC cis rs2153535 0.58 rs9505455 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8478389 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9379216 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8481002 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7450817 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8481188 chr6:8784178~8785445:+ LIHC cis rs2153535 0.56 rs2210798 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8481289 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6597327 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8481924 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7753192 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8482404 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7763190 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8483964 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs1414352 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8485314 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1577471 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8485672 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1120392 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8486820 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1335641 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8487627 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1335643 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8487788 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9378554 ENSG00000230939.1 RP11-314C16.1 -5.82 1.38e-08 8.29e-06 -0.36 -0.3 Motion sickness; chr6:8488235 chr6:8784178~8785445:+ LIHC cis rs7927592 0.912 rs55767696 ENSG00000212093.1 AP000807.1 5.82 1.38e-08 8.31e-06 0.33 0.3 Total body bone mineral density; chr11:68607652 chr11:68506083~68506166:- LIHC cis rs2243480 1 rs410128 ENSG00000226824.5 RP4-756H11.3 -5.82 1.39e-08 8.31e-06 -0.51 -0.3 Diabetic kidney disease; chr7:66138186 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs316307 ENSG00000273142.1 RP11-458F8.4 -5.82 1.39e-08 8.31e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66105184 chr7:66902857~66906297:+ LIHC cis rs7617773 0.78 rs35297486 ENSG00000229759.1 MRPS18AP1 5.82 1.39e-08 8.31e-06 0.37 0.3 Coronary artery disease; chr3:48336657 chr3:48256350~48256938:- LIHC cis rs2998286 0.862 rs2993981 ENSG00000254635.4 WAC-AS1 -5.82 1.39e-08 8.34e-06 -0.37 -0.3 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28506552 chr10:28522652~28532743:- LIHC cis rs2998286 0.862 rs2993982 ENSG00000254635.4 WAC-AS1 -5.82 1.39e-08 8.34e-06 -0.37 -0.3 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28506559 chr10:28522652~28532743:- LIHC cis rs1023500 0.573 rs133381 ENSG00000237037.8 NDUFA6-AS1 5.81 1.4e-08 8.38e-06 0.36 0.3 Schizophrenia; chr22:42074604 chr22:42090931~42137742:+ LIHC cis rs2522056 0.932 rs1012793 ENSG00000233006.5 AC034220.3 -5.81 1.4e-08 8.38e-06 -0.31 -0.3 Fibrinogen;Lymphocyte counts; chr5:132445653 chr5:132311285~132369916:- LIHC cis rs2882667 0.537 rs7704790 ENSG00000253404.1 AC034243.1 5.81 1.4e-08 8.4e-06 0.36 0.3 Age-related hearing impairment (SNP x SNP interaction); chr5:139074407 chr5:138744434~138753309:- LIHC cis rs1185460 0.546 rs17075 ENSG00000271751.1 RP11-110I1.14 5.81 1.4e-08 8.4e-06 0.39 0.3 Coronary artery disease; chr11:119088621 chr11:119065263~119065677:- LIHC cis rs7927592 0.913 rs7127948 ENSG00000212093.1 AP000807.1 5.81 1.41e-08 8.45e-06 0.33 0.3 Total body bone mineral density; chr11:68595594 chr11:68506083~68506166:- LIHC cis rs748404 0.66 rs690446 ENSG00000205771.5 CATSPER2P1 -5.81 1.41e-08 8.46e-06 -0.36 -0.3 Lung cancer; chr15:43469066 chr15:43726918~43747094:- LIHC cis rs748404 0.66 rs518288 ENSG00000205771.5 CATSPER2P1 -5.81 1.41e-08 8.46e-06 -0.36 -0.3 Lung cancer; chr15:43471801 chr15:43726918~43747094:- LIHC cis rs748404 0.66 rs690472 ENSG00000205771.5 CATSPER2P1 -5.81 1.41e-08 8.46e-06 -0.36 -0.3 Lung cancer; chr15:43472170 chr15:43726918~43747094:- LIHC cis rs748404 0.631 rs560191 ENSG00000205771.5 CATSPER2P1 -5.81 1.41e-08 8.46e-06 -0.36 -0.3 Lung cancer; chr15:43475576 chr15:43726918~43747094:- LIHC cis rs9326248 0.817 rs6589598 ENSG00000236267.1 AP006216.5 5.81 1.41e-08 8.46e-06 0.3 0.3 Blood protein levels; chr11:117131687 chr11:116813204~116814003:- LIHC cis rs9487094 0.666 rs4946967 ENSG00000260273.1 RP11-425D10.10 5.81 1.41e-08 8.46e-06 0.35 0.3 Height; chr6:109357369 chr6:109382795~109383666:+ LIHC cis rs11098499 0.954 rs6849171 ENSG00000245958.5 RP11-33B1.1 -5.81 1.41e-08 8.46e-06 -0.31 -0.3 Corneal astigmatism; chr4:119488394 chr4:119454791~119552025:+ LIHC cis rs8072100 0.967 rs7219303 ENSG00000228782.6 CTD-2026D20.3 -5.81 1.41e-08 8.47e-06 -0.32 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47660335 chr17:47450568~47492492:- LIHC cis rs6686842 1 rs11209718 ENSG00000235358.1 RP11-399E6.1 5.81 1.42e-08 8.48e-06 0.33 0.3 Height; chr1:41223266 chr1:41242373~41284861:+ LIHC cis rs6686842 1 rs12134073 ENSG00000235358.1 RP11-399E6.1 5.81 1.42e-08 8.48e-06 0.33 0.3 Height; chr1:41223611 chr1:41242373~41284861:+ LIHC cis rs6686842 0.896 rs11209725 ENSG00000235358.1 RP11-399E6.1 5.81 1.42e-08 8.48e-06 0.33 0.3 Height; chr1:41228345 chr1:41242373~41284861:+ LIHC cis rs6142102 0.961 rs4911411 ENSG00000276073.1 RP5-1125A11.7 -5.81 1.42e-08 8.48e-06 -0.33 -0.3 Skin pigmentation; chr20:34128036 chr20:33985617~33988989:- LIHC cis rs2243480 1 rs12698509 ENSG00000273142.1 RP11-458F8.4 -5.81 1.42e-08 8.48e-06 -0.37 -0.3 Diabetic kidney disease; chr7:65953889 chr7:66902857~66906297:+ LIHC cis rs7119038 0.774 rs7945144 ENSG00000255239.1 AP002954.6 -5.81 1.42e-08 8.49e-06 -0.38 -0.3 Sjögren's syndrome; chr11:118738007 chr11:118688039~118690600:- LIHC cis rs10875746 0.669 rs11168510 ENSG00000240399.1 RP1-228P16.1 -5.81 1.42e-08 8.49e-06 -0.32 -0.3 Longevity (90 years and older); chr12:48291772 chr12:48054813~48055591:- LIHC cis rs7927592 0.913 rs10896329 ENSG00000212093.1 AP000807.1 5.81 1.42e-08 8.49e-06 0.33 0.3 Total body bone mineral density; chr11:68482561 chr11:68506083~68506166:- LIHC cis rs34779708 0.801 rs12255409 ENSG00000230534.5 RP11-297A16.2 5.81 1.42e-08 8.5e-06 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35246497 chr10:35098006~35127020:- LIHC cis rs6921919 0.638 rs9468344 ENSG00000216901.1 AL022393.7 5.81 1.42e-08 8.51e-06 0.34 0.3 Autism spectrum disorder or schizophrenia; chr6:28341792 chr6:28176188~28176674:+ LIHC cis rs1150668 0.764 rs9368565 ENSG00000204709.4 LINC01556 -5.81 1.42e-08 8.52e-06 -0.34 -0.3 Pubertal anthropometrics; chr6:28377433 chr6:28943877~28944537:+ LIHC cis rs1150668 0.796 rs1052215 ENSG00000204709.4 LINC01556 -5.81 1.42e-08 8.52e-06 -0.34 -0.3 Pubertal anthropometrics; chr6:28380381 chr6:28943877~28944537:+ LIHC cis rs2274273 0.84 rs66486619 ENSG00000258413.1 RP11-665C16.6 -5.81 1.43e-08 8.54e-06 -0.34 -0.3 Protein biomarker; chr14:55402837 chr14:55262767~55272075:- LIHC cis rs7927592 0.913 rs948316 ENSG00000212093.1 AP000807.1 5.81 1.43e-08 8.57e-06 0.33 0.3 Total body bone mineral density; chr11:68542202 chr11:68506083~68506166:- LIHC cis rs1729407 0.786 rs5096 ENSG00000254851.1 RP11-109L13.1 -5.81 1.43e-08 8.57e-06 -0.35 -0.3 Apolipoprotein A-IV levels; chr11:116822379 chr11:117135528~117138582:+ LIHC cis rs6061231 0.654 rs2427322 ENSG00000273619.1 RP5-908M14.9 -5.81 1.43e-08 8.57e-06 -0.25 -0.3 Colorectal cancer; chr20:62404314 chr20:62386303~62386970:- LIHC cis rs1003645 0.861 rs6505500 ENSG00000275944.1 RP11-104J23.1 5.81 1.44e-08 8.59e-06 0.32 0.3 Blood protein levels; chr17:36019746 chr17:36001419~36011618:+ LIHC cis rs2739330 0.929 rs5751777 ENSG00000099984.9 GSTT2 -5.81 1.44e-08 8.59e-06 -0.35 -0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23980123~23983911:+ LIHC cis rs1577917 0.793 rs9362245 ENSG00000234155.1 RP11-30P6.6 5.81 1.44e-08 8.59e-06 0.36 0.3 Response to antipsychotic treatment; chr6:85786602 chr6:85387219~85390186:- LIHC cis rs6589219 0.908 rs7130173 ENSG00000196167.8 COLCA1 -5.81 1.44e-08 8.63e-06 -0.33 -0.3 Colorectal cancer; chr11:111283347 chr11:111290787~111305045:- LIHC cis rs12908161 0.96 rs11633450 ENSG00000259295.5 CSPG4P12 5.81 1.45e-08 8.64e-06 0.41 0.3 Schizophrenia; chr15:84764056 chr15:85191438~85213905:+ LIHC cis rs150992 0.609 rs447044 ENSG00000248489.1 CTD-2007H13.3 5.81 1.45e-08 8.64e-06 0.44 0.3 Body mass index; chr5:98995572 chr5:98929171~98995013:+ LIHC cis rs12908161 0.959 rs34028043 ENSG00000259295.5 CSPG4P12 5.81 1.45e-08 8.64e-06 0.41 0.3 Schizophrenia; chr15:84688354 chr15:85191438~85213905:+ LIHC cis rs12908161 0.959 rs34784022 ENSG00000259295.5 CSPG4P12 5.81 1.45e-08 8.64e-06 0.41 0.3 Schizophrenia; chr15:84688675 chr15:85191438~85213905:+ LIHC cis rs12908161 0.959 rs12908699 ENSG00000259295.5 CSPG4P12 5.81 1.45e-08 8.64e-06 0.41 0.3 Schizophrenia; chr15:84697172 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs35316992 ENSG00000259295.5 CSPG4P12 5.81 1.45e-08 8.64e-06 0.41 0.3 Schizophrenia; chr15:84704902 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs4643294 ENSG00000259295.5 CSPG4P12 5.81 1.45e-08 8.64e-06 0.41 0.3 Schizophrenia; chr15:84707022 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs62021219 ENSG00000259295.5 CSPG4P12 5.81 1.45e-08 8.64e-06 0.41 0.3 Schizophrenia; chr15:84712928 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs34900908 ENSG00000259295.5 CSPG4P12 5.81 1.45e-08 8.64e-06 0.41 0.3 Schizophrenia; chr15:84714368 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs35524990 ENSG00000259295.5 CSPG4P12 5.81 1.45e-08 8.64e-06 0.41 0.3 Schizophrenia; chr15:84714972 chr15:85191438~85213905:+ LIHC cis rs997154 0.608 rs8007089 ENSG00000279656.1 RP11-298I3.6 5.81 1.45e-08 8.64e-06 0.49 0.3 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22922704 chr14:23023083~23024217:- LIHC cis rs11673344 0.566 rs256735 ENSG00000226686.6 LINC01535 -5.81 1.45e-08 8.65e-06 -0.36 -0.3 Obesity-related traits; chr19:37375141 chr19:37251912~37265535:+ LIHC cis rs11673344 0.566 rs185369 ENSG00000226686.6 LINC01535 -5.81 1.45e-08 8.65e-06 -0.36 -0.3 Obesity-related traits; chr19:37376137 chr19:37251912~37265535:+ LIHC cis rs8059260 0.668 rs74423828 ENSG00000274038.1 RP11-66H6.4 -5.81 1.45e-08 8.66e-06 -0.52 -0.3 Alcohol consumption over the past year; chr16:10975574 chr16:11056556~11057034:+ LIHC cis rs2274273 0.773 rs8006525 ENSG00000258413.1 RP11-665C16.6 -5.81 1.45e-08 8.68e-06 -0.34 -0.3 Protein biomarker; chr14:55346676 chr14:55262767~55272075:- LIHC cis rs2274273 0.87 rs10134339 ENSG00000258413.1 RP11-665C16.6 -5.81 1.45e-08 8.68e-06 -0.34 -0.3 Protein biomarker; chr14:55347662 chr14:55262767~55272075:- LIHC cis rs2274273 0.87 rs28716725 ENSG00000258413.1 RP11-665C16.6 -5.81 1.45e-08 8.68e-06 -0.34 -0.3 Protein biomarker; chr14:55349892 chr14:55262767~55272075:- LIHC cis rs2274273 0.84 rs7159144 ENSG00000258413.1 RP11-665C16.6 -5.81 1.45e-08 8.68e-06 -0.34 -0.3 Protein biomarker; chr14:55354606 chr14:55262767~55272075:- LIHC cis rs7927592 0.913 rs7106339 ENSG00000212093.1 AP000807.1 5.81 1.46e-08 8.69e-06 0.33 0.3 Total body bone mineral density; chr11:68472773 chr11:68506083~68506166:- LIHC cis rs4934494 1 rs4934494 ENSG00000232936.4 RP11-80H5.2 5.81 1.46e-08 8.69e-06 0.37 0.3 Red blood cell count; chr10:89687662 chr10:89645282~89650667:+ LIHC cis rs2762353 0.574 rs9461204 ENSG00000242387.1 HIST1H2APS2 -5.81 1.46e-08 8.69e-06 -0.39 -0.3 Blood metabolite levels; chr6:25718238 chr6:25882026~25882395:- LIHC cis rs2153535 0.546 rs1335640 ENSG00000230939.1 RP11-314C16.1 -5.81 1.46e-08 8.71e-06 -0.36 -0.3 Motion sickness; chr6:8485092 chr6:8784178~8785445:+ LIHC cis rs72627509 1 rs72627509 ENSG00000269949.1 RP11-738E22.3 5.81 1.46e-08 8.72e-06 0.41 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56972885 chr4:56960927~56961373:- LIHC cis rs62355901 0.505 rs3733951 ENSG00000271828.1 CTD-2310F14.1 -5.81 1.46e-08 8.72e-06 -0.48 -0.3 Breast cancer; chr5:56833976 chr5:56927874~56929573:+ LIHC cis rs4660456 0.572 rs7519348 ENSG00000237899.1 RP4-739H11.3 -5.81 1.47e-08 8.74e-06 -0.37 -0.3 Platelet count; chr1:40694532 chr1:40669089~40687588:- LIHC cis rs2735413 0.563 rs117731654 ENSG00000276007.1 RP11-358L22.3 5.81 1.47e-08 8.75e-06 0.4 0.3 Systolic blood pressure (alcohol consumption interaction); chr16:78013450 chr16:78123243~78124332:+ LIHC cis rs2735413 0.563 rs72800909 ENSG00000276007.1 RP11-358L22.3 5.81 1.47e-08 8.75e-06 0.4 0.3 Systolic blood pressure (alcohol consumption interaction); chr16:78013605 chr16:78123243~78124332:+ LIHC cis rs2243480 0.764 rs2460423 ENSG00000273142.1 RP11-458F8.4 -5.8 1.47e-08 8.78e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66136229 chr7:66902857~66906297:+ LIHC cis rs7927592 0.913 rs10896330 ENSG00000212093.1 AP000807.1 5.8 1.48e-08 8.81e-06 0.33 0.3 Total body bone mineral density; chr11:68487530 chr11:68506083~68506166:- LIHC cis rs1185460 1 rs7938944 ENSG00000271751.1 RP11-110I1.14 -5.8 1.48e-08 8.81e-06 -0.4 -0.3 Coronary artery disease; chr11:119083356 chr11:119065263~119065677:- LIHC cis rs6686842 1 rs2749418 ENSG00000235358.1 RP11-399E6.1 -5.8 1.48e-08 8.82e-06 -0.33 -0.3 Height; chr1:41044002 chr1:41242373~41284861:+ LIHC cis rs3096299 0.781 rs2170839 ENSG00000274627.1 RP11-104N10.2 5.8 1.48e-08 8.82e-06 0.31 0.3 Multiple myeloma (IgH translocation); chr16:89343044 chr16:89516797~89522217:+ LIHC cis rs7945705 0.714 rs2653570 ENSG00000254860.4 TMEM9B-AS1 5.8 1.48e-08 8.84e-06 0.3 0.3 Hemoglobin concentration; chr11:8966276 chr11:8964675~8977527:+ LIHC cis rs7945705 0.747 rs2568020 ENSG00000254860.4 TMEM9B-AS1 5.8 1.48e-08 8.84e-06 0.3 0.3 Hemoglobin concentration; chr11:8973168 chr11:8964675~8977527:+ LIHC cis rs7945705 0.719 rs2012680 ENSG00000254860.4 TMEM9B-AS1 5.8 1.48e-08 8.84e-06 0.3 0.3 Hemoglobin concentration; chr11:8974512 chr11:8964675~8977527:+ LIHC cis rs6801605 1 rs6801605 ENSG00000271916.1 RP11-884K10.6 5.8 1.49e-08 8.85e-06 0.42 0.3 Blood protein levels; chr3:53842191 chr3:53797764~53798019:- LIHC cis rs2274273 0.744 rs8011808 ENSG00000258413.1 RP11-665C16.6 -5.8 1.49e-08 8.85e-06 -0.35 -0.3 Protein biomarker; chr14:55356626 chr14:55262767~55272075:- LIHC cis rs113835537 0.529 rs17065 ENSG00000255517.5 CTD-3074O7.5 -5.8 1.49e-08 8.88e-06 -0.38 -0.3 Airway imaging phenotypes; chr11:66509564 chr11:66473490~66480233:- LIHC cis rs9326248 0.53 rs7112513 ENSG00000236267.1 AP006216.5 5.8 1.49e-08 8.88e-06 0.34 0.3 Blood protein levels; chr11:117166645 chr11:116813204~116814003:- LIHC cis rs2243480 1 rs316313 ENSG00000273142.1 RP11-458F8.4 -5.8 1.49e-08 8.88e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66128561 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs316312 ENSG00000273142.1 RP11-458F8.4 -5.8 1.49e-08 8.88e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66131504 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs419603 ENSG00000273142.1 RP11-458F8.4 -5.8 1.49e-08 8.88e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66132354 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs431076 ENSG00000273142.1 RP11-458F8.4 -5.8 1.49e-08 8.88e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66135333 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs2460422 ENSG00000273142.1 RP11-458F8.4 -5.8 1.49e-08 8.88e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66136518 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs316334 ENSG00000273142.1 RP11-458F8.4 -5.8 1.49e-08 8.88e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66137139 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs316330 ENSG00000273142.1 RP11-458F8.4 -5.8 1.49e-08 8.88e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66140385 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs316326 ENSG00000273142.1 RP11-458F8.4 -5.8 1.49e-08 8.88e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66144466 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs316325 ENSG00000273142.1 RP11-458F8.4 -5.8 1.49e-08 8.88e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66144531 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs316321 ENSG00000273142.1 RP11-458F8.4 -5.8 1.49e-08 8.88e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66146626 chr7:66902857~66906297:+ LIHC cis rs645901 1 rs645901 ENSG00000254851.1 RP11-109L13.1 -5.8 1.5e-08 8.9e-06 -0.38 -0.3 Plateletcrit; chr11:116831646 chr11:117135528~117138582:+ LIHC cis rs2297363 1 rs3777411 ENSG00000213073.4 RP11-288H12.3 -5.8 1.5e-08 8.95e-06 -0.32 -0.3 Total cholesterol levels;Blood protein levels; chr6:160055913 chr6:160093082~160096212:+ LIHC cis rs34779708 0.733 rs16935945 ENSG00000230534.5 RP11-297A16.2 5.8 1.51e-08 8.95e-06 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35251392 chr10:35098006~35127020:- LIHC cis rs2153535 0.542 rs6905925 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8439797 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs6905934 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8439810 chr6:8784178~8785445:+ LIHC cis rs2153535 0.542 rs915353 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8440137 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2327050 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8440397 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs4404802 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8441819 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1932275 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8442100 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1932276 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8442360 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs915352 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8442533 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs915351 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8442560 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2327056 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8443072 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs3938660 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8443102 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs915350 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8443253 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1577467 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8444008 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1577468 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8444033 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs1855765 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8444092 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9406143 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 8.95e-06 -0.37 -0.3 Motion sickness; chr6:8444350 chr6:8784178~8785445:+ LIHC cis rs8177376 0.906 rs8177380 ENSG00000254905.1 RP11-712L6.7 -5.8 1.51e-08 8.97e-06 -0.44 -0.3 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126295671 chr11:126292922~126294254:- LIHC cis rs6142102 0.961 rs2235597 ENSG00000276073.1 RP5-1125A11.7 -5.8 1.51e-08 8.98e-06 -0.34 -0.3 Skin pigmentation; chr20:34077808 chr20:33985617~33988989:- LIHC cis rs6142102 0.886 rs4911147 ENSG00000276073.1 RP5-1125A11.7 -5.8 1.51e-08 8.98e-06 -0.34 -0.3 Skin pigmentation; chr20:34079801 chr20:33985617~33988989:- LIHC cis rs6142102 0.961 rs8123521 ENSG00000276073.1 RP5-1125A11.7 -5.8 1.51e-08 8.98e-06 -0.34 -0.3 Skin pigmentation; chr20:34081079 chr20:33985617~33988989:- LIHC cis rs7927592 0.913 rs7123564 ENSG00000212093.1 AP000807.1 5.8 1.51e-08 8.99e-06 0.33 0.3 Total body bone mineral density; chr11:68594696 chr11:68506083~68506166:- LIHC cis rs8177376 0.813 rs667627 ENSG00000254905.1 RP11-712L6.7 5.8 1.51e-08 8.99e-06 0.44 0.3 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126277802 chr11:126292922~126294254:- LIHC cis rs8177376 1 rs671492 ENSG00000254905.1 RP11-712L6.7 5.8 1.51e-08 8.99e-06 0.44 0.3 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126280025 chr11:126292922~126294254:- LIHC cis rs2439831 0.867 rs2447196 ENSG00000205771.5 CATSPER2P1 5.8 1.51e-08 8.99e-06 0.45 0.3 Lung cancer in ever smokers; chr15:43601620 chr15:43726918~43747094:- LIHC cis rs113835537 0.529 rs75683511 ENSG00000255517.5 CTD-3074O7.5 -5.8 1.51e-08 8.99e-06 -0.38 -0.3 Airway imaging phenotypes; chr11:66507555 chr11:66473490~66480233:- LIHC cis rs1729407 0.786 rs5100 ENSG00000254851.1 RP11-109L13.1 -5.8 1.51e-08 9e-06 -0.35 -0.3 Apolipoprotein A-IV levels; chr11:116821978 chr11:117135528~117138582:+ LIHC cis rs2153535 0.58 rs2184586 ENSG00000230939.1 RP11-314C16.1 -5.8 1.51e-08 9e-06 -0.36 -0.3 Motion sickness; chr6:8473949 chr6:8784178~8785445:+ LIHC cis rs9532669 0.963 rs1056835 ENSG00000176268.5 CYCSP34 5.8 1.52e-08 9.03e-06 0.33 0.3 Cervical cancer; chr13:40932585 chr13:40863599~40863902:- LIHC cis rs9341808 0.754 rs3805885 ENSG00000272129.1 RP11-250B2.6 -5.8 1.52e-08 9.03e-06 -0.29 -0.3 Sitting height ratio; chr6:80287034 chr6:80355424~80356859:+ LIHC cis rs12744310 0.666 rs34762587 ENSG00000235358.1 RP11-399E6.1 5.8 1.54e-08 9.13e-06 0.35 0.3 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41286793 chr1:41242373~41284861:+ LIHC cis rs1005277 0.522 rs289645 ENSG00000263064.2 RP11-291L22.7 5.8 1.54e-08 9.16e-06 0.31 0.3 Extrinsic epigenetic age acceleration; chr10:37654714 chr10:38448689~38448949:+ LIHC cis rs11098499 0.954 rs7436506 ENSG00000245958.5 RP11-33B1.1 -5.8 1.54e-08 9.17e-06 -0.31 -0.3 Corneal astigmatism; chr4:119472614 chr4:119454791~119552025:+ LIHC cis rs72627509 0.951 rs72606404 ENSG00000269949.1 RP11-738E22.3 5.8 1.55e-08 9.19e-06 0.4 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56975047 chr4:56960927~56961373:- LIHC cis rs2739330 0.791 rs4822458 ENSG00000099984.9 GSTT2 -5.79 1.55e-08 9.22e-06 -0.34 -0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23980123~23983911:+ LIHC cis rs2297363 1 rs1130861 ENSG00000213073.4 RP11-288H12.3 -5.79 1.56e-08 9.27e-06 -0.35 -0.3 Total cholesterol levels;Blood protein levels; chr6:160090322 chr6:160093082~160096212:+ LIHC cis rs9388451 0.874 rs9398787 ENSG00000237742.5 RP11-624M8.1 -5.79 1.56e-08 9.27e-06 -0.28 -0.3 Brugada syndrome; chr6:125769462 chr6:125578558~125749190:- LIHC cis rs2933343 0.729 rs1680780 ENSG00000231305.3 RP11-723O4.2 5.79 1.56e-08 9.27e-06 0.33 0.3 IgG glycosylation; chr3:128893816 chr3:128861313~128871540:- LIHC cis rs2933343 0.729 rs1680781 ENSG00000231305.3 RP11-723O4.2 5.79 1.56e-08 9.27e-06 0.33 0.3 IgG glycosylation; chr3:128893987 chr3:128861313~128871540:- LIHC cis rs12681287 0.64 rs12544463 ENSG00000250569.1 NTAN1P2 5.79 1.56e-08 9.27e-06 0.35 0.3 Caudate activity during reward; chr8:86468885 chr8:86481754~86483002:- LIHC cis rs8072100 0.902 rs12051716 ENSG00000228782.6 CTD-2026D20.3 -5.79 1.57e-08 9.29e-06 -0.32 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47505029 chr17:47450568~47492492:- LIHC cis rs6142102 1 rs4911412 ENSG00000276073.1 RP5-1125A11.7 -5.79 1.57e-08 9.29e-06 -0.33 -0.3 Skin pigmentation; chr20:34128629 chr20:33985617~33988989:- LIHC cis rs2243480 1 rs2462569 ENSG00000273142.1 RP11-458F8.4 5.79 1.57e-08 9.29e-06 0.36 0.3 Diabetic kidney disease; chr7:66009859 chr7:66902857~66906297:+ LIHC cis rs523522 0.892 rs4767916 ENSG00000278344.1 RP11-18C24.8 5.79 1.57e-08 9.29e-06 0.36 0.3 High light scatter reticulocyte count; chr12:120586229 chr12:120500735~120501090:- LIHC cis rs523522 0.926 rs10849766 ENSG00000278344.1 RP11-18C24.8 5.79 1.57e-08 9.29e-06 0.36 0.3 High light scatter reticulocyte count; chr12:120588091 chr12:120500735~120501090:- LIHC cis rs9532669 0.963 rs1056824 ENSG00000176268.5 CYCSP34 5.79 1.57e-08 9.3e-06 0.33 0.3 Cervical cancer; chr13:40932748 chr13:40863599~40863902:- LIHC cis rs7115242 1 rs7115242 ENSG00000236267.1 AP006216.5 -5.79 1.57e-08 9.31e-06 -0.38 -0.3 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117037567 chr11:116813204~116814003:- LIHC cis rs8059260 0.545 rs2286972 ENSG00000274038.1 RP11-66H6.4 -5.79 1.58e-08 9.36e-06 -0.49 -0.3 Alcohol consumption over the past year; chr16:11061141 chr16:11056556~11057034:+ LIHC cis rs748404 0.66 rs2602141 ENSG00000205771.5 CATSPER2P1 -5.79 1.58e-08 9.36e-06 -0.35 -0.3 Lung cancer; chr15:43432448 chr15:43726918~43747094:- LIHC cis rs11676348 0.818 rs7425447 ENSG00000261338.2 RP11-378A13.1 -5.79 1.58e-08 9.37e-06 -0.31 -0.3 Ulcerative colitis; chr2:218115460 chr2:218255319~218257366:+ LIHC cis rs11676348 0.846 rs13009946 ENSG00000261338.2 RP11-378A13.1 -5.79 1.58e-08 9.37e-06 -0.3 -0.3 Ulcerative colitis; chr2:218143029 chr2:218255319~218257366:+ LIHC cis rs8100891 0.537 rs7258196 ENSG00000267213.4 AC007773.2 -5.79 1.58e-08 9.39e-06 -0.38 -0.3 Neuroticism; chr19:32453659 chr19:32390050~32405560:- LIHC cis rs11096990 0.551 rs11724855 ENSG00000249207.1 RP11-360F5.1 -5.79 1.58e-08 9.39e-06 -0.31 -0.3 Cognitive function; chr4:39163379 chr4:39112677~39126818:- LIHC cis rs2153535 0.541 rs945304 ENSG00000230939.1 RP11-314C16.1 -5.79 1.59e-08 9.4e-06 -0.37 -0.3 Motion sickness; chr6:8442659 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1889715 ENSG00000230939.1 RP11-314C16.1 -5.79 1.59e-08 9.4e-06 -0.37 -0.3 Motion sickness; chr6:8443242 chr6:8784178~8785445:+ LIHC cis rs950027 0.967 rs2643718 ENSG00000259520.4 CTD-2651B20.3 -5.79 1.59e-08 9.42e-06 -0.36 -0.3 Response to fenofibrate (adiponectin levels); chr15:45502464 chr15:45251580~45279251:- LIHC cis rs5758511 0.573 rs1569451 ENSG00000237037.8 NDUFA6-AS1 5.79 1.59e-08 9.44e-06 0.35 0.3 Birth weight; chr22:41836287 chr22:42090931~42137742:+ LIHC cis rs9549367 0.804 rs9549704 ENSG00000269125.1 RP11-98F14.11 -5.79 1.59e-08 9.45e-06 -0.38 -0.3 Platelet distribution width; chr13:113230873 chr13:113165002~113165183:- LIHC cis rs7927592 0.956 rs6591341 ENSG00000212093.1 AP000807.1 5.79 1.6e-08 9.45e-06 0.32 0.3 Total body bone mineral density; chr11:68568010 chr11:68506083~68506166:- LIHC cis rs3096299 0.802 rs3102336 ENSG00000274627.1 RP11-104N10.2 5.79 1.6e-08 9.47e-06 0.31 0.3 Multiple myeloma (IgH translocation); chr16:89375598 chr16:89516797~89522217:+ LIHC cis rs3808502 0.527 rs2736374 ENSG00000255394.4 C8orf49 -5.79 1.6e-08 9.47e-06 -0.42 -0.3 Neuroticism; chr8:11256319 chr8:11761256~11763223:+ LIHC cis rs8059260 0.611 rs34143079 ENSG00000274038.1 RP11-66H6.4 -5.79 1.6e-08 9.48e-06 -0.51 -0.3 Alcohol consumption over the past year; chr16:11069069 chr16:11056556~11057034:+ LIHC cis rs8059260 0.541 rs7195452 ENSG00000274038.1 RP11-66H6.4 -5.79 1.6e-08 9.48e-06 -0.51 -0.3 Alcohol consumption over the past year; chr16:11069469 chr16:11056556~11057034:+ LIHC cis rs2882667 0.505 rs7721110 ENSG00000253404.1 AC034243.1 5.79 1.61e-08 9.51e-06 0.38 0.3 Age-related hearing impairment (SNP x SNP interaction); chr5:139146817 chr5:138744434~138753309:- LIHC cis rs2522056 0.808 rs2706373 ENSG00000233006.5 AC034220.3 -5.79 1.61e-08 9.51e-06 -0.31 -0.3 Fibrinogen;Lymphocyte counts; chr5:132468564 chr5:132311285~132369916:- LIHC cis rs2522056 1 rs2522062 ENSG00000233006.5 AC034220.3 -5.79 1.61e-08 9.51e-06 -0.31 -0.3 Fibrinogen;Lymphocyte counts; chr5:132469724 chr5:132311285~132369916:- LIHC cis rs2522056 1 rs2522063 ENSG00000233006.5 AC034220.3 -5.79 1.61e-08 9.51e-06 -0.31 -0.3 Fibrinogen;Lymphocyte counts; chr5:132469899 chr5:132311285~132369916:- LIHC cis rs2522056 1 rs2706379 ENSG00000233006.5 AC034220.3 -5.79 1.61e-08 9.51e-06 -0.31 -0.3 Fibrinogen;Lymphocyte counts; chr5:132470043 chr5:132311285~132369916:- LIHC cis rs150992 0.505 rs167798 ENSG00000248489.1 CTD-2007H13.3 5.79 1.61e-08 9.53e-06 0.47 0.3 Body mass index; chr5:98972150 chr5:98929171~98995013:+ LIHC cis rs150992 0.571 rs34488 ENSG00000248489.1 CTD-2007H13.3 5.79 1.61e-08 9.53e-06 0.47 0.3 Body mass index; chr5:98977773 chr5:98929171~98995013:+ LIHC cis rs35160687 0.798 rs6547674 ENSG00000273080.1 RP11-301O19.1 -5.79 1.61e-08 9.53e-06 -0.38 -0.3 Night sleep phenotypes; chr2:86325796 chr2:86195590~86196049:+ LIHC cis rs35160687 0.798 rs11127029 ENSG00000273080.1 RP11-301O19.1 -5.79 1.61e-08 9.53e-06 -0.38 -0.3 Night sleep phenotypes; chr2:86327502 chr2:86195590~86196049:+ LIHC cis rs9487094 0.666 rs13219952 ENSG00000260273.1 RP11-425D10.10 5.79 1.61e-08 9.54e-06 0.35 0.3 Height; chr6:109391084 chr6:109382795~109383666:+ LIHC cis rs2243480 1 rs313807 ENSG00000273142.1 RP11-458F8.4 -5.79 1.62e-08 9.55e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66034494 chr7:66902857~66906297:+ LIHC cis rs2243480 0.901 rs313808 ENSG00000273142.1 RP11-458F8.4 -5.79 1.62e-08 9.55e-06 -0.36 -0.3 Diabetic kidney disease; chr7:66034886 chr7:66902857~66906297:+ LIHC cis rs11098499 0.863 rs1010739 ENSG00000245958.5 RP11-33B1.1 -5.79 1.62e-08 9.56e-06 -0.32 -0.3 Corneal astigmatism; chr4:119542316 chr4:119454791~119552025:+ LIHC cis rs9341808 0.754 rs3812126 ENSG00000272129.1 RP11-250B2.6 -5.79 1.62e-08 9.56e-06 -0.29 -0.3 Sitting height ratio; chr6:80242984 chr6:80355424~80356859:+ LIHC cis rs3096299 0.679 rs3102338 ENSG00000274627.1 RP11-104N10.2 5.79 1.62e-08 9.57e-06 0.31 0.3 Multiple myeloma (IgH translocation); chr16:89375842 chr16:89516797~89522217:+ LIHC cis rs7916697 0.626 rs61854803 ENSG00000233590.1 RP11-153K11.3 -5.79 1.62e-08 9.59e-06 -0.36 -0.3 Optic disc area; chr10:68254881 chr10:68233251~68242379:- LIHC cis rs2565722 0.508 rs1620969 ENSG00000243831.1 RP1-81D8.4 -5.79 1.63e-08 9.61e-06 -0.4 -0.3 Blood protein levels; chr6:160776036 chr6:160666228~160676523:- LIHC cis rs113835537 0.529 rs2277302 ENSG00000255517.5 CTD-3074O7.5 -5.79 1.63e-08 9.61e-06 -0.33 -0.3 Airway imaging phenotypes; chr11:66473411 chr11:66473490~66480233:- LIHC cis rs9326248 0.861 rs4938343 ENSG00000236267.1 AP006216.5 5.79 1.63e-08 9.62e-06 0.31 0.3 Blood protein levels; chr11:117132812 chr11:116813204~116814003:- LIHC cis rs7396835 0.866 rs6589571 ENSG00000254851.1 RP11-109L13.1 -5.79 1.63e-08 9.63e-06 -0.48 -0.3 Quantitative traits; chr11:116809702 chr11:117135528~117138582:+ LIHC cis rs9388451 0.839 rs3799709 ENSG00000237742.5 RP11-624M8.1 -5.79 1.63e-08 9.63e-06 -0.27 -0.3 Brugada syndrome; chr6:125757215 chr6:125578558~125749190:- LIHC cis rs150992 0.72 rs469018 ENSG00000248489.1 CTD-2007H13.3 5.79 1.64e-08 9.66e-06 0.43 0.3 Body mass index; chr5:98953530 chr5:98929171~98995013:+ LIHC cis rs17301013 0.507 rs2760057 ENSG00000227373.4 RP11-160H22.5 5.79 1.64e-08 9.67e-06 0.5 0.3 Systemic lupus erythematosus; chr1:174743384 chr1:174115300~174160004:- LIHC cis rs7429990 0.965 rs2882668 ENSG00000229759.1 MRPS18AP1 5.78 1.64e-08 9.67e-06 0.32 0.3 Educational attainment (years of education); chr3:47938816 chr3:48256350~48256938:- LIHC cis rs2933343 0.621 rs789242 ENSG00000231305.3 RP11-723O4.2 5.78 1.64e-08 9.67e-06 0.33 0.3 IgG glycosylation; chr3:128866864 chr3:128861313~128871540:- LIHC cis rs1005277 0.54 rs1814077 ENSG00000263064.2 RP11-291L22.7 5.78 1.64e-08 9.69e-06 0.3 0.3 Extrinsic epigenetic age acceleration; chr10:37703090 chr10:38448689~38448949:+ LIHC cis rs9326248 0.861 rs7120309 ENSG00000236267.1 AP006216.5 5.78 1.65e-08 9.72e-06 0.31 0.3 Blood protein levels; chr11:117172100 chr11:116813204~116814003:- LIHC cis rs9326248 0.861 rs7120449 ENSG00000236267.1 AP006216.5 5.78 1.65e-08 9.72e-06 0.31 0.3 Blood protein levels; chr11:117172183 chr11:116813204~116814003:- LIHC cis rs524281 0.861 rs2177054 ENSG00000255320.1 RP11-755F10.1 5.78 1.65e-08 9.72e-06 0.39 0.3 Electroencephalogram traits; chr11:66177141 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs3953856 ENSG00000255320.1 RP11-755F10.1 5.78 1.65e-08 9.72e-06 0.39 0.3 Electroencephalogram traits; chr11:66198437 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs2889313 ENSG00000255320.1 RP11-755F10.1 5.78 1.65e-08 9.72e-06 0.39 0.3 Electroencephalogram traits; chr11:66198595 chr11:66244840~66246239:- LIHC cis rs2243480 1 rs2257790 ENSG00000273142.1 RP11-458F8.4 -5.78 1.65e-08 9.73e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66135463 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs316332 ENSG00000273142.1 RP11-458F8.4 -5.78 1.65e-08 9.73e-06 -0.37 -0.3 Diabetic kidney disease; chr7:66139312 chr7:66902857~66906297:+ LIHC cis rs17826219 0.733 rs7221691 ENSG00000263531.1 RP13-753N3.1 -5.78 1.65e-08 9.75e-06 -0.51 -0.3 Body mass index; chr17:30396601 chr17:30863921~30864940:- LIHC cis rs8059260 0.604 rs16957984 ENSG00000274038.1 RP11-66H6.4 -5.78 1.65e-08 9.75e-06 -0.5 -0.3 Alcohol consumption over the past year; chr16:11051105 chr16:11056556~11057034:+ LIHC cis rs5769707 0.681 rs9616329 ENSG00000235111.1 RP1-29C18.8 -5.78 1.66e-08 9.77e-06 -0.35 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49632666 chr22:49612657~49615716:- LIHC cis rs2243480 1 rs422164 ENSG00000164669.11 INTS4P1 5.78 1.66e-08 9.77e-06 0.51 0.3 Diabetic kidney disease; chr7:66121618 chr7:65141225~65234216:+ LIHC cis rs7927592 0.956 rs10896341 ENSG00000212093.1 AP000807.1 5.78 1.66e-08 9.79e-06 0.33 0.3 Total body bone mineral density; chr11:68545712 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs67947146 ENSG00000212093.1 AP000807.1 5.78 1.66e-08 9.79e-06 0.33 0.3 Total body bone mineral density; chr11:68547512 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs7104345 ENSG00000212093.1 AP000807.1 5.78 1.66e-08 9.79e-06 0.33 0.3 Total body bone mineral density; chr11:68549304 chr11:68506083~68506166:- LIHC cis rs7927592 0.913 rs12284933 ENSG00000212093.1 AP000807.1 5.78 1.66e-08 9.79e-06 0.33 0.3 Total body bone mineral density; chr11:68552021 chr11:68506083~68506166:- LIHC cis rs7927592 0.871 rs11228284 ENSG00000212093.1 AP000807.1 5.78 1.66e-08 9.79e-06 0.33 0.3 Total body bone mineral density; chr11:68555299 chr11:68506083~68506166:- LIHC cis rs904251 0.6 rs1874736 ENSG00000204110.6 RP1-153P14.8 -5.78 1.67e-08 9.8e-06 -0.36 -0.3 Cognitive performance; chr6:37480218 chr6:37507348~37535616:+ LIHC cis rs7927592 0.871 rs871212 ENSG00000212093.1 AP000807.1 5.78 1.67e-08 9.8e-06 0.33 0.3 Total body bone mineral density; chr11:68581227 chr11:68506083~68506166:- LIHC cis rs8177376 1 rs17656 ENSG00000254905.1 RP11-712L6.7 5.78 1.67e-08 9.84e-06 0.44 0.3 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126263287 chr11:126292922~126294254:- LIHC cis rs2836950 0.501 rs11702505 ENSG00000255568.3 BRWD1-AS2 -5.78 1.68e-08 9.87e-06 -0.25 -0.3 Menarche (age at onset); chr21:39328688 chr21:39313935~39314962:+ LIHC cis rs2836950 0.501 rs2836985 ENSG00000255568.3 BRWD1-AS2 -5.78 1.68e-08 9.87e-06 -0.25 -0.3 Menarche (age at onset); chr21:39329243 chr21:39313935~39314962:+ LIHC cis rs4356975 0.563 rs7676472 ENSG00000249956.3 RP11-790I12.2 5.78 1.68e-08 9.9e-06 0.33 0.3 Obesity-related traits; chr4:69090226 chr4:69408836~69423164:+ LIHC cis rs9487094 0.689 rs699700 ENSG00000260273.1 RP11-425D10.10 5.78 1.69e-08 9.91e-06 0.35 0.3 Height; chr6:109367528 chr6:109382795~109383666:+ LIHC cis rs9487094 0.689 rs11251 ENSG00000260273.1 RP11-425D10.10 5.78 1.69e-08 9.91e-06 0.35 0.3 Height; chr6:109368704 chr6:109382795~109383666:+ LIHC cis rs8059260 0.604 rs34215426 ENSG00000274038.1 RP11-66H6.4 -5.78 1.69e-08 9.92e-06 -0.47 -0.3 Alcohol consumption over the past year; chr16:11113614 chr16:11056556~11057034:+ LIHC cis rs6904897 0.563 rs6569976 ENSG00000232876.1 CTA-212D2.2 -5.78 1.69e-08 9.92e-06 -0.34 -0.3 Mean corpuscular volume;Mean corpuscular hemoglobin; chr6:134903615 chr6:135055033~135060550:+ LIHC cis rs2735413 0.563 rs11640933 ENSG00000276007.1 RP11-358L22.3 5.78 1.69e-08 9.93e-06 0.42 0.3 Systolic blood pressure (alcohol consumption interaction); chr16:78031710 chr16:78123243~78124332:+ LIHC cis rs7131987 0.903 rs7308125 ENSG00000257176.2 RP11-996F15.2 -5.78 1.7e-08 9.97e-06 -0.34 -0.3 QT interval; chr12:29272278 chr12:29280418~29317848:- LIHC cis rs72627509 1 rs57265257 ENSG00000269949.1 RP11-738E22.3 5.78 1.7e-08 9.97e-06 0.4 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56973114 chr4:56960927~56961373:- LIHC cis rs6589219 0.954 rs3802840 ENSG00000196167.8 COLCA1 5.78 1.7e-08 1e-05 0.33 0.3 Colorectal cancer; chr11:111300921 chr11:111290787~111305045:- LIHC cis rs11096990 0.593 rs4580660 ENSG00000249207.1 RP11-360F5.1 -5.78 1.71e-08 1e-05 -0.3 -0.3 Cognitive function; chr4:39152216 chr4:39112677~39126818:- LIHC cis rs7927592 0.956 rs12274114 ENSG00000212093.1 AP000807.1 5.78 1.71e-08 1e-05 0.33 0.3 Total body bone mineral density; chr11:68488109 chr11:68506083~68506166:- LIHC cis rs12681287 0.64 rs6471309 ENSG00000250569.1 NTAN1P2 5.78 1.71e-08 1.01e-05 0.36 0.3 Caudate activity during reward; chr8:86375531 chr8:86481754~86483002:- LIHC cis rs2882667 0.505 rs6596465 ENSG00000253404.1 AC034243.1 -5.78 1.71e-08 1.01e-05 -0.38 -0.3 Age-related hearing impairment (SNP x SNP interaction); chr5:139147337 chr5:138744434~138753309:- LIHC cis rs1062177 0.855 rs6884630 ENSG00000213433.5 RPLP1P6 -5.78 1.71e-08 1.01e-05 -0.32 -0.3 Preschool internalizing problems; chr5:151889436 chr5:151765859~151766378:- LIHC cis rs12681287 0.673 rs4464946 ENSG00000250569.1 NTAN1P2 5.78 1.72e-08 1.01e-05 0.36 0.3 Caudate activity during reward; chr8:86314030 chr8:86481754~86483002:- LIHC cis rs2882667 0.627 rs1549203 ENSG00000253404.1 AC034243.1 -5.78 1.72e-08 1.01e-05 -0.39 -0.3 Age-related hearing impairment (SNP x SNP interaction); chr5:139132655 chr5:138744434~138753309:- LIHC cis rs67180937 0.553 rs2936023 ENSG00000272750.1 RP11-378J18.8 5.78 1.72e-08 1.01e-05 0.35 0.3 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222656989 chr1:222658867~222661512:- LIHC cis rs11907546 1 rs11907546 ENSG00000276073.1 RP5-1125A11.7 -5.78 1.72e-08 1.01e-05 -0.32 -0.3 Cancer (pleiotropy);Cancer; chr20:34131991 chr20:33985617~33988989:- LIHC cis rs9341808 0.727 rs9352809 ENSG00000272129.1 RP11-250B2.6 5.78 1.72e-08 1.01e-05 0.29 0.3 Sitting height ratio; chr6:80289599 chr6:80355424~80356859:+ LIHC cis rs3812049 0.737 rs1112956 ENSG00000245937.6 LINC01184 -5.78 1.72e-08 1.01e-05 -0.38 -0.3 Lymphocyte counts;Red cell distribution width; chr5:128098106 chr5:127940426~128083172:- LIHC cis rs7927592 0.763 rs3740628 ENSG00000212093.1 AP000807.1 5.78 1.72e-08 1.01e-05 0.3 0.3 Total body bone mineral density; chr11:68613947 chr11:68506083~68506166:- LIHC cis rs7927592 0.956 rs12365160 ENSG00000212093.1 AP000807.1 5.78 1.72e-08 1.01e-05 0.33 0.3 Total body bone mineral density; chr11:68482951 chr11:68506083~68506166:- LIHC cis rs7927592 0.956 rs11228256 ENSG00000212093.1 AP000807.1 5.78 1.72e-08 1.01e-05 0.33 0.3 Total body bone mineral density; chr11:68483992 chr11:68506083~68506166:- LIHC cis rs11722779 0.903 rs13130741 ENSG00000246560.2 RP11-10L12.4 5.78 1.73e-08 1.01e-05 0.34 0.3 Schizophrenia; chr4:103035799 chr4:102828055~102844075:+ LIHC cis rs7688540 0.771 rs61792116 ENSG00000275426.1 CH17-262A2.1 5.78 1.73e-08 1.01e-05 0.42 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:307288 chr4:149738~150317:+ LIHC cis rs8059260 0.604 rs76969865 ENSG00000274038.1 RP11-66H6.4 -5.78 1.73e-08 1.01e-05 -0.49 -0.3 Alcohol consumption over the past year; chr16:11050092 chr16:11056556~11057034:+ LIHC cis rs2243480 1 rs4718333 ENSG00000226824.5 RP4-756H11.3 5.78 1.73e-08 1.01e-05 0.48 0.3 Diabetic kidney disease; chr7:66307771 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs7792391 ENSG00000226824.5 RP4-756H11.3 5.78 1.73e-08 1.01e-05 0.48 0.3 Diabetic kidney disease; chr7:66308442 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs10247526 ENSG00000226824.5 RP4-756H11.3 5.78 1.73e-08 1.01e-05 0.48 0.3 Diabetic kidney disease; chr7:66315709 chr7:66654538~66669855:+ LIHC cis rs2243480 0.908 rs1532573 ENSG00000226824.5 RP4-756H11.3 5.78 1.73e-08 1.01e-05 0.48 0.3 Diabetic kidney disease; chr7:66333815 chr7:66654538~66669855:+ LIHC cis rs8040855 0.93 rs6496767 ENSG00000259295.5 CSPG4P12 -5.78 1.73e-08 1.01e-05 -0.43 -0.3 Bulimia nervosa; chr15:85159522 chr15:85191438~85213905:+ LIHC cis rs9487094 0.666 rs3757235 ENSG00000260273.1 RP11-425D10.10 5.77 1.73e-08 1.01e-05 0.35 0.3 Height; chr6:109390638 chr6:109382795~109383666:+ LIHC cis rs1577917 0.959 rs2816822 ENSG00000234155.1 RP11-30P6.6 5.77 1.73e-08 1.01e-05 0.36 0.3 Response to antipsychotic treatment; chr6:85948574 chr6:85387219~85390186:- LIHC cis rs150992 0.632 rs1472622 ENSG00000248489.1 CTD-2007H13.3 -5.77 1.73e-08 1.01e-05 -0.44 -0.3 Body mass index; chr5:99000749 chr5:98929171~98995013:+ LIHC cis rs7688540 0.771 rs6599318 ENSG00000275426.1 CH17-262A2.1 5.77 1.74e-08 1.02e-05 0.41 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:250179 chr4:149738~150317:+ LIHC cis rs2739330 0.76 rs5751760 ENSG00000206090.4 AP000350.7 5.77 1.74e-08 1.02e-05 0.36 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23939998~23942798:+ LIHC cis rs6589219 0.954 rs4520624 ENSG00000196167.8 COLCA1 -5.77 1.74e-08 1.02e-05 -0.34 -0.3 Colorectal cancer; chr11:111301485 chr11:111290787~111305045:- LIHC cis rs11690935 0.959 rs7562356 ENSG00000228389.1 AC068039.4 5.77 1.74e-08 1.02e-05 0.39 0.3 Schizophrenia; chr2:171770101 chr2:171773482~171775844:+ LIHC cis rs10875746 0.669 rs10875792 ENSG00000240399.1 RP1-228P16.1 -5.77 1.74e-08 1.02e-05 -0.32 -0.3 Longevity (90 years and older); chr12:48303640 chr12:48054813~48055591:- LIHC cis rs10875746 0.623 rs10875793 ENSG00000240399.1 RP1-228P16.1 -5.77 1.74e-08 1.02e-05 -0.32 -0.3 Longevity (90 years and older); chr12:48303647 chr12:48054813~48055591:- LIHC cis rs524281 0.861 rs6591207 ENSG00000255320.1 RP11-755F10.1 5.77 1.75e-08 1.02e-05 0.39 0.3 Electroencephalogram traits; chr11:66182203 chr11:66244840~66246239:- LIHC cis rs739496 0.843 rs598711 ENSG00000226469.1 ADAM1B 5.77 1.75e-08 1.03e-05 0.37 0.3 Platelet count; chr12:111535336 chr12:111927018~111929017:+ LIHC cis rs739496 0.843 rs598710 ENSG00000226469.1 ADAM1B 5.77 1.75e-08 1.03e-05 0.37 0.3 Platelet count; chr12:111535337 chr12:111927018~111929017:+ LIHC cis rs10833905 0.641 rs11026854 ENSG00000246225.5 RP11-17A1.3 -5.77 1.75e-08 1.03e-05 -0.39 -0.3 Sudden cardiac arrest; chr11:22940325 chr11:22829380~22945393:+ LIHC cis rs748404 0.66 rs689767 ENSG00000205771.5 CATSPER2P1 -5.77 1.76e-08 1.03e-05 -0.35 -0.3 Lung cancer; chr15:43429879 chr15:43726918~43747094:- LIHC cis rs748404 0.66 rs2439845 ENSG00000205771.5 CATSPER2P1 -5.77 1.76e-08 1.03e-05 -0.35 -0.3 Lung cancer; chr15:43430412 chr15:43726918~43747094:- LIHC cis rs748404 0.631 rs2467745 ENSG00000205771.5 CATSPER2P1 -5.77 1.76e-08 1.03e-05 -0.35 -0.3 Lung cancer; chr15:43430544 chr15:43726918~43747094:- LIHC cis rs748404 0.66 rs2439846 ENSG00000205771.5 CATSPER2P1 -5.77 1.76e-08 1.03e-05 -0.35 -0.3 Lung cancer; chr15:43448772 chr15:43726918~43747094:- LIHC cis rs748404 0.66 rs2467741 ENSG00000205771.5 CATSPER2P1 -5.77 1.76e-08 1.03e-05 -0.35 -0.3 Lung cancer; chr15:43450428 chr15:43726918~43747094:- LIHC cis rs8028182 0.636 rs4886716 ENSG00000260269.4 CTD-2323K18.1 -5.77 1.76e-08 1.03e-05 -0.39 -0.3 Sudden cardiac arrest; chr15:75563681 chr15:75527150~75601205:- LIHC cis rs10875746 0.624 rs7297298 ENSG00000240399.1 RP1-228P16.1 -5.77 1.76e-08 1.03e-05 -0.32 -0.3 Longevity (90 years and older); chr12:48278523 chr12:48054813~48055591:- LIHC cis rs748404 0.69 rs2924369 ENSG00000205771.5 CATSPER2P1 5.77 1.76e-08 1.03e-05 0.36 0.3 Lung cancer; chr15:43485787 chr15:43726918~43747094:- LIHC cis rs748404 0.69 rs1079309 ENSG00000205771.5 CATSPER2P1 -5.77 1.76e-08 1.03e-05 -0.36 -0.3 Lung cancer; chr15:43490966 chr15:43726918~43747094:- LIHC cis rs67311347 1 rs6801859 ENSG00000223797.4 ENTPD3-AS1 -5.77 1.76e-08 1.03e-05 -0.23 -0.3 Renal cell carcinoma; chr3:40451727 chr3:40313802~40453329:- LIHC cis rs8100891 0.537 rs58591218 ENSG00000267213.4 AC007773.2 -5.77 1.76e-08 1.03e-05 -0.4 -0.3 Neuroticism; chr19:32399876 chr19:32390050~32405560:- LIHC cis rs9487094 0.778 rs13214717 ENSG00000260273.1 RP11-425D10.10 5.77 1.76e-08 1.03e-05 0.43 0.3 Height; chr6:109573151 chr6:109382795~109383666:+ LIHC cis rs2153535 0.58 rs4960411 ENSG00000230939.1 RP11-314C16.1 -5.77 1.77e-08 1.03e-05 -0.37 -0.3 Motion sickness; chr6:8437998 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs4960412 ENSG00000230939.1 RP11-314C16.1 -5.77 1.77e-08 1.03e-05 -0.37 -0.3 Motion sickness; chr6:8438028 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs4960413 ENSG00000230939.1 RP11-314C16.1 -5.77 1.77e-08 1.03e-05 -0.37 -0.3 Motion sickness; chr6:8438233 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs4960414 ENSG00000230939.1 RP11-314C16.1 -5.77 1.77e-08 1.03e-05 -0.37 -0.3 Motion sickness; chr6:8438308 chr6:8784178~8785445:+ LIHC cis rs2153535 0.542 rs9393012 ENSG00000230939.1 RP11-314C16.1 -5.77 1.77e-08 1.03e-05 -0.37 -0.3 Motion sickness; chr6:8439576 chr6:8784178~8785445:+ LIHC cis rs11098499 1 rs1011054 ENSG00000260091.1 RP11-33B1.4 5.77 1.77e-08 1.04e-05 0.22 0.3 Corneal astigmatism; chr4:119281232 chr4:119409333~119410233:+ LIHC cis rs1185460 1 rs1799993 ENSG00000271751.1 RP11-110I1.14 5.77 1.78e-08 1.04e-05 0.4 0.3 Coronary artery disease; chr11:119087417 chr11:119065263~119065677:- LIHC cis rs12681287 0.547 rs6471360 ENSG00000250569.1 NTAN1P2 -5.77 1.78e-08 1.04e-05 -0.36 -0.3 Caudate activity during reward; chr8:86501240 chr8:86481754~86483002:- LIHC cis rs12458462 0.787 rs56006341 ENSG00000274828.1 RP11-567M16.6 5.77 1.78e-08 1.04e-05 0.3 0.3 Monocyte count; chr18:79679844 chr18:79677287~79679358:- LIHC cis rs12458462 0.851 rs3859317 ENSG00000274828.1 RP11-567M16.6 5.77 1.78e-08 1.04e-05 0.3 0.3 Monocyte count; chr18:79683093 chr18:79677287~79679358:- LIHC cis rs4356975 0.563 rs7685151 ENSG00000249956.3 RP11-790I12.2 5.77 1.78e-08 1.04e-05 0.33 0.3 Obesity-related traits; chr4:69114055 chr4:69408836~69423164:+ LIHC cis rs524281 0.861 rs10791855 ENSG00000255320.1 RP11-755F10.1 5.77 1.78e-08 1.04e-05 0.39 0.3 Electroencephalogram traits; chr11:66196266 chr11:66244840~66246239:- LIHC cis rs2933343 0.649 rs789219 ENSG00000231305.3 RP11-723O4.2 5.77 1.78e-08 1.04e-05 0.33 0.3 IgG glycosylation; chr3:128873677 chr3:128861313~128871540:- LIHC cis rs3096299 0.781 rs3102381 ENSG00000274627.1 RP11-104N10.2 5.77 1.79e-08 1.04e-05 0.31 0.3 Multiple myeloma (IgH translocation); chr16:89343312 chr16:89516797~89522217:+ LIHC cis rs10256972 0.685 rs10263665 ENSG00000229043.2 AC091729.9 -5.77 1.79e-08 1.04e-05 -0.34 -0.3 Endometriosis;Longevity; chr7:1070992 chr7:1160374~1165267:+ LIHC cis rs7927592 0.913 rs12363722 ENSG00000212093.1 AP000807.1 5.77 1.79e-08 1.05e-05 0.33 0.3 Total body bone mineral density; chr11:68468823 chr11:68506083~68506166:- LIHC cis rs7927592 0.871 rs12360903 ENSG00000212093.1 AP000807.1 5.77 1.79e-08 1.05e-05 0.33 0.3 Total body bone mineral density; chr11:68468846 chr11:68506083~68506166:- LIHC cis rs7688540 0.771 rs61795001 ENSG00000275426.1 CH17-262A2.1 5.77 1.79e-08 1.05e-05 0.41 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:248268 chr4:149738~150317:+ LIHC cis rs6822297 0.542 rs35499018 ENSG00000240005.4 RP11-293A21.1 -5.77 1.8e-08 1.05e-05 -0.35 -0.3 Obesity-related traits; chr4:27004489 chr4:26859806~26860599:- LIHC cis rs2998286 0.862 rs2807728 ENSG00000254635.4 WAC-AS1 5.77 1.8e-08 1.05e-05 0.36 0.3 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28526504 chr10:28522652~28532743:- LIHC cis rs7617773 0.78 rs34523942 ENSG00000229759.1 MRPS18AP1 5.77 1.8e-08 1.05e-05 0.36 0.3 Coronary artery disease; chr3:48301179 chr3:48256350~48256938:- LIHC cis rs524281 0.861 rs7946917 ENSG00000255320.1 RP11-755F10.1 5.77 1.8e-08 1.05e-05 0.39 0.3 Electroencephalogram traits; chr11:66189106 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs10791854 ENSG00000255320.1 RP11-755F10.1 5.77 1.8e-08 1.05e-05 0.39 0.3 Electroencephalogram traits; chr11:66196072 chr11:66244840~66246239:- LIHC cis rs10875746 0.669 rs61940962 ENSG00000240399.1 RP1-228P16.1 -5.77 1.8e-08 1.05e-05 -0.33 -0.3 Longevity (90 years and older); chr12:48201694 chr12:48054813~48055591:- LIHC cis rs34779708 0.706 rs36027395 ENSG00000230534.5 RP11-297A16.2 5.77 1.8e-08 1.05e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35261395 chr10:35098006~35127020:- LIHC cis rs9326248 0.53 rs1242229 ENSG00000280143.1 AP000892.6 5.77 1.8e-08 1.05e-05 0.38 0.3 Blood protein levels; chr11:117191654 chr11:117204967~117210292:+ LIHC cis rs11098499 0.954 rs17005535 ENSG00000245958.5 RP11-33B1.1 -5.77 1.81e-08 1.05e-05 -0.31 -0.3 Corneal astigmatism; chr4:119490407 chr4:119454791~119552025:+ LIHC cis rs7115242 0.8 rs7131536 ENSG00000236267.1 AP006216.5 5.77 1.81e-08 1.05e-05 0.33 0.3 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117128730 chr11:116813204~116814003:- LIHC cis rs9487094 0.666 rs2277113 ENSG00000260273.1 RP11-425D10.10 5.77 1.81e-08 1.05e-05 0.34 0.3 Height; chr6:109454233 chr6:109382795~109383666:+ LIHC cis rs2933343 0.601 rs1680759 ENSG00000231305.3 RP11-723O4.2 5.77 1.81e-08 1.05e-05 0.33 0.3 IgG glycosylation; chr3:128876053 chr3:128861313~128871540:- LIHC cis rs2933343 0.601 rs1680758 ENSG00000231305.3 RP11-723O4.2 5.77 1.81e-08 1.05e-05 0.33 0.3 IgG glycosylation; chr3:128876054 chr3:128861313~128871540:- LIHC cis rs2933343 0.649 rs789214 ENSG00000231305.3 RP11-723O4.2 5.77 1.81e-08 1.05e-05 0.33 0.3 IgG glycosylation; chr3:128876152 chr3:128861313~128871540:- LIHC cis rs2933343 0.729 rs789224 ENSG00000231305.3 RP11-723O4.2 5.77 1.81e-08 1.05e-05 0.33 0.3 IgG glycosylation; chr3:128879388 chr3:128861313~128871540:- LIHC cis rs2933343 0.761 rs789225 ENSG00000231305.3 RP11-723O4.2 5.77 1.81e-08 1.05e-05 0.33 0.3 IgG glycosylation; chr3:128881386 chr3:128861313~128871540:- LIHC cis rs8072100 0.967 rs8072644 ENSG00000228782.6 CTD-2026D20.3 -5.77 1.81e-08 1.06e-05 -0.32 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47575998 chr17:47450568~47492492:- LIHC cis rs8177376 0.861 rs604255 ENSG00000254905.1 RP11-712L6.7 5.77 1.82e-08 1.06e-05 0.47 0.3 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126327131 chr11:126292922~126294254:- LIHC cis rs4356975 0.563 rs4508963 ENSG00000249956.3 RP11-790I12.2 5.77 1.82e-08 1.06e-05 0.34 0.3 Obesity-related traits; chr4:69118770 chr4:69408836~69423164:+ LIHC cis rs8059260 0.604 rs12929596 ENSG00000274038.1 RP11-66H6.4 -5.77 1.82e-08 1.06e-05 -0.49 -0.3 Alcohol consumption over the past year; chr16:11105495 chr16:11056556~11057034:+ LIHC cis rs11690935 1 rs312924 ENSG00000228389.1 AC068039.4 -5.77 1.82e-08 1.06e-05 -0.38 -0.3 Schizophrenia; chr2:171707511 chr2:171773482~171775844:+ LIHC cis rs2735413 0.564 rs73580867 ENSG00000276007.1 RP11-358L22.3 5.77 1.82e-08 1.06e-05 0.4 0.3 Systolic blood pressure (alcohol consumption interaction); chr16:78087056 chr16:78123243~78124332:+ LIHC cis rs2735413 0.564 rs8051817 ENSG00000276007.1 RP11-358L22.3 5.77 1.82e-08 1.06e-05 0.4 0.3 Systolic blood pressure (alcohol consumption interaction); chr16:78087357 chr16:78123243~78124332:+ LIHC cis rs13068223 0.503 rs34277251 ENSG00000243926.1 TIPARP-AS1 5.77 1.82e-08 1.06e-05 0.28 0.3 Age-related hearing impairment (SNP x SNP interaction); chr3:156703736 chr3:156671862~156674378:- LIHC cis rs1003645 0.861 rs7222703 ENSG00000275944.1 RP11-104J23.1 5.77 1.82e-08 1.06e-05 0.32 0.3 Blood protein levels; chr17:36014155 chr17:36001419~36011618:+ LIHC cis rs1003645 0.906 rs8065543 ENSG00000275944.1 RP11-104J23.1 5.77 1.82e-08 1.06e-05 0.32 0.3 Blood protein levels; chr17:36014962 chr17:36001419~36011618:+ LIHC cis rs12908161 1 rs12911736 ENSG00000259295.5 CSPG4P12 5.76 1.83e-08 1.07e-05 0.41 0.3 Schizophrenia; chr15:84696777 chr15:85191438~85213905:+ LIHC cis rs6589219 1 rs6589220 ENSG00000196167.8 COLCA1 -5.76 1.83e-08 1.07e-05 -0.34 -0.3 Colorectal cancer; chr11:111302565 chr11:111290787~111305045:- LIHC cis rs2980439 0.846 rs2980437 ENSG00000253893.2 FAM85B 5.76 1.83e-08 1.07e-05 0.34 0.3 Neuroticism; chr8:8237241 chr8:8167819~8226614:- LIHC cis rs2283792 1 rs5999521 ENSG00000224086.5 LL22NC03-86G7.1 -5.76 1.83e-08 1.07e-05 -0.27 -0.3 Multiple sclerosis; chr22:21792110 chr22:21938293~21977632:+ LIHC cis rs9389248 0.69 rs1028314 ENSG00000232876.1 CTA-212D2.2 5.76 1.84e-08 1.07e-05 0.35 0.3 High light scatter reticulocyte percentage of red cells; chr6:134934572 chr6:135055033~135060550:+ LIHC cis rs2842992 0.872 rs9456440 ENSG00000237927.1 RP3-393E18.2 -5.76 1.84e-08 1.07e-05 -0.37 -0.3 Age-related macular degeneration (geographic atrophy); chr6:159653431 chr6:159586955~159589169:- LIHC cis rs2842992 0.915 rs2758350 ENSG00000237927.1 RP3-393E18.2 -5.76 1.85e-08 1.08e-05 -0.37 -0.3 Age-related macular degeneration (geographic atrophy); chr6:159697024 chr6:159586955~159589169:- LIHC cis rs11098499 0.954 rs13107475 ENSG00000245958.5 RP11-33B1.1 -5.76 1.85e-08 1.08e-05 -0.31 -0.3 Corneal astigmatism; chr4:119471856 chr4:119454791~119552025:+ LIHC cis rs17711722 0.565 rs73372653 ENSG00000228409.4 CCT6P1 -5.76 1.85e-08 1.08e-05 -0.24 -0.3 Calcium levels; chr7:65977808 chr7:65751142~65763354:+ LIHC cis rs9326248 0.53 rs6589576 ENSG00000236267.1 AP006216.5 -5.76 1.85e-08 1.08e-05 -0.33 -0.3 Blood protein levels; chr11:116865072 chr11:116813204~116814003:- LIHC cis rs34779708 0.733 rs12777960 ENSG00000230534.5 RP11-297A16.2 5.76 1.85e-08 1.08e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35252098 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs60553075 ENSG00000230534.5 RP11-297A16.2 5.76 1.85e-08 1.08e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35253534 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs12240638 ENSG00000230534.5 RP11-297A16.2 5.76 1.85e-08 1.08e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35253682 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs61449529 ENSG00000230534.5 RP11-297A16.2 5.76 1.85e-08 1.08e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35254986 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs59287215 ENSG00000230534.5 RP11-297A16.2 5.76 1.85e-08 1.08e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35255066 chr10:35098006~35127020:- LIHC cis rs34779708 0.702 rs35969476 ENSG00000230534.5 RP11-297A16.2 5.76 1.85e-08 1.08e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35255390 chr10:35098006~35127020:- LIHC cis rs4356975 0.583 rs11936822 ENSG00000249956.3 RP11-790I12.2 5.76 1.86e-08 1.08e-05 0.33 0.3 Obesity-related traits; chr4:69114229 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs34814736 ENSG00000249956.3 RP11-790I12.2 5.76 1.86e-08 1.08e-05 0.33 0.3 Obesity-related traits; chr4:69114760 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs11933459 ENSG00000249956.3 RP11-790I12.2 5.76 1.86e-08 1.08e-05 0.33 0.3 Obesity-related traits; chr4:69116045 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs6600895 ENSG00000249956.3 RP11-790I12.2 5.76 1.86e-08 1.08e-05 0.33 0.3 Obesity-related traits; chr4:69117694 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs12505466 ENSG00000249956.3 RP11-790I12.2 5.76 1.86e-08 1.08e-05 0.33 0.3 Obesity-related traits; chr4:69119944 chr4:69408836~69423164:+ LIHC cis rs7429990 0.932 rs6803741 ENSG00000229759.1 MRPS18AP1 -5.76 1.86e-08 1.08e-05 -0.33 -0.3 Educational attainment (years of education); chr3:48082050 chr3:48256350~48256938:- LIHC cis rs739496 0.843 rs10774629 ENSG00000226469.1 ADAM1B -5.76 1.86e-08 1.08e-05 -0.37 -0.3 Platelet count; chr12:111582410 chr12:111927018~111929017:+ LIHC cis rs1577917 0.804 rs2786854 ENSG00000234155.1 RP11-30P6.6 5.76 1.86e-08 1.08e-05 0.36 0.3 Response to antipsychotic treatment; chr6:85959022 chr6:85387219~85390186:- LIHC cis rs8059260 0.604 rs34573672 ENSG00000274038.1 RP11-66H6.4 -5.76 1.87e-08 1.09e-05 -0.49 -0.3 Alcohol consumption over the past year; chr16:11111882 chr16:11056556~11057034:+ LIHC cis rs2153535 0.58 rs4140586 ENSG00000230939.1 RP11-314C16.1 -5.76 1.88e-08 1.09e-05 -0.36 -0.3 Motion sickness; chr6:8502959 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs4140585 ENSG00000230939.1 RP11-314C16.1 -5.76 1.88e-08 1.09e-05 -0.36 -0.3 Motion sickness; chr6:8503065 chr6:8784178~8785445:+ LIHC cis rs2933343 0.7 rs789233 ENSG00000231305.3 RP11-723O4.2 5.76 1.88e-08 1.09e-05 0.33 0.3 IgG glycosylation; chr3:128884307 chr3:128861313~128871540:- LIHC cis rs35160687 0.798 rs2367233 ENSG00000273080.1 RP11-301O19.1 -5.76 1.89e-08 1.1e-05 -0.38 -0.3 Night sleep phenotypes; chr2:86314543 chr2:86195590~86196049:+ LIHC cis rs17301013 0.861 rs2038025 ENSG00000227373.4 RP11-160H22.5 5.76 1.89e-08 1.1e-05 0.38 0.3 Systemic lupus erythematosus; chr1:174574712 chr1:174115300~174160004:- LIHC cis rs4423214 0.592 rs78300366 ENSG00000254682.1 RP11-660L16.2 -5.76 1.89e-08 1.1e-05 -0.42 -0.3 Vitamin D levels; chr11:71494468 chr11:71448674~71452157:+ LIHC cis rs2739330 0.76 rs5760095 ENSG00000206090.4 AP000350.7 5.76 1.89e-08 1.1e-05 0.35 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23939998~23942798:+ LIHC cis rs1185460 0.546 rs549893 ENSG00000271751.1 RP11-110I1.14 5.76 1.89e-08 1.1e-05 0.38 0.3 Coronary artery disease; chr11:119089022 chr11:119065263~119065677:- LIHC cis rs5769765 0.646 rs9627789 ENSG00000278869.1 CITF22-49E9.3 5.76 1.9e-08 1.1e-05 0.47 0.3 Schizophrenia; chr22:49906914 chr22:49933198~49934074:- LIHC cis rs11098499 0.954 rs10006525 ENSG00000245958.5 RP11-33B1.1 -5.76 1.9e-08 1.1e-05 -0.31 -0.3 Corneal astigmatism; chr4:119487776 chr4:119454791~119552025:+ LIHC cis rs5769707 0.632 rs135872 ENSG00000235111.1 RP1-29C18.8 -5.76 1.9e-08 1.1e-05 -0.36 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49615652 chr22:49612657~49615716:- LIHC cis rs6589219 0.908 rs10789822 ENSG00000196167.8 COLCA1 -5.76 1.9e-08 1.1e-05 -0.33 -0.3 Colorectal cancer; chr11:111291966 chr11:111290787~111305045:- LIHC cis rs2283792 1 rs13943 ENSG00000224086.5 LL22NC03-86G7.1 -5.76 1.9e-08 1.1e-05 -0.27 -0.3 Multiple sclerosis; chr22:21761913 chr22:21938293~21977632:+ LIHC cis rs5769707 0.681 rs916360 ENSG00000235111.1 RP1-29C18.8 -5.76 1.91e-08 1.11e-05 -0.36 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49648324 chr22:49612657~49615716:- LIHC cis rs6142102 0.778 rs6059581 ENSG00000276073.1 RP5-1125A11.7 -5.76 1.91e-08 1.11e-05 -0.33 -0.3 Skin pigmentation; chr20:33940582 chr20:33985617~33988989:- LIHC cis rs62355900 0.627 rs72758096 ENSG00000271828.1 CTD-2310F14.1 5.76 1.92e-08 1.11e-05 0.47 0.3 Endometriosis; chr5:56870367 chr5:56927874~56929573:+ LIHC cis rs9388451 0.874 rs1159974 ENSG00000237742.5 RP11-624M8.1 5.76 1.92e-08 1.11e-05 0.27 0.3 Brugada syndrome; chr6:125769131 chr6:125578558~125749190:- LIHC cis rs2933343 0.621 rs6764682 ENSG00000231305.3 RP11-723O4.2 -5.76 1.92e-08 1.11e-05 -0.33 -0.3 IgG glycosylation; chr3:128849540 chr3:128861313~128871540:- LIHC cis rs72627509 0.951 rs17087335 ENSG00000269949.1 RP11-738E22.3 5.76 1.92e-08 1.11e-05 0.39 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56972417 chr4:56960927~56961373:- LIHC cis rs1029738 0.659 rs1608553 ENSG00000228649.7 AC005682.5 5.76 1.92e-08 1.11e-05 0.35 0.3 Fibrinogen levels; chr7:22856612 chr7:22854178~22861579:+ LIHC cis rs8059260 0.668 rs16957894 ENSG00000274038.1 RP11-66H6.4 -5.75 1.93e-08 1.12e-05 -0.5 -0.3 Alcohol consumption over the past year; chr16:10996501 chr16:11056556~11057034:+ LIHC cis rs34779708 0.766 rs35308730 ENSG00000230534.5 RP11-297A16.2 5.75 1.93e-08 1.12e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35260868 chr10:35098006~35127020:- LIHC cis rs34779708 0.736 rs34195979 ENSG00000230534.5 RP11-297A16.2 5.75 1.93e-08 1.12e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35260889 chr10:35098006~35127020:- LIHC cis rs34779708 0.649 rs34421369 ENSG00000230534.5 RP11-297A16.2 5.75 1.93e-08 1.12e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35261347 chr10:35098006~35127020:- LIHC cis rs34779708 0.677 rs112355105 ENSG00000230534.5 RP11-297A16.2 5.75 1.93e-08 1.12e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35261366 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs12254018 ENSG00000230534.5 RP11-297A16.2 5.75 1.93e-08 1.12e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35261713 chr10:35098006~35127020:- LIHC cis rs113835537 0.529 rs12099041 ENSG00000255517.5 CTD-3074O7.5 -5.75 1.94e-08 1.12e-05 -0.33 -0.3 Airway imaging phenotypes; chr11:66465302 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs7928882 ENSG00000255517.5 CTD-3074O7.5 -5.75 1.94e-08 1.12e-05 -0.33 -0.3 Airway imaging phenotypes; chr11:66467294 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs57691879 ENSG00000255517.5 CTD-3074O7.5 -5.75 1.94e-08 1.12e-05 -0.33 -0.3 Airway imaging phenotypes; chr11:66469133 chr11:66473490~66480233:- LIHC cis rs7824557 0.564 rs13260727 ENSG00000255394.4 C8orf49 5.75 1.94e-08 1.12e-05 0.42 0.3 Retinal vascular caliber; chr8:11375351 chr8:11761256~11763223:+ LIHC cis rs34779708 0.931 rs17582416 ENSG00000230534.5 RP11-297A16.2 5.75 1.94e-08 1.12e-05 0.38 0.3 Inflammatory bowel disease;Crohn's disease; chr10:34998722 chr10:35098006~35127020:- LIHC cis rs12291225 0.585 rs10832246 ENSG00000251991.1 RNU7-49P 5.75 1.94e-08 1.12e-05 0.31 0.3 Sense of smell; chr11:14359282 chr11:14478892~14478953:+ LIHC cis rs12291225 0.585 rs11023197 ENSG00000251991.1 RNU7-49P 5.75 1.94e-08 1.12e-05 0.31 0.3 Sense of smell; chr11:14359452 chr11:14478892~14478953:+ LIHC cis rs7617773 0.709 rs4404473 ENSG00000229759.1 MRPS18AP1 5.75 1.94e-08 1.12e-05 0.37 0.3 Coronary artery disease; chr3:48312136 chr3:48256350~48256938:- LIHC cis rs1577917 0.92 rs1337842 ENSG00000234155.1 RP11-30P6.6 5.75 1.95e-08 1.13e-05 0.36 0.3 Response to antipsychotic treatment; chr6:85965379 chr6:85387219~85390186:- LIHC cis rs6142102 0.961 rs2268088 ENSG00000276073.1 RP5-1125A11.7 -5.75 1.95e-08 1.13e-05 -0.33 -0.3 Skin pigmentation; chr20:34061258 chr20:33985617~33988989:- LIHC cis rs6142102 0.961 rs2284388 ENSG00000276073.1 RP5-1125A11.7 -5.75 1.95e-08 1.13e-05 -0.33 -0.3 Skin pigmentation; chr20:34067935 chr20:33985617~33988989:- LIHC cis rs2455601 1 rs2455601 ENSG00000254860.4 TMEM9B-AS1 5.75 1.95e-08 1.13e-05 0.37 0.3 Schizophrenia; chr11:8877853 chr11:8964675~8977527:+ LIHC cis rs2243480 1 rs316322 ENSG00000273142.1 RP11-458F8.4 -5.75 1.95e-08 1.13e-05 -0.37 -0.3 Diabetic kidney disease; chr7:66146246 chr7:66902857~66906297:+ LIHC cis rs7927592 0.956 rs10896348 ENSG00000212093.1 AP000807.1 5.75 1.96e-08 1.14e-05 0.32 0.3 Total body bone mineral density; chr11:68589900 chr11:68506083~68506166:- LIHC cis rs2998286 0.862 rs2807740 ENSG00000254635.4 WAC-AS1 -5.75 1.97e-08 1.14e-05 -0.36 -0.3 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28495554 chr10:28522652~28532743:- LIHC cis rs2998286 0.862 rs2807738 ENSG00000254635.4 WAC-AS1 -5.75 1.97e-08 1.14e-05 -0.36 -0.3 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28496479 chr10:28522652~28532743:- LIHC cis rs2153535 0.58 rs7341381 ENSG00000230939.1 RP11-314C16.1 -5.75 1.97e-08 1.14e-05 -0.36 -0.3 Motion sickness; chr6:8470304 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1414344 ENSG00000230939.1 RP11-314C16.1 -5.75 1.97e-08 1.14e-05 -0.36 -0.3 Motion sickness; chr6:8471132 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2152348 ENSG00000230939.1 RP11-314C16.1 -5.75 1.97e-08 1.14e-05 -0.36 -0.3 Motion sickness; chr6:8474068 chr6:8784178~8785445:+ LIHC cis rs9326248 0.813 rs7115562 ENSG00000236267.1 AP006216.5 5.75 1.97e-08 1.14e-05 0.31 0.3 Blood protein levels; chr11:117149754 chr11:116813204~116814003:- LIHC cis rs150992 0.609 rs451141 ENSG00000248489.1 CTD-2007H13.3 -5.75 1.98e-08 1.14e-05 -0.43 -0.3 Body mass index; chr5:98991691 chr5:98929171~98995013:+ LIHC cis rs2439831 0.618 rs8023508 ENSG00000205771.5 CATSPER2P1 5.75 1.99e-08 1.15e-05 0.43 0.3 Lung cancer in ever smokers; chr15:43883905 chr15:43726918~43747094:- LIHC cis rs2998286 0.784 rs2993987 ENSG00000254635.4 WAC-AS1 -5.75 1.99e-08 1.15e-05 -0.37 -0.3 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28511241 chr10:28522652~28532743:- LIHC cis rs12681287 0.517 rs13249753 ENSG00000250569.1 NTAN1P2 5.75 1.99e-08 1.15e-05 0.35 0.3 Caudate activity during reward; chr8:86500987 chr8:86481754~86483002:- LIHC cis rs12681287 0.752 rs10956786 ENSG00000250569.1 NTAN1P2 5.75 1.99e-08 1.15e-05 0.37 0.3 Caudate activity during reward; chr8:86289008 chr8:86481754~86483002:- LIHC cis rs12681287 0.752 rs10112123 ENSG00000250569.1 NTAN1P2 5.75 1.99e-08 1.15e-05 0.37 0.3 Caudate activity during reward; chr8:86290099 chr8:86481754~86483002:- LIHC cis rs227275 0.556 rs7676765 ENSG00000246560.2 RP11-10L12.4 -5.75 1.99e-08 1.15e-05 -0.34 -0.3 Allergic disease (asthma, hay fever or eczema); chr4:103016776 chr4:102828055~102844075:+ LIHC cis rs12744310 0.666 rs7548367 ENSG00000235358.1 RP11-399E6.1 -5.75 2e-08 1.15e-05 -0.34 -0.3 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41295408 chr1:41242373~41284861:+ LIHC cis rs12744310 0.666 rs6660666 ENSG00000235358.1 RP11-399E6.1 -5.75 2e-08 1.15e-05 -0.34 -0.3 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41297346 chr1:41242373~41284861:+ LIHC cis rs7131987 0.903 rs67517901 ENSG00000257176.2 RP11-996F15.2 -5.75 2e-08 1.15e-05 -0.34 -0.3 QT interval; chr12:29268413 chr12:29280418~29317848:- LIHC cis rs7131987 0.903 rs6487796 ENSG00000257176.2 RP11-996F15.2 -5.75 2e-08 1.15e-05 -0.34 -0.3 QT interval; chr12:29269831 chr12:29280418~29317848:- LIHC cis rs6589219 0.954 rs7122375 ENSG00000196167.8 COLCA1 -5.75 2e-08 1.15e-05 -0.33 -0.3 Colorectal cancer; chr11:111300346 chr11:111290787~111305045:- LIHC cis rs2153535 0.58 rs1414348 ENSG00000230939.1 RP11-314C16.1 -5.75 2.01e-08 1.15e-05 -0.36 -0.3 Motion sickness; chr6:8471707 chr6:8784178~8785445:+ LIHC cis rs7688540 0.771 rs4582105 ENSG00000275426.1 CH17-262A2.1 5.75 2.01e-08 1.16e-05 0.41 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:252553 chr4:149738~150317:+ LIHC cis rs7688540 0.771 rs74984113 ENSG00000275426.1 CH17-262A2.1 5.75 2.01e-08 1.16e-05 0.41 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:256733 chr4:149738~150317:+ LIHC cis rs7927592 0.956 rs10896334 ENSG00000212093.1 AP000807.1 5.75 2.02e-08 1.16e-05 0.32 0.3 Total body bone mineral density; chr11:68514026 chr11:68506083~68506166:- LIHC cis rs7927592 0.956 rs10896337 ENSG00000212093.1 AP000807.1 5.75 2.02e-08 1.16e-05 0.32 0.3 Total body bone mineral density; chr11:68516768 chr11:68506083~68506166:- LIHC cis rs62355900 0.627 rs16886449 ENSG00000271828.1 CTD-2310F14.1 5.75 2.02e-08 1.16e-05 0.47 0.3 Endometriosis; chr5:56880479 chr5:56927874~56929573:+ LIHC cis rs62355900 0.627 rs895380 ENSG00000271828.1 CTD-2310F14.1 5.75 2.02e-08 1.16e-05 0.47 0.3 Endometriosis; chr5:56881321 chr5:56927874~56929573:+ LIHC cis rs2735413 0.563 rs8046446 ENSG00000276007.1 RP11-358L22.3 5.75 2.03e-08 1.17e-05 0.4 0.3 Systolic blood pressure (alcohol consumption interaction); chr16:78015689 chr16:78123243~78124332:+ LIHC cis rs6844153 0.823 rs12642922 ENSG00000240005.4 RP11-293A21.1 -5.75 2.03e-08 1.17e-05 -0.42 -0.3 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:27025996 chr4:26859806~26860599:- LIHC cis rs1029738 0.615 rs3757447 ENSG00000228649.7 AC005682.5 5.75 2.03e-08 1.17e-05 0.35 0.3 Fibrinogen levels; chr7:22855116 chr7:22854178~22861579:+ LIHC cis rs9487094 0.644 rs910730 ENSG00000260273.1 RP11-425D10.10 5.74 2.03e-08 1.17e-05 0.34 0.3 Height; chr6:109447092 chr6:109382795~109383666:+ LIHC cis rs7429990 0.965 rs319686 ENSG00000229759.1 MRPS18AP1 5.74 2.05e-08 1.18e-05 0.31 0.3 Educational attainment (years of education); chr3:47888930 chr3:48256350~48256938:- LIHC cis rs1729407 0.741 rs1263177 ENSG00000254851.1 RP11-109L13.1 -5.74 2.05e-08 1.18e-05 -0.34 -0.3 Apolipoprotein A-IV levels; chr11:116819996 chr11:117135528~117138582:+ LIHC cis rs8072100 0.764 rs4794371 ENSG00000228782.6 CTD-2026D20.3 -5.74 2.05e-08 1.18e-05 -0.32 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47550327 chr17:47450568~47492492:- LIHC cis rs6142102 0.923 rs6059635 ENSG00000276073.1 RP5-1125A11.7 -5.74 2.05e-08 1.18e-05 -0.33 -0.3 Skin pigmentation; chr20:34025687 chr20:33985617~33988989:- LIHC cis rs2836974 0.563 rs6517522 ENSG00000255568.3 BRWD1-AS2 5.74 2.06e-08 1.18e-05 0.28 0.3 Cognitive function; chr21:39181919 chr21:39313935~39314962:+ LIHC cis rs1062177 0.855 rs6892117 ENSG00000213433.5 RPLP1P6 5.74 2.06e-08 1.18e-05 0.33 0.3 Preschool internalizing problems; chr5:151885424 chr5:151765859~151766378:- LIHC cis rs7927592 0.956 rs12277225 ENSG00000212093.1 AP000807.1 5.74 2.07e-08 1.19e-05 0.32 0.3 Total body bone mineral density; chr11:68573499 chr11:68506083~68506166:- LIHC cis rs710216 0.536 rs710221 ENSG00000227533.4 SLC2A1-AS1 5.74 2.07e-08 1.19e-05 0.33 0.3 Red cell distribution width; chr1:42948529 chr1:42959049~42983358:+ LIHC cis rs9389248 0.69 rs6939543 ENSG00000232876.1 CTA-212D2.2 5.74 2.07e-08 1.19e-05 0.35 0.3 High light scatter reticulocyte percentage of red cells; chr6:134934005 chr6:135055033~135060550:+ LIHC cis rs1075265 0.584 rs7590846 ENSG00000233266.1 HMGB1P31 5.74 2.07e-08 1.19e-05 0.37 0.3 Chronotype;Morning vs. evening chronotype; chr2:54051530 chr2:54051334~54051760:+ LIHC cis rs12908161 0.96 rs34452033 ENSG00000259295.5 CSPG4P12 5.74 2.07e-08 1.19e-05 0.41 0.3 Schizophrenia; chr15:84678762 chr15:85191438~85213905:+ LIHC cis rs6479901 1 rs10740133 ENSG00000232075.1 MRPL35P2 -5.74 2.08e-08 1.19e-05 -0.32 -0.3 Intelligence (multi-trait analysis); chr10:63517676 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs7358191 ENSG00000232075.1 MRPL35P2 -5.74 2.08e-08 1.19e-05 -0.32 -0.3 Intelligence (multi-trait analysis); chr10:63519028 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs7358152 ENSG00000232075.1 MRPL35P2 -5.74 2.08e-08 1.19e-05 -0.32 -0.3 Intelligence (multi-trait analysis); chr10:63519138 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs10822179 ENSG00000232075.1 MRPL35P2 -5.74 2.08e-08 1.19e-05 -0.32 -0.3 Intelligence (multi-trait analysis); chr10:63520404 chr10:63634317~63634827:- LIHC cis rs8072100 0.875 rs9635762 ENSG00000228782.6 CTD-2026D20.3 -5.74 2.08e-08 1.19e-05 -0.32 -0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47571080 chr17:47450568~47492492:- LIHC cis rs524281 0.861 rs10896085 ENSG00000255320.1 RP11-755F10.1 5.74 2.08e-08 1.19e-05 0.39 0.3 Electroencephalogram traits; chr11:66146361 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs7931544 ENSG00000255320.1 RP11-755F10.1 5.74 2.08e-08 1.19e-05 0.39 0.3 Electroencephalogram traits; chr11:66149563 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs10896087 ENSG00000255320.1 RP11-755F10.1 5.74 2.08e-08 1.19e-05 0.39 0.3 Electroencephalogram traits; chr11:66157078 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs4013917 ENSG00000255320.1 RP11-755F10.1 5.74 2.08e-08 1.19e-05 0.39 0.3 Electroencephalogram traits; chr11:66158714 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs918299 ENSG00000255320.1 RP11-755F10.1 5.74 2.08e-08 1.19e-05 0.39 0.3 Electroencephalogram traits; chr11:66160136 chr11:66244840~66246239:- LIHC cis rs11098499 0.866 rs72676074 ENSG00000245958.5 RP11-33B1.1 -5.74 2.08e-08 1.19e-05 -0.31 -0.3 Corneal astigmatism; chr4:119438686 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs12502423 ENSG00000245958.5 RP11-33B1.1 -5.74 2.08e-08 1.2e-05 -0.31 -0.3 Corneal astigmatism; chr4:119503017 chr4:119454791~119552025:+ LIHC cis rs739496 0.793 rs655107 ENSG00000226469.1 ADAM1B 5.74 2.09e-08 1.2e-05 0.36 0.3 Platelet count; chr12:111558753 chr12:111927018~111929017:+ LIHC cis rs739496 0.843 rs642536 ENSG00000226469.1 ADAM1B 5.74 2.09e-08 1.2e-05 0.36 0.3 Platelet count; chr12:111559219 chr12:111927018~111929017:+ LIHC cis rs739496 0.843 rs848129 ENSG00000226469.1 ADAM1B 5.74 2.09e-08 1.2e-05 0.36 0.3 Platelet count; chr12:111559698 chr12:111927018~111929017:+ LIHC cis rs875971 0.545 rs6460298 ENSG00000226824.5 RP4-756H11.3 -5.74 2.09e-08 1.2e-05 -0.38 -0.3 Aortic root size; chr7:66442783 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs35459055 ENSG00000226824.5 RP4-756H11.3 -5.74 2.09e-08 1.2e-05 -0.38 -0.3 Aortic root size; chr7:66479399 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs75577046 ENSG00000226824.5 RP4-756H11.3 -5.74 2.09e-08 1.2e-05 -0.38 -0.3 Aortic root size; chr7:66493729 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs3735147 ENSG00000226824.5 RP4-756H11.3 -5.74 2.09e-08 1.2e-05 -0.38 -0.3 Aortic root size; chr7:66505541 chr7:66654538~66669855:+ LIHC cis rs875971 0.83 rs6976714 ENSG00000237310.1 GS1-124K5.4 5.74 2.09e-08 1.2e-05 0.27 0.3 Aortic root size; chr7:66426474 chr7:66493706~66495474:+ LIHC cis rs875971 0.651 rs2420596 ENSG00000237310.1 GS1-124K5.4 5.74 2.09e-08 1.2e-05 0.27 0.3 Aortic root size; chr7:66450996 chr7:66493706~66495474:+ LIHC cis rs875971 0.52 rs2420597 ENSG00000237310.1 GS1-124K5.4 5.74 2.09e-08 1.2e-05 0.27 0.3 Aortic root size; chr7:66450999 chr7:66493706~66495474:+ LIHC cis rs2243480 0.803 rs36127118 ENSG00000273142.1 RP11-458F8.4 -5.74 2.09e-08 1.2e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66100518 chr7:66902857~66906297:+ LIHC cis rs7688540 0.656 rs79657896 ENSG00000275426.1 CH17-262A2.1 5.74 2.09e-08 1.2e-05 0.42 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:305472 chr4:149738~150317:+ LIHC cis rs7429990 0.965 rs9854454 ENSG00000229759.1 MRPS18AP1 -5.74 2.1e-08 1.2e-05 -0.31 -0.3 Educational attainment (years of education); chr3:47971307 chr3:48256350~48256938:- LIHC cis rs17507216 0.718 rs72751657 ENSG00000278603.1 RP13-608F4.5 5.74 2.1e-08 1.2e-05 0.63 0.3 Excessive daytime sleepiness; chr15:82581259 chr15:82472203~82472426:+ LIHC cis rs2243480 1 rs160643 ENSG00000273142.1 RP11-458F8.4 -5.74 2.1e-08 1.2e-05 -0.34 -0.3 Diabetic kidney disease; chr7:66093235 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs160642 ENSG00000273142.1 RP11-458F8.4 -5.74 2.1e-08 1.2e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66093386 chr7:66902857~66906297:+ LIHC cis rs2243480 0.614 rs34032527 ENSG00000273142.1 RP11-458F8.4 -5.74 2.1e-08 1.2e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66100154 chr7:66902857~66906297:+ LIHC cis rs6479891 1 rs4746138 ENSG00000232075.1 MRPL35P2 5.74 2.11e-08 1.21e-05 0.35 0.3 Arthritis (juvenile idiopathic); chr10:63481981 chr10:63634317~63634827:- LIHC cis rs2455601 0.744 rs11042107 ENSG00000254860.4 TMEM9B-AS1 5.74 2.11e-08 1.21e-05 0.37 0.3 Schizophrenia; chr11:8884324 chr11:8964675~8977527:+ LIHC cis rs8100891 0.537 rs113427979 ENSG00000267213.4 AC007773.2 -5.74 2.11e-08 1.21e-05 -0.39 -0.3 Neuroticism; chr19:32364502 chr19:32390050~32405560:- LIHC cis rs1155848 0.571 rs7983556 ENSG00000227354.5 RBM26-AS1 5.74 2.11e-08 1.21e-05 0.52 0.3 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79608777 chr13:79406309~79424328:+ LIHC cis rs2522056 1 rs2522056 ENSG00000233006.5 AC034220.3 -5.74 2.11e-08 1.21e-05 -0.31 -0.3 Fibrinogen;Lymphocyte counts; chr5:132466034 chr5:132311285~132369916:- LIHC cis rs4713118 0.621 rs9295755 ENSG00000219392.1 RP1-265C24.5 5.74 2.12e-08 1.21e-05 0.44 0.3 Parkinson's disease; chr6:28065396 chr6:28115628~28116551:+ LIHC cis rs12285276 0.75 rs11038658 ENSG00000205106.4 DKFZp779M0652 -5.74 2.12e-08 1.21e-05 -0.3 -0.3 Visceral fat; chr11:45791762 chr11:45771432~45772358:+ LIHC cis rs7429990 0.93 rs13075457 ENSG00000229759.1 MRPS18AP1 -5.74 2.12e-08 1.21e-05 -0.31 -0.3 Educational attainment (years of education); chr3:48013063 chr3:48256350~48256938:- LIHC cis rs7429990 0.93 rs11130152 ENSG00000229759.1 MRPS18AP1 -5.74 2.12e-08 1.21e-05 -0.31 -0.3 Educational attainment (years of education); chr3:48014919 chr3:48256350~48256938:- LIHC cis rs6479901 0.947 rs10761781 ENSG00000232075.1 MRPL35P2 5.74 2.13e-08 1.22e-05 0.32 0.3 Intelligence (multi-trait analysis); chr10:63524843 chr10:63634317~63634827:- LIHC cis rs524281 0.637 rs7126075 ENSG00000255320.1 RP11-755F10.1 5.74 2.13e-08 1.22e-05 0.39 0.3 Electroencephalogram traits; chr11:66173092 chr11:66244840~66246239:- LIHC cis rs62355900 0.627 rs726501 ENSG00000271828.1 CTD-2310F14.1 5.74 2.13e-08 1.22e-05 0.48 0.3 Endometriosis; chr5:56832039 chr5:56927874~56929573:+ LIHC cis rs853679 0.567 rs16894091 ENSG00000204709.4 LINC01556 -5.74 2.14e-08 1.22e-05 -0.39 -0.3 Depression; chr6:28422360 chr6:28943877~28944537:+ LIHC cis rs9487094 0.689 rs9480936 ENSG00000260273.1 RP11-425D10.10 5.74 2.14e-08 1.22e-05 0.36 0.3 Height; chr6:109358227 chr6:109382795~109383666:+ LIHC cis rs1029738 0.615 rs717624 ENSG00000228649.7 AC005682.5 5.74 2.15e-08 1.23e-05 0.35 0.3 Fibrinogen levels; chr7:22854868 chr7:22854178~22861579:+ LIHC cis rs7429990 0.965 rs796566 ENSG00000229759.1 MRPS18AP1 5.73 2.15e-08 1.23e-05 0.31 0.3 Educational attainment (years of education); chr3:47896864 chr3:48256350~48256938:- LIHC cis rs10875746 0.556 rs4760619 ENSG00000240399.1 RP1-228P16.1 -5.73 2.15e-08 1.23e-05 -0.38 -0.3 Longevity (90 years and older); chr12:48106148 chr12:48054813~48055591:- LIHC cis rs2243480 1 rs781157 ENSG00000273142.1 RP11-458F8.4 -5.73 2.16e-08 1.23e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66013324 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs781156 ENSG00000273142.1 RP11-458F8.4 -5.73 2.16e-08 1.23e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66014154 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs781149 ENSG00000273142.1 RP11-458F8.4 -5.73 2.16e-08 1.23e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66016297 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs451396 ENSG00000273142.1 RP11-458F8.4 -5.73 2.16e-08 1.23e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66019087 chr7:66902857~66906297:+ LIHC cis rs2243480 0.901 rs58207111 ENSG00000273142.1 RP11-458F8.4 -5.73 2.16e-08 1.23e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66021736 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs1167613 ENSG00000273142.1 RP11-458F8.4 -5.73 2.16e-08 1.23e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66022452 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs1715235 ENSG00000273142.1 RP11-458F8.4 -5.73 2.16e-08 1.23e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66023407 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs313799 ENSG00000273142.1 RP11-458F8.4 -5.73 2.16e-08 1.23e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66029343 chr7:66902857~66906297:+ LIHC cis rs2522056 1 rs6874639 ENSG00000233006.5 AC034220.3 5.73 2.16e-08 1.24e-05 0.31 0.3 Fibrinogen;Lymphocyte counts; chr5:132443024 chr5:132311285~132369916:- LIHC cis rs875971 0.545 rs73152714 ENSG00000226824.5 RP4-756H11.3 -5.73 2.16e-08 1.24e-05 -0.38 -0.3 Aortic root size; chr7:66534641 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs4718364 ENSG00000226824.5 RP4-756H11.3 -5.73 2.16e-08 1.24e-05 -0.38 -0.3 Aortic root size; chr7:66536353 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs6961853 ENSG00000226824.5 RP4-756H11.3 -5.73 2.16e-08 1.24e-05 -0.38 -0.3 Aortic root size; chr7:66537035 chr7:66654538~66669855:+ LIHC cis rs875971 0.528 rs801213 ENSG00000226824.5 RP4-756H11.3 5.73 2.16e-08 1.24e-05 0.38 0.3 Aortic root size; chr7:66549931 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs801212 ENSG00000226824.5 RP4-756H11.3 5.73 2.16e-08 1.24e-05 0.38 0.3 Aortic root size; chr7:66550643 chr7:66654538~66669855:+ LIHC cis rs11676348 0.783 rs4674252 ENSG00000261338.2 RP11-378A13.1 -5.73 2.16e-08 1.24e-05 -0.3 -0.3 Ulcerative colitis; chr2:218119755 chr2:218255319~218257366:+ LIHC cis rs11676348 0.714 rs4674254 ENSG00000261338.2 RP11-378A13.1 -5.73 2.16e-08 1.24e-05 -0.3 -0.3 Ulcerative colitis; chr2:218121354 chr2:218255319~218257366:+ LIHC cis rs2243480 1 rs160646 ENSG00000164669.11 INTS4P1 5.73 2.17e-08 1.24e-05 0.5 0.3 Diabetic kidney disease; chr7:66091293 chr7:65141225~65234216:+ LIHC cis rs1005277 0.522 rs11011343 ENSG00000263064.2 RP11-291L22.7 5.73 2.17e-08 1.24e-05 0.3 0.3 Extrinsic epigenetic age acceleration; chr10:37713770 chr10:38448689~38448949:+ LIHC cis rs853679 0.517 rs12332979 ENSG00000219392.1 RP1-265C24.5 -5.73 2.17e-08 1.24e-05 -0.46 -0.3 Depression; chr6:28173770 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs67878650 ENSG00000219392.1 RP1-265C24.5 -5.73 2.17e-08 1.24e-05 -0.46 -0.3 Depression; chr6:28174809 chr6:28115628~28116551:+ LIHC cis rs853679 0.569 rs9348798 ENSG00000219392.1 RP1-265C24.5 -5.73 2.17e-08 1.24e-05 -0.46 -0.3 Depression; chr6:28175233 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9380065 ENSG00000219392.1 RP1-265C24.5 -5.73 2.17e-08 1.24e-05 -0.46 -0.3 Depression; chr6:28176973 chr6:28115628~28116551:+ LIHC cis rs904251 0.523 rs12202055 ENSG00000204110.6 RP1-153P14.8 -5.73 2.17e-08 1.24e-05 -0.37 -0.3 Cognitive performance; chr6:37518304 chr6:37507348~37535616:+ LIHC cis rs2153535 0.58 rs2327060 ENSG00000230939.1 RP11-314C16.1 -5.73 2.17e-08 1.24e-05 -0.36 -0.3 Motion sickness; chr6:8446878 chr6:8784178~8785445:+ LIHC cis rs6142102 0.923 rs2268078 ENSG00000276073.1 RP5-1125A11.7 -5.73 2.18e-08 1.24e-05 -0.34 -0.3 Skin pigmentation; chr20:34008898 chr20:33985617~33988989:- LIHC cis rs7119038 0.818 rs11217040 ENSG00000255239.1 AP002954.6 -5.73 2.18e-08 1.24e-05 -0.38 -0.3 Sjögren's syndrome; chr11:118809939 chr11:118688039~118690600:- LIHC cis rs67180937 0.583 rs61827168 ENSG00000272750.1 RP11-378J18.8 5.73 2.18e-08 1.24e-05 0.35 0.3 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222634138 chr1:222658867~222661512:- LIHC cis rs3096299 0.685 rs2911244 ENSG00000261118.1 RP11-104N10.1 5.73 2.18e-08 1.24e-05 0.3 0.3 Multiple myeloma (IgH translocation); chr16:89455452 chr16:89492017~89504460:- LIHC cis rs739496 0.843 rs616559 ENSG00000226469.1 ADAM1B -5.73 2.19e-08 1.25e-05 -0.35 -0.3 Platelet count; chr12:111565546 chr12:111927018~111929017:+ LIHC cis rs7927592 0.913 rs12294029 ENSG00000212093.1 AP000807.1 5.73 2.2e-08 1.25e-05 0.32 0.3 Total body bone mineral density; chr11:68489591 chr11:68506083~68506166:- LIHC cis rs875971 0.545 rs12671152 ENSG00000226824.5 RP4-756H11.3 -5.73 2.2e-08 1.26e-05 -0.39 -0.3 Aortic root size; chr7:66311140 chr7:66654538~66669855:+ LIHC cis rs7916697 0.54 rs4551651 ENSG00000233590.1 RP11-153K11.3 -5.73 2.21e-08 1.26e-05 -0.36 -0.3 Optic disc area; chr10:68264772 chr10:68233251~68242379:- LIHC cis rs7208859 0.614 rs4794874 ENSG00000263531.1 RP13-753N3.1 -5.73 2.21e-08 1.26e-05 -0.49 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30514300 chr17:30863921~30864940:- LIHC cis rs7208859 0.614 rs7216394 ENSG00000263531.1 RP13-753N3.1 -5.73 2.21e-08 1.26e-05 -0.49 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30498738 chr17:30863921~30864940:- LIHC cis rs2980439 0.525 rs2980508 ENSG00000253893.2 FAM85B -5.73 2.21e-08 1.26e-05 -0.35 -0.3 Neuroticism; chr8:8314210 chr8:8167819~8226614:- LIHC cis rs72627509 0.904 rs17081933 ENSG00000269949.1 RP11-738E22.3 5.73 2.22e-08 1.26e-05 0.4 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56956703 chr4:56960927~56961373:- LIHC cis rs11673344 0.566 rs2385181 ENSG00000226686.6 LINC01535 -5.73 2.23e-08 1.27e-05 -0.36 -0.3 Obesity-related traits; chr19:37395428 chr19:37251912~37265535:+ LIHC cis rs6686842 0.965 rs1472570 ENSG00000235358.1 RP11-399E6.1 -5.73 2.23e-08 1.27e-05 -0.32 -0.3 Height; chr1:41248412 chr1:41242373~41284861:+ LIHC cis rs12681287 0.604 rs13279589 ENSG00000250569.1 NTAN1P2 5.73 2.23e-08 1.27e-05 0.35 0.3 Caudate activity during reward; chr8:86465494 chr8:86481754~86483002:- LIHC cis rs4453827 0.865 rs11705918 ENSG00000271916.1 RP11-884K10.6 5.73 2.23e-08 1.27e-05 0.71 0.3 Blood protein levels; chr3:53755671 chr3:53797764~53798019:- LIHC cis rs7927592 0.763 rs2513277 ENSG00000212093.1 AP000807.1 5.73 2.23e-08 1.27e-05 0.29 0.3 Total body bone mineral density; chr11:68593419 chr11:68506083~68506166:- LIHC cis rs7927592 0.763 rs4340059 ENSG00000212093.1 AP000807.1 5.73 2.23e-08 1.27e-05 0.29 0.3 Total body bone mineral density; chr11:68594965 chr11:68506083~68506166:- LIHC cis rs113835537 0.529 rs11227499 ENSG00000255517.5 CTD-3074O7.5 -5.73 2.25e-08 1.28e-05 -0.31 -0.3 Airway imaging phenotypes; chr11:66505353 chr11:66473490~66480233:- LIHC cis rs8040855 0.77 rs8023774 ENSG00000259295.5 CSPG4P12 -5.73 2.25e-08 1.28e-05 -0.46 -0.3 Bulimia nervosa; chr15:85155685 chr15:85191438~85213905:+ LIHC cis rs150992 0.587 rs1393210 ENSG00000248489.1 CTD-2007H13.3 -5.73 2.25e-08 1.28e-05 -0.43 -0.3 Body mass index; chr5:99025892 chr5:98929171~98995013:+ LIHC cis rs150992 0.587 rs11242567 ENSG00000248489.1 CTD-2007H13.3 -5.73 2.25e-08 1.28e-05 -0.43 -0.3 Body mass index; chr5:99028686 chr5:98929171~98995013:+ LIHC cis rs2153535 0.58 rs6913100 ENSG00000230939.1 RP11-314C16.1 -5.73 2.25e-08 1.28e-05 -0.36 -0.3 Motion sickness; chr6:8456622 chr6:8784178~8785445:+ LIHC cis rs1005277 0.579 rs2472183 ENSG00000263064.2 RP11-291L22.7 5.73 2.25e-08 1.28e-05 0.3 0.3 Extrinsic epigenetic age acceleration; chr10:38103567 chr10:38448689~38448949:+ LIHC cis rs7688540 0.623 rs11735968 ENSG00000275426.1 CH17-262A2.1 5.73 2.26e-08 1.29e-05 0.43 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:245031 chr4:149738~150317:+ LIHC cis rs1062177 0.855 rs6896664 ENSG00000213433.5 RPLP1P6 -5.73 2.26e-08 1.29e-05 -0.32 -0.3 Preschool internalizing problems; chr5:151885713 chr5:151765859~151766378:- LIHC cis rs3779195 0.52 rs17169479 ENSG00000272950.1 RP11-307C18.1 5.72 2.27e-08 1.29e-05 0.47 0.3 Sex hormone-binding globulin levels; chr7:98238721 chr7:98322853~98323430:+ LIHC cis rs34779708 0.733 rs3853672 ENSG00000230534.5 RP11-297A16.2 5.72 2.27e-08 1.29e-05 0.37 0.3 Inflammatory bowel disease;Crohn's disease; chr10:35260678 chr10:35098006~35127020:- LIHC cis rs12681287 0.888 rs13042 ENSG00000250569.1 NTAN1P2 5.72 2.27e-08 1.29e-05 0.34 0.3 Caudate activity during reward; chr8:86472684 chr8:86481754~86483002:- LIHC cis rs6921919 0.609 rs1005127 ENSG00000216901.1 AL022393.7 5.72 2.27e-08 1.29e-05 0.37 0.3 Autism spectrum disorder or schizophrenia; chr6:28399881 chr6:28176188~28176674:+ LIHC cis rs853679 0.515 rs4580862 ENSG00000216901.1 AL022393.7 5.72 2.27e-08 1.29e-05 0.37 0.3 Depression; chr6:28399886 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs4357130 ENSG00000216901.1 AL022393.7 5.72 2.27e-08 1.29e-05 0.37 0.3 Autism spectrum disorder or schizophrenia; chr6:28399906 chr6:28176188~28176674:+ LIHC cis rs4934494 0.768 rs67111731 ENSG00000232936.4 RP11-80H5.2 5.72 2.27e-08 1.29e-05 0.38 0.3 Red blood cell count; chr10:89659528 chr10:89645282~89650667:+ LIHC cis rs1005277 0.505 rs13503 ENSG00000263064.2 RP11-291L22.7 -5.72 2.27e-08 1.29e-05 -0.3 -0.3 Extrinsic epigenetic age acceleration; chr10:37950915 chr10:38448689~38448949:+ LIHC cis rs1005277 0.505 rs7069702 ENSG00000263064.2 RP11-291L22.7 -5.72 2.27e-08 1.29e-05 -0.3 -0.3 Extrinsic epigenetic age acceleration; chr10:37958431 chr10:38448689~38448949:+ LIHC cis rs6921919 0.583 rs2041230 ENSG00000216901.1 AL022393.7 5.72 2.27e-08 1.29e-05 0.37 0.3 Autism spectrum disorder or schizophrenia; chr6:28397738 chr6:28176188~28176674:+ LIHC cis rs9308062 1 rs9308062 ENSG00000273449.1 RP11-218F10.3 -5.72 2.28e-08 1.29e-05 -0.29 -0.3 Small cell lung carcinoma; chr4:163517048 chr4:163529771~163530697:+ LIHC cis rs2243480 0.908 rs313822 ENSG00000226824.5 RP4-756H11.3 -5.72 2.28e-08 1.29e-05 -0.48 -0.3 Diabetic kidney disease; chr7:66108952 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs313820 ENSG00000226824.5 RP4-756H11.3 -5.72 2.28e-08 1.29e-05 -0.48 -0.3 Diabetic kidney disease; chr7:66109479 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs313824 ENSG00000226824.5 RP4-756H11.3 -5.72 2.28e-08 1.29e-05 -0.48 -0.3 Diabetic kidney disease; chr7:66116220 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs186378 ENSG00000226824.5 RP4-756H11.3 -5.72 2.28e-08 1.29e-05 -0.48 -0.3 Diabetic kidney disease; chr7:66117071 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs160637 ENSG00000226824.5 RP4-756H11.3 -5.72 2.28e-08 1.29e-05 -0.48 -0.3 Diabetic kidney disease; chr7:66119331 chr7:66654538~66669855:+ LIHC cis rs4423214 0.592 rs1790349 ENSG00000254682.1 RP11-660L16.2 -5.72 2.28e-08 1.3e-05 -0.4 -0.3 Vitamin D levels; chr11:71431304 chr11:71448674~71452157:+ LIHC cis rs875971 0.571 rs160641 ENSG00000237310.1 GS1-124K5.4 -5.72 2.28e-08 1.3e-05 -0.28 -0.3 Aortic root size; chr7:66112359 chr7:66493706~66495474:+ LIHC cis rs8177376 1 rs563011 ENSG00000254905.1 RP11-712L6.7 -5.72 2.29e-08 1.3e-05 -0.44 -0.3 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126281527 chr11:126292922~126294254:- LIHC cis rs1005277 0.522 rs289649 ENSG00000263064.2 RP11-291L22.7 5.72 2.29e-08 1.3e-05 0.3 0.3 Extrinsic epigenetic age acceleration; chr10:37686456 chr10:38448689~38448949:+ LIHC cis rs875971 0.545 rs66594357 ENSG00000226824.5 RP4-756H11.3 -5.72 2.29e-08 1.3e-05 -0.38 -0.3 Aortic root size; chr7:66327797 chr7:66654538~66669855:+ LIHC cis rs113835537 0.529 rs75003264 ENSG00000255517.5 CTD-3074O7.5 -5.72 2.3e-08 1.3e-05 -0.38 -0.3 Airway imaging phenotypes; chr11:66488628 chr11:66473490~66480233:- LIHC cis rs11098499 0.954 rs12499324 ENSG00000245958.5 RP11-33B1.1 -5.72 2.3e-08 1.31e-05 -0.3 -0.3 Corneal astigmatism; chr4:119472631 chr4:119454791~119552025:+ LIHC cis rs6479891 0.908 rs12412946 ENSG00000232075.1 MRPL35P2 5.72 2.3e-08 1.31e-05 0.35 0.3 Arthritis (juvenile idiopathic); chr10:63529792 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs59035163 ENSG00000232075.1 MRPL35P2 5.72 2.3e-08 1.31e-05 0.35 0.3 Arthritis (juvenile idiopathic); chr10:63532283 chr10:63634317~63634827:- LIHC cis rs9326248 1 rs664922 ENSG00000236267.1 AP006216.5 5.72 2.31e-08 1.31e-05 0.3 0.3 Blood protein levels; chr11:117200179 chr11:116813204~116814003:- LIHC cis rs2243480 0.803 rs160649 ENSG00000273142.1 RP11-458F8.4 -5.72 2.31e-08 1.31e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66078212 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs160648 ENSG00000273142.1 RP11-458F8.4 -5.72 2.31e-08 1.31e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66078397 chr7:66902857~66906297:+ LIHC cis rs1150668 0.796 rs213236 ENSG00000204709.4 LINC01556 5.72 2.32e-08 1.32e-05 0.33 0.3 Pubertal anthropometrics; chr6:28356620 chr6:28943877~28944537:+ LIHC cis rs524281 0.861 rs9736673 ENSG00000255320.1 RP11-755F10.1 5.72 2.32e-08 1.32e-05 0.38 0.3 Electroencephalogram traits; chr11:66156553 chr11:66244840~66246239:- LIHC cis rs8100891 0.537 rs2111504 ENSG00000267213.4 AC007773.2 -5.72 2.32e-08 1.32e-05 -0.36 -0.3 Neuroticism; chr19:32426549 chr19:32390050~32405560:- LIHC cis rs7927592 0.717 rs7126451 ENSG00000212093.1 AP000807.1 -5.72 2.33e-08 1.32e-05 -0.3 -0.3 Total body bone mineral density; chr11:68489918 chr11:68506083~68506166:- LIHC cis rs8177376 1 rs534804 ENSG00000254905.1 RP11-712L6.7 5.72 2.33e-08 1.32e-05 0.42 0.3 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126205873 chr11:126292922~126294254:- LIHC cis rs904251 0.6 rs4714068 ENSG00000204110.6 RP1-153P14.8 -5.72 2.33e-08 1.32e-05 -0.35 -0.3 Cognitive performance; chr6:37487866 chr6:37507348~37535616:+ LIHC cis rs2739330 0.828 rs4822451 ENSG00000099984.9 GSTT2 -5.72 2.33e-08 1.32e-05 -0.35 -0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23980123~23983911:+ LIHC cis rs875971 0.545 rs75840613 ENSG00000226824.5 RP4-756H11.3 -5.72 2.33e-08 1.32e-05 -0.38 -0.3 Aortic root size; chr7:66376399 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs73148639 ENSG00000226824.5 RP4-756H11.3 -5.72 2.33e-08 1.32e-05 -0.38 -0.3 Aortic root size; chr7:66390342 chr7:66654538~66669855:+ LIHC cis rs1577917 0.883 rs2660575 ENSG00000234155.1 RP11-30P6.6 5.72 2.34e-08 1.32e-05 0.35 0.3 Response to antipsychotic treatment; chr6:85975277 chr6:85387219~85390186:- LIHC cis rs904251 0.523 rs914348 ENSG00000204110.6 RP1-153P14.8 -5.72 2.34e-08 1.32e-05 -0.36 -0.3 Cognitive performance; chr6:37516953 chr6:37507348~37535616:+ LIHC cis rs1005277 0.522 rs289648 ENSG00000263064.2 RP11-291L22.7 5.72 2.34e-08 1.32e-05 0.3 0.3 Extrinsic epigenetic age acceleration; chr10:37682909 chr10:38448689~38448949:+ LIHC cis rs4453827 0.821 rs73092085 ENSG00000271916.1 RP11-884K10.6 5.72 2.34e-08 1.33e-05 0.72 0.3 Blood protein levels; chr3:53750295 chr3:53797764~53798019:- LIHC cis rs12681287 0.752 rs4389908 ENSG00000250569.1 NTAN1P2 5.72 2.35e-08 1.33e-05 0.37 0.3 Caudate activity during reward; chr8:86262623 chr8:86481754~86483002:- LIHC cis rs12681287 0.752 rs12681438 ENSG00000250569.1 NTAN1P2 5.72 2.35e-08 1.33e-05 0.37 0.3 Caudate activity during reward; chr8:86280860 chr8:86481754~86483002:- LIHC cis rs12681287 0.752 rs13262673 ENSG00000250569.1 NTAN1P2 5.72 2.35e-08 1.33e-05 0.37 0.3 Caudate activity during reward; chr8:86281371 chr8:86481754~86483002:- LIHC cis rs150992 0.536 rs179053 ENSG00000248489.1 CTD-2007H13.3 5.72 2.35e-08 1.33e-05 0.47 0.3 Body mass index; chr5:98979890 chr5:98929171~98995013:+ LIHC cis rs150992 0.536 rs161729 ENSG00000248489.1 CTD-2007H13.3 5.72 2.35e-08 1.33e-05 0.47 0.3 Body mass index; chr5:98982477 chr5:98929171~98995013:+ LIHC cis rs150992 0.536 rs161730 ENSG00000248489.1 CTD-2007H13.3 5.72 2.35e-08 1.33e-05 0.47 0.3 Body mass index; chr5:98982631 chr5:98929171~98995013:+ LIHC cis rs2998286 0.862 rs2993980 ENSG00000254635.4 WAC-AS1 -5.72 2.35e-08 1.33e-05 -0.37 -0.3 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28506286 chr10:28522652~28532743:- LIHC cis rs1005277 0.522 rs7090858 ENSG00000263064.2 RP11-291L22.7 -5.72 2.35e-08 1.33e-05 -0.3 -0.3 Extrinsic epigenetic age acceleration; chr10:37714742 chr10:38448689~38448949:+ LIHC cis rs12681287 0.752 rs4534114 ENSG00000250569.1 NTAN1P2 5.72 2.35e-08 1.33e-05 0.37 0.3 Caudate activity during reward; chr8:86259727 chr8:86481754~86483002:- LIHC cis rs7927592 0.83 rs10896339 ENSG00000212093.1 AP000807.1 5.72 2.36e-08 1.33e-05 0.32 0.3 Total body bone mineral density; chr11:68535378 chr11:68506083~68506166:- LIHC cis rs739496 0.843 rs610769 ENSG00000226469.1 ADAM1B 5.72 2.36e-08 1.34e-05 0.36 0.3 Platelet count; chr12:111561766 chr12:111927018~111929017:+ LIHC cis rs739496 0.843 rs595529 ENSG00000226469.1 ADAM1B 5.72 2.36e-08 1.34e-05 0.36 0.3 Platelet count; chr12:111562844 chr12:111927018~111929017:+ LIHC cis rs228614 0.51 rs223438 ENSG00000230069.3 LRRC37A15P 5.72 2.36e-08 1.34e-05 0.26 0.3 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798584 chr4:102727274~102730721:- LIHC cis rs7927592 0.956 rs12271290 ENSG00000212093.1 AP000807.1 -5.72 2.36e-08 1.34e-05 -0.32 -0.3 Total body bone mineral density; chr11:68558768 chr11:68506083~68506166:- LIHC cis rs72627509 0.904 rs17081935 ENSG00000269949.1 RP11-738E22.3 5.72 2.37e-08 1.34e-05 0.4 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56957310 chr4:56960927~56961373:- LIHC cis rs113835537 0.529 rs10501397 ENSG00000255517.5 CTD-3074O7.5 -5.72 2.37e-08 1.34e-05 -0.32 -0.3 Airway imaging phenotypes; chr11:66505505 chr11:66473490~66480233:- LIHC cis rs9487094 0.666 rs4946970 ENSG00000260273.1 RP11-425D10.10 5.72 2.38e-08 1.34e-05 0.35 0.3 Height; chr6:109384807 chr6:109382795~109383666:+ LIHC cis rs2243480 1 rs160655 ENSG00000226824.5 RP4-756H11.3 -5.72 2.38e-08 1.35e-05 -0.48 -0.3 Diabetic kidney disease; chr7:66068227 chr7:66654538~66669855:+ LIHC cis rs4934494 0.768 rs2094214 ENSG00000232936.4 RP11-80H5.2 5.72 2.38e-08 1.35e-05 0.38 0.3 Red blood cell count; chr10:89649624 chr10:89645282~89650667:+ LIHC cis rs9326248 0.861 rs1871757 ENSG00000236267.1 AP006216.5 5.72 2.38e-08 1.35e-05 0.3 0.3 Blood protein levels; chr11:117159865 chr11:116813204~116814003:- LIHC cis rs10256972 0.521 rs7457418 ENSG00000229043.2 AC091729.9 -5.71 2.39e-08 1.35e-05 -0.35 -0.3 Endometriosis;Longevity; chr7:1070619 chr7:1160374~1165267:+ LIHC cis rs11690935 0.959 rs6705200 ENSG00000228389.1 AC068039.4 5.71 2.4e-08 1.36e-05 0.39 0.3 Schizophrenia; chr2:171781090 chr2:171773482~171775844:+ LIHC cis rs2243480 1 rs313831 ENSG00000226824.5 RP4-756H11.3 -5.71 2.4e-08 1.36e-05 -0.48 -0.3 Diabetic kidney disease; chr7:66086239 chr7:66654538~66669855:+ LIHC cis rs6142102 0.961 rs4911401 ENSG00000276073.1 RP5-1125A11.7 -5.71 2.4e-08 1.36e-05 -0.33 -0.3 Skin pigmentation; chr20:34066756 chr20:33985617~33988989:- LIHC cis rs12701220 0.655 rs7778968 ENSG00000229043.2 AC091729.9 -5.71 2.4e-08 1.36e-05 -0.41 -0.3 Bronchopulmonary dysplasia; chr7:1104986 chr7:1160374~1165267:+ LIHC cis rs1075265 0.568 rs7604357 ENSG00000233266.1 HMGB1P31 5.71 2.4e-08 1.36e-05 0.36 0.3 Chronotype;Morning vs. evening chronotype; chr2:54074026 chr2:54051334~54051760:+ LIHC cis rs1862618 0.525 rs2662019 ENSG00000271828.1 CTD-2310F14.1 -5.71 2.4e-08 1.36e-05 -0.43 -0.3 Initial pursuit acceleration; chr5:56967277 chr5:56927874~56929573:+ LIHC cis rs2243480 1 rs1499614 ENSG00000273142.1 RP11-458F8.4 -5.71 2.41e-08 1.36e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66265811 chr7:66902857~66906297:+ LIHC cis rs1891275 0.551 rs11186640 ENSG00000228701.1 TNKS2-AS1 -5.71 2.41e-08 1.36e-05 -0.39 -0.3 Intelligence (multi-trait analysis); chr10:91640674 chr10:91782839~91798291:- LIHC cis rs2243480 1 rs1723267 ENSG00000273142.1 RP11-458F8.4 -5.71 2.42e-08 1.37e-05 -0.36 -0.3 Diabetic kidney disease; chr7:66008327 chr7:66902857~66906297:+ LIHC cis rs71007656 1 rs71007656 ENSG00000263064.2 RP11-291L22.7 5.71 2.42e-08 1.37e-05 0.3 0.3 Extrinsic epigenetic age acceleration; chr10:37681922 chr10:38448689~38448949:+ LIHC cis rs1005277 0.54 rs2145487 ENSG00000263064.2 RP11-291L22.7 5.71 2.42e-08 1.37e-05 0.3 0.3 Extrinsic epigenetic age acceleration; chr10:37721149 chr10:38448689~38448949:+ LIHC cis rs1005277 0.54 rs4934907 ENSG00000263064.2 RP11-291L22.7 5.71 2.42e-08 1.37e-05 0.3 0.3 Extrinsic epigenetic age acceleration; chr10:37726302 chr10:38448689~38448949:+ LIHC cis rs1005277 0.54 rs11011351 ENSG00000263064.2 RP11-291L22.7 5.71 2.42e-08 1.37e-05 0.3 0.3 Extrinsic epigenetic age acceleration; chr10:37741597 chr10:38448689~38448949:+ LIHC cis rs11690935 0.959 rs7608403 ENSG00000228389.1 AC068039.4 5.71 2.43e-08 1.37e-05 0.39 0.3 Schizophrenia; chr2:171790255 chr2:171773482~171775844:+ LIHC cis rs72627509 0.951 rs6554401 ENSG00000269949.1 RP11-738E22.3 5.71 2.43e-08 1.37e-05 0.38 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56959170 chr4:56960927~56961373:- LIHC cis rs9326248 1 rs664082 ENSG00000236267.1 AP006216.5 5.71 2.43e-08 1.37e-05 0.3 0.3 Blood protein levels; chr11:117200354 chr11:116813204~116814003:- LIHC cis rs8072100 0.967 rs4239162 ENSG00000228782.6 CTD-2026D20.3 5.71 2.43e-08 1.37e-05 0.32 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47678444 chr17:47450568~47492492:- LIHC cis rs8072100 0.967 rs4239163 ENSG00000228782.6 CTD-2026D20.3 5.71 2.43e-08 1.37e-05 0.32 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47678588 chr17:47450568~47492492:- LIHC cis rs11673344 0.544 rs6508721 ENSG00000226686.6 LINC01535 -5.71 2.43e-08 1.37e-05 -0.36 -0.3 Obesity-related traits; chr19:37419119 chr19:37251912~37265535:+ LIHC cis rs11673344 0.566 rs7254009 ENSG00000226686.6 LINC01535 -5.71 2.43e-08 1.37e-05 -0.36 -0.3 Obesity-related traits; chr19:37427707 chr19:37251912~37265535:+ LIHC cis rs10510102 0.935 rs79360006 ENSG00000276742.1 RP11-500G22.4 5.71 2.43e-08 1.37e-05 0.46 0.3 Breast cancer; chr10:121912856 chr10:121956782~121957098:+ LIHC cis rs853679 0.517 rs9295761 ENSG00000219392.1 RP1-265C24.5 -5.71 2.44e-08 1.38e-05 -0.46 -0.3 Depression; chr6:28180209 chr6:28115628~28116551:+ LIHC cis rs2153535 0.562 rs9379211 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8463694 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1319169 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8464223 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs965706 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8464475 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6938071 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8464612 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs9406160 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8464674 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1335636 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8464814 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs986060 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8465195 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9393021 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8465890 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9406161 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8465911 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9405390 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8465976 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9405391 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8466315 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9406163 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8466409 chr6:8784178~8785445:+ LIHC cis rs2153535 0.504 rs9405393 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8467199 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2184584 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8468174 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs7774752 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8468745 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1034272 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8469102 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9505450 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8469669 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9406164 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8469815 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7341201 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8470037 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7341206 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8470256 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7341382 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8470316 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7341383 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8470401 chr6:8784178~8785445:+ LIHC cis rs2153535 0.504 rs9328472 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8470615 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1414345 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8471304 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6905237 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8471557 chr6:8784178~8785445:+ LIHC cis rs2153535 0.542 rs4440510 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8471585 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs1414347 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8471598 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1414349 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8472057 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1414350 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8472098 chr6:8784178~8785445:+ LIHC cis rs2153535 0.526 rs7748404 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8472267 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9392224 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8472381 chr6:8784178~8785445:+ LIHC cis rs2153535 0.542 rs9378553 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8472399 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs1855768 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8472736 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1932280 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8473421 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1932281 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8473532 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6900007 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8473802 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2184585 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8473935 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6902001 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8476822 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs4960423 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8476977 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1932282 ENSG00000230939.1 RP11-314C16.1 -5.71 2.44e-08 1.38e-05 -0.36 -0.3 Motion sickness; chr6:8477097 chr6:8784178~8785445:+ LIHC cis rs11673344 0.566 rs1968251 ENSG00000226686.6 LINC01535 -5.71 2.46e-08 1.39e-05 -0.36 -0.29 Obesity-related traits; chr19:37457005 chr19:37251912~37265535:+ LIHC cis rs1150668 0.796 rs2531825 ENSG00000204709.4 LINC01556 5.71 2.47e-08 1.39e-05 0.33 0.29 Pubertal anthropometrics; chr6:28381487 chr6:28943877~28944537:+ LIHC cis rs11673344 0.566 rs10419281 ENSG00000226686.6 LINC01535 -5.71 2.47e-08 1.39e-05 -0.36 -0.29 Obesity-related traits; chr19:37459351 chr19:37251912~37265535:+ LIHC cis rs6142102 0.812 rs761236 ENSG00000276073.1 RP5-1125A11.7 -5.71 2.47e-08 1.39e-05 -0.33 -0.29 Skin pigmentation; chr20:33932245 chr20:33985617~33988989:- LIHC cis rs4356203 1 rs4356203 ENSG00000272034.1 SNORD14A 5.71 2.48e-08 1.4e-05 0.34 0.29 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17138601 chr11:17074654~17074744:- LIHC cis rs9322193 0.847 rs4870054 ENSG00000231760.4 RP11-350J20.5 5.71 2.49e-08 1.4e-05 0.37 0.29 Lung cancer; chr6:149848402 chr6:149796151~149826294:- LIHC cis rs17711722 0.503 rs453835 ENSG00000228409.4 CCT6P1 5.71 2.49e-08 1.4e-05 0.23 0.29 Calcium levels; chr7:66046172 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs313809 ENSG00000273142.1 RP11-458F8.4 -5.71 2.49e-08 1.4e-05 -0.36 -0.29 Diabetic kidney disease; chr7:66034996 chr7:66902857~66906297:+ LIHC cis rs494459 0.536 rs10790267 ENSG00000255422.1 AP002954.4 -5.71 2.49e-08 1.4e-05 -0.34 -0.29 Height; chr11:118856460 chr11:118704607~118750263:+ LIHC cis rs494459 0.536 rs11217067 ENSG00000255422.1 AP002954.4 -5.71 2.49e-08 1.4e-05 -0.34 -0.29 Height; chr11:118856623 chr11:118704607~118750263:+ LIHC cis rs2510897 0.675 rs4936442 ENSG00000255422.1 AP002954.4 -5.71 2.49e-08 1.4e-05 -0.34 -0.29 Height; chr11:118857611 chr11:118704607~118750263:+ LIHC cis rs9326248 0.53 rs1242229 ENSG00000236267.1 AP006216.5 5.71 2.5e-08 1.41e-05 0.33 0.29 Blood protein levels; chr11:117191654 chr11:116813204~116814003:- LIHC cis rs524281 0.861 rs7941431 ENSG00000255320.1 RP11-755F10.1 5.71 2.51e-08 1.41e-05 0.39 0.29 Electroencephalogram traits; chr11:66192686 chr11:66244840~66246239:- LIHC cis rs10510102 0.935 rs11200257 ENSG00000276742.1 RP11-500G22.4 5.71 2.51e-08 1.41e-05 0.45 0.29 Breast cancer; chr10:121917232 chr10:121956782~121957098:+ LIHC cis rs113835537 0.529 rs3179961 ENSG00000255517.5 CTD-3074O7.5 -5.71 2.51e-08 1.41e-05 -0.33 -0.29 Airway imaging phenotypes; chr11:66476983 chr11:66473490~66480233:- LIHC cis rs11690935 0.851 rs9808259 ENSG00000228389.1 AC068039.4 5.71 2.51e-08 1.41e-05 0.4 0.29 Schizophrenia; chr2:171792464 chr2:171773482~171775844:+ LIHC cis rs9532669 0.926 rs2875421 ENSG00000176268.5 CYCSP34 5.71 2.52e-08 1.41e-05 0.33 0.29 Cervical cancer; chr13:40936536 chr13:40863599~40863902:- LIHC cis rs853679 0.567 rs16894091 ENSG00000216901.1 AL022393.7 -5.7 2.53e-08 1.42e-05 -0.39 -0.29 Depression; chr6:28422360 chr6:28176188~28176674:+ LIHC cis rs9326248 1 rs585849 ENSG00000236267.1 AP006216.5 5.7 2.53e-08 1.42e-05 0.3 0.29 Blood protein levels; chr11:117198345 chr11:116813204~116814003:- LIHC cis rs1005277 0.577 rs4934906 ENSG00000263064.2 RP11-291L22.7 5.7 2.53e-08 1.42e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:37726100 chr10:38448689~38448949:+ LIHC cis rs9549367 0.713 rs510160 ENSG00000269125.1 RP11-98F14.11 5.7 2.53e-08 1.42e-05 0.34 0.29 Platelet distribution width; chr13:113168167 chr13:113165002~113165183:- LIHC cis rs2998286 0.906 rs2807742 ENSG00000254635.4 WAC-AS1 -5.7 2.53e-08 1.42e-05 -0.36 -0.29 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28492438 chr10:28522652~28532743:- LIHC cis rs9487094 0.553 rs13191995 ENSG00000260273.1 RP11-425D10.10 5.7 2.54e-08 1.43e-05 0.49 0.29 Height; chr6:109645257 chr6:109382795~109383666:+ LIHC cis rs6844153 0.877 rs10939146 ENSG00000240005.4 RP11-293A21.1 -5.7 2.54e-08 1.43e-05 -0.42 -0.29 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26978399 chr4:26859806~26860599:- LIHC cis rs9487094 0.666 rs7748669 ENSG00000260273.1 RP11-425D10.10 5.7 2.54e-08 1.43e-05 0.35 0.29 Height; chr6:109424139 chr6:109382795~109383666:+ LIHC cis rs2072510 0.722 rs2540496 ENSG00000257715.1 RP11-256L6.2 -5.7 2.54e-08 1.43e-05 -0.3 -0.29 Metabolite levels (small molecules and protein measures); chr12:96012725 chr12:96025323~96027971:+ LIHC cis rs2072510 0.722 rs2540495 ENSG00000257715.1 RP11-256L6.2 -5.7 2.54e-08 1.43e-05 -0.3 -0.29 Metabolite levels (small molecules and protein measures); chr12:96012945 chr12:96025323~96027971:+ LIHC cis rs2153535 0.58 rs6597318 ENSG00000230939.1 RP11-314C16.1 -5.7 2.55e-08 1.43e-05 -0.35 -0.29 Motion sickness; chr6:8437056 chr6:8784178~8785445:+ LIHC cis rs2522056 1 rs7730247 ENSG00000233006.5 AC034220.3 -5.7 2.55e-08 1.43e-05 -0.31 -0.29 Fibrinogen;Lymphocyte counts; chr5:132445596 chr5:132311285~132369916:- LIHC cis rs739496 0.843 rs616668 ENSG00000226469.1 ADAM1B 5.7 2.56e-08 1.44e-05 0.36 0.29 Platelet count; chr12:111536476 chr12:111927018~111929017:+ LIHC cis rs739496 0.843 rs583140 ENSG00000226469.1 ADAM1B 5.7 2.56e-08 1.44e-05 0.36 0.29 Platelet count; chr12:111548150 chr12:111927018~111929017:+ LIHC cis rs739496 0.843 rs848132 ENSG00000226469.1 ADAM1B 5.7 2.56e-08 1.44e-05 0.36 0.29 Platelet count; chr12:111552175 chr12:111927018~111929017:+ LIHC cis rs2243480 1 rs160652 ENSG00000226824.5 RP4-756H11.3 -5.7 2.57e-08 1.44e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66073444 chr7:66654538~66669855:+ LIHC cis rs2153535 0.58 rs2143357 ENSG00000230939.1 RP11-314C16.1 -5.7 2.57e-08 1.44e-05 -0.36 -0.29 Motion sickness; chr6:8496963 chr6:8784178~8785445:+ LIHC cis rs9487094 0.6 rs9372213 ENSG00000260273.1 RP11-425D10.10 5.7 2.57e-08 1.44e-05 0.36 0.29 Height; chr6:109370985 chr6:109382795~109383666:+ LIHC cis rs2739330 0.828 rs4822454 ENSG00000099984.9 GSTT2 -5.7 2.57e-08 1.44e-05 -0.35 -0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23980123~23983911:+ LIHC cis rs12681287 0.547 rs60982560 ENSG00000250569.1 NTAN1P2 5.7 2.58e-08 1.44e-05 0.35 0.29 Caudate activity during reward; chr8:86502817 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs13280468 ENSG00000250569.1 NTAN1P2 5.7 2.58e-08 1.44e-05 0.35 0.29 Caudate activity during reward; chr8:86326223 chr8:86481754~86483002:- LIHC cis rs2153535 0.601 rs9393030 ENSG00000230939.1 RP11-314C16.1 -5.7 2.59e-08 1.45e-05 -0.36 -0.29 Motion sickness; chr6:8516256 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9328479 ENSG00000230939.1 RP11-314C16.1 -5.7 2.59e-08 1.45e-05 -0.36 -0.29 Motion sickness; chr6:8519413 chr6:8784178~8785445:+ LIHC cis rs2836974 0.583 rs9981884 ENSG00000255568.3 BRWD1-AS2 5.7 2.59e-08 1.45e-05 0.28 0.29 Cognitive function; chr21:39213707 chr21:39313935~39314962:+ LIHC cis rs875971 0.545 rs17138149 ENSG00000237310.1 GS1-124K5.4 5.7 2.59e-08 1.45e-05 0.28 0.29 Aortic root size; chr7:66228193 chr7:66493706~66495474:+ LIHC cis rs7131987 0.65 rs11050208 ENSG00000275476.1 RP11-996F15.4 -5.7 2.59e-08 1.45e-05 -0.36 -0.29 QT interval; chr12:29357436 chr12:29277397~29277882:- LIHC cis rs2933343 0.649 rs789216 ENSG00000231305.3 RP11-723O4.2 5.7 2.59e-08 1.45e-05 0.33 0.29 IgG glycosylation; chr3:128875660 chr3:128861313~128871540:- LIHC cis rs1005277 0.505 rs200939 ENSG00000263064.2 RP11-291L22.7 5.7 2.59e-08 1.45e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:37850555 chr10:38448689~38448949:+ LIHC cis rs7916697 0.593 rs7912895 ENSG00000233590.1 RP11-153K11.3 -5.7 2.59e-08 1.45e-05 -0.36 -0.29 Optic disc area; chr10:68261741 chr10:68233251~68242379:- LIHC cis rs875971 0.545 rs1547529 ENSG00000237310.1 GS1-124K5.4 5.7 2.59e-08 1.45e-05 0.28 0.29 Aortic root size; chr7:66258859 chr7:66493706~66495474:+ LIHC cis rs4356975 0.527 rs60423649 ENSG00000249956.3 RP11-790I12.2 5.7 2.6e-08 1.45e-05 0.35 0.29 Obesity-related traits; chr4:69127952 chr4:69408836~69423164:+ LIHC cis rs11690935 0.959 rs67204065 ENSG00000228389.1 AC068039.4 5.7 2.6e-08 1.45e-05 0.39 0.29 Schizophrenia; chr2:171816114 chr2:171773482~171775844:+ LIHC cis rs1005277 0.505 rs200935 ENSG00000263064.2 RP11-291L22.7 5.7 2.6e-08 1.45e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:37843882 chr10:38448689~38448949:+ LIHC cis rs1005277 0.505 rs200936 ENSG00000263064.2 RP11-291L22.7 5.7 2.6e-08 1.45e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:37846007 chr10:38448689~38448949:+ LIHC cis rs1005277 0.505 rs200937 ENSG00000263064.2 RP11-291L22.7 5.7 2.6e-08 1.45e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:37846844 chr10:38448689~38448949:+ LIHC cis rs1005277 0.505 rs200910 ENSG00000263064.2 RP11-291L22.7 5.7 2.6e-08 1.45e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:37819248 chr10:38448689~38448949:+ LIHC cis rs9341808 0.528 rs2322753 ENSG00000272129.1 RP11-250B2.6 5.7 2.6e-08 1.46e-05 0.29 0.29 Sitting height ratio; chr6:80333148 chr6:80355424~80356859:+ LIHC cis rs9341808 0.556 rs2223875 ENSG00000272129.1 RP11-250B2.6 5.7 2.6e-08 1.46e-05 0.29 0.29 Sitting height ratio; chr6:80335735 chr6:80355424~80356859:+ LIHC cis rs12908161 0.959 rs3748376 ENSG00000259295.5 CSPG4P12 5.7 2.61e-08 1.46e-05 0.41 0.29 Schizophrenia; chr15:84785121 chr15:85191438~85213905:+ LIHC cis rs1005277 0.505 rs719569 ENSG00000263064.2 RP11-291L22.7 -5.7 2.61e-08 1.46e-05 -0.3 -0.29 Extrinsic epigenetic age acceleration; chr10:37865487 chr10:38448689~38448949:+ LIHC cis rs1005277 0.522 rs200943 ENSG00000263064.2 RP11-291L22.7 5.7 2.61e-08 1.46e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:37859802 chr10:38448689~38448949:+ LIHC cis rs2933343 0.621 rs728838 ENSG00000231305.3 RP11-723O4.2 5.7 2.62e-08 1.46e-05 0.32 0.29 IgG glycosylation; chr3:128870170 chr3:128861313~128871540:- LIHC cis rs9399137 0.507 rs4896118 ENSG00000232876.1 CTA-212D2.2 5.7 2.62e-08 1.46e-05 0.34 0.29 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134954927 chr6:135055033~135060550:+ LIHC cis rs12908161 0.959 rs34342559 ENSG00000259295.5 CSPG4P12 5.7 2.62e-08 1.46e-05 0.4 0.29 Schizophrenia; chr15:84788040 chr15:85191438~85213905:+ LIHC cis rs12908161 0.959 rs62019472 ENSG00000259295.5 CSPG4P12 5.7 2.62e-08 1.46e-05 0.4 0.29 Schizophrenia; chr15:84788262 chr15:85191438~85213905:+ LIHC cis rs12908161 0.959 rs35557864 ENSG00000259295.5 CSPG4P12 5.7 2.62e-08 1.46e-05 0.4 0.29 Schizophrenia; chr15:84788398 chr15:85191438~85213905:+ LIHC cis rs9487094 0.517 rs3778474 ENSG00000260273.1 RP11-425D10.10 5.7 2.63e-08 1.47e-05 0.35 0.29 Height; chr6:109374782 chr6:109382795~109383666:+ LIHC cis rs931127 0.532 rs4930304 ENSG00000265874.1 MIR4489 5.7 2.63e-08 1.47e-05 0.42 0.29 Systemic lupus erythematosus; chr11:65695976 chr11:65649192~65649253:+ LIHC cis rs2153535 0.58 rs6929206 ENSG00000230939.1 RP11-314C16.1 -5.7 2.63e-08 1.47e-05 -0.36 -0.29 Motion sickness; chr6:8447728 chr6:8784178~8785445:+ LIHC cis rs4925166 1 rs4925166 ENSG00000260647.1 RP1-178F10.1 5.7 2.63e-08 1.47e-05 0.34 0.29 Multiple sclerosis; chr17:18307496 chr17:18268080~18268828:+ LIHC cis rs7714584 1 rs4958426 ENSG00000197083.10 ZNF300P1 5.7 2.64e-08 1.47e-05 0.46 0.29 Crohn's disease; chr5:150898784 chr5:150930645~150946289:- LIHC cis rs11098499 0.954 rs7681544 ENSG00000245958.5 RP11-33B1.1 -5.7 2.64e-08 1.48e-05 -0.3 -0.29 Corneal astigmatism; chr4:119490100 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs11940028 ENSG00000245958.5 RP11-33B1.1 -5.7 2.64e-08 1.48e-05 -0.3 -0.29 Corneal astigmatism; chr4:119490752 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs11935596 ENSG00000245958.5 RP11-33B1.1 -5.7 2.64e-08 1.48e-05 -0.3 -0.29 Corneal astigmatism; chr4:119491302 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs12507964 ENSG00000245958.5 RP11-33B1.1 -5.7 2.64e-08 1.48e-05 -0.3 -0.29 Corneal astigmatism; chr4:119491906 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs11098530 ENSG00000245958.5 RP11-33B1.1 -5.7 2.64e-08 1.48e-05 -0.3 -0.29 Corneal astigmatism; chr4:119491999 chr4:119454791~119552025:+ LIHC cis rs6589219 0.954 rs3802841 ENSG00000196167.8 COLCA1 -5.7 2.64e-08 1.48e-05 -0.33 -0.29 Colorectal cancer; chr11:111300947 chr11:111290787~111305045:- LIHC cis rs6589219 0.954 rs3802842 ENSG00000196167.8 COLCA1 -5.7 2.64e-08 1.48e-05 -0.33 -0.29 Colorectal cancer; chr11:111300984 chr11:111290787~111305045:- LIHC cis rs2243480 1 rs387676 ENSG00000273142.1 RP11-458F8.4 -5.7 2.65e-08 1.48e-05 -0.36 -0.29 Diabetic kidney disease; chr7:66133233 chr7:66902857~66906297:+ LIHC cis rs6589219 0.908 rs10891246 ENSG00000196167.8 COLCA1 -5.7 2.65e-08 1.48e-05 -0.33 -0.29 Colorectal cancer; chr11:111299815 chr11:111290787~111305045:- LIHC cis rs6589219 0.954 rs10789823 ENSG00000196167.8 COLCA1 -5.7 2.65e-08 1.48e-05 -0.34 -0.29 Colorectal cancer; chr11:111301678 chr11:111290787~111305045:- LIHC cis rs17023223 0.537 rs10923759 ENSG00000231365.4 RP11-418J17.1 5.7 2.65e-08 1.48e-05 0.36 0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119149571 chr1:119140396~119275973:+ LIHC cis rs67180937 0.583 rs3008622 ENSG00000272750.1 RP11-378J18.8 5.7 2.66e-08 1.48e-05 0.35 0.29 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222632356 chr1:222658867~222661512:- LIHC cis rs950169 0.922 rs67804993 ENSG00000259295.5 CSPG4P12 5.69 2.66e-08 1.49e-05 0.4 0.29 Schizophrenia; chr15:84560799 chr15:85191438~85213905:+ LIHC cis rs11690935 0.959 rs1113389 ENSG00000228389.1 AC068039.4 5.69 2.66e-08 1.49e-05 0.39 0.29 Schizophrenia; chr2:171778855 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs7355594 ENSG00000228389.1 AC068039.4 5.69 2.66e-08 1.49e-05 0.39 0.29 Schizophrenia; chr2:171782938 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs10497374 ENSG00000228389.1 AC068039.4 5.69 2.66e-08 1.49e-05 0.39 0.29 Schizophrenia; chr2:171784113 chr2:171773482~171775844:+ LIHC cis rs6479901 0.947 rs7083823 ENSG00000232075.1 MRPL35P2 -5.69 2.67e-08 1.49e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63510912 chr10:63634317~63634827:- LIHC cis rs8027365 1 rs8027365 ENSG00000260269.4 CTD-2323K18.1 -5.69 2.67e-08 1.49e-05 -0.38 -0.29 Breast cancer; chr15:75516399 chr15:75527150~75601205:- LIHC cis rs4356975 0.509 rs5014975 ENSG00000249956.3 RP11-790I12.2 5.69 2.68e-08 1.49e-05 0.35 0.29 Obesity-related traits; chr4:69130244 chr4:69408836~69423164:+ LIHC cis rs2274273 0.87 rs10144345 ENSG00000258413.1 RP11-665C16.6 -5.69 2.68e-08 1.49e-05 -0.34 -0.29 Protein biomarker; chr14:55381019 chr14:55262767~55272075:- LIHC cis rs2274273 0.87 rs3783650 ENSG00000258413.1 RP11-665C16.6 -5.69 2.68e-08 1.49e-05 -0.34 -0.29 Protein biomarker; chr14:55382254 chr14:55262767~55272075:- LIHC cis rs12681287 0.571 rs10097450 ENSG00000250569.1 NTAN1P2 -5.69 2.68e-08 1.5e-05 -0.35 -0.29 Caudate activity during reward; chr8:86346448 chr8:86481754~86483002:- LIHC cis rs2933343 0.7 rs1680778 ENSG00000231305.3 RP11-723O4.2 5.69 2.69e-08 1.5e-05 0.33 0.29 IgG glycosylation; chr3:128895342 chr3:128861313~128871540:- LIHC cis rs2739330 0.828 rs5760099 ENSG00000099984.9 GSTT2 -5.69 2.69e-08 1.5e-05 -0.34 -0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23980123~23983911:+ LIHC cis rs2243480 1 rs316327 ENSG00000273142.1 RP11-458F8.4 5.69 2.69e-08 1.5e-05 0.37 0.29 Diabetic kidney disease; chr7:66144214 chr7:66902857~66906297:+ LIHC cis rs11098499 0.954 rs11098525 ENSG00000245958.5 RP11-33B1.1 -5.69 2.69e-08 1.5e-05 -0.3 -0.29 Corneal astigmatism; chr4:119468997 chr4:119454791~119552025:+ LIHC cis rs524281 0.861 rs10896090 ENSG00000255320.1 RP11-755F10.1 5.69 2.7e-08 1.5e-05 0.39 0.29 Electroencephalogram traits; chr11:66177715 chr11:66244840~66246239:- LIHC cis rs67180937 0.733 rs35725247 ENSG00000272750.1 RP11-378J18.8 -5.69 2.7e-08 1.5e-05 -0.3 -0.29 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222706825 chr1:222658867~222661512:- LIHC cis rs6479891 1 rs12414159 ENSG00000232075.1 MRPL35P2 5.69 2.71e-08 1.51e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63479017 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs10995543 ENSG00000232075.1 MRPL35P2 5.69 2.71e-08 1.51e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63479787 chr10:63634317~63634827:- LIHC cis rs8059260 0.604 rs12102345 ENSG00000274038.1 RP11-66H6.4 -5.69 2.71e-08 1.51e-05 -0.48 -0.29 Alcohol consumption over the past year; chr16:11053863 chr16:11056556~11057034:+ LIHC cis rs853679 0.527 rs213228 ENSG00000216901.1 AL022393.7 5.69 2.72e-08 1.51e-05 0.37 0.29 Depression; chr6:28363475 chr6:28176188~28176674:+ LIHC cis rs9326248 0.569 rs4938315 ENSG00000280143.1 AP000892.6 5.69 2.72e-08 1.52e-05 0.36 0.29 Blood protein levels; chr11:116860489 chr11:117204967~117210292:+ LIHC cis rs10833905 0.697 rs10766983 ENSG00000246225.5 RP11-17A1.3 -5.69 2.73e-08 1.52e-05 -0.38 -0.29 Sudden cardiac arrest; chr11:22924603 chr11:22829380~22945393:+ LIHC cis rs12908161 1 rs11638290 ENSG00000259295.5 CSPG4P12 5.69 2.73e-08 1.52e-05 0.4 0.29 Schizophrenia; chr15:84684405 chr15:85191438~85213905:+ LIHC cis rs4538475 0.53 rs6449168 ENSG00000214846.4 RP11-115L11.1 5.69 2.73e-08 1.52e-05 0.38 0.29 Parkinson's disease; chr4:15726090 chr4:15730962~15731627:- LIHC cis rs1150668 0.83 rs2023493 ENSG00000204709.4 LINC01556 5.69 2.73e-08 1.52e-05 0.33 0.29 Pubertal anthropometrics; chr6:28432385 chr6:28943877~28944537:+ LIHC cis rs6142102 0.961 rs4911407 ENSG00000276073.1 RP5-1125A11.7 -5.69 2.75e-08 1.53e-05 -0.33 -0.29 Skin pigmentation; chr20:34095759 chr20:33985617~33988989:- LIHC cis rs2243480 1 rs316331 ENSG00000226824.5 RP4-756H11.3 5.69 2.75e-08 1.53e-05 0.48 0.29 Diabetic kidney disease; chr7:66139635 chr7:66654538~66669855:+ LIHC cis rs9326248 0.53 rs2471884 ENSG00000236267.1 AP006216.5 5.69 2.75e-08 1.53e-05 0.33 0.29 Blood protein levels; chr11:117139604 chr11:116813204~116814003:- LIHC cis rs6686842 1 rs213754 ENSG00000235358.1 RP11-399E6.1 -5.69 2.75e-08 1.53e-05 -0.32 -0.29 Height; chr1:41133176 chr1:41242373~41284861:+ LIHC cis rs8059260 0.604 rs9302458 ENSG00000274038.1 RP11-66H6.4 -5.69 2.75e-08 1.53e-05 -0.48 -0.29 Alcohol consumption over the past year; chr16:11050352 chr16:11056556~11057034:+ LIHC cis rs12681287 1 rs12681287 ENSG00000250569.1 NTAN1P2 -5.69 2.75e-08 1.53e-05 -0.36 -0.29 Caudate activity during reward; chr8:86257307 chr8:86481754~86483002:- LIHC cis rs875971 0.545 rs316324 ENSG00000237310.1 GS1-124K5.4 -5.69 2.76e-08 1.53e-05 -0.28 -0.29 Aortic root size; chr7:66145627 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs316323 ENSG00000237310.1 GS1-124K5.4 -5.69 2.76e-08 1.53e-05 -0.28 -0.29 Aortic root size; chr7:66146002 chr7:66493706~66495474:+ LIHC cis rs1150668 0.796 rs1005125 ENSG00000204709.4 LINC01556 5.69 2.76e-08 1.54e-05 0.33 0.29 Pubertal anthropometrics; chr6:28399578 chr6:28943877~28944537:+ LIHC cis rs7586673 0.866 rs747003 ENSG00000227403.1 AC009299.3 5.69 2.77e-08 1.54e-05 0.36 0.29 Intelligence (multi-trait analysis); chr2:161059898 chr2:161244739~161249050:+ LIHC cis rs2933343 0.649 rs2638845 ENSG00000231305.3 RP11-723O4.2 5.69 2.77e-08 1.54e-05 0.33 0.29 IgG glycosylation; chr3:128868526 chr3:128861313~128871540:- LIHC cis rs2933343 0.649 rs728839 ENSG00000231305.3 RP11-723O4.2 5.69 2.77e-08 1.54e-05 0.33 0.29 IgG glycosylation; chr3:128870516 chr3:128861313~128871540:- LIHC cis rs11690935 0.959 rs10167419 ENSG00000228389.1 AC068039.4 5.69 2.78e-08 1.54e-05 0.39 0.29 Schizophrenia; chr2:171793316 chr2:171773482~171775844:+ LIHC cis rs1153858 0.945 rs16943246 ENSG00000259520.4 CTD-2651B20.3 -5.69 2.78e-08 1.54e-05 -0.37 -0.29 Homoarginine levels; chr15:45428399 chr15:45251580~45279251:- LIHC cis rs9326248 1 rs4938344 ENSG00000236267.1 AP006216.5 5.69 2.79e-08 1.55e-05 0.3 0.29 Blood protein levels; chr11:117133033 chr11:116813204~116814003:- LIHC cis rs8028182 0.636 rs7163907 ENSG00000260269.4 CTD-2323K18.1 -5.69 2.79e-08 1.55e-05 -0.38 -0.29 Sudden cardiac arrest; chr15:75552756 chr15:75527150~75601205:- LIHC cis rs5769765 0.773 rs9616751 ENSG00000278869.1 CITF22-49E9.3 5.69 2.8e-08 1.55e-05 0.53 0.29 Schizophrenia; chr22:49828588 chr22:49933198~49934074:- LIHC cis rs2274273 0.87 rs946059 ENSG00000258413.1 RP11-665C16.6 -5.69 2.8e-08 1.56e-05 -0.34 -0.29 Protein biomarker; chr14:55380748 chr14:55262767~55272075:- LIHC cis rs6589219 1 rs6589219 ENSG00000196167.8 COLCA1 -5.69 2.81e-08 1.56e-05 -0.34 -0.29 Colorectal cancer; chr11:111302186 chr11:111290787~111305045:- LIHC cis rs11672691 0.627 rs6508981 ENSG00000267107.5 PCAT19 5.68 2.81e-08 1.56e-05 0.36 0.29 Prostate cancer; chr19:41483668 chr19:41454169~41500649:- LIHC cis rs12681287 0.517 rs34596274 ENSG00000250569.1 NTAN1P2 5.68 2.81e-08 1.56e-05 0.35 0.29 Caudate activity during reward; chr8:86505450 chr8:86481754~86483002:- LIHC cis rs7131987 0.801 rs6487804 ENSG00000257176.2 RP11-996F15.2 -5.68 2.81e-08 1.56e-05 -0.33 -0.29 QT interval; chr12:29302001 chr12:29280418~29317848:- LIHC cis rs3779195 0.697 rs13232861 ENSG00000272950.1 RP11-307C18.1 5.68 2.82e-08 1.57e-05 0.42 0.29 Sex hormone-binding globulin levels; chr7:98299769 chr7:98322853~98323430:+ LIHC cis rs8100891 0.506 rs10408437 ENSG00000267213.4 AC007773.2 -5.68 2.83e-08 1.57e-05 -0.38 -0.29 Neuroticism; chr19:32497094 chr19:32390050~32405560:- LIHC cis rs2762353 0.553 rs9467581 ENSG00000242387.1 HIST1H2APS2 -5.68 2.84e-08 1.57e-05 -0.37 -0.29 Blood metabolite levels; chr6:25710320 chr6:25882026~25882395:- LIHC cis rs7115242 0.748 rs1035237 ENSG00000280143.1 AP000892.6 5.68 2.84e-08 1.57e-05 0.36 0.29 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116857134 chr11:117204967~117210292:+ LIHC cis rs2522056 0.932 rs2522064 ENSG00000233006.5 AC034220.3 -5.68 2.84e-08 1.57e-05 -0.3 -0.29 Fibrinogen;Lymphocyte counts; chr5:132470796 chr5:132311285~132369916:- LIHC cis rs12681287 1 rs7833786 ENSG00000250569.1 NTAN1P2 -5.68 2.84e-08 1.58e-05 -0.35 -0.29 Caudate activity during reward; chr8:86259145 chr8:86481754~86483002:- LIHC cis rs6479901 0.947 rs7068144 ENSG00000232075.1 MRPL35P2 -5.68 2.84e-08 1.58e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63514500 chr10:63634317~63634827:- LIHC cis rs2739330 0.76 rs1007888 ENSG00000206090.4 AP000350.7 5.68 2.84e-08 1.58e-05 0.35 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23939998~23942798:+ LIHC cis rs6921919 0.583 rs9461459 ENSG00000216901.1 AL022393.7 5.68 2.85e-08 1.58e-05 0.36 0.29 Autism spectrum disorder or schizophrenia; chr6:28394139 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs28360638 ENSG00000216901.1 AL022393.7 5.68 2.85e-08 1.58e-05 0.36 0.29 Autism spectrum disorder or schizophrenia; chr6:28394552 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs9468368 ENSG00000216901.1 AL022393.7 5.68 2.85e-08 1.58e-05 0.36 0.29 Autism spectrum disorder or schizophrenia; chr6:28397172 chr6:28176188~28176674:+ LIHC cis rs7927592 0.956 rs11228277 ENSG00000212093.1 AP000807.1 5.68 2.85e-08 1.58e-05 0.31 0.29 Total body bone mineral density; chr11:68540856 chr11:68506083~68506166:- LIHC cis rs7927592 0.956 rs11228278 ENSG00000212093.1 AP000807.1 5.68 2.85e-08 1.58e-05 0.31 0.29 Total body bone mineral density; chr11:68541062 chr11:68506083~68506166:- LIHC cis rs6589219 0.908 rs7103178 ENSG00000196167.8 COLCA1 -5.68 2.86e-08 1.58e-05 -0.32 -0.29 Colorectal cancer; chr11:111294284 chr11:111290787~111305045:- LIHC cis rs8028182 0.636 rs62027209 ENSG00000260269.4 CTD-2323K18.1 -5.68 2.86e-08 1.58e-05 -0.38 -0.29 Sudden cardiac arrest; chr15:75579285 chr15:75527150~75601205:- LIHC cis rs10510102 0.935 rs77447688 ENSG00000276742.1 RP11-500G22.4 5.68 2.86e-08 1.58e-05 0.48 0.29 Breast cancer; chr10:121925721 chr10:121956782~121957098:+ LIHC cis rs9388451 0.874 rs7739566 ENSG00000237742.5 RP11-624M8.1 -5.68 2.86e-08 1.58e-05 -0.27 -0.29 Brugada syndrome; chr6:125773611 chr6:125578558~125749190:- LIHC cis rs9388451 0.839 rs4897155 ENSG00000237742.5 RP11-624M8.1 -5.68 2.86e-08 1.58e-05 -0.27 -0.29 Brugada syndrome; chr6:125773998 chr6:125578558~125749190:- LIHC cis rs6142102 0.961 rs6120519 ENSG00000276073.1 RP5-1125A11.7 -5.68 2.88e-08 1.6e-05 -0.32 -0.29 Skin pigmentation; chr20:34100307 chr20:33985617~33988989:- LIHC cis rs1005277 0.522 rs1208767 ENSG00000263064.2 RP11-291L22.7 5.68 2.89e-08 1.6e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:37753367 chr10:38448689~38448949:+ LIHC cis rs12681287 0.547 rs7465511 ENSG00000250569.1 NTAN1P2 5.68 2.89e-08 1.6e-05 0.35 0.29 Caudate activity during reward; chr8:86509252 chr8:86481754~86483002:- LIHC cis rs2283792 1 rs3810610 ENSG00000224086.5 LL22NC03-86G7.1 -5.68 2.89e-08 1.6e-05 -0.27 -0.29 Multiple sclerosis; chr22:21761209 chr22:21938293~21977632:+ LIHC cis rs739496 0.843 rs621899 ENSG00000226469.1 ADAM1B 5.68 2.89e-08 1.6e-05 0.36 0.29 Platelet count; chr12:111547047 chr12:111927018~111929017:+ LIHC cis rs739496 0.843 rs625093 ENSG00000226469.1 ADAM1B 5.68 2.89e-08 1.6e-05 0.36 0.29 Platelet count; chr12:111550628 chr12:111927018~111929017:+ LIHC cis rs739496 0.843 rs638791 ENSG00000226469.1 ADAM1B 5.68 2.89e-08 1.6e-05 0.36 0.29 Platelet count; chr12:111551432 chr12:111927018~111929017:+ LIHC cis rs6479891 1 rs4745729 ENSG00000232075.1 MRPL35P2 5.68 2.9e-08 1.6e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63517323 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs12416349 ENSG00000232075.1 MRPL35P2 5.68 2.9e-08 1.6e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63517783 chr10:63634317~63634827:- LIHC cis rs2283792 0.567 rs2027789 ENSG00000224086.5 LL22NC03-86G7.1 -5.68 2.9e-08 1.6e-05 -0.33 -0.29 Multiple sclerosis; chr22:21933490 chr22:21938293~21977632:+ LIHC cis rs9487094 0.644 rs9320288 ENSG00000260273.1 RP11-425D10.10 5.68 2.9e-08 1.61e-05 0.34 0.29 Height; chr6:109446727 chr6:109382795~109383666:+ LIHC cis rs12291225 0.585 rs12270374 ENSG00000251991.1 RNU7-49P 5.68 2.91e-08 1.61e-05 0.31 0.29 Sense of smell; chr11:14353533 chr11:14478892~14478953:+ LIHC cis rs2153535 0.58 rs9505457 ENSG00000230939.1 RP11-314C16.1 -5.68 2.92e-08 1.61e-05 -0.36 -0.29 Motion sickness; chr6:8478909 chr6:8784178~8785445:+ LIHC cis rs2153535 0.56 rs9379214 ENSG00000230939.1 RP11-314C16.1 -5.68 2.92e-08 1.61e-05 -0.36 -0.29 Motion sickness; chr6:8480637 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2225765 ENSG00000230939.1 RP11-314C16.1 -5.68 2.92e-08 1.61e-05 -0.36 -0.29 Motion sickness; chr6:8481552 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1577472 ENSG00000230939.1 RP11-314C16.1 -5.68 2.92e-08 1.61e-05 -0.36 -0.29 Motion sickness; chr6:8485982 chr6:8784178~8785445:+ LIHC cis rs2153535 0.542 rs1120393 ENSG00000230939.1 RP11-314C16.1 -5.68 2.92e-08 1.61e-05 -0.36 -0.29 Motion sickness; chr6:8486657 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9406165 ENSG00000230939.1 RP11-314C16.1 -5.68 2.92e-08 1.61e-05 -0.36 -0.29 Motion sickness; chr6:8488604 chr6:8784178~8785445:+ LIHC cis rs2153535 0.563 rs4428546 ENSG00000230939.1 RP11-314C16.1 -5.68 2.92e-08 1.61e-05 -0.36 -0.29 Motion sickness; chr6:8490143 chr6:8784178~8785445:+ LIHC cis rs2153535 0.505 rs1335629 ENSG00000230939.1 RP11-314C16.1 -5.68 2.92e-08 1.61e-05 -0.36 -0.29 Motion sickness; chr6:8491630 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs763376 ENSG00000230939.1 RP11-314C16.1 -5.68 2.92e-08 1.61e-05 -0.36 -0.29 Motion sickness; chr6:8492543 chr6:8784178~8785445:+ LIHC cis rs7945705 0.902 rs2012696 ENSG00000254860.4 TMEM9B-AS1 -5.68 2.92e-08 1.61e-05 -0.3 -0.29 Hemoglobin concentration; chr11:8974271 chr11:8964675~8977527:+ LIHC cis rs11690935 0.959 rs11904009 ENSG00000228389.1 AC068039.4 5.68 2.93e-08 1.62e-05 0.4 0.29 Schizophrenia; chr2:171770833 chr2:171773482~171775844:+ LIHC cis rs7119038 0.818 rs6589686 ENSG00000255239.1 AP002954.6 -5.68 2.93e-08 1.62e-05 -0.37 -0.29 Sjögren's syndrome; chr11:118741856 chr11:118688039~118690600:- LIHC cis rs113835537 0.529 rs10896125 ENSG00000255517.5 CTD-3074O7.5 -5.68 2.94e-08 1.63e-05 -0.32 -0.29 Airway imaging phenotypes; chr11:66521262 chr11:66473490~66480233:- LIHC cis rs11098499 0.954 rs6849561 ENSG00000245958.5 RP11-33B1.1 5.68 2.95e-08 1.63e-05 0.31 0.29 Corneal astigmatism; chr4:119488539 chr4:119454791~119552025:+ LIHC cis rs12681287 0.571 rs13254675 ENSG00000250569.1 NTAN1P2 5.68 2.95e-08 1.63e-05 0.35 0.29 Caudate activity during reward; chr8:86341365 chr8:86481754~86483002:- LIHC cis rs12681287 0.605 rs13262672 ENSG00000250569.1 NTAN1P2 5.68 2.95e-08 1.63e-05 0.35 0.29 Caudate activity during reward; chr8:86343583 chr8:86481754~86483002:- LIHC cis rs150992 0.609 rs4703049 ENSG00000248489.1 CTD-2007H13.3 5.68 2.95e-08 1.63e-05 0.43 0.29 Body mass index; chr5:99004679 chr5:98929171~98995013:+ LIHC cis rs9341808 0.5 rs2223873 ENSG00000272129.1 RP11-250B2.6 5.68 2.95e-08 1.63e-05 0.29 0.29 Sitting height ratio; chr6:80338571 chr6:80355424~80356859:+ LIHC cis rs1075265 0.584 rs1559037 ENSG00000233266.1 HMGB1P31 5.68 2.95e-08 1.63e-05 0.37 0.29 Chronotype;Morning vs. evening chronotype; chr2:54051448 chr2:54051334~54051760:+ LIHC cis rs9487094 0.643 rs730089 ENSG00000260273.1 RP11-425D10.10 5.68 2.95e-08 1.63e-05 0.35 0.29 Height; chr6:109393881 chr6:109382795~109383666:+ LIHC cis rs7429990 0.866 rs3732529 ENSG00000229759.1 MRPS18AP1 5.68 2.95e-08 1.63e-05 0.31 0.29 Educational attainment (years of education); chr3:47928619 chr3:48256350~48256938:- LIHC cis rs7429990 0.932 rs60446735 ENSG00000229759.1 MRPS18AP1 5.68 2.95e-08 1.63e-05 0.31 0.29 Educational attainment (years of education); chr3:47929958 chr3:48256350~48256938:- LIHC cis rs227275 0.525 rs7698608 ENSG00000230069.3 LRRC37A15P -5.67 2.96e-08 1.63e-05 -0.26 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:103016817 chr4:102727274~102730721:- LIHC cis rs2212361 0.615 rs6483345 ENSG00000255893.1 RP11-685N10.1 -5.67 2.96e-08 1.63e-05 -0.29 -0.29 Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction); chr11:94530983 chr11:94472908~94473570:- LIHC cis rs9640161 0.75 rs11765644 ENSG00000261305.1 RP4-584D14.7 5.67 2.96e-08 1.64e-05 0.37 0.29 Blood protein levels;Circulating chemerin levels; chr7:150329250 chr7:150341771~150342607:+ LIHC cis rs4934494 0.635 rs12572869 ENSG00000232936.4 RP11-80H5.2 5.67 2.99e-08 1.65e-05 0.38 0.29 Red blood cell count; chr10:89653611 chr10:89645282~89650667:+ LIHC cis rs13068223 0.935 rs1560414 ENSG00000243926.1 TIPARP-AS1 5.67 2.99e-08 1.65e-05 0.28 0.29 Age-related hearing impairment (SNP x SNP interaction); chr3:156723960 chr3:156671862~156674378:- LIHC cis rs734999 0.967 rs10752745 ENSG00000225931.3 RP3-395M20.7 5.67 3e-08 1.65e-05 0.32 0.29 Ulcerative colitis; chr1:2576499 chr1:2566410~2569888:+ LIHC cis rs7927592 0.956 rs948315 ENSG00000212093.1 AP000807.1 5.67 3e-08 1.65e-05 0.32 0.29 Total body bone mineral density; chr11:68541672 chr11:68506083~68506166:- LIHC cis rs4356975 0.527 rs57102579 ENSG00000249956.3 RP11-790I12.2 5.67 3e-08 1.65e-05 0.35 0.29 Obesity-related traits; chr4:69125476 chr4:69408836~69423164:+ LIHC cis rs4356975 0.527 rs4385139 ENSG00000249956.3 RP11-790I12.2 5.67 3e-08 1.65e-05 0.35 0.29 Obesity-related traits; chr4:69125911 chr4:69408836~69423164:+ LIHC cis rs4356975 0.527 rs4694645 ENSG00000249956.3 RP11-790I12.2 5.67 3e-08 1.65e-05 0.35 0.29 Obesity-related traits; chr4:69127200 chr4:69408836~69423164:+ LIHC cis rs12908161 0.92 rs35758837 ENSG00000259295.5 CSPG4P12 5.67 3e-08 1.65e-05 0.4 0.29 Schizophrenia; chr15:84768151 chr15:85191438~85213905:+ LIHC cis rs11098499 0.954 rs3733520 ENSG00000245958.5 RP11-33B1.1 -5.67 3e-08 1.65e-05 -0.3 -0.29 Corneal astigmatism; chr4:119502325 chr4:119454791~119552025:+ LIHC cis rs2243480 0.803 rs160649 ENSG00000226824.5 RP4-756H11.3 -5.67 3.01e-08 1.66e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66078212 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs160648 ENSG00000226824.5 RP4-756H11.3 -5.67 3.01e-08 1.66e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66078397 chr7:66654538~66669855:+ LIHC cis rs739496 0.793 rs76604970 ENSG00000226469.1 ADAM1B 5.67 3.01e-08 1.66e-05 0.36 0.29 Platelet count; chr12:111529351 chr12:111927018~111929017:+ LIHC cis rs8100891 0.537 rs16967057 ENSG00000267213.4 AC007773.2 5.67 3.02e-08 1.66e-05 0.36 0.29 Neuroticism; chr19:32423172 chr19:32390050~32405560:- LIHC cis rs67180937 0.733 rs61824331 ENSG00000272750.1 RP11-378J18.8 -5.67 3.02e-08 1.67e-05 -0.3 -0.29 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222708030 chr1:222658867~222661512:- LIHC cis rs7945705 0.837 rs2742474 ENSG00000254860.4 TMEM9B-AS1 5.67 3.04e-08 1.67e-05 0.3 0.29 Hemoglobin concentration; chr11:8980542 chr11:8964675~8977527:+ LIHC cis rs7945705 0.869 rs2742471 ENSG00000254860.4 TMEM9B-AS1 5.67 3.04e-08 1.67e-05 0.3 0.29 Hemoglobin concentration; chr11:8982406 chr11:8964675~8977527:+ LIHC cis rs12468226 0.606 rs79092351 ENSG00000273456.1 RP11-686O6.2 5.67 3.05e-08 1.68e-05 0.38 0.29 Urate levels; chr2:202204388 chr2:202374932~202375604:- LIHC cis rs2243480 1 rs313832 ENSG00000226824.5 RP4-756H11.3 -5.67 3.05e-08 1.68e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66085904 chr7:66654538~66669855:+ LIHC cis rs11676348 0.846 rs7607437 ENSG00000261338.2 RP11-378A13.1 -5.67 3.06e-08 1.68e-05 -0.3 -0.29 Ulcerative colitis; chr2:218143669 chr2:218255319~218257366:+ LIHC cis rs6479901 0.947 rs7097698 ENSG00000232075.1 MRPL35P2 -5.67 3.06e-08 1.68e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63513635 chr10:63634317~63634827:- LIHC cis rs875971 0.767 rs12668005 ENSG00000237310.1 GS1-124K5.4 5.67 3.07e-08 1.69e-05 0.26 0.29 Aortic root size; chr7:66444034 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs11765791 ENSG00000237310.1 GS1-124K5.4 5.67 3.07e-08 1.69e-05 0.26 0.29 Aortic root size; chr7:66471587 chr7:66493706~66495474:+ LIHC cis rs524281 0.861 rs7943911 ENSG00000255320.1 RP11-755F10.1 5.67 3.07e-08 1.69e-05 0.38 0.29 Electroencephalogram traits; chr11:66175583 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs10750778 ENSG00000255320.1 RP11-755F10.1 5.67 3.07e-08 1.69e-05 0.38 0.29 Electroencephalogram traits; chr11:66181177 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs6591208 ENSG00000255320.1 RP11-755F10.1 5.67 3.07e-08 1.69e-05 0.38 0.29 Electroencephalogram traits; chr11:66182218 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs10896091 ENSG00000255320.1 RP11-755F10.1 5.67 3.07e-08 1.69e-05 0.38 0.29 Electroencephalogram traits; chr11:66183354 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs7929909 ENSG00000255320.1 RP11-755F10.1 5.67 3.07e-08 1.69e-05 0.38 0.29 Electroencephalogram traits; chr11:66184227 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs10896094 ENSG00000255320.1 RP11-755F10.1 5.67 3.07e-08 1.69e-05 0.38 0.29 Electroencephalogram traits; chr11:66191735 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs2293121 ENSG00000255320.1 RP11-755F10.1 5.67 3.07e-08 1.69e-05 0.38 0.29 Electroencephalogram traits; chr11:66193876 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs2177053 ENSG00000255320.1 RP11-755F10.1 5.67 3.07e-08 1.69e-05 0.38 0.29 Electroencephalogram traits; chr11:66198674 chr11:66244840~66246239:- LIHC cis rs524281 0.814 rs10896098 ENSG00000255320.1 RP11-755F10.1 5.67 3.07e-08 1.69e-05 0.38 0.29 Electroencephalogram traits; chr11:66200945 chr11:66244840~66246239:- LIHC cis rs12908161 1 rs36033486 ENSG00000259295.5 CSPG4P12 5.67 3.07e-08 1.69e-05 0.4 0.29 Schizophrenia; chr15:84776461 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs12908549 ENSG00000259295.5 CSPG4P12 5.67 3.07e-08 1.69e-05 0.4 0.29 Schizophrenia; chr15:84779120 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs12903134 ENSG00000259295.5 CSPG4P12 5.67 3.07e-08 1.69e-05 0.4 0.29 Schizophrenia; chr15:84794468 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs35726233 ENSG00000259295.5 CSPG4P12 5.67 3.07e-08 1.69e-05 0.4 0.29 Schizophrenia; chr15:84794569 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs35960805 ENSG00000259295.5 CSPG4P12 5.67 3.07e-08 1.69e-05 0.4 0.29 Schizophrenia; chr15:84800749 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs12912388 ENSG00000259295.5 CSPG4P12 5.67 3.07e-08 1.69e-05 0.4 0.29 Schizophrenia; chr15:84801319 chr15:85191438~85213905:+ LIHC cis rs2799081 1 rs2799081 ENSG00000216901.1 AL022393.7 5.67 3.07e-08 1.69e-05 0.35 0.29 Myopia; chr6:28302807 chr6:28176188~28176674:+ LIHC cis rs227275 0.525 rs28445579 ENSG00000246560.2 RP11-10L12.4 5.67 3.08e-08 1.69e-05 0.33 0.29 Allergic disease (asthma, hay fever or eczema); chr4:103016438 chr4:102828055~102844075:+ LIHC cis rs11722779 0.935 rs7676736 ENSG00000246560.2 RP11-10L12.4 5.67 3.08e-08 1.69e-05 0.33 0.29 Schizophrenia; chr4:103016729 chr4:102828055~102844075:+ LIHC cis rs11673344 0.566 rs2385180 ENSG00000226686.6 LINC01535 -5.67 3.08e-08 1.69e-05 -0.36 -0.29 Obesity-related traits; chr19:37431454 chr19:37251912~37265535:+ LIHC cis rs12681287 0.752 rs7822268 ENSG00000250569.1 NTAN1P2 5.67 3.09e-08 1.7e-05 0.36 0.29 Caudate activity during reward; chr8:86294211 chr8:86481754~86483002:- LIHC cis rs6479891 1 rs2893922 ENSG00000232075.1 MRPL35P2 -5.67 3.09e-08 1.7e-05 -0.34 -0.29 Arthritis (juvenile idiopathic); chr10:63487259 chr10:63634317~63634827:- LIHC cis rs2735413 0.918 rs4888731 ENSG00000276007.1 RP11-358L22.3 -5.67 3.09e-08 1.7e-05 -0.31 -0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78046521 chr16:78123243~78124332:+ LIHC cis rs12681287 0.888 rs2976201 ENSG00000250569.1 NTAN1P2 5.67 3.09e-08 1.7e-05 0.35 0.29 Caudate activity during reward; chr8:86323708 chr8:86481754~86483002:- LIHC cis rs1577917 0.816 rs12664099 ENSG00000234155.1 RP11-30P6.6 5.67 3.09e-08 1.7e-05 0.35 0.29 Response to antipsychotic treatment; chr6:85938854 chr6:85387219~85390186:- LIHC cis rs113835537 0.529 rs3892818 ENSG00000255517.5 CTD-3074O7.5 -5.67 3.09e-08 1.7e-05 -0.32 -0.29 Airway imaging phenotypes; chr11:66472720 chr11:66473490~66480233:- LIHC cis rs6686842 1 rs12125555 ENSG00000235358.1 RP11-399E6.1 5.67 3.09e-08 1.7e-05 0.32 0.29 Height; chr1:41241439 chr1:41242373~41284861:+ LIHC cis rs2243480 1 rs316307 ENSG00000226824.5 RP4-756H11.3 -5.67 3.09e-08 1.7e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66105184 chr7:66654538~66669855:+ LIHC cis rs13631 0.928 rs9411308 ENSG00000268996.3 MAN1B1-AS1 5.67 3.1e-08 1.7e-05 0.32 0.29 Cerebrospinal fluid biomarker levels; chr9:137105663 chr9:137084946~137086817:- LIHC cis rs2933343 0.729 rs1683816 ENSG00000231305.3 RP11-723O4.2 -5.67 3.1e-08 1.7e-05 -0.32 -0.29 IgG glycosylation; chr3:128932352 chr3:128861313~128871540:- LIHC cis rs7115242 0.858 rs6589592 ENSG00000236267.1 AP006216.5 5.67 3.11e-08 1.71e-05 0.39 0.29 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117087191 chr11:116813204~116814003:- LIHC cis rs2153535 0.58 rs962590 ENSG00000230939.1 RP11-314C16.1 -5.67 3.11e-08 1.71e-05 -0.36 -0.29 Motion sickness; chr6:8450666 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs5001324 ENSG00000230939.1 RP11-314C16.1 -5.67 3.11e-08 1.71e-05 -0.36 -0.29 Motion sickness; chr6:8451371 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs5001322 ENSG00000230939.1 RP11-314C16.1 -5.67 3.11e-08 1.71e-05 -0.36 -0.29 Motion sickness; chr6:8451375 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs969422 ENSG00000230939.1 RP11-314C16.1 -5.67 3.11e-08 1.71e-05 -0.36 -0.29 Motion sickness; chr6:8451547 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs969421 ENSG00000230939.1 RP11-314C16.1 -5.67 3.11e-08 1.71e-05 -0.36 -0.29 Motion sickness; chr6:8451716 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs969420 ENSG00000230939.1 RP11-314C16.1 -5.67 3.11e-08 1.71e-05 -0.36 -0.29 Motion sickness; chr6:8451733 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7741456 ENSG00000230939.1 RP11-314C16.1 -5.67 3.11e-08 1.71e-05 -0.36 -0.29 Motion sickness; chr6:8452191 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7742689 ENSG00000230939.1 RP11-314C16.1 -5.67 3.11e-08 1.71e-05 -0.36 -0.29 Motion sickness; chr6:8452200 chr6:8784178~8785445:+ LIHC cis rs2243480 1 rs160655 ENSG00000273142.1 RP11-458F8.4 -5.66 3.12e-08 1.71e-05 -0.36 -0.29 Diabetic kidney disease; chr7:66068227 chr7:66902857~66906297:+ LIHC cis rs1185460 1 rs1185460 ENSG00000271751.1 RP11-110I1.14 5.66 3.12e-08 1.71e-05 0.41 0.29 Coronary artery disease; chr11:119072723 chr11:119065263~119065677:- LIHC cis rs2688482 0.512 rs3103954 ENSG00000242086.7 LINC00969 5.66 3.13e-08 1.72e-05 0.37 0.29 Lung disease severity in cystic fibrosis; chr3:195789759 chr3:195658062~195739964:+ LIHC cis rs5769707 0.632 rs5770601 ENSG00000235111.1 RP1-29C18.8 -5.66 3.16e-08 1.73e-05 -0.36 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49628255 chr22:49612657~49615716:- LIHC cis rs5756813 0.87 rs5756812 ENSG00000233360.4 Z83844.1 -5.66 3.16e-08 1.73e-05 -0.37 -0.29 Optic cup area;Vertical cup-disc ratio; chr22:37777106 chr22:37641832~37658377:- LIHC cis rs6479901 0.947 rs7082076 ENSG00000232075.1 MRPL35P2 -5.66 3.16e-08 1.73e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63517185 chr10:63634317~63634827:- LIHC cis rs875971 0.545 rs7783889 ENSG00000237310.1 GS1-124K5.4 5.66 3.17e-08 1.74e-05 0.28 0.29 Aortic root size; chr7:66283366 chr7:66493706~66495474:+ LIHC cis rs4698412 0.874 rs3213710 ENSG00000214846.4 RP11-115L11.1 -5.66 3.17e-08 1.74e-05 -0.37 -0.29 Parkinson's disease; chr4:15715698 chr4:15730962~15731627:- LIHC cis rs11098499 0.691 rs10028773 ENSG00000245958.5 RP11-33B1.1 5.66 3.17e-08 1.74e-05 0.29 0.29 Corneal astigmatism; chr4:119344104 chr4:119454791~119552025:+ LIHC cis rs1155848 0.571 rs6563127 ENSG00000227354.5 RBM26-AS1 5.66 3.18e-08 1.74e-05 0.51 0.29 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79642012 chr13:79406309~79424328:+ LIHC cis rs2153535 0.542 rs915354 ENSG00000230939.1 RP11-314C16.1 -5.66 3.19e-08 1.75e-05 -0.36 -0.29 Motion sickness; chr6:8440124 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs5001130 ENSG00000230939.1 RP11-314C16.1 -5.66 3.19e-08 1.75e-05 -0.36 -0.29 Motion sickness; chr6:8442065 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2327057 ENSG00000230939.1 RP11-314C16.1 -5.66 3.19e-08 1.75e-05 -0.36 -0.29 Motion sickness; chr6:8443086 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1577466 ENSG00000230939.1 RP11-314C16.1 -5.66 3.19e-08 1.75e-05 -0.36 -0.29 Motion sickness; chr6:8443959 chr6:8784178~8785445:+ LIHC cis rs7927592 0.956 rs55816191 ENSG00000212093.1 AP000807.1 5.66 3.19e-08 1.75e-05 0.31 0.29 Total body bone mineral density; chr11:68495511 chr11:68506083~68506166:- LIHC cis rs2836950 0.501 rs13047518 ENSG00000255568.3 BRWD1-AS2 -5.66 3.19e-08 1.75e-05 -0.24 -0.29 Menarche (age at onset); chr21:39335381 chr21:39313935~39314962:+ LIHC cis rs2739330 0.796 rs5760106 ENSG00000099984.9 GSTT2 5.66 3.2e-08 1.75e-05 0.33 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23980123~23983911:+ LIHC cis rs9640161 0.789 rs2098053 ENSG00000261305.1 RP4-584D14.7 5.66 3.2e-08 1.75e-05 0.38 0.29 Blood protein levels;Circulating chemerin levels; chr7:150346116 chr7:150341771~150342607:+ LIHC cis rs150992 0.536 rs10479348 ENSG00000248489.1 CTD-2007H13.3 -5.66 3.2e-08 1.75e-05 -0.47 -0.29 Body mass index; chr5:99013022 chr5:98929171~98995013:+ LIHC cis rs2153535 0.58 rs1932283 ENSG00000230939.1 RP11-314C16.1 -5.66 3.21e-08 1.75e-05 -0.36 -0.29 Motion sickness; chr6:8477428 chr6:8784178~8785445:+ LIHC cis rs4934494 0.768 rs12572608 ENSG00000232936.4 RP11-80H5.2 -5.66 3.21e-08 1.76e-05 -0.37 -0.29 Red blood cell count; chr10:89647170 chr10:89645282~89650667:+ LIHC cis rs12681287 0.605 rs6471296 ENSG00000250569.1 NTAN1P2 -5.66 3.22e-08 1.76e-05 -0.35 -0.29 Caudate activity during reward; chr8:86362425 chr8:86481754~86483002:- LIHC cis rs6686842 1 rs213748 ENSG00000235358.1 RP11-399E6.1 -5.66 3.22e-08 1.76e-05 -0.32 -0.29 Height; chr1:41163058 chr1:41242373~41284861:+ LIHC cis rs6686842 1 rs213747 ENSG00000235358.1 RP11-399E6.1 -5.66 3.22e-08 1.76e-05 -0.32 -0.29 Height; chr1:41163066 chr1:41242373~41284861:+ LIHC cis rs6686842 1 rs2363803 ENSG00000235358.1 RP11-399E6.1 5.66 3.22e-08 1.76e-05 0.32 0.29 Height; chr1:41171857 chr1:41242373~41284861:+ LIHC cis rs6686842 1 rs34454389 ENSG00000235358.1 RP11-399E6.1 5.66 3.22e-08 1.76e-05 0.32 0.29 Height; chr1:41197564 chr1:41242373~41284861:+ LIHC cis rs7104764 0.833 rs12574034 ENSG00000277290.1 RP11-326C3.16 5.66 3.23e-08 1.76e-05 0.25 0.29 Menarche (age at onset); chr11:212262 chr11:243099~243483:- LIHC cis rs7429990 0.864 rs11712464 ENSG00000229759.1 MRPS18AP1 5.66 3.23e-08 1.77e-05 0.32 0.29 Educational attainment (years of education); chr3:47724057 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs56376646 ENSG00000229759.1 MRPS18AP1 5.66 3.23e-08 1.77e-05 0.32 0.29 Educational attainment (years of education); chr3:47732588 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs11927129 ENSG00000229759.1 MRPS18AP1 5.66 3.23e-08 1.77e-05 0.32 0.29 Educational attainment (years of education); chr3:47745413 chr3:48256350~48256938:- LIHC cis rs11098499 0.954 rs10518328 ENSG00000245958.5 RP11-33B1.1 -5.66 3.24e-08 1.77e-05 -0.3 -0.29 Corneal astigmatism; chr4:119480624 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs6822679 ENSG00000245958.5 RP11-33B1.1 -5.66 3.24e-08 1.77e-05 -0.3 -0.29 Corneal astigmatism; chr4:119481547 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs4577559 ENSG00000245958.5 RP11-33B1.1 -5.66 3.24e-08 1.77e-05 -0.3 -0.29 Corneal astigmatism; chr4:119482888 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs7656252 ENSG00000245958.5 RP11-33B1.1 -5.66 3.24e-08 1.77e-05 -0.3 -0.29 Corneal astigmatism; chr4:119483113 chr4:119454791~119552025:+ LIHC cis rs11098499 0.865 rs28845498 ENSG00000245958.5 RP11-33B1.1 -5.66 3.24e-08 1.77e-05 -0.3 -0.29 Corneal astigmatism; chr4:119484031 chr4:119454791~119552025:+ LIHC cis rs11098499 0.865 rs28753180 ENSG00000245958.5 RP11-33B1.1 -5.66 3.24e-08 1.77e-05 -0.3 -0.29 Corneal astigmatism; chr4:119484212 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs56270433 ENSG00000245958.5 RP11-33B1.1 -5.66 3.24e-08 1.77e-05 -0.3 -0.29 Corneal astigmatism; chr4:119484875 chr4:119454791~119552025:+ LIHC cis rs7927592 0.956 rs7126340 ENSG00000212093.1 AP000807.1 5.66 3.24e-08 1.77e-05 0.32 0.29 Total body bone mineral density; chr11:68489825 chr11:68506083~68506166:- LIHC cis rs12681287 0.517 rs68008113 ENSG00000250569.1 NTAN1P2 5.66 3.24e-08 1.77e-05 0.35 0.29 Caudate activity during reward; chr8:86508665 chr8:86481754~86483002:- LIHC cis rs3096299 0.719 rs2353581 ENSG00000261118.1 RP11-104N10.1 5.66 3.24e-08 1.77e-05 0.29 0.29 Multiple myeloma (IgH translocation); chr16:89452500 chr16:89492017~89504460:- LIHC cis rs7429990 0.965 rs7619882 ENSG00000229759.1 MRPS18AP1 5.66 3.25e-08 1.77e-05 0.31 0.29 Educational attainment (years of education); chr3:47943334 chr3:48256350~48256938:- LIHC cis rs10129255 0.509 rs756583 ENSG00000211972.2 IGHV3-66 5.66 3.25e-08 1.77e-05 0.22 0.29 Kawasaki disease; chr14:106680002 chr14:106675017~106675544:- LIHC cis rs9660180 0.783 rs1107910 ENSG00000231050.1 RP1-140A9.1 5.66 3.25e-08 1.78e-05 0.27 0.29 Body mass index; chr1:1760882 chr1:1891471~1892658:+ LIHC cis rs5756813 1 rs1074407 ENSG00000233360.4 Z83844.1 -5.66 3.25e-08 1.78e-05 -0.35 -0.29 Optic cup area;Vertical cup-disc ratio; chr22:37760176 chr22:37641832~37658377:- LIHC cis rs9487094 0.666 rs746794 ENSG00000260273.1 RP11-425D10.10 5.66 3.25e-08 1.78e-05 0.34 0.29 Height; chr6:109391534 chr6:109382795~109383666:+ LIHC cis rs4934494 0.911 rs7098233 ENSG00000232936.4 RP11-80H5.2 -5.66 3.26e-08 1.78e-05 -0.36 -0.29 Red blood cell count; chr10:89663111 chr10:89645282~89650667:+ LIHC cis rs11676348 0.818 rs7423433 ENSG00000261338.2 RP11-378A13.1 -5.66 3.26e-08 1.78e-05 -0.3 -0.29 Ulcerative colitis; chr2:218120361 chr2:218255319~218257366:+ LIHC cis rs8177376 0.906 rs1613842 ENSG00000254905.1 RP11-712L6.7 5.66 3.26e-08 1.78e-05 0.44 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126326015 chr11:126292922~126294254:- LIHC cis rs8177376 0.906 rs1695739 ENSG00000254905.1 RP11-712L6.7 5.66 3.26e-08 1.78e-05 0.44 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126326280 chr11:126292922~126294254:- LIHC cis rs77204473 0.793 rs11216206 ENSG00000254851.1 RP11-109L13.1 5.66 3.27e-08 1.79e-05 0.45 0.29 Sum eosinophil basophil counts;Eosinophil counts; chr11:116972709 chr11:117135528~117138582:+ LIHC cis rs7927592 0.956 rs10896343 ENSG00000212093.1 AP000807.1 5.66 3.28e-08 1.79e-05 0.32 0.29 Total body bone mineral density; chr11:68550392 chr11:68506083~68506166:- LIHC cis rs319690 1 rs319690 ENSG00000229759.1 MRPS18AP1 5.66 3.28e-08 1.79e-05 0.31 0.29 Diastolic blood pressure;Systolic blood pressure;Blood pressure; chr3:47885994 chr3:48256350~48256938:- LIHC cis rs854624 0.818 rs1719201 ENSG00000278690.1 RP11-104J23.2 5.66 3.29e-08 1.79e-05 0.42 0.29 Blood protein levels; chr17:36011795 chr17:36012504~36012891:+ LIHC cis rs2153535 0.58 rs1928184 ENSG00000230939.1 RP11-314C16.1 -5.66 3.29e-08 1.79e-05 -0.36 -0.29 Motion sickness; chr6:8531875 chr6:8784178~8785445:+ LIHC cis rs6061231 0.624 rs8668 ENSG00000273619.1 RP5-908M14.9 5.66 3.29e-08 1.79e-05 0.26 0.29 Colorectal cancer; chr20:62389008 chr20:62386303~62386970:- LIHC cis rs11676348 0.783 rs13035513 ENSG00000261338.2 RP11-378A13.1 -5.66 3.29e-08 1.79e-05 -0.3 -0.29 Ulcerative colitis; chr2:218095957 chr2:218255319~218257366:+ LIHC cis rs997154 0.655 rs7147394 ENSG00000279656.1 RP11-298I3.6 5.65 3.3e-08 1.8e-05 0.47 0.29 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22941845 chr14:23023083~23024217:- LIHC cis rs9549367 0.713 rs1323315 ENSG00000269125.1 RP11-98F14.11 5.65 3.3e-08 1.8e-05 0.33 0.29 Platelet distribution width; chr13:113205344 chr13:113165002~113165183:- LIHC cis rs12681287 0.752 rs6985427 ENSG00000250569.1 NTAN1P2 5.65 3.31e-08 1.8e-05 0.36 0.29 Caudate activity during reward; chr8:86290516 chr8:86481754~86483002:- LIHC cis rs2243480 1 rs464895 ENSG00000226824.5 RP4-756H11.3 -5.65 3.31e-08 1.81e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66062119 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs781150 ENSG00000273142.1 RP11-458F8.4 -5.65 3.32e-08 1.81e-05 -0.36 -0.29 Diabetic kidney disease; chr7:66015986 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs313798 ENSG00000273142.1 RP11-458F8.4 -5.65 3.32e-08 1.81e-05 -0.36 -0.29 Diabetic kidney disease; chr7:66028044 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs35396113 ENSG00000273142.1 RP11-458F8.4 -5.65 3.32e-08 1.81e-05 -0.36 -0.29 Diabetic kidney disease; chr7:66030474 chr7:66902857~66906297:+ LIHC cis rs12908161 0.959 rs12906348 ENSG00000259295.5 CSPG4P12 5.65 3.32e-08 1.81e-05 0.4 0.29 Schizophrenia; chr15:84786190 chr15:85191438~85213905:+ LIHC cis rs6142102 0.886 rs6142098 ENSG00000276073.1 RP5-1125A11.7 -5.65 3.32e-08 1.81e-05 -0.32 -0.29 Skin pigmentation; chr20:34100488 chr20:33985617~33988989:- LIHC cis rs6142102 0.961 rs6087557 ENSG00000276073.1 RP5-1125A11.7 -5.65 3.32e-08 1.81e-05 -0.32 -0.29 Skin pigmentation; chr20:34110469 chr20:33985617~33988989:- LIHC cis rs12468226 1 rs11899836 ENSG00000273456.1 RP11-686O6.2 5.65 3.33e-08 1.81e-05 0.42 0.29 Urate levels; chr2:202371316 chr2:202374932~202375604:- LIHC cis rs8100891 0.537 rs73034216 ENSG00000267213.4 AC007773.2 -5.65 3.34e-08 1.82e-05 -0.38 -0.29 Neuroticism; chr19:32392510 chr19:32390050~32405560:- LIHC cis rs11690935 0.959 rs6745143 ENSG00000228389.1 AC068039.4 5.65 3.34e-08 1.82e-05 0.39 0.29 Schizophrenia; chr2:171793872 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs6758704 ENSG00000228389.1 AC068039.4 5.65 3.34e-08 1.82e-05 0.39 0.29 Schizophrenia; chr2:171798587 chr2:171773482~171775844:+ LIHC cis rs10510102 0.935 rs11200260 ENSG00000276742.1 RP11-500G22.4 5.65 3.34e-08 1.82e-05 0.46 0.29 Breast cancer; chr10:121920169 chr10:121956782~121957098:+ LIHC cis rs7176527 0.5 rs895571 ENSG00000189136.7 UBE2Q2P1 -5.65 3.35e-08 1.82e-05 -0.24 -0.29 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84573922 chr15:84526781~84571216:- LIHC cis rs6142102 0.962 rs2206448 ENSG00000276073.1 RP5-1125A11.7 -5.65 3.35e-08 1.82e-05 -0.32 -0.29 Skin pigmentation; chr20:34121719 chr20:33985617~33988989:- LIHC cis rs6142102 1 rs4911409 ENSG00000276073.1 RP5-1125A11.7 -5.65 3.35e-08 1.82e-05 -0.32 -0.29 Skin pigmentation; chr20:34122904 chr20:33985617~33988989:- LIHC cis rs11672691 0.67 rs758643 ENSG00000267107.5 PCAT19 -5.65 3.36e-08 1.83e-05 -0.35 -0.29 Prostate cancer; chr19:41485616 chr19:41454169~41500649:- LIHC cis rs12157904 0.793 rs6000849 ENSG00000233360.4 Z83844.1 5.65 3.36e-08 1.83e-05 0.58 0.29 Response to anti-depressant treatment in major depressive disorder; chr22:37635922 chr22:37641832~37658377:- LIHC cis rs11690935 0.959 rs35391289 ENSG00000228389.1 AC068039.4 5.65 3.36e-08 1.83e-05 0.4 0.29 Schizophrenia; chr2:171778473 chr2:171773482~171775844:+ LIHC cis rs2111504 0.583 rs1008425 ENSG00000267213.4 AC007773.2 5.65 3.36e-08 1.83e-05 0.29 0.29 Bipolar disorder; chr19:32361239 chr19:32390050~32405560:- LIHC cis rs2111504 0.559 rs12460112 ENSG00000267213.4 AC007773.2 5.65 3.36e-08 1.83e-05 0.29 0.29 Bipolar disorder; chr19:32363928 chr19:32390050~32405560:- LIHC cis rs1577917 0.545 rs9294338 ENSG00000234155.1 RP11-30P6.6 -5.65 3.36e-08 1.83e-05 -0.35 -0.29 Response to antipsychotic treatment; chr6:85764650 chr6:85387219~85390186:- LIHC cis rs3785309 0.519 rs7197253 ENSG00000268836.1 LA16c-OS12.2 -5.65 3.36e-08 1.83e-05 -0.54 -0.29 Immature fraction of reticulocytes; chr16:226550 chr16:185748~186294:- LIHC cis rs9326248 0.954 rs521171 ENSG00000236267.1 AP006216.5 5.65 3.37e-08 1.83e-05 0.3 0.29 Blood protein levels; chr11:117193977 chr11:116813204~116814003:- LIHC cis rs2762353 0.574 rs9467574 ENSG00000242387.1 HIST1H2APS2 -5.65 3.37e-08 1.83e-05 -0.37 -0.29 Blood metabolite levels; chr6:25705490 chr6:25882026~25882395:- LIHC cis rs748404 0.588 rs506120 ENSG00000205771.5 CATSPER2P1 -5.65 3.38e-08 1.84e-05 -0.36 -0.29 Lung cancer; chr15:43509826 chr15:43726918~43747094:- LIHC cis rs2274273 0.686 rs28631821 ENSG00000258413.1 RP11-665C16.6 -5.65 3.38e-08 1.84e-05 -0.34 -0.29 Protein biomarker; chr14:55379269 chr14:55262767~55272075:- LIHC cis rs3096299 0.754 rs3096296 ENSG00000274627.1 RP11-104N10.2 5.65 3.38e-08 1.84e-05 0.3 0.29 Multiple myeloma (IgH translocation); chr16:89344602 chr16:89516797~89522217:+ LIHC cis rs9640161 0.789 rs6964110 ENSG00000261305.1 RP4-584D14.7 5.65 3.38e-08 1.84e-05 0.35 0.29 Blood protein levels;Circulating chemerin levels; chr7:150344747 chr7:150341771~150342607:+ LIHC cis rs498872 1 rs498872 ENSG00000255239.1 AP002954.6 5.65 3.38e-08 1.84e-05 0.38 0.29 Glioma; chr11:118606652 chr11:118688039~118690600:- LIHC cis rs853679 0.517 rs9468297 ENSG00000219392.1 RP1-265C24.5 -5.65 3.38e-08 1.84e-05 -0.46 -0.29 Depression; chr6:28151096 chr6:28115628~28116551:+ LIHC cis rs189798 0.592 rs10111263 ENSG00000254340.1 RP11-10A14.3 -5.65 3.39e-08 1.84e-05 -0.28 -0.29 Myopia (pathological); chr8:9111923 chr8:9141424~9145435:+ LIHC cis rs3758785 0.621 rs7128673 ENSG00000255893.1 RP11-685N10.1 -5.65 3.39e-08 1.84e-05 -0.32 -0.29 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94453072 chr11:94472908~94473570:- LIHC cis rs3858145 0.546 rs7912806 ENSG00000233590.1 RP11-153K11.3 5.65 3.39e-08 1.84e-05 0.39 0.29 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68296578 chr10:68233251~68242379:- LIHC cis rs8028182 0.609 rs8038760 ENSG00000260269.4 CTD-2323K18.1 -5.65 3.4e-08 1.85e-05 -0.38 -0.29 Sudden cardiac arrest; chr15:75449754 chr15:75527150~75601205:- LIHC cis rs9341808 0.587 rs3805859 ENSG00000272129.1 RP11-250B2.6 5.65 3.4e-08 1.85e-05 0.29 0.29 Sitting height ratio; chr6:80339229 chr6:80355424~80356859:+ LIHC cis rs17023223 0.537 rs10923756 ENSG00000231365.4 RP11-418J17.1 -5.65 3.4e-08 1.85e-05 -0.36 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119132025 chr1:119140396~119275973:+ LIHC cis rs9487094 0.689 rs1074766 ENSG00000260273.1 RP11-425D10.10 5.65 3.4e-08 1.85e-05 0.35 0.29 Height; chr6:109360263 chr6:109382795~109383666:+ LIHC cis rs6479891 1 rs16918567 ENSG00000232075.1 MRPL35P2 5.65 3.4e-08 1.85e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63534910 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs16918573 ENSG00000232075.1 MRPL35P2 5.65 3.4e-08 1.85e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63541045 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs12414796 ENSG00000232075.1 MRPL35P2 5.65 3.4e-08 1.85e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63543327 chr10:63634317~63634827:- LIHC cis rs11690935 0.959 rs6433314 ENSG00000228389.1 AC068039.4 5.65 3.4e-08 1.85e-05 0.4 0.29 Schizophrenia; chr2:171804461 chr2:171773482~171775844:+ LIHC cis rs10510102 0.872 rs11200268 ENSG00000276742.1 RP11-500G22.4 5.65 3.41e-08 1.85e-05 0.48 0.29 Breast cancer; chr10:121932661 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs11200269 ENSG00000276742.1 RP11-500G22.4 5.65 3.41e-08 1.85e-05 0.48 0.29 Breast cancer; chr10:121934021 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs11498944 ENSG00000276742.1 RP11-500G22.4 5.65 3.41e-08 1.85e-05 0.48 0.29 Breast cancer; chr10:121938748 chr10:121956782~121957098:+ LIHC cis rs10510102 0.81 rs12267347 ENSG00000276742.1 RP11-500G22.4 5.65 3.41e-08 1.85e-05 0.48 0.29 Breast cancer; chr10:121939110 chr10:121956782~121957098:+ LIHC cis rs10510102 0.808 rs12253007 ENSG00000276742.1 RP11-500G22.4 5.65 3.41e-08 1.85e-05 0.48 0.29 Breast cancer; chr10:121939360 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs79865971 ENSG00000276742.1 RP11-500G22.4 5.65 3.41e-08 1.85e-05 0.48 0.29 Breast cancer; chr10:121941208 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs74318512 ENSG00000276742.1 RP11-500G22.4 5.65 3.41e-08 1.85e-05 0.48 0.29 Breast cancer; chr10:121941465 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs12257207 ENSG00000276742.1 RP11-500G22.4 5.65 3.41e-08 1.85e-05 0.48 0.29 Breast cancer; chr10:121941737 chr10:121956782~121957098:+ LIHC cis rs13068223 0.568 rs7636965 ENSG00000243926.1 TIPARP-AS1 5.65 3.41e-08 1.85e-05 0.31 0.29 Age-related hearing impairment (SNP x SNP interaction); chr3:156700615 chr3:156671862~156674378:- LIHC cis rs2842992 0.83 rs2758352 ENSG00000237927.1 RP3-393E18.2 -5.65 3.41e-08 1.85e-05 -0.37 -0.29 Age-related macular degeneration (geographic atrophy); chr6:159701889 chr6:159586955~159589169:- LIHC cis rs150992 0.587 rs4703052 ENSG00000248489.1 CTD-2007H13.3 -5.65 3.41e-08 1.85e-05 -0.42 -0.29 Body mass index; chr5:99008818 chr5:98929171~98995013:+ LIHC cis rs12681287 0.547 rs13249177 ENSG00000250569.1 NTAN1P2 5.65 3.42e-08 1.86e-05 0.35 0.29 Caudate activity during reward; chr8:86500805 chr8:86481754~86483002:- LIHC cis rs11690935 1 rs1554166 ENSG00000228389.1 AC068039.4 5.65 3.43e-08 1.86e-05 0.38 0.29 Schizophrenia; chr2:171685099 chr2:171773482~171775844:+ LIHC cis rs2243480 1 rs316329 ENSG00000273142.1 RP11-458F8.4 -5.65 3.44e-08 1.87e-05 -0.36 -0.29 Diabetic kidney disease; chr7:66143429 chr7:66902857~66906297:+ LIHC cis rs12681287 0.752 rs1080170 ENSG00000250569.1 NTAN1P2 5.65 3.44e-08 1.87e-05 0.36 0.29 Caudate activity during reward; chr8:86297879 chr8:86481754~86483002:- LIHC cis rs4535700 0.501 rs6943341 ENSG00000226278.1 PSPHP1 5.65 3.44e-08 1.87e-05 0.35 0.29 Macular telangiectasia type 2; chr7:55907489 chr7:55764797~55773288:+ LIHC cis rs9487094 0.922 rs68042406 ENSG00000260273.1 RP11-425D10.10 5.65 3.44e-08 1.87e-05 0.36 0.29 Height; chr6:109482392 chr6:109382795~109383666:+ LIHC cis rs8059260 0.604 rs741176 ENSG00000274038.1 RP11-66H6.4 5.65 3.45e-08 1.87e-05 0.48 0.29 Alcohol consumption over the past year; chr16:11051953 chr16:11056556~11057034:+ LIHC cis rs1799810 1 rs1158867 ENSG00000236682.1 AC068282.3 5.65 3.45e-08 1.87e-05 0.42 0.29 Self-rated health; chr2:127419801 chr2:127389130~127400580:+ LIHC cis rs7927592 0.956 rs12281742 ENSG00000212093.1 AP000807.1 -5.65 3.46e-08 1.87e-05 -0.31 -0.29 Total body bone mineral density; chr11:68536161 chr11:68506083~68506166:- LIHC cis rs2243480 1 rs160646 ENSG00000273142.1 RP11-458F8.4 -5.65 3.46e-08 1.87e-05 -0.35 -0.29 Diabetic kidney disease; chr7:66091293 chr7:66902857~66906297:+ LIHC cis rs8072100 0.87 rs10432035 ENSG00000228782.6 CTD-2026D20.3 -5.65 3.46e-08 1.88e-05 -0.32 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47547547 chr17:47450568~47492492:- LIHC cis rs9549367 0.789 rs3764124 ENSG00000269125.1 RP11-98F14.11 -5.65 3.47e-08 1.88e-05 -0.36 -0.29 Platelet distribution width; chr13:113243006 chr13:113165002~113165183:- LIHC cis rs10875746 0.855 rs10875728 ENSG00000240399.1 RP1-228P16.1 -5.65 3.47e-08 1.88e-05 -0.3 -0.29 Longevity (90 years and older); chr12:48032609 chr12:48054813~48055591:- LIHC cis rs4910157 1 rs4910157 ENSG00000254860.4 TMEM9B-AS1 -5.65 3.47e-08 1.88e-05 -0.29 -0.29 Tonsillectomy; chr11:8919668 chr11:8964675~8977527:+ LIHC cis rs2243480 1 rs316327 ENSG00000226824.5 RP4-756H11.3 5.65 3.47e-08 1.88e-05 0.48 0.29 Diabetic kidney disease; chr7:66144214 chr7:66654538~66669855:+ LIHC cis rs17270561 0.583 rs12662869 ENSG00000216436.2 HIST1H2APS1 5.65 3.47e-08 1.88e-05 0.36 0.29 Iron status biomarkers; chr6:25784253 chr6:25732497~25732827:+ LIHC cis rs6904897 0.538 rs4639353 ENSG00000232876.1 CTA-212D2.2 5.64 3.48e-08 1.88e-05 0.33 0.29 Mean corpuscular volume;Mean corpuscular hemoglobin; chr6:134903190 chr6:135055033~135060550:+ LIHC cis rs34779708 0.733 rs11010146 ENSG00000230534.5 RP11-297A16.2 5.64 3.48e-08 1.89e-05 0.37 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35252633 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs7083266 ENSG00000230534.5 RP11-297A16.2 5.64 3.48e-08 1.89e-05 0.37 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35252704 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs7086715 ENSG00000230534.5 RP11-297A16.2 5.64 3.48e-08 1.89e-05 0.37 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35252912 chr10:35098006~35127020:- LIHC cis rs34779708 0.733 rs12249814 ENSG00000230534.5 RP11-297A16.2 5.64 3.48e-08 1.89e-05 0.37 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35253829 chr10:35098006~35127020:- LIHC cis rs2243480 1 rs466983 ENSG00000226824.5 RP4-756H11.3 -5.64 3.48e-08 1.89e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66055509 chr7:66654538~66669855:+ LIHC cis rs4356975 0.563 rs6600896 ENSG00000249956.3 RP11-790I12.2 5.64 3.49e-08 1.89e-05 0.33 0.29 Obesity-related traits; chr4:69121000 chr4:69408836~69423164:+ LIHC cis rs4356975 0.563 rs6600897 ENSG00000249956.3 RP11-790I12.2 5.64 3.49e-08 1.89e-05 0.33 0.29 Obesity-related traits; chr4:69121531 chr4:69408836~69423164:+ LIHC cis rs12681287 0.608 rs2953511 ENSG00000250569.1 NTAN1P2 5.64 3.49e-08 1.89e-05 0.35 0.29 Caudate activity during reward; chr8:86328641 chr8:86481754~86483002:- LIHC cis rs12681287 0.647 rs2953510 ENSG00000250569.1 NTAN1P2 5.64 3.49e-08 1.89e-05 0.35 0.29 Caudate activity during reward; chr8:86329685 chr8:86481754~86483002:- LIHC cis rs12681287 0.605 rs2953509 ENSG00000250569.1 NTAN1P2 5.64 3.49e-08 1.89e-05 0.35 0.29 Caudate activity during reward; chr8:86330965 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs7816629 ENSG00000250569.1 NTAN1P2 5.64 3.49e-08 1.89e-05 0.35 0.29 Caudate activity during reward; chr8:86338559 chr8:86481754~86483002:- LIHC cis rs12681287 0.64 rs7820234 ENSG00000250569.1 NTAN1P2 5.64 3.49e-08 1.89e-05 0.35 0.29 Caudate activity during reward; chr8:86338721 chr8:86481754~86483002:- LIHC cis rs9409565 0.502 rs509022 ENSG00000231806.2 PCAT7 5.64 3.5e-08 1.89e-05 0.35 0.29 Colorectal cancer (alcohol consumption interaction); chr9:94566989 chr9:94555069~94568127:+ LIHC cis rs2153535 0.58 rs9378551 ENSG00000230939.1 RP11-314C16.1 -5.64 3.5e-08 1.89e-05 -0.35 -0.29 Motion sickness; chr6:8463511 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9378552 ENSG00000230939.1 RP11-314C16.1 -5.64 3.5e-08 1.89e-05 -0.35 -0.29 Motion sickness; chr6:8463515 chr6:8784178~8785445:+ LIHC cis rs6479901 0.894 rs4518976 ENSG00000232075.1 MRPL35P2 -5.64 3.5e-08 1.9e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63319017 chr10:63634317~63634827:- LIHC cis rs8059260 0.604 rs12928945 ENSG00000274038.1 RP11-66H6.4 -5.64 3.51e-08 1.9e-05 -0.48 -0.29 Alcohol consumption over the past year; chr16:11106309 chr16:11056556~11057034:+ LIHC cis rs875971 0.545 rs4718348 ENSG00000237310.1 GS1-124K5.4 5.64 3.51e-08 1.9e-05 0.29 0.29 Aortic root size; chr7:66441589 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs4441996 ENSG00000237310.1 GS1-124K5.4 -5.64 3.51e-08 1.9e-05 -0.28 -0.29 Aortic root size; chr7:66123233 chr7:66493706~66495474:+ LIHC cis rs13068223 0.84 rs11709829 ENSG00000243926.1 TIPARP-AS1 5.64 3.51e-08 1.9e-05 0.28 0.29 Age-related hearing impairment (SNP x SNP interaction); chr3:156716300 chr3:156671862~156674378:- LIHC cis rs10875746 0.669 rs11168508 ENSG00000240399.1 RP1-228P16.1 -5.64 3.52e-08 1.9e-05 -0.31 -0.29 Longevity (90 years and older); chr12:48289728 chr12:48054813~48055591:- LIHC cis rs4731207 0.592 rs6967988 ENSG00000224897.5 POT1-AS1 5.64 3.52e-08 1.9e-05 0.34 0.29 Cutaneous malignant melanoma; chr7:124930418 chr7:124929873~125179315:+ LIHC cis rs1729407 0.706 rs1268354 ENSG00000254851.1 RP11-109L13.1 -5.64 3.52e-08 1.9e-05 -0.34 -0.29 Apolipoprotein A-IV levels; chr11:116819862 chr11:117135528~117138582:+ LIHC cis rs11676348 0.846 rs7594532 ENSG00000261338.2 RP11-378A13.1 -5.64 3.52e-08 1.9e-05 -0.3 -0.29 Ulcerative colitis; chr2:218143277 chr2:218255319~218257366:+ LIHC cis rs11676348 0.818 rs6436031 ENSG00000261338.2 RP11-378A13.1 -5.64 3.53e-08 1.91e-05 -0.3 -0.29 Ulcerative colitis; chr2:218114536 chr2:218255319~218257366:+ LIHC cis rs8072100 0.967 rs4794058 ENSG00000228782.6 CTD-2026D20.3 -5.64 3.53e-08 1.91e-05 -0.32 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47519732 chr17:47450568~47492492:- LIHC cis rs7734985 0.659 rs12517958 ENSG00000250551.1 RP11-254I22.1 5.64 3.53e-08 1.91e-05 0.36 0.29 IgG glycosylation; chr5:96173749 chr5:96050115~96215519:+ LIHC cis rs7429990 0.864 rs319693 ENSG00000229759.1 MRPS18AP1 5.64 3.54e-08 1.92e-05 0.33 0.29 Educational attainment (years of education); chr3:47845090 chr3:48256350~48256938:- LIHC cis rs4423214 0.798 rs1894100 ENSG00000254682.1 RP11-660L16.2 -5.64 3.55e-08 1.92e-05 -0.38 -0.29 Vitamin D levels; chr11:71419297 chr11:71448674~71452157:+ LIHC cis rs7899628 1 rs7899628 ENSG00000226864.1 ATE1-AS1 -5.64 3.55e-08 1.92e-05 -0.38 -0.29 Breast cancer; chr10:121904429 chr10:121928312~121951965:+ LIHC cis rs12681287 0.547 rs66808088 ENSG00000250569.1 NTAN1P2 5.64 3.56e-08 1.92e-05 0.35 0.29 Caudate activity during reward; chr8:86508983 chr8:86481754~86483002:- LIHC cis rs2522056 0.808 rs17771891 ENSG00000233006.5 AC034220.3 5.64 3.56e-08 1.92e-05 0.32 0.29 Fibrinogen;Lymphocyte counts; chr5:132408510 chr5:132311285~132369916:- LIHC cis rs11676348 0.818 rs7426289 ENSG00000261338.2 RP11-378A13.1 -5.64 3.57e-08 1.93e-05 -0.3 -0.29 Ulcerative colitis; chr2:218101592 chr2:218255319~218257366:+ LIHC cis rs34779708 0.733 rs16935948 ENSG00000230534.5 RP11-297A16.2 5.64 3.57e-08 1.93e-05 0.36 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35260820 chr10:35098006~35127020:- LIHC cis rs2111504 0.559 rs7250813 ENSG00000267213.4 AC007773.2 5.64 3.57e-08 1.93e-05 0.29 0.29 Bipolar disorder; chr19:32358815 chr19:32390050~32405560:- LIHC cis rs11690935 1 rs6757773 ENSG00000228389.1 AC068039.4 -5.64 3.58e-08 1.93e-05 -0.38 -0.29 Schizophrenia; chr2:171693120 chr2:171773482~171775844:+ LIHC cis rs9487094 0.62 rs6939953 ENSG00000260273.1 RP11-425D10.10 5.64 3.58e-08 1.94e-05 0.35 0.29 Height; chr6:109390116 chr6:109382795~109383666:+ LIHC cis rs739496 0.843 rs10774631 ENSG00000226469.1 ADAM1B -5.64 3.58e-08 1.94e-05 -0.36 -0.29 Platelet count; chr12:111585197 chr12:111927018~111929017:+ LIHC cis rs7119038 0.509 rs10892260 ENSG00000255239.1 AP002954.6 -5.64 3.58e-08 1.94e-05 -0.39 -0.29 Sjögren's syndrome; chr11:118712816 chr11:118688039~118690600:- LIHC cis rs524281 0.861 rs7120326 ENSG00000255320.1 RP11-755F10.1 5.64 3.59e-08 1.94e-05 0.38 0.29 Electroencephalogram traits; chr11:66081785 chr11:66244840~66246239:- LIHC cis rs12908161 0.96 rs62019463 ENSG00000259295.5 CSPG4P12 5.64 3.59e-08 1.94e-05 0.4 0.29 Schizophrenia; chr15:84744856 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs62019464 ENSG00000259295.5 CSPG4P12 5.64 3.59e-08 1.94e-05 0.4 0.29 Schizophrenia; chr15:84751238 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs12910012 ENSG00000259295.5 CSPG4P12 5.64 3.59e-08 1.94e-05 0.4 0.29 Schizophrenia; chr15:84755431 chr15:85191438~85213905:+ LIHC cis rs34779708 0.733 rs7087099 ENSG00000230534.5 RP11-297A16.2 5.64 3.6e-08 1.94e-05 0.37 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35253054 chr10:35098006~35127020:- LIHC cis rs34779708 0.801 rs12246600 ENSG00000230534.5 RP11-297A16.2 5.64 3.6e-08 1.94e-05 0.36 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35249193 chr10:35098006~35127020:- LIHC cis rs34779708 0.801 rs12098720 ENSG00000230534.5 RP11-297A16.2 5.64 3.6e-08 1.94e-05 0.36 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35249755 chr10:35098006~35127020:- LIHC cis rs12908161 1 rs12905057 ENSG00000259295.5 CSPG4P12 5.64 3.6e-08 1.94e-05 0.4 0.29 Schizophrenia; chr15:84667534 chr15:85191438~85213905:+ LIHC cis rs9487094 0.689 rs8465 ENSG00000260273.1 RP11-425D10.10 5.64 3.6e-08 1.95e-05 0.35 0.29 Height; chr6:109367335 chr6:109382795~109383666:+ LIHC cis rs9487094 0.666 rs974034 ENSG00000260273.1 RP11-425D10.10 5.64 3.6e-08 1.95e-05 0.35 0.29 Height; chr6:109368228 chr6:109382795~109383666:+ LIHC cis rs7688540 0.771 rs11248013 ENSG00000275426.1 CH17-262A2.1 5.64 3.61e-08 1.95e-05 0.41 0.29 Facial morphology (factor 6, height of vermillion lower lip); chr4:317636 chr4:149738~150317:+ LIHC cis rs2933343 1 rs2933343 ENSG00000231305.3 RP11-723O4.2 5.64 3.61e-08 1.95e-05 0.33 0.29 IgG glycosylation; chr3:128939649 chr3:128861313~128871540:- LIHC cis rs1577917 0.839 rs6929514 ENSG00000234155.1 RP11-30P6.6 5.64 3.61e-08 1.95e-05 0.35 0.29 Response to antipsychotic treatment; chr6:85816050 chr6:85387219~85390186:- LIHC cis rs12681287 0.517 rs7462883 ENSG00000250569.1 NTAN1P2 5.64 3.62e-08 1.95e-05 0.35 0.29 Caudate activity during reward; chr8:86514562 chr8:86481754~86483002:- LIHC cis rs5769707 0.706 rs2071903 ENSG00000235111.1 RP1-29C18.8 -5.64 3.62e-08 1.96e-05 -0.36 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49640869 chr22:49612657~49615716:- LIHC cis rs7688540 0.771 rs11730202 ENSG00000275426.1 CH17-262A2.1 5.64 3.64e-08 1.96e-05 0.4 0.29 Facial morphology (factor 6, height of vermillion lower lip); chr4:216307 chr4:149738~150317:+ LIHC cis rs7429990 0.828 rs55823596 ENSG00000229759.1 MRPS18AP1 5.64 3.64e-08 1.96e-05 0.33 0.29 Educational attainment (years of education); chr3:47758541 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs4858853 ENSG00000229759.1 MRPS18AP1 5.64 3.64e-08 1.96e-05 0.33 0.29 Educational attainment (years of education); chr3:47760605 chr3:48256350~48256938:- LIHC cis rs113835537 0.529 rs11227515 ENSG00000255517.5 CTD-3074O7.5 -5.64 3.64e-08 1.96e-05 -0.31 -0.29 Airway imaging phenotypes; chr11:66519912 chr11:66473490~66480233:- LIHC cis rs904251 0.523 rs2776874 ENSG00000204110.6 RP1-153P14.8 -5.64 3.64e-08 1.96e-05 -0.35 -0.29 Cognitive performance; chr6:37515421 chr6:37507348~37535616:+ LIHC cis rs11690935 1 rs6433311 ENSG00000228389.1 AC068039.4 -5.64 3.65e-08 1.97e-05 -0.38 -0.29 Schizophrenia; chr2:171692738 chr2:171773482~171775844:+ LIHC cis rs2522056 1 rs2706339 ENSG00000233006.5 AC034220.3 -5.64 3.65e-08 1.97e-05 -0.31 -0.29 Fibrinogen;Lymphocyte counts; chr5:132464413 chr5:132311285~132369916:- LIHC cis rs11690935 0.959 rs1474074 ENSG00000228389.1 AC068039.4 5.64 3.66e-08 1.97e-05 0.4 0.29 Schizophrenia; chr2:171803342 chr2:171773482~171775844:+ LIHC cis rs10510102 0.688 rs11812208 ENSG00000276742.1 RP11-500G22.4 5.64 3.66e-08 1.97e-05 0.47 0.29 Breast cancer; chr10:121924831 chr10:121956782~121957098:+ LIHC cis rs67180937 0.553 rs2936020 ENSG00000272750.1 RP11-378J18.8 5.64 3.66e-08 1.97e-05 0.33 0.29 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222655754 chr1:222658867~222661512:- LIHC cis rs7927592 0.513 rs3853616 ENSG00000212093.1 AP000807.1 5.63 3.66e-08 1.97e-05 0.3 0.29 Total body bone mineral density; chr11:68430784 chr11:68506083~68506166:- LIHC cis rs11098499 0.954 rs6834796 ENSG00000245958.5 RP11-33B1.1 -5.63 3.67e-08 1.98e-05 -0.3 -0.29 Corneal astigmatism; chr4:119493538 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs11729521 ENSG00000245958.5 RP11-33B1.1 -5.63 3.67e-08 1.98e-05 -0.3 -0.29 Corneal astigmatism; chr4:119495633 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs11734241 ENSG00000245958.5 RP11-33B1.1 -5.63 3.67e-08 1.98e-05 -0.3 -0.29 Corneal astigmatism; chr4:119495717 chr4:119454791~119552025:+ LIHC cis rs2153535 0.58 rs7741403 ENSG00000230939.1 RP11-314C16.1 5.63 3.67e-08 1.98e-05 0.36 0.29 Motion sickness; chr6:8530345 chr6:8784178~8785445:+ LIHC cis rs12681287 0.547 rs56752411 ENSG00000250569.1 NTAN1P2 5.63 3.68e-08 1.98e-05 0.35 0.29 Caudate activity during reward; chr8:86502927 chr8:86481754~86483002:- LIHC cis rs113835537 0.529 rs75685325 ENSG00000255517.5 CTD-3074O7.5 -5.63 3.69e-08 1.99e-05 -0.38 -0.29 Airway imaging phenotypes; chr11:66467771 chr11:66473490~66480233:- LIHC cis rs2762353 0.526 rs3936052 ENSG00000216436.2 HIST1H2APS1 -5.63 3.71e-08 2e-05 -0.35 -0.29 Blood metabolite levels; chr6:25715306 chr6:25732497~25732827:+ LIHC cis rs10170846 0.861 rs4674677 ENSG00000261428.2 RP11-16P6.1 5.63 3.71e-08 2e-05 0.3 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222664939 chr2:222566899~222569719:- LIHC cis rs6479891 1 rs7087279 ENSG00000232075.1 MRPL35P2 -5.63 3.71e-08 2e-05 -0.34 -0.29 Arthritis (juvenile idiopathic); chr10:63532176 chr10:63634317~63634827:- LIHC cis rs2735413 0.599 rs73562710 ENSG00000276007.1 RP11-358L22.3 5.63 3.71e-08 2e-05 0.39 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78090709 chr16:78123243~78124332:+ LIHC cis rs2735413 0.564 rs79006334 ENSG00000276007.1 RP11-358L22.3 5.63 3.71e-08 2e-05 0.39 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78091057 chr16:78123243~78124332:+ LIHC cis rs12681287 0.752 rs2917557 ENSG00000250569.1 NTAN1P2 5.63 3.72e-08 2e-05 0.36 0.29 Caudate activity during reward; chr8:86301842 chr8:86481754~86483002:- LIHC cis rs12681287 0.752 rs4282548 ENSG00000250569.1 NTAN1P2 5.63 3.73e-08 2.01e-05 0.36 0.29 Caudate activity during reward; chr8:86258563 chr8:86481754~86483002:- LIHC cis rs2243480 1 rs56016656 ENSG00000226824.5 RP4-756H11.3 -5.63 3.73e-08 2.01e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65918494 chr7:66654538~66669855:+ LIHC cis rs2243480 0.803 rs55700941 ENSG00000226824.5 RP4-756H11.3 -5.63 3.73e-08 2.01e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65924813 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs36033484 ENSG00000226824.5 RP4-756H11.3 -5.63 3.73e-08 2.01e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65925571 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs34193460 ENSG00000226824.5 RP4-756H11.3 -5.63 3.73e-08 2.01e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65928123 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs34560516 ENSG00000226824.5 RP4-756H11.3 -5.63 3.73e-08 2.01e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65939105 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs57057549 ENSG00000226824.5 RP4-756H11.3 -5.63 3.73e-08 2.01e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65940751 chr7:66654538~66669855:+ LIHC cis rs2243480 0.808 rs12698508 ENSG00000226824.5 RP4-756H11.3 -5.63 3.73e-08 2.01e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65946971 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs2961102 ENSG00000226824.5 RP4-756H11.3 -5.63 3.73e-08 2.01e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65959671 chr7:66654538~66669855:+ LIHC cis rs7429990 0.932 rs7620736 ENSG00000229759.1 MRPS18AP1 -5.63 3.73e-08 2.01e-05 -0.31 -0.29 Educational attainment (years of education); chr3:48068479 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs6791834 ENSG00000229759.1 MRPS18AP1 -5.63 3.73e-08 2.01e-05 -0.31 -0.29 Educational attainment (years of education); chr3:48073598 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs35689209 ENSG00000229759.1 MRPS18AP1 -5.63 3.73e-08 2.01e-05 -0.31 -0.29 Educational attainment (years of education); chr3:48078273 chr3:48256350~48256938:- LIHC cis rs2243480 1 rs1723269 ENSG00000273142.1 RP11-458F8.4 -5.63 3.73e-08 2.01e-05 -0.36 -0.29 Diabetic kidney disease; chr7:66007799 chr7:66902857~66906297:+ LIHC cis rs523522 1 rs523522 ENSG00000278344.1 RP11-18C24.8 5.63 3.73e-08 2.01e-05 0.35 0.29 High light scatter reticulocyte count; chr12:120582447 chr12:120500735~120501090:- LIHC cis rs2153535 0.58 rs7767926 ENSG00000230939.1 RP11-314C16.1 -5.63 3.74e-08 2.01e-05 -0.35 -0.29 Motion sickness; chr6:8453324 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7748455 ENSG00000230939.1 RP11-314C16.1 -5.63 3.74e-08 2.01e-05 -0.35 -0.29 Motion sickness; chr6:8453392 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7743418 ENSG00000230939.1 RP11-314C16.1 -5.63 3.74e-08 2.01e-05 -0.36 -0.29 Motion sickness; chr6:8437895 chr6:8784178~8785445:+ LIHC cis rs9487094 0.6 rs1885690 ENSG00000260273.1 RP11-425D10.10 5.63 3.74e-08 2.01e-05 0.34 0.29 Height; chr6:109351795 chr6:109382795~109383666:+ LIHC cis rs860295 1 rs822490 ENSG00000203761.5 MSTO2P -5.63 3.75e-08 2.01e-05 -0.23 -0.29 Body mass index; chr1:155853180 chr1:155745829~155750137:+ LIHC cis rs12744310 0.887 rs12037129 ENSG00000235358.1 RP11-399E6.1 5.63 3.75e-08 2.01e-05 0.4 0.29 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41328629 chr1:41242373~41284861:+ LIHC cis rs17023223 0.537 rs12085308 ENSG00000231365.4 RP11-418J17.1 -5.63 3.75e-08 2.01e-05 -0.35 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119134930 chr1:119140396~119275973:+ LIHC cis rs11676348 0.818 rs6436033 ENSG00000261338.2 RP11-378A13.1 -5.63 3.75e-08 2.02e-05 -0.3 -0.29 Ulcerative colitis; chr2:218119040 chr2:218255319~218257366:+ LIHC cis rs34779708 0.733 rs7070778 ENSG00000230534.5 RP11-297A16.2 5.63 3.76e-08 2.02e-05 0.37 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35252760 chr10:35098006~35127020:- LIHC cis rs12291225 0.585 rs4517475 ENSG00000251991.1 RNU7-49P 5.63 3.77e-08 2.02e-05 0.31 0.29 Sense of smell; chr11:14364599 chr11:14478892~14478953:+ LIHC cis rs7927592 0.956 rs7944870 ENSG00000212093.1 AP000807.1 5.63 3.77e-08 2.02e-05 0.31 0.29 Total body bone mineral density; chr11:68541640 chr11:68506083~68506166:- LIHC cis rs739496 0.744 rs848130 ENSG00000226469.1 ADAM1B 5.63 3.77e-08 2.02e-05 0.35 0.29 Platelet count; chr12:111572027 chr12:111927018~111929017:+ LIHC cis rs2522056 1 rs2522054 ENSG00000233006.5 AC034220.3 -5.63 3.77e-08 2.03e-05 -0.31 -0.29 Fibrinogen;Lymphocyte counts; chr5:132463834 chr5:132311285~132369916:- LIHC cis rs7714584 1 rs931058 ENSG00000197083.10 ZNF300P1 5.63 3.78e-08 2.03e-05 0.44 0.29 Crohn's disease; chr5:150954136 chr5:150930645~150946289:- LIHC cis rs6479901 0.947 rs7085862 ENSG00000232075.1 MRPL35P2 -5.63 3.79e-08 2.04e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63486687 chr10:63634317~63634827:- LIHC cis rs9660180 0.875 rs4648727 ENSG00000268575.1 RP1-283E3.8 5.63 3.8e-08 2.04e-05 0.28 0.29 Body mass index; chr1:1844830 chr1:1702736~1737688:- LIHC cis rs3858145 0.5 rs4633337 ENSG00000233590.1 RP11-153K11.3 5.63 3.8e-08 2.04e-05 0.4 0.29 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68285970 chr10:68233251~68242379:- LIHC cis rs2735413 0.564 rs11863846 ENSG00000276007.1 RP11-358L22.3 5.63 3.82e-08 2.05e-05 0.39 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78085660 chr16:78123243~78124332:+ LIHC cis rs2735413 0.564 rs7192226 ENSG00000276007.1 RP11-358L22.3 5.63 3.82e-08 2.05e-05 0.39 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78086363 chr16:78123243~78124332:+ LIHC cis rs6142102 0.961 rs2235596 ENSG00000276073.1 RP5-1125A11.7 5.63 3.82e-08 2.05e-05 0.32 0.29 Skin pigmentation; chr20:34096503 chr20:33985617~33988989:- LIHC cis rs1577917 0.883 rs1415749 ENSG00000234155.1 RP11-30P6.6 -5.63 3.83e-08 2.05e-05 -0.35 -0.29 Response to antipsychotic treatment; chr6:86069366 chr6:85387219~85390186:- LIHC cis rs2284219 0.565 rs2284217 ENSG00000226874.1 AC005154.8 -5.63 3.83e-08 2.06e-05 -0.34 -0.29 Type 2 diabetes; chr7:30673992 chr7:30544053~30544431:+ LIHC cis rs6479891 0.908 rs2616631 ENSG00000232075.1 MRPL35P2 5.63 3.83e-08 2.06e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63448154 chr10:63634317~63634827:- LIHC cis rs7743045 0.504 rs4946385 ENSG00000253194.1 RP11-351A11.1 5.63 3.84e-08 2.06e-05 0.38 0.29 Mean platelet volume; chr6:118985247 chr6:118934785~119031541:+ LIHC cis rs6142102 1 rs4911410 ENSG00000276073.1 RP5-1125A11.7 -5.63 3.84e-08 2.06e-05 -0.32 -0.29 Skin pigmentation; chr20:34123168 chr20:33985617~33988989:- LIHC cis rs12134133 1 rs2782840 ENSG00000274245.1 RP11-357P18.2 5.63 3.84e-08 2.06e-05 0.44 0.29 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207310838 chr1:207372559~207373252:+ LIHC cis rs7429990 0.965 rs34380889 ENSG00000229759.1 MRPS18AP1 5.63 3.84e-08 2.06e-05 0.31 0.29 Educational attainment (years of education); chr3:47905692 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs4858871 ENSG00000229759.1 MRPS18AP1 5.63 3.84e-08 2.06e-05 0.31 0.29 Educational attainment (years of education); chr3:47911915 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs6772396 ENSG00000229759.1 MRPS18AP1 5.63 3.84e-08 2.06e-05 0.31 0.29 Educational attainment (years of education); chr3:47918280 chr3:48256350~48256938:- LIHC cis rs997154 0.655 rs8015121 ENSG00000279656.1 RP11-298I3.6 5.63 3.84e-08 2.06e-05 0.48 0.29 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22906042 chr14:23023083~23024217:- LIHC cis rs5769707 0.656 rs135878 ENSG00000235111.1 RP1-29C18.8 -5.62 3.87e-08 2.07e-05 -0.35 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49620721 chr22:49612657~49615716:- LIHC cis rs11676348 0.846 rs6723449 ENSG00000261338.2 RP11-378A13.1 5.62 3.87e-08 2.07e-05 0.3 0.29 Ulcerative colitis; chr2:218132857 chr2:218255319~218257366:+ LIHC cis rs12908161 1 rs17600551 ENSG00000259295.5 CSPG4P12 5.62 3.87e-08 2.07e-05 0.39 0.29 Schizophrenia; chr15:84776027 chr15:85191438~85213905:+ LIHC cis rs12908161 1 rs62019469 ENSG00000259295.5 CSPG4P12 5.62 3.87e-08 2.07e-05 0.39 0.29 Schizophrenia; chr15:84777989 chr15:85191438~85213905:+ LIHC cis rs8059260 0.736 rs7202408 ENSG00000274038.1 RP11-66H6.4 -5.62 3.88e-08 2.08e-05 -0.48 -0.29 Alcohol consumption over the past year; chr16:10984758 chr16:11056556~11057034:+ LIHC cis rs227275 0.554 rs223421 ENSG00000230069.3 LRRC37A15P -5.62 3.9e-08 2.09e-05 -0.26 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102805861 chr4:102727274~102730721:- LIHC cis rs7945705 0.747 rs10840158 ENSG00000254860.4 TMEM9B-AS1 5.62 3.91e-08 2.09e-05 0.29 0.29 Hemoglobin concentration; chr11:8999350 chr11:8964675~8977527:+ LIHC cis rs875971 0.545 rs6979636 ENSG00000226824.5 RP4-756H11.3 -5.62 3.91e-08 2.1e-05 -0.37 -0.29 Aortic root size; chr7:66276638 chr7:66654538~66669855:+ LIHC cis rs8059260 0.604 rs35715760 ENSG00000274038.1 RP11-66H6.4 -5.62 3.91e-08 2.1e-05 -0.47 -0.29 Alcohol consumption over the past year; chr16:11102091 chr16:11056556~11057034:+ LIHC cis rs875971 0.545 rs316316 ENSG00000237310.1 GS1-124K5.4 -5.62 3.91e-08 2.1e-05 -0.28 -0.29 Aortic root size; chr7:66149270 chr7:66493706~66495474:+ LIHC cis rs2153535 0.58 rs4960433 ENSG00000230939.1 RP11-314C16.1 -5.62 3.92e-08 2.1e-05 -0.35 -0.29 Motion sickness; chr6:8523464 chr6:8784178~8785445:+ LIHC cis rs524281 0.861 rs7124165 ENSG00000255320.1 RP11-755F10.1 5.62 3.93e-08 2.11e-05 0.38 0.29 Electroencephalogram traits; chr11:66133747 chr11:66244840~66246239:- LIHC cis rs9326248 0.911 rs474339 ENSG00000236267.1 AP006216.5 5.62 3.93e-08 2.11e-05 0.29 0.29 Blood protein levels; chr11:117188836 chr11:116813204~116814003:- LIHC cis rs2153535 0.601 rs2327054 ENSG00000230939.1 RP11-314C16.1 -5.62 3.93e-08 2.11e-05 -0.36 -0.29 Motion sickness; chr6:8442897 chr6:8784178~8785445:+ LIHC cis rs2153535 0.623 rs2327055 ENSG00000230939.1 RP11-314C16.1 -5.62 3.93e-08 2.11e-05 -0.36 -0.29 Motion sickness; chr6:8442912 chr6:8784178~8785445:+ LIHC cis rs875971 0.545 rs12670811 ENSG00000226824.5 RP4-756H11.3 -5.62 3.93e-08 2.11e-05 -0.37 -0.29 Aortic root size; chr7:66358032 chr7:66654538~66669855:+ LIHC cis rs2153535 0.58 rs1932284 ENSG00000230939.1 RP11-314C16.1 -5.62 3.93e-08 2.11e-05 -0.35 -0.29 Motion sickness; chr6:8477461 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1932285 ENSG00000230939.1 RP11-314C16.1 -5.62 3.93e-08 2.11e-05 -0.35 -0.29 Motion sickness; chr6:8477486 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7775909 ENSG00000230939.1 RP11-314C16.1 -5.62 3.93e-08 2.11e-05 -0.35 -0.29 Motion sickness; chr6:8477545 chr6:8784178~8785445:+ LIHC cis rs12681287 0.511 rs7839601 ENSG00000250569.1 NTAN1P2 5.62 3.94e-08 2.11e-05 0.35 0.29 Caudate activity during reward; chr8:86491610 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs7459877 ENSG00000250569.1 NTAN1P2 5.62 3.94e-08 2.11e-05 0.35 0.29 Caudate activity during reward; chr8:86493431 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs7837569 ENSG00000250569.1 NTAN1P2 5.62 3.94e-08 2.11e-05 0.35 0.29 Caudate activity during reward; chr8:86495137 chr8:86481754~86483002:- LIHC cis rs12681287 0.517 rs34367154 ENSG00000250569.1 NTAN1P2 5.62 3.94e-08 2.11e-05 0.35 0.29 Caudate activity during reward; chr8:86496520 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs9942792 ENSG00000250569.1 NTAN1P2 5.62 3.94e-08 2.11e-05 0.35 0.29 Caudate activity during reward; chr8:86496817 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs9942793 ENSG00000250569.1 NTAN1P2 5.62 3.94e-08 2.11e-05 0.35 0.29 Caudate activity during reward; chr8:86496862 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs9942823 ENSG00000250569.1 NTAN1P2 5.62 3.94e-08 2.11e-05 0.35 0.29 Caudate activity during reward; chr8:86496948 chr8:86481754~86483002:- LIHC cis rs6921919 0.583 rs7764722 ENSG00000216901.1 AL022393.7 5.62 3.95e-08 2.11e-05 0.36 0.29 Autism spectrum disorder or schizophrenia; chr6:28386756 chr6:28176188~28176674:+ LIHC cis rs11098499 0.954 rs10006706 ENSG00000245958.5 RP11-33B1.1 -5.62 3.96e-08 2.12e-05 -0.31 -0.29 Corneal astigmatism; chr4:119487997 chr4:119454791~119552025:+ LIHC cis rs875971 0.545 rs10950036 ENSG00000226824.5 RP4-756H11.3 -5.62 3.97e-08 2.12e-05 -0.37 -0.29 Aortic root size; chr7:66353241 chr7:66654538~66669855:+ LIHC cis rs6479891 0.915 rs2616628 ENSG00000232075.1 MRPL35P2 5.62 3.97e-08 2.12e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63460197 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs2393980 ENSG00000232075.1 MRPL35P2 5.62 3.97e-08 2.12e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63464750 chr10:63634317~63634827:- LIHC cis rs6479891 0.818 rs59215788 ENSG00000232075.1 MRPL35P2 5.62 3.97e-08 2.12e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63474074 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs59246603 ENSG00000232075.1 MRPL35P2 5.62 3.97e-08 2.12e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63474182 chr10:63634317~63634827:- LIHC cis rs6479891 0.818 rs2393976 ENSG00000232075.1 MRPL35P2 5.62 3.97e-08 2.12e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63493679 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs72837056 ENSG00000232075.1 MRPL35P2 5.62 3.97e-08 2.12e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63500718 chr10:63634317~63634827:- LIHC cis rs6479891 0.818 rs11815969 ENSG00000232075.1 MRPL35P2 5.62 3.97e-08 2.12e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63506095 chr10:63634317~63634827:- LIHC cis rs2153535 0.58 rs7767780 ENSG00000230939.1 RP11-314C16.1 -5.62 3.97e-08 2.12e-05 -0.35 -0.29 Motion sickness; chr6:8453229 chr6:8784178~8785445:+ LIHC cis rs7586673 0.964 rs34444368 ENSG00000227403.1 AC009299.3 -5.62 3.97e-08 2.12e-05 -0.36 -0.29 Intelligence (multi-trait analysis); chr2:161097706 chr2:161244739~161249050:+ LIHC cis rs2933343 0.679 rs789221 ENSG00000231305.3 RP11-723O4.2 5.62 3.98e-08 2.13e-05 0.32 0.29 IgG glycosylation; chr3:128872782 chr3:128861313~128871540:- LIHC cis rs5758511 0.68 rs5758662 ENSG00000237037.8 NDUFA6-AS1 -5.62 3.98e-08 2.13e-05 -0.37 -0.29 Birth weight; chr22:42232082 chr22:42090931~42137742:+ LIHC cis rs34779708 0.702 rs7087150 ENSG00000230534.5 RP11-297A16.2 5.62 3.99e-08 2.13e-05 0.36 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35253210 chr10:35098006~35127020:- LIHC cis rs11098499 0.865 rs4001305 ENSG00000245958.5 RP11-33B1.1 -5.62 3.99e-08 2.14e-05 -0.3 -0.29 Corneal astigmatism; chr4:119438081 chr4:119454791~119552025:+ LIHC cis rs7131987 0.622 rs7294598 ENSG00000275476.1 RP11-996F15.4 5.62 4e-08 2.14e-05 0.34 0.29 QT interval; chr12:29379056 chr12:29277397~29277882:- LIHC cis rs2153535 0.58 rs2327064 ENSG00000230939.1 RP11-314C16.1 -5.62 4e-08 2.14e-05 -0.36 -0.29 Motion sickness; chr6:8453819 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7761937 ENSG00000230939.1 RP11-314C16.1 -5.62 4e-08 2.14e-05 -0.36 -0.29 Motion sickness; chr6:8459201 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9406167 ENSG00000230939.1 RP11-314C16.1 -5.62 4.01e-08 2.14e-05 -0.36 -0.29 Motion sickness; chr6:8502619 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6597334 ENSG00000230939.1 RP11-314C16.1 -5.62 4.01e-08 2.14e-05 -0.36 -0.29 Motion sickness; chr6:8504546 chr6:8784178~8785445:+ LIHC cis rs3096299 0.9 rs3114867 ENSG00000261118.1 RP11-104N10.1 5.62 4.01e-08 2.14e-05 0.29 0.29 Multiple myeloma (IgH translocation); chr16:89362559 chr16:89492017~89504460:- LIHC cis rs7927592 0.913 rs12283755 ENSG00000212093.1 AP000807.1 5.62 4.01e-08 2.15e-05 0.32 0.29 Total body bone mineral density; chr11:68604190 chr11:68506083~68506166:- LIHC cis rs6686842 0.965 rs10157966 ENSG00000235358.1 RP11-399E6.1 -5.62 4.02e-08 2.15e-05 -0.32 -0.29 Height; chr1:41256904 chr1:41242373~41284861:+ LIHC cis rs2243480 1 rs4149468 ENSG00000226824.5 RP4-756H11.3 -5.62 4.02e-08 2.15e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66360703 chr7:66654538~66669855:+ LIHC cis rs7714584 1 rs17800886 ENSG00000197083.10 ZNF300P1 5.62 4.02e-08 2.15e-05 0.45 0.29 Crohn's disease; chr5:150929977 chr5:150930645~150946289:- LIHC cis rs62229266 0.605 rs11701331 ENSG00000231106.2 LINC01436 5.62 4.03e-08 2.15e-05 0.32 0.29 Mitral valve prolapse; chr21:36086094 chr21:36005338~36007838:+ LIHC cis rs150992 0.587 rs13179812 ENSG00000248489.1 CTD-2007H13.3 -5.62 4.03e-08 2.15e-05 -0.42 -0.29 Body mass index; chr5:99021029 chr5:98929171~98995013:+ LIHC cis rs2072510 0.722 rs2247330 ENSG00000257715.1 RP11-256L6.2 5.62 4.03e-08 2.15e-05 0.29 0.29 Metabolite levels (small molecules and protein measures); chr12:96030344 chr12:96025323~96027971:+ LIHC cis rs875971 0.545 rs2420456 ENSG00000237310.1 GS1-124K5.4 5.62 4.03e-08 2.15e-05 0.28 0.29 Aortic root size; chr7:66280619 chr7:66493706~66495474:+ LIHC cis rs5758659 1 rs134873 ENSG00000227370.1 RP4-669P10.19 -5.62 4.04e-08 2.16e-05 -0.32 -0.29 Cognitive function; chr22:42261560 chr22:42132543~42132998:+ LIHC cis rs2735413 0.564 rs7201557 ENSG00000276007.1 RP11-358L22.3 5.62 4.04e-08 2.16e-05 0.4 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78076162 chr16:78123243~78124332:+ LIHC cis rs9487094 0.689 rs3818933 ENSG00000260273.1 RP11-425D10.10 5.62 4.05e-08 2.16e-05 0.35 0.29 Height; chr6:109370741 chr6:109382795~109383666:+ LIHC cis rs9487094 0.689 rs9487076 ENSG00000260273.1 RP11-425D10.10 5.62 4.05e-08 2.16e-05 0.35 0.29 Height; chr6:109371524 chr6:109382795~109383666:+ LIHC cis rs875971 0.545 rs7787063 ENSG00000237310.1 GS1-124K5.4 5.62 4.06e-08 2.17e-05 0.28 0.29 Aortic root size; chr7:66164012 chr7:66493706~66495474:+ LIHC cis rs2243480 1 rs2243480 ENSG00000164669.11 INTS4P1 5.62 4.06e-08 2.17e-05 0.51 0.29 Diabetic kidney disease; chr7:66134209 chr7:65141225~65234216:+ LIHC cis rs13068223 0.617 rs13061457 ENSG00000243926.1 TIPARP-AS1 5.61 4.07e-08 2.17e-05 0.27 0.29 Age-related hearing impairment (SNP x SNP interaction); chr3:156725596 chr3:156671862~156674378:- LIHC cis rs7429990 0.965 rs319692 ENSG00000229759.1 MRPS18AP1 5.61 4.08e-08 2.18e-05 0.31 0.29 Educational attainment (years of education); chr3:47882827 chr3:48256350~48256938:- LIHC cis rs875971 0.545 rs4718348 ENSG00000226824.5 RP4-756H11.3 -5.61 4.09e-08 2.18e-05 -0.38 -0.29 Aortic root size; chr7:66441589 chr7:66654538~66669855:+ LIHC cis rs524281 0.861 rs3862386 ENSG00000255320.1 RP11-755F10.1 5.61 4.1e-08 2.19e-05 0.38 0.29 Electroencephalogram traits; chr11:66126953 chr11:66244840~66246239:- LIHC cis rs7131987 0.903 rs11050161 ENSG00000257176.2 RP11-996F15.2 -5.61 4.1e-08 2.19e-05 -0.34 -0.29 QT interval; chr12:29267116 chr12:29280418~29317848:- LIHC cis rs7131987 0.903 rs11050162 ENSG00000257176.2 RP11-996F15.2 -5.61 4.1e-08 2.19e-05 -0.34 -0.29 QT interval; chr12:29267121 chr12:29280418~29317848:- LIHC cis rs12701220 0.655 rs9638973 ENSG00000229043.2 AC091729.9 -5.61 4.1e-08 2.19e-05 -0.4 -0.29 Bronchopulmonary dysplasia; chr7:1094042 chr7:1160374~1165267:+ LIHC cis rs12701220 0.655 rs7799656 ENSG00000229043.2 AC091729.9 -5.61 4.1e-08 2.19e-05 -0.4 -0.29 Bronchopulmonary dysplasia; chr7:1100879 chr7:1160374~1165267:+ LIHC cis rs2019137 0.589 rs7560701 ENSG00000274877.1 RP11-65I12.1 -5.61 4.11e-08 2.19e-05 -0.36 -0.29 Lymphocyte counts; chr2:113269305 chr2:113237595~113240825:+ LIHC cis rs8100891 0.537 rs10415744 ENSG00000267213.4 AC007773.2 -5.61 4.11e-08 2.19e-05 -0.37 -0.29 Neuroticism; chr19:32389674 chr19:32390050~32405560:- LIHC cis rs12468226 1 rs76284304 ENSG00000273456.1 RP11-686O6.2 5.61 4.12e-08 2.2e-05 0.42 0.29 Urate levels; chr2:202427116 chr2:202374932~202375604:- LIHC cis rs10875746 0.669 rs10875772 ENSG00000240399.1 RP1-228P16.1 -5.61 4.12e-08 2.2e-05 -0.32 -0.29 Longevity (90 years and older); chr12:48215770 chr12:48054813~48055591:- LIHC cis rs2735413 0.522 rs2075737 ENSG00000276007.1 RP11-358L22.3 5.61 4.12e-08 2.2e-05 0.36 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78023077 chr16:78123243~78124332:+ LIHC cis rs2153535 0.58 rs2327053 ENSG00000230939.1 RP11-314C16.1 -5.61 4.12e-08 2.2e-05 -0.36 -0.29 Motion sickness; chr6:8442894 chr6:8784178~8785445:+ LIHC cis rs2243480 1 rs13310597 ENSG00000226824.5 RP4-756H11.3 -5.61 4.13e-08 2.2e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66133553 chr7:66654538~66669855:+ LIHC cis rs227275 0.525 rs1080081 ENSG00000246560.2 RP11-10L12.4 5.61 4.14e-08 2.21e-05 0.33 0.29 Allergic disease (asthma, hay fever or eczema); chr4:103029268 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs4699049 ENSG00000246560.2 RP11-10L12.4 5.61 4.14e-08 2.21e-05 0.33 0.29 Allergic disease (asthma, hay fever or eczema); chr4:103030467 chr4:102828055~102844075:+ LIHC cis rs6142102 0.812 rs6059554 ENSG00000276073.1 RP5-1125A11.7 -5.61 4.15e-08 2.21e-05 -0.32 -0.29 Skin pigmentation; chr20:33926286 chr20:33985617~33988989:- LIHC cis rs227275 0.525 rs17215211 ENSG00000246560.2 RP11-10L12.4 5.61 4.16e-08 2.22e-05 0.33 0.29 Allergic disease (asthma, hay fever or eczema); chr4:103025961 chr4:102828055~102844075:+ LIHC cis rs2842992 0.714 rs2495278 ENSG00000237927.1 RP3-393E18.2 -5.61 4.16e-08 2.22e-05 -0.36 -0.29 Age-related macular degeneration (geographic atrophy); chr6:159702642 chr6:159586955~159589169:- LIHC cis rs9640161 0.75 rs11769348 ENSG00000261305.1 RP4-584D14.7 -5.61 4.16e-08 2.22e-05 -0.37 -0.29 Blood protein levels;Circulating chemerin levels; chr7:150329664 chr7:150341771~150342607:+ LIHC cis rs34779708 0.741 rs34397613 ENSG00000230534.5 RP11-297A16.2 5.61 4.17e-08 2.22e-05 0.37 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35261385 chr10:35098006~35127020:- LIHC cis rs62229266 0.605 rs2835275 ENSG00000231106.2 LINC01436 5.61 4.17e-08 2.22e-05 0.32 0.29 Mitral valve prolapse; chr21:36087703 chr21:36005338~36007838:+ LIHC cis rs6921919 0.583 rs16894060 ENSG00000216901.1 AL022393.7 5.61 4.17e-08 2.22e-05 0.37 0.29 Autism spectrum disorder or schizophrenia; chr6:28394694 chr6:28176188~28176674:+ LIHC cis rs2243480 1 rs35820085 ENSG00000226824.5 RP4-756H11.3 -5.61 4.17e-08 2.22e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65977771 chr7:66654538~66669855:+ LIHC cis rs950169 0.84 rs62019457 ENSG00000259295.5 CSPG4P12 5.61 4.18e-08 2.23e-05 0.39 0.29 Schizophrenia; chr15:84558911 chr15:85191438~85213905:+ LIHC cis rs2243480 1 rs160643 ENSG00000226824.5 RP4-756H11.3 -5.61 4.18e-08 2.23e-05 -0.45 -0.29 Diabetic kidney disease; chr7:66093235 chr7:66654538~66669855:+ LIHC cis rs11690935 0.959 rs12692974 ENSG00000228389.1 AC068039.4 5.61 4.21e-08 2.24e-05 0.4 0.29 Schizophrenia; chr2:171806746 chr2:171773482~171775844:+ LIHC cis rs5769707 0.605 rs9616702 ENSG00000235111.1 RP1-29C18.8 -5.61 4.21e-08 2.24e-05 -0.35 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49632290 chr22:49612657~49615716:- LIHC cis rs9326248 0.53 rs7940310 ENSG00000236267.1 AP006216.5 5.61 4.22e-08 2.24e-05 0.32 0.29 Blood protein levels; chr11:117153765 chr11:116813204~116814003:- LIHC cis rs5758659 0.845 rs5758645 ENSG00000227370.1 RP4-669P10.19 -5.61 4.23e-08 2.25e-05 -0.34 -0.29 Cognitive function; chr22:42202945 chr22:42132543~42132998:+ LIHC cis rs7927592 0.546 rs638076 ENSG00000212093.1 AP000807.1 5.61 4.23e-08 2.25e-05 0.29 0.29 Total body bone mineral density; chr11:68435112 chr11:68506083~68506166:- LIHC cis rs887829 0.641 rs10179094 ENSG00000233445.1 RPL17P11 5.61 4.23e-08 2.25e-05 0.31 0.29 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233689179 chr2:233721522~233722065:- LIHC cis rs62388641 0.802 rs13202504 ENSG00000272279.1 RP11-157J24.2 5.61 4.24e-08 2.26e-05 0.63 0.29 Daytime sleep phenotypes; chr6:1537640 chr6:1528364~1528911:- LIHC cis rs11676348 0.846 rs11677534 ENSG00000261338.2 RP11-378A13.1 -5.61 4.25e-08 2.26e-05 -0.3 -0.29 Ulcerative colitis; chr2:218142337 chr2:218255319~218257366:+ LIHC cis rs12681287 0.547 rs6998303 ENSG00000250569.1 NTAN1P2 5.61 4.26e-08 2.27e-05 0.35 0.29 Caudate activity during reward; chr8:86497956 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs13267858 ENSG00000250569.1 NTAN1P2 5.61 4.26e-08 2.27e-05 0.35 0.29 Caudate activity during reward; chr8:86498642 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs7461366 ENSG00000250569.1 NTAN1P2 5.61 4.26e-08 2.27e-05 0.35 0.29 Caudate activity during reward; chr8:86499456 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs4961197 ENSG00000250569.1 NTAN1P2 5.61 4.26e-08 2.27e-05 0.35 0.29 Caudate activity during reward; chr8:86500207 chr8:86481754~86483002:- LIHC cis rs17301013 0.861 rs12568655 ENSG00000227373.4 RP11-160H22.5 5.61 4.27e-08 2.27e-05 0.37 0.29 Systemic lupus erythematosus; chr1:174465194 chr1:174115300~174160004:- LIHC cis rs2153535 0.623 rs2152346 ENSG00000230939.1 RP11-314C16.1 -5.61 4.27e-08 2.27e-05 -0.35 -0.29 Motion sickness; chr6:8454419 chr6:8784178~8785445:+ LIHC cis rs1211375 0.606 rs1203977 ENSG00000268836.1 LA16c-OS12.2 -5.61 4.27e-08 2.27e-05 -0.31 -0.29 Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin; chr16:206279 chr16:185748~186294:- LIHC cis rs34779708 0.801 rs34592588 ENSG00000230534.5 RP11-297A16.2 5.61 4.28e-08 2.27e-05 0.36 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35251206 chr10:35098006~35127020:- LIHC cis rs2243480 0.901 rs778732 ENSG00000226824.5 RP4-756H11.3 -5.61 4.28e-08 2.27e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66357373 chr7:66654538~66669855:+ LIHC cis rs2735413 0.563 rs17776016 ENSG00000276007.1 RP11-358L22.3 -5.61 4.28e-08 2.28e-05 -0.38 -0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78013920 chr16:78123243~78124332:+ LIHC cis rs12681287 0.547 rs11992656 ENSG00000250569.1 NTAN1P2 -5.61 4.28e-08 2.28e-05 -0.35 -0.29 Caudate activity during reward; chr8:86522641 chr8:86481754~86483002:- LIHC cis rs2243480 1 rs316329 ENSG00000226824.5 RP4-756H11.3 -5.61 4.28e-08 2.28e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66143429 chr7:66654538~66669855:+ LIHC cis rs35828350 1 rs35828350 ENSG00000259295.5 CSPG4P12 5.61 4.28e-08 2.28e-05 0.41 0.29 Autism spectrum disorder or schizophrenia; chr15:84812610 chr15:85191438~85213905:+ LIHC cis rs10461617 0.617 rs1423623 ENSG00000271828.1 CTD-2310F14.1 -5.6 4.3e-08 2.28e-05 -0.37 -0.29 Type 2 diabetes; chr5:56769748 chr5:56927874~56929573:+ LIHC cis rs7927592 0.83 rs7120635 ENSG00000212093.1 AP000807.1 5.6 4.3e-08 2.28e-05 0.31 0.29 Total body bone mineral density; chr11:68493825 chr11:68506083~68506166:- LIHC cis rs12908161 1 rs12899981 ENSG00000259295.5 CSPG4P12 5.6 4.31e-08 2.29e-05 0.4 0.29 Schizophrenia; chr15:84759142 chr15:85191438~85213905:+ LIHC cis rs12701220 0.696 rs12112029 ENSG00000229043.2 AC091729.9 -5.6 4.31e-08 2.29e-05 -0.4 -0.29 Bronchopulmonary dysplasia; chr7:1098253 chr7:1160374~1165267:+ LIHC cis rs889312 0.504 rs62355900 ENSG00000271828.1 CTD-2310F14.1 5.6 4.31e-08 2.29e-05 0.46 0.29 Breast cancer (early onset);Breast cancer; chr5:56756868 chr5:56927874~56929573:+ LIHC cis rs2243480 0.764 rs2460423 ENSG00000226824.5 RP4-756H11.3 -5.6 4.32e-08 2.29e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66136229 chr7:66654538~66669855:+ LIHC cis rs12157904 0.793 rs2071767 ENSG00000233360.4 Z83844.1 5.6 4.33e-08 2.3e-05 0.56 0.29 Response to anti-depressant treatment in major depressive disorder; chr22:37629814 chr22:37641832~37658377:- LIHC cis rs6479891 1 rs9415708 ENSG00000232075.1 MRPL35P2 5.6 4.33e-08 2.3e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63430282 chr10:63634317~63634827:- LIHC cis rs2243480 1 rs160639 ENSG00000226824.5 RP4-756H11.3 -5.6 4.34e-08 2.3e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66115000 chr7:66654538~66669855:+ LIHC cis rs11690935 0.959 rs2292815 ENSG00000228389.1 AC068039.4 5.6 4.35e-08 2.31e-05 0.39 0.29 Schizophrenia; chr2:171730141 chr2:171773482~171775844:+ LIHC cis rs9640161 0.673 rs34489187 ENSG00000261305.1 RP4-584D14.7 5.6 4.35e-08 2.31e-05 0.37 0.29 Blood protein levels;Circulating chemerin levels; chr7:150347290 chr7:150341771~150342607:+ LIHC cis rs8059260 0.541 rs12917947 ENSG00000274038.1 RP11-66H6.4 -5.6 4.36e-08 2.31e-05 -0.5 -0.29 Alcohol consumption over the past year; chr16:11116386 chr16:11056556~11057034:+ LIHC cis rs7714584 1 rs11746807 ENSG00000197083.10 ZNF300P1 5.6 4.36e-08 2.31e-05 0.45 0.29 Crohn's disease; chr5:150920857 chr5:150930645~150946289:- LIHC cis rs2243480 0.901 rs34807232 ENSG00000226824.5 RP4-756H11.3 -5.6 4.38e-08 2.32e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66500146 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs35823062 ENSG00000226824.5 RP4-756H11.3 -5.6 4.38e-08 2.32e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66500834 chr7:66654538~66669855:+ LIHC cis rs7429990 0.965 rs2631721 ENSG00000229759.1 MRPS18AP1 5.6 4.39e-08 2.33e-05 0.31 0.29 Educational attainment (years of education); chr3:47881807 chr3:48256350~48256938:- LIHC cis rs2735413 0.564 rs6564508 ENSG00000276007.1 RP11-358L22.3 5.6 4.39e-08 2.33e-05 0.39 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78082678 chr16:78123243~78124332:+ LIHC cis rs12681287 0.511 rs4129535 ENSG00000250569.1 NTAN1P2 5.6 4.4e-08 2.33e-05 0.35 0.29 Caudate activity during reward; chr8:86511865 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs6985066 ENSG00000250569.1 NTAN1P2 5.6 4.4e-08 2.33e-05 0.35 0.29 Caudate activity during reward; chr8:86514210 chr8:86481754~86483002:- LIHC cis rs10510102 0.935 rs11200263 ENSG00000226864.1 ATE1-AS1 5.6 4.4e-08 2.33e-05 0.48 0.29 Breast cancer; chr10:121922836 chr10:121928312~121951965:+ LIHC cis rs2111504 0.583 rs2111503 ENSG00000267213.4 AC007773.2 5.6 4.4e-08 2.33e-05 0.3 0.29 Bipolar disorder; chr19:32383819 chr19:32390050~32405560:- LIHC cis rs9326248 1 rs3736120 ENSG00000236267.1 AP006216.5 5.6 4.4e-08 2.33e-05 0.3 0.29 Blood protein levels; chr11:117161409 chr11:116813204~116814003:- LIHC cis rs7688540 0.723 rs17521834 ENSG00000275426.1 CH17-262A2.1 -5.6 4.4e-08 2.33e-05 -0.41 -0.29 Facial morphology (factor 6, height of vermillion lower lip); chr4:231660 chr4:149738~150317:+ LIHC cis rs1005277 0.579 rs2474584 ENSG00000263064.2 RP11-291L22.7 5.6 4.41e-08 2.34e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38127461 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs1548255 ENSG00000263064.2 RP11-291L22.7 5.6 4.41e-08 2.34e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38128265 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474586 ENSG00000263064.2 RP11-291L22.7 5.6 4.41e-08 2.34e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38129954 chr10:38448689~38448949:+ LIHC cis rs12157904 0.793 rs2051593 ENSG00000233360.4 Z83844.1 -5.6 4.41e-08 2.34e-05 -0.58 -0.29 Response to anti-depressant treatment in major depressive disorder; chr22:37652027 chr22:37641832~37658377:- LIHC cis rs9487094 0.67 rs1885691 ENSG00000260273.1 RP11-425D10.10 5.6 4.41e-08 2.34e-05 0.35 0.29 Height; chr6:109382188 chr6:109382795~109383666:+ LIHC cis rs9487094 0.644 rs3757230 ENSG00000260273.1 RP11-425D10.10 5.6 4.41e-08 2.34e-05 0.35 0.29 Height; chr6:109383239 chr6:109382795~109383666:+ LIHC cis rs9487094 0.644 rs3757231 ENSG00000260273.1 RP11-425D10.10 5.6 4.41e-08 2.34e-05 0.35 0.29 Height; chr6:109383248 chr6:109382795~109383666:+ LIHC cis rs6479901 0.947 rs7074735 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63459519 chr10:63634317~63634827:- LIHC cis rs6479901 0.802 rs7075205 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63459834 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs10995540 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63460170 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs10159609 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63461168 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs10995541 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63473575 chr10:63634317~63634827:- LIHC cis rs6479901 0.894 rs10761773 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63480322 chr10:63634317~63634827:- LIHC cis rs6479901 0.894 rs2393978 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63482050 chr10:63634317~63634827:- LIHC cis rs6479901 0.895 rs10822173 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63483842 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs7915680 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63484544 chr10:63634317~63634827:- LIHC cis rs6479901 0.894 rs9919452 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63488812 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs10761776 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63491217 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs7910662 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63493940 chr10:63634317~63634827:- LIHC cis rs6479901 0.624 rs10822175 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63495414 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs9971294 ENSG00000232075.1 MRPL35P2 -5.6 4.41e-08 2.34e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63503108 chr10:63634317~63634827:- LIHC cis rs2153535 0.58 rs9378556 ENSG00000230939.1 RP11-314C16.1 -5.6 4.41e-08 2.34e-05 -0.35 -0.29 Motion sickness; chr6:8514462 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9406171 ENSG00000230939.1 RP11-314C16.1 -5.6 4.41e-08 2.34e-05 -0.35 -0.29 Motion sickness; chr6:8515129 chr6:8784178~8785445:+ LIHC cis rs2153535 0.54 rs9378557 ENSG00000230939.1 RP11-314C16.1 -5.6 4.41e-08 2.34e-05 -0.35 -0.29 Motion sickness; chr6:8517148 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2143355 ENSG00000230939.1 RP11-314C16.1 -5.6 4.41e-08 2.34e-05 -0.35 -0.29 Motion sickness; chr6:8517623 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2143354 ENSG00000230939.1 RP11-314C16.1 -5.6 4.41e-08 2.34e-05 -0.35 -0.29 Motion sickness; chr6:8517674 chr6:8784178~8785445:+ LIHC cis rs2243480 1 rs34970380 ENSG00000226824.5 RP4-756H11.3 -5.6 4.43e-08 2.34e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65966506 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs73148097 ENSG00000226824.5 RP4-756H11.3 -5.6 4.43e-08 2.34e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65966800 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs906134 ENSG00000226824.5 RP4-756H11.3 -5.6 4.43e-08 2.34e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65979301 chr7:66654538~66669855:+ LIHC cis rs6479891 1 rs72837070 ENSG00000232075.1 MRPL35P2 5.6 4.43e-08 2.34e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63514919 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs61853635 ENSG00000232075.1 MRPL35P2 5.6 4.43e-08 2.34e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63516750 chr10:63634317~63634827:- LIHC cis rs6142102 0.812 rs725478 ENSG00000276073.1 RP5-1125A11.7 5.6 4.44e-08 2.35e-05 0.32 0.29 Skin pigmentation; chr20:33930548 chr20:33985617~33988989:- LIHC cis rs875971 0.545 rs316305 ENSG00000237310.1 GS1-124K5.4 -5.6 4.44e-08 2.35e-05 -0.28 -0.29 Aortic root size; chr7:66152984 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs316306 ENSG00000237310.1 GS1-124K5.4 -5.6 4.44e-08 2.35e-05 -0.28 -0.29 Aortic root size; chr7:66153687 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs10950025 ENSG00000237310.1 GS1-124K5.4 5.6 4.44e-08 2.35e-05 0.28 0.29 Aortic root size; chr7:66158946 chr7:66493706~66495474:+ LIHC cis rs875971 0.52 rs12666485 ENSG00000237310.1 GS1-124K5.4 5.6 4.44e-08 2.35e-05 0.28 0.29 Aortic root size; chr7:66160135 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs67688847 ENSG00000237310.1 GS1-124K5.4 5.6 4.44e-08 2.35e-05 0.28 0.29 Aortic root size; chr7:66161064 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs12673308 ENSG00000237310.1 GS1-124K5.4 5.6 4.44e-08 2.35e-05 0.28 0.29 Aortic root size; chr7:66166374 chr7:66493706~66495474:+ LIHC cis rs10170846 0.861 rs6740452 ENSG00000261428.2 RP11-16P6.1 5.6 4.44e-08 2.35e-05 0.3 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222653733 chr2:222566899~222569719:- LIHC cis rs10170846 0.789 rs972650 ENSG00000261428.2 RP11-16P6.1 5.6 4.44e-08 2.35e-05 0.3 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222655568 chr2:222566899~222569719:- LIHC cis rs10170846 0.861 rs12694582 ENSG00000261428.2 RP11-16P6.1 5.6 4.44e-08 2.35e-05 0.3 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222657236 chr2:222566899~222569719:- LIHC cis rs10170846 0.731 rs10180632 ENSG00000261428.2 RP11-16P6.1 5.6 4.44e-08 2.35e-05 0.3 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222661665 chr2:222566899~222569719:- LIHC cis rs10170846 0.8 rs10180462 ENSG00000261428.2 RP11-16P6.1 5.6 4.44e-08 2.35e-05 0.3 0.29 Schizophrenia (inflammation and infection response interaction); chr2:222661666 chr2:222566899~222569719:- LIHC cis rs2111504 0.583 rs1015839 ENSG00000267213.4 AC007773.2 5.6 4.44e-08 2.35e-05 0.29 0.29 Bipolar disorder; chr19:32390365 chr19:32390050~32405560:- LIHC cis rs8100891 0.537 rs73034207 ENSG00000267213.4 AC007773.2 -5.6 4.44e-08 2.35e-05 -0.39 -0.29 Neuroticism; chr19:32384863 chr19:32390050~32405560:- LIHC cis rs10510102 0.872 rs7906271 ENSG00000276742.1 RP11-500G22.4 -5.6 4.44e-08 2.35e-05 -0.46 -0.29 Breast cancer; chr10:121948207 chr10:121956782~121957098:+ LIHC cis rs831571 0.703 rs831566 ENSG00000280620.1 SCAANT1 -5.6 4.46e-08 2.36e-05 -0.4 -0.29 Type 2 diabetes; chr3:64090262 chr3:63911518~63911772:- LIHC cis rs11098499 0.821 rs10032151 ENSG00000245958.5 RP11-33B1.1 -5.6 4.46e-08 2.36e-05 -0.3 -0.29 Corneal astigmatism; chr4:119470473 chr4:119454791~119552025:+ LIHC cis rs11098499 0.865 rs10032158 ENSG00000245958.5 RP11-33B1.1 -5.6 4.46e-08 2.36e-05 -0.3 -0.29 Corneal astigmatism; chr4:119470477 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs6838814 ENSG00000245958.5 RP11-33B1.1 -5.6 4.46e-08 2.36e-05 -0.3 -0.29 Corneal astigmatism; chr4:119471288 chr4:119454791~119552025:+ LIHC cis rs227275 0.554 rs223319 ENSG00000230069.3 LRRC37A15P -5.6 4.47e-08 2.36e-05 -0.26 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102881157 chr4:102727274~102730721:- LIHC cis rs228614 0.509 rs223318 ENSG00000230069.3 LRRC37A15P -5.6 4.47e-08 2.36e-05 -0.26 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102881422 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs223315 ENSG00000230069.3 LRRC37A15P -5.6 4.47e-08 2.36e-05 -0.26 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102884286 chr4:102727274~102730721:- LIHC cis rs12458462 0.851 rs62097746 ENSG00000274828.1 RP11-567M16.6 5.6 4.48e-08 2.37e-05 0.31 0.29 Monocyte count; chr18:79727508 chr18:79677287~79679358:- LIHC cis rs12458462 0.851 rs60298379 ENSG00000274828.1 RP11-567M16.6 5.6 4.48e-08 2.37e-05 0.31 0.29 Monocyte count; chr18:79728422 chr18:79677287~79679358:- LIHC cis rs12458462 0.812 rs36073957 ENSG00000274828.1 RP11-567M16.6 5.6 4.48e-08 2.37e-05 0.31 0.29 Monocyte count; chr18:79728441 chr18:79677287~79679358:- LIHC cis rs12458462 0.851 rs2169249 ENSG00000274828.1 RP11-567M16.6 5.6 4.48e-08 2.37e-05 0.31 0.29 Monocyte count; chr18:79729649 chr18:79677287~79679358:- LIHC cis rs12681287 0.752 rs12548328 ENSG00000250569.1 NTAN1P2 5.6 4.5e-08 2.38e-05 0.36 0.29 Caudate activity during reward; chr8:86298990 chr8:86481754~86483002:- LIHC cis rs7945705 0.869 rs4909952 ENSG00000254860.4 TMEM9B-AS1 -5.6 4.5e-08 2.38e-05 -0.29 -0.29 Hemoglobin concentration; chr11:8942399 chr11:8964675~8977527:+ LIHC cis rs7916697 0.891 rs7897809 ENSG00000233590.1 RP11-153K11.3 -5.6 4.5e-08 2.38e-05 -0.35 -0.29 Optic disc area; chr10:68240536 chr10:68233251~68242379:- LIHC cis rs12908161 1 rs11637142 ENSG00000259295.5 CSPG4P12 5.6 4.51e-08 2.38e-05 0.39 0.29 Schizophrenia; chr15:84752696 chr15:85191438~85213905:+ LIHC cis rs7927592 0.913 rs7118897 ENSG00000212093.1 AP000807.1 5.6 4.52e-08 2.39e-05 0.31 0.29 Total body bone mineral density; chr11:68593212 chr11:68506083~68506166:- LIHC cis rs2933343 0.553 rs789212 ENSG00000231305.3 RP11-723O4.2 5.6 4.52e-08 2.39e-05 0.32 0.29 IgG glycosylation; chr3:128968069 chr3:128861313~128871540:- LIHC cis rs7714584 1 rs11743488 ENSG00000197083.10 ZNF300P1 5.6 4.53e-08 2.39e-05 0.45 0.29 Crohn's disease; chr5:150899656 chr5:150930645~150946289:- LIHC cis rs11690935 0.959 rs10194102 ENSG00000228389.1 AC068039.4 5.59 4.53e-08 2.39e-05 0.39 0.29 Schizophrenia; chr2:171769633 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs7572215 ENSG00000228389.1 AC068039.4 5.59 4.53e-08 2.39e-05 0.39 0.29 Schizophrenia; chr2:171777718 chr2:171773482~171775844:+ LIHC cis rs11690935 0.918 rs11757 ENSG00000228389.1 AC068039.4 5.59 4.53e-08 2.39e-05 0.39 0.29 Schizophrenia; chr2:171784535 chr2:171773482~171775844:+ LIHC cis rs5769707 0.681 rs739236 ENSG00000235111.1 RP1-29C18.8 -5.59 4.54e-08 2.4e-05 -0.35 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49647954 chr22:49612657~49615716:- LIHC cis rs739496 0.947 rs2339816 ENSG00000226469.1 ADAM1B 5.59 4.54e-08 2.4e-05 0.35 0.29 Platelet count; chr12:111474384 chr12:111927018~111929017:+ LIHC cis rs7615952 0.515 rs4441610 ENSG00000171084.14 FAM86JP 5.59 4.55e-08 2.4e-05 0.49 0.29 Blood pressure (smoking interaction); chr3:125962464 chr3:125916620~125930024:+ LIHC cis rs2072510 0.683 rs2540486 ENSG00000257715.1 RP11-256L6.2 -5.59 4.56e-08 2.41e-05 -0.29 -0.29 Metabolite levels (small molecules and protein measures); chr12:96037229 chr12:96025323~96027971:+ LIHC cis rs2243480 1 rs778729 ENSG00000226824.5 RP4-756H11.3 -5.59 4.56e-08 2.41e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66359432 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs778687 ENSG00000226824.5 RP4-756H11.3 -5.59 4.56e-08 2.41e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66370832 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs778679 ENSG00000226824.5 RP4-756H11.3 -5.59 4.56e-08 2.41e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66375924 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs778704 ENSG00000226824.5 RP4-756H11.3 -5.59 4.56e-08 2.41e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66398480 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs778693 ENSG00000226824.5 RP4-756H11.3 -5.59 4.56e-08 2.41e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66407358 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs778691 ENSG00000226824.5 RP4-756H11.3 -5.59 4.56e-08 2.41e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66408105 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs13235972 ENSG00000226824.5 RP4-756H11.3 -5.59 4.56e-08 2.41e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66418618 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs34192067 ENSG00000226824.5 RP4-756H11.3 -5.59 4.56e-08 2.41e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66422670 chr7:66654538~66669855:+ LIHC cis rs6142102 0.778 rs4911374 ENSG00000276073.1 RP5-1125A11.7 -5.59 4.56e-08 2.41e-05 -0.32 -0.29 Skin pigmentation; chr20:33928195 chr20:33985617~33988989:- LIHC cis rs7829975 0.514 rs2979151 ENSG00000253893.2 FAM85B 5.59 4.57e-08 2.41e-05 0.34 0.29 Mood instability; chr8:8400509 chr8:8167819~8226614:- LIHC cis rs875971 0.545 rs11767262 ENSG00000237310.1 GS1-124K5.4 5.59 4.58e-08 2.41e-05 0.28 0.29 Aortic root size; chr7:66302237 chr7:66493706~66495474:+ LIHC cis rs6479891 1 rs12784772 ENSG00000232075.1 MRPL35P2 5.59 4.58e-08 2.42e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63435695 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs77494594 ENSG00000232075.1 MRPL35P2 5.59 4.58e-08 2.42e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63437549 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs2466128 ENSG00000232075.1 MRPL35P2 5.59 4.58e-08 2.42e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63448561 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs2719815 ENSG00000232075.1 MRPL35P2 5.59 4.58e-08 2.42e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63450534 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs2616630 ENSG00000232075.1 MRPL35P2 5.59 4.58e-08 2.42e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63453579 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs2616629 ENSG00000232075.1 MRPL35P2 5.59 4.58e-08 2.42e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63454056 chr10:63634317~63634827:- LIHC cis rs9341808 0.754 rs3793000 ENSG00000272129.1 RP11-250B2.6 5.59 4.58e-08 2.42e-05 0.28 0.29 Sitting height ratio; chr6:80285420 chr6:80355424~80356859:+ LIHC cis rs6479891 1 rs61853589 ENSG00000232075.1 MRPL35P2 5.59 4.58e-08 2.42e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63427351 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs9414803 ENSG00000232075.1 MRPL35P2 5.59 4.58e-08 2.42e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63428309 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs9415707 ENSG00000232075.1 MRPL35P2 5.59 4.58e-08 2.42e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63428530 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs12413029 ENSG00000232075.1 MRPL35P2 5.59 4.58e-08 2.42e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63429366 chr10:63634317~63634827:- LIHC cis rs2929278 0.736 rs2412823 ENSG00000205771.5 CATSPER2P1 5.59 4.59e-08 2.42e-05 0.35 0.29 Schizophrenia; chr15:43935072 chr15:43726918~43747094:- LIHC cis rs875971 0.545 rs73376394 ENSG00000237310.1 GS1-124K5.4 5.59 4.59e-08 2.42e-05 0.27 0.29 Aortic root size; chr7:66172694 chr7:66493706~66495474:+ LIHC cis rs10935480 0.771 rs7634817 ENSG00000239445.4 ST3GAL6-AS1 5.59 4.6e-08 2.42e-05 0.36 0.29 Blood protein levels; chr3:98743681 chr3:98714330~98732651:- LIHC cis rs7429990 0.965 rs7653368 ENSG00000229759.1 MRPS18AP1 5.59 4.6e-08 2.43e-05 0.3 0.29 Educational attainment (years of education); chr3:47943871 chr3:48256350~48256938:- LIHC cis rs2243480 1 rs316317 ENSG00000226824.5 RP4-756H11.3 -5.59 4.61e-08 2.43e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66148650 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs316304 ENSG00000226824.5 RP4-756H11.3 -5.59 4.61e-08 2.43e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66151907 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs2465120 ENSG00000226824.5 RP4-756H11.3 -5.59 4.61e-08 2.43e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66155987 chr7:66654538~66669855:+ LIHC cis rs2243480 0.908 rs2460431 ENSG00000226824.5 RP4-756H11.3 5.59 4.61e-08 2.43e-05 0.48 0.29 Diabetic kidney disease; chr7:66157859 chr7:66654538~66669855:+ LIHC cis rs2243480 0.711 rs2460426 ENSG00000226824.5 RP4-756H11.3 5.59 4.61e-08 2.43e-05 0.48 0.29 Diabetic kidney disease; chr7:66158142 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs4718309 ENSG00000226824.5 RP4-756H11.3 5.59 4.61e-08 2.43e-05 0.48 0.29 Diabetic kidney disease; chr7:66162777 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs6460274 ENSG00000226824.5 RP4-756H11.3 5.59 4.61e-08 2.43e-05 0.48 0.29 Diabetic kidney disease; chr7:66163497 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs7787230 ENSG00000226824.5 RP4-756H11.3 5.59 4.61e-08 2.43e-05 0.48 0.29 Diabetic kidney disease; chr7:66164112 chr7:66654538~66669855:+ LIHC cis rs7945705 0.902 rs2016942 ENSG00000254860.4 TMEM9B-AS1 -5.59 4.62e-08 2.43e-05 -0.29 -0.29 Hemoglobin concentration; chr11:8917240 chr11:8964675~8977527:+ LIHC cis rs2933343 0.729 rs813732 ENSG00000231305.3 RP11-723O4.2 5.59 4.62e-08 2.44e-05 0.32 0.29 IgG glycosylation; chr3:128900514 chr3:128861313~128871540:- LIHC cis rs524281 0.648 rs10896089 ENSG00000255320.1 RP11-755F10.1 5.59 4.63e-08 2.44e-05 0.38 0.29 Electroencephalogram traits; chr11:66168821 chr11:66244840~66246239:- LIHC cis rs8059260 0.544 rs34846673 ENSG00000274038.1 RP11-66H6.4 -5.59 4.63e-08 2.44e-05 -0.47 -0.29 Alcohol consumption over the past year; chr16:11102829 chr16:11056556~11057034:+ LIHC cis rs2243480 1 rs56291018 ENSG00000226824.5 RP4-756H11.3 -5.59 4.63e-08 2.44e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65925352 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs2460427 ENSG00000237310.1 GS1-124K5.4 -5.59 4.63e-08 2.44e-05 -0.28 -0.29 Aortic root size; chr7:66154218 chr7:66493706~66495474:+ LIHC cis rs12908161 1 rs17601029 ENSG00000259295.5 CSPG4P12 5.59 4.63e-08 2.44e-05 0.39 0.29 Schizophrenia; chr15:84804478 chr15:85191438~85213905:+ LIHC cis rs12701220 0.553 rs7782024 ENSG00000229043.2 AC091729.9 -5.59 4.64e-08 2.44e-05 -0.4 -0.29 Bronchopulmonary dysplasia; chr7:1117866 chr7:1160374~1165267:+ LIHC cis rs228614 0.51 rs223328 ENSG00000230069.3 LRRC37A15P -5.59 4.64e-08 2.44e-05 -0.26 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873379 chr4:102727274~102730721:- LIHC cis rs228614 0.536 rs223325 ENSG00000230069.3 LRRC37A15P -5.59 4.64e-08 2.44e-05 -0.26 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102875751 chr4:102727274~102730721:- LIHC cis rs9640161 0.75 rs11764936 ENSG00000261305.1 RP4-584D14.7 5.59 4.65e-08 2.45e-05 0.36 0.29 Blood protein levels;Circulating chemerin levels; chr7:150328826 chr7:150341771~150342607:+ LIHC cis rs2283792 0.967 rs11704205 ENSG00000224086.5 LL22NC03-86G7.1 -5.59 4.68e-08 2.46e-05 -0.26 -0.29 Multiple sclerosis; chr22:21790964 chr22:21938293~21977632:+ LIHC cis rs7586673 0.866 rs7579662 ENSG00000227403.1 AC009299.3 -5.59 4.68e-08 2.46e-05 -0.35 -0.29 Intelligence (multi-trait analysis); chr2:161059299 chr2:161244739~161249050:+ LIHC cis rs10510102 0.935 rs12246704 ENSG00000276742.1 RP11-500G22.4 5.59 4.68e-08 2.46e-05 0.44 0.29 Breast cancer; chr10:121906165 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200243 ENSG00000276742.1 RP11-500G22.4 5.59 4.68e-08 2.46e-05 0.44 0.29 Breast cancer; chr10:121906888 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200244 ENSG00000276742.1 RP11-500G22.4 5.59 4.68e-08 2.46e-05 0.44 0.29 Breast cancer; chr10:121906944 chr10:121956782~121957098:+ LIHC cis rs734999 0.967 rs6671426 ENSG00000225931.3 RP3-395M20.7 5.59 4.69e-08 2.47e-05 0.32 0.29 Ulcerative colitis; chr1:2572795 chr1:2566410~2569888:+ LIHC cis rs12681287 0.752 rs13255058 ENSG00000250569.1 NTAN1P2 5.59 4.69e-08 2.47e-05 0.36 0.29 Caudate activity during reward; chr8:86275216 chr8:86481754~86483002:- LIHC cis rs11690935 0.879 rs908671 ENSG00000228389.1 AC068039.4 5.59 4.69e-08 2.47e-05 0.39 0.29 Schizophrenia; chr2:171833755 chr2:171773482~171775844:+ LIHC cis rs9322193 0.607 rs9383941 ENSG00000268592.3 RAET1E-AS1 -5.59 4.7e-08 2.47e-05 -0.38 -0.29 Lung cancer; chr6:149912100 chr6:149863494~149919507:+ LIHC cis rs7209700 0.742 rs999323 ENSG00000228782.6 CTD-2026D20.3 -5.59 4.7e-08 2.47e-05 -0.32 -0.29 IgG glycosylation; chr17:47294237 chr17:47450568~47492492:- LIHC cis rs11690935 1 rs312918 ENSG00000228389.1 AC068039.4 5.59 4.71e-08 2.48e-05 0.37 0.29 Schizophrenia; chr2:171713077 chr2:171773482~171775844:+ LIHC cis rs12468226 1 rs13426118 ENSG00000273456.1 RP11-686O6.2 5.59 4.74e-08 2.49e-05 0.41 0.29 Urate levels; chr2:202390762 chr2:202374932~202375604:- LIHC cis rs2243480 1 rs160646 ENSG00000226824.5 RP4-756H11.3 -5.59 4.76e-08 2.5e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66091293 chr7:66654538~66669855:+ LIHC cis rs2153535 0.58 rs7767756 ENSG00000230939.1 RP11-314C16.1 -5.59 4.77e-08 2.5e-05 -0.35 -0.29 Motion sickness; chr6:8453195 chr6:8784178~8785445:+ LIHC cis rs860295 0.812 rs11264413 ENSG00000203761.5 MSTO2P -5.59 4.77e-08 2.51e-05 -0.24 -0.29 Body mass index; chr1:155818865 chr1:155745829~155750137:+ LIHC cis rs9532669 0.927 rs9532670 ENSG00000168852.11 TPTE2P5 -5.58 4.77e-08 2.51e-05 -0.33 -0.29 Cervical cancer; chr13:40927691 chr13:40822296~40921749:- LIHC cis rs72627509 0.904 rs7687767 ENSG00000269949.1 RP11-738E22.3 -5.58 4.78e-08 2.51e-05 -0.37 -0.29 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56958766 chr4:56960927~56961373:- LIHC cis rs1023500 0.505 rs134899 ENSG00000227370.1 RP4-669P10.19 -5.58 4.78e-08 2.51e-05 -0.31 -0.29 Schizophrenia; chr22:42287024 chr22:42132543~42132998:+ LIHC cis rs7429990 0.965 rs1061003 ENSG00000229759.1 MRPS18AP1 5.58 4.78e-08 2.51e-05 0.31 0.29 Educational attainment (years of education); chr3:47851089 chr3:48256350~48256938:- LIHC cis rs2522056 1 rs11242113 ENSG00000233006.5 AC034220.3 -5.58 4.78e-08 2.51e-05 -0.3 -0.29 Fibrinogen;Lymphocyte counts; chr5:132441542 chr5:132311285~132369916:- LIHC cis rs62229266 0.647 rs59397717 ENSG00000231106.2 LINC01436 5.58 4.78e-08 2.51e-05 0.32 0.29 Mitral valve prolapse; chr21:36079427 chr21:36005338~36007838:+ LIHC cis rs2153535 0.505 rs9405395 ENSG00000230939.1 RP11-314C16.1 -5.58 4.79e-08 2.52e-05 -0.35 -0.29 Motion sickness; chr6:8468389 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9392223 ENSG00000230939.1 RP11-314C16.1 -5.58 4.79e-08 2.52e-05 -0.35 -0.29 Motion sickness; chr6:8468417 chr6:8784178~8785445:+ LIHC cis rs12468226 1 rs79919139 ENSG00000273456.1 RP11-686O6.2 5.58 4.79e-08 2.52e-05 0.42 0.29 Urate levels; chr2:202382786 chr2:202374932~202375604:- LIHC cis rs12468226 0.935 rs75597391 ENSG00000273456.1 RP11-686O6.2 5.58 4.79e-08 2.52e-05 0.42 0.29 Urate levels; chr2:202398850 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs12472408 ENSG00000273456.1 RP11-686O6.2 5.58 4.79e-08 2.52e-05 0.42 0.29 Urate levels; chr2:202413973 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs115170232 ENSG00000273456.1 RP11-686O6.2 5.58 4.79e-08 2.52e-05 0.42 0.29 Urate levels; chr2:202416790 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs16839149 ENSG00000273456.1 RP11-686O6.2 5.58 4.79e-08 2.52e-05 0.42 0.29 Urate levels; chr2:202427621 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs76528043 ENSG00000273456.1 RP11-686O6.2 5.58 4.79e-08 2.52e-05 0.42 0.29 Urate levels; chr2:202466116 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs12468226 ENSG00000273456.1 RP11-686O6.2 5.58 4.79e-08 2.52e-05 0.42 0.29 Urate levels; chr2:202472278 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs75040639 ENSG00000273456.1 RP11-686O6.2 5.58 4.79e-08 2.52e-05 0.42 0.29 Urate levels; chr2:202486973 chr2:202374932~202375604:- LIHC cis rs12468226 0.872 rs115187557 ENSG00000273456.1 RP11-686O6.2 5.58 4.79e-08 2.52e-05 0.42 0.29 Urate levels; chr2:202495351 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs74508472 ENSG00000273456.1 RP11-686O6.2 5.58 4.79e-08 2.52e-05 0.42 0.29 Urate levels; chr2:202517290 chr2:202374932~202375604:- LIHC cis rs8100891 0.537 rs3746016 ENSG00000267213.4 AC007773.2 -5.58 4.79e-08 2.52e-05 -0.38 -0.29 Neuroticism; chr19:32386353 chr19:32390050~32405560:- LIHC cis rs2274273 0.87 rs3825616 ENSG00000258413.1 RP11-665C16.6 -5.58 4.79e-08 2.52e-05 -0.34 -0.29 Protein biomarker; chr14:55386570 chr14:55262767~55272075:- LIHC cis rs10510102 0.872 rs7907815 ENSG00000276742.1 RP11-500G22.4 5.58 4.8e-08 2.52e-05 0.47 0.29 Breast cancer; chr10:121965951 chr10:121956782~121957098:+ LIHC cis rs3779195 0.697 rs1688606 ENSG00000272950.1 RP11-307C18.1 5.58 4.81e-08 2.52e-05 0.41 0.29 Sex hormone-binding globulin levels; chr7:98345539 chr7:98322853~98323430:+ LIHC cis rs380904 0.517 rs11775744 ENSG00000254859.1 RP11-661A12.5 -5.58 4.82e-08 2.53e-05 -0.55 -0.29 Venous thromboembolism (SNP x SNP interaction); chr8:143567022 chr8:143541973~143549729:- LIHC cis rs2243480 1 rs160642 ENSG00000226824.5 RP4-756H11.3 -5.58 4.82e-08 2.53e-05 -0.46 -0.29 Diabetic kidney disease; chr7:66093386 chr7:66654538~66669855:+ LIHC cis rs2243480 0.614 rs34032527 ENSG00000226824.5 RP4-756H11.3 -5.58 4.82e-08 2.53e-05 -0.46 -0.29 Diabetic kidney disease; chr7:66100154 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs2462569 ENSG00000226824.5 RP4-756H11.3 5.58 4.83e-08 2.53e-05 0.46 0.29 Diabetic kidney disease; chr7:66009859 chr7:66654538~66669855:+ LIHC cis rs11676348 0.811 rs4674255 ENSG00000261338.2 RP11-378A13.1 -5.58 4.83e-08 2.53e-05 -0.3 -0.29 Ulcerative colitis; chr2:218122602 chr2:218255319~218257366:+ LIHC cis rs11676348 0.846 rs3890158 ENSG00000261338.2 RP11-378A13.1 -5.58 4.83e-08 2.53e-05 -0.3 -0.29 Ulcerative colitis; chr2:218125569 chr2:218255319~218257366:+ LIHC cis rs11722779 0.844 rs223345 ENSG00000230069.3 LRRC37A15P -5.58 4.83e-08 2.53e-05 -0.26 -0.29 Schizophrenia; chr4:102859366 chr4:102727274~102730721:- LIHC cis rs1005277 0.522 rs289647 ENSG00000263064.2 RP11-291L22.7 5.58 4.84e-08 2.54e-05 0.29 0.29 Extrinsic epigenetic age acceleration; chr10:37679350 chr10:38448689~38448949:+ LIHC cis rs9326248 0.953 rs488962 ENSG00000236267.1 AP006216.5 -5.58 4.84e-08 2.54e-05 -0.29 -0.29 Blood protein levels; chr11:117201809 chr11:116813204~116814003:- LIHC cis rs9326248 0.953 rs634960 ENSG00000236267.1 AP006216.5 -5.58 4.84e-08 2.54e-05 -0.29 -0.29 Blood protein levels; chr11:117202247 chr11:116813204~116814003:- LIHC cis rs12681287 0.927 rs2976177 ENSG00000250569.1 NTAN1P2 5.58 4.84e-08 2.54e-05 0.34 0.29 Caudate activity during reward; chr8:86320103 chr8:86481754~86483002:- LIHC cis rs7945705 0.869 rs11042154 ENSG00000254860.4 TMEM9B-AS1 5.58 4.84e-08 2.54e-05 0.29 0.29 Hemoglobin concentration; chr11:9008153 chr11:8964675~8977527:+ LIHC cis rs5769707 0.681 rs2071902 ENSG00000235111.1 RP1-29C18.8 -5.58 4.85e-08 2.54e-05 -0.35 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49640890 chr22:49612657~49615716:- LIHC cis rs11722779 0.873 rs223344 ENSG00000230069.3 LRRC37A15P -5.58 4.85e-08 2.54e-05 -0.26 -0.29 Schizophrenia; chr4:102859765 chr4:102727274~102730721:- LIHC cis rs11722779 0.775 rs223341 ENSG00000230069.3 LRRC37A15P -5.58 4.85e-08 2.54e-05 -0.26 -0.29 Schizophrenia; chr4:102862343 chr4:102727274~102730721:- LIHC cis rs9318086 0.578 rs2077709 ENSG00000205861.10 C1QTNF9B-AS1 5.58 4.85e-08 2.54e-05 0.32 0.29 Myopia (pathological); chr13:23901934 chr13:23888889~23897263:+ LIHC cis rs11690935 1 rs3795999 ENSG00000228389.1 AC068039.4 -5.58 4.85e-08 2.54e-05 -0.38 -0.29 Schizophrenia; chr2:171687973 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs4668412 ENSG00000228389.1 AC068039.4 5.58 4.86e-08 2.55e-05 0.39 0.29 Schizophrenia; chr2:171763260 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs13419987 ENSG00000228389.1 AC068039.4 5.58 4.86e-08 2.55e-05 0.39 0.29 Schizophrenia; chr2:171767404 chr2:171773482~171775844:+ LIHC cis rs62355901 1 rs62355901 ENSG00000271828.1 CTD-2310F14.1 5.58 4.87e-08 2.55e-05 0.46 0.29 Breast cancer; chr5:56757708 chr5:56927874~56929573:+ LIHC cis rs12744310 0.525 rs12406967 ENSG00000235358.1 RP11-399E6.1 5.58 4.87e-08 2.55e-05 0.34 0.29 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41319742 chr1:41242373~41284861:+ LIHC cis rs12744310 0.502 rs2154317 ENSG00000235358.1 RP11-399E6.1 5.58 4.87e-08 2.55e-05 0.34 0.29 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41320120 chr1:41242373~41284861:+ LIHC cis rs2284219 0.565 rs2284217 ENSG00000196295.10 AC005154.6 -5.58 4.87e-08 2.55e-05 -0.23 -0.29 Type 2 diabetes; chr7:30673992 chr7:30516309~30594809:- LIHC cis rs5769707 0.706 rs763128 ENSG00000235111.1 RP1-29C18.8 -5.58 4.89e-08 2.56e-05 -0.35 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49624397 chr22:49612657~49615716:- LIHC cis rs950776 0.518 rs8053 ENSG00000261762.1 RP11-650L12.2 -5.58 4.89e-08 2.56e-05 -0.38 -0.29 Sudden cardiac arrest; chr15:78548878 chr15:78589123~78591276:- LIHC cis rs1005277 0.505 rs10827836 ENSG00000263064.2 RP11-291L22.7 -5.58 4.9e-08 2.57e-05 -0.3 -0.29 Extrinsic epigenetic age acceleration; chr10:37926513 chr10:38448689~38448949:+ LIHC cis rs11690935 0.959 rs973889 ENSG00000228389.1 AC068039.4 5.58 4.91e-08 2.57e-05 0.39 0.29 Schizophrenia; chr2:171723444 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs11897196 ENSG00000228389.1 AC068039.4 5.58 4.91e-08 2.57e-05 0.39 0.29 Schizophrenia; chr2:171729085 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs10207085 ENSG00000228389.1 AC068039.4 5.58 4.91e-08 2.57e-05 0.39 0.29 Schizophrenia; chr2:171729375 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs7604918 ENSG00000228389.1 AC068039.4 5.58 4.91e-08 2.57e-05 0.39 0.29 Schizophrenia; chr2:171731584 chr2:171773482~171775844:+ LIHC cis rs2243480 1 rs73142166 ENSG00000226824.5 RP4-756H11.3 -5.58 4.92e-08 2.58e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65910845 chr7:66654538~66669855:+ LIHC cis rs853679 0.517 rs4713146 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28143758 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9393894 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28144784 chr6:28115628~28116551:+ LIHC cis rs853679 0.513 rs9468296 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28145952 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs4711164 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28147378 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs4711165 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28147406 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs4713148 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28148143 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9348794 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28149979 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9295758 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28152885 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs17774663 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28153120 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9468298 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28154567 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9295759 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28156691 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9348796 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28158424 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs11552219 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28159056 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9393895 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28159843 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9357066 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28162053 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9368556 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28163375 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9368557 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28163759 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9380059 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28164580 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9380060 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28164825 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs35227624 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28164948 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9380061 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28165025 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9368558 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28165528 chr6:28115628~28116551:+ LIHC cis rs4713118 0.587 rs9393899 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Parkinson's disease; chr6:28165750 chr6:28115628~28116551:+ LIHC cis rs4713118 0.527 rs4713151 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Parkinson's disease; chr6:28168578 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9393901 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28169019 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs3173443 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28169249 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs4713152 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28169676 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9348797 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28169755 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9380062 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28169791 chr6:28115628~28116551:+ LIHC cis rs853679 0.542 rs9380063 ENSG00000219392.1 RP1-265C24.5 -5.58 4.93e-08 2.58e-05 -0.45 -0.29 Depression; chr6:28170075 chr6:28115628~28116551:+ LIHC cis rs11098499 0.954 rs17006190 ENSG00000245958.5 RP11-33B1.1 -5.58 4.93e-08 2.58e-05 -0.3 -0.29 Corneal astigmatism; chr4:119497683 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs28685688 ENSG00000245958.5 RP11-33B1.1 -5.58 4.93e-08 2.58e-05 -0.3 -0.29 Corneal astigmatism; chr4:119499179 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs7687843 ENSG00000245958.5 RP11-33B1.1 -5.58 4.93e-08 2.58e-05 -0.3 -0.29 Corneal astigmatism; chr4:119500056 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs2306455 ENSG00000245958.5 RP11-33B1.1 -5.58 4.93e-08 2.58e-05 -0.3 -0.29 Corneal astigmatism; chr4:119500814 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs10031483 ENSG00000245958.5 RP11-33B1.1 -5.58 4.93e-08 2.58e-05 -0.3 -0.29 Corneal astigmatism; chr4:119501481 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs10031665 ENSG00000245958.5 RP11-33B1.1 -5.58 4.93e-08 2.58e-05 -0.3 -0.29 Corneal astigmatism; chr4:119501697 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs3733519 ENSG00000245958.5 RP11-33B1.1 -5.58 4.93e-08 2.58e-05 -0.3 -0.29 Corneal astigmatism; chr4:119502293 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs3733523 ENSG00000245958.5 RP11-33B1.1 -5.58 4.93e-08 2.58e-05 -0.3 -0.29 Corneal astigmatism; chr4:119502564 chr4:119454791~119552025:+ LIHC cis rs2522056 1 rs2057655 ENSG00000233006.5 AC034220.3 5.58 4.93e-08 2.58e-05 0.3 0.29 Fibrinogen;Lymphocyte counts; chr5:132471932 chr5:132311285~132369916:- LIHC cis rs1150668 0.796 rs2247002 ENSG00000204709.4 LINC01556 5.58 4.94e-08 2.58e-05 0.32 0.29 Pubertal anthropometrics; chr6:28430174 chr6:28943877~28944537:+ LIHC cis rs1150668 0.796 rs728122 ENSG00000204709.4 LINC01556 5.58 4.94e-08 2.58e-05 0.32 0.29 Pubertal anthropometrics; chr6:28431347 chr6:28943877~28944537:+ LIHC cis rs7617773 0.78 rs13084616 ENSG00000229759.1 MRPS18AP1 -5.58 4.94e-08 2.59e-05 -0.35 -0.29 Coronary artery disease; chr3:48298209 chr3:48256350~48256938:- LIHC cis rs2153535 0.58 rs1414342 ENSG00000230939.1 RP11-314C16.1 -5.58 4.94e-08 2.59e-05 -0.35 -0.29 Motion sickness; chr6:8462319 chr6:8784178~8785445:+ LIHC cis rs739496 0.602 rs79209359 ENSG00000226469.1 ADAM1B 5.58 4.95e-08 2.59e-05 0.35 0.29 Platelet count; chr12:111529357 chr12:111927018~111929017:+ LIHC cis rs8100891 0.537 rs10417152 ENSG00000267213.4 AC007773.2 -5.58 4.96e-08 2.59e-05 -0.37 -0.29 Neuroticism; chr19:32397994 chr19:32390050~32405560:- LIHC cis rs1005277 0.579 rs2472173 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38085710 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2472174 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38086454 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474563 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38087010 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs9418322 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38088368 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs9299760 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38088992 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2023351 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38089886 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474567 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38093564 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2472175 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38093973 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2472176 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38093993 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2983343 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38094404 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474569 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38094563 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2504143 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38094778 chr10:38448689~38448949:+ LIHC cis rs1005277 0.602 rs2504142 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38094865 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474571 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38095711 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2472181 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38097836 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474574 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38098367 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2504140 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38098651 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474575 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38098973 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2472182 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38099937 chr10:38448689~38448949:+ LIHC cis rs1005277 0.541 rs2263163 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38100959 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2021649 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38103194 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2505197 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38104382 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2505196 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38104635 chr10:38448689~38448949:+ LIHC cis rs1005277 0.541 rs2505193 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38105710 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474580 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38109785 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2504148 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38111860 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs176886 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38115046 chr10:38448689~38448949:+ LIHC cis rs1005277 0.557 rs176887 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38117166 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474594 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38137733 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs11011461 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38142499 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs1985707 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38145170 chr10:38448689~38448949:+ LIHC cis rs1005277 0.557 rs1854563 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38146033 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2505237 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38149970 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474599 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38150011 chr10:38448689~38448949:+ LIHC cis rs1005277 0.54 rs2224248 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38162958 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474608 ENSG00000263064.2 RP11-291L22.7 5.58 4.96e-08 2.59e-05 0.3 0.29 Extrinsic epigenetic age acceleration; chr10:38168181 chr10:38448689~38448949:+ LIHC cis rs875971 0.862 rs10276077 ENSG00000237310.1 GS1-124K5.4 -5.58 4.98e-08 2.6e-05 -0.26 -0.29 Aortic root size; chr7:66263424 chr7:66493706~66495474:+ LIHC cis rs950776 0.518 rs1979907 ENSG00000261762.1 RP11-650L12.2 -5.58 4.99e-08 2.6e-05 -0.37 -0.29 Sudden cardiac arrest; chr15:78549897 chr15:78589123~78591276:- LIHC cis rs2688482 0.512 rs3103953 ENSG00000242086.7 LINC00969 -5.58 4.99e-08 2.61e-05 -0.37 -0.29 Lung disease severity in cystic fibrosis; chr3:195793726 chr3:195658062~195739964:+ LIHC cis rs11690935 0.959 rs2674484 ENSG00000228389.1 AC068039.4 5.58 4.99e-08 2.61e-05 0.39 0.29 Schizophrenia; chr2:171718102 chr2:171773482~171775844:+ LIHC cis rs10510102 0.81 rs11200240 ENSG00000276742.1 RP11-500G22.4 5.58 4.99e-08 2.61e-05 0.44 0.29 Breast cancer; chr10:121903265 chr10:121956782~121957098:+ LIHC cis rs10510102 0.688 rs56094144 ENSG00000276742.1 RP11-500G22.4 5.58 4.99e-08 2.61e-05 0.44 0.29 Breast cancer; chr10:121903941 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs74914751 ENSG00000276742.1 RP11-500G22.4 5.58 4.99e-08 2.61e-05 0.44 0.29 Breast cancer; chr10:121904496 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200242 ENSG00000276742.1 RP11-500G22.4 5.58 4.99e-08 2.61e-05 0.44 0.29 Breast cancer; chr10:121905378 chr10:121956782~121957098:+ LIHC cis rs2274273 0.87 rs4597235 ENSG00000258413.1 RP11-665C16.6 -5.58 5e-08 2.61e-05 -0.33 -0.29 Protein biomarker; chr14:55385269 chr14:55262767~55272075:- LIHC cis rs7945705 0.902 rs10769979 ENSG00000254860.4 TMEM9B-AS1 -5.58 5e-08 2.61e-05 -0.3 -0.29 Hemoglobin concentration; chr11:8989112 chr11:8964675~8977527:+ LIHC cis rs12134133 1 rs2661357 ENSG00000274245.1 RP11-357P18.2 5.58 5.02e-08 2.62e-05 0.44 0.29 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207310593 chr1:207372559~207373252:+ LIHC cis rs4934494 0.727 rs2418929 ENSG00000232936.4 RP11-80H5.2 5.58 5.03e-08 2.62e-05 0.36 0.29 Red blood cell count; chr10:89741720 chr10:89645282~89650667:+ LIHC cis rs7914558 0.902 rs3736922 ENSG00000236937.2 PTGES3P4 -5.58 5.03e-08 2.62e-05 -0.34 -0.29 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103090875 chr10:102845595~102845950:+ LIHC cis rs5758511 0.68 rs17002902 ENSG00000237037.8 NDUFA6-AS1 -5.57 5.04e-08 2.63e-05 -0.36 -0.29 Birth weight; chr22:42229503 chr22:42090931~42137742:+ LIHC cis rs116175783 0.793 rs1267044 ENSG00000227403.1 AC009299.3 5.57 5.05e-08 2.63e-05 0.44 0.29 Intelligence (multi-trait analysis); chr2:161271100 chr2:161244739~161249050:+ LIHC cis rs116175783 0.557 rs1146025 ENSG00000227403.1 AC009299.3 5.57 5.05e-08 2.63e-05 0.44 0.29 Intelligence (multi-trait analysis); chr2:161283301 chr2:161244739~161249050:+ LIHC cis rs11690935 1 rs6721680 ENSG00000228389.1 AC068039.4 -5.57 5.05e-08 2.64e-05 -0.38 -0.29 Schizophrenia; chr2:171687403 chr2:171773482~171775844:+ LIHC cis rs6921919 0.609 rs9461455 ENSG00000216901.1 AL022393.7 5.57 5.06e-08 2.64e-05 0.36 0.29 Autism spectrum disorder or schizophrenia; chr6:28361954 chr6:28176188~28176674:+ LIHC cis rs2739330 0.796 rs1006771 ENSG00000099984.9 GSTT2 -5.57 5.07e-08 2.64e-05 -0.32 -0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23980123~23983911:+ LIHC cis rs8059260 0.668 rs75637865 ENSG00000274038.1 RP11-66H6.4 -5.57 5.07e-08 2.64e-05 -0.48 -0.29 Alcohol consumption over the past year; chr16:10982439 chr16:11056556~11057034:+ LIHC cis rs2442825 0.526 rs6443237 ENSG00000206573.7 THUMPD3-AS1 -5.57 5.08e-08 2.65e-05 -0.31 -0.29 Cerebrospinal fluid clusterin levels; chr3:9395777 chr3:9349689~9398579:- LIHC cis rs1577917 0.771 rs9362237 ENSG00000234155.1 RP11-30P6.6 -5.57 5.08e-08 2.65e-05 -0.37 -0.29 Response to antipsychotic treatment; chr6:85699346 chr6:85387219~85390186:- LIHC cis rs8072100 0.967 rs7221548 ENSG00000228782.6 CTD-2026D20.3 -5.57 5.09e-08 2.65e-05 -0.31 -0.29 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47505586 chr17:47450568~47492492:- LIHC cis rs1577917 0.839 rs12664634 ENSG00000234155.1 RP11-30P6.6 5.57 5.1e-08 2.66e-05 0.34 0.29 Response to antipsychotic treatment; chr6:85869696 chr6:85387219~85390186:- LIHC cis rs2153535 0.58 rs9406158 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8463919 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9406159 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8464626 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1335637 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8464868 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9406162 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8465963 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9393022 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8466355 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs9392222 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8467416 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs6932434 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8467446 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1034273 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8467912 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs9328471 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8468609 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs9505451 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8469717 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9393023 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8469761 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1414346 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8471341 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6905242 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8471566 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1932279 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8473420 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2152347 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8474048 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9379213 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8474712 chr6:8784178~8785445:+ LIHC cis rs950169 0.922 rs4842939 ENSG00000259728.4 LINC00933 -5.57 5.1e-08 2.66e-05 -0.41 -0.29 Schizophrenia; chr15:84159214 chr15:84570649~84580175:+ LIHC cis rs2153535 0.58 rs7766852 ENSG00000230939.1 RP11-314C16.1 -5.57 5.1e-08 2.66e-05 -0.35 -0.29 Motion sickness; chr6:8472184 chr6:8784178~8785445:+ LIHC cis rs7617773 0.925 rs34513961 ENSG00000229759.1 MRPS18AP1 5.57 5.1e-08 2.66e-05 0.36 0.29 Coronary artery disease; chr3:48132163 chr3:48256350~48256938:- LIHC cis rs853679 0.567 rs1005126 ENSG00000216901.1 AL022393.7 5.57 5.1e-08 2.66e-05 0.39 0.29 Depression; chr6:28399846 chr6:28176188~28176674:+ LIHC cis rs9487094 0.689 rs9487066 ENSG00000260273.1 RP11-425D10.10 5.57 5.11e-08 2.66e-05 0.35 0.29 Height; chr6:109347707 chr6:109382795~109383666:+ LIHC cis rs9487094 0.644 rs9320286 ENSG00000260273.1 RP11-425D10.10 5.57 5.11e-08 2.66e-05 0.34 0.29 Height; chr6:109403734 chr6:109382795~109383666:+ LIHC cis rs7119038 0.509 rs10790261 ENSG00000255239.1 AP002954.6 5.57 5.13e-08 2.67e-05 0.38 0.29 Sjögren's syndrome; chr11:118709038 chr11:118688039~118690600:- LIHC cis rs7119038 0.509 rs11216960 ENSG00000255239.1 AP002954.6 -5.57 5.13e-08 2.67e-05 -0.38 -0.29 Sjögren's syndrome; chr11:118707164 chr11:118688039~118690600:- LIHC cis rs7119038 0.509 rs10892256 ENSG00000255239.1 AP002954.6 -5.57 5.13e-08 2.67e-05 -0.38 -0.29 Sjögren's syndrome; chr11:118707996 chr11:118688039~118690600:- LIHC cis rs7119038 0.509 rs10892257 ENSG00000255239.1 AP002954.6 -5.57 5.13e-08 2.67e-05 -0.38 -0.29 Sjögren's syndrome; chr11:118708618 chr11:118688039~118690600:- LIHC cis rs7131987 0.903 rs2194519 ENSG00000257176.2 RP11-996F15.2 5.57 5.13e-08 2.67e-05 0.33 0.29 QT interval; chr12:29270650 chr12:29280418~29317848:- LIHC cis rs6479891 0.818 rs9415700 ENSG00000232075.1 MRPL35P2 5.57 5.14e-08 2.67e-05 0.33 0.29 Arthritis (juvenile idiopathic); chr10:63385805 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs9415701 ENSG00000232075.1 MRPL35P2 5.57 5.14e-08 2.67e-05 0.33 0.29 Arthritis (juvenile idiopathic); chr10:63391749 chr10:63634317~63634827:- LIHC cis rs739496 0.843 rs7398705 ENSG00000226469.1 ADAM1B -5.57 5.14e-08 2.67e-05 -0.34 -0.29 Platelet count; chr12:111578212 chr12:111927018~111929017:+ LIHC cis rs227275 0.554 rs223333 ENSG00000230069.3 LRRC37A15P -5.57 5.15e-08 2.68e-05 -0.26 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102868653 chr4:102727274~102730721:- LIHC cis rs73086581 1 rs17215340 ENSG00000229539.1 RP11-119B16.2 -5.57 5.15e-08 2.68e-05 -0.5 -0.29 Response to antidepressants in depression; chr20:3989526 chr20:3888239~3888868:- LIHC cis rs9326248 0.652 rs7128382 ENSG00000236267.1 AP006216.5 5.57 5.16e-08 2.68e-05 0.3 0.29 Blood protein levels; chr11:117152771 chr11:116813204~116814003:- LIHC cis rs9487094 0.666 rs6920372 ENSG00000260273.1 RP11-425D10.10 5.57 5.16e-08 2.68e-05 0.34 0.29 Height; chr6:109402736 chr6:109382795~109383666:+ LIHC cis rs10170846 0.861 rs7571732 ENSG00000261428.2 RP11-16P6.1 -5.57 5.16e-08 2.69e-05 -0.3 -0.29 Schizophrenia (inflammation and infection response interaction); chr2:222673597 chr2:222566899~222569719:- LIHC cis rs950776 0.518 rs3813571 ENSG00000261762.1 RP11-650L12.2 5.57 5.17e-08 2.69e-05 0.37 0.29 Sudden cardiac arrest; chr15:78540450 chr15:78589123~78591276:- LIHC cis rs12787909 1 rs12787909 ENSG00000278768.1 BACE1-AS 5.57 5.17e-08 2.69e-05 0.53 0.29 Lipoprotein (a) - cholesterol levels; chr11:117675767 chr11:117290874~117293571:+ LIHC cis rs2274273 0.87 rs10149420 ENSG00000258413.1 RP11-665C16.6 -5.57 5.18e-08 2.69e-05 -0.34 -0.29 Protein biomarker; chr14:55387539 chr14:55262767~55272075:- LIHC cis rs6142102 0.778 rs6059555 ENSG00000276073.1 RP5-1125A11.7 -5.57 5.2e-08 2.7e-05 -0.32 -0.29 Skin pigmentation; chr20:33926518 chr20:33985617~33988989:- LIHC cis rs11098499 0.909 rs10017335 ENSG00000245958.5 RP11-33B1.1 5.57 5.2e-08 2.7e-05 0.31 0.29 Corneal astigmatism; chr4:119460368 chr4:119454791~119552025:+ LIHC cis rs2842992 0.83 rs2758320 ENSG00000237927.1 RP3-393E18.2 -5.57 5.21e-08 2.71e-05 -0.36 -0.29 Age-related macular degeneration (geographic atrophy); chr6:159649644 chr6:159586955~159589169:- LIHC cis rs2735413 0.564 rs73578755 ENSG00000276007.1 RP11-358L22.3 5.57 5.21e-08 2.71e-05 0.4 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78074912 chr16:78123243~78124332:+ LIHC cis rs1499614 1 rs1267817 ENSG00000226824.5 RP4-756H11.3 -5.57 5.21e-08 2.71e-05 -0.48 -0.29 Gout; chr7:66645053 chr7:66654538~66669855:+ LIHC cis rs7429990 0.965 rs319685 ENSG00000229759.1 MRPS18AP1 5.57 5.22e-08 2.71e-05 0.3 0.29 Educational attainment (years of education); chr3:47890494 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs319684 ENSG00000229759.1 MRPS18AP1 5.57 5.22e-08 2.71e-05 0.3 0.29 Educational attainment (years of education); chr3:47890784 chr3:48256350~48256938:- LIHC cis rs7429990 0.932 rs810334 ENSG00000229759.1 MRPS18AP1 5.57 5.22e-08 2.71e-05 0.3 0.29 Educational attainment (years of education); chr3:47893813 chr3:48256350~48256938:- LIHC cis rs6479901 0.947 rs12573212 ENSG00000232075.1 MRPL35P2 -5.57 5.22e-08 2.71e-05 -0.32 -0.29 Intelligence (multi-trait analysis); chr10:63458665 chr10:63634317~63634827:- LIHC cis rs6479901 0.895 rs10822172 ENSG00000232075.1 MRPL35P2 -5.57 5.23e-08 2.72e-05 -0.31 -0.29 Intelligence (multi-trait analysis); chr10:63455478 chr10:63634317~63634827:- LIHC cis rs524281 0.861 rs12226649 ENSG00000255320.1 RP11-755F10.1 5.57 5.24e-08 2.72e-05 0.37 0.29 Electroencephalogram traits; chr11:66074576 chr11:66244840~66246239:- LIHC cis rs11098499 0.909 rs9994810 ENSG00000245958.5 RP11-33B1.1 -5.57 5.26e-08 2.73e-05 -0.3 -0.29 Corneal astigmatism; chr4:119460435 chr4:119454791~119552025:+ LIHC cis rs2243480 1 rs316318 ENSG00000226824.5 RP4-756H11.3 -5.57 5.26e-08 2.73e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66147917 chr7:66654538~66669855:+ LIHC cis rs6921919 0.583 rs4642462 ENSG00000216901.1 AL022393.7 5.57 5.27e-08 2.73e-05 0.36 0.29 Autism spectrum disorder or schizophrenia; chr6:28421474 chr6:28176188~28176674:+ LIHC cis rs1075265 0.547 rs6741891 ENSG00000233266.1 HMGB1P31 5.57 5.27e-08 2.74e-05 0.35 0.29 Chronotype;Morning vs. evening chronotype; chr2:54088529 chr2:54051334~54051760:+ LIHC cis rs739496 0.649 rs666727 ENSG00000226469.1 ADAM1B 5.57 5.27e-08 2.74e-05 0.35 0.29 Platelet count; chr12:111551854 chr12:111927018~111929017:+ LIHC cis rs9318086 0.712 rs9318100 ENSG00000205861.10 C1QTNF9B-AS1 5.57 5.27e-08 2.74e-05 0.32 0.29 Myopia (pathological); chr13:23868343 chr13:23888889~23897263:+ LIHC cis rs8059260 0.544 rs12925161 ENSG00000274038.1 RP11-66H6.4 -5.57 5.28e-08 2.74e-05 -0.47 -0.29 Alcohol consumption over the past year; chr16:11112719 chr16:11056556~11057034:+ LIHC cis rs17711722 0.523 rs365896 ENSG00000228409.4 CCT6P1 5.57 5.28e-08 2.74e-05 0.22 0.29 Calcium levels; chr7:66045710 chr7:65751142~65763354:+ LIHC cis rs3096299 0.642 rs12934829 ENSG00000261118.1 RP11-104N10.1 5.57 5.28e-08 2.74e-05 0.29 0.29 Multiple myeloma (IgH translocation); chr16:89456941 chr16:89492017~89504460:- LIHC cis rs227275 0.556 rs11731885 ENSG00000246560.2 RP11-10L12.4 5.57 5.29e-08 2.75e-05 0.32 0.29 Allergic disease (asthma, hay fever or eczema); chr4:103010913 chr4:102828055~102844075:+ LIHC cis rs1005277 0.522 rs1208681 ENSG00000263064.2 RP11-291L22.7 5.57 5.29e-08 2.75e-05 0.29 0.29 Extrinsic epigenetic age acceleration; chr10:37804047 chr10:38448689~38448949:+ LIHC cis rs10875746 0.669 rs10783244 ENSG00000240399.1 RP1-228P16.1 -5.56 5.31e-08 2.76e-05 -0.31 -0.29 Longevity (90 years and older); chr12:48271206 chr12:48054813~48055591:- LIHC cis rs7923609 0.902 rs10822182 ENSG00000232075.1 MRPL35P2 -5.56 5.33e-08 2.76e-05 -0.32 -0.29 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63565718 chr10:63634317~63634827:- LIHC cis rs9411298 0.63 rs9411299 ENSG00000268996.3 MAN1B1-AS1 -5.56 5.33e-08 2.76e-05 -0.33 -0.29 Monocyte percentage of white cells; chr9:137044341 chr9:137084946~137086817:- LIHC cis rs1322639 0.531 rs11751421 ENSG00000261039.2 RP11-417E7.2 5.56 5.33e-08 2.77e-05 0.3 0.29 Pulse pressure; chr6:169174898 chr6:169175304~169182740:- LIHC cis rs11690935 0.959 rs7597387 ENSG00000228389.1 AC068039.4 5.56 5.34e-08 2.77e-05 0.38 0.29 Schizophrenia; chr2:171720606 chr2:171773482~171775844:+ LIHC cis rs10875746 0.625 rs2898065 ENSG00000240399.1 RP1-228P16.1 -5.56 5.34e-08 2.77e-05 -0.31 -0.29 Longevity (90 years and older); chr12:48250836 chr12:48054813~48055591:- LIHC cis rs2153535 0.58 rs1832101 ENSG00000230939.1 RP11-314C16.1 -5.56 5.34e-08 2.77e-05 -0.35 -0.29 Motion sickness; chr6:8459944 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1119690 ENSG00000230939.1 RP11-314C16.1 -5.56 5.34e-08 2.77e-05 -0.35 -0.29 Motion sickness; chr6:8460427 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1119689 ENSG00000230939.1 RP11-314C16.1 -5.56 5.34e-08 2.77e-05 -0.35 -0.29 Motion sickness; chr6:8460521 chr6:8784178~8785445:+ LIHC cis rs9903692 0.909 rs11079806 ENSG00000278765.1 RP5-890E16.5 5.56 5.36e-08 2.78e-05 0.36 0.29 Pulse pressure; chr17:48065318 chr17:48066704~48067293:- LIHC cis rs5769707 0.681 rs4622843 ENSG00000235111.1 RP1-29C18.8 -5.56 5.36e-08 2.78e-05 -0.35 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49643268 chr22:49612657~49615716:- LIHC cis rs3096299 0.9 rs4785663 ENSG00000261118.1 RP11-104N10.1 5.56 5.36e-08 2.78e-05 0.29 0.29 Multiple myeloma (IgH translocation); chr16:89368480 chr16:89492017~89504460:- LIHC cis rs2153535 0.58 rs6597332 ENSG00000230939.1 RP11-314C16.1 -5.56 5.36e-08 2.78e-05 -0.35 -0.29 Motion sickness; chr6:8504515 chr6:8784178~8785445:+ LIHC cis rs10875746 0.729 rs1990028 ENSG00000240399.1 RP1-228P16.1 -5.56 5.36e-08 2.78e-05 -0.3 -0.29 Longevity (90 years and older); chr12:48014230 chr12:48054813~48055591:- LIHC cis rs2153535 0.58 rs4587214 ENSG00000230939.1 RP11-314C16.1 -5.56 5.37e-08 2.78e-05 -0.35 -0.29 Motion sickness; chr6:8453886 chr6:8784178~8785445:+ LIHC cis rs12701220 0.655 rs10241018 ENSG00000229043.2 AC091729.9 -5.56 5.37e-08 2.78e-05 -0.4 -0.29 Bronchopulmonary dysplasia; chr7:1105138 chr7:1160374~1165267:+ LIHC cis rs2153535 0.58 rs1855769 ENSG00000230939.1 RP11-314C16.1 -5.56 5.38e-08 2.79e-05 -0.35 -0.29 Motion sickness; chr6:8472862 chr6:8784178~8785445:+ LIHC cis rs9487094 0.689 rs9487069 ENSG00000260273.1 RP11-425D10.10 5.56 5.38e-08 2.79e-05 0.33 0.29 Height; chr6:109358652 chr6:109382795~109383666:+ LIHC cis rs9388451 0.839 rs9401845 ENSG00000237742.5 RP11-624M8.1 -5.56 5.38e-08 2.79e-05 -0.27 -0.29 Brugada syndrome; chr6:125782972 chr6:125578558~125749190:- LIHC cis rs2283792 0.967 rs5755099 ENSG00000224086.5 LL22NC03-86G7.1 -5.56 5.39e-08 2.79e-05 -0.26 -0.29 Multiple sclerosis; chr22:21770751 chr22:21938293~21977632:+ LIHC cis rs524281 0.692 rs10896076 ENSG00000255320.1 RP11-755F10.1 5.56 5.39e-08 2.79e-05 0.37 0.29 Electroencephalogram traits; chr11:66073197 chr11:66244840~66246239:- LIHC cis rs2243480 1 rs465359 ENSG00000226824.5 RP4-756H11.3 -5.56 5.39e-08 2.79e-05 -0.46 -0.29 Diabetic kidney disease; chr7:66093177 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs462853 ENSG00000226824.5 RP4-756H11.3 -5.56 5.39e-08 2.79e-05 -0.46 -0.29 Diabetic kidney disease; chr7:66093180 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs160644 ENSG00000226824.5 RP4-756H11.3 -5.56 5.39e-08 2.79e-05 -0.46 -0.29 Diabetic kidney disease; chr7:66093199 chr7:66654538~66669855:+ LIHC cis rs6479901 0.947 rs10740123 ENSG00000232075.1 MRPL35P2 -5.56 5.4e-08 2.79e-05 -0.31 -0.29 Intelligence (multi-trait analysis); chr10:63404755 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs10761767 ENSG00000232075.1 MRPL35P2 -5.56 5.4e-08 2.79e-05 -0.31 -0.29 Intelligence (multi-trait analysis); chr10:63432671 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs10761768 ENSG00000232075.1 MRPL35P2 -5.56 5.4e-08 2.79e-05 -0.31 -0.29 Intelligence (multi-trait analysis); chr10:63434369 chr10:63634317~63634827:- LIHC cis rs2243480 1 rs709607 ENSG00000164669.11 INTS4P1 -5.56 5.4e-08 2.8e-05 -0.51 -0.29 Diabetic kidney disease; chr7:65984554 chr7:65141225~65234216:+ LIHC cis rs7916697 0.947 rs1900004 ENSG00000233590.1 RP11-153K11.3 -5.56 5.41e-08 2.8e-05 -0.34 -0.29 Optic disc area; chr10:68241124 chr10:68233251~68242379:- LIHC cis rs2998286 0.862 rs1339704 ENSG00000254635.4 WAC-AS1 -5.56 5.41e-08 2.8e-05 -0.36 -0.29 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28527400 chr10:28522652~28532743:- LIHC cis rs6921919 0.583 rs11755942 ENSG00000216901.1 AL022393.7 5.56 5.44e-08 2.82e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28401760 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs6908137 ENSG00000216901.1 AL022393.7 5.56 5.44e-08 2.82e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28402616 chr6:28176188~28176674:+ LIHC cis rs5758511 0.68 rs5758667 ENSG00000237037.8 NDUFA6-AS1 -5.56 5.44e-08 2.82e-05 -0.36 -0.29 Birth weight; chr22:42237198 chr22:42090931~42137742:+ LIHC cis rs4432842 0.646 rs10037593 ENSG00000249198.1 RP11-772C9.1 5.56 5.45e-08 2.82e-05 0.35 0.29 Birth weight; chr5:57762092 chr5:57751192~57751717:- LIHC cis rs6479901 0.947 rs10761764 ENSG00000232075.1 MRPL35P2 -5.56 5.45e-08 2.82e-05 -0.31 -0.29 Intelligence (multi-trait analysis); chr10:63429143 chr10:63634317~63634827:- LIHC cis rs6479901 0.846 rs7917169 ENSG00000232075.1 MRPL35P2 -5.56 5.45e-08 2.82e-05 -0.31 -0.29 Intelligence (multi-trait analysis); chr10:63433181 chr10:63634317~63634827:- LIHC cis rs2153535 0.58 rs7743995 ENSG00000230939.1 RP11-314C16.1 -5.56 5.45e-08 2.82e-05 -0.35 -0.29 Motion sickness; chr6:8495979 chr6:8784178~8785445:+ LIHC cis rs1150668 0.796 rs1124132 ENSG00000204709.4 LINC01556 5.56 5.46e-08 2.82e-05 0.32 0.29 Pubertal anthropometrics; chr6:28412544 chr6:28943877~28944537:+ LIHC cis rs7714584 1 rs4579248 ENSG00000197083.10 ZNF300P1 5.56 5.46e-08 2.82e-05 0.46 0.29 Crohn's disease; chr5:150888589 chr5:150930645~150946289:- LIHC cis rs67180937 0.553 rs2088514 ENSG00000272750.1 RP11-378J18.8 -5.56 5.46e-08 2.82e-05 -0.32 -0.29 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222658030 chr1:222658867~222661512:- LIHC cis rs12908161 0.959 rs17534709 ENSG00000259295.5 CSPG4P12 5.56 5.47e-08 2.83e-05 0.39 0.29 Schizophrenia; chr15:84771166 chr15:85191438~85213905:+ LIHC cis rs2735413 0.564 rs8059851 ENSG00000276007.1 RP11-358L22.3 5.56 5.47e-08 2.83e-05 0.39 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78084435 chr16:78123243~78124332:+ LIHC cis rs853679 0.517 rs1904840 ENSG00000219392.1 RP1-265C24.5 -5.56 5.48e-08 2.83e-05 -0.45 -0.29 Depression; chr6:28140454 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9368555 ENSG00000219392.1 RP1-265C24.5 -5.56 5.48e-08 2.83e-05 -0.45 -0.29 Depression; chr6:28141189 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9393893 ENSG00000219392.1 RP1-265C24.5 -5.56 5.48e-08 2.83e-05 -0.45 -0.29 Depression; chr6:28141484 chr6:28115628~28116551:+ LIHC cis rs2735413 0.564 rs11859770 ENSG00000276007.1 RP11-358L22.3 5.56 5.48e-08 2.83e-05 0.39 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78092837 chr16:78123243~78124332:+ LIHC cis rs2762353 0.526 rs6456693 ENSG00000216436.2 HIST1H2APS1 5.56 5.49e-08 2.83e-05 0.35 0.29 Blood metabolite levels; chr6:25709859 chr6:25732497~25732827:+ LIHC cis rs10510102 1 rs6585764 ENSG00000226864.1 ATE1-AS1 5.56 5.49e-08 2.84e-05 0.46 0.29 Breast cancer; chr10:121837308 chr10:121928312~121951965:+ LIHC cis rs2153535 0.58 rs2327067 ENSG00000230939.1 RP11-314C16.1 -5.56 5.51e-08 2.84e-05 -0.35 -0.29 Motion sickness; chr6:8518249 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs9328477 ENSG00000230939.1 RP11-314C16.1 -5.56 5.51e-08 2.84e-05 -0.35 -0.29 Motion sickness; chr6:8518876 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9328478 ENSG00000230939.1 RP11-314C16.1 -5.56 5.51e-08 2.84e-05 -0.35 -0.29 Motion sickness; chr6:8518950 chr6:8784178~8785445:+ LIHC cis rs34779708 0.766 rs7913451 ENSG00000230534.5 RP11-297A16.2 5.56 5.52e-08 2.85e-05 0.37 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35262597 chr10:35098006~35127020:- LIHC cis rs34779708 0.766 rs7897088 ENSG00000230534.5 RP11-297A16.2 5.56 5.52e-08 2.85e-05 0.37 0.29 Inflammatory bowel disease;Crohn's disease; chr10:35262639 chr10:35098006~35127020:- LIHC cis rs7429990 0.965 rs4858881 ENSG00000229759.1 MRPS18AP1 -5.56 5.52e-08 2.85e-05 -0.3 -0.29 Educational attainment (years of education); chr3:48082306 chr3:48256350~48256938:- LIHC cis rs10875746 0.669 rs1021313 ENSG00000240399.1 RP1-228P16.1 -5.56 5.56e-08 2.87e-05 -0.31 -0.29 Longevity (90 years and older); chr12:48244258 chr12:48054813~48055591:- LIHC cis rs5769707 0.632 rs135876 ENSG00000235111.1 RP1-29C18.8 -5.56 5.57e-08 2.87e-05 -0.35 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49619925 chr22:49612657~49615716:- LIHC cis rs11098499 0.954 rs2389803 ENSG00000245958.5 RP11-33B1.1 5.56 5.57e-08 2.87e-05 0.31 0.29 Corneal astigmatism; chr4:119472356 chr4:119454791~119552025:+ LIHC cis rs17711722 0.565 rs4275112 ENSG00000228409.4 CCT6P1 5.56 5.57e-08 2.87e-05 0.23 0.29 Calcium levels; chr7:65733651 chr7:65751142~65763354:+ LIHC cis rs9326248 1 rs9326248 ENSG00000236267.1 AP006216.5 5.56 5.58e-08 2.88e-05 0.29 0.29 Blood protein levels; chr11:117128509 chr11:116813204~116814003:- LIHC cis rs7811142 0.667 rs3873746 ENSG00000242294.5 STAG3L5P 5.56 5.59e-08 2.88e-05 0.3 0.29 Platelet count; chr7:100337474 chr7:100336079~100351900:+ LIHC cis rs7429990 1 rs1684942 ENSG00000229759.1 MRPS18AP1 5.55 5.59e-08 2.88e-05 0.3 0.29 Educational attainment (years of education); chr3:47859213 chr3:48256350~48256938:- LIHC cis rs7429990 0.965 rs800762 ENSG00000229759.1 MRPS18AP1 5.55 5.59e-08 2.88e-05 0.3 0.29 Educational attainment (years of education); chr3:47864080 chr3:48256350~48256938:- LIHC cis rs5756813 1 rs1129448 ENSG00000233360.4 Z83844.1 -5.55 5.6e-08 2.88e-05 -0.35 -0.29 Optic cup area;Vertical cup-disc ratio; chr22:37774019 chr22:37641832~37658377:- LIHC cis rs6964833 1 rs34324835 ENSG00000123965.13 PMS2P5 5.55 5.6e-08 2.89e-05 0.52 0.29 Menarche (age at onset); chr7:74717986 chr7:74894116~74897835:+ LIHC cis rs2243480 0.522 rs431168 ENSG00000273142.1 RP11-458F8.4 -5.55 5.62e-08 2.89e-05 -0.38 -0.29 Diabetic kidney disease; chr7:66046617 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs160652 ENSG00000273142.1 RP11-458F8.4 -5.55 5.62e-08 2.9e-05 -0.35 -0.29 Diabetic kidney disease; chr7:66073444 chr7:66902857~66906297:+ LIHC cis rs227275 0.554 rs223424 ENSG00000230069.3 LRRC37A15P -5.55 5.62e-08 2.9e-05 -0.26 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102804177 chr4:102727274~102730721:- LIHC cis rs9388451 0.805 rs1028481 ENSG00000237742.5 RP11-624M8.1 -5.55 5.63e-08 2.9e-05 -0.27 -0.29 Brugada syndrome; chr6:125785427 chr6:125578558~125749190:- LIHC cis rs6920372 0.799 rs9480947 ENSG00000260273.1 RP11-425D10.10 5.55 5.65e-08 2.91e-05 0.34 0.29 Height; chr6:109397362 chr6:109382795~109383666:+ LIHC cis rs8059260 0.604 rs9940096 ENSG00000274038.1 RP11-66H6.4 -5.55 5.66e-08 2.92e-05 -0.48 -0.29 Alcohol consumption over the past year; chr16:11045737 chr16:11056556~11057034:+ LIHC cis rs1729407 0.814 rs2542051 ENSG00000254851.1 RP11-109L13.1 5.55 5.67e-08 2.92e-05 0.34 0.29 Apolipoprotein A-IV levels; chr11:116827022 chr11:117135528~117138582:+ LIHC cis rs227275 0.554 rs223422 ENSG00000230069.3 LRRC37A15P -5.55 5.68e-08 2.92e-05 -0.26 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102805616 chr4:102727274~102730721:- LIHC cis rs227275 0.524 rs223423 ENSG00000230069.3 LRRC37A15P -5.55 5.68e-08 2.92e-05 -0.26 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102804737 chr4:102727274~102730721:- LIHC cis rs2283792 0.935 rs8141851 ENSG00000224086.5 LL22NC03-86G7.1 -5.55 5.68e-08 2.92e-05 -0.26 -0.29 Multiple sclerosis; chr22:21812161 chr22:21938293~21977632:+ LIHC cis rs8028182 0.636 rs7171507 ENSG00000260269.4 CTD-2323K18.1 -5.55 5.69e-08 2.93e-05 -0.38 -0.29 Sudden cardiac arrest; chr15:75444946 chr15:75527150~75601205:- LIHC cis rs9487094 0.666 rs2211288 ENSG00000260273.1 RP11-425D10.10 5.55 5.7e-08 2.93e-05 0.34 0.29 Height; chr6:109383848 chr6:109382795~109383666:+ LIHC cis rs1150668 0.796 rs2531832 ENSG00000204709.4 LINC01556 5.55 5.7e-08 2.93e-05 0.32 0.29 Pubertal anthropometrics; chr6:28421445 chr6:28943877~28944537:+ LIHC cis rs904251 0.828 rs1757178 ENSG00000204110.6 RP1-153P14.8 5.55 5.71e-08 2.94e-05 0.37 0.29 Cognitive performance; chr6:37518534 chr6:37507348~37535616:+ LIHC cis rs6921919 0.551 rs13201753 ENSG00000216901.1 AL022393.7 5.55 5.72e-08 2.94e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28363351 chr6:28176188~28176674:+ LIHC cis rs2243480 0.803 rs36127118 ENSG00000226824.5 RP4-756H11.3 -5.55 5.72e-08 2.94e-05 -0.46 -0.29 Diabetic kidney disease; chr7:66100518 chr7:66654538~66669855:+ LIHC cis rs7208859 0.614 rs216477 ENSG00000263531.1 RP13-753N3.1 -5.55 5.72e-08 2.94e-05 -0.49 -0.29 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30539726 chr17:30863921~30864940:- LIHC cis rs6686842 0.965 rs4660184 ENSG00000235358.1 RP11-399E6.1 -5.55 5.73e-08 2.95e-05 -0.31 -0.29 Height; chr1:41058866 chr1:41242373~41284861:+ LIHC cis rs2243480 1 rs313803 ENSG00000226824.5 RP4-756H11.3 -5.55 5.73e-08 2.95e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66049744 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs313802 ENSG00000226824.5 RP4-756H11.3 -5.55 5.73e-08 2.95e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66051386 chr7:66654538~66669855:+ LIHC cis rs2243480 0.803 rs403089 ENSG00000226824.5 RP4-756H11.3 -5.55 5.73e-08 2.95e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66052736 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs458291 ENSG00000226824.5 RP4-756H11.3 -5.55 5.73e-08 2.95e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66055492 chr7:66654538~66669855:+ LIHC cis rs5758511 0.514 rs5751240 ENSG00000237037.8 NDUFA6-AS1 -5.55 5.73e-08 2.95e-05 -0.36 -0.29 Birth weight; chr22:42199252 chr22:42090931~42137742:+ LIHC cis rs875971 0.545 rs6460276 ENSG00000237310.1 GS1-124K5.4 5.55 5.74e-08 2.95e-05 0.27 0.29 Aortic root size; chr7:66182290 chr7:66493706~66495474:+ LIHC cis rs6479901 0.947 rs10995530 ENSG00000232075.1 MRPL35P2 -5.55 5.74e-08 2.95e-05 -0.31 -0.29 Intelligence (multi-trait analysis); chr10:63419654 chr10:63634317~63634827:- LIHC cis rs6479901 0.894 rs10740124 ENSG00000232075.1 MRPL35P2 -5.55 5.74e-08 2.95e-05 -0.31 -0.29 Intelligence (multi-trait analysis); chr10:63426034 chr10:63634317~63634827:- LIHC cis rs6479901 0.841 rs72837019 ENSG00000232075.1 MRPL35P2 -5.55 5.74e-08 2.95e-05 -0.31 -0.29 Intelligence (multi-trait analysis); chr10:63427258 chr10:63634317~63634827:- LIHC cis rs3096299 0.667 rs2965947 ENSG00000261118.1 RP11-104N10.1 5.55 5.75e-08 2.96e-05 0.28 0.29 Multiple myeloma (IgH translocation); chr16:89452262 chr16:89492017~89504460:- LIHC cis rs17507216 0.718 rs4779033 ENSG00000278603.1 RP13-608F4.5 -5.55 5.76e-08 2.96e-05 -0.6 -0.29 Excessive daytime sleepiness; chr15:82576634 chr15:82472203~82472426:+ LIHC cis rs1005277 0.522 rs1208684 ENSG00000263064.2 RP11-291L22.7 5.55 5.76e-08 2.96e-05 0.29 0.29 Extrinsic epigenetic age acceleration; chr10:37805008 chr10:38448689~38448949:+ LIHC cis rs853679 0.567 rs13196606 ENSG00000204709.4 LINC01556 5.55 5.77e-08 2.96e-05 0.37 0.29 Depression; chr6:28402301 chr6:28943877~28944537:+ LIHC cis rs1005277 0.522 rs9417256 ENSG00000263064.2 RP11-291L22.7 5.55 5.77e-08 2.97e-05 0.29 0.29 Extrinsic epigenetic age acceleration; chr10:37688062 chr10:38448689~38448949:+ LIHC cis rs2998286 0.862 rs2993989 ENSG00000254635.4 WAC-AS1 -5.55 5.78e-08 2.97e-05 -0.36 -0.29 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28512986 chr10:28522652~28532743:- LIHC cis rs9532669 0.963 rs4942012 ENSG00000176268.5 CYCSP34 5.55 5.78e-08 2.97e-05 0.32 0.29 Cervical cancer; chr13:40939112 chr13:40863599~40863902:- LIHC cis rs2980439 0.87 rs2945230 ENSG00000253893.2 FAM85B -5.55 5.79e-08 2.98e-05 -0.37 -0.29 Neuroticism; chr8:8252414 chr8:8167819~8226614:- LIHC cis rs853679 0.517 rs9380058 ENSG00000219392.1 RP1-265C24.5 -5.55 5.79e-08 2.98e-05 -0.44 -0.29 Depression; chr6:28159666 chr6:28115628~28116551:+ LIHC cis rs2243480 1 rs6958420 ENSG00000226824.5 RP4-756H11.3 5.55 5.8e-08 2.98e-05 0.47 0.29 Diabetic kidney disease; chr7:66286184 chr7:66654538~66669855:+ LIHC cis rs950169 0.922 rs11631096 ENSG00000259295.5 CSPG4P12 5.55 5.8e-08 2.98e-05 0.39 0.29 Schizophrenia; chr15:84557698 chr15:85191438~85213905:+ LIHC cis rs1005277 0.579 rs2474568 ENSG00000263064.2 RP11-291L22.7 5.55 5.81e-08 2.98e-05 0.29 0.29 Extrinsic epigenetic age acceleration; chr10:38094219 chr10:38448689~38448949:+ LIHC cis rs7688540 0.771 rs10021364 ENSG00000275426.1 CH17-262A2.1 -5.55 5.81e-08 2.98e-05 -0.4 -0.29 Facial morphology (factor 6, height of vermillion lower lip); chr4:316902 chr4:149738~150317:+ LIHC cis rs150992 0.587 rs4703340 ENSG00000248489.1 CTD-2007H13.3 -5.55 5.82e-08 2.99e-05 -0.42 -0.29 Body mass index; chr5:99009083 chr5:98929171~98995013:+ LIHC cis rs587080 0.624 rs512715 ENSG00000245532.5 NEAT1 -5.55 5.84e-08 3e-05 -0.3 -0.29 Plateletcrit; chr11:65423737 chr11:65422774~65445540:+ LIHC cis rs7586673 1 rs7586673 ENSG00000227403.1 AC009299.3 -5.55 5.84e-08 3e-05 -0.35 -0.29 Intelligence (multi-trait analysis); chr2:161067009 chr2:161244739~161249050:+ LIHC cis rs12908161 0.959 rs61074241 ENSG00000259295.5 CSPG4P12 5.55 5.84e-08 3e-05 0.41 0.29 Schizophrenia; chr15:84790165 chr15:85191438~85213905:+ LIHC cis rs734999 1 rs10797432 ENSG00000225931.3 RP3-395M20.7 5.55 5.86e-08 3.01e-05 0.31 0.29 Ulcerative colitis; chr1:2569899 chr1:2566410~2569888:+ LIHC cis rs3096299 0.591 rs748940 ENSG00000261118.1 RP11-104N10.1 5.55 5.87e-08 3.01e-05 0.29 0.29 Multiple myeloma (IgH translocation); chr16:89374349 chr16:89492017~89504460:- LIHC cis rs6479891 1 rs4746195 ENSG00000232075.1 MRPL35P2 5.55 5.87e-08 3.01e-05 0.33 0.29 Arthritis (juvenile idiopathic); chr10:63547893 chr10:63634317~63634827:- LIHC cis rs6142102 1 rs12480839 ENSG00000276073.1 RP5-1125A11.7 -5.55 5.88e-08 3.02e-05 -0.32 -0.29 Skin pigmentation; chr20:34139624 chr20:33985617~33988989:- LIHC cis rs957448 0.554 rs12541408 ENSG00000253704.1 RP11-267M23.4 5.54 5.89e-08 3.02e-05 0.33 0.29 Nonsyndromic cleft lip with cleft palate; chr8:94573579 chr8:94553722~94569745:+ LIHC cis rs7734985 0.634 rs10062171 ENSG00000250551.1 RP11-254I22.1 5.54 5.89e-08 3.02e-05 0.35 0.29 IgG glycosylation; chr5:96173996 chr5:96050115~96215519:+ LIHC cis rs2243480 1 rs6964245 ENSG00000226824.5 RP4-756H11.3 5.54 5.89e-08 3.02e-05 0.47 0.29 Diabetic kidney disease; chr7:66253730 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs6964530 ENSG00000226824.5 RP4-756H11.3 5.54 5.89e-08 3.02e-05 0.47 0.29 Diabetic kidney disease; chr7:66253864 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs10807701 ENSG00000226824.5 RP4-756H11.3 5.54 5.89e-08 3.02e-05 0.47 0.29 Diabetic kidney disease; chr7:66259699 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1499613 ENSG00000226824.5 RP4-756H11.3 5.54 5.89e-08 3.02e-05 0.47 0.29 Diabetic kidney disease; chr7:66265873 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1553174 ENSG00000226824.5 RP4-756H11.3 5.54 5.89e-08 3.02e-05 0.47 0.29 Diabetic kidney disease; chr7:66266207 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs10950032 ENSG00000226824.5 RP4-756H11.3 5.54 5.89e-08 3.02e-05 0.47 0.29 Diabetic kidney disease; chr7:66273604 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1392104 ENSG00000226824.5 RP4-756H11.3 5.54 5.89e-08 3.02e-05 0.47 0.29 Diabetic kidney disease; chr7:66294120 chr7:66654538~66669855:+ LIHC cis rs9326248 0.53 rs6589575 ENSG00000280143.1 AP000892.6 5.54 5.9e-08 3.03e-05 0.35 0.29 Blood protein levels; chr11:116862594 chr11:117204967~117210292:+ LIHC cis rs9326248 0.53 rs718847 ENSG00000280143.1 AP000892.6 5.54 5.9e-08 3.03e-05 0.35 0.29 Blood protein levels; chr11:116863430 chr11:117204967~117210292:+ LIHC cis rs2243480 1 rs4718334 ENSG00000226824.5 RP4-756H11.3 5.54 5.9e-08 3.03e-05 0.46 0.29 Diabetic kidney disease; chr7:66324467 chr7:66654538~66669855:+ LIHC cis rs2153535 0.563 rs1796687 ENSG00000230939.1 RP11-314C16.1 -5.54 5.91e-08 3.03e-05 -0.35 -0.29 Motion sickness; chr6:8535885 chr6:8784178~8785445:+ LIHC cis rs4706831 0.625 rs638056 ENSG00000272129.1 RP11-250B2.6 -5.54 5.93e-08 3.04e-05 -0.29 -0.29 Joint mobility (Beighton score); chr6:80271091 chr6:80355424~80356859:+ LIHC cis rs7923609 0.902 rs10733793 ENSG00000232075.1 MRPL35P2 -5.54 5.93e-08 3.04e-05 -0.32 -0.29 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63564049 chr10:63634317~63634827:- LIHC cis rs113835537 0.529 rs57724777 ENSG00000255517.5 CTD-3074O7.5 -5.54 5.93e-08 3.04e-05 -0.37 -0.29 Airway imaging phenotypes; chr11:66468960 chr11:66473490~66480233:- LIHC cis rs11098499 0.954 rs6848389 ENSG00000245958.5 RP11-33B1.1 -5.54 5.94e-08 3.04e-05 -0.29 -0.29 Corneal astigmatism; chr4:119481467 chr4:119454791~119552025:+ LIHC cis rs2153535 0.521 rs6939827 ENSG00000230939.1 RP11-314C16.1 -5.54 5.96e-08 3.05e-05 -0.35 -0.29 Motion sickness; chr6:8461127 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9393019 ENSG00000230939.1 RP11-314C16.1 -5.54 5.96e-08 3.05e-05 -0.35 -0.29 Motion sickness; chr6:8461858 chr6:8784178~8785445:+ LIHC cis rs3096299 0.967 rs2911257 ENSG00000261118.1 RP11-104N10.1 5.54 5.97e-08 3.06e-05 0.29 0.29 Multiple myeloma (IgH translocation); chr16:89417726 chr16:89492017~89504460:- LIHC cis rs2153535 0.58 rs1410766 ENSG00000230939.1 RP11-314C16.1 -5.54 5.97e-08 3.06e-05 -0.35 -0.29 Motion sickness; chr6:8525127 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1328862 ENSG00000230939.1 RP11-314C16.1 -5.54 5.97e-08 3.06e-05 -0.35 -0.29 Motion sickness; chr6:8526448 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs1928183 ENSG00000230939.1 RP11-314C16.1 -5.54 5.97e-08 3.06e-05 -0.35 -0.29 Motion sickness; chr6:8529785 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6597337 ENSG00000230939.1 RP11-314C16.1 -5.54 5.97e-08 3.06e-05 -0.35 -0.29 Motion sickness; chr6:8531419 chr6:8784178~8785445:+ LIHC cis rs227275 0.527 rs223308 ENSG00000230069.3 LRRC37A15P -5.54 5.98e-08 3.06e-05 -0.26 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102891342 chr4:102727274~102730721:- LIHC cis rs2243480 0.901 rs778730 ENSG00000226824.5 RP4-756H11.3 -5.54 5.99e-08 3.07e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66358338 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1964692 ENSG00000226824.5 RP4-756H11.3 -5.54 5.99e-08 3.07e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65989196 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs2456483 ENSG00000226824.5 RP4-756H11.3 -5.54 5.99e-08 3.07e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65996588 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs2949697 ENSG00000226824.5 RP4-756H11.3 -5.54 5.99e-08 3.07e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65999249 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1701750 ENSG00000226824.5 RP4-756H11.3 -5.54 5.99e-08 3.07e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66002158 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1701758 ENSG00000226824.5 RP4-756H11.3 -5.54 5.99e-08 3.07e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66005214 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs1701759 ENSG00000226824.5 RP4-756H11.3 -5.54 5.99e-08 3.07e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66005945 chr7:66654538~66669855:+ LIHC cis rs2072510 0.722 rs2660895 ENSG00000257715.1 RP11-256L6.2 -5.54 6e-08 3.07e-05 -0.29 -0.29 Metabolite levels (small molecules and protein measures); chr12:96029669 chr12:96025323~96027971:+ LIHC cis rs11098499 0.738 rs28408407 ENSG00000245958.5 RP11-33B1.1 -5.54 6e-08 3.07e-05 -0.3 -0.29 Corneal astigmatism; chr4:119454875 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs1809406 ENSG00000245958.5 RP11-33B1.1 -5.54 6e-08 3.07e-05 -0.3 -0.29 Corneal astigmatism; chr4:119455967 chr4:119454791~119552025:+ LIHC cis rs11098499 0.865 rs2389809 ENSG00000245958.5 RP11-33B1.1 -5.54 6e-08 3.07e-05 -0.3 -0.29 Corneal astigmatism; chr4:119456244 chr4:119454791~119552025:+ LIHC cis rs11098499 0.697 rs10020027 ENSG00000245958.5 RP11-33B1.1 -5.54 6e-08 3.07e-05 -0.3 -0.29 Corneal astigmatism; chr4:119460724 chr4:119454791~119552025:+ LIHC cis rs11098499 0.779 rs7356491 ENSG00000245958.5 RP11-33B1.1 -5.54 6e-08 3.07e-05 -0.3 -0.29 Corneal astigmatism; chr4:119460819 chr4:119454791~119552025:+ LIHC cis rs11676348 0.846 rs4674259 ENSG00000261338.2 RP11-378A13.1 -5.54 6e-08 3.07e-05 -0.29 -0.29 Ulcerative colitis; chr2:218126282 chr2:218255319~218257366:+ LIHC cis rs8100891 0.537 rs10409835 ENSG00000267213.4 AC007773.2 -5.54 6.01e-08 3.07e-05 -0.37 -0.29 Neuroticism; chr19:32397754 chr19:32390050~32405560:- LIHC cis rs4356203 0.905 rs11024148 ENSG00000272034.1 SNORD14A -5.54 6.01e-08 3.07e-05 -0.31 -0.29 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17074512 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs7107283 ENSG00000272034.1 SNORD14A 5.54 6.01e-08 3.07e-05 0.31 0.29 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17067856 chr11:17074654~17074744:- LIHC cis rs433852 0.904 rs8102492 ENSG00000232871.7 SEC1P 5.54 6.02e-08 3.08e-05 0.34 0.29 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48637552 chr19:48638071~48682245:+ LIHC cis rs739496 0.947 rs28362508 ENSG00000226469.1 ADAM1B 5.54 6.02e-08 3.08e-05 0.35 0.29 Platelet count; chr12:111446611 chr12:111927018~111929017:+ LIHC cis rs9487094 0.67 rs12212476 ENSG00000260273.1 RP11-425D10.10 5.54 6.03e-08 3.08e-05 0.34 0.29 Height; chr6:109501402 chr6:109382795~109383666:+ LIHC cis rs9487094 0.67 rs12198938 ENSG00000260273.1 RP11-425D10.10 5.54 6.03e-08 3.08e-05 0.34 0.29 Height; chr6:109501429 chr6:109382795~109383666:+ LIHC cis rs853679 0.517 rs9393898 ENSG00000219392.1 RP1-265C24.5 -5.54 6.03e-08 3.08e-05 -0.44 -0.29 Depression; chr6:28162598 chr6:28115628~28116551:+ LIHC cis rs860295 0.65 rs28662267 ENSG00000203761.5 MSTO2P -5.54 6.04e-08 3.09e-05 -0.24 -0.29 Body mass index; chr1:155710658 chr1:155745829~155750137:+ LIHC cis rs228614 0.536 rs223420 ENSG00000230069.3 LRRC37A15P -5.54 6.05e-08 3.09e-05 -0.26 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102806853 chr4:102727274~102730721:- LIHC cis rs1577917 0.839 rs6454492 ENSG00000234155.1 RP11-30P6.6 5.54 6.06e-08 3.1e-05 0.35 0.29 Response to antipsychotic treatment; chr6:85773496 chr6:85387219~85390186:- LIHC cis rs10875746 0.669 rs11168496 ENSG00000240399.1 RP1-228P16.1 -5.54 6.07e-08 3.1e-05 -0.31 -0.29 Longevity (90 years and older); chr12:48257072 chr12:48054813~48055591:- LIHC cis rs227275 0.554 rs223409 ENSG00000230069.3 LRRC37A15P -5.54 6.07e-08 3.1e-05 -0.26 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102815023 chr4:102727274~102730721:- LIHC cis rs2243480 1 rs316313 ENSG00000226824.5 RP4-756H11.3 -5.54 6.09e-08 3.11e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66128561 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs316312 ENSG00000226824.5 RP4-756H11.3 -5.54 6.09e-08 3.11e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66131504 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs419603 ENSG00000226824.5 RP4-756H11.3 -5.54 6.09e-08 3.11e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66132354 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs431076 ENSG00000226824.5 RP4-756H11.3 -5.54 6.09e-08 3.11e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66135333 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs2460422 ENSG00000226824.5 RP4-756H11.3 -5.54 6.09e-08 3.11e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66136518 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs316334 ENSG00000226824.5 RP4-756H11.3 -5.54 6.09e-08 3.11e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66137139 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs316330 ENSG00000226824.5 RP4-756H11.3 -5.54 6.09e-08 3.11e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66140385 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs316326 ENSG00000226824.5 RP4-756H11.3 -5.54 6.09e-08 3.11e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66144466 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs316325 ENSG00000226824.5 RP4-756H11.3 -5.54 6.09e-08 3.11e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66144531 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs316321 ENSG00000226824.5 RP4-756H11.3 -5.54 6.09e-08 3.11e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66146626 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs6460307 ENSG00000237310.1 GS1-124K5.4 5.54 6.1e-08 3.11e-05 0.25 0.29 Aortic root size; chr7:66595884 chr7:66493706~66495474:+ LIHC cis rs10875746 0.669 rs11168459 ENSG00000240399.1 RP1-228P16.1 -5.54 6.1e-08 3.11e-05 -0.32 -0.29 Longevity (90 years and older); chr12:48202458 chr12:48054813~48055591:- LIHC cis rs12908161 1 rs12908161 ENSG00000259295.5 CSPG4P12 5.54 6.11e-08 3.12e-05 0.4 0.29 Schizophrenia; chr15:84664594 chr15:85191438~85213905:+ LIHC cis rs7923609 0.902 rs10740136 ENSG00000232075.1 MRPL35P2 -5.54 6.11e-08 3.12e-05 -0.32 -0.29 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63569862 chr10:63634317~63634827:- LIHC cis rs6921919 0.583 rs4254981 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28403625 chr6:28176188~28176674:+ LIHC cis rs6921919 0.525 rs6929825 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28411182 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs35599905 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28411886 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs1124131 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28412471 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs6899389 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28413363 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs6922374 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28413495 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs6899603 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28413528 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs6922429 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28413568 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs6922169 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28415155 chr6:28176188~28176674:+ LIHC cis rs6921919 0.559 rs13210866 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28416065 chr6:28176188~28176674:+ LIHC cis rs6921919 0.609 rs36018474 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28417752 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs13201726 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28417774 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs2027361 ENSG00000216901.1 AL022393.7 5.54 6.12e-08 3.12e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28420531 chr6:28176188~28176674:+ LIHC cis rs12681287 0.752 rs7846635 ENSG00000250569.1 NTAN1P2 5.54 6.14e-08 3.13e-05 0.35 0.29 Caudate activity during reward; chr8:86292052 chr8:86481754~86483002:- LIHC cis rs2735413 0.563 rs72800918 ENSG00000276007.1 RP11-358L22.3 5.54 6.15e-08 3.13e-05 0.4 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78026834 chr16:78123243~78124332:+ LIHC cis rs2842992 0.724 rs9347340 ENSG00000237927.1 RP3-393E18.2 5.54 6.15e-08 3.13e-05 0.34 0.29 Age-related macular degeneration (geographic atrophy); chr6:159767859 chr6:159586955~159589169:- LIHC cis rs8100891 0.537 rs10415145 ENSG00000267213.4 AC007773.2 5.54 6.16e-08 3.14e-05 0.36 0.29 Neuroticism; chr19:32350147 chr19:32390050~32405560:- LIHC cis rs9487094 0.645 rs12529505 ENSG00000260273.1 RP11-425D10.10 -5.54 6.16e-08 3.14e-05 -0.46 -0.29 Height; chr6:109625358 chr6:109382795~109383666:+ LIHC cis rs853679 0.517 rs9393896 ENSG00000219392.1 RP1-265C24.5 -5.54 6.17e-08 3.14e-05 -0.45 -0.29 Depression; chr6:28159925 chr6:28115628~28116551:+ LIHC cis rs853679 0.517 rs9393897 ENSG00000219392.1 RP1-265C24.5 -5.54 6.17e-08 3.14e-05 -0.45 -0.29 Depression; chr6:28159932 chr6:28115628~28116551:+ LIHC cis rs2504916 0.83 rs2504934 ENSG00000272841.1 RP3-428L16.2 5.54 6.18e-08 3.15e-05 0.42 0.29 Response to hepatitis C treatment; chr6:160360634 chr6:160990318~160992342:- LIHC cis rs12291225 0.546 rs12291662 ENSG00000251991.1 RNU7-49P 5.54 6.18e-08 3.15e-05 0.3 0.29 Sense of smell; chr11:14321403 chr11:14478892~14478953:+ LIHC cis rs12291225 0.545 rs11023187 ENSG00000251991.1 RNU7-49P 5.54 6.18e-08 3.15e-05 0.3 0.29 Sense of smell; chr11:14324013 chr11:14478892~14478953:+ LIHC cis rs12291225 0.585 rs11023194 ENSG00000251991.1 RNU7-49P 5.54 6.18e-08 3.15e-05 0.3 0.29 Sense of smell; chr11:14348223 chr11:14478892~14478953:+ LIHC cis rs7586673 0.93 rs7591506 ENSG00000227403.1 AC009299.3 -5.54 6.18e-08 3.15e-05 -0.35 -0.29 Intelligence (multi-trait analysis); chr2:161104414 chr2:161244739~161249050:+ LIHC cis rs3858145 0.505 rs12765827 ENSG00000233590.1 RP11-153K11.3 5.53 6.22e-08 3.17e-05 0.4 0.29 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68286821 chr10:68233251~68242379:- LIHC cis rs8100891 0.537 rs4805758 ENSG00000267213.4 AC007773.2 -5.53 6.24e-08 3.17e-05 -0.38 -0.29 Neuroticism; chr19:32375518 chr19:32390050~32405560:- LIHC cis rs2243480 0.908 rs4718273 ENSG00000226824.5 RP4-756H11.3 5.53 6.24e-08 3.17e-05 0.47 0.29 Diabetic kidney disease; chr7:65751112 chr7:66654538~66669855:+ LIHC cis rs4718428 0.705 rs4717331 ENSG00000232546.1 RP11-458F8.1 -5.53 6.24e-08 3.18e-05 -0.26 -0.29 Corneal structure; chr7:66913899 chr7:66848496~66858136:+ LIHC cis rs875971 0.862 rs1875057 ENSG00000237310.1 GS1-124K5.4 -5.53 6.25e-08 3.18e-05 -0.25 -0.29 Aortic root size; chr7:66266868 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6960446 ENSG00000237310.1 GS1-124K5.4 -5.53 6.25e-08 3.18e-05 -0.25 -0.29 Aortic root size; chr7:66268272 chr7:66493706~66495474:+ LIHC cis rs875971 0.789 rs10260426 ENSG00000237310.1 GS1-124K5.4 -5.53 6.25e-08 3.18e-05 -0.25 -0.29 Aortic root size; chr7:66271055 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs7783779 ENSG00000237310.1 GS1-124K5.4 -5.53 6.25e-08 3.18e-05 -0.25 -0.29 Aortic root size; chr7:66331639 chr7:66493706~66495474:+ LIHC cis rs1005277 0.579 rs2505194 ENSG00000263064.2 RP11-291L22.7 5.53 6.26e-08 3.18e-05 0.29 0.29 Extrinsic epigenetic age acceleration; chr10:38104953 chr10:38448689~38448949:+ LIHC cis rs2153535 0.504 rs5001323 ENSG00000230939.1 RP11-314C16.1 -5.53 6.26e-08 3.18e-05 -0.35 -0.29 Motion sickness; chr6:8451372 chr6:8784178~8785445:+ LIHC cis rs7927592 0.913 rs7116994 ENSG00000212093.1 AP000807.1 5.53 6.26e-08 3.19e-05 0.31 0.29 Total body bone mineral density; chr11:68487159 chr11:68506083~68506166:- LIHC cis rs3779195 0.86 rs12704986 ENSG00000272950.1 RP11-307C18.1 5.53 6.27e-08 3.19e-05 0.4 0.29 Sex hormone-binding globulin levels; chr7:98357118 chr7:98322853~98323430:+ LIHC cis rs3779195 0.858 rs3779196 ENSG00000272950.1 RP11-307C18.1 5.53 6.27e-08 3.19e-05 0.4 0.29 Sex hormone-binding globulin levels; chr7:98360794 chr7:98322853~98323430:+ LIHC cis rs3779195 0.789 rs6965424 ENSG00000272950.1 RP11-307C18.1 5.53 6.27e-08 3.19e-05 0.4 0.29 Sex hormone-binding globulin levels; chr7:98361813 chr7:98322853~98323430:+ LIHC cis rs11690935 0.959 rs12692973 ENSG00000228389.1 AC068039.4 -5.53 6.29e-08 3.2e-05 -0.38 -0.29 Schizophrenia; chr2:171785547 chr2:171773482~171775844:+ LIHC cis rs6479891 0.908 rs7078456 ENSG00000232075.1 MRPL35P2 -5.53 6.29e-08 3.2e-05 -0.33 -0.29 Arthritis (juvenile idiopathic); chr10:63509719 chr10:63634317~63634827:- LIHC cis rs8177376 0.953 rs73017385 ENSG00000254905.1 RP11-712L6.7 5.53 6.29e-08 3.2e-05 0.44 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126309680 chr11:126292922~126294254:- LIHC cis rs8177376 0.953 rs3862627 ENSG00000254905.1 RP11-712L6.7 5.53 6.29e-08 3.2e-05 0.44 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126311697 chr11:126292922~126294254:- LIHC cis rs8177376 0.953 rs73017394 ENSG00000254905.1 RP11-712L6.7 5.53 6.29e-08 3.2e-05 0.44 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126311952 chr11:126292922~126294254:- LIHC cis rs4356203 0.905 rs17472886 ENSG00000272034.1 SNORD14A -5.53 6.3e-08 3.2e-05 -0.31 -0.29 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17064620 chr11:17074654~17074744:- LIHC cis rs11098499 0.738 rs72918577 ENSG00000245958.5 RP11-33B1.1 -5.53 6.3e-08 3.2e-05 -0.3 -0.29 Corneal astigmatism; chr4:119405546 chr4:119454791~119552025:+ LIHC cis rs17711722 0.522 rs62469933 ENSG00000228409.4 CCT6P1 -5.53 6.31e-08 3.21e-05 -0.23 -0.29 Calcium levels; chr7:65800652 chr7:65751142~65763354:+ LIHC cis rs2880765 0.566 rs17553249 ENSG00000259295.5 CSPG4P12 5.53 6.31e-08 3.21e-05 0.41 0.29 Coronary artery disease; chr15:85463463 chr15:85191438~85213905:+ LIHC cis rs739496 0.947 rs2301621 ENSG00000226469.1 ADAM1B 5.53 6.31e-08 3.21e-05 0.35 0.29 Platelet count; chr12:111457468 chr12:111927018~111929017:+ LIHC cis rs739496 0.895 rs2283357 ENSG00000226469.1 ADAM1B 5.53 6.31e-08 3.21e-05 0.35 0.29 Platelet count; chr12:111459575 chr12:111927018~111929017:+ LIHC cis rs739496 0.947 rs7134740 ENSG00000226469.1 ADAM1B 5.53 6.31e-08 3.21e-05 0.35 0.29 Platelet count; chr12:111489935 chr12:111927018~111929017:+ LIHC cis rs9326248 0.53 rs2075292 ENSG00000280143.1 AP000892.6 5.53 6.31e-08 3.21e-05 0.36 0.29 Blood protein levels; chr11:116861796 chr11:117204967~117210292:+ LIHC cis rs2283792 0.967 rs5999823 ENSG00000224086.5 LL22NC03-86G7.1 -5.53 6.33e-08 3.21e-05 -0.26 -0.29 Multiple sclerosis; chr22:21856587 chr22:21938293~21977632:+ LIHC cis rs2283792 0.935 rs2283794 ENSG00000224086.5 LL22NC03-86G7.1 -5.53 6.33e-08 3.21e-05 -0.26 -0.29 Multiple sclerosis; chr22:21858180 chr22:21938293~21977632:+ LIHC cis rs2243480 0.901 rs12530490 ENSG00000226824.5 RP4-756H11.3 5.53 6.33e-08 3.22e-05 0.47 0.29 Diabetic kidney disease; chr7:66226660 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs7778911 ENSG00000226824.5 RP4-756H11.3 5.53 6.33e-08 3.22e-05 0.47 0.29 Diabetic kidney disease; chr7:66229519 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1979823 ENSG00000226824.5 RP4-756H11.3 5.53 6.33e-08 3.22e-05 0.47 0.29 Diabetic kidney disease; chr7:66239626 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1723270 ENSG00000226824.5 RP4-756H11.3 -5.53 6.33e-08 3.22e-05 -0.48 -0.29 Diabetic kidney disease; chr7:66004843 chr7:66654538~66669855:+ LIHC cis rs8028182 0.636 rs11637068 ENSG00000260269.4 CTD-2323K18.1 -5.53 6.33e-08 3.22e-05 -0.38 -0.29 Sudden cardiac arrest; chr15:75450661 chr15:75527150~75601205:- LIHC cis rs12681287 0.927 rs2953517 ENSG00000250569.1 NTAN1P2 5.53 6.34e-08 3.22e-05 0.34 0.29 Caudate activity during reward; chr8:86319784 chr8:86481754~86483002:- LIHC cis rs7119038 0.774 rs73005426 ENSG00000255239.1 AP002954.6 -5.53 6.34e-08 3.22e-05 -0.36 -0.29 Sjögren's syndrome; chr11:118810374 chr11:118688039~118690600:- LIHC cis rs7923609 0.902 rs4633333 ENSG00000232075.1 MRPL35P2 -5.53 6.35e-08 3.23e-05 -0.32 -0.29 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63568779 chr10:63634317~63634827:- LIHC cis rs2243480 1 rs160633 ENSG00000273142.1 RP11-458F8.4 -5.53 6.36e-08 3.23e-05 -0.35 -0.29 Diabetic kidney disease; chr7:66063241 chr7:66902857~66906297:+ LIHC cis rs4356975 0.563 rs3924192 ENSG00000249956.3 RP11-790I12.2 -5.53 6.38e-08 3.24e-05 -0.34 -0.29 Obesity-related traits; chr4:69105246 chr4:69408836~69423164:+ LIHC cis rs12468226 1 rs6739198 ENSG00000273456.1 RP11-686O6.2 5.53 6.38e-08 3.24e-05 0.41 0.29 Urate levels; chr2:202492273 chr2:202374932~202375604:- LIHC cis rs7829975 0.593 rs2921061 ENSG00000253893.2 FAM85B -5.53 6.38e-08 3.24e-05 -0.38 -0.29 Mood instability; chr8:8460105 chr8:8167819~8226614:- LIHC cis rs11690935 0.959 rs3770451 ENSG00000228389.1 AC068039.4 5.53 6.4e-08 3.25e-05 0.39 0.29 Schizophrenia; chr2:171812205 chr2:171773482~171775844:+ LIHC cis rs860295 0.812 rs6657670 ENSG00000203761.5 MSTO2P -5.53 6.4e-08 3.25e-05 -0.23 -0.29 Body mass index; chr1:155818076 chr1:155745829~155750137:+ LIHC cis rs2243480 1 rs4718270 ENSG00000226824.5 RP4-756H11.3 -5.53 6.4e-08 3.25e-05 -0.47 -0.29 Diabetic kidney disease; chr7:65737415 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs2900904 ENSG00000226824.5 RP4-756H11.3 -5.53 6.4e-08 3.25e-05 -0.47 -0.29 Diabetic kidney disease; chr7:65739282 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs6460260 ENSG00000226824.5 RP4-756H11.3 5.53 6.4e-08 3.25e-05 0.47 0.29 Diabetic kidney disease; chr7:65750468 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs6460261 ENSG00000226824.5 RP4-756H11.3 5.53 6.4e-08 3.25e-05 0.47 0.29 Diabetic kidney disease; chr7:65750593 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs67775320 ENSG00000237310.1 GS1-124K5.4 5.53 6.4e-08 3.25e-05 0.27 0.29 Aortic root size; chr7:66193792 chr7:66493706~66495474:+ LIHC cis rs6479901 0.557 rs4746125 ENSG00000232075.1 MRPL35P2 5.53 6.41e-08 3.25e-05 0.33 0.29 Intelligence (multi-trait analysis); chr10:63393125 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs72837025 ENSG00000232075.1 MRPL35P2 5.53 6.41e-08 3.25e-05 0.33 0.29 Arthritis (juvenile idiopathic); chr10:63434731 chr10:63634317~63634827:- LIHC cis rs496547 0.588 rs473298 ENSG00000255422.1 AP002954.4 -5.53 6.42e-08 3.25e-05 -0.32 -0.29 Hip minimal joint space width; chr11:118808678 chr11:118704607~118750263:+ LIHC cis rs2243480 1 rs387676 ENSG00000226824.5 RP4-756H11.3 -5.53 6.42e-08 3.26e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66133233 chr7:66654538~66669855:+ LIHC cis rs2739330 0.734 rs2000467 ENSG00000099984.9 GSTT2 5.53 6.42e-08 3.26e-05 0.34 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23980123~23983911:+ LIHC cis rs12908161 1 rs56864281 ENSG00000259295.5 CSPG4P12 5.53 6.44e-08 3.26e-05 0.4 0.29 Schizophrenia; chr15:84814418 chr15:85191438~85213905:+ LIHC cis rs6686842 0.931 rs4360513 ENSG00000235358.1 RP11-399E6.1 5.53 6.45e-08 3.27e-05 0.31 0.29 Height; chr1:41015127 chr1:41242373~41284861:+ LIHC cis rs739496 0.793 rs607316 ENSG00000226469.1 ADAM1B 5.53 6.45e-08 3.27e-05 0.34 0.29 Platelet count; chr12:111531644 chr12:111927018~111929017:+ LIHC cis rs17711722 0.522 rs6957759 ENSG00000228409.4 CCT6P1 -5.53 6.46e-08 3.27e-05 -0.23 -0.29 Calcium levels; chr7:65806798 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs316322 ENSG00000226824.5 RP4-756H11.3 -5.53 6.47e-08 3.28e-05 -0.47 -0.29 Diabetic kidney disease; chr7:66146246 chr7:66654538~66669855:+ LIHC cis rs11690935 1 rs35549875 ENSG00000228389.1 AC068039.4 -5.53 6.48e-08 3.28e-05 -0.38 -0.29 Schizophrenia; chr2:171675882 chr2:171773482~171775844:+ LIHC cis rs12744310 0.502 rs2363812 ENSG00000235358.1 RP11-399E6.1 5.53 6.49e-08 3.29e-05 0.34 0.29 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41326895 chr1:41242373~41284861:+ LIHC cis rs752590 0.806 rs4849174 ENSG00000189223.12 PAX8-AS1 -5.53 6.49e-08 3.29e-05 -0.4 -0.29 Mucinous ovarian carcinoma; chr2:113215890 chr2:113211522~113276581:+ LIHC cis rs5769707 0.568 rs2011097 ENSG00000235111.1 RP1-29C18.8 -5.53 6.5e-08 3.29e-05 -0.34 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49624421 chr22:49612657~49615716:- LIHC cis rs17023223 0.537 rs10923754 ENSG00000231365.4 RP11-418J17.1 -5.53 6.5e-08 3.29e-05 -0.35 -0.29 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119126017 chr1:119140396~119275973:+ LIHC cis rs12744310 0.502 rs12725272 ENSG00000235358.1 RP11-399E6.1 5.53 6.51e-08 3.3e-05 0.33 0.29 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41324190 chr1:41242373~41284861:+ LIHC cis rs12571093 0.773 rs61854802 ENSG00000233590.1 RP11-153K11.3 -5.53 6.51e-08 3.3e-05 -0.46 -0.29 Optic nerve measurement (disc area); chr10:68249815 chr10:68233251~68242379:- LIHC cis rs7945705 0.902 rs11042152 ENSG00000254860.4 TMEM9B-AS1 -5.53 6.51e-08 3.3e-05 -0.3 -0.29 Hemoglobin concentration; chr11:8999440 chr11:8964675~8977527:+ LIHC cis rs5769707 0.616 rs135869 ENSG00000235111.1 RP1-29C18.8 -5.53 6.52e-08 3.3e-05 -0.34 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49614718 chr22:49612657~49615716:- LIHC cis rs2111504 0.583 rs2868082 ENSG00000267213.4 AC007773.2 5.53 6.53e-08 3.3e-05 0.29 0.29 Bipolar disorder; chr19:32368475 chr19:32390050~32405560:- LIHC cis rs1150668 0.745 rs213238 ENSG00000204709.4 LINC01556 5.52 6.54e-08 3.31e-05 0.32 0.29 Pubertal anthropometrics; chr6:28354216 chr6:28943877~28944537:+ LIHC cis rs1577917 0.545 rs1335443 ENSG00000234155.1 RP11-30P6.6 5.52 6.55e-08 3.31e-05 0.33 0.29 Response to antipsychotic treatment; chr6:85769019 chr6:85387219~85390186:- LIHC cis rs6479901 0.894 rs1061259 ENSG00000232075.1 MRPL35P2 -5.52 6.55e-08 3.31e-05 -0.31 -0.29 Intelligence (multi-trait analysis); chr10:63465484 chr10:63634317~63634827:- LIHC cis rs6480314 0.636 rs61854790 ENSG00000233590.1 RP11-153K11.3 -5.52 6.56e-08 3.32e-05 -0.45 -0.29 Optic nerve measurement (disc area); chr10:68242491 chr10:68233251~68242379:- LIHC cis rs2933343 0.729 rs6767104 ENSG00000231305.3 RP11-723O4.2 -5.52 6.56e-08 3.32e-05 -0.32 -0.29 IgG glycosylation; chr3:128929274 chr3:128861313~128871540:- LIHC cis rs2072510 0.683 rs2246973 ENSG00000257715.1 RP11-256L6.2 -5.52 6.57e-08 3.32e-05 -0.29 -0.29 Metabolite levels (small molecules and protein measures); chr12:96034097 chr12:96025323~96027971:+ LIHC cis rs2072510 0.683 rs2246972 ENSG00000257715.1 RP11-256L6.2 -5.52 6.57e-08 3.32e-05 -0.29 -0.29 Metabolite levels (small molecules and protein measures); chr12:96034111 chr12:96025323~96027971:+ LIHC cis rs2735413 0.564 rs78898310 ENSG00000276007.1 RP11-358L22.3 5.52 6.57e-08 3.32e-05 0.39 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78081613 chr16:78123243~78124332:+ LIHC cis rs4660456 0.572 rs10789191 ENSG00000237899.1 RP4-739H11.3 5.52 6.59e-08 3.33e-05 0.36 0.29 Platelet count; chr1:40690819 chr1:40669089~40687588:- LIHC cis rs7131987 0.65 rs6487808 ENSG00000275476.1 RP11-996F15.4 5.52 6.59e-08 3.33e-05 0.33 0.29 QT interval; chr12:29310426 chr12:29277397~29277882:- LIHC cis rs2153535 0.58 rs2327062 ENSG00000230939.1 RP11-314C16.1 -5.52 6.6e-08 3.34e-05 -0.35 -0.29 Motion sickness; chr6:8453625 chr6:8784178~8785445:+ LIHC cis rs3779195 1 rs3779195 ENSG00000272950.1 RP11-307C18.1 -5.52 6.6e-08 3.34e-05 -0.41 -0.29 Sex hormone-binding globulin levels; chr7:98364050 chr7:98322853~98323430:+ LIHC cis rs11098499 0.954 rs11098526 ENSG00000245958.5 RP11-33B1.1 -5.52 6.61e-08 3.34e-05 -0.3 -0.29 Corneal astigmatism; chr4:119469204 chr4:119454791~119552025:+ LIHC cis rs12468226 1 rs76021735 ENSG00000273456.1 RP11-686O6.2 5.52 6.62e-08 3.35e-05 0.41 0.29 Urate levels; chr2:202511476 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs57080353 ENSG00000273456.1 RP11-686O6.2 5.52 6.62e-08 3.35e-05 0.41 0.29 Urate levels; chr2:202511824 chr2:202374932~202375604:- LIHC cis rs12468226 0.81 rs3736578 ENSG00000273456.1 RP11-686O6.2 5.52 6.62e-08 3.35e-05 0.41 0.29 Urate levels; chr2:202519989 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs116439150 ENSG00000273456.1 RP11-686O6.2 5.52 6.62e-08 3.35e-05 0.41 0.29 Urate levels; chr2:202523814 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs12467409 ENSG00000273456.1 RP11-686O6.2 5.52 6.62e-08 3.35e-05 0.41 0.29 Urate levels; chr2:202529625 chr2:202374932~202375604:- LIHC cis rs2153535 0.58 rs4451187 ENSG00000230939.1 RP11-314C16.1 -5.52 6.64e-08 3.35e-05 -0.35 -0.29 Motion sickness; chr6:8473677 chr6:8784178~8785445:+ LIHC cis rs2153535 0.504 rs4493781 ENSG00000230939.1 RP11-314C16.1 -5.52 6.64e-08 3.35e-05 -0.35 -0.29 Motion sickness; chr6:8473708 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs5026687 ENSG00000230939.1 RP11-314C16.1 -5.52 6.64e-08 3.35e-05 -0.35 -0.29 Motion sickness; chr6:8473724 chr6:8784178~8785445:+ LIHC cis rs12701220 0.655 rs12702117 ENSG00000229043.2 AC091729.9 -5.52 6.64e-08 3.35e-05 -0.4 -0.29 Bronchopulmonary dysplasia; chr7:1109066 chr7:1160374~1165267:+ LIHC cis rs11098499 0.954 rs10518331 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119402440 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs13133522 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119403269 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs35091806 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119404374 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs35165976 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119404475 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs2389802 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119404577 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs6846442 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119405168 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs71614422 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119438185 chr4:119454791~119552025:+ LIHC cis rs11098499 0.738 rs34566984 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119440115 chr4:119454791~119552025:+ LIHC cis rs11098499 0.738 rs34965784 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119440431 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs17009122 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119441248 chr4:119454791~119552025:+ LIHC cis rs11098499 0.505 rs75122014 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119441271 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs9685777 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119444810 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs71614438 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119450097 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs66506550 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119450290 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs7659501 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119450397 chr4:119454791~119552025:+ LIHC cis rs11098499 0.657 rs71614442 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119458191 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs2892848 ENSG00000245958.5 RP11-33B1.1 -5.52 6.64e-08 3.35e-05 -0.3 -0.29 Corneal astigmatism; chr4:119460186 chr4:119454791~119552025:+ LIHC cis rs1862618 0.853 rs1833896 ENSG00000271828.1 CTD-2310F14.1 5.52 6.66e-08 3.36e-05 0.4 0.29 Initial pursuit acceleration; chr5:56801842 chr5:56927874~56929573:+ LIHC cis rs1862618 0.853 rs1862619 ENSG00000271828.1 CTD-2310F14.1 5.52 6.66e-08 3.36e-05 0.4 0.29 Initial pursuit acceleration; chr5:56802429 chr5:56927874~56929573:+ LIHC cis rs1862618 0.853 rs1559282 ENSG00000271828.1 CTD-2310F14.1 5.52 6.66e-08 3.36e-05 0.4 0.29 Initial pursuit acceleration; chr5:56803548 chr5:56927874~56929573:+ LIHC cis rs1005277 0.579 rs2505248 ENSG00000263064.2 RP11-291L22.7 5.52 6.68e-08 3.37e-05 0.29 0.29 Extrinsic epigenetic age acceleration; chr10:38170169 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs176880 ENSG00000263064.2 RP11-291L22.7 -5.52 6.68e-08 3.37e-05 -0.29 -0.29 Extrinsic epigenetic age acceleration; chr10:38112489 chr10:38448689~38448949:+ LIHC cis rs12134133 1 rs2564973 ENSG00000274245.1 RP11-357P18.2 5.52 6.68e-08 3.37e-05 0.44 0.29 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207306759 chr1:207372559~207373252:+ LIHC cis rs7811142 0.666 rs28401739 ENSG00000242294.5 STAG3L5P 5.52 6.68e-08 3.37e-05 0.3 0.29 Platelet count; chr7:100308061 chr7:100336079~100351900:+ LIHC cis rs9388451 0.839 rs11154331 ENSG00000237742.5 RP11-624M8.1 -5.52 6.69e-08 3.37e-05 -0.26 -0.29 Brugada syndrome; chr6:125790283 chr6:125578558~125749190:- LIHC cis rs7927592 0.513 rs901823 ENSG00000212093.1 AP000807.1 5.52 6.69e-08 3.37e-05 0.29 0.29 Total body bone mineral density; chr11:68438110 chr11:68506083~68506166:- LIHC cis rs12594515 0.6 rs12903858 ENSG00000273972.1 CTD-2306A12.1 -5.52 6.7e-08 3.38e-05 -0.32 -0.29 Weight;Waist circumference; chr15:45679968 chr15:45702640~45703183:+ LIHC cis rs6480314 0.636 rs61854792 ENSG00000233590.1 RP11-153K11.3 -5.52 6.7e-08 3.38e-05 -0.45 -0.29 Optic nerve measurement (disc area); chr10:68243902 chr10:68233251~68242379:- LIHC cis rs853679 0.517 rs1904841 ENSG00000219392.1 RP1-265C24.5 -5.52 6.74e-08 3.4e-05 -0.44 -0.29 Depression; chr6:28140307 chr6:28115628~28116551:+ LIHC cis rs2243480 1 rs1499614 ENSG00000226824.5 RP4-756H11.3 -5.52 6.75e-08 3.4e-05 -0.46 -0.29 Diabetic kidney disease; chr7:66265811 chr7:66654538~66669855:+ LIHC cis rs17711722 0.522 rs4642526 ENSG00000228409.4 CCT6P1 -5.52 6.76e-08 3.41e-05 -0.22 -0.29 Calcium levels; chr7:65751755 chr7:65751142~65763354:+ LIHC cis rs10510102 0.935 rs7906667 ENSG00000276742.1 RP11-500G22.4 5.52 6.76e-08 3.41e-05 0.43 0.29 Breast cancer; chr10:121909142 chr10:121956782~121957098:+ LIHC cis rs7945705 0.902 rs10769980 ENSG00000254860.4 TMEM9B-AS1 -5.52 6.78e-08 3.41e-05 -0.29 -0.29 Hemoglobin concentration; chr11:8992633 chr11:8964675~8977527:+ LIHC cis rs1577917 0.796 rs12661231 ENSG00000234155.1 RP11-30P6.6 5.52 6.78e-08 3.41e-05 0.34 0.29 Response to antipsychotic treatment; chr6:85834753 chr6:85387219~85390186:- LIHC cis rs2735413 0.563 rs11647117 ENSG00000276007.1 RP11-358L22.3 5.52 6.79e-08 3.42e-05 0.38 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78024165 chr16:78123243~78124332:+ LIHC cis rs202072 0.872 rs445714 ENSG00000215022.6 RP1-257A7.4 -5.52 6.79e-08 3.42e-05 -0.33 -0.29 HIV-1 viral setpoint; chr6:13280726 chr6:13264861~13295586:- LIHC cis rs6921919 0.583 rs740621 ENSG00000216901.1 AL022393.7 5.52 6.79e-08 3.42e-05 0.36 0.29 Autism spectrum disorder or schizophrenia; chr6:28430010 chr6:28176188~28176674:+ LIHC cis rs4535700 0.501 rs9642405 ENSG00000226278.1 PSPHP1 5.52 6.79e-08 3.42e-05 0.34 0.29 Macular telangiectasia type 2; chr7:55910473 chr7:55764797~55773288:+ LIHC cis rs10510102 1 rs7923678 ENSG00000226864.1 ATE1-AS1 5.52 6.81e-08 3.43e-05 0.45 0.29 Breast cancer; chr10:121832546 chr10:121928312~121951965:+ LIHC cis rs62388641 1 rs62388641 ENSG00000272279.1 RP11-157J24.2 5.52 6.81e-08 3.43e-05 0.63 0.29 Daytime sleep phenotypes; chr6:1539849 chr6:1528364~1528911:- LIHC cis rs496547 0.719 rs472641 ENSG00000255422.1 AP002954.4 -5.52 6.82e-08 3.43e-05 -0.33 -0.29 Hip minimal joint space width; chr11:118746835 chr11:118704607~118750263:+ LIHC cis rs2072510 0.722 rs2247323 ENSG00000257715.1 RP11-256L6.2 -5.52 6.83e-08 3.44e-05 -0.28 -0.29 Metabolite levels (small molecules and protein measures); chr12:96030478 chr12:96025323~96027971:+ LIHC cis rs2072510 0.722 rs2247313 ENSG00000257715.1 RP11-256L6.2 -5.52 6.83e-08 3.44e-05 -0.28 -0.29 Metabolite levels (small molecules and protein measures); chr12:96030669 chr12:96025323~96027971:+ LIHC cis rs2072510 0.722 rs2247309 ENSG00000257715.1 RP11-256L6.2 -5.52 6.83e-08 3.44e-05 -0.28 -0.29 Metabolite levels (small molecules and protein measures); chr12:96030764 chr12:96025323~96027971:+ LIHC cis rs2072510 0.75 rs2660898 ENSG00000257715.1 RP11-256L6.2 -5.52 6.83e-08 3.44e-05 -0.28 -0.29 Metabolite levels (small molecules and protein measures); chr12:96032219 chr12:96025323~96027971:+ LIHC cis rs875971 0.545 rs67397473 ENSG00000237310.1 GS1-124K5.4 5.52 6.83e-08 3.44e-05 0.27 0.29 Aortic root size; chr7:66168318 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs10950027 ENSG00000237310.1 GS1-124K5.4 5.52 6.83e-08 3.44e-05 0.27 0.29 Aortic root size; chr7:66169164 chr7:66493706~66495474:+ LIHC cis rs6480314 0.542 rs17231637 ENSG00000233590.1 RP11-153K11.3 5.52 6.84e-08 3.45e-05 0.44 0.29 Optic nerve measurement (disc area); chr10:68270137 chr10:68233251~68242379:- LIHC cis rs524281 0.861 rs10791858 ENSG00000255320.1 RP11-755F10.1 5.52 6.85e-08 3.45e-05 0.38 0.29 Electroencephalogram traits; chr11:66210925 chr11:66244840~66246239:- LIHC cis rs524281 0.817 rs10791859 ENSG00000255320.1 RP11-755F10.1 5.52 6.85e-08 3.45e-05 0.38 0.29 Electroencephalogram traits; chr11:66210982 chr11:66244840~66246239:- LIHC cis rs7927592 0.513 rs7950129 ENSG00000212093.1 AP000807.1 5.52 6.85e-08 3.45e-05 0.29 0.29 Total body bone mineral density; chr11:68435435 chr11:68506083~68506166:- LIHC cis rs5769707 0.681 rs4824068 ENSG00000235111.1 RP1-29C18.8 -5.52 6.85e-08 3.45e-05 -0.35 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49631153 chr22:49612657~49615716:- LIHC cis rs4731207 0.596 rs6980448 ENSG00000224897.5 POT1-AS1 5.52 6.86e-08 3.45e-05 0.33 0.29 Cutaneous malignant melanoma; chr7:124929364 chr7:124929873~125179315:+ LIHC cis rs853679 0.517 rs4713150 ENSG00000219392.1 RP1-265C24.5 -5.52 6.86e-08 3.45e-05 -0.45 -0.29 Depression; chr6:28168434 chr6:28115628~28116551:+ LIHC cis rs6480314 0.636 rs7914274 ENSG00000233590.1 RP11-153K11.3 -5.52 6.87e-08 3.46e-05 -0.45 -0.29 Optic nerve measurement (disc area); chr10:68240300 chr10:68233251~68242379:- LIHC cis rs9890032 0.934 rs3760318 ENSG00000263531.1 RP13-753N3.1 5.52 6.87e-08 3.46e-05 0.35 0.29 Hip circumference adjusted for BMI; chr17:30920697 chr17:30863921~30864940:- LIHC cis rs17507216 0.609 rs1431716 ENSG00000278603.1 RP13-608F4.5 5.52 6.88e-08 3.46e-05 0.6 0.29 Excessive daytime sleepiness; chr15:82676180 chr15:82472203~82472426:+ LIHC cis rs11096990 0.551 rs2060005 ENSG00000249207.1 RP11-360F5.1 -5.52 6.89e-08 3.46e-05 -0.29 -0.29 Cognitive function; chr4:39160901 chr4:39112677~39126818:- LIHC cis rs2153535 0.563 rs1737585 ENSG00000230939.1 RP11-314C16.1 5.51 6.89e-08 3.47e-05 0.35 0.29 Motion sickness; chr6:8536361 chr6:8784178~8785445:+ LIHC cis rs11690935 0.921 rs908670 ENSG00000228389.1 AC068039.4 5.51 6.91e-08 3.48e-05 0.38 0.29 Schizophrenia; chr2:171833670 chr2:171773482~171775844:+ LIHC cis rs2283792 1 rs2266967 ENSG00000224086.5 LL22NC03-86G7.1 -5.51 6.91e-08 3.48e-05 -0.26 -0.29 Multiple sclerosis; chr22:21802500 chr22:21938293~21977632:+ LIHC cis rs5758659 0.904 rs5758653 ENSG00000227370.1 RP4-669P10.19 -5.51 6.92e-08 3.48e-05 -0.32 -0.29 Cognitive function; chr22:42217479 chr22:42132543~42132998:+ LIHC cis rs12681287 0.577 rs11992955 ENSG00000250569.1 NTAN1P2 -5.51 6.93e-08 3.49e-05 -0.35 -0.29 Caudate activity during reward; chr8:86518257 chr8:86481754~86483002:- LIHC cis rs2243480 1 rs1039664 ENSG00000226824.5 RP4-756H11.3 -5.51 6.94e-08 3.49e-05 -0.47 -0.29 Diabetic kidney disease; chr7:65984729 chr7:66654538~66669855:+ LIHC cis rs2735413 0.564 rs73580821 ENSG00000276007.1 RP11-358L22.3 5.51 6.94e-08 3.49e-05 0.39 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78076407 chr16:78123243~78124332:+ LIHC cis rs11722779 0.935 rs11938650 ENSG00000246560.2 RP11-10L12.4 5.51 6.94e-08 3.49e-05 0.33 0.29 Schizophrenia; chr4:103021639 chr4:102828055~102844075:+ LIHC cis rs860295 0.812 rs3820594 ENSG00000203761.5 MSTO2P -5.51 6.96e-08 3.5e-05 -0.23 -0.29 Body mass index; chr1:155859720 chr1:155745829~155750137:+ LIHC cis rs2842992 0.915 rs2842958 ENSG00000237927.1 RP3-393E18.2 -5.51 6.97e-08 3.5e-05 -0.36 -0.29 Age-related macular degeneration (geographic atrophy); chr6:159687393 chr6:159586955~159589169:- LIHC cis rs2842992 0.915 rs2758335 ENSG00000237927.1 RP3-393E18.2 -5.51 6.97e-08 3.5e-05 -0.36 -0.29 Age-related macular degeneration (geographic atrophy); chr6:159689979 chr6:159586955~159589169:- LIHC cis rs2842992 0.872 rs1570318 ENSG00000237927.1 RP3-393E18.2 -5.51 6.97e-08 3.5e-05 -0.36 -0.29 Age-related macular degeneration (geographic atrophy); chr6:159690441 chr6:159586955~159589169:- LIHC cis rs904251 0.523 rs9369005 ENSG00000204110.6 RP1-153P14.8 -5.51 6.98e-08 3.51e-05 -0.34 -0.29 Cognitive performance; chr6:37515333 chr6:37507348~37535616:+ LIHC cis rs10875746 0.669 rs61941006 ENSG00000240399.1 RP1-228P16.1 -5.51 6.99e-08 3.51e-05 -0.31 -0.29 Longevity (90 years and older); chr12:48237350 chr12:48054813~48055591:- LIHC cis rs5769707 0.632 rs1476037 ENSG00000235111.1 RP1-29C18.8 -5.51 6.99e-08 3.51e-05 -0.34 -0.29 Monocyte percentage of white cells;Monocyte count; chr22:49597729 chr22:49612657~49615716:- LIHC cis rs12701220 0.895 rs12534778 ENSG00000229043.2 AC091729.9 5.51 7e-08 3.51e-05 0.4 0.29 Bronchopulmonary dysplasia; chr7:1026225 chr7:1160374~1165267:+ LIHC cis rs2877649 0.793 rs10140911 ENSG00000258744.1 RP11-80A15.1 -5.51 7.01e-08 3.52e-05 -0.55 -0.29 Smooth-surface caries; chr14:24446177 chr14:24501594~24508688:+ LIHC cis rs9318086 0.648 rs4067969 ENSG00000205861.10 C1QTNF9B-AS1 -5.51 7.01e-08 3.52e-05 -0.33 -0.29 Myopia (pathological); chr13:23894981 chr13:23888889~23897263:+ LIHC cis rs11690935 0.959 rs10204501 ENSG00000228389.1 AC068039.4 5.51 7.01e-08 3.52e-05 0.38 0.29 Schizophrenia; chr2:171732355 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs10204502 ENSG00000228389.1 AC068039.4 5.51 7.01e-08 3.52e-05 0.38 0.29 Schizophrenia; chr2:171732356 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs10204622 ENSG00000228389.1 AC068039.4 5.51 7.01e-08 3.52e-05 0.38 0.29 Schizophrenia; chr2:171732472 chr2:171773482~171775844:+ LIHC cis rs72627509 0.857 rs56155140 ENSG00000269949.1 RP11-738E22.3 5.51 7.01e-08 3.52e-05 0.38 0.29 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56958285 chr4:56960927~56961373:- LIHC cis rs524281 0.861 rs10896077 ENSG00000255320.1 RP11-755F10.1 5.51 7.03e-08 3.53e-05 0.37 0.29 Electroencephalogram traits; chr11:66084262 chr11:66244840~66246239:- LIHC cis rs524281 0.817 rs7115081 ENSG00000255320.1 RP11-755F10.1 5.51 7.03e-08 3.53e-05 0.37 0.29 Electroencephalogram traits; chr11:66086070 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs11227403 ENSG00000255320.1 RP11-755F10.1 5.51 7.03e-08 3.53e-05 0.37 0.29 Electroencephalogram traits; chr11:66090957 chr11:66244840~66246239:- LIHC cis rs2842992 0.915 rs2842980 ENSG00000237927.1 RP3-393E18.2 -5.51 7.03e-08 3.53e-05 -0.36 -0.29 Age-related macular degeneration (geographic atrophy); chr6:159679084 chr6:159586955~159589169:- LIHC cis rs9487094 0.696 rs1853330 ENSG00000260273.1 RP11-425D10.10 5.51 7.03e-08 3.53e-05 0.34 0.29 Height; chr6:109375548 chr6:109382795~109383666:+ LIHC cis rs2243480 0.908 rs55876148 ENSG00000226824.5 RP4-756H11.3 -5.51 7.03e-08 3.53e-05 -0.48 -0.29 Diabetic kidney disease; chr7:65914813 chr7:66654538~66669855:+ LIHC cis rs11676348 0.818 rs4674256 ENSG00000261338.2 RP11-378A13.1 -5.51 7.05e-08 3.54e-05 -0.29 -0.29 Ulcerative colitis; chr2:218123170 chr2:218255319~218257366:+ LIHC cis rs11676348 0.846 rs4674257 ENSG00000261338.2 RP11-378A13.1 -5.51 7.05e-08 3.54e-05 -0.29 -0.29 Ulcerative colitis; chr2:218124051 chr2:218255319~218257366:+ LIHC cis rs2243480 1 rs427044 ENSG00000226824.5 RP4-756H11.3 -5.51 7.06e-08 3.54e-05 -0.46 -0.29 Diabetic kidney disease; chr7:66043558 chr7:66654538~66669855:+ LIHC cis rs2933343 0.679 rs1091938 ENSG00000231305.3 RP11-723O4.2 5.51 7.06e-08 3.54e-05 0.31 0.29 IgG glycosylation; chr3:128918182 chr3:128861313~128871540:- LIHC cis rs6480314 0.542 rs12572967 ENSG00000233590.1 RP11-153K11.3 -5.51 7.07e-08 3.55e-05 -0.44 -0.29 Optic nerve measurement (disc area); chr10:68270873 chr10:68233251~68242379:- LIHC cis rs3779195 0.524 rs76976120 ENSG00000272950.1 RP11-307C18.1 -5.51 7.07e-08 3.55e-05 -0.45 -0.29 Sex hormone-binding globulin levels; chr7:98264860 chr7:98322853~98323430:+ LIHC cis rs3779195 0.585 rs73709460 ENSG00000272950.1 RP11-307C18.1 -5.51 7.07e-08 3.55e-05 -0.45 -0.29 Sex hormone-binding globulin levels; chr7:98265942 chr7:98322853~98323430:+ LIHC cis rs3779195 0.585 rs56694862 ENSG00000272950.1 RP11-307C18.1 -5.51 7.07e-08 3.55e-05 -0.45 -0.29 Sex hormone-binding globulin levels; chr7:98267808 chr7:98322853~98323430:+ LIHC cis rs7429990 0.965 rs319682 ENSG00000229759.1 MRPS18AP1 5.51 7.08e-08 3.55e-05 0.3 0.29 Educational attainment (years of education); chr3:47873628 chr3:48256350~48256938:- LIHC cis rs6142102 0.812 rs4911375 ENSG00000276073.1 RP5-1125A11.7 -5.51 7.08e-08 3.55e-05 -0.32 -0.29 Skin pigmentation; chr20:33928216 chr20:33985617~33988989:- LIHC cis rs739496 0.947 rs11608565 ENSG00000226469.1 ADAM1B 5.51 7.09e-08 3.56e-05 0.35 0.29 Platelet count; chr12:111484122 chr12:111927018~111929017:+ LIHC cis rs739496 0.947 rs55851737 ENSG00000226469.1 ADAM1B 5.51 7.09e-08 3.56e-05 0.35 0.29 Platelet count; chr12:111499034 chr12:111927018~111929017:+ LIHC cis rs11098499 0.908 rs9995234 ENSG00000245958.5 RP11-33B1.1 -5.51 7.09e-08 3.56e-05 -0.3 -0.29 Corneal astigmatism; chr4:119400672 chr4:119454791~119552025:+ LIHC cis rs4356203 0.905 rs7938820 ENSG00000272034.1 SNORD14A 5.51 7.1e-08 3.56e-05 0.31 0.29 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17055905 chr11:17074654~17074744:- LIHC cis rs4934494 0.768 rs12571268 ENSG00000232936.4 RP11-80H5.2 5.51 7.1e-08 3.56e-05 0.36 0.29 Red blood cell count; chr10:89698830 chr10:89645282~89650667:+ LIHC cis rs9388451 0.839 rs3799711 ENSG00000237742.5 RP11-624M8.1 5.51 7.1e-08 3.56e-05 0.26 0.29 Brugada syndrome; chr6:125754167 chr6:125578558~125749190:- LIHC cis rs7714584 1 rs11167526 ENSG00000197083.10 ZNF300P1 5.51 7.11e-08 3.56e-05 0.45 0.29 Crohn's disease; chr5:150952919 chr5:150930645~150946289:- LIHC cis rs5758659 1 rs5758677 ENSG00000227370.1 RP4-669P10.19 -5.51 7.12e-08 3.57e-05 -0.32 -0.29 Cognitive function; chr22:42247033 chr22:42132543~42132998:+ LIHC cis rs7945705 0.747 rs1980429 ENSG00000254860.4 TMEM9B-AS1 5.51 7.12e-08 3.57e-05 0.29 0.29 Hemoglobin concentration; chr11:8988927 chr11:8964675~8977527:+ LIHC cis rs2153535 0.601 rs9502715 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8455476 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6912193 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8456073 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6912374 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8456190 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs6908504 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8456545 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7755284 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8457246 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7769020 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8457491 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9392220 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8457713 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9379206 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8457788 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs9405386 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8457834 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs9379207 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8457953 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9393016 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8458340 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs4960421 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8459059 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs4960422 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8459076 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs7742794 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8459490 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9505448 ENSG00000230939.1 RP11-314C16.1 -5.51 7.12e-08 3.57e-05 -0.35 -0.29 Motion sickness; chr6:8459571 chr6:8784178~8785445:+ LIHC cis rs6921919 0.583 rs3800328 ENSG00000216901.1 AL022393.7 5.51 7.13e-08 3.57e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28423066 chr6:28176188~28176674:+ LIHC cis rs6921919 0.609 rs67211468 ENSG00000216901.1 AL022393.7 5.51 7.13e-08 3.57e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28424210 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs740622 ENSG00000216901.1 AL022393.7 5.51 7.13e-08 3.57e-05 0.35 0.29 Autism spectrum disorder or schizophrenia; chr6:28430514 chr6:28176188~28176674:+ LIHC cis rs2243480 1 rs55895244 ENSG00000226824.5 RP4-756H11.3 -5.51 7.14e-08 3.58e-05 -0.47 -0.29 Diabetic kidney disease; chr7:65922691 chr7:66654538~66669855:+ LIHC cis rs2153535 0.562 rs6901765 ENSG00000230939.1 RP11-314C16.1 -5.51 7.17e-08 3.59e-05 -0.35 -0.29 Motion sickness; chr6:8455203 chr6:8784178~8785445:+ LIHC cis rs228614 0.51 rs223415 ENSG00000230069.3 LRRC37A15P -5.51 7.18e-08 3.59e-05 -0.26 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102811016 chr4:102727274~102730721:- LIHC cis rs17301013 0.861 rs10912824 ENSG00000227373.4 RP11-160H22.5 5.51 7.19e-08 3.6e-05 0.37 0.29 Systemic lupus erythematosus; chr1:174625846 chr1:174115300~174160004:- LIHC cis rs12681287 0.927 rs7003059 ENSG00000250569.1 NTAN1P2 5.51 7.2e-08 3.6e-05 0.34 0.29 Caudate activity during reward; chr8:86318484 chr8:86481754~86483002:- LIHC cis rs6480314 0.636 rs77760458 ENSG00000233590.1 RP11-153K11.3 -5.51 7.21e-08 3.61e-05 -0.45 -0.29 Optic nerve measurement (disc area); chr10:68244248 chr10:68233251~68242379:- LIHC cis rs6480314 0.636 rs61854797 ENSG00000233590.1 RP11-153K11.3 -5.51 7.21e-08 3.61e-05 -0.45 -0.29 Optic nerve measurement (disc area); chr10:68245854 chr10:68233251~68242379:- LIHC cis rs1005277 0.579 rs2505240 ENSG00000263064.2 RP11-291L22.7 5.51 7.21e-08 3.61e-05 0.29 0.29 Extrinsic epigenetic age acceleration; chr10:38153491 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2505241 ENSG00000263064.2 RP11-291L22.7 5.51 7.21e-08 3.61e-05 0.29 0.29 Extrinsic epigenetic age acceleration; chr10:38153493 chr10:38448689~38448949:+ LIHC cis rs7743045 0.504 rs4946382 ENSG00000253194.1 RP11-351A11.1 5.51 7.22e-08 3.61e-05 0.37 0.29 Mean platelet volume; chr6:118979312 chr6:118934785~119031541:+ LIHC cis rs4718428 0.705 rs13220977 ENSG00000232546.1 RP11-458F8.1 5.51 7.23e-08 3.62e-05 0.26 0.29 Corneal structure; chr7:66872661 chr7:66848496~66858136:+ LIHC cis rs228614 0.51 rs223410 ENSG00000230069.3 LRRC37A15P -5.51 7.23e-08 3.62e-05 -0.26 -0.29 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102813568 chr4:102727274~102730721:- LIHC cis rs12701220 0.655 rs6955290 ENSG00000229043.2 AC091729.9 5.51 7.25e-08 3.63e-05 0.39 0.29 Bronchopulmonary dysplasia; chr7:1111430 chr7:1160374~1165267:+ LIHC cis rs2072510 0.593 rs2540499 ENSG00000257715.1 RP11-256L6.2 5.51 7.25e-08 3.63e-05 0.42 0.29 Metabolite levels (small molecules and protein measures); chr12:96006091 chr12:96025323~96027971:+ LIHC cis rs2153535 0.58 rs7743686 ENSG00000230939.1 RP11-314C16.1 -5.5 7.26e-08 3.63e-05 -0.35 -0.29 Motion sickness; chr6:8525878 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs718504 ENSG00000230939.1 RP11-314C16.1 -5.5 7.26e-08 3.63e-05 -0.35 -0.29 Motion sickness; chr6:8527279 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs9328487 ENSG00000230939.1 RP11-314C16.1 -5.5 7.26e-08 3.63e-05 -0.35 -0.29 Motion sickness; chr6:8529145 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9328488 ENSG00000230939.1 RP11-314C16.1 -5.5 7.26e-08 3.63e-05 -0.35 -0.29 Motion sickness; chr6:8529178 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs7775274 ENSG00000230939.1 RP11-314C16.1 -5.5 7.26e-08 3.63e-05 -0.35 -0.29 Motion sickness; chr6:8530070 chr6:8784178~8785445:+ LIHC cis rs2153535 0.623 rs6597338 ENSG00000230939.1 RP11-314C16.1 -5.5 7.26e-08 3.63e-05 -0.35 -0.29 Motion sickness; chr6:8533275 chr6:8784178~8785445:+ LIHC cis rs7945705 0.87 rs1109305 ENSG00000254860.4 TMEM9B-AS1 -5.5 7.26e-08 3.63e-05 -0.29 -0.29 Hemoglobin concentration; chr11:8933725 chr11:8964675~8977527:+ LIHC cis rs6479891 1 rs10437345 ENSG00000232075.1 MRPL35P2 -5.5 7.27e-08 3.64e-05 -0.33 -0.29 Arthritis (juvenile idiopathic); chr10:63443186 chr10:63634317~63634827:- LIHC cis rs8177376 1 rs674218 ENSG00000254905.1 RP11-712L6.7 5.5 7.29e-08 3.64e-05 0.42 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126239165 chr11:126292922~126294254:- LIHC cis rs17711722 0.565 rs73372653 ENSG00000226002.1 RP11-460N20.5 5.5 7.3e-08 3.65e-05 0.3 0.29 Calcium levels; chr7:65977808 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs73150014 ENSG00000226824.5 RP4-756H11.3 -5.5 7.31e-08 3.65e-05 -0.47 -0.29 Diabetic kidney disease; chr7:65985932 chr7:66654538~66669855:+ LIHC cis rs2153535 0.58 rs6597325 ENSG00000230939.1 RP11-314C16.1 -5.5 7.31e-08 3.65e-05 -0.35 -0.29 Motion sickness; chr6:8460820 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6918391 ENSG00000230939.1 RP11-314C16.1 -5.5 7.31e-08 3.65e-05 -0.35 -0.29 Motion sickness; chr6:8460945 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9379210 ENSG00000230939.1 RP11-314C16.1 -5.5 7.31e-08 3.65e-05 -0.35 -0.29 Motion sickness; chr6:8461695 chr6:8784178~8785445:+ LIHC cis rs2297363 0.502 rs4709393 ENSG00000213073.4 RP11-288H12.3 -5.5 7.31e-08 3.65e-05 -0.28 -0.29 Total cholesterol levels;Blood protein levels; chr6:160051000 chr6:160093082~160096212:+ LIHC cis rs4535700 0.501 rs57251705 ENSG00000226278.1 PSPHP1 5.5 7.31e-08 3.65e-05 0.34 0.29 Macular telangiectasia type 2; chr7:55913390 chr7:55764797~55773288:+ LIHC cis rs9467711 0.651 rs17587597 ENSG00000216436.2 HIST1H2APS1 5.5 7.31e-08 3.66e-05 0.75 0.29 Autism spectrum disorder or schizophrenia; chr6:25986223 chr6:25732497~25732827:+ LIHC cis rs2243480 1 rs437889 ENSG00000226824.5 RP4-756H11.3 -5.5 7.33e-08 3.66e-05 -0.46 -0.29 Diabetic kidney disease; chr7:66044247 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs402418 ENSG00000226824.5 RP4-756H11.3 -5.5 7.33e-08 3.66e-05 -0.46 -0.29 Diabetic kidney disease; chr7:66044482 chr7:66654538~66669855:+ LIHC cis rs2243480 0.803 rs423187 ENSG00000226824.5 RP4-756H11.3 -5.5 7.33e-08 3.66e-05 -0.46 -0.29 Diabetic kidney disease; chr7:66044512 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs431318 ENSG00000226824.5 RP4-756H11.3 -5.5 7.33e-08 3.66e-05 -0.46 -0.29 Diabetic kidney disease; chr7:66046610 chr7:66654538~66669855:+ LIHC cis rs227275 0.554 rs223357 ENSG00000230069.3 LRRC37A15P -5.5 7.34e-08 3.67e-05 -0.26 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102851095 chr4:102727274~102730721:- LIHC cis rs8177376 0.953 rs73017399 ENSG00000254905.1 RP11-712L6.7 5.5 7.35e-08 3.67e-05 0.43 0.29 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126316417 chr11:126292922~126294254:- LIHC cis rs524281 0.817 rs10791849 ENSG00000255320.1 RP11-755F10.1 5.5 7.35e-08 3.67e-05 0.37 0.29 Electroencephalogram traits; chr11:66123126 chr11:66244840~66246239:- LIHC cis rs2153535 0.563 rs6942177 ENSG00000230939.1 RP11-314C16.1 5.5 7.35e-08 3.67e-05 0.35 0.29 Motion sickness; chr6:8534227 chr6:8784178~8785445:+ LIHC cis rs227275 0.554 rs223359 ENSG00000230069.3 LRRC37A15P -5.5 7.36e-08 3.68e-05 -0.26 -0.29 Allergic disease (asthma, hay fever or eczema); chr4:102849422 chr4:102727274~102730721:- LIHC cis rs2439831 1 rs527921 ENSG00000205771.5 CATSPER2P1 5.5 7.36e-08 3.68e-05 0.42 0.29 Lung cancer in ever smokers; chr15:43478218 chr15:43726918~43747094:- LIHC cis rs524281 0.814 rs10896093 ENSG00000255320.1 RP11-755F10.1 5.5 7.37e-08 3.68e-05 0.38 0.29 Electroencephalogram traits; chr11:66190940 chr11:66244840~66246239:- LIHC cis rs2153535 0.58 rs6914276 ENSG00000230939.1 RP11-314C16.1 5.5 7.37e-08 3.68e-05 0.35 0.29 Motion sickness; chr6:8450202 chr6:8784178~8785445:+ LIHC cis rs17507216 0.718 rs72753931 ENSG00000278603.1 RP13-608F4.5 5.5 7.37e-08 3.68e-05 0.59 0.29 Excessive daytime sleepiness; chr15:82721485 chr15:82472203~82472426:+ LIHC cis rs2933343 0.553 rs35979399 ENSG00000231305.3 RP11-723O4.2 5.5 7.37e-08 3.68e-05 0.32 0.29 IgG glycosylation; chr3:128978470 chr3:128861313~128871540:- LIHC cis rs2933343 0.533 rs11915889 ENSG00000231305.3 RP11-723O4.2 5.5 7.37e-08 3.68e-05 0.32 0.29 IgG glycosylation; chr3:128982023 chr3:128861313~128871540:- LIHC cis rs2739330 0.828 rs5760098 ENSG00000099984.9 GSTT2 -5.5 7.37e-08 3.68e-05 -0.34 -0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23980123~23983911:+ LIHC cis rs11690935 1 rs34542126 ENSG00000228389.1 AC068039.4 -5.5 7.38e-08 3.68e-05 -0.37 -0.29 Schizophrenia; chr2:171686195 chr2:171773482~171775844:+ LIHC cis rs2739330 0.731 rs2000468 ENSG00000206090.4 AP000350.7 5.5 7.38e-08 3.69e-05 0.34 0.29 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23939998~23942798:+ LIHC cis rs6686842 0.965 rs2802551 ENSG00000235358.1 RP11-399E6.1 5.5 7.39e-08 3.69e-05 0.31 0.29 Height; chr1:41031771 chr1:41242373~41284861:+ LIHC cis rs6686842 0.866 rs2802550 ENSG00000235358.1 RP11-399E6.1 5.5 7.39e-08 3.69e-05 0.31 0.29 Height; chr1:41031956 chr1:41242373~41284861:+ LIHC cis rs7914558 1 rs7920251 ENSG00000236937.2 PTGES3P4 5.5 7.39e-08 3.69e-05 0.34 0.29 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103190440 chr10:102845595~102845950:+ LIHC cis rs2735413 0.564 rs73580826 ENSG00000276007.1 RP11-358L22.3 5.5 7.39e-08 3.69e-05 0.39 0.29 Systolic blood pressure (alcohol consumption interaction); chr16:78076992 chr16:78123243~78124332:+ LIHC cis rs3096299 0.679 rs3096322 ENSG00000274627.1 RP11-104N10.2 -5.5 7.4e-08 3.69e-05 -0.3 -0.29 Multiple myeloma (IgH translocation); chr16:89374715 chr16:89516797~89522217:+ LIHC cis rs2243480 1 rs13310597 ENSG00000273142.1 RP11-458F8.4 -5.5 7.4e-08 3.7e-05 -0.35 -0.29 Diabetic kidney disease; chr7:66133553 chr7:66902857~66906297:+ LIHC cis rs11673344 0.566 rs11666708 ENSG00000226686.6 LINC01535 -5.5 7.42e-08 3.7e-05 -0.35 -0.29 Obesity-related traits; chr19:37396208 chr19:37251912~37265535:+ LIHC cis rs2933343 1 rs1683782 ENSG00000231305.3 RP11-723O4.2 5.5 7.43e-08 3.71e-05 0.32 0.29 IgG glycosylation; chr3:128921434 chr3:128861313~128871540:- LIHC cis rs7131987 0.683 rs3782511 ENSG00000275476.1 RP11-996F15.4 -5.5 7.45e-08 3.72e-05 -0.34 -0.29 QT interval; chr12:29343291 chr12:29277397~29277882:- LIHC cis rs6479891 0.908 rs61853639 ENSG00000232075.1 MRPL35P2 5.5 7.46e-08 3.72e-05 0.34 0.29 Arthritis (juvenile idiopathic); chr10:63545353 chr10:63634317~63634827:- LIHC cis rs11690935 0.959 rs3770452 ENSG00000228389.1 AC068039.4 5.5 7.46e-08 3.72e-05 0.38 0.29 Schizophrenia; chr2:171812172 chr2:171773482~171775844:+ LIHC cis rs2933343 0.953 rs2933344 ENSG00000231305.3 RP11-723O4.2 5.5 7.48e-08 3.73e-05 0.32 0.29 IgG glycosylation; chr3:128939872 chr3:128861313~128871540:- LIHC cis rs1577917 0.545 rs7755958 ENSG00000234155.1 RP11-30P6.6 -5.5 7.5e-08 3.74e-05 -0.33 -0.29 Response to antipsychotic treatment; chr6:85778793 chr6:85387219~85390186:- LIHC cis rs1577917 0.839 rs1596990 ENSG00000234155.1 RP11-30P6.6 5.5 7.52e-08 3.75e-05 0.34 0.28 Response to antipsychotic treatment; chr6:85840974 chr6:85387219~85390186:- LIHC cis rs1577917 0.916 rs12661611 ENSG00000234155.1 RP11-30P6.6 5.5 7.52e-08 3.75e-05 0.34 0.28 Response to antipsychotic treatment; chr6:85844117 chr6:85387219~85390186:- LIHC cis rs1577917 0.637 rs1838957 ENSG00000234155.1 RP11-30P6.6 5.5 7.52e-08 3.75e-05 0.34 0.28 Response to antipsychotic treatment; chr6:85855338 chr6:85387219~85390186:- LIHC cis rs1577917 0.839 rs1838956 ENSG00000234155.1 RP11-30P6.6 5.5 7.52e-08 3.75e-05 0.34 0.28 Response to antipsychotic treatment; chr6:85855545 chr6:85387219~85390186:- LIHC cis rs1577917 0.839 rs12216103 ENSG00000234155.1 RP11-30P6.6 5.5 7.52e-08 3.75e-05 0.34 0.28 Response to antipsychotic treatment; chr6:85861410 chr6:85387219~85390186:- LIHC cis rs7916697 0.578 rs4745951 ENSG00000233590.1 RP11-153K11.3 5.5 7.52e-08 3.75e-05 0.36 0.28 Optic disc area; chr10:68236867 chr10:68233251~68242379:- LIHC cis rs10170846 0.893 rs1447108 ENSG00000261428.2 RP11-16P6.1 5.5 7.53e-08 3.75e-05 0.29 0.28 Schizophrenia (inflammation and infection response interaction); chr2:222677512 chr2:222566899~222569719:- LIHC cis rs7119038 0.509 rs10892258 ENSG00000255239.1 AP002954.6 5.5 7.53e-08 3.75e-05 0.37 0.28 Sjögren's syndrome; chr11:118709156 chr11:118688039~118690600:- LIHC cis rs6683071 0.688 rs2378604 ENSG00000272750.1 RP11-378J18.8 -5.5 7.54e-08 3.76e-05 -0.33 -0.28 Cognitive performance; chr1:222730968 chr1:222658867~222661512:- LIHC cis rs2072510 0.722 rs2540489 ENSG00000257715.1 RP11-256L6.2 -5.5 7.55e-08 3.76e-05 -0.29 -0.28 Metabolite levels (small molecules and protein measures); chr12:96032724 chr12:96025323~96027971:+ LIHC cis rs2072510 0.683 rs2246990 ENSG00000257715.1 RP11-256L6.2 -5.5 7.55e-08 3.76e-05 -0.29 -0.28 Metabolite levels (small molecules and protein measures); chr12:96033524 chr12:96025323~96027971:+ LIHC cis rs887829 0.641 rs10197460 ENSG00000233445.1 RPL17P11 5.5 7.55e-08 3.76e-05 0.3 0.28 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233680544 chr2:233721522~233722065:- LIHC cis rs887829 0.641 rs10167119 ENSG00000233445.1 RPL17P11 5.5 7.55e-08 3.76e-05 0.3 0.28 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233680666 chr2:233721522~233722065:- LIHC cis rs929596 0.501 rs4530361 ENSG00000233445.1 RPL17P11 5.5 7.55e-08 3.76e-05 0.3 0.28 Total bilirubin levels in HIV-1 infection; chr2:233681395 chr2:233721522~233722065:- LIHC cis rs887829 0.641 rs7586110 ENSG00000233445.1 RPL17P11 5.5 7.55e-08 3.76e-05 0.3 0.28 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233681881 chr2:233721522~233722065:- LIHC cis rs2283792 1 rs5749806 ENSG00000224086.5 LL22NC03-86G7.1 -5.5 7.56e-08 3.76e-05 -0.26 -0.28 Multiple sclerosis; chr22:21752329 chr22:21938293~21977632:+ LIHC cis rs150992 0.655 rs327807 ENSG00000248489.1 CTD-2007H13.3 -5.5 7.57e-08 3.77e-05 -0.41 -0.28 Body mass index; chr5:98942448 chr5:98929171~98995013:+ LIHC cis rs11676348 0.818 rs1126579 ENSG00000261338.2 RP11-378A13.1 -5.5 7.58e-08 3.77e-05 -0.29 -0.28 Ulcerative colitis; chr2:218136011 chr2:218255319~218257366:+ LIHC cis rs9322193 0.923 rs4869750 ENSG00000223701.3 RAET1E-AS1 5.5 7.59e-08 3.78e-05 0.37 0.28 Lung cancer; chr6:149855996 chr6:149884431~149919508:+ LIHC cis rs17507216 0.681 rs28877110 ENSG00000278603.1 RP13-608F4.5 5.5 7.59e-08 3.78e-05 0.6 0.28 Excessive daytime sleepiness; chr15:82672111 chr15:82472203~82472426:+ LIHC cis rs831571 0.668 rs34723451 ENSG00000280620.1 SCAANT1 5.5 7.59e-08 3.78e-05 0.42 0.28 Type 2 diabetes; chr3:64096160 chr3:63911518~63911772:- LIHC cis rs9487094 0.696 rs11153188 ENSG00000260273.1 RP11-425D10.10 5.5 7.59e-08 3.78e-05 0.34 0.28 Height; chr6:109558247 chr6:109382795~109383666:+ LIHC cis rs6589219 0.788 rs11213823 ENSG00000196167.8 COLCA1 -5.5 7.59e-08 3.78e-05 -0.32 -0.28 Colorectal cancer; chr11:111299265 chr11:111290787~111305045:- LIHC cis rs2735413 0.563 rs11646833 ENSG00000276007.1 RP11-358L22.3 5.5 7.6e-08 3.78e-05 0.38 0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78023482 chr16:78123243~78124332:+ LIHC cis rs9532669 0.89 rs4941999 ENSG00000176268.5 CYCSP34 5.5 7.6e-08 3.78e-05 0.33 0.28 Cervical cancer; chr13:40859926 chr13:40863599~40863902:- LIHC cis rs5756813 0.715 rs5756825 ENSG00000233360.4 Z83844.1 -5.5 7.61e-08 3.79e-05 -0.34 -0.28 Optic cup area;Vertical cup-disc ratio; chr22:37803943 chr22:37641832~37658377:- LIHC cis rs2243480 1 rs59794892 ENSG00000226824.5 RP4-756H11.3 -5.5 7.62e-08 3.79e-05 -0.47 -0.28 Diabetic kidney disease; chr7:65950886 chr7:66654538~66669855:+ LIHC cis rs2243480 0.803 rs36004293 ENSG00000226824.5 RP4-756H11.3 -5.5 7.62e-08 3.79e-05 -0.47 -0.28 Diabetic kidney disease; chr7:65951525 chr7:66654538~66669855:+ LIHC cis rs2243480 0.803 rs35268390 ENSG00000226824.5 RP4-756H11.3 -5.5 7.62e-08 3.79e-05 -0.47 -0.28 Diabetic kidney disease; chr7:65951549 chr7:66654538~66669855:+ LIHC cis rs1005277 0.579 rs2474587 ENSG00000263064.2 RP11-291L22.7 5.5 7.63e-08 3.8e-05 0.29 0.28 Extrinsic epigenetic age acceleration; chr10:38131738 chr10:38448689~38448949:+ LIHC cis rs1005277 0.579 rs2474588 ENSG00000263064.2 RP11-291L22.7 5.5 7.63e-08 3.8e-05 0.29 0.28 Extrinsic epigenetic age acceleration; chr10:38131942 chr10:38448689~38448949:+ LIHC cis rs11676348 0.846 rs4674260 ENSG00000261338.2 RP11-378A13.1 -5.5 7.64e-08 3.8e-05 -0.29 -0.28 Ulcerative colitis; chr2:218137653 chr2:218255319~218257366:+ LIHC cis rs11690935 0.921 rs6710698 ENSG00000228389.1 AC068039.4 5.49 7.65e-08 3.8e-05 0.37 0.28 Schizophrenia; chr2:171739568 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs10184866 ENSG00000228389.1 AC068039.4 5.49 7.65e-08 3.8e-05 0.37 0.28 Schizophrenia; chr2:171752446 chr2:171773482~171775844:+ LIHC cis rs11098499 0.863 rs3736115 ENSG00000245958.5 RP11-33B1.1 5.49 7.66e-08 3.81e-05 0.3 0.28 Corneal astigmatism; chr4:119567548 chr4:119454791~119552025:+ LIHC cis rs875971 0.862 rs778736 ENSG00000237310.1 GS1-124K5.4 5.49 7.68e-08 3.81e-05 0.25 0.28 Aortic root size; chr7:66348861 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs2901152 ENSG00000237310.1 GS1-124K5.4 -5.49 7.68e-08 3.81e-05 -0.25 -0.28 Aortic root size; chr7:66300017 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs10263690 ENSG00000237310.1 GS1-124K5.4 -5.49 7.68e-08 3.81e-05 -0.25 -0.28 Aortic root size; chr7:66301466 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs10250544 ENSG00000237310.1 GS1-124K5.4 -5.49 7.68e-08 3.81e-05 -0.25 -0.28 Aortic root size; chr7:66301574 chr7:66493706~66495474:+ LIHC cis rs875971 0.895 rs12531677 ENSG00000237310.1 GS1-124K5.4 -5.49 7.68e-08 3.81e-05 -0.25 -0.28 Aortic root size; chr7:66304099 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs7798630 ENSG00000237310.1 GS1-124K5.4 -5.49 7.68e-08 3.81e-05 -0.25 -0.28 Aortic root size; chr7:66306492 chr7:66493706~66495474:+ LIHC cis rs875971 0.755 rs10228885 ENSG00000237310.1 GS1-124K5.4 -5.49 7.68e-08 3.81e-05 -0.25 -0.28 Aortic root size; chr7:66315542 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs3893216 ENSG00000237310.1 GS1-124K5.4 -5.49 7.68e-08 3.81e-05 -0.25 -0.28 Aortic root size; chr7:66325720 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6958294 ENSG00000237310.1 GS1-124K5.4 -5.49 7.68e-08 3.81e-05 -0.25 -0.28 Aortic root size; chr7:66329809 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs2088655 ENSG00000237310.1 GS1-124K5.4 -5.49 7.68e-08 3.81e-05 -0.25 -0.28 Aortic root size; chr7:66330724 chr7:66493706~66495474:+ LIHC cis rs875971 0.895 rs10447522 ENSG00000237310.1 GS1-124K5.4 -5.49 7.68e-08 3.81e-05 -0.25 -0.28 Aortic root size; chr7:66331087 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs2088653 ENSG00000237310.1 GS1-124K5.4 -5.49 7.68e-08 3.81e-05 -0.25 -0.28 Aortic root size; chr7:66343621 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6460293 ENSG00000237310.1 GS1-124K5.4 -5.49 7.68e-08 3.81e-05 -0.25 -0.28 Aortic root size; chr7:66345205 chr7:66493706~66495474:+ LIHC cis rs6921919 0.583 rs35560946 ENSG00000216901.1 AL022393.7 5.49 7.7e-08 3.82e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28427660 chr6:28176188~28176674:+ LIHC cis rs6686842 0.864 rs6662279 ENSG00000235358.1 RP11-399E6.1 -5.49 7.7e-08 3.82e-05 -0.31 -0.28 Height; chr1:41087889 chr1:41242373~41284861:+ LIHC cis rs853679 0.517 rs9283884 ENSG00000219392.1 RP1-265C24.5 5.49 7.71e-08 3.83e-05 0.45 0.28 Depression; chr6:28167882 chr6:28115628~28116551:+ LIHC cis rs7914558 0.932 rs4307650 ENSG00000236937.2 PTGES3P4 5.49 7.71e-08 3.83e-05 0.34 0.28 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103200095 chr10:102845595~102845950:+ LIHC cis rs4731207 0.596 rs6466968 ENSG00000224897.5 POT1-AS1 -5.49 7.72e-08 3.83e-05 -0.34 -0.28 Cutaneous malignant melanoma; chr7:124943303 chr7:124929873~125179315:+ LIHC cis rs2072510 0.722 rs763874 ENSG00000257715.1 RP11-256L6.2 -5.49 7.72e-08 3.83e-05 -0.29 -0.28 Metabolite levels (small molecules and protein measures); chr12:96026435 chr12:96025323~96027971:+ LIHC cis rs2243480 0.901 rs57126451 ENSG00000226824.5 RP4-756H11.3 -5.49 7.74e-08 3.84e-05 -0.47 -0.28 Diabetic kidney disease; chr7:65951319 chr7:66654538~66669855:+ LIHC cis rs950776 0.518 rs2292117 ENSG00000261762.1 RP11-650L12.2 5.49 7.77e-08 3.86e-05 0.37 0.28 Sudden cardiac arrest; chr15:78542347 chr15:78589123~78591276:- LIHC cis rs11098499 0.908 rs11098527 ENSG00000245958.5 RP11-33B1.1 -5.49 7.77e-08 3.86e-05 -0.29 -0.28 Corneal astigmatism; chr4:119478751 chr4:119454791~119552025:+ LIHC cis rs11722779 0.81 rs223417 ENSG00000230069.3 LRRC37A15P -5.49 7.78e-08 3.86e-05 -0.26 -0.28 Schizophrenia; chr4:102810568 chr4:102727274~102730721:- LIHC cis rs11722779 0.805 rs223416 ENSG00000230069.3 LRRC37A15P -5.49 7.78e-08 3.86e-05 -0.26 -0.28 Schizophrenia; chr4:102810580 chr4:102727274~102730721:- LIHC cis rs1150668 0.83 rs2531831 ENSG00000204709.4 LINC01556 5.49 7.78e-08 3.86e-05 0.32 0.28 Pubertal anthropometrics; chr6:28420988 chr6:28943877~28944537:+ LIHC cis rs6589219 0.908 rs3087967 ENSG00000196167.8 COLCA1 -5.49 7.78e-08 3.86e-05 -0.32 -0.28 Colorectal cancer; chr11:111286111 chr11:111290787~111305045:- LIHC cis rs875971 0.545 rs17138156 ENSG00000237310.1 GS1-124K5.4 5.49 7.78e-08 3.86e-05 0.27 0.28 Aortic root size; chr7:66249708 chr7:66493706~66495474:+ LIHC cis rs7119038 0.509 rs11216964 ENSG00000255239.1 AP002954.6 -5.49 7.78e-08 3.86e-05 -0.38 -0.28 Sjögren's syndrome; chr11:118711186 chr11:118688039~118690600:- LIHC cis rs7119038 0.509 rs10892259 ENSG00000255239.1 AP002954.6 -5.49 7.78e-08 3.86e-05 -0.38 -0.28 Sjögren's syndrome; chr11:118712293 chr11:118688039~118690600:- LIHC cis rs12681287 0.64 rs12549332 ENSG00000250569.1 NTAN1P2 5.49 7.78e-08 3.86e-05 0.34 0.28 Caudate activity during reward; chr8:86341163 chr8:86481754~86483002:- LIHC cis rs6921919 0.583 rs16894108 ENSG00000216901.1 AL022393.7 5.49 7.79e-08 3.86e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28434013 chr6:28176188~28176674:+ LIHC cis rs227275 0.524 rs150894 ENSG00000230069.3 LRRC37A15P -5.49 7.79e-08 3.86e-05 -0.26 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102811541 chr4:102727274~102730721:- LIHC cis rs7119038 0.509 rs11216961 ENSG00000255239.1 AP002954.6 -5.49 7.79e-08 3.86e-05 -0.38 -0.28 Sjögren's syndrome; chr11:118709629 chr11:118688039~118690600:- LIHC cis rs875971 0.545 rs66594357 ENSG00000237310.1 GS1-124K5.4 5.49 7.8e-08 3.87e-05 0.27 0.28 Aortic root size; chr7:66327797 chr7:66493706~66495474:+ LIHC cis rs4535700 0.501 rs2135116 ENSG00000226278.1 PSPHP1 5.49 7.81e-08 3.87e-05 0.34 0.28 Macular telangiectasia type 2; chr7:55923451 chr7:55764797~55773288:+ LIHC cis rs11722779 0.692 rs223414 ENSG00000230069.3 LRRC37A15P -5.49 7.82e-08 3.88e-05 -0.26 -0.28 Schizophrenia; chr4:102811688 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223405 ENSG00000230069.3 LRRC37A15P -5.49 7.84e-08 3.88e-05 -0.26 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102815894 chr4:102727274~102730721:- LIHC cis rs1577917 0.71 rs1059306 ENSG00000234155.1 RP11-30P6.6 -5.49 7.84e-08 3.89e-05 -0.36 -0.28 Response to antipsychotic treatment; chr6:85678391 chr6:85387219~85390186:- LIHC cis rs2243480 1 rs781157 ENSG00000226824.5 RP4-756H11.3 -5.49 7.86e-08 3.89e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66013324 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs781156 ENSG00000226824.5 RP4-756H11.3 -5.49 7.86e-08 3.89e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66014154 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs781149 ENSG00000226824.5 RP4-756H11.3 -5.49 7.86e-08 3.89e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66016297 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs451396 ENSG00000226824.5 RP4-756H11.3 -5.49 7.86e-08 3.89e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66019087 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs58207111 ENSG00000226824.5 RP4-756H11.3 -5.49 7.86e-08 3.89e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66021736 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1167613 ENSG00000226824.5 RP4-756H11.3 -5.49 7.86e-08 3.89e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66022452 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1715235 ENSG00000226824.5 RP4-756H11.3 -5.49 7.86e-08 3.89e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66023407 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs313799 ENSG00000226824.5 RP4-756H11.3 -5.49 7.86e-08 3.89e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66029343 chr7:66654538~66669855:+ LIHC cis rs7131987 0.834 rs12228468 ENSG00000257176.2 RP11-996F15.2 5.49 7.86e-08 3.89e-05 0.32 0.28 QT interval; chr12:29300677 chr12:29280418~29317848:- LIHC cis rs12571093 0.803 rs61854829 ENSG00000233590.1 RP11-153K11.3 -5.49 7.86e-08 3.89e-05 -0.45 -0.28 Optic nerve measurement (disc area); chr10:68273286 chr10:68233251~68242379:- LIHC cis rs1023500 0.505 rs134901 ENSG00000227370.1 RP4-669P10.19 -5.49 7.87e-08 3.9e-05 -0.3 -0.28 Schizophrenia; chr22:42287514 chr22:42132543~42132998:+ LIHC cis rs2880765 0.545 rs17553734 ENSG00000259295.5 CSPG4P12 -5.49 7.88e-08 3.9e-05 -0.39 -0.28 Coronary artery disease; chr15:85469828 chr15:85191438~85213905:+ LIHC cis rs875971 0.825 rs6951503 ENSG00000237310.1 GS1-124K5.4 -5.49 7.88e-08 3.9e-05 -0.25 -0.28 Aortic root size; chr7:66253949 chr7:66493706~66495474:+ LIHC cis rs8059260 0.736 rs16957883 ENSG00000274038.1 RP11-66H6.4 -5.49 7.89e-08 3.9e-05 -0.47 -0.28 Alcohol consumption over the past year; chr16:10994788 chr16:11056556~11057034:+ LIHC cis rs150992 0.504 rs7723242 ENSG00000248489.1 CTD-2007H13.3 -5.49 7.89e-08 3.91e-05 -0.45 -0.28 Body mass index; chr5:99023408 chr5:98929171~98995013:+ LIHC cis rs150992 0.504 rs7719562 ENSG00000248489.1 CTD-2007H13.3 -5.49 7.89e-08 3.91e-05 -0.45 -0.28 Body mass index; chr5:99029419 chr5:98929171~98995013:+ LIHC cis rs150992 0.504 rs4583911 ENSG00000248489.1 CTD-2007H13.3 -5.49 7.89e-08 3.91e-05 -0.45 -0.28 Body mass index; chr5:99031401 chr5:98929171~98995013:+ LIHC cis rs150992 0.537 rs1604450 ENSG00000248489.1 CTD-2007H13.3 -5.49 7.89e-08 3.91e-05 -0.45 -0.28 Body mass index; chr5:99036274 chr5:98929171~98995013:+ LIHC cis rs150992 0.504 rs7719649 ENSG00000248489.1 CTD-2007H13.3 5.49 7.89e-08 3.91e-05 0.45 0.28 Body mass index; chr5:99036711 chr5:98929171~98995013:+ LIHC cis rs638893 1 rs28827279 ENSG00000255422.1 AP002954.4 -5.49 7.9e-08 3.91e-05 -0.46 -0.28 Vitiligo; chr11:118830054 chr11:118704607~118750263:+ LIHC cis rs2243480 1 rs10807702 ENSG00000226824.5 RP4-756H11.3 -5.49 7.92e-08 3.92e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66302856 chr7:66654538~66669855:+ LIHC cis rs5756813 0.833 rs5756819 ENSG00000233360.4 Z83844.1 -5.49 7.93e-08 3.92e-05 -0.35 -0.28 Optic cup area;Vertical cup-disc ratio; chr22:37792188 chr22:37641832~37658377:- LIHC cis rs1062177 0.855 rs919263 ENSG00000213433.5 RPLP1P6 -5.49 7.94e-08 3.93e-05 -0.3 -0.28 Preschool internalizing problems; chr5:151886292 chr5:151765859~151766378:- LIHC cis rs4934494 0.768 rs17125834 ENSG00000232936.4 RP11-80H5.2 5.49 7.94e-08 3.93e-05 0.36 0.28 Red blood cell count; chr10:89673405 chr10:89645282~89650667:+ LIHC cis rs4934494 0.768 rs12571918 ENSG00000232936.4 RP11-80H5.2 5.49 7.94e-08 3.93e-05 0.36 0.28 Red blood cell count; chr10:89674920 chr10:89645282~89650667:+ LIHC cis rs4934494 0.768 rs12776306 ENSG00000232936.4 RP11-80H5.2 5.49 7.94e-08 3.93e-05 0.36 0.28 Red blood cell count; chr10:89676300 chr10:89645282~89650667:+ LIHC cis rs4934494 0.768 rs7078321 ENSG00000232936.4 RP11-80H5.2 5.49 7.94e-08 3.93e-05 0.36 0.28 Red blood cell count; chr10:89678341 chr10:89645282~89650667:+ LIHC cis rs4934494 0.768 rs34379399 ENSG00000232936.4 RP11-80H5.2 5.49 7.94e-08 3.93e-05 0.36 0.28 Red blood cell count; chr10:89683526 chr10:89645282~89650667:+ LIHC cis rs7731783 1 rs7731783 ENSG00000247679.2 RP11-1277A3.1 5.49 7.95e-08 3.93e-05 0.34 0.28 Methadone dose in opioid dependence; chr5:177633311 chr5:177611253~177619754:+ LIHC cis rs11992162 1 rs7460395 ENSG00000255394.4 C8orf49 5.49 7.96e-08 3.94e-05 0.39 0.28 Monocyte count; chr8:11977866 chr8:11761256~11763223:+ LIHC cis rs875971 0.545 rs6460281 ENSG00000237310.1 GS1-124K5.4 5.49 7.96e-08 3.94e-05 0.27 0.28 Aortic root size; chr7:66216128 chr7:66493706~66495474:+ LIHC cis rs1075265 0.528 rs2018747 ENSG00000233266.1 HMGB1P31 5.49 7.97e-08 3.94e-05 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:54082487 chr2:54051334~54051760:+ LIHC cis rs7811142 0.562 rs7786844 ENSG00000242294.5 STAG3L5P 5.49 7.98e-08 3.95e-05 0.29 0.28 Platelet count; chr7:100336385 chr7:100336079~100351900:+ LIHC cis rs9318086 0.712 rs1886970 ENSG00000205861.10 C1QTNF9B-AS1 -5.49 7.99e-08 3.95e-05 -0.32 -0.28 Myopia (pathological); chr13:23866359 chr13:23888889~23897263:+ LIHC cis rs496547 0.719 rs598373 ENSG00000255422.1 AP002954.4 -5.49 8e-08 3.95e-05 -0.33 -0.28 Hip minimal joint space width; chr11:118793668 chr11:118704607~118750263:+ LIHC cis rs7429990 0.965 rs319689 ENSG00000229759.1 MRPS18AP1 5.49 8e-08 3.96e-05 0.29 0.28 Educational attainment (years of education); chr3:47886677 chr3:48256350~48256938:- LIHC cis rs12291225 0.546 rs12795545 ENSG00000251991.1 RNU7-49P 5.49 8.02e-08 3.97e-05 0.3 0.28 Sense of smell; chr11:14334018 chr11:14478892~14478953:+ LIHC cis rs2072510 0.722 rs2540490 ENSG00000257715.1 RP11-256L6.2 -5.49 8.02e-08 3.97e-05 -0.29 -0.28 Metabolite levels (small molecules and protein measures); chr12:96032494 chr12:96025323~96027971:+ LIHC cis rs950169 0.65 rs12902052 ENSG00000225151.9 GOLGA2P7 -5.49 8.02e-08 3.97e-05 -0.37 -0.28 Schizophrenia; chr15:84582607 chr15:84199311~84230136:- LIHC cis rs1005277 0.505 rs10827835 ENSG00000263064.2 RP11-291L22.7 -5.49 8.03e-08 3.97e-05 -0.29 -0.28 Extrinsic epigenetic age acceleration; chr10:37861781 chr10:38448689~38448949:+ LIHC cis rs17507216 0.588 rs28864981 ENSG00000278603.1 RP13-608F4.5 5.49 8.03e-08 3.97e-05 0.59 0.28 Excessive daytime sleepiness; chr15:82695420 chr15:82472203~82472426:+ LIHC cis rs7916697 0.593 rs10762198 ENSG00000233590.1 RP11-153K11.3 5.49 8.04e-08 3.97e-05 0.34 0.28 Optic disc area; chr10:68263296 chr10:68233251~68242379:- LIHC cis rs9388451 0.807 rs1268070 ENSG00000237742.5 RP11-624M8.1 -5.49 8.05e-08 3.98e-05 -0.27 -0.28 Brugada syndrome; chr6:125720018 chr6:125578558~125749190:- LIHC cis rs116175783 0.557 rs62197071 ENSG00000227403.1 AC009299.3 5.48 8.07e-08 3.99e-05 0.43 0.28 Intelligence (multi-trait analysis); chr2:161292703 chr2:161244739~161249050:+ LIHC cis rs116175783 0.557 rs16845757 ENSG00000227403.1 AC009299.3 5.48 8.07e-08 3.99e-05 0.43 0.28 Intelligence (multi-trait analysis); chr2:161299749 chr2:161244739~161249050:+ LIHC cis rs7927592 0.645 rs7950900 ENSG00000212093.1 AP000807.1 5.48 8.07e-08 3.99e-05 0.3 0.28 Total body bone mineral density; chr11:68526077 chr11:68506083~68506166:- LIHC cis rs62229266 0.587 rs62229264 ENSG00000231106.2 LINC01436 5.48 8.08e-08 3.99e-05 0.32 0.28 Mitral valve prolapse; chr21:36079915 chr21:36005338~36007838:+ LIHC cis rs6921919 0.583 rs9468367 ENSG00000216901.1 AL022393.7 5.48 8.09e-08 3.99e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28392469 chr6:28176188~28176674:+ LIHC cis rs2243480 1 rs313813 ENSG00000226824.5 RP4-756H11.3 -5.48 8.09e-08 4e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66038513 chr7:66654538~66669855:+ LIHC cis rs2153535 0.542 rs9505465 ENSG00000230939.1 RP11-314C16.1 -5.48 8.1e-08 4e-05 -0.35 -0.28 Motion sickness; chr6:8510613 chr6:8784178~8785445:+ LIHC cis rs2739330 0.828 rs4820572 ENSG00000099984.9 GSTT2 -5.48 8.11e-08 4e-05 -0.33 -0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23980123~23983911:+ LIHC cis rs950169 0.922 rs4338765 ENSG00000225151.9 GOLGA2P7 -5.48 8.12e-08 4.01e-05 -0.35 -0.28 Schizophrenia; chr15:84248084 chr15:84199311~84230136:- LIHC cis rs2283792 1 rs5749986 ENSG00000224086.5 LL22NC03-86G7.1 5.48 8.12e-08 4.01e-05 0.26 0.28 Multiple sclerosis; chr22:21803372 chr22:21938293~21977632:+ LIHC cis rs227275 0.554 rs149576 ENSG00000230069.3 LRRC37A15P -5.48 8.12e-08 4.01e-05 -0.26 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102811411 chr4:102727274~102730721:- LIHC cis rs11722779 0.873 rs223346 ENSG00000230069.3 LRRC37A15P -5.48 8.13e-08 4.01e-05 -0.25 -0.28 Schizophrenia; chr4:102859339 chr4:102727274~102730721:- LIHC cis rs887829 0.667 rs7577677 ENSG00000233445.1 RPL17P11 5.48 8.13e-08 4.01e-05 0.3 0.28 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233681970 chr2:233721522~233722065:- LIHC cis rs1005277 0.54 rs1987431 ENSG00000263064.2 RP11-291L22.7 5.48 8.14e-08 4.02e-05 0.29 0.28 Extrinsic epigenetic age acceleration; chr10:37699959 chr10:38448689~38448949:+ LIHC cis rs2283792 1 rs6928 ENSG00000224086.5 LL22NC03-86G7.1 -5.48 8.14e-08 4.02e-05 -0.26 -0.28 Multiple sclerosis; chr22:21760715 chr22:21938293~21977632:+ LIHC cis rs2933343 0.533 rs13086121 ENSG00000231305.3 RP11-723O4.2 5.48 8.17e-08 4.03e-05 0.32 0.28 IgG glycosylation; chr3:128985447 chr3:128861313~128871540:- LIHC cis rs12468226 0.938 rs3731700 ENSG00000273456.1 RP11-686O6.2 5.48 8.18e-08 4.03e-05 0.41 0.28 Urate levels; chr2:202291213 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs12464254 ENSG00000273456.1 RP11-686O6.2 5.48 8.18e-08 4.03e-05 0.41 0.28 Urate levels; chr2:202301641 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs12471060 ENSG00000273456.1 RP11-686O6.2 5.48 8.18e-08 4.03e-05 0.41 0.28 Urate levels; chr2:202309597 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs80315897 ENSG00000273456.1 RP11-686O6.2 5.48 8.18e-08 4.03e-05 0.41 0.28 Urate levels; chr2:202318044 chr2:202374932~202375604:- LIHC cis rs879620 1 rs879620 ENSG00000262185.1 RP11-462G12.1 5.48 8.18e-08 4.04e-05 0.36 0.28 Hip circumference;Body mass index; chr16:3965728 chr16:3947609~3950444:- LIHC cis rs2243480 1 rs781150 ENSG00000226824.5 RP4-756H11.3 -5.48 8.19e-08 4.04e-05 -0.47 -0.28 Diabetic kidney disease; chr7:66015986 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs313798 ENSG00000226824.5 RP4-756H11.3 -5.48 8.19e-08 4.04e-05 -0.47 -0.28 Diabetic kidney disease; chr7:66028044 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs35396113 ENSG00000226824.5 RP4-756H11.3 -5.48 8.19e-08 4.04e-05 -0.47 -0.28 Diabetic kidney disease; chr7:66030474 chr7:66654538~66669855:+ LIHC cis rs9487094 0.689 rs9487064 ENSG00000260273.1 RP11-425D10.10 5.48 8.19e-08 4.04e-05 0.34 0.28 Height; chr6:109346560 chr6:109382795~109383666:+ LIHC cis rs7927592 0.956 rs7104877 ENSG00000212093.1 AP000807.1 -5.48 8.2e-08 4.04e-05 -0.31 -0.28 Total body bone mineral density; chr11:68610134 chr11:68506083~68506166:- LIHC cis rs2153535 0.58 rs9328484 ENSG00000230939.1 RP11-314C16.1 -5.48 8.21e-08 4.05e-05 -0.35 -0.28 Motion sickness; chr6:8524610 chr6:8784178~8785445:+ LIHC cis rs4934494 0.768 rs17126269 ENSG00000232936.4 RP11-80H5.2 5.48 8.22e-08 4.05e-05 0.36 0.28 Red blood cell count; chr10:89694974 chr10:89645282~89650667:+ LIHC cis rs4934494 0.768 rs768805 ENSG00000232936.4 RP11-80H5.2 5.48 8.22e-08 4.05e-05 0.36 0.28 Red blood cell count; chr10:89695448 chr10:89645282~89650667:+ LIHC cis rs4356203 0.905 rs7927240 ENSG00000272034.1 SNORD14A -5.48 8.23e-08 4.05e-05 -0.31 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17056681 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs7946165 ENSG00000272034.1 SNORD14A -5.48 8.23e-08 4.05e-05 -0.31 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17057080 chr11:17074654~17074744:- LIHC cis rs4356203 0.875 rs7939614 ENSG00000272034.1 SNORD14A -5.48 8.23e-08 4.05e-05 -0.31 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17058073 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs9919600 ENSG00000272034.1 SNORD14A -5.48 8.23e-08 4.05e-05 -0.31 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17058198 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs9919540 ENSG00000272034.1 SNORD14A -5.48 8.23e-08 4.05e-05 -0.31 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17058786 chr11:17074654~17074744:- LIHC cis rs7714584 1 rs76433514 ENSG00000197083.10 ZNF300P1 5.48 8.23e-08 4.06e-05 0.44 0.28 Crohn's disease; chr5:150926970 chr5:150930645~150946289:- LIHC cis rs228614 0.51 rs223412 ENSG00000230069.3 LRRC37A15P -5.48 8.24e-08 4.06e-05 -0.26 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102812443 chr4:102727274~102730721:- LIHC cis rs3096299 0.685 rs4785568 ENSG00000261118.1 RP11-104N10.1 5.48 8.24e-08 4.06e-05 0.28 0.28 Multiple myeloma (IgH translocation); chr16:89487299 chr16:89492017~89504460:- LIHC cis rs2836950 0.772 rs62222988 ENSG00000255568.3 BRWD1-AS2 -5.48 8.24e-08 4.06e-05 -0.26 -0.28 Menarche (age at onset); chr21:39197582 chr21:39313935~39314962:+ LIHC cis rs2842992 1 rs2758322 ENSG00000237927.1 RP3-393E18.2 -5.48 8.26e-08 4.07e-05 -0.35 -0.28 Age-related macular degeneration (geographic atrophy); chr6:159654156 chr6:159586955~159589169:- LIHC cis rs2283792 1 rs2283792 ENSG00000224086.5 LL22NC03-86G7.1 -5.48 8.27e-08 4.07e-05 -0.26 -0.28 Multiple sclerosis; chr22:21776836 chr22:21938293~21977632:+ LIHC cis rs6921919 0.515 rs1558205 ENSG00000216901.1 AL022393.7 -5.48 8.27e-08 4.07e-05 -0.35 -0.28 Autism spectrum disorder or schizophrenia; chr6:28414485 chr6:28176188~28176674:+ LIHC cis rs11676348 0.729 rs13013361 ENSG00000261338.2 RP11-378A13.1 -5.48 8.28e-08 4.08e-05 -0.29 -0.28 Ulcerative colitis; chr2:218082792 chr2:218255319~218257366:+ LIHC cis rs5769707 0.632 rs135877 ENSG00000235111.1 RP1-29C18.8 -5.48 8.3e-08 4.08e-05 -0.34 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49620354 chr22:49612657~49615716:- LIHC cis rs496547 0.52 rs11216963 ENSG00000255239.1 AP002954.6 -5.48 8.3e-08 4.08e-05 -0.38 -0.28 Hip minimal joint space width; chr11:118710105 chr11:118688039~118690600:- LIHC cis rs17711722 0.565 rs4717276 ENSG00000228409.4 CCT6P1 -5.48 8.31e-08 4.09e-05 -0.22 -0.28 Calcium levels; chr7:65829754 chr7:65751142~65763354:+ LIHC cis rs5758659 1 rs134882 ENSG00000227370.1 RP4-669P10.19 -5.48 8.31e-08 4.09e-05 -0.32 -0.28 Cognitive function; chr22:42274959 chr22:42132543~42132998:+ LIHC cis rs7714584 1 rs11747065 ENSG00000197083.10 ZNF300P1 5.48 8.31e-08 4.09e-05 0.44 0.28 Crohn's disease; chr5:150915924 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs11740172 ENSG00000197083.10 ZNF300P1 5.48 8.31e-08 4.09e-05 0.44 0.28 Crohn's disease; chr5:150920716 chr5:150930645~150946289:- LIHC cis rs2243480 1 rs313814 ENSG00000226824.5 RP4-756H11.3 -5.48 8.32e-08 4.09e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66038306 chr7:66654538~66669855:+ LIHC cis rs11098499 0.954 rs12508504 ENSG00000245958.5 RP11-33B1.1 -5.48 8.33e-08 4.09e-05 -0.29 -0.28 Corneal astigmatism; chr4:119489452 chr4:119454791~119552025:+ LIHC cis rs2243480 1 rs6966322 ENSG00000226824.5 RP4-756H11.3 5.48 8.33e-08 4.1e-05 0.46 0.28 Diabetic kidney disease; chr7:66181767 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs4145008 ENSG00000226824.5 RP4-756H11.3 5.48 8.33e-08 4.1e-05 0.46 0.28 Diabetic kidney disease; chr7:66182524 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs4718315 ENSG00000226824.5 RP4-756H11.3 5.48 8.33e-08 4.1e-05 0.46 0.28 Diabetic kidney disease; chr7:66183554 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs4718316 ENSG00000226824.5 RP4-756H11.3 5.48 8.33e-08 4.1e-05 0.46 0.28 Diabetic kidney disease; chr7:66183744 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1873494 ENSG00000226824.5 RP4-756H11.3 5.48 8.33e-08 4.1e-05 0.46 0.28 Diabetic kidney disease; chr7:66184912 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs6959002 ENSG00000226824.5 RP4-756H11.3 5.48 8.33e-08 4.1e-05 0.46 0.28 Diabetic kidney disease; chr7:66185509 chr7:66654538~66669855:+ LIHC cis rs6504950 0.548 rs714896 ENSG00000275710.1 RP11-257O5.4 5.48 8.35e-08 4.11e-05 0.48 0.28 Breast cancer; chr17:55179621 chr17:54964474~54964679:+ LIHC cis rs6504950 0.579 rs7212321 ENSG00000275710.1 RP11-257O5.4 5.48 8.35e-08 4.11e-05 0.48 0.28 Breast cancer; chr17:55181076 chr17:54964474~54964679:+ LIHC cis rs9318086 0.648 rs78881146 ENSG00000205861.10 C1QTNF9B-AS1 -5.48 8.36e-08 4.11e-05 -0.33 -0.28 Myopia (pathological); chr13:23894565 chr13:23888889~23897263:+ LIHC cis rs2072510 0.683 rs2660840 ENSG00000257715.1 RP11-256L6.2 -5.48 8.38e-08 4.12e-05 -0.29 -0.28 Metabolite levels (small molecules and protein measures); chr12:96038729 chr12:96025323~96027971:+ LIHC cis rs2243480 0.711 rs2420172 ENSG00000226824.5 RP4-756H11.3 5.48 8.4e-08 4.13e-05 0.46 0.28 Diabetic kidney disease; chr7:66170354 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs6974723 ENSG00000226824.5 RP4-756H11.3 5.48 8.4e-08 4.13e-05 0.46 0.28 Diabetic kidney disease; chr7:66172952 chr7:66654538~66669855:+ LIHC cis rs5769707 0.681 rs8137111 ENSG00000235111.1 RP1-29C18.8 -5.48 8.41e-08 4.13e-05 -0.35 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49650102 chr22:49612657~49615716:- LIHC cis rs62229266 0.572 rs4816518 ENSG00000231106.2 LINC01436 5.48 8.42e-08 4.14e-05 0.32 0.28 Mitral valve prolapse; chr21:36081009 chr21:36005338~36007838:+ LIHC cis rs2243480 1 rs9769882 ENSG00000226824.5 RP4-756H11.3 5.48 8.42e-08 4.14e-05 0.46 0.28 Diabetic kidney disease; chr7:66177938 chr7:66654538~66669855:+ LIHC cis rs12134133 1 rs2782842 ENSG00000274245.1 RP11-357P18.2 5.48 8.42e-08 4.14e-05 0.44 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207310231 chr1:207372559~207373252:+ LIHC cis rs9640161 0.789 rs28432021 ENSG00000261305.1 RP4-584D14.7 5.48 8.43e-08 4.14e-05 0.35 0.28 Blood protein levels;Circulating chemerin levels; chr7:150349146 chr7:150341771~150342607:+ LIHC cis rs9640161 0.789 rs28439010 ENSG00000261305.1 RP4-584D14.7 5.48 8.43e-08 4.14e-05 0.35 0.28 Blood protein levels;Circulating chemerin levels; chr7:150349187 chr7:150341771~150342607:+ LIHC cis rs12157904 0.793 rs8142714 ENSG00000233360.4 Z83844.1 5.48 8.47e-08 4.16e-05 0.58 0.28 Response to anti-depressant treatment in major depressive disorder; chr22:37641931 chr22:37641832~37658377:- LIHC cis rs7714584 1 rs11739677 ENSG00000197083.10 ZNF300P1 5.48 8.47e-08 4.16e-05 0.44 0.28 Crohn's disease; chr5:150915321 chr5:150930645~150946289:- LIHC cis rs4731207 0.689 rs1481341 ENSG00000224897.5 POT1-AS1 5.48 8.48e-08 4.16e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:124927069 chr7:124929873~125179315:+ LIHC cis rs1150668 0.83 rs2859365 ENSG00000204709.4 LINC01556 -5.48 8.48e-08 4.16e-05 -0.32 -0.28 Pubertal anthropometrics; chr6:28423688 chr6:28943877~28944537:+ LIHC cis rs2976388 0.524 rs7012804 ENSG00000253196.1 RP11-706C16.7 5.47 8.49e-08 4.17e-05 0.28 0.28 Urinary tract infection frequency; chr8:142763232 chr8:142763116~142766427:+ LIHC cis rs9487094 0.813 rs3799835 ENSG00000260273.1 RP11-425D10.10 5.47 8.49e-08 4.17e-05 0.39 0.28 Height; chr6:109372084 chr6:109382795~109383666:+ LIHC cis rs9487094 0.666 rs736830 ENSG00000260273.1 RP11-425D10.10 5.47 8.49e-08 4.17e-05 0.34 0.28 Height; chr6:109392096 chr6:109382795~109383666:+ LIHC cis rs11690935 0.959 rs6759575 ENSG00000228389.1 AC068039.4 5.47 8.49e-08 4.17e-05 0.38 0.28 Schizophrenia; chr2:171832558 chr2:171773482~171775844:+ LIHC cis rs2739330 0.828 rs5760107 ENSG00000099984.9 GSTT2 -5.47 8.5e-08 4.17e-05 -0.33 -0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23980123~23983911:+ LIHC cis rs2739330 0.731 rs5751792 ENSG00000228039.3 KB-1125A3.10 5.47 8.5e-08 4.17e-05 0.34 0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23963780~23964374:+ LIHC cis rs2243480 1 rs313807 ENSG00000226824.5 RP4-756H11.3 -5.47 8.51e-08 4.17e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66034494 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs313808 ENSG00000226824.5 RP4-756H11.3 -5.47 8.51e-08 4.17e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66034886 chr7:66654538~66669855:+ LIHC cis rs1005277 0.579 rs2505257 ENSG00000263064.2 RP11-291L22.7 5.47 8.51e-08 4.17e-05 0.29 0.28 Extrinsic epigenetic age acceleration; chr10:38083736 chr10:38448689~38448949:+ LIHC cis rs739496 0.843 rs688812 ENSG00000226469.1 ADAM1B 5.47 8.52e-08 4.18e-05 0.35 0.28 Platelet count; chr12:111524777 chr12:111927018~111929017:+ LIHC cis rs17301013 0.829 rs2006197 ENSG00000227373.4 RP11-160H22.5 5.47 8.52e-08 4.18e-05 0.36 0.28 Systemic lupus erythematosus; chr1:174432825 chr1:174115300~174160004:- LIHC cis rs875971 0.522 rs1617484 ENSG00000164669.11 INTS4P1 -5.47 8.54e-08 4.19e-05 -0.39 -0.28 Aortic root size; chr7:65998108 chr7:65141225~65234216:+ LIHC cis rs6480314 0.542 rs61854804 ENSG00000233590.1 RP11-153K11.3 -5.47 8.55e-08 4.2e-05 -0.45 -0.28 Optic nerve measurement (disc area); chr10:68255819 chr10:68233251~68242379:- LIHC cis rs524281 0.861 rs1862005 ENSG00000255320.1 RP11-755F10.1 5.47 8.57e-08 4.2e-05 0.37 0.28 Electroencephalogram traits; chr11:66095931 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs7935336 ENSG00000255320.1 RP11-755F10.1 5.47 8.57e-08 4.2e-05 0.37 0.28 Electroencephalogram traits; chr11:66097854 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs11227409 ENSG00000255320.1 RP11-755F10.1 5.47 8.57e-08 4.2e-05 0.37 0.28 Electroencephalogram traits; chr11:66103467 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs11607393 ENSG00000255320.1 RP11-755F10.1 5.47 8.57e-08 4.2e-05 0.37 0.28 Electroencephalogram traits; chr11:66107678 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs10896080 ENSG00000255320.1 RP11-755F10.1 5.47 8.57e-08 4.2e-05 0.37 0.28 Electroencephalogram traits; chr11:66109325 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs11227411 ENSG00000255320.1 RP11-755F10.1 5.47 8.57e-08 4.2e-05 0.37 0.28 Electroencephalogram traits; chr11:66112007 chr11:66244840~66246239:- LIHC cis rs62355901 0.599 rs10513090 ENSG00000271828.1 CTD-2310F14.1 -5.47 8.57e-08 4.2e-05 -0.51 -0.28 Breast cancer; chr5:56758238 chr5:56927874~56929573:+ LIHC cis rs2842992 0.83 rs2025189 ENSG00000237927.1 RP3-393E18.2 -5.47 8.57e-08 4.2e-05 -0.35 -0.28 Age-related macular degeneration (geographic atrophy); chr6:159716486 chr6:159586955~159589169:- LIHC cis rs2842992 0.83 rs2495279 ENSG00000237927.1 RP3-393E18.2 -5.47 8.57e-08 4.2e-05 -0.35 -0.28 Age-related macular degeneration (geographic atrophy); chr6:159717764 chr6:159586955~159589169:- LIHC cis rs17711722 0.523 rs313812 ENSG00000228409.4 CCT6P1 5.47 8.58e-08 4.21e-05 0.22 0.28 Calcium levels; chr7:66040056 chr7:65751142~65763354:+ LIHC cis rs4934494 0.768 rs1409357 ENSG00000232936.4 RP11-80H5.2 5.47 8.58e-08 4.21e-05 0.36 0.28 Red blood cell count; chr10:89669719 chr10:89645282~89650667:+ LIHC cis rs7131987 0.617 rs3764953 ENSG00000275476.1 RP11-996F15.4 -5.47 8.59e-08 4.21e-05 -0.34 -0.28 QT interval; chr12:29349303 chr12:29277397~29277882:- LIHC cis rs1577917 0.839 rs6454504 ENSG00000234155.1 RP11-30P6.6 5.47 8.61e-08 4.22e-05 0.34 0.28 Response to antipsychotic treatment; chr6:85870612 chr6:85387219~85390186:- LIHC cis rs8072100 0.967 rs8074149 ENSG00000228782.6 CTD-2026D20.3 -5.47 8.61e-08 4.22e-05 -0.31 -0.28 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47506009 chr17:47450568~47492492:- LIHC cis rs11096990 0.593 rs35552004 ENSG00000249207.1 RP11-360F5.1 -5.47 8.62e-08 4.22e-05 -0.29 -0.28 Cognitive function; chr4:39170914 chr4:39112677~39126818:- LIHC cis rs4535700 0.501 rs28828764 ENSG00000226278.1 PSPHP1 5.47 8.63e-08 4.23e-05 0.34 0.28 Macular telangiectasia type 2; chr7:55920986 chr7:55764797~55773288:+ LIHC cis rs11722779 0.815 rs223347 ENSG00000230069.3 LRRC37A15P -5.47 8.63e-08 4.23e-05 -0.25 -0.28 Schizophrenia; chr4:102858815 chr4:102727274~102730721:- LIHC cis rs8100891 0.537 rs4805755 ENSG00000267213.4 AC007773.2 5.47 8.64e-08 4.23e-05 0.36 0.28 Neuroticism; chr19:32363564 chr19:32390050~32405560:- LIHC cis rs7131987 0.903 rs1035604 ENSG00000257176.2 RP11-996F15.2 -5.47 8.65e-08 4.24e-05 -0.33 -0.28 QT interval; chr12:29240169 chr12:29280418~29317848:- LIHC cis rs11690935 0.959 rs10803863 ENSG00000228389.1 AC068039.4 -5.47 8.65e-08 4.24e-05 -0.38 -0.28 Schizophrenia; chr2:171678827 chr2:171773482~171775844:+ LIHC cis rs11690935 1 rs12053003 ENSG00000228389.1 AC068039.4 -5.47 8.65e-08 4.24e-05 -0.38 -0.28 Schizophrenia; chr2:171680840 chr2:171773482~171775844:+ LIHC cis rs172166 0.585 rs149963 ENSG00000204709.4 LINC01556 5.47 8.67e-08 4.25e-05 0.32 0.28 Cardiac Troponin-T levels; chr6:28049354 chr6:28943877~28944537:+ LIHC cis rs8072100 0.817 rs7213086 ENSG00000228782.6 CTD-2026D20.3 5.47 8.67e-08 4.25e-05 0.31 0.28 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47674944 chr17:47450568~47492492:- LIHC cis rs8072100 0.967 rs62076549 ENSG00000228782.6 CTD-2026D20.3 -5.47 8.69e-08 4.25e-05 -0.31 -0.28 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47502189 chr17:47450568~47492492:- LIHC cis rs2880765 0.566 rs17553790 ENSG00000259295.5 CSPG4P12 -5.47 8.7e-08 4.26e-05 -0.39 -0.28 Coronary artery disease; chr15:85470434 chr15:85191438~85213905:+ LIHC cis rs8072100 0.817 rs11869940 ENSG00000228782.6 CTD-2026D20.3 -5.47 8.7e-08 4.26e-05 -0.31 -0.28 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47501069 chr17:47450568~47492492:- LIHC cis rs12468226 1 rs7565875 ENSG00000273456.1 RP11-686O6.2 5.47 8.71e-08 4.26e-05 0.4 0.28 Urate levels; chr2:202516412 chr2:202374932~202375604:- LIHC cis rs7945705 0.712 rs61876274 ENSG00000254860.4 TMEM9B-AS1 -5.47 8.71e-08 4.27e-05 -0.29 -0.28 Hemoglobin concentration; chr11:8997643 chr11:8964675~8977527:+ LIHC cis rs13631 0.965 rs9411307 ENSG00000268996.3 MAN1B1-AS1 5.47 8.72e-08 4.27e-05 0.31 0.28 Cerebrospinal fluid biomarker levels; chr9:137100495 chr9:137084946~137086817:- LIHC cis rs875971 0.862 rs11763189 ENSG00000237310.1 GS1-124K5.4 5.47 8.73e-08 4.27e-05 0.25 0.28 Aortic root size; chr7:66518542 chr7:66493706~66495474:+ LIHC cis rs202072 0.872 rs377704 ENSG00000215022.6 RP1-257A7.4 -5.47 8.73e-08 4.27e-05 -0.33 -0.28 HIV-1 viral setpoint; chr6:13279787 chr6:13264861~13295586:- LIHC cis rs6921919 0.583 rs1054372 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28368965 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs9468354 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28370024 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs7773051 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28372539 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs12697938 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28373322 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs13437294 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28373758 chr6:28176188~28176674:+ LIHC cis rs6921919 0.609 rs9468357 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28374276 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs34513104 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28375566 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs9461456 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28376039 chr6:28176188~28176674:+ LIHC cis rs6921919 0.525 rs9468360 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28376661 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs16894021 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28377249 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs11751693 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28377306 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs7749736 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28378254 chr6:28176188~28176674:+ LIHC cis rs6921919 0.525 rs9468361 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28378541 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs7775132 ENSG00000216901.1 AL022393.7 5.47 8.73e-08 4.27e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28379236 chr6:28176188~28176674:+ LIHC cis rs9640161 0.871 rs56156367 ENSG00000261305.1 RP4-584D14.7 5.47 8.74e-08 4.28e-05 0.36 0.28 Blood protein levels;Circulating chemerin levels; chr7:150350112 chr7:150341771~150342607:+ LIHC cis rs950169 0.887 rs220333 ENSG00000259295.5 CSPG4P12 5.47 8.74e-08 4.28e-05 0.39 0.28 Schizophrenia; chr15:84547902 chr15:85191438~85213905:+ LIHC cis rs2283792 1 rs5999515 ENSG00000224086.5 LL22NC03-86G7.1 5.47 8.76e-08 4.28e-05 0.26 0.28 Multiple sclerosis; chr22:21790812 chr22:21938293~21977632:+ LIHC cis rs12681287 0.605 rs2976181 ENSG00000250569.1 NTAN1P2 5.47 8.77e-08 4.29e-05 0.34 0.28 Caudate activity during reward; chr8:86332241 chr8:86481754~86483002:- LIHC cis rs113835537 0.627 rs4630309 ENSG00000255517.5 CTD-3074O7.5 5.47 8.79e-08 4.3e-05 0.34 0.28 Airway imaging phenotypes; chr11:66565601 chr11:66473490~66480233:- LIHC cis rs9318086 0.673 rs7981928 ENSG00000205861.10 C1QTNF9B-AS1 -5.47 8.8e-08 4.3e-05 -0.32 -0.28 Myopia (pathological); chr13:23861041 chr13:23888889~23897263:+ LIHC cis rs2739330 0.828 rs5760102 ENSG00000099984.9 GSTT2 -5.47 8.81e-08 4.31e-05 -0.33 -0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23980123~23983911:+ LIHC cis rs2153535 0.58 rs7745043 ENSG00000230939.1 RP11-314C16.1 -5.47 8.82e-08 4.31e-05 -0.35 -0.28 Motion sickness; chr6:8513274 chr6:8784178~8785445:+ LIHC cis rs904251 0.797 rs1757177 ENSG00000204110.6 RP1-153P14.8 -5.47 8.83e-08 4.32e-05 -0.36 -0.28 Cognitive performance; chr6:37518594 chr6:37507348~37535616:+ LIHC cis rs2153535 0.563 rs7739249 ENSG00000230939.1 RP11-314C16.1 -5.47 8.84e-08 4.32e-05 -0.34 -0.28 Motion sickness; chr6:8534357 chr6:8784178~8785445:+ LIHC cis rs6504950 0.745 rs12949718 ENSG00000275710.1 RP11-257O5.4 -5.47 8.84e-08 4.32e-05 -0.35 -0.28 Breast cancer; chr17:54904492 chr17:54964474~54964679:+ LIHC cis rs2243480 1 rs313809 ENSG00000226824.5 RP4-756H11.3 -5.47 8.85e-08 4.33e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66034996 chr7:66654538~66669855:+ LIHC cis rs8059260 0.604 rs741177 ENSG00000274038.1 RP11-66H6.4 -5.47 8.86e-08 4.33e-05 -0.46 -0.28 Alcohol consumption over the past year; chr16:11051791 chr16:11056556~11057034:+ LIHC cis rs1499614 0.901 rs2178742 ENSG00000273142.1 RP11-458F8.4 -5.47 8.86e-08 4.33e-05 -0.35 -0.28 Gout; chr7:66732812 chr7:66902857~66906297:+ LIHC cis rs11098499 0.618 rs35265692 ENSG00000245958.5 RP11-33B1.1 -5.47 8.87e-08 4.33e-05 -0.29 -0.28 Corneal astigmatism; chr4:119403980 chr4:119454791~119552025:+ LIHC cis rs6940638 0.688 rs9393795 ENSG00000216901.1 AL022393.7 5.47 8.87e-08 4.34e-05 0.37 0.28 Intelligence (multi-trait analysis); chr6:27249940 chr6:28176188~28176674:+ LIHC cis rs12681287 0.547 rs9297921 ENSG00000250569.1 NTAN1P2 -5.47 8.89e-08 4.34e-05 -0.34 -0.28 Caudate activity during reward; chr8:86530058 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs9297922 ENSG00000250569.1 NTAN1P2 -5.47 8.89e-08 4.34e-05 -0.34 -0.28 Caudate activity during reward; chr8:86530089 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs35871312 ENSG00000250569.1 NTAN1P2 -5.47 8.89e-08 4.34e-05 -0.34 -0.28 Caudate activity during reward; chr8:86530991 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs10087788 ENSG00000250569.1 NTAN1P2 -5.47 8.89e-08 4.34e-05 -0.34 -0.28 Caudate activity during reward; chr8:86531946 chr8:86481754~86483002:- LIHC cis rs12681287 0.547 rs10956873 ENSG00000250569.1 NTAN1P2 -5.47 8.89e-08 4.34e-05 -0.34 -0.28 Caudate activity during reward; chr8:86534800 chr8:86481754~86483002:- LIHC cis rs12681287 0.511 rs9297923 ENSG00000250569.1 NTAN1P2 -5.47 8.89e-08 4.34e-05 -0.34 -0.28 Caudate activity during reward; chr8:86536761 chr8:86481754~86483002:- LIHC cis rs2933343 0.951 rs789218 ENSG00000231305.3 RP11-723O4.2 5.47 8.89e-08 4.34e-05 0.33 0.28 IgG glycosylation; chr3:128873827 chr3:128861313~128871540:- LIHC cis rs12681287 0.577 rs10481197 ENSG00000250569.1 NTAN1P2 -5.47 8.9e-08 4.35e-05 -0.34 -0.28 Caudate activity during reward; chr8:86534323 chr8:86481754~86483002:- LIHC cis rs11098499 0.779 rs80242894 ENSG00000245958.5 RP11-33B1.1 -5.47 8.91e-08 4.35e-05 -0.3 -0.28 Corneal astigmatism; chr4:119454597 chr4:119454791~119552025:+ LIHC cis rs227275 0.554 rs223339 ENSG00000230069.3 LRRC37A15P -5.47 8.92e-08 4.36e-05 -0.26 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102864700 chr4:102727274~102730721:- LIHC cis rs8059260 0.736 rs12149904 ENSG00000274038.1 RP11-66H6.4 -5.47 8.92e-08 4.36e-05 -0.47 -0.28 Alcohol consumption over the past year; chr16:10991789 chr16:11056556~11057034:+ LIHC cis rs11098499 0.954 rs10017543 ENSG00000245958.5 RP11-33B1.1 -5.46 8.94e-08 4.37e-05 -0.3 -0.28 Corneal astigmatism; chr4:119400265 chr4:119454791~119552025:+ LIHC cis rs11098499 0.908 rs7695996 ENSG00000245958.5 RP11-33B1.1 -5.46 8.94e-08 4.37e-05 -0.3 -0.28 Corneal astigmatism; chr4:119400878 chr4:119454791~119552025:+ LIHC cis rs227275 0.556 rs6842179 ENSG00000230069.3 LRRC37A15P -5.46 8.98e-08 4.38e-05 -0.26 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103018363 chr4:102727274~102730721:- LIHC cis rs11690935 0.959 rs4667694 ENSG00000228389.1 AC068039.4 5.46 8.99e-08 4.39e-05 0.38 0.28 Schizophrenia; chr2:171748889 chr2:171773482~171775844:+ LIHC cis rs4403732 1 rs4237333 ENSG00000230526.1 RP11-472G21.2 5.46 9.02e-08 4.4e-05 0.36 0.28 Coronary artery disease; chr10:71877468 chr10:71878356~71879107:+ LIHC cis rs2735413 0.563 rs72800915 ENSG00000276007.1 RP11-358L22.3 5.46 9.04e-08 4.41e-05 0.38 0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78021880 chr16:78123243~78124332:+ LIHC cis rs6921919 0.583 rs9468355 ENSG00000216901.1 AL022393.7 5.46 9.06e-08 4.42e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28374100 chr6:28176188~28176674:+ LIHC cis rs875971 0.862 rs11773628 ENSG00000237310.1 GS1-124K5.4 -5.46 9.07e-08 4.42e-05 -0.25 -0.28 Aortic root size; chr7:66517644 chr7:66493706~66495474:+ LIHC cis rs9388451 0.839 rs9321054 ENSG00000237742.5 RP11-624M8.1 5.46 9.07e-08 4.42e-05 0.26 0.28 Brugada syndrome; chr6:125758822 chr6:125578558~125749190:- LIHC cis rs4535700 0.543 rs2174459 ENSG00000226278.1 PSPHP1 5.46 9.07e-08 4.42e-05 0.34 0.28 Macular telangiectasia type 2; chr7:55923600 chr7:55764797~55773288:+ LIHC cis rs2283792 0.967 rs5999550 ENSG00000224086.5 LL22NC03-86G7.1 -5.46 9.08e-08 4.43e-05 -0.26 -0.28 Multiple sclerosis; chr22:21796997 chr22:21938293~21977632:+ LIHC cis rs1789 0.592 rs1125378 ENSG00000273133.1 RP11-799M12.2 -5.46 9.08e-08 4.43e-05 -0.42 -0.28 Blood protein levels; chr4:15538867 chr4:15563698~15564253:- LIHC cis rs9487094 0.67 rs11754340 ENSG00000260273.1 RP11-425D10.10 5.46 9.1e-08 4.43e-05 0.33 0.28 Height; chr6:109584789 chr6:109382795~109383666:+ LIHC cis rs7945705 0.869 rs7925728 ENSG00000254860.4 TMEM9B-AS1 5.46 9.11e-08 4.44e-05 0.28 0.28 Hemoglobin concentration; chr11:8991455 chr11:8964675~8977527:+ LIHC cis rs875971 0.862 rs4718330 ENSG00000237310.1 GS1-124K5.4 -5.46 9.11e-08 4.44e-05 -0.26 -0.28 Aortic root size; chr7:66250256 chr7:66493706~66495474:+ LIHC cis rs2153535 0.563 rs1737586 ENSG00000230939.1 RP11-314C16.1 -5.46 9.12e-08 4.45e-05 -0.35 -0.28 Motion sickness; chr6:8535664 chr6:8784178~8785445:+ LIHC cis rs4356203 0.846 rs1685932 ENSG00000272034.1 SNORD14A -5.46 9.12e-08 4.45e-05 -0.3 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17202356 chr11:17074654~17074744:- LIHC cis rs875971 0.545 rs73378304 ENSG00000226824.5 RP4-756H11.3 -5.46 9.13e-08 4.45e-05 -0.35 -0.28 Aortic root size; chr7:66175760 chr7:66654538~66669855:+ LIHC cis rs5758659 0.967 rs5758670 ENSG00000227370.1 RP4-669P10.19 -5.46 9.13e-08 4.45e-05 -0.32 -0.28 Cognitive function; chr22:42240681 chr22:42132543~42132998:+ LIHC cis rs2283792 1 rs1892846 ENSG00000224086.5 LL22NC03-86G7.1 -5.46 9.14e-08 4.46e-05 -0.26 -0.28 Multiple sclerosis; chr22:21832190 chr22:21938293~21977632:+ LIHC cis rs2283792 1 rs1892848 ENSG00000224086.5 LL22NC03-86G7.1 -5.46 9.14e-08 4.46e-05 -0.26 -0.28 Multiple sclerosis; chr22:21832273 chr22:21938293~21977632:+ LIHC cis rs875971 0.545 rs6460298 ENSG00000237310.1 GS1-124K5.4 5.46 9.16e-08 4.46e-05 0.27 0.28 Aortic root size; chr7:66442783 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs35459055 ENSG00000237310.1 GS1-124K5.4 5.46 9.16e-08 4.46e-05 0.27 0.28 Aortic root size; chr7:66479399 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs75577046 ENSG00000237310.1 GS1-124K5.4 5.46 9.16e-08 4.46e-05 0.27 0.28 Aortic root size; chr7:66493729 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs3735147 ENSG00000237310.1 GS1-124K5.4 5.46 9.16e-08 4.46e-05 0.27 0.28 Aortic root size; chr7:66505541 chr7:66493706~66495474:+ LIHC cis rs11690935 0.959 rs7586207 ENSG00000228389.1 AC068039.4 5.46 9.17e-08 4.46e-05 0.38 0.28 Schizophrenia; chr2:171814584 chr2:171773482~171775844:+ LIHC cis rs116175783 0.557 rs1733180 ENSG00000227403.1 AC009299.3 -5.46 9.17e-08 4.46e-05 -0.44 -0.28 Intelligence (multi-trait analysis); chr2:161277119 chr2:161244739~161249050:+ LIHC cis rs7131987 0.834 rs1989478 ENSG00000257176.2 RP11-996F15.2 -5.46 9.18e-08 4.47e-05 -0.32 -0.28 QT interval; chr12:29289296 chr12:29280418~29317848:- LIHC cis rs950169 0.922 rs17531523 ENSG00000225151.9 GOLGA2P7 -5.46 9.19e-08 4.48e-05 -0.37 -0.28 Schizophrenia; chr15:84589218 chr15:84199311~84230136:- LIHC cis rs875971 0.79 rs10257911 ENSG00000237310.1 GS1-124K5.4 -5.46 9.2e-08 4.48e-05 -0.25 -0.28 Aortic root size; chr7:66278783 chr7:66493706~66495474:+ LIHC cis rs1499614 1 rs2659913 ENSG00000226824.5 RP4-756H11.3 -5.46 9.21e-08 4.48e-05 -0.46 -0.28 Gout; chr7:66692349 chr7:66654538~66669855:+ LIHC cis rs1499614 1 rs2707840 ENSG00000226824.5 RP4-756H11.3 -5.46 9.21e-08 4.48e-05 -0.46 -0.28 Gout; chr7:66693028 chr7:66654538~66669855:+ LIHC cis rs1499614 1 rs2659911 ENSG00000226824.5 RP4-756H11.3 -5.46 9.21e-08 4.48e-05 -0.46 -0.28 Gout; chr7:66693433 chr7:66654538~66669855:+ LIHC cis rs1499614 1 rs2707838 ENSG00000226824.5 RP4-756H11.3 -5.46 9.21e-08 4.48e-05 -0.46 -0.28 Gout; chr7:66694214 chr7:66654538~66669855:+ LIHC cis rs1499614 1 rs60326618 ENSG00000226824.5 RP4-756H11.3 -5.46 9.21e-08 4.48e-05 -0.46 -0.28 Gout; chr7:66701371 chr7:66654538~66669855:+ LIHC cis rs1499614 1 rs2707830 ENSG00000226824.5 RP4-756H11.3 -5.46 9.21e-08 4.48e-05 -0.46 -0.28 Gout; chr7:66702658 chr7:66654538~66669855:+ LIHC cis rs1499614 1 rs2707828 ENSG00000226824.5 RP4-756H11.3 -5.46 9.21e-08 4.48e-05 -0.46 -0.28 Gout; chr7:66706390 chr7:66654538~66669855:+ LIHC cis rs1499614 0.803 rs1922723 ENSG00000226824.5 RP4-756H11.3 -5.46 9.21e-08 4.48e-05 -0.46 -0.28 Gout; chr7:66710076 chr7:66654538~66669855:+ LIHC cis rs1499614 1 rs2659903 ENSG00000226824.5 RP4-756H11.3 -5.46 9.21e-08 4.48e-05 -0.46 -0.28 Gout; chr7:66715944 chr7:66654538~66669855:+ LIHC cis rs1499614 1 rs2141924 ENSG00000226824.5 RP4-756H11.3 -5.46 9.21e-08 4.48e-05 -0.46 -0.28 Gout; chr7:66721259 chr7:66654538~66669855:+ LIHC cis rs7615952 0.558 rs17334039 ENSG00000171084.14 FAM86JP 5.46 9.21e-08 4.48e-05 0.39 0.28 Blood pressure (smoking interaction); chr3:125821465 chr3:125916620~125930024:+ LIHC cis rs228614 0.536 rs223419 ENSG00000230069.3 LRRC37A15P -5.46 9.21e-08 4.48e-05 -0.26 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102808586 chr4:102727274~102730721:- LIHC cis rs228614 0.536 rs223418 ENSG00000230069.3 LRRC37A15P -5.46 9.21e-08 4.48e-05 -0.26 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102809336 chr4:102727274~102730721:- LIHC cis rs2880765 0.545 rs11631739 ENSG00000259295.5 CSPG4P12 5.46 9.23e-08 4.49e-05 0.39 0.28 Coronary artery disease; chr15:85469347 chr15:85191438~85213905:+ LIHC cis rs524281 0.861 rs11227410 ENSG00000255320.1 RP11-755F10.1 5.46 9.23e-08 4.49e-05 0.37 0.28 Electroencephalogram traits; chr11:66105925 chr11:66244840~66246239:- LIHC cis rs9388451 0.874 rs3734634 ENSG00000237742.5 RP11-624M8.1 -5.46 9.24e-08 4.49e-05 -0.26 -0.28 Brugada syndrome; chr6:125790654 chr6:125578558~125749190:- LIHC cis rs4356975 0.563 rs4274916 ENSG00000249956.3 RP11-790I12.2 5.46 9.24e-08 4.49e-05 0.32 0.28 Obesity-related traits; chr4:69122660 chr4:69408836~69423164:+ LIHC cis rs524281 0.773 rs11227413 ENSG00000255320.1 RP11-755F10.1 5.46 9.26e-08 4.5e-05 0.37 0.28 Electroencephalogram traits; chr11:66116225 chr11:66244840~66246239:- LIHC cis rs12468226 0.938 rs76501067 ENSG00000273456.1 RP11-686O6.2 5.46 9.26e-08 4.51e-05 0.4 0.28 Urate levels; chr2:202318042 chr2:202374932~202375604:- LIHC cis rs9467711 0.651 rs72832596 ENSG00000216436.2 HIST1H2APS1 5.46 9.26e-08 4.51e-05 0.77 0.28 Autism spectrum disorder or schizophrenia; chr6:25962723 chr6:25732497~25732827:+ LIHC cis rs11690935 1 rs11678984 ENSG00000228389.1 AC068039.4 -5.46 9.27e-08 4.51e-05 -0.37 -0.28 Schizophrenia; chr2:171679338 chr2:171773482~171775844:+ LIHC cis rs1075265 0.633 rs4671190 ENSG00000233266.1 HMGB1P31 5.46 9.27e-08 4.51e-05 0.35 0.28 Chronotype;Morning vs. evening chronotype; chr2:54085604 chr2:54051334~54051760:+ LIHC cis rs3096299 0.802 rs3102336 ENSG00000261118.1 RP11-104N10.1 5.46 9.29e-08 4.52e-05 0.29 0.28 Multiple myeloma (IgH translocation); chr16:89375598 chr16:89492017~89504460:- LIHC cis rs2877649 0.793 rs113112510 ENSG00000258744.1 RP11-80A15.1 -5.46 9.32e-08 4.53e-05 -0.59 -0.28 Smooth-surface caries; chr14:24457648 chr14:24501594~24508688:+ LIHC cis rs2153535 0.58 rs9406170 ENSG00000230939.1 RP11-314C16.1 -5.46 9.32e-08 4.53e-05 -0.35 -0.28 Motion sickness; chr6:8513920 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9379222 ENSG00000230939.1 RP11-314C16.1 -5.46 9.32e-08 4.53e-05 -0.35 -0.28 Motion sickness; chr6:8514555 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9406172 ENSG00000230939.1 RP11-314C16.1 -5.46 9.32e-08 4.53e-05 -0.35 -0.28 Motion sickness; chr6:8515231 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9406174 ENSG00000230939.1 RP11-314C16.1 -5.46 9.32e-08 4.53e-05 -0.35 -0.28 Motion sickness; chr6:8516531 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2143356 ENSG00000230939.1 RP11-314C16.1 -5.46 9.32e-08 4.53e-05 -0.35 -0.28 Motion sickness; chr6:8517442 chr6:8784178~8785445:+ LIHC cis rs7714584 1 rs58717741 ENSG00000197083.10 ZNF300P1 5.46 9.33e-08 4.53e-05 0.44 0.28 Crohn's disease; chr5:150905374 chr5:150930645~150946289:- LIHC cis rs1061377 0.501 rs62308278 ENSG00000249207.1 RP11-360F5.1 -5.46 9.34e-08 4.54e-05 -0.29 -0.28 Uric acid levels; chr4:39161038 chr4:39112677~39126818:- LIHC cis rs9425766 0.566 rs12079820 ENSG00000227373.4 RP11-160H22.5 5.46 9.34e-08 4.54e-05 0.36 0.28 Life satisfaction; chr1:174240771 chr1:174115300~174160004:- LIHC cis rs2739330 0.761 rs5760176 ENSG00000228039.3 KB-1125A3.10 -5.46 9.35e-08 4.54e-05 -0.34 -0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23963780~23964374:+ LIHC cis rs4934494 0.768 rs58163515 ENSG00000232936.4 RP11-80H5.2 5.46 9.35e-08 4.54e-05 0.36 0.28 Red blood cell count; chr10:89637807 chr10:89645282~89650667:+ LIHC cis rs734999 1 rs734999 ENSG00000225931.3 RP3-395M20.7 5.46 9.35e-08 4.54e-05 0.31 0.28 Ulcerative colitis; chr1:2581777 chr1:2566410~2569888:+ LIHC cis rs734999 1 rs2016366 ENSG00000225931.3 RP3-395M20.7 5.46 9.35e-08 4.54e-05 0.31 0.28 Ulcerative colitis; chr1:2582239 chr1:2566410~2569888:+ LIHC cis rs11098499 0.866 rs10518329 ENSG00000245958.5 RP11-33B1.1 -5.46 9.37e-08 4.55e-05 -0.28 -0.28 Corneal astigmatism; chr4:119480680 chr4:119454791~119552025:+ LIHC cis rs950776 0.518 rs2869544 ENSG00000261762.1 RP11-650L12.2 -5.46 9.38e-08 4.56e-05 -0.37 -0.28 Sudden cardiac arrest; chr15:78547058 chr15:78589123~78591276:- LIHC cis rs8059260 0.604 rs11863415 ENSG00000274038.1 RP11-66H6.4 -5.46 9.38e-08 4.56e-05 -0.46 -0.28 Alcohol consumption over the past year; chr16:11053237 chr16:11056556~11057034:+ LIHC cis rs7945705 0.967 rs34842234 ENSG00000254860.4 TMEM9B-AS1 -5.46 9.39e-08 4.56e-05 -0.28 -0.28 Hemoglobin concentration; chr11:8870347 chr11:8964675~8977527:+ LIHC cis rs7945705 0.967 rs7123861 ENSG00000254860.4 TMEM9B-AS1 -5.46 9.39e-08 4.56e-05 -0.28 -0.28 Hemoglobin concentration; chr11:8870776 chr11:8964675~8977527:+ LIHC cis rs10510102 1 rs11200181 ENSG00000276742.1 RP11-500G22.4 5.46 9.39e-08 4.56e-05 0.43 0.28 Breast cancer; chr10:121828528 chr10:121956782~121957098:+ LIHC cis rs17507216 0.628 rs8032321 ENSG00000278603.1 RP13-608F4.5 5.46 9.39e-08 4.56e-05 0.59 0.28 Excessive daytime sleepiness; chr15:82698956 chr15:82472203~82472426:+ LIHC cis rs17507216 0.628 rs8040488 ENSG00000278603.1 RP13-608F4.5 5.46 9.39e-08 4.56e-05 0.59 0.28 Excessive daytime sleepiness; chr15:82699081 chr15:82472203~82472426:+ LIHC cis rs9326248 0.817 rs1242127 ENSG00000236267.1 AP006216.5 -5.46 9.41e-08 4.57e-05 -0.28 -0.28 Blood protein levels; chr11:117205848 chr11:116813204~116814003:- LIHC cis rs5758659 0.512 rs4822072 ENSG00000227370.1 RP4-669P10.19 -5.46 9.41e-08 4.57e-05 -0.33 -0.28 Cognitive function; chr22:41964829 chr22:42132543~42132998:+ LIHC cis rs7131987 0.874 rs10843366 ENSG00000257176.2 RP11-996F15.2 -5.46 9.41e-08 4.57e-05 -0.33 -0.28 QT interval; chr12:29254970 chr12:29280418~29317848:- LIHC cis rs7131987 0.845 rs2042511 ENSG00000257176.2 RP11-996F15.2 -5.46 9.41e-08 4.57e-05 -0.33 -0.28 QT interval; chr12:29255847 chr12:29280418~29317848:- LIHC cis rs7131987 0.903 rs10843371 ENSG00000257176.2 RP11-996F15.2 -5.46 9.41e-08 4.57e-05 -0.33 -0.28 QT interval; chr12:29261299 chr12:29280418~29317848:- LIHC cis rs2283792 1 rs6518986 ENSG00000224086.5 LL22NC03-86G7.1 -5.46 9.41e-08 4.57e-05 -0.26 -0.28 Multiple sclerosis; chr22:21831058 chr22:21938293~21977632:+ LIHC cis rs12744310 0.502 rs12027253 ENSG00000235358.1 RP11-399E6.1 5.45 9.43e-08 4.58e-05 0.33 0.28 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41342569 chr1:41242373~41284861:+ LIHC cis rs3779195 0.929 rs4268041 ENSG00000272950.1 RP11-307C18.1 -5.45 9.43e-08 4.58e-05 -0.37 -0.28 Sex hormone-binding globulin levels; chr7:98376226 chr7:98322853~98323430:+ LIHC cis rs12458462 0.665 rs2035085 ENSG00000274828.1 RP11-567M16.6 5.45 9.44e-08 4.58e-05 0.3 0.28 Monocyte count; chr18:79725280 chr18:79677287~79679358:- LIHC cis rs2739330 0.828 rs2330635 ENSG00000099984.9 GSTT2 -5.45 9.44e-08 4.58e-05 -0.33 -0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23980123~23983911:+ LIHC cis rs2998286 0.862 rs2790448 ENSG00000254635.4 WAC-AS1 -5.45 9.44e-08 4.58e-05 -0.35 -0.28 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28512828 chr10:28522652~28532743:- LIHC cis rs2998286 0.822 rs2807734 ENSG00000254635.4 WAC-AS1 -5.45 9.44e-08 4.58e-05 -0.35 -0.28 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28513036 chr10:28522652~28532743:- LIHC cis rs2998286 0.822 rs2095901 ENSG00000254635.4 WAC-AS1 -5.45 9.44e-08 4.58e-05 -0.35 -0.28 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28514790 chr10:28522652~28532743:- LIHC cis rs801193 0.527 rs2707837 ENSG00000237310.1 GS1-124K5.4 5.45 9.46e-08 4.59e-05 0.25 0.28 Aortic root size; chr7:66716086 chr7:66493706~66495474:+ LIHC cis rs9425766 0.566 rs56188862 ENSG00000227373.4 RP11-160H22.5 5.45 9.46e-08 4.59e-05 0.36 0.28 Life satisfaction; chr1:174220131 chr1:174115300~174160004:- LIHC cis rs875971 0.545 rs73376401 ENSG00000237310.1 GS1-124K5.4 5.45 9.47e-08 4.59e-05 0.27 0.28 Aortic root size; chr7:66174841 chr7:66493706~66495474:+ LIHC cis rs11690935 0.959 rs6722757 ENSG00000228389.1 AC068039.4 5.45 9.48e-08 4.6e-05 0.38 0.28 Schizophrenia; chr2:171735453 chr2:171773482~171775844:+ LIHC cis rs9341808 0.754 rs6907729 ENSG00000272129.1 RP11-250B2.6 -5.45 9.48e-08 4.6e-05 -0.28 -0.28 Sitting height ratio; chr6:80295205 chr6:80355424~80356859:+ LIHC cis rs6142102 0.961 rs4911408 ENSG00000276073.1 RP5-1125A11.7 -5.45 9.49e-08 4.6e-05 -0.32 -0.28 Skin pigmentation; chr20:34112760 chr20:33985617~33988989:- LIHC cis rs9318086 0.648 rs7331047 ENSG00000205861.10 C1QTNF9B-AS1 -5.45 9.49e-08 4.6e-05 -0.33 -0.28 Myopia (pathological); chr13:23893203 chr13:23888889~23897263:+ LIHC cis rs9318086 0.648 rs9510927 ENSG00000205861.10 C1QTNF9B-AS1 -5.45 9.49e-08 4.6e-05 -0.33 -0.28 Myopia (pathological); chr13:23893502 chr13:23888889~23897263:+ LIHC cis rs875971 0.862 rs778720 ENSG00000237310.1 GS1-124K5.4 -5.45 9.5e-08 4.61e-05 -0.25 -0.28 Aortic root size; chr7:66381288 chr7:66493706~66495474:+ LIHC cis rs5769707 0.656 rs135875 ENSG00000235111.1 RP1-29C18.8 -5.45 9.51e-08 4.61e-05 -0.34 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49618771 chr22:49612657~49615716:- LIHC cis rs2877649 0.793 rs111536428 ENSG00000258744.1 RP11-80A15.1 -5.45 9.51e-08 4.61e-05 -0.58 -0.28 Smooth-surface caries; chr14:24460326 chr14:24501594~24508688:+ LIHC cis rs1577917 0.839 rs9450333 ENSG00000234155.1 RP11-30P6.6 5.45 9.53e-08 4.62e-05 0.34 0.28 Response to antipsychotic treatment; chr6:85810037 chr6:85387219~85390186:- LIHC cis rs17301013 0.932 rs1016466 ENSG00000227373.4 RP11-160H22.5 5.45 9.53e-08 4.62e-05 0.34 0.28 Systemic lupus erythematosus; chr1:174570652 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs10753086 ENSG00000227373.4 RP11-160H22.5 5.45 9.53e-08 4.62e-05 0.34 0.28 Systemic lupus erythematosus; chr1:174580802 chr1:174115300~174160004:- LIHC cis rs227275 0.525 rs724446 ENSG00000230069.3 LRRC37A15P -5.45 9.53e-08 4.62e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103010206 chr4:102727274~102730721:- LIHC cis rs113835537 0.529 rs17495838 ENSG00000255517.5 CTD-3074O7.5 -5.45 9.54e-08 4.63e-05 -0.37 -0.28 Airway imaging phenotypes; chr11:66428794 chr11:66473490~66480233:- LIHC cis rs2929278 0.638 rs2016840 ENSG00000166763.7 STRCP1 -5.45 9.54e-08 4.63e-05 -0.36 -0.28 Schizophrenia; chr15:43919670 chr15:43699488~43718184:- LIHC cis rs116175783 0.557 rs1146024 ENSG00000227403.1 AC009299.3 5.45 9.55e-08 4.63e-05 0.43 0.28 Intelligence (multi-trait analysis); chr2:161282740 chr2:161244739~161249050:+ LIHC cis rs638893 1 rs638893 ENSG00000255422.1 AP002954.4 -5.45 9.56e-08 4.64e-05 -0.46 -0.28 Vitiligo; chr11:118827828 chr11:118704607~118750263:+ LIHC cis rs6686842 1 rs213742 ENSG00000235358.1 RP11-399E6.1 -5.45 9.56e-08 4.64e-05 -0.31 -0.28 Height; chr1:41155455 chr1:41242373~41284861:+ LIHC cis rs2283792 0.967 rs743409 ENSG00000224086.5 LL22NC03-86G7.1 -5.45 9.57e-08 4.64e-05 -0.27 -0.28 Multiple sclerosis; chr22:21774926 chr22:21938293~21977632:+ LIHC cis rs11647589 0.834 rs6497491 ENSG00000262995.1 CTD-2194A8.2 -5.45 9.58e-08 4.64e-05 -0.27 -0.28 Blood metabolite levels; chr16:20468691 chr16:20440266~20447000:- LIHC cis rs4728142 0.738 rs3807306 ENSG00000275106.1 RP11-309L24.10 5.45 9.61e-08 4.65e-05 0.38 0.28 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128940626 chr7:128952527~128953316:- LIHC cis rs2739330 0.587 rs4820571 ENSG00000228039.3 KB-1125A3.10 5.45 9.61e-08 4.66e-05 0.35 0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23963780~23964374:+ LIHC cis rs6480314 0.573 rs12573244 ENSG00000233590.1 RP11-153K11.3 -5.45 9.62e-08 4.66e-05 -0.45 -0.28 Optic nerve measurement (disc area); chr10:68241488 chr10:68233251~68242379:- LIHC cis rs6480314 0.542 rs11814858 ENSG00000233590.1 RP11-153K11.3 -5.45 9.62e-08 4.66e-05 -0.45 -0.28 Optic nerve measurement (disc area); chr10:68241950 chr10:68233251~68242379:- LIHC cis rs6480314 0.636 rs61854788 ENSG00000233590.1 RP11-153K11.3 -5.45 9.62e-08 4.66e-05 -0.45 -0.28 Optic nerve measurement (disc area); chr10:68241980 chr10:68233251~68242379:- LIHC cis rs7945705 0.902 rs10743095 ENSG00000254860.4 TMEM9B-AS1 -5.45 9.62e-08 4.66e-05 -0.28 -0.28 Hemoglobin concentration; chr11:8915437 chr11:8964675~8977527:+ LIHC cis rs12908161 1 rs35630683 ENSG00000259295.5 CSPG4P12 5.45 9.62e-08 4.66e-05 0.39 0.28 Schizophrenia; chr15:84806000 chr15:85191438~85213905:+ LIHC cis rs7945705 0.935 rs11042103 ENSG00000254860.4 TMEM9B-AS1 -5.45 9.63e-08 4.67e-05 -0.28 -0.28 Hemoglobin concentration; chr11:8867153 chr11:8964675~8977527:+ LIHC cis rs17301013 0.9 rs56347239 ENSG00000227373.4 RP11-160H22.5 5.45 9.65e-08 4.67e-05 0.35 0.28 Systemic lupus erythematosus; chr1:174564476 chr1:174115300~174160004:- LIHC cis rs2877649 0.793 rs76640748 ENSG00000258744.1 RP11-80A15.1 -5.45 9.65e-08 4.67e-05 -0.59 -0.28 Smooth-surface caries; chr14:24457239 chr14:24501594~24508688:+ LIHC cis rs10510102 1 rs11200181 ENSG00000226864.1 ATE1-AS1 5.45 9.67e-08 4.68e-05 0.45 0.28 Breast cancer; chr10:121828528 chr10:121928312~121951965:+ LIHC cis rs11098499 0.954 rs11098524 ENSG00000245958.5 RP11-33B1.1 -5.45 9.67e-08 4.68e-05 -0.3 -0.28 Corneal astigmatism; chr4:119468877 chr4:119454791~119552025:+ LIHC cis rs6921919 0.583 rs7759191 ENSG00000216901.1 AL022393.7 5.45 9.69e-08 4.69e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28385657 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs7764737 ENSG00000216901.1 AL022393.7 5.45 9.69e-08 4.69e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28386838 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs9461458 ENSG00000216901.1 AL022393.7 5.45 9.69e-08 4.69e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28388098 chr6:28176188~28176674:+ LIHC cis rs6921919 0.609 rs9468365 ENSG00000216901.1 AL022393.7 5.45 9.69e-08 4.69e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28390189 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs1361385 ENSG00000216901.1 AL022393.7 5.45 9.69e-08 4.69e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28390543 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs1416918 ENSG00000216901.1 AL022393.7 5.45 9.69e-08 4.69e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28390558 chr6:28176188~28176674:+ LIHC cis rs1075232 0.51 rs78884938 ENSG00000270055.1 CTD-3092A11.2 -5.45 9.69e-08 4.69e-05 -0.53 -0.28 Survival in colorectal cancer (non-distant metastatic); chr15:31218682 chr15:30487963~30490313:+ LIHC cis rs11098499 0.954 rs3890049 ENSG00000245958.5 RP11-33B1.1 -5.45 9.7e-08 4.69e-05 -0.29 -0.28 Corneal astigmatism; chr4:119405128 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs67265404 ENSG00000245958.5 RP11-33B1.1 -5.45 9.7e-08 4.69e-05 -0.29 -0.28 Corneal astigmatism; chr4:119438115 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs71629403 ENSG00000245958.5 RP11-33B1.1 -5.45 9.7e-08 4.69e-05 -0.29 -0.28 Corneal astigmatism; chr4:119451412 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs28571712 ENSG00000245958.5 RP11-33B1.1 -5.45 9.7e-08 4.69e-05 -0.29 -0.28 Corneal astigmatism; chr4:119454825 chr4:119454791~119552025:+ LIHC cis rs11098499 0.865 rs9994730 ENSG00000245958.5 RP11-33B1.1 -5.45 9.7e-08 4.69e-05 -0.29 -0.28 Corneal astigmatism; chr4:119460409 chr4:119454791~119552025:+ LIHC cis rs853679 0.517 rs868987 ENSG00000219392.1 RP1-265C24.5 5.45 9.7e-08 4.69e-05 0.44 0.28 Depression; chr6:28142370 chr6:28115628~28116551:+ LIHC cis rs950776 0.518 rs4243083 ENSG00000261762.1 RP11-650L12.2 -5.45 9.7e-08 4.69e-05 -0.37 -0.28 Sudden cardiac arrest; chr15:78541488 chr15:78589123~78591276:- LIHC cis rs1577917 0.785 rs1885607 ENSG00000234155.1 RP11-30P6.6 -5.45 9.71e-08 4.7e-05 -0.36 -0.28 Response to antipsychotic treatment; chr6:85685187 chr6:85387219~85390186:- LIHC cis rs12134133 1 rs2802237 ENSG00000274245.1 RP11-357P18.2 5.45 9.72e-08 4.7e-05 0.43 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207300825 chr1:207372559~207373252:+ LIHC cis rs801193 0.569 rs2659908 ENSG00000237310.1 GS1-124K5.4 5.45 9.72e-08 4.7e-05 0.25 0.28 Aortic root size; chr7:66695835 chr7:66493706~66495474:+ LIHC cis rs801193 0.569 rs7782587 ENSG00000237310.1 GS1-124K5.4 5.45 9.72e-08 4.7e-05 0.25 0.28 Aortic root size; chr7:66701485 chr7:66493706~66495474:+ LIHC cis rs801193 0.569 rs4717315 ENSG00000237310.1 GS1-124K5.4 5.45 9.72e-08 4.7e-05 0.25 0.28 Aortic root size; chr7:66713338 chr7:66493706~66495474:+ LIHC cis rs7586673 0.93 rs2884364 ENSG00000227403.1 AC009299.3 -5.45 9.72e-08 4.7e-05 -0.35 -0.28 Intelligence (multi-trait analysis); chr2:161121136 chr2:161244739~161249050:+ LIHC cis rs8177376 1 rs73017350 ENSG00000254905.1 RP11-712L6.7 5.45 9.72e-08 4.7e-05 0.41 0.28 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126246064 chr11:126292922~126294254:- LIHC cis rs11722779 0.869 rs223323 ENSG00000230069.3 LRRC37A15P -5.45 9.76e-08 4.72e-05 -0.25 -0.28 Schizophrenia; chr4:102878412 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs223316 ENSG00000230069.3 LRRC37A15P -5.45 9.76e-08 4.72e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102881949 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs223314 ENSG00000230069.3 LRRC37A15P -5.45 9.76e-08 4.72e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102884642 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223313 ENSG00000230069.3 LRRC37A15P -5.45 9.76e-08 4.72e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102886563 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs7254 ENSG00000230069.3 LRRC37A15P -5.45 9.76e-08 4.72e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102888488 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223311 ENSG00000230069.3 LRRC37A15P -5.45 9.76e-08 4.72e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102888757 chr4:102727274~102730721:- LIHC cis rs11722779 0.566 rs6822658 ENSG00000230069.3 LRRC37A15P -5.45 9.76e-08 4.72e-05 -0.25 -0.28 Schizophrenia; chr4:102891964 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs6823625 ENSG00000230069.3 LRRC37A15P -5.45 9.76e-08 4.72e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892437 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs6846762 ENSG00000230069.3 LRRC37A15P -5.45 9.76e-08 4.72e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892577 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs4699032 ENSG00000230069.3 LRRC37A15P -5.45 9.76e-08 4.72e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892724 chr4:102727274~102730721:- LIHC cis rs17301013 0.932 rs7542389 ENSG00000227373.4 RP11-160H22.5 5.45 9.76e-08 4.72e-05 0.34 0.28 Systemic lupus erythematosus; chr1:174565104 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs12074753 ENSG00000227373.4 RP11-160H22.5 5.45 9.76e-08 4.72e-05 0.34 0.28 Systemic lupus erythematosus; chr1:174565768 chr1:174115300~174160004:- LIHC cis rs12157904 0.793 rs6000853 ENSG00000233360.4 Z83844.1 5.45 9.76e-08 4.72e-05 0.57 0.28 Response to anti-depressant treatment in major depressive disorder; chr22:37649481 chr22:37641832~37658377:- LIHC cis rs8028182 0.636 rs4886707 ENSG00000260269.4 CTD-2323K18.1 -5.45 9.76e-08 4.72e-05 -0.37 -0.28 Sudden cardiac arrest; chr15:75463126 chr15:75527150~75601205:- LIHC cis rs11690935 0.959 rs66835971 ENSG00000228389.1 AC068039.4 5.45 9.77e-08 4.72e-05 0.38 0.28 Schizophrenia; chr2:171820949 chr2:171773482~171775844:+ LIHC cis rs950169 0.922 rs11633534 ENSG00000225151.9 GOLGA2P7 -5.45 9.8e-08 4.73e-05 -0.36 -0.28 Schizophrenia; chr15:84581411 chr15:84199311~84230136:- LIHC cis rs7688540 0.771 rs77234191 ENSG00000275426.1 CH17-262A2.1 5.45 9.8e-08 4.74e-05 0.39 0.28 Facial morphology (factor 6, height of vermillion lower lip); chr4:264505 chr4:149738~150317:+ LIHC cis rs1134634 0.52 rs4280723 ENSG00000273133.1 RP11-799M12.2 5.45 9.83e-08 4.75e-05 0.35 0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15574095 chr4:15563698~15564253:- LIHC cis rs1185460 1 rs15818 ENSG00000271751.1 RP11-110I1.14 -5.45 9.83e-08 4.75e-05 -0.39 -0.28 Coronary artery disease; chr11:119081463 chr11:119065263~119065677:- LIHC cis rs7945705 0.87 rs10840142 ENSG00000254860.4 TMEM9B-AS1 -5.45 9.83e-08 4.75e-05 -0.28 -0.28 Hemoglobin concentration; chr11:8884531 chr11:8964675~8977527:+ LIHC cis rs4731207 0.596 rs1026837 ENSG00000224897.5 POT1-AS1 5.45 9.85e-08 4.75e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125033025 chr7:124929873~125179315:+ LIHC cis rs4356203 0.905 rs7930058 ENSG00000272034.1 SNORD14A -5.45 9.85e-08 4.76e-05 -0.31 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17045071 chr11:17074654~17074744:- LIHC cis rs6480314 0.542 rs61854824 ENSG00000233590.1 RP11-153K11.3 -5.45 9.86e-08 4.76e-05 -0.44 -0.28 Optic nerve measurement (disc area); chr10:68270438 chr10:68233251~68242379:- LIHC cis rs6480314 0.542 rs12572954 ENSG00000233590.1 RP11-153K11.3 -5.45 9.86e-08 4.76e-05 -0.44 -0.28 Optic nerve measurement (disc area); chr10:68270766 chr10:68233251~68242379:- LIHC cis rs6480314 0.542 rs12572960 ENSG00000233590.1 RP11-153K11.3 -5.45 9.86e-08 4.76e-05 -0.44 -0.28 Optic nerve measurement (disc area); chr10:68270966 chr10:68233251~68242379:- LIHC cis rs12571093 0.803 rs2241969 ENSG00000233590.1 RP11-153K11.3 -5.45 9.86e-08 4.76e-05 -0.44 -0.28 Optic nerve measurement (disc area); chr10:68271253 chr10:68233251~68242379:- LIHC cis rs6480314 0.542 rs17231644 ENSG00000233590.1 RP11-153K11.3 5.45 9.86e-08 4.76e-05 0.44 0.28 Optic nerve measurement (disc area); chr10:68270301 chr10:68233251~68242379:- LIHC cis rs4535700 0.504 rs66528253 ENSG00000226278.1 PSPHP1 5.45 9.86e-08 4.76e-05 0.33 0.28 Macular telangiectasia type 2; chr7:55929070 chr7:55764797~55773288:+ LIHC cis rs12744310 0.502 rs12045676 ENSG00000235358.1 RP11-399E6.1 5.45 9.87e-08 4.76e-05 0.33 0.28 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41342591 chr1:41242373~41284861:+ LIHC cis rs12744310 0.502 rs12044881 ENSG00000235358.1 RP11-399E6.1 5.45 9.87e-08 4.76e-05 0.33 0.28 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41342598 chr1:41242373~41284861:+ LIHC cis rs6600671 0.899 rs2319971 ENSG00000231429.2 RP11-343N15.2 -5.45 9.88e-08 4.77e-05 -0.34 -0.28 Hip geometry; chr1:121485184 chr1:121412719~121429274:+ LIHC cis rs7927592 0.513 rs653056 ENSG00000212093.1 AP000807.1 5.45 9.89e-08 4.77e-05 0.28 0.28 Total body bone mineral density; chr11:68436157 chr11:68506083~68506166:- LIHC cis rs904251 0.6 rs2270687 ENSG00000204110.6 RP1-153P14.8 -5.45 9.9e-08 4.78e-05 -0.35 -0.28 Cognitive performance; chr6:37450487 chr6:37507348~37535616:+ LIHC cis rs7927592 0.645 rs7936582 ENSG00000212093.1 AP000807.1 5.44 9.94e-08 4.79e-05 0.29 0.28 Total body bone mineral density; chr11:68525462 chr11:68506083~68506166:- LIHC cis rs950169 0.922 rs11638445 ENSG00000225151.9 GOLGA2P7 -5.44 9.94e-08 4.8e-05 -0.37 -0.28 Schizophrenia; chr15:84594463 chr15:84199311~84230136:- LIHC cis rs113835537 0.529 rs17580784 ENSG00000255517.5 CTD-3074O7.5 -5.44 9.95e-08 4.8e-05 -0.37 -0.28 Airway imaging phenotypes; chr11:66447388 chr11:66473490~66480233:- LIHC cis rs2933343 0.63 rs75824035 ENSG00000231305.3 RP11-723O4.2 5.44 9.95e-08 4.8e-05 0.31 0.28 IgG glycosylation; chr3:128934142 chr3:128861313~128871540:- LIHC cis rs5769707 0.605 rs6009791 ENSG00000235111.1 RP1-29C18.8 -5.44 9.96e-08 4.8e-05 -0.34 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49631617 chr22:49612657~49615716:- LIHC cis rs7916697 0.947 rs9783176 ENSG00000233590.1 RP11-153K11.3 -5.44 9.98e-08 4.81e-05 -0.34 -0.28 Optic disc area; chr10:68242636 chr10:68233251~68242379:- LIHC cis rs228614 0.51 rs223362 ENSG00000230069.3 LRRC37A15P -5.44 9.99e-08 4.82e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102848077 chr4:102727274~102730721:- LIHC cis rs2243480 1 rs958550 ENSG00000273142.1 RP11-458F8.4 5.44 9.99e-08 4.82e-05 0.34 0.28 Diabetic kidney disease; chr7:66170692 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs160633 ENSG00000226824.5 RP4-756H11.3 -5.44 1e-07 4.82e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66063241 chr7:66654538~66669855:+ LIHC cis rs12571093 0.803 rs36103935 ENSG00000233590.1 RP11-153K11.3 -5.44 1e-07 4.82e-05 -0.45 -0.28 Optic nerve measurement (disc area); chr10:68273171 chr10:68233251~68242379:- LIHC cis rs1499614 1 rs1267818 ENSG00000226824.5 RP4-756H11.3 -5.44 1e-07 4.82e-05 -0.47 -0.28 Gout; chr7:66642037 chr7:66654538~66669855:+ LIHC cis rs5769707 0.616 rs6009786 ENSG00000235111.1 RP1-29C18.8 -5.44 1e-07 4.83e-05 -0.34 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49621497 chr22:49612657~49615716:- LIHC cis rs228614 0.543 rs223330 ENSG00000230069.3 LRRC37A15P -5.44 1e-07 4.84e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102872502 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223329 ENSG00000230069.3 LRRC37A15P -5.44 1e-07 4.84e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873031 chr4:102727274~102730721:- LIHC cis rs228614 0.536 rs223327 ENSG00000230069.3 LRRC37A15P -5.44 1e-07 4.84e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873560 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223326 ENSG00000230069.3 LRRC37A15P -5.44 1e-07 4.84e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873770 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223324 ENSG00000230069.3 LRRC37A15P -5.44 1e-07 4.84e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102876177 chr4:102727274~102730721:- LIHC cis rs4731207 0.564 rs13234634 ENSG00000224897.5 POT1-AS1 5.44 1.01e-07 4.84e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125035979 chr7:124929873~125179315:+ LIHC cis rs1499614 1 rs1638731 ENSG00000226824.5 RP4-756H11.3 -5.44 1.01e-07 4.85e-05 -0.46 -0.28 Gout; chr7:66679692 chr7:66654538~66669855:+ LIHC cis rs1499614 1 rs1882655 ENSG00000226824.5 RP4-756H11.3 5.44 1.01e-07 4.85e-05 0.46 0.28 Gout; chr7:66682070 chr7:66654538~66669855:+ LIHC cis rs1499614 0.831 rs3800822 ENSG00000226824.5 RP4-756H11.3 5.44 1.01e-07 4.85e-05 0.46 0.28 Gout; chr7:66682162 chr7:66654538~66669855:+ LIHC cis rs5758659 1 rs5758659 ENSG00000227370.1 RP4-669P10.19 -5.44 1.01e-07 4.85e-05 -0.32 -0.28 Cognitive function; chr22:42225997 chr22:42132543~42132998:+ LIHC cis rs2749592 0.55 rs7917262 ENSG00000263064.2 RP11-291L22.7 -5.44 1.01e-07 4.85e-05 -0.29 -0.28 Age-related hearing impairment (SNP x SNP interaction); chr10:37585674 chr10:38448689~38448949:+ LIHC cis rs2749592 0.55 rs9733309 ENSG00000263064.2 RP11-291L22.7 -5.44 1.01e-07 4.85e-05 -0.29 -0.28 Age-related hearing impairment (SNP x SNP interaction); chr10:37593477 chr10:38448689~38448949:+ LIHC cis rs2749592 0.55 rs7081464 ENSG00000263064.2 RP11-291L22.7 -5.44 1.01e-07 4.85e-05 -0.29 -0.28 Age-related hearing impairment (SNP x SNP interaction); chr10:37595009 chr10:38448689~38448949:+ LIHC cis rs2749592 0.531 rs994804 ENSG00000263064.2 RP11-291L22.7 -5.44 1.01e-07 4.85e-05 -0.29 -0.28 Age-related hearing impairment (SNP x SNP interaction); chr10:37611212 chr10:38448689~38448949:+ LIHC cis rs8072100 0.846 rs6503796 ENSG00000228782.6 CTD-2026D20.3 5.44 1.01e-07 4.85e-05 0.31 0.28 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47687883 chr17:47450568~47492492:- LIHC cis rs6921919 0.887 rs7766356 ENSG00000204709.4 LINC01556 5.44 1.01e-07 4.85e-05 0.49 0.28 Autism spectrum disorder or schizophrenia; chr6:28432761 chr6:28943877~28944537:+ LIHC cis rs950169 0.881 rs72750843 ENSG00000225151.9 GOLGA2P7 -5.44 1.01e-07 4.86e-05 -0.37 -0.28 Schizophrenia; chr15:84592552 chr15:84199311~84230136:- LIHC cis rs4731207 0.596 rs1871776 ENSG00000224897.5 POT1-AS1 5.44 1.01e-07 4.86e-05 0.35 0.28 Cutaneous malignant melanoma; chr7:125034594 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1871775 ENSG00000224897.5 POT1-AS1 5.44 1.01e-07 4.86e-05 0.35 0.28 Cutaneous malignant melanoma; chr7:125034598 chr7:124929873~125179315:+ LIHC cis rs8005677 1 rs1956880 ENSG00000257285.4 RP11-298I3.1 5.44 1.01e-07 4.86e-05 0.28 0.28 Cognitive ability (multi-trait analysis); chr14:22924798 chr14:22929609~22955562:+ LIHC cis rs12744310 0.502 rs4660187 ENSG00000235358.1 RP11-399E6.1 5.44 1.01e-07 4.86e-05 0.33 0.28 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41333488 chr1:41242373~41284861:+ LIHC cis rs2842992 0.83 rs752779 ENSG00000237927.1 RP3-393E18.2 -5.44 1.01e-07 4.86e-05 -0.34 -0.28 Age-related macular degeneration (geographic atrophy); chr6:159712925 chr6:159586955~159589169:- LIHC cis rs11690935 0.921 rs10200608 ENSG00000228389.1 AC068039.4 5.44 1.01e-07 4.86e-05 0.38 0.28 Schizophrenia; chr2:171741419 chr2:171773482~171775844:+ LIHC cis rs7586673 1 rs16845584 ENSG00000227403.1 AC009299.3 5.44 1.01e-07 4.87e-05 0.34 0.28 Intelligence (multi-trait analysis); chr2:161067319 chr2:161244739~161249050:+ LIHC cis rs12744310 0.666 rs6600370 ENSG00000235358.1 RP11-399E6.1 5.44 1.01e-07 4.87e-05 0.32 0.28 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41302891 chr1:41242373~41284861:+ LIHC cis rs228614 0.51 rs150893 ENSG00000230069.3 LRRC37A15P 5.44 1.01e-07 4.88e-05 0.26 0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102817075 chr4:102727274~102730721:- LIHC cis rs875971 0.545 rs6979636 ENSG00000237310.1 GS1-124K5.4 5.44 1.01e-07 4.88e-05 0.27 0.28 Aortic root size; chr7:66276638 chr7:66493706~66495474:+ LIHC cis rs12681287 0.604 rs41469550 ENSG00000250569.1 NTAN1P2 -5.44 1.01e-07 4.88e-05 -0.33 -0.28 Caudate activity during reward; chr8:86394315 chr8:86481754~86483002:- LIHC cis rs2153535 0.601 rs4140584 ENSG00000230939.1 RP11-314C16.1 5.44 1.01e-07 4.88e-05 0.35 0.28 Motion sickness; chr6:8540381 chr6:8784178~8785445:+ LIHC cis rs12468226 1 rs13389798 ENSG00000273456.1 RP11-686O6.2 5.44 1.02e-07 4.89e-05 0.41 0.28 Urate levels; chr2:202348370 chr2:202374932~202375604:- LIHC cis rs10170846 0.893 rs12614976 ENSG00000261428.2 RP11-16P6.1 5.44 1.02e-07 4.9e-05 0.29 0.28 Schizophrenia (inflammation and infection response interaction); chr2:222678177 chr2:222566899~222569719:- LIHC cis rs2008905 1 rs2008905 ENSG00000272034.1 SNORD14A 5.44 1.02e-07 4.9e-05 0.33 0.28 Schizophrenia; chr11:17163076 chr11:17074654~17074744:- LIHC cis rs12468226 0.938 rs12463937 ENSG00000273456.1 RP11-686O6.2 5.44 1.02e-07 4.91e-05 0.41 0.28 Urate levels; chr2:202246543 chr2:202374932~202375604:- LIHC cis rs7688540 0.61 rs6830496 ENSG00000275426.1 CH17-262A2.1 5.44 1.02e-07 4.91e-05 0.38 0.28 Facial morphology (factor 6, height of vermillion lower lip); chr4:221985 chr4:149738~150317:+ LIHC cis rs2998286 0.822 rs2807737 ENSG00000254635.4 WAC-AS1 -5.44 1.02e-07 4.92e-05 -0.34 -0.28 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28501052 chr10:28522652~28532743:- LIHC cis rs10510102 0.872 rs7906462 ENSG00000276742.1 RP11-500G22.4 5.44 1.02e-07 4.93e-05 0.44 0.28 Breast cancer; chr10:121948098 chr10:121956782~121957098:+ LIHC cis rs9487094 0.67 rs11755641 ENSG00000260273.1 RP11-425D10.10 5.44 1.03e-07 4.93e-05 0.33 0.28 Height; chr6:109586733 chr6:109382795~109383666:+ LIHC cis rs6964833 1 rs36044436 ENSG00000123965.13 PMS2P5 5.44 1.03e-07 4.94e-05 0.52 0.28 Menarche (age at onset); chr7:74675495 chr7:74894116~74897835:+ LIHC cis rs227275 0.554 rs223404 ENSG00000230069.3 LRRC37A15P -5.44 1.03e-07 4.96e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102816951 chr4:102727274~102730721:- LIHC cis rs5769707 0.732 rs135865 ENSG00000235111.1 RP1-29C18.8 -5.44 1.03e-07 4.97e-05 -0.32 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49611181 chr22:49612657~49615716:- LIHC cis rs4660456 0.597 rs7518568 ENSG00000237899.1 RP4-739H11.3 5.44 1.04e-07 4.97e-05 0.35 0.28 Platelet count; chr1:40708508 chr1:40669089~40687588:- LIHC cis rs2274273 0.87 rs6573009 ENSG00000258413.1 RP11-665C16.6 -5.44 1.04e-07 4.97e-05 -0.32 -0.28 Protein biomarker; chr14:55215606 chr14:55262767~55272075:- LIHC cis rs524281 0.861 rs3825067 ENSG00000255320.1 RP11-755F10.1 -5.44 1.04e-07 4.98e-05 -0.37 -0.28 Electroencephalogram traits; chr11:66110948 chr11:66244840~66246239:- LIHC cis rs4713118 0.715 rs200480 ENSG00000216901.1 AL022393.7 5.44 1.04e-07 4.98e-05 0.32 0.28 Parkinson's disease; chr6:27805886 chr6:28176188~28176674:+ LIHC cis rs950776 0.518 rs55690619 ENSG00000261762.1 RP11-650L12.2 -5.44 1.04e-07 4.98e-05 -0.37 -0.28 Sudden cardiac arrest; chr15:78541270 chr15:78589123~78591276:- LIHC cis rs2032366 0.606 rs1377171 ENSG00000267279.1 RP11-879F14.2 -5.44 1.04e-07 4.99e-05 -0.34 -0.28 Obesity-related traits; chr18:61606810 chr18:61585746~61606916:- LIHC cis rs6142102 1 rs4911414 ENSG00000276073.1 RP5-1125A11.7 -5.44 1.04e-07 4.99e-05 -0.32 -0.28 Skin pigmentation; chr20:34141638 chr20:33985617~33988989:- LIHC cis rs7714584 1 rs12656600 ENSG00000197083.10 ZNF300P1 5.44 1.04e-07 5e-05 0.43 0.28 Crohn's disease; chr5:150932310 chr5:150930645~150946289:- LIHC cis rs875971 0.862 rs12537823 ENSG00000237310.1 GS1-124K5.4 5.44 1.04e-07 5e-05 0.25 0.28 Aortic root size; chr7:66255897 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs10282433 ENSG00000237310.1 GS1-124K5.4 -5.44 1.04e-07 5e-05 -0.25 -0.28 Aortic root size; chr7:66256452 chr7:66493706~66495474:+ LIHC cis rs17301013 0.932 rs10912804 ENSG00000227373.4 RP11-160H22.5 5.44 1.04e-07 5.01e-05 0.34 0.28 Systemic lupus erythematosus; chr1:174527412 chr1:174115300~174160004:- LIHC cis rs17301013 0.9 rs12088073 ENSG00000227373.4 RP11-160H22.5 5.44 1.04e-07 5.01e-05 0.34 0.28 Systemic lupus erythematosus; chr1:174528504 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs10912807 ENSG00000227373.4 RP11-160H22.5 5.44 1.04e-07 5.01e-05 0.34 0.28 Systemic lupus erythematosus; chr1:174547228 chr1:174115300~174160004:- LIHC cis rs496547 0.686 rs540180 ENSG00000255422.1 AP002954.4 -5.43 1.04e-07 5.01e-05 -0.32 -0.28 Hip minimal joint space width; chr11:118782920 chr11:118704607~118750263:+ LIHC cis rs496547 0.686 rs2508916 ENSG00000255422.1 AP002954.4 -5.43 1.04e-07 5.01e-05 -0.32 -0.28 Hip minimal joint space width; chr11:118783942 chr11:118704607~118750263:+ LIHC cis rs11098499 0.754 rs1980025 ENSG00000245958.5 RP11-33B1.1 5.43 1.04e-07 5.01e-05 0.29 0.28 Corneal astigmatism; chr4:119331651 chr4:119454791~119552025:+ LIHC cis rs7119038 0.509 rs11216956 ENSG00000255239.1 AP002954.6 -5.43 1.05e-07 5.02e-05 -0.38 -0.28 Sjögren's syndrome; chr11:118704617 chr11:118688039~118690600:- LIHC cis rs4356203 0.87 rs214900 ENSG00000272034.1 SNORD14A 5.43 1.05e-07 5.02e-05 0.3 0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17206215 chr11:17074654~17074744:- LIHC cis rs62229266 0.626 rs2835268 ENSG00000231106.2 LINC01436 5.43 1.05e-07 5.02e-05 0.31 0.28 Mitral valve prolapse; chr21:36076838 chr21:36005338~36007838:+ LIHC cis rs17301013 0.861 rs7521870 ENSG00000227373.4 RP11-160H22.5 -5.43 1.05e-07 5.02e-05 -0.35 -0.28 Systemic lupus erythematosus; chr1:174497239 chr1:174115300~174160004:- LIHC cis rs5769707 0.554 rs10854876 ENSG00000235111.1 RP1-29C18.8 -5.43 1.05e-07 5.02e-05 -0.34 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49616922 chr22:49612657~49615716:- LIHC cis rs2933343 1 rs1680795 ENSG00000231305.3 RP11-723O4.2 5.43 1.05e-07 5.02e-05 0.32 0.28 IgG glycosylation; chr3:128901545 chr3:128861313~128871540:- LIHC cis rs2836974 0.666 rs4818015 ENSG00000255568.3 BRWD1-AS2 5.43 1.05e-07 5.04e-05 0.24 0.28 Cognitive function; chr21:39303567 chr21:39313935~39314962:+ LIHC cis rs4718428 0.672 rs4718412 ENSG00000232546.1 RP11-458F8.1 5.43 1.05e-07 5.04e-05 0.25 0.28 Corneal structure; chr7:66821880 chr7:66848496~66858136:+ LIHC cis rs2243480 0.831 rs7806717 ENSG00000226824.5 RP4-756H11.3 5.43 1.05e-07 5.04e-05 0.46 0.28 Diabetic kidney disease; chr7:65928187 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs78803505 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65917585 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs34933526 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65918212 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs34577383 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65920739 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs6949812 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65922114 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs6970243 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65923503 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs7794661 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65924743 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs7795242 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65925107 chr7:66654538~66669855:+ LIHC cis rs2243480 0.708 rs35310401 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65925372 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs35058610 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65925938 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs2177703 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65926730 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs35432774 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65928032 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs56985706 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65929575 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs60683927 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65929781 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs58062456 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65929865 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs34529418 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65938222 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs35087093 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65940221 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs35046236 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65943626 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs36068983 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65944004 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs68189316 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65944182 chr7:66654538~66669855:+ LIHC cis rs2243480 0.803 rs34804747 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65947955 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs11538349 ENSG00000226824.5 RP4-756H11.3 -5.43 1.05e-07 5.04e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65956884 chr7:66654538~66669855:+ LIHC cis rs1577917 0.883 rs1337854 ENSG00000234155.1 RP11-30P6.6 -5.43 1.05e-07 5.04e-05 -0.34 -0.28 Response to antipsychotic treatment; chr6:86014297 chr6:85387219~85390186:- LIHC cis rs7927592 0.956 rs11228258 ENSG00000212093.1 AP000807.1 -5.43 1.06e-07 5.05e-05 -0.31 -0.28 Total body bone mineral density; chr11:68486860 chr11:68506083~68506166:- LIHC cis rs6589219 0.753 rs4548657 ENSG00000196167.8 COLCA1 -5.43 1.06e-07 5.06e-05 -0.31 -0.28 Colorectal cancer; chr11:111269318 chr11:111290787~111305045:- LIHC cis rs11690935 0.959 rs6709156 ENSG00000228389.1 AC068039.4 5.43 1.06e-07 5.07e-05 0.38 0.28 Schizophrenia; chr2:171735434 chr2:171773482~171775844:+ LIHC cis rs5769707 0.681 rs1107514 ENSG00000235111.1 RP1-29C18.8 -5.43 1.06e-07 5.08e-05 -0.35 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49648735 chr22:49612657~49615716:- LIHC cis rs6921919 0.583 rs6928771 ENSG00000216901.1 AL022393.7 5.43 1.06e-07 5.08e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28407432 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs6928773 ENSG00000216901.1 AL022393.7 5.43 1.06e-07 5.08e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28407433 chr6:28176188~28176674:+ LIHC cis rs11098499 0.954 rs11098524 ENSG00000260091.1 RP11-33B1.4 -5.43 1.06e-07 5.08e-05 -0.21 -0.28 Corneal astigmatism; chr4:119468877 chr4:119409333~119410233:+ LIHC cis rs950169 0.58 rs17532346 ENSG00000259295.5 CSPG4P12 5.43 1.06e-07 5.08e-05 0.38 0.28 Schizophrenia; chr15:84628264 chr15:85191438~85213905:+ LIHC cis rs4706831 0.647 rs627240 ENSG00000272129.1 RP11-250B2.6 -5.43 1.06e-07 5.08e-05 -0.28 -0.28 Joint mobility (Beighton score); chr6:80276168 chr6:80355424~80356859:+ LIHC cis rs10510102 0.872 rs78369301 ENSG00000276742.1 RP11-500G22.4 5.43 1.07e-07 5.09e-05 0.45 0.28 Breast cancer; chr10:121858527 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs75339296 ENSG00000276742.1 RP11-500G22.4 5.43 1.07e-07 5.09e-05 0.45 0.28 Breast cancer; chr10:121859895 chr10:121956782~121957098:+ LIHC cis rs6921919 0.583 rs3734563 ENSG00000216901.1 AL022393.7 5.43 1.07e-07 5.09e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28381948 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs1591913 ENSG00000216901.1 AL022393.7 5.43 1.07e-07 5.09e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28383951 chr6:28176188~28176674:+ LIHC cis rs2243480 0.522 rs778717 ENSG00000226824.5 RP4-756H11.3 -5.43 1.07e-07 5.1e-05 -0.5 -0.28 Diabetic kidney disease; chr7:66383164 chr7:66654538~66669855:+ LIHC cis rs17655730 0.52 rs2178798 ENSG00000277290.1 RP11-326C3.16 -5.43 1.07e-07 5.11e-05 -0.23 -0.28 Mean platelet volume; chr11:254869 chr11:243099~243483:- LIHC cis rs7923609 0.967 rs2393986 ENSG00000232075.1 MRPL35P2 -5.43 1.07e-07 5.11e-05 -0.31 -0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63560246 chr10:63634317~63634827:- LIHC cis rs6686842 1 rs213734 ENSG00000235358.1 RP11-399E6.1 -5.43 1.07e-07 5.11e-05 -0.3 -0.28 Height; chr1:41110027 chr1:41242373~41284861:+ LIHC cis rs1185460 1 rs7127212 ENSG00000271751.1 RP11-110I1.14 5.43 1.07e-07 5.11e-05 0.38 0.28 Coronary artery disease; chr11:119082492 chr11:119065263~119065677:- LIHC cis rs2153535 0.601 rs9505472 ENSG00000230939.1 RP11-314C16.1 -5.43 1.07e-07 5.11e-05 -0.35 -0.28 Motion sickness; chr6:8538532 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs9505473 ENSG00000230939.1 RP11-314C16.1 -5.43 1.07e-07 5.11e-05 -0.35 -0.28 Motion sickness; chr6:8538544 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs9502719 ENSG00000230939.1 RP11-314C16.1 -5.43 1.07e-07 5.11e-05 -0.35 -0.28 Motion sickness; chr6:8540799 chr6:8784178~8785445:+ LIHC cis rs2153535 0.547 rs9502720 ENSG00000230939.1 RP11-314C16.1 -5.43 1.07e-07 5.11e-05 -0.35 -0.28 Motion sickness; chr6:8541129 chr6:8784178~8785445:+ LIHC cis rs2153535 0.547 rs9505475 ENSG00000230939.1 RP11-314C16.1 -5.43 1.07e-07 5.11e-05 -0.35 -0.28 Motion sickness; chr6:8542657 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs6906170 ENSG00000230939.1 RP11-314C16.1 -5.43 1.07e-07 5.11e-05 -0.35 -0.28 Motion sickness; chr6:8542895 chr6:8784178~8785445:+ LIHC cis rs9903692 0.954 rs6847 ENSG00000278765.1 RP5-890E16.5 -5.43 1.07e-07 5.11e-05 -0.36 -0.28 Pulse pressure; chr17:48070445 chr17:48066704~48067293:- LIHC cis rs1005277 0.565 rs2474565 ENSG00000263064.2 RP11-291L22.7 5.43 1.07e-07 5.12e-05 0.29 0.28 Extrinsic epigenetic age acceleration; chr10:38091900 chr10:38448689~38448949:+ LIHC cis rs7916697 0.898 rs1900005 ENSG00000233590.1 RP11-153K11.3 5.43 1.07e-07 5.12e-05 0.34 0.28 Optic disc area; chr10:68238298 chr10:68233251~68242379:- LIHC cis rs860295 0.812 rs10908481 ENSG00000203761.5 MSTO2P -5.43 1.07e-07 5.12e-05 -0.23 -0.28 Body mass index; chr1:155743859 chr1:155745829~155750137:+ LIHC cis rs5758659 1 rs5758660 ENSG00000227370.1 RP4-669P10.19 -5.43 1.08e-07 5.13e-05 -0.32 -0.28 Cognitive function; chr22:42227712 chr22:42132543~42132998:+ LIHC cis rs2274273 0.84 rs6573020 ENSG00000258413.1 RP11-665C16.6 -5.43 1.08e-07 5.14e-05 -0.32 -0.28 Protein biomarker; chr14:55404734 chr14:55262767~55272075:- LIHC cis rs11690935 0.959 rs10206062 ENSG00000228389.1 AC068039.4 5.43 1.08e-07 5.14e-05 0.38 0.28 Schizophrenia; chr2:171720766 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs12692970 ENSG00000228389.1 AC068039.4 5.43 1.08e-07 5.14e-05 0.38 0.28 Schizophrenia; chr2:171737687 chr2:171773482~171775844:+ LIHC cis rs12468226 0.938 rs80282360 ENSG00000273456.1 RP11-686O6.2 5.43 1.08e-07 5.14e-05 0.41 0.28 Urate levels; chr2:202275121 chr2:202374932~202375604:- LIHC cis rs12701220 0.604 rs12702122 ENSG00000229043.2 AC091729.9 -5.43 1.08e-07 5.14e-05 -0.39 -0.28 Bronchopulmonary dysplasia; chr7:1109858 chr7:1160374~1165267:+ LIHC cis rs227275 0.555 rs223403 ENSG00000230069.3 LRRC37A15P -5.43 1.08e-07 5.15e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102817086 chr4:102727274~102730721:- LIHC cis rs3096299 0.719 rs2911262 ENSG00000261118.1 RP11-104N10.1 5.43 1.08e-07 5.15e-05 0.28 0.28 Multiple myeloma (IgH translocation); chr16:89448633 chr16:89492017~89504460:- LIHC cis rs2283792 0.967 rs3810609 ENSG00000224086.5 LL22NC03-86G7.1 -5.43 1.08e-07 5.16e-05 -0.26 -0.28 Multiple sclerosis; chr22:21758513 chr22:21938293~21977632:+ LIHC cis rs875971 0.545 rs75840613 ENSG00000237310.1 GS1-124K5.4 5.43 1.08e-07 5.16e-05 0.27 0.28 Aortic root size; chr7:66376399 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs73148639 ENSG00000237310.1 GS1-124K5.4 5.43 1.08e-07 5.16e-05 0.27 0.28 Aortic root size; chr7:66390342 chr7:66493706~66495474:+ LIHC cis rs2933343 1 rs6785869 ENSG00000231305.3 RP11-723O4.2 5.43 1.09e-07 5.18e-05 0.32 0.28 IgG glycosylation; chr3:128924301 chr3:128861313~128871540:- LIHC cis rs2933343 1 rs1683778 ENSG00000231305.3 RP11-723O4.2 5.43 1.09e-07 5.18e-05 0.32 0.28 IgG glycosylation; chr3:128925752 chr3:128861313~128871540:- LIHC cis rs2072510 0.593 rs2540498 ENSG00000257715.1 RP11-256L6.2 -5.43 1.09e-07 5.19e-05 -0.41 -0.28 Metabolite levels (small molecules and protein measures); chr12:96006791 chr12:96025323~96027971:+ LIHC cis rs12681287 0.608 rs13270090 ENSG00000250569.1 NTAN1P2 -5.43 1.09e-07 5.19e-05 -0.34 -0.28 Caudate activity during reward; chr8:86541069 chr8:86481754~86483002:- LIHC cis rs1223397 0.938 rs20500 ENSG00000215022.6 RP1-257A7.4 5.43 1.09e-07 5.19e-05 0.32 0.28 Blood pressure; chr6:13294744 chr6:13264861~13295586:- LIHC cis rs7209700 0.742 rs7217710 ENSG00000228782.6 CTD-2026D20.3 5.43 1.09e-07 5.19e-05 0.31 0.28 IgG glycosylation; chr17:47293216 chr17:47450568~47492492:- LIHC cis rs4862307 0.688 rs6552741 ENSG00000250726.1 RP11-616K6.1 -5.43 1.09e-07 5.19e-05 -0.29 -0.28 Serum dimethylarginine levels (asymmetric/symetric ratio); chr4:184069182 chr4:184072403~184073039:+ LIHC cis rs2243480 1 rs34136756 ENSG00000226824.5 RP4-756H11.3 -5.43 1.09e-07 5.19e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65916269 chr7:66654538~66669855:+ LIHC cis rs9487094 0.67 rs12193719 ENSG00000260273.1 RP11-425D10.10 5.43 1.09e-07 5.2e-05 0.33 0.28 Height; chr6:109589051 chr6:109382795~109383666:+ LIHC cis rs9487094 0.644 rs1960325 ENSG00000260273.1 RP11-425D10.10 5.43 1.09e-07 5.2e-05 0.33 0.28 Height; chr6:109592105 chr6:109382795~109383666:+ LIHC cis rs6920372 0.731 rs2357124 ENSG00000260273.1 RP11-425D10.10 5.43 1.09e-07 5.2e-05 0.34 0.28 Height; chr6:109551060 chr6:109382795~109383666:+ LIHC cis rs4731207 0.596 rs7806530 ENSG00000224897.5 POT1-AS1 -5.43 1.09e-07 5.2e-05 -0.34 -0.28 Cutaneous malignant melanoma; chr7:125019830 chr7:124929873~125179315:+ LIHC cis rs227275 0.524 rs223337 ENSG00000230069.3 LRRC37A15P -5.43 1.1e-07 5.22e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102865214 chr4:102727274~102730721:- LIHC cis rs4718428 0.705 rs3800817 ENSG00000232546.1 RP11-458F8.1 -5.42 1.1e-07 5.25e-05 -0.25 -0.28 Corneal structure; chr7:66798563 chr7:66848496~66858136:+ LIHC cis rs496547 0.686 rs477014 ENSG00000255422.1 AP002954.4 -5.42 1.1e-07 5.26e-05 -0.32 -0.28 Hip minimal joint space width; chr11:118808277 chr11:118704607~118750263:+ LIHC cis rs496547 0.557 rs516719 ENSG00000255422.1 AP002954.4 -5.42 1.1e-07 5.26e-05 -0.32 -0.28 Hip minimal joint space width; chr11:118808736 chr11:118704607~118750263:+ LIHC cis rs853679 0.527 rs213228 ENSG00000204709.4 LINC01556 5.42 1.11e-07 5.26e-05 0.35 0.28 Depression; chr6:28363475 chr6:28943877~28944537:+ LIHC cis rs7714584 1 rs11741861 ENSG00000197083.10 ZNF300P1 -5.42 1.11e-07 5.26e-05 -0.43 -0.28 Crohn's disease; chr5:150898347 chr5:150930645~150946289:- LIHC cis rs12468226 0.938 rs77062060 ENSG00000273456.1 RP11-686O6.2 5.42 1.11e-07 5.27e-05 0.4 0.28 Urate levels; chr2:202285639 chr2:202374932~202375604:- LIHC cis rs5769707 0.681 rs8140095 ENSG00000235111.1 RP1-29C18.8 -5.42 1.11e-07 5.27e-05 -0.35 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49650147 chr22:49612657~49615716:- LIHC cis rs6686842 1 rs213733 ENSG00000235358.1 RP11-399E6.1 -5.42 1.11e-07 5.27e-05 -0.3 -0.28 Height; chr1:41111317 chr1:41242373~41284861:+ LIHC cis rs7914558 1 rs10748838 ENSG00000236937.2 PTGES3P4 5.42 1.11e-07 5.28e-05 0.33 0.28 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103184229 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs3758543 ENSG00000236937.2 PTGES3P4 5.42 1.11e-07 5.28e-05 0.33 0.28 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103184987 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs4917997 ENSG00000236937.2 PTGES3P4 5.42 1.11e-07 5.28e-05 0.33 0.28 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103185456 chr10:102845595~102845950:+ LIHC cis rs7914558 1 rs7077097 ENSG00000236937.2 PTGES3P4 5.42 1.11e-07 5.28e-05 0.33 0.28 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103185706 chr10:102845595~102845950:+ LIHC cis rs7914558 1 rs7077291 ENSG00000236937.2 PTGES3P4 5.42 1.11e-07 5.28e-05 0.33 0.28 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103185994 chr10:102845595~102845950:+ LIHC cis rs5769707 0.609 rs2071890 ENSG00000235111.1 RP1-29C18.8 -5.42 1.11e-07 5.28e-05 -0.34 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49607643 chr22:49612657~49615716:- LIHC cis rs8059260 0.544 rs7205916 ENSG00000274038.1 RP11-66H6.4 -5.42 1.11e-07 5.28e-05 -0.4 -0.28 Alcohol consumption over the past year; chr16:11095399 chr16:11056556~11057034:+ LIHC cis rs227275 0.556 rs6842179 ENSG00000246560.2 RP11-10L12.4 5.42 1.11e-07 5.28e-05 0.32 0.28 Allergic disease (asthma, hay fever or eczema); chr4:103018363 chr4:102828055~102844075:+ LIHC cis rs12468226 1 rs7597469 ENSG00000273456.1 RP11-686O6.2 5.42 1.11e-07 5.29e-05 0.4 0.28 Urate levels; chr2:202329547 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs113877751 ENSG00000273456.1 RP11-686O6.2 5.42 1.11e-07 5.29e-05 0.4 0.28 Urate levels; chr2:202329998 chr2:202374932~202375604:- LIHC cis rs12468226 0.935 rs113021930 ENSG00000273456.1 RP11-686O6.2 5.42 1.11e-07 5.29e-05 0.4 0.28 Urate levels; chr2:202330448 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs113491584 ENSG00000273456.1 RP11-686O6.2 5.42 1.11e-07 5.29e-05 0.4 0.28 Urate levels; chr2:202331724 chr2:202374932~202375604:- LIHC cis rs4731207 0.596 rs2017928 ENSG00000224897.5 POT1-AS1 5.42 1.11e-07 5.29e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125032269 chr7:124929873~125179315:+ LIHC cis rs9341808 0.683 rs7771449 ENSG00000272129.1 RP11-250B2.6 5.42 1.12e-07 5.3e-05 0.27 0.28 Sitting height ratio; chr6:80210260 chr6:80355424~80356859:+ LIHC cis rs5769765 0.955 rs4075330 ENSG00000278869.1 CITF22-49E9.3 5.42 1.12e-07 5.3e-05 0.43 0.28 Schizophrenia; chr22:49909601 chr22:49933198~49934074:- LIHC cis rs9341808 0.718 rs910266 ENSG00000272129.1 RP11-250B2.6 5.42 1.12e-07 5.3e-05 0.27 0.28 Sitting height ratio; chr6:80211453 chr6:80355424~80356859:+ LIHC cis rs12468226 0.873 rs59293950 ENSG00000273456.1 RP11-686O6.2 5.42 1.12e-07 5.31e-05 0.41 0.28 Urate levels; chr2:202214069 chr2:202374932~202375604:- LIHC cis rs12468226 0.873 rs12472035 ENSG00000273456.1 RP11-686O6.2 5.42 1.12e-07 5.31e-05 0.41 0.28 Urate levels; chr2:202221970 chr2:202374932~202375604:- LIHC cis rs2243480 1 rs73142162 ENSG00000226824.5 RP4-756H11.3 -5.42 1.12e-07 5.31e-05 -0.47 -0.28 Diabetic kidney disease; chr7:65909309 chr7:66654538~66669855:+ LIHC cis rs950776 0.518 rs8025429 ENSG00000261762.1 RP11-650L12.2 -5.42 1.12e-07 5.31e-05 -0.37 -0.28 Sudden cardiac arrest; chr15:78544020 chr15:78589123~78591276:- LIHC cis rs2243480 1 rs2420171 ENSG00000226824.5 RP4-756H11.3 5.42 1.12e-07 5.31e-05 0.46 0.28 Diabetic kidney disease; chr7:66172773 chr7:66654538~66669855:+ LIHC cis rs5758511 0.68 rs739146 ENSG00000237037.8 NDUFA6-AS1 -5.42 1.12e-07 5.31e-05 -0.35 -0.28 Birth weight; chr22:42264408 chr22:42090931~42137742:+ LIHC cis rs9341808 0.718 rs2143887 ENSG00000272129.1 RP11-250B2.6 5.42 1.12e-07 5.31e-05 0.27 0.28 Sitting height ratio; chr6:80207570 chr6:80355424~80356859:+ LIHC cis rs1075265 0.584 rs4671178 ENSG00000233266.1 HMGB1P31 -5.42 1.12e-07 5.32e-05 -0.35 -0.28 Chronotype;Morning vs. evening chronotype; chr2:54056356 chr2:54051334~54051760:+ LIHC cis rs6686842 1 rs6600365 ENSG00000235358.1 RP11-399E6.1 -5.42 1.12e-07 5.32e-05 -0.3 -0.28 Height; chr1:41090581 chr1:41242373~41284861:+ LIHC cis rs6686842 0.932 rs1008505 ENSG00000235358.1 RP11-399E6.1 -5.42 1.12e-07 5.32e-05 -0.3 -0.28 Height; chr1:41094563 chr1:41242373~41284861:+ LIHC cis rs6686842 1 rs17571940 ENSG00000235358.1 RP11-399E6.1 -5.42 1.12e-07 5.32e-05 -0.3 -0.28 Height; chr1:41100519 chr1:41242373~41284861:+ LIHC cis rs6686842 1 rs479493 ENSG00000235358.1 RP11-399E6.1 -5.42 1.12e-07 5.32e-05 -0.3 -0.28 Height; chr1:41101530 chr1:41242373~41284861:+ LIHC cis rs6686842 1 rs656917 ENSG00000235358.1 RP11-399E6.1 -5.42 1.12e-07 5.32e-05 -0.3 -0.28 Height; chr1:41104036 chr1:41242373~41284861:+ LIHC cis rs2522056 1 rs886286 ENSG00000233006.5 AC034220.3 -5.42 1.12e-07 5.33e-05 -0.29 -0.28 Fibrinogen;Lymphocyte counts; chr5:132459905 chr5:132311285~132369916:- LIHC cis rs2522056 1 rs757105 ENSG00000233006.5 AC034220.3 -5.42 1.12e-07 5.33e-05 -0.29 -0.28 Fibrinogen;Lymphocyte counts; chr5:132459971 chr5:132311285~132369916:- LIHC cis rs2522056 1 rs2522047 ENSG00000233006.5 AC034220.3 -5.42 1.12e-07 5.33e-05 -0.29 -0.28 Fibrinogen;Lymphocyte counts; chr5:132460190 chr5:132311285~132369916:- LIHC cis rs2522056 1 rs2706393 ENSG00000233006.5 AC034220.3 -5.42 1.12e-07 5.33e-05 -0.29 -0.28 Fibrinogen;Lymphocyte counts; chr5:132460375 chr5:132311285~132369916:- LIHC cis rs2522056 1 rs2706395 ENSG00000233006.5 AC034220.3 -5.42 1.12e-07 5.33e-05 -0.29 -0.28 Fibrinogen;Lymphocyte counts; chr5:132461111 chr5:132311285~132369916:- LIHC cis rs10912872 0.564 rs11807475 ENSG00000225704.2 RP4-798A17.5 5.42 1.12e-07 5.33e-05 0.25 0.28 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr1:171371960 chr1:171345089~171345320:+ LIHC cis rs2933343 1 rs1683776 ENSG00000231305.3 RP11-723O4.2 5.42 1.12e-07 5.33e-05 0.32 0.28 IgG glycosylation; chr3:128903917 chr3:128861313~128871540:- LIHC cis rs12291225 0.585 rs10832242 ENSG00000251991.1 RNU7-49P -5.42 1.12e-07 5.34e-05 -0.29 -0.28 Sense of smell; chr11:14318958 chr11:14478892~14478953:+ LIHC cis rs524281 0.861 rs10750780 ENSG00000255320.1 RP11-755F10.1 5.42 1.13e-07 5.35e-05 0.38 0.28 Electroencephalogram traits; chr11:66207121 chr11:66244840~66246239:- LIHC cis rs2243480 1 rs13247184 ENSG00000226824.5 RP4-756H11.3 -5.42 1.13e-07 5.36e-05 -0.47 -0.28 Diabetic kidney disease; chr7:65893941 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs35283677 ENSG00000226824.5 RP4-756H11.3 -5.42 1.13e-07 5.36e-05 -0.47 -0.28 Diabetic kidney disease; chr7:65894246 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs35421653 ENSG00000226824.5 RP4-756H11.3 -5.42 1.13e-07 5.36e-05 -0.47 -0.28 Diabetic kidney disease; chr7:65898442 chr7:66654538~66669855:+ LIHC cis rs5769707 0.667 rs4824069 ENSG00000235111.1 RP1-29C18.8 -5.42 1.13e-07 5.36e-05 -0.34 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49636677 chr22:49612657~49615716:- LIHC cis rs227275 0.525 rs13150426 ENSG00000230069.3 LRRC37A15P -5.42 1.13e-07 5.36e-05 -0.26 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103013743 chr4:102727274~102730721:- LIHC cis rs4728142 0.593 rs7808907 ENSG00000275106.1 RP11-309L24.10 5.42 1.13e-07 5.36e-05 0.34 0.28 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128944030 chr7:128952527~128953316:- LIHC cis rs2933343 0.553 rs35076317 ENSG00000231305.3 RP11-723O4.2 5.42 1.13e-07 5.38e-05 0.31 0.28 IgG glycosylation; chr3:128996692 chr3:128861313~128871540:- LIHC cis rs12468226 0.606 rs10445793 ENSG00000273456.1 RP11-686O6.2 5.42 1.14e-07 5.38e-05 0.37 0.28 Urate levels; chr2:202190799 chr2:202374932~202375604:- LIHC cis rs6142102 1 rs6142102 ENSG00000276073.1 RP5-1125A11.7 -5.42 1.14e-07 5.39e-05 -0.31 -0.28 Skin pigmentation; chr20:34116821 chr20:33985617~33988989:- LIHC cis rs67180937 0.7 rs12043288 ENSG00000272750.1 RP11-378J18.8 -5.42 1.14e-07 5.39e-05 -0.29 -0.28 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222732952 chr1:222658867~222661512:- LIHC cis rs5756813 0.705 rs6000886 ENSG00000233360.4 Z83844.1 -5.42 1.14e-07 5.39e-05 -0.35 -0.28 Optic cup area;Vertical cup-disc ratio; chr22:37780663 chr22:37641832~37658377:- LIHC cis rs9318086 0.712 rs3794339 ENSG00000205861.10 C1QTNF9B-AS1 -5.42 1.14e-07 5.39e-05 -0.32 -0.28 Myopia (pathological); chr13:23859926 chr13:23888889~23897263:+ LIHC cis rs202072 0.872 rs413120 ENSG00000215022.6 RP1-257A7.4 5.42 1.14e-07 5.4e-05 0.31 0.28 HIV-1 viral setpoint; chr6:13280409 chr6:13264861~13295586:- LIHC cis rs875971 0.767 rs1643394 ENSG00000237310.1 GS1-124K5.4 5.42 1.14e-07 5.4e-05 0.25 0.28 Aortic root size; chr7:66371107 chr7:66493706~66495474:+ LIHC cis rs4718428 0.705 rs11028 ENSG00000232546.1 RP11-458F8.1 -5.42 1.14e-07 5.41e-05 -0.25 -0.28 Corneal structure; chr7:66811230 chr7:66848496~66858136:+ LIHC cis rs7923609 0.967 rs10740134 ENSG00000232075.1 MRPL35P2 -5.42 1.14e-07 5.41e-05 -0.31 -0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63555673 chr10:63634317~63634827:- LIHC cis rs9487094 0.689 rs9487103 ENSG00000260273.1 RP11-425D10.10 5.42 1.14e-07 5.42e-05 0.33 0.28 Height; chr6:109430292 chr6:109382795~109383666:+ LIHC cis rs13631 0.894 rs7856589 ENSG00000268996.3 MAN1B1-AS1 -5.42 1.15e-07 5.43e-05 -0.3 -0.28 Cerebrospinal fluid biomarker levels; chr9:137109469 chr9:137084946~137086817:- LIHC cis rs2297363 1 rs2282140 ENSG00000213073.4 RP11-288H12.3 -5.42 1.15e-07 5.44e-05 -0.33 -0.28 Total cholesterol levels;Blood protein levels; chr6:160073489 chr6:160093082~160096212:+ LIHC cis rs957448 1 rs12679345 ENSG00000253704.1 RP11-267M23.4 5.42 1.15e-07 5.44e-05 0.33 0.28 Nonsyndromic cleft lip with cleft palate; chr8:94552305 chr8:94553722~94569745:+ LIHC cis rs2286503 0.966 rs6949233 ENSG00000228649.7 AC005682.5 5.42 1.15e-07 5.45e-05 0.34 0.28 Fibrinogen; chr7:22818572 chr7:22854178~22861579:+ LIHC cis rs5769707 0.749 rs8137251 ENSG00000235111.1 RP1-29C18.8 -5.42 1.15e-07 5.45e-05 -0.33 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49643021 chr22:49612657~49615716:- LIHC cis rs12468226 0.938 rs57571703 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202281997 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs78928733 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202283787 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs116109808 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202287356 chr2:202374932~202375604:- LIHC cis rs12468226 0.873 rs78175596 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202287993 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs56684065 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202289528 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs1474001 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202290230 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs76664732 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202296298 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs16841867 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202303512 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs79117531 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202307690 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs16839065 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202308774 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs115418918 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202315145 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs114922024 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202315958 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs77261109 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202316233 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs12466003 ENSG00000273456.1 RP11-686O6.2 5.42 1.15e-07 5.45e-05 0.4 0.28 Urate levels; chr2:202317317 chr2:202374932~202375604:- LIHC cis rs7945705 0.967 rs1569408 ENSG00000254860.4 TMEM9B-AS1 -5.42 1.15e-07 5.46e-05 -0.28 -0.28 Hemoglobin concentration; chr11:8888185 chr11:8964675~8977527:+ LIHC cis rs524281 0.861 rs10750779 ENSG00000255320.1 RP11-755F10.1 5.41 1.16e-07 5.47e-05 0.38 0.28 Electroencephalogram traits; chr11:66207120 chr11:66244840~66246239:- LIHC cis rs17301013 0.896 rs6425287 ENSG00000227373.4 RP11-160H22.5 5.41 1.16e-07 5.48e-05 0.34 0.28 Systemic lupus erythematosus; chr1:174566264 chr1:174115300~174160004:- LIHC cis rs4731207 0.596 rs9332427 ENSG00000224897.5 POT1-AS1 5.41 1.16e-07 5.48e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:124936904 chr7:124929873~125179315:+ LIHC cis rs2243480 1 rs2257790 ENSG00000226824.5 RP4-756H11.3 -5.41 1.16e-07 5.48e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66135463 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs316332 ENSG00000226824.5 RP4-756H11.3 -5.41 1.16e-07 5.48e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66139312 chr7:66654538~66669855:+ LIHC cis rs4934494 0.727 rs12572012 ENSG00000232936.4 RP11-80H5.2 5.41 1.16e-07 5.48e-05 0.35 0.28 Red blood cell count; chr10:89727892 chr10:89645282~89650667:+ LIHC cis rs4934494 0.727 rs3758388 ENSG00000232936.4 RP11-80H5.2 5.41 1.16e-07 5.48e-05 0.35 0.28 Red blood cell count; chr10:89729222 chr10:89645282~89650667:+ LIHC cis rs4934494 0.727 rs12783582 ENSG00000232936.4 RP11-80H5.2 5.41 1.16e-07 5.48e-05 0.35 0.28 Red blood cell count; chr10:89735210 chr10:89645282~89650667:+ LIHC cis rs7945705 0.87 rs4929922 ENSG00000254860.4 TMEM9B-AS1 5.41 1.16e-07 5.49e-05 0.28 0.28 Hemoglobin concentration; chr11:8954229 chr11:8964675~8977527:+ LIHC cis rs12468226 0.81 rs77090459 ENSG00000273456.1 RP11-686O6.2 5.41 1.16e-07 5.49e-05 0.41 0.28 Urate levels; chr2:202542132 chr2:202374932~202375604:- LIHC cis rs6589219 0.788 rs1987128 ENSG00000196167.8 COLCA1 -5.41 1.16e-07 5.5e-05 -0.31 -0.28 Colorectal cancer; chr11:111281771 chr11:111290787~111305045:- LIHC cis rs9425766 0.541 rs4652274 ENSG00000227373.4 RP11-160H22.5 5.41 1.17e-07 5.51e-05 0.36 0.28 Life satisfaction; chr1:174249434 chr1:174115300~174160004:- LIHC cis rs9487094 0.813 rs34131679 ENSG00000260273.1 RP11-425D10.10 5.41 1.17e-07 5.52e-05 0.39 0.28 Height; chr6:109375848 chr6:109382795~109383666:+ LIHC cis rs1577917 0.839 rs12055653 ENSG00000234155.1 RP11-30P6.6 5.41 1.17e-07 5.52e-05 0.34 0.28 Response to antipsychotic treatment; chr6:85836945 chr6:85387219~85390186:- LIHC cis rs8059260 0.668 rs16957855 ENSG00000274038.1 RP11-66H6.4 -5.41 1.17e-07 5.52e-05 -0.47 -0.28 Alcohol consumption over the past year; chr16:10977116 chr16:11056556~11057034:+ LIHC cis rs8059260 0.736 rs78121798 ENSG00000274038.1 RP11-66H6.4 -5.41 1.17e-07 5.52e-05 -0.47 -0.28 Alcohol consumption over the past year; chr16:10984224 chr16:11056556~11057034:+ LIHC cis rs2286503 1 rs2286499 ENSG00000228649.7 AC005682.5 5.41 1.17e-07 5.53e-05 0.34 0.28 Fibrinogen; chr7:22817858 chr7:22854178~22861579:+ LIHC cis rs7615952 0.688 rs12638224 ENSG00000171084.14 FAM86JP 5.41 1.17e-07 5.53e-05 0.39 0.28 Blood pressure (smoking interaction); chr3:125822477 chr3:125916620~125930024:+ LIHC cis rs7429990 0.965 rs777015 ENSG00000229759.1 MRPS18AP1 5.41 1.17e-07 5.54e-05 0.3 0.28 Educational attainment (years of education); chr3:47895582 chr3:48256350~48256938:- LIHC cis rs6142102 1 rs6059672 ENSG00000276073.1 RP5-1125A11.7 -5.41 1.17e-07 5.54e-05 -0.32 -0.28 Skin pigmentation; chr20:34117662 chr20:33985617~33988989:- LIHC cis rs2933343 1 rs2630252 ENSG00000231305.3 RP11-723O4.2 5.41 1.17e-07 5.55e-05 0.32 0.28 IgG glycosylation; chr3:128905929 chr3:128861313~128871540:- LIHC cis rs3858145 0.588 rs10998059 ENSG00000233590.1 RP11-153K11.3 5.41 1.18e-07 5.56e-05 0.37 0.28 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68302750 chr10:68233251~68242379:- LIHC cis rs12285276 1 rs12285276 ENSG00000205106.4 DKFZp779M0652 5.41 1.18e-07 5.56e-05 0.28 0.28 Visceral fat; chr11:45792030 chr11:45771432~45772358:+ LIHC cis rs5758659 0.967 rs5751250 ENSG00000227370.1 RP4-669P10.19 -5.41 1.18e-07 5.56e-05 -0.31 -0.28 Cognitive function; chr22:42243639 chr22:42132543~42132998:+ LIHC cis rs9425766 0.591 rs2049991 ENSG00000227373.4 RP11-160H22.5 5.41 1.18e-07 5.56e-05 0.36 0.28 Life satisfaction; chr1:174356428 chr1:174115300~174160004:- LIHC cis rs4266144 0.562 rs56357317 ENSG00000244515.1 KRT18P34 -5.41 1.18e-07 5.56e-05 -0.31 -0.28 Coronary artery disease; chr3:157117385 chr3:157162663~157163932:- LIHC cis rs7131987 0.683 rs12366505 ENSG00000275476.1 RP11-996F15.4 -5.41 1.18e-07 5.56e-05 -0.33 -0.28 QT interval; chr12:29321177 chr12:29277397~29277882:- LIHC cis rs7131987 0.65 rs12366527 ENSG00000275476.1 RP11-996F15.4 -5.41 1.18e-07 5.56e-05 -0.33 -0.28 QT interval; chr12:29321323 chr12:29277397~29277882:- LIHC cis rs7131987 0.65 rs7311912 ENSG00000275476.1 RP11-996F15.4 -5.41 1.18e-07 5.56e-05 -0.33 -0.28 QT interval; chr12:29322770 chr12:29277397~29277882:- LIHC cis rs9318086 0.648 rs35449605 ENSG00000205861.10 C1QTNF9B-AS1 -5.41 1.18e-07 5.56e-05 -0.32 -0.28 Myopia (pathological); chr13:23898443 chr13:23888889~23897263:+ LIHC cis rs9487094 0.67 rs13199135 ENSG00000260273.1 RP11-425D10.10 5.41 1.18e-07 5.57e-05 0.33 0.28 Height; chr6:109588639 chr6:109382795~109383666:+ LIHC cis rs10170846 0.893 rs11692810 ENSG00000261428.2 RP11-16P6.1 -5.41 1.18e-07 5.57e-05 -0.29 -0.28 Schizophrenia (inflammation and infection response interaction); chr2:222679377 chr2:222566899~222569719:- LIHC cis rs12701220 0.655 rs34344742 ENSG00000229043.2 AC091729.9 -5.41 1.18e-07 5.58e-05 -0.39 -0.28 Bronchopulmonary dysplasia; chr7:1109652 chr7:1160374~1165267:+ LIHC cis rs5769765 0.954 rs910799 ENSG00000278869.1 CITF22-49E9.3 -5.41 1.18e-07 5.59e-05 -0.43 -0.28 Schizophrenia; chr22:49884920 chr22:49933198~49934074:- LIHC cis rs860295 0.812 rs7556519 ENSG00000203761.5 MSTO2P -5.41 1.18e-07 5.59e-05 -0.23 -0.28 Body mass index; chr1:155857755 chr1:155745829~155750137:+ LIHC cis rs4284742 1 rs4284742 ENSG00000273837.1 LLNLR-470E3.1 5.41 1.19e-07 5.61e-05 0.34 0.28 Aggressive periodontitis; chr19:51628480 chr19:51639478~51639931:- LIHC cis rs853679 0.538 rs13199081 ENSG00000216901.1 AL022393.7 5.41 1.19e-07 5.61e-05 0.37 0.28 Depression; chr6:28364057 chr6:28176188~28176674:+ LIHC cis rs11722779 0.869 rs223323 ENSG00000246560.2 RP11-10L12.4 5.41 1.19e-07 5.61e-05 0.31 0.28 Schizophrenia; chr4:102878412 chr4:102828055~102844075:+ LIHC cis rs227275 0.554 rs223316 ENSG00000246560.2 RP11-10L12.4 5.41 1.19e-07 5.61e-05 0.31 0.28 Allergic disease (asthma, hay fever or eczema); chr4:102881949 chr4:102828055~102844075:+ LIHC cis rs227275 0.554 rs223314 ENSG00000246560.2 RP11-10L12.4 5.41 1.19e-07 5.61e-05 0.31 0.28 Allergic disease (asthma, hay fever or eczema); chr4:102884642 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223313 ENSG00000246560.2 RP11-10L12.4 5.41 1.19e-07 5.61e-05 0.31 0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102886563 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs7254 ENSG00000246560.2 RP11-10L12.4 5.41 1.19e-07 5.61e-05 0.31 0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102888488 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223311 ENSG00000246560.2 RP11-10L12.4 5.41 1.19e-07 5.61e-05 0.31 0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102888757 chr4:102828055~102844075:+ LIHC cis rs11722779 0.566 rs6822658 ENSG00000246560.2 RP11-10L12.4 5.41 1.19e-07 5.61e-05 0.31 0.28 Schizophrenia; chr4:102891964 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs6823625 ENSG00000246560.2 RP11-10L12.4 5.41 1.19e-07 5.61e-05 0.31 0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892437 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs6846762 ENSG00000246560.2 RP11-10L12.4 5.41 1.19e-07 5.61e-05 0.31 0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892577 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs4699032 ENSG00000246560.2 RP11-10L12.4 5.41 1.19e-07 5.61e-05 0.31 0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892724 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs28445579 ENSG00000230069.3 LRRC37A15P -5.41 1.19e-07 5.62e-05 -0.26 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103016438 chr4:102727274~102730721:- LIHC cis rs11089937 0.929 rs5750624 ENSG00000211639.2 IGLV4-60 5.41 1.19e-07 5.62e-05 0.24 0.28 Periodontitis (PAL4Q3); chr22:22165354 chr22:22162199~22162681:+ LIHC cis rs227275 0.556 rs4235407 ENSG00000230069.3 LRRC37A15P -5.41 1.19e-07 5.62e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102897427 chr4:102727274~102730721:- LIHC cis rs875971 0.545 rs6970498 ENSG00000237310.1 GS1-124K5.4 5.41 1.19e-07 5.63e-05 0.27 0.28 Aortic root size; chr7:66275908 chr7:66493706~66495474:+ LIHC cis rs11673344 0.566 rs256733 ENSG00000226686.6 LINC01535 5.41 1.19e-07 5.63e-05 0.34 0.28 Obesity-related traits; chr19:37384729 chr19:37251912~37265535:+ LIHC cis rs12468226 1 rs16824599 ENSG00000273456.1 RP11-686O6.2 5.41 1.19e-07 5.63e-05 0.42 0.28 Urate levels; chr2:202358243 chr2:202374932~202375604:- LIHC cis rs11722779 0.935 rs7676736 ENSG00000230069.3 LRRC37A15P -5.41 1.19e-07 5.63e-05 -0.26 -0.28 Schizophrenia; chr4:103016729 chr4:102727274~102730721:- LIHC cis rs12468226 1 rs16839090 ENSG00000273456.1 RP11-686O6.2 5.41 1.2e-07 5.64e-05 0.41 0.28 Urate levels; chr2:202348338 chr2:202374932~202375604:- LIHC cis rs11690935 0.798 rs13018768 ENSG00000228389.1 AC068039.4 5.41 1.2e-07 5.64e-05 0.37 0.28 Schizophrenia; chr2:171742082 chr2:171773482~171775844:+ LIHC cis rs9487094 0.666 rs1074765 ENSG00000260273.1 RP11-425D10.10 -5.41 1.2e-07 5.66e-05 -0.33 -0.28 Height; chr6:109360458 chr6:109382795~109383666:+ LIHC cis rs6686842 0.965 rs2802548 ENSG00000235358.1 RP11-399E6.1 -5.41 1.2e-07 5.66e-05 -0.31 -0.28 Height; chr1:41035441 chr1:41242373~41284861:+ LIHC cis rs6686842 0.897 rs2802565 ENSG00000235358.1 RP11-399E6.1 -5.41 1.2e-07 5.67e-05 -0.31 -0.28 Height; chr1:41086147 chr1:41242373~41284861:+ LIHC cis rs1153858 0.887 rs28569043 ENSG00000259520.4 CTD-2651B20.3 -5.41 1.2e-07 5.68e-05 -0.34 -0.28 Homoarginine levels; chr15:45438728 chr15:45251580~45279251:- LIHC cis rs227275 0.556 rs11722779 ENSG00000230069.3 LRRC37A15P -5.41 1.21e-07 5.68e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102906331 chr4:102727274~102730721:- LIHC cis rs9425766 0.566 rs10912773 ENSG00000227373.4 RP11-160H22.5 5.41 1.21e-07 5.69e-05 0.36 0.28 Life satisfaction; chr1:174374567 chr1:174115300~174160004:- LIHC cis rs7615952 0.688 rs17334074 ENSG00000171084.14 FAM86JP -5.41 1.21e-07 5.69e-05 -0.38 -0.28 Blood pressure (smoking interaction); chr3:125821617 chr3:125916620~125930024:+ LIHC cis rs6921919 0.515 rs1339898 ENSG00000204709.4 LINC01556 5.41 1.21e-07 5.69e-05 0.34 0.28 Autism spectrum disorder or schizophrenia; chr6:28427729 chr6:28943877~28944537:+ LIHC cis rs55757919 1 rs55757919 ENSG00000231742.4 LINC01273 5.41 1.21e-07 5.7e-05 0.36 0.28 Monocyte percentage of white cells; chr20:50132011 chr20:50172550~50176671:+ LIHC cis rs227275 0.556 rs223426 ENSG00000230069.3 LRRC37A15P -5.41 1.21e-07 5.72e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102801330 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs223425 ENSG00000230069.3 LRRC37A15P -5.41 1.21e-07 5.72e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102802836 chr4:102727274~102730721:- LIHC cis rs6686842 0.965 rs2802566 ENSG00000235358.1 RP11-399E6.1 -5.41 1.22e-07 5.73e-05 -0.31 -0.28 Height; chr1:41086309 chr1:41242373~41284861:+ LIHC cis rs5769765 0.773 rs9616391 ENSG00000278869.1 CITF22-49E9.3 5.4 1.22e-07 5.74e-05 0.46 0.28 Schizophrenia; chr22:49920925 chr22:49933198~49934074:- LIHC cis rs2243480 1 rs1638734 ENSG00000226824.5 RP4-756H11.3 -5.4 1.22e-07 5.75e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66632552 chr7:66654538~66669855:+ LIHC cis rs11098499 0.779 rs28495013 ENSG00000245958.5 RP11-33B1.1 -5.4 1.22e-07 5.75e-05 -0.29 -0.28 Corneal astigmatism; chr4:119454676 chr4:119454791~119552025:+ LIHC cis rs3096299 0.685 rs4785676 ENSG00000261118.1 RP11-104N10.1 5.4 1.22e-07 5.75e-05 0.28 0.28 Multiple myeloma (IgH translocation); chr16:89487216 chr16:89492017~89504460:- LIHC cis rs2153535 0.58 rs9505467 ENSG00000230939.1 RP11-314C16.1 -5.4 1.22e-07 5.76e-05 -0.35 -0.28 Motion sickness; chr6:8519986 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1360054 ENSG00000230939.1 RP11-314C16.1 -5.4 1.22e-07 5.76e-05 -0.35 -0.28 Motion sickness; chr6:8520144 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9328483 ENSG00000230939.1 RP11-314C16.1 -5.4 1.22e-07 5.76e-05 -0.35 -0.28 Motion sickness; chr6:8521062 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9393033 ENSG00000230939.1 RP11-314C16.1 -5.4 1.22e-07 5.76e-05 -0.35 -0.28 Motion sickness; chr6:8521213 chr6:8784178~8785445:+ LIHC cis rs2153535 0.541 rs6938688 ENSG00000230939.1 RP11-314C16.1 -5.4 1.22e-07 5.76e-05 -0.35 -0.28 Motion sickness; chr6:8521396 chr6:8784178~8785445:+ LIHC cis rs6589219 0.754 rs7105857 ENSG00000196167.8 COLCA1 -5.4 1.22e-07 5.76e-05 -0.31 -0.28 Colorectal cancer; chr11:111300019 chr11:111290787~111305045:- LIHC cis rs4356203 0.875 rs7125607 ENSG00000272034.1 SNORD14A -5.4 1.23e-07 5.77e-05 -0.31 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17074603 chr11:17074654~17074744:- LIHC cis rs950169 0.922 rs11635505 ENSG00000259295.5 CSPG4P12 -5.4 1.23e-07 5.77e-05 -0.37 -0.28 Schizophrenia; chr15:84553803 chr15:85191438~85213905:+ LIHC cis rs4731207 0.698 rs962863 ENSG00000224897.5 POT1-AS1 -5.4 1.23e-07 5.77e-05 -0.33 -0.28 Cutaneous malignant melanoma; chr7:124918285 chr7:124929873~125179315:+ LIHC cis rs2933343 1 rs789237 ENSG00000231305.3 RP11-723O4.2 5.4 1.23e-07 5.79e-05 0.31 0.28 IgG glycosylation; chr3:128918118 chr3:128861313~128871540:- LIHC cis rs950776 0.518 rs4886571 ENSG00000261762.1 RP11-650L12.2 -5.4 1.23e-07 5.8e-05 -0.36 -0.28 Sudden cardiac arrest; chr15:78541416 chr15:78589123~78591276:- LIHC cis rs1577917 0.771 rs3812133 ENSG00000234155.1 RP11-30P6.6 5.4 1.23e-07 5.8e-05 0.39 0.28 Response to antipsychotic treatment; chr6:85644693 chr6:85387219~85390186:- LIHC cis rs2243480 1 rs937108 ENSG00000226824.5 RP4-756H11.3 -5.4 1.23e-07 5.8e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65963465 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs35542501 ENSG00000226824.5 RP4-756H11.3 -5.4 1.23e-07 5.8e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65966228 chr7:66654538~66669855:+ LIHC cis rs2243480 0.711 rs1626926 ENSG00000226824.5 RP4-756H11.3 -5.4 1.23e-07 5.8e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65970805 chr7:66654538~66669855:+ LIHC cis rs2243480 0.708 rs781141 ENSG00000226824.5 RP4-756H11.3 -5.4 1.23e-07 5.8e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65973566 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs781142 ENSG00000226824.5 RP4-756H11.3 -5.4 1.23e-07 5.8e-05 -0.46 -0.28 Diabetic kidney disease; chr7:65973791 chr7:66654538~66669855:+ LIHC cis rs7923609 0.841 rs10761786 ENSG00000232075.1 MRPL35P2 -5.4 1.24e-07 5.81e-05 -0.3 -0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63576447 chr10:63634317~63634827:- LIHC cis rs13068223 0.84 rs1469536 ENSG00000243926.1 TIPARP-AS1 5.4 1.24e-07 5.81e-05 0.27 0.28 Age-related hearing impairment (SNP x SNP interaction); chr3:156710038 chr3:156671862~156674378:- LIHC cis rs3096299 0.679 rs3102338 ENSG00000261118.1 RP11-104N10.1 5.4 1.24e-07 5.82e-05 0.29 0.28 Multiple myeloma (IgH translocation); chr16:89375842 chr16:89492017~89504460:- LIHC cis rs17023223 0.537 rs12086686 ENSG00000231365.4 RP11-418J17.1 -5.4 1.24e-07 5.83e-05 -0.35 -0.28 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119146461 chr1:119140396~119275973:+ LIHC cis rs17023223 0.537 rs12085616 ENSG00000231365.4 RP11-418J17.1 -5.4 1.24e-07 5.83e-05 -0.35 -0.28 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119146525 chr1:119140396~119275973:+ LIHC cis rs17711722 0.523 rs365896 ENSG00000226824.5 RP4-756H11.3 5.4 1.24e-07 5.83e-05 0.33 0.28 Calcium levels; chr7:66045710 chr7:66654538~66669855:+ LIHC cis rs4731207 0.698 rs4731218 ENSG00000224897.5 POT1-AS1 5.4 1.24e-07 5.83e-05 0.33 0.28 Cutaneous malignant melanoma; chr7:124831961 chr7:124929873~125179315:+ LIHC cis rs8177376 0.861 rs4340064 ENSG00000254905.1 RP11-712L6.7 5.4 1.24e-07 5.83e-05 0.41 0.28 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126242165 chr11:126292922~126294254:- LIHC cis rs228614 0.51 rs170565 ENSG00000230069.3 LRRC37A15P -5.4 1.24e-07 5.83e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798277 chr4:102727274~102730721:- LIHC cis rs875971 0.862 rs778724 ENSG00000237310.1 GS1-124K5.4 5.4 1.24e-07 5.83e-05 0.25 0.28 Aortic root size; chr7:66364304 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs778686 ENSG00000237310.1 GS1-124K5.4 5.4 1.24e-07 5.83e-05 0.25 0.28 Aortic root size; chr7:66370923 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs778684 ENSG00000237310.1 GS1-124K5.4 5.4 1.24e-07 5.83e-05 0.25 0.28 Aortic root size; chr7:66371416 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs778680 ENSG00000237310.1 GS1-124K5.4 5.4 1.24e-07 5.83e-05 0.25 0.28 Aortic root size; chr7:66375427 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs11769079 ENSG00000237310.1 GS1-124K5.4 5.4 1.24e-07 5.83e-05 0.25 0.28 Aortic root size; chr7:66377141 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs1695820 ENSG00000237310.1 GS1-124K5.4 5.4 1.24e-07 5.83e-05 0.25 0.28 Aortic root size; chr7:66379576 chr7:66493706~66495474:+ LIHC cis rs875971 0.83 rs778715 ENSG00000237310.1 GS1-124K5.4 5.4 1.24e-07 5.83e-05 0.25 0.28 Aortic root size; chr7:66384222 chr7:66493706~66495474:+ LIHC cis rs875971 0.83 rs809025 ENSG00000237310.1 GS1-124K5.4 5.4 1.24e-07 5.83e-05 0.25 0.28 Aortic root size; chr7:66384832 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs778702 ENSG00000237310.1 GS1-124K5.4 5.4 1.24e-07 5.83e-05 0.25 0.28 Aortic root size; chr7:66399848 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs1643375 ENSG00000237310.1 GS1-124K5.4 5.4 1.24e-07 5.83e-05 0.25 0.28 Aortic root size; chr7:66407690 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6962717 ENSG00000237310.1 GS1-124K5.4 5.4 1.24e-07 5.83e-05 0.25 0.28 Aortic root size; chr7:66418748 chr7:66493706~66495474:+ LIHC cis rs172166 0.56 rs203878 ENSG00000204709.4 LINC01556 5.4 1.24e-07 5.84e-05 0.31 0.28 Cardiac Troponin-T levels; chr6:28081218 chr6:28943877~28944537:+ LIHC cis rs904251 0.525 rs12200378 ENSG00000204110.6 RP1-153P14.8 -5.4 1.24e-07 5.84e-05 -0.34 -0.28 Cognitive performance; chr6:37457528 chr6:37507348~37535616:+ LIHC cis rs227275 0.555 rs223402 ENSG00000230069.3 LRRC37A15P -5.4 1.24e-07 5.84e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102817198 chr4:102727274~102730721:- LIHC cis rs1005277 0.579 rs176838 ENSG00000263064.2 RP11-291L22.7 -5.4 1.25e-07 5.85e-05 -0.29 -0.28 Extrinsic epigenetic age acceleration; chr10:38082971 chr10:38448689~38448949:+ LIHC cis rs7131987 0.903 rs1991114 ENSG00000257176.2 RP11-996F15.2 -5.4 1.25e-07 5.85e-05 -0.32 -0.28 QT interval; chr12:29239149 chr12:29280418~29317848:- LIHC cis rs6686842 0.932 rs3157 ENSG00000235358.1 RP11-399E6.1 5.4 1.25e-07 5.85e-05 0.31 0.28 Height; chr1:41027439 chr1:41242373~41284861:+ LIHC cis rs9487094 0.689 rs7754650 ENSG00000260273.1 RP11-425D10.10 5.4 1.25e-07 5.86e-05 0.32 0.28 Height; chr6:109405536 chr6:109382795~109383666:+ LIHC cis rs227275 0.556 rs7676765 ENSG00000230069.3 LRRC37A15P 5.4 1.25e-07 5.86e-05 0.26 0.28 Allergic disease (asthma, hay fever or eczema); chr4:103016776 chr4:102727274~102730721:- LIHC cis rs9549367 0.713 rs1755690 ENSG00000269125.1 RP11-98F14.11 5.4 1.26e-07 5.89e-05 0.32 0.28 Platelet distribution width; chr13:113169952 chr13:113165002~113165183:- LIHC cis rs6921919 0.583 rs7740351 ENSG00000216901.1 AL022393.7 5.4 1.26e-07 5.89e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28431635 chr6:28176188~28176674:+ LIHC cis rs6921919 0.583 rs2071965 ENSG00000216901.1 AL022393.7 5.4 1.26e-07 5.89e-05 0.35 0.28 Autism spectrum disorder or schizophrenia; chr6:28435448 chr6:28176188~28176674:+ LIHC cis rs875971 0.545 rs73152714 ENSG00000237310.1 GS1-124K5.4 5.4 1.26e-07 5.89e-05 0.27 0.28 Aortic root size; chr7:66534641 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs4718364 ENSG00000237310.1 GS1-124K5.4 5.4 1.26e-07 5.89e-05 0.27 0.28 Aortic root size; chr7:66536353 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs6961853 ENSG00000237310.1 GS1-124K5.4 5.4 1.26e-07 5.89e-05 0.27 0.28 Aortic root size; chr7:66537035 chr7:66493706~66495474:+ LIHC cis rs875971 0.528 rs801213 ENSG00000237310.1 GS1-124K5.4 -5.4 1.26e-07 5.89e-05 -0.27 -0.28 Aortic root size; chr7:66549931 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs801212 ENSG00000237310.1 GS1-124K5.4 -5.4 1.26e-07 5.89e-05 -0.27 -0.28 Aortic root size; chr7:66550643 chr7:66493706~66495474:+ LIHC cis rs11722779 0.869 rs223350 ENSG00000230069.3 LRRC37A15P -5.4 1.26e-07 5.91e-05 -0.26 -0.28 Schizophrenia; chr4:102856899 chr4:102727274~102730721:- LIHC cis rs6597981 0.675 rs4963120 ENSG00000255142.1 AP006621.6 -5.4 1.26e-07 5.91e-05 -0.26 -0.28 Breast cancer; chr11:825777 chr11:781645~782105:+ LIHC cis rs4731207 0.596 rs6964090 ENSG00000224897.5 POT1-AS1 5.4 1.26e-07 5.92e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125027062 chr7:124929873~125179315:+ LIHC cis rs2522056 1 rs2706383 ENSG00000233006.5 AC034220.3 -5.4 1.26e-07 5.92e-05 -0.29 -0.28 Fibrinogen;Lymphocyte counts; chr5:132456710 chr5:132311285~132369916:- LIHC cis rs2243480 1 rs1723267 ENSG00000226824.5 RP4-756H11.3 -5.4 1.26e-07 5.93e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66008327 chr7:66654538~66669855:+ LIHC cis rs227275 0.556 rs6815526 ENSG00000230069.3 LRRC37A15P -5.4 1.27e-07 5.93e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102899729 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs28367331 ENSG00000230069.3 LRRC37A15P -5.4 1.27e-07 5.93e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102900734 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs6824070 ENSG00000230069.3 LRRC37A15P -5.4 1.27e-07 5.93e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102901676 chr4:102727274~102730721:- LIHC cis rs11722779 0.935 rs6856176 ENSG00000230069.3 LRRC37A15P -5.4 1.27e-07 5.93e-05 -0.25 -0.28 Schizophrenia; chr4:102902574 chr4:102727274~102730721:- LIHC cis rs4934494 0.681 rs1129777 ENSG00000232936.4 RP11-80H5.2 5.4 1.27e-07 5.94e-05 0.35 0.28 Red blood cell count; chr10:89709168 chr10:89645282~89650667:+ LIHC cis rs4934494 0.727 rs3824607 ENSG00000232936.4 RP11-80H5.2 5.4 1.27e-07 5.94e-05 0.35 0.28 Red blood cell count; chr10:89711258 chr10:89645282~89650667:+ LIHC cis rs4934494 0.681 rs3740035 ENSG00000232936.4 RP11-80H5.2 5.4 1.27e-07 5.94e-05 0.35 0.28 Red blood cell count; chr10:89716708 chr10:89645282~89650667:+ LIHC cis rs4934494 0.681 rs34591435 ENSG00000232936.4 RP11-80H5.2 5.4 1.27e-07 5.94e-05 0.35 0.28 Red blood cell count; chr10:89721691 chr10:89645282~89650667:+ LIHC cis rs4934494 0.727 rs12783845 ENSG00000232936.4 RP11-80H5.2 5.4 1.27e-07 5.94e-05 0.35 0.28 Red blood cell count; chr10:89722872 chr10:89645282~89650667:+ LIHC cis rs11676348 0.791 rs4133195 ENSG00000261338.2 RP11-378A13.1 5.4 1.27e-07 5.94e-05 0.28 0.28 Ulcerative colitis; chr2:218086522 chr2:218255319~218257366:+ LIHC cis rs916888 0.821 rs199499 ENSG00000262881.1 RP11-669E14.4 -5.4 1.27e-07 5.95e-05 -0.52 -0.28 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788132 chr17:45907670~45910779:- LIHC cis rs5769707 0.632 rs135871 ENSG00000235111.1 RP1-29C18.8 -5.4 1.27e-07 5.96e-05 -0.34 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49615321 chr22:49612657~49615716:- LIHC cis rs12134133 1 rs2782846 ENSG00000274245.1 RP11-357P18.2 5.4 1.27e-07 5.97e-05 0.42 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207300495 chr1:207372559~207373252:+ LIHC cis rs2153535 0.601 rs1737581 ENSG00000230939.1 RP11-314C16.1 -5.4 1.28e-07 5.98e-05 -0.35 -0.28 Motion sickness; chr6:8538905 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs2015281 ENSG00000230939.1 RP11-314C16.1 -5.4 1.28e-07 5.98e-05 -0.35 -0.28 Motion sickness; chr6:8539440 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs9505474 ENSG00000230939.1 RP11-314C16.1 -5.4 1.28e-07 5.98e-05 -0.35 -0.28 Motion sickness; chr6:8539561 chr6:8784178~8785445:+ LIHC cis rs2153535 0.584 rs9502723 ENSG00000230939.1 RP11-314C16.1 -5.4 1.28e-07 5.98e-05 -0.35 -0.28 Motion sickness; chr6:8541271 chr6:8784178~8785445:+ LIHC cis rs8100891 0.537 rs4805754 ENSG00000267213.4 AC007773.2 -5.4 1.28e-07 5.99e-05 -0.36 -0.28 Neuroticism; chr19:32346260 chr19:32390050~32405560:- LIHC cis rs10170846 0.893 rs10932967 ENSG00000261428.2 RP11-16P6.1 5.4 1.28e-07 5.99e-05 0.29 0.28 Schizophrenia (inflammation and infection response interaction); chr2:222679392 chr2:222566899~222569719:- LIHC cis rs4356203 0.905 rs7939750 ENSG00000272034.1 SNORD14A -5.4 1.28e-07 5.99e-05 -0.31 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17058208 chr11:17074654~17074744:- LIHC cis rs7923609 0.756 rs6479908 ENSG00000232075.1 MRPL35P2 5.4 1.28e-07 5.99e-05 0.3 0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63573888 chr10:63634317~63634827:- LIHC cis rs875971 0.825 rs4587224 ENSG00000237310.1 GS1-124K5.4 -5.4 1.28e-07 5.99e-05 -0.25 -0.28 Aortic root size; chr7:66271195 chr7:66493706~66495474:+ LIHC cis rs875971 0.792 rs6971752 ENSG00000237310.1 GS1-124K5.4 -5.4 1.28e-07 5.99e-05 -0.25 -0.28 Aortic root size; chr7:66272999 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs10950033 ENSG00000237310.1 GS1-124K5.4 -5.4 1.28e-07 5.99e-05 -0.25 -0.28 Aortic root size; chr7:66274686 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs11760844 ENSG00000237310.1 GS1-124K5.4 -5.4 1.28e-07 5.99e-05 -0.25 -0.28 Aortic root size; chr7:66274896 chr7:66493706~66495474:+ LIHC cis rs3096299 0.632 rs4399533 ENSG00000261118.1 RP11-104N10.1 5.4 1.28e-07 6e-05 0.28 0.28 Multiple myeloma (IgH translocation); chr16:89472974 chr16:89492017~89504460:- LIHC cis rs12468226 0.873 rs12470401 ENSG00000273456.1 RP11-686O6.2 5.39 1.28e-07 6.01e-05 0.41 0.28 Urate levels; chr2:202236436 chr2:202374932~202375604:- LIHC cis rs9318086 0.712 rs9510917 ENSG00000205861.10 C1QTNF9B-AS1 -5.39 1.29e-07 6.02e-05 -0.32 -0.28 Myopia (pathological); chr13:23868707 chr13:23888889~23897263:+ LIHC cis rs10510102 0.935 rs10466217 ENSG00000276742.1 RP11-500G22.4 5.39 1.29e-07 6.03e-05 0.45 0.28 Breast cancer; chr10:121860362 chr10:121956782~121957098:+ LIHC cis rs9487094 0.813 rs35969918 ENSG00000260273.1 RP11-425D10.10 5.39 1.29e-07 6.03e-05 0.41 0.28 Height; chr6:109441837 chr6:109382795~109383666:+ LIHC cis rs17301013 0.861 rs61826916 ENSG00000227373.4 RP11-160H22.5 5.39 1.29e-07 6.03e-05 0.36 0.28 Systemic lupus erythematosus; chr1:174616048 chr1:174115300~174160004:- LIHC cis rs6589219 0.721 rs12296076 ENSG00000196167.8 COLCA1 -5.39 1.29e-07 6.04e-05 -0.3 -0.28 Colorectal cancer; chr11:111295779 chr11:111290787~111305045:- LIHC cis rs4538475 0.556 rs4266290 ENSG00000214846.4 RP11-115L11.1 5.39 1.29e-07 6.05e-05 0.35 0.28 Parkinson's disease; chr4:15735495 chr4:15730962~15731627:- LIHC cis rs4538475 0.556 rs4403048 ENSG00000214846.4 RP11-115L11.1 5.39 1.29e-07 6.05e-05 0.35 0.28 Parkinson's disease; chr4:15735497 chr4:15730962~15731627:- LIHC cis rs4731207 0.565 rs1904972 ENSG00000224897.5 POT1-AS1 5.39 1.29e-07 6.05e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125029633 chr7:124929873~125179315:+ LIHC cis rs4731207 0.536 rs1904971 ENSG00000224897.5 POT1-AS1 5.39 1.29e-07 6.05e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125029641 chr7:124929873~125179315:+ LIHC cis rs875971 0.862 rs11984115 ENSG00000237310.1 GS1-124K5.4 -5.39 1.29e-07 6.05e-05 -0.25 -0.28 Aortic root size; chr7:66308872 chr7:66493706~66495474:+ LIHC cis rs1577917 0.545 rs9450325 ENSG00000234155.1 RP11-30P6.6 -5.39 1.29e-07 6.05e-05 -0.32 -0.28 Response to antipsychotic treatment; chr6:85766096 chr6:85387219~85390186:- LIHC cis rs11098499 0.866 rs7665125 ENSG00000245958.5 RP11-33B1.1 -5.39 1.3e-07 6.06e-05 -0.28 -0.28 Corneal astigmatism; chr4:119480924 chr4:119454791~119552025:+ LIHC cis rs5769707 0.837 rs5770599 ENSG00000235111.1 RP1-29C18.8 -5.39 1.3e-07 6.06e-05 -0.32 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49626333 chr22:49612657~49615716:- LIHC cis rs2739330 0.796 rs5760097 ENSG00000099984.9 GSTT2 -5.39 1.3e-07 6.1e-05 -0.33 -0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23980123~23983911:+ LIHC cis rs496547 0.721 rs2508570 ENSG00000255422.1 AP002954.4 -5.39 1.3e-07 6.1e-05 -0.32 -0.28 Hip minimal joint space width; chr11:118807900 chr11:118704607~118750263:+ LIHC cis rs496547 0.686 rs591756 ENSG00000255422.1 AP002954.4 -5.39 1.3e-07 6.1e-05 -0.32 -0.28 Hip minimal joint space width; chr11:118808172 chr11:118704607~118750263:+ LIHC cis rs5769707 0.604 rs1018814 ENSG00000235111.1 RP1-29C18.8 -5.39 1.3e-07 6.1e-05 -0.34 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49643252 chr22:49612657~49615716:- LIHC cis rs11098499 0.58 rs12509234 ENSG00000245958.5 RP11-33B1.1 -5.39 1.31e-07 6.11e-05 -0.29 -0.28 Corneal astigmatism; chr4:119398279 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs10014719 ENSG00000245958.5 RP11-33B1.1 -5.39 1.31e-07 6.11e-05 -0.29 -0.28 Corneal astigmatism; chr4:119399560 chr4:119454791~119552025:+ LIHC cis rs11722779 0.935 rs11938650 ENSG00000230069.3 LRRC37A15P -5.39 1.31e-07 6.11e-05 -0.26 -0.28 Schizophrenia; chr4:103021639 chr4:102727274~102730721:- LIHC cis rs875971 0.862 rs4236208 ENSG00000237310.1 GS1-124K5.4 -5.39 1.31e-07 6.11e-05 -0.25 -0.28 Aortic root size; chr7:66284091 chr7:66493706~66495474:+ LIHC cis rs853679 0.517 rs9357065 ENSG00000219392.1 RP1-265C24.5 -5.39 1.31e-07 6.11e-05 -0.44 -0.28 Depression; chr6:28161802 chr6:28115628~28116551:+ LIHC cis rs12157904 0.744 rs34680058 ENSG00000233360.4 Z83844.1 5.39 1.31e-07 6.12e-05 0.57 0.28 Response to anti-depressant treatment in major depressive disorder; chr22:37657901 chr22:37641832~37658377:- LIHC cis rs227275 0.525 rs4698874 ENSG00000230069.3 LRRC37A15P -5.39 1.31e-07 6.12e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103009354 chr4:102727274~102730721:- LIHC cis rs4660456 0.596 rs1534956 ENSG00000237899.1 RP4-739H11.3 5.39 1.31e-07 6.12e-05 0.35 0.28 Platelet count; chr1:40720771 chr1:40669089~40687588:- LIHC cis rs10910092 1 rs10910092 ENSG00000225931.3 RP3-395M20.7 5.39 1.31e-07 6.13e-05 0.3 0.28 Ulcerative colitis; chr1:2570077 chr1:2566410~2569888:+ LIHC cis rs11690935 0.959 rs76324055 ENSG00000228389.1 AC068039.4 5.39 1.31e-07 6.13e-05 0.38 0.28 Schizophrenia; chr2:171763640 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs77280952 ENSG00000228389.1 AC068039.4 5.39 1.31e-07 6.13e-05 0.38 0.28 Schizophrenia; chr2:171763641 chr2:171773482~171775844:+ LIHC cis rs11690935 0.959 rs75922913 ENSG00000228389.1 AC068039.4 5.39 1.31e-07 6.13e-05 0.38 0.28 Schizophrenia; chr2:171763642 chr2:171773482~171775844:+ LIHC cis rs8059260 0.736 rs74391397 ENSG00000274038.1 RP11-66H6.4 -5.39 1.31e-07 6.13e-05 -0.5 -0.28 Alcohol consumption over the past year; chr16:10975570 chr16:11056556~11057034:+ LIHC cis rs3096299 0.933 rs889576 ENSG00000261118.1 RP11-104N10.1 -5.39 1.31e-07 6.14e-05 -0.28 -0.28 Multiple myeloma (IgH translocation); chr16:89363245 chr16:89492017~89504460:- LIHC cis rs9487094 0.813 rs61233650 ENSG00000260273.1 RP11-425D10.10 5.39 1.32e-07 6.15e-05 0.39 0.28 Height; chr6:109365409 chr6:109382795~109383666:+ LIHC cis rs17711722 0.528 rs73138179 ENSG00000228409.4 CCT6P1 -5.39 1.32e-07 6.16e-05 -0.22 -0.28 Calcium levels; chr7:65829495 chr7:65751142~65763354:+ LIHC cis rs4731207 0.596 rs7782410 ENSG00000224897.5 POT1-AS1 5.39 1.32e-07 6.17e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:124931050 chr7:124929873~125179315:+ LIHC cis rs2032366 0.606 rs9965972 ENSG00000267279.1 RP11-879F14.2 -5.39 1.32e-07 6.18e-05 -0.34 -0.28 Obesity-related traits; chr18:61609468 chr18:61585746~61606916:- LIHC cis rs4535700 0.501 rs11765577 ENSG00000226278.1 PSPHP1 5.39 1.33e-07 6.19e-05 0.33 0.28 Macular telangiectasia type 2; chr7:55930245 chr7:55764797~55773288:+ LIHC cis rs17301013 0.896 rs13375788 ENSG00000227373.4 RP11-160H22.5 5.39 1.33e-07 6.2e-05 0.34 0.28 Systemic lupus erythematosus; chr1:174524207 chr1:174115300~174160004:- LIHC cis rs875971 0.862 rs709596 ENSG00000237310.1 GS1-124K5.4 5.39 1.33e-07 6.21e-05 0.25 0.28 Aortic root size; chr7:66360926 chr7:66493706~66495474:+ LIHC cis rs2243480 1 rs1723269 ENSG00000226824.5 RP4-756H11.3 -5.39 1.33e-07 6.21e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66007799 chr7:66654538~66669855:+ LIHC cis rs7615952 0.688 rs12638240 ENSG00000171084.14 FAM86JP 5.39 1.33e-07 6.22e-05 0.39 0.28 Blood pressure (smoking interaction); chr3:125822395 chr3:125916620~125930024:+ LIHC cis rs875971 0.798 rs6460304 ENSG00000237310.1 GS1-124K5.4 5.39 1.33e-07 6.22e-05 0.25 0.28 Aortic root size; chr7:66499741 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6945775 ENSG00000237310.1 GS1-124K5.4 5.39 1.33e-07 6.22e-05 0.25 0.28 Aortic root size; chr7:66503987 chr7:66493706~66495474:+ LIHC cis rs10510102 0.935 rs12245528 ENSG00000276742.1 RP11-500G22.4 -5.39 1.33e-07 6.23e-05 -0.44 -0.28 Breast cancer; chr10:121881006 chr10:121956782~121957098:+ LIHC cis rs6918586 0.565 rs13196986 ENSG00000216436.2 HIST1H2APS1 5.39 1.34e-07 6.23e-05 0.38 0.28 Schizophrenia; chr6:26090224 chr6:25732497~25732827:+ LIHC cis rs4948102 0.642 rs6593297 ENSG00000226278.1 PSPHP1 5.39 1.34e-07 6.24e-05 0.31 0.28 Plasma homocysteine levels (post-methionine load test); chr7:56054365 chr7:55764797~55773288:+ LIHC cis rs10510102 0.872 rs11200277 ENSG00000226864.1 ATE1-AS1 5.39 1.34e-07 6.24e-05 0.47 0.28 Breast cancer; chr10:121944295 chr10:121928312~121951965:+ LIHC cis rs10875746 0.669 rs10875767 ENSG00000240399.1 RP1-228P16.1 -5.39 1.34e-07 6.24e-05 -0.3 -0.28 Longevity (90 years and older); chr12:48205474 chr12:48054813~48055591:- LIHC cis rs1035539 1 rs1035539 ENSG00000280152.1 RP11-331F4.5 5.39 1.34e-07 6.24e-05 0.29 0.28 Alcoholic chronic pancreatitis; chr16:75242877 chr16:75245994~75250077:- LIHC cis rs6479901 0.947 rs7909692 ENSG00000232075.1 MRPL35P2 -5.39 1.34e-07 6.24e-05 -0.31 -0.28 Intelligence (multi-trait analysis); chr10:63368517 chr10:63634317~63634827:- LIHC cis rs12468226 0.873 rs79071680 ENSG00000273456.1 RP11-686O6.2 5.39 1.34e-07 6.25e-05 0.42 0.28 Urate levels; chr2:202191520 chr2:202374932~202375604:- LIHC cis rs12468226 0.873 rs79860867 ENSG00000273456.1 RP11-686O6.2 5.39 1.34e-07 6.25e-05 0.42 0.28 Urate levels; chr2:202192397 chr2:202374932~202375604:- LIHC cis rs2998286 0.862 rs2185293 ENSG00000254635.4 WAC-AS1 -5.39 1.34e-07 6.25e-05 -0.35 -0.28 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28519170 chr10:28522652~28532743:- LIHC cis rs2998286 0.862 rs2807732 ENSG00000254635.4 WAC-AS1 -5.39 1.34e-07 6.25e-05 -0.35 -0.28 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28520318 chr10:28522652~28532743:- LIHC cis rs2998286 0.666 rs2491251 ENSG00000254635.4 WAC-AS1 -5.39 1.34e-07 6.25e-05 -0.35 -0.28 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28525363 chr10:28522652~28532743:- LIHC cis rs875971 0.83 rs6950137 ENSG00000237310.1 GS1-124K5.4 5.39 1.34e-07 6.26e-05 0.25 0.28 Aortic root size; chr7:66511623 chr7:66493706~66495474:+ LIHC cis rs4731207 0.596 rs10255638 ENSG00000224897.5 POT1-AS1 -5.39 1.34e-07 6.26e-05 -0.34 -0.28 Cutaneous malignant melanoma; chr7:124936201 chr7:124929873~125179315:+ LIHC cis rs7914558 0.901 rs1926034 ENSG00000236937.2 PTGES3P4 5.39 1.34e-07 6.26e-05 0.34 0.28 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103069345 chr10:102845595~102845950:+ LIHC cis rs9326248 1 rs664971 ENSG00000236267.1 AP006216.5 -5.39 1.35e-07 6.27e-05 -0.29 -0.28 Blood protein levels; chr11:117200141 chr11:116813204~116814003:- LIHC cis rs10510102 0.935 rs11200258 ENSG00000226864.1 ATE1-AS1 5.39 1.35e-07 6.27e-05 0.45 0.28 Breast cancer; chr10:121918392 chr10:121928312~121951965:+ LIHC cis rs875971 0.798 rs57739047 ENSG00000237310.1 GS1-124K5.4 5.39 1.35e-07 6.27e-05 0.25 0.28 Aortic root size; chr7:66507579 chr7:66493706~66495474:+ LIHC cis rs12157904 0.793 rs13055684 ENSG00000233360.4 Z83844.1 5.39 1.35e-07 6.28e-05 0.58 0.28 Response to anti-depressant treatment in major depressive disorder; chr22:37639908 chr22:37641832~37658377:- LIHC cis rs739496 0.615 rs77684561 ENSG00000226469.1 ADAM1B 5.39 1.35e-07 6.28e-05 0.37 0.28 Platelet count; chr12:111623919 chr12:111927018~111929017:+ LIHC cis rs6480314 0.542 rs7894859 ENSG00000233590.1 RP11-153K11.3 -5.39 1.35e-07 6.28e-05 -0.45 -0.28 Optic nerve measurement (disc area); chr10:68234620 chr10:68233251~68242379:- LIHC cis rs12908161 0.959 rs2175567 ENSG00000259295.5 CSPG4P12 5.38 1.35e-07 6.29e-05 0.39 0.28 Schizophrenia; chr15:84657715 chr15:85191438~85213905:+ LIHC cis rs12571093 0.803 rs17297418 ENSG00000233590.1 RP11-153K11.3 5.38 1.35e-07 6.29e-05 0.43 0.28 Optic nerve measurement (disc area); chr10:68271894 chr10:68233251~68242379:- LIHC cis rs12468226 0.938 rs114177656 ENSG00000273456.1 RP11-686O6.2 5.38 1.35e-07 6.3e-05 0.4 0.28 Urate levels; chr2:202291596 chr2:202374932~202375604:- LIHC cis rs4919694 0.536 rs12414777 ENSG00000236937.2 PTGES3P4 5.38 1.35e-07 6.3e-05 0.37 0.28 Arsenic metabolism; chr10:102938024 chr10:102845595~102845950:+ LIHC cis rs9318086 0.663 rs2312295 ENSG00000205861.10 C1QTNF9B-AS1 -5.38 1.36e-07 6.31e-05 -0.32 -0.28 Myopia (pathological); chr13:23883605 chr13:23888889~23897263:+ LIHC cis rs9487094 0.67 rs12194061 ENSG00000260273.1 RP11-425D10.10 5.38 1.36e-07 6.33e-05 0.33 0.28 Height; chr6:109546439 chr6:109382795~109383666:+ LIHC cis rs2060793 0.712 rs6486202 ENSG00000251991.1 RNU7-49P 5.38 1.36e-07 6.34e-05 0.31 0.28 Vitamin D levels; chr11:14777260 chr11:14478892~14478953:+ LIHC cis rs2842992 0.83 rs2025190 ENSG00000237927.1 RP3-393E18.2 -5.38 1.36e-07 6.35e-05 -0.34 -0.28 Age-related macular degeneration (geographic atrophy); chr6:159717209 chr6:159586955~159589169:- LIHC cis rs5758511 0.68 rs1107553 ENSG00000237037.8 NDUFA6-AS1 -5.38 1.37e-07 6.35e-05 -0.35 -0.28 Birth weight; chr22:42271467 chr22:42090931~42137742:+ LIHC cis rs11690935 0.959 rs6738445 ENSG00000228389.1 AC068039.4 -5.38 1.37e-07 6.36e-05 -0.37 -0.28 Schizophrenia; chr2:171743105 chr2:171773482~171775844:+ LIHC cis rs2836950 0.84 rs12482317 ENSG00000255568.3 BRWD1-AS2 -5.38 1.37e-07 6.36e-05 -0.25 -0.28 Menarche (age at onset); chr21:39216315 chr21:39313935~39314962:+ LIHC cis rs4356203 0.905 rs594034 ENSG00000272034.1 SNORD14A -5.38 1.37e-07 6.36e-05 -0.3 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17200833 chr11:17074654~17074744:- LIHC cis rs227275 0.525 rs2086499 ENSG00000230069.3 LRRC37A15P -5.38 1.37e-07 6.37e-05 -0.26 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103008672 chr4:102727274~102730721:- LIHC cis rs2735413 0.846 rs72800943 ENSG00000276007.1 RP11-358L22.3 -5.38 1.37e-07 6.37e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78045658 chr16:78123243~78124332:+ LIHC cis rs2735413 0.846 rs12923290 ENSG00000276007.1 RP11-358L22.3 -5.38 1.37e-07 6.37e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78046059 chr16:78123243~78124332:+ LIHC cis rs2735413 0.881 rs12923218 ENSG00000276007.1 RP11-358L22.3 -5.38 1.37e-07 6.37e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78046377 chr16:78123243~78124332:+ LIHC cis rs2735413 0.875 rs12923229 ENSG00000276007.1 RP11-358L22.3 -5.38 1.37e-07 6.37e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78046405 chr16:78123243~78124332:+ LIHC cis rs2735413 0.918 rs4888733 ENSG00000276007.1 RP11-358L22.3 -5.38 1.37e-07 6.37e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78046626 chr16:78123243~78124332:+ LIHC cis rs2735413 0.752 rs11642442 ENSG00000276007.1 RP11-358L22.3 -5.38 1.37e-07 6.37e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78046903 chr16:78123243~78124332:+ LIHC cis rs2735413 0.918 rs11643649 ENSG00000276007.1 RP11-358L22.3 -5.38 1.37e-07 6.37e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78047302 chr16:78123243~78124332:+ LIHC cis rs2735413 0.918 rs56397244 ENSG00000276007.1 RP11-358L22.3 -5.38 1.37e-07 6.37e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78047469 chr16:78123243~78124332:+ LIHC cis rs2735413 0.918 rs34094825 ENSG00000276007.1 RP11-358L22.3 -5.38 1.37e-07 6.37e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78047495 chr16:78123243~78124332:+ LIHC cis rs496547 0.686 rs524590 ENSG00000255422.1 AP002954.4 -5.38 1.37e-07 6.38e-05 -0.32 -0.28 Hip minimal joint space width; chr11:118769354 chr11:118704607~118750263:+ LIHC cis rs950776 0.616 rs3743077 ENSG00000261762.1 RP11-650L12.2 5.38 1.37e-07 6.39e-05 0.36 0.28 Sudden cardiac arrest; chr15:78602554 chr15:78589123~78591276:- LIHC cis rs7916697 0.947 rs7916410 ENSG00000233590.1 RP11-153K11.3 5.38 1.37e-07 6.39e-05 0.34 0.28 Optic disc area; chr10:68235910 chr10:68233251~68242379:- LIHC cis rs854624 0.818 rs1719201 ENSG00000275944.1 RP11-104J23.1 5.38 1.38e-07 6.39e-05 0.34 0.28 Blood protein levels; chr17:36011795 chr17:36001419~36011618:+ LIHC cis rs4731207 0.596 rs1481337 ENSG00000224897.5 POT1-AS1 5.38 1.38e-07 6.39e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125027742 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1904973 ENSG00000224897.5 POT1-AS1 5.38 1.38e-07 6.39e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125029493 chr7:124929873~125179315:+ LIHC cis rs10510102 0.935 rs11200252 ENSG00000226864.1 ATE1-AS1 5.38 1.38e-07 6.4e-05 0.45 0.28 Breast cancer; chr10:121914728 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs12254184 ENSG00000226864.1 ATE1-AS1 5.38 1.38e-07 6.4e-05 0.45 0.28 Breast cancer; chr10:121914971 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200253 ENSG00000226864.1 ATE1-AS1 5.38 1.38e-07 6.4e-05 0.45 0.28 Breast cancer; chr10:121915114 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200254 ENSG00000226864.1 ATE1-AS1 5.38 1.38e-07 6.4e-05 0.45 0.28 Breast cancer; chr10:121915241 chr10:121928312~121951965:+ LIHC cis rs2933343 0.859 rs789245 ENSG00000231305.3 RP11-723O4.2 5.38 1.38e-07 6.4e-05 0.33 0.28 IgG glycosylation; chr3:128864737 chr3:128861313~128871540:- LIHC cis rs950169 0.84 rs72748702 ENSG00000259295.5 CSPG4P12 5.38 1.38e-07 6.41e-05 0.37 0.28 Schizophrenia; chr15:84246494 chr15:85191438~85213905:+ LIHC cis rs12701220 0.655 rs7784403 ENSG00000229043.2 AC091729.9 -5.38 1.38e-07 6.41e-05 -0.4 -0.28 Bronchopulmonary dysplasia; chr7:1113441 chr7:1160374~1165267:+ LIHC cis rs2836950 0.762 rs8134638 ENSG00000255568.3 BRWD1-AS2 -5.38 1.38e-07 6.42e-05 -0.25 -0.28 Menarche (age at onset); chr21:39272244 chr21:39313935~39314962:+ LIHC cis rs9341808 0.727 rs9361599 ENSG00000272129.1 RP11-250B2.6 5.38 1.38e-07 6.43e-05 0.27 0.28 Sitting height ratio; chr6:80315525 chr6:80355424~80356859:+ LIHC cis rs8059260 0.736 rs16957854 ENSG00000274038.1 RP11-66H6.4 -5.38 1.39e-07 6.44e-05 -0.49 -0.28 Alcohol consumption over the past year; chr16:10976466 chr16:11056556~11057034:+ LIHC cis rs875971 0.862 rs13226170 ENSG00000237310.1 GS1-124K5.4 5.38 1.39e-07 6.44e-05 0.24 0.28 Aortic root size; chr7:66534311 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs2420611 ENSG00000237310.1 GS1-124K5.4 5.38 1.39e-07 6.44e-05 0.24 0.28 Aortic root size; chr7:66534333 chr7:66493706~66495474:+ LIHC cis rs17270561 0.666 rs4712976 ENSG00000216436.2 HIST1H2APS1 -5.38 1.39e-07 6.45e-05 -0.34 -0.28 Iron status biomarkers; chr6:25841975 chr6:25732497~25732827:+ LIHC cis rs4660214 0.666 rs10493087 ENSG00000182109.6 RP11-69E11.4 -5.38 1.39e-07 6.45e-05 -0.3 -0.28 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39251584 chr1:39522280~39546187:- LIHC cis rs4660214 0.666 rs11205828 ENSG00000182109.6 RP11-69E11.4 -5.38 1.39e-07 6.45e-05 -0.3 -0.28 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39253674 chr1:39522280~39546187:- LIHC cis rs2688482 0.557 rs3103952 ENSG00000242086.7 LINC00969 5.38 1.39e-07 6.45e-05 0.35 0.28 Lung disease severity in cystic fibrosis; chr3:195795819 chr3:195658062~195739964:+ LIHC cis rs2762353 0.595 rs9467591 ENSG00000242387.1 HIST1H2APS2 5.38 1.4e-07 6.48e-05 0.32 0.28 Blood metabolite levels; chr6:25742471 chr6:25882026~25882395:- LIHC cis rs4660456 0.619 rs753753 ENSG00000237899.1 RP4-739H11.3 -5.38 1.4e-07 6.48e-05 -0.35 -0.28 Platelet count; chr1:40771716 chr1:40669089~40687588:- LIHC cis rs10129255 0.957 rs10136560 ENSG00000223648.3 IGHV3-64 5.38 1.4e-07 6.49e-05 0.21 0.28 Kawasaki disease; chr14:106787630 chr14:106643132~106658258:- LIHC cis rs496547 0.719 rs1790189 ENSG00000255422.1 AP002954.4 -5.38 1.4e-07 6.5e-05 -0.32 -0.28 Hip minimal joint space width; chr11:118781617 chr11:118704607~118750263:+ LIHC cis rs7916697 0.947 rs4745950 ENSG00000233590.1 RP11-153K11.3 5.38 1.4e-07 6.5e-05 0.34 0.28 Optic disc area; chr10:68236698 chr10:68233251~68242379:- LIHC cis rs10129255 0.957 rs12589190 ENSG00000223648.3 IGHV3-64 5.38 1.4e-07 6.5e-05 0.21 0.28 Kawasaki disease; chr14:106783079 chr14:106643132~106658258:- LIHC cis rs9487094 0.645 rs34533653 ENSG00000260273.1 RP11-425D10.10 5.38 1.4e-07 6.51e-05 0.47 0.28 Height; chr6:109479488 chr6:109382795~109383666:+ LIHC cis rs10510102 1 rs7923678 ENSG00000276742.1 RP11-500G22.4 5.38 1.4e-07 6.51e-05 0.42 0.28 Breast cancer; chr10:121832546 chr10:121956782~121957098:+ LIHC cis rs2367970 0.57 rs7123583 ENSG00000254851.1 RP11-109L13.1 5.38 1.41e-07 6.53e-05 0.34 0.28 HDL cholesterol; chr11:116729305 chr11:117135528~117138582:+ LIHC cis rs801193 0.569 rs2707824 ENSG00000237310.1 GS1-124K5.4 5.38 1.41e-07 6.54e-05 0.24 0.28 Aortic root size; chr7:66724256 chr7:66493706~66495474:+ LIHC cis rs11690935 0.959 rs12185567 ENSG00000228389.1 AC068039.4 -5.38 1.42e-07 6.57e-05 -0.37 -0.28 Schizophrenia; chr2:171704219 chr2:171773482~171775844:+ LIHC cis rs887829 0.57 rs7608175 ENSG00000233445.1 RPL17P11 -5.38 1.42e-07 6.57e-05 -0.29 -0.28 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233690443 chr2:233721522~233722065:- LIHC cis rs2933343 0.649 rs1683786 ENSG00000231305.3 RP11-723O4.2 5.37 1.42e-07 6.58e-05 0.31 0.28 IgG glycosylation; chr3:128908109 chr3:128861313~128871540:- LIHC cis rs2933343 0.7 rs876754 ENSG00000231305.3 RP11-723O4.2 5.37 1.42e-07 6.58e-05 0.31 0.28 IgG glycosylation; chr3:128908910 chr3:128861313~128871540:- LIHC cis rs9318086 0.624 rs9510909 ENSG00000205861.10 C1QTNF9B-AS1 -5.37 1.42e-07 6.59e-05 -0.32 -0.28 Myopia (pathological); chr13:23862621 chr13:23888889~23897263:+ LIHC cis rs2739330 0.796 rs2154594 ENSG00000099984.9 GSTT2 5.37 1.42e-07 6.59e-05 0.33 0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23980123~23983911:+ LIHC cis rs17711722 0.51 rs11767457 ENSG00000228409.4 CCT6P1 -5.37 1.42e-07 6.59e-05 -0.22 -0.28 Calcium levels; chr7:65825628 chr7:65751142~65763354:+ LIHC cis rs6479901 0.947 rs6479897 ENSG00000232075.1 MRPL35P2 -5.37 1.43e-07 6.6e-05 -0.31 -0.28 Intelligence (multi-trait analysis); chr10:63376868 chr10:63634317~63634827:- LIHC cis rs9341808 0.739 rs4706831 ENSG00000272129.1 RP11-250B2.6 5.37 1.43e-07 6.6e-05 0.27 0.28 Sitting height ratio; chr6:80297982 chr6:80355424~80356859:+ LIHC cis rs875971 0.502 rs11769702 ENSG00000237310.1 GS1-124K5.4 5.37 1.43e-07 6.6e-05 0.27 0.28 Aortic root size; chr7:66255529 chr7:66493706~66495474:+ LIHC cis rs7131987 0.621 rs6487805 ENSG00000275476.1 RP11-996F15.4 5.37 1.43e-07 6.62e-05 0.32 0.28 QT interval; chr12:29304617 chr12:29277397~29277882:- LIHC cis rs227275 0.527 rs223338 ENSG00000230069.3 LRRC37A15P -5.37 1.43e-07 6.62e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102864959 chr4:102727274~102730721:- LIHC cis rs9487094 0.689 rs9487070 ENSG00000260273.1 RP11-425D10.10 5.37 1.43e-07 6.62e-05 0.33 0.28 Height; chr6:109361200 chr6:109382795~109383666:+ LIHC cis rs6479901 0.895 rs7902187 ENSG00000232075.1 MRPL35P2 -5.37 1.43e-07 6.62e-05 -0.31 -0.28 Intelligence (multi-trait analysis); chr10:63333375 chr10:63634317~63634827:- LIHC cis rs10510102 0.935 rs11200257 ENSG00000226864.1 ATE1-AS1 5.37 1.43e-07 6.63e-05 0.45 0.28 Breast cancer; chr10:121917232 chr10:121928312~121951965:+ LIHC cis rs227275 0.554 rs223439 ENSG00000230069.3 LRRC37A15P -5.37 1.44e-07 6.65e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102798377 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs223436 ENSG00000230069.3 LRRC37A15P -5.37 1.44e-07 6.65e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102798749 chr4:102727274~102730721:- LIHC cis rs4660214 0.666 rs7553009 ENSG00000182109.6 RP11-69E11.4 -5.37 1.44e-07 6.66e-05 -0.3 -0.28 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39247441 chr1:39522280~39546187:- LIHC cis rs5769707 0.681 rs2319346 ENSG00000235111.1 RP1-29C18.8 -5.37 1.44e-07 6.67e-05 -0.34 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49635992 chr22:49612657~49615716:- LIHC cis rs4731207 0.57 rs7784616 ENSG00000224897.5 POT1-AS1 5.37 1.44e-07 6.67e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125037140 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6466988 ENSG00000224897.5 POT1-AS1 5.37 1.44e-07 6.67e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125038062 chr7:124929873~125179315:+ LIHC cis rs7916697 0.588 rs10823165 ENSG00000233590.1 RP11-153K11.3 5.37 1.44e-07 6.68e-05 0.36 0.28 Optic disc area; chr10:68248269 chr10:68233251~68242379:- LIHC cis rs801193 0.591 rs4506088 ENSG00000237310.1 GS1-124K5.4 -5.37 1.45e-07 6.68e-05 -0.24 -0.28 Aortic root size; chr7:66670470 chr7:66493706~66495474:+ LIHC cis rs11123170 0.64 rs2863240 ENSG00000189223.12 PAX8-AS1 5.37 1.45e-07 6.69e-05 0.4 0.28 Renal function-related traits (BUN); chr2:113212539 chr2:113211522~113276581:+ LIHC cis rs227275 0.525 rs13150426 ENSG00000246560.2 RP11-10L12.4 5.37 1.45e-07 6.69e-05 0.32 0.28 Allergic disease (asthma, hay fever or eczema); chr4:103013743 chr4:102828055~102844075:+ LIHC cis rs2735413 0.918 rs12931394 ENSG00000276007.1 RP11-358L22.3 -5.37 1.45e-07 6.69e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78047732 chr16:78123243~78124332:+ LIHC cis rs2153535 0.58 rs6921036 ENSG00000230939.1 RP11-314C16.1 -5.37 1.45e-07 6.69e-05 -0.34 -0.28 Motion sickness; chr6:8455167 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6926759 ENSG00000230939.1 RP11-314C16.1 -5.37 1.45e-07 6.69e-05 -0.34 -0.28 Motion sickness; chr6:8455943 chr6:8784178~8785445:+ LIHC cis rs6480314 0.542 rs61854805 ENSG00000233590.1 RP11-153K11.3 -5.37 1.45e-07 6.7e-05 -0.44 -0.28 Optic nerve measurement (disc area); chr10:68255826 chr10:68233251~68242379:- LIHC cis rs172166 0.561 rs149971 ENSG00000204709.4 LINC01556 5.37 1.45e-07 6.71e-05 0.32 0.28 Cardiac Troponin-T levels; chr6:28014374 chr6:28943877~28944537:+ LIHC cis rs7131987 0.65 rs10843384 ENSG00000275476.1 RP11-996F15.4 -5.37 1.45e-07 6.72e-05 -0.33 -0.28 QT interval; chr12:29319476 chr12:29277397~29277882:- LIHC cis rs12468226 0.935 rs113188021 ENSG00000273456.1 RP11-686O6.2 5.37 1.46e-07 6.72e-05 0.4 0.28 Urate levels; chr2:202336237 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs6731027 ENSG00000273456.1 RP11-686O6.2 5.37 1.46e-07 6.72e-05 0.4 0.28 Urate levels; chr2:202337443 chr2:202374932~202375604:- LIHC cis rs12571093 0.803 rs61854825 ENSG00000233590.1 RP11-153K11.3 -5.37 1.46e-07 6.73e-05 -0.44 -0.28 Optic nerve measurement (disc area); chr10:68271535 chr10:68233251~68242379:- LIHC cis rs12571093 0.803 rs61854826 ENSG00000233590.1 RP11-153K11.3 -5.37 1.46e-07 6.73e-05 -0.44 -0.28 Optic nerve measurement (disc area); chr10:68271801 chr10:68233251~68242379:- LIHC cis rs950169 0.887 rs35986397 ENSG00000259295.5 CSPG4P12 5.37 1.46e-07 6.73e-05 0.38 0.28 Schizophrenia; chr15:84400409 chr15:85191438~85213905:+ LIHC cis rs2153535 0.563 rs1796688 ENSG00000230939.1 RP11-314C16.1 -5.37 1.46e-07 6.74e-05 -0.35 -0.28 Motion sickness; chr6:8536190 chr6:8784178~8785445:+ LIHC cis rs2153535 0.526 rs1796689 ENSG00000230939.1 RP11-314C16.1 -5.37 1.46e-07 6.74e-05 -0.35 -0.28 Motion sickness; chr6:8536200 chr6:8784178~8785445:+ LIHC cis rs875971 0.862 rs6460290 ENSG00000237310.1 GS1-124K5.4 -5.37 1.46e-07 6.75e-05 -0.25 -0.28 Aortic root size; chr7:66344119 chr7:66493706~66495474:+ LIHC cis rs1577917 0.883 rs9450375 ENSG00000234155.1 RP11-30P6.6 -5.37 1.46e-07 6.75e-05 -0.33 -0.28 Response to antipsychotic treatment; chr6:86046911 chr6:85387219~85390186:- LIHC cis rs1577917 0.883 rs2166664 ENSG00000234155.1 RP11-30P6.6 5.37 1.46e-07 6.75e-05 0.33 0.28 Response to antipsychotic treatment; chr6:85886904 chr6:85387219~85390186:- LIHC cis rs1577917 0.883 rs9450348 ENSG00000234155.1 RP11-30P6.6 5.37 1.46e-07 6.75e-05 0.33 0.28 Response to antipsychotic treatment; chr6:85888318 chr6:85387219~85390186:- LIHC cis rs11673344 0.583 rs7247090 ENSG00000226686.6 LINC01535 5.37 1.47e-07 6.77e-05 0.33 0.28 Obesity-related traits; chr19:37522509 chr19:37251912~37265535:+ LIHC cis rs2243480 1 rs2420170 ENSG00000226824.5 RP4-756H11.3 5.37 1.47e-07 6.77e-05 0.46 0.28 Diabetic kidney disease; chr7:66191066 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs7804223 ENSG00000226824.5 RP4-756H11.3 5.37 1.47e-07 6.77e-05 0.46 0.28 Diabetic kidney disease; chr7:66199572 chr7:66654538~66669855:+ LIHC cis rs11676348 0.755 rs6436026 ENSG00000261338.2 RP11-378A13.1 -5.37 1.47e-07 6.77e-05 -0.29 -0.28 Ulcerative colitis; chr2:218087015 chr2:218255319~218257366:+ LIHC cis rs11676348 0.791 rs6726126 ENSG00000261338.2 RP11-378A13.1 -5.37 1.47e-07 6.77e-05 -0.29 -0.28 Ulcerative colitis; chr2:218087510 chr2:218255319~218257366:+ LIHC cis rs2243480 1 rs1546059 ENSG00000226824.5 RP4-756H11.3 5.37 1.47e-07 6.77e-05 0.46 0.28 Diabetic kidney disease; chr7:66189722 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs6958289 ENSG00000226824.5 RP4-756H11.3 5.37 1.47e-07 6.77e-05 0.46 0.28 Diabetic kidney disease; chr7:66192124 chr7:66654538~66669855:+ LIHC cis rs75920871 0.589 rs67201490 ENSG00000254851.1 RP11-109L13.1 -5.37 1.47e-07 6.78e-05 -0.55 -0.28 Subjective well-being; chr11:117212288 chr11:117135528~117138582:+ LIHC cis rs75920871 0.64 rs4938357 ENSG00000254851.1 RP11-109L13.1 -5.37 1.47e-07 6.78e-05 -0.55 -0.28 Subjective well-being; chr11:117213324 chr11:117135528~117138582:+ LIHC cis rs75920871 0.589 rs56081989 ENSG00000254851.1 RP11-109L13.1 -5.37 1.47e-07 6.78e-05 -0.55 -0.28 Subjective well-being; chr11:117214589 chr11:117135528~117138582:+ LIHC cis rs7811142 0.83 rs6979910 ENSG00000242294.5 STAG3L5P 5.37 1.47e-07 6.79e-05 0.29 0.28 Platelet count; chr7:100343007 chr7:100336079~100351900:+ LIHC cis rs67180937 0.733 rs17532708 ENSG00000272750.1 RP11-378J18.8 -5.37 1.47e-07 6.79e-05 -0.28 -0.28 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222726085 chr1:222658867~222661512:- LIHC cis rs8059260 0.604 rs16957966 ENSG00000274038.1 RP11-66H6.4 -5.37 1.47e-07 6.79e-05 -0.46 -0.28 Alcohol consumption over the past year; chr16:11046280 chr16:11056556~11057034:+ LIHC cis rs228614 0.51 rs6830407 ENSG00000230069.3 LRRC37A15P -5.37 1.48e-07 6.8e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102895366 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs4699033 ENSG00000230069.3 LRRC37A15P -5.37 1.48e-07 6.81e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102897577 chr4:102727274~102730721:- LIHC cis rs832187 0.64 rs3774729 ENSG00000280620.1 SCAANT1 5.37 1.48e-07 6.82e-05 0.38 0.28 Schizophrenia; chr3:63996406 chr3:63911518~63911772:- LIHC cis rs2919917 1 rs1021156 ENSG00000254352.1 RP11-578O24.2 5.37 1.48e-07 6.82e-05 0.37 0.28 Lymphocyte counts; chr8:78663569 chr8:78723796~78724136:- LIHC cis rs875971 0.862 rs13232191 ENSG00000237310.1 GS1-124K5.4 5.37 1.48e-07 6.83e-05 0.24 0.28 Aortic root size; chr7:66521661 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs35378740 ENSG00000237310.1 GS1-124K5.4 5.37 1.48e-07 6.83e-05 0.24 0.28 Aortic root size; chr7:66522725 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs10950043 ENSG00000237310.1 GS1-124K5.4 5.37 1.48e-07 6.83e-05 0.24 0.28 Aortic root size; chr7:66523623 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs17747530 ENSG00000237310.1 GS1-124K5.4 5.37 1.48e-07 6.83e-05 0.24 0.28 Aortic root size; chr7:66529742 chr7:66493706~66495474:+ LIHC cis rs875971 0.767 rs61348003 ENSG00000237310.1 GS1-124K5.4 5.37 1.48e-07 6.83e-05 0.24 0.28 Aortic root size; chr7:66540947 chr7:66493706~66495474:+ LIHC cis rs904251 0.6 rs12211110 ENSG00000204110.6 RP1-153P14.8 -5.37 1.49e-07 6.84e-05 -0.34 -0.28 Cognitive performance; chr6:37498456 chr6:37507348~37535616:+ LIHC cis rs17711722 0.565 rs4717276 ENSG00000226824.5 RP4-756H11.3 -5.37 1.49e-07 6.84e-05 -0.33 -0.28 Calcium levels; chr7:65829754 chr7:66654538~66669855:+ LIHC cis rs7429990 0.864 rs13091913 ENSG00000229759.1 MRPS18AP1 -5.37 1.49e-07 6.84e-05 -0.3 -0.28 Educational attainment (years of education); chr3:47762307 chr3:48256350~48256938:- LIHC cis rs2877649 0.793 rs10133116 ENSG00000258744.1 RP11-80A15.1 -5.37 1.49e-07 6.84e-05 -0.55 -0.28 Smooth-surface caries; chr14:24456164 chr14:24501594~24508688:+ LIHC cis rs12468226 1 rs7587234 ENSG00000273456.1 RP11-686O6.2 5.37 1.49e-07 6.85e-05 0.41 0.28 Urate levels; chr2:202351699 chr2:202374932~202375604:- LIHC cis rs2762353 0.526 rs9461203 ENSG00000216436.2 HIST1H2APS1 5.37 1.49e-07 6.86e-05 0.32 0.28 Blood metabolite levels; chr6:25710327 chr6:25732497~25732827:+ LIHC cis rs2762353 0.526 rs6912391 ENSG00000216436.2 HIST1H2APS1 5.37 1.49e-07 6.86e-05 0.32 0.28 Blood metabolite levels; chr6:25710535 chr6:25732497~25732827:+ LIHC cis rs801193 0.569 rs2659907 ENSG00000237310.1 GS1-124K5.4 5.37 1.49e-07 6.87e-05 0.24 0.28 Aortic root size; chr7:66699045 chr7:66493706~66495474:+ LIHC cis rs950169 0.922 rs11630507 ENSG00000259295.5 CSPG4P12 5.37 1.49e-07 6.87e-05 0.38 0.28 Schizophrenia; chr15:84552494 chr15:85191438~85213905:+ LIHC cis rs6085948 1 rs6054856 ENSG00000238102.1 RP11-19D2.1 -5.36 1.5e-07 6.88e-05 -0.4 -0.28 Interleukin-10 levels; chr20:7266592 chr20:7256580~7258214:- LIHC cis rs4718428 0.672 rs4718412 ENSG00000230295.1 RP11-458F8.2 5.36 1.5e-07 6.9e-05 0.24 0.28 Corneal structure; chr7:66821880 chr7:66880708~66882981:+ LIHC cis rs9425766 0.566 rs4447042 ENSG00000227373.4 RP11-160H22.5 5.36 1.5e-07 6.91e-05 0.36 0.28 Life satisfaction; chr1:174212747 chr1:174115300~174160004:- LIHC cis rs12468226 0.938 rs116601501 ENSG00000273456.1 RP11-686O6.2 5.36 1.5e-07 6.91e-05 0.4 0.28 Urate levels; chr2:202274567 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs76658848 ENSG00000273456.1 RP11-686O6.2 5.36 1.5e-07 6.91e-05 0.4 0.28 Urate levels; chr2:202275548 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs74454549 ENSG00000273456.1 RP11-686O6.2 5.36 1.5e-07 6.91e-05 0.4 0.28 Urate levels; chr2:202288044 chr2:202374932~202375604:- LIHC cis rs5769707 0.632 rs6009782 ENSG00000235111.1 RP1-29C18.8 -5.36 1.5e-07 6.91e-05 -0.33 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49617164 chr22:49612657~49615716:- LIHC cis rs2245008 0.762 rs168800 ENSG00000260932.1 RP11-483P21.6 -5.36 1.51e-07 6.92e-05 -0.53 -0.28 Pursuit maintenance gain; chr16:83946786 chr16:83929796~83931223:- LIHC cis rs113835537 0.529 rs2279865 ENSG00000255517.5 CTD-3074O7.5 -5.36 1.51e-07 6.96e-05 -0.31 -0.28 Airway imaging phenotypes; chr11:66435554 chr11:66473490~66480233:- LIHC cis rs113835537 0.502 rs7104378 ENSG00000255517.5 CTD-3074O7.5 -5.36 1.51e-07 6.96e-05 -0.31 -0.28 Airway imaging phenotypes; chr11:66449204 chr11:66473490~66480233:- LIHC cis rs11690935 0.959 rs10166005 ENSG00000228389.1 AC068039.4 5.36 1.52e-07 6.97e-05 0.37 0.28 Schizophrenia; chr2:171750784 chr2:171773482~171775844:+ LIHC cis rs8040855 0.86 rs7172266 ENSG00000259295.5 CSPG4P12 -5.36 1.52e-07 6.97e-05 -0.42 -0.28 Bulimia nervosa; chr15:85172982 chr15:85191438~85213905:+ LIHC cis rs7615952 0.736 rs9862893 ENSG00000171084.14 FAM86JP 5.36 1.52e-07 6.98e-05 0.49 0.28 Blood pressure (smoking interaction); chr3:125968131 chr3:125916620~125930024:+ LIHC cis rs172166 0.538 rs149956 ENSG00000204709.4 LINC01556 5.36 1.52e-07 6.98e-05 0.31 0.28 Cardiac Troponin-T levels; chr6:28068473 chr6:28943877~28944537:+ LIHC cis rs12468226 1 rs112306637 ENSG00000273456.1 RP11-686O6.2 5.36 1.52e-07 6.99e-05 0.4 0.28 Urate levels; chr2:202334195 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs111252524 ENSG00000273456.1 RP11-686O6.2 5.36 1.52e-07 6.99e-05 0.4 0.28 Urate levels; chr2:202334465 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs112753638 ENSG00000273456.1 RP11-686O6.2 5.36 1.52e-07 6.99e-05 0.4 0.28 Urate levels; chr2:202334496 chr2:202374932~202375604:- LIHC cis rs1134634 0.52 rs28419165 ENSG00000273133.1 RP11-799M12.2 -5.36 1.52e-07 7e-05 -0.35 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15587722 chr4:15563698~15564253:- LIHC cis rs6479891 1 rs9415705 ENSG00000232075.1 MRPL35P2 5.36 1.52e-07 7e-05 0.32 0.28 Arthritis (juvenile idiopathic); chr10:63401790 chr10:63634317~63634827:- LIHC cis rs2283792 0.871 rs8136867 ENSG00000224086.5 LL22NC03-86G7.1 -5.36 1.52e-07 7e-05 -0.26 -0.28 Multiple sclerosis; chr22:21850504 chr22:21938293~21977632:+ LIHC cis rs11673344 0.566 rs1545755 ENSG00000226686.6 LINC01535 5.36 1.53e-07 7e-05 0.34 0.28 Obesity-related traits; chr19:37490607 chr19:37251912~37265535:+ LIHC cis rs4934494 0.768 rs34993776 ENSG00000232936.4 RP11-80H5.2 5.36 1.53e-07 7e-05 0.36 0.28 Red blood cell count; chr10:89681932 chr10:89645282~89650667:+ LIHC cis rs4718428 0.705 rs28648401 ENSG00000232546.1 RP11-458F8.1 -5.36 1.53e-07 7e-05 -0.25 -0.28 Corneal structure; chr7:66902145 chr7:66848496~66858136:+ LIHC cis rs4718428 0.607 rs66954441 ENSG00000232546.1 RP11-458F8.1 -5.36 1.53e-07 7e-05 -0.25 -0.28 Corneal structure; chr7:66904222 chr7:66848496~66858136:+ LIHC cis rs4718428 0.705 rs4718424 ENSG00000232546.1 RP11-458F8.1 -5.36 1.53e-07 7e-05 -0.25 -0.28 Corneal structure; chr7:66911108 chr7:66848496~66858136:+ LIHC cis rs7586673 0.893 rs889925 ENSG00000227403.1 AC009299.3 -5.36 1.53e-07 7.02e-05 -0.34 -0.28 Intelligence (multi-trait analysis); chr2:161115086 chr2:161244739~161249050:+ LIHC cis rs9291683 0.588 rs35866697 ENSG00000250413.1 RP11-448G15.1 -5.36 1.53e-07 7.02e-05 -0.35 -0.28 Bone mineral density; chr4:10016980 chr4:10006482~10009725:+ LIHC cis rs9291683 0.588 rs35099040 ENSG00000250413.1 RP11-448G15.1 -5.36 1.53e-07 7.02e-05 -0.35 -0.28 Bone mineral density; chr4:10017215 chr4:10006482~10009725:+ LIHC cis rs875971 0.861 rs801215 ENSG00000237310.1 GS1-124K5.4 -5.36 1.53e-07 7.02e-05 -0.24 -0.28 Aortic root size; chr7:66546951 chr7:66493706~66495474:+ LIHC cis rs72627509 0.904 rs3796529 ENSG00000269949.1 RP11-738E22.3 5.36 1.53e-07 7.04e-05 0.36 0.28 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56931248 chr4:56960927~56961373:- LIHC cis rs7916697 0.891 rs4746748 ENSG00000233590.1 RP11-153K11.3 5.36 1.53e-07 7.04e-05 0.33 0.28 Optic disc area; chr10:68249631 chr10:68233251~68242379:- LIHC cis rs7916697 0.842 rs4746749 ENSG00000233590.1 RP11-153K11.3 5.36 1.53e-07 7.04e-05 0.33 0.28 Optic disc area; chr10:68249632 chr10:68233251~68242379:- LIHC cis rs7945705 0.902 rs7479407 ENSG00000254860.4 TMEM9B-AS1 -5.36 1.53e-07 7.04e-05 -0.28 -0.28 Hemoglobin concentration; chr11:9001874 chr11:8964675~8977527:+ LIHC cis rs4356203 0.905 rs11024158 ENSG00000272034.1 SNORD14A 5.36 1.54e-07 7.05e-05 0.3 0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17103621 chr11:17074654~17074744:- LIHC cis rs9425766 0.541 rs12691474 ENSG00000227373.4 RP11-160H22.5 5.36 1.54e-07 7.06e-05 0.36 0.28 Life satisfaction; chr1:174200867 chr1:174115300~174160004:- LIHC cis rs12468226 1 rs116635509 ENSG00000273456.1 RP11-686O6.2 5.36 1.55e-07 7.08e-05 0.4 0.28 Urate levels; chr2:202460027 chr2:202374932~202375604:- LIHC cis rs6479901 0.843 rs9414802 ENSG00000232075.1 MRPL35P2 5.36 1.55e-07 7.09e-05 0.31 0.28 Intelligence (multi-trait analysis); chr10:63391622 chr10:63634317~63634827:- LIHC cis rs10875746 0.669 rs10431526 ENSG00000240399.1 RP1-228P16.1 -5.36 1.55e-07 7.09e-05 -0.3 -0.28 Longevity (90 years and older); chr12:48296360 chr12:48054813~48055591:- LIHC cis rs4718428 0.705 rs12698547 ENSG00000232546.1 RP11-458F8.1 -5.36 1.55e-07 7.09e-05 -0.25 -0.28 Corneal structure; chr7:66813271 chr7:66848496~66858136:+ LIHC cis rs11098499 0.954 rs12510138 ENSG00000260091.1 RP11-33B1.4 -5.36 1.55e-07 7.1e-05 -0.2 -0.28 Corneal astigmatism; chr4:119502780 chr4:119409333~119410233:+ LIHC cis rs12291225 0.585 rs34171876 ENSG00000251991.1 RNU7-49P 5.36 1.55e-07 7.1e-05 0.29 0.28 Sense of smell; chr11:14332411 chr11:14478892~14478953:+ LIHC cis rs739496 0.947 rs7299849 ENSG00000226469.1 ADAM1B 5.36 1.55e-07 7.11e-05 0.34 0.28 Platelet count; chr12:111417657 chr12:111927018~111929017:+ LIHC cis rs739496 0.947 rs7973120 ENSG00000226469.1 ADAM1B 5.36 1.55e-07 7.11e-05 0.34 0.28 Platelet count; chr12:111418934 chr12:111927018~111929017:+ LIHC cis rs739496 0.947 rs739497 ENSG00000226469.1 ADAM1B 5.36 1.55e-07 7.11e-05 0.34 0.28 Platelet count; chr12:111420282 chr12:111927018~111929017:+ LIHC cis rs4731207 0.596 rs10269342 ENSG00000224897.5 POT1-AS1 -5.36 1.55e-07 7.12e-05 -0.34 -0.28 Cutaneous malignant melanoma; chr7:125053791 chr7:124929873~125179315:+ LIHC cis rs10129255 0.957 rs7493713 ENSG00000223648.3 IGHV3-64 5.36 1.56e-07 7.13e-05 0.21 0.28 Kawasaki disease; chr14:106783685 chr14:106643132~106658258:- LIHC cis rs10129255 0.912 rs35468694 ENSG00000223648.3 IGHV3-64 5.36 1.56e-07 7.13e-05 0.21 0.28 Kawasaki disease; chr14:106784199 chr14:106643132~106658258:- LIHC cis rs10129255 0.957 rs8019272 ENSG00000223648.3 IGHV3-64 5.36 1.56e-07 7.13e-05 0.21 0.28 Kawasaki disease; chr14:106784709 chr14:106643132~106658258:- LIHC cis rs2877649 0.51 rs10083509 ENSG00000258744.1 RP11-80A15.1 5.36 1.56e-07 7.13e-05 0.49 0.28 Smooth-surface caries; chr14:24438841 chr14:24501594~24508688:+ LIHC cis rs227275 0.556 rs4235407 ENSG00000246560.2 RP11-10L12.4 5.36 1.56e-07 7.15e-05 0.31 0.28 Allergic disease (asthma, hay fever or eczema); chr4:102897427 chr4:102828055~102844075:+ LIHC cis rs875971 0.862 rs4149461 ENSG00000237310.1 GS1-124K5.4 -5.36 1.56e-07 7.16e-05 -0.25 -0.28 Aortic root size; chr7:66279745 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs10261398 ENSG00000237310.1 GS1-124K5.4 -5.36 1.56e-07 7.16e-05 -0.25 -0.28 Aortic root size; chr7:66285177 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs10224872 ENSG00000237310.1 GS1-124K5.4 -5.36 1.56e-07 7.16e-05 -0.25 -0.28 Aortic root size; chr7:66294786 chr7:66493706~66495474:+ LIHC cis rs4718428 0.672 rs36038499 ENSG00000232546.1 RP11-458F8.1 -5.36 1.57e-07 7.16e-05 -0.25 -0.28 Corneal structure; chr7:66824628 chr7:66848496~66858136:+ LIHC cis rs116175783 0.557 rs10490567 ENSG00000227403.1 AC009299.3 5.36 1.57e-07 7.17e-05 0.42 0.28 Intelligence (multi-trait analysis); chr2:161317267 chr2:161244739~161249050:+ LIHC cis rs638893 0.842 rs480791 ENSG00000255422.1 AP002954.4 -5.36 1.57e-07 7.18e-05 -0.49 -0.28 Vitiligo; chr11:118833546 chr11:118704607~118750263:+ LIHC cis rs875971 0.862 rs778734 ENSG00000237310.1 GS1-124K5.4 5.36 1.57e-07 7.18e-05 0.25 0.28 Aortic root size; chr7:66349862 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs949930 ENSG00000237310.1 GS1-124K5.4 -5.36 1.57e-07 7.18e-05 -0.25 -0.28 Aortic root size; chr7:66301835 chr7:66493706~66495474:+ LIHC cis rs875971 0.928 rs2036263 ENSG00000237310.1 GS1-124K5.4 -5.36 1.57e-07 7.18e-05 -0.25 -0.28 Aortic root size; chr7:66335210 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs10240949 ENSG00000237310.1 GS1-124K5.4 -5.36 1.57e-07 7.18e-05 -0.25 -0.28 Aortic root size; chr7:66339430 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs7782704 ENSG00000237310.1 GS1-124K5.4 -5.36 1.57e-07 7.18e-05 -0.25 -0.28 Aortic root size; chr7:66340379 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6959268 ENSG00000237310.1 GS1-124K5.4 -5.36 1.57e-07 7.18e-05 -0.25 -0.28 Aortic root size; chr7:66347979 chr7:66493706~66495474:+ LIHC cis rs2439831 1 rs565007 ENSG00000205771.5 CATSPER2P1 -5.36 1.57e-07 7.19e-05 -0.38 -0.28 Lung cancer in ever smokers; chr15:43424443 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs550239 ENSG00000205771.5 CATSPER2P1 -5.36 1.57e-07 7.19e-05 -0.38 -0.28 Lung cancer in ever smokers; chr15:43427999 chr15:43726918~43747094:- LIHC cis rs10510102 1 rs6585764 ENSG00000276742.1 RP11-500G22.4 5.36 1.57e-07 7.19e-05 0.42 0.28 Breast cancer; chr10:121837308 chr10:121956782~121957098:+ LIHC cis rs113835537 0.529 rs116867234 ENSG00000255517.5 CTD-3074O7.5 -5.36 1.57e-07 7.19e-05 -0.36 -0.28 Airway imaging phenotypes; chr11:66441553 chr11:66473490~66480233:- LIHC cis rs113835537 0.529 rs60358007 ENSG00000255517.5 CTD-3074O7.5 -5.36 1.57e-07 7.19e-05 -0.36 -0.28 Airway imaging phenotypes; chr11:66454882 chr11:66473490~66480233:- LIHC cis rs8040855 0.894 rs4843023 ENSG00000259295.5 CSPG4P12 -5.35 1.57e-07 7.2e-05 -0.39 -0.28 Bulimia nervosa; chr15:85162641 chr15:85191438~85213905:+ LIHC cis rs10899021 0.512 rs2186955 ENSG00000279353.1 RP11-864N7.4 -5.35 1.57e-07 7.2e-05 -0.42 -0.28 Response to metformin (IC50); chr11:74664430 chr11:74698231~74699658:- LIHC cis rs4660456 0.572 rs1008204 ENSG00000237899.1 RP4-739H11.3 5.35 1.57e-07 7.2e-05 0.34 0.28 Platelet count; chr1:40700189 chr1:40669089~40687588:- LIHC cis rs4535700 0.501 rs28678267 ENSG00000226278.1 PSPHP1 5.35 1.58e-07 7.22e-05 0.33 0.28 Macular telangiectasia type 2; chr7:55941797 chr7:55764797~55773288:+ LIHC cis rs4535700 0.501 rs11765531 ENSG00000226278.1 PSPHP1 5.35 1.58e-07 7.22e-05 0.33 0.28 Macular telangiectasia type 2; chr7:55942594 chr7:55764797~55773288:+ LIHC cis rs4535700 0.501 rs10227764 ENSG00000226278.1 PSPHP1 5.35 1.58e-07 7.22e-05 0.33 0.28 Macular telangiectasia type 2; chr7:55944729 chr7:55764797~55773288:+ LIHC cis rs4535700 0.501 rs60517461 ENSG00000226278.1 PSPHP1 5.35 1.58e-07 7.22e-05 0.33 0.28 Macular telangiectasia type 2; chr7:55949952 chr7:55764797~55773288:+ LIHC cis rs4934494 0.822 rs3962370 ENSG00000232936.4 RP11-80H5.2 5.35 1.58e-07 7.23e-05 0.34 0.28 Red blood cell count; chr10:89777763 chr10:89645282~89650667:+ LIHC cis rs4934494 0.727 rs1590566 ENSG00000232936.4 RP11-80H5.2 5.35 1.58e-07 7.23e-05 0.34 0.28 Red blood cell count; chr10:89778781 chr10:89645282~89650667:+ LIHC cis rs2153535 0.58 rs1119688 ENSG00000230939.1 RP11-314C16.1 -5.35 1.58e-07 7.23e-05 -0.34 -0.28 Motion sickness; chr6:8460617 chr6:8784178~8785445:+ LIHC cis rs5769765 0.862 rs56377703 ENSG00000278869.1 CITF22-49E9.3 5.35 1.58e-07 7.24e-05 0.46 0.28 Schizophrenia; chr22:49913292 chr22:49933198~49934074:- LIHC cis rs950169 0.922 rs12910334 ENSG00000259295.5 CSPG4P12 5.35 1.59e-07 7.25e-05 0.38 0.28 Schizophrenia; chr15:84403620 chr15:85191438~85213905:+ LIHC cis rs6589219 0.826 rs36029541 ENSG00000196167.8 COLCA1 -5.35 1.59e-07 7.25e-05 -0.31 -0.28 Colorectal cancer; chr11:111269217 chr11:111290787~111305045:- LIHC cis rs950169 0.922 rs12915832 ENSG00000259728.4 LINC00933 5.35 1.59e-07 7.26e-05 0.4 0.28 Schizophrenia; chr15:84568226 chr15:84570649~84580175:+ LIHC cis rs10875746 0.624 rs10875777 ENSG00000240399.1 RP1-228P16.1 -5.35 1.59e-07 7.27e-05 -0.3 -0.28 Longevity (90 years and older); chr12:48228288 chr12:48054813~48055591:- LIHC cis rs12701220 0.655 rs6463317 ENSG00000229043.2 AC091729.9 -5.35 1.59e-07 7.27e-05 -0.38 -0.28 Bronchopulmonary dysplasia; chr7:1119607 chr7:1160374~1165267:+ LIHC cis rs228614 0.51 rs223356 ENSG00000230069.3 LRRC37A15P -5.35 1.6e-07 7.3e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102852344 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223353 ENSG00000230069.3 LRRC37A15P -5.35 1.6e-07 7.3e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102854547 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223352 ENSG00000230069.3 LRRC37A15P -5.35 1.6e-07 7.3e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102855710 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223349 ENSG00000230069.3 LRRC37A15P -5.35 1.6e-07 7.3e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102857277 chr4:102727274~102730721:- LIHC cis rs2274273 0.805 rs10131926 ENSG00000258413.1 RP11-665C16.6 -5.35 1.61e-07 7.32e-05 -0.32 -0.28 Protein biomarker; chr14:55246528 chr14:55262767~55272075:- LIHC cis rs875971 0.545 rs73146609 ENSG00000237310.1 GS1-124K5.4 5.35 1.61e-07 7.33e-05 0.26 0.28 Aortic root size; chr7:66302477 chr7:66493706~66495474:+ LIHC cis rs7131987 0.65 rs11050188 ENSG00000275476.1 RP11-996F15.4 -5.35 1.61e-07 7.34e-05 -0.33 -0.28 QT interval; chr12:29320175 chr12:29277397~29277882:- LIHC cis rs4356203 0.905 rs10832743 ENSG00000272034.1 SNORD14A -5.35 1.61e-07 7.34e-05 -0.3 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17194933 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs550667 ENSG00000272034.1 SNORD14A -5.35 1.61e-07 7.34e-05 -0.3 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17197428 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs656623 ENSG00000272034.1 SNORD14A -5.35 1.61e-07 7.34e-05 -0.3 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17197632 chr11:17074654~17074744:- LIHC cis rs55665837 0.539 rs10500804 ENSG00000251991.1 RNU7-49P 5.35 1.61e-07 7.35e-05 0.3 0.28 Vitamin D levels; chr11:14888727 chr11:14478892~14478953:+ LIHC cis rs9425766 0.566 rs4442420 ENSG00000227373.4 RP11-160H22.5 5.35 1.61e-07 7.35e-05 0.36 0.28 Life satisfaction; chr1:174199667 chr1:174115300~174160004:- LIHC cis rs6683071 0.54 rs1391558 ENSG00000272750.1 RP11-378J18.8 5.35 1.62e-07 7.36e-05 0.33 0.28 Cognitive performance; chr1:222674687 chr1:222658867~222661512:- LIHC cis rs11146838 1 rs11146838 ENSG00000275858.1 RP11-291L22.8 5.35 1.62e-07 7.36e-05 0.32 0.28 Breast cancer; chr10:38856846 chr10:38450738~38451069:- LIHC cis rs11098499 0.82 rs6829903 ENSG00000245958.5 RP11-33B1.1 -5.35 1.62e-07 7.37e-05 -0.29 -0.28 Corneal astigmatism; chr4:119585729 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs7669520 ENSG00000245958.5 RP11-33B1.1 -5.35 1.62e-07 7.37e-05 -0.29 -0.28 Corneal astigmatism; chr4:119594123 chr4:119454791~119552025:+ LIHC cis rs7916410 0.512 rs1900003 ENSG00000233590.1 RP11-153K11.3 -5.35 1.62e-07 7.37e-05 -0.33 -0.28 Optic disc area; chr10:68244794 chr10:68233251~68242379:- LIHC cis rs7916697 0.578 rs1900002 ENSG00000233590.1 RP11-153K11.3 -5.35 1.62e-07 7.37e-05 -0.33 -0.28 Optic disc area; chr10:68244795 chr10:68233251~68242379:- LIHC cis rs12468226 1 rs7597156 ENSG00000273456.1 RP11-686O6.2 5.35 1.62e-07 7.37e-05 0.39 0.28 Urate levels; chr2:202329339 chr2:202374932~202375604:- LIHC cis rs17301013 0.861 rs1894200 ENSG00000227373.4 RP11-160H22.5 -5.35 1.62e-07 7.37e-05 -0.35 -0.28 Systemic lupus erythematosus; chr1:174842039 chr1:174115300~174160004:- LIHC cis rs72638986 1 rs6474359 ENSG00000254165.1 RP11-503E24.2 -5.35 1.62e-07 7.37e-05 -0.45 -0.28 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count; chr8:41691676 chr8:42537529~42538304:- LIHC cis rs9326248 0.603 rs7396061 ENSG00000236267.1 AP006216.5 5.35 1.62e-07 7.37e-05 0.28 0.28 Blood protein levels; chr11:116880158 chr11:116813204~116814003:- LIHC cis rs875971 0.756 rs2901210 ENSG00000237310.1 GS1-124K5.4 -5.35 1.62e-07 7.38e-05 -0.24 -0.28 Aortic root size; chr7:66552518 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs13536 ENSG00000237310.1 GS1-124K5.4 -5.35 1.62e-07 7.38e-05 -0.24 -0.28 Aortic root size; chr7:66554203 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs801209 ENSG00000237310.1 GS1-124K5.4 -5.35 1.62e-07 7.38e-05 -0.24 -0.28 Aortic root size; chr7:66554403 chr7:66493706~66495474:+ LIHC cis rs11098499 0.954 rs10008392 ENSG00000245958.5 RP11-33B1.1 -5.35 1.62e-07 7.39e-05 -0.29 -0.28 Corneal astigmatism; chr4:119397684 chr4:119454791~119552025:+ LIHC cis rs7429990 0.864 rs4858863 ENSG00000229759.1 MRPS18AP1 -5.35 1.63e-07 7.4e-05 -0.31 -0.28 Educational attainment (years of education); chr3:47814143 chr3:48256350~48256938:- LIHC cis rs9326248 0.501 rs4938351 ENSG00000280143.1 AP000892.6 5.35 1.63e-07 7.4e-05 0.32 0.28 Blood protein levels; chr11:117151636 chr11:117204967~117210292:+ LIHC cis rs875971 0.862 rs7796162 ENSG00000237310.1 GS1-124K5.4 -5.35 1.63e-07 7.43e-05 -0.24 -0.28 Aortic root size; chr7:66280771 chr7:66493706~66495474:+ LIHC cis rs2427308 0.607 rs1741635 ENSG00000273619.1 RP5-908M14.9 5.35 1.63e-07 7.43e-05 0.3 0.28 Colorectal cancer; chr20:62363141 chr20:62386303~62386970:- LIHC cis rs7131987 0.65 rs11050187 ENSG00000275476.1 RP11-996F15.4 -5.35 1.63e-07 7.43e-05 -0.33 -0.28 QT interval; chr12:29319943 chr12:29277397~29277882:- LIHC cis rs7131987 0.65 rs16934135 ENSG00000275476.1 RP11-996F15.4 -5.35 1.63e-07 7.43e-05 -0.33 -0.28 QT interval; chr12:29331030 chr12:29277397~29277882:- LIHC cis rs2439831 0.85 rs12442297 ENSG00000205771.5 CATSPER2P1 -5.35 1.63e-07 7.43e-05 -0.44 -0.28 Lung cancer in ever smokers; chr15:43876272 chr15:43726918~43747094:- LIHC cis rs227275 0.554 rs223467 ENSG00000230069.3 LRRC37A15P -5.35 1.63e-07 7.44e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102779721 chr4:102727274~102730721:- LIHC cis rs2439831 0.85 rs544122 ENSG00000205771.5 CATSPER2P1 -5.35 1.64e-07 7.44e-05 -0.41 -0.28 Lung cancer in ever smokers; chr15:43483534 chr15:43726918~43747094:- LIHC cis rs2842992 0.872 rs2758330 ENSG00000237927.1 RP3-393E18.2 -5.35 1.64e-07 7.45e-05 -0.35 -0.28 Age-related macular degeneration (geographic atrophy); chr6:159683812 chr6:159586955~159589169:- LIHC cis rs73186030 0.546 rs67931976 ENSG00000272758.4 RP11-299J3.8 5.35 1.64e-07 7.45e-05 0.46 0.28 Serum parathyroid hormone levels; chr3:122386868 chr3:122416207~122443180:+ LIHC cis rs2933343 1 rs1680784 ENSG00000231305.3 RP11-723O4.2 5.35 1.64e-07 7.47e-05 0.32 0.28 IgG glycosylation; chr3:128925615 chr3:128861313~128871540:- LIHC cis rs853679 0.55 rs6901017 ENSG00000219392.1 RP1-265C24.5 -5.35 1.64e-07 7.47e-05 -0.42 -0.28 Depression; chr6:28184805 chr6:28115628~28116551:+ LIHC cis rs75920871 0.589 rs4938342 ENSG00000254851.1 RP11-109L13.1 -5.35 1.64e-07 7.47e-05 -0.54 -0.28 Subjective well-being; chr11:117132704 chr11:117135528~117138582:+ LIHC cis rs7916697 1 rs7916697 ENSG00000233590.1 RP11-153K11.3 5.35 1.65e-07 7.48e-05 0.33 0.28 Optic disc area; chr10:68232096 chr10:68233251~68242379:- LIHC cis rs6921919 0.525 rs16894095 ENSG00000216901.1 AL022393.7 5.35 1.65e-07 7.48e-05 0.34 0.28 Autism spectrum disorder or schizophrenia; chr6:28422453 chr6:28176188~28176674:+ LIHC cis rs4731207 0.596 rs9969187 ENSG00000224897.5 POT1-AS1 5.35 1.65e-07 7.5e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125021418 chr7:124929873~125179315:+ LIHC cis rs524281 0.861 rs580891 ENSG00000255320.1 RP11-755F10.1 5.35 1.65e-07 7.51e-05 0.34 0.28 Electroencephalogram traits; chr11:66187210 chr11:66244840~66246239:- LIHC cis rs4718428 0.705 rs62465692 ENSG00000232546.1 RP11-458F8.1 -5.35 1.65e-07 7.51e-05 -0.25 -0.28 Corneal structure; chr7:66830758 chr7:66848496~66858136:+ LIHC cis rs4718428 0.662 rs34577323 ENSG00000232546.1 RP11-458F8.1 -5.35 1.65e-07 7.51e-05 -0.25 -0.28 Corneal structure; chr7:66845054 chr7:66848496~66858136:+ LIHC cis rs4718428 0.705 rs4717328 ENSG00000232546.1 RP11-458F8.1 -5.35 1.65e-07 7.51e-05 -0.25 -0.28 Corneal structure; chr7:66887678 chr7:66848496~66858136:+ LIHC cis rs4718428 0.705 rs4718422 ENSG00000232546.1 RP11-458F8.1 -5.35 1.65e-07 7.51e-05 -0.25 -0.28 Corneal structure; chr7:66894282 chr7:66848496~66858136:+ LIHC cis rs4718428 0.705 rs13231140 ENSG00000232546.1 RP11-458F8.1 -5.35 1.65e-07 7.51e-05 -0.25 -0.28 Corneal structure; chr7:66896631 chr7:66848496~66858136:+ LIHC cis rs6480314 0.542 rs10998045 ENSG00000233590.1 RP11-153K11.3 -5.35 1.65e-07 7.51e-05 -0.43 -0.28 Optic nerve measurement (disc area); chr10:68269626 chr10:68233251~68242379:- LIHC cis rs1499614 0.803 rs1796229 ENSG00000226824.5 RP4-756H11.3 -5.35 1.65e-07 7.51e-05 -0.46 -0.28 Gout; chr7:66654674 chr7:66654538~66669855:+ LIHC cis rs1499614 0.901 rs3936 ENSG00000226824.5 RP4-756H11.3 -5.35 1.65e-07 7.51e-05 -0.46 -0.28 Gout; chr7:66661502 chr7:66654538~66669855:+ LIHC cis rs12134133 1 rs1782468 ENSG00000274245.1 RP11-357P18.2 5.35 1.65e-07 7.51e-05 0.39 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207297070 chr1:207372559~207373252:+ LIHC cis rs4718428 0.672 rs12530806 ENSG00000232546.1 RP11-458F8.1 -5.35 1.65e-07 7.52e-05 -0.25 -0.28 Corneal structure; chr7:66925737 chr7:66848496~66858136:+ LIHC cis rs6479891 1 rs10761745 ENSG00000232075.1 MRPL35P2 -5.35 1.66e-07 7.52e-05 -0.32 -0.28 Arthritis (juvenile idiopathic); chr10:63341311 chr10:63634317~63634827:- LIHC cis rs6686842 0.965 rs10889792 ENSG00000235358.1 RP11-399E6.1 -5.34 1.66e-07 7.53e-05 -0.31 -0.28 Height; chr1:41025213 chr1:41242373~41284861:+ LIHC cis rs7429990 0.864 rs7629850 ENSG00000229759.1 MRPS18AP1 -5.34 1.66e-07 7.54e-05 -0.31 -0.28 Educational attainment (years of education); chr3:47815592 chr3:48256350~48256938:- LIHC cis rs875971 0.895 rs6460278 ENSG00000237310.1 GS1-124K5.4 -5.34 1.66e-07 7.54e-05 -0.25 -0.28 Aortic root size; chr7:66197749 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6460279 ENSG00000237310.1 GS1-124K5.4 -5.34 1.66e-07 7.54e-05 -0.25 -0.28 Aortic root size; chr7:66197774 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs28491091 ENSG00000237310.1 GS1-124K5.4 -5.34 1.66e-07 7.54e-05 -0.25 -0.28 Aortic root size; chr7:66204077 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6952182 ENSG00000237310.1 GS1-124K5.4 -5.34 1.66e-07 7.54e-05 -0.25 -0.28 Aortic root size; chr7:66218330 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6964437 ENSG00000237310.1 GS1-124K5.4 -5.34 1.66e-07 7.54e-05 -0.25 -0.28 Aortic root size; chr7:66221457 chr7:66493706~66495474:+ LIHC cis rs2933343 0.729 rs1683780 ENSG00000231305.3 RP11-723O4.2 5.34 1.66e-07 7.54e-05 0.31 0.28 IgG glycosylation; chr3:128921396 chr3:128861313~128871540:- LIHC cis rs7615952 0.688 rs4422259 ENSG00000171084.14 FAM86JP 5.34 1.67e-07 7.56e-05 0.39 0.28 Blood pressure (smoking interaction); chr3:125826988 chr3:125916620~125930024:+ LIHC cis rs4718428 0.672 rs13241598 ENSG00000232546.1 RP11-458F8.1 -5.34 1.67e-07 7.57e-05 -0.25 -0.28 Corneal structure; chr7:66835665 chr7:66848496~66858136:+ LIHC cis rs17301013 0.861 rs333418 ENSG00000227373.4 RP11-160H22.5 5.34 1.67e-07 7.58e-05 0.36 0.28 Systemic lupus erythematosus; chr1:174707294 chr1:174115300~174160004:- LIHC cis rs17301013 0.828 rs332783 ENSG00000227373.4 RP11-160H22.5 5.34 1.67e-07 7.58e-05 0.36 0.28 Systemic lupus erythematosus; chr1:174719260 chr1:174115300~174160004:- LIHC cis rs17301013 0.861 rs170768 ENSG00000227373.4 RP11-160H22.5 5.34 1.67e-07 7.58e-05 0.36 0.28 Systemic lupus erythematosus; chr1:174720787 chr1:174115300~174160004:- LIHC cis rs17301013 0.861 rs332796 ENSG00000227373.4 RP11-160H22.5 5.34 1.67e-07 7.58e-05 0.36 0.28 Systemic lupus erythematosus; chr1:174727142 chr1:174115300~174160004:- LIHC cis rs17301013 0.861 rs332799 ENSG00000227373.4 RP11-160H22.5 5.34 1.67e-07 7.58e-05 0.36 0.28 Systemic lupus erythematosus; chr1:174731110 chr1:174115300~174160004:- LIHC cis rs7945705 0.967 rs10840141 ENSG00000254860.4 TMEM9B-AS1 -5.34 1.67e-07 7.59e-05 -0.27 -0.28 Hemoglobin concentration; chr11:8880671 chr11:8964675~8977527:+ LIHC cis rs2153535 0.58 rs7747306 ENSG00000230939.1 RP11-314C16.1 5.34 1.68e-07 7.6e-05 0.34 0.28 Motion sickness; chr6:8453430 chr6:8784178~8785445:+ LIHC cis rs3096299 0.503 rs9925045 ENSG00000261118.1 RP11-104N10.1 5.34 1.68e-07 7.6e-05 0.28 0.28 Multiple myeloma (IgH translocation); chr16:89490068 chr16:89492017~89504460:- LIHC cis rs10129255 0.536 rs3944157 ENSG00000211972.2 IGHV3-66 5.34 1.68e-07 7.62e-05 0.21 0.28 Kawasaki disease; chr14:106682286 chr14:106675017~106675544:- LIHC cis rs13068223 0.819 rs11917436 ENSG00000243926.1 TIPARP-AS1 5.34 1.68e-07 7.62e-05 0.26 0.28 Age-related hearing impairment (SNP x SNP interaction); chr3:156747839 chr3:156671862~156674378:- LIHC cis rs3096299 0.679 rs3096322 ENSG00000261118.1 RP11-104N10.1 -5.34 1.68e-07 7.63e-05 -0.28 -0.28 Multiple myeloma (IgH translocation); chr16:89374715 chr16:89492017~89504460:- LIHC cis rs2286503 1 rs2286498 ENSG00000228649.7 AC005682.5 -5.34 1.68e-07 7.63e-05 -0.34 -0.28 Fibrinogen; chr7:22817885 chr7:22854178~22861579:+ LIHC cis rs739496 0.947 rs2283358 ENSG00000226469.1 ADAM1B 5.34 1.69e-07 7.65e-05 0.34 0.28 Platelet count; chr12:111427761 chr12:111927018~111929017:+ LIHC cis rs739496 0.947 rs2285520 ENSG00000226469.1 ADAM1B 5.34 1.69e-07 7.65e-05 0.34 0.28 Platelet count; chr12:111429683 chr12:111927018~111929017:+ LIHC cis rs2735413 0.918 rs12918959 ENSG00000276007.1 RP11-358L22.3 -5.34 1.69e-07 7.65e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78047822 chr16:78123243~78124332:+ LIHC cis rs684603 1 rs684603 ENSG00000246174.6 KCTD21-AS1 -5.34 1.69e-07 7.65e-05 -0.35 -0.28 Number of common colds; chr11:78102803 chr11:78139771~78175323:+ LIHC cis rs9487094 0.666 rs12529733 ENSG00000260273.1 RP11-425D10.10 5.34 1.69e-07 7.66e-05 0.33 0.28 Height; chr6:109332929 chr6:109382795~109383666:+ LIHC cis rs12744310 0.502 rs2364531 ENSG00000235358.1 RP11-399E6.1 5.34 1.7e-07 7.67e-05 0.32 0.28 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41338544 chr1:41242373~41284861:+ LIHC cis rs4660456 0.529 rs61779237 ENSG00000237899.1 RP4-739H11.3 5.34 1.7e-07 7.68e-05 0.35 0.28 Platelet count; chr1:40685300 chr1:40669089~40687588:- LIHC cis rs2032366 0.606 rs7226896 ENSG00000267279.1 RP11-879F14.2 -5.34 1.7e-07 7.69e-05 -0.33 -0.28 Obesity-related traits; chr18:61608946 chr18:61585746~61606916:- LIHC cis rs4731207 0.596 rs12535807 ENSG00000224897.5 POT1-AS1 5.34 1.7e-07 7.69e-05 0.33 0.28 Cutaneous malignant melanoma; chr7:124951379 chr7:124929873~125179315:+ LIHC cis rs638893 0.853 rs4938549 ENSG00000255422.1 AP002954.4 -5.34 1.7e-07 7.69e-05 -0.46 -0.28 Vitiligo; chr11:118830888 chr11:118704607~118750263:+ LIHC cis rs638893 0.898 rs530646 ENSG00000255422.1 AP002954.4 -5.34 1.7e-07 7.69e-05 -0.46 -0.28 Vitiligo; chr11:118830959 chr11:118704607~118750263:+ LIHC cis rs638893 0.947 rs12808822 ENSG00000255422.1 AP002954.4 -5.34 1.7e-07 7.69e-05 -0.46 -0.28 Vitiligo; chr11:118831560 chr11:118704607~118750263:+ LIHC cis rs2243480 1 rs3885839 ENSG00000226824.5 RP4-756H11.3 -5.34 1.7e-07 7.69e-05 -0.47 -0.28 Diabetic kidney disease; chr7:65825416 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs3813708 ENSG00000226824.5 RP4-756H11.3 -5.34 1.7e-07 7.69e-05 -0.47 -0.28 Diabetic kidney disease; chr7:65840645 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs73142122 ENSG00000226824.5 RP4-756H11.3 -5.34 1.7e-07 7.69e-05 -0.47 -0.28 Diabetic kidney disease; chr7:65846311 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs73142137 ENSG00000226824.5 RP4-756H11.3 -5.34 1.7e-07 7.69e-05 -0.47 -0.28 Diabetic kidney disease; chr7:65878455 chr7:66654538~66669855:+ LIHC cis rs875971 0.83 rs778711 ENSG00000237310.1 GS1-124K5.4 5.34 1.71e-07 7.71e-05 0.24 0.28 Aortic root size; chr7:66386670 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs1083554 ENSG00000237310.1 GS1-124K5.4 5.34 1.71e-07 7.71e-05 0.24 0.28 Aortic root size; chr7:66387354 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs778707 ENSG00000237310.1 GS1-124K5.4 5.34 1.71e-07 7.71e-05 0.24 0.28 Aortic root size; chr7:66392040 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs778705 ENSG00000237310.1 GS1-124K5.4 5.34 1.71e-07 7.71e-05 0.24 0.28 Aortic root size; chr7:66396128 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs778697 ENSG00000237310.1 GS1-124K5.4 5.34 1.71e-07 7.71e-05 0.24 0.28 Aortic root size; chr7:66405439 chr7:66493706~66495474:+ LIHC cis rs875971 0.798 rs7789615 ENSG00000237310.1 GS1-124K5.4 5.34 1.71e-07 7.71e-05 0.24 0.28 Aortic root size; chr7:66413674 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6978028 ENSG00000237310.1 GS1-124K5.4 5.34 1.71e-07 7.71e-05 0.24 0.28 Aortic root size; chr7:66421313 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6947339 ENSG00000237310.1 GS1-124K5.4 5.34 1.71e-07 7.71e-05 0.24 0.28 Aortic root size; chr7:66423483 chr7:66493706~66495474:+ LIHC cis rs2735413 0.67 rs11861339 ENSG00000276007.1 RP11-358L22.3 5.34 1.71e-07 7.71e-05 0.37 0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78060493 chr16:78123243~78124332:+ LIHC cis rs12468226 0.873 rs78798541 ENSG00000273456.1 RP11-686O6.2 5.34 1.71e-07 7.72e-05 0.42 0.28 Urate levels; chr2:202194708 chr2:202374932~202375604:- LIHC cis rs4731207 0.596 rs1600737 ENSG00000224897.5 POT1-AS1 5.34 1.71e-07 7.72e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:124999493 chr7:124929873~125179315:+ LIHC cis rs4731207 0.57 rs1600738 ENSG00000224897.5 POT1-AS1 5.34 1.71e-07 7.72e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:124999495 chr7:124929873~125179315:+ LIHC cis rs1134634 0.52 rs28522268 ENSG00000273133.1 RP11-799M12.2 -5.34 1.71e-07 7.72e-05 -0.35 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15601844 chr4:15563698~15564253:- LIHC cis rs6480314 0.542 rs17297383 ENSG00000233590.1 RP11-153K11.3 -5.34 1.71e-07 7.73e-05 -0.42 -0.28 Optic nerve measurement (disc area); chr10:68269106 chr10:68233251~68242379:- LIHC cis rs7176527 0.579 rs366717 ENSG00000189136.7 UBE2Q2P1 -5.34 1.71e-07 7.74e-05 -0.24 -0.28 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84544848 chr15:84526781~84571216:- LIHC cis rs2243480 0.831 rs57294491 ENSG00000226824.5 RP4-756H11.3 5.34 1.72e-07 7.74e-05 0.45 0.28 Diabetic kidney disease; chr7:66219914 chr7:66654538~66669855:+ LIHC cis rs739496 0.895 rs7965040 ENSG00000226469.1 ADAM1B 5.34 1.72e-07 7.77e-05 0.33 0.28 Platelet count; chr12:111482491 chr12:111927018~111929017:+ LIHC cis rs739496 0.947 rs6490162 ENSG00000226469.1 ADAM1B 5.34 1.72e-07 7.77e-05 0.33 0.28 Platelet count; chr12:111503316 chr12:111927018~111929017:+ LIHC cis rs12134133 1 rs2802235 ENSG00000274245.1 RP11-357P18.2 5.34 1.72e-07 7.78e-05 0.42 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207298454 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs2490261 ENSG00000274245.1 RP11-357P18.2 5.34 1.72e-07 7.78e-05 0.42 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207304124 chr1:207372559~207373252:+ LIHC cis rs6085948 1 rs4815987 ENSG00000238102.1 RP11-19D2.1 5.34 1.72e-07 7.78e-05 0.4 0.28 Interleukin-10 levels; chr20:7259968 chr20:7256580~7258214:- LIHC cis rs6085948 0.953 rs6117725 ENSG00000238102.1 RP11-19D2.1 5.34 1.72e-07 7.78e-05 0.4 0.28 Interleukin-10 levels; chr20:7262362 chr20:7256580~7258214:- LIHC cis rs2274273 0.87 rs1952087 ENSG00000258413.1 RP11-665C16.6 -5.34 1.73e-07 7.78e-05 -0.31 -0.28 Protein biomarker; chr14:55216493 chr14:55262767~55272075:- LIHC cis rs2735413 0.881 rs12921945 ENSG00000276007.1 RP11-358L22.3 -5.34 1.73e-07 7.78e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78046236 chr16:78123243~78124332:+ LIHC cis rs2735413 0.846 rs12923626 ENSG00000276007.1 RP11-358L22.3 -5.34 1.73e-07 7.78e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78046242 chr16:78123243~78124332:+ LIHC cis rs2735413 0.881 rs12927515 ENSG00000276007.1 RP11-358L22.3 -5.34 1.73e-07 7.78e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78046244 chr16:78123243~78124332:+ LIHC cis rs7474896 0.616 rs2474561 ENSG00000263064.2 RP11-291L22.7 5.34 1.73e-07 7.79e-05 0.33 0.28 Obesity (extreme); chr10:38084616 chr10:38448689~38448949:+ LIHC cis rs7529073 0.545 rs1431985 ENSG00000274895.1 RP11-478J18.2 -5.34 1.73e-07 7.79e-05 -0.3 -0.28 Schizophrenia; chr1:213974903 chr1:213983793~213986419:- LIHC cis rs6479901 0.895 rs10740112 ENSG00000232075.1 MRPL35P2 -5.34 1.73e-07 7.8e-05 -0.3 -0.28 Intelligence (multi-trait analysis); chr10:63322315 chr10:63634317~63634827:- LIHC cis rs6479901 0.895 rs10740113 ENSG00000232075.1 MRPL35P2 -5.34 1.73e-07 7.8e-05 -0.3 -0.28 Intelligence (multi-trait analysis); chr10:63322516 chr10:63634317~63634827:- LIHC cis rs6479901 0.895 rs10740114 ENSG00000232075.1 MRPL35P2 -5.34 1.73e-07 7.8e-05 -0.3 -0.28 Intelligence (multi-trait analysis); chr10:63322659 chr10:63634317~63634827:- LIHC cis rs2243480 0.706 rs34466769 ENSG00000226824.5 RP4-756H11.3 -5.34 1.74e-07 7.82e-05 -0.41 -0.28 Diabetic kidney disease; chr7:65988305 chr7:66654538~66669855:+ LIHC cis rs9487094 0.67 rs2277114 ENSG00000260273.1 RP11-425D10.10 5.34 1.74e-07 7.83e-05 0.33 0.28 Height; chr6:109506513 chr6:109382795~109383666:+ LIHC cis rs9487094 0.67 rs13220915 ENSG00000260273.1 RP11-425D10.10 5.34 1.74e-07 7.83e-05 0.33 0.28 Height; chr6:109503623 chr6:109382795~109383666:+ LIHC cis rs9291683 0.53 rs17246501 ENSG00000250413.1 RP11-448G15.1 -5.34 1.74e-07 7.84e-05 -0.36 -0.28 Bone mineral density; chr4:9984086 chr4:10006482~10009725:+ LIHC cis rs875971 0.545 rs10950036 ENSG00000237310.1 GS1-124K5.4 5.33 1.74e-07 7.85e-05 0.26 0.28 Aortic root size; chr7:66353241 chr7:66493706~66495474:+ LIHC cis rs9487094 0.813 rs11753645 ENSG00000260273.1 RP11-425D10.10 5.33 1.75e-07 7.88e-05 0.39 0.28 Height; chr6:109373851 chr6:109382795~109383666:+ LIHC cis rs10875746 0.669 rs9634261 ENSG00000240399.1 RP1-228P16.1 -5.33 1.75e-07 7.88e-05 -0.29 -0.28 Longevity (90 years and older); chr12:48293088 chr12:48054813~48055591:- LIHC cis rs113835537 0.529 rs79798028 ENSG00000255517.5 CTD-3074O7.5 -5.33 1.75e-07 7.9e-05 -0.31 -0.28 Airway imaging phenotypes; chr11:66431891 chr11:66473490~66480233:- LIHC cis rs4731207 0.596 rs3903522 ENSG00000224897.5 POT1-AS1 5.33 1.75e-07 7.9e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125028088 chr7:124929873~125179315:+ LIHC cis rs4731207 0.535 rs1351471 ENSG00000224897.5 POT1-AS1 5.33 1.75e-07 7.9e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125031961 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1871774 ENSG00000224897.5 POT1-AS1 5.33 1.75e-07 7.9e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125034844 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1871773 ENSG00000224897.5 POT1-AS1 5.33 1.75e-07 7.9e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125034885 chr7:124929873~125179315:+ LIHC cis rs7714584 1 rs12659118 ENSG00000197083.10 ZNF300P1 5.33 1.75e-07 7.9e-05 0.43 0.28 Crohn's disease; chr5:150945060 chr5:150930645~150946289:- LIHC cis rs2243480 1 rs383402 ENSG00000226824.5 RP4-756H11.3 5.33 1.76e-07 7.9e-05 0.45 0.28 Diabetic kidney disease; chr7:66121666 chr7:66654538~66669855:+ LIHC cis rs12571093 0.773 rs10762197 ENSG00000233590.1 RP11-153K11.3 5.33 1.76e-07 7.91e-05 0.43 0.28 Optic nerve measurement (disc area); chr10:68249498 chr10:68233251~68242379:- LIHC cis rs9318086 0.712 rs9510916 ENSG00000205861.10 C1QTNF9B-AS1 -5.33 1.76e-07 7.93e-05 -0.31 -0.28 Myopia (pathological); chr13:23868650 chr13:23888889~23897263:+ LIHC cis rs17711722 0.523 rs313812 ENSG00000226824.5 RP4-756H11.3 5.33 1.76e-07 7.94e-05 0.32 0.28 Calcium levels; chr7:66040056 chr7:66654538~66669855:+ LIHC cis rs1577917 0.771 rs7742201 ENSG00000234155.1 RP11-30P6.6 5.33 1.77e-07 7.95e-05 0.35 0.28 Response to antipsychotic treatment; chr6:85723212 chr6:85387219~85390186:- LIHC cis rs4356203 0.905 rs214940 ENSG00000272034.1 SNORD14A -5.33 1.77e-07 7.95e-05 -0.3 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17165308 chr11:17074654~17074744:- LIHC cis rs2243480 0.708 rs35825036 ENSG00000226824.5 RP4-756H11.3 -5.33 1.77e-07 7.96e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66521515 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs13237037 ENSG00000226824.5 RP4-756H11.3 -5.33 1.77e-07 7.96e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66532895 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs13237344 ENSG00000226824.5 RP4-756H11.3 -5.33 1.77e-07 7.96e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66557269 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1796228 ENSG00000226824.5 RP4-756H11.3 -5.33 1.77e-07 7.96e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66568097 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1267820 ENSG00000226824.5 RP4-756H11.3 -5.33 1.77e-07 7.96e-05 -0.46 -0.28 Diabetic kidney disease; chr7:66585308 chr7:66654538~66669855:+ LIHC cis rs853679 0.567 rs2232427 ENSG00000216901.1 AL022393.7 5.33 1.77e-07 7.96e-05 0.37 0.28 Depression; chr6:28391932 chr6:28176188~28176674:+ LIHC cis rs4718428 0.705 rs10267335 ENSG00000232546.1 RP11-458F8.1 -5.33 1.77e-07 7.96e-05 -0.25 -0.28 Corneal structure; chr7:66938233 chr7:66848496~66858136:+ LIHC cis rs4731207 0.596 rs12534466 ENSG00000224897.5 POT1-AS1 5.33 1.77e-07 7.97e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125028369 chr7:124929873~125179315:+ LIHC cis rs11098499 1 rs13435802 ENSG00000245958.5 RP11-33B1.1 5.33 1.77e-07 7.97e-05 0.3 0.28 Corneal astigmatism; chr4:119256805 chr4:119454791~119552025:+ LIHC cis rs12134133 1 rs2802232 ENSG00000274245.1 RP11-357P18.2 5.33 1.78e-07 7.98e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207294806 chr1:207372559~207373252:+ LIHC cis rs5758511 0.68 rs1033459 ENSG00000237037.8 NDUFA6-AS1 -5.33 1.78e-07 7.99e-05 -0.35 -0.28 Birth weight; chr22:42223061 chr22:42090931~42137742:+ LIHC cis rs5758511 0.68 rs1033460 ENSG00000237037.8 NDUFA6-AS1 -5.33 1.78e-07 7.99e-05 -0.35 -0.28 Birth weight; chr22:42223302 chr22:42090931~42137742:+ LIHC cis rs5758511 0.679 rs55867855 ENSG00000237037.8 NDUFA6-AS1 -5.33 1.78e-07 7.99e-05 -0.35 -0.28 Birth weight; chr22:42227252 chr22:42090931~42137742:+ LIHC cis rs11098499 0.863 rs10019674 ENSG00000245958.5 RP11-33B1.1 5.33 1.78e-07 7.99e-05 0.29 0.28 Corneal astigmatism; chr4:119522334 chr4:119454791~119552025:+ LIHC cis rs2153535 0.58 rs6421948 ENSG00000230939.1 RP11-314C16.1 -5.33 1.78e-07 7.99e-05 -0.34 -0.28 Motion sickness; chr6:8530787 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs6421949 ENSG00000230939.1 RP11-314C16.1 -5.33 1.78e-07 7.99e-05 -0.34 -0.28 Motion sickness; chr6:8531536 chr6:8784178~8785445:+ LIHC cis rs4731207 0.596 rs2219953 ENSG00000224897.5 POT1-AS1 5.33 1.78e-07 8e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125031861 chr7:124929873~125179315:+ LIHC cis rs72627509 0.857 rs2227901 ENSG00000269949.1 RP11-738E22.3 -5.33 1.78e-07 8e-05 -0.37 -0.28 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56932023 chr4:56960927~56961373:- LIHC cis rs56205728 0.546 rs62021888 ENSG00000273855.1 RP11-133K1.12 -5.33 1.78e-07 8e-05 -0.38 -0.28 Schizophrenia; chr15:40291359 chr15:40285468~40285909:- LIHC cis rs8059260 0.736 rs113120936 ENSG00000274038.1 RP11-66H6.4 -5.33 1.78e-07 8e-05 -0.46 -0.28 Alcohol consumption over the past year; chr16:10989474 chr16:11056556~11057034:+ LIHC cis rs227275 0.525 rs17215211 ENSG00000230069.3 LRRC37A15P -5.33 1.78e-07 8.01e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103025961 chr4:102727274~102730721:- LIHC cis rs8177376 0.906 rs240559 ENSG00000254905.1 RP11-712L6.7 5.33 1.78e-07 8.01e-05 0.4 0.28 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126321217 chr11:126292922~126294254:- LIHC cis rs62355901 0.599 rs751990 ENSG00000271828.1 CTD-2310F14.1 5.33 1.78e-07 8.01e-05 0.5 0.28 Breast cancer; chr5:56743292 chr5:56927874~56929573:+ LIHC cis rs875971 0.545 rs316328 ENSG00000237310.1 GS1-124K5.4 -5.33 1.79e-07 8.03e-05 -0.25 -0.28 Aortic root size; chr7:66143851 chr7:66493706~66495474:+ LIHC cis rs2072510 0.569 rs7970524 ENSG00000257715.1 RP11-256L6.2 -5.33 1.79e-07 8.03e-05 -0.4 -0.28 Metabolite levels (small molecules and protein measures); chr12:95996374 chr12:96025323~96027971:+ LIHC cis rs150992 0.603 rs326481 ENSG00000248489.1 CTD-2007H13.3 5.33 1.79e-07 8.03e-05 0.44 0.28 Body mass index; chr5:98949581 chr5:98929171~98995013:+ LIHC cis rs1061377 1 rs9996285 ENSG00000249685.1 RP11-360F5.3 5.33 1.79e-07 8.03e-05 0.33 0.28 Uric acid levels; chr4:39130556 chr4:39133913~39135608:+ LIHC cis rs227275 0.525 rs1080081 ENSG00000230069.3 LRRC37A15P -5.33 1.79e-07 8.05e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103029268 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs4699049 ENSG00000230069.3 LRRC37A15P -5.33 1.79e-07 8.05e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103030467 chr4:102727274~102730721:- LIHC cis rs11098499 0.865 rs28634456 ENSG00000245958.5 RP11-33B1.1 -5.33 1.79e-07 8.05e-05 -0.29 -0.28 Corneal astigmatism; chr4:119454623 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs78332141 ENSG00000245958.5 RP11-33B1.1 -5.33 1.79e-07 8.05e-05 -0.29 -0.28 Corneal astigmatism; chr4:119454627 chr4:119454791~119552025:+ LIHC cis rs7586673 0.857 rs16845580 ENSG00000227403.1 AC009299.3 -5.33 1.8e-07 8.08e-05 -0.34 -0.28 Intelligence (multi-trait analysis); chr2:161064373 chr2:161244739~161249050:+ LIHC cis rs5769707 0.837 rs5769709 ENSG00000235111.1 RP1-29C18.8 -5.33 1.8e-07 8.09e-05 -0.32 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49628109 chr22:49612657~49615716:- LIHC cis rs17711722 0.528 rs73138179 ENSG00000226002.1 RP11-460N20.5 5.33 1.8e-07 8.09e-05 0.29 0.28 Calcium levels; chr7:65829495 chr7:65084103~65100232:+ LIHC cis rs11098499 0.863 rs59732491 ENSG00000245958.5 RP11-33B1.1 -5.33 1.81e-07 8.11e-05 -0.28 -0.28 Corneal astigmatism; chr4:119568433 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs11723090 ENSG00000245958.5 RP11-33B1.1 -5.33 1.81e-07 8.11e-05 -0.28 -0.28 Corneal astigmatism; chr4:119569437 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs11098532 ENSG00000245958.5 RP11-33B1.1 -5.33 1.81e-07 8.11e-05 -0.28 -0.28 Corneal astigmatism; chr4:119569571 chr4:119454791~119552025:+ LIHC cis rs6479901 0.895 rs1579045 ENSG00000232075.1 MRPL35P2 -5.33 1.81e-07 8.11e-05 -0.3 -0.28 Intelligence (multi-trait analysis); chr10:63210688 chr10:63634317~63634827:- LIHC cis rs6479901 0.895 rs7920159 ENSG00000232075.1 MRPL35P2 -5.33 1.81e-07 8.11e-05 -0.3 -0.28 Intelligence (multi-trait analysis); chr10:63212416 chr10:63634317~63634827:- LIHC cis rs6479901 0.841 rs10822148 ENSG00000232075.1 MRPL35P2 -5.33 1.81e-07 8.11e-05 -0.3 -0.28 Intelligence (multi-trait analysis); chr10:63219487 chr10:63634317~63634827:- LIHC cis rs1061377 0.748 rs13117988 ENSG00000249207.1 RP11-360F5.1 -5.33 1.81e-07 8.11e-05 -0.28 -0.28 Uric acid levels; chr4:39092219 chr4:39112677~39126818:- LIHC cis rs2842992 0.83 rs1853259 ENSG00000237927.1 RP3-393E18.2 5.33 1.81e-07 8.11e-05 0.34 0.28 Age-related macular degeneration (geographic atrophy); chr6:159726409 chr6:159586955~159589169:- LIHC cis rs2842992 0.789 rs2842969 ENSG00000237927.1 RP3-393E18.2 -5.33 1.81e-07 8.11e-05 -0.34 -0.28 Age-related macular degeneration (geographic atrophy); chr6:159724332 chr6:159586955~159589169:- LIHC cis rs875971 0.545 rs2173571 ENSG00000237310.1 GS1-124K5.4 5.33 1.81e-07 8.11e-05 0.26 0.28 Aortic root size; chr7:66305392 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs11770063 ENSG00000237310.1 GS1-124K5.4 5.33 1.81e-07 8.11e-05 0.26 0.28 Aortic root size; chr7:66318029 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs3936065 ENSG00000237310.1 GS1-124K5.4 5.33 1.81e-07 8.11e-05 0.26 0.28 Aortic root size; chr7:66325577 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs4718335 ENSG00000237310.1 GS1-124K5.4 5.33 1.81e-07 8.11e-05 0.26 0.28 Aortic root size; chr7:66339619 chr7:66493706~66495474:+ LIHC cis rs4934494 0.727 rs67827533 ENSG00000232936.4 RP11-80H5.2 5.33 1.81e-07 8.12e-05 0.35 0.28 Red blood cell count; chr10:89745626 chr10:89645282~89650667:+ LIHC cis rs11098499 0.863 rs12508173 ENSG00000245958.5 RP11-33B1.1 -5.33 1.81e-07 8.13e-05 -0.29 -0.28 Corneal astigmatism; chr4:119397371 chr4:119454791~119552025:+ LIHC cis rs11098499 0.908 rs12504149 ENSG00000245958.5 RP11-33B1.1 -5.33 1.81e-07 8.13e-05 -0.29 -0.28 Corneal astigmatism; chr4:119397422 chr4:119454791~119552025:+ LIHC cis rs6439153 0.55 rs789223 ENSG00000231305.3 RP11-723O4.2 5.33 1.81e-07 8.13e-05 0.31 0.28 Pneumococcal bacteremia; chr3:128952303 chr3:128861313~128871540:- LIHC cis rs9549367 0.789 rs6577031 ENSG00000269125.1 RP11-98F14.11 5.33 1.81e-07 8.13e-05 0.31 0.28 Platelet distribution width; chr13:113223868 chr13:113165002~113165183:- LIHC cis rs7923609 0.756 rs12768534 ENSG00000232075.1 MRPL35P2 -5.33 1.82e-07 8.15e-05 -0.29 -0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63581137 chr10:63634317~63634827:- LIHC cis rs5769707 0.837 rs1573726 ENSG00000235111.1 RP1-29C18.8 -5.33 1.82e-07 8.16e-05 -0.33 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49639224 chr22:49612657~49615716:- LIHC cis rs9326248 0.53 rs236918 ENSG00000280143.1 AP000892.6 -5.33 1.82e-07 8.16e-05 -0.36 -0.28 Blood protein levels; chr11:117220893 chr11:117204967~117210292:+ LIHC cis rs2739330 0.76 rs5760095 ENSG00000099984.9 GSTT2 -5.33 1.82e-07 8.17e-05 -0.33 -0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23980123~23983911:+ LIHC cis rs950169 0.887 rs12903946 ENSG00000225151.9 GOLGA2P7 -5.33 1.82e-07 8.17e-05 -0.35 -0.28 Schizophrenia; chr15:84399732 chr15:84199311~84230136:- LIHC cis rs950169 0.887 rs62029593 ENSG00000225151.9 GOLGA2P7 -5.33 1.82e-07 8.17e-05 -0.35 -0.28 Schizophrenia; chr15:84400482 chr15:84199311~84230136:- LIHC cis rs950169 0.81 rs62029594 ENSG00000225151.9 GOLGA2P7 -5.33 1.82e-07 8.17e-05 -0.35 -0.28 Schizophrenia; chr15:84400554 chr15:84199311~84230136:- LIHC cis rs950169 0.881 rs62029596 ENSG00000225151.9 GOLGA2P7 -5.33 1.82e-07 8.17e-05 -0.35 -0.28 Schizophrenia; chr15:84400736 chr15:84199311~84230136:- LIHC cis rs950169 0.881 rs4081123 ENSG00000225151.9 GOLGA2P7 -5.33 1.82e-07 8.17e-05 -0.35 -0.28 Schizophrenia; chr15:84401537 chr15:84199311~84230136:- LIHC cis rs950169 0.881 rs62029599 ENSG00000225151.9 GOLGA2P7 -5.33 1.82e-07 8.17e-05 -0.35 -0.28 Schizophrenia; chr15:84401867 chr15:84199311~84230136:- LIHC cis rs950169 0.8 rs4099846 ENSG00000225151.9 GOLGA2P7 -5.33 1.82e-07 8.17e-05 -0.35 -0.28 Schizophrenia; chr15:84402196 chr15:84199311~84230136:- LIHC cis rs5769707 0.592 rs6009783 ENSG00000235111.1 RP1-29C18.8 -5.33 1.82e-07 8.17e-05 -0.33 -0.28 Monocyte percentage of white cells;Monocyte count; chr22:49617353 chr22:49612657~49615716:- LIHC cis rs9487094 0.553 rs11968891 ENSG00000260273.1 RP11-425D10.10 5.33 1.82e-07 8.17e-05 0.47 0.28 Height; chr6:109548647 chr6:109382795~109383666:+ LIHC cis rs1075265 0.568 rs10865278 ENSG00000233266.1 HMGB1P31 5.33 1.82e-07 8.17e-05 0.34 0.28 Chronotype;Morning vs. evening chronotype; chr2:54074902 chr2:54051334~54051760:+ LIHC cis rs9291683 0.588 rs2240721 ENSG00000250413.1 RP11-448G15.1 -5.33 1.83e-07 8.18e-05 -0.35 -0.28 Bone mineral density; chr4:10018940 chr4:10006482~10009725:+ LIHC cis rs2877649 0.793 rs77165598 ENSG00000258744.1 RP11-80A15.1 -5.33 1.83e-07 8.19e-05 -0.56 -0.28 Smooth-surface caries; chr14:24458813 chr14:24501594~24508688:+ LIHC cis rs6479891 1 rs9414780 ENSG00000232075.1 MRPL35P2 5.33 1.83e-07 8.2e-05 0.32 0.28 Arthritis (juvenile idiopathic); chr10:63241673 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs4469774 ENSG00000232075.1 MRPL35P2 5.33 1.83e-07 8.21e-05 0.32 0.28 Arthritis (juvenile idiopathic); chr10:63550017 chr10:63634317~63634827:- LIHC cis rs7131987 0.903 rs10843367 ENSG00000257176.2 RP11-996F15.2 -5.32 1.83e-07 8.21e-05 -0.32 -0.28 QT interval; chr12:29255447 chr12:29280418~29317848:- LIHC cis rs7131987 0.903 rs7302129 ENSG00000257176.2 RP11-996F15.2 -5.32 1.83e-07 8.21e-05 -0.32 -0.28 QT interval; chr12:29262347 chr12:29280418~29317848:- LIHC cis rs1322639 0.571 rs13204417 ENSG00000261039.2 RP11-417E7.2 5.32 1.83e-07 8.21e-05 0.29 0.28 Pulse pressure; chr6:169175260 chr6:169175304~169182740:- LIHC cis rs860295 0.812 rs4278368 ENSG00000203761.5 MSTO2P -5.32 1.83e-07 8.21e-05 -0.22 -0.28 Body mass index; chr1:155752766 chr1:155745829~155750137:+ LIHC cis rs5758511 0.68 rs5758684 ENSG00000237037.8 NDUFA6-AS1 -5.32 1.83e-07 8.21e-05 -0.35 -0.28 Birth weight; chr22:42253503 chr22:42090931~42137742:+ LIHC cis rs9291683 0.552 rs11736410 ENSG00000250413.1 RP11-448G15.1 -5.32 1.84e-07 8.22e-05 -0.35 -0.28 Bone mineral density; chr4:10015617 chr4:10006482~10009725:+ LIHC cis rs2337406 0.866 rs4280141 ENSG00000274576.2 IGHV2-70 5.32 1.84e-07 8.22e-05 0.28 0.28 Alzheimer's disease (late onset); chr14:106780476 chr14:106770577~106771020:- LIHC cis rs6921919 0.583 rs16894060 ENSG00000204709.4 LINC01556 5.32 1.84e-07 8.23e-05 0.34 0.28 Autism spectrum disorder or schizophrenia; chr6:28394694 chr6:28943877~28944537:+ LIHC cis rs228614 0.536 rs223477 ENSG00000230069.3 LRRC37A15P -5.32 1.84e-07 8.24e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769099 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs65671 ENSG00000230069.3 LRRC37A15P -5.32 1.84e-07 8.24e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102801081 chr4:102727274~102730721:- LIHC cis rs524281 0.684 rs7946447 ENSG00000255320.1 RP11-755F10.1 5.32 1.84e-07 8.24e-05 0.35 0.28 Electroencephalogram traits; chr11:66096867 chr11:66244840~66246239:- LIHC cis rs6480314 0.542 rs10998046 ENSG00000233590.1 RP11-153K11.3 -5.32 1.84e-07 8.24e-05 -0.42 -0.28 Optic nerve measurement (disc area); chr10:68269641 chr10:68233251~68242379:- LIHC cis rs17023223 0.581 rs61808932 ENSG00000231365.4 RP11-418J17.1 -5.32 1.84e-07 8.25e-05 -0.35 -0.28 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119101197 chr1:119140396~119275973:+ LIHC cis rs12468226 1 rs16839077 ENSG00000273456.1 RP11-686O6.2 5.32 1.84e-07 8.25e-05 0.4 0.28 Urate levels; chr2:202343970 chr2:202374932~202375604:- LIHC cis rs12468226 1 rs58288071 ENSG00000273456.1 RP11-686O6.2 5.32 1.84e-07 8.25e-05 0.4 0.28 Urate levels; chr2:202350016 chr2:202374932~202375604:- LIHC cis rs2153535 0.563 rs1737584 ENSG00000230939.1 RP11-314C16.1 -5.32 1.84e-07 8.26e-05 -0.34 -0.28 Motion sickness; chr6:8536509 chr6:8784178~8785445:+ LIHC cis rs67311347 1 rs7631893 ENSG00000223797.4 ENTPD3-AS1 5.32 1.85e-07 8.26e-05 0.22 0.28 Renal cell carcinoma; chr3:40399378 chr3:40313802~40453329:- LIHC cis rs875971 0.862 rs2909688 ENSG00000237310.1 GS1-124K5.4 5.32 1.85e-07 8.26e-05 0.24 0.28 Aortic root size; chr7:66376625 chr7:66493706~66495474:+ LIHC cis rs524281 0.861 rs535395 ENSG00000255320.1 RP11-755F10.1 -5.32 1.85e-07 8.27e-05 -0.34 -0.28 Electroencephalogram traits; chr11:66139063 chr11:66244840~66246239:- LIHC cis rs17711722 0.565 rs4275112 ENSG00000226824.5 RP4-756H11.3 5.32 1.85e-07 8.29e-05 0.33 0.28 Calcium levels; chr7:65733651 chr7:66654538~66669855:+ LIHC cis rs4731207 0.698 rs6945104 ENSG00000224897.5 POT1-AS1 5.32 1.86e-07 8.3e-05 0.33 0.28 Cutaneous malignant melanoma; chr7:124917861 chr7:124929873~125179315:+ LIHC cis rs950776 0.518 rs12916483 ENSG00000261762.1 RP11-650L12.2 5.32 1.86e-07 8.3e-05 0.36 0.28 Sudden cardiac arrest; chr15:78540055 chr15:78589123~78591276:- LIHC cis rs8028182 0.549 rs11072542 ENSG00000260269.4 CTD-2323K18.1 5.32 1.86e-07 8.31e-05 0.36 0.28 Sudden cardiac arrest; chr15:75342258 chr15:75527150~75601205:- LIHC cis rs6085948 0.861 rs11907461 ENSG00000228888.1 LINC01428 -5.32 1.86e-07 8.32e-05 -0.48 -0.28 Interleukin-10 levels; chr20:7251766 chr20:7146467~7254202:- LIHC cis rs2274273 0.588 rs7145727 ENSG00000258413.1 RP11-665C16.6 -5.32 1.86e-07 8.33e-05 -0.33 -0.28 Protein biomarker; chr14:55380855 chr14:55262767~55272075:- LIHC cis rs2522056 1 rs2522050 ENSG00000233006.5 AC034220.3 -5.32 1.86e-07 8.33e-05 -0.29 -0.28 Fibrinogen;Lymphocyte counts; chr5:132460917 chr5:132311285~132369916:- LIHC cis rs9318086 0.687 rs9507182 ENSG00000205861.10 C1QTNF9B-AS1 -5.32 1.87e-07 8.37e-05 -0.31 -0.28 Myopia (pathological); chr13:23868226 chr13:23888889~23897263:+ LIHC cis rs2933343 0.7 rs883602 ENSG00000231305.3 RP11-723O4.2 5.32 1.87e-07 8.37e-05 0.3 0.28 IgG glycosylation; chr3:128935109 chr3:128861313~128871540:- LIHC cis rs1499614 1 rs34250985 ENSG00000273142.1 RP11-458F8.4 -5.32 1.88e-07 8.38e-05 -0.37 -0.28 Gout; chr7:66696075 chr7:66902857~66906297:+ LIHC cis rs6921919 0.806 rs213230 ENSG00000216901.1 AL022393.7 5.32 1.88e-07 8.39e-05 0.36 0.28 Autism spectrum disorder or schizophrenia; chr6:28362487 chr6:28176188~28176674:+ LIHC cis rs524281 0.861 rs11227415 ENSG00000255320.1 RP11-755F10.1 -5.32 1.88e-07 8.4e-05 -0.36 -0.28 Electroencephalogram traits; chr11:66117988 chr11:66244840~66246239:- LIHC cis rs11098499 0.863 rs9884402 ENSG00000245958.5 RP11-33B1.1 -5.32 1.88e-07 8.4e-05 -0.28 -0.28 Corneal astigmatism; chr4:119568827 chr4:119454791~119552025:+ LIHC cis rs11098499 0.731 rs9995026 ENSG00000245958.5 RP11-33B1.1 -5.32 1.88e-07 8.4e-05 -0.28 -0.28 Corneal astigmatism; chr4:119569344 chr4:119454791~119552025:+ LIHC cis rs2243480 1 rs2533288 ENSG00000226824.5 RP4-756H11.3 -5.32 1.89e-07 8.42e-05 -0.45 -0.28 Diabetic kidney disease; chr7:66591724 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs2707844 ENSG00000226824.5 RP4-756H11.3 -5.32 1.89e-07 8.42e-05 -0.45 -0.28 Diabetic kidney disease; chr7:66594522 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs1796220 ENSG00000226824.5 RP4-756H11.3 -5.32 1.89e-07 8.42e-05 -0.45 -0.28 Diabetic kidney disease; chr7:66597113 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs2707831 ENSG00000226824.5 RP4-756H11.3 -5.32 1.89e-07 8.42e-05 -0.45 -0.28 Diabetic kidney disease; chr7:66597524 chr7:66654538~66669855:+ LIHC cis rs1150668 0.799 rs853684 ENSG00000204709.4 LINC01556 5.32 1.89e-07 8.43e-05 0.31 0.28 Pubertal anthropometrics; chr6:28326773 chr6:28943877~28944537:+ LIHC cis rs4731207 0.596 rs1994024 ENSG00000224897.5 POT1-AS1 5.32 1.89e-07 8.43e-05 0.33 0.28 Cutaneous malignant melanoma; chr7:125020791 chr7:124929873~125179315:+ LIHC cis rs6683071 0.688 rs3008637 ENSG00000272750.1 RP11-378J18.8 5.32 1.89e-07 8.45e-05 0.32 0.28 Cognitive performance; chr1:222684427 chr1:222658867~222661512:- LIHC cis rs950169 0.84 rs62029595 ENSG00000259295.5 CSPG4P12 5.32 1.89e-07 8.45e-05 0.38 0.28 Schizophrenia; chr15:84400603 chr15:85191438~85213905:+ LIHC cis rs12134133 1 rs28371583 ENSG00000274245.1 RP11-357P18.2 5.32 1.9e-07 8.46e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207321334 chr1:207372559~207373252:+ LIHC cis rs1150668 0.799 rs9301 ENSG00000204709.4 LINC01556 5.32 1.9e-07 8.47e-05 0.31 0.28 Pubertal anthropometrics; chr6:28324929 chr6:28943877~28944537:+ LIHC cis rs2933343 0.7 rs2624910 ENSG00000231305.3 RP11-723O4.2 5.32 1.9e-07 8.47e-05 0.3 0.28 IgG glycosylation; chr3:128931432 chr3:128861313~128871540:- LIHC cis rs875971 0.862 rs880166 ENSG00000237310.1 GS1-124K5.4 -5.32 1.9e-07 8.48e-05 -0.25 -0.28 Aortic root size; chr7:66205775 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs1638735 ENSG00000226824.5 RP4-756H11.3 -5.32 1.9e-07 8.48e-05 -0.36 -0.28 Aortic root size; chr7:66630751 chr7:66654538~66669855:+ LIHC cis rs5758511 0.68 rs58654759 ENSG00000237037.8 NDUFA6-AS1 -5.32 1.9e-07 8.49e-05 -0.35 -0.28 Birth weight; chr22:42246570 chr22:42090931~42137742:+ LIHC cis rs7923609 0.811 rs3847326 ENSG00000232075.1 MRPL35P2 5.32 1.9e-07 8.49e-05 0.3 0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63572099 chr10:63634317~63634827:- LIHC cis rs11647589 0.784 rs1700804 ENSG00000262995.1 CTD-2194A8.2 5.32 1.91e-07 8.5e-05 0.26 0.28 Blood metabolite levels; chr16:20477047 chr16:20440266~20447000:- LIHC cis rs2153535 0.601 rs330105 ENSG00000230939.1 RP11-314C16.1 -5.32 1.91e-07 8.51e-05 -0.35 -0.28 Motion sickness; chr6:8543748 chr6:8784178~8785445:+ LIHC cis rs9527 0.662 rs10883783 ENSG00000236937.2 PTGES3P4 5.32 1.91e-07 8.52e-05 0.38 0.28 Arsenic metabolism; chr10:102831395 chr10:102845595~102845950:+ LIHC cis rs6683071 0.643 rs35507977 ENSG00000272750.1 RP11-378J18.8 -5.32 1.91e-07 8.53e-05 -0.32 -0.28 Cognitive performance; chr1:222700776 chr1:222658867~222661512:- LIHC cis rs67180937 0.553 rs11485123 ENSG00000272750.1 RP11-378J18.8 -5.32 1.91e-07 8.53e-05 -0.32 -0.28 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222704833 chr1:222658867~222661512:- LIHC cis rs6683071 0.688 rs2936049 ENSG00000272750.1 RP11-378J18.8 5.32 1.91e-07 8.53e-05 0.32 0.28 Cognitive performance; chr1:222684825 chr1:222658867~222661512:- LIHC cis rs2243480 1 rs67728539 ENSG00000226824.5 RP4-756H11.3 -5.32 1.91e-07 8.53e-05 -0.45 -0.28 Diabetic kidney disease; chr7:65913137 chr7:66654538~66669855:+ LIHC cis rs2739330 0.731 rs5751792 ENSG00000099984.9 GSTT2 -5.32 1.92e-07 8.54e-05 -0.33 -0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23980123~23983911:+ LIHC cis rs7916410 0.512 rs61854783 ENSG00000233590.1 RP11-153K11.3 -5.32 1.92e-07 8.55e-05 -0.43 -0.28 Optic disc area; chr10:68236307 chr10:68233251~68242379:- LIHC cis rs831571 0.55 rs153734 ENSG00000280620.1 SCAANT1 5.32 1.93e-07 8.59e-05 0.37 0.28 Type 2 diabetes; chr3:64092333 chr3:63911518~63911772:- LIHC cis rs2283792 1 rs5999750 ENSG00000224086.5 LL22NC03-86G7.1 -5.32 1.93e-07 8.59e-05 -0.25 -0.28 Multiple sclerosis; chr22:21833720 chr22:21938293~21977632:+ LIHC cis rs950776 0.648 rs57945453 ENSG00000261762.1 RP11-650L12.2 5.31 1.93e-07 8.59e-05 0.36 0.28 Sudden cardiac arrest; chr15:78570503 chr15:78589123~78591276:- LIHC cis rs5769765 0.908 rs138880 ENSG00000278869.1 CITF22-49E9.3 5.31 1.93e-07 8.6e-05 0.44 0.28 Schizophrenia; chr22:49824963 chr22:49933198~49934074:- LIHC cis rs2933343 0.729 rs1680794 ENSG00000231305.3 RP11-723O4.2 5.31 1.93e-07 8.6e-05 0.3 0.28 IgG glycosylation; chr3:128901547 chr3:128861313~128871540:- LIHC cis rs875971 0.825 rs1129531 ENSG00000237310.1 GS1-124K5.4 -5.31 1.93e-07 8.6e-05 -0.25 -0.28 Aortic root size; chr7:66154117 chr7:66493706~66495474:+ LIHC cis rs992157 0.73 rs2382828 ENSG00000261338.2 RP11-378A13.1 5.31 1.93e-07 8.61e-05 0.3 0.28 Colorectal cancer; chr2:218319769 chr2:218255319~218257366:+ LIHC cis rs992157 0.672 rs2382829 ENSG00000261338.2 RP11-378A13.1 5.31 1.93e-07 8.61e-05 0.3 0.28 Colorectal cancer; chr2:218319894 chr2:218255319~218257366:+ LIHC cis rs992157 0.73 rs4280446 ENSG00000261338.2 RP11-378A13.1 5.31 1.93e-07 8.61e-05 0.3 0.28 Colorectal cancer; chr2:218319998 chr2:218255319~218257366:+ LIHC cis rs992157 0.764 rs4552182 ENSG00000261338.2 RP11-378A13.1 5.31 1.93e-07 8.61e-05 0.3 0.28 Colorectal cancer; chr2:218320149 chr2:218255319~218257366:+ LIHC cis rs992157 0.764 rs4423579 ENSG00000261338.2 RP11-378A13.1 5.31 1.93e-07 8.61e-05 0.3 0.28 Colorectal cancer; chr2:218320310 chr2:218255319~218257366:+ LIHC cis rs9291683 0.517 rs11736479 ENSG00000250413.1 RP11-448G15.1 -5.31 1.93e-07 8.61e-05 -0.35 -0.28 Bone mineral density; chr4:10015763 chr4:10006482~10009725:+ LIHC cis rs9291683 0.588 rs13113730 ENSG00000250413.1 RP11-448G15.1 -5.31 1.93e-07 8.61e-05 -0.35 -0.28 Bone mineral density; chr4:10016004 chr4:10006482~10009725:+ LIHC cis rs9291683 0.588 rs6857693 ENSG00000250413.1 RP11-448G15.1 -5.31 1.93e-07 8.61e-05 -0.35 -0.28 Bone mineral density; chr4:10016811 chr4:10006482~10009725:+ LIHC cis rs9291683 0.588 rs6844329 ENSG00000250413.1 RP11-448G15.1 -5.31 1.93e-07 8.61e-05 -0.35 -0.28 Bone mineral density; chr4:10016920 chr4:10006482~10009725:+ LIHC cis rs9291683 0.588 rs3796829 ENSG00000250413.1 RP11-448G15.1 -5.31 1.93e-07 8.61e-05 -0.35 -0.28 Bone mineral density; chr4:10017514 chr4:10006482~10009725:+ LIHC cis rs3733585 0.773 rs13107466 ENSG00000250413.1 RP11-448G15.1 -5.31 1.93e-07 8.61e-05 -0.35 -0.28 Cleft plate (environmental tobacco smoke interaction); chr4:10017766 chr4:10006482~10009725:+ LIHC cis rs9291683 0.588 rs13133766 ENSG00000250413.1 RP11-448G15.1 -5.31 1.93e-07 8.61e-05 -0.35 -0.28 Bone mineral density; chr4:10018108 chr4:10006482~10009725:+ LIHC cis rs7714584 1 rs7724558 ENSG00000197083.10 ZNF300P1 5.31 1.93e-07 8.61e-05 0.44 0.28 Crohn's disease; chr5:150949304 chr5:150930645~150946289:- LIHC cis rs10510102 0.935 rs12245528 ENSG00000226864.1 ATE1-AS1 -5.31 1.94e-07 8.61e-05 -0.45 -0.28 Breast cancer; chr10:121881006 chr10:121928312~121951965:+ LIHC cis rs4731207 0.57 rs2086505 ENSG00000224897.5 POT1-AS1 5.31 1.94e-07 8.62e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125024103 chr7:124929873~125179315:+ LIHC cis rs227275 0.525 rs724446 ENSG00000246560.2 RP11-10L12.4 5.31 1.94e-07 8.62e-05 0.31 0.28 Allergic disease (asthma, hay fever or eczema); chr4:103010206 chr4:102828055~102844075:+ LIHC cis rs496547 0.654 rs688161 ENSG00000255422.1 AP002954.4 -5.31 1.94e-07 8.63e-05 -0.31 -0.28 Hip minimal joint space width; chr11:118807001 chr11:118704607~118750263:+ LIHC cis rs4356203 0.905 rs11024159 ENSG00000272034.1 SNORD14A -5.31 1.94e-07 8.64e-05 -0.3 -0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17105795 chr11:17074654~17074744:- LIHC cis rs875971 0.756 rs4718328 ENSG00000237310.1 GS1-124K5.4 -5.31 1.94e-07 8.64e-05 -0.25 -0.28 Aortic root size; chr7:66228350 chr7:66493706~66495474:+ LIHC cis rs9341808 0.754 rs9352817 ENSG00000272129.1 RP11-250B2.6 5.31 1.94e-07 8.64e-05 0.27 0.28 Sitting height ratio; chr6:80316162 chr6:80355424~80356859:+ LIHC cis rs2153535 0.58 rs718502 ENSG00000230939.1 RP11-314C16.1 -5.31 1.94e-07 8.65e-05 -0.34 -0.28 Motion sickness; chr6:8527167 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs718503 ENSG00000230939.1 RP11-314C16.1 -5.31 1.94e-07 8.65e-05 -0.34 -0.28 Motion sickness; chr6:8527230 chr6:8784178~8785445:+ LIHC cis rs227275 0.554 rs223399 ENSG00000230069.3 LRRC37A15P -5.31 1.95e-07 8.65e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:102820800 chr4:102727274~102730721:- LIHC cis rs2933343 0.7 rs1683777 ENSG00000231305.3 RP11-723O4.2 5.31 1.95e-07 8.65e-05 0.3 0.28 IgG glycosylation; chr3:128906037 chr3:128861313~128871540:- LIHC cis rs2933343 0.7 rs1680788 ENSG00000231305.3 RP11-723O4.2 5.31 1.95e-07 8.65e-05 0.3 0.28 IgG glycosylation; chr3:128906475 chr3:128861313~128871540:- LIHC cis rs2933343 0.7 rs789240 ENSG00000231305.3 RP11-723O4.2 5.31 1.95e-07 8.65e-05 0.3 0.28 IgG glycosylation; chr3:128911792 chr3:128861313~128871540:- LIHC cis rs2933343 0.7 rs789239 ENSG00000231305.3 RP11-723O4.2 5.31 1.95e-07 8.65e-05 0.3 0.28 IgG glycosylation; chr3:128914965 chr3:128861313~128871540:- LIHC cis rs2933343 0.7 rs789238 ENSG00000231305.3 RP11-723O4.2 5.31 1.95e-07 8.65e-05 0.3 0.28 IgG glycosylation; chr3:128917872 chr3:128861313~128871540:- LIHC cis rs172166 0.516 rs2791333 ENSG00000204709.4 LINC01556 5.31 1.95e-07 8.66e-05 0.31 0.28 Cardiac Troponin-T levels; chr6:28143336 chr6:28943877~28944537:+ LIHC cis rs1005277 0.603 rs1998062 ENSG00000263064.2 RP11-291L22.7 5.31 1.95e-07 8.66e-05 0.29 0.28 Extrinsic epigenetic age acceleration; chr10:38168724 chr10:38448689~38448949:+ LIHC cis rs2998286 0.862 rs2807763 ENSG00000254635.4 WAC-AS1 5.31 1.95e-07 8.66e-05 0.34 0.28 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28528702 chr10:28522652~28532743:- LIHC cis rs4731207 0.596 rs6945951 ENSG00000224897.5 POT1-AS1 5.31 1.95e-07 8.67e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125027146 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs3900363 ENSG00000224897.5 POT1-AS1 5.31 1.95e-07 8.67e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125027907 chr7:124929873~125179315:+ LIHC cis rs2267708 0.504 rs3903523 ENSG00000224897.5 POT1-AS1 5.31 1.95e-07 8.67e-05 0.34 0.28 Chronic lymphocytic leukemia; chr7:125027978 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs3903521 ENSG00000224897.5 POT1-AS1 5.31 1.95e-07 8.67e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125028130 chr7:124929873~125179315:+ LIHC cis rs10510102 0.935 rs4627017 ENSG00000226864.1 ATE1-AS1 5.31 1.95e-07 8.67e-05 0.44 0.28 Breast cancer; chr10:121901878 chr10:121928312~121951965:+ LIHC cis rs875971 0.502 rs2465121 ENSG00000237310.1 GS1-124K5.4 -5.31 1.95e-07 8.69e-05 -0.26 -0.28 Aortic root size; chr7:66156017 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs1796226 ENSG00000237310.1 GS1-124K5.4 5.31 1.96e-07 8.7e-05 0.26 0.28 Aortic root size; chr7:66622723 chr7:66493706~66495474:+ LIHC cis rs9291683 0.588 rs3756238 ENSG00000250413.1 RP11-448G15.1 -5.31 1.96e-07 8.7e-05 -0.35 -0.28 Bone mineral density; chr4:10011578 chr4:10006482~10009725:+ LIHC cis rs9291683 0.588 rs3756237 ENSG00000250413.1 RP11-448G15.1 -5.31 1.96e-07 8.7e-05 -0.35 -0.28 Bone mineral density; chr4:10011754 chr4:10006482~10009725:+ LIHC cis rs9291683 0.588 rs3756236 ENSG00000250413.1 RP11-448G15.1 -5.31 1.96e-07 8.7e-05 -0.35 -0.28 Bone mineral density; chr4:10011839 chr4:10006482~10009725:+ LIHC cis rs9291683 0.552 rs10939655 ENSG00000250413.1 RP11-448G15.1 -5.31 1.96e-07 8.7e-05 -0.35 -0.28 Bone mineral density; chr4:10013018 chr4:10006482~10009725:+ LIHC cis rs12701220 0.52 rs7803208 ENSG00000229043.2 AC091729.9 -5.31 1.96e-07 8.7e-05 -0.34 -0.28 Bronchopulmonary dysplasia; chr7:1122448 chr7:1160374~1165267:+ LIHC cis rs2243480 0.522 rs1638736 ENSG00000273142.1 RP11-458F8.4 -5.31 1.96e-07 8.71e-05 -0.37 -0.28 Diabetic kidney disease; chr7:66627321 chr7:66902857~66906297:+ LIHC cis rs2735413 0.918 rs1922621 ENSG00000276007.1 RP11-358L22.3 -5.31 1.96e-07 8.71e-05 -0.3 -0.28 Systolic blood pressure (alcohol consumption interaction); chr16:78041118 chr16:78123243~78124332:+ LIHC cis rs853679 0.55 rs9295762 ENSG00000219392.1 RP1-265C24.5 5.31 1.96e-07 8.72e-05 0.41 0.28 Depression; chr6:28187640 chr6:28115628~28116551:+ LIHC cis rs9549367 0.577 rs3024718 ENSG00000269125.1 RP11-98F14.11 5.31 1.97e-07 8.73e-05 0.34 0.28 Platelet distribution width; chr13:113159539 chr13:113165002~113165183:- LIHC cis rs2933343 0.7 rs6787833 ENSG00000231305.3 RP11-723O4.2 5.31 1.97e-07 8.75e-05 0.3 0.28 IgG glycosylation; chr3:128937341 chr3:128861313~128871540:- LIHC cis rs11098499 0.697 rs28655325 ENSG00000245958.5 RP11-33B1.1 -5.31 1.97e-07 8.76e-05 -0.29 -0.28 Corneal astigmatism; chr4:119451844 chr4:119454791~119552025:+ LIHC cis rs227275 0.556 rs11731885 ENSG00000230069.3 LRRC37A15P -5.31 1.97e-07 8.76e-05 -0.25 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103010913 chr4:102727274~102730721:- LIHC cis rs17507216 0.718 rs72751662 ENSG00000278603.1 RP13-608F4.5 5.31 1.98e-07 8.77e-05 0.58 0.28 Excessive daytime sleepiness; chr15:82594705 chr15:82472203~82472426:+ LIHC cis rs9487094 0.62 rs7768973 ENSG00000260273.1 RP11-425D10.10 5.31 1.98e-07 8.78e-05 0.33 0.28 Height; chr6:109424122 chr6:109382795~109383666:+ LIHC cis rs17818399 0.597 rs13385693 ENSG00000279254.1 RP11-536C12.1 -5.31 1.98e-07 8.8e-05 -0.32 -0.28 Height; chr2:46640019 chr2:46668870~46670778:+ LIHC cis rs4538475 0.556 rs4263397 ENSG00000214846.4 RP11-115L11.1 -5.31 1.98e-07 8.8e-05 -0.34 -0.28 Parkinson's disease; chr4:15737767 chr4:15730962~15731627:- LIHC cis rs12134133 1 rs6660557 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207281251 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs7521457 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207283802 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs7553157 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207283922 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs7553339 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207284075 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs12134133 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207284500 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs6668683 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207285846 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs10494889 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207286963 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs1429904 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207288539 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs2782854 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207289369 chr1:207372559~207373252:+ LIHC cis rs12134133 0.962 rs2564970 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207290696 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs2782851 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207291717 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs2782850 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207292092 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs2782848 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207293407 chr1:207372559~207373252:+ LIHC cis rs12134133 0.962 rs2039543 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207294228 chr1:207372559~207373252:+ LIHC cis rs12134133 0.962 rs2782847 ENSG00000274245.1 RP11-357P18.2 5.31 1.98e-07 8.8e-05 0.41 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207295766 chr1:207372559~207373252:+ LIHC cis rs228614 0.51 rs223358 ENSG00000230069.3 LRRC37A15P -5.31 1.98e-07 8.8e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102849637 chr4:102727274~102730721:- LIHC cis rs5758511 0.68 rs5758681 ENSG00000237037.8 NDUFA6-AS1 -5.31 1.98e-07 8.8e-05 -0.34 -0.28 Birth weight; chr22:42249085 chr22:42090931~42137742:+ LIHC cis rs7131987 0.621 rs11050181 ENSG00000275476.1 RP11-996F15.4 -5.31 1.98e-07 8.8e-05 -0.32 -0.28 QT interval; chr12:29314736 chr12:29277397~29277882:- LIHC cis rs5769765 1 rs1033665 ENSG00000278869.1 CITF22-49E9.3 5.31 1.98e-07 8.8e-05 0.41 0.28 Schizophrenia; chr22:49858479 chr22:49933198~49934074:- LIHC cis rs4731207 0.596 rs1600739 ENSG00000224897.5 POT1-AS1 -5.31 1.98e-07 8.8e-05 -0.34 -0.28 Cutaneous malignant melanoma; chr7:124999552 chr7:124929873~125179315:+ LIHC cis rs4731207 0.57 rs7784614 ENSG00000224897.5 POT1-AS1 5.31 1.99e-07 8.81e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125037137 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6466987 ENSG00000224897.5 POT1-AS1 5.31 1.99e-07 8.81e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125037677 chr7:124929873~125179315:+ LIHC cis rs12468226 0.873 rs1474267 ENSG00000273456.1 RP11-686O6.2 -5.31 1.99e-07 8.81e-05 -0.43 -0.28 Urate levels; chr2:202178596 chr2:202374932~202375604:- LIHC cis rs7131987 0.621 rs57803026 ENSG00000275476.1 RP11-996F15.4 -5.31 2e-07 8.85e-05 -0.33 -0.28 QT interval; chr12:29344573 chr12:29277397~29277882:- LIHC cis rs9640161 0.75 rs4395803 ENSG00000261305.1 RP4-584D14.7 5.31 2e-07 8.85e-05 0.35 0.28 Blood protein levels;Circulating chemerin levels; chr7:150328278 chr7:150341771~150342607:+ LIHC cis rs1150668 0.83 rs213240 ENSG00000204709.4 LINC01556 5.31 2e-07 8.86e-05 0.31 0.28 Pubertal anthropometrics; chr6:28348098 chr6:28943877~28944537:+ LIHC cis rs2739330 0.76 rs1007888 ENSG00000099984.9 GSTT2 -5.31 2e-07 8.88e-05 -0.33 -0.28 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23980123~23983911:+ LIHC cis rs853679 0.55 rs1233699 ENSG00000219392.1 RP1-265C24.5 -5.31 2e-07 8.88e-05 -0.41 -0.28 Depression; chr6:28201380 chr6:28115628~28116551:+ LIHC cis rs6479891 1 rs4746974 ENSG00000232075.1 MRPL35P2 5.31 2e-07 8.88e-05 0.32 0.28 Arthritis (juvenile idiopathic); chr10:63132292 chr10:63634317~63634827:- LIHC cis rs950169 0.845 rs4502182 ENSG00000259295.5 CSPG4P12 5.31 2.01e-07 8.89e-05 0.37 0.28 Schizophrenia; chr15:84254768 chr15:85191438~85213905:+ LIHC cis rs2274273 0.87 rs10147434 ENSG00000258413.1 RP11-665C16.6 -5.31 2.01e-07 8.91e-05 -0.31 -0.28 Protein biomarker; chr14:55208129 chr14:55262767~55272075:- LIHC cis rs4731207 0.591 rs9691875 ENSG00000224897.5 POT1-AS1 5.31 2.01e-07 8.92e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125035651 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs13234368 ENSG00000224897.5 POT1-AS1 5.31 2.01e-07 8.92e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125036000 chr7:124929873~125179315:+ LIHC cis rs7209700 0.547 rs8078614 ENSG00000228782.6 CTD-2026D20.3 -5.31 2.02e-07 8.92e-05 -0.35 -0.28 IgG glycosylation; chr17:47274139 chr17:47450568~47492492:- LIHC cis rs1005277 0.683 rs7923868 ENSG00000263064.2 RP11-291L22.7 5.31 2.02e-07 8.93e-05 0.29 0.28 Extrinsic epigenetic age acceleration; chr10:37700838 chr10:38448689~38448949:+ LIHC cis rs4731207 0.596 rs9641759 ENSG00000224897.5 POT1-AS1 5.31 2.02e-07 8.93e-05 0.34 0.28 Cutaneous malignant melanoma; chr7:125026156 chr7:124929873~125179315:+ LIHC cis rs1150668 0.796 rs9468372 ENSG00000204709.4 LINC01556 5.31 2.02e-07 8.94e-05 0.31 0.28 Pubertal anthropometrics; chr6:28411584 chr6:28943877~28944537:+ LIHC cis rs950169 0.922 rs12915832 ENSG00000259295.5 CSPG4P12 5.31 2.02e-07 8.95e-05 0.38 0.28 Schizophrenia; chr15:84568226 chr15:85191438~85213905:+ LIHC cis rs10510102 0.935 rs11200201 ENSG00000276742.1 RP11-500G22.4 5.31 2.02e-07 8.95e-05 0.45 0.28 Breast cancer; chr10:121864790 chr10:121956782~121957098:+ LIHC cis rs6480314 0.522 rs17231602 ENSG00000233590.1 RP11-153K11.3 -5.31 2.03e-07 8.96e-05 -0.44 -0.28 Optic nerve measurement (disc area); chr10:68252532 chr10:68233251~68242379:- LIHC cis rs10510102 0.935 rs12240893 ENSG00000226864.1 ATE1-AS1 5.31 2.03e-07 8.97e-05 0.45 0.28 Breast cancer; chr10:121870572 chr10:121928312~121951965:+ LIHC cis rs853679 0.567 rs13209596 ENSG00000216901.1 AL022393.7 5.3 2.03e-07 8.98e-05 0.37 0.28 Depression; chr6:28428413 chr6:28176188~28176674:+ LIHC cis rs853679 0.567 rs9969098 ENSG00000216901.1 AL022393.7 5.3 2.03e-07 8.98e-05 0.37 0.28 Depression; chr6:28430971 chr6:28176188~28176674:+ LIHC cis rs853679 0.567 rs7740429 ENSG00000216901.1 AL022393.7 5.3 2.03e-07 8.98e-05 0.37 0.28 Depression; chr6:28431469 chr6:28176188~28176674:+ LIHC cis rs853679 0.567 rs16894106 ENSG00000216901.1 AL022393.7 5.3 2.03e-07 8.98e-05 0.37 0.28 Depression; chr6:28432562 chr6:28176188~28176674:+ LIHC cis rs6479901 0.895 rs7897326 ENSG00000232075.1 MRPL35P2 -5.3 2.04e-07 9e-05 -0.3 -0.28 Intelligence (multi-trait analysis); chr10:63306059 chr10:63634317~63634827:- LIHC cis rs7209700 0.644 rs7214468 ENSG00000228782.6 CTD-2026D20.3 -5.3 2.04e-07 9.01e-05 -0.31 -0.28 IgG glycosylation; chr17:47293400 chr17:47450568~47492492:- LIHC cis rs6479901 0.895 rs3211105 ENSG00000232075.1 MRPL35P2 -5.3 2.04e-07 9.03e-05 -0.3 -0.28 Intelligence (multi-trait analysis); chr10:63185604 chr10:63634317~63634827:- LIHC cis rs1150668 0.768 rs1150716 ENSG00000204709.4 LINC01556 5.3 2.04e-07 9.03e-05 0.3 0.28 Pubertal anthropometrics; chr6:28294921 chr6:28943877~28944537:+ LIHC cis rs9389248 0.69 rs728030 ENSG00000232876.1 CTA-212D2.2 5.3 2.05e-07 9.05e-05 0.32 0.28 High light scatter reticulocyte percentage of red cells; chr6:134925156 chr6:135055033~135060550:+ LIHC cis rs6683071 0.688 rs3811465 ENSG00000272750.1 RP11-378J18.8 -5.3 2.05e-07 9.05e-05 -0.32 -0.28 Cognitive performance; chr1:222712777 chr1:222658867~222661512:- LIHC cis rs603446 1 rs603446 ENSG00000254851.1 RP11-109L13.1 -5.3 2.05e-07 9.06e-05 -0.33 -0.28 Triglycerides; chr11:116783719 chr11:117135528~117138582:+ LIHC cis rs2933343 0.672 rs1872545 ENSG00000231305.3 RP11-723O4.2 5.3 2.05e-07 9.06e-05 0.3 0.28 IgG glycosylation; chr3:128926196 chr3:128861313~128871540:- LIHC cis rs3096299 0.692 rs4785565 ENSG00000261118.1 RP11-104N10.1 5.3 2.05e-07 9.07e-05 0.27 0.28 Multiple myeloma (IgH translocation); chr16:89449351 chr16:89492017~89504460:- LIHC cis rs8059260 0.668 rs8055893 ENSG00000274038.1 RP11-66H6.4 -5.3 2.05e-07 9.08e-05 -0.44 -0.28 Alcohol consumption over the past year; chr16:10977938 chr16:11056556~11057034:+ LIHC cis rs858239 0.73 rs858289 ENSG00000226816.2 AC005082.12 5.3 2.05e-07 9.08e-05 0.36 0.28 Cerebrospinal fluid biomarker levels; chr7:23208539 chr7:23206013~23208045:+ LIHC cis rs2439831 0.702 rs28699233 ENSG00000205771.5 CATSPER2P1 -5.3 2.06e-07 9.08e-05 -0.47 -0.28 Lung cancer in ever smokers; chr15:43830668 chr15:43726918~43747094:- LIHC cis rs228614 0.51 rs3774987 ENSG00000230069.3 LRRC37A15P -5.3 2.06e-07 9.1e-05 -0.25 -0.28 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799709 chr4:102727274~102730721:- LIHC cis rs4356203 0.933 rs12801545 ENSG00000272034.1 SNORD14A 5.3 2.06e-07 9.1e-05 0.33 0.28 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17244629 chr11:17074654~17074744:- LIHC cis rs9388451 0.839 rs4897157 ENSG00000237742.5 RP11-624M8.1 -5.3 2.07e-07 9.12e-05 -0.26 -0.28 Brugada syndrome; chr6:125781835 chr6:125578558~125749190:- LIHC cis rs10129255 0.957 rs10142918 ENSG00000223648.3 IGHV3-64 5.3 2.07e-07 9.14e-05 0.21 0.28 Kawasaki disease; chr14:106782206 chr14:106643132~106658258:- LIHC cis rs10129255 0.957 rs10142859 ENSG00000223648.3 IGHV3-64 5.3 2.07e-07 9.14e-05 0.21 0.28 Kawasaki disease; chr14:106782238 chr14:106643132~106658258:- LIHC cis rs6921919 0.525 rs11760133 ENSG00000216901.1 AL022393.7 5.3 2.08e-07 9.17e-05 0.34 0.28 Autism spectrum disorder or schizophrenia; chr6:28418962 chr6:28176188~28176674:+ LIHC cis rs9487094 0.744 rs13199519 ENSG00000260273.1 RP11-425D10.10 5.3 2.08e-07 9.17e-05 0.38 0.28 Height; chr6:109387972 chr6:109382795~109383666:+ LIHC cis rs6964833 1 rs17515241 ENSG00000123965.13 PMS2P5 -5.3 2.08e-07 9.17e-05 -0.48 -0.28 Menarche (age at onset); chr7:74717695 chr7:74894116~74897835:+ LIHC cis rs9549367 0.713 rs4907598 ENSG00000269125.1 RP11-98F14.11 5.3 2.08e-07 9.18e-05 0.32 0.28 Platelet distribution width; chr13:113207071 chr13:113165002~113165183:- LIHC cis rs875971 0.545 rs13311962 ENSG00000237310.1 GS1-124K5.4 -5.3 2.08e-07 9.19e-05 -0.26 -0.28 Aortic root size; chr7:66603142 chr7:66493706~66495474:+ LIHC cis rs10510102 0.935 rs12264495 ENSG00000226864.1 ATE1-AS1 5.3 2.08e-07 9.19e-05 0.44 0.28 Breast cancer; chr10:121919967 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs11200261 ENSG00000226864.1 ATE1-AS1 5.3 2.08e-07 9.19e-05 0.44 0.28 Breast cancer; chr10:121921133 chr10:121928312~121951965:+ LIHC cis rs950169 0.922 rs67804993 ENSG00000225151.9 GOLGA2P7 -5.3 2.08e-07 9.19e-05 -0.34 -0.28 Schizophrenia; chr15:84560799 chr15:84199311~84230136:- LIHC cis rs853679 0.567 rs7774981 ENSG00000216901.1 AL022393.7 5.3 2.09e-07 9.2e-05 0.37 0.28 Depression; chr6:28379133 chr6:28176188~28176674:+ LIHC cis rs853679 0.567 rs7754960 ENSG00000216901.1 AL022393.7 5.3 2.09e-07 9.2e-05 0.37 0.28 Depression; chr6:28379168 chr6:28176188~28176674:+ LIHC cis rs1030877 0.515 rs17030766 ENSG00000235319.1 AC012360.4 5.3 2.09e-07 9.23e-05 0.37 0.28 Obesity-related traits; chr2:105295448 chr2:105324210~105330529:+ LIHC cis rs6479901 0.895 rs10761746 ENSG00000232075.1 MRPL35P2 -5.3 2.09e-07 9.24e-05 -0.3 -0.28 Intelligence (multi-trait analysis); chr10:63345134 chr10:63634317~63634827:- LIHC cis rs12134133 1 rs28371614 ENSG00000274245.1 RP11-357P18.2 5.3 2.1e-07 9.26e-05 0.42 0.28 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207331929 chr1:207372559~207373252:+ LIHC cis rs227275 0.556 rs724447 ENSG00000246560.2 RP11-10L12.4 -5.3 2.1e-07 9.28e-05 -0.31 -0.28 Allergic disease (asthma, hay fever or eczema); chr4:103010149 chr4:102828055~102844075:+ LIHC cis rs11098499 0.909 rs9759478 ENSG00000245958.5 RP11-33B1.1 -5.3 2.11e-07 9.28e-05 -0.29 -0.28 Corneal astigmatism; chr4:119446843 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs13140391 ENSG00000245958.5 RP11-33B1.1 -5.3 2.11e-07 9.29e-05 -0.28 -0.28 Corneal astigmatism; chr4:119582282 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs13140409 ENSG00000245958.5 RP11-33B1.1 -5.3 2.11e-07 9.29e-05 -0.28 -0.28 Corneal astigmatism; chr4:119582305 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs6833334 ENSG00000245958.5 RP11-33B1.1 -5.3 2.11e-07 9.29e-05 -0.28 -0.28 Corneal astigmatism; chr4:119583072 chr4:119454791~119552025:+ LIHC cis rs2153535 0.58 rs6597335 ENSG00000230939.1 RP11-314C16.1 -5.3 2.11e-07 9.3e-05 -0.34 -0.28 Motion sickness; chr6:8527481 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs9328486 ENSG00000230939.1 RP11-314C16.1 -5.3 2.11e-07 9.3e-05 -0.34 -0.28 Motion sickness; chr6:8527775 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs2183112 ENSG00000230939.1 RP11-314C16.1 -5.3 2.11e-07 9.3e-05 -0.34 -0.28 Motion sickness; chr6:8527979 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs2143353 ENSG00000230939.1 RP11-314C16.1 -5.3 2.11e-07 9.3e-05 -0.34 -0.28 Motion sickness; chr6:8529878 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs2143352 ENSG00000230939.1 RP11-314C16.1 -5.3 2.11e-07 9.3e-05 -0.34 -0.28 Motion sickness; chr6:8530015 chr6:8784178~8785445:+ LIHC cis rs2153535 0.601 rs7741024 ENSG00000230939.1 RP11-314C16.1 -5.3 2.11e-07 9.3e-05 -0.34 -0.28 Motion sickness; chr6:8530080 chr6:8784178~8785445:+ LIHC cis rs7923609 0.783 rs4746203 ENSG00000232075.1 MRPL35P2 5.3 2.11e-07 9.3e-05 0.3 0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63564237 chr10:63634317~63634827:- LIHC cis rs7615952 0.688 rs9754526 ENSG00000171084.14 FAM86JP 5.3 2.12e-07 9.34e-05 0.38 0.28 Blood pressure (smoking interaction); chr3:125824023 chr3:125916620~125930024:+ LIHC cis rs875971 0.571 rs78668714 ENSG00000237310.1 GS1-124K5.4 5.3 2.12e-07 9.35e-05 0.26 0.28 Aortic root size; chr7:66474464 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs73150604 ENSG00000237310.1 GS1-124K5.4 5.3 2.12e-07 9.35e-05 0.26 0.28 Aortic root size; chr7:66480545 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs7810213 ENSG00000237310.1 GS1-124K5.4 5.3 2.12e-07 9.35e-05 0.26 0.28 Aortic root size; chr7:66481592 chr7:66493706~66495474:+ LIHC cis rs1134634 0.52 rs4393989 ENSG00000273133.1 RP11-799M12.2 -5.3 2.13e-07 9.37e-05 -0.35 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15614276 chr4:15563698~15564253:- LIHC cis rs1134634 0.52 rs10003739 ENSG00000273133.1 RP11-799M12.2 -5.3 2.13e-07 9.37e-05 -0.35 -0.28 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15617063 chr4:15563698~15564253:- LIHC cis rs11673344 0.734 rs320887 ENSG00000226686.6 LINC01535 -5.3 2.13e-07 9.37e-05 -0.42 -0.28 Obesity-related traits; chr19:37202536 chr19:37251912~37265535:+ LIHC cis rs7615952 0.512 rs34085484 ENSG00000171084.14 FAM86JP 5.3 2.13e-07 9.37e-05 0.38 0.28 Blood pressure (smoking interaction); chr3:125825343 chr3:125916620~125930024:+ LIHC cis rs7615952 0.575 rs35949599 ENSG00000171084.14 FAM86JP 5.3 2.13e-07 9.37e-05 0.38 0.28 Blood pressure (smoking interaction); chr3:125825359 chr3:125916620~125930024:+ LIHC cis rs7615952 0.608 rs35668111 ENSG00000171084.14 FAM86JP 5.3 2.13e-07 9.37e-05 0.38 0.28 Blood pressure (smoking interaction); chr3:125825792 chr3:125916620~125930024:+ LIHC cis rs7923609 0.811 rs4746204 ENSG00000232075.1 MRPL35P2 5.29 2.14e-07 9.4e-05 0.3 0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63568758 chr10:63634317~63634827:- LIHC cis rs7923609 0.783 rs7907451 ENSG00000232075.1 MRPL35P2 5.29 2.14e-07 9.4e-05 0.3 0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63568980 chr10:63634317~63634827:- LIHC cis rs7923609 0.783 rs7100409 ENSG00000232075.1 MRPL35P2 5.29 2.14e-07 9.4e-05 0.3 0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63570435 chr10:63634317~63634827:- LIHC cis rs7923609 0.703 rs7100413 ENSG00000232075.1 MRPL35P2 5.29 2.14e-07 9.4e-05 0.3 0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63570448 chr10:63634317~63634827:- LIHC cis rs7923609 0.811 rs3847325 ENSG00000232075.1 MRPL35P2 5.29 2.14e-07 9.4e-05 0.3 0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63571751 chr10:63634317~63634827:- LIHC cis rs2153535 0.601 rs7738877 ENSG00000230939.1 RP11-314C16.1 -5.29 2.14e-07 9.4e-05 -0.33 -0.28 Motion sickness; chr6:8541997 chr6:8784178~8785445:+ LIHC cis rs10129255 0.957 rs10136817 ENSG00000223648.3 IGHV3-64 5.29 2.14e-07 9.41e-05 0.21 0.28 Kawasaki disease; chr14:106787730 chr14:106643132~106658258:- LIHC cis rs7587476 0.765 rs2121284 ENSG00000229267.2 AC072062.1 5.29 2.14e-07 9.41e-05 0.33 0.28 Neuroblastoma; chr2:214791536 chr2:214810229~214963274:+ LIHC cis rs11690935 0.885 rs6727017 ENSG00000228389.1 AC068039.4 5.29 2.14e-07 9.41e-05 0.36 0.28 Schizophrenia; chr2:171910337 chr2:171773482~171775844:+ LIHC cis rs9487094 0.689 rs4636056 ENSG00000260273.1 RP11-425D10.10 5.29 2.14e-07 9.43e-05 0.32 0.28 Height; chr6:109409679 chr6:109382795~109383666:+ LIHC cis rs875971 0.545 rs6969224 ENSG00000237310.1 GS1-124K5.4 5.29 2.14e-07 9.43e-05 0.26 0.28 Aortic root size; chr7:66370011 chr7:66493706~66495474:+ LIHC cis rs2243480 1 rs4718269 ENSG00000226824.5 RP4-756H11.3 5.29 2.14e-07 9.44e-05 0.45 0.28 Diabetic kidney disease; chr7:65735810 chr7:66654538~66669855:+ LIHC cis rs9527 0.641 rs4919684 ENSG00000236937.2 PTGES3P4 5.29 2.15e-07 9.44e-05 0.38 0.28 Arsenic metabolism; chr10:102827267 chr10:102845595~102845950:+ LIHC cis rs2153535 0.541 rs6923558 ENSG00000230939.1 RP11-314C16.1 -5.29 2.15e-07 9.45e-05 -0.34 -0.28 Motion sickness; chr6:8461234 chr6:8784178~8785445:+ LIHC cis rs2153535 0.58 rs1577470 ENSG00000230939.1 RP11-314C16.1 -5.29 2.15e-07 9.45e-05 -0.34 -0.28 Motion sickness; chr6:8462193 chr6:8784178~8785445:+ LIHC cis rs2842992 0.915 rs2758321 ENSG00000237927.1 RP3-393E18.2 -5.29 2.16e-07 9.5e-05 -0.34 -0.28 Age-related macular degeneration (geographic atrophy); chr6:159650579 chr6:159586955~159589169:- LIHC cis rs6479901 0.67 rs12240740 ENSG00000232075.1 MRPL35P2 -5.29 2.17e-07 9.52e-05 -0.31 -0.28 Intelligence (multi-trait analysis); chr10:63147478 chr10:63634317~63634827:- LIHC cis rs7923609 0.756 rs7077256 ENSG00000232075.1 MRPL35P2 5.29 2.17e-07 9.53e-05 0.29 0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63576425 chr10:63634317~63634827:- LIHC cis rs7923609 0.729 rs7902616 ENSG00000232075.1 MRPL35P2 5.29 2.17e-07 9.53e-05 0.29 0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63576613 chr10:63634317~63634827:- LIHC cis rs7923609 0.756 rs10822183 ENSG00000232075.1 MRPL35P2 5.29 2.17e-07 9.53e-05 0.29 0.28 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63577381 chr10:63634317~63634827:- LIHC cis rs7567389 0.744 rs6430934 ENSG00000236682.1 AC068282.3 5.29 2.17e-07 9.54e-05 0.4 0.28 Self-rated health; chr2:127243257 chr2:127389130~127400580:+ LIHC cis rs2283792 0.677 rs13340063 ENSG00000224086.5 LL22NC03-86G7.1 5.29 2.18e-07 9.56e-05 0.25 0.28 Multiple sclerosis; chr22:21742717 chr22:21938293~21977632:+ LIHC cis rs10510102 0.935 rs11200203 ENSG00000226864.1 ATE1-AS1 5.29 2.18e-07 9.57e-05 0.45 0.28 Breast cancer; chr10:121874014 chr10:121928312~121951965:+ LIHC cis rs6683071 0.643 rs34433664 ENSG00000272750.1 RP11-378J18.8 -5.29 2.18e-07 9.57e-05 -0.32 -0.28 Cognitive performance; chr1:222709607 chr1:222658867~222661512:- LIHC cis rs6479901 0.894 rs10761732 ENSG00000232075.1 MRPL35P2 -5.29 2.18e-07 9.57e-05 -0.3 -0.28 Intelligence (multi-trait analysis); chr10:63268497 chr10:63634317~63634827:- LIHC cis rs2274273 0.934 rs8021940 ENSG00000258413.1 RP11-665C16.6 -5.29 2.18e-07 9.58e-05 -0.31 -0.28 Protein biomarker; chr14:55252997 chr14:55262767~55272075:- LIHC cis rs10510102 0.935 rs11200218 ENSG00000226864.1 ATE1-AS1 5.29 2.18e-07 9.59e-05 0.43 0.28 Breast cancer; chr10:121886410 chr10:121928312~121951965:+ LIHC cis rs1862618 0.853 rs6450409 ENSG00000271828.1 CTD-2310F14.1 5.29 2.18e-07 9.59e-05 0.38 0.28 Initial pursuit acceleration; chr5:56805572 chr5:56927874~56929573:+ LIHC cis rs2274273 0.837 rs6573010 ENSG00000258413.1 RP11-665C16.6 -5.29 2.19e-07 9.6e-05 -0.31 -0.28 Protein biomarker; chr14:55254874 chr14:55262767~55272075:- LIHC cis rs6085948 0.861 rs6117729 ENSG00000228888.1 LINC01428 -5.29 2.19e-07 9.6e-05 -0.39 -0.28 Interleukin-10 levels; chr20:7267542 chr20:7146467~7254202:- LIHC cis rs875971 0.545 rs73142265 ENSG00000237310.1 GS1-124K5.4 5.29 2.19e-07 9.6e-05 0.26 0.28 Aortic root size; chr7:66234510 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs73378304 ENSG00000237310.1 GS1-124K5.4 5.29 2.19e-07 9.6e-05 0.26 0.28 Aortic root size; chr7:66175760 chr7:66493706~66495474:+ LIHC cis rs638893 1 rs636736 ENSG00000255422.1 AP002954.4 -5.29 2.19e-07 9.61e-05 -0.46 -0.28 Vitiligo; chr11:118834436 chr11:118704607~118750263:+ LIHC cis rs6479901 0.895 rs10761728 ENSG00000232075.1 MRPL35P2 -5.29 2.19e-07 9.63e-05 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63235808 chr10:63634317~63634827:- LIHC cis rs2749592 0.531 rs10764134 ENSG00000263064.2 RP11-291L22.7 -5.29 2.19e-07 9.64e-05 -0.28 -0.27 Age-related hearing impairment (SNP x SNP interaction); chr10:37567732 chr10:38448689~38448949:+ LIHC cis rs2998286 0.862 rs2993990 ENSG00000254635.4 WAC-AS1 -5.29 2.2e-07 9.64e-05 -0.34 -0.27 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28518041 chr10:28522652~28532743:- LIHC cis rs10510102 0.935 rs12240893 ENSG00000276742.1 RP11-500G22.4 5.29 2.2e-07 9.64e-05 0.44 0.27 Breast cancer; chr10:121870572 chr10:121956782~121957098:+ LIHC cis rs2739330 0.789 rs5760109 ENSG00000099984.9 GSTT2 -5.29 2.2e-07 9.64e-05 -0.32 -0.27 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23980123~23983911:+ LIHC cis rs9425766 0.679 rs2049992 ENSG00000227373.4 RP11-160H22.5 5.29 2.2e-07 9.66e-05 0.33 0.27 Life satisfaction; chr1:174356554 chr1:174115300~174160004:- LIHC cis rs6479901 0.841 rs10761721 ENSG00000232075.1 MRPL35P2 -5.29 2.2e-07 9.67e-05 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63178644 chr10:63634317~63634827:- LIHC cis rs6480314 0.636 rs61854782 ENSG00000233590.1 RP11-153K11.3 -5.29 2.2e-07 9.67e-05 -0.43 -0.27 Optic nerve measurement (disc area); chr10:68231992 chr10:68233251~68242379:- LIHC cis rs16858210 0.874 rs7618182 ENSG00000234371.6 RPSAP31 5.29 2.2e-07 9.67e-05 0.36 0.27 Menopause (age at onset); chr3:183889215 chr3:183884924~183888449:+ LIHC cis rs2735413 0.875 rs8053987 ENSG00000276007.1 RP11-358L22.3 5.29 2.21e-07 9.68e-05 0.3 0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78050937 chr16:78123243~78124332:+ LIHC cis rs904251 0.6 rs9380673 ENSG00000204110.6 RP1-153P14.8 -5.29 2.21e-07 9.69e-05 -0.34 -0.27 Cognitive performance; chr6:37447349 chr6:37507348~37535616:+ LIHC cis rs7131987 0.903 rs11050152 ENSG00000257176.2 RP11-996F15.2 -5.29 2.22e-07 9.73e-05 -0.32 -0.27 QT interval; chr12:29251491 chr12:29280418~29317848:- LIHC cis rs10510102 0.872 rs10887003 ENSG00000276742.1 RP11-500G22.4 5.29 2.22e-07 9.73e-05 0.44 0.27 Breast cancer; chr10:121864660 chr10:121956782~121957098:+ LIHC cis rs8059260 0.544 rs16958051 ENSG00000274038.1 RP11-66H6.4 5.29 2.22e-07 9.73e-05 0.45 0.27 Alcohol consumption over the past year; chr16:11097362 chr16:11056556~11057034:+ LIHC cis rs739496 0.895 rs2073950 ENSG00000226469.1 ADAM1B 5.29 2.22e-07 9.73e-05 0.34 0.27 Platelet count; chr12:111456268 chr12:111927018~111929017:+ LIHC cis rs950169 0.922 rs62028133 ENSG00000259295.5 CSPG4P12 5.29 2.22e-07 9.73e-05 0.37 0.27 Schizophrenia; chr15:84250623 chr15:85191438~85213905:+ LIHC cis rs950169 0.723 rs17589320 ENSG00000259295.5 CSPG4P12 5.29 2.22e-07 9.73e-05 0.37 0.27 Schizophrenia; chr15:84251244 chr15:85191438~85213905:+ LIHC cis rs112990264 0.568 rs3006239 ENSG00000198468.6 FLVCR1-AS1 5.29 2.22e-07 9.74e-05 0.61 0.27 Itch intensity from mosquito bite; chr1:212812498 chr1:212852108~212858088:- LIHC cis rs2243480 0.522 rs12698511 ENSG00000273142.1 RP11-458F8.4 -5.29 2.22e-07 9.74e-05 -0.36 -0.27 Diabetic kidney disease; chr7:66009932 chr7:66902857~66906297:+ LIHC cis rs227275 0.554 rs223363 ENSG00000230069.3 LRRC37A15P -5.29 2.23e-07 9.76e-05 -0.25 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102846182 chr4:102727274~102730721:- LIHC cis rs5758511 0.68 rs5758682 ENSG00000237037.8 NDUFA6-AS1 -5.29 2.23e-07 9.76e-05 -0.34 -0.27 Birth weight; chr22:42249196 chr22:42090931~42137742:+ LIHC cis rs5758511 0.68 rs34107327 ENSG00000237037.8 NDUFA6-AS1 -5.29 2.23e-07 9.76e-05 -0.34 -0.27 Birth weight; chr22:42252347 chr22:42090931~42137742:+ LIHC cis rs4731207 0.596 rs900047 ENSG00000224897.5 POT1-AS1 -5.29 2.23e-07 9.76e-05 -0.33 -0.27 Cutaneous malignant melanoma; chr7:125033319 chr7:124929873~125179315:+ LIHC cis rs6479891 1 rs12416113 ENSG00000232075.1 MRPL35P2 5.29 2.23e-07 9.77e-05 0.32 0.27 Arthritis (juvenile idiopathic); chr10:63136717 chr10:63634317~63634827:- LIHC cis rs1577917 0.816 rs1838952 ENSG00000234155.1 RP11-30P6.6 5.29 2.23e-07 9.77e-05 0.32 0.27 Response to antipsychotic treatment; chr6:85891426 chr6:85387219~85390186:- LIHC cis rs887829 0.57 rs10168333 ENSG00000233445.1 RPL17P11 5.29 2.23e-07 9.78e-05 0.29 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233688342 chr2:233721522~233722065:- LIHC cis rs9487094 0.666 rs7751582 ENSG00000260273.1 RP11-425D10.10 5.29 2.24e-07 9.8e-05 0.32 0.27 Height; chr6:109427644 chr6:109382795~109383666:+ LIHC cis rs2739330 0.761 rs5760176 ENSG00000099984.9 GSTT2 5.29 2.24e-07 9.81e-05 0.33 0.27 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23980123~23983911:+ LIHC cis rs9322193 0.607 rs9322229 ENSG00000268592.3 RAET1E-AS1 5.29 2.24e-07 9.81e-05 0.36 0.27 Lung cancer; chr6:149908949 chr6:149863494~149919507:+ LIHC cis rs9322193 0.607 rs9322229 ENSG00000216906.2 RP11-350J20.9 5.29 2.24e-07 9.81e-05 0.29 0.27 Lung cancer; chr6:149908949 chr6:149904243~149906418:+ LIHC cis rs950776 0.616 rs56276142 ENSG00000261762.1 RP11-650L12.2 5.29 2.24e-07 9.82e-05 0.34 0.27 Sudden cardiac arrest; chr15:78597453 chr15:78589123~78591276:- LIHC cis rs950776 0.616 rs6495307 ENSG00000261762.1 RP11-650L12.2 5.29 2.24e-07 9.82e-05 0.34 0.27 Sudden cardiac arrest; chr15:78597979 chr15:78589123~78591276:- LIHC cis rs950776 0.616 rs12901300 ENSG00000261762.1 RP11-650L12.2 5.29 2.24e-07 9.82e-05 0.34 0.27 Sudden cardiac arrest; chr15:78600610 chr15:78589123~78591276:- LIHC cis rs4731207 0.596 rs10228686 ENSG00000224897.5 POT1-AS1 5.29 2.24e-07 9.82e-05 0.34 0.27 Cutaneous malignant melanoma; chr7:125023032 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs1994025 ENSG00000224897.5 POT1-AS1 5.29 2.24e-07 9.82e-05 0.34 0.27 Cutaneous malignant melanoma; chr7:125023805 chr7:124929873~125179315:+ LIHC cis rs12134133 0.688 rs6540875 ENSG00000274245.1 RP11-357P18.2 5.29 2.24e-07 9.82e-05 0.42 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207221686 chr1:207372559~207373252:+ LIHC cis rs7209700 0.708 rs2292865 ENSG00000228782.6 CTD-2026D20.3 -5.28 2.24e-07 9.83e-05 -0.31 -0.27 IgG glycosylation; chr17:47287356 chr17:47450568~47492492:- LIHC cis rs10833905 0.756 rs11529712 ENSG00000246225.5 RP11-17A1.3 -5.28 2.25e-07 9.84e-05 -0.35 -0.27 Sudden cardiac arrest; chr11:22964066 chr11:22829380~22945393:+ LIHC cis rs6085948 1 rs6085948 ENSG00000238102.1 RP11-19D2.1 5.28 2.25e-07 9.87e-05 0.4 0.27 Interleukin-10 levels; chr20:7252703 chr20:7256580~7258214:- LIHC cis rs73193808 0.614 rs2832255 ENSG00000224649.1 AF124730.4 -5.28 2.25e-07 9.87e-05 -0.33 -0.27 Coronary artery disease; chr21:29191846 chr21:29182027~29187795:- LIHC cis rs9326248 0.861 rs494356 ENSG00000236267.1 AP006216.5 5.28 2.25e-07 9.87e-05 0.29 0.27 Blood protein levels; chr11:117201254 chr11:116813204~116814003:- LIHC cis rs1577917 0.958 rs12212480 ENSG00000234155.1 RP11-30P6.6 5.28 2.26e-07 9.89e-05 0.36 0.27 Response to antipsychotic treatment; chr6:85749059 chr6:85387219~85390186:- LIHC cis rs1062177 0.855 rs919262 ENSG00000213433.5 RPLP1P6 5.28 2.26e-07 9.9e-05 0.3 0.27 Preschool internalizing problems; chr5:151886523 chr5:151765859~151766378:- LIHC cis rs7119038 0.818 rs11217042 ENSG00000255239.1 AP002954.6 -5.28 2.26e-07 9.9e-05 -0.35 -0.27 Sjögren's syndrome; chr11:118811819 chr11:118688039~118690600:- LIHC cis rs1075265 0.547 rs11125520 ENSG00000233266.1 HMGB1P31 5.28 2.26e-07 9.9e-05 0.34 0.27 Chronotype;Morning vs. evening chronotype; chr2:54076696 chr2:54051334~54051760:+ LIHC cis rs755249 0.51 rs1184716 ENSG00000182109.6 RP11-69E11.4 5.28 2.26e-07 9.9e-05 0.29 0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39380817 chr1:39522280~39546187:- LIHC cis rs7916697 0.628 rs10998036 ENSG00000233590.1 RP11-153K11.3 5.28 2.28e-07 9.95e-05 0.37 0.27 Optic disc area; chr10:68256921 chr10:68233251~68242379:- LIHC cis rs1322639 0.697 rs12661910 ENSG00000261039.2 RP11-417E7.2 -5.28 2.28e-07 9.96e-05 -0.37 -0.27 Pulse pressure; chr6:169184293 chr6:169175304~169182740:- LIHC cis rs801193 0.569 rs2659893 ENSG00000237310.1 GS1-124K5.4 5.28 2.28e-07 9.98e-05 0.24 0.27 Aortic root size; chr7:66735006 chr7:66493706~66495474:+ LIHC cis rs801193 0.569 rs2659892 ENSG00000237310.1 GS1-124K5.4 5.28 2.28e-07 9.98e-05 0.24 0.27 Aortic root size; chr7:66735318 chr7:66493706~66495474:+ LIHC cis rs801193 0.548 rs2659891 ENSG00000237310.1 GS1-124K5.4 5.28 2.28e-07 9.98e-05 0.24 0.27 Aortic root size; chr7:66736127 chr7:66493706~66495474:+ LIHC cis rs801193 0.569 rs2707847 ENSG00000237310.1 GS1-124K5.4 5.28 2.28e-07 9.98e-05 0.24 0.27 Aortic root size; chr7:66737884 chr7:66493706~66495474:+ LIHC cis rs801193 0.548 rs7805152 ENSG00000237310.1 GS1-124K5.4 5.28 2.28e-07 9.98e-05 0.24 0.27 Aortic root size; chr7:66744266 chr7:66493706~66495474:+ LIHC cis rs801193 0.569 rs11761542 ENSG00000237310.1 GS1-124K5.4 5.28 2.28e-07 9.98e-05 0.24 0.27 Aortic root size; chr7:66753209 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs73142265 ENSG00000273142.1 RP11-458F8.4 5.28 2.29e-07 1e-04 0.26 0.27 Aortic root size; chr7:66234510 chr7:66902857~66906297:+ LIHC cis rs9326248 0.52 rs2735183 ENSG00000280143.1 AP000892.6 5.28 2.29e-07 1e-04 0.32 0.27 Blood protein levels; chr11:117144479 chr11:117204967~117210292:+ LIHC cis rs4266144 0.562 rs2086667 ENSG00000244515.1 KRT18P34 -5.28 2.29e-07 1e-04 -0.3 -0.27 Coronary artery disease; chr3:157118728 chr3:157162663~157163932:- LIHC cis rs17711722 0.51 rs11767457 ENSG00000226002.1 RP11-460N20.5 5.28 2.29e-07 1e-04 0.29 0.27 Calcium levels; chr7:65825628 chr7:65084103~65100232:+ LIHC cis rs202072 0.872 rs202042 ENSG00000215022.6 RP1-257A7.4 5.28 2.29e-07 1e-04 0.31 0.27 HIV-1 viral setpoint; chr6:13277482 chr6:13264861~13295586:- LIHC cis rs8059260 0.541 rs35126143 ENSG00000274038.1 RP11-66H6.4 -5.28 2.3e-07 1e-04 -0.47 -0.27 Alcohol consumption over the past year; chr16:11070455 chr16:11056556~11057034:+ LIHC cis rs6479901 0.895 rs7073932 ENSG00000232075.1 MRPL35P2 -5.28 2.3e-07 1e-04 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63350160 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs7083356 ENSG00000232075.1 MRPL35P2 -5.28 2.3e-07 1e-04 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63356028 chr10:63634317~63634827:- LIHC cis rs17301013 0.932 rs3737651 ENSG00000227373.4 RP11-160H22.5 -5.28 2.3e-07 0.000101 -0.33 -0.27 Systemic lupus erythematosus; chr1:174475414 chr1:174115300~174160004:- LIHC cis rs6479901 0.894 rs10761748 ENSG00000232075.1 MRPL35P2 -5.28 2.3e-07 0.000101 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63350216 chr10:63634317~63634827:- LIHC cis rs6479901 0.846 rs7082926 ENSG00000232075.1 MRPL35P2 -5.28 2.3e-07 0.000101 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63355771 chr10:63634317~63634827:- LIHC cis rs9487094 0.666 rs9480956 ENSG00000260273.1 RP11-425D10.10 5.28 2.3e-07 0.000101 0.32 0.27 Height; chr6:109424305 chr6:109382795~109383666:+ LIHC cis rs9487094 0.689 rs12214147 ENSG00000260273.1 RP11-425D10.10 5.28 2.3e-07 0.000101 0.32 0.27 Height; chr6:109425054 chr6:109382795~109383666:+ LIHC cis rs9487094 0.689 rs17070591 ENSG00000260273.1 RP11-425D10.10 5.28 2.3e-07 0.000101 0.32 0.27 Height; chr6:109426518 chr6:109382795~109383666:+ LIHC cis rs950169 0.8 rs34302901 ENSG00000259295.5 CSPG4P12 5.28 2.3e-07 0.000101 0.37 0.27 Schizophrenia; chr15:84567712 chr15:85191438~85213905:+ LIHC cis rs7923609 0.812 rs10822184 ENSG00000232075.1 MRPL35P2 5.28 2.3e-07 0.000101 0.3 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63577393 chr10:63634317~63634827:- LIHC cis rs7811142 0.83 rs6955367 ENSG00000242294.5 STAG3L5P 5.28 2.3e-07 0.000101 0.28 0.27 Platelet count; chr7:100363571 chr7:100336079~100351900:+ LIHC cis rs6600671 1 rs4844381 ENSG00000231429.2 RP11-343N15.2 -5.28 2.31e-07 0.000101 -0.31 -0.27 Hip geometry; chr1:121443040 chr1:121412719~121429274:+ LIHC cis rs12285276 0.576 rs2593756 ENSG00000205106.4 DKFZp779M0652 5.28 2.31e-07 0.000101 0.27 0.27 Visceral fat; chr11:45746850 chr11:45771432~45772358:+ LIHC cis rs6921919 0.515 rs1558205 ENSG00000204709.4 LINC01556 -5.28 2.31e-07 0.000101 -0.34 -0.27 Autism spectrum disorder or schizophrenia; chr6:28414485 chr6:28943877~28944537:+ LIHC cis rs950776 0.518 rs952215 ENSG00000261762.1 RP11-650L12.2 -5.28 2.31e-07 0.000101 -0.36 -0.27 Sudden cardiac arrest; chr15:78526811 chr15:78589123~78591276:- LIHC cis rs1865760 0.82 rs9348697 ENSG00000216436.2 HIST1H2APS1 -5.28 2.31e-07 0.000101 -0.31 -0.27 Height; chr6:25890606 chr6:25732497~25732827:+ LIHC cis rs7131987 0.65 rs7973786 ENSG00000275476.1 RP11-996F15.4 -5.28 2.32e-07 0.000101 -0.32 -0.27 QT interval; chr12:29309811 chr12:29277397~29277882:- LIHC cis rs11098499 0.908 rs7696649 ENSG00000245958.5 RP11-33B1.1 -5.28 2.32e-07 0.000101 -0.29 -0.27 Corneal astigmatism; chr4:119401022 chr4:119454791~119552025:+ LIHC cis rs9532669 0.926 rs2039119 ENSG00000168852.11 TPTE2P5 -5.28 2.32e-07 0.000101 -0.32 -0.27 Cervical cancer; chr13:40872432 chr13:40822296~40921749:- LIHC cis rs2522056 1 rs2405528 ENSG00000233006.5 AC034220.3 -5.28 2.32e-07 0.000101 -0.29 -0.27 Fibrinogen;Lymphocyte counts; chr5:132458606 chr5:132311285~132369916:- LIHC cis rs7131987 0.65 rs4331146 ENSG00000275476.1 RP11-996F15.4 -5.28 2.33e-07 0.000101 -0.32 -0.27 QT interval; chr12:29287150 chr12:29277397~29277882:- LIHC cis rs9425766 0.64 rs6693423 ENSG00000227373.4 RP11-160H22.5 5.28 2.33e-07 0.000102 0.33 0.27 Life satisfaction; chr1:174364680 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs60363188 ENSG00000227373.4 RP11-160H22.5 5.28 2.33e-07 0.000102 0.33 0.27 Life satisfaction; chr1:174375959 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs12084119 ENSG00000227373.4 RP11-160H22.5 5.28 2.33e-07 0.000102 0.33 0.27 Life satisfaction; chr1:174377138 chr1:174115300~174160004:- LIHC cis rs75920871 0.562 rs68137714 ENSG00000254851.1 RP11-109L13.1 -5.28 2.33e-07 0.000102 -0.52 -0.27 Subjective well-being; chr11:117154641 chr11:117135528~117138582:+ LIHC cis rs860295 0.812 rs12407800 ENSG00000203761.5 MSTO2P -5.28 2.33e-07 0.000102 -0.22 -0.27 Body mass index; chr1:155790951 chr1:155745829~155750137:+ LIHC cis rs3096299 0.685 rs4785675 ENSG00000261118.1 RP11-104N10.1 5.28 2.34e-07 0.000102 0.28 0.27 Multiple myeloma (IgH translocation); chr16:89473566 chr16:89492017~89504460:- LIHC cis rs3096299 0.685 rs4238830 ENSG00000261118.1 RP11-104N10.1 5.28 2.34e-07 0.000102 0.28 0.27 Multiple myeloma (IgH translocation); chr16:89473833 chr16:89492017~89504460:- LIHC cis rs6686842 1 rs6663565 ENSG00000235358.1 RP11-399E6.1 -5.28 2.34e-07 0.000102 -0.3 -0.27 Height; chr1:41098016 chr1:41242373~41284861:+ LIHC cis rs6844153 0.938 rs16878655 ENSG00000240005.4 RP11-293A21.1 5.28 2.34e-07 0.000102 0.38 0.27 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26964655 chr4:26859806~26860599:- LIHC cis rs17301013 0.897 rs1793291 ENSG00000227373.4 RP11-160H22.5 -5.28 2.34e-07 0.000102 -0.36 -0.27 Systemic lupus erythematosus; chr1:174822675 chr1:174115300~174160004:- LIHC cis rs2286503 1 rs2286501 ENSG00000228649.7 AC005682.5 5.28 2.34e-07 0.000102 0.33 0.27 Fibrinogen; chr7:22817166 chr7:22854178~22861579:+ LIHC cis rs739496 0.947 rs2239195 ENSG00000226469.1 ADAM1B 5.28 2.34e-07 0.000102 0.34 0.27 Platelet count; chr12:111443505 chr12:111927018~111929017:+ LIHC cis rs7923609 0.811 rs7899657 ENSG00000232075.1 MRPL35P2 5.28 2.34e-07 0.000102 0.3 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63563505 chr10:63634317~63634827:- LIHC cis rs860295 0.812 rs12081192 ENSG00000203761.5 MSTO2P -5.28 2.34e-07 0.000102 -0.22 -0.27 Body mass index; chr1:155768253 chr1:155745829~155750137:+ LIHC cis rs7829975 0.564 rs2921060 ENSG00000253893.2 FAM85B 5.28 2.34e-07 0.000102 0.35 0.27 Mood instability; chr8:8460307 chr8:8167819~8226614:- LIHC cis rs992157 0.644 rs6741757 ENSG00000261338.2 RP11-378A13.1 5.28 2.35e-07 0.000102 0.3 0.27 Colorectal cancer; chr2:218318025 chr2:218255319~218257366:+ LIHC cis rs950776 0.593 rs6495306 ENSG00000261762.1 RP11-650L12.2 -5.28 2.35e-07 0.000102 -0.36 -0.27 Sudden cardiac arrest; chr15:78573551 chr15:78589123~78591276:- LIHC cis rs4639966 0.589 rs480958 ENSG00000255239.1 AP002954.6 5.28 2.35e-07 0.000102 0.33 0.27 Systemic lupus erythematosus; chr11:118707281 chr11:118688039~118690600:- LIHC cis rs6921919 0.945 rs61289879 ENSG00000216901.1 AL022393.7 5.28 2.35e-07 0.000102 0.43 0.27 Autism spectrum disorder or schizophrenia; chr6:28451385 chr6:28176188~28176674:+ LIHC cis rs10510102 0.935 rs79360006 ENSG00000226864.1 ATE1-AS1 5.28 2.35e-07 0.000102 0.44 0.27 Breast cancer; chr10:121912856 chr10:121928312~121951965:+ LIHC cis rs2243480 0.522 rs778717 ENSG00000273142.1 RP11-458F8.4 -5.28 2.35e-07 0.000103 -0.37 -0.27 Diabetic kidney disease; chr7:66383164 chr7:66902857~66906297:+ LIHC cis rs875971 0.895 rs4145009 ENSG00000237310.1 GS1-124K5.4 -5.28 2.35e-07 0.000103 -0.25 -0.27 Aortic root size; chr7:66261628 chr7:66493706~66495474:+ LIHC cis rs2243480 0.803 rs13224048 ENSG00000226824.5 RP4-756H11.3 -5.28 2.35e-07 0.000103 -0.45 -0.27 Diabetic kidney disease; chr7:66528779 chr7:66654538~66669855:+ LIHC cis rs875971 0.862 rs10256544 ENSG00000237310.1 GS1-124K5.4 5.28 2.35e-07 0.000103 0.25 0.27 Aortic root size; chr7:66210141 chr7:66493706~66495474:+ LIHC cis rs2439831 0.85 rs28413881 ENSG00000205771.5 CATSPER2P1 -5.27 2.36e-07 0.000103 -0.44 -0.27 Lung cancer in ever smokers; chr15:43881901 chr15:43726918~43747094:- LIHC cis rs4731207 0.596 rs6466966 ENSG00000224897.5 POT1-AS1 -5.27 2.36e-07 0.000103 -0.33 -0.27 Cutaneous malignant melanoma; chr7:124940273 chr7:124929873~125179315:+ LIHC cis rs7923609 0.811 rs10822181 ENSG00000232075.1 MRPL35P2 5.27 2.36e-07 0.000103 0.3 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63565366 chr10:63634317~63634827:- LIHC cis rs9487094 0.67 rs10457195 ENSG00000260273.1 RP11-425D10.10 5.27 2.36e-07 0.000103 0.33 0.27 Height; chr6:109534269 chr6:109382795~109383666:+ LIHC cis rs875971 0.862 rs7786892 ENSG00000237310.1 GS1-124K5.4 -5.27 2.37e-07 0.000103 -0.25 -0.27 Aortic root size; chr7:66163889 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs2420174 ENSG00000237310.1 GS1-124K5.4 -5.27 2.37e-07 0.000103 -0.25 -0.27 Aortic root size; chr7:66180374 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs2420173 ENSG00000237310.1 GS1-124K5.4 -5.27 2.37e-07 0.000103 -0.25 -0.27 Aortic root size; chr7:66180412 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs4718319 ENSG00000237310.1 GS1-124K5.4 -5.27 2.37e-07 0.000103 -0.25 -0.27 Aortic root size; chr7:66187797 chr7:66493706~66495474:+ LIHC cis rs875971 0.723 rs28391294 ENSG00000237310.1 GS1-124K5.4 -5.27 2.37e-07 0.000103 -0.25 -0.27 Aortic root size; chr7:66189328 chr7:66493706~66495474:+ LIHC cis rs875971 0.83 rs6967708 ENSG00000237310.1 GS1-124K5.4 -5.27 2.37e-07 0.000103 -0.25 -0.27 Aortic root size; chr7:66192326 chr7:66493706~66495474:+ LIHC cis rs875971 0.895 rs7782806 ENSG00000237310.1 GS1-124K5.4 -5.27 2.37e-07 0.000103 -0.25 -0.27 Aortic root size; chr7:66192910 chr7:66493706~66495474:+ LIHC cis rs950169 0.763 rs35372971 ENSG00000259295.5 CSPG4P12 5.27 2.37e-07 0.000103 0.37 0.27 Schizophrenia; chr15:84387097 chr15:85191438~85213905:+ LIHC cis rs172166 0.516 rs1225710 ENSG00000204709.4 LINC01556 -5.27 2.37e-07 0.000103 -0.31 -0.27 Cardiac Troponin-T levels; chr6:28132862 chr6:28943877~28944537:+ LIHC cis rs17270561 0.666 rs9356988 ENSG00000216436.2 HIST1H2APS1 -5.27 2.38e-07 0.000103 -0.33 -0.27 Iron status biomarkers; chr6:25777253 chr6:25732497~25732827:+ LIHC cis rs853679 0.567 rs3799499 ENSG00000216901.1 AL022393.7 5.27 2.38e-07 0.000103 0.37 0.27 Depression; chr6:28386473 chr6:28176188~28176674:+ LIHC cis rs875971 0.798 rs12698522 ENSG00000237310.1 GS1-124K5.4 5.27 2.38e-07 0.000104 0.24 0.27 Aortic root size; chr7:66502354 chr7:66493706~66495474:+ LIHC cis rs875971 0.83 rs28714531 ENSG00000237310.1 GS1-124K5.4 5.27 2.38e-07 0.000104 0.24 0.27 Aortic root size; chr7:66503250 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs12698526 ENSG00000237310.1 GS1-124K5.4 5.27 2.38e-07 0.000104 0.24 0.27 Aortic root size; chr7:66504118 chr7:66493706~66495474:+ LIHC cis rs4731207 0.698 rs10954045 ENSG00000224897.5 POT1-AS1 5.27 2.38e-07 0.000104 0.32 0.27 Cutaneous malignant melanoma; chr7:124858101 chr7:124929873~125179315:+ LIHC cis rs9487094 0.67 rs12528781 ENSG00000260273.1 RP11-425D10.10 5.27 2.38e-07 0.000104 0.32 0.27 Height; chr6:109608105 chr6:109382795~109383666:+ LIHC cis rs5756813 1 rs5756813 ENSG00000233360.4 Z83844.1 5.27 2.38e-07 0.000104 0.32 0.27 Optic cup area;Vertical cup-disc ratio; chr22:37779470 chr22:37641832~37658377:- LIHC cis rs9326248 0.53 rs236918 ENSG00000236267.1 AP006216.5 -5.27 2.38e-07 0.000104 -0.32 -0.27 Blood protein levels; chr11:117220893 chr11:116813204~116814003:- LIHC cis rs9640161 0.702 rs1962004 ENSG00000261305.1 RP4-584D14.7 5.27 2.39e-07 0.000104 0.35 0.27 Blood protein levels;Circulating chemerin levels; chr7:150323292 chr7:150341771~150342607:+ LIHC cis rs228614 0.51 rs6830407 ENSG00000246560.2 RP11-10L12.4 5.27 2.4e-07 0.000104 0.31 0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102895366 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs4699033 ENSG00000246560.2 RP11-10L12.4 5.27 2.4e-07 0.000104 0.31 0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102897577 chr4:102828055~102844075:+ LIHC cis rs11690935 1 rs2138348 ENSG00000228389.1 AC068039.4 -5.27 2.4e-07 0.000104 -0.37 -0.27 Schizophrenia; chr2:171701662 chr2:171773482~171775844:+ LIHC cis rs10510102 0.935 rs11200201 ENSG00000226864.1 ATE1-AS1 5.27 2.4e-07 0.000104 0.46 0.27 Breast cancer; chr10:121864790 chr10:121928312~121951965:+ LIHC cis rs12701220 0.901 rs12701708 ENSG00000229043.2 AC091729.9 -5.27 2.41e-07 0.000104 -0.37 -0.27 Bronchopulmonary dysplasia; chr7:1050697 chr7:1160374~1165267:+ LIHC cis rs4718428 0.705 rs12536410 ENSG00000232546.1 RP11-458F8.1 -5.27 2.41e-07 0.000104 -0.25 -0.27 Corneal structure; chr7:66789303 chr7:66848496~66858136:+ LIHC cis rs4718428 0.705 rs68168107 ENSG00000232546.1 RP11-458F8.1 -5.27 2.41e-07 0.000104 -0.25 -0.27 Corneal structure; chr7:66790251 chr7:66848496~66858136:+ LIHC cis rs4731207 0.596 rs10244797 ENSG00000224897.5 POT1-AS1 5.27 2.41e-07 0.000105 0.33 0.27 Cutaneous malignant melanoma; chr7:124931630 chr7:124929873~125179315:+ LIHC cis rs4731207 0.505 rs7791488 ENSG00000224897.5 POT1-AS1 5.27 2.41e-07 0.000105 0.33 0.27 Cutaneous malignant melanoma; chr7:124938214 chr7:124929873~125179315:+ LIHC cis rs67311347 0.955 rs2123999 ENSG00000223797.4 ENTPD3-AS1 5.27 2.41e-07 0.000105 0.22 0.27 Renal cell carcinoma; chr3:40337247 chr3:40313802~40453329:- LIHC cis rs950169 0.922 rs62028133 ENSG00000225151.9 GOLGA2P7 -5.27 2.41e-07 0.000105 -0.34 -0.27 Schizophrenia; chr15:84250623 chr15:84199311~84230136:- LIHC cis rs950169 0.723 rs17589320 ENSG00000225151.9 GOLGA2P7 -5.27 2.41e-07 0.000105 -0.34 -0.27 Schizophrenia; chr15:84251244 chr15:84199311~84230136:- LIHC cis rs228614 0.51 rs223397 ENSG00000230069.3 LRRC37A15P -5.27 2.42e-07 0.000105 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102821494 chr4:102727274~102730721:- LIHC cis rs2998286 0.784 rs998362 ENSG00000254635.4 WAC-AS1 -5.27 2.42e-07 0.000105 -0.34 -0.27 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28528129 chr10:28522652~28532743:- LIHC cis rs6479901 0.841 rs10733787 ENSG00000232075.1 MRPL35P2 -5.27 2.43e-07 0.000105 -0.31 -0.27 Intelligence (multi-trait analysis); chr10:63147078 chr10:63634317~63634827:- LIHC cis rs2153535 0.526 rs9406179 ENSG00000230939.1 RP11-314C16.1 -5.27 2.43e-07 0.000105 -0.34 -0.27 Motion sickness; chr6:8537991 chr6:8784178~8785445:+ LIHC cis rs7131987 0.65 rs7957339 ENSG00000275476.1 RP11-996F15.4 -5.27 2.43e-07 0.000106 -0.32 -0.27 QT interval; chr12:29303562 chr12:29277397~29277882:- LIHC cis rs1134634 0.52 rs13121363 ENSG00000273133.1 RP11-799M12.2 5.27 2.44e-07 0.000106 0.34 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15567369 chr4:15563698~15564253:- LIHC cis rs1134634 0.52 rs13116304 ENSG00000273133.1 RP11-799M12.2 5.27 2.44e-07 0.000106 0.34 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15567523 chr4:15563698~15564253:- LIHC cis rs2735413 0.918 rs12598024 ENSG00000276007.1 RP11-358L22.3 -5.27 2.44e-07 0.000106 -0.29 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78045217 chr16:78123243~78124332:+ LIHC cis rs875971 0.825 rs1000464 ENSG00000237310.1 GS1-124K5.4 -5.27 2.44e-07 0.000106 -0.25 -0.27 Aortic root size; chr7:66312922 chr7:66493706~66495474:+ LIHC cis rs2933343 0.7 rs1680779 ENSG00000231305.3 RP11-723O4.2 5.27 2.45e-07 0.000106 0.31 0.27 IgG glycosylation; chr3:128895927 chr3:128861313~128871540:- LIHC cis rs9326248 0.52 rs74830 ENSG00000280143.1 AP000892.6 -5.27 2.45e-07 0.000106 -0.31 -0.27 Blood protein levels; chr11:117219842 chr11:117204967~117210292:+ LIHC cis rs9640161 0.711 rs55881542 ENSG00000261305.1 RP4-584D14.7 5.27 2.45e-07 0.000106 0.35 0.27 Blood protein levels;Circulating chemerin levels; chr7:150328645 chr7:150341771~150342607:+ LIHC cis rs7945705 0.935 rs11042102 ENSG00000254860.4 TMEM9B-AS1 -5.27 2.46e-07 0.000106 -0.27 -0.27 Hemoglobin concentration; chr11:8860617 chr11:8964675~8977527:+ LIHC cis rs7945705 0.934 rs1988709 ENSG00000254860.4 TMEM9B-AS1 -5.27 2.46e-07 0.000106 -0.27 -0.27 Hemoglobin concentration; chr11:8861343 chr11:8964675~8977527:+ LIHC cis rs950169 0.845 rs4502182 ENSG00000225151.9 GOLGA2P7 -5.27 2.46e-07 0.000107 -0.34 -0.27 Schizophrenia; chr15:84254768 chr15:84199311~84230136:- LIHC cis rs950169 0.922 rs12906983 ENSG00000259295.5 CSPG4P12 5.27 2.46e-07 0.000107 0.37 0.27 Schizophrenia; chr15:84262270 chr15:85191438~85213905:+ LIHC cis rs11089937 0.963 rs5757098 ENSG00000211639.2 IGLV4-60 -5.27 2.46e-07 0.000107 -0.23 -0.27 Periodontitis (PAL4Q3); chr22:22154322 chr22:22162199~22162681:+ LIHC cis rs7923609 0.811 rs12245367 ENSG00000232075.1 MRPL35P2 5.27 2.48e-07 0.000107 0.3 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63561704 chr10:63634317~63634827:- LIHC cis rs4731207 0.596 rs12055904 ENSG00000224897.5 POT1-AS1 5.27 2.48e-07 0.000107 0.34 0.27 Cutaneous malignant melanoma; chr7:125022810 chr7:124929873~125179315:+ LIHC cis rs4356203 0.905 rs615358 ENSG00000272034.1 SNORD14A -5.27 2.48e-07 0.000107 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17188885 chr11:17074654~17074744:- LIHC cis rs6061231 0.544 rs2427314 ENSG00000273619.1 RP5-908M14.9 -5.27 2.48e-07 0.000107 -0.24 -0.27 Colorectal cancer; chr20:62398610 chr20:62386303~62386970:- LIHC cis rs11098499 1 rs11098499 ENSG00000245958.5 RP11-33B1.1 -5.27 2.48e-07 0.000107 -0.29 -0.27 Corneal astigmatism; chr4:119266456 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs10213554 ENSG00000245958.5 RP11-33B1.1 5.27 2.48e-07 0.000107 0.28 0.27 Corneal astigmatism; chr4:119339630 chr4:119454791~119552025:+ LIHC cis rs875971 0.545 rs2279757 ENSG00000237310.1 GS1-124K5.4 5.26 2.49e-07 0.000108 0.26 0.27 Aortic root size; chr7:66363676 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs11766183 ENSG00000237310.1 GS1-124K5.4 5.26 2.49e-07 0.000108 0.26 0.27 Aortic root size; chr7:66374173 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs1065265 ENSG00000237310.1 GS1-124K5.4 5.26 2.49e-07 0.000108 0.26 0.27 Aortic root size; chr7:66376216 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs7811204 ENSG00000237310.1 GS1-124K5.4 5.26 2.49e-07 0.000108 0.26 0.27 Aortic root size; chr7:66387213 chr7:66493706~66495474:+ LIHC cis rs16858210 0.874 rs1879256 ENSG00000234371.6 RPSAP31 5.26 2.49e-07 0.000108 0.35 0.27 Menopause (age at onset); chr3:183891273 chr3:183884924~183888449:+ LIHC cis rs6479891 1 rs11818194 ENSG00000232075.1 MRPL35P2 5.26 2.49e-07 0.000108 0.32 0.27 Arthritis (juvenile idiopathic); chr10:63420692 chr10:63634317~63634827:- LIHC cis rs950776 0.518 rs11636131 ENSG00000261762.1 RP11-650L12.2 5.26 2.49e-07 0.000108 0.36 0.27 Sudden cardiac arrest; chr15:78529264 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs11632604 ENSG00000261762.1 RP11-650L12.2 5.26 2.49e-07 0.000108 0.36 0.27 Sudden cardiac arrest; chr15:78529572 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs12910289 ENSG00000261762.1 RP11-650L12.2 5.26 2.49e-07 0.000108 0.36 0.27 Sudden cardiac arrest; chr15:78529723 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs12910100 ENSG00000261762.1 RP11-650L12.2 5.26 2.49e-07 0.000108 0.36 0.27 Sudden cardiac arrest; chr15:78530325 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs12915428 ENSG00000261762.1 RP11-650L12.2 5.26 2.49e-07 0.000108 0.36 0.27 Sudden cardiac arrest; chr15:78531026 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs11630349 ENSG00000261762.1 RP11-650L12.2 5.26 2.49e-07 0.000108 0.36 0.27 Sudden cardiac arrest; chr15:78532266 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs12906284 ENSG00000261762.1 RP11-650L12.2 5.26 2.49e-07 0.000108 0.36 0.27 Sudden cardiac arrest; chr15:78532763 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs12906846 ENSG00000261762.1 RP11-650L12.2 5.26 2.49e-07 0.000108 0.36 0.27 Sudden cardiac arrest; chr15:78532953 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs12907169 ENSG00000261762.1 RP11-650L12.2 5.26 2.49e-07 0.000108 0.36 0.27 Sudden cardiac arrest; chr15:78533156 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs12906951 ENSG00000261762.1 RP11-650L12.2 5.26 2.49e-07 0.000108 0.36 0.27 Sudden cardiac arrest; chr15:78533220 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs56007453 ENSG00000261762.1 RP11-650L12.2 5.26 2.49e-07 0.000108 0.36 0.27 Sudden cardiac arrest; chr15:78533897 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs12916999 ENSG00000261762.1 RP11-650L12.2 5.26 2.49e-07 0.000108 0.36 0.27 Sudden cardiac arrest; chr15:78534570 chr15:78589123~78591276:- LIHC cis rs950169 0.84 rs62029595 ENSG00000225151.9 GOLGA2P7 -5.26 2.49e-07 0.000108 -0.34 -0.27 Schizophrenia; chr15:84400603 chr15:84199311~84230136:- LIHC cis rs2836974 0.666 rs12626405 ENSG00000255568.3 BRWD1-AS2 -5.26 2.49e-07 0.000108 -0.23 -0.27 Cognitive function; chr21:39291195 chr21:39313935~39314962:+ LIHC cis rs7811142 0.775 rs1059129 ENSG00000242294.5 STAG3L5P 5.26 2.49e-07 0.000108 0.28 0.27 Platelet count; chr7:100328899 chr7:100336079~100351900:+ LIHC cis rs116175783 0.557 rs2042487 ENSG00000227403.1 AC009299.3 5.26 2.49e-07 0.000108 0.42 0.27 Intelligence (multi-trait analysis); chr2:161293734 chr2:161244739~161249050:+ LIHC cis rs2032366 0.606 rs6567225 ENSG00000267279.1 RP11-879F14.2 5.26 2.49e-07 0.000108 0.33 0.27 Obesity-related traits; chr18:61607418 chr18:61585746~61606916:- LIHC cis rs9487094 0.778 rs11757877 ENSG00000260273.1 RP11-425D10.10 5.26 2.49e-07 0.000108 0.38 0.27 Height; chr6:109360679 chr6:109382795~109383666:+ LIHC cis rs875971 0.545 rs12670811 ENSG00000237310.1 GS1-124K5.4 5.26 2.49e-07 0.000108 0.26 0.27 Aortic root size; chr7:66358032 chr7:66493706~66495474:+ LIHC cis rs12701220 0.948 rs12690826 ENSG00000229043.2 AC091729.9 -5.26 2.49e-07 0.000108 -0.39 -0.27 Bronchopulmonary dysplasia; chr7:1041982 chr7:1160374~1165267:+ LIHC cis rs5769765 0.862 rs9616392 ENSG00000278869.1 CITF22-49E9.3 5.26 2.5e-07 0.000108 0.44 0.27 Schizophrenia; chr22:49921057 chr22:49933198~49934074:- LIHC cis rs5769765 0.955 rs9616394 ENSG00000278869.1 CITF22-49E9.3 5.26 2.5e-07 0.000108 0.44 0.27 Schizophrenia; chr22:49921279 chr22:49933198~49934074:- LIHC cis rs860295 0.812 rs12024257 ENSG00000203761.5 MSTO2P -5.26 2.5e-07 0.000108 -0.22 -0.27 Body mass index; chr1:155810745 chr1:155745829~155750137:+ LIHC cis rs9487094 0.922 rs10872034 ENSG00000260273.1 RP11-425D10.10 5.26 2.5e-07 0.000108 0.33 0.27 Height; chr6:109486036 chr6:109382795~109383666:+ LIHC cis rs2439831 0.702 rs3784275 ENSG00000205771.5 CATSPER2P1 -5.26 2.5e-07 0.000108 -0.46 -0.27 Lung cancer in ever smokers; chr15:43799188 chr15:43726918~43747094:- LIHC cis rs62355901 0.599 rs12657013 ENSG00000271828.1 CTD-2310F14.1 5.26 2.51e-07 0.000108 0.5 0.27 Breast cancer; chr5:56739441 chr5:56927874~56929573:+ LIHC cis rs11096990 0.552 rs7655170 ENSG00000249207.1 RP11-360F5.1 -5.26 2.51e-07 0.000109 -0.28 -0.27 Cognitive function; chr4:39171984 chr4:39112677~39126818:- LIHC cis rs227275 0.525 rs4698874 ENSG00000246560.2 RP11-10L12.4 5.26 2.51e-07 0.000109 0.31 0.27 Allergic disease (asthma, hay fever or eczema); chr4:103009354 chr4:102828055~102844075:+ LIHC cis rs2739330 0.652 rs2000469 ENSG00000099984.9 GSTT2 -5.26 2.52e-07 0.000109 -0.33 -0.27 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23980123~23983911:+ LIHC cis rs9549367 0.724 rs7985335 ENSG00000269125.1 RP11-98F14.11 5.26 2.52e-07 0.000109 0.31 0.27 Platelet distribution width; chr13:113214930 chr13:113165002~113165183:- LIHC cis rs17711722 0.522 rs4642526 ENSG00000226824.5 RP4-756H11.3 -5.26 2.52e-07 0.000109 -0.33 -0.27 Calcium levels; chr7:65751755 chr7:66654538~66669855:+ LIHC cis rs6479901 0.895 rs10740119 ENSG00000232075.1 MRPL35P2 -5.26 2.53e-07 0.000109 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63365477 chr10:63634317~63634827:- LIHC cis rs10875746 0.669 rs10467101 ENSG00000240399.1 RP1-228P16.1 -5.26 2.53e-07 0.000109 -0.3 -0.27 Longevity (90 years and older); chr12:48213954 chr12:48054813~48055591:- LIHC cis rs6479901 0.895 rs10822162 ENSG00000232075.1 MRPL35P2 -5.26 2.53e-07 0.000109 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63364320 chr10:63634317~63634827:- LIHC cis rs2836974 0.644 rs9978775 ENSG00000255568.3 BRWD1-AS2 -5.26 2.53e-07 0.000109 -0.23 -0.27 Cognitive function; chr21:39322600 chr21:39313935~39314962:+ LIHC cis rs4731207 0.596 rs1006334 ENSG00000224897.5 POT1-AS1 5.26 2.53e-07 0.000109 0.33 0.27 Cutaneous malignant melanoma; chr7:124988253 chr7:124929873~125179315:+ LIHC cis rs9487094 0.922 rs10782162 ENSG00000260273.1 RP11-425D10.10 -5.26 2.53e-07 0.000109 -0.34 -0.27 Height; chr6:109485060 chr6:109382795~109383666:+ LIHC cis rs6600671 1 rs12047116 ENSG00000231429.2 RP11-343N15.2 -5.26 2.54e-07 0.00011 -0.32 -0.27 Hip geometry; chr1:121443912 chr1:121412719~121429274:+ LIHC cis rs6600671 0.967 rs11249347 ENSG00000231429.2 RP11-343N15.2 -5.26 2.54e-07 0.00011 -0.32 -0.27 Hip geometry; chr1:121446489 chr1:121412719~121429274:+ LIHC cis rs9326248 0.52 rs6589602 ENSG00000280143.1 AP000892.6 5.26 2.54e-07 0.00011 0.31 0.27 Blood protein levels; chr11:117166349 chr11:117204967~117210292:+ LIHC cis rs9326248 0.539 rs7120565 ENSG00000280143.1 AP000892.6 5.26 2.54e-07 0.00011 0.31 0.27 Blood protein levels; chr11:117172233 chr11:117204967~117210292:+ LIHC cis rs950169 0.8 rs34302901 ENSG00000259728.4 LINC00933 5.26 2.54e-07 0.00011 0.39 0.27 Schizophrenia; chr15:84567712 chr15:84570649~84580175:+ LIHC cis rs227275 0.586 rs223448 ENSG00000230069.3 LRRC37A15P -5.26 2.54e-07 0.00011 -0.25 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102792189 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs223442 ENSG00000230069.3 LRRC37A15P -5.26 2.54e-07 0.00011 -0.25 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102793960 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs223441 ENSG00000230069.3 LRRC37A15P -5.26 2.54e-07 0.00011 -0.25 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102794228 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs150895 ENSG00000230069.3 LRRC37A15P -5.26 2.54e-07 0.00011 -0.25 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102791432 chr4:102727274~102730721:- LIHC cis rs7119038 0.818 rs17122453 ENSG00000255239.1 AP002954.6 -5.26 2.54e-07 0.00011 -0.34 -0.27 Sjögren's syndrome; chr11:118812855 chr11:118688039~118690600:- LIHC cis rs9291683 0.588 rs2240722 ENSG00000250413.1 RP11-448G15.1 -5.26 2.55e-07 0.00011 -0.35 -0.27 Bone mineral density; chr4:10019133 chr4:10006482~10009725:+ LIHC cis rs73186030 0.546 rs73188327 ENSG00000272758.4 RP11-299J3.8 5.26 2.55e-07 0.00011 0.47 0.27 Serum parathyroid hormone levels; chr3:122394819 chr3:122416207~122443180:+ LIHC cis rs62355901 0.599 rs62355881 ENSG00000271828.1 CTD-2310F14.1 5.26 2.55e-07 0.00011 0.5 0.27 Breast cancer; chr5:56737266 chr5:56927874~56929573:+ LIHC cis rs62355901 0.545 rs2113084 ENSG00000271828.1 CTD-2310F14.1 5.26 2.55e-07 0.00011 0.5 0.27 Breast cancer; chr5:56737844 chr5:56927874~56929573:+ LIHC cis rs875971 0.862 rs28470208 ENSG00000237310.1 GS1-124K5.4 -5.26 2.55e-07 0.00011 -0.25 -0.27 Aortic root size; chr7:66119713 chr7:66493706~66495474:+ LIHC cis rs3096299 0.748 rs3102339 ENSG00000261118.1 RP11-104N10.1 5.26 2.56e-07 0.00011 0.28 0.27 Multiple myeloma (IgH translocation); chr16:89376303 chr16:89492017~89504460:- LIHC cis rs7429990 0.828 rs11712152 ENSG00000229759.1 MRPS18AP1 5.26 2.56e-07 0.00011 0.3 0.27 Educational attainment (years of education); chr3:47655314 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs12635438 ENSG00000229759.1 MRPS18AP1 5.26 2.56e-07 0.00011 0.3 0.27 Educational attainment (years of education); chr3:47693210 chr3:48256350~48256938:- LIHC cis rs6479901 0.841 rs1904297 ENSG00000232075.1 MRPL35P2 -5.26 2.56e-07 0.00011 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63255428 chr10:63634317~63634827:- LIHC cis rs9425766 0.64 rs6685314 ENSG00000227373.4 RP11-160H22.5 5.26 2.56e-07 0.00011 0.33 0.27 Life satisfaction; chr1:174089905 chr1:174115300~174160004:- LIHC cis rs9425766 0.655 rs4652169 ENSG00000227373.4 RP11-160H22.5 5.26 2.56e-07 0.00011 0.33 0.27 Life satisfaction; chr1:174095343 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs6691711 ENSG00000227373.4 RP11-160H22.5 5.26 2.56e-07 0.00011 0.33 0.27 Life satisfaction; chr1:174100283 chr1:174115300~174160004:- LIHC cis rs4718428 0.576 rs12698546 ENSG00000232546.1 RP11-458F8.1 -5.26 2.57e-07 0.000111 -0.25 -0.27 Corneal structure; chr7:66801919 chr7:66848496~66858136:+ LIHC cis rs887829 0.57 rs10175809 ENSG00000233445.1 RPL17P11 5.26 2.57e-07 0.000111 0.29 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233688219 chr2:233721522~233722065:- LIHC cis rs7714584 1 rs4958852 ENSG00000197083.10 ZNF300P1 5.26 2.58e-07 0.000111 0.44 0.27 Crohn's disease; chr5:150951069 chr5:150930645~150946289:- LIHC cis rs2735413 0.881 rs11150036 ENSG00000276007.1 RP11-358L22.3 -5.26 2.58e-07 0.000111 -0.29 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78041790 chr16:78123243~78124332:+ LIHC cis rs2735413 0.918 rs11150037 ENSG00000276007.1 RP11-358L22.3 -5.26 2.58e-07 0.000111 -0.29 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78041877 chr16:78123243~78124332:+ LIHC cis rs2735413 0.918 rs4888725 ENSG00000276007.1 RP11-358L22.3 -5.26 2.58e-07 0.000111 -0.29 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78042864 chr16:78123243~78124332:+ LIHC cis rs2735413 0.881 rs4888727 ENSG00000276007.1 RP11-358L22.3 -5.26 2.58e-07 0.000111 -0.29 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78043141 chr16:78123243~78124332:+ LIHC cis rs2735413 0.918 rs36068555 ENSG00000276007.1 RP11-358L22.3 -5.26 2.58e-07 0.000111 -0.29 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78043185 chr16:78123243~78124332:+ LIHC cis rs2735413 0.918 rs4888728 ENSG00000276007.1 RP11-358L22.3 -5.26 2.58e-07 0.000111 -0.29 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78043302 chr16:78123243~78124332:+ LIHC cis rs2735413 0.813 rs11644471 ENSG00000276007.1 RP11-358L22.3 -5.26 2.58e-07 0.000111 -0.29 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78043340 chr16:78123243~78124332:+ LIHC cis rs2735413 0.781 rs11649473 ENSG00000276007.1 RP11-358L22.3 -5.26 2.58e-07 0.000111 -0.29 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78043341 chr16:78123243~78124332:+ LIHC cis rs2735413 0.918 rs7190752 ENSG00000276007.1 RP11-358L22.3 -5.26 2.58e-07 0.000111 -0.29 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78043533 chr16:78123243~78124332:+ LIHC cis rs2735413 0.918 rs2344494 ENSG00000276007.1 RP11-358L22.3 -5.26 2.58e-07 0.000111 -0.29 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78044214 chr16:78123243~78124332:+ LIHC cis rs73081554 0.611 rs4681852 ENSG00000272360.1 RP11-359I18.5 -5.26 2.58e-07 0.000111 -0.41 -0.27 Rheumatoid arthritis; chr3:58423446 chr3:58490830~58491291:- LIHC cis rs7945705 0.967 rs10769970 ENSG00000254860.4 TMEM9B-AS1 -5.26 2.58e-07 0.000111 -0.27 -0.27 Hemoglobin concentration; chr11:8896390 chr11:8964675~8977527:+ LIHC cis rs7945705 0.967 rs10840148 ENSG00000254860.4 TMEM9B-AS1 -5.26 2.58e-07 0.000111 -0.27 -0.27 Hemoglobin concentration; chr11:8901981 chr11:8964675~8977527:+ LIHC cis rs7945705 0.935 rs10769971 ENSG00000254860.4 TMEM9B-AS1 -5.26 2.58e-07 0.000111 -0.27 -0.27 Hemoglobin concentration; chr11:8903729 chr11:8964675~8977527:+ LIHC cis rs7945705 0.967 rs10769973 ENSG00000254860.4 TMEM9B-AS1 -5.26 2.58e-07 0.000111 -0.27 -0.27 Hemoglobin concentration; chr11:8907068 chr11:8964675~8977527:+ LIHC cis rs11722779 0.935 rs3857200 ENSG00000246560.2 RP11-10L12.4 5.26 2.59e-07 0.000111 0.3 0.27 Schizophrenia; chr4:103001864 chr4:102828055~102844075:+ LIHC cis rs6921919 1 rs6921919 ENSG00000204709.4 LINC01556 5.26 2.59e-07 0.000111 0.38 0.27 Autism spectrum disorder or schizophrenia; chr6:28357424 chr6:28943877~28944537:+ LIHC cis rs227275 0.525 rs11097796 ENSG00000230069.3 LRRC37A15P -5.26 2.59e-07 0.000111 -0.25 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:103002401 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs11097797 ENSG00000230069.3 LRRC37A15P -5.26 2.59e-07 0.000111 -0.25 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:103002507 chr4:102727274~102730721:- LIHC cis rs4731207 0.698 rs7796150 ENSG00000224897.5 POT1-AS1 5.26 2.59e-07 0.000111 0.33 0.27 Cutaneous malignant melanoma; chr7:124881163 chr7:124929873~125179315:+ LIHC cis rs227275 0.525 rs10029073 ENSG00000230069.3 LRRC37A15P -5.26 2.59e-07 0.000112 -0.25 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:103006991 chr4:102727274~102730721:- LIHC cis rs6479901 0.895 rs10761722 ENSG00000232075.1 MRPL35P2 -5.26 2.6e-07 0.000112 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63195287 chr10:63634317~63634827:- LIHC cis rs9291683 0.588 rs2240724 ENSG00000250413.1 RP11-448G15.1 -5.26 2.6e-07 0.000112 -0.34 -0.27 Bone mineral density; chr4:10019666 chr4:10006482~10009725:+ LIHC cis rs9291683 0.588 rs12647117 ENSG00000250413.1 RP11-448G15.1 -5.26 2.6e-07 0.000112 -0.34 -0.27 Bone mineral density; chr4:10020435 chr4:10006482~10009725:+ LIHC cis rs17711722 0.51 rs11767457 ENSG00000224316.1 RP11-479O9.2 5.26 2.6e-07 0.000112 0.24 0.27 Calcium levels; chr7:65825628 chr7:65773620~65802067:+ LIHC cis rs6479901 0.895 rs67963837 ENSG00000232075.1 MRPL35P2 -5.26 2.61e-07 0.000112 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63247111 chr10:63634317~63634827:- LIHC cis rs992157 0.764 rs2891079 ENSG00000261338.2 RP11-378A13.1 5.26 2.61e-07 0.000112 0.3 0.27 Colorectal cancer; chr2:218319968 chr2:218255319~218257366:+ LIHC cis rs10875746 0.669 rs11168516 ENSG00000240399.1 RP1-228P16.1 -5.26 2.61e-07 0.000112 -0.29 -0.27 Longevity (90 years and older); chr12:48308282 chr12:48054813~48055591:- LIHC cis rs1499614 1 rs34250985 ENSG00000226824.5 RP4-756H11.3 -5.25 2.62e-07 0.000112 -0.49 -0.27 Gout; chr7:66696075 chr7:66654538~66669855:+ LIHC cis rs6479901 0.789 rs7081614 ENSG00000232075.1 MRPL35P2 -5.25 2.62e-07 0.000112 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63252088 chr10:63634317~63634827:- LIHC cis rs4731207 0.698 rs10954048 ENSG00000224897.5 POT1-AS1 5.25 2.62e-07 0.000113 0.32 0.27 Cutaneous malignant melanoma; chr7:124893686 chr7:124929873~125179315:+ LIHC cis rs62355901 0.653 rs16886206 ENSG00000271828.1 CTD-2310F14.1 5.25 2.62e-07 0.000113 0.5 0.27 Breast cancer; chr5:56742321 chr5:56927874~56929573:+ LIHC cis rs957448 0.554 rs10956919 ENSG00000253704.1 RP11-267M23.4 5.25 2.62e-07 0.000113 0.31 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94572945 chr8:94553722~94569745:+ LIHC cis rs957448 0.554 rs12540967 ENSG00000253704.1 RP11-267M23.4 5.25 2.62e-07 0.000113 0.31 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94576862 chr8:94553722~94569745:+ LIHC cis rs9326248 0.52 rs236919 ENSG00000280143.1 AP000892.6 5.25 2.63e-07 0.000113 0.31 0.27 Blood protein levels; chr11:117224645 chr11:117204967~117210292:+ LIHC cis rs7429990 0.864 rs883662 ENSG00000229759.1 MRPS18AP1 5.25 2.63e-07 0.000113 0.3 0.27 Educational attainment (years of education); chr3:47619342 chr3:48256350~48256938:- LIHC cis rs4731207 0.623 rs34865746 ENSG00000224897.5 POT1-AS1 5.25 2.63e-07 0.000113 0.33 0.27 Cutaneous malignant melanoma; chr7:124999865 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7799518 ENSG00000224897.5 POT1-AS1 5.25 2.63e-07 0.000113 0.33 0.27 Cutaneous malignant melanoma; chr7:124935630 chr7:124929873~125179315:+ LIHC cis rs16858210 0.874 rs6792309 ENSG00000234371.6 RPSAP31 5.25 2.64e-07 0.000113 0.35 0.27 Menopause (age at onset); chr3:183889873 chr3:183884924~183888449:+ LIHC cis rs2842992 0.83 rs1535475 ENSG00000237927.1 RP3-393E18.2 -5.25 2.64e-07 0.000113 -0.34 -0.27 Age-related macular degeneration (geographic atrophy); chr6:159727903 chr6:159586955~159589169:- LIHC cis rs7429990 0.864 rs6442081 ENSG00000229759.1 MRPS18AP1 -5.25 2.64e-07 0.000113 -0.29 -0.27 Educational attainment (years of education); chr3:47728890 chr3:48256350~48256938:- LIHC cis rs875971 0.862 rs1612452 ENSG00000237310.1 GS1-124K5.4 -5.25 2.64e-07 0.000113 -0.25 -0.27 Aortic root size; chr7:66108909 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs1167390 ENSG00000237310.1 GS1-124K5.4 -5.25 2.64e-07 0.000113 -0.25 -0.27 Aortic root size; chr7:66110906 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs35034167 ENSG00000237310.1 GS1-124K5.4 -5.25 2.64e-07 0.000113 -0.25 -0.27 Aortic root size; chr7:66115179 chr7:66493706~66495474:+ LIHC cis rs116175783 0.557 rs62197075 ENSG00000227403.1 AC009299.3 5.25 2.65e-07 0.000114 0.41 0.27 Intelligence (multi-trait analysis); chr2:161312613 chr2:161244739~161249050:+ LIHC cis rs7209700 0.889 rs11079769 ENSG00000228782.6 CTD-2026D20.3 -5.25 2.65e-07 0.000114 -0.31 -0.27 IgG glycosylation; chr17:47272365 chr17:47450568~47492492:- LIHC cis rs875971 0.545 rs73142233 ENSG00000273142.1 RP11-458F8.4 5.25 2.66e-07 0.000114 0.26 0.27 Aortic root size; chr7:66221293 chr7:66902857~66906297:+ LIHC cis rs9291683 0.53 rs73227883 ENSG00000250413.1 RP11-448G15.1 -5.25 2.66e-07 0.000114 -0.36 -0.27 Bone mineral density; chr4:9977655 chr4:10006482~10009725:+ LIHC cis rs524281 0.861 rs10896081 ENSG00000255320.1 RP11-755F10.1 5.25 2.66e-07 0.000114 0.36 0.27 Electroencephalogram traits; chr11:66112883 chr11:66244840~66246239:- LIHC cis rs950776 0.593 rs588765 ENSG00000261762.1 RP11-650L12.2 -5.25 2.66e-07 0.000114 -0.36 -0.27 Sudden cardiac arrest; chr15:78573083 chr15:78589123~78591276:- LIHC cis rs227275 0.554 rs223388 ENSG00000230069.3 LRRC37A15P -5.25 2.66e-07 0.000114 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102828287 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs223386 ENSG00000230069.3 LRRC37A15P -5.25 2.66e-07 0.000114 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102829111 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs223385 ENSG00000230069.3 LRRC37A15P -5.25 2.66e-07 0.000114 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102829159 chr4:102727274~102730721:- LIHC cis rs11722779 0.873 rs223384 ENSG00000230069.3 LRRC37A15P -5.25 2.66e-07 0.000114 -0.24 -0.27 Schizophrenia; chr4:102829976 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs223383 ENSG00000230069.3 LRRC37A15P -5.25 2.66e-07 0.000114 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102830094 chr4:102727274~102730721:- LIHC cis rs875971 0.862 rs1983372 ENSG00000237310.1 GS1-124K5.4 -5.25 2.67e-07 0.000114 -0.25 -0.27 Aortic root size; chr7:66146364 chr7:66493706~66495474:+ LIHC cis rs227275 0.554 rs223395 ENSG00000230069.3 LRRC37A15P -5.25 2.67e-07 0.000115 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102823801 chr4:102727274~102730721:- LIHC cis rs7945705 0.902 rs1560569 ENSG00000254860.4 TMEM9B-AS1 5.25 2.67e-07 0.000115 0.27 0.27 Hemoglobin concentration; chr11:8918340 chr11:8964675~8977527:+ LIHC cis rs7923609 0.756 rs7910951 ENSG00000232075.1 MRPL35P2 5.25 2.68e-07 0.000115 0.29 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63578544 chr10:63634317~63634827:- LIHC cis rs7923609 0.756 rs7911761 ENSG00000232075.1 MRPL35P2 5.25 2.68e-07 0.000115 0.29 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63578993 chr10:63634317~63634827:- LIHC cis rs2735413 0.75 rs75500355 ENSG00000276007.1 RP11-358L22.3 5.25 2.68e-07 0.000115 0.35 0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78041499 chr16:78123243~78124332:+ LIHC cis rs4356203 0.87 rs214901 ENSG00000272034.1 SNORD14A 5.25 2.68e-07 0.000115 0.29 0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17206181 chr11:17074654~17074744:- LIHC cis rs2274273 0.84 rs10467798 ENSG00000258413.1 RP11-665C16.6 -5.25 2.68e-07 0.000115 -0.31 -0.27 Protein biomarker; chr14:55258209 chr14:55262767~55272075:- LIHC cis rs2274273 0.934 rs2341621 ENSG00000258413.1 RP11-665C16.6 -5.25 2.68e-07 0.000115 -0.31 -0.27 Protein biomarker; chr14:55259707 chr14:55262767~55272075:- LIHC cis rs4650994 0.544 rs4652301 ENSG00000273384.1 RP5-1098D14.1 5.25 2.68e-07 0.000115 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr1:178530664 chr1:178651706~178652282:+ LIHC cis rs4650994 0.544 rs10798613 ENSG00000273384.1 RP5-1098D14.1 5.25 2.68e-07 0.000115 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr1:178530887 chr1:178651706~178652282:+ LIHC cis rs9399135 0.773 rs1331308 ENSG00000232876.1 CTA-212D2.2 5.25 2.69e-07 0.000115 0.3 0.27 Red blood cell count; chr6:135083984 chr6:135055033~135060550:+ LIHC cis rs2111504 0.583 rs10853921 ENSG00000267213.4 AC007773.2 -5.25 2.7e-07 0.000116 -0.28 -0.27 Bipolar disorder; chr19:32370899 chr19:32390050~32405560:- LIHC cis rs10510102 0.935 rs12262776 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121884532 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs12264952 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121885673 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs12244866 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121886013 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs12266597 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121886062 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs12245018 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121886195 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200217 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121886372 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs10887008 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121886714 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs12268872 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121887426 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs9630107 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121887713 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs10887010 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121888542 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs11200220 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121889949 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200221 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121890134 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs10887011 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121890203 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs10887012 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121890454 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs11200222 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121891177 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200223 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121891416 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs10887013 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121891546 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs11200225 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121891948 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200226 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121891988 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs10887014 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121892322 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs11818735 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121892472 chr10:121928312~121951965:+ LIHC cis rs10510102 0.81 rs12259902 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121893017 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200228 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121893358 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200229 ENSG00000226864.1 ATE1-AS1 5.25 2.7e-07 0.000116 0.43 0.27 Breast cancer; chr10:121893519 chr10:121928312~121951965:+ LIHC cis rs875971 0.545 rs4718325 ENSG00000237310.1 GS1-124K5.4 5.25 2.7e-07 0.000116 0.26 0.27 Aortic root size; chr7:66215323 chr7:66493706~66495474:+ LIHC cis rs9487094 0.67 rs10782163 ENSG00000260273.1 RP11-425D10.10 5.25 2.71e-07 0.000116 0.32 0.27 Height; chr6:109533040 chr6:109382795~109383666:+ LIHC cis rs7119038 0.58 rs7123726 ENSG00000255239.1 AP002954.6 -5.25 2.71e-07 0.000116 -0.35 -0.27 Sjögren's syndrome; chr11:118823838 chr11:118688039~118690600:- LIHC cis rs6504950 0.579 rs17712917 ENSG00000275710.1 RP11-257O5.4 5.25 2.71e-07 0.000116 0.45 0.27 Breast cancer; chr17:55194004 chr17:54964474~54964679:+ LIHC cis rs950776 0.518 rs4886572 ENSG00000261762.1 RP11-650L12.2 -5.25 2.71e-07 0.000116 -0.35 -0.27 Sudden cardiac arrest; chr15:78545110 chr15:78589123~78591276:- LIHC cis rs1499614 1 rs2707832 ENSG00000226824.5 RP4-756H11.3 -5.25 2.71e-07 0.000116 -0.43 -0.27 Gout; chr7:66671562 chr7:66654538~66669855:+ LIHC cis rs2749592 0.55 rs10764135 ENSG00000263064.2 RP11-291L22.7 -5.25 2.71e-07 0.000116 -0.28 -0.27 Age-related hearing impairment (SNP x SNP interaction); chr10:37577917 chr10:38448689~38448949:+ LIHC cis rs2749592 0.55 rs12255038 ENSG00000263064.2 RP11-291L22.7 -5.25 2.71e-07 0.000116 -0.28 -0.27 Age-related hearing impairment (SNP x SNP interaction); chr10:37580404 chr10:38448689~38448949:+ LIHC cis rs2749592 0.505 rs7915670 ENSG00000263064.2 RP11-291L22.7 -5.25 2.71e-07 0.000116 -0.28 -0.27 Age-related hearing impairment (SNP x SNP interaction); chr10:37581284 chr10:38448689~38448949:+ LIHC cis rs10510102 0.935 rs10510101 ENSG00000226864.1 ATE1-AS1 5.25 2.71e-07 0.000116 0.43 0.27 Breast cancer; chr10:121898614 chr10:121928312~121951965:+ LIHC cis rs13631 0.728 rs7466635 ENSG00000268996.3 MAN1B1-AS1 -5.25 2.72e-07 0.000116 -0.29 -0.27 Cerebrospinal fluid biomarker levels; chr9:137085965 chr9:137084946~137086817:- LIHC cis rs992157 0.764 rs1870123 ENSG00000261338.2 RP11-378A13.1 5.25 2.73e-07 0.000117 0.3 0.27 Colorectal cancer; chr2:218322975 chr2:218255319~218257366:+ LIHC cis rs4731207 0.596 rs7810654 ENSG00000224897.5 POT1-AS1 5.25 2.73e-07 0.000117 0.33 0.27 Cutaneous malignant melanoma; chr7:125005035 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7810299 ENSG00000224897.5 POT1-AS1 5.25 2.73e-07 0.000117 0.33 0.27 Cutaneous malignant melanoma; chr7:125005050 chr7:124929873~125179315:+ LIHC cis rs4660214 0.756 rs11205823 ENSG00000182109.6 RP11-69E11.4 -5.25 2.73e-07 0.000117 -0.3 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39248566 chr1:39522280~39546187:- LIHC cis rs9291683 0.609 rs12507050 ENSG00000250413.1 RP11-448G15.1 -5.25 2.73e-07 0.000117 -0.34 -0.27 Bone mineral density; chr4:10005681 chr4:10006482~10009725:+ LIHC cis rs7945705 0.967 rs10769968 ENSG00000254860.4 TMEM9B-AS1 -5.25 2.73e-07 0.000117 -0.27 -0.27 Hemoglobin concentration; chr11:8886036 chr11:8964675~8977527:+ LIHC cis rs6479901 0.894 rs10822165 ENSG00000232075.1 MRPL35P2 -5.25 2.74e-07 0.000117 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63387199 chr10:63634317~63634827:- LIHC cis rs6479901 0.841 rs10761720 ENSG00000232075.1 MRPL35P2 -5.25 2.74e-07 0.000117 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63139023 chr10:63634317~63634827:- LIHC cis rs875971 0.545 rs73142245 ENSG00000237310.1 GS1-124K5.4 5.25 2.74e-07 0.000117 0.26 0.27 Aortic root size; chr7:66226662 chr7:66493706~66495474:+ LIHC cis rs1134634 0.52 rs10034328 ENSG00000273133.1 RP11-799M12.2 -5.24 2.75e-07 0.000117 -0.34 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15616764 chr4:15563698~15564253:- LIHC cis rs7684253 0.587 rs9685436 ENSG00000269949.1 RP11-738E22.3 -5.24 2.75e-07 0.000117 -0.33 -0.27 Migraine; chr4:56881195 chr4:56960927~56961373:- LIHC cis rs10129255 0.957 rs8022165 ENSG00000223648.3 IGHV3-64 5.24 2.75e-07 0.000117 0.2 0.27 Kawasaki disease; chr14:106781682 chr14:106643132~106658258:- LIHC cis rs10129255 0.917 rs8022493 ENSG00000223648.3 IGHV3-64 5.24 2.75e-07 0.000117 0.2 0.27 Kawasaki disease; chr14:106781820 chr14:106643132~106658258:- LIHC cis rs3096299 0.685 rs3803682 ENSG00000261118.1 RP11-104N10.1 5.24 2.75e-07 0.000118 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89478228 chr16:89492017~89504460:- LIHC cis rs3096299 0.685 rs3803681 ENSG00000261118.1 RP11-104N10.1 5.24 2.75e-07 0.000118 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89478348 chr16:89492017~89504460:- LIHC cis rs4731207 0.596 rs11761669 ENSG00000224897.5 POT1-AS1 -5.24 2.75e-07 0.000118 -0.33 -0.27 Cutaneous malignant melanoma; chr7:124946247 chr7:124929873~125179315:+ LIHC cis rs17301013 0.932 rs2072760 ENSG00000227373.4 RP11-160H22.5 5.24 2.76e-07 0.000118 0.33 0.27 Systemic lupus erythematosus; chr1:174510186 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs10912797 ENSG00000227373.4 RP11-160H22.5 5.24 2.76e-07 0.000118 0.33 0.27 Systemic lupus erythematosus; chr1:174511225 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs6668053 ENSG00000227373.4 RP11-160H22.5 5.24 2.76e-07 0.000118 0.33 0.27 Systemic lupus erythematosus; chr1:174515139 chr1:174115300~174160004:- LIHC cis rs904251 0.737 rs914347 ENSG00000204110.6 RP1-153P14.8 -5.24 2.76e-07 0.000118 -0.35 -0.27 Cognitive performance; chr6:37517194 chr6:37507348~37535616:+ LIHC cis rs17711722 0.522 rs6957759 ENSG00000226824.5 RP4-756H11.3 -5.24 2.76e-07 0.000118 -0.33 -0.27 Calcium levels; chr7:65806798 chr7:66654538~66669855:+ LIHC cis rs957448 0.607 rs12680842 ENSG00000253704.1 RP11-267M23.4 5.24 2.77e-07 0.000118 0.31 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94570378 chr8:94553722~94569745:+ LIHC cis rs957448 0.554 rs12680855 ENSG00000253704.1 RP11-267M23.4 5.24 2.77e-07 0.000118 0.31 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94570427 chr8:94553722~94569745:+ LIHC cis rs7131987 0.683 rs7954278 ENSG00000275476.1 RP11-996F15.4 -5.24 2.77e-07 0.000118 -0.32 -0.27 QT interval; chr12:29306357 chr12:29277397~29277882:- LIHC cis rs4660214 0.694 rs16866216 ENSG00000182109.6 RP11-69E11.4 -5.24 2.78e-07 0.000118 -0.29 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39208916 chr1:39522280~39546187:- LIHC cis rs10510102 0.872 rs7916008 ENSG00000226864.1 ATE1-AS1 5.24 2.78e-07 0.000118 0.46 0.27 Breast cancer; chr10:121943578 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs7916380 ENSG00000226864.1 ATE1-AS1 5.24 2.78e-07 0.000118 0.46 0.27 Breast cancer; chr10:121943773 chr10:121928312~121951965:+ LIHC cis rs10510102 0.808 rs7920024 ENSG00000226864.1 ATE1-AS1 5.24 2.78e-07 0.000118 0.46 0.27 Breast cancer; chr10:121944063 chr10:121928312~121951965:+ LIHC cis rs10129255 0.957 rs10140904 ENSG00000223648.3 IGHV3-64 5.24 2.78e-07 0.000118 0.21 0.27 Kawasaki disease; chr14:106776558 chr14:106643132~106658258:- LIHC cis rs6480314 0.542 rs1007848 ENSG00000233590.1 RP11-153K11.3 -5.24 2.78e-07 0.000119 -0.43 -0.27 Optic nerve measurement (disc area); chr10:68258549 chr10:68233251~68242379:- LIHC cis rs6480314 0.542 rs61854807 ENSG00000233590.1 RP11-153K11.3 -5.24 2.78e-07 0.000119 -0.43 -0.27 Optic nerve measurement (disc area); chr10:68258948 chr10:68233251~68242379:- LIHC cis rs6480314 0.616 rs12571093 ENSG00000233590.1 RP11-153K11.3 -5.24 2.78e-07 0.000119 -0.43 -0.27 Optic nerve measurement (disc area); chr10:68259614 chr10:68233251~68242379:- LIHC cis rs6480314 0.542 rs7476012 ENSG00000233590.1 RP11-153K11.3 -5.24 2.78e-07 0.000119 -0.43 -0.27 Optic nerve measurement (disc area); chr10:68259950 chr10:68233251~68242379:- LIHC cis rs496547 0.686 rs487728 ENSG00000255422.1 AP002954.4 -5.24 2.78e-07 0.000119 -0.31 -0.27 Hip minimal joint space width; chr11:118750785 chr11:118704607~118750263:+ LIHC cis rs6061231 0.583 rs2427313 ENSG00000273619.1 RP5-908M14.9 -5.24 2.79e-07 0.000119 -0.24 -0.27 Colorectal cancer; chr20:62395619 chr20:62386303~62386970:- LIHC cis rs3096299 0.967 rs7205785 ENSG00000261118.1 RP11-104N10.1 5.24 2.79e-07 0.000119 0.28 0.27 Multiple myeloma (IgH translocation); chr16:89392576 chr16:89492017~89504460:- LIHC cis rs10129255 0.957 rs6576233 ENSG00000223648.3 IGHV3-64 5.24 2.79e-07 0.000119 0.2 0.27 Kawasaki disease; chr14:106787239 chr14:106643132~106658258:- LIHC cis rs11673344 0.566 rs8109103 ENSG00000226686.6 LINC01535 5.24 2.79e-07 0.000119 0.33 0.27 Obesity-related traits; chr19:37503209 chr19:37251912~37265535:+ LIHC cis rs875971 0.893 rs62465470 ENSG00000237310.1 GS1-124K5.4 -5.24 2.79e-07 0.000119 -0.25 -0.27 Aortic root size; chr7:66136231 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs4368860 ENSG00000237310.1 GS1-124K5.4 -5.24 2.79e-07 0.000119 -0.25 -0.27 Aortic root size; chr7:66143495 chr7:66493706~66495474:+ LIHC cis rs4356203 0.905 rs11821773 ENSG00000272034.1 SNORD14A -5.24 2.79e-07 0.000119 -0.3 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17095807 chr11:17074654~17074744:- LIHC cis rs4731207 0.596 rs2170351 ENSG00000224897.5 POT1-AS1 5.24 2.79e-07 0.000119 0.33 0.27 Cutaneous malignant melanoma; chr7:125002143 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6956910 ENSG00000224897.5 POT1-AS1 5.24 2.79e-07 0.000119 0.33 0.27 Cutaneous malignant melanoma; chr7:125002310 chr7:124929873~125179315:+ LIHC cis rs11098499 0.863 rs17050695 ENSG00000245958.5 RP11-33B1.1 -5.24 2.79e-07 0.000119 -0.28 -0.27 Corneal astigmatism; chr4:119568372 chr4:119454791~119552025:+ LIHC cis rs3096299 0.719 rs2965945 ENSG00000261118.1 RP11-104N10.1 5.24 2.8e-07 0.000119 0.26 0.27 Multiple myeloma (IgH translocation); chr16:89447609 chr16:89492017~89504460:- LIHC cis rs2274273 0.901 rs10140801 ENSG00000258413.1 RP11-665C16.6 -5.24 2.8e-07 0.000119 -0.31 -0.27 Protein biomarker; chr14:55263686 chr14:55262767~55272075:- LIHC cis rs853679 0.55 rs1225598 ENSG00000219392.1 RP1-265C24.5 -5.24 2.8e-07 0.000119 -0.41 -0.27 Depression; chr6:28193021 chr6:28115628~28116551:+ LIHC cis rs853679 0.55 rs1150689 ENSG00000219392.1 RP1-265C24.5 -5.24 2.8e-07 0.000119 -0.41 -0.27 Depression; chr6:28197321 chr6:28115628~28116551:+ LIHC cis rs853679 0.55 rs1225599 ENSG00000219392.1 RP1-265C24.5 -5.24 2.8e-07 0.000119 -0.41 -0.27 Depression; chr6:28197412 chr6:28115628~28116551:+ LIHC cis rs853679 0.574 rs1233705 ENSG00000219392.1 RP1-265C24.5 -5.24 2.8e-07 0.000119 -0.41 -0.27 Depression; chr6:28198669 chr6:28115628~28116551:+ LIHC cis rs853679 0.55 rs1233707 ENSG00000219392.1 RP1-265C24.5 -5.24 2.8e-07 0.000119 -0.41 -0.27 Depression; chr6:28205175 chr6:28115628~28116551:+ LIHC cis rs853679 0.55 rs1233704 ENSG00000219392.1 RP1-265C24.5 5.24 2.8e-07 0.000119 0.41 0.27 Depression; chr6:28199145 chr6:28115628~28116551:+ LIHC cis rs10833905 0.756 rs12286745 ENSG00000246225.5 RP11-17A1.3 -5.24 2.8e-07 0.000119 -0.35 -0.27 Sudden cardiac arrest; chr11:22980573 chr11:22829380~22945393:+ LIHC cis rs6479901 0.947 rs10822150 ENSG00000232075.1 MRPL35P2 -5.24 2.8e-07 0.000119 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63257736 chr10:63634317~63634827:- LIHC cis rs6479901 0.793 rs10761733 ENSG00000232075.1 MRPL35P2 -5.24 2.8e-07 0.000119 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63275024 chr10:63634317~63634827:- LIHC cis rs6479901 0.895 rs4417159 ENSG00000232075.1 MRPL35P2 -5.24 2.8e-07 0.000119 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63285938 chr10:63634317~63634827:- LIHC cis rs6479901 0.947 rs10995493 ENSG00000232075.1 MRPL35P2 -5.24 2.8e-07 0.000119 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63287266 chr10:63634317~63634827:- LIHC cis rs6479901 0.841 rs7913332 ENSG00000232075.1 MRPL35P2 -5.24 2.8e-07 0.000119 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63293890 chr10:63634317~63634827:- LIHC cis rs6479901 0.895 rs7093899 ENSG00000232075.1 MRPL35P2 -5.24 2.8e-07 0.000119 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63294576 chr10:63634317~63634827:- LIHC cis rs950169 0.58 rs35516100 ENSG00000259295.5 CSPG4P12 5.24 2.81e-07 0.000119 0.37 0.27 Schizophrenia; chr15:84652199 chr15:85191438~85213905:+ LIHC cis rs950169 0.58 rs62021208 ENSG00000259295.5 CSPG4P12 5.24 2.81e-07 0.000119 0.37 0.27 Schizophrenia; chr15:84653013 chr15:85191438~85213905:+ LIHC cis rs4713118 0.614 rs9380007 ENSG00000216901.1 AL022393.7 5.24 2.81e-07 0.00012 0.31 0.27 Parkinson's disease; chr6:27692729 chr6:28176188~28176674:+ LIHC cis rs9487094 0.689 rs9480949 ENSG00000260273.1 RP11-425D10.10 5.24 2.81e-07 0.00012 0.32 0.27 Height; chr6:109407238 chr6:109382795~109383666:+ LIHC cis rs10129255 0.957 rs28887506 ENSG00000223648.3 IGHV3-64 5.24 2.82e-07 0.00012 0.21 0.27 Kawasaki disease; chr14:106785589 chr14:106643132~106658258:- LIHC cis rs2933343 0.7 rs1683787 ENSG00000231305.3 RP11-723O4.2 -5.24 2.82e-07 0.00012 -0.3 -0.27 IgG glycosylation; chr3:128908178 chr3:128861313~128871540:- LIHC cis rs150992 0.603 rs246251 ENSG00000248489.1 CTD-2007H13.3 5.24 2.82e-07 0.00012 0.43 0.27 Body mass index; chr5:98942362 chr5:98929171~98995013:+ LIHC cis rs150992 0.569 rs326482 ENSG00000248489.1 CTD-2007H13.3 5.24 2.82e-07 0.00012 0.43 0.27 Body mass index; chr5:98951115 chr5:98929171~98995013:+ LIHC cis rs5769765 0.773 rs138834 ENSG00000278869.1 CITF22-49E9.3 5.24 2.82e-07 0.00012 0.47 0.27 Schizophrenia; chr22:49786849 chr22:49933198~49934074:- LIHC cis rs7674212 0.772 rs13113099 ENSG00000230069.3 LRRC37A15P -5.24 2.82e-07 0.00012 -0.25 -0.27 Type 2 diabetes; chr4:103052965 chr4:102727274~102730721:- LIHC cis rs2243480 0.522 rs73150635 ENSG00000273142.1 RP11-458F8.4 -5.24 2.82e-07 0.00012 -0.37 -0.27 Diabetic kidney disease; chr7:66507503 chr7:66902857~66906297:+ LIHC cis rs4948102 0.642 rs766333 ENSG00000226278.1 PSPHP1 -5.24 2.82e-07 0.00012 -0.3 -0.27 Plasma homocysteine levels (post-methionine load test); chr7:56059011 chr7:55764797~55773288:+ LIHC cis rs7743045 0.504 rs10499090 ENSG00000253194.1 RP11-351A11.1 5.24 2.82e-07 0.00012 0.35 0.27 Mean platelet volume; chr6:119000386 chr6:118934785~119031541:+ LIHC cis rs5758511 0.68 rs5758657 ENSG00000237037.8 NDUFA6-AS1 -5.24 2.82e-07 0.00012 -0.34 -0.27 Birth weight; chr22:42222663 chr22:42090931~42137742:+ LIHC cis rs7131987 0.718 rs7976961 ENSG00000275476.1 RP11-996F15.4 -5.24 2.82e-07 0.00012 -0.32 -0.27 QT interval; chr12:29310155 chr12:29277397~29277882:- LIHC cis rs2762353 0.526 rs12215823 ENSG00000216436.2 HIST1H2APS1 -5.24 2.83e-07 0.00012 -0.32 -0.27 Blood metabolite levels; chr6:25725846 chr6:25732497~25732827:+ LIHC cis rs7923609 0.74 rs10761784 ENSG00000232075.1 MRPL35P2 -5.24 2.83e-07 0.00012 -0.3 -0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63548990 chr10:63634317~63634827:- LIHC cis rs73081554 0.611 rs4681851 ENSG00000272360.1 RP11-359I18.5 -5.24 2.83e-07 0.00012 -0.41 -0.27 Rheumatoid arthritis; chr3:58410164 chr3:58490830~58491291:- LIHC cis rs1134634 0.52 rs7661102 ENSG00000273133.1 RP11-799M12.2 -5.24 2.84e-07 0.000121 -0.34 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15596914 chr4:15563698~15564253:- LIHC cis rs1134634 0.52 rs56041141 ENSG00000273133.1 RP11-799M12.2 -5.24 2.84e-07 0.000121 -0.34 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15598222 chr4:15563698~15564253:- LIHC cis rs1061377 0.585 rs3733271 ENSG00000249207.1 RP11-360F5.1 -5.24 2.84e-07 0.000121 -0.28 -0.27 Uric acid levels; chr4:39047948 chr4:39112677~39126818:- LIHC cis rs9527 0.662 rs10786714 ENSG00000236937.2 PTGES3P4 5.24 2.84e-07 0.000121 0.38 0.27 Arsenic metabolism; chr10:102838849 chr10:102845595~102845950:+ LIHC cis rs1061377 0.585 rs12648581 ENSG00000249207.1 RP11-360F5.1 -5.24 2.84e-07 0.000121 -0.28 -0.27 Uric acid levels; chr4:39054024 chr4:39112677~39126818:- LIHC cis rs11098499 1 rs12506395 ENSG00000245958.5 RP11-33B1.1 -5.24 2.85e-07 0.000121 -0.3 -0.27 Corneal astigmatism; chr4:119263939 chr4:119454791~119552025:+ LIHC cis rs3096299 0.632 rs8051537 ENSG00000261118.1 RP11-104N10.1 5.24 2.85e-07 0.000121 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89477976 chr16:89492017~89504460:- LIHC cis rs75920871 0.841 rs78442878 ENSG00000254851.1 RP11-109L13.1 -5.24 2.85e-07 0.000121 -0.45 -0.27 Subjective well-being; chr11:117052138 chr11:117135528~117138582:+ LIHC cis rs7923609 0.756 rs7090758 ENSG00000232075.1 MRPL35P2 5.24 2.85e-07 0.000121 0.29 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63575555 chr10:63634317~63634827:- LIHC cis rs950169 0.58 rs11630887 ENSG00000259295.5 CSPG4P12 5.24 2.85e-07 0.000121 0.37 0.27 Schizophrenia; chr15:84649784 chr15:85191438~85213905:+ LIHC cis rs113835537 0.877 rs2229456 ENSG00000255517.5 CTD-3074O7.5 -5.24 2.86e-07 0.000121 -0.36 -0.27 Airway imaging phenotypes; chr11:66561270 chr11:66473490~66480233:- LIHC cis rs6479901 0.947 rs10822167 ENSG00000232075.1 MRPL35P2 -5.24 2.86e-07 0.000121 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63398991 chr10:63634317~63634827:- LIHC cis rs5758511 0.573 rs738248 ENSG00000237037.8 NDUFA6-AS1 5.24 2.86e-07 0.000121 0.32 0.27 Birth weight; chr22:41800463 chr22:42090931~42137742:+ LIHC cis rs5758511 0.541 rs6002494 ENSG00000237037.8 NDUFA6-AS1 5.24 2.86e-07 0.000121 0.32 0.27 Birth weight; chr22:41803856 chr22:42090931~42137742:+ LIHC cis rs5758511 0.513 rs7292782 ENSG00000237037.8 NDUFA6-AS1 5.24 2.86e-07 0.000121 0.32 0.27 Birth weight; chr22:41804320 chr22:42090931~42137742:+ LIHC cis rs5758511 0.573 rs5996069 ENSG00000237037.8 NDUFA6-AS1 5.24 2.86e-07 0.000121 0.32 0.27 Birth weight; chr22:41805181 chr22:42090931~42137742:+ LIHC cis rs875971 0.862 rs1968126 ENSG00000237310.1 GS1-124K5.4 -5.24 2.87e-07 0.000122 -0.24 -0.27 Aortic root size; chr7:66592017 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6460306 ENSG00000237310.1 GS1-124K5.4 -5.24 2.87e-07 0.000122 -0.24 -0.27 Aortic root size; chr7:66595806 chr7:66493706~66495474:+ LIHC cis rs7429990 0.803 rs6776963 ENSG00000229759.1 MRPS18AP1 -5.24 2.87e-07 0.000122 -0.3 -0.27 Educational attainment (years of education); chr3:47789251 chr3:48256350~48256938:- LIHC cis rs12468226 1 rs74766638 ENSG00000273456.1 RP11-686O6.2 5.24 2.87e-07 0.000122 0.41 0.27 Urate levels; chr2:202445168 chr2:202374932~202375604:- LIHC cis rs875971 0.545 rs2420612 ENSG00000237310.1 GS1-124K5.4 5.24 2.87e-07 0.000122 0.26 0.27 Aortic root size; chr7:66536825 chr7:66493706~66495474:+ LIHC cis rs6589219 0.721 rs6589218 ENSG00000196167.8 COLCA1 -5.24 2.87e-07 0.000122 -0.3 -0.27 Colorectal cancer; chr11:111296832 chr11:111290787~111305045:- LIHC cis rs5769765 1 rs5770728 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49866336 chr22:49933198~49934074:- LIHC cis rs5769765 0.778 rs4574208 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49863090 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs5769760 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49866048 chr22:49933198~49934074:- LIHC cis rs5769765 0.955 rs2295406 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49866521 chr22:49933198~49934074:- LIHC cis rs5769765 0.955 rs8139758 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49867475 chr22:49933198~49934074:- LIHC cis rs5769765 0.913 rs2319462 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49869722 chr22:49933198~49934074:- LIHC cis rs5769765 0.955 rs5769761 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49869993 chr22:49933198~49934074:- LIHC cis rs5769765 0.954 rs5769762 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49870394 chr22:49933198~49934074:- LIHC cis rs5769765 0.908 rs2319464 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49872129 chr22:49933198~49934074:- LIHC cis rs5769765 0.955 rs2319465 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49872136 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs34774661 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49873860 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs4824106 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49874174 chr22:49933198~49934074:- LIHC cis rs5769765 0.954 rs5770739 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49874366 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs5770741 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49876567 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs5770742 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49876661 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs4597652 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49876922 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs5769764 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49877136 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs5769765 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49877528 chr22:49933198~49934074:- LIHC cis rs5769765 0.865 rs4824108 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49877780 chr22:49933198~49934074:- LIHC cis rs5769765 0.908 rs4824109 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49877812 chr22:49933198~49934074:- LIHC cis rs5769765 0.837 rs4824110 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49877983 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs8184990 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49879526 chr22:49933198~49934074:- LIHC cis rs5769765 0.955 rs5769767 ENSG00000278869.1 CITF22-49E9.3 -5.24 2.88e-07 0.000122 -0.4 -0.27 Schizophrenia; chr22:49883261 chr22:49933198~49934074:- LIHC cis rs9425766 0.655 rs6666767 ENSG00000227373.4 RP11-160H22.5 5.24 2.88e-07 0.000122 0.33 0.27 Life satisfaction; chr1:174357564 chr1:174115300~174160004:- LIHC cis rs113835537 0.808 rs10896128 ENSG00000255517.5 CTD-3074O7.5 -5.24 2.88e-07 0.000122 -0.38 -0.27 Airway imaging phenotypes; chr11:66557058 chr11:66473490~66480233:- LIHC cis rs11096990 0.613 rs12505690 ENSG00000249207.1 RP11-360F5.1 -5.23 2.89e-07 0.000122 -0.28 -0.27 Cognitive function; chr4:39167425 chr4:39112677~39126818:- LIHC cis rs1577917 1 rs1962716 ENSG00000234155.1 RP11-30P6.6 5.23 2.89e-07 0.000123 0.35 0.27 Response to antipsychotic treatment; chr6:85938718 chr6:85387219~85390186:- LIHC cis rs2842992 0.872 rs2758315 ENSG00000237927.1 RP3-393E18.2 -5.23 2.89e-07 0.000123 -0.33 -0.27 Age-related macular degeneration (geographic atrophy); chr6:159737608 chr6:159586955~159589169:- LIHC cis rs2439831 1 rs690316 ENSG00000205771.5 CATSPER2P1 -5.23 2.9e-07 0.000123 -0.37 -0.27 Lung cancer in ever smokers; chr15:43445682 chr15:43726918~43747094:- LIHC cis rs10510102 0.935 rs11200237 ENSG00000226864.1 ATE1-AS1 5.23 2.9e-07 0.000123 0.43 0.27 Breast cancer; chr10:121900715 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs78525391 ENSG00000226864.1 ATE1-AS1 5.23 2.9e-07 0.000123 0.43 0.27 Breast cancer; chr10:121901102 chr10:121928312~121951965:+ LIHC cis rs6085948 0.861 rs6077169 ENSG00000228888.1 LINC01428 -5.23 2.9e-07 0.000123 -0.39 -0.27 Interleukin-10 levels; chr20:7267815 chr20:7146467~7254202:- LIHC cis rs4718428 0.672 rs12530806 ENSG00000230295.1 RP11-458F8.2 -5.23 2.9e-07 0.000123 -0.23 -0.27 Corneal structure; chr7:66925737 chr7:66880708~66882981:+ LIHC cis rs6921919 0.848 rs6903652 ENSG00000204709.4 LINC01556 5.23 2.9e-07 0.000123 0.37 0.27 Autism spectrum disorder or schizophrenia; chr6:28354343 chr6:28943877~28944537:+ LIHC cis rs887829 0.57 rs6736508 ENSG00000233445.1 RPL17P11 5.23 2.9e-07 0.000123 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233687101 chr2:233721522~233722065:- LIHC cis rs1150668 0.799 rs1736891 ENSG00000204709.4 LINC01556 5.23 2.91e-07 0.000123 0.31 0.27 Pubertal anthropometrics; chr6:28219323 chr6:28943877~28944537:+ LIHC cis rs4356203 0.905 rs2052188 ENSG00000272034.1 SNORD14A 5.23 2.91e-07 0.000123 0.29 0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17105123 chr11:17074654~17074744:- LIHC cis rs10510102 0.935 rs10887016 ENSG00000226864.1 ATE1-AS1 5.23 2.91e-07 0.000123 0.43 0.27 Breast cancer; chr10:121893830 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs10887018 ENSG00000226864.1 ATE1-AS1 5.23 2.91e-07 0.000123 0.43 0.27 Breast cancer; chr10:121894457 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200230 ENSG00000226864.1 ATE1-AS1 5.23 2.91e-07 0.000123 0.43 0.27 Breast cancer; chr10:121895117 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200234 ENSG00000226864.1 ATE1-AS1 5.23 2.91e-07 0.000123 0.43 0.27 Breast cancer; chr10:121895851 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs12244951 ENSG00000226864.1 ATE1-AS1 5.23 2.91e-07 0.000123 0.43 0.27 Breast cancer; chr10:121896879 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs74362676 ENSG00000226864.1 ATE1-AS1 5.23 2.91e-07 0.000123 0.43 0.27 Breast cancer; chr10:121898216 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs3750837 ENSG00000226864.1 ATE1-AS1 5.23 2.91e-07 0.000123 0.43 0.27 Breast cancer; chr10:121899080 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs3750836 ENSG00000226864.1 ATE1-AS1 5.23 2.91e-07 0.000123 0.43 0.27 Breast cancer; chr10:121899087 chr10:121928312~121951965:+ LIHC cis rs2842992 0.958 rs2758318 ENSG00000237927.1 RP3-393E18.2 -5.23 2.92e-07 0.000123 -0.34 -0.27 Age-related macular degeneration (geographic atrophy); chr6:159648605 chr6:159586955~159589169:- LIHC cis rs2842992 1 rs2842992 ENSG00000237927.1 RP3-393E18.2 -5.23 2.92e-07 0.000123 -0.34 -0.27 Age-related macular degeneration (geographic atrophy); chr6:159650127 chr6:159586955~159589169:- LIHC cis rs875971 0.862 rs2024192 ENSG00000237310.1 GS1-124K5.4 -5.23 2.92e-07 0.000123 -0.24 -0.27 Aortic root size; chr7:66576460 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs6955837 ENSG00000237310.1 GS1-124K5.4 -5.23 2.92e-07 0.000123 -0.24 -0.27 Aortic root size; chr7:66578155 chr7:66493706~66495474:+ LIHC cis rs875971 0.825 rs10281499 ENSG00000237310.1 GS1-124K5.4 -5.23 2.92e-07 0.000123 -0.24 -0.27 Aortic root size; chr7:66583979 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs4718377 ENSG00000237310.1 GS1-124K5.4 -5.23 2.92e-07 0.000123 -0.24 -0.27 Aortic root size; chr7:66584691 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs10278014 ENSG00000237310.1 GS1-124K5.4 -5.23 2.92e-07 0.000123 -0.24 -0.27 Aortic root size; chr7:66586277 chr7:66493706~66495474:+ LIHC cis rs6480314 0.636 rs34888891 ENSG00000233590.1 RP11-153K11.3 -5.23 2.92e-07 0.000124 -0.41 -0.27 Optic nerve measurement (disc area); chr10:68242351 chr10:68233251~68242379:- LIHC cis rs4731207 0.596 rs2170354 ENSG00000224897.5 POT1-AS1 5.23 2.92e-07 0.000124 0.34 0.27 Cutaneous malignant melanoma; chr7:125025865 chr7:124929873~125179315:+ LIHC cis rs9291683 0.588 rs4280729 ENSG00000250413.1 RP11-448G15.1 -5.23 2.92e-07 0.000124 -0.34 -0.27 Bone mineral density; chr4:10012237 chr4:10006482~10009725:+ LIHC cis rs9291683 0.552 rs10939656 ENSG00000250413.1 RP11-448G15.1 -5.23 2.92e-07 0.000124 -0.34 -0.27 Bone mineral density; chr4:10013022 chr4:10006482~10009725:+ LIHC cis rs9326248 0.581 rs10892076 ENSG00000280143.1 AP000892.6 5.23 2.93e-07 0.000124 0.31 0.27 Blood protein levels; chr11:117118220 chr11:117204967~117210292:+ LIHC cis rs1577917 0.959 rs16876540 ENSG00000234155.1 RP11-30P6.6 5.23 2.93e-07 0.000124 0.36 0.27 Response to antipsychotic treatment; chr6:85902801 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs35761942 ENSG00000234155.1 RP11-30P6.6 5.23 2.93e-07 0.000124 0.36 0.27 Response to antipsychotic treatment; chr6:85919786 chr6:85387219~85390186:- LIHC cis rs1150668 0.768 rs1233713 ENSG00000204709.4 LINC01556 5.23 2.93e-07 0.000124 0.3 0.27 Pubertal anthropometrics; chr6:28230503 chr6:28943877~28944537:+ LIHC cis rs8059260 0.673 rs74985998 ENSG00000274038.1 RP11-66H6.4 -5.23 2.94e-07 0.000124 -0.44 -0.27 Alcohol consumption over the past year; chr16:10967208 chr16:11056556~11057034:+ LIHC cis rs116175783 0.557 rs3769968 ENSG00000227403.1 AC009299.3 5.23 2.94e-07 0.000124 0.41 0.27 Intelligence (multi-trait analysis); chr2:161309640 chr2:161244739~161249050:+ LIHC cis rs860295 0.627 rs11264410 ENSG00000203761.5 MSTO2P -5.23 2.95e-07 0.000125 -0.22 -0.27 Body mass index; chr1:155775558 chr1:155745829~155750137:+ LIHC cis rs10510102 0.935 rs11818001 ENSG00000226864.1 ATE1-AS1 -5.23 2.95e-07 0.000125 -0.42 -0.27 Breast cancer; chr10:121884830 chr10:121928312~121951965:+ LIHC cis rs950169 0.58 rs11633762 ENSG00000259295.5 CSPG4P12 5.23 2.95e-07 0.000125 0.38 0.27 Schizophrenia; chr15:84643921 chr15:85191438~85213905:+ LIHC cis rs875971 0.545 rs12671152 ENSG00000237310.1 GS1-124K5.4 5.23 2.95e-07 0.000125 0.27 0.27 Aortic root size; chr7:66311140 chr7:66493706~66495474:+ LIHC cis rs8031584 0.672 rs17815726 ENSG00000270015.1 RP11-540B6.6 5.23 2.96e-07 0.000125 0.38 0.27 Huntington's disease progression; chr15:31021049 chr15:30926514~30928407:+ LIHC cis rs4731207 0.596 rs11767649 ENSG00000224897.5 POT1-AS1 -5.23 2.96e-07 0.000125 -0.33 -0.27 Cutaneous malignant melanoma; chr7:124997463 chr7:124929873~125179315:+ LIHC cis rs2735413 0.875 rs8045975 ENSG00000276007.1 RP11-358L22.3 5.23 2.96e-07 0.000125 0.3 0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78056290 chr16:78123243~78124332:+ LIHC cis rs17507216 0.718 rs72751675 ENSG00000278603.1 RP13-608F4.5 5.23 2.96e-07 0.000125 0.58 0.27 Excessive daytime sleepiness; chr15:82630452 chr15:82472203~82472426:+ LIHC cis rs17818399 0.62 rs6544906 ENSG00000279254.1 RP11-536C12.1 -5.23 2.96e-07 0.000125 -0.31 -0.27 Height; chr2:46636733 chr2:46668870~46670778:+ LIHC cis rs875971 0.862 rs908915 ENSG00000237310.1 GS1-124K5.4 -5.23 2.97e-07 0.000125 -0.25 -0.27 Aortic root size; chr7:66149664 chr7:66493706~66495474:+ LIHC cis rs6479901 0.895 rs7916224 ENSG00000232075.1 MRPL35P2 -5.23 2.97e-07 0.000125 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63144843 chr10:63634317~63634827:- LIHC cis rs9291683 0.53 rs6449196 ENSG00000250413.1 RP11-448G15.1 5.23 2.97e-07 0.000125 0.35 0.27 Bone mineral density; chr4:9972036 chr4:10006482~10009725:+ LIHC cis rs6479901 0.512 rs7082090 ENSG00000232075.1 MRPL35P2 5.23 2.97e-07 0.000125 0.32 0.27 Intelligence (multi-trait analysis); chr10:63239252 chr10:63634317~63634827:- LIHC cis rs5769765 0.632 rs13056783 ENSG00000278869.1 CITF22-49E9.3 -5.23 2.97e-07 0.000126 -0.4 -0.27 Schizophrenia; chr22:49865504 chr22:49933198~49934074:- LIHC cis rs887829 0.57 rs10203266 ENSG00000233445.1 RPL17P11 5.23 2.98e-07 0.000126 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233687722 chr2:233721522~233722065:- LIHC cis rs4718428 0.705 rs12536410 ENSG00000230295.1 RP11-458F8.2 -5.23 2.98e-07 0.000126 -0.23 -0.27 Corneal structure; chr7:66789303 chr7:66880708~66882981:+ LIHC cis rs4718428 0.705 rs68168107 ENSG00000230295.1 RP11-458F8.2 -5.23 2.98e-07 0.000126 -0.23 -0.27 Corneal structure; chr7:66790251 chr7:66880708~66882981:+ LIHC cis rs1577917 0.958 rs34622605 ENSG00000234155.1 RP11-30P6.6 5.23 2.98e-07 0.000126 0.36 0.27 Response to antipsychotic treatment; chr6:85746801 chr6:85387219~85390186:- LIHC cis rs875971 0.862 rs6460282 ENSG00000237310.1 GS1-124K5.4 -5.23 2.98e-07 0.000126 -0.25 -0.27 Aortic root size; chr7:66226259 chr7:66493706~66495474:+ LIHC cis rs2286503 1 rs2286503 ENSG00000228649.7 AC005682.5 5.23 2.98e-07 0.000126 0.33 0.27 Fibrinogen; chr7:22816987 chr7:22854178~22861579:+ LIHC cis rs1155848 0.571 rs6563125 ENSG00000227354.5 RBM26-AS1 5.23 2.98e-07 0.000126 0.47 0.27 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79630618 chr13:79406309~79424328:+ LIHC cis rs1155848 0.571 rs58739959 ENSG00000227354.5 RBM26-AS1 5.23 2.98e-07 0.000126 0.47 0.27 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79633468 chr13:79406309~79424328:+ LIHC cis rs4731207 0.698 rs7811608 ENSG00000224897.5 POT1-AS1 -5.23 2.98e-07 0.000126 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124807794 chr7:124929873~125179315:+ LIHC cis rs6479891 1 rs4745706 ENSG00000232075.1 MRPL35P2 5.23 2.99e-07 0.000126 0.32 0.27 Arthritis (juvenile idiopathic); chr10:63399820 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs12415038 ENSG00000232075.1 MRPL35P2 5.23 2.99e-07 0.000126 0.32 0.27 Arthritis (juvenile idiopathic); chr10:63401098 chr10:63634317~63634827:- LIHC cis rs591584 0.59 rs7107559 ENSG00000255893.1 RP11-685N10.1 5.23 2.99e-07 0.000126 0.27 0.27 Macrophage Migration Inhibitory Factor levels; chr11:94590508 chr11:94472908~94473570:- LIHC cis rs202072 0.872 rs375661 ENSG00000215022.6 RP1-257A7.4 -5.23 2.99e-07 0.000126 -0.31 -0.27 HIV-1 viral setpoint; chr6:13279199 chr6:13264861~13295586:- LIHC cis rs2439831 1 rs690002 ENSG00000205771.5 CATSPER2P1 -5.23 2.99e-07 0.000126 -0.37 -0.27 Lung cancer in ever smokers; chr15:43437151 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs537115 ENSG00000205771.5 CATSPER2P1 -5.23 2.99e-07 0.000126 -0.37 -0.27 Lung cancer in ever smokers; chr15:43437750 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs2245908 ENSG00000205771.5 CATSPER2P1 -5.23 2.99e-07 0.000126 -0.37 -0.27 Lung cancer in ever smokers; chr15:43439256 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs2444029 ENSG00000205771.5 CATSPER2P1 -5.23 2.99e-07 0.000126 -0.37 -0.27 Lung cancer in ever smokers; chr15:43445286 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs2467740 ENSG00000205771.5 CATSPER2P1 -5.23 2.99e-07 0.000126 -0.37 -0.27 Lung cancer in ever smokers; chr15:43454594 chr15:43726918~43747094:- LIHC cis rs4356203 0.905 rs621246 ENSG00000272034.1 SNORD14A -5.23 2.99e-07 0.000126 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17182218 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs635802 ENSG00000272034.1 SNORD14A -5.23 2.99e-07 0.000126 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17183246 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs662711 ENSG00000272034.1 SNORD14A -5.23 2.99e-07 0.000126 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17184641 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs598946 ENSG00000272034.1 SNORD14A -5.23 2.99e-07 0.000126 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17187540 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs545773 ENSG00000272034.1 SNORD14A -5.23 2.99e-07 0.000126 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17192089 chr11:17074654~17074744:- LIHC cis rs4356203 0.792 rs677540 ENSG00000272034.1 SNORD14A -5.23 2.99e-07 0.000126 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17192212 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs511119 ENSG00000272034.1 SNORD14A -5.23 2.99e-07 0.000126 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17193570 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs1989405 ENSG00000272034.1 SNORD14A 5.23 2.99e-07 0.000126 0.29 0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17163272 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs214939 ENSG00000272034.1 SNORD14A 5.23 2.99e-07 0.000126 0.29 0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17165992 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs214936 ENSG00000272034.1 SNORD14A 5.23 2.99e-07 0.000126 0.29 0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17169472 chr11:17074654~17074744:- LIHC cis rs2739330 0.76 rs1002286 ENSG00000206090.4 AP000350.7 -5.23 2.99e-07 0.000126 -0.31 -0.27 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23939998~23942798:+ LIHC cis rs950169 0.922 rs12910334 ENSG00000225151.9 GOLGA2P7 -5.23 2.99e-07 0.000126 -0.34 -0.27 Schizophrenia; chr15:84403620 chr15:84199311~84230136:- LIHC cis rs10510102 0.872 rs10887003 ENSG00000226864.1 ATE1-AS1 5.23 2.99e-07 0.000126 0.45 0.27 Breast cancer; chr10:121864660 chr10:121928312~121951965:+ LIHC cis rs10129255 0.785 rs10150044 ENSG00000223648.3 IGHV3-64 5.23 3e-07 0.000126 0.2 0.27 Kawasaki disease; chr14:106775695 chr14:106643132~106658258:- LIHC cis rs17711722 0.522 rs62469933 ENSG00000226824.5 RP4-756H11.3 -5.23 3e-07 0.000126 -0.33 -0.27 Calcium levels; chr7:65800652 chr7:66654538~66669855:+ LIHC cis rs72627509 0.638 rs7658601 ENSG00000269949.1 RP11-738E22.3 5.23 3e-07 0.000127 0.36 0.27 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56915181 chr4:56960927~56961373:- LIHC cis rs1134634 0.52 rs4698403 ENSG00000273133.1 RP11-799M12.2 -5.23 3e-07 0.000127 -0.34 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15628204 chr4:15563698~15564253:- LIHC cis rs36715 0.953 rs2617613 ENSG00000245937.6 LINC01184 5.23 3.01e-07 0.000127 0.33 0.27 Breast cancer; chr5:128216897 chr5:127940426~128083172:- LIHC cis rs36715 0.868 rs2546147 ENSG00000245937.6 LINC01184 5.23 3.01e-07 0.000127 0.33 0.27 Breast cancer; chr5:128216898 chr5:127940426~128083172:- LIHC cis rs73186030 0.546 rs73188388 ENSG00000272758.4 RP11-299J3.8 5.23 3.01e-07 0.000127 0.48 0.27 Serum parathyroid hormone levels; chr3:122399229 chr3:122416207~122443180:+ LIHC cis rs1061377 0.748 rs13117988 ENSG00000249685.1 RP11-360F5.3 5.23 3.01e-07 0.000127 0.33 0.27 Uric acid levels; chr4:39092219 chr4:39133913~39135608:+ LIHC cis rs6479901 0.895 rs10733788 ENSG00000232075.1 MRPL35P2 -5.23 3.01e-07 0.000127 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63158105 chr10:63634317~63634827:- LIHC cis rs7131987 0.65 rs10843377 ENSG00000275476.1 RP11-996F15.4 5.23 3.01e-07 0.000127 0.33 0.27 QT interval; chr12:29284120 chr12:29277397~29277882:- LIHC cis rs9533799 0.559 rs9533796 ENSG00000227258.4 SMIM2-AS1 -5.23 3.01e-07 0.000127 -0.32 -0.27 Amyotrophic lateral sclerosis; chr13:44216310 chr13:44110451~44240517:+ LIHC cis rs1577917 0.545 rs9344548 ENSG00000234155.1 RP11-30P6.6 -5.23 3.01e-07 0.000127 -0.31 -0.27 Response to antipsychotic treatment; chr6:85777619 chr6:85387219~85390186:- LIHC cis rs752590 0.65 rs6751201 ENSG00000189223.12 PAX8-AS1 5.23 3.02e-07 0.000127 0.39 0.27 Mucinous ovarian carcinoma; chr2:113195122 chr2:113211522~113276581:+ LIHC cis rs10129255 0.957 rs10137980 ENSG00000223648.3 IGHV3-64 5.23 3.02e-07 0.000127 0.2 0.27 Kawasaki disease; chr14:106775735 chr14:106643132~106658258:- LIHC cis rs8040855 0.965 rs4843027 ENSG00000259295.5 CSPG4P12 -5.23 3.02e-07 0.000127 -0.38 -0.27 Bulimia nervosa; chr15:85171892 chr15:85191438~85213905:+ LIHC cis rs2274273 0.837 rs7142857 ENSG00000258413.1 RP11-665C16.6 -5.23 3.02e-07 0.000127 -0.31 -0.27 Protein biomarker; chr14:55237410 chr14:55262767~55272075:- LIHC cis rs11123170 0.65 rs2289897 ENSG00000189223.12 PAX8-AS1 -5.23 3.02e-07 0.000127 -0.4 -0.27 Renal function-related traits (BUN); chr2:113219877 chr2:113211522~113276581:+ LIHC cis rs6479891 1 rs9414799 ENSG00000232075.1 MRPL35P2 5.23 3.02e-07 0.000127 0.32 0.27 Arthritis (juvenile idiopathic); chr10:63369842 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs4746119 ENSG00000232075.1 MRPL35P2 5.23 3.02e-07 0.000127 0.32 0.27 Arthritis (juvenile idiopathic); chr10:63370157 chr10:63634317~63634827:- LIHC cis rs11098499 0.954 rs6820115 ENSG00000245958.5 RP11-33B1.1 -5.23 3.03e-07 0.000128 -0.27 -0.27 Corneal astigmatism; chr4:119477027 chr4:119454791~119552025:+ LIHC cis rs950776 0.518 rs3813572 ENSG00000261762.1 RP11-650L12.2 5.23 3.03e-07 0.000128 0.36 0.27 Sudden cardiac arrest; chr15:78540246 chr15:78589123~78591276:- LIHC cis rs228614 0.536 rs223437 ENSG00000230069.3 LRRC37A15P -5.23 3.03e-07 0.000128 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798736 chr4:102727274~102730721:- LIHC cis rs1061377 1 rs6829450 ENSG00000249685.1 RP11-360F5.3 5.23 3.03e-07 0.000128 0.33 0.27 Uric acid levels; chr4:39114721 chr4:39133913~39135608:+ LIHC cis rs7665090 0.51 rs223498 ENSG00000246560.2 RP11-10L12.4 -5.22 3.04e-07 0.000128 -0.31 -0.27 Primary biliary cholangitis; chr4:102730805 chr4:102828055~102844075:+ LIHC cis rs9487094 0.813 rs3799840 ENSG00000260273.1 RP11-425D10.10 5.22 3.04e-07 0.000128 0.37 0.27 Height; chr6:109381443 chr6:109382795~109383666:+ LIHC cis rs9487094 0.744 rs2275652 ENSG00000260273.1 RP11-425D10.10 5.22 3.04e-07 0.000128 0.37 0.27 Height; chr6:109382480 chr6:109382795~109383666:+ LIHC cis rs2243480 1 rs34702770 ENSG00000226824.5 RP4-756H11.3 -5.22 3.04e-07 0.000128 -0.45 -0.27 Diabetic kidney disease; chr7:65879836 chr7:66654538~66669855:+ LIHC cis rs2243480 0.803 rs35480979 ENSG00000226824.5 RP4-756H11.3 -5.22 3.04e-07 0.000128 -0.45 -0.27 Diabetic kidney disease; chr7:65892097 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs34637256 ENSG00000226824.5 RP4-756H11.3 -5.22 3.04e-07 0.000128 -0.45 -0.27 Diabetic kidney disease; chr7:65895144 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs35391607 ENSG00000226824.5 RP4-756H11.3 -5.22 3.04e-07 0.000128 -0.45 -0.27 Diabetic kidney disease; chr7:65895842 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs13220979 ENSG00000226824.5 RP4-756H11.3 -5.22 3.04e-07 0.000128 -0.45 -0.27 Diabetic kidney disease; chr7:65898217 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs34974928 ENSG00000226824.5 RP4-756H11.3 -5.22 3.04e-07 0.000128 -0.45 -0.27 Diabetic kidney disease; chr7:65899019 chr7:66654538~66669855:+ LIHC cis rs13068223 0.819 rs8792 ENSG00000243926.1 TIPARP-AS1 -5.22 3.04e-07 0.000128 -0.25 -0.27 Age-related hearing impairment (SNP x SNP interaction); chr3:156747639 chr3:156671862~156674378:- LIHC cis rs950169 0.58 rs11636189 ENSG00000259295.5 CSPG4P12 5.22 3.04e-07 0.000128 0.37 0.27 Schizophrenia; chr15:84650323 chr15:85191438~85213905:+ LIHC cis rs11098499 0.82 rs2389885 ENSG00000245958.5 RP11-33B1.1 -5.22 3.04e-07 0.000128 -0.29 -0.27 Corneal astigmatism; chr4:119612776 chr4:119454791~119552025:+ LIHC cis rs7688540 0.771 rs78343340 ENSG00000275426.1 CH17-262A2.1 5.22 3.04e-07 0.000128 0.35 0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:273648 chr4:149738~150317:+ LIHC cis rs1023500 0.505 rs134886 ENSG00000227370.1 RP4-669P10.19 5.22 3.05e-07 0.000128 0.28 0.27 Schizophrenia; chr22:42277850 chr22:42132543~42132998:+ LIHC cis rs804280 0.662 rs11250164 ENSG00000255394.4 C8orf49 -5.22 3.06e-07 0.000129 -0.36 -0.27 Myopia (pathological); chr8:11753177 chr8:11761256~11763223:+ LIHC cis rs8040855 0.756 rs2342118 ENSG00000259295.5 CSPG4P12 -5.22 3.06e-07 0.000129 -0.41 -0.27 Bulimia nervosa; chr15:85149785 chr15:85191438~85213905:+ LIHC cis rs2522056 0.935 rs757104 ENSG00000233006.5 AC034220.3 -5.22 3.06e-07 0.000129 -0.29 -0.27 Fibrinogen;Lymphocyte counts; chr5:132459537 chr5:132311285~132369916:- LIHC cis rs75920871 0.513 rs76904522 ENSG00000254851.1 RP11-109L13.1 -5.22 3.06e-07 0.000129 -0.52 -0.27 Subjective well-being; chr11:117144147 chr11:117135528~117138582:+ LIHC cis rs75920871 0.513 rs113560866 ENSG00000254851.1 RP11-109L13.1 -5.22 3.06e-07 0.000129 -0.52 -0.27 Subjective well-being; chr11:117144473 chr11:117135528~117138582:+ LIHC cis rs9487094 0.813 rs67857472 ENSG00000260273.1 RP11-425D10.10 5.22 3.07e-07 0.000129 0.38 0.27 Height; chr6:109359125 chr6:109382795~109383666:+ LIHC cis rs6142102 1 rs6059673 ENSG00000276073.1 RP5-1125A11.7 -5.22 3.07e-07 0.000129 -0.31 -0.27 Skin pigmentation; chr20:34117755 chr20:33985617~33988989:- LIHC cis rs2565722 0.508 rs1652483 ENSG00000243831.1 RP1-81D8.4 5.22 3.07e-07 0.000129 0.36 0.27 Blood protein levels; chr6:160777051 chr6:160666228~160676523:- LIHC cis rs5756813 0.754 rs4821708 ENSG00000233360.4 Z83844.1 5.22 3.07e-07 0.000129 0.34 0.27 Optic cup area;Vertical cup-disc ratio; chr22:37768099 chr22:37641832~37658377:- LIHC cis rs2565722 0.508 rs1652486 ENSG00000243831.1 RP1-81D8.4 5.22 3.08e-07 0.000129 0.36 0.27 Blood protein levels; chr6:160778168 chr6:160666228~160676523:- LIHC cis rs2565722 0.508 rs1782601 ENSG00000243831.1 RP1-81D8.4 5.22 3.08e-07 0.000129 0.36 0.27 Blood protein levels; chr6:160778181 chr6:160666228~160676523:- LIHC cis rs2565722 0.508 rs1652487 ENSG00000243831.1 RP1-81D8.4 5.22 3.08e-07 0.000129 0.36 0.27 Blood protein levels; chr6:160778362 chr6:160666228~160676523:- LIHC cis rs11098499 0.908 rs28499576 ENSG00000245958.5 RP11-33B1.1 -5.22 3.08e-07 0.000129 -0.28 -0.27 Corneal astigmatism; chr4:119465522 chr4:119454791~119552025:+ LIHC cis rs7131987 0.65 rs7954871 ENSG00000275476.1 RP11-996F15.4 -5.22 3.08e-07 0.000129 -0.32 -0.27 QT interval; chr12:29306799 chr12:29277397~29277882:- LIHC cis rs6061231 0.761 rs2427312 ENSG00000273619.1 RP5-908M14.9 -5.22 3.09e-07 0.00013 -0.33 -0.27 Colorectal cancer; chr20:62395535 chr20:62386303~62386970:- LIHC cis rs4356203 0.875 rs214935 ENSG00000272034.1 SNORD14A -5.22 3.09e-07 0.00013 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17171575 chr11:17074654~17074744:- LIHC cis rs875971 0.545 rs4441996 ENSG00000226824.5 RP4-756H11.3 5.22 3.1e-07 0.00013 0.35 0.27 Aortic root size; chr7:66123233 chr7:66654538~66669855:+ LIHC cis rs6504950 0.579 rs8075983 ENSG00000275710.1 RP11-257O5.4 5.22 3.1e-07 0.00013 0.45 0.27 Breast cancer; chr17:55194557 chr17:54964474~54964679:+ LIHC cis rs4356203 0.87 rs7936310 ENSG00000272034.1 SNORD14A 5.22 3.11e-07 0.00013 0.29 0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17248741 chr11:17074654~17074744:- LIHC cis rs6479891 1 rs9415696 ENSG00000232075.1 MRPL35P2 5.22 3.11e-07 0.00013 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63374588 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs9415697 ENSG00000232075.1 MRPL35P2 5.22 3.11e-07 0.00013 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63375377 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs724553 ENSG00000232075.1 MRPL35P2 5.22 3.11e-07 0.00013 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63380624 chr10:63634317~63634827:- LIHC cis rs4731207 0.596 rs12537431 ENSG00000224897.5 POT1-AS1 5.22 3.11e-07 0.00013 0.33 0.27 Cutaneous malignant melanoma; chr7:124946502 chr7:124929873~125179315:+ LIHC cis rs4731207 0.561 rs12706631 ENSG00000224897.5 POT1-AS1 5.22 3.11e-07 0.00013 0.33 0.27 Cutaneous malignant melanoma; chr7:124946526 chr7:124929873~125179315:+ LIHC cis rs2243480 1 rs12698509 ENSG00000226824.5 RP4-756H11.3 -5.22 3.11e-07 0.00013 -0.44 -0.27 Diabetic kidney disease; chr7:65953889 chr7:66654538~66669855:+ LIHC cis rs12701220 0.948 rs10275712 ENSG00000229043.2 AC091729.9 -5.22 3.11e-07 0.000131 -0.39 -0.27 Bronchopulmonary dysplasia; chr7:1043282 chr7:1160374~1165267:+ LIHC cis rs2274273 0.905 rs17128183 ENSG00000258413.1 RP11-665C16.6 5.22 3.11e-07 0.000131 0.3 0.27 Protein biomarker; chr14:55112795 chr14:55262767~55272075:- LIHC cis rs950169 0.887 rs12903946 ENSG00000259295.5 CSPG4P12 5.22 3.11e-07 0.000131 0.37 0.27 Schizophrenia; chr15:84399732 chr15:85191438~85213905:+ LIHC cis rs950169 0.887 rs62029593 ENSG00000259295.5 CSPG4P12 5.22 3.11e-07 0.000131 0.37 0.27 Schizophrenia; chr15:84400482 chr15:85191438~85213905:+ LIHC cis rs950169 0.81 rs62029594 ENSG00000259295.5 CSPG4P12 5.22 3.11e-07 0.000131 0.37 0.27 Schizophrenia; chr15:84400554 chr15:85191438~85213905:+ LIHC cis rs950169 0.881 rs62029596 ENSG00000259295.5 CSPG4P12 5.22 3.11e-07 0.000131 0.37 0.27 Schizophrenia; chr15:84400736 chr15:85191438~85213905:+ LIHC cis rs950169 0.881 rs4081123 ENSG00000259295.5 CSPG4P12 5.22 3.11e-07 0.000131 0.37 0.27 Schizophrenia; chr15:84401537 chr15:85191438~85213905:+ LIHC cis rs950169 0.881 rs62029599 ENSG00000259295.5 CSPG4P12 5.22 3.11e-07 0.000131 0.37 0.27 Schizophrenia; chr15:84401867 chr15:85191438~85213905:+ LIHC cis rs950169 0.8 rs4099846 ENSG00000259295.5 CSPG4P12 5.22 3.11e-07 0.000131 0.37 0.27 Schizophrenia; chr15:84402196 chr15:85191438~85213905:+ LIHC cis rs3096299 0.719 rs2965817 ENSG00000261118.1 RP11-104N10.1 5.22 3.12e-07 0.000131 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89446826 chr16:89492017~89504460:- LIHC cis rs2439831 1 rs471229 ENSG00000205771.5 CATSPER2P1 -5.22 3.12e-07 0.000131 -0.37 -0.27 Lung cancer in ever smokers; chr15:43441796 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs2439841 ENSG00000205771.5 CATSPER2P1 -5.22 3.12e-07 0.000131 -0.37 -0.27 Lung cancer in ever smokers; chr15:43442551 chr15:43726918~43747094:- LIHC cis rs1577917 0.545 rs1832070 ENSG00000234155.1 RP11-30P6.6 -5.22 3.12e-07 0.000131 -0.31 -0.27 Response to antipsychotic treatment; chr6:85773454 chr6:85387219~85390186:- LIHC cis rs12468226 0.873 rs76552560 ENSG00000273456.1 RP11-686O6.2 5.22 3.13e-07 0.000131 0.41 0.27 Urate levels; chr2:202173123 chr2:202374932~202375604:- LIHC cis rs4948102 0.597 rs12669623 ENSG00000226278.1 PSPHP1 -5.22 3.13e-07 0.000131 -0.31 -0.27 Plasma homocysteine levels (post-methionine load test); chr7:56071486 chr7:55764797~55773288:+ LIHC cis rs9291683 0.551 rs2276961 ENSG00000250413.1 RP11-448G15.1 -5.22 3.13e-07 0.000131 -0.34 -0.27 Bone mineral density; chr4:10021357 chr4:10006482~10009725:+ LIHC cis rs6600671 0.934 rs11249348 ENSG00000231429.2 RP11-343N15.2 -5.22 3.13e-07 0.000131 -0.31 -0.27 Hip geometry; chr1:121446444 chr1:121412719~121429274:+ LIHC cis rs6686842 0.798 rs12037263 ENSG00000235358.1 RP11-399E6.1 5.22 3.14e-07 0.000132 0.3 0.27 Height; chr1:41016828 chr1:41242373~41284861:+ LIHC cis rs739496 0.793 rs73199895 ENSG00000226469.1 ADAM1B 5.22 3.14e-07 0.000132 0.33 0.27 Platelet count; chr12:111428283 chr12:111927018~111929017:+ LIHC cis rs6921919 0.583 rs35560946 ENSG00000204709.4 LINC01556 5.22 3.15e-07 0.000132 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28427660 chr6:28943877~28944537:+ LIHC cis rs3096299 0.967 rs2911256 ENSG00000261118.1 RP11-104N10.1 5.22 3.15e-07 0.000132 0.28 0.27 Multiple myeloma (IgH translocation); chr16:89418688 chr16:89492017~89504460:- LIHC cis rs5769707 0.609 rs739247 ENSG00000235111.1 RP1-29C18.8 -5.22 3.15e-07 0.000132 -0.33 -0.27 Monocyte percentage of white cells;Monocyte count; chr22:49603009 chr22:49612657~49615716:- LIHC cis rs10510102 0.935 rs12251175 ENSG00000226864.1 ATE1-AS1 5.22 3.15e-07 0.000132 0.43 0.27 Breast cancer; chr10:121889015 chr10:121928312~121951965:+ LIHC cis rs17301013 0.965 rs7548540 ENSG00000227373.4 RP11-160H22.5 5.22 3.15e-07 0.000132 0.33 0.27 Systemic lupus erythematosus; chr1:174411672 chr1:174115300~174160004:- LIHC cis rs2565722 0.508 rs1652481 ENSG00000243831.1 RP1-81D8.4 5.22 3.15e-07 0.000132 0.36 0.27 Blood protein levels; chr6:160776850 chr6:160666228~160676523:- LIHC cis rs2072510 0.569 rs61937880 ENSG00000257715.1 RP11-256L6.2 -5.22 3.16e-07 0.000132 -0.41 -0.27 Metabolite levels (small molecules and protein measures); chr12:95997089 chr12:96025323~96027971:+ LIHC cis rs7714584 1 rs59531858 ENSG00000197083.10 ZNF300P1 5.22 3.16e-07 0.000132 0.44 0.27 Crohn's disease; chr5:150867501 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs12656538 ENSG00000197083.10 ZNF300P1 5.22 3.16e-07 0.000132 0.44 0.27 Crohn's disease; chr5:150871818 chr5:150930645~150946289:- LIHC cis rs950169 0.922 rs12906983 ENSG00000225151.9 GOLGA2P7 -5.22 3.16e-07 0.000132 -0.34 -0.27 Schizophrenia; chr15:84262270 chr15:84199311~84230136:- LIHC cis rs6921919 0.551 rs13201753 ENSG00000204709.4 LINC01556 5.22 3.16e-07 0.000132 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28363351 chr6:28943877~28944537:+ LIHC cis rs992157 0.764 rs4672886 ENSG00000261338.2 RP11-378A13.1 -5.22 3.16e-07 0.000132 -0.29 -0.27 Colorectal cancer; chr2:218320822 chr2:218255319~218257366:+ LIHC cis rs2286503 1 rs1029740 ENSG00000228649.7 AC005682.5 5.22 3.16e-07 0.000132 0.33 0.27 Fibrinogen; chr7:22833967 chr7:22854178~22861579:+ LIHC cis rs4731207 0.698 rs12537161 ENSG00000224897.5 POT1-AS1 5.22 3.17e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124898536 chr7:124929873~125179315:+ LIHC cis rs875971 0.862 rs6460302 ENSG00000237310.1 GS1-124K5.4 5.22 3.17e-07 0.000133 0.24 0.27 Aortic root size; chr7:66495270 chr7:66493706~66495474:+ LIHC cis rs1061377 0.748 rs35904472 ENSG00000249207.1 RP11-360F5.1 -5.22 3.17e-07 0.000133 -0.28 -0.27 Uric acid levels; chr4:39094901 chr4:39112677~39126818:- LIHC cis rs4718428 0.705 rs10267335 ENSG00000230295.1 RP11-458F8.2 -5.22 3.18e-07 0.000133 -0.23 -0.27 Corneal structure; chr7:66938233 chr7:66880708~66882981:+ LIHC cis rs4731207 0.698 rs34600520 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124850884 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10271687 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124853677 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10228376 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124853689 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10156168 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124854356 chr7:124929873~125179315:+ LIHC cis rs4731207 0.662 rs10246553 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124854880 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs11975788 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124857757 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10233306 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124858363 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs6959712 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124858949 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4422720 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124859348 chr7:124929873~125179315:+ LIHC cis rs4731207 0.751 rs4584095 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124860156 chr7:124929873~125179315:+ LIHC cis rs4731207 0.724 rs57458159 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124860756 chr7:124929873~125179315:+ LIHC cis rs4731207 0.655 rs7808203 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124862082 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs6961292 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124863135 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs7782327 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124865897 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs7782340 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124865971 chr7:124929873~125179315:+ LIHC cis rs4731207 0.724 rs6953168 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124866287 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs6973812 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124866696 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs12538333 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124868303 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10272583 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124869397 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs12536575 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124870222 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs9886177 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124873396 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4463363 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124873716 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs6466954 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124875292 chr7:124929873~125179315:+ LIHC cis rs4731207 0.662 rs6973134 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124875319 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs7789859 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124879418 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4379394 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124879573 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4311608 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124879653 chr7:124929873~125179315:+ LIHC cis rs4731207 0.661 rs6466956 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124880312 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs7799938 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124881337 chr7:124929873~125179315:+ LIHC cis rs4731207 0.671 rs12530981 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124881668 chr7:124929873~125179315:+ LIHC cis rs4731207 0.697 rs4360235 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124886488 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs7778544 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124887427 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4279518 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124888032 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs6956638 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124890061 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs6960683 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124890314 chr7:124929873~125179315:+ LIHC cis rs4731207 0.724 rs10224946 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124891284 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs6966415 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124891415 chr7:124929873~125179315:+ LIHC cis rs4731207 0.662 rs7357296 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124892662 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4377885 ENSG00000224897.5 POT1-AS1 -5.22 3.18e-07 0.000133 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124893626 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10245872 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124895199 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10954049 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124895396 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs7793441 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124896184 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10223980 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124896504 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10228682 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124897982 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10236403 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124899488 chr7:124929873~125179315:+ LIHC cis rs4731207 0.662 rs4283967 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124900481 chr7:124929873~125179315:+ LIHC cis rs4731207 0.724 rs4383910 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124900787 chr7:124929873~125179315:+ LIHC cis rs4731207 0.541 rs6960027 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124902957 chr7:124929873~125179315:+ LIHC cis rs4731207 0.662 rs35630355 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124909279 chr7:124929873~125179315:+ LIHC cis rs4731207 0.724 rs6968693 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124909922 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs7794631 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124911871 chr7:124929873~125179315:+ LIHC cis rs4731207 0.689 rs2054585 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124912393 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs1904975 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124912748 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs3919896 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124912953 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs12538083 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124914003 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs7794710 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124921061 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs12533560 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124921828 chr7:124929873~125179315:+ LIHC cis rs4731207 0.597 rs12536017 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124922247 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs28409696 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124922461 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs6968187 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124923286 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs6949341 ENSG00000224897.5 POT1-AS1 5.22 3.18e-07 0.000133 0.32 0.27 Cutaneous malignant melanoma; chr7:124924122 chr7:124929873~125179315:+ LIHC cis rs10833905 0.756 rs10833866 ENSG00000246225.5 RP11-17A1.3 -5.22 3.19e-07 0.000133 -0.36 -0.27 Sudden cardiac arrest; chr11:22955270 chr11:22829380~22945393:+ LIHC cis rs113835537 0.735 rs519380 ENSG00000255517.5 CTD-3074O7.5 -5.21 3.19e-07 0.000133 -0.35 -0.27 Airway imaging phenotypes; chr11:66641938 chr11:66473490~66480233:- LIHC cis rs6504950 0.745 rs9914088 ENSG00000275710.1 RP11-257O5.4 5.21 3.19e-07 0.000133 0.35 0.27 Breast cancer; chr17:54902624 chr17:54964474~54964679:+ LIHC cis rs11098499 0.662 rs13108589 ENSG00000245958.5 RP11-33B1.1 -5.21 3.19e-07 0.000133 -0.27 -0.27 Corneal astigmatism; chr4:119346947 chr4:119454791~119552025:+ LIHC cis rs73081554 0.611 rs35975336 ENSG00000272360.1 RP11-359I18.5 -5.21 3.2e-07 0.000133 -0.41 -0.27 Rheumatoid arthritis; chr3:58465907 chr3:58490830~58491291:- LIHC cis rs4731207 0.596 rs7799523 ENSG00000224897.5 POT1-AS1 5.21 3.2e-07 0.000133 0.33 0.27 Cutaneous malignant melanoma; chr7:124951979 chr7:124929873~125179315:+ LIHC cis rs4731207 0.569 rs7799535 ENSG00000224897.5 POT1-AS1 5.21 3.2e-07 0.000133 0.33 0.27 Cutaneous malignant melanoma; chr7:124952006 chr7:124929873~125179315:+ LIHC cis rs17301013 0.965 rs2179214 ENSG00000227373.4 RP11-160H22.5 5.21 3.2e-07 0.000134 0.33 0.27 Systemic lupus erythematosus; chr1:174413954 chr1:174115300~174160004:- LIHC cis rs17301013 0.93 rs7523263 ENSG00000227373.4 RP11-160H22.5 5.21 3.2e-07 0.000134 0.33 0.27 Systemic lupus erythematosus; chr1:174414542 chr1:174115300~174160004:- LIHC cis rs7714584 1 rs17727568 ENSG00000197083.10 ZNF300P1 5.21 3.21e-07 0.000134 0.44 0.27 Crohn's disease; chr5:150865126 chr5:150930645~150946289:- LIHC cis rs4731207 0.698 rs11979724 ENSG00000224897.5 POT1-AS1 -5.21 3.21e-07 0.000134 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124810991 chr7:124929873~125179315:+ LIHC cis rs3096299 0.658 rs34590044 ENSG00000261118.1 RP11-104N10.1 5.21 3.22e-07 0.000134 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89476749 chr16:89492017~89504460:- LIHC cis rs2836974 0.623 rs34240248 ENSG00000255568.3 BRWD1-AS2 -5.21 3.22e-07 0.000134 -0.23 -0.27 Cognitive function; chr21:39313313 chr21:39313935~39314962:+ LIHC cis rs2439831 1 rs2467743 ENSG00000205771.5 CATSPER2P1 -5.21 3.23e-07 0.000135 -0.37 -0.27 Lung cancer in ever smokers; chr15:43458148 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs2245176 ENSG00000205771.5 CATSPER2P1 -5.21 3.23e-07 0.000135 -0.37 -0.27 Lung cancer in ever smokers; chr15:43458564 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs2245054 ENSG00000205771.5 CATSPER2P1 -5.21 3.23e-07 0.000135 -0.37 -0.27 Lung cancer in ever smokers; chr15:43459711 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs2264876 ENSG00000205771.5 CATSPER2P1 -5.21 3.23e-07 0.000135 -0.37 -0.27 Lung cancer in ever smokers; chr15:43465221 chr15:43726918~43747094:- LIHC cis rs6964833 1 rs4717906 ENSG00000123965.13 PMS2P5 5.21 3.23e-07 0.000135 0.45 0.27 Menarche (age at onset); chr7:74671923 chr7:74894116~74897835:+ LIHC cis rs4731207 0.698 rs10261610 ENSG00000224897.5 POT1-AS1 -5.21 3.23e-07 0.000135 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124810523 chr7:124929873~125179315:+ LIHC cis rs9549367 0.756 rs9603814 ENSG00000269125.1 RP11-98F14.11 5.21 3.24e-07 0.000135 0.3 0.27 Platelet distribution width; chr13:113246468 chr13:113165002~113165183:- LIHC cis rs524281 0.817 rs10896092 ENSG00000255320.1 RP11-755F10.1 5.21 3.24e-07 0.000135 0.34 0.27 Electroencephalogram traits; chr11:66190575 chr11:66244840~66246239:- LIHC cis rs4713118 0.662 rs9380046 ENSG00000219392.1 RP1-265C24.5 -5.21 3.24e-07 0.000135 -0.4 -0.27 Parkinson's disease; chr6:28062721 chr6:28115628~28116551:+ LIHC cis rs11676348 0.935 rs4674250 ENSG00000261338.2 RP11-378A13.1 -5.21 3.24e-07 0.000135 -0.28 -0.27 Ulcerative colitis; chr2:218112808 chr2:218255319~218257366:+ LIHC cis rs12908161 1 rs35808647 ENSG00000259295.5 CSPG4P12 5.21 3.24e-07 0.000135 0.38 0.27 Schizophrenia; chr15:84834210 chr15:85191438~85213905:+ LIHC cis rs17818399 0.574 rs6544907 ENSG00000279254.1 RP11-536C12.1 -5.21 3.24e-07 0.000135 -0.31 -0.27 Height; chr2:46641180 chr2:46668870~46670778:+ LIHC cis rs62355901 0.551 rs12659430 ENSG00000271828.1 CTD-2310F14.1 5.21 3.24e-07 0.000135 0.5 0.27 Breast cancer; chr5:56736792 chr5:56927874~56929573:+ LIHC cis rs1150668 0.835 rs1233696 ENSG00000204709.4 LINC01556 5.21 3.24e-07 0.000135 0.3 0.27 Pubertal anthropometrics; chr6:28175232 chr6:28943877~28944537:+ LIHC cis rs1577917 0.771 rs2484355 ENSG00000234155.1 RP11-30P6.6 5.21 3.25e-07 0.000135 0.35 0.27 Response to antipsychotic treatment; chr6:85684685 chr6:85387219~85390186:- LIHC cis rs875971 0.862 rs7809814 ENSG00000237310.1 GS1-124K5.4 -5.21 3.25e-07 0.000135 -0.25 -0.27 Aortic root size; chr7:66150410 chr7:66493706~66495474:+ LIHC cis rs172166 0.516 rs1150670 ENSG00000204709.4 LINC01556 5.21 3.26e-07 0.000136 0.3 0.27 Cardiac Troponin-T levels; chr6:28162781 chr6:28943877~28944537:+ LIHC cis rs172166 0.516 rs2021826 ENSG00000204709.4 LINC01556 5.21 3.26e-07 0.000136 0.3 0.27 Cardiac Troponin-T levels; chr6:28164978 chr6:28943877~28944537:+ LIHC cis rs10510102 0.935 rs11200187 ENSG00000226864.1 ATE1-AS1 5.21 3.26e-07 0.000136 0.44 0.27 Breast cancer; chr10:121843050 chr10:121928312~121951965:+ LIHC cis rs62355901 0.653 rs62355882 ENSG00000271828.1 CTD-2310F14.1 5.21 3.26e-07 0.000136 0.51 0.27 Breast cancer; chr5:56749283 chr5:56927874~56929573:+ LIHC cis rs4731207 0.536 rs2127967 ENSG00000224897.5 POT1-AS1 5.21 3.27e-07 0.000136 0.33 0.27 Cutaneous malignant melanoma; chr7:124965618 chr7:124929873~125179315:+ LIHC cis rs2998286 0.862 rs2153300 ENSG00000254635.4 WAC-AS1 -5.21 3.27e-07 0.000136 -0.34 -0.27 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28519041 chr10:28522652~28532743:- LIHC cis rs992157 0.764 rs62183964 ENSG00000261338.2 RP11-378A13.1 5.21 3.27e-07 0.000136 0.29 0.27 Colorectal cancer; chr2:218321869 chr2:218255319~218257366:+ LIHC cis rs4731207 0.698 rs6977407 ENSG00000224897.5 POT1-AS1 5.21 3.28e-07 0.000136 0.32 0.27 Cutaneous malignant melanoma; chr7:124858948 chr7:124929873~125179315:+ LIHC cis rs7429990 0.864 rs7637372 ENSG00000229759.1 MRPS18AP1 -5.21 3.28e-07 0.000136 -0.29 -0.27 Educational attainment (years of education); chr3:47750385 chr3:48256350~48256938:- LIHC cis rs4713118 0.505 rs156740 ENSG00000204709.4 LINC01556 5.21 3.28e-07 0.000136 0.31 0.27 Parkinson's disease; chr6:27992657 chr6:28943877~28944537:+ LIHC cis rs10129255 1 rs4612959 ENSG00000223648.3 IGHV3-64 5.21 3.28e-07 0.000136 0.21 0.27 Kawasaki disease; chr14:106767055 chr14:106643132~106658258:- LIHC cis rs4660214 0.666 rs587404 ENSG00000182109.6 RP11-69E11.4 5.21 3.28e-07 0.000137 0.29 0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39442834 chr1:39522280~39546187:- LIHC cis rs12701220 0.901 rs12701713 ENSG00000229043.2 AC091729.9 -5.21 3.28e-07 0.000137 -0.37 -0.27 Bronchopulmonary dysplasia; chr7:1050869 chr7:1160374~1165267:+ LIHC cis rs36715 0.909 rs152906 ENSG00000245937.6 LINC01184 5.21 3.28e-07 0.000137 0.33 0.27 Breast cancer; chr5:128216148 chr5:127940426~128083172:- LIHC cis rs17301013 0.932 rs727279 ENSG00000227373.4 RP11-160H22.5 5.21 3.28e-07 0.000137 0.33 0.27 Systemic lupus erythematosus; chr1:174496026 chr1:174115300~174160004:- LIHC cis rs17301013 0.794 rs6425283 ENSG00000227373.4 RP11-160H22.5 5.21 3.28e-07 0.000137 0.33 0.27 Systemic lupus erythematosus; chr1:174499853 chr1:174115300~174160004:- LIHC cis rs6479901 0.793 rs10822154 ENSG00000232075.1 MRPL35P2 -5.21 3.28e-07 0.000137 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63299284 chr10:63634317~63634827:- LIHC cis rs950169 0.84 rs72748702 ENSG00000225151.9 GOLGA2P7 -5.21 3.29e-07 0.000137 -0.33 -0.27 Schizophrenia; chr15:84246494 chr15:84199311~84230136:- LIHC cis rs4356203 0.905 rs6486352 ENSG00000272034.1 SNORD14A 5.21 3.29e-07 0.000137 0.29 0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17150823 chr11:17074654~17074744:- LIHC cis rs10510102 0.872 rs12264046 ENSG00000226864.1 ATE1-AS1 5.21 3.29e-07 0.000137 0.43 0.27 Breast cancer; chr10:121894996 chr10:121928312~121951965:+ LIHC cis rs2749592 0.55 rs4934881 ENSG00000263064.2 RP11-291L22.7 -5.21 3.3e-07 0.000137 -0.28 -0.27 Age-related hearing impairment (SNP x SNP interaction); chr10:37625418 chr10:38448689~38448949:+ LIHC cis rs4731207 0.698 rs34618371 ENSG00000224897.5 POT1-AS1 5.21 3.3e-07 0.000137 0.32 0.27 Cutaneous malignant melanoma; chr7:124856116 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4552839 ENSG00000224897.5 POT1-AS1 5.21 3.3e-07 0.000137 0.32 0.27 Cutaneous malignant melanoma; chr7:124859460 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs6466955 ENSG00000224897.5 POT1-AS1 5.21 3.3e-07 0.000137 0.32 0.27 Cutaneous malignant melanoma; chr7:124878712 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs7796015 ENSG00000224897.5 POT1-AS1 5.21 3.3e-07 0.000137 0.32 0.27 Cutaneous malignant melanoma; chr7:124881092 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4319000 ENSG00000224897.5 POT1-AS1 5.21 3.3e-07 0.000137 0.32 0.27 Cutaneous malignant melanoma; chr7:124888001 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs6415362 ENSG00000224897.5 POT1-AS1 5.21 3.3e-07 0.000137 0.32 0.27 Cutaneous malignant melanoma; chr7:124890596 chr7:124929873~125179315:+ LIHC cis rs4731207 0.724 rs10229152 ENSG00000224897.5 POT1-AS1 5.21 3.3e-07 0.000137 0.32 0.27 Cutaneous malignant melanoma; chr7:124898231 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10252039 ENSG00000224897.5 POT1-AS1 5.21 3.3e-07 0.000137 0.32 0.27 Cutaneous malignant melanoma; chr7:124899483 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10255209 ENSG00000224897.5 POT1-AS1 5.21 3.3e-07 0.000137 0.32 0.27 Cutaneous malignant melanoma; chr7:124914873 chr7:124929873~125179315:+ LIHC cis rs4731207 0.662 rs2219954 ENSG00000224897.5 POT1-AS1 5.21 3.3e-07 0.000137 0.32 0.27 Cutaneous malignant melanoma; chr7:124915801 chr7:124929873~125179315:+ LIHC cis rs4731207 0.724 rs4146110 ENSG00000224897.5 POT1-AS1 5.21 3.3e-07 0.000137 0.32 0.27 Cutaneous malignant melanoma; chr7:124921154 chr7:124929873~125179315:+ LIHC cis rs950169 0.922 rs62021167 ENSG00000225151.9 GOLGA2P7 -5.21 3.3e-07 0.000137 -0.35 -0.27 Schizophrenia; chr15:84574820 chr15:84199311~84230136:- LIHC cis rs9890032 0.934 rs7225461 ENSG00000263531.1 RP13-753N3.1 5.21 3.3e-07 0.000137 0.33 0.27 Hip circumference adjusted for BMI; chr17:30932881 chr17:30863921~30864940:- LIHC cis rs950169 0.922 rs11630507 ENSG00000225151.9 GOLGA2P7 -5.21 3.3e-07 0.000137 -0.34 -0.27 Schizophrenia; chr15:84552494 chr15:84199311~84230136:- LIHC cis rs172166 0.538 rs1150686 ENSG00000204709.4 LINC01556 5.21 3.31e-07 0.000137 0.3 0.27 Cardiac Troponin-T levels; chr6:28193493 chr6:28943877~28944537:+ LIHC cis rs1150688 1 rs1150688 ENSG00000204709.4 LINC01556 5.21 3.31e-07 0.000137 0.3 0.27 Autism spectrum disorder or schizophrenia; chr6:28195002 chr6:28943877~28944537:+ LIHC cis rs7429990 0.833 rs1486915 ENSG00000229759.1 MRPS18AP1 -5.21 3.31e-07 0.000137 -0.29 -0.27 Educational attainment (years of education); chr3:47781053 chr3:48256350~48256938:- LIHC cis rs7688540 0.771 rs17164747 ENSG00000275426.1 CH17-262A2.1 5.21 3.31e-07 0.000138 0.35 0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:266798 chr4:149738~150317:+ LIHC cis rs7688540 0.771 rs79366248 ENSG00000275426.1 CH17-262A2.1 5.21 3.31e-07 0.000138 0.35 0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:272870 chr4:149738~150317:+ LIHC cis rs227275 0.525 rs7698608 ENSG00000246560.2 RP11-10L12.4 5.21 3.31e-07 0.000138 0.3 0.27 Allergic disease (asthma, hay fever or eczema); chr4:103016817 chr4:102828055~102844075:+ LIHC cis rs2980439 0.846 rs2980437 ENSG00000253981.4 ALG1L13P -5.21 3.32e-07 0.000138 -0.31 -0.27 Neuroticism; chr8:8237241 chr8:8236003~8244667:- LIHC cis rs875971 0.545 rs6950988 ENSG00000237310.1 GS1-124K5.4 5.21 3.32e-07 0.000138 0.26 0.27 Aortic root size; chr7:66511428 chr7:66493706~66495474:+ LIHC cis rs12908161 0.959 rs1051168 ENSG00000259295.5 CSPG4P12 5.21 3.33e-07 0.000138 0.38 0.27 Schizophrenia; chr15:84657289 chr15:85191438~85213905:+ LIHC cis rs1061377 0.674 rs34506243 ENSG00000249207.1 RP11-360F5.1 -5.21 3.33e-07 0.000138 -0.27 -0.27 Uric acid levels; chr4:39082702 chr4:39112677~39126818:- LIHC cis rs875971 0.862 rs10274883 ENSG00000237310.1 GS1-124K5.4 -5.21 3.33e-07 0.000139 -0.24 -0.27 Aortic root size; chr7:66651104 chr7:66493706~66495474:+ LIHC cis rs801193 0.569 rs881285 ENSG00000237310.1 GS1-124K5.4 -5.21 3.33e-07 0.000139 -0.24 -0.27 Aortic root size; chr7:66654433 chr7:66493706~66495474:+ LIHC cis rs801193 0.569 rs3846973 ENSG00000237310.1 GS1-124K5.4 -5.21 3.33e-07 0.000139 -0.24 -0.27 Aortic root size; chr7:66655048 chr7:66493706~66495474:+ LIHC cis rs801193 0.569 rs2013908 ENSG00000237310.1 GS1-124K5.4 -5.21 3.33e-07 0.000139 -0.24 -0.27 Aortic root size; chr7:66656082 chr7:66493706~66495474:+ LIHC cis rs801193 0.548 rs2109297 ENSG00000237310.1 GS1-124K5.4 -5.21 3.33e-07 0.000139 -0.24 -0.27 Aortic root size; chr7:66657397 chr7:66493706~66495474:+ LIHC cis rs801193 0.569 rs6978178 ENSG00000237310.1 GS1-124K5.4 -5.21 3.33e-07 0.000139 -0.24 -0.27 Aortic root size; chr7:66658097 chr7:66493706~66495474:+ LIHC cis rs801193 0.591 rs721717 ENSG00000237310.1 GS1-124K5.4 -5.21 3.33e-07 0.000139 -0.24 -0.27 Aortic root size; chr7:66665305 chr7:66493706~66495474:+ LIHC cis rs801193 0.569 rs6951302 ENSG00000237310.1 GS1-124K5.4 -5.21 3.33e-07 0.000139 -0.24 -0.27 Aortic root size; chr7:66667525 chr7:66493706~66495474:+ LIHC cis rs17301013 0.794 rs1793293 ENSG00000227373.4 RP11-160H22.5 -5.21 3.34e-07 0.000139 -0.35 -0.27 Systemic lupus erythematosus; chr1:174774451 chr1:174115300~174160004:- LIHC cis rs2274273 0.934 rs10140869 ENSG00000258413.1 RP11-665C16.6 -5.21 3.34e-07 0.000139 -0.32 -0.27 Protein biomarker; chr14:55328565 chr14:55262767~55272075:- LIHC cis rs1134634 0.52 rs28661857 ENSG00000273133.1 RP11-799M12.2 -5.21 3.34e-07 0.000139 -0.34 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15589842 chr4:15563698~15564253:- LIHC cis rs10510102 0.935 rs12253283 ENSG00000276742.1 RP11-500G22.4 -5.21 3.34e-07 0.000139 -0.41 -0.27 Breast cancer; chr10:121909740 chr10:121956782~121957098:+ LIHC cis rs4731207 0.698 rs7801140 ENSG00000224897.5 POT1-AS1 5.21 3.35e-07 0.000139 0.32 0.27 Cutaneous malignant melanoma; chr7:124865707 chr7:124929873~125179315:+ LIHC cis rs4731207 0.662 rs7782031 ENSG00000224897.5 POT1-AS1 5.21 3.35e-07 0.000139 0.32 0.27 Cutaneous malignant melanoma; chr7:124865730 chr7:124929873~125179315:+ LIHC cis rs10875746 0.551 rs12322347 ENSG00000240399.1 RP1-228P16.1 -5.21 3.35e-07 0.000139 -0.29 -0.27 Longevity (90 years and older); chr12:48313915 chr12:48054813~48055591:- LIHC cis rs10875746 0.551 rs12322348 ENSG00000240399.1 RP1-228P16.1 -5.21 3.35e-07 0.000139 -0.29 -0.27 Longevity (90 years and older); chr12:48313916 chr12:48054813~48055591:- LIHC cis rs6479891 0.915 rs9415699 ENSG00000232075.1 MRPL35P2 -5.21 3.35e-07 0.000139 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63383798 chr10:63634317~63634827:- LIHC cis rs228614 0.509 rs223486 ENSG00000230069.3 LRRC37A15P -5.21 3.35e-07 0.000139 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102763796 chr4:102727274~102730721:- LIHC cis rs6921919 0.945 rs7765989 ENSG00000216901.1 AL022393.7 5.2 3.35e-07 0.000139 0.42 0.27 Autism spectrum disorder or schizophrenia; chr6:28432518 chr6:28176188~28176674:+ LIHC cis rs9425766 0.631 rs10158289 ENSG00000227373.4 RP11-160H22.5 5.2 3.35e-07 0.000139 0.33 0.27 Life satisfaction; chr1:174081529 chr1:174115300~174160004:- LIHC cis rs10129255 0.912 rs61997792 ENSG00000223648.3 IGHV3-64 5.2 3.36e-07 0.000139 0.21 0.27 Kawasaki disease; chr14:106799304 chr14:106643132~106658258:- LIHC cis rs950776 0.518 rs12903129 ENSG00000261762.1 RP11-650L12.2 5.2 3.36e-07 0.00014 0.35 0.27 Sudden cardiac arrest; chr15:78527264 chr15:78589123~78591276:- LIHC cis rs1134634 0.52 rs73127647 ENSG00000273133.1 RP11-799M12.2 -5.2 3.36e-07 0.00014 -0.34 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15639969 chr4:15563698~15564253:- LIHC cis rs950776 0.518 rs952216 ENSG00000261762.1 RP11-650L12.2 5.2 3.37e-07 0.00014 0.35 0.27 Sudden cardiac arrest; chr15:78526860 chr15:78589123~78591276:- LIHC cis rs9467711 0.651 rs13192713 ENSG00000216436.2 HIST1H2APS1 5.2 3.37e-07 0.00014 0.73 0.27 Autism spectrum disorder or schizophrenia; chr6:25943006 chr6:25732497~25732827:+ LIHC cis rs9467711 0.651 rs35778245 ENSG00000216436.2 HIST1H2APS1 5.2 3.37e-07 0.00014 0.73 0.27 Autism spectrum disorder or schizophrenia; chr6:25944575 chr6:25732497~25732827:+ LIHC cis rs9467711 0.651 rs2051539 ENSG00000216436.2 HIST1H2APS1 5.2 3.37e-07 0.00014 0.73 0.27 Autism spectrum disorder or schizophrenia; chr6:25947031 chr6:25732497~25732827:+ LIHC cis rs2877649 0.51 rs10083379 ENSG00000258744.1 RP11-80A15.1 -5.2 3.37e-07 0.00014 -0.48 -0.27 Smooth-surface caries; chr14:24438856 chr14:24501594~24508688:+ LIHC cis rs10510102 0.935 rs7906667 ENSG00000226864.1 ATE1-AS1 5.2 3.37e-07 0.00014 0.43 0.27 Breast cancer; chr10:121909142 chr10:121928312~121951965:+ LIHC cis rs2836974 0.644 rs61300849 ENSG00000255568.3 BRWD1-AS2 -5.2 3.38e-07 0.00014 -0.23 -0.27 Cognitive function; chr21:39308268 chr21:39313935~39314962:+ LIHC cis rs465969 0.744 rs7758483 ENSG00000255389.1 C6orf3 -5.2 3.38e-07 0.00014 -0.58 -0.27 Psoriasis; chr6:111467945 chr6:111599875~111602295:+ LIHC cis rs8059260 0.736 rs16957872 ENSG00000274038.1 RP11-66H6.4 -5.2 3.39e-07 0.00014 -0.45 -0.27 Alcohol consumption over the past year; chr16:10988835 chr16:11056556~11057034:+ LIHC cis rs4731207 0.596 rs1871772 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125038818 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6948283 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125039469 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs6977613 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125041737 chr7:124929873~125179315:+ LIHC cis rs4731207 0.562 rs6975534 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125046407 chr7:124929873~125179315:+ LIHC cis rs4731207 0.561 rs6975148 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125046454 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6959632 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125050992 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6466990 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125051458 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1600741 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125052238 chr7:124929873~125179315:+ LIHC cis rs4731207 0.591 rs1481336 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125056685 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs12537473 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124946657 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs10954053 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124946761 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs13233978 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124947566 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs34555990 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124947790 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs28817916 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124948496 chr7:124929873~125179315:+ LIHC cis rs4731207 0.57 rs10954055 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124949178 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs12113765 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124949630 chr7:124929873~125179315:+ LIHC cis rs4731207 0.591 rs11772336 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124949742 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6961441 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124950817 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6971413 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124952614 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs6466970 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124952701 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs2127971 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124955255 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs6466972 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124956195 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10239507 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124956731 chr7:124929873~125179315:+ LIHC cis rs4731207 0.535 rs28820311 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124958935 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs7777126 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124959688 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs10954056 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124960480 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs12538641 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124960617 chr7:124929873~125179315:+ LIHC cis rs4731207 0.536 rs13307657 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124960810 chr7:124929873~125179315:+ LIHC cis rs4731207 0.535 rs7806126 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124961821 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs10260039 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124963492 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs12531844 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124963846 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs922711 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124964250 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs11980178 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124964606 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs1011721 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124965105 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1011722 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124965153 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1011723 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124965207 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6466973 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124965372 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs922712 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124966996 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs922713 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124967005 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10276834 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:124967495 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7794538 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125008796 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs10270051 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125009339 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10274384 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125010383 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs7811203 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125013320 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10500098 ENSG00000224897.5 POT1-AS1 5.2 3.39e-07 0.00014 0.33 0.27 Cutaneous malignant melanoma; chr7:125018001 chr7:124929873~125179315:+ LIHC cis rs2836974 0.568 rs2836969 ENSG00000255568.3 BRWD1-AS2 -5.2 3.39e-07 0.00014 -0.23 -0.27 Cognitive function; chr21:39276339 chr21:39313935~39314962:+ LIHC cis rs2836974 0.584 rs6517535 ENSG00000255568.3 BRWD1-AS2 -5.2 3.39e-07 0.00014 -0.23 -0.27 Cognitive function; chr21:39281426 chr21:39313935~39314962:+ LIHC cis rs2836974 0.627 rs7278985 ENSG00000255568.3 BRWD1-AS2 -5.2 3.39e-07 0.00014 -0.23 -0.27 Cognitive function; chr21:39281841 chr21:39313935~39314962:+ LIHC cis rs4713118 0.513 rs149878 ENSG00000216901.1 AL022393.7 5.2 3.39e-07 0.00014 0.33 0.27 Parkinson's disease; chr6:27910960 chr6:28176188~28176674:+ LIHC cis rs7945705 0.967 rs10840147 ENSG00000254860.4 TMEM9B-AS1 -5.2 3.4e-07 0.000141 -0.27 -0.27 Hemoglobin concentration; chr11:8899157 chr11:8964675~8977527:+ LIHC cis rs11098499 0.955 rs6815725 ENSG00000245958.5 RP11-33B1.1 -5.2 3.41e-07 0.000141 -0.29 -0.27 Corneal astigmatism; chr4:119237255 chr4:119454791~119552025:+ LIHC cis rs11098499 0.955 rs1551 ENSG00000245958.5 RP11-33B1.1 -5.2 3.41e-07 0.000141 -0.29 -0.27 Corneal astigmatism; chr4:119237345 chr4:119454791~119552025:+ LIHC cis rs11098499 0.955 rs11931312 ENSG00000245958.5 RP11-33B1.1 -5.2 3.41e-07 0.000141 -0.29 -0.27 Corneal astigmatism; chr4:119237868 chr4:119454791~119552025:+ LIHC cis rs5758511 0.596 rs55644935 ENSG00000237037.8 NDUFA6-AS1 -5.2 3.41e-07 0.000141 -0.34 -0.27 Birth weight; chr22:42270063 chr22:42090931~42137742:+ LIHC cis rs4356203 0.875 rs680205 ENSG00000272034.1 SNORD14A -5.2 3.41e-07 0.000141 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17186210 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs536628 ENSG00000272034.1 SNORD14A -5.2 3.41e-07 0.000141 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17186545 chr11:17074654~17074744:- LIHC cis rs4731207 0.596 rs10280341 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:124943881 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs12111658 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:124944714 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs12111660 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:124944741 chr7:124929873~125179315:+ LIHC cis rs4731207 0.569 rs1600746 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:124945041 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1600745 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:124945129 chr7:124929873~125179315:+ LIHC cis rs4731207 0.623 rs1600744 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:124945906 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7779594 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:124996941 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs11767737 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:124997851 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1531715 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:124998153 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1531716 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:124998484 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1552119 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:124998822 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs13231916 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:125000171 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs11763920 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:125000826 chr7:124929873~125179315:+ LIHC cis rs4731207 0.569 rs1986124 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:125001663 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1531717 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:125004636 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7810120 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:125004891 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7778875 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:125005392 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs12538171 ENSG00000224897.5 POT1-AS1 5.2 3.42e-07 0.000141 0.33 0.27 Cutaneous malignant melanoma; chr7:125005516 chr7:124929873~125179315:+ LIHC cis rs9640161 0.789 rs2373751 ENSG00000261305.1 RP4-584D14.7 5.2 3.42e-07 0.000141 0.35 0.27 Blood protein levels;Circulating chemerin levels; chr7:150324510 chr7:150341771~150342607:+ LIHC cis rs9640161 0.636 rs56190213 ENSG00000261305.1 RP4-584D14.7 5.2 3.42e-07 0.000141 0.35 0.27 Blood protein levels;Circulating chemerin levels; chr7:150328631 chr7:150341771~150342607:+ LIHC cis rs10510102 0.935 rs7923634 ENSG00000226864.1 ATE1-AS1 5.2 3.42e-07 0.000142 0.43 0.27 Breast cancer; chr10:121832800 chr10:121928312~121951965:+ LIHC cis rs7945705 0.902 rs10743093 ENSG00000254860.4 TMEM9B-AS1 -5.2 3.42e-07 0.000142 -0.28 -0.27 Hemoglobin concentration; chr11:8847582 chr11:8964675~8977527:+ LIHC cis rs1577917 1 rs12192992 ENSG00000234155.1 RP11-30P6.6 5.2 3.42e-07 0.000142 0.36 0.27 Response to antipsychotic treatment; chr6:85900197 chr6:85387219~85390186:- LIHC cis rs8028182 0.549 rs10775209 ENSG00000260269.4 CTD-2323K18.1 5.2 3.42e-07 0.000142 0.35 0.27 Sudden cardiac arrest; chr15:75342418 chr15:75527150~75601205:- LIHC cis rs2836950 0.805 rs2836961 ENSG00000255568.3 BRWD1-AS2 -5.2 3.43e-07 0.000142 -0.24 -0.27 Menarche (age at onset); chr21:39255094 chr21:39313935~39314962:+ LIHC cis rs4731207 0.698 rs2040926 ENSG00000224897.5 POT1-AS1 5.2 3.43e-07 0.000142 0.32 0.27 Cutaneous malignant melanoma; chr7:124817241 chr7:124929873~125179315:+ LIHC cis rs11098499 0.908 rs28559989 ENSG00000245958.5 RP11-33B1.1 -5.2 3.45e-07 0.000142 -0.28 -0.27 Corneal astigmatism; chr4:119465472 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs28632018 ENSG00000245958.5 RP11-33B1.1 -5.2 3.45e-07 0.000142 -0.28 -0.27 Corneal astigmatism; chr4:119465575 chr4:119454791~119552025:+ LIHC cis rs7688540 0.771 rs11723615 ENSG00000275426.1 CH17-262A2.1 5.2 3.45e-07 0.000143 0.35 0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:283194 chr4:149738~150317:+ LIHC cis rs11098499 0.697 rs11941899 ENSG00000245958.5 RP11-33B1.1 -5.2 3.45e-07 0.000143 -0.28 -0.27 Corneal astigmatism; chr4:119461603 chr4:119454791~119552025:+ LIHC cis rs11098499 0.821 rs28665282 ENSG00000245958.5 RP11-33B1.1 -5.2 3.45e-07 0.000143 -0.28 -0.27 Corneal astigmatism; chr4:119463031 chr4:119454791~119552025:+ LIHC cis rs11098499 0.738 rs10026493 ENSG00000245958.5 RP11-33B1.1 -5.2 3.45e-07 0.000143 -0.28 -0.27 Corneal astigmatism; chr4:119463039 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs7681214 ENSG00000245958.5 RP11-33B1.1 -5.2 3.45e-07 0.000143 -0.28 -0.27 Corneal astigmatism; chr4:119464165 chr4:119454791~119552025:+ LIHC cis rs11098499 0.908 rs71614449 ENSG00000245958.5 RP11-33B1.1 -5.2 3.45e-07 0.000143 -0.28 -0.27 Corneal astigmatism; chr4:119465900 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs35063680 ENSG00000245958.5 RP11-33B1.1 -5.2 3.45e-07 0.000143 -0.28 -0.27 Corneal astigmatism; chr4:119465947 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs34858317 ENSG00000245958.5 RP11-33B1.1 -5.2 3.45e-07 0.000143 -0.28 -0.27 Corneal astigmatism; chr4:119465955 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs17046116 ENSG00000245958.5 RP11-33B1.1 -5.2 3.45e-07 0.000143 -0.28 -0.27 Corneal astigmatism; chr4:119466104 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs17046118 ENSG00000245958.5 RP11-33B1.1 -5.2 3.45e-07 0.000143 -0.28 -0.27 Corneal astigmatism; chr4:119466341 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs7654587 ENSG00000245958.5 RP11-33B1.1 -5.2 3.45e-07 0.000143 -0.28 -0.27 Corneal astigmatism; chr4:119467251 chr4:119454791~119552025:+ LIHC cis rs950169 0.881 rs150965 ENSG00000259295.5 CSPG4P12 5.2 3.45e-07 0.000143 0.37 0.27 Schizophrenia; chr15:84537296 chr15:85191438~85213905:+ LIHC cis rs9326248 0.53 rs6589576 ENSG00000280143.1 AP000892.6 -5.2 3.45e-07 0.000143 -0.34 -0.27 Blood protein levels; chr11:116865072 chr11:117204967~117210292:+ LIHC cis rs875971 0.545 rs10950029 ENSG00000237310.1 GS1-124K5.4 5.2 3.46e-07 0.000143 0.25 0.27 Aortic root size; chr7:66169334 chr7:66493706~66495474:+ LIHC cis rs1150668 0.835 rs203869 ENSG00000204709.4 LINC01556 5.2 3.46e-07 0.000143 0.3 0.27 Pubertal anthropometrics; chr6:28073041 chr6:28943877~28944537:+ LIHC cis rs10129255 0.957 rs6576228 ENSG00000223648.3 IGHV3-64 5.2 3.46e-07 0.000143 0.2 0.27 Kawasaki disease; chr14:106778401 chr14:106643132~106658258:- LIHC cis rs1577917 0.958 rs10944137 ENSG00000234155.1 RP11-30P6.6 5.2 3.47e-07 0.000143 0.36 0.27 Response to antipsychotic treatment; chr6:85744596 chr6:85387219~85390186:- LIHC cis rs36715 0.951 rs36698 ENSG00000245937.6 LINC01184 5.2 3.47e-07 0.000143 0.33 0.27 Breast cancer; chr5:128214057 chr5:127940426~128083172:- LIHC cis rs5758511 0.68 rs5758651 ENSG00000237037.8 NDUFA6-AS1 -5.2 3.47e-07 0.000143 -0.34 -0.27 Birth weight; chr22:42213142 chr22:42090931~42137742:+ LIHC cis rs5758511 0.68 rs5758652 ENSG00000237037.8 NDUFA6-AS1 -5.2 3.47e-07 0.000143 -0.34 -0.27 Birth weight; chr22:42216402 chr22:42090931~42137742:+ LIHC cis rs12908161 0.92 rs12904605 ENSG00000259295.5 CSPG4P12 5.2 3.47e-07 0.000144 0.38 0.27 Schizophrenia; chr15:84658188 chr15:85191438~85213905:+ LIHC cis rs4356203 0.905 rs10832733 ENSG00000272034.1 SNORD14A -5.2 3.49e-07 0.000144 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17089725 chr11:17074654~17074744:- LIHC cis rs11690935 1 rs312925 ENSG00000228389.1 AC068039.4 5.2 3.49e-07 0.000144 0.36 0.27 Schizophrenia; chr2:171707412 chr2:171773482~171775844:+ LIHC cis rs11690935 0.694 rs312921 ENSG00000228389.1 AC068039.4 5.2 3.49e-07 0.000144 0.36 0.27 Schizophrenia; chr2:171710715 chr2:171773482~171775844:+ LIHC cis rs950169 0.84 rs2896002 ENSG00000225151.9 GOLGA2P7 -5.2 3.49e-07 0.000144 -0.34 -0.27 Schizophrenia; chr15:84390423 chr15:84199311~84230136:- LIHC cis rs950169 0.887 rs3860265 ENSG00000225151.9 GOLGA2P7 -5.2 3.49e-07 0.000144 -0.34 -0.27 Schizophrenia; chr15:84390487 chr15:84199311~84230136:- LIHC cis rs950169 0.724 rs11632668 ENSG00000225151.9 GOLGA2P7 -5.2 3.49e-07 0.000144 -0.34 -0.27 Schizophrenia; chr15:84393989 chr15:84199311~84230136:- LIHC cis rs950169 0.881 rs34591918 ENSG00000225151.9 GOLGA2P7 -5.2 3.49e-07 0.000144 -0.34 -0.27 Schizophrenia; chr15:84396135 chr15:84199311~84230136:- LIHC cis rs1061377 0.748 rs35904472 ENSG00000249685.1 RP11-360F5.3 5.2 3.5e-07 0.000144 0.33 0.27 Uric acid levels; chr4:39094901 chr4:39133913~39135608:+ LIHC cis rs12134133 0.752 rs6540874 ENSG00000274245.1 RP11-357P18.2 5.2 3.5e-07 0.000145 0.41 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207221638 chr1:207372559~207373252:+ LIHC cis rs5769765 0.955 rs5770750 ENSG00000278869.1 CITF22-49E9.3 -5.2 3.5e-07 0.000145 -0.4 -0.27 Schizophrenia; chr22:49883180 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs910800 ENSG00000278869.1 CITF22-49E9.3 -5.2 3.5e-07 0.000145 -0.4 -0.27 Schizophrenia; chr22:49884994 chr22:49933198~49934074:- LIHC cis rs5769765 0.874 rs4624 ENSG00000278869.1 CITF22-49E9.3 -5.2 3.5e-07 0.000145 -0.4 -0.27 Schizophrenia; chr22:49888269 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs2092982 ENSG00000278869.1 CITF22-49E9.3 -5.2 3.5e-07 0.000145 -0.4 -0.27 Schizophrenia; chr22:49888556 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs738711 ENSG00000278869.1 CITF22-49E9.3 -5.2 3.5e-07 0.000145 -0.4 -0.27 Schizophrenia; chr22:49888955 chr22:49933198~49934074:- LIHC cis rs10510102 0.935 rs7098562 ENSG00000226864.1 ATE1-AS1 5.2 3.51e-07 0.000145 0.42 0.27 Breast cancer; chr10:121902148 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs7098822 ENSG00000226864.1 ATE1-AS1 5.2 3.51e-07 0.000145 0.42 0.27 Breast cancer; chr10:121902157 chr10:121928312~121951965:+ LIHC cis rs4731207 0.735 rs12155120 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124838178 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs12154816 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124838245 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10269011 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124838759 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs12666427 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124839298 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs34014883 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124840523 chr7:124929873~125179315:+ LIHC cis rs4731207 0.672 rs3213667 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124840815 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs3815221 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124841191 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4728010 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124841366 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4731222 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124841581 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4728011 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124841658 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4728012 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124841744 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs11980925 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124843653 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10085793 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124844112 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs2079368 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124845257 chr7:124929873~125179315:+ LIHC cis rs4731207 0.671 rs10085867 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124846114 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10085888 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124846337 chr7:124929873~125179315:+ LIHC cis rs712039 0.652 rs7226252 ENSG00000276054.1 RP11-378E13.3 5.2 3.51e-07 0.000145 0.33 0.27 Tuberculosis; chr17:37434812 chr17:37386886~37387926:+ LIHC cis rs712039 0.652 rs67879888 ENSG00000276054.1 RP11-378E13.3 5.2 3.51e-07 0.000145 0.33 0.27 Tuberculosis; chr17:37435211 chr17:37386886~37387926:+ LIHC cis rs6479901 0.841 rs10995453 ENSG00000232075.1 MRPL35P2 -5.2 3.51e-07 0.000145 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63174571 chr10:63634317~63634827:- LIHC cis rs4731207 0.596 rs10081375 ENSG00000224897.5 POT1-AS1 5.2 3.51e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124933121 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs13228116 ENSG00000224897.5 POT1-AS1 -5.2 3.51e-07 0.000145 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124840452 chr7:124929873~125179315:+ LIHC cis rs5769765 0.865 rs3788730 ENSG00000278869.1 CITF22-49E9.3 -5.2 3.52e-07 0.000145 -0.4 -0.27 Schizophrenia; chr22:49851047 chr22:49933198~49934074:- LIHC cis rs13068223 1 rs13068223 ENSG00000243926.1 TIPARP-AS1 5.2 3.52e-07 0.000145 0.26 0.27 Age-related hearing impairment (SNP x SNP interaction); chr3:156753166 chr3:156671862~156674378:- LIHC cis rs1577917 0.917 rs35738006 ENSG00000234155.1 RP11-30P6.6 5.2 3.52e-07 0.000145 0.36 0.27 Response to antipsychotic treatment; chr6:85936591 chr6:85387219~85390186:- LIHC cis rs950776 0.752 rs62010328 ENSG00000261762.1 RP11-650L12.2 5.2 3.52e-07 0.000145 0.34 0.27 Sudden cardiac arrest; chr15:78602629 chr15:78589123~78591276:- LIHC cis rs9326248 0.906 rs171052 ENSG00000236267.1 AP006216.5 -5.2 3.52e-07 0.000145 -0.28 -0.27 Blood protein levels; chr11:117211047 chr11:116813204~116814003:- LIHC cis rs2842992 0.789 rs2475566 ENSG00000237927.1 RP3-393E18.2 -5.2 3.52e-07 0.000145 -0.33 -0.27 Age-related macular degeneration (geographic atrophy); chr6:159727709 chr6:159586955~159589169:- LIHC cis rs950776 0.684 rs61012457 ENSG00000261762.1 RP11-650L12.2 5.19 3.53e-07 0.000145 0.35 0.27 Sudden cardiac arrest; chr15:78573352 chr15:78589123~78591276:- LIHC cis rs228614 0.534 rs223387 ENSG00000230069.3 LRRC37A15P -5.19 3.53e-07 0.000145 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102828359 chr4:102727274~102730721:- LIHC cis rs4731207 0.596 rs6466963 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124932234 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs6466964 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124932346 chr7:124929873~125179315:+ LIHC cis rs4731207 0.623 rs12706629 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124933991 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10231491 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124934037 chr7:124929873~125179315:+ LIHC cis rs4731207 0.535 rs11769711 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124934870 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10081290 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124935454 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10081226 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124935475 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs7780392 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124935601 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10272889 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124936587 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1481332 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124937208 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7786384 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124937216 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1481331 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124937271 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10954050 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124937847 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7790975 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124937890 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7791399 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124937918 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7795605 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124938393 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7795611 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124938402 chr7:124929873~125179315:+ LIHC cis rs4731207 0.505 rs7795233 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124938414 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10252072 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124938582 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10954051 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124939182 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs11981797 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124939397 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1383751 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124939667 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6466965 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124939672 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs2402756 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124939728 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1994023 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124940616 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs1994022 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124940823 chr7:124929873~125179315:+ LIHC cis rs4731207 0.619 rs4461840 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124941011 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10231355 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124941164 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs10279816 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124941526 chr7:124929873~125179315:+ LIHC cis rs4731207 0.533 rs1481340 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124941997 chr7:124929873~125179315:+ LIHC cis rs2267708 0.506 rs1842616 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Chronic lymphocytic leukemia; chr7:124942118 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1842615 ENSG00000224897.5 POT1-AS1 5.19 3.53e-07 0.000145 0.32 0.27 Cutaneous malignant melanoma; chr7:124942817 chr7:124929873~125179315:+ LIHC cis rs7586673 0.93 rs6432667 ENSG00000227403.1 AC009299.3 -5.19 3.53e-07 0.000146 -0.33 -0.27 Intelligence (multi-trait analysis); chr2:161048490 chr2:161244739~161249050:+ LIHC cis rs4639966 0.589 rs480958 ENSG00000255422.1 AP002954.4 -5.19 3.53e-07 0.000146 -0.32 -0.27 Systemic lupus erythematosus; chr11:118707281 chr11:118704607~118750263:+ LIHC cis rs7714584 1 rs61530785 ENSG00000197083.10 ZNF300P1 5.19 3.54e-07 0.000146 0.43 0.27 Crohn's disease; chr5:150881802 chr5:150930645~150946289:- LIHC cis rs11722779 0.903 rs13130741 ENSG00000230069.3 LRRC37A15P -5.19 3.54e-07 0.000146 -0.25 -0.27 Schizophrenia; chr4:103035799 chr4:102727274~102730721:- LIHC cis rs6479901 0.557 rs12773283 ENSG00000232075.1 MRPL35P2 -5.19 3.54e-07 0.000146 -0.31 -0.27 Intelligence (multi-trait analysis); chr10:63298464 chr10:63634317~63634827:- LIHC cis rs6479901 0.895 rs7918743 ENSG00000232075.1 MRPL35P2 -5.19 3.54e-07 0.000146 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63333302 chr10:63634317~63634827:- LIHC cis rs641862 1 rs641862 ENSG00000229152.2 ANKRD10-IT1 5.19 3.55e-07 0.000146 0.34 0.27 Obesity-related traits; chr13:110137885 chr13:110894639~110899172:- LIHC cis rs4731207 0.698 rs4731217 ENSG00000224897.5 POT1-AS1 -5.19 3.55e-07 0.000146 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124831835 chr7:124929873~125179315:+ LIHC cis rs4660214 0.614 rs6688708 ENSG00000182109.6 RP11-69E11.4 -5.19 3.55e-07 0.000146 -0.28 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39293321 chr1:39522280~39546187:- LIHC cis rs227275 0.525 rs4699046 ENSG00000230069.3 LRRC37A15P -5.19 3.55e-07 0.000146 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:103004514 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs4699047 ENSG00000230069.3 LRRC37A15P -5.19 3.55e-07 0.000146 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:103005385 chr4:102727274~102730721:- LIHC cis rs950169 0.922 rs2033284 ENSG00000259295.5 CSPG4P12 5.19 3.55e-07 0.000146 0.37 0.27 Schizophrenia; chr15:84391575 chr15:85191438~85213905:+ LIHC cis rs10129255 0.957 rs8014696 ENSG00000223648.3 IGHV3-64 -5.19 3.56e-07 0.000146 -0.21 -0.27 Kawasaki disease; chr14:106769752 chr14:106643132~106658258:- LIHC cis rs4731207 0.596 rs10264766 ENSG00000224897.5 POT1-AS1 5.19 3.56e-07 0.000146 0.33 0.27 Cutaneous malignant melanoma; chr7:124932862 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6971179 ENSG00000224897.5 POT1-AS1 5.19 3.56e-07 0.000146 0.33 0.27 Cutaneous malignant melanoma; chr7:124952297 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10247349 ENSG00000224897.5 POT1-AS1 5.19 3.56e-07 0.000146 0.33 0.27 Cutaneous malignant melanoma; chr7:124967441 chr7:124929873~125179315:+ LIHC cis rs875971 0.545 rs73142245 ENSG00000273142.1 RP11-458F8.4 5.19 3.56e-07 0.000147 0.26 0.27 Aortic root size; chr7:66226662 chr7:66902857~66906297:+ LIHC cis rs9487094 0.813 rs34320275 ENSG00000260273.1 RP11-425D10.10 5.19 3.57e-07 0.000147 0.39 0.27 Height; chr6:109436760 chr6:109382795~109383666:+ LIHC cis rs5769707 0.967 rs4524218 ENSG00000235111.1 RP1-29C18.8 -5.19 3.57e-07 0.000147 -0.31 -0.27 Monocyte percentage of white cells;Monocyte count; chr22:49624991 chr22:49612657~49615716:- LIHC cis rs1061377 0.748 rs10856841 ENSG00000249207.1 RP11-360F5.1 -5.19 3.57e-07 0.000147 -0.28 -0.27 Uric acid levels; chr4:39095240 chr4:39112677~39126818:- LIHC cis rs5769707 0.935 rs5770594 ENSG00000235111.1 RP1-29C18.8 -5.19 3.57e-07 0.000147 -0.31 -0.27 Monocyte percentage of white cells;Monocyte count; chr22:49624849 chr22:49612657~49615716:- LIHC cis rs2267708 0.509 rs6959972 ENSG00000224897.5 POT1-AS1 5.19 3.57e-07 0.000147 0.33 0.27 Chronic lymphocytic leukemia; chr7:124977054 chr7:124929873~125179315:+ LIHC cis rs12468226 0.873 rs60722019 ENSG00000273456.1 RP11-686O6.2 5.19 3.57e-07 0.000147 0.39 0.27 Urate levels; chr2:202282060 chr2:202374932~202375604:- LIHC cis rs72627509 0.904 rs12645070 ENSG00000269949.1 RP11-738E22.3 5.19 3.57e-07 0.000147 0.36 0.27 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56903940 chr4:56960927~56961373:- LIHC cis rs4731207 0.672 rs66823127 ENSG00000224897.5 POT1-AS1 -5.19 3.58e-07 0.000147 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124832275 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10250911 ENSG00000224897.5 POT1-AS1 -5.19 3.58e-07 0.000147 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124832980 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs2896361 ENSG00000224897.5 POT1-AS1 -5.19 3.58e-07 0.000147 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124833771 chr7:124929873~125179315:+ LIHC cis rs6589219 0.721 rs7944895 ENSG00000196167.8 COLCA1 -5.19 3.58e-07 0.000147 -0.29 -0.27 Colorectal cancer; chr11:111297051 chr11:111290787~111305045:- LIHC cis rs992157 0.764 rs2382827 ENSG00000261338.2 RP11-378A13.1 5.19 3.58e-07 0.000147 0.29 0.27 Colorectal cancer; chr2:218319664 chr2:218255319~218257366:+ LIHC cis rs992157 0.764 rs2891076 ENSG00000261338.2 RP11-378A13.1 5.19 3.58e-07 0.000147 0.29 0.27 Colorectal cancer; chr2:218319675 chr2:218255319~218257366:+ LIHC cis rs992157 0.764 rs2891077 ENSG00000261338.2 RP11-378A13.1 5.19 3.58e-07 0.000147 0.29 0.27 Colorectal cancer; chr2:218319707 chr2:218255319~218257366:+ LIHC cis rs992157 0.73 rs2891078 ENSG00000261338.2 RP11-378A13.1 5.19 3.58e-07 0.000147 0.29 0.27 Colorectal cancer; chr2:218319709 chr2:218255319~218257366:+ LIHC cis rs4731207 0.672 rs11983251 ENSG00000224897.5 POT1-AS1 -5.19 3.58e-07 0.000147 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124819871 chr7:124929873~125179315:+ LIHC cis rs5769765 0.825 rs7511620 ENSG00000278869.1 CITF22-49E9.3 5.19 3.58e-07 0.000147 0.44 0.27 Schizophrenia; chr22:49914284 chr22:49933198~49934074:- LIHC cis rs4731207 0.564 rs2127972 ENSG00000224897.5 POT1-AS1 5.19 3.58e-07 0.000147 0.33 0.27 Cutaneous malignant melanoma; chr7:125025491 chr7:124929873~125179315:+ LIHC cis rs950169 0.881 rs34117475 ENSG00000259295.5 CSPG4P12 5.19 3.59e-07 0.000147 0.37 0.27 Schizophrenia; chr15:84565212 chr15:85191438~85213905:+ LIHC cis rs1150668 0.799 rs2142730 ENSG00000204709.4 LINC01556 5.19 3.59e-07 0.000148 0.3 0.27 Pubertal anthropometrics; chr6:28298372 chr6:28943877~28944537:+ LIHC cis rs9291683 0.588 rs3733586 ENSG00000250413.1 RP11-448G15.1 -5.19 3.59e-07 0.000148 -0.34 -0.27 Bone mineral density; chr4:9995910 chr4:10006482~10009725:+ LIHC cis rs8059260 0.604 rs8052325 ENSG00000274038.1 RP11-66H6.4 -5.19 3.59e-07 0.000148 -0.44 -0.27 Alcohol consumption over the past year; chr16:11044121 chr16:11056556~11057034:+ LIHC cis rs10510102 1 rs10886994 ENSG00000226864.1 ATE1-AS1 5.19 3.6e-07 0.000148 0.44 0.27 Breast cancer; chr10:121841075 chr10:121928312~121951965:+ LIHC cis rs12680842 0.883 rs13265241 ENSG00000253704.1 RP11-267M23.4 5.19 3.6e-07 0.000148 0.31 0.27 Body mass index; chr8:94575129 chr8:94553722~94569745:+ LIHC cis rs6479901 0.895 rs1904296 ENSG00000232075.1 MRPL35P2 -5.19 3.6e-07 0.000148 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63173019 chr10:63634317~63634827:- LIHC cis rs950169 0.881 rs4842852 ENSG00000259295.5 CSPG4P12 5.19 3.6e-07 0.000148 0.36 0.27 Schizophrenia; chr15:84387263 chr15:85191438~85213905:+ LIHC cis rs950169 0.84 rs4842853 ENSG00000259295.5 CSPG4P12 5.19 3.6e-07 0.000148 0.36 0.27 Schizophrenia; chr15:84387606 chr15:85191438~85213905:+ LIHC cis rs950169 0.922 rs4842946 ENSG00000259295.5 CSPG4P12 5.19 3.6e-07 0.000148 0.36 0.27 Schizophrenia; chr15:84387633 chr15:85191438~85213905:+ LIHC cis rs950169 0.84 rs4842854 ENSG00000259295.5 CSPG4P12 5.19 3.6e-07 0.000148 0.36 0.27 Schizophrenia; chr15:84387641 chr15:85191438~85213905:+ LIHC cis rs12682352 0.535 rs12677550 ENSG00000173295.6 FAM86B3P -5.19 3.61e-07 0.000148 -0.36 -0.27 Neuroticism; chr8:8786812 chr8:8228595~8244865:+ LIHC cis rs3096299 0.658 rs3934737 ENSG00000261118.1 RP11-104N10.1 5.19 3.61e-07 0.000148 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89493801 chr16:89492017~89504460:- LIHC cis rs5769765 0.74 rs2103932 ENSG00000278869.1 CITF22-49E9.3 -5.19 3.61e-07 0.000148 -0.4 -0.27 Schizophrenia; chr22:49878867 chr22:49933198~49934074:- LIHC cis rs3096299 0.503 rs4785677 ENSG00000261118.1 RP11-104N10.1 5.19 3.62e-07 0.000149 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89488693 chr16:89492017~89504460:- LIHC cis rs4731207 0.724 rs10257255 ENSG00000224897.5 POT1-AS1 -5.19 3.62e-07 0.000149 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124839624 chr7:124929873~125179315:+ LIHC cis rs4731207 0.671 rs4731221 ENSG00000224897.5 POT1-AS1 -5.19 3.62e-07 0.000149 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124841349 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4731223 ENSG00000224897.5 POT1-AS1 -5.19 3.62e-07 0.000149 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124843218 chr7:124929873~125179315:+ LIHC cis rs172166 0.516 rs2622322 ENSG00000204709.4 LINC01556 5.19 3.62e-07 0.000149 0.3 0.27 Cardiac Troponin-T levels; chr6:28149665 chr6:28943877~28944537:+ LIHC cis rs17023223 0.537 rs12092807 ENSG00000231365.4 RP11-418J17.1 5.19 3.63e-07 0.000149 0.34 0.27 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119208021 chr1:119140396~119275973:+ LIHC cis rs524281 0.861 rs11227426 ENSG00000255320.1 RP11-755F10.1 5.19 3.63e-07 0.000149 0.34 0.27 Electroencephalogram traits; chr11:66204480 chr11:66244840~66246239:- LIHC cis rs950169 0.84 rs2896002 ENSG00000259295.5 CSPG4P12 5.19 3.63e-07 0.000149 0.36 0.27 Schizophrenia; chr15:84390423 chr15:85191438~85213905:+ LIHC cis rs950169 0.887 rs3860265 ENSG00000259295.5 CSPG4P12 5.19 3.63e-07 0.000149 0.36 0.27 Schizophrenia; chr15:84390487 chr15:85191438~85213905:+ LIHC cis rs950169 0.724 rs11632668 ENSG00000259295.5 CSPG4P12 5.19 3.63e-07 0.000149 0.36 0.27 Schizophrenia; chr15:84393989 chr15:85191438~85213905:+ LIHC cis rs950169 0.881 rs34591918 ENSG00000259295.5 CSPG4P12 5.19 3.63e-07 0.000149 0.36 0.27 Schizophrenia; chr15:84396135 chr15:85191438~85213905:+ LIHC cis rs2153535 0.584 rs9502721 ENSG00000230939.1 RP11-314C16.1 -5.19 3.63e-07 0.000149 -0.34 -0.27 Motion sickness; chr6:8541146 chr6:8784178~8785445:+ LIHC cis rs2153535 0.607 rs9502722 ENSG00000230939.1 RP11-314C16.1 -5.19 3.63e-07 0.000149 -0.34 -0.27 Motion sickness; chr6:8541250 chr6:8784178~8785445:+ LIHC cis rs75920871 0.589 rs7941150 ENSG00000254851.1 RP11-109L13.1 -5.19 3.63e-07 0.000149 -0.53 -0.27 Subjective well-being; chr11:117221105 chr11:117135528~117138582:+ LIHC cis rs875971 0.522 rs1701760 ENSG00000164669.11 INTS4P1 -5.19 3.63e-07 0.000149 -0.38 -0.27 Aortic root size; chr7:66008701 chr7:65141225~65234216:+ LIHC cis rs858239 0.665 rs858306 ENSG00000226816.2 AC005082.12 5.19 3.64e-07 0.00015 0.36 0.27 Cerebrospinal fluid biomarker levels; chr7:23203135 chr7:23206013~23208045:+ LIHC cis rs2836974 0.605 rs2836971 ENSG00000255568.3 BRWD1-AS2 -5.19 3.64e-07 0.00015 -0.23 -0.27 Cognitive function; chr21:39280114 chr21:39313935~39314962:+ LIHC cis rs9467711 0.538 rs36012762 ENSG00000216436.2 HIST1H2APS1 5.19 3.65e-07 0.00015 0.66 0.27 Autism spectrum disorder or schizophrenia; chr6:25980295 chr6:25732497~25732827:+ LIHC cis rs9467711 0.591 rs13192365 ENSG00000216436.2 HIST1H2APS1 5.19 3.65e-07 0.00015 0.66 0.27 Autism spectrum disorder or schizophrenia; chr6:25993740 chr6:25732497~25732827:+ LIHC cis rs9467711 0.591 rs35528636 ENSG00000216436.2 HIST1H2APS1 5.19 3.65e-07 0.00015 0.66 0.27 Autism spectrum disorder or schizophrenia; chr6:25995473 chr6:25732497~25732827:+ LIHC cis rs6061231 0.556 rs6121571 ENSG00000273619.1 RP5-908M14.9 -5.19 3.65e-07 0.00015 -0.24 -0.27 Colorectal cancer; chr20:62402267 chr20:62386303~62386970:- LIHC cis rs1577917 0.958 rs2225754 ENSG00000234155.1 RP11-30P6.6 5.19 3.65e-07 0.00015 0.35 0.27 Response to antipsychotic treatment; chr6:85739980 chr6:85387219~85390186:- LIHC cis rs4731207 0.596 rs12113770 ENSG00000224897.5 POT1-AS1 5.19 3.65e-07 0.00015 0.33 0.27 Cutaneous malignant melanoma; chr7:124949686 chr7:124929873~125179315:+ LIHC cis rs4731207 0.537 rs6466974 ENSG00000224897.5 POT1-AS1 5.19 3.65e-07 0.00015 0.33 0.27 Cutaneous malignant melanoma; chr7:124969456 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10264210 ENSG00000224897.5 POT1-AS1 5.19 3.65e-07 0.00015 0.33 0.27 Cutaneous malignant melanoma; chr7:124971540 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1031956 ENSG00000224897.5 POT1-AS1 5.19 3.65e-07 0.00015 0.33 0.27 Cutaneous malignant melanoma; chr7:124987129 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs1031959 ENSG00000224897.5 POT1-AS1 5.19 3.65e-07 0.00015 0.33 0.27 Cutaneous malignant melanoma; chr7:124987259 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs1552118 ENSG00000224897.5 POT1-AS1 5.19 3.65e-07 0.00015 0.33 0.27 Cutaneous malignant melanoma; chr7:124988804 chr7:124929873~125179315:+ LIHC cis rs2836974 0.644 rs719230 ENSG00000255568.3 BRWD1-AS2 -5.19 3.65e-07 0.00015 -0.23 -0.27 Cognitive function; chr21:39304381 chr21:39313935~39314962:+ LIHC cis rs10129255 0.912 rs6576227 ENSG00000223648.3 IGHV3-64 5.19 3.65e-07 0.00015 0.2 0.27 Kawasaki disease; chr14:106778202 chr14:106643132~106658258:- LIHC cis rs875971 0.862 rs801195 ENSG00000237310.1 GS1-124K5.4 -5.19 3.66e-07 0.00015 -0.23 -0.27 Aortic root size; chr7:66561128 chr7:66493706~66495474:+ LIHC cis rs5758511 0.68 rs5758688 ENSG00000237037.8 NDUFA6-AS1 -5.19 3.66e-07 0.00015 -0.34 -0.27 Birth weight; chr22:42266495 chr22:42090931~42137742:+ LIHC cis rs904251 0.797 rs1776460 ENSG00000204110.6 RP1-153P14.8 -5.19 3.66e-07 0.00015 -0.34 -0.27 Cognitive performance; chr6:37517708 chr6:37507348~37535616:+ LIHC cis rs9291683 0.588 rs12506364 ENSG00000250413.1 RP11-448G15.1 -5.19 3.66e-07 0.00015 -0.34 -0.27 Bone mineral density; chr4:10021824 chr4:10006482~10009725:+ LIHC cis rs227275 0.525 rs13117110 ENSG00000230069.3 LRRC37A15P -5.19 3.67e-07 0.000151 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:103003981 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs13144033 ENSG00000230069.3 LRRC37A15P -5.19 3.67e-07 0.000151 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:103004032 chr4:102727274~102730721:- LIHC cis rs1134634 0.52 rs3822298 ENSG00000273133.1 RP11-799M12.2 -5.19 3.68e-07 0.000151 -0.34 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15554780 chr4:15563698~15564253:- LIHC cis rs2836974 0.584 rs7276774 ENSG00000255568.3 BRWD1-AS2 -5.19 3.68e-07 0.000151 -0.23 -0.27 Cognitive function; chr21:39256799 chr21:39313935~39314962:+ LIHC cis rs5769765 0.954 rs6009900 ENSG00000278869.1 CITF22-49E9.3 5.19 3.68e-07 0.000151 0.42 0.27 Schizophrenia; chr22:49842962 chr22:49933198~49934074:- LIHC cis rs6964833 0.935 rs35735900 ENSG00000123965.13 PMS2P5 5.19 3.69e-07 0.000151 0.44 0.27 Menarche (age at onset); chr7:74651887 chr7:74894116~74897835:+ LIHC cis rs2060793 0.741 rs1542291 ENSG00000251991.1 RNU7-49P 5.19 3.69e-07 0.000151 0.3 0.27 Vitamin D levels; chr11:14784720 chr11:14478892~14478953:+ LIHC cis rs875971 0.545 rs4718325 ENSG00000273142.1 RP11-458F8.4 5.19 3.7e-07 0.000151 0.26 0.27 Aortic root size; chr7:66215323 chr7:66902857~66906297:+ LIHC cis rs4356203 0.905 rs7946010 ENSG00000272034.1 SNORD14A 5.19 3.7e-07 0.000151 0.29 0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17154510 chr11:17074654~17074744:- LIHC cis rs16858210 0.874 rs11918588 ENSG00000234371.6 RPSAP31 5.19 3.7e-07 0.000152 0.35 0.27 Menopause (age at onset); chr3:183883927 chr3:183884924~183888449:+ LIHC cis rs10510102 0.935 rs11200183 ENSG00000226864.1 ATE1-AS1 5.19 3.7e-07 0.000152 0.43 0.27 Breast cancer; chr10:121829908 chr10:121928312~121951965:+ LIHC cis rs113835537 0.877 rs2229455 ENSG00000255517.5 CTD-3074O7.5 -5.19 3.7e-07 0.000152 -0.36 -0.27 Airway imaging phenotypes; chr11:66560584 chr11:66473490~66480233:- LIHC cis rs2933343 0.7 rs1683779 ENSG00000231305.3 RP11-723O4.2 5.18 3.71e-07 0.000152 0.3 0.27 IgG glycosylation; chr3:128923205 chr3:128861313~128871540:- LIHC cis rs17826219 0.561 rs562840 ENSG00000266490.1 CTD-2349P21.9 5.18 3.71e-07 0.000152 0.32 0.27 Body mass index; chr17:30622372 chr17:30792372~30792833:+ LIHC cis rs7674212 1 rs7674212 ENSG00000230069.3 LRRC37A15P -5.18 3.72e-07 0.000152 -0.25 -0.27 Type 2 diabetes; chr4:103067742 chr4:102727274~102730721:- LIHC cis rs638893 1 rs649338 ENSG00000255422.1 AP002954.4 -5.18 3.72e-07 0.000152 -0.46 -0.27 Vitiligo; chr11:118834945 chr11:118704607~118750263:+ LIHC cis rs4731207 0.698 rs4728009 ENSG00000224897.5 POT1-AS1 5.18 3.72e-07 0.000152 0.32 0.27 Cutaneous malignant melanoma; chr7:124830907 chr7:124929873~125179315:+ LIHC cis rs9487094 0.744 rs13192476 ENSG00000260273.1 RP11-425D10.10 5.18 3.72e-07 0.000152 0.37 0.27 Height; chr6:109403951 chr6:109382795~109383666:+ LIHC cis rs5769707 0.967 rs2071904 ENSG00000235111.1 RP1-29C18.8 -5.18 3.72e-07 0.000152 -0.31 -0.27 Monocyte percentage of white cells;Monocyte count; chr22:49640829 chr22:49612657~49615716:- LIHC cis rs11098499 1 rs6849889 ENSG00000245958.5 RP11-33B1.1 -5.18 3.72e-07 0.000152 -0.29 -0.27 Corneal astigmatism; chr4:119265193 chr4:119454791~119552025:+ LIHC cis rs2153535 0.505 rs1737583 ENSG00000230939.1 RP11-314C16.1 -5.18 3.73e-07 0.000152 -0.34 -0.27 Motion sickness; chr6:8536579 chr6:8784178~8785445:+ LIHC cis rs2153535 0.563 rs3117071 ENSG00000230939.1 RP11-314C16.1 -5.18 3.73e-07 0.000152 -0.34 -0.27 Motion sickness; chr6:8537675 chr6:8784178~8785445:+ LIHC cis rs4356203 0.905 rs35933265 ENSG00000272034.1 SNORD14A -5.18 3.73e-07 0.000153 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17093707 chr11:17074654~17074744:- LIHC cis rs860295 0.756 rs7546258 ENSG00000203761.5 MSTO2P -5.18 3.73e-07 0.000153 -0.22 -0.27 Body mass index; chr1:155728854 chr1:155745829~155750137:+ LIHC cis rs4965006 0.749 rs6598176 ENSG00000273568.1 RP11-417L19.6 5.18 3.73e-07 0.000153 0.34 0.27 Posterior cortical atrophy and Alzheimer's disease; chr12:131940903 chr12:131934642~131934928:+ LIHC cis rs6921919 0.887 rs16894116 ENSG00000216901.1 AL022393.7 5.18 3.74e-07 0.000153 0.42 0.27 Autism spectrum disorder or schizophrenia; chr6:28447190 chr6:28176188~28176674:+ LIHC cis rs7714584 1 rs17800987 ENSG00000197083.10 ZNF300P1 5.18 3.74e-07 0.000153 0.41 0.27 Crohn's disease; chr5:150943866 chr5:150930645~150946289:- LIHC cis rs2735413 0.564 rs11863954 ENSG00000276007.1 RP11-358L22.3 -5.18 3.74e-07 0.000153 -0.36 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78093252 chr16:78123243~78124332:+ LIHC cis rs2111504 0.945 rs1861780 ENSG00000267213.4 AC007773.2 -5.18 3.74e-07 0.000153 -0.35 -0.27 Bipolar disorder; chr19:32372138 chr19:32390050~32405560:- LIHC cis rs10129255 0.585 rs2008440 ENSG00000211970.3 IGHV4-61 -5.18 3.74e-07 0.000153 -0.21 -0.27 Kawasaki disease; chr14:106654988 chr14:106639119~106639657:- LIHC cis rs875971 0.862 rs801206 ENSG00000237310.1 GS1-124K5.4 -5.18 3.75e-07 0.000153 -0.23 -0.27 Aortic root size; chr7:66556979 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs801204 ENSG00000237310.1 GS1-124K5.4 -5.18 3.75e-07 0.000153 -0.23 -0.27 Aortic root size; chr7:66557934 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs801203 ENSG00000237310.1 GS1-124K5.4 -5.18 3.75e-07 0.000153 -0.23 -0.27 Aortic root size; chr7:66558025 chr7:66493706~66495474:+ LIHC cis rs875971 0.825 rs801202 ENSG00000237310.1 GS1-124K5.4 -5.18 3.75e-07 0.000153 -0.23 -0.27 Aortic root size; chr7:66558942 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs801194 ENSG00000237310.1 GS1-124K5.4 -5.18 3.75e-07 0.000153 -0.23 -0.27 Aortic root size; chr7:66563508 chr7:66493706~66495474:+ LIHC cis rs13068223 1 rs34111024 ENSG00000243926.1 TIPARP-AS1 5.18 3.75e-07 0.000153 0.25 0.27 Age-related hearing impairment (SNP x SNP interaction); chr3:156748947 chr3:156671862~156674378:- LIHC cis rs13068223 1 rs36126086 ENSG00000243926.1 TIPARP-AS1 5.18 3.75e-07 0.000153 0.25 0.27 Age-related hearing impairment (SNP x SNP interaction); chr3:156749028 chr3:156671862~156674378:- LIHC cis rs227275 0.554 rs223382 ENSG00000230069.3 LRRC37A15P -5.18 3.75e-07 0.000153 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102831145 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223377 ENSG00000230069.3 LRRC37A15P -5.18 3.75e-07 0.000153 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102834919 chr4:102727274~102730721:- LIHC cis rs4731207 0.698 rs6960504 ENSG00000224897.5 POT1-AS1 5.18 3.75e-07 0.000153 0.32 0.27 Cutaneous malignant melanoma; chr7:124890260 chr7:124929873~125179315:+ LIHC cis rs1075265 0.547 rs41385746 ENSG00000233266.1 HMGB1P31 -5.18 3.75e-07 0.000153 -0.33 -0.27 Chronotype;Morning vs. evening chronotype; chr2:54077893 chr2:54051334~54051760:+ LIHC cis rs6479901 0.895 rs7092139 ENSG00000232075.1 MRPL35P2 -5.18 3.76e-07 0.000154 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63306540 chr10:63634317~63634827:- LIHC cis rs6479901 1 rs7092539 ENSG00000232075.1 MRPL35P2 -5.18 3.76e-07 0.000154 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63306749 chr10:63634317~63634827:- LIHC cis rs1577917 0.917 rs2197651 ENSG00000234155.1 RP11-30P6.6 5.18 3.76e-07 0.000154 0.36 0.27 Response to antipsychotic treatment; chr6:85785724 chr6:85387219~85390186:- LIHC cis rs1729407 0.933 rs1729405 ENSG00000236267.1 AP006216.5 5.18 3.76e-07 0.000154 0.26 0.27 Apolipoprotein A-IV levels; chr11:116808044 chr11:116813204~116814003:- LIHC cis rs1065852 0.526 rs8138080 ENSG00000237037.8 NDUFA6-AS1 5.18 3.77e-07 0.000154 0.37 0.27 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42000367 chr22:42090931~42137742:+ LIHC cis rs8100891 0.506 rs4804992 ENSG00000267213.4 AC007773.2 -5.18 3.77e-07 0.000154 -0.35 -0.27 Neuroticism; chr19:32367885 chr19:32390050~32405560:- LIHC cis rs875971 0.545 rs1267814 ENSG00000237310.1 GS1-124K5.4 -5.18 3.77e-07 0.000154 -0.25 -0.27 Aortic root size; chr7:66579422 chr7:66493706~66495474:+ LIHC cis rs6964833 0.935 rs13238996 ENSG00000123965.13 PMS2P5 5.18 3.77e-07 0.000154 0.49 0.27 Menarche (age at onset); chr7:74655318 chr7:74894116~74897835:+ LIHC cis rs3812049 0.737 rs790155 ENSG00000245937.6 LINC01184 5.18 3.78e-07 0.000154 0.35 0.27 Lymphocyte counts;Red cell distribution width; chr5:128162688 chr5:127940426~128083172:- LIHC cis rs3812049 0.737 rs790154 ENSG00000245937.6 LINC01184 5.18 3.78e-07 0.000154 0.35 0.27 Lymphocyte counts;Red cell distribution width; chr5:128165543 chr5:127940426~128083172:- LIHC cis rs10510102 0.872 rs78369301 ENSG00000226864.1 ATE1-AS1 5.18 3.78e-07 0.000155 0.45 0.27 Breast cancer; chr10:121858527 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs75339296 ENSG00000226864.1 ATE1-AS1 5.18 3.78e-07 0.000155 0.45 0.27 Breast cancer; chr10:121859895 chr10:121928312~121951965:+ LIHC cis rs4356203 0.905 rs7396382 ENSG00000272034.1 SNORD14A 5.18 3.78e-07 0.000155 0.29 0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17129925 chr11:17074654~17074744:- LIHC cis rs10510102 0.935 rs77447688 ENSG00000226864.1 ATE1-AS1 5.18 3.79e-07 0.000155 0.45 0.27 Breast cancer; chr10:121925721 chr10:121928312~121951965:+ LIHC cis rs10510102 0.688 rs74570569 ENSG00000226864.1 ATE1-AS1 5.18 3.79e-07 0.000155 0.45 0.27 Breast cancer; chr10:121945347 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs7076727 ENSG00000226864.1 ATE1-AS1 5.18 3.79e-07 0.000155 0.45 0.27 Breast cancer; chr10:121947000 chr10:121928312~121951965:+ LIHC cis rs10510102 0.745 rs7076882 ENSG00000226864.1 ATE1-AS1 5.18 3.79e-07 0.000155 0.45 0.27 Breast cancer; chr10:121947039 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs7077035 ENSG00000226864.1 ATE1-AS1 5.18 3.79e-07 0.000155 0.45 0.27 Breast cancer; chr10:121947130 chr10:121928312~121951965:+ LIHC cis rs4731207 0.596 rs7787605 ENSG00000224897.5 POT1-AS1 5.18 3.8e-07 0.000155 0.33 0.27 Cutaneous malignant melanoma; chr7:125019928 chr7:124929873~125179315:+ LIHC cis rs10510102 0.935 rs7098562 ENSG00000276742.1 RP11-500G22.4 5.18 3.8e-07 0.000155 0.4 0.27 Breast cancer; chr10:121902148 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs7098822 ENSG00000276742.1 RP11-500G22.4 5.18 3.8e-07 0.000155 0.4 0.27 Breast cancer; chr10:121902157 chr10:121956782~121957098:+ LIHC cis rs524281 0.861 rs10896095 ENSG00000255320.1 RP11-755F10.1 5.18 3.8e-07 0.000155 0.34 0.27 Electroencephalogram traits; chr11:66195089 chr11:66244840~66246239:- LIHC cis rs524281 0.861 rs10791856 ENSG00000255320.1 RP11-755F10.1 5.18 3.8e-07 0.000155 0.34 0.27 Electroencephalogram traits; chr11:66197179 chr11:66244840~66246239:- LIHC cis rs4731207 0.596 rs723443 ENSG00000224897.5 POT1-AS1 5.18 3.8e-07 0.000155 0.32 0.27 Cutaneous malignant melanoma; chr7:125019247 chr7:124929873~125179315:+ LIHC cis rs9527 0.662 rs743575 ENSG00000236937.2 PTGES3P4 5.18 3.81e-07 0.000155 0.37 0.27 Arsenic metabolism; chr10:102835149 chr10:102845595~102845950:+ LIHC cis rs8024893 0.764 rs7182721 ENSG00000270055.1 CTD-3092A11.2 5.18 3.81e-07 0.000155 0.38 0.27 Red cell distribution width; chr15:31239730 chr15:30487963~30490313:+ LIHC cis rs4731207 0.536 rs10254199 ENSG00000224897.5 POT1-AS1 5.18 3.81e-07 0.000155 0.33 0.27 Cutaneous malignant melanoma; chr7:125015062 chr7:124929873~125179315:+ LIHC cis rs6479891 1 rs868798 ENSG00000232075.1 MRPL35P2 5.18 3.81e-07 0.000156 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63135250 chr10:63634317~63634827:- LIHC cis rs73081554 0.611 rs13071861 ENSG00000272360.1 RP11-359I18.5 -5.18 3.82e-07 0.000156 -0.4 -0.27 Rheumatoid arthritis; chr3:58385605 chr3:58490830~58491291:- LIHC cis rs875971 0.545 rs17138149 ENSG00000226824.5 RP4-756H11.3 -5.18 3.82e-07 0.000156 -0.34 -0.27 Aortic root size; chr7:66228193 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs2707851 ENSG00000237310.1 GS1-124K5.4 -5.18 3.83e-07 0.000156 -0.26 -0.27 Aortic root size; chr7:66624178 chr7:66493706~66495474:+ LIHC cis rs4660214 0.666 rs11205839 ENSG00000182109.6 RP11-69E11.4 -5.18 3.83e-07 0.000156 -0.28 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39268061 chr1:39522280~39546187:- LIHC cis rs17711722 0.503 rs453835 ENSG00000224316.1 RP11-479O9.2 -5.18 3.84e-07 0.000156 -0.24 -0.27 Calcium levels; chr7:66046172 chr7:65773620~65802067:+ LIHC cis rs6479901 0.841 rs10995505 ENSG00000232075.1 MRPL35P2 5.18 3.84e-07 0.000156 0.3 0.27 Intelligence (multi-trait analysis); chr10:63331399 chr10:63634317~63634827:- LIHC cis rs4731207 0.596 rs7788458 ENSG00000224897.5 POT1-AS1 5.18 3.85e-07 0.000157 0.33 0.27 Cutaneous malignant melanoma; chr7:124990087 chr7:124929873~125179315:+ LIHC cis rs9318086 0.712 rs12875437 ENSG00000205861.10 C1QTNF9B-AS1 -5.18 3.85e-07 0.000157 -0.3 -0.27 Myopia (pathological); chr13:23879817 chr13:23888889~23897263:+ LIHC cis rs4731207 0.967 rs2267708 ENSG00000224897.5 POT1-AS1 -5.18 3.85e-07 0.000157 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124752458 chr7:124929873~125179315:+ LIHC cis rs8028182 0.549 rs7402844 ENSG00000260269.4 CTD-2323K18.1 5.18 3.85e-07 0.000157 0.35 0.27 Sudden cardiac arrest; chr15:75345055 chr15:75527150~75601205:- LIHC cis rs7688540 0.771 rs12505835 ENSG00000275426.1 CH17-262A2.1 5.18 3.86e-07 0.000157 0.35 0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:303736 chr4:149738~150317:+ LIHC cis rs9291683 0.551 rs62295971 ENSG00000250413.1 RP11-448G15.1 -5.18 3.86e-07 0.000157 -0.35 -0.27 Bone mineral density; chr4:9976518 chr4:10006482~10009725:+ LIHC cis rs10510102 0.935 rs12246704 ENSG00000226864.1 ATE1-AS1 5.18 3.87e-07 0.000157 0.43 0.27 Breast cancer; chr10:121906165 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200243 ENSG00000226864.1 ATE1-AS1 5.18 3.87e-07 0.000157 0.43 0.27 Breast cancer; chr10:121906888 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200244 ENSG00000226864.1 ATE1-AS1 5.18 3.87e-07 0.000157 0.43 0.27 Breast cancer; chr10:121906944 chr10:121928312~121951965:+ LIHC cis rs7131987 0.834 rs11050167 ENSG00000257176.2 RP11-996F15.2 -5.18 3.88e-07 0.000158 -0.32 -0.27 QT interval; chr12:29273454 chr12:29280418~29317848:- LIHC cis rs17711722 0.565 rs73372653 ENSG00000224316.1 RP11-479O9.2 5.18 3.88e-07 0.000158 0.24 0.27 Calcium levels; chr7:65977808 chr7:65773620~65802067:+ LIHC cis rs2877649 0.51 rs10083382 ENSG00000258744.1 RP11-80A15.1 5.18 3.88e-07 0.000158 0.48 0.27 Smooth-surface caries; chr14:24438911 chr14:24501594~24508688:+ LIHC cis rs6479891 1 rs4525102 ENSG00000232075.1 MRPL35P2 -5.18 3.88e-07 0.000158 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63326513 chr10:63634317~63634827:- LIHC cis rs6479891 0.841 rs7092504 ENSG00000232075.1 MRPL35P2 -5.18 3.88e-07 0.000158 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63329679 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs4133250 ENSG00000232075.1 MRPL35P2 -5.18 3.88e-07 0.000158 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63332645 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs10995506 ENSG00000232075.1 MRPL35P2 -5.18 3.88e-07 0.000158 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63334706 chr10:63634317~63634827:- LIHC cis rs2799081 1 rs2799081 ENSG00000204709.4 LINC01556 5.18 3.89e-07 0.000158 0.32 0.27 Myopia; chr6:28302807 chr6:28943877~28944537:+ LIHC cis rs875971 0.545 rs316324 ENSG00000226824.5 RP4-756H11.3 5.17 3.9e-07 0.000159 0.34 0.27 Aortic root size; chr7:66145627 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs316323 ENSG00000226824.5 RP4-756H11.3 5.17 3.9e-07 0.000159 0.34 0.27 Aortic root size; chr7:66146002 chr7:66654538~66669855:+ LIHC cis rs4650994 0.525 rs4316329 ENSG00000273384.1 RP5-1098D14.1 5.17 3.91e-07 0.000159 0.33 0.27 HDL cholesterol;HDL cholesterol levels; chr1:178540198 chr1:178651706~178652282:+ LIHC cis rs7131987 0.65 rs3782509 ENSG00000275476.1 RP11-996F15.4 -5.17 3.91e-07 0.000159 -0.31 -0.27 QT interval; chr12:29300845 chr12:29277397~29277882:- LIHC cis rs5760092 0.572 rs738806 ENSG00000273295.1 AP000350.5 5.17 3.91e-07 0.000159 0.32 0.27 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23901432~23907068:- LIHC cis rs5769765 1 rs4824112 ENSG00000278869.1 CITF22-49E9.3 5.17 3.91e-07 0.000159 0.43 0.27 Schizophrenia; chr22:49890697 chr22:49933198~49934074:- LIHC cis rs5769765 0.913 rs4824111 ENSG00000278869.1 CITF22-49E9.3 -5.17 3.91e-07 0.000159 -0.43 -0.27 Schizophrenia; chr22:49890657 chr22:49933198~49934074:- LIHC cis rs4731207 0.724 rs2057907 ENSG00000224897.5 POT1-AS1 -5.17 3.91e-07 0.000159 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124803630 chr7:124929873~125179315:+ LIHC cis rs2836974 0.674 rs1011413 ENSG00000255568.3 BRWD1-AS2 -5.17 3.92e-07 0.000159 -0.23 -0.27 Cognitive function; chr21:39266315 chr21:39313935~39314962:+ LIHC cis rs17270561 0.666 rs1141034 ENSG00000216436.2 HIST1H2APS1 -5.17 3.92e-07 0.00016 -0.32 -0.27 Iron status biomarkers; chr6:25780104 chr6:25732497~25732827:+ LIHC cis rs4731207 0.672 rs7792883 ENSG00000224897.5 POT1-AS1 -5.17 3.92e-07 0.00016 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124807967 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs2402753 ENSG00000224897.5 POT1-AS1 -5.17 3.92e-07 0.00016 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124808205 chr7:124929873~125179315:+ LIHC cis rs4731207 0.672 rs2896360 ENSG00000224897.5 POT1-AS1 -5.17 3.92e-07 0.00016 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124808462 chr7:124929873~125179315:+ LIHC cis rs2933343 0.909 rs1683817 ENSG00000231305.3 RP11-723O4.2 5.17 3.93e-07 0.00016 0.31 0.27 IgG glycosylation; chr3:128932693 chr3:128861313~128871540:- LIHC cis rs4731207 0.596 rs7802007 ENSG00000224897.5 POT1-AS1 5.17 3.94e-07 0.00016 0.33 0.27 Cutaneous malignant melanoma; chr7:124997980 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs998054 ENSG00000224897.5 POT1-AS1 5.17 3.94e-07 0.00016 0.33 0.27 Cutaneous malignant melanoma; chr7:125000433 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1481333 ENSG00000224897.5 POT1-AS1 5.17 3.94e-07 0.00016 0.33 0.27 Cutaneous malignant melanoma; chr7:125003005 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs6466978 ENSG00000224897.5 POT1-AS1 5.17 3.94e-07 0.00016 0.33 0.27 Cutaneous malignant melanoma; chr7:125003732 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1531718 ENSG00000224897.5 POT1-AS1 5.17 3.94e-07 0.00016 0.33 0.27 Cutaneous malignant melanoma; chr7:125004723 chr7:124929873~125179315:+ LIHC cis rs9595066 0.627 rs4941486 ENSG00000230731.2 RP11-478K15.6 5.17 3.94e-07 0.00016 0.33 0.27 Schizophrenia; chr13:44175021 chr13:44234118~44243192:- LIHC cis rs5758511 0.68 rs5758687 ENSG00000237037.8 NDUFA6-AS1 -5.17 3.95e-07 0.00016 -0.34 -0.27 Birth weight; chr22:42260582 chr22:42090931~42137742:+ LIHC cis rs4356203 0.905 rs214906 ENSG00000272034.1 SNORD14A 5.17 3.95e-07 0.000161 0.29 0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17159793 chr11:17074654~17074744:- LIHC cis rs2439831 1 rs1814538 ENSG00000205771.5 CATSPER2P1 5.17 3.95e-07 0.000161 0.37 0.27 Lung cancer in ever smokers; chr15:43467576 chr15:43726918~43747094:- LIHC cis rs228614 0.51 rs223400 ENSG00000230069.3 LRRC37A15P -5.17 3.97e-07 0.000161 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102820439 chr4:102727274~102730721:- LIHC cis rs2274273 0.87 rs7160523 ENSG00000258413.1 RP11-665C16.6 -5.17 3.97e-07 0.000161 -0.3 -0.27 Protein biomarker; chr14:55127842 chr14:55262767~55272075:- LIHC cis rs950169 0.881 rs4842852 ENSG00000225151.9 GOLGA2P7 -5.17 3.97e-07 0.000161 -0.33 -0.27 Schizophrenia; chr15:84387263 chr15:84199311~84230136:- LIHC cis rs950169 0.84 rs4842853 ENSG00000225151.9 GOLGA2P7 -5.17 3.97e-07 0.000161 -0.33 -0.27 Schizophrenia; chr15:84387606 chr15:84199311~84230136:- LIHC cis rs950169 0.922 rs4842946 ENSG00000225151.9 GOLGA2P7 -5.17 3.97e-07 0.000161 -0.33 -0.27 Schizophrenia; chr15:84387633 chr15:84199311~84230136:- LIHC cis rs950169 0.84 rs4842854 ENSG00000225151.9 GOLGA2P7 -5.17 3.97e-07 0.000161 -0.33 -0.27 Schizophrenia; chr15:84387641 chr15:84199311~84230136:- LIHC cis rs755249 0.501 rs1889830 ENSG00000182109.6 RP11-69E11.4 -5.17 3.98e-07 0.000161 -0.29 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39264500 chr1:39522280~39546187:- LIHC cis rs2439831 1 rs690263 ENSG00000205771.5 CATSPER2P1 -5.17 3.98e-07 0.000162 -0.37 -0.27 Lung cancer in ever smokers; chr15:43412267 chr15:43726918~43747094:- LIHC cis rs2337406 0.789 rs12050392 ENSG00000274576.2 IGHV2-70 -5.17 3.98e-07 0.000162 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106779073 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs74092505 ENSG00000274576.2 IGHV2-70 -5.17 3.98e-07 0.000162 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106779163 chr14:106770577~106771020:- LIHC cis rs2337406 0.789 rs74092507 ENSG00000274576.2 IGHV2-70 -5.17 3.98e-07 0.000162 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106779174 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs74092511 ENSG00000274576.2 IGHV2-70 -5.17 3.98e-07 0.000162 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106779234 chr14:106770577~106771020:- LIHC cis rs5758511 0.637 rs5751244 ENSG00000237037.8 NDUFA6-AS1 -5.17 3.98e-07 0.000162 -0.34 -0.27 Birth weight; chr22:42221405 chr22:42090931~42137742:+ LIHC cis rs12571093 0.803 rs2241970 ENSG00000233590.1 RP11-153K11.3 5.17 3.98e-07 0.000162 0.41 0.27 Optic nerve measurement (disc area); chr10:68271310 chr10:68233251~68242379:- LIHC cis rs887829 0.57 rs4553819 ENSG00000233445.1 RPL17P11 5.17 3.99e-07 0.000162 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233685437 chr2:233721522~233722065:- LIHC cis rs4663969 0.541 rs11902131 ENSG00000233445.1 RPL17P11 5.17 3.99e-07 0.000162 0.28 0.27 Total bilirubin levels in HIV-1 infection; chr2:233685623 chr2:233721522~233722065:- LIHC cis rs6479901 0.894 rs7098614 ENSG00000232075.1 MRPL35P2 -5.17 3.99e-07 0.000162 -0.29 -0.27 Intelligence (multi-trait analysis); chr10:63355667 chr10:63634317~63634827:- LIHC cis rs2565722 0.563 rs1247560 ENSG00000243831.1 RP1-81D8.4 5.17 3.99e-07 0.000162 0.36 0.27 Blood protein levels; chr6:160783788 chr6:160666228~160676523:- LIHC cis rs9326248 0.53 rs11216316 ENSG00000280143.1 AP000892.6 -5.17 4e-07 0.000162 -0.35 -0.27 Blood protein levels; chr11:117210784 chr11:117204967~117210292:+ LIHC cis rs10129255 0.957 rs10141052 ENSG00000223648.3 IGHV3-64 5.17 4e-07 0.000162 0.2 0.27 Kawasaki disease; chr14:106776528 chr14:106643132~106658258:- LIHC cis rs10129255 0.957 rs10141009 ENSG00000223648.3 IGHV3-64 5.17 4e-07 0.000162 0.2 0.27 Kawasaki disease; chr14:106776695 chr14:106643132~106658258:- LIHC cis rs116175783 0.557 rs3731768 ENSG00000227403.1 AC009299.3 5.17 4e-07 0.000162 0.42 0.27 Intelligence (multi-trait analysis); chr2:161250809 chr2:161244739~161249050:+ LIHC cis rs36715 1 rs36697 ENSG00000245937.6 LINC01184 5.17 4e-07 0.000162 0.33 0.27 Breast cancer; chr5:128213921 chr5:127940426~128083172:- LIHC cis rs4731207 0.698 rs2402755 ENSG00000224897.5 POT1-AS1 -5.17 4.01e-07 0.000163 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124808554 chr7:124929873~125179315:+ LIHC cis rs11690935 0.851 rs10174055 ENSG00000228389.1 AC068039.4 5.17 4.02e-07 0.000163 0.36 0.27 Schizophrenia; chr2:171993303 chr2:171773482~171775844:+ LIHC cis rs2836974 0.584 rs34436313 ENSG00000255568.3 BRWD1-AS2 -5.17 4.02e-07 0.000163 -0.23 -0.27 Cognitive function; chr21:39313320 chr21:39313935~39314962:+ LIHC cis rs599083 0.53 rs491347 ENSG00000212093.1 AP000807.1 -5.17 4.02e-07 0.000163 -0.29 -0.27 Bone mineral density (spine); chr11:68402220 chr11:68506083~68506166:- LIHC cis rs599083 0.53 rs686921 ENSG00000212093.1 AP000807.1 -5.17 4.02e-07 0.000163 -0.29 -0.27 Bone mineral density (spine); chr11:68403365 chr11:68506083~68506166:- LIHC cis rs11690935 0.851 rs7573003 ENSG00000228389.1 AC068039.4 5.17 4.03e-07 0.000163 0.35 0.27 Schizophrenia; chr2:171884905 chr2:171773482~171775844:+ LIHC cis rs2842992 0.83 rs2758312 ENSG00000237927.1 RP3-393E18.2 -5.17 4.03e-07 0.000164 -0.33 -0.27 Age-related macular degeneration (geographic atrophy); chr6:159732420 chr6:159586955~159589169:- LIHC cis rs10833905 0.756 rs10833870 ENSG00000246225.5 RP11-17A1.3 -5.17 4.03e-07 0.000164 -0.35 -0.27 Sudden cardiac arrest; chr11:22967878 chr11:22829380~22945393:+ LIHC cis rs10833905 0.701 rs4923047 ENSG00000246225.5 RP11-17A1.3 -5.17 4.03e-07 0.000164 -0.35 -0.27 Sudden cardiac arrest; chr11:22970056 chr11:22829380~22945393:+ LIHC cis rs228614 0.51 rs223435 ENSG00000230069.3 LRRC37A15P -5.17 4.04e-07 0.000164 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799826 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs223367 ENSG00000230069.3 LRRC37A15P -5.17 4.05e-07 0.000164 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102843836 chr4:102727274~102730721:- LIHC cis rs10129255 0.957 rs10136781 ENSG00000223648.3 IGHV3-64 5.17 4.05e-07 0.000164 0.2 0.27 Kawasaki disease; chr14:106780451 chr14:106643132~106658258:- LIHC cis rs7665090 0.806 rs434644 ENSG00000230069.3 LRRC37A15P 5.17 4.06e-07 0.000164 0.25 0.27 Primary biliary cholangitis; chr4:102662032 chr4:102727274~102730721:- LIHC cis rs7665090 0.806 rs413967 ENSG00000230069.3 LRRC37A15P 5.17 4.06e-07 0.000164 0.25 0.27 Primary biliary cholangitis; chr4:102662039 chr4:102727274~102730721:- LIHC cis rs7665090 0.806 rs404574 ENSG00000230069.3 LRRC37A15P 5.17 4.06e-07 0.000164 0.25 0.27 Primary biliary cholangitis; chr4:102662051 chr4:102727274~102730721:- LIHC cis rs712039 0.652 rs853227 ENSG00000276054.1 RP11-378E13.3 5.17 4.06e-07 0.000165 0.34 0.27 Tuberculosis; chr17:37437428 chr17:37386886~37387926:+ LIHC cis rs950169 0.881 rs34117475 ENSG00000259728.4 LINC00933 5.17 4.06e-07 0.000165 0.39 0.27 Schizophrenia; chr15:84565212 chr15:84570649~84580175:+ LIHC cis rs1005277 0.579 rs2474595 ENSG00000263064.2 RP11-291L22.7 -5.17 4.07e-07 0.000165 -0.28 -0.27 Extrinsic epigenetic age acceleration; chr10:38137854 chr10:38448689~38448949:+ LIHC cis rs11098499 0.909 rs73842633 ENSG00000245958.5 RP11-33B1.1 -5.17 4.07e-07 0.000165 -0.28 -0.27 Corneal astigmatism; chr4:119454309 chr4:119454791~119552025:+ LIHC cis rs10510102 0.935 rs12255859 ENSG00000226864.1 ATE1-AS1 5.17 4.07e-07 0.000165 0.43 0.27 Breast cancer; chr10:121831661 chr10:121928312~121951965:+ LIHC cis rs9291683 0.53 rs35908990 ENSG00000250413.1 RP11-448G15.1 -5.17 4.07e-07 0.000165 -0.35 -0.27 Bone mineral density; chr4:9974481 chr4:10006482~10009725:+ LIHC cis rs4731207 0.507 rs10954052 ENSG00000224897.5 POT1-AS1 5.17 4.08e-07 0.000165 0.33 0.27 Cutaneous malignant melanoma; chr7:124946757 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs2170353 ENSG00000224897.5 POT1-AS1 5.17 4.08e-07 0.000165 0.33 0.27 Cutaneous malignant melanoma; chr7:124955115 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs2402760 ENSG00000224897.5 POT1-AS1 5.17 4.08e-07 0.000165 0.33 0.27 Cutaneous malignant melanoma; chr7:124955866 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6466971 ENSG00000224897.5 POT1-AS1 5.17 4.08e-07 0.000165 0.33 0.27 Cutaneous malignant melanoma; chr7:124955953 chr7:124929873~125179315:+ LIHC cis rs4731207 0.623 rs28807101 ENSG00000224897.5 POT1-AS1 5.17 4.08e-07 0.000165 0.33 0.27 Cutaneous malignant melanoma; chr7:124958772 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs12536146 ENSG00000224897.5 POT1-AS1 5.17 4.08e-07 0.000165 0.33 0.27 Cutaneous malignant melanoma; chr7:124960577 chr7:124929873~125179315:+ LIHC cis rs11098499 0.909 rs7681978 ENSG00000245958.5 RP11-33B1.1 -5.17 4.09e-07 0.000166 -0.28 -0.27 Corneal astigmatism; chr4:119462620 chr4:119454791~119552025:+ LIHC cis rs227275 0.525 rs28778380 ENSG00000230069.3 LRRC37A15P -5.16 4.09e-07 0.000166 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:103006416 chr4:102727274~102730721:- LIHC cis rs916888 0.773 rs1378358 ENSG00000274883.1 Metazoa_SRP -5.16 4.09e-07 0.000166 -0.42 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45931806~45932083:+ LIHC cis rs4718428 0.705 rs4717331 ENSG00000230295.1 RP11-458F8.2 -5.16 4.1e-07 0.000166 -0.23 -0.27 Corneal structure; chr7:66913899 chr7:66880708~66882981:+ LIHC cis rs599083 0.53 rs546803 ENSG00000212093.1 AP000807.1 -5.16 4.11e-07 0.000166 -0.3 -0.27 Bone mineral density (spine); chr11:68418924 chr11:68506083~68506166:- LIHC cis rs2739330 0.76 rs5751760 ENSG00000099984.9 GSTT2 -5.16 4.11e-07 0.000166 -0.32 -0.27 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23980123~23983911:+ LIHC cis rs875971 0.545 rs316316 ENSG00000226824.5 RP4-756H11.3 5.16 4.11e-07 0.000166 0.34 0.27 Aortic root size; chr7:66149270 chr7:66654538~66669855:+ LIHC cis rs4718428 0.705 rs28648401 ENSG00000230295.1 RP11-458F8.2 -5.16 4.11e-07 0.000166 -0.23 -0.27 Corneal structure; chr7:66902145 chr7:66880708~66882981:+ LIHC cis rs4718428 0.607 rs66954441 ENSG00000230295.1 RP11-458F8.2 -5.16 4.11e-07 0.000166 -0.23 -0.27 Corneal structure; chr7:66904222 chr7:66880708~66882981:+ LIHC cis rs4718428 0.705 rs4718424 ENSG00000230295.1 RP11-458F8.2 -5.16 4.11e-07 0.000166 -0.23 -0.27 Corneal structure; chr7:66911108 chr7:66880708~66882981:+ LIHC cis rs6921919 0.848 rs6903823 ENSG00000204709.4 LINC01556 5.16 4.11e-07 0.000166 0.37 0.27 Autism spectrum disorder or schizophrenia; chr6:28354519 chr6:28943877~28944537:+ LIHC cis rs4731207 0.596 rs12112909 ENSG00000224897.5 POT1-AS1 5.16 4.12e-07 0.000167 0.33 0.27 Cutaneous malignant melanoma; chr7:124944780 chr7:124929873~125179315:+ LIHC cis rs10129255 0.957 rs12590799 ENSG00000223648.3 IGHV3-64 5.16 4.12e-07 0.000167 0.2 0.27 Kawasaki disease; chr14:106779713 chr14:106643132~106658258:- LIHC cis rs950169 0.8 rs4842847 ENSG00000259295.5 CSPG4P12 5.16 4.12e-07 0.000167 0.36 0.27 Schizophrenia; chr15:84262447 chr15:85191438~85213905:+ LIHC cis rs887829 0.57 rs6724485 ENSG00000233445.1 RPL17P11 5.16 4.13e-07 0.000167 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233684170 chr2:233721522~233722065:- LIHC cis rs887829 0.57 rs4347832 ENSG00000233445.1 RPL17P11 5.16 4.13e-07 0.000167 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233684395 chr2:233721522~233722065:- LIHC cis rs887829 0.57 rs4261716 ENSG00000233445.1 RPL17P11 5.16 4.13e-07 0.000167 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233684471 chr2:233721522~233722065:- LIHC cis rs887829 0.57 rs13002774 ENSG00000233445.1 RPL17P11 5.16 4.13e-07 0.000167 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233685060 chr2:233721522~233722065:- LIHC cis rs887829 0.531 rs4338954 ENSG00000233445.1 RPL17P11 5.16 4.13e-07 0.000167 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233685285 chr2:233721522~233722065:- LIHC cis rs4650994 0.525 rs11806608 ENSG00000273384.1 RP5-1098D14.1 5.16 4.13e-07 0.000167 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr1:178542240 chr1:178651706~178652282:+ LIHC cis rs4731207 0.698 rs6466948 ENSG00000224897.5 POT1-AS1 -5.16 4.13e-07 0.000167 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124804709 chr7:124929873~125179315:+ LIHC cis rs4731207 0.671 rs6466949 ENSG00000224897.5 POT1-AS1 -5.16 4.13e-07 0.000167 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124804846 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10270784 ENSG00000224897.5 POT1-AS1 -5.16 4.13e-07 0.000167 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124806154 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10260227 ENSG00000224897.5 POT1-AS1 -5.16 4.13e-07 0.000167 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124806432 chr7:124929873~125179315:+ LIHC cis rs4731207 0.671 rs7811607 ENSG00000224897.5 POT1-AS1 -5.16 4.13e-07 0.000167 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124807789 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs7793258 ENSG00000224897.5 POT1-AS1 -5.16 4.13e-07 0.000167 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124807958 chr7:124929873~125179315:+ LIHC cis rs7615952 0.515 rs7637246 ENSG00000171084.14 FAM86JP 5.16 4.13e-07 0.000167 0.44 0.27 Blood pressure (smoking interaction); chr3:125959863 chr3:125916620~125930024:+ LIHC cis rs10129255 0.5 rs4774189 ENSG00000223648.3 IGHV3-64 5.16 4.14e-07 0.000167 0.19 0.27 Kawasaki disease; chr14:106768275 chr14:106643132~106658258:- LIHC cis rs4731207 0.596 rs1471572 ENSG00000224897.5 POT1-AS1 5.16 4.14e-07 0.000167 0.33 0.27 Cutaneous malignant melanoma; chr7:125010888 chr7:124929873~125179315:+ LIHC cis rs9291683 0.53 rs11723970 ENSG00000250413.1 RP11-448G15.1 -5.16 4.14e-07 0.000167 -0.35 -0.27 Bone mineral density; chr4:9978838 chr4:10006482~10009725:+ LIHC cis rs3733585 0.805 rs882222 ENSG00000250413.1 RP11-448G15.1 -5.16 4.14e-07 0.000167 -0.35 -0.27 Cleft plate (environmental tobacco smoke interaction); chr4:9979670 chr4:10006482~10009725:+ LIHC cis rs9291683 0.53 rs882223 ENSG00000250413.1 RP11-448G15.1 -5.16 4.14e-07 0.000167 -0.35 -0.27 Bone mineral density; chr4:9980001 chr4:10006482~10009725:+ LIHC cis rs227275 0.554 rs223319 ENSG00000246560.2 RP11-10L12.4 5.16 4.14e-07 0.000167 0.3 0.27 Allergic disease (asthma, hay fever or eczema); chr4:102881157 chr4:102828055~102844075:+ LIHC cis rs228614 0.509 rs223318 ENSG00000246560.2 RP11-10L12.4 5.16 4.14e-07 0.000167 0.3 0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102881422 chr4:102828055~102844075:+ LIHC cis rs227275 0.554 rs223315 ENSG00000246560.2 RP11-10L12.4 5.16 4.14e-07 0.000167 0.3 0.27 Allergic disease (asthma, hay fever or eczema); chr4:102884286 chr4:102828055~102844075:+ LIHC cis rs10510102 0.935 rs12258426 ENSG00000276742.1 RP11-500G22.4 5.16 4.15e-07 0.000167 0.43 0.27 Breast cancer; chr10:121882189 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs12266380 ENSG00000276742.1 RP11-500G22.4 5.16 4.15e-07 0.000167 0.43 0.27 Breast cancer; chr10:121882559 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200212 ENSG00000276742.1 RP11-500G22.4 5.16 4.15e-07 0.000167 0.43 0.27 Breast cancer; chr10:121883145 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200213 ENSG00000276742.1 RP11-500G22.4 5.16 4.15e-07 0.000167 0.43 0.27 Breast cancer; chr10:121883228 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs12247749 ENSG00000276742.1 RP11-500G22.4 5.16 4.15e-07 0.000167 0.43 0.27 Breast cancer; chr10:121884196 chr10:121956782~121957098:+ LIHC cis rs8072100 0.817 rs9905581 ENSG00000228782.6 CTD-2026D20.3 5.16 4.15e-07 0.000167 0.3 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469819 chr17:47450568~47492492:- LIHC cis rs6921919 0.848 rs56131013 ENSG00000204709.4 LINC01556 5.16 4.15e-07 0.000168 0.37 0.27 Autism spectrum disorder or schizophrenia; chr6:28352900 chr6:28943877~28944537:+ LIHC cis rs638893 0.717 rs622690 ENSG00000255422.1 AP002954.4 -5.16 4.15e-07 0.000168 -0.46 -0.27 Vitiligo; chr11:118833556 chr11:118704607~118750263:+ LIHC cis rs5769765 0.955 rs1321 ENSG00000278869.1 CITF22-49E9.3 5.16 4.15e-07 0.000168 0.4 0.27 Schizophrenia; chr22:49903787 chr22:49933198~49934074:- LIHC cis rs9487094 0.778 rs61318425 ENSG00000260273.1 RP11-425D10.10 5.16 4.16e-07 0.000168 0.38 0.27 Height; chr6:109427303 chr6:109382795~109383666:+ LIHC cis rs2337406 0.714 rs117798641 ENSG00000274576.2 IGHV2-70 -5.16 4.16e-07 0.000168 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106777984 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs7152038 ENSG00000274576.2 IGHV2-70 -5.16 4.16e-07 0.000168 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106778230 chr14:106770577~106771020:- LIHC cis rs4662750 0.603 rs10208043 ENSG00000236682.1 AC068282.3 5.16 4.16e-07 0.000168 0.34 0.27 Renal cell carcinoma; chr2:127631768 chr2:127389130~127400580:+ LIHC cis rs4662750 0.58 rs10183797 ENSG00000236682.1 AC068282.3 5.16 4.16e-07 0.000168 0.34 0.27 Renal cell carcinoma; chr2:127631847 chr2:127389130~127400580:+ LIHC cis rs4662750 0.539 rs10186397 ENSG00000236682.1 AC068282.3 5.16 4.16e-07 0.000168 0.34 0.27 Renal cell carcinoma; chr2:127632049 chr2:127389130~127400580:+ LIHC cis rs228614 0.51 rs223434 ENSG00000230069.3 LRRC37A15P -5.16 4.16e-07 0.000168 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799902 chr4:102727274~102730721:- LIHC cis rs4731207 0.596 rs10275296 ENSG00000224897.5 POT1-AS1 5.16 4.16e-07 0.000168 0.33 0.27 Cutaneous malignant melanoma; chr7:125041238 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6466989 ENSG00000224897.5 POT1-AS1 5.16 4.16e-07 0.000168 0.33 0.27 Cutaneous malignant melanoma; chr7:125050909 chr7:124929873~125179315:+ LIHC cis rs4731207 0.569 rs75791754 ENSG00000224897.5 POT1-AS1 -5.16 4.17e-07 0.000168 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124824863 chr7:124929873~125179315:+ LIHC cis rs4731207 0.598 rs2301930 ENSG00000224897.5 POT1-AS1 -5.16 4.17e-07 0.000168 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124825043 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10250202 ENSG00000224897.5 POT1-AS1 -5.16 4.17e-07 0.000168 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124825455 chr7:124929873~125179315:+ LIHC cis rs4731207 0.672 rs2286174 ENSG00000224897.5 POT1-AS1 -5.16 4.17e-07 0.000168 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124825822 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4731216 ENSG00000224897.5 POT1-AS1 -5.16 4.17e-07 0.000168 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124826458 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10263573 ENSG00000224897.5 POT1-AS1 -5.16 4.17e-07 0.000168 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124829213 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs35184624 ENSG00000224897.5 POT1-AS1 -5.16 4.17e-07 0.000168 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124829533 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs17147583 ENSG00000224897.5 POT1-AS1 -5.16 4.17e-07 0.000168 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124830071 chr7:124929873~125179315:+ LIHC cis rs860295 0.967 rs6665227 ENSG00000203761.5 MSTO2P -5.16 4.18e-07 0.000169 -0.22 -0.27 Body mass index; chr1:155740669 chr1:155745829~155750137:+ LIHC cis rs1061377 0.71 rs12503506 ENSG00000249207.1 RP11-360F5.1 -5.16 4.18e-07 0.000169 -0.27 -0.27 Uric acid levels; chr4:39082553 chr4:39112677~39126818:- LIHC cis rs875971 0.545 rs17138156 ENSG00000226824.5 RP4-756H11.3 -5.16 4.19e-07 0.000169 -0.34 -0.27 Aortic root size; chr7:66249708 chr7:66654538~66669855:+ LIHC cis rs1577917 1 rs2324843 ENSG00000234155.1 RP11-30P6.6 5.16 4.2e-07 0.000169 0.36 0.27 Response to antipsychotic treatment; chr6:85907783 chr6:85387219~85390186:- LIHC cis rs2836950 0.501 rs62223052 ENSG00000255568.3 BRWD1-AS2 -5.16 4.2e-07 0.000169 -0.22 -0.27 Menarche (age at onset); chr21:39336776 chr21:39313935~39314962:+ LIHC cis rs4731207 0.596 rs1481339 ENSG00000224897.5 POT1-AS1 5.16 4.2e-07 0.00017 0.33 0.27 Cutaneous malignant melanoma; chr7:125068183 chr7:124929873~125179315:+ LIHC cis rs4731207 0.624 rs1031955 ENSG00000224897.5 POT1-AS1 5.16 4.2e-07 0.00017 0.33 0.27 Cutaneous malignant melanoma; chr7:125070804 chr7:124929873~125179315:+ LIHC cis rs860295 0.719 rs490608 ENSG00000203761.5 MSTO2P -5.16 4.2e-07 0.00017 -0.21 -0.27 Body mass index; chr1:155713079 chr1:155745829~155750137:+ LIHC cis rs3096299 0.685 rs12935112 ENSG00000261118.1 RP11-104N10.1 -5.16 4.21e-07 0.00017 -0.26 -0.27 Multiple myeloma (IgH translocation); chr16:89476450 chr16:89492017~89504460:- LIHC cis rs4660214 0.666 rs7414381 ENSG00000182109.6 RP11-69E11.4 -5.16 4.21e-07 0.00017 -0.28 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39275848 chr1:39522280~39546187:- LIHC cis rs4660214 0.666 rs3116387 ENSG00000182109.6 RP11-69E11.4 -5.16 4.21e-07 0.00017 -0.28 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39277197 chr1:39522280~39546187:- LIHC cis rs4660214 0.614 rs1537815 ENSG00000182109.6 RP11-69E11.4 -5.16 4.21e-07 0.00017 -0.28 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39278946 chr1:39522280~39546187:- LIHC cis rs4660214 0.789 rs1984142 ENSG00000182109.6 RP11-69E11.4 -5.16 4.21e-07 0.00017 -0.28 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39279936 chr1:39522280~39546187:- LIHC cis rs12554020 0.892 rs3815563 ENSG00000227603.1 RP11-165J3.6 5.16 4.22e-07 0.00017 0.35 0.27 Schizophrenia; chr9:93450864 chr9:93435332~93437121:- LIHC cis rs12554020 1 rs7853605 ENSG00000227603.1 RP11-165J3.6 5.16 4.22e-07 0.00017 0.35 0.27 Schizophrenia; chr9:93451247 chr9:93435332~93437121:- LIHC cis rs1150668 0.799 rs1150707 ENSG00000204709.4 LINC01556 5.16 4.22e-07 0.00017 0.3 0.27 Pubertal anthropometrics; chr6:28229827 chr6:28943877~28944537:+ LIHC cis rs1150668 0.799 rs7206 ENSG00000204709.4 LINC01556 5.16 4.22e-07 0.00017 0.3 0.27 Pubertal anthropometrics; chr6:28233360 chr6:28943877~28944537:+ LIHC cis rs9467711 0.591 rs28360595 ENSG00000216436.2 HIST1H2APS1 5.16 4.22e-07 0.00017 0.72 0.27 Autism spectrum disorder or schizophrenia; chr6:26029816 chr6:25732497~25732827:+ LIHC cis rs8072100 0.817 rs9892497 ENSG00000228782.6 CTD-2026D20.3 5.16 4.23e-07 0.00017 0.3 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47468553 chr17:47450568~47492492:- LIHC cis rs4731207 0.596 rs10274820 ENSG00000224897.5 POT1-AS1 5.16 4.23e-07 0.00017 0.33 0.27 Cutaneous malignant melanoma; chr7:124989610 chr7:124929873~125179315:+ LIHC cis rs10510102 0.935 rs12243529 ENSG00000276742.1 RP11-500G22.4 5.16 4.23e-07 0.00017 0.42 0.27 Breast cancer; chr10:121880321 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs12250677 ENSG00000276742.1 RP11-500G22.4 5.16 4.23e-07 0.00017 0.42 0.27 Breast cancer; chr10:121880575 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs12243874 ENSG00000276742.1 RP11-500G22.4 5.16 4.23e-07 0.00017 0.42 0.27 Breast cancer; chr10:121880788 chr10:121956782~121957098:+ LIHC cis rs5758511 0.68 rs5751243 ENSG00000237037.8 NDUFA6-AS1 -5.16 4.23e-07 0.00017 -0.34 -0.27 Birth weight; chr22:42221171 chr22:42090931~42137742:+ LIHC cis rs1023500 0.505 rs134874 ENSG00000227370.1 RP4-669P10.19 -5.16 4.23e-07 0.00017 -0.27 -0.27 Schizophrenia; chr22:42265138 chr22:42132543~42132998:+ LIHC cis rs10833905 0.756 rs11026868 ENSG00000246225.5 RP11-17A1.3 -5.16 4.23e-07 0.000171 -0.35 -0.27 Sudden cardiac arrest; chr11:22971305 chr11:22829380~22945393:+ LIHC cis rs2439831 0.85 rs67541383 ENSG00000205771.5 CATSPER2P1 -5.16 4.23e-07 0.000171 -0.45 -0.27 Lung cancer in ever smokers; chr15:43880350 chr15:43726918~43747094:- LIHC cis rs4731207 0.565 rs7776744 ENSG00000224897.5 POT1-AS1 5.16 4.24e-07 0.000171 0.33 0.27 Cutaneous malignant melanoma; chr7:124959695 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs13240512 ENSG00000224897.5 POT1-AS1 5.16 4.24e-07 0.000171 0.32 0.27 Cutaneous malignant melanoma; chr7:124931836 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10231818 ENSG00000224897.5 POT1-AS1 5.16 4.24e-07 0.000171 0.32 0.27 Cutaneous malignant melanoma; chr7:124934130 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10264288 ENSG00000224897.5 POT1-AS1 5.16 4.24e-07 0.000171 0.32 0.27 Cutaneous malignant melanoma; chr7:124934473 chr7:124929873~125179315:+ LIHC cis rs36715 0.953 rs2546146 ENSG00000245937.6 LINC01184 5.16 4.24e-07 0.000171 0.32 0.27 Breast cancer; chr5:128210847 chr5:127940426~128083172:- LIHC cis rs6479901 0.846 rs10761761 ENSG00000232075.1 MRPL35P2 -5.16 4.24e-07 0.000171 -0.29 -0.27 Intelligence (multi-trait analysis); chr10:63419398 chr10:63634317~63634827:- LIHC cis rs2153535 0.546 rs9378559 ENSG00000230939.1 RP11-314C16.1 -5.16 4.24e-07 0.000171 -0.34 -0.27 Motion sickness; chr6:8538825 chr6:8784178~8785445:+ LIHC cis rs4718428 0.705 rs3800817 ENSG00000230295.1 RP11-458F8.2 -5.16 4.24e-07 0.000171 -0.23 -0.27 Corneal structure; chr7:66798563 chr7:66880708~66882981:+ LIHC cis rs9467711 0.591 rs13214280 ENSG00000216436.2 HIST1H2APS1 5.16 4.25e-07 0.000171 0.65 0.27 Autism spectrum disorder or schizophrenia; chr6:26008392 chr6:25732497~25732827:+ LIHC cis rs17507216 0.628 rs28607761 ENSG00000278603.1 RP13-608F4.5 5.16 4.26e-07 0.000172 0.56 0.27 Excessive daytime sleepiness; chr15:82715317 chr15:82472203~82472426:+ LIHC cis rs465969 1 rs4509157 ENSG00000255389.1 C6orf3 -5.16 4.27e-07 0.000172 -0.53 -0.27 Psoriasis; chr6:111513875 chr6:111599875~111602295:+ LIHC cis rs150992 0.609 rs366353 ENSG00000248489.1 CTD-2007H13.3 -5.16 4.27e-07 0.000172 -0.39 -0.27 Body mass index; chr5:98995663 chr5:98929171~98995013:+ LIHC cis rs7209700 0.6 rs7218632 ENSG00000228782.6 CTD-2026D20.3 -5.16 4.28e-07 0.000172 -0.3 -0.27 IgG glycosylation; chr17:47287787 chr17:47450568~47492492:- LIHC cis rs3096299 0.967 rs28575874 ENSG00000261118.1 RP11-104N10.1 5.16 4.28e-07 0.000172 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89403482 chr16:89492017~89504460:- LIHC cis rs6921919 0.583 rs3734563 ENSG00000204709.4 LINC01556 5.16 4.29e-07 0.000173 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28381948 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs1591913 ENSG00000204709.4 LINC01556 5.16 4.29e-07 0.000173 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28383951 chr6:28943877~28944537:+ LIHC cis rs9487094 0.626 rs1980591 ENSG00000260273.1 RP11-425D10.10 5.16 4.29e-07 0.000173 0.31 0.27 Height; chr6:109618620 chr6:109382795~109383666:+ LIHC cis rs9487094 0.696 rs12191353 ENSG00000260273.1 RP11-425D10.10 5.16 4.29e-07 0.000173 0.31 0.27 Height; chr6:109620772 chr6:109382795~109383666:+ LIHC cis rs7916697 0.947 rs56238729 ENSG00000233590.1 RP11-153K11.3 -5.16 4.29e-07 0.000173 -0.32 -0.27 Optic disc area; chr10:68241883 chr10:68233251~68242379:- LIHC cis rs860295 1 rs6427287 ENSG00000203761.5 MSTO2P -5.16 4.29e-07 0.000173 -0.21 -0.27 Body mass index; chr1:155753629 chr1:155745829~155750137:+ LIHC cis rs1061377 0.674 rs34506243 ENSG00000249685.1 RP11-360F5.3 5.16 4.3e-07 0.000173 0.32 0.27 Uric acid levels; chr4:39082702 chr4:39133913~39135608:+ LIHC cis rs6479901 0.947 rs10740128 ENSG00000232075.1 MRPL35P2 -5.16 4.3e-07 0.000173 -0.3 -0.27 Intelligence (multi-trait analysis); chr10:63490783 chr10:63634317~63634827:- LIHC cis rs11690935 0.921 rs3770445 ENSG00000228389.1 AC068039.4 5.15 4.31e-07 0.000173 0.36 0.27 Schizophrenia; chr2:171852409 chr2:171773482~171775844:+ LIHC cis rs11722779 0.844 rs3974602 ENSG00000246560.2 RP11-10L12.4 5.15 4.31e-07 0.000173 0.3 0.27 Schizophrenia; chr4:102928840 chr4:102828055~102844075:+ LIHC cis rs916888 0.773 rs538628 ENSG00000274883.1 Metazoa_SRP -5.15 4.32e-07 0.000174 -0.42 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45931806~45932083:+ LIHC cis rs957448 1 rs1055800 ENSG00000253704.1 RP11-267M23.4 -5.15 4.32e-07 0.000174 -0.32 -0.27 Nonsyndromic cleft lip with cleft palate; chr8:94510810 chr8:94553722~94569745:+ LIHC cis rs12701220 0.901 rs12701710 ENSG00000229043.2 AC091729.9 5.15 4.33e-07 0.000174 0.37 0.27 Bronchopulmonary dysplasia; chr7:1050760 chr7:1160374~1165267:+ LIHC cis rs3096299 0.658 rs4291902 ENSG00000261118.1 RP11-104N10.1 5.15 4.33e-07 0.000174 0.26 0.27 Multiple myeloma (IgH translocation); chr16:89493907 chr16:89492017~89504460:- LIHC cis rs10510102 0.688 rs76573813 ENSG00000226864.1 ATE1-AS1 5.15 4.34e-07 0.000174 0.45 0.27 Breast cancer; chr10:121928955 chr10:121928312~121951965:+ LIHC cis rs801193 0.569 rs11772819 ENSG00000237310.1 GS1-124K5.4 5.15 4.34e-07 0.000174 0.24 0.27 Aortic root size; chr7:66752983 chr7:66493706~66495474:+ LIHC cis rs3096299 0.967 rs2965830 ENSG00000261118.1 RP11-104N10.1 5.15 4.35e-07 0.000175 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89393882 chr16:89492017~89504460:- LIHC cis rs801193 0.569 rs7800620 ENSG00000237310.1 GS1-124K5.4 5.15 4.35e-07 0.000175 0.24 0.27 Aortic root size; chr7:66758701 chr7:66493706~66495474:+ LIHC cis rs17711722 0.528 rs73138179 ENSG00000224316.1 RP11-479O9.2 5.15 4.36e-07 0.000175 0.24 0.27 Calcium levels; chr7:65829495 chr7:65773620~65802067:+ LIHC cis rs116175783 0.557 rs16845844 ENSG00000227403.1 AC009299.3 -5.15 4.36e-07 0.000175 -0.41 -0.27 Intelligence (multi-trait analysis); chr2:161408759 chr2:161244739~161249050:+ LIHC cis rs10510102 0.935 rs7083278 ENSG00000226864.1 ATE1-AS1 5.15 4.36e-07 0.000175 0.43 0.27 Breast cancer; chr10:121853758 chr10:121928312~121951965:+ LIHC cis rs950169 0.922 rs11630760 ENSG00000225151.9 GOLGA2P7 -5.15 4.36e-07 0.000175 -0.34 -0.27 Schizophrenia; chr15:84570106 chr15:84199311~84230136:- LIHC cis rs950169 0.887 rs71395453 ENSG00000225151.9 GOLGA2P7 -5.15 4.36e-07 0.000175 -0.34 -0.27 Schizophrenia; chr15:84570259 chr15:84199311~84230136:- LIHC cis rs1322639 0.614 rs9689800 ENSG00000261039.2 RP11-417E7.2 5.15 4.36e-07 0.000175 0.27 0.27 Pulse pressure; chr6:169172850 chr6:169175304~169182740:- LIHC cis rs7587476 0.601 rs13021937 ENSG00000229267.2 AC072062.1 5.15 4.36e-07 0.000175 0.33 0.27 Neuroblastoma; chr2:214809213 chr2:214810229~214963274:+ LIHC cis rs7587476 0.531 rs35933323 ENSG00000229267.2 AC072062.1 5.15 4.36e-07 0.000175 0.33 0.27 Neuroblastoma; chr2:214809366 chr2:214810229~214963274:+ LIHC cis rs7923609 0.871 rs12245149 ENSG00000232075.1 MRPL35P2 5.15 4.36e-07 0.000175 0.29 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63561387 chr10:63634317~63634827:- LIHC cis rs950169 0.922 rs4586394 ENSG00000259728.4 LINC00933 -5.15 4.37e-07 0.000176 -0.4 -0.27 Schizophrenia; chr15:84153633 chr15:84570649~84580175:+ LIHC cis rs10912872 0.672 rs7516677 ENSG00000225704.2 RP4-798A17.5 5.15 4.38e-07 0.000176 0.24 0.27 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr1:171372697 chr1:171345089~171345320:+ LIHC cis rs4731207 0.596 rs6466979 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125007975 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs7794565 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125008914 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10270055 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125009352 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7799712 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125009663 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7799771 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125009883 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10258873 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125010435 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10274513 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125010483 chr7:124929873~125179315:+ LIHC cis rs4731207 0.591 rs1471571 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125010820 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs4507709 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125011479 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1481343 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125012217 chr7:124929873~125179315:+ LIHC cis rs4731207 0.536 rs7792731 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125013382 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7792654 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125013583 chr7:124929873~125179315:+ LIHC cis rs4731207 0.651 rs1525619 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125014487 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1525618 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125014652 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs13224820 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125015345 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs9640828 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125015427 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6957525 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125016323 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6466982 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125016734 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs7776821 ENSG00000224897.5 POT1-AS1 5.15 4.38e-07 0.000176 0.33 0.27 Cutaneous malignant melanoma; chr7:125017450 chr7:124929873~125179315:+ LIHC cis rs9487094 0.6 rs10457193 ENSG00000260273.1 RP11-425D10.10 5.15 4.38e-07 0.000176 0.32 0.27 Height; chr6:109507364 chr6:109382795~109383666:+ LIHC cis rs9487094 0.558 rs10457194 ENSG00000260273.1 RP11-425D10.10 5.15 4.38e-07 0.000176 0.32 0.27 Height; chr6:109507366 chr6:109382795~109383666:+ LIHC cis rs4731207 0.698 rs10227821 ENSG00000224897.5 POT1-AS1 -5.15 4.39e-07 0.000176 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124809533 chr7:124929873~125179315:+ LIHC cis rs4731207 0.735 rs17147494 ENSG00000224897.5 POT1-AS1 -5.15 4.39e-07 0.000176 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124809781 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs17147496 ENSG00000224897.5 POT1-AS1 -5.15 4.39e-07 0.000176 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124809814 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs11978628 ENSG00000224897.5 POT1-AS1 -5.15 4.39e-07 0.000176 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124809843 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs11978656 ENSG00000224897.5 POT1-AS1 -5.15 4.39e-07 0.000176 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124809911 chr7:124929873~125179315:+ LIHC cis rs10510102 0.872 rs116521083 ENSG00000226864.1 ATE1-AS1 5.15 4.4e-07 0.000177 0.46 0.27 Breast cancer; chr10:121950611 chr10:121928312~121951965:+ LIHC cis rs10510102 0.748 rs4589226 ENSG00000226864.1 ATE1-AS1 5.15 4.4e-07 0.000177 0.46 0.27 Breast cancer; chr10:121951073 chr10:121928312~121951965:+ LIHC cis rs10510102 0.81 rs34738294 ENSG00000226864.1 ATE1-AS1 5.15 4.4e-07 0.000177 0.46 0.27 Breast cancer; chr10:121951357 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs12258234 ENSG00000226864.1 ATE1-AS1 5.15 4.4e-07 0.000177 0.46 0.27 Breast cancer; chr10:121952828 chr10:121928312~121951965:+ LIHC cis rs10510102 0.515 rs11200285 ENSG00000226864.1 ATE1-AS1 5.15 4.4e-07 0.000177 0.46 0.27 Breast cancer; chr10:121953931 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs75831447 ENSG00000226864.1 ATE1-AS1 5.15 4.4e-07 0.000177 0.46 0.27 Breast cancer; chr10:121953963 chr10:121928312~121951965:+ LIHC cis rs10510102 0.63 rs79960726 ENSG00000226864.1 ATE1-AS1 5.15 4.4e-07 0.000177 0.46 0.27 Breast cancer; chr10:121954358 chr10:121928312~121951965:+ LIHC cis rs17507216 0.671 rs4779035 ENSG00000278603.1 RP13-608F4.5 5.15 4.4e-07 0.000177 0.55 0.27 Excessive daytime sleepiness; chr15:82591686 chr15:82472203~82472426:+ LIHC cis rs4731207 0.596 rs7789392 ENSG00000224897.5 POT1-AS1 5.15 4.4e-07 0.000177 0.32 0.27 Cutaneous malignant melanoma; chr7:124971022 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7810643 ENSG00000224897.5 POT1-AS1 5.15 4.4e-07 0.000177 0.32 0.27 Cutaneous malignant melanoma; chr7:124971356 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs12531996 ENSG00000224897.5 POT1-AS1 5.15 4.4e-07 0.000177 0.32 0.27 Cutaneous malignant melanoma; chr7:124979406 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6942997 ENSG00000224897.5 POT1-AS1 5.15 4.4e-07 0.000177 0.32 0.27 Cutaneous malignant melanoma; chr7:125008425 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7794959 ENSG00000224897.5 POT1-AS1 5.15 4.4e-07 0.000177 0.32 0.27 Cutaneous malignant melanoma; chr7:125009085 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs1471569 ENSG00000224897.5 POT1-AS1 5.15 4.4e-07 0.000177 0.32 0.27 Cutaneous malignant melanoma; chr7:125010667 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7779244 ENSG00000224897.5 POT1-AS1 5.15 4.4e-07 0.000177 0.32 0.27 Cutaneous malignant melanoma; chr7:125012876 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs6960622 ENSG00000224897.5 POT1-AS1 5.15 4.4e-07 0.000177 0.32 0.27 Cutaneous malignant melanoma; chr7:125014026 chr7:124929873~125179315:+ LIHC cis rs916888 0.773 rs169201 ENSG00000274883.1 Metazoa_SRP -5.15 4.4e-07 0.000177 -0.42 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45931806~45932083:+ LIHC cis rs2929278 0.561 rs3099045 ENSG00000166763.7 STRCP1 5.15 4.4e-07 0.000177 0.35 0.27 Schizophrenia; chr15:43631757 chr15:43699488~43718184:- LIHC cis rs4731207 0.698 rs2286173 ENSG00000224897.5 POT1-AS1 -5.15 4.43e-07 0.000178 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124825897 chr7:124929873~125179315:+ LIHC cis rs11098499 0.954 rs1480931 ENSG00000260091.1 RP11-33B1.4 -5.15 4.43e-07 0.000178 -0.19 -0.27 Corneal astigmatism; chr4:119474654 chr4:119409333~119410233:+ LIHC cis rs4650994 0.525 rs4650991 ENSG00000273384.1 RP5-1098D14.1 5.15 4.44e-07 0.000178 0.34 0.27 HDL cholesterol;HDL cholesterol levels; chr1:178542030 chr1:178651706~178652282:+ LIHC cis rs6479901 1 rs6479901 ENSG00000232075.1 MRPL35P2 -5.15 4.44e-07 0.000178 -0.29 -0.27 Intelligence (multi-trait analysis); chr10:63421016 chr10:63634317~63634827:- LIHC cis rs950169 0.686 rs12906474 ENSG00000259295.5 CSPG4P12 5.15 4.44e-07 0.000178 0.37 0.27 Schizophrenia; chr15:84566006 chr15:85191438~85213905:+ LIHC cis rs950169 0.81 rs2879976 ENSG00000259295.5 CSPG4P12 5.15 4.44e-07 0.000178 0.37 0.27 Schizophrenia; chr15:84566347 chr15:85191438~85213905:+ LIHC cis rs67311347 1 rs56992941 ENSG00000223797.4 ENTPD3-AS1 5.15 4.44e-07 0.000178 0.21 0.27 Renal cell carcinoma; chr3:40430943 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs4974017 ENSG00000223797.4 ENTPD3-AS1 5.15 4.44e-07 0.000178 0.21 0.27 Renal cell carcinoma; chr3:40432028 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs6762997 ENSG00000223797.4 ENTPD3-AS1 5.15 4.44e-07 0.000178 0.21 0.27 Renal cell carcinoma; chr3:40436660 chr3:40313802~40453329:- LIHC cis rs875971 0.545 rs801199 ENSG00000237310.1 GS1-124K5.4 -5.15 4.45e-07 0.000178 -0.25 -0.27 Aortic root size; chr7:66560286 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs1638724 ENSG00000237310.1 GS1-124K5.4 -5.15 4.45e-07 0.000178 -0.25 -0.27 Aortic root size; chr7:66575494 chr7:66493706~66495474:+ LIHC cis rs228614 0.509 rs223480 ENSG00000230069.3 LRRC37A15P -5.15 4.45e-07 0.000178 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766881 chr4:102727274~102730721:- LIHC cis rs957448 0.554 rs4735297 ENSG00000253704.1 RP11-267M23.4 5.15 4.45e-07 0.000179 0.31 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94577112 chr8:94553722~94569745:+ LIHC cis rs4731207 0.596 rs1026839 ENSG00000224897.5 POT1-AS1 -5.15 4.46e-07 0.000179 -0.33 -0.27 Cutaneous malignant melanoma; chr7:125032545 chr7:124929873~125179315:+ LIHC cis rs4660214 0.666 rs2275187 ENSG00000182109.6 RP11-69E11.4 -5.15 4.46e-07 0.000179 -0.28 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39297570 chr1:39522280~39546187:- LIHC cis rs228614 0.536 rs223484 ENSG00000230069.3 LRRC37A15P -5.15 4.46e-07 0.000179 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102764314 chr4:102727274~102730721:- LIHC cis rs875971 0.862 rs6971059 ENSG00000237310.1 GS1-124K5.4 -5.15 4.47e-07 0.000179 -0.23 -0.27 Aortic root size; chr7:66602045 chr7:66493706~66495474:+ LIHC cis rs875971 0.789 rs7808013 ENSG00000237310.1 GS1-124K5.4 -5.15 4.47e-07 0.000179 -0.23 -0.27 Aortic root size; chr7:66606209 chr7:66493706~66495474:+ LIHC cis rs875971 0.825 rs7384021 ENSG00000237310.1 GS1-124K5.4 -5.15 4.47e-07 0.000179 -0.23 -0.27 Aortic root size; chr7:66612917 chr7:66493706~66495474:+ LIHC cis rs875971 0.825 rs66981195 ENSG00000237310.1 GS1-124K5.4 -5.15 4.47e-07 0.000179 -0.23 -0.27 Aortic root size; chr7:66614048 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs3926380 ENSG00000237310.1 GS1-124K5.4 -5.15 4.47e-07 0.000179 -0.23 -0.27 Aortic root size; chr7:66615658 chr7:66493706~66495474:+ LIHC cis rs875971 0.825 rs1860472 ENSG00000237310.1 GS1-124K5.4 -5.15 4.47e-07 0.000179 -0.23 -0.27 Aortic root size; chr7:66617736 chr7:66493706~66495474:+ LIHC cis rs2337406 0.866 rs57684263 ENSG00000274576.2 IGHV2-70 -5.15 4.48e-07 0.000179 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106777263 chr14:106770577~106771020:- LIHC cis rs4660214 0.639 rs6699928 ENSG00000182109.6 RP11-69E11.4 -5.15 4.48e-07 0.000179 -0.28 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39267827 chr1:39522280~39546187:- LIHC cis rs2243480 1 rs34815098 ENSG00000226824.5 RP4-756H11.3 -5.15 4.48e-07 0.000179 -0.44 -0.27 Diabetic kidney disease; chr7:65827267 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs4548056 ENSG00000226824.5 RP4-756H11.3 -5.15 4.48e-07 0.000179 -0.44 -0.27 Diabetic kidney disease; chr7:65833886 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs7456042 ENSG00000226824.5 RP4-756H11.3 -5.15 4.48e-07 0.000179 -0.44 -0.27 Diabetic kidney disease; chr7:65834791 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs35735127 ENSG00000226824.5 RP4-756H11.3 -5.15 4.48e-07 0.000179 -0.44 -0.27 Diabetic kidney disease; chr7:65835436 chr7:66654538~66669855:+ LIHC cis rs2243480 0.901 rs35256305 ENSG00000226824.5 RP4-756H11.3 -5.15 4.48e-07 0.000179 -0.44 -0.27 Diabetic kidney disease; chr7:65841418 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs73142121 ENSG00000226824.5 RP4-756H11.3 -5.15 4.48e-07 0.000179 -0.44 -0.27 Diabetic kidney disease; chr7:65846219 chr7:66654538~66669855:+ LIHC cis rs2243480 0.803 rs34004500 ENSG00000226824.5 RP4-756H11.3 -5.15 4.48e-07 0.000179 -0.44 -0.27 Diabetic kidney disease; chr7:65847191 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs35825738 ENSG00000226824.5 RP4-756H11.3 -5.15 4.48e-07 0.000179 -0.44 -0.27 Diabetic kidney disease; chr7:65853040 chr7:66654538~66669855:+ LIHC cis rs9291683 0.609 rs3796836 ENSG00000250413.1 RP11-448G15.1 -5.15 4.48e-07 0.000179 -0.34 -0.27 Bone mineral density; chr4:10009721 chr4:10006482~10009725:+ LIHC cis rs4731207 0.509 rs6977699 ENSG00000224897.5 POT1-AS1 5.15 4.49e-07 0.00018 0.33 0.27 Cutaneous malignant melanoma; chr7:124977055 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10233589 ENSG00000224897.5 POT1-AS1 -5.15 4.49e-07 0.00018 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124828545 chr7:124929873~125179315:+ LIHC cis rs10510102 0.935 rs11200203 ENSG00000276742.1 RP11-500G22.4 5.15 4.49e-07 0.00018 0.42 0.27 Breast cancer; chr10:121874014 chr10:121956782~121957098:+ LIHC cis rs4660214 0.666 rs598415 ENSG00000182109.6 RP11-69E11.4 5.15 4.49e-07 0.00018 0.28 0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39366735 chr1:39522280~39546187:- LIHC cis rs3096299 0.967 rs28689480 ENSG00000261118.1 RP11-104N10.1 5.15 4.5e-07 0.00018 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89393685 chr16:89492017~89504460:- LIHC cis rs6479891 1 rs9414800 ENSG00000232075.1 MRPL35P2 5.15 4.5e-07 0.00018 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63371522 chr10:63634317~63634827:- LIHC cis rs950169 0.8 rs4842847 ENSG00000225151.9 GOLGA2P7 -5.15 4.5e-07 0.00018 -0.33 -0.27 Schizophrenia; chr15:84262447 chr15:84199311~84230136:- LIHC cis rs6479901 0.947 rs10761755 ENSG00000232075.1 MRPL35P2 -5.15 4.5e-07 0.00018 -0.29 -0.27 Intelligence (multi-trait analysis); chr10:63412212 chr10:63634317~63634827:- LIHC cis rs6479901 0.895 rs10761757 ENSG00000232075.1 MRPL35P2 -5.15 4.5e-07 0.00018 -0.29 -0.27 Intelligence (multi-trait analysis); chr10:63412790 chr10:63634317~63634827:- LIHC cis rs5769765 0.954 rs1569954 ENSG00000278869.1 CITF22-49E9.3 -5.15 4.51e-07 0.000181 -0.39 -0.27 Schizophrenia; chr22:49850423 chr22:49933198~49934074:- LIHC cis rs4356203 0.905 rs7123301 ENSG00000272034.1 SNORD14A -5.15 4.52e-07 0.000181 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17141880 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs512852 ENSG00000272034.1 SNORD14A -5.15 4.52e-07 0.000181 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17193382 chr11:17074654~17074744:- LIHC cis rs916888 0.773 rs199445 ENSG00000274883.1 Metazoa_SRP -5.15 4.52e-07 0.000181 -0.42 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45931806~45932083:+ LIHC cis rs916888 0.773 rs199443 ENSG00000274883.1 Metazoa_SRP -5.15 4.52e-07 0.000181 -0.42 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45931806~45932083:+ LIHC cis rs4731207 0.596 rs1481330 ENSG00000224897.5 POT1-AS1 5.15 4.52e-07 0.000181 0.33 0.27 Cutaneous malignant melanoma; chr7:124991309 chr7:124929873~125179315:+ LIHC cis rs5769765 1 rs764813 ENSG00000278869.1 CITF22-49E9.3 5.14 4.52e-07 0.000181 0.4 0.27 Schizophrenia; chr22:49892524 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs768618 ENSG00000278869.1 CITF22-49E9.3 5.14 4.52e-07 0.000181 0.4 0.27 Schizophrenia; chr22:49893179 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs768619 ENSG00000278869.1 CITF22-49E9.3 5.14 4.52e-07 0.000181 0.4 0.27 Schizophrenia; chr22:49893618 chr22:49933198~49934074:- LIHC cis rs5769765 0.862 rs9616774 ENSG00000278869.1 CITF22-49E9.3 5.14 4.52e-07 0.000181 0.4 0.27 Schizophrenia; chr22:49896951 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs8138941 ENSG00000278869.1 CITF22-49E9.3 5.14 4.52e-07 0.000181 0.4 0.27 Schizophrenia; chr22:49897030 chr22:49933198~49934074:- LIHC cis rs10181042 0.581 rs1177285 ENSG00000271889.1 RP11-493E12.1 5.14 4.52e-07 0.000181 0.33 0.27 Crohn's disease; chr2:61123002 chr2:61151433~61162105:- LIHC cis rs10510102 0.935 rs12243529 ENSG00000226864.1 ATE1-AS1 5.14 4.53e-07 0.000181 0.44 0.27 Breast cancer; chr10:121880321 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs12250677 ENSG00000226864.1 ATE1-AS1 5.14 4.53e-07 0.000181 0.44 0.27 Breast cancer; chr10:121880575 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs12243874 ENSG00000226864.1 ATE1-AS1 5.14 4.53e-07 0.000181 0.44 0.27 Breast cancer; chr10:121880788 chr10:121928312~121951965:+ LIHC cis rs227275 0.525 rs223332 ENSG00000230069.3 LRRC37A15P -5.14 4.53e-07 0.000181 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102869029 chr4:102727274~102730721:- LIHC cis rs1134634 0.52 rs10008889 ENSG00000273133.1 RP11-799M12.2 -5.14 4.53e-07 0.000181 -0.34 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15622896 chr4:15563698~15564253:- LIHC cis rs4731207 0.698 rs720615 ENSG00000224897.5 POT1-AS1 -5.14 4.53e-07 0.000181 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124812652 chr7:124929873~125179315:+ LIHC cis rs4731207 0.735 rs720616 ENSG00000224897.5 POT1-AS1 -5.14 4.53e-07 0.000181 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124812907 chr7:124929873~125179315:+ LIHC cis rs4731207 0.662 rs6466950 ENSG00000224897.5 POT1-AS1 -5.14 4.53e-07 0.000181 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124813020 chr7:124929873~125179315:+ LIHC cis rs4731207 0.646 rs7783781 ENSG00000224897.5 POT1-AS1 -5.14 4.53e-07 0.000181 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124814359 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10260710 ENSG00000224897.5 POT1-AS1 -5.14 4.53e-07 0.000181 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124815932 chr7:124929873~125179315:+ LIHC cis rs4731207 0.672 rs62478914 ENSG00000224897.5 POT1-AS1 -5.14 4.53e-07 0.000181 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124816600 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs7781148 ENSG00000224897.5 POT1-AS1 -5.14 4.53e-07 0.000181 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124817990 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs1468378 ENSG00000224897.5 POT1-AS1 -5.14 4.53e-07 0.000181 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124818305 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs1468377 ENSG00000224897.5 POT1-AS1 -5.14 4.53e-07 0.000181 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124818545 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10243736 ENSG00000224897.5 POT1-AS1 -5.14 4.53e-07 0.000181 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124818912 chr7:124929873~125179315:+ LIHC cis rs17507216 0.628 rs4627310 ENSG00000278603.1 RP13-608F4.5 5.14 4.53e-07 0.000181 0.56 0.27 Excessive daytime sleepiness; chr15:82708330 chr15:82472203~82472426:+ LIHC cis rs17507216 0.628 rs28371837 ENSG00000278603.1 RP13-608F4.5 5.14 4.53e-07 0.000181 0.56 0.27 Excessive daytime sleepiness; chr15:82714435 chr15:82472203~82472426:+ LIHC cis rs2998286 0.862 rs1416816 ENSG00000254635.4 WAC-AS1 -5.14 4.54e-07 0.000181 -0.33 -0.27 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28503491 chr10:28522652~28532743:- LIHC cis rs7429990 0.833 rs7649393 ENSG00000229759.1 MRPS18AP1 -5.14 4.54e-07 0.000182 -0.28 -0.27 Educational attainment (years of education); chr3:47727501 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs7638103 ENSG00000229759.1 MRPS18AP1 -5.14 4.54e-07 0.000182 -0.28 -0.27 Educational attainment (years of education); chr3:47727585 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs11130148 ENSG00000229759.1 MRPS18AP1 -5.14 4.54e-07 0.000182 -0.28 -0.27 Educational attainment (years of education); chr3:47729797 chr3:48256350~48256938:- LIHC cis rs4731207 0.565 rs10227119 ENSG00000224897.5 POT1-AS1 5.14 4.55e-07 0.000182 0.32 0.27 Cutaneous malignant melanoma; chr7:124953726 chr7:124929873~125179315:+ LIHC cis rs1577917 0.958 rs12193904 ENSG00000234155.1 RP11-30P6.6 5.14 4.55e-07 0.000182 0.35 0.27 Response to antipsychotic treatment; chr6:85742985 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs11754330 ENSG00000234155.1 RP11-30P6.6 5.14 4.55e-07 0.000182 0.35 0.27 Response to antipsychotic treatment; chr6:85745352 chr6:85387219~85390186:- LIHC cis rs3096299 0.658 rs4785679 ENSG00000261118.1 RP11-104N10.1 5.14 4.55e-07 0.000182 0.26 0.27 Multiple myeloma (IgH translocation); chr16:89499705 chr16:89492017~89504460:- LIHC cis rs10510102 0.81 rs11200240 ENSG00000226864.1 ATE1-AS1 5.14 4.55e-07 0.000182 0.42 0.27 Breast cancer; chr10:121903265 chr10:121928312~121951965:+ LIHC cis rs10510102 0.688 rs56094144 ENSG00000226864.1 ATE1-AS1 5.14 4.55e-07 0.000182 0.42 0.27 Breast cancer; chr10:121903941 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs74914751 ENSG00000226864.1 ATE1-AS1 5.14 4.55e-07 0.000182 0.42 0.27 Breast cancer; chr10:121904496 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200242 ENSG00000226864.1 ATE1-AS1 5.14 4.55e-07 0.000182 0.42 0.27 Breast cancer; chr10:121905378 chr10:121928312~121951965:+ LIHC cis rs11690935 0.921 rs7355523 ENSG00000228389.1 AC068039.4 5.14 4.55e-07 0.000182 0.36 0.27 Schizophrenia; chr2:171887911 chr2:171773482~171775844:+ LIHC cis rs10800713 0.908 rs6686605 ENSG00000260088.1 RP11-92G12.3 -5.14 4.56e-07 0.000182 -0.37 -0.27 Tandem gait; chr1:200539440 chr1:200669507~200694250:+ LIHC cis rs17826219 0.636 rs8080829 ENSG00000266490.1 CTD-2349P21.9 5.14 4.57e-07 0.000182 0.34 0.27 Body mass index; chr17:30731712 chr17:30792372~30792833:+ LIHC cis rs71520386 0.632 rs10224419 ENSG00000228649.7 AC005682.5 5.14 4.58e-07 0.000183 0.34 0.27 Fibrinogen levels; chr7:22830397 chr7:22854178~22861579:+ LIHC cis rs2337406 0.866 rs4773949 ENSG00000274576.2 IGHV2-70 5.14 4.58e-07 0.000183 0.28 0.27 Alzheimer's disease (late onset); chr14:106808070 chr14:106770577~106771020:- LIHC cis rs887829 0.57 rs13015720 ENSG00000233445.1 RPL17P11 5.14 4.58e-07 0.000183 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233692353 chr2:233721522~233722065:- LIHC cis rs7209700 0.963 rs1000232 ENSG00000228782.6 CTD-2026D20.3 -5.14 4.59e-07 0.000183 -0.3 -0.27 IgG glycosylation; chr17:47279195 chr17:47450568~47492492:- LIHC cis rs4731207 0.698 rs2107936 ENSG00000224897.5 POT1-AS1 -5.14 4.59e-07 0.000183 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124808987 chr7:124929873~125179315:+ LIHC cis rs7923609 0.871 rs2393984 ENSG00000232075.1 MRPL35P2 5.14 4.59e-07 0.000183 0.29 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63555211 chr10:63634317~63634827:- LIHC cis rs7923609 0.871 rs6479905 ENSG00000232075.1 MRPL35P2 5.14 4.59e-07 0.000183 0.29 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63555471 chr10:63634317~63634827:- LIHC cis rs7923609 0.811 rs7919685 ENSG00000232075.1 MRPL35P2 5.14 4.59e-07 0.000183 0.29 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63556040 chr10:63634317~63634827:- LIHC cis rs7923609 0.749 rs12247907 ENSG00000232075.1 MRPL35P2 5.14 4.59e-07 0.000183 0.29 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63557285 chr10:63634317~63634827:- LIHC cis rs7923609 0.746 rs7070761 ENSG00000232075.1 MRPL35P2 5.14 4.59e-07 0.000183 0.29 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63557296 chr10:63634317~63634827:- LIHC cis rs7923609 0.871 rs7898861 ENSG00000232075.1 MRPL35P2 5.14 4.59e-07 0.000183 0.29 0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63559918 chr10:63634317~63634827:- LIHC cis rs2337406 0.866 rs7152809 ENSG00000274576.2 IGHV2-70 -5.14 4.59e-07 0.000183 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106778385 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs7152832 ENSG00000274576.2 IGHV2-70 -5.14 4.59e-07 0.000183 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106778427 chr14:106770577~106771020:- LIHC cis rs7193541 0.691 rs3851728 ENSG00000261079.1 RP11-252A24.3 5.14 4.59e-07 0.000183 0.29 0.27 Multiple myeloma; chr16:74446762 chr16:74367462~74369826:+ LIHC cis rs17301013 0.932 rs6664764 ENSG00000227373.4 RP11-160H22.5 5.14 4.59e-07 0.000183 0.33 0.27 Systemic lupus erythematosus; chr1:174443402 chr1:174115300~174160004:- LIHC cis rs4731207 0.596 rs6963594 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124969179 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6967707 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124969301 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs6967420 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124969306 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10226659 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124969814 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10256218 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124969928 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10275346 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124970292 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7806807 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124971246 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs10234592 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124971602 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs2402757 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124971659 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1585967 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124973290 chr7:124929873~125179315:+ LIHC cis rs4731207 0.591 rs12535300 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124973853 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs10954057 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124973884 chr7:124929873~125179315:+ LIHC cis rs4731207 0.591 rs28634794 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124974376 chr7:124929873~125179315:+ LIHC cis rs4731207 0.651 rs28710776 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124974418 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs12539580 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124979350 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs12531311 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124985492 chr7:124929873~125179315:+ LIHC cis rs4731207 0.503 rs1481325 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124985699 chr7:124929873~125179315:+ LIHC cis rs4731207 0.533 rs1481326 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124985930 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs10954060 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124985983 chr7:124929873~125179315:+ LIHC cis rs4731207 0.565 rs4355714 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124987467 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1481327 ENSG00000224897.5 POT1-AS1 5.14 4.59e-07 0.000183 0.33 0.27 Cutaneous malignant melanoma; chr7:124988228 chr7:124929873~125179315:+ LIHC cis rs1153858 0.945 rs1974981 ENSG00000259520.4 CTD-2651B20.3 5.14 4.61e-07 0.000184 0.33 0.27 Homoarginine levels; chr15:45436925 chr15:45251580~45279251:- LIHC cis rs7208859 0.573 rs55661352 ENSG00000266490.1 CTD-2349P21.9 5.14 4.61e-07 0.000184 0.34 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30718610 chr17:30792372~30792833:+ LIHC cis rs2998286 0.862 rs2486637 ENSG00000254635.4 WAC-AS1 -5.14 4.63e-07 0.000184 -0.33 -0.27 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28505085 chr10:28522652~28532743:- LIHC cis rs8040855 0.965 rs6496766 ENSG00000259295.5 CSPG4P12 -5.14 4.63e-07 0.000184 -0.37 -0.27 Bulimia nervosa; chr15:85159144 chr15:85191438~85213905:+ LIHC cis rs8040855 1 rs6496768 ENSG00000259295.5 CSPG4P12 -5.14 4.63e-07 0.000184 -0.37 -0.27 Bulimia nervosa; chr15:85159701 chr15:85191438~85213905:+ LIHC cis rs2998286 0.815 rs332132 ENSG00000254635.4 WAC-AS1 -5.14 4.63e-07 0.000184 -0.34 -0.27 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28565185 chr10:28522652~28532743:- LIHC cis rs2274273 0.967 rs2340931 ENSG00000258413.1 RP11-665C16.6 -5.14 4.63e-07 0.000184 -0.3 -0.27 Protein biomarker; chr14:55150219 chr14:55262767~55272075:- LIHC cis rs13631 0.697 rs1018330 ENSG00000268996.3 MAN1B1-AS1 5.14 4.63e-07 0.000184 0.29 0.27 Cerebrospinal fluid biomarker levels; chr9:137085933 chr9:137084946~137086817:- LIHC cis rs11722779 0.903 rs4530634 ENSG00000230069.3 LRRC37A15P -5.14 4.63e-07 0.000185 -0.24 -0.27 Schizophrenia; chr4:102937924 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs7676943 ENSG00000230069.3 LRRC37A15P -5.14 4.63e-07 0.000185 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102938135 chr4:102727274~102730721:- LIHC cis rs11722779 0.901 rs28674656 ENSG00000230069.3 LRRC37A15P -5.14 4.63e-07 0.000185 -0.24 -0.27 Schizophrenia; chr4:102944396 chr4:102727274~102730721:- LIHC cis rs11722779 0.838 rs3974494 ENSG00000230069.3 LRRC37A15P -5.14 4.63e-07 0.000185 -0.24 -0.27 Schizophrenia; chr4:102945323 chr4:102727274~102730721:- LIHC cis rs950169 0.84 rs62019457 ENSG00000225151.9 GOLGA2P7 -5.14 4.64e-07 0.000185 -0.33 -0.27 Schizophrenia; chr15:84558911 chr15:84199311~84230136:- LIHC cis rs8072100 0.817 rs12449647 ENSG00000228782.6 CTD-2026D20.3 5.14 4.64e-07 0.000185 0.3 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47471592 chr17:47450568~47492492:- LIHC cis rs2072510 0.569 rs7134860 ENSG00000257715.1 RP11-256L6.2 -5.14 4.64e-07 0.000185 -0.41 -0.27 Metabolite levels (small molecules and protein measures); chr12:95996580 chr12:96025323~96027971:+ LIHC cis rs2072510 0.569 rs7134975 ENSG00000257715.1 RP11-256L6.2 -5.14 4.64e-07 0.000185 -0.41 -0.27 Metabolite levels (small molecules and protein measures); chr12:95996642 chr12:96025323~96027971:+ LIHC cis rs2072510 0.569 rs7306086 ENSG00000257715.1 RP11-256L6.2 -5.14 4.64e-07 0.000185 -0.41 -0.27 Metabolite levels (small molecules and protein measures); chr12:95996724 chr12:96025323~96027971:+ LIHC cis rs950169 0.922 rs2033284 ENSG00000225151.9 GOLGA2P7 -5.14 4.64e-07 0.000185 -0.33 -0.27 Schizophrenia; chr15:84391575 chr15:84199311~84230136:- LIHC cis rs9595908 0.9 rs9591137 ENSG00000212293.1 SNORA16 5.14 4.64e-07 0.000185 0.31 0.27 Body mass index; chr13:32578345 chr13:32420390~32420516:- LIHC cis rs2836974 0.666 rs1888487 ENSG00000255568.3 BRWD1-AS2 -5.14 4.64e-07 0.000185 -0.23 -0.27 Cognitive function; chr21:39311333 chr21:39313935~39314962:+ LIHC cis rs4731207 0.596 rs10081336 ENSG00000224897.5 POT1-AS1 5.14 4.65e-07 0.000185 0.33 0.27 Cutaneous malignant melanoma; chr7:124935891 chr7:124929873~125179315:+ LIHC cis rs4948102 0.595 rs7793921 ENSG00000226278.1 PSPHP1 -5.14 4.66e-07 0.000186 -0.29 -0.27 Plasma homocysteine levels (post-methionine load test); chr7:56053188 chr7:55764797~55773288:+ LIHC cis rs4948102 0.595 rs10255049 ENSG00000226278.1 PSPHP1 -5.14 4.66e-07 0.000186 -0.29 -0.27 Plasma homocysteine levels (post-methionine load test); chr7:56053611 chr7:55764797~55773288:+ LIHC cis rs9409565 0.513 rs16912862 ENSG00000231806.2 PCAT7 -5.14 4.66e-07 0.000186 -0.32 -0.27 Colorectal cancer (alcohol consumption interaction); chr9:94287723 chr9:94555069~94568127:+ LIHC cis rs6921919 0.583 rs1054372 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28368965 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs9468354 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28370024 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs7773051 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28372539 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs12697938 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28373322 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs13437294 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28373758 chr6:28943877~28944537:+ LIHC cis rs6921919 0.609 rs9468357 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28374276 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs34513104 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28375566 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs9461456 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28376039 chr6:28943877~28944537:+ LIHC cis rs6921919 0.525 rs9468360 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28376661 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs16894021 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28377249 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs11751693 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28377306 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs7749736 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28378254 chr6:28943877~28944537:+ LIHC cis rs6921919 0.525 rs9468361 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28378541 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs7775132 ENSG00000204709.4 LINC01556 5.14 4.66e-07 0.000186 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28379236 chr6:28943877~28944537:+ LIHC cis rs11098499 0.954 rs9993199 ENSG00000260091.1 RP11-33B1.4 5.14 4.66e-07 0.000186 0.18 0.27 Corneal astigmatism; chr4:119471718 chr4:119409333~119410233:+ LIHC cis rs4731207 0.596 rs1871771 ENSG00000224897.5 POT1-AS1 5.14 4.67e-07 0.000186 0.33 0.27 Cutaneous malignant melanoma; chr7:125038997 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs6977313 ENSG00000224897.5 POT1-AS1 5.14 4.67e-07 0.000186 0.33 0.27 Cutaneous malignant melanoma; chr7:125041678 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1026836 ENSG00000224897.5 POT1-AS1 5.14 4.67e-07 0.000186 0.33 0.27 Cutaneous malignant melanoma; chr7:125043578 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1525612 ENSG00000224897.5 POT1-AS1 5.14 4.67e-07 0.000186 0.33 0.27 Cutaneous malignant melanoma; chr7:125043993 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs6952915 ENSG00000224897.5 POT1-AS1 5.14 4.67e-07 0.000186 0.33 0.27 Cutaneous malignant melanoma; chr7:125045898 chr7:124929873~125179315:+ LIHC cis rs4731207 0.564 rs6466992 ENSG00000224897.5 POT1-AS1 5.14 4.67e-07 0.000186 0.33 0.27 Cutaneous malignant melanoma; chr7:125052112 chr7:124929873~125179315:+ LIHC cis rs8072100 0.748 rs9908016 ENSG00000228782.6 CTD-2026D20.3 5.14 4.68e-07 0.000186 0.3 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47473995 chr17:47450568~47492492:- LIHC cis rs8072100 0.782 rs28507314 ENSG00000228782.6 CTD-2026D20.3 5.14 4.68e-07 0.000186 0.3 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47474036 chr17:47450568~47492492:- LIHC cis rs7119038 0.818 rs76704408 ENSG00000255239.1 AP002954.6 -5.14 4.68e-07 0.000186 -0.34 -0.27 Sjögren's syndrome; chr11:118812618 chr11:118688039~118690600:- LIHC cis rs6479891 0.841 rs7085869 ENSG00000232075.1 MRPL35P2 -5.14 4.69e-07 0.000187 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63310403 chr10:63634317~63634827:- LIHC cis rs1862618 0.853 rs1423620 ENSG00000271828.1 CTD-2310F14.1 5.14 4.69e-07 0.000187 0.37 0.27 Initial pursuit acceleration; chr5:56805169 chr5:56927874~56929573:+ LIHC cis rs8005677 1 rs1043209 ENSG00000257285.4 RP11-298I3.1 -5.14 4.69e-07 0.000187 -0.27 -0.27 Cognitive ability (multi-trait analysis); chr14:22904777 chr14:22929609~22955562:+ LIHC cis rs17711722 0.653 rs2460421 ENSG00000224316.1 RP11-479O9.2 -5.14 4.7e-07 0.000187 -0.25 -0.27 Calcium levels; chr7:66026136 chr7:65773620~65802067:+ LIHC cis rs10510102 0.935 rs7921873 ENSG00000276742.1 RP11-500G22.4 5.14 4.71e-07 0.000187 0.42 0.27 Breast cancer; chr10:121881736 chr10:121956782~121957098:+ LIHC cis rs1134634 0.52 rs11932730 ENSG00000273133.1 RP11-799M12.2 5.14 4.71e-07 0.000187 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15564135 chr4:15563698~15564253:- LIHC cis rs10129255 0.957 rs11846893 ENSG00000223648.3 IGHV3-64 5.14 4.71e-07 0.000187 0.2 0.27 Kawasaki disease; chr14:106779068 chr14:106643132~106658258:- LIHC cis rs12157904 1 rs5995487 ENSG00000233360.4 Z83844.1 5.14 4.71e-07 0.000187 0.59 0.27 Response to anti-depressant treatment in major depressive disorder; chr22:37636081 chr22:37641832~37658377:- LIHC cis rs1134634 0.52 rs28528670 ENSG00000273133.1 RP11-799M12.2 -5.14 4.72e-07 0.000188 -0.34 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15591295 chr4:15563698~15564253:- LIHC cis rs10510102 0.872 rs12244199 ENSG00000276742.1 RP11-500G22.4 5.14 4.72e-07 0.000188 0.45 0.27 Breast cancer; chr10:121965117 chr10:121956782~121957098:+ LIHC cis rs2439831 1 rs2444032 ENSG00000205771.5 CATSPER2P1 -5.14 4.73e-07 0.000188 -0.37 -0.27 Lung cancer in ever smokers; chr15:43463148 chr15:43726918~43747094:- LIHC cis rs16858210 0.826 rs35494670 ENSG00000234371.6 RPSAP31 5.14 4.74e-07 0.000188 0.34 0.27 Menopause (age at onset); chr3:183888569 chr3:183884924~183888449:+ LIHC cis rs4934494 0.727 rs55823491 ENSG00000232936.4 RP11-80H5.2 5.14 4.74e-07 0.000188 0.34 0.27 Red blood cell count; chr10:89757598 chr10:89645282~89650667:+ LIHC cis rs1223397 0.938 rs20499 ENSG00000215022.6 RP1-257A7.4 -5.13 4.75e-07 0.000188 -0.33 -0.27 Blood pressure; chr6:13294772 chr6:13264861~13295586:- LIHC cis rs4731207 0.596 rs719972 ENSG00000224897.5 POT1-AS1 5.13 4.75e-07 0.000188 0.32 0.27 Cutaneous malignant melanoma; chr7:124991743 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1021080 ENSG00000224897.5 POT1-AS1 5.13 4.75e-07 0.000188 0.32 0.27 Cutaneous malignant melanoma; chr7:124993751 chr7:124929873~125179315:+ LIHC cis rs4731207 0.535 rs1552120 ENSG00000224897.5 POT1-AS1 5.13 4.75e-07 0.000188 0.32 0.27 Cutaneous malignant melanoma; chr7:124999184 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs4406330 ENSG00000224897.5 POT1-AS1 5.13 4.75e-07 0.000188 0.32 0.27 Cutaneous malignant melanoma; chr7:125001437 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1013754 ENSG00000224897.5 POT1-AS1 5.13 4.75e-07 0.000188 0.32 0.27 Cutaneous malignant melanoma; chr7:125001993 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs12533918 ENSG00000224897.5 POT1-AS1 5.13 4.75e-07 0.000188 0.32 0.27 Cutaneous malignant melanoma; chr7:125007209 chr7:124929873~125179315:+ LIHC cis rs950169 0.84 rs12905223 ENSG00000225151.9 GOLGA2P7 -5.13 4.75e-07 0.000189 -0.34 -0.27 Schizophrenia; chr15:84571037 chr15:84199311~84230136:- LIHC cis rs9425766 0.64 rs17301013 ENSG00000227373.4 RP11-160H22.5 5.13 4.75e-07 0.000189 0.33 0.27 Life satisfaction; chr1:174343675 chr1:174115300~174160004:- LIHC cis rs7131987 0.65 rs7301398 ENSG00000275476.1 RP11-996F15.4 -5.13 4.76e-07 0.000189 -0.31 -0.27 QT interval; chr12:29302457 chr12:29277397~29277882:- LIHC cis rs7131987 0.65 rs7301188 ENSG00000275476.1 RP11-996F15.4 -5.13 4.76e-07 0.000189 -0.31 -0.27 QT interval; chr12:29302458 chr12:29277397~29277882:- LIHC cis rs4356203 0.87 rs214926 ENSG00000272034.1 SNORD14A -5.13 4.76e-07 0.000189 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17210255 chr11:17074654~17074744:- LIHC cis rs9467711 0.591 rs116201501 ENSG00000216436.2 HIST1H2APS1 5.13 4.78e-07 0.000189 0.65 0.27 Autism spectrum disorder or schizophrenia; chr6:25998921 chr6:25732497~25732827:+ LIHC cis rs9467711 0.591 rs72834617 ENSG00000216436.2 HIST1H2APS1 5.13 4.78e-07 0.000189 0.65 0.27 Autism spectrum disorder or schizophrenia; chr6:25998947 chr6:25732497~25732827:+ LIHC cis rs6479891 1 rs6479899 ENSG00000232075.1 MRPL35P2 -5.13 4.78e-07 0.000189 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63379287 chr10:63634317~63634827:- LIHC cis rs4934494 0.768 rs1926139 ENSG00000232936.4 RP11-80H5.2 5.13 4.78e-07 0.000189 0.34 0.27 Red blood cell count; chr10:89753395 chr10:89645282~89650667:+ LIHC cis rs4934494 0.727 rs12570750 ENSG00000232936.4 RP11-80H5.2 5.13 4.78e-07 0.000189 0.34 0.27 Red blood cell count; chr10:89761273 chr10:89645282~89650667:+ LIHC cis rs4934494 0.723 rs17127001 ENSG00000232936.4 RP11-80H5.2 5.13 4.78e-07 0.000189 0.34 0.27 Red blood cell count; chr10:89762932 chr10:89645282~89650667:+ LIHC cis rs4934494 0.727 rs36019294 ENSG00000232936.4 RP11-80H5.2 5.13 4.78e-07 0.000189 0.34 0.27 Red blood cell count; chr10:89777822 chr10:89645282~89650667:+ LIHC cis rs4934494 0.636 rs34408087 ENSG00000232936.4 RP11-80H5.2 5.13 4.78e-07 0.000189 0.34 0.27 Red blood cell count; chr10:89783794 chr10:89645282~89650667:+ LIHC cis rs10129255 0.957 rs12590735 ENSG00000223648.3 IGHV3-64 5.13 4.78e-07 0.00019 0.2 0.27 Kawasaki disease; chr14:106779660 chr14:106643132~106658258:- LIHC cis rs853679 0.55 rs1150692 ENSG00000219392.1 RP1-265C24.5 -5.13 4.78e-07 0.00019 -0.42 -0.27 Depression; chr6:28206179 chr6:28115628~28116551:+ LIHC cis rs931127 0.554 rs11227261 ENSG00000265874.1 MIR4489 -5.13 4.79e-07 0.00019 -0.37 -0.27 Systemic lupus erythematosus; chr11:65695372 chr11:65649192~65649253:+ LIHC cis rs7714584 1 rs11167515 ENSG00000197083.10 ZNF300P1 5.13 4.79e-07 0.00019 0.42 0.27 Crohn's disease; chr5:150859909 chr5:150930645~150946289:- LIHC cis rs367615 0.552 rs2963024 ENSG00000249476.1 CTD-2587M2.1 -5.13 4.79e-07 0.00019 -0.31 -0.27 Colorectal cancer (SNP x SNP interaction); chr5:109395072 chr5:109237120~109326369:- LIHC cis rs4731207 0.562 rs6466991 ENSG00000224897.5 POT1-AS1 5.13 4.8e-07 0.00019 0.33 0.27 Cutaneous malignant melanoma; chr7:125051912 chr7:124929873~125179315:+ LIHC cis rs5760092 0.572 rs738806 ENSG00000218537.1 MIF-AS1 5.13 4.8e-07 0.00019 0.4 0.27 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23894426~23898930:- LIHC cis rs904251 0.797 rs1757181 ENSG00000204110.6 RP1-153P14.8 5.13 4.8e-07 0.00019 0.34 0.27 Cognitive performance; chr6:37517952 chr6:37507348~37535616:+ LIHC cis rs10510102 0.872 rs56108883 ENSG00000226864.1 ATE1-AS1 5.13 4.82e-07 0.000191 0.42 0.27 Breast cancer; chr10:121825567 chr10:121928312~121951965:+ LIHC cis rs16858210 0.913 rs1879255 ENSG00000234371.6 RPSAP31 5.13 4.82e-07 0.000191 0.35 0.27 Menopause (age at onset); chr3:183891657 chr3:183884924~183888449:+ LIHC cis rs16858210 0.837 rs1879254 ENSG00000234371.6 RPSAP31 5.13 4.82e-07 0.000191 0.35 0.27 Menopause (age at onset); chr3:183891683 chr3:183884924~183888449:+ LIHC cis rs2060793 0.741 rs10734227 ENSG00000251991.1 RNU7-49P 5.13 4.82e-07 0.000191 0.3 0.27 Vitamin D levels; chr11:14767471 chr11:14478892~14478953:+ LIHC cis rs765787 0.53 rs12905246 ENSG00000259520.4 CTD-2651B20.3 -5.13 4.82e-07 0.000191 -0.31 -0.27 Uric acid levels; chr15:45208643 chr15:45251580~45279251:- LIHC cis rs1577917 0.958 rs13213899 ENSG00000234155.1 RP11-30P6.6 5.13 4.82e-07 0.000191 0.35 0.27 Response to antipsychotic treatment; chr6:85763422 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs10806337 ENSG00000234155.1 RP11-30P6.6 5.13 4.82e-07 0.000191 0.35 0.27 Response to antipsychotic treatment; chr6:85764531 chr6:85387219~85390186:- LIHC cis rs9326248 0.581 rs10892076 ENSG00000236267.1 AP006216.5 5.13 4.83e-07 0.000191 0.27 0.27 Blood protein levels; chr11:117118220 chr11:116813204~116814003:- LIHC cis rs116175783 0.557 rs62194490 ENSG00000227403.1 AC009299.3 5.13 4.84e-07 0.000192 0.41 0.27 Intelligence (multi-trait analysis); chr2:161344287 chr2:161244739~161249050:+ LIHC cis rs73186030 0.546 rs6791616 ENSG00000272758.4 RP11-299J3.8 5.13 4.84e-07 0.000192 0.45 0.27 Serum parathyroid hormone levels; chr3:122388388 chr3:122416207~122443180:+ LIHC cis rs2439831 1 rs2584726 ENSG00000205771.5 CATSPER2P1 -5.13 4.84e-07 0.000192 -0.36 -0.27 Lung cancer in ever smokers; chr15:43423184 chr15:43726918~43747094:- LIHC cis rs7615952 0.546 rs2922194 ENSG00000171084.14 FAM86JP 5.13 4.85e-07 0.000192 0.47 0.27 Blood pressure (smoking interaction); chr3:125613419 chr3:125916620~125930024:+ LIHC cis rs380904 0.519 rs10102146 ENSG00000254859.1 RP11-661A12.5 5.13 4.85e-07 0.000192 0.51 0.27 Venous thromboembolism (SNP x SNP interaction); chr8:143566986 chr8:143541973~143549729:- LIHC cis rs4731207 0.596 rs6954614 ENSG00000224897.5 POT1-AS1 5.13 4.86e-07 0.000192 0.33 0.27 Cutaneous malignant melanoma; chr7:124989740 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7788066 ENSG00000224897.5 POT1-AS1 5.13 4.86e-07 0.000192 0.33 0.27 Cutaneous malignant melanoma; chr7:124990091 chr7:124929873~125179315:+ LIHC cis rs4731207 0.536 rs34630567 ENSG00000224897.5 POT1-AS1 5.13 4.86e-07 0.000192 0.33 0.27 Cutaneous malignant melanoma; chr7:124990609 chr7:124929873~125179315:+ LIHC cis rs10510102 0.872 rs11200267 ENSG00000226864.1 ATE1-AS1 5.13 4.86e-07 0.000193 0.47 0.27 Breast cancer; chr10:121929851 chr10:121928312~121951965:+ LIHC cis rs4713118 0.662 rs149961 ENSG00000219392.1 RP1-265C24.5 -5.13 4.86e-07 0.000193 -0.39 -0.27 Parkinson's disease; chr6:28047791 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs9357060 ENSG00000219392.1 RP1-265C24.5 -5.13 4.86e-07 0.000193 -0.39 -0.27 Parkinson's disease; chr6:28056708 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs9468271 ENSG00000219392.1 RP1-265C24.5 -5.13 4.86e-07 0.000193 -0.39 -0.27 Parkinson's disease; chr6:28056792 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs9380045 ENSG00000219392.1 RP1-265C24.5 -5.13 4.86e-07 0.000193 -0.39 -0.27 Parkinson's disease; chr6:28057501 chr6:28115628~28116551:+ LIHC cis rs4713118 0.616 rs9348789 ENSG00000219392.1 RP1-265C24.5 -5.13 4.86e-07 0.000193 -0.39 -0.27 Parkinson's disease; chr6:28057708 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs9468274 ENSG00000219392.1 RP1-265C24.5 -5.13 4.86e-07 0.000193 -0.39 -0.27 Parkinson's disease; chr6:28058299 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs9468275 ENSG00000219392.1 RP1-265C24.5 -5.13 4.86e-07 0.000193 -0.39 -0.27 Parkinson's disease; chr6:28058358 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs9468276 ENSG00000219392.1 RP1-265C24.5 -5.13 4.86e-07 0.000193 -0.39 -0.27 Parkinson's disease; chr6:28059910 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs9468277 ENSG00000219392.1 RP1-265C24.5 -5.13 4.86e-07 0.000193 -0.39 -0.27 Parkinson's disease; chr6:28060612 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs9468278 ENSG00000219392.1 RP1-265C24.5 -5.13 4.86e-07 0.000193 -0.39 -0.27 Parkinson's disease; chr6:28060704 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs13218430 ENSG00000219392.1 RP1-265C24.5 -5.13 4.86e-07 0.000193 -0.39 -0.27 Parkinson's disease; chr6:28062059 chr6:28115628~28116551:+ LIHC cis rs6921919 0.583 rs7759191 ENSG00000204709.4 LINC01556 5.13 4.86e-07 0.000193 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28385657 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs7764737 ENSG00000204709.4 LINC01556 5.13 4.86e-07 0.000193 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28386838 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs9461458 ENSG00000204709.4 LINC01556 5.13 4.86e-07 0.000193 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28388098 chr6:28943877~28944537:+ LIHC cis rs6921919 0.609 rs9468365 ENSG00000204709.4 LINC01556 5.13 4.86e-07 0.000193 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28390189 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs1361385 ENSG00000204709.4 LINC01556 5.13 4.86e-07 0.000193 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28390543 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs1416918 ENSG00000204709.4 LINC01556 5.13 4.86e-07 0.000193 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28390558 chr6:28943877~28944537:+ LIHC cis rs992157 0.764 rs2015863 ENSG00000261338.2 RP11-378A13.1 -5.13 4.87e-07 0.000193 -0.29 -0.27 Colorectal cancer; chr2:218320438 chr2:218255319~218257366:+ LIHC cis rs5769765 1 rs5770755 ENSG00000278869.1 CITF22-49E9.3 -5.13 4.88e-07 0.000193 -0.4 -0.27 Schizophrenia; chr22:49886488 chr22:49933198~49934074:- LIHC cis rs11722779 0.838 rs4533776 ENSG00000230069.3 LRRC37A15P -5.13 4.88e-07 0.000193 -0.24 -0.27 Schizophrenia; chr4:102912732 chr4:102727274~102730721:- LIHC cis rs11722779 0.838 rs6821247 ENSG00000230069.3 LRRC37A15P -5.13 4.88e-07 0.000193 -0.24 -0.27 Schizophrenia; chr4:102913483 chr4:102727274~102730721:- LIHC cis rs228614 0.514 rs59550147 ENSG00000230069.3 LRRC37A15P -5.13 4.88e-07 0.000193 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102914239 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs9917919 ENSG00000230069.3 LRRC37A15P -5.13 4.88e-07 0.000193 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102918497 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs3974608 ENSG00000230069.3 LRRC37A15P -5.13 4.88e-07 0.000193 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102925641 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs10028116 ENSG00000230069.3 LRRC37A15P -5.13 4.88e-07 0.000193 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102931421 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs9307281 ENSG00000230069.3 LRRC37A15P -5.13 4.88e-07 0.000193 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102934971 chr4:102727274~102730721:- LIHC cis rs11722779 0.903 rs6533037 ENSG00000230069.3 LRRC37A15P -5.13 4.88e-07 0.000193 -0.24 -0.27 Schizophrenia; chr4:102935865 chr4:102727274~102730721:- LIHC cis rs858239 0.633 rs858300 ENSG00000226816.2 AC005082.12 5.13 4.88e-07 0.000193 0.35 0.27 Cerebrospinal fluid biomarker levels; chr7:23205012 chr7:23206013~23208045:+ LIHC cis rs950169 0.58 rs4603535 ENSG00000259295.5 CSPG4P12 5.13 4.89e-07 0.000193 0.37 0.27 Schizophrenia; chr15:84630641 chr15:85191438~85213905:+ LIHC cis rs957448 0.554 rs72674877 ENSG00000253704.1 RP11-267M23.4 5.13 4.89e-07 0.000193 0.31 0.27 Nonsyndromic cleft lip with cleft palate; chr8:94580479 chr8:94553722~94569745:+ LIHC cis rs4650994 0.544 rs6682815 ENSG00000273384.1 RP5-1098D14.1 5.13 4.89e-07 0.000193 0.33 0.27 HDL cholesterol;HDL cholesterol levels; chr1:178531974 chr1:178651706~178652282:+ LIHC cis rs875971 0.545 rs73142233 ENSG00000237310.1 GS1-124K5.4 5.13 4.9e-07 0.000194 0.25 0.27 Aortic root size; chr7:66221293 chr7:66493706~66495474:+ LIHC cis rs4718428 0.705 rs13227468 ENSG00000230295.1 RP11-458F8.2 -5.13 4.91e-07 0.000194 -0.23 -0.27 Corneal structure; chr7:66968576 chr7:66880708~66882981:+ LIHC cis rs9992667 0.955 rs1962053 ENSG00000231160.8 KLF3-AS1 5.13 4.91e-07 0.000194 0.36 0.27 Eosinophil percentage of granulocytes; chr4:38610736 chr4:38612701~38664883:- LIHC cis rs9992667 0.955 rs28510735 ENSG00000231160.8 KLF3-AS1 5.13 4.91e-07 0.000194 0.36 0.27 Eosinophil percentage of granulocytes; chr4:38612320 chr4:38612701~38664883:- LIHC cis rs9992667 0.955 rs6819274 ENSG00000231160.8 KLF3-AS1 5.13 4.91e-07 0.000194 0.36 0.27 Eosinophil percentage of granulocytes; chr4:38614306 chr4:38612701~38664883:- LIHC cis rs875971 0.825 rs28480509 ENSG00000237310.1 GS1-124K5.4 -5.13 4.93e-07 0.000195 -0.24 -0.27 Aortic root size; chr7:66634237 chr7:66493706~66495474:+ LIHC cis rs5769765 0.773 rs9616395 ENSG00000278869.1 CITF22-49E9.3 5.13 4.93e-07 0.000195 0.42 0.27 Schizophrenia; chr22:49924155 chr22:49933198~49934074:- LIHC cis rs801193 0.569 rs13242290 ENSG00000237310.1 GS1-124K5.4 -5.13 4.93e-07 0.000195 -0.23 -0.27 Aortic root size; chr7:66656898 chr7:66493706~66495474:+ LIHC cis rs6921919 0.583 rs7740351 ENSG00000204709.4 LINC01556 5.13 4.94e-07 0.000195 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28431635 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs2071965 ENSG00000204709.4 LINC01556 5.13 4.94e-07 0.000195 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28435448 chr6:28943877~28944537:+ LIHC cis rs6589219 0.826 rs10891241 ENSG00000196167.8 COLCA1 -5.13 4.95e-07 0.000195 -0.3 -0.27 Colorectal cancer; chr11:111272783 chr11:111290787~111305045:- LIHC cis rs2337406 0.5 rs7152934 ENSG00000274576.2 IGHV2-70 -5.13 4.95e-07 0.000195 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106778702 chr14:106770577~106771020:- LIHC cis rs853679 0.55 rs1233701 ENSG00000219392.1 RP1-265C24.5 5.13 4.95e-07 0.000195 0.4 0.27 Depression; chr6:28200948 chr6:28115628~28116551:+ LIHC cis rs1075265 0.568 rs959286 ENSG00000233266.1 HMGB1P31 5.13 4.96e-07 0.000196 0.33 0.27 Chronotype;Morning vs. evening chronotype; chr2:54078941 chr2:54051334~54051760:+ LIHC cis rs5769765 0.773 rs9616206 ENSG00000278869.1 CITF22-49E9.3 5.13 4.96e-07 0.000196 0.44 0.27 Schizophrenia; chr22:49917199 chr22:49933198~49934074:- LIHC cis rs1150668 0.799 rs1150705 ENSG00000204709.4 LINC01556 5.13 4.96e-07 0.000196 0.3 0.27 Pubertal anthropometrics; chr6:28226008 chr6:28943877~28944537:+ LIHC cis rs8072100 0.748 rs9912592 ENSG00000228782.6 CTD-2026D20.3 5.13 4.97e-07 0.000196 0.3 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47479579 chr17:47450568~47492492:- LIHC cis rs72627509 0.904 rs781663 ENSG00000269949.1 RP11-738E22.3 5.13 4.97e-07 0.000196 0.35 0.27 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56915588 chr4:56960927~56961373:- LIHC cis rs950169 0.922 rs4338765 ENSG00000259295.5 CSPG4P12 5.13 4.98e-07 0.000196 0.36 0.27 Schizophrenia; chr15:84248084 chr15:85191438~85213905:+ LIHC cis rs4731207 0.596 rs1871770 ENSG00000224897.5 POT1-AS1 5.13 4.98e-07 0.000196 0.33 0.27 Cutaneous malignant melanoma; chr7:124990785 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs1481329 ENSG00000224897.5 POT1-AS1 5.13 4.98e-07 0.000196 0.33 0.27 Cutaneous malignant melanoma; chr7:124991280 chr7:124929873~125179315:+ LIHC cis rs202072 0.769 rs495895 ENSG00000215022.6 RP1-257A7.4 -5.13 4.98e-07 0.000196 -0.31 -0.27 HIV-1 viral setpoint; chr6:13277683 chr6:13264861~13295586:- LIHC cis rs755249 0.958 rs17264866 ENSG00000182109.6 RP11-69E11.4 5.13 4.98e-07 0.000196 0.37 0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39557105 chr1:39522280~39546187:- LIHC cis rs227275 0.554 rs223381 ENSG00000230069.3 LRRC37A15P -5.13 4.98e-07 0.000197 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102832578 chr4:102727274~102730721:- LIHC cis rs11690935 0.885 rs7602037 ENSG00000228389.1 AC068039.4 5.12 4.99e-07 0.000197 0.35 0.27 Schizophrenia; chr2:171961268 chr2:171773482~171775844:+ LIHC cis rs10875746 0.551 rs11168536 ENSG00000240399.1 RP1-228P16.1 -5.12 4.99e-07 0.000197 -0.29 -0.27 Longevity (90 years and older); chr12:48351268 chr12:48054813~48055591:- LIHC cis rs875971 0.502 rs2465121 ENSG00000226824.5 RP4-756H11.3 5.12 4.99e-07 0.000197 0.34 0.27 Aortic root size; chr7:66156017 chr7:66654538~66669855:+ LIHC cis rs950169 0.922 rs67804993 ENSG00000259728.4 LINC00933 5.12 5e-07 0.000197 0.38 0.27 Schizophrenia; chr15:84560799 chr15:84570649~84580175:+ LIHC cis rs4925386 0.808 rs1741634 ENSG00000273619.1 RP5-908M14.9 5.12 5e-07 0.000197 0.21 0.27 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62350923 chr20:62386303~62386970:- LIHC cis rs73186030 0.546 rs55857899 ENSG00000272758.4 RP11-299J3.8 5.12 5.01e-07 0.000197 0.46 0.27 Serum parathyroid hormone levels; chr3:122390705 chr3:122416207~122443180:+ LIHC cis rs73186030 0.546 rs73188320 ENSG00000272758.4 RP11-299J3.8 5.12 5.01e-07 0.000197 0.46 0.27 Serum parathyroid hormone levels; chr3:122391694 chr3:122416207~122443180:+ LIHC cis rs1075265 0.527 rs959285 ENSG00000233266.1 HMGB1P31 5.12 5.01e-07 0.000197 0.33 0.27 Chronotype;Morning vs. evening chronotype; chr2:54078964 chr2:54051334~54051760:+ LIHC cis rs4948102 0.667 rs7811270 ENSG00000226278.1 PSPHP1 -5.12 5.02e-07 0.000198 -0.31 -0.27 Plasma homocysteine levels (post-methionine load test); chr7:56072297 chr7:55764797~55773288:+ LIHC cis rs6921919 0.583 rs9468367 ENSG00000204709.4 LINC01556 5.12 5.02e-07 0.000198 0.33 0.27 Autism spectrum disorder or schizophrenia; chr6:28392469 chr6:28943877~28944537:+ LIHC cis rs3812049 0.506 rs36694 ENSG00000245937.6 LINC01184 5.12 5.02e-07 0.000198 0.33 0.27 Lymphocyte counts;Red cell distribution width; chr5:128213263 chr5:127940426~128083172:- LIHC cis rs10129255 0.957 rs8009073 ENSG00000223648.3 IGHV3-64 5.12 5.03e-07 0.000198 0.2 0.27 Kawasaki disease; chr14:106777278 chr14:106643132~106658258:- LIHC cis rs3096299 0.719 rs2911265 ENSG00000261118.1 RP11-104N10.1 5.12 5.04e-07 0.000198 0.26 0.27 Multiple myeloma (IgH translocation); chr16:89444920 chr16:89492017~89504460:- LIHC cis rs6977955 0.877 rs9648346 ENSG00000234336.5 JAZF1-AS1 -5.12 5.04e-07 0.000199 -0.38 -0.27 Allergic disease (asthma, hay fever or eczema); chr7:28120494 chr7:28180322~28243917:+ LIHC cis rs227275 0.525 rs13113923 ENSG00000246560.2 RP11-10L12.4 5.12 5.05e-07 0.000199 0.3 0.27 Allergic disease (asthma, hay fever or eczema); chr4:102918936 chr4:102828055~102844075:+ LIHC cis rs36715 1 rs36693 ENSG00000245937.6 LINC01184 5.12 5.05e-07 0.000199 0.33 0.27 Breast cancer; chr5:128213008 chr5:127940426~128083172:- LIHC cis rs950169 0.922 rs12912934 ENSG00000225151.9 GOLGA2P7 -5.12 5.06e-07 0.000199 -0.34 -0.27 Schizophrenia; chr15:84571216 chr15:84199311~84230136:- LIHC cis rs1555322 0.53 rs2425047 ENSG00000279253.1 RP4-614O4.13 5.12 5.06e-07 0.000199 0.34 0.27 Attention deficit hyperactivity disorder; chr20:35283872 chr20:35262727~35264187:- LIHC cis rs4535700 0.501 rs57153841 ENSG00000226278.1 PSPHP1 5.12 5.07e-07 0.000199 0.33 0.27 Macular telangiectasia type 2; chr7:55927400 chr7:55764797~55773288:+ LIHC cis rs2877649 0.793 rs114984773 ENSG00000258744.1 RP11-80A15.1 -5.12 5.07e-07 0.000199 -0.56 -0.27 Smooth-surface caries; chr14:24453640 chr14:24501594~24508688:+ LIHC cis rs2877649 0.793 rs112428482 ENSG00000258744.1 RP11-80A15.1 -5.12 5.07e-07 0.000199 -0.56 -0.27 Smooth-surface caries; chr14:24453907 chr14:24501594~24508688:+ LIHC cis rs734999 0.967 rs10797434 ENSG00000225931.3 RP3-395M20.7 5.12 5.07e-07 2e-04 0.29 0.27 Ulcerative colitis; chr1:2579841 chr1:2566410~2569888:+ LIHC cis rs4731207 0.698 rs16871295 ENSG00000224897.5 POT1-AS1 -5.12 5.08e-07 2e-04 -0.32 -0.27 Cutaneous malignant melanoma; chr7:124821234 chr7:124929873~125179315:+ LIHC cis rs5769765 0.955 rs9616204 ENSG00000278869.1 CITF22-49E9.3 5.12 5.08e-07 2e-04 0.43 0.27 Schizophrenia; chr22:49909882 chr22:49933198~49934074:- LIHC cis rs5769765 0.955 rs9616368 ENSG00000278869.1 CITF22-49E9.3 5.12 5.08e-07 2e-04 0.43 0.27 Schizophrenia; chr22:49909885 chr22:49933198~49934074:- LIHC cis rs1061377 0.748 rs10856841 ENSG00000249685.1 RP11-360F5.3 5.12 5.09e-07 2e-04 0.32 0.27 Uric acid levels; chr4:39095240 chr4:39133913~39135608:+ LIHC cis rs10829156 0.699 rs10764584 ENSG00000225527.1 RP11-383B4.4 5.12 5.09e-07 2e-04 0.43 0.27 Sudden cardiac arrest; chr10:18546396 chr10:18531849~18533336:- LIHC cis rs7119038 0.818 rs10892288 ENSG00000255239.1 AP002954.6 -5.12 5.09e-07 2e-04 -0.38 -0.27 Sjögren's syndrome; chr11:118773985 chr11:118688039~118690600:- LIHC cis rs7119038 0.818 rs56043232 ENSG00000255239.1 AP002954.6 -5.12 5.09e-07 2e-04 -0.38 -0.27 Sjögren's syndrome; chr11:118777664 chr11:118688039~118690600:- LIHC cis rs1577917 0.958 rs34765423 ENSG00000234155.1 RP11-30P6.6 5.12 5.1e-07 0.000201 0.36 0.27 Response to antipsychotic treatment; chr6:85774730 chr6:85387219~85390186:- LIHC cis rs228614 0.536 rs223475 ENSG00000230069.3 LRRC37A15P -5.12 5.11e-07 0.000201 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771986 chr4:102727274~102730721:- LIHC cis rs228614 0.536 rs223474 ENSG00000230069.3 LRRC37A15P -5.12 5.11e-07 0.000201 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102772007 chr4:102727274~102730721:- LIHC cis rs9322193 0.607 rs10457852 ENSG00000268592.3 RAET1E-AS1 5.12 5.12e-07 0.000201 0.36 0.27 Lung cancer; chr6:149880584 chr6:149863494~149919507:+ LIHC cis rs5758511 0.68 rs1107554 ENSG00000237037.8 NDUFA6-AS1 -5.12 5.12e-07 0.000201 -0.33 -0.27 Birth weight; chr22:42271588 chr22:42090931~42137742:+ LIHC cis rs4718428 0.705 rs12698547 ENSG00000230295.1 RP11-458F8.2 -5.12 5.12e-07 0.000201 -0.23 -0.27 Corneal structure; chr7:66813271 chr7:66880708~66882981:+ LIHC cis rs11722779 0.935 rs3857200 ENSG00000230069.3 LRRC37A15P -5.12 5.12e-07 0.000201 -0.24 -0.27 Schizophrenia; chr4:103001864 chr4:102727274~102730721:- LIHC cis rs496547 0.719 rs476246 ENSG00000255422.1 AP002954.4 5.12 5.13e-07 0.000202 0.3 0.27 Hip minimal joint space width; chr11:118747211 chr11:118704607~118750263:+ LIHC cis rs4731207 0.596 rs723444 ENSG00000224897.5 POT1-AS1 5.12 5.14e-07 0.000202 0.32 0.27 Cutaneous malignant melanoma; chr7:125019170 chr7:124929873~125179315:+ LIHC cis rs4660214 0.666 rs596062 ENSG00000182109.6 RP11-69E11.4 5.12 5.14e-07 0.000202 0.28 0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39360333 chr1:39522280~39546187:- LIHC cis rs4660214 0.666 rs6704246 ENSG00000182109.6 RP11-69E11.4 -5.12 5.14e-07 0.000202 -0.28 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39343612 chr1:39522280~39546187:- LIHC cis rs9549367 0.826 rs2302755 ENSG00000269125.1 RP11-98F14.11 -5.12 5.15e-07 0.000202 -0.3 -0.27 Platelet distribution width; chr13:113244104 chr13:113165002~113165183:- LIHC cis rs1563304 1 rs1563304 ENSG00000214401.4 KANSL1-AS1 5.12 5.15e-07 0.000202 0.52 0.27 Neuroticism; chr17:46797087 chr17:46193576~46196723:+ LIHC cis rs2735413 0.918 rs4887932 ENSG00000276007.1 RP11-358L22.3 -5.12 5.17e-07 0.000203 -0.29 -0.27 Systolic blood pressure (alcohol consumption interaction); chr16:78044453 chr16:78123243~78124332:+ LIHC cis rs4862307 0.688 rs6552743 ENSG00000250726.1 RP11-616K6.1 5.12 5.18e-07 0.000203 0.28 0.27 Serum dimethylarginine levels (asymmetric/symetric ratio); chr4:184069363 chr4:184072403~184073039:+ LIHC cis rs9532669 0.889 rs7333447 ENSG00000176268.5 CYCSP34 5.12 5.18e-07 0.000203 0.29 0.27 Cervical cancer; chr13:40917586 chr13:40863599~40863902:- LIHC cis rs801193 0.569 rs10950050 ENSG00000237310.1 GS1-124K5.4 5.12 5.18e-07 0.000203 0.23 0.27 Aortic root size; chr7:66774601 chr7:66493706~66495474:+ LIHC cis rs7688540 0.723 rs9684973 ENSG00000275426.1 CH17-262A2.1 5.12 5.19e-07 0.000204 0.36 0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:245032 chr4:149738~150317:+ LIHC cis rs3096299 0.838 rs4785561 ENSG00000261118.1 RP11-104N10.1 5.12 5.19e-07 0.000204 0.3 0.27 Multiple myeloma (IgH translocation); chr16:89362644 chr16:89492017~89504460:- LIHC cis rs2933343 0.729 rs813945 ENSG00000231305.3 RP11-723O4.2 5.12 5.2e-07 0.000204 0.3 0.27 IgG glycosylation; chr3:128942094 chr3:128861313~128871540:- LIHC cis rs1061377 0.965 rs7690465 ENSG00000249685.1 RP11-360F5.3 5.12 5.2e-07 0.000204 0.32 0.27 Uric acid levels; chr4:39147015 chr4:39133913~39135608:+ LIHC cis rs2337406 0.866 rs8003852 ENSG00000274576.2 IGHV2-70 -5.12 5.21e-07 0.000204 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106776648 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs988131 ENSG00000274576.2 IGHV2-70 -5.12 5.21e-07 0.000204 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106776833 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs8005518 ENSG00000274576.2 IGHV2-70 -5.12 5.21e-07 0.000204 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106777009 chr14:106770577~106771020:- LIHC cis rs2032447 0.714 rs199734 ENSG00000242387.1 HIST1H2APS2 5.12 5.21e-07 0.000204 0.34 0.27 Intelligence (multi-trait analysis); chr6:25940165 chr6:25882026~25882395:- LIHC cis rs2980439 0.846 rs2980437 ENSG00000173295.6 FAM86B3P -5.12 5.21e-07 0.000204 -0.33 -0.27 Neuroticism; chr8:8237241 chr8:8228595~8244865:+ LIHC cis rs4356203 0.905 rs214937 ENSG00000272034.1 SNORD14A 5.12 5.22e-07 0.000204 0.29 0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17168005 chr11:17074654~17074744:- LIHC cis rs9992667 0.911 rs28360925 ENSG00000231160.8 KLF3-AS1 5.12 5.22e-07 0.000205 0.36 0.27 Eosinophil percentage of granulocytes; chr4:38615676 chr4:38612701~38664883:- LIHC cis rs2337406 0.866 rs74092512 ENSG00000274576.2 IGHV2-70 -5.12 5.22e-07 0.000205 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106779306 chr14:106770577~106771020:- LIHC cis rs2337406 0.789 rs74092514 ENSG00000274576.2 IGHV2-70 -5.12 5.22e-07 0.000205 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106779385 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs74092520 ENSG00000274576.2 IGHV2-70 -5.12 5.22e-07 0.000205 -0.27 -0.27 Alzheimer's disease (late onset); chr14:106779632 chr14:106770577~106771020:- LIHC cis rs6163 0.588 rs12763284 ENSG00000236937.2 PTGES3P4 -5.12 5.22e-07 0.000205 -0.32 -0.27 Waist circumference;Hip circumference; chr10:102748445 chr10:102845595~102845950:+ LIHC cis rs2919917 1 rs3808619 ENSG00000254352.1 RP11-578O24.2 5.12 5.22e-07 0.000205 0.36 0.27 Lymphocyte counts; chr8:78665491 chr8:78723796~78724136:- LIHC cis rs6479891 1 rs1904295 ENSG00000232075.1 MRPL35P2 -5.12 5.22e-07 0.000205 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63223116 chr10:63634317~63634827:- LIHC cis rs6479901 0.512 rs6415875 ENSG00000232075.1 MRPL35P2 -5.12 5.22e-07 0.000205 -0.31 -0.27 Intelligence (multi-trait analysis); chr10:63226657 chr10:63634317~63634827:- LIHC cis rs6479901 0.512 rs4439410 ENSG00000232075.1 MRPL35P2 -5.12 5.22e-07 0.000205 -0.31 -0.27 Intelligence (multi-trait analysis); chr10:63239012 chr10:63634317~63634827:- LIHC cis rs6479891 0.908 rs11819167 ENSG00000232075.1 MRPL35P2 5.12 5.22e-07 0.000205 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63216409 chr10:63634317~63634827:- LIHC cis rs6479891 0.915 rs4281380 ENSG00000232075.1 MRPL35P2 -5.12 5.22e-07 0.000205 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63227938 chr10:63634317~63634827:- LIHC cis rs2032447 0.714 rs199725 ENSG00000242387.1 HIST1H2APS2 5.12 5.22e-07 0.000205 0.33 0.27 Intelligence (multi-trait analysis); chr6:25953456 chr6:25882026~25882395:- LIHC cis rs5769765 0.908 rs9616390 ENSG00000278869.1 CITF22-49E9.3 5.12 5.23e-07 0.000205 0.44 0.27 Schizophrenia; chr22:49920641 chr22:49933198~49934074:- LIHC cis rs36715 1 rs251213 ENSG00000245937.6 LINC01184 5.12 5.23e-07 0.000205 0.33 0.27 Breast cancer; chr5:128209913 chr5:127940426~128083172:- LIHC cis rs36715 1 rs251212 ENSG00000245937.6 LINC01184 5.12 5.23e-07 0.000205 0.33 0.27 Breast cancer; chr5:128210218 chr5:127940426~128083172:- LIHC cis rs36715 1 rs2617621 ENSG00000245937.6 LINC01184 5.12 5.23e-07 0.000205 0.33 0.27 Breast cancer; chr5:128210574 chr5:127940426~128083172:- LIHC cis rs36715 1 rs181850 ENSG00000245937.6 LINC01184 5.12 5.23e-07 0.000205 0.33 0.27 Breast cancer; chr5:128211795 chr5:127940426~128083172:- LIHC cis rs36715 0.953 rs185177 ENSG00000245937.6 LINC01184 5.12 5.23e-07 0.000205 0.33 0.27 Breast cancer; chr5:128212118 chr5:127940426~128083172:- LIHC cis rs12468226 1 rs111542497 ENSG00000273456.1 RP11-686O6.2 5.12 5.23e-07 0.000205 0.37 0.27 Urate levels; chr2:202330369 chr2:202374932~202375604:- LIHC cis rs858239 0.73 rs858290 ENSG00000226816.2 AC005082.12 5.12 5.23e-07 0.000205 0.35 0.27 Cerebrospinal fluid biomarker levels; chr7:23208417 chr7:23206013~23208045:+ LIHC cis rs11098499 0.863 rs6835635 ENSG00000245958.5 RP11-33B1.1 -5.12 5.23e-07 0.000205 -0.28 -0.27 Corneal astigmatism; chr4:119537712 chr4:119454791~119552025:+ LIHC cis rs1729407 0.647 rs2727791 ENSG00000236267.1 AP006216.5 5.11 5.24e-07 0.000205 0.26 0.27 Apolipoprotein A-IV levels; chr11:116813846 chr11:116813204~116814003:- LIHC cis rs17818399 0.62 rs3087822 ENSG00000279254.1 RP11-536C12.1 5.11 5.25e-07 0.000206 0.31 0.27 Height; chr2:46624894 chr2:46668870~46670778:+ LIHC cis rs228614 0.51 rs223447 ENSG00000230069.3 LRRC37A15P -5.11 5.25e-07 0.000206 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102792202 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223446 ENSG00000230069.3 LRRC37A15P -5.11 5.25e-07 0.000206 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793025 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223445 ENSG00000230069.3 LRRC37A15P -5.11 5.25e-07 0.000206 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793337 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223443 ENSG00000230069.3 LRRC37A15P -5.11 5.25e-07 0.000206 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793629 chr4:102727274~102730721:- LIHC cis rs1501911 0.588 rs819227 ENSG00000248489.1 CTD-2007H13.3 -5.11 5.25e-07 0.000206 -0.42 -0.27 Lung function (FEV1/FVC); chr5:98994161 chr5:98929171~98995013:+ LIHC cis rs10875746 0.551 rs3185921 ENSG00000240399.1 RP1-228P16.1 -5.11 5.25e-07 0.000206 -0.29 -0.27 Longevity (90 years and older); chr12:48340948 chr12:48054813~48055591:- LIHC cis rs12468226 0.938 rs13392645 ENSG00000273456.1 RP11-686O6.2 5.11 5.26e-07 0.000206 0.37 0.27 Urate levels; chr2:202270116 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs7568159 ENSG00000273456.1 RP11-686O6.2 5.11 5.26e-07 0.000206 0.37 0.27 Urate levels; chr2:202286226 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs7585867 ENSG00000273456.1 RP11-686O6.2 5.11 5.26e-07 0.000206 0.37 0.27 Urate levels; chr2:202287040 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs58834901 ENSG00000273456.1 RP11-686O6.2 5.11 5.26e-07 0.000206 0.37 0.27 Urate levels; chr2:202288169 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs1474002 ENSG00000273456.1 RP11-686O6.2 5.11 5.26e-07 0.000206 0.37 0.27 Urate levels; chr2:202290195 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs6753044 ENSG00000273456.1 RP11-686O6.2 5.11 5.26e-07 0.000206 0.37 0.27 Urate levels; chr2:202300710 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs55681656 ENSG00000273456.1 RP11-686O6.2 5.11 5.26e-07 0.000206 0.37 0.27 Urate levels; chr2:202319041 chr2:202374932~202375604:- LIHC cis rs12701220 0.857 rs1057558 ENSG00000229043.2 AC091729.9 -5.11 5.27e-07 0.000206 -0.37 -0.27 Bronchopulmonary dysplasia; chr7:1022730 chr7:1160374~1165267:+ LIHC cis rs875971 0.862 rs9791712 ENSG00000237310.1 GS1-124K5.4 -5.11 5.27e-07 0.000206 -0.24 -0.27 Aortic root size; chr7:66640176 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs9791713 ENSG00000237310.1 GS1-124K5.4 -5.11 5.27e-07 0.000206 -0.24 -0.27 Aortic root size; chr7:66640211 chr7:66493706~66495474:+ LIHC cis rs5769765 0.773 rs9616378 ENSG00000278869.1 CITF22-49E9.3 5.11 5.27e-07 0.000206 0.44 0.27 Schizophrenia; chr22:49918325 chr22:49933198~49934074:- LIHC cis rs5769765 0.819 rs9616379 ENSG00000278869.1 CITF22-49E9.3 5.11 5.27e-07 0.000206 0.44 0.27 Schizophrenia; chr22:49918387 chr22:49933198~49934074:- LIHC cis rs5769765 0.862 rs9616380 ENSG00000278869.1 CITF22-49E9.3 5.11 5.27e-07 0.000206 0.44 0.27 Schizophrenia; chr22:49918577 chr22:49933198~49934074:- LIHC cis rs5769765 0.862 rs9616381 ENSG00000278869.1 CITF22-49E9.3 5.11 5.27e-07 0.000206 0.44 0.27 Schizophrenia; chr22:49918734 chr22:49933198~49934074:- LIHC cis rs5769765 0.773 rs58375955 ENSG00000278869.1 CITF22-49E9.3 5.11 5.27e-07 0.000206 0.44 0.27 Schizophrenia; chr22:49918982 chr22:49933198~49934074:- LIHC cis rs5769765 0.773 rs9616382 ENSG00000278869.1 CITF22-49E9.3 5.11 5.27e-07 0.000206 0.44 0.27 Schizophrenia; chr22:49919331 chr22:49933198~49934074:- LIHC cis rs5769765 0.773 rs9616383 ENSG00000278869.1 CITF22-49E9.3 5.11 5.27e-07 0.000206 0.44 0.27 Schizophrenia; chr22:49919366 chr22:49933198~49934074:- LIHC cis rs5769765 0.862 rs9616384 ENSG00000278869.1 CITF22-49E9.3 5.11 5.27e-07 0.000206 0.44 0.27 Schizophrenia; chr22:49919434 chr22:49933198~49934074:- LIHC cis rs5769765 0.862 rs9616385 ENSG00000278869.1 CITF22-49E9.3 5.11 5.27e-07 0.000206 0.44 0.27 Schizophrenia; chr22:49919476 chr22:49933198~49934074:- LIHC cis rs5769765 0.862 rs9616386 ENSG00000278869.1 CITF22-49E9.3 5.11 5.27e-07 0.000206 0.44 0.27 Schizophrenia; chr22:49919531 chr22:49933198~49934074:- LIHC cis rs5769765 0.908 rs9616388 ENSG00000278869.1 CITF22-49E9.3 5.11 5.27e-07 0.000206 0.44 0.27 Schizophrenia; chr22:49919790 chr22:49933198~49934074:- LIHC cis rs1134634 0.52 rs75099653 ENSG00000273133.1 RP11-799M12.2 -5.11 5.28e-07 0.000207 -0.33 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15626397 chr4:15563698~15564253:- LIHC cis rs4660214 0.666 rs61783383 ENSG00000182109.6 RP11-69E11.4 -5.11 5.29e-07 0.000207 -0.28 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39341346 chr1:39522280~39546187:- LIHC cis rs4660214 0.666 rs2256614 ENSG00000182109.6 RP11-69E11.4 5.11 5.29e-07 0.000207 0.28 0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39359046 chr1:39522280~39546187:- LIHC cis rs6163 0.588 rs67506723 ENSG00000236937.2 PTGES3P4 5.11 5.29e-07 0.000207 0.32 0.27 Waist circumference;Hip circumference; chr10:102749307 chr10:102845595~102845950:+ LIHC cis rs875971 0.571 rs160641 ENSG00000226824.5 RP4-756H11.3 5.11 5.3e-07 0.000207 0.34 0.27 Aortic root size; chr7:66112359 chr7:66654538~66669855:+ LIHC cis rs2060793 0.659 rs1839834 ENSG00000251991.1 RNU7-49P 5.11 5.3e-07 0.000207 0.3 0.27 Vitamin D levels; chr11:14807914 chr11:14478892~14478953:+ LIHC cis rs67311347 1 rs977652 ENSG00000223797.4 ENTPD3-AS1 5.11 5.3e-07 0.000207 0.21 0.27 Renal cell carcinoma; chr3:40437678 chr3:40313802~40453329:- LIHC cis rs4731207 0.698 rs6942933 ENSG00000224897.5 POT1-AS1 -5.11 5.31e-07 0.000208 -0.31 -0.27 Cutaneous malignant melanoma; chr7:124804468 chr7:124929873~125179315:+ LIHC cis rs72627509 0.629 rs1718824 ENSG00000269949.1 RP11-738E22.3 -5.11 5.32e-07 0.000208 -0.34 -0.27 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57037581 chr4:56960927~56961373:- LIHC cis rs227275 0.554 rs223390 ENSG00000230069.3 LRRC37A15P -5.11 5.33e-07 0.000208 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102827640 chr4:102727274~102730721:- LIHC cis rs16858210 0.874 rs35717944 ENSG00000234371.6 RPSAP31 5.11 5.33e-07 0.000208 0.35 0.27 Menopause (age at onset); chr3:183889573 chr3:183884924~183888449:+ LIHC cis rs9595908 0.863 rs11616287 ENSG00000212293.1 SNORA16 5.11 5.33e-07 0.000208 0.32 0.27 Body mass index; chr13:32580139 chr13:32420390~32420516:- LIHC cis rs6479901 0.512 rs7100372 ENSG00000232075.1 MRPL35P2 -5.11 5.34e-07 0.000209 -0.31 -0.27 Intelligence (multi-trait analysis); chr10:63304484 chr10:63634317~63634827:- LIHC cis rs6479891 0.778 rs7896676 ENSG00000232075.1 MRPL35P2 -5.11 5.34e-07 0.000209 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63305542 chr10:63634317~63634827:- LIHC cis rs6479891 0.915 rs7896677 ENSG00000232075.1 MRPL35P2 -5.11 5.34e-07 0.000209 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63305545 chr10:63634317~63634827:- LIHC cis rs6479891 0.818 rs9299455 ENSG00000232075.1 MRPL35P2 -5.11 5.34e-07 0.000209 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63313841 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs7899715 ENSG00000232075.1 MRPL35P2 -5.11 5.34e-07 0.000209 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63318695 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs10740117 ENSG00000232075.1 MRPL35P2 -5.11 5.34e-07 0.000209 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63338517 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs6479894 ENSG00000232075.1 MRPL35P2 -5.11 5.34e-07 0.000209 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63338981 chr10:63634317~63634827:- LIHC cis rs6479891 0.915 rs7091664 ENSG00000232075.1 MRPL35P2 -5.11 5.34e-07 0.000209 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63342040 chr10:63634317~63634827:- LIHC cis rs8072100 0.805 rs67919208 ENSG00000228782.6 CTD-2026D20.3 5.11 5.34e-07 0.000209 0.29 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47694507 chr17:47450568~47492492:- LIHC cis rs17301013 0.861 rs7538650 ENSG00000227373.4 RP11-160H22.5 -5.11 5.35e-07 0.000209 -0.34 -0.27 Systemic lupus erythematosus; chr1:174788821 chr1:174115300~174160004:- LIHC cis rs17023223 0.509 rs7542832 ENSG00000231365.4 RP11-418J17.1 -5.11 5.35e-07 0.000209 -0.33 -0.27 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119220106 chr1:119140396~119275973:+ LIHC cis rs1061377 1 rs35116118 ENSG00000249685.1 RP11-360F5.3 5.11 5.35e-07 0.000209 0.32 0.27 Uric acid levels; chr4:39127293 chr4:39133913~39135608:+ LIHC cis rs7119038 0.774 rs11217020 ENSG00000255239.1 AP002954.6 -5.11 5.36e-07 0.000209 -0.38 -0.27 Sjögren's syndrome; chr11:118768644 chr11:118688039~118690600:- LIHC cis rs62355901 0.599 rs62355899 ENSG00000271828.1 CTD-2310F14.1 5.11 5.36e-07 0.000209 0.5 0.27 Breast cancer; chr5:56754638 chr5:56927874~56929573:+ LIHC cis rs6479891 1 rs9414793 ENSG00000232075.1 MRPL35P2 -5.11 5.36e-07 0.00021 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63315349 chr10:63634317~63634827:- LIHC cis rs227275 0.556 rs223398 ENSG00000230069.3 LRRC37A15P -5.11 5.37e-07 0.00021 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102821256 chr4:102727274~102730721:- LIHC cis rs2877649 1 rs75683693 ENSG00000258744.1 RP11-80A15.1 -5.11 5.37e-07 0.00021 -0.53 -0.27 Smooth-surface caries; chr14:24460434 chr14:24501594~24508688:+ LIHC cis rs916888 0.773 rs9896243 ENSG00000274883.1 Metazoa_SRP -5.11 5.37e-07 0.00021 -0.4 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45931806~45932083:+ LIHC cis rs4731207 0.623 rs719973 ENSG00000224897.5 POT1-AS1 5.11 5.37e-07 0.00021 0.32 0.27 Cutaneous malignant melanoma; chr7:124991673 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7802210 ENSG00000224897.5 POT1-AS1 5.11 5.37e-07 0.00021 0.32 0.27 Cutaneous malignant melanoma; chr7:124992406 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs10954062 ENSG00000224897.5 POT1-AS1 5.11 5.37e-07 0.00021 0.32 0.27 Cutaneous malignant melanoma; chr7:124996406 chr7:124929873~125179315:+ LIHC cis rs228614 0.51 rs223392 ENSG00000230069.3 LRRC37A15P -5.11 5.37e-07 0.00021 -0.24 -0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102824599 chr4:102727274~102730721:- LIHC cis rs12134133 0.752 rs4844579 ENSG00000274245.1 RP11-357P18.2 5.11 5.37e-07 0.00021 0.42 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207204546 chr1:207372559~207373252:+ LIHC cis rs9322193 0.607 rs9371228 ENSG00000223701.3 RAET1E-AS1 -5.11 5.37e-07 0.00021 -0.35 -0.27 Lung cancer; chr6:149921977 chr6:149884431~149919508:+ LIHC cis rs7429990 0.864 rs7612219 ENSG00000229759.1 MRPS18AP1 -5.11 5.37e-07 0.00021 -0.28 -0.27 Educational attainment (years of education); chr3:47739676 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs35148469 ENSG00000229759.1 MRPS18AP1 -5.11 5.37e-07 0.00021 -0.28 -0.27 Educational attainment (years of education); chr3:47739873 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs17079785 ENSG00000229759.1 MRPS18AP1 -5.11 5.37e-07 0.00021 -0.28 -0.27 Educational attainment (years of education); chr3:47743160 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs6442082 ENSG00000229759.1 MRPS18AP1 -5.11 5.37e-07 0.00021 -0.28 -0.27 Educational attainment (years of education); chr3:47743991 chr3:48256350~48256938:- LIHC cis rs7429990 0.747 rs6442083 ENSG00000229759.1 MRPS18AP1 -5.11 5.37e-07 0.00021 -0.28 -0.27 Educational attainment (years of education); chr3:47744305 chr3:48256350~48256938:- LIHC cis rs7429990 0.786 rs13064183 ENSG00000229759.1 MRPS18AP1 -5.11 5.37e-07 0.00021 -0.28 -0.27 Educational attainment (years of education); chr3:47745405 chr3:48256350~48256938:- LIHC cis rs6921919 0.583 rs6907950 ENSG00000204709.4 LINC01556 5.11 5.38e-07 0.00021 0.32 0.27 Autism spectrum disorder or schizophrenia; chr6:28402469 chr6:28943877~28944537:+ LIHC cis rs950169 0.887 rs35986397 ENSG00000259728.4 LINC00933 5.11 5.38e-07 0.00021 0.38 0.27 Schizophrenia; chr15:84400409 chr15:84570649~84580175:+ LIHC cis rs13068223 0.967 rs344035 ENSG00000243926.1 TIPARP-AS1 -5.11 5.39e-07 0.00021 -0.25 -0.27 Age-related hearing impairment (SNP x SNP interaction); chr3:156743490 chr3:156671862~156674378:- LIHC cis rs17023223 0.537 rs3936018 ENSG00000231365.4 RP11-418J17.1 -5.11 5.4e-07 0.000211 -0.35 -0.27 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119139747 chr1:119140396~119275973:+ LIHC cis rs6964833 1 rs4717907 ENSG00000123965.13 PMS2P5 5.11 5.4e-07 0.000211 0.43 0.27 Menarche (age at onset); chr7:74672169 chr7:74894116~74897835:+ LIHC cis rs11603023 0.569 rs573905 ENSG00000255422.1 AP002954.4 -5.11 5.4e-07 0.000211 -0.31 -0.27 Cholesterol, total; chr11:118701558 chr11:118704607~118750263:+ LIHC cis rs5758511 0.68 rs5758686 ENSG00000237037.8 NDUFA6-AS1 -5.11 5.4e-07 0.000211 -0.33 -0.27 Birth weight; chr22:42259371 chr22:42090931~42137742:+ LIHC cis rs950776 0.714 rs17408276 ENSG00000261762.1 RP11-650L12.2 5.11 5.4e-07 0.000211 0.34 0.27 Sudden cardiac arrest; chr15:78589276 chr15:78589123~78591276:- LIHC cis rs61041384 0.661 rs4759411 ENSG00000256092.2 RP13-942N8.1 -5.11 5.42e-07 0.000212 -0.43 -0.27 Schizophrenia; chr12:123256296 chr12:123363868~123366113:+ LIHC cis rs860295 1 rs6427286 ENSG00000203761.5 MSTO2P -5.11 5.43e-07 0.000212 -0.21 -0.27 Body mass index; chr1:155753506 chr1:155745829~155750137:+ LIHC cis rs10510102 0.935 rs7907871 ENSG00000276742.1 RP11-500G22.4 5.11 5.44e-07 0.000212 0.45 0.27 Breast cancer; chr10:121878185 chr10:121956782~121957098:+ LIHC cis rs4731207 0.724 rs35535003 ENSG00000224897.5 POT1-AS1 -5.11 5.44e-07 0.000212 -0.31 -0.27 Cutaneous malignant melanoma; chr7:124802410 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs4731214 ENSG00000224897.5 POT1-AS1 -5.11 5.44e-07 0.000212 -0.31 -0.27 Cutaneous malignant melanoma; chr7:124802851 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs2158677 ENSG00000224897.5 POT1-AS1 -5.11 5.44e-07 0.000212 -0.31 -0.27 Cutaneous malignant melanoma; chr7:124803912 chr7:124929873~125179315:+ LIHC cis rs4731207 0.671 rs5022495 ENSG00000224897.5 POT1-AS1 -5.11 5.44e-07 0.000212 -0.31 -0.27 Cutaneous malignant melanoma; chr7:124803970 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs10248775 ENSG00000224897.5 POT1-AS1 -5.11 5.44e-07 0.000212 -0.31 -0.27 Cutaneous malignant melanoma; chr7:124804153 chr7:124929873~125179315:+ LIHC cis rs4731207 0.698 rs6963177 ENSG00000224897.5 POT1-AS1 -5.11 5.44e-07 0.000212 -0.31 -0.27 Cutaneous malignant melanoma; chr7:124804550 chr7:124929873~125179315:+ LIHC cis rs524281 0.861 rs471484 ENSG00000255320.1 RP11-755F10.1 5.11 5.45e-07 0.000212 0.33 0.27 Electroencephalogram traits; chr11:66187673 chr11:66244840~66246239:- LIHC cis rs5769765 0.728 rs6520064 ENSG00000278869.1 CITF22-49E9.3 5.11 5.45e-07 0.000212 0.39 0.27 Schizophrenia; chr22:49900821 chr22:49933198~49934074:- LIHC cis rs5769765 0.773 rs6520065 ENSG00000278869.1 CITF22-49E9.3 5.11 5.45e-07 0.000212 0.39 0.27 Schizophrenia; chr22:49900822 chr22:49933198~49934074:- LIHC cis rs3733589 1 rs13101772 ENSG00000250413.1 RP11-448G15.1 5.11 5.45e-07 0.000212 0.47 0.27 Renal overload gout; chr4:9996100 chr4:10006482~10009725:+ LIHC cis rs2033711 0.654 rs734380 ENSG00000269473.1 CTD-2619J13.19 5.11 5.45e-07 0.000213 0.32 0.27 Uric acid clearance; chr19:58387596 chr19:58440448~58445849:+ LIHC cis rs4731207 0.596 rs10252579 ENSG00000224897.5 POT1-AS1 5.11 5.45e-07 0.000213 0.33 0.27 Cutaneous malignant melanoma; chr7:124997052 chr7:124929873~125179315:+ LIHC cis rs10181042 0.612 rs1177282 ENSG00000271889.1 RP11-493E12.1 5.11 5.46e-07 0.000213 0.32 0.27 Crohn's disease; chr2:61130642 chr2:61151433~61162105:- LIHC cis rs8072100 0.817 rs9912101 ENSG00000228782.6 CTD-2026D20.3 5.11 5.46e-07 0.000213 0.3 0.27 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469712 chr17:47450568~47492492:- LIHC cis rs17301013 0.932 rs12077622 ENSG00000227373.4 RP11-160H22.5 5.11 5.46e-07 0.000213 0.32 0.27 Systemic lupus erythematosus; chr1:174442507 chr1:174115300~174160004:- LIHC cis rs9291683 0.609 rs55959894 ENSG00000250413.1 RP11-448G15.1 -5.11 5.47e-07 0.000213 -0.33 -0.27 Bone mineral density; chr4:10024956 chr4:10006482~10009725:+ LIHC cis rs9291683 0.609 rs13149985 ENSG00000250413.1 RP11-448G15.1 -5.11 5.47e-07 0.000213 -0.33 -0.27 Bone mineral density; chr4:10026766 chr4:10006482~10009725:+ LIHC cis rs150992 0.568 rs34498 ENSG00000248489.1 CTD-2007H13.3 5.11 5.47e-07 0.000213 0.41 0.27 Body mass index; chr5:98960690 chr5:98929171~98995013:+ LIHC cis rs30380 0.632 rs149189 ENSG00000272109.1 CTD-2260A17.3 -5.11 5.47e-07 0.000213 -0.34 -0.27 Cerebrospinal fluid biomarker levels; chr5:96802101 chr5:96804353~96806105:+ LIHC cis rs30380 0.632 rs26495 ENSG00000272109.1 CTD-2260A17.3 -5.11 5.47e-07 0.000213 -0.34 -0.27 Cerebrospinal fluid biomarker levels; chr5:96802137 chr5:96804353~96806105:+ LIHC cis rs30380 0.632 rs26496 ENSG00000272109.1 CTD-2260A17.3 -5.11 5.47e-07 0.000213 -0.34 -0.27 Cerebrospinal fluid biomarker levels; chr5:96802179 chr5:96804353~96806105:+ LIHC cis rs7945705 0.967 rs56316046 ENSG00000254860.4 TMEM9B-AS1 -5.11 5.48e-07 0.000213 -0.27 -0.27 Hemoglobin concentration; chr11:8855051 chr11:8964675~8977527:+ LIHC cis rs6977955 1 rs6977955 ENSG00000234336.5 JAZF1-AS1 5.11 5.48e-07 0.000213 0.38 0.27 Allergic disease (asthma, hay fever or eczema); chr7:28117268 chr7:28180322~28243917:+ LIHC cis rs860295 0.702 rs475550 ENSG00000203761.5 MSTO2P -5.11 5.48e-07 0.000214 -0.22 -0.27 Body mass index; chr1:155682290 chr1:155745829~155750137:+ LIHC cis rs6921919 0.945 rs16901847 ENSG00000216901.1 AL022393.7 5.11 5.48e-07 0.000214 0.41 0.27 Autism spectrum disorder or schizophrenia; chr6:28408074 chr6:28176188~28176674:+ LIHC cis rs9318086 0.712 rs9318099 ENSG00000205861.10 C1QTNF9B-AS1 5.11 5.49e-07 0.000214 0.3 0.27 Myopia (pathological); chr13:23868323 chr13:23888889~23897263:+ LIHC cis rs2836974 0.932 rs2150415 ENSG00000255568.3 BRWD1-AS2 5.11 5.49e-07 0.000214 0.29 0.27 Cognitive function; chr21:39243441 chr21:39313935~39314962:+ LIHC cis rs228614 0.543 rs223330 ENSG00000246560.2 RP11-10L12.4 5.11 5.49e-07 0.000214 0.29 0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102872502 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223329 ENSG00000246560.2 RP11-10L12.4 5.11 5.49e-07 0.000214 0.29 0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873031 chr4:102828055~102844075:+ LIHC cis rs228614 0.536 rs223327 ENSG00000246560.2 RP11-10L12.4 5.11 5.49e-07 0.000214 0.29 0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873560 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223326 ENSG00000246560.2 RP11-10L12.4 5.11 5.49e-07 0.000214 0.29 0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873770 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223324 ENSG00000246560.2 RP11-10L12.4 5.11 5.49e-07 0.000214 0.29 0.27 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102876177 chr4:102828055~102844075:+ LIHC cis rs9487094 0.677 rs4428538 ENSG00000260273.1 RP11-425D10.10 5.11 5.49e-07 0.000214 0.45 0.27 Height; chr6:109409645 chr6:109382795~109383666:+ LIHC cis rs10510102 0.935 rs10466217 ENSG00000226864.1 ATE1-AS1 5.11 5.5e-07 0.000214 0.44 0.27 Breast cancer; chr10:121860362 chr10:121928312~121951965:+ LIHC cis rs11098499 0.909 rs10026736 ENSG00000245958.5 RP11-33B1.1 -5.11 5.5e-07 0.000214 -0.28 -0.27 Corneal astigmatism; chr4:119463167 chr4:119454791~119552025:+ LIHC cis rs6600671 1 rs6600671 ENSG00000231429.2 RP11-343N15.2 5.11 5.5e-07 0.000214 0.33 0.27 Hip geometry; chr1:121458637 chr1:121412719~121429274:+ LIHC cis rs887829 0.57 rs45615240 ENSG00000233445.1 RPL17P11 5.1 5.5e-07 0.000214 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233690650 chr2:233721522~233722065:- LIHC cis rs6479901 0.895 rs9629895 ENSG00000232075.1 MRPL35P2 -5.1 5.51e-07 0.000215 -0.29 -0.27 Intelligence (multi-trait analysis); chr10:63363027 chr10:63634317~63634827:- LIHC cis rs5769765 0.908 rs9616370 ENSG00000278869.1 CITF22-49E9.3 -5.1 5.52e-07 0.000215 -0.43 -0.27 Schizophrenia; chr22:49912668 chr22:49933198~49934074:- LIHC cis rs7688540 0.771 rs11722197 ENSG00000275426.1 CH17-262A2.1 5.1 5.53e-07 0.000215 0.35 0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:287918 chr4:149738~150317:+ LIHC cis rs7688540 0.771 rs11723261 ENSG00000275426.1 CH17-262A2.1 5.1 5.53e-07 0.000215 0.35 0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:288710 chr4:149738~150317:+ LIHC cis rs7615952 0.546 rs11718647 ENSG00000171084.14 FAM86JP 5.1 5.53e-07 0.000215 0.46 0.27 Blood pressure (smoking interaction); chr3:125633178 chr3:125916620~125930024:+ LIHC cis rs36715 1 rs36702 ENSG00000245937.6 LINC01184 5.1 5.53e-07 0.000215 0.33 0.27 Breast cancer; chr5:128217031 chr5:127940426~128083172:- LIHC cis rs524281 0.861 rs485857 ENSG00000255320.1 RP11-755F10.1 5.1 5.53e-07 0.000215 0.33 0.27 Electroencephalogram traits; chr11:66192048 chr11:66244840~66246239:- LIHC cis rs4731207 0.596 rs6967887 ENSG00000224897.5 POT1-AS1 5.1 5.53e-07 0.000215 0.32 0.27 Cutaneous malignant melanoma; chr7:124969436 chr7:124929873~125179315:+ LIHC cis rs524281 0.861 rs12049852 ENSG00000255320.1 RP11-755F10.1 5.1 5.54e-07 0.000215 0.33 0.27 Electroencephalogram traits; chr11:66117231 chr11:66244840~66246239:- LIHC cis rs6480314 0.542 rs2120902 ENSG00000233590.1 RP11-153K11.3 -5.1 5.54e-07 0.000215 -0.41 -0.27 Optic nerve measurement (disc area); chr10:68260465 chr10:68233251~68242379:- LIHC cis rs36715 1 rs40527 ENSG00000245937.6 LINC01184 5.1 5.54e-07 0.000216 0.32 0.27 Breast cancer; chr5:128214560 chr5:127940426~128083172:- LIHC cis rs1134634 0.52 rs16892140 ENSG00000273133.1 RP11-799M12.2 -5.1 5.54e-07 0.000216 -0.33 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15546927 chr4:15563698~15564253:- LIHC cis rs9992667 0.955 rs10025499 ENSG00000231160.8 KLF3-AS1 5.1 5.56e-07 0.000216 0.36 0.27 Eosinophil percentage of granulocytes; chr4:38619373 chr4:38612701~38664883:- LIHC cis rs17826219 0.706 rs8075357 ENSG00000266490.1 CTD-2349P21.9 5.1 5.57e-07 0.000217 0.33 0.27 Body mass index; chr17:30730179 chr17:30792372~30792833:+ LIHC cis rs73193808 0.639 rs2832248 ENSG00000224649.1 AF124730.4 5.1 5.57e-07 0.000217 0.31 0.27 Coronary artery disease; chr21:29184660 chr21:29182027~29187795:- LIHC cis rs950169 0.887 rs35986397 ENSG00000225151.9 GOLGA2P7 -5.1 5.58e-07 0.000217 -0.33 -0.27 Schizophrenia; chr15:84400409 chr15:84199311~84230136:- LIHC cis rs7429990 0.864 rs13086149 ENSG00000229759.1 MRPS18AP1 -5.1 5.58e-07 0.000217 -0.28 -0.27 Educational attainment (years of education); chr3:47784158 chr3:48256350~48256938:- LIHC cis rs5769765 0.773 rs9616208 ENSG00000278869.1 CITF22-49E9.3 5.1 5.58e-07 0.000217 0.44 0.27 Schizophrenia; chr22:49919711 chr22:49933198~49934074:- LIHC cis rs7209700 0.777 rs8073827 ENSG00000228782.6 CTD-2026D20.3 -5.1 5.58e-07 0.000217 -0.3 -0.27 IgG glycosylation; chr17:47267296 chr17:47450568~47492492:- LIHC cis rs4731207 0.672 rs10249081 ENSG00000224897.5 POT1-AS1 -5.1 5.59e-07 0.000217 -0.31 -0.27 Cutaneous malignant melanoma; chr7:124828465 chr7:124929873~125179315:+ LIHC cis rs8005677 1 rs2295685 ENSG00000257285.4 RP11-298I3.1 5.1 5.59e-07 0.000217 0.27 0.27 Cognitive ability (multi-trait analysis); chr14:22928944 chr14:22929609~22955562:+ LIHC cis rs8005677 1 rs4982710 ENSG00000257285.4 RP11-298I3.1 5.1 5.59e-07 0.000217 0.27 0.27 Cognitive ability (multi-trait analysis); chr14:22929693 chr14:22929609~22955562:+ LIHC cis rs11123170 0.64 rs2863240 ENSG00000274877.1 RP11-65I12.1 5.1 5.59e-07 0.000217 0.36 0.27 Renal function-related traits (BUN); chr2:113212539 chr2:113237595~113240825:+ LIHC cis rs4356203 0.818 rs214927 ENSG00000272034.1 SNORD14A -5.1 5.59e-07 0.000217 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17209698 chr11:17074654~17074744:- LIHC cis rs875971 0.545 rs1796217 ENSG00000237310.1 GS1-124K5.4 -5.1 5.61e-07 0.000218 -0.25 -0.27 Aortic root size; chr7:66620931 chr7:66493706~66495474:+ LIHC cis rs3096299 0.658 rs12443705 ENSG00000261118.1 RP11-104N10.1 5.1 5.62e-07 0.000218 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89480646 chr16:89492017~89504460:- LIHC cis rs2439831 0.702 rs495175 ENSG00000205771.5 CATSPER2P1 -5.1 5.62e-07 0.000218 -0.36 -0.27 Lung cancer in ever smokers; chr15:43506486 chr15:43726918~43747094:- LIHC cis rs72627509 0.904 rs58408429 ENSG00000269949.1 RP11-738E22.3 5.1 5.62e-07 0.000219 0.35 0.27 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56903658 chr4:56960927~56961373:- LIHC cis rs3096299 0.933 rs2965823 ENSG00000261118.1 RP11-104N10.1 5.1 5.64e-07 0.000219 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89388516 chr16:89492017~89504460:- LIHC cis rs599083 0.53 rs2508834 ENSG00000212093.1 AP000807.1 -5.1 5.64e-07 0.000219 -0.29 -0.27 Bone mineral density (spine); chr11:68407886 chr11:68506083~68506166:- LIHC cis rs524281 0.861 rs7937281 ENSG00000255320.1 RP11-755F10.1 5.1 5.64e-07 0.000219 0.33 0.27 Electroencephalogram traits; chr11:66182603 chr11:66244840~66246239:- LIHC cis rs4934494 0.768 rs34663515 ENSG00000232936.4 RP11-80H5.2 5.1 5.65e-07 0.000219 0.33 0.27 Red blood cell count; chr10:89632786 chr10:89645282~89650667:+ LIHC cis rs2998286 0.862 rs2790460 ENSG00000254635.4 WAC-AS1 -5.1 5.66e-07 0.00022 -0.32 -0.27 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28502093 chr10:28522652~28532743:- LIHC cis rs2439831 1 rs2256764 ENSG00000205771.5 CATSPER2P1 -5.1 5.66e-07 0.00022 -0.4 -0.27 Lung cancer in ever smokers; chr15:43443565 chr15:43726918~43747094:- LIHC cis rs2565722 0.563 rs1247559 ENSG00000243831.1 RP1-81D8.4 5.1 5.66e-07 0.00022 0.35 0.27 Blood protein levels; chr6:160782724 chr6:160666228~160676523:- LIHC cis rs875971 0.502 rs1796227 ENSG00000237310.1 GS1-124K5.4 -5.1 5.66e-07 0.00022 -0.25 -0.27 Aortic root size; chr7:66622032 chr7:66493706~66495474:+ LIHC cis rs4731207 0.596 rs1525614 ENSG00000224897.5 POT1-AS1 5.1 5.67e-07 0.00022 0.32 0.27 Cutaneous malignant melanoma; chr7:125018546 chr7:124929873~125179315:+ LIHC cis rs916888 0.773 rs199451 ENSG00000274883.1 Metazoa_SRP -5.1 5.67e-07 0.00022 -0.42 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45931806~45932083:+ LIHC cis rs5769765 0.908 rs4074304 ENSG00000278869.1 CITF22-49E9.3 5.1 5.68e-07 0.00022 0.44 0.27 Schizophrenia; chr22:49915798 chr22:49933198~49934074:- LIHC cis rs5769765 0.908 rs9616376 ENSG00000278869.1 CITF22-49E9.3 5.1 5.68e-07 0.00022 0.44 0.27 Schizophrenia; chr22:49917181 chr22:49933198~49934074:- LIHC cis rs5769765 0.819 rs9616377 ENSG00000278869.1 CITF22-49E9.3 5.1 5.68e-07 0.00022 0.44 0.27 Schizophrenia; chr22:49917232 chr22:49933198~49934074:- LIHC cis rs7208859 0.623 rs56018041 ENSG00000266490.1 CTD-2349P21.9 5.1 5.68e-07 0.00022 0.33 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732967 chr17:30792372~30792833:+ LIHC cis rs7119038 0.818 rs57494551 ENSG00000255239.1 AP002954.6 -5.1 5.68e-07 0.00022 -0.38 -0.27 Sjögren's syndrome; chr11:118790689 chr11:118688039~118690600:- LIHC cis rs2243480 1 rs410128 ENSG00000273142.1 RP11-458F8.4 -5.1 5.68e-07 0.000221 -0.34 -0.27 Diabetic kidney disease; chr7:66138186 chr7:66902857~66906297:+ LIHC cis rs1150668 0.796 rs213237 ENSG00000204709.4 LINC01556 5.1 5.69e-07 0.000221 0.29 0.27 Pubertal anthropometrics; chr6:28356161 chr6:28943877~28944537:+ LIHC cis rs2274273 0.934 rs17740741 ENSG00000258413.1 RP11-665C16.6 -5.1 5.7e-07 0.000221 -0.32 -0.27 Protein biomarker; chr14:55295994 chr14:55262767~55272075:- LIHC cis rs2274273 0.901 rs68046603 ENSG00000258413.1 RP11-665C16.6 -5.1 5.7e-07 0.000221 -0.32 -0.27 Protein biomarker; chr14:55296085 chr14:55262767~55272075:- LIHC cis rs2274273 0.901 rs12050099 ENSG00000258413.1 RP11-665C16.6 -5.1 5.7e-07 0.000221 -0.32 -0.27 Protein biomarker; chr14:55297613 chr14:55262767~55272075:- LIHC cis rs887829 0.57 rs10168155 ENSG00000233445.1 RPL17P11 5.1 5.7e-07 0.000221 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233688190 chr2:233721522~233722065:- LIHC cis rs887829 0.57 rs11680450 ENSG00000233445.1 RPL17P11 5.1 5.7e-07 0.000221 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233688837 chr2:233721522~233722065:- LIHC cis rs887829 0.57 rs10171367 ENSG00000233445.1 RPL17P11 5.1 5.7e-07 0.000221 0.28 0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233689021 chr2:233721522~233722065:- LIHC cis rs9595066 0.715 rs9567366 ENSG00000230731.2 RP11-478K15.6 -5.1 5.71e-07 0.000221 -0.31 -0.27 Schizophrenia; chr13:44108837 chr13:44234118~44243192:- LIHC cis rs7916697 0.578 rs61854799 ENSG00000233590.1 RP11-153K11.3 -5.1 5.71e-07 0.000222 -0.34 -0.27 Optic disc area; chr10:68246902 chr10:68233251~68242379:- LIHC cis rs7208859 0.673 rs450585 ENSG00000266490.1 CTD-2349P21.9 5.1 5.72e-07 0.000222 0.31 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30624021 chr17:30792372~30792833:+ LIHC cis rs17711722 0.583 rs10085415 ENSG00000224316.1 RP11-479O9.2 -5.1 5.73e-07 0.000222 -0.27 -0.27 Calcium levels; chr7:65628655 chr7:65773620~65802067:+ LIHC cis rs2427308 0.643 rs477859 ENSG00000273619.1 RP5-908M14.9 5.1 5.73e-07 0.000222 0.29 0.27 Colorectal cancer; chr20:62362541 chr20:62386303~62386970:- LIHC cis rs916888 0.773 rs199448 ENSG00000274883.1 Metazoa_SRP -5.1 5.74e-07 0.000222 -0.41 -0.27 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45931806~45932083:+ LIHC cis rs2439831 1 rs689826 ENSG00000205771.5 CATSPER2P1 -5.1 5.75e-07 0.000223 -0.36 -0.27 Lung cancer in ever smokers; chr15:43457718 chr15:43726918~43747094:- LIHC cis rs11098499 0.82 rs11737395 ENSG00000245958.5 RP11-33B1.1 -5.1 5.76e-07 0.000223 -0.28 -0.27 Corneal astigmatism; chr4:119599549 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs6849561 ENSG00000260091.1 RP11-33B1.4 5.1 5.76e-07 0.000223 0.19 0.27 Corneal astigmatism; chr4:119488539 chr4:119409333~119410233:+ LIHC cis rs7615952 0.546 rs111812401 ENSG00000171084.14 FAM86JP 5.1 5.76e-07 0.000223 0.46 0.27 Blood pressure (smoking interaction); chr3:125642651 chr3:125916620~125930024:+ LIHC cis rs7615952 0.546 rs2979350 ENSG00000171084.14 FAM86JP 5.1 5.76e-07 0.000223 0.46 0.27 Blood pressure (smoking interaction); chr3:125643371 chr3:125916620~125930024:+ LIHC cis rs950169 0.922 rs11635505 ENSG00000225151.9 GOLGA2P7 5.1 5.76e-07 0.000223 0.33 0.27 Schizophrenia; chr15:84553803 chr15:84199311~84230136:- LIHC cis rs7714584 0.793 rs12653039 ENSG00000197083.10 ZNF300P1 5.1 5.76e-07 0.000223 0.43 0.27 Crohn's disease; chr5:150873069 chr5:150930645~150946289:- LIHC cis rs7119038 0.774 rs10892290 ENSG00000255239.1 AP002954.6 -5.1 5.77e-07 0.000224 -0.38 -0.27 Sjögren's syndrome; chr11:118782794 chr11:118688039~118690600:- LIHC cis rs7119038 0.774 rs874621 ENSG00000255239.1 AP002954.6 -5.1 5.77e-07 0.000224 -0.38 -0.27 Sjögren's syndrome; chr11:118784936 chr11:118688039~118690600:- LIHC cis rs858239 0.665 rs858305 ENSG00000226816.2 AC005082.12 -5.1 5.78e-07 0.000224 -0.35 -0.27 Cerebrospinal fluid biomarker levels; chr7:23203211 chr7:23206013~23208045:+ LIHC cis rs6479891 1 rs11814792 ENSG00000232075.1 MRPL35P2 5.09 5.78e-07 0.000224 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63157799 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs12413415 ENSG00000232075.1 MRPL35P2 5.09 5.78e-07 0.000224 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63159751 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs4747045 ENSG00000232075.1 MRPL35P2 5.09 5.78e-07 0.000224 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63166722 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs4466712 ENSG00000232075.1 MRPL35P2 5.09 5.78e-07 0.000224 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63173508 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs72829170 ENSG00000232075.1 MRPL35P2 5.09 5.78e-07 0.000224 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63180529 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs61855465 ENSG00000232075.1 MRPL35P2 5.09 5.78e-07 0.000224 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63196847 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs12413730 ENSG00000232075.1 MRPL35P2 5.09 5.78e-07 0.000224 0.31 0.27 Arthritis (juvenile idiopathic); chr10:63204388 chr10:63634317~63634827:- LIHC cis rs887829 0.57 rs6759892 ENSG00000233445.1 RPL17P11 -5.09 5.78e-07 0.000224 -0.28 -0.27 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233693023 chr2:233721522~233722065:- LIHC cis rs6903823 0.527 rs4713158 ENSG00000204709.4 LINC01556 5.09 5.79e-07 0.000224 0.3 0.27 Pulmonary function; chr6:28309994 chr6:28943877~28944537:+ LIHC cis rs1322639 0.574 rs9689193 ENSG00000261039.2 RP11-417E7.2 -5.09 5.79e-07 0.000224 -0.38 -0.27 Pulse pressure; chr6:169187979 chr6:169175304~169182740:- LIHC cis rs9322193 0.607 rs9371228 ENSG00000268592.3 RAET1E-AS1 -5.09 5.79e-07 0.000224 -0.37 -0.27 Lung cancer; chr6:149921977 chr6:149863494~149919507:+ LIHC cis rs10510102 0.935 rs7923634 ENSG00000276742.1 RP11-500G22.4 5.09 5.8e-07 0.000225 0.41 0.27 Breast cancer; chr10:121832800 chr10:121956782~121957098:+ LIHC cis rs17826219 0.706 rs61643715 ENSG00000266490.1 CTD-2349P21.9 5.09 5.81e-07 0.000225 0.33 0.27 Body mass index; chr17:30730744 chr17:30792372~30792833:+ LIHC cis rs599083 0.53 rs576118 ENSG00000212093.1 AP000807.1 -5.09 5.81e-07 0.000225 -0.29 -0.27 Bone mineral density (spine); chr11:68410240 chr11:68506083~68506166:- LIHC cis rs7688540 0.771 rs11729365 ENSG00000275426.1 CH17-262A2.1 5.09 5.82e-07 0.000225 0.34 0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:278735 chr4:149738~150317:+ LIHC cis rs7688540 0.771 rs11722521 ENSG00000275426.1 CH17-262A2.1 5.09 5.82e-07 0.000225 0.34 0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:282976 chr4:149738~150317:+ LIHC cis rs7688540 0.771 rs7665727 ENSG00000275426.1 CH17-262A2.1 5.09 5.82e-07 0.000225 0.34 0.27 Facial morphology (factor 6, height of vermillion lower lip); chr4:283268 chr4:149738~150317:+ LIHC cis rs875971 0.54 rs736270 ENSG00000164669.11 INTS4P1 -5.09 5.82e-07 0.000225 -0.37 -0.27 Aortic root size; chr7:65963835 chr7:65141225~65234216:+ LIHC cis rs1061377 0.513 rs2566162 ENSG00000249207.1 RP11-360F5.1 -5.09 5.82e-07 0.000225 -0.33 -0.27 Uric acid levels; chr4:39126453 chr4:39112677~39126818:- LIHC cis rs2274273 0.837 rs56949365 ENSG00000258413.1 RP11-665C16.6 -5.09 5.83e-07 0.000225 -0.32 -0.27 Protein biomarker; chr14:55323360 chr14:55262767~55272075:- LIHC cis rs2274273 0.87 rs4496026 ENSG00000258413.1 RP11-665C16.6 -5.09 5.83e-07 0.000225 -0.32 -0.27 Protein biomarker; chr14:55323794 chr14:55262767~55272075:- LIHC cis rs2274273 0.87 rs4366639 ENSG00000258413.1 RP11-665C16.6 -5.09 5.83e-07 0.000225 -0.32 -0.27 Protein biomarker; chr14:55323798 chr14:55262767~55272075:- LIHC cis rs2274273 0.87 rs11625423 ENSG00000258413.1 RP11-665C16.6 -5.09 5.83e-07 0.000225 -0.32 -0.27 Protein biomarker; chr14:55329195 chr14:55262767~55272075:- LIHC cis rs2283792 0.765 rs34550586 ENSG00000224086.5 LL22NC03-86G7.1 -5.09 5.83e-07 0.000226 -0.24 -0.27 Multiple sclerosis; chr22:21791345 chr22:21938293~21977632:+ LIHC cis rs6480314 0.542 rs61854816 ENSG00000233590.1 RP11-153K11.3 -5.09 5.85e-07 0.000226 -0.41 -0.27 Optic nerve measurement (disc area); chr10:68269051 chr10:68233251~68242379:- LIHC cis rs1577917 0.958 rs12205492 ENSG00000234155.1 RP11-30P6.6 5.09 5.85e-07 0.000226 0.35 0.27 Response to antipsychotic treatment; chr6:85766258 chr6:85387219~85390186:- LIHC cis rs10129255 0.957 rs8009464 ENSG00000223648.3 IGHV3-64 5.09 5.85e-07 0.000226 0.2 0.27 Kawasaki disease; chr14:106777611 chr14:106643132~106658258:- LIHC cis rs4660214 0.666 rs2275186 ENSG00000182109.6 RP11-69E11.4 -5.09 5.85e-07 0.000226 -0.28 -0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39300383 chr1:39522280~39546187:- LIHC cis rs2836974 0.565 rs2836939 ENSG00000255568.3 BRWD1-AS2 5.09 5.86e-07 0.000227 0.38 0.27 Cognitive function; chr21:39206620 chr21:39313935~39314962:+ LIHC cis rs17301013 0.932 rs6425282 ENSG00000227373.4 RP11-160H22.5 5.09 5.86e-07 0.000227 0.32 0.27 Systemic lupus erythematosus; chr1:174493387 chr1:174115300~174160004:- LIHC cis rs7714584 1 rs1428552 ENSG00000197083.10 ZNF300P1 5.09 5.86e-07 0.000227 0.4 0.27 Crohn's disease; chr5:150880269 chr5:150930645~150946289:- LIHC cis rs5769707 1 rs5769707 ENSG00000235111.1 RP1-29C18.8 -5.09 5.87e-07 0.000227 -0.3 -0.27 Monocyte percentage of white cells;Monocyte count; chr22:49619754 chr22:49612657~49615716:- LIHC cis rs858239 0.636 rs7808488 ENSG00000226816.2 AC005082.12 5.09 5.88e-07 0.000227 0.35 0.27 Cerebrospinal fluid biomarker levels; chr7:23182251 chr7:23206013~23208045:+ LIHC cis rs5769765 1 rs2295408 ENSG00000278869.1 CITF22-49E9.3 -5.09 5.88e-07 0.000227 -0.39 -0.27 Schizophrenia; chr22:49867403 chr22:49933198~49934074:- LIHC cis rs5769765 1 rs2295409 ENSG00000278869.1 CITF22-49E9.3 -5.09 5.88e-07 0.000227 -0.39 -0.27 Schizophrenia; chr22:49867412 chr22:49933198~49934074:- LIHC cis rs189798 0.807 rs9949 ENSG00000254340.1 RP11-10A14.3 5.09 5.88e-07 0.000227 0.32 0.27 Myopia (pathological); chr8:9137002 chr8:9141424~9145435:+ LIHC cis rs5769707 0.904 rs7288869 ENSG00000235111.1 RP1-29C18.8 -5.09 5.89e-07 0.000227 -0.3 -0.27 Monocyte percentage of white cells;Monocyte count; chr22:49621679 chr22:49612657~49615716:- LIHC cis rs17301013 0.932 rs6425281 ENSG00000227373.4 RP11-160H22.5 5.09 5.89e-07 0.000228 0.33 0.27 Systemic lupus erythematosus; chr1:174449784 chr1:174115300~174160004:- LIHC cis rs3096299 0.503 rs9940093 ENSG00000261118.1 RP11-104N10.1 5.09 5.89e-07 0.000228 0.26 0.27 Multiple myeloma (IgH translocation); chr16:89492297 chr16:89492017~89504460:- LIHC cis rs227275 0.527 rs223308 ENSG00000246560.2 RP11-10L12.4 5.09 5.89e-07 0.000228 0.3 0.27 Allergic disease (asthma, hay fever or eczema); chr4:102891342 chr4:102828055~102844075:+ LIHC cis rs11690935 0.851 rs7581072 ENSG00000228389.1 AC068039.4 5.09 5.9e-07 0.000228 0.36 0.27 Schizophrenia; chr2:171994938 chr2:171773482~171775844:+ LIHC cis rs6479901 0.895 rs7082066 ENSG00000232075.1 MRPL35P2 -5.09 5.9e-07 0.000228 -0.29 -0.27 Intelligence (multi-trait analysis); chr10:63239211 chr10:63634317~63634827:- LIHC cis rs4731207 0.506 rs12531282 ENSG00000224897.5 POT1-AS1 5.09 5.9e-07 0.000228 0.32 0.27 Cutaneous malignant melanoma; chr7:124985408 chr7:124929873~125179315:+ LIHC cis rs11089937 0.609 rs2213158 ENSG00000211639.2 IGLV4-60 5.09 5.91e-07 0.000228 0.23 0.27 Periodontitis (PAL4Q3); chr22:22138099 chr22:22162199~22162681:+ LIHC cis rs11089937 0.637 rs2213159 ENSG00000211639.2 IGLV4-60 5.09 5.91e-07 0.000228 0.23 0.27 Periodontitis (PAL4Q3); chr22:22138100 chr22:22162199~22162681:+ LIHC cis rs7714584 1 rs11746108 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150885060 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs11739619 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150885100 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs11167519 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150885845 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs11167520 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150886077 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs73284141 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150886524 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs3906527 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150886830 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs2345001 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150886956 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs3906528 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150887156 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs2880791 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150887814 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs3857422 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150889047 chr5:150930645~150946289:- LIHC cis rs7714584 0.59 rs4352593 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150889770 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs7709464 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150889879 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs10053750 ENSG00000197083.10 ZNF300P1 5.09 5.92e-07 0.000229 0.4 0.27 Crohn's disease; chr5:150890489 chr5:150930645~150946289:- LIHC cis rs7119038 0.731 rs10892283 ENSG00000255239.1 AP002954.6 -5.09 5.93e-07 0.000229 -0.38 -0.27 Sjögren's syndrome; chr11:118766272 chr11:118688039~118690600:- LIHC cis rs7119038 0.818 rs10892286 ENSG00000255239.1 AP002954.6 -5.09 5.93e-07 0.000229 -0.38 -0.27 Sjögren's syndrome; chr11:118771376 chr11:118688039~118690600:- LIHC cis rs6479891 0.524 rs10740107 ENSG00000232075.1 MRPL35P2 -5.09 5.93e-07 0.000229 -0.3 -0.27 Arthritis (juvenile idiopathic); chr10:63184557 chr10:63634317~63634827:- LIHC cis rs4650994 0.525 rs10913567 ENSG00000273384.1 RP5-1098D14.1 5.09 5.95e-07 0.000229 0.33 0.27 HDL cholesterol;HDL cholesterol levels; chr1:178542806 chr1:178651706~178652282:+ LIHC cis rs4650994 0.507 rs12405456 ENSG00000273384.1 RP5-1098D14.1 5.09 5.95e-07 0.000229 0.33 0.27 HDL cholesterol;HDL cholesterol levels; chr1:178543196 chr1:178651706~178652282:+ LIHC cis rs524281 0.861 rs7942894 ENSG00000255320.1 RP11-755F10.1 5.09 5.95e-07 0.00023 0.33 0.27 Electroencephalogram traits; chr11:66209054 chr11:66244840~66246239:- LIHC cis rs6479901 0.895 rs10822157 ENSG00000232075.1 MRPL35P2 -5.09 5.96e-07 0.00023 -0.29 -0.27 Intelligence (multi-trait analysis); chr10:63329720 chr10:63634317~63634827:- LIHC cis rs6921919 0.609 rs9461455 ENSG00000204709.4 LINC01556 5.09 5.97e-07 0.00023 0.32 0.27 Autism spectrum disorder or schizophrenia; chr6:28361954 chr6:28943877~28944537:+ LIHC cis rs529413 0.61 rs565238 ENSG00000259237.1 RP11-209E8.1 5.09 5.97e-07 0.00023 0.34 0.27 Itch intensity from mosquito bite adjusted by bite size; chr15:53206017 chr15:53116365~53129698:+ LIHC cis rs6479891 1 rs7895348 ENSG00000232075.1 MRPL35P2 -5.09 5.97e-07 0.00023 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63349781 chr10:63634317~63634827:- LIHC cis rs10129255 0.536 rs6576201 ENSG00000211972.2 IGHV3-66 -5.09 5.97e-07 0.00023 -0.19 -0.27 Kawasaki disease; chr14:106683696 chr14:106675017~106675544:- LIHC cis rs4934494 0.813 rs34928397 ENSG00000232936.4 RP11-80H5.2 5.09 5.97e-07 0.00023 0.34 0.27 Red blood cell count; chr10:89766842 chr10:89645282~89650667:+ LIHC cis rs10129255 0.536 rs10139058 ENSG00000211972.2 IGHV3-66 5.09 5.97e-07 0.00023 0.2 0.27 Kawasaki disease; chr14:106685899 chr14:106675017~106675544:- LIHC cis rs10129255 0.536 rs8004835 ENSG00000211972.2 IGHV3-66 5.09 5.97e-07 0.00023 0.2 0.27 Kawasaki disease; chr14:106686361 chr14:106675017~106675544:- LIHC cis rs10510102 0.935 rs11818001 ENSG00000276742.1 RP11-500G22.4 -5.09 5.98e-07 0.00023 -0.39 -0.27 Breast cancer; chr10:121884830 chr10:121956782~121957098:+ LIHC cis rs227275 0.554 rs223454 ENSG00000230069.3 LRRC37A15P -5.09 5.98e-07 0.000231 -0.24 -0.27 Allergic disease (asthma, hay fever or eczema); chr4:102789773 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs2086499 ENSG00000246560.2 RP11-10L12.4 5.09 5.98e-07 0.000231 0.31 0.27 Allergic disease (asthma, hay fever or eczema); chr4:103008672 chr4:102828055~102844075:+ LIHC cis rs1134634 0.52 rs7682586 ENSG00000273133.1 RP11-799M12.2 -5.09 5.98e-07 0.000231 -0.34 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15624620 chr4:15563698~15564253:- LIHC cis rs950169 0.922 rs11631096 ENSG00000225151.9 GOLGA2P7 -5.09 5.98e-07 0.000231 -0.33 -0.27 Schizophrenia; chr15:84557698 chr15:84199311~84230136:- LIHC cis rs2274273 0.967 rs1009978 ENSG00000258413.1 RP11-665C16.6 -5.09 5.99e-07 0.000231 -0.3 -0.27 Protein biomarker; chr14:55136343 chr14:55262767~55272075:- LIHC cis rs950169 0.922 rs11633075 ENSG00000225151.9 GOLGA2P7 -5.09 5.99e-07 0.000231 -0.34 -0.27 Schizophrenia; chr15:84570741 chr15:84199311~84230136:- LIHC cis rs11098499 0.863 rs1010740 ENSG00000245958.5 RP11-33B1.1 5.09 6e-07 0.000231 0.28 0.27 Corneal astigmatism; chr4:119542254 chr4:119454791~119552025:+ LIHC cis rs7429990 0.864 rs13085978 ENSG00000229759.1 MRPS18AP1 5.09 6.01e-07 0.000232 0.29 0.27 Educational attainment (years of education); chr3:47608585 chr3:48256350~48256938:- LIHC cis rs7429990 0.727 rs61675361 ENSG00000229759.1 MRPS18AP1 5.09 6.01e-07 0.000232 0.29 0.27 Educational attainment (years of education); chr3:47610630 chr3:48256350~48256938:- LIHC cis rs4356203 0.811 rs214920 ENSG00000272034.1 SNORD14A -5.09 6.01e-07 0.000232 -0.29 -0.27 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17216402 chr11:17074654~17074744:- LIHC cis rs73186030 0.546 rs55780469 ENSG00000272758.4 RP11-299J3.8 5.09 6.01e-07 0.000232 0.44 0.27 Serum parathyroid hormone levels; chr3:122388590 chr3:122416207~122443180:+ LIHC cis rs4660214 0.666 rs597311 ENSG00000182109.6 RP11-69E11.4 5.09 6.01e-07 0.000232 0.28 0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39355254 chr1:39522280~39546187:- LIHC cis rs4660214 0.615 rs597708 ENSG00000182109.6 RP11-69E11.4 5.09 6.01e-07 0.000232 0.28 0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39355291 chr1:39522280~39546187:- LIHC cis rs4660214 0.666 rs636156 ENSG00000182109.6 RP11-69E11.4 5.09 6.01e-07 0.000232 0.28 0.27 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39356065 chr1:39522280~39546187:- LIHC cis rs950776 0.506 rs12915366 ENSG00000261762.1 RP11-650L12.2 5.09 6.01e-07 0.000232 0.35 0.27 Sudden cardiac arrest; chr15:78539411 chr15:78589123~78591276:- LIHC cis rs950776 0.531 rs12915652 ENSG00000261762.1 RP11-650L12.2 5.09 6.01e-07 0.000232 0.35 0.27 Sudden cardiac arrest; chr15:78539586 chr15:78589123~78591276:- LIHC cis rs10510102 0.935 rs12255859 ENSG00000276742.1 RP11-500G22.4 5.09 6.02e-07 0.000232 0.41 0.27 Breast cancer; chr10:121831661 chr10:121956782~121957098:+ LIHC cis rs172166 0.561 rs149973 ENSG00000204709.4 LINC01556 5.09 6.02e-07 0.000232 0.3 0.27 Cardiac Troponin-T levels; chr6:28015835 chr6:28943877~28944537:+ LIHC cis rs172166 0.561 rs149974 ENSG00000204709.4 LINC01556 5.09 6.02e-07 0.000232 0.3 0.27 Cardiac Troponin-T levels; chr6:28017318 chr6:28943877~28944537:+ LIHC cis rs7429990 0.833 rs6777632 ENSG00000229759.1 MRPS18AP1 -5.09 6.03e-07 0.000232 -0.28 -0.27 Educational attainment (years of education); chr3:47748775 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs13098128 ENSG00000229759.1 MRPS18AP1 -5.09 6.03e-07 0.000232 -0.28 -0.27 Educational attainment (years of education); chr3:47756066 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs7637950 ENSG00000229759.1 MRPS18AP1 -5.09 6.03e-07 0.000232 -0.28 -0.27 Educational attainment (years of education); chr3:47758204 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs6442085 ENSG00000229759.1 MRPS18AP1 -5.09 6.03e-07 0.000232 -0.28 -0.27 Educational attainment (years of education); chr3:47760080 chr3:48256350~48256938:- LIHC cis rs12701220 0.744 rs2030958 ENSG00000229043.2 AC091729.9 -5.09 6.04e-07 0.000233 -0.38 -0.27 Bronchopulmonary dysplasia; chr7:1036374 chr7:1160374~1165267:+ LIHC cis rs1134634 0.52 rs2041671 ENSG00000273133.1 RP11-799M12.2 -5.09 6.04e-07 0.000233 -0.33 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15550575 chr4:15563698~15564253:- LIHC cis rs1134634 0.52 rs11943107 ENSG00000273133.1 RP11-799M12.2 -5.09 6.05e-07 0.000233 -0.33 -0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15573042 chr4:15563698~15564253:- LIHC cis rs12285276 0.504 rs7120278 ENSG00000205106.4 DKFZp779M0652 5.09 6.05e-07 0.000233 0.28 0.27 Visceral fat; chr11:45796560 chr11:45771432~45772358:+ LIHC cis rs4862307 0.72 rs12650935 ENSG00000250726.1 RP11-616K6.1 5.09 6.05e-07 0.000233 0.28 0.27 Serum dimethylarginine levels (asymmetric/symetric ratio); chr4:184068412 chr4:184072403~184073039:+ LIHC cis rs7208859 0.623 rs8082537 ENSG00000266490.1 CTD-2349P21.9 5.09 6.05e-07 0.000233 0.32 0.27 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30688914 chr17:30792372~30792833:+ LIHC cis rs6061231 0.561 rs67072353 ENSG00000273619.1 RP5-908M14.9 -5.09 6.06e-07 0.000233 -0.3 -0.27 Colorectal cancer; chr20:62365646 chr20:62386303~62386970:- LIHC cis rs2933343 0.7 rs2249514 ENSG00000231305.3 RP11-723O4.2 5.09 6.06e-07 0.000233 0.3 0.27 IgG glycosylation; chr3:128924969 chr3:128861313~128871540:- LIHC cis rs2933343 0.7 rs2630257 ENSG00000231305.3 RP11-723O4.2 5.09 6.06e-07 0.000233 0.3 0.27 IgG glycosylation; chr3:128925172 chr3:128861313~128871540:- LIHC cis rs2933343 0.729 rs1680785 ENSG00000231305.3 RP11-723O4.2 5.09 6.06e-07 0.000233 0.3 0.27 IgG glycosylation; chr3:128925973 chr3:128861313~128871540:- LIHC cis rs2933343 0.729 rs1680786 ENSG00000231305.3 RP11-723O4.2 5.09 6.06e-07 0.000233 0.3 0.27 IgG glycosylation; chr3:128925997 chr3:128861313~128871540:- LIHC cis rs6479901 0.895 rs7909555 ENSG00000232075.1 MRPL35P2 -5.09 6.06e-07 0.000233 -0.29 -0.27 Intelligence (multi-trait analysis); chr10:63273348 chr10:63634317~63634827:- LIHC cis rs6479901 0.846 rs7907462 ENSG00000232075.1 MRPL35P2 -5.09 6.06e-07 0.000233 -0.29 -0.27 Intelligence (multi-trait analysis); chr10:63295773 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs7085018 ENSG00000232075.1 MRPL35P2 -5.09 6.07e-07 0.000234 -0.29 -0.27 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63526907 chr10:63634317~63634827:- LIHC cis rs12134133 0.719 rs6696142 ENSG00000274245.1 RP11-357P18.2 5.08 6.07e-07 0.000234 0.41 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207228898 chr1:207372559~207373252:+ LIHC cis rs12134133 0.752 rs57003024 ENSG00000274245.1 RP11-357P18.2 5.08 6.07e-07 0.000234 0.41 0.27 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207230999 chr1:207372559~207373252:+ LIHC cis rs2741012 0.755 rs2741023 ENSG00000233445.1 RPL17P11 -5.08 6.08e-07 0.000234 -0.39 -0.27 Total bilirubin levels in HIV-1 infection; chr2:233608068 chr2:233721522~233722065:- LIHC cis rs2565722 0.507 rs1247567 ENSG00000243831.1 RP1-81D8.4 5.08 6.08e-07 0.000234 0.35 0.27 Blood protein levels; chr6:160787265 chr6:160666228~160676523:- LIHC cis rs7811142 0.779 rs111312383 ENSG00000242294.5 STAG3L5P 5.08 6.09e-07 0.000234 0.29 0.27 Platelet count; chr7:100307702 chr7:100336079~100351900:+ LIHC cis rs2243480 1 rs709607 ENSG00000226824.5 RP4-756H11.3 5.08 6.09e-07 0.000235 0.44 0.27 Diabetic kidney disease; chr7:65984554 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs10261710 ENSG00000226824.5 RP4-756H11.3 -5.08 6.11e-07 0.000235 -0.34 -0.27 Aortic root size; chr7:66249202 chr7:66654538~66669855:+ LIHC cis rs6479891 1 rs7081275 ENSG00000232075.1 MRPL35P2 -5.08 6.11e-07 0.000235 -0.31 -0.27 Arthritis (juvenile idiopathic); chr10:63346791 chr10:63634317~63634827:- LIHC cis rs3096299 0.685 rs12446145 ENSG00000261118.1 RP11-104N10.1 5.08 6.11e-07 0.000235 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89476287 chr16:89492017~89504460:- LIHC cis rs7615952 0.546 rs2979340 ENSG00000171084.14 FAM86JP 5.08 6.11e-07 0.000235 0.47 0.27 Blood pressure (smoking interaction); chr3:125622540 chr3:125916620~125930024:+ LIHC cis rs7615952 0.546 rs2979338 ENSG00000171084.14 FAM86JP 5.08 6.11e-07 0.000235 0.47 0.27 Blood pressure (smoking interaction); chr3:125624282 chr3:125916620~125930024:+ LIHC cis rs7615952 0.546 rs2922171 ENSG00000171084.14 FAM86JP 5.08 6.11e-07 0.000235 0.47 0.27 Blood pressure (smoking interaction); chr3:125624349 chr3:125916620~125930024:+ LIHC cis rs7615952 0.546 rs112919177 ENSG00000171084.14 FAM86JP 5.08 6.11e-07 0.000235 0.47 0.27 Blood pressure (smoking interaction); chr3:125627226 chr3:125916620~125930024:+ LIHC cis rs7615952 0.546 rs4428131 ENSG00000171084.14 FAM86JP 5.08 6.11e-07 0.000235 0.47 0.27 Blood pressure (smoking interaction); chr3:125627635 chr3:125916620~125930024:+ LIHC cis rs6480314 0.542 rs4592311 ENSG00000233590.1 RP11-153K11.3 -5.08 6.12e-07 0.000235 -0.41 -0.27 Optic nerve measurement (disc area); chr10:68268492 chr10:68233251~68242379:- LIHC cis rs6480314 0.542 rs79081413 ENSG00000233590.1 RP11-153K11.3 -5.08 6.12e-07 0.000235 -0.41 -0.27 Optic nerve measurement (disc area); chr10:68268746 chr10:68233251~68242379:- LIHC cis rs6480314 0.542 rs17231630 ENSG00000233590.1 RP11-153K11.3 -5.08 6.12e-07 0.000235 -0.41 -0.27 Optic nerve measurement (disc area); chr10:68268960 chr10:68233251~68242379:- LIHC cis rs8059260 1 rs7205474 ENSG00000274038.1 RP11-66H6.4 -5.08 6.12e-07 0.000235 -0.4 -0.27 Alcohol consumption over the past year; chr16:10949556 chr16:11056556~11057034:+ LIHC cis rs8059260 0.877 rs111352543 ENSG00000274038.1 RP11-66H6.4 -5.08 6.12e-07 0.000235 -0.4 -0.27 Alcohol consumption over the past year; chr16:10949603 chr16:11056556~11057034:+ LIHC cis rs5769765 0.773 rs11090920 ENSG00000278869.1 CITF22-49E9.3 5.08 6.12e-07 0.000235 0.41 0.27 Schizophrenia; chr22:49926457 chr22:49933198~49934074:- LIHC cis rs1023500 0.505 rs134885 ENSG00000227370.1 RP4-669P10.19 -5.08 6.13e-07 0.000236 -0.27 -0.27 Schizophrenia; chr22:42277805 chr22:42132543~42132998:+ LIHC cis rs3096299 0.874 rs3102342 ENSG00000261118.1 RP11-104N10.1 5.08 6.13e-07 0.000236 0.27 0.27 Multiple myeloma (IgH translocation); chr16:89385167 chr16:89492017~89504460:- LIHC cis rs1501911 0.566 rs709388 ENSG00000248489.1 CTD-2007H13.3 5.08 6.14e-07 0.000236 0.42 0.27 Lung function (FEV1/FVC); chr5:98994037 chr5:98929171~98995013:+ LIHC cis rs1501911 0.566 rs709387 ENSG00000248489.1 CTD-2007H13.3 5.08 6.14e-07 0.000236 0.42 0.27 Lung function (FEV1/FVC); chr5:98994337 chr5:98929171~98995013:+ LIHC cis rs1501911 0.588 rs709386 ENSG00000248489.1 CTD-2007H13.3 5.08 6.14e-07 0.000236 0.42 0.27 Lung function (FEV1/FVC); chr5:98994346 chr5:98929171~98995013:+ LIHC cis rs2032366 0.606 rs713485 ENSG00000267279.1 RP11-879F14.2 -5.08 6.15e-07 0.000236 -0.32 -0.26 Obesity-related traits; chr18:61603692 chr18:61585746~61606916:- LIHC cis rs17301013 0.861 rs10218528 ENSG00000227373.4 RP11-160H22.5 5.08 6.15e-07 0.000236 0.34 0.26 Systemic lupus erythematosus; chr1:174478450 chr1:174115300~174160004:- LIHC cis rs875971 0.508 rs6947808 ENSG00000237310.1 GS1-124K5.4 -5.08 6.15e-07 0.000237 -0.24 -0.26 Aortic root size; chr7:66580095 chr7:66493706~66495474:+ LIHC cis rs11690935 0.921 rs7594711 ENSG00000228389.1 AC068039.4 5.08 6.16e-07 0.000237 0.37 0.26 Schizophrenia; chr2:172030734 chr2:171773482~171775844:+ LIHC cis rs4948102 0.599 rs2230197 ENSG00000226278.1 PSPHP1 -5.08 6.16e-07 0.000237 -0.3 -0.26 Plasma homocysteine levels (post-methionine load test); chr7:56058667 chr7:55764797~55773288:+ LIHC cis rs7412746 0.646 rs1972060 ENSG00000231073.1 RP11-316M1.3 5.08 6.16e-07 0.000237 0.26 0.26 Melanoma; chr1:150965118 chr1:150973123~150975534:+ LIHC cis rs71520386 0.632 rs28526185 ENSG00000228649.7 AC005682.5 -5.08 6.16e-07 0.000237 -0.34 -0.26 Fibrinogen levels; chr7:22831699 chr7:22854178~22861579:+ LIHC cis rs875971 0.545 rs73142245 ENSG00000226824.5 RP4-756H11.3 -5.08 6.16e-07 0.000237 -0.34 -0.26 Aortic root size; chr7:66226662 chr7:66654538~66669855:+ LIHC cis rs9438901 0.655 rs609320 ENSG00000261349.1 RP3-465N24.5 5.08 6.17e-07 0.000237 0.28 0.26 Red cell distribution width; chr1:25390874 chr1:25266102~25267136:- LIHC cis rs9527 0.662 rs4919687 ENSG00000236937.2 PTGES3P4 5.08 6.17e-07 0.000237 0.37 0.26 Arsenic metabolism; chr10:102835491 chr10:102845595~102845950:+ LIHC cis rs7208859 0.623 rs59447372 ENSG00000266490.1 CTD-2349P21.9 5.08 6.18e-07 0.000237 0.33 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30730567 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs8079891 ENSG00000266490.1 CTD-2349P21.9 5.08 6.18e-07 0.000237 0.33 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30731845 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs73267858 ENSG00000266490.1 CTD-2349P21.9 5.08 6.18e-07 0.000237 0.33 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732719 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs56095789 ENSG00000266490.1 CTD-2349P21.9 5.08 6.18e-07 0.000237 0.33 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733152 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11656844 ENSG00000266490.1 CTD-2349P21.9 5.08 6.18e-07 0.000237 0.33 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733579 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11652533 ENSG00000266490.1 CTD-2349P21.9 5.08 6.18e-07 0.000237 0.33 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733583 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11652631 ENSG00000266490.1 CTD-2349P21.9 5.08 6.18e-07 0.000237 0.33 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733748 chr17:30792372~30792833:+ LIHC cis rs6479891 1 rs9414788 ENSG00000232075.1 MRPL35P2 -5.08 6.18e-07 0.000238 -0.31 -0.26 Arthritis (juvenile idiopathic); chr10:63296952 chr10:63634317~63634827:- LIHC cis rs5769765 0.954 rs5770707 ENSG00000278869.1 CITF22-49E9.3 -5.08 6.19e-07 0.000238 -0.39 -0.26 Schizophrenia; chr22:49850885 chr22:49933198~49934074:- LIHC cis rs8059260 1 rs8059260 ENSG00000274038.1 RP11-66H6.4 -5.08 6.19e-07 0.000238 -0.39 -0.26 Alcohol consumption over the past year; chr16:10966294 chr16:11056556~11057034:+ LIHC cis rs860295 1 rs10908482 ENSG00000203761.5 MSTO2P -5.08 6.22e-07 0.000239 -0.21 -0.26 Body mass index; chr1:155744082 chr1:155745829~155750137:+ LIHC cis rs2033711 0.622 rs975947 ENSG00000269473.1 CTD-2619J13.19 5.08 6.22e-07 0.000239 0.32 0.26 Uric acid clearance; chr19:58386826 chr19:58440448~58445849:+ LIHC cis rs11690935 0.959 rs6724337 ENSG00000228389.1 AC068039.4 5.08 6.22e-07 0.000239 0.36 0.26 Schizophrenia; chr2:171878819 chr2:171773482~171775844:+ LIHC cis rs2286503 0.901 rs10950922 ENSG00000228649.7 AC005682.5 5.08 6.23e-07 0.000239 0.32 0.26 Fibrinogen; chr7:22814387 chr7:22854178~22861579:+ LIHC cis rs2286503 0.966 rs2286507 ENSG00000228649.7 AC005682.5 5.08 6.23e-07 0.000239 0.32 0.26 Fibrinogen; chr7:22815141 chr7:22854178~22861579:+ LIHC cis rs2286503 0.901 rs2286505 ENSG00000228649.7 AC005682.5 5.08 6.23e-07 0.000239 0.32 0.26 Fibrinogen; chr7:22815221 chr7:22854178~22861579:+ LIHC cis rs1577917 0.958 rs1335442 ENSG00000234155.1 RP11-30P6.6 5.08 6.23e-07 0.000239 0.35 0.26 Response to antipsychotic treatment; chr6:85756974 chr6:85387219~85390186:- LIHC cis rs2565722 0.607 rs1247564 ENSG00000243831.1 RP1-81D8.4 5.08 6.24e-07 0.00024 0.35 0.26 Blood protein levels; chr6:160785618 chr6:160666228~160676523:- LIHC cis rs6479901 0.895 rs907 ENSG00000232075.1 MRPL35P2 -5.08 6.24e-07 0.00024 -0.29 -0.26 Intelligence (multi-trait analysis); chr10:63176919 chr10:63634317~63634827:- LIHC cis rs9532669 0.963 rs9532662 ENSG00000176268.5 CYCSP34 5.08 6.25e-07 0.00024 0.29 0.26 Cervical cancer; chr13:40926215 chr13:40863599~40863902:- LIHC cis rs6479891 1 rs6479891 ENSG00000232075.1 MRPL35P2 5.08 6.26e-07 0.00024 0.32 0.26 Arthritis (juvenile idiopathic); chr10:63246696 chr10:63634317~63634827:- LIHC cis rs10875746 0.903 rs11168370 ENSG00000240399.1 RP1-228P16.1 -5.08 6.27e-07 0.00024 -0.27 -0.26 Longevity (90 years and older); chr12:48041497 chr12:48054813~48055591:- LIHC cis rs853679 0.567 rs6905380 ENSG00000216901.1 AL022393.7 5.08 6.27e-07 0.000241 0.36 0.26 Depression; chr6:28407125 chr6:28176188~28176674:+ LIHC cis rs10833905 0.701 rs11026873 ENSG00000246225.5 RP11-17A1.3 -5.08 6.27e-07 0.000241 -0.35 -0.26 Sudden cardiac arrest; chr11:22983116 chr11:22829380~22945393:+ LIHC cis rs6479901 0.793 rs4450077 ENSG00000232075.1 MRPL35P2 -5.08 6.28e-07 0.000241 -0.29 -0.26 Intelligence (multi-trait analysis); chr10:63253976 chr10:63634317~63634827:- LIHC cis rs6479901 0.841 rs4469770 ENSG00000232075.1 MRPL35P2 -5.08 6.28e-07 0.000241 -0.29 -0.26 Intelligence (multi-trait analysis); chr10:63254152 chr10:63634317~63634827:- LIHC cis rs11089937 0.597 rs5757024 ENSG00000211639.2 IGLV4-60 5.08 6.28e-07 0.000241 0.22 0.26 Periodontitis (PAL4Q3); chr22:22137415 chr22:22162199~22162681:+ LIHC cis rs11089937 0.597 rs5757026 ENSG00000211639.2 IGLV4-60 5.08 6.28e-07 0.000241 0.22 0.26 Periodontitis (PAL4Q3); chr22:22137556 chr22:22162199~22162681:+ LIHC cis rs11089937 0.597 rs5757027 ENSG00000211639.2 IGLV4-60 5.08 6.28e-07 0.000241 0.22 0.26 Periodontitis (PAL4Q3); chr22:22137683 chr22:22162199~22162681:+ LIHC cis rs599083 0.53 rs667126 ENSG00000212093.1 AP000807.1 -5.08 6.29e-07 0.000241 -0.29 -0.26 Bone mineral density (spine); chr11:68410260 chr11:68506083~68506166:- LIHC cis rs8091660 0.929 rs11082685 ENSG00000278983.1 RP11-426J5.3 5.08 6.29e-07 0.000241 0.38 0.26 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48566806 chr18:48564795~48568342:+ LIHC cis rs72627509 0.857 rs781658 ENSG00000269949.1 RP11-738E22.3 5.08 6.3e-07 0.000242 0.35 0.26 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56913401 chr4:56960927~56961373:- LIHC cis rs875971 0.545 rs67397473 ENSG00000226824.5 RP4-756H11.3 -5.08 6.31e-07 0.000242 -0.34 -0.26 Aortic root size; chr7:66168318 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs10950027 ENSG00000226824.5 RP4-756H11.3 -5.08 6.31e-07 0.000242 -0.34 -0.26 Aortic root size; chr7:66169164 chr7:66654538~66669855:+ LIHC cis rs7412746 0.658 rs8444 ENSG00000231073.1 RP11-316M1.3 5.08 6.31e-07 0.000242 0.27 0.26 Melanoma; chr1:150966095 chr1:150973123~150975534:+ LIHC cis rs116175783 0.557 rs7349280 ENSG00000227403.1 AC009299.3 5.08 6.31e-07 0.000242 0.41 0.26 Intelligence (multi-trait analysis); chr2:161354120 chr2:161244739~161249050:+ LIHC cis rs875971 0.545 rs316305 ENSG00000226824.5 RP4-756H11.3 5.08 6.31e-07 0.000242 0.34 0.26 Aortic root size; chr7:66152984 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs316306 ENSG00000226824.5 RP4-756H11.3 5.08 6.31e-07 0.000242 0.34 0.26 Aortic root size; chr7:66153687 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs10950025 ENSG00000226824.5 RP4-756H11.3 -5.08 6.31e-07 0.000242 -0.34 -0.26 Aortic root size; chr7:66158946 chr7:66654538~66669855:+ LIHC cis rs875971 0.52 rs12666485 ENSG00000226824.5 RP4-756H11.3 -5.08 6.31e-07 0.000242 -0.34 -0.26 Aortic root size; chr7:66160135 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs67688847 ENSG00000226824.5 RP4-756H11.3 -5.08 6.31e-07 0.000242 -0.34 -0.26 Aortic root size; chr7:66161064 chr7:66654538~66669855:+ LIHC cis rs875971 0.545 rs12673308 ENSG00000226824.5 RP4-756H11.3 -5.08 6.31e-07 0.000242 -0.34 -0.26 Aortic root size; chr7:66166374 chr7:66654538~66669855:+ LIHC cis rs4731207 0.596 rs1481328 ENSG00000224897.5 POT1-AS1 -5.08 6.31e-07 0.000242 -0.33 -0.26 Cutaneous malignant melanoma; chr7:124990972 chr7:124929873~125179315:+ LIHC cis rs11123170 0.64 rs931472 ENSG00000189223.12 PAX8-AS1 5.08 6.32e-07 0.000242 0.37 0.26 Renal function-related traits (BUN); chr2:113212371 chr2:113211522~113276581:+ LIHC cis rs7119038 0.774 rs2004781 ENSG00000255239.1 AP002954.6 -5.08 6.33e-07 0.000242 -0.38 -0.26 Sjögren's syndrome; chr11:118748544 chr11:118688039~118690600:- LIHC cis rs7119038 0.818 rs3889239 ENSG00000255239.1 AP002954.6 -5.08 6.33e-07 0.000242 -0.38 -0.26 Sjögren's syndrome; chr11:118749251 chr11:118688039~118690600:- LIHC cis rs6600671 0.934 rs12131379 ENSG00000231429.2 RP11-343N15.2 -5.08 6.33e-07 0.000243 -0.3 -0.26 Hip geometry; chr1:121551639 chr1:121412719~121429274:+ LIHC cis rs72627509 0.68 rs66790703 ENSG00000269949.1 RP11-738E22.3 5.08 6.34e-07 0.000243 0.35 0.26 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56907742 chr4:56960927~56961373:- LIHC cis rs72627509 0.767 rs6853156 ENSG00000269949.1 RP11-738E22.3 5.08 6.34e-07 0.000243 0.35 0.26 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56908677 chr4:56960927~56961373:- LIHC cis rs227275 0.554 rs223371 ENSG00000230069.3 LRRC37A15P -5.08 6.35e-07 0.000243 -0.24 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102838032 chr4:102727274~102730721:- LIHC cis rs6085948 1 rs6077170 ENSG00000228888.1 LINC01428 5.08 6.35e-07 0.000243 0.36 0.26 Interleukin-10 levels; chr20:7268888 chr20:7146467~7254202:- LIHC cis rs227275 0.556 rs724447 ENSG00000230069.3 LRRC37A15P 5.08 6.36e-07 0.000244 0.24 0.26 Allergic disease (asthma, hay fever or eczema); chr4:103010149 chr4:102727274~102730721:- LIHC cis rs10833905 1 rs10833902 ENSG00000246225.5 RP11-17A1.3 -5.08 6.36e-07 0.000244 -0.33 -0.26 Sudden cardiac arrest; chr11:23013647 chr11:22829380~22945393:+ LIHC cis rs2243480 0.706 rs6460257 ENSG00000226824.5 RP4-756H11.3 -5.08 6.37e-07 0.000244 -0.39 -0.26 Diabetic kidney disease; chr7:65731813 chr7:66654538~66669855:+ LIHC cis rs916888 0.773 rs199439 ENSG00000274883.1 Metazoa_SRP -5.08 6.37e-07 0.000244 -0.41 -0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45931806~45932083:+ LIHC cis rs131777 0.708 rs131749 ENSG00000205559.3 CHKB-AS1 5.08 6.37e-07 0.000244 0.35 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586195 chr22:50583026~50583877:+ LIHC cis rs4948102 0.642 rs4948104 ENSG00000226278.1 PSPHP1 -5.07 6.38e-07 0.000244 -0.31 -0.26 Plasma homocysteine levels (post-methionine load test); chr7:56074826 chr7:55764797~55773288:+ LIHC cis rs2877649 0.793 rs7157349 ENSG00000258744.1 RP11-80A15.1 -5.07 6.38e-07 0.000244 -0.53 -0.26 Smooth-surface caries; chr14:24454327 chr14:24501594~24508688:+ LIHC cis rs2877649 0.793 rs7142374 ENSG00000258744.1 RP11-80A15.1 -5.07 6.38e-07 0.000244 -0.53 -0.26 Smooth-surface caries; chr14:24454903 chr14:24501594~24508688:+ LIHC cis rs2877649 0.793 rs10129753 ENSG00000258744.1 RP11-80A15.1 -5.07 6.38e-07 0.000244 -0.53 -0.26 Smooth-surface caries; chr14:24455010 chr14:24501594~24508688:+ LIHC cis rs2877649 0.793 rs17103869 ENSG00000258744.1 RP11-80A15.1 -5.07 6.38e-07 0.000244 -0.53 -0.26 Smooth-surface caries; chr14:24455778 chr14:24501594~24508688:+ LIHC cis rs6921919 0.583 rs4642462 ENSG00000204709.4 LINC01556 5.07 6.38e-07 0.000244 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28421474 chr6:28943877~28944537:+ LIHC cis rs1577917 0.958 rs11755642 ENSG00000234155.1 RP11-30P6.6 5.07 6.4e-07 0.000245 0.34 0.26 Response to antipsychotic treatment; chr6:85740348 chr6:85387219~85390186:- LIHC cis rs6600671 1 rs4844607 ENSG00000231429.2 RP11-343N15.2 5.07 6.4e-07 0.000245 0.3 0.26 Hip geometry; chr1:121442201 chr1:121412719~121429274:+ LIHC cis rs950169 0.544 rs62021193 ENSG00000259295.5 CSPG4P12 5.07 6.4e-07 0.000245 0.36 0.26 Schizophrenia; chr15:84627352 chr15:85191438~85213905:+ LIHC cis rs950169 0.58 rs17598114 ENSG00000259295.5 CSPG4P12 5.07 6.4e-07 0.000245 0.36 0.26 Schizophrenia; chr15:84628086 chr15:85191438~85213905:+ LIHC cis rs12701220 0.894 rs13224488 ENSG00000229043.2 AC091729.9 -5.07 6.42e-07 0.000245 -0.37 -0.26 Bronchopulmonary dysplasia; chr7:1012717 chr7:1160374~1165267:+ LIHC cis rs950776 0.518 rs12902493 ENSG00000261762.1 RP11-650L12.2 5.07 6.43e-07 0.000246 0.35 0.26 Sudden cardiac arrest; chr15:78526933 chr15:78589123~78591276:- LIHC cis rs9425766 0.64 rs10912734 ENSG00000227373.4 RP11-160H22.5 5.07 6.45e-07 0.000247 0.32 0.26 Life satisfaction; chr1:174141977 chr1:174115300~174160004:- LIHC cis rs5769765 0.817 rs8142561 ENSG00000278869.1 CITF22-49E9.3 5.07 6.46e-07 0.000247 0.39 0.26 Schizophrenia; chr22:49898102 chr22:49933198~49934074:- LIHC cis rs5769765 0.955 rs8138687 ENSG00000278869.1 CITF22-49E9.3 5.07 6.46e-07 0.000247 0.39 0.26 Schizophrenia; chr22:49898221 chr22:49933198~49934074:- LIHC cis rs5769765 0.955 rs8135816 ENSG00000278869.1 CITF22-49E9.3 5.07 6.46e-07 0.000247 0.39 0.26 Schizophrenia; chr22:49898328 chr22:49933198~49934074:- LIHC cis rs5769765 0.818 rs8140681 ENSG00000278869.1 CITF22-49E9.3 5.07 6.46e-07 0.000247 0.39 0.26 Schizophrenia; chr22:49898433 chr22:49933198~49934074:- LIHC cis rs5769765 0.825 rs9616780 ENSG00000278869.1 CITF22-49E9.3 5.07 6.46e-07 0.000247 0.39 0.26 Schizophrenia; chr22:49899115 chr22:49933198~49934074:- LIHC cis rs11089937 0.597 rs5750582 ENSG00000211639.2 IGLV4-60 5.07 6.46e-07 0.000247 0.22 0.26 Periodontitis (PAL4Q3); chr22:22137690 chr22:22162199~22162681:+ LIHC cis rs11089937 0.626 rs5757028 ENSG00000211639.2 IGLV4-60 5.07 6.46e-07 0.000247 0.22 0.26 Periodontitis (PAL4Q3); chr22:22137699 chr22:22162199~22162681:+ LIHC cis rs7615952 0.546 rs2979333 ENSG00000171084.14 FAM86JP 5.07 6.46e-07 0.000247 0.46 0.26 Blood pressure (smoking interaction); chr3:125641499 chr3:125916620~125930024:+ LIHC cis rs881375 0.678 rs10760125 ENSG00000226752.6 PSMD5-AS1 -5.07 6.47e-07 0.000247 -0.27 -0.26 Rheumatoid arthritis; chr9:120900312 chr9:120824828~120854385:+ LIHC cis rs881375 0.654 rs10760126 ENSG00000226752.6 PSMD5-AS1 -5.07 6.47e-07 0.000247 -0.27 -0.26 Rheumatoid arthritis; chr9:120900340 chr9:120824828~120854385:+ LIHC cis rs10129255 0.957 rs11847726 ENSG00000223648.3 IGHV3-64 5.07 6.47e-07 0.000247 0.2 0.26 Kawasaki disease; chr14:106779116 chr14:106643132~106658258:- LIHC cis rs950169 0.881 rs150965 ENSG00000225151.9 GOLGA2P7 -5.07 6.47e-07 0.000247 -0.34 -0.26 Schizophrenia; chr15:84537296 chr15:84199311~84230136:- LIHC cis rs6142102 0.812 rs6120440 ENSG00000276073.1 RP5-1125A11.7 5.07 6.48e-07 0.000248 0.32 0.26 Skin pigmentation; chr20:33929779 chr20:33985617~33988989:- LIHC cis rs12908161 0.853 rs12912342 ENSG00000259295.5 CSPG4P12 5.07 6.48e-07 0.000248 0.34 0.26 Schizophrenia; chr15:84704985 chr15:85191438~85213905:+ LIHC cis rs1134634 0.52 rs4280724 ENSG00000273133.1 RP11-799M12.2 -5.07 6.49e-07 0.000248 -0.33 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15574128 chr4:15563698~15564253:- LIHC cis rs1134634 0.52 rs7665390 ENSG00000273133.1 RP11-799M12.2 -5.07 6.49e-07 0.000248 -0.33 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15576115 chr4:15563698~15564253:- LIHC cis rs6479901 0.557 rs7920768 ENSG00000232075.1 MRPL35P2 -5.07 6.49e-07 0.000248 -0.31 -0.26 Intelligence (multi-trait analysis); chr10:63300754 chr10:63634317~63634827:- LIHC cis rs887829 0.57 rs12623271 ENSG00000233445.1 RPL17P11 5.07 6.49e-07 0.000248 0.28 0.26 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233691295 chr2:233721522~233722065:- LIHC cis rs887829 0.57 rs10445704 ENSG00000233445.1 RPL17P11 5.07 6.49e-07 0.000248 0.28 0.26 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233691628 chr2:233721522~233722065:- LIHC cis rs6085948 0.861 rs8121934 ENSG00000228888.1 LINC01428 -5.07 6.49e-07 0.000248 -0.46 -0.26 Interleukin-10 levels; chr20:7263706 chr20:7146467~7254202:- LIHC cis rs739496 0.947 rs12580300 ENSG00000226469.1 ADAM1B 5.07 6.5e-07 0.000248 0.32 0.26 Platelet count; chr12:111411467 chr12:111927018~111929017:+ LIHC cis rs739496 0.895 rs7977752 ENSG00000226469.1 ADAM1B 5.07 6.5e-07 0.000248 0.32 0.26 Platelet count; chr12:111412426 chr12:111927018~111929017:+ LIHC cis rs11098499 1 rs58601355 ENSG00000245958.5 RP11-33B1.1 -5.07 6.52e-07 0.000249 -0.28 -0.26 Corneal astigmatism; chr4:119265212 chr4:119454791~119552025:+ LIHC cis rs6479901 0.789 rs10822146 ENSG00000232075.1 MRPL35P2 -5.07 6.52e-07 0.000249 -0.28 -0.26 Intelligence (multi-trait analysis); chr10:63191707 chr10:63634317~63634827:- LIHC cis rs6479901 0.841 rs10465990 ENSG00000232075.1 MRPL35P2 -5.07 6.52e-07 0.000249 -0.28 -0.26 Intelligence (multi-trait analysis); chr10:63200776 chr10:63634317~63634827:- LIHC cis rs6479901 0.793 rs4335432 ENSG00000232075.1 MRPL35P2 -5.07 6.52e-07 0.000249 -0.28 -0.26 Intelligence (multi-trait analysis); chr10:63226057 chr10:63634317~63634827:- LIHC cis rs6479901 0.841 rs6479889 ENSG00000232075.1 MRPL35P2 -5.07 6.52e-07 0.000249 -0.28 -0.26 Intelligence (multi-trait analysis); chr10:63228867 chr10:63634317~63634827:- LIHC cis rs7587476 0.601 rs6715570 ENSG00000229267.2 AC072062.1 5.07 6.54e-07 0.000249 0.33 0.26 Neuroblastoma; chr2:214808716 chr2:214810229~214963274:+ LIHC cis rs2274273 0.934 rs10139337 ENSG00000258413.1 RP11-665C16.6 -5.07 6.54e-07 0.00025 -0.32 -0.26 Protein biomarker; chr14:55275395 chr14:55262767~55272075:- LIHC cis rs7811142 0.779 rs28680963 ENSG00000242294.5 STAG3L5P 5.07 6.54e-07 0.00025 0.29 0.26 Platelet count; chr7:100307852 chr7:100336079~100351900:+ LIHC cis rs875971 0.545 rs316328 ENSG00000226824.5 RP4-756H11.3 5.07 6.55e-07 0.00025 0.32 0.26 Aortic root size; chr7:66143851 chr7:66654538~66669855:+ LIHC cis rs2274273 0.87 rs7153612 ENSG00000258413.1 RP11-665C16.6 -5.07 6.55e-07 0.00025 -0.31 -0.26 Protein biomarker; chr14:55322044 chr14:55262767~55272075:- LIHC cis rs227275 0.531 rs223460 ENSG00000230069.3 LRRC37A15P -5.07 6.55e-07 0.00025 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102782903 chr4:102727274~102730721:- LIHC cis rs4660214 0.568 rs6692769 ENSG00000182109.6 RP11-69E11.4 -5.07 6.56e-07 0.00025 -0.28 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39217503 chr1:39522280~39546187:- LIHC cis rs853679 0.527 rs853690 ENSG00000204709.4 LINC01556 5.07 6.56e-07 0.00025 0.3 0.26 Depression; chr6:28317705 chr6:28943877~28944537:+ LIHC cis rs17818399 0.781 rs12105006 ENSG00000279254.1 RP11-536C12.1 5.07 6.59e-07 0.000251 0.32 0.26 Height; chr2:46635447 chr2:46668870~46670778:+ LIHC cis rs887829 0.57 rs6753569 ENSG00000233445.1 RPL17P11 5.07 6.59e-07 0.000251 0.28 0.26 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233687171 chr2:233721522~233722065:- LIHC cis rs887829 0.57 rs6736743 ENSG00000233445.1 RPL17P11 5.07 6.59e-07 0.000251 0.28 0.26 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233687304 chr2:233721522~233722065:- LIHC cis rs4718428 0.672 rs36038499 ENSG00000230295.1 RP11-458F8.2 -5.07 6.59e-07 0.000252 -0.22 -0.26 Corneal structure; chr7:66824628 chr7:66880708~66882981:+ LIHC cis rs10510102 0.935 rs11200260 ENSG00000226864.1 ATE1-AS1 5.07 6.6e-07 0.000252 0.43 0.26 Breast cancer; chr10:121920169 chr10:121928312~121951965:+ LIHC cis rs227275 0.525 rs6419160 ENSG00000230069.3 LRRC37A15P -5.07 6.62e-07 0.000252 -0.24 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102938648 chr4:102727274~102730721:- LIHC cis rs228614 0.509 rs223482 ENSG00000230069.3 LRRC37A15P -5.07 6.62e-07 0.000252 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766051 chr4:102727274~102730721:- LIHC cis rs228614 0.509 rs223481 ENSG00000230069.3 LRRC37A15P -5.07 6.62e-07 0.000252 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766860 chr4:102727274~102730721:- LIHC cis rs228614 0.536 rs223478 ENSG00000230069.3 LRRC37A15P -5.07 6.62e-07 0.000252 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102768648 chr4:102727274~102730721:- LIHC cis rs228614 0.536 rs150898 ENSG00000230069.3 LRRC37A15P -5.07 6.62e-07 0.000252 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769234 chr4:102727274~102730721:- LIHC cis rs9425766 0.679 rs7552830 ENSG00000227373.4 RP11-160H22.5 5.07 6.62e-07 0.000252 0.32 0.26 Life satisfaction; chr1:174321643 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs7523938 ENSG00000227373.4 RP11-160H22.5 5.07 6.62e-07 0.000252 0.32 0.26 Life satisfaction; chr1:174327373 chr1:174115300~174160004:- LIHC cis rs9425766 0.64 rs6681780 ENSG00000227373.4 RP11-160H22.5 5.07 6.62e-07 0.000252 0.32 0.26 Life satisfaction; chr1:174328980 chr1:174115300~174160004:- LIHC cis rs9425766 0.55 rs57366619 ENSG00000227373.4 RP11-160H22.5 5.07 6.62e-07 0.000252 0.32 0.26 Life satisfaction; chr1:174334929 chr1:174115300~174160004:- LIHC cis rs227275 0.554 rs223485 ENSG00000230069.3 LRRC37A15P -5.07 6.62e-07 0.000252 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102764018 chr4:102727274~102730721:- LIHC cis rs17711722 0.503 rs453835 ENSG00000226002.1 RP11-460N20.5 -5.07 6.63e-07 0.000253 -0.28 -0.26 Calcium levels; chr7:66046172 chr7:65084103~65100232:+ LIHC cis rs6479891 1 rs9415680 ENSG00000232075.1 MRPL35P2 -5.07 6.64e-07 0.000253 -0.31 -0.26 Arthritis (juvenile idiopathic); chr10:63261130 chr10:63634317~63634827:- LIHC cis rs765787 0.53 rs12442533 ENSG00000259520.4 CTD-2651B20.3 -5.07 6.65e-07 0.000253 -0.3 -0.26 Uric acid levels; chr15:45237433 chr15:45251580~45279251:- LIHC cis rs10510102 0.935 rs11200183 ENSG00000276742.1 RP11-500G22.4 5.07 6.66e-07 0.000254 0.41 0.26 Breast cancer; chr10:121829908 chr10:121956782~121957098:+ LIHC cis rs36715 1 rs36705 ENSG00000245937.6 LINC01184 5.07 6.66e-07 0.000254 0.33 0.26 Breast cancer; chr5:128218794 chr5:127940426~128083172:- LIHC cis rs881375 0.678 rs9886724 ENSG00000226752.6 PSMD5-AS1 -5.07 6.67e-07 0.000254 -0.27 -0.26 Rheumatoid arthritis; chr9:120902741 chr9:120824828~120854385:+ LIHC cis rs881375 0.678 rs4836834 ENSG00000226752.6 PSMD5-AS1 -5.07 6.67e-07 0.000254 -0.27 -0.26 Rheumatoid arthritis; chr9:120903623 chr9:120824828~120854385:+ LIHC cis rs881375 0.631 rs10739577 ENSG00000226752.6 PSMD5-AS1 -5.07 6.67e-07 0.000254 -0.27 -0.26 Rheumatoid arthritis; chr9:120906576 chr9:120824828~120854385:+ LIHC cis rs11648785 0.735 rs868372 ENSG00000221819.5 GAS8-AS1 -5.07 6.68e-07 0.000254 -0.35 -0.26 Tanning; chr16:90031587 chr16:90028908~90029367:- LIHC cis rs10875746 0.551 rs1471998 ENSG00000240399.1 RP1-228P16.1 -5.07 6.69e-07 0.000255 -0.28 -0.26 Longevity (90 years and older); chr12:48318219 chr12:48054813~48055591:- LIHC cis rs10875746 0.551 rs2054904 ENSG00000240399.1 RP1-228P16.1 -5.07 6.69e-07 0.000255 -0.28 -0.26 Longevity (90 years and older); chr12:48330571 chr12:48054813~48055591:- LIHC cis rs950776 0.752 rs7182583 ENSG00000261762.1 RP11-650L12.2 5.07 6.69e-07 0.000255 0.33 0.26 Sudden cardiac arrest; chr15:78606868 chr15:78589123~78591276:- LIHC cis rs10129255 1 rs10134517 ENSG00000223648.3 IGHV3-64 5.06 6.69e-07 0.000255 0.2 0.26 Kawasaki disease; chr14:106718498 chr14:106643132~106658258:- LIHC cis rs12468226 0.938 rs55668474 ENSG00000273456.1 RP11-686O6.2 5.06 6.69e-07 0.000255 0.37 0.26 Urate levels; chr2:202265559 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs16824590 ENSG00000273456.1 RP11-686O6.2 5.06 6.69e-07 0.000255 0.37 0.26 Urate levels; chr2:202272624 chr2:202374932~202375604:- LIHC cis rs12468226 0.938 rs77018809 ENSG00000273456.1 RP11-686O6.2 5.06 6.69e-07 0.000255 0.37 0.26 Urate levels; chr2:202273166 chr2:202374932~202375604:- LIHC cis rs17711722 0.523 rs365896 ENSG00000273024.4 INTS4P2 5.06 6.7e-07 0.000255 0.28 0.26 Calcium levels; chr7:66045710 chr7:65647864~65715661:+ LIHC cis rs2836974 0.526 rs1888488 ENSG00000255568.3 BRWD1-AS2 -5.06 6.71e-07 0.000256 -0.22 -0.26 Cognitive function; chr21:39314595 chr21:39313935~39314962:+ LIHC cis rs4713118 0.662 rs149900 ENSG00000219392.1 RP1-265C24.5 -5.06 6.72e-07 0.000256 -0.39 -0.26 Parkinson's disease; chr6:28046819 chr6:28115628~28116551:+ LIHC cis rs227275 0.524 rs223337 ENSG00000246560.2 RP11-10L12.4 5.06 6.72e-07 0.000256 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102865214 chr4:102828055~102844075:+ LIHC cis rs2439831 1 rs2467736 ENSG00000205771.5 CATSPER2P1 -5.06 6.73e-07 0.000256 -0.36 -0.26 Lung cancer in ever smokers; chr15:43492719 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs2444250 ENSG00000205771.5 CATSPER2P1 -5.06 6.73e-07 0.000256 -0.36 -0.26 Lung cancer in ever smokers; chr15:43492853 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs101094 ENSG00000205771.5 CATSPER2P1 -5.06 6.73e-07 0.000256 -0.36 -0.26 Lung cancer in ever smokers; chr15:43495124 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs689781 ENSG00000205771.5 CATSPER2P1 -5.06 6.73e-07 0.000256 -0.36 -0.26 Lung cancer in ever smokers; chr15:43499899 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs2584725 ENSG00000205771.5 CATSPER2P1 -5.06 6.73e-07 0.000256 -0.36 -0.26 Lung cancer in ever smokers; chr15:43500937 chr15:43726918~43747094:- LIHC cis rs4731207 0.698 rs727506 ENSG00000224897.5 POT1-AS1 -5.06 6.73e-07 0.000256 -0.31 -0.26 Cutaneous malignant melanoma; chr7:124821973 chr7:124929873~125179315:+ LIHC cis rs950776 0.616 rs647041 ENSG00000261762.1 RP11-650L12.2 -5.06 6.73e-07 0.000256 -0.34 -0.26 Sudden cardiac arrest; chr15:78588139 chr15:78589123~78591276:- LIHC cis rs4639966 0.569 rs603486 ENSG00000255239.1 AP002954.6 5.06 6.74e-07 0.000256 0.32 0.26 Systemic lupus erythematosus; chr11:118716638 chr11:118688039~118690600:- LIHC cis rs6565180 0.926 rs12446288 ENSG00000183604.13 SMG1P5 5.06 6.74e-07 0.000256 0.28 0.26 Tonsillectomy; chr16:30377388 chr16:30267553~30335374:- LIHC cis rs6479891 1 rs10733790 ENSG00000232075.1 MRPL35P2 -5.06 6.74e-07 0.000257 -0.31 -0.26 Arthritis (juvenile idiopathic); chr10:63340574 chr10:63634317~63634827:- LIHC cis rs2072510 0.593 rs2540497 ENSG00000257715.1 RP11-256L6.2 -5.06 6.75e-07 0.000257 -0.41 -0.26 Metabolite levels (small molecules and protein measures); chr12:96010497 chr12:96025323~96027971:+ LIHC cis rs10129255 0.509 rs756583 ENSG00000223648.3 IGHV3-64 5.06 6.75e-07 0.000257 0.19 0.26 Kawasaki disease; chr14:106680002 chr14:106643132~106658258:- LIHC cis rs6600671 1 rs12145080 ENSG00000231429.2 RP11-343N15.2 5.06 6.76e-07 0.000257 0.3 0.26 Hip geometry; chr1:121443673 chr1:121412719~121429274:+ LIHC cis rs2283792 1 rs9607287 ENSG00000224086.5 LL22NC03-86G7.1 -5.06 6.76e-07 0.000257 -0.24 -0.26 Multiple sclerosis; chr22:21809136 chr22:21938293~21977632:+ LIHC cis rs7412746 0.611 rs2280627 ENSG00000231073.1 RP11-316M1.3 5.06 6.77e-07 0.000257 0.26 0.26 Melanoma; chr1:150963396 chr1:150973123~150975534:+ LIHC cis rs9595908 1 rs9591134 ENSG00000212293.1 SNORA16 5.06 6.78e-07 0.000258 0.31 0.26 Body mass index; chr13:32574079 chr13:32420390~32420516:- LIHC cis rs67311347 1 rs7641495 ENSG00000223797.4 ENTPD3-AS1 -5.06 6.78e-07 0.000258 -0.21 -0.26 Renal cell carcinoma; chr3:40453199 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs962847 ENSG00000223797.4 ENTPD3-AS1 -5.06 6.78e-07 0.000258 -0.21 -0.26 Renal cell carcinoma; chr3:40453665 chr3:40313802~40453329:- LIHC cis rs5769765 0.955 rs9616367 ENSG00000278869.1 CITF22-49E9.3 5.06 6.79e-07 0.000258 0.43 0.26 Schizophrenia; chr22:49909867 chr22:49933198~49934074:- LIHC cis rs1134634 0.52 rs73125606 ENSG00000273133.1 RP11-799M12.2 -5.06 6.79e-07 0.000258 -0.33 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15545691 chr4:15563698~15564253:- LIHC cis rs1134634 0.52 rs10025837 ENSG00000273133.1 RP11-799M12.2 -5.06 6.79e-07 0.000258 -0.33 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15548362 chr4:15563698~15564253:- LIHC cis rs7714584 1 rs7714584 ENSG00000197083.10 ZNF300P1 5.06 6.79e-07 0.000258 0.4 0.26 Crohn's disease; chr5:150890858 chr5:150930645~150946289:- LIHC cis rs465969 0.744 rs3851228 ENSG00000255389.1 C6orf3 5.06 6.8e-07 0.000258 0.43 0.26 Psoriasis; chr6:111526988 chr6:111599875~111602295:+ LIHC cis rs7208859 0.673 rs216440 ENSG00000266490.1 CTD-2349P21.9 5.06 6.8e-07 0.000258 0.31 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30601291 chr17:30792372~30792833:+ LIHC cis rs7208859 0.573 rs79505916 ENSG00000266490.1 CTD-2349P21.9 5.06 6.8e-07 0.000259 0.33 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30735308 chr17:30792372~30792833:+ LIHC cis rs2072510 0.569 rs61937881 ENSG00000257715.1 RP11-256L6.2 -5.06 6.8e-07 0.000259 -0.4 -0.26 Metabolite levels (small molecules and protein measures); chr12:95999809 chr12:96025323~96027971:+ LIHC cis rs2072510 0.569 rs17677343 ENSG00000257715.1 RP11-256L6.2 -5.06 6.8e-07 0.000259 -0.4 -0.26 Metabolite levels (small molecules and protein measures); chr12:96003303 chr12:96025323~96027971:+ LIHC cis rs950169 0.922 rs11630760 ENSG00000259295.5 CSPG4P12 5.06 6.82e-07 0.000259 0.36 0.26 Schizophrenia; chr15:84570106 chr15:85191438~85213905:+ LIHC cis rs950169 0.887 rs71395453 ENSG00000259295.5 CSPG4P12 5.06 6.82e-07 0.000259 0.36 0.26 Schizophrenia; chr15:84570259 chr15:85191438~85213905:+ LIHC cis rs227275 0.556 rs11722779 ENSG00000246560.2 RP11-10L12.4 5.06 6.82e-07 0.000259 0.3 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102906331 chr4:102828055~102844075:+ LIHC cis rs12554020 0.786 rs78547192 ENSG00000227603.1 RP11-165J3.6 5.06 6.82e-07 0.000259 0.46 0.26 Schizophrenia; chr9:93597221 chr9:93435332~93437121:- LIHC cis rs228614 0.51 rs223472 ENSG00000230069.3 LRRC37A15P -5.06 6.82e-07 0.000259 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102774327 chr4:102727274~102730721:- LIHC cis rs1134634 0.52 rs1473166 ENSG00000273133.1 RP11-799M12.2 -5.06 6.83e-07 0.000259 -0.33 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15555868 chr4:15563698~15564253:- LIHC cis rs4934494 0.768 rs11330 ENSG00000232936.4 RP11-80H5.2 -5.06 6.83e-07 0.000259 -0.32 -0.26 Red blood cell count; chr10:89634322 chr10:89645282~89650667:+ LIHC cis rs12468226 0.882 rs116437099 ENSG00000273456.1 RP11-686O6.2 5.06 6.83e-07 0.000259 0.36 0.26 Urate levels; chr2:202299250 chr2:202374932~202375604:- LIHC cis rs1005277 0.579 rs1621040 ENSG00000276805.1 RP11-291L22.6 5.06 6.83e-07 0.00026 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38208304 chr10:38451030~38451785:+ LIHC cis rs7923609 0.841 rs2163188 ENSG00000232075.1 MRPL35P2 5.06 6.85e-07 0.00026 0.28 0.26 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63554951 chr10:63634317~63634827:- LIHC cis rs12908161 0.959 rs11637728 ENSG00000259295.5 CSPG4P12 5.06 6.85e-07 0.00026 0.36 0.26 Schizophrenia; chr15:84660161 chr15:85191438~85213905:+ LIHC cis rs524281 0.814 rs1055615 ENSG00000255320.1 RP11-755F10.1 5.06 6.85e-07 0.00026 0.32 0.26 Electroencephalogram traits; chr11:66079451 chr11:66244840~66246239:- LIHC cis rs9425766 0.679 rs4650989 ENSG00000227373.4 RP11-160H22.5 5.06 6.86e-07 0.00026 0.32 0.26 Life satisfaction; chr1:174289739 chr1:174115300~174160004:- LIHC cis rs2337406 1 rs78631692 ENSG00000274576.2 IGHV2-70 -5.06 6.86e-07 0.000261 -0.31 -0.26 Alzheimer's disease (late onset); chr14:106709371 chr14:106770577~106771020:- LIHC cis rs10875746 0.669 rs4760701 ENSG00000240399.1 RP1-228P16.1 -5.06 6.87e-07 0.000261 -0.27 -0.26 Longevity (90 years and older); chr12:48304735 chr12:48054813~48055591:- LIHC cis rs950169 0.922 rs62029585 ENSG00000259728.4 LINC00933 5.06 6.88e-07 0.000261 0.38 0.26 Schizophrenia; chr15:84397176 chr15:84570649~84580175:+ LIHC cis rs1134634 0.52 rs872678 ENSG00000273133.1 RP11-799M12.2 -5.06 6.88e-07 0.000261 -0.33 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15654075 chr4:15563698~15564253:- LIHC cis rs9425766 0.523 rs6668959 ENSG00000227373.4 RP11-160H22.5 5.06 6.88e-07 0.000261 0.32 0.26 Life satisfaction; chr1:174088488 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs12563301 ENSG00000227373.4 RP11-160H22.5 5.06 6.88e-07 0.000261 0.32 0.26 Life satisfaction; chr1:174090924 chr1:174115300~174160004:- LIHC cis rs9425766 0.665 rs7553788 ENSG00000227373.4 RP11-160H22.5 5.06 6.88e-07 0.000261 0.32 0.26 Life satisfaction; chr1:174093773 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs6682017 ENSG00000227373.4 RP11-160H22.5 5.06 6.88e-07 0.000261 0.32 0.26 Life satisfaction; chr1:174097809 chr1:174115300~174160004:- LIHC cis rs9425766 0.655 rs2145376 ENSG00000227373.4 RP11-160H22.5 5.06 6.88e-07 0.000261 0.32 0.26 Life satisfaction; chr1:174098911 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs6663794 ENSG00000227373.4 RP11-160H22.5 5.06 6.88e-07 0.000261 0.32 0.26 Life satisfaction; chr1:174099791 chr1:174115300~174160004:- LIHC cis rs9425766 0.64 rs6658769 ENSG00000227373.4 RP11-160H22.5 5.06 6.88e-07 0.000261 0.32 0.26 Life satisfaction; chr1:174100843 chr1:174115300~174160004:- LIHC cis rs904251 0.861 rs1757171 ENSG00000204110.6 RP1-153P14.8 -5.06 6.89e-07 0.000261 -0.33 -0.26 Cognitive performance; chr6:37519268 chr6:37507348~37535616:+ LIHC cis rs10510102 0.872 rs12264046 ENSG00000276742.1 RP11-500G22.4 5.06 6.89e-07 0.000261 0.4 0.26 Breast cancer; chr10:121894996 chr10:121956782~121957098:+ LIHC cis rs8059260 0.736 rs8049278 ENSG00000274038.1 RP11-66H6.4 -5.06 6.89e-07 0.000262 -0.43 -0.26 Alcohol consumption over the past year; chr16:10968766 chr16:11056556~11057034:+ LIHC cis rs1134634 0.52 rs2160044 ENSG00000273133.1 RP11-799M12.2 -5.06 6.89e-07 0.000262 -0.33 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15556720 chr4:15563698~15564253:- LIHC cis rs1061377 1 rs1036036 ENSG00000249685.1 RP11-360F5.3 5.06 6.9e-07 0.000262 0.32 0.26 Uric acid levels; chr4:39111104 chr4:39133913~39135608:+ LIHC cis rs1499614 1 rs2707832 ENSG00000230295.1 RP11-458F8.2 -5.06 6.9e-07 0.000262 -0.26 -0.26 Gout; chr7:66671562 chr7:66880708~66882981:+ LIHC cis rs11672691 0.519 rs10407939 ENSG00000267107.5 PCAT19 5.06 6.91e-07 0.000262 0.32 0.26 Prostate cancer; chr19:41502561 chr19:41454169~41500649:- LIHC cis rs712039 0.652 rs712038 ENSG00000276054.1 RP11-378E13.3 5.06 6.91e-07 0.000262 0.33 0.26 Tuberculosis; chr17:37402468 chr17:37386886~37387926:+ LIHC cis rs712039 0.652 rs829160 ENSG00000276054.1 RP11-378E13.3 5.06 6.91e-07 0.000262 0.33 0.26 Tuberculosis; chr17:37403002 chr17:37386886~37387926:+ LIHC cis rs7714584 1 rs59043558 ENSG00000197083.10 ZNF300P1 5.06 6.91e-07 0.000262 0.4 0.26 Crohn's disease; chr5:150955100 chr5:150930645~150946289:- LIHC cis rs712039 0.652 rs1102920 ENSG00000276054.1 RP11-378E13.3 5.06 6.92e-07 0.000263 0.33 0.26 Tuberculosis; chr17:37400850 chr17:37386886~37387926:+ LIHC cis rs10510102 0.935 rs12262776 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121884532 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs12264952 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121885673 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs12244866 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121886013 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs12266597 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121886062 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs12245018 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121886195 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200217 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121886372 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs10887008 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121886714 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs12268872 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121887426 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs9630107 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121887713 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs10887010 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121888542 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs11200220 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121889949 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200221 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121890134 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs10887011 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121890203 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs10887012 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121890454 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs11200222 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121891177 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200223 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121891416 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs10887013 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121891546 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs11200225 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121891948 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200226 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121891988 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs10887014 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121892322 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs11818735 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121892472 chr10:121956782~121957098:+ LIHC cis rs10510102 0.81 rs12259902 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121893017 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200228 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121893358 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200229 ENSG00000276742.1 RP11-500G22.4 5.06 6.92e-07 0.000263 0.4 0.26 Breast cancer; chr10:121893519 chr10:121956782~121957098:+ LIHC cis rs4718428 0.705 rs13220977 ENSG00000230295.1 RP11-458F8.2 5.06 6.93e-07 0.000263 0.22 0.26 Corneal structure; chr7:66872661 chr7:66880708~66882981:+ LIHC cis rs2836974 0.666 rs2836975 ENSG00000255568.3 BRWD1-AS2 -5.06 6.93e-07 0.000263 -0.22 -0.26 Cognitive function; chr21:39291694 chr21:39313935~39314962:+ LIHC cis rs6683071 0.738 rs2030076 ENSG00000272750.1 RP11-378J18.8 -5.06 6.94e-07 0.000263 -0.31 -0.26 Cognitive performance; chr1:222701624 chr1:222658867~222661512:- LIHC cis rs12468226 1 rs77435512 ENSG00000273456.1 RP11-686O6.2 5.06 6.96e-07 0.000264 0.37 0.26 Urate levels; chr2:202334165 chr2:202374932~202375604:- LIHC cis rs6479891 1 rs61853336 ENSG00000232075.1 MRPL35P2 5.06 6.97e-07 0.000264 0.31 0.26 Arthritis (juvenile idiopathic); chr10:63140115 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs4746994 ENSG00000232075.1 MRPL35P2 5.06 6.97e-07 0.000264 0.31 0.26 Arthritis (juvenile idiopathic); chr10:63145564 chr10:63634317~63634827:- LIHC cis rs5756813 0.754 rs4821706 ENSG00000233360.4 Z83844.1 5.06 7e-07 0.000265 0.34 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37758683 chr22:37641832~37658377:- LIHC cis rs916888 0.773 rs199457 ENSG00000274883.1 Metazoa_SRP -5.06 7.01e-07 0.000265 -0.41 -0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45931806~45932083:+ LIHC cis rs916888 0.687 rs199456 ENSG00000274883.1 Metazoa_SRP -5.06 7.01e-07 0.000265 -0.41 -0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45931806~45932083:+ LIHC cis rs10510102 1 rs10510102 ENSG00000226864.1 ATE1-AS1 -5.06 7.01e-07 0.000265 -0.44 -0.26 Breast cancer; chr10:121865675 chr10:121928312~121951965:+ LIHC cis rs4731207 0.646 rs67453484 ENSG00000224897.5 POT1-AS1 -5.06 7.01e-07 0.000266 -0.32 -0.26 Cutaneous malignant melanoma; chr7:124814470 chr7:124929873~125179315:+ LIHC cis rs1134634 0.52 rs12645849 ENSG00000273133.1 RP11-799M12.2 -5.06 7.01e-07 0.000266 -0.33 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15627457 chr4:15563698~15564253:- LIHC cis rs73186030 0.591 rs56098325 ENSG00000272758.4 RP11-299J3.8 5.06 7.01e-07 0.000266 0.52 0.26 Serum parathyroid hormone levels; chr3:122342362 chr3:122416207~122443180:+ LIHC cis rs9291683 0.588 rs35438220 ENSG00000250413.1 RP11-448G15.1 -5.06 7.02e-07 0.000266 -0.34 -0.26 Bone mineral density; chr4:9997774 chr4:10006482~10009725:+ LIHC cis rs9291683 0.588 rs11732054 ENSG00000250413.1 RP11-448G15.1 -5.06 7.02e-07 0.000266 -0.34 -0.26 Bone mineral density; chr4:9998253 chr4:10006482~10009725:+ LIHC cis rs4356203 0.87 rs1979603 ENSG00000272034.1 SNORD14A -5.06 7.02e-07 0.000266 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17261839 chr11:17074654~17074744:- LIHC cis rs67311347 0.869 rs6790495 ENSG00000223797.4 ENTPD3-AS1 5.06 7.02e-07 0.000266 0.21 0.26 Renal cell carcinoma; chr3:40325279 chr3:40313802~40453329:- LIHC cis rs67311347 0.869 rs7646899 ENSG00000223797.4 ENTPD3-AS1 5.06 7.02e-07 0.000266 0.21 0.26 Renal cell carcinoma; chr3:40325491 chr3:40313802~40453329:- LIHC cis rs992157 0.764 rs10932774 ENSG00000261338.2 RP11-378A13.1 5.05 7.04e-07 0.000266 0.28 0.26 Colorectal cancer; chr2:218326846 chr2:218255319~218257366:+ LIHC cis rs6921919 0.583 rs3800328 ENSG00000204709.4 LINC01556 5.05 7.05e-07 0.000267 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28423066 chr6:28943877~28944537:+ LIHC cis rs6921919 0.609 rs67211468 ENSG00000204709.4 LINC01556 5.05 7.05e-07 0.000267 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28424210 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs740622 ENSG00000204709.4 LINC01556 5.05 7.05e-07 0.000267 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28430514 chr6:28943877~28944537:+ LIHC cis rs6921919 1 rs6922111 ENSG00000204709.4 LINC01556 5.05 7.06e-07 0.000267 0.37 0.26 Autism spectrum disorder or schizophrenia; chr6:28357531 chr6:28943877~28944537:+ LIHC cis rs712039 0.652 rs2680719 ENSG00000276054.1 RP11-378E13.3 5.05 7.07e-07 0.000267 0.33 0.26 Tuberculosis; chr17:37451351 chr17:37386886~37387926:+ LIHC cis rs1005277 0.557 rs2983338 ENSG00000276805.1 RP11-291L22.6 5.05 7.07e-07 0.000268 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38261806 chr10:38451030~38451785:+ LIHC cis rs875971 0.54 rs781152 ENSG00000164669.11 INTS4P1 -5.05 7.07e-07 0.000268 -0.38 -0.26 Aortic root size; chr7:66014585 chr7:65141225~65234216:+ LIHC cis rs1499614 0.901 rs2178742 ENSG00000226824.5 RP4-756H11.3 -5.05 7.07e-07 0.000268 -0.44 -0.26 Gout; chr7:66732812 chr7:66654538~66669855:+ LIHC cis rs2842992 0.83 rs2842966 ENSG00000237927.1 RP3-393E18.2 -5.05 7.08e-07 0.000268 -0.32 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159720560 chr6:159586955~159589169:- LIHC cis rs10129255 0.556 rs9324093 ENSG00000211972.2 IGHV3-66 5.05 7.08e-07 0.000268 0.2 0.26 Kawasaki disease; chr14:106683893 chr14:106675017~106675544:- LIHC cis rs17711722 0.727 rs781151 ENSG00000164669.11 INTS4P1 -5.05 7.1e-07 0.000269 -0.38 -0.26 Calcium levels; chr7:66014891 chr7:65141225~65234216:+ LIHC cis rs36715 0.953 rs36706 ENSG00000245937.6 LINC01184 5.05 7.1e-07 0.000269 0.33 0.26 Breast cancer; chr5:128221006 chr5:127940426~128083172:- LIHC cis rs2877649 0.793 rs74805728 ENSG00000258744.1 RP11-80A15.1 -5.05 7.11e-07 0.000269 -0.55 -0.26 Smooth-surface caries; chr14:24446631 chr14:24501594~24508688:+ LIHC cis rs17270561 0.697 rs9366633 ENSG00000216436.2 HIST1H2APS1 -5.05 7.11e-07 0.000269 -0.32 -0.26 Iron status biomarkers; chr6:25837826 chr6:25732497~25732827:+ LIHC cis rs931127 0.554 rs34007146 ENSG00000265874.1 MIR4489 5.05 7.12e-07 0.000269 0.37 0.26 Systemic lupus erythematosus; chr11:65710483 chr11:65649192~65649253:+ LIHC cis rs10912872 0.634 rs10912842 ENSG00000225704.2 RP4-798A17.5 5.05 7.13e-07 0.00027 0.23 0.26 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr1:171365688 chr1:171345089~171345320:+ LIHC cis rs7208859 0.623 rs216423 ENSG00000266490.1 CTD-2349P21.9 5.05 7.13e-07 0.00027 0.31 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30615091 chr17:30792372~30792833:+ LIHC cis rs3931020 0.566 rs1327086 ENSG00000272864.1 RP11-17E13.2 -5.05 7.15e-07 0.00027 -0.38 -0.26 Resistin levels; chr1:74805348 chr1:74698769~74699333:- LIHC cis rs875971 0.545 rs73142265 ENSG00000226824.5 RP4-756H11.3 -5.05 7.15e-07 0.00027 -0.33 -0.26 Aortic root size; chr7:66234510 chr7:66654538~66669855:+ LIHC cis rs2283792 0.967 rs5749998 ENSG00000224086.5 LL22NC03-86G7.1 -5.05 7.16e-07 0.000271 -0.24 -0.26 Multiple sclerosis; chr22:21808085 chr22:21938293~21977632:+ LIHC cis rs1005277 0.579 rs2103938 ENSG00000276805.1 RP11-291L22.6 5.05 7.16e-07 0.000271 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38205070 chr10:38451030~38451785:+ LIHC cis rs1062177 0.855 rs1346489 ENSG00000213433.5 RPLP1P6 -5.05 7.16e-07 0.000271 -0.28 -0.26 Preschool internalizing problems; chr5:151886973 chr5:151765859~151766378:- LIHC cis rs12134133 0.752 rs6673080 ENSG00000274245.1 RP11-357P18.2 5.05 7.16e-07 0.000271 0.41 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207216859 chr1:207372559~207373252:+ LIHC cis rs10510102 0.935 rs11200187 ENSG00000276742.1 RP11-500G22.4 5.05 7.18e-07 0.000271 0.41 0.26 Breast cancer; chr10:121843050 chr10:121956782~121957098:+ LIHC cis rs6600671 0.934 rs12060031 ENSG00000231429.2 RP11-343N15.2 5.05 7.18e-07 0.000271 0.32 0.26 Hip geometry; chr1:121501652 chr1:121412719~121429274:+ LIHC cis rs7714584 1 rs1428551 ENSG00000197083.10 ZNF300P1 5.05 7.18e-07 0.000271 0.4 0.26 Crohn's disease; chr5:150880270 chr5:150930645~150946289:- LIHC cis rs2439831 0.867 rs3809481 ENSG00000205771.5 CATSPER2P1 -5.05 7.19e-07 0.000272 -0.42 -0.26 Lung cancer in ever smokers; chr15:43370631 chr15:43726918~43747094:- LIHC cis rs6480314 0.522 rs61854800 ENSG00000233590.1 RP11-153K11.3 -5.05 7.2e-07 0.000272 -0.44 -0.26 Optic nerve measurement (disc area); chr10:68248271 chr10:68233251~68242379:- LIHC cis rs227275 0.527 rs223338 ENSG00000246560.2 RP11-10L12.4 5.05 7.21e-07 0.000273 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102864959 chr4:102828055~102844075:+ LIHC cis rs11690935 0.688 rs7600835 ENSG00000228389.1 AC068039.4 5.05 7.22e-07 0.000273 0.32 0.26 Schizophrenia; chr2:171665317 chr2:171773482~171775844:+ LIHC cis rs2877649 0.793 rs74984901 ENSG00000258744.1 RP11-80A15.1 -5.05 7.22e-07 0.000273 -0.55 -0.26 Smooth-surface caries; chr14:24443571 chr14:24501594~24508688:+ LIHC cis rs2877649 0.793 rs77892475 ENSG00000258744.1 RP11-80A15.1 -5.05 7.22e-07 0.000273 -0.55 -0.26 Smooth-surface caries; chr14:24443683 chr14:24501594~24508688:+ LIHC cis rs2877649 0.793 rs80192295 ENSG00000258744.1 RP11-80A15.1 -5.05 7.22e-07 0.000273 -0.55 -0.26 Smooth-surface caries; chr14:24445120 chr14:24501594~24508688:+ LIHC cis rs2877649 0.793 rs78663777 ENSG00000258744.1 RP11-80A15.1 -5.05 7.22e-07 0.000273 -0.55 -0.26 Smooth-surface caries; chr14:24445990 chr14:24501594~24508688:+ LIHC cis rs875971 0.545 rs7787063 ENSG00000226824.5 RP4-756H11.3 -5.05 7.23e-07 0.000273 -0.34 -0.26 Aortic root size; chr7:66164012 chr7:66654538~66669855:+ LIHC cis rs7119038 0.818 rs56758835 ENSG00000255239.1 AP002954.6 -5.05 7.23e-07 0.000273 -0.38 -0.26 Sjögren's syndrome; chr11:118744631 chr11:118688039~118690600:- LIHC cis rs7119038 0.818 rs1048024 ENSG00000255239.1 AP002954.6 -5.05 7.23e-07 0.000273 -0.38 -0.26 Sjögren's syndrome; chr11:118748067 chr11:118688039~118690600:- LIHC cis rs858239 0.698 rs858295 ENSG00000226816.2 AC005082.12 5.05 7.23e-07 0.000273 0.35 0.26 Cerebrospinal fluid biomarker levels; chr7:23205950 chr7:23206013~23208045:+ LIHC cis rs1005277 0.529 rs1780125 ENSG00000276805.1 RP11-291L22.6 5.05 7.25e-07 0.000274 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38242448 chr10:38451030~38451785:+ LIHC cis rs1005277 0.502 rs2800484 ENSG00000276805.1 RP11-291L22.6 5.05 7.25e-07 0.000274 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38253487 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2800485 ENSG00000276805.1 RP11-291L22.6 5.05 7.25e-07 0.000274 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38253660 chr10:38451030~38451785:+ LIHC cis rs9549367 0.789 rs9577218 ENSG00000269125.1 RP11-98F14.11 -5.05 7.27e-07 0.000274 -0.3 -0.26 Platelet distribution width; chr13:113240597 chr13:113165002~113165183:- LIHC cis rs1061377 0.513 rs6840214 ENSG00000249207.1 RP11-360F5.1 5.05 7.27e-07 0.000274 0.32 0.26 Uric acid levels; chr4:39118999 chr4:39112677~39126818:- LIHC cis rs6480314 0.542 rs10998044 ENSG00000233590.1 RP11-153K11.3 -5.05 7.27e-07 0.000274 -0.41 -0.26 Optic nerve measurement (disc area); chr10:68269508 chr10:68233251~68242379:- LIHC cis rs1134634 0.52 rs10022610 ENSG00000273133.1 RP11-799M12.2 -5.05 7.28e-07 0.000275 -0.33 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15635864 chr4:15563698~15564253:- LIHC cis rs875971 0.545 rs6460281 ENSG00000273142.1 RP11-458F8.4 5.05 7.29e-07 0.000275 0.25 0.26 Aortic root size; chr7:66216128 chr7:66902857~66906297:+ LIHC cis rs2337406 0.866 rs112089985 ENSG00000274576.2 IGHV2-70 -5.05 7.31e-07 0.000276 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106780074 chr14:106770577~106771020:- LIHC cis rs7412746 0.611 rs752376 ENSG00000231073.1 RP11-316M1.3 5.05 7.31e-07 0.000276 0.26 0.26 Melanoma; chr1:150968905 chr1:150973123~150975534:+ LIHC cis rs7665090 0.51 rs223498 ENSG00000230069.3 LRRC37A15P 5.05 7.31e-07 0.000276 0.24 0.26 Primary biliary cholangitis; chr4:102730805 chr4:102727274~102730721:- LIHC cis rs950169 0.922 rs11631096 ENSG00000259728.4 LINC00933 5.05 7.31e-07 0.000276 0.38 0.26 Schizophrenia; chr15:84557698 chr15:84570649~84580175:+ LIHC cis rs17265703 0.524 rs12107092 ENSG00000272758.4 RP11-299J3.8 5.05 7.31e-07 0.000276 0.47 0.26 Phosphorus levels; chr3:122405001 chr3:122416207~122443180:+ LIHC cis rs875971 0.545 rs10950029 ENSG00000226824.5 RP4-756H11.3 -5.05 7.33e-07 0.000277 -0.33 -0.26 Aortic root size; chr7:66169334 chr7:66654538~66669855:+ LIHC cis rs228614 0.536 rs150897 ENSG00000230069.3 LRRC37A15P -5.05 7.34e-07 0.000277 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769309 chr4:102727274~102730721:- LIHC cis rs7208859 0.673 rs216424 ENSG00000266490.1 CTD-2349P21.9 5.05 7.34e-07 0.000277 0.31 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30616046 chr17:30792372~30792833:+ LIHC cis rs417065 0.516 rs6687168 ENSG00000227634.1 RP11-431K24.3 -5.05 7.35e-07 0.000277 -0.32 -0.26 Psoriasis; chr1:8208853 chr1:8208672~8215210:+ LIHC cis rs11098499 0.955 rs11944880 ENSG00000245958.5 RP11-33B1.1 5.05 7.35e-07 0.000277 0.28 0.26 Corneal astigmatism; chr4:119238179 chr4:119454791~119552025:+ LIHC cis rs4650994 0.544 rs6675811 ENSG00000273384.1 RP5-1098D14.1 5.05 7.36e-07 0.000278 0.32 0.26 HDL cholesterol;HDL cholesterol levels; chr1:178529933 chr1:178651706~178652282:+ LIHC cis rs4650994 0.544 rs4132058 ENSG00000273384.1 RP5-1098D14.1 5.05 7.36e-07 0.000278 0.32 0.26 HDL cholesterol;HDL cholesterol levels; chr1:178536422 chr1:178651706~178652282:+ LIHC cis rs8018967 1 rs8018967 ENSG00000258695.2 RP3-414A15.2 -5.05 7.36e-07 0.000278 -0.29 -0.26 Blood metabolite ratios; chr14:73510230 chr14:73522878~73530610:+ LIHC cis rs2032447 0.714 rs175319 ENSG00000242387.1 HIST1H2APS2 5.05 7.37e-07 0.000278 0.34 0.26 Intelligence (multi-trait analysis); chr6:25955944 chr6:25882026~25882395:- LIHC cis rs2998286 0.862 rs946594 ENSG00000254635.4 WAC-AS1 -5.04 7.38e-07 0.000278 -0.32 -0.26 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28503318 chr10:28522652~28532743:- LIHC cis rs2998286 0.862 rs1416817 ENSG00000254635.4 WAC-AS1 -5.04 7.38e-07 0.000278 -0.32 -0.26 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28503548 chr10:28522652~28532743:- LIHC cis rs2337406 0.866 rs79901786 ENSG00000274576.2 IGHV2-70 -5.04 7.38e-07 0.000278 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106777623 chr14:106770577~106771020:- LIHC cis rs30380 0.632 rs27045 ENSG00000272109.1 CTD-2260A17.3 -5.04 7.39e-07 0.000279 -0.33 -0.26 Cerebrospinal fluid biomarker levels; chr5:96803158 chr5:96804353~96806105:+ LIHC cis rs10800713 0.607 rs6682828 ENSG00000260088.1 RP11-92G12.3 -5.04 7.4e-07 0.000279 -0.33 -0.26 Tandem gait; chr1:200537968 chr1:200669507~200694250:+ LIHC cis rs529413 0.527 rs1508030 ENSG00000259237.1 RP11-209E8.1 5.04 7.4e-07 0.000279 0.35 0.26 Itch intensity from mosquito bite adjusted by bite size; chr15:53157752 chr15:53116365~53129698:+ LIHC cis rs599083 0.53 rs640569 ENSG00000212093.1 AP000807.1 -5.04 7.41e-07 0.000279 -0.29 -0.26 Bone mineral density (spine); chr11:68417352 chr11:68506083~68506166:- LIHC cis rs599083 0.53 rs2472415 ENSG00000212093.1 AP000807.1 -5.04 7.41e-07 0.000279 -0.29 -0.26 Bone mineral density (spine); chr11:68418148 chr11:68506083~68506166:- LIHC cis rs11079159 0.837 rs4794559 ENSG00000263096.1 RP11-515O17.2 5.04 7.41e-07 0.000279 0.36 0.26 QRS duration; chr17:55286939 chr17:55271504~55273653:- LIHC cis rs11098499 0.604 rs2389886 ENSG00000245958.5 RP11-33B1.1 -5.04 7.41e-07 0.000279 -0.27 -0.26 Corneal astigmatism; chr4:119649267 chr4:119454791~119552025:+ LIHC cis rs1065852 0.503 rs9620006 ENSG00000237037.8 NDUFA6-AS1 -5.04 7.42e-07 0.00028 -0.36 -0.26 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42003543 chr22:42090931~42137742:+ LIHC cis rs10256972 0.521 rs7811577 ENSG00000199023.2 MIR339 -5.04 7.44e-07 0.00028 -0.31 -0.26 Endometriosis;Longevity; chr7:1063193 chr7:1022935~1023045:- LIHC cis rs11676348 0.967 rs4674258 ENSG00000261338.2 RP11-378A13.1 -5.04 7.45e-07 0.00028 -0.27 -0.26 Ulcerative colitis; chr2:218125863 chr2:218255319~218257366:+ LIHC cis rs950169 0.686 rs12906474 ENSG00000259728.4 LINC00933 5.04 7.45e-07 0.00028 0.38 0.26 Schizophrenia; chr15:84566006 chr15:84570649~84580175:+ LIHC cis rs950169 0.81 rs2879976 ENSG00000259728.4 LINC00933 5.04 7.45e-07 0.00028 0.38 0.26 Schizophrenia; chr15:84566347 chr15:84570649~84580175:+ LIHC cis rs4660214 0.666 rs625384 ENSG00000182109.6 RP11-69E11.4 5.04 7.45e-07 0.000281 0.28 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39427421 chr1:39522280~39546187:- LIHC cis rs2337406 0.852 rs12050239 ENSG00000274576.2 IGHV2-70 -5.04 7.45e-07 0.000281 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106781132 chr14:106770577~106771020:- LIHC cis rs2299587 0.519 rs3850746 ENSG00000253671.1 RP11-806O11.1 5.04 7.46e-07 0.000281 0.31 0.26 Economic and political preferences; chr8:17930027 chr8:17808941~17820868:+ LIHC cis rs6479901 0.894 rs10761747 ENSG00000232075.1 MRPL35P2 5.04 7.46e-07 0.000281 0.28 0.26 Intelligence (multi-trait analysis); chr10:63348396 chr10:63634317~63634827:- LIHC cis rs638893 0.947 rs1170396 ENSG00000255422.1 AP002954.4 -5.04 7.46e-07 0.000281 -0.44 -0.26 Vitiligo; chr11:118833108 chr11:118704607~118750263:+ LIHC cis rs4731207 0.698 rs886704 ENSG00000224897.5 POT1-AS1 5.04 7.47e-07 0.000281 0.31 0.26 Cutaneous malignant melanoma; chr7:124782212 chr7:124929873~125179315:+ LIHC cis rs9425766 0.679 rs57919173 ENSG00000227373.4 RP11-160H22.5 5.04 7.49e-07 0.000282 0.32 0.26 Life satisfaction; chr1:174159856 chr1:174115300~174160004:- LIHC cis rs11098499 1 rs3749591 ENSG00000245958.5 RP11-33B1.1 -5.04 7.5e-07 0.000282 -0.28 -0.26 Corneal astigmatism; chr4:119292875 chr4:119454791~119552025:+ LIHC cis rs10833905 1 rs2114466 ENSG00000246225.5 RP11-17A1.3 -5.04 7.51e-07 0.000283 -0.32 -0.26 Sudden cardiac arrest; chr11:23014841 chr11:22829380~22945393:+ LIHC cis rs10875746 0.669 rs10875770 ENSG00000240399.1 RP1-228P16.1 -5.04 7.51e-07 0.000283 -0.29 -0.26 Longevity (90 years and older); chr12:48206737 chr12:48054813~48055591:- LIHC cis rs1061377 1 rs28607301 ENSG00000249685.1 RP11-360F5.3 5.04 7.51e-07 0.000283 0.31 0.26 Uric acid levels; chr4:39136460 chr4:39133913~39135608:+ LIHC cis rs2439831 0.867 rs2447208 ENSG00000275601.1 AC011330.13 -5.04 7.52e-07 0.000283 -0.38 -0.26 Lung cancer in ever smokers; chr15:43641697 chr15:43642389~43643023:- LIHC cis rs11098499 1 rs35643470 ENSG00000245958.5 RP11-33B1.1 -5.04 7.52e-07 0.000283 -0.28 -0.26 Corneal astigmatism; chr4:119263793 chr4:119454791~119552025:+ LIHC cis rs11098499 0.955 rs56386062 ENSG00000245958.5 RP11-33B1.1 -5.04 7.52e-07 0.000283 -0.29 -0.26 Corneal astigmatism; chr4:119233980 chr4:119454791~119552025:+ LIHC cis rs11098499 0.955 rs4145951 ENSG00000245958.5 RP11-33B1.1 -5.04 7.52e-07 0.000283 -0.29 -0.26 Corneal astigmatism; chr4:119234662 chr4:119454791~119552025:+ LIHC cis rs11098499 0.955 rs35916640 ENSG00000245958.5 RP11-33B1.1 -5.04 7.52e-07 0.000283 -0.29 -0.26 Corneal astigmatism; chr4:119234697 chr4:119454791~119552025:+ LIHC cis rs11098499 0.955 rs13113112 ENSG00000245958.5 RP11-33B1.1 -5.04 7.52e-07 0.000283 -0.29 -0.26 Corneal astigmatism; chr4:119234885 chr4:119454791~119552025:+ LIHC cis rs7131987 0.509 rs11050173 ENSG00000257176.2 RP11-996F15.2 -5.04 7.53e-07 0.000283 -0.32 -0.26 QT interval; chr12:29288540 chr12:29280418~29317848:- LIHC cis rs8072100 0.837 rs8070463 ENSG00000228782.6 CTD-2026D20.3 5.04 7.54e-07 0.000284 0.28 0.26 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47691470 chr17:47450568~47492492:- LIHC cis rs1322639 0.618 rs9505942 ENSG00000261039.2 RP11-417E7.2 -5.04 7.55e-07 0.000284 -0.36 -0.26 Pulse pressure; chr6:169191698 chr6:169175304~169182740:- LIHC cis rs1005277 0.579 rs1740735 ENSG00000276805.1 RP11-291L22.6 5.04 7.55e-07 0.000284 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38208849 chr10:38451030~38451785:+ LIHC cis rs116175783 0.557 rs3769963 ENSG00000227403.1 AC009299.3 5.04 7.55e-07 0.000284 0.4 0.26 Intelligence (multi-trait analysis); chr2:161350999 chr2:161244739~161249050:+ LIHC cis rs9903692 0.954 rs7224014 ENSG00000278765.1 RP5-890E16.5 5.04 7.55e-07 0.000284 0.35 0.26 Pulse pressure; chr17:48073499 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs2240122 ENSG00000278765.1 RP5-890E16.5 5.04 7.55e-07 0.000284 0.35 0.26 Pulse pressure; chr17:48075197 chr17:48066704~48067293:- LIHC cis rs9903692 0.738 rs35202025 ENSG00000278765.1 RP5-890E16.5 5.04 7.55e-07 0.000284 0.35 0.26 Pulse pressure; chr17:48075355 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs9747001 ENSG00000278765.1 RP5-890E16.5 5.04 7.55e-07 0.000284 0.35 0.26 Pulse pressure; chr17:48077307 chr17:48066704~48067293:- LIHC cis rs9903692 0.909 rs12952163 ENSG00000278765.1 RP5-890E16.5 5.04 7.55e-07 0.000284 0.35 0.26 Pulse pressure; chr17:48082029 chr17:48066704~48067293:- LIHC cis rs9903692 0.648 rs35361214 ENSG00000278765.1 RP5-890E16.5 5.04 7.55e-07 0.000284 0.35 0.26 Pulse pressure; chr17:48087729 chr17:48066704~48067293:- LIHC cis rs9903692 0.697 rs6504024 ENSG00000278765.1 RP5-890E16.5 5.04 7.55e-07 0.000284 0.35 0.26 Pulse pressure; chr17:48088224 chr17:48066704~48067293:- LIHC cis rs9903692 0.779 rs6504025 ENSG00000278765.1 RP5-890E16.5 5.04 7.55e-07 0.000284 0.35 0.26 Pulse pressure; chr17:48088711 chr17:48066704~48067293:- LIHC cis rs2439831 0.557 rs13329084 ENSG00000205771.5 CATSPER2P1 5.04 7.57e-07 0.000285 0.42 0.26 Lung cancer in ever smokers; chr15:43858865 chr15:43726918~43747094:- LIHC cis rs13392177 0.543 rs12623716 ENSG00000261338.2 RP11-378A13.1 -5.04 7.57e-07 0.000285 -0.27 -0.26 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218208295 chr2:218255319~218257366:+ LIHC cis rs2836974 0.965 rs2836965 ENSG00000255568.3 BRWD1-AS2 -5.04 7.57e-07 0.000285 -0.3 -0.26 Cognitive function; chr21:39261705 chr21:39313935~39314962:+ LIHC cis rs11690935 0.921 rs4668414 ENSG00000228389.1 AC068039.4 5.04 7.58e-07 0.000285 0.36 0.26 Schizophrenia; chr2:171847781 chr2:171773482~171775844:+ LIHC cis rs9549367 0.577 rs3024713 ENSG00000269125.1 RP11-98F14.11 -5.04 7.59e-07 0.000285 -0.35 -0.26 Platelet distribution width; chr13:113159007 chr13:113165002~113165183:- LIHC cis rs228614 0.51 rs50034 ENSG00000230069.3 LRRC37A15P -5.04 7.6e-07 0.000286 -0.24 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102832214 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs223380 ENSG00000230069.3 LRRC37A15P -5.04 7.6e-07 0.000286 -0.24 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102833343 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs223379 ENSG00000230069.3 LRRC37A15P -5.04 7.6e-07 0.000286 -0.24 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102833434 chr4:102727274~102730721:- LIHC cis rs30380 0.632 rs27640 ENSG00000272109.1 CTD-2260A17.3 -5.04 7.6e-07 0.000286 -0.33 -0.26 Cerebrospinal fluid biomarker levels; chr5:96792202 chr5:96804353~96806105:+ LIHC cis rs30380 0.666 rs26512 ENSG00000272109.1 CTD-2260A17.3 -5.04 7.6e-07 0.000286 -0.33 -0.26 Cerebrospinal fluid biomarker levels; chr5:96792697 chr5:96804353~96806105:+ LIHC cis rs10510102 1 rs10886994 ENSG00000276742.1 RP11-500G22.4 5.04 7.6e-07 0.000286 0.41 0.26 Breast cancer; chr10:121841075 chr10:121956782~121957098:+ LIHC cis rs30380 0.632 rs26489 ENSG00000272109.1 CTD-2260A17.3 -5.04 7.6e-07 0.000286 -0.33 -0.26 Cerebrospinal fluid biomarker levels; chr5:96797724 chr5:96804353~96806105:+ LIHC cis rs30380 0.632 rs26500 ENSG00000272109.1 CTD-2260A17.3 -5.04 7.6e-07 0.000286 -0.33 -0.26 Cerebrospinal fluid biomarker levels; chr5:96798009 chr5:96804353~96806105:+ LIHC cis rs2877649 0.51 rs17103743 ENSG00000258744.1 RP11-80A15.1 -5.04 7.6e-07 0.000286 -0.47 -0.26 Smooth-surface caries; chr14:24438346 chr14:24501594~24508688:+ LIHC cis rs7119038 0.865 rs11217044 ENSG00000255239.1 AP002954.6 -5.04 7.61e-07 0.000286 -0.33 -0.26 Sjögren's syndrome; chr11:118825313 chr11:118688039~118690600:- LIHC cis rs6085948 0.861 rs6085947 ENSG00000228888.1 LINC01428 5.04 7.61e-07 0.000286 0.45 0.26 Interleukin-10 levels; chr20:7252181 chr20:7146467~7254202:- LIHC cis rs4660214 0.666 rs2490946 ENSG00000182109.6 RP11-69E11.4 5.04 7.61e-07 0.000286 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39371955 chr1:39522280~39546187:- LIHC cis rs8028182 0.609 rs10220738 ENSG00000260269.4 CTD-2323K18.1 5.04 7.62e-07 0.000286 0.35 0.26 Sudden cardiac arrest; chr15:75374205 chr15:75527150~75601205:- LIHC cis rs228614 0.509 rs223476 ENSG00000230069.3 LRRC37A15P -5.04 7.63e-07 0.000287 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771000 chr4:102727274~102730721:- LIHC cis rs228614 0.509 rs150896 ENSG00000230069.3 LRRC37A15P -5.04 7.63e-07 0.000287 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771186 chr4:102727274~102730721:- LIHC cis rs9640161 0.789 rs10282458 ENSG00000261305.1 RP4-584D14.7 5.04 7.63e-07 0.000287 0.32 0.26 Blood protein levels;Circulating chemerin levels; chr7:150348213 chr7:150341771~150342607:+ LIHC cis rs950169 0.58 rs11634322 ENSG00000259295.5 CSPG4P12 5.04 7.64e-07 0.000287 0.36 0.26 Schizophrenia; chr15:84628978 chr15:85191438~85213905:+ LIHC cis rs5756813 0.688 rs56114444 ENSG00000233360.4 Z83844.1 5.04 7.64e-07 0.000287 0.35 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37727357 chr22:37641832~37658377:- LIHC cis rs5756813 0.754 rs3788529 ENSG00000233360.4 Z83844.1 5.04 7.64e-07 0.000287 0.34 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37762702 chr22:37641832~37658377:- LIHC cis rs150992 0.603 rs161732 ENSG00000248489.1 CTD-2007H13.3 -5.04 7.65e-07 0.000287 -0.41 -0.26 Body mass index; chr5:98941418 chr5:98929171~98995013:+ LIHC cis rs875971 0.545 rs6460276 ENSG00000226824.5 RP4-756H11.3 -5.04 7.65e-07 0.000287 -0.33 -0.26 Aortic root size; chr7:66182290 chr7:66654538~66669855:+ LIHC cis rs6480314 0.706 rs2394465 ENSG00000233590.1 RP11-153K11.3 5.04 7.67e-07 0.000288 0.31 0.26 Optic nerve measurement (disc area); chr10:68224349 chr10:68233251~68242379:- LIHC cis rs11722779 0.935 rs6533046 ENSG00000246560.2 RP11-10L12.4 5.04 7.67e-07 0.000288 0.29 0.26 Schizophrenia; chr4:102965917 chr4:102828055~102844075:+ LIHC cis rs2153535 0.601 rs9379224 ENSG00000230939.1 RP11-314C16.1 -5.04 7.68e-07 0.000288 -0.33 -0.26 Motion sickness; chr6:8538180 chr6:8784178~8785445:+ LIHC cis rs6984305 0.541 rs17716118 ENSG00000279949.1 RP11-10A14.9 5.04 7.68e-07 0.000288 0.51 0.26 Liver enzyme levels (alkaline phosphatase); chr8:9322624 chr8:9158063~9158621:+ LIHC cis rs9425766 0.679 rs12079062 ENSG00000227373.4 RP11-160H22.5 5.04 7.7e-07 0.000289 0.32 0.26 Life satisfaction; chr1:174110446 chr1:174115300~174160004:- LIHC cis rs2929278 0.638 rs2016840 ENSG00000205771.5 CATSPER2P1 5.04 7.71e-07 0.000289 0.33 0.26 Schizophrenia; chr15:43919670 chr15:43726918~43747094:- LIHC cis rs2337406 0.866 rs4583128 ENSG00000274576.2 IGHV2-70 -5.04 7.72e-07 0.000289 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106780669 chr14:106770577~106771020:- LIHC cis rs2337406 0.929 rs59263250 ENSG00000274576.2 IGHV2-70 -5.04 7.72e-07 0.000289 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106781183 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs58083017 ENSG00000274576.2 IGHV2-70 -5.04 7.72e-07 0.000289 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106781256 chr14:106770577~106771020:- LIHC cis rs2337406 0.789 rs60390024 ENSG00000274576.2 IGHV2-70 -5.04 7.72e-07 0.000289 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106781327 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs74092532 ENSG00000274576.2 IGHV2-70 -5.04 7.72e-07 0.000289 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106781363 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs74092534 ENSG00000274576.2 IGHV2-70 -5.04 7.72e-07 0.000289 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106781364 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs74092535 ENSG00000274576.2 IGHV2-70 -5.04 7.72e-07 0.000289 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106781722 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs74092537 ENSG00000274576.2 IGHV2-70 -5.04 7.72e-07 0.000289 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106781883 chr14:106770577~106771020:- LIHC cis rs2337406 0.81 rs74092538 ENSG00000274576.2 IGHV2-70 -5.04 7.72e-07 0.000289 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106781942 chr14:106770577~106771020:- LIHC cis rs11676348 0.901 rs7562334 ENSG00000261338.2 RP11-378A13.1 -5.04 7.73e-07 0.00029 -0.27 -0.26 Ulcerative colitis; chr2:218138637 chr2:218255319~218257366:+ LIHC cis rs11676348 0.967 rs4672873 ENSG00000261338.2 RP11-378A13.1 -5.04 7.73e-07 0.00029 -0.27 -0.26 Ulcerative colitis; chr2:218140487 chr2:218255319~218257366:+ LIHC cis rs7412746 0.658 rs11204750 ENSG00000231073.1 RP11-316M1.3 5.04 7.73e-07 0.00029 0.26 0.26 Melanoma; chr1:150967268 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs6656535 ENSG00000231073.1 RP11-316M1.3 5.04 7.73e-07 0.00029 0.26 0.26 Melanoma; chr1:150967881 chr1:150973123~150975534:+ LIHC cis rs228614 0.51 rs223378 ENSG00000230069.3 LRRC37A15P -5.04 7.74e-07 0.00029 -0.24 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102833488 chr4:102727274~102730721:- LIHC cis rs901683 0.702 rs17159090 ENSG00000230869.1 CTGLF10P 5.04 7.75e-07 0.00029 0.66 0.26 Mean corpuscular volume;Red blood cell traits; chr10:45712353 chr10:45678692~45700532:+ LIHC cis rs9903692 0.954 rs875065 ENSG00000278765.1 RP5-890E16.5 5.03 7.75e-07 0.000291 0.34 0.26 Pulse pressure; chr17:48062207 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs875066 ENSG00000278765.1 RP5-890E16.5 5.03 7.75e-07 0.000291 0.34 0.26 Pulse pressure; chr17:48062370 chr17:48066704~48067293:- LIHC cis rs6479901 0.639 rs871690 ENSG00000232075.1 MRPL35P2 -5.03 7.75e-07 0.000291 -0.3 -0.26 Intelligence (multi-trait analysis); chr10:63134299 chr10:63634317~63634827:- LIHC cis rs4934494 0.768 rs72818784 ENSG00000232936.4 RP11-80H5.2 5.03 7.75e-07 0.000291 0.35 0.26 Red blood cell count; chr10:89789657 chr10:89645282~89650667:+ LIHC cis rs950169 0.519 rs7237 ENSG00000259295.5 CSPG4P12 5.03 7.76e-07 0.000291 0.36 0.26 Schizophrenia; chr15:84643346 chr15:85191438~85213905:+ LIHC cis rs10129255 0.5 rs10143242 ENSG00000223648.3 IGHV3-64 5.03 7.77e-07 0.000291 0.18 0.26 Kawasaki disease; chr14:106681814 chr14:106643132~106658258:- LIHC cis rs10510102 0.688 rs11812208 ENSG00000226864.1 ATE1-AS1 5.03 7.77e-07 0.000291 0.44 0.26 Breast cancer; chr10:121924831 chr10:121928312~121951965:+ LIHC cis rs2283792 1 rs2006893 ENSG00000224086.5 LL22NC03-86G7.1 -5.03 7.77e-07 0.000291 -0.24 -0.26 Multiple sclerosis; chr22:21774389 chr22:21938293~21977632:+ LIHC cis rs7897654 0.571 rs12765002 ENSG00000236937.2 PTGES3P4 5.03 7.78e-07 0.000292 0.34 0.26 Schizophrenia; chr10:102875591 chr10:102845595~102845950:+ LIHC cis rs2439831 0.85 rs7181039 ENSG00000205771.5 CATSPER2P1 -5.03 7.79e-07 0.000292 -0.41 -0.26 Lung cancer in ever smokers; chr15:43886914 chr15:43726918~43747094:- LIHC cis rs7714584 1 rs12652003 ENSG00000197083.10 ZNF300P1 5.03 7.79e-07 0.000292 0.41 0.26 Crohn's disease; chr5:150852383 chr5:150930645~150946289:- LIHC cis rs1023500 0.505 rs134891 ENSG00000227370.1 RP4-669P10.19 -5.03 7.8e-07 0.000292 -0.27 -0.26 Schizophrenia; chr22:42279876 chr22:42132543~42132998:+ LIHC cis rs875971 0.545 rs4718325 ENSG00000226824.5 RP4-756H11.3 -5.03 7.8e-07 0.000292 -0.33 -0.26 Aortic root size; chr7:66215323 chr7:66654538~66669855:+ LIHC cis rs9890032 1 rs28539246 ENSG00000263531.1 RP13-753N3.1 5.03 7.8e-07 0.000292 0.32 0.26 Hip circumference adjusted for BMI; chr17:30899612 chr17:30863921~30864940:- LIHC cis rs9890032 0.967 rs9897628 ENSG00000263531.1 RP13-753N3.1 5.03 7.8e-07 0.000292 0.32 0.26 Hip circumference adjusted for BMI; chr17:30899634 chr17:30863921~30864940:- LIHC cis rs7209700 0.708 rs15908 ENSG00000228782.6 CTD-2026D20.3 -5.03 7.8e-07 0.000292 -0.29 -0.26 IgG glycosylation; chr17:47290971 chr17:47450568~47492492:- LIHC cis rs10256972 0.616 rs6957733 ENSG00000199023.2 MIR339 -5.03 7.8e-07 0.000292 -0.31 -0.26 Endometriosis;Longevity; chr7:1066691 chr7:1022935~1023045:- LIHC cis rs7714584 1 rs10041072 ENSG00000197083.10 ZNF300P1 5.03 7.81e-07 0.000293 0.4 0.26 Crohn's disease; chr5:150880080 chr5:150930645~150946289:- LIHC cis rs5769765 0.908 rs9616211 ENSG00000278869.1 CITF22-49E9.3 5.03 7.81e-07 0.000293 0.41 0.26 Schizophrenia; chr22:49924028 chr22:49933198~49934074:- LIHC cis rs5769765 0.817 rs9616212 ENSG00000278869.1 CITF22-49E9.3 5.03 7.81e-07 0.000293 0.41 0.26 Schizophrenia; chr22:49924039 chr22:49933198~49934074:- LIHC cis rs9903692 0.954 rs12936731 ENSG00000278765.1 RP5-890E16.5 5.03 7.82e-07 0.000293 0.34 0.26 Pulse pressure; chr17:48050997 chr17:48066704~48067293:- LIHC cis rs9903692 0.909 rs9899275 ENSG00000278765.1 RP5-890E16.5 5.03 7.82e-07 0.000293 0.34 0.26 Pulse pressure; chr17:48051953 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs12450620 ENSG00000278765.1 RP5-890E16.5 5.03 7.82e-07 0.000293 0.34 0.26 Pulse pressure; chr17:48052892 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs7212202 ENSG00000278765.1 RP5-890E16.5 5.03 7.82e-07 0.000293 0.34 0.26 Pulse pressure; chr17:48055361 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs34750858 ENSG00000278765.1 RP5-890E16.5 5.03 7.82e-07 0.000293 0.34 0.26 Pulse pressure; chr17:48055575 chr17:48066704~48067293:- LIHC cis rs6546886 0.536 rs828868 ENSG00000217702.2 RP11-287D1.4 5.03 7.82e-07 0.000293 0.31 0.26 Dialysis-related mortality; chr2:74097377 chr2:74130583~74135395:+ LIHC cis rs9399135 0.773 rs949895 ENSG00000232876.1 CTA-212D2.2 -5.03 7.83e-07 0.000293 -0.29 -0.26 Red blood cell count; chr6:135084221 chr6:135055033~135060550:+ LIHC cis rs7119038 0.818 rs2077579 ENSG00000255239.1 AP002954.6 -5.03 7.84e-07 0.000293 -0.38 -0.26 Sjögren's syndrome; chr11:118748338 chr11:118688039~118690600:- LIHC cis rs10510102 0.935 rs10887016 ENSG00000276742.1 RP11-500G22.4 5.03 7.86e-07 0.000294 0.4 0.26 Breast cancer; chr10:121893830 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs10887018 ENSG00000276742.1 RP11-500G22.4 5.03 7.86e-07 0.000294 0.4 0.26 Breast cancer; chr10:121894457 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200230 ENSG00000276742.1 RP11-500G22.4 5.03 7.86e-07 0.000294 0.4 0.26 Breast cancer; chr10:121895117 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs11200234 ENSG00000276742.1 RP11-500G22.4 5.03 7.86e-07 0.000294 0.4 0.26 Breast cancer; chr10:121895851 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs12244951 ENSG00000276742.1 RP11-500G22.4 5.03 7.86e-07 0.000294 0.4 0.26 Breast cancer; chr10:121896879 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs74362676 ENSG00000276742.1 RP11-500G22.4 5.03 7.86e-07 0.000294 0.4 0.26 Breast cancer; chr10:121898216 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs3750837 ENSG00000276742.1 RP11-500G22.4 5.03 7.86e-07 0.000294 0.4 0.26 Breast cancer; chr10:121899080 chr10:121956782~121957098:+ LIHC cis rs10510102 0.872 rs3750836 ENSG00000276742.1 RP11-500G22.4 5.03 7.86e-07 0.000294 0.4 0.26 Breast cancer; chr10:121899087 chr10:121956782~121957098:+ LIHC cis rs73193808 0.614 rs2245023 ENSG00000224649.1 AF124730.4 5.03 7.86e-07 0.000294 0.31 0.26 Coronary artery disease; chr21:29174539 chr21:29182027~29187795:- LIHC cis rs4356203 0.87 rs7935219 ENSG00000272034.1 SNORD14A 5.03 7.87e-07 0.000294 0.28 0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17146640 chr11:17074654~17074744:- LIHC cis rs11690935 0.885 rs6725388 ENSG00000228389.1 AC068039.4 5.03 7.87e-07 0.000295 0.34 0.26 Schizophrenia; chr2:171873505 chr2:171773482~171775844:+ LIHC cis rs1577917 0.958 rs12213331 ENSG00000234155.1 RP11-30P6.6 5.03 7.87e-07 0.000295 0.34 0.26 Response to antipsychotic treatment; chr6:85795079 chr6:85387219~85390186:- LIHC cis rs916888 0.773 rs199534 ENSG00000274883.1 Metazoa_SRP -5.03 7.88e-07 0.000295 -0.41 -0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45931806~45932083:+ LIHC cis rs9425766 0.679 rs12085290 ENSG00000227373.4 RP11-160H22.5 -5.03 7.88e-07 0.000295 -0.3 -0.26 Life satisfaction; chr1:174124699 chr1:174115300~174160004:- LIHC cis rs950169 0.922 rs11633075 ENSG00000259295.5 CSPG4P12 5.03 7.89e-07 0.000295 0.36 0.26 Schizophrenia; chr15:84570741 chr15:85191438~85213905:+ LIHC cis rs5769765 0.874 rs11703411 ENSG00000278869.1 CITF22-49E9.3 -5.03 7.89e-07 0.000295 -0.39 -0.26 Schizophrenia; chr22:49865103 chr22:49933198~49934074:- LIHC cis rs4731207 0.596 rs2402763 ENSG00000224897.5 POT1-AS1 5.03 7.89e-07 0.000295 0.33 0.26 Cutaneous malignant melanoma; chr7:125069678 chr7:124929873~125179315:+ LIHC cis rs7714584 1 rs4958848 ENSG00000197083.10 ZNF300P1 5.03 7.89e-07 0.000295 0.39 0.26 Crohn's disease; chr5:150891560 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs11167521 ENSG00000197083.10 ZNF300P1 5.03 7.89e-07 0.000295 0.39 0.26 Crohn's disease; chr5:150892223 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs10057988 ENSG00000197083.10 ZNF300P1 5.03 7.89e-07 0.000295 0.39 0.26 Crohn's disease; chr5:150892500 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs10052606 ENSG00000197083.10 ZNF300P1 5.03 7.89e-07 0.000295 0.39 0.26 Crohn's disease; chr5:150892655 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs2217266 ENSG00000197083.10 ZNF300P1 5.03 7.89e-07 0.000295 0.39 0.26 Crohn's disease; chr5:150893059 chr5:150930645~150946289:- LIHC cis rs2836974 0.568 rs4816620 ENSG00000255568.3 BRWD1-AS2 -5.03 7.89e-07 0.000295 -0.22 -0.26 Cognitive function; chr21:39241860 chr21:39313935~39314962:+ LIHC cis rs9291683 0.552 rs17187075 ENSG00000250413.1 RP11-448G15.1 -5.03 7.9e-07 0.000295 -0.33 -0.26 Bone mineral density; chr4:9988704 chr4:10006482~10009725:+ LIHC cis rs17301013 0.932 rs11804941 ENSG00000227373.4 RP11-160H22.5 -5.03 7.9e-07 0.000295 -0.32 -0.26 Systemic lupus erythematosus; chr1:174624074 chr1:174115300~174160004:- LIHC cis rs202072 0.872 rs202044 ENSG00000215022.6 RP1-257A7.4 -5.03 7.91e-07 0.000296 -0.31 -0.26 HIV-1 viral setpoint; chr6:13275718 chr6:13264861~13295586:- LIHC cis rs6479891 1 rs9415692 ENSG00000232075.1 MRPL35P2 5.03 7.92e-07 0.000296 0.31 0.26 Arthritis (juvenile idiopathic); chr10:63355392 chr10:63634317~63634827:- LIHC cis rs11690935 0.885 rs10202823 ENSG00000228389.1 AC068039.4 5.03 7.93e-07 0.000296 0.35 0.26 Schizophrenia; chr2:171923622 chr2:171773482~171775844:+ LIHC cis rs9992667 0.955 rs28560778 ENSG00000231160.8 KLF3-AS1 5.03 7.93e-07 0.000297 0.36 0.26 Eosinophil percentage of granulocytes; chr4:38609668 chr4:38612701~38664883:- LIHC cis rs10129255 1 rs10129319 ENSG00000223648.3 IGHV3-64 5.03 7.94e-07 0.000297 0.2 0.26 Kawasaki disease; chr14:106767996 chr14:106643132~106658258:- LIHC cis rs77204473 0.557 rs7111854 ENSG00000254851.1 RP11-109L13.1 5.03 7.95e-07 0.000297 0.43 0.26 Sum eosinophil basophil counts;Eosinophil counts; chr11:116906110 chr11:117135528~117138582:+ LIHC cis rs6977955 1 rs10951192 ENSG00000234336.5 JAZF1-AS1 5.03 7.95e-07 0.000297 0.38 0.26 Allergic disease (asthma, hay fever or eczema); chr7:28121414 chr7:28180322~28243917:+ LIHC cis rs36715 0.868 rs251387 ENSG00000245937.6 LINC01184 5.03 7.96e-07 0.000297 0.32 0.26 Breast cancer; chr5:128211488 chr5:127940426~128083172:- LIHC cis rs5758511 0.634 rs1001587 ENSG00000237037.8 NDUFA6-AS1 -5.03 7.97e-07 0.000298 -0.33 -0.26 Birth weight; chr22:42274105 chr22:42090931~42137742:+ LIHC cis rs1005277 0.579 rs1780139 ENSG00000276805.1 RP11-291L22.6 5.03 7.98e-07 0.000298 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38214090 chr10:38451030~38451785:+ LIHC cis rs4731207 0.596 rs2402762 ENSG00000224897.5 POT1-AS1 5.03 7.99e-07 0.000298 0.32 0.26 Cutaneous malignant melanoma; chr7:124959792 chr7:124929873~125179315:+ LIHC cis rs9425766 0.679 rs10912761 ENSG00000227373.4 RP11-160H22.5 5.03 8e-07 0.000299 0.32 0.26 Life satisfaction; chr1:174312466 chr1:174115300~174160004:- LIHC cis rs10510102 0.935 rs11200218 ENSG00000276742.1 RP11-500G22.4 5.03 8.01e-07 0.000299 0.4 0.26 Breast cancer; chr10:121886410 chr10:121956782~121957098:+ LIHC cis rs1134634 0.52 rs741180 ENSG00000273133.1 RP11-799M12.2 -5.03 8.02e-07 0.000299 -0.33 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15561787 chr4:15563698~15564253:- LIHC cis rs2439831 1 rs2601014 ENSG00000205771.5 CATSPER2P1 -5.03 8.02e-07 0.000299 -0.39 -0.26 Lung cancer in ever smokers; chr15:43463815 chr15:43726918~43747094:- LIHC cis rs17711722 0.523 rs313812 ENSG00000273024.4 INTS4P2 5.03 8.03e-07 3e-04 0.27 0.26 Calcium levels; chr7:66040056 chr7:65647864~65715661:+ LIHC cis rs9291683 0.588 rs34501273 ENSG00000250413.1 RP11-448G15.1 -5.03 8.04e-07 3e-04 -0.33 -0.26 Bone mineral density; chr4:9995372 chr4:10006482~10009725:+ LIHC cis rs227275 0.556 rs4455413 ENSG00000246560.2 RP11-10L12.4 5.03 8.04e-07 3e-04 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102971925 chr4:102828055~102844075:+ LIHC cis rs7923609 0.841 rs7920036 ENSG00000232075.1 MRPL35P2 -5.03 8.04e-07 3e-04 -0.29 -0.26 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63534100 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs7920058 ENSG00000232075.1 MRPL35P2 -5.03 8.04e-07 3e-04 -0.29 -0.26 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63534164 chr10:63634317~63634827:- LIHC cis rs17060993 0.618 rs17056484 ENSG00000228451.3 SDAD1P1 -5.03 8.04e-07 3e-04 -0.46 -0.26 Musician's dystonia; chr8:26990811 chr8:26379259~26382953:- LIHC cis rs6964833 0.786 rs35633336 ENSG00000123965.13 PMS2P5 5.03 8.05e-07 3e-04 0.44 0.26 Menarche (age at onset); chr7:74643961 chr7:74894116~74897835:+ LIHC cis rs6964833 0.935 rs34630792 ENSG00000123965.13 PMS2P5 5.03 8.05e-07 3e-04 0.44 0.26 Menarche (age at onset); chr7:74646869 chr7:74894116~74897835:+ LIHC cis rs17507216 0.628 rs28737193 ENSG00000278603.1 RP13-608F4.5 5.03 8.06e-07 0.000301 0.54 0.26 Excessive daytime sleepiness; chr15:82701318 chr15:82472203~82472426:+ LIHC cis rs4718428 0.705 rs62465692 ENSG00000230295.1 RP11-458F8.2 -5.03 8.07e-07 0.000301 -0.22 -0.26 Corneal structure; chr7:66830758 chr7:66880708~66882981:+ LIHC cis rs4718428 0.662 rs34577323 ENSG00000230295.1 RP11-458F8.2 -5.03 8.07e-07 0.000301 -0.22 -0.26 Corneal structure; chr7:66845054 chr7:66880708~66882981:+ LIHC cis rs4718428 0.705 rs4717328 ENSG00000230295.1 RP11-458F8.2 -5.03 8.07e-07 0.000301 -0.22 -0.26 Corneal structure; chr7:66887678 chr7:66880708~66882981:+ LIHC cis rs4718428 0.705 rs4718422 ENSG00000230295.1 RP11-458F8.2 -5.03 8.07e-07 0.000301 -0.22 -0.26 Corneal structure; chr7:66894282 chr7:66880708~66882981:+ LIHC cis rs4718428 0.705 rs13231140 ENSG00000230295.1 RP11-458F8.2 -5.03 8.07e-07 0.000301 -0.22 -0.26 Corneal structure; chr7:66896631 chr7:66880708~66882981:+ LIHC cis rs1555322 0.53 rs932562 ENSG00000279253.1 RP4-614O4.13 -5.03 8.07e-07 0.000301 -0.34 -0.26 Attention deficit hyperactivity disorder; chr20:35283507 chr20:35262727~35264187:- LIHC cis rs1555322 0.53 rs2275275 ENSG00000279253.1 RP4-614O4.13 -5.03 8.07e-07 0.000301 -0.34 -0.26 Attention deficit hyperactivity disorder; chr20:35284508 chr20:35262727~35264187:- LIHC cis rs2297363 0.502 rs4709395 ENSG00000213073.4 RP11-288H12.3 -5.03 8.08e-07 0.000301 -0.28 -0.26 Total cholesterol levels;Blood protein levels; chr6:160057757 chr6:160093082~160096212:+ LIHC cis rs10875746 0.551 rs1471997 ENSG00000240399.1 RP1-228P16.1 -5.03 8.08e-07 0.000301 -0.28 -0.26 Longevity (90 years and older); chr12:48329812 chr12:48054813~48055591:- LIHC cis rs9322193 0.607 rs6557165 ENSG00000268592.3 RAET1E-AS1 -5.03 8.09e-07 0.000301 -0.33 -0.26 Lung cancer; chr6:149906883 chr6:149863494~149919507:+ LIHC cis rs11098499 0.789 rs10212719 ENSG00000245958.5 RP11-33B1.1 -5.03 8.1e-07 0.000302 -0.27 -0.26 Corneal astigmatism; chr4:119333282 chr4:119454791~119552025:+ LIHC cis rs9903692 0.779 rs2285863 ENSG00000278765.1 RP5-890E16.5 5.03 8.11e-07 0.000302 0.34 0.26 Pulse pressure; chr17:48048616 chr17:48066704~48067293:- LIHC cis rs5758511 0.689 rs5758691 ENSG00000237037.8 NDUFA6-AS1 -5.03 8.11e-07 0.000302 -0.33 -0.26 Birth weight; chr22:42272498 chr22:42090931~42137742:+ LIHC cis rs1061377 1 rs10026775 ENSG00000249685.1 RP11-360F5.3 5.03 8.13e-07 0.000303 0.32 0.26 Uric acid levels; chr4:39115155 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs3733276 ENSG00000249685.1 RP11-360F5.3 5.03 8.13e-07 0.000303 0.32 0.26 Uric acid levels; chr4:39115291 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs3733277 ENSG00000249685.1 RP11-360F5.3 5.03 8.13e-07 0.000303 0.32 0.26 Uric acid levels; chr4:39115483 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs3733278 ENSG00000249685.1 RP11-360F5.3 5.03 8.13e-07 0.000303 0.32 0.26 Uric acid levels; chr4:39115615 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs3733279 ENSG00000249685.1 RP11-360F5.3 5.03 8.13e-07 0.000303 0.32 0.26 Uric acid levels; chr4:39115625 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs10018049 ENSG00000249685.1 RP11-360F5.3 5.03 8.13e-07 0.000303 0.32 0.26 Uric acid levels; chr4:39115781 chr4:39133913~39135608:+ LIHC cis rs9291683 0.588 rs3796842 ENSG00000250413.1 RP11-448G15.1 -5.02 8.15e-07 0.000304 -0.33 -0.26 Bone mineral density; chr4:9994227 chr4:10006482~10009725:+ LIHC cis rs6479891 1 rs12415984 ENSG00000232075.1 MRPL35P2 5.02 8.16e-07 0.000304 0.3 0.26 Arthritis (juvenile idiopathic); chr10:63150528 chr10:63634317~63634827:- LIHC cis rs6921919 0.583 rs7764722 ENSG00000204709.4 LINC01556 5.02 8.18e-07 0.000305 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28386756 chr6:28943877~28944537:+ LIHC cis rs12134133 1 rs61822697 ENSG00000274245.1 RP11-357P18.2 5.02 8.18e-07 0.000305 0.41 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207311819 chr1:207372559~207373252:+ LIHC cis rs11098499 0.954 rs12508504 ENSG00000260091.1 RP11-33B1.4 -5.02 8.19e-07 0.000305 -0.19 -0.26 Corneal astigmatism; chr4:119489452 chr4:119409333~119410233:+ LIHC cis rs712039 0.652 rs736424 ENSG00000276054.1 RP11-378E13.3 5.02 8.19e-07 0.000305 0.32 0.26 Tuberculosis; chr17:37429263 chr17:37386886~37387926:+ LIHC cis rs12571093 0.803 rs61854839 ENSG00000233590.1 RP11-153K11.3 -5.02 8.2e-07 0.000305 -0.42 -0.26 Optic nerve measurement (disc area); chr10:68284859 chr10:68233251~68242379:- LIHC cis rs6479891 1 rs10761730 ENSG00000232075.1 MRPL35P2 -5.02 8.21e-07 0.000306 -0.3 -0.26 Arthritis (juvenile idiopathic); chr10:63257293 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs7916282 ENSG00000232075.1 MRPL35P2 -5.02 8.21e-07 0.000306 -0.3 -0.26 Arthritis (juvenile idiopathic); chr10:63272051 chr10:63634317~63634827:- LIHC cis rs6479891 0.915 rs9415682 ENSG00000232075.1 MRPL35P2 -5.02 8.21e-07 0.000306 -0.3 -0.26 Arthritis (juvenile idiopathic); chr10:63274057 chr10:63634317~63634827:- LIHC cis rs6479891 0.778 rs10761735 ENSG00000232075.1 MRPL35P2 -5.02 8.21e-07 0.000306 -0.3 -0.26 Arthritis (juvenile idiopathic); chr10:63284158 chr10:63634317~63634827:- LIHC cis rs6479891 1 rs9414786 ENSG00000232075.1 MRPL35P2 -5.02 8.21e-07 0.000306 -0.3 -0.26 Arthritis (juvenile idiopathic); chr10:63284562 chr10:63634317~63634827:- LIHC cis rs6479891 0.822 rs6479892 ENSG00000232075.1 MRPL35P2 -5.02 8.21e-07 0.000306 -0.3 -0.26 Arthritis (juvenile idiopathic); chr10:63292472 chr10:63634317~63634827:- LIHC cis rs12468226 0.746 rs75987655 ENSG00000273456.1 RP11-686O6.2 5.02 8.21e-07 0.000306 0.4 0.26 Urate levels; chr2:202581913 chr2:202374932~202375604:- LIHC cis rs9425766 0.64 rs7512930 ENSG00000227373.4 RP11-160H22.5 5.02 8.21e-07 0.000306 0.32 0.26 Life satisfaction; chr1:174319464 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs7523460 ENSG00000227373.4 RP11-160H22.5 5.02 8.21e-07 0.000306 0.32 0.26 Life satisfaction; chr1:174319664 chr1:174115300~174160004:- LIHC cis rs950169 0.541 rs10795 ENSG00000259295.5 CSPG4P12 5.02 8.22e-07 0.000306 0.36 0.26 Schizophrenia; chr15:84634066 chr15:85191438~85213905:+ LIHC cis rs950169 0.58 rs36126054 ENSG00000259295.5 CSPG4P12 5.02 8.22e-07 0.000306 0.36 0.26 Schizophrenia; chr15:84634492 chr15:85191438~85213905:+ LIHC cis rs603446 0.967 rs180375 ENSG00000254851.1 RP11-109L13.1 5.02 8.22e-07 0.000306 0.32 0.26 Triglycerides; chr11:116720324 chr11:117135528~117138582:+ LIHC cis rs881375 0.678 rs7031752 ENSG00000226752.6 PSMD5-AS1 -5.02 8.22e-07 0.000306 -0.27 -0.26 Rheumatoid arthritis; chr9:120901204 chr9:120824828~120854385:+ LIHC cis rs117618124 0.546 rs16963169 ENSG00000263823.1 RP11-326K13.4 -5.02 8.23e-07 0.000306 -0.62 -0.26 Breast cancer;Breast cancer (estrogen-receptor negative); chr18:32343256 chr18:31942575~31944156:+ LIHC cis rs11690935 0.879 rs13017585 ENSG00000228389.1 AC068039.4 5.02 8.23e-07 0.000306 0.37 0.26 Schizophrenia; chr2:171865298 chr2:171773482~171775844:+ LIHC cis rs5769765 0.624 rs2285187 ENSG00000278869.1 CITF22-49E9.3 5.02 8.24e-07 0.000307 0.4 0.26 Schizophrenia; chr22:49791784 chr22:49933198~49934074:- LIHC cis rs17301013 0.507 rs72713512 ENSG00000227373.4 RP11-160H22.5 5.02 8.24e-07 0.000307 0.34 0.26 Systemic lupus erythematosus; chr1:174283505 chr1:174115300~174160004:- LIHC cis rs11676348 0.935 rs6716276 ENSG00000261338.2 RP11-378A13.1 -5.02 8.26e-07 0.000307 -0.28 -0.26 Ulcerative colitis; chr2:218097482 chr2:218255319~218257366:+ LIHC cis rs2337406 0.636 rs74090069 ENSG00000274576.2 IGHV2-70 -5.02 8.26e-07 0.000307 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106777532 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs74090071 ENSG00000274576.2 IGHV2-70 -5.02 8.26e-07 0.000307 -0.27 -0.26 Alzheimer's disease (late onset); chr14:106777533 chr14:106770577~106771020:- LIHC cis rs7615952 0.546 rs11717632 ENSG00000171084.14 FAM86JP 5.02 8.26e-07 0.000307 0.45 0.26 Blood pressure (smoking interaction); chr3:125602286 chr3:125916620~125930024:+ LIHC cis rs7615952 0.546 rs2922197 ENSG00000171084.14 FAM86JP 5.02 8.26e-07 0.000307 0.45 0.26 Blood pressure (smoking interaction); chr3:125603188 chr3:125916620~125930024:+ LIHC cis rs67311347 1 rs1454497 ENSG00000223797.4 ENTPD3-AS1 -5.02 8.27e-07 0.000308 -0.21 -0.26 Renal cell carcinoma; chr3:40454835 chr3:40313802~40453329:- LIHC cis rs9487094 0.71 rs71558370 ENSG00000260273.1 RP11-425D10.10 5.02 8.28e-07 0.000308 0.44 0.26 Height; chr6:109455700 chr6:109382795~109383666:+ LIHC cis rs57502260 0.68 rs7104806 ENSG00000212093.1 AP000807.1 5.02 8.28e-07 0.000308 0.34 0.26 Total body bone mineral density (age 45-60); chr11:68454720 chr11:68506083~68506166:- LIHC cis rs7131987 0.903 rs2194518 ENSG00000257176.2 RP11-996F15.2 -5.02 8.28e-07 0.000308 -0.31 -0.26 QT interval; chr12:29266527 chr12:29280418~29317848:- LIHC cis rs2919917 1 rs2953475 ENSG00000254352.1 RP11-578O24.2 -5.02 8.29e-07 0.000308 -0.36 -0.26 Lymphocyte counts; chr8:78725903 chr8:78723796~78724136:- LIHC cis rs2243480 1 rs2243480 ENSG00000273142.1 RP11-458F8.4 -5.02 8.29e-07 0.000308 -0.33 -0.26 Diabetic kidney disease; chr7:66134209 chr7:66902857~66906297:+ LIHC cis rs5769707 0.967 rs8141807 ENSG00000235111.1 RP1-29C18.8 -5.02 8.31e-07 0.000309 -0.31 -0.26 Monocyte percentage of white cells;Monocyte count; chr22:49650090 chr22:49612657~49615716:- LIHC cis rs1065852 0.526 rs9623489 ENSG00000237037.8 NDUFA6-AS1 -5.02 8.32e-07 0.000309 -0.36 -0.26 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42001022 chr22:42090931~42137742:+ LIHC cis rs1065852 0.526 rs9623490 ENSG00000237037.8 NDUFA6-AS1 -5.02 8.32e-07 0.000309 -0.36 -0.26 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42002262 chr22:42090931~42137742:+ LIHC cis rs1065852 0.526 rs59993856 ENSG00000237037.8 NDUFA6-AS1 -5.02 8.32e-07 0.000309 -0.36 -0.26 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42007976 chr22:42090931~42137742:+ LIHC cis rs7209700 0.962 rs56327427 ENSG00000228782.6 CTD-2026D20.3 -5.02 8.32e-07 0.000309 -0.29 -0.26 IgG glycosylation; chr17:47277380 chr17:47450568~47492492:- LIHC cis rs9903692 0.909 rs8078125 ENSG00000278765.1 RP5-890E16.5 5.02 8.32e-07 0.000309 0.35 0.26 Pulse pressure; chr17:48068347 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs11651097 ENSG00000278765.1 RP5-890E16.5 5.02 8.32e-07 0.000309 0.35 0.26 Pulse pressure; chr17:48069677 chr17:48066704~48067293:- LIHC cis rs7923609 0.967 rs7082470 ENSG00000232075.1 MRPL35P2 -5.02 8.32e-07 0.000309 -0.29 -0.26 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63517266 chr10:63634317~63634827:- LIHC cis rs172166 0.516 rs1225618 ENSG00000204709.4 LINC01556 5.02 8.32e-07 0.000309 0.29 0.26 Cardiac Troponin-T levels; chr6:28161935 chr6:28943877~28944537:+ LIHC cis rs7665090 0.87 rs228615 ENSG00000230069.3 LRRC37A15P 5.02 8.36e-07 0.00031 0.25 0.26 Primary biliary cholangitis; chr4:102658303 chr4:102727274~102730721:- LIHC cis rs11216126 1 rs12421652 ENSG00000254851.1 RP11-109L13.1 5.02 8.37e-07 0.000311 0.4 0.26 HDL cholesterol; chr11:116755159 chr11:117135528~117138582:+ LIHC cis rs4718428 0.672 rs13241598 ENSG00000230295.1 RP11-458F8.2 -5.02 8.38e-07 0.000311 -0.22 -0.26 Corneal structure; chr7:66835665 chr7:66880708~66882981:+ LIHC cis rs72627509 0.638 rs78933653 ENSG00000269949.1 RP11-738E22.3 5.02 8.38e-07 0.000311 0.36 0.26 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56988674 chr4:56960927~56961373:- LIHC cis rs801193 0.844 rs732465 ENSG00000237310.1 GS1-124K5.4 5.02 8.39e-07 0.000312 0.24 0.26 Aortic root size; chr7:66533463 chr7:66493706~66495474:+ LIHC cis rs7587476 0.601 rs1129804 ENSG00000229267.2 AC072062.1 5.02 8.39e-07 0.000312 0.33 0.26 Neuroblastoma; chr2:214809599 chr2:214810229~214963274:+ LIHC cis rs7587476 0.601 rs17489363 ENSG00000229267.2 AC072062.1 5.02 8.39e-07 0.000312 0.33 0.26 Neuroblastoma; chr2:214809617 chr2:214810229~214963274:+ LIHC cis rs875971 0.545 rs73376401 ENSG00000226824.5 RP4-756H11.3 -5.02 8.39e-07 0.000312 -0.33 -0.26 Aortic root size; chr7:66174841 chr7:66654538~66669855:+ LIHC cis rs2919917 1 rs3736169 ENSG00000254352.1 RP11-578O24.2 5.02 8.4e-07 0.000312 0.35 0.26 Lymphocyte counts; chr8:78675620 chr8:78723796~78724136:- LIHC cis rs4356203 0.87 rs10741724 ENSG00000272034.1 SNORD14A -5.02 8.4e-07 0.000312 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17231604 chr11:17074654~17074744:- LIHC cis rs11690935 0.885 rs6750058 ENSG00000228389.1 AC068039.4 5.02 8.4e-07 0.000312 0.34 0.26 Schizophrenia; chr2:171930399 chr2:171773482~171775844:+ LIHC cis rs9890032 0.967 rs7342976 ENSG00000263531.1 RP13-753N3.1 5.02 8.41e-07 0.000312 0.32 0.26 Hip circumference adjusted for BMI; chr17:30863001 chr17:30863921~30864940:- LIHC cis rs801193 0.773 rs801207 ENSG00000237310.1 GS1-124K5.4 -5.02 8.42e-07 0.000312 -0.24 -0.26 Aortic root size; chr7:66555603 chr7:66493706~66495474:+ LIHC cis rs875971 0.543 rs801191 ENSG00000237310.1 GS1-124K5.4 -5.02 8.42e-07 0.000312 -0.24 -0.26 Aortic root size; chr7:66567968 chr7:66493706~66495474:+ LIHC cis rs6600671 1 rs10903159 ENSG00000231429.2 RP11-343N15.2 -5.02 8.42e-07 0.000313 -0.3 -0.26 Hip geometry; chr1:121440138 chr1:121412719~121429274:+ LIHC cis rs227275 0.525 rs28778380 ENSG00000246560.2 RP11-10L12.4 5.02 8.43e-07 0.000313 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:103006416 chr4:102828055~102844075:+ LIHC cis rs8005677 0.962 rs10130756 ENSG00000257285.4 RP11-298I3.1 5.02 8.44e-07 0.000313 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22927391 chr14:22929609~22955562:+ LIHC cis rs12701220 0.725 rs13242971 ENSG00000229043.2 AC091729.9 -5.02 8.45e-07 0.000313 -0.37 -0.26 Bronchopulmonary dysplasia; chr7:1015879 chr7:1160374~1165267:+ LIHC cis rs8059260 0.542 rs80000109 ENSG00000274038.1 RP11-66H6.4 -5.02 8.45e-07 0.000313 -0.44 -0.26 Alcohol consumption over the past year; chr16:11031457 chr16:11056556~11057034:+ LIHC cis rs228614 0.51 rs223453 ENSG00000230069.3 LRRC37A15P -5.02 8.45e-07 0.000314 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102789895 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs6815526 ENSG00000246560.2 RP11-10L12.4 5.02 8.47e-07 0.000314 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102899729 chr4:102828055~102844075:+ LIHC cis rs227275 0.556 rs28367331 ENSG00000246560.2 RP11-10L12.4 5.02 8.47e-07 0.000314 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102900734 chr4:102828055~102844075:+ LIHC cis rs227275 0.556 rs6824070 ENSG00000246560.2 RP11-10L12.4 5.02 8.47e-07 0.000314 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102901676 chr4:102828055~102844075:+ LIHC cis rs11722779 0.935 rs6856176 ENSG00000246560.2 RP11-10L12.4 5.02 8.47e-07 0.000314 0.29 0.26 Schizophrenia; chr4:102902574 chr4:102828055~102844075:+ LIHC cis rs8040855 1 rs8040855 ENSG00000259295.5 CSPG4P12 -5.02 8.47e-07 0.000314 -0.37 -0.26 Bulimia nervosa; chr15:85155976 chr15:85191438~85213905:+ LIHC cis rs1499614 1 rs1267817 ENSG00000230295.1 RP11-458F8.2 -5.02 8.49e-07 0.000315 -0.28 -0.26 Gout; chr7:66645053 chr7:66880708~66882981:+ LIHC cis rs9487094 0.67 rs749517 ENSG00000260273.1 RP11-425D10.10 -5.02 8.5e-07 0.000315 -0.31 -0.26 Height; chr6:109531713 chr6:109382795~109383666:+ LIHC cis rs227275 0.525 rs4699046 ENSG00000246560.2 RP11-10L12.4 5.02 8.51e-07 0.000315 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:103004514 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs4699047 ENSG00000246560.2 RP11-10L12.4 5.02 8.51e-07 0.000315 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:103005385 chr4:102828055~102844075:+ LIHC cis rs4356203 0.87 rs10832751 ENSG00000272034.1 SNORD14A -5.02 8.51e-07 0.000315 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17252469 chr11:17074654~17074744:- LIHC cis rs1075265 0.568 rs10865277 ENSG00000233266.1 HMGB1P31 5.02 8.51e-07 0.000315 0.32 0.26 Chronotype;Morning vs. evening chronotype; chr2:54074865 chr2:54051334~54051760:+ LIHC cis rs4356203 0.875 rs11024136 ENSG00000272034.1 SNORD14A -5.02 8.51e-07 0.000315 -0.29 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17042850 chr11:17074654~17074744:- LIHC cis rs3096299 0.728 rs1011749 ENSG00000261118.1 RP11-104N10.1 5.02 8.52e-07 0.000316 0.26 0.26 Multiple myeloma (IgH translocation); chr16:89444461 chr16:89492017~89504460:- LIHC cis rs228614 0.51 rs223451 ENSG00000230069.3 LRRC37A15P -5.01 8.55e-07 0.000316 -0.24 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102791032 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223450 ENSG00000230069.3 LRRC37A15P -5.01 8.55e-07 0.000316 -0.24 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102791052 chr4:102727274~102730721:- LIHC cis rs10129255 0.957 rs10138532 ENSG00000223648.3 IGHV3-64 5.01 8.55e-07 0.000317 0.2 0.26 Kawasaki disease; chr14:106803901 chr14:106643132~106658258:- LIHC cis rs11690935 0.885 rs6752812 ENSG00000228389.1 AC068039.4 5.01 8.56e-07 0.000317 0.35 0.26 Schizophrenia; chr2:171986588 chr2:171773482~171775844:+ LIHC cis rs57502260 0.764 rs3867143 ENSG00000212093.1 AP000807.1 5.01 8.56e-07 0.000317 0.34 0.26 Total body bone mineral density (age 45-60); chr11:68455606 chr11:68506083~68506166:- LIHC cis rs138341189 1 rs138341189 ENSG00000212093.1 AP000807.1 5.01 8.56e-07 0.000317 0.34 0.26 Monobrow; chr11:68456954 chr11:68506083~68506166:- LIHC cis rs73086581 0.617 rs2300213 ENSG00000229539.1 RP11-119B16.2 -5.01 8.56e-07 0.000317 -0.29 -0.26 Response to antidepressants in depression; chr20:4006076 chr20:3888239~3888868:- LIHC cis rs7429990 0.864 rs3888 ENSG00000229759.1 MRPS18AP1 -5.01 8.57e-07 0.000317 -0.28 -0.26 Educational attainment (years of education); chr3:47816085 chr3:48256350~48256938:- LIHC cis rs7209700 0.889 rs16941801 ENSG00000228782.6 CTD-2026D20.3 -5.01 8.58e-07 0.000317 -0.29 -0.26 IgG glycosylation; chr17:47277177 chr17:47450568~47492492:- LIHC cis rs227275 0.525 rs13117110 ENSG00000246560.2 RP11-10L12.4 5.01 8.59e-07 0.000318 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:103003981 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs13144033 ENSG00000246560.2 RP11-10L12.4 5.01 8.59e-07 0.000318 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:103004032 chr4:102828055~102844075:+ LIHC cis rs148406912 1 rs148406912 ENSG00000254851.1 RP11-109L13.1 5.01 8.6e-07 0.000318 0.42 0.26 Lobe attachment (rater-scored or self-reported); chr11:116967001 chr11:117135528~117138582:+ LIHC cis rs5769765 0.954 rs5770709 ENSG00000278869.1 CITF22-49E9.3 -5.01 8.6e-07 0.000318 -0.38 -0.26 Schizophrenia; chr22:49851548 chr22:49933198~49934074:- LIHC cis rs367615 0.537 rs17161729 ENSG00000249476.1 CTD-2587M2.1 -5.01 8.6e-07 0.000318 -0.31 -0.26 Colorectal cancer (SNP x SNP interaction); chr5:109324827 chr5:109237120~109326369:- LIHC cis rs9425766 0.679 rs4650990 ENSG00000227373.4 RP11-160H22.5 5.01 8.61e-07 0.000318 0.32 0.26 Life satisfaction; chr1:174289943 chr1:174115300~174160004:- LIHC cis rs9326248 0.731 rs90192 ENSG00000236267.1 AP006216.5 5.01 8.61e-07 0.000318 0.27 0.26 Blood protein levels; chr11:117188631 chr11:116813204~116814003:- LIHC cis rs10129255 1 rs10129255 ENSG00000223648.3 IGHV3-64 -5.01 8.61e-07 0.000319 -0.2 -0.26 Kawasaki disease; chr14:106767970 chr14:106643132~106658258:- LIHC cis rs9425766 0.679 rs6670617 ENSG00000227373.4 RP11-160H22.5 5.01 8.62e-07 0.000319 0.32 0.26 Life satisfaction; chr1:174277574 chr1:174115300~174160004:- LIHC cis rs2032366 0.591 rs7241479 ENSG00000267279.1 RP11-879F14.2 -5.01 8.63e-07 0.000319 -0.32 -0.26 Obesity-related traits; chr18:61631923 chr18:61585746~61606916:- LIHC cis rs2032366 0.654 rs7227661 ENSG00000267279.1 RP11-879F14.2 -5.01 8.63e-07 0.000319 -0.32 -0.26 Obesity-related traits; chr18:61632275 chr18:61585746~61606916:- LIHC cis rs9425766 0.679 rs9787001 ENSG00000227373.4 RP11-160H22.5 5.01 8.63e-07 0.000319 0.32 0.26 Life satisfaction; chr1:174222556 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs972361 ENSG00000227373.4 RP11-160H22.5 5.01 8.63e-07 0.000319 0.32 0.26 Life satisfaction; chr1:174228270 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs6667267 ENSG00000227373.4 RP11-160H22.5 5.01 8.63e-07 0.000319 0.32 0.26 Life satisfaction; chr1:174243623 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs2064149 ENSG00000227373.4 RP11-160H22.5 5.01 8.63e-07 0.000319 0.32 0.26 Life satisfaction; chr1:174255856 chr1:174115300~174160004:- LIHC cis rs6479901 0.639 rs10995448 ENSG00000232075.1 MRPL35P2 -5.01 8.65e-07 0.00032 -0.3 -0.26 Intelligence (multi-trait analysis); chr10:63127299 chr10:63634317~63634827:- LIHC cis rs6479901 0.639 rs7082200 ENSG00000232075.1 MRPL35P2 -5.01 8.65e-07 0.00032 -0.3 -0.26 Intelligence (multi-trait analysis); chr10:63128561 chr10:63634317~63634827:- LIHC cis rs2836974 0.563 rs997147 ENSG00000255568.3 BRWD1-AS2 -5.01 8.65e-07 0.00032 -0.22 -0.26 Cognitive function; chr21:39323399 chr21:39313935~39314962:+ LIHC cis rs4650994 0.525 rs2493848 ENSG00000273384.1 RP5-1098D14.1 -5.01 8.65e-07 0.00032 -0.33 -0.26 HDL cholesterol;HDL cholesterol levels; chr1:178578703 chr1:178651706~178652282:+ LIHC cis rs2836974 0.568 rs11910906 ENSG00000255568.3 BRWD1-AS2 -5.01 8.66e-07 0.00032 -0.22 -0.26 Cognitive function; chr21:39313736 chr21:39313935~39314962:+ LIHC cis rs6921919 0.583 rs16894108 ENSG00000204709.4 LINC01556 5.01 8.66e-07 0.00032 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28434013 chr6:28943877~28944537:+ LIHC cis rs950169 0.922 rs12912934 ENSG00000259295.5 CSPG4P12 5.01 8.66e-07 0.00032 0.36 0.26 Schizophrenia; chr15:84571216 chr15:85191438~85213905:+ LIHC cis rs4356203 0.87 rs2171615 ENSG00000272034.1 SNORD14A -5.01 8.66e-07 0.00032 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17231094 chr11:17074654~17074744:- LIHC cis rs6142102 0.924 rs6059662 ENSG00000276073.1 RP5-1125A11.7 5.01 8.66e-07 0.00032 0.29 0.26 Skin pigmentation; chr20:34087921 chr20:33985617~33988989:- LIHC cis rs1577917 0.629 rs7761762 ENSG00000234155.1 RP11-30P6.6 -5.01 8.66e-07 0.00032 -0.32 -0.26 Response to antipsychotic treatment; chr6:85496250 chr6:85387219~85390186:- LIHC cis rs2032366 0.591 rs9783921 ENSG00000267279.1 RP11-879F14.2 5.01 8.67e-07 0.00032 0.31 0.26 Obesity-related traits; chr18:61635219 chr18:61585746~61606916:- LIHC cis rs13392177 0.684 rs6720449 ENSG00000261338.2 RP11-378A13.1 -5.01 8.67e-07 0.00032 -0.27 -0.26 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218216255 chr2:218255319~218257366:+ LIHC cis rs116175783 0.557 rs16845829 ENSG00000227403.1 AC009299.3 5.01 8.69e-07 0.000321 0.4 0.26 Intelligence (multi-trait analysis); chr2:161399960 chr2:161244739~161249050:+ LIHC cis rs9595908 1 rs718444 ENSG00000212293.1 SNORA16 5.01 8.7e-07 0.000321 0.31 0.26 Body mass index; chr13:32572915 chr13:32420390~32420516:- LIHC cis rs9595908 1 rs7332115 ENSG00000212293.1 SNORA16 5.01 8.7e-07 0.000321 0.31 0.26 Body mass index; chr13:32573411 chr13:32420390~32420516:- LIHC cis rs9595908 1 rs7332763 ENSG00000212293.1 SNORA16 5.01 8.7e-07 0.000321 0.31 0.26 Body mass index; chr13:32573751 chr13:32420390~32420516:- LIHC cis rs7429990 0.864 rs4858860 ENSG00000229759.1 MRPS18AP1 -5.01 8.7e-07 0.000321 -0.28 -0.26 Educational attainment (years of education); chr3:47817344 chr3:48256350~48256938:- LIHC cis rs11673344 0.526 rs8101610 ENSG00000226686.6 LINC01535 -5.01 8.71e-07 0.000322 -0.39 -0.26 Obesity-related traits; chr19:37566604 chr19:37251912~37265535:+ LIHC cis rs12468226 1 rs3731696 ENSG00000273456.1 RP11-686O6.2 5.01 8.72e-07 0.000322 0.39 0.26 Urate levels; chr2:202567081 chr2:202374932~202375604:- LIHC cis rs12468226 0.81 rs115255999 ENSG00000273456.1 RP11-686O6.2 5.01 8.72e-07 0.000322 0.39 0.26 Urate levels; chr2:202572326 chr2:202374932~202375604:- LIHC cis rs11603023 0.874 rs577396 ENSG00000255422.1 AP002954.4 -5.01 8.72e-07 0.000322 -0.29 -0.26 Cholesterol, total; chr11:118628753 chr11:118704607~118750263:+ LIHC cis rs11603023 0.874 rs11216934 ENSG00000255422.1 AP002954.4 -5.01 8.72e-07 0.000322 -0.29 -0.26 Cholesterol, total; chr11:118630742 chr11:118704607~118750263:+ LIHC cis rs4660214 0.666 rs1180376 ENSG00000182109.6 RP11-69E11.4 5.01 8.72e-07 0.000322 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39418761 chr1:39522280~39546187:- LIHC cis rs7714584 1 rs7724036 ENSG00000197083.10 ZNF300P1 -5.01 8.73e-07 0.000322 -0.38 -0.26 Crohn's disease; chr5:150905246 chr5:150930645~150946289:- LIHC cis rs5769765 0.773 rs4075331 ENSG00000278869.1 CITF22-49E9.3 5.01 8.73e-07 0.000322 0.39 0.26 Schizophrenia; chr22:49909202 chr22:49933198~49934074:- LIHC cis rs9322193 0.607 rs4870078 ENSG00000231760.4 RP11-350J20.5 -5.01 8.73e-07 0.000322 -0.35 -0.26 Lung cancer; chr6:149880676 chr6:149796151~149826294:- LIHC cis rs1075265 0.633 rs7591431 ENSG00000233266.1 HMGB1P31 5.01 8.74e-07 0.000322 0.32 0.26 Chronotype;Morning vs. evening chronotype; chr2:53995028 chr2:54051334~54051760:+ LIHC cis rs9467711 0.591 rs35902160 ENSG00000216436.2 HIST1H2APS1 5.01 8.74e-07 0.000322 0.67 0.26 Autism spectrum disorder or schizophrenia; chr6:26128310 chr6:25732497~25732827:+ LIHC cis rs202072 0.729 rs202038 ENSG00000215022.6 RP1-257A7.4 5.01 8.74e-07 0.000323 0.31 0.26 HIV-1 viral setpoint; chr6:13288416 chr6:13264861~13295586:- LIHC cis rs5769765 0.773 rs7410291 ENSG00000278869.1 CITF22-49E9.3 5.01 8.75e-07 0.000323 0.39 0.26 Schizophrenia; chr22:49906430 chr22:49933198~49934074:- LIHC cis rs4731207 0.596 rs1404898 ENSG00000224897.5 POT1-AS1 5.01 8.75e-07 0.000323 0.32 0.26 Cutaneous malignant melanoma; chr7:125054285 chr7:124929873~125179315:+ LIHC cis rs12701220 0.894 rs12539012 ENSG00000229043.2 AC091729.9 -5.01 8.75e-07 0.000323 -0.37 -0.26 Bronchopulmonary dysplasia; chr7:1012497 chr7:1160374~1165267:+ LIHC cis rs916888 0.773 rs199533 ENSG00000274883.1 Metazoa_SRP -5.01 8.76e-07 0.000323 -0.41 -0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45931806~45932083:+ LIHC cis rs524281 0.506 rs560393 ENSG00000255320.1 RP11-755F10.1 5.01 8.77e-07 0.000323 0.33 0.26 Electroencephalogram traits; chr11:66238006 chr11:66244840~66246239:- LIHC cis rs950169 0.922 rs62029585 ENSG00000259295.5 CSPG4P12 5.01 8.77e-07 0.000324 0.36 0.26 Schizophrenia; chr15:84397176 chr15:85191438~85213905:+ LIHC cis rs755249 0.51 rs613511 ENSG00000182109.6 RP11-69E11.4 5.01 8.78e-07 0.000324 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39367801 chr1:39522280~39546187:- LIHC cis rs4660214 0.666 rs629093 ENSG00000182109.6 RP11-69E11.4 5.01 8.78e-07 0.000324 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39367831 chr1:39522280~39546187:- LIHC cis rs4660214 0.666 rs663449 ENSG00000182109.6 RP11-69E11.4 5.01 8.78e-07 0.000324 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39378286 chr1:39522280~39546187:- LIHC cis rs11098499 0.754 rs17049949 ENSG00000245958.5 RP11-33B1.1 -5.01 8.78e-07 0.000324 -0.27 -0.26 Corneal astigmatism; chr4:119334135 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs7689729 ENSG00000245958.5 RP11-33B1.1 -5.01 8.78e-07 0.000324 -0.27 -0.26 Corneal astigmatism; chr4:119335037 chr4:119454791~119552025:+ LIHC cis rs10028773 0.7 rs7690338 ENSG00000245958.5 RP11-33B1.1 -5.01 8.78e-07 0.000324 -0.27 -0.26 Educational attainment; chr4:119335313 chr4:119454791~119552025:+ LIHC cis rs11098499 0.865 rs3956464 ENSG00000245958.5 RP11-33B1.1 -5.01 8.78e-07 0.000324 -0.27 -0.26 Corneal astigmatism; chr4:119335609 chr4:119454791~119552025:+ LIHC cis rs11098499 0.619 rs28502463 ENSG00000245958.5 RP11-33B1.1 -5.01 8.78e-07 0.000324 -0.27 -0.26 Corneal astigmatism; chr4:119335868 chr4:119454791~119552025:+ LIHC cis rs11098499 0.648 rs2002047 ENSG00000245958.5 RP11-33B1.1 -5.01 8.78e-07 0.000324 -0.27 -0.26 Corneal astigmatism; chr4:119336073 chr4:119454791~119552025:+ LIHC cis rs11098499 0.775 rs2002049 ENSG00000245958.5 RP11-33B1.1 -5.01 8.78e-07 0.000324 -0.27 -0.26 Corneal astigmatism; chr4:119336262 chr4:119454791~119552025:+ LIHC cis rs931127 0.617 rs10896027 ENSG00000265874.1 MIR4489 5.01 8.79e-07 0.000324 0.35 0.26 Systemic lupus erythematosus; chr11:65653289 chr11:65649192~65649253:+ LIHC cis rs950027 0.787 rs2433616 ENSG00000259433.2 CTD-2651B20.4 -5.01 8.79e-07 0.000324 -0.35 -0.26 Response to fenofibrate (adiponectin levels); chr15:45436401 chr15:45330209~45332634:- LIHC cis rs5769707 0.967 rs739248 ENSG00000235111.1 RP1-29C18.8 -5.01 8.8e-07 0.000324 -0.3 -0.26 Monocyte percentage of white cells;Monocyte count; chr22:49631557 chr22:49612657~49615716:- LIHC cis rs5769707 0.609 rs135861 ENSG00000235111.1 RP1-29C18.8 -5.01 8.8e-07 0.000324 -0.31 -0.26 Monocyte percentage of white cells;Monocyte count; chr22:49604470 chr22:49612657~49615716:- LIHC cis rs2032366 0.606 rs9783923 ENSG00000267279.1 RP11-879F14.2 -5.01 8.8e-07 0.000324 -0.32 -0.26 Obesity-related traits; chr18:61635518 chr18:61585746~61606916:- LIHC cis rs6479891 1 rs7099425 ENSG00000232075.1 MRPL35P2 -5.01 8.81e-07 0.000325 -0.3 -0.26 Arthritis (juvenile idiopathic); chr10:63200957 chr10:63634317~63634827:- LIHC cis rs7714584 1 rs7714415 ENSG00000197083.10 ZNF300P1 5.01 8.82e-07 0.000325 0.39 0.26 Crohn's disease; chr5:150890730 chr5:150930645~150946289:- LIHC cis rs4660214 0.666 rs2275188 ENSG00000182109.6 RP11-69E11.4 -5.01 8.82e-07 0.000325 -0.28 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39283249 chr1:39522280~39546187:- LIHC cis rs755249 0.51 rs599892 ENSG00000182109.6 RP11-69E11.4 5.01 8.83e-07 0.000325 0.28 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39457212 chr1:39522280~39546187:- LIHC cis rs5758511 0.633 rs5751258 ENSG00000237037.8 NDUFA6-AS1 -5.01 8.83e-07 0.000325 -0.33 -0.26 Birth weight; chr22:42267865 chr22:42090931~42137742:+ LIHC cis rs2836974 0.666 rs11910705 ENSG00000255568.3 BRWD1-AS2 -5.01 8.86e-07 0.000326 -0.22 -0.26 Cognitive function; chr21:39313678 chr21:39313935~39314962:+ LIHC cis rs11098499 0.954 rs28572238 ENSG00000245958.5 RP11-33B1.1 -5.01 8.86e-07 0.000326 -0.28 -0.26 Corneal astigmatism; chr4:119395531 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs28714195 ENSG00000245958.5 RP11-33B1.1 -5.01 8.86e-07 0.000326 -0.28 -0.26 Corneal astigmatism; chr4:119395795 chr4:119454791~119552025:+ LIHC cis rs5769765 0.908 rs9616217 ENSG00000278869.1 CITF22-49E9.3 5.01 8.86e-07 0.000326 0.4 0.26 Schizophrenia; chr22:49925298 chr22:49933198~49934074:- LIHC cis rs9918079 0.884 rs11728037 ENSG00000273133.1 RP11-799M12.2 -5.01 8.87e-07 0.000327 -0.44 -0.26 Obesity-related traits; chr4:15593275 chr4:15563698~15564253:- LIHC cis rs765787 0.53 rs2899378 ENSG00000259520.4 CTD-2651B20.3 -5.01 8.88e-07 0.000327 -0.3 -0.26 Uric acid levels; chr15:45245386 chr15:45251580~45279251:- LIHC cis rs6480314 0.542 rs4403687 ENSG00000233590.1 RP11-153K11.3 -5.01 8.89e-07 0.000327 -0.39 -0.26 Optic nerve measurement (disc area); chr10:68268295 chr10:68233251~68242379:- LIHC cis rs11098499 0.863 rs13134665 ENSG00000245958.5 RP11-33B1.1 -5.01 8.89e-07 0.000327 -0.28 -0.26 Corneal astigmatism; chr4:119505275 chr4:119454791~119552025:+ LIHC cis rs2439831 0.85 rs558656 ENSG00000205771.5 CATSPER2P1 -5.01 8.9e-07 0.000327 -0.35 -0.26 Lung cancer in ever smokers; chr15:43431316 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs2467739 ENSG00000205771.5 CATSPER2P1 -5.01 8.9e-07 0.000327 -0.35 -0.26 Lung cancer in ever smokers; chr15:43447998 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs2245790 ENSG00000205771.5 CATSPER2P1 -5.01 8.9e-07 0.000327 -0.35 -0.26 Lung cancer in ever smokers; chr15:43452259 chr15:43726918~43747094:- LIHC cis rs4356203 0.87 rs214922 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17215576 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs214921 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17215914 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs214918 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17218302 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs214915 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17220226 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs214914 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17220345 chr11:17074654~17074744:- LIHC cis rs4356203 0.84 rs214911 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17220691 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs214910 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17221242 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs214909 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17221731 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs603618 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17224815 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs618331 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17225789 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs7949699 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17226161 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs10832745 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17228128 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs11024204 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17228258 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs10832746 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17228406 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs10832747 ENSG00000272034.1 SNORD14A -5.01 8.9e-07 0.000327 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17228472 chr11:17074654~17074744:- LIHC cis rs8028182 0.549 rs7402293 ENSG00000260269.4 CTD-2323K18.1 5.01 8.91e-07 0.000328 0.35 0.26 Sudden cardiac arrest; chr15:75343796 chr15:75527150~75601205:- LIHC cis rs10833905 0.756 rs11026869 ENSG00000246225.5 RP11-17A1.3 -5.01 8.92e-07 0.000328 -0.34 -0.26 Sudden cardiac arrest; chr11:22973361 chr11:22829380~22945393:+ LIHC cis rs1061377 1 rs1036037 ENSG00000249685.1 RP11-360F5.3 5.01 8.92e-07 0.000328 0.31 0.26 Uric acid levels; chr4:39111272 chr4:39133913~39135608:+ LIHC cis rs7674212 0.865 rs13149311 ENSG00000230069.3 LRRC37A15P -5.01 8.94e-07 0.000329 -0.24 -0.26 Type 2 diabetes; chr4:103056543 chr4:102727274~102730721:- LIHC cis rs6479901 0.793 rs7070693 ENSG00000232075.1 MRPL35P2 -5.01 8.96e-07 0.000329 -0.29 -0.26 Intelligence (multi-trait analysis); chr10:63256402 chr10:63634317~63634827:- LIHC cis rs116175783 0.557 rs62197081 ENSG00000227403.1 AC009299.3 5.01 8.96e-07 0.000329 0.4 0.26 Intelligence (multi-trait analysis); chr2:161336814 chr2:161244739~161249050:+ LIHC cis rs4718428 0.705 rs11028 ENSG00000230295.1 RP11-458F8.2 -5 8.96e-07 0.00033 -0.22 -0.26 Corneal structure; chr7:66811230 chr7:66880708~66882981:+ LIHC cis rs4356203 0.875 rs667984 ENSG00000272034.1 SNORD14A -5 8.96e-07 0.00033 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17179219 chr11:17074654~17074744:- LIHC cis rs2877649 0.793 rs10133998 ENSG00000258744.1 RP11-80A15.1 -5 8.98e-07 0.00033 -0.52 -0.26 Smooth-surface caries; chr14:24447550 chr14:24501594~24508688:+ LIHC cis rs2439831 1 rs689596 ENSG00000205771.5 CATSPER2P1 -5 8.99e-07 0.00033 -0.36 -0.26 Lung cancer in ever smokers; chr15:43469519 chr15:43726918~43747094:- LIHC cis rs10875746 0.551 rs3751273 ENSG00000240399.1 RP1-228P16.1 -5 8.99e-07 0.00033 -0.28 -0.26 Longevity (90 years and older); chr12:48345655 chr12:48054813~48055591:- LIHC cis rs5769765 0.955 rs9616366 ENSG00000278869.1 CITF22-49E9.3 5 8.99e-07 0.00033 0.39 0.26 Schizophrenia; chr22:49907530 chr22:49933198~49934074:- LIHC cis rs5769765 0.955 rs8135963 ENSG00000278869.1 CITF22-49E9.3 5 8.99e-07 0.00033 0.39 0.26 Schizophrenia; chr22:49907828 chr22:49933198~49934074:- LIHC cis rs1865760 0.929 rs12195653 ENSG00000216436.2 HIST1H2APS1 -5 8.99e-07 0.00033 -0.29 -0.26 Height; chr6:25958393 chr6:25732497~25732827:+ LIHC cis rs10829156 0.699 rs6482516 ENSG00000240291.1 RP11-499P20.2 5 8.99e-07 0.000331 0.38 0.26 Sudden cardiac arrest; chr10:18550421 chr10:18513115~18545651:- LIHC cis rs2836974 0.666 rs35182074 ENSG00000255568.3 BRWD1-AS2 -5 9e-07 0.000331 -0.22 -0.26 Cognitive function; chr21:39313358 chr21:39313935~39314962:+ LIHC cis rs12554020 0.786 rs78619366 ENSG00000227603.1 RP11-165J3.6 5 9e-07 0.000331 0.46 0.26 Schizophrenia; chr9:93590541 chr9:93435332~93437121:- LIHC cis rs1061377 0.748 rs12642261 ENSG00000249207.1 RP11-360F5.1 -5 9e-07 0.000331 -0.26 -0.26 Uric acid levels; chr4:39096278 chr4:39112677~39126818:- LIHC cis rs8040855 0.931 rs11855471 ENSG00000259295.5 CSPG4P12 -5 9e-07 0.000331 -0.37 -0.26 Bulimia nervosa; chr15:85175976 chr15:85191438~85213905:+ LIHC cis rs17301013 0.932 rs6671824 ENSG00000227373.4 RP11-160H22.5 5 9e-07 0.000331 0.32 0.26 Systemic lupus erythematosus; chr1:174603721 chr1:174115300~174160004:- LIHC cis rs10510102 0.935 rs4627017 ENSG00000276742.1 RP11-500G22.4 5 9.01e-07 0.000331 0.4 0.26 Breast cancer; chr10:121901878 chr10:121956782~121957098:+ LIHC cis rs2243480 0.522 rs73150635 ENSG00000226824.5 RP4-756H11.3 -5 9.01e-07 0.000331 -0.47 -0.26 Diabetic kidney disease; chr7:66507503 chr7:66654538~66669855:+ LIHC cis rs30380 0.632 rs27434 ENSG00000272109.1 CTD-2260A17.3 -5 9.02e-07 0.000331 -0.33 -0.26 Cerebrospinal fluid biomarker levels; chr5:96793809 chr5:96804353~96806105:+ LIHC cis rs992157 0.764 rs13020391 ENSG00000261338.2 RP11-378A13.1 -5 9.02e-07 0.000331 -0.28 -0.26 Colorectal cancer; chr2:218319713 chr2:218255319~218257366:+ LIHC cis rs11098499 1 rs13116504 ENSG00000245958.5 RP11-33B1.1 -5 9.02e-07 0.000331 -0.28 -0.26 Corneal astigmatism; chr4:119288257 chr4:119454791~119552025:+ LIHC cis rs10510102 0.935 rs12251175 ENSG00000276742.1 RP11-500G22.4 5 9.03e-07 0.000332 0.4 0.26 Breast cancer; chr10:121889015 chr10:121956782~121957098:+ LIHC cis rs17507216 0.718 rs7161977 ENSG00000278603.1 RP13-608F4.5 5 9.04e-07 0.000332 0.55 0.26 Excessive daytime sleepiness; chr15:82646782 chr15:82472203~82472426:+ LIHC cis rs603446 0.583 rs180377 ENSG00000254851.1 RP11-109L13.1 -5 9.04e-07 0.000332 -0.31 -0.26 Triglycerides; chr11:116718411 chr11:117135528~117138582:+ LIHC cis rs7688540 0.68 rs77762064 ENSG00000275426.1 CH17-262A2.1 5 9.06e-07 0.000333 0.34 0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:281154 chr4:149738~150317:+ LIHC cis rs17711722 0.583 rs10085415 ENSG00000164669.11 INTS4P1 5 9.08e-07 0.000334 0.37 0.26 Calcium levels; chr7:65628655 chr7:65141225~65234216:+ LIHC cis rs4718428 0.705 rs13227468 ENSG00000232546.1 RP11-458F8.1 -5 9.08e-07 0.000334 -0.24 -0.26 Corneal structure; chr7:66968576 chr7:66848496~66858136:+ LIHC cis rs10256972 0.521 rs10280960 ENSG00000199023.2 MIR339 -5 9.09e-07 0.000334 -0.3 -0.26 Endometriosis;Longevity; chr7:1064061 chr7:1022935~1023045:- LIHC cis rs5758511 0.633 rs5758690 ENSG00000237037.8 NDUFA6-AS1 -5 9.09e-07 0.000334 -0.33 -0.26 Birth weight; chr22:42272289 chr22:42090931~42137742:+ LIHC cis rs5758511 0.68 rs1001586 ENSG00000237037.8 NDUFA6-AS1 -5 9.09e-07 0.000334 -0.33 -0.26 Birth weight; chr22:42274287 chr22:42090931~42137742:+ LIHC cis rs227275 0.525 rs10029073 ENSG00000246560.2 RP11-10L12.4 5 9.09e-07 0.000334 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:103006991 chr4:102828055~102844075:+ LIHC cis rs11098499 1 rs28374891 ENSG00000245958.5 RP11-33B1.1 -5 9.1e-07 0.000334 -0.28 -0.26 Corneal astigmatism; chr4:119262395 chr4:119454791~119552025:+ LIHC cis rs227275 0.525 rs11097796 ENSG00000246560.2 RP11-10L12.4 5 9.1e-07 0.000334 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:103002401 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs11097797 ENSG00000246560.2 RP11-10L12.4 5 9.1e-07 0.000334 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:103002507 chr4:102828055~102844075:+ LIHC cis rs3096299 0.754 rs2965816 ENSG00000261118.1 RP11-104N10.1 -5 9.1e-07 0.000334 -0.25 -0.26 Multiple myeloma (IgH translocation); chr16:89447775 chr16:89492017~89504460:- LIHC cis rs10129255 1 rs10129407 ENSG00000223648.3 IGHV3-64 5 9.12e-07 0.000335 0.2 0.26 Kawasaki disease; chr14:106767956 chr14:106643132~106658258:- LIHC cis rs2877649 0.793 rs77673327 ENSG00000258744.1 RP11-80A15.1 -5 9.12e-07 0.000335 -0.52 -0.26 Smooth-surface caries; chr14:24446065 chr14:24501594~24508688:+ LIHC cis rs7829975 0.623 rs10087493 ENSG00000173295.6 FAM86B3P -5 9.13e-07 0.000335 -0.34 -0.26 Mood instability; chr8:8516047 chr8:8228595~8244865:+ LIHC cis rs2836974 0.59 rs9974757 ENSG00000255568.3 BRWD1-AS2 -5 9.14e-07 0.000335 -0.22 -0.26 Cognitive function; chr21:39245318 chr21:39313935~39314962:+ LIHC cis rs10800713 0.866 rs6703783 ENSG00000260088.1 RP11-92G12.3 -5 9.15e-07 0.000336 -0.36 -0.26 Tandem gait; chr1:200544290 chr1:200669507~200694250:+ LIHC cis rs1023500 0.505 rs134889 ENSG00000227370.1 RP4-669P10.19 -5 9.15e-07 0.000336 -0.27 -0.26 Schizophrenia; chr22:42278344 chr22:42132543~42132998:+ LIHC cis rs12478296 0.685 rs6705935 ENSG00000261186.2 RP11-341N2.1 -5 9.15e-07 0.000336 -0.35 -0.26 Obesity-related traits; chr2:242052959 chr2:242087351~242088457:- LIHC cis rs4356203 0.87 rs7937176 ENSG00000272034.1 SNORD14A -5 9.16e-07 0.000336 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17258198 chr11:17074654~17074744:- LIHC cis rs12134133 0.752 rs6683677 ENSG00000274245.1 RP11-357P18.2 5 9.18e-07 0.000337 0.4 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207228335 chr1:207372559~207373252:+ LIHC cis rs73186030 0.546 rs67818421 ENSG00000272758.4 RP11-299J3.8 5 9.19e-07 0.000337 0.45 0.26 Serum parathyroid hormone levels; chr3:122389871 chr3:122416207~122443180:+ LIHC cis rs73186030 0.546 rs9857972 ENSG00000272758.4 RP11-299J3.8 5 9.19e-07 0.000337 0.45 0.26 Serum parathyroid hormone levels; chr3:122390602 chr3:122416207~122443180:+ LIHC cis rs6504950 0.566 rs12937360 ENSG00000275710.1 RP11-257O5.4 5 9.21e-07 0.000338 0.3 0.26 Breast cancer; chr17:54968937 chr17:54964474~54964679:+ LIHC cis rs7923609 0.902 rs7897379 ENSG00000232075.1 MRPL35P2 -5 9.22e-07 0.000338 -0.29 -0.26 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63541965 chr10:63634317~63634827:- LIHC cis rs3096299 0.933 rs747485 ENSG00000261118.1 RP11-104N10.1 5 9.22e-07 0.000338 0.27 0.26 Multiple myeloma (IgH translocation); chr16:89407686 chr16:89492017~89504460:- LIHC cis rs712039 0.652 rs853206 ENSG00000276054.1 RP11-378E13.3 5 9.23e-07 0.000338 0.33 0.26 Tuberculosis; chr17:37464692 chr17:37386886~37387926:+ LIHC cis rs73193808 0.614 rs2832251 ENSG00000224649.1 AF124730.4 5 9.24e-07 0.000339 0.31 0.26 Coronary artery disease; chr21:29187231 chr21:29182027~29187795:- LIHC cis rs73186030 0.623 rs16832958 ENSG00000272758.4 RP11-299J3.8 5 9.25e-07 0.000339 0.31 0.26 Serum parathyroid hormone levels; chr3:122299646 chr3:122416207~122443180:+ LIHC cis rs12478296 1 rs6743297 ENSG00000261186.2 RP11-341N2.1 -5 9.26e-07 0.000339 -0.35 -0.26 Obesity-related traits; chr2:242071663 chr2:242087351~242088457:- LIHC cis rs12478296 0.892 rs11897561 ENSG00000261186.2 RP11-341N2.1 -5 9.26e-07 0.000339 -0.35 -0.26 Obesity-related traits; chr2:242072825 chr2:242087351~242088457:- LIHC cis rs875971 0.502 rs6460311 ENSG00000237310.1 GS1-124K5.4 -5 9.29e-07 0.00034 -0.25 -0.26 Aortic root size; chr7:66646886 chr7:66493706~66495474:+ LIHC cis rs7587476 0.601 rs17489231 ENSG00000229267.2 AC072062.1 5 9.29e-07 0.00034 0.33 0.26 Neuroblastoma; chr2:214809015 chr2:214810229~214963274:+ LIHC cis rs5758511 0.633 rs5758689 ENSG00000237037.8 NDUFA6-AS1 -5 9.31e-07 0.000341 -0.33 -0.26 Birth weight; chr22:42268966 chr22:42090931~42137742:+ LIHC cis rs1150668 0.965 rs1654774 ENSG00000204709.4 LINC01556 5 9.31e-07 0.000341 0.3 0.26 Pubertal anthropometrics; chr6:28128502 chr6:28943877~28944537:+ LIHC cis rs1865760 0.964 rs9295677 ENSG00000216436.2 HIST1H2APS1 -5 9.31e-07 0.000341 -0.3 -0.26 Height; chr6:25933484 chr6:25732497~25732827:+ LIHC cis rs12571093 0.504 rs4443961 ENSG00000233590.1 RP11-153K11.3 5 9.31e-07 0.000341 0.4 0.26 Optic nerve measurement (disc area); chr10:68285725 chr10:68233251~68242379:- LIHC cis rs853679 0.527 rs1997660 ENSG00000204709.4 LINC01556 5 9.31e-07 0.000341 0.29 0.26 Depression; chr6:28301886 chr6:28943877~28944537:+ LIHC cis rs853679 0.527 rs9468333 ENSG00000204709.4 LINC01556 5 9.31e-07 0.000341 0.29 0.26 Depression; chr6:28303421 chr6:28943877~28944537:+ LIHC cis rs3733585 0.781 rs13103879 ENSG00000250413.1 RP11-448G15.1 5 9.31e-07 0.000341 0.33 0.26 Cleft plate (environmental tobacco smoke interaction); chr4:9971255 chr4:10006482~10009725:+ LIHC cis rs7246657 0.943 rs3745765 ENSG00000276846.1 CTD-3220F14.3 5 9.32e-07 0.000341 0.32 0.26 Coronary artery calcification; chr19:37363333 chr19:37314868~37315620:- LIHC cis rs7429990 0.864 rs12495520 ENSG00000229759.1 MRPS18AP1 -5 9.33e-07 0.000341 -0.28 -0.26 Educational attainment (years of education); chr3:47766269 chr3:48256350~48256938:- LIHC cis rs17507216 0.667 rs13379724 ENSG00000278603.1 RP13-608F4.5 5 9.33e-07 0.000341 0.52 0.26 Excessive daytime sleepiness; chr15:82619892 chr15:82472203~82472426:+ LIHC cis rs4660214 0.614 rs11205802 ENSG00000182109.6 RP11-69E11.4 -5 9.34e-07 0.000342 -0.28 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39233442 chr1:39522280~39546187:- LIHC cis rs4660214 0.614 rs10888715 ENSG00000182109.6 RP11-69E11.4 -5 9.34e-07 0.000342 -0.28 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39233572 chr1:39522280~39546187:- LIHC cis rs5756813 0.688 rs34891095 ENSG00000233360.4 Z83844.1 5 9.35e-07 0.000342 0.35 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37730575 chr22:37641832~37658377:- LIHC cis rs5756813 0.688 rs2413483 ENSG00000233360.4 Z83844.1 5 9.35e-07 0.000342 0.35 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37731943 chr22:37641832~37658377:- LIHC cis rs5756813 0.688 rs8140207 ENSG00000233360.4 Z83844.1 5 9.35e-07 0.000342 0.35 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37734452 chr22:37641832~37658377:- LIHC cis rs7412746 0.658 rs1546376 ENSG00000231073.1 RP11-316M1.3 5 9.35e-07 0.000342 0.26 0.26 Melanoma; chr1:150965185 chr1:150973123~150975534:+ LIHC cis rs9291683 0.551 rs2240720 ENSG00000250413.1 RP11-448G15.1 -5 9.37e-07 0.000343 -0.33 -0.26 Bone mineral density; chr4:10018856 chr4:10006482~10009725:+ LIHC cis rs10510102 0.935 rs7083278 ENSG00000276742.1 RP11-500G22.4 5 9.37e-07 0.000343 0.4 0.26 Breast cancer; chr10:121853758 chr10:121956782~121957098:+ LIHC cis rs17301013 0.861 rs1793319 ENSG00000227373.4 RP11-160H22.5 5 9.38e-07 0.000343 0.34 0.26 Systemic lupus erythematosus; chr1:174795470 chr1:174115300~174160004:- LIHC cis rs4731207 0.698 rs7778956 ENSG00000224897.5 POT1-AS1 4.99 9.41e-07 0.000344 0.31 0.26 Cutaneous malignant melanoma; chr7:124887679 chr7:124929873~125179315:+ LIHC cis rs7208859 0.673 rs73263981 ENSG00000266490.1 CTD-2349P21.9 4.99 9.41e-07 0.000344 0.31 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30593484 chr17:30792372~30792833:+ LIHC cis rs4934494 0.834 rs1359624 ENSG00000232936.4 RP11-80H5.2 4.99 9.44e-07 0.000345 0.28 0.26 Red blood cell count; chr10:89635671 chr10:89645282~89650667:+ LIHC cis rs7811142 0.83 rs7792959 ENSG00000242294.5 STAG3L5P 4.99 9.44e-07 0.000345 0.28 0.26 Platelet count; chr7:100374780 chr7:100336079~100351900:+ LIHC cis rs1061377 0.748 rs12642261 ENSG00000249685.1 RP11-360F5.3 4.99 9.44e-07 0.000345 0.32 0.26 Uric acid levels; chr4:39096278 chr4:39133913~39135608:+ LIHC cis rs2274273 0.673 rs2209808 ENSG00000258413.1 RP11-665C16.6 -4.99 9.45e-07 0.000346 -0.31 -0.26 Protein biomarker; chr14:55340977 chr14:55262767~55272075:- LIHC cis rs11673344 0.526 rs17303902 ENSG00000226686.6 LINC01535 4.99 9.47e-07 0.000346 0.39 0.26 Obesity-related traits; chr19:37551912 chr19:37251912~37265535:+ LIHC cis rs11673344 0.526 rs55754546 ENSG00000226686.6 LINC01535 4.99 9.47e-07 0.000346 0.39 0.26 Obesity-related traits; chr19:37552860 chr19:37251912~37265535:+ LIHC cis rs10833905 0.756 rs12291247 ENSG00000246225.5 RP11-17A1.3 -4.99 9.47e-07 0.000346 -0.34 -0.26 Sudden cardiac arrest; chr11:22979817 chr11:22829380~22945393:+ LIHC cis rs73193808 0.639 rs2832241 ENSG00000224649.1 AF124730.4 4.99 9.47e-07 0.000346 0.31 0.26 Coronary artery disease; chr21:29179715 chr21:29182027~29187795:- LIHC cis rs227275 0.525 rs7688940 ENSG00000230069.3 LRRC37A15P -4.99 9.48e-07 0.000346 -0.24 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102994153 chr4:102727274~102730721:- LIHC cis rs712039 0.652 rs829161 ENSG00000276054.1 RP11-378E13.3 -4.99 9.48e-07 0.000346 -0.33 -0.26 Tuberculosis; chr17:37403775 chr17:37386886~37387926:+ LIHC cis rs2877649 1 rs737247 ENSG00000258744.1 RP11-80A15.1 -4.99 9.48e-07 0.000346 -0.52 -0.26 Smooth-surface caries; chr14:24457991 chr14:24501594~24508688:+ LIHC cis rs2877649 1 rs737245 ENSG00000258744.1 RP11-80A15.1 -4.99 9.48e-07 0.000346 -0.52 -0.26 Smooth-surface caries; chr14:24458176 chr14:24501594~24508688:+ LIHC cis rs2877649 1 rs59448251 ENSG00000258744.1 RP11-80A15.1 -4.99 9.48e-07 0.000346 -0.52 -0.26 Smooth-surface caries; chr14:24459246 chr14:24501594~24508688:+ LIHC cis rs2877649 1 rs57259303 ENSG00000258744.1 RP11-80A15.1 -4.99 9.48e-07 0.000346 -0.52 -0.26 Smooth-surface caries; chr14:24459328 chr14:24501594~24508688:+ LIHC cis rs2929278 0.736 rs2412823 ENSG00000166763.7 STRCP1 -4.99 9.5e-07 0.000347 -0.32 -0.26 Schizophrenia; chr15:43935072 chr15:43699488~43718184:- LIHC cis rs2274273 0.837 rs59871474 ENSG00000258413.1 RP11-665C16.6 -4.99 9.51e-07 0.000347 -0.31 -0.26 Protein biomarker; chr14:55312645 chr14:55262767~55272075:- LIHC cis rs6921919 0.583 rs740621 ENSG00000204709.4 LINC01556 4.99 9.52e-07 0.000348 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28430010 chr6:28943877~28944537:+ LIHC cis rs2834188 1 rs2834190 ENSG00000272659.1 AP000295.10 4.99 9.52e-07 0.000348 0.37 0.26 Narcolepsy; chr21:33320706 chr21:33309491~33310181:+ LIHC cis rs801193 0.548 rs6975044 ENSG00000237310.1 GS1-124K5.4 4.99 9.55e-07 0.000348 0.23 0.26 Aortic root size; chr7:66762495 chr7:66493706~66495474:+ LIHC cis rs6921919 1 rs6921919 ENSG00000216901.1 AL022393.7 4.99 9.55e-07 0.000349 0.37 0.26 Autism spectrum disorder or schizophrenia; chr6:28357424 chr6:28176188~28176674:+ LIHC cis rs4356203 0.87 rs7342262 ENSG00000272034.1 SNORD14A -4.99 9.55e-07 0.000349 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17264260 chr11:17074654~17074744:- LIHC cis rs1061377 0.965 rs6833654 ENSG00000249685.1 RP11-360F5.3 4.99 9.56e-07 0.000349 0.31 0.26 Uric acid levels; chr4:39110701 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs1036038 ENSG00000249685.1 RP11-360F5.3 4.99 9.56e-07 0.000349 0.31 0.26 Uric acid levels; chr4:39111383 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs1560396 ENSG00000249685.1 RP11-360F5.3 4.99 9.56e-07 0.000349 0.31 0.26 Uric acid levels; chr4:39112092 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs1560397 ENSG00000249685.1 RP11-360F5.3 4.99 9.56e-07 0.000349 0.31 0.26 Uric acid levels; chr4:39112265 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs2381285 ENSG00000249685.1 RP11-360F5.3 4.99 9.56e-07 0.000349 0.31 0.26 Uric acid levels; chr4:39112775 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs2163272 ENSG00000249685.1 RP11-360F5.3 4.99 9.56e-07 0.000349 0.31 0.26 Uric acid levels; chr4:39112790 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs2163273 ENSG00000249685.1 RP11-360F5.3 4.99 9.56e-07 0.000349 0.31 0.26 Uric acid levels; chr4:39112835 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs62310332 ENSG00000249685.1 RP11-360F5.3 4.99 9.56e-07 0.000349 0.31 0.26 Uric acid levels; chr4:39112939 chr4:39133913~39135608:+ LIHC cis rs1061377 0.965 rs3796510 ENSG00000249685.1 RP11-360F5.3 4.99 9.56e-07 0.000349 0.31 0.26 Uric acid levels; chr4:39113309 chr4:39133913~39135608:+ LIHC cis rs1061377 0.932 rs6855118 ENSG00000249685.1 RP11-360F5.3 4.99 9.56e-07 0.000349 0.31 0.26 Uric acid levels; chr4:39114322 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs6829234 ENSG00000249685.1 RP11-360F5.3 4.99 9.56e-07 0.000349 0.31 0.26 Uric acid levels; chr4:39114586 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs6812540 ENSG00000249685.1 RP11-360F5.3 4.99 9.56e-07 0.000349 0.31 0.26 Uric acid levels; chr4:39114803 chr4:39133913~39135608:+ LIHC cis rs599083 0.569 rs685095 ENSG00000212093.1 AP000807.1 -4.99 9.57e-07 0.000349 -0.29 -0.26 Bone mineral density (spine); chr11:68402908 chr11:68506083~68506166:- LIHC cis rs2877649 0.793 rs1956921 ENSG00000258744.1 RP11-80A15.1 4.99 9.57e-07 0.000349 0.55 0.26 Smooth-surface caries; chr14:24510210 chr14:24501594~24508688:+ LIHC cis rs227275 0.525 rs13113923 ENSG00000230069.3 LRRC37A15P -4.99 9.58e-07 0.000349 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102918936 chr4:102727274~102730721:- LIHC cis rs73186030 0.591 rs28630628 ENSG00000272758.4 RP11-299J3.8 4.99 9.58e-07 0.000349 0.47 0.26 Serum parathyroid hormone levels; chr3:122386769 chr3:122416207~122443180:+ LIHC cis rs7923609 0.846 rs7075901 ENSG00000232075.1 MRPL35P2 -4.99 9.58e-07 0.000349 -0.29 -0.26 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63521234 chr10:63634317~63634827:- LIHC cis rs1061377 1 rs3796509 ENSG00000249685.1 RP11-360F5.3 4.99 9.58e-07 0.00035 0.32 0.26 Uric acid levels; chr4:39108566 chr4:39133913~39135608:+ LIHC cis rs17270561 0.636 rs9348696 ENSG00000216436.2 HIST1H2APS1 -4.99 9.59e-07 0.00035 -0.31 -0.26 Iron status biomarkers; chr6:25781710 chr6:25732497~25732827:+ LIHC cis rs9291683 0.53 rs4235346 ENSG00000250413.1 RP11-448G15.1 4.99 9.59e-07 0.00035 0.34 0.26 Bone mineral density; chr4:9943672 chr4:10006482~10009725:+ LIHC cis rs6723226 0.75 rs762019 ENSG00000276334.1 AL133243.1 4.99 9.6e-07 0.00035 0.28 0.26 Intelligence (multi-trait analysis); chr2:32463533 chr2:32521927~32523547:+ LIHC cis rs12571093 0.541 rs7893837 ENSG00000233590.1 RP11-153K11.3 -4.99 9.61e-07 0.00035 -0.42 -0.26 Optic nerve measurement (disc area); chr10:68295578 chr10:68233251~68242379:- LIHC cis rs6480314 0.522 rs11816028 ENSG00000233590.1 RP11-153K11.3 -4.99 9.61e-07 0.00035 -0.42 -0.26 Optic nerve measurement (disc area); chr10:68296566 chr10:68233251~68242379:- LIHC cis rs6479891 1 rs7070052 ENSG00000232075.1 MRPL35P2 -4.99 9.62e-07 0.000351 -0.3 -0.26 Arthritis (juvenile idiopathic); chr10:63144054 chr10:63634317~63634827:- LIHC cis rs11089937 0.667 rs5757081 ENSG00000211639.2 IGLV4-60 4.99 9.63e-07 0.000351 0.23 0.26 Periodontitis (PAL4Q3); chr22:22146272 chr22:22162199~22162681:+ LIHC cis rs228614 0.536 rs223375 ENSG00000230069.3 LRRC37A15P -4.99 9.63e-07 0.000351 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102836484 chr4:102727274~102730721:- LIHC cis rs6964833 0.935 rs34762099 ENSG00000123965.13 PMS2P5 4.99 9.63e-07 0.000351 0.44 0.26 Menarche (age at onset); chr7:74636378 chr7:74894116~74897835:+ LIHC cis rs7714584 1 rs10463310 ENSG00000197083.10 ZNF300P1 4.99 9.63e-07 0.000351 0.4 0.26 Crohn's disease; chr5:150881343 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs73284126 ENSG00000197083.10 ZNF300P1 4.99 9.63e-07 0.000351 0.4 0.26 Crohn's disease; chr5:150881745 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs7732945 ENSG00000197083.10 ZNF300P1 4.99 9.63e-07 0.000351 0.4 0.26 Crohn's disease; chr5:150882039 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs1820682 ENSG00000197083.10 ZNF300P1 4.99 9.63e-07 0.000351 0.4 0.26 Crohn's disease; chr5:150882580 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs4560537 ENSG00000197083.10 ZNF300P1 4.99 9.63e-07 0.000351 0.4 0.26 Crohn's disease; chr5:150883024 chr5:150930645~150946289:- LIHC cis rs202072 0.729 rs202040 ENSG00000215022.6 RP1-257A7.4 -4.99 9.64e-07 0.000351 -0.31 -0.26 HIV-1 viral setpoint; chr6:13288303 chr6:13264861~13295586:- LIHC cis rs4650994 0.525 rs4457535 ENSG00000273384.1 RP5-1098D14.1 -4.99 9.65e-07 0.000352 -0.32 -0.26 HDL cholesterol;HDL cholesterol levels; chr1:178528051 chr1:178651706~178652282:+ LIHC cis rs11123170 0.64 rs1015754 ENSG00000189223.12 PAX8-AS1 4.99 9.65e-07 0.000352 0.37 0.26 Renal function-related traits (BUN); chr2:113210413 chr2:113211522~113276581:+ LIHC cis rs113835537 1 rs113835537 ENSG00000255517.5 CTD-3074O7.5 -4.99 9.67e-07 0.000352 -0.35 -0.26 Airway imaging phenotypes; chr11:66572168 chr11:66473490~66480233:- LIHC cis rs950776 0.714 rs514743 ENSG00000261762.1 RP11-650L12.2 -4.99 9.68e-07 0.000353 -0.33 -0.26 Sudden cardiac arrest; chr15:78591885 chr15:78589123~78591276:- LIHC cis rs12554020 0.579 rs79056932 ENSG00000227603.1 RP11-165J3.6 4.99 9.68e-07 0.000353 0.47 0.26 Schizophrenia; chr9:93585431 chr9:93435332~93437121:- LIHC cis rs11098499 0.955 rs13114751 ENSG00000245958.5 RP11-33B1.1 -4.99 9.68e-07 0.000353 -0.28 -0.26 Corneal astigmatism; chr4:119235462 chr4:119454791~119552025:+ LIHC cis rs11098499 0.913 rs35271032 ENSG00000245958.5 RP11-33B1.1 -4.99 9.68e-07 0.000353 -0.28 -0.26 Corneal astigmatism; chr4:119235504 chr4:119454791~119552025:+ LIHC cis rs950169 0.84 rs2896002 ENSG00000259728.4 LINC00933 4.99 9.68e-07 0.000353 0.37 0.26 Schizophrenia; chr15:84390423 chr15:84570649~84580175:+ LIHC cis rs950169 0.887 rs3860265 ENSG00000259728.4 LINC00933 4.99 9.68e-07 0.000353 0.37 0.26 Schizophrenia; chr15:84390487 chr15:84570649~84580175:+ LIHC cis rs950169 0.724 rs11632668 ENSG00000259728.4 LINC00933 4.99 9.68e-07 0.000353 0.37 0.26 Schizophrenia; chr15:84393989 chr15:84570649~84580175:+ LIHC cis rs950169 0.881 rs34591918 ENSG00000259728.4 LINC00933 4.99 9.68e-07 0.000353 0.37 0.26 Schizophrenia; chr15:84396135 chr15:84570649~84580175:+ LIHC cis rs36715 1 rs251386 ENSG00000245937.6 LINC01184 4.99 9.69e-07 0.000353 0.32 0.26 Breast cancer; chr5:128211606 chr5:127940426~128083172:- LIHC cis rs950169 0.84 rs62019457 ENSG00000259728.4 LINC00933 4.99 9.7e-07 0.000353 0.37 0.26 Schizophrenia; chr15:84558911 chr15:84570649~84580175:+ LIHC cis rs9595066 0.712 rs4391951 ENSG00000230731.2 RP11-478K15.6 -4.99 9.71e-07 0.000354 -0.3 -0.26 Schizophrenia; chr13:44180935 chr13:44234118~44243192:- LIHC cis rs2749592 0.513 rs1208708 ENSG00000099251.13 HSD17B7P2 4.99 9.72e-07 0.000354 0.3 0.26 Age-related hearing impairment (SNP x SNP interaction); chr10:37796648 chr10:38356380~38378505:+ LIHC cis rs8005677 0.828 rs2295680 ENSG00000279656.1 RP11-298I3.6 -4.99 9.72e-07 0.000354 -0.29 -0.26 Cognitive ability (multi-trait analysis); chr14:22905226 chr14:23023083~23024217:- LIHC cis rs875971 0.755 rs76288834 ENSG00000237310.1 GS1-124K5.4 -4.99 9.74e-07 0.000355 -0.23 -0.26 Aortic root size; chr7:66604815 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs67775320 ENSG00000226824.5 RP4-756H11.3 -4.99 9.75e-07 0.000355 -0.33 -0.26 Aortic root size; chr7:66193792 chr7:66654538~66669855:+ LIHC cis rs7714584 1 rs6579806 ENSG00000197083.10 ZNF300P1 4.99 9.76e-07 0.000355 0.39 0.26 Crohn's disease; chr5:150891522 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs57001853 ENSG00000197083.10 ZNF300P1 4.99 9.76e-07 0.000355 0.39 0.26 Crohn's disease; chr5:150892890 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs1816256 ENSG00000197083.10 ZNF300P1 4.99 9.76e-07 0.000355 0.39 0.26 Crohn's disease; chr5:150893291 chr5:150930645~150946289:- LIHC cis rs10510102 0.935 rs12258426 ENSG00000226864.1 ATE1-AS1 4.99 9.77e-07 0.000355 0.43 0.26 Breast cancer; chr10:121882189 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs12266380 ENSG00000226864.1 ATE1-AS1 4.99 9.77e-07 0.000355 0.43 0.26 Breast cancer; chr10:121882559 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200212 ENSG00000226864.1 ATE1-AS1 4.99 9.77e-07 0.000355 0.43 0.26 Breast cancer; chr10:121883145 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs11200213 ENSG00000226864.1 ATE1-AS1 4.99 9.77e-07 0.000355 0.43 0.26 Breast cancer; chr10:121883228 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs12247749 ENSG00000226864.1 ATE1-AS1 4.99 9.77e-07 0.000355 0.43 0.26 Breast cancer; chr10:121884196 chr10:121928312~121951965:+ LIHC cis rs8005677 1 rs8006409 ENSG00000257285.4 RP11-298I3.1 4.99 9.77e-07 0.000355 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22927302 chr14:22929609~22955562:+ LIHC cis rs2274273 0.87 rs11625001 ENSG00000258413.1 RP11-665C16.6 -4.99 9.77e-07 0.000356 -0.31 -0.26 Protein biomarker; chr14:55291442 chr14:55262767~55272075:- LIHC cis rs2274273 0.87 rs67514154 ENSG00000258413.1 RP11-665C16.6 -4.99 9.77e-07 0.000356 -0.31 -0.26 Protein biomarker; chr14:55300664 chr14:55262767~55272075:- LIHC cis rs875971 0.545 rs1638735 ENSG00000237310.1 GS1-124K5.4 4.99 9.78e-07 0.000356 0.26 0.26 Aortic root size; chr7:66630751 chr7:66493706~66495474:+ LIHC cis rs13392177 0.672 rs1877715 ENSG00000261338.2 RP11-378A13.1 4.99 9.79e-07 0.000356 0.27 0.26 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218187823 chr2:218255319~218257366:+ LIHC cis rs2836974 0.555 rs35909862 ENSG00000255568.3 BRWD1-AS2 -4.99 9.8e-07 0.000356 -0.22 -0.26 Cognitive function; chr21:39249232 chr21:39313935~39314962:+ LIHC cis rs2581828 0.646 rs2564923 ENSG00000242142.1 SERBP1P3 4.99 9.8e-07 0.000356 0.3 0.26 Crohn's disease; chr3:53069246 chr3:53064283~53065091:- LIHC cis rs4731207 0.623 rs1481342 ENSG00000224897.5 POT1-AS1 4.99 9.81e-07 0.000357 0.32 0.26 Cutaneous malignant melanoma; chr7:125011425 chr7:124929873~125179315:+ LIHC cis rs11089937 0.626 rs4821781 ENSG00000211639.2 IGLV4-60 4.99 9.81e-07 0.000357 0.22 0.26 Periodontitis (PAL4Q3); chr22:22138845 chr22:22162199~22162681:+ LIHC cis rs11089937 0.626 rs5750589 ENSG00000211639.2 IGLV4-60 4.99 9.81e-07 0.000357 0.22 0.26 Periodontitis (PAL4Q3); chr22:22139655 chr22:22162199~22162681:+ LIHC cis rs11089937 0.626 rs5757038 ENSG00000211639.2 IGLV4-60 4.99 9.81e-07 0.000357 0.22 0.26 Periodontitis (PAL4Q3); chr22:22140149 chr22:22162199~22162681:+ LIHC cis rs11096990 0.613 rs1451821 ENSG00000249207.1 RP11-360F5.1 4.99 9.82e-07 0.000357 0.27 0.26 Cognitive function; chr4:39178797 chr4:39112677~39126818:- LIHC cis rs4934494 0.768 rs12771413 ENSG00000232936.4 RP11-80H5.2 -4.99 9.83e-07 0.000357 -0.31 -0.26 Red blood cell count; chr10:89633010 chr10:89645282~89650667:+ LIHC cis rs2243480 1 rs160634 ENSG00000226824.5 RP4-756H11.3 4.99 9.83e-07 0.000357 0.4 0.26 Diabetic kidney disease; chr7:66063677 chr7:66654538~66669855:+ LIHC cis rs11079159 0.606 rs1114603 ENSG00000263096.1 RP11-515O17.2 4.99 9.83e-07 0.000357 0.34 0.26 QRS duration; chr17:55291706 chr17:55271504~55273653:- LIHC cis rs36715 0.953 rs251214 ENSG00000245937.6 LINC01184 4.99 9.84e-07 0.000358 0.32 0.26 Breast cancer; chr5:128209046 chr5:127940426~128083172:- LIHC cis rs2919917 1 rs13269243 ENSG00000254352.1 RP11-578O24.2 4.99 9.85e-07 0.000358 0.35 0.26 Lymphocyte counts; chr8:78669501 chr8:78723796~78724136:- LIHC cis rs11123170 0.65 rs2289897 ENSG00000274877.1 RP11-65I12.1 -4.99 9.85e-07 0.000358 -0.36 -0.26 Renal function-related traits (BUN); chr2:113219877 chr2:113237595~113240825:+ LIHC cis rs12134133 0.752 rs61821050 ENSG00000274245.1 RP11-357P18.2 4.98 9.87e-07 0.000359 0.4 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207235253 chr1:207372559~207373252:+ LIHC cis rs12134133 0.752 rs61821051 ENSG00000274245.1 RP11-357P18.2 4.98 9.87e-07 0.000359 0.4 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207235624 chr1:207372559~207373252:+ LIHC cis rs950169 0.922 rs11630507 ENSG00000259728.4 LINC00933 4.98 9.89e-07 0.000359 0.37 0.26 Schizophrenia; chr15:84552494 chr15:84570649~84580175:+ LIHC cis rs4660214 0.666 rs1775656 ENSG00000182109.6 RP11-69E11.4 4.98 9.89e-07 0.000359 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39445329 chr1:39522280~39546187:- LIHC cis rs172166 0.561 rs149976 ENSG00000204709.4 LINC01556 -4.98 9.89e-07 0.000359 -0.29 -0.26 Cardiac Troponin-T levels; chr6:28019998 chr6:28943877~28944537:+ LIHC cis rs6600671 1 rs1591882 ENSG00000231429.2 RP11-343N15.2 -4.98 9.9e-07 0.00036 -0.3 -0.26 Hip geometry; chr1:121441455 chr1:121412719~121429274:+ LIHC cis rs2439831 1 rs561863 ENSG00000205771.5 CATSPER2P1 -4.98 9.9e-07 0.00036 -0.36 -0.26 Lung cancer in ever smokers; chr15:43469154 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs689616 ENSG00000205771.5 CATSPER2P1 -4.98 9.9e-07 0.00036 -0.36 -0.26 Lung cancer in ever smokers; chr15:43469703 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs689647 ENSG00000205771.5 CATSPER2P1 -4.98 9.9e-07 0.00036 -0.36 -0.26 Lung cancer in ever smokers; chr15:43469998 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs2251538 ENSG00000205771.5 CATSPER2P1 -4.98 9.9e-07 0.00036 -0.36 -0.26 Lung cancer in ever smokers; chr15:43475011 chr15:43726918~43747094:- LIHC cis rs6921919 0.832 rs17312661 ENSG00000204709.4 LINC01556 4.98 9.93e-07 0.00036 0.44 0.26 Autism spectrum disorder or schizophrenia; chr6:28332559 chr6:28943877~28944537:+ LIHC cis rs950027 0.787 rs1547487 ENSG00000259433.2 CTD-2651B20.4 -4.98 9.94e-07 0.000361 -0.35 -0.26 Response to fenofibrate (adiponectin levels); chr15:45431785 chr15:45330209~45332634:- LIHC cis rs17270561 0.609 rs1408271 ENSG00000216436.2 HIST1H2APS1 -4.98 9.94e-07 0.000361 -0.31 -0.26 Iron status biomarkers; chr6:25859393 chr6:25732497~25732827:+ LIHC cis rs950169 0.84 rs12905223 ENSG00000259295.5 CSPG4P12 4.98 9.95e-07 0.000361 0.36 0.26 Schizophrenia; chr15:84571037 chr15:85191438~85213905:+ LIHC cis rs10800713 0.954 rs6665951 ENSG00000260088.1 RP11-92G12.3 -4.98 9.95e-07 0.000361 -0.33 -0.26 Tandem gait; chr1:200589235 chr1:200669507~200694250:+ LIHC cis rs801193 0.569 rs13226966 ENSG00000237310.1 GS1-124K5.4 4.98 9.96e-07 0.000361 0.23 0.26 Aortic root size; chr7:66768636 chr7:66493706~66495474:+ LIHC cis rs6964833 0.873 rs4717905 ENSG00000123965.13 PMS2P5 4.98 9.96e-07 0.000362 0.44 0.26 Menarche (age at onset); chr7:74668903 chr7:74894116~74897835:+ LIHC cis rs9467711 0.591 rs16891235 ENSG00000216436.2 HIST1H2APS1 4.98 9.97e-07 0.000362 0.66 0.26 Autism spectrum disorder or schizophrenia; chr6:26017314 chr6:25732497~25732827:+ LIHC cis rs9467711 0.591 rs3734528 ENSG00000216436.2 HIST1H2APS1 4.98 9.97e-07 0.000362 0.66 0.26 Autism spectrum disorder or schizophrenia; chr6:26022016 chr6:25732497~25732827:+ LIHC cis rs10998036 0.591 rs10823171 ENSG00000233590.1 RP11-153K11.3 4.98 9.97e-07 0.000362 0.38 0.26 Optic cup area; chr10:68292171 chr10:68233251~68242379:- LIHC cis rs6921919 0.583 rs9461459 ENSG00000204709.4 LINC01556 4.98 9.99e-07 0.000362 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28394139 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs28360638 ENSG00000204709.4 LINC01556 4.98 9.99e-07 0.000362 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28394552 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs9468368 ENSG00000204709.4 LINC01556 4.98 9.99e-07 0.000362 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28397172 chr6:28943877~28944537:+ LIHC cis rs7688540 0.709 rs4538423 ENSG00000275426.1 CH17-262A2.1 4.98 9.99e-07 0.000363 0.37 0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:213241 chr4:149738~150317:+ LIHC cis rs7429990 0.864 rs6785669 ENSG00000229759.1 MRPS18AP1 -4.98 9.99e-07 0.000363 -0.28 -0.26 Educational attainment (years of education); chr3:47715771 chr3:48256350~48256938:- LIHC cis rs7429990 0.833 rs6442079 ENSG00000229759.1 MRPS18AP1 -4.98 9.99e-07 0.000363 -0.28 -0.26 Educational attainment (years of education); chr3:47721044 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs13094264 ENSG00000229759.1 MRPS18AP1 -4.98 9.99e-07 0.000363 -0.28 -0.26 Educational attainment (years of education); chr3:47722723 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs4858851 ENSG00000229759.1 MRPS18AP1 -4.98 9.99e-07 0.000363 -0.28 -0.26 Educational attainment (years of education); chr3:47724165 chr3:48256350~48256938:- LIHC cis rs7429990 0.833 rs34777284 ENSG00000229759.1 MRPS18AP1 -4.98 9.99e-07 0.000363 -0.28 -0.26 Educational attainment (years of education); chr3:47726585 chr3:48256350~48256938:- LIHC cis rs2274273 0.868 rs6573007 ENSG00000258413.1 RP11-665C16.6 -4.98 1e-06 0.000363 -0.29 -0.26 Protein biomarker; chr14:55159220 chr14:55262767~55272075:- LIHC cis rs853679 0.527 rs853683 ENSG00000204709.4 LINC01556 4.98 1e-06 0.000363 0.29 0.26 Depression; chr6:28327262 chr6:28943877~28944537:+ LIHC cis rs2834188 0.889 rs8134026 ENSG00000272659.1 AP000295.10 -4.98 1e-06 0.000364 -0.39 -0.26 Narcolepsy; chr21:33298793 chr21:33309491~33310181:+ LIHC cis rs227275 0.588 rs223458 ENSG00000246560.2 RP11-10L12.4 4.98 1e-06 0.000364 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102788414 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223459 ENSG00000246560.2 RP11-10L12.4 4.98 1e-06 0.000364 0.29 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102788229 chr4:102828055~102844075:+ LIHC cis rs11676348 0.805 rs13007219 ENSG00000261338.2 RP11-378A13.1 -4.98 1e-06 0.000364 -0.27 -0.26 Ulcerative colitis; chr2:218099136 chr2:218255319~218257366:+ LIHC cis rs227275 0.554 rs223457 ENSG00000230069.3 LRRC37A15P -4.98 1.01e-06 0.000365 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102788506 chr4:102727274~102730721:- LIHC cis rs6921919 0.583 rs6928771 ENSG00000204709.4 LINC01556 4.98 1.01e-06 0.000365 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28407432 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs6928773 ENSG00000204709.4 LINC01556 4.98 1.01e-06 0.000365 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28407433 chr6:28943877~28944537:+ LIHC cis rs5769765 0.671 rs138832 ENSG00000278869.1 CITF22-49E9.3 4.98 1.01e-06 0.000365 0.38 0.26 Schizophrenia; chr22:49784434 chr22:49933198~49934074:- LIHC cis rs12554020 0.582 rs79565493 ENSG00000227603.1 RP11-165J3.6 4.98 1.01e-06 0.000365 0.49 0.26 Schizophrenia; chr9:93634820 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs74421510 ENSG00000227603.1 RP11-165J3.6 4.98 1.01e-06 0.000365 0.49 0.26 Schizophrenia; chr9:93634872 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs55783552 ENSG00000227603.1 RP11-165J3.6 4.98 1.01e-06 0.000365 0.49 0.26 Schizophrenia; chr9:93637205 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs80228675 ENSG00000227603.1 RP11-165J3.6 4.98 1.01e-06 0.000365 0.49 0.26 Schizophrenia; chr9:93637918 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs79391190 ENSG00000227603.1 RP11-165J3.6 4.98 1.01e-06 0.000365 0.49 0.26 Schizophrenia; chr9:93637992 chr9:93435332~93437121:- LIHC cis rs875971 0.502 rs2465121 ENSG00000273142.1 RP11-458F8.4 -4.98 1.01e-06 0.000365 -0.25 -0.26 Aortic root size; chr7:66156017 chr7:66902857~66906297:+ LIHC cis rs12468226 0.873 rs3181153 ENSG00000273456.1 RP11-686O6.2 -4.98 1.01e-06 0.000366 -0.37 -0.26 Urate levels; chr2:202205155 chr2:202374932~202375604:- LIHC cis rs228614 0.51 rs223455 ENSG00000246560.2 RP11-10L12.4 4.98 1.01e-06 0.000366 0.29 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102789026 chr4:102828055~102844075:+ LIHC cis rs10448080 0.879 rs240946 ENSG00000246339.5 EXTL3-AS1 4.98 1.01e-06 0.000366 0.25 0.26 Height; chr8:28711388 chr8:28696198~28701464:- LIHC cis rs950776 0.518 rs62008194 ENSG00000261762.1 RP11-650L12.2 4.98 1.01e-06 0.000366 0.34 0.26 Sudden cardiac arrest; chr15:78521463 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs12900783 ENSG00000261762.1 RP11-650L12.2 4.98 1.01e-06 0.000366 0.34 0.26 Sudden cardiac arrest; chr15:78523181 chr15:78589123~78591276:- LIHC cis rs950776 0.518 rs12594391 ENSG00000261762.1 RP11-650L12.2 4.98 1.01e-06 0.000366 0.34 0.26 Sudden cardiac arrest; chr15:78523898 chr15:78589123~78591276:- LIHC cis rs72627509 0.68 rs79641006 ENSG00000269949.1 RP11-738E22.3 4.98 1.01e-06 0.000366 0.35 0.26 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56981277 chr4:56960927~56961373:- LIHC cis rs950169 0.922 rs6603022 ENSG00000225151.9 GOLGA2P7 4.98 1.01e-06 0.000366 0.32 0.26 Schizophrenia; chr15:84161418 chr15:84199311~84230136:- LIHC cis rs950169 0.922 rs11639244 ENSG00000225151.9 GOLGA2P7 -4.98 1.01e-06 0.000366 -0.32 -0.26 Schizophrenia; chr15:84163898 chr15:84199311~84230136:- LIHC cis rs6480314 0.522 rs10733842 ENSG00000233590.1 RP11-153K11.3 4.98 1.01e-06 0.000366 0.4 0.26 Optic nerve measurement (disc area); chr10:68299286 chr10:68233251~68242379:- LIHC cis rs17301013 0.932 rs6664864 ENSG00000227373.4 RP11-160H22.5 4.98 1.01e-06 0.000366 0.31 0.26 Systemic lupus erythematosus; chr1:174622912 chr1:174115300~174160004:- LIHC cis rs5756813 0.754 rs11089854 ENSG00000233360.4 Z83844.1 4.98 1.01e-06 0.000367 0.34 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37752875 chr22:37641832~37658377:- LIHC cis rs71520386 0.632 rs1029738 ENSG00000228649.7 AC005682.5 -4.98 1.01e-06 0.000367 -0.34 -0.26 Fibrinogen levels; chr7:22834428 chr7:22854178~22861579:+ LIHC cis rs8059260 0.736 rs2302558 ENSG00000274038.1 RP11-66H6.4 -4.98 1.01e-06 0.000367 -0.41 -0.26 Alcohol consumption over the past year; chr16:10969154 chr16:11056556~11057034:+ LIHC cis rs8067287 0.688 rs11654431 ENSG00000205312.7 KRT17P4 4.98 1.01e-06 0.000368 0.4 0.26 Diabetic kidney disease; chr17:16941549 chr17:16847635~16852777:- LIHC cis rs8067287 0.688 rs58928848 ENSG00000205312.7 KRT17P4 4.98 1.01e-06 0.000368 0.4 0.26 Diabetic kidney disease; chr17:16941562 chr17:16847635~16852777:- LIHC cis rs4731207 0.698 rs7795492 ENSG00000224897.5 POT1-AS1 4.98 1.01e-06 0.000368 0.31 0.26 Cutaneous malignant melanoma; chr7:124884077 chr7:124929873~125179315:+ LIHC cis rs1420585 1 rs12597905 ENSG00000260614.1 RP11-491F9.1 -4.98 1.02e-06 0.000368 -0.37 -0.26 Pursuit maintenance gain; chr16:48968092 chr16:49287430~49290227:+ LIHC cis rs7085104 0.727 rs12773892 ENSG00000236937.2 PTGES3P4 4.98 1.02e-06 0.000368 0.34 0.26 Immature fraction of reticulocytes;Schizophrenia; chr10:102871420 chr10:102845595~102845950:+ LIHC cis rs7829975 0.593 rs2921077 ENSG00000253893.2 FAM85B -4.98 1.02e-06 0.000368 -0.32 -0.26 Mood instability; chr8:8446992 chr8:8167819~8226614:- LIHC cis rs9549367 0.577 rs3024711 ENSG00000269125.1 RP11-98F14.11 -4.98 1.02e-06 0.000368 -0.35 -0.26 Platelet distribution width; chr13:113158954 chr13:113165002~113165183:- LIHC cis rs9487094 0.67 rs1476388 ENSG00000260273.1 RP11-425D10.10 4.98 1.02e-06 0.000368 0.31 0.26 Height; chr6:109518783 chr6:109382795~109383666:+ LIHC cis rs5769765 0.955 rs7511159 ENSG00000278869.1 CITF22-49E9.3 4.98 1.02e-06 0.000369 0.39 0.26 Schizophrenia; chr22:49914248 chr22:49933198~49934074:- LIHC cis rs10170846 0.53 rs56353541 ENSG00000261428.2 RP11-16P6.1 4.98 1.02e-06 0.000369 0.28 0.26 Schizophrenia (inflammation and infection response interaction); chr2:222556468 chr2:222566899~222569719:- LIHC cis rs6921919 0.789 rs17301128 ENSG00000216901.1 AL022393.7 4.98 1.02e-06 0.000369 0.35 0.26 Autism spectrum disorder or schizophrenia; chr6:28340257 chr6:28176188~28176674:+ LIHC cis rs4356203 0.875 rs527810 ENSG00000272034.1 SNORD14A -4.98 1.02e-06 0.00037 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17179519 chr11:17074654~17074744:- LIHC cis rs4356203 0.905 rs589319 ENSG00000272034.1 SNORD14A -4.98 1.02e-06 0.00037 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17181050 chr11:17074654~17074744:- LIHC cis rs4731207 0.596 rs10257712 ENSG00000224897.5 POT1-AS1 4.98 1.02e-06 0.000371 0.32 0.26 Cutaneous malignant melanoma; chr7:124958025 chr7:124929873~125179315:+ LIHC cis rs7412746 0.634 rs4451553 ENSG00000231073.1 RP11-316M1.3 4.98 1.02e-06 0.000371 0.26 0.26 Melanoma; chr1:150964853 chr1:150973123~150975534:+ LIHC cis rs2836974 0.565 rs34304022 ENSG00000255568.3 BRWD1-AS2 4.98 1.02e-06 0.000371 0.38 0.26 Cognitive function; chr21:39207693 chr21:39313935~39314962:+ LIHC cis rs5769765 0.908 rs9616213 ENSG00000278869.1 CITF22-49E9.3 4.98 1.03e-06 0.000371 0.4 0.26 Schizophrenia; chr22:49924203 chr22:49933198~49934074:- LIHC cis rs3096299 0.563 rs4600467 ENSG00000261118.1 RP11-104N10.1 4.98 1.03e-06 0.000371 0.26 0.26 Multiple myeloma (IgH translocation); chr16:89496108 chr16:89492017~89504460:- LIHC cis rs6504950 0.566 rs7226272 ENSG00000275710.1 RP11-257O5.4 4.98 1.03e-06 0.000371 0.29 0.26 Breast cancer; chr17:54969086 chr17:54964474~54964679:+ LIHC cis rs7208859 0.524 rs73263982 ENSG00000266490.1 CTD-2349P21.9 4.98 1.03e-06 0.000371 0.31 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30593606 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs216433 ENSG00000266490.1 CTD-2349P21.9 4.98 1.03e-06 0.000371 0.31 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30594842 chr17:30792372~30792833:+ LIHC cis rs1061377 0.965 rs7677729 ENSG00000249685.1 RP11-360F5.3 4.98 1.03e-06 0.000371 0.31 0.26 Uric acid levels; chr4:39120370 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs3796511 ENSG00000249685.1 RP11-360F5.3 4.98 1.03e-06 0.000371 0.31 0.26 Uric acid levels; chr4:39120586 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs3733274 ENSG00000249685.1 RP11-360F5.3 4.98 1.03e-06 0.000371 0.31 0.26 Uric acid levels; chr4:39120957 chr4:39133913~39135608:+ LIHC cis rs1185460 1 rs4614 ENSG00000271751.1 RP11-110I1.14 -4.98 1.03e-06 0.000372 -0.36 -0.26 Coronary artery disease; chr11:119081661 chr11:119065263~119065677:- LIHC cis rs599083 0.53 rs583545 ENSG00000212093.1 AP000807.1 -4.98 1.03e-06 0.000372 -0.28 -0.26 Bone mineral density (spine); chr11:68411167 chr11:68506083~68506166:- LIHC cis rs599083 0.53 rs689179 ENSG00000212093.1 AP000807.1 -4.98 1.03e-06 0.000372 -0.28 -0.26 Bone mineral density (spine); chr11:68411698 chr11:68506083~68506166:- LIHC cis rs12478296 1 rs56162244 ENSG00000261186.2 RP11-341N2.1 -4.98 1.03e-06 0.000372 -0.35 -0.26 Obesity-related traits; chr2:242076539 chr2:242087351~242088457:- LIHC cis rs17301013 0.932 rs1754355 ENSG00000227373.4 RP11-160H22.5 -4.98 1.03e-06 0.000372 -0.31 -0.26 Systemic lupus erythematosus; chr1:174807407 chr1:174115300~174160004:- LIHC cis rs11098499 0.954 rs9998585 ENSG00000260091.1 RP11-33B1.4 -4.98 1.03e-06 0.000372 -0.18 -0.26 Corneal astigmatism; chr4:119475647 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs6842762 ENSG00000260091.1 RP11-33B1.4 -4.98 1.03e-06 0.000372 -0.18 -0.26 Corneal astigmatism; chr4:119477081 chr4:119409333~119410233:+ LIHC cis rs2274273 0.87 rs10145203 ENSG00000258413.1 RP11-665C16.6 -4.98 1.03e-06 0.000372 -0.31 -0.26 Protein biomarker; chr14:55317740 chr14:55262767~55272075:- LIHC cis rs712039 0.652 rs829163 ENSG00000276054.1 RP11-378E13.3 4.98 1.03e-06 0.000372 0.33 0.26 Tuberculosis; chr17:37405936 chr17:37386886~37387926:+ LIHC cis rs860295 1 rs822527 ENSG00000203761.5 MSTO2P 4.98 1.03e-06 0.000374 0.21 0.26 Body mass index; chr1:155768262 chr1:155745829~155750137:+ LIHC cis rs1065852 0.526 rs9611711 ENSG00000237037.8 NDUFA6-AS1 -4.98 1.03e-06 0.000374 -0.36 -0.26 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42014691 chr22:42090931~42137742:+ LIHC cis rs1062753 0.922 rs9611712 ENSG00000237037.8 NDUFA6-AS1 -4.98 1.03e-06 0.000374 -0.36 -0.26 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42014989 chr22:42090931~42137742:+ LIHC cis rs765787 0.53 rs12910270 ENSG00000259520.4 CTD-2651B20.3 -4.97 1.04e-06 0.000374 -0.3 -0.26 Uric acid levels; chr15:45219888 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs12915804 ENSG00000259520.4 CTD-2651B20.3 -4.97 1.04e-06 0.000374 -0.3 -0.26 Uric acid levels; chr15:45220364 chr15:45251580~45279251:- LIHC cis rs765787 0.556 rs12915965 ENSG00000259520.4 CTD-2651B20.3 -4.97 1.04e-06 0.000374 -0.3 -0.26 Uric acid levels; chr15:45220449 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs12440238 ENSG00000259520.4 CTD-2651B20.3 -4.97 1.04e-06 0.000374 -0.3 -0.26 Uric acid levels; chr15:45220707 chr15:45251580~45279251:- LIHC cis rs853679 0.527 rs707907 ENSG00000204709.4 LINC01556 4.97 1.04e-06 0.000374 0.29 0.26 Depression; chr6:28323463 chr6:28943877~28944537:+ LIHC cis rs11098499 1 rs10029750 ENSG00000245958.5 RP11-33B1.1 -4.97 1.04e-06 0.000374 -0.28 -0.26 Corneal astigmatism; chr4:119251388 chr4:119454791~119552025:+ LIHC cis rs7688540 0.771 rs5003261 ENSG00000275426.1 CH17-262A2.1 4.97 1.04e-06 0.000374 0.37 0.26 Facial morphology (factor 6, height of vermillion lower lip); chr4:213234 chr4:149738~150317:+ LIHC cis rs1061377 1 rs1982009 ENSG00000249685.1 RP11-360F5.3 4.97 1.04e-06 0.000374 0.31 0.26 Uric acid levels; chr4:39123253 chr4:39133913~39135608:+ LIHC cis rs1061377 0.965 rs1138494 ENSG00000249685.1 RP11-360F5.3 4.97 1.04e-06 0.000374 0.31 0.26 Uric acid levels; chr4:39123315 chr4:39133913~39135608:+ LIHC cis rs1061377 0.965 rs1046655 ENSG00000249685.1 RP11-360F5.3 4.97 1.04e-06 0.000374 0.31 0.26 Uric acid levels; chr4:39126127 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs7694760 ENSG00000249685.1 RP11-360F5.3 4.97 1.04e-06 0.000374 0.31 0.26 Uric acid levels; chr4:39126481 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs34771104 ENSG00000249685.1 RP11-360F5.3 4.97 1.04e-06 0.000374 0.31 0.26 Uric acid levels; chr4:39127432 chr4:39133913~39135608:+ LIHC cis rs1061377 0.965 rs11728058 ENSG00000249685.1 RP11-360F5.3 4.97 1.04e-06 0.000374 0.31 0.26 Uric acid levels; chr4:39128224 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs17508864 ENSG00000249685.1 RP11-360F5.3 4.97 1.04e-06 0.000374 0.31 0.26 Uric acid levels; chr4:39129025 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs1897136 ENSG00000249685.1 RP11-360F5.3 4.97 1.04e-06 0.000374 0.31 0.26 Uric acid levels; chr4:39131242 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs1897137 ENSG00000249685.1 RP11-360F5.3 4.97 1.04e-06 0.000374 0.31 0.26 Uric acid levels; chr4:39131387 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs7681116 ENSG00000249685.1 RP11-360F5.3 4.97 1.04e-06 0.000374 0.31 0.26 Uric acid levels; chr4:39133015 chr4:39133913~39135608:+ LIHC cis rs1061377 0.965 rs10018622 ENSG00000249685.1 RP11-360F5.3 4.97 1.04e-06 0.000374 0.31 0.26 Uric acid levels; chr4:39133944 chr4:39133913~39135608:+ LIHC cis rs4650994 0.544 rs2811314 ENSG00000273384.1 RP5-1098D14.1 -4.97 1.04e-06 0.000374 -0.32 -0.26 HDL cholesterol;HDL cholesterol levels; chr1:178650048 chr1:178651706~178652282:+ LIHC cis rs4356975 0.563 rs4535394 ENSG00000249956.3 RP11-790I12.2 -4.97 1.04e-06 0.000375 -0.29 -0.26 Obesity-related traits; chr4:69122735 chr4:69408836~69423164:+ LIHC cis rs10129255 0.536 rs3944157 ENSG00000223648.3 IGHV3-64 4.97 1.04e-06 0.000375 0.18 0.26 Kawasaki disease; chr14:106682286 chr14:106643132~106658258:- LIHC cis rs950776 0.518 rs1504545 ENSG00000261762.1 RP11-650L12.2 -4.97 1.04e-06 0.000375 -0.34 -0.26 Sudden cardiac arrest; chr15:78526129 chr15:78589123~78591276:- LIHC cis rs1223397 0.938 rs3817742 ENSG00000215022.6 RP1-257A7.4 -4.97 1.04e-06 0.000375 -0.31 -0.26 Blood pressure; chr6:13279320 chr6:13264861~13295586:- LIHC cis rs17301013 0.93 rs6425279 ENSG00000227373.4 RP11-160H22.5 -4.97 1.04e-06 0.000375 -0.31 -0.26 Systemic lupus erythematosus; chr1:174418717 chr1:174115300~174160004:- LIHC cis rs4356203 0.87 rs214919 ENSG00000272034.1 SNORD14A -4.97 1.04e-06 0.000376 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17217157 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs214916 ENSG00000272034.1 SNORD14A -4.97 1.04e-06 0.000376 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17220102 chr11:17074654~17074744:- LIHC cis rs875971 0.545 rs1796222 ENSG00000237310.1 GS1-124K5.4 -4.97 1.04e-06 0.000376 -0.24 -0.26 Aortic root size; chr7:66592167 chr7:66493706~66495474:+ LIHC cis rs17023223 0.581 rs12064109 ENSG00000231365.4 RP11-418J17.1 -4.97 1.04e-06 0.000376 -0.33 -0.26 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119099673 chr1:119140396~119275973:+ LIHC cis rs5756813 0.635 rs4820301 ENSG00000233360.4 Z83844.1 4.97 1.04e-06 0.000376 0.35 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37730357 chr22:37641832~37658377:- LIHC cis rs5756813 0.688 rs12484064 ENSG00000233360.4 Z83844.1 4.97 1.04e-06 0.000376 0.35 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37730739 chr22:37641832~37658377:- LIHC cis rs1005277 0.579 rs1780133 ENSG00000276805.1 RP11-291L22.6 4.97 1.04e-06 0.000376 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38210581 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs1780136 ENSG00000276805.1 RP11-291L22.6 4.97 1.04e-06 0.000376 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38212525 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs1780138 ENSG00000276805.1 RP11-291L22.6 4.97 1.04e-06 0.000376 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38212726 chr10:38451030~38451785:+ LIHC cis rs1005277 0.602 rs1780141 ENSG00000276805.1 RP11-291L22.6 4.97 1.04e-06 0.000376 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38215371 chr10:38451030~38451785:+ LIHC cis rs1005277 0.541 rs1740741 ENSG00000276805.1 RP11-291L22.6 4.97 1.04e-06 0.000376 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38226406 chr10:38451030~38451785:+ LIHC cis rs1005277 0.528 rs2057228 ENSG00000276805.1 RP11-291L22.6 4.97 1.04e-06 0.000376 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38226838 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs1740742 ENSG00000276805.1 RP11-291L22.6 4.97 1.04e-06 0.000376 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38229932 chr10:38451030~38451785:+ LIHC cis rs1005277 0.602 rs1740743 ENSG00000276805.1 RP11-291L22.6 4.97 1.04e-06 0.000376 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38230294 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs1740745 ENSG00000276805.1 RP11-291L22.6 4.97 1.04e-06 0.000376 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38231128 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs1740747 ENSG00000276805.1 RP11-291L22.6 4.97 1.04e-06 0.000376 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38231537 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs1740749 ENSG00000276805.1 RP11-291L22.6 4.97 1.04e-06 0.000376 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38232718 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs1780115 ENSG00000276805.1 RP11-291L22.6 4.97 1.04e-06 0.000376 0.32 0.26 Extrinsic epigenetic age acceleration; chr10:38235845 chr10:38451030~38451785:+ LIHC cis rs9903692 0.954 rs2109984 ENSG00000278765.1 RP5-890E16.5 4.97 1.04e-06 0.000376 0.35 0.26 Pulse pressure; chr17:48093737 chr17:48066704~48067293:- LIHC cis rs6479891 1 rs11817689 ENSG00000232075.1 MRPL35P2 -4.97 1.04e-06 0.000376 -0.3 -0.26 Arthritis (juvenile idiopathic); chr10:63164457 chr10:63634317~63634827:- LIHC cis rs9487094 0.626 rs10457192 ENSG00000260273.1 RP11-425D10.10 4.97 1.04e-06 0.000377 0.31 0.26 Height; chr6:109507271 chr6:109382795~109383666:+ LIHC cis rs2836974 0.623 rs7280326 ENSG00000255568.3 BRWD1-AS2 -4.97 1.04e-06 0.000377 -0.21 -0.26 Cognitive function; chr21:39328482 chr21:39313935~39314962:+ LIHC cis rs8059260 1 rs6498139 ENSG00000274038.1 RP11-66H6.4 -4.97 1.05e-06 0.000377 -0.39 -0.26 Alcohol consumption over the past year; chr16:10954066 chr16:11056556~11057034:+ LIHC cis rs8059260 1 rs7185978 ENSG00000274038.1 RP11-66H6.4 -4.97 1.05e-06 0.000377 -0.39 -0.26 Alcohol consumption over the past year; chr16:10954417 chr16:11056556~11057034:+ LIHC cis rs10510102 0.935 rs7921873 ENSG00000226864.1 ATE1-AS1 4.97 1.05e-06 0.000377 0.43 0.26 Breast cancer; chr10:121881736 chr10:121928312~121951965:+ LIHC cis rs10510102 0.935 rs10510101 ENSG00000276742.1 RP11-500G22.4 4.97 1.05e-06 0.000378 0.39 0.26 Breast cancer; chr10:121898614 chr10:121956782~121957098:+ LIHC cis rs4713118 0.662 rs9393881 ENSG00000219392.1 RP1-265C24.5 -4.97 1.05e-06 0.000378 -0.37 -0.26 Parkinson's disease; chr6:28055973 chr6:28115628~28116551:+ LIHC cis rs875971 0.545 rs6460276 ENSG00000273142.1 RP11-458F8.4 4.97 1.05e-06 0.000378 0.25 0.26 Aortic root size; chr7:66182290 chr7:66902857~66906297:+ LIHC cis rs30380 0.587 rs469674 ENSG00000272109.1 CTD-2260A17.3 -4.97 1.05e-06 0.000378 -0.33 -0.26 Cerebrospinal fluid biomarker levels; chr5:96794312 chr5:96804353~96806105:+ LIHC cis rs916888 0.773 rs199447 ENSG00000274883.1 Metazoa_SRP -4.97 1.05e-06 0.000378 -0.41 -0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45931806~45932083:+ LIHC cis rs6479891 1 rs4746149 ENSG00000232075.1 MRPL35P2 -4.97 1.05e-06 0.000378 -0.29 -0.26 Arthritis (juvenile idiopathic); chr10:63497633 chr10:63634317~63634827:- LIHC cis rs7208859 0.623 rs9898084 ENSG00000266490.1 CTD-2349P21.9 4.97 1.05e-06 0.000379 0.33 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30755316 chr17:30792372~30792833:+ LIHC cis rs11098499 0.955 rs13129661 ENSG00000245958.5 RP11-33B1.1 -4.97 1.05e-06 0.000379 -0.29 -0.26 Corneal astigmatism; chr4:119231754 chr4:119454791~119552025:+ LIHC cis rs227275 0.554 rs223466 ENSG00000230069.3 LRRC37A15P -4.97 1.05e-06 0.000379 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102780039 chr4:102727274~102730721:- LIHC cis rs12554020 0.579 rs78814851 ENSG00000227603.1 RP11-165J3.6 4.97 1.05e-06 0.000379 0.45 0.26 Schizophrenia; chr9:93590652 chr9:93435332~93437121:- LIHC cis rs9487094 0.67 rs6911700 ENSG00000260273.1 RP11-425D10.10 4.97 1.05e-06 0.000379 0.3 0.26 Height; chr6:109676091 chr6:109382795~109383666:+ LIHC cis rs7811142 0.83 rs10085549 ENSG00000242294.5 STAG3L5P 4.97 1.05e-06 0.00038 0.27 0.26 Platelet count; chr7:100385512 chr7:100336079~100351900:+ LIHC cis rs367615 0.552 rs3828603 ENSG00000249476.1 CTD-2587M2.1 -4.97 1.06e-06 0.00038 -0.3 -0.26 Colorectal cancer (SNP x SNP interaction); chr5:109376367 chr5:109237120~109326369:- LIHC cis rs2274273 0.805 rs11628437 ENSG00000258413.1 RP11-665C16.6 -4.97 1.06e-06 0.000381 -0.31 -0.26 Protein biomarker; chr14:55308750 chr14:55262767~55272075:- LIHC cis rs5758511 0.689 rs56906457 ENSG00000237037.8 NDUFA6-AS1 -4.97 1.06e-06 0.000381 -0.5 -0.26 Birth weight; chr22:42232329 chr22:42090931~42137742:+ LIHC cis rs875971 0.545 rs10261710 ENSG00000237310.1 GS1-124K5.4 4.97 1.06e-06 0.000381 0.25 0.26 Aortic root size; chr7:66249202 chr7:66493706~66495474:+ LIHC cis rs1061377 0.513 rs2712000 ENSG00000249207.1 RP11-360F5.1 -4.97 1.06e-06 0.000381 -0.33 -0.26 Uric acid levels; chr4:39135462 chr4:39112677~39126818:- LIHC cis rs1577917 0.958 rs12192546 ENSG00000234155.1 RP11-30P6.6 -4.97 1.06e-06 0.000381 -0.35 -0.26 Response to antipsychotic treatment; chr6:85766766 chr6:85387219~85390186:- LIHC cis rs860295 1 rs822478 ENSG00000203761.5 MSTO2P 4.97 1.06e-06 0.000382 0.21 0.26 Body mass index; chr1:155824178 chr1:155745829~155750137:+ LIHC cis rs2842992 0.789 rs4709376 ENSG00000237927.1 RP3-393E18.2 -4.97 1.06e-06 0.000382 -0.32 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159805305 chr6:159586955~159589169:- LIHC cis rs6600671 1 rs11249350 ENSG00000231429.2 RP11-343N15.2 -4.97 1.06e-06 0.000383 -0.3 -0.26 Hip geometry; chr1:121436587 chr1:121412719~121429274:+ LIHC cis rs7587476 0.862 rs13001462 ENSG00000229267.2 AC072062.1 -4.97 1.06e-06 0.000383 -0.33 -0.26 Neuroblastoma; chr2:214813622 chr2:214810229~214963274:+ LIHC cis rs7714584 1 rs3900064 ENSG00000197083.10 ZNF300P1 -4.97 1.06e-06 0.000383 -0.38 -0.26 Crohn's disease; chr5:150884852 chr5:150930645~150946289:- LIHC cis rs9291683 0.588 rs13121211 ENSG00000250413.1 RP11-448G15.1 -4.97 1.06e-06 0.000383 -0.33 -0.26 Bone mineral density; chr4:9997915 chr4:10006482~10009725:+ LIHC cis rs7587476 0.822 rs13018304 ENSG00000229267.2 AC072062.1 -4.97 1.07e-06 0.000383 -0.33 -0.26 Neuroblastoma; chr2:214817494 chr2:214810229~214963274:+ LIHC cis rs13392177 0.684 rs11682371 ENSG00000261338.2 RP11-378A13.1 -4.97 1.07e-06 0.000383 -0.27 -0.26 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218214790 chr2:218255319~218257366:+ LIHC cis rs13392177 0.684 rs6720105 ENSG00000261338.2 RP11-378A13.1 -4.97 1.07e-06 0.000383 -0.27 -0.26 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218215995 chr2:218255319~218257366:+ LIHC cis rs67311347 1 rs7625736 ENSG00000223797.4 ENTPD3-AS1 -4.97 1.07e-06 0.000383 -0.21 -0.26 Renal cell carcinoma; chr3:40399854 chr3:40313802~40453329:- LIHC cis rs16858210 0.647 rs12107414 ENSG00000234371.6 RPSAP31 4.97 1.07e-06 0.000383 0.35 0.26 Menopause (age at onset); chr3:183856760 chr3:183884924~183888449:+ LIHC cis rs2274273 0.84 rs72715769 ENSG00000258413.1 RP11-665C16.6 -4.97 1.07e-06 0.000383 -0.31 -0.26 Protein biomarker; chr14:55295711 chr14:55262767~55272075:- LIHC cis rs2274273 0.87 rs66696758 ENSG00000258413.1 RP11-665C16.6 -4.97 1.07e-06 0.000383 -0.31 -0.26 Protein biomarker; chr14:55299791 chr14:55262767~55272075:- LIHC cis rs12468226 0.938 rs10931993 ENSG00000273456.1 RP11-686O6.2 4.97 1.07e-06 0.000383 0.37 0.26 Urate levels; chr2:202243017 chr2:202374932~202375604:- LIHC cis rs227275 0.525 rs1383733 ENSG00000230069.3 LRRC37A15P -4.97 1.07e-06 0.000384 -0.24 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102995297 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223463 ENSG00000230069.3 LRRC37A15P -4.97 1.07e-06 0.000384 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780620 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs223462 ENSG00000230069.3 LRRC37A15P -4.97 1.07e-06 0.000384 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102780661 chr4:102727274~102730721:- LIHC cis rs12468226 0.817 rs2350360 ENSG00000273456.1 RP11-686O6.2 -4.97 1.07e-06 0.000385 -0.37 -0.26 Urate levels; chr2:202222980 chr2:202374932~202375604:- LIHC cis rs6600671 1 rs2185281 ENSG00000231429.2 RP11-343N15.2 -4.97 1.07e-06 0.000385 -0.3 -0.26 Hip geometry; chr1:121438132 chr1:121412719~121429274:+ LIHC cis rs5769707 0.521 rs739244 ENSG00000235111.1 RP1-29C18.8 -4.97 1.07e-06 0.000385 -0.31 -0.26 Monocyte percentage of white cells;Monocyte count; chr22:49666510 chr22:49612657~49615716:- LIHC cis rs8059260 0.542 rs7184915 ENSG00000274038.1 RP11-66H6.4 -4.97 1.07e-06 0.000385 -0.44 -0.26 Alcohol consumption over the past year; chr16:11034509 chr16:11056556~11057034:+ LIHC cis rs1062753 0.961 rs9620007 ENSG00000237037.8 NDUFA6-AS1 -4.97 1.07e-06 0.000385 -0.35 -0.26 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42009653 chr22:42090931~42137742:+ LIHC cis rs9487094 0.67 rs34928881 ENSG00000260273.1 RP11-425D10.10 4.97 1.07e-06 0.000385 0.31 0.26 Height; chr6:109526846 chr6:109382795~109383666:+ LIHC cis rs2442825 0.54 rs35728233 ENSG00000206573.7 THUMPD3-AS1 -4.97 1.07e-06 0.000385 -0.31 -0.26 Cerebrospinal fluid clusterin levels; chr3:9387510 chr3:9349689~9398579:- LIHC cis rs2998286 0.723 rs332146 ENSG00000254635.4 WAC-AS1 -4.97 1.07e-06 0.000385 -0.33 -0.26 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28580255 chr10:28522652~28532743:- LIHC cis rs1023500 0.505 rs134888 ENSG00000227370.1 RP4-669P10.19 -4.97 1.07e-06 0.000386 -0.27 -0.26 Schizophrenia; chr22:42278275 chr22:42132543~42132998:+ LIHC cis rs4356203 0.87 rs7925692 ENSG00000272034.1 SNORD14A 4.97 1.07e-06 0.000386 0.28 0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17249575 chr11:17074654~17074744:- LIHC cis rs6921919 0.609 rs1005127 ENSG00000204709.4 LINC01556 4.97 1.08e-06 0.000387 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28399881 chr6:28943877~28944537:+ LIHC cis rs853679 0.515 rs4580862 ENSG00000204709.4 LINC01556 4.97 1.08e-06 0.000387 0.32 0.26 Depression; chr6:28399886 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs4357130 ENSG00000204709.4 LINC01556 4.97 1.08e-06 0.000387 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28399906 chr6:28943877~28944537:+ LIHC cis rs9487605 1 rs9487605 ENSG00000271789.1 RP5-1112D6.7 -4.97 1.08e-06 0.000387 -0.26 -0.26 Inflammatory skin disease; chr6:111261682 chr6:111297126~111298510:+ LIHC cis rs8005677 1 rs1956881 ENSG00000257285.4 RP11-298I3.1 4.97 1.08e-06 0.000387 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22924860 chr14:22929609~22955562:+ LIHC cis rs950169 0.922 rs11630760 ENSG00000259728.4 LINC00933 4.97 1.08e-06 0.000387 0.38 0.26 Schizophrenia; chr15:84570106 chr15:84570649~84580175:+ LIHC cis rs950169 0.887 rs71395453 ENSG00000259728.4 LINC00933 4.97 1.08e-06 0.000387 0.38 0.26 Schizophrenia; chr15:84570259 chr15:84570649~84580175:+ LIHC cis rs2243480 0.522 rs1638736 ENSG00000226824.5 RP4-756H11.3 -4.97 1.08e-06 0.000388 -0.46 -0.26 Diabetic kidney disease; chr7:66627321 chr7:66654538~66669855:+ LIHC cis rs7412746 0.658 rs6677420 ENSG00000231073.1 RP11-316M1.3 4.97 1.08e-06 0.000388 0.26 0.26 Melanoma; chr1:150974014 chr1:150973123~150975534:+ LIHC cis rs10510102 0.935 rs11200237 ENSG00000276742.1 RP11-500G22.4 4.97 1.08e-06 0.000388 0.39 0.26 Breast cancer; chr10:121900715 chr10:121956782~121957098:+ LIHC cis rs10510102 0.935 rs78525391 ENSG00000276742.1 RP11-500G22.4 4.97 1.08e-06 0.000388 0.39 0.26 Breast cancer; chr10:121901102 chr10:121956782~121957098:+ LIHC cis rs9425766 0.692 rs4652294 ENSG00000227373.4 RP11-160H22.5 4.97 1.08e-06 0.000388 0.32 0.26 Life satisfaction; chr1:174272027 chr1:174115300~174160004:- LIHC cis rs1065852 0.526 rs12166549 ENSG00000237037.8 NDUFA6-AS1 -4.97 1.08e-06 0.000388 -0.35 -0.26 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42014415 chr22:42090931~42137742:+ LIHC cis rs3823536 0.5 rs4728144 ENSG00000275106.1 RP11-309L24.10 -4.97 1.08e-06 0.000388 -0.31 -0.26 Sjögren's syndrome; chr7:129000280 chr7:128952527~128953316:- LIHC cis rs2739330 0.627 rs9608219 ENSG00000206090.4 AP000350.7 4.97 1.08e-06 0.000389 0.3 0.26 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23939998~23942798:+ LIHC cis rs2274273 0.805 rs7159808 ENSG00000258413.1 RP11-665C16.6 -4.97 1.08e-06 0.000389 -0.29 -0.26 Protein biomarker; chr14:55157609 chr14:55262767~55272075:- LIHC cis rs597539 0.616 rs72945243 ENSG00000250508.1 RP11-757G1.6 -4.97 1.08e-06 0.000389 -0.38 -0.26 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68865890 chr11:68870664~68874542:+ LIHC cis rs3096299 0.967 rs2965827 ENSG00000261118.1 RP11-104N10.1 -4.97 1.08e-06 0.000389 -0.26 -0.26 Multiple myeloma (IgH translocation); chr16:89390942 chr16:89492017~89504460:- LIHC cis rs7714584 1 rs59321715 ENSG00000197083.10 ZNF300P1 4.97 1.08e-06 0.000389 0.42 0.26 Crohn's disease; chr5:150933918 chr5:150930645~150946289:- LIHC cis rs1577917 0.917 rs12202170 ENSG00000234155.1 RP11-30P6.6 4.97 1.09e-06 0.00039 0.34 0.26 Response to antipsychotic treatment; chr6:85880668 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs10455449 ENSG00000234155.1 RP11-30P6.6 4.97 1.09e-06 0.00039 0.34 0.26 Response to antipsychotic treatment; chr6:85882508 chr6:85387219~85390186:- LIHC cis rs1115240 0.502 rs10138374 ENSG00000257842.4 NOVA1-AS1 -4.97 1.09e-06 0.00039 -0.27 -0.26 Educational attainment (years of education); chr14:26696367 chr14:26598412~26806467:+ LIHC cis rs875971 0.508 rs10258739 ENSG00000237310.1 GS1-124K5.4 -4.96 1.09e-06 0.00039 -0.23 -0.26 Aortic root size; chr7:66597948 chr7:66493706~66495474:+ LIHC cis rs7809950 1 rs4727684 ENSG00000238832.1 snoU109 -4.96 1.09e-06 0.00039 -0.3 -0.26 Coronary artery disease; chr7:107586025 chr7:107603363~107603507:+ LIHC cis rs6085948 0.861 rs17394617 ENSG00000228888.1 LINC01428 -4.96 1.09e-06 0.000391 -0.49 -0.26 Interleukin-10 levels; chr20:7249043 chr20:7146467~7254202:- LIHC cis rs10129255 0.5 rs6576225 ENSG00000223648.3 IGHV3-64 4.96 1.09e-06 0.000391 0.18 0.26 Kawasaki disease; chr14:106778120 chr14:106643132~106658258:- LIHC cis rs10129255 0.5 rs6576226 ENSG00000223648.3 IGHV3-64 4.96 1.09e-06 0.000391 0.18 0.26 Kawasaki disease; chr14:106778135 chr14:106643132~106658258:- LIHC cis rs752590 0.806 rs4849174 ENSG00000274877.1 RP11-65I12.1 -4.96 1.09e-06 0.000391 -0.34 -0.26 Mucinous ovarian carcinoma; chr2:113215890 chr2:113237595~113240825:+ LIHC cis rs2032366 0.606 rs1452597 ENSG00000267279.1 RP11-879F14.2 -4.96 1.09e-06 0.000392 -0.31 -0.26 Obesity-related traits; chr18:61590985 chr18:61585746~61606916:- LIHC cis rs9322193 0.607 rs10457852 ENSG00000223701.3 RAET1E-AS1 4.96 1.09e-06 0.000392 0.33 0.26 Lung cancer; chr6:149880584 chr6:149884431~149919508:+ LIHC cis rs9532669 0.926 rs9532657 ENSG00000168852.11 TPTE2P5 -4.96 1.09e-06 0.000392 -0.28 -0.26 Cervical cancer; chr13:40918208 chr13:40822296~40921749:- LIHC cis rs1577917 1 rs12201571 ENSG00000234155.1 RP11-30P6.6 4.96 1.09e-06 0.000392 0.34 0.26 Response to antipsychotic treatment; chr6:85900032 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs11759855 ENSG00000234155.1 RP11-30P6.6 4.96 1.09e-06 0.000392 0.34 0.26 Response to antipsychotic treatment; chr6:85901123 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs1857964 ENSG00000234155.1 RP11-30P6.6 4.96 1.09e-06 0.000392 0.34 0.26 Response to antipsychotic treatment; chr6:85926276 chr6:85387219~85390186:- LIHC cis rs1577917 0.798 rs7772384 ENSG00000234155.1 RP11-30P6.6 4.96 1.09e-06 0.000392 0.34 0.26 Response to antipsychotic treatment; chr6:85929962 chr6:85387219~85390186:- LIHC cis rs950776 0.593 rs555018 ENSG00000261762.1 RP11-650L12.2 -4.96 1.09e-06 0.000392 -0.34 -0.26 Sudden cardiac arrest; chr15:78586900 chr15:78589123~78591276:- LIHC cis rs7208859 0.673 rs216435 ENSG00000266490.1 CTD-2349P21.9 4.96 1.09e-06 0.000392 0.31 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595719 chr17:30792372~30792833:+ LIHC cis rs801193 0.839 rs12534943 ENSG00000237310.1 GS1-124K5.4 -4.96 1.1e-06 0.000392 -0.23 -0.26 Aortic root size; chr7:66605533 chr7:66493706~66495474:+ LIHC cis rs6085948 0.817 rs17394645 ENSG00000228888.1 LINC01428 -4.96 1.1e-06 0.000393 -0.49 -0.26 Interleukin-10 levels; chr20:7250193 chr20:7146467~7254202:- LIHC cis rs3096299 0.935 rs3114890 ENSG00000261118.1 RP11-104N10.1 4.96 1.1e-06 0.000393 0.27 0.26 Multiple myeloma (IgH translocation); chr16:89383138 chr16:89492017~89504460:- LIHC cis rs8005677 1 rs7145494 ENSG00000257285.4 RP11-298I3.1 4.96 1.1e-06 0.000393 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22930581 chr14:22929609~22955562:+ LIHC cis rs8005677 1 rs7155857 ENSG00000257285.4 RP11-298I3.1 4.96 1.1e-06 0.000393 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22930850 chr14:22929609~22955562:+ LIHC cis rs116175783 0.557 rs62188123 ENSG00000227403.1 AC009299.3 4.96 1.1e-06 0.000393 0.4 0.26 Intelligence (multi-trait analysis); chr2:161385335 chr2:161244739~161249050:+ LIHC cis rs9500256 0.967 rs4928431 ENSG00000272541.1 XXbac-BPGBPG55C20.1 4.96 1.1e-06 0.000394 0.28 0.26 Eosinophilic esophagitis (pediatric); chr6:57979980 chr6:57855891~57856468:- LIHC cis rs901683 0.702 rs4418752 ENSG00000230869.1 CTGLF10P -4.96 1.1e-06 0.000394 -0.53 -0.26 Mean corpuscular volume;Red blood cell traits; chr10:45607523 chr10:45678692~45700532:+ LIHC cis rs5769765 0.913 rs8135071 ENSG00000278869.1 CITF22-49E9.3 4.96 1.1e-06 0.000394 0.38 0.26 Schizophrenia; chr22:49905939 chr22:49933198~49934074:- LIHC cis rs5756813 0.727 rs58765732 ENSG00000233360.4 Z83844.1 4.96 1.1e-06 0.000394 0.33 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37764787 chr22:37641832~37658377:- LIHC cis rs2439831 1 rs28666488 ENSG00000205771.5 CATSPER2P1 -4.96 1.1e-06 0.000394 -0.35 -0.26 Lung cancer in ever smokers; chr15:43448892 chr15:43726918~43747094:- LIHC cis rs7246657 0.943 rs8106839 ENSG00000276846.1 CTD-3220F14.3 4.96 1.1e-06 0.000394 0.34 0.26 Coronary artery calcification; chr19:37467573 chr19:37314868~37315620:- LIHC cis rs10833905 0.756 rs3866928 ENSG00000246225.5 RP11-17A1.3 -4.96 1.1e-06 0.000395 -0.34 -0.26 Sudden cardiac arrest; chr11:22981094 chr11:22829380~22945393:+ LIHC cis rs4650994 0.525 rs10913574 ENSG00000273384.1 RP5-1098D14.1 4.96 1.1e-06 0.000395 0.33 0.26 HDL cholesterol;HDL cholesterol levels; chr1:178567347 chr1:178651706~178652282:+ LIHC cis rs860295 1 rs708611 ENSG00000203761.5 MSTO2P 4.96 1.1e-06 0.000395 0.2 0.26 Body mass index; chr1:155773519 chr1:155745829~155750137:+ LIHC cis rs860295 1 rs7541060 ENSG00000203761.5 MSTO2P -4.96 1.1e-06 0.000395 -0.2 -0.26 Body mass index; chr1:155758297 chr1:155745829~155750137:+ LIHC cis rs875971 0.545 rs2460427 ENSG00000226824.5 RP4-756H11.3 4.96 1.1e-06 0.000395 0.33 0.26 Aortic root size; chr7:66154218 chr7:66654538~66669855:+ LIHC cis rs10912872 0.531 rs12407579 ENSG00000225704.2 RP4-798A17.5 4.96 1.11e-06 0.000396 0.23 0.26 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr1:171371553 chr1:171345089~171345320:+ LIHC cis rs3096299 1 rs3096299 ENSG00000261118.1 RP11-104N10.1 4.96 1.11e-06 0.000396 0.27 0.26 Multiple myeloma (IgH translocation); chr16:89382255 chr16:89492017~89504460:- LIHC cis rs950776 0.518 rs12914694 ENSG00000261762.1 RP11-650L12.2 4.96 1.11e-06 0.000396 0.34 0.26 Sudden cardiac arrest; chr15:78522102 chr15:78589123~78591276:- LIHC cis rs4266144 0.563 rs61124401 ENSG00000244515.1 KRT18P34 -4.96 1.11e-06 0.000397 -0.28 -0.26 Coronary artery disease; chr3:157123130 chr3:157162663~157163932:- LIHC cis rs6921919 0.583 rs4254981 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28403625 chr6:28943877~28944537:+ LIHC cis rs6921919 0.525 rs6929825 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28411182 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs35599905 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28411886 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs1124131 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28412471 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs6899389 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28413363 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs6922374 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28413495 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs6899603 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28413528 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs6922429 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28413568 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs6922169 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28415155 chr6:28943877~28944537:+ LIHC cis rs6921919 0.559 rs13210866 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28416065 chr6:28943877~28944537:+ LIHC cis rs6921919 0.609 rs36018474 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28417752 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs13201726 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28417774 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs2027361 ENSG00000204709.4 LINC01556 4.96 1.11e-06 0.000397 0.32 0.26 Autism spectrum disorder or schizophrenia; chr6:28420531 chr6:28943877~28944537:+ LIHC cis rs11098499 0.863 rs3822192 ENSG00000245958.5 RP11-33B1.1 -4.96 1.11e-06 0.000397 -0.28 -0.26 Corneal astigmatism; chr4:119524565 chr4:119454791~119552025:+ LIHC cis rs2929278 0.617 rs4617832 ENSG00000166763.7 STRCP1 -4.96 1.11e-06 0.000397 -0.34 -0.26 Schizophrenia; chr15:43738381 chr15:43699488~43718184:- LIHC cis rs30380 0.632 rs30186 ENSG00000272109.1 CTD-2260A17.3 -4.96 1.11e-06 0.000398 -0.33 -0.26 Cerebrospinal fluid biomarker levels; chr5:96788744 chr5:96804353~96806105:+ LIHC cis rs27434 0.821 rs28337 ENSG00000272109.1 CTD-2260A17.3 -4.96 1.11e-06 0.000398 -0.33 -0.26 Ankylosing spondylitis; chr5:96789611 chr5:96804353~96806105:+ LIHC cis rs30380 0.587 rs30185 ENSG00000272109.1 CTD-2260A17.3 -4.96 1.11e-06 0.000398 -0.33 -0.26 Cerebrospinal fluid biomarker levels; chr5:96789762 chr5:96804353~96806105:+ LIHC cis rs12478296 0.901 rs59477854 ENSG00000261186.2 RP11-341N2.1 -4.96 1.11e-06 0.000398 -0.35 -0.26 Obesity-related traits; chr2:242073339 chr2:242087351~242088457:- LIHC cis rs2877649 1 rs12323581 ENSG00000258744.1 RP11-80A15.1 -4.96 1.11e-06 0.000398 -0.51 -0.26 Smooth-surface caries; chr14:24475358 chr14:24501594~24508688:+ LIHC cis rs7119038 0.818 rs10892280 ENSG00000255239.1 AP002954.6 -4.96 1.11e-06 0.000398 -0.37 -0.26 Sjögren's syndrome; chr11:118741108 chr11:118688039~118690600:- LIHC cis rs875971 0.545 rs73142233 ENSG00000226824.5 RP4-756H11.3 -4.96 1.12e-06 0.000399 -0.33 -0.26 Aortic root size; chr7:66221293 chr7:66654538~66669855:+ LIHC cis rs1061377 1 rs7685082 ENSG00000249685.1 RP11-360F5.3 4.96 1.12e-06 0.000399 0.31 0.26 Uric acid levels; chr4:39116472 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs9998481 ENSG00000249685.1 RP11-360F5.3 4.96 1.12e-06 0.000399 0.31 0.26 Uric acid levels; chr4:39117215 chr4:39133913~39135608:+ LIHC cis rs2337406 0.789 rs60000589 ENSG00000274576.2 IGHV2-70 -4.96 1.12e-06 0.000399 -0.26 -0.26 Alzheimer's disease (late onset); chr14:106782459 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs111881598 ENSG00000274576.2 IGHV2-70 -4.96 1.12e-06 0.000399 -0.26 -0.26 Alzheimer's disease (late onset); chr14:106783113 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs61164979 ENSG00000274576.2 IGHV2-70 -4.96 1.12e-06 0.000399 -0.26 -0.26 Alzheimer's disease (late onset); chr14:106783133 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs61419485 ENSG00000274576.2 IGHV2-70 -4.96 1.12e-06 0.000399 -0.26 -0.26 Alzheimer's disease (late onset); chr14:106783374 chr14:106770577~106771020:- LIHC cis rs4660456 0.504 rs491619 ENSG00000237899.1 RP4-739H11.3 4.96 1.12e-06 4e-04 0.34 0.26 Platelet count; chr1:40641688 chr1:40669089~40687588:- LIHC cis rs7923609 0.936 rs10761779 ENSG00000232075.1 MRPL35P2 -4.96 1.12e-06 4e-04 -0.28 -0.26 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63515167 chr10:63634317~63634827:- LIHC cis rs11722779 0.935 rs7681629 ENSG00000246560.2 RP11-10L12.4 4.96 1.12e-06 4e-04 0.29 0.26 Schizophrenia; chr4:102974407 chr4:102828055~102844075:+ LIHC cis rs11722779 0.844 rs17033381 ENSG00000246560.2 RP11-10L12.4 4.96 1.12e-06 4e-04 0.29 0.26 Schizophrenia; chr4:102974952 chr4:102828055~102844075:+ LIHC cis rs227275 0.556 rs4699044 ENSG00000246560.2 RP11-10L12.4 4.96 1.12e-06 4e-04 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102976939 chr4:102828055~102844075:+ LIHC cis rs227275 0.556 rs4699045 ENSG00000246560.2 RP11-10L12.4 4.96 1.12e-06 4e-04 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102977009 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs3974604 ENSG00000230069.3 LRRC37A15P -4.96 1.12e-06 4e-04 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102928601 chr4:102727274~102730721:- LIHC cis rs5756813 0.754 rs34848977 ENSG00000233360.4 Z83844.1 4.96 1.12e-06 4e-04 0.34 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37769580 chr22:37641832~37658377:- LIHC cis rs4356203 0.783 rs7113964 ENSG00000272034.1 SNORD14A -4.96 1.12e-06 4e-04 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17234374 chr11:17074654~17074744:- LIHC cis rs4356203 0.87 rs11024208 ENSG00000272034.1 SNORD14A -4.96 1.12e-06 4e-04 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17238432 chr11:17074654~17074744:- LIHC cis rs4356203 0.678 rs1125737 ENSG00000272034.1 SNORD14A -4.96 1.12e-06 4e-04 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17242386 chr11:17074654~17074744:- LIHC cis rs4731207 0.596 rs7795199 ENSG00000224897.5 POT1-AS1 4.96 1.12e-06 0.000401 0.31 0.26 Cutaneous malignant melanoma; chr7:124938291 chr7:124929873~125179315:+ LIHC cis rs4731207 0.596 rs7795218 ENSG00000224897.5 POT1-AS1 4.96 1.12e-06 0.000401 0.31 0.26 Cutaneous malignant melanoma; chr7:124938326 chr7:124929873~125179315:+ LIHC cis rs9322193 0.566 rs3922947 ENSG00000268592.3 RAET1E-AS1 -4.96 1.12e-06 0.000401 -0.36 -0.26 Lung cancer; chr6:149924856 chr6:149863494~149919507:+ LIHC cis rs8031584 1 rs35239376 ENSG00000270015.1 RP11-540B6.6 -4.96 1.12e-06 0.000401 -0.35 -0.26 Huntington's disease progression; chr15:30998335 chr15:30926514~30928407:+ LIHC cis rs950776 0.714 rs615470 ENSG00000261762.1 RP11-650L12.2 -4.96 1.12e-06 0.000401 -0.32 -0.26 Sudden cardiac arrest; chr15:78593646 chr15:78589123~78591276:- LIHC cis rs11098499 0.863 rs1383532 ENSG00000245958.5 RP11-33B1.1 4.96 1.13e-06 0.000401 0.27 0.26 Corneal astigmatism; chr4:119513249 chr4:119454791~119552025:+ LIHC cis rs9291683 0.588 rs17246745 ENSG00000250413.1 RP11-448G15.1 -4.96 1.13e-06 0.000402 -0.33 -0.26 Bone mineral density; chr4:9992959 chr4:10006482~10009725:+ LIHC cis rs765787 0.505 rs4439707 ENSG00000259520.4 CTD-2651B20.3 -4.96 1.13e-06 0.000402 -0.3 -0.26 Uric acid levels; chr15:45232018 chr15:45251580~45279251:- LIHC cis rs2439831 0.867 rs3101443 ENSG00000275601.1 AC011330.13 -4.96 1.13e-06 0.000402 -0.39 -0.26 Lung cancer in ever smokers; chr15:43620174 chr15:43642389~43643023:- LIHC cis rs7674212 0.865 rs1481279 ENSG00000230069.3 LRRC37A15P 4.96 1.13e-06 0.000403 0.24 0.26 Type 2 diabetes; chr4:103056781 chr4:102727274~102730721:- LIHC cis rs9494142 0.592 rs1547247 ENSG00000232876.1 CTA-212D2.2 -4.96 1.13e-06 0.000403 -0.33 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts; chr6:135069698 chr6:135055033~135060550:+ LIHC cis rs9903692 0.909 rs1468270 ENSG00000278765.1 RP5-890E16.5 4.96 1.13e-06 0.000403 0.34 0.26 Pulse pressure; chr17:48047829 chr17:48066704~48067293:- LIHC cis rs10256972 0.521 rs871019 ENSG00000199023.2 MIR339 -4.96 1.13e-06 0.000403 -0.3 -0.26 Endometriosis;Longevity; chr7:1065594 chr7:1022935~1023045:- LIHC cis rs4698412 0.531 rs6852450 ENSG00000214846.4 RP11-115L11.1 -4.96 1.13e-06 0.000404 -0.32 -0.26 Parkinson's disease; chr4:15741363 chr4:15730962~15731627:- LIHC cis rs2836974 0.644 rs4818017 ENSG00000255568.3 BRWD1-AS2 -4.96 1.13e-06 0.000404 -0.21 -0.26 Cognitive function; chr21:39318635 chr21:39313935~39314962:+ LIHC cis rs875971 0.545 rs67775320 ENSG00000273142.1 RP11-458F8.4 4.96 1.13e-06 0.000404 0.25 0.26 Aortic root size; chr7:66193792 chr7:66902857~66906297:+ LIHC cis rs712039 0.687 rs11656455 ENSG00000276054.1 RP11-378E13.3 4.96 1.13e-06 0.000404 0.33 0.26 Tuberculosis; chr17:37411798 chr17:37386886~37387926:+ LIHC cis rs1577917 1 rs13194429 ENSG00000234155.1 RP11-30P6.6 4.96 1.14e-06 0.000405 0.34 0.26 Response to antipsychotic treatment; chr6:85936987 chr6:85387219~85390186:- LIHC cis rs7714584 1 rs1000113 ENSG00000197083.10 ZNF300P1 4.96 1.14e-06 0.000405 0.41 0.26 Crohn's disease; chr5:150860514 chr5:150930645~150946289:- LIHC cis rs3096299 0.933 rs28608022 ENSG00000261118.1 RP11-104N10.1 4.96 1.14e-06 0.000405 0.26 0.26 Multiple myeloma (IgH translocation); chr16:89387884 chr16:89492017~89504460:- LIHC cis rs12468226 0.679 rs6435133 ENSG00000273456.1 RP11-686O6.2 -4.96 1.14e-06 0.000405 -0.37 -0.26 Urate levels; chr2:202209237 chr2:202374932~202375604:- LIHC cis rs2032447 0.714 rs2051540 ENSG00000242387.1 HIST1H2APS2 4.96 1.14e-06 0.000405 0.33 0.26 Intelligence (multi-trait analysis); chr6:25946969 chr6:25882026~25882395:- LIHC cis rs4356203 0.87 rs12286505 ENSG00000272034.1 SNORD14A 4.96 1.14e-06 0.000405 0.28 0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17142178 chr11:17074654~17074744:- LIHC cis rs755249 0.51 rs582883 ENSG00000182109.6 RP11-69E11.4 4.96 1.14e-06 0.000405 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39369868 chr1:39522280~39546187:- LIHC cis rs6828577 1 rs6854328 ENSG00000269893.5 SNHG8 4.96 1.14e-06 0.000405 0.28 0.26 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118762337 chr4:118278709~118279823:+ LIHC cis rs13392177 0.66 rs62185964 ENSG00000261338.2 RP11-378A13.1 -4.96 1.14e-06 0.000405 -0.27 -0.26 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218209022 chr2:218255319~218257366:+ LIHC cis rs13392177 0.684 rs62185965 ENSG00000261338.2 RP11-378A13.1 -4.96 1.14e-06 0.000405 -0.27 -0.26 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218209056 chr2:218255319~218257366:+ LIHC cis rs13392177 0.66 rs10932762 ENSG00000261338.2 RP11-378A13.1 -4.96 1.14e-06 0.000405 -0.27 -0.26 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218211490 chr2:218255319~218257366:+ LIHC cis rs5769765 0.908 rs9627788 ENSG00000278869.1 CITF22-49E9.3 4.96 1.14e-06 0.000406 0.38 0.26 Schizophrenia; chr22:49906790 chr22:49933198~49934074:- LIHC cis rs12478296 0.685 rs35577962 ENSG00000261186.2 RP11-341N2.1 -4.95 1.14e-06 0.000406 -0.35 -0.26 Obesity-related traits; chr2:242051424 chr2:242087351~242088457:- LIHC cis rs11089937 0.626 rs9622968 ENSG00000211639.2 IGLV4-60 4.95 1.14e-06 0.000406 0.23 0.26 Periodontitis (PAL4Q3); chr22:22144916 chr22:22162199~22162681:+ LIHC cis rs916888 0.821 rs70600 ENSG00000274883.1 Metazoa_SRP -4.95 1.14e-06 0.000407 -0.41 -0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45931806~45932083:+ LIHC cis rs228614 0.536 rs223420 ENSG00000246560.2 RP11-10L12.4 4.95 1.14e-06 0.000407 0.29 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102806853 chr4:102828055~102844075:+ LIHC cis rs10829156 0.66 rs7910506 ENSG00000225527.1 RP11-383B4.4 4.95 1.14e-06 0.000407 0.42 0.26 Sudden cardiac arrest; chr10:18518128 chr10:18531849~18533336:- LIHC cis rs712039 0.652 rs17137970 ENSG00000276054.1 RP11-378E13.3 4.95 1.14e-06 0.000408 0.32 0.26 Tuberculosis; chr17:37411739 chr17:37386886~37387926:+ LIHC cis rs7734985 0.686 rs6865159 ENSG00000250551.1 RP11-254I22.1 -4.95 1.15e-06 0.000408 -0.33 -0.26 IgG glycosylation; chr5:96112290 chr5:96050115~96215519:+ LIHC cis rs12468226 0.938 rs4675274 ENSG00000273456.1 RP11-686O6.2 -4.95 1.15e-06 0.000408 -0.37 -0.26 Urate levels; chr2:202243145 chr2:202374932~202375604:- LIHC cis rs1714507 0.533 rs2731118 ENSG00000272087.1 RP11-379F4.7 -4.95 1.15e-06 0.000408 -0.29 -0.26 Subjective well-being; chr3:158589942 chr3:158693120~158693768:- LIHC cis rs1714507 0.533 rs2573179 ENSG00000272087.1 RP11-379F4.7 -4.95 1.15e-06 0.000408 -0.29 -0.26 Subjective well-being; chr3:158590018 chr3:158693120~158693768:- LIHC cis rs9903692 0.954 rs7217496 ENSG00000278765.1 RP5-890E16.5 4.95 1.15e-06 0.000408 0.34 0.26 Pulse pressure; chr17:48076840 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs8065670 ENSG00000278765.1 RP5-890E16.5 -4.95 1.15e-06 0.000408 -0.34 -0.26 Pulse pressure; chr17:48096478 chr17:48066704~48067293:- LIHC cis rs9903692 0.866 rs11079807 ENSG00000278765.1 RP5-890E16.5 -4.95 1.15e-06 0.000408 -0.34 -0.26 Pulse pressure; chr17:48098685 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs10853094 ENSG00000278765.1 RP5-890E16.5 -4.95 1.15e-06 0.000408 -0.34 -0.26 Pulse pressure; chr17:48098700 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs4794441 ENSG00000278765.1 RP5-890E16.5 -4.95 1.15e-06 0.000408 -0.34 -0.26 Pulse pressure; chr17:48099094 chr17:48066704~48067293:- LIHC cis rs9903692 0.908 rs12950402 ENSG00000278765.1 RP5-890E16.5 -4.95 1.15e-06 0.000408 -0.34 -0.26 Pulse pressure; chr17:48102752 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs11079808 ENSG00000278765.1 RP5-890E16.5 -4.95 1.15e-06 0.000408 -0.34 -0.26 Pulse pressure; chr17:48102870 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs4794448 ENSG00000278765.1 RP5-890E16.5 -4.95 1.15e-06 0.000408 -0.34 -0.26 Pulse pressure; chr17:48103445 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs68175794 ENSG00000278765.1 RP5-890E16.5 -4.95 1.15e-06 0.000408 -0.34 -0.26 Pulse pressure; chr17:48103742 chr17:48066704~48067293:- LIHC cis rs9903692 0.862 rs12943543 ENSG00000278765.1 RP5-890E16.5 -4.95 1.15e-06 0.000408 -0.34 -0.26 Pulse pressure; chr17:48104003 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs4794451 ENSG00000278765.1 RP5-890E16.5 -4.95 1.15e-06 0.000408 -0.34 -0.26 Pulse pressure; chr17:48107419 chr17:48066704~48067293:- LIHC cis rs9903692 0.862 rs4794453 ENSG00000278765.1 RP5-890E16.5 -4.95 1.15e-06 0.000408 -0.34 -0.26 Pulse pressure; chr17:48107564 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs8077860 ENSG00000278765.1 RP5-890E16.5 -4.95 1.15e-06 0.000408 -0.34 -0.26 Pulse pressure; chr17:48107973 chr17:48066704~48067293:- LIHC cis rs10995505 0.578 rs1533068 ENSG00000232075.1 MRPL35P2 -4.95 1.15e-06 0.000408 -0.29 -0.26 Intelligence (multi-trait analysis); chr10:63132407 chr10:63634317~63634827:- LIHC cis rs7208859 0.524 rs8069400 ENSG00000266490.1 CTD-2349P21.9 4.95 1.15e-06 0.000409 0.33 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748949 chr17:30792372~30792833:+ LIHC cis rs17507216 0.628 rs4513065 ENSG00000278603.1 RP13-608F4.5 4.95 1.15e-06 0.000409 0.54 0.26 Excessive daytime sleepiness; chr15:82712096 chr15:82472203~82472426:+ LIHC cis rs2274273 0.87 rs7153645 ENSG00000258413.1 RP11-665C16.6 -4.95 1.15e-06 0.000409 -0.31 -0.26 Protein biomarker; chr14:55304800 chr14:55262767~55272075:- LIHC cis rs2274273 0.87 rs10139083 ENSG00000258413.1 RP11-665C16.6 -4.95 1.15e-06 0.000409 -0.31 -0.26 Protein biomarker; chr14:55316017 chr14:55262767~55272075:- LIHC cis rs1134634 0.52 rs4698408 ENSG00000273133.1 RP11-799M12.2 -4.95 1.15e-06 0.00041 -0.32 -0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15657425 chr4:15563698~15564253:- LIHC cis rs7131987 0.65 rs67146951 ENSG00000275476.1 RP11-996F15.4 -4.95 1.15e-06 0.00041 -0.3 -0.26 QT interval; chr12:29297620 chr12:29277397~29277882:- LIHC cis rs7131987 0.65 rs10843382 ENSG00000275476.1 RP11-996F15.4 -4.95 1.15e-06 0.00041 -0.3 -0.26 QT interval; chr12:29298788 chr12:29277397~29277882:- LIHC cis rs9322193 0.566 rs3922947 ENSG00000223701.3 RAET1E-AS1 -4.95 1.15e-06 0.00041 -0.34 -0.26 Lung cancer; chr6:149924856 chr6:149884431~149919508:+ LIHC cis rs9425766 0.679 rs6681390 ENSG00000227373.4 RP11-160H22.5 4.95 1.15e-06 0.00041 0.31 0.26 Life satisfaction; chr1:174261331 chr1:174115300~174160004:- LIHC cis rs11089937 0.597 rs2213156 ENSG00000211639.2 IGLV4-60 4.95 1.15e-06 0.000411 0.22 0.26 Periodontitis (PAL4Q3); chr22:22137852 chr22:22162199~22162681:+ LIHC cis rs11089937 0.626 rs2213157 ENSG00000211639.2 IGLV4-60 4.95 1.15e-06 0.000411 0.22 0.26 Periodontitis (PAL4Q3); chr22:22137997 chr22:22162199~22162681:+ LIHC cis rs11089937 0.626 rs9622955 ENSG00000211639.2 IGLV4-60 4.95 1.15e-06 0.000411 0.22 0.26 Periodontitis (PAL4Q3); chr22:22138343 chr22:22162199~22162681:+ LIHC cis rs1577917 0.958 rs72907388 ENSG00000234155.1 RP11-30P6.6 4.95 1.16e-06 0.000411 0.34 0.26 Response to antipsychotic treatment; chr6:85730489 chr6:85387219~85390186:- LIHC cis rs2929278 0.589 rs2411284 ENSG00000166763.7 STRCP1 -4.95 1.16e-06 0.000412 -0.34 -0.26 Schizophrenia; chr15:43746701 chr15:43699488~43718184:- LIHC cis rs6921919 0.789 rs6912584 ENSG00000204709.4 LINC01556 4.95 1.16e-06 0.000412 0.35 0.26 Autism spectrum disorder or schizophrenia; chr6:28341813 chr6:28943877~28944537:+ LIHC cis rs11971779 0.68 rs7801613 ENSG00000273391.1 RP11-634H22.1 -4.95 1.16e-06 0.000412 -0.23 -0.26 Diisocyanate-induced asthma; chr7:139355181 chr7:139359032~139359566:- LIHC cis rs1322639 0.614 rs6937001 ENSG00000261039.2 RP11-417E7.2 4.95 1.16e-06 0.000412 0.37 0.26 Pulse pressure; chr6:169164991 chr6:169175304~169182740:- LIHC cis rs202072 1 rs202053 ENSG00000215022.6 RP1-257A7.4 -4.95 1.16e-06 0.000412 -0.29 -0.26 HIV-1 viral setpoint; chr6:13273411 chr6:13264861~13295586:- LIHC cis rs2243480 1 rs1618893 ENSG00000226824.5 RP4-756H11.3 -4.95 1.16e-06 0.000412 -0.39 -0.26 Diabetic kidney disease; chr7:66631132 chr7:66654538~66669855:+ LIHC cis rs4660214 0.666 rs12025847 ENSG00000182109.6 RP11-69E11.4 -4.95 1.16e-06 0.000413 -0.27 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39300977 chr1:39522280~39546187:- LIHC cis rs2243480 0.615 rs34363376 ENSG00000226824.5 RP4-756H11.3 -4.95 1.16e-06 0.000413 -0.43 -0.26 Diabetic kidney disease; chr7:66474549 chr7:66654538~66669855:+ LIHC cis rs1061377 1 rs1061377 ENSG00000249685.1 RP11-360F5.3 4.95 1.16e-06 0.000413 0.31 0.26 Uric acid levels; chr4:39123130 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs13109200 ENSG00000249685.1 RP11-360F5.3 4.95 1.16e-06 0.000413 0.31 0.26 Uric acid levels; chr4:39124396 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs13144374 ENSG00000249685.1 RP11-360F5.3 4.95 1.16e-06 0.000413 0.31 0.26 Uric acid levels; chr4:39128859 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs36090629 ENSG00000249685.1 RP11-360F5.3 4.95 1.16e-06 0.000413 0.31 0.26 Uric acid levels; chr4:39137195 chr4:39133913~39135608:+ LIHC cis rs860295 1 rs860295 ENSG00000203761.5 MSTO2P 4.95 1.16e-06 0.000413 0.2 0.26 Body mass index; chr1:155797917 chr1:155745829~155750137:+ LIHC cis rs7412746 0.658 rs10888397 ENSG00000231073.1 RP11-316M1.3 -4.95 1.16e-06 0.000413 -0.25 -0.26 Melanoma; chr1:150914276 chr1:150973123~150975534:+ LIHC cis rs11089937 0.589 rs4239891 ENSG00000211639.2 IGLV4-60 4.95 1.16e-06 0.000413 0.22 0.26 Periodontitis (PAL4Q3); chr22:22165674 chr22:22162199~22162681:+ LIHC cis rs6921919 1 rs35875412 ENSG00000216901.1 AL022393.7 4.95 1.16e-06 0.000413 0.4 0.26 Autism spectrum disorder or schizophrenia; chr6:28364041 chr6:28176188~28176674:+ LIHC cis rs12468226 0.817 rs6722588 ENSG00000273456.1 RP11-686O6.2 -4.95 1.16e-06 0.000414 -0.38 -0.26 Urate levels; chr2:202187163 chr2:202374932~202375604:- LIHC cis rs9341808 0.935 rs1535825 ENSG00000272129.1 RP11-250B2.6 -4.95 1.17e-06 0.000414 -0.26 -0.26 Sitting height ratio; chr6:80228869 chr6:80355424~80356859:+ LIHC cis rs643506 0.739 rs647071 ENSG00000254990.4 RP11-108O10.2 4.95 1.17e-06 0.000414 0.28 0.26 Breast cancer; chr11:111790731 chr11:111768668~111778350:- LIHC cis rs1061377 0.87 rs73238544 ENSG00000249685.1 RP11-360F5.3 4.95 1.17e-06 0.000414 0.31 0.26 Uric acid levels; chr4:39137343 chr4:39133913~39135608:+ LIHC cis rs9291683 0.53 rs13115193 ENSG00000250413.1 RP11-448G15.1 -4.95 1.17e-06 0.000415 -0.34 -0.26 Bone mineral density; chr4:9980567 chr4:10006482~10009725:+ LIHC cis rs11098499 0.908 rs9995234 ENSG00000260091.1 RP11-33B1.4 -4.95 1.17e-06 0.000415 -0.19 -0.26 Corneal astigmatism; chr4:119400672 chr4:119409333~119410233:+ LIHC cis rs7429990 0.864 rs6806860 ENSG00000229759.1 MRPS18AP1 -4.95 1.17e-06 0.000416 -0.27 -0.26 Educational attainment (years of education); chr3:47708218 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs6768699 ENSG00000229759.1 MRPS18AP1 -4.95 1.17e-06 0.000416 -0.27 -0.26 Educational attainment (years of education); chr3:47711258 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs6786001 ENSG00000229759.1 MRPS18AP1 -4.95 1.17e-06 0.000416 -0.27 -0.26 Educational attainment (years of education); chr3:47718500 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs12495204 ENSG00000229759.1 MRPS18AP1 -4.95 1.17e-06 0.000416 -0.27 -0.26 Educational attainment (years of education); chr3:47720540 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs7618758 ENSG00000229759.1 MRPS18AP1 -4.95 1.17e-06 0.000416 -0.27 -0.26 Educational attainment (years of education); chr3:47720993 chr3:48256350~48256938:- LIHC cis rs11098499 1 rs7659194 ENSG00000245958.5 RP11-33B1.1 -4.95 1.17e-06 0.000416 -0.27 -0.26 Corneal astigmatism; chr4:119285992 chr4:119454791~119552025:+ LIHC cis rs227275 0.525 rs3974604 ENSG00000246560.2 RP11-10L12.4 4.95 1.17e-06 0.000416 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102928601 chr4:102828055~102844075:+ LIHC cis rs9318086 0.753 rs9553094 ENSG00000205861.10 C1QTNF9B-AS1 4.95 1.17e-06 0.000417 0.29 0.26 Myopia (pathological); chr13:23900474 chr13:23888889~23897263:+ LIHC cis rs950169 0.922 rs4842940 ENSG00000225151.9 GOLGA2P7 4.95 1.17e-06 0.000417 0.31 0.26 Schizophrenia; chr15:84162473 chr15:84199311~84230136:- LIHC cis rs950169 0.922 rs4842941 ENSG00000225151.9 GOLGA2P7 4.95 1.17e-06 0.000417 0.31 0.26 Schizophrenia; chr15:84162560 chr15:84199311~84230136:- LIHC cis rs950169 0.922 rs12911223 ENSG00000225151.9 GOLGA2P7 4.95 1.17e-06 0.000417 0.31 0.26 Schizophrenia; chr15:84162919 chr15:84199311~84230136:- LIHC cis rs950169 0.845 rs4106951 ENSG00000225151.9 GOLGA2P7 -4.95 1.17e-06 0.000417 -0.31 -0.26 Schizophrenia; chr15:84164642 chr15:84199311~84230136:- LIHC cis rs7811142 0.83 rs11768967 ENSG00000242294.5 STAG3L5P 4.95 1.17e-06 0.000417 0.27 0.26 Platelet count; chr7:100370021 chr7:100336079~100351900:+ LIHC cis rs7811142 0.83 rs6975660 ENSG00000242294.5 STAG3L5P 4.95 1.17e-06 0.000417 0.27 0.26 Platelet count; chr7:100377643 chr7:100336079~100351900:+ LIHC cis rs7811142 0.83 rs73401443 ENSG00000242294.5 STAG3L5P 4.95 1.17e-06 0.000417 0.27 0.26 Platelet count; chr7:100379959 chr7:100336079~100351900:+ LIHC cis rs6802315 0.604 rs4680467 ENSG00000272087.1 RP11-379F4.7 4.95 1.17e-06 0.000417 0.3 0.26 Periodontitis (CDC/AAP); chr3:158782988 chr3:158693120~158693768:- LIHC cis rs1499614 1 rs1267818 ENSG00000230295.1 RP11-458F8.2 -4.95 1.18e-06 0.000417 -0.27 -0.26 Gout; chr7:66642037 chr7:66880708~66882981:+ LIHC cis rs10129255 0.518 rs10150460 ENSG00000223648.3 IGHV3-64 -4.95 1.18e-06 0.000417 -0.18 -0.26 Kawasaki disease; chr14:106677179 chr14:106643132~106658258:- LIHC cis rs67311347 1 rs4973898 ENSG00000223797.4 ENTPD3-AS1 -4.95 1.18e-06 0.000418 -0.2 -0.26 Renal cell carcinoma; chr3:40418041 chr3:40313802~40453329:- LIHC cis rs228614 0.51 rs223463 ENSG00000246560.2 RP11-10L12.4 4.95 1.18e-06 0.000419 0.28 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780620 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs223462 ENSG00000246560.2 RP11-10L12.4 4.95 1.18e-06 0.000419 0.28 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102780661 chr4:102828055~102844075:+ LIHC cis rs1020064 0.895 rs2250659 ENSG00000235319.1 AC012360.4 -4.95 1.18e-06 0.000419 -0.36 -0.26 AIDS; chr2:105273227 chr2:105324210~105330529:+ LIHC cis rs1030877 0.515 rs2576736 ENSG00000235319.1 AC012360.4 -4.95 1.18e-06 0.000419 -0.36 -0.26 Obesity-related traits; chr2:105274514 chr2:105324210~105330529:+ LIHC cis rs6600671 0.934 rs11249431 ENSG00000231429.2 RP11-343N15.2 4.95 1.18e-06 0.000419 0.32 0.26 Hip geometry; chr1:121544405 chr1:121412719~121429274:+ LIHC cis rs2274273 0.87 rs17741542 ENSG00000258413.1 RP11-665C16.6 4.95 1.18e-06 0.00042 0.31 0.26 Protein biomarker; chr14:55339143 chr14:55262767~55272075:- LIHC cis rs643506 0.817 rs623491 ENSG00000254990.4 RP11-108O10.2 4.95 1.19e-06 0.00042 0.27 0.26 Breast cancer; chr11:111830546 chr11:111768668~111778350:- LIHC cis rs5758511 0.68 rs739147 ENSG00000237037.8 NDUFA6-AS1 -4.95 1.19e-06 0.00042 -0.32 -0.26 Birth weight; chr22:42275060 chr22:42090931~42137742:+ LIHC cis rs5758511 0.68 rs56111723 ENSG00000237037.8 NDUFA6-AS1 -4.95 1.19e-06 0.000421 -0.32 -0.26 Birth weight; chr22:42268877 chr22:42090931~42137742:+ LIHC cis rs73186030 0.687 rs55636509 ENSG00000272758.4 RP11-299J3.8 4.95 1.19e-06 0.000422 0.49 0.26 Serum parathyroid hormone levels; chr3:122351816 chr3:122416207~122443180:+ LIHC cis rs5769765 0.773 rs7290751 ENSG00000278869.1 CITF22-49E9.3 4.95 1.19e-06 0.000422 0.4 0.26 Schizophrenia; chr22:49924664 chr22:49933198~49934074:- LIHC cis rs5769765 0.779 rs12170530 ENSG00000278869.1 CITF22-49E9.3 4.95 1.19e-06 0.000422 0.4 0.26 Schizophrenia; chr22:49924774 chr22:49933198~49934074:- LIHC cis rs5769765 0.908 rs9616216 ENSG00000278869.1 CITF22-49E9.3 4.95 1.19e-06 0.000422 0.4 0.26 Schizophrenia; chr22:49925279 chr22:49933198~49934074:- LIHC cis rs5769765 0.908 rs9627800 ENSG00000278869.1 CITF22-49E9.3 4.95 1.19e-06 0.000422 0.4 0.26 Schizophrenia; chr22:49925703 chr22:49933198~49934074:- LIHC cis rs5769765 0.865 rs10854860 ENSG00000278869.1 CITF22-49E9.3 4.95 1.19e-06 0.000422 0.4 0.26 Schizophrenia; chr22:49926381 chr22:49933198~49934074:- LIHC cis rs1061377 0.76 rs7678457 ENSG00000249685.1 RP11-360F5.3 4.95 1.19e-06 0.000422 0.31 0.26 Uric acid levels; chr4:39136041 chr4:39133913~39135608:+ LIHC cis rs227275 0.525 rs11737544 ENSG00000230069.3 LRRC37A15P -4.95 1.19e-06 0.000422 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102983877 chr4:102727274~102730721:- LIHC cis rs58749629 1 rs3827066 ENSG00000269549.2 RP3-461P17.10 4.95 1.19e-06 0.000422 0.54 0.26 Abdominal aortic aneurysm; chr20:45957384 chr20:45445431~45448580:+ LIHC cis rs9291683 0.609 rs7678012 ENSG00000250413.1 RP11-448G15.1 -4.95 1.19e-06 0.000423 -0.32 -0.26 Bone mineral density; chr4:9992148 chr4:10006482~10009725:+ LIHC cis rs4728142 1 rs4728142 ENSG00000275106.1 RP11-309L24.10 -4.95 1.19e-06 0.000423 -0.37 -0.26 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128933913 chr7:128952527~128953316:- LIHC cis rs3096299 0.933 rs3114848 ENSG00000261118.1 RP11-104N10.1 4.94 1.2e-06 0.000423 0.26 0.26 Multiple myeloma (IgH translocation); chr16:89386363 chr16:89492017~89504460:- LIHC cis rs11690935 0.918 rs12692978 ENSG00000228389.1 AC068039.4 4.94 1.2e-06 0.000423 0.37 0.26 Schizophrenia; chr2:171869471 chr2:171773482~171775844:+ LIHC cis rs7131987 0.621 rs3782506 ENSG00000275476.1 RP11-996F15.4 4.94 1.2e-06 0.000424 0.3 0.26 QT interval; chr12:29292489 chr12:29277397~29277882:- LIHC cis rs739496 0.894 rs11065898 ENSG00000226469.1 ADAM1B 4.94 1.2e-06 0.000424 0.31 0.26 Platelet count; chr12:111424771 chr12:111927018~111929017:+ LIHC cis rs11089937 0.626 rs5757051 ENSG00000211639.2 IGLV4-60 -4.94 1.2e-06 0.000425 -0.22 -0.26 Periodontitis (PAL4Q3); chr22:22141753 chr22:22162199~22162681:+ LIHC cis rs6479901 0.639 rs10995450 ENSG00000232075.1 MRPL35P2 4.94 1.2e-06 0.000426 0.29 0.26 Intelligence (multi-trait analysis); chr10:63129151 chr10:63634317~63634827:- LIHC cis rs1223397 0.938 rs9395602 ENSG00000215022.6 RP1-257A7.4 -4.94 1.2e-06 0.000426 -0.29 -0.26 Blood pressure; chr6:13278521 chr6:13264861~13295586:- LIHC cis rs71520386 0.632 rs12535331 ENSG00000228649.7 AC005682.5 4.94 1.21e-06 0.000426 0.33 0.26 Fibrinogen levels; chr7:22838485 chr7:22854178~22861579:+ LIHC cis rs2439831 1 rs2254321 ENSG00000205771.5 CATSPER2P1 -4.94 1.21e-06 0.000426 -0.36 -0.26 Lung cancer in ever smokers; chr15:43415344 chr15:43726918~43747094:- LIHC cis rs228614 0.51 rs223459 ENSG00000230069.3 LRRC37A15P -4.94 1.21e-06 0.000427 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102788229 chr4:102727274~102730721:- LIHC cis rs11722779 0.903 rs6830193 ENSG00000246560.2 RP11-10L12.4 4.94 1.21e-06 0.000427 0.29 0.26 Schizophrenia; chr4:102955457 chr4:102828055~102844075:+ LIHC cis rs4650994 0.544 rs11579513 ENSG00000273384.1 RP5-1098D14.1 4.94 1.21e-06 0.000427 0.32 0.26 HDL cholesterol;HDL cholesterol levels; chr1:178526957 chr1:178651706~178652282:+ LIHC cis rs1061377 1 rs7675782 ENSG00000249685.1 RP11-360F5.3 4.94 1.21e-06 0.000427 0.31 0.26 Uric acid levels; chr4:39120048 chr4:39133913~39135608:+ LIHC cis rs11722779 0.787 rs6533040 ENSG00000246560.2 RP11-10L12.4 4.94 1.21e-06 0.000428 0.29 0.26 Schizophrenia; chr4:102951421 chr4:102828055~102844075:+ LIHC cis rs6802315 0.604 rs2115941 ENSG00000272087.1 RP11-379F4.7 4.94 1.21e-06 0.000428 0.3 0.26 Periodontitis (CDC/AAP); chr3:158781906 chr3:158693120~158693768:- LIHC cis rs228614 0.51 rs223455 ENSG00000230069.3 LRRC37A15P -4.94 1.21e-06 0.000428 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102789026 chr4:102727274~102730721:- LIHC cis rs11722779 0.844 rs10003326 ENSG00000246560.2 RP11-10L12.4 4.94 1.21e-06 0.000428 0.29 0.26 Schizophrenia; chr4:102948193 chr4:102828055~102844075:+ LIHC cis rs11098499 0.691 rs10028773 ENSG00000260091.1 RP11-33B1.4 4.94 1.21e-06 0.000428 0.18 0.26 Corneal astigmatism; chr4:119344104 chr4:119409333~119410233:+ LIHC cis rs950169 0.763 rs35372971 ENSG00000225151.9 GOLGA2P7 -4.94 1.21e-06 0.000428 -0.32 -0.26 Schizophrenia; chr15:84387097 chr15:84199311~84230136:- LIHC cis rs8031584 1 rs890159 ENSG00000270015.1 RP11-540B6.6 -4.94 1.21e-06 0.000428 -0.35 -0.26 Huntington's disease progression; chr15:30999431 chr15:30926514~30928407:+ LIHC cis rs11676348 0.904 rs10804264 ENSG00000261338.2 RP11-378A13.1 -4.94 1.21e-06 0.000428 -0.27 -0.26 Ulcerative colitis; chr2:218091086 chr2:218255319~218257366:+ LIHC cis rs227275 0.588 rs223458 ENSG00000230069.3 LRRC37A15P -4.94 1.22e-06 0.000429 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102788414 chr4:102727274~102730721:- LIHC cis rs7714584 1 rs2344180 ENSG00000197083.10 ZNF300P1 4.94 1.22e-06 0.000429 0.39 0.26 Crohn's disease; chr5:150887795 chr5:150930645~150946289:- LIHC cis rs11992186 0.505 rs7845203 ENSG00000253893.2 FAM85B -4.94 1.22e-06 0.000429 -0.35 -0.26 Neuroticism; chr8:8287918 chr8:8167819~8226614:- LIHC cis rs9487094 0.813 rs12524502 ENSG00000260273.1 RP11-425D10.10 4.94 1.22e-06 0.000429 0.35 0.26 Height; chr6:109333018 chr6:109382795~109383666:+ LIHC cis rs4713118 0.629 rs203890 ENSG00000219392.1 RP1-265C24.5 -4.94 1.22e-06 0.00043 -0.38 -0.26 Parkinson's disease; chr6:28054470 chr6:28115628~28116551:+ LIHC cis rs4218 0.689 rs11853828 ENSG00000277144.1 RP11-59H7.4 -4.94 1.22e-06 0.00043 -0.29 -0.26 Social communication problems; chr15:59136031 chr15:59115547~59116089:- LIHC cis rs2919917 1 rs10093797 ENSG00000254352.1 RP11-578O24.2 4.94 1.22e-06 0.00043 0.34 0.26 Lymphocyte counts; chr8:78660478 chr8:78723796~78724136:- LIHC cis rs2842992 0.83 rs2842974 ENSG00000237927.1 RP3-393E18.2 -4.94 1.22e-06 0.00043 -0.31 -0.26 Age-related macular degeneration (geographic atrophy); chr6:159738002 chr6:159586955~159589169:- LIHC cis rs10875746 0.551 rs10875799 ENSG00000240399.1 RP1-228P16.1 -4.94 1.22e-06 0.000431 -0.27 -0.26 Longevity (90 years and older); chr12:48347096 chr12:48054813~48055591:- LIHC cis rs11098499 0.863 rs1010739 ENSG00000260091.1 RP11-33B1.4 -4.94 1.22e-06 0.000431 -0.19 -0.26 Corneal astigmatism; chr4:119542316 chr4:119409333~119410233:+ LIHC cis rs2836974 0.568 rs419469 ENSG00000255568.3 BRWD1-AS2 4.94 1.22e-06 0.000431 0.22 0.26 Cognitive function; chr21:39165308 chr21:39313935~39314962:+ LIHC cis rs2032447 0.714 rs199736 ENSG00000242387.1 HIST1H2APS2 4.94 1.22e-06 0.000431 0.32 0.26 Intelligence (multi-trait analysis); chr6:25936559 chr6:25882026~25882395:- LIHC cis rs71520386 0.632 rs9691076 ENSG00000228649.7 AC005682.5 -4.94 1.22e-06 0.000431 -0.33 -0.26 Fibrinogen levels; chr7:22829742 chr7:22854178~22861579:+ LIHC cis rs950169 0.881 rs4842852 ENSG00000259728.4 LINC00933 4.94 1.22e-06 0.000431 0.37 0.26 Schizophrenia; chr15:84387263 chr15:84570649~84580175:+ LIHC cis rs950169 0.84 rs4842853 ENSG00000259728.4 LINC00933 4.94 1.22e-06 0.000431 0.37 0.26 Schizophrenia; chr15:84387606 chr15:84570649~84580175:+ LIHC cis rs950169 0.922 rs4842946 ENSG00000259728.4 LINC00933 4.94 1.22e-06 0.000431 0.37 0.26 Schizophrenia; chr15:84387633 chr15:84570649~84580175:+ LIHC cis rs950169 0.84 rs4842854 ENSG00000259728.4 LINC00933 4.94 1.22e-06 0.000431 0.37 0.26 Schizophrenia; chr15:84387641 chr15:84570649~84580175:+ LIHC cis rs202072 0.729 rs202030 ENSG00000215022.6 RP1-257A7.4 -4.94 1.22e-06 0.000431 -0.3 -0.26 HIV-1 viral setpoint; chr6:13291920 chr6:13264861~13295586:- LIHC cis rs7674212 1 rs7691873 ENSG00000230069.3 LRRC37A15P 4.94 1.23e-06 0.000433 0.24 0.26 Type 2 diabetes; chr4:103066742 chr4:102727274~102730721:- LIHC cis rs2439831 0.702 rs3759791 ENSG00000275601.1 AC011330.13 -4.94 1.23e-06 0.000433 -0.37 -0.26 Lung cancer in ever smokers; chr15:43798600 chr15:43642389~43643023:- LIHC cis rs5769707 0.967 rs2051626 ENSG00000235111.1 RP1-29C18.8 -4.94 1.23e-06 0.000433 -0.29 -0.26 Monocyte percentage of white cells;Monocyte count; chr22:49615325 chr22:49612657~49615716:- LIHC cis rs875971 0.522 rs10807697 ENSG00000164669.11 INTS4P1 -4.94 1.23e-06 0.000433 -0.36 -0.26 Aortic root size; chr7:65951183 chr7:65141225~65234216:+ LIHC cis rs1015362 0.869 rs6088411 ENSG00000276073.1 RP5-1125A11.7 4.94 1.23e-06 0.000433 0.3 0.26 Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling; chr20:34152101 chr20:33985617~33988989:- LIHC cis rs529413 1 rs504519 ENSG00000259237.1 RP11-209E8.1 4.94 1.23e-06 0.000433 0.35 0.26 Itch intensity from mosquito bite adjusted by bite size; chr15:53251029 chr15:53116365~53129698:+ LIHC cis rs3096299 0.685 rs8050512 ENSG00000261118.1 RP11-104N10.1 4.94 1.23e-06 0.000434 0.26 0.26 Multiple myeloma (IgH translocation); chr16:89485912 chr16:89492017~89504460:- LIHC cis rs8059260 0.736 rs79361721 ENSG00000274038.1 RP11-66H6.4 -4.94 1.24e-06 0.000435 -0.44 -0.26 Alcohol consumption over the past year; chr16:10968082 chr16:11056556~11057034:+ LIHC cis rs2836974 0.644 rs2836981 ENSG00000255568.3 BRWD1-AS2 -4.94 1.24e-06 0.000435 -0.21 -0.26 Cognitive function; chr21:39316439 chr21:39313935~39314962:+ LIHC cis rs73186030 0.687 rs16833080 ENSG00000272758.4 RP11-299J3.8 -4.94 1.24e-06 0.000435 -0.45 -0.26 Serum parathyroid hormone levels; chr3:122382060 chr3:122416207~122443180:+ LIHC cis rs6479891 0.915 rs10740110 ENSG00000232075.1 MRPL35P2 -4.94 1.24e-06 0.000435 -0.3 -0.26 Arthritis (juvenile idiopathic); chr10:63283461 chr10:63634317~63634827:- LIHC cis rs9291683 0.588 rs12507330 ENSG00000250413.1 RP11-448G15.1 -4.94 1.24e-06 0.000436 -0.33 -0.26 Bone mineral density; chr4:10000571 chr4:10006482~10009725:+ LIHC cis rs2688482 0.557 rs2550236 ENSG00000242086.7 LINC00969 4.94 1.24e-06 0.000436 0.32 0.26 Lung disease severity in cystic fibrosis; chr3:195795450 chr3:195658062~195739964:+ LIHC cis rs1555322 0.53 rs6060341 ENSG00000279253.1 RP4-614O4.13 4.94 1.24e-06 0.000436 0.34 0.26 Attention deficit hyperactivity disorder; chr20:35275830 chr20:35262727~35264187:- LIHC cis rs7587476 0.784 rs36086595 ENSG00000229267.2 AC072062.1 -4.94 1.24e-06 0.000436 -0.33 -0.26 Neuroblastoma; chr2:214815569 chr2:214810229~214963274:+ LIHC cis rs7587476 0.822 rs6726763 ENSG00000229267.2 AC072062.1 -4.94 1.24e-06 0.000436 -0.33 -0.26 Neuroblastoma; chr2:214816856 chr2:214810229~214963274:+ LIHC cis rs1005277 0.522 rs289650 ENSG00000263064.2 RP11-291L22.7 4.94 1.24e-06 0.000437 0.25 0.26 Extrinsic epigenetic age acceleration; chr10:37686577 chr10:38448689~38448949:+ LIHC cis rs227275 0.525 rs28845922 ENSG00000230069.3 LRRC37A15P -4.94 1.24e-06 0.000438 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102981959 chr4:102727274~102730721:- LIHC cis rs7429990 0.76 rs319694 ENSG00000229759.1 MRPS18AP1 4.94 1.25e-06 0.000438 0.27 0.26 Educational attainment (years of education); chr3:47843463 chr3:48256350~48256938:- LIHC cis rs4731207 0.596 rs10252798 ENSG00000224897.5 POT1-AS1 4.94 1.25e-06 0.000439 0.31 0.26 Cutaneous malignant melanoma; chr7:124997157 chr7:124929873~125179315:+ LIHC cis rs2565722 0.622 rs1937480 ENSG00000243831.1 RP1-81D8.4 4.94 1.25e-06 0.000439 0.37 0.26 Blood protein levels; chr6:160883291 chr6:160666228~160676523:- LIHC cis rs227275 0.556 rs12508069 ENSG00000246560.2 RP11-10L12.4 4.94 1.25e-06 0.000439 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102983598 chr4:102828055~102844075:+ LIHC cis rs227275 0.527 rs12500379 ENSG00000246560.2 RP11-10L12.4 4.94 1.25e-06 0.000439 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102983665 chr4:102828055~102844075:+ LIHC cis rs227275 0.556 rs10015289 ENSG00000246560.2 RP11-10L12.4 4.94 1.25e-06 0.000439 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102984956 chr4:102828055~102844075:+ LIHC cis rs227275 0.556 rs6852141 ENSG00000246560.2 RP11-10L12.4 4.94 1.25e-06 0.000439 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102986439 chr4:102828055~102844075:+ LIHC cis rs228614 0.509 rs4455415 ENSG00000246560.2 RP11-10L12.4 4.94 1.25e-06 0.000439 0.29 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102993663 chr4:102828055~102844075:+ LIHC cis rs8005677 1 rs8006396 ENSG00000257285.4 RP11-298I3.1 4.94 1.25e-06 0.00044 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22911641 chr14:22929609~22955562:+ LIHC cis rs8005677 1 rs4981446 ENSG00000257285.4 RP11-298I3.1 4.94 1.25e-06 0.00044 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22912204 chr14:22929609~22955562:+ LIHC cis rs8005677 1 rs4982706 ENSG00000257285.4 RP11-298I3.1 4.94 1.25e-06 0.00044 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22912488 chr14:22929609~22955562:+ LIHC cis rs8005677 1 rs10148215 ENSG00000257285.4 RP11-298I3.1 4.94 1.25e-06 0.00044 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22913136 chr14:22929609~22955562:+ LIHC cis rs8005677 0.926 rs34344888 ENSG00000257285.4 RP11-298I3.1 4.94 1.25e-06 0.00044 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22918376 chr14:22929609~22955562:+ LIHC cis rs8005677 0.962 rs34917191 ENSG00000257285.4 RP11-298I3.1 4.94 1.25e-06 0.00044 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22918419 chr14:22929609~22955562:+ LIHC cis rs8005677 1 rs1951119 ENSG00000257285.4 RP11-298I3.1 4.94 1.25e-06 0.00044 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22919117 chr14:22929609~22955562:+ LIHC cis rs8005677 1 rs2295683 ENSG00000257285.4 RP11-298I3.1 4.94 1.25e-06 0.00044 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22919173 chr14:22929609~22955562:+ LIHC cis rs8005677 1 rs4981449 ENSG00000257285.4 RP11-298I3.1 4.94 1.25e-06 0.00044 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22919662 chr14:22929609~22955562:+ LIHC cis rs227275 0.556 rs9999303 ENSG00000246560.2 RP11-10L12.4 4.94 1.25e-06 0.00044 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102986881 chr4:102828055~102844075:+ LIHC cis rs6600671 0.934 rs67718113 ENSG00000231429.2 RP11-343N15.2 4.94 1.25e-06 0.00044 0.32 0.26 Hip geometry; chr1:121497112 chr1:121412719~121429274:+ LIHC cis rs10129255 0.957 rs10150241 ENSG00000223648.3 IGHV3-64 -4.94 1.25e-06 0.00044 -0.19 -0.26 Kawasaki disease; chr14:106775945 chr14:106643132~106658258:- LIHC cis rs113835537 0.877 rs2275998 ENSG00000255517.5 CTD-3074O7.5 -4.93 1.25e-06 0.000441 -0.34 -0.26 Airway imaging phenotypes; chr11:66559110 chr11:66473490~66480233:- LIHC cis rs6600671 1 rs4844616 ENSG00000231429.2 RP11-343N15.2 -4.93 1.26e-06 0.000441 -0.3 -0.26 Hip geometry; chr1:121429348 chr1:121412719~121429274:+ LIHC cis rs7714584 1 rs11957134 ENSG00000197083.10 ZNF300P1 -4.93 1.26e-06 0.000441 -0.4 -0.26 Crohn's disease; chr5:150851388 chr5:150930645~150946289:- LIHC cis rs4660214 0.666 rs663892 ENSG00000182109.6 RP11-69E11.4 4.93 1.26e-06 0.000441 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39424005 chr1:39522280~39546187:- LIHC cis rs4660214 0.666 rs1180384 ENSG00000182109.6 RP11-69E11.4 4.93 1.26e-06 0.000441 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39427102 chr1:39522280~39546187:- LIHC cis rs950169 0.686 rs12906474 ENSG00000225151.9 GOLGA2P7 -4.93 1.26e-06 0.000442 -0.32 -0.26 Schizophrenia; chr15:84566006 chr15:84199311~84230136:- LIHC cis rs950169 0.81 rs2879976 ENSG00000225151.9 GOLGA2P7 -4.93 1.26e-06 0.000442 -0.32 -0.26 Schizophrenia; chr15:84566347 chr15:84199311~84230136:- LIHC cis rs9425766 0.679 rs2860846 ENSG00000227373.4 RP11-160H22.5 4.93 1.26e-06 0.000442 0.31 0.26 Life satisfaction; chr1:174106786 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs2860847 ENSG00000227373.4 RP11-160H22.5 4.93 1.26e-06 0.000442 0.31 0.26 Life satisfaction; chr1:174106787 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs6672986 ENSG00000227373.4 RP11-160H22.5 4.93 1.26e-06 0.000442 0.31 0.26 Life satisfaction; chr1:174107726 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs7533430 ENSG00000227373.4 RP11-160H22.5 4.93 1.26e-06 0.000442 0.31 0.26 Life satisfaction; chr1:174109279 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs7526024 ENSG00000227373.4 RP11-160H22.5 4.93 1.26e-06 0.000442 0.31 0.26 Life satisfaction; chr1:174109722 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs12079063 ENSG00000227373.4 RP11-160H22.5 4.93 1.26e-06 0.000442 0.31 0.26 Life satisfaction; chr1:174110447 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs12094341 ENSG00000227373.4 RP11-160H22.5 4.93 1.26e-06 0.000442 0.31 0.26 Life satisfaction; chr1:174110562 chr1:174115300~174160004:- LIHC cis rs10129255 0.5 rs8011115 ENSG00000223648.3 IGHV3-64 4.93 1.26e-06 0.000442 0.18 0.26 Kawasaki disease; chr14:106786292 chr14:106643132~106658258:- LIHC cis rs12571093 0.773 rs4142047 ENSG00000233590.1 RP11-153K11.3 -4.93 1.26e-06 0.000442 -0.4 -0.26 Optic nerve measurement (disc area); chr10:68261498 chr10:68233251~68242379:- LIHC cis rs227275 0.525 rs223332 ENSG00000246560.2 RP11-10L12.4 4.93 1.26e-06 0.000442 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102869029 chr4:102828055~102844075:+ LIHC cis rs950776 0.752 rs62010327 ENSG00000261762.1 RP11-650L12.2 4.93 1.26e-06 0.000443 0.33 0.26 Sudden cardiac arrest; chr15:78600442 chr15:78589123~78591276:- LIHC cis rs875971 0.505 rs6955582 ENSG00000164669.11 INTS4P1 -4.93 1.26e-06 0.000443 -0.36 -0.26 Aortic root size; chr7:65966699 chr7:65141225~65234216:+ LIHC cis rs4862307 0.514 rs7696176 ENSG00000250726.1 RP11-616K6.1 4.93 1.27e-06 0.000444 0.28 0.26 Serum dimethylarginine levels (asymmetric/symetric ratio); chr4:184093237 chr4:184072403~184073039:+ LIHC cis rs1865760 0.622 rs9968910 ENSG00000216436.2 HIST1H2APS1 -4.93 1.27e-06 0.000445 -0.34 -0.26 Height; chr6:26071867 chr6:25732497~25732827:+ LIHC cis rs10847980 0.623 rs7955367 ENSG00000256092.2 RP13-942N8.1 4.93 1.27e-06 0.000445 0.42 0.26 Adiponectin levels; chr12:123344245 chr12:123363868~123366113:+ LIHC cis rs1247318 1 rs1247318 ENSG00000243831.1 RP1-81D8.4 4.93 1.27e-06 0.000446 0.4 0.26 Aging; chr6:160912905 chr6:160666228~160676523:- LIHC cis rs2274273 0.87 rs59629906 ENSG00000258413.1 RP11-665C16.6 -4.93 1.27e-06 0.000446 -0.31 -0.26 Protein biomarker; chr14:55314471 chr14:55262767~55272075:- LIHC cis rs12134133 1 rs6658718 ENSG00000274245.1 RP11-357P18.2 4.93 1.27e-06 0.000446 0.36 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207285561 chr1:207372559~207373252:+ LIHC cis rs6421571 0.565 rs10892263 ENSG00000255239.1 AP002954.6 -4.93 1.27e-06 0.000446 -0.37 -0.26 Primary biliary cholangitis; chr11:118716610 chr11:118688039~118690600:- LIHC cis rs227275 0.525 rs223461 ENSG00000230069.3 LRRC37A15P -4.93 1.27e-06 0.000447 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102782372 chr4:102727274~102730721:- LIHC cis rs12468226 0.873 rs6435138 ENSG00000273456.1 RP11-686O6.2 -4.93 1.27e-06 0.000447 -0.37 -0.26 Urate levels; chr2:202234310 chr2:202374932~202375604:- LIHC cis rs9487094 0.813 rs12528712 ENSG00000260273.1 RP11-425D10.10 4.93 1.28e-06 0.000448 0.35 0.26 Height; chr6:109339681 chr6:109382795~109383666:+ LIHC cis rs11722779 0.844 rs3974602 ENSG00000230069.3 LRRC37A15P -4.93 1.28e-06 0.000448 -0.23 -0.26 Schizophrenia; chr4:102928840 chr4:102727274~102730721:- LIHC cis rs7119038 0.818 rs10892289 ENSG00000255239.1 AP002954.6 -4.93 1.28e-06 0.000448 -0.37 -0.26 Sjögren's syndrome; chr11:118775294 chr11:118688039~118690600:- LIHC cis rs10256972 0.521 rs7457418 ENSG00000199023.2 MIR339 -4.93 1.28e-06 0.000448 -0.3 -0.26 Endometriosis;Longevity; chr7:1070619 chr7:1022935~1023045:- LIHC cis rs875971 0.54 rs1723268 ENSG00000164669.11 INTS4P1 -4.93 1.28e-06 0.000449 -0.36 -0.26 Aortic root size; chr7:66008093 chr7:65141225~65234216:+ LIHC cis rs9595908 0.9 rs9595850 ENSG00000212293.1 SNORA16 4.93 1.28e-06 0.000449 0.29 0.26 Body mass index; chr13:32579773 chr13:32420390~32420516:- LIHC cis rs4266144 0.592 rs1545854 ENSG00000244515.1 KRT18P34 4.93 1.28e-06 0.00045 0.28 0.26 Coronary artery disease; chr3:157122349 chr3:157162663~157163932:- LIHC cis rs9903692 0.954 rs9899461 ENSG00000278765.1 RP5-890E16.5 -4.93 1.28e-06 0.00045 -0.34 -0.26 Pulse pressure; chr17:48051991 chr17:48066704~48067293:- LIHC cis rs9326248 0.53 rs11216316 ENSG00000236267.1 AP006216.5 -4.93 1.28e-06 0.00045 -0.3 -0.26 Blood protein levels; chr11:117210784 chr11:116813204~116814003:- LIHC cis rs12468226 0.938 rs3843338 ENSG00000273456.1 RP11-686O6.2 -4.93 1.29e-06 0.000451 -0.36 -0.26 Urate levels; chr2:202246102 chr2:202374932~202375604:- LIHC cis rs9660180 0.62 rs34298494 ENSG00000231050.1 RP1-140A9.1 -4.93 1.29e-06 0.000452 -0.28 -0.26 Body mass index; chr1:1731963 chr1:1891471~1892658:+ LIHC cis rs11971779 0.68 rs4398844 ENSG00000273391.1 RP11-634H22.1 4.93 1.29e-06 0.000452 0.23 0.26 Diisocyanate-induced asthma; chr7:139358393 chr7:139359032~139359566:- LIHC cis rs11722779 0.935 rs3974481 ENSG00000230069.3 LRRC37A15P -4.93 1.29e-06 0.000453 -0.23 -0.26 Schizophrenia; chr4:102956834 chr4:102727274~102730721:- LIHC cis rs75920871 0.589 rs56061158 ENSG00000254851.1 RP11-109L13.1 -4.93 1.29e-06 0.000453 -0.52 -0.26 Subjective well-being; chr11:117216402 chr11:117135528~117138582:+ LIHC cis rs12554020 0.892 rs78816659 ENSG00000227603.1 RP11-165J3.6 4.93 1.29e-06 0.000453 0.44 0.26 Schizophrenia; chr9:93575141 chr9:93435332~93437121:- LIHC cis rs2153535 0.601 rs2327091 ENSG00000230939.1 RP11-314C16.1 -4.93 1.29e-06 0.000453 -0.32 -0.26 Motion sickness; chr6:8540136 chr6:8784178~8785445:+ LIHC cis rs6504950 0.566 rs7208403 ENSG00000275710.1 RP11-257O5.4 4.93 1.29e-06 0.000453 0.29 0.26 Breast cancer; chr17:54969306 chr17:54964474~54964679:+ LIHC cis rs6479901 0.696 rs931972 ENSG00000232075.1 MRPL35P2 -4.93 1.29e-06 0.000454 -0.28 -0.26 Intelligence (multi-trait analysis); chr10:63150467 chr10:63634317~63634827:- LIHC cis rs6964833 0.872 rs4717903 ENSG00000123965.13 PMS2P5 4.93 1.29e-06 0.000454 0.42 0.26 Menarche (age at onset); chr7:74653827 chr7:74894116~74897835:+ LIHC cis rs5769765 0.908 rs9616396 ENSG00000278869.1 CITF22-49E9.3 4.93 1.3e-06 0.000454 0.4 0.26 Schizophrenia; chr22:49924177 chr22:49933198~49934074:- LIHC cis rs8059260 1 rs8057540 ENSG00000274038.1 RP11-66H6.4 -4.93 1.3e-06 0.000454 -0.39 -0.26 Alcohol consumption over the past year; chr16:10951985 chr16:11056556~11057034:+ LIHC cis rs2932538 0.922 rs4838961 ENSG00000225075.1 RP11-426L16.3 -4.93 1.3e-06 0.000454 -0.33 -0.26 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112621345 chr1:112693688~112696621:- LIHC cis rs61041384 0.661 rs4474478 ENSG00000256092.2 RP13-942N8.1 -4.93 1.3e-06 0.000454 -0.42 -0.26 Schizophrenia; chr12:123249821 chr12:123363868~123366113:+ LIHC cis rs603446 0.967 rs180346 ENSG00000254851.1 RP11-109L13.1 -4.93 1.3e-06 0.000454 -0.33 -0.26 Triglycerides; chr11:116741943 chr11:117135528~117138582:+ LIHC cis rs6600671 1 rs10903161 ENSG00000231429.2 RP11-343N15.2 -4.93 1.3e-06 0.000454 -0.29 -0.26 Hip geometry; chr1:121436882 chr1:121412719~121429274:+ LIHC cis rs860295 0.812 rs2297775 ENSG00000203761.5 MSTO2P 4.93 1.3e-06 0.000455 0.2 0.26 Body mass index; chr1:155765221 chr1:155745829~155750137:+ LIHC cis rs11676348 0.935 rs4674248 ENSG00000261338.2 RP11-378A13.1 -4.93 1.3e-06 0.000455 -0.27 -0.26 Ulcerative colitis; chr2:218095408 chr2:218255319~218257366:+ LIHC cis rs2919917 1 rs2046338 ENSG00000254352.1 RP11-578O24.2 4.93 1.3e-06 0.000455 0.35 0.26 Lymphocyte counts; chr8:78723734 chr8:78723796~78724136:- LIHC cis rs4713118 0.513 rs2294480 ENSG00000216901.1 AL022393.7 4.93 1.3e-06 0.000455 0.29 0.26 Parkinson's disease; chr6:27616182 chr6:28176188~28176674:+ LIHC cis rs1023500 0.505 rs2143139 ENSG00000227370.1 RP4-669P10.19 -4.93 1.3e-06 0.000455 -0.27 -0.26 Schizophrenia; chr22:42218395 chr22:42132543~42132998:+ LIHC cis rs9425766 0.679 rs6695636 ENSG00000227373.4 RP11-160H22.5 4.93 1.3e-06 0.000455 0.31 0.26 Life satisfaction; chr1:174303087 chr1:174115300~174160004:- LIHC cis rs4650994 0.544 rs4075631 ENSG00000273384.1 RP5-1098D14.1 4.93 1.3e-06 0.000456 0.32 0.26 HDL cholesterol;HDL cholesterol levels; chr1:178537459 chr1:178651706~178652282:+ LIHC cis rs7615952 0.515 rs7630575 ENSG00000171084.14 FAM86JP 4.93 1.3e-06 0.000456 0.43 0.26 Blood pressure (smoking interaction); chr3:125963487 chr3:125916620~125930024:+ LIHC cis rs9425766 0.679 rs7537517 ENSG00000227373.4 RP11-160H22.5 4.93 1.3e-06 0.000456 0.31 0.26 Life satisfaction; chr1:174207225 chr1:174115300~174160004:- LIHC cis rs4660214 0.666 rs3116398 ENSG00000182109.6 RP11-69E11.4 -4.93 1.3e-06 0.000456 -0.27 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39314130 chr1:39522280~39546187:- LIHC cis rs4713118 0.629 rs149899 ENSG00000219392.1 RP1-265C24.5 -4.93 1.3e-06 0.000456 -0.38 -0.26 Parkinson's disease; chr6:28052201 chr6:28115628~28116551:+ LIHC cis rs4713118 0.629 rs172165 ENSG00000219392.1 RP1-265C24.5 -4.93 1.3e-06 0.000456 -0.38 -0.26 Parkinson's disease; chr6:28053036 chr6:28115628~28116551:+ LIHC cis rs4713118 0.597 rs172166 ENSG00000219392.1 RP1-265C24.5 -4.93 1.3e-06 0.000456 -0.38 -0.26 Parkinson's disease; chr6:28053042 chr6:28115628~28116551:+ LIHC cis rs4713118 0.629 rs203889 ENSG00000219392.1 RP1-265C24.5 -4.93 1.3e-06 0.000456 -0.38 -0.26 Parkinson's disease; chr6:28053997 chr6:28115628~28116551:+ LIHC cis rs5769707 0.872 rs5770604 ENSG00000235111.1 RP1-29C18.8 -4.93 1.3e-06 0.000456 -0.3 -0.26 Monocyte percentage of white cells;Monocyte count; chr22:49637024 chr22:49612657~49615716:- LIHC cis rs11671005 0.735 rs34188294 ENSG00000269473.1 CTD-2619J13.19 4.93 1.3e-06 0.000457 0.44 0.26 Mean platelet volume; chr19:58408190 chr19:58440448~58445849:+ LIHC cis rs17711722 0.727 rs2658585 ENSG00000164669.11 INTS4P1 -4.93 1.3e-06 0.000457 -0.36 -0.26 Calcium levels; chr7:65996954 chr7:65141225~65234216:+ LIHC cis rs227275 0.525 rs7663876 ENSG00000230069.3 LRRC37A15P -4.93 1.31e-06 0.000458 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102966174 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs6821173 ENSG00000230069.3 LRRC37A15P -4.93 1.31e-06 0.000458 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102966404 chr4:102727274~102730721:- LIHC cis rs755249 0.529 rs604316 ENSG00000182109.6 RP11-69E11.4 4.93 1.31e-06 0.000458 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39413694 chr1:39522280~39546187:- LIHC cis rs9400467 0.528 rs457492 ENSG00000271789.1 RP5-1112D6.7 -4.93 1.31e-06 0.000458 -0.25 -0.26 Amino acid levels;Blood metabolite levels; chr6:111320647 chr6:111297126~111298510:+ LIHC cis rs10129255 0.544 rs61997583 ENSG00000211970.3 IGHV4-61 -4.93 1.31e-06 0.000458 -0.21 -0.26 Kawasaki disease; chr14:106654351 chr14:106639119~106639657:- LIHC cis rs2439831 0.85 rs28718261 ENSG00000166763.7 STRCP1 4.93 1.31e-06 0.000458 0.4 0.26 Lung cancer in ever smokers; chr15:43751595 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs28595038 ENSG00000166763.7 STRCP1 4.93 1.31e-06 0.000458 0.4 0.26 Lung cancer in ever smokers; chr15:43752661 chr15:43699488~43718184:- LIHC cis rs72627509 0.857 rs55762216 ENSG00000269949.1 RP11-738E22.3 4.93 1.31e-06 0.000459 0.35 0.26 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56899565 chr4:56960927~56961373:- LIHC cis rs228614 0.51 rs223356 ENSG00000246560.2 RP11-10L12.4 4.93 1.31e-06 0.000459 0.29 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102852344 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223353 ENSG00000246560.2 RP11-10L12.4 4.93 1.31e-06 0.000459 0.29 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102854547 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223352 ENSG00000246560.2 RP11-10L12.4 4.93 1.31e-06 0.000459 0.29 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102855710 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223349 ENSG00000246560.2 RP11-10L12.4 4.93 1.31e-06 0.000459 0.29 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102857277 chr4:102828055~102844075:+ LIHC cis rs2243480 1 rs160634 ENSG00000273142.1 RP11-458F8.4 4.93 1.31e-06 0.000459 0.3 0.26 Diabetic kidney disease; chr7:66063677 chr7:66902857~66906297:+ LIHC cis rs1322639 0.614 rs7751131 ENSG00000261039.2 RP11-417E7.2 -4.93 1.31e-06 0.00046 -0.35 -0.26 Pulse pressure; chr6:169178615 chr6:169175304~169182740:- LIHC cis rs1322639 0.574 rs9364360 ENSG00000261039.2 RP11-417E7.2 -4.93 1.31e-06 0.00046 -0.35 -0.26 Pulse pressure; chr6:169180079 chr6:169175304~169182740:- LIHC cis rs950776 0.684 rs692780 ENSG00000261762.1 RP11-650L12.2 -4.92 1.32e-06 0.00046 -0.33 -0.26 Sudden cardiac arrest; chr15:78584163 chr15:78589123~78591276:- LIHC cis rs2274273 0.905 rs10134800 ENSG00000258413.1 RP11-665C16.6 -4.92 1.32e-06 0.000461 -0.29 -0.26 Protein biomarker; chr14:55168491 chr14:55262767~55272075:- LIHC cis rs12468226 0.817 rs12693965 ENSG00000273456.1 RP11-686O6.2 -4.92 1.32e-06 0.000461 -0.37 -0.26 Urate levels; chr2:202210188 chr2:202374932~202375604:- LIHC cis rs12468226 0.873 rs3769817 ENSG00000273456.1 RP11-686O6.2 -4.92 1.32e-06 0.000461 -0.37 -0.26 Urate levels; chr2:202214584 chr2:202374932~202375604:- LIHC cis rs12468226 0.873 rs6435134 ENSG00000273456.1 RP11-686O6.2 -4.92 1.32e-06 0.000461 -0.37 -0.26 Urate levels; chr2:202214857 chr2:202374932~202375604:- LIHC cis rs9525927 0.57 rs7400099 ENSG00000230731.2 RP11-478K15.6 -4.92 1.32e-06 0.000461 -0.29 -0.26 Dupuytren's disease; chr13:44230344 chr13:44234118~44243192:- LIHC cis rs5769765 0.778 rs8137331 ENSG00000278869.1 CITF22-49E9.3 4.92 1.32e-06 0.000461 0.4 0.26 Schizophrenia; chr22:49919710 chr22:49933198~49934074:- LIHC cis rs11098499 0.954 rs17005535 ENSG00000260091.1 RP11-33B1.4 -4.92 1.32e-06 0.000462 -0.18 -0.26 Corneal astigmatism; chr4:119490407 chr4:119409333~119410233:+ LIHC cis rs453301 0.631 rs17700611 ENSG00000253893.2 FAM85B 4.92 1.32e-06 0.000462 0.39 0.26 Joint mobility (Beighton score); chr8:8936144 chr8:8167819~8226614:- LIHC cis rs11098499 0.754 rs9991959 ENSG00000245958.5 RP11-33B1.1 4.92 1.32e-06 0.000462 0.26 0.26 Corneal astigmatism; chr4:119332618 chr4:119454791~119552025:+ LIHC cis rs9425766 0.679 rs7555067 ENSG00000227373.4 RP11-160H22.5 4.92 1.33e-06 0.000463 0.31 0.26 Life satisfaction; chr1:174297504 chr1:174115300~174160004:- LIHC cis rs227275 0.525 rs6853193 ENSG00000246560.2 RP11-10L12.4 4.92 1.33e-06 0.000463 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102994888 chr4:102828055~102844075:+ LIHC cis rs2762353 0.526 rs6901027 ENSG00000216436.2 HIST1H2APS1 4.92 1.33e-06 0.000463 0.31 0.26 Blood metabolite levels; chr6:25708814 chr6:25732497~25732827:+ LIHC cis rs875971 0.522 rs1880556 ENSG00000164669.11 INTS4P1 -4.92 1.33e-06 0.000465 -0.37 -0.26 Aortic root size; chr7:65967557 chr7:65141225~65234216:+ LIHC cis rs11089937 0.626 rs5757056 ENSG00000211639.2 IGLV4-60 4.92 1.33e-06 0.000465 0.22 0.26 Periodontitis (PAL4Q3); chr22:22142491 chr22:22162199~22162681:+ LIHC cis rs875971 0.545 rs17138149 ENSG00000273142.1 RP11-458F8.4 4.92 1.33e-06 0.000465 0.24 0.26 Aortic root size; chr7:66228193 chr7:66902857~66906297:+ LIHC cis rs6964833 0.873 rs4717905 ENSG00000277053.3 GTF2IP1 -4.92 1.33e-06 0.000465 -0.31 -0.26 Menarche (age at onset); chr7:74668903 chr7:75185385~75237696:- LIHC cis rs5769765 0.865 rs9616369 ENSG00000278869.1 CITF22-49E9.3 4.92 1.33e-06 0.000465 0.38 0.26 Schizophrenia; chr22:49910943 chr22:49933198~49934074:- LIHC cis rs881375 0.678 rs7021049 ENSG00000226752.6 PSMD5-AS1 -4.92 1.33e-06 0.000466 -0.27 -0.26 Rheumatoid arthritis; chr9:120921704 chr9:120824828~120854385:+ LIHC cis rs1030877 0.515 rs2576742 ENSG00000235319.1 AC012360.4 -4.92 1.34e-06 0.000466 -0.35 -0.26 Obesity-related traits; chr2:105282365 chr2:105324210~105330529:+ LIHC cis rs4356203 0.792 rs620241 ENSG00000272034.1 SNORD14A -4.92 1.34e-06 0.000466 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17175343 chr11:17074654~17074744:- LIHC cis rs228614 0.51 rs223470 ENSG00000230069.3 LRRC37A15P -4.92 1.34e-06 0.000467 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102778004 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223468 ENSG00000230069.3 LRRC37A15P -4.92 1.34e-06 0.000467 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102779265 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223465 ENSG00000230069.3 LRRC37A15P -4.92 1.34e-06 0.000467 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780174 chr4:102727274~102730721:- LIHC cis rs228614 0.51 rs223464 ENSG00000230069.3 LRRC37A15P -4.92 1.34e-06 0.000467 -0.23 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780603 chr4:102727274~102730721:- LIHC cis rs2253762 0.527 rs11200323 ENSG00000276742.1 RP11-500G22.4 -4.92 1.34e-06 0.000467 -0.39 -0.26 Breast cancer; chr10:122008869 chr10:121956782~121957098:+ LIHC cis rs2243480 0.522 rs12698511 ENSG00000226824.5 RP4-756H11.3 -4.92 1.34e-06 0.000468 -0.46 -0.26 Diabetic kidney disease; chr7:66009932 chr7:66654538~66669855:+ LIHC cis rs9425766 0.679 rs2901785 ENSG00000227373.4 RP11-160H22.5 4.92 1.34e-06 0.000468 0.31 0.26 Life satisfaction; chr1:174135605 chr1:174115300~174160004:- LIHC cis rs755249 0.501 rs2484749 ENSG00000182109.6 RP11-69E11.4 -4.92 1.34e-06 0.000468 -0.28 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39293283 chr1:39522280~39546187:- LIHC cis rs1714507 0.533 rs1714516 ENSG00000272087.1 RP11-379F4.7 4.92 1.34e-06 0.000468 0.29 0.26 Subjective well-being; chr3:158575835 chr3:158693120~158693768:- LIHC cis rs1061377 1 rs9999327 ENSG00000249685.1 RP11-360F5.3 4.92 1.34e-06 0.000469 0.31 0.26 Uric acid levels; chr4:39110111 chr4:39133913~39135608:+ LIHC cis rs2153535 0.562 rs10458225 ENSG00000230939.1 RP11-314C16.1 4.92 1.35e-06 0.000469 0.3 0.26 Motion sickness; chr6:8385771 chr6:8784178~8785445:+ LIHC cis rs4660214 0.666 rs683135 ENSG00000182109.6 RP11-69E11.4 4.92 1.35e-06 0.000469 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39429788 chr1:39522280~39546187:- LIHC cis rs17711722 0.727 rs1880555 ENSG00000164669.11 INTS4P1 -4.92 1.35e-06 0.00047 -0.36 -0.26 Calcium levels; chr7:65967580 chr7:65141225~65234216:+ LIHC cis rs12554020 0.786 rs79804179 ENSG00000227603.1 RP11-165J3.6 4.92 1.35e-06 0.00047 0.44 0.26 Schizophrenia; chr9:93486200 chr9:93435332~93437121:- LIHC cis rs227275 0.554 rs223339 ENSG00000246560.2 RP11-10L12.4 4.92 1.35e-06 0.00047 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102864700 chr4:102828055~102844075:+ LIHC cis rs11098499 0.604 rs2389882 ENSG00000245958.5 RP11-33B1.1 -4.92 1.35e-06 0.00047 -0.26 -0.26 Corneal astigmatism; chr4:119645578 chr4:119454791~119552025:+ LIHC cis rs950169 0.922 rs12910334 ENSG00000259728.4 LINC00933 4.92 1.35e-06 0.000471 0.37 0.26 Schizophrenia; chr15:84403620 chr15:84570649~84580175:+ LIHC cis rs11676348 0.935 rs2230054 ENSG00000261338.2 RP11-378A13.1 -4.92 1.35e-06 0.000471 -0.27 -0.26 Ulcerative colitis; chr2:218135587 chr2:218255319~218257366:+ LIHC cis rs11690935 0.843 rs9784123 ENSG00000228389.1 AC068039.4 4.92 1.35e-06 0.000471 0.34 0.26 Schizophrenia; chr2:171928495 chr2:171773482~171775844:+ LIHC cis rs11690935 0.843 rs9784070 ENSG00000228389.1 AC068039.4 4.92 1.35e-06 0.000471 0.34 0.26 Schizophrenia; chr2:171928497 chr2:171773482~171775844:+ LIHC cis rs1865760 0.622 rs10946807 ENSG00000216436.2 HIST1H2APS1 -4.92 1.35e-06 0.000471 -0.34 -0.26 Height; chr6:26079410 chr6:25732497~25732827:+ LIHC cis rs4650994 0.525 rs2761463 ENSG00000273384.1 RP5-1098D14.1 -4.92 1.35e-06 0.000471 -0.32 -0.26 HDL cholesterol;HDL cholesterol levels; chr1:178588002 chr1:178651706~178652282:+ LIHC cis rs4660214 0.666 rs588326 ENSG00000182109.6 RP11-69E11.4 4.92 1.35e-06 0.000472 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39443054 chr1:39522280~39546187:- LIHC cis rs12571093 0.571 rs7899387 ENSG00000233590.1 RP11-153K11.3 4.92 1.35e-06 0.000472 0.41 0.26 Optic nerve measurement (disc area); chr10:68293278 chr10:68233251~68242379:- LIHC cis rs13392177 0.684 rs11695527 ENSG00000261338.2 RP11-378A13.1 4.92 1.35e-06 0.000472 0.26 0.26 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218203380 chr2:218255319~218257366:+ LIHC cis rs11676348 0.935 rs13007992 ENSG00000261338.2 RP11-378A13.1 -4.92 1.36e-06 0.000472 -0.27 -0.26 Ulcerative colitis; chr2:218099328 chr2:218255319~218257366:+ LIHC cis rs6921919 0.789 rs11970439 ENSG00000204709.4 LINC01556 4.92 1.36e-06 0.000472 0.35 0.26 Autism spectrum disorder or schizophrenia; chr6:28335687 chr6:28943877~28944537:+ LIHC cis rs2412819 0.559 rs8040336 ENSG00000205771.5 CATSPER2P1 -4.92 1.36e-06 0.000473 -0.29 -0.26 Lung cancer; chr15:43761419 chr15:43726918~43747094:- LIHC cis rs950169 0.922 rs11633075 ENSG00000259728.4 LINC00933 4.92 1.36e-06 0.000474 0.37 0.26 Schizophrenia; chr15:84570741 chr15:84570649~84580175:+ LIHC cis rs11673344 0.573 rs73039109 ENSG00000226686.6 LINC01535 4.92 1.36e-06 0.000474 0.4 0.26 Obesity-related traits; chr19:36891073 chr19:37251912~37265535:+ LIHC cis rs10129255 0.518 rs8009612 ENSG00000223648.3 IGHV3-64 4.92 1.36e-06 0.000475 0.18 0.26 Kawasaki disease; chr14:106777510 chr14:106643132~106658258:- LIHC cis rs7702057 0.53 rs17138866 ENSG00000271918.1 CTD-2287O16.5 4.92 1.36e-06 0.000475 0.36 0.26 Amyotrophic lateral sclerosis; chr5:116088914 chr5:116083807~116085416:- LIHC cis rs7702057 0.53 rs59429923 ENSG00000271918.1 CTD-2287O16.5 4.92 1.36e-06 0.000475 0.36 0.26 Amyotrophic lateral sclerosis; chr5:116089241 chr5:116083807~116085416:- LIHC cis rs11098499 0.722 rs7673476 ENSG00000245958.5 RP11-33B1.1 -4.92 1.37e-06 0.000475 -0.26 -0.26 Corneal astigmatism; chr4:119327528 chr4:119454791~119552025:+ LIHC cis rs2836974 0.644 rs1882779 ENSG00000255568.3 BRWD1-AS2 -4.92 1.37e-06 0.000476 -0.22 -0.26 Cognitive function; chr21:39319012 chr21:39313935~39314962:+ LIHC cis rs10129255 0.913 rs28861466 ENSG00000223648.3 IGHV3-64 4.92 1.37e-06 0.000476 0.2 0.26 Kawasaki disease; chr14:106718572 chr14:106643132~106658258:- LIHC cis rs7429990 0.694 rs7645846 ENSG00000229759.1 MRPS18AP1 -4.92 1.37e-06 0.000477 -0.27 -0.26 Educational attainment (years of education); chr3:47740829 chr3:48256350~48256938:- LIHC cis rs30380 0.586 rs28119 ENSG00000272109.1 CTD-2260A17.3 -4.92 1.37e-06 0.000477 -0.33 -0.26 Cerebrospinal fluid biomarker levels; chr5:96796030 chr5:96804353~96806105:+ LIHC cis rs30380 0.632 rs26491 ENSG00000272109.1 CTD-2260A17.3 -4.92 1.37e-06 0.000477 -0.33 -0.26 Cerebrospinal fluid biomarker levels; chr5:96798410 chr5:96804353~96806105:+ LIHC cis rs1030877 0.515 rs1020064 ENSG00000235319.1 AC012360.4 -4.92 1.37e-06 0.000477 -0.35 -0.26 Obesity-related traits; chr2:105281283 chr2:105324210~105330529:+ LIHC cis rs1030877 0.515 rs2576741 ENSG00000235319.1 AC012360.4 -4.92 1.37e-06 0.000477 -0.35 -0.26 Obesity-related traits; chr2:105281507 chr2:105324210~105330529:+ LIHC cis rs3096299 0.933 rs2965934 ENSG00000261118.1 RP11-104N10.1 4.92 1.37e-06 0.000478 0.26 0.26 Multiple myeloma (IgH translocation); chr16:89414821 chr16:89492017~89504460:- LIHC cis rs7811142 1 rs6953107 ENSG00000242294.5 STAG3L5P 4.92 1.37e-06 0.000478 0.31 0.26 Platelet count; chr7:100498041 chr7:100336079~100351900:+ LIHC cis rs7246657 0.882 rs59224125 ENSG00000276846.1 CTD-3220F14.3 4.92 1.37e-06 0.000478 0.31 0.26 Coronary artery calcification; chr19:37472303 chr19:37314868~37315620:- LIHC cis rs10129255 0.5 rs8004923 ENSG00000223648.3 IGHV3-64 4.92 1.38e-06 0.000478 0.18 0.26 Kawasaki disease; chr14:106785926 chr14:106643132~106658258:- LIHC cis rs4674676 1 rs4674676 ENSG00000261428.2 RP11-16P6.1 4.92 1.38e-06 0.000478 0.31 0.26 Chin dimples; chr2:222664393 chr2:222566899~222569719:- LIHC cis rs17826219 0.706 rs609472 ENSG00000266490.1 CTD-2349P21.9 4.92 1.38e-06 0.000479 0.31 0.26 Body mass index; chr17:30624409 chr17:30792372~30792833:+ LIHC cis rs524281 0.506 rs2298466 ENSG00000255320.1 RP11-755F10.1 4.92 1.38e-06 0.000479 0.32 0.26 Electroencephalogram traits; chr11:66243809 chr11:66244840~66246239:- LIHC cis rs12554020 0.681 rs74816254 ENSG00000227603.1 RP11-165J3.6 4.92 1.38e-06 0.000479 0.43 0.26 Schizophrenia; chr9:93486661 chr9:93435332~93437121:- LIHC cis rs12554020 0.786 rs79068125 ENSG00000227603.1 RP11-165J3.6 4.92 1.38e-06 0.000479 0.43 0.26 Schizophrenia; chr9:93486957 chr9:93435332~93437121:- LIHC cis rs12554020 0.786 rs79330192 ENSG00000227603.1 RP11-165J3.6 4.92 1.38e-06 0.000479 0.43 0.26 Schizophrenia; chr9:93487542 chr9:93435332~93437121:- LIHC cis rs7119038 0.818 rs11826521 ENSG00000255239.1 AP002954.6 -4.92 1.38e-06 0.000479 -0.37 -0.26 Sjögren's syndrome; chr11:118739840 chr11:118688039~118690600:- LIHC cis rs8059260 1 rs6498138 ENSG00000274038.1 RP11-66H6.4 4.92 1.38e-06 0.000479 0.38 0.26 Alcohol consumption over the past year; chr16:10951421 chr16:11056556~11057034:+ LIHC cis rs36715 0.953 rs36700 ENSG00000245937.6 LINC01184 4.91 1.38e-06 0.00048 0.32 0.26 Breast cancer; chr5:128215581 chr5:127940426~128083172:- LIHC cis rs2919917 1 rs1384804 ENSG00000254352.1 RP11-578O24.2 4.91 1.38e-06 0.00048 0.34 0.26 Lymphocyte counts; chr8:78659987 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs10093654 ENSG00000254352.1 RP11-578O24.2 4.91 1.38e-06 0.00048 0.34 0.26 Lymphocyte counts; chr8:78660360 chr8:78723796~78724136:- LIHC cis rs12157904 1 rs2071770 ENSG00000233360.4 Z83844.1 4.91 1.38e-06 0.00048 0.57 0.26 Response to anti-depressant treatment in major depressive disorder; chr22:37630740 chr22:37641832~37658377:- LIHC cis rs638893 0.588 rs529717 ENSG00000278376.1 RP11-158I9.8 -4.91 1.38e-06 0.00048 -0.47 -0.26 Vitiligo; chr11:118769372 chr11:118791254~118793137:+ LIHC cis rs638893 0.588 rs2508929 ENSG00000278376.1 RP11-158I9.8 -4.91 1.38e-06 0.00048 -0.47 -0.26 Vitiligo; chr11:118770742 chr11:118791254~118793137:+ LIHC cis rs638893 0.636 rs548167 ENSG00000278376.1 RP11-158I9.8 -4.91 1.38e-06 0.00048 -0.47 -0.26 Vitiligo; chr11:118777687 chr11:118791254~118793137:+ LIHC cis rs638893 0.685 rs486651 ENSG00000278376.1 RP11-158I9.8 -4.91 1.38e-06 0.00048 -0.47 -0.26 Vitiligo; chr11:118779150 chr11:118791254~118793137:+ LIHC cis rs7131987 0.868 rs737160 ENSG00000257176.2 RP11-996F15.2 -4.91 1.38e-06 0.00048 -0.29 -0.26 QT interval; chr12:29276079 chr12:29280418~29317848:- LIHC cis rs11722779 0.873 rs223346 ENSG00000246560.2 RP11-10L12.4 4.91 1.38e-06 0.00048 0.29 0.26 Schizophrenia; chr4:102859339 chr4:102828055~102844075:+ LIHC cis rs9890032 0.52 rs2321926 ENSG00000263531.1 RP13-753N3.1 4.91 1.38e-06 0.000481 0.34 0.26 Hip circumference adjusted for BMI; chr17:30714534 chr17:30863921~30864940:- LIHC cis rs67311347 0.955 rs11717036 ENSG00000223797.4 ENTPD3-AS1 -4.91 1.38e-06 0.000481 -0.21 -0.26 Renal cell carcinoma; chr3:40338087 chr3:40313802~40453329:- LIHC cis rs11098499 0.754 rs1849457 ENSG00000245958.5 RP11-33B1.1 -4.91 1.38e-06 0.000481 -0.26 -0.26 Corneal astigmatism; chr4:119333200 chr4:119454791~119552025:+ LIHC cis rs7811142 0.945 rs34989573 ENSG00000242294.5 STAG3L5P 4.91 1.38e-06 0.000481 0.31 0.26 Platelet count; chr7:100500272 chr7:100336079~100351900:+ LIHC cis rs12468226 1 rs2350809 ENSG00000273456.1 RP11-686O6.2 4.91 1.38e-06 0.000481 0.36 0.26 Urate levels; chr2:202464210 chr2:202374932~202375604:- LIHC cis rs2337406 0.81 rs7161739 ENSG00000274576.2 IGHV2-70 -4.91 1.38e-06 0.000481 -0.26 -0.26 Alzheimer's disease (late onset); chr14:106776118 chr14:106770577~106771020:- LIHC cis rs4660214 0.724 rs10788933 ENSG00000182109.6 RP11-69E11.4 -4.91 1.39e-06 0.000481 -0.27 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39229483 chr1:39522280~39546187:- LIHC cis rs11098499 0.604 rs2389887 ENSG00000245958.5 RP11-33B1.1 -4.91 1.39e-06 0.000481 -0.27 -0.26 Corneal astigmatism; chr4:119649489 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs10212714 ENSG00000245958.5 RP11-33B1.1 -4.91 1.39e-06 0.000481 -0.26 -0.26 Corneal astigmatism; chr4:119333147 chr4:119454791~119552025:+ LIHC cis rs16858210 0.648 rs79478990 ENSG00000234371.6 RPSAP31 4.91 1.39e-06 0.000482 0.33 0.26 Menopause (age at onset); chr3:183869306 chr3:183884924~183888449:+ LIHC cis rs67311347 1 rs9968170 ENSG00000223797.4 ENTPD3-AS1 -4.91 1.39e-06 0.000482 -0.2 -0.26 Renal cell carcinoma; chr3:40452783 chr3:40313802~40453329:- LIHC cis rs2274273 0.935 rs8004787 ENSG00000258413.1 RP11-665C16.6 -4.91 1.39e-06 0.000482 -0.28 -0.26 Protein biomarker; chr14:55140648 chr14:55262767~55272075:- LIHC cis rs2274273 0.905 rs2075601 ENSG00000258413.1 RP11-665C16.6 -4.91 1.39e-06 0.000482 -0.28 -0.26 Protein biomarker; chr14:55142516 chr14:55262767~55272075:- LIHC cis rs4934494 0.689 rs17127596 ENSG00000232936.4 RP11-80H5.2 -4.91 1.39e-06 0.000482 -0.31 -0.26 Red blood cell count; chr10:89816128 chr10:89645282~89650667:+ LIHC cis rs12134133 1 rs6673333 ENSG00000274245.1 RP11-357P18.2 4.91 1.39e-06 0.000483 0.39 0.26 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207285802 chr1:207372559~207373252:+ LIHC cis rs2836974 0.899 rs114399588 ENSG00000255568.3 BRWD1-AS2 4.91 1.39e-06 0.000483 0.3 0.26 Cognitive function; chr21:39282032 chr21:39313935~39314962:+ LIHC cis rs2836974 0.965 rs8131126 ENSG00000255568.3 BRWD1-AS2 4.91 1.39e-06 0.000483 0.3 0.26 Cognitive function; chr21:39283828 chr21:39313935~39314962:+ LIHC cis rs10129255 0.5 rs6576230 ENSG00000223648.3 IGHV3-64 4.91 1.39e-06 0.000483 0.18 0.26 Kawasaki disease; chr14:106778539 chr14:106643132~106658258:- LIHC cis rs875971 0.545 rs6460281 ENSG00000226824.5 RP4-756H11.3 -4.91 1.39e-06 0.000483 -0.32 -0.26 Aortic root size; chr7:66216128 chr7:66654538~66669855:+ LIHC cis rs11603023 0.874 rs483598 ENSG00000255422.1 AP002954.4 -4.91 1.39e-06 0.000483 -0.28 -0.26 Cholesterol, total; chr11:118638950 chr11:118704607~118750263:+ LIHC cis rs7429990 0.828 rs6792350 ENSG00000229759.1 MRPS18AP1 -4.91 1.39e-06 0.000483 -0.27 -0.26 Educational attainment (years of education); chr3:47797451 chr3:48256350~48256938:- LIHC cis rs11098499 0.644 rs10050092 ENSG00000245958.5 RP11-33B1.1 -4.91 1.39e-06 0.000483 -0.26 -0.26 Corneal astigmatism; chr4:119610930 chr4:119454791~119552025:+ LIHC cis rs2439831 0.85 rs524417 ENSG00000205771.5 CATSPER2P1 -4.91 1.4e-06 0.000484 -0.35 -0.26 Lung cancer in ever smokers; chr15:43480176 chr15:43726918~43747094:- LIHC cis rs2439831 0.85 rs2439832 ENSG00000205771.5 CATSPER2P1 -4.91 1.4e-06 0.000484 -0.35 -0.26 Lung cancer in ever smokers; chr15:43487488 chr15:43726918~43747094:- LIHC cis rs8059260 0.736 rs7195509 ENSG00000274038.1 RP11-66H6.4 -4.91 1.4e-06 0.000484 -0.41 -0.26 Alcohol consumption over the past year; chr16:10951572 chr16:11056556~11057034:+ LIHC cis rs2439831 0.85 rs60883262 ENSG00000166763.7 STRCP1 4.91 1.4e-06 0.000485 0.39 0.26 Lung cancer in ever smokers; chr15:43784305 chr15:43699488~43718184:- LIHC cis rs6600671 1 rs11249351 ENSG00000231429.2 RP11-343N15.2 -4.91 1.4e-06 0.000485 -0.29 -0.26 Hip geometry; chr1:121430082 chr1:121412719~121429274:+ LIHC cis rs6600671 0.967 rs12069545 ENSG00000231429.2 RP11-343N15.2 -4.91 1.4e-06 0.000485 -0.29 -0.26 Hip geometry; chr1:121430343 chr1:121412719~121429274:+ LIHC cis rs7937890 0.572 rs2597218 ENSG00000251991.1 RNU7-49P 4.91 1.4e-06 0.000486 0.29 0.26 Mitochondrial DNA levels; chr11:14510792 chr11:14478892~14478953:+ LIHC cis rs2919917 1 rs1441438 ENSG00000254352.1 RP11-578O24.2 -4.91 1.4e-06 0.000486 -0.36 -0.26 Lymphocyte counts; chr8:78729534 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs1545228 ENSG00000254352.1 RP11-578O24.2 -4.91 1.4e-06 0.000486 -0.36 -0.26 Lymphocyte counts; chr8:78732202 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs894221 ENSG00000254352.1 RP11-578O24.2 -4.91 1.4e-06 0.000486 -0.36 -0.26 Lymphocyte counts; chr8:78736822 chr8:78723796~78724136:- LIHC cis rs8005677 1 rs4982709 ENSG00000257285.4 RP11-298I3.1 4.91 1.4e-06 0.000487 0.26 0.26 Cognitive ability (multi-trait analysis); chr14:22925490 chr14:22929609~22955562:+ LIHC cis rs1555322 0.505 rs591590 ENSG00000279253.1 RP4-614O4.13 4.91 1.41e-06 0.000488 0.34 0.26 Attention deficit hyperactivity disorder; chr20:35278225 chr20:35262727~35264187:- LIHC cis rs9549367 0.789 rs6577034 ENSG00000269125.1 RP11-98F14.11 -4.91 1.41e-06 0.000488 -0.29 -0.26 Platelet distribution width; chr13:113225586 chr13:113165002~113165183:- LIHC cis rs2274273 0.875 rs2075602 ENSG00000258413.1 RP11-665C16.6 -4.91 1.41e-06 0.000488 -0.28 -0.26 Protein biomarker; chr14:55143056 chr14:55262767~55272075:- LIHC cis rs11098499 0.954 rs10008459 ENSG00000260091.1 RP11-33B1.4 -4.91 1.41e-06 0.000489 -0.18 -0.26 Corneal astigmatism; chr4:119473076 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs2127821 ENSG00000260091.1 RP11-33B1.4 -4.91 1.41e-06 0.000489 -0.18 -0.26 Corneal astigmatism; chr4:119473380 chr4:119409333~119410233:+ LIHC cis rs3733585 0.781 rs13103690 ENSG00000250413.1 RP11-448G15.1 4.91 1.41e-06 0.000489 0.33 0.26 Cleft plate (environmental tobacco smoke interaction); chr4:9971154 chr4:10006482~10009725:+ LIHC cis rs875971 0.522 rs2949690 ENSG00000164669.11 INTS4P1 4.91 1.41e-06 0.000489 0.36 0.26 Aortic root size; chr7:66018255 chr7:65141225~65234216:+ LIHC cis rs9549367 0.789 rs2287250 ENSG00000269125.1 RP11-98F14.11 4.91 1.41e-06 0.000489 0.29 0.26 Platelet distribution width; chr13:113235160 chr13:113165002~113165183:- LIHC cis rs16886181 0.512 rs12652988 ENSG00000271828.1 CTD-2310F14.1 4.91 1.41e-06 0.000489 0.49 0.26 Breast cancer (early onset); chr5:56739539 chr5:56927874~56929573:+ LIHC cis rs11098499 0.954 rs7681544 ENSG00000260091.1 RP11-33B1.4 -4.91 1.41e-06 0.000489 -0.18 -0.26 Corneal astigmatism; chr4:119490100 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs11940028 ENSG00000260091.1 RP11-33B1.4 -4.91 1.41e-06 0.000489 -0.18 -0.26 Corneal astigmatism; chr4:119490752 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs11935596 ENSG00000260091.1 RP11-33B1.4 -4.91 1.41e-06 0.000489 -0.18 -0.26 Corneal astigmatism; chr4:119491302 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs12507964 ENSG00000260091.1 RP11-33B1.4 -4.91 1.41e-06 0.000489 -0.18 -0.26 Corneal astigmatism; chr4:119491906 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs11098530 ENSG00000260091.1 RP11-33B1.4 -4.91 1.41e-06 0.000489 -0.18 -0.26 Corneal astigmatism; chr4:119491999 chr4:119409333~119410233:+ LIHC cis rs71520386 0.634 rs13240023 ENSG00000228649.7 AC005682.5 -4.91 1.42e-06 0.00049 -0.33 -0.26 Fibrinogen levels; chr7:22827874 chr7:22854178~22861579:+ LIHC cis rs228614 0.51 rs223452 ENSG00000230069.3 LRRC37A15P -4.91 1.42e-06 0.00049 -0.24 -0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102790277 chr4:102727274~102730721:- LIHC cis rs765787 0.556 rs10851422 ENSG00000259520.4 CTD-2651B20.3 -4.91 1.42e-06 0.00049 -0.3 -0.26 Uric acid levels; chr15:45221540 chr15:45251580~45279251:- LIHC cis rs1150668 1 rs1150668 ENSG00000204709.4 LINC01556 4.91 1.42e-06 0.00049 0.29 0.26 Pubertal anthropometrics; chr6:28162011 chr6:28943877~28944537:+ LIHC cis rs755249 0.501 rs2490945 ENSG00000182109.6 RP11-69E11.4 4.91 1.42e-06 0.00049 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39371672 chr1:39522280~39546187:- LIHC cis rs2032366 0.63 rs12457579 ENSG00000267279.1 RP11-879F14.2 -4.91 1.42e-06 0.000491 -0.31 -0.26 Obesity-related traits; chr18:61629575 chr18:61585746~61606916:- LIHC cis rs16858210 0.837 rs11716104 ENSG00000234371.6 RPSAP31 4.91 1.42e-06 0.000491 0.33 0.26 Menopause (age at onset); chr3:183864211 chr3:183884924~183888449:+ LIHC cis rs6600671 0.899 rs6674392 ENSG00000231429.2 RP11-343N15.2 -4.91 1.42e-06 0.000491 -0.3 -0.26 Hip geometry; chr1:121518864 chr1:121412719~121429274:+ LIHC cis rs9595066 0.627 rs4942287 ENSG00000230731.2 RP11-478K15.6 -4.91 1.42e-06 0.000491 -0.3 -0.26 Schizophrenia; chr13:44160560 chr13:44234118~44243192:- LIHC cis rs9890032 1 rs9890032 ENSG00000263531.1 RP13-753N3.1 -4.91 1.42e-06 0.000491 -0.31 -0.26 Hip circumference adjusted for BMI; chr17:30838916 chr17:30863921~30864940:- LIHC cis rs7429990 0.864 rs3915654 ENSG00000229759.1 MRPS18AP1 -4.91 1.42e-06 0.000491 -0.27 -0.26 Educational attainment (years of education); chr3:47827132 chr3:48256350~48256938:- LIHC cis rs7429990 0.833 rs35582375 ENSG00000229759.1 MRPS18AP1 -4.91 1.42e-06 0.000491 -0.27 -0.26 Educational attainment (years of education); chr3:47829639 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs13077230 ENSG00000229759.1 MRPS18AP1 -4.91 1.42e-06 0.000491 -0.27 -0.26 Educational attainment (years of education); chr3:47832232 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs11130150 ENSG00000229759.1 MRPS18AP1 -4.91 1.42e-06 0.000491 -0.27 -0.26 Educational attainment (years of education); chr3:47832449 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs11710199 ENSG00000229759.1 MRPS18AP1 -4.91 1.42e-06 0.000491 -0.27 -0.26 Educational attainment (years of education); chr3:47836588 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs17290490 ENSG00000229759.1 MRPS18AP1 -4.91 1.42e-06 0.000491 -0.27 -0.26 Educational attainment (years of education); chr3:47841237 chr3:48256350~48256938:- LIHC cis rs2877649 0.59 rs75152230 ENSG00000258744.1 RP11-80A15.1 -4.91 1.42e-06 0.000491 -0.51 -0.26 Smooth-surface caries; chr14:24465850 chr14:24501594~24508688:+ LIHC cis rs10129255 0.518 rs10136903 ENSG00000223648.3 IGHV3-64 4.91 1.42e-06 0.000491 0.18 0.26 Kawasaki disease; chr14:106778866 chr14:106643132~106658258:- LIHC cis rs10129255 0.518 rs11847766 ENSG00000223648.3 IGHV3-64 4.91 1.42e-06 0.000491 0.18 0.26 Kawasaki disease; chr14:106779186 chr14:106643132~106658258:- LIHC cis rs734999 0.967 rs10797433 ENSG00000225931.3 RP3-395M20.7 4.91 1.42e-06 0.000491 0.28 0.26 Ulcerative colitis; chr1:2570571 chr1:2566410~2569888:+ LIHC cis rs10847980 0.623 rs28613486 ENSG00000256092.2 RP13-942N8.1 4.91 1.42e-06 0.000491 0.42 0.26 Adiponectin levels; chr12:123382721 chr12:123363868~123366113:+ LIHC cis rs1714507 0.533 rs2731120 ENSG00000272087.1 RP11-379F4.7 -4.91 1.42e-06 0.000491 -0.29 -0.26 Subjective well-being; chr3:158579844 chr3:158693120~158693768:- LIHC cis rs1714507 0.515 rs2731112 ENSG00000272087.1 RP11-379F4.7 4.91 1.42e-06 0.000491 0.29 0.26 Subjective well-being; chr3:158572439 chr3:158693120~158693768:- LIHC cis rs1714507 0.533 rs2731122 ENSG00000272087.1 RP11-379F4.7 4.91 1.42e-06 0.000491 0.29 0.26 Subjective well-being; chr3:158577491 chr3:158693120~158693768:- LIHC cis rs7208859 0.673 rs216420 ENSG00000266490.1 CTD-2349P21.9 4.91 1.42e-06 0.000492 0.3 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30611490 chr17:30792372~30792833:+ LIHC cis rs875971 0.522 rs4502988 ENSG00000164669.11 INTS4P1 -4.91 1.42e-06 0.000492 -0.36 -0.26 Aortic root size; chr7:65832759 chr7:65141225~65234216:+ LIHC cis rs875971 0.522 rs2008188 ENSG00000164669.11 INTS4P1 -4.91 1.42e-06 0.000492 -0.36 -0.26 Aortic root size; chr7:65964026 chr7:65141225~65234216:+ LIHC cis rs2836974 0.644 rs11088471 ENSG00000255568.3 BRWD1-AS2 -4.91 1.42e-06 0.000492 -0.21 -0.26 Cognitive function; chr21:39327387 chr21:39313935~39314962:+ LIHC cis rs7714584 1 rs60134818 ENSG00000197083.10 ZNF300P1 4.91 1.42e-06 0.000493 0.39 0.26 Crohn's disease; chr5:150881481 chr5:150930645~150946289:- LIHC cis rs12554020 0.681 rs76725109 ENSG00000227603.1 RP11-165J3.6 4.91 1.43e-06 0.000493 0.49 0.26 Schizophrenia; chr9:93639802 chr9:93435332~93437121:- LIHC cis rs227275 0.556 rs223449 ENSG00000230069.3 LRRC37A15P -4.91 1.43e-06 0.000493 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102791180 chr4:102727274~102730721:- LIHC cis rs7246657 0.943 rs10409204 ENSG00000276846.1 CTD-3220F14.3 4.91 1.43e-06 0.000494 0.33 0.26 Coronary artery calcification; chr19:37426790 chr19:37314868~37315620:- LIHC cis rs2412819 0.599 rs2470120 ENSG00000166763.7 STRCP1 4.91 1.43e-06 0.000494 0.33 0.26 Lung cancer; chr15:43636872 chr15:43699488~43718184:- LIHC cis rs10829156 0.66 rs11014830 ENSG00000240291.1 RP11-499P20.2 4.91 1.43e-06 0.000494 0.38 0.26 Sudden cardiac arrest; chr10:18551504 chr10:18513115~18545651:- LIHC cis rs10829156 0.66 rs10828901 ENSG00000240291.1 RP11-499P20.2 4.91 1.43e-06 0.000494 0.38 0.26 Sudden cardiac arrest; chr10:18552161 chr10:18513115~18545651:- LIHC cis rs2929278 0.562 rs8033846 ENSG00000166763.7 STRCP1 -4.91 1.43e-06 0.000494 -0.34 -0.26 Schizophrenia; chr15:43743165 chr15:43699488~43718184:- LIHC cis rs11098499 0.863 rs3822190 ENSG00000245958.5 RP11-33B1.1 -4.91 1.43e-06 0.000494 -0.27 -0.26 Corneal astigmatism; chr4:119506943 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs3822191 ENSG00000245958.5 RP11-33B1.1 -4.91 1.43e-06 0.000494 -0.27 -0.26 Corneal astigmatism; chr4:119506946 chr4:119454791~119552025:+ LIHC cis rs17507216 0.667 rs72753916 ENSG00000278603.1 RP13-608F4.5 4.91 1.43e-06 0.000494 0.5 0.26 Excessive daytime sleepiness; chr15:82684001 chr15:82472203~82472426:+ LIHC cis rs2439831 1 rs2439850 ENSG00000205771.5 CATSPER2P1 -4.91 1.43e-06 0.000495 -0.35 -0.26 Lung cancer in ever smokers; chr15:43492656 chr15:43726918~43747094:- LIHC cis rs2929278 0.617 rs694461 ENSG00000166763.7 STRCP1 -4.91 1.43e-06 0.000495 -0.34 -0.26 Schizophrenia; chr15:43803865 chr15:43699488~43718184:- LIHC cis rs9291683 0.609 rs13141233 ENSG00000250413.1 RP11-448G15.1 -4.91 1.43e-06 0.000496 -0.32 -0.26 Bone mineral density; chr4:10027105 chr4:10006482~10009725:+ LIHC cis rs9291683 0.609 rs34709913 ENSG00000250413.1 RP11-448G15.1 -4.91 1.43e-06 0.000496 -0.32 -0.26 Bone mineral density; chr4:10027331 chr4:10006482~10009725:+ LIHC cis rs7937890 0.593 rs2597189 ENSG00000251991.1 RNU7-49P 4.91 1.44e-06 0.000496 0.29 0.26 Mitochondrial DNA levels; chr11:14490514 chr11:14478892~14478953:+ LIHC cis rs17711722 0.701 rs781143 ENSG00000164669.11 INTS4P1 -4.91 1.44e-06 0.000497 -0.36 -0.26 Calcium levels; chr7:65974892 chr7:65141225~65234216:+ LIHC cis rs30380 0.632 rs26497 ENSG00000272109.1 CTD-2260A17.3 -4.91 1.44e-06 0.000497 -0.33 -0.26 Cerebrospinal fluid biomarker levels; chr5:96803064 chr5:96804353~96806105:+ LIHC cis rs712039 0.652 rs11656503 ENSG00000276054.1 RP11-378E13.3 4.91 1.44e-06 0.000497 0.32 0.26 Tuberculosis; chr17:37411934 chr17:37386886~37387926:+ LIHC cis rs9291683 0.609 rs36084205 ENSG00000250413.1 RP11-448G15.1 -4.91 1.44e-06 0.000497 -0.32 -0.26 Bone mineral density; chr4:10027054 chr4:10006482~10009725:+ LIHC cis rs7246657 0.882 rs13345148 ENSG00000276846.1 CTD-3220F14.3 4.91 1.44e-06 0.000498 0.32 0.26 Coronary artery calcification; chr19:37328729 chr19:37314868~37315620:- LIHC cis rs7714584 1 rs59980321 ENSG00000197083.10 ZNF300P1 4.91 1.44e-06 0.000498 0.39 0.26 Crohn's disease; chr5:150862251 chr5:150930645~150946289:- LIHC cis rs875971 0.522 rs781144 ENSG00000164669.11 INTS4P1 -4.91 1.44e-06 0.000499 -0.36 -0.26 Aortic root size; chr7:65975357 chr7:65141225~65234216:+ LIHC cis rs9532669 0.926 rs7329302 ENSG00000176268.5 CYCSP34 -4.91 1.45e-06 0.000499 -0.28 -0.26 Cervical cancer; chr13:40962396 chr13:40863599~40863902:- LIHC cis rs4731207 0.596 rs4624966 ENSG00000224897.5 POT1-AS1 4.9 1.45e-06 5e-04 0.31 0.26 Cutaneous malignant melanoma; chr7:124986417 chr7:124929873~125179315:+ LIHC cis rs4731207 0.623 rs4506149 ENSG00000224897.5 POT1-AS1 4.9 1.45e-06 5e-04 0.31 0.26 Cutaneous malignant melanoma; chr7:124986419 chr7:124929873~125179315:+ LIHC cis rs7580658 0.614 rs7585198 ENSG00000236682.1 AC068282.3 4.9 1.45e-06 0.000501 0.32 0.26 Protein C levels; chr2:127205059 chr2:127389130~127400580:+ LIHC cis rs4650994 0.507 rs12141152 ENSG00000273384.1 RP5-1098D14.1 4.9 1.45e-06 0.000501 0.32 0.26 HDL cholesterol;HDL cholesterol levels; chr1:178545030 chr1:178651706~178652282:+ LIHC cis rs116175783 0.557 rs72877940 ENSG00000227403.1 AC009299.3 4.9 1.45e-06 0.000502 0.39 0.26 Intelligence (multi-trait analysis); chr2:161403965 chr2:161244739~161249050:+ LIHC cis rs2877649 0.793 rs79756911 ENSG00000258744.1 RP11-80A15.1 -4.9 1.45e-06 0.000502 -0.52 -0.26 Smooth-surface caries; chr14:24438374 chr14:24501594~24508688:+ LIHC cis rs2735413 0.918 rs12925605 ENSG00000276007.1 RP11-358L22.3 -4.9 1.45e-06 0.000502 -0.28 -0.26 Systolic blood pressure (alcohol consumption interaction); chr16:78037818 chr16:78123243~78124332:+ LIHC cis rs9425766 0.679 rs4652234 ENSG00000227373.4 RP11-160H22.5 4.9 1.46e-06 0.000502 0.31 0.26 Life satisfaction; chr1:174181712 chr1:174115300~174160004:- LIHC cis rs9425766 0.732 rs6658543 ENSG00000227373.4 RP11-160H22.5 4.9 1.46e-06 0.000502 0.31 0.26 Life satisfaction; chr1:174183338 chr1:174115300~174160004:- LIHC cis rs9487094 0.813 rs12528566 ENSG00000260273.1 RP11-425D10.10 4.9 1.46e-06 0.000502 0.35 0.26 Height; chr6:109416945 chr6:109382795~109383666:+ LIHC cis rs7412746 0.658 rs12405726 ENSG00000231073.1 RP11-316M1.3 4.9 1.46e-06 0.000502 0.27 0.26 Melanoma; chr1:150983652 chr1:150973123~150975534:+ LIHC cis rs17301013 0.932 rs4233195 ENSG00000227373.4 RP11-160H22.5 -4.9 1.46e-06 0.000503 -0.31 -0.26 Systemic lupus erythematosus; chr1:174806736 chr1:174115300~174160004:- LIHC cis rs4660214 0.666 rs1180383 ENSG00000182109.6 RP11-69E11.4 4.9 1.46e-06 0.000503 0.27 0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39380595 chr1:39522280~39546187:- LIHC cis rs12468226 0.873 rs6761131 ENSG00000273456.1 RP11-686O6.2 -4.9 1.46e-06 0.000503 -0.36 -0.26 Urate levels; chr2:202237675 chr2:202374932~202375604:- LIHC cis rs7923609 0.776 rs10761785 ENSG00000232075.1 MRPL35P2 -4.9 1.46e-06 0.000504 -0.28 -0.26 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63559006 chr10:63634317~63634827:- LIHC cis rs12468226 0.817 rs6435135 ENSG00000273456.1 RP11-686O6.2 -4.9 1.46e-06 0.000504 -0.37 -0.26 Urate levels; chr2:202217469 chr2:202374932~202375604:- LIHC cis rs9834975 0.815 rs9874163 ENSG00000272758.4 RP11-299J3.8 -4.9 1.46e-06 0.000504 -0.28 -0.26 Diastolic blood pressure; chr3:122386581 chr3:122416207~122443180:+ LIHC cis rs2274273 0.87 rs8021583 ENSG00000258413.1 RP11-665C16.6 -4.9 1.46e-06 0.000504 -0.31 -0.26 Protein biomarker; chr14:55282889 chr14:55262767~55272075:- LIHC cis rs228614 0.51 rs223434 ENSG00000246560.2 RP11-10L12.4 4.9 1.47e-06 0.000505 0.29 0.26 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799902 chr4:102828055~102844075:+ LIHC cis rs6822297 0.504 rs10010180 ENSG00000240005.4 RP11-293A21.1 4.9 1.47e-06 0.000505 0.3 0.26 Obesity-related traits; chr4:26984359 chr4:26859806~26860599:- LIHC cis rs4964805 0.537 rs11111750 ENSG00000257681.1 RP11-341G23.4 4.9 1.47e-06 0.000506 0.26 0.26 Attention deficit hyperactivity disorder; chr12:103761762 chr12:103746315~103768858:- LIHC cis rs4934494 0.727 rs12764076 ENSG00000232936.4 RP11-80H5.2 4.9 1.47e-06 0.000506 0.32 0.26 Red blood cell count; chr10:89630443 chr10:89645282~89650667:+ LIHC cis rs4934494 0.634 rs12762448 ENSG00000232936.4 RP11-80H5.2 4.9 1.47e-06 0.000506 0.32 0.26 Red blood cell count; chr10:89630483 chr10:89645282~89650667:+ LIHC cis rs2243480 1 rs1404147 ENSG00000228409.4 CCT6P1 4.9 1.47e-06 0.000506 0.27 0.26 Diabetic kidney disease; chr7:65799537 chr7:65751142~65763354:+ LIHC cis rs17507216 0.718 rs17158403 ENSG00000278603.1 RP13-608F4.5 4.9 1.47e-06 0.000506 0.5 0.26 Excessive daytime sleepiness; chr15:82572478 chr15:82472203~82472426:+ LIHC cis rs4660214 0.666 rs1984143 ENSG00000182109.6 RP11-69E11.4 -4.9 1.47e-06 0.000506 -0.27 -0.26 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39290645 chr1:39522280~39546187:- LIHC cis rs11096990 0.634 rs4975002 ENSG00000249685.1 RP11-360F5.3 -4.9 1.47e-06 0.000507 -0.3 -0.26 Cognitive function; chr4:39286733 chr4:39133913~39135608:+ LIHC cis rs7829975 0.606 rs10112585 ENSG00000253893.2 FAM85B 4.9 1.47e-06 0.000507 0.3 0.26 Mood instability; chr8:8937520 chr8:8167819~8226614:- LIHC cis rs17711722 0.74 rs7809991 ENSG00000164669.11 INTS4P1 -4.9 1.47e-06 0.000507 -0.36 -0.26 Calcium levels; chr7:65941231 chr7:65141225~65234216:+ LIHC cis rs227275 0.525 rs7685399 ENSG00000230069.3 LRRC37A15P -4.9 1.47e-06 0.000507 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102991926 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs4623004 ENSG00000230069.3 LRRC37A15P -4.9 1.47e-06 0.000507 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:103000141 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs223449 ENSG00000246560.2 RP11-10L12.4 4.9 1.47e-06 0.000507 0.29 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102791180 chr4:102828055~102844075:+ LIHC cis rs11672691 0.519 rs12973063 ENSG00000267107.5 PCAT19 4.9 1.47e-06 0.000507 0.31 0.26 Prostate cancer; chr19:41503757 chr19:41454169~41500649:- LIHC cis rs11098499 0.955 rs7685268 ENSG00000245958.5 RP11-33B1.1 -4.9 1.47e-06 0.000507 -0.28 -0.26 Corneal astigmatism; chr4:119241033 chr4:119454791~119552025:+ LIHC cis rs6163 0.588 rs11191392 ENSG00000236937.2 PTGES3P4 4.9 1.47e-06 0.000508 0.31 0.26 Waist circumference;Hip circumference; chr10:102767194 chr10:102845595~102845950:+ LIHC cis rs5769765 0.671 rs138841 ENSG00000278869.1 CITF22-49E9.3 4.9 1.47e-06 0.000508 0.39 0.26 Schizophrenia; chr22:49788312 chr22:49933198~49934074:- LIHC cis rs367615 0.552 rs2963023 ENSG00000249476.1 CTD-2587M2.1 -4.9 1.47e-06 0.000508 -0.3 -0.26 Colorectal cancer (SNP x SNP interaction); chr5:109394369 chr5:109237120~109326369:- LIHC cis rs2337406 0.866 rs988130 ENSG00000274576.2 IGHV2-70 -4.9 1.48e-06 0.000508 -0.26 -0.26 Alzheimer's disease (late onset); chr14:106777154 chr14:106770577~106771020:- LIHC cis rs2243480 1 rs160634 ENSG00000228409.4 CCT6P1 -4.9 1.48e-06 0.000509 -0.26 -0.26 Diabetic kidney disease; chr7:66063677 chr7:65751142~65763354:+ LIHC cis rs12478296 0.685 rs67829386 ENSG00000261186.2 RP11-341N2.1 -4.9 1.48e-06 0.000509 -0.34 -0.26 Obesity-related traits; chr2:242050125 chr2:242087351~242088457:- LIHC cis rs9467711 0.591 rs10484435 ENSG00000216436.2 HIST1H2APS1 4.9 1.48e-06 0.000509 0.68 0.26 Autism spectrum disorder or schizophrenia; chr6:26031583 chr6:25732497~25732827:+ LIHC cis rs10829156 0.699 rs10828879 ENSG00000240291.1 RP11-499P20.2 4.9 1.48e-06 0.000509 0.38 0.26 Sudden cardiac arrest; chr10:18546425 chr10:18513115~18545651:- LIHC cis rs875971 0.862 rs6944374 ENSG00000237310.1 GS1-124K5.4 -4.9 1.48e-06 0.00051 -0.23 -0.26 Aortic root size; chr7:66221942 chr7:66493706~66495474:+ LIHC cis rs7937890 0.56 rs2597194 ENSG00000251991.1 RNU7-49P 4.9 1.48e-06 0.00051 0.29 0.26 Mitochondrial DNA levels; chr11:14475723 chr11:14478892~14478953:+ LIHC cis rs524281 0.506 rs512421 ENSG00000255320.1 RP11-755F10.1 4.9 1.48e-06 0.00051 0.32 0.26 Electroencephalogram traits; chr11:66217697 chr11:66244840~66246239:- LIHC cis rs950169 0.922 rs12906983 ENSG00000259728.4 LINC00933 4.9 1.48e-06 0.00051 0.37 0.26 Schizophrenia; chr15:84262270 chr15:84570649~84580175:+ LIHC cis rs2836974 0.568 rs2183573 ENSG00000255568.3 BRWD1-AS2 -4.9 1.48e-06 0.00051 -0.22 -0.26 Cognitive function; chr21:39202379 chr21:39313935~39314962:+ LIHC cis rs9425766 0.54 rs2294492 ENSG00000227373.4 RP11-160H22.5 4.9 1.48e-06 0.000511 0.31 0.26 Life satisfaction; chr1:174157884 chr1:174115300~174160004:- LIHC cis rs2739330 0.731 rs4822450 ENSG00000099984.9 GSTT2 -4.9 1.49e-06 0.000512 -0.3 -0.26 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23980123~23983911:+ LIHC cis rs853679 0.55 rs1237875 ENSG00000219392.1 RP1-265C24.5 4.9 1.49e-06 0.000512 0.39 0.26 Depression; chr6:28205232 chr6:28115628~28116551:+ LIHC cis rs4356203 0.543 rs214093 ENSG00000272034.1 SNORD14A -4.9 1.49e-06 0.000513 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17273241 chr11:17074654~17074744:- LIHC cis rs4356203 0.519 rs214092 ENSG00000272034.1 SNORD14A -4.9 1.49e-06 0.000513 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17273499 chr11:17074654~17074744:- LIHC cis rs5769765 0.817 rs11912619 ENSG00000278869.1 CITF22-49E9.3 4.9 1.49e-06 0.000513 0.4 0.26 Schizophrenia; chr22:49923753 chr22:49933198~49934074:- LIHC cis rs5769765 0.73 rs62233964 ENSG00000278869.1 CITF22-49E9.3 4.9 1.49e-06 0.000513 0.4 0.26 Schizophrenia; chr22:49923762 chr22:49933198~49934074:- LIHC cis rs6921919 0.848 rs6903652 ENSG00000216901.1 AL022393.7 4.9 1.49e-06 0.000513 0.35 0.26 Autism spectrum disorder or schizophrenia; chr6:28354343 chr6:28176188~28176674:+ LIHC cis rs603446 0.678 rs664059 ENSG00000254851.1 RP11-109L13.1 -4.9 1.49e-06 0.000514 -0.3 -0.26 Triglycerides; chr11:116771421 chr11:117135528~117138582:+ LIHC cis rs75920871 0.589 rs73008568 ENSG00000254851.1 RP11-109L13.1 -4.9 1.49e-06 0.000514 -0.52 -0.26 Subjective well-being; chr11:117194291 chr11:117135528~117138582:+ LIHC cis rs453301 0.686 rs6601280 ENSG00000173295.6 FAM86B3P 4.9 1.5e-06 0.000514 0.38 0.26 Joint mobility (Beighton score); chr8:9051726 chr8:8228595~8244865:+ LIHC cis rs524281 0.64 rs61895584 ENSG00000255320.1 RP11-755F10.1 -4.9 1.5e-06 0.000516 -0.37 -0.26 Electroencephalogram traits; chr11:66042738 chr11:66244840~66246239:- LIHC cis rs950776 0.518 rs62008174 ENSG00000261762.1 RP11-650L12.2 4.9 1.5e-06 0.000516 0.34 0.26 Sudden cardiac arrest; chr15:78516605 chr15:78589123~78591276:- LIHC cis rs950169 0.881 rs34117475 ENSG00000225151.9 GOLGA2P7 -4.9 1.5e-06 0.000517 -0.32 -0.26 Schizophrenia; chr15:84565212 chr15:84199311~84230136:- LIHC cis rs1061377 1 rs4974998 ENSG00000249685.1 RP11-360F5.3 4.9 1.5e-06 0.000517 0.31 0.26 Uric acid levels; chr4:39109129 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs7673299 ENSG00000249685.1 RP11-360F5.3 4.9 1.5e-06 0.000517 0.31 0.26 Uric acid levels; chr4:39109138 chr4:39133913~39135608:+ LIHC cis rs8059260 0.551 rs7187539 ENSG00000274038.1 RP11-66H6.4 -4.9 1.5e-06 0.000517 -0.4 -0.26 Alcohol consumption over the past year; chr16:10964900 chr16:11056556~11057034:+ LIHC cis rs9467711 0.591 rs35249036 ENSG00000216436.2 HIST1H2APS1 4.9 1.5e-06 0.000517 0.64 0.26 Autism spectrum disorder or schizophrenia; chr6:26025935 chr6:25732497~25732827:+ LIHC cis rs638893 0.53 rs1961138 ENSG00000278376.1 RP11-158I9.8 -4.9 1.5e-06 0.000517 -0.47 -0.26 Vitiligo; chr11:118748714 chr11:118791254~118793137:+ LIHC cis rs638893 0.578 rs485901 ENSG00000278376.1 RP11-158I9.8 -4.9 1.5e-06 0.000517 -0.47 -0.26 Vitiligo; chr11:118751536 chr11:118791254~118793137:+ LIHC cis rs638893 0.578 rs580079 ENSG00000278376.1 RP11-158I9.8 -4.9 1.5e-06 0.000517 -0.47 -0.26 Vitiligo; chr11:118754900 chr11:118791254~118793137:+ LIHC cis rs904251 0.828 rs2797803 ENSG00000204110.6 RP1-153P14.8 -4.9 1.51e-06 0.000518 -0.32 -0.26 Cognitive performance; chr6:37519564 chr6:37507348~37535616:+ LIHC cis rs2243480 0.708 rs13242216 ENSG00000226824.5 RP4-756H11.3 -4.9 1.51e-06 0.000518 -0.43 -0.26 Diabetic kidney disease; chr7:66433290 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs67536397 ENSG00000226824.5 RP4-756H11.3 -4.9 1.51e-06 0.000518 -0.43 -0.26 Diabetic kidney disease; chr7:66482930 chr7:66654538~66669855:+ LIHC cis rs2243480 1 rs58669269 ENSG00000226824.5 RP4-756H11.3 -4.9 1.51e-06 0.000518 -0.43 -0.26 Diabetic kidney disease; chr7:66486966 chr7:66654538~66669855:+ LIHC cis rs227275 0.525 rs7672319 ENSG00000230069.3 LRRC37A15P -4.9 1.51e-06 0.000518 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102990002 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs6533051 ENSG00000230069.3 LRRC37A15P -4.9 1.51e-06 0.000518 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102990065 chr4:102727274~102730721:- LIHC cis rs1167827 0.68 rs1167796 ENSG00000127957.15 PMS2P3 4.9 1.51e-06 0.000518 0.24 0.26 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75543861 chr7:75502930~75528148:- LIHC cis rs227275 0.525 rs6533052 ENSG00000230069.3 LRRC37A15P -4.9 1.51e-06 0.000518 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102990624 chr4:102727274~102730721:- LIHC cis rs9291683 0.609 rs4622999 ENSG00000250413.1 RP11-448G15.1 -4.9 1.51e-06 0.000519 -0.32 -0.26 Bone mineral density; chr4:10001771 chr4:10006482~10009725:+ LIHC cis rs30380 0.632 rs26498 ENSG00000272109.1 CTD-2260A17.3 4.9 1.51e-06 0.000519 0.33 0.26 Cerebrospinal fluid biomarker levels; chr5:96803109 chr5:96804353~96806105:+ LIHC cis rs227275 0.525 rs3974485 ENSG00000230069.3 LRRC37A15P -4.9 1.51e-06 0.000519 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102993283 chr4:102727274~102730721:- LIHC cis rs10129255 1 rs10141557 ENSG00000223648.3 IGHV3-64 4.9 1.51e-06 0.000519 0.2 0.26 Kawasaki disease; chr14:106767990 chr14:106643132~106658258:- LIHC cis rs950169 0.845 rs4106951 ENSG00000259728.4 LINC00933 4.9 1.51e-06 0.00052 0.35 0.26 Schizophrenia; chr15:84164642 chr15:84570649~84580175:+ LIHC cis rs950169 0.922 rs4842940 ENSG00000259728.4 LINC00933 -4.9 1.51e-06 0.00052 -0.35 -0.26 Schizophrenia; chr15:84162473 chr15:84570649~84580175:+ LIHC cis rs950169 0.922 rs4842941 ENSG00000259728.4 LINC00933 -4.9 1.51e-06 0.00052 -0.35 -0.26 Schizophrenia; chr15:84162560 chr15:84570649~84580175:+ LIHC cis rs950169 0.922 rs12911223 ENSG00000259728.4 LINC00933 -4.9 1.51e-06 0.00052 -0.35 -0.26 Schizophrenia; chr15:84162919 chr15:84570649~84580175:+ LIHC cis rs9834975 0.967 rs6787230 ENSG00000272758.4 RP11-299J3.8 -4.9 1.51e-06 0.00052 -0.28 -0.26 Diastolic blood pressure; chr3:122392403 chr3:122416207~122443180:+ LIHC cis rs6142102 0.59 rs6059691 ENSG00000276073.1 RP5-1125A11.7 4.9 1.51e-06 0.00052 0.29 0.26 Skin pigmentation; chr20:34149161 chr20:33985617~33988989:- LIHC cis rs904251 0.861 rs2776877 ENSG00000204110.6 RP1-153P14.8 -4.9 1.51e-06 0.00052 -0.32 -0.26 Cognitive performance; chr6:37519359 chr6:37507348~37535616:+ LIHC cis rs904251 0.864 rs2797801 ENSG00000204110.6 RP1-153P14.8 -4.9 1.51e-06 0.00052 -0.32 -0.26 Cognitive performance; chr6:37519385 chr6:37507348~37535616:+ LIHC cis rs904251 0.797 rs2776878 ENSG00000204110.6 RP1-153P14.8 -4.9 1.51e-06 0.00052 -0.32 -0.26 Cognitive performance; chr6:37519497 chr6:37507348~37535616:+ LIHC cis rs7714584 1 rs7736554 ENSG00000197083.10 ZNF300P1 4.9 1.52e-06 0.000521 0.39 0.26 Crohn's disease; chr5:150878746 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs7736873 ENSG00000197083.10 ZNF300P1 4.9 1.52e-06 0.000521 0.39 0.26 Crohn's disease; chr5:150878920 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs7716903 ENSG00000197083.10 ZNF300P1 4.9 1.52e-06 0.000521 0.39 0.26 Crohn's disease; chr5:150879012 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs11747270 ENSG00000197083.10 ZNF300P1 -4.9 1.52e-06 0.000521 -0.39 -0.26 Crohn's disease; chr5:150879305 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs11167518 ENSG00000197083.10 ZNF300P1 4.9 1.52e-06 0.000521 0.39 0.26 Crohn's disease; chr5:150879358 chr5:150930645~150946289:- LIHC cis rs904251 0.766 rs1757175 ENSG00000204110.6 RP1-153P14.8 -4.9 1.52e-06 0.000521 -0.32 -0.26 Cognitive performance; chr6:37518918 chr6:37507348~37535616:+ LIHC cis rs904251 0.828 rs1757174 ENSG00000204110.6 RP1-153P14.8 -4.9 1.52e-06 0.000521 -0.32 -0.26 Cognitive performance; chr6:37518919 chr6:37507348~37535616:+ LIHC cis rs904251 0.861 rs1757173 ENSG00000204110.6 RP1-153P14.8 -4.9 1.52e-06 0.000521 -0.32 -0.26 Cognitive performance; chr6:37519176 chr6:37507348~37535616:+ LIHC cis rs904251 0.861 rs1757169 ENSG00000204110.6 RP1-153P14.8 -4.9 1.52e-06 0.000521 -0.32 -0.26 Cognitive performance; chr6:37519300 chr6:37507348~37535616:+ LIHC cis rs2337406 0.866 rs8015361 ENSG00000274576.2 IGHV2-70 -4.9 1.52e-06 0.000521 -0.26 -0.26 Alzheimer's disease (late onset); chr14:106783991 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs74090151 ENSG00000274576.2 IGHV2-70 -4.9 1.52e-06 0.000521 -0.26 -0.26 Alzheimer's disease (late onset); chr14:106785377 chr14:106770577~106771020:- LIHC cis rs9291683 0.679 rs13137795 ENSG00000250413.1 RP11-448G15.1 -4.89 1.52e-06 0.000522 -0.32 -0.26 Bone mineral density; chr4:10049882 chr4:10006482~10009725:+ LIHC cis rs875971 0.522 rs4718285 ENSG00000164669.11 INTS4P1 -4.89 1.52e-06 0.000522 -0.36 -0.26 Aortic root size; chr7:65827018 chr7:65141225~65234216:+ LIHC cis rs17711722 0.64 rs13237956 ENSG00000164669.11 INTS4P1 -4.89 1.52e-06 0.000522 -0.36 -0.26 Calcium levels; chr7:65853042 chr7:65141225~65234216:+ LIHC cis rs875971 0.516 rs6945322 ENSG00000164669.11 INTS4P1 -4.89 1.52e-06 0.000522 -0.36 -0.26 Aortic root size; chr7:65871069 chr7:65141225~65234216:+ LIHC cis rs17711722 0.701 rs4467826 ENSG00000164669.11 INTS4P1 -4.89 1.52e-06 0.000522 -0.36 -0.26 Calcium levels; chr7:65903721 chr7:65141225~65234216:+ LIHC cis rs240993 0.809 rs11153277 ENSG00000271789.1 RP5-1112D6.7 -4.89 1.52e-06 0.000522 -0.26 -0.26 Inflammatory skin disease;Psoriasis; chr6:111259358 chr6:111297126~111298510:+ LIHC cis rs1865760 0.964 rs9379802 ENSG00000216436.2 HIST1H2APS1 -4.89 1.52e-06 0.000523 -0.29 -0.26 Height; chr6:25933670 chr6:25732497~25732827:+ LIHC cis rs734999 0.933 rs4648648 ENSG00000225931.3 RP3-395M20.7 4.89 1.52e-06 0.000523 0.28 0.26 Ulcerative colitis; chr1:2581013 chr1:2566410~2569888:+ LIHC cis rs9549367 0.789 rs2287244 ENSG00000269125.1 RP11-98F14.11 4.89 1.52e-06 0.000523 0.29 0.26 Platelet distribution width; chr13:113232859 chr13:113165002~113165183:- LIHC cis rs10800713 0.954 rs10800710 ENSG00000260088.1 RP11-92G12.3 -4.89 1.52e-06 0.000523 -0.35 -0.26 Tandem gait; chr1:200569240 chr1:200669507~200694250:+ LIHC cis rs10800713 0.954 rs10800711 ENSG00000260088.1 RP11-92G12.3 -4.89 1.52e-06 0.000523 -0.35 -0.26 Tandem gait; chr1:200569757 chr1:200669507~200694250:+ LIHC cis rs10800713 0.954 rs12092148 ENSG00000260088.1 RP11-92G12.3 -4.89 1.52e-06 0.000523 -0.35 -0.26 Tandem gait; chr1:200570655 chr1:200669507~200694250:+ LIHC cis rs10800713 0.826 rs11586257 ENSG00000260088.1 RP11-92G12.3 -4.89 1.52e-06 0.000523 -0.35 -0.26 Tandem gait; chr1:200572236 chr1:200669507~200694250:+ LIHC cis rs10800713 0.954 rs10800712 ENSG00000260088.1 RP11-92G12.3 -4.89 1.52e-06 0.000523 -0.35 -0.26 Tandem gait; chr1:200576059 chr1:200669507~200694250:+ LIHC cis rs2439831 1 rs2253708 ENSG00000205771.5 CATSPER2P1 -4.89 1.53e-06 0.000524 -0.35 -0.26 Lung cancer in ever smokers; chr15:43505075 chr15:43726918~43747094:- LIHC cis rs752590 0.806 rs874898 ENSG00000189223.12 PAX8-AS1 -4.89 1.53e-06 0.000524 -0.35 -0.26 Mucinous ovarian carcinoma; chr2:113216619 chr2:113211522~113276581:+ LIHC cis rs734999 0.967 rs4486391 ENSG00000225931.3 RP3-395M20.7 4.89 1.53e-06 0.000525 0.28 0.26 Ulcerative colitis; chr1:2581616 chr1:2566410~2569888:+ LIHC cis rs1729407 0.774 rs2849167 ENSG00000236267.1 AP006216.5 -4.89 1.53e-06 0.000526 -0.25 -0.26 Apolipoprotein A-IV levels; chr11:116814028 chr11:116813204~116814003:- LIHC cis rs9487094 0.813 rs13195517 ENSG00000260273.1 RP11-425D10.10 4.89 1.53e-06 0.000527 0.35 0.26 Height; chr6:109415050 chr6:109382795~109383666:+ LIHC cis rs10833905 0.756 rs11026870 ENSG00000246225.5 RP11-17A1.3 -4.89 1.53e-06 0.000527 -0.33 -0.26 Sudden cardiac arrest; chr11:22973501 chr11:22829380~22945393:+ LIHC cis rs10833905 0.756 rs2303514 ENSG00000246225.5 RP11-17A1.3 -4.89 1.54e-06 0.000527 -0.34 -0.26 Sudden cardiac arrest; chr11:22983988 chr11:22829380~22945393:+ LIHC cis rs9322193 0.607 rs9383941 ENSG00000223701.3 RAET1E-AS1 -4.89 1.54e-06 0.000529 -0.32 -0.26 Lung cancer; chr6:149912100 chr6:149884431~149919508:+ LIHC cis rs10510102 0.516 rs10887034 ENSG00000276742.1 RP11-500G22.4 4.89 1.55e-06 0.00053 0.44 0.26 Breast cancer; chr10:121973996 chr10:121956782~121957098:+ LIHC cis rs4356203 0.519 rs214097 ENSG00000272034.1 SNORD14A -4.89 1.55e-06 0.00053 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17269952 chr11:17074654~17074744:- LIHC cis rs17711722 0.701 rs781145 ENSG00000164669.11 INTS4P1 -4.89 1.55e-06 0.00053 -0.36 -0.26 Calcium levels; chr7:65975383 chr7:65141225~65234216:+ LIHC cis rs2929278 0.561 rs2927071 ENSG00000166763.7 STRCP1 4.89 1.55e-06 0.00053 0.33 0.26 Schizophrenia; chr15:43626883 chr15:43699488~43718184:- LIHC cis rs5769765 0.908 rs138864 ENSG00000278869.1 CITF22-49E9.3 4.89 1.55e-06 0.000531 0.41 0.26 Schizophrenia; chr22:49811064 chr22:49933198~49934074:- LIHC cis rs3824488 0.599 rs16909859 ENSG00000237857.2 RP11-435O5.2 -4.89 1.55e-06 0.000531 -0.34 -0.26 Neuroticism; chr9:95442510 chr9:95414834~95426796:- LIHC cis rs7811142 0.83 rs1063945 ENSG00000242294.5 STAG3L5P 4.89 1.55e-06 0.000532 0.27 0.26 Platelet count; chr7:100332824 chr7:100336079~100351900:+ LIHC cis rs7811142 0.83 rs11761253 ENSG00000242294.5 STAG3L5P 4.89 1.55e-06 0.000532 0.27 0.26 Platelet count; chr7:100341698 chr7:100336079~100351900:+ LIHC cis rs2032366 0.63 rs1377172 ENSG00000267279.1 RP11-879F14.2 -4.89 1.55e-06 0.000533 -0.31 -0.26 Obesity-related traits; chr18:61629148 chr18:61585746~61606916:- LIHC cis rs5760092 0.572 rs738806 ENSG00000231271.1 AP000350.8 4.89 1.55e-06 0.000533 0.34 0.26 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23949918~23954042:+ LIHC cis rs1555322 0.53 rs7004 ENSG00000279253.1 RP4-614O4.13 -4.89 1.55e-06 0.000533 -0.34 -0.26 Attention deficit hyperactivity disorder; chr20:35278950 chr20:35262727~35264187:- LIHC cis rs71520386 0.632 rs10254365 ENSG00000228649.7 AC005682.5 -4.89 1.56e-06 0.000534 -0.33 -0.26 Fibrinogen levels; chr7:22825135 chr7:22854178~22861579:+ LIHC cis rs11098499 0.863 rs3775843 ENSG00000245958.5 RP11-33B1.1 -4.89 1.56e-06 0.000535 -0.27 -0.26 Corneal astigmatism; chr4:119506689 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs3775844 ENSG00000245958.5 RP11-33B1.1 -4.89 1.56e-06 0.000535 -0.27 -0.26 Corneal astigmatism; chr4:119506878 chr4:119454791~119552025:+ LIHC cis rs10129255 0.5 rs1974468 ENSG00000223648.3 IGHV3-64 4.89 1.56e-06 0.000535 0.18 0.26 Kawasaki disease; chr14:106686149 chr14:106643132~106658258:- LIHC cis rs11096990 0.593 rs4580660 ENSG00000249685.1 RP11-360F5.3 4.89 1.56e-06 0.000535 0.31 0.26 Cognitive function; chr4:39152216 chr4:39133913~39135608:+ LIHC cis rs2439831 0.867 rs2614811 ENSG00000275601.1 AC011330.13 -4.89 1.56e-06 0.000536 -0.38 -0.26 Lung cancer in ever smokers; chr15:43621289 chr15:43642389~43643023:- LIHC cis rs1065852 0.526 rs2097561 ENSG00000237037.8 NDUFA6-AS1 -4.89 1.57e-06 0.000536 -0.35 -0.26 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41993427 chr22:42090931~42137742:+ LIHC cis rs1065852 0.526 rs2097562 ENSG00000237037.8 NDUFA6-AS1 -4.89 1.57e-06 0.000536 -0.35 -0.26 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41993496 chr22:42090931~42137742:+ LIHC cis rs1065852 0.526 rs7290907 ENSG00000237037.8 NDUFA6-AS1 -4.89 1.57e-06 0.000536 -0.35 -0.26 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41994205 chr22:42090931~42137742:+ LIHC cis rs1065852 0.526 rs7290655 ENSG00000237037.8 NDUFA6-AS1 -4.89 1.57e-06 0.000536 -0.35 -0.26 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41994221 chr22:42090931~42137742:+ LIHC cis rs12701220 0.847 rs10272002 ENSG00000229043.2 AC091729.9 -4.89 1.57e-06 0.000536 -0.36 -0.26 Bronchopulmonary dysplasia; chr7:1007979 chr7:1160374~1165267:+ LIHC cis rs643506 0.817 rs610437 ENSG00000254990.4 RP11-108O10.2 4.89 1.57e-06 0.000537 0.27 0.26 Breast cancer; chr11:111825716 chr11:111768668~111778350:- LIHC cis rs1030877 0.515 rs1866038 ENSG00000235319.1 AC012360.4 -4.89 1.57e-06 0.000537 -0.35 -0.26 Obesity-related traits; chr2:105262065 chr2:105324210~105330529:+ LIHC cis rs875971 0.522 rs34973832 ENSG00000164669.11 INTS4P1 -4.89 1.57e-06 0.000537 -0.36 -0.26 Aortic root size; chr7:65931217 chr7:65141225~65234216:+ LIHC cis rs4650994 0.525 rs4993304 ENSG00000273384.1 RP5-1098D14.1 4.89 1.57e-06 0.000537 0.32 0.26 HDL cholesterol;HDL cholesterol levels; chr1:178566009 chr1:178651706~178652282:+ LIHC cis rs17826219 0.561 rs11655876 ENSG00000266490.1 CTD-2349P21.9 4.89 1.57e-06 0.000538 0.3 0.26 Body mass index; chr17:30690132 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9907197 ENSG00000266490.1 CTD-2349P21.9 4.89 1.57e-06 0.000538 0.3 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30691245 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9915963 ENSG00000266490.1 CTD-2349P21.9 4.89 1.57e-06 0.000538 0.3 0.26 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30692625 chr17:30792372~30792833:+ LIHC cis rs2581828 0.656 rs1864367 ENSG00000242142.1 SERBP1P3 4.89 1.57e-06 0.000538 0.29 0.26 Crohn's disease; chr3:53077688 chr3:53064283~53065091:- LIHC cis rs2836974 0.627 rs8127986 ENSG00000255568.3 BRWD1-AS2 -4.89 1.57e-06 0.000539 -0.21 -0.26 Cognitive function; chr21:39315285 chr21:39313935~39314962:+ LIHC cis rs7568498 0.564 rs10490563 ENSG00000227403.1 AC009299.3 4.89 1.57e-06 0.000539 0.33 0.26 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161057657 chr2:161244739~161249050:+ LIHC cis rs7568498 0.564 rs9287807 ENSG00000227403.1 AC009299.3 4.89 1.57e-06 0.000539 0.33 0.26 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161058850 chr2:161244739~161249050:+ LIHC cis rs6565180 1 rs8049108 ENSG00000183604.13 SMG1P5 -4.89 1.57e-06 0.000539 -0.26 -0.26 Tonsillectomy; chr16:30365165 chr16:30267553~30335374:- LIHC cis rs2836974 0.644 rs2410123 ENSG00000255568.3 BRWD1-AS2 -4.89 1.58e-06 0.000539 -0.21 -0.26 Cognitive function; chr21:39328167 chr21:39313935~39314962:+ LIHC cis rs16858210 0.657 rs73177515 ENSG00000234371.6 RPSAP31 4.89 1.58e-06 0.00054 0.34 0.26 Menopause (age at onset); chr3:183849037 chr3:183884924~183888449:+ LIHC cis rs875971 0.508 rs10242423 ENSG00000237310.1 GS1-124K5.4 -4.89 1.58e-06 0.00054 -0.23 -0.26 Aortic root size; chr7:66594188 chr7:66493706~66495474:+ LIHC cis rs875971 0.508 rs10253883 ENSG00000237310.1 GS1-124K5.4 -4.89 1.58e-06 0.00054 -0.23 -0.26 Aortic root size; chr7:66596151 chr7:66493706~66495474:+ LIHC cis rs2274273 0.837 rs10141552 ENSG00000258413.1 RP11-665C16.6 4.89 1.58e-06 0.00054 0.31 0.26 Protein biomarker; chr14:55279373 chr14:55262767~55272075:- LIHC cis rs2735413 0.75 rs76833828 ENSG00000276007.1 RP11-358L22.3 4.89 1.58e-06 0.000541 0.34 0.26 Systolic blood pressure (alcohol consumption interaction); chr16:78037098 chr16:78123243~78124332:+ LIHC cis rs875971 0.522 rs1701760 ENSG00000224316.1 RP11-479O9.2 4.89 1.58e-06 0.000542 0.26 0.26 Aortic root size; chr7:66008701 chr7:65773620~65802067:+ LIHC cis rs8091660 0.929 rs12456253 ENSG00000278983.1 RP11-426J5.3 -4.89 1.58e-06 0.000542 -0.35 -0.26 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48550603 chr18:48564795~48568342:+ LIHC cis rs1061377 1 rs9997089 ENSG00000249685.1 RP11-360F5.3 4.89 1.59e-06 0.000542 0.3 0.26 Uric acid levels; chr4:39119263 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs28465556 ENSG00000249685.1 RP11-360F5.3 4.89 1.59e-06 0.000542 0.3 0.26 Uric acid levels; chr4:39119569 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs10027813 ENSG00000249685.1 RP11-360F5.3 4.89 1.59e-06 0.000542 0.3 0.26 Uric acid levels; chr4:39119818 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs9990755 ENSG00000249685.1 RP11-360F5.3 4.89 1.59e-06 0.000542 0.3 0.26 Uric acid levels; chr4:39119819 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs7676008 ENSG00000249685.1 RP11-360F5.3 4.89 1.59e-06 0.000542 0.3 0.26 Uric acid levels; chr4:39120154 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs7655122 ENSG00000249685.1 RP11-360F5.3 4.89 1.59e-06 0.000542 0.3 0.26 Uric acid levels; chr4:39120396 chr4:39133913~39135608:+ LIHC cis rs1061377 0.965 rs3733275 ENSG00000249685.1 RP11-360F5.3 4.89 1.59e-06 0.000542 0.3 0.26 Uric acid levels; chr4:39121077 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs13182 ENSG00000249685.1 RP11-360F5.3 4.89 1.59e-06 0.000542 0.3 0.26 Uric acid levels; chr4:39121293 chr4:39133913~39135608:+ LIHC cis rs950169 0.58 rs11634320 ENSG00000259295.5 CSPG4P12 -4.89 1.59e-06 0.000543 -0.34 -0.26 Schizophrenia; chr15:84628952 chr15:85191438~85213905:+ LIHC cis rs4650994 0.525 rs2224811 ENSG00000273384.1 RP5-1098D14.1 -4.89 1.59e-06 0.000543 -0.32 -0.26 HDL cholesterol;HDL cholesterol levels; chr1:178575188 chr1:178651706~178652282:+ LIHC cis rs4650994 0.525 rs2493858 ENSG00000273384.1 RP5-1098D14.1 4.89 1.59e-06 0.000543 0.32 0.26 HDL cholesterol;HDL cholesterol levels; chr1:178572075 chr1:178651706~178652282:+ LIHC cis rs4650994 0.525 rs2493860 ENSG00000273384.1 RP5-1098D14.1 4.89 1.59e-06 0.000543 0.32 0.26 HDL cholesterol;HDL cholesterol levels; chr1:178572357 chr1:178651706~178652282:+ LIHC cis rs875971 0.522 rs1917563 ENSG00000164669.11 INTS4P1 4.89 1.59e-06 0.000543 0.36 0.26 Aortic root size; chr7:65950660 chr7:65141225~65234216:+ LIHC cis rs2283792 1 rs3788332 ENSG00000224086.5 LL22NC03-86G7.1 -4.89 1.59e-06 0.000543 -0.23 -0.26 Multiple sclerosis; chr22:21817278 chr22:21938293~21977632:+ LIHC cis rs57502260 0.915 rs7106320 ENSG00000212093.1 AP000807.1 4.89 1.59e-06 0.000543 0.33 0.26 Total body bone mineral density (age 45-60); chr11:68442650 chr11:68506083~68506166:- LIHC cis rs57502260 0.915 rs75202638 ENSG00000212093.1 AP000807.1 4.89 1.59e-06 0.000543 0.33 0.26 Total body bone mineral density (age 45-60); chr11:68442953 chr11:68506083~68506166:- LIHC cis rs916888 0.61 rs199436 ENSG00000260075.1 NSFP1 -4.89 1.59e-06 0.000543 -0.31 -0.26 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:46372855~46487141:+ LIHC cis rs227275 0.554 rs223466 ENSG00000246560.2 RP11-10L12.4 4.89 1.59e-06 0.000544 0.28 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102780039 chr4:102828055~102844075:+ LIHC cis rs11217036 1 rs11217036 ENSG00000255239.1 AP002954.6 -4.89 1.59e-06 0.000544 -0.37 -0.26 Allergy; chr11:118805063 chr11:118688039~118690600:- LIHC cis rs7119038 0.774 rs11217038 ENSG00000255239.1 AP002954.6 -4.89 1.59e-06 0.000544 -0.37 -0.26 Sjögren's syndrome; chr11:118806646 chr11:118688039~118690600:- LIHC cis rs7119038 0.731 rs28409215 ENSG00000255239.1 AP002954.6 -4.89 1.59e-06 0.000544 -0.37 -0.26 Sjögren's syndrome; chr11:118808595 chr11:118688039~118690600:- LIHC cis rs2919917 0.915 rs2046339 ENSG00000254352.1 RP11-578O24.2 4.88 1.59e-06 0.000545 0.35 0.26 Lymphocyte counts; chr8:78724283 chr8:78723796~78724136:- LIHC cis rs4356203 0.543 rs214081 ENSG00000272034.1 SNORD14A -4.88 1.59e-06 0.000545 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17278107 chr11:17074654~17074744:- LIHC cis rs16858210 0.874 rs73177525 ENSG00000234371.6 RPSAP31 4.88 1.6e-06 0.000545 0.33 0.26 Menopause (age at onset); chr3:183852498 chr3:183884924~183888449:+ LIHC cis rs10129255 0.556 rs8010005 ENSG00000223648.3 IGHV3-64 4.88 1.6e-06 0.000545 0.18 0.26 Kawasaki disease; chr14:106777987 chr14:106643132~106658258:- LIHC cis rs10129255 0.556 rs6576224 ENSG00000223648.3 IGHV3-64 4.88 1.6e-06 0.000545 0.18 0.26 Kawasaki disease; chr14:106777997 chr14:106643132~106658258:- LIHC cis rs10129255 0.518 rs8010020 ENSG00000223648.3 IGHV3-64 4.88 1.6e-06 0.000545 0.18 0.26 Kawasaki disease; chr14:106778016 chr14:106643132~106658258:- LIHC cis rs7714584 1 rs1863998 ENSG00000197083.10 ZNF300P1 4.88 1.6e-06 0.000546 0.38 0.26 Crohn's disease; chr5:150892191 chr5:150930645~150946289:- LIHC cis rs1061377 1 rs2890659 ENSG00000249685.1 RP11-360F5.3 4.88 1.6e-06 0.000546 0.3 0.26 Uric acid levels; chr4:39125401 chr4:39133913~39135608:+ LIHC cis rs1061377 0.932 rs35464499 ENSG00000249685.1 RP11-360F5.3 4.88 1.6e-06 0.000546 0.3 0.26 Uric acid levels; chr4:39127670 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs35437629 ENSG00000249685.1 RP11-360F5.3 4.88 1.6e-06 0.000546 0.3 0.26 Uric acid levels; chr4:39131712 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs7657926 ENSG00000249685.1 RP11-360F5.3 4.88 1.6e-06 0.000546 0.3 0.26 Uric acid levels; chr4:39132443 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs11096982 ENSG00000249685.1 RP11-360F5.3 4.88 1.6e-06 0.000546 0.3 0.26 Uric acid levels; chr4:39133247 chr4:39133913~39135608:+ LIHC cis rs1061377 1 rs11727875 ENSG00000249685.1 RP11-360F5.3 4.88 1.6e-06 0.000546 0.3 0.26 Uric acid levels; chr4:39133699 chr4:39133913~39135608:+ LIHC cis rs4650994 0.525 rs2811295 ENSG00000273384.1 RP5-1098D14.1 -4.88 1.6e-06 0.000547 -0.31 -0.26 HDL cholesterol;HDL cholesterol levels; chr1:178582132 chr1:178651706~178652282:+ LIHC cis rs62355901 0.556 rs2897972 ENSG00000271828.1 CTD-2310F14.1 4.88 1.6e-06 0.000547 0.49 0.26 Breast cancer; chr5:56750525 chr5:56927874~56929573:+ LIHC cis rs4356203 0.543 rs214088 ENSG00000272034.1 SNORD14A -4.88 1.6e-06 0.000547 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17276578 chr11:17074654~17074744:- LIHC cis rs4356203 0.519 rs214084 ENSG00000272034.1 SNORD14A -4.88 1.6e-06 0.000547 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17277267 chr11:17074654~17074744:- LIHC cis rs4356203 0.519 rs214082 ENSG00000272034.1 SNORD14A -4.88 1.6e-06 0.000547 -0.28 -0.26 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17277843 chr11:17074654~17074744:- LIHC cis rs9992667 0.955 rs9998440 ENSG00000231160.8 KLF3-AS1 -4.88 1.6e-06 0.000547 -0.34 -0.26 Eosinophil percentage of granulocytes; chr4:38606180 chr4:38612701~38664883:- LIHC cis rs67311347 1 rs2276871 ENSG00000223797.4 ENTPD3-AS1 4.88 1.6e-06 0.000547 0.2 0.26 Renal cell carcinoma; chr3:40457782 chr3:40313802~40453329:- LIHC cis rs6480314 0.542 rs61854809 ENSG00000233590.1 RP11-153K11.3 -4.88 1.6e-06 0.000547 -0.39 -0.26 Optic nerve measurement (disc area); chr10:68262847 chr10:68233251~68242379:- LIHC cis rs6480314 0.542 rs61854810 ENSG00000233590.1 RP11-153K11.3 -4.88 1.6e-06 0.000547 -0.39 -0.26 Optic nerve measurement (disc area); chr10:68264139 chr10:68233251~68242379:- LIHC cis rs6480314 0.542 rs61854811 ENSG00000233590.1 RP11-153K11.3 -4.88 1.6e-06 0.000547 -0.39 -0.26 Optic nerve measurement (disc area); chr10:68264474 chr10:68233251~68242379:- LIHC cis rs9291683 0.509 rs6849717 ENSG00000250413.1 RP11-448G15.1 4.88 1.6e-06 0.000548 0.33 0.26 Bone mineral density; chr4:9957095 chr4:10006482~10009725:+ LIHC cis rs1577917 0.883 rs12214536 ENSG00000234155.1 RP11-30P6.6 4.88 1.6e-06 0.000548 0.31 0.26 Response to antipsychotic treatment; chr6:86080592 chr6:85387219~85390186:- LIHC cis rs150992 0.504 rs6878136 ENSG00000248489.1 CTD-2007H13.3 -4.88 1.61e-06 0.000548 -0.39 -0.26 Body mass index; chr5:99022487 chr5:98929171~98995013:+ LIHC cis rs6828577 0.817 rs298996 ENSG00000269893.5 SNHG8 4.88 1.61e-06 0.000549 0.26 0.26 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118703590 chr4:118278709~118279823:+ LIHC cis rs950169 0.922 rs62029585 ENSG00000225151.9 GOLGA2P7 -4.88 1.61e-06 0.000549 -0.32 -0.26 Schizophrenia; chr15:84397176 chr15:84199311~84230136:- LIHC cis rs1577917 0.958 rs13213551 ENSG00000234155.1 RP11-30P6.6 4.88 1.61e-06 0.000549 0.33 0.26 Response to antipsychotic treatment; chr6:85898983 chr6:85387219~85390186:- LIHC cis rs1577917 0.876 rs12201992 ENSG00000234155.1 RP11-30P6.6 4.88 1.61e-06 0.000549 0.33 0.26 Response to antipsychotic treatment; chr6:85908501 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs12201880 ENSG00000234155.1 RP11-30P6.6 4.88 1.61e-06 0.000549 0.33 0.26 Response to antipsychotic treatment; chr6:85917289 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs7756203 ENSG00000234155.1 RP11-30P6.6 4.88 1.61e-06 0.000549 0.33 0.26 Response to antipsychotic treatment; chr6:85917989 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs10944161 ENSG00000234155.1 RP11-30P6.6 4.88 1.61e-06 0.000549 0.33 0.26 Response to antipsychotic treatment; chr6:85920658 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs1857965 ENSG00000234155.1 RP11-30P6.6 4.88 1.61e-06 0.000549 0.33 0.26 Response to antipsychotic treatment; chr6:85921058 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs34622557 ENSG00000234155.1 RP11-30P6.6 4.88 1.61e-06 0.000549 0.33 0.26 Response to antipsychotic treatment; chr6:85921134 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs1911553 ENSG00000234155.1 RP11-30P6.6 4.88 1.61e-06 0.000549 0.33 0.26 Response to antipsychotic treatment; chr6:85921174 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs7771342 ENSG00000234155.1 RP11-30P6.6 4.88 1.61e-06 0.000549 0.33 0.26 Response to antipsychotic treatment; chr6:85922218 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs1995688 ENSG00000234155.1 RP11-30P6.6 4.88 1.61e-06 0.000549 0.33 0.26 Response to antipsychotic treatment; chr6:85922601 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs12154056 ENSG00000234155.1 RP11-30P6.6 4.88 1.61e-06 0.000549 0.33 0.26 Response to antipsychotic treatment; chr6:85924376 chr6:85387219~85390186:- LIHC cis rs11098499 0.954 rs10006525 ENSG00000260091.1 RP11-33B1.4 -4.88 1.61e-06 0.000549 -0.18 -0.26 Corneal astigmatism; chr4:119487776 chr4:119409333~119410233:+ LIHC cis rs6480314 0.522 rs10733841 ENSG00000233590.1 RP11-153K11.3 4.88 1.61e-06 0.000549 0.4 0.26 Optic nerve measurement (disc area); chr10:68293520 chr10:68233251~68242379:- LIHC cis rs367615 0.552 rs2963022 ENSG00000249476.1 CTD-2587M2.1 -4.88 1.61e-06 0.00055 -0.3 -0.26 Colorectal cancer (SNP x SNP interaction); chr5:109391484 chr5:109237120~109326369:- LIHC cis rs5758511 0.68 rs5758692 ENSG00000205702.9 CYP2D7 4.88 1.61e-06 0.00055 0.31 0.26 Birth weight; chr22:42273023 chr22:42140203~42144577:- LIHC cis rs2274273 0.87 rs8018110 ENSG00000258413.1 RP11-665C16.6 -4.88 1.62e-06 0.000551 -0.28 -0.26 Protein biomarker; chr14:55174996 chr14:55262767~55272075:- LIHC cis rs11098499 0.954 rs6849171 ENSG00000260091.1 RP11-33B1.4 -4.88 1.62e-06 0.000551 -0.18 -0.26 Corneal astigmatism; chr4:119488394 chr4:119409333~119410233:+ LIHC cis rs5756813 0.782 rs3171656 ENSG00000233360.4 Z83844.1 4.88 1.62e-06 0.000552 0.33 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37776206 chr22:37641832~37658377:- LIHC cis rs5756813 0.754 rs15691 ENSG00000233360.4 Z83844.1 4.88 1.62e-06 0.000552 0.33 0.26 Optic cup area;Vertical cup-disc ratio; chr22:37776373 chr22:37641832~37658377:- LIHC cis rs73193808 0.614 rs9976839 ENSG00000224649.1 AF124730.4 4.88 1.62e-06 0.000552 0.3 0.26 Coronary artery disease; chr21:29190389 chr21:29182027~29187795:- LIHC cis rs765787 0.53 rs12439643 ENSG00000259520.4 CTD-2651B20.3 -4.88 1.62e-06 0.000552 -0.28 -0.26 Uric acid levels; chr15:45237569 chr15:45251580~45279251:- LIHC cis rs1153858 0.848 rs9806699 ENSG00000259520.4 CTD-2651B20.3 -4.88 1.62e-06 0.000553 -0.31 -0.26 Homoarginine levels; chr15:45448194 chr15:45251580~45279251:- LIHC cis rs10129255 0.913 rs10140943 ENSG00000223648.3 IGHV3-64 4.88 1.62e-06 0.000553 0.2 0.26 Kawasaki disease; chr14:106767441 chr14:106643132~106658258:- LIHC cis rs2243480 1 rs34703416 ENSG00000226824.5 RP4-756H11.3 -4.88 1.63e-06 0.000553 -0.42 -0.26 Diabetic kidney disease; chr7:65835655 chr7:66654538~66669855:+ LIHC cis rs1005277 0.579 rs1740732 ENSG00000276805.1 RP11-291L22.6 4.88 1.63e-06 0.000553 0.31 0.26 Extrinsic epigenetic age acceleration; chr10:38202457 chr10:38451030~38451785:+ LIHC cis rs12554020 0.786 rs6479482 ENSG00000227603.1 RP11-165J3.6 4.88 1.63e-06 0.000554 0.34 0.26 Schizophrenia; chr9:93435814 chr9:93435332~93437121:- LIHC cis rs12554020 0.786 rs7036984 ENSG00000227603.1 RP11-165J3.6 4.88 1.63e-06 0.000554 0.34 0.26 Schizophrenia; chr9:93438258 chr9:93435332~93437121:- LIHC cis rs1577917 0.958 rs7747897 ENSG00000234155.1 RP11-30P6.6 4.88 1.63e-06 0.000554 0.33 0.26 Response to antipsychotic treatment; chr6:85937631 chr6:85387219~85390186:- LIHC cis rs202072 0.872 rs202045 ENSG00000215022.6 RP1-257A7.4 -4.88 1.63e-06 0.000554 -0.3 -0.26 HIV-1 viral setpoint; chr6:13275682 chr6:13264861~13295586:- LIHC cis rs227275 0.525 rs223461 ENSG00000246560.2 RP11-10L12.4 4.88 1.63e-06 0.000554 0.28 0.26 Allergic disease (asthma, hay fever or eczema); chr4:102782372 chr4:102828055~102844075:+ LIHC cis rs42490 0.506 rs160429 ENSG00000251136.7 RP11-37B2.1 4.88 1.63e-06 0.000554 0.23 0.26 Leprosy; chr8:89661255 chr8:89609409~89757727:- LIHC cis rs875971 0.545 rs17138156 ENSG00000273142.1 RP11-458F8.4 4.88 1.63e-06 0.000555 0.24 0.26 Aortic root size; chr7:66249708 chr7:66902857~66906297:+ LIHC cis rs1577917 0.958 rs36053156 ENSG00000234155.1 RP11-30P6.6 4.88 1.63e-06 0.000555 0.34 0.26 Response to antipsychotic treatment; chr6:85865791 chr6:85387219~85390186:- LIHC cis rs1865760 0.534 rs72834629 ENSG00000216436.2 HIST1H2APS1 -4.88 1.63e-06 0.000555 -0.34 -0.26 Height; chr6:26022804 chr6:25732497~25732827:+ LIHC cis rs2439831 1 rs689754 ENSG00000205771.5 CATSPER2P1 -4.88 1.63e-06 0.000555 -0.35 -0.26 Lung cancer in ever smokers; chr15:43483697 chr15:43726918~43747094:- LIHC cis rs603446 0.967 rs180365 ENSG00000254851.1 RP11-109L13.1 -4.88 1.63e-06 0.000555 -0.31 -0.26 Triglycerides; chr11:116725458 chr11:117135528~117138582:+ LIHC cis rs875971 0.522 rs4718286 ENSG00000164669.11 INTS4P1 -4.88 1.63e-06 0.000556 -0.36 -0.26 Aortic root size; chr7:65827777 chr7:65141225~65234216:+ LIHC cis rs17711722 0.585 rs6942660 ENSG00000164669.11 INTS4P1 -4.88 1.63e-06 0.000556 -0.36 -0.26 Calcium levels; chr7:65837419 chr7:65141225~65234216:+ LIHC cis rs17711722 0.701 rs55773927 ENSG00000164669.11 INTS4P1 -4.88 1.63e-06 0.000556 -0.36 -0.26 Calcium levels; chr7:65872915 chr7:65141225~65234216:+ LIHC cis rs17711722 0.727 rs35850374 ENSG00000164669.11 INTS4P1 -4.88 1.63e-06 0.000556 -0.36 -0.26 Calcium levels; chr7:65892789 chr7:65141225~65234216:+ LIHC cis rs7429990 0.864 rs3772399 ENSG00000229759.1 MRPS18AP1 -4.88 1.64e-06 0.000556 -0.26 -0.26 Educational attainment (years of education); chr3:47826237 chr3:48256350~48256938:- LIHC cis rs2274273 0.6 rs10134317 ENSG00000258413.1 RP11-665C16.6 -4.88 1.64e-06 0.000557 -0.31 -0.26 Protein biomarker; chr14:55326730 chr14:55262767~55272075:- LIHC cis rs950776 0.593 rs481134 ENSG00000261762.1 RP11-650L12.2 4.88 1.64e-06 0.000557 0.33 0.26 Sudden cardiac arrest; chr15:78585221 chr15:78589123~78591276:- LIHC cis rs8059260 0.668 rs7199305 ENSG00000274038.1 RP11-66H6.4 4.88 1.64e-06 0.000558 0.42 0.26 Alcohol consumption over the past year; chr16:11006476 chr16:11056556~11057034:+ LIHC cis rs9487094 0.67 rs12197950 ENSG00000260273.1 RP11-425D10.10 4.88 1.64e-06 0.000558 0.3 0.26 Height; chr6:109642186 chr6:109382795~109383666:+ LIHC cis rs6600671 1 rs1832558 ENSG00000231429.2 RP11-343N15.2 -4.88 1.64e-06 0.000558 -0.29 -0.26 Hip geometry; chr1:121435521 chr1:121412719~121429274:+ LIHC cis rs6600671 0.967 rs11249349 ENSG00000231429.2 RP11-343N15.2 -4.88 1.64e-06 0.000558 -0.29 -0.26 Hip geometry; chr1:121437310 chr1:121412719~121429274:+ LIHC cis rs11098499 0.754 rs10518300 ENSG00000245958.5 RP11-33B1.1 4.88 1.64e-06 0.000559 0.27 0.26 Corneal astigmatism; chr4:119328344 chr4:119454791~119552025:+ LIHC cis rs367615 0.552 rs10042721 ENSG00000249476.1 CTD-2587M2.1 -4.88 1.64e-06 0.000559 -0.29 -0.26 Colorectal cancer (SNP x SNP interaction); chr5:109378269 chr5:109237120~109326369:- LIHC cis rs6085948 1 rs1033603 ENSG00000228888.1 LINC01428 4.88 1.65e-06 0.00056 0.34 0.26 Interleukin-10 levels; chr20:7267540 chr20:7146467~7254202:- LIHC cis rs7665147 1 rs7665147 ENSG00000269949.1 RP11-738E22.3 4.88 1.65e-06 0.00056 0.33 0.26 Platelet count; chr4:56901161 chr4:56960927~56961373:- LIHC cis rs9834975 0.903 rs9873684 ENSG00000272758.4 RP11-299J3.8 -4.88 1.65e-06 0.00056 -0.28 -0.26 Diastolic blood pressure; chr3:122386273 chr3:122416207~122443180:+ LIHC cis rs11673344 0.518 rs73033134 ENSG00000226686.6 LINC01535 4.88 1.65e-06 0.000561 0.38 0.26 Obesity-related traits; chr19:37596046 chr19:37251912~37265535:+ LIHC cis rs227275 0.525 rs5028609 ENSG00000230069.3 LRRC37A15P -4.88 1.65e-06 0.000561 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102959294 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs6815540 ENSG00000230069.3 LRRC37A15P -4.88 1.65e-06 0.000561 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102959922 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs4698867 ENSG00000230069.3 LRRC37A15P -4.88 1.65e-06 0.000561 -0.23 -0.26 Allergic disease (asthma, hay fever or eczema); chr4:102961049 chr4:102727274~102730721:- LIHC cis rs755249 0.501 rs621807 ENSG00000182109.6 RP11-69E11.4 4.88 1.65e-06 0.000562 0.27 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39376771 chr1:39522280~39546187:- LIHC cis rs13068223 0.904 rs13322900 ENSG00000243926.1 TIPARP-AS1 4.88 1.65e-06 0.000562 0.24 0.25 Age-related hearing impairment (SNP x SNP interaction); chr3:156732229 chr3:156671862~156674378:- LIHC cis rs9425766 0.628 rs6425274 ENSG00000227373.4 RP11-160H22.5 4.88 1.65e-06 0.000562 0.31 0.25 Life satisfaction; chr1:174144270 chr1:174115300~174160004:- LIHC cis rs9425766 0.566 rs6696076 ENSG00000227373.4 RP11-160H22.5 4.88 1.65e-06 0.000562 0.31 0.25 Life satisfaction; chr1:174149900 chr1:174115300~174160004:- LIHC cis rs11098499 0.913 rs11098496 ENSG00000245958.5 RP11-33B1.1 -4.88 1.65e-06 0.000562 -0.27 -0.25 Corneal astigmatism; chr4:119246311 chr4:119454791~119552025:+ LIHC cis rs6921919 0.848 rs6903823 ENSG00000216901.1 AL022393.7 4.88 1.65e-06 0.000562 0.35 0.25 Autism spectrum disorder or schizophrenia; chr6:28354519 chr6:28176188~28176674:+ LIHC cis rs13392177 0.672 rs4674270 ENSG00000261338.2 RP11-378A13.1 -4.88 1.66e-06 0.000563 -0.26 -0.25 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218188418 chr2:218255319~218257366:+ LIHC cis rs5769707 0.846 rs5770610 ENSG00000235111.1 RP1-29C18.8 -4.88 1.66e-06 0.000563 -0.3 -0.25 Monocyte percentage of white cells;Monocyte count; chr22:49643249 chr22:49612657~49615716:- LIHC cis rs8059260 0.542 rs11860851 ENSG00000274038.1 RP11-66H6.4 -4.88 1.66e-06 0.000563 -0.43 -0.25 Alcohol consumption over the past year; chr16:11033893 chr16:11056556~11057034:+ LIHC cis rs2998286 0.723 rs2772435 ENSG00000254635.4 WAC-AS1 -4.88 1.66e-06 0.000564 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28546534 chr10:28522652~28532743:- LIHC cis rs2998286 0.723 rs2807759 ENSG00000254635.4 WAC-AS1 -4.88 1.66e-06 0.000564 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28548682 chr10:28522652~28532743:- LIHC cis rs2998286 0.723 rs332121 ENSG00000254635.4 WAC-AS1 -4.88 1.66e-06 0.000564 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28552285 chr10:28522652~28532743:- LIHC cis rs2998286 0.572 rs332124 ENSG00000254635.4 WAC-AS1 -4.88 1.66e-06 0.000564 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28553545 chr10:28522652~28532743:- LIHC cis rs2998286 0.723 rs332126 ENSG00000254635.4 WAC-AS1 -4.88 1.66e-06 0.000564 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28556866 chr10:28522652~28532743:- LIHC cis rs2998286 0.723 rs332128 ENSG00000254635.4 WAC-AS1 -4.88 1.66e-06 0.000564 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28559399 chr10:28522652~28532743:- LIHC cis rs2998286 0.723 rs231202 ENSG00000254635.4 WAC-AS1 -4.88 1.66e-06 0.000564 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28560111 chr10:28522652~28532743:- LIHC cis rs2998286 0.723 rs332131 ENSG00000254635.4 WAC-AS1 -4.88 1.66e-06 0.000564 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28564933 chr10:28522652~28532743:- LIHC cis rs2998286 0.768 rs332137 ENSG00000254635.4 WAC-AS1 -4.88 1.66e-06 0.000564 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28570050 chr10:28522652~28532743:- LIHC cis rs2998286 0.768 rs332140 ENSG00000254635.4 WAC-AS1 -4.88 1.66e-06 0.000564 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28570431 chr10:28522652~28532743:- LIHC cis rs2998286 0.723 rs332142 ENSG00000254635.4 WAC-AS1 -4.88 1.66e-06 0.000564 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28575026 chr10:28522652~28532743:- LIHC cis rs2998286 0.723 rs332143 ENSG00000254635.4 WAC-AS1 -4.88 1.66e-06 0.000564 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28575777 chr10:28522652~28532743:- LIHC cis rs7811142 0.83 rs118119933 ENSG00000242294.5 STAG3L5P 4.88 1.66e-06 0.000564 0.31 0.25 Platelet count; chr7:100341427 chr7:100336079~100351900:+ LIHC cis rs957448 0.948 rs72674867 ENSG00000253704.1 RP11-267M23.4 4.88 1.66e-06 0.000564 0.31 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94565973 chr8:94553722~94569745:+ LIHC cis rs10129255 0.5 rs1024350 ENSG00000223648.3 IGHV3-64 4.88 1.66e-06 0.000564 0.18 0.25 Kawasaki disease; chr14:106685105 chr14:106643132~106658258:- LIHC cis rs10129255 0.518 rs7143784 ENSG00000223648.3 IGHV3-64 4.88 1.66e-06 0.000564 0.18 0.25 Kawasaki disease; chr14:106687277 chr14:106643132~106658258:- LIHC cis rs4938303 0.671 rs2008915 ENSG00000254851.1 RP11-109L13.1 -4.88 1.66e-06 0.000565 -0.33 -0.25 Triglycerides; chr11:116732418 chr11:117135528~117138582:+ LIHC cis rs8059260 0.736 rs3871209 ENSG00000274038.1 RP11-66H6.4 -4.88 1.66e-06 0.000565 -0.41 -0.25 Alcohol consumption over the past year; chr16:10962907 chr16:11056556~11057034:+ LIHC cis rs116175783 0.557 rs62188138 ENSG00000227403.1 AC009299.3 4.88 1.67e-06 0.000566 0.39 0.25 Intelligence (multi-trait analysis); chr2:161410935 chr2:161244739~161249050:+ LIHC cis rs116175783 0.557 rs6710414 ENSG00000227403.1 AC009299.3 4.88 1.67e-06 0.000566 0.39 0.25 Intelligence (multi-trait analysis); chr2:161412004 chr2:161244739~161249050:+ LIHC cis rs7119038 0.818 rs11217032 ENSG00000255239.1 AP002954.6 -4.88 1.67e-06 0.000566 -0.36 -0.25 Sjögren's syndrome; chr11:118798896 chr11:118688039~118690600:- LIHC cis rs7119038 0.818 rs11217033 ENSG00000255239.1 AP002954.6 -4.88 1.67e-06 0.000566 -0.36 -0.25 Sjögren's syndrome; chr11:118802997 chr11:118688039~118690600:- LIHC cis rs11098499 0.913 rs10010696 ENSG00000245958.5 RP11-33B1.1 -4.88 1.67e-06 0.000566 -0.27 -0.25 Corneal astigmatism; chr4:119243148 chr4:119454791~119552025:+ LIHC cis rs11098499 1 rs6837898 ENSG00000245958.5 RP11-33B1.1 -4.88 1.67e-06 0.000566 -0.27 -0.25 Corneal astigmatism; chr4:119257999 chr4:119454791~119552025:+ LIHC cis rs12468226 0.938 rs6435139 ENSG00000273456.1 RP11-686O6.2 -4.88 1.67e-06 0.000566 -0.36 -0.25 Urate levels; chr2:202255145 chr2:202374932~202375604:- LIHC cis rs10975870 0.847 rs10975921 ENSG00000236924.1 RP11-390F4.6 -4.87 1.67e-06 0.000566 -0.31 -0.25 Body mass index; chr9:6940115 chr9:6645956~6670635:+ LIHC cis rs7412746 0.658 rs12067685 ENSG00000231073.1 RP11-316M1.3 4.87 1.67e-06 0.000567 0.26 0.25 Melanoma; chr1:150980441 chr1:150973123~150975534:+ LIHC cis rs2836974 0.644 rs2836982 ENSG00000255568.3 BRWD1-AS2 -4.87 1.67e-06 0.000567 -0.21 -0.25 Cognitive function; chr21:39317245 chr21:39313935~39314962:+ LIHC cis rs6951245 0.529 rs76001997 ENSG00000229043.2 AC091729.9 -4.87 1.67e-06 0.000567 -0.46 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1112979 chr7:1160374~1165267:+ LIHC cis rs3096299 0.933 rs2965824 ENSG00000261118.1 RP11-104N10.1 4.87 1.67e-06 0.000568 0.26 0.25 Multiple myeloma (IgH translocation); chr16:89388898 chr16:89492017~89504460:- LIHC cis rs131777 0.532 rs131747 ENSG00000205559.3 CHKB-AS1 -4.87 1.67e-06 0.000568 -0.27 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586645 chr22:50583026~50583877:+ LIHC cis rs10129255 0.556 rs9324093 ENSG00000223648.3 IGHV3-64 4.87 1.68e-06 0.000569 0.18 0.25 Kawasaki disease; chr14:106683893 chr14:106643132~106658258:- LIHC cis rs6600671 1 rs4844380 ENSG00000231429.2 RP11-343N15.2 -4.87 1.68e-06 0.000569 -0.29 -0.25 Hip geometry; chr1:121451764 chr1:121412719~121429274:+ LIHC cis rs11673344 0.526 rs35153242 ENSG00000226686.6 LINC01535 -4.87 1.68e-06 0.000569 -0.39 -0.25 Obesity-related traits; chr19:37660841 chr19:37251912~37265535:+ LIHC cis rs73193808 0.639 rs2832237 ENSG00000224649.1 AF124730.4 4.87 1.68e-06 0.000569 0.3 0.25 Coronary artery disease; chr21:29175362 chr21:29182027~29187795:- LIHC cis rs2439831 0.717 rs28495368 ENSG00000275601.1 AC011330.13 -4.87 1.68e-06 0.000569 -0.38 -0.25 Lung cancer in ever smokers; chr15:43603444 chr15:43642389~43643023:- LIHC cis rs755249 1 rs61779359 ENSG00000182109.6 RP11-69E11.4 4.87 1.68e-06 0.00057 0.34 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39544563 chr1:39522280~39546187:- LIHC cis rs755249 0.959 rs61781363 ENSG00000182109.6 RP11-69E11.4 4.87 1.68e-06 0.00057 0.34 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39546761 chr1:39522280~39546187:- LIHC cis rs755249 1 rs4660808 ENSG00000182109.6 RP11-69E11.4 4.87 1.68e-06 0.00057 0.34 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39552837 chr1:39522280~39546187:- LIHC cis rs755249 1 rs61781364 ENSG00000182109.6 RP11-69E11.4 4.87 1.68e-06 0.00057 0.34 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39553919 chr1:39522280~39546187:- LIHC cis rs11089937 0.597 rs4145535 ENSG00000211639.2 IGLV4-60 4.87 1.68e-06 0.00057 0.22 0.25 Periodontitis (PAL4Q3); chr22:22143981 chr22:22162199~22162681:+ LIHC cis rs11722779 0.838 rs4533776 ENSG00000246560.2 RP11-10L12.4 4.87 1.68e-06 0.00057 0.29 0.25 Schizophrenia; chr4:102912732 chr4:102828055~102844075:+ LIHC cis rs11722779 0.838 rs6821247 ENSG00000246560.2 RP11-10L12.4 4.87 1.68e-06 0.00057 0.29 0.25 Schizophrenia; chr4:102913483 chr4:102828055~102844075:+ LIHC cis rs228614 0.514 rs59550147 ENSG00000246560.2 RP11-10L12.4 4.87 1.68e-06 0.00057 0.29 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102914239 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs9917919 ENSG00000246560.2 RP11-10L12.4 4.87 1.68e-06 0.00057 0.29 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102918497 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs3974608 ENSG00000246560.2 RP11-10L12.4 4.87 1.68e-06 0.00057 0.29 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102925641 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs10028116 ENSG00000246560.2 RP11-10L12.4 4.87 1.68e-06 0.00057 0.29 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102931421 chr4:102828055~102844075:+ LIHC cis rs227275 0.554 rs9307281 ENSG00000246560.2 RP11-10L12.4 4.87 1.68e-06 0.00057 0.29 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102934971 chr4:102828055~102844075:+ LIHC cis rs11722779 0.903 rs6533037 ENSG00000246560.2 RP11-10L12.4 4.87 1.68e-06 0.00057 0.29 0.25 Schizophrenia; chr4:102935865 chr4:102828055~102844075:+ LIHC cis rs4356203 0.87 rs10766381 ENSG00000272034.1 SNORD14A -4.87 1.69e-06 0.000571 -0.28 -0.25 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17235498 chr11:17074654~17074744:- LIHC cis rs17270561 0.779 rs12210620 ENSG00000272810.1 U91328.22 -4.87 1.69e-06 0.000571 -0.33 -0.25 Iron status biomarkers; chr6:25884557 chr6:26013241~26013757:+ LIHC cis rs1005277 0.579 rs1621040 ENSG00000275858.1 RP11-291L22.8 4.87 1.69e-06 0.000572 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38208304 chr10:38450738~38451069:- LIHC cis rs887829 0.57 rs7563561 ENSG00000233445.1 RPL17P11 4.87 1.69e-06 0.000572 0.26 0.25 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233690345 chr2:233721522~233722065:- LIHC cis rs875971 0.522 rs7784623 ENSG00000164669.11 INTS4P1 -4.87 1.69e-06 0.000572 -0.36 -0.25 Aortic root size; chr7:65930047 chr7:65141225~65234216:+ LIHC cis rs8067287 0.688 rs11651187 ENSG00000205312.7 KRT17P4 4.87 1.69e-06 0.000572 0.39 0.25 Diabetic kidney disease; chr17:16942088 chr17:16847635~16852777:- LIHC cis rs11098499 0.863 rs7664986 ENSG00000245958.5 RP11-33B1.1 -4.87 1.69e-06 0.000573 -0.27 -0.25 Corneal astigmatism; chr4:119508797 chr4:119454791~119552025:+ LIHC cis rs11098499 0.818 rs10008791 ENSG00000245958.5 RP11-33B1.1 -4.87 1.69e-06 0.000573 -0.27 -0.25 Corneal astigmatism; chr4:119510314 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs11736416 ENSG00000245958.5 RP11-33B1.1 -4.87 1.69e-06 0.000573 -0.27 -0.25 Corneal astigmatism; chr4:119510506 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs3775845 ENSG00000245958.5 RP11-33B1.1 -4.87 1.69e-06 0.000573 -0.27 -0.25 Corneal astigmatism; chr4:119511292 chr4:119454791~119552025:+ LIHC cis rs12554020 0.582 rs77133953 ENSG00000227603.1 RP11-165J3.6 4.87 1.69e-06 0.000573 0.48 0.25 Schizophrenia; chr9:93635287 chr9:93435332~93437121:- LIHC cis rs950169 0.8 rs34302901 ENSG00000225151.9 GOLGA2P7 -4.87 1.69e-06 0.000574 -0.32 -0.25 Schizophrenia; chr15:84567712 chr15:84199311~84230136:- LIHC cis rs11673344 0.526 rs73035160 ENSG00000226686.6 LINC01535 4.87 1.7e-06 0.000574 0.39 0.25 Obesity-related traits; chr19:37655135 chr19:37251912~37265535:+ LIHC cis rs11673344 0.526 rs1871196 ENSG00000226686.6 LINC01535 4.87 1.7e-06 0.000574 0.39 0.25 Obesity-related traits; chr19:37656022 chr19:37251912~37265535:+ LIHC cis rs4660214 0.666 rs4660550 ENSG00000182109.6 RP11-69E11.4 -4.87 1.7e-06 0.000574 -0.27 -0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39222787 chr1:39522280~39546187:- LIHC cis rs11098499 0.82 rs28535956 ENSG00000245958.5 RP11-33B1.1 4.87 1.7e-06 0.000574 0.26 0.25 Corneal astigmatism; chr4:119615703 chr4:119454791~119552025:+ LIHC cis rs524281 0.817 rs10896097 ENSG00000255320.1 RP11-755F10.1 4.87 1.7e-06 0.000575 0.32 0.25 Electroencephalogram traits; chr11:66200482 chr11:66244840~66246239:- LIHC cis rs5769707 0.967 rs9616327 ENSG00000235111.1 RP1-29C18.8 -4.87 1.7e-06 0.000575 -0.29 -0.25 Monocyte percentage of white cells;Monocyte count; chr22:49617243 chr22:49612657~49615716:- LIHC cis rs4650994 0.525 rs2493865 ENSG00000273384.1 RP5-1098D14.1 -4.87 1.7e-06 0.000576 -0.32 -0.25 HDL cholesterol;HDL cholesterol levels; chr1:178575881 chr1:178651706~178652282:+ LIHC cis rs6921919 0.789 rs6912584 ENSG00000216901.1 AL022393.7 4.87 1.7e-06 0.000577 0.35 0.25 Autism spectrum disorder or schizophrenia; chr6:28341813 chr6:28176188~28176674:+ LIHC cis rs7714584 1 rs4958842 ENSG00000197083.10 ZNF300P1 4.87 1.71e-06 0.000578 0.41 0.25 Crohn's disease; chr5:150845315 chr5:150930645~150946289:- LIHC cis rs6546886 0.536 rs828870 ENSG00000217702.2 RP11-287D1.4 -4.87 1.71e-06 0.000578 -0.3 -0.25 Dialysis-related mortality; chr2:74095117 chr2:74130583~74135395:+ LIHC cis rs950169 0.922 rs12912934 ENSG00000259728.4 LINC00933 4.87 1.71e-06 0.000579 0.37 0.25 Schizophrenia; chr15:84571216 chr15:84570649~84580175:+ LIHC cis rs950776 0.684 rs11637635 ENSG00000261762.1 RP11-650L12.2 -4.87 1.71e-06 0.000579 -0.33 -0.25 Sudden cardiac arrest; chr15:78584808 chr15:78589123~78591276:- LIHC cis rs10129255 0.5 rs6576232 ENSG00000223648.3 IGHV3-64 4.87 1.71e-06 0.000579 0.18 0.25 Kawasaki disease; chr14:106787090 chr14:106643132~106658258:- LIHC cis rs10833905 1 rs12417226 ENSG00000246225.5 RP11-17A1.3 -4.87 1.71e-06 0.000579 -0.31 -0.25 Sudden cardiac arrest; chr11:23017289 chr11:22829380~22945393:+ LIHC cis rs228614 0.51 rs223470 ENSG00000246560.2 RP11-10L12.4 4.87 1.72e-06 0.00058 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102778004 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223468 ENSG00000246560.2 RP11-10L12.4 4.87 1.72e-06 0.00058 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102779265 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223465 ENSG00000246560.2 RP11-10L12.4 4.87 1.72e-06 0.00058 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780174 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223464 ENSG00000246560.2 RP11-10L12.4 4.87 1.72e-06 0.00058 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780603 chr4:102828055~102844075:+ LIHC cis rs11763147 1 rs11763147 ENSG00000164669.11 INTS4P1 4.87 1.72e-06 0.00058 0.36 0.25 Corneal structure; chr7:65861834 chr7:65141225~65234216:+ LIHC cis rs17826219 0.706 rs57698184 ENSG00000266490.1 CTD-2349P21.9 4.87 1.72e-06 0.00058 0.32 0.25 Body mass index; chr17:30737900 chr17:30792372~30792833:+ LIHC cis rs17826219 0.706 rs9893922 ENSG00000266490.1 CTD-2349P21.9 4.87 1.72e-06 0.00058 0.32 0.25 Body mass index; chr17:30741407 chr17:30792372~30792833:+ LIHC cis rs17826219 0.5 rs9891256 ENSG00000266490.1 CTD-2349P21.9 4.87 1.72e-06 0.00058 0.32 0.25 Body mass index; chr17:30745674 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs7503335 ENSG00000266490.1 CTD-2349P21.9 4.87 1.72e-06 0.00058 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746944 chr17:30792372~30792833:+ LIHC cis rs10875746 0.551 rs2054903 ENSG00000240399.1 RP1-228P16.1 -4.87 1.72e-06 0.000581 -0.27 -0.25 Longevity (90 years and older); chr12:48330710 chr12:48054813~48055591:- LIHC cis rs10800713 0.826 rs6427834 ENSG00000260088.1 RP11-92G12.3 -4.87 1.72e-06 0.000581 -0.35 -0.25 Tandem gait; chr1:200561936 chr1:200669507~200694250:+ LIHC cis rs9660180 0.62 rs3817856 ENSG00000231050.1 RP1-140A9.1 -4.87 1.72e-06 0.000581 -0.28 -0.25 Body mass index; chr1:1732392 chr1:1891471~1892658:+ LIHC cis rs13392177 0.66 rs12988046 ENSG00000261338.2 RP11-378A13.1 -4.87 1.72e-06 0.000582 -0.26 -0.25 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218209081 chr2:218255319~218257366:+ LIHC cis rs11098499 0.954 rs12502423 ENSG00000260091.1 RP11-33B1.4 -4.87 1.72e-06 0.000582 -0.18 -0.25 Corneal astigmatism; chr4:119503017 chr4:119409333~119410233:+ LIHC cis rs6600671 0.902 rs2222371 ENSG00000231429.2 RP11-343N15.2 4.87 1.72e-06 0.000582 0.31 0.25 Hip geometry; chr1:121547320 chr1:121412719~121429274:+ LIHC cis rs4964805 0.594 rs3751204 ENSG00000257681.1 RP11-341G23.4 4.87 1.72e-06 0.000582 0.26 0.25 Attention deficit hyperactivity disorder; chr12:103777677 chr12:103746315~103768858:- LIHC cis rs9388451 1 rs9388451 ENSG00000237742.5 RP11-624M8.1 -4.87 1.73e-06 0.000583 -0.24 -0.25 Brugada syndrome; chr6:125769231 chr6:125578558~125749190:- LIHC cis rs1061377 1 rs9998867 ENSG00000249685.1 RP11-360F5.3 4.87 1.73e-06 0.000583 0.3 0.25 Uric acid levels; chr4:39117542 chr4:39133913~39135608:+ LIHC cis rs2439831 0.702 rs7171750 ENSG00000166763.7 STRCP1 4.87 1.73e-06 0.000583 0.39 0.25 Lung cancer in ever smokers; chr15:43733660 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs11070408 ENSG00000166763.7 STRCP1 4.87 1.73e-06 0.000583 0.39 0.25 Lung cancer in ever smokers; chr15:43742590 chr15:43699488~43718184:- LIHC cis rs12554020 0.786 rs56073019 ENSG00000227603.1 RP11-165J3.6 4.87 1.73e-06 0.000584 0.43 0.25 Schizophrenia; chr9:93491169 chr9:93435332~93437121:- LIHC cis rs12554020 0.786 rs75576302 ENSG00000227603.1 RP11-165J3.6 4.87 1.73e-06 0.000584 0.43 0.25 Schizophrenia; chr9:93492940 chr9:93435332~93437121:- LIHC cis rs12554020 0.786 rs76703294 ENSG00000227603.1 RP11-165J3.6 4.87 1.73e-06 0.000584 0.43 0.25 Schizophrenia; chr9:93493884 chr9:93435332~93437121:- LIHC cis rs12554020 0.786 rs12553389 ENSG00000227603.1 RP11-165J3.6 4.87 1.73e-06 0.000584 0.43 0.25 Schizophrenia; chr9:93500979 chr9:93435332~93437121:- LIHC cis rs12554020 0.786 rs78865387 ENSG00000227603.1 RP11-165J3.6 4.87 1.73e-06 0.000584 0.43 0.25 Schizophrenia; chr9:93501827 chr9:93435332~93437121:- LIHC cis rs228614 0.51 rs223447 ENSG00000246560.2 RP11-10L12.4 4.87 1.73e-06 0.000584 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102792202 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223446 ENSG00000246560.2 RP11-10L12.4 4.87 1.73e-06 0.000584 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793025 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223445 ENSG00000246560.2 RP11-10L12.4 4.87 1.73e-06 0.000584 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793337 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223443 ENSG00000246560.2 RP11-10L12.4 4.87 1.73e-06 0.000584 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793629 chr4:102828055~102844075:+ LIHC cis rs1023500 0.505 rs134878 ENSG00000227370.1 RP4-669P10.19 -4.87 1.73e-06 0.000584 -0.26 -0.25 Schizophrenia; chr22:42267868 chr22:42132543~42132998:+ LIHC cis rs6951245 0.554 rs10270249 ENSG00000229043.2 AC091729.9 -4.87 1.73e-06 0.000584 -0.46 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1112250 chr7:1160374~1165267:+ LIHC cis rs6951245 0.554 rs79367977 ENSG00000229043.2 AC091729.9 -4.87 1.73e-06 0.000584 -0.46 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1113021 chr7:1160374~1165267:+ LIHC cis rs755249 0.508 rs624971 ENSG00000182109.6 RP11-69E11.4 4.87 1.73e-06 0.000585 0.26 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39393275 chr1:39522280~39546187:- LIHC cis rs2836974 0.627 rs9981301 ENSG00000255568.3 BRWD1-AS2 -4.87 1.73e-06 0.000585 -0.21 -0.25 Cognitive function; chr21:39314152 chr21:39313935~39314962:+ LIHC cis rs5769765 0.955 rs61136468 ENSG00000278869.1 CITF22-49E9.3 4.87 1.73e-06 0.000585 0.38 0.25 Schizophrenia; chr22:49919031 chr22:49933198~49934074:- LIHC cis rs2439831 1 rs2439831 ENSG00000205771.5 CATSPER2P1 -4.87 1.74e-06 0.000585 -0.34 -0.25 Lung cancer in ever smokers; chr15:43492277 chr15:43726918~43747094:- LIHC cis rs931127 0.554 rs3372 ENSG00000265874.1 MIR4489 4.87 1.74e-06 0.000586 0.38 0.25 Systemic lupus erythematosus; chr11:65717747 chr11:65649192~65649253:+ LIHC cis rs9903692 0.954 rs8076380 ENSG00000278765.1 RP5-890E16.5 -4.87 1.74e-06 0.000586 -0.34 -0.25 Pulse pressure; chr17:48113028 chr17:48066704~48067293:- LIHC cis rs9903692 0.789 rs12601675 ENSG00000278765.1 RP5-890E16.5 -4.87 1.74e-06 0.000586 -0.34 -0.25 Pulse pressure; chr17:48113566 chr17:48066704~48067293:- LIHC cis rs9903692 0.754 rs12602948 ENSG00000278765.1 RP5-890E16.5 -4.87 1.74e-06 0.000586 -0.34 -0.25 Pulse pressure; chr17:48113567 chr17:48066704~48067293:- LIHC cis rs1865760 0.964 rs3799373 ENSG00000216436.2 HIST1H2APS1 -4.87 1.74e-06 0.000586 -0.28 -0.25 Height; chr6:25928945 chr6:25732497~25732827:+ LIHC cis rs9549367 0.789 rs9604040 ENSG00000269125.1 RP11-98F14.11 4.87 1.74e-06 0.000587 0.29 0.25 Platelet distribution width; chr13:113256297 chr13:113165002~113165183:- LIHC cis rs875971 0.545 rs10950029 ENSG00000273142.1 RP11-458F8.4 4.87 1.74e-06 0.000587 0.24 0.25 Aortic root size; chr7:66169334 chr7:66902857~66906297:+ LIHC cis rs1577917 0.958 rs67024565 ENSG00000234155.1 RP11-30P6.6 4.87 1.74e-06 0.000587 0.34 0.25 Response to antipsychotic treatment; chr6:85844279 chr6:85387219~85390186:- LIHC cis rs950776 0.518 rs12910978 ENSG00000261762.1 RP11-650L12.2 4.87 1.74e-06 0.000587 0.34 0.25 Sudden cardiac arrest; chr15:78517675 chr15:78589123~78591276:- LIHC cis rs950776 0.507 rs12912673 ENSG00000261762.1 RP11-650L12.2 4.87 1.74e-06 0.000587 0.34 0.25 Sudden cardiac arrest; chr15:78517874 chr15:78589123~78591276:- LIHC cis rs950169 0.58 rs2271431 ENSG00000259295.5 CSPG4P12 4.87 1.74e-06 0.000587 0.35 0.25 Schizophrenia; chr15:84646233 chr15:85191438~85213905:+ LIHC cis rs10800713 0.908 rs10919978 ENSG00000260088.1 RP11-92G12.3 -4.87 1.74e-06 0.000587 -0.35 -0.25 Tandem gait; chr1:200576923 chr1:200669507~200694250:+ LIHC cis rs10800713 0.954 rs4353125 ENSG00000260088.1 RP11-92G12.3 -4.87 1.74e-06 0.000587 -0.35 -0.25 Tandem gait; chr1:200582178 chr1:200669507~200694250:+ LIHC cis rs8072100 0.875 rs7208530 ENSG00000228782.6 CTD-2026D20.3 4.87 1.74e-06 0.000587 0.28 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47466741 chr17:47450568~47492492:- LIHC cis rs8072100 0.875 rs12451409 ENSG00000228782.6 CTD-2026D20.3 4.87 1.74e-06 0.000587 0.28 0.25 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47467490 chr17:47450568~47492492:- LIHC cis rs1555322 0.53 rs2425044 ENSG00000279253.1 RP4-614O4.13 -4.87 1.74e-06 0.000588 -0.34 -0.25 Attention deficit hyperactivity disorder; chr20:35281932 chr20:35262727~35264187:- LIHC cis rs957448 1 rs72674866 ENSG00000253704.1 RP11-267M23.4 4.87 1.75e-06 0.000588 0.31 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94564619 chr8:94553722~94569745:+ LIHC cis rs957448 1 rs55897841 ENSG00000253704.1 RP11-267M23.4 4.87 1.75e-06 0.000588 0.31 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94565042 chr8:94553722~94569745:+ LIHC cis rs9595908 1 rs7999125 ENSG00000212293.1 SNORA16 4.87 1.75e-06 0.000589 0.3 0.25 Body mass index; chr13:32571858 chr13:32420390~32420516:- LIHC cis rs9291683 0.53 rs11723591 ENSG00000250413.1 RP11-448G15.1 -4.87 1.75e-06 0.000589 -0.34 -0.25 Bone mineral density; chr4:9983774 chr4:10006482~10009725:+ LIHC cis rs494453 0.883 rs474722 ENSG00000227811.2 FAM212B-AS1 -4.87 1.75e-06 0.00059 -0.29 -0.25 Osteoporosis-related phenotypes; chr1:111674356 chr1:111739841~111747798:+ LIHC cis rs228614 0.536 rs223419 ENSG00000246560.2 RP11-10L12.4 4.86 1.75e-06 0.00059 0.29 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102808586 chr4:102828055~102844075:+ LIHC cis rs228614 0.536 rs223418 ENSG00000246560.2 RP11-10L12.4 4.86 1.75e-06 0.00059 0.29 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102809336 chr4:102828055~102844075:+ LIHC cis rs916888 0.821 rs199504 ENSG00000274883.1 Metazoa_SRP 4.86 1.75e-06 0.00059 0.4 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:45931806~45932083:+ LIHC cis rs17711722 1 rs17711722 ENSG00000164669.11 INTS4P1 4.86 1.75e-06 0.00059 0.36 0.25 Calcium levels; chr7:65806210 chr7:65141225~65234216:+ LIHC cis rs17711722 0.675 rs6947132 ENSG00000164669.11 INTS4P1 4.86 1.75e-06 0.00059 0.36 0.25 Calcium levels; chr7:65808508 chr7:65141225~65234216:+ LIHC cis rs10510102 0.872 rs10887032 ENSG00000226864.1 ATE1-AS1 -4.86 1.75e-06 0.00059 -0.42 -0.25 Breast cancer; chr10:121955887 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs12246693 ENSG00000226864.1 ATE1-AS1 4.86 1.75e-06 0.00059 0.42 0.25 Breast cancer; chr10:121957373 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs12248806 ENSG00000226864.1 ATE1-AS1 4.86 1.75e-06 0.00059 0.42 0.25 Breast cancer; chr10:121958638 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs12255832 ENSG00000226864.1 ATE1-AS1 4.86 1.75e-06 0.00059 0.42 0.25 Breast cancer; chr10:121958762 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs12247367 ENSG00000226864.1 ATE1-AS1 4.86 1.75e-06 0.00059 0.42 0.25 Breast cancer; chr10:121961556 chr10:121928312~121951965:+ LIHC cis rs889312 0.532 rs16886181 ENSG00000271828.1 CTD-2310F14.1 4.86 1.75e-06 0.00059 0.4 0.25 Breast cancer (early onset);Breast cancer; chr5:56733416 chr5:56927874~56929573:+ LIHC cis rs932287 0.54 rs4910442 ENSG00000254860.4 TMEM9B-AS1 -4.86 1.75e-06 0.00059 -0.26 -0.25 Colonoscopy-negative controls vs population controls; chr11:9022790 chr11:8964675~8977527:+ LIHC cis rs10833905 0.756 rs78740029 ENSG00000246225.5 RP11-17A1.3 -4.86 1.75e-06 0.00059 -0.33 -0.25 Sudden cardiac arrest; chr11:22977330 chr11:22829380~22945393:+ LIHC cis rs1061377 1 rs7664078 ENSG00000249685.1 RP11-360F5.3 4.86 1.75e-06 0.000591 0.3 0.25 Uric acid levels; chr4:39116583 chr4:39133913~39135608:+ LIHC cis rs1865760 1 rs9348698 ENSG00000216436.2 HIST1H2APS1 -4.86 1.76e-06 0.000591 -0.28 -0.25 Height; chr6:25929461 chr6:25732497~25732827:+ LIHC cis rs6480314 0.522 rs2120900 ENSG00000233590.1 RP11-153K11.3 4.86 1.76e-06 0.000591 0.4 0.25 Optic nerve measurement (disc area); chr10:68296052 chr10:68233251~68242379:- LIHC cis rs7760535 0.656 rs1883136 ENSG00000255389.1 C6orf3 -4.86 1.76e-06 0.000591 -0.24 -0.25 Metabolic traits; chr6:111585820 chr6:111599875~111602295:+ LIHC cis rs881375 0.692 rs2072438 ENSG00000226752.6 PSMD5-AS1 -4.86 1.76e-06 0.000591 -0.26 -0.25 Rheumatoid arthritis; chr9:120889023 chr9:120824828~120854385:+ LIHC cis rs2877649 1 rs737246 ENSG00000258744.1 RP11-80A15.1 -4.86 1.76e-06 0.000591 -0.5 -0.25 Smooth-surface caries; chr14:24458107 chr14:24501594~24508688:+ LIHC cis rs529413 0.61 rs566855 ENSG00000259237.1 RP11-209E8.1 4.86 1.76e-06 0.000591 0.33 0.25 Itch intensity from mosquito bite adjusted by bite size; chr15:53205097 chr15:53116365~53129698:+ LIHC cis rs1865760 1 rs9393675 ENSG00000216436.2 HIST1H2APS1 -4.86 1.76e-06 0.000592 -0.28 -0.25 Height; chr6:25929888 chr6:25732497~25732827:+ LIHC cis rs1061377 0.803 rs6857761 ENSG00000249685.1 RP11-360F5.3 4.86 1.76e-06 0.000592 0.3 0.25 Uric acid levels; chr4:39118353 chr4:39133913~39135608:+ LIHC cis rs950169 0.922 rs4338765 ENSG00000259728.4 LINC00933 4.86 1.76e-06 0.000592 0.36 0.25 Schizophrenia; chr15:84248084 chr15:84570649~84580175:+ LIHC cis rs755249 0.508 rs12023553 ENSG00000182109.6 RP11-69E11.4 -4.86 1.76e-06 0.000592 -0.27 -0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39205820 chr1:39522280~39546187:- LIHC cis rs10129255 1 rs11627342 ENSG00000223648.3 IGHV3-64 4.86 1.76e-06 0.000592 0.19 0.25 Kawasaki disease; chr14:106675823 chr14:106643132~106658258:- LIHC cis rs1865760 0.786 rs1436308 ENSG00000216436.2 HIST1H2APS1 -4.86 1.76e-06 0.000593 -0.29 -0.25 Height; chr6:25939339 chr6:25732497~25732827:+ LIHC cis rs1865760 0.929 rs1436307 ENSG00000216436.2 HIST1H2APS1 -4.86 1.76e-06 0.000593 -0.29 -0.25 Height; chr6:25939495 chr6:25732497~25732827:+ LIHC cis rs1865760 0.892 rs9379806 ENSG00000216436.2 HIST1H2APS1 -4.86 1.76e-06 0.000593 -0.29 -0.25 Height; chr6:25940730 chr6:25732497~25732827:+ LIHC cis rs228614 0.51 rs223410 ENSG00000246560.2 RP11-10L12.4 4.86 1.76e-06 0.000593 0.29 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102813568 chr4:102828055~102844075:+ LIHC cis rs1865760 0.929 rs1816546 ENSG00000216436.2 HIST1H2APS1 -4.86 1.76e-06 0.000593 -0.29 -0.25 Height; chr6:25938024 chr6:25732497~25732827:+ LIHC cis rs202072 0.72 rs4602719 ENSG00000215022.6 RP1-257A7.4 -4.86 1.76e-06 0.000593 -0.29 -0.25 HIV-1 viral setpoint; chr6:13295270 chr6:13264861~13295586:- LIHC cis rs9595908 0.965 rs7335710 ENSG00000212293.1 SNORA16 4.86 1.77e-06 0.000593 0.3 0.25 Body mass index; chr13:32561287 chr13:32420390~32420516:- LIHC cis rs11971779 0.616 rs6967932 ENSG00000273391.1 RP11-634H22.1 4.86 1.77e-06 0.000593 0.23 0.25 Diisocyanate-induced asthma; chr7:139337635 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs11765421 ENSG00000273391.1 RP11-634H22.1 4.86 1.77e-06 0.000593 0.23 0.25 Diisocyanate-induced asthma; chr7:139340348 chr7:139359032~139359566:- LIHC cis rs2836950 0.501 rs2070865 ENSG00000255568.3 BRWD1-AS2 -4.86 1.77e-06 0.000595 -0.21 -0.25 Menarche (age at onset); chr21:39343593 chr21:39313935~39314962:+ LIHC cis rs5769707 0.967 rs1018812 ENSG00000235111.1 RP1-29C18.8 -4.86 1.77e-06 0.000595 -0.29 -0.25 Monocyte percentage of white cells;Monocyte count; chr22:49616425 chr22:49612657~49615716:- LIHC cis rs5769707 0.935 rs9616332 ENSG00000235111.1 RP1-29C18.8 -4.86 1.77e-06 0.000595 -0.3 -0.25 Monocyte percentage of white cells;Monocyte count; chr22:49654030 chr22:49612657~49615716:- LIHC cis rs5769765 0.908 rs56351880 ENSG00000278869.1 CITF22-49E9.3 4.86 1.77e-06 0.000596 0.4 0.25 Schizophrenia; chr22:49922949 chr22:49933198~49934074:- LIHC cis rs4865169 0.595 rs9998008 ENSG00000269949.1 RP11-738E22.3 4.86 1.77e-06 0.000596 0.32 0.25 Breast cancer; chr4:56899886 chr4:56960927~56961373:- LIHC cis rs72627509 0.68 rs3733309 ENSG00000269949.1 RP11-738E22.3 4.86 1.78e-06 0.000596 0.35 0.25 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56991022 chr4:56960927~56961373:- LIHC cis rs7811142 0.945 rs6974282 ENSG00000242294.5 STAG3L5P 4.86 1.78e-06 0.000596 0.31 0.25 Platelet count; chr7:100500672 chr7:100336079~100351900:+ LIHC cis rs7811142 0.945 rs6978739 ENSG00000242294.5 STAG3L5P 4.86 1.78e-06 0.000596 0.31 0.25 Platelet count; chr7:100501057 chr7:100336079~100351900:+ LIHC cis rs6480314 0.522 rs7902936 ENSG00000233590.1 RP11-153K11.3 4.86 1.78e-06 0.000596 0.4 0.25 Optic nerve measurement (disc area); chr10:68299584 chr10:68233251~68242379:- LIHC cis rs12571093 0.571 rs7903251 ENSG00000233590.1 RP11-153K11.3 4.86 1.78e-06 0.000596 0.4 0.25 Optic nerve measurement (disc area); chr10:68299969 chr10:68233251~68242379:- LIHC cis rs2243480 0.522 rs431168 ENSG00000226824.5 RP4-756H11.3 -4.86 1.78e-06 0.000597 -0.45 -0.25 Diabetic kidney disease; chr7:66046617 chr7:66654538~66669855:+ LIHC cis rs17301013 0.932 rs7555533 ENSG00000227373.4 RP11-160H22.5 4.86 1.78e-06 0.000597 0.31 0.25 Systemic lupus erythematosus; chr1:174589983 chr1:174115300~174160004:- LIHC cis rs17301013 0.861 rs6672148 ENSG00000227373.4 RP11-160H22.5 4.86 1.78e-06 0.000597 0.31 0.25 Systemic lupus erythematosus; chr1:174604016 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs10912813 ENSG00000227373.4 RP11-160H22.5 4.86 1.78e-06 0.000597 0.31 0.25 Systemic lupus erythematosus; chr1:174607342 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs67967476 ENSG00000227373.4 RP11-160H22.5 4.86 1.78e-06 0.000597 0.31 0.25 Systemic lupus erythematosus; chr1:174616119 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs6683602 ENSG00000227373.4 RP11-160H22.5 4.86 1.78e-06 0.000597 0.31 0.25 Systemic lupus erythematosus; chr1:174617615 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs6696197 ENSG00000227373.4 RP11-160H22.5 4.86 1.78e-06 0.000597 0.31 0.25 Systemic lupus erythematosus; chr1:174617860 chr1:174115300~174160004:- LIHC cis rs17301013 0.612 rs56199565 ENSG00000227373.4 RP11-160H22.5 4.86 1.78e-06 0.000598 0.31 0.25 Systemic lupus erythematosus; chr1:174640992 chr1:174115300~174160004:- LIHC cis rs1247318 1 rs1247320 ENSG00000243831.1 RP1-81D8.4 4.86 1.78e-06 0.000598 0.35 0.25 Aging; chr6:160912749 chr6:160666228~160676523:- LIHC cis rs72627509 0.638 rs78272732 ENSG00000269949.1 RP11-738E22.3 4.86 1.78e-06 0.000598 0.35 0.25 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57004371 chr4:56960927~56961373:- LIHC cis rs202072 0.72 rs1550526 ENSG00000215022.6 RP1-257A7.4 -4.86 1.78e-06 0.000598 -0.29 -0.25 HIV-1 viral setpoint; chr6:13295283 chr6:13264861~13295586:- LIHC cis rs10847980 0.623 rs28681105 ENSG00000256092.2 RP13-942N8.1 4.86 1.78e-06 0.000598 0.42 0.25 Adiponectin levels; chr12:123390978 chr12:123363868~123366113:+ LIHC cis rs10847980 0.623 rs28501453 ENSG00000256092.2 RP13-942N8.1 4.86 1.78e-06 0.000598 0.42 0.25 Adiponectin levels; chr12:123392765 chr12:123363868~123366113:+ LIHC cis rs11096990 0.551 rs2060005 ENSG00000249685.1 RP11-360F5.3 4.86 1.78e-06 0.000599 0.31 0.25 Cognitive function; chr4:39160901 chr4:39133913~39135608:+ LIHC cis rs9425766 0.679 rs6656188 ENSG00000227373.4 RP11-160H22.5 4.86 1.78e-06 0.000599 0.31 0.25 Life satisfaction; chr1:174183550 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs12087441 ENSG00000227373.4 RP11-160H22.5 4.86 1.78e-06 0.000599 0.31 0.25 Life satisfaction; chr1:174188696 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs4652237 ENSG00000227373.4 RP11-160H22.5 4.86 1.78e-06 0.000599 0.31 0.25 Life satisfaction; chr1:174189718 chr1:174115300~174160004:- LIHC cis rs4218 0.731 rs11539756 ENSG00000277144.1 RP11-59H7.4 -4.86 1.79e-06 0.000599 -0.29 -0.25 Social communication problems; chr15:59136912 chr15:59115547~59116089:- LIHC cis rs10129255 0.5 rs2105989 ENSG00000223648.3 IGHV3-64 4.86 1.79e-06 0.000599 0.18 0.25 Kawasaki disease; chr14:106682199 chr14:106643132~106658258:- LIHC cis rs1061377 0.513 rs2711994 ENSG00000249207.1 RP11-360F5.1 4.86 1.79e-06 0.000599 0.3 0.25 Uric acid levels; chr4:39148121 chr4:39112677~39126818:- LIHC cis rs4731207 0.596 rs12540261 ENSG00000224897.5 POT1-AS1 4.86 1.79e-06 0.000599 0.3 0.25 Cutaneous malignant melanoma; chr7:124946783 chr7:124929873~125179315:+ LIHC cis rs9890032 1 rs3764419 ENSG00000263531.1 RP13-753N3.1 4.86 1.79e-06 6e-04 0.31 0.25 Hip circumference adjusted for BMI; chr17:30837005 chr17:30863921~30864940:- LIHC cis rs7412746 0.658 rs2272214 ENSG00000231073.1 RP11-316M1.3 4.86 1.79e-06 0.000601 0.25 0.25 Melanoma; chr1:150958986 chr1:150973123~150975534:+ LIHC cis rs875971 0.522 rs6960048 ENSG00000164669.11 INTS4P1 -4.86 1.79e-06 0.000601 -0.36 -0.25 Aortic root size; chr7:65943052 chr7:65141225~65234216:+ LIHC cis rs61160187 0.51 rs4700393 ENSG00000272308.1 RP11-231G3.1 -4.86 1.79e-06 0.000601 -0.3 -0.25 Educational attainment (years of education);Educational attainment (college completion); chr5:60802440 chr5:60866457~60866935:- LIHC cis rs9903692 0.954 rs8080662 ENSG00000278765.1 RP5-890E16.5 -4.86 1.79e-06 0.000601 -0.34 -0.25 Pulse pressure; chr17:48113457 chr17:48066704~48067293:- LIHC cis rs5769765 0.646 rs9616205 ENSG00000278869.1 CITF22-49E9.3 4.86 1.79e-06 0.000602 0.4 0.25 Schizophrenia; chr22:49916267 chr22:49933198~49934074:- LIHC cis rs228614 0.51 rs223328 ENSG00000246560.2 RP11-10L12.4 4.86 1.8e-06 0.000602 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873379 chr4:102828055~102844075:+ LIHC cis rs228614 0.536 rs223325 ENSG00000246560.2 RP11-10L12.4 4.86 1.8e-06 0.000602 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102875751 chr4:102828055~102844075:+ LIHC cis rs367615 0.552 rs2963025 ENSG00000249476.1 CTD-2587M2.1 -4.86 1.8e-06 0.000602 -0.29 -0.25 Colorectal cancer (SNP x SNP interaction); chr5:109397555 chr5:109237120~109326369:- LIHC cis rs2836974 0.568 rs7282604 ENSG00000255568.3 BRWD1-AS2 -4.86 1.8e-06 0.000602 -0.22 -0.25 Cognitive function; chr21:39164984 chr21:39313935~39314962:+ LIHC cis rs11098499 0.955 rs1397608 ENSG00000245958.5 RP11-33B1.1 -4.86 1.8e-06 0.000602 -0.27 -0.25 Corneal astigmatism; chr4:119240589 chr4:119454791~119552025:+ LIHC cis rs11098499 0.955 rs7684942 ENSG00000245958.5 RP11-33B1.1 -4.86 1.8e-06 0.000602 -0.27 -0.25 Corneal astigmatism; chr4:119241046 chr4:119454791~119552025:+ LIHC cis rs72627509 0.904 rs56281640 ENSG00000269949.1 RP11-738E22.3 4.86 1.8e-06 0.000603 0.34 0.25 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56899650 chr4:56960927~56961373:- LIHC cis rs6085948 0.861 rs6085955 ENSG00000228888.1 LINC01428 -4.86 1.8e-06 0.000603 -0.44 -0.25 Interleukin-10 levels; chr20:7258347 chr20:7146467~7254202:- LIHC cis rs11123170 0.64 rs931472 ENSG00000274877.1 RP11-65I12.1 4.86 1.8e-06 0.000603 0.34 0.25 Renal function-related traits (BUN); chr2:113212371 chr2:113237595~113240825:+ LIHC cis rs71520386 0.632 rs10279864 ENSG00000228649.7 AC005682.5 -4.86 1.8e-06 0.000604 -0.33 -0.25 Fibrinogen levels; chr7:22824205 chr7:22854178~22861579:+ LIHC cis rs2877649 1 rs17104012 ENSG00000258744.1 RP11-80A15.1 4.86 1.8e-06 0.000604 0.53 0.25 Smooth-surface caries; chr14:24461115 chr14:24501594~24508688:+ LIHC cis rs875971 0.505 rs1723275 ENSG00000164669.11 INTS4P1 4.86 1.8e-06 0.000604 0.35 0.25 Aortic root size; chr7:66039646 chr7:65141225~65234216:+ LIHC cis rs73186030 0.764 rs56236741 ENSG00000272758.4 RP11-299J3.8 4.86 1.8e-06 0.000605 0.46 0.25 Serum parathyroid hormone levels; chr3:122379136 chr3:122416207~122443180:+ LIHC cis rs950169 0.84 rs72748702 ENSG00000259728.4 LINC00933 4.86 1.81e-06 0.000605 0.36 0.25 Schizophrenia; chr15:84246494 chr15:84570649~84580175:+ LIHC cis rs9291683 0.538 rs11727199 ENSG00000250413.1 RP11-448G15.1 -4.86 1.81e-06 0.000605 -0.32 -0.25 Bone mineral density; chr4:10034566 chr4:10006482~10009725:+ LIHC cis rs712039 0.652 rs853196 ENSG00000276054.1 RP11-378E13.3 4.86 1.81e-06 0.000605 0.31 0.25 Tuberculosis; chr17:37488553 chr17:37386886~37387926:+ LIHC cis rs12468226 0.574 rs4675271 ENSG00000273456.1 RP11-686O6.2 -4.86 1.81e-06 0.000605 -0.32 -0.25 Urate levels; chr2:202170967 chr2:202374932~202375604:- LIHC cis rs2836974 0.966 rs2836977 ENSG00000255568.3 BRWD1-AS2 4.86 1.81e-06 0.000605 0.28 0.25 Cognitive function; chr21:39294140 chr21:39313935~39314962:+ LIHC cis rs2836974 0.865 rs34778912 ENSG00000255568.3 BRWD1-AS2 4.86 1.81e-06 0.000605 0.28 0.25 Cognitive function; chr21:39295111 chr21:39313935~39314962:+ LIHC cis rs2836974 0.865 rs7282624 ENSG00000255568.3 BRWD1-AS2 4.86 1.81e-06 0.000605 0.28 0.25 Cognitive function; chr21:39295114 chr21:39313935~39314962:+ LIHC cis rs2836974 0.931 rs13625 ENSG00000255568.3 BRWD1-AS2 4.86 1.81e-06 0.000605 0.28 0.25 Cognitive function; chr21:39297157 chr21:39313935~39314962:+ LIHC cis rs1061377 1 rs12646251 ENSG00000249685.1 RP11-360F5.3 4.86 1.81e-06 0.000606 0.31 0.25 Uric acid levels; chr4:39132751 chr4:39133913~39135608:+ LIHC cis rs9291683 0.53 rs4697698 ENSG00000250413.1 RP11-448G15.1 -4.86 1.81e-06 0.000606 -0.33 -0.25 Bone mineral density; chr4:9940953 chr4:10006482~10009725:+ LIHC cis rs11722779 0.873 rs6533041 ENSG00000230069.3 LRRC37A15P -4.86 1.81e-06 0.000607 -0.23 -0.25 Schizophrenia; chr4:102951615 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs4699037 ENSG00000230069.3 LRRC37A15P -4.86 1.81e-06 0.000607 -0.23 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102957010 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs3857198 ENSG00000230069.3 LRRC37A15P -4.86 1.81e-06 0.000607 -0.23 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102957720 chr4:102727274~102730721:- LIHC cis rs11722779 0.935 rs3857199 ENSG00000230069.3 LRRC37A15P -4.86 1.81e-06 0.000607 -0.23 -0.25 Schizophrenia; chr4:102957991 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs4699039 ENSG00000230069.3 LRRC37A15P -4.86 1.81e-06 0.000607 -0.23 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102958354 chr4:102727274~102730721:- LIHC cis rs10129255 0.642 rs11624918 ENSG00000211970.3 IGHV4-61 -4.86 1.81e-06 0.000607 -0.2 -0.25 Kawasaki disease; chr14:106664672 chr14:106639119~106639657:- LIHC cis rs4820294 0.516 rs12484441 ENSG00000233360.4 Z83844.1 4.86 1.81e-06 0.000608 0.37 0.25 Fat distribution (HIV); chr22:37701352 chr22:37641832~37658377:- LIHC cis rs950169 0.922 rs62021167 ENSG00000259295.5 CSPG4P12 4.86 1.82e-06 0.000608 0.35 0.25 Schizophrenia; chr15:84574820 chr15:85191438~85213905:+ LIHC cis rs875971 0.522 rs709604 ENSG00000164669.11 INTS4P1 4.86 1.82e-06 0.000608 0.36 0.25 Aortic root size; chr7:66032447 chr7:65141225~65234216:+ LIHC cis rs11098499 0.863 rs3775841 ENSG00000245958.5 RP11-33B1.1 -4.86 1.82e-06 0.000608 -0.27 -0.25 Corneal astigmatism; chr4:119504622 chr4:119454791~119552025:+ LIHC cis rs3096299 0.933 rs3096297 ENSG00000261118.1 RP11-104N10.1 4.86 1.82e-06 0.000608 0.26 0.25 Multiple myeloma (IgH translocation); chr16:89386747 chr16:89492017~89504460:- LIHC cis rs227275 0.525 rs6853193 ENSG00000230069.3 LRRC37A15P -4.86 1.82e-06 0.000609 -0.23 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102994888 chr4:102727274~102730721:- LIHC cis rs13068223 0.74 rs344028 ENSG00000243926.1 TIPARP-AS1 4.86 1.82e-06 0.000609 0.27 0.25 Age-related hearing impairment (SNP x SNP interaction); chr3:156747980 chr3:156671862~156674378:- LIHC cis rs2797160 0.651 rs1269176 ENSG00000237742.5 RP11-624M8.1 -4.86 1.82e-06 0.000609 -0.25 -0.25 Endometrial cancer; chr6:125708536 chr6:125578558~125749190:- LIHC cis rs9467711 0.651 rs16891264 ENSG00000216436.2 HIST1H2APS1 -4.86 1.82e-06 0.00061 -0.69 -0.25 Autism spectrum disorder or schizophrenia; chr6:26072217 chr6:25732497~25732827:+ LIHC cis rs2439831 0.867 rs2927072 ENSG00000275601.1 AC011330.13 -4.86 1.82e-06 0.00061 -0.37 -0.25 Lung cancer in ever smokers; chr15:43630200 chr15:43642389~43643023:- LIHC cis rs2439831 0.867 rs2920781 ENSG00000275601.1 AC011330.13 -4.86 1.82e-06 0.00061 -0.37 -0.25 Lung cancer in ever smokers; chr15:43632484 chr15:43642389~43643023:- LIHC cis rs2439831 0.764 rs2447193 ENSG00000275601.1 AC011330.13 -4.86 1.82e-06 0.00061 -0.37 -0.25 Lung cancer in ever smokers; chr15:43637535 chr15:43642389~43643023:- LIHC cis rs950776 0.593 rs601079 ENSG00000261762.1 RP11-650L12.2 -4.86 1.82e-06 0.00061 -0.32 -0.25 Sudden cardiac arrest; chr15:78577237 chr15:78589123~78591276:- LIHC cis rs950776 0.593 rs680244 ENSG00000261762.1 RP11-650L12.2 -4.86 1.82e-06 0.00061 -0.32 -0.25 Sudden cardiac arrest; chr15:78578946 chr15:78589123~78591276:- LIHC cis rs7412746 0.611 rs10888398 ENSG00000231073.1 RP11-316M1.3 -4.86 1.82e-06 0.00061 -0.25 -0.25 Melanoma; chr1:150914306 chr1:150973123~150975534:+ LIHC cis rs10510102 0.872 rs7906271 ENSG00000226864.1 ATE1-AS1 -4.86 1.82e-06 0.00061 -0.42 -0.25 Breast cancer; chr10:121948207 chr10:121928312~121951965:+ LIHC cis rs9487094 0.67 rs7767525 ENSG00000260273.1 RP11-425D10.10 4.86 1.82e-06 0.000611 0.3 0.25 Height; chr6:109646187 chr6:109382795~109383666:+ LIHC cis rs9487094 0.504 rs71541003 ENSG00000260273.1 RP11-425D10.10 4.86 1.82e-06 0.000611 0.3 0.25 Height; chr6:109652694 chr6:109382795~109383666:+ LIHC cis rs9487094 0.67 rs3899233 ENSG00000260273.1 RP11-425D10.10 4.86 1.82e-06 0.000611 0.3 0.25 Height; chr6:109655791 chr6:109382795~109383666:+ LIHC cis rs9532669 0.926 rs9562254 ENSG00000176268.5 CYCSP34 -4.86 1.82e-06 0.000611 -0.28 -0.25 Cervical cancer; chr13:40960902 chr13:40863599~40863902:- LIHC cis rs228614 0.51 rs223415 ENSG00000246560.2 RP11-10L12.4 4.86 1.82e-06 0.000611 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102811016 chr4:102828055~102844075:+ LIHC cis rs8040855 0.576 rs62022528 ENSG00000259295.5 CSPG4P12 4.86 1.83e-06 0.000611 0.41 0.25 Bulimia nervosa; chr15:84992030 chr15:85191438~85213905:+ LIHC cis rs3096299 0.685 rs4329923 ENSG00000261118.1 RP11-104N10.1 4.86 1.83e-06 0.000611 0.26 0.25 Multiple myeloma (IgH translocation); chr16:89493770 chr16:89492017~89504460:- LIHC cis rs11672691 0.756 rs8107333 ENSG00000267107.5 PCAT19 4.86 1.83e-06 0.000611 0.3 0.25 Prostate cancer; chr19:41481965 chr19:41454169~41500649:- LIHC cis rs227275 0.554 rs223467 ENSG00000246560.2 RP11-10L12.4 4.86 1.83e-06 0.000612 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102779721 chr4:102828055~102844075:+ LIHC cis rs950169 0.922 rs12915832 ENSG00000225151.9 GOLGA2P7 -4.86 1.83e-06 0.000612 -0.32 -0.25 Schizophrenia; chr15:84568226 chr15:84199311~84230136:- LIHC cis rs56205728 0.601 rs3784399 ENSG00000273855.1 RP11-133K1.12 -4.86 1.83e-06 0.000612 -0.35 -0.25 Schizophrenia; chr15:40306093 chr15:40285468~40285909:- LIHC cis rs11676348 1 rs11676348 ENSG00000261338.2 RP11-378A13.1 -4.86 1.83e-06 0.000613 -0.26 -0.25 Ulcerative colitis; chr2:218145423 chr2:218255319~218257366:+ LIHC cis rs10256972 0.616 rs6463001 ENSG00000199023.2 MIR339 -4.86 1.83e-06 0.000613 -0.29 -0.25 Endometriosis;Longevity; chr7:1068636 chr7:1022935~1023045:- LIHC cis rs11722779 0.815 rs223347 ENSG00000246560.2 RP11-10L12.4 4.86 1.83e-06 0.000613 0.28 0.25 Schizophrenia; chr4:102858815 chr4:102828055~102844075:+ LIHC cis rs16858210 0.874 rs34113436 ENSG00000234371.6 RPSAP31 4.85 1.84e-06 0.000615 0.33 0.25 Menopause (age at onset); chr3:183856048 chr3:183884924~183888449:+ LIHC cis rs4660214 0.59 rs11205885 ENSG00000182109.6 RP11-69E11.4 -4.85 1.84e-06 0.000616 -0.27 -0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39306633 chr1:39522280~39546187:- LIHC cis rs950169 0.922 rs8037078 ENSG00000259728.4 LINC00933 -4.85 1.85e-06 0.000617 -0.36 -0.25 Schizophrenia; chr15:84150119 chr15:84570649~84580175:+ LIHC cis rs17711722 0.503 rs453835 ENSG00000236529.1 RP13-254B10.1 -4.85 1.85e-06 0.000618 -0.24 -0.25 Calcium levels; chr7:66046172 chr7:65840212~65840596:+ LIHC cis rs7208859 0.524 rs77498725 ENSG00000266490.1 CTD-2349P21.9 4.85 1.85e-06 0.000618 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30736968 chr17:30792372~30792833:+ LIHC cis rs7208859 0.524 rs59923796 ENSG00000266490.1 CTD-2349P21.9 4.85 1.85e-06 0.000618 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737901 chr17:30792372~30792833:+ LIHC cis rs17826219 0.5 rs57005940 ENSG00000266490.1 CTD-2349P21.9 4.85 1.85e-06 0.000618 0.32 0.25 Body mass index; chr17:30739311 chr17:30792372~30792833:+ LIHC cis rs7208859 0.573 rs73267872 ENSG00000266490.1 CTD-2349P21.9 4.85 1.85e-06 0.000618 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30740189 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs56812022 ENSG00000266490.1 CTD-2349P21.9 4.85 1.85e-06 0.000618 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741715 chr17:30792372~30792833:+ LIHC cis rs7208859 0.524 rs57670615 ENSG00000266490.1 CTD-2349P21.9 4.85 1.85e-06 0.000618 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30742480 chr17:30792372~30792833:+ LIHC cis rs17826219 0.5 rs2874724 ENSG00000266490.1 CTD-2349P21.9 4.85 1.85e-06 0.000618 0.32 0.25 Body mass index; chr17:30745415 chr17:30792372~30792833:+ LIHC cis rs17826219 0.568 rs9898097 ENSG00000266490.1 CTD-2349P21.9 4.85 1.85e-06 0.000618 0.32 0.25 Body mass index; chr17:30745654 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9911490 ENSG00000266490.1 CTD-2349P21.9 4.85 1.85e-06 0.000618 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30745995 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs7503542 ENSG00000266490.1 CTD-2349P21.9 4.85 1.85e-06 0.000618 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746812 chr17:30792372~30792833:+ LIHC cis rs7208859 0.573 rs11656278 ENSG00000266490.1 CTD-2349P21.9 4.85 1.85e-06 0.000618 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748170 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs6505207 ENSG00000266490.1 CTD-2349P21.9 4.85 1.85e-06 0.000618 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749553 chr17:30792372~30792833:+ LIHC cis rs875971 0.83 rs12673450 ENSG00000237310.1 GS1-124K5.4 4.85 1.85e-06 0.000618 0.22 0.25 Aortic root size; chr7:66544233 chr7:66493706~66495474:+ LIHC cis rs10129255 0.5 rs8014529 ENSG00000223648.3 IGHV3-64 4.85 1.85e-06 0.000618 0.18 0.25 Kawasaki disease; chr14:106784065 chr14:106643132~106658258:- LIHC cis rs10129255 0.5 rs12101190 ENSG00000223648.3 IGHV3-64 4.85 1.85e-06 0.000618 0.18 0.25 Kawasaki disease; chr14:106784149 chr14:106643132~106658258:- LIHC cis rs10129255 0.518 rs8004895 ENSG00000223648.3 IGHV3-64 4.85 1.85e-06 0.000618 0.18 0.25 Kawasaki disease; chr14:106785139 chr14:106643132~106658258:- LIHC cis rs1577917 1 rs6940458 ENSG00000234155.1 RP11-30P6.6 4.85 1.85e-06 0.000618 0.33 0.25 Response to antipsychotic treatment; chr6:85935274 chr6:85387219~85390186:- LIHC cis rs1865760 0.534 rs2032444 ENSG00000216436.2 HIST1H2APS1 -4.85 1.85e-06 0.000618 -0.34 -0.25 Height; chr6:26046516 chr6:25732497~25732827:+ LIHC cis rs763121 0.853 rs138712 ENSG00000273076.1 RP3-508I15.22 4.85 1.85e-06 0.000618 0.29 0.25 Menopause (age at onset); chr22:38745595 chr22:38743495~38743910:+ LIHC cis rs17270561 0.779 rs17271767 ENSG00000272810.1 U91328.22 -4.85 1.85e-06 0.000619 -0.33 -0.25 Iron status biomarkers; chr6:25886693 chr6:26013241~26013757:+ LIHC cis rs62355901 0.599 rs12655060 ENSG00000271828.1 CTD-2310F14.1 4.85 1.86e-06 0.000619 0.48 0.25 Breast cancer; chr5:56720808 chr5:56927874~56929573:+ LIHC cis rs11096990 0.634 rs7564 ENSG00000249685.1 RP11-360F5.3 -4.85 1.86e-06 0.000619 -0.3 -0.25 Cognitive function; chr4:39285702 chr4:39133913~39135608:+ LIHC cis rs1005277 0.579 rs2103938 ENSG00000275858.1 RP11-291L22.8 4.85 1.86e-06 0.00062 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38205070 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1780139 ENSG00000275858.1 RP11-291L22.8 4.85 1.86e-06 0.00062 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38214090 chr10:38450738~38451069:- LIHC cis rs6921919 0.525 rs11760133 ENSG00000204709.4 LINC01556 4.85 1.86e-06 0.00062 0.31 0.25 Autism spectrum disorder or schizophrenia; chr6:28418962 chr6:28943877~28944537:+ LIHC cis rs10129255 0.536 rs17113249 ENSG00000223648.3 IGHV3-64 4.85 1.86e-06 0.000621 0.18 0.25 Kawasaki disease; chr14:106678273 chr14:106643132~106658258:- LIHC cis rs2877649 1 rs9323503 ENSG00000258744.1 RP11-80A15.1 -4.85 1.86e-06 0.000621 -0.49 -0.25 Smooth-surface caries; chr14:24466389 chr14:24501594~24508688:+ LIHC cis rs2877649 1 rs57120899 ENSG00000258744.1 RP11-80A15.1 -4.85 1.86e-06 0.000621 -0.49 -0.25 Smooth-surface caries; chr14:24467052 chr14:24501594~24508688:+ LIHC cis rs2877649 1 rs60777821 ENSG00000258744.1 RP11-80A15.1 -4.85 1.86e-06 0.000621 -0.49 -0.25 Smooth-surface caries; chr14:24467107 chr14:24501594~24508688:+ LIHC cis rs2877649 1 rs10220332 ENSG00000258744.1 RP11-80A15.1 -4.85 1.86e-06 0.000621 -0.49 -0.25 Smooth-surface caries; chr14:24468273 chr14:24501594~24508688:+ LIHC cis rs2877649 1 rs112410718 ENSG00000258744.1 RP11-80A15.1 -4.85 1.86e-06 0.000621 -0.49 -0.25 Smooth-surface caries; chr14:24473350 chr14:24501594~24508688:+ LIHC cis rs2032447 0.677 rs199737 ENSG00000242387.1 HIST1H2APS2 4.85 1.86e-06 0.000621 0.33 0.25 Intelligence (multi-trait analysis); chr6:25933310 chr6:25882026~25882395:- LIHC cis rs202072 0.585 rs2119485 ENSG00000215022.6 RP1-257A7.4 4.85 1.86e-06 0.000621 0.27 0.25 HIV-1 viral setpoint; chr6:13278030 chr6:13264861~13295586:- LIHC cis rs6921919 0.525 rs16894095 ENSG00000204709.4 LINC01556 4.85 1.86e-06 0.000621 0.31 0.25 Autism spectrum disorder or schizophrenia; chr6:28422453 chr6:28943877~28944537:+ LIHC cis rs9291683 0.595 rs13145442 ENSG00000250413.1 RP11-448G15.1 -4.85 1.86e-06 0.000622 -0.32 -0.25 Bone mineral density; chr4:10035637 chr4:10006482~10009725:+ LIHC cis rs9291683 0.595 rs11731110 ENSG00000250413.1 RP11-448G15.1 -4.85 1.86e-06 0.000622 -0.32 -0.25 Bone mineral density; chr4:10035722 chr4:10006482~10009725:+ LIHC cis rs9291683 0.595 rs10939665 ENSG00000250413.1 RP11-448G15.1 -4.85 1.86e-06 0.000622 -0.32 -0.25 Bone mineral density; chr4:10036004 chr4:10006482~10009725:+ LIHC cis rs950169 0.8 rs4842847 ENSG00000259728.4 LINC00933 4.85 1.87e-06 0.000622 0.36 0.25 Schizophrenia; chr15:84262447 chr15:84570649~84580175:+ LIHC cis rs9549367 0.789 rs7317558 ENSG00000269125.1 RP11-98F14.11 -4.85 1.87e-06 0.000622 -0.29 -0.25 Platelet distribution width; chr13:113239311 chr13:113165002~113165183:- LIHC cis rs9549367 0.826 rs1885688 ENSG00000269125.1 RP11-98F14.11 -4.85 1.87e-06 0.000622 -0.29 -0.25 Platelet distribution width; chr13:113239922 chr13:113165002~113165183:- LIHC cis rs853679 0.506 rs1150693 ENSG00000219392.1 RP1-265C24.5 -4.85 1.87e-06 0.000623 -0.39 -0.25 Depression; chr6:28206812 chr6:28115628~28116551:+ LIHC cis rs227275 0.554 rs6810668 ENSG00000246560.2 RP11-10L12.4 4.85 1.87e-06 0.000623 0.29 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102987574 chr4:102828055~102844075:+ LIHC cis rs10829156 0.625 rs7082235 ENSG00000225527.1 RP11-383B4.4 -4.85 1.87e-06 0.000623 -0.4 -0.25 Sudden cardiac arrest; chr10:18536765 chr10:18531849~18533336:- LIHC cis rs7246657 0.882 rs6508716 ENSG00000276846.1 CTD-3220F14.3 4.85 1.87e-06 0.000623 0.31 0.25 Coronary artery calcification; chr19:37328108 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs7257672 ENSG00000276846.1 CTD-3220F14.3 4.85 1.87e-06 0.000623 0.31 0.25 Coronary artery calcification; chr19:37332957 chr19:37314868~37315620:- LIHC cis rs7246657 0.891 rs7257495 ENSG00000276846.1 CTD-3220F14.3 4.85 1.87e-06 0.000623 0.31 0.25 Coronary artery calcification; chr19:37332974 chr19:37314868~37315620:- LIHC cis rs2877649 0.51 rs73593299 ENSG00000258744.1 RP11-80A15.1 -4.85 1.87e-06 0.000623 -0.46 -0.25 Smooth-surface caries; chr14:24438440 chr14:24501594~24508688:+ LIHC cis rs10510102 1 rs10510102 ENSG00000276742.1 RP11-500G22.4 -4.85 1.87e-06 0.000624 -0.4 -0.25 Breast cancer; chr10:121865675 chr10:121956782~121957098:+ LIHC cis rs10975870 0.847 rs10815484 ENSG00000236924.1 RP11-390F4.6 -4.85 1.87e-06 0.000624 -0.31 -0.25 Body mass index; chr9:6939403 chr9:6645956~6670635:+ LIHC cis rs10975870 0.847 rs10815485 ENSG00000236924.1 RP11-390F4.6 -4.85 1.87e-06 0.000624 -0.31 -0.25 Body mass index; chr9:6939457 chr9:6645956~6670635:+ LIHC cis rs10975870 0.847 rs7862859 ENSG00000236924.1 RP11-390F4.6 -4.85 1.87e-06 0.000624 -0.31 -0.25 Body mass index; chr9:6939866 chr9:6645956~6670635:+ LIHC cis rs2439831 0.85 rs7168158 ENSG00000166763.7 STRCP1 4.85 1.87e-06 0.000624 0.39 0.25 Lung cancer in ever smokers; chr15:43758178 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs7174208 ENSG00000166763.7 STRCP1 4.85 1.87e-06 0.000624 0.39 0.25 Lung cancer in ever smokers; chr15:43760484 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs12101756 ENSG00000166763.7 STRCP1 4.85 1.87e-06 0.000624 0.39 0.25 Lung cancer in ever smokers; chr15:43761689 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs3862142 ENSG00000166763.7 STRCP1 4.85 1.87e-06 0.000624 0.39 0.25 Lung cancer in ever smokers; chr15:43772608 chr15:43699488~43718184:- LIHC cis rs2439831 0.702 rs2788 ENSG00000166763.7 STRCP1 4.85 1.87e-06 0.000624 0.39 0.25 Lung cancer in ever smokers; chr15:43772688 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs28891769 ENSG00000166763.7 STRCP1 4.85 1.87e-06 0.000624 0.39 0.25 Lung cancer in ever smokers; chr15:43780662 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs28578398 ENSG00000166763.7 STRCP1 4.85 1.87e-06 0.000624 0.39 0.25 Lung cancer in ever smokers; chr15:43782848 chr15:43699488~43718184:- LIHC cis rs35099186 0.583 rs10790800 ENSG00000255062.1 RP11-712L6.5 -4.85 1.87e-06 0.000624 -0.3 -0.25 Coronary artery disease; chr11:126392743 chr11:126294298~126304318:- LIHC cis rs6600671 1 rs1986111 ENSG00000231429.2 RP11-343N15.2 -4.85 1.88e-06 0.000625 -0.3 -0.25 Hip geometry; chr1:121462934 chr1:121412719~121429274:+ LIHC cis rs11673344 0.526 rs17244713 ENSG00000226686.6 LINC01535 4.85 1.88e-06 0.000625 0.38 0.25 Obesity-related traits; chr19:37559938 chr19:37251912~37265535:+ LIHC cis rs11673344 0.526 rs17244769 ENSG00000226686.6 LINC01535 4.85 1.88e-06 0.000625 0.38 0.25 Obesity-related traits; chr19:37562031 chr19:37251912~37265535:+ LIHC cis rs11673344 0.526 rs8111790 ENSG00000226686.6 LINC01535 4.85 1.88e-06 0.000625 0.38 0.25 Obesity-related traits; chr19:37565861 chr19:37251912~37265535:+ LIHC cis rs11673344 0.526 rs55909413 ENSG00000226686.6 LINC01535 4.85 1.88e-06 0.000625 0.38 0.25 Obesity-related traits; chr19:37578663 chr19:37251912~37265535:+ LIHC cis rs11673344 0.526 rs55865869 ENSG00000226686.6 LINC01535 4.85 1.88e-06 0.000625 0.38 0.25 Obesity-related traits; chr19:37578683 chr19:37251912~37265535:+ LIHC cis rs11673344 0.502 rs17304703 ENSG00000226686.6 LINC01535 4.85 1.88e-06 0.000625 0.38 0.25 Obesity-related traits; chr19:37582646 chr19:37251912~37265535:+ LIHC cis rs11673344 0.526 rs73033122 ENSG00000226686.6 LINC01535 4.85 1.88e-06 0.000625 0.38 0.25 Obesity-related traits; chr19:37586006 chr19:37251912~37265535:+ LIHC cis rs57502260 0.704 rs2306862 ENSG00000212093.1 AP000807.1 4.85 1.88e-06 0.000625 0.33 0.25 Total body bone mineral density (age 45-60); chr11:68410042 chr11:68506083~68506166:- LIHC cis rs17818399 0.597 rs12104572 ENSG00000279254.1 RP11-536C12.1 -4.85 1.88e-06 0.000626 -0.29 -0.25 Height; chr2:46635327 chr2:46668870~46670778:+ LIHC cis rs853679 0.506 rs1150711 ENSG00000204709.4 LINC01556 4.85 1.88e-06 0.000626 0.29 0.25 Depression; chr6:28240757 chr6:28943877~28944537:+ LIHC cis rs6445975 0.726 rs7639532 ENSG00000272360.1 RP11-359I18.5 4.85 1.88e-06 0.000627 0.29 0.25 Systemic lupus erythematosus; chr3:58481929 chr3:58490830~58491291:- LIHC cis rs1865760 1 rs7770139 ENSG00000216436.2 HIST1H2APS1 -4.85 1.88e-06 0.000627 -0.28 -0.25 Height; chr6:25925595 chr6:25732497~25732827:+ LIHC cis rs893363 0.559 rs3774611 ENSG00000271916.1 RP11-884K10.6 -4.85 1.89e-06 0.000628 -0.31 -0.25 Axial length; chr3:53806638 chr3:53797764~53798019:- LIHC cis rs7119038 0.818 rs6589684 ENSG00000255239.1 AP002954.6 4.85 1.89e-06 0.000628 0.36 0.25 Sjögren's syndrome; chr11:118740248 chr11:118688039~118690600:- LIHC cis rs2834655 0.861 rs11700925 ENSG00000237945.6 LINC00649 -4.85 1.89e-06 0.000628 -0.45 -0.25 Immune response to smallpox vaccine (IL-6); chr21:34865359 chr21:33915534~33977691:+ LIHC cis rs10800713 0.908 rs6670625 ENSG00000260088.1 RP11-92G12.3 -4.85 1.89e-06 0.000628 -0.35 -0.25 Tandem gait; chr1:200587514 chr1:200669507~200694250:+ LIHC cis rs6085948 0.861 rs6054849 ENSG00000228888.1 LINC01428 -4.85 1.89e-06 0.000628 -0.43 -0.25 Interleukin-10 levels; chr20:7251460 chr20:7146467~7254202:- LIHC cis rs6921919 0.583 rs2041230 ENSG00000204709.4 LINC01556 4.85 1.89e-06 0.000629 0.31 0.25 Autism spectrum disorder or schizophrenia; chr6:28397738 chr6:28943877~28944537:+ LIHC cis rs30380 0.506 rs469735 ENSG00000272109.1 CTD-2260A17.3 -4.85 1.89e-06 0.000629 -0.33 -0.25 Cerebrospinal fluid biomarker levels; chr5:96794311 chr5:96804353~96806105:+ LIHC cis rs5769765 1 rs2319458 ENSG00000278869.1 CITF22-49E9.3 4.85 1.89e-06 0.000629 0.39 0.25 Schizophrenia; chr22:49842658 chr22:49933198~49934074:- LIHC cis rs12478296 0.901 rs59191623 ENSG00000261186.2 RP11-341N2.1 -4.85 1.89e-06 0.000629 -0.34 -0.25 Obesity-related traits; chr2:242086444 chr2:242087351~242088457:- LIHC cis rs73193808 0.639 rs9984810 ENSG00000224649.1 AF124730.4 4.85 1.89e-06 0.00063 0.3 0.25 Coronary artery disease; chr21:29181059 chr21:29182027~29187795:- LIHC cis rs73193808 0.614 rs4817274 ENSG00000224649.1 AF124730.4 4.85 1.89e-06 0.00063 0.3 0.25 Coronary artery disease; chr21:29181296 chr21:29182027~29187795:- LIHC cis rs73193808 0.639 rs9976274 ENSG00000224649.1 AF124730.4 4.85 1.89e-06 0.00063 0.3 0.25 Coronary artery disease; chr21:29181615 chr21:29182027~29187795:- LIHC cis rs73193808 0.59 rs2832244 ENSG00000224649.1 AF124730.4 4.85 1.89e-06 0.00063 0.3 0.25 Coronary artery disease; chr21:29181713 chr21:29182027~29187795:- LIHC cis rs2274273 0.84 rs7144737 ENSG00000258413.1 RP11-665C16.6 -4.85 1.89e-06 0.00063 -0.3 -0.25 Protein biomarker; chr14:55356228 chr14:55262767~55272075:- LIHC cis rs9903692 0.954 rs2051821 ENSG00000278765.1 RP5-890E16.5 4.85 1.9e-06 0.000631 0.33 0.25 Pulse pressure; chr17:48066153 chr17:48066704~48067293:- LIHC cis rs10800713 0.862 rs7533417 ENSG00000260088.1 RP11-92G12.3 -4.85 1.9e-06 0.000631 -0.35 -0.25 Tandem gait; chr1:200558177 chr1:200669507~200694250:+ LIHC cis rs957448 0.554 rs12682601 ENSG00000253704.1 RP11-267M23.4 4.85 1.9e-06 0.000631 0.3 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94582492 chr8:94553722~94569745:+ LIHC cis rs67311347 1 rs11129876 ENSG00000223797.4 ENTPD3-AS1 -4.85 1.9e-06 0.000631 -0.2 -0.25 Renal cell carcinoma; chr3:40360145 chr3:40313802~40453329:- LIHC cis rs116175783 0.557 rs16845770 ENSG00000227403.1 AC009299.3 4.85 1.9e-06 0.000631 0.39 0.25 Intelligence (multi-trait analysis); chr2:161325276 chr2:161244739~161249050:+ LIHC cis rs7246657 0.943 rs6508711 ENSG00000276846.1 CTD-3220F14.3 4.85 1.9e-06 0.000632 0.31 0.25 Coronary artery calcification; chr19:37324232 chr19:37314868~37315620:- LIHC cis rs734999 0.967 rs6667605 ENSG00000225931.3 RP3-395M20.7 4.85 1.9e-06 0.000633 0.28 0.25 Ulcerative colitis; chr1:2571341 chr1:2566410~2569888:+ LIHC cis rs734999 0.967 rs6672381 ENSG00000225931.3 RP3-395M20.7 4.85 1.9e-06 0.000633 0.28 0.25 Ulcerative colitis; chr1:2571395 chr1:2566410~2569888:+ LIHC cis rs67311347 1 rs1466237 ENSG00000223797.4 ENTPD3-AS1 4.85 1.9e-06 0.000633 0.2 0.25 Renal cell carcinoma; chr3:40420535 chr3:40313802~40453329:- LIHC cis rs1865760 0.929 rs2876693 ENSG00000216436.2 HIST1H2APS1 -4.85 1.9e-06 0.000633 -0.28 -0.25 Height; chr6:25954206 chr6:25732497~25732827:+ LIHC cis rs2998286 0.54 rs332158 ENSG00000254635.4 WAC-AS1 -4.85 1.91e-06 0.000634 -0.33 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28595433 chr10:28522652~28532743:- LIHC cis rs1061377 1 rs4974997 ENSG00000249685.1 RP11-360F5.3 4.85 1.91e-06 0.000634 0.31 0.25 Uric acid levels; chr4:39109151 chr4:39133913~39135608:+ LIHC cis rs16928809 0.52 rs74050440 ENSG00000183562.3 CTC-343N3.1 4.85 1.91e-06 0.000634 0.55 0.25 Bilirubin levels; chr11:2941213 chr11:2989863~2991344:+ LIHC cis rs12478296 0.901 rs58906257 ENSG00000261186.2 RP11-341N2.1 -4.85 1.91e-06 0.000634 -0.34 -0.25 Obesity-related traits; chr2:242086097 chr2:242087351~242088457:- LIHC cis rs2836974 0.602 rs2037925 ENSG00000255568.3 BRWD1-AS2 -4.85 1.91e-06 0.000635 -0.21 -0.25 Cognitive function; chr21:39328005 chr21:39313935~39314962:+ LIHC cis rs10129255 0.576 rs2157616 ENSG00000223648.3 IGHV3-64 4.85 1.91e-06 0.000635 0.18 0.25 Kawasaki disease; chr14:106767802 chr14:106643132~106658258:- LIHC cis rs12554020 0.892 rs7028729 ENSG00000227603.1 RP11-165J3.6 4.85 1.91e-06 0.000635 0.34 0.25 Schizophrenia; chr9:93443206 chr9:93435332~93437121:- LIHC cis rs4934494 0.681 rs12572928 ENSG00000232936.4 RP11-80H5.2 4.85 1.91e-06 0.000636 0.33 0.25 Red blood cell count; chr10:89793792 chr10:89645282~89650667:+ LIHC cis rs13068223 1 rs9868587 ENSG00000243926.1 TIPARP-AS1 4.85 1.92e-06 0.000637 0.24 0.25 Age-related hearing impairment (SNP x SNP interaction); chr3:156743800 chr3:156671862~156674378:- LIHC cis rs2337406 0.866 rs78462736 ENSG00000274576.2 IGHV2-70 -4.85 1.92e-06 0.000638 -0.26 -0.25 Alzheimer's disease (late onset); chr14:106779942 chr14:106770577~106771020:- LIHC cis rs10129255 0.5 rs11628999 ENSG00000223648.3 IGHV3-64 4.85 1.92e-06 0.000639 0.18 0.25 Kawasaki disease; chr14:106800208 chr14:106643132~106658258:- LIHC cis rs17270561 0.779 rs78589800 ENSG00000272810.1 U91328.22 -4.84 1.92e-06 0.000639 -0.33 -0.25 Iron status biomarkers; chr6:25883272 chr6:26013241~26013757:+ LIHC cis rs6421571 0.564 rs11216972 ENSG00000255239.1 AP002954.6 -4.84 1.92e-06 0.000639 -0.35 -0.25 Primary biliary cholangitis; chr11:118715117 chr11:118688039~118690600:- LIHC cis rs67180937 0.778 rs3002126 ENSG00000272750.1 RP11-378J18.8 -4.84 1.93e-06 0.00064 -0.31 -0.25 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222676939 chr1:222658867~222661512:- LIHC cis rs57502260 0.749 rs67446678 ENSG00000212093.1 AP000807.1 4.84 1.93e-06 0.000641 0.32 0.25 Total body bone mineral density (age 45-60); chr11:68459998 chr11:68506083~68506166:- LIHC cis rs9291683 0.595 rs13150928 ENSG00000250413.1 RP11-448G15.1 -4.84 1.93e-06 0.000641 -0.32 -0.25 Bone mineral density; chr4:10051337 chr4:10006482~10009725:+ LIHC cis rs6901152 0.508 rs12527836 ENSG00000217648.1 RP1-95L4.4 4.84 1.93e-06 0.000642 0.29 0.25 Acute lymphoblastic leukemia (childhood); chr6:143370306 chr6:143342246~143343383:+ LIHC cis rs3096299 0.967 rs11648663 ENSG00000261118.1 RP11-104N10.1 4.84 1.93e-06 0.000642 0.26 0.25 Multiple myeloma (IgH translocation); chr16:89399899 chr16:89492017~89504460:- LIHC cis rs881375 0.678 rs10760129 ENSG00000226752.6 PSMD5-AS1 -4.84 1.94e-06 0.000643 -0.26 -0.25 Rheumatoid arthritis; chr9:120937905 chr9:120824828~120854385:+ LIHC cis rs7829975 0.626 rs907183 ENSG00000173295.6 FAM86B3P -4.84 1.94e-06 0.000643 -0.32 -0.25 Mood instability; chr8:8872251 chr8:8228595~8244865:+ LIHC cis rs11098499 0.954 rs4309825 ENSG00000245958.5 RP11-33B1.1 4.84 1.94e-06 0.000644 0.27 0.25 Corneal astigmatism; chr4:119393726 chr4:119454791~119552025:+ LIHC cis rs2717559 0.542 rs10956986 ENSG00000253196.1 RP11-706C16.7 -4.84 1.94e-06 0.000644 -0.27 -0.25 Urinary tract infection frequency; chr8:142805185 chr8:142763116~142766427:+ LIHC cis rs5769765 0.908 rs138867 ENSG00000278869.1 CITF22-49E9.3 -4.84 1.94e-06 0.000644 -0.4 -0.25 Schizophrenia; chr22:49814055 chr22:49933198~49934074:- LIHC cis rs13392177 0.647 rs6718220 ENSG00000261338.2 RP11-378A13.1 -4.84 1.94e-06 0.000644 -0.26 -0.25 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218201795 chr2:218255319~218257366:+ LIHC cis rs10829156 0.699 rs4747353 ENSG00000240291.1 RP11-499P20.2 4.84 1.94e-06 0.000644 0.38 0.25 Sudden cardiac arrest; chr10:18548028 chr10:18513115~18545651:- LIHC cis rs61041384 0.661 rs74240771 ENSG00000256092.2 RP13-942N8.1 -4.84 1.94e-06 0.000644 -0.4 -0.25 Schizophrenia; chr12:123212416 chr12:123363868~123366113:+ LIHC cis rs950776 0.714 rs660652 ENSG00000261762.1 RP11-650L12.2 -4.84 1.94e-06 0.000644 -0.31 -0.25 Sudden cardiac arrest; chr15:78595490 chr15:78589123~78591276:- LIHC cis rs950776 0.714 rs472054 ENSG00000261762.1 RP11-650L12.2 -4.84 1.94e-06 0.000644 -0.31 -0.25 Sudden cardiac arrest; chr15:78595652 chr15:78589123~78591276:- LIHC cis rs7811142 1 rs68116612 ENSG00000242294.5 STAG3L5P 4.84 1.94e-06 0.000645 0.27 0.25 Platelet count; chr7:100408870 chr7:100336079~100351900:+ LIHC cis rs11098499 0.954 rs10518328 ENSG00000260091.1 RP11-33B1.4 -4.84 1.95e-06 0.000645 -0.18 -0.25 Corneal astigmatism; chr4:119480624 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs6822679 ENSG00000260091.1 RP11-33B1.4 -4.84 1.95e-06 0.000645 -0.18 -0.25 Corneal astigmatism; chr4:119481547 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs4577559 ENSG00000260091.1 RP11-33B1.4 -4.84 1.95e-06 0.000645 -0.18 -0.25 Corneal astigmatism; chr4:119482888 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs7656252 ENSG00000260091.1 RP11-33B1.4 -4.84 1.95e-06 0.000645 -0.18 -0.25 Corneal astigmatism; chr4:119483113 chr4:119409333~119410233:+ LIHC cis rs11098499 0.865 rs28845498 ENSG00000260091.1 RP11-33B1.4 -4.84 1.95e-06 0.000645 -0.18 -0.25 Corneal astigmatism; chr4:119484031 chr4:119409333~119410233:+ LIHC cis rs11098499 0.865 rs28753180 ENSG00000260091.1 RP11-33B1.4 -4.84 1.95e-06 0.000645 -0.18 -0.25 Corneal astigmatism; chr4:119484212 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs56270433 ENSG00000260091.1 RP11-33B1.4 -4.84 1.95e-06 0.000645 -0.18 -0.25 Corneal astigmatism; chr4:119484875 chr4:119409333~119410233:+ LIHC cis rs57502260 0.651 rs3781586 ENSG00000212093.1 AP000807.1 4.84 1.95e-06 0.000646 0.33 0.25 Total body bone mineral density (age 45-60); chr11:68431925 chr11:68506083~68506166:- LIHC cis rs1153858 1 rs4775911 ENSG00000259433.2 CTD-2651B20.4 4.84 1.95e-06 0.000647 0.34 0.25 Homoarginine levels; chr15:45357589 chr15:45330209~45332634:- LIHC cis rs79040073 0.53 rs1055254 ENSG00000259531.2 RP11-295H24.3 4.84 1.96e-06 0.000648 0.41 0.25 Lung cancer in ever smokers; chr15:49328003 chr15:49365124~49366685:- LIHC cis rs79040073 0.53 rs2078024 ENSG00000259531.2 RP11-295H24.3 4.84 1.96e-06 0.000648 0.41 0.25 Lung cancer in ever smokers; chr15:49329413 chr15:49365124~49366685:- LIHC cis rs1061377 1 rs10030904 ENSG00000249685.1 RP11-360F5.3 4.84 1.96e-06 0.000649 0.3 0.25 Uric acid levels; chr4:39113603 chr4:39133913~39135608:+ LIHC cis rs367615 0.512 rs414724 ENSG00000249476.1 CTD-2587M2.1 4.84 1.96e-06 0.000649 0.3 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109334720 chr5:109237120~109326369:- LIHC cis rs227275 0.525 rs6533050 ENSG00000230069.3 LRRC37A15P -4.84 1.96e-06 0.00065 -0.23 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102979044 chr4:102727274~102730721:- LIHC cis rs227275 0.525 rs10032234 ENSG00000230069.3 LRRC37A15P -4.84 1.96e-06 0.00065 -0.23 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102980538 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs3886723 ENSG00000230069.3 LRRC37A15P -4.84 1.96e-06 0.00065 -0.23 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102983013 chr4:102727274~102730721:- LIHC cis rs228614 0.517 rs3886722 ENSG00000230069.3 LRRC37A15P -4.84 1.96e-06 0.00065 -0.23 -0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102983084 chr4:102727274~102730721:- LIHC cis rs712039 0.617 rs60118041 ENSG00000276054.1 RP11-378E13.3 4.84 1.96e-06 0.00065 0.31 0.25 Tuberculosis; chr17:37443151 chr17:37386886~37387926:+ LIHC cis rs11096990 0.634 rs11947159 ENSG00000249685.1 RP11-360F5.3 -4.84 1.96e-06 0.000651 -0.3 -0.25 Cognitive function; chr4:39286900 chr4:39133913~39135608:+ LIHC cis rs5769765 0.671 rs138844 ENSG00000278869.1 CITF22-49E9.3 4.84 1.97e-06 0.000652 0.38 0.25 Schizophrenia; chr22:49790836 chr22:49933198~49934074:- LIHC cis rs7714584 1 rs7732643 ENSG00000197083.10 ZNF300P1 4.84 1.97e-06 0.000652 0.38 0.25 Crohn's disease; chr5:150881874 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs2344181 ENSG00000197083.10 ZNF300P1 4.84 1.97e-06 0.000652 0.38 0.25 Crohn's disease; chr5:150883012 chr5:150930645~150946289:- LIHC cis rs11079159 0.585 rs8079998 ENSG00000263096.1 RP11-515O17.2 4.84 1.97e-06 0.000652 0.33 0.25 QRS duration; chr17:55308138 chr17:55271504~55273653:- LIHC cis rs2836974 0.666 rs4624474 ENSG00000255568.3 BRWD1-AS2 -4.84 1.97e-06 0.000652 -0.21 -0.25 Cognitive function; chr21:39314401 chr21:39313935~39314962:+ LIHC cis rs17270561 0.779 rs12209218 ENSG00000272810.1 U91328.22 -4.84 1.97e-06 0.000653 -0.33 -0.25 Iron status biomarkers; chr6:25887548 chr6:26013241~26013757:+ LIHC cis rs4266290 0.597 rs2286879 ENSG00000214846.4 RP11-115L11.1 4.84 1.97e-06 0.000653 0.33 0.25 Parkinson's disease; chr4:15739257 chr4:15730962~15731627:- LIHC cis rs916888 0.779 rs199498 ENSG00000214401.4 KANSL1-AS1 4.84 1.97e-06 0.000653 0.31 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:46193576~46196723:+ LIHC cis rs17301013 0.932 rs6425280 ENSG00000227373.4 RP11-160H22.5 4.84 1.97e-06 0.000653 0.31 0.25 Systemic lupus erythematosus; chr1:174422186 chr1:174115300~174160004:- LIHC cis rs4934494 0.768 rs12570813 ENSG00000232936.4 RP11-80H5.2 4.84 1.97e-06 0.000653 0.31 0.25 Red blood cell count; chr10:89630974 chr10:89645282~89650667:+ LIHC cis rs12365302 0.617 rs2666907 ENSG00000205106.4 DKFZp779M0652 4.84 1.97e-06 0.000653 0.26 0.25 Diastolic blood pressure; chr11:45745913 chr11:45771432~45772358:+ LIHC cis rs6480314 0.615 rs61857174 ENSG00000233590.1 RP11-153K11.3 -4.84 1.97e-06 0.000654 -0.45 -0.25 Optic nerve measurement (disc area); chr10:68184233 chr10:68233251~68242379:- LIHC cis rs6480314 0.711 rs61857175 ENSG00000233590.1 RP11-153K11.3 -4.84 1.97e-06 0.000654 -0.45 -0.25 Optic nerve measurement (disc area); chr10:68186026 chr10:68233251~68242379:- LIHC cis rs1865760 0.568 rs2032450 ENSG00000216436.2 HIST1H2APS1 -4.84 1.97e-06 0.000654 -0.29 -0.25 Height; chr6:25992886 chr6:25732497~25732827:+ LIHC cis rs1865760 0.713 rs2013063 ENSG00000216436.2 HIST1H2APS1 -4.84 1.97e-06 0.000654 -0.29 -0.25 Height; chr6:25993870 chr6:25732497~25732827:+ LIHC cis rs4356203 0.519 rs214083 ENSG00000272034.1 SNORD14A -4.84 1.97e-06 0.000654 -0.28 -0.25 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17277312 chr11:17074654~17074744:- LIHC cis rs2337406 0.929 rs12050200 ENSG00000274576.2 IGHV2-70 -4.84 1.98e-06 0.000654 -0.26 -0.25 Alzheimer's disease (late onset); chr14:106780983 chr14:106770577~106771020:- LIHC cis rs10129255 0.5 rs7157975 ENSG00000223648.3 IGHV3-64 4.84 1.98e-06 0.000656 0.18 0.25 Kawasaki disease; chr14:106804049 chr14:106643132~106658258:- LIHC cis rs12291225 0.679 rs10832240 ENSG00000251991.1 RNU7-49P 4.84 1.98e-06 0.000656 0.27 0.25 Sense of smell; chr11:14283198 chr11:14478892~14478953:+ LIHC cis rs950169 0.84 rs62029595 ENSG00000259728.4 LINC00933 4.84 1.98e-06 0.000656 0.36 0.25 Schizophrenia; chr15:84400603 chr15:84570649~84580175:+ LIHC cis rs860295 0.676 rs2666826 ENSG00000203761.5 MSTO2P -4.84 1.98e-06 0.000657 -0.2 -0.25 Body mass index; chr1:155688294 chr1:155745829~155750137:+ LIHC cis rs202072 0.872 rs202046 ENSG00000215022.6 RP1-257A7.4 -4.84 1.98e-06 0.000657 -0.29 -0.25 HIV-1 viral setpoint; chr6:13275338 chr6:13264861~13295586:- LIHC cis rs3198697 1 rs3198697 ENSG00000263335.1 AF001548.5 -4.84 1.99e-06 0.000657 -0.39 -0.25 Triglycerides; chr16:15036083 chr16:15726674~15732993:+ LIHC cis rs11098499 0.955 rs35197422 ENSG00000245958.5 RP11-33B1.1 -4.84 1.99e-06 0.000657 -0.27 -0.25 Corneal astigmatism; chr4:119248159 chr4:119454791~119552025:+ LIHC cis rs11098499 0.955 rs1511015 ENSG00000245958.5 RP11-33B1.1 -4.84 1.99e-06 0.000657 -0.27 -0.25 Corneal astigmatism; chr4:119249318 chr4:119454791~119552025:+ LIHC cis rs9291683 0.588 rs17247314 ENSG00000250413.1 RP11-448G15.1 -4.84 1.99e-06 0.000657 -0.32 -0.25 Bone mineral density; chr4:10003119 chr4:10006482~10009725:+ LIHC cis rs712039 0.583 rs853223 ENSG00000276054.1 RP11-378E13.3 4.84 1.99e-06 0.000658 0.31 0.25 Tuberculosis; chr17:37431050 chr17:37386886~37387926:+ LIHC cis rs11098499 0.865 rs11098513 ENSG00000245958.5 RP11-33B1.1 -4.84 1.99e-06 0.000658 -0.27 -0.25 Corneal astigmatism; chr4:119394920 chr4:119454791~119552025:+ LIHC cis rs7115242 0.925 rs7925256 ENSG00000236267.1 AP006216.5 4.84 1.99e-06 0.000659 0.35 0.25 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117174619 chr11:116813204~116814003:- LIHC cis rs950169 0.922 rs2033284 ENSG00000259728.4 LINC00933 4.84 1.99e-06 0.000659 0.36 0.25 Schizophrenia; chr15:84391575 chr15:84570649~84580175:+ LIHC cis rs12908161 0.92 rs12904605 ENSG00000225151.9 GOLGA2P7 -4.84 1.99e-06 0.000659 -0.32 -0.25 Schizophrenia; chr15:84658188 chr15:84199311~84230136:- LIHC cis rs7208859 0.673 rs216418 ENSG00000266490.1 CTD-2349P21.9 4.84 1.99e-06 0.000659 0.3 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30609519 chr17:30792372~30792833:+ LIHC cis rs2688482 0.512 rs3103954 ENSG00000207650.1 MIR570 4.84 1.99e-06 0.000659 0.33 0.25 Lung disease severity in cystic fibrosis; chr3:195789759 chr3:195699401~195699497:+ LIHC cis rs6964833 1 rs4717906 ENSG00000277053.3 GTF2IP1 -4.84 1.99e-06 0.000659 -0.3 -0.25 Menarche (age at onset); chr7:74671923 chr7:75185385~75237696:- LIHC cis rs6479901 0.723 rs7088045 ENSG00000232075.1 MRPL35P2 -4.84 1.99e-06 0.000659 -0.27 -0.25 Intelligence (multi-trait analysis); chr10:63319637 chr10:63634317~63634827:- LIHC cis rs198389 0.589 rs535107 ENSG00000242349.4 NPPA-AS1 4.84 2e-06 0.00066 0.26 0.25 B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome; chr1:11829411 chr1:11841017~11848079:+ LIHC cis rs8005677 1 rs8014936 ENSG00000257285.4 RP11-298I3.1 4.84 2e-06 0.00066 0.25 0.25 Cognitive ability (multi-trait analysis); chr14:22905936 chr14:22929609~22955562:+ LIHC cis rs8005677 1 rs8016061 ENSG00000257285.4 RP11-298I3.1 4.84 2e-06 0.00066 0.25 0.25 Cognitive ability (multi-trait analysis); chr14:22906600 chr14:22929609~22955562:+ LIHC cis rs8005677 1 rs8005677 ENSG00000257285.4 RP11-298I3.1 4.84 2e-06 0.00066 0.25 0.25 Cognitive ability (multi-trait analysis); chr14:22907469 chr14:22929609~22955562:+ LIHC cis rs42490 0.51 rs218917 ENSG00000251136.7 RP11-37B2.1 -4.84 2e-06 0.00066 -0.23 -0.25 Leprosy; chr8:89688902 chr8:89609409~89757727:- LIHC cis rs1020064 0.609 rs2576748 ENSG00000235319.1 AC012360.4 4.84 2e-06 0.000661 0.32 0.25 AIDS; chr2:105294801 chr2:105324210~105330529:+ LIHC cis rs7412746 0.658 rs6658066 ENSG00000231073.1 RP11-316M1.3 4.84 2e-06 0.000661 0.25 0.25 Melanoma; chr1:150946461 chr1:150973123~150975534:+ LIHC cis rs950169 0.544 rs2036949 ENSG00000259295.5 CSPG4P12 4.84 2e-06 0.000661 0.35 0.25 Schizophrenia; chr15:84620374 chr15:85191438~85213905:+ LIHC cis rs10829156 0.699 rs4747353 ENSG00000225527.1 RP11-383B4.4 -4.84 2e-06 0.000661 -0.4 -0.25 Sudden cardiac arrest; chr10:18548028 chr10:18531849~18533336:- LIHC cis rs11098499 0.954 rs10034623 ENSG00000260091.1 RP11-33B1.4 -4.84 2e-06 0.000661 -0.18 -0.25 Corneal astigmatism; chr4:119476674 chr4:119409333~119410233:+ LIHC cis rs6951245 0.554 rs58210047 ENSG00000229043.2 AC091729.9 -4.84 2e-06 0.000662 -0.46 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1109745 chr7:1160374~1165267:+ LIHC cis rs8028182 0.636 rs12909863 ENSG00000260269.4 CTD-2323K18.1 -4.84 2e-06 0.000662 -0.31 -0.25 Sudden cardiac arrest; chr15:75533481 chr15:75527150~75601205:- LIHC cis rs8028182 0.636 rs12708520 ENSG00000260269.4 CTD-2323K18.1 -4.84 2e-06 0.000662 -0.31 -0.25 Sudden cardiac arrest; chr15:75538198 chr15:75527150~75601205:- LIHC cis rs17301013 0.761 rs332805 ENSG00000227373.4 RP11-160H22.5 4.84 2e-06 0.000662 0.31 0.25 Systemic lupus erythematosus; chr1:174652487 chr1:174115300~174160004:- LIHC cis rs17301013 0.861 rs34819375 ENSG00000227373.4 RP11-160H22.5 4.84 2e-06 0.000662 0.31 0.25 Systemic lupus erythematosus; chr1:174654958 chr1:174115300~174160004:- LIHC cis rs9425766 0.679 rs2143114 ENSG00000227373.4 RP11-160H22.5 4.84 2e-06 0.000662 0.31 0.25 Life satisfaction; chr1:174192292 chr1:174115300~174160004:- LIHC cis rs7714584 1 rs1428554 ENSG00000197083.10 ZNF300P1 4.84 2e-06 0.000662 0.38 0.25 Crohn's disease; chr5:150878054 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs7715981 ENSG00000197083.10 ZNF300P1 4.84 2e-06 0.000662 0.38 0.25 Crohn's disease; chr5:150878545 chr5:150930645~150946289:- LIHC cis rs10510102 0.516 rs11200300 ENSG00000276742.1 RP11-500G22.4 4.84 2e-06 0.000662 0.41 0.25 Breast cancer; chr10:121977489 chr10:121956782~121957098:+ LIHC cis rs7811142 0.775 rs1636980 ENSG00000242294.5 STAG3L5P -4.84 2.01e-06 0.000663 -0.27 -0.25 Platelet count; chr7:100341241 chr7:100336079~100351900:+ LIHC cis rs950169 0.763 rs35372971 ENSG00000259728.4 LINC00933 4.84 2.01e-06 0.000663 0.36 0.25 Schizophrenia; chr15:84387097 chr15:84570649~84580175:+ LIHC cis rs7811142 1 rs6972167 ENSG00000242294.5 STAG3L5P 4.84 2.01e-06 0.000664 0.3 0.25 Platelet count; chr7:100482390 chr7:100336079~100351900:+ LIHC cis rs1065852 0.526 rs9611700 ENSG00000237037.8 NDUFA6-AS1 -4.84 2.01e-06 0.000664 -0.35 -0.25 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42005510 chr22:42090931~42137742:+ LIHC cis rs1065852 0.526 rs2413663 ENSG00000237037.8 NDUFA6-AS1 -4.84 2.01e-06 0.000664 -0.35 -0.25 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42006395 chr22:42090931~42137742:+ LIHC cis rs12291225 0.753 rs1431374 ENSG00000251991.1 RNU7-49P 4.84 2.01e-06 0.000664 0.27 0.25 Sense of smell; chr11:14282429 chr11:14478892~14478953:+ LIHC cis rs12291225 0.679 rs7934671 ENSG00000251991.1 RNU7-49P 4.84 2.01e-06 0.000664 0.27 0.25 Sense of smell; chr11:14283555 chr11:14478892~14478953:+ LIHC cis rs12291225 0.679 rs11023178 ENSG00000251991.1 RNU7-49P 4.84 2.01e-06 0.000664 0.27 0.25 Sense of smell; chr11:14288736 chr11:14478892~14478953:+ LIHC cis rs12554020 0.579 rs74740549 ENSG00000227603.1 RP11-165J3.6 4.84 2.01e-06 0.000664 0.43 0.25 Schizophrenia; chr9:93480399 chr9:93435332~93437121:- LIHC cis rs1555322 0.53 rs2425042 ENSG00000279253.1 RP4-614O4.13 -4.84 2.01e-06 0.000665 -0.33 -0.25 Attention deficit hyperactivity disorder; chr20:35278092 chr20:35262727~35264187:- LIHC cis rs1005277 0.579 rs1740735 ENSG00000275858.1 RP11-291L22.8 4.84 2.01e-06 0.000665 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38208849 chr10:38450738~38451069:- LIHC cis rs116175783 0.557 rs1267058 ENSG00000227403.1 AC009299.3 -4.84 2.01e-06 0.000665 -0.39 -0.25 Intelligence (multi-trait analysis); chr2:161264934 chr2:161244739~161249050:+ LIHC cis rs11098499 0.909 rs28555550 ENSG00000245958.5 RP11-33B1.1 -4.84 2.02e-06 0.000665 -0.27 -0.25 Corneal astigmatism; chr4:119289885 chr4:119454791~119552025:+ LIHC cis rs11098499 1 rs28419773 ENSG00000245958.5 RP11-33B1.1 -4.84 2.02e-06 0.000665 -0.27 -0.25 Corneal astigmatism; chr4:119289906 chr4:119454791~119552025:+ LIHC cis rs11098499 1 rs11726229 ENSG00000245958.5 RP11-33B1.1 -4.84 2.02e-06 0.000665 -0.27 -0.25 Corneal astigmatism; chr4:119290425 chr4:119454791~119552025:+ LIHC cis rs9487094 0.665 rs13207864 ENSG00000260273.1 RP11-425D10.10 4.83 2.02e-06 0.000666 0.36 0.25 Height; chr6:109708527 chr6:109382795~109383666:+ LIHC cis rs950169 0.922 rs8037078 ENSG00000225151.9 GOLGA2P7 4.83 2.02e-06 0.000666 0.32 0.25 Schizophrenia; chr15:84150119 chr15:84199311~84230136:- LIHC cis rs1577917 0.958 rs13219504 ENSG00000234155.1 RP11-30P6.6 4.83 2.02e-06 0.000668 0.34 0.25 Response to antipsychotic treatment; chr6:85847199 chr6:85387219~85390186:- LIHC cis rs12701220 0.803 rs12701432 ENSG00000229043.2 AC091729.9 -4.83 2.02e-06 0.000668 -0.35 -0.25 Bronchopulmonary dysplasia; chr7:1012817 chr7:1160374~1165267:+ LIHC cis rs9467711 0.651 rs13220395 ENSG00000216436.2 HIST1H2APS1 -4.83 2.02e-06 0.000668 -0.6 -0.25 Autism spectrum disorder or schizophrenia; chr6:26055140 chr6:25732497~25732827:+ LIHC cis rs62355901 0.599 rs12656399 ENSG00000271828.1 CTD-2310F14.1 4.83 2.03e-06 0.000669 0.48 0.25 Breast cancer; chr5:56731016 chr5:56927874~56929573:+ LIHC cis rs62355901 0.551 rs72756073 ENSG00000271828.1 CTD-2310F14.1 4.83 2.03e-06 0.000669 0.48 0.25 Breast cancer; chr5:56732554 chr5:56927874~56929573:+ LIHC cis rs62355901 0.551 rs61103728 ENSG00000271828.1 CTD-2310F14.1 4.83 2.03e-06 0.000669 0.48 0.25 Breast cancer; chr5:56733066 chr5:56927874~56929573:+ LIHC cis rs9903692 0.908 rs8066391 ENSG00000278765.1 RP5-890E16.5 -4.83 2.03e-06 0.000669 -0.33 -0.25 Pulse pressure; chr17:48117934 chr17:48066704~48067293:- LIHC cis rs1065852 0.526 rs56234624 ENSG00000237037.8 NDUFA6-AS1 -4.83 2.03e-06 0.000669 -0.35 -0.25 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41992822 chr22:42090931~42137742:+ LIHC cis rs879620 1 rs2531995 ENSG00000262185.1 RP11-462G12.1 -4.83 2.03e-06 0.000669 -0.33 -0.25 Hip circumference;Body mass index; chr16:3963466 chr16:3947609~3950444:- LIHC cis rs8028182 0.636 rs28432989 ENSG00000260269.4 CTD-2323K18.1 -4.83 2.03e-06 0.000669 -0.32 -0.25 Sudden cardiac arrest; chr15:75475956 chr15:75527150~75601205:- LIHC cis rs591584 0.59 rs7126782 ENSG00000255893.1 RP11-685N10.1 -4.83 2.03e-06 0.00067 -0.25 -0.25 Macrophage Migration Inhibitory Factor levels; chr11:94590674 chr11:94472908~94473570:- LIHC cis rs8005677 0.962 rs8003934 ENSG00000257285.4 RP11-298I3.1 4.83 2.03e-06 0.00067 0.25 0.25 Cognitive ability (multi-trait analysis); chr14:22931933 chr14:22929609~22955562:+ LIHC cis rs755249 0.508 rs586057 ENSG00000182109.6 RP11-69E11.4 4.83 2.03e-06 0.00067 0.26 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39393122 chr1:39522280~39546187:- LIHC cis rs1499614 1 rs1638731 ENSG00000230295.1 RP11-458F8.2 -4.83 2.03e-06 0.00067 -0.26 -0.25 Gout; chr7:66679692 chr7:66880708~66882981:+ LIHC cis rs1499614 1 rs1882655 ENSG00000230295.1 RP11-458F8.2 4.83 2.03e-06 0.00067 0.26 0.25 Gout; chr7:66682070 chr7:66880708~66882981:+ LIHC cis rs1499614 0.831 rs3800822 ENSG00000230295.1 RP11-458F8.2 4.83 2.03e-06 0.00067 0.26 0.25 Gout; chr7:66682162 chr7:66880708~66882981:+ LIHC cis rs2439831 1 rs690436 ENSG00000205771.5 CATSPER2P1 -4.83 2.04e-06 0.000671 -0.34 -0.25 Lung cancer in ever smokers; chr15:43469007 chr15:43726918~43747094:- LIHC cis rs2439831 1 rs2264239 ENSG00000205771.5 CATSPER2P1 -4.83 2.04e-06 0.000671 -0.34 -0.25 Lung cancer in ever smokers; chr15:43473335 chr15:43726918~43747094:- LIHC cis rs10129255 0.556 rs6576222 ENSG00000223648.3 IGHV3-64 4.83 2.04e-06 0.000671 0.18 0.25 Kawasaki disease; chr14:106776442 chr14:106643132~106658258:- LIHC cis rs10129255 0.536 rs6576223 ENSG00000223648.3 IGHV3-64 4.83 2.04e-06 0.000671 0.18 0.25 Kawasaki disease; chr14:106776448 chr14:106643132~106658258:- LIHC cis rs10129255 0.5 rs988134 ENSG00000223648.3 IGHV3-64 4.83 2.04e-06 0.000671 0.18 0.25 Kawasaki disease; chr14:106776698 chr14:106643132~106658258:- LIHC cis rs10129255 0.5 rs988133 ENSG00000223648.3 IGHV3-64 4.83 2.04e-06 0.000671 0.18 0.25 Kawasaki disease; chr14:106776724 chr14:106643132~106658258:- LIHC cis rs10129255 0.518 rs8009594 ENSG00000223648.3 IGHV3-64 4.83 2.04e-06 0.000671 0.18 0.25 Kawasaki disease; chr14:106777494 chr14:106643132~106658258:- LIHC cis rs765787 0.53 rs12440321 ENSG00000259520.4 CTD-2651B20.3 -4.83 2.04e-06 0.000672 -0.29 -0.25 Uric acid levels; chr15:45237187 chr15:45251580~45279251:- LIHC cis rs2842992 0.747 rs733319 ENSG00000237927.1 RP3-393E18.2 -4.83 2.04e-06 0.000672 -0.31 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159800443 chr6:159586955~159589169:- LIHC cis rs4650994 0.525 rs4650997 ENSG00000273384.1 RP5-1098D14.1 4.83 2.04e-06 0.000672 0.32 0.25 HDL cholesterol;HDL cholesterol levels; chr1:178561609 chr1:178651706~178652282:+ LIHC cis rs12908161 0.959 rs17598603 ENSG00000259295.5 CSPG4P12 -4.83 2.04e-06 0.000674 -0.35 -0.25 Schizophrenia; chr15:84656980 chr15:85191438~85213905:+ LIHC cis rs10129255 0.5 rs4774008 ENSG00000223648.3 IGHV3-64 4.83 2.05e-06 0.000674 0.18 0.25 Kawasaki disease; chr14:106681273 chr14:106643132~106658258:- LIHC cis rs8091660 0.862 rs12607412 ENSG00000278983.1 RP11-426J5.3 4.83 2.05e-06 0.000675 0.36 0.25 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48545949 chr18:48564795~48568342:+ LIHC cis rs2565722 0.622 rs2465844 ENSG00000243831.1 RP1-81D8.4 4.83 2.05e-06 0.000675 0.36 0.25 Blood protein levels; chr6:160876340 chr6:160666228~160676523:- LIHC cis rs17711722 0.565 rs73372653 ENSG00000226824.5 RP4-756H11.3 -4.83 2.05e-06 0.000675 -0.3 -0.25 Calcium levels; chr7:65977808 chr7:66654538~66669855:+ LIHC cis rs227275 0.53 rs3960788 ENSG00000246560.2 RP11-10L12.4 4.83 2.05e-06 0.000675 0.29 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102994461 chr4:102828055~102844075:+ LIHC cis rs950169 0.922 rs62028133 ENSG00000259728.4 LINC00933 4.83 2.05e-06 0.000676 0.35 0.25 Schizophrenia; chr15:84250623 chr15:84570649~84580175:+ LIHC cis rs950169 0.723 rs17589320 ENSG00000259728.4 LINC00933 4.83 2.05e-06 0.000676 0.35 0.25 Schizophrenia; chr15:84251244 chr15:84570649~84580175:+ LIHC cis rs11971779 0.648 rs10230407 ENSG00000273391.1 RP11-634H22.1 4.83 2.05e-06 0.000676 0.23 0.25 Diisocyanate-induced asthma; chr7:139419147 chr7:139359032~139359566:- LIHC cis rs2998286 0.723 rs332152 ENSG00000254635.4 WAC-AS1 -4.83 2.06e-06 0.000677 -0.32 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28585602 chr10:28522652~28532743:- LIHC cis rs1061377 1 rs2381284 ENSG00000249685.1 RP11-360F5.3 4.83 2.06e-06 0.000678 0.3 0.25 Uric acid levels; chr4:39117976 chr4:39133913~39135608:+ LIHC cis rs801193 0.805 rs12532355 ENSG00000237310.1 GS1-124K5.4 -4.83 2.06e-06 0.000679 -0.23 -0.25 Aortic root size; chr7:66605597 chr7:66493706~66495474:+ LIHC cis rs1558001 0.87 rs6963424 ENSG00000230196.1 DDX43P3 4.83 2.07e-06 0.00068 0.27 0.25 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81782085 chr7:81610884~81611326:- LIHC cis rs1558001 0.834 rs10242244 ENSG00000230196.1 DDX43P3 4.83 2.07e-06 0.00068 0.27 0.25 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81782090 chr7:81610884~81611326:- LIHC cis rs7897654 0.571 rs12767543 ENSG00000236937.2 PTGES3P4 4.83 2.07e-06 0.00068 0.33 0.25 Schizophrenia; chr10:102871906 chr10:102845595~102845950:+ LIHC cis rs7897654 0.571 rs7920697 ENSG00000236937.2 PTGES3P4 4.83 2.07e-06 0.00068 0.33 0.25 Schizophrenia; chr10:102873580 chr10:102845595~102845950:+ LIHC cis rs7246657 0.943 rs10415937 ENSG00000276846.1 CTD-3220F14.3 4.83 2.07e-06 0.000682 0.31 0.25 Coronary artery calcification; chr19:37339162 chr19:37314868~37315620:- LIHC cis rs7208859 0.673 rs9915139 ENSG00000266490.1 CTD-2349P21.9 4.83 2.07e-06 0.000682 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831497 chr17:30792372~30792833:+ LIHC cis rs11971779 0.68 rs10242419 ENSG00000273391.1 RP11-634H22.1 -4.83 2.08e-06 0.000683 -0.22 -0.25 Diisocyanate-induced asthma; chr7:139404634 chr7:139359032~139359566:- LIHC cis rs9807989 0.507 rs13021177 ENSG00000234389.1 AC007278.3 4.83 2.08e-06 0.000683 0.27 0.25 Asthma; chr2:102440033 chr2:102438713~102440475:+ LIHC cis rs597539 0.617 rs669659 ENSG00000250508.1 RP11-757G1.6 -4.83 2.08e-06 0.000683 -0.37 -0.25 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68868155 chr11:68870664~68874542:+ LIHC cis rs597539 0.617 rs598353 ENSG00000250508.1 RP11-757G1.6 -4.83 2.08e-06 0.000683 -0.37 -0.25 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68868302 chr11:68870664~68874542:+ LIHC cis rs42490 0.51 rs7003919 ENSG00000251136.7 RP11-37B2.1 4.83 2.08e-06 0.000684 0.23 0.25 Leprosy; chr8:89688185 chr8:89609409~89757727:- LIHC cis rs12291225 0.645 rs3763950 ENSG00000251991.1 RNU7-49P 4.83 2.08e-06 0.000684 0.27 0.25 Sense of smell; chr11:14256503 chr11:14478892~14478953:+ LIHC cis rs11098499 0.722 rs1814814 ENSG00000245958.5 RP11-33B1.1 -4.83 2.08e-06 0.000684 -0.25 -0.25 Corneal astigmatism; chr4:119336969 chr4:119454791~119552025:+ LIHC cis rs7914558 1 rs11191542 ENSG00000236937.2 PTGES3P4 4.83 2.08e-06 0.000685 0.3 0.25 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103064567 chr10:102845595~102845950:+ LIHC cis rs950776 0.79 rs2067808 ENSG00000261762.1 RP11-650L12.2 4.83 2.08e-06 0.000685 0.33 0.25 Sudden cardiac arrest; chr15:78619438 chr15:78589123~78591276:- LIHC cis rs9291683 0.595 rs11722930 ENSG00000250413.1 RP11-448G15.1 -4.83 2.09e-06 0.000686 -0.32 -0.25 Bone mineral density; chr4:10033830 chr4:10006482~10009725:+ LIHC cis rs9291683 0.595 rs3733585 ENSG00000250413.1 RP11-448G15.1 -4.83 2.09e-06 0.000686 -0.32 -0.25 Bone mineral density; chr4:10034715 chr4:10006482~10009725:+ LIHC cis rs9291683 0.561 rs3733584 ENSG00000250413.1 RP11-448G15.1 -4.83 2.09e-06 0.000686 -0.32 -0.25 Bone mineral density; chr4:10034882 chr4:10006482~10009725:+ LIHC cis rs1865760 0.713 rs7766342 ENSG00000216436.2 HIST1H2APS1 -4.83 2.09e-06 0.000686 -0.29 -0.25 Height; chr6:25990446 chr6:25732497~25732827:+ LIHC cis rs1865760 0.713 rs9461229 ENSG00000216436.2 HIST1H2APS1 -4.83 2.09e-06 0.000686 -0.29 -0.25 Height; chr6:25992051 chr6:25732497~25732827:+ LIHC cis rs7131987 0.801 rs962866 ENSG00000257176.2 RP11-996F15.2 -4.83 2.09e-06 0.000686 -0.28 -0.25 QT interval; chr12:29281214 chr12:29280418~29317848:- LIHC cis rs7131987 0.834 rs7139273 ENSG00000257176.2 RP11-996F15.2 -4.83 2.09e-06 0.000686 -0.28 -0.25 QT interval; chr12:29281717 chr12:29280418~29317848:- LIHC cis rs17301013 0.896 rs6425292 ENSG00000227373.4 RP11-160H22.5 4.83 2.09e-06 0.000687 0.31 0.25 Systemic lupus erythematosus; chr1:174618364 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs6689170 ENSG00000227373.4 RP11-160H22.5 4.83 2.09e-06 0.000687 0.31 0.25 Systemic lupus erythematosus; chr1:174639596 chr1:174115300~174160004:- LIHC cis rs2836974 1 rs2836974 ENSG00000255568.3 BRWD1-AS2 -4.83 2.09e-06 0.000687 -0.28 -0.25 Cognitive function; chr21:39291255 chr21:39313935~39314962:+ LIHC cis rs11098499 0.954 rs7436506 ENSG00000260091.1 RP11-33B1.4 -4.83 2.09e-06 0.000687 -0.18 -0.25 Corneal astigmatism; chr4:119472614 chr4:119409333~119410233:+ LIHC cis rs916888 0.61 rs199453 ENSG00000260075.1 NSFP1 4.83 2.1e-06 0.000688 0.31 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:46372855~46487141:+ LIHC cis rs2834188 1 rs2834188 ENSG00000272659.1 AP000295.10 -4.83 2.1e-06 0.000688 -0.37 -0.25 Narcolepsy; chr21:33316948 chr21:33309491~33310181:+ LIHC cis rs2834188 0.961 rs8130807 ENSG00000272659.1 AP000295.10 -4.83 2.1e-06 0.000688 -0.37 -0.25 Narcolepsy; chr21:33317708 chr21:33309491~33310181:+ LIHC cis rs1150668 0.699 rs12214383 ENSG00000204709.4 LINC01556 -4.83 2.1e-06 0.000688 -0.27 -0.25 Pubertal anthropometrics; chr6:28255953 chr6:28943877~28944537:+ LIHC cis rs1061377 0.722 rs34803689 ENSG00000249685.1 RP11-360F5.3 4.83 2.1e-06 0.000688 0.3 0.25 Uric acid levels; chr4:39116665 chr4:39133913~39135608:+ LIHC cis rs9890032 0.532 rs1808257 ENSG00000263531.1 RP13-753N3.1 4.83 2.1e-06 0.000688 0.33 0.25 Hip circumference adjusted for BMI; chr17:30712948 chr17:30863921~30864940:- LIHC cis rs3204270 1 rs3204270 ENSG00000281517.1 Metazoa_SRP -4.83 2.1e-06 0.000689 -0.56 -0.25 Dental caries; chr17:81715021 chr17:81718849~81719095:- LIHC cis rs765787 0.53 rs3759892 ENSG00000259520.4 CTD-2651B20.3 -4.83 2.1e-06 0.00069 -0.29 -0.25 Uric acid levels; chr15:45250511 chr15:45251580~45279251:- LIHC cis rs2929278 0.589 rs7174732 ENSG00000166763.7 STRCP1 -4.83 2.1e-06 0.00069 -0.33 -0.25 Schizophrenia; chr15:43746265 chr15:43699488~43718184:- LIHC cis rs1134634 0.52 rs16892152 ENSG00000273133.1 RP11-799M12.2 -4.83 2.11e-06 0.000691 -0.32 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr4:15559630 chr4:15563698~15564253:- LIHC cis rs11098499 0.78 rs7680914 ENSG00000245958.5 RP11-33B1.1 -4.83 2.11e-06 0.000692 -0.27 -0.25 Corneal astigmatism; chr4:119641898 chr4:119454791~119552025:+ LIHC cis rs7246657 0.943 rs10414904 ENSG00000276846.1 CTD-3220F14.3 4.83 2.11e-06 0.000692 0.31 0.25 Coronary artery calcification; chr19:37339186 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs10417844 ENSG00000276846.1 CTD-3220F14.3 4.83 2.11e-06 0.000692 0.31 0.25 Coronary artery calcification; chr19:37346685 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs1373991 ENSG00000276846.1 CTD-3220F14.3 4.83 2.11e-06 0.000692 0.31 0.25 Coronary artery calcification; chr19:37348009 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs10405407 ENSG00000276846.1 CTD-3220F14.3 4.83 2.11e-06 0.000692 0.31 0.25 Coronary artery calcification; chr19:37348262 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs12709813 ENSG00000276846.1 CTD-3220F14.3 4.83 2.11e-06 0.000692 0.31 0.25 Coronary artery calcification; chr19:37354081 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs13345116 ENSG00000276846.1 CTD-3220F14.3 4.83 2.11e-06 0.000692 0.31 0.25 Coronary artery calcification; chr19:37356196 chr19:37314868~37315620:- LIHC cis rs7246657 0.765 rs7247259 ENSG00000276846.1 CTD-3220F14.3 4.83 2.11e-06 0.000692 0.31 0.25 Coronary artery calcification; chr19:37360188 chr19:37314868~37315620:- LIHC cis rs12701220 0.504 rs12702092 ENSG00000229043.2 AC091729.9 -4.82 2.12e-06 0.000694 -0.37 -0.25 Bronchopulmonary dysplasia; chr7:1106232 chr7:1160374~1165267:+ LIHC cis rs2032447 0.672 rs9379811 ENSG00000242387.1 HIST1H2APS2 4.82 2.12e-06 0.000695 0.32 0.25 Intelligence (multi-trait analysis); chr6:25954969 chr6:25882026~25882395:- LIHC cis rs17507216 0.718 rs4779034 ENSG00000278603.1 RP13-608F4.5 4.82 2.12e-06 0.000695 0.5 0.25 Excessive daytime sleepiness; chr15:82576799 chr15:82472203~82472426:+ LIHC cis rs7897654 0.571 rs12771681 ENSG00000236937.2 PTGES3P4 4.82 2.12e-06 0.000695 0.33 0.25 Schizophrenia; chr10:102875863 chr10:102845595~102845950:+ LIHC cis rs1061377 1 rs4974931 ENSG00000249685.1 RP11-360F5.3 4.82 2.12e-06 0.000695 0.31 0.25 Uric acid levels; chr4:39108896 chr4:39133913~39135608:+ LIHC cis rs7412746 0.658 rs4970987 ENSG00000231073.1 RP11-316M1.3 4.82 2.12e-06 0.000695 0.26 0.25 Melanoma; chr1:150977206 chr1:150973123~150975534:+ LIHC cis rs7412746 0.634 rs12562939 ENSG00000231073.1 RP11-316M1.3 4.82 2.12e-06 0.000695 0.26 0.25 Melanoma; chr1:150978976 chr1:150973123~150975534:+ LIHC cis rs67311347 0.956 rs13066971 ENSG00000223797.4 ENTPD3-AS1 -4.82 2.12e-06 0.000695 -0.2 -0.25 Renal cell carcinoma; chr3:40421019 chr3:40313802~40453329:- LIHC cis rs116175783 0.557 rs72876083 ENSG00000227403.1 AC009299.3 4.82 2.12e-06 0.000695 0.39 0.25 Intelligence (multi-trait analysis); chr2:161327527 chr2:161244739~161249050:+ LIHC cis rs801193 0.569 rs35070132 ENSG00000237310.1 GS1-124K5.4 4.82 2.12e-06 0.000695 0.22 0.25 Aortic root size; chr7:66773096 chr7:66493706~66495474:+ LIHC cis rs9487094 0.744 rs13220304 ENSG00000260273.1 RP11-425D10.10 4.82 2.12e-06 0.000696 0.35 0.25 Height; chr6:109331033 chr6:109382795~109383666:+ LIHC cis rs77204473 0.744 rs17120523 ENSG00000254851.1 RP11-109L13.1 4.82 2.13e-06 0.000696 0.56 0.25 Sum eosinophil basophil counts;Eosinophil counts; chr11:117223875 chr11:117135528~117138582:+ LIHC cis rs7246657 0.943 rs4803347 ENSG00000276846.1 CTD-3220F14.3 4.82 2.13e-06 0.000696 0.31 0.25 Coronary artery calcification; chr19:37357115 chr19:37314868~37315620:- LIHC cis rs2739330 0.731 rs2000468 ENSG00000099984.9 GSTT2 -4.82 2.13e-06 0.000696 -0.3 -0.25 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23980123~23983911:+ LIHC cis rs755249 0.501 rs4660669 ENSG00000182109.6 RP11-69E11.4 -4.82 2.13e-06 0.000697 -0.27 -0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39341786 chr1:39522280~39546187:- LIHC cis rs6977955 1 rs917117 ENSG00000234336.5 JAZF1-AS1 -4.82 2.13e-06 0.000698 -0.36 -0.25 Allergic disease (asthma, hay fever or eczema); chr7:28136686 chr7:28180322~28243917:+ LIHC cis rs10800713 0.954 rs6660637 ENSG00000260088.1 RP11-92G12.3 -4.82 2.13e-06 0.000698 -0.35 -0.25 Tandem gait; chr1:200550893 chr1:200669507~200694250:+ LIHC cis rs10800713 0.954 rs10737572 ENSG00000260088.1 RP11-92G12.3 -4.82 2.13e-06 0.000698 -0.35 -0.25 Tandem gait; chr1:200552003 chr1:200669507~200694250:+ LIHC cis rs6600671 0.899 rs11249432 ENSG00000231429.2 RP11-343N15.2 -4.82 2.13e-06 0.000698 -0.29 -0.25 Hip geometry; chr1:121541678 chr1:121412719~121429274:+ LIHC cis rs12554020 0.579 rs76025942 ENSG00000227603.1 RP11-165J3.6 4.82 2.13e-06 0.000698 0.44 0.25 Schizophrenia; chr9:93605618 chr9:93435332~93437121:- LIHC cis rs10429558 0.609 rs76290025 ENSG00000227603.1 RP11-165J3.6 4.82 2.13e-06 0.000698 0.44 0.25 Neuroticism; chr9:93608100 chr9:93435332~93437121:- LIHC cis rs2836974 0.59 rs11911822 ENSG00000255568.3 BRWD1-AS2 -4.82 2.13e-06 0.000699 -0.21 -0.25 Cognitive function; chr21:39235917 chr21:39313935~39314962:+ LIHC cis rs1322639 0.657 rs12203887 ENSG00000261039.2 RP11-417E7.2 -4.82 2.14e-06 7e-04 -0.35 -0.25 Pulse pressure; chr6:169172157 chr6:169175304~169182740:- LIHC cis rs12134133 1 rs4844590 ENSG00000274245.1 RP11-357P18.2 4.82 2.14e-06 7e-04 0.37 0.25 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207322784 chr1:207372559~207373252:+ LIHC cis rs2337406 0.929 rs11847182 ENSG00000274576.2 IGHV2-70 -4.82 2.14e-06 7e-04 -0.29 -0.25 Alzheimer's disease (late onset); chr14:106697724 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs8012619 ENSG00000274576.2 IGHV2-70 -4.82 2.14e-06 0.000701 -0.26 -0.25 Alzheimer's disease (late onset); chr14:106793907 chr14:106770577~106771020:- LIHC cis rs71520386 0.632 rs9692432 ENSG00000228649.7 AC005682.5 -4.82 2.14e-06 0.000701 -0.32 -0.25 Fibrinogen levels; chr7:22829244 chr7:22854178~22861579:+ LIHC cis rs71520386 0.632 rs71520387 ENSG00000228649.7 AC005682.5 -4.82 2.14e-06 0.000701 -0.32 -0.25 Fibrinogen levels; chr7:22830057 chr7:22854178~22861579:+ LIHC cis rs71520386 0.632 rs10224244 ENSG00000228649.7 AC005682.5 -4.82 2.14e-06 0.000701 -0.32 -0.25 Fibrinogen levels; chr7:22830455 chr7:22854178~22861579:+ LIHC cis rs5769765 0.908 rs7410318 ENSG00000278869.1 CITF22-49E9.3 4.82 2.14e-06 0.000702 0.39 0.25 Schizophrenia; chr22:49923401 chr22:49933198~49934074:- LIHC cis rs1061377 0.501 rs62308278 ENSG00000249685.1 RP11-360F5.3 4.82 2.14e-06 0.000702 0.31 0.25 Uric acid levels; chr4:39161038 chr4:39133913~39135608:+ LIHC cis rs367615 0.552 rs2115511 ENSG00000249476.1 CTD-2587M2.1 -4.82 2.15e-06 0.000702 -0.29 -0.25 Colorectal cancer (SNP x SNP interaction); chr5:109389702 chr5:109237120~109326369:- LIHC cis rs7208859 0.623 rs9914242 ENSG00000266490.1 CTD-2349P21.9 4.82 2.15e-06 0.000702 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889227 chr17:30792372~30792833:+ LIHC cis rs1322639 0.614 rs6925188 ENSG00000261039.2 RP11-417E7.2 -4.82 2.15e-06 0.000703 -0.36 -0.25 Pulse pressure; chr6:169163242 chr6:169175304~169182740:- LIHC cis rs30380 0.553 rs152280 ENSG00000272109.1 CTD-2260A17.3 -4.82 2.15e-06 0.000703 -0.33 -0.25 Cerebrospinal fluid biomarker levels; chr5:96826239 chr5:96804353~96806105:+ LIHC cis rs5769765 0.837 rs7284417 ENSG00000278869.1 CITF22-49E9.3 4.82 2.15e-06 0.000703 0.37 0.25 Schizophrenia; chr22:49920698 chr22:49933198~49934074:- LIHC cis rs4964805 0.594 rs4964830 ENSG00000257681.1 RP11-341G23.4 -4.82 2.15e-06 0.000704 -0.26 -0.25 Attention deficit hyperactivity disorder; chr12:103775130 chr12:103746315~103768858:- LIHC cis rs10129255 0.517 rs11625572 ENSG00000211970.3 IGHV4-61 -4.82 2.15e-06 0.000704 -0.2 -0.25 Kawasaki disease; chr14:106656426 chr14:106639119~106639657:- LIHC cis rs2439831 1 rs28628574 ENSG00000205771.5 CATSPER2P1 -4.82 2.15e-06 0.000704 -0.41 -0.25 Lung cancer in ever smokers; chr15:43509840 chr15:43726918~43747094:- LIHC cis rs2836974 0.644 rs2836986 ENSG00000255568.3 BRWD1-AS2 -4.82 2.16e-06 0.000705 -0.21 -0.25 Cognitive function; chr21:39330210 chr21:39313935~39314962:+ LIHC cis rs1061377 1 rs9990742 ENSG00000249685.1 RP11-360F5.3 4.82 2.16e-06 0.000705 0.3 0.25 Uric acid levels; chr4:39119794 chr4:39133913~39135608:+ LIHC cis rs597539 0.652 rs604524 ENSG00000250508.1 RP11-757G1.6 -4.82 2.16e-06 0.000705 -0.37 -0.25 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68862461 chr11:68870664~68874542:+ LIHC cis rs875971 0.508 rs10950045 ENSG00000237310.1 GS1-124K5.4 -4.82 2.16e-06 0.000705 -0.23 -0.25 Aortic root size; chr7:66601386 chr7:66493706~66495474:+ LIHC cis rs801193 0.839 rs6968619 ENSG00000237310.1 GS1-124K5.4 -4.82 2.16e-06 0.000705 -0.23 -0.25 Aortic root size; chr7:66603880 chr7:66493706~66495474:+ LIHC cis rs4356203 0.905 rs6486354 ENSG00000272034.1 SNORD14A -4.82 2.16e-06 0.000705 -0.27 -0.25 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17178561 chr11:17074654~17074744:- LIHC cis rs765787 0.53 rs7167731 ENSG00000259520.4 CTD-2651B20.3 -4.82 2.16e-06 0.000705 -0.29 -0.25 Uric acid levels; chr15:45218702 chr15:45251580~45279251:- LIHC cis rs2274273 0.905 rs8007944 ENSG00000258413.1 RP11-665C16.6 -4.82 2.16e-06 0.000706 -0.28 -0.25 Protein biomarker; chr14:55110098 chr14:55262767~55272075:- LIHC cis rs5769765 0.908 rs138866 ENSG00000278869.1 CITF22-49E9.3 -4.82 2.16e-06 0.000706 -0.39 -0.25 Schizophrenia; chr22:49812255 chr22:49933198~49934074:- LIHC cis rs2834188 0.883 rs16997869 ENSG00000272659.1 AP000295.10 4.82 2.16e-06 0.000706 0.37 0.25 Narcolepsy; chr21:33324562 chr21:33309491~33310181:+ LIHC cis rs11079159 1 rs876719 ENSG00000263096.1 RP11-515O17.2 4.82 2.16e-06 0.000707 0.35 0.25 QRS duration; chr17:55289205 chr17:55271504~55273653:- LIHC cis rs10129255 0.518 rs12590732 ENSG00000223648.3 IGHV3-64 -4.82 2.17e-06 0.000707 -0.18 -0.25 Kawasaki disease; chr14:106779612 chr14:106643132~106658258:- LIHC cis rs7714584 1 rs34156253 ENSG00000197083.10 ZNF300P1 4.82 2.17e-06 0.000708 0.4 0.25 Crohn's disease; chr5:150846668 chr5:150930645~150946289:- LIHC cis rs2834188 0.924 rs2850015 ENSG00000272659.1 AP000295.10 -4.82 2.17e-06 0.000709 -0.37 -0.25 Narcolepsy; chr21:33324959 chr21:33309491~33310181:+ LIHC cis rs4660214 0.666 rs6698791 ENSG00000182109.6 RP11-69E11.4 -4.82 2.17e-06 0.000709 -0.27 -0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39469104 chr1:39522280~39546187:- LIHC cis rs7914558 1 rs10883824 ENSG00000236937.2 PTGES3P4 4.82 2.17e-06 0.000709 0.3 0.25 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103053140 chr10:102845595~102845950:+ LIHC cis rs4660214 0.666 rs7538300 ENSG00000182109.6 RP11-69E11.4 -4.82 2.17e-06 0.000709 -0.27 -0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39187092 chr1:39522280~39546187:- LIHC cis rs2072510 0.593 rs2660900 ENSG00000257715.1 RP11-256L6.2 -4.82 2.17e-06 0.00071 -0.39 -0.25 Metabolite levels (small molecules and protein measures); chr12:96011299 chr12:96025323~96027971:+ LIHC cis rs2072510 0.593 rs2540493 ENSG00000257715.1 RP11-256L6.2 -4.82 2.17e-06 0.00071 -0.39 -0.25 Metabolite levels (small molecules and protein measures); chr12:96022064 chr12:96025323~96027971:+ LIHC cis rs2072510 0.593 rs2660838 ENSG00000257715.1 RP11-256L6.2 -4.82 2.17e-06 0.00071 -0.39 -0.25 Metabolite levels (small molecules and protein measures); chr12:96022605 chr12:96025323~96027971:+ LIHC cis rs1005277 0.557 rs2983338 ENSG00000275858.1 RP11-291L22.8 4.82 2.17e-06 0.00071 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38261806 chr10:38450738~38451069:- LIHC cis rs5758511 0.68 rs1107553 ENSG00000205702.9 CYP2D7 4.82 2.18e-06 0.000712 0.3 0.25 Birth weight; chr22:42271467 chr22:42140203~42144577:- LIHC cis rs10510102 0.872 rs28586586 ENSG00000226864.1 ATE1-AS1 4.82 2.18e-06 0.000712 0.43 0.25 Breast cancer; chr10:121950228 chr10:121928312~121951965:+ LIHC cis rs8059260 0.542 rs11860777 ENSG00000274038.1 RP11-66H6.4 -4.82 2.18e-06 0.000712 -0.42 -0.25 Alcohol consumption over the past year; chr16:11033718 chr16:11056556~11057034:+ LIHC cis rs11098499 0.604 rs34278750 ENSG00000245958.5 RP11-33B1.1 -4.82 2.18e-06 0.000712 -0.26 -0.25 Corneal astigmatism; chr4:119649981 chr4:119454791~119552025:+ LIHC cis rs7615304 0.617 rs343994 ENSG00000243926.1 TIPARP-AS1 -4.82 2.18e-06 0.000713 -0.24 -0.25 Interleukin-2 levels; chr3:156787575 chr3:156671862~156674378:- LIHC cis rs73193808 0.639 rs7277858 ENSG00000224649.1 AF124730.4 4.82 2.19e-06 0.000713 0.3 0.25 Coronary artery disease; chr21:29180556 chr21:29182027~29187795:- LIHC cis rs6600671 1 rs2319969 ENSG00000231429.2 RP11-343N15.2 -4.82 2.19e-06 0.000713 -0.31 -0.25 Hip geometry; chr1:121465481 chr1:121412719~121429274:+ LIHC cis rs4731207 0.741 rs1557969 ENSG00000224897.5 POT1-AS1 -4.82 2.19e-06 0.000714 -0.3 -0.25 Cutaneous malignant melanoma; chr7:124765684 chr7:124929873~125179315:+ LIHC cis rs2836974 0.899 rs68004583 ENSG00000255568.3 BRWD1-AS2 4.82 2.19e-06 0.000715 0.28 0.25 Cognitive function; chr21:39287661 chr21:39313935~39314962:+ LIHC cis rs9903692 0.954 rs12941295 ENSG00000278765.1 RP5-890E16.5 -4.82 2.2e-06 0.000716 -0.33 -0.25 Pulse pressure; chr17:48110825 chr17:48066704~48067293:- LIHC cis rs1577917 0.958 rs2875456 ENSG00000234155.1 RP11-30P6.6 4.82 2.2e-06 0.000716 0.34 0.25 Response to antipsychotic treatment; chr6:85892566 chr6:85387219~85390186:- LIHC cis rs9291683 0.632 rs13101785 ENSG00000250413.1 RP11-448G15.1 -4.82 2.2e-06 0.000716 -0.32 -0.25 Bone mineral density; chr4:10041291 chr4:10006482~10009725:+ LIHC cis rs9291683 0.618 rs13137343 ENSG00000250413.1 RP11-448G15.1 -4.82 2.2e-06 0.000716 -0.32 -0.25 Bone mineral density; chr4:10041404 chr4:10006482~10009725:+ LIHC cis rs2274273 0.905 rs28429419 ENSG00000258413.1 RP11-665C16.6 -4.82 2.2e-06 0.000717 -0.28 -0.25 Protein biomarker; chr14:55108075 chr14:55262767~55272075:- LIHC cis rs72627509 0.629 rs1277313 ENSG00000269949.1 RP11-738E22.3 -4.82 2.2e-06 0.000718 -0.32 -0.25 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57037782 chr4:56960927~56961373:- LIHC cis rs10129255 0.5 rs10131875 ENSG00000223648.3 IGHV3-64 4.82 2.2e-06 0.000718 0.18 0.25 Kawasaki disease; chr14:106792798 chr14:106643132~106658258:- LIHC cis rs755249 0.959 rs72663520 ENSG00000182109.6 RP11-69E11.4 4.82 2.2e-06 0.000718 0.33 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39537738 chr1:39522280~39546187:- LIHC cis rs8028182 0.636 rs28737338 ENSG00000260269.4 CTD-2323K18.1 -4.82 2.2e-06 0.000718 -0.32 -0.25 Sudden cardiac arrest; chr15:75476338 chr15:75527150~75601205:- LIHC cis rs9500256 0.966 rs1322446 ENSG00000272541.1 XXbac-BPGBPG55C20.1 -4.82 2.2e-06 0.000719 -0.28 -0.25 Eosinophilic esophagitis (pediatric); chr6:57985672 chr6:57855891~57856468:- LIHC cis rs6142102 0.607 rs6088408 ENSG00000276073.1 RP5-1125A11.7 4.82 2.21e-06 0.000719 0.31 0.25 Skin pigmentation; chr20:34146800 chr20:33985617~33988989:- LIHC cis rs6597981 0.592 rs10902218 ENSG00000255284.1 AP006621.5 -4.82 2.21e-06 0.00072 -0.27 -0.25 Breast cancer; chr11:743813 chr11:777578~784297:+ LIHC cis rs7811142 0.943 rs111493473 ENSG00000242294.5 STAG3L5P 4.82 2.21e-06 0.00072 0.3 0.25 Platelet count; chr7:100452119 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs7809801 ENSG00000242294.5 STAG3L5P 4.82 2.21e-06 0.00072 0.3 0.25 Platelet count; chr7:100474408 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs11766752 ENSG00000242294.5 STAG3L5P 4.82 2.21e-06 0.00072 0.3 0.25 Platelet count; chr7:100475669 chr7:100336079~100351900:+ LIHC cis rs2919917 0.915 rs3899796 ENSG00000254352.1 RP11-578O24.2 4.82 2.21e-06 0.00072 0.34 0.25 Lymphocyte counts; chr8:78655847 chr8:78723796~78724136:- LIHC cis rs603446 0.935 rs180372 ENSG00000254851.1 RP11-109L13.1 -4.82 2.21e-06 0.00072 -0.31 -0.25 Triglycerides; chr11:116721218 chr11:117135528~117138582:+ LIHC cis rs6822297 0.504 rs7681802 ENSG00000240005.4 RP11-293A21.1 4.82 2.21e-06 0.000721 0.3 0.25 Obesity-related traits; chr4:26989777 chr4:26859806~26860599:- LIHC cis rs160451 1 rs160441 ENSG00000251136.7 RP11-37B2.1 4.82 2.21e-06 0.000721 0.23 0.25 Leprosy; chr8:89644760 chr8:89609409~89757727:- LIHC cis rs11673344 0.526 rs17305193 ENSG00000226686.6 LINC01535 4.81 2.22e-06 0.000722 0.38 0.25 Obesity-related traits; chr19:37598764 chr19:37251912~37265535:+ LIHC cis rs7209700 0.894 rs7212751 ENSG00000228782.6 CTD-2026D20.3 -4.81 2.22e-06 0.000722 -0.28 -0.25 IgG glycosylation; chr17:47278133 chr17:47450568~47492492:- LIHC cis rs7412746 0.611 rs7556661 ENSG00000231073.1 RP11-316M1.3 4.81 2.22e-06 0.000723 0.25 0.25 Melanoma; chr1:150919533 chr1:150973123~150975534:+ LIHC cis rs116175783 0.557 rs62188136 ENSG00000227403.1 AC009299.3 4.81 2.22e-06 0.000724 0.39 0.25 Intelligence (multi-trait analysis); chr2:161399439 chr2:161244739~161249050:+ LIHC cis rs11971779 0.68 rs7795520 ENSG00000273391.1 RP11-634H22.1 4.81 2.22e-06 0.000724 0.22 0.25 Diisocyanate-induced asthma; chr7:139394461 chr7:139359032~139359566:- LIHC cis rs875971 0.545 rs73376394 ENSG00000226824.5 RP4-756H11.3 -4.81 2.22e-06 0.000724 -0.32 -0.25 Aortic root size; chr7:66172694 chr7:66654538~66669855:+ LIHC cis rs1005277 0.529 rs1780125 ENSG00000275858.1 RP11-291L22.8 4.81 2.22e-06 0.000724 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38242448 chr10:38450738~38451069:- LIHC cis rs1005277 0.502 rs2800484 ENSG00000275858.1 RP11-291L22.8 4.81 2.22e-06 0.000724 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38253487 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2800485 ENSG00000275858.1 RP11-291L22.8 4.81 2.22e-06 0.000724 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38253660 chr10:38450738~38451069:- LIHC cis rs643506 0.874 rs648544 ENSG00000254990.4 RP11-108O10.2 4.81 2.23e-06 0.000725 0.27 0.25 Breast cancer; chr11:111795404 chr11:111768668~111778350:- LIHC cis rs202072 0.72 rs454563 ENSG00000215022.6 RP1-257A7.4 -4.81 2.23e-06 0.000726 -0.29 -0.25 HIV-1 viral setpoint; chr6:13295304 chr6:13264861~13295586:- LIHC cis rs1322639 0.614 rs9294967 ENSG00000261039.2 RP11-417E7.2 4.81 2.23e-06 0.000726 0.35 0.25 Pulse pressure; chr6:169165311 chr6:169175304~169182740:- LIHC cis rs2877649 1 rs76534589 ENSG00000258744.1 RP11-80A15.1 -4.81 2.23e-06 0.000727 -0.52 -0.25 Smooth-surface caries; chr14:24459703 chr14:24501594~24508688:+ LIHC cis rs10129255 0.5 rs6576231 ENSG00000223648.3 IGHV3-64 4.81 2.24e-06 0.000728 0.18 0.25 Kawasaki disease; chr14:106783693 chr14:106643132~106658258:- LIHC cis rs12291225 0.639 rs61883858 ENSG00000251991.1 RNU7-49P 4.81 2.24e-06 0.000728 0.27 0.25 Sense of smell; chr11:14273162 chr11:14478892~14478953:+ LIHC cis rs12291225 0.679 rs11023170 ENSG00000251991.1 RNU7-49P 4.81 2.24e-06 0.000728 0.27 0.25 Sense of smell; chr11:14273363 chr11:14478892~14478953:+ LIHC cis rs12291225 0.679 rs11023172 ENSG00000251991.1 RNU7-49P 4.81 2.24e-06 0.000728 0.27 0.25 Sense of smell; chr11:14273821 chr11:14478892~14478953:+ LIHC cis rs12291225 0.679 rs4757245 ENSG00000251991.1 RNU7-49P 4.81 2.24e-06 0.000728 0.27 0.25 Sense of smell; chr11:14276326 chr11:14478892~14478953:+ LIHC cis rs10510102 0.516 rs78586895 ENSG00000276742.1 RP11-500G22.4 4.81 2.24e-06 0.000728 0.41 0.25 Breast cancer; chr10:121977081 chr10:121956782~121957098:+ LIHC cis rs12291225 0.679 rs34238445 ENSG00000251991.1 RNU7-49P 4.81 2.24e-06 0.000728 0.27 0.25 Sense of smell; chr11:14294369 chr11:14478892~14478953:+ LIHC cis rs10829156 0.699 rs10828879 ENSG00000225527.1 RP11-383B4.4 -4.81 2.24e-06 0.000728 -0.39 -0.25 Sudden cardiac arrest; chr10:18546425 chr10:18531849~18533336:- LIHC cis rs2919917 0.915 rs2953477 ENSG00000254352.1 RP11-578O24.2 4.81 2.24e-06 0.000729 0.34 0.25 Lymphocyte counts; chr8:78712370 chr8:78723796~78724136:- LIHC cis rs7829975 0.567 rs6601273 ENSG00000253893.2 FAM85B 4.81 2.24e-06 0.00073 0.3 0.25 Mood instability; chr8:8939009 chr8:8167819~8226614:- LIHC cis rs904251 0.861 rs2776875 ENSG00000204110.6 RP1-153P14.8 -4.81 2.24e-06 0.00073 -0.32 -0.25 Cognitive performance; chr6:37519020 chr6:37507348~37535616:+ LIHC cis rs7945705 0.52 rs1984791 ENSG00000254860.4 TMEM9B-AS1 -4.81 2.25e-06 0.00073 -0.27 -0.25 Hemoglobin concentration; chr11:9013480 chr11:8964675~8977527:+ LIHC cis rs7119038 0.774 rs11217037 ENSG00000255239.1 AP002954.6 -4.81 2.25e-06 0.00073 -0.36 -0.25 Sjögren's syndrome; chr11:118806377 chr11:118688039~118690600:- LIHC cis rs12554020 0.686 rs77734990 ENSG00000227603.1 RP11-165J3.6 4.81 2.25e-06 0.000731 0.43 0.25 Schizophrenia; chr9:93561870 chr9:93435332~93437121:- LIHC cis rs12554020 0.686 rs56275034 ENSG00000227603.1 RP11-165J3.6 4.81 2.25e-06 0.000731 0.43 0.25 Schizophrenia; chr9:93563474 chr9:93435332~93437121:- LIHC cis rs12554020 0.892 rs75775593 ENSG00000227603.1 RP11-165J3.6 4.81 2.25e-06 0.000731 0.43 0.25 Schizophrenia; chr9:93568611 chr9:93435332~93437121:- LIHC cis rs30380 1 rs27710 ENSG00000272109.1 CTD-2260A17.3 4.81 2.25e-06 0.000731 0.31 0.25 Cerebrospinal fluid biomarker levels; chr5:96790494 chr5:96804353~96806105:+ LIHC cis rs9291683 0.525 rs12506455 ENSG00000250413.1 RP11-448G15.1 -4.81 2.25e-06 0.000732 -0.32 -0.25 Bone mineral density; chr4:10029945 chr4:10006482~10009725:+ LIHC cis rs12291225 0.637 rs8570 ENSG00000251991.1 RNU7-49P 4.81 2.25e-06 0.000732 0.27 0.25 Sense of smell; chr11:14279213 chr11:14478892~14478953:+ LIHC cis rs3096299 0.967 rs28644774 ENSG00000261118.1 RP11-104N10.1 4.81 2.26e-06 0.000733 0.26 0.25 Multiple myeloma (IgH translocation); chr16:89405773 chr16:89492017~89504460:- LIHC cis rs603446 0.967 rs180361 ENSG00000254851.1 RP11-109L13.1 -4.81 2.27e-06 0.000736 -0.31 -0.25 Triglycerides; chr11:116727933 chr11:117135528~117138582:+ LIHC cis rs228614 0.51 rs223405 ENSG00000246560.2 RP11-10L12.4 4.81 2.27e-06 0.000736 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102815894 chr4:102828055~102844075:+ LIHC cis rs11098499 0.954 rs12499324 ENSG00000260091.1 RP11-33B1.4 -4.81 2.27e-06 0.000737 -0.18 -0.25 Corneal astigmatism; chr4:119472631 chr4:119409333~119410233:+ LIHC cis rs513088 0.515 rs476197 ENSG00000225171.2 DUTP6 4.81 2.27e-06 0.000737 0.31 0.25 Schizophrenia; chr1:166704178 chr1:166868748~166869209:+ LIHC cis rs9549367 0.773 rs9549717 ENSG00000269125.1 RP11-98F14.11 -4.81 2.27e-06 0.000737 -0.28 -0.25 Platelet distribution width; chr13:113254512 chr13:113165002~113165183:- LIHC cis rs6061231 0.546 rs482220 ENSG00000273619.1 RP5-908M14.9 4.81 2.27e-06 0.000737 0.21 0.25 Colorectal cancer; chr20:62352426 chr20:62386303~62386970:- LIHC cis rs8177253 0.665 rs8177178 ENSG00000244062.1 RP11-404G16.2 4.81 2.27e-06 0.000738 0.26 0.25 Iron status biomarkers; chr3:133744428 chr3:133760300~133762363:+ LIHC cis rs1577917 0.883 rs6454505 ENSG00000234155.1 RP11-30P6.6 4.81 2.27e-06 0.000738 0.3 0.25 Response to antipsychotic treatment; chr6:85882644 chr6:85387219~85390186:- LIHC cis rs9291683 0.632 rs12508991 ENSG00000250413.1 RP11-448G15.1 -4.81 2.27e-06 0.000738 -0.32 -0.25 Bone mineral density; chr4:10039480 chr4:10006482~10009725:+ LIHC cis rs9291683 0.632 rs11734786 ENSG00000250413.1 RP11-448G15.1 -4.81 2.27e-06 0.000738 -0.32 -0.25 Bone mineral density; chr4:10039875 chr4:10006482~10009725:+ LIHC cis rs9291683 0.632 rs7679916 ENSG00000250413.1 RP11-448G15.1 -4.81 2.27e-06 0.000738 -0.32 -0.25 Bone mineral density; chr4:10040536 chr4:10006482~10009725:+ LIHC cis rs9291683 0.632 rs13137074 ENSG00000250413.1 RP11-448G15.1 -4.81 2.27e-06 0.000738 -0.32 -0.25 Bone mineral density; chr4:10041218 chr4:10006482~10009725:+ LIHC cis rs950169 0.887 rs12903946 ENSG00000259728.4 LINC00933 4.81 2.27e-06 0.000738 0.36 0.25 Schizophrenia; chr15:84399732 chr15:84570649~84580175:+ LIHC cis rs950169 0.887 rs62029593 ENSG00000259728.4 LINC00933 4.81 2.27e-06 0.000738 0.36 0.25 Schizophrenia; chr15:84400482 chr15:84570649~84580175:+ LIHC cis rs950169 0.81 rs62029594 ENSG00000259728.4 LINC00933 4.81 2.27e-06 0.000738 0.36 0.25 Schizophrenia; chr15:84400554 chr15:84570649~84580175:+ LIHC cis rs950169 0.881 rs62029596 ENSG00000259728.4 LINC00933 4.81 2.27e-06 0.000738 0.36 0.25 Schizophrenia; chr15:84400736 chr15:84570649~84580175:+ LIHC cis rs950169 0.881 rs4081123 ENSG00000259728.4 LINC00933 4.81 2.27e-06 0.000738 0.36 0.25 Schizophrenia; chr15:84401537 chr15:84570649~84580175:+ LIHC cis rs950169 0.881 rs62029599 ENSG00000259728.4 LINC00933 4.81 2.27e-06 0.000738 0.36 0.25 Schizophrenia; chr15:84401867 chr15:84570649~84580175:+ LIHC cis rs950169 0.8 rs4099846 ENSG00000259728.4 LINC00933 4.81 2.27e-06 0.000738 0.36 0.25 Schizophrenia; chr15:84402196 chr15:84570649~84580175:+ LIHC cis rs7897654 0.571 rs12764049 ENSG00000236937.2 PTGES3P4 4.81 2.27e-06 0.000739 0.33 0.25 Schizophrenia; chr10:102875199 chr10:102845595~102845950:+ LIHC cis rs1065852 0.526 rs9607869 ENSG00000237037.8 NDUFA6-AS1 -4.81 2.28e-06 0.000739 -0.35 -0.25 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42022106 chr22:42090931~42137742:+ LIHC cis rs8005677 0.828 rs712486 ENSG00000279656.1 RP11-298I3.6 4.81 2.28e-06 0.000741 0.28 0.25 Cognitive ability (multi-trait analysis); chr14:22955832 chr14:23023083~23024217:- LIHC cis rs712039 0.617 rs36081240 ENSG00000276054.1 RP11-378E13.3 4.81 2.28e-06 0.000741 0.32 0.25 Tuberculosis; chr17:37424955 chr17:37386886~37387926:+ LIHC cis rs2834188 1 rs4408796 ENSG00000272659.1 AP000295.10 4.81 2.28e-06 0.000741 0.37 0.25 Narcolepsy; chr21:33326436 chr21:33309491~33310181:+ LIHC cis rs6921919 0.848 rs56131013 ENSG00000216901.1 AL022393.7 4.81 2.28e-06 0.000741 0.35 0.25 Autism spectrum disorder or schizophrenia; chr6:28352900 chr6:28176188~28176674:+ LIHC cis rs2929278 0.617 rs533143 ENSG00000166763.7 STRCP1 4.81 2.28e-06 0.000741 0.32 0.25 Schizophrenia; chr15:43896656 chr15:43699488~43718184:- LIHC cis rs11216126 1 rs11602240 ENSG00000254851.1 RP11-109L13.1 4.81 2.28e-06 0.000741 0.39 0.25 HDL cholesterol; chr11:116762082 chr11:117135528~117138582:+ LIHC cis rs11098499 0.644 rs2389880 ENSG00000245958.5 RP11-33B1.1 -4.81 2.29e-06 0.000742 -0.26 -0.25 Corneal astigmatism; chr4:119638715 chr4:119454791~119552025:+ LIHC cis rs3733585 0.783 rs13148371 ENSG00000250413.1 RP11-448G15.1 -4.81 2.29e-06 0.000742 -0.32 -0.25 Cleft plate (environmental tobacco smoke interaction); chr4:10030937 chr4:10006482~10009725:+ LIHC cis rs2836974 0.897 rs35386515 ENSG00000255568.3 BRWD1-AS2 4.81 2.29e-06 0.000742 0.28 0.25 Cognitive function; chr21:39160121 chr21:39313935~39314962:+ LIHC cis rs2836974 0.863 rs8128026 ENSG00000255568.3 BRWD1-AS2 4.81 2.29e-06 0.000742 0.28 0.25 Cognitive function; chr21:39161776 chr21:39313935~39314962:+ LIHC cis rs11098499 0.866 rs10518329 ENSG00000260091.1 RP11-33B1.4 -4.81 2.29e-06 0.000743 -0.17 -0.25 Corneal astigmatism; chr4:119480680 chr4:119409333~119410233:+ LIHC cis rs875971 0.54 rs4717275 ENSG00000164669.11 INTS4P1 4.81 2.29e-06 0.000743 0.35 0.25 Aortic root size; chr7:65800193 chr7:65141225~65234216:+ LIHC cis rs8059260 0.542 rs7196077 ENSG00000274038.1 RP11-66H6.4 -4.81 2.29e-06 0.000744 -0.41 -0.25 Alcohol consumption over the past year; chr16:11033198 chr16:11056556~11057034:+ LIHC cis rs17818399 0.62 rs1080871 ENSG00000279254.1 RP11-536C12.1 -4.81 2.29e-06 0.000744 -0.29 -0.25 Height; chr2:46627569 chr2:46668870~46670778:+ LIHC cis rs17818399 0.62 rs7598578 ENSG00000279254.1 RP11-536C12.1 -4.81 2.29e-06 0.000744 -0.29 -0.25 Height; chr2:46629946 chr2:46668870~46670778:+ LIHC cis rs17818399 0.62 rs1598517 ENSG00000279254.1 RP11-536C12.1 -4.81 2.29e-06 0.000744 -0.29 -0.25 Height; chr2:46630262 chr2:46668870~46670778:+ LIHC cis rs17818399 0.62 rs6739397 ENSG00000279254.1 RP11-536C12.1 -4.81 2.29e-06 0.000744 -0.29 -0.25 Height; chr2:46631182 chr2:46668870~46670778:+ LIHC cis rs1005277 0.579 rs1780137 ENSG00000276805.1 RP11-291L22.6 4.81 2.29e-06 0.000744 0.31 0.25 Extrinsic epigenetic age acceleration; chr10:38212547 chr10:38451030~38451785:+ LIHC cis rs950169 0.887 rs220333 ENSG00000225151.9 GOLGA2P7 -4.81 2.3e-06 0.000745 -0.32 -0.25 Schizophrenia; chr15:84547902 chr15:84199311~84230136:- LIHC cis rs12554020 0.892 rs16909273 ENSG00000227603.1 RP11-165J3.6 4.81 2.3e-06 0.000745 0.42 0.25 Schizophrenia; chr9:93532820 chr9:93435332~93437121:- LIHC cis rs12554020 0.892 rs12551084 ENSG00000227603.1 RP11-165J3.6 4.81 2.3e-06 0.000745 0.42 0.25 Schizophrenia; chr9:93538013 chr9:93435332~93437121:- LIHC cis rs12554020 1 rs35540150 ENSG00000227603.1 RP11-165J3.6 4.81 2.3e-06 0.000745 0.42 0.25 Schizophrenia; chr9:93538572 chr9:93435332~93437121:- LIHC cis rs12554020 0.792 rs79419498 ENSG00000227603.1 RP11-165J3.6 4.81 2.3e-06 0.000745 0.42 0.25 Schizophrenia; chr9:93504701 chr9:93435332~93437121:- LIHC cis rs12554020 0.892 rs78046549 ENSG00000227603.1 RP11-165J3.6 4.81 2.3e-06 0.000745 0.42 0.25 Schizophrenia; chr9:93506196 chr9:93435332~93437121:- LIHC cis rs12554020 0.892 rs76977206 ENSG00000227603.1 RP11-165J3.6 4.81 2.3e-06 0.000745 0.42 0.25 Schizophrenia; chr9:93518181 chr9:93435332~93437121:- LIHC cis rs12554020 0.786 rs883785 ENSG00000227603.1 RP11-165J3.6 4.81 2.3e-06 0.000745 0.42 0.25 Schizophrenia; chr9:93519841 chr9:93435332~93437121:- LIHC cis rs12554020 0.681 rs883783 ENSG00000227603.1 RP11-165J3.6 4.81 2.3e-06 0.000745 0.42 0.25 Schizophrenia; chr9:93519987 chr9:93435332~93437121:- LIHC cis rs8040855 0.627 rs3816105 ENSG00000259295.5 CSPG4P12 4.81 2.3e-06 0.000746 0.39 0.25 Bulimia nervosa; chr15:85097680 chr15:85191438~85213905:+ LIHC cis rs8040855 0.627 rs2304418 ENSG00000259295.5 CSPG4P12 4.81 2.3e-06 0.000746 0.39 0.25 Bulimia nervosa; chr15:85097752 chr15:85191438~85213905:+ LIHC cis rs4660214 0.666 rs11205739 ENSG00000182109.6 RP11-69E11.4 -4.81 2.3e-06 0.000746 -0.27 -0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39190729 chr1:39522280~39546187:- LIHC cis rs7208859 0.623 rs7220999 ENSG00000266490.1 CTD-2349P21.9 4.81 2.3e-06 0.000746 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822280 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs55638872 ENSG00000266490.1 CTD-2349P21.9 4.81 2.3e-06 0.000746 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822534 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9899268 ENSG00000266490.1 CTD-2349P21.9 4.81 2.3e-06 0.000746 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30823237 chr17:30792372~30792833:+ LIHC cis rs1322639 0.657 rs9355135 ENSG00000261039.2 RP11-417E7.2 -4.81 2.3e-06 0.000746 -0.35 -0.25 Pulse pressure; chr6:169172911 chr6:169175304~169182740:- LIHC cis rs6480314 0.522 rs61857273 ENSG00000233590.1 RP11-153K11.3 -4.81 2.3e-06 0.000747 -0.41 -0.25 Optic nerve measurement (disc area); chr10:68307530 chr10:68233251~68242379:- LIHC cis rs5769707 0.609 rs2007024 ENSG00000235111.1 RP1-29C18.8 -4.81 2.3e-06 0.000747 -0.3 -0.25 Monocyte percentage of white cells;Monocyte count; chr22:49595167 chr22:49612657~49615716:- LIHC cis rs2948294 0.588 rs12544596 ENSG00000253893.2 FAM85B -4.81 2.31e-06 0.000747 -0.29 -0.25 Red cell distribution width; chr8:8258824 chr8:8167819~8226614:- LIHC cis rs11098499 0.863 rs1383533 ENSG00000245958.5 RP11-33B1.1 -4.81 2.31e-06 0.000748 -0.26 -0.25 Corneal astigmatism; chr4:119513421 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs2291185 ENSG00000245958.5 RP11-33B1.1 -4.81 2.31e-06 0.000748 -0.26 -0.25 Corneal astigmatism; chr4:119513678 chr4:119454791~119552025:+ LIHC cis rs2337406 0.925 rs11851094 ENSG00000274576.2 IGHV2-70 -4.81 2.32e-06 0.000751 -0.28 -0.25 Alzheimer's disease (late onset); chr14:106688967 chr14:106770577~106771020:- LIHC cis rs860295 0.966 rs821551 ENSG00000203761.5 MSTO2P -4.81 2.32e-06 0.000751 -0.21 -0.25 Body mass index; chr1:155718789 chr1:155745829~155750137:+ LIHC cis rs227275 0.525 rs2866417 ENSG00000230069.3 LRRC37A15P -4.81 2.32e-06 0.000751 -0.23 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102993481 chr4:102727274~102730721:- LIHC cis rs2032366 0.583 rs1452594 ENSG00000267279.1 RP11-879F14.2 -4.81 2.32e-06 0.000751 -0.3 -0.25 Obesity-related traits; chr18:61590689 chr18:61585746~61606916:- LIHC cis rs228614 0.51 rs223358 ENSG00000246560.2 RP11-10L12.4 4.81 2.32e-06 0.000751 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102849637 chr4:102828055~102844075:+ LIHC cis rs5769765 0.862 rs7410537 ENSG00000278869.1 CITF22-49E9.3 4.8 2.32e-06 0.000752 0.39 0.25 Schizophrenia; chr22:49923682 chr22:49933198~49934074:- LIHC cis rs73186030 0.764 rs55744726 ENSG00000272758.4 RP11-299J3.8 4.8 2.32e-06 0.000753 0.46 0.25 Serum parathyroid hormone levels; chr3:122368907 chr3:122416207~122443180:+ LIHC cis rs73186030 0.764 rs73186095 ENSG00000272758.4 RP11-299J3.8 4.8 2.32e-06 0.000753 0.46 0.25 Serum parathyroid hormone levels; chr3:122372769 chr3:122416207~122443180:+ LIHC cis rs73186030 0.764 rs67446552 ENSG00000272758.4 RP11-299J3.8 4.8 2.32e-06 0.000753 0.46 0.25 Serum parathyroid hormone levels; chr3:122377448 chr3:122416207~122443180:+ LIHC cis rs73186030 0.764 rs67706840 ENSG00000272758.4 RP11-299J3.8 4.8 2.32e-06 0.000753 0.46 0.25 Serum parathyroid hormone levels; chr3:122377717 chr3:122416207~122443180:+ LIHC cis rs73186030 0.764 rs16833078 ENSG00000272758.4 RP11-299J3.8 4.8 2.32e-06 0.000753 0.46 0.25 Serum parathyroid hormone levels; chr3:122380747 chr3:122416207~122443180:+ LIHC cis rs12887734 0.546 rs4900597 ENSG00000258534.1 CTD-2134A5.4 4.8 2.33e-06 0.000753 0.28 0.25 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103800327 chr14:103854366~103880111:- LIHC cis rs2283792 0.764 rs2298432 ENSG00000224086.5 LL22NC03-86G7.1 -4.8 2.33e-06 0.000753 -0.24 -0.25 Multiple sclerosis; chr22:21768900 chr22:21938293~21977632:+ LIHC cis rs2032447 0.714 rs199739 ENSG00000242387.1 HIST1H2APS2 4.8 2.33e-06 0.000753 0.33 0.25 Intelligence (multi-trait analysis); chr6:25960281 chr6:25882026~25882395:- LIHC cis rs5769765 0.862 rs138870 ENSG00000278869.1 CITF22-49E9.3 4.8 2.33e-06 0.000753 0.4 0.25 Schizophrenia; chr22:49816089 chr22:49933198~49934074:- LIHC cis rs2834188 1 rs2843994 ENSG00000272659.1 AP000295.10 -4.8 2.33e-06 0.000753 -0.39 -0.25 Narcolepsy; chr21:33334564 chr21:33309491~33310181:+ LIHC cis rs227275 0.556 rs223398 ENSG00000246560.2 RP11-10L12.4 4.8 2.33e-06 0.000754 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102821256 chr4:102828055~102844075:+ LIHC cis rs12478296 0.786 rs55876934 ENSG00000261186.2 RP11-341N2.1 -4.8 2.33e-06 0.000756 -0.36 -0.25 Obesity-related traits; chr2:242091665 chr2:242087351~242088457:- LIHC cis rs12478296 1 rs56292923 ENSG00000261186.2 RP11-341N2.1 -4.8 2.34e-06 0.000756 -0.36 -0.25 Obesity-related traits; chr2:242097835 chr2:242087351~242088457:- LIHC cis rs67311347 0.822 rs11709089 ENSG00000223797.4 ENTPD3-AS1 4.8 2.34e-06 0.000757 0.21 0.25 Renal cell carcinoma; chr3:40309993 chr3:40313802~40453329:- LIHC cis rs2749592 0.531 rs1208559 ENSG00000099251.13 HSD17B7P2 -4.8 2.35e-06 0.000759 -0.29 -0.25 Age-related hearing impairment (SNP x SNP interaction); chr10:37932442 chr10:38356380~38378505:+ LIHC cis rs1030877 0.515 rs920217 ENSG00000235319.1 AC012360.4 4.8 2.35e-06 0.000759 0.34 0.25 Obesity-related traits; chr2:105288205 chr2:105324210~105330529:+ LIHC cis rs950169 0.922 rs11639244 ENSG00000259728.4 LINC00933 4.8 2.35e-06 0.00076 0.35 0.25 Schizophrenia; chr15:84163898 chr15:84570649~84580175:+ LIHC cis rs950169 0.922 rs6603022 ENSG00000259728.4 LINC00933 -4.8 2.35e-06 0.00076 -0.35 -0.25 Schizophrenia; chr15:84161418 chr15:84570649~84580175:+ LIHC cis rs2749097 0.825 rs11208265 ENSG00000244256.3 RN7SL130P -4.8 2.35e-06 0.00076 -0.29 -0.25 Alcohol consumption (transferrin glycosylation); chr1:63659563 chr1:63655743~63656047:+ LIHC cis rs1061377 0.861 rs35739603 ENSG00000249685.1 RP11-360F5.3 4.8 2.35e-06 0.00076 0.31 0.25 Uric acid levels; chr4:39107938 chr4:39133913~39135608:+ LIHC cis rs5758511 0.68 rs5758688 ENSG00000205702.9 CYP2D7 4.8 2.35e-06 0.00076 0.3 0.25 Birth weight; chr22:42266495 chr22:42140203~42144577:- LIHC cis rs6822297 0.522 rs9998971 ENSG00000240005.4 RP11-293A21.1 4.8 2.35e-06 0.000761 0.3 0.25 Obesity-related traits; chr4:27000082 chr4:26859806~26860599:- LIHC cis rs6822297 0.504 rs12152700 ENSG00000240005.4 RP11-293A21.1 4.8 2.35e-06 0.000761 0.3 0.25 Obesity-related traits; chr4:27005029 chr4:26859806~26860599:- LIHC cis rs712039 0.652 rs853200 ENSG00000276054.1 RP11-378E13.3 4.8 2.35e-06 0.000761 0.32 0.25 Tuberculosis; chr17:37444013 chr17:37386886~37387926:+ LIHC cis rs228614 0.51 rs223392 ENSG00000246560.2 RP11-10L12.4 4.8 2.35e-06 0.000761 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102824599 chr4:102828055~102844075:+ LIHC cis rs4356203 0.87 rs10832748 ENSG00000272034.1 SNORD14A -4.8 2.36e-06 0.000761 -0.27 -0.25 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17230184 chr11:17074654~17074744:- LIHC cis rs7429990 0.727 rs319695 ENSG00000229759.1 MRPS18AP1 -4.8 2.36e-06 0.000762 -0.27 -0.25 Educational attainment (years of education); chr3:47842749 chr3:48256350~48256938:- LIHC cis rs2836974 0.831 rs2836964 ENSG00000255568.3 BRWD1-AS2 4.8 2.36e-06 0.000762 0.28 0.25 Cognitive function; chr21:39259080 chr21:39313935~39314962:+ LIHC cis rs2836974 0.931 rs2836968 ENSG00000255568.3 BRWD1-AS2 4.8 2.36e-06 0.000762 0.28 0.25 Cognitive function; chr21:39270460 chr21:39313935~39314962:+ LIHC cis rs2836974 0.931 rs7283569 ENSG00000255568.3 BRWD1-AS2 4.8 2.36e-06 0.000762 0.28 0.25 Cognitive function; chr21:39272136 chr21:39313935~39314962:+ LIHC cis rs2836974 0.931 rs2836972 ENSG00000255568.3 BRWD1-AS2 4.8 2.36e-06 0.000762 0.28 0.25 Cognitive function; chr21:39280216 chr21:39313935~39314962:+ LIHC cis rs2836974 0.965 rs7354783 ENSG00000255568.3 BRWD1-AS2 4.8 2.36e-06 0.000762 0.28 0.25 Cognitive function; chr21:39281066 chr21:39313935~39314962:+ LIHC cis rs2836974 0.931 rs8132285 ENSG00000255568.3 BRWD1-AS2 4.8 2.36e-06 0.000762 0.28 0.25 Cognitive function; chr21:39283826 chr21:39313935~39314962:+ LIHC cis rs12554020 0.582 rs75018698 ENSG00000227603.1 RP11-165J3.6 4.8 2.36e-06 0.000762 0.46 0.25 Schizophrenia; chr9:93647025 chr9:93435332~93437121:- LIHC cis rs2834188 1 rs2026254 ENSG00000272659.1 AP000295.10 -4.8 2.36e-06 0.000762 -0.37 -0.25 Narcolepsy; chr21:33315727 chr21:33309491~33310181:+ LIHC cis rs1862618 1 rs1862618 ENSG00000271828.1 CTD-2310F14.1 4.8 2.36e-06 0.000762 0.35 0.25 Initial pursuit acceleration; chr5:56800488 chr5:56927874~56929573:+ LIHC cis rs7246657 0.943 rs4803229 ENSG00000276846.1 CTD-3220F14.3 4.8 2.36e-06 0.000762 0.31 0.25 Coronary artery calcification; chr19:37373780 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs1559229 ENSG00000276846.1 CTD-3220F14.3 4.8 2.36e-06 0.000762 0.31 0.25 Coronary artery calcification; chr19:37385295 chr19:37314868~37315620:- LIHC cis rs7246657 0.882 rs6508719 ENSG00000276846.1 CTD-3220F14.3 4.8 2.36e-06 0.000762 0.31 0.25 Coronary artery calcification; chr19:37386517 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs4452075 ENSG00000276846.1 CTD-3220F14.3 4.8 2.36e-06 0.000762 0.31 0.25 Coronary artery calcification; chr19:37388687 chr19:37314868~37315620:- LIHC cis rs11673344 0.526 rs2291001 ENSG00000226686.6 LINC01535 4.8 2.36e-06 0.000763 0.38 0.25 Obesity-related traits; chr19:37594431 chr19:37251912~37265535:+ LIHC cis rs8177253 0.696 rs4459901 ENSG00000244062.1 RP11-404G16.2 4.8 2.36e-06 0.000764 0.25 0.25 Iron status biomarkers; chr3:133746855 chr3:133760300~133762363:+ LIHC cis rs67311347 1 rs11714912 ENSG00000223797.4 ENTPD3-AS1 -4.8 2.37e-06 0.000764 -0.2 -0.25 Renal cell carcinoma; chr3:40452574 chr3:40313802~40453329:- LIHC cis rs529413 1 rs518792 ENSG00000259237.1 RP11-209E8.1 4.8 2.37e-06 0.000764 0.35 0.25 Itch intensity from mosquito bite adjusted by bite size; chr15:53247959 chr15:53116365~53129698:+ LIHC cis rs10129255 0.5 rs7161740 ENSG00000223648.3 IGHV3-64 4.8 2.37e-06 0.000764 0.18 0.25 Kawasaki disease; chr14:106776119 chr14:106643132~106658258:- LIHC cis rs11098499 0.954 rs11098525 ENSG00000260091.1 RP11-33B1.4 -4.8 2.37e-06 0.000764 -0.18 -0.25 Corneal astigmatism; chr4:119468997 chr4:119409333~119410233:+ LIHC cis rs11096990 0.634 rs17754 ENSG00000249685.1 RP11-360F5.3 4.8 2.37e-06 0.000765 0.3 0.25 Cognitive function; chr4:39287688 chr4:39133913~39135608:+ LIHC cis rs2836974 0.897 rs34394827 ENSG00000255568.3 BRWD1-AS2 4.8 2.37e-06 0.000765 0.28 0.25 Cognitive function; chr21:39156161 chr21:39313935~39314962:+ LIHC cis rs11096990 0.613 rs12505690 ENSG00000249685.1 RP11-360F5.3 4.8 2.38e-06 0.000768 0.3 0.25 Cognitive function; chr4:39167425 chr4:39133913~39135608:+ LIHC cis rs2836950 0.501 rs1474490 ENSG00000255568.3 BRWD1-AS2 -4.8 2.38e-06 0.000768 -0.21 -0.25 Menarche (age at onset); chr21:39344210 chr21:39313935~39314962:+ LIHC cis rs227275 0.554 rs223390 ENSG00000246560.2 RP11-10L12.4 4.8 2.38e-06 0.000769 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102827640 chr4:102828055~102844075:+ LIHC cis rs875971 0.545 rs6979636 ENSG00000273142.1 RP11-458F8.4 4.8 2.38e-06 0.000769 0.24 0.25 Aortic root size; chr7:66276638 chr7:66902857~66906297:+ LIHC cis rs4925386 1 rs1889201 ENSG00000273619.1 RP5-908M14.9 4.8 2.38e-06 0.000769 0.2 0.25 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62348019 chr20:62386303~62386970:- LIHC cis rs1198872 0.516 rs1734413 ENSG00000272275.1 RP11-791G15.2 -4.8 2.38e-06 0.000769 -0.3 -0.25 Cardiac Troponin-T levels; chr2:10772910 chr2:10767875~10770058:- LIHC cis rs7688540 0.713 rs4624608 ENSG00000275426.1 CH17-262A2.1 4.8 2.39e-06 0.00077 0.34 0.25 Facial morphology (factor 6, height of vermillion lower lip); chr4:213204 chr4:149738~150317:+ LIHC cis rs712039 0.652 rs853222 ENSG00000276054.1 RP11-378E13.3 4.8 2.39e-06 0.000771 0.32 0.25 Tuberculosis; chr17:37429923 chr17:37386886~37387926:+ LIHC cis rs7131987 0.868 rs7958210 ENSG00000257176.2 RP11-996F15.2 -4.8 2.39e-06 0.000771 -0.29 -0.25 QT interval; chr12:29242248 chr12:29280418~29317848:- LIHC cis rs7829975 0.572 rs7005000 ENSG00000253893.2 FAM85B 4.8 2.39e-06 0.000772 0.3 0.25 Mood instability; chr8:8939092 chr8:8167819~8226614:- LIHC cis rs11098499 0.865 rs10213221 ENSG00000245958.5 RP11-33B1.1 -4.8 2.39e-06 0.000772 -0.26 -0.25 Corneal astigmatism; chr4:119334771 chr4:119454791~119552025:+ LIHC cis rs7829975 0.522 rs6601689 ENSG00000253893.2 FAM85B -4.8 2.4e-06 0.000773 -0.34 -0.25 Mood instability; chr8:8314761 chr8:8167819~8226614:- LIHC cis rs7246657 0.943 rs3803895 ENSG00000276846.1 CTD-3220F14.3 4.8 2.4e-06 0.000773 0.31 0.25 Coronary artery calcification; chr19:37407767 chr19:37314868~37315620:- LIHC cis rs1030877 0.515 rs2576735 ENSG00000235319.1 AC012360.4 -4.8 2.4e-06 0.000773 -0.35 -0.25 Obesity-related traits; chr2:105272382 chr2:105324210~105330529:+ LIHC cis rs3087243 0.519 rs11571315 ENSG00000213925.3 NPM1P33 4.8 2.4e-06 0.000773 0.25 0.25 Rheumatoid arthritis;Type 1 diabetes;Hypothyroidism; chr2:203866178 chr2:203772631~203773502:- LIHC cis rs17711722 0.503 rs453835 ENSG00000226824.5 RP4-756H11.3 4.8 2.4e-06 0.000774 0.3 0.25 Calcium levels; chr7:66046172 chr7:66654538~66669855:+ LIHC cis rs17270561 0.723 rs12213243 ENSG00000272810.1 U91328.22 -4.8 2.4e-06 0.000774 -0.33 -0.25 Iron status biomarkers; chr6:25889880 chr6:26013241~26013757:+ LIHC cis rs9903692 0.908 rs11079809 ENSG00000278765.1 RP5-890E16.5 -4.8 2.4e-06 0.000774 -0.33 -0.25 Pulse pressure; chr17:48120859 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs3744346 ENSG00000278765.1 RP5-890E16.5 -4.8 2.4e-06 0.000774 -0.33 -0.25 Pulse pressure; chr17:48121514 chr17:48066704~48067293:- LIHC cis rs9903692 0.908 rs7222136 ENSG00000278765.1 RP5-890E16.5 -4.8 2.4e-06 0.000774 -0.33 -0.25 Pulse pressure; chr17:48122230 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs1010228 ENSG00000278765.1 RP5-890E16.5 -4.8 2.4e-06 0.000774 -0.33 -0.25 Pulse pressure; chr17:48122986 chr17:48066704~48067293:- LIHC cis rs367615 0.537 rs10463600 ENSG00000249476.1 CTD-2587M2.1 4.8 2.4e-06 0.000774 0.29 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109327935 chr5:109237120~109326369:- LIHC cis rs6964833 0.935 rs35735900 ENSG00000277053.3 GTF2IP1 -4.8 2.4e-06 0.000775 -0.3 -0.25 Menarche (age at onset); chr7:74651887 chr7:75185385~75237696:- LIHC cis rs887829 0.57 rs6753320 ENSG00000233445.1 RPL17P11 -4.8 2.41e-06 0.000776 -0.26 -0.25 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233686969 chr2:233721522~233722065:- LIHC cis rs1005277 0.579 rs1780133 ENSG00000275858.1 RP11-291L22.8 4.8 2.41e-06 0.000776 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38210581 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1780136 ENSG00000275858.1 RP11-291L22.8 4.8 2.41e-06 0.000776 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38212525 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1780138 ENSG00000275858.1 RP11-291L22.8 4.8 2.41e-06 0.000776 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38212726 chr10:38450738~38451069:- LIHC cis rs1005277 0.602 rs1780141 ENSG00000275858.1 RP11-291L22.8 4.8 2.41e-06 0.000776 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38215371 chr10:38450738~38451069:- LIHC cis rs1005277 0.541 rs1740741 ENSG00000275858.1 RP11-291L22.8 4.8 2.41e-06 0.000776 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38226406 chr10:38450738~38451069:- LIHC cis rs1005277 0.528 rs2057228 ENSG00000275858.1 RP11-291L22.8 4.8 2.41e-06 0.000776 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38226838 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1740742 ENSG00000275858.1 RP11-291L22.8 4.8 2.41e-06 0.000776 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38229932 chr10:38450738~38451069:- LIHC cis rs1005277 0.602 rs1740743 ENSG00000275858.1 RP11-291L22.8 4.8 2.41e-06 0.000776 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38230294 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1740745 ENSG00000275858.1 RP11-291L22.8 4.8 2.41e-06 0.000776 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38231128 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1740747 ENSG00000275858.1 RP11-291L22.8 4.8 2.41e-06 0.000776 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38231537 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1740749 ENSG00000275858.1 RP11-291L22.8 4.8 2.41e-06 0.000776 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38232718 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1780115 ENSG00000275858.1 RP11-291L22.8 4.8 2.41e-06 0.000776 0.28 0.25 Extrinsic epigenetic age acceleration; chr10:38235845 chr10:38450738~38451069:- LIHC cis rs10510102 0.935 rs7907871 ENSG00000226864.1 ATE1-AS1 4.8 2.41e-06 0.000777 0.44 0.25 Breast cancer; chr10:121878185 chr10:121928312~121951965:+ LIHC cis rs7615952 0.641 rs4490307 ENSG00000171084.14 FAM86JP 4.8 2.41e-06 0.000777 0.38 0.25 Blood pressure (smoking interaction); chr3:125993833 chr3:125916620~125930024:+ LIHC cis rs10975870 0.847 rs10975913 ENSG00000236924.1 RP11-390F4.6 -4.8 2.42e-06 0.000778 -0.31 -0.25 Body mass index; chr9:6935297 chr9:6645956~6670635:+ LIHC cis rs9834975 0.935 rs9863881 ENSG00000272758.4 RP11-299J3.8 -4.8 2.42e-06 0.000778 -0.28 -0.25 Diastolic blood pressure; chr3:122381176 chr3:122416207~122443180:+ LIHC cis rs2932538 0.961 rs4240534 ENSG00000225075.1 RP11-426L16.3 -4.8 2.42e-06 0.000778 -0.32 -0.25 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112632807 chr1:112693688~112696621:- LIHC cis rs11971779 0.715 rs11772771 ENSG00000273391.1 RP11-634H22.1 4.8 2.42e-06 0.000779 0.23 0.25 Diisocyanate-induced asthma; chr7:139374057 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs4728465 ENSG00000273391.1 RP11-634H22.1 4.8 2.42e-06 0.000779 0.23 0.25 Diisocyanate-induced asthma; chr7:139384315 chr7:139359032~139359566:- LIHC cis rs11971779 0.715 rs55714903 ENSG00000273391.1 RP11-634H22.1 4.8 2.42e-06 0.000779 0.23 0.25 Diisocyanate-induced asthma; chr7:139389844 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs66491565 ENSG00000273391.1 RP11-634H22.1 4.8 2.42e-06 0.000779 0.23 0.25 Diisocyanate-induced asthma; chr7:139404231 chr7:139359032~139359566:- LIHC cis rs7208859 0.623 rs426434 ENSG00000266490.1 CTD-2349P21.9 4.8 2.42e-06 0.000779 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30598335 chr17:30792372~30792833:+ LIHC cis rs7914558 1 rs67908413 ENSG00000236937.2 PTGES3P4 4.8 2.42e-06 0.00078 0.29 0.25 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103005232 chr10:102845595~102845950:+ LIHC cis rs1888560 0.556 rs12588573 ENSG00000199461.1 Y_RNA -4.8 2.43e-06 0.000781 -0.31 -0.25 Blood protein levels; chr14:20678425 chr14:20679411~20679512:+ LIHC cis rs11098499 0.954 rs10017543 ENSG00000260091.1 RP11-33B1.4 -4.8 2.43e-06 0.000782 -0.18 -0.25 Corneal astigmatism; chr4:119400265 chr4:119409333~119410233:+ LIHC cis rs11098499 0.908 rs7695996 ENSG00000260091.1 RP11-33B1.4 -4.8 2.43e-06 0.000782 -0.18 -0.25 Corneal astigmatism; chr4:119400878 chr4:119409333~119410233:+ LIHC cis rs6085948 0.861 rs6085954 ENSG00000228888.1 LINC01428 -4.79 2.44e-06 0.000784 -0.44 -0.25 Interleukin-10 levels; chr20:7257602 chr20:7146467~7254202:- LIHC cis rs7131987 0.903 rs11050163 ENSG00000257176.2 RP11-996F15.2 -4.79 2.44e-06 0.000784 -0.29 -0.25 QT interval; chr12:29267465 chr12:29280418~29317848:- LIHC cis rs9549367 0.865 rs9549366 ENSG00000269125.1 RP11-98F14.11 -4.79 2.44e-06 0.000784 -0.28 -0.25 Platelet distribution width; chr13:113253330 chr13:113165002~113165183:- LIHC cis rs9549367 0.789 rs9577220 ENSG00000269125.1 RP11-98F14.11 -4.79 2.44e-06 0.000784 -0.28 -0.25 Platelet distribution width; chr13:113253980 chr13:113165002~113165183:- LIHC cis rs9549367 0.789 rs9549716 ENSG00000269125.1 RP11-98F14.11 -4.79 2.44e-06 0.000784 -0.28 -0.25 Platelet distribution width; chr13:113254164 chr13:113165002~113165183:- LIHC cis rs12134133 1 rs28371597 ENSG00000274245.1 RP11-357P18.2 4.79 2.44e-06 0.000785 0.38 0.25 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207323551 chr1:207372559~207373252:+ LIHC cis rs7246657 0.943 rs4803460 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37394326 chr19:37314868~37315620:- LIHC cis rs7246657 0.882 rs4803539 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37406620 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs10406177 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37417045 chr19:37314868~37315620:- LIHC cis rs7246657 0.882 rs28623164 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37422551 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs7252346 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37423780 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs2891699 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37429335 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs9676967 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37437187 chr19:37314868~37315620:- LIHC cis rs7246657 0.882 rs8112610 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37437828 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs8109632 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37440223 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs7255407 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37443034 chr19:37314868~37315620:- LIHC cis rs7246657 0.941 rs7256130 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37443079 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs2112923 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37449425 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs3760825 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37454699 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs10420754 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37468470 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs2081096 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37473798 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs7253091 ENSG00000276846.1 CTD-3220F14.3 4.79 2.44e-06 0.000785 0.31 0.25 Coronary artery calcification; chr19:37476312 chr19:37314868~37315620:- LIHC cis rs7208859 0.623 rs60890550 ENSG00000266490.1 CTD-2349P21.9 4.79 2.45e-06 0.000786 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30703843 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs11653955 ENSG00000266490.1 CTD-2349P21.9 4.79 2.45e-06 0.000786 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30706274 chr17:30792372~30792833:+ LIHC cis rs72675573 0.723 rs6702275 ENSG00000235612.1 RP1-158P9.1 -4.79 2.45e-06 0.000786 -0.33 -0.25 Monocyte count; chr1:56079811 chr1:56145721~56155224:+ LIHC cis rs1062177 0.826 rs2053063 ENSG00000253921.1 CTB-113P19.3 -4.79 2.45e-06 0.000786 -0.29 -0.25 Preschool internalizing problems; chr5:151787203 chr5:151753992~151767247:+ LIHC cis rs1062177 1 rs2964571 ENSG00000253921.1 CTB-113P19.3 -4.79 2.45e-06 0.000786 -0.29 -0.25 Preschool internalizing problems; chr5:151791695 chr5:151753992~151767247:+ LIHC cis rs1062177 1 rs2915869 ENSG00000253921.1 CTB-113P19.3 -4.79 2.45e-06 0.000786 -0.29 -0.25 Preschool internalizing problems; chr5:151791948 chr5:151753992~151767247:+ LIHC cis rs1062177 1 rs2347596 ENSG00000253921.1 CTB-113P19.3 -4.79 2.45e-06 0.000786 -0.29 -0.25 Preschool internalizing problems; chr5:151799638 chr5:151753992~151767247:+ LIHC cis rs6480314 0.542 rs12570281 ENSG00000233590.1 RP11-153K11.3 -4.79 2.45e-06 0.000786 -0.39 -0.25 Optic nerve measurement (disc area); chr10:68267237 chr10:68233251~68242379:- LIHC cis rs6480314 0.542 rs61854813 ENSG00000233590.1 RP11-153K11.3 -4.79 2.45e-06 0.000786 -0.39 -0.25 Optic nerve measurement (disc area); chr10:68267464 chr10:68233251~68242379:- LIHC cis rs12571093 0.803 rs61854814 ENSG00000233590.1 RP11-153K11.3 -4.79 2.45e-06 0.000786 -0.39 -0.25 Optic nerve measurement (disc area); chr10:68267639 chr10:68233251~68242379:- LIHC cis rs957448 1 rs28817653 ENSG00000253704.1 RP11-267M23.4 4.79 2.45e-06 0.000786 0.3 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94557822 chr8:94553722~94569745:+ LIHC cis rs6600671 0.934 rs7528274 ENSG00000231429.2 RP11-343N15.2 -4.79 2.45e-06 0.000787 -0.29 -0.25 Hip geometry; chr1:121545103 chr1:121412719~121429274:+ LIHC cis rs2439831 0.85 rs10163054 ENSG00000166763.7 STRCP1 4.79 2.45e-06 0.000787 0.38 0.25 Lung cancer in ever smokers; chr15:43755440 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs12442129 ENSG00000166763.7 STRCP1 4.79 2.45e-06 0.000787 0.38 0.25 Lung cancer in ever smokers; chr15:43763658 chr15:43699488~43718184:- LIHC cis rs2439831 0.702 rs7175032 ENSG00000166763.7 STRCP1 4.79 2.45e-06 0.000787 0.38 0.25 Lung cancer in ever smokers; chr15:43768038 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs2277531 ENSG00000166763.7 STRCP1 4.79 2.45e-06 0.000787 0.38 0.25 Lung cancer in ever smokers; chr15:43776871 chr15:43699488~43718184:- LIHC cis rs2739330 0.587 rs4820571 ENSG00000206090.4 AP000350.7 4.79 2.45e-06 0.000787 0.3 0.25 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23939998~23942798:+ LIHC cis rs9500256 1 rs9500256 ENSG00000272541.1 XXbac-BPGBPG55C20.1 -4.79 2.45e-06 0.000788 -0.28 -0.25 Eosinophilic esophagitis (pediatric); chr6:57982677 chr6:57855891~57856468:- LIHC cis rs7209700 0.638 rs4629025 ENSG00000228782.6 CTD-2026D20.3 -4.79 2.45e-06 0.000788 -0.28 -0.25 IgG glycosylation; chr17:47260069 chr17:47450568~47492492:- LIHC cis rs597539 0.617 rs686348 ENSG00000250508.1 RP11-757G1.6 -4.79 2.46e-06 0.000789 -0.37 -0.25 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68869528 chr11:68870664~68874542:+ LIHC cis rs597539 0.652 rs686877 ENSG00000250508.1 RP11-757G1.6 -4.79 2.46e-06 0.000789 -0.37 -0.25 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68869701 chr11:68870664~68874542:+ LIHC cis rs597539 0.652 rs579136 ENSG00000250508.1 RP11-757G1.6 -4.79 2.46e-06 0.000789 -0.37 -0.25 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68870008 chr11:68870664~68874542:+ LIHC cis rs597539 0.652 rs10792001 ENSG00000250508.1 RP11-757G1.6 -4.79 2.46e-06 0.000789 -0.37 -0.25 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68870269 chr11:68870664~68874542:+ LIHC cis rs597539 0.652 rs613128 ENSG00000250508.1 RP11-757G1.6 -4.79 2.46e-06 0.000789 -0.37 -0.25 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68870590 chr11:68870664~68874542:+ LIHC cis rs227275 0.556 rs4455413 ENSG00000230069.3 LRRC37A15P -4.79 2.46e-06 0.00079 -0.22 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102971925 chr4:102727274~102730721:- LIHC cis rs2439831 0.867 rs11856184 ENSG00000275601.1 AC011330.13 -4.79 2.46e-06 0.00079 -0.37 -0.25 Lung cancer in ever smokers; chr15:43626964 chr15:43642389~43643023:- LIHC cis rs2439831 0.867 rs2447211 ENSG00000275601.1 AC011330.13 -4.79 2.46e-06 0.00079 -0.37 -0.25 Lung cancer in ever smokers; chr15:43644153 chr15:43642389~43643023:- LIHC cis rs2439831 0.571 rs2470121 ENSG00000275601.1 AC011330.13 -4.79 2.46e-06 0.00079 -0.37 -0.25 Lung cancer in ever smokers; chr15:43645420 chr15:43642389~43643023:- LIHC cis rs4713118 0.662 rs156744 ENSG00000219392.1 RP1-265C24.5 -4.79 2.46e-06 0.000791 -0.37 -0.25 Parkinson's disease; chr6:27999496 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs149946 ENSG00000219392.1 RP1-265C24.5 4.79 2.46e-06 0.000791 0.37 0.25 Parkinson's disease; chr6:28002253 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs149947 ENSG00000219392.1 RP1-265C24.5 -4.79 2.46e-06 0.000791 -0.37 -0.25 Parkinson's disease; chr6:28004655 chr6:28115628~28116551:+ LIHC cis rs12554020 0.786 rs10429558 ENSG00000227603.1 RP11-165J3.6 4.79 2.46e-06 0.000791 0.34 0.25 Schizophrenia; chr9:93574508 chr9:93435332~93437121:- LIHC cis rs957448 1 rs60655325 ENSG00000253704.1 RP11-267M23.4 4.79 2.47e-06 0.000791 0.3 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94552606 chr8:94553722~94569745:+ LIHC cis rs957448 1 rs16916881 ENSG00000253704.1 RP11-267M23.4 4.79 2.47e-06 0.000791 0.3 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94554042 chr8:94553722~94569745:+ LIHC cis rs8028182 0.636 rs8034317 ENSG00000260269.4 CTD-2323K18.1 -4.79 2.47e-06 0.000793 -0.32 -0.25 Sudden cardiac arrest; chr15:75472002 chr15:75527150~75601205:- LIHC cis rs1023500 0.505 rs134887 ENSG00000227370.1 RP4-669P10.19 -4.79 2.47e-06 0.000793 -0.26 -0.25 Schizophrenia; chr22:42278233 chr22:42132543~42132998:+ LIHC cis rs2932538 0.885 rs6691025 ENSG00000225075.1 RP11-426L16.3 -4.79 2.47e-06 0.000793 -0.32 -0.25 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112634448 chr1:112693688~112696621:- LIHC cis rs17711722 0.583 rs11768292 ENSG00000164669.11 INTS4P1 4.79 2.47e-06 0.000793 0.38 0.25 Calcium levels; chr7:66009814 chr7:65141225~65234216:+ LIHC cis rs7702057 0.53 rs1129495 ENSG00000271918.1 CTD-2287O16.5 4.79 2.47e-06 0.000793 0.35 0.25 Amyotrophic lateral sclerosis; chr5:116092684 chr5:116083807~116085416:- LIHC cis rs7702057 0.53 rs61105089 ENSG00000271918.1 CTD-2287O16.5 4.79 2.47e-06 0.000793 0.35 0.25 Amyotrophic lateral sclerosis; chr5:116096514 chr5:116083807~116085416:- LIHC cis rs7702057 0.53 rs2136213 ENSG00000271918.1 CTD-2287O16.5 4.79 2.47e-06 0.000793 0.35 0.25 Amyotrophic lateral sclerosis; chr5:116098716 chr5:116083807~116085416:- LIHC cis rs7702057 0.53 rs4921060 ENSG00000271918.1 CTD-2287O16.5 4.79 2.47e-06 0.000793 0.35 0.25 Amyotrophic lateral sclerosis; chr5:116109004 chr5:116083807~116085416:- LIHC cis rs7702057 0.53 rs58510083 ENSG00000271918.1 CTD-2287O16.5 4.79 2.47e-06 0.000793 0.35 0.25 Amyotrophic lateral sclerosis; chr5:116109101 chr5:116083807~116085416:- LIHC cis rs7702057 0.53 rs61672521 ENSG00000271918.1 CTD-2287O16.5 4.79 2.47e-06 0.000793 0.35 0.25 Amyotrophic lateral sclerosis; chr5:116112548 chr5:116083807~116085416:- LIHC cis rs11216126 1 rs4938309 ENSG00000254851.1 RP11-109L13.1 4.79 2.47e-06 0.000794 0.39 0.25 HDL cholesterol; chr11:116756339 chr11:117135528~117138582:+ LIHC cis rs3096299 0.504 rs4785574 ENSG00000261118.1 RP11-104N10.1 4.79 2.48e-06 0.000794 0.25 0.25 Multiple myeloma (IgH translocation); chr16:89502467 chr16:89492017~89504460:- LIHC cis rs6951245 0.638 rs4720486 ENSG00000229043.2 AC091729.9 -4.79 2.48e-06 0.000795 -0.45 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1107128 chr7:1160374~1165267:+ LIHC cis rs6951245 0.554 rs11761322 ENSG00000229043.2 AC091729.9 -4.79 2.48e-06 0.000795 -0.45 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1112021 chr7:1160374~1165267:+ LIHC cis rs7811142 1 rs11559117 ENSG00000242294.5 STAG3L5P 4.79 2.48e-06 0.000795 0.3 0.25 Platelet count; chr7:100478991 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs4463351 ENSG00000242294.5 STAG3L5P 4.79 2.48e-06 0.000795 0.3 0.25 Platelet count; chr7:100480603 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs60844404 ENSG00000242294.5 STAG3L5P 4.79 2.48e-06 0.000795 0.3 0.25 Platelet count; chr7:100482851 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs11763511 ENSG00000242294.5 STAG3L5P 4.79 2.48e-06 0.000795 0.3 0.25 Platelet count; chr7:100484321 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs60478351 ENSG00000242294.5 STAG3L5P 4.79 2.48e-06 0.000795 0.3 0.25 Platelet count; chr7:100491394 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs7787620 ENSG00000242294.5 STAG3L5P 4.79 2.48e-06 0.000795 0.3 0.25 Platelet count; chr7:100491611 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs11769700 ENSG00000242294.5 STAG3L5P 4.79 2.48e-06 0.000795 0.3 0.25 Platelet count; chr7:100492426 chr7:100336079~100351900:+ LIHC cis rs712039 0.652 rs1829453 ENSG00000276054.1 RP11-378E13.3 4.79 2.48e-06 0.000795 0.31 0.25 Tuberculosis; chr17:37449741 chr17:37386886~37387926:+ LIHC cis rs524281 0.861 rs7941469 ENSG00000255320.1 RP11-755F10.1 -4.79 2.48e-06 0.000795 -0.31 -0.25 Electroencephalogram traits; chr11:66132681 chr11:66244840~66246239:- LIHC cis rs11971779 0.68 rs6467837 ENSG00000273391.1 RP11-634H22.1 4.79 2.48e-06 0.000796 0.22 0.25 Diisocyanate-induced asthma; chr7:139338829 chr7:139359032~139359566:- LIHC cis rs11971779 0.715 rs7787398 ENSG00000273391.1 RP11-634H22.1 4.79 2.48e-06 0.000796 0.22 0.25 Diisocyanate-induced asthma; chr7:139377100 chr7:139359032~139359566:- LIHC cis rs712039 0.652 rs853224 ENSG00000276054.1 RP11-378E13.3 4.79 2.49e-06 0.000796 0.32 0.25 Tuberculosis; chr17:37431229 chr17:37386886~37387926:+ LIHC cis rs5769765 0.908 rs138889 ENSG00000278869.1 CITF22-49E9.3 4.79 2.49e-06 0.000796 0.38 0.25 Schizophrenia; chr22:49833025 chr22:49933198~49934074:- LIHC cis rs30380 0.587 rs151940 ENSG00000272109.1 CTD-2260A17.3 -4.79 2.49e-06 0.000797 -0.32 -0.25 Cerebrospinal fluid biomarker levels; chr5:96812074 chr5:96804353~96806105:+ LIHC cis rs17711722 0.565 rs4275112 ENSG00000273024.4 INTS4P2 4.79 2.49e-06 0.000798 0.27 0.25 Calcium levels; chr7:65733651 chr7:65647864~65715661:+ LIHC cis rs9595908 0.9 rs9595883 ENSG00000212293.1 SNORA16 4.79 2.49e-06 0.000798 0.29 0.25 Body mass index; chr13:32593563 chr13:32420390~32420516:- LIHC cis rs1865760 0.713 rs1130000 ENSG00000216436.2 HIST1H2APS1 -4.79 2.49e-06 0.000798 -0.29 -0.25 Height; chr6:25985168 chr6:25732497~25732827:+ LIHC cis rs4713118 0.662 rs175954 ENSG00000219392.1 RP1-265C24.5 -4.79 2.49e-06 0.000799 -0.37 -0.25 Parkinson's disease; chr6:28043807 chr6:28115628~28116551:+ LIHC cis rs9500256 0.903 rs726783 ENSG00000272541.1 XXbac-BPGBPG55C20.1 -4.79 2.5e-06 0.000799 -0.27 -0.25 Eosinophilic esophagitis (pediatric); chr6:58006583 chr6:57855891~57856468:- LIHC cis rs8028182 0.666 rs4886708 ENSG00000260269.4 CTD-2323K18.1 -4.79 2.5e-06 8e-04 -0.32 -0.25 Sudden cardiac arrest; chr15:75470267 chr15:75527150~75601205:- LIHC cis rs11971779 0.68 rs7783619 ENSG00000273391.1 RP11-634H22.1 4.79 2.5e-06 8e-04 0.22 0.25 Diisocyanate-induced asthma; chr7:139376691 chr7:139359032~139359566:- LIHC cis rs7246657 0.943 rs6508732 ENSG00000276846.1 CTD-3220F14.3 4.79 2.5e-06 8e-04 0.31 0.25 Coronary artery calcification; chr19:37509566 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs7255785 ENSG00000276846.1 CTD-3220F14.3 4.79 2.5e-06 8e-04 0.31 0.25 Coronary artery calcification; chr19:37480781 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs7255996 ENSG00000276846.1 CTD-3220F14.3 4.79 2.5e-06 8e-04 0.31 0.25 Coronary artery calcification; chr19:37480797 chr19:37314868~37315620:- LIHC cis rs7914558 1 rs10883826 ENSG00000236937.2 PTGES3P4 4.79 2.5e-06 0.000802 0.29 0.25 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103071062 chr10:102845595~102845950:+ LIHC cis rs1030877 0.515 rs2679893 ENSG00000235319.1 AC012360.4 -4.79 2.51e-06 0.000802 -0.34 -0.25 Obesity-related traits; chr2:105293097 chr2:105324210~105330529:+ LIHC cis rs10129255 1 rs8012033 ENSG00000223648.3 IGHV3-64 4.79 2.51e-06 0.000802 0.19 0.25 Kawasaki disease; chr14:106678854 chr14:106643132~106658258:- LIHC cis rs765787 0.53 rs12904265 ENSG00000259520.4 CTD-2651B20.3 -4.79 2.51e-06 0.000803 -0.29 -0.25 Uric acid levels; chr15:45234515 chr15:45251580~45279251:- LIHC cis rs9834975 0.9 rs9878861 ENSG00000272758.4 RP11-299J3.8 -4.79 2.51e-06 0.000804 -0.28 -0.25 Diastolic blood pressure; chr3:122394139 chr3:122416207~122443180:+ LIHC cis rs9834975 0.967 rs9841311 ENSG00000272758.4 RP11-299J3.8 -4.79 2.51e-06 0.000804 -0.28 -0.25 Diastolic blood pressure; chr3:122394494 chr3:122416207~122443180:+ LIHC cis rs5756813 0.727 rs13055462 ENSG00000233360.4 Z83844.1 4.79 2.51e-06 0.000804 0.32 0.25 Optic cup area;Vertical cup-disc ratio; chr22:37788678 chr22:37641832~37658377:- LIHC cis rs11096990 0.552 rs7655170 ENSG00000249685.1 RP11-360F5.3 4.79 2.52e-06 0.000805 0.3 0.25 Cognitive function; chr4:39171984 chr4:39133913~39135608:+ LIHC cis rs7208859 0.623 rs7214570 ENSG00000266490.1 CTD-2349P21.9 4.79 2.52e-06 0.000805 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30820146 chr17:30792372~30792833:+ LIHC cis rs6163 0.588 rs3818708 ENSG00000236937.2 PTGES3P4 4.79 2.52e-06 0.000805 0.3 0.25 Waist circumference;Hip circumference; chr10:102743827 chr10:102845595~102845950:+ LIHC cis rs1577917 0.874 rs11756621 ENSG00000234155.1 RP11-30P6.6 4.79 2.52e-06 0.000805 0.34 0.25 Response to antipsychotic treatment; chr6:86030345 chr6:85387219~85390186:- LIHC cis rs2929278 0.617 rs12908467 ENSG00000166763.7 STRCP1 -4.79 2.52e-06 0.000806 -0.33 -0.25 Schizophrenia; chr15:43755232 chr15:43699488~43718184:- LIHC cis rs7131987 0.903 rs10843373 ENSG00000257176.2 RP11-996F15.2 -4.79 2.52e-06 0.000806 -0.29 -0.25 QT interval; chr12:29267675 chr12:29280418~29317848:- LIHC cis rs12291225 0.679 rs4756786 ENSG00000251991.1 RNU7-49P 4.79 2.52e-06 0.000807 0.27 0.25 Sense of smell; chr11:14264354 chr11:14478892~14478953:+ LIHC cis rs11098499 0.863 rs11098531 ENSG00000245958.5 RP11-33B1.1 -4.79 2.53e-06 0.000808 -0.26 -0.25 Corneal astigmatism; chr4:119543846 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs28718422 ENSG00000245958.5 RP11-33B1.1 -4.79 2.53e-06 0.000808 -0.26 -0.25 Corneal astigmatism; chr4:119545149 chr4:119454791~119552025:+ LIHC cis rs11098499 0.818 rs12498599 ENSG00000245958.5 RP11-33B1.1 -4.79 2.53e-06 0.000808 -0.26 -0.25 Corneal astigmatism; chr4:119547348 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs10009626 ENSG00000245958.5 RP11-33B1.1 -4.79 2.53e-06 0.000808 -0.26 -0.25 Corneal astigmatism; chr4:119548850 chr4:119454791~119552025:+ LIHC cis rs7131987 0.903 rs67150462 ENSG00000257176.2 RP11-996F15.2 -4.79 2.53e-06 0.000808 -0.29 -0.25 QT interval; chr12:29240392 chr12:29280418~29317848:- LIHC cis rs4660214 0.666 rs636083 ENSG00000182109.6 RP11-69E11.4 4.79 2.53e-06 0.000809 0.27 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39356009 chr1:39522280~39546187:- LIHC cis rs881375 0.715 rs10985073 ENSG00000226752.6 PSMD5-AS1 -4.79 2.53e-06 0.000809 -0.25 -0.25 Rheumatoid arthritis; chr9:120881577 chr9:120824828~120854385:+ LIHC cis rs11971779 0.59 rs6467839 ENSG00000273391.1 RP11-634H22.1 4.79 2.53e-06 0.000809 0.22 0.25 Diisocyanate-induced asthma; chr7:139378044 chr7:139359032~139359566:- LIHC cis rs11098499 0.863 rs9997631 ENSG00000245958.5 RP11-33B1.1 -4.79 2.53e-06 0.000809 -0.26 -0.25 Corneal astigmatism; chr4:119548840 chr4:119454791~119552025:+ LIHC cis rs765787 0.53 rs11070444 ENSG00000259520.4 CTD-2651B20.3 -4.79 2.53e-06 0.000809 -0.29 -0.25 Uric acid levels; chr15:45220923 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs11070445 ENSG00000259520.4 CTD-2651B20.3 -4.79 2.53e-06 0.000809 -0.29 -0.25 Uric acid levels; chr15:45220965 chr15:45251580~45279251:- LIHC cis rs7246657 0.943 rs7248733 ENSG00000276846.1 CTD-3220F14.3 4.79 2.53e-06 0.000809 0.31 0.25 Coronary artery calcification; chr19:37505459 chr19:37314868~37315620:- LIHC cis rs11098499 0.82 rs28394116 ENSG00000245958.5 RP11-33B1.1 -4.79 2.53e-06 0.00081 -0.26 -0.25 Corneal astigmatism; chr4:119603128 chr4:119454791~119552025:+ LIHC cis rs7702057 0.53 rs1567330 ENSG00000271918.1 CTD-2287O16.5 4.79 2.54e-06 0.000811 0.34 0.25 Amyotrophic lateral sclerosis; chr5:116077348 chr5:116083807~116085416:- LIHC cis rs202072 0.676 rs202048 ENSG00000215022.6 RP1-257A7.4 -4.79 2.54e-06 0.000811 -0.3 -0.25 HIV-1 viral setpoint; chr6:13274269 chr6:13264861~13295586:- LIHC cis rs7208859 0.573 rs73267865 ENSG00000266490.1 CTD-2349P21.9 4.79 2.54e-06 0.000812 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737186 chr17:30792372~30792833:+ LIHC cis rs2834188 1 rs13050445 ENSG00000272659.1 AP000295.10 4.79 2.54e-06 0.000812 0.38 0.25 Narcolepsy; chr21:33331291 chr21:33309491~33310181:+ LIHC cis rs2834188 1 rs2252930 ENSG00000272659.1 AP000295.10 4.79 2.54e-06 0.000812 0.38 0.25 Narcolepsy; chr21:33331895 chr21:33309491~33310181:+ LIHC cis rs7587476 0.784 rs62202001 ENSG00000229267.2 AC072062.1 -4.79 2.54e-06 0.000812 -0.32 -0.25 Neuroblastoma; chr2:214825635 chr2:214810229~214963274:+ LIHC cis rs7587476 0.736 rs62202002 ENSG00000229267.2 AC072062.1 -4.79 2.54e-06 0.000812 -0.32 -0.25 Neuroblastoma; chr2:214825876 chr2:214810229~214963274:+ LIHC cis rs7587476 0.682 rs13009646 ENSG00000229267.2 AC072062.1 -4.79 2.54e-06 0.000812 -0.32 -0.25 Neuroblastoma; chr2:214826535 chr2:214810229~214963274:+ LIHC cis rs1577917 1 rs955227 ENSG00000234155.1 RP11-30P6.6 4.79 2.54e-06 0.000813 0.34 0.25 Response to antipsychotic treatment; chr6:85941314 chr6:85387219~85390186:- LIHC cis rs12291225 0.679 rs11605531 ENSG00000251991.1 RNU7-49P 4.79 2.54e-06 0.000813 0.27 0.25 Sense of smell; chr11:14270048 chr11:14478892~14478953:+ LIHC cis rs73193808 0.639 rs2832242 ENSG00000224649.1 AF124730.4 4.79 2.54e-06 0.000813 0.3 0.25 Coronary artery disease; chr21:29179864 chr21:29182027~29187795:- LIHC cis rs10129255 0.5 rs8006888 ENSG00000223648.3 IGHV3-64 4.79 2.54e-06 0.000813 0.18 0.25 Kawasaki disease; chr14:106782219 chr14:106643132~106658258:- LIHC cis rs13068223 0.74 rs343999 ENSG00000243926.1 TIPARP-AS1 -4.79 2.54e-06 0.000813 -0.26 -0.25 Age-related hearing impairment (SNP x SNP interaction); chr3:156734050 chr3:156671862~156674378:- LIHC cis rs10129255 0.5 rs34326748 ENSG00000223648.3 IGHV3-64 4.79 2.54e-06 0.000813 0.18 0.25 Kawasaki disease; chr14:106782523 chr14:106643132~106658258:- LIHC cis rs10129255 0.5 rs10143385 ENSG00000223648.3 IGHV3-64 4.79 2.54e-06 0.000813 0.18 0.25 Kawasaki disease; chr14:106782559 chr14:106643132~106658258:- LIHC cis rs9834975 0.901 rs10934600 ENSG00000272758.4 RP11-299J3.8 -4.79 2.55e-06 0.000814 -0.28 -0.25 Diastolic blood pressure; chr3:122477270 chr3:122416207~122443180:+ LIHC cis rs9834975 0.967 rs7642161 ENSG00000272758.4 RP11-299J3.8 -4.79 2.55e-06 0.000814 -0.28 -0.25 Diastolic blood pressure; chr3:122480385 chr3:122416207~122443180:+ LIHC cis rs11096990 0.551 rs11724855 ENSG00000249685.1 RP11-360F5.3 4.79 2.55e-06 0.000814 0.31 0.25 Cognitive function; chr4:39163379 chr4:39133913~39135608:+ LIHC cis rs227275 0.525 rs5028609 ENSG00000246560.2 RP11-10L12.4 4.79 2.55e-06 0.000814 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102959294 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs6815540 ENSG00000246560.2 RP11-10L12.4 4.79 2.55e-06 0.000814 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102959922 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs4698867 ENSG00000246560.2 RP11-10L12.4 4.79 2.55e-06 0.000814 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102961049 chr4:102828055~102844075:+ LIHC cis rs2842992 0.789 rs2146163 ENSG00000237927.1 RP3-393E18.2 -4.78 2.55e-06 0.000814 -0.31 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159803314 chr6:159586955~159589169:- LIHC cis rs645901 1 rs645901 ENSG00000236267.1 AP006216.5 4.78 2.55e-06 0.000814 0.26 0.25 Plateletcrit; chr11:116831646 chr11:116813204~116814003:- LIHC cis rs801193 0.844 rs2244022 ENSG00000237310.1 GS1-124K5.4 4.78 2.55e-06 0.000814 0.23 0.25 Aortic root size; chr7:66737443 chr7:66493706~66495474:+ LIHC cis rs6951245 0.554 rs76243429 ENSG00000229043.2 AC091729.9 -4.78 2.55e-06 0.000815 -0.45 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1112907 chr7:1160374~1165267:+ LIHC cis rs11672691 0.519 rs7249258 ENSG00000267107.5 PCAT19 -4.78 2.55e-06 0.000816 -0.3 -0.25 Prostate cancer; chr19:41501959 chr19:41454169~41500649:- LIHC cis rs10129255 0.536 rs10142951 ENSG00000223648.3 IGHV3-64 4.78 2.56e-06 0.000816 0.18 0.25 Kawasaki disease; chr14:106782337 chr14:106643132~106658258:- LIHC cis rs11098499 0.78 rs12504773 ENSG00000245958.5 RP11-33B1.1 -4.78 2.56e-06 0.000817 -0.26 -0.25 Corneal astigmatism; chr4:119640994 chr4:119454791~119552025:+ LIHC cis rs2836974 0.897 rs8133146 ENSG00000255568.3 BRWD1-AS2 4.78 2.56e-06 0.000817 0.28 0.25 Cognitive function; chr21:39242372 chr21:39313935~39314962:+ LIHC cis rs6480314 0.522 rs4746754 ENSG00000233590.1 RP11-153K11.3 4.78 2.56e-06 0.000817 0.39 0.25 Optic nerve measurement (disc area); chr10:68289862 chr10:68233251~68242379:- LIHC cis rs6480314 0.522 rs10762204 ENSG00000233590.1 RP11-153K11.3 4.78 2.56e-06 0.000817 0.39 0.25 Optic nerve measurement (disc area); chr10:68290006 chr10:68233251~68242379:- LIHC cis rs12571093 0.571 rs10762205 ENSG00000233590.1 RP11-153K11.3 4.78 2.56e-06 0.000817 0.39 0.25 Optic nerve measurement (disc area); chr10:68290145 chr10:68233251~68242379:- LIHC cis rs950169 0.845 rs4502182 ENSG00000259728.4 LINC00933 4.78 2.56e-06 0.000817 0.35 0.25 Schizophrenia; chr15:84254768 chr15:84570649~84580175:+ LIHC cis rs12130219 1 rs34428306 ENSG00000237975.5 FLG-AS1 4.78 2.56e-06 0.000818 0.43 0.25 Inflammatory skin disease; chr1:152211840 chr1:152168125~152445456:+ LIHC cis rs1577917 1 rs1577917 ENSG00000234155.1 RP11-30P6.6 4.78 2.56e-06 0.000818 0.32 0.25 Response to antipsychotic treatment; chr6:85982222 chr6:85387219~85390186:- LIHC cis rs367615 0.552 rs2963010 ENSG00000249476.1 CTD-2587M2.1 -4.78 2.57e-06 0.00082 -0.29 -0.25 Colorectal cancer (SNP x SNP interaction); chr5:109401342 chr5:109237120~109326369:- LIHC cis rs875971 0.571 rs160641 ENSG00000273142.1 RP11-458F8.4 -4.78 2.57e-06 0.000821 -0.24 -0.25 Aortic root size; chr7:66112359 chr7:66902857~66906297:+ LIHC cis rs6480314 0.615 rs61857179 ENSG00000233590.1 RP11-153K11.3 -4.78 2.57e-06 0.000821 -0.45 -0.25 Optic nerve measurement (disc area); chr10:68188243 chr10:68233251~68242379:- LIHC cis rs11971779 0.68 rs1862879 ENSG00000273391.1 RP11-634H22.1 4.78 2.58e-06 0.000822 0.22 0.25 Diisocyanate-induced asthma; chr7:139335205 chr7:139359032~139359566:- LIHC cis rs71520386 0.632 rs10253651 ENSG00000228649.7 AC005682.5 -4.78 2.58e-06 0.000822 -0.32 -0.25 Fibrinogen levels; chr7:22830564 chr7:22854178~22861579:+ LIHC cis rs748404 0.697 rs513970 ENSG00000166763.7 STRCP1 4.78 2.58e-06 0.000823 0.31 0.25 Lung cancer; chr15:43287368 chr15:43699488~43718184:- LIHC cis rs1865760 1 rs2071297 ENSG00000216436.2 HIST1H2APS1 4.78 2.58e-06 0.000824 0.28 0.25 Height; chr6:25924285 chr6:25732497~25732827:+ LIHC cis rs2921036 0.545 rs4840975 ENSG00000253893.2 FAM85B 4.78 2.58e-06 0.000824 0.38 0.25 Neuroticism; chr8:8505748 chr8:8167819~8226614:- LIHC cis rs11971779 0.688 rs1862880 ENSG00000273391.1 RP11-634H22.1 4.78 2.58e-06 0.000824 0.23 0.25 Diisocyanate-induced asthma; chr7:139335354 chr7:139359032~139359566:- LIHC cis rs17507216 0.718 rs28587782 ENSG00000278603.1 RP13-608F4.5 4.78 2.58e-06 0.000824 0.51 0.25 Excessive daytime sleepiness; chr15:82576881 chr15:82472203~82472426:+ LIHC cis rs10129255 0.5 rs8022547 ENSG00000223648.3 IGHV3-64 4.78 2.58e-06 0.000824 0.18 0.25 Kawasaki disease; chr14:106781985 chr14:106643132~106658258:- LIHC cis rs643506 0.874 rs615642 ENSG00000254990.4 RP11-108O10.2 4.78 2.59e-06 0.000825 0.27 0.25 Breast cancer; chr11:111778697 chr11:111768668~111778350:- LIHC cis rs9834975 0.967 rs12487598 ENSG00000272758.4 RP11-299J3.8 -4.78 2.59e-06 0.000826 -0.28 -0.25 Diastolic blood pressure; chr3:122459755 chr3:122416207~122443180:+ LIHC cis rs9834975 0.967 rs6771095 ENSG00000272758.4 RP11-299J3.8 -4.78 2.59e-06 0.000826 -0.28 -0.25 Diastolic blood pressure; chr3:122472888 chr3:122416207~122443180:+ LIHC cis rs2877649 1 rs76403925 ENSG00000258744.1 RP11-80A15.1 -4.78 2.59e-06 0.000826 -0.51 -0.25 Smooth-surface caries; chr14:24461307 chr14:24501594~24508688:+ LIHC cis rs11779988 0.528 rs208029 ENSG00000253671.1 RP11-806O11.1 -4.78 2.59e-06 0.000826 -0.33 -0.25 Breast cancer; chr8:17983478 chr8:17808941~17820868:+ LIHC cis rs4925386 0.808 rs1760073 ENSG00000273619.1 RP5-908M14.9 4.78 2.59e-06 0.000827 0.2 0.25 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62351050 chr20:62386303~62386970:- LIHC cis rs11971779 0.68 rs4732369 ENSG00000273391.1 RP11-634H22.1 4.78 2.59e-06 0.000827 0.22 0.25 Diisocyanate-induced asthma; chr7:139384427 chr7:139359032~139359566:- LIHC cis rs11098499 0.863 rs12498539 ENSG00000245958.5 RP11-33B1.1 -4.78 2.6e-06 0.000828 -0.26 -0.25 Corneal astigmatism; chr4:119547215 chr4:119454791~119552025:+ LIHC cis rs6479891 0.915 rs10761744 ENSG00000232075.1 MRPL35P2 -4.78 2.6e-06 0.000828 -0.29 -0.25 Arthritis (juvenile idiopathic); chr10:63341266 chr10:63634317~63634827:- LIHC cis rs17301013 0.861 rs332770 ENSG00000227373.4 RP11-160H22.5 4.78 2.6e-06 0.000829 0.31 0.25 Systemic lupus erythematosus; chr1:174681511 chr1:174115300~174160004:- LIHC cis rs9409787 1 rs9409787 ENSG00000231806.2 PCAT7 -4.78 2.6e-06 0.00083 -0.36 -0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr9:94499290 chr9:94555069~94568127:+ LIHC cis rs1150668 0.699 rs1736895 ENSG00000204709.4 LINC01556 4.78 2.61e-06 0.00083 0.27 0.25 Pubertal anthropometrics; chr6:28252048 chr6:28943877~28944537:+ LIHC cis rs5769765 0.908 rs138891 ENSG00000278869.1 CITF22-49E9.3 4.78 2.61e-06 0.000831 0.38 0.25 Schizophrenia; chr22:49834093 chr22:49933198~49934074:- LIHC cis rs7714584 1 rs61270113 ENSG00000197083.10 ZNF300P1 4.78 2.61e-06 0.000831 0.39 0.25 Crohn's disease; chr5:150846701 chr5:150930645~150946289:- LIHC cis rs11098499 0.644 rs7693919 ENSG00000245958.5 RP11-33B1.1 -4.78 2.61e-06 0.000832 -0.25 -0.25 Corneal astigmatism; chr4:119619416 chr4:119454791~119552025:+ LIHC cis rs9467711 0.591 rs13216785 ENSG00000216436.2 HIST1H2APS1 4.78 2.61e-06 0.000832 0.63 0.25 Autism spectrum disorder or schizophrenia; chr6:26078957 chr6:25732497~25732827:+ LIHC cis rs10129255 0.557 rs4043727 ENSG00000211970.3 IGHV4-61 -4.78 2.61e-06 0.000832 -0.2 -0.25 Kawasaki disease; chr14:106649820 chr14:106639119~106639657:- LIHC cis rs2032366 0.63 rs6567226 ENSG00000267279.1 RP11-879F14.2 -4.78 2.61e-06 0.000833 -0.31 -0.25 Obesity-related traits; chr18:61635689 chr18:61585746~61606916:- LIHC cis rs12712135 0.706 rs6543114 ENSG00000234389.1 AC007278.3 4.78 2.62e-06 0.000833 0.28 0.25 Blood protein levels; chr2:102309534 chr2:102438713~102440475:+ LIHC cis rs2836974 0.644 rs11088472 ENSG00000255568.3 BRWD1-AS2 -4.78 2.62e-06 0.000833 -0.21 -0.25 Cognitive function; chr21:39327450 chr21:39313935~39314962:+ LIHC cis rs13068223 0.74 rs344003 ENSG00000243926.1 TIPARP-AS1 -4.78 2.62e-06 0.000834 -0.26 -0.25 Age-related hearing impairment (SNP x SNP interaction); chr3:156739931 chr3:156671862~156674378:- LIHC cis rs13068223 0.792 rs344034 ENSG00000243926.1 TIPARP-AS1 -4.78 2.62e-06 0.000834 -0.26 -0.25 Age-related hearing impairment (SNP x SNP interaction); chr3:156745215 chr3:156671862~156674378:- LIHC cis rs7811142 1 rs113738841 ENSG00000242294.5 STAG3L5P 4.78 2.62e-06 0.000834 0.3 0.25 Platelet count; chr7:100483683 chr7:100336079~100351900:+ LIHC cis rs5769765 0.624 rs138843 ENSG00000278869.1 CITF22-49E9.3 4.78 2.62e-06 0.000835 0.39 0.25 Schizophrenia; chr22:49789514 chr22:49933198~49934074:- LIHC cis rs227275 0.554 rs223457 ENSG00000246560.2 RP11-10L12.4 4.78 2.62e-06 0.000835 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102788506 chr4:102828055~102844075:+ LIHC cis rs67311347 1 rs9849992 ENSG00000223797.4 ENTPD3-AS1 4.78 2.62e-06 0.000835 0.2 0.25 Renal cell carcinoma; chr3:40360649 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs11715214 ENSG00000223797.4 ENTPD3-AS1 4.78 2.62e-06 0.000835 0.2 0.25 Renal cell carcinoma; chr3:40361513 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs9860162 ENSG00000223797.4 ENTPD3-AS1 4.78 2.62e-06 0.000835 0.2 0.25 Renal cell carcinoma; chr3:40362384 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs11914297 ENSG00000223797.4 ENTPD3-AS1 4.78 2.62e-06 0.000835 0.2 0.25 Renal cell carcinoma; chr3:40368579 chr3:40313802~40453329:- LIHC cis rs3091242 0.935 rs3093632 ENSG00000261349.1 RP3-465N24.5 -4.78 2.62e-06 0.000835 -0.24 -0.25 Erythrocyte sedimentation rate; chr1:25357521 chr1:25266102~25267136:- LIHC cis rs881375 0.678 rs10760128 ENSG00000226752.6 PSMD5-AS1 -4.78 2.63e-06 0.000837 -0.26 -0.25 Rheumatoid arthritis; chr9:120934047 chr9:120824828~120854385:+ LIHC cis rs12701220 0.894 rs12701406 ENSG00000229043.2 AC091729.9 -4.78 2.63e-06 0.000837 -0.35 -0.25 Bronchopulmonary dysplasia; chr7:1010647 chr7:1160374~1165267:+ LIHC cis rs2842992 0.673 rs6930904 ENSG00000237927.1 RP3-393E18.2 -4.78 2.63e-06 0.000837 -0.31 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159796401 chr6:159586955~159589169:- LIHC cis rs2842992 0.789 rs9364536 ENSG00000237927.1 RP3-393E18.2 -4.78 2.63e-06 0.000837 -0.31 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159804527 chr6:159586955~159589169:- LIHC cis rs11098499 0.909 rs79026312 ENSG00000245958.5 RP11-33B1.1 -4.78 2.64e-06 0.00084 -0.27 -0.25 Corneal astigmatism; chr4:119519522 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs35111518 ENSG00000245958.5 RP11-33B1.1 -4.78 2.64e-06 0.00084 -0.27 -0.25 Corneal astigmatism; chr4:119519527 chr4:119454791~119552025:+ LIHC cis rs2439831 0.717 rs690170 ENSG00000205771.5 CATSPER2P1 -4.78 2.65e-06 0.000841 -0.39 -0.25 Lung cancer in ever smokers; chr15:43518224 chr15:43726918~43747094:- LIHC cis rs11098499 0.754 rs4107728 ENSG00000245958.5 RP11-33B1.1 -4.78 2.65e-06 0.000841 -0.26 -0.25 Corneal astigmatism; chr4:119332755 chr4:119454791~119552025:+ LIHC cis rs172166 0.694 rs203884 ENSG00000216901.1 AL022393.7 4.78 2.65e-06 0.000842 0.31 0.25 Cardiac Troponin-T levels; chr6:28109596 chr6:28176188~28176674:+ LIHC cis rs2880765 0.545 rs17553734 ENSG00000259630.2 CTD-2262B20.1 4.78 2.65e-06 0.000842 0.35 0.25 Coronary artery disease; chr15:85469828 chr15:85415228~85415633:+ LIHC cis rs1062177 0.774 rs2964574 ENSG00000253921.1 CTB-113P19.3 -4.78 2.65e-06 0.000842 -0.29 -0.25 Preschool internalizing problems; chr5:151776150 chr5:151753992~151767247:+ LIHC cis rs1062177 0.906 rs2964573 ENSG00000253921.1 CTB-113P19.3 -4.78 2.65e-06 0.000842 -0.29 -0.25 Preschool internalizing problems; chr5:151780561 chr5:151753992~151767247:+ LIHC cis rs227275 0.525 rs7663876 ENSG00000246560.2 RP11-10L12.4 4.78 2.65e-06 0.000842 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102966174 chr4:102828055~102844075:+ LIHC cis rs227275 0.556 rs6821173 ENSG00000246560.2 RP11-10L12.4 4.78 2.65e-06 0.000842 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102966404 chr4:102828055~102844075:+ LIHC cis rs7429990 0.833 rs869508 ENSG00000229759.1 MRPS18AP1 4.78 2.65e-06 0.000842 0.28 0.25 Educational attainment (years of education); chr3:47571812 chr3:48256350~48256938:- LIHC cis rs10833905 0.756 rs76866579 ENSG00000246225.5 RP11-17A1.3 -4.78 2.65e-06 0.000843 -0.33 -0.25 Sudden cardiac arrest; chr11:22977331 chr11:22829380~22945393:+ LIHC cis rs950169 0.84 rs12905223 ENSG00000259728.4 LINC00933 4.78 2.65e-06 0.000843 0.36 0.25 Schizophrenia; chr15:84571037 chr15:84570649~84580175:+ LIHC cis rs10871290 1 rs10871290 ENSG00000261079.1 RP11-252A24.3 -4.78 2.65e-06 0.000844 -0.29 -0.25 Breast cancer; chr16:74438798 chr16:74367462~74369826:+ LIHC cis rs3733585 0.781 rs4292328 ENSG00000250413.1 RP11-448G15.1 4.78 2.66e-06 0.000845 0.32 0.25 Cleft plate (environmental tobacco smoke interaction); chr4:9969338 chr4:10006482~10009725:+ LIHC cis rs11098499 0.754 rs7672372 ENSG00000245958.5 RP11-33B1.1 -4.78 2.66e-06 0.000845 -0.26 -0.25 Corneal astigmatism; chr4:119327251 chr4:119454791~119552025:+ LIHC cis rs4820294 0.547 rs62236743 ENSG00000233360.4 Z83844.1 4.78 2.66e-06 0.000845 0.36 0.25 Fat distribution (HIV); chr22:37700046 chr22:37641832~37658377:- LIHC cis rs4820294 0.516 rs12627973 ENSG00000233360.4 Z83844.1 4.78 2.66e-06 0.000845 0.36 0.25 Fat distribution (HIV); chr22:37700690 chr22:37641832~37658377:- LIHC cis rs957448 1 rs1055797 ENSG00000253704.1 RP11-267M23.4 4.78 2.66e-06 0.000845 0.31 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94511005 chr8:94553722~94569745:+ LIHC cis rs71520386 0.579 rs4394299 ENSG00000228649.7 AC005682.5 -4.78 2.66e-06 0.000845 -0.32 -0.25 Fibrinogen levels; chr7:22825763 chr7:22854178~22861579:+ LIHC cis rs10129255 0.646 rs55995061 ENSG00000223648.3 IGHV3-64 4.78 2.66e-06 0.000846 0.19 0.25 Kawasaki disease; chr14:106799309 chr14:106643132~106658258:- LIHC cis rs8040855 0.965 rs11073990 ENSG00000259295.5 CSPG4P12 4.78 2.66e-06 0.000846 0.34 0.25 Bulimia nervosa; chr15:85168070 chr15:85191438~85213905:+ LIHC cis rs7246657 0.882 rs10412043 ENSG00000276846.1 CTD-3220F14.3 4.78 2.66e-06 0.000846 0.31 0.25 Coronary artery calcification; chr19:37335724 chr19:37314868~37315620:- LIHC cis rs2836974 0.568 rs452377 ENSG00000255568.3 BRWD1-AS2 4.78 2.66e-06 0.000847 0.21 0.25 Cognitive function; chr21:39165257 chr21:39313935~39314962:+ LIHC cis rs11673344 0.583 rs10421436 ENSG00000226686.6 LINC01535 -4.78 2.67e-06 0.000847 -0.3 -0.25 Obesity-related traits; chr19:37394601 chr19:37251912~37265535:+ LIHC cis rs3091242 0.967 rs3091240 ENSG00000261349.1 RP3-465N24.5 -4.78 2.67e-06 0.000847 -0.24 -0.25 Erythrocyte sedimentation rate; chr1:25350444 chr1:25266102~25267136:- LIHC cis rs3091242 1 rs3091242 ENSG00000261349.1 RP3-465N24.5 -4.77 2.67e-06 0.000848 -0.24 -0.25 Erythrocyte sedimentation rate; chr1:25348294 chr1:25266102~25267136:- LIHC cis rs367615 0.552 rs2416210 ENSG00000249476.1 CTD-2587M2.1 -4.77 2.67e-06 0.000849 -0.29 -0.25 Colorectal cancer (SNP x SNP interaction); chr5:109405436 chr5:109237120~109326369:- LIHC cis rs875971 0.505 rs2462573 ENSG00000164669.11 INTS4P1 4.77 2.67e-06 0.000849 0.35 0.25 Aortic root size; chr7:66042405 chr7:65141225~65234216:+ LIHC cis rs12908161 0.959 rs1051168 ENSG00000225151.9 GOLGA2P7 -4.77 2.67e-06 0.000849 -0.32 -0.25 Schizophrenia; chr15:84657289 chr15:84199311~84230136:- LIHC cis rs10510102 0.516 rs11200301 ENSG00000276742.1 RP11-500G22.4 4.77 2.67e-06 0.000849 0.41 0.25 Breast cancer; chr10:121977976 chr10:121956782~121957098:+ LIHC cis rs8091660 0.929 rs3744827 ENSG00000278983.1 RP11-426J5.3 -4.77 2.68e-06 0.00085 -0.37 -0.25 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48569572 chr18:48564795~48568342:+ LIHC cis rs5758511 0.68 rs5758682 ENSG00000205702.9 CYP2D7 4.77 2.68e-06 0.00085 0.29 0.25 Birth weight; chr22:42249196 chr22:42140203~42144577:- LIHC cis rs5758511 0.68 rs34107327 ENSG00000205702.9 CYP2D7 4.77 2.68e-06 0.00085 0.29 0.25 Birth weight; chr22:42252347 chr22:42140203~42144577:- LIHC cis rs2310173 0.933 rs4851534 ENSG00000281162.1 LINC01127 -4.77 2.68e-06 0.00085 -0.27 -0.25 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:102037937 chr2:101962056~101987167:+ LIHC cis rs7714584 1 rs11950957 ENSG00000197083.10 ZNF300P1 4.77 2.68e-06 0.000851 0.38 0.25 Crohn's disease; chr5:150874352 chr5:150930645~150946289:- LIHC cis rs7714584 0.793 rs11958146 ENSG00000197083.10 ZNF300P1 4.77 2.68e-06 0.000851 0.38 0.25 Crohn's disease; chr5:150874596 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs11951694 ENSG00000197083.10 ZNF300P1 4.77 2.68e-06 0.000851 0.38 0.25 Crohn's disease; chr5:150874776 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs11955172 ENSG00000197083.10 ZNF300P1 4.77 2.68e-06 0.000851 0.38 0.25 Crohn's disease; chr5:150874816 chr5:150930645~150946289:- LIHC cis rs7714584 0.793 rs11955174 ENSG00000197083.10 ZNF300P1 4.77 2.68e-06 0.000851 0.38 0.25 Crohn's disease; chr5:150874829 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs10061105 ENSG00000197083.10 ZNF300P1 4.77 2.68e-06 0.000851 0.38 0.25 Crohn's disease; chr5:150875623 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs6579803 ENSG00000197083.10 ZNF300P1 4.77 2.68e-06 0.000851 0.38 0.25 Crohn's disease; chr5:150875997 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs6579804 ENSG00000197083.10 ZNF300P1 4.77 2.68e-06 0.000851 0.38 0.25 Crohn's disease; chr5:150876369 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs7734928 ENSG00000197083.10 ZNF300P1 4.77 2.68e-06 0.000851 0.38 0.25 Crohn's disease; chr5:150877051 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs10463240 ENSG00000197083.10 ZNF300P1 4.77 2.68e-06 0.000851 0.38 0.25 Crohn's disease; chr5:150877291 chr5:150930645~150946289:- LIHC cis rs1062177 1 rs72802204 ENSG00000253921.1 CTB-113P19.3 -4.77 2.68e-06 0.000852 -0.29 -0.25 Preschool internalizing problems; chr5:151803622 chr5:151753992~151767247:+ LIHC cis rs113084984 0.642 rs13021546 ENSG00000271952.1 RP11-245G13.2 -4.77 2.68e-06 0.000852 -0.31 -0.25 Breast cancer; chr2:11540917 chr2:10878269~10885118:+ LIHC cis rs11673344 0.526 rs2306201 ENSG00000226686.6 LINC01535 4.77 2.68e-06 0.000852 0.37 0.25 Obesity-related traits; chr19:37586573 chr19:37251912~37265535:+ LIHC cis rs1865760 0.929 rs9467646 ENSG00000216436.2 HIST1H2APS1 -4.77 2.68e-06 0.000852 -0.28 -0.25 Height; chr6:25957180 chr6:25732497~25732827:+ LIHC cis rs9834975 0.967 rs7638180 ENSG00000272758.4 RP11-299J3.8 -4.77 2.69e-06 0.000853 -0.28 -0.25 Diastolic blood pressure; chr3:122431449 chr3:122416207~122443180:+ LIHC cis rs3015497 0.653 rs2356456 ENSG00000269906.1 RP11-248J18.2 4.77 2.69e-06 0.000853 0.32 0.25 Mean platelet volume; chr14:50626498 chr14:50662511~50663178:- LIHC cis rs2243480 1 rs958550 ENSG00000226824.5 RP4-756H11.3 4.77 2.69e-06 0.000853 0.4 0.25 Diabetic kidney disease; chr7:66170692 chr7:66654538~66669855:+ LIHC cis rs8040855 0.965 rs1961276 ENSG00000259295.5 CSPG4P12 4.77 2.69e-06 0.000853 0.36 0.25 Bulimia nervosa; chr15:85170986 chr15:85191438~85213905:+ LIHC cis rs17711722 0.523 rs365896 ENSG00000224316.1 RP11-479O9.2 -4.77 2.69e-06 0.000854 -0.22 -0.25 Calcium levels; chr7:66045710 chr7:65773620~65802067:+ LIHC cis rs11098499 0.954 rs6847248 ENSG00000245958.5 RP11-33B1.1 -4.77 2.69e-06 0.000855 -0.27 -0.25 Corneal astigmatism; chr4:119304800 chr4:119454791~119552025:+ LIHC cis rs9834975 0.935 rs6771201 ENSG00000272758.4 RP11-299J3.8 -4.77 2.7e-06 0.000855 -0.28 -0.25 Diastolic blood pressure; chr3:122382874 chr3:122416207~122443180:+ LIHC cis rs228614 0.536 rs223437 ENSG00000246560.2 RP11-10L12.4 4.77 2.7e-06 0.000855 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798736 chr4:102828055~102844075:+ LIHC cis rs11971779 0.616 rs7784192 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139354903 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs3924296 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139357181 chr7:139359032~139359566:- LIHC cis rs11971779 0.527 rs4379397 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139358639 chr7:139359032~139359566:- LIHC cis rs11971779 0.774 rs6467838 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139358755 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs6961812 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139359062 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs6962366 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139359121 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs3924445 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139359426 chr7:139359032~139359566:- LIHC cis rs11971779 0.585 rs3922848 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139361464 chr7:139359032~139359566:- LIHC cis rs11971779 0.59 rs6944104 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139366374 chr7:139359032~139359566:- LIHC cis rs11971779 0.616 rs6944244 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139366440 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs7799598 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139367087 chr7:139359032~139359566:- LIHC cis rs11971779 0.553 rs7799742 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139367132 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs10229249 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139367764 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs11772026 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139367843 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs1133067 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139368323 chr7:139359032~139359566:- LIHC cis rs11971779 0.616 rs1133068 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139368397 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs6949599 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139369442 chr7:139359032~139359566:- LIHC cis rs11971779 0.616 rs6949963 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139369579 chr7:139359032~139359566:- LIHC cis rs11971779 0.555 rs6950143 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139369672 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs6954531 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139369960 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs6954547 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139369988 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs7788777 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139370447 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs6963867 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139375218 chr7:139359032~139359566:- LIHC cis rs11971779 0.618 rs10085814 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139379343 chr7:139359032~139359566:- LIHC cis rs11971779 0.715 rs10085527 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139379614 chr7:139359032~139359566:- LIHC cis rs11971779 0.65 rs10085842 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139379836 chr7:139359032~139359566:- LIHC cis rs11971779 0.648 rs28754644 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139380311 chr7:139359032~139359566:- LIHC cis rs11971779 0.715 rs6954219 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139380364 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs6467840 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139380655 chr7:139359032~139359566:- LIHC cis rs11971779 0.564 rs6467841 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139381346 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs7792752 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139381450 chr7:139359032~139359566:- LIHC cis rs11971779 0.616 rs6974907 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139383983 chr7:139359032~139359566:- LIHC cis rs11971779 0.584 rs10236055 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139385245 chr7:139359032~139359566:- LIHC cis rs11971779 0.584 rs6942519 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139385344 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs6467843 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139385777 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs2355785 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139386237 chr7:139359032~139359566:- LIHC cis rs11971779 0.588 rs6972408 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139386728 chr7:139359032~139359566:- LIHC cis rs11971779 0.625 rs2355784 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139387747 chr7:139359032~139359566:- LIHC cis rs11971779 0.616 rs2883772 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139388010 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs28579232 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139388370 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs2355783 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139391133 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs111461944 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139393157 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs12154842 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139393738 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs6467846 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139394639 chr7:139359032~139359566:- LIHC cis rs11971779 0.648 rs6467849 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139395766 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs1986447 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139397334 chr7:139359032~139359566:- LIHC cis rs11971779 0.59 rs9642120 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139399225 chr7:139359032~139359566:- LIHC cis rs11971779 0.648 rs7799165 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139400211 chr7:139359032~139359566:- LIHC cis rs11971779 0.618 rs9640925 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139400542 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs7804388 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139401667 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs4732373 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139401789 chr7:139359032~139359566:- LIHC cis rs11971779 0.618 rs6943788 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139402951 chr7:139359032~139359566:- LIHC cis rs11971779 0.523 rs10279160 ENSG00000273391.1 RP11-634H22.1 4.77 2.7e-06 0.000855 0.22 0.25 Diisocyanate-induced asthma; chr7:139406015 chr7:139359032~139359566:- LIHC cis rs2337406 0.704 rs1858679 ENSG00000274576.2 IGHV2-70 -4.77 2.7e-06 0.000855 -0.29 -0.25 Alzheimer's disease (late onset); chr14:106706726 chr14:106770577~106771020:- LIHC cis rs5758511 0.637 rs5751244 ENSG00000205702.9 CYP2D7 4.77 2.7e-06 0.000855 0.3 0.25 Birth weight; chr22:42221405 chr22:42140203~42144577:- LIHC cis rs950169 0.58 rs1061737 ENSG00000259295.5 CSPG4P12 4.77 2.7e-06 0.000856 0.35 0.25 Schizophrenia; chr15:84640559 chr15:85191438~85213905:+ LIHC cis rs7615304 0.617 rs2054880 ENSG00000243926.1 TIPARP-AS1 -4.77 2.7e-06 0.000856 -0.24 -0.25 Interleukin-2 levels; chr3:156782192 chr3:156671862~156674378:- LIHC cis rs2877649 0.51 rs73593291 ENSG00000258744.1 RP11-80A15.1 -4.77 2.7e-06 0.000856 -0.46 -0.25 Smooth-surface caries; chr14:24436888 chr14:24501594~24508688:+ LIHC cis rs7119038 0.818 rs77209083 ENSG00000255239.1 AP002954.6 -4.77 2.7e-06 0.000857 -0.36 -0.25 Sjögren's syndrome; chr11:118736860 chr11:118688039~118690600:- LIHC cis rs30380 0.553 rs27527 ENSG00000272109.1 CTD-2260A17.3 -4.77 2.71e-06 0.000857 -0.32 -0.25 Cerebrospinal fluid biomarker levels; chr5:96816265 chr5:96804353~96806105:+ LIHC cis rs5756813 0.7 rs1894525 ENSG00000233360.4 Z83844.1 4.77 2.71e-06 0.000858 0.32 0.25 Optic cup area;Vertical cup-disc ratio; chr22:37790393 chr22:37641832~37658377:- LIHC cis rs6504622 0.702 rs3851792 ENSG00000262879.4 RP11-156P1.3 4.77 2.71e-06 0.000858 0.26 0.25 Orofacial clefts; chr17:46982458 chr17:46984045~47100323:- LIHC cis rs67311347 0.544 rs60329764 ENSG00000223797.4 ENTPD3-AS1 -4.77 2.71e-06 0.000858 -0.21 -0.25 Renal cell carcinoma; chr3:40293130 chr3:40313802~40453329:- LIHC cis rs4650994 0.623 rs35854525 ENSG00000213057.5 C1orf220 -4.77 2.71e-06 0.000859 -0.22 -0.25 HDL cholesterol;HDL cholesterol levels; chr1:178649469 chr1:178542752~178548889:+ LIHC cis rs7119038 0.509 rs10892258 ENSG00000255422.1 AP002954.4 -4.77 2.71e-06 0.000859 -0.32 -0.25 Sjögren's syndrome; chr11:118709156 chr11:118704607~118750263:+ LIHC cis rs899997 1 rs11072794 ENSG00000261143.1 ADAMTS7P3 4.77 2.72e-06 0.00086 0.3 0.25 Coronary artery disease or large artery stroke; chr15:78714240 chr15:77976042~77993057:+ LIHC cis rs4964805 0.594 rs3812805 ENSG00000257681.1 RP11-341G23.4 4.77 2.72e-06 0.00086 0.26 0.25 Attention deficit hyperactivity disorder; chr12:103777094 chr12:103746315~103768858:- LIHC cis rs1577917 0.958 rs12198876 ENSG00000234155.1 RP11-30P6.6 4.77 2.72e-06 0.00086 0.34 0.25 Response to antipsychotic treatment; chr6:85815758 chr6:85387219~85390186:- LIHC cis rs2739330 0.791 rs9612520 ENSG00000206090.4 AP000350.7 4.77 2.72e-06 0.000861 0.29 0.25 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23939998~23942798:+ LIHC cis rs3733585 0.753 rs1122141 ENSG00000250413.1 RP11-448G15.1 4.77 2.72e-06 0.000861 0.32 0.25 Cleft plate (environmental tobacco smoke interaction); chr4:9945654 chr4:10006482~10009725:+ LIHC cis rs367615 0.537 rs431669 ENSG00000249476.1 CTD-2587M2.1 4.77 2.72e-06 0.000861 0.29 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109327414 chr5:109237120~109326369:- LIHC cis rs7119038 0.629 rs11216994 ENSG00000255239.1 AP002954.6 -4.77 2.72e-06 0.000861 -0.34 -0.25 Sjögren's syndrome; chr11:118732811 chr11:118688039~118690600:- LIHC cis rs7119038 0.629 rs11216995 ENSG00000255239.1 AP002954.6 -4.77 2.72e-06 0.000861 -0.34 -0.25 Sjögren's syndrome; chr11:118732817 chr11:118688039~118690600:- LIHC cis rs2243480 1 rs1618893 ENSG00000230295.1 RP11-458F8.2 -4.77 2.73e-06 0.000862 -0.24 -0.25 Diabetic kidney disease; chr7:66631132 chr7:66880708~66882981:+ LIHC cis rs899997 1 rs11072793 ENSG00000261143.1 ADAMTS7P3 4.77 2.73e-06 0.000864 0.3 0.25 Coronary artery disease or large artery stroke; chr15:78714100 chr15:77976042~77993057:+ LIHC cis rs6480314 0.522 rs80326649 ENSG00000233590.1 RP11-153K11.3 -4.77 2.73e-06 0.000864 -0.41 -0.25 Optic nerve measurement (disc area); chr10:68285667 chr10:68233251~68242379:- LIHC cis rs5758511 0.68 rs58654759 ENSG00000205702.9 CYP2D7 4.77 2.73e-06 0.000865 0.29 0.25 Birth weight; chr22:42246570 chr22:42140203~42144577:- LIHC cis rs12468226 0.872 rs1061157 ENSG00000273456.1 RP11-686O6.2 4.77 2.73e-06 0.000865 0.38 0.25 Urate levels; chr2:202556476 chr2:202374932~202375604:- LIHC cis rs9834975 0.935 rs10045 ENSG00000272758.4 RP11-299J3.8 -4.77 2.73e-06 0.000865 -0.28 -0.25 Diastolic blood pressure; chr3:122426105 chr3:122416207~122443180:+ LIHC cis rs4356975 0.697 rs5002700 ENSG00000196472.4 RP13-644M16.4 4.77 2.74e-06 0.000865 0.27 0.25 Obesity-related traits; chr4:69155637 chr4:69181660~69182372:+ LIHC cis rs10912872 0.672 rs1018392 ENSG00000225704.2 RP4-798A17.5 4.77 2.74e-06 0.000867 0.22 0.25 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr1:171384725 chr1:171345089~171345320:+ LIHC cis rs7208859 0.623 rs609063 ENSG00000266490.1 CTD-2349P21.9 4.77 2.74e-06 0.000867 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30624495 chr17:30792372~30792833:+ LIHC cis rs5769765 0.862 rs138856 ENSG00000278869.1 CITF22-49E9.3 4.77 2.75e-06 0.000868 0.4 0.25 Schizophrenia; chr22:49805730 chr22:49933198~49934074:- LIHC cis rs5769765 0.862 rs138857 ENSG00000278869.1 CITF22-49E9.3 4.77 2.75e-06 0.000868 0.4 0.25 Schizophrenia; chr22:49805941 chr22:49933198~49934074:- LIHC cis rs67311347 0.866 rs9826419 ENSG00000223797.4 ENTPD3-AS1 4.77 2.75e-06 0.000868 0.21 0.25 Renal cell carcinoma; chr3:40310560 chr3:40313802~40453329:- LIHC cis rs67311347 0.866 rs3214006 ENSG00000223797.4 ENTPD3-AS1 4.77 2.75e-06 0.000868 0.21 0.25 Renal cell carcinoma; chr3:40310643 chr3:40313802~40453329:- LIHC cis rs17301013 0.896 rs332773 ENSG00000227373.4 RP11-160H22.5 4.77 2.75e-06 0.000868 0.3 0.25 Systemic lupus erythematosus; chr1:174695711 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs444678 ENSG00000227373.4 RP11-160H22.5 4.77 2.75e-06 0.000868 0.3 0.25 Systemic lupus erythematosus; chr1:174706080 chr1:174115300~174160004:- LIHC cis rs17301013 0.896 rs332791 ENSG00000227373.4 RP11-160H22.5 4.77 2.75e-06 0.000868 0.3 0.25 Systemic lupus erythematosus; chr1:174709784 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs332795 ENSG00000227373.4 RP11-160H22.5 4.77 2.75e-06 0.000868 0.3 0.25 Systemic lupus erythematosus; chr1:174726785 chr1:174115300~174160004:- LIHC cis rs71520386 0.632 rs12532938 ENSG00000228649.7 AC005682.5 -4.77 2.75e-06 0.000868 -0.32 -0.25 Fibrinogen levels; chr7:22820876 chr7:22854178~22861579:+ LIHC cis rs9425766 0.679 rs6681618 ENSG00000227373.4 RP11-160H22.5 -4.77 2.75e-06 0.000869 -0.3 -0.25 Life satisfaction; chr1:174201203 chr1:174115300~174160004:- LIHC cis rs11098499 0.866 rs3756156 ENSG00000245958.5 RP11-33B1.1 -4.77 2.75e-06 0.000869 -0.26 -0.25 Corneal astigmatism; chr4:119603686 chr4:119454791~119552025:+ LIHC cis rs9549367 0.713 rs4907599 ENSG00000269125.1 RP11-98F14.11 4.77 2.75e-06 0.000869 0.29 0.25 Platelet distribution width; chr13:113207127 chr13:113165002~113165183:- LIHC cis rs11098499 0.955 rs1511019 ENSG00000245958.5 RP11-33B1.1 -4.77 2.75e-06 0.00087 -0.27 -0.25 Corneal astigmatism; chr4:119244852 chr4:119454791~119552025:+ LIHC cis rs4660214 0.666 rs10888788 ENSG00000182109.6 RP11-69E11.4 -4.77 2.76e-06 0.000871 -0.27 -0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39472024 chr1:39522280~39546187:- LIHC cis rs11098499 0.863 rs10004484 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000871 -0.27 -0.25 Corneal astigmatism; chr4:119521273 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs1155576 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000871 -0.27 -0.25 Corneal astigmatism; chr4:119529004 chr4:119454791~119552025:+ LIHC cis rs2439831 0.702 rs3759791 ENSG00000166763.7 STRCP1 4.77 2.76e-06 0.000872 0.37 0.25 Lung cancer in ever smokers; chr15:43798600 chr15:43699488~43718184:- LIHC cis rs11098499 0.863 rs34868248 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119521275 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs3733525 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119525893 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs3775847 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119526487 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs3775848 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119526569 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs10013305 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119529269 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs3775849 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119529753 chr4:119454791~119552025:+ LIHC cis rs11098499 0.818 rs7688802 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119530513 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs7695620 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119531621 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs12502389 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119533036 chr4:119454791~119552025:+ LIHC cis rs11098499 0.821 rs3775852 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119533401 chr4:119454791~119552025:+ LIHC cis rs11098499 0.82 rs6534140 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119534156 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs7657849 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119534339 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs10034450 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119534494 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs1480939 ENSG00000245958.5 RP11-33B1.1 -4.77 2.76e-06 0.000872 -0.26 -0.25 Corneal astigmatism; chr4:119535772 chr4:119454791~119552025:+ LIHC cis rs1729407 0.706 rs1268354 ENSG00000236267.1 AP006216.5 4.77 2.76e-06 0.000872 0.23 0.25 Apolipoprotein A-IV levels; chr11:116819862 chr11:116813204~116814003:- LIHC cis rs12936587 0.535 rs6502615 ENSG00000223979.2 SMCR2 4.77 2.76e-06 0.000872 0.33 0.25 Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference; chr17:17708709 chr17:17674026~17677688:- LIHC cis rs1322639 0.614 rs6940913 ENSG00000261039.2 RP11-417E7.2 -4.77 2.76e-06 0.000873 -0.35 -0.25 Pulse pressure; chr6:169163571 chr6:169175304~169182740:- LIHC cis rs2998286 0.723 rs332161 ENSG00000254635.4 WAC-AS1 4.77 2.76e-06 0.000873 0.31 0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28599911 chr10:28522652~28532743:- LIHC cis rs1062177 0.95 rs892005 ENSG00000253921.1 CTB-113P19.3 -4.77 2.77e-06 0.000873 -0.29 -0.25 Preschool internalizing problems; chr5:151801060 chr5:151753992~151767247:+ LIHC cis rs367615 0.506 rs246102 ENSG00000249476.1 CTD-2587M2.1 -4.77 2.77e-06 0.000873 -0.29 -0.25 Colorectal cancer (SNP x SNP interaction); chr5:109363994 chr5:109237120~109326369:- LIHC cis rs9467711 0.591 rs13195692 ENSG00000216436.2 HIST1H2APS1 4.77 2.77e-06 0.000873 0.64 0.25 Autism spectrum disorder or schizophrenia; chr6:26044145 chr6:25732497~25732827:+ LIHC cis rs9640161 0.617 rs73170169 ENSG00000261305.1 RP4-584D14.7 4.77 2.77e-06 0.000873 0.31 0.25 Blood protein levels;Circulating chemerin levels; chr7:150310947 chr7:150341771~150342607:+ LIHC cis rs1062177 1 rs2964584 ENSG00000253921.1 CTB-113P19.3 -4.77 2.77e-06 0.000873 -0.29 -0.25 Preschool internalizing problems; chr5:151763317 chr5:151753992~151767247:+ LIHC cis rs6445975 0.726 rs4330265 ENSG00000272360.1 RP11-359I18.5 -4.77 2.77e-06 0.000873 -0.29 -0.25 Systemic lupus erythematosus; chr3:58482301 chr3:58490830~58491291:- LIHC cis rs9890032 0.618 rs55872374 ENSG00000263531.1 RP13-753N3.1 4.77 2.77e-06 0.000873 0.33 0.25 Hip circumference adjusted for BMI; chr17:30822863 chr17:30863921~30864940:- LIHC cis rs6901152 0.508 rs972151 ENSG00000217648.1 RP1-95L4.4 -4.77 2.77e-06 0.000874 -0.29 -0.25 Acute lymphoblastic leukemia (childhood); chr6:143364252 chr6:143342246~143343383:+ LIHC cis rs12554020 0.681 rs78792144 ENSG00000227603.1 RP11-165J3.6 4.77 2.77e-06 0.000874 0.45 0.25 Schizophrenia; chr9:93583725 chr9:93435332~93437121:- LIHC cis rs17270561 0.636 rs1575535 ENSG00000216436.2 HIST1H2APS1 -4.77 2.77e-06 0.000874 -0.3 -0.25 Iron status biomarkers; chr6:25809681 chr6:25732497~25732827:+ LIHC cis rs1396485 0.607 rs4921070 ENSG00000271918.1 CTD-2287O16.5 4.77 2.77e-06 0.000874 0.3 0.25 Inflammatory biomarkers; chr5:116176269 chr5:116083807~116085416:- LIHC cis rs6901152 0.508 rs6928185 ENSG00000217648.1 RP1-95L4.4 -4.77 2.77e-06 0.000874 -0.29 -0.25 Acute lymphoblastic leukemia (childhood); chr6:143363518 chr6:143342246~143343383:+ LIHC cis rs7914558 1 rs943036 ENSG00000236937.2 PTGES3P4 4.77 2.77e-06 0.000874 0.29 0.25 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103076290 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs943035 ENSG00000236937.2 PTGES3P4 4.77 2.77e-06 0.000874 0.29 0.25 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103079395 chr10:102845595~102845950:+ LIHC cis rs7914558 0.966 rs7921574 ENSG00000236937.2 PTGES3P4 4.77 2.77e-06 0.000874 0.29 0.25 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103081213 chr10:102845595~102845950:+ LIHC cis rs57502260 0.704 rs41478448 ENSG00000212093.1 AP000807.1 4.77 2.77e-06 0.000874 0.32 0.25 Total body bone mineral density (age 45-60); chr11:68414153 chr11:68506083~68506166:- LIHC cis rs7829975 0.606 rs6422352 ENSG00000253893.2 FAM85B 4.77 2.77e-06 0.000875 0.3 0.25 Mood instability; chr8:8936683 chr8:8167819~8226614:- LIHC cis rs2274273 0.624 rs2026633 ENSG00000258413.1 RP11-665C16.6 -4.77 2.77e-06 0.000875 -0.29 -0.25 Protein biomarker; chr14:55322459 chr14:55262767~55272075:- LIHC cis rs7811142 0.83 rs11771936 ENSG00000242294.5 STAG3L5P 4.77 2.77e-06 0.000875 0.27 0.25 Platelet count; chr7:100345660 chr7:100336079~100351900:+ LIHC cis rs7811142 0.779 rs77370288 ENSG00000242294.5 STAG3L5P 4.77 2.77e-06 0.000875 0.27 0.25 Platelet count; chr7:100350274 chr7:100336079~100351900:+ LIHC cis rs2919917 1 rs13280202 ENSG00000254352.1 RP11-578O24.2 -4.77 2.78e-06 0.000876 -0.35 -0.25 Lymphocyte counts; chr8:78700238 chr8:78723796~78724136:- LIHC cis rs12478296 0.792 rs6755390 ENSG00000261186.2 RP11-341N2.1 -4.77 2.78e-06 0.000876 -0.35 -0.25 Obesity-related traits; chr2:242070847 chr2:242087351~242088457:- LIHC cis rs5758511 0.68 rs5751243 ENSG00000205702.9 CYP2D7 4.77 2.78e-06 0.000877 0.29 0.25 Birth weight; chr22:42221171 chr22:42140203~42144577:- LIHC cis rs7811142 1 rs4472444 ENSG00000242294.5 STAG3L5P 4.77 2.78e-06 0.000877 0.29 0.25 Platelet count; chr7:100473135 chr7:100336079~100351900:+ LIHC cis rs227275 0.554 rs223454 ENSG00000246560.2 RP11-10L12.4 4.77 2.78e-06 0.000877 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102789773 chr4:102828055~102844075:+ LIHC cis rs12554020 0.786 rs7035657 ENSG00000227603.1 RP11-165J3.6 -4.77 2.78e-06 0.000877 -0.33 -0.25 Schizophrenia; chr9:93434769 chr9:93435332~93437121:- LIHC cis rs2688482 0.512 rs3103953 ENSG00000207650.1 MIR570 -4.77 2.78e-06 0.000877 -0.33 -0.25 Lung disease severity in cystic fibrosis; chr3:195793726 chr3:195699401~195699497:+ LIHC cis rs7760535 0.93 rs7742244 ENSG00000255389.1 C6orf3 -4.77 2.79e-06 0.000878 -0.27 -0.25 Metabolic traits; chr6:111531459 chr6:111599875~111602295:+ LIHC cis rs2976388 0.647 rs2082801 ENSG00000253196.1 RP11-706C16.7 4.77 2.79e-06 0.000878 0.24 0.25 Urinary tract infection frequency; chr8:142705043 chr8:142763116~142766427:+ LIHC cis rs6921919 0.583 rs11755942 ENSG00000204709.4 LINC01556 4.77 2.79e-06 0.000878 0.3 0.25 Autism spectrum disorder or schizophrenia; chr6:28401760 chr6:28943877~28944537:+ LIHC cis rs6921919 0.583 rs6908137 ENSG00000204709.4 LINC01556 4.77 2.79e-06 0.000878 0.3 0.25 Autism spectrum disorder or schizophrenia; chr6:28402616 chr6:28943877~28944537:+ LIHC cis rs7714584 1 rs1896708 ENSG00000197083.10 ZNF300P1 4.77 2.79e-06 0.000879 0.38 0.25 Crohn's disease; chr5:150865514 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs7709650 ENSG00000197083.10 ZNF300P1 4.77 2.79e-06 0.000879 0.38 0.25 Crohn's disease; chr5:150867123 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs12054923 ENSG00000197083.10 ZNF300P1 4.77 2.79e-06 0.000879 0.38 0.25 Crohn's disease; chr5:150869497 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs77698001 ENSG00000197083.10 ZNF300P1 4.77 2.79e-06 0.000879 0.38 0.25 Crohn's disease; chr5:150870805 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs2115069 ENSG00000197083.10 ZNF300P1 4.77 2.79e-06 0.000879 0.38 0.25 Crohn's disease; chr5:150872803 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs10463307 ENSG00000197083.10 ZNF300P1 4.77 2.79e-06 0.000879 0.38 0.25 Crohn's disease; chr5:150875058 chr5:150930645~150946289:- LIHC cis rs4820294 0.516 rs12627943 ENSG00000233360.4 Z83844.1 4.77 2.79e-06 0.000879 0.36 0.25 Fat distribution (HIV); chr22:37700327 chr22:37641832~37658377:- LIHC cis rs11098499 0.954 rs13107475 ENSG00000260091.1 RP11-33B1.4 -4.77 2.8e-06 0.000881 -0.18 -0.25 Corneal astigmatism; chr4:119471856 chr4:119409333~119410233:+ LIHC cis rs5756813 0.754 rs4821711 ENSG00000233360.4 Z83844.1 4.76 2.8e-06 0.000881 0.32 0.25 Optic cup area;Vertical cup-disc ratio; chr22:37785108 chr22:37641832~37658377:- LIHC cis rs10129255 0.957 rs8009948 ENSG00000223648.3 IGHV3-64 4.76 2.8e-06 0.000882 0.19 0.25 Kawasaki disease; chr14:106805607 chr14:106643132~106658258:- LIHC cis rs7412746 0.634 rs12409208 ENSG00000231073.1 RP11-316M1.3 4.76 2.8e-06 0.000882 0.25 0.25 Melanoma; chr1:150887579 chr1:150973123~150975534:+ LIHC cis rs860295 0.775 rs822508 ENSG00000203761.5 MSTO2P -4.76 2.8e-06 0.000883 -0.21 -0.25 Body mass index; chr1:155880767 chr1:155745829~155750137:+ LIHC cis rs1499614 1 rs2659913 ENSG00000230295.1 RP11-458F8.2 -4.76 2.81e-06 0.000883 -0.26 -0.25 Gout; chr7:66692349 chr7:66880708~66882981:+ LIHC cis rs1499614 1 rs2707840 ENSG00000230295.1 RP11-458F8.2 -4.76 2.81e-06 0.000883 -0.26 -0.25 Gout; chr7:66693028 chr7:66880708~66882981:+ LIHC cis rs1499614 1 rs2659911 ENSG00000230295.1 RP11-458F8.2 -4.76 2.81e-06 0.000883 -0.26 -0.25 Gout; chr7:66693433 chr7:66880708~66882981:+ LIHC cis rs1499614 1 rs2707838 ENSG00000230295.1 RP11-458F8.2 -4.76 2.81e-06 0.000883 -0.26 -0.25 Gout; chr7:66694214 chr7:66880708~66882981:+ LIHC cis rs1499614 1 rs60326618 ENSG00000230295.1 RP11-458F8.2 -4.76 2.81e-06 0.000883 -0.26 -0.25 Gout; chr7:66701371 chr7:66880708~66882981:+ LIHC cis rs1499614 1 rs2707830 ENSG00000230295.1 RP11-458F8.2 -4.76 2.81e-06 0.000883 -0.26 -0.25 Gout; chr7:66702658 chr7:66880708~66882981:+ LIHC cis rs1499614 1 rs2707828 ENSG00000230295.1 RP11-458F8.2 -4.76 2.81e-06 0.000883 -0.26 -0.25 Gout; chr7:66706390 chr7:66880708~66882981:+ LIHC cis rs1499614 0.803 rs1922723 ENSG00000230295.1 RP11-458F8.2 -4.76 2.81e-06 0.000883 -0.26 -0.25 Gout; chr7:66710076 chr7:66880708~66882981:+ LIHC cis rs1499614 1 rs2659903 ENSG00000230295.1 RP11-458F8.2 -4.76 2.81e-06 0.000883 -0.26 -0.25 Gout; chr7:66715944 chr7:66880708~66882981:+ LIHC cis rs1499614 1 rs2141924 ENSG00000230295.1 RP11-458F8.2 -4.76 2.81e-06 0.000883 -0.26 -0.25 Gout; chr7:66721259 chr7:66880708~66882981:+ LIHC cis rs12554020 0.892 rs10217595 ENSG00000227603.1 RP11-165J3.6 4.76 2.81e-06 0.000883 0.36 0.25 Schizophrenia; chr9:93418609 chr9:93435332~93437121:- LIHC cis rs12554020 0.892 rs10117236 ENSG00000227603.1 RP11-165J3.6 4.76 2.81e-06 0.000883 0.36 0.25 Schizophrenia; chr9:93419731 chr9:93435332~93437121:- LIHC cis rs12554020 0.892 rs7863760 ENSG00000227603.1 RP11-165J3.6 4.76 2.81e-06 0.000883 0.36 0.25 Schizophrenia; chr9:93420287 chr9:93435332~93437121:- LIHC cis rs8031584 0.679 rs34017474 ENSG00000270015.1 RP11-540B6.6 -4.76 2.81e-06 0.000883 -0.25 -0.25 Huntington's disease progression; chr15:30938408 chr15:30926514~30928407:+ LIHC cis rs2337406 0.85 rs1858678 ENSG00000274576.2 IGHV2-70 -4.76 2.81e-06 0.000883 -0.29 -0.25 Alzheimer's disease (late onset); chr14:106706790 chr14:106770577~106771020:- LIHC cis rs10129255 0.912 rs8011090 ENSG00000223648.3 IGHV3-64 4.76 2.81e-06 0.000884 0.19 0.25 Kawasaki disease; chr14:106678896 chr14:106643132~106658258:- LIHC cis rs227275 0.531 rs223460 ENSG00000246560.2 RP11-10L12.4 4.76 2.81e-06 0.000884 0.27 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102782903 chr4:102828055~102844075:+ LIHC cis rs7209700 0.745 rs8074348 ENSG00000228782.6 CTD-2026D20.3 -4.76 2.81e-06 0.000884 -0.28 -0.25 IgG glycosylation; chr17:47276047 chr17:47450568~47492492:- LIHC cis rs11079159 1 rs11079159 ENSG00000263096.1 RP11-515O17.2 4.76 2.81e-06 0.000885 0.34 0.25 QRS duration; chr17:55296189 chr17:55271504~55273653:- LIHC cis rs1061377 0.513 rs2566163 ENSG00000249207.1 RP11-360F5.1 -4.76 2.81e-06 0.000885 -0.31 -0.25 Uric acid levels; chr4:39128345 chr4:39112677~39126818:- LIHC cis rs1322639 0.614 rs6900200 ENSG00000261039.2 RP11-417E7.2 -4.76 2.81e-06 0.000886 -0.35 -0.25 Pulse pressure; chr6:169166078 chr6:169175304~169182740:- LIHC cis rs10256972 0.685 rs10263665 ENSG00000199023.2 MIR339 -4.76 2.82e-06 0.000888 -0.29 -0.25 Endometriosis;Longevity; chr7:1070992 chr7:1022935~1023045:- LIHC cis rs2442825 0.508 rs2648545 ENSG00000206573.7 THUMPD3-AS1 -4.76 2.82e-06 0.000888 -0.21 -0.25 Cerebrospinal fluid clusterin levels; chr3:9347539 chr3:9349689~9398579:- LIHC cis rs2836974 0.897 rs2836925 ENSG00000255568.3 BRWD1-AS2 4.76 2.82e-06 0.000888 0.28 0.25 Cognitive function; chr21:39160427 chr21:39313935~39314962:+ LIHC cis rs67311347 0.866 rs1454491 ENSG00000223797.4 ENTPD3-AS1 4.76 2.82e-06 0.000888 0.21 0.25 Renal cell carcinoma; chr3:40311156 chr3:40313802~40453329:- LIHC cis rs11971779 0.715 rs10954646 ENSG00000273391.1 RP11-634H22.1 -4.76 2.83e-06 0.00089 -0.22 -0.25 Diisocyanate-induced asthma; chr7:139376323 chr7:139359032~139359566:- LIHC cis rs2439831 0.85 rs2957637 ENSG00000275601.1 AC011330.13 -4.76 2.83e-06 0.00089 -0.37 -0.25 Lung cancer in ever smokers; chr15:43658920 chr15:43642389~43643023:- LIHC cis rs4731207 0.844 rs34204767 ENSG00000224897.5 POT1-AS1 -4.76 2.83e-06 0.00089 -0.3 -0.25 Cutaneous malignant melanoma; chr7:124761710 chr7:124929873~125179315:+ LIHC cis rs5758511 0.68 rs5758686 ENSG00000205702.9 CYP2D7 4.76 2.83e-06 0.00089 0.29 0.25 Birth weight; chr22:42259371 chr22:42140203~42144577:- LIHC cis rs1062177 1 rs2915878 ENSG00000253921.1 CTB-113P19.3 -4.76 2.83e-06 0.00089 -0.29 -0.25 Preschool internalizing problems; chr5:151770101 chr5:151753992~151767247:+ LIHC cis rs1062177 1 rs2915877 ENSG00000253921.1 CTB-113P19.3 -4.76 2.83e-06 0.00089 -0.29 -0.25 Preschool internalizing problems; chr5:151771040 chr5:151753992~151767247:+ LIHC cis rs1062177 1 rs2964576 ENSG00000253921.1 CTB-113P19.3 -4.76 2.83e-06 0.00089 -0.29 -0.25 Preschool internalizing problems; chr5:151771041 chr5:151753992~151767247:+ LIHC cis rs1062177 1 rs6890099 ENSG00000253921.1 CTB-113P19.3 -4.76 2.83e-06 0.00089 -0.29 -0.25 Preschool internalizing problems; chr5:151772401 chr5:151753992~151767247:+ LIHC cis rs916888 0.61 rs199530 ENSG00000260075.1 NSFP1 -4.76 2.83e-06 0.00089 -0.31 -0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:46372855~46487141:+ LIHC cis rs2439831 0.85 rs8023458 ENSG00000166763.7 STRCP1 4.76 2.83e-06 0.000891 0.38 0.25 Lung cancer in ever smokers; chr15:43788741 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs16963953 ENSG00000166763.7 STRCP1 4.76 2.83e-06 0.000891 0.38 0.25 Lung cancer in ever smokers; chr15:43789521 chr15:43699488~43718184:- LIHC cis rs2919917 1 rs10093127 ENSG00000254352.1 RP11-578O24.2 4.76 2.83e-06 0.000891 0.34 0.25 Lymphocyte counts; chr8:78686869 chr8:78723796~78724136:- LIHC cis rs417065 0.516 rs6661746 ENSG00000227634.1 RP11-431K24.3 -4.76 2.84e-06 0.000892 -0.31 -0.25 Psoriasis; chr1:8208560 chr1:8208672~8215210:+ LIHC cis rs1062177 1 rs2915882 ENSG00000253921.1 CTB-113P19.3 -4.76 2.84e-06 0.000892 -0.29 -0.25 Preschool internalizing problems; chr5:151765875 chr5:151753992~151767247:+ LIHC cis rs1062177 1 rs2915880 ENSG00000253921.1 CTB-113P19.3 -4.76 2.84e-06 0.000892 -0.29 -0.25 Preschool internalizing problems; chr5:151767773 chr5:151753992~151767247:+ LIHC cis rs1062177 0.826 rs2915879 ENSG00000253921.1 CTB-113P19.3 -4.76 2.84e-06 0.000892 -0.29 -0.25 Preschool internalizing problems; chr5:151767881 chr5:151753992~151767247:+ LIHC cis rs79040073 0.563 rs7167852 ENSG00000259531.2 RP11-295H24.3 4.76 2.84e-06 0.000893 0.41 0.25 Lung cancer in ever smokers; chr15:49250004 chr15:49365124~49366685:- LIHC cis rs11098499 0.863 rs7678400 ENSG00000245958.5 RP11-33B1.1 -4.76 2.84e-06 0.000894 -0.26 -0.25 Corneal astigmatism; chr4:119540802 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs1480936 ENSG00000245958.5 RP11-33B1.1 -4.76 2.84e-06 0.000894 -0.26 -0.25 Corneal astigmatism; chr4:119541706 chr4:119454791~119552025:+ LIHC cis rs227275 0.556 rs9999303 ENSG00000230069.3 LRRC37A15P -4.76 2.84e-06 0.000894 -0.22 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102986881 chr4:102727274~102730721:- LIHC cis rs5758511 0.68 rs5758662 ENSG00000205702.9 CYP2D7 4.76 2.85e-06 0.000894 0.29 0.25 Birth weight; chr22:42232082 chr22:42140203~42144577:- LIHC cis rs227275 0.556 rs12508069 ENSG00000230069.3 LRRC37A15P -4.76 2.85e-06 0.000895 -0.22 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102983598 chr4:102727274~102730721:- LIHC cis rs227275 0.527 rs12500379 ENSG00000230069.3 LRRC37A15P -4.76 2.85e-06 0.000895 -0.22 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102983665 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs10015289 ENSG00000230069.3 LRRC37A15P -4.76 2.85e-06 0.000895 -0.22 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102984956 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs6852141 ENSG00000230069.3 LRRC37A15P -4.76 2.85e-06 0.000895 -0.22 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102986439 chr4:102727274~102730721:- LIHC cis rs228614 0.509 rs4455415 ENSG00000230069.3 LRRC37A15P -4.76 2.85e-06 0.000895 -0.22 -0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102993663 chr4:102727274~102730721:- LIHC cis rs2836974 0.568 rs442972 ENSG00000255568.3 BRWD1-AS2 -4.76 2.85e-06 0.000895 -0.21 -0.25 Cognitive function; chr21:39162831 chr21:39313935~39314962:+ LIHC cis rs12554020 0.582 rs76849659 ENSG00000227603.1 RP11-165J3.6 4.76 2.85e-06 0.000897 0.46 0.25 Schizophrenia; chr9:93685420 chr9:93435332~93437121:- LIHC cis rs7587476 0.784 rs34112702 ENSG00000229267.2 AC072062.1 -4.76 2.86e-06 0.000897 -0.32 -0.25 Neuroblastoma; chr2:214831278 chr2:214810229~214963274:+ LIHC cis rs7587476 0.784 rs13008641 ENSG00000229267.2 AC072062.1 -4.76 2.86e-06 0.000897 -0.32 -0.25 Neuroblastoma; chr2:214833309 chr2:214810229~214963274:+ LIHC cis rs7587476 0.784 rs13032278 ENSG00000229267.2 AC072062.1 -4.76 2.86e-06 0.000897 -0.32 -0.25 Neuroblastoma; chr2:214833310 chr2:214810229~214963274:+ LIHC cis rs1061377 0.513 rs2566166 ENSG00000249207.1 RP11-360F5.1 4.76 2.86e-06 0.000898 0.3 0.25 Uric acid levels; chr4:39148404 chr4:39112677~39126818:- LIHC cis rs11971779 0.68 rs6467848 ENSG00000273391.1 RP11-634H22.1 4.76 2.86e-06 0.000898 0.22 0.25 Diisocyanate-induced asthma; chr7:139395459 chr7:139359032~139359566:- LIHC cis rs901683 0.702 rs17157944 ENSG00000230869.1 CTGLF10P -4.76 2.86e-06 0.000898 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45652818 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs17157945 ENSG00000230869.1 CTGLF10P -4.76 2.86e-06 0.000898 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45652853 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs76130427 ENSG00000230869.1 CTGLF10P -4.76 2.86e-06 0.000898 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45656835 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs79337279 ENSG00000230869.1 CTGLF10P -4.76 2.86e-06 0.000898 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45658092 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs76025266 ENSG00000230869.1 CTGLF10P -4.76 2.86e-06 0.000898 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45660828 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs112713257 ENSG00000230869.1 CTGLF10P -4.76 2.86e-06 0.000898 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45661792 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs77236316 ENSG00000230869.1 CTGLF10P -4.76 2.86e-06 0.000898 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45662972 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs74572856 ENSG00000230869.1 CTGLF10P -4.76 2.86e-06 0.000898 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45663334 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs77387136 ENSG00000230869.1 CTGLF10P -4.76 2.86e-06 0.000898 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45666654 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs76555487 ENSG00000230869.1 CTGLF10P -4.76 2.86e-06 0.000898 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45666706 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs79596920 ENSG00000230869.1 CTGLF10P -4.76 2.86e-06 0.000898 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45667306 chr10:45678692~45700532:+ LIHC cis rs950169 0.922 rs11635505 ENSG00000259728.4 LINC00933 -4.76 2.86e-06 0.000898 -0.35 -0.25 Schizophrenia; chr15:84553803 chr15:84570649~84580175:+ LIHC cis rs10181042 0.514 rs1177283 ENSG00000271889.1 RP11-493E12.1 4.76 2.86e-06 0.000899 0.29 0.25 Crohn's disease; chr2:61121669 chr2:61151433~61162105:- LIHC cis rs1322639 0.614 rs6908401 ENSG00000261039.2 RP11-417E7.2 4.76 2.87e-06 9e-04 0.34 0.25 Pulse pressure; chr6:169164621 chr6:169175304~169182740:- LIHC cis rs2060793 0.519 rs1357332 ENSG00000251991.1 RNU7-49P 4.76 2.87e-06 0.000902 0.28 0.25 Vitamin D levels; chr11:14618570 chr11:14478892~14478953:+ LIHC cis rs9291683 0.509 rs998676 ENSG00000250413.1 RP11-448G15.1 4.76 2.87e-06 0.000902 0.32 0.25 Bone mineral density; chr4:9946940 chr4:10006482~10009725:+ LIHC cis rs11098499 0.604 rs10022185 ENSG00000245958.5 RP11-33B1.1 -4.76 2.87e-06 0.000902 -0.26 -0.25 Corneal astigmatism; chr4:119650610 chr4:119454791~119552025:+ LIHC cis rs4650994 0.507 rs56229230 ENSG00000273384.1 RP5-1098D14.1 4.76 2.87e-06 0.000902 0.32 0.25 HDL cholesterol;HDL cholesterol levels; chr1:178557428 chr1:178651706~178652282:+ LIHC cis rs7412746 0.566 rs11204743 ENSG00000231073.1 RP11-316M1.3 4.76 2.87e-06 0.000902 0.25 0.25 Melanoma; chr1:150917930 chr1:150973123~150975534:+ LIHC cis rs11123170 0.64 rs1015754 ENSG00000274877.1 RP11-65I12.1 4.76 2.87e-06 0.000902 0.33 0.25 Renal function-related traits (BUN); chr2:113210413 chr2:113237595~113240825:+ LIHC cis rs1577917 0.876 rs66986937 ENSG00000234155.1 RP11-30P6.6 4.76 2.88e-06 0.000903 0.34 0.25 Response to antipsychotic treatment; chr6:85822473 chr6:85387219~85390186:- LIHC cis rs7809950 1 rs3801948 ENSG00000238832.1 snoU109 -4.76 2.88e-06 0.000903 -0.29 -0.25 Coronary artery disease; chr7:107598002 chr7:107603363~107603507:+ LIHC cis rs957448 1 rs957448 ENSG00000253704.1 RP11-267M23.4 4.76 2.88e-06 0.000903 0.3 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94529074 chr8:94553722~94569745:+ LIHC cis rs957448 1 rs72674855 ENSG00000253704.1 RP11-267M23.4 4.76 2.88e-06 0.000903 0.3 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94536706 chr8:94553722~94569745:+ LIHC cis rs1322639 0.614 rs6903921 ENSG00000261039.2 RP11-417E7.2 -4.76 2.88e-06 0.000903 -0.36 -0.25 Pulse pressure; chr6:169163862 chr6:169175304~169182740:- LIHC cis rs1322639 0.614 rs6925950 ENSG00000261039.2 RP11-417E7.2 -4.76 2.88e-06 0.000903 -0.36 -0.25 Pulse pressure; chr6:169163863 chr6:169175304~169182740:- LIHC cis rs7131987 0.903 rs918873 ENSG00000257176.2 RP11-996F15.2 -4.76 2.88e-06 0.000904 -0.29 -0.25 QT interval; chr12:29237568 chr12:29280418~29317848:- LIHC cis rs12554020 0.792 rs11975 ENSG00000227603.1 RP11-165J3.6 4.76 2.88e-06 0.000905 0.33 0.25 Schizophrenia; chr9:93565409 chr9:93435332~93437121:- LIHC cis rs12554020 0.892 rs7870210 ENSG00000227603.1 RP11-165J3.6 4.76 2.88e-06 0.000905 0.33 0.25 Schizophrenia; chr9:93569534 chr9:93435332~93437121:- LIHC cis rs12554020 0.892 rs7860098 ENSG00000227603.1 RP11-165J3.6 4.76 2.88e-06 0.000905 0.33 0.25 Schizophrenia; chr9:93569562 chr9:93435332~93437121:- LIHC cis rs12554020 0.786 rs60076242 ENSG00000227603.1 RP11-165J3.6 4.76 2.88e-06 0.000905 0.33 0.25 Schizophrenia; chr9:93571634 chr9:93435332~93437121:- LIHC cis rs4731207 0.844 rs2402749 ENSG00000224897.5 POT1-AS1 -4.76 2.88e-06 0.000905 -0.3 -0.25 Cutaneous malignant melanoma; chr7:124749669 chr7:124929873~125179315:+ LIHC cis rs4731207 0.844 rs33935352 ENSG00000224897.5 POT1-AS1 -4.76 2.88e-06 0.000905 -0.3 -0.25 Cutaneous malignant melanoma; chr7:124755256 chr7:124929873~125179315:+ LIHC cis rs4731207 0.844 rs2267707 ENSG00000224897.5 POT1-AS1 -4.76 2.88e-06 0.000905 -0.3 -0.25 Cutaneous malignant melanoma; chr7:124756972 chr7:124929873~125179315:+ LIHC cis rs4731207 0.844 rs2299903 ENSG00000224897.5 POT1-AS1 -4.76 2.88e-06 0.000905 -0.3 -0.25 Cutaneous malignant melanoma; chr7:124757288 chr7:124929873~125179315:+ LIHC cis rs4731207 0.844 rs4731208 ENSG00000224897.5 POT1-AS1 -4.76 2.88e-06 0.000905 -0.3 -0.25 Cutaneous malignant melanoma; chr7:124758142 chr7:124929873~125179315:+ LIHC cis rs9487094 0.813 rs13203252 ENSG00000260273.1 RP11-425D10.10 4.76 2.89e-06 0.000906 0.35 0.25 Height; chr6:109351533 chr6:109382795~109383666:+ LIHC cis rs2243480 1 rs1404147 ENSG00000226824.5 RP4-756H11.3 -4.76 2.89e-06 0.000906 -0.4 -0.25 Diabetic kidney disease; chr7:65799537 chr7:66654538~66669855:+ LIHC cis rs4713118 0.662 rs149901 ENSG00000219392.1 RP1-265C24.5 -4.76 2.89e-06 0.000906 -0.36 -0.25 Parkinson's disease; chr6:27997725 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs464312 ENSG00000219392.1 RP1-265C24.5 -4.76 2.89e-06 0.000906 -0.36 -0.25 Parkinson's disease; chr6:27999813 chr6:28115628~28116551:+ LIHC cis rs4713118 0.662 rs469228 ENSG00000219392.1 RP1-265C24.5 -4.76 2.89e-06 0.000906 -0.36 -0.25 Parkinson's disease; chr6:28002926 chr6:28115628~28116551:+ LIHC cis rs4713118 0.54 rs469227 ENSG00000219392.1 RP1-265C24.5 -4.76 2.89e-06 0.000906 -0.36 -0.25 Parkinson's disease; chr6:28002927 chr6:28115628~28116551:+ LIHC cis rs12478296 1 rs6732595 ENSG00000261186.2 RP11-341N2.1 -4.76 2.89e-06 0.000906 -0.35 -0.25 Obesity-related traits; chr2:242093187 chr2:242087351~242088457:- LIHC cis rs11603023 0.874 rs613243 ENSG00000255422.1 AP002954.4 -4.76 2.89e-06 0.000906 -0.27 -0.25 Cholesterol, total; chr11:118643304 chr11:118704607~118750263:+ LIHC cis rs11098499 0.909 rs9994810 ENSG00000260091.1 RP11-33B1.4 -4.76 2.89e-06 0.000906 -0.18 -0.25 Corneal astigmatism; chr4:119460435 chr4:119409333~119410233:+ LIHC cis rs7119038 0.509 rs11216956 ENSG00000255422.1 AP002954.4 4.76 2.9e-06 0.000908 0.33 0.25 Sjögren's syndrome; chr11:118704617 chr11:118704607~118750263:+ LIHC cis rs2439831 0.85 rs10438303 ENSG00000166763.7 STRCP1 4.76 2.9e-06 0.000908 0.38 0.25 Lung cancer in ever smokers; chr15:43724219 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs28504496 ENSG00000166763.7 STRCP1 4.76 2.9e-06 0.000908 0.38 0.25 Lung cancer in ever smokers; chr15:43724685 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs12441127 ENSG00000166763.7 STRCP1 4.76 2.9e-06 0.000908 0.38 0.25 Lung cancer in ever smokers; chr15:43728977 chr15:43699488~43718184:- LIHC cis rs6479891 0.722 rs4746951 ENSG00000232075.1 MRPL35P2 4.76 2.9e-06 0.000908 0.27 0.25 Arthritis (juvenile idiopathic); chr10:63123839 chr10:63634317~63634827:- LIHC cis rs1501911 0.545 rs4703345 ENSG00000248489.1 CTD-2007H13.3 -4.76 2.9e-06 0.000909 -0.39 -0.25 Lung function (FEV1/FVC); chr5:99016679 chr5:98929171~98995013:+ LIHC cis rs7809950 1 rs2520260 ENSG00000238832.1 snoU109 -4.76 2.9e-06 0.000909 -0.3 -0.25 Coronary artery disease; chr7:107532349 chr7:107603363~107603507:+ LIHC cis rs1223397 0.938 rs3817738 ENSG00000215022.6 RP1-257A7.4 -4.76 2.9e-06 0.000909 -0.28 -0.25 Blood pressure; chr6:13279156 chr6:13264861~13295586:- LIHC cis rs9834975 1 rs9818363 ENSG00000272758.4 RP11-299J3.8 -4.76 2.91e-06 0.00091 -0.28 -0.25 Diastolic blood pressure; chr3:122393444 chr3:122416207~122443180:+ LIHC cis rs9834975 0.873 rs9882772 ENSG00000272758.4 RP11-299J3.8 -4.76 2.91e-06 0.000911 -0.28 -0.25 Diastolic blood pressure; chr3:122391302 chr3:122416207~122443180:+ LIHC cis rs4660214 0.789 rs1180375 ENSG00000182109.6 RP11-69E11.4 4.76 2.91e-06 0.000911 0.26 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39415368 chr1:39522280~39546187:- LIHC cis rs2337406 0.866 rs8016203 ENSG00000274576.2 IGHV2-70 -4.76 2.91e-06 0.000912 -0.25 -0.25 Alzheimer's disease (late onset); chr14:106780575 chr14:106770577~106771020:- LIHC cis rs2337406 1 rs78857163 ENSG00000274576.2 IGHV2-70 -4.76 2.91e-06 0.000912 -0.28 -0.25 Alzheimer's disease (late onset); chr14:106707435 chr14:106770577~106771020:- LIHC cis rs5769707 0.967 rs9616713 ENSG00000235111.1 RP1-29C18.8 -4.76 2.91e-06 0.000912 -0.29 -0.25 Monocyte percentage of white cells;Monocyte count; chr22:49655461 chr22:49612657~49615716:- LIHC cis rs728616 1 rs56317427 ENSG00000225484.5 NUTM2B-AS1 -4.76 2.91e-06 0.000912 -0.54 -0.25 Chronic obstructive pulmonary disease-related biomarkers; chr10:80102178 chr10:79663088~79826594:- LIHC cis rs950776 0.593 rs621849 ENSG00000261762.1 RP11-650L12.2 -4.76 2.92e-06 0.000913 -0.31 -0.25 Sudden cardiac arrest; chr15:78580519 chr15:78589123~78591276:- LIHC cis rs10129255 0.5 rs2105991 ENSG00000223648.3 IGHV3-64 4.76 2.92e-06 0.000914 0.17 0.25 Kawasaki disease; chr14:106682022 chr14:106643132~106658258:- LIHC cis rs643506 0.874 rs618421 ENSG00000254990.4 RP11-108O10.2 4.76 2.92e-06 0.000914 0.27 0.25 Breast cancer; chr11:111778085 chr11:111768668~111778350:- LIHC cis rs4964805 0.594 rs954920 ENSG00000257681.1 RP11-341G23.4 4.76 2.92e-06 0.000914 0.26 0.25 Attention deficit hyperactivity disorder; chr12:103779532 chr12:103746315~103768858:- LIHC cis rs916888 0.821 rs199506 ENSG00000274883.1 Metazoa_SRP 4.76 2.92e-06 0.000914 0.39 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45931806~45932083:+ LIHC cis rs875971 0.54 rs4717275 ENSG00000224316.1 RP11-479O9.2 -4.76 2.92e-06 0.000915 -0.25 -0.25 Aortic root size; chr7:65800193 chr7:65773620~65802067:+ LIHC cis rs1865760 0.566 rs3752420 ENSG00000216436.2 HIST1H2APS1 -4.76 2.93e-06 0.000916 -0.29 -0.25 Height; chr6:26026907 chr6:25732497~25732827:+ LIHC cis rs7923609 0.936 rs10761778 ENSG00000232075.1 MRPL35P2 -4.76 2.93e-06 0.000916 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63514022 chr10:63634317~63634827:- LIHC cis rs2834188 1 rs2096464 ENSG00000272659.1 AP000295.10 4.76 2.93e-06 0.000916 0.37 0.25 Narcolepsy; chr21:33313744 chr21:33309491~33310181:+ LIHC cis rs1577917 1 rs13196930 ENSG00000234155.1 RP11-30P6.6 4.76 2.93e-06 0.000917 0.33 0.25 Response to antipsychotic treatment; chr6:85942527 chr6:85387219~85390186:- LIHC cis rs2919917 1 rs2919936 ENSG00000254352.1 RP11-578O24.2 4.76 2.93e-06 0.000917 0.34 0.25 Lymphocyte counts; chr8:78721772 chr8:78723796~78724136:- LIHC cis rs11098499 0.738 rs72918577 ENSG00000260091.1 RP11-33B1.4 -4.76 2.93e-06 0.000917 -0.18 -0.25 Corneal astigmatism; chr4:119405546 chr4:119409333~119410233:+ LIHC cis rs6479891 0.63 rs10995447 ENSG00000232075.1 MRPL35P2 4.75 2.93e-06 0.000917 0.27 0.25 Arthritis (juvenile idiopathic); chr10:63119761 chr10:63634317~63634827:- LIHC cis rs875971 0.545 rs10950025 ENSG00000273142.1 RP11-458F8.4 4.75 2.93e-06 0.000917 0.24 0.25 Aortic root size; chr7:66158946 chr7:66902857~66906297:+ LIHC cis rs875971 0.52 rs12666485 ENSG00000273142.1 RP11-458F8.4 4.75 2.93e-06 0.000917 0.24 0.25 Aortic root size; chr7:66160135 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs67688847 ENSG00000273142.1 RP11-458F8.4 4.75 2.93e-06 0.000917 0.24 0.25 Aortic root size; chr7:66161064 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs12673308 ENSG00000273142.1 RP11-458F8.4 4.75 2.93e-06 0.000917 0.24 0.25 Aortic root size; chr7:66166374 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs316305 ENSG00000273142.1 RP11-458F8.4 -4.75 2.93e-06 0.000917 -0.24 -0.25 Aortic root size; chr7:66152984 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs316306 ENSG00000273142.1 RP11-458F8.4 -4.75 2.93e-06 0.000917 -0.24 -0.25 Aortic root size; chr7:66153687 chr7:66902857~66906297:+ LIHC cis rs10829156 0.625 rs10828906 ENSG00000240291.1 RP11-499P20.2 4.75 2.93e-06 0.000918 0.38 0.25 Sudden cardiac arrest; chr10:18552866 chr10:18513115~18545651:- LIHC cis rs4650994 0.525 rs2493864 ENSG00000273384.1 RP5-1098D14.1 4.75 2.94e-06 0.000918 0.31 0.25 HDL cholesterol;HDL cholesterol levels; chr1:178575868 chr1:178651706~178652282:+ LIHC cis rs67311347 0.955 rs4973999 ENSG00000223797.4 ENTPD3-AS1 4.75 2.94e-06 0.000919 0.19 0.25 Renal cell carcinoma; chr3:40418892 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs1466236 ENSG00000223797.4 ENTPD3-AS1 4.75 2.94e-06 0.000919 0.19 0.25 Renal cell carcinoma; chr3:40420671 chr3:40313802~40453329:- LIHC cis rs12908161 0.853 rs11633788 ENSG00000259295.5 CSPG4P12 4.75 2.94e-06 0.000919 0.31 0.25 Schizophrenia; chr15:84761911 chr15:85191438~85213905:+ LIHC cis rs12478296 0.892 rs60545379 ENSG00000261186.2 RP11-341N2.1 -4.75 2.94e-06 0.000921 -0.35 -0.25 Obesity-related traits; chr2:242092239 chr2:242087351~242088457:- LIHC cis rs6479901 0.512 rs4746244 ENSG00000232075.1 MRPL35P2 -4.75 2.95e-06 0.000922 -0.3 -0.25 Intelligence (multi-trait analysis); chr10:63599941 chr10:63634317~63634827:- LIHC cis rs228614 0.536 rs223475 ENSG00000246560.2 RP11-10L12.4 4.75 2.95e-06 0.000923 0.27 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771986 chr4:102828055~102844075:+ LIHC cis rs228614 0.536 rs223474 ENSG00000246560.2 RP11-10L12.4 4.75 2.95e-06 0.000923 0.27 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102772007 chr4:102828055~102844075:+ LIHC cis rs7246657 0.943 rs2126977 ENSG00000276846.1 CTD-3220F14.3 -4.75 2.95e-06 0.000923 -0.31 -0.25 Coronary artery calcification; chr19:37504845 chr19:37314868~37315620:- LIHC cis rs16858210 0.607 rs35205152 ENSG00000234371.6 RPSAP31 4.75 2.95e-06 0.000923 0.35 0.25 Menopause (age at onset); chr3:183845541 chr3:183884924~183888449:+ LIHC cis rs2836974 0.897 rs3945 ENSG00000255568.3 BRWD1-AS2 4.75 2.95e-06 0.000923 0.29 0.25 Cognitive function; chr21:39194141 chr21:39313935~39314962:+ LIHC cis rs7429990 0.864 rs35698005 ENSG00000229759.1 MRPS18AP1 -4.75 2.95e-06 0.000923 -0.26 -0.25 Educational attainment (years of education); chr3:47800558 chr3:48256350~48256938:- LIHC cis rs9291683 0.609 rs12500810 ENSG00000250413.1 RP11-448G15.1 -4.75 2.95e-06 0.000923 -0.31 -0.25 Bone mineral density; chr4:10029444 chr4:10006482~10009725:+ LIHC cis rs6921919 0.806 rs213230 ENSG00000204709.4 LINC01556 4.75 2.95e-06 0.000924 0.32 0.25 Autism spectrum disorder or schizophrenia; chr6:28362487 chr6:28943877~28944537:+ LIHC cis rs1223397 0.938 rs3817737 ENSG00000215022.6 RP1-257A7.4 -4.75 2.96e-06 0.000924 -0.29 -0.25 Blood pressure; chr6:13278850 chr6:13264861~13295586:- LIHC cis rs2337406 1 rs17113331 ENSG00000274576.2 IGHV2-70 -4.75 2.96e-06 0.000924 -0.28 -0.25 Alzheimer's disease (late onset); chr14:106703843 chr14:106770577~106771020:- LIHC cis rs4650994 0.816 rs2209169 ENSG00000273384.1 RP5-1098D14.1 -4.75 2.96e-06 0.000925 -0.29 -0.25 HDL cholesterol;HDL cholesterol levels; chr1:178632357 chr1:178651706~178652282:+ LIHC cis rs7246657 0.943 rs6508733 ENSG00000276846.1 CTD-3220F14.3 4.75 2.96e-06 0.000925 0.31 0.25 Coronary artery calcification; chr19:37509646 chr19:37314868~37315620:- LIHC cis rs739496 0.947 rs34368158 ENSG00000226469.1 ADAM1B 4.75 2.96e-06 0.000926 0.31 0.25 Platelet count; chr12:111408224 chr12:111927018~111929017:+ LIHC cis rs2337406 0.866 rs11488879 ENSG00000274576.2 IGHV2-70 -4.75 2.96e-06 0.000926 -0.26 -0.25 Alzheimer's disease (late onset); chr14:106786097 chr14:106770577~106771020:- LIHC cis rs1577917 1 rs10944163 ENSG00000234155.1 RP11-30P6.6 4.75 2.96e-06 0.000927 0.33 0.25 Response to antipsychotic treatment; chr6:85948975 chr6:85387219~85390186:- LIHC cis rs12554020 0.681 rs75519210 ENSG00000227603.1 RP11-165J3.6 4.75 2.97e-06 0.000927 0.46 0.25 Schizophrenia; chr9:93661448 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs112401922 ENSG00000227603.1 RP11-165J3.6 4.75 2.97e-06 0.000927 0.46 0.25 Schizophrenia; chr9:93661517 chr9:93435332~93437121:- LIHC cis rs11098499 0.82 rs13128602 ENSG00000245958.5 RP11-33B1.1 4.75 2.97e-06 0.000927 0.27 0.25 Corneal astigmatism; chr4:119538211 chr4:119454791~119552025:+ LIHC cis rs957448 0.948 rs11992893 ENSG00000253704.1 RP11-267M23.4 4.75 2.97e-06 0.000928 0.3 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94508473 chr8:94553722~94569745:+ LIHC cis rs957448 1 rs12678305 ENSG00000253704.1 RP11-267M23.4 4.75 2.97e-06 0.000928 0.3 0.25 Nonsyndromic cleft lip with cleft palate; chr8:94508911 chr8:94553722~94569745:+ LIHC cis rs2470135 1 rs2470135 ENSG00000166763.7 STRCP1 4.75 2.97e-06 0.000928 0.31 0.25 Diastolic blood pressure; chr15:43703591 chr15:43699488~43718184:- LIHC cis rs2274273 0.868 rs9919926 ENSG00000258413.1 RP11-665C16.6 -4.75 2.97e-06 0.000928 -0.3 -0.25 Protein biomarker; chr14:55347172 chr14:55262767~55272075:- LIHC cis rs875971 0.545 rs7787063 ENSG00000273142.1 RP11-458F8.4 4.75 2.97e-06 0.000928 0.24 0.25 Aortic root size; chr7:66164012 chr7:66902857~66906297:+ LIHC cis rs11098499 0.821 rs10032151 ENSG00000260091.1 RP11-33B1.4 -4.75 2.97e-06 0.000928 -0.18 -0.25 Corneal astigmatism; chr4:119470473 chr4:119409333~119410233:+ LIHC cis rs11098499 0.865 rs10032158 ENSG00000260091.1 RP11-33B1.4 -4.75 2.97e-06 0.000928 -0.18 -0.25 Corneal astigmatism; chr4:119470477 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs6838814 ENSG00000260091.1 RP11-33B1.4 -4.75 2.97e-06 0.000928 -0.18 -0.25 Corneal astigmatism; chr4:119471288 chr4:119409333~119410233:+ LIHC cis rs1322639 0.575 rs9294966 ENSG00000261039.2 RP11-417E7.2 -4.75 2.97e-06 0.000928 -0.35 -0.25 Pulse pressure; chr6:169165223 chr6:169175304~169182740:- LIHC cis rs1322639 0.614 rs7768154 ENSG00000261039.2 RP11-417E7.2 -4.75 2.97e-06 0.000928 -0.35 -0.25 Pulse pressure; chr6:169165375 chr6:169175304~169182740:- LIHC cis rs4650994 0.525 rs4651000 ENSG00000273384.1 RP5-1098D14.1 4.75 2.97e-06 0.000929 0.31 0.25 HDL cholesterol;HDL cholesterol levels; chr1:178563088 chr1:178651706~178652282:+ LIHC cis rs16858210 0.529 rs10937154 ENSG00000234371.6 RPSAP31 4.75 2.98e-06 0.000929 0.34 0.25 Menopause (age at onset); chr3:183851701 chr3:183884924~183888449:+ LIHC cis rs11673344 0.583 rs10425719 ENSG00000226686.6 LINC01535 -4.75 2.98e-06 0.00093 -0.3 -0.25 Obesity-related traits; chr19:37459896 chr19:37251912~37265535:+ LIHC cis rs2836974 0.568 rs377098 ENSG00000255568.3 BRWD1-AS2 -4.75 2.98e-06 0.00093 -0.21 -0.25 Cognitive function; chr21:39163290 chr21:39313935~39314962:+ LIHC cis rs643506 0.874 rs4245045 ENSG00000254990.4 RP11-108O10.2 4.75 2.98e-06 0.000931 0.27 0.25 Breast cancer; chr11:111789200 chr11:111768668~111778350:- LIHC cis rs7208859 0.623 rs8081299 ENSG00000266490.1 CTD-2349P21.9 4.75 2.98e-06 0.000932 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777278 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs8068645 ENSG00000266490.1 CTD-2349P21.9 4.75 2.98e-06 0.000932 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777324 chr17:30792372~30792833:+ LIHC cis rs2439831 0.85 rs3825783 ENSG00000275601.1 AC011330.13 -4.75 2.99e-06 0.000932 -0.37 -0.25 Lung cancer in ever smokers; chr15:43810111 chr15:43642389~43643023:- LIHC cis rs10129255 1 rs9324091 ENSG00000223648.3 IGHV3-64 4.75 2.99e-06 0.000932 0.19 0.25 Kawasaki disease; chr14:106676625 chr14:106643132~106658258:- LIHC cis rs8028182 0.636 rs4886699 ENSG00000260269.4 CTD-2323K18.1 -4.75 2.99e-06 0.000933 -0.31 -0.25 Sudden cardiac arrest; chr15:75399962 chr15:75527150~75601205:- LIHC cis rs2834188 1 rs2409488 ENSG00000272659.1 AP000295.10 -4.75 2.99e-06 0.000933 -0.37 -0.25 Narcolepsy; chr21:33316609 chr21:33309491~33310181:+ LIHC cis rs2836974 0.568 rs429955 ENSG00000255568.3 BRWD1-AS2 4.75 2.99e-06 0.000934 0.21 0.25 Cognitive function; chr21:39167834 chr21:39313935~39314962:+ LIHC cis rs929596 0.561 rs7564935 ENSG00000233445.1 RPL17P11 4.75 3e-06 0.000935 0.28 0.25 Total bilirubin levels in HIV-1 infection; chr2:233736540 chr2:233721522~233722065:- LIHC cis rs10129255 0.536 rs10139058 ENSG00000223648.3 IGHV3-64 4.75 3e-06 0.000935 0.18 0.25 Kawasaki disease; chr14:106685899 chr14:106643132~106658258:- LIHC cis rs10129255 0.536 rs8004835 ENSG00000223648.3 IGHV3-64 4.75 3e-06 0.000935 0.18 0.25 Kawasaki disease; chr14:106686361 chr14:106643132~106658258:- LIHC cis rs11216126 1 rs4938307 ENSG00000254851.1 RP11-109L13.1 4.75 3e-06 0.000935 0.38 0.25 HDL cholesterol; chr11:116733798 chr11:117135528~117138582:+ LIHC cis rs7829975 0.606 rs891570 ENSG00000253893.2 FAM85B 4.75 3e-06 0.000936 0.3 0.25 Mood instability; chr8:8936944 chr8:8167819~8226614:- LIHC cis rs9291683 0.632 rs10939669 ENSG00000250413.1 RP11-448G15.1 -4.75 3e-06 0.000936 -0.31 -0.25 Bone mineral density; chr4:10044203 chr4:10006482~10009725:+ LIHC cis rs7914558 1 rs7911789 ENSG00000236937.2 PTGES3P4 4.75 3e-06 0.000937 0.29 0.25 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102996617 chr10:102845595~102845950:+ LIHC cis rs1558001 1 rs6467872 ENSG00000230196.1 DDX43P3 4.75 3e-06 0.000937 0.26 0.25 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81775566 chr7:81610884~81611326:- LIHC cis rs2310173 0.612 rs3819369 ENSG00000281162.1 LINC01127 -4.75 3e-06 0.000937 -0.27 -0.25 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:102016120 chr2:101962056~101987167:+ LIHC cis rs7702057 0.53 rs17138879 ENSG00000271918.1 CTD-2287O16.5 -4.75 3e-06 0.000937 -0.34 -0.25 Amyotrophic lateral sclerosis; chr5:116089730 chr5:116083807~116085416:- LIHC cis rs1062177 0.826 rs2915873 ENSG00000253921.1 CTB-113P19.3 -4.75 3.01e-06 0.000938 -0.29 -0.25 Preschool internalizing problems; chr5:151777097 chr5:151753992~151767247:+ LIHC cis rs9549367 0.789 rs8001506 ENSG00000269125.1 RP11-98F14.11 -4.75 3.01e-06 0.000938 -0.28 -0.25 Platelet distribution width; chr13:113212839 chr13:113165002~113165183:- LIHC cis rs9291683 0.632 rs11734375 ENSG00000250413.1 RP11-448G15.1 -4.75 3.01e-06 0.000938 -0.31 -0.25 Bone mineral density; chr4:10044674 chr4:10006482~10009725:+ LIHC cis rs2337406 0.85 rs11849578 ENSG00000274576.2 IGHV2-70 -4.75 3.01e-06 0.000939 -0.29 -0.25 Alzheimer's disease (late onset); chr14:106670302 chr14:106770577~106771020:- LIHC cis rs2836974 0.965 rs2836967 ENSG00000255568.3 BRWD1-AS2 4.75 3.01e-06 0.000939 0.28 0.25 Cognitive function; chr21:39267176 chr21:39313935~39314962:+ LIHC cis rs2836974 0.965 rs8130984 ENSG00000255568.3 BRWD1-AS2 4.75 3.01e-06 0.000939 0.28 0.25 Cognitive function; chr21:39268040 chr21:39313935~39314962:+ LIHC cis rs2836974 0.965 rs6517538 ENSG00000255568.3 BRWD1-AS2 4.75 3.01e-06 0.000939 0.28 0.25 Cognitive function; chr21:39284316 chr21:39313935~39314962:+ LIHC cis rs9487094 0.626 rs12192776 ENSG00000260273.1 RP11-425D10.10 4.75 3.01e-06 0.000939 0.29 0.25 Height; chr6:109634150 chr6:109382795~109383666:+ LIHC cis rs9487094 0.67 rs12194157 ENSG00000260273.1 RP11-425D10.10 4.75 3.01e-06 0.000939 0.29 0.25 Height; chr6:109640141 chr6:109382795~109383666:+ LIHC cis rs62355901 0.551 rs60856350 ENSG00000271828.1 CTD-2310F14.1 4.75 3.01e-06 0.00094 0.47 0.25 Breast cancer; chr5:56727093 chr5:56927874~56929573:+ LIHC cis rs30380 0.573 rs469783 ENSG00000272109.1 CTD-2260A17.3 -4.75 3.01e-06 0.00094 -0.3 -0.25 Cerebrospinal fluid biomarker levels; chr5:96785820 chr5:96804353~96806105:+ LIHC cis rs12554020 0.786 rs12349299 ENSG00000227603.1 RP11-165J3.6 4.75 3.01e-06 0.00094 0.36 0.25 Schizophrenia; chr9:93412482 chr9:93435332~93437121:- LIHC cis rs228614 0.51 rs223472 ENSG00000246560.2 RP11-10L12.4 4.75 3.01e-06 0.00094 0.27 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102774327 chr4:102828055~102844075:+ LIHC cis rs17711722 0.523 rs313812 ENSG00000224316.1 RP11-479O9.2 -4.75 3.01e-06 0.00094 -0.22 -0.25 Calcium levels; chr7:66040056 chr7:65773620~65802067:+ LIHC cis rs2439831 0.85 rs16965120 ENSG00000275601.1 AC011330.13 -4.75 3.02e-06 0.000942 -0.37 -0.25 Lung cancer in ever smokers; chr15:43808144 chr15:43642389~43643023:- LIHC cis rs1714507 0.533 rs1620229 ENSG00000272087.1 RP11-379F4.7 4.75 3.02e-06 0.000942 0.28 0.25 Subjective well-being; chr3:158575469 chr3:158693120~158693768:- LIHC cis rs7662987 0.793 rs7669660 ENSG00000272777.1 RP11-571L19.8 4.75 3.02e-06 0.000942 0.54 0.25 Smoking initiation; chr4:99071451 chr4:99067256~99068125:- LIHC cis rs67311347 0.955 rs12487955 ENSG00000223797.4 ENTPD3-AS1 4.75 3.02e-06 0.000942 0.2 0.25 Renal cell carcinoma; chr3:40371362 chr3:40313802~40453329:- LIHC cis rs11098499 0.566 rs7664440 ENSG00000245958.5 RP11-33B1.1 -4.75 3.02e-06 0.000943 -0.26 -0.25 Corneal astigmatism; chr4:119657385 chr4:119454791~119552025:+ LIHC cis rs812925 0.512 rs7558954 ENSG00000271889.1 RP11-493E12.1 4.75 3.02e-06 0.000943 0.29 0.25 Immature fraction of reticulocytes; chr2:61157771 chr2:61151433~61162105:- LIHC cis rs5760092 0.572 rs738806 ENSG00000250470.1 AP000351.3 4.75 3.03e-06 0.000943 0.34 0.25 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23976904~23977585:- LIHC cis rs227275 0.555 rs223402 ENSG00000246560.2 RP11-10L12.4 4.75 3.03e-06 0.000943 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102817198 chr4:102828055~102844075:+ LIHC cis rs9487094 0.922 rs59056467 ENSG00000260273.1 RP11-425D10.10 4.75 3.03e-06 0.000944 0.29 0.25 Height; chr6:109446728 chr6:109382795~109383666:+ LIHC cis rs10510102 0.935 rs12253283 ENSG00000226864.1 ATE1-AS1 -4.75 3.03e-06 0.000944 -0.39 -0.25 Breast cancer; chr10:121909740 chr10:121928312~121951965:+ LIHC cis rs8059260 0.668 rs74737820 ENSG00000274038.1 RP11-66H6.4 -4.75 3.03e-06 0.000944 -0.41 -0.25 Alcohol consumption over the past year; chr16:10972240 chr16:11056556~11057034:+ LIHC cis rs228614 0.536 rs223477 ENSG00000246560.2 RP11-10L12.4 4.75 3.03e-06 0.000945 0.27 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769099 chr4:102828055~102844075:+ LIHC cis rs11722779 0.903 rs4530634 ENSG00000246560.2 RP11-10L12.4 4.75 3.04e-06 0.000946 0.28 0.25 Schizophrenia; chr4:102937924 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs7676943 ENSG00000246560.2 RP11-10L12.4 4.75 3.04e-06 0.000946 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102938135 chr4:102828055~102844075:+ LIHC cis rs11722779 0.901 rs28674656 ENSG00000246560.2 RP11-10L12.4 4.75 3.04e-06 0.000946 0.28 0.25 Schizophrenia; chr4:102944396 chr4:102828055~102844075:+ LIHC cis rs11722779 0.838 rs3974494 ENSG00000246560.2 RP11-10L12.4 4.75 3.04e-06 0.000946 0.28 0.25 Schizophrenia; chr4:102945323 chr4:102828055~102844075:+ LIHC cis rs728616 0.558 rs61859793 ENSG00000225484.5 NUTM2B-AS1 -4.75 3.04e-06 0.000946 -0.48 -0.25 Chronic obstructive pulmonary disease-related biomarkers; chr10:79927007 chr10:79663088~79826594:- LIHC cis rs7246657 0.943 rs4802136 ENSG00000276846.1 CTD-3220F14.3 4.75 3.04e-06 0.000947 0.3 0.25 Coronary artery calcification; chr19:37358909 chr19:37314868~37315620:- LIHC cis rs11971779 0.523 rs10234578 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139353242 chr7:139359032~139359566:- LIHC cis rs11971779 0.59 rs4732374 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139406707 chr7:139359032~139359566:- LIHC cis rs11971779 0.648 rs9642121 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139407875 chr7:139359032~139359566:- LIHC cis rs11971779 0.584 rs7786469 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139409875 chr7:139359032~139359566:- LIHC cis rs11971779 0.584 rs17613864 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139410841 chr7:139359032~139359566:- LIHC cis rs11971779 0.555 rs4728466 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139411619 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs4732376 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139413278 chr7:139359032~139359566:- LIHC cis rs11971779 0.648 rs6974099 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139413820 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs10261557 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139414291 chr7:139359032~139359566:- LIHC cis rs11971779 0.553 rs11973507 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139414715 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs10265718 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139415322 chr7:139359032~139359566:- LIHC cis rs11971779 0.553 rs10085770 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139415603 chr7:139359032~139359566:- LIHC cis rs11971779 0.616 rs10269683 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139416122 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs2355788 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139417151 chr7:139359032~139359566:- LIHC cis rs11971779 0.618 rs3778931 ENSG00000273391.1 RP11-634H22.1 4.75 3.04e-06 0.000947 0.22 0.25 Diisocyanate-induced asthma; chr7:139417744 chr7:139359032~139359566:- LIHC cis rs11089937 0.597 rs11089925 ENSG00000211639.2 IGLV4-60 4.75 3.04e-06 0.000947 0.21 0.25 Periodontitis (PAL4Q3); chr22:22137267 chr22:22162199~22162681:+ LIHC cis rs1003645 1 rs8075916 ENSG00000275944.1 RP11-104J23.1 4.75 3.04e-06 0.000947 0.25 0.25 Blood protein levels; chr17:36016808 chr17:36001419~36011618:+ LIHC cis rs6163 0.588 rs10786706 ENSG00000236937.2 PTGES3P4 4.75 3.05e-06 0.000948 0.3 0.25 Waist circumference;Hip circumference; chr10:102740902 chr10:102845595~102845950:+ LIHC cis rs67311347 0.955 rs6599100 ENSG00000223797.4 ENTPD3-AS1 4.75 3.05e-06 0.000948 0.2 0.25 Renal cell carcinoma; chr3:40405871 chr3:40313802~40453329:- LIHC cis rs7208859 0.623 rs11657990 ENSG00000266490.1 CTD-2349P21.9 4.75 3.05e-06 0.000949 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797182 chr17:30792372~30792833:+ LIHC cis rs9291683 0.655 rs35750364 ENSG00000250413.1 RP11-448G15.1 -4.75 3.05e-06 0.000949 -0.31 -0.25 Bone mineral density; chr4:10047425 chr4:10006482~10009725:+ LIHC cis rs9807989 0.507 rs11465721 ENSG00000234389.1 AC007278.3 4.75 3.05e-06 0.00095 0.27 0.25 Asthma; chr2:102446780 chr2:102438713~102440475:+ LIHC cis rs7208859 0.573 rs56031503 ENSG00000266490.1 CTD-2349P21.9 4.75 3.06e-06 0.00095 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748647 chr17:30792372~30792833:+ LIHC cis rs7923609 0.967 rs7095571 ENSG00000232075.1 MRPL35P2 -4.75 3.06e-06 0.000951 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63391199 chr10:63634317~63634827:- LIHC cis rs12887734 0.524 rs12588797 ENSG00000258534.1 CTD-2134A5.4 4.75 3.06e-06 0.000951 0.27 0.25 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103833683 chr14:103854366~103880111:- LIHC cis rs11722779 0.935 rs6533046 ENSG00000230069.3 LRRC37A15P -4.75 3.06e-06 0.000952 -0.22 -0.25 Schizophrenia; chr4:102965917 chr4:102727274~102730721:- LIHC cis rs7246657 0.943 rs28373708 ENSG00000276846.1 CTD-3220F14.3 4.75 3.06e-06 0.000952 0.31 0.25 Coronary artery calcification; chr19:37485757 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs1382357 ENSG00000276846.1 CTD-3220F14.3 4.75 3.06e-06 0.000952 0.31 0.25 Coronary artery calcification; chr19:37486707 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs2045908 ENSG00000276846.1 CTD-3220F14.3 4.75 3.06e-06 0.000952 0.31 0.25 Coronary artery calcification; chr19:37488866 chr19:37314868~37315620:- LIHC cis rs2976388 0.609 rs2164308 ENSG00000253741.1 CTD-2292P10.4 4.75 3.06e-06 0.000952 0.28 0.25 Urinary tract infection frequency; chr8:142704241 chr8:142702252~142726973:- LIHC cis rs2836974 0.863 rs1065242 ENSG00000255568.3 BRWD1-AS2 4.75 3.06e-06 0.000952 0.28 0.25 Cognitive function; chr21:39195790 chr21:39313935~39314962:+ LIHC cis rs7714584 1 rs7705542 ENSG00000197083.10 ZNF300P1 4.75 3.06e-06 0.000953 0.38 0.25 Crohn's disease; chr5:150848756 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs11749391 ENSG00000197083.10 ZNF300P1 4.75 3.06e-06 0.000953 0.38 0.25 Crohn's disease; chr5:150849504 chr5:150930645~150946289:- LIHC cis rs9467711 0.591 rs13196552 ENSG00000216436.2 HIST1H2APS1 4.75 3.06e-06 0.000953 0.64 0.25 Autism spectrum disorder or schizophrenia; chr6:25973976 chr6:25732497~25732827:+ LIHC cis rs9467711 0.591 rs56294283 ENSG00000216436.2 HIST1H2APS1 4.75 3.06e-06 0.000953 0.64 0.25 Autism spectrum disorder or schizophrenia; chr6:25975871 chr6:25732497~25732827:+ LIHC cis rs8028182 0.636 rs11636199 ENSG00000260269.4 CTD-2323K18.1 -4.75 3.07e-06 0.000953 -0.31 -0.25 Sudden cardiac arrest; chr15:75532996 chr15:75527150~75601205:- LIHC cis rs1729407 0.695 rs1263176 ENSG00000236267.1 AP006216.5 4.75 3.07e-06 0.000954 0.23 0.25 Apolipoprotein A-IV levels; chr11:116819407 chr11:116813204~116814003:- LIHC cis rs12157904 1 rs5995481 ENSG00000233360.4 Z83844.1 4.74 3.07e-06 0.000954 0.49 0.25 Response to anti-depressant treatment in major depressive disorder; chr22:37608195 chr22:37641832~37658377:- LIHC cis rs12554020 0.892 rs6479483 ENSG00000227603.1 RP11-165J3.6 4.74 3.07e-06 0.000954 0.33 0.25 Schizophrenia; chr9:93441746 chr9:93435332~93437121:- LIHC cis rs5769765 0.658 rs2157536 ENSG00000278869.1 CITF22-49E9.3 4.74 3.07e-06 0.000954 0.38 0.25 Schizophrenia; chr22:49796532 chr22:49933198~49934074:- LIHC cis rs901683 0.702 rs77819548 ENSG00000230869.1 CTGLF10P -4.74 3.07e-06 0.000955 -0.64 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45642760 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs112909171 ENSG00000230869.1 CTGLF10P -4.74 3.07e-06 0.000955 -0.64 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45645322 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs78275508 ENSG00000230869.1 CTGLF10P -4.74 3.07e-06 0.000955 -0.64 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45645365 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs75203622 ENSG00000230869.1 CTGLF10P -4.74 3.07e-06 0.000955 -0.64 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45645457 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs75605891 ENSG00000230869.1 CTGLF10P -4.74 3.07e-06 0.000955 -0.64 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45645607 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs74595557 ENSG00000230869.1 CTGLF10P -4.74 3.07e-06 0.000955 -0.64 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45648173 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs76232026 ENSG00000230869.1 CTGLF10P -4.74 3.07e-06 0.000955 -0.64 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45648688 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs17157941 ENSG00000230869.1 CTGLF10P -4.74 3.07e-06 0.000955 -0.64 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45651298 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs80162657 ENSG00000230869.1 CTGLF10P -4.74 3.07e-06 0.000955 -0.64 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45652344 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs74470893 ENSG00000230869.1 CTGLF10P -4.74 3.07e-06 0.000955 -0.64 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45663939 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs76238709 ENSG00000230869.1 CTGLF10P -4.74 3.07e-06 0.000955 -0.64 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45666294 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs113325959 ENSG00000230869.1 CTGLF10P -4.74 3.07e-06 0.000955 -0.64 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45670577 chr10:45678692~45700532:+ LIHC cis rs2877649 0.51 rs10144287 ENSG00000258744.1 RP11-80A15.1 -4.74 3.08e-06 0.000956 -0.46 -0.25 Smooth-surface caries; chr14:24437643 chr14:24501594~24508688:+ LIHC cis rs5756813 0.727 rs4821703 ENSG00000233360.4 Z83844.1 4.74 3.08e-06 0.000957 0.32 0.25 Optic cup area;Vertical cup-disc ratio; chr22:37740669 chr22:37641832~37658377:- LIHC cis rs227275 0.525 rs11737544 ENSG00000246560.2 RP11-10L12.4 4.74 3.08e-06 0.000957 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102983877 chr4:102828055~102844075:+ LIHC cis rs116139393 0.54 rs12539942 ENSG00000187953.9 PMS2CL -4.74 3.08e-06 0.000957 -0.25 -0.25 Alzheimer's disease (APOE e4 interaction); chr7:6736954 chr7:6710128~6753862:+ LIHC cis rs7923609 0.967 rs10761751 ENSG00000232075.1 MRPL35P2 -4.74 3.09e-06 0.00096 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63395125 chr10:63634317~63634827:- LIHC cis rs1061377 1 rs12499266 ENSG00000249685.1 RP11-360F5.3 -4.74 3.09e-06 0.00096 -0.3 -0.25 Uric acid levels; chr4:39118133 chr4:39133913~39135608:+ LIHC cis rs6931421 1 rs6931421 ENSG00000272129.1 RP11-250B2.6 4.74 3.09e-06 0.00096 0.26 0.25 Sitting height ratio; chr6:80170421 chr6:80355424~80356859:+ LIHC cis rs2739330 0.587 rs4820571 ENSG00000099984.9 GSTT2 -4.74 3.1e-06 0.000961 -0.3 -0.25 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23980123~23983911:+ LIHC cis rs11098499 0.57 rs6832740 ENSG00000245958.5 RP11-33B1.1 -4.74 3.1e-06 0.000961 -0.25 -0.25 Corneal astigmatism; chr4:119624981 chr4:119454791~119552025:+ LIHC cis rs11098499 0.644 rs6855918 ENSG00000245958.5 RP11-33B1.1 -4.74 3.1e-06 0.000961 -0.25 -0.25 Corneal astigmatism; chr4:119625144 chr4:119454791~119552025:+ LIHC cis rs6997458 0.749 rs13270041 ENSG00000253549.4 RP11-317J10.2 4.74 3.1e-06 0.000961 0.27 0.25 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85450734 chr8:85441851~85464915:- LIHC cis rs712039 0.652 rs8069062 ENSG00000276054.1 RP11-378E13.3 4.74 3.1e-06 0.000962 0.31 0.25 Tuberculosis; chr17:37469202 chr17:37386886~37387926:+ LIHC cis rs712039 0.652 rs60112577 ENSG00000276054.1 RP11-378E13.3 4.74 3.1e-06 0.000962 0.31 0.25 Tuberculosis; chr17:37473105 chr17:37386886~37387926:+ LIHC cis rs2439831 0.867 rs12443102 ENSG00000275601.1 AC011330.13 -4.74 3.1e-06 0.000963 -0.37 -0.25 Lung cancer in ever smokers; chr15:43639905 chr15:43642389~43643023:- LIHC cis rs9467711 0.591 rs34791189 ENSG00000216436.2 HIST1H2APS1 4.74 3.1e-06 0.000963 0.63 0.25 Autism spectrum disorder or schizophrenia; chr6:26035578 chr6:25732497~25732827:+ LIHC cis rs875971 0.522 rs1617484 ENSG00000224316.1 RP11-479O9.2 4.74 3.1e-06 0.000964 0.24 0.25 Aortic root size; chr7:65998108 chr7:65773620~65802067:+ LIHC cis rs11971779 0.553 rs36002669 ENSG00000273391.1 RP11-634H22.1 4.74 3.11e-06 0.000964 0.22 0.25 Diisocyanate-induced asthma; chr7:139428415 chr7:139359032~139359566:- LIHC cis rs11098499 0.604 rs17051352 ENSG00000245958.5 RP11-33B1.1 -4.74 3.11e-06 0.000964 -0.27 -0.25 Corneal astigmatism; chr4:119660272 chr4:119454791~119552025:+ LIHC cis rs2836974 0.897 rs2836973 ENSG00000255568.3 BRWD1-AS2 4.74 3.11e-06 0.000965 0.28 0.25 Cognitive function; chr21:39283002 chr21:39313935~39314962:+ LIHC cis rs42490 0.903 rs184302 ENSG00000251136.7 RP11-37B2.1 -4.74 3.11e-06 0.000966 -0.22 -0.25 Leprosy; chr8:89704396 chr8:89609409~89757727:- LIHC cis rs62355901 0.599 rs62355875 ENSG00000271828.1 CTD-2310F14.1 4.74 3.12e-06 0.000966 0.47 0.25 Breast cancer; chr5:56729353 chr5:56927874~56929573:+ LIHC cis rs62355901 0.599 rs62355876 ENSG00000271828.1 CTD-2310F14.1 4.74 3.12e-06 0.000966 0.47 0.25 Breast cancer; chr5:56729373 chr5:56927874~56929573:+ LIHC cis rs71520386 0.632 rs35353454 ENSG00000228649.7 AC005682.5 -4.74 3.12e-06 0.000967 -0.32 -0.25 Fibrinogen levels; chr7:22822120 chr7:22854178~22861579:+ LIHC cis rs7208859 0.673 rs73271887 ENSG00000266490.1 CTD-2349P21.9 4.74 3.12e-06 0.000967 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827917 chr17:30792372~30792833:+ LIHC cis rs7131987 0.934 rs2216854 ENSG00000257176.2 RP11-996F15.2 -4.74 3.12e-06 0.000967 -0.28 -0.25 QT interval; chr12:29270527 chr12:29280418~29317848:- LIHC cis rs9843304 0.529 rs34895718 ENSG00000244503.1 RP11-278L15.6 4.74 3.12e-06 0.000967 0.25 0.25 Gallstone disease; chr3:149487430 chr3:149494660~149495995:+ LIHC cis rs367615 0.512 rs246104 ENSG00000249476.1 CTD-2587M2.1 -4.74 3.12e-06 0.000968 -0.29 -0.25 Colorectal cancer (SNP x SNP interaction); chr5:109365281 chr5:109237120~109326369:- LIHC cis rs638893 0.636 rs6589687 ENSG00000278376.1 RP11-158I9.8 -4.74 3.12e-06 0.000968 -0.45 -0.25 Vitiligo; chr11:118744951 chr11:118791254~118793137:+ LIHC cis rs7119038 0.818 rs7942535 ENSG00000255239.1 AP002954.6 4.74 3.13e-06 0.000969 0.31 0.25 Sjögren's syndrome; chr11:118810755 chr11:118688039~118690600:- LIHC cis rs597539 0.652 rs584108 ENSG00000250508.1 RP11-757G1.6 4.74 3.13e-06 0.000969 0.38 0.25 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68862814 chr11:68870664~68874542:+ LIHC cis rs9890032 0.581 rs62070592 ENSG00000263531.1 RP13-753N3.1 4.74 3.13e-06 0.00097 0.33 0.25 Hip circumference adjusted for BMI; chr17:30695531 chr17:30863921~30864940:- LIHC cis rs57502260 0.704 rs923346 ENSG00000212093.1 AP000807.1 4.74 3.13e-06 0.00097 0.32 0.25 Total body bone mineral density (age 45-60); chr11:68414907 chr11:68506083~68506166:- LIHC cis rs73186030 0.764 rs6438725 ENSG00000272758.4 RP11-299J3.8 4.74 3.14e-06 0.000971 0.45 0.25 Serum parathyroid hormone levels; chr3:122369259 chr3:122416207~122443180:+ LIHC cis rs73186030 0.764 rs9834317 ENSG00000272758.4 RP11-299J3.8 4.74 3.14e-06 0.000971 0.45 0.25 Serum parathyroid hormone levels; chr3:122370512 chr3:122416207~122443180:+ LIHC cis rs73186030 0.764 rs9881201 ENSG00000272758.4 RP11-299J3.8 4.74 3.14e-06 0.000971 0.45 0.25 Serum parathyroid hormone levels; chr3:122375838 chr3:122416207~122443180:+ LIHC cis rs1005277 0.579 rs1780121 ENSG00000276805.1 RP11-291L22.6 4.74 3.14e-06 0.000972 0.31 0.25 Extrinsic epigenetic age acceleration; chr10:38240509 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs1780122 ENSG00000276805.1 RP11-291L22.6 4.74 3.14e-06 0.000972 0.31 0.25 Extrinsic epigenetic age acceleration; chr10:38240581 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs1780145 ENSG00000276805.1 RP11-291L22.6 4.74 3.14e-06 0.000972 0.31 0.25 Extrinsic epigenetic age acceleration; chr10:38248142 chr10:38451030~38451785:+ LIHC cis rs6921919 1 rs6922111 ENSG00000216901.1 AL022393.7 4.74 3.14e-06 0.000972 0.35 0.25 Autism spectrum disorder or schizophrenia; chr6:28357531 chr6:28176188~28176674:+ LIHC cis rs5758511 0.68 rs5758667 ENSG00000205702.9 CYP2D7 4.74 3.14e-06 0.000973 0.29 0.25 Birth weight; chr22:42237198 chr22:42140203~42144577:- LIHC cis rs733592 0.507 rs7299704 ENSG00000240399.1 RP1-228P16.1 4.74 3.14e-06 0.000973 0.24 0.25 Plateletcrit; chr12:48050705 chr12:48054813~48055591:- LIHC cis rs1558001 0.87 rs6972704 ENSG00000230196.1 DDX43P3 4.74 3.14e-06 0.000974 0.26 0.25 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81784021 chr7:81610884~81611326:- LIHC cis rs17301013 0.932 rs1793297 ENSG00000227373.4 RP11-160H22.5 -4.74 3.15e-06 0.000975 -0.3 -0.25 Systemic lupus erythematosus; chr1:174784411 chr1:174115300~174160004:- LIHC cis rs7131987 0.903 rs7974221 ENSG00000257176.2 RP11-996F15.2 -4.74 3.15e-06 0.000975 -0.28 -0.25 QT interval; chr12:29246515 chr12:29280418~29317848:- LIHC cis rs71520386 0.632 rs9654968 ENSG00000228649.7 AC005682.5 -4.74 3.15e-06 0.000975 -0.32 -0.25 Fibrinogen levels; chr7:22836697 chr7:22854178~22861579:+ LIHC cis rs7412746 0.658 rs11581757 ENSG00000231073.1 RP11-316M1.3 4.74 3.15e-06 0.000975 0.25 0.25 Melanoma; chr1:150919768 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs12090215 ENSG00000231073.1 RP11-316M1.3 4.74 3.15e-06 0.000975 0.25 0.25 Melanoma; chr1:150921184 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs72704682 ENSG00000231073.1 RP11-316M1.3 4.74 3.15e-06 0.000975 0.25 0.25 Melanoma; chr1:150925201 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs72704685 ENSG00000231073.1 RP11-316M1.3 4.74 3.15e-06 0.000975 0.25 0.25 Melanoma; chr1:150925211 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs4970986 ENSG00000231073.1 RP11-316M1.3 4.74 3.15e-06 0.000975 0.25 0.25 Melanoma; chr1:150935479 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs59024312 ENSG00000231073.1 RP11-316M1.3 4.74 3.15e-06 0.000975 0.25 0.25 Melanoma; chr1:150936529 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs7521719 ENSG00000231073.1 RP11-316M1.3 4.74 3.15e-06 0.000975 0.25 0.25 Melanoma; chr1:150940658 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs7528773 ENSG00000231073.1 RP11-316M1.3 4.74 3.15e-06 0.000975 0.25 0.25 Melanoma; chr1:150943399 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs3843843 ENSG00000231073.1 RP11-316M1.3 4.74 3.15e-06 0.000975 0.25 0.25 Melanoma; chr1:150945608 chr1:150973123~150975534:+ LIHC cis rs7412746 0.634 rs2124952 ENSG00000231073.1 RP11-316M1.3 4.74 3.15e-06 0.000975 0.25 0.25 Melanoma; chr1:150951298 chr1:150973123~150975534:+ LIHC cis rs10129255 0.53 rs8008811 ENSG00000211970.3 IGHV4-61 -4.74 3.15e-06 0.000975 -0.2 -0.25 Kawasaki disease; chr14:106652273 chr14:106639119~106639657:- LIHC cis rs10129255 0.542 rs8009795 ENSG00000211970.3 IGHV4-61 -4.74 3.15e-06 0.000975 -0.2 -0.25 Kawasaki disease; chr14:106652287 chr14:106639119~106639657:- LIHC cis rs10129255 0.528 rs8008831 ENSG00000211970.3 IGHV4-61 -4.74 3.15e-06 0.000975 -0.2 -0.25 Kawasaki disease; chr14:106652290 chr14:106639119~106639657:- LIHC cis rs6964833 0.872 rs4717903 ENSG00000277053.3 GTF2IP1 -4.74 3.15e-06 0.000976 -0.3 -0.25 Menarche (age at onset); chr7:74653827 chr7:75185385~75237696:- LIHC cis rs11098499 0.863 rs10030660 ENSG00000245958.5 RP11-33B1.1 -4.74 3.15e-06 0.000976 -0.26 -0.25 Corneal astigmatism; chr4:119515549 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs13149407 ENSG00000245958.5 RP11-33B1.1 -4.74 3.15e-06 0.000976 -0.26 -0.25 Corneal astigmatism; chr4:119516670 chr4:119454791~119552025:+ LIHC cis rs17826219 0.636 rs2449770 ENSG00000266490.1 CTD-2349P21.9 4.74 3.15e-06 0.000976 0.32 0.25 Body mass index; chr17:30774046 chr17:30792372~30792833:+ LIHC cis rs7208859 0.524 rs59913838 ENSG00000266490.1 CTD-2349P21.9 4.74 3.15e-06 0.000976 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774545 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs8067338 ENSG00000266490.1 CTD-2349P21.9 4.74 3.15e-06 0.000976 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775327 chr17:30792372~30792833:+ LIHC cis rs2834188 1 rs2252931 ENSG00000272659.1 AP000295.10 -4.74 3.15e-06 0.000976 -0.38 -0.25 Narcolepsy; chr21:33332014 chr21:33309491~33310181:+ LIHC cis rs2060793 0.741 rs10741656 ENSG00000251991.1 RNU7-49P 4.74 3.16e-06 0.000977 0.28 0.25 Vitamin D levels; chr11:14803699 chr11:14478892~14478953:+ LIHC cis rs1729407 0.741 rs1263177 ENSG00000236267.1 AP006216.5 4.74 3.16e-06 0.000978 0.23 0.25 Apolipoprotein A-IV levels; chr11:116819996 chr11:116813204~116814003:- LIHC cis rs9467711 0.591 rs67296946 ENSG00000216436.2 HIST1H2APS1 4.74 3.16e-06 0.000978 0.64 0.25 Autism spectrum disorder or schizophrenia; chr6:26048331 chr6:25732497~25732827:+ LIHC cis rs9467711 0.591 rs13201821 ENSG00000216436.2 HIST1H2APS1 4.74 3.16e-06 0.000978 0.64 0.25 Autism spectrum disorder or schizophrenia; chr6:26057553 chr6:25732497~25732827:+ LIHC cis rs2976388 0.647 rs2244163 ENSG00000253196.1 RP11-706C16.7 4.74 3.17e-06 0.00098 0.24 0.25 Urinary tract infection frequency; chr8:142703082 chr8:142763116~142766427:+ LIHC cis rs11089937 0.597 rs5750579 ENSG00000211639.2 IGLV4-60 4.74 3.17e-06 0.000981 0.21 0.25 Periodontitis (PAL4Q3); chr22:22136581 chr22:22162199~22162681:+ LIHC cis rs1065852 0.526 rs11090066 ENSG00000237037.8 NDUFA6-AS1 -4.74 3.17e-06 0.000982 -0.34 -0.25 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42002191 chr22:42090931~42137742:+ LIHC cis rs498872 0.507 rs10892247 ENSG00000255239.1 AP002954.6 -4.74 3.17e-06 0.000982 -0.34 -0.25 Glioma; chr11:118619361 chr11:118688039~118690600:- LIHC cis rs2243480 0.708 rs35825036 ENSG00000230295.1 RP11-458F8.2 -4.74 3.18e-06 0.000982 -0.26 -0.25 Diabetic kidney disease; chr7:66521515 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs13237037 ENSG00000230295.1 RP11-458F8.2 -4.74 3.18e-06 0.000982 -0.26 -0.25 Diabetic kidney disease; chr7:66532895 chr7:66880708~66882981:+ LIHC cis rs2243480 0.901 rs13237344 ENSG00000230295.1 RP11-458F8.2 -4.74 3.18e-06 0.000982 -0.26 -0.25 Diabetic kidney disease; chr7:66557269 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1796228 ENSG00000230295.1 RP11-458F8.2 -4.74 3.18e-06 0.000982 -0.26 -0.25 Diabetic kidney disease; chr7:66568097 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1267820 ENSG00000230295.1 RP11-458F8.2 -4.74 3.18e-06 0.000982 -0.26 -0.25 Diabetic kidney disease; chr7:66585308 chr7:66880708~66882981:+ LIHC cis rs16858210 0.607 rs60244260 ENSG00000234371.6 RPSAP31 4.74 3.18e-06 0.000982 0.34 0.25 Menopause (age at onset); chr3:183852946 chr3:183884924~183888449:+ LIHC cis rs7914558 1 rs10786733 ENSG00000236937.2 PTGES3P4 4.74 3.18e-06 0.000982 0.29 0.25 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103035190 chr10:102845595~102845950:+ LIHC cis rs9467711 0.591 rs35335639 ENSG00000216436.2 HIST1H2APS1 4.74 3.18e-06 0.000983 0.63 0.25 Autism spectrum disorder or schizophrenia; chr6:26038453 chr6:25732497~25732827:+ LIHC cis rs2739330 0.789 rs5760109 ENSG00000206090.4 AP000350.7 4.74 3.19e-06 0.000985 0.29 0.25 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23939998~23942798:+ LIHC cis rs6442522 0.772 rs3890477 ENSG00000249786.6 EAF1-AS1 4.74 3.19e-06 0.000985 0.29 0.25 Uric acid levels; chr3:15447816 chr3:15436171~15455940:- LIHC cis rs6565180 0.926 rs8046445 ENSG00000183604.13 SMG1P5 -4.74 3.19e-06 0.000986 -0.25 -0.25 Tonsillectomy; chr16:30374941 chr16:30267553~30335374:- LIHC cis rs10129255 1 rs61997605 ENSG00000223648.3 IGHV3-64 4.74 3.2e-06 0.000987 0.19 0.25 Kawasaki disease; chr14:106678368 chr14:106643132~106658258:- LIHC cis rs712039 0.652 rs1616371 ENSG00000276054.1 RP11-378E13.3 4.74 3.2e-06 0.000988 0.3 0.25 Tuberculosis; chr17:37413714 chr17:37386886~37387926:+ LIHC cis rs67311347 1 rs2276870 ENSG00000223797.4 ENTPD3-AS1 -4.74 3.2e-06 0.000988 -0.2 -0.25 Renal cell carcinoma; chr3:40457691 chr3:40313802~40453329:- LIHC cis rs4694744 0.576 rs1080755 ENSG00000264696.1 AC108078.1 4.74 3.2e-06 0.000988 0.35 0.25 Bacteremia; chr4:69478923 chr4:69479331~69479434:+ LIHC cis rs7208859 0.623 rs1061342 ENSG00000266490.1 CTD-2349P21.9 4.74 3.2e-06 0.000988 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787445 chr17:30792372~30792833:+ LIHC cis rs2919917 1 rs1483573 ENSG00000254352.1 RP11-578O24.2 4.74 3.2e-06 0.000988 0.34 0.25 Lymphocyte counts; chr8:78711382 chr8:78723796~78724136:- LIHC cis rs1062177 0.951 rs2915876 ENSG00000253921.1 CTB-113P19.3 -4.74 3.2e-06 0.000988 -0.29 -0.25 Preschool internalizing problems; chr5:151771184 chr5:151753992~151767247:+ LIHC cis rs1062177 1 rs17741826 ENSG00000253921.1 CTB-113P19.3 4.74 3.2e-06 0.000988 0.29 0.25 Preschool internalizing problems; chr5:151769701 chr5:151753992~151767247:+ LIHC cis rs1061377 0.965 rs7669376 ENSG00000249685.1 RP11-360F5.3 4.74 3.2e-06 0.000989 0.3 0.25 Uric acid levels; chr4:39116717 chr4:39133913~39135608:+ LIHC cis rs7945705 0.837 rs10769981 ENSG00000254860.4 TMEM9B-AS1 -4.74 3.2e-06 0.000989 -0.26 -0.25 Hemoglobin concentration; chr11:9002913 chr11:8964675~8977527:+ LIHC cis rs831571 0.703 rs55714137 ENSG00000280620.1 SCAANT1 4.74 3.21e-06 0.00099 0.38 0.25 Type 2 diabetes; chr3:64091103 chr3:63911518~63911772:- LIHC cis rs6997458 0.742 rs10095352 ENSG00000253549.4 RP11-317J10.2 4.74 3.21e-06 0.000991 0.27 0.25 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85460203 chr8:85441851~85464915:- LIHC cis rs6997458 0.742 rs3758077 ENSG00000253549.4 RP11-317J10.2 4.74 3.21e-06 0.000991 0.27 0.25 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85463274 chr8:85441851~85464915:- LIHC cis rs9788721 0.63 rs77681598 ENSG00000261762.1 RP11-650L12.2 -4.73 3.21e-06 0.000992 -0.3 -0.25 Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern; chr15:78613761 chr15:78589123~78591276:- LIHC cis rs1555322 0.53 rs2425049 ENSG00000279253.1 RP4-614O4.13 -4.73 3.21e-06 0.000992 -0.32 -0.25 Attention deficit hyperactivity disorder; chr20:35286917 chr20:35262727~35264187:- LIHC cis rs11098499 0.955 rs1511018 ENSG00000245958.5 RP11-33B1.1 -4.73 3.21e-06 0.000992 -0.27 -0.25 Corneal astigmatism; chr4:119240425 chr4:119454791~119552025:+ LIHC cis rs7412746 0.611 rs11204748 ENSG00000231073.1 RP11-316M1.3 4.73 3.22e-06 0.000992 0.24 0.25 Melanoma; chr1:150954893 chr1:150973123~150975534:+ LIHC cis rs1062177 1 rs2964585 ENSG00000253921.1 CTB-113P19.3 -4.73 3.22e-06 0.000993 -0.29 -0.25 Preschool internalizing problems; chr5:151762334 chr5:151753992~151767247:+ LIHC cis rs1062177 1 rs2964578 ENSG00000253921.1 CTB-113P19.3 -4.73 3.22e-06 0.000993 -0.29 -0.25 Preschool internalizing problems; chr5:151767637 chr5:151753992~151767247:+ LIHC cis rs11098499 0.954 rs11098526 ENSG00000260091.1 RP11-33B1.4 -4.73 3.22e-06 0.000993 -0.18 -0.25 Corneal astigmatism; chr4:119469204 chr4:119409333~119410233:+ LIHC cis rs9834975 0.935 rs6788318 ENSG00000272758.4 RP11-299J3.8 -4.73 3.22e-06 0.000994 -0.28 -0.25 Diastolic blood pressure; chr3:122387672 chr3:122416207~122443180:+ LIHC cis rs2565722 0.609 rs9365227 ENSG00000243831.1 RP1-81D8.4 4.73 3.22e-06 0.000995 0.35 0.25 Blood protein levels; chr6:160876893 chr6:160666228~160676523:- LIHC cis rs2565722 0.665 rs9347466 ENSG00000243831.1 RP1-81D8.4 4.73 3.22e-06 0.000995 0.35 0.25 Blood protein levels; chr6:160876894 chr6:160666228~160676523:- LIHC cis rs17301013 0.803 rs2187562 ENSG00000227373.4 RP11-160H22.5 4.73 3.23e-06 0.000995 0.29 0.25 Systemic lupus erythematosus; chr1:174842513 chr1:174115300~174160004:- LIHC cis rs1558001 0.87 rs10233468 ENSG00000230196.1 DDX43P3 4.73 3.23e-06 0.000996 0.26 0.25 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81788605 chr7:81610884~81611326:- LIHC cis rs2337406 0.706 rs74090742 ENSG00000274576.2 IGHV2-70 -4.73 3.23e-06 0.000996 -0.28 -0.25 Alzheimer's disease (late onset); chr14:106696601 chr14:106770577~106771020:- LIHC cis rs2337406 1 rs61268362 ENSG00000274576.2 IGHV2-70 -4.73 3.23e-06 0.000996 -0.28 -0.25 Alzheimer's disease (late onset); chr14:106697010 chr14:106770577~106771020:- LIHC cis rs2337406 0.85 rs8014460 ENSG00000274576.2 IGHV2-70 -4.73 3.23e-06 0.000996 -0.28 -0.25 Alzheimer's disease (late onset); chr14:106697140 chr14:106770577~106771020:- LIHC cis rs7714584 1 rs10065172 ENSG00000197083.10 ZNF300P1 4.73 3.23e-06 0.000996 0.38 0.25 Crohn's disease; chr5:150848436 chr5:150930645~150946289:- LIHC cis rs2836974 0.897 rs8132568 ENSG00000255568.3 BRWD1-AS2 4.73 3.23e-06 0.000996 0.28 0.25 Cognitive function; chr21:39155990 chr21:39313935~39314962:+ LIHC cis rs9843304 0.585 rs9847009 ENSG00000244503.1 RP11-278L15.6 -4.73 3.23e-06 0.000996 -0.3 -0.25 Gallstone disease; chr3:149490380 chr3:149494660~149495995:+ LIHC cis rs7208859 0.673 rs1347359 ENSG00000266490.1 CTD-2349P21.9 4.73 3.24e-06 0.000998 0.29 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587511 chr17:30792372~30792833:+ LIHC cis rs1865760 0.927 rs6915834 ENSG00000216436.2 HIST1H2APS1 -4.73 3.24e-06 0.000998 -0.28 -0.25 Height; chr6:25935199 chr6:25732497~25732827:+ LIHC cis rs1865760 0.892 rs2328903 ENSG00000216436.2 HIST1H2APS1 -4.73 3.24e-06 0.000998 -0.28 -0.25 Height; chr6:25935537 chr6:25732497~25732827:+ LIHC cis rs1865760 0.892 rs6456705 ENSG00000216436.2 HIST1H2APS1 -4.73 3.24e-06 0.000998 -0.28 -0.25 Height; chr6:25935828 chr6:25732497~25732827:+ LIHC cis rs1865760 0.929 rs9358896 ENSG00000216436.2 HIST1H2APS1 -4.73 3.24e-06 0.000999 -0.28 -0.25 Height; chr6:25942969 chr6:25732497~25732827:+ LIHC cis rs12478296 0.681 rs55802421 ENSG00000261186.2 RP11-341N2.1 -4.73 3.24e-06 0.000999 -0.35 -0.25 Obesity-related traits; chr2:242091811 chr2:242087351~242088457:- LIHC cis rs12478296 0.681 rs56357900 ENSG00000261186.2 RP11-341N2.1 -4.73 3.24e-06 0.000999 -0.35 -0.25 Obesity-related traits; chr2:242091815 chr2:242087351~242088457:- LIHC cis rs10829156 0.66 rs11014830 ENSG00000225527.1 RP11-383B4.4 -4.73 3.24e-06 0.000999 -0.39 -0.25 Sudden cardiac arrest; chr10:18551504 chr10:18531849~18533336:- LIHC cis rs10829156 0.66 rs10828901 ENSG00000225527.1 RP11-383B4.4 -4.73 3.24e-06 0.000999 -0.39 -0.25 Sudden cardiac arrest; chr10:18552161 chr10:18531849~18533336:- LIHC cis rs4845875 0.514 rs198406 ENSG00000242349.4 NPPA-AS1 -4.73 3.24e-06 0.001 -0.26 -0.25 Midregional pro atrial natriuretic peptide levels; chr1:11837535 chr1:11841017~11848079:+ LIHC cis rs4845875 0.535 rs198408 ENSG00000242349.4 NPPA-AS1 -4.73 3.24e-06 0.001 -0.26 -0.25 Midregional pro atrial natriuretic peptide levels; chr1:11838073 chr1:11841017~11848079:+ LIHC cis rs17301013 0.932 rs332771 ENSG00000227373.4 RP11-160H22.5 4.73 3.24e-06 0.001 0.3 0.25 Systemic lupus erythematosus; chr1:174704141 chr1:174115300~174160004:- LIHC cis rs17301013 0.861 rs332789 ENSG00000227373.4 RP11-160H22.5 4.73 3.24e-06 0.001 0.3 0.25 Systemic lupus erythematosus; chr1:174735754 chr1:174115300~174160004:- LIHC cis rs17301013 0.932 rs461910 ENSG00000227373.4 RP11-160H22.5 4.73 3.24e-06 0.001 0.3 0.25 Systemic lupus erythematosus; chr1:174736351 chr1:174115300~174160004:- LIHC cis rs6723226 0.75 rs3769597 ENSG00000276334.1 AL133243.1 4.73 3.25e-06 0.001 0.27 0.25 Intelligence (multi-trait analysis); chr2:32466332 chr2:32521927~32523547:+ LIHC cis rs11064837 0.504 rs34500179 ENSG00000248636.5 RP11-768F21.1 4.73 3.25e-06 0.001 0.4 0.25 Schizophrenia; chr12:119631047 chr12:119387987~119668079:- LIHC cis rs4713118 0.662 rs149948 ENSG00000219392.1 RP1-265C24.5 -4.73 3.25e-06 0.001 -0.36 -0.25 Parkinson's disease; chr6:28007039 chr6:28115628~28116551:+ LIHC cis rs11673344 0.832 rs56080874 ENSG00000226686.6 LINC01535 4.73 3.25e-06 0.001 0.38 0.25 Obesity-related traits; chr19:37085487 chr19:37251912~37265535:+ LIHC cis rs899997 1 rs11634628 ENSG00000261143.1 ADAMTS7P3 4.73 3.25e-06 0.001 0.3 0.25 Coronary artery disease or large artery stroke; chr15:78713237 chr15:77976042~77993057:+ LIHC cis rs17711722 0.528 rs73138179 ENSG00000236529.1 RP13-254B10.1 4.73 3.25e-06 0.001 0.23 0.25 Calcium levels; chr7:65829495 chr7:65840212~65840596:+ LIHC cis rs7662987 0.793 rs7684735 ENSG00000272777.1 RP11-571L19.8 4.73 3.25e-06 0.001 0.54 0.25 Smoking initiation; chr4:99070355 chr4:99067256~99068125:- LIHC cis rs2836974 0.836 rs8129355 ENSG00000255568.3 BRWD1-AS2 4.73 3.26e-06 0.001 0.28 0.25 Cognitive function; chr21:39207943 chr21:39313935~39314962:+ LIHC cis rs2836974 0.899 rs34978594 ENSG00000255568.3 BRWD1-AS2 4.73 3.26e-06 0.001 0.28 0.25 Cognitive function; chr21:39208077 chr21:39313935~39314962:+ LIHC cis rs3733585 0.806 rs7375599 ENSG00000250413.1 RP11-448G15.1 -4.73 3.26e-06 0.001 -0.32 -0.25 Cleft plate (environmental tobacco smoke interaction); chr4:9953294 chr4:10006482~10009725:+ LIHC cis rs6951245 0.529 rs10262070 ENSG00000229043.2 AC091729.9 -4.73 3.26e-06 0.001 -0.45 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1102102 chr7:1160374~1165267:+ LIHC cis rs2749097 0.825 rs11208261 ENSG00000244256.3 RN7SL130P -4.73 3.26e-06 0.001 -0.29 -0.25 Alcohol consumption (transferrin glycosylation); chr1:63658331 chr1:63655743~63656047:+ LIHC cis rs9525916 1 rs9525916 ENSG00000230731.2 RP11-478K15.6 4.73 3.26e-06 0.001 0.27 0.25 Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction); chr13:44128733 chr13:44234118~44243192:- LIHC cis rs1499614 0.803 rs1796229 ENSG00000230295.1 RP11-458F8.2 -4.73 3.26e-06 0.001 -0.26 -0.25 Gout; chr7:66654674 chr7:66880708~66882981:+ LIHC cis rs1499614 0.901 rs3936 ENSG00000230295.1 RP11-458F8.2 -4.73 3.26e-06 0.001 -0.26 -0.25 Gout; chr7:66661502 chr7:66880708~66882981:+ LIHC cis rs7208859 0.562 rs8078897 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779239 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9914499 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780570 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs12006 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783634 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs3752021 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784025 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs55938328 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30789992 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs55961983 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792268 chr17:30792372~30792833:+ LIHC cis rs17826219 0.568 rs7213925 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Body mass index; chr17:30794616 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11658945 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795491 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11650982 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30802937 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9915546 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805126 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9895815 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811015 chr17:30792372~30792833:+ LIHC cis rs17826219 0.706 rs73271850 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Body mass index; chr17:30815122 chr17:30792372~30792833:+ LIHC cis rs17826219 0.636 rs79565452 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Body mass index; chr17:30815823 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs7208088 ENSG00000266490.1 CTD-2349P21.9 4.73 3.26e-06 0.001 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816649 chr17:30792372~30792833:+ LIHC cis rs2836974 0.932 rs8128734 ENSG00000255568.3 BRWD1-AS2 4.73 3.27e-06 0.00101 0.28 0.25 Cognitive function; chr21:39197585 chr21:39313935~39314962:+ LIHC cis rs2274273 0.905 rs2147961 ENSG00000258413.1 RP11-665C16.6 -4.73 3.27e-06 0.00101 -0.27 -0.25 Protein biomarker; chr14:55118663 chr14:55262767~55272075:- LIHC cis rs2842992 0.83 rs1998365 ENSG00000237927.1 RP3-393E18.2 -4.73 3.28e-06 0.00101 -0.3 -0.25 Age-related macular degeneration (geographic atrophy); chr6:159758503 chr6:159586955~159589169:- LIHC cis rs172166 0.61 rs276369 ENSG00000204709.4 LINC01556 4.73 3.28e-06 0.00101 0.27 0.25 Cardiac Troponin-T levels; chr6:27951465 chr6:28943877~28944537:+ LIHC cis rs67311347 1 rs9865348 ENSG00000223797.4 ENTPD3-AS1 4.73 3.28e-06 0.00101 0.2 0.25 Renal cell carcinoma; chr3:40356167 chr3:40313802~40453329:- LIHC cis rs7209700 0.708 rs2292699 ENSG00000228782.6 CTD-2026D20.3 4.73 3.28e-06 0.00101 0.28 0.25 IgG glycosylation; chr17:47284929 chr17:47450568~47492492:- LIHC cis rs765787 0.53 rs12915027 ENSG00000259520.4 CTD-2651B20.3 -4.73 3.28e-06 0.00101 -0.29 -0.25 Uric acid levels; chr15:45220428 chr15:45251580~45279251:- LIHC cis rs7208859 0.623 rs7220289 ENSG00000266490.1 CTD-2349P21.9 4.73 3.28e-06 0.00101 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30776744 chr17:30792372~30792833:+ LIHC cis rs9487094 0.961 rs9480957 ENSG00000260273.1 RP11-425D10.10 4.73 3.29e-06 0.00101 0.32 0.25 Height; chr6:109430398 chr6:109382795~109383666:+ LIHC cis rs8031584 1 rs11638409 ENSG00000270015.1 RP11-540B6.6 -4.73 3.29e-06 0.00101 -0.32 -0.25 Huntington's disease progression; chr15:30995987 chr15:30926514~30928407:+ LIHC cis rs8031584 1 rs11634216 ENSG00000270015.1 RP11-540B6.6 -4.73 3.29e-06 0.00101 -0.32 -0.25 Huntington's disease progression; chr15:30996467 chr15:30926514~30928407:+ LIHC cis rs11098499 0.909 rs10017335 ENSG00000260091.1 RP11-33B1.4 4.73 3.29e-06 0.00101 0.18 0.25 Corneal astigmatism; chr4:119460368 chr4:119409333~119410233:+ LIHC cis rs367615 0.512 rs814153 ENSG00000249476.1 CTD-2587M2.1 4.73 3.29e-06 0.00101 0.29 0.25 Colorectal cancer (SNP x SNP interaction); chr5:109332128 chr5:109237120~109326369:- LIHC cis rs1005277 0.579 rs1614236 ENSG00000276805.1 RP11-291L22.6 4.73 3.29e-06 0.00101 0.3 0.25 Extrinsic epigenetic age acceleration; chr10:38214068 chr10:38451030~38451785:+ LIHC cis rs9903692 0.954 rs1860866 ENSG00000278765.1 RP5-890E16.5 -4.73 3.3e-06 0.00101 -0.33 -0.25 Pulse pressure; chr17:48123669 chr17:48066704~48067293:- LIHC cis rs950776 0.518 rs12591557 ENSG00000261762.1 RP11-650L12.2 4.73 3.3e-06 0.00101 0.33 0.25 Sudden cardiac arrest; chr15:78519390 chr15:78589123~78591276:- LIHC cis rs10129255 0.5 rs59939897 ENSG00000223648.3 IGHV3-64 4.73 3.3e-06 0.00101 0.18 0.25 Kawasaki disease; chr14:106783414 chr14:106643132~106658258:- LIHC cis rs643506 0.874 rs645411 ENSG00000254990.4 RP11-108O10.2 4.73 3.3e-06 0.00101 0.26 0.25 Breast cancer; chr11:111823766 chr11:111768668~111778350:- LIHC cis rs17270561 0.723 rs12192635 ENSG00000272810.1 U91328.22 -4.73 3.3e-06 0.00101 -0.32 -0.25 Iron status biomarkers; chr6:25880679 chr6:26013241~26013757:+ LIHC cis rs11096990 0.572 rs35040563 ENSG00000249685.1 RP11-360F5.3 4.73 3.3e-06 0.00101 0.3 0.25 Cognitive function; chr4:39154262 chr4:39133913~39135608:+ LIHC cis rs7119038 0.774 rs11217001 ENSG00000255239.1 AP002954.6 -4.73 3.3e-06 0.00102 -0.35 -0.25 Sjögren's syndrome; chr11:118736337 chr11:118688039~118690600:- LIHC cis rs765787 0.53 rs2899379 ENSG00000259520.4 CTD-2651B20.3 -4.73 3.3e-06 0.00102 -0.29 -0.25 Uric acid levels; chr15:45242601 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs12903149 ENSG00000259520.4 CTD-2651B20.3 -4.73 3.3e-06 0.00102 -0.29 -0.25 Uric acid levels; chr15:45246878 chr15:45251580~45279251:- LIHC cis rs10510102 0.872 rs12240306 ENSG00000226864.1 ATE1-AS1 4.73 3.3e-06 0.00102 0.42 0.25 Breast cancer; chr10:121963391 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs12240308 ENSG00000226864.1 ATE1-AS1 4.73 3.3e-06 0.00102 0.42 0.25 Breast cancer; chr10:121963407 chr10:121928312~121951965:+ LIHC cis rs4660214 0.724 rs2484751 ENSG00000182109.6 RP11-69E11.4 -4.73 3.31e-06 0.00102 -0.27 -0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39282867 chr1:39522280~39546187:- LIHC cis rs804280 0.509 rs12719915 ENSG00000255495.1 AC145124.2 -4.73 3.31e-06 0.00102 -0.3 -0.25 Myopia (pathological); chr8:11928746 chr8:12194467~12196280:+ LIHC cis rs8059260 0.542 rs16957948 ENSG00000274038.1 RP11-66H6.4 -4.73 3.31e-06 0.00102 -0.41 -0.25 Alcohol consumption over the past year; chr16:11034208 chr16:11056556~11057034:+ LIHC cis rs12554020 0.892 rs59483310 ENSG00000227603.1 RP11-165J3.6 4.73 3.31e-06 0.00102 0.34 0.25 Schizophrenia; chr9:93503318 chr9:93435332~93437121:- LIHC cis rs9500256 0.967 rs1012500 ENSG00000272541.1 XXbac-BPGBPG55C20.1 -4.73 3.31e-06 0.00102 -0.27 -0.25 Eosinophilic esophagitis (pediatric); chr6:57978391 chr6:57855891~57856468:- LIHC cis rs5756813 0.754 rs8136757 ENSG00000233360.4 Z83844.1 4.73 3.32e-06 0.00102 0.31 0.25 Optic cup area;Vertical cup-disc ratio; chr22:37789964 chr22:37641832~37658377:- LIHC cis rs5756813 0.754 rs8137848 ENSG00000233360.4 Z83844.1 4.73 3.32e-06 0.00102 0.31 0.25 Optic cup area;Vertical cup-disc ratio; chr22:37789987 chr22:37641832~37658377:- LIHC cis rs10829156 0.699 rs6482516 ENSG00000225527.1 RP11-383B4.4 -4.73 3.32e-06 0.00102 -0.38 -0.25 Sudden cardiac arrest; chr10:18550421 chr10:18531849~18533336:- LIHC cis rs875971 0.545 rs67397473 ENSG00000273142.1 RP11-458F8.4 4.73 3.33e-06 0.00102 0.24 0.25 Aortic root size; chr7:66168318 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs10950027 ENSG00000273142.1 RP11-458F8.4 4.73 3.33e-06 0.00102 0.24 0.25 Aortic root size; chr7:66169164 chr7:66902857~66906297:+ LIHC cis rs13315871 1 rs11706420 ENSG00000272182.1 RP11-802O23.3 -4.73 3.33e-06 0.00102 -0.57 -0.25 Cholesterol, total; chr3:58406684 chr3:58428255~58428815:+ LIHC cis rs899997 1 rs11629824 ENSG00000261143.1 ADAMTS7P3 4.73 3.33e-06 0.00102 0.3 0.25 Coronary artery disease or large artery stroke; chr15:78713182 chr15:77976042~77993057:+ LIHC cis rs5769707 0.967 rs763127 ENSG00000235111.1 RP1-29C18.8 -4.73 3.33e-06 0.00102 -0.28 -0.25 Monocyte percentage of white cells;Monocyte count; chr22:49612430 chr22:49612657~49615716:- LIHC cis rs4948102 0.551 rs4275190 ENSG00000226278.1 PSPHP1 -4.73 3.33e-06 0.00102 -0.28 -0.25 Plasma homocysteine levels (post-methionine load test); chr7:56036695 chr7:55764797~55773288:+ LIHC cis rs42490 0.903 rs218948 ENSG00000251136.7 RP11-37B2.1 -4.73 3.33e-06 0.00102 -0.22 -0.25 Leprosy; chr8:89705617 chr8:89609409~89757727:- LIHC cis rs752590 0.65 rs6751201 ENSG00000274877.1 RP11-65I12.1 4.73 3.33e-06 0.00102 0.33 0.25 Mucinous ovarian carcinoma; chr2:113195122 chr2:113237595~113240825:+ LIHC cis rs1865760 0.566 rs2032445 ENSG00000216436.2 HIST1H2APS1 -4.73 3.34e-06 0.00102 -0.29 -0.25 Height; chr6:26044584 chr6:25732497~25732827:+ LIHC cis rs4650994 0.525 rs4076563 ENSG00000273384.1 RP5-1098D14.1 4.73 3.34e-06 0.00103 0.31 0.25 HDL cholesterol;HDL cholesterol levels; chr1:178547766 chr1:178651706~178652282:+ LIHC cis rs10800713 0.954 rs6673474 ENSG00000260088.1 RP11-92G12.3 -4.73 3.34e-06 0.00103 -0.34 -0.25 Tandem gait; chr1:200594991 chr1:200669507~200694250:+ LIHC cis rs9457247 0.602 rs12209395 ENSG00000227598.1 RP1-167A14.2 -4.73 3.35e-06 0.00103 -0.27 -0.25 Crohn's disease; chr6:167050426 chr6:166969626~166999065:- LIHC cis rs62355901 0.545 rs57850701 ENSG00000271828.1 CTD-2310F14.1 4.73 3.35e-06 0.00103 0.47 0.25 Breast cancer; chr5:56728529 chr5:56927874~56929573:+ LIHC cis rs1865760 0.566 rs9358902 ENSG00000216436.2 HIST1H2APS1 -4.73 3.35e-06 0.00103 -0.29 -0.25 Height; chr6:26058342 chr6:25732497~25732827:+ LIHC cis rs603446 0.967 rs108533 ENSG00000254851.1 RP11-109L13.1 4.73 3.36e-06 0.00103 0.29 0.25 Triglycerides; chr11:116730995 chr11:117135528~117138582:+ LIHC cis rs11971779 0.68 rs6962637 ENSG00000273391.1 RP11-634H22.1 4.73 3.36e-06 0.00103 0.22 0.25 Diisocyanate-induced asthma; chr7:139366604 chr7:139359032~139359566:- LIHC cis rs9992667 0.955 rs73232876 ENSG00000231160.8 KLF3-AS1 4.73 3.36e-06 0.00103 0.34 0.25 Eosinophil percentage of granulocytes; chr4:38645888 chr4:38612701~38664883:- LIHC cis rs11098499 0.78 rs7692994 ENSG00000245958.5 RP11-33B1.1 -4.73 3.36e-06 0.00103 -0.25 -0.25 Corneal astigmatism; chr4:119506334 chr4:119454791~119552025:+ LIHC cis rs643506 0.874 rs614144 ENSG00000254990.4 RP11-108O10.2 4.72 3.37e-06 0.00103 0.26 0.25 Breast cancer; chr11:111797895 chr11:111768668~111778350:- LIHC cis rs228614 0.51 rs223435 ENSG00000246560.2 RP11-10L12.4 4.72 3.37e-06 0.00103 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799826 chr4:102828055~102844075:+ LIHC cis rs748404 0.697 rs572959 ENSG00000166763.7 STRCP1 4.72 3.37e-06 0.00103 0.3 0.25 Lung cancer; chr15:43258304 chr15:43699488~43718184:- LIHC cis rs748404 0.697 rs554001 ENSG00000166763.7 STRCP1 4.72 3.37e-06 0.00103 0.3 0.25 Lung cancer; chr15:43259721 chr15:43699488~43718184:- LIHC cis rs2836974 0.568 rs371625 ENSG00000255568.3 BRWD1-AS2 -4.72 3.37e-06 0.00103 -0.21 -0.25 Cognitive function; chr21:39163345 chr21:39313935~39314962:+ LIHC cis rs2836974 0.526 rs418359 ENSG00000255568.3 BRWD1-AS2 -4.72 3.37e-06 0.00103 -0.21 -0.25 Cognitive function; chr21:39164808 chr21:39313935~39314962:+ LIHC cis rs7923609 0.905 rs7092784 ENSG00000232075.1 MRPL35P2 -4.72 3.37e-06 0.00103 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63454989 chr10:63634317~63634827:- LIHC cis rs7662987 0.793 rs4699700 ENSG00000272777.1 RP11-571L19.8 4.72 3.37e-06 0.00103 0.56 0.25 Smoking initiation; chr4:99077184 chr4:99067256~99068125:- LIHC cis rs2274273 0.934 rs10144418 ENSG00000258413.1 RP11-665C16.6 -4.72 3.37e-06 0.00103 -0.3 -0.25 Protein biomarker; chr14:55350990 chr14:55262767~55272075:- LIHC cis rs11971779 0.68 rs2355787 ENSG00000273391.1 RP11-634H22.1 -4.72 3.37e-06 0.00103 -0.22 -0.25 Diisocyanate-induced asthma; chr7:139405182 chr7:139359032~139359566:- LIHC cis rs899997 1 rs9888691 ENSG00000261143.1 ADAMTS7P3 4.72 3.37e-06 0.00103 0.3 0.25 Coronary artery disease or large artery stroke; chr15:78717704 chr15:77976042~77993057:+ LIHC cis rs1577917 1 rs12200330 ENSG00000234155.1 RP11-30P6.6 4.72 3.37e-06 0.00103 0.33 0.25 Response to antipsychotic treatment; chr6:85946935 chr6:85387219~85390186:- LIHC cis rs7615952 0.546 rs11711150 ENSG00000171084.14 FAM86JP 4.72 3.37e-06 0.00103 0.44 0.25 Blood pressure (smoking interaction); chr3:125596819 chr3:125916620~125930024:+ LIHC cis rs2998286 0.723 rs332168 ENSG00000254635.4 WAC-AS1 -4.72 3.38e-06 0.00104 -0.3 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28607488 chr10:28522652~28532743:- LIHC cis rs9467711 0.651 rs1045537 ENSG00000216436.2 HIST1H2APS1 4.72 3.38e-06 0.00104 0.65 0.25 Autism spectrum disorder or schizophrenia; chr6:26096520 chr6:25732497~25732827:+ LIHC cis rs9467711 0.651 rs35402046 ENSG00000216436.2 HIST1H2APS1 4.72 3.38e-06 0.00104 0.65 0.25 Autism spectrum disorder or schizophrenia; chr6:26099244 chr6:25732497~25732827:+ LIHC cis rs9467711 0.651 rs66790453 ENSG00000216436.2 HIST1H2APS1 4.72 3.38e-06 0.00104 0.65 0.25 Autism spectrum disorder or schizophrenia; chr6:26106860 chr6:25732497~25732827:+ LIHC cis rs9467711 0.651 rs13197334 ENSG00000216436.2 HIST1H2APS1 4.72 3.38e-06 0.00104 0.65 0.25 Autism spectrum disorder or schizophrenia; chr6:26122420 chr6:25732497~25732827:+ LIHC cis rs9467711 0.651 rs16891334 ENSG00000216436.2 HIST1H2APS1 4.72 3.38e-06 0.00104 0.65 0.25 Autism spectrum disorder or schizophrenia; chr6:26124075 chr6:25732497~25732827:+ LIHC cis rs7829975 0.617 rs4841071 ENSG00000253893.2 FAM85B -4.72 3.38e-06 0.00104 -0.29 -0.25 Mood instability; chr8:8933634 chr8:8167819~8226614:- LIHC cis rs950169 0.58 rs11635597 ENSG00000259295.5 CSPG4P12 4.72 3.38e-06 0.00104 0.34 0.25 Schizophrenia; chr15:84622468 chr15:85191438~85213905:+ LIHC cis rs10829156 0.732 rs7075678 ENSG00000240291.1 RP11-499P20.2 4.72 3.38e-06 0.00104 0.39 0.25 Sudden cardiac arrest; chr10:18585174 chr10:18513115~18545651:- LIHC cis rs7829975 0.617 rs4841072 ENSG00000253893.2 FAM85B 4.72 3.38e-06 0.00104 0.29 0.25 Mood instability; chr8:8933743 chr8:8167819~8226614:- LIHC cis rs831571 0.668 rs17069879 ENSG00000280620.1 SCAANT1 -4.72 3.38e-06 0.00104 -0.36 -0.25 Type 2 diabetes; chr3:64097741 chr3:63911518~63911772:- LIHC cis rs11216126 1 rs11216129 ENSG00000254851.1 RP11-109L13.1 4.72 3.4e-06 0.00104 0.37 0.25 HDL cholesterol; chr11:116749540 chr11:117135528~117138582:+ LIHC cis rs2836974 0.897 rs11911112 ENSG00000255568.3 BRWD1-AS2 4.72 3.4e-06 0.00104 0.28 0.25 Cognitive function; chr21:39156420 chr21:39313935~39314962:+ LIHC cis rs2836974 0.831 rs11911149 ENSG00000255568.3 BRWD1-AS2 4.72 3.4e-06 0.00104 0.28 0.25 Cognitive function; chr21:39156449 chr21:39313935~39314962:+ LIHC cis rs875971 0.66 rs1860470 ENSG00000273024.4 INTS4P2 4.72 3.4e-06 0.00104 0.28 0.25 Aortic root size; chr7:66638707 chr7:65647864~65715661:+ LIHC cis rs7923609 0.967 rs7912893 ENSG00000232075.1 MRPL35P2 -4.72 3.4e-06 0.00104 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63402240 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs7896783 ENSG00000232075.1 MRPL35P2 -4.72 3.4e-06 0.00104 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63402393 chr10:63634317~63634827:- LIHC cis rs7923609 0.934 rs7923544 ENSG00000232075.1 MRPL35P2 -4.72 3.4e-06 0.00104 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63422496 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs10761762 ENSG00000232075.1 MRPL35P2 -4.72 3.4e-06 0.00104 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63424957 chr10:63634317~63634827:- LIHC cis rs7923609 0.934 rs10761763 ENSG00000232075.1 MRPL35P2 -4.72 3.4e-06 0.00104 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63428558 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs3740331 ENSG00000232075.1 MRPL35P2 -4.72 3.4e-06 0.00104 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63432528 chr10:63634317~63634827:- LIHC cis rs7208859 0.623 rs55811708 ENSG00000266490.1 CTD-2349P21.9 4.72 3.4e-06 0.00104 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777713 chr17:30792372~30792833:+ LIHC cis rs1577917 1 rs12208493 ENSG00000234155.1 RP11-30P6.6 4.72 3.4e-06 0.00104 0.33 0.25 Response to antipsychotic treatment; chr6:85952549 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs12213149 ENSG00000234155.1 RP11-30P6.6 4.72 3.4e-06 0.00104 0.33 0.25 Response to antipsychotic treatment; chr6:85958926 chr6:85387219~85390186:- LIHC cis rs11098499 1 rs11098500 ENSG00000245958.5 RP11-33B1.1 -4.72 3.41e-06 0.00104 -0.26 -0.25 Corneal astigmatism; chr4:119298084 chr4:119454791~119552025:+ LIHC cis rs2283792 0.905 rs5755694 ENSG00000224086.5 LL22NC03-86G7.1 -4.72 3.41e-06 0.00104 -0.23 -0.25 Multiple sclerosis; chr22:21846241 chr22:21938293~21977632:+ LIHC cis rs1577917 0.958 rs10944144 ENSG00000234155.1 RP11-30P6.6 4.72 3.41e-06 0.00105 0.33 0.25 Response to antipsychotic treatment; chr6:85828037 chr6:85387219~85390186:- LIHC cis rs4713118 0.662 rs149970 ENSG00000219392.1 RP1-265C24.5 -4.72 3.42e-06 0.00105 -0.35 -0.25 Parkinson's disease; chr6:28012442 chr6:28115628~28116551:+ LIHC cis rs8040855 0.627 rs12904238 ENSG00000259295.5 CSPG4P12 4.72 3.42e-06 0.00105 0.39 0.25 Bulimia nervosa; chr15:85096610 chr15:85191438~85213905:+ LIHC cis rs338389 0.542 rs6494709 ENSG00000260657.2 RP11-315D16.4 -4.72 3.42e-06 0.00105 -0.39 -0.25 Survival in rectal cancer; chr15:68001672 chr15:68267792~68277994:- LIHC cis rs643506 0.874 rs582465 ENSG00000254990.4 RP11-108O10.2 4.72 3.42e-06 0.00105 0.27 0.25 Breast cancer; chr11:111797861 chr11:111768668~111778350:- LIHC cis rs643506 0.874 rs613292 ENSG00000254990.4 RP11-108O10.2 4.72 3.42e-06 0.00105 0.27 0.25 Breast cancer; chr11:111798081 chr11:111768668~111778350:- LIHC cis rs683257 0.673 rs72990126 ENSG00000234147.1 RP3-460G2.2 -4.72 3.42e-06 0.00105 -0.4 -0.25 Facial emotion recognition (angry faces); chr6:140850534 chr6:140845958~140852924:- LIHC cis rs2439831 0.85 rs3816792 ENSG00000275601.1 AC011330.13 4.72 3.42e-06 0.00105 0.34 0.25 Lung cancer in ever smokers; chr15:43824788 chr15:43642389~43643023:- LIHC cis rs11673344 0.77 rs7257135 ENSG00000226686.6 LINC01535 4.72 3.42e-06 0.00105 0.38 0.25 Obesity-related traits; chr19:37088726 chr19:37251912~37265535:+ LIHC cis rs2337406 0.789 rs9324095 ENSG00000274576.2 IGHV2-70 -4.72 3.42e-06 0.00105 -0.26 -0.25 Alzheimer's disease (late onset); chr14:106795885 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs58154560 ENSG00000274576.2 IGHV2-70 -4.72 3.42e-06 0.00105 -0.26 -0.25 Alzheimer's disease (late onset); chr14:106799601 chr14:106770577~106771020:- LIHC cis rs7923609 0.967 rs3956912 ENSG00000232075.1 MRPL35P2 -4.72 3.43e-06 0.00105 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63446121 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs10509186 ENSG00000232075.1 MRPL35P2 -4.72 3.43e-06 0.00105 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63447258 chr10:63634317~63634827:- LIHC cis rs67311347 0.824 rs73073561 ENSG00000223797.4 ENTPD3-AS1 4.72 3.43e-06 0.00105 0.21 0.25 Renal cell carcinoma; chr3:40315807 chr3:40313802~40453329:- LIHC cis rs7923609 0.967 rs3999089 ENSG00000232075.1 MRPL35P2 4.72 3.43e-06 0.00105 0.28 0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63444048 chr10:63634317~63634827:- LIHC cis rs831571 0.695 rs73120926 ENSG00000280620.1 SCAANT1 4.72 3.43e-06 0.00105 0.36 0.25 Type 2 diabetes; chr3:64051274 chr3:63911518~63911772:- LIHC cis rs228614 0.509 rs223476 ENSG00000246560.2 RP11-10L12.4 4.72 3.44e-06 0.00105 0.27 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771000 chr4:102828055~102844075:+ LIHC cis rs228614 0.509 rs150896 ENSG00000246560.2 RP11-10L12.4 4.72 3.44e-06 0.00105 0.27 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771186 chr4:102828055~102844075:+ LIHC cis rs11098499 0.909 rs9759478 ENSG00000260091.1 RP11-33B1.4 -4.72 3.44e-06 0.00105 -0.18 -0.25 Corneal astigmatism; chr4:119446843 chr4:119409333~119410233:+ LIHC cis rs6085948 0.953 rs6077166 ENSG00000228888.1 LINC01428 4.72 3.44e-06 0.00105 0.33 0.25 Interleukin-10 levels; chr20:7252921 chr20:7146467~7254202:- LIHC cis rs11722779 0.787 rs6533040 ENSG00000230069.3 LRRC37A15P -4.72 3.44e-06 0.00105 -0.22 -0.25 Schizophrenia; chr4:102951421 chr4:102727274~102730721:- LIHC cis rs11722779 0.903 rs6830193 ENSG00000230069.3 LRRC37A15P -4.72 3.44e-06 0.00105 -0.22 -0.25 Schizophrenia; chr4:102955457 chr4:102727274~102730721:- LIHC cis rs875971 0.545 rs316324 ENSG00000273142.1 RP11-458F8.4 -4.72 3.45e-06 0.00105 -0.24 -0.25 Aortic root size; chr7:66145627 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs316323 ENSG00000273142.1 RP11-458F8.4 -4.72 3.45e-06 0.00105 -0.24 -0.25 Aortic root size; chr7:66146002 chr7:66902857~66906297:+ LIHC cis rs1865760 0.713 rs6928951 ENSG00000216436.2 HIST1H2APS1 -4.72 3.45e-06 0.00105 -0.28 -0.25 Height; chr6:25995326 chr6:25732497~25732827:+ LIHC cis rs11089937 0.626 rs5757017 ENSG00000211639.2 IGLV4-60 4.72 3.45e-06 0.00105 0.21 0.25 Periodontitis (PAL4Q3); chr22:22135947 chr22:22162199~22162681:+ LIHC cis rs3096299 0.754 rs3102382 ENSG00000274627.1 RP11-104N10.2 4.72 3.45e-06 0.00105 0.25 0.25 Multiple myeloma (IgH translocation); chr16:89343334 chr16:89516797~89522217:+ LIHC cis rs11722779 0.844 rs10003326 ENSG00000230069.3 LRRC37A15P -4.72 3.45e-06 0.00106 -0.22 -0.25 Schizophrenia; chr4:102948193 chr4:102727274~102730721:- LIHC cis rs11722779 0.935 rs3974481 ENSG00000246560.2 RP11-10L12.4 4.72 3.45e-06 0.00106 0.28 0.25 Schizophrenia; chr4:102956834 chr4:102828055~102844075:+ LIHC cis rs7923609 0.967 rs10761752 ENSG00000232075.1 MRPL35P2 -4.72 3.45e-06 0.00106 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63400561 chr10:63634317~63634827:- LIHC cis rs1005277 0.579 rs1780116 ENSG00000276805.1 RP11-291L22.6 4.72 3.46e-06 0.00106 0.3 0.25 Extrinsic epigenetic age acceleration; chr10:38237693 chr10:38451030~38451785:+ LIHC cis rs11096990 0.656 rs9993224 ENSG00000249685.1 RP11-360F5.3 -4.72 3.46e-06 0.00106 -0.29 -0.25 Cognitive function; chr4:39298578 chr4:39133913~39135608:+ LIHC cis rs7208859 0.524 rs8065744 ENSG00000266490.1 CTD-2349P21.9 4.72 3.46e-06 0.00106 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30772431 chr17:30792372~30792833:+ LIHC cis rs17826219 0.706 rs8071236 ENSG00000266490.1 CTD-2349P21.9 4.72 3.46e-06 0.00106 0.31 0.25 Body mass index; chr17:30772984 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs56163556 ENSG00000266490.1 CTD-2349P21.9 4.72 3.46e-06 0.00106 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774850 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs73269923 ENSG00000266490.1 CTD-2349P21.9 4.72 3.46e-06 0.00106 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775553 chr17:30792372~30792833:+ LIHC cis rs7208859 0.573 rs8064686 ENSG00000266490.1 CTD-2349P21.9 4.72 3.46e-06 0.00106 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30807821 chr17:30792372~30792833:+ LIHC cis rs9532669 0.963 rs4941391 ENSG00000176268.5 CYCSP34 4.72 3.46e-06 0.00106 0.29 0.25 Cervical cancer; chr13:40939787 chr13:40863599~40863902:- LIHC cis rs2735413 0.75 rs60659587 ENSG00000276007.1 RP11-358L22.3 4.72 3.47e-06 0.00106 0.33 0.25 Systolic blood pressure (alcohol consumption interaction); chr16:78037657 chr16:78123243~78124332:+ LIHC cis rs875971 0.505 rs1167386 ENSG00000164669.11 INTS4P1 4.72 3.47e-06 0.00106 0.35 0.25 Aortic root size; chr7:66048109 chr7:65141225~65234216:+ LIHC cis rs875971 0.505 rs1167385 ENSG00000164669.11 INTS4P1 4.72 3.47e-06 0.00106 0.35 0.25 Aortic root size; chr7:66048321 chr7:65141225~65234216:+ LIHC cis rs4964805 0.594 rs10861096 ENSG00000257681.1 RP11-341G23.4 4.72 3.47e-06 0.00106 0.25 0.25 Attention deficit hyperactivity disorder; chr12:103775578 chr12:103746315~103768858:- LIHC cis rs6480314 0.542 rs7079054 ENSG00000233590.1 RP11-153K11.3 -4.72 3.47e-06 0.00106 -0.38 -0.25 Optic nerve measurement (disc area); chr10:68266404 chr10:68233251~68242379:- LIHC cis rs929596 0.517 rs3806592 ENSG00000233445.1 RPL17P11 4.72 3.47e-06 0.00106 0.29 0.25 Total bilirubin levels in HIV-1 infection; chr2:233717290 chr2:233721522~233722065:- LIHC cis rs2060793 0.519 rs7931291 ENSG00000251991.1 RNU7-49P -4.72 3.47e-06 0.00106 -0.27 -0.25 Vitamin D levels; chr11:14622880 chr11:14478892~14478953:+ LIHC cis rs2749592 0.531 rs1208559 ENSG00000275858.1 RP11-291L22.8 -4.72 3.47e-06 0.00106 -0.27 -0.25 Age-related hearing impairment (SNP x SNP interaction); chr10:37932442 chr10:38450738~38451069:- LIHC cis rs893363 0.559 rs893365 ENSG00000271916.1 RP11-884K10.6 -4.72 3.47e-06 0.00106 -0.3 -0.25 Axial length; chr3:53807119 chr3:53797764~53798019:- LIHC cis rs12908161 0.959 rs11637728 ENSG00000225151.9 GOLGA2P7 -4.72 3.47e-06 0.00106 -0.31 -0.25 Schizophrenia; chr15:84660161 chr15:84199311~84230136:- LIHC cis rs881375 0.715 rs11794516 ENSG00000226752.6 PSMD5-AS1 -4.72 3.48e-06 0.00106 -0.25 -0.25 Rheumatoid arthritis; chr9:120877952 chr9:120824828~120854385:+ LIHC cis rs950169 0.887 rs220333 ENSG00000259728.4 LINC00933 4.72 3.48e-06 0.00106 0.36 0.25 Schizophrenia; chr15:84547902 chr15:84570649~84580175:+ LIHC cis rs10829156 0.66 rs7918933 ENSG00000225527.1 RP11-383B4.4 -4.72 3.48e-06 0.00106 -0.39 -0.25 Sudden cardiac arrest; chr10:18517434 chr10:18531849~18533336:- LIHC cis rs11971779 0.793 rs4732366 ENSG00000273391.1 RP11-634H22.1 4.72 3.48e-06 0.00106 0.23 0.25 Diisocyanate-induced asthma; chr7:139343099 chr7:139359032~139359566:- LIHC cis rs755249 0.501 rs2455648 ENSG00000182109.6 RP11-69E11.4 4.72 3.48e-06 0.00106 0.27 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39178040 chr1:39522280~39546187:- LIHC cis rs75920871 0.589 rs2075547 ENSG00000254851.1 RP11-109L13.1 -4.72 3.49e-06 0.00106 -0.49 -0.25 Subjective well-being; chr11:117197818 chr11:117135528~117138582:+ LIHC cis rs67311347 1 rs9822644 ENSG00000223797.4 ENTPD3-AS1 4.72 3.49e-06 0.00107 0.2 0.25 Renal cell carcinoma; chr3:40385118 chr3:40313802~40453329:- LIHC cis rs5758511 0.633 rs5758689 ENSG00000205702.9 CYP2D7 4.72 3.49e-06 0.00107 0.29 0.25 Birth weight; chr22:42268966 chr22:42140203~42144577:- LIHC cis rs3091242 0.933 rs10903129 ENSG00000224183.1 SDHDP6 -4.72 3.49e-06 0.00107 -0.28 -0.25 Erythrocyte sedimentation rate; chr1:25442446 chr1:25294164~25294643:- LIHC cis rs9595908 0.9 rs7981943 ENSG00000212293.1 SNORA16 4.72 3.5e-06 0.00107 0.28 0.25 Body mass index; chr13:32593754 chr13:32420390~32420516:- LIHC cis rs9595908 0.9 rs7327429 ENSG00000212293.1 SNORA16 4.72 3.5e-06 0.00107 0.28 0.25 Body mass index; chr13:32595259 chr13:32420390~32420516:- LIHC cis rs17711722 0.528 rs73138179 ENSG00000226824.5 RP4-756H11.3 -4.72 3.5e-06 0.00107 -0.29 -0.25 Calcium levels; chr7:65829495 chr7:66654538~66669855:+ LIHC cis rs7208859 0.623 rs3752019 ENSG00000266490.1 CTD-2349P21.9 4.72 3.5e-06 0.00107 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824687 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs73271869 ENSG00000266490.1 CTD-2349P21.9 4.72 3.5e-06 0.00107 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30825203 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs73271872 ENSG00000266490.1 CTD-2349P21.9 4.72 3.5e-06 0.00107 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30825210 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs56146117 ENSG00000266490.1 CTD-2349P21.9 4.72 3.5e-06 0.00107 0.32 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30826307 chr17:30792372~30792833:+ LIHC cis rs17826219 0.568 rs9907834 ENSG00000266490.1 CTD-2349P21.9 4.72 3.5e-06 0.00107 0.32 0.25 Body mass index; chr17:30826995 chr17:30792372~30792833:+ LIHC cis rs1061377 0.71 rs12503506 ENSG00000249685.1 RP11-360F5.3 4.72 3.5e-06 0.00107 0.3 0.25 Uric acid levels; chr4:39082553 chr4:39133913~39135608:+ LIHC cis rs11089937 1 rs11089937 ENSG00000211639.2 IGLV4-60 4.72 3.51e-06 0.00107 0.22 0.25 Periodontitis (PAL4Q3); chr22:22152176 chr22:22162199~22162681:+ LIHC cis rs9992667 0.955 rs73232881 ENSG00000231160.8 KLF3-AS1 4.72 3.51e-06 0.00107 0.34 0.25 Eosinophil percentage of granulocytes; chr4:38662510 chr4:38612701~38664883:- LIHC cis rs2439831 0.85 rs28509275 ENSG00000166763.7 STRCP1 4.72 3.51e-06 0.00107 0.4 0.25 Lung cancer in ever smokers; chr15:43805907 chr15:43699488~43718184:- LIHC cis rs7923609 0.967 rs7085621 ENSG00000232075.1 MRPL35P2 -4.72 3.51e-06 0.00107 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63449166 chr10:63634317~63634827:- LIHC cis rs7923609 0.936 rs10740125 ENSG00000232075.1 MRPL35P2 -4.72 3.51e-06 0.00107 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63449849 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs10740126 ENSG00000232075.1 MRPL35P2 -4.72 3.51e-06 0.00107 -0.28 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63451175 chr10:63634317~63634827:- LIHC cis rs916888 0.697 rs199516 ENSG00000274883.1 Metazoa_SRP 4.72 3.51e-06 0.00107 0.38 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45931806~45932083:+ LIHC cis rs916888 0.821 rs199514 ENSG00000274883.1 Metazoa_SRP 4.72 3.51e-06 0.00107 0.38 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45931806~45932083:+ LIHC cis rs916888 0.821 rs199512 ENSG00000274883.1 Metazoa_SRP 4.72 3.51e-06 0.00107 0.38 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45931806~45932083:+ LIHC cis rs916888 0.821 rs199509 ENSG00000274883.1 Metazoa_SRP 4.72 3.51e-06 0.00107 0.38 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45931806~45932083:+ LIHC cis rs916888 0.821 rs199507 ENSG00000274883.1 Metazoa_SRP 4.72 3.51e-06 0.00107 0.38 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45931806~45932083:+ LIHC cis rs916888 0.821 rs415430 ENSG00000274883.1 Metazoa_SRP 4.72 3.51e-06 0.00107 0.38 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45931806~45932083:+ LIHC cis rs916888 0.779 rs430685 ENSG00000274883.1 Metazoa_SRP 4.72 3.51e-06 0.00107 0.38 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45931806~45932083:+ LIHC cis rs916888 0.821 rs199505 ENSG00000274883.1 Metazoa_SRP 4.72 3.51e-06 0.00107 0.38 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45931806~45932083:+ LIHC cis rs916888 0.821 rs70602 ENSG00000274883.1 Metazoa_SRP 4.72 3.51e-06 0.00107 0.38 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45931806~45932083:+ LIHC cis rs2877649 0.51 rs17103735 ENSG00000258744.1 RP11-80A15.1 -4.72 3.51e-06 0.00107 -0.47 -0.25 Smooth-surface caries; chr14:24436961 chr14:24501594~24508688:+ LIHC cis rs5769765 0.704 rs138837 ENSG00000278869.1 CITF22-49E9.3 4.72 3.51e-06 0.00107 0.37 0.25 Schizophrenia; chr22:49787066 chr22:49933198~49934074:- LIHC cis rs9467711 0.591 rs56195001 ENSG00000216436.2 HIST1H2APS1 4.72 3.52e-06 0.00107 0.63 0.25 Autism spectrum disorder or schizophrenia; chr6:25975937 chr6:25732497~25732827:+ LIHC cis rs7412746 0.646 rs10399947 ENSG00000231073.1 RP11-316M1.3 4.72 3.52e-06 0.00107 0.24 0.25 Melanoma; chr1:150889484 chr1:150973123~150975534:+ LIHC cis rs12554020 0.786 rs79469056 ENSG00000227603.1 RP11-165J3.6 4.72 3.52e-06 0.00107 0.42 0.25 Schizophrenia; chr9:93453807 chr9:93435332~93437121:- LIHC cis rs12554020 0.786 rs12554164 ENSG00000227603.1 RP11-165J3.6 4.72 3.52e-06 0.00107 0.42 0.25 Schizophrenia; chr9:93456677 chr9:93435332~93437121:- LIHC cis rs12554020 0.786 rs16909158 ENSG00000227603.1 RP11-165J3.6 4.72 3.52e-06 0.00107 0.42 0.25 Schizophrenia; chr9:93457882 chr9:93435332~93437121:- LIHC cis rs11098499 0.754 rs10518300 ENSG00000260091.1 RP11-33B1.4 4.72 3.52e-06 0.00107 0.18 0.25 Corneal astigmatism; chr4:119328344 chr4:119409333~119410233:+ LIHC cis rs1729407 0.786 rs5096 ENSG00000236267.1 AP006216.5 4.72 3.52e-06 0.00107 0.23 0.25 Apolipoprotein A-IV levels; chr11:116822379 chr11:116813204~116814003:- LIHC cis rs2060793 0.741 rs2060794 ENSG00000251991.1 RNU7-49P 4.72 3.52e-06 0.00107 0.28 0.25 Vitamin D levels; chr11:14791437 chr11:14478892~14478953:+ LIHC cis rs2060793 0.741 rs3740823 ENSG00000251991.1 RNU7-49P 4.72 3.52e-06 0.00107 0.28 0.25 Vitamin D levels; chr11:14804158 chr11:14478892~14478953:+ LIHC cis rs9788721 0.592 rs28564957 ENSG00000261762.1 RP11-650L12.2 -4.72 3.52e-06 0.00107 -0.3 -0.25 Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern; chr15:78613765 chr15:78589123~78591276:- LIHC cis rs11722779 0.873 rs223344 ENSG00000246560.2 RP11-10L12.4 4.72 3.52e-06 0.00108 0.28 0.25 Schizophrenia; chr4:102859765 chr4:102828055~102844075:+ LIHC cis rs11722779 0.775 rs223341 ENSG00000246560.2 RP11-10L12.4 4.72 3.52e-06 0.00108 0.28 0.25 Schizophrenia; chr4:102862343 chr4:102828055~102844075:+ LIHC cis rs11722779 0.844 rs223345 ENSG00000246560.2 RP11-10L12.4 4.71 3.53e-06 0.00108 0.28 0.25 Schizophrenia; chr4:102859366 chr4:102828055~102844075:+ LIHC cis rs198389 0.617 rs503040 ENSG00000242349.4 NPPA-AS1 -4.71 3.53e-06 0.00108 -0.25 -0.25 B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome; chr1:11830638 chr1:11841017~11848079:+ LIHC cis rs17301013 0.73 rs12060177 ENSG00000227373.4 RP11-160H22.5 4.71 3.54e-06 0.00108 0.3 0.25 Systemic lupus erythematosus; chr1:174618545 chr1:174115300~174160004:- LIHC cis rs11096990 0.634 rs12648793 ENSG00000249685.1 RP11-360F5.3 -4.71 3.54e-06 0.00108 -0.29 -0.25 Cognitive function; chr4:39284473 chr4:39133913~39135608:+ LIHC cis rs9834975 0.967 rs6438737 ENSG00000272758.4 RP11-299J3.8 4.71 3.54e-06 0.00108 0.27 0.25 Diastolic blood pressure; chr3:122510127 chr3:122416207~122443180:+ LIHC cis rs603446 0.901 rs180344 ENSG00000254851.1 RP11-109L13.1 -4.71 3.54e-06 0.00108 -0.31 -0.25 Triglycerides; chr11:116742468 chr11:117135528~117138582:+ LIHC cis rs5758511 0.68 rs739146 ENSG00000205702.9 CYP2D7 4.71 3.54e-06 0.00108 0.29 0.25 Birth weight; chr22:42264408 chr22:42140203~42144577:- LIHC cis rs11098499 0.779 rs6815934 ENSG00000245958.5 RP11-33B1.1 -4.71 3.55e-06 0.00108 -0.24 -0.25 Corneal astigmatism; chr4:119346155 chr4:119454791~119552025:+ LIHC cis rs11098499 0.955 rs35434465 ENSG00000245958.5 RP11-33B1.1 -4.71 3.55e-06 0.00108 -0.27 -0.25 Corneal astigmatism; chr4:119248223 chr4:119454791~119552025:+ LIHC cis rs367615 0.552 rs7720036 ENSG00000249476.1 CTD-2587M2.1 -4.71 3.55e-06 0.00108 -0.29 -0.25 Colorectal cancer (SNP x SNP interaction); chr5:109374998 chr5:109237120~109326369:- LIHC cis rs11098499 0.604 rs12642411 ENSG00000245958.5 RP11-33B1.1 -4.71 3.55e-06 0.00108 -0.26 -0.25 Corneal astigmatism; chr4:119659370 chr4:119454791~119552025:+ LIHC cis rs7587476 0.784 rs17424051 ENSG00000229267.2 AC072062.1 -4.71 3.55e-06 0.00108 -0.31 -0.25 Neuroblastoma; chr2:214824268 chr2:214810229~214963274:+ LIHC cis rs228614 0.51 rs223400 ENSG00000246560.2 RP11-10L12.4 4.71 3.56e-06 0.00108 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102820439 chr4:102828055~102844075:+ LIHC cis rs1558001 0.799 rs765499 ENSG00000230196.1 DDX43P3 4.71 3.56e-06 0.00108 0.26 0.25 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81791012 chr7:81610884~81611326:- LIHC cis rs7412746 0.586 rs2864882 ENSG00000231073.1 RP11-316M1.3 4.71 3.56e-06 0.00108 0.24 0.25 Melanoma; chr1:150910561 chr1:150973123~150975534:+ LIHC cis rs643506 0.874 rs640651 ENSG00000254990.4 RP11-108O10.2 4.71 3.56e-06 0.00108 0.26 0.25 Breast cancer; chr11:111858188 chr11:111768668~111778350:- LIHC cis rs12134133 1 rs7522618 ENSG00000274245.1 RP11-357P18.2 4.71 3.57e-06 0.00109 0.37 0.25 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207244081 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs11580382 ENSG00000274245.1 RP11-357P18.2 4.71 3.57e-06 0.00109 0.37 0.25 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207245047 chr1:207372559~207373252:+ LIHC cis rs7246657 0.943 rs7252325 ENSG00000276846.1 CTD-3220F14.3 4.71 3.57e-06 0.00109 0.3 0.25 Coronary artery calcification; chr19:37439743 chr19:37314868~37315620:- LIHC cis rs2836974 0.897 rs2836928 ENSG00000255568.3 BRWD1-AS2 4.71 3.57e-06 0.00109 0.29 0.25 Cognitive function; chr21:39171394 chr21:39313935~39314962:+ LIHC cis rs4731207 0.594 rs6968500 ENSG00000224897.5 POT1-AS1 4.71 3.57e-06 0.00109 0.28 0.25 Cutaneous malignant melanoma; chr7:124791668 chr7:124929873~125179315:+ LIHC cis rs875971 0.545 rs73376401 ENSG00000273142.1 RP11-458F8.4 4.71 3.57e-06 0.00109 0.24 0.25 Aortic root size; chr7:66174841 chr7:66902857~66906297:+ LIHC cis rs2274273 0.624 rs66551709 ENSG00000258413.1 RP11-665C16.6 -4.71 3.57e-06 0.00109 -0.3 -0.25 Protein biomarker; chr14:55324304 chr14:55262767~55272075:- LIHC cis rs2274273 0.624 rs67795323 ENSG00000258413.1 RP11-665C16.6 -4.71 3.57e-06 0.00109 -0.3 -0.25 Protein biomarker; chr14:55331115 chr14:55262767~55272075:- LIHC cis rs2274273 0.624 rs8005450 ENSG00000258413.1 RP11-665C16.6 -4.71 3.57e-06 0.00109 -0.3 -0.25 Protein biomarker; chr14:55332447 chr14:55262767~55272075:- LIHC cis rs7208859 0.623 rs8075163 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779292 chr17:30792372~30792833:+ LIHC cis rs17826219 0.706 rs8075107 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Body mass index; chr17:30779631 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs7223209 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780202 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs7223404 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780345 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9916725 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780453 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9916727 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780454 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs73269945 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781741 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9897728 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781786 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs1054400 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30782936 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs1054397 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783178 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9890558 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783337 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9912283 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783355 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs3752020 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784107 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9890855 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784689 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9893422 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784697 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9891166 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784884 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs73269974 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785366 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs34756112 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785998 chr17:30792372~30792833:+ LIHC cis rs7208859 0.573 rs60724269 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786255 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs76633166 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786347 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs1061346 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787211 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs1061343 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787258 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs73269988 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30791127 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9899525 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793278 chr17:30792372~30792833:+ LIHC cis rs7208859 0.524 rs11653098 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795483 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9911784 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797562 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9911997 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797630 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9890862 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30798432 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs78071511 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30801136 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs2035494 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803375 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs3794796 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803862 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9915566 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805140 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11657369 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809450 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs8075341 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809547 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs73271842 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30810137 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs8077116 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813144 chr17:30792372~30792833:+ LIHC cis rs7208859 0.524 rs28760584 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813999 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs7212991 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816731 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs28627615 ENSG00000266490.1 CTD-2349P21.9 4.71 3.58e-06 0.00109 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30818799 chr17:30792372~30792833:+ LIHC cis rs9640161 0.789 rs13223702 ENSG00000261305.1 RP4-584D14.7 4.71 3.58e-06 0.00109 0.33 0.25 Blood protein levels;Circulating chemerin levels; chr7:150361879 chr7:150341771~150342607:+ LIHC cis rs875971 0.66 rs3764903 ENSG00000273024.4 INTS4P2 4.71 3.58e-06 0.00109 0.28 0.25 Aortic root size; chr7:66633495 chr7:65647864~65715661:+ LIHC cis rs227275 0.525 rs1383733 ENSG00000246560.2 RP11-10L12.4 4.71 3.58e-06 0.00109 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102995297 chr4:102828055~102844075:+ LIHC cis rs591584 0.59 rs10765689 ENSG00000255893.1 RP11-685N10.1 -4.71 3.58e-06 0.00109 -0.25 -0.25 Macrophage Migration Inhibitory Factor levels; chr11:94589519 chr11:94472908~94473570:- LIHC cis rs202072 0.585 rs3817735 ENSG00000215022.6 RP1-257A7.4 -4.71 3.59e-06 0.00109 -0.26 -0.25 HIV-1 viral setpoint; chr6:13278416 chr6:13264861~13295586:- LIHC cis rs13315871 1 rs9864325 ENSG00000272182.1 RP11-802O23.3 4.71 3.59e-06 0.00109 0.56 0.25 Cholesterol, total; chr3:58351119 chr3:58428255~58428815:+ LIHC cis rs10129255 0.912 rs67410411 ENSG00000223648.3 IGHV3-64 4.71 3.59e-06 0.00109 0.19 0.25 Kawasaki disease; chr14:106680324 chr14:106643132~106658258:- LIHC cis rs2243480 0.803 rs13224048 ENSG00000230295.1 RP11-458F8.2 -4.71 3.6e-06 0.00109 -0.26 -0.25 Diabetic kidney disease; chr7:66528779 chr7:66880708~66882981:+ LIHC cis rs804280 0.509 rs12719915 ENSG00000255394.4 C8orf49 -4.71 3.6e-06 0.00109 -0.32 -0.25 Myopia (pathological); chr8:11928746 chr8:11761256~11763223:+ LIHC cis rs11971779 0.648 rs9656512 ENSG00000273391.1 RP11-634H22.1 4.71 3.6e-06 0.0011 0.22 0.25 Diisocyanate-induced asthma; chr7:139369300 chr7:139359032~139359566:- LIHC cis rs228614 0.51 rs3774987 ENSG00000246560.2 RP11-10L12.4 4.71 3.6e-06 0.0011 0.27 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799709 chr4:102828055~102844075:+ LIHC cis rs6600671 0.934 rs11249429 ENSG00000231429.2 RP11-343N15.2 4.71 3.61e-06 0.0011 0.28 0.25 Hip geometry; chr1:121549282 chr1:121412719~121429274:+ LIHC cis rs643506 0.874 rs625477 ENSG00000254990.4 RP11-108O10.2 4.71 3.61e-06 0.0011 0.27 0.25 Breast cancer; chr11:111790962 chr11:111768668~111778350:- LIHC cis rs7665090 1 rs2125211 ENSG00000230069.3 LRRC37A15P 4.71 3.61e-06 0.0011 0.25 0.25 Primary biliary cholangitis; chr4:102638719 chr4:102727274~102730721:- LIHC cis rs7246657 0.943 rs7255952 ENSG00000276846.1 CTD-3220F14.3 4.71 3.61e-06 0.0011 0.32 0.25 Coronary artery calcification; chr19:37497895 chr19:37314868~37315620:- LIHC cis rs2932538 0.922 rs12048528 ENSG00000225075.1 RP11-426L16.3 -4.71 3.61e-06 0.0011 -0.32 -0.25 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112667912 chr1:112693688~112696621:- LIHC cis rs7568498 0.517 rs11678856 ENSG00000227403.1 AC009299.3 4.71 3.61e-06 0.0011 0.32 0.25 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161068932 chr2:161244739~161249050:+ LIHC cis rs7923609 0.967 rs10761766 ENSG00000232075.1 MRPL35P2 -4.71 3.62e-06 0.0011 -0.27 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63430567 chr10:63634317~63634827:- LIHC cis rs9525927 0.57 rs9316074 ENSG00000230731.2 RP11-478K15.6 4.71 3.62e-06 0.0011 0.28 0.25 Dupuytren's disease; chr13:44229045 chr13:44234118~44243192:- LIHC cis rs11971779 0.616 rs10278377 ENSG00000273391.1 RP11-634H22.1 4.71 3.62e-06 0.0011 0.22 0.25 Diisocyanate-induced asthma; chr7:139418325 chr7:139359032~139359566:- LIHC cis rs11971779 0.648 rs6946113 ENSG00000273391.1 RP11-634H22.1 4.71 3.62e-06 0.0011 0.22 0.25 Diisocyanate-induced asthma; chr7:139421380 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs6946393 ENSG00000273391.1 RP11-634H22.1 4.71 3.62e-06 0.0011 0.22 0.25 Diisocyanate-induced asthma; chr7:139421423 chr7:139359032~139359566:- LIHC cis rs11971779 0.553 rs10269108 ENSG00000273391.1 RP11-634H22.1 4.71 3.62e-06 0.0011 0.22 0.25 Diisocyanate-induced asthma; chr7:139421586 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs9683 ENSG00000273391.1 RP11-634H22.1 4.71 3.62e-06 0.0011 0.22 0.25 Diisocyanate-induced asthma; chr7:139422993 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs10085901 ENSG00000273391.1 RP11-634H22.1 4.71 3.62e-06 0.0011 0.22 0.25 Diisocyanate-induced asthma; chr7:139424243 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs10085902 ENSG00000273391.1 RP11-634H22.1 4.71 3.62e-06 0.0011 0.22 0.25 Diisocyanate-induced asthma; chr7:139424359 chr7:139359032~139359566:- LIHC cis rs11971779 0.617 rs66652773 ENSG00000273391.1 RP11-634H22.1 4.71 3.62e-06 0.0011 0.22 0.25 Diisocyanate-induced asthma; chr7:139424827 chr7:139359032~139359566:- LIHC cis rs11971779 0.648 rs10085708 ENSG00000273391.1 RP11-634H22.1 4.71 3.62e-06 0.0011 0.22 0.25 Diisocyanate-induced asthma; chr7:139426208 chr7:139359032~139359566:- LIHC cis rs5758511 0.68 rs5758684 ENSG00000205702.9 CYP2D7 4.71 3.62e-06 0.0011 0.29 0.25 Birth weight; chr22:42253503 chr22:42140203~42144577:- LIHC cis rs227275 0.525 rs10032234 ENSG00000246560.2 RP11-10L12.4 4.71 3.62e-06 0.0011 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102980538 chr4:102828055~102844075:+ LIHC cis rs227275 0.556 rs3886723 ENSG00000246560.2 RP11-10L12.4 4.71 3.62e-06 0.0011 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102983013 chr4:102828055~102844075:+ LIHC cis rs228614 0.517 rs3886722 ENSG00000246560.2 RP11-10L12.4 4.71 3.62e-06 0.0011 0.28 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102983084 chr4:102828055~102844075:+ LIHC cis rs2439831 0.85 rs2228368 ENSG00000275601.1 AC011330.13 -4.71 3.62e-06 0.0011 -0.36 -0.25 Lung cancer in ever smokers; chr15:43809812 chr15:43642389~43643023:- LIHC cis rs16858210 0.607 rs59321941 ENSG00000234371.6 RPSAP31 4.71 3.62e-06 0.0011 0.33 0.25 Menopause (age at onset); chr3:183853236 chr3:183884924~183888449:+ LIHC cis rs227275 0.555 rs223403 ENSG00000246560.2 RP11-10L12.4 4.71 3.63e-06 0.0011 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102817086 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs6533050 ENSG00000246560.2 RP11-10L12.4 4.71 3.63e-06 0.0011 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102979044 chr4:102828055~102844075:+ LIHC cis rs7246657 0.943 rs10426666 ENSG00000276846.1 CTD-3220F14.3 4.71 3.63e-06 0.0011 0.32 0.25 Coronary artery calcification; chr19:37337612 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs4969487 ENSG00000276846.1 CTD-3220F14.3 4.71 3.63e-06 0.0011 0.32 0.25 Coronary artery calcification; chr19:37340137 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs28402338 ENSG00000276846.1 CTD-3220F14.3 4.71 3.63e-06 0.0011 0.32 0.25 Coronary artery calcification; chr19:37343021 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs10417503 ENSG00000276846.1 CTD-3220F14.3 4.71 3.63e-06 0.0011 0.32 0.25 Coronary artery calcification; chr19:37351833 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs10403613 ENSG00000276846.1 CTD-3220F14.3 4.71 3.63e-06 0.0011 0.32 0.25 Coronary artery calcification; chr19:37353404 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs9304566 ENSG00000276846.1 CTD-3220F14.3 4.71 3.63e-06 0.0011 0.32 0.25 Coronary artery calcification; chr19:37354602 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs10422967 ENSG00000276846.1 CTD-3220F14.3 4.71 3.63e-06 0.0011 0.32 0.25 Coronary artery calcification; chr19:37359235 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs4417644 ENSG00000276846.1 CTD-3220F14.3 4.71 3.63e-06 0.0011 0.32 0.25 Coronary artery calcification; chr19:37361570 chr19:37314868~37315620:- LIHC cis rs2739330 0.828 rs4820572 ENSG00000206090.4 AP000350.7 4.71 3.64e-06 0.0011 0.28 0.25 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23939998~23942798:+ LIHC cis rs1062177 1 rs1062177 ENSG00000253921.1 CTB-113P19.3 -4.71 3.64e-06 0.0011 -0.28 -0.25 Preschool internalizing problems; chr5:151805140 chr5:151753992~151767247:+ LIHC cis rs7662987 0.793 rs28730632 ENSG00000272777.1 RP11-571L19.8 4.71 3.64e-06 0.0011 0.55 0.25 Smoking initiation; chr4:99074552 chr4:99067256~99068125:- LIHC cis rs4814920 0.756 rs1543472 ENSG00000275142.1 RP5-999L4.2 4.71 3.64e-06 0.0011 0.44 0.25 Bipolar disorder (body mass index interaction); chr20:19867383 chr20:19871891~19872284:+ LIHC cis rs5758511 0.68 rs1033459 ENSG00000205702.9 CYP2D7 4.71 3.64e-06 0.00111 0.29 0.25 Birth weight; chr22:42223061 chr22:42140203~42144577:- LIHC cis rs5758511 0.68 rs1033460 ENSG00000205702.9 CYP2D7 4.71 3.64e-06 0.00111 0.29 0.25 Birth weight; chr22:42223302 chr22:42140203~42144577:- LIHC cis rs5758511 0.679 rs55867855 ENSG00000205702.9 CYP2D7 4.71 3.64e-06 0.00111 0.29 0.25 Birth weight; chr22:42227252 chr22:42140203~42144577:- LIHC cis rs11722779 0.935 rs7681629 ENSG00000230069.3 LRRC37A15P -4.71 3.64e-06 0.00111 -0.22 -0.25 Schizophrenia; chr4:102974407 chr4:102727274~102730721:- LIHC cis rs11722779 0.844 rs17033381 ENSG00000230069.3 LRRC37A15P -4.71 3.64e-06 0.00111 -0.22 -0.25 Schizophrenia; chr4:102974952 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs4699044 ENSG00000230069.3 LRRC37A15P -4.71 3.64e-06 0.00111 -0.22 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102976939 chr4:102727274~102730721:- LIHC cis rs227275 0.556 rs4699045 ENSG00000230069.3 LRRC37A15P -4.71 3.64e-06 0.00111 -0.22 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102977009 chr4:102727274~102730721:- LIHC cis rs227275 0.554 rs223334 ENSG00000246560.2 RP11-10L12.4 -4.71 3.64e-06 0.00111 -0.28 -0.25 Allergic disease (asthma, hay fever or eczema); chr4:102867054 chr4:102828055~102844075:+ LIHC cis rs12134133 0.962 rs17258843 ENSG00000274245.1 RP11-357P18.2 4.71 3.64e-06 0.00111 0.37 0.25 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207241387 chr1:207372559~207373252:+ LIHC cis rs643506 0.874 rs609007 ENSG00000254990.4 RP11-108O10.2 -4.71 3.64e-06 0.00111 -0.27 -0.25 Breast cancer; chr11:111848870 chr11:111768668~111778350:- LIHC cis rs17818399 0.815 rs17768132 ENSG00000279254.1 RP11-536C12.1 4.71 3.64e-06 0.00111 0.3 0.25 Height; chr2:46636110 chr2:46668870~46670778:+ LIHC cis rs7662987 0.793 rs12106 ENSG00000272777.1 RP11-571L19.8 4.71 3.64e-06 0.00111 0.54 0.25 Smoking initiation; chr4:99072199 chr4:99067256~99068125:- LIHC cis rs1865760 1 rs3799371 ENSG00000216436.2 HIST1H2APS1 4.71 3.64e-06 0.00111 0.28 0.25 Height; chr6:25912588 chr6:25732497~25732827:+ LIHC cis rs643506 0.874 rs4936786 ENSG00000254990.4 RP11-108O10.2 4.71 3.64e-06 0.00111 0.26 0.25 Breast cancer; chr11:111856504 chr11:111768668~111778350:- LIHC cis rs2877649 0.51 rs10129168 ENSG00000258744.1 RP11-80A15.1 -4.71 3.65e-06 0.00111 -0.45 -0.25 Smooth-surface caries; chr14:24436858 chr14:24501594~24508688:+ LIHC cis rs2877649 0.623 rs3742521 ENSG00000258744.1 RP11-80A15.1 -4.71 3.65e-06 0.00111 -0.45 -0.25 Smooth-surface caries; chr14:24437309 chr14:24501594~24508688:+ LIHC cis rs2877649 0.623 rs3742522 ENSG00000258744.1 RP11-80A15.1 -4.71 3.65e-06 0.00111 -0.45 -0.25 Smooth-surface caries; chr14:24437328 chr14:24501594~24508688:+ LIHC cis rs4694744 0.576 rs13141436 ENSG00000264696.1 AC108078.1 4.71 3.65e-06 0.00111 0.38 0.25 Bacteremia; chr4:69476861 chr4:69479331~69479434:+ LIHC cis rs4694744 0.543 rs34285519 ENSG00000264696.1 AC108078.1 4.71 3.65e-06 0.00111 0.38 0.25 Bacteremia; chr4:69477263 chr4:69479331~69479434:+ LIHC cis rs9291683 0.53 rs10939620 ENSG00000250413.1 RP11-448G15.1 4.71 3.65e-06 0.00111 0.32 0.25 Bone mineral density; chr4:9944508 chr4:10006482~10009725:+ LIHC cis rs5758659 0.716 rs86669 ENSG00000227370.1 RP4-669P10.19 -4.71 3.65e-06 0.00111 -0.27 -0.25 Cognitive function; chr22:42284794 chr22:42132543~42132998:+ LIHC cis rs529413 1 rs535699 ENSG00000259237.1 RP11-209E8.1 4.71 3.66e-06 0.00111 0.34 0.25 Itch intensity from mosquito bite adjusted by bite size; chr15:53249900 chr15:53116365~53129698:+ LIHC cis rs6480314 0.522 rs4746756 ENSG00000233590.1 RP11-153K11.3 4.71 3.66e-06 0.00111 0.38 0.25 Optic nerve measurement (disc area); chr10:68301188 chr10:68233251~68242379:- LIHC cis rs7246657 0.943 rs7258692 ENSG00000276846.1 CTD-3220F14.3 4.71 3.66e-06 0.00111 0.32 0.25 Coronary artery calcification; chr19:37327927 chr19:37314868~37315620:- LIHC cis rs2439831 0.702 rs8033995 ENSG00000166763.7 STRCP1 4.71 3.66e-06 0.00111 0.37 0.25 Lung cancer in ever smokers; chr15:43721311 chr15:43699488~43718184:- LIHC cis rs5769707 0.967 rs5770585 ENSG00000235111.1 RP1-29C18.8 -4.71 3.67e-06 0.00111 -0.28 -0.25 Monocyte percentage of white cells;Monocyte count; chr22:49614226 chr22:49612657~49615716:- LIHC cis rs1020064 0.945 rs1030878 ENSG00000235319.1 AC012360.4 -4.71 3.68e-06 0.00112 -0.34 -0.25 AIDS; chr2:105294141 chr2:105324210~105330529:+ LIHC cis rs1030877 0.515 rs2679895 ENSG00000235319.1 AC012360.4 -4.71 3.68e-06 0.00112 -0.34 -0.25 Obesity-related traits; chr2:105290023 chr2:105324210~105330529:+ LIHC cis rs4964805 0.672 rs11111757 ENSG00000257681.1 RP11-341G23.4 4.71 3.68e-06 0.00112 0.25 0.25 Attention deficit hyperactivity disorder; chr12:103766984 chr12:103746315~103768858:- LIHC cis rs11722779 0.658 rs6533044 ENSG00000230069.3 LRRC37A15P -4.71 3.68e-06 0.00112 -0.22 -0.25 Schizophrenia; chr4:102965261 chr4:102727274~102730721:- LIHC cis rs67311347 1 rs9874499 ENSG00000223797.4 ENTPD3-AS1 4.71 3.69e-06 0.00112 0.2 0.25 Renal cell carcinoma; chr3:40400417 chr3:40313802~40453329:- LIHC cis rs7811142 0.943 rs28578163 ENSG00000242294.5 STAG3L5P 4.71 3.69e-06 0.00112 0.29 0.25 Platelet count; chr7:100447131 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs67239991 ENSG00000242294.5 STAG3L5P 4.71 3.69e-06 0.00112 0.29 0.25 Platelet count; chr7:100448881 chr7:100336079~100351900:+ LIHC cis rs2834188 1 rs9982088 ENSG00000272659.1 AP000295.10 -4.71 3.69e-06 0.00112 -0.36 -0.25 Narcolepsy; chr21:33314536 chr21:33309491~33310181:+ LIHC cis rs6479901 0.793 rs10761725 ENSG00000232075.1 MRPL35P2 -4.71 3.69e-06 0.00112 -0.27 -0.25 Intelligence (multi-trait analysis); chr10:63214777 chr10:63634317~63634827:- LIHC cis rs10129255 0.957 rs6576233 ENSG00000211970.3 IGHV4-61 -4.71 3.69e-06 0.00112 -0.19 -0.25 Kawasaki disease; chr14:106787239 chr14:106639119~106639657:- LIHC cis rs61160187 0.51 rs6893642 ENSG00000272308.1 RP11-231G3.1 -4.71 3.69e-06 0.00112 -0.29 -0.25 Educational attainment (years of education);Educational attainment (college completion); chr5:60821896 chr5:60866457~60866935:- LIHC cis rs61160187 0.51 rs3936423 ENSG00000272308.1 RP11-231G3.1 -4.71 3.69e-06 0.00112 -0.29 -0.25 Educational attainment (years of education);Educational attainment (college completion); chr5:60823134 chr5:60866457~60866935:- LIHC cis rs61160187 0.51 rs1445293 ENSG00000272308.1 RP11-231G3.1 -4.71 3.69e-06 0.00112 -0.29 -0.25 Educational attainment (years of education);Educational attainment (college completion); chr5:60823910 chr5:60866457~60866935:- LIHC cis rs4700393 0.967 rs4700394 ENSG00000272308.1 RP11-231G3.1 4.71 3.69e-06 0.00112 0.29 0.25 Intelligence (multi-trait analysis); chr5:60821375 chr5:60866457~60866935:- LIHC cis rs11098499 0.954 rs10518331 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119402440 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs13133522 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119403269 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs35091806 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119404374 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs35165976 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119404475 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs2389802 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119404577 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs6846442 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119405168 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs71614422 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119438185 chr4:119409333~119410233:+ LIHC cis rs11098499 0.738 rs34566984 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119440115 chr4:119409333~119410233:+ LIHC cis rs11098499 0.738 rs34965784 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119440431 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs17009122 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119441248 chr4:119409333~119410233:+ LIHC cis rs11098499 0.505 rs75122014 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119441271 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs9685777 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119444810 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs71614438 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119450097 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs66506550 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119450290 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs7659501 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119450397 chr4:119409333~119410233:+ LIHC cis rs11098499 0.657 rs71614442 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119458191 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs2892848 ENSG00000260091.1 RP11-33B1.4 -4.7 3.7e-06 0.00112 -0.18 -0.25 Corneal astigmatism; chr4:119460186 chr4:119409333~119410233:+ LIHC cis rs2836974 0.863 rs8132333 ENSG00000255568.3 BRWD1-AS2 4.7 3.7e-06 0.00112 0.27 0.25 Cognitive function; chr21:39155974 chr21:39313935~39314962:+ LIHC cis rs75920871 0.764 rs4938326 ENSG00000254851.1 RP11-109L13.1 -4.7 3.71e-06 0.00112 -0.51 -0.25 Subjective well-being; chr11:117034748 chr11:117135528~117138582:+ LIHC cis rs1865760 0.566 rs2032449 ENSG00000216436.2 HIST1H2APS1 -4.7 3.71e-06 0.00112 -0.28 -0.25 Height; chr6:26026371 chr6:25732497~25732827:+ LIHC cis rs11098499 0.863 rs13136462 ENSG00000245958.5 RP11-33B1.1 -4.7 3.71e-06 0.00112 -0.26 -0.25 Corneal astigmatism; chr4:119622018 chr4:119454791~119552025:+ LIHC cis rs12134133 0.962 rs6682586 ENSG00000274245.1 RP11-357P18.2 4.7 3.71e-06 0.00112 0.36 0.25 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207243122 chr1:207372559~207373252:+ LIHC cis rs12134133 0.962 rs6668560 ENSG00000274245.1 RP11-357P18.2 4.7 3.71e-06 0.00112 0.36 0.25 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207243462 chr1:207372559~207373252:+ LIHC cis rs1065852 0.526 rs1062753 ENSG00000237037.8 NDUFA6-AS1 -4.7 3.71e-06 0.00112 -0.34 -0.25 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41996807 chr22:42090931~42137742:+ LIHC cis rs643506 0.874 rs680096 ENSG00000254990.4 RP11-108O10.2 4.7 3.71e-06 0.00112 0.26 0.25 Breast cancer; chr11:111837945 chr11:111768668~111778350:- LIHC cis rs643506 0.874 rs10789849 ENSG00000254990.4 RP11-108O10.2 4.7 3.71e-06 0.00112 0.26 0.25 Breast cancer; chr11:111845347 chr11:111768668~111778350:- LIHC cis rs4266144 1 rs4266144 ENSG00000241770.1 RP11-555M1.3 -4.7 3.72e-06 0.00112 -0.3 -0.25 Coronary artery disease; chr3:157134803 chr3:157163452~157169133:+ LIHC cis rs73193808 0.666 rs7276548 ENSG00000224649.1 AF124730.4 4.7 3.72e-06 0.00112 0.29 0.25 Coronary artery disease; chr21:29180518 chr21:29182027~29187795:- LIHC cis rs4964805 0.58 rs10861097 ENSG00000257681.1 RP11-341G23.4 4.7 3.72e-06 0.00113 0.25 0.25 Attention deficit hyperactivity disorder; chr12:103776696 chr12:103746315~103768858:- LIHC cis rs4938573 0.526 rs11216973 ENSG00000255239.1 AP002954.6 -4.7 3.72e-06 0.00113 -0.36 -0.25 Follicular lymphoma; chr11:118716292 chr11:118688039~118690600:- LIHC cis rs765787 0.53 rs12906537 ENSG00000259520.4 CTD-2651B20.3 -4.7 3.72e-06 0.00113 -0.29 -0.25 Uric acid levels; chr15:45227863 chr15:45251580~45279251:- LIHC cis rs875971 0.545 rs2460427 ENSG00000273142.1 RP11-458F8.4 -4.7 3.72e-06 0.00113 -0.24 -0.25 Aortic root size; chr7:66154218 chr7:66902857~66906297:+ LIHC cis rs3733589 1 rs3796840 ENSG00000250413.1 RP11-448G15.1 4.7 3.72e-06 0.00113 0.43 0.25 Renal overload gout; chr4:10006497 chr4:10006482~10009725:+ LIHC cis rs17270561 0.943 rs76703022 ENSG00000216436.2 HIST1H2APS1 -4.7 3.73e-06 0.00113 -0.39 -0.25 Iron status biomarkers; chr6:25703301 chr6:25732497~25732827:+ LIHC cis rs12701220 0.894 rs10257744 ENSG00000229043.2 AC091729.9 -4.7 3.73e-06 0.00113 -0.35 -0.25 Bronchopulmonary dysplasia; chr7:1005976 chr7:1160374~1165267:+ LIHC cis rs55726902 0.506 rs1006476 ENSG00000276691.1 RP5-1057I20.5 4.7 3.73e-06 0.00113 0.47 0.25 Allergic disease (asthma, hay fever or eczema); chr12:47785564 chr12:47788426~47788971:+ LIHC cis rs1558001 0.834 rs2108032 ENSG00000230196.1 DDX43P3 4.7 3.73e-06 0.00113 0.26 0.25 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81788019 chr7:81610884~81611326:- LIHC cis rs1558001 0.87 rs969705 ENSG00000230196.1 DDX43P3 4.7 3.73e-06 0.00113 0.26 0.25 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81789770 chr7:81610884~81611326:- LIHC cis rs9487094 0.67 rs729888 ENSG00000260273.1 RP11-425D10.10 -4.7 3.73e-06 0.00113 -0.3 -0.25 Height; chr6:109636120 chr6:109382795~109383666:+ LIHC cis rs2834188 1 rs1018741 ENSG00000272659.1 AP000295.10 -4.7 3.73e-06 0.00113 -0.36 -0.25 Narcolepsy; chr21:33314040 chr21:33309491~33310181:+ LIHC cis rs2834188 1 rs1018742 ENSG00000272659.1 AP000295.10 -4.7 3.73e-06 0.00113 -0.36 -0.25 Narcolepsy; chr21:33314076 chr21:33309491~33310181:+ LIHC cis rs11971779 0.618 rs13068 ENSG00000273391.1 RP11-634H22.1 4.7 3.74e-06 0.00113 0.22 0.25 Diisocyanate-induced asthma; chr7:139419395 chr7:139359032~139359566:- LIHC cis rs2998286 0.723 rs332172 ENSG00000254635.4 WAC-AS1 -4.7 3.74e-06 0.00113 -0.32 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28610394 chr10:28522652~28532743:- LIHC cis rs2998286 0.723 rs332186 ENSG00000254635.4 WAC-AS1 -4.7 3.74e-06 0.00113 -0.32 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28624674 chr10:28522652~28532743:- LIHC cis rs2998286 0.723 rs332187 ENSG00000254635.4 WAC-AS1 -4.7 3.74e-06 0.00113 -0.32 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28624887 chr10:28522652~28532743:- LIHC cis rs748404 0.697 rs493177 ENSG00000166763.7 STRCP1 4.7 3.74e-06 0.00113 0.3 0.25 Lung cancer; chr15:43251060 chr15:43699488~43718184:- LIHC cis rs1077773 0.509 rs6461315 ENSG00000237773.4 AC003075.4 -4.7 3.74e-06 0.00113 -0.31 -0.25 Ulcerative colitis;Inflammatory bowel disease; chr7:17408820 chr7:17279834~17299357:- LIHC cis rs79040073 0.53 rs8029506 ENSG00000259531.2 RP11-295H24.3 4.7 3.74e-06 0.00113 0.41 0.25 Lung cancer in ever smokers; chr15:49274543 chr15:49365124~49366685:- LIHC cis rs1558001 0.87 rs975359 ENSG00000230196.1 DDX43P3 4.7 3.75e-06 0.00113 0.26 0.25 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81781600 chr7:81610884~81611326:- LIHC cis rs6921919 0.583 rs9468370 ENSG00000204709.4 LINC01556 4.7 3.75e-06 0.00113 0.3 0.25 Autism spectrum disorder or schizophrenia; chr6:28401163 chr6:28943877~28944537:+ LIHC cis rs227275 0.525 rs2866417 ENSG00000246560.2 RP11-10L12.4 4.7 3.75e-06 0.00113 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102993481 chr4:102828055~102844075:+ LIHC cis rs453301 0.686 rs13252797 ENSG00000253893.2 FAM85B -4.7 3.76e-06 0.00113 -0.35 -0.25 Joint mobility (Beighton score); chr8:9003920 chr8:8167819~8226614:- LIHC cis rs11098499 0.58 rs12509234 ENSG00000260091.1 RP11-33B1.4 -4.7 3.76e-06 0.00114 -0.18 -0.25 Corneal astigmatism; chr4:119398279 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs10014719 ENSG00000260091.1 RP11-33B1.4 -4.7 3.76e-06 0.00114 -0.18 -0.25 Corneal astigmatism; chr4:119399560 chr4:119409333~119410233:+ LIHC cis rs950776 0.647 rs495956 ENSG00000261762.1 RP11-650L12.2 -4.7 3.76e-06 0.00114 -0.31 -0.25 Sudden cardiac arrest; chr15:78577588 chr15:78589123~78591276:- LIHC cis rs950776 0.616 rs495090 ENSG00000261762.1 RP11-650L12.2 -4.7 3.76e-06 0.00114 -0.31 -0.25 Sudden cardiac arrest; chr15:78577661 chr15:78589123~78591276:- LIHC cis rs950776 0.722 rs471889 ENSG00000261762.1 RP11-650L12.2 -4.7 3.76e-06 0.00114 -0.31 -0.25 Sudden cardiac arrest; chr15:78577893 chr15:78589123~78591276:- LIHC cis rs9834975 0.967 rs12152463 ENSG00000272758.4 RP11-299J3.8 -4.7 3.76e-06 0.00114 -0.28 -0.25 Diastolic blood pressure; chr3:122381600 chr3:122416207~122443180:+ LIHC cis rs1577917 0.654 rs9450284 ENSG00000234155.1 RP11-30P6.6 -4.7 3.76e-06 0.00114 -0.3 -0.25 Response to antipsychotic treatment; chr6:85489611 chr6:85387219~85390186:- LIHC cis rs67311347 0.866 rs56331709 ENSG00000223797.4 ENTPD3-AS1 4.7 3.77e-06 0.00114 0.21 0.25 Renal cell carcinoma; chr3:40315067 chr3:40313802~40453329:- LIHC cis rs9595908 0.9 rs1324415 ENSG00000212293.1 SNORA16 4.7 3.77e-06 0.00114 0.29 0.25 Body mass index; chr13:32600186 chr13:32420390~32420516:- LIHC cis rs901683 0.702 rs114085432 ENSG00000230869.1 CTGLF10P -4.7 3.77e-06 0.00114 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45645317 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs115133418 ENSG00000230869.1 CTGLF10P -4.7 3.77e-06 0.00114 -0.65 -0.25 Mean corpuscular volume;Red blood cell traits; chr10:45645318 chr10:45678692~45700532:+ LIHC cis rs1577917 1 rs10498958 ENSG00000234155.1 RP11-30P6.6 -4.7 3.77e-06 0.00114 -0.33 -0.25 Response to antipsychotic treatment; chr6:85939987 chr6:85387219~85390186:- LIHC cis rs6445975 0.726 rs6764512 ENSG00000272360.1 RP11-359I18.5 4.7 3.77e-06 0.00114 0.29 0.25 Systemic lupus erythematosus; chr3:58482509 chr3:58490830~58491291:- LIHC cis rs712039 0.652 rs853197 ENSG00000276054.1 RP11-378E13.3 4.7 3.78e-06 0.00114 0.31 0.25 Tuberculosis; chr17:37488610 chr17:37386886~37387926:+ LIHC cis rs916888 0.773 rs199535 ENSG00000274883.1 Metazoa_SRP -4.7 3.78e-06 0.00114 -0.39 -0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45931806~45932083:+ LIHC cis rs11673344 0.665 rs74435359 ENSG00000226686.6 LINC01535 4.7 3.78e-06 0.00114 0.39 0.25 Obesity-related traits; chr19:36955252 chr19:37251912~37265535:+ LIHC cis rs9595908 0.827 rs7321262 ENSG00000212293.1 SNORA16 4.7 3.79e-06 0.00114 0.29 0.25 Body mass index; chr13:32597942 chr13:32420390~32420516:- LIHC cis rs11992162 1 rs7460395 ENSG00000255495.1 AC145124.2 4.7 3.79e-06 0.00114 0.31 0.25 Monocyte count; chr8:11977866 chr8:12194467~12196280:+ LIHC cis rs67311347 1 rs9854493 ENSG00000223797.4 ENTPD3-AS1 4.7 3.79e-06 0.00114 0.2 0.25 Renal cell carcinoma; chr3:40382131 chr3:40313802~40453329:- LIHC cis rs6997458 0.742 rs20571 ENSG00000253549.4 RP11-317J10.2 4.7 3.79e-06 0.00114 0.27 0.25 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85439768 chr8:85441851~85464915:- LIHC cis rs67311347 0.956 rs9817233 ENSG00000223797.4 ENTPD3-AS1 4.7 3.79e-06 0.00114 0.2 0.25 Renal cell carcinoma; chr3:40384127 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs9817142 ENSG00000223797.4 ENTPD3-AS1 4.7 3.79e-06 0.00114 0.2 0.25 Renal cell carcinoma; chr3:40384283 chr3:40313802~40453329:- LIHC cis rs9388451 0.626 rs9385383 ENSG00000237742.5 RP11-624M8.1 -4.7 3.79e-06 0.00114 -0.23 -0.25 Brugada syndrome; chr6:125765144 chr6:125578558~125749190:- LIHC cis rs7119038 0.509 rs11216961 ENSG00000255422.1 AP002954.4 4.7 3.79e-06 0.00114 0.32 0.25 Sjögren's syndrome; chr11:118709629 chr11:118704607~118750263:+ LIHC cis rs11079159 0.628 rs884301 ENSG00000263096.1 RP11-515O17.2 4.7 3.79e-06 0.00114 0.33 0.25 QRS duration; chr17:55290103 chr17:55271504~55273653:- LIHC cis rs2929278 0.617 rs575082 ENSG00000166763.7 STRCP1 -4.7 3.8e-06 0.00114 -0.32 -0.25 Schizophrenia; chr15:43817944 chr15:43699488~43718184:- LIHC cis rs2929278 0.617 rs2955969 ENSG00000166763.7 STRCP1 -4.7 3.8e-06 0.00114 -0.32 -0.25 Schizophrenia; chr15:43822329 chr15:43699488~43718184:- LIHC cis rs12304921 0.748 rs17125375 ENSG00000277201.1 AC087884.1 4.7 3.8e-06 0.00115 0.29 0.25 Type 2 diabetes; chr12:51105936 chr12:51049921~51050025:+ LIHC cis rs227275 0.554 rs223333 ENSG00000246560.2 RP11-10L12.4 4.7 3.81e-06 0.00115 0.27 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102868653 chr4:102828055~102844075:+ LIHC cis rs7945705 0.782 rs2742545 ENSG00000254860.4 TMEM9B-AS1 4.7 3.81e-06 0.00115 0.24 0.25 Hemoglobin concentration; chr11:8862761 chr11:8964675~8977527:+ LIHC cis rs7945705 0.84 rs10840136 ENSG00000254860.4 TMEM9B-AS1 4.7 3.81e-06 0.00115 0.24 0.25 Hemoglobin concentration; chr11:8863477 chr11:8964675~8977527:+ LIHC cis rs10170846 0.626 rs9288575 ENSG00000261428.2 RP11-16P6.1 4.7 3.81e-06 0.00115 0.29 0.25 Schizophrenia (inflammation and infection response interaction); chr2:222630414 chr2:222566899~222569719:- LIHC cis rs67311347 1 rs7634375 ENSG00000223797.4 ENTPD3-AS1 4.7 3.81e-06 0.00115 0.2 0.25 Renal cell carcinoma; chr3:40390455 chr3:40313802~40453329:- LIHC cis rs5758511 0.573 rs139558 ENSG00000237037.8 NDUFA6-AS1 4.7 3.81e-06 0.00115 0.29 0.25 Birth weight; chr22:41793547 chr22:42090931~42137742:+ LIHC cis rs11722779 0.873 rs6533041 ENSG00000246560.2 RP11-10L12.4 4.7 3.81e-06 0.00115 0.28 0.25 Schizophrenia; chr4:102951615 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs4699037 ENSG00000246560.2 RP11-10L12.4 4.7 3.81e-06 0.00115 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102957010 chr4:102828055~102844075:+ LIHC cis rs227275 0.556 rs3857198 ENSG00000246560.2 RP11-10L12.4 4.7 3.81e-06 0.00115 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102957720 chr4:102828055~102844075:+ LIHC cis rs11722779 0.935 rs3857199 ENSG00000246560.2 RP11-10L12.4 4.7 3.81e-06 0.00115 0.28 0.25 Schizophrenia; chr4:102957991 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs4699039 ENSG00000246560.2 RP11-10L12.4 4.7 3.81e-06 0.00115 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102958354 chr4:102828055~102844075:+ LIHC cis rs643506 0.845 rs607327 ENSG00000254990.4 RP11-108O10.2 4.7 3.81e-06 0.00115 0.26 0.25 Breast cancer; chr11:111824985 chr11:111768668~111778350:- LIHC cis rs643506 0.874 rs663511 ENSG00000254990.4 RP11-108O10.2 4.7 3.81e-06 0.00115 0.26 0.25 Breast cancer; chr11:111839311 chr11:111768668~111778350:- LIHC cis rs67311347 0.544 rs2278929 ENSG00000223797.4 ENTPD3-AS1 -4.7 3.83e-06 0.00115 -0.2 -0.25 Renal cell carcinoma; chr3:40309517 chr3:40313802~40453329:- LIHC cis rs11089937 0.857 rs5750578 ENSG00000211639.2 IGLV4-60 4.7 3.83e-06 0.00115 0.23 0.25 Periodontitis (PAL4Q3); chr22:22136444 chr22:22162199~22162681:+ LIHC cis rs2243480 1 rs1638734 ENSG00000230295.1 RP11-458F8.2 -4.7 3.83e-06 0.00115 -0.26 -0.25 Diabetic kidney disease; chr7:66632552 chr7:66880708~66882981:+ LIHC cis rs6480314 0.522 rs10047388 ENSG00000233590.1 RP11-153K11.3 4.7 3.83e-06 0.00115 0.38 0.25 Optic nerve measurement (disc area); chr10:68300456 chr10:68233251~68242379:- LIHC cis rs10829156 0.66 rs10764587 ENSG00000225527.1 RP11-383B4.4 -4.7 3.83e-06 0.00115 -0.4 -0.25 Sudden cardiac arrest; chr10:18548901 chr10:18531849~18533336:- LIHC cis rs643506 0.874 rs687152 ENSG00000254990.4 RP11-108O10.2 4.7 3.83e-06 0.00115 0.26 0.25 Breast cancer; chr11:111850950 chr11:111768668~111778350:- LIHC cis rs7208859 0.623 rs170051 ENSG00000266490.1 CTD-2349P21.9 4.7 3.83e-06 0.00115 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587135 chr17:30792372~30792833:+ LIHC cis rs904251 0.861 rs1757180 ENSG00000204110.6 RP1-153P14.8 -4.7 3.84e-06 0.00116 -0.32 -0.25 Cognitive performance; chr6:37518369 chr6:37507348~37535616:+ LIHC cis rs10129255 0.5 rs9324092 ENSG00000223648.3 IGHV3-64 -4.7 3.84e-06 0.00116 -0.17 -0.25 Kawasaki disease; chr14:106683806 chr14:106643132~106658258:- LIHC cis rs12554020 0.786 rs76640831 ENSG00000227603.1 RP11-165J3.6 4.7 3.84e-06 0.00116 0.42 0.25 Schizophrenia; chr9:93474133 chr9:93435332~93437121:- LIHC cis rs2749097 0.825 rs6671606 ENSG00000244256.3 RN7SL130P -4.7 3.85e-06 0.00116 -0.29 -0.25 Alcohol consumption (transferrin glycosylation); chr1:63658197 chr1:63655743~63656047:+ LIHC cis rs7119038 0.629 rs10892271 ENSG00000255239.1 AP002954.6 -4.7 3.85e-06 0.00116 -0.35 -0.25 Sjögren's syndrome; chr11:118727835 chr11:118688039~118690600:- LIHC cis rs17711722 0.522 rs4642526 ENSG00000273024.4 INTS4P2 -4.7 3.85e-06 0.00116 -0.26 -0.25 Calcium levels; chr7:65751755 chr7:65647864~65715661:+ LIHC cis rs2337406 1 rs11846866 ENSG00000274576.2 IGHV2-70 -4.7 3.85e-06 0.00116 -0.28 -0.25 Alzheimer's disease (late onset); chr14:106703003 chr14:106770577~106771020:- LIHC cis rs7208859 0.51 rs216402 ENSG00000266490.1 CTD-2349P21.9 4.7 3.85e-06 0.00116 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30590108 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs216434 ENSG00000266490.1 CTD-2349P21.9 4.7 3.85e-06 0.00116 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595317 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs216439 ENSG00000266490.1 CTD-2349P21.9 4.7 3.85e-06 0.00116 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30600866 chr17:30792372~30792833:+ LIHC cis rs1865760 0.566 rs9379821 ENSG00000216436.2 HIST1H2APS1 -4.7 3.85e-06 0.00116 -0.29 -0.25 Height; chr6:26054040 chr6:25732497~25732827:+ LIHC cis rs11098499 0.863 rs12508173 ENSG00000260091.1 RP11-33B1.4 -4.7 3.85e-06 0.00116 -0.18 -0.25 Corneal astigmatism; chr4:119397371 chr4:119409333~119410233:+ LIHC cis rs11098499 0.908 rs12504149 ENSG00000260091.1 RP11-33B1.4 -4.7 3.85e-06 0.00116 -0.18 -0.25 Corneal astigmatism; chr4:119397422 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs17006190 ENSG00000260091.1 RP11-33B1.4 -4.7 3.85e-06 0.00116 -0.17 -0.25 Corneal astigmatism; chr4:119497683 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs28685688 ENSG00000260091.1 RP11-33B1.4 -4.7 3.85e-06 0.00116 -0.17 -0.25 Corneal astigmatism; chr4:119499179 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs7687843 ENSG00000260091.1 RP11-33B1.4 -4.7 3.85e-06 0.00116 -0.17 -0.25 Corneal astigmatism; chr4:119500056 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs2306455 ENSG00000260091.1 RP11-33B1.4 -4.7 3.85e-06 0.00116 -0.17 -0.25 Corneal astigmatism; chr4:119500814 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs10031483 ENSG00000260091.1 RP11-33B1.4 -4.7 3.85e-06 0.00116 -0.17 -0.25 Corneal astigmatism; chr4:119501481 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs10031665 ENSG00000260091.1 RP11-33B1.4 -4.7 3.85e-06 0.00116 -0.17 -0.25 Corneal astigmatism; chr4:119501697 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs3733519 ENSG00000260091.1 RP11-33B1.4 -4.7 3.85e-06 0.00116 -0.17 -0.25 Corneal astigmatism; chr4:119502293 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs3733523 ENSG00000260091.1 RP11-33B1.4 -4.7 3.85e-06 0.00116 -0.17 -0.25 Corneal astigmatism; chr4:119502564 chr4:119409333~119410233:+ LIHC cis rs6802315 0.604 rs9881462 ENSG00000272087.1 RP11-379F4.7 4.7 3.86e-06 0.00116 0.28 0.25 Periodontitis (CDC/AAP); chr3:158763333 chr3:158693120~158693768:- LIHC cis rs643506 0.874 rs631318 ENSG00000254990.4 RP11-108O10.2 -4.7 3.86e-06 0.00116 -0.26 -0.25 Breast cancer; chr11:111806971 chr11:111768668~111778350:- LIHC cis rs2921073 0.605 rs2976933 ENSG00000253893.2 FAM85B -4.69 3.87e-06 0.00116 -0.34 -0.25 Parkinson's disease; chr8:8397365 chr8:8167819~8226614:- LIHC cis rs9368481 0.729 rs9379950 ENSG00000241549.7 GUSBP2 -4.69 3.87e-06 0.00116 -0.26 -0.25 Autism spectrum disorder or schizophrenia; chr6:26993769 chr6:26871484~26956554:- LIHC cis rs9368481 1 rs9368481 ENSG00000241549.7 GUSBP2 -4.69 3.87e-06 0.00116 -0.26 -0.25 Autism spectrum disorder or schizophrenia; chr6:26993982 chr6:26871484~26956554:- LIHC cis rs227275 0.525 rs28845922 ENSG00000246560.2 RP11-10L12.4 4.69 3.87e-06 0.00116 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102981959 chr4:102828055~102844075:+ LIHC cis rs4766897 0.543 rs10850001 ENSG00000226469.1 ADAM1B -4.69 3.87e-06 0.00116 -0.27 -0.25 Fibrinogen levels; chr12:112115228 chr12:111927018~111929017:+ LIHC cis rs8040855 0.657 rs6496733 ENSG00000259295.5 CSPG4P12 -4.69 3.87e-06 0.00116 -0.38 -0.25 Bulimia nervosa; chr15:85129945 chr15:85191438~85213905:+ LIHC cis rs16858210 0.648 rs57604063 ENSG00000234371.6 RPSAP31 4.69 3.87e-06 0.00116 0.33 0.25 Menopause (age at onset); chr3:183860901 chr3:183884924~183888449:+ LIHC cis rs16858210 0.607 rs57874587 ENSG00000234371.6 RPSAP31 4.69 3.87e-06 0.00116 0.33 0.25 Menopause (age at onset); chr3:183866961 chr3:183884924~183888449:+ LIHC cis rs1318937 1 rs11713836 ENSG00000224660.1 SH3BP5-AS1 4.69 3.88e-06 0.00117 0.24 0.25 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15253304 chr3:15254184~15264493:+ LIHC cis rs2337406 1 rs1858677 ENSG00000274576.2 IGHV2-70 -4.69 3.88e-06 0.00117 -0.28 -0.25 Alzheimer's disease (late onset); chr14:106706828 chr14:106770577~106771020:- LIHC cis rs2060793 0.712 rs10741654 ENSG00000251991.1 RNU7-49P 4.69 3.88e-06 0.00117 0.28 0.25 Vitamin D levels; chr11:14726506 chr11:14478892~14478953:+ LIHC cis rs7937890 0.505 rs9971395 ENSG00000251991.1 RNU7-49P 4.69 3.88e-06 0.00117 0.28 0.25 Mitochondrial DNA levels; chr11:14745580 chr11:14478892~14478953:+ LIHC cis rs7937890 0.506 rs10741655 ENSG00000251991.1 RNU7-49P 4.69 3.88e-06 0.00117 0.28 0.25 Mitochondrial DNA levels; chr11:14746838 chr11:14478892~14478953:+ LIHC cis rs11098499 0.954 rs6834796 ENSG00000260091.1 RP11-33B1.4 -4.69 3.88e-06 0.00117 -0.17 -0.25 Corneal astigmatism; chr4:119493538 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs11729521 ENSG00000260091.1 RP11-33B1.4 -4.69 3.88e-06 0.00117 -0.17 -0.25 Corneal astigmatism; chr4:119495633 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs11734241 ENSG00000260091.1 RP11-33B1.4 -4.69 3.88e-06 0.00117 -0.17 -0.25 Corneal astigmatism; chr4:119495717 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs7437420 ENSG00000245958.5 RP11-33B1.1 -4.69 3.88e-06 0.00117 -0.26 -0.25 Corneal astigmatism; chr4:119391748 chr4:119454791~119552025:+ LIHC cis rs10510102 0.872 rs11200268 ENSG00000226864.1 ATE1-AS1 4.69 3.88e-06 0.00117 0.42 0.25 Breast cancer; chr10:121932661 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs11200269 ENSG00000226864.1 ATE1-AS1 4.69 3.88e-06 0.00117 0.42 0.25 Breast cancer; chr10:121934021 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs11498944 ENSG00000226864.1 ATE1-AS1 4.69 3.88e-06 0.00117 0.42 0.25 Breast cancer; chr10:121938748 chr10:121928312~121951965:+ LIHC cis rs10510102 0.81 rs12267347 ENSG00000226864.1 ATE1-AS1 4.69 3.88e-06 0.00117 0.42 0.25 Breast cancer; chr10:121939110 chr10:121928312~121951965:+ LIHC cis rs10510102 0.808 rs12253007 ENSG00000226864.1 ATE1-AS1 4.69 3.88e-06 0.00117 0.42 0.25 Breast cancer; chr10:121939360 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs79865971 ENSG00000226864.1 ATE1-AS1 4.69 3.88e-06 0.00117 0.42 0.25 Breast cancer; chr10:121941208 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs74318512 ENSG00000226864.1 ATE1-AS1 4.69 3.88e-06 0.00117 0.42 0.25 Breast cancer; chr10:121941465 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs12257207 ENSG00000226864.1 ATE1-AS1 4.69 3.88e-06 0.00117 0.42 0.25 Breast cancer; chr10:121941737 chr10:121928312~121951965:+ LIHC cis rs11098499 0.908 rs11098527 ENSG00000260091.1 RP11-33B1.4 -4.69 3.88e-06 0.00117 -0.17 -0.25 Corneal astigmatism; chr4:119478751 chr4:119409333~119410233:+ LIHC cis rs5756813 0.727 rs4820303 ENSG00000233360.4 Z83844.1 4.69 3.88e-06 0.00117 0.32 0.25 Optic cup area;Vertical cup-disc ratio; chr22:37738159 chr22:37641832~37658377:- LIHC cis rs5756813 0.727 rs4239889 ENSG00000233360.4 Z83844.1 4.69 3.88e-06 0.00117 0.32 0.25 Optic cup area;Vertical cup-disc ratio; chr22:37744345 chr22:37641832~37658377:- LIHC cis rs227275 0.525 rs6419160 ENSG00000246560.2 RP11-10L12.4 4.69 3.89e-06 0.00117 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102938648 chr4:102828055~102844075:+ LIHC cis rs7412746 0.611 rs4970984 ENSG00000231073.1 RP11-316M1.3 4.69 3.89e-06 0.00117 0.24 0.25 Melanoma; chr1:150914901 chr1:150973123~150975534:+ LIHC cis rs2274273 0.868 rs1572611 ENSG00000258413.1 RP11-665C16.6 -4.69 3.89e-06 0.00117 -0.29 -0.25 Protein biomarker; chr14:55367156 chr14:55262767~55272075:- LIHC cis rs960902 0.747 rs7595792 ENSG00000213553.4 RPLP0P6 4.69 3.89e-06 0.00117 0.2 0.25 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37502480 chr2:38481851~38482804:+ LIHC cis rs62355900 0.5 rs832401 ENSG00000271828.1 CTD-2310F14.1 -4.69 3.89e-06 0.00117 -0.39 -0.25 Endometriosis; chr5:56968297 chr5:56927874~56929573:+ LIHC cis rs12134133 0.962 rs11120512 ENSG00000274245.1 RP11-357P18.2 -4.69 3.89e-06 0.00117 -0.36 -0.25 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207240370 chr1:207372559~207373252:+ LIHC cis rs1555322 0.53 rs8122819 ENSG00000279253.1 RP4-614O4.13 -4.69 3.89e-06 0.00117 -0.33 -0.25 Attention deficit hyperactivity disorder; chr20:35293783 chr20:35262727~35264187:- LIHC cis rs765787 0.53 rs12904331 ENSG00000259520.4 CTD-2651B20.3 -4.69 3.89e-06 0.00117 -0.29 -0.25 Uric acid levels; chr15:45226095 chr15:45251580~45279251:- LIHC cis rs6997458 0.742 rs4566 ENSG00000253549.4 RP11-317J10.2 4.69 3.89e-06 0.00117 0.26 0.25 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85448853 chr8:85441851~85464915:- LIHC cis rs9834975 0.903 rs56131302 ENSG00000272758.4 RP11-299J3.8 -4.69 3.89e-06 0.00117 -0.27 -0.25 Diastolic blood pressure; chr3:122499141 chr3:122416207~122443180:+ LIHC cis rs9834975 0.935 rs6438735 ENSG00000272758.4 RP11-299J3.8 -4.69 3.89e-06 0.00117 -0.27 -0.25 Diastolic blood pressure; chr3:122500539 chr3:122416207~122443180:+ LIHC cis rs1823913 0.927 rs35530564 ENSG00000227542.1 AC092614.2 4.69 3.9e-06 0.00117 0.25 0.25 Obesity-related traits; chr2:191247324 chr2:191229165~191246172:- LIHC cis rs4862307 0.754 rs6846007 ENSG00000250726.1 RP11-616K6.1 -4.69 3.9e-06 0.00117 -0.27 -0.25 Serum dimethylarginine levels (asymmetric/symetric ratio); chr4:184070451 chr4:184072403~184073039:+ LIHC cis rs6600671 0.966 rs6600664 ENSG00000231429.2 RP11-343N15.2 -4.69 3.91e-06 0.00117 -0.28 -0.25 Hip geometry; chr1:121480638 chr1:121412719~121429274:+ LIHC cis rs6600671 0.932 rs6600663 ENSG00000231429.2 RP11-343N15.2 -4.69 3.91e-06 0.00117 -0.28 -0.25 Hip geometry; chr1:121480639 chr1:121412719~121429274:+ LIHC cis rs748404 0.65 rs556851 ENSG00000166763.7 STRCP1 4.69 3.91e-06 0.00117 0.31 0.25 Lung cancer; chr15:43279021 chr15:43699488~43718184:- LIHC cis rs748404 0.697 rs567357 ENSG00000166763.7 STRCP1 4.69 3.91e-06 0.00117 0.31 0.25 Lung cancer; chr15:43279192 chr15:43699488~43718184:- LIHC cis rs11603023 0.967 rs7936556 ENSG00000255422.1 AP002954.4 4.69 3.91e-06 0.00117 0.27 0.25 Cholesterol, total; chr11:118630582 chr11:118704607~118750263:+ LIHC cis rs875971 0.545 rs4441996 ENSG00000273142.1 RP11-458F8.4 -4.69 3.92e-06 0.00118 -0.24 -0.25 Aortic root size; chr7:66123233 chr7:66902857~66906297:+ LIHC cis rs6142102 0.527 rs1015362 ENSG00000276073.1 RP5-1125A11.7 4.69 3.92e-06 0.00118 0.28 0.25 Skin pigmentation; chr20:34150806 chr20:33985617~33988989:- LIHC cis rs17711722 0.51 rs11767457 ENSG00000236529.1 RP13-254B10.1 4.69 3.93e-06 0.00118 0.23 0.25 Calcium levels; chr7:65825628 chr7:65840212~65840596:+ LIHC cis rs1577917 1 rs10455455 ENSG00000234155.1 RP11-30P6.6 4.69 3.93e-06 0.00118 0.33 0.25 Response to antipsychotic treatment; chr6:85960496 chr6:85387219~85390186:- LIHC cis rs1865760 0.964 rs6932113 ENSG00000216436.2 HIST1H2APS1 -4.69 3.93e-06 0.00118 -0.27 -0.25 Height; chr6:25912870 chr6:25732497~25732827:+ LIHC cis rs1865760 1 rs7757666 ENSG00000216436.2 HIST1H2APS1 -4.69 3.93e-06 0.00118 -0.27 -0.25 Height; chr6:25902398 chr6:25732497~25732827:+ LIHC cis rs1865760 1 rs6910138 ENSG00000216436.2 HIST1H2APS1 -4.69 3.93e-06 0.00118 -0.27 -0.25 Height; chr6:25904124 chr6:25732497~25732827:+ LIHC cis rs1865760 1 rs6910174 ENSG00000216436.2 HIST1H2APS1 -4.69 3.93e-06 0.00118 -0.27 -0.25 Height; chr6:25904186 chr6:25732497~25732827:+ LIHC cis rs1865760 1 rs6905887 ENSG00000216436.2 HIST1H2APS1 -4.69 3.93e-06 0.00118 -0.27 -0.25 Height; chr6:25911875 chr6:25732497~25732827:+ LIHC cis rs10510102 0.516 rs3936070 ENSG00000276742.1 RP11-500G22.4 4.69 3.93e-06 0.00118 0.42 0.25 Breast cancer; chr10:121974440 chr10:121956782~121957098:+ LIHC cis rs67311347 0.544 rs12633295 ENSG00000223797.4 ENTPD3-AS1 -4.69 3.93e-06 0.00118 -0.2 -0.25 Renal cell carcinoma; chr3:40293801 chr3:40313802~40453329:- LIHC cis rs5758511 0.68 rs5758681 ENSG00000205702.9 CYP2D7 4.69 3.93e-06 0.00118 0.29 0.25 Birth weight; chr22:42249085 chr22:42140203~42144577:- LIHC cis rs5758511 0.68 rs5758657 ENSG00000205702.9 CYP2D7 4.69 3.93e-06 0.00118 0.29 0.25 Birth weight; chr22:42222663 chr22:42140203~42144577:- LIHC cis rs1729407 0.786 rs5100 ENSG00000236267.1 AP006216.5 4.69 3.94e-06 0.00118 0.23 0.25 Apolipoprotein A-IV levels; chr11:116821978 chr11:116813204~116814003:- LIHC cis rs11098499 0.909 rs10020034 ENSG00000245958.5 RP11-33B1.1 -4.69 3.95e-06 0.00119 -0.26 -0.25 Corneal astigmatism; chr4:119373176 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs59394118 ENSG00000245958.5 RP11-33B1.1 -4.69 3.95e-06 0.00119 -0.26 -0.25 Corneal astigmatism; chr4:119374396 chr4:119454791~119552025:+ LIHC cis rs11098499 0.865 rs9996417 ENSG00000245958.5 RP11-33B1.1 -4.69 3.95e-06 0.00119 -0.26 -0.25 Corneal astigmatism; chr4:119374707 chr4:119454791~119552025:+ LIHC cis rs1165668 0.785 rs1165681 ENSG00000257327.1 RP11-650K20.3 -4.69 3.95e-06 0.00119 -0.29 -0.25 Coronary heart disease (SNP X SNP interaction); chr12:103931333 chr12:103841451~103844664:+ LIHC cis rs2834188 1 rs2834187 ENSG00000272659.1 AP000295.10 -4.69 3.95e-06 0.00119 -0.36 -0.25 Narcolepsy; chr21:33315105 chr21:33309491~33310181:+ LIHC cis rs2836974 0.644 rs7281853 ENSG00000255568.3 BRWD1-AS2 -4.69 3.95e-06 0.00119 -0.21 -0.25 Cognitive function; chr21:39321564 chr21:39313935~39314962:+ LIHC cis rs12554020 0.582 rs7033532 ENSG00000227603.1 RP11-165J3.6 4.69 3.96e-06 0.00119 0.45 0.25 Schizophrenia; chr9:93644962 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs7038310 ENSG00000227603.1 RP11-165J3.6 4.69 3.96e-06 0.00119 0.45 0.25 Schizophrenia; chr9:93645638 chr9:93435332~93437121:- LIHC cis rs5758511 0.633 rs5758690 ENSG00000205702.9 CYP2D7 4.69 3.96e-06 0.00119 0.29 0.25 Birth weight; chr22:42272289 chr22:42140203~42144577:- LIHC cis rs5758511 0.68 rs1001586 ENSG00000205702.9 CYP2D7 4.69 3.96e-06 0.00119 0.29 0.25 Birth weight; chr22:42274287 chr22:42140203~42144577:- LIHC cis rs8067287 0.688 rs11078356 ENSG00000205312.7 KRT17P4 -4.69 3.96e-06 0.00119 -0.38 -0.25 Diabetic kidney disease; chr17:16942894 chr17:16847635~16852777:- LIHC cis rs11603023 0.805 rs687190 ENSG00000255422.1 AP002954.4 -4.69 3.96e-06 0.00119 -0.27 -0.25 Cholesterol, total; chr11:118671674 chr11:118704607~118750263:+ LIHC cis rs597539 0.652 rs501799 ENSG00000250508.1 RP11-757G1.6 -4.69 3.97e-06 0.00119 -0.36 -0.25 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68863772 chr11:68870664~68874542:+ LIHC cis rs2310173 0.575 rs2110563 ENSG00000281162.1 LINC01127 -4.69 3.97e-06 0.00119 -0.27 -0.25 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:102011971 chr2:101962056~101987167:+ LIHC cis rs2243480 1 rs2533288 ENSG00000230295.1 RP11-458F8.2 -4.69 3.97e-06 0.00119 -0.26 -0.25 Diabetic kidney disease; chr7:66591724 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs2707844 ENSG00000230295.1 RP11-458F8.2 -4.69 3.97e-06 0.00119 -0.26 -0.25 Diabetic kidney disease; chr7:66594522 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1796220 ENSG00000230295.1 RP11-458F8.2 -4.69 3.97e-06 0.00119 -0.26 -0.25 Diabetic kidney disease; chr7:66597113 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs2707831 ENSG00000230295.1 RP11-458F8.2 -4.69 3.97e-06 0.00119 -0.26 -0.25 Diabetic kidney disease; chr7:66597524 chr7:66880708~66882981:+ LIHC cis rs71520386 0.632 rs10269414 ENSG00000228649.7 AC005682.5 -4.69 3.98e-06 0.00119 -0.32 -0.25 Fibrinogen levels; chr7:22816674 chr7:22854178~22861579:+ LIHC cis rs71520386 0.632 rs2286500 ENSG00000228649.7 AC005682.5 -4.69 3.98e-06 0.00119 -0.32 -0.25 Fibrinogen levels; chr7:22817185 chr7:22854178~22861579:+ LIHC cis rs6997458 0.713 rs1543852 ENSG00000253549.4 RP11-317J10.2 4.69 3.98e-06 0.00119 0.27 0.25 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85440529 chr8:85441851~85464915:- LIHC cis rs2439831 0.85 rs28718261 ENSG00000275601.1 AC011330.13 -4.69 3.98e-06 0.00119 -0.36 -0.25 Lung cancer in ever smokers; chr15:43751595 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs28595038 ENSG00000275601.1 AC011330.13 -4.69 3.98e-06 0.00119 -0.36 -0.25 Lung cancer in ever smokers; chr15:43752661 chr15:43642389~43643023:- LIHC cis rs2998286 0.723 rs332177 ENSG00000254635.4 WAC-AS1 -4.69 3.98e-06 0.00119 -0.32 -0.25 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28618221 chr10:28522652~28532743:- LIHC cis rs7937890 0.507 rs4463820 ENSG00000251991.1 RNU7-49P 4.69 3.98e-06 0.00119 0.27 0.25 Mitochondrial DNA levels; chr11:14534796 chr11:14478892~14478953:+ LIHC cis rs11098499 0.865 rs4001305 ENSG00000260091.1 RP11-33B1.4 -4.69 3.98e-06 0.00119 -0.18 -0.25 Corneal astigmatism; chr4:119438081 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs3890049 ENSG00000260091.1 RP11-33B1.4 -4.69 3.98e-06 0.00119 -0.17 -0.25 Corneal astigmatism; chr4:119405128 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs67265404 ENSG00000260091.1 RP11-33B1.4 -4.69 3.98e-06 0.00119 -0.17 -0.25 Corneal astigmatism; chr4:119438115 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs71629403 ENSG00000260091.1 RP11-33B1.4 -4.69 3.98e-06 0.00119 -0.17 -0.25 Corneal astigmatism; chr4:119451412 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs28571712 ENSG00000260091.1 RP11-33B1.4 -4.69 3.98e-06 0.00119 -0.17 -0.25 Corneal astigmatism; chr4:119454825 chr4:119409333~119410233:+ LIHC cis rs11098499 0.865 rs9994730 ENSG00000260091.1 RP11-33B1.4 -4.69 3.98e-06 0.00119 -0.17 -0.25 Corneal astigmatism; chr4:119460409 chr4:119409333~119410233:+ LIHC cis rs12701220 0.522 rs1881116 ENSG00000229043.2 AC091729.9 -4.69 3.98e-06 0.00119 -0.31 -0.25 Bronchopulmonary dysplasia; chr7:1014322 chr7:1160374~1165267:+ LIHC cis rs10833905 0.818 rs10833876 ENSG00000246225.5 RP11-17A1.3 -4.69 3.98e-06 0.00119 -0.33 -0.25 Sudden cardiac arrest; chr11:22985076 chr11:22829380~22945393:+ LIHC cis rs11098499 0.644 rs34835603 ENSG00000245958.5 RP11-33B1.1 -4.69 3.99e-06 0.00119 -0.25 -0.25 Corneal astigmatism; chr4:119632273 chr4:119454791~119552025:+ LIHC cis rs5758511 0.68 rs739147 ENSG00000205702.9 CYP2D7 4.69 3.99e-06 0.00119 0.29 0.25 Birth weight; chr22:42275060 chr22:42140203~42144577:- LIHC cis rs11971779 0.68 rs17613690 ENSG00000273391.1 RP11-634H22.1 -4.69 3.99e-06 0.00119 -0.22 -0.25 Diisocyanate-induced asthma; chr7:139403655 chr7:139359032~139359566:- LIHC cis rs17818399 0.708 rs13000706 ENSG00000279254.1 RP11-536C12.1 -4.69 3.99e-06 0.0012 -0.28 -0.25 Height; chr2:46611108 chr2:46668870~46670778:+ LIHC cis rs748404 0.697 rs493444 ENSG00000166763.7 STRCP1 4.69 3.99e-06 0.0012 0.31 0.25 Lung cancer; chr15:43274272 chr15:43699488~43718184:- LIHC cis rs1862618 0.853 rs1423621 ENSG00000271828.1 CTD-2310F14.1 4.69 3.99e-06 0.0012 0.34 0.25 Initial pursuit acceleration; chr5:56805208 chr5:56927874~56929573:+ LIHC cis rs2283792 0.776 rs9610458 ENSG00000224086.5 LL22NC03-86G7.1 -4.69 3.99e-06 0.0012 -0.23 -0.25 Multiple sclerosis; chr22:21851064 chr22:21938293~21977632:+ LIHC cis rs1558001 0.87 rs2158729 ENSG00000230196.1 DDX43P3 4.69 4e-06 0.0012 0.26 0.25 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81790712 chr7:81610884~81611326:- LIHC cis rs12554020 0.504 rs74369348 ENSG00000227603.1 RP11-165J3.6 4.69 4e-06 0.0012 0.45 0.25 Schizophrenia; chr9:93664902 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs76863038 ENSG00000227603.1 RP11-165J3.6 4.69 4e-06 0.0012 0.45 0.25 Schizophrenia; chr9:93666143 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs56310424 ENSG00000227603.1 RP11-165J3.6 4.69 4e-06 0.0012 0.45 0.25 Schizophrenia; chr9:93666313 chr9:93435332~93437121:- LIHC cis rs12554020 0.504 rs12551694 ENSG00000227603.1 RP11-165J3.6 4.69 4e-06 0.0012 0.45 0.25 Schizophrenia; chr9:93666619 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs12555927 ENSG00000227603.1 RP11-165J3.6 4.69 4e-06 0.0012 0.45 0.25 Schizophrenia; chr9:93666800 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs3829059 ENSG00000227603.1 RP11-165J3.6 4.69 4e-06 0.0012 0.45 0.25 Schizophrenia; chr9:93668874 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs76499753 ENSG00000227603.1 RP11-165J3.6 4.69 4e-06 0.0012 0.45 0.25 Schizophrenia; chr9:93670155 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs1963 ENSG00000227603.1 RP11-165J3.6 4.69 4e-06 0.0012 0.45 0.25 Schizophrenia; chr9:93670315 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs76244171 ENSG00000227603.1 RP11-165J3.6 4.69 4e-06 0.0012 0.45 0.25 Schizophrenia; chr9:93673473 chr9:93435332~93437121:- LIHC cis rs2739330 0.828 rs2330635 ENSG00000206090.4 AP000350.7 4.69 4e-06 0.0012 0.29 0.25 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23939998~23942798:+ LIHC cis rs227275 0.525 rs7685399 ENSG00000246560.2 RP11-10L12.4 4.69 4.01e-06 0.0012 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102991926 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs4623004 ENSG00000246560.2 RP11-10L12.4 4.69 4.01e-06 0.0012 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:103000141 chr4:102828055~102844075:+ LIHC cis rs10129255 0.518 rs2006284 ENSG00000223648.3 IGHV3-64 4.69 4.01e-06 0.0012 0.17 0.25 Kawasaki disease; chr14:106676185 chr14:106643132~106658258:- LIHC cis rs2797160 0.651 rs1268093 ENSG00000237742.5 RP11-624M8.1 4.69 4.01e-06 0.0012 0.23 0.25 Endometrial cancer; chr6:125708089 chr6:125578558~125749190:- LIHC cis rs853679 0.657 rs1778483 ENSG00000204709.4 LINC01556 4.69 4.01e-06 0.0012 0.28 0.25 Depression; chr6:28273214 chr6:28943877~28944537:+ LIHC cis rs853679 0.657 rs1778482 ENSG00000204709.4 LINC01556 4.69 4.01e-06 0.0012 0.28 0.25 Depression; chr6:28273215 chr6:28943877~28944537:+ LIHC cis rs916888 0.531 rs183211 ENSG00000260075.1 NSFP1 4.69 4.01e-06 0.0012 0.3 0.25 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:46372855~46487141:+ LIHC cis rs6901152 0.525 rs974754 ENSG00000217648.1 RP1-95L4.4 -4.69 4.02e-06 0.0012 -0.29 -0.25 Acute lymphoblastic leukemia (childhood); chr6:143366384 chr6:143342246~143343383:+ LIHC cis rs7119038 0.629 rs73001429 ENSG00000255239.1 AP002954.6 -4.69 4.02e-06 0.0012 -0.33 -0.25 Sjögren's syndrome; chr11:118732456 chr11:118688039~118690600:- LIHC cis rs11089937 0.568 rs59356111 ENSG00000211639.2 IGLV4-60 4.69 4.02e-06 0.0012 0.21 0.25 Periodontitis (PAL4Q3); chr22:22136175 chr22:22162199~22162681:+ LIHC cis rs11089937 0.626 rs5757019 ENSG00000211639.2 IGLV4-60 4.69 4.02e-06 0.0012 0.21 0.25 Periodontitis (PAL4Q3); chr22:22136286 chr22:22162199~22162681:+ LIHC cis rs11779988 0.545 rs427168 ENSG00000253671.1 RP11-806O11.1 -4.69 4.02e-06 0.0012 -0.33 -0.25 Breast cancer; chr8:17927320 chr8:17808941~17820868:+ LIHC cis rs11779988 0.545 rs4124900 ENSG00000253671.1 RP11-806O11.1 -4.69 4.02e-06 0.0012 -0.33 -0.25 Breast cancer; chr8:17927757 chr8:17808941~17820868:+ LIHC cis rs5769765 0.837 rs8142737 ENSG00000278869.1 CITF22-49E9.3 4.69 4.02e-06 0.0012 0.36 0.25 Schizophrenia; chr22:49898241 chr22:49933198~49934074:- LIHC cis rs11779988 0.545 rs422746 ENSG00000253671.1 RP11-806O11.1 -4.69 4.02e-06 0.0012 -0.33 -0.25 Breast cancer; chr8:17926977 chr8:17808941~17820868:+ LIHC cis rs1865760 1 rs3799372 ENSG00000216436.2 HIST1H2APS1 -4.69 4.02e-06 0.0012 -0.27 -0.25 Height; chr6:25922083 chr6:25732497~25732827:+ LIHC cis rs1865760 0.963 rs1540273 ENSG00000216436.2 HIST1H2APS1 -4.69 4.02e-06 0.0012 -0.27 -0.25 Height; chr6:25923930 chr6:25732497~25732827:+ LIHC cis rs1865760 1 rs9358895 ENSG00000216436.2 HIST1H2APS1 -4.69 4.02e-06 0.0012 -0.27 -0.25 Height; chr6:25924427 chr6:25732497~25732827:+ LIHC cis rs875971 0.545 rs316328 ENSG00000273142.1 RP11-458F8.4 -4.69 4.02e-06 0.0012 -0.22 -0.25 Aortic root size; chr7:66143851 chr7:66902857~66906297:+ LIHC cis rs2929278 0.617 rs3087657 ENSG00000166763.7 STRCP1 4.69 4.02e-06 0.0012 0.3 0.25 Schizophrenia; chr15:43771661 chr15:43699488~43718184:- LIHC cis rs11096990 0.593 rs35552004 ENSG00000249685.1 RP11-360F5.3 4.69 4.02e-06 0.0012 0.3 0.25 Cognitive function; chr4:39170914 chr4:39133913~39135608:+ LIHC cis rs6951245 0.554 rs75075857 ENSG00000229043.2 AC091729.9 -4.69 4.03e-06 0.0012 -0.44 -0.25 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1100662 chr7:1160374~1165267:+ LIHC cis rs227275 0.525 rs3974485 ENSG00000246560.2 RP11-10L12.4 4.69 4.03e-06 0.0012 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102993283 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs6533052 ENSG00000246560.2 RP11-10L12.4 4.69 4.03e-06 0.00121 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102990624 chr4:102828055~102844075:+ LIHC cis rs1003645 1 rs9908216 ENSG00000275944.1 RP11-104J23.1 4.69 4.03e-06 0.00121 0.24 0.25 Blood protein levels; chr17:36018981 chr17:36001419~36011618:+ LIHC cis rs17818399 0.781 rs34449783 ENSG00000279254.1 RP11-536C12.1 -4.69 4.03e-06 0.00121 -0.3 -0.25 Height; chr2:46636416 chr2:46668870~46670778:+ LIHC cis rs17818399 0.815 rs17768138 ENSG00000279254.1 RP11-536C12.1 -4.69 4.03e-06 0.00121 -0.3 -0.25 Height; chr2:46641078 chr2:46668870~46670778:+ LIHC cis rs227275 0.525 rs7672319 ENSG00000246560.2 RP11-10L12.4 4.69 4.04e-06 0.00121 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102990002 chr4:102828055~102844075:+ LIHC cis rs227275 0.525 rs6533051 ENSG00000246560.2 RP11-10L12.4 4.69 4.04e-06 0.00121 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102990065 chr4:102828055~102844075:+ LIHC cis rs733592 0.56 rs2158515 ENSG00000240399.1 RP1-228P16.1 -4.69 4.04e-06 0.00121 -0.24 -0.25 Plateletcrit; chr12:48113885 chr12:48054813~48055591:- LIHC cis rs2739330 0.828 rs5760107 ENSG00000206090.4 AP000350.7 4.69 4.04e-06 0.00121 0.29 0.25 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23939998~23942798:+ LIHC cis rs8005677 1 rs4982712 ENSG00000257285.4 RP11-298I3.1 4.69 4.04e-06 0.00121 0.25 0.25 Cognitive ability (multi-trait analysis); chr14:22934519 chr14:22929609~22955562:+ LIHC cis rs9903692 0.908 rs9807087 ENSG00000278765.1 RP5-890E16.5 -4.69 4.04e-06 0.00121 -0.33 -0.25 Pulse pressure; chr17:48126776 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs7209730 ENSG00000278765.1 RP5-890E16.5 -4.69 4.04e-06 0.00121 -0.33 -0.25 Pulse pressure; chr17:48130137 chr17:48066704~48067293:- LIHC cis rs61041384 1 rs76872194 ENSG00000256092.2 RP13-942N8.1 -4.69 4.04e-06 0.00121 -0.39 -0.25 Schizophrenia; chr12:123208816 chr12:123363868~123366113:+ LIHC cis rs67311347 0.869 rs9832311 ENSG00000223797.4 ENTPD3-AS1 4.69 4.04e-06 0.00121 0.2 0.25 Renal cell carcinoma; chr3:40339831 chr3:40313802~40453329:- LIHC cis rs228614 0.536 rs150897 ENSG00000246560.2 RP11-10L12.4 4.68 4.05e-06 0.00121 0.27 0.25 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769309 chr4:102828055~102844075:+ LIHC cis rs4660456 0.542 rs850009 ENSG00000237899.1 RP4-739H11.3 4.68 4.05e-06 0.00121 0.33 0.25 Platelet count; chr1:40643593 chr1:40669089~40687588:- LIHC cis rs10510102 0.872 rs3862129 ENSG00000226864.1 ATE1-AS1 4.68 4.05e-06 0.00121 0.39 0.25 Breast cancer; chr10:121824460 chr10:121928312~121951965:+ LIHC cis rs7208859 0.673 rs216409 ENSG00000266490.1 CTD-2349P21.9 -4.68 4.05e-06 0.00121 -0.29 -0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30579251 chr17:30792372~30792833:+ LIHC cis rs2919917 1 rs7839152 ENSG00000254352.1 RP11-578O24.2 4.68 4.06e-06 0.00121 0.33 0.25 Lymphocyte counts; chr8:78677777 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs28429528 ENSG00000254352.1 RP11-578O24.2 4.68 4.06e-06 0.00121 0.33 0.25 Lymphocyte counts; chr8:78678782 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs9298316 ENSG00000254352.1 RP11-578O24.2 4.68 4.06e-06 0.00121 0.33 0.25 Lymphocyte counts; chr8:78680191 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs7842142 ENSG00000254352.1 RP11-578O24.2 4.68 4.06e-06 0.00121 0.33 0.25 Lymphocyte counts; chr8:78681501 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs11785966 ENSG00000254352.1 RP11-578O24.2 4.68 4.06e-06 0.00121 0.33 0.25 Lymphocyte counts; chr8:78681851 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs10092335 ENSG00000254352.1 RP11-578O24.2 4.68 4.06e-06 0.00121 0.33 0.25 Lymphocyte counts; chr8:78686218 chr8:78723796~78724136:- LIHC cis rs4660214 0.666 rs1537818 ENSG00000182109.6 RP11-69E11.4 -4.68 4.06e-06 0.00121 -0.26 -0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39181366 chr1:39522280~39546187:- LIHC cis rs11971779 0.793 rs11764426 ENSG00000273391.1 RP11-634H22.1 4.68 4.06e-06 0.00121 0.23 0.25 Diisocyanate-induced asthma; chr7:139339304 chr7:139359032~139359566:- LIHC cis rs2439831 0.85 rs7168158 ENSG00000275601.1 AC011330.13 -4.68 4.06e-06 0.00121 -0.36 -0.25 Lung cancer in ever smokers; chr15:43758178 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs7174208 ENSG00000275601.1 AC011330.13 -4.68 4.06e-06 0.00121 -0.36 -0.25 Lung cancer in ever smokers; chr15:43760484 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs12101756 ENSG00000275601.1 AC011330.13 -4.68 4.06e-06 0.00121 -0.36 -0.25 Lung cancer in ever smokers; chr15:43761689 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs3862142 ENSG00000275601.1 AC011330.13 -4.68 4.06e-06 0.00121 -0.36 -0.25 Lung cancer in ever smokers; chr15:43772608 chr15:43642389~43643023:- LIHC cis rs2439831 0.702 rs2788 ENSG00000275601.1 AC011330.13 -4.68 4.06e-06 0.00121 -0.36 -0.25 Lung cancer in ever smokers; chr15:43772688 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs28891769 ENSG00000275601.1 AC011330.13 -4.68 4.06e-06 0.00121 -0.36 -0.25 Lung cancer in ever smokers; chr15:43780662 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs28578398 ENSG00000275601.1 AC011330.13 -4.68 4.06e-06 0.00121 -0.36 -0.25 Lung cancer in ever smokers; chr15:43782848 chr15:43642389~43643023:- LIHC cis rs11098499 0.722 rs28713555 ENSG00000245958.5 RP11-33B1.1 -4.68 4.06e-06 0.00121 -0.25 -0.25 Corneal astigmatism; chr4:119330840 chr4:119454791~119552025:+ LIHC cis rs11098499 0.743 rs11098501 ENSG00000245958.5 RP11-33B1.1 -4.68 4.06e-06 0.00121 -0.25 -0.25 Corneal astigmatism; chr4:119330862 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs11098502 ENSG00000245958.5 RP11-33B1.1 -4.68 4.06e-06 0.00121 -0.25 -0.25 Corneal astigmatism; chr4:119330908 chr4:119454791~119552025:+ LIHC cis rs11098499 0.708 rs11732686 ENSG00000245958.5 RP11-33B1.1 -4.68 4.06e-06 0.00121 -0.25 -0.25 Corneal astigmatism; chr4:119331175 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs11724409 ENSG00000245958.5 RP11-33B1.1 -4.68 4.06e-06 0.00121 -0.25 -0.25 Corneal astigmatism; chr4:119331206 chr4:119454791~119552025:+ LIHC cis rs11971779 0.715 rs6467856 ENSG00000273391.1 RP11-634H22.1 4.68 4.06e-06 0.00121 0.22 0.25 Diisocyanate-induced asthma; chr7:139442553 chr7:139359032~139359566:- LIHC cis rs12134133 1 rs6660254 ENSG00000274245.1 RP11-357P18.2 4.68 4.07e-06 0.00121 0.37 0.25 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207272746 chr1:207372559~207373252:+ LIHC cis rs10129255 0.536 rs6576201 ENSG00000223648.3 IGHV3-64 -4.68 4.07e-06 0.00121 -0.17 -0.25 Kawasaki disease; chr14:106683696 chr14:106643132~106658258:- LIHC cis rs10510102 0.872 rs56108883 ENSG00000276742.1 RP11-500G22.4 4.68 4.07e-06 0.00122 0.37 0.25 Breast cancer; chr10:121825567 chr10:121956782~121957098:+ LIHC cis rs2929278 0.617 rs663214 ENSG00000166763.7 STRCP1 -4.68 4.08e-06 0.00122 -0.3 -0.25 Schizophrenia; chr15:43821584 chr15:43699488~43718184:- LIHC cis rs11079159 0.637 rs7218159 ENSG00000263096.1 RP11-515O17.2 -4.68 4.08e-06 0.00122 -0.44 -0.25 QRS duration; chr17:55277434 chr17:55271504~55273653:- LIHC cis rs17507216 0.671 rs28582623 ENSG00000278603.1 RP13-608F4.5 4.68 4.08e-06 0.00122 0.48 0.25 Excessive daytime sleepiness; chr15:82577381 chr15:82472203~82472426:+ LIHC cis rs6445975 0.726 rs6762098 ENSG00000272360.1 RP11-359I18.5 -4.68 4.08e-06 0.00122 -0.29 -0.25 Systemic lupus erythematosus; chr3:58482701 chr3:58490830~58491291:- LIHC cis rs5769765 0.862 rs138897 ENSG00000278869.1 CITF22-49E9.3 4.68 4.08e-06 0.00122 0.37 0.25 Schizophrenia; chr22:49837419 chr22:49933198~49934074:- LIHC cis rs4650994 0.525 rs4650996 ENSG00000273384.1 RP5-1098D14.1 4.68 4.08e-06 0.00122 0.31 0.25 HDL cholesterol;HDL cholesterol levels; chr1:178548230 chr1:178651706~178652282:+ LIHC cis rs7945705 0.902 rs7930026 ENSG00000254860.4 TMEM9B-AS1 -4.68 4.09e-06 0.00122 -0.26 -0.25 Hemoglobin concentration; chr11:8992092 chr11:8964675~8977527:+ LIHC cis rs929596 0.556 rs4477910 ENSG00000233445.1 RPL17P11 4.68 4.09e-06 0.00122 0.28 0.25 Total bilirubin levels in HIV-1 infection; chr2:233735091 chr2:233721522~233722065:- LIHC cis rs3733585 0.674 rs7375643 ENSG00000250413.1 RP11-448G15.1 4.68 4.09e-06 0.00122 0.31 0.25 Cleft plate (environmental tobacco smoke interaction); chr4:9953615 chr4:10006482~10009725:+ LIHC cis rs11089937 0.524 rs2877021 ENSG00000211639.2 IGLV4-60 4.68 4.09e-06 0.00122 0.21 0.25 Periodontitis (PAL4Q3); chr22:22165909 chr22:22162199~22162681:+ LIHC cis rs6479901 0.588 rs10740105 ENSG00000232075.1 MRPL35P2 -4.68 4.09e-06 0.00122 -0.28 -0.25 Intelligence (multi-trait analysis); chr10:63129957 chr10:63634317~63634827:- LIHC cis rs2337406 1 rs7145172 ENSG00000274576.2 IGHV2-70 -4.68 4.09e-06 0.00122 -0.28 -0.25 Alzheimer's disease (late onset); chr14:106704924 chr14:106770577~106771020:- LIHC cis rs2581828 0.656 rs2253685 ENSG00000242142.1 SERBP1P3 4.68 4.09e-06 0.00122 0.28 0.25 Crohn's disease; chr3:53085687 chr3:53064283~53065091:- LIHC cis rs2581828 0.656 rs2253796 ENSG00000242142.1 SERBP1P3 4.68 4.09e-06 0.00122 0.28 0.25 Crohn's disease; chr3:53086082 chr3:53064283~53065091:- LIHC cis rs2581828 0.656 rs11130338 ENSG00000242142.1 SERBP1P3 4.68 4.09e-06 0.00122 0.28 0.25 Crohn's disease; chr3:53086908 chr3:53064283~53065091:- LIHC cis rs2929278 0.561 rs62018952 ENSG00000275601.1 AC011330.13 4.68 4.1e-06 0.00122 0.31 0.25 Schizophrenia; chr15:43788539 chr15:43642389~43643023:- LIHC cis rs11098499 0.697 rs35280960 ENSG00000245958.5 RP11-33B1.1 -4.68 4.1e-06 0.00122 -0.26 -0.25 Corneal astigmatism; chr4:119335904 chr4:119454791~119552025:+ LIHC cis rs11098499 0.908 rs7696649 ENSG00000260091.1 RP11-33B1.4 -4.68 4.1e-06 0.00122 -0.18 -0.25 Corneal astigmatism; chr4:119401022 chr4:119409333~119410233:+ LIHC cis rs860295 0.541 rs11264359 ENSG00000203761.5 MSTO2P -4.68 4.11e-06 0.00122 -0.2 -0.25 Body mass index; chr1:155313038 chr1:155745829~155750137:+ LIHC cis rs8177376 0.906 rs487450 ENSG00000254905.1 RP11-712L6.7 4.68 4.11e-06 0.00122 0.39 0.25 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126188474 chr11:126292922~126294254:- LIHC cis rs8024893 0.841 rs79265647 ENSG00000270055.1 CTD-3092A11.2 -4.68 4.11e-06 0.00122 -0.41 -0.25 Red cell distribution width; chr15:31251362 chr15:30487963~30490313:+ LIHC cis rs12291225 0.877 rs11023160 ENSG00000251991.1 RNU7-49P 4.68 4.11e-06 0.00123 0.26 0.25 Sense of smell; chr11:14242679 chr11:14478892~14478953:+ LIHC cis rs11722779 0.869 rs223350 ENSG00000246560.2 RP11-10L12.4 4.68 4.11e-06 0.00123 0.28 0.25 Schizophrenia; chr4:102856899 chr4:102828055~102844075:+ LIHC cis rs8064024 0.68 rs3747613 ENSG00000267077.1 RP11-127I20.5 -4.68 4.12e-06 0.00123 -0.25 -0.25 Cancer; chr16:4858503 chr16:4795265~4796532:- LIHC cis rs1577917 0.958 rs10944147 ENSG00000234155.1 RP11-30P6.6 4.68 4.12e-06 0.00123 0.33 0.25 Response to antipsychotic treatment; chr6:85841068 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs13201730 ENSG00000234155.1 RP11-30P6.6 4.68 4.12e-06 0.00123 0.33 0.25 Response to antipsychotic treatment; chr6:85846929 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs12196377 ENSG00000234155.1 RP11-30P6.6 4.68 4.12e-06 0.00123 0.33 0.25 Response to antipsychotic treatment; chr6:85857057 chr6:85387219~85390186:- LIHC cis rs417065 0.516 rs6701941 ENSG00000227634.1 RP11-431K24.3 -4.68 4.12e-06 0.00123 -0.3 -0.25 Psoriasis; chr1:8208655 chr1:8208672~8215210:+ LIHC cis rs11098499 0.863 rs58452170 ENSG00000245958.5 RP11-33B1.1 -4.68 4.12e-06 0.00123 -0.26 -0.25 Corneal astigmatism; chr4:119538519 chr4:119454791~119552025:+ LIHC cis rs9326248 0.52 rs74830 ENSG00000236267.1 AP006216.5 -4.68 4.12e-06 0.00123 -0.25 -0.25 Blood protein levels; chr11:117219842 chr11:116813204~116814003:- LIHC cis rs755249 0.874 rs61779310 ENSG00000182109.6 RP11-69E11.4 4.68 4.13e-06 0.00123 0.32 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39476625 chr1:39522280~39546187:- LIHC cis rs755249 0.833 rs61779313 ENSG00000182109.6 RP11-69E11.4 4.68 4.13e-06 0.00123 0.32 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39478577 chr1:39522280~39546187:- LIHC cis rs227275 0.554 rs223359 ENSG00000246560.2 RP11-10L12.4 4.68 4.13e-06 0.00123 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102849422 chr4:102828055~102844075:+ LIHC cis rs227275 0.554 rs223357 ENSG00000246560.2 RP11-10L12.4 4.68 4.13e-06 0.00123 0.28 0.25 Allergic disease (asthma, hay fever or eczema); chr4:102851095 chr4:102828055~102844075:+ LIHC cis rs13068223 0.74 rs237250 ENSG00000243926.1 TIPARP-AS1 4.68 4.13e-06 0.00123 0.26 0.25 Age-related hearing impairment (SNP x SNP interaction); chr3:156726594 chr3:156671862~156674378:- LIHC cis rs11098499 0.954 rs6848389 ENSG00000260091.1 RP11-33B1.4 -4.68 4.14e-06 0.00123 -0.17 -0.25 Corneal astigmatism; chr4:119481467 chr4:119409333~119410233:+ LIHC cis rs4964805 0.594 rs4981036 ENSG00000257681.1 RP11-341G23.4 4.68 4.14e-06 0.00123 0.25 0.25 Attention deficit hyperactivity disorder; chr12:103770566 chr12:103746315~103768858:- LIHC cis rs5769765 0.955 rs6520066 ENSG00000278869.1 CITF22-49E9.3 4.68 4.14e-06 0.00123 0.36 0.25 Schizophrenia; chr22:49901340 chr22:49933198~49934074:- LIHC cis rs2243480 1 rs6964245 ENSG00000230295.1 RP11-458F8.2 4.68 4.15e-06 0.00123 0.26 0.25 Diabetic kidney disease; chr7:66253730 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs6964530 ENSG00000230295.1 RP11-458F8.2 4.68 4.15e-06 0.00123 0.26 0.25 Diabetic kidney disease; chr7:66253864 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs10807701 ENSG00000230295.1 RP11-458F8.2 4.68 4.15e-06 0.00123 0.26 0.25 Diabetic kidney disease; chr7:66259699 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1499613 ENSG00000230295.1 RP11-458F8.2 4.68 4.15e-06 0.00123 0.26 0.25 Diabetic kidney disease; chr7:66265873 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1553174 ENSG00000230295.1 RP11-458F8.2 4.68 4.15e-06 0.00123 0.26 0.25 Diabetic kidney disease; chr7:66266207 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs10950032 ENSG00000230295.1 RP11-458F8.2 4.68 4.15e-06 0.00123 0.26 0.25 Diabetic kidney disease; chr7:66273604 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1392104 ENSG00000230295.1 RP11-458F8.2 4.68 4.15e-06 0.00123 0.26 0.25 Diabetic kidney disease; chr7:66294120 chr7:66880708~66882981:+ LIHC cis rs2274273 0.87 rs11851169 ENSG00000258413.1 RP11-665C16.6 -4.68 4.15e-06 0.00124 -0.29 -0.25 Protein biomarker; chr14:55349214 chr14:55262767~55272075:- LIHC cis rs2274273 0.805 rs28612464 ENSG00000258413.1 RP11-665C16.6 -4.68 4.15e-06 0.00124 -0.29 -0.25 Protein biomarker; chr14:55349693 chr14:55262767~55272075:- LIHC cis rs2274273 0.773 rs28430823 ENSG00000258413.1 RP11-665C16.6 -4.68 4.15e-06 0.00124 -0.29 -0.25 Protein biomarker; chr14:55349842 chr14:55262767~55272075:- LIHC cis rs2274273 0.87 rs17741831 ENSG00000258413.1 RP11-665C16.6 -4.68 4.15e-06 0.00124 -0.29 -0.25 Protein biomarker; chr14:55349997 chr14:55262767~55272075:- LIHC cis rs12130219 1 rs12733173 ENSG00000237975.5 FLG-AS1 4.68 4.15e-06 0.00124 0.42 0.25 Inflammatory skin disease; chr1:152201496 chr1:152168125~152445456:+ LIHC cis rs1555322 0.53 rs2425043 ENSG00000279253.1 RP4-614O4.13 -4.68 4.15e-06 0.00124 -0.32 -0.25 Attention deficit hyperactivity disorder; chr20:35280899 chr20:35262727~35264187:- LIHC cis rs11971779 0.588 rs2003531 ENSG00000273391.1 RP11-634H22.1 4.68 4.16e-06 0.00124 0.22 0.25 Diisocyanate-induced asthma; chr7:139441832 chr7:139359032~139359566:- LIHC cis rs748404 0.697 rs546170 ENSG00000166763.7 STRCP1 4.68 4.16e-06 0.00124 0.3 0.25 Lung cancer; chr15:43272651 chr15:43699488~43718184:- LIHC cis rs1322639 0.614 rs6925201 ENSG00000261039.2 RP11-417E7.2 4.68 4.16e-06 0.00124 0.32 0.25 Pulse pressure; chr6:169163262 chr6:169175304~169182740:- LIHC cis rs6487679 1 rs7298108 ENSG00000111788.10 RP11-22B23.1 -4.68 4.16e-06 0.00124 -0.28 -0.25 Non-alcoholic fatty liver disease histology (AST); chr12:9223572 chr12:9277235~9313241:+ LIHC cis rs755249 0.501 rs661316 ENSG00000182109.6 RP11-69E11.4 4.68 4.17e-06 0.00124 0.26 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39165625 chr1:39522280~39546187:- LIHC cis rs11098499 0.615 rs28850368 ENSG00000245958.5 RP11-33B1.1 -4.68 4.17e-06 0.00124 -0.25 -0.25 Corneal astigmatism; chr4:119633158 chr4:119454791~119552025:+ LIHC cis rs11098499 0.644 rs28787668 ENSG00000245958.5 RP11-33B1.1 -4.68 4.17e-06 0.00124 -0.25 -0.25 Corneal astigmatism; chr4:119633532 chr4:119454791~119552025:+ LIHC cis rs4356975 0.697 rs6849081 ENSG00000196472.4 RP13-644M16.4 4.68 4.17e-06 0.00124 0.27 0.25 Obesity-related traits; chr4:69144840 chr4:69181660~69182372:+ LIHC cis rs4356975 0.649 rs59421013 ENSG00000196472.4 RP13-644M16.4 4.68 4.17e-06 0.00124 0.27 0.25 Obesity-related traits; chr4:69149131 chr4:69181660~69182372:+ LIHC cis rs4356975 0.697 rs58039330 ENSG00000196472.4 RP13-644M16.4 4.68 4.17e-06 0.00124 0.27 0.25 Obesity-related traits; chr4:69149529 chr4:69181660~69182372:+ LIHC cis rs4356975 0.66 rs60567038 ENSG00000196472.4 RP13-644M16.4 4.68 4.17e-06 0.00124 0.27 0.25 Obesity-related traits; chr4:69150135 chr4:69181660~69182372:+ LIHC cis rs4356975 0.697 rs58366569 ENSG00000196472.4 RP13-644M16.4 4.68 4.17e-06 0.00124 0.27 0.25 Obesity-related traits; chr4:69150626 chr4:69181660~69182372:+ LIHC cis rs1062177 0.826 rs1549920 ENSG00000253921.1 CTB-113P19.3 -4.68 4.18e-06 0.00124 -0.28 -0.25 Preschool internalizing problems; chr5:151761283 chr5:151753992~151767247:+ LIHC cis rs17301013 0.932 rs1653627 ENSG00000227373.4 RP11-160H22.5 -4.68 4.18e-06 0.00124 -0.3 -0.25 Systemic lupus erythematosus; chr1:174771879 chr1:174115300~174160004:- LIHC cis rs7923609 0.934 rs10761771 ENSG00000232075.1 MRPL35P2 -4.68 4.18e-06 0.00124 -0.27 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63470404 chr10:63634317~63634827:- LIHC cis rs7923609 0.869 rs10733792 ENSG00000232075.1 MRPL35P2 -4.68 4.18e-06 0.00124 -0.27 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63472779 chr10:63634317~63634827:- LIHC cis rs7923609 0.838 rs7909960 ENSG00000232075.1 MRPL35P2 -4.68 4.18e-06 0.00124 -0.27 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63479417 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs7915779 ENSG00000232075.1 MRPL35P2 -4.68 4.18e-06 0.00124 -0.27 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63484484 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs2393977 ENSG00000232075.1 MRPL35P2 -4.68 4.18e-06 0.00124 -0.27 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63487849 chr10:63634317~63634827:- LIHC cis rs7923609 0.905 rs10740129 ENSG00000232075.1 MRPL35P2 -4.68 4.18e-06 0.00124 -0.27 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63491048 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs10509189 ENSG00000232075.1 MRPL35P2 -4.68 4.18e-06 0.00124 -0.27 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63504366 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs4486511 ENSG00000232075.1 MRPL35P2 -4.68 4.18e-06 0.00124 -0.27 -0.25 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63504506 chr10:63634317~63634827:- LIHC cis rs7208859 0.573 rs4055105 ENSG00000266490.1 CTD-2349P21.9 4.68 4.18e-06 0.00124 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775532 chr17:30792372~30792833:+ LIHC cis rs10129255 0.5 rs2027902 ENSG00000223648.3 IGHV3-64 4.68 4.19e-06 0.00125 0.17 0.25 Kawasaki disease; chr14:106807157 chr14:106643132~106658258:- LIHC cis rs3812762 0.692 rs10840116 ENSG00000254860.4 TMEM9B-AS1 -4.68 4.19e-06 0.00125 -0.26 -0.25 Hypospadias; chr11:8743570 chr11:8964675~8977527:+ LIHC cis rs30380 1 rs27529 ENSG00000272109.1 CTD-2260A17.3 -4.68 4.19e-06 0.00125 -0.3 -0.25 Cerebrospinal fluid biomarker levels; chr5:96790605 chr5:96804353~96806105:+ LIHC cis rs17270561 0.943 rs76703022 ENSG00000272810.1 U91328.22 -4.68 4.19e-06 0.00125 -0.32 -0.25 Iron status biomarkers; chr6:25703301 chr6:26013241~26013757:+ LIHC cis rs7937890 0.559 rs10766184 ENSG00000251991.1 RNU7-49P 4.68 4.19e-06 0.00125 0.27 0.25 Mitochondrial DNA levels; chr11:14521031 chr11:14478892~14478953:+ LIHC cis rs12478296 1 rs66612947 ENSG00000261186.2 RP11-341N2.1 -4.68 4.2e-06 0.00125 -0.35 -0.25 Obesity-related traits; chr2:242093811 chr2:242087351~242088457:- LIHC cis rs1577917 1 rs12205548 ENSG00000234155.1 RP11-30P6.6 4.68 4.2e-06 0.00125 0.33 0.25 Response to antipsychotic treatment; chr6:86050052 chr6:85387219~85390186:- LIHC cis rs2976388 0.647 rs2164307 ENSG00000253196.1 RP11-706C16.7 4.68 4.2e-06 0.00125 0.24 0.25 Urinary tract infection frequency; chr8:142707413 chr8:142763116~142766427:+ LIHC cis rs5758511 0.68 rs17002902 ENSG00000205702.9 CYP2D7 4.68 4.2e-06 0.00125 0.29 0.25 Birth weight; chr22:42229503 chr22:42140203~42144577:- LIHC cis rs7246657 0.943 rs10424574 ENSG00000276846.1 CTD-3220F14.3 4.68 4.2e-06 0.00125 0.32 0.25 Coronary artery calcification; chr19:37347491 chr19:37314868~37315620:- LIHC cis rs5758511 0.634 rs1001587 ENSG00000205702.9 CYP2D7 4.68 4.2e-06 0.00125 0.29 0.25 Birth weight; chr22:42274105 chr22:42140203~42144577:- LIHC cis rs2836974 0.897 rs8132419 ENSG00000255568.3 BRWD1-AS2 4.68 4.2e-06 0.00125 0.27 0.25 Cognitive function; chr21:39155901 chr21:39313935~39314962:+ LIHC cis rs7208859 0.623 rs11651857 ENSG00000266490.1 CTD-2349P21.9 4.68 4.2e-06 0.00125 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30599344 chr17:30792372~30792833:+ LIHC cis rs2439831 0.85 rs60883262 ENSG00000275601.1 AC011330.13 -4.68 4.2e-06 0.00125 -0.36 -0.25 Lung cancer in ever smokers; chr15:43784305 chr15:43642389~43643023:- LIHC cis rs9368481 0.761 rs12661756 ENSG00000241549.7 GUSBP2 4.68 4.21e-06 0.00125 0.25 0.25 Autism spectrum disorder or schizophrenia; chr6:27035704 chr6:26871484~26956554:- LIHC cis rs6569038 0.669 rs2884078 ENSG00000253194.1 RP11-351A11.1 -4.68 4.21e-06 0.00125 -0.32 -0.25 Epstein-Barr virus copy number in lymphoblastoid cell lines; chr6:119065019 chr6:118934785~119031541:+ LIHC cis rs1062177 1 rs2964612 ENSG00000253921.1 CTB-113P19.3 -4.68 4.21e-06 0.00125 -0.29 -0.25 Preschool internalizing problems; chr5:151819189 chr5:151753992~151767247:+ LIHC cis rs7615952 0.515 rs4267608 ENSG00000171084.14 FAM86JP 4.68 4.21e-06 0.00125 0.41 0.25 Blood pressure (smoking interaction); chr3:125961657 chr3:125916620~125930024:+ LIHC cis rs875971 0.545 rs73376394 ENSG00000273142.1 RP11-458F8.4 4.68 4.22e-06 0.00125 0.23 0.25 Aortic root size; chr7:66172694 chr7:66902857~66906297:+ LIHC cis rs11096990 0.656 rs3796513 ENSG00000249685.1 RP11-360F5.3 -4.68 4.22e-06 0.00125 -0.29 -0.25 Cognitive function; chr4:39289462 chr4:39133913~39135608:+ LIHC cis rs11096990 0.656 rs2123027 ENSG00000249685.1 RP11-360F5.3 -4.68 4.22e-06 0.00125 -0.29 -0.25 Cognitive function; chr4:39289493 chr4:39133913~39135608:+ LIHC cis rs11096990 0.634 rs10029074 ENSG00000249685.1 RP11-360F5.3 -4.68 4.22e-06 0.00125 -0.29 -0.25 Cognitive function; chr4:39290882 chr4:39133913~39135608:+ LIHC cis rs11096990 0.634 rs1564710 ENSG00000249685.1 RP11-360F5.3 -4.68 4.22e-06 0.00125 -0.29 -0.25 Cognitive function; chr4:39291178 chr4:39133913~39135608:+ LIHC cis rs11096990 0.634 rs6815855 ENSG00000249685.1 RP11-360F5.3 -4.68 4.22e-06 0.00125 -0.29 -0.25 Cognitive function; chr4:39294926 chr4:39133913~39135608:+ LIHC cis rs6921919 0.789 rs17301128 ENSG00000204709.4 LINC01556 4.68 4.22e-06 0.00125 0.33 0.25 Autism spectrum disorder or schizophrenia; chr6:28340257 chr6:28943877~28944537:+ LIHC cis rs17711722 0.522 rs4642526 ENSG00000224316.1 RP11-479O9.2 4.68 4.22e-06 0.00125 0.22 0.25 Calcium levels; chr7:65751755 chr7:65773620~65802067:+ LIHC cis rs4706831 0.647 rs9350847 ENSG00000272129.1 RP11-250B2.6 4.68 4.23e-06 0.00126 0.24 0.25 Joint mobility (Beighton score); chr6:80179300 chr6:80355424~80356859:+ LIHC cis rs10129255 0.872 rs8015406 ENSG00000223648.3 IGHV3-64 4.68 4.23e-06 0.00126 0.19 0.25 Kawasaki disease; chr14:106670611 chr14:106643132~106658258:- LIHC cis rs4660214 0.666 rs4617393 ENSG00000182109.6 RP11-69E11.4 -4.68 4.23e-06 0.00126 -0.26 -0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39474551 chr1:39522280~39546187:- LIHC cis rs7208859 0.524 rs60114476 ENSG00000266490.1 CTD-2349P21.9 4.68 4.23e-06 0.00126 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770649 chr17:30792372~30792833:+ LIHC cis rs11971779 0.648 rs6967836 ENSG00000273391.1 RP11-634H22.1 4.68 4.23e-06 0.00126 0.22 0.25 Diisocyanate-induced asthma; chr7:139395198 chr7:139359032~139359566:- LIHC cis rs7119038 0.509 rs10892260 ENSG00000255422.1 AP002954.4 4.67 4.24e-06 0.00126 0.32 0.25 Sjögren's syndrome; chr11:118712816 chr11:118704607~118750263:+ LIHC cis rs73186030 0.764 rs4491840 ENSG00000272758.4 RP11-299J3.8 4.67 4.24e-06 0.00126 0.45 0.25 Serum parathyroid hormone levels; chr3:122361900 chr3:122416207~122443180:+ LIHC cis rs61041384 0.661 rs77015199 ENSG00000256092.2 RP13-942N8.1 -4.67 4.24e-06 0.00126 -0.38 -0.25 Schizophrenia; chr12:123197090 chr12:123363868~123366113:+ LIHC cis rs61041384 0.661 rs74240768 ENSG00000256092.2 RP13-942N8.1 -4.67 4.24e-06 0.00126 -0.38 -0.25 Schizophrenia; chr12:123199429 chr12:123363868~123366113:+ LIHC cis rs61041384 0.661 rs74240769 ENSG00000256092.2 RP13-942N8.1 -4.67 4.24e-06 0.00126 -0.38 -0.25 Schizophrenia; chr12:123203681 chr12:123363868~123366113:+ LIHC cis rs61041384 0.661 rs74917517 ENSG00000256092.2 RP13-942N8.1 -4.67 4.24e-06 0.00126 -0.38 -0.25 Schizophrenia; chr12:123204258 chr12:123363868~123366113:+ LIHC cis rs61041384 0.661 rs4759407 ENSG00000256092.2 RP13-942N8.1 -4.67 4.24e-06 0.00126 -0.38 -0.25 Schizophrenia; chr12:123205127 chr12:123363868~123366113:+ LIHC cis rs12130219 1 rs12130219 ENSG00000237975.5 FLG-AS1 4.67 4.25e-06 0.00126 0.42 0.25 Inflammatory skin disease; chr1:152189630 chr1:152168125~152445456:+ LIHC cis rs6901152 0.525 rs989696 ENSG00000217648.1 RP1-95L4.4 -4.67 4.25e-06 0.00126 -0.29 -0.25 Acute lymphoblastic leukemia (childhood); chr6:143373165 chr6:143342246~143343383:+ LIHC cis rs812925 0.553 rs1177307 ENSG00000271889.1 RP11-493E12.1 4.67 4.25e-06 0.00126 0.29 0.25 Immature fraction of reticulocytes; chr2:61160253 chr2:61151433~61162105:- LIHC cis rs11098499 0.954 rs3733520 ENSG00000260091.1 RP11-33B1.4 -4.67 4.25e-06 0.00126 -0.17 -0.25 Corneal astigmatism; chr4:119502325 chr4:119409333~119410233:+ LIHC cis rs755249 0.501 rs2484133 ENSG00000182109.6 RP11-69E11.4 4.67 4.25e-06 0.00126 0.26 0.25 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39188322 chr1:39522280~39546187:- LIHC cis rs11064837 0.504 rs746297 ENSG00000248636.5 RP11-768F21.1 4.67 4.25e-06 0.00126 0.4 0.25 Schizophrenia; chr12:119604996 chr12:119387987~119668079:- LIHC cis rs6997458 0.606 rs1493302 ENSG00000253549.4 RP11-317J10.2 4.67 4.25e-06 0.00126 0.26 0.25 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85437051 chr8:85441851~85464915:- LIHC cis rs7208859 0.573 rs8070182 ENSG00000266490.1 CTD-2349P21.9 4.67 4.26e-06 0.00126 0.31 0.25 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30808576 chr17:30792372~30792833:+ LIHC cis rs1558001 0.87 rs6960640 ENSG00000230196.1 DDX43P3 4.67 4.26e-06 0.00126 0.26 0.25 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81794268 chr7:81610884~81611326:- LIHC cis rs10871290 0.65 rs28484753 ENSG00000261079.1 RP11-252A24.3 4.67 4.26e-06 0.00126 0.27 0.25 Breast cancer; chr16:74455497 chr16:74367462~74369826:+ LIHC cis rs67311347 1 rs17078813 ENSG00000223797.4 ENTPD3-AS1 4.67 4.26e-06 0.00126 0.2 0.25 Renal cell carcinoma; chr3:40392671 chr3:40313802~40453329:- LIHC cis rs875971 0.862 rs1860469 ENSG00000237310.1 GS1-124K5.4 -4.67 4.26e-06 0.00126 -0.21 -0.25 Aortic root size; chr7:66641888 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs4718383 ENSG00000237310.1 GS1-124K5.4 -4.67 4.26e-06 0.00126 -0.21 -0.25 Aortic root size; chr7:66643422 chr7:66493706~66495474:+ LIHC cis rs8059260 0.668 rs16957839 ENSG00000274038.1 RP11-66H6.4 -4.67 4.26e-06 0.00126 -0.41 -0.25 Alcohol consumption over the past year; chr16:10962521 chr16:11056556~11057034:+ LIHC cis rs1005277 0.579 rs1740737 ENSG00000276805.1 RP11-291L22.6 4.67 4.27e-06 0.00126 0.3 0.25 Extrinsic epigenetic age acceleration; chr10:38210437 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2749616 ENSG00000276805.1 RP11-291L22.6 4.67 4.27e-06 0.00126 0.3 0.25 Extrinsic epigenetic age acceleration; chr10:38222065 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs1780146 ENSG00000276805.1 RP11-291L22.6 4.67 4.27e-06 0.00126 0.3 0.25 Extrinsic epigenetic age acceleration; chr10:38228946 chr10:38451030~38451785:+ LIHC cis rs2439831 0.85 rs10438303 ENSG00000275601.1 AC011330.13 -4.67 4.27e-06 0.00127 -0.36 -0.24 Lung cancer in ever smokers; chr15:43724219 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs28504496 ENSG00000275601.1 AC011330.13 -4.67 4.27e-06 0.00127 -0.36 -0.24 Lung cancer in ever smokers; chr15:43724685 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs12441127 ENSG00000275601.1 AC011330.13 -4.67 4.27e-06 0.00127 -0.36 -0.24 Lung cancer in ever smokers; chr15:43728977 chr15:43642389~43643023:- LIHC cis rs12134133 0.962 rs7526658 ENSG00000274245.1 RP11-357P18.2 4.67 4.28e-06 0.00127 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207240098 chr1:207372559~207373252:+ LIHC cis rs2274273 0.624 rs7151754 ENSG00000258413.1 RP11-665C16.6 -4.67 4.28e-06 0.00127 -0.3 -0.24 Protein biomarker; chr14:55321783 chr14:55262767~55272075:- LIHC cis rs748404 0.631 rs3809482 ENSG00000205771.5 CATSPER2P1 -4.67 4.28e-06 0.00127 -0.3 -0.24 Lung cancer; chr15:43369604 chr15:43726918~43747094:- LIHC cis rs881375 0.678 rs10118357 ENSG00000226752.6 PSMD5-AS1 -4.67 4.28e-06 0.00127 -0.25 -0.24 Rheumatoid arthritis; chr9:120917790 chr9:120824828~120854385:+ LIHC cis rs42490 0.903 rs7824932 ENSG00000251136.7 RP11-37B2.1 4.67 4.29e-06 0.00127 0.22 0.24 Leprosy; chr8:89703848 chr8:89609409~89757727:- LIHC cis rs61041384 0.661 rs79033960 ENSG00000256092.2 RP13-942N8.1 -4.67 4.29e-06 0.00127 -0.38 -0.24 Schizophrenia; chr12:123196388 chr12:123363868~123366113:+ LIHC cis rs11671005 0.735 rs11084544 ENSG00000269473.1 CTD-2619J13.19 4.67 4.29e-06 0.00127 0.4 0.24 Mean platelet volume; chr19:58428760 chr19:58440448~58445849:+ LIHC cis rs2581828 0.656 rs2581787 ENSG00000242142.1 SERBP1P3 4.67 4.3e-06 0.00127 0.28 0.24 Crohn's disease; chr3:53093661 chr3:53064283~53065091:- LIHC cis rs11971779 0.616 rs6467836 ENSG00000273391.1 RP11-634H22.1 4.67 4.3e-06 0.00127 0.22 0.24 Diisocyanate-induced asthma; chr7:139338771 chr7:139359032~139359566:- LIHC cis rs227275 0.525 rs7688940 ENSG00000246560.2 RP11-10L12.4 4.67 4.3e-06 0.00127 0.28 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102994153 chr4:102828055~102844075:+ LIHC cis rs2439831 0.85 rs8023458 ENSG00000275601.1 AC011330.13 -4.67 4.3e-06 0.00127 -0.36 -0.24 Lung cancer in ever smokers; chr15:43788741 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs16963953 ENSG00000275601.1 AC011330.13 -4.67 4.3e-06 0.00127 -0.36 -0.24 Lung cancer in ever smokers; chr15:43789521 chr15:43642389~43643023:- LIHC cis rs2834288 0.5 rs2834304 ENSG00000237945.6 LINC00649 4.67 4.3e-06 0.00127 0.32 0.24 Gut microbiota (bacterial taxa); chr21:33949550 chr21:33915534~33977691:+ LIHC cis rs11098499 0.789 rs9991166 ENSG00000245958.5 RP11-33B1.1 -4.67 4.3e-06 0.00127 -0.25 -0.24 Corneal astigmatism; chr4:119316696 chr4:119454791~119552025:+ LIHC cis rs11098499 0.708 rs10005237 ENSG00000245958.5 RP11-33B1.1 -4.67 4.3e-06 0.00127 -0.25 -0.24 Corneal astigmatism; chr4:119316742 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs10213267 ENSG00000245958.5 RP11-33B1.1 -4.67 4.3e-06 0.00127 -0.25 -0.24 Corneal astigmatism; chr4:119317919 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs10212775 ENSG00000245958.5 RP11-33B1.1 -4.67 4.3e-06 0.00127 -0.25 -0.24 Corneal astigmatism; chr4:119318089 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs11732087 ENSG00000245958.5 RP11-33B1.1 -4.67 4.3e-06 0.00127 -0.25 -0.24 Corneal astigmatism; chr4:119318676 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs2964 ENSG00000245958.5 RP11-33B1.1 -4.67 4.3e-06 0.00127 -0.25 -0.24 Corneal astigmatism; chr4:119318976 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs1511025 ENSG00000245958.5 RP11-33B1.1 -4.67 4.3e-06 0.00127 -0.25 -0.24 Corneal astigmatism; chr4:119319083 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs12510269 ENSG00000245958.5 RP11-33B1.1 -4.67 4.3e-06 0.00127 -0.25 -0.24 Corneal astigmatism; chr4:119320491 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs12506610 ENSG00000245958.5 RP11-33B1.1 -4.67 4.3e-06 0.00127 -0.25 -0.24 Corneal astigmatism; chr4:119320504 chr4:119454791~119552025:+ LIHC cis rs11098499 0.743 rs10003567 ENSG00000245958.5 RP11-33B1.1 -4.67 4.3e-06 0.00127 -0.25 -0.24 Corneal astigmatism; chr4:119320519 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs10006259 ENSG00000245958.5 RP11-33B1.1 -4.67 4.3e-06 0.00127 -0.25 -0.24 Corneal astigmatism; chr4:119320990 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs28652763 ENSG00000245958.5 RP11-33B1.1 -4.67 4.3e-06 0.00127 -0.25 -0.24 Corneal astigmatism; chr4:119321157 chr4:119454791~119552025:+ LIHC cis rs8059260 0.673 rs7188928 ENSG00000274038.1 RP11-66H6.4 -4.67 4.3e-06 0.00127 -0.38 -0.24 Alcohol consumption over the past year; chr16:10964896 chr16:11056556~11057034:+ LIHC cis rs2929278 0.617 rs11070410 ENSG00000166763.7 STRCP1 -4.67 4.31e-06 0.00127 -0.32 -0.24 Schizophrenia; chr15:43764847 chr15:43699488~43718184:- LIHC cis rs28829049 0.597 rs12745238 ENSG00000270728.1 RP4-657E11.10 -4.67 4.31e-06 0.00127 -0.22 -0.24 QRS duration in Tripanosoma cruzi seropositivity; chr1:19067216 chr1:19297080~19297903:+ LIHC cis rs2310173 0.575 rs719248 ENSG00000281162.1 LINC01127 -4.67 4.31e-06 0.00128 -0.27 -0.24 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:102007413 chr2:101962056~101987167:+ LIHC cis rs2072510 0.683 rs2660840 ENSG00000257878.1 RP11-256L6.3 -4.67 4.32e-06 0.00128 -0.22 -0.24 Metabolite levels (small molecules and protein measures); chr12:96038729 chr12:95996521~96011489:+ LIHC cis rs2581828 0.656 rs2253656 ENSG00000242142.1 SERBP1P3 4.67 4.32e-06 0.00128 0.28 0.24 Crohn's disease; chr3:53085083 chr3:53064283~53065091:- LIHC cis rs9322193 0.607 rs9322229 ENSG00000223701.3 RAET1E-AS1 4.67 4.32e-06 0.00128 0.3 0.24 Lung cancer; chr6:149908949 chr6:149884431~149919508:+ LIHC cis rs67311347 0.544 rs12635762 ENSG00000223797.4 ENTPD3-AS1 -4.67 4.33e-06 0.00128 -0.21 -0.24 Renal cell carcinoma; chr3:40291268 chr3:40313802~40453329:- LIHC cis rs12134133 1 rs11580387 ENSG00000274245.1 RP11-357P18.2 4.67 4.33e-06 0.00128 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207245063 chr1:207372559~207373252:+ LIHC cis rs7923609 1 rs12355784 ENSG00000232075.1 MRPL35P2 -4.67 4.33e-06 0.00128 -0.28 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63361805 chr10:63634317~63634827:- LIHC cis rs2564921 0.791 rs36033494 ENSG00000242142.1 SERBP1P3 4.67 4.33e-06 0.00128 0.28 0.24 Height; chr3:53082835 chr3:53064283~53065091:- LIHC cis rs4650994 0.789 rs2476559 ENSG00000273384.1 RP5-1098D14.1 -4.67 4.34e-06 0.00128 -0.29 -0.24 HDL cholesterol;HDL cholesterol levels; chr1:178623784 chr1:178651706~178652282:+ LIHC cis rs6479901 0.557 rs1009984 ENSG00000232075.1 MRPL35P2 -4.67 4.34e-06 0.00128 -0.27 -0.24 Intelligence (multi-trait analysis); chr10:63156709 chr10:63634317~63634827:- LIHC cis rs17711722 0.565 rs4717276 ENSG00000224316.1 RP11-479O9.2 4.67 4.34e-06 0.00128 0.22 0.24 Calcium levels; chr7:65829754 chr7:65773620~65802067:+ LIHC cis rs72675573 1 rs72675573 ENSG00000235612.1 RP1-158P9.1 -4.67 4.35e-06 0.00129 -0.32 -0.24 Monocyte count; chr1:56171209 chr1:56145721~56155224:+ LIHC cis rs916888 0.61 rs199452 ENSG00000260075.1 NSFP1 4.67 4.35e-06 0.00129 0.3 0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:46372855~46487141:+ LIHC cis rs4964805 0.594 rs10861095 ENSG00000257681.1 RP11-341G23.4 4.67 4.36e-06 0.00129 0.25 0.24 Attention deficit hyperactivity disorder; chr12:103771609 chr12:103746315~103768858:- LIHC cis rs11971779 0.68 rs11980313 ENSG00000273391.1 RP11-634H22.1 4.67 4.36e-06 0.00129 0.22 0.24 Diisocyanate-induced asthma; chr7:139349897 chr7:139359032~139359566:- LIHC cis rs11971779 0.584 rs6962029 ENSG00000273391.1 RP11-634H22.1 4.67 4.36e-06 0.00129 0.22 0.24 Diisocyanate-induced asthma; chr7:139349973 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs6962186 ENSG00000273391.1 RP11-634H22.1 4.67 4.36e-06 0.00129 0.22 0.24 Diisocyanate-induced asthma; chr7:139350060 chr7:139359032~139359566:- LIHC cis rs2933343 0.951 rs9871612 ENSG00000231305.3 RP11-723O4.2 4.67 4.36e-06 0.00129 0.28 0.24 IgG glycosylation; chr3:128851559 chr3:128861313~128871540:- LIHC cis rs643506 0.874 rs1633471 ENSG00000254990.4 RP11-108O10.2 4.67 4.37e-06 0.00129 0.26 0.24 Breast cancer; chr11:111819607 chr11:111768668~111778350:- LIHC cis rs7208859 0.623 rs73269913 ENSG00000266490.1 CTD-2349P21.9 4.67 4.37e-06 0.00129 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765165 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs7217984 ENSG00000266490.1 CTD-2349P21.9 4.67 4.37e-06 0.00129 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765748 chr17:30792372~30792833:+ LIHC cis rs1865760 1 rs6938233 ENSG00000216436.2 HIST1H2APS1 -4.67 4.37e-06 0.00129 -0.27 -0.24 Height; chr6:25913849 chr6:25732497~25732827:+ LIHC cis rs9326248 0.52 rs236919 ENSG00000236267.1 AP006216.5 4.67 4.37e-06 0.00129 0.24 0.24 Blood protein levels; chr11:117224645 chr11:116813204~116814003:- LIHC cis rs5758511 0.68 rs5758651 ENSG00000205702.9 CYP2D7 4.67 4.37e-06 0.00129 0.29 0.24 Birth weight; chr22:42213142 chr22:42140203~42144577:- LIHC cis rs5758511 0.68 rs5758652 ENSG00000205702.9 CYP2D7 4.67 4.37e-06 0.00129 0.29 0.24 Birth weight; chr22:42216402 chr22:42140203~42144577:- LIHC cis rs10871290 0.551 rs3863435 ENSG00000261079.1 RP11-252A24.3 -4.67 4.37e-06 0.00129 -0.28 -0.24 Breast cancer; chr16:74431498 chr16:74367462~74369826:+ LIHC cis rs7209700 0.862 rs2015729 ENSG00000228782.6 CTD-2026D20.3 -4.67 4.38e-06 0.00129 -0.27 -0.24 IgG glycosylation; chr17:47277127 chr17:47450568~47492492:- LIHC cis rs957448 1 rs72674843 ENSG00000253704.1 RP11-267M23.4 4.67 4.38e-06 0.00129 0.3 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94520772 chr8:94553722~94569745:+ LIHC cis rs2842992 0.789 rs9365093 ENSG00000237927.1 RP3-393E18.2 -4.67 4.38e-06 0.00129 -0.3 -0.24 Age-related macular degeneration (geographic atrophy); chr6:159754787 chr6:159586955~159589169:- LIHC cis rs227275 0.554 rs6810668 ENSG00000230069.3 LRRC37A15P -4.67 4.38e-06 0.00129 -0.22 -0.24 Allergic disease (asthma, hay fever or eczema); chr4:102987574 chr4:102727274~102730721:- LIHC cis rs875971 0.502 rs6460311 ENSG00000273142.1 RP11-458F8.4 -4.67 4.38e-06 0.00129 -0.24 -0.24 Aortic root size; chr7:66646886 chr7:66902857~66906297:+ LIHC cis rs529413 1 rs529413 ENSG00000259237.1 RP11-209E8.1 -4.67 4.38e-06 0.00129 -0.33 -0.24 Itch intensity from mosquito bite adjusted by bite size; chr15:53250548 chr15:53116365~53129698:+ LIHC cis rs733592 0.507 rs7138917 ENSG00000240399.1 RP1-228P16.1 -4.67 4.38e-06 0.00129 -0.24 -0.24 Plateletcrit; chr12:48061472 chr12:48054813~48055591:- LIHC cis rs7829975 0.623 rs10087493 ENSG00000253981.4 ALG1L13P -4.67 4.38e-06 0.00129 -0.29 -0.24 Mood instability; chr8:8516047 chr8:8236003~8244667:- LIHC cis rs61041384 0.661 rs74240770 ENSG00000256092.2 RP13-942N8.1 -4.67 4.39e-06 0.00129 -0.38 -0.24 Schizophrenia; chr12:123207195 chr12:123363868~123366113:+ LIHC cis rs7246657 0.943 rs10405064 ENSG00000276846.1 CTD-3220F14.3 4.67 4.39e-06 0.0013 0.32 0.24 Coronary artery calcification; chr19:37370959 chr19:37314868~37315620:- LIHC cis rs7412746 0.658 rs12410394 ENSG00000231073.1 RP11-316M1.3 4.67 4.39e-06 0.0013 0.25 0.24 Melanoma; chr1:150887710 chr1:150973123~150975534:+ LIHC cis rs11098499 0.863 rs7699064 ENSG00000245958.5 RP11-33B1.1 4.67 4.4e-06 0.0013 0.26 0.24 Corneal astigmatism; chr4:119507154 chr4:119454791~119552025:+ LIHC cis rs9322193 0.847 rs4870054 ENSG00000216906.2 RP11-350J20.9 4.67 4.4e-06 0.0013 0.25 0.24 Lung cancer; chr6:149848402 chr6:149904243~149906418:+ LIHC cis rs42490 0.903 rs218900 ENSG00000251136.7 RP11-37B2.1 -4.67 4.41e-06 0.0013 -0.23 -0.24 Leprosy; chr8:89718678 chr8:89609409~89757727:- LIHC cis rs42490 0.903 rs218901 ENSG00000251136.7 RP11-37B2.1 -4.67 4.41e-06 0.0013 -0.23 -0.24 Leprosy; chr8:89719089 chr8:89609409~89757727:- LIHC cis rs3733589 1 rs13151113 ENSG00000250413.1 RP11-448G15.1 4.67 4.41e-06 0.0013 0.44 0.24 Renal overload gout; chr4:10016554 chr4:10006482~10009725:+ LIHC cis rs34524635 1 rs34524635 ENSG00000232075.1 MRPL35P2 -4.67 4.41e-06 0.0013 -0.27 -0.24 Vascular endothelial growth factor levels; chr10:63501417 chr10:63634317~63634827:- LIHC cis rs3091242 0.933 rs11802413 ENSG00000224183.1 SDHDP6 4.67 4.41e-06 0.0013 0.28 0.24 Erythrocyte sedimentation rate; chr1:25434429 chr1:25294164~25294643:- LIHC cis rs4713118 0.662 rs149969 ENSG00000219392.1 RP1-265C24.5 -4.67 4.41e-06 0.0013 -0.35 -0.24 Parkinson's disease; chr6:28009959 chr6:28115628~28116551:+ LIHC cis rs4660214 0.666 rs10888682 ENSG00000182109.6 RP11-69E11.4 -4.67 4.41e-06 0.0013 -0.26 -0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39157635 chr1:39522280~39546187:- LIHC cis rs4660214 0.666 rs11205698 ENSG00000182109.6 RP11-69E11.4 -4.67 4.41e-06 0.0013 -0.26 -0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39158708 chr1:39522280~39546187:- LIHC cis rs2919917 1 rs1054283 ENSG00000254352.1 RP11-578O24.2 4.67 4.41e-06 0.0013 0.34 0.24 Lymphocyte counts; chr8:78698475 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs7010897 ENSG00000254352.1 RP11-578O24.2 4.67 4.41e-06 0.0013 0.34 0.24 Lymphocyte counts; chr8:78708119 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs11986947 ENSG00000254352.1 RP11-578O24.2 4.67 4.41e-06 0.0013 0.34 0.24 Lymphocyte counts; chr8:78708957 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs2717539 ENSG00000254352.1 RP11-578O24.2 4.67 4.41e-06 0.0013 0.34 0.24 Lymphocyte counts; chr8:78716804 chr8:78723796~78724136:- LIHC cis rs2919917 0.793 rs2625664 ENSG00000254352.1 RP11-578O24.2 4.67 4.41e-06 0.0013 0.34 0.24 Lymphocyte counts; chr8:78718373 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs1026920 ENSG00000254352.1 RP11-578O24.2 4.67 4.41e-06 0.0013 0.34 0.24 Lymphocyte counts; chr8:78719775 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs2717538 ENSG00000254352.1 RP11-578O24.2 4.67 4.41e-06 0.0013 0.34 0.24 Lymphocyte counts; chr8:78720914 chr8:78723796~78724136:- LIHC cis rs17711722 0.522 rs6957759 ENSG00000273024.4 INTS4P2 -4.67 4.41e-06 0.0013 -0.26 -0.24 Calcium levels; chr7:65806798 chr7:65647864~65715661:+ LIHC cis rs1075265 0.553 rs2692532 ENSG00000272156.1 RP11-477N3.1 -4.67 4.42e-06 0.0013 -0.3 -0.24 Chronotype;Morning vs. evening chronotype; chr2:53778962 chr2:54082554~54085066:+ LIHC cis rs7809950 1 rs2107713 ENSG00000238832.1 snoU109 -4.67 4.42e-06 0.0013 -0.28 -0.24 Coronary artery disease; chr7:107591924 chr7:107603363~107603507:+ LIHC cis rs116175783 0.557 rs2303318 ENSG00000227403.1 AC009299.3 4.67 4.43e-06 0.00131 0.38 0.24 Intelligence (multi-trait analysis); chr2:161367984 chr2:161244739~161249050:+ LIHC cis rs10853057 0.541 rs77675516 ENSG00000214174.7 AMZ2P1 4.67 4.43e-06 0.00131 0.54 0.24 White matter microstructure (global fractional anisotropy); chr17:65050690 chr17:64966550~64975576:- LIHC cis rs10853057 0.541 rs8076716 ENSG00000214174.7 AMZ2P1 4.67 4.43e-06 0.00131 0.54 0.24 White matter microstructure (global fractional anisotropy); chr17:65051891 chr17:64966550~64975576:- LIHC cis rs7119038 0.509 rs11216960 ENSG00000255422.1 AP002954.4 4.67 4.43e-06 0.00131 0.32 0.24 Sjögren's syndrome; chr11:118707164 chr11:118704607~118750263:+ LIHC cis rs7119038 0.509 rs10892256 ENSG00000255422.1 AP002954.4 4.67 4.43e-06 0.00131 0.32 0.24 Sjögren's syndrome; chr11:118707996 chr11:118704607~118750263:+ LIHC cis rs7119038 0.509 rs10892257 ENSG00000255422.1 AP002954.4 4.67 4.43e-06 0.00131 0.32 0.24 Sjögren's syndrome; chr11:118708618 chr11:118704607~118750263:+ LIHC cis rs7119038 0.509 rs10790261 ENSG00000255422.1 AP002954.4 -4.67 4.43e-06 0.00131 -0.32 -0.24 Sjögren's syndrome; chr11:118709038 chr11:118704607~118750263:+ LIHC cis rs7665090 0.87 rs228616 ENSG00000230069.3 LRRC37A15P 4.67 4.43e-06 0.00131 0.23 0.24 Primary biliary cholangitis; chr4:102658534 chr4:102727274~102730721:- LIHC cis rs11098499 0.738 rs28408407 ENSG00000260091.1 RP11-33B1.4 -4.67 4.43e-06 0.00131 -0.17 -0.24 Corneal astigmatism; chr4:119454875 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs1809406 ENSG00000260091.1 RP11-33B1.4 -4.67 4.43e-06 0.00131 -0.17 -0.24 Corneal astigmatism; chr4:119455967 chr4:119409333~119410233:+ LIHC cis rs11098499 0.865 rs2389809 ENSG00000260091.1 RP11-33B1.4 -4.67 4.43e-06 0.00131 -0.17 -0.24 Corneal astigmatism; chr4:119456244 chr4:119409333~119410233:+ LIHC cis rs11098499 0.697 rs10020027 ENSG00000260091.1 RP11-33B1.4 -4.67 4.43e-06 0.00131 -0.17 -0.24 Corneal astigmatism; chr4:119460724 chr4:119409333~119410233:+ LIHC cis rs11098499 0.779 rs7356491 ENSG00000260091.1 RP11-33B1.4 -4.67 4.43e-06 0.00131 -0.17 -0.24 Corneal astigmatism; chr4:119460819 chr4:119409333~119410233:+ LIHC cis rs10129255 0.872 rs1858683 ENSG00000223648.3 IGHV3-64 4.66 4.44e-06 0.00131 0.19 0.24 Kawasaki disease; chr14:106670217 chr14:106643132~106658258:- LIHC cis rs11096990 0.634 rs10019594 ENSG00000249685.1 RP11-360F5.3 -4.66 4.44e-06 0.00131 -0.29 -0.24 Cognitive function; chr4:39287127 chr4:39133913~39135608:+ LIHC cis rs1247318 1 rs1247329 ENSG00000243831.1 RP1-81D8.4 4.66 4.44e-06 0.00131 0.34 0.24 Aging; chr6:160906725 chr6:160666228~160676523:- LIHC cis rs1247318 1 rs1247327 ENSG00000243831.1 RP1-81D8.4 4.66 4.44e-06 0.00131 0.34 0.24 Aging; chr6:160907424 chr6:160666228~160676523:- LIHC cis rs1247318 1 rs1247326 ENSG00000243831.1 RP1-81D8.4 4.66 4.44e-06 0.00131 0.34 0.24 Aging; chr6:160907524 chr6:160666228~160676523:- LIHC cis rs1247318 1 rs1247323 ENSG00000243831.1 RP1-81D8.4 4.66 4.44e-06 0.00131 0.34 0.24 Aging; chr6:160908981 chr6:160666228~160676523:- LIHC cis rs7246657 0.943 rs713256 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37374463 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs8111782 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37377002 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs9917081 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37385714 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs10404920 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37390654 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs10405325 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37392575 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs12981532 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37398378 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs7246993 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37399252 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs10413602 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37400590 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs10422074 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37403334 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs10407084 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37416890 chr19:37314868~37315620:- LIHC cis rs7246657 0.823 rs4802236 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37428344 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs7252099 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37442878 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs7255972 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37442939 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs2303131 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37445123 chr19:37314868~37315620:- LIHC cis rs7246657 0.882 rs10422667 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37446974 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs1015848 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37454372 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs1015849 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37455278 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs4801759 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37464083 chr19:37314868~37315620:- LIHC cis rs7246657 0.943 rs13343502 ENSG00000276846.1 CTD-3220F14.3 4.66 4.45e-06 0.00131 0.32 0.24 Coronary artery calcification; chr19:37471390 chr19:37314868~37315620:- LIHC cis rs11971779 0.616 rs1862878 ENSG00000273391.1 RP11-634H22.1 4.66 4.45e-06 0.00131 0.22 0.24 Diisocyanate-induced asthma; chr7:139335168 chr7:139359032~139359566:- LIHC cis rs7412746 0.611 rs12410869 ENSG00000231073.1 RP11-316M1.3 4.66 4.45e-06 0.00131 0.24 0.24 Melanoma; chr1:150883677 chr1:150973123~150975534:+ LIHC cis rs7412746 0.611 rs36008098 ENSG00000231073.1 RP11-316M1.3 4.66 4.45e-06 0.00131 0.24 0.24 Melanoma; chr1:150884330 chr1:150973123~150975534:+ LIHC cis rs11648785 0.661 rs870856 ENSG00000221819.5 GAS8-AS1 -4.66 4.45e-06 0.00131 -0.32 -0.24 Tanning; chr16:90023055 chr16:90028908~90029367:- LIHC cis rs9903692 0.954 rs9889470 ENSG00000278765.1 RP5-890E16.5 4.66 4.46e-06 0.00131 0.33 0.24 Pulse pressure; chr17:48233713 chr17:48066704~48067293:- LIHC cis rs228614 0.536 rs223375 ENSG00000246560.2 RP11-10L12.4 4.66 4.46e-06 0.00131 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102836484 chr4:102828055~102844075:+ LIHC cis rs496547 0.52 rs11216963 ENSG00000255422.1 AP002954.4 4.66 4.46e-06 0.00131 0.32 0.24 Hip minimal joint space width; chr11:118710105 chr11:118704607~118750263:+ LIHC cis rs4694744 0.624 rs1569344 ENSG00000264696.1 AC108078.1 4.66 4.47e-06 0.00132 0.38 0.24 Bacteremia; chr4:69475674 chr4:69479331~69479434:+ LIHC cis rs11971779 0.688 rs8137 ENSG00000273391.1 RP11-634H22.1 -4.66 4.47e-06 0.00132 -0.21 -0.24 Diisocyanate-induced asthma; chr7:139419715 chr7:139359032~139359566:- LIHC cis rs2337406 0.789 rs112027230 ENSG00000274576.2 IGHV2-70 -4.66 4.47e-06 0.00132 -0.26 -0.24 Alzheimer's disease (late onset); chr14:106810329 chr14:106770577~106771020:- LIHC cis rs42490 0.903 rs218899 ENSG00000251136.7 RP11-37B2.1 -4.66 4.47e-06 0.00132 -0.22 -0.24 Leprosy; chr8:89717279 chr8:89609409~89757727:- LIHC cis rs2439831 0.867 rs45585139 ENSG00000205771.5 CATSPER2P1 -4.66 4.48e-06 0.00132 -0.39 -0.24 Lung cancer in ever smokers; chr15:43408229 chr15:43726918~43747094:- LIHC cis rs10975870 0.847 rs7876040 ENSG00000236924.1 RP11-390F4.6 -4.66 4.48e-06 0.00132 -0.3 -0.24 Body mass index; chr9:6936305 chr9:6645956~6670635:+ LIHC cis rs11098499 0.754 rs878372 ENSG00000245958.5 RP11-33B1.1 -4.66 4.48e-06 0.00132 -0.25 -0.24 Corneal astigmatism; chr4:119317625 chr4:119454791~119552025:+ LIHC cis rs4660214 0.724 rs10888683 ENSG00000182109.6 RP11-69E11.4 4.66 4.48e-06 0.00132 0.25 0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39157997 chr1:39522280~39546187:- LIHC cis rs4660456 0.576 rs2780948 ENSG00000237899.1 RP4-739H11.3 -4.66 4.49e-06 0.00132 -0.3 -0.24 Platelet count; chr1:40776205 chr1:40669089~40687588:- LIHC cis rs712039 1 rs712039 ENSG00000276054.1 RP11-378E13.3 4.66 4.49e-06 0.00132 0.29 0.24 Tuberculosis; chr17:37490447 chr17:37386886~37387926:+ LIHC cis rs11671005 0.57 rs73062110 ENSG00000269473.1 CTD-2619J13.19 4.66 4.49e-06 0.00132 0.4 0.24 Mean platelet volume; chr19:58425275 chr19:58440448~58445849:+ LIHC cis rs113835537 0.668 rs12223908 ENSG00000255517.5 CTD-3074O7.5 -4.66 4.49e-06 0.00132 -0.36 -0.24 Airway imaging phenotypes; chr11:66573301 chr11:66473490~66480233:- LIHC cis rs2439831 0.85 rs2228368 ENSG00000166763.7 STRCP1 4.66 4.49e-06 0.00132 0.38 0.24 Lung cancer in ever smokers; chr15:43809812 chr15:43699488~43718184:- LIHC cis rs2880765 0.566 rs17553790 ENSG00000259630.2 CTD-2262B20.1 4.66 4.49e-06 0.00132 0.34 0.24 Coronary artery disease; chr15:85470434 chr15:85415228~85415633:+ LIHC cis rs2562456 0.917 rs11085463 ENSG00000268555.1 RP11-678G14.3 4.66 4.49e-06 0.00132 0.31 0.24 Pain; chr19:21568500 chr19:21570822~21587322:- LIHC cis rs643506 0.79 rs688095 ENSG00000254990.4 RP11-108O10.2 4.66 4.49e-06 0.00132 0.26 0.24 Breast cancer; chr11:111808047 chr11:111768668~111778350:- LIHC cis rs643506 0.817 rs658373 ENSG00000254990.4 RP11-108O10.2 4.66 4.49e-06 0.00132 0.26 0.24 Breast cancer; chr11:111812267 chr11:111768668~111778350:- LIHC cis rs11096990 0.634 rs2062229 ENSG00000249685.1 RP11-360F5.3 4.66 4.5e-06 0.00132 0.29 0.24 Cognitive function; chr4:39285146 chr4:39133913~39135608:+ LIHC cis rs10871290 0.881 rs7498574 ENSG00000261079.1 RP11-252A24.3 -4.66 4.5e-06 0.00132 -0.28 -0.24 Breast cancer; chr16:74438763 chr16:74367462~74369826:+ LIHC cis rs228614 0.51 rs223362 ENSG00000246560.2 RP11-10L12.4 4.66 4.5e-06 0.00132 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102848077 chr4:102828055~102844075:+ LIHC cis rs3734905 1 rs1033458 ENSG00000266896.1 RP1-266L20.9 4.66 4.51e-06 0.00133 0.3 0.24 HIV-1 control; chr6:169594698 chr6:169770413~169772042:+ LIHC cis rs11971779 0.715 rs7781459 ENSG00000273391.1 RP11-634H22.1 4.66 4.51e-06 0.00133 0.22 0.24 Diisocyanate-induced asthma; chr7:139409136 chr7:139359032~139359566:- LIHC cis rs9487094 0.67 rs12197838 ENSG00000260273.1 RP11-425D10.10 4.66 4.51e-06 0.00133 0.29 0.24 Height; chr6:109672088 chr6:109382795~109383666:+ LIHC cis rs11668505 1 rs11666244 ENSG00000259108.2 CTD-3098H1.2 4.66 4.51e-06 0.00133 0.32 0.24 Lung function (FVC); chr19:47842984 chr19:47863483~47865341:- LIHC cis rs11668505 1 rs11666316 ENSG00000259108.2 CTD-3098H1.2 4.66 4.51e-06 0.00133 0.32 0.24 Lung function (FVC); chr19:47843246 chr19:47863483~47865341:- LIHC cis rs11668505 1 rs11670620 ENSG00000259108.2 CTD-3098H1.2 4.66 4.51e-06 0.00133 0.32 0.24 Lung function (FVC); chr19:47843268 chr19:47863483~47865341:- LIHC cis rs11668505 0.965 rs12459855 ENSG00000259108.2 CTD-3098H1.2 4.66 4.51e-06 0.00133 0.32 0.24 Lung function (FVC); chr19:47843664 chr19:47863483~47865341:- LIHC cis rs11668505 1 rs12459926 ENSG00000259108.2 CTD-3098H1.2 4.66 4.51e-06 0.00133 0.32 0.24 Lung function (FVC); chr19:47843831 chr19:47863483~47865341:- LIHC cis rs11668505 1 rs12984385 ENSG00000259108.2 CTD-3098H1.2 4.66 4.51e-06 0.00133 0.32 0.24 Lung function (FVC); chr19:47844114 chr19:47863483~47865341:- LIHC cis rs11668505 0.804 rs34982374 ENSG00000259108.2 CTD-3098H1.2 4.66 4.51e-06 0.00133 0.32 0.24 Lung function (FVC); chr19:47844196 chr19:47863483~47865341:- LIHC cis rs11668505 1 rs11667492 ENSG00000259108.2 CTD-3098H1.2 4.66 4.51e-06 0.00133 0.32 0.24 Lung function (FVC); chr19:47844342 chr19:47863483~47865341:- LIHC cis rs11668505 1 rs12977458 ENSG00000259108.2 CTD-3098H1.2 4.66 4.51e-06 0.00133 0.32 0.24 Lung function (FVC); chr19:47844857 chr19:47863483~47865341:- LIHC cis rs11668505 1 rs11668505 ENSG00000259108.2 CTD-3098H1.2 4.66 4.51e-06 0.00133 0.32 0.24 Lung function (FVC); chr19:47845106 chr19:47863483~47865341:- LIHC cis rs6445975 0.531 rs6804460 ENSG00000272360.1 RP11-359I18.5 4.66 4.51e-06 0.00133 0.33 0.24 Systemic lupus erythematosus; chr3:58380130 chr3:58490830~58491291:- LIHC cis rs6445975 0.666 rs6445974 ENSG00000272360.1 RP11-359I18.5 4.66 4.51e-06 0.00133 0.33 0.24 Systemic lupus erythematosus; chr3:58381110 chr3:58490830~58491291:- LIHC cis rs673078 0.66 rs61945176 ENSG00000275759.1 RP11-131L12.3 -4.66 4.51e-06 0.00133 -0.31 -0.24 Glucose homeostasis traits; chr12:118204735 chr12:118428281~118428870:+ LIHC cis rs3096299 0.967 rs16965692 ENSG00000261118.1 RP11-104N10.1 4.66 4.51e-06 0.00133 0.25 0.24 Multiple myeloma (IgH translocation); chr16:89405074 chr16:89492017~89504460:- LIHC cis rs11098499 0.954 rs10008392 ENSG00000260091.1 RP11-33B1.4 -4.66 4.52e-06 0.00133 -0.18 -0.24 Corneal astigmatism; chr4:119397684 chr4:119409333~119410233:+ LIHC cis rs71520386 0.607 rs28660425 ENSG00000228649.7 AC005682.5 -4.66 4.52e-06 0.00133 -0.32 -0.24 Fibrinogen levels; chr7:22818532 chr7:22854178~22861579:+ LIHC cis rs755249 1 rs2293476 ENSG00000182109.6 RP11-69E11.4 -4.66 4.53e-06 0.00133 -0.33 -0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39571175 chr1:39522280~39546187:- LIHC cis rs899997 1 rs4887078 ENSG00000261143.1 ADAMTS7P3 4.66 4.53e-06 0.00133 0.29 0.24 Coronary artery disease or large artery stroke; chr15:78718731 chr15:77976042~77993057:+ LIHC cis rs67311347 1 rs4973878 ENSG00000223797.4 ENTPD3-AS1 4.66 4.53e-06 0.00133 0.19 0.24 Renal cell carcinoma; chr3:40366074 chr3:40313802~40453329:- LIHC cis rs79040073 0.53 rs17475228 ENSG00000259531.2 RP11-295H24.3 4.66 4.54e-06 0.00133 0.4 0.24 Lung cancer in ever smokers; chr15:49269619 chr15:49365124~49366685:- LIHC cis rs2749097 0.825 rs2749100 ENSG00000244256.3 RN7SL130P 4.66 4.54e-06 0.00133 0.28 0.24 Alcohol consumption (transferrin glycosylation); chr1:63659308 chr1:63655743~63656047:+ LIHC cis rs11673344 0.832 rs112380313 ENSG00000226686.6 LINC01535 4.66 4.54e-06 0.00134 0.38 0.24 Obesity-related traits; chr19:37027979 chr19:37251912~37265535:+ LIHC cis rs11673344 0.832 rs76470527 ENSG00000226686.6 LINC01535 4.66 4.54e-06 0.00134 0.38 0.24 Obesity-related traits; chr19:37035981 chr19:37251912~37265535:+ LIHC cis rs643506 0.874 rs618031 ENSG00000254990.4 RP11-108O10.2 4.66 4.55e-06 0.00134 0.27 0.24 Breast cancer; chr11:111778139 chr11:111768668~111778350:- LIHC cis rs2836974 0.829 rs34227163 ENSG00000255568.3 BRWD1-AS2 4.66 4.55e-06 0.00134 0.28 0.24 Cognitive function; chr21:39180017 chr21:39313935~39314962:+ LIHC cis rs7429990 0.864 rs883663 ENSG00000229759.1 MRPS18AP1 -4.66 4.55e-06 0.00134 -0.26 -0.24 Educational attainment (years of education); chr3:47619306 chr3:48256350~48256938:- LIHC cis rs228614 0.51 rs223451 ENSG00000246560.2 RP11-10L12.4 4.66 4.55e-06 0.00134 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102791032 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223450 ENSG00000246560.2 RP11-10L12.4 4.66 4.55e-06 0.00134 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102791052 chr4:102828055~102844075:+ LIHC cis rs3733589 1 rs35249656 ENSG00000250413.1 RP11-448G15.1 4.66 4.55e-06 0.00134 0.39 0.24 Renal overload gout; chr4:10036918 chr4:10006482~10009725:+ LIHC cis rs7246657 0.943 rs10420722 ENSG00000276846.1 CTD-3220F14.3 4.66 4.55e-06 0.00134 0.32 0.24 Coronary artery calcification; chr19:37482872 chr19:37314868~37315620:- LIHC cis rs2836974 0.602 rs2836987 ENSG00000255568.3 BRWD1-AS2 -4.66 4.55e-06 0.00134 -0.2 -0.24 Cognitive function; chr21:39334668 chr21:39313935~39314962:+ LIHC cis rs7714584 1 rs75774363 ENSG00000197083.10 ZNF300P1 4.66 4.55e-06 0.00134 0.38 0.24 Crohn's disease; chr5:150844160 chr5:150930645~150946289:- LIHC cis rs453301 0.686 rs6601280 ENSG00000253981.4 ALG1L13P 4.66 4.55e-06 0.00134 0.34 0.24 Joint mobility (Beighton score); chr8:9051726 chr8:8236003~8244667:- LIHC cis rs7208859 0.573 rs11654035 ENSG00000266490.1 CTD-2349P21.9 4.66 4.56e-06 0.00134 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809408 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs7208441 ENSG00000266490.1 CTD-2349P21.9 4.66 4.56e-06 0.00134 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816845 chr17:30792372~30792833:+ LIHC cis rs11098499 0.662 rs13108589 ENSG00000260091.1 RP11-33B1.4 -4.66 4.56e-06 0.00134 -0.17 -0.24 Corneal astigmatism; chr4:119346947 chr4:119409333~119410233:+ LIHC cis rs2842992 0.789 rs6908680 ENSG00000237927.1 RP3-393E18.2 -4.66 4.57e-06 0.00134 -0.3 -0.24 Age-related macular degeneration (geographic atrophy); chr6:159797177 chr6:159586955~159589169:- LIHC cis rs960902 0.747 rs13387905 ENSG00000213553.4 RPLP0P6 4.66 4.57e-06 0.00134 0.2 0.24 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37501482 chr2:38481851~38482804:+ LIHC cis rs960902 0.747 rs9941697 ENSG00000213553.4 RPLP0P6 4.66 4.57e-06 0.00134 0.2 0.24 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37501544 chr2:38481851~38482804:+ LIHC cis rs11098499 0.644 rs7676296 ENSG00000245958.5 RP11-33B1.1 -4.66 4.57e-06 0.00134 -0.25 -0.24 Corneal astigmatism; chr4:119634532 chr4:119454791~119552025:+ LIHC cis rs67311347 0.911 rs9849224 ENSG00000223797.4 ENTPD3-AS1 4.66 4.57e-06 0.00134 0.19 0.24 Renal cell carcinoma; chr3:40351071 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs2168111 ENSG00000223797.4 ENTPD3-AS1 4.66 4.57e-06 0.00134 0.19 0.24 Renal cell carcinoma; chr3:40353834 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs9834052 ENSG00000223797.4 ENTPD3-AS1 4.66 4.57e-06 0.00134 0.19 0.24 Renal cell carcinoma; chr3:40357569 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs7612015 ENSG00000223797.4 ENTPD3-AS1 4.66 4.57e-06 0.00134 0.19 0.24 Renal cell carcinoma; chr3:40358483 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs4246666 ENSG00000223797.4 ENTPD3-AS1 4.66 4.57e-06 0.00134 0.19 0.24 Renal cell carcinoma; chr3:40366179 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs2887995 ENSG00000223797.4 ENTPD3-AS1 4.66 4.57e-06 0.00134 0.19 0.24 Renal cell carcinoma; chr3:40367538 chr3:40313802~40453329:- LIHC cis rs4934494 0.689 rs17127588 ENSG00000232936.4 RP11-80H5.2 4.66 4.57e-06 0.00134 0.29 0.24 Red blood cell count; chr10:89815887 chr10:89645282~89650667:+ LIHC cis rs1577917 1 rs12196411 ENSG00000234155.1 RP11-30P6.6 4.66 4.58e-06 0.00134 0.33 0.24 Response to antipsychotic treatment; chr6:86070044 chr6:85387219~85390186:- LIHC cis rs11671005 0.735 rs34873624 ENSG00000269473.1 CTD-2619J13.19 4.66 4.58e-06 0.00134 0.4 0.24 Mean platelet volume; chr19:58432035 chr19:58440448~58445849:+ LIHC cis rs11671005 0.693 rs34230465 ENSG00000269473.1 CTD-2619J13.19 4.66 4.58e-06 0.00134 0.4 0.24 Mean platelet volume; chr19:58432209 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs3764529 ENSG00000269473.1 CTD-2619J13.19 4.66 4.58e-06 0.00134 0.4 0.24 Mean platelet volume; chr19:58433722 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs1122955 ENSG00000269473.1 CTD-2619J13.19 4.66 4.58e-06 0.00134 0.4 0.24 Mean platelet volume; chr19:58434836 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs11668814 ENSG00000269473.1 CTD-2619J13.19 4.66 4.58e-06 0.00134 0.4 0.24 Mean platelet volume; chr19:58435466 chr19:58440448~58445849:+ LIHC cis rs11971779 0.838 rs4728468 ENSG00000273391.1 RP11-634H22.1 4.66 4.58e-06 0.00134 0.23 0.24 Diisocyanate-induced asthma; chr7:139438232 chr7:139359032~139359566:- LIHC cis rs11098499 0.908 rs1002152 ENSG00000245958.5 RP11-33B1.1 -4.66 4.58e-06 0.00134 -0.25 -0.24 Corneal astigmatism; chr4:119352232 chr4:119454791~119552025:+ LIHC cis rs1865760 0.566 rs9467663 ENSG00000216436.2 HIST1H2APS1 -4.66 4.58e-06 0.00134 -0.28 -0.24 Height; chr6:26021228 chr6:25732497~25732827:+ LIHC cis rs5758511 0.68 rs5758687 ENSG00000205702.9 CYP2D7 4.66 4.59e-06 0.00135 0.29 0.24 Birth weight; chr22:42260582 chr22:42140203~42144577:- LIHC cis rs4694744 0.576 rs13142440 ENSG00000264696.1 AC108078.1 4.66 4.59e-06 0.00135 0.37 0.24 Bacteremia; chr4:69480846 chr4:69479331~69479434:+ LIHC cis rs4694744 0.576 rs13119049 ENSG00000264696.1 AC108078.1 4.66 4.59e-06 0.00135 0.37 0.24 Bacteremia; chr4:69480847 chr4:69479331~69479434:+ LIHC cis rs1062177 1 rs973529 ENSG00000253921.1 CTB-113P19.3 -4.66 4.59e-06 0.00135 -0.28 -0.24 Preschool internalizing problems; chr5:151808597 chr5:151753992~151767247:+ LIHC cis rs4938303 0.718 rs3212282 ENSG00000254851.1 RP11-109L13.1 -4.66 4.59e-06 0.00135 -0.31 -0.24 Triglycerides; chr11:116731229 chr11:117135528~117138582:+ LIHC cis rs228614 0.51 rs50034 ENSG00000246560.2 RP11-10L12.4 4.66 4.6e-06 0.00135 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102832214 chr4:102828055~102844075:+ LIHC cis rs227275 0.556 rs223380 ENSG00000246560.2 RP11-10L12.4 4.66 4.6e-06 0.00135 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102833343 chr4:102828055~102844075:+ LIHC cis rs227275 0.556 rs223379 ENSG00000246560.2 RP11-10L12.4 4.66 4.6e-06 0.00135 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102833434 chr4:102828055~102844075:+ LIHC cis rs1558001 0.87 rs2158728 ENSG00000230196.1 DDX43P3 -4.66 4.6e-06 0.00135 -0.26 -0.24 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81783286 chr7:81610884~81611326:- LIHC cis rs6565180 0.962 rs6565183 ENSG00000183604.13 SMG1P5 -4.66 4.61e-06 0.00135 -0.25 -0.24 Tonsillectomy; chr16:30371434 chr16:30267553~30335374:- LIHC cis rs765787 0.53 rs10851423 ENSG00000259520.4 CTD-2651B20.3 -4.66 4.61e-06 0.00135 -0.28 -0.24 Uric acid levels; chr15:45223752 chr15:45251580~45279251:- LIHC cis rs765787 0.53 rs12913123 ENSG00000259520.4 CTD-2651B20.3 -4.66 4.61e-06 0.00135 -0.28 -0.24 Uric acid levels; chr15:45224227 chr15:45251580~45279251:- LIHC cis rs728616 0.867 rs17098720 ENSG00000225484.5 NUTM2B-AS1 -4.66 4.61e-06 0.00135 -0.53 -0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80080480 chr10:79663088~79826594:- LIHC cis rs728616 0.717 rs12414332 ENSG00000225484.5 NUTM2B-AS1 -4.66 4.61e-06 0.00135 -0.53 -0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80081199 chr10:79663088~79826594:- LIHC cis rs71520386 0.632 rs2286509 ENSG00000228649.7 AC005682.5 -4.66 4.61e-06 0.00135 -0.32 -0.24 Fibrinogen levels; chr7:22814832 chr7:22854178~22861579:+ LIHC cis rs1005277 0.691 rs2474558 ENSG00000276805.1 RP11-291L22.6 -4.66 4.61e-06 0.00135 -0.31 -0.24 Extrinsic epigenetic age acceleration; chr10:38197213 chr10:38451030~38451785:+ LIHC cis rs3733585 0.806 rs11723382 ENSG00000250413.1 RP11-448G15.1 4.66 4.62e-06 0.00135 0.31 0.24 Cleft plate (environmental tobacco smoke interaction); chr4:9953036 chr4:10006482~10009725:+ LIHC cis rs5756813 0.754 rs762982 ENSG00000233360.4 Z83844.1 -4.66 4.62e-06 0.00135 -0.32 -0.24 Optic cup area;Vertical cup-disc ratio; chr22:37748228 chr22:37641832~37658377:- LIHC cis rs12681287 0.604 rs71502657 ENSG00000254088.1 SLC2A3P4 4.66 4.62e-06 0.00135 0.29 0.24 Caudate activity during reward; chr8:86466552 chr8:86503591~86505061:+ LIHC cis rs7809950 1 rs12668402 ENSG00000238832.1 snoU109 -4.66 4.62e-06 0.00135 -0.3 -0.24 Coronary artery disease; chr7:107532575 chr7:107603363~107603507:+ LIHC cis rs7712401 0.56 rs13168225 ENSG00000263432.2 RN7SL689P -4.66 4.62e-06 0.00135 -0.37 -0.24 Mean platelet volume; chr5:123011569 chr5:123022487~123022783:- LIHC cis rs4731207 1 rs4731207 ENSG00000224897.5 POT1-AS1 -4.66 4.63e-06 0.00136 -0.29 -0.24 Cutaneous malignant melanoma; chr7:124756591 chr7:124929873~125179315:+ LIHC cis rs17711722 0.522 rs62469933 ENSG00000273024.4 INTS4P2 -4.66 4.63e-06 0.00136 -0.26 -0.24 Calcium levels; chr7:65800652 chr7:65647864~65715661:+ LIHC cis rs1061377 0.748 rs6812316 ENSG00000249685.1 RP11-360F5.3 4.66 4.64e-06 0.00136 0.3 0.24 Uric acid levels; chr4:39106617 chr4:39133913~39135608:+ LIHC cis rs6480314 0.831 rs11813170 ENSG00000233590.1 RP11-153K11.3 -4.66 4.64e-06 0.00136 -0.36 -0.24 Optic nerve measurement (disc area); chr10:68215366 chr10:68233251~68242379:- LIHC cis rs227275 0.554 rs223409 ENSG00000246560.2 RP11-10L12.4 4.65 4.64e-06 0.00136 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102815023 chr4:102828055~102844075:+ LIHC cis rs6901152 0.508 rs1345990 ENSG00000217648.1 RP1-95L4.4 -4.65 4.64e-06 0.00136 -0.29 -0.24 Acute lymphoblastic leukemia (childhood); chr6:143365727 chr6:143342246~143343383:+ LIHC cis rs7937890 0.561 rs2575849 ENSG00000251991.1 RNU7-49P 4.65 4.65e-06 0.00136 0.26 0.24 Mitochondrial DNA levels; chr11:14518093 chr11:14478892~14478953:+ LIHC cis rs2032447 0.714 rs199726 ENSG00000242387.1 HIST1H2APS2 4.65 4.65e-06 0.00136 0.31 0.24 Intelligence (multi-trait analysis); chr6:25953132 chr6:25882026~25882395:- LIHC cis rs11098499 0.663 rs9996501 ENSG00000245958.5 RP11-33B1.1 -4.65 4.65e-06 0.00136 -0.25 -0.24 Corneal astigmatism; chr4:119317763 chr4:119454791~119552025:+ LIHC cis rs11098499 0.697 rs28458294 ENSG00000245958.5 RP11-33B1.1 -4.65 4.65e-06 0.00136 -0.25 -0.24 Corneal astigmatism; chr4:119317769 chr4:119454791~119552025:+ LIHC cis rs11098499 0.663 rs28369503 ENSG00000245958.5 RP11-33B1.1 -4.65 4.65e-06 0.00136 -0.25 -0.24 Corneal astigmatism; chr4:119317770 chr4:119454791~119552025:+ LIHC cis rs7208859 0.623 rs55724095 ENSG00000266490.1 CTD-2349P21.9 4.65 4.65e-06 0.00136 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30826040 chr17:30792372~30792833:+ LIHC cis rs17826219 0.568 rs9903854 ENSG00000266490.1 CTD-2349P21.9 4.65 4.65e-06 0.00136 0.31 0.24 Body mass index; chr17:30826980 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs80355557 ENSG00000266490.1 CTD-2349P21.9 4.65 4.65e-06 0.00136 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827403 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9911173 ENSG00000266490.1 CTD-2349P21.9 4.65 4.65e-06 0.00136 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827732 chr17:30792372~30792833:+ LIHC cis rs7121538 1 rs61884030 ENSG00000251991.1 RNU7-49P -4.65 4.66e-06 0.00136 -0.35 -0.24 HDL cholesterol; chr11:14422997 chr11:14478892~14478953:+ LIHC cis rs3091242 0.867 rs602052 ENSG00000224183.1 SDHDP6 -4.65 4.66e-06 0.00136 -0.28 -0.24 Erythrocyte sedimentation rate; chr1:25395715 chr1:25294164~25294643:- LIHC cis rs17270561 0.887 rs9358870 ENSG00000272810.1 U91328.22 -4.65 4.66e-06 0.00136 -0.32 -0.24 Iron status biomarkers; chr6:25718982 chr6:26013241~26013757:+ LIHC cis rs2581828 0.656 rs2253209 ENSG00000242142.1 SERBP1P3 4.65 4.66e-06 0.00137 0.28 0.24 Crohn's disease; chr3:53081144 chr3:53064283~53065091:- LIHC cis rs2581828 0.694 rs2336725 ENSG00000242142.1 SERBP1P3 4.65 4.66e-06 0.00137 0.28 0.24 Crohn's disease; chr3:53084723 chr3:53064283~53065091:- LIHC cis rs9326248 0.52 rs6589602 ENSG00000236267.1 AP006216.5 4.65 4.66e-06 0.00137 0.25 0.24 Blood protein levels; chr11:117166349 chr11:116813204~116814003:- LIHC cis rs9326248 0.539 rs7120565 ENSG00000236267.1 AP006216.5 4.65 4.66e-06 0.00137 0.25 0.24 Blood protein levels; chr11:117172233 chr11:116813204~116814003:- LIHC cis rs9291683 0.595 rs35250962 ENSG00000250413.1 RP11-448G15.1 -4.65 4.67e-06 0.00137 -0.31 -0.24 Bone mineral density; chr4:10046647 chr4:10006482~10009725:+ LIHC cis rs5758511 0.633 rs5751258 ENSG00000205702.9 CYP2D7 4.65 4.67e-06 0.00137 0.29 0.24 Birth weight; chr22:42267865 chr22:42140203~42144577:- LIHC cis rs1065852 0.526 rs739296 ENSG00000237037.8 NDUFA6-AS1 4.65 4.67e-06 0.00137 0.33 0.24 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41993944 chr22:42090931~42137742:+ LIHC cis rs202072 0.729 rs8541 ENSG00000215022.6 RP1-257A7.4 -4.65 4.67e-06 0.00137 -0.29 -0.24 HIV-1 viral setpoint; chr6:13290006 chr6:13264861~13295586:- LIHC cis rs3812762 0.871 rs3844100 ENSG00000254860.4 TMEM9B-AS1 -4.65 4.67e-06 0.00137 -0.26 -0.24 Hypospadias; chr11:8796261 chr11:8964675~8977527:+ LIHC cis rs71520386 0.632 rs12532922 ENSG00000228649.7 AC005682.5 -4.65 4.67e-06 0.00137 -0.32 -0.24 Fibrinogen levels; chr7:22820796 chr7:22854178~22861579:+ LIHC cis rs71520386 0.632 rs10224533 ENSG00000228649.7 AC005682.5 -4.65 4.67e-06 0.00137 -0.32 -0.24 Fibrinogen levels; chr7:22821522 chr7:22854178~22861579:+ LIHC cis rs875971 0.66 rs10263935 ENSG00000273024.4 INTS4P2 -4.65 4.67e-06 0.00137 -0.27 -0.24 Aortic root size; chr7:66631041 chr7:65647864~65715661:+ LIHC cis rs67311347 1 rs12494022 ENSG00000223797.4 ENTPD3-AS1 4.65 4.67e-06 0.00137 0.2 0.24 Renal cell carcinoma; chr3:40385161 chr3:40313802~40453329:- LIHC cis rs7567389 0.626 rs11683344 ENSG00000236682.1 AC068282.3 -4.65 4.68e-06 0.00137 -0.38 -0.24 Self-rated health; chr2:127198676 chr2:127389130~127400580:+ LIHC cis rs1075232 1 rs4450360 ENSG00000270055.1 CTD-3092A11.2 -4.65 4.68e-06 0.00137 -0.48 -0.24 Survival in colorectal cancer (non-distant metastatic); chr15:31389827 chr15:30487963~30490313:+ LIHC cis rs1075232 1 rs72722847 ENSG00000270055.1 CTD-3092A11.2 -4.65 4.68e-06 0.00137 -0.48 -0.24 Survival in colorectal cancer (non-distant metastatic); chr15:31390143 chr15:30487963~30490313:+ LIHC cis rs7210990 0.931 rs1029809 ENSG00000234324.1 RPL9P2 4.65 4.69e-06 0.00137 0.3 0.24 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr17:16252921 chr17:15443639~15444191:+ LIHC cis rs812925 0.515 rs1177308 ENSG00000271889.1 RP11-493E12.1 4.65 4.69e-06 0.00137 0.29 0.24 Immature fraction of reticulocytes; chr2:61160119 chr2:61151433~61162105:- LIHC cis rs7119038 0.818 rs6421571 ENSG00000255239.1 AP002954.6 4.65 4.7e-06 0.00137 0.36 0.24 Sjögren's syndrome; chr11:118873063 chr11:118688039~118690600:- LIHC cis rs7208859 0.573 rs7222803 ENSG00000266490.1 CTD-2349P21.9 4.65 4.7e-06 0.00137 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792879 chr17:30792372~30792833:+ LIHC cis rs11971779 0.68 rs4728467 ENSG00000273391.1 RP11-634H22.1 4.65 4.7e-06 0.00138 0.23 0.24 Diisocyanate-induced asthma; chr7:139435816 chr7:139359032~139359566:- LIHC cis rs17507216 0.718 rs7165690 ENSG00000278603.1 RP13-608F4.5 4.65 4.71e-06 0.00138 0.49 0.24 Excessive daytime sleepiness; chr15:82654804 chr15:82472203~82472426:+ LIHC cis rs2276314 1 rs4799834 ENSG00000278986.1 RP11-723J4.3 -4.65 4.71e-06 0.00138 -0.3 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:35986280 chr18:35972151~35973916:+ LIHC cis rs2276314 0.857 rs7237599 ENSG00000278986.1 RP11-723J4.3 -4.65 4.71e-06 0.00138 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36059433 chr18:35972151~35973916:+ LIHC cis rs2976388 0.669 rs1836633 ENSG00000253196.1 RP11-706C16.7 4.65 4.71e-06 0.00138 0.24 0.24 Urinary tract infection frequency; chr8:142693174 chr8:142763116~142766427:+ LIHC cis rs79040073 0.53 rs17396612 ENSG00000259531.2 RP11-295H24.3 4.65 4.71e-06 0.00138 0.4 0.24 Lung cancer in ever smokers; chr15:49257746 chr15:49365124~49366685:- LIHC cis rs4713118 0.629 rs203888 ENSG00000219392.1 RP1-265C24.5 -4.65 4.71e-06 0.00138 -0.35 -0.24 Parkinson's disease; chr6:28053811 chr6:28115628~28116551:+ LIHC cis rs7914558 0.966 rs3902934 ENSG00000236937.2 PTGES3P4 4.65 4.72e-06 0.00138 0.29 0.24 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102986892 chr10:102845595~102845950:+ LIHC cis rs10833905 1 rs10430910 ENSG00000246225.5 RP11-17A1.3 -4.65 4.72e-06 0.00138 -0.3 -0.24 Sudden cardiac arrest; chr11:23015273 chr11:22829380~22945393:+ LIHC cis rs7914558 0.902 rs7092200 ENSG00000236937.2 PTGES3P4 4.65 4.72e-06 0.00138 0.29 0.24 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103085115 chr10:102845595~102845950:+ LIHC cis rs3091242 0.933 rs7541095 ENSG00000224183.1 SDHDP6 -4.65 4.72e-06 0.00138 -0.28 -0.24 Erythrocyte sedimentation rate; chr1:25434800 chr1:25294164~25294643:- LIHC cis rs2274273 0.805 rs60972460 ENSG00000258413.1 RP11-665C16.6 -4.65 4.72e-06 0.00138 -0.27 -0.24 Protein biomarker; chr14:55105055 chr14:55262767~55272075:- LIHC cis rs7937890 0.504 rs2575822 ENSG00000251991.1 RNU7-49P 4.65 4.73e-06 0.00138 0.26 0.24 Mitochondrial DNA levels; chr11:14498305 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2575823 ENSG00000251991.1 RNU7-49P 4.65 4.73e-06 0.00138 0.26 0.24 Mitochondrial DNA levels; chr11:14499808 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2597221 ENSG00000251991.1 RNU7-49P 4.65 4.73e-06 0.00138 0.26 0.24 Mitochondrial DNA levels; chr11:14505529 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs6486197 ENSG00000251991.1 RNU7-49P 4.65 4.73e-06 0.00138 0.26 0.24 Mitochondrial DNA levels; chr11:14508328 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2597219 ENSG00000251991.1 RNU7-49P 4.65 4.73e-06 0.00138 0.26 0.24 Mitochondrial DNA levels; chr11:14509320 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2597217 ENSG00000251991.1 RNU7-49P 4.65 4.73e-06 0.00138 0.26 0.24 Mitochondrial DNA levels; chr11:14511337 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2575852 ENSG00000251991.1 RNU7-49P 4.65 4.73e-06 0.00138 0.26 0.24 Mitochondrial DNA levels; chr11:14511822 chr11:14478892~14478953:+ LIHC cis rs7937890 0.531 rs2597216 ENSG00000251991.1 RNU7-49P 4.65 4.73e-06 0.00138 0.26 0.24 Mitochondrial DNA levels; chr11:14512370 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2575853 ENSG00000251991.1 RNU7-49P 4.65 4.73e-06 0.00138 0.26 0.24 Mitochondrial DNA levels; chr11:14512417 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs1548074 ENSG00000251991.1 RNU7-49P 4.65 4.73e-06 0.00138 0.26 0.24 Mitochondrial DNA levels; chr11:14513279 chr11:14478892~14478953:+ LIHC cis rs30380 1 rs26510 ENSG00000272109.1 CTD-2260A17.3 -4.65 4.73e-06 0.00138 -0.3 -0.24 Cerebrospinal fluid biomarker levels; chr5:96790207 chr5:96804353~96806105:+ LIHC cis rs1005277 0.579 rs1740732 ENSG00000275858.1 RP11-291L22.8 4.65 4.73e-06 0.00138 0.27 0.24 Extrinsic epigenetic age acceleration; chr10:38202457 chr10:38450738~38451069:- LIHC cis rs7246657 0.943 rs10404602 ENSG00000276846.1 CTD-3220F14.3 4.65 4.73e-06 0.00138 0.32 0.24 Coronary artery calcification; chr19:37334731 chr19:37314868~37315620:- LIHC cis rs2276314 1 rs9956938 ENSG00000278986.1 RP11-723J4.3 -4.65 4.73e-06 0.00138 -0.3 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:35987098 chr18:35972151~35973916:+ LIHC cis rs12554020 0.582 rs74842678 ENSG00000227603.1 RP11-165J3.6 4.65 4.74e-06 0.00138 0.45 0.24 Schizophrenia; chr9:93658926 chr9:93435332~93437121:- LIHC cis rs916888 0.779 rs199528 ENSG00000274883.1 Metazoa_SRP -4.65 4.74e-06 0.00138 -0.39 -0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45931806~45932083:+ LIHC cis rs916888 0.821 rs199525 ENSG00000274883.1 Metazoa_SRP -4.65 4.74e-06 0.00138 -0.39 -0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45931806~45932083:+ LIHC cis rs11098499 0.789 rs1980024 ENSG00000245958.5 RP11-33B1.1 -4.65 4.74e-06 0.00138 -0.25 -0.24 Corneal astigmatism; chr4:119331892 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs34425882 ENSG00000245958.5 RP11-33B1.1 -4.65 4.74e-06 0.00138 -0.25 -0.24 Corneal astigmatism; chr4:119332022 chr4:119454791~119552025:+ LIHC cis rs6802315 0.575 rs1864508 ENSG00000272087.1 RP11-379F4.7 4.65 4.74e-06 0.00138 0.28 0.24 Periodontitis (CDC/AAP); chr3:158765024 chr3:158693120~158693768:- LIHC cis rs8024893 0.764 rs7182545 ENSG00000270055.1 CTD-3092A11.2 -4.65 4.74e-06 0.00138 -0.35 -0.24 Red cell distribution width; chr15:31239638 chr15:30487963~30490313:+ LIHC cis rs9601248 0.627 rs2146593 ENSG00000227354.5 RBM26-AS1 4.65 4.74e-06 0.00138 0.31 0.24 Major depressive disorder; chr13:79605977 chr13:79406309~79424328:+ LIHC cis rs765787 0.505 rs12593605 ENSG00000259520.4 CTD-2651B20.3 -4.65 4.74e-06 0.00139 -0.28 -0.24 Uric acid levels; chr15:45205250 chr15:45251580~45279251:- LIHC cis rs3733589 0.744 rs6821843 ENSG00000250413.1 RP11-448G15.1 -4.65 4.74e-06 0.00139 -0.39 -0.24 Renal overload gout; chr4:10050904 chr4:10006482~10009725:+ LIHC cis rs881375 0.678 rs10760130 ENSG00000226752.6 PSMD5-AS1 -4.65 4.74e-06 0.00139 -0.25 -0.24 Rheumatoid arthritis; chr9:120939712 chr9:120824828~120854385:+ LIHC cis rs9807989 0.507 rs6734762 ENSG00000234389.1 AC007278.3 4.65 4.75e-06 0.00139 0.26 0.24 Asthma; chr2:102446466 chr2:102438713~102440475:+ LIHC cis rs17023223 0.553 rs72691108 ENSG00000231365.4 RP11-418J17.1 -4.65 4.75e-06 0.00139 -0.31 -0.24 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119219552 chr1:119140396~119275973:+ LIHC cis rs11098499 0.754 rs1546503 ENSG00000245958.5 RP11-33B1.1 -4.65 4.75e-06 0.00139 -0.25 -0.24 Corneal astigmatism; chr4:119320012 chr4:119454791~119552025:+ LIHC cis rs11098499 0.708 rs1546506 ENSG00000245958.5 RP11-33B1.1 -4.65 4.75e-06 0.00139 -0.25 -0.24 Corneal astigmatism; chr4:119320085 chr4:119454791~119552025:+ LIHC cis rs12908161 0.959 rs2175567 ENSG00000225151.9 GOLGA2P7 -4.65 4.75e-06 0.00139 -0.31 -0.24 Schizophrenia; chr15:84657715 chr15:84199311~84230136:- LIHC cis rs11673344 0.74 rs113752815 ENSG00000226686.6 LINC01535 4.65 4.75e-06 0.00139 0.38 0.24 Obesity-related traits; chr19:37043829 chr19:37251912~37265535:+ LIHC cis rs3733589 0.59 rs35201034 ENSG00000250413.1 RP11-448G15.1 4.65 4.75e-06 0.00139 0.38 0.24 Renal overload gout; chr4:10005827 chr4:10006482~10009725:+ LIHC cis rs950776 0.752 rs2869546 ENSG00000261762.1 RP11-650L12.2 -4.65 4.76e-06 0.00139 -0.3 -0.24 Sudden cardiac arrest; chr15:78615003 chr15:78589123~78591276:- LIHC cis rs597539 0.652 rs611046 ENSG00000250508.1 RP11-757G1.6 -4.65 4.76e-06 0.00139 -0.36 -0.24 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68864236 chr11:68870664~68874542:+ LIHC cis rs11671005 0.735 rs11668420 ENSG00000269473.1 CTD-2619J13.19 4.65 4.76e-06 0.00139 0.4 0.24 Mean platelet volume; chr19:58426469 chr19:58440448~58445849:+ LIHC cis rs227275 0.556 rs223426 ENSG00000246560.2 RP11-10L12.4 4.65 4.76e-06 0.00139 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102801330 chr4:102828055~102844075:+ LIHC cis rs227275 0.554 rs223425 ENSG00000246560.2 RP11-10L12.4 4.65 4.76e-06 0.00139 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102802836 chr4:102828055~102844075:+ LIHC cis rs4862307 0.754 rs6846208 ENSG00000250726.1 RP11-616K6.1 4.65 4.77e-06 0.00139 0.27 0.24 Serum dimethylarginine levels (asymmetric/symetric ratio); chr4:184070550 chr4:184072403~184073039:+ LIHC cis rs11971779 0.818 rs12056045 ENSG00000273391.1 RP11-634H22.1 4.65 4.77e-06 0.00139 0.23 0.24 Diisocyanate-induced asthma; chr7:139340684 chr7:139359032~139359566:- LIHC cis rs8005677 0.962 rs11157931 ENSG00000257285.4 RP11-298I3.1 4.65 4.78e-06 0.00139 0.25 0.24 Cognitive ability (multi-trait analysis); chr14:22933984 chr14:22929609~22955562:+ LIHC cis rs12304921 0.622 rs67466786 ENSG00000277201.1 AC087884.1 4.65 4.78e-06 0.00139 0.28 0.24 Type 2 diabetes; chr12:51111553 chr12:51049921~51050025:+ LIHC cis rs12304921 0.683 rs60910794 ENSG00000277201.1 AC087884.1 4.65 4.78e-06 0.00139 0.28 0.24 Type 2 diabetes; chr12:51113851 chr12:51049921~51050025:+ LIHC cis rs12304921 0.626 rs73105025 ENSG00000277201.1 AC087884.1 4.65 4.78e-06 0.00139 0.28 0.24 Type 2 diabetes; chr12:51114623 chr12:51049921~51050025:+ LIHC cis rs116139393 0.656 rs10244591 ENSG00000187953.9 PMS2CL -4.65 4.79e-06 0.0014 -0.25 -0.24 Alzheimer's disease (APOE e4 interaction); chr7:6731467 chr7:6710128~6753862:+ LIHC cis rs1322639 0.614 rs6900964 ENSG00000261039.2 RP11-417E7.2 -4.65 4.79e-06 0.0014 -0.34 -0.24 Pulse pressure; chr6:169166668 chr6:169175304~169182740:- LIHC cis rs7811142 0.83 rs77861211 ENSG00000242294.5 STAG3L5P 4.65 4.79e-06 0.0014 0.27 0.24 Platelet count; chr7:100364473 chr7:100336079~100351900:+ LIHC cis rs7811142 0.83 rs11769057 ENSG00000242294.5 STAG3L5P 4.65 4.79e-06 0.0014 0.27 0.24 Platelet count; chr7:100367038 chr7:100336079~100351900:+ LIHC cis rs6683071 0.601 rs3002129 ENSG00000272750.1 RP11-378J18.8 4.65 4.8e-06 0.0014 0.28 0.24 Cognitive performance; chr1:222681993 chr1:222658867~222661512:- LIHC cis rs7208859 0.623 rs73269916 ENSG00000266490.1 CTD-2349P21.9 4.65 4.8e-06 0.0014 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30769308 chr17:30792372~30792833:+ LIHC cis rs8177253 0.633 rs10935073 ENSG00000244062.1 RP11-404G16.2 4.65 4.8e-06 0.0014 0.25 0.24 Iron status biomarkers; chr3:133720340 chr3:133760300~133762363:+ LIHC cis rs957448 1 rs957447 ENSG00000253704.1 RP11-267M23.4 4.65 4.8e-06 0.0014 0.3 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94528995 chr8:94553722~94569745:+ LIHC cis rs957448 1 rs72674852 ENSG00000253704.1 RP11-267M23.4 4.65 4.8e-06 0.0014 0.3 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94536523 chr8:94553722~94569745:+ LIHC cis rs957448 1 rs16916874 ENSG00000253704.1 RP11-267M23.4 4.65 4.8e-06 0.0014 0.3 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94537749 chr8:94553722~94569745:+ LIHC cis rs11096990 0.656 rs4580661 ENSG00000249685.1 RP11-360F5.3 -4.65 4.8e-06 0.0014 -0.29 -0.24 Cognitive function; chr4:39294730 chr4:39133913~39135608:+ LIHC cis rs1865760 0.602 rs9467662 ENSG00000216436.2 HIST1H2APS1 -4.65 4.8e-06 0.0014 -0.28 -0.24 Height; chr6:26021099 chr6:25732497~25732827:+ LIHC cis rs11098499 0.691 rs9996644 ENSG00000245958.5 RP11-33B1.1 -4.65 4.81e-06 0.0014 -0.25 -0.24 Corneal astigmatism; chr4:119317722 chr4:119454791~119552025:+ LIHC cis rs11098499 0.691 rs9996494 ENSG00000245958.5 RP11-33B1.1 -4.65 4.81e-06 0.0014 -0.25 -0.24 Corneal astigmatism; chr4:119317725 chr4:119454791~119552025:+ LIHC cis rs603446 0.935 rs180376 ENSG00000254851.1 RP11-109L13.1 -4.65 4.81e-06 0.0014 -0.3 -0.24 Triglycerides; chr11:116719323 chr11:117135528~117138582:+ LIHC cis rs17711722 0.522 rs6957759 ENSG00000224316.1 RP11-479O9.2 4.65 4.81e-06 0.0014 0.22 0.24 Calcium levels; chr7:65806798 chr7:65773620~65802067:+ LIHC cis rs12130219 1 rs1552994 ENSG00000237975.5 FLG-AS1 4.65 4.81e-06 0.0014 0.42 0.24 Inflammatory skin disease; chr1:152198985 chr1:152168125~152445456:+ LIHC cis rs7246657 0.891 rs7253114 ENSG00000276846.1 CTD-3220F14.3 4.65 4.81e-06 0.0014 0.3 0.24 Coronary artery calcification; chr19:37497823 chr19:37314868~37315620:- LIHC cis rs2439831 0.85 rs8042868 ENSG00000275601.1 AC011330.13 -4.65 4.82e-06 0.0014 -0.37 -0.24 Lung cancer in ever smokers; chr15:43647444 chr15:43642389~43643023:- LIHC cis rs957448 1 rs1048029 ENSG00000253704.1 RP11-267M23.4 4.65 4.82e-06 0.0014 0.3 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94510149 chr8:94553722~94569745:+ LIHC cis rs2439831 0.85 rs16950562 ENSG00000166763.7 STRCP1 4.65 4.82e-06 0.0014 0.38 0.24 Lung cancer in ever smokers; chr15:43744166 chr15:43699488~43718184:- LIHC cis rs643506 0.817 rs1940392 ENSG00000254990.4 RP11-108O10.2 4.65 4.82e-06 0.0014 0.26 0.24 Breast cancer; chr11:111906122 chr11:111768668~111778350:- LIHC cis rs72634501 0.568 rs590214 ENSG00000182109.6 RP11-69E11.4 4.65 4.83e-06 0.00141 0.26 0.24 HDL cholesterol; chr1:39146821 chr1:39522280~39546187:- LIHC cis rs1420585 1 rs12597905 ENSG00000260769.1 RP11-491F9.5 -4.65 4.83e-06 0.00141 -0.31 -0.24 Pursuit maintenance gain; chr16:48968092 chr16:49337167~49338993:+ LIHC cis rs2836974 0.897 rs1541102 ENSG00000255568.3 BRWD1-AS2 4.65 4.84e-06 0.00141 0.28 0.24 Cognitive function; chr21:39256839 chr21:39313935~39314962:+ LIHC cis rs228614 0.509 rs223480 ENSG00000246560.2 RP11-10L12.4 4.65 4.84e-06 0.00141 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766881 chr4:102828055~102844075:+ LIHC cis rs7809950 1 rs10274041 ENSG00000238832.1 snoU109 4.65 4.84e-06 0.00141 0.29 0.24 Coronary artery disease; chr7:107621111 chr7:107603363~107603507:+ LIHC cis rs2439831 1 rs527921 ENSG00000166763.7 STRCP1 -4.65 4.84e-06 0.00141 -0.37 -0.24 Lung cancer in ever smokers; chr15:43478218 chr15:43699488~43718184:- LIHC cis rs228614 0.536 rs223484 ENSG00000246560.2 RP11-10L12.4 4.65 4.84e-06 0.00141 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102764314 chr4:102828055~102844075:+ LIHC cis rs4650994 0.593 rs2811309 ENSG00000273384.1 RP5-1098D14.1 -4.65 4.84e-06 0.00141 -0.3 -0.24 HDL cholesterol;HDL cholesterol levels; chr1:178638549 chr1:178651706~178652282:+ LIHC cis rs11098499 0.779 rs10011097 ENSG00000245958.5 RP11-33B1.1 -4.65 4.84e-06 0.00141 -0.26 -0.24 Corneal astigmatism; chr4:119389204 chr4:119454791~119552025:+ LIHC cis rs1865760 0.602 rs2157050 ENSG00000216436.2 HIST1H2APS1 -4.65 4.84e-06 0.00141 -0.28 -0.24 Height; chr6:26020203 chr6:25732497~25732827:+ LIHC cis rs2836974 0.568 rs414850 ENSG00000255568.3 BRWD1-AS2 4.65 4.84e-06 0.00141 0.21 0.24 Cognitive function; chr21:39171411 chr21:39313935~39314962:+ LIHC cis rs8005677 1 rs11157930 ENSG00000257285.4 RP11-298I3.1 4.65 4.84e-06 0.00141 0.25 0.24 Cognitive ability (multi-trait analysis); chr14:22933962 chr14:22929609~22955562:+ LIHC cis rs11971779 0.68 rs7805767 ENSG00000273391.1 RP11-634H22.1 4.65 4.85e-06 0.00141 0.22 0.24 Diisocyanate-induced asthma; chr7:139426669 chr7:139359032~139359566:- LIHC cis rs11971779 0.648 rs6467852 ENSG00000273391.1 RP11-634H22.1 4.65 4.85e-06 0.00141 0.22 0.24 Diisocyanate-induced asthma; chr7:139427845 chr7:139359032~139359566:- LIHC cis rs11971779 0.616 rs7779314 ENSG00000273391.1 RP11-634H22.1 4.65 4.85e-06 0.00141 0.22 0.24 Diisocyanate-induced asthma; chr7:139427950 chr7:139359032~139359566:- LIHC cis rs11971779 0.715 rs7779390 ENSG00000273391.1 RP11-634H22.1 4.65 4.85e-06 0.00141 0.22 0.24 Diisocyanate-induced asthma; chr7:139428207 chr7:139359032~139359566:- LIHC cis rs11971779 0.584 rs34762928 ENSG00000273391.1 RP11-634H22.1 4.65 4.85e-06 0.00141 0.22 0.24 Diisocyanate-induced asthma; chr7:139428422 chr7:139359032~139359566:- LIHC cis rs11971779 0.68 rs11760420 ENSG00000273391.1 RP11-634H22.1 4.65 4.85e-06 0.00141 0.22 0.24 Diisocyanate-induced asthma; chr7:139430022 chr7:139359032~139359566:- LIHC cis rs11971779 0.553 rs10228643 ENSG00000273391.1 RP11-634H22.1 4.65 4.85e-06 0.00141 0.22 0.24 Diisocyanate-induced asthma; chr7:139430674 chr7:139359032~139359566:- LIHC cis rs11098499 0.618 rs35265692 ENSG00000260091.1 RP11-33B1.4 -4.65 4.85e-06 0.00141 -0.17 -0.24 Corneal astigmatism; chr4:119403980 chr4:119409333~119410233:+ LIHC cis rs755249 0.508 rs6703800 ENSG00000182109.6 RP11-69E11.4 -4.65 4.85e-06 0.00141 -0.25 -0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39160970 chr1:39522280~39546187:- LIHC cis rs4660214 0.724 rs12117785 ENSG00000182109.6 RP11-69E11.4 -4.65 4.85e-06 0.00141 -0.25 -0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39162739 chr1:39522280~39546187:- LIHC cis rs4694744 0.583 rs1569342 ENSG00000264696.1 AC108078.1 4.65 4.85e-06 0.00141 0.38 0.24 Bacteremia; chr4:69475832 chr4:69479331~69479434:+ LIHC cis rs2439831 0.85 rs544122 ENSG00000166763.7 STRCP1 4.65 4.85e-06 0.00141 0.37 0.24 Lung cancer in ever smokers; chr15:43483534 chr15:43699488~43718184:- LIHC cis rs901683 0.702 rs73292848 ENSG00000230869.1 CTGLF10P -4.65 4.86e-06 0.00141 -0.53 -0.24 Mean corpuscular volume;Red blood cell traits; chr10:45674304 chr10:45678692~45700532:+ LIHC cis rs11096990 0.634 rs6829064 ENSG00000249685.1 RP11-360F5.3 -4.65 4.86e-06 0.00141 -0.29 -0.24 Cognitive function; chr4:39290192 chr4:39133913~39135608:+ LIHC cis rs765787 0.53 rs12592055 ENSG00000259520.4 CTD-2651B20.3 -4.64 4.86e-06 0.00142 -0.28 -0.24 Uric acid levels; chr15:45222279 chr15:45251580~45279251:- LIHC cis rs17711722 0.565 rs4717276 ENSG00000273024.4 INTS4P2 -4.64 4.87e-06 0.00142 -0.26 -0.24 Calcium levels; chr7:65829754 chr7:65647864~65715661:+ LIHC cis rs858239 0.699 rs1881200 ENSG00000226816.2 AC005082.12 -4.64 4.87e-06 0.00142 -0.32 -0.24 Cerebrospinal fluid biomarker levels; chr7:23162018 chr7:23206013~23208045:+ LIHC cis rs11098499 0.754 rs878376 ENSG00000245958.5 RP11-33B1.1 -4.64 4.87e-06 0.00142 -0.25 -0.24 Corneal astigmatism; chr4:119316547 chr4:119454791~119552025:+ LIHC cis rs7714584 1 rs1428555 ENSG00000197083.10 ZNF300P1 -4.64 4.87e-06 0.00142 -0.37 -0.24 Crohn's disease; chr5:150877829 chr5:150930645~150946289:- LIHC cis rs7208859 0.623 rs56325146 ENSG00000266490.1 CTD-2349P21.9 4.64 4.88e-06 0.00142 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824006 chr17:30792372~30792833:+ LIHC cis rs7208859 0.562 rs216408 ENSG00000266490.1 CTD-2349P21.9 -4.64 4.89e-06 0.00142 -0.29 -0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30580739 chr17:30792372~30792833:+ LIHC cis rs2253762 0.527 rs11200323 ENSG00000226864.1 ATE1-AS1 -4.64 4.89e-06 0.00142 -0.39 -0.24 Breast cancer; chr10:122008869 chr10:121928312~121951965:+ LIHC cis rs904251 0.861 rs1776456 ENSG00000204110.6 RP1-153P14.8 -4.64 4.89e-06 0.00142 -0.3 -0.24 Cognitive performance; chr6:37516922 chr6:37507348~37535616:+ LIHC cis rs113084984 0.634 rs12466575 ENSG00000271952.1 RP11-245G13.2 -4.64 4.89e-06 0.00142 -0.32 -0.24 Breast cancer; chr2:11523294 chr2:10878269~10885118:+ LIHC cis rs7412746 0.621 rs11204749 ENSG00000231073.1 RP11-316M1.3 4.64 4.89e-06 0.00142 0.24 0.24 Melanoma; chr1:150957087 chr1:150973123~150975534:+ LIHC cis rs6442522 0.809 rs17041143 ENSG00000249786.6 EAF1-AS1 4.64 4.9e-06 0.00142 0.29 0.24 Uric acid levels; chr3:15444338 chr3:15436171~15455940:- LIHC cis rs7208859 0.623 rs9906957 ENSG00000266490.1 CTD-2349P21.9 4.64 4.9e-06 0.00142 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30830737 chr17:30792372~30792833:+ LIHC cis rs2842992 0.672 rs4708845 ENSG00000237927.1 RP3-393E18.2 -4.64 4.9e-06 0.00142 -0.3 -0.24 Age-related macular degeneration (geographic atrophy); chr6:159798569 chr6:159586955~159589169:- LIHC cis rs2842992 0.789 rs2342446 ENSG00000237927.1 RP3-393E18.2 -4.64 4.9e-06 0.00142 -0.3 -0.24 Age-related macular degeneration (geographic atrophy); chr6:159799655 chr6:159586955~159589169:- LIHC cis rs6964833 1 rs4717907 ENSG00000277053.3 GTF2IP1 -4.64 4.9e-06 0.00142 -0.28 -0.24 Menarche (age at onset); chr7:74672169 chr7:75185385~75237696:- LIHC cis rs2312236 0.673 rs67425138 ENSG00000225171.2 DUTP6 -4.64 4.9e-06 0.00143 -0.32 -0.24 Post-traumatic stress disorder; chr1:166744413 chr1:166868748~166869209:+ LIHC cis rs7811142 1 rs2406253 ENSG00000242294.5 STAG3L5P 4.64 4.9e-06 0.00143 0.29 0.24 Platelet count; chr7:100479650 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs2897358 ENSG00000242294.5 STAG3L5P 4.64 4.9e-06 0.00143 0.29 0.24 Platelet count; chr7:100491017 chr7:100336079~100351900:+ LIHC cis rs3758785 0.623 rs13447720 ENSG00000255893.1 RP11-685N10.1 -4.64 4.91e-06 0.00143 -0.29 -0.24 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94432160 chr11:94472908~94473570:- LIHC cis rs7809950 0.798 rs10281535 ENSG00000238832.1 snoU109 4.64 4.91e-06 0.00143 0.29 0.24 Coronary artery disease; chr7:107589173 chr7:107603363~107603507:+ LIHC cis rs7809950 0.954 rs2189839 ENSG00000238832.1 snoU109 4.64 4.91e-06 0.00143 0.29 0.24 Coronary artery disease; chr7:107589581 chr7:107603363~107603507:+ LIHC cis rs1577917 1 rs1415753 ENSG00000234155.1 RP11-30P6.6 4.64 4.91e-06 0.00143 0.33 0.24 Response to antipsychotic treatment; chr6:86043356 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs1577919 ENSG00000234155.1 RP11-30P6.6 4.64 4.91e-06 0.00143 0.33 0.24 Response to antipsychotic treatment; chr6:86047578 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs12203493 ENSG00000234155.1 RP11-30P6.6 4.64 4.91e-06 0.00143 0.33 0.24 Response to antipsychotic treatment; chr6:86048924 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs12665321 ENSG00000234155.1 RP11-30P6.6 4.64 4.91e-06 0.00143 0.33 0.24 Response to antipsychotic treatment; chr6:86059571 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs12203924 ENSG00000234155.1 RP11-30P6.6 4.64 4.91e-06 0.00143 0.33 0.24 Response to antipsychotic treatment; chr6:86066694 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs12196175 ENSG00000234155.1 RP11-30P6.6 4.64 4.91e-06 0.00143 0.33 0.24 Response to antipsychotic treatment; chr6:86069652 chr6:85387219~85390186:- LIHC cis rs748404 0.578 rs4547312 ENSG00000166763.7 STRCP1 4.64 4.91e-06 0.00143 0.3 0.24 Lung cancer; chr15:43339940 chr15:43699488~43718184:- LIHC cis rs11671005 0.735 rs11667591 ENSG00000269473.1 CTD-2619J13.19 4.64 4.91e-06 0.00143 0.4 0.24 Mean platelet volume; chr19:58426270 chr19:58440448~58445849:+ LIHC cis rs7811142 0.72 rs7795656 ENSG00000242294.5 STAG3L5P 4.64 4.92e-06 0.00143 0.26 0.24 Platelet count; chr7:100352674 chr7:100336079~100351900:+ LIHC cis rs7412746 0.634 rs12096831 ENSG00000231073.1 RP11-316M1.3 4.64 4.92e-06 0.00143 0.24 0.24 Melanoma; chr1:150891637 chr1:150973123~150975534:+ LIHC cis rs7914558 1 rs3740387 ENSG00000236937.2 PTGES3P4 4.64 4.92e-06 0.00143 0.29 0.24 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103089711 chr10:102845595~102845950:+ LIHC cis rs13083990 1 rs13083990 ENSG00000272758.4 RP11-299J3.8 4.64 4.93e-06 0.00143 0.26 0.24 Cardiac Troponin-T levels; chr3:122295719 chr3:122416207~122443180:+ LIHC cis rs1555322 0.53 rs6060347 ENSG00000279253.1 RP4-614O4.13 -4.64 4.93e-06 0.00143 -0.31 -0.24 Attention deficit hyperactivity disorder; chr20:35286348 chr20:35262727~35264187:- LIHC cis rs17214007 0.877 rs1569300 ENSG00000263335.1 AF001548.5 -4.64 4.93e-06 0.00143 -0.31 -0.24 Cognitive function; chr16:15776891 chr16:15726674~15732993:+ LIHC cis rs2276314 0.857 rs62101402 ENSG00000278986.1 RP11-723J4.3 -4.64 4.94e-06 0.00143 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36049472 chr18:35972151~35973916:+ LIHC cis rs72675573 1 rs1331861 ENSG00000235612.1 RP1-158P9.1 -4.64 4.94e-06 0.00143 -0.31 -0.24 Monocyte count; chr1:56170733 chr1:56145721~56155224:+ LIHC cis rs11064837 0.504 rs11064846 ENSG00000248636.5 RP11-768F21.1 4.64 4.94e-06 0.00143 0.39 0.24 Schizophrenia; chr12:119616346 chr12:119387987~119668079:- LIHC cis rs2929278 0.617 rs524908 ENSG00000166763.7 STRCP1 -4.64 4.95e-06 0.00144 -0.32 -0.24 Schizophrenia; chr15:43895793 chr15:43699488~43718184:- LIHC cis rs916888 0.647 rs199449 ENSG00000260075.1 NSFP1 4.64 4.95e-06 0.00144 0.3 0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:46372855~46487141:+ LIHC cis rs17711722 0.522 rs62469933 ENSG00000224316.1 RP11-479O9.2 4.64 4.96e-06 0.00144 0.22 0.24 Calcium levels; chr7:65800652 chr7:65773620~65802067:+ LIHC cis rs2274273 0.934 rs10137307 ENSG00000258413.1 RP11-665C16.6 -4.64 4.96e-06 0.00144 -0.29 -0.24 Protein biomarker; chr14:55378467 chr14:55262767~55272075:- LIHC cis rs2565722 0.583 rs2489945 ENSG00000243831.1 RP1-81D8.4 -4.64 4.96e-06 0.00144 -0.33 -0.24 Blood protein levels; chr6:160876692 chr6:160666228~160676523:- LIHC cis rs2337406 0.929 rs12050233 ENSG00000274576.2 IGHV2-70 -4.64 4.96e-06 0.00144 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106781123 chr14:106770577~106771020:- LIHC cis rs2337406 0.852 rs12050466 ENSG00000274576.2 IGHV2-70 -4.64 4.96e-06 0.00144 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106781131 chr14:106770577~106771020:- LIHC cis rs9341808 0.617 rs9294170 ENSG00000272129.1 RP11-250B2.6 4.64 4.96e-06 0.00144 0.23 0.24 Sitting height ratio; chr6:80104363 chr6:80355424~80356859:+ LIHC cis rs6545883 0.525 rs1729662 ENSG00000271889.1 RP11-493E12.1 4.64 4.97e-06 0.00144 0.29 0.24 Tuberculosis; chr2:61164170 chr2:61151433~61162105:- LIHC cis rs2274273 0.967 rs8009670 ENSG00000258413.1 RP11-665C16.6 -4.64 4.97e-06 0.00144 -0.27 -0.24 Protein biomarker; chr14:55116759 chr14:55262767~55272075:- LIHC cis rs7474896 0.561 rs2474603 ENSG00000263064.2 RP11-291L22.7 4.64 4.97e-06 0.00144 0.32 0.24 Obesity (extreme); chr10:38156754 chr10:38448689~38448949:+ LIHC cis rs4964805 0.505 rs15918 ENSG00000257681.1 RP11-341G23.4 4.64 4.97e-06 0.00144 0.25 0.24 Attention deficit hyperactivity disorder; chr12:103773246 chr12:103746315~103768858:- LIHC cis rs7809950 0.784 rs7803102 ENSG00000238832.1 snoU109 4.64 4.97e-06 0.00144 0.29 0.24 Coronary artery disease; chr7:107608484 chr7:107603363~107603507:+ LIHC cis rs9903692 0.657 rs1452665 ENSG00000278765.1 RP5-890E16.5 4.64 4.98e-06 0.00144 0.33 0.24 Pulse pressure; chr17:48219789 chr17:48066704~48067293:- LIHC cis rs6951245 0.58 rs77101766 ENSG00000229043.2 AC091729.9 -4.64 4.98e-06 0.00144 -0.45 -0.24 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1082802 chr7:1160374~1165267:+ LIHC cis rs2836974 0.899 rs2836938 ENSG00000255568.3 BRWD1-AS2 4.64 4.98e-06 0.00145 0.27 0.24 Cognitive function; chr21:39202265 chr21:39313935~39314962:+ LIHC cis rs2439831 0.702 rs7171750 ENSG00000275601.1 AC011330.13 -4.64 4.98e-06 0.00145 -0.35 -0.24 Lung cancer in ever smokers; chr15:43733660 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs11070408 ENSG00000275601.1 AC011330.13 -4.64 4.98e-06 0.00145 -0.35 -0.24 Lung cancer in ever smokers; chr15:43742590 chr15:43642389~43643023:- LIHC cis rs193541 0.564 rs407230 ENSG00000263432.2 RN7SL689P -4.64 4.98e-06 0.00145 -0.38 -0.24 Glucose homeostasis traits; chr5:123010032 chr5:123022487~123022783:- LIHC cis rs9890032 0.618 rs1979507 ENSG00000263531.1 RP13-753N3.1 4.64 4.99e-06 0.00145 0.33 0.24 Hip circumference adjusted for BMI; chr17:30811002 chr17:30863921~30864940:- LIHC cis rs4694744 0.576 rs28419590 ENSG00000264696.1 AC108078.1 4.64 4.99e-06 0.00145 0.37 0.24 Bacteremia; chr4:69480962 chr4:69479331~69479434:+ LIHC cis rs4694744 0.576 rs1977017 ENSG00000264696.1 AC108078.1 4.64 4.99e-06 0.00145 0.37 0.24 Bacteremia; chr4:69481634 chr4:69479331~69479434:+ LIHC cis rs10829156 0.786 rs7077786 ENSG00000240291.1 RP11-499P20.2 4.64 4.99e-06 0.00145 0.39 0.24 Sudden cardiac arrest; chr10:18603453 chr10:18513115~18545651:- LIHC cis rs2929278 0.617 rs524908 ENSG00000275601.1 AC011330.13 4.64 4.99e-06 0.00145 0.3 0.24 Schizophrenia; chr15:43895793 chr15:43642389~43643023:- LIHC cis rs9595066 0.627 rs4432167 ENSG00000230731.2 RP11-478K15.6 -4.64 5e-06 0.00145 -0.29 -0.24 Schizophrenia; chr13:44178225 chr13:44234118~44243192:- LIHC cis rs916888 0.61 rs199444 ENSG00000260075.1 NSFP1 4.64 5e-06 0.00145 0.3 0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:46372855~46487141:+ LIHC cis rs916888 0.61 rs199442 ENSG00000260075.1 NSFP1 4.64 5e-06 0.00145 0.3 0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:46372855~46487141:+ LIHC cis rs12134133 1 rs1583090 ENSG00000274245.1 RP11-357P18.2 4.64 5e-06 0.00145 0.37 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207262438 chr1:207372559~207373252:+ LIHC cis rs228614 0.509 rs223486 ENSG00000246560.2 RP11-10L12.4 4.64 5.01e-06 0.00145 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102763796 chr4:102828055~102844075:+ LIHC cis rs12887734 0.524 rs4906364 ENSG00000258534.1 CTD-2134A5.4 -4.64 5.01e-06 0.00145 -0.27 -0.24 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103748005 chr14:103854366~103880111:- LIHC cis rs12571093 0.571 rs4517412 ENSG00000233590.1 RP11-153K11.3 4.64 5.01e-06 0.00145 0.38 0.24 Optic nerve measurement (disc area); chr10:68303779 chr10:68233251~68242379:- LIHC cis rs12571093 0.571 rs7097498 ENSG00000233590.1 RP11-153K11.3 4.64 5.01e-06 0.00145 0.38 0.24 Optic nerve measurement (disc area); chr10:68303780 chr10:68233251~68242379:- LIHC cis rs1865760 0.963 rs9356991 ENSG00000216436.2 HIST1H2APS1 -4.64 5.02e-06 0.00146 -0.27 -0.24 Height; chr6:25901530 chr6:25732497~25732827:+ LIHC cis rs7665090 0.87 rs228614 ENSG00000230069.3 LRRC37A15P 4.64 5.02e-06 0.00146 0.23 0.24 Primary biliary cholangitis; chr4:102657480 chr4:102727274~102730721:- LIHC cis rs11098499 0.908 rs2017057 ENSG00000245958.5 RP11-33B1.1 -4.64 5.02e-06 0.00146 -0.26 -0.24 Corneal astigmatism; chr4:119336556 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs3822194 ENSG00000245958.5 RP11-33B1.1 -4.64 5.02e-06 0.00146 -0.26 -0.24 Corneal astigmatism; chr4:119550493 chr4:119454791~119552025:+ LIHC cis rs4650994 0.525 rs17361286 ENSG00000273384.1 RP5-1098D14.1 4.64 5.03e-06 0.00146 0.31 0.24 HDL cholesterol;HDL cholesterol levels; chr1:178552781 chr1:178651706~178652282:+ LIHC cis rs3096299 0.967 rs2965935 ENSG00000261118.1 RP11-104N10.1 -4.64 5.03e-06 0.00146 -0.24 -0.24 Multiple myeloma (IgH translocation); chr16:89414866 chr16:89492017~89504460:- LIHC cis rs2836974 0.932 rs6517523 ENSG00000255568.3 BRWD1-AS2 4.64 5.04e-06 0.00146 0.28 0.24 Cognitive function; chr21:39185406 chr21:39313935~39314962:+ LIHC cis rs12304921 0.748 rs12580097 ENSG00000277201.1 AC087884.1 4.64 5.04e-06 0.00146 0.28 0.24 Type 2 diabetes; chr12:51107103 chr12:51049921~51050025:+ LIHC cis rs6442522 0.809 rs972685 ENSG00000249786.6 EAF1-AS1 4.64 5.04e-06 0.00146 0.29 0.24 Uric acid levels; chr3:15442762 chr3:15436171~15455940:- LIHC cis rs2243480 1 rs1723267 ENSG00000228409.4 CCT6P1 4.64 5.04e-06 0.00146 0.26 0.24 Diabetic kidney disease; chr7:66008327 chr7:65751142~65763354:+ LIHC cis rs7208859 0.623 rs79607958 ENSG00000266490.1 CTD-2349P21.9 4.64 5.05e-06 0.00146 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607530 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs75136574 ENSG00000266490.1 CTD-2349P21.9 4.64 5.05e-06 0.00146 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607531 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs77544470 ENSG00000266490.1 CTD-2349P21.9 4.64 5.05e-06 0.00146 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607532 chr17:30792372~30792833:+ LIHC cis rs1247318 0.95 rs935183 ENSG00000243831.1 RP1-81D8.4 4.64 5.05e-06 0.00146 0.34 0.24 Aging; chr6:160914221 chr6:160666228~160676523:- LIHC cis rs1247318 1 rs935182 ENSG00000243831.1 RP1-81D8.4 4.64 5.05e-06 0.00146 0.34 0.24 Aging; chr6:160914344 chr6:160666228~160676523:- LIHC cis rs6951245 0.554 rs35126802 ENSG00000229043.2 AC091729.9 -4.64 5.05e-06 0.00146 -0.44 -0.24 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1095206 chr7:1160374~1165267:+ LIHC cis rs6951245 0.554 rs78999139 ENSG00000229043.2 AC091729.9 -4.64 5.05e-06 0.00146 -0.44 -0.24 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1098889 chr7:1160374~1165267:+ LIHC cis rs6951245 0.58 rs78894484 ENSG00000229043.2 AC091729.9 -4.64 5.05e-06 0.00146 -0.44 -0.24 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1099085 chr7:1160374~1165267:+ LIHC cis rs6951245 0.554 rs4724294 ENSG00000229043.2 AC091729.9 -4.64 5.05e-06 0.00146 -0.44 -0.24 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1100059 chr7:1160374~1165267:+ LIHC cis rs4731207 0.844 rs12673697 ENSG00000224897.5 POT1-AS1 -4.64 5.05e-06 0.00146 -0.29 -0.24 Cutaneous malignant melanoma; chr7:124754952 chr7:124929873~125179315:+ LIHC cis rs2836974 0.899 rs34176878 ENSG00000255568.3 BRWD1-AS2 4.64 5.05e-06 0.00146 0.28 0.24 Cognitive function; chr21:39176929 chr21:39313935~39314962:+ LIHC cis rs67311347 0.955 rs11719205 ENSG00000223797.4 ENTPD3-AS1 4.64 5.06e-06 0.00146 0.2 0.24 Renal cell carcinoma; chr3:40375767 chr3:40313802~40453329:- LIHC cis rs7121538 1 rs7121538 ENSG00000251991.1 RNU7-49P -4.64 5.06e-06 0.00146 -0.35 -0.24 HDL cholesterol; chr11:14482917 chr11:14478892~14478953:+ LIHC cis rs11098499 0.675 rs11098534 ENSG00000245958.5 RP11-33B1.1 -4.64 5.06e-06 0.00147 -0.25 -0.24 Corneal astigmatism; chr4:119635617 chr4:119454791~119552025:+ LIHC cis rs3733589 0.59 rs7657096 ENSG00000250413.1 RP11-448G15.1 4.64 5.07e-06 0.00147 0.39 0.24 Renal overload gout; chr4:10002376 chr4:10006482~10009725:+ LIHC cis rs2439831 0.85 rs10163054 ENSG00000275601.1 AC011330.13 -4.64 5.07e-06 0.00147 -0.35 -0.24 Lung cancer in ever smokers; chr15:43755440 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs12442129 ENSG00000275601.1 AC011330.13 -4.64 5.07e-06 0.00147 -0.35 -0.24 Lung cancer in ever smokers; chr15:43763658 chr15:43642389~43643023:- LIHC cis rs2439831 0.702 rs7175032 ENSG00000275601.1 AC011330.13 -4.64 5.07e-06 0.00147 -0.35 -0.24 Lung cancer in ever smokers; chr15:43768038 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs2277531 ENSG00000275601.1 AC011330.13 -4.64 5.07e-06 0.00147 -0.35 -0.24 Lung cancer in ever smokers; chr15:43776871 chr15:43642389~43643023:- LIHC cis rs2243480 1 rs73150014 ENSG00000230295.1 RP11-458F8.2 -4.64 5.07e-06 0.00147 -0.26 -0.24 Diabetic kidney disease; chr7:65985932 chr7:66880708~66882981:+ LIHC cis rs7849270 0.959 rs4836641 ENSG00000268707.1 RP11-247A12.7 4.64 5.07e-06 0.00147 0.28 0.24 Blood metabolite ratios; chr9:129149953 chr9:129170434~129170940:+ LIHC cis rs2439831 0.85 rs3742982 ENSG00000275601.1 AC011330.13 -4.64 5.07e-06 0.00147 -0.36 -0.24 Lung cancer in ever smokers; chr15:43884483 chr15:43642389~43643023:- LIHC cis rs172166 0.611 rs203883 ENSG00000216901.1 AL022393.7 4.64 5.08e-06 0.00147 0.31 0.24 Cardiac Troponin-T levels; chr6:28110578 chr6:28176188~28176674:+ LIHC cis rs172166 0.611 rs203882 ENSG00000216901.1 AL022393.7 4.64 5.08e-06 0.00147 0.31 0.24 Cardiac Troponin-T levels; chr6:28110724 chr6:28176188~28176674:+ LIHC cis rs172166 0.694 rs1770131 ENSG00000216901.1 AL022393.7 4.64 5.08e-06 0.00147 0.31 0.24 Cardiac Troponin-T levels; chr6:28118635 chr6:28176188~28176674:+ LIHC cis rs11971779 0.68 rs6947215 ENSG00000273391.1 RP11-634H22.1 4.63 5.09e-06 0.00147 0.2 0.24 Diisocyanate-induced asthma; chr7:139341892 chr7:139359032~139359566:- LIHC cis rs67311347 1 rs17078511 ENSG00000223797.4 ENTPD3-AS1 4.63 5.1e-06 0.00147 0.2 0.24 Renal cell carcinoma; chr3:40354763 chr3:40313802~40453329:- LIHC cis rs11098499 0.754 rs1511017 ENSG00000245958.5 RP11-33B1.1 -4.63 5.1e-06 0.00147 -0.25 -0.24 Corneal astigmatism; chr4:119329650 chr4:119454791~119552025:+ LIHC cis rs11098499 0.789 rs12498994 ENSG00000245958.5 RP11-33B1.1 -4.63 5.1e-06 0.00147 -0.25 -0.24 Corneal astigmatism; chr4:119329663 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs12507565 ENSG00000245958.5 RP11-33B1.1 -4.63 5.1e-06 0.00147 -0.25 -0.24 Corneal astigmatism; chr4:119329966 chr4:119454791~119552025:+ LIHC cis rs11098499 0.826 rs12511640 ENSG00000245958.5 RP11-33B1.1 -4.63 5.1e-06 0.00147 -0.25 -0.24 Corneal astigmatism; chr4:119330093 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs1980026 ENSG00000245958.5 RP11-33B1.1 -4.63 5.1e-06 0.00147 -0.25 -0.24 Corneal astigmatism; chr4:119330488 chr4:119454791~119552025:+ LIHC cis rs228614 0.51 rs223412 ENSG00000246560.2 RP11-10L12.4 4.63 5.1e-06 0.00148 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102812443 chr4:102828055~102844075:+ LIHC cis rs35395352 1 rs35395352 ENSG00000227634.1 RP11-431K24.3 -4.63 5.1e-06 0.00148 -0.3 -0.24 Strep throat; chr1:8206769 chr1:8208672~8215210:+ LIHC cis rs67311347 0.91 rs7617361 ENSG00000223797.4 ENTPD3-AS1 4.63 5.1e-06 0.00148 0.2 0.24 Renal cell carcinoma; chr3:40331768 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs11714032 ENSG00000223797.4 ENTPD3-AS1 4.63 5.11e-06 0.00148 0.2 0.24 Renal cell carcinoma; chr3:40390114 chr3:40313802~40453329:- LIHC cis rs812925 0.512 rs1729674 ENSG00000271889.1 RP11-493E12.1 4.63 5.11e-06 0.00148 0.29 0.24 Immature fraction of reticulocytes; chr2:61162602 chr2:61151433~61162105:- LIHC cis rs11971779 0.774 rs7785906 ENSG00000273391.1 RP11-634H22.1 4.63 5.11e-06 0.00148 0.23 0.24 Diisocyanate-induced asthma; chr7:139437906 chr7:139359032~139359566:- LIHC cis rs748404 0.697 rs530188 ENSG00000166763.7 STRCP1 4.63 5.11e-06 0.00148 0.3 0.24 Lung cancer; chr15:43253116 chr15:43699488~43718184:- LIHC cis rs3015497 0.554 rs8011039 ENSG00000269906.1 RP11-248J18.2 4.63 5.11e-06 0.00148 0.31 0.24 Mean platelet volume; chr14:50624549 chr14:50662511~50663178:- LIHC cis rs703842 0.963 rs2069506 ENSG00000270039.1 RP11-571M6.17 -4.63 5.11e-06 0.00148 -0.35 -0.24 Multiple sclerosis; chr12:57749071 chr12:57803838~57804415:+ LIHC cis rs11098499 0.644 rs3806808 ENSG00000245958.5 RP11-33B1.1 -4.63 5.11e-06 0.00148 -0.25 -0.24 Corneal astigmatism; chr4:119629930 chr4:119454791~119552025:+ LIHC cis rs12157904 1 rs6000842 ENSG00000233360.4 Z83844.1 4.63 5.12e-06 0.00148 0.47 0.24 Response to anti-depressant treatment in major depressive disorder; chr22:37610246 chr22:37641832~37658377:- LIHC cis rs7208859 0.623 rs28556733 ENSG00000266490.1 CTD-2349P21.9 4.63 5.12e-06 0.00148 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30756927 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs28433704 ENSG00000266490.1 CTD-2349P21.9 4.63 5.12e-06 0.00148 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757267 chr17:30792372~30792833:+ LIHC cis rs17826219 0.706 rs55764512 ENSG00000266490.1 CTD-2349P21.9 4.63 5.12e-06 0.00148 0.31 0.24 Body mass index; chr17:30758740 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs12103508 ENSG00000266490.1 CTD-2349P21.9 4.63 5.12e-06 0.00148 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759763 chr17:30792372~30792833:+ LIHC cis rs7208859 0.524 rs11653605 ENSG00000266490.1 CTD-2349P21.9 4.63 5.12e-06 0.00148 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30761367 chr17:30792372~30792833:+ LIHC cis rs2735413 0.918 rs1922612 ENSG00000276007.1 RP11-358L22.3 -4.63 5.12e-06 0.00148 -0.27 -0.24 Systolic blood pressure (alcohol consumption interaction); chr16:78019086 chr16:78123243~78124332:+ LIHC cis rs5769765 0.908 rs7410601 ENSG00000278869.1 CITF22-49E9.3 4.63 5.15e-06 0.00149 0.38 0.24 Schizophrenia; chr22:49923539 chr22:49933198~49934074:- LIHC cis rs5769765 0.671 rs138833 ENSG00000278869.1 CITF22-49E9.3 4.63 5.15e-06 0.00149 0.36 0.24 Schizophrenia; chr22:49785269 chr22:49933198~49934074:- LIHC cis rs2439831 1 rs2601014 ENSG00000166763.7 STRCP1 4.63 5.15e-06 0.00149 0.38 0.24 Lung cancer in ever smokers; chr15:43463815 chr15:43699488~43718184:- LIHC cis rs4356203 0.905 rs651513 ENSG00000272034.1 SNORD14A -4.63 5.16e-06 0.00149 -0.26 -0.24 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17177781 chr11:17074654~17074744:- LIHC cis rs875971 0.522 rs709604 ENSG00000224316.1 RP11-479O9.2 -4.63 5.16e-06 0.00149 -0.24 -0.24 Aortic root size; chr7:66032447 chr7:65773620~65802067:+ LIHC cis rs957448 0.948 rs1470153 ENSG00000253704.1 RP11-267M23.4 4.63 5.17e-06 0.00149 0.3 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94514587 chr8:94553722~94569745:+ LIHC cis rs7131987 0.845 rs7299861 ENSG00000257176.2 RP11-996F15.2 -4.63 5.17e-06 0.00149 -0.28 -0.24 QT interval; chr12:29256734 chr12:29280418~29317848:- LIHC cis rs7131987 0.934 rs7316004 ENSG00000257176.2 RP11-996F15.2 -4.63 5.17e-06 0.00149 -0.28 -0.24 QT interval; chr12:29258765 chr12:29280418~29317848:- LIHC cis rs7131987 0.903 rs2216853 ENSG00000257176.2 RP11-996F15.2 -4.63 5.17e-06 0.00149 -0.28 -0.24 QT interval; chr12:29260315 chr12:29280418~29317848:- LIHC cis rs7131987 0.868 rs10771508 ENSG00000257176.2 RP11-996F15.2 -4.63 5.17e-06 0.00149 -0.28 -0.24 QT interval; chr12:29261278 chr12:29280418~29317848:- LIHC cis rs643506 0.874 rs673679 ENSG00000254990.4 RP11-108O10.2 4.63 5.17e-06 0.00149 0.26 0.24 Breast cancer; chr11:111816076 chr11:111768668~111778350:- LIHC cis rs733592 0.524 rs10875741 ENSG00000240399.1 RP1-228P16.1 -4.63 5.17e-06 0.00149 -0.23 -0.24 Plateletcrit; chr12:48099139 chr12:48054813~48055591:- LIHC cis rs733592 0.507 rs7304428 ENSG00000240399.1 RP1-228P16.1 -4.63 5.17e-06 0.00149 -0.23 -0.24 Plateletcrit; chr12:48100492 chr12:48054813~48055591:- LIHC cis rs4660456 0.556 rs823674 ENSG00000237899.1 RP4-739H11.3 -4.63 5.18e-06 0.00149 -0.29 -0.24 Platelet count; chr1:40774799 chr1:40669089~40687588:- LIHC cis rs1247318 1 rs1247328 ENSG00000243831.1 RP1-81D8.4 4.63 5.19e-06 0.0015 0.34 0.24 Aging; chr6:160907039 chr6:160666228~160676523:- LIHC cis rs12134133 0.888 rs11580394 ENSG00000274245.1 RP11-357P18.2 4.63 5.19e-06 0.0015 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207238567 chr1:207372559~207373252:+ LIHC cis rs12134133 0.962 rs7516416 ENSG00000274245.1 RP11-357P18.2 4.63 5.19e-06 0.0015 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207241050 chr1:207372559~207373252:+ LIHC cis rs12134133 0.962 rs6673890 ENSG00000274245.1 RP11-357P18.2 4.63 5.19e-06 0.0015 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207241788 chr1:207372559~207373252:+ LIHC cis rs712039 0.652 rs866465 ENSG00000276054.1 RP11-378E13.3 4.63 5.2e-06 0.0015 0.31 0.24 Tuberculosis; chr17:37499298 chr17:37386886~37387926:+ LIHC cis rs67311347 0.955 rs4974068 ENSG00000223797.4 ENTPD3-AS1 4.63 5.21e-06 0.0015 0.2 0.24 Renal cell carcinoma; chr3:40335438 chr3:40313802~40453329:- LIHC cis rs11096990 0.634 rs6531706 ENSG00000249685.1 RP11-360F5.3 -4.63 5.21e-06 0.0015 -0.29 -0.24 Cognitive function; chr4:39294547 chr4:39133913~39135608:+ LIHC cis rs929596 0.793 rs13009407 ENSG00000233445.1 RPL17P11 4.63 5.22e-06 0.0015 0.37 0.24 Total bilirubin levels in HIV-1 infection; chr2:233743701 chr2:233721522~233722065:- LIHC cis rs2998286 0.723 rs332154 ENSG00000254635.4 WAC-AS1 -4.63 5.22e-06 0.00151 -0.31 -0.24 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28591465 chr10:28522652~28532743:- LIHC cis rs2998286 0.723 rs332156 ENSG00000254635.4 WAC-AS1 -4.63 5.22e-06 0.00151 -0.31 -0.24 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28593152 chr10:28522652~28532743:- LIHC cis rs2348418 0.733 rs7294486 ENSG00000247934.4 RP11-967K21.1 -4.63 5.23e-06 0.00151 -0.21 -0.24 Lung function (FEV1);Lung function (FVC); chr12:28181989 chr12:28163298~28190738:- LIHC cis rs5758511 0.508 rs58099562 ENSG00000237037.8 NDUFA6-AS1 -4.63 5.24e-06 0.00151 -0.45 -0.24 Birth weight; chr22:42057768 chr22:42090931~42137742:+ LIHC cis rs2243480 0.901 rs12530490 ENSG00000230295.1 RP11-458F8.2 4.63 5.24e-06 0.00151 0.25 0.24 Diabetic kidney disease; chr7:66226660 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs7778911 ENSG00000230295.1 RP11-458F8.2 4.63 5.24e-06 0.00151 0.25 0.24 Diabetic kidney disease; chr7:66229519 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1979823 ENSG00000230295.1 RP11-458F8.2 4.63 5.24e-06 0.00151 0.25 0.24 Diabetic kidney disease; chr7:66239626 chr7:66880708~66882981:+ LIHC cis rs11971779 0.68 rs4077889 ENSG00000273391.1 RP11-634H22.1 4.63 5.24e-06 0.00151 0.22 0.24 Diisocyanate-induced asthma; chr7:139349168 chr7:139359032~139359566:- LIHC cis rs673078 0.66 rs7974718 ENSG00000275759.1 RP11-131L12.3 -4.63 5.24e-06 0.00151 -0.31 -0.24 Glucose homeostasis traits; chr12:118243258 chr12:118428281~118428870:+ LIHC cis rs9595908 0.9 rs731414 ENSG00000212293.1 SNORA16 4.63 5.24e-06 0.00151 0.28 0.24 Body mass index; chr13:32601160 chr13:32420390~32420516:- LIHC cis rs172166 0.694 rs1631552 ENSG00000216901.1 AL022393.7 4.63 5.24e-06 0.00151 0.31 0.24 Cardiac Troponin-T levels; chr6:28121921 chr6:28176188~28176674:+ LIHC cis rs12554020 1 rs12554020 ENSG00000227603.1 RP11-165J3.6 4.63 5.25e-06 0.00151 0.32 0.24 Schizophrenia; chr9:93507955 chr9:93435332~93437121:- LIHC cis rs4660214 0.666 rs6600290 ENSG00000182109.6 RP11-69E11.4 -4.63 5.25e-06 0.00151 -0.25 -0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39157151 chr1:39522280~39546187:- LIHC cis rs7945705 0.875 rs2568065 ENSG00000254860.4 TMEM9B-AS1 4.63 5.25e-06 0.00151 0.24 0.24 Hemoglobin concentration; chr11:8868101 chr11:8964675~8977527:+ LIHC cis rs11971779 0.752 rs4732371 ENSG00000273391.1 RP11-634H22.1 4.63 5.25e-06 0.00151 0.22 0.24 Diisocyanate-induced asthma; chr7:139392571 chr7:139359032~139359566:- LIHC cis rs2032447 0.714 rs129129 ENSG00000242387.1 HIST1H2APS2 4.63 5.26e-06 0.00152 0.3 0.24 Intelligence (multi-trait analysis); chr6:25960801 chr6:25882026~25882395:- LIHC cis rs9400467 0.508 rs1676863 ENSG00000271789.1 RP5-1112D6.7 -4.63 5.26e-06 0.00152 -0.24 -0.24 Amino acid levels;Blood metabolite levels; chr6:111320387 chr6:111297126~111298510:+ LIHC cis rs7914558 1 rs10509757 ENSG00000236937.2 PTGES3P4 4.63 5.26e-06 0.00152 0.28 0.24 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102993203 chr10:102845595~102845950:+ LIHC cis rs9807989 0.507 rs4479442 ENSG00000234389.1 AC007278.3 4.63 5.26e-06 0.00152 0.26 0.24 Asthma; chr2:102437614 chr2:102438713~102440475:+ LIHC cis rs2836974 0.831 rs6517521 ENSG00000255568.3 BRWD1-AS2 4.63 5.26e-06 0.00152 0.28 0.24 Cognitive function; chr21:39179662 chr21:39313935~39314962:+ LIHC cis rs11079159 0.958 rs11656277 ENSG00000263096.1 RP11-515O17.2 4.63 5.27e-06 0.00152 0.33 0.24 QRS duration; chr17:55293686 chr17:55271504~55273653:- LIHC cis rs4731207 0.967 rs2299902 ENSG00000224897.5 POT1-AS1 -4.63 5.27e-06 0.00152 -0.29 -0.24 Cutaneous malignant melanoma; chr7:124757760 chr7:124929873~125179315:+ LIHC cis rs4731207 0.967 rs3807544 ENSG00000224897.5 POT1-AS1 -4.63 5.27e-06 0.00152 -0.29 -0.24 Cutaneous malignant melanoma; chr7:124760651 chr7:124929873~125179315:+ LIHC cis rs9595908 0.9 rs9595890 ENSG00000212293.1 SNORA16 4.63 5.27e-06 0.00152 0.28 0.24 Body mass index; chr13:32597518 chr13:32420390~32420516:- LIHC cis rs71520386 0.607 rs4308627 ENSG00000228649.7 AC005682.5 -4.63 5.27e-06 0.00152 -0.31 -0.24 Fibrinogen levels; chr7:22840285 chr7:22854178~22861579:+ LIHC cis rs8028182 0.636 rs62027181 ENSG00000260269.4 CTD-2323K18.1 -4.63 5.28e-06 0.00152 -0.3 -0.24 Sudden cardiac arrest; chr15:75547611 chr15:75527150~75601205:- LIHC cis rs12554020 1 rs59582399 ENSG00000227603.1 RP11-165J3.6 4.63 5.28e-06 0.00152 0.32 0.24 Schizophrenia; chr9:93523881 chr9:93435332~93437121:- LIHC cis rs227275 0.586 rs223448 ENSG00000246560.2 RP11-10L12.4 4.63 5.28e-06 0.00152 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102792189 chr4:102828055~102844075:+ LIHC cis rs227275 0.554 rs223442 ENSG00000246560.2 RP11-10L12.4 4.63 5.28e-06 0.00152 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102793960 chr4:102828055~102844075:+ LIHC cis rs227275 0.554 rs223441 ENSG00000246560.2 RP11-10L12.4 4.63 5.28e-06 0.00152 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102794228 chr4:102828055~102844075:+ LIHC cis rs6480314 0.522 rs4363487 ENSG00000233590.1 RP11-153K11.3 4.63 5.28e-06 0.00152 0.38 0.24 Optic nerve measurement (disc area); chr10:68301809 chr10:68233251~68242379:- LIHC cis rs6480314 0.522 rs10762214 ENSG00000233590.1 RP11-153K11.3 4.63 5.28e-06 0.00152 0.38 0.24 Optic nerve measurement (disc area); chr10:68302555 chr10:68233251~68242379:- LIHC cis rs6480314 0.522 rs12769008 ENSG00000233590.1 RP11-153K11.3 4.63 5.28e-06 0.00152 0.38 0.24 Optic nerve measurement (disc area); chr10:68302836 chr10:68233251~68242379:- LIHC cis rs6480314 0.522 rs61857263 ENSG00000233590.1 RP11-153K11.3 4.63 5.28e-06 0.00152 0.38 0.24 Optic nerve measurement (disc area); chr10:68303370 chr10:68233251~68242379:- LIHC cis rs6480314 0.614 rs7067601 ENSG00000233590.1 RP11-153K11.3 4.63 5.28e-06 0.00152 0.38 0.24 Optic nerve measurement (disc area); chr10:68304213 chr10:68233251~68242379:- LIHC cis rs12571093 0.571 rs10740295 ENSG00000233590.1 RP11-153K11.3 4.63 5.28e-06 0.00152 0.38 0.24 Optic nerve measurement (disc area); chr10:68304313 chr10:68233251~68242379:- LIHC cis rs6480314 0.522 rs10733843 ENSG00000233590.1 RP11-153K11.3 4.63 5.28e-06 0.00152 0.38 0.24 Optic nerve measurement (disc area); chr10:68304752 chr10:68233251~68242379:- LIHC cis rs12571093 0.571 rs10823175 ENSG00000233590.1 RP11-153K11.3 4.63 5.28e-06 0.00152 0.38 0.24 Optic nerve measurement (disc area); chr10:68306024 chr10:68233251~68242379:- LIHC cis rs6480314 0.522 rs4746759 ENSG00000233590.1 RP11-153K11.3 4.63 5.28e-06 0.00152 0.38 0.24 Optic nerve measurement (disc area); chr10:68306040 chr10:68233251~68242379:- LIHC cis rs6480314 0.522 rs4746760 ENSG00000233590.1 RP11-153K11.3 4.63 5.28e-06 0.00152 0.38 0.24 Optic nerve measurement (disc area); chr10:68306122 chr10:68233251~68242379:- LIHC cis rs17818399 0.815 rs62136873 ENSG00000279254.1 RP11-536C12.1 -4.63 5.28e-06 0.00152 -0.3 -0.24 Height; chr2:46634098 chr2:46668870~46670778:+ LIHC cis rs227275 0.554 rs150895 ENSG00000246560.2 RP11-10L12.4 4.63 5.29e-06 0.00152 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102791432 chr4:102828055~102844075:+ LIHC cis rs11098499 0.754 rs7672594 ENSG00000245958.5 RP11-33B1.1 -4.63 5.29e-06 0.00152 -0.25 -0.24 Corneal astigmatism; chr4:119327388 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs7672778 ENSG00000245958.5 RP11-33B1.1 -4.63 5.29e-06 0.00152 -0.25 -0.24 Corneal astigmatism; chr4:119327430 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs12513083 ENSG00000245958.5 RP11-33B1.1 -4.63 5.29e-06 0.00152 -0.25 -0.24 Corneal astigmatism; chr4:119328457 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs12509621 ENSG00000245958.5 RP11-33B1.1 -4.63 5.29e-06 0.00152 -0.25 -0.24 Corneal astigmatism; chr4:119328505 chr4:119454791~119552025:+ LIHC cis rs2948294 0.545 rs11776397 ENSG00000253893.2 FAM85B -4.63 5.3e-06 0.00152 -0.28 -0.24 Red cell distribution width; chr8:8257639 chr8:8167819~8226614:- LIHC cis rs2877649 0.59 rs11538256 ENSG00000258744.1 RP11-80A15.1 -4.63 5.3e-06 0.00152 -0.5 -0.24 Smooth-surface caries; chr14:24440423 chr14:24501594~24508688:+ LIHC cis rs367615 0.512 rs246105 ENSG00000249476.1 CTD-2587M2.1 4.63 5.3e-06 0.00152 0.28 0.24 Colorectal cancer (SNP x SNP interaction); chr5:109337245 chr5:109237120~109326369:- LIHC cis rs11096990 0.613 rs1451821 ENSG00000249685.1 RP11-360F5.3 -4.63 5.3e-06 0.00153 -0.3 -0.24 Cognitive function; chr4:39178797 chr4:39133913~39135608:+ LIHC cis rs8072100 0.537 rs9912450 ENSG00000228782.6 CTD-2026D20.3 4.63 5.3e-06 0.00153 0.28 0.24 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47324842 chr17:47450568~47492492:- LIHC cis rs4698412 0.646 rs4698120 ENSG00000214846.4 RP11-115L11.1 -4.63 5.31e-06 0.00153 -0.29 -0.24 Parkinson's disease; chr4:15741709 chr4:15730962~15731627:- LIHC cis rs12280210 0.557 rs7112937 ENSG00000254851.1 RP11-109L13.1 4.63 5.31e-06 0.00153 0.38 0.24 Lobe attachment (rater-scored or self-reported); chr11:117009740 chr11:117135528~117138582:+ LIHC cis rs7714584 1 rs10078968 ENSG00000197083.10 ZNF300P1 4.63 5.31e-06 0.00153 0.37 0.24 Crohn's disease; chr5:150864711 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs1896709 ENSG00000197083.10 ZNF300P1 4.63 5.31e-06 0.00153 0.37 0.24 Crohn's disease; chr5:150865470 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs1896707 ENSG00000197083.10 ZNF300P1 4.63 5.31e-06 0.00153 0.37 0.24 Crohn's disease; chr5:150865567 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs6862814 ENSG00000197083.10 ZNF300P1 4.63 5.31e-06 0.00153 0.37 0.24 Crohn's disease; chr5:150865697 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs7709388 ENSG00000197083.10 ZNF300P1 4.63 5.31e-06 0.00153 0.37 0.24 Crohn's disease; chr5:150866977 chr5:150930645~150946289:- LIHC cis rs7714584 0.793 rs7709721 ENSG00000197083.10 ZNF300P1 4.63 5.31e-06 0.00153 0.37 0.24 Crohn's disease; chr5:150867296 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs9324660 ENSG00000197083.10 ZNF300P1 4.63 5.31e-06 0.00153 0.37 0.24 Crohn's disease; chr5:150877492 chr5:150930645~150946289:- LIHC cis rs7119038 0.818 rs10892287 ENSG00000255239.1 AP002954.6 4.63 5.31e-06 0.00153 0.35 0.24 Sjögren's syndrome; chr11:118772290 chr11:118688039~118690600:- LIHC cis rs11098499 0.863 rs1480940 ENSG00000245958.5 RP11-33B1.1 -4.63 5.32e-06 0.00153 -0.26 -0.24 Corneal astigmatism; chr4:119536527 chr4:119454791~119552025:+ LIHC cis rs5756813 0.754 rs5750495 ENSG00000233360.4 Z83844.1 -4.63 5.32e-06 0.00153 -0.31 -0.24 Optic cup area;Vertical cup-disc ratio; chr22:37783113 chr22:37641832~37658377:- LIHC cis rs5756813 0.668 rs6000881 ENSG00000233360.4 Z83844.1 -4.62 5.33e-06 0.00153 -0.29 -0.24 Optic cup area;Vertical cup-disc ratio; chr22:37758537 chr22:37641832~37658377:- LIHC cis rs11098499 0.954 rs10006877 ENSG00000245958.5 RP11-33B1.1 -4.62 5.33e-06 0.00153 -0.26 -0.24 Corneal astigmatism; chr4:119321638 chr4:119454791~119552025:+ LIHC cis rs7811142 0.943 rs111757992 ENSG00000242294.5 STAG3L5P 4.62 5.33e-06 0.00153 0.27 0.24 Platelet count; chr7:100418731 chr7:100336079~100351900:+ LIHC cis rs6600671 1 rs7532615 ENSG00000231429.2 RP11-343N15.2 4.62 5.34e-06 0.00154 0.27 0.24 Hip geometry; chr1:121430980 chr1:121412719~121429274:+ LIHC cis rs6921919 0.583 rs9468355 ENSG00000204709.4 LINC01556 4.62 5.34e-06 0.00154 0.29 0.24 Autism spectrum disorder or schizophrenia; chr6:28374100 chr6:28943877~28944537:+ LIHC cis rs2032447 0.641 rs442601 ENSG00000242387.1 HIST1H2APS2 4.62 5.35e-06 0.00154 0.31 0.24 Intelligence (multi-trait analysis); chr6:25934296 chr6:25882026~25882395:- LIHC cis rs950169 0.58 rs11634320 ENSG00000225151.9 GOLGA2P7 4.62 5.35e-06 0.00154 0.3 0.24 Schizophrenia; chr15:84628952 chr15:84199311~84230136:- LIHC cis rs5769707 0.967 rs9616701 ENSG00000235111.1 RP1-29C18.8 -4.62 5.35e-06 0.00154 -0.28 -0.24 Monocyte percentage of white cells;Monocyte count; chr22:49631898 chr22:49612657~49615716:- LIHC cis rs5756813 0.668 rs4821704 ENSG00000233360.4 Z83844.1 4.62 5.36e-06 0.00154 0.29 0.24 Optic cup area;Vertical cup-disc ratio; chr22:37750578 chr22:37641832~37658377:- LIHC cis rs1030877 0.521 rs2576747 ENSG00000235319.1 AC012360.4 -4.62 5.36e-06 0.00154 -0.29 -0.24 Obesity-related traits; chr2:105362219 chr2:105324210~105330529:+ LIHC cis rs931127 0.512 rs58950470 ENSG00000265874.1 MIR4489 4.62 5.36e-06 0.00154 0.35 0.24 Systemic lupus erythematosus; chr11:65616284 chr11:65649192~65649253:+ LIHC cis rs11971779 0.715 rs10265 ENSG00000273391.1 RP11-634H22.1 4.62 5.36e-06 0.00154 0.21 0.24 Diisocyanate-induced asthma; chr7:139341406 chr7:139359032~139359566:- LIHC cis rs11971779 0.616 rs6965143 ENSG00000273391.1 RP11-634H22.1 4.62 5.36e-06 0.00154 0.21 0.24 Diisocyanate-induced asthma; chr7:139341862 chr7:139359032~139359566:- LIHC cis rs11971779 0.616 rs11771715 ENSG00000273391.1 RP11-634H22.1 4.62 5.36e-06 0.00154 0.21 0.24 Diisocyanate-induced asthma; chr7:139342750 chr7:139359032~139359566:- LIHC cis rs10510102 0.872 rs12248004 ENSG00000226864.1 ATE1-AS1 4.62 5.36e-06 0.00154 0.44 0.24 Breast cancer; chr10:121972215 chr10:121928312~121951965:+ LIHC cis rs11098499 0.954 rs10006706 ENSG00000260091.1 RP11-33B1.4 -4.62 5.37e-06 0.00154 -0.17 -0.24 Corneal astigmatism; chr4:119487997 chr4:119409333~119410233:+ LIHC cis rs11668505 1 rs7248427 ENSG00000259108.2 CTD-3098H1.2 4.62 5.37e-06 0.00154 0.31 0.24 Lung function (FVC); chr19:47842904 chr19:47863483~47865341:- LIHC cis rs17376456 0.825 rs10075217 ENSG00000251023.1 RP11-549J18.1 -4.62 5.37e-06 0.00154 -0.47 -0.24 Diabetic retinopathy; chr5:93841068 chr5:93860669~93863825:- LIHC cis rs801193 0.591 rs9986881 ENSG00000224316.1 RP11-479O9.2 4.62 5.38e-06 0.00155 0.22 0.24 Aortic root size; chr7:66708053 chr7:65773620~65802067:+ LIHC cis rs2564921 0.73 rs2564929 ENSG00000242142.1 SERBP1P3 -4.62 5.38e-06 0.00155 -0.31 -0.24 Height; chr3:53084188 chr3:53064283~53065091:- LIHC cis rs72675573 0.925 rs12116494 ENSG00000235612.1 RP1-158P9.1 -4.62 5.39e-06 0.00155 -0.32 -0.24 Monocyte count; chr1:56166668 chr1:56145721~56155224:+ LIHC cis rs2581828 0.607 rs2581784 ENSG00000242142.1 SERBP1P3 4.62 5.39e-06 0.00155 0.28 0.24 Crohn's disease; chr3:53088354 chr3:53064283~53065091:- LIHC cis rs2581828 0.656 rs891368 ENSG00000242142.1 SERBP1P3 4.62 5.39e-06 0.00155 0.28 0.24 Crohn's disease; chr3:53089257 chr3:53064283~53065091:- LIHC cis rs2581828 0.656 rs1078968 ENSG00000242142.1 SERBP1P3 4.62 5.39e-06 0.00155 0.28 0.24 Crohn's disease; chr3:53089470 chr3:53064283~53065091:- LIHC cis rs4988958 0.565 rs3755265 ENSG00000234389.1 AC007278.3 4.62 5.39e-06 0.00155 0.26 0.24 Asthma (childhood onset); chr2:102436356 chr2:102438713~102440475:+ LIHC cis rs7811142 0.887 rs111972532 ENSG00000242294.5 STAG3L5P 4.62 5.4e-06 0.00155 0.29 0.24 Platelet count; chr7:100471465 chr7:100336079~100351900:+ LIHC cis rs16858210 0.542 rs12636826 ENSG00000234371.6 RPSAP31 4.62 5.4e-06 0.00155 0.33 0.24 Menopause (age at onset); chr3:183840793 chr3:183884924~183888449:+ LIHC cis rs7714584 1 rs2004711 ENSG00000197083.10 ZNF300P1 4.62 5.4e-06 0.00155 0.38 0.24 Crohn's disease; chr5:150845506 chr5:150930645~150946289:- LIHC cis rs765787 0.53 rs12909987 ENSG00000259520.4 CTD-2651B20.3 4.62 5.4e-06 0.00155 0.27 0.24 Uric acid levels; chr15:45220009 chr15:45251580~45279251:- LIHC cis rs2274273 0.84 rs1045002 ENSG00000258413.1 RP11-665C16.6 -4.62 5.4e-06 0.00155 -0.29 -0.24 Protein biomarker; chr14:55351799 chr14:55262767~55272075:- LIHC cis rs9467711 0.591 rs13206501 ENSG00000216436.2 HIST1H2APS1 4.62 5.4e-06 0.00155 0.62 0.24 Autism spectrum disorder or schizophrenia; chr6:26109920 chr6:25732497~25732827:+ LIHC cis rs9467711 0.591 rs16891315 ENSG00000216436.2 HIST1H2APS1 4.62 5.4e-06 0.00155 0.62 0.24 Autism spectrum disorder or schizophrenia; chr6:26111528 chr6:25732497~25732827:+ LIHC cis rs1247318 1 rs1247361 ENSG00000243831.1 RP1-81D8.4 4.62 5.4e-06 0.00155 0.35 0.24 Aging; chr6:160920237 chr6:160666228~160676523:- LIHC cis rs9992667 1 rs10032639 ENSG00000231160.8 KLF3-AS1 4.62 5.4e-06 0.00155 0.32 0.24 Eosinophil percentage of granulocytes; chr4:38673107 chr4:38612701~38664883:- LIHC cis rs17818399 0.547 rs7607633 ENSG00000239332.4 LINC01119 -4.62 5.41e-06 0.00155 -0.34 -0.24 Height; chr2:46532288 chr2:46816697~46859007:+ LIHC cis rs11098499 0.909 rs10026736 ENSG00000260091.1 RP11-33B1.4 -4.62 5.41e-06 0.00155 -0.18 -0.24 Corneal astigmatism; chr4:119463167 chr4:119409333~119410233:+ LIHC cis rs42490 0.873 rs218895 ENSG00000251136.7 RP11-37B2.1 -4.62 5.42e-06 0.00156 -0.22 -0.24 Leprosy; chr8:89714320 chr8:89609409~89757727:- LIHC cis rs875971 0.545 rs316316 ENSG00000273142.1 RP11-458F8.4 -4.62 5.42e-06 0.00156 -0.23 -0.24 Aortic root size; chr7:66149270 chr7:66902857~66906297:+ LIHC cis rs7914558 1 rs1890184 ENSG00000236937.2 PTGES3P4 4.62 5.42e-06 0.00156 0.28 0.24 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102988702 chr10:102845595~102845950:+ LIHC cis rs2033711 0.503 rs6510141 ENSG00000269473.1 CTD-2619J13.19 -4.62 5.42e-06 0.00156 -0.3 -0.24 Uric acid clearance; chr19:58374419 chr19:58440448~58445849:+ LIHC cis rs1865760 0.566 rs2032443 ENSG00000216436.2 HIST1H2APS1 -4.62 5.42e-06 0.00156 -0.28 -0.24 Height; chr6:26046574 chr6:25732497~25732827:+ LIHC cis rs6142102 0.651 rs6088412 ENSG00000276073.1 RP5-1125A11.7 4.62 5.43e-06 0.00156 0.29 0.24 Skin pigmentation; chr20:34154262 chr20:33985617~33988989:- LIHC cis rs957448 1 rs7829886 ENSG00000253704.1 RP11-267M23.4 4.62 5.43e-06 0.00156 0.29 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94485160 chr8:94553722~94569745:+ LIHC cis rs748404 0.697 rs501884 ENSG00000166763.7 STRCP1 4.62 5.43e-06 0.00156 0.3 0.24 Lung cancer; chr15:43261784 chr15:43699488~43718184:- LIHC cis rs748404 0.697 rs504417 ENSG00000166763.7 STRCP1 4.62 5.43e-06 0.00156 0.3 0.24 Lung cancer; chr15:43262028 chr15:43699488~43718184:- LIHC cis rs8040855 0.659 rs8037886 ENSG00000259295.5 CSPG4P12 -4.62 5.43e-06 0.00156 -0.38 -0.24 Bulimia nervosa; chr15:85143533 chr15:85191438~85213905:+ LIHC cis rs7914558 1 rs8139 ENSG00000236937.2 PTGES3P4 4.62 5.43e-06 0.00156 0.29 0.24 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:103088366 chr10:102845595~102845950:+ LIHC cis rs12304921 0.683 rs17125401 ENSG00000277201.1 AC087884.1 4.62 5.44e-06 0.00156 0.28 0.24 Type 2 diabetes; chr12:51120569 chr12:51049921~51050025:+ LIHC cis rs9326248 0.581 rs7120515 ENSG00000236267.1 AP006216.5 4.62 5.44e-06 0.00156 0.25 0.24 Blood protein levels; chr11:117121210 chr11:116813204~116814003:- LIHC cis rs8028182 0.636 rs28623700 ENSG00000260269.4 CTD-2323K18.1 -4.62 5.44e-06 0.00156 -0.3 -0.24 Sudden cardiac arrest; chr15:75557373 chr15:75527150~75601205:- LIHC cis rs8028182 0.577 rs28693593 ENSG00000260269.4 CTD-2323K18.1 -4.62 5.44e-06 0.00156 -0.3 -0.24 Sudden cardiac arrest; chr15:75557435 chr15:75527150~75601205:- LIHC cis rs2310173 0.575 rs2071008 ENSG00000281162.1 LINC01127 -4.62 5.45e-06 0.00156 -0.27 -0.24 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:101998817 chr2:101962056~101987167:+ LIHC cis rs11146838 1 rs11146838 ENSG00000099251.13 HSD17B7P2 4.62 5.45e-06 0.00156 0.29 0.24 Breast cancer; chr10:38856846 chr10:38356380~38378505:+ LIHC cis rs9834975 1 rs9834975 ENSG00000272758.4 RP11-299J3.8 -4.62 5.45e-06 0.00156 -0.27 -0.24 Diastolic blood pressure; chr3:122398816 chr3:122416207~122443180:+ LIHC cis rs2276314 1 rs16967317 ENSG00000278986.1 RP11-723J4.3 -4.62 5.45e-06 0.00156 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:35993437 chr18:35972151~35973916:+ LIHC cis rs5758511 0.68 rs5758692 ENSG00000237037.8 NDUFA6-AS1 -4.62 5.46e-06 0.00157 -0.31 -0.24 Birth weight; chr22:42273023 chr22:42090931~42137742:+ LIHC cis rs1865760 0.928 rs9295673 ENSG00000216436.2 HIST1H2APS1 -4.62 5.47e-06 0.00157 -0.27 -0.24 Height; chr6:25911866 chr6:25732497~25732827:+ LIHC cis rs10510102 0.872 rs7906462 ENSG00000226864.1 ATE1-AS1 4.62 5.47e-06 0.00157 0.39 0.24 Breast cancer; chr10:121948098 chr10:121928312~121951965:+ LIHC cis rs2310173 0.575 rs4850993 ENSG00000281162.1 LINC01127 -4.62 5.47e-06 0.00157 -0.26 -0.24 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:102006004 chr2:101962056~101987167:+ LIHC cis rs7429990 0.833 rs6442072 ENSG00000229759.1 MRPS18AP1 -4.62 5.48e-06 0.00157 -0.25 -0.24 Educational attainment (years of education); chr3:47642960 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs13061412 ENSG00000229759.1 MRPS18AP1 -4.62 5.48e-06 0.00157 -0.25 -0.24 Educational attainment (years of education); chr3:47660092 chr3:48256350~48256938:- LIHC cis rs7429990 0.803 rs6773732 ENSG00000229759.1 MRPS18AP1 -4.62 5.48e-06 0.00157 -0.25 -0.24 Educational attainment (years of education); chr3:47677772 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs4410463 ENSG00000229759.1 MRPS18AP1 -4.62 5.48e-06 0.00157 -0.25 -0.24 Educational attainment (years of education); chr3:47693907 chr3:48256350~48256938:- LIHC cis rs9291683 0.595 rs35501905 ENSG00000250413.1 RP11-448G15.1 -4.62 5.48e-06 0.00157 -0.31 -0.24 Bone mineral density; chr4:10051807 chr4:10006482~10009725:+ LIHC cis rs1865760 0.623 rs12216125 ENSG00000216436.2 HIST1H2APS1 -4.62 5.49e-06 0.00157 -0.32 -0.24 Height; chr6:25997230 chr6:25732497~25732827:+ LIHC cis rs651907 0.557 rs3094296 ENSG00000244119.1 PDCL3P4 4.62 5.49e-06 0.00157 0.25 0.24 Colorectal cancer; chr3:101681323 chr3:101712472~101713191:+ LIHC cis rs58950470 0.521 rs7950197 ENSG00000265874.1 MIR4489 -4.62 5.5e-06 0.00158 -0.3 -0.24 Schizophrenia; chr11:65678655 chr11:65649192~65649253:+ LIHC cis rs2337406 0.866 rs58850145 ENSG00000274576.2 IGHV2-70 -4.62 5.5e-06 0.00158 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106806185 chr14:106770577~106771020:- LIHC cis rs17036023 1 rs17036023 ENSG00000203865.8 ATP1A1-AS1 4.62 5.5e-06 0.00158 0.42 0.24 Asthma (childhood onset); chr1:116587089 chr1:116392247~116418622:- LIHC cis rs12554020 0.786 rs75395683 ENSG00000227603.1 RP11-165J3.6 4.62 5.51e-06 0.00158 0.37 0.24 Schizophrenia; chr9:93415128 chr9:93435332~93437121:- LIHC cis rs12554020 1 rs55846141 ENSG00000227603.1 RP11-165J3.6 4.62 5.51e-06 0.00158 0.37 0.24 Schizophrenia; chr9:93427679 chr9:93435332~93437121:- LIHC cis rs2836974 0.739 rs12482181 ENSG00000255568.3 BRWD1-AS2 4.62 5.51e-06 0.00158 0.28 0.24 Cognitive function; chr21:39176926 chr21:39313935~39314962:+ LIHC cis rs2836974 0.897 rs14194 ENSG00000255568.3 BRWD1-AS2 4.62 5.51e-06 0.00158 0.28 0.24 Cognitive function; chr21:39177540 chr21:39313935~39314962:+ LIHC cis rs5756813 0.754 rs13057133 ENSG00000233360.4 Z83844.1 4.62 5.51e-06 0.00158 0.31 0.24 Optic cup area;Vertical cup-disc ratio; chr22:37783466 chr22:37641832~37658377:- LIHC cis rs5756813 0.754 rs11705616 ENSG00000233360.4 Z83844.1 4.62 5.51e-06 0.00158 0.31 0.24 Optic cup area;Vertical cup-disc ratio; chr22:37784480 chr22:37641832~37658377:- LIHC cis rs748404 0.697 rs505249 ENSG00000166763.7 STRCP1 4.62 5.51e-06 0.00158 0.3 0.24 Lung cancer; chr15:43267762 chr15:43699488~43718184:- LIHC cis rs11098499 0.82 rs13122709 ENSG00000245958.5 RP11-33B1.1 -4.62 5.51e-06 0.00158 -0.25 -0.24 Corneal astigmatism; chr4:119634201 chr4:119454791~119552025:+ LIHC cis rs9896933 0.887 rs78483419 ENSG00000263063.1 RP11-388C12.1 -4.62 5.51e-06 0.00158 -0.34 -0.24 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82913008 chr17:82713908~82716255:- LIHC cis rs17826219 0.5 rs28452421 ENSG00000266490.1 CTD-2349P21.9 4.62 5.51e-06 0.00158 0.31 0.24 Body mass index; chr17:30756962 chr17:30792372~30792833:+ LIHC cis rs7208859 0.573 rs28779471 ENSG00000266490.1 CTD-2349P21.9 4.62 5.51e-06 0.00158 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757351 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11658022 ENSG00000266490.1 CTD-2349P21.9 4.62 5.51e-06 0.00158 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758341 chr17:30792372~30792833:+ LIHC cis rs17826219 0.5 rs61685770 ENSG00000266490.1 CTD-2349P21.9 4.62 5.51e-06 0.00158 0.31 0.24 Body mass index; chr17:30758695 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs57486336 ENSG00000266490.1 CTD-2349P21.9 4.62 5.51e-06 0.00158 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758713 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs12103440 ENSG00000266490.1 CTD-2349P21.9 4.62 5.51e-06 0.00158 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759639 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11657777 ENSG00000266490.1 CTD-2349P21.9 4.62 5.51e-06 0.00158 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30764767 chr17:30792372~30792833:+ LIHC cis rs11098499 0.954 rs3733524 ENSG00000260091.1 RP11-33B1.4 -4.62 5.52e-06 0.00158 -0.17 -0.24 Corneal astigmatism; chr4:119502574 chr4:119409333~119410233:+ LIHC cis rs7429990 0.864 rs2882611 ENSG00000229759.1 MRPS18AP1 -4.62 5.52e-06 0.00158 -0.25 -0.24 Educational attainment (years of education); chr3:47651532 chr3:48256350~48256938:- LIHC cis rs7474896 0.507 rs2474555 ENSG00000263064.2 RP11-291L22.7 4.62 5.52e-06 0.00158 0.32 0.24 Obesity (extreme); chr10:38176292 chr10:38448689~38448949:+ LIHC cis rs643506 1 rs1788955 ENSG00000254990.4 RP11-108O10.2 4.62 5.52e-06 0.00158 0.27 0.24 Breast cancer; chr11:111760274 chr11:111768668~111778350:- LIHC cis rs4650994 0.524 rs2209170 ENSG00000273384.1 RP5-1098D14.1 -4.62 5.53e-06 0.00158 -0.3 -0.24 HDL cholesterol;HDL cholesterol levels; chr1:178638253 chr1:178651706~178652282:+ LIHC cis rs2842992 0.789 rs2277072 ENSG00000237927.1 RP3-393E18.2 -4.62 5.54e-06 0.00159 -0.29 -0.24 Age-related macular degeneration (geographic atrophy); chr6:159761813 chr6:159586955~159589169:- LIHC cis rs2842992 0.83 rs2273819 ENSG00000237927.1 RP3-393E18.2 -4.62 5.54e-06 0.00159 -0.29 -0.24 Age-related macular degeneration (geographic atrophy); chr6:159762293 chr6:159586955~159589169:- LIHC cis rs7119038 0.509 rs11216964 ENSG00000255422.1 AP002954.4 4.62 5.56e-06 0.00159 0.31 0.24 Sjögren's syndrome; chr11:118711186 chr11:118704607~118750263:+ LIHC cis rs7119038 0.509 rs10892259 ENSG00000255422.1 AP002954.4 4.62 5.56e-06 0.00159 0.31 0.24 Sjögren's syndrome; chr11:118712293 chr11:118704607~118750263:+ LIHC cis rs7412746 0.611 rs72704679 ENSG00000231073.1 RP11-316M1.3 4.62 5.56e-06 0.00159 0.24 0.24 Melanoma; chr1:150925001 chr1:150973123~150975534:+ LIHC cis rs9733 0.526 rs6587542 ENSG00000231073.1 RP11-316M1.3 4.62 5.56e-06 0.00159 0.24 0.24 Tonsillectomy; chr1:150935225 chr1:150973123~150975534:+ LIHC cis rs7412746 0.611 rs4970931 ENSG00000231073.1 RP11-316M1.3 4.62 5.56e-06 0.00159 0.24 0.24 Melanoma; chr1:150938251 chr1:150973123~150975534:+ LIHC cis rs7412746 0.611 rs9661876 ENSG00000231073.1 RP11-316M1.3 4.62 5.56e-06 0.00159 0.24 0.24 Melanoma; chr1:150938435 chr1:150973123~150975534:+ LIHC cis rs9733 0.503 rs7556451 ENSG00000231073.1 RP11-316M1.3 4.62 5.56e-06 0.00159 0.24 0.24 Tonsillectomy; chr1:150940666 chr1:150973123~150975534:+ LIHC cis rs7412746 0.611 rs2271076 ENSG00000231073.1 RP11-316M1.3 4.62 5.56e-06 0.00159 0.24 0.24 Melanoma; chr1:150944181 chr1:150973123~150975534:+ LIHC cis rs8067287 0.688 rs8081126 ENSG00000205312.7 KRT17P4 4.62 5.56e-06 0.00159 0.37 0.24 Diabetic kidney disease; chr17:16942048 chr17:16847635~16852777:- LIHC cis rs11098499 0.644 rs10012252 ENSG00000245958.5 RP11-33B1.1 -4.62 5.56e-06 0.00159 -0.25 -0.24 Corneal astigmatism; chr4:119637984 chr4:119454791~119552025:+ LIHC cis rs5758511 0.68 rs5758698 ENSG00000205702.9 CYP2D7 4.62 5.57e-06 0.00159 0.29 0.24 Birth weight; chr22:42288812 chr22:42140203~42144577:- LIHC cis rs2929278 0.561 rs62018952 ENSG00000166763.7 STRCP1 -4.62 5.57e-06 0.00159 -0.32 -0.24 Schizophrenia; chr15:43788539 chr15:43699488~43718184:- LIHC cis rs2060793 0.539 rs962025 ENSG00000251991.1 RNU7-49P 4.62 5.57e-06 0.00159 0.27 0.24 Vitamin D levels; chr11:14618744 chr11:14478892~14478953:+ LIHC cis rs875971 0.545 rs6970498 ENSG00000273142.1 RP11-458F8.4 4.61 5.57e-06 0.00159 0.23 0.24 Aortic root size; chr7:66275908 chr7:66902857~66906297:+ LIHC cis rs2932538 0.845 rs6682678 ENSG00000225075.1 RP11-426L16.3 -4.61 5.57e-06 0.00159 -0.32 -0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112664298 chr1:112693688~112696621:- LIHC cis rs673078 0.66 rs17586342 ENSG00000275759.1 RP11-131L12.3 -4.61 5.57e-06 0.00159 -0.3 -0.24 Glucose homeostasis traits; chr12:118162399 chr12:118428281~118428870:+ LIHC cis rs57502260 1 rs57502260 ENSG00000212093.1 AP000807.1 4.61 5.58e-06 0.00159 0.3 0.24 Total body bone mineral density (age 45-60); chr11:68453437 chr11:68506083~68506166:- LIHC cis rs57502260 0.764 rs7105218 ENSG00000212093.1 AP000807.1 4.61 5.58e-06 0.00159 0.3 0.24 Total body bone mineral density (age 45-60); chr11:68454993 chr11:68506083~68506166:- LIHC cis rs75920871 0.61 rs11216169 ENSG00000254851.1 RP11-109L13.1 -4.61 5.58e-06 0.00159 -0.5 -0.24 Subjective well-being; chr11:116873673 chr11:117135528~117138582:+ LIHC cis rs4934494 0.768 rs3740034 ENSG00000232936.4 RP11-80H5.2 4.61 5.58e-06 0.0016 0.28 0.24 Red blood cell count; chr10:89634902 chr10:89645282~89650667:+ LIHC cis rs7937890 0.559 rs2597188 ENSG00000251991.1 RNU7-49P 4.61 5.58e-06 0.0016 0.26 0.24 Mitochondrial DNA levels; chr11:14495360 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2597187 ENSG00000251991.1 RNU7-49P 4.61 5.58e-06 0.0016 0.26 0.24 Mitochondrial DNA levels; chr11:14495473 chr11:14478892~14478953:+ LIHC cis rs7246657 0.943 rs2291004 ENSG00000276846.1 CTD-3220F14.3 4.61 5.59e-06 0.0016 0.31 0.24 Coronary artery calcification; chr19:37507050 chr19:37314868~37315620:- LIHC cis rs733592 0.524 rs10875744 ENSG00000240399.1 RP1-228P16.1 4.61 5.59e-06 0.0016 0.23 0.24 Plateletcrit; chr12:48104657 chr12:48054813~48055591:- LIHC cis rs748404 0.723 rs560134 ENSG00000166763.7 STRCP1 4.61 5.6e-06 0.0016 0.3 0.24 Lung cancer; chr15:43263501 chr15:43699488~43718184:- LIHC cis rs12887734 0.524 rs12888002 ENSG00000258534.1 CTD-2134A5.4 -4.61 5.6e-06 0.0016 -0.27 -0.24 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103772310 chr14:103854366~103880111:- LIHC cis rs7937890 0.559 rs2167160 ENSG00000251991.1 RNU7-49P 4.61 5.6e-06 0.0016 0.26 0.24 Mitochondrial DNA levels; chr11:14485903 chr11:14478892~14478953:+ LIHC cis rs7937890 0.531 rs2575859 ENSG00000251991.1 RNU7-49P 4.61 5.6e-06 0.0016 0.26 0.24 Mitochondrial DNA levels; chr11:14489190 chr11:14478892~14478953:+ LIHC cis rs6445975 0.726 rs7616659 ENSG00000272360.1 RP11-359I18.5 -4.61 5.6e-06 0.0016 -0.29 -0.24 Systemic lupus erythematosus; chr3:58481860 chr3:58490830~58491291:- LIHC cis rs4356203 0.543 rs214081 ENSG00000260196.1 RP1-239B22.5 -4.61 5.6e-06 0.0016 -0.29 -0.24 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17278107 chr11:17380649~17383531:+ LIHC cis rs11673344 0.636 rs7255595 ENSG00000226686.6 LINC01535 4.61 5.61e-06 0.0016 0.37 0.24 Obesity-related traits; chr19:36896260 chr19:37251912~37265535:+ LIHC cis rs228614 0.509 rs223482 ENSG00000246560.2 RP11-10L12.4 4.61 5.62e-06 0.00161 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766051 chr4:102828055~102844075:+ LIHC cis rs228614 0.509 rs223481 ENSG00000246560.2 RP11-10L12.4 4.61 5.62e-06 0.00161 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766860 chr4:102828055~102844075:+ LIHC cis rs228614 0.536 rs223478 ENSG00000246560.2 RP11-10L12.4 4.61 5.62e-06 0.00161 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102768648 chr4:102828055~102844075:+ LIHC cis rs228614 0.536 rs150898 ENSG00000246560.2 RP11-10L12.4 4.61 5.62e-06 0.00161 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769234 chr4:102828055~102844075:+ LIHC cis rs11098499 0.754 rs10213554 ENSG00000260091.1 RP11-33B1.4 4.61 5.62e-06 0.00161 0.17 0.24 Corneal astigmatism; chr4:119339630 chr4:119409333~119410233:+ LIHC cis rs11098499 0.865 rs11722183 ENSG00000245958.5 RP11-33B1.1 -4.61 5.62e-06 0.00161 -0.26 -0.24 Corneal astigmatism; chr4:119359442 chr4:119454791~119552025:+ LIHC cis rs227275 0.554 rs223485 ENSG00000246560.2 RP11-10L12.4 4.61 5.62e-06 0.00161 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102764018 chr4:102828055~102844075:+ LIHC cis rs28829049 0.508 rs4578242 ENSG00000270728.1 RP4-657E11.10 -4.61 5.62e-06 0.00161 -0.22 -0.24 QRS duration in Tripanosoma cruzi seropositivity; chr1:19065071 chr1:19297080~19297903:+ LIHC cis rs7615952 0.599 rs6438953 ENSG00000171084.14 FAM86JP 4.61 5.63e-06 0.00161 0.37 0.24 Blood pressure (smoking interaction); chr3:126006108 chr3:125916620~125930024:+ LIHC cis rs7615952 0.599 rs1044215 ENSG00000171084.14 FAM86JP 4.61 5.63e-06 0.00161 0.37 0.24 Blood pressure (smoking interaction); chr3:126006716 chr3:125916620~125930024:+ LIHC cis rs3893377 0.848 rs10023845 ENSG00000214846.4 RP11-115L11.1 -4.61 5.63e-06 0.00161 -0.31 -0.24 Current cigarettes per day in chronic obstructive pulmonary disease; chr4:15739628 chr4:15730962~15731627:- LIHC cis rs728616 0.867 rs2152548 ENSG00000225484.5 NUTM2B-AS1 -4.61 5.63e-06 0.00161 -0.57 -0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80042911 chr10:79663088~79826594:- LIHC cis rs3738443 0.868 rs7546908 ENSG00000259865.1 RP11-488L18.10 -4.61 5.64e-06 0.00161 -0.21 -0.24 Alcohol dependence; chr1:247200531 chr1:247187281~247188526:- LIHC cis rs12701220 0.817 rs1058729 ENSG00000229043.2 AC091729.9 -4.61 5.64e-06 0.00161 -0.33 -0.24 Bronchopulmonary dysplasia; chr7:1047647 chr7:1160374~1165267:+ LIHC cis rs11098499 0.71 rs4145952 ENSG00000245958.5 RP11-33B1.1 -4.61 5.64e-06 0.00161 -0.24 -0.24 Corneal astigmatism; chr4:119234651 chr4:119454791~119552025:+ LIHC cis rs4660214 0.724 rs7554301 ENSG00000182109.6 RP11-69E11.4 -4.61 5.64e-06 0.00161 -0.26 -0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39177792 chr1:39522280~39546187:- LIHC cis rs748404 0.578 rs2584701 ENSG00000166763.7 STRCP1 4.61 5.64e-06 0.00161 0.3 0.24 Lung cancer; chr15:43392741 chr15:43699488~43718184:- LIHC cis rs7208859 0.623 rs8067035 ENSG00000266490.1 CTD-2349P21.9 4.61 5.64e-06 0.00161 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775170 chr17:30792372~30792833:+ LIHC cis rs4356203 0.543 rs214093 ENSG00000260196.1 RP1-239B22.5 -4.61 5.65e-06 0.00161 -0.3 -0.24 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17273241 chr11:17380649~17383531:+ LIHC cis rs4356203 0.519 rs214092 ENSG00000260196.1 RP1-239B22.5 -4.61 5.65e-06 0.00161 -0.3 -0.24 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17273499 chr11:17380649~17383531:+ LIHC cis rs1322639 0.614 rs9455889 ENSG00000261039.2 RP11-417E7.2 -4.61 5.65e-06 0.00161 -0.33 -0.24 Pulse pressure; chr6:169165992 chr6:169175304~169182740:- LIHC cis rs2348418 0.733 rs4931078 ENSG00000247934.4 RP11-967K21.1 -4.61 5.65e-06 0.00161 -0.22 -0.24 Lung function (FEV1);Lung function (FVC); chr12:28215067 chr12:28163298~28190738:- LIHC cis rs244293 0.831 rs8072090 ENSG00000275710.1 RP11-257O5.4 4.61 5.65e-06 0.00161 0.26 0.24 Menarche (age at onset); chr17:55097073 chr17:54964474~54964679:+ LIHC cis rs2836974 0.932 rs13048178 ENSG00000255568.3 BRWD1-AS2 4.61 5.65e-06 0.00161 0.27 0.24 Cognitive function; chr21:39189086 chr21:39313935~39314962:+ LIHC cis rs12554020 0.892 rs7025805 ENSG00000227603.1 RP11-165J3.6 -4.61 5.65e-06 0.00161 -0.32 -0.24 Schizophrenia; chr9:93481463 chr9:93435332~93437121:- LIHC cis rs11098499 0.874 rs13139045 ENSG00000245958.5 RP11-33B1.1 -4.61 5.66e-06 0.00161 -0.25 -0.24 Corneal astigmatism; chr4:119247433 chr4:119454791~119552025:+ LIHC cis rs2274273 0.624 rs1972221 ENSG00000258413.1 RP11-665C16.6 -4.61 5.66e-06 0.00162 -0.29 -0.24 Protein biomarker; chr14:55318663 chr14:55262767~55272075:- LIHC cis rs2797160 0.904 rs1612274 ENSG00000237742.5 RP11-624M8.1 4.61 5.66e-06 0.00162 0.25 0.24 Endometrial cancer; chr6:125693761 chr6:125578558~125749190:- LIHC cis rs7809950 0.862 rs12112877 ENSG00000238832.1 snoU109 -4.61 5.66e-06 0.00162 -0.3 -0.24 Coronary artery disease; chr7:107300879 chr7:107603363~107603507:+ LIHC cis rs728616 0.867 rs57257258 ENSG00000225484.5 NUTM2B-AS1 -4.61 5.67e-06 0.00162 -0.52 -0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80084264 chr10:79663088~79826594:- LIHC cis rs728616 1 rs728616 ENSG00000225484.5 NUTM2B-AS1 -4.61 5.67e-06 0.00162 -0.52 -0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80088158 chr10:79663088~79826594:- LIHC cis rs728616 1 rs728615 ENSG00000225484.5 NUTM2B-AS1 -4.61 5.67e-06 0.00162 -0.52 -0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80088333 chr10:79663088~79826594:- LIHC cis rs3096299 0.967 rs2965932 ENSG00000261118.1 RP11-104N10.1 -4.61 5.67e-06 0.00162 -0.25 -0.24 Multiple myeloma (IgH translocation); chr16:89410643 chr16:89492017~89504460:- LIHC cis rs2439831 0.85 rs3736180 ENSG00000275601.1 AC011330.13 -4.61 5.67e-06 0.00162 -0.35 -0.24 Lung cancer in ever smokers; chr15:43814426 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs28684672 ENSG00000275601.1 AC011330.13 -4.61 5.67e-06 0.00162 -0.35 -0.24 Lung cancer in ever smokers; chr15:43815464 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs12440573 ENSG00000275601.1 AC011330.13 -4.61 5.67e-06 0.00162 -0.35 -0.24 Lung cancer in ever smokers; chr15:43816799 chr15:43642389~43643023:- LIHC cis rs73193808 0.59 rs9981735 ENSG00000224649.1 AF124730.4 4.61 5.67e-06 0.00162 0.28 0.24 Coronary artery disease; chr21:29195543 chr21:29182027~29187795:- LIHC cis rs73193808 0.59 rs9982010 ENSG00000224649.1 AF124730.4 4.61 5.67e-06 0.00162 0.28 0.24 Coronary artery disease; chr21:29195855 chr21:29182027~29187795:- LIHC cis rs11079159 0.628 rs884303 ENSG00000263096.1 RP11-515O17.2 4.61 5.68e-06 0.00162 0.32 0.24 QRS duration; chr17:55289939 chr17:55271504~55273653:- LIHC cis rs7937890 0.559 rs6486193 ENSG00000251991.1 RNU7-49P 4.61 5.68e-06 0.00162 0.23 0.24 Mitochondrial DNA levels; chr11:14416061 chr11:14478892~14478953:+ LIHC cis rs638893 1 rs636736 ENSG00000255239.1 AP002954.6 4.61 5.68e-06 0.00162 0.42 0.24 Vitiligo; chr11:118834436 chr11:118688039~118690600:- LIHC cis rs651907 0.557 rs7629753 ENSG00000244119.1 PDCL3P4 -4.61 5.68e-06 0.00162 -0.24 -0.24 Colorectal cancer; chr3:101653078 chr3:101712472~101713191:+ LIHC cis rs1865760 1 rs7739966 ENSG00000216436.2 HIST1H2APS1 -4.61 5.68e-06 0.00162 -0.27 -0.24 Height; chr6:25905812 chr6:25732497~25732827:+ LIHC cis rs1865760 1 rs56118523 ENSG00000216436.2 HIST1H2APS1 -4.61 5.68e-06 0.00162 -0.27 -0.24 Height; chr6:25908747 chr6:25732497~25732827:+ LIHC cis rs1865760 1 rs12209482 ENSG00000216436.2 HIST1H2APS1 -4.61 5.68e-06 0.00162 -0.27 -0.24 Height; chr6:25909001 chr6:25732497~25732827:+ LIHC cis rs1865760 0.963 rs3846838 ENSG00000216436.2 HIST1H2APS1 -4.61 5.68e-06 0.00162 -0.27 -0.24 Height; chr6:25911547 chr6:25732497~25732827:+ LIHC cis rs916888 0.61 rs199446 ENSG00000260075.1 NSFP1 -4.61 5.68e-06 0.00162 -0.3 -0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:46372855~46487141:+ LIHC cis rs916888 0.61 rs199536 ENSG00000260075.1 NSFP1 -4.61 5.68e-06 0.00162 -0.3 -0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:46372855~46487141:+ LIHC cis rs2243480 1 rs313803 ENSG00000230295.1 RP11-458F8.2 -4.61 5.69e-06 0.00162 -0.25 -0.24 Diabetic kidney disease; chr7:66049744 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs313802 ENSG00000230295.1 RP11-458F8.2 -4.61 5.69e-06 0.00162 -0.25 -0.24 Diabetic kidney disease; chr7:66051386 chr7:66880708~66882981:+ LIHC cis rs2243480 0.803 rs403089 ENSG00000230295.1 RP11-458F8.2 -4.61 5.69e-06 0.00162 -0.25 -0.24 Diabetic kidney disease; chr7:66052736 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs458291 ENSG00000230295.1 RP11-458F8.2 -4.61 5.69e-06 0.00162 -0.25 -0.24 Diabetic kidney disease; chr7:66055492 chr7:66880708~66882981:+ LIHC cis rs1499614 0.522 rs13247442 ENSG00000226824.5 RP4-756H11.3 -4.61 5.69e-06 0.00162 -0.47 -0.24 Gout; chr7:66723871 chr7:66654538~66669855:+ LIHC cis rs10129255 0.584 rs11161001 ENSG00000211970.3 IGHV4-61 -4.61 5.7e-06 0.00163 -0.19 -0.24 Kawasaki disease; chr14:106652664 chr14:106639119~106639657:- LIHC cis rs3931020 0.566 rs1409782 ENSG00000272864.1 RP11-17E13.2 -4.61 5.7e-06 0.00163 -0.36 -0.24 Resistin levels; chr1:74807251 chr1:74698769~74699333:- LIHC cis rs11096990 0.679 rs6531707 ENSG00000249685.1 RP11-360F5.3 -4.61 5.71e-06 0.00163 -0.29 -0.24 Cognitive function; chr4:39296064 chr4:39133913~39135608:+ LIHC cis rs4578769 0.959 rs3851816 ENSG00000265943.1 RP11-739L10.1 4.61 5.71e-06 0.00163 0.31 0.24 Eosinophil percentage of white cells; chr18:22866880 chr18:22699481~22933764:- LIHC cis rs72675573 0.788 rs12568575 ENSG00000235612.1 RP1-158P9.1 -4.61 5.72e-06 0.00163 -0.33 -0.24 Monocyte count; chr1:56103537 chr1:56145721~56155224:+ LIHC cis rs58950470 0.849 rs7122657 ENSG00000265874.1 MIR4489 4.61 5.72e-06 0.00163 0.35 0.24 Schizophrenia; chr11:65610557 chr11:65649192~65649253:+ LIHC cis rs2581828 0.656 rs2581786 ENSG00000242142.1 SERBP1P3 4.61 5.72e-06 0.00163 0.28 0.24 Crohn's disease; chr3:53092127 chr3:53064283~53065091:- LIHC cis rs7131987 0.868 rs11050151 ENSG00000257176.2 RP11-996F15.2 -4.61 5.73e-06 0.00163 -0.27 -0.24 QT interval; chr12:29250075 chr12:29280418~29317848:- LIHC cis rs73086581 0.592 rs6037702 ENSG00000229539.1 RP11-119B16.2 -4.61 5.73e-06 0.00163 -0.27 -0.24 Response to antidepressants in depression; chr20:3955745 chr20:3888239~3888868:- LIHC cis rs2274273 0.624 rs10141396 ENSG00000258413.1 RP11-665C16.6 -4.61 5.74e-06 0.00163 -0.3 -0.24 Protein biomarker; chr14:55350207 chr14:55262767~55272075:- LIHC cis rs6480314 0.522 rs10762210 ENSG00000233590.1 RP11-153K11.3 4.61 5.74e-06 0.00163 0.37 0.24 Optic nerve measurement (disc area); chr10:68290860 chr10:68233251~68242379:- LIHC cis rs2439831 1 rs2256764 ENSG00000166763.7 STRCP1 4.61 5.74e-06 0.00163 0.37 0.24 Lung cancer in ever smokers; chr15:43443565 chr15:43699488~43718184:- LIHC cis rs2274273 0.901 rs7147136 ENSG00000258413.1 RP11-665C16.6 -4.61 5.75e-06 0.00164 -0.29 -0.24 Protein biomarker; chr14:55359970 chr14:55262767~55272075:- LIHC cis rs2274273 0.901 rs17674563 ENSG00000258413.1 RP11-665C16.6 -4.61 5.75e-06 0.00164 -0.29 -0.24 Protein biomarker; chr14:55364407 chr14:55262767~55272075:- LIHC cis rs228614 0.51 rs223453 ENSG00000246560.2 RP11-10L12.4 4.61 5.75e-06 0.00164 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102789895 chr4:102828055~102844075:+ LIHC cis rs3733589 1 rs3733589 ENSG00000250413.1 RP11-448G15.1 -4.61 5.76e-06 0.00164 -0.43 -0.24 Renal overload gout; chr4:9985700 chr4:10006482~10009725:+ LIHC cis rs2581828 0.656 rs11242 ENSG00000242142.1 SERBP1P3 -4.61 5.76e-06 0.00164 -0.28 -0.24 Crohn's disease; chr3:53091906 chr3:53064283~53065091:- LIHC cis rs2276314 0.857 rs6507158 ENSG00000278986.1 RP11-723J4.3 -4.61 5.77e-06 0.00164 -0.28 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36056103 chr18:35972151~35973916:+ LIHC cis rs6723226 0.572 rs176404 ENSG00000276334.1 AL133243.1 -4.61 5.77e-06 0.00164 -0.27 -0.24 Intelligence (multi-trait analysis); chr2:32413778 chr2:32521927~32523547:+ LIHC cis rs12701220 0.894 rs10263252 ENSG00000229043.2 AC091729.9 -4.61 5.77e-06 0.00164 -0.34 -0.24 Bronchopulmonary dysplasia; chr7:1010313 chr7:1160374~1165267:+ LIHC cis rs5758511 0.689 rs5758691 ENSG00000205702.9 CYP2D7 4.61 5.77e-06 0.00164 0.28 0.24 Birth weight; chr22:42272498 chr22:42140203~42144577:- LIHC cis rs2439831 1 rs7173487 ENSG00000166763.7 STRCP1 4.61 5.77e-06 0.00164 0.37 0.24 Lung cancer in ever smokers; chr15:43458041 chr15:43699488~43718184:- LIHC cis rs9291683 0.567 rs12499857 ENSG00000250413.1 RP11-448G15.1 -4.61 5.77e-06 0.00164 -0.31 -0.24 Bone mineral density; chr4:9993752 chr4:10006482~10009725:+ LIHC cis rs73193808 0.614 rs11088112 ENSG00000224649.1 AF124730.4 4.61 5.78e-06 0.00164 0.28 0.24 Coronary artery disease; chr21:29193915 chr21:29182027~29187795:- LIHC cis rs7945705 0.818 rs2742537 ENSG00000254860.4 TMEM9B-AS1 4.61 5.78e-06 0.00165 0.23 0.24 Hemoglobin concentration; chr11:8886842 chr11:8964675~8977527:+ LIHC cis rs2337406 0.778 rs58113768 ENSG00000274576.2 IGHV2-70 -4.61 5.79e-06 0.00165 -0.28 -0.24 Alzheimer's disease (late onset); chr14:106700213 chr14:106770577~106771020:- LIHC cis rs13315871 1 rs4362735 ENSG00000272182.1 RP11-802O23.3 4.61 5.79e-06 0.00165 0.59 0.24 Cholesterol, total; chr3:58444166 chr3:58428255~58428815:+ LIHC cis rs7809950 0.954 rs2894466 ENSG00000238832.1 snoU109 4.61 5.79e-06 0.00165 0.29 0.24 Coronary artery disease; chr7:107602464 chr7:107603363~107603507:+ LIHC cis rs7809950 0.834 rs3801946 ENSG00000238832.1 snoU109 4.61 5.79e-06 0.00165 0.29 0.24 Coronary artery disease; chr7:107602550 chr7:107603363~107603507:+ LIHC cis rs7809950 0.954 rs3779494 ENSG00000238832.1 snoU109 4.61 5.79e-06 0.00165 0.29 0.24 Coronary artery disease; chr7:107609910 chr7:107603363~107603507:+ LIHC cis rs75920871 0.764 rs80259223 ENSG00000254851.1 RP11-109L13.1 -4.61 5.81e-06 0.00165 -0.51 -0.24 Subjective well-being; chr11:117053602 chr11:117135528~117138582:+ LIHC cis rs6480314 0.831 rs1900009 ENSG00000233590.1 RP11-153K11.3 -4.6 5.83e-06 0.00166 -0.36 -0.24 Optic nerve measurement (disc area); chr10:68217940 chr10:68233251~68242379:- LIHC cis rs79040073 0.53 rs17476940 ENSG00000259531.2 RP11-295H24.3 -4.6 5.83e-06 0.00166 -0.39 -0.24 Lung cancer in ever smokers; chr15:49332587 chr15:49365124~49366685:- LIHC cis rs2243480 1 rs466983 ENSG00000230295.1 RP11-458F8.2 -4.6 5.84e-06 0.00166 -0.25 -0.24 Diabetic kidney disease; chr7:66055509 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1723269 ENSG00000228409.4 CCT6P1 4.6 5.84e-06 0.00166 0.26 0.24 Diabetic kidney disease; chr7:66007799 chr7:65751142~65763354:+ LIHC cis rs1865760 1 rs9358893 ENSG00000216436.2 HIST1H2APS1 -4.6 5.84e-06 0.00166 -0.27 -0.24 Height; chr6:25921533 chr6:25732497~25732827:+ LIHC cis rs7119038 0.779 rs73005502 ENSG00000255239.1 AP002954.6 -4.6 5.84e-06 0.00166 -0.35 -0.24 Sjögren's syndrome; chr11:118827197 chr11:118688039~118690600:- LIHC cis rs2919917 1 rs1872072 ENSG00000254352.1 RP11-578O24.2 4.6 5.84e-06 0.00166 0.33 0.24 Lymphocyte counts; chr8:78689185 chr8:78723796~78724136:- LIHC cis rs6921919 0.789 rs11970439 ENSG00000216901.1 AL022393.7 4.6 5.84e-06 0.00166 0.34 0.24 Autism spectrum disorder or schizophrenia; chr6:28335687 chr6:28176188~28176674:+ LIHC cis rs17826219 0.706 rs28469200 ENSG00000266490.1 CTD-2349P21.9 4.6 5.84e-06 0.00166 0.3 0.24 Body mass index; chr17:30806554 chr17:30792372~30792833:+ LIHC cis rs7208859 0.573 rs7214313 ENSG00000266490.1 CTD-2349P21.9 4.6 5.84e-06 0.00166 0.3 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811578 chr17:30792372~30792833:+ LIHC cis rs8064024 0.65 rs12926178 ENSG00000267077.1 RP11-127I20.5 -4.6 5.85e-06 0.00166 -0.25 -0.24 Cancer; chr16:4855914 chr16:4795265~4796532:- LIHC cis rs1865760 1 rs3830057 ENSG00000216436.2 HIST1H2APS1 -4.6 5.86e-06 0.00166 -0.27 -0.24 Height; chr6:25918282 chr6:25732497~25732827:+ LIHC cis rs1865760 1 rs3752421 ENSG00000216436.2 HIST1H2APS1 -4.6 5.86e-06 0.00166 -0.27 -0.24 Height; chr6:25918460 chr6:25732497~25732827:+ LIHC cis rs929596 0.561 rs11891311 ENSG00000233445.1 RPL17P11 -4.6 5.86e-06 0.00166 -0.28 -0.24 Total bilirubin levels in HIV-1 infection; chr2:233730664 chr2:233721522~233722065:- LIHC cis rs748404 0.587 rs9920879 ENSG00000205771.5 CATSPER2P1 -4.6 5.86e-06 0.00167 -0.29 -0.24 Lung cancer; chr15:43347572 chr15:43726918~43747094:- LIHC cis rs748404 0.631 rs7166812 ENSG00000205771.5 CATSPER2P1 -4.6 5.86e-06 0.00167 -0.29 -0.24 Lung cancer; chr15:43352562 chr15:43726918~43747094:- LIHC cis rs748404 0.631 rs1133395 ENSG00000205771.5 CATSPER2P1 -4.6 5.86e-06 0.00167 -0.29 -0.24 Lung cancer; chr15:43358186 chr15:43726918~43747094:- LIHC cis rs11098499 0.535 rs7671759 ENSG00000245958.5 RP11-33B1.1 -4.6 5.86e-06 0.00167 -0.25 -0.24 Corneal astigmatism; chr4:119326939 chr4:119454791~119552025:+ LIHC cis rs712039 0.652 rs853232 ENSG00000276054.1 RP11-378E13.3 4.6 5.87e-06 0.00167 0.3 0.24 Tuberculosis; chr17:37481076 chr17:37386886~37387926:+ LIHC cis rs1865760 1 rs9467636 ENSG00000216436.2 HIST1H2APS1 -4.6 5.87e-06 0.00167 -0.27 -0.24 Height; chr6:25919321 chr6:25732497~25732827:+ LIHC cis rs3893377 0.848 rs10222984 ENSG00000214846.4 RP11-115L11.1 4.6 5.87e-06 0.00167 0.3 0.24 Current cigarettes per day in chronic obstructive pulmonary disease; chr4:15740080 chr4:15730962~15731627:- LIHC cis rs1558001 0.84 rs34619691 ENSG00000230196.1 DDX43P3 -4.6 5.87e-06 0.00167 -0.26 -0.24 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81831584 chr7:81610884~81611326:- LIHC cis rs11971779 0.68 rs4732370 ENSG00000273391.1 RP11-634H22.1 -4.6 5.87e-06 0.00167 -0.21 -0.24 Diisocyanate-induced asthma; chr7:139392494 chr7:139359032~139359566:- LIHC cis rs61041384 0.661 rs74240781 ENSG00000256092.2 RP13-942N8.1 -4.6 5.88e-06 0.00167 -0.39 -0.24 Schizophrenia; chr12:123308154 chr12:123363868~123366113:+ LIHC cis rs2834288 0.5 rs881230 ENSG00000237945.6 LINC00649 4.6 5.88e-06 0.00167 0.31 0.24 Gut microbiota (bacterial taxa); chr21:33950521 chr21:33915534~33977691:+ LIHC cis rs2834288 0.5 rs881231 ENSG00000237945.6 LINC00649 4.6 5.88e-06 0.00167 0.31 0.24 Gut microbiota (bacterial taxa); chr21:33950526 chr21:33915534~33977691:+ LIHC cis rs2834288 0.5 rs7280837 ENSG00000237945.6 LINC00649 4.6 5.88e-06 0.00167 0.31 0.24 Gut microbiota (bacterial taxa); chr21:33951533 chr21:33915534~33977691:+ LIHC cis rs2834288 0.5 rs4817602 ENSG00000237945.6 LINC00649 4.6 5.88e-06 0.00167 0.31 0.24 Gut microbiota (bacterial taxa); chr21:33952354 chr21:33915534~33977691:+ LIHC cis rs10771431 0.967 rs7137443 ENSG00000111788.10 RP11-22B23.1 4.6 5.88e-06 0.00167 0.22 0.24 Breast size; chr12:9219433 chr12:9277235~9313241:+ LIHC cis rs227275 0.554 rs223367 ENSG00000246560.2 RP11-10L12.4 4.6 5.88e-06 0.00167 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102843836 chr4:102828055~102844075:+ LIHC cis rs3733589 0.744 rs16892493 ENSG00000250413.1 RP11-448G15.1 -4.6 5.89e-06 0.00167 -0.39 -0.24 Renal overload gout; chr4:10040023 chr4:10006482~10009725:+ LIHC cis rs12554020 0.685 rs55893789 ENSG00000227603.1 RP11-165J3.6 4.6 5.89e-06 0.00167 0.36 0.24 Schizophrenia; chr9:93408608 chr9:93435332~93437121:- LIHC cis rs12554020 0.681 rs78759589 ENSG00000227603.1 RP11-165J3.6 4.6 5.89e-06 0.00167 0.36 0.24 Schizophrenia; chr9:93409518 chr9:93435332~93437121:- LIHC cis rs11098499 0.909 rs11723757 ENSG00000245958.5 RP11-33B1.1 -4.6 5.89e-06 0.00167 -0.26 -0.24 Corneal astigmatism; chr4:119378514 chr4:119454791~119552025:+ LIHC cis rs11971779 0.793 rs11543827 ENSG00000273391.1 RP11-634H22.1 4.6 5.89e-06 0.00167 0.22 0.24 Diisocyanate-induced asthma; chr7:139347947 chr7:139359032~139359566:- LIHC cis rs875971 0.638 rs35986979 ENSG00000273024.4 INTS4P2 4.6 5.9e-06 0.00167 0.27 0.24 Aortic root size; chr7:66624003 chr7:65647864~65715661:+ LIHC cis rs2834288 0.5 rs2051189 ENSG00000237945.6 LINC00649 4.6 5.9e-06 0.00167 0.31 0.24 Gut microbiota (bacterial taxa); chr21:33949712 chr21:33915534~33977691:+ LIHC cis rs67311347 1 rs9835219 ENSG00000223797.4 ENTPD3-AS1 4.6 5.9e-06 0.00168 0.2 0.24 Renal cell carcinoma; chr3:40382602 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs7642552 ENSG00000223797.4 ENTPD3-AS1 4.6 5.9e-06 0.00168 0.2 0.24 Renal cell carcinoma; chr3:40383325 chr3:40313802~40453329:- LIHC cis rs2932538 0.922 rs7527076 ENSG00000225075.1 RP11-426L16.3 4.6 5.9e-06 0.00168 0.31 0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112607859 chr1:112693688~112696621:- LIHC cis rs2932538 0.846 rs7546203 ENSG00000225075.1 RP11-426L16.3 4.6 5.9e-06 0.00168 0.31 0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112611907 chr1:112693688~112696621:- LIHC cis rs79040073 0.563 rs73392233 ENSG00000259531.2 RP11-295H24.3 4.6 5.91e-06 0.00168 0.4 0.24 Lung cancer in ever smokers; chr15:49214881 chr15:49365124~49366685:- LIHC cis rs79040073 0.53 rs79452929 ENSG00000259531.2 RP11-295H24.3 4.6 5.91e-06 0.00168 0.4 0.24 Lung cancer in ever smokers; chr15:49216166 chr15:49365124~49366685:- LIHC cis rs79040073 0.53 rs57560518 ENSG00000259531.2 RP11-295H24.3 4.6 5.91e-06 0.00168 0.4 0.24 Lung cancer in ever smokers; chr15:49218760 chr15:49365124~49366685:- LIHC cis rs7923609 0.869 rs9971352 ENSG00000232075.1 MRPL35P2 -4.6 5.91e-06 0.00168 -0.27 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63505348 chr10:63634317~63634827:- LIHC cis rs2072510 0.932 rs2070614 ENSG00000257715.1 RP11-256L6.2 -4.6 5.91e-06 0.00168 -0.25 -0.24 Metabolite levels (small molecules and protein measures); chr12:95996558 chr12:96025323~96027971:+ LIHC cis rs8064024 0.62 rs9923349 ENSG00000267077.1 RP11-127I20.5 4.6 5.92e-06 0.00168 0.25 0.24 Cancer; chr16:4855123 chr16:4795265~4796532:- LIHC cis rs7412746 0.658 rs6669855 ENSG00000231073.1 RP11-316M1.3 4.6 5.92e-06 0.00168 0.24 0.24 Melanoma; chr1:150888753 chr1:150973123~150975534:+ LIHC cis rs10129255 0.53 rs11624912 ENSG00000223648.3 IGHV3-64 4.6 5.92e-06 0.00168 0.17 0.24 Kawasaki disease; chr14:106673891 chr14:106643132~106658258:- LIHC cis rs2111504 0.806 rs7252443 ENSG00000267213.4 AC007773.2 -4.6 5.92e-06 0.00168 -0.26 -0.24 Bipolar disorder; chr19:32449827 chr19:32390050~32405560:- LIHC cis rs9595908 1 rs9591143 ENSG00000212293.1 SNORA16 4.6 5.92e-06 0.00168 0.28 0.24 Body mass index; chr13:32585301 chr13:32420390~32420516:- LIHC cis rs9595908 1 rs9591145 ENSG00000212293.1 SNORA16 4.6 5.92e-06 0.00168 0.28 0.24 Body mass index; chr13:32587322 chr13:32420390~32420516:- LIHC cis rs9595908 1 rs3742320 ENSG00000212293.1 SNORA16 4.6 5.92e-06 0.00168 0.28 0.24 Body mass index; chr13:32590281 chr13:32420390~32420516:- LIHC cis rs11098499 0.954 rs878373 ENSG00000245958.5 RP11-33B1.1 -4.6 5.93e-06 0.00168 -0.26 -0.24 Corneal astigmatism; chr4:119316329 chr4:119454791~119552025:+ LIHC cis rs4578769 0.842 rs8093152 ENSG00000265943.1 RP11-739L10.1 4.6 5.94e-06 0.00168 0.31 0.24 Eosinophil percentage of white cells; chr18:22867925 chr18:22699481~22933764:- LIHC cis rs6545883 0.525 rs1729658 ENSG00000271889.1 RP11-493E12.1 4.6 5.94e-06 0.00168 0.28 0.24 Tuberculosis; chr2:61146385 chr2:61151433~61162105:- LIHC cis rs7760535 0.93 rs10872069 ENSG00000255389.1 C6orf3 -4.6 5.94e-06 0.00169 -0.26 -0.24 Metabolic traits; chr6:111540523 chr6:111599875~111602295:+ LIHC cis rs8040855 0.756 rs12909477 ENSG00000259295.5 CSPG4P12 -4.6 5.94e-06 0.00169 -0.38 -0.24 Bulimia nervosa; chr15:85146644 chr15:85191438~85213905:+ LIHC cis rs7131987 0.903 rs7970390 ENSG00000257176.2 RP11-996F15.2 -4.6 5.95e-06 0.00169 -0.27 -0.24 QT interval; chr12:29245722 chr12:29280418~29317848:- LIHC cis rs9595066 0.627 rs4394973 ENSG00000230731.2 RP11-478K15.6 -4.6 5.95e-06 0.00169 -0.28 -0.24 Schizophrenia; chr13:44179173 chr13:44234118~44243192:- LIHC cis rs2932538 0.922 rs2932535 ENSG00000225075.1 RP11-426L16.3 -4.6 5.97e-06 0.00169 -0.31 -0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112658790 chr1:112693688~112696621:- LIHC cis rs7208859 0.623 rs216436 ENSG00000266490.1 CTD-2349P21.9 4.6 5.97e-06 0.00169 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595882 chr17:30792372~30792833:+ LIHC cis rs11098499 0.73 rs12505735 ENSG00000245958.5 RP11-33B1.1 -4.6 5.97e-06 0.00169 -0.25 -0.24 Corneal astigmatism; chr4:119611801 chr4:119454791~119552025:+ LIHC cis rs7131987 0.509 rs11050173 ENSG00000275476.1 RP11-996F15.4 -4.6 5.98e-06 0.00169 -0.3 -0.24 QT interval; chr12:29288540 chr12:29277397~29277882:- LIHC cis rs728616 0.867 rs56235549 ENSG00000225484.5 NUTM2B-AS1 -4.6 5.98e-06 0.00169 -0.54 -0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80075192 chr10:79663088~79826594:- LIHC cis rs3091242 0.934 rs686631 ENSG00000224183.1 SDHDP6 -4.6 5.98e-06 0.0017 -0.27 -0.24 Erythrocyte sedimentation rate; chr1:25393108 chr1:25294164~25294643:- LIHC cis rs7567389 0.583 rs11683427 ENSG00000236682.1 AC068282.3 -4.6 5.98e-06 0.0017 -0.36 -0.24 Self-rated health; chr2:127198967 chr2:127389130~127400580:+ LIHC cis rs17818399 0.547 rs7607308 ENSG00000239332.4 LINC01119 -4.6 5.98e-06 0.0017 -0.34 -0.24 Height; chr2:46531965 chr2:46816697~46859007:+ LIHC cis rs881375 0.631 rs2416808 ENSG00000226752.6 PSMD5-AS1 -4.6 5.99e-06 0.0017 -0.25 -0.24 Rheumatoid arthritis; chr9:120944005 chr9:120824828~120854385:+ LIHC cis rs2245008 0.774 rs253135 ENSG00000260932.1 RP11-483P21.6 -4.6 5.99e-06 0.0017 -0.43 -0.24 Pursuit maintenance gain; chr16:83945238 chr16:83929796~83931223:- LIHC cis rs7809950 1 rs7809950 ENSG00000238832.1 snoU109 4.6 5.99e-06 0.0017 0.29 0.24 Coronary artery disease; chr7:107597362 chr7:107603363~107603507:+ LIHC cis rs2834288 0.5 rs2834305 ENSG00000237945.6 LINC00649 4.6 5.99e-06 0.0017 0.31 0.24 Gut microbiota (bacterial taxa); chr21:33955321 chr21:33915534~33977691:+ LIHC cis rs13217239 0.646 rs10946888 ENSG00000241549.7 GUSBP2 4.6 6e-06 0.0017 0.24 0.24 Schizophrenia; chr6:26983899 chr6:26871484~26956554:- LIHC cis rs6472235 0.681 rs58881093 ENSG00000272010.1 CTD-3025N20.3 -4.6 6.01e-06 0.0017 -0.33 -0.24 Plateletcrit;Myopia (pathological); chr8:65952396 chr8:65591850~65592472:- LIHC cis rs9992667 0.955 rs11937257 ENSG00000231160.8 KLF3-AS1 4.6 6.01e-06 0.0017 0.33 0.24 Eosinophil percentage of granulocytes; chr4:38643839 chr4:38612701~38664883:- LIHC cis rs6504622 0.755 rs7216950 ENSG00000262879.4 RP11-156P1.3 -4.6 6.01e-06 0.0017 -0.26 -0.24 Orofacial clefts; chr17:47011089 chr17:46984045~47100323:- LIHC cis rs2348418 0.733 rs2019011 ENSG00000247934.4 RP11-967K21.1 4.6 6.02e-06 0.00171 0.22 0.24 Lung function (FEV1);Lung function (FVC); chr12:28228144 chr12:28163298~28190738:- LIHC cis rs2836974 0.568 rs2142111 ENSG00000255568.3 BRWD1-AS2 4.6 6.02e-06 0.00171 0.21 0.24 Cognitive function; chr21:39177363 chr21:39313935~39314962:+ LIHC cis rs11098499 0.909 rs1546504 ENSG00000245958.5 RP11-33B1.1 -4.6 6.03e-06 0.00171 -0.26 -0.24 Corneal astigmatism; chr4:119320024 chr4:119454791~119552025:+ LIHC cis rs881375 0.678 rs10985102 ENSG00000226752.6 PSMD5-AS1 -4.6 6.03e-06 0.00171 -0.25 -0.24 Rheumatoid arthritis; chr9:120945219 chr9:120824828~120854385:+ LIHC cis rs875971 0.528 rs801213 ENSG00000273142.1 RP11-458F8.4 -4.6 6.03e-06 0.00171 -0.23 -0.24 Aortic root size; chr7:66549931 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs801212 ENSG00000273142.1 RP11-458F8.4 -4.6 6.03e-06 0.00171 -0.23 -0.24 Aortic root size; chr7:66550643 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs73152714 ENSG00000273142.1 RP11-458F8.4 4.6 6.03e-06 0.00171 0.23 0.24 Aortic root size; chr7:66534641 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs4718364 ENSG00000273142.1 RP11-458F8.4 4.6 6.03e-06 0.00171 0.23 0.24 Aortic root size; chr7:66536353 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs6961853 ENSG00000273142.1 RP11-458F8.4 4.6 6.03e-06 0.00171 0.23 0.24 Aortic root size; chr7:66537035 chr7:66902857~66906297:+ LIHC cis rs10510102 0.516 rs12242799 ENSG00000276742.1 RP11-500G22.4 4.6 6.04e-06 0.00171 0.39 0.24 Breast cancer; chr10:121980067 chr10:121956782~121957098:+ LIHC cis rs2243480 1 rs34970380 ENSG00000230295.1 RP11-458F8.2 -4.6 6.04e-06 0.00171 -0.26 -0.24 Diabetic kidney disease; chr7:65966506 chr7:66880708~66882981:+ LIHC cis rs2243480 0.901 rs73148097 ENSG00000230295.1 RP11-458F8.2 -4.6 6.04e-06 0.00171 -0.26 -0.24 Diabetic kidney disease; chr7:65966800 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs906134 ENSG00000230295.1 RP11-458F8.2 -4.6 6.04e-06 0.00171 -0.26 -0.24 Diabetic kidney disease; chr7:65979301 chr7:66880708~66882981:+ LIHC cis rs748404 0.578 rs2012467 ENSG00000205771.5 CATSPER2P1 -4.6 6.04e-06 0.00171 -0.29 -0.24 Lung cancer; chr15:43398367 chr15:43726918~43747094:- LIHC cis rs7712401 0.584 rs28373879 ENSG00000263432.2 RN7SL689P 4.6 6.05e-06 0.00171 0.33 0.24 Mean platelet volume; chr5:123036707 chr5:123022487~123022783:- LIHC cis rs8091660 0.929 rs2175564 ENSG00000278983.1 RP11-426J5.3 4.6 6.05e-06 0.00171 0.35 0.24 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48570838 chr18:48564795~48568342:+ LIHC cis rs9388451 0.626 rs3799712 ENSG00000237742.5 RP11-624M8.1 -4.6 6.05e-06 0.00171 -0.23 -0.24 Brugada syndrome; chr6:125753957 chr6:125578558~125749190:- LIHC cis rs17301013 0.932 rs2987869 ENSG00000227373.4 RP11-160H22.5 -4.6 6.05e-06 0.00171 -0.29 -0.24 Systemic lupus erythematosus; chr1:174820269 chr1:174115300~174160004:- LIHC cis rs17301013 0.827 rs1793309 ENSG00000227373.4 RP11-160H22.5 -4.6 6.05e-06 0.00171 -0.29 -0.24 Systemic lupus erythematosus; chr1:174826199 chr1:174115300~174160004:- LIHC cis rs42490 0.546 rs160437 ENSG00000251136.7 RP11-37B2.1 4.6 6.06e-06 0.00171 0.21 0.24 Leprosy; chr8:89669656 chr8:89609409~89757727:- LIHC cis rs287982 1 rs112307255 ENSG00000269973.1 RP11-95D17.1 -4.6 6.06e-06 0.00172 -0.23 -0.24 Nonsyndromic cleft lip with cleft palate; chr2:9842137 chr2:9936360~9939590:+ LIHC cis rs9291683 0.526 rs7695555 ENSG00000250413.1 RP11-448G15.1 -4.6 6.07e-06 0.00172 -0.32 -0.24 Bone mineral density; chr4:10000032 chr4:10006482~10009725:+ LIHC cis rs3931020 0.548 rs2134836 ENSG00000272864.1 RP11-17E13.2 -4.6 6.07e-06 0.00172 -0.35 -0.24 Resistin levels; chr1:74805962 chr1:74698769~74699333:- LIHC cis rs3931020 0.548 rs12145183 ENSG00000272864.1 RP11-17E13.2 -4.6 6.07e-06 0.00172 -0.35 -0.24 Resistin levels; chr1:74806796 chr1:74698769~74699333:- LIHC cis rs6997458 0.712 rs9987281 ENSG00000253549.4 RP11-317J10.2 -4.6 6.07e-06 0.00172 -0.26 -0.24 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85436601 chr8:85441851~85464915:- LIHC cis rs901683 0.702 rs78757497 ENSG00000230869.1 CTGLF10P -4.6 6.08e-06 0.00172 -0.52 -0.24 Mean corpuscular volume;Red blood cell traits; chr10:45666470 chr10:45678692~45700532:+ LIHC cis rs7208859 0.623 rs9895785 ENSG00000266490.1 CTD-2349P21.9 -4.6 6.09e-06 0.00172 -0.3 -0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780690 chr17:30792372~30792833:+ LIHC cis rs12304921 0.816 rs67478184 ENSG00000277201.1 AC087884.1 4.6 6.09e-06 0.00172 0.28 0.24 Type 2 diabetes; chr12:51114267 chr12:51049921~51050025:+ LIHC cis rs11098499 0.754 rs2036857 ENSG00000245958.5 RP11-33B1.1 -4.6 6.09e-06 0.00172 -0.25 -0.24 Corneal astigmatism; chr4:119328085 chr4:119454791~119552025:+ LIHC cis rs17711722 0.51 rs11767457 ENSG00000226824.5 RP4-756H11.3 -4.6 6.09e-06 0.00172 -0.28 -0.24 Calcium levels; chr7:65825628 chr7:66654538~66669855:+ LIHC cis rs12304921 0.748 rs56847302 ENSG00000277201.1 AC087884.1 4.59 6.1e-06 0.00173 0.28 0.24 Type 2 diabetes; chr12:51113093 chr12:51049921~51050025:+ LIHC cis rs9992667 0.955 rs1000571 ENSG00000231160.8 KLF3-AS1 4.59 6.1e-06 0.00173 0.33 0.24 Eosinophil percentage of granulocytes; chr4:38661274 chr4:38612701~38664883:- LIHC cis rs9992667 0.955 rs12507197 ENSG00000231160.8 KLF3-AS1 4.59 6.1e-06 0.00173 0.33 0.24 Eosinophil percentage of granulocytes; chr4:38662039 chr4:38612701~38664883:- LIHC cis rs9992667 0.955 rs60029573 ENSG00000231160.8 KLF3-AS1 4.59 6.1e-06 0.00173 0.33 0.24 Eosinophil percentage of granulocytes; chr4:38662242 chr4:38612701~38664883:- LIHC cis rs9992667 0.955 rs2078179 ENSG00000231160.8 KLF3-AS1 4.59 6.1e-06 0.00173 0.33 0.24 Eosinophil percentage of granulocytes; chr4:38662878 chr4:38612701~38664883:- LIHC cis rs9992667 0.664 rs112691446 ENSG00000231160.8 KLF3-AS1 4.59 6.1e-06 0.00173 0.33 0.24 Eosinophil percentage of granulocytes; chr4:38663521 chr4:38612701~38664883:- LIHC cis rs9992667 0.868 rs113071828 ENSG00000231160.8 KLF3-AS1 4.59 6.1e-06 0.00173 0.33 0.24 Eosinophil percentage of granulocytes; chr4:38664197 chr4:38612701~38664883:- LIHC cis rs9992667 0.911 rs28656945 ENSG00000231160.8 KLF3-AS1 4.59 6.1e-06 0.00173 0.33 0.24 Eosinophil percentage of granulocytes; chr4:38665125 chr4:38612701~38664883:- LIHC cis rs10510102 0.516 rs12256693 ENSG00000276742.1 RP11-500G22.4 4.59 6.1e-06 0.00173 0.41 0.24 Breast cancer; chr10:121976839 chr10:121956782~121957098:+ LIHC cis rs10028773 0.7 rs7671797 ENSG00000245958.5 RP11-33B1.1 -4.59 6.11e-06 0.00173 -0.25 -0.24 Educational attainment; chr4:119327002 chr4:119454791~119552025:+ LIHC cis rs8040855 0.627 rs11632658 ENSG00000259295.5 CSPG4P12 -4.59 6.11e-06 0.00173 -0.37 -0.24 Bulimia nervosa; chr15:85062982 chr15:85191438~85213905:+ LIHC cis rs1165668 0.785 rs2070908 ENSG00000257327.1 RP11-650K20.3 -4.59 6.11e-06 0.00173 -0.28 -0.24 Coronary heart disease (SNP X SNP interaction); chr12:103930404 chr12:103841451~103844664:+ LIHC cis rs7937890 0.559 rs2575836 ENSG00000251991.1 RNU7-49P 4.59 6.11e-06 0.00173 0.26 0.24 Mitochondrial DNA levels; chr11:14476318 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2575837 ENSG00000251991.1 RNU7-49P 4.59 6.11e-06 0.00173 0.26 0.24 Mitochondrial DNA levels; chr11:14476455 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2575838 ENSG00000251991.1 RNU7-49P 4.59 6.11e-06 0.00173 0.26 0.24 Mitochondrial DNA levels; chr11:14476675 chr11:14478892~14478953:+ LIHC cis rs7937890 0.535 rs2575857 ENSG00000251991.1 RNU7-49P 4.59 6.11e-06 0.00173 0.26 0.24 Mitochondrial DNA levels; chr11:14479750 chr11:14478892~14478953:+ LIHC cis rs2243480 1 rs1723269 ENSG00000230295.1 RP11-458F8.2 -4.59 6.12e-06 0.00173 -0.25 -0.24 Diabetic kidney disease; chr7:66007799 chr7:66880708~66882981:+ LIHC cis rs6142102 0.651 rs1015361 ENSG00000276073.1 RP5-1125A11.7 4.59 6.12e-06 0.00173 0.27 0.24 Skin pigmentation; chr20:34150880 chr20:33985617~33988989:- LIHC cis rs2243480 1 rs1039664 ENSG00000230295.1 RP11-458F8.2 -4.59 6.13e-06 0.00173 -0.25 -0.24 Diabetic kidney disease; chr7:65984729 chr7:66880708~66882981:+ LIHC cis rs11098499 0.866 rs72676074 ENSG00000260091.1 RP11-33B1.4 -4.59 6.13e-06 0.00173 -0.17 -0.24 Corneal astigmatism; chr4:119438686 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs28884220 ENSG00000245958.5 RP11-33B1.1 -4.59 6.15e-06 0.00174 -0.25 -0.24 Corneal astigmatism; chr4:119386056 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs28793658 ENSG00000245958.5 RP11-33B1.1 -4.59 6.15e-06 0.00174 -0.25 -0.24 Corneal astigmatism; chr4:119386059 chr4:119454791~119552025:+ LIHC cis rs2836974 0.932 rs2234543 ENSG00000255568.3 BRWD1-AS2 4.59 6.15e-06 0.00174 0.27 0.24 Cognitive function; chr21:39200146 chr21:39313935~39314962:+ LIHC cis rs11971779 0.711 rs6961204 ENSG00000273391.1 RP11-634H22.1 4.59 6.15e-06 0.00174 0.23 0.24 Diisocyanate-induced asthma; chr7:139362653 chr7:139359032~139359566:- LIHC cis rs11098499 0.754 rs2036860 ENSG00000245958.5 RP11-33B1.1 -4.59 6.15e-06 0.00174 -0.25 -0.24 Corneal astigmatism; chr4:119327779 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs2036856 ENSG00000245958.5 RP11-33B1.1 -4.59 6.15e-06 0.00174 -0.25 -0.24 Corneal astigmatism; chr4:119328133 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs4443261 ENSG00000245958.5 RP11-33B1.1 -4.59 6.15e-06 0.00174 -0.25 -0.24 Corneal astigmatism; chr4:119328146 chr4:119454791~119552025:+ LIHC cis rs1062753 0.527 rs6002560 ENSG00000237037.8 NDUFA6-AS1 4.59 6.15e-06 0.00174 0.34 0.24 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41960882 chr22:42090931~42137742:+ LIHC cis rs42490 0.844 rs444078 ENSG00000251136.7 RP11-37B2.1 -4.59 6.16e-06 0.00174 -0.22 -0.24 Leprosy; chr8:89701558 chr8:89609409~89757727:- LIHC cis rs4713118 0.513 rs149962 ENSG00000219392.1 RP1-265C24.5 -4.59 6.17e-06 0.00174 -0.32 -0.24 Parkinson's disease; chr6:28048140 chr6:28115628~28116551:+ LIHC cis rs4713118 0.513 rs9368547 ENSG00000219392.1 RP1-265C24.5 -4.59 6.17e-06 0.00174 -0.32 -0.24 Parkinson's disease; chr6:28060289 chr6:28115628~28116551:+ LIHC cis rs4713118 0.513 rs183244 ENSG00000219392.1 RP1-265C24.5 -4.59 6.17e-06 0.00174 -0.32 -0.24 Parkinson's disease; chr6:28064060 chr6:28115628~28116551:+ LIHC cis rs4713118 0.513 rs149950 ENSG00000219392.1 RP1-265C24.5 -4.59 6.17e-06 0.00174 -0.32 -0.24 Parkinson's disease; chr6:28065261 chr6:28115628~28116551:+ LIHC cis rs4713118 0.513 rs149951 ENSG00000219392.1 RP1-265C24.5 -4.59 6.17e-06 0.00174 -0.32 -0.24 Parkinson's disease; chr6:28065309 chr6:28115628~28116551:+ LIHC cis rs2929278 0.617 rs575082 ENSG00000275601.1 AC011330.13 4.59 6.17e-06 0.00174 0.3 0.24 Schizophrenia; chr15:43817944 chr15:43642389~43643023:- LIHC cis rs2929278 0.617 rs2955969 ENSG00000275601.1 AC011330.13 4.59 6.17e-06 0.00174 0.3 0.24 Schizophrenia; chr15:43822329 chr15:43642389~43643023:- LIHC cis rs2337406 0.85 rs11161008 ENSG00000274576.2 IGHV2-70 -4.59 6.17e-06 0.00174 -0.27 -0.24 Alzheimer's disease (late onset); chr14:106705261 chr14:106770577~106771020:- LIHC cis rs2976388 0.573 rs1529865 ENSG00000253196.1 RP11-706C16.7 4.59 6.18e-06 0.00174 0.23 0.24 Urinary tract infection frequency; chr8:142707753 chr8:142763116~142766427:+ LIHC cis rs2976388 0.609 rs1560986 ENSG00000253196.1 RP11-706C16.7 4.59 6.18e-06 0.00174 0.23 0.24 Urinary tract infection frequency; chr8:142708357 chr8:142763116~142766427:+ LIHC cis rs2976388 0.609 rs2376491 ENSG00000253196.1 RP11-706C16.7 4.59 6.18e-06 0.00174 0.23 0.24 Urinary tract infection frequency; chr8:142709516 chr8:142763116~142766427:+ LIHC cis rs2337406 0.866 rs4774019 ENSG00000274576.2 IGHV2-70 -4.59 6.18e-06 0.00175 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106805386 chr14:106770577~106771020:- LIHC cis rs1577917 1 rs12661204 ENSG00000234155.1 RP11-30P6.6 4.59 6.19e-06 0.00175 0.32 0.24 Response to antipsychotic treatment; chr6:85968868 chr6:85387219~85390186:- LIHC cis rs11098499 0.575 rs907204 ENSG00000245958.5 RP11-33B1.1 -4.59 6.19e-06 0.00175 -0.25 -0.24 Corneal astigmatism; chr4:119317499 chr4:119454791~119552025:+ LIHC cis rs11098499 0.575 rs907205 ENSG00000245958.5 RP11-33B1.1 -4.59 6.19e-06 0.00175 -0.25 -0.24 Corneal astigmatism; chr4:119317509 chr4:119454791~119552025:+ LIHC cis rs7429990 0.864 rs2133601 ENSG00000229759.1 MRPS18AP1 -4.59 6.19e-06 0.00175 -0.25 -0.24 Educational attainment (years of education); chr3:47692525 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs6792497 ENSG00000229759.1 MRPS18AP1 -4.59 6.19e-06 0.00175 -0.25 -0.24 Educational attainment (years of education); chr3:47693684 chr3:48256350~48256938:- LIHC cis rs71520386 0.607 rs11767419 ENSG00000228649.7 AC005682.5 -4.59 6.19e-06 0.00175 -0.31 -0.24 Fibrinogen levels; chr7:22839364 chr7:22854178~22861579:+ LIHC cis rs12554020 0.892 rs6479487 ENSG00000227603.1 RP11-165J3.6 4.59 6.2e-06 0.00175 0.31 0.24 Schizophrenia; chr9:93475091 chr9:93435332~93437121:- LIHC cis rs875971 0.545 rs66594357 ENSG00000273142.1 RP11-458F8.4 4.59 6.2e-06 0.00175 0.23 0.24 Aortic root size; chr7:66327797 chr7:66902857~66906297:+ LIHC cis rs79349575 0.811 rs1057897 ENSG00000248278.1 SUMO2P17 4.59 6.2e-06 0.00175 0.3 0.24 Type 2 diabetes; chr17:48928147 chr17:48874860~48908983:- LIHC cis rs2836974 0.568 rs8130795 ENSG00000255568.3 BRWD1-AS2 4.59 6.2e-06 0.00175 0.2 0.24 Cognitive function; chr21:39178057 chr21:39313935~39314962:+ LIHC cis rs11722228 0.508 rs2241472 ENSG00000261490.1 RP11-448G15.3 4.59 6.2e-06 0.00175 0.32 0.24 Urate levels;Serum uric acid levels;Gout; chr4:10084278 chr4:10068089~10073019:- LIHC cis rs58749629 1 rs58749629 ENSG00000269549.2 RP3-461P17.10 4.59 6.21e-06 0.00175 0.49 0.24 Abdominal aortic aneurysm; chr20:45942678 chr20:45445431~45448580:+ LIHC cis rs7474896 0.616 rs2505239 ENSG00000263064.2 RP11-291L22.7 4.59 6.21e-06 0.00175 0.32 0.24 Obesity (extreme); chr10:38151837 chr10:38448689~38448949:+ LIHC cis rs1005277 0.522 rs289643 ENSG00000099251.13 HSD17B7P2 4.59 6.21e-06 0.00175 0.28 0.24 Extrinsic epigenetic age acceleration; chr10:37652566 chr10:38356380~38378505:+ LIHC cis rs1865760 0.566 rs10807006 ENSG00000216436.2 HIST1H2APS1 -4.59 6.21e-06 0.00175 -0.28 -0.24 Height; chr6:26048524 chr6:25732497~25732827:+ LIHC cis rs1865760 0.566 rs7772312 ENSG00000216436.2 HIST1H2APS1 -4.59 6.21e-06 0.00175 -0.28 -0.24 Height; chr6:26049388 chr6:25732497~25732827:+ LIHC cis rs1865760 0.508 rs9379820 ENSG00000216436.2 HIST1H2APS1 -4.59 6.21e-06 0.00175 -0.28 -0.24 Height; chr6:26049696 chr6:25732497~25732827:+ LIHC cis rs2834288 0.5 rs7277248 ENSG00000237945.6 LINC00649 4.59 6.22e-06 0.00175 0.31 0.24 Gut microbiota (bacterial taxa); chr21:33957948 chr21:33915534~33977691:+ LIHC cis rs10771431 0.935 rs1988852 ENSG00000111788.10 RP11-22B23.1 4.59 6.22e-06 0.00175 0.22 0.24 Breast size; chr12:9220266 chr12:9277235~9313241:+ LIHC cis rs748404 0.697 rs475227 ENSG00000166763.7 STRCP1 4.59 6.22e-06 0.00176 0.3 0.24 Lung cancer; chr15:43254248 chr15:43699488~43718184:- LIHC cis rs4660214 0.666 rs11205696 ENSG00000182109.6 RP11-69E11.4 -4.59 6.22e-06 0.00176 -0.25 -0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39155880 chr1:39522280~39546187:- LIHC cis rs1577917 0.916 rs12198730 ENSG00000234155.1 RP11-30P6.6 4.59 6.23e-06 0.00176 0.32 0.24 Response to antipsychotic treatment; chr6:85845420 chr6:85387219~85390186:- LIHC cis rs1555322 0.53 rs2425053 ENSG00000279253.1 RP4-614O4.13 -4.59 6.23e-06 0.00176 -0.32 -0.24 Attention deficit hyperactivity disorder; chr20:35294017 chr20:35262727~35264187:- LIHC cis rs11098499 0.954 rs6857105 ENSG00000245958.5 RP11-33B1.1 -4.59 6.24e-06 0.00176 -0.26 -0.24 Corneal astigmatism; chr4:119301143 chr4:119454791~119552025:+ LIHC cis rs12554020 0.582 rs7038293 ENSG00000227603.1 RP11-165J3.6 4.59 6.24e-06 0.00176 0.44 0.24 Schizophrenia; chr9:93646314 chr9:93435332~93437121:- LIHC cis rs12554020 0.582 rs79049472 ENSG00000227603.1 RP11-165J3.6 4.59 6.24e-06 0.00176 0.44 0.24 Schizophrenia; chr9:93647116 chr9:93435332~93437121:- LIHC cis rs7429990 0.833 rs2030596 ENSG00000229759.1 MRPS18AP1 -4.59 6.24e-06 0.00176 -0.25 -0.24 Educational attainment (years of education); chr3:47701712 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs2047559 ENSG00000229759.1 MRPS18AP1 -4.59 6.24e-06 0.00176 -0.25 -0.24 Educational attainment (years of education); chr3:47704695 chr3:48256350~48256938:- LIHC cis rs7809950 1 rs12667527 ENSG00000238832.1 snoU109 -4.59 6.26e-06 0.00177 -0.29 -0.24 Coronary artery disease; chr7:107446524 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs4727680 ENSG00000238832.1 snoU109 -4.59 6.26e-06 0.00177 -0.29 -0.24 Coronary artery disease; chr7:107446962 chr7:107603363~107603507:+ LIHC cis rs2836974 0.932 rs6517526 ENSG00000255568.3 BRWD1-AS2 4.59 6.26e-06 0.00177 0.27 0.24 Cognitive function; chr21:39209604 chr21:39313935~39314962:+ LIHC cis rs2836974 0.932 rs6517527 ENSG00000255568.3 BRWD1-AS2 4.59 6.26e-06 0.00177 0.27 0.24 Cognitive function; chr21:39209825 chr21:39313935~39314962:+ LIHC cis rs7587476 0.689 rs78989396 ENSG00000229267.2 AC072062.1 -4.59 6.27e-06 0.00177 -0.31 -0.24 Neuroblastoma; chr2:214850092 chr2:214810229~214963274:+ LIHC cis rs2932538 0.922 rs9429694 ENSG00000225075.1 RP11-426L16.3 4.59 6.28e-06 0.00177 0.31 0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112615667 chr1:112693688~112696621:- LIHC cis rs1577917 0.958 rs12665542 ENSG00000234155.1 RP11-30P6.6 4.59 6.28e-06 0.00177 0.32 0.24 Response to antipsychotic treatment; chr6:85834725 chr6:85387219~85390186:- LIHC cis rs960902 0.747 rs13009200 ENSG00000213553.4 RPLP0P6 4.59 6.29e-06 0.00177 0.2 0.24 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37485353 chr2:38481851~38482804:+ LIHC cis rs673078 0.571 rs7963464 ENSG00000275759.1 RP11-131L12.3 -4.59 6.29e-06 0.00177 -0.31 -0.24 Glucose homeostasis traits; chr12:118264924 chr12:118428281~118428870:+ LIHC cis rs8005677 0.798 rs4982713 ENSG00000279656.1 RP11-298I3.6 4.59 6.29e-06 0.00177 0.27 0.24 Cognitive ability (multi-trait analysis); chr14:22934893 chr14:23023083~23024217:- LIHC cis rs8005677 0.798 rs35615180 ENSG00000279656.1 RP11-298I3.6 4.59 6.29e-06 0.00177 0.27 0.24 Cognitive ability (multi-trait analysis); chr14:22935180 chr14:23023083~23024217:- LIHC cis rs11098499 0.754 rs9999724 ENSG00000245958.5 RP11-33B1.1 -4.59 6.29e-06 0.00177 -0.25 -0.24 Corneal astigmatism; chr4:119318789 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs714899 ENSG00000245958.5 RP11-33B1.1 -4.59 6.29e-06 0.00177 -0.25 -0.24 Corneal astigmatism; chr4:119321880 chr4:119454791~119552025:+ LIHC cis rs929596 0.556 rs10168416 ENSG00000233445.1 RPL17P11 4.59 6.3e-06 0.00178 0.27 0.24 Total bilirubin levels in HIV-1 infection; chr2:233688441 chr2:233721522~233722065:- LIHC cis rs804280 0.662 rs11250164 ENSG00000255495.1 AC145124.2 -4.59 6.31e-06 0.00178 -0.3 -0.24 Myopia (pathological); chr8:11753177 chr8:12194467~12196280:+ LIHC cis rs72675573 1 rs12145670 ENSG00000235612.1 RP1-158P9.1 -4.59 6.31e-06 0.00178 -0.31 -0.24 Monocyte count; chr1:56172718 chr1:56145721~56155224:+ LIHC cis rs1577917 0.958 rs1591438 ENSG00000234155.1 RP11-30P6.6 4.59 6.32e-06 0.00178 0.32 0.24 Response to antipsychotic treatment; chr6:85815496 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs1591437 ENSG00000234155.1 RP11-30P6.6 4.59 6.32e-06 0.00178 0.32 0.24 Response to antipsychotic treatment; chr6:85815587 chr6:85387219~85390186:- LIHC cis rs17826219 0.636 rs12946563 ENSG00000266490.1 CTD-2349P21.9 4.59 6.32e-06 0.00178 0.31 0.24 Body mass index; chr17:30776148 chr17:30792372~30792833:+ LIHC cis rs6977955 1 rs11495981 ENSG00000234336.5 JAZF1-AS1 4.59 6.33e-06 0.00178 0.34 0.24 Allergic disease (asthma, hay fever or eczema); chr7:28137682 chr7:28180322~28243917:+ LIHC cis rs7412746 0.658 rs4970982 ENSG00000231073.1 RP11-316M1.3 4.59 6.33e-06 0.00178 0.24 0.24 Melanoma; chr1:150892608 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs11204739 ENSG00000231073.1 RP11-316M1.3 4.59 6.33e-06 0.00178 0.24 0.24 Melanoma; chr1:150893284 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs12097963 ENSG00000231073.1 RP11-316M1.3 4.59 6.33e-06 0.00178 0.24 0.24 Melanoma; chr1:150897974 chr1:150973123~150975534:+ LIHC cis rs7429990 0.864 rs7429162 ENSG00000229759.1 MRPS18AP1 -4.59 6.33e-06 0.00178 -0.25 -0.24 Educational attainment (years of education); chr3:47683845 chr3:48256350~48256938:- LIHC cis rs79040073 0.53 rs73392262 ENSG00000259531.2 RP11-295H24.3 4.59 6.34e-06 0.00178 0.4 0.24 Lung cancer in ever smokers; chr15:49229513 chr15:49365124~49366685:- LIHC cis rs10800713 0.954 rs6427835 ENSG00000260088.1 RP11-92G12.3 -4.59 6.34e-06 0.00178 -0.33 -0.24 Tandem gait; chr1:200591725 chr1:200669507~200694250:+ LIHC cis rs67311347 0.911 rs58282210 ENSG00000223797.4 ENTPD3-AS1 4.59 6.34e-06 0.00179 0.2 0.24 Renal cell carcinoma; chr3:40376452 chr3:40313802~40453329:- LIHC cis rs17818399 0.547 rs35178974 ENSG00000239332.4 LINC01119 -4.59 6.34e-06 0.00179 -0.34 -0.24 Height; chr2:46536759 chr2:46816697~46859007:+ LIHC cis rs11064837 0.504 rs11064850 ENSG00000248636.5 RP11-768F21.1 4.59 6.35e-06 0.00179 0.38 0.24 Schizophrenia; chr12:119617981 chr12:119387987~119668079:- LIHC cis rs11064837 0.504 rs10774508 ENSG00000248636.5 RP11-768F21.1 4.59 6.35e-06 0.00179 0.38 0.24 Schizophrenia; chr12:119632301 chr12:119387987~119668079:- LIHC cis rs875971 0.545 rs2420612 ENSG00000273142.1 RP11-458F8.4 4.59 6.36e-06 0.00179 0.23 0.24 Aortic root size; chr7:66536825 chr7:66902857~66906297:+ LIHC cis rs1160985 0.967 rs7259620 ENSG00000214855.8 APOC1P1 -4.59 6.36e-06 0.00179 -0.29 -0.24 C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels; chr19:44904531 chr19:44926804~44931386:+ LIHC cis rs2919917 1 rs2717547 ENSG00000254352.1 RP11-578O24.2 -4.59 6.36e-06 0.00179 -0.33 -0.24 Lymphocyte counts; chr8:78744754 chr8:78723796~78724136:- LIHC cis rs7587476 0.784 rs13026390 ENSG00000229267.2 AC072062.1 4.59 6.36e-06 0.00179 0.3 0.24 Neuroblastoma; chr2:214822351 chr2:214810229~214963274:+ LIHC cis rs11098499 0.818 rs55825515 ENSG00000245958.5 RP11-33B1.1 -4.59 6.36e-06 0.00179 -0.26 -0.24 Corneal astigmatism; chr4:119565247 chr4:119454791~119552025:+ LIHC cis rs10262624 1 rs2106747 ENSG00000234286.1 AC006026.13 -4.59 6.37e-06 0.00179 -0.27 -0.24 Schizophrenia; chr7:23871880 chr7:23680195~23680786:- LIHC cis rs7246657 0.943 rs10420430 ENSG00000276846.1 CTD-3220F14.3 4.59 6.37e-06 0.00179 0.31 0.24 Coronary artery calcification; chr19:37403292 chr19:37314868~37315620:- LIHC cis rs1499614 0.901 rs2178742 ENSG00000230295.1 RP11-458F8.2 -4.58 6.38e-06 0.00179 -0.26 -0.24 Gout; chr7:66732812 chr7:66880708~66882981:+ LIHC cis rs1153858 1 rs1554521 ENSG00000259433.2 CTD-2651B20.4 4.58 6.38e-06 0.0018 0.33 0.24 Homoarginine levels; chr15:45371991 chr15:45330209~45332634:- LIHC cis rs10510102 0.516 rs79528809 ENSG00000276742.1 RP11-500G22.4 4.58 6.39e-06 0.0018 0.39 0.24 Breast cancer; chr10:121980309 chr10:121956782~121957098:+ LIHC cis rs10829156 0.898 rs7923072 ENSG00000240291.1 RP11-499P20.2 4.58 6.4e-06 0.0018 0.37 0.24 Sudden cardiac arrest; chr10:18649305 chr10:18513115~18545651:- LIHC cis rs2581828 0.656 rs2581782 ENSG00000242142.1 SERBP1P3 4.58 6.4e-06 0.0018 0.28 0.24 Crohn's disease; chr3:53088241 chr3:53064283~53065091:- LIHC cis rs2581828 0.656 rs2581783 ENSG00000242142.1 SERBP1P3 4.58 6.4e-06 0.0018 0.28 0.24 Crohn's disease; chr3:53088242 chr3:53064283~53065091:- LIHC cis rs2276314 0.857 rs4799408 ENSG00000278986.1 RP11-723J4.3 4.58 6.4e-06 0.0018 0.29 0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36009019 chr18:35972151~35973916:+ LIHC cis rs67311347 1 rs11706148 ENSG00000223797.4 ENTPD3-AS1 4.58 6.4e-06 0.0018 0.2 0.24 Renal cell carcinoma; chr3:40365752 chr3:40313802~40453329:- LIHC cis rs7714584 1 rs4958843 ENSG00000197083.10 ZNF300P1 4.58 6.4e-06 0.0018 0.37 0.24 Crohn's disease; chr5:150845362 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs4958424 ENSG00000197083.10 ZNF300P1 4.58 6.4e-06 0.0018 0.37 0.24 Crohn's disease; chr5:150845474 chr5:150930645~150946289:- LIHC cis rs7714584 0.826 rs34005003 ENSG00000197083.10 ZNF300P1 4.58 6.4e-06 0.0018 0.37 0.24 Crohn's disease; chr5:150845637 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs11748151 ENSG00000197083.10 ZNF300P1 4.58 6.4e-06 0.0018 0.37 0.24 Crohn's disease; chr5:150846730 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs11748158 ENSG00000197083.10 ZNF300P1 4.58 6.4e-06 0.0018 0.37 0.24 Crohn's disease; chr5:150846783 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs10058821 ENSG00000197083.10 ZNF300P1 4.58 6.4e-06 0.0018 0.37 0.24 Crohn's disease; chr5:150846823 chr5:150930645~150946289:- LIHC cis rs7121538 0.932 rs34055103 ENSG00000251991.1 RNU7-49P -4.58 6.4e-06 0.0018 -0.35 -0.24 HDL cholesterol; chr11:14524935 chr11:14478892~14478953:+ LIHC cis rs12134133 0.927 rs4844589 ENSG00000274245.1 RP11-357P18.2 4.58 6.41e-06 0.0018 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207259285 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs6540893 ENSG00000274245.1 RP11-357P18.2 4.58 6.41e-06 0.0018 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207262382 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs61822674 ENSG00000274245.1 RP11-357P18.2 4.58 6.41e-06 0.0018 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207263378 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs10442696 ENSG00000274245.1 RP11-357P18.2 4.58 6.41e-06 0.0018 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207264783 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs7535532 ENSG00000274245.1 RP11-357P18.2 4.58 6.41e-06 0.0018 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207264991 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs7543117 ENSG00000274245.1 RP11-357P18.2 4.58 6.41e-06 0.0018 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207265351 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs6684804 ENSG00000274245.1 RP11-357P18.2 4.58 6.41e-06 0.0018 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207265670 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs11582249 ENSG00000274245.1 RP11-357P18.2 4.58 6.41e-06 0.0018 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207268263 chr1:207372559~207373252:+ LIHC cis rs17711722 0.565 rs4275112 ENSG00000224316.1 RP11-479O9.2 -4.58 6.42e-06 0.0018 -0.22 -0.24 Calcium levels; chr7:65733651 chr7:65773620~65802067:+ LIHC cis rs10510102 0.872 rs11814703 ENSG00000226864.1 ATE1-AS1 4.58 6.42e-06 0.0018 0.41 0.24 Breast cancer; chr10:121964774 chr10:121928312~121951965:+ LIHC cis rs957448 1 rs12680965 ENSG00000253704.1 RP11-267M23.4 4.58 6.42e-06 0.0018 0.29 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94554069 chr8:94553722~94569745:+ LIHC cis rs17818399 0.547 rs13020299 ENSG00000239332.4 LINC01119 -4.58 6.43e-06 0.00181 -0.34 -0.24 Height; chr2:46531578 chr2:46816697~46859007:+ LIHC cis rs11971779 0.715 rs6943973 ENSG00000273391.1 RP11-634H22.1 4.58 6.43e-06 0.00181 0.21 0.24 Diisocyanate-induced asthma; chr7:139345147 chr7:139359032~139359566:- LIHC cis rs2836974 0.897 rs35391055 ENSG00000255568.3 BRWD1-AS2 4.58 6.43e-06 0.00181 0.27 0.24 Cognitive function; chr21:39153590 chr21:39313935~39314962:+ LIHC cis rs2836974 0.897 rs2836924 ENSG00000255568.3 BRWD1-AS2 4.58 6.43e-06 0.00181 0.27 0.24 Cognitive function; chr21:39153713 chr21:39313935~39314962:+ LIHC cis rs2836974 0.897 rs4817996 ENSG00000255568.3 BRWD1-AS2 4.58 6.43e-06 0.00181 0.27 0.24 Cognitive function; chr21:39153833 chr21:39313935~39314962:+ LIHC cis rs2836974 0.897 rs6517513 ENSG00000255568.3 BRWD1-AS2 4.58 6.43e-06 0.00181 0.27 0.24 Cognitive function; chr21:39154952 chr21:39313935~39314962:+ LIHC cis rs2836974 0.899 rs6517514 ENSG00000255568.3 BRWD1-AS2 4.58 6.43e-06 0.00181 0.27 0.24 Cognitive function; chr21:39155169 chr21:39313935~39314962:+ LIHC cis rs2836974 0.829 rs8128191 ENSG00000255568.3 BRWD1-AS2 4.58 6.43e-06 0.00181 0.27 0.24 Cognitive function; chr21:39155385 chr21:39313935~39314962:+ LIHC cis rs1729407 0.659 rs2542050 ENSG00000236267.1 AP006216.5 4.58 6.44e-06 0.00181 0.23 0.24 Apolipoprotein A-IV levels; chr11:116826401 chr11:116813204~116814003:- LIHC cis rs1223397 1 rs1232392 ENSG00000215022.6 RP1-257A7.4 -4.58 6.44e-06 0.00181 -0.28 -0.24 Blood pressure; chr6:13272439 chr6:13264861~13295586:- LIHC cis rs5758511 0.68 rs56111723 ENSG00000205702.9 CYP2D7 4.58 6.44e-06 0.00181 0.28 0.24 Birth weight; chr22:42268877 chr22:42140203~42144577:- LIHC cis rs10510102 0.516 rs11200306 ENSG00000276742.1 RP11-500G22.4 4.58 6.45e-06 0.00181 0.38 0.24 Breast cancer; chr10:121980862 chr10:121956782~121957098:+ LIHC cis rs763121 0.853 rs2072798 ENSG00000273076.1 RP3-508I15.22 4.58 6.45e-06 0.00181 0.28 0.24 Menopause (age at onset); chr22:38752478 chr22:38743495~38743910:+ LIHC cis rs6921919 0.832 rs17312661 ENSG00000216901.1 AL022393.7 4.58 6.45e-06 0.00181 0.41 0.24 Autism spectrum disorder or schizophrenia; chr6:28332559 chr6:28176188~28176674:+ LIHC cis rs2337406 1 rs75651733 ENSG00000274576.2 IGHV2-70 -4.58 6.46e-06 0.00181 -0.28 -0.24 Alzheimer's disease (late onset); chr14:106701309 chr14:106770577~106771020:- LIHC cis rs7945705 0.935 rs2653567 ENSG00000254860.4 TMEM9B-AS1 4.58 6.46e-06 0.00181 0.23 0.24 Hemoglobin concentration; chr11:8868083 chr11:8964675~8977527:+ LIHC cis rs4660214 0.666 rs7554206 ENSG00000182109.6 RP11-69E11.4 -4.58 6.47e-06 0.00181 -0.25 -0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39463568 chr1:39522280~39546187:- LIHC cis rs12134133 1 rs7526831 ENSG00000274245.1 RP11-357P18.2 4.58 6.47e-06 0.00181 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207265261 chr1:207372559~207373252:+ LIHC cis rs11098499 0.754 rs938056 ENSG00000245958.5 RP11-33B1.1 -4.58 6.47e-06 0.00182 -0.25 -0.24 Corneal astigmatism; chr4:119316298 chr4:119454791~119552025:+ LIHC cis rs875971 0.642 rs35526611 ENSG00000273024.4 INTS4P2 4.58 6.47e-06 0.00182 0.27 0.24 Aortic root size; chr7:66629021 chr7:65647864~65715661:+ LIHC cis rs2932538 0.961 rs1238 ENSG00000225075.1 RP11-426L16.3 -4.58 6.47e-06 0.00182 -0.31 -0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112671475 chr1:112693688~112696621:- LIHC cis rs1555322 0.53 rs6058224 ENSG00000279253.1 RP4-614O4.13 -4.58 6.48e-06 0.00182 -0.32 -0.24 Attention deficit hyperactivity disorder; chr20:35293971 chr20:35262727~35264187:- LIHC cis rs1005277 0.563 rs2505215 ENSG00000276805.1 RP11-291L22.6 4.58 6.48e-06 0.00182 0.29 0.24 Extrinsic epigenetic age acceleration; chr10:38192345 chr10:38451030~38451785:+ LIHC cis rs1005277 0.563 rs2505216 ENSG00000276805.1 RP11-291L22.6 4.58 6.48e-06 0.00182 0.29 0.24 Extrinsic epigenetic age acceleration; chr10:38193902 chr10:38451030~38451785:+ LIHC cis rs1005277 0.563 rs2800550 ENSG00000276805.1 RP11-291L22.6 4.58 6.48e-06 0.00182 0.29 0.24 Extrinsic epigenetic age acceleration; chr10:38194001 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2749612 ENSG00000276805.1 RP11-291L22.6 4.58 6.48e-06 0.00182 0.29 0.24 Extrinsic epigenetic age acceleration; chr10:38199682 chr10:38451030~38451785:+ LIHC cis rs6801605 0.743 rs4687752 ENSG00000271916.1 RP11-884K10.6 -4.58 6.48e-06 0.00182 -0.31 -0.24 Blood protein levels; chr3:53850191 chr3:53797764~53798019:- LIHC cis rs11673344 0.67 rs73039188 ENSG00000226686.6 LINC01535 4.58 6.48e-06 0.00182 0.37 0.24 Obesity-related traits; chr19:36922449 chr19:37251912~37265535:+ LIHC cis rs2976388 0.647 rs2585154 ENSG00000253196.1 RP11-706C16.7 4.58 6.49e-06 0.00182 0.23 0.24 Urinary tract infection frequency; chr8:142702067 chr8:142763116~142766427:+ LIHC cis rs7246657 0.943 rs4802766 ENSG00000276846.1 CTD-3220F14.3 4.58 6.49e-06 0.00182 0.31 0.24 Coronary artery calcification; chr19:37491031 chr19:37314868~37315620:- LIHC cis rs748404 0.601 rs489964 ENSG00000205771.5 CATSPER2P1 4.58 6.49e-06 0.00182 0.29 0.24 Lung cancer; chr15:43225356 chr15:43726918~43747094:- LIHC cis rs2348418 0.8 rs6487667 ENSG00000247934.4 RP11-967K21.1 -4.58 6.5e-06 0.00182 -0.22 -0.24 Lung function (FEV1);Lung function (FVC); chr12:28195643 chr12:28163298~28190738:- LIHC cis rs2929278 0.588 rs688009 ENSG00000275601.1 AC011330.13 -4.58 6.5e-06 0.00182 -0.3 -0.24 Schizophrenia; chr15:43864104 chr15:43642389~43643023:- LIHC cis rs11722779 0.658 rs6533044 ENSG00000246560.2 RP11-10L12.4 4.58 6.5e-06 0.00182 0.27 0.24 Schizophrenia; chr4:102965261 chr4:102828055~102844075:+ LIHC cis rs712039 0.652 rs34711199 ENSG00000276054.1 RP11-378E13.3 4.58 6.51e-06 0.00182 0.3 0.24 Tuberculosis; chr17:37497933 chr17:37386886~37387926:+ LIHC cis rs875971 0.545 rs2173571 ENSG00000273142.1 RP11-458F8.4 4.58 6.51e-06 0.00182 0.23 0.24 Aortic root size; chr7:66305392 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs11770063 ENSG00000273142.1 RP11-458F8.4 4.58 6.51e-06 0.00182 0.23 0.24 Aortic root size; chr7:66318029 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs3936065 ENSG00000273142.1 RP11-458F8.4 4.58 6.51e-06 0.00182 0.23 0.24 Aortic root size; chr7:66325577 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs4718335 ENSG00000273142.1 RP11-458F8.4 4.58 6.51e-06 0.00182 0.23 0.24 Aortic root size; chr7:66339619 chr7:66902857~66906297:+ LIHC cis rs10129255 0.5 rs10142931 ENSG00000223648.3 IGHV3-64 4.58 6.51e-06 0.00183 0.17 0.24 Kawasaki disease; chr14:106782288 chr14:106643132~106658258:- LIHC cis rs2348418 0.701 rs6487670 ENSG00000247934.4 RP11-967K21.1 -4.58 6.51e-06 0.00183 -0.22 -0.24 Lung function (FEV1);Lung function (FVC); chr12:28210856 chr12:28163298~28190738:- LIHC cis rs1577917 1 rs955197 ENSG00000234155.1 RP11-30P6.6 4.58 6.51e-06 0.00183 0.32 0.24 Response to antipsychotic treatment; chr6:86019957 chr6:85387219~85390186:- LIHC cis rs2439831 1 rs689754 ENSG00000166763.7 STRCP1 4.58 6.52e-06 0.00183 0.34 0.24 Lung cancer in ever smokers; chr15:43483697 chr15:43699488~43718184:- LIHC cis rs3733589 1 rs3796831 ENSG00000250413.1 RP11-448G15.1 4.58 6.52e-06 0.00183 0.42 0.24 Renal overload gout; chr4:10014328 chr4:10006482~10009725:+ LIHC cis rs7121538 0.932 rs11023242 ENSG00000251991.1 RNU7-49P -4.58 6.52e-06 0.00183 -0.35 -0.24 HDL cholesterol; chr11:14507553 chr11:14478892~14478953:+ LIHC cis rs10129255 0.957 rs2007467 ENSG00000223648.3 IGHV3-64 -4.58 6.52e-06 0.00183 -0.18 -0.24 Kawasaki disease; chr14:106771605 chr14:106643132~106658258:- LIHC cis rs2749097 0.825 rs11208264 ENSG00000244256.3 RN7SL130P -4.58 6.52e-06 0.00183 -0.27 -0.24 Alcohol consumption (transferrin glycosylation); chr1:63659401 chr1:63655743~63656047:+ LIHC cis rs42490 0.837 rs218916 ENSG00000251136.7 RP11-37B2.1 -4.58 6.53e-06 0.00183 -0.22 -0.24 Leprosy; chr8:89688709 chr8:89609409~89757727:- LIHC cis rs77204473 0.557 rs9971422 ENSG00000254851.1 RP11-109L13.1 4.58 6.54e-06 0.00183 0.38 0.24 Sum eosinophil basophil counts;Eosinophil counts; chr11:116966657 chr11:117135528~117138582:+ LIHC cis rs7829975 0.688 rs7827182 ENSG00000253981.4 ALG1L13P 4.58 6.56e-06 0.00184 0.28 0.24 Mood instability; chr8:8522961 chr8:8236003~8244667:- LIHC cis rs10995505 0.589 rs2896496 ENSG00000232075.1 MRPL35P2 -4.58 6.56e-06 0.00184 -0.26 -0.24 Intelligence (multi-trait analysis); chr10:63123622 chr10:63634317~63634827:- LIHC cis rs17826219 0.706 rs2322197 ENSG00000266490.1 CTD-2349P21.9 4.58 6.56e-06 0.00184 0.3 0.24 Body mass index; chr17:30778787 chr17:30792372~30792833:+ LIHC cis rs11096990 0.613 rs9997015 ENSG00000249685.1 RP11-360F5.3 -4.58 6.56e-06 0.00184 -0.29 -0.24 Cognitive function; chr4:39222677 chr4:39133913~39135608:+ LIHC cis rs875971 0.522 rs2949690 ENSG00000224316.1 RP11-479O9.2 -4.58 6.57e-06 0.00184 -0.24 -0.24 Aortic root size; chr7:66018255 chr7:65773620~65802067:+ LIHC cis rs2932538 0.961 rs2932539 ENSG00000225075.1 RP11-426L16.3 -4.58 6.57e-06 0.00184 -0.31 -0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112673164 chr1:112693688~112696621:- LIHC cis rs2581828 0.656 rs2564921 ENSG00000242142.1 SERBP1P3 -4.58 6.57e-06 0.00184 -0.27 -0.24 Crohn's disease; chr3:53091569 chr3:53064283~53065091:- LIHC cis rs11971779 0.68 rs6978680 ENSG00000273391.1 RP11-634H22.1 -4.58 6.58e-06 0.00184 -0.21 -0.24 Diisocyanate-induced asthma; chr7:139427302 chr7:139359032~139359566:- LIHC cis rs5756813 0.646 rs875300 ENSG00000233360.4 Z83844.1 -4.58 6.58e-06 0.00184 -0.29 -0.24 Optic cup area;Vertical cup-disc ratio; chr22:37761798 chr22:37641832~37658377:- LIHC cis rs12701220 0.894 rs12701348 ENSG00000229043.2 AC091729.9 -4.58 6.58e-06 0.00184 -0.33 -0.24 Bronchopulmonary dysplasia; chr7:999821 chr7:1160374~1165267:+ LIHC cis rs17507216 0.591 rs7163848 ENSG00000278603.1 RP13-608F4.5 4.58 6.59e-06 0.00184 0.48 0.24 Excessive daytime sleepiness; chr15:82729563 chr15:82472203~82472426:+ LIHC cis rs1823913 0.892 rs35596292 ENSG00000227542.1 AC092614.2 4.58 6.59e-06 0.00185 0.25 0.24 Obesity-related traits; chr2:191246890 chr2:191229165~191246172:- LIHC cis rs9675120 0.675 rs8072476 ENSG00000262006.1 RP11-700H6.4 -4.58 6.6e-06 0.00185 -0.26 -0.24 Cerebrospinal fluid biomarker levels; chr17:50845858 chr17:50909637~50910232:- LIHC cis rs2243480 1 rs73142166 ENSG00000230295.1 RP11-458F8.2 -4.58 6.6e-06 0.00185 -0.26 -0.24 Diabetic kidney disease; chr7:65910845 chr7:66880708~66882981:+ LIHC cis rs17818399 0.548 rs1989720 ENSG00000279254.1 RP11-536C12.1 -4.58 6.6e-06 0.00185 -0.28 -0.24 Height; chr2:46627225 chr2:46668870~46670778:+ LIHC cis rs950169 0.881 rs150965 ENSG00000259728.4 LINC00933 4.58 6.6e-06 0.00185 0.35 0.24 Schizophrenia; chr15:84537296 chr15:84570649~84580175:+ LIHC cis rs2274273 0.553 rs56166765 ENSG00000258413.1 RP11-665C16.6 -4.58 6.6e-06 0.00185 -0.29 -0.24 Protein biomarker; chr14:55271300 chr14:55262767~55272075:- LIHC cis rs11096990 0.613 rs6829660 ENSG00000249685.1 RP11-360F5.3 4.58 6.62e-06 0.00185 0.29 0.24 Cognitive function; chr4:39280943 chr4:39133913~39135608:+ LIHC cis rs2739330 0.791 rs4822458 ENSG00000206090.4 AP000350.7 4.58 6.63e-06 0.00185 0.28 0.24 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23939998~23942798:+ LIHC cis rs5758511 0.596 rs55644935 ENSG00000205702.9 CYP2D7 4.58 6.63e-06 0.00185 0.28 0.24 Birth weight; chr22:42270063 chr22:42140203~42144577:- LIHC cis rs367615 0.537 rs1965670 ENSG00000249476.1 CTD-2587M2.1 -4.58 6.63e-06 0.00186 -0.28 -0.24 Colorectal cancer (SNP x SNP interaction); chr5:109314097 chr5:109237120~109326369:- LIHC cis rs2749097 0.825 rs11208260 ENSG00000244256.3 RN7SL130P -4.58 6.63e-06 0.00186 -0.28 -0.24 Alcohol consumption (transferrin glycosylation); chr1:63657608 chr1:63655743~63656047:+ LIHC cis rs2243480 1 rs4718333 ENSG00000230295.1 RP11-458F8.2 4.58 6.64e-06 0.00186 0.25 0.24 Diabetic kidney disease; chr7:66307771 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs7792391 ENSG00000230295.1 RP11-458F8.2 4.58 6.64e-06 0.00186 0.25 0.24 Diabetic kidney disease; chr7:66308442 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs10247526 ENSG00000230295.1 RP11-458F8.2 4.58 6.64e-06 0.00186 0.25 0.24 Diabetic kidney disease; chr7:66315709 chr7:66880708~66882981:+ LIHC cis rs2243480 0.908 rs1532573 ENSG00000230295.1 RP11-458F8.2 4.58 6.64e-06 0.00186 0.25 0.24 Diabetic kidney disease; chr7:66333815 chr7:66880708~66882981:+ LIHC cis rs10829156 0.699 rs1917209 ENSG00000225527.1 RP11-383B4.4 -4.58 6.65e-06 0.00186 -0.39 -0.24 Sudden cardiac arrest; chr10:18543631 chr10:18531849~18533336:- LIHC cis rs7809950 1 rs2808 ENSG00000238832.1 snoU109 4.58 6.65e-06 0.00186 0.29 0.24 Coronary artery disease; chr7:107620411 chr7:107603363~107603507:+ LIHC cis rs2929278 0.589 rs11638972 ENSG00000166763.7 STRCP1 -4.58 6.65e-06 0.00186 -0.3 -0.24 Schizophrenia; chr15:43782493 chr15:43699488~43718184:- LIHC cis rs12134133 1 rs11584921 ENSG00000274245.1 RP11-357P18.2 4.58 6.65e-06 0.00186 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207268630 chr1:207372559~207373252:+ LIHC cis rs1729407 0.565 rs2849173 ENSG00000236267.1 AP006216.5 4.58 6.66e-06 0.00186 0.23 0.24 Apolipoprotein A-IV levels; chr11:116826605 chr11:116813204~116814003:- LIHC cis rs12554020 0.786 rs6479495 ENSG00000227603.1 RP11-165J3.6 4.58 6.66e-06 0.00186 0.33 0.24 Schizophrenia; chr9:93572320 chr9:93435332~93437121:- LIHC cis rs4713118 0.669 rs200997 ENSG00000216901.1 AL022393.7 4.58 6.66e-06 0.00186 0.3 0.24 Parkinson's disease; chr6:27844037 chr6:28176188~28176674:+ LIHC cis rs2976388 0.609 rs2717603 ENSG00000253741.1 CTD-2292P10.4 -4.58 6.66e-06 0.00186 -0.27 -0.24 Urinary tract infection frequency; chr8:142721775 chr8:142702252~142726973:- LIHC cis rs172166 0.694 rs203893 ENSG00000216901.1 AL022393.7 4.58 6.67e-06 0.00186 0.31 0.24 Cardiac Troponin-T levels; chr6:28094288 chr6:28176188~28176674:+ LIHC cis rs172166 0.652 rs476167 ENSG00000216901.1 AL022393.7 4.58 6.67e-06 0.00186 0.31 0.24 Cardiac Troponin-T levels; chr6:28098110 chr6:28176188~28176674:+ LIHC cis rs172166 0.694 rs203892 ENSG00000216901.1 AL022393.7 4.58 6.67e-06 0.00186 0.31 0.24 Cardiac Troponin-T levels; chr6:28099418 chr6:28176188~28176674:+ LIHC cis rs172166 0.694 rs188105 ENSG00000216901.1 AL022393.7 4.58 6.67e-06 0.00186 0.31 0.24 Cardiac Troponin-T levels; chr6:28103615 chr6:28176188~28176674:+ LIHC cis rs950169 0.922 rs17531523 ENSG00000259728.4 LINC00933 4.58 6.67e-06 0.00186 0.35 0.24 Schizophrenia; chr15:84589218 chr15:84570649~84580175:+ LIHC cis rs7923609 0.812 rs10761753 ENSG00000232075.1 MRPL35P2 -4.58 6.67e-06 0.00186 -0.27 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63402143 chr10:63634317~63634827:- LIHC cis rs2337406 0.714 rs2337463 ENSG00000274576.2 IGHV2-70 -4.57 6.67e-06 0.00187 -0.27 -0.24 Alzheimer's disease (late onset); chr14:106816066 chr14:106770577~106771020:- LIHC cis rs10129255 0.828 rs10140989 ENSG00000223648.3 IGHV3-64 4.57 6.67e-06 0.00187 0.19 0.24 Kawasaki disease; chr14:106668657 chr14:106643132~106658258:- LIHC cis rs58950470 0.887 rs1784223 ENSG00000265874.1 MIR4489 4.57 6.68e-06 0.00187 0.34 0.24 Schizophrenia; chr11:65612777 chr11:65649192~65649253:+ LIHC cis rs3733589 0.744 rs7685958 ENSG00000250413.1 RP11-448G15.1 4.57 6.69e-06 0.00187 0.39 0.24 Renal overload gout; chr4:10041226 chr4:10006482~10009725:+ LIHC cis rs748404 0.65 rs518234 ENSG00000166763.7 STRCP1 4.57 6.69e-06 0.00187 0.3 0.24 Lung cancer; chr15:43281223 chr15:43699488~43718184:- LIHC cis rs748404 0.65 rs518261 ENSG00000166763.7 STRCP1 4.57 6.69e-06 0.00187 0.3 0.24 Lung cancer; chr15:43281231 chr15:43699488~43718184:- LIHC cis rs11098499 0.779 rs7674500 ENSG00000245958.5 RP11-33B1.1 -4.57 6.7e-06 0.00187 -0.25 -0.24 Corneal astigmatism; chr4:119382438 chr4:119454791~119552025:+ LIHC cis rs11098499 0.865 rs4507344 ENSG00000245958.5 RP11-33B1.1 -4.57 6.7e-06 0.00187 -0.25 -0.24 Corneal astigmatism; chr4:119386330 chr4:119454791~119552025:+ LIHC cis rs11098499 0.697 rs4373140 ENSG00000245958.5 RP11-33B1.1 -4.57 6.7e-06 0.00187 -0.25 -0.24 Corneal astigmatism; chr4:119386543 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs13113483 ENSG00000245958.5 RP11-33B1.1 -4.57 6.7e-06 0.00187 -0.25 -0.24 Corneal astigmatism; chr4:119387884 chr4:119454791~119552025:+ LIHC cis rs11098499 0.542 rs10440343 ENSG00000245958.5 RP11-33B1.1 -4.57 6.7e-06 0.00187 -0.25 -0.24 Corneal astigmatism; chr4:119388632 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs28668716 ENSG00000245958.5 RP11-33B1.1 -4.57 6.7e-06 0.00187 -0.25 -0.24 Corneal astigmatism; chr4:119388720 chr4:119454791~119552025:+ LIHC cis rs11098499 0.542 rs7677836 ENSG00000245958.5 RP11-33B1.1 -4.57 6.7e-06 0.00187 -0.25 -0.24 Corneal astigmatism; chr4:119389483 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs10002083 ENSG00000245958.5 RP11-33B1.1 -4.57 6.7e-06 0.00187 -0.25 -0.24 Corneal astigmatism; chr4:119389997 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs10024844 ENSG00000245958.5 RP11-33B1.1 -4.57 6.7e-06 0.00187 -0.25 -0.24 Corneal astigmatism; chr4:119390373 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs4345162 ENSG00000245958.5 RP11-33B1.1 -4.57 6.7e-06 0.00187 -0.25 -0.24 Corneal astigmatism; chr4:119391804 chr4:119454791~119552025:+ LIHC cis rs11098499 0.657 rs4463052 ENSG00000245958.5 RP11-33B1.1 -4.57 6.7e-06 0.00187 -0.25 -0.24 Corneal astigmatism; chr4:119392103 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs13151285 ENSG00000245958.5 RP11-33B1.1 -4.57 6.7e-06 0.00187 -0.25 -0.24 Corneal astigmatism; chr4:119393586 chr4:119454791~119552025:+ LIHC cis rs4650994 0.816 rs2811301 ENSG00000273384.1 RP5-1098D14.1 -4.57 6.7e-06 0.00187 -0.28 -0.24 HDL cholesterol;HDL cholesterol levels; chr1:178625061 chr1:178651706~178652282:+ LIHC cis rs2439831 0.85 rs12441861 ENSG00000166763.7 STRCP1 4.57 6.71e-06 0.00187 0.37 0.24 Lung cancer in ever smokers; chr15:43768685 chr15:43699488~43718184:- LIHC cis rs6565180 0.926 rs4788413 ENSG00000183604.13 SMG1P5 4.57 6.72e-06 0.00188 0.26 0.24 Tonsillectomy; chr16:30399124 chr16:30267553~30335374:- LIHC cis rs6061231 0.518 rs639836 ENSG00000273619.1 RP5-908M14.9 4.57 6.72e-06 0.00188 0.19 0.24 Colorectal cancer; chr20:62351167 chr20:62386303~62386970:- LIHC cis rs2243480 1 rs56016656 ENSG00000230295.1 RP11-458F8.2 -4.57 6.73e-06 0.00188 -0.26 -0.24 Diabetic kidney disease; chr7:65918494 chr7:66880708~66882981:+ LIHC cis rs2243480 0.803 rs55700941 ENSG00000230295.1 RP11-458F8.2 -4.57 6.73e-06 0.00188 -0.26 -0.24 Diabetic kidney disease; chr7:65924813 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs36033484 ENSG00000230295.1 RP11-458F8.2 -4.57 6.73e-06 0.00188 -0.26 -0.24 Diabetic kidney disease; chr7:65925571 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs34193460 ENSG00000230295.1 RP11-458F8.2 -4.57 6.73e-06 0.00188 -0.26 -0.24 Diabetic kidney disease; chr7:65928123 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs34560516 ENSG00000230295.1 RP11-458F8.2 -4.57 6.73e-06 0.00188 -0.26 -0.24 Diabetic kidney disease; chr7:65939105 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs57057549 ENSG00000230295.1 RP11-458F8.2 -4.57 6.73e-06 0.00188 -0.26 -0.24 Diabetic kidney disease; chr7:65940751 chr7:66880708~66882981:+ LIHC cis rs2243480 0.808 rs12698508 ENSG00000230295.1 RP11-458F8.2 -4.57 6.73e-06 0.00188 -0.26 -0.24 Diabetic kidney disease; chr7:65946971 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs2961102 ENSG00000230295.1 RP11-458F8.2 -4.57 6.73e-06 0.00188 -0.26 -0.24 Diabetic kidney disease; chr7:65959671 chr7:66880708~66882981:+ LIHC cis rs5756813 0.754 rs4820307 ENSG00000233360.4 Z83844.1 4.57 6.73e-06 0.00188 0.31 0.24 Optic cup area;Vertical cup-disc ratio; chr22:37779948 chr22:37641832~37658377:- LIHC cis rs5756813 0.754 rs4820308 ENSG00000233360.4 Z83844.1 4.57 6.73e-06 0.00188 0.31 0.24 Optic cup area;Vertical cup-disc ratio; chr22:37780209 chr22:37641832~37658377:- LIHC cis rs929596 0.561 rs6431625 ENSG00000233445.1 RPL17P11 4.57 6.73e-06 0.00188 0.28 0.24 Total bilirubin levels in HIV-1 infection; chr2:233729266 chr2:233721522~233722065:- LIHC cis rs2948294 0.588 rs4840913 ENSG00000253893.2 FAM85B -4.57 6.73e-06 0.00188 -0.28 -0.24 Red cell distribution width; chr8:8259384 chr8:8167819~8226614:- LIHC cis rs287982 1 rs72780999 ENSG00000269973.1 RP11-95D17.1 -4.57 6.74e-06 0.00188 -0.23 -0.24 Nonsyndromic cleft lip with cleft palate; chr2:9841841 chr2:9936360~9939590:+ LIHC cis rs1150668 0.699 rs2394049 ENSG00000204709.4 LINC01556 4.57 6.74e-06 0.00188 0.26 0.24 Pubertal anthropometrics; chr6:28271903 chr6:28943877~28944537:+ LIHC cis rs17301013 0.896 rs3118980 ENSG00000227373.4 RP11-160H22.5 -4.57 6.75e-06 0.00188 -0.29 -0.24 Systemic lupus erythematosus; chr1:174793701 chr1:174115300~174160004:- LIHC cis rs7709377 0.516 rs56322212 ENSG00000271918.1 CTD-2287O16.5 4.57 6.75e-06 0.00188 0.29 0.24 Metabolite levels (X-11787); chr5:116161992 chr5:116083807~116085416:- LIHC cis rs67311347 1 rs2305522 ENSG00000223797.4 ENTPD3-AS1 4.57 6.75e-06 0.00188 0.19 0.24 Renal cell carcinoma; chr3:40387867 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs7636719 ENSG00000223797.4 ENTPD3-AS1 4.57 6.75e-06 0.00188 0.19 0.24 Renal cell carcinoma; chr3:40390593 chr3:40313802~40453329:- LIHC cis rs11971779 0.878 rs4732378 ENSG00000273391.1 RP11-634H22.1 4.57 6.75e-06 0.00188 0.24 0.24 Diisocyanate-induced asthma; chr7:139435649 chr7:139359032~139359566:- LIHC cis rs8028182 0.636 rs8028277 ENSG00000260269.4 CTD-2323K18.1 -4.57 6.75e-06 0.00188 -0.3 -0.24 Sudden cardiac arrest; chr15:75391744 chr15:75527150~75601205:- LIHC cis rs4356203 0.543 rs214088 ENSG00000260196.1 RP1-239B22.5 -4.57 6.75e-06 0.00188 -0.29 -0.24 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17276578 chr11:17380649~17383531:+ LIHC cis rs4356203 0.519 rs214084 ENSG00000260196.1 RP1-239B22.5 -4.57 6.75e-06 0.00188 -0.29 -0.24 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17277267 chr11:17380649~17383531:+ LIHC cis rs4356203 0.519 rs214082 ENSG00000260196.1 RP1-239B22.5 -4.57 6.75e-06 0.00188 -0.29 -0.24 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17277843 chr11:17380649~17383531:+ LIHC cis rs728616 0.867 rs17606361 ENSG00000225484.5 NUTM2B-AS1 -4.57 6.75e-06 0.00188 -0.54 -0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80085655 chr10:79663088~79826594:- LIHC cis rs728616 0.764 rs61859016 ENSG00000225484.5 NUTM2B-AS1 -4.57 6.75e-06 0.00188 -0.54 -0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80092744 chr10:79663088~79826594:- LIHC cis rs11098499 0.754 rs12711071 ENSG00000245958.5 RP11-33B1.1 -4.57 6.77e-06 0.00189 -0.25 -0.24 Corneal astigmatism; chr4:119319779 chr4:119454791~119552025:+ LIHC cis rs11089937 0.559 rs2330014 ENSG00000211639.2 IGLV4-60 4.57 6.77e-06 0.00189 0.21 0.24 Periodontitis (PAL4Q3); chr22:22166155 chr22:22162199~22162681:+ LIHC cis rs3091242 0.933 rs10903130 ENSG00000224183.1 SDHDP6 -4.57 6.78e-06 0.00189 -0.28 -0.24 Erythrocyte sedimentation rate; chr1:25442730 chr1:25294164~25294643:- LIHC cis rs3091242 0.933 rs11249251 ENSG00000224183.1 SDHDP6 -4.57 6.78e-06 0.00189 -0.28 -0.24 Erythrocyte sedimentation rate; chr1:25443697 chr1:25294164~25294643:- LIHC cis rs2276314 0.857 rs8087539 ENSG00000278986.1 RP11-723J4.3 -4.57 6.78e-06 0.00189 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36051574 chr18:35972151~35973916:+ LIHC cis rs17270561 0.943 rs4478398 ENSG00000216436.2 HIST1H2APS1 -4.57 6.79e-06 0.00189 -0.38 -0.24 Iron status biomarkers; chr6:25694456 chr6:25732497~25732827:+ LIHC cis rs10995505 0.589 rs4601646 ENSG00000232075.1 MRPL35P2 -4.57 6.79e-06 0.00189 -0.26 -0.24 Intelligence (multi-trait analysis); chr10:63120520 chr10:63634317~63634827:- LIHC cis rs11098499 0.954 rs12505469 ENSG00000245958.5 RP11-33B1.1 -4.57 6.8e-06 0.0019 -0.25 -0.24 Corneal astigmatism; chr4:119328430 chr4:119454791~119552025:+ LIHC cis rs227275 0.554 rs223421 ENSG00000246560.2 RP11-10L12.4 4.57 6.81e-06 0.0019 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102805861 chr4:102828055~102844075:+ LIHC cis rs75920871 0.609 rs1473177 ENSG00000254851.1 RP11-109L13.1 -4.57 6.81e-06 0.0019 -0.49 -0.24 Subjective well-being; chr11:116888616 chr11:117135528~117138582:+ LIHC cis rs10871290 0.881 rs4099290 ENSG00000261079.1 RP11-252A24.3 -4.57 6.81e-06 0.0019 -0.28 -0.24 Breast cancer; chr16:74434991 chr16:74367462~74369826:+ LIHC cis rs528808 1 rs528808 ENSG00000219755.1 RP1-199J3.5 4.57 6.82e-06 0.0019 0.45 0.24 Age-related hearing impairment; chr6:99656413 chr6:99575712~99576456:+ LIHC cis rs2562456 0.876 rs62110202 ENSG00000268555.1 RP11-678G14.3 4.57 6.82e-06 0.0019 0.31 0.24 Pain; chr19:21571799 chr19:21570822~21587322:- LIHC cis rs6921919 0.887 rs7766356 ENSG00000216901.1 AL022393.7 4.57 6.83e-06 0.0019 0.42 0.24 Autism spectrum disorder or schizophrenia; chr6:28432761 chr6:28176188~28176674:+ LIHC cis rs755249 0.508 rs10888688 ENSG00000182109.6 RP11-69E11.4 -4.57 6.83e-06 0.0019 -0.25 -0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39171633 chr1:39522280~39546187:- LIHC cis rs733592 0.507 rs56129148 ENSG00000240399.1 RP1-228P16.1 -4.57 6.83e-06 0.0019 -0.23 -0.24 Plateletcrit; chr12:48091747 chr12:48054813~48055591:- LIHC cis rs957448 0.904 rs56302978 ENSG00000253704.1 RP11-267M23.4 4.57 6.83e-06 0.0019 0.29 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94505883 chr8:94553722~94569745:+ LIHC cis rs9903692 0.865 rs7220520 ENSG00000278765.1 RP5-890E16.5 4.57 6.83e-06 0.0019 0.3 0.24 Pulse pressure; chr17:48090580 chr17:48066704~48067293:- LIHC cis rs2877649 1 rs2076946 ENSG00000258744.1 RP11-80A15.1 -4.57 6.83e-06 0.0019 -0.47 -0.24 Smooth-surface caries; chr14:24482617 chr14:24501594~24508688:+ LIHC cis rs4660214 0.724 rs11205695 ENSG00000182109.6 RP11-69E11.4 -4.57 6.84e-06 0.0019 -0.25 -0.24 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39155285 chr1:39522280~39546187:- LIHC cis rs3733589 1 rs4345181 ENSG00000250413.1 RP11-448G15.1 4.57 6.85e-06 0.00191 0.42 0.24 Renal overload gout; chr4:10025240 chr4:10006482~10009725:+ LIHC cis rs1520333 0.602 rs967426 ENSG00000254352.1 RP11-578O24.2 4.57 6.86e-06 0.00191 0.25 0.24 Multiple sclerosis; chr8:78585664 chr8:78723796~78724136:- LIHC cis rs2834188 0.889 rs1467849 ENSG00000272659.1 AP000295.10 -4.57 6.86e-06 0.00191 -0.35 -0.24 Narcolepsy; chr21:33309764 chr21:33309491~33310181:+ LIHC cis rs7714584 1 rs7734778 ENSG00000197083.10 ZNF300P1 4.57 6.87e-06 0.00191 0.36 0.24 Crohn's disease; chr5:150876994 chr5:150930645~150946289:- LIHC cis rs172166 0.694 rs203877 ENSG00000216901.1 AL022393.7 4.57 6.87e-06 0.00191 0.31 0.24 Cardiac Troponin-T levels; chr6:28080846 chr6:28176188~28176674:+ LIHC cis rs2749097 0.825 rs2658432 ENSG00000244256.3 RN7SL130P -4.57 6.87e-06 0.00191 -0.28 -0.24 Alcohol consumption (transferrin glycosylation); chr1:63659153 chr1:63655743~63656047:+ LIHC cis rs2749097 0.825 rs2819176 ENSG00000244256.3 RN7SL130P -4.57 6.87e-06 0.00191 -0.28 -0.24 Alcohol consumption (transferrin glycosylation); chr1:63659159 chr1:63655743~63656047:+ LIHC cis rs67311347 1 rs6599094 ENSG00000223797.4 ENTPD3-AS1 4.57 6.88e-06 0.00191 0.19 0.24 Renal cell carcinoma; chr3:40358102 chr3:40313802~40453329:- LIHC cis rs7429990 0.864 rs2049301 ENSG00000229759.1 MRPS18AP1 -4.57 6.88e-06 0.00191 -0.25 -0.24 Educational attainment (years of education); chr3:47681369 chr3:48256350~48256938:- LIHC cis rs556990 0.574 rs473598 ENSG00000269125.1 RP11-98F14.11 -4.57 6.88e-06 0.00191 -0.28 -0.24 Blood protein levels; chr13:113146875 chr13:113165002~113165183:- LIHC cis rs7727544 0.684 rs272874 ENSG00000233006.5 AC034220.3 -4.57 6.88e-06 0.00191 -0.25 -0.24 Blood metabolite levels; chr5:132339353 chr5:132311285~132369916:- LIHC cis rs7829975 0.742 rs12547493 ENSG00000173295.6 FAM86B3P -4.57 6.89e-06 0.00192 -0.32 -0.24 Mood instability; chr8:8804024 chr8:8228595~8244865:+ LIHC cis rs12931792 0.682 rs12373113 ENSG00000183604.13 SMG1P5 4.57 6.89e-06 0.00192 0.22 0.24 Tonsillectomy; chr16:30176192 chr16:30267553~30335374:- LIHC cis rs12931792 0.682 rs12373078 ENSG00000183604.13 SMG1P5 4.57 6.89e-06 0.00192 0.22 0.24 Tonsillectomy; chr16:30176355 chr16:30267553~30335374:- LIHC cis rs75920871 0.688 rs76972960 ENSG00000254851.1 RP11-109L13.1 -4.57 6.89e-06 0.00192 -0.51 -0.24 Subjective well-being; chr11:117045962 chr11:117135528~117138582:+ LIHC cis rs929596 0.517 rs1875263 ENSG00000233445.1 RPL17P11 4.57 6.89e-06 0.00192 0.28 0.24 Total bilirubin levels in HIV-1 infection; chr2:233716976 chr2:233721522~233722065:- LIHC cis rs4964805 0.549 rs1976256 ENSG00000257681.1 RP11-341G23.4 4.57 6.89e-06 0.00192 0.25 0.24 Attention deficit hyperactivity disorder; chr12:103763121 chr12:103746315~103768858:- LIHC cis rs67311347 0.955 rs9821036 ENSG00000223797.4 ENTPD3-AS1 4.57 6.9e-06 0.00192 0.19 0.24 Renal cell carcinoma; chr3:40337516 chr3:40313802~40453329:- LIHC cis rs957448 1 rs72674861 ENSG00000253704.1 RP11-267M23.4 4.57 6.9e-06 0.00192 0.29 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94550051 chr8:94553722~94569745:+ LIHC cis rs4578769 0.765 rs35998712 ENSG00000266850.1 RP11-370A5.1 -4.57 6.9e-06 0.00192 -0.29 -0.24 Eosinophil percentage of white cells; chr18:22873654 chr18:22723491~22907721:- LIHC cis rs2739330 0.796 rs5760106 ENSG00000206090.4 AP000350.7 -4.57 6.91e-06 0.00192 -0.27 -0.24 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23939998~23942798:+ LIHC cis rs7193541 0.965 rs4402594 ENSG00000262904.1 TMPOP2 -4.57 6.91e-06 0.00192 -0.21 -0.24 Multiple myeloma; chr16:74667462 chr16:74667506~74668706:+ LIHC cis rs2976388 0.609 rs2572909 ENSG00000253741.1 CTD-2292P10.4 -4.57 6.91e-06 0.00192 -0.27 -0.24 Urinary tract infection frequency; chr8:142725046 chr8:142702252~142726973:- LIHC cis rs2976388 0.609 rs2585140 ENSG00000253741.1 CTD-2292P10.4 -4.57 6.91e-06 0.00192 -0.27 -0.24 Urinary tract infection frequency; chr8:142725478 chr8:142702252~142726973:- LIHC cis rs12304921 0.683 rs12582592 ENSG00000277201.1 AC087884.1 4.57 6.92e-06 0.00192 0.28 0.24 Type 2 diabetes; chr12:51119825 chr12:51049921~51050025:+ LIHC cis rs4964805 0.549 rs2292682 ENSG00000257681.1 RP11-341G23.4 4.57 6.93e-06 0.00192 0.25 0.24 Attention deficit hyperactivity disorder; chr12:103762742 chr12:103746315~103768858:- LIHC cis rs2276314 0.857 rs16967327 ENSG00000278986.1 RP11-723J4.3 -4.57 6.93e-06 0.00192 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36007073 chr18:35972151~35973916:+ LIHC cis rs17301013 0.729 rs12094143 ENSG00000227373.4 RP11-160H22.5 4.57 6.93e-06 0.00193 0.29 0.24 Systemic lupus erythematosus; chr1:174511986 chr1:174115300~174160004:- LIHC cis rs763121 0.853 rs1062687 ENSG00000273076.1 RP3-508I15.22 4.57 6.93e-06 0.00193 0.27 0.24 Menopause (age at onset); chr22:38738710 chr22:38743495~38743910:+ LIHC cis rs858239 0.699 rs1881201 ENSG00000226816.2 AC005082.12 -4.57 6.94e-06 0.00193 -0.31 -0.24 Cerebrospinal fluid biomarker levels; chr7:23154394 chr7:23206013~23208045:+ LIHC cis rs30380 1 rs151964 ENSG00000272109.1 CTD-2260A17.3 -4.57 6.94e-06 0.00193 -0.3 -0.24 Cerebrospinal fluid biomarker levels; chr5:96787963 chr5:96804353~96806105:+ LIHC cis rs8028182 0.636 rs8036884 ENSG00000260269.4 CTD-2323K18.1 -4.57 6.94e-06 0.00193 -0.3 -0.24 Sudden cardiac arrest; chr15:75570552 chr15:75527150~75601205:- LIHC cis rs8028182 0.636 rs4075522 ENSG00000260269.4 CTD-2323K18.1 -4.57 6.94e-06 0.00193 -0.3 -0.24 Sudden cardiac arrest; chr15:75571994 chr15:75527150~75601205:- LIHC cis rs651907 0.557 rs34181125 ENSG00000244119.1 PDCL3P4 4.57 6.94e-06 0.00193 0.25 0.24 Colorectal cancer; chr3:101771434 chr3:101712472~101713191:+ LIHC cis rs12291225 0.877 rs2303974 ENSG00000251991.1 RNU7-49P 4.57 6.94e-06 0.00193 0.26 0.24 Sense of smell; chr11:14243433 chr11:14478892~14478953:+ LIHC cis rs748404 0.631 rs7167882 ENSG00000205771.5 CATSPER2P1 -4.57 6.94e-06 0.00193 -0.29 -0.24 Lung cancer; chr15:43386465 chr15:43726918~43747094:- LIHC cis rs603446 0.967 rs180340 ENSG00000254851.1 RP11-109L13.1 -4.57 6.95e-06 0.00193 -0.3 -0.24 Triglycerides; chr11:116745686 chr11:117135528~117138582:+ LIHC cis rs7714584 1 rs6875011 ENSG00000197083.10 ZNF300P1 4.57 6.95e-06 0.00193 0.38 0.24 Crohn's disease; chr5:150803148 chr5:150930645~150946289:- LIHC cis rs2243480 1 rs35820085 ENSG00000230295.1 RP11-458F8.2 -4.57 6.95e-06 0.00193 -0.26 -0.24 Diabetic kidney disease; chr7:65977771 chr7:66880708~66882981:+ LIHC cis rs957448 0.796 rs72674824 ENSG00000253704.1 RP11-267M23.4 4.57 6.95e-06 0.00193 0.29 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94477053 chr8:94553722~94569745:+ LIHC cis rs5758511 0.68 rs1107554 ENSG00000205702.9 CYP2D7 4.57 6.95e-06 0.00193 0.28 0.24 Birth weight; chr22:42271588 chr22:42140203~42144577:- LIHC cis rs957448 1 rs12543207 ENSG00000253704.1 RP11-267M23.4 4.57 6.95e-06 0.00193 0.29 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94485202 chr8:94553722~94569745:+ LIHC cis rs11710088 0.707 rs35551531 ENSG00000244503.1 RP11-278L15.6 4.57 6.96e-06 0.00193 0.25 0.24 QRS duration; chr3:149489199 chr3:149494660~149495995:+ LIHC cis rs7246657 0.943 rs7259968 ENSG00000276846.1 CTD-3220F14.3 4.57 6.96e-06 0.00193 0.29 0.24 Coronary artery calcification; chr19:37320952 chr19:37314868~37315620:- LIHC cis rs9467711 0.591 rs60512607 ENSG00000216436.2 HIST1H2APS1 4.57 6.96e-06 0.00193 0.62 0.24 Autism spectrum disorder or schizophrenia; chr6:26053943 chr6:25732497~25732827:+ LIHC cis rs3893377 0.848 rs3893376 ENSG00000214846.4 RP11-115L11.1 4.57 6.96e-06 0.00193 0.3 0.24 Current cigarettes per day in chronic obstructive pulmonary disease; chr4:15740451 chr4:15730962~15731627:- LIHC cis rs3091242 0.935 rs4233043 ENSG00000224183.1 SDHDP6 -4.57 6.96e-06 0.00193 -0.28 -0.24 Erythrocyte sedimentation rate; chr1:25438992 chr1:25294164~25294643:- LIHC cis rs240993 0.909 rs11153279 ENSG00000271789.1 RP5-1112D6.7 4.57 6.97e-06 0.00194 0.24 0.24 Inflammatory skin disease;Psoriasis; chr6:111266063 chr6:111297126~111298510:+ LIHC cis rs748404 0.697 rs498227 ENSG00000166763.7 STRCP1 4.56 6.98e-06 0.00194 0.3 0.24 Lung cancer; chr15:43280854 chr15:43699488~43718184:- LIHC cis rs2243480 0.901 rs778732 ENSG00000230295.1 RP11-458F8.2 -4.56 6.98e-06 0.00194 -0.25 -0.24 Diabetic kidney disease; chr7:66357373 chr7:66880708~66882981:+ LIHC cis rs9318086 0.935 rs2025701 ENSG00000205861.10 C1QTNF9B-AS1 -4.56 6.98e-06 0.00194 -0.27 -0.24 Myopia (pathological); chr13:23866442 chr13:23888889~23897263:+ LIHC cis rs67311347 1 rs10510708 ENSG00000223797.4 ENTPD3-AS1 4.56 6.98e-06 0.00194 0.19 0.24 Renal cell carcinoma; chr3:40363279 chr3:40313802~40453329:- LIHC cis rs6997458 0.742 rs6988475 ENSG00000253549.4 RP11-317J10.2 4.56 6.98e-06 0.00194 0.26 0.24 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85471039 chr8:85441851~85464915:- LIHC cis rs11064837 0.504 rs2393522 ENSG00000248636.5 RP11-768F21.1 4.56 6.98e-06 0.00194 0.38 0.24 Schizophrenia; chr12:119617552 chr12:119387987~119668079:- LIHC cis rs916888 0.61 rs199438 ENSG00000260075.1 NSFP1 4.56 6.98e-06 0.00194 0.29 0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:46372855~46487141:+ LIHC cis rs651907 0.557 rs3094297 ENSG00000244119.1 PDCL3P4 4.56 7e-06 0.00194 0.24 0.24 Colorectal cancer; chr3:101680416 chr3:101712472~101713191:+ LIHC cis rs3015497 0.653 rs2356455 ENSG00000269906.1 RP11-248J18.2 4.56 7e-06 0.00194 0.3 0.24 Mean platelet volume; chr14:50626424 chr14:50662511~50663178:- LIHC cis rs916888 0.61 rs199529 ENSG00000274883.1 Metazoa_SRP -4.56 7e-06 0.00194 -0.36 -0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:45931806~45932083:+ LIHC cis rs875971 0.545 rs73146609 ENSG00000273142.1 RP11-458F8.4 4.56 7.01e-06 0.00194 0.23 0.24 Aortic root size; chr7:66302477 chr7:66902857~66906297:+ LIHC cis rs7937890 0.559 rs2597196 ENSG00000251991.1 RNU7-49P -4.56 7.02e-06 0.00195 -0.26 -0.24 Mitochondrial DNA levels; chr11:14470055 chr11:14478892~14478953:+ LIHC cis rs2310173 0.966 rs7588933 ENSG00000281162.1 LINC01127 -4.56 7.02e-06 0.00195 -0.26 -0.24 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:102046190 chr2:101962056~101987167:+ LIHC cis rs2274273 0.84 rs10142448 ENSG00000258413.1 RP11-665C16.6 4.56 7.03e-06 0.00195 0.27 0.24 Protein biomarker; chr14:55371390 chr14:55262767~55272075:- LIHC cis rs228614 0.51 rs65671 ENSG00000246560.2 RP11-10L12.4 4.56 7.03e-06 0.00195 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102801081 chr4:102828055~102844075:+ LIHC cis rs733592 0.507 rs3825403 ENSG00000240399.1 RP1-228P16.1 -4.56 7.03e-06 0.00195 -0.23 -0.24 Plateletcrit; chr12:48063376 chr12:48054813~48055591:- LIHC cis rs11168351 0.591 rs4258439 ENSG00000240399.1 RP1-228P16.1 -4.56 7.03e-06 0.00195 -0.23 -0.24 Bipolar disorder and schizophrenia; chr12:48074869 chr12:48054813~48055591:- LIHC cis rs733592 0.507 rs10747529 ENSG00000240399.1 RP1-228P16.1 -4.56 7.03e-06 0.00195 -0.23 -0.24 Plateletcrit; chr12:48079586 chr12:48054813~48055591:- LIHC cis rs2439831 0.681 rs825740 ENSG00000166763.7 STRCP1 4.56 7.04e-06 0.00195 0.33 0.24 Lung cancer in ever smokers; chr15:43300210 chr15:43699488~43718184:- LIHC cis rs7811142 0.943 rs67196635 ENSG00000242294.5 STAG3L5P 4.56 7.04e-06 0.00195 0.28 0.24 Platelet count; chr7:100427941 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs6962151 ENSG00000242294.5 STAG3L5P 4.56 7.04e-06 0.00195 0.28 0.24 Platelet count; chr7:100430861 chr7:100336079~100351900:+ LIHC cis rs7811142 0.943 rs67483801 ENSG00000242294.5 STAG3L5P 4.56 7.04e-06 0.00195 0.28 0.24 Platelet count; chr7:100434135 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs11761784 ENSG00000242294.5 STAG3L5P 4.56 7.04e-06 0.00195 0.28 0.24 Platelet count; chr7:100442347 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs112317829 ENSG00000242294.5 STAG3L5P 4.56 7.04e-06 0.00195 0.28 0.24 Platelet count; chr7:100445550 chr7:100336079~100351900:+ LIHC cis rs853679 0.513 rs13437444 ENSG00000219392.1 RP1-265C24.5 -4.56 7.04e-06 0.00195 -0.41 -0.24 Depression; chr6:28103220 chr6:28115628~28116551:+ LIHC cis rs597539 0.654 rs655816 ENSG00000250508.1 RP11-757G1.6 -4.56 7.05e-06 0.00195 -0.35 -0.24 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68858937 chr11:68870664~68874542:+ LIHC cis rs597539 0.69 rs497149 ENSG00000250508.1 RP11-757G1.6 -4.56 7.05e-06 0.00195 -0.35 -0.24 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68859171 chr11:68870664~68874542:+ LIHC cis rs3812762 0.871 rs11042068 ENSG00000254860.4 TMEM9B-AS1 4.56 7.05e-06 0.00195 0.27 0.24 Hypospadias; chr11:8794052 chr11:8964675~8977527:+ LIHC cis rs11779988 0.545 rs454692 ENSG00000253671.1 RP11-806O11.1 -4.56 7.05e-06 0.00196 -0.31 -0.24 Breast cancer; chr8:17931789 chr8:17808941~17820868:+ LIHC cis rs79040073 0.53 rs8025550 ENSG00000259531.2 RP11-295H24.3 -4.56 7.07e-06 0.00196 -0.4 -0.24 Lung cancer in ever smokers; chr15:49222870 chr15:49365124~49366685:- LIHC cis rs7665090 0.87 rs228613 ENSG00000230069.3 LRRC37A15P 4.56 7.07e-06 0.00196 0.23 0.24 Primary biliary cholangitis; chr4:102656308 chr4:102727274~102730721:- LIHC cis rs8028182 0.636 rs7163451 ENSG00000260269.4 CTD-2323K18.1 -4.56 7.07e-06 0.00196 -0.3 -0.24 Sudden cardiac arrest; chr15:75568735 chr15:75527150~75601205:- LIHC cis rs7914558 0.966 rs10883817 ENSG00000236937.2 PTGES3P4 4.56 7.08e-06 0.00196 0.28 0.24 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102995674 chr10:102845595~102845950:+ LIHC cis rs3091242 0.9 rs4649086 ENSG00000224183.1 SDHDP6 -4.56 7.08e-06 0.00196 -0.27 -0.24 Erythrocyte sedimentation rate; chr1:25452476 chr1:25294164~25294643:- LIHC cis rs3091242 0.933 rs34006994 ENSG00000224183.1 SDHDP6 4.56 7.08e-06 0.00196 0.27 0.24 Erythrocyte sedimentation rate; chr1:25454177 chr1:25294164~25294643:- LIHC cis rs3091242 0.933 rs61775167 ENSG00000224183.1 SDHDP6 4.56 7.08e-06 0.00196 0.27 0.24 Erythrocyte sedimentation rate; chr1:25454402 chr1:25294164~25294643:- LIHC cis rs3091242 0.902 rs36003018 ENSG00000224183.1 SDHDP6 4.56 7.08e-06 0.00196 0.27 0.24 Erythrocyte sedimentation rate; chr1:25457827 chr1:25294164~25294643:- LIHC cis rs3091242 0.933 rs35403885 ENSG00000224183.1 SDHDP6 4.56 7.08e-06 0.00196 0.27 0.24 Erythrocyte sedimentation rate; chr1:25458060 chr1:25294164~25294643:- LIHC cis rs2243480 1 rs56291018 ENSG00000230295.1 RP11-458F8.2 -4.56 7.08e-06 0.00196 -0.25 -0.24 Diabetic kidney disease; chr7:65925352 chr7:66880708~66882981:+ LIHC cis rs2276314 0.857 rs62101393 ENSG00000278986.1 RP11-723J4.3 -4.56 7.08e-06 0.00196 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36012205 chr18:35972151~35973916:+ LIHC cis rs2276314 0.857 rs62101394 ENSG00000278986.1 RP11-723J4.3 -4.56 7.08e-06 0.00196 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36012336 chr18:35972151~35973916:+ LIHC cis rs2276314 0.857 rs4799409 ENSG00000278986.1 RP11-723J4.3 -4.56 7.08e-06 0.00196 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36012639 chr18:35972151~35973916:+ LIHC cis rs1247318 1 rs1247360 ENSG00000243831.1 RP1-81D8.4 4.56 7.09e-06 0.00196 0.35 0.24 Aging; chr6:160920176 chr6:160666228~160676523:- LIHC cis rs7809950 1 rs7786801 ENSG00000238832.1 snoU109 -4.56 7.09e-06 0.00196 -0.29 -0.24 Coronary artery disease; chr7:107445444 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs10234355 ENSG00000238832.1 snoU109 -4.56 7.09e-06 0.00196 -0.29 -0.24 Coronary artery disease; chr7:107446072 chr7:107603363~107603507:+ LIHC cis rs7216064 0.589 rs7213585 ENSG00000278740.1 RP11-147L13.14 4.56 7.09e-06 0.00197 0.29 0.24 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68066200 chr17:68188547~68189165:+ LIHC cis rs17214007 0.877 rs11075280 ENSG00000263335.1 AF001548.5 -4.56 7.1e-06 0.00197 -0.31 -0.24 Cognitive function; chr16:15776630 chr16:15726674~15732993:+ LIHC cis rs11971779 0.68 rs11764236 ENSG00000273391.1 RP11-634H22.1 4.56 7.1e-06 0.00197 0.22 0.24 Diisocyanate-induced asthma; chr7:139433768 chr7:139359032~139359566:- LIHC cis rs11971779 0.648 rs66463279 ENSG00000273391.1 RP11-634H22.1 4.56 7.1e-06 0.00197 0.22 0.24 Diisocyanate-induced asthma; chr7:139433915 chr7:139359032~139359566:- LIHC cis rs10829156 0.625 rs10828906 ENSG00000225527.1 RP11-383B4.4 -4.56 7.11e-06 0.00197 -0.38 -0.24 Sudden cardiac arrest; chr10:18552866 chr10:18531849~18533336:- LIHC cis rs17818399 0.547 rs4952831 ENSG00000239332.4 LINC01119 -4.56 7.11e-06 0.00197 -0.34 -0.24 Height; chr2:46534042 chr2:46816697~46859007:+ LIHC cis rs17818399 0.547 rs4952833 ENSG00000239332.4 LINC01119 -4.56 7.11e-06 0.00197 -0.34 -0.24 Height; chr2:46534895 chr2:46816697~46859007:+ LIHC cis rs2919917 1 rs2919917 ENSG00000254352.1 RP11-578O24.2 -4.56 7.11e-06 0.00197 -0.34 -0.24 Lymphocyte counts; chr8:78745028 chr8:78723796~78724136:- LIHC cis rs1823913 0.927 rs13025919 ENSG00000227542.1 AC092614.2 4.56 7.12e-06 0.00197 0.24 0.24 Obesity-related traits; chr2:191260175 chr2:191229165~191246172:- LIHC cis rs513088 0.515 rs579100 ENSG00000225171.2 DUTP6 -4.56 7.12e-06 0.00197 -0.29 -0.24 Schizophrenia; chr1:166705052 chr1:166868748~166869209:+ LIHC cis rs12304921 0.872 rs17122760 ENSG00000277201.1 AC087884.1 4.56 7.12e-06 0.00197 0.27 0.24 Type 2 diabetes; chr12:51125323 chr12:51049921~51050025:+ LIHC cis rs71520386 0.53 rs10256628 ENSG00000228649.7 AC005682.5 -4.56 7.12e-06 0.00197 -0.31 -0.24 Fibrinogen levels; chr7:22843640 chr7:22854178~22861579:+ LIHC cis rs7809950 1 rs3801944 ENSG00000238832.1 snoU109 4.56 7.12e-06 0.00197 0.29 0.24 Coronary artery disease; chr7:107615103 chr7:107603363~107603507:+ LIHC cis rs11098499 0.779 rs7699346 ENSG00000245958.5 RP11-33B1.1 -4.56 7.13e-06 0.00197 -0.25 -0.24 Corneal astigmatism; chr4:119389387 chr4:119454791~119552025:+ LIHC cis rs10833905 0.756 rs16910406 ENSG00000246225.5 RP11-17A1.3 4.56 7.13e-06 0.00197 0.31 0.24 Sudden cardiac arrest; chr11:22984200 chr11:22829380~22945393:+ LIHC cis rs673078 0.66 rs61945219 ENSG00000275759.1 RP11-131L12.3 -4.56 7.13e-06 0.00197 -0.3 -0.24 Glucose homeostasis traits; chr12:118272916 chr12:118428281~118428870:+ LIHC cis rs8028182 0.636 rs4451914 ENSG00000260269.4 CTD-2323K18.1 -4.56 7.14e-06 0.00198 -0.3 -0.24 Sudden cardiac arrest; chr15:75447483 chr15:75527150~75601205:- LIHC cis rs1223397 0.938 rs3817741 ENSG00000215022.6 RP1-257A7.4 4.56 7.15e-06 0.00198 0.28 0.24 Blood pressure; chr6:13279275 chr6:13264861~13295586:- LIHC cis rs7809950 1 rs10258385 ENSG00000238832.1 snoU109 4.56 7.15e-06 0.00198 0.29 0.24 Coronary artery disease; chr7:107602905 chr7:107603363~107603507:+ LIHC cis rs1322639 0.614 rs9364356 ENSG00000261039.2 RP11-417E7.2 -4.56 7.16e-06 0.00198 -0.33 -0.24 Pulse pressure; chr6:169167013 chr6:169175304~169182740:- LIHC cis rs1030877 0.557 rs2576752 ENSG00000235319.1 AC012360.4 -4.56 7.16e-06 0.00198 -0.29 -0.24 Obesity-related traits; chr2:105362304 chr2:105324210~105330529:+ LIHC cis rs10510102 0.872 rs3862129 ENSG00000276742.1 RP11-500G22.4 4.56 7.16e-06 0.00198 0.36 0.24 Breast cancer; chr10:121824460 chr10:121956782~121957098:+ LIHC cis rs79349575 0.783 rs1994970 ENSG00000248278.1 SUMO2P17 -4.56 7.17e-06 0.00198 -0.29 -0.24 Type 2 diabetes; chr17:48936765 chr17:48874860~48908983:- LIHC cis rs7216064 0.532 rs3890640 ENSG00000278740.1 RP11-147L13.14 -4.56 7.17e-06 0.00198 -0.29 -0.24 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68056912 chr17:68188547~68189165:+ LIHC cis rs72675573 0.888 rs12144217 ENSG00000235612.1 RP1-158P9.1 -4.56 7.17e-06 0.00198 -0.31 -0.24 Monocyte count; chr1:56156019 chr1:56145721~56155224:+ LIHC cis rs7714584 1 rs13361189 ENSG00000197083.10 ZNF300P1 4.56 7.18e-06 0.00199 0.38 0.24 Crohn's disease; chr5:150843825 chr5:150930645~150946289:- LIHC cis rs950169 0.58 rs11634322 ENSG00000225151.9 GOLGA2P7 -4.56 7.18e-06 0.00199 -0.3 -0.24 Schizophrenia; chr15:84628978 chr15:84199311~84230136:- LIHC cis rs7586970 0.583 rs16829088 ENSG00000224063.4 AC007319.1 4.56 7.18e-06 0.00199 0.36 0.24 Coronary heart disease; chr2:187527181 chr2:187003220~187554663:+ LIHC cis rs17301013 0.932 rs2987874 ENSG00000227373.4 RP11-160H22.5 -4.56 7.18e-06 0.00199 -0.29 -0.24 Systemic lupus erythematosus; chr1:174801053 chr1:174115300~174160004:- LIHC cis rs6600671 1 rs10794671 ENSG00000231429.2 RP11-343N15.2 -4.56 7.18e-06 0.00199 -0.27 -0.24 Hip geometry; chr1:121426382 chr1:121412719~121429274:+ LIHC cis rs6600671 1 rs1856572 ENSG00000231429.2 RP11-343N15.2 -4.56 7.18e-06 0.00199 -0.27 -0.24 Hip geometry; chr1:121427719 chr1:121412719~121429274:+ LIHC cis rs2274273 0.84 rs11626751 ENSG00000258413.1 RP11-665C16.6 -4.56 7.19e-06 0.00199 -0.28 -0.24 Protein biomarker; chr14:55368509 chr14:55262767~55272075:- LIHC cis rs7829975 0.688 rs7817376 ENSG00000253981.4 ALG1L13P -4.56 7.19e-06 0.00199 -0.29 -0.24 Mood instability; chr8:8523020 chr8:8236003~8244667:- LIHC cis rs67311347 1 rs12488805 ENSG00000223797.4 ENTPD3-AS1 4.56 7.19e-06 0.00199 0.2 0.24 Renal cell carcinoma; chr3:40381378 chr3:40313802~40453329:- LIHC cis rs11064837 0.504 rs11064845 ENSG00000248636.5 RP11-768F21.1 -4.56 7.19e-06 0.00199 -0.38 -0.24 Schizophrenia; chr12:119614124 chr12:119387987~119668079:- LIHC cis rs11098499 0.661 rs10015965 ENSG00000245958.5 RP11-33B1.1 -4.56 7.2e-06 0.00199 -0.23 -0.24 Corneal astigmatism; chr4:119347082 chr4:119454791~119552025:+ LIHC cis rs67311347 0.824 rs59922539 ENSG00000223797.4 ENTPD3-AS1 4.56 7.2e-06 0.00199 0.2 0.24 Renal cell carcinoma; chr3:40295619 chr3:40313802~40453329:- LIHC cis rs2243480 1 rs781150 ENSG00000230295.1 RP11-458F8.2 -4.56 7.2e-06 0.00199 -0.25 -0.24 Diabetic kidney disease; chr7:66015986 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs313798 ENSG00000230295.1 RP11-458F8.2 -4.56 7.2e-06 0.00199 -0.25 -0.24 Diabetic kidney disease; chr7:66028044 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs35396113 ENSG00000230295.1 RP11-458F8.2 -4.56 7.2e-06 0.00199 -0.25 -0.24 Diabetic kidney disease; chr7:66030474 chr7:66880708~66882981:+ LIHC cis rs7923609 0.935 rs10995477 ENSG00000232075.1 MRPL35P2 -4.56 7.2e-06 0.00199 -0.26 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63250912 chr10:63634317~63634827:- LIHC cis rs2274273 0.624 rs7150234 ENSG00000258413.1 RP11-665C16.6 -4.56 7.21e-06 0.00199 -0.29 -0.24 Protein biomarker; chr14:55335463 chr14:55262767~55272075:- LIHC cis rs3091242 0.933 rs9438905 ENSG00000224183.1 SDHDP6 -4.56 7.21e-06 0.00199 -0.28 -0.24 Erythrocyte sedimentation rate; chr1:25437686 chr1:25294164~25294643:- LIHC cis rs30380 1 rs30187 ENSG00000272109.1 CTD-2260A17.3 -4.56 7.21e-06 0.00199 -0.29 -0.24 Cerebrospinal fluid biomarker levels; chr5:96788627 chr5:96804353~96806105:+ LIHC cis rs875971 0.66 rs1860468 ENSG00000273024.4 INTS4P2 4.56 7.21e-06 0.00199 0.27 0.24 Aortic root size; chr7:66642265 chr7:65647864~65715661:+ LIHC cis rs11971779 0.648 rs6947309 ENSG00000273391.1 RP11-634H22.1 4.56 7.21e-06 0.00199 0.21 0.24 Diisocyanate-induced asthma; chr7:139351084 chr7:139359032~139359566:- LIHC cis rs2276314 1 rs2276314 ENSG00000278986.1 RP11-723J4.3 4.56 7.22e-06 0.002 0.29 0.24 Endometriosis;Drug-induced torsades de pointes; chr18:35977503 chr18:35972151~35973916:+ LIHC cis rs7702057 0.53 rs3946989 ENSG00000271918.1 CTD-2287O16.5 4.56 7.22e-06 0.002 0.33 0.24 Amyotrophic lateral sclerosis; chr5:116078431 chr5:116083807~116085416:- LIHC cis rs7714584 1 rs73282234 ENSG00000197083.10 ZNF300P1 4.56 7.22e-06 0.002 0.39 0.24 Crohn's disease; chr5:150816362 chr5:150930645~150946289:- LIHC cis rs881375 0.678 rs1014530 ENSG00000226752.6 PSMD5-AS1 -4.56 7.22e-06 0.002 -0.25 -0.24 Rheumatoid arthritis; chr9:120922814 chr9:120824828~120854385:+ LIHC cis rs881375 0.678 rs7037195 ENSG00000226752.6 PSMD5-AS1 -4.56 7.22e-06 0.002 -0.25 -0.24 Rheumatoid arthritis; chr9:120921722 chr9:120824828~120854385:+ LIHC cis rs3091242 0.933 rs11249250 ENSG00000224183.1 SDHDP6 -4.56 7.23e-06 0.002 -0.28 -0.24 Erythrocyte sedimentation rate; chr1:25441118 chr1:25294164~25294643:- LIHC cis rs6940638 0.637 rs13217239 ENSG00000216901.1 AL022393.7 4.56 7.23e-06 0.002 0.34 0.24 Intelligence (multi-trait analysis); chr6:27287188 chr6:28176188~28176674:+ LIHC cis rs7702057 0.53 rs17138834 ENSG00000271918.1 CTD-2287O16.5 -4.56 7.23e-06 0.002 -0.32 -0.24 Amyotrophic lateral sclerosis; chr5:116076625 chr5:116083807~116085416:- LIHC cis rs11098499 0.697 rs4560394 ENSG00000245958.5 RP11-33B1.1 -4.56 7.24e-06 0.002 -0.25 -0.24 Corneal astigmatism; chr4:119392280 chr4:119454791~119552025:+ LIHC cis rs7119038 0.779 rs11217045 ENSG00000255239.1 AP002954.6 -4.56 7.25e-06 0.002 -0.35 -0.24 Sjögren's syndrome; chr11:118827156 chr11:118688039~118690600:- LIHC cis rs7119038 0.865 rs11217046 ENSG00000255239.1 AP002954.6 -4.56 7.25e-06 0.002 -0.35 -0.24 Sjögren's syndrome; chr11:118828198 chr11:118688039~118690600:- LIHC cis rs1005277 0.522 rs289645 ENSG00000099251.13 HSD17B7P2 4.56 7.25e-06 0.002 0.28 0.24 Extrinsic epigenetic age acceleration; chr10:37654714 chr10:38356380~38378505:+ LIHC cis rs11079159 0.606 rs4239192 ENSG00000263096.1 RP11-515O17.2 4.56 7.25e-06 0.002 0.3 0.24 QRS duration; chr17:55299143 chr17:55271504~55273653:- LIHC cis rs9291683 0.53 rs998675 ENSG00000250413.1 RP11-448G15.1 -4.56 7.25e-06 0.002 -0.31 -0.24 Bone mineral density; chr4:9947205 chr4:10006482~10009725:+ LIHC cis rs227275 0.554 rs223395 ENSG00000246560.2 RP11-10L12.4 4.56 7.26e-06 0.002 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102823801 chr4:102828055~102844075:+ LIHC cis rs67311347 0.544 rs13097602 ENSG00000223797.4 ENTPD3-AS1 -4.56 7.26e-06 0.002 -0.2 -0.24 Renal cell carcinoma; chr3:40297756 chr3:40313802~40453329:- LIHC cis rs2245008 0.774 rs253136 ENSG00000260932.1 RP11-483P21.6 4.56 7.26e-06 0.002 0.41 0.24 Pursuit maintenance gain; chr16:83945996 chr16:83929796~83931223:- LIHC cis rs10829156 0.773 rs7909552 ENSG00000240291.1 RP11-499P20.2 4.56 7.26e-06 0.002 0.36 0.24 Sudden cardiac arrest; chr10:18620407 chr10:18513115~18545651:- LIHC cis rs12468226 0.873 rs2350358 ENSG00000273456.1 RP11-686O6.2 -4.56 7.26e-06 0.00201 -0.33 -0.24 Urate levels; chr2:202199771 chr2:202374932~202375604:- LIHC cis rs42490 0.934 rs218946 ENSG00000251136.7 RP11-37B2.1 -4.56 7.27e-06 0.00201 -0.22 -0.24 Leprosy; chr8:89704478 chr8:89609409~89757727:- LIHC cis rs2243480 0.908 rs55876148 ENSG00000230295.1 RP11-458F8.2 -4.56 7.27e-06 0.00201 -0.26 -0.24 Diabetic kidney disease; chr7:65914813 chr7:66880708~66882981:+ LIHC cis rs228614 0.51 rs170565 ENSG00000246560.2 RP11-10L12.4 4.56 7.27e-06 0.00201 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798277 chr4:102828055~102844075:+ LIHC cis rs7119038 0.629 rs10892273 ENSG00000255239.1 AP002954.6 -4.56 7.28e-06 0.00201 -0.33 -0.24 Sjögren's syndrome; chr11:118732100 chr11:118688039~118690600:- LIHC cis rs4718428 1 rs4718428 ENSG00000273142.1 RP11-458F8.4 -4.56 7.28e-06 0.00201 -0.23 -0.24 Corneal structure; chr7:66956459 chr7:66902857~66906297:+ LIHC cis rs113835537 0.877 rs77239910 ENSG00000255517.5 CTD-3074O7.5 -4.56 7.29e-06 0.00201 -0.43 -0.24 Airway imaging phenotypes; chr11:66562168 chr11:66473490~66480233:- LIHC cis rs1714507 0.533 rs1435642 ENSG00000272087.1 RP11-379F4.7 -4.56 7.29e-06 0.00201 -0.26 -0.24 Subjective well-being; chr3:158582432 chr3:158693120~158693768:- LIHC cis rs7587476 1 rs1542173 ENSG00000229267.2 AC072062.1 4.56 7.29e-06 0.00201 0.31 0.24 Neuroblastoma; chr2:214792836 chr2:214810229~214963274:+ LIHC cis rs10129255 0.5 rs988132 ENSG00000223648.3 IGHV3-64 4.56 7.29e-06 0.00201 0.17 0.24 Kawasaki disease; chr14:106776758 chr14:106643132~106658258:- LIHC cis rs2276314 0.857 rs28435069 ENSG00000278986.1 RP11-723J4.3 -4.55 7.3e-06 0.00202 -0.28 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36048512 chr18:35972151~35973916:+ LIHC cis rs2243480 0.901 rs778730 ENSG00000230295.1 RP11-458F8.2 -4.55 7.3e-06 0.00202 -0.25 -0.24 Diabetic kidney disease; chr7:66358338 chr7:66880708~66882981:+ LIHC cis rs950169 0.544 rs62021193 ENSG00000225151.9 GOLGA2P7 -4.55 7.31e-06 0.00202 -0.3 -0.24 Schizophrenia; chr15:84627352 chr15:84199311~84230136:- LIHC cis rs950169 0.58 rs17598114 ENSG00000225151.9 GOLGA2P7 -4.55 7.31e-06 0.00202 -0.3 -0.24 Schizophrenia; chr15:84628086 chr15:84199311~84230136:- LIHC cis rs11637445 0.589 rs4776989 ENSG00000260657.2 RP11-315D16.4 -4.55 7.31e-06 0.00202 -0.34 -0.24 Posterior cortical atrophy and Alzheimer's disease; chr15:67838346 chr15:68267792~68277994:- LIHC cis rs3733589 0.59 rs6836200 ENSG00000250413.1 RP11-448G15.1 -4.55 7.31e-06 0.00202 -0.4 -0.24 Renal overload gout; chr4:9985291 chr4:10006482~10009725:+ LIHC cis rs227275 0.554 rs223388 ENSG00000246560.2 RP11-10L12.4 4.55 7.32e-06 0.00202 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102828287 chr4:102828055~102844075:+ LIHC cis rs227275 0.554 rs223386 ENSG00000246560.2 RP11-10L12.4 4.55 7.32e-06 0.00202 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102829111 chr4:102828055~102844075:+ LIHC cis rs227275 0.554 rs223385 ENSG00000246560.2 RP11-10L12.4 4.55 7.32e-06 0.00202 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102829159 chr4:102828055~102844075:+ LIHC cis rs11722779 0.873 rs223384 ENSG00000246560.2 RP11-10L12.4 4.55 7.32e-06 0.00202 0.27 0.24 Schizophrenia; chr4:102829976 chr4:102828055~102844075:+ LIHC cis rs227275 0.554 rs223383 ENSG00000246560.2 RP11-10L12.4 4.55 7.32e-06 0.00202 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102830094 chr4:102828055~102844075:+ LIHC cis rs7709377 0.516 rs7701736 ENSG00000271918.1 CTD-2287O16.5 4.55 7.32e-06 0.00202 0.29 0.24 Metabolite levels (X-11787); chr5:116185318 chr5:116083807~116085416:- LIHC cis rs6997458 0.742 rs10111039 ENSG00000253549.4 RP11-317J10.2 4.55 7.33e-06 0.00202 0.26 0.24 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85484427 chr8:85441851~85464915:- LIHC cis rs6442522 0.772 rs3846127 ENSG00000249786.6 EAF1-AS1 4.55 7.34e-06 0.00202 0.28 0.24 Uric acid levels; chr3:15450020 chr3:15436171~15455940:- LIHC cis rs2032447 0.839 rs199750 ENSG00000242387.1 HIST1H2APS2 -4.55 7.34e-06 0.00202 -0.3 -0.24 Intelligence (multi-trait analysis); chr6:26016234 chr6:25882026~25882395:- LIHC cis rs8064024 0.901 rs930855 ENSG00000267077.1 RP11-127I20.5 4.55 7.34e-06 0.00203 0.24 0.24 Cancer; chr16:4814178 chr16:4795265~4796532:- LIHC cis rs2072510 0.683 rs2540486 ENSG00000257878.1 RP11-256L6.3 -4.55 7.35e-06 0.00203 -0.21 -0.24 Metabolite levels (small molecules and protein measures); chr12:96037229 chr12:95996521~96011489:+ LIHC cis rs12134133 1 rs7532664 ENSG00000274245.1 RP11-357P18.2 4.55 7.35e-06 0.00203 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207253598 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs55638602 ENSG00000274245.1 RP11-357P18.2 4.55 7.35e-06 0.00203 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207255597 chr1:207372559~207373252:+ LIHC cis rs12134133 1 rs4844588 ENSG00000274245.1 RP11-357P18.2 4.55 7.35e-06 0.00203 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207256323 chr1:207372559~207373252:+ LIHC cis rs8064024 0.783 rs2341986 ENSG00000267077.1 RP11-127I20.5 4.55 7.35e-06 0.00203 0.24 0.24 Cancer; chr16:4769495 chr16:4795265~4796532:- LIHC cis rs11098499 0.754 rs1980025 ENSG00000260091.1 RP11-33B1.4 4.55 7.35e-06 0.00203 0.17 0.24 Corneal astigmatism; chr4:119331651 chr4:119409333~119410233:+ LIHC cis rs2243480 1 rs1723267 ENSG00000230295.1 RP11-458F8.2 -4.55 7.36e-06 0.00203 -0.25 -0.24 Diabetic kidney disease; chr7:66008327 chr7:66880708~66882981:+ LIHC cis rs3733589 0.59 rs16892419 ENSG00000250413.1 RP11-448G15.1 -4.55 7.36e-06 0.00203 -0.38 -0.24 Renal overload gout; chr4:10034078 chr4:10006482~10009725:+ LIHC cis rs875971 0.54 rs1723268 ENSG00000224316.1 RP11-479O9.2 4.55 7.37e-06 0.00203 0.24 0.24 Aortic root size; chr7:66008093 chr7:65773620~65802067:+ LIHC cis rs5760092 0.755 rs4585126 ENSG00000228039.3 KB-1125A3.10 -4.55 7.37e-06 0.00203 -0.31 -0.24 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23963780~23964374:+ LIHC cis rs7131987 0.903 rs2194520 ENSG00000257176.2 RP11-996F15.2 -4.55 7.37e-06 0.00203 -0.28 -0.24 QT interval; chr12:29270779 chr12:29280418~29317848:- LIHC cis rs11676348 0.808 rs4674267 ENSG00000261338.2 RP11-378A13.1 -4.55 7.39e-06 0.00204 -0.25 -0.24 Ulcerative colitis; chr2:218181714 chr2:218255319~218257366:+ LIHC cis rs1577917 0.958 rs12215232 ENSG00000234155.1 RP11-30P6.6 4.55 7.39e-06 0.00204 0.33 0.24 Response to antipsychotic treatment; chr6:86075712 chr6:85387219~85390186:- LIHC cis rs2749592 0.513 rs1208708 ENSG00000275858.1 RP11-291L22.8 4.55 7.4e-06 0.00204 0.26 0.24 Age-related hearing impairment (SNP x SNP interaction); chr10:37796648 chr10:38450738~38451069:- LIHC cis rs2348418 0.765 rs12368743 ENSG00000247934.4 RP11-967K21.1 -4.55 7.4e-06 0.00204 -0.22 -0.24 Lung function (FEV1);Lung function (FVC); chr12:28192409 chr12:28163298~28190738:- LIHC cis rs748404 0.586 rs2584700 ENSG00000205771.5 CATSPER2P1 -4.55 7.4e-06 0.00204 -0.29 -0.24 Lung cancer; chr15:43393134 chr15:43726918~43747094:- LIHC cis rs2070488 0.813 rs3749387 ENSG00000229589.1 ACVR2B-AS1 4.55 7.4e-06 0.00204 0.27 0.24 Electrocardiographic conduction measures; chr3:38454702 chr3:38451027~38454820:- LIHC cis rs4834770 1 rs878374 ENSG00000245958.5 RP11-33B1.1 -4.55 7.41e-06 0.00204 -0.23 -0.24 Blood protein levels; chr4:119316409 chr4:119454791~119552025:+ LIHC cis rs2919917 0.956 rs10112388 ENSG00000254352.1 RP11-578O24.2 4.55 7.41e-06 0.00204 0.33 0.24 Lymphocyte counts; chr8:78691512 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs6980663 ENSG00000254352.1 RP11-578O24.2 4.55 7.41e-06 0.00204 0.33 0.24 Lymphocyte counts; chr8:78691589 chr8:78723796~78724136:- LIHC cis rs2919917 1 rs7001074 ENSG00000254352.1 RP11-578O24.2 4.55 7.41e-06 0.00204 0.33 0.24 Lymphocyte counts; chr8:78691689 chr8:78723796~78724136:- LIHC cis rs3812762 1 rs3812762 ENSG00000254860.4 TMEM9B-AS1 4.55 7.41e-06 0.00204 0.27 0.24 Hypospadias; chr11:8730093 chr11:8964675~8977527:+ LIHC cis rs1198872 0.571 rs902130 ENSG00000272275.1 RP11-791G15.2 -4.55 7.42e-06 0.00204 -0.28 -0.24 Cardiac Troponin-T levels; chr2:10770843 chr2:10767875~10770058:- LIHC cis rs916888 0.61 rs199454 ENSG00000260075.1 NSFP1 -4.55 7.42e-06 0.00204 -0.29 -0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:46372855~46487141:+ LIHC cis rs7119038 0.629 rs11217000 ENSG00000255239.1 AP002954.6 -4.55 7.43e-06 0.00205 -0.33 -0.24 Sjögren's syndrome; chr11:118734275 chr11:118688039~118690600:- LIHC cis rs12478296 0.786 rs28802397 ENSG00000261186.2 RP11-341N2.1 -4.55 7.43e-06 0.00205 -0.34 -0.24 Obesity-related traits; chr2:242107579 chr2:242087351~242088457:- LIHC cis rs2836974 0.568 rs428602 ENSG00000255568.3 BRWD1-AS2 4.55 7.44e-06 0.00205 0.2 0.24 Cognitive function; chr21:39175078 chr21:39313935~39314962:+ LIHC cis rs11098499 0.754 rs17595608 ENSG00000245958.5 RP11-33B1.1 -4.55 7.45e-06 0.00205 -0.24 -0.24 Corneal astigmatism; chr4:119329351 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs1980027 ENSG00000245958.5 RP11-33B1.1 -4.55 7.45e-06 0.00205 -0.24 -0.24 Corneal astigmatism; chr4:119330422 chr4:119454791~119552025:+ LIHC cis rs2834188 0.924 rs2007849 ENSG00000272659.1 AP000295.10 -4.55 7.45e-06 0.00205 -0.35 -0.24 Narcolepsy; chr21:33308811 chr21:33309491~33310181:+ LIHC cis rs2834188 0.924 rs6517160 ENSG00000272659.1 AP000295.10 -4.55 7.45e-06 0.00205 -0.35 -0.24 Narcolepsy; chr21:33311207 chr21:33309491~33310181:+ LIHC cis rs73198271 0.583 rs11781985 ENSG00000253893.2 FAM85B -4.55 7.46e-06 0.00205 -0.33 -0.24 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8732273 chr8:8167819~8226614:- LIHC cis rs6504622 0.755 rs36056466 ENSG00000262879.4 RP11-156P1.3 -4.55 7.46e-06 0.00205 -0.25 -0.24 Orofacial clefts; chr17:47006017 chr17:46984045~47100323:- LIHC cis rs2243480 1 rs781157 ENSG00000228409.4 CCT6P1 4.55 7.47e-06 0.00206 0.26 0.24 Diabetic kidney disease; chr7:66013324 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs781156 ENSG00000228409.4 CCT6P1 4.55 7.47e-06 0.00206 0.26 0.24 Diabetic kidney disease; chr7:66014154 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs781149 ENSG00000228409.4 CCT6P1 4.55 7.47e-06 0.00206 0.26 0.24 Diabetic kidney disease; chr7:66016297 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs451396 ENSG00000228409.4 CCT6P1 4.55 7.47e-06 0.00206 0.26 0.24 Diabetic kidney disease; chr7:66019087 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs58207111 ENSG00000228409.4 CCT6P1 4.55 7.47e-06 0.00206 0.26 0.24 Diabetic kidney disease; chr7:66021736 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1167613 ENSG00000228409.4 CCT6P1 4.55 7.47e-06 0.00206 0.26 0.24 Diabetic kidney disease; chr7:66022452 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1715235 ENSG00000228409.4 CCT6P1 4.55 7.47e-06 0.00206 0.26 0.24 Diabetic kidney disease; chr7:66023407 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs313799 ENSG00000228409.4 CCT6P1 4.55 7.47e-06 0.00206 0.26 0.24 Diabetic kidney disease; chr7:66029343 chr7:65751142~65763354:+ LIHC cis rs8040855 0.627 rs4842863 ENSG00000259295.5 CSPG4P12 4.55 7.47e-06 0.00206 0.37 0.24 Bulimia nervosa; chr15:85098974 chr15:85191438~85213905:+ LIHC cis rs116139393 0.536 rs13247186 ENSG00000187953.9 PMS2CL -4.55 7.47e-06 0.00206 -0.25 -0.24 Alzheimer's disease (APOE e4 interaction); chr7:6729524 chr7:6710128~6753862:+ LIHC cis rs7209700 0.778 rs3851807 ENSG00000228782.6 CTD-2026D20.3 -4.55 7.48e-06 0.00206 -0.26 -0.24 IgG glycosylation; chr17:47274153 chr17:47450568~47492492:- LIHC cis rs11098499 0.913 rs67073020 ENSG00000245958.5 RP11-33B1.1 -4.55 7.49e-06 0.00206 -0.26 -0.24 Corneal astigmatism; chr4:119231402 chr4:119454791~119552025:+ LIHC cis rs17023223 0.537 rs12086549 ENSG00000231365.4 RP11-418J17.1 4.55 7.49e-06 0.00206 0.28 0.24 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119071714 chr1:119140396~119275973:+ LIHC cis rs10181042 0.514 rs1177288 ENSG00000271889.1 RP11-493E12.1 4.55 7.49e-06 0.00206 0.28 0.24 Crohn's disease; chr2:61125850 chr2:61151433~61162105:- LIHC cis rs17270561 0.943 rs4478398 ENSG00000272810.1 U91328.22 -4.55 7.49e-06 0.00206 -0.32 -0.24 Iron status biomarkers; chr6:25694456 chr6:26013241~26013757:+ LIHC cis rs12304921 0.625 rs17125369 ENSG00000277201.1 AC087884.1 4.55 7.51e-06 0.00207 0.28 0.24 Type 2 diabetes; chr12:51102876 chr12:51049921~51050025:+ LIHC cis rs1075232 0.655 rs78959602 ENSG00000270055.1 CTD-3092A11.2 -4.55 7.51e-06 0.00207 -0.47 -0.24 Survival in colorectal cancer (non-distant metastatic); chr15:31268581 chr15:30487963~30490313:+ LIHC cis rs42490 0.903 rs393891 ENSG00000251136.7 RP11-37B2.1 -4.55 7.52e-06 0.00207 -0.21 -0.24 Leprosy; chr8:89701556 chr8:89609409~89757727:- LIHC cis rs643506 0.845 rs7114594 ENSG00000254990.4 RP11-108O10.2 4.55 7.52e-06 0.00207 0.26 0.24 Breast cancer; chr11:111897389 chr11:111768668~111778350:- LIHC cis rs5769765 0.773 rs7410304 ENSG00000278869.1 CITF22-49E9.3 4.55 7.53e-06 0.00207 0.37 0.24 Schizophrenia; chr22:49923187 chr22:49933198~49934074:- LIHC cis rs6565180 0.791 rs4247355 ENSG00000183604.13 SMG1P5 4.55 7.53e-06 0.00207 0.25 0.24 Tonsillectomy; chr16:30380778 chr16:30267553~30335374:- LIHC cis rs6085948 1 rs6054856 ENSG00000228888.1 LINC01428 -4.55 7.54e-06 0.00207 -0.32 -0.24 Interleukin-10 levels; chr20:7266592 chr20:7146467~7254202:- LIHC cis rs10262624 1 rs10257777 ENSG00000234286.1 AC006026.13 -4.55 7.54e-06 0.00207 -0.27 -0.24 Schizophrenia; chr7:23871362 chr7:23680195~23680786:- LIHC cis rs2276314 1 rs4799832 ENSG00000278986.1 RP11-723J4.3 -4.55 7.55e-06 0.00208 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:35979683 chr18:35972151~35973916:+ LIHC cis rs2276314 1 rs8086395 ENSG00000278986.1 RP11-723J4.3 -4.55 7.55e-06 0.00208 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:35984629 chr18:35972151~35973916:+ LIHC cis rs2276314 0.947 rs3898595 ENSG00000278986.1 RP11-723J4.3 -4.55 7.55e-06 0.00208 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:35985922 chr18:35972151~35973916:+ LIHC cis rs2976388 0.587 rs2717606 ENSG00000253741.1 CTD-2292P10.4 -4.55 7.55e-06 0.00208 -0.27 -0.24 Urinary tract infection frequency; chr8:142718078 chr8:142702252~142726973:- LIHC cis rs2976388 0.609 rs2585144 ENSG00000253741.1 CTD-2292P10.4 -4.55 7.55e-06 0.00208 -0.27 -0.24 Urinary tract infection frequency; chr8:142718851 chr8:142702252~142726973:- LIHC cis rs4650994 0.816 rs2811303 ENSG00000273384.1 RP5-1098D14.1 -4.55 7.56e-06 0.00208 -0.28 -0.24 HDL cholesterol;HDL cholesterol levels; chr1:178626511 chr1:178651706~178652282:+ LIHC cis rs7587476 1 rs7587476 ENSG00000229267.2 AC072062.1 4.55 7.56e-06 0.00208 0.31 0.24 Neuroblastoma; chr2:214789163 chr2:214810229~214963274:+ LIHC cis rs67311347 1 rs9829800 ENSG00000223797.4 ENTPD3-AS1 4.55 7.56e-06 0.00208 0.19 0.24 Renal cell carcinoma; chr3:40402436 chr3:40313802~40453329:- LIHC cis rs10129255 0.518 rs28378320 ENSG00000223648.3 IGHV3-64 4.55 7.56e-06 0.00208 0.17 0.24 Kawasaki disease; chr14:106808609 chr14:106643132~106658258:- LIHC cis rs42490 0.903 rs218902 ENSG00000251136.7 RP11-37B2.1 4.55 7.57e-06 0.00208 0.22 0.24 Leprosy; chr8:89719986 chr8:89609409~89757727:- LIHC cis rs597539 0.654 rs619727 ENSG00000250508.1 RP11-757G1.6 -4.55 7.57e-06 0.00208 -0.36 -0.24 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68860067 chr11:68870664~68874542:+ LIHC cis rs2932538 0.961 rs4838960 ENSG00000225075.1 RP11-426L16.3 -4.55 7.57e-06 0.00208 -0.3 -0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112621010 chr1:112693688~112696621:- LIHC cis rs2274273 0.588 rs2880103 ENSG00000258413.1 RP11-665C16.6 -4.55 7.57e-06 0.00208 -0.29 -0.24 Protein biomarker; chr14:55271114 chr14:55262767~55272075:- LIHC cis rs2274273 0.563 rs79163357 ENSG00000258413.1 RP11-665C16.6 -4.55 7.57e-06 0.00208 -0.29 -0.24 Protein biomarker; chr14:55271731 chr14:55262767~55272075:- LIHC cis rs12554020 0.786 rs78271342 ENSG00000227603.1 RP11-165J3.6 4.55 7.58e-06 0.00208 0.4 0.24 Schizophrenia; chr9:93468959 chr9:93435332~93437121:- LIHC cis rs2836974 0.932 rs11910151 ENSG00000255568.3 BRWD1-AS2 4.55 7.58e-06 0.00208 0.27 0.24 Cognitive function; chr21:39188336 chr21:39313935~39314962:+ LIHC cis rs6565180 1 rs11646130 ENSG00000183604.13 SMG1P5 -4.55 7.59e-06 0.00209 -0.26 -0.24 Tonsillectomy; chr16:30365638 chr16:30267553~30335374:- LIHC cis rs7246657 0.943 rs1035479 ENSG00000276846.1 CTD-3220F14.3 -4.55 7.59e-06 0.00209 -0.29 -0.24 Coronary artery calcification; chr19:37402398 chr19:37314868~37315620:- LIHC cis rs12887734 0.524 rs4906363 ENSG00000258534.1 CTD-2134A5.4 -4.55 7.59e-06 0.00209 -0.27 -0.24 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103743902 chr14:103854366~103880111:- LIHC cis rs2439831 0.85 rs28858500 ENSG00000275601.1 AC011330.13 -4.55 7.59e-06 0.00209 -0.35 -0.24 Lung cancer in ever smokers; chr15:43864744 chr15:43642389~43643023:- LIHC cis rs7829975 0.623 rs10087493 ENSG00000253893.2 FAM85B 4.55 7.61e-06 0.00209 0.29 0.24 Mood instability; chr8:8516047 chr8:8167819~8226614:- LIHC cis rs2932538 0.961 rs2932534 ENSG00000225075.1 RP11-426L16.3 4.55 7.61e-06 0.00209 0.3 0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112658175 chr1:112693688~112696621:- LIHC cis rs11098499 0.863 rs3822195 ENSG00000245958.5 RP11-33B1.1 -4.55 7.61e-06 0.00209 -0.25 -0.24 Corneal astigmatism; chr4:119550505 chr4:119454791~119552025:+ LIHC cis rs8059260 0.668 rs7206753 ENSG00000274038.1 RP11-66H6.4 -4.55 7.62e-06 0.00209 -0.36 -0.24 Alcohol consumption over the past year; chr16:10974987 chr16:11056556~11057034:+ LIHC cis rs4662750 0.527 rs10164978 ENSG00000236682.1 AC068282.3 4.55 7.62e-06 0.00209 0.31 0.24 Renal cell carcinoma; chr2:127627649 chr2:127389130~127400580:+ LIHC cis rs2749097 0.825 rs10889436 ENSG00000244256.3 RN7SL130P -4.54 7.64e-06 0.0021 -0.28 -0.24 Alcohol consumption (transferrin glycosylation); chr1:63658226 chr1:63655743~63656047:+ LIHC cis rs3091242 0.933 rs35530120 ENSG00000224183.1 SDHDP6 4.54 7.64e-06 0.0021 0.27 0.24 Erythrocyte sedimentation rate; chr1:25458960 chr1:25294164~25294643:- LIHC cis rs7915414 0.951 rs2901783 ENSG00000230338.1 MTND4P19 4.54 7.64e-06 0.0021 0.25 0.24 Clopidogrel active metabolite levels; chr10:94693342 chr10:94774156~94774633:- LIHC cis rs6142102 0.651 rs6119463 ENSG00000276073.1 RP5-1125A11.7 4.54 7.64e-06 0.0021 0.27 0.24 Skin pigmentation; chr20:34149412 chr20:33985617~33988989:- LIHC cis rs6600671 0.967 rs4844613 ENSG00000231429.2 RP11-343N15.2 -4.54 7.64e-06 0.0021 -0.27 -0.24 Hip geometry; chr1:121431913 chr1:121412719~121429274:+ LIHC cis rs79349575 0.749 rs519537 ENSG00000248278.1 SUMO2P17 4.54 7.64e-06 0.0021 0.29 0.24 Type 2 diabetes; chr17:48893778 chr17:48874860~48908983:- LIHC cis rs7809950 0.953 rs1468336 ENSG00000238832.1 snoU109 4.54 7.65e-06 0.0021 0.29 0.24 Coronary artery disease; chr7:107567805 chr7:107603363~107603507:+ LIHC cis rs9425766 0.679 rs4650945 ENSG00000227373.4 RP11-160H22.5 -4.54 7.66e-06 0.0021 -0.29 -0.24 Life satisfaction; chr1:174114966 chr1:174115300~174160004:- LIHC cis rs2243480 0.831 rs57294491 ENSG00000230295.1 RP11-458F8.2 4.54 7.66e-06 0.0021 0.25 0.24 Diabetic kidney disease; chr7:66219914 chr7:66880708~66882981:+ LIHC cis rs2836974 0.897 rs2836933 ENSG00000255568.3 BRWD1-AS2 4.54 7.66e-06 0.0021 0.27 0.24 Cognitive function; chr21:39192276 chr21:39313935~39314962:+ LIHC cis rs6997458 0.742 rs2307075 ENSG00000253549.4 RP11-317J10.2 4.54 7.66e-06 0.0021 0.26 0.24 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85475999 chr8:85441851~85464915:- LIHC cis rs16858210 0.874 rs10937153 ENSG00000234371.6 RPSAP31 -4.54 7.67e-06 0.0021 -0.3 -0.24 Menopause (age at onset); chr3:183845137 chr3:183884924~183888449:+ LIHC cis rs7224610 0.57 rs963955 ENSG00000263096.1 RP11-515O17.2 -4.54 7.67e-06 0.0021 -0.31 -0.24 Urate levels; chr17:55309465 chr17:55271504~55273653:- LIHC cis rs11971779 0.793 rs4728464 ENSG00000273391.1 RP11-634H22.1 -4.54 7.67e-06 0.0021 -0.22 -0.24 Diisocyanate-induced asthma; chr7:139332924 chr7:139359032~139359566:- LIHC cis rs2348418 0.733 rs7137557 ENSG00000247934.4 RP11-967K21.1 4.54 7.67e-06 0.00211 0.22 0.24 Lung function (FEV1);Lung function (FVC); chr12:28221259 chr12:28163298~28190738:- LIHC cis rs2348418 0.733 rs12425200 ENSG00000247934.4 RP11-967K21.1 4.54 7.67e-06 0.00211 0.22 0.24 Lung function (FEV1);Lung function (FVC); chr12:28237896 chr12:28163298~28190738:- LIHC cis rs783540 0.5 rs7163840 ENSG00000278603.1 RP13-608F4.5 -4.54 7.67e-06 0.00211 -0.31 -0.24 Schizophrenia; chr15:82729551 chr15:82472203~82472426:+ LIHC cis rs9368481 0.743 rs9368480 ENSG00000241549.7 GUSBP2 4.54 7.68e-06 0.00211 0.26 0.24 Autism spectrum disorder or schizophrenia; chr6:26987971 chr6:26871484~26956554:- LIHC cis rs748404 0.697 rs574065 ENSG00000166763.7 STRCP1 -4.54 7.68e-06 0.00211 -0.29 -0.24 Lung cancer; chr15:43258457 chr15:43699488~43718184:- LIHC cis rs4964805 0.594 rs751448 ENSG00000257681.1 RP11-341G23.4 4.54 7.68e-06 0.00211 0.25 0.24 Attention deficit hyperactivity disorder; chr12:103773407 chr12:103746315~103768858:- LIHC cis rs10829156 0.898 rs6482565 ENSG00000240291.1 RP11-499P20.2 4.54 7.68e-06 0.00211 0.37 0.24 Sudden cardiac arrest; chr10:18611664 chr10:18513115~18545651:- LIHC cis rs2337406 0.866 rs2027901 ENSG00000274576.2 IGHV2-70 -4.54 7.68e-06 0.00211 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106807164 chr14:106770577~106771020:- LIHC cis rs4713118 0.513 rs149954 ENSG00000219392.1 RP1-265C24.5 -4.54 7.68e-06 0.00211 -0.32 -0.24 Parkinson's disease; chr6:28067468 chr6:28115628~28116551:+ LIHC cis rs6545883 0.525 rs1177274 ENSG00000271889.1 RP11-493E12.1 4.54 7.68e-06 0.00211 0.28 0.24 Tuberculosis; chr2:61141397 chr2:61151433~61162105:- LIHC cis rs2877649 1 rs8020496 ENSG00000258744.1 RP11-80A15.1 4.54 7.69e-06 0.00211 0.45 0.24 Smooth-surface caries; chr14:24484544 chr14:24501594~24508688:+ LIHC cis rs11098499 0.754 rs28643450 ENSG00000245958.5 RP11-33B1.1 -4.54 7.7e-06 0.00211 -0.24 -0.24 Corneal astigmatism; chr4:119324087 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs10017371 ENSG00000245958.5 RP11-33B1.1 -4.54 7.7e-06 0.00211 -0.25 -0.24 Corneal astigmatism; chr4:119372621 chr4:119454791~119552025:+ LIHC cis rs9487094 0.885 rs59906308 ENSG00000260273.1 RP11-425D10.10 4.54 7.7e-06 0.00211 0.29 0.24 Height; chr6:109438349 chr6:109382795~109383666:+ LIHC cis rs12478296 0.786 rs72620862 ENSG00000261186.2 RP11-341N2.1 -4.54 7.71e-06 0.00211 -0.34 -0.24 Obesity-related traits; chr2:242102636 chr2:242087351~242088457:- LIHC cis rs12478296 1 rs66466023 ENSG00000261186.2 RP11-341N2.1 -4.54 7.71e-06 0.00211 -0.34 -0.24 Obesity-related traits; chr2:242104000 chr2:242087351~242088457:- LIHC cis rs12478296 0.901 rs56318767 ENSG00000261186.2 RP11-341N2.1 -4.54 7.71e-06 0.00211 -0.34 -0.24 Obesity-related traits; chr2:242104440 chr2:242087351~242088457:- LIHC cis rs1247318 1 rs1247321 ENSG00000243831.1 RP1-81D8.4 4.54 7.71e-06 0.00211 0.34 0.24 Aging; chr6:160911178 chr6:160666228~160676523:- LIHC cis rs2565722 0.583 rs2465841 ENSG00000243831.1 RP1-81D8.4 4.54 7.71e-06 0.00212 0.32 0.24 Blood protein levels; chr6:160874122 chr6:160666228~160676523:- LIHC cis rs2565722 0.622 rs1937483 ENSG00000243831.1 RP1-81D8.4 4.54 7.71e-06 0.00212 0.32 0.24 Blood protein levels; chr6:160874566 chr6:160666228~160676523:- LIHC cis rs71520386 0.607 rs28617621 ENSG00000228649.7 AC005682.5 -4.54 7.72e-06 0.00212 -0.31 -0.24 Fibrinogen levels; chr7:22818063 chr7:22854178~22861579:+ LIHC cis rs11637445 0.589 rs7497457 ENSG00000260657.2 RP11-315D16.4 -4.54 7.72e-06 0.00212 -0.34 -0.24 Posterior cortical atrophy and Alzheimer's disease; chr15:67840385 chr15:68267792~68277994:- LIHC cis rs5756813 0.646 rs3788528 ENSG00000233360.4 Z83844.1 -4.54 7.72e-06 0.00212 -0.28 -0.24 Optic cup area;Vertical cup-disc ratio; chr22:37750426 chr22:37641832~37658377:- LIHC cis rs9487094 0.922 rs1048203 ENSG00000260273.1 RP11-425D10.10 4.54 7.73e-06 0.00212 0.29 0.24 Height; chr6:109441033 chr6:109382795~109383666:+ LIHC cis rs6997458 0.742 rs1908075 ENSG00000253549.4 RP11-317J10.2 4.54 7.73e-06 0.00212 0.26 0.24 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85434567 chr8:85441851~85464915:- LIHC cis rs6997458 0.742 rs11985733 ENSG00000253549.4 RP11-317J10.2 4.54 7.73e-06 0.00212 0.26 0.24 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85434845 chr8:85441851~85464915:- LIHC cis rs6997458 0.742 rs11985029 ENSG00000253549.4 RP11-317J10.2 4.54 7.73e-06 0.00212 0.26 0.24 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85434887 chr8:85441851~85464915:- LIHC cis rs2274273 0.84 rs3742569 ENSG00000258413.1 RP11-665C16.6 -4.54 7.73e-06 0.00212 -0.28 -0.24 Protein biomarker; chr14:55351988 chr14:55262767~55272075:- LIHC cis rs3916 0.794 rs10431386 ENSG00000277423.1 RP11-173P15.9 -4.54 7.73e-06 0.00212 -0.27 -0.24 Urinary metabolites (H-NMR features); chr12:120691123 chr12:120703867~120704282:+ LIHC cis rs1160985 0.967 rs1038026 ENSG00000214855.8 APOC1P1 -4.54 7.74e-06 0.00212 -0.29 -0.24 C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels; chr19:44901805 chr19:44926804~44931386:+ LIHC cis rs7714584 1 rs76548544 ENSG00000197083.10 ZNF300P1 4.54 7.74e-06 0.00212 0.37 0.24 Crohn's disease; chr5:150843953 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs73282255 ENSG00000197083.10 ZNF300P1 4.54 7.74e-06 0.00212 0.37 0.24 Crohn's disease; chr5:150844085 chr5:150930645~150946289:- LIHC cis rs73186030 0.92 rs17265703 ENSG00000272758.4 RP11-299J3.8 -4.54 7.74e-06 0.00212 -0.45 -0.24 Serum parathyroid hormone levels; chr3:122329797 chr3:122416207~122443180:+ LIHC cis rs2976388 0.609 rs2585145 ENSG00000253741.1 CTD-2292P10.4 -4.54 7.75e-06 0.00212 -0.27 -0.24 Urinary tract infection frequency; chr8:142718039 chr8:142702252~142726973:- LIHC cis rs11089937 0.626 rs5757013 ENSG00000211639.2 IGLV4-60 4.54 7.75e-06 0.00212 0.2 0.24 Periodontitis (PAL4Q3); chr22:22135544 chr22:22162199~22162681:+ LIHC cis rs11089937 0.626 rs5757014 ENSG00000211639.2 IGLV4-60 4.54 7.75e-06 0.00212 0.2 0.24 Periodontitis (PAL4Q3); chr22:22135612 chr22:22162199~22162681:+ LIHC cis rs12701220 0.522 rs12701455 ENSG00000229043.2 AC091729.9 -4.54 7.75e-06 0.00212 -0.31 -0.24 Bronchopulmonary dysplasia; chr7:1015773 chr7:1160374~1165267:+ LIHC cis rs2243480 1 rs437889 ENSG00000230295.1 RP11-458F8.2 -4.54 7.75e-06 0.00213 -0.25 -0.24 Diabetic kidney disease; chr7:66044247 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs402418 ENSG00000230295.1 RP11-458F8.2 -4.54 7.75e-06 0.00213 -0.25 -0.24 Diabetic kidney disease; chr7:66044482 chr7:66880708~66882981:+ LIHC cis rs2243480 0.803 rs423187 ENSG00000230295.1 RP11-458F8.2 -4.54 7.75e-06 0.00213 -0.25 -0.24 Diabetic kidney disease; chr7:66044512 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs431318 ENSG00000230295.1 RP11-458F8.2 -4.54 7.75e-06 0.00213 -0.25 -0.24 Diabetic kidney disease; chr7:66046610 chr7:66880708~66882981:+ LIHC cis rs61160187 0.583 rs6449503 ENSG00000272308.1 RP11-231G3.1 4.54 7.76e-06 0.00213 0.28 0.24 Educational attainment (years of education);Educational attainment (college completion); chr5:60799445 chr5:60866457~60866935:- LIHC cis rs1061377 0.748 rs11096977 ENSG00000249685.1 RP11-360F5.3 4.54 7.77e-06 0.00213 0.29 0.24 Uric acid levels; chr4:39106186 chr4:39133913~39135608:+ LIHC cis rs1061377 0.748 rs6810770 ENSG00000249685.1 RP11-360F5.3 4.54 7.77e-06 0.00213 0.29 0.24 Uric acid levels; chr4:39106545 chr4:39133913~39135608:+ LIHC cis rs11148252 0.904 rs9526927 ENSG00000278238.1 RP11-245D16.4 -4.54 7.78e-06 0.00213 -0.23 -0.24 Lewy body disease; chr13:52477492 chr13:52454775~52455331:- LIHC cis rs960902 0.592 rs6753503 ENSG00000213553.4 RPLP0P6 -4.54 7.78e-06 0.00213 -0.19 -0.24 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37509024 chr2:38481851~38482804:+ LIHC cis rs75920871 0.61 rs74341458 ENSG00000254851.1 RP11-109L13.1 -4.54 7.79e-06 0.00213 -0.48 -0.24 Subjective well-being; chr11:116880833 chr11:117135528~117138582:+ LIHC cis rs12291225 0.679 rs11369 ENSG00000251991.1 RNU7-49P 4.54 7.8e-06 0.00214 0.26 0.24 Sense of smell; chr11:14266550 chr11:14478892~14478953:+ LIHC cis rs12291225 0.679 rs11238 ENSG00000251991.1 RNU7-49P -4.54 7.8e-06 0.00214 -0.26 -0.24 Sense of smell; chr11:14266582 chr11:14478892~14478953:+ LIHC cis rs6480314 0.542 rs7078967 ENSG00000233590.1 RP11-153K11.3 -4.54 7.8e-06 0.00214 -0.36 -0.24 Optic nerve measurement (disc area); chr10:68266564 chr10:68233251~68242379:- LIHC cis rs17270561 0.779 rs12209218 ENSG00000216436.2 HIST1H2APS1 -4.54 7.81e-06 0.00214 -0.37 -0.24 Iron status biomarkers; chr6:25887548 chr6:25732497~25732827:+ LIHC cis rs728616 0.867 rs56271768 ENSG00000225484.5 NUTM2B-AS1 -4.54 7.81e-06 0.00214 -0.5 -0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80077295 chr10:79663088~79826594:- LIHC cis rs763121 0.853 rs138706 ENSG00000273076.1 RP3-508I15.22 4.54 7.82e-06 0.00214 0.27 0.24 Menopause (age at onset); chr22:38741829 chr22:38743495~38743910:+ LIHC cis rs4578769 0.959 rs6507323 ENSG00000265943.1 RP11-739L10.1 -4.54 7.82e-06 0.00214 -0.3 -0.24 Eosinophil percentage of white cells; chr18:22846715 chr18:22699481~22933764:- LIHC cis rs198389 0.589 rs198391 ENSG00000242349.4 NPPA-AS1 4.54 7.83e-06 0.00214 0.25 0.24 B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome; chr1:11816360 chr1:11841017~11848079:+ LIHC cis rs7246657 0.943 rs10415358 ENSG00000276846.1 CTD-3220F14.3 4.54 7.83e-06 0.00214 0.31 0.24 Coronary artery calcification; chr19:37317961 chr19:37314868~37315620:- LIHC cis rs11098499 0.554 rs2175381 ENSG00000245958.5 RP11-33B1.1 -4.54 7.83e-06 0.00214 -0.23 -0.24 Corneal astigmatism; chr4:119344812 chr4:119454791~119552025:+ LIHC cis rs4663866 0.505 rs3739064 ENSG00000186235.9 AC016757.3 4.54 7.84e-06 0.00215 0.44 0.24 Irritable bowel syndrome; chr2:238267745 chr2:238224552~238231677:- LIHC cis rs673078 0.607 rs4442583 ENSG00000275759.1 RP11-131L12.3 -4.54 7.84e-06 0.00215 -0.31 -0.24 Glucose homeostasis traits; chr12:118367914 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs61943370 ENSG00000275759.1 RP11-131L12.3 -4.54 7.84e-06 0.00215 -0.31 -0.24 Glucose homeostasis traits; chr12:118369469 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs61943371 ENSG00000275759.1 RP11-131L12.3 -4.54 7.84e-06 0.00215 -0.31 -0.24 Glucose homeostasis traits; chr12:118369600 chr12:118428281~118428870:+ LIHC cis rs2735413 0.958 rs1922611 ENSG00000276007.1 RP11-358L22.3 -4.54 7.84e-06 0.00215 -0.27 -0.24 Systolic blood pressure (alcohol consumption interaction); chr16:78019224 chr16:78123243~78124332:+ LIHC cis rs2735413 1 rs2735413 ENSG00000276007.1 RP11-358L22.3 -4.54 7.84e-06 0.00215 -0.27 -0.24 Systolic blood pressure (alcohol consumption interaction); chr16:78019746 chr16:78123243~78124332:+ LIHC cis rs2735413 0.957 rs2735414 ENSG00000276007.1 RP11-358L22.3 -4.54 7.84e-06 0.00215 -0.27 -0.24 Systolic blood pressure (alcohol consumption interaction); chr16:78019761 chr16:78123243~78124332:+ LIHC cis rs9890032 0.57 rs8068504 ENSG00000263531.1 RP13-753N3.1 4.54 7.85e-06 0.00215 0.32 0.24 Hip circumference adjusted for BMI; chr17:30785052 chr17:30863921~30864940:- LIHC cis rs7044106 0.791 rs10818473 ENSG00000238181.2 AHCYP2 -4.54 7.85e-06 0.00215 -0.27 -0.24 Hip circumference adjusted for BMI; chr9:120721877 chr9:120720673~120721972:+ LIHC cis rs7811142 0.83 rs78256546 ENSG00000242294.5 STAG3L5P 4.54 7.85e-06 0.00215 0.26 0.24 Platelet count; chr7:100355347 chr7:100336079~100351900:+ LIHC cis rs7811142 0.83 rs41280971 ENSG00000242294.5 STAG3L5P 4.54 7.85e-06 0.00215 0.26 0.24 Platelet count; chr7:100356834 chr7:100336079~100351900:+ LIHC cis rs7811142 0.83 rs3087502 ENSG00000242294.5 STAG3L5P 4.54 7.85e-06 0.00215 0.26 0.24 Platelet count; chr7:100357741 chr7:100336079~100351900:+ LIHC cis rs7811142 0.83 rs61735533 ENSG00000242294.5 STAG3L5P 4.54 7.85e-06 0.00215 0.26 0.24 Platelet count; chr7:100358243 chr7:100336079~100351900:+ LIHC cis rs7811142 0.83 rs11761426 ENSG00000242294.5 STAG3L5P 4.54 7.85e-06 0.00215 0.26 0.24 Platelet count; chr7:100359270 chr7:100336079~100351900:+ LIHC cis rs763121 0.853 rs138709 ENSG00000273076.1 RP3-508I15.22 4.54 7.86e-06 0.00215 0.27 0.24 Menopause (age at onset); chr22:38743211 chr22:38743495~38743910:+ LIHC cis rs3809863 0.602 rs11650072 ENSG00000228782.6 CTD-2026D20.3 4.54 7.86e-06 0.00215 0.27 0.24 Glaucoma (primary open-angle); chr17:47316299 chr17:47450568~47492492:- LIHC cis rs11098499 0.599 rs3864142 ENSG00000245958.5 RP11-33B1.1 -4.54 7.86e-06 0.00215 -0.23 -0.24 Corneal astigmatism; chr4:119345036 chr4:119454791~119552025:+ LIHC cis rs11098499 0.605 rs6833140 ENSG00000245958.5 RP11-33B1.1 -4.54 7.86e-06 0.00215 -0.23 -0.24 Corneal astigmatism; chr4:119345667 chr4:119454791~119552025:+ LIHC cis rs929596 0.585 rs2018985 ENSG00000233445.1 RPL17P11 4.54 7.86e-06 0.00215 0.28 0.24 Total bilirubin levels in HIV-1 infection; chr2:233740214 chr2:233721522~233722065:- LIHC cis rs2337406 1 rs11850709 ENSG00000274576.2 IGHV2-70 -4.54 7.86e-06 0.00215 -0.28 -0.24 Alzheimer's disease (late onset); chr14:106670844 chr14:106770577~106771020:- LIHC cis rs10883723 0.518 rs10786679 ENSG00000236937.2 PTGES3P4 -4.54 7.86e-06 0.00215 -0.33 -0.24 Allergic disease (asthma, hay fever or eczema); chr10:102555910 chr10:102845595~102845950:+ LIHC cis rs10129255 0.83 rs61997609 ENSG00000223648.3 IGHV3-64 4.54 7.87e-06 0.00215 0.18 0.24 Kawasaki disease; chr14:106692376 chr14:106643132~106658258:- LIHC cis rs79040073 0.53 rs3784630 ENSG00000259531.2 RP11-295H24.3 4.54 7.87e-06 0.00215 0.39 0.24 Lung cancer in ever smokers; chr15:49322952 chr15:49365124~49366685:- LIHC cis rs10129255 0.5 rs8021941 ENSG00000223648.3 IGHV3-64 4.54 7.88e-06 0.00215 0.17 0.24 Kawasaki disease; chr14:106781490 chr14:106643132~106658258:- LIHC cis rs11671005 0.735 rs45617039 ENSG00000269473.1 CTD-2619J13.19 4.54 7.88e-06 0.00215 0.4 0.24 Mean platelet volume; chr19:58439729 chr19:58440448~58445849:+ LIHC cis rs1247318 0.806 rs585649 ENSG00000243831.1 RP1-81D8.4 4.54 7.88e-06 0.00216 0.34 0.24 Aging; chr6:160943752 chr6:160666228~160676523:- LIHC cis rs8091660 0.893 rs1567656 ENSG00000278983.1 RP11-426J5.3 -4.54 7.88e-06 0.00216 -0.35 -0.24 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48568420 chr18:48564795~48568342:+ LIHC cis rs1865760 1 rs2071301 ENSG00000216436.2 HIST1H2APS1 -4.54 7.89e-06 0.00216 -0.26 -0.24 Height; chr6:25914035 chr6:25732497~25732827:+ LIHC cis rs10129255 0.536 rs17113249 ENSG00000211972.2 IGHV3-66 4.54 7.89e-06 0.00216 0.17 0.24 Kawasaki disease; chr14:106678273 chr14:106675017~106675544:- LIHC cis rs227275 0.554 rs223404 ENSG00000246560.2 RP11-10L12.4 4.54 7.89e-06 0.00216 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102816951 chr4:102828055~102844075:+ LIHC cis rs2932538 0.961 rs10745332 ENSG00000225075.1 RP11-426L16.3 -4.54 7.9e-06 0.00216 -0.31 -0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112646431 chr1:112693688~112696621:- LIHC cis rs9807989 0.507 rs2058659 ENSG00000234389.1 AC007278.3 -4.54 7.9e-06 0.00216 -0.26 -0.24 Asthma; chr2:102438096 chr2:102438713~102440475:+ LIHC cis rs9388451 0.626 rs7748729 ENSG00000237742.5 RP11-624M8.1 -4.54 7.9e-06 0.00216 -0.22 -0.24 Brugada syndrome; chr6:125756235 chr6:125578558~125749190:- LIHC cis rs8005677 0.798 rs61977741 ENSG00000279656.1 RP11-298I3.6 4.54 7.91e-06 0.00216 0.27 0.24 Cognitive ability (multi-trait analysis); chr14:22931770 chr14:23023083~23024217:- LIHC cis rs875971 0.638 rs6960778 ENSG00000273024.4 INTS4P2 4.54 7.91e-06 0.00216 0.27 0.24 Aortic root size; chr7:66606610 chr7:65647864~65715661:+ LIHC cis rs875971 0.66 rs7807930 ENSG00000273024.4 INTS4P2 4.54 7.91e-06 0.00216 0.27 0.24 Aortic root size; chr7:66622178 chr7:65647864~65715661:+ LIHC cis rs61160187 0.51 rs7709716 ENSG00000272308.1 RP11-231G3.1 -4.54 7.91e-06 0.00216 -0.29 -0.24 Educational attainment (years of education);Educational attainment (college completion); chr5:60800056 chr5:60866457~60866935:- LIHC cis rs10028773 0.6 rs4001390 ENSG00000245958.5 RP11-33B1.1 -4.54 7.93e-06 0.00217 -0.23 -0.24 Educational attainment; chr4:119344628 chr4:119454791~119552025:+ LIHC cis rs11098499 0.691 rs2136911 ENSG00000245958.5 RP11-33B1.1 -4.54 7.93e-06 0.00217 -0.23 -0.24 Corneal astigmatism; chr4:119344704 chr4:119454791~119552025:+ LIHC cis rs10028773 0.568 rs6838457 ENSG00000245958.5 RP11-33B1.1 -4.54 7.93e-06 0.00217 -0.23 -0.24 Educational attainment; chr4:119346212 chr4:119454791~119552025:+ LIHC cis rs11098499 0.535 rs10005542 ENSG00000245958.5 RP11-33B1.1 -4.54 7.93e-06 0.00217 -0.23 -0.24 Corneal astigmatism; chr4:119347147 chr4:119454791~119552025:+ LIHC cis rs643506 1 rs643506 ENSG00000254990.4 RP11-108O10.2 4.54 7.93e-06 0.00217 0.27 0.24 Breast cancer; chr11:111765903 chr11:111768668~111778350:- LIHC cis rs643506 1 rs612345 ENSG00000254990.4 RP11-108O10.2 4.54 7.93e-06 0.00217 0.27 0.24 Breast cancer; chr11:111768398 chr11:111768668~111778350:- LIHC cis rs643506 0.967 rs2850248 ENSG00000254990.4 RP11-108O10.2 4.54 7.93e-06 0.00217 0.27 0.24 Breast cancer; chr11:111774100 chr11:111768668~111778350:- LIHC cis rs67311347 0.544 rs7644181 ENSG00000223797.4 ENTPD3-AS1 -4.54 7.93e-06 0.00217 -0.2 -0.24 Renal cell carcinoma; chr3:40314174 chr3:40313802~40453329:- LIHC cis rs7615952 0.599 rs6438955 ENSG00000171084.14 FAM86JP 4.54 7.93e-06 0.00217 0.37 0.24 Blood pressure (smoking interaction); chr3:126011490 chr3:125916620~125930024:+ LIHC cis rs9304742 1 rs9304742 ENSG00000213801.4 ZNF816-ZNF321P 4.54 7.93e-06 0.00217 0.23 0.24 Psoriasis; chr19:52948038 chr19:52927135~52942601:- LIHC cis rs58950470 0.927 rs1193851 ENSG00000265874.1 MIR4489 4.54 7.93e-06 0.00217 0.34 0.24 Schizophrenia; chr11:65618735 chr11:65649192~65649253:+ LIHC cis rs67311347 0.955 rs6773383 ENSG00000223797.4 ENTPD3-AS1 4.54 7.94e-06 0.00217 0.19 0.24 Renal cell carcinoma; chr3:40335921 chr3:40313802~40453329:- LIHC cis rs7811142 0.72 rs112622797 ENSG00000242294.5 STAG3L5P 4.54 7.94e-06 0.00217 0.27 0.24 Platelet count; chr7:100319793 chr7:100336079~100351900:+ LIHC cis rs1577917 1 rs12663690 ENSG00000234155.1 RP11-30P6.6 -4.54 7.95e-06 0.00217 -0.31 -0.24 Response to antipsychotic treatment; chr6:85930444 chr6:85387219~85390186:- LIHC cis rs2929278 0.546 rs686666 ENSG00000166763.7 STRCP1 4.54 7.95e-06 0.00217 0.32 0.24 Schizophrenia; chr15:43869352 chr15:43699488~43718184:- LIHC cis rs67311347 1 rs11720360 ENSG00000223797.4 ENTPD3-AS1 4.54 7.95e-06 0.00217 0.2 0.24 Renal cell carcinoma; chr3:40406906 chr3:40313802~40453329:- LIHC cis rs2276314 0.762 rs3826600 ENSG00000278986.1 RP11-723J4.3 -4.54 7.96e-06 0.00217 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36029090 chr18:35972151~35973916:+ LIHC cis rs2276314 0.857 rs72883058 ENSG00000278986.1 RP11-723J4.3 -4.54 7.96e-06 0.00217 -0.29 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36032954 chr18:35972151~35973916:+ LIHC cis rs929596 0.597 rs10173355 ENSG00000233445.1 RPL17P11 4.54 7.96e-06 0.00218 0.27 0.24 Total bilirubin levels in HIV-1 infection; chr2:233688675 chr2:233721522~233722065:- LIHC cis rs61160187 0.51 rs10077663 ENSG00000272308.1 RP11-231G3.1 -4.54 7.97e-06 0.00218 -0.29 -0.24 Educational attainment (years of education);Educational attainment (college completion); chr5:60807665 chr5:60866457~60866935:- LIHC cis rs3733589 0.744 rs10516197 ENSG00000250413.1 RP11-448G15.1 4.54 7.97e-06 0.00218 0.38 0.24 Renal overload gout; chr4:10040476 chr4:10006482~10009725:+ LIHC cis rs12291225 0.679 rs1043237 ENSG00000251991.1 RNU7-49P 4.54 7.97e-06 0.00218 0.25 0.24 Sense of smell; chr11:14267507 chr11:14478892~14478953:+ LIHC cis rs929596 0.639 rs7571915 ENSG00000233445.1 RPL17P11 4.54 7.98e-06 0.00218 0.26 0.24 Total bilirubin levels in HIV-1 infection; chr2:233677928 chr2:233721522~233722065:- LIHC cis rs929596 0.556 rs10202865 ENSG00000233445.1 RPL17P11 4.54 7.98e-06 0.00218 0.26 0.24 Total bilirubin levels in HIV-1 infection; chr2:233679061 chr2:233721522~233722065:- LIHC cis rs11779988 0.545 rs415840 ENSG00000253671.1 RP11-806O11.1 -4.54 7.98e-06 0.00218 -0.32 -0.24 Breast cancer; chr8:17924625 chr8:17808941~17820868:+ LIHC cis rs6997458 0.742 rs10091566 ENSG00000253549.4 RP11-317J10.2 4.53 7.98e-06 0.00218 0.26 0.24 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85429330 chr8:85441851~85464915:- LIHC cis rs4834770 0.792 rs7676969 ENSG00000245958.5 RP11-33B1.1 -4.53 7.98e-06 0.00218 -0.24 -0.24 Blood protein levels; chr4:119252569 chr4:119454791~119552025:+ LIHC cis rs228614 0.534 rs223387 ENSG00000246560.2 RP11-10L12.4 4.53 7.99e-06 0.00218 0.27 0.24 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102828359 chr4:102828055~102844075:+ LIHC cis rs7714584 0.793 rs2161363 ENSG00000197083.10 ZNF300P1 4.53 7.99e-06 0.00218 0.38 0.24 Crohn's disease; chr5:150802517 chr5:150930645~150946289:- LIHC cis rs901683 0.85 rs73291113 ENSG00000230869.1 CTGLF10P -4.53 7.99e-06 0.00218 -0.51 -0.24 Mean corpuscular volume;Red blood cell traits; chr10:45599617 chr10:45678692~45700532:+ LIHC cis rs4713118 0.513 rs149958 ENSG00000219392.1 RP1-265C24.5 -4.53 7.99e-06 0.00218 -0.32 -0.24 Parkinson's disease; chr6:28045839 chr6:28115628~28116551:+ LIHC cis rs4713118 0.513 rs149959 ENSG00000219392.1 RP1-265C24.5 -4.53 7.99e-06 0.00218 -0.32 -0.24 Parkinson's disease; chr6:28046076 chr6:28115628~28116551:+ LIHC cis rs4713118 0.513 rs156738 ENSG00000219392.1 RP1-265C24.5 -4.53 7.99e-06 0.00218 -0.32 -0.24 Parkinson's disease; chr6:28046247 chr6:28115628~28116551:+ LIHC cis rs7193541 0.965 rs7199068 ENSG00000262904.1 TMPOP2 -4.53 8e-06 0.00218 -0.21 -0.24 Multiple myeloma; chr16:74664365 chr16:74667506~74668706:+ LIHC cis rs7849270 0.959 rs3118628 ENSG00000268707.1 RP11-247A12.7 4.53 8e-06 0.00218 0.28 0.24 Blood metabolite ratios; chr9:129123000 chr9:129170434~129170940:+ LIHC cis rs79040073 0.53 rs113085328 ENSG00000259531.2 RP11-295H24.3 4.53 8e-06 0.00218 0.39 0.24 Lung cancer in ever smokers; chr15:49223704 chr15:49365124~49366685:- LIHC cis rs3733589 1 rs10516195 ENSG00000250413.1 RP11-448G15.1 4.53 8.01e-06 0.00219 0.43 0.24 Renal overload gout; chr4:10000209 chr4:10006482~10009725:+ LIHC cis rs2111504 0.806 rs10403559 ENSG00000267213.4 AC007773.2 -4.53 8.02e-06 0.00219 -0.26 -0.24 Bipolar disorder; chr19:32462195 chr19:32390050~32405560:- LIHC cis rs9834975 0.935 rs6438724 ENSG00000272758.4 RP11-299J3.8 -4.53 8.02e-06 0.00219 -0.27 -0.24 Diastolic blood pressure; chr3:122364841 chr3:122416207~122443180:+ LIHC cis rs12478296 1 rs55742408 ENSG00000261186.2 RP11-341N2.1 -4.53 8.03e-06 0.00219 -0.34 -0.24 Obesity-related traits; chr2:242098926 chr2:242087351~242088457:- LIHC cis rs12478296 1 rs12469535 ENSG00000261186.2 RP11-341N2.1 -4.53 8.03e-06 0.00219 -0.34 -0.24 Obesity-related traits; chr2:242101996 chr2:242087351~242088457:- LIHC cis rs1501911 0.611 rs1875529 ENSG00000248489.1 CTD-2007H13.3 -4.53 8.04e-06 0.00219 -0.36 -0.24 Lung function (FEV1/FVC); chr5:99033350 chr5:98929171~98995013:+ LIHC cis rs2998286 0.643 rs332181 ENSG00000254635.4 WAC-AS1 -4.53 8.04e-06 0.00219 -0.31 -0.24 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28621187 chr10:28522652~28532743:- LIHC cis rs2274273 0.624 rs7151581 ENSG00000258413.1 RP11-665C16.6 4.53 8.05e-06 0.0022 0.3 0.24 Protein biomarker; chr14:55321727 chr14:55262767~55272075:- LIHC cis rs2836974 0.602 rs8130854 ENSG00000255568.3 BRWD1-AS2 -4.53 8.05e-06 0.0022 -0.2 -0.24 Cognitive function; chr21:39335115 chr21:39313935~39314962:+ LIHC cis rs2836974 0.605 rs2836988 ENSG00000255568.3 BRWD1-AS2 -4.53 8.05e-06 0.0022 -0.2 -0.24 Cognitive function; chr21:39336049 chr21:39313935~39314962:+ LIHC cis rs7811142 0.945 rs6955362 ENSG00000242294.5 STAG3L5P 4.53 8.06e-06 0.0022 0.29 0.24 Platelet count; chr7:100458543 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs6975514 ENSG00000242294.5 STAG3L5P 4.53 8.06e-06 0.0022 0.29 0.24 Platelet count; chr7:100458597 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs7811142 ENSG00000242294.5 STAG3L5P 4.53 8.06e-06 0.0022 0.29 0.24 Platelet count; chr7:100467820 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs11773661 ENSG00000242294.5 STAG3L5P 4.53 8.06e-06 0.0022 0.29 0.24 Platelet count; chr7:100475446 chr7:100336079~100351900:+ LIHC cis rs7811142 0.943 rs66958101 ENSG00000242294.5 STAG3L5P 4.53 8.06e-06 0.0022 0.29 0.24 Platelet count; chr7:100476397 chr7:100336079~100351900:+ LIHC cis rs12134133 1 rs61822669 ENSG00000274245.1 RP11-357P18.2 4.53 8.06e-06 0.0022 0.36 0.24 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207247869 chr1:207372559~207373252:+ LIHC cis rs950169 0.922 rs62021167 ENSG00000259728.4 LINC00933 4.53 8.07e-06 0.0022 0.34 0.24 Schizophrenia; chr15:84574820 chr15:84570649~84580175:+ LIHC cis rs4964805 0.505 rs4981032 ENSG00000257681.1 RP11-341G23.4 4.53 8.07e-06 0.0022 0.24 0.24 Attention deficit hyperactivity disorder; chr12:103772086 chr12:103746315~103768858:- LIHC cis rs4964805 0.594 rs9132 ENSG00000257681.1 RP11-341G23.4 4.53 8.07e-06 0.0022 0.24 0.24 Attention deficit hyperactivity disorder; chr12:103772465 chr12:103746315~103768858:- LIHC cis rs10995505 0.589 rs10822140 ENSG00000232075.1 MRPL35P2 -4.53 8.07e-06 0.0022 -0.26 -0.24 Intelligence (multi-trait analysis); chr10:63123267 chr10:63634317~63634827:- LIHC cis rs9595908 0.897 rs10083285 ENSG00000212293.1 SNORA16 4.53 8.08e-06 0.0022 0.27 0.24 Body mass index; chr13:32557205 chr13:32420390~32420516:- LIHC cis rs6433895 0.667 rs35702511 ENSG00000236153.1 AC104076.3 -4.53 8.08e-06 0.0022 -0.33 -0.24 Lymphocyte counts; chr2:181153379 chr2:180979427~180980090:- LIHC cis rs11971779 0.68 rs10271297 ENSG00000273391.1 RP11-634H22.1 4.53 8.08e-06 0.0022 0.21 0.24 Diisocyanate-induced asthma; chr7:139367564 chr7:139359032~139359566:- LIHC cis rs2932538 0.922 rs61818800 ENSG00000225075.1 RP11-426L16.3 4.53 8.09e-06 0.0022 0.31 0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112605949 chr1:112693688~112696621:- LIHC cis rs11668505 0.965 rs3745752 ENSG00000259108.2 CTD-3098H1.2 4.53 8.09e-06 0.0022 0.3 0.24 Lung function (FVC); chr19:47836043 chr19:47863483~47865341:- LIHC cis rs1577917 0.916 rs12203358 ENSG00000234155.1 RP11-30P6.6 4.53 8.09e-06 0.0022 0.31 0.24 Response to antipsychotic treatment; chr6:85893506 chr6:85387219~85390186:- LIHC cis rs875971 0.502 rs11769702 ENSG00000273142.1 RP11-458F8.4 4.53 8.09e-06 0.00221 0.23 0.24 Aortic root size; chr7:66255529 chr7:66902857~66906297:+ LIHC cis rs202072 0.585 rs1512414 ENSG00000215022.6 RP1-257A7.4 -4.53 8.1e-06 0.00221 -0.25 -0.24 HIV-1 viral setpoint; chr6:13276183 chr6:13264861~13295586:- LIHC cis rs10829156 0.57 rs7904365 ENSG00000240291.1 RP11-499P20.2 4.53 8.1e-06 0.00221 0.37 0.24 Sudden cardiac arrest; chr10:18542375 chr10:18513115~18545651:- LIHC cis rs853679 0.723 rs1736904 ENSG00000216901.1 AL022393.7 4.53 8.1e-06 0.00221 0.29 0.24 Depression; chr6:28251492 chr6:28176188~28176674:+ LIHC cis rs7586970 0.556 rs7573488 ENSG00000224063.4 AC007319.1 4.53 8.1e-06 0.00221 0.36 0.24 Coronary heart disease; chr2:187533353 chr2:187003220~187554663:+ LIHC cis rs7586970 0.583 rs6434220 ENSG00000224063.4 AC007319.1 4.53 8.1e-06 0.00221 0.36 0.24 Coronary heart disease; chr2:187537266 chr2:187003220~187554663:+ LIHC cis rs643506 0.715 rs11214031 ENSG00000254990.4 RP11-108O10.2 4.53 8.11e-06 0.00221 0.26 0.24 Breast cancer; chr11:111895315 chr11:111768668~111778350:- LIHC cis rs11096990 0.634 rs7654501 ENSG00000249685.1 RP11-360F5.3 -4.53 8.12e-06 0.00221 -0.28 -0.24 Cognitive function; chr4:39282364 chr4:39133913~39135608:+ LIHC cis rs11971779 0.68 rs6960876 ENSG00000273391.1 RP11-634H22.1 -4.53 8.13e-06 0.00221 -0.21 -0.24 Diisocyanate-induced asthma; chr7:139427430 chr7:139359032~139359566:- LIHC cis rs11098499 0.618 rs6858383 ENSG00000245958.5 RP11-33B1.1 -4.53 8.13e-06 0.00221 -0.25 -0.24 Corneal astigmatism; chr4:119375617 chr4:119454791~119552025:+ LIHC cis rs11098499 0.697 rs6832410 ENSG00000245958.5 RP11-33B1.1 -4.53 8.13e-06 0.00221 -0.25 -0.24 Corneal astigmatism; chr4:119375645 chr4:119454791~119552025:+ LIHC cis rs11098499 0.865 rs1112817 ENSG00000245958.5 RP11-33B1.1 -4.53 8.13e-06 0.00221 -0.25 -0.24 Corneal astigmatism; chr4:119376645 chr4:119454791~119552025:+ LIHC cis rs11098499 0.779 rs10016060 ENSG00000245958.5 RP11-33B1.1 -4.53 8.13e-06 0.00221 -0.25 -0.24 Corneal astigmatism; chr4:119377257 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs10005644 ENSG00000245958.5 RP11-33B1.1 -4.53 8.13e-06 0.00221 -0.25 -0.24 Corneal astigmatism; chr4:119377322 chr4:119454791~119552025:+ LIHC cis rs11098499 0.697 rs10016448 ENSG00000245958.5 RP11-33B1.1 -4.53 8.13e-06 0.00221 -0.25 -0.24 Corneal astigmatism; chr4:119377690 chr4:119454791~119552025:+ LIHC cis rs11098499 0.657 rs9996569 ENSG00000245958.5 RP11-33B1.1 -4.53 8.13e-06 0.00221 -0.25 -0.24 Corneal astigmatism; chr4:119377849 chr4:119454791~119552025:+ LIHC cis rs11098499 0.908 rs11729050 ENSG00000245958.5 RP11-33B1.1 -4.53 8.13e-06 0.00221 -0.25 -0.24 Corneal astigmatism; chr4:119378911 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs28429722 ENSG00000245958.5 RP11-33B1.1 -4.53 8.13e-06 0.00221 -0.25 -0.24 Corneal astigmatism; chr4:119378938 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs10014845 ENSG00000245958.5 RP11-33B1.1 -4.53 8.13e-06 0.00221 -0.25 -0.24 Corneal astigmatism; chr4:119379922 chr4:119454791~119552025:+ LIHC cis rs2877649 0.793 rs78218947 ENSG00000258744.1 RP11-80A15.1 -4.53 8.13e-06 0.00221 -0.49 -0.24 Smooth-surface caries; chr14:24437590 chr14:24501594~24508688:+ LIHC cis rs2877649 0.793 rs80093911 ENSG00000258744.1 RP11-80A15.1 -4.53 8.13e-06 0.00221 -0.49 -0.24 Smooth-surface caries; chr14:24437634 chr14:24501594~24508688:+ LIHC cis rs2877649 0.793 rs77629187 ENSG00000258744.1 RP11-80A15.1 -4.53 8.13e-06 0.00221 -0.49 -0.24 Smooth-surface caries; chr14:24437749 chr14:24501594~24508688:+ LIHC cis rs227275 0.554 rs223439 ENSG00000246560.2 RP11-10L12.4 4.53 8.13e-06 0.00222 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102798377 chr4:102828055~102844075:+ LIHC cis rs227275 0.554 rs223436 ENSG00000246560.2 RP11-10L12.4 4.53 8.13e-06 0.00222 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102798749 chr4:102828055~102844075:+ LIHC cis rs673078 0.607 rs11068926 ENSG00000275759.1 RP11-131L12.3 -4.53 8.14e-06 0.00222 -0.31 -0.24 Glucose homeostasis traits; chr12:118367320 chr12:118428281~118428870:+ LIHC cis rs74181299 0.684 rs1420183 ENSG00000225889.6 AC074289.1 4.53 8.14e-06 0.00222 0.27 0.24 Pulse pressure; chr2:65082854 chr2:64143239~64252859:+ LIHC cis rs67311347 0.911 rs6775936 ENSG00000223797.4 ENTPD3-AS1 4.53 8.14e-06 0.00222 0.19 0.24 Renal cell carcinoma; chr3:40335908 chr3:40313802~40453329:- LIHC cis rs11668505 0.965 rs11667607 ENSG00000259108.2 CTD-3098H1.2 4.53 8.15e-06 0.00222 0.3 0.24 Lung function (FVC); chr19:47835459 chr19:47863483~47865341:- LIHC cis rs11673344 0.801 rs56343212 ENSG00000226686.6 LINC01535 4.53 8.15e-06 0.00222 0.37 0.24 Obesity-related traits; chr19:37167684 chr19:37251912~37265535:+ LIHC cis rs8177253 0.632 rs6782523 ENSG00000244062.1 RP11-404G16.2 4.53 8.15e-06 0.00222 0.24 0.24 Iron status biomarkers; chr3:133720073 chr3:133760300~133762363:+ LIHC cis rs7665090 0.87 rs227361 ENSG00000230069.3 LRRC37A15P -4.53 8.15e-06 0.00222 -0.22 -0.24 Primary biliary cholangitis; chr4:102665820 chr4:102727274~102730721:- LIHC cis rs673078 0.66 rs2280711 ENSG00000275759.1 RP11-131L12.3 -4.53 8.16e-06 0.00222 -0.3 -0.24 Glucose homeostasis traits; chr12:118212149 chr12:118428281~118428870:+ LIHC cis rs2688482 0.512 rs3103954 ENSG00000185485.13 SDHAP1 4.53 8.16e-06 0.00222 0.28 0.24 Lung disease severity in cystic fibrosis; chr3:195789759 chr3:195959748~195990318:- LIHC cis rs12220777 0.748 rs11201641 ENSG00000230091.5 TMEM254-AS1 4.53 8.17e-06 0.00222 0.29 0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80091975 chr10:80046860~80078912:- LIHC cis rs12220777 0.748 rs7920814 ENSG00000230091.5 TMEM254-AS1 4.53 8.17e-06 0.00222 0.29 0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80095713 chr10:80046860~80078912:- LIHC cis rs12220777 0.748 rs6584955 ENSG00000230091.5 TMEM254-AS1 4.53 8.17e-06 0.00222 0.29 0.24 Chronic obstructive pulmonary disease-related biomarkers; chr10:80100568 chr10:80046860~80078912:- LIHC cis rs887829 0.694 rs6749496 ENSG00000233445.1 RPL17P11 4.53 8.18e-06 0.00223 0.28 0.24 Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels; chr2:233715640 chr2:233721522~233722065:- LIHC cis rs16958440 0.867 rs77348110 ENSG00000267724.1 RP11-49K24.8 4.53 8.18e-06 0.00223 0.37 0.24 Sitting height ratio; chr18:47147796 chr18:47105946~47108062:+ LIHC cis rs6997458 0.742 rs955007 ENSG00000253549.4 RP11-317J10.2 4.53 8.18e-06 0.00223 0.25 0.24 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85458166 chr8:85441851~85464915:- LIHC cis rs8040855 0.627 rs1532776 ENSG00000259295.5 CSPG4P12 4.53 8.18e-06 0.00223 0.37 0.24 Bulimia nervosa; chr15:85081383 chr15:85191438~85213905:+ LIHC cis rs11673344 0.548 rs2058852 ENSG00000226686.6 LINC01535 4.53 8.19e-06 0.00223 0.33 0.24 Obesity-related traits; chr19:37673701 chr19:37251912~37265535:+ LIHC cis rs12554020 0.892 rs12341488 ENSG00000227603.1 RP11-165J3.6 4.53 8.19e-06 0.00223 0.32 0.24 Schizophrenia; chr9:93568889 chr9:93435332~93437121:- LIHC cis rs12554020 0.786 rs7857183 ENSG00000227603.1 RP11-165J3.6 4.53 8.19e-06 0.00223 0.32 0.24 Schizophrenia; chr9:93569762 chr9:93435332~93437121:- LIHC cis rs67311347 0.868 rs10865895 ENSG00000223797.4 ENTPD3-AS1 4.53 8.19e-06 0.00223 0.19 0.24 Renal cell carcinoma; chr3:40337186 chr3:40313802~40453329:- LIHC cis rs853679 0.527 rs853693 ENSG00000204709.4 LINC01556 4.53 8.2e-06 0.00223 0.26 0.24 Depression; chr6:28314871 chr6:28943877~28944537:+ LIHC cis rs12887734 0.546 rs12886637 ENSG00000258534.1 CTD-2134A5.4 4.53 8.2e-06 0.00223 0.26 0.24 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103756555 chr14:103854366~103880111:- LIHC cis rs2834188 0.924 rs2834177 ENSG00000272659.1 AP000295.10 -4.53 8.22e-06 0.00223 -0.34 -0.24 Narcolepsy; chr21:33304501 chr21:33309491~33310181:+ LIHC cis rs8005677 0.828 rs12589539 ENSG00000279656.1 RP11-298I3.6 4.53 8.22e-06 0.00224 0.27 0.24 Cognitive ability (multi-trait analysis); chr14:22927471 chr14:23023083~23024217:- LIHC cis rs2439831 0.702 rs2467402 ENSG00000166763.7 STRCP1 -4.53 8.23e-06 0.00224 -0.36 -0.24 Lung cancer in ever smokers; chr15:43732292 chr15:43699488~43718184:- LIHC cis rs11722779 0.692 rs223414 ENSG00000246560.2 RP11-10L12.4 4.53 8.23e-06 0.00224 0.27 0.24 Schizophrenia; chr4:102811688 chr4:102828055~102844075:+ LIHC cis rs7208859 0.673 rs423151 ENSG00000266490.1 CTD-2349P21.9 4.53 8.23e-06 0.00224 0.28 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30625268 chr17:30792372~30792833:+ LIHC cis rs4865169 0.595 rs4865165 ENSG00000269949.1 RP11-738E22.3 -4.53 8.24e-06 0.00224 -0.29 -0.24 Breast cancer; chr4:56899380 chr4:56960927~56961373:- LIHC cis rs712039 0.617 rs853201 ENSG00000276054.1 RP11-378E13.3 4.53 8.24e-06 0.00224 0.3 0.24 Tuberculosis; chr17:37444086 chr17:37386886~37387926:+ LIHC cis rs2948294 0.545 rs11776397 ENSG00000253981.4 ALG1L13P 4.53 8.24e-06 0.00224 0.28 0.24 Red cell distribution width; chr8:8257639 chr8:8236003~8244667:- LIHC cis rs7121538 0.932 rs16930180 ENSG00000251991.1 RNU7-49P -4.53 8.25e-06 0.00224 -0.35 -0.24 HDL cholesterol; chr11:14450731 chr11:14478892~14478953:+ LIHC cis rs6479891 0.63 rs4545434 ENSG00000232075.1 MRPL35P2 4.53 8.25e-06 0.00224 0.27 0.24 Arthritis (juvenile idiopathic); chr10:63115985 chr10:63634317~63634827:- LIHC cis rs2439831 0.85 rs7169988 ENSG00000166763.7 STRCP1 4.53 8.25e-06 0.00224 0.37 0.24 Lung cancer in ever smokers; chr15:43768237 chr15:43699488~43718184:- LIHC cis rs957448 0.503 rs752460 ENSG00000253704.1 RP11-267M23.4 4.53 8.25e-06 0.00224 0.27 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94477994 chr8:94553722~94569745:+ LIHC cis rs12681366 0.801 rs4735293 ENSG00000253704.1 RP11-267M23.4 4.53 8.25e-06 0.00224 0.27 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94478175 chr8:94553722~94569745:+ LIHC cis rs11722228 0.549 rs56146302 ENSG00000261490.1 RP11-448G15.3 4.53 8.26e-06 0.00224 0.31 0.24 Urate levels;Serum uric acid levels;Gout; chr4:10079428 chr4:10068089~10073019:- LIHC cis rs11722228 0.549 rs55848383 ENSG00000261490.1 RP11-448G15.3 4.53 8.26e-06 0.00224 0.31 0.24 Urate levels;Serum uric acid levels;Gout; chr4:10079493 chr4:10068089~10073019:- LIHC cis rs67311347 1 rs2305521 ENSG00000223797.4 ENTPD3-AS1 4.53 8.26e-06 0.00225 0.19 0.24 Renal cell carcinoma; chr3:40387692 chr3:40313802~40453329:- LIHC cis rs2439831 0.85 rs3825783 ENSG00000166763.7 STRCP1 4.53 8.27e-06 0.00225 0.37 0.24 Lung cancer in ever smokers; chr15:43810111 chr15:43699488~43718184:- LIHC cis rs1062177 0.826 rs2915822 ENSG00000253921.1 CTB-113P19.3 4.53 8.28e-06 0.00225 0.27 0.24 Preschool internalizing problems; chr5:151751340 chr5:151753992~151767247:+ LIHC cis rs160451 0.966 rs218886 ENSG00000251136.7 RP11-37B2.1 -4.53 8.28e-06 0.00225 -0.21 -0.24 Leprosy; chr8:89678365 chr8:89609409~89757727:- LIHC cis rs11098499 0.863 rs6858592 ENSG00000245958.5 RP11-33B1.1 -4.53 8.29e-06 0.00225 -0.25 -0.24 Corneal astigmatism; chr4:119537537 chr4:119454791~119552025:+ LIHC cis rs160451 0.933 rs218888 ENSG00000251136.7 RP11-37B2.1 -4.53 8.3e-06 0.00225 -0.21 -0.24 Leprosy; chr8:89679693 chr8:89609409~89757727:- LIHC cis rs4834770 0.685 rs4496567 ENSG00000245958.5 RP11-33B1.1 -4.53 8.3e-06 0.00226 -0.24 -0.24 Blood protein levels; chr4:119254470 chr4:119454791~119552025:+ LIHC cis rs950027 0.787 rs1153845 ENSG00000259433.2 CTD-2651B20.4 4.53 8.31e-06 0.00226 0.32 0.24 Response to fenofibrate (adiponectin levels); chr15:45432531 chr15:45330209~45332634:- LIHC cis rs8040855 0.627 rs72757059 ENSG00000259295.5 CSPG4P12 4.53 8.32e-06 0.00226 0.37 0.24 Bulimia nervosa; chr15:85059918 chr15:85191438~85213905:+ LIHC cis rs7702057 0.53 rs6890263 ENSG00000271918.1 CTD-2287O16.5 4.53 8.32e-06 0.00226 0.32 0.24 Amyotrophic lateral sclerosis; chr5:116079739 chr5:116083807~116085416:- LIHC cis rs172166 0.694 rs536704 ENSG00000216901.1 AL022393.7 4.53 8.33e-06 0.00226 0.3 0.24 Cardiac Troponin-T levels; chr6:28124825 chr6:28176188~28176674:+ LIHC cis rs2333021 0.689 rs2535897 ENSG00000259015.1 RP11-109N23.6 -4.53 8.34e-06 0.00227 -0.28 -0.24 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72967514 chr14:72960595~72961993:+ LIHC cis rs2274273 0.84 rs10136596 ENSG00000258413.1 RP11-665C16.6 -4.53 8.34e-06 0.00227 -0.28 -0.24 Protein biomarker; chr14:55370055 chr14:55262767~55272075:- LIHC cis rs11079159 0.606 rs4239193 ENSG00000263096.1 RP11-515O17.2 4.52 8.35e-06 0.00227 0.3 0.24 QRS duration; chr17:55299163 chr17:55271504~55273653:- LIHC cis rs1247318 1 rs1247308 ENSG00000243831.1 RP1-81D8.4 4.52 8.35e-06 0.00227 0.34 0.24 Aging; chr6:160916170 chr6:160666228~160676523:- LIHC cis rs9992667 1 rs9992667 ENSG00000231160.8 KLF3-AS1 4.52 8.36e-06 0.00227 0.32 0.24 Eosinophil percentage of granulocytes; chr4:38678565 chr4:38612701~38664883:- LIHC cis rs950169 0.544 rs12913702 ENSG00000225151.9 GOLGA2P7 -4.52 8.36e-06 0.00227 -0.3 -0.24 Schizophrenia; chr15:84609953 chr15:84199311~84230136:- LIHC cis rs950169 0.509 rs71395455 ENSG00000225151.9 GOLGA2P7 -4.52 8.36e-06 0.00227 -0.3 -0.24 Schizophrenia; chr15:84610573 chr15:84199311~84230136:- LIHC cis rs734999 0.545 rs6698817 ENSG00000225931.3 RP3-395M20.7 -4.52 8.36e-06 0.00227 -0.25 -0.24 Ulcerative colitis; chr1:2632744 chr1:2566410~2569888:+ LIHC cis rs734999 0.545 rs12752515 ENSG00000225931.3 RP3-395M20.7 -4.52 8.36e-06 0.00227 -0.25 -0.24 Ulcerative colitis; chr1:2633026 chr1:2566410~2569888:+ LIHC cis rs227275 0.524 rs150894 ENSG00000246560.2 RP11-10L12.4 4.52 8.37e-06 0.00227 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102811541 chr4:102828055~102844075:+ LIHC cis rs12554020 1 rs7048853 ENSG00000227603.1 RP11-165J3.6 4.52 8.37e-06 0.00227 0.31 0.24 Schizophrenia; chr9:93490896 chr9:93435332~93437121:- LIHC cis rs875971 0.545 rs6460298 ENSG00000273142.1 RP11-458F8.4 4.52 8.37e-06 0.00227 0.23 0.24 Aortic root size; chr7:66442783 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs35459055 ENSG00000273142.1 RP11-458F8.4 4.52 8.37e-06 0.00227 0.23 0.24 Aortic root size; chr7:66479399 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs75577046 ENSG00000273142.1 RP11-458F8.4 4.52 8.37e-06 0.00227 0.23 0.24 Aortic root size; chr7:66493729 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs3735147 ENSG00000273142.1 RP11-458F8.4 4.52 8.37e-06 0.00227 0.23 0.24 Aortic root size; chr7:66505541 chr7:66902857~66906297:+ LIHC cis rs11098499 0.663 rs9996501 ENSG00000260091.1 RP11-33B1.4 -4.52 8.37e-06 0.00227 -0.17 -0.24 Corneal astigmatism; chr4:119317763 chr4:119409333~119410233:+ LIHC cis rs11098499 0.697 rs28458294 ENSG00000260091.1 RP11-33B1.4 -4.52 8.37e-06 0.00227 -0.17 -0.24 Corneal astigmatism; chr4:119317769 chr4:119409333~119410233:+ LIHC cis rs11098499 0.663 rs28369503 ENSG00000260091.1 RP11-33B1.4 -4.52 8.37e-06 0.00227 -0.17 -0.24 Corneal astigmatism; chr4:119317770 chr4:119409333~119410233:+ LIHC cis rs61160187 0.51 rs6872863 ENSG00000272308.1 RP11-231G3.1 -4.52 8.38e-06 0.00227 -0.28 -0.24 Educational attainment (years of education);Educational attainment (college completion); chr5:60792321 chr5:60866457~60866935:- LIHC cis rs61160187 0.527 rs6873181 ENSG00000272308.1 RP11-231G3.1 -4.52 8.38e-06 0.00227 -0.28 -0.24 Educational attainment (years of education);Educational attainment (college completion); chr5:60792423 chr5:60866457~60866935:- LIHC cis rs61160187 0.527 rs6894672 ENSG00000272308.1 RP11-231G3.1 -4.52 8.38e-06 0.00227 -0.28 -0.24 Educational attainment (years of education);Educational attainment (college completion); chr5:60792428 chr5:60866457~60866935:- LIHC cis rs61160187 0.51 rs4235481 ENSG00000272308.1 RP11-231G3.1 -4.52 8.38e-06 0.00227 -0.28 -0.24 Educational attainment (years of education);Educational attainment (college completion); chr5:60797560 chr5:60866457~60866935:- LIHC cis rs7044106 0.791 rs4836830 ENSG00000238181.2 AHCYP2 -4.52 8.38e-06 0.00227 -0.27 -0.24 Hip circumference adjusted for BMI; chr9:120721390 chr9:120720673~120721972:+ LIHC cis rs4938303 0.718 rs10892023 ENSG00000254851.1 RP11-109L13.1 -4.52 8.39e-06 0.00228 -0.31 -0.24 Triglycerides; chr11:116727532 chr11:117135528~117138582:+ LIHC cis rs10510102 0.872 rs12246728 ENSG00000226864.1 ATE1-AS1 4.52 8.39e-06 0.00228 0.4 0.24 Breast cancer; chr10:121966618 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs12261371 ENSG00000226864.1 ATE1-AS1 4.52 8.39e-06 0.00228 0.4 0.24 Breast cancer; chr10:121966686 chr10:121928312~121951965:+ LIHC cis rs10510102 0.808 rs17102804 ENSG00000226864.1 ATE1-AS1 4.52 8.39e-06 0.00228 0.4 0.24 Breast cancer; chr10:121968365 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs12265369 ENSG00000226864.1 ATE1-AS1 4.52 8.39e-06 0.00228 0.4 0.24 Breast cancer; chr10:121968455 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs12265542 ENSG00000226864.1 ATE1-AS1 4.52 8.39e-06 0.00228 0.4 0.24 Breast cancer; chr10:121968740 chr10:121928312~121951965:+ LIHC cis rs10510102 0.872 rs11200293 ENSG00000226864.1 ATE1-AS1 4.52 8.39e-06 0.00228 0.4 0.24 Breast cancer; chr10:121969195 chr10:121928312~121951965:+ LIHC cis rs2276314 0.857 rs8097597 ENSG00000278986.1 RP11-723J4.3 -4.52 8.39e-06 0.00228 -0.28 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36039485 chr18:35972151~35973916:+ LIHC cis rs67311347 1 rs112619360 ENSG00000223797.4 ENTPD3-AS1 4.52 8.4e-06 0.00228 0.19 0.24 Renal cell carcinoma; chr3:40391154 chr3:40313802~40453329:- LIHC cis rs929596 0.606 rs10178992 ENSG00000233445.1 RPL17P11 4.52 8.4e-06 0.00228 0.27 0.24 Total bilirubin levels in HIV-1 infection; chr2:233749231 chr2:233721522~233722065:- LIHC cis rs929596 0.606 rs7604115 ENSG00000233445.1 RPL17P11 4.52 8.4e-06 0.00228 0.27 0.24 Total bilirubin levels in HIV-1 infection; chr2:233749470 chr2:233721522~233722065:- LIHC cis rs11722779 0.81 rs223417 ENSG00000246560.2 RP11-10L12.4 4.52 8.4e-06 0.00228 0.27 0.24 Schizophrenia; chr4:102810568 chr4:102828055~102844075:+ LIHC cis rs11722779 0.805 rs223416 ENSG00000246560.2 RP11-10L12.4 4.52 8.4e-06 0.00228 0.27 0.24 Schizophrenia; chr4:102810580 chr4:102828055~102844075:+ LIHC cis rs17711722 0.701 rs781143 ENSG00000224316.1 RP11-479O9.2 4.52 8.4e-06 0.00228 0.24 0.24 Calcium levels; chr7:65974892 chr7:65773620~65802067:+ LIHC cis rs11668505 1 rs66475008 ENSG00000259108.2 CTD-3098H1.2 4.52 8.4e-06 0.00228 0.3 0.24 Lung function (FVC); chr19:47846054 chr19:47863483~47865341:- LIHC cis rs7714584 1 rs80075680 ENSG00000197083.10 ZNF300P1 4.52 8.41e-06 0.00228 0.37 0.24 Crohn's disease; chr5:150844175 chr5:150930645~150946289:- LIHC cis rs4713118 0.513 rs156739 ENSG00000219392.1 RP1-265C24.5 -4.52 8.41e-06 0.00228 -0.32 -0.24 Parkinson's disease; chr6:28045632 chr6:28115628~28116551:+ LIHC cis rs5758659 0.819 rs134871 ENSG00000227370.1 RP4-669P10.19 -4.52 8.42e-06 0.00228 -0.25 -0.24 Cognitive function; chr22:42256710 chr22:42132543~42132998:+ LIHC cis rs11951515 0.508 rs11958046 ENSG00000248240.1 RP11-159F24.5 -4.52 8.43e-06 0.00228 -0.3 -0.24 Metabolite levels (X-11787); chr5:43583287 chr5:43515274~43525310:+ LIHC cis rs673078 0.607 rs11068919 ENSG00000275759.1 RP11-131L12.3 -4.52 8.43e-06 0.00228 -0.3 -0.24 Glucose homeostasis traits; chr12:118354925 chr12:118428281~118428870:+ LIHC cis rs7809950 1 rs7778270 ENSG00000238832.1 snoU109 4.52 8.43e-06 0.00229 0.29 0.24 Coronary artery disease; chr7:107584222 chr7:107603363~107603507:+ LIHC cis rs62355901 0.509 rs116154674 ENSG00000271828.1 CTD-2310F14.1 4.52 8.44e-06 0.00229 0.45 0.24 Breast cancer; chr5:56710833 chr5:56927874~56929573:+ LIHC cis rs603446 0.967 rs180370 ENSG00000254851.1 RP11-109L13.1 -4.52 8.45e-06 0.00229 -0.29 -0.24 Triglycerides; chr11:116721649 chr11:117135528~117138582:+ LIHC cis rs703842 1 rs2072052 ENSG00000270039.1 RP11-571M6.17 -4.52 8.45e-06 0.00229 -0.34 -0.24 Multiple sclerosis; chr12:57752936 chr12:57803838~57804415:+ LIHC cis rs2348418 0.733 rs2169752 ENSG00000247934.4 RP11-967K21.1 -4.52 8.46e-06 0.00229 -0.21 -0.24 Lung function (FEV1);Lung function (FVC); chr12:28239279 chr12:28163298~28190738:- LIHC cis rs2836974 0.533 rs418298 ENSG00000255568.3 BRWD1-AS2 4.52 8.47e-06 0.0023 0.21 0.24 Cognitive function; chr21:39164728 chr21:39313935~39314962:+ LIHC cis rs2581828 0.656 rs2564940 ENSG00000242142.1 SERBP1P3 4.52 8.47e-06 0.0023 0.27 0.24 Crohn's disease; chr3:53073553 chr3:53064283~53065091:- LIHC cis rs2243480 1 rs6958420 ENSG00000230295.1 RP11-458F8.2 4.52 8.47e-06 0.0023 0.25 0.24 Diabetic kidney disease; chr7:66286184 chr7:66880708~66882981:+ LIHC cis rs603446 0.967 rs2849179 ENSG00000254851.1 RP11-109L13.1 -4.52 8.48e-06 0.0023 -0.29 -0.24 Triglycerides; chr11:116750080 chr11:117135528~117138582:+ LIHC cis rs7702057 0.53 rs1567331 ENSG00000271918.1 CTD-2287O16.5 4.52 8.48e-06 0.0023 0.32 0.24 Amyotrophic lateral sclerosis; chr5:116078627 chr5:116083807~116085416:- LIHC cis rs7702057 0.53 rs1567332 ENSG00000271918.1 CTD-2287O16.5 4.52 8.48e-06 0.0023 0.32 0.24 Amyotrophic lateral sclerosis; chr5:116078690 chr5:116083807~116085416:- LIHC cis rs193541 0.632 rs415417 ENSG00000263432.2 RN7SL689P -4.52 8.49e-06 0.0023 -0.37 -0.24 Glucose homeostasis traits; chr5:122987189 chr5:123022487~123022783:- LIHC cis rs193541 0.632 rs62377425 ENSG00000263432.2 RN7SL689P -4.52 8.49e-06 0.0023 -0.37 -0.24 Glucose homeostasis traits; chr5:122996930 chr5:123022487~123022783:- LIHC cis rs193541 0.632 rs34714850 ENSG00000263432.2 RN7SL689P -4.52 8.49e-06 0.0023 -0.37 -0.24 Glucose homeostasis traits; chr5:122997000 chr5:123022487~123022783:- LIHC cis rs11098499 0.826 rs4472123 ENSG00000245958.5 RP11-33B1.1 -4.52 8.49e-06 0.0023 -0.24 -0.24 Corneal astigmatism; chr4:119315475 chr4:119454791~119552025:+ LIHC cis rs7829975 0.742 rs12547493 ENSG00000254340.1 RP11-10A14.3 -4.52 8.49e-06 0.0023 -0.26 -0.24 Mood instability; chr8:8804024 chr8:9141424~9145435:+ LIHC cis rs160451 0.933 rs218889 ENSG00000251136.7 RP11-37B2.1 -4.52 8.5e-06 0.0023 -0.21 -0.24 Leprosy; chr8:89679935 chr8:89609409~89757727:- LIHC cis rs11971779 0.68 rs7808740 ENSG00000273391.1 RP11-634H22.1 4.52 8.51e-06 0.0023 0.21 0.24 Diisocyanate-induced asthma; chr7:139344209 chr7:139359032~139359566:- LIHC cis rs9992667 1 rs68191221 ENSG00000231160.8 KLF3-AS1 4.52 8.51e-06 0.0023 0.32 0.24 Eosinophil percentage of granulocytes; chr4:38675441 chr4:38612701~38664883:- LIHC cis rs1005277 0.579 rs1614236 ENSG00000275858.1 RP11-291L22.8 4.52 8.51e-06 0.0023 0.27 0.24 Extrinsic epigenetic age acceleration; chr10:38214068 chr10:38450738~38451069:- LIHC cis rs7714584 1 rs10051804 ENSG00000197083.10 ZNF300P1 4.52 8.52e-06 0.0023 0.37 0.24 Crohn's disease; chr5:150846862 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs10051924 ENSG00000197083.10 ZNF300P1 4.52 8.52e-06 0.0023 0.37 0.24 Crohn's disease; chr5:150847077 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs17111376 ENSG00000197083.10 ZNF300P1 4.52 8.52e-06 0.0023 0.37 0.24 Crohn's disease; chr5:150847337 chr5:150930645~150946289:- LIHC cis rs651907 0.557 rs3806654 ENSG00000244119.1 PDCL3P4 4.52 8.52e-06 0.00231 0.24 0.24 Colorectal cancer; chr3:101677685 chr3:101712472~101713191:+ LIHC cis rs1577917 1 rs12201741 ENSG00000234155.1 RP11-30P6.6 4.52 8.52e-06 0.00231 0.31 0.24 Response to antipsychotic treatment; chr6:85892901 chr6:85387219~85390186:- LIHC cis rs1558001 0.811 rs56118176 ENSG00000230196.1 DDX43P3 -4.52 8.52e-06 0.00231 -0.25 -0.24 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81847201 chr7:81610884~81611326:- LIHC cis rs3733585 0.781 rs6449183 ENSG00000250413.1 RP11-448G15.1 4.52 8.52e-06 0.00231 0.3 0.24 Cleft plate (environmental tobacco smoke interaction); chr4:9969067 chr4:10006482~10009725:+ LIHC cis rs13068223 1 rs13095806 ENSG00000243926.1 TIPARP-AS1 -4.52 8.53e-06 0.00231 -0.22 -0.24 Age-related hearing impairment (SNP x SNP interaction); chr3:156738271 chr3:156671862~156674378:- LIHC cis rs2834188 0.924 rs2409487 ENSG00000272659.1 AP000295.10 -4.52 8.54e-06 0.00231 -0.35 -0.24 Narcolepsy; chr21:33312653 chr21:33309491~33310181:+ LIHC cis rs6061231 0.597 rs624313 ENSG00000273619.1 RP5-908M14.9 4.52 8.55e-06 0.00231 0.19 0.24 Colorectal cancer; chr20:62352356 chr20:62386303~62386970:- LIHC cis rs4650994 0.623 rs35854525 ENSG00000273384.1 RP5-1098D14.1 -4.52 8.55e-06 0.00231 -0.3 -0.24 HDL cholesterol;HDL cholesterol levels; chr1:178649469 chr1:178651706~178652282:+ LIHC cis rs62355901 0.552 rs16886128 ENSG00000271828.1 CTD-2310F14.1 4.52 8.56e-06 0.00232 0.45 0.24 Breast cancer; chr5:56702258 chr5:56927874~56929573:+ LIHC cis rs2929278 0.617 rs533143 ENSG00000275601.1 AC011330.13 -4.52 8.56e-06 0.00232 -0.29 -0.24 Schizophrenia; chr15:43896656 chr15:43642389~43643023:- LIHC cis rs10262624 1 rs2106748 ENSG00000234286.1 AC006026.13 -4.52 8.57e-06 0.00232 -0.27 -0.24 Schizophrenia; chr7:23871694 chr7:23680195~23680786:- LIHC cis rs10262624 1 rs2390847 ENSG00000234286.1 AC006026.13 -4.52 8.57e-06 0.00232 -0.27 -0.24 Schizophrenia; chr7:23872082 chr7:23680195~23680786:- LIHC cis rs11971779 0.68 rs10229358 ENSG00000273391.1 RP11-634H22.1 -4.52 8.57e-06 0.00232 -0.21 -0.24 Diisocyanate-induced asthma; chr7:139367799 chr7:139359032~139359566:- LIHC cis rs11079159 0.565 rs4794563 ENSG00000263096.1 RP11-515O17.2 4.52 8.57e-06 0.00232 0.3 0.24 QRS duration; chr17:55304524 chr17:55271504~55273653:- LIHC cis rs651907 0.557 rs3864012 ENSG00000244119.1 PDCL3P4 4.52 8.58e-06 0.00232 0.24 0.24 Colorectal cancer; chr3:101678779 chr3:101712472~101713191:+ LIHC cis rs72634501 0.517 rs6600289 ENSG00000182109.6 RP11-69E11.4 -4.52 8.58e-06 0.00232 -0.25 -0.24 HDL cholesterol; chr1:39148140 chr1:39522280~39546187:- LIHC cis rs763121 0.853 rs138713 ENSG00000273076.1 RP3-508I15.22 4.52 8.59e-06 0.00232 0.27 0.24 Menopause (age at onset); chr22:38746610 chr22:38743495~38743910:+ LIHC cis rs2243480 1 rs781150 ENSG00000228409.4 CCT6P1 4.52 8.61e-06 0.00233 0.26 0.24 Diabetic kidney disease; chr7:66015986 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs313798 ENSG00000228409.4 CCT6P1 4.52 8.61e-06 0.00233 0.26 0.24 Diabetic kidney disease; chr7:66028044 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs35396113 ENSG00000228409.4 CCT6P1 4.52 8.61e-06 0.00233 0.26 0.24 Diabetic kidney disease; chr7:66030474 chr7:65751142~65763354:+ LIHC cis rs2842992 0.709 rs1853257 ENSG00000237927.1 RP3-393E18.2 -4.52 8.62e-06 0.00233 -0.29 -0.24 Age-related macular degeneration (geographic atrophy); chr6:159791678 chr6:159586955~159589169:- LIHC cis rs11671005 0.693 rs11668821 ENSG00000269473.1 CTD-2619J13.19 4.52 8.62e-06 0.00233 0.39 0.24 Mean platelet volume; chr19:58444446 chr19:58440448~58445849:+ LIHC cis rs11671005 0.616 rs12980907 ENSG00000269473.1 CTD-2619J13.19 4.52 8.62e-06 0.00233 0.39 0.24 Mean platelet volume; chr19:58444959 chr19:58440448~58445849:+ LIHC cis rs4964805 0.549 rs11111752 ENSG00000257681.1 RP11-341G23.4 4.52 8.62e-06 0.00233 0.25 0.24 Attention deficit hyperactivity disorder; chr12:103762774 chr12:103746315~103768858:- LIHC cis rs643506 0.874 rs634983 ENSG00000254990.4 RP11-108O10.2 4.52 8.62e-06 0.00233 0.25 0.24 Breast cancer; chr11:111876703 chr11:111768668~111778350:- LIHC cis rs11971779 0.816 rs11979272 ENSG00000273391.1 RP11-634H22.1 4.52 8.62e-06 0.00233 0.23 0.24 Diisocyanate-induced asthma; chr7:139389323 chr7:139359032~139359566:- LIHC cis rs2111504 0.806 rs2903738 ENSG00000267213.4 AC007773.2 -4.52 8.62e-06 0.00233 -0.26 -0.24 Bipolar disorder; chr19:32455137 chr19:32390050~32405560:- LIHC cis rs2111504 0.806 rs10421787 ENSG00000267213.4 AC007773.2 -4.52 8.62e-06 0.00233 -0.26 -0.24 Bipolar disorder; chr19:32460316 chr19:32390050~32405560:- LIHC cis rs10129255 1 rs11621409 ENSG00000223648.3 IGHV3-64 4.52 8.62e-06 0.00233 0.18 0.24 Kawasaki disease; chr14:106695603 chr14:106643132~106658258:- LIHC cis rs11971779 0.527 rs1076349 ENSG00000273391.1 RP11-634H22.1 4.52 8.63e-06 0.00233 0.22 0.24 Diisocyanate-induced asthma; chr7:139441748 chr7:139359032~139359566:- LIHC cis rs11971779 0.65 rs4732380 ENSG00000273391.1 RP11-634H22.1 4.52 8.63e-06 0.00233 0.22 0.24 Diisocyanate-induced asthma; chr7:139442113 chr7:139359032~139359566:- LIHC cis rs11971779 0.715 rs6467853 ENSG00000273391.1 RP11-634H22.1 4.52 8.63e-06 0.00233 0.22 0.24 Diisocyanate-induced asthma; chr7:139442281 chr7:139359032~139359566:- LIHC cis rs11971779 0.715 rs6467854 ENSG00000273391.1 RP11-634H22.1 4.52 8.63e-06 0.00233 0.22 0.24 Diisocyanate-induced asthma; chr7:139442337 chr7:139359032~139359566:- LIHC cis rs8040855 0.627 rs12909130 ENSG00000259295.5 CSPG4P12 4.52 8.63e-06 0.00233 0.37 0.24 Bulimia nervosa; chr15:85047270 chr15:85191438~85213905:+ LIHC cis rs17711722 0.701 rs781145 ENSG00000224316.1 RP11-479O9.2 4.52 8.63e-06 0.00233 0.24 0.24 Calcium levels; chr7:65975383 chr7:65773620~65802067:+ LIHC cis rs7119038 0.774 rs73005423 ENSG00000255239.1 AP002954.6 -4.52 8.64e-06 0.00233 -0.34 -0.24 Sjögren's syndrome; chr11:118810370 chr11:118688039~118690600:- LIHC cis rs7945705 0.747 rs1123936 ENSG00000254860.4 TMEM9B-AS1 4.52 8.65e-06 0.00234 0.23 0.24 Hemoglobin concentration; chr11:8981759 chr11:8964675~8977527:+ LIHC cis rs7945705 0.692 rs2742470 ENSG00000254860.4 TMEM9B-AS1 4.52 8.65e-06 0.00234 0.23 0.24 Hemoglobin concentration; chr11:8982455 chr11:8964675~8977527:+ LIHC cis rs11098499 0.909 rs11723839 ENSG00000245958.5 RP11-33B1.1 -4.52 8.66e-06 0.00234 -0.25 -0.24 Corneal astigmatism; chr4:119378518 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs12506546 ENSG00000245958.5 RP11-33B1.1 -4.52 8.66e-06 0.00234 -0.25 -0.24 Corneal astigmatism; chr4:119380463 chr4:119454791~119552025:+ LIHC cis rs7923609 0.841 rs10740131 ENSG00000232075.1 MRPL35P2 -4.52 8.67e-06 0.00234 -0.27 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63511728 chr10:63634317~63634827:- LIHC cis rs172166 0.769 rs149965 ENSG00000219392.1 RP1-265C24.5 -4.52 8.67e-06 0.00234 -0.32 -0.24 Cardiac Troponin-T levels; chr6:28050911 chr6:28115628~28116551:+ LIHC cis rs4356203 0.87 rs214925 ENSG00000272034.1 SNORD14A -4.52 8.67e-06 0.00234 -0.26 -0.24 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17213037 chr11:17074654~17074744:- LIHC cis rs2243480 1 rs781157 ENSG00000230295.1 RP11-458F8.2 -4.52 8.68e-06 0.00234 -0.25 -0.24 Diabetic kidney disease; chr7:66013324 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs781156 ENSG00000230295.1 RP11-458F8.2 -4.52 8.68e-06 0.00234 -0.25 -0.24 Diabetic kidney disease; chr7:66014154 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs781149 ENSG00000230295.1 RP11-458F8.2 -4.52 8.68e-06 0.00234 -0.25 -0.24 Diabetic kidney disease; chr7:66016297 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs451396 ENSG00000230295.1 RP11-458F8.2 -4.52 8.68e-06 0.00234 -0.25 -0.24 Diabetic kidney disease; chr7:66019087 chr7:66880708~66882981:+ LIHC cis rs2243480 0.901 rs58207111 ENSG00000230295.1 RP11-458F8.2 -4.52 8.68e-06 0.00234 -0.25 -0.24 Diabetic kidney disease; chr7:66021736 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1167613 ENSG00000230295.1 RP11-458F8.2 -4.52 8.68e-06 0.00234 -0.25 -0.24 Diabetic kidney disease; chr7:66022452 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1715235 ENSG00000230295.1 RP11-458F8.2 -4.52 8.68e-06 0.00234 -0.25 -0.24 Diabetic kidney disease; chr7:66023407 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs313799 ENSG00000230295.1 RP11-458F8.2 -4.52 8.68e-06 0.00234 -0.25 -0.24 Diabetic kidney disease; chr7:66029343 chr7:66880708~66882981:+ LIHC cis rs4561483 0.801 rs33660 ENSG00000261560.1 RP11-166B2.3 -4.52 8.69e-06 0.00235 -0.27 -0.24 Testicular germ cell tumor; chr16:11868001 chr16:11881075~11882569:- LIHC cis rs4356203 0.519 rs214083 ENSG00000260196.1 RP1-239B22.5 -4.52 8.69e-06 0.00235 -0.29 -0.24 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17277312 chr11:17380649~17383531:+ LIHC cis rs57502260 1 rs56312530 ENSG00000212093.1 AP000807.1 4.52 8.69e-06 0.00235 0.3 0.24 Total body bone mineral density (age 45-60); chr11:68451947 chr11:68506083~68506166:- LIHC cis rs2929278 0.617 rs11070410 ENSG00000275601.1 AC011330.13 4.52 8.7e-06 0.00235 0.29 0.24 Schizophrenia; chr15:43764847 chr15:43642389~43643023:- LIHC cis rs7615952 0.599 rs2279821 ENSG00000171084.14 FAM86JP 4.52 8.7e-06 0.00235 0.38 0.24 Blood pressure (smoking interaction); chr3:126015465 chr3:125916620~125930024:+ LIHC cis rs4650994 0.623 rs2248666 ENSG00000213057.5 C1orf220 -4.52 8.71e-06 0.00235 -0.2 -0.24 HDL cholesterol;HDL cholesterol levels; chr1:178651466 chr1:178542752~178548889:+ LIHC cis rs2243480 0.522 rs73150635 ENSG00000230295.1 RP11-458F8.2 -4.52 8.71e-06 0.00235 -0.27 -0.24 Diabetic kidney disease; chr7:66507503 chr7:66880708~66882981:+ LIHC cis rs2337406 1 rs3858878 ENSG00000274576.2 IGHV2-70 -4.52 8.71e-06 0.00235 -0.27 -0.24 Alzheimer's disease (late onset); chr14:106688061 chr14:106770577~106771020:- LIHC cis rs2976388 0.565 rs2572905 ENSG00000253196.1 RP11-706C16.7 4.52 8.71e-06 0.00235 0.23 0.24 Urinary tract infection frequency; chr8:142715686 chr8:142763116~142766427:+ LIHC cis rs2976388 0.647 rs2572906 ENSG00000253196.1 RP11-706C16.7 4.52 8.71e-06 0.00235 0.23 0.24 Urinary tract infection frequency; chr8:142716851 chr8:142763116~142766427:+ LIHC cis rs10262624 1 rs4722286 ENSG00000234286.1 AC006026.13 4.52 8.71e-06 0.00235 0.26 0.24 Schizophrenia; chr7:23874005 chr7:23680195~23680786:- LIHC cis rs2337406 0.866 rs2301535 ENSG00000274576.2 IGHV2-70 -4.52 8.72e-06 0.00235 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106790663 chr14:106770577~106771020:- LIHC cis rs60733400 0.817 rs4648657 ENSG00000225931.3 RP3-395M20.7 -4.52 8.72e-06 0.00235 -0.25 -0.24 Multiple sclerosis; chr1:2629296 chr1:2566410~2569888:+ LIHC cis rs2274273 0.624 rs7147247 ENSG00000258413.1 RP11-665C16.6 -4.52 8.72e-06 0.00235 -0.29 -0.24 Protein biomarker; chr14:55310995 chr14:55262767~55272075:- LIHC cis rs17270561 1 rs17270561 ENSG00000216436.2 HIST1H2APS1 4.51 8.73e-06 0.00235 0.36 0.24 Iron status biomarkers; chr6:25820211 chr6:25732497~25732827:+ LIHC cis rs6442522 0.966 rs3856828 ENSG00000249786.6 EAF1-AS1 4.51 8.73e-06 0.00235 0.27 0.24 Uric acid levels; chr3:15447490 chr3:15436171~15455940:- LIHC cis rs10829156 0.738 rs4748502 ENSG00000240291.1 RP11-499P20.2 4.51 8.73e-06 0.00235 0.35 0.24 Sudden cardiac arrest; chr10:18647032 chr10:18513115~18545651:- LIHC cis rs11096990 0.656 rs7686161 ENSG00000249685.1 RP11-360F5.3 -4.51 8.73e-06 0.00235 -0.28 -0.24 Cognitive function; chr4:39283201 chr4:39133913~39135608:+ LIHC cis rs11096990 0.593 rs7662880 ENSG00000249685.1 RP11-360F5.3 -4.51 8.73e-06 0.00235 -0.28 -0.24 Cognitive function; chr4:39283604 chr4:39133913~39135608:+ LIHC cis rs9992667 0.955 rs28418927 ENSG00000231160.8 KLF3-AS1 4.51 8.73e-06 0.00236 0.32 0.24 Eosinophil percentage of granulocytes; chr4:38624509 chr4:38612701~38664883:- LIHC cis rs10510102 0.872 rs12259144 ENSG00000226864.1 ATE1-AS1 4.51 8.75e-06 0.00236 0.4 0.24 Breast cancer; chr10:121965433 chr10:121928312~121951965:+ LIHC cis rs875971 0.522 rs781144 ENSG00000224316.1 RP11-479O9.2 4.51 8.75e-06 0.00236 0.24 0.24 Aortic root size; chr7:65975357 chr7:65773620~65802067:+ LIHC cis rs7829975 0.688 rs7827182 ENSG00000173295.6 FAM86B3P 4.51 8.76e-06 0.00236 0.3 0.24 Mood instability; chr8:8522961 chr8:8228595~8244865:+ LIHC cis rs7567389 0.568 rs7568070 ENSG00000236682.1 AC068282.3 -4.51 8.76e-06 0.00236 -0.36 -0.24 Self-rated health; chr2:127195478 chr2:127389130~127400580:+ LIHC cis rs2337406 1 rs17095456 ENSG00000274576.2 IGHV2-70 -4.51 8.76e-06 0.00236 -0.27 -0.24 Alzheimer's disease (late onset); chr14:106676559 chr14:106770577~106771020:- LIHC cis rs2337406 0.925 rs2011167 ENSG00000274576.2 IGHV2-70 -4.51 8.76e-06 0.00236 -0.27 -0.24 Alzheimer's disease (late onset); chr14:106680831 chr14:106770577~106771020:- LIHC cis rs921968 0.565 rs586194 ENSG00000272555.1 RP11-459I19.1 -4.51 8.77e-06 0.00236 -0.26 -0.24 Mean corpuscular hemoglobin concentration; chr2:218745710 chr2:218818690~218819144:+ LIHC cis rs748404 0.723 rs573169 ENSG00000166763.7 STRCP1 4.51 8.79e-06 0.00237 0.29 0.24 Lung cancer; chr15:43258383 chr15:43699488~43718184:- LIHC cis rs748404 0.697 rs524547 ENSG00000166763.7 STRCP1 4.51 8.79e-06 0.00237 0.29 0.24 Lung cancer; chr15:43258825 chr15:43699488~43718184:- LIHC cis rs901683 0.85 rs113722818 ENSG00000230869.1 CTGLF10P -4.51 8.79e-06 0.00237 -0.57 -0.24 Mean corpuscular volume;Red blood cell traits; chr10:45597760 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs112184470 ENSG00000230869.1 CTGLF10P -4.51 8.79e-06 0.00237 -0.57 -0.24 Mean corpuscular volume;Red blood cell traits; chr10:45597854 chr10:45678692~45700532:+ LIHC cis rs9595908 1 rs7992980 ENSG00000212293.1 SNORA16 4.51 8.79e-06 0.00237 0.27 0.24 Body mass index; chr13:32607005 chr13:32420390~32420516:- LIHC cis rs17270561 0.887 rs9358870 ENSG00000216436.2 HIST1H2APS1 -4.51 8.81e-06 0.00237 -0.37 -0.24 Iron status biomarkers; chr6:25718982 chr6:25732497~25732827:+ LIHC cis rs1247318 1 rs9364580 ENSG00000243831.1 RP1-81D8.4 4.51 8.81e-06 0.00237 0.34 0.24 Aging; chr6:160901895 chr6:160666228~160676523:- LIHC cis rs11098499 0.863 rs1552095 ENSG00000245958.5 RP11-33B1.1 -4.51 8.81e-06 0.00237 -0.25 -0.24 Corneal astigmatism; chr4:119539151 chr4:119454791~119552025:+ LIHC cis rs4578769 0.788 rs12962334 ENSG00000266850.1 RP11-370A5.1 4.51 8.82e-06 0.00238 0.26 0.24 Eosinophil percentage of white cells; chr18:22897971 chr18:22723491~22907721:- LIHC cis rs875971 0.571 rs78668714 ENSG00000273142.1 RP11-458F8.4 4.51 8.82e-06 0.00238 0.23 0.24 Aortic root size; chr7:66474464 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs73150604 ENSG00000273142.1 RP11-458F8.4 4.51 8.82e-06 0.00238 0.23 0.24 Aortic root size; chr7:66480545 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs7810213 ENSG00000273142.1 RP11-458F8.4 4.51 8.82e-06 0.00238 0.23 0.24 Aortic root size; chr7:66481592 chr7:66902857~66906297:+ LIHC cis rs7246657 0.943 rs35540940 ENSG00000276846.1 CTD-3220F14.3 4.51 8.82e-06 0.00238 0.32 0.24 Coronary artery calcification; chr19:37517333 chr19:37314868~37315620:- LIHC cis rs6565180 0.783 rs9888967 ENSG00000183604.13 SMG1P5 4.51 8.83e-06 0.00238 0.25 0.24 Tonsillectomy; chr16:30396658 chr16:30267553~30335374:- LIHC cis rs875971 0.545 rs1796219 ENSG00000273142.1 RP11-458F8.4 -4.51 8.83e-06 0.00238 -0.23 -0.24 Aortic root size; chr7:66645977 chr7:66902857~66906297:+ LIHC cis rs2976388 0.609 rs1469811 ENSG00000253741.1 CTD-2292P10.4 -4.51 8.83e-06 0.00238 -0.27 -0.24 Urinary tract infection frequency; chr8:142706581 chr8:142702252~142726973:- LIHC cis rs8040855 0.627 rs12900012 ENSG00000259295.5 CSPG4P12 4.51 8.83e-06 0.00238 0.37 0.24 Bulimia nervosa; chr15:85046955 chr15:85191438~85213905:+ LIHC cis rs7893279 0.505 rs12762481 ENSG00000225527.1 RP11-383B4.4 4.51 8.84e-06 0.00238 0.33 0.24 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18640251 chr10:18531849~18533336:- LIHC cis rs2735413 0.75 rs67126435 ENSG00000276007.1 RP11-358L22.3 4.51 8.84e-06 0.00238 0.32 0.24 Systolic blood pressure (alcohol consumption interaction); chr16:78032540 chr16:78123243~78124332:+ LIHC cis rs12554020 0.786 rs16909150 ENSG00000227603.1 RP11-165J3.6 -4.51 8.85e-06 0.00238 -0.39 -0.24 Schizophrenia; chr9:93454464 chr9:93435332~93437121:- LIHC cis rs7945705 0.818 rs2653613 ENSG00000254860.4 TMEM9B-AS1 4.51 8.85e-06 0.00238 0.24 0.24 Hemoglobin concentration; chr11:8857558 chr11:8964675~8977527:+ LIHC cis rs2276314 0.857 rs56230698 ENSG00000278986.1 RP11-723J4.3 -4.51 8.86e-06 0.00238 -0.28 -0.24 Endometriosis;Drug-induced torsades de pointes; chr18:36048922 chr18:35972151~35973916:+ LIHC cis rs1150668 0.699 rs1531681 ENSG00000204709.4 LINC01556 4.51 8.86e-06 0.00239 0.26 0.24 Pubertal anthropometrics; chr6:28259100 chr6:28943877~28944537:+ LIHC cis rs1005277 0.691 rs2474558 ENSG00000275858.1 RP11-291L22.8 -4.51 8.86e-06 0.00239 -0.27 -0.24 Extrinsic epigenetic age acceleration; chr10:38197213 chr10:38450738~38451069:- LIHC cis rs10129255 0.701 rs2005643 ENSG00000211970.3 IGHV4-61 -4.51 8.87e-06 0.00239 -0.18 -0.24 Kawasaki disease; chr14:106676288 chr14:106639119~106639657:- LIHC cis rs2243480 1 rs316331 ENSG00000230295.1 RP11-458F8.2 4.51 8.87e-06 0.00239 0.25 0.24 Diabetic kidney disease; chr7:66139635 chr7:66880708~66882981:+ LIHC cis rs9487094 0.885 rs13212766 ENSG00000260273.1 RP11-425D10.10 4.51 8.87e-06 0.00239 0.28 0.24 Height; chr6:109384228 chr6:109382795~109383666:+ LIHC cis rs9487094 0.961 rs3757234 ENSG00000260273.1 RP11-425D10.10 4.51 8.87e-06 0.00239 0.28 0.24 Height; chr6:109385087 chr6:109382795~109383666:+ LIHC cis rs9487094 0.961 rs1923725 ENSG00000260273.1 RP11-425D10.10 4.51 8.87e-06 0.00239 0.28 0.24 Height; chr6:109387685 chr6:109382795~109383666:+ LIHC cis rs9487094 0.961 rs12524639 ENSG00000260273.1 RP11-425D10.10 4.51 8.87e-06 0.00239 0.28 0.24 Height; chr6:109388256 chr6:109382795~109383666:+ LIHC cis rs929596 0.793 rs2741045 ENSG00000233445.1 RPL17P11 4.51 8.87e-06 0.00239 0.34 0.24 Total bilirubin levels in HIV-1 infection; chr2:233671494 chr2:233721522~233722065:- LIHC cis rs875971 0.545 rs75840613 ENSG00000273142.1 RP11-458F8.4 4.51 8.88e-06 0.00239 0.23 0.24 Aortic root size; chr7:66376399 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs73148639 ENSG00000273142.1 RP11-458F8.4 4.51 8.88e-06 0.00239 0.23 0.24 Aortic root size; chr7:66390342 chr7:66902857~66906297:+ LIHC cis rs6565180 0.888 rs12447833 ENSG00000183604.13 SMG1P5 4.51 8.88e-06 0.00239 0.25 0.24 Tonsillectomy; chr16:30378993 chr16:30267553~30335374:- LIHC cis rs380904 0.552 rs10099003 ENSG00000254859.1 RP11-661A12.5 -4.51 8.89e-06 0.00239 -0.42 -0.24 Venous thromboembolism (SNP x SNP interaction); chr8:143563290 chr8:143541973~143549729:- LIHC cis rs42490 0.873 rs218903 ENSG00000251136.7 RP11-37B2.1 -4.51 8.9e-06 0.00239 -0.22 -0.24 Leprosy; chr8:89721458 chr8:89609409~89757727:- LIHC cis rs2274273 0.624 rs66464079 ENSG00000258413.1 RP11-665C16.6 -4.51 8.9e-06 0.00239 -0.29 -0.24 Protein biomarker; chr14:55299446 chr14:55262767~55272075:- LIHC cis rs9368481 0.761 rs4713062 ENSG00000241549.7 GUSBP2 -4.51 8.9e-06 0.00239 -0.25 -0.24 Autism spectrum disorder or schizophrenia; chr6:26980416 chr6:26871484~26956554:- LIHC cis rs11779988 0.545 rs398806 ENSG00000253671.1 RP11-806O11.1 -4.51 8.91e-06 0.0024 -0.31 -0.24 Breast cancer; chr8:17928717 chr8:17808941~17820868:+ LIHC cis rs11779988 0.545 rs438873 ENSG00000253671.1 RP11-806O11.1 -4.51 8.91e-06 0.0024 -0.31 -0.24 Breast cancer; chr8:17929007 chr8:17808941~17820868:+ LIHC cis rs901683 0.702 rs113019116 ENSG00000230869.1 CTGLF10P -4.51 8.91e-06 0.0024 -0.57 -0.24 Mean corpuscular volume;Red blood cell traits; chr10:45598491 chr10:45678692~45700532:+ LIHC cis rs7429990 0.864 rs1403579 ENSG00000229759.1 MRPS18AP1 4.51 8.91e-06 0.0024 0.26 0.24 Educational attainment (years of education); chr3:47617889 chr3:48256350~48256938:- LIHC cis rs2274273 0.624 rs78205412 ENSG00000258413.1 RP11-665C16.6 -4.51 8.91e-06 0.0024 -0.29 -0.24 Protein biomarker; chr14:55314532 chr14:55262767~55272075:- LIHC cis rs7923609 1 rs4400684 ENSG00000232075.1 MRPL35P2 -4.51 8.92e-06 0.0024 -0.26 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63252927 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs4454603 ENSG00000232075.1 MRPL35P2 -4.51 8.92e-06 0.0024 -0.26 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63252990 chr10:63634317~63634827:- LIHC cis rs2274273 0.719 rs17740551 ENSG00000258413.1 RP11-665C16.6 -4.51 8.92e-06 0.0024 -0.3 -0.24 Protein biomarker; chr14:55284607 chr14:55262767~55272075:- LIHC cis rs17270561 0.779 rs12210620 ENSG00000216436.2 HIST1H2APS1 -4.51 8.93e-06 0.0024 -0.36 -0.24 Iron status biomarkers; chr6:25884557 chr6:25732497~25732827:+ LIHC cis rs4694744 0.576 rs13104260 ENSG00000264696.1 AC108078.1 4.51 8.94e-06 0.0024 0.35 0.24 Bacteremia; chr4:69482372 chr4:69479331~69479434:+ LIHC cis rs2348418 0.733 rs1824769 ENSG00000247934.4 RP11-967K21.1 -4.51 8.95e-06 0.0024 -0.21 -0.24 Lung function (FEV1);Lung function (FVC); chr12:28202322 chr12:28163298~28190738:- LIHC cis rs2348418 0.671 rs2169753 ENSG00000247934.4 RP11-967K21.1 -4.51 8.95e-06 0.0024 -0.21 -0.24 Lung function (FEV1);Lung function (FVC); chr12:28203481 chr12:28163298~28190738:- LIHC cis rs9903692 1 rs9903692 ENSG00000278765.1 RP5-890E16.5 4.51 8.95e-06 0.00241 0.31 0.24 Pulse pressure; chr17:48196567 chr17:48066704~48067293:- LIHC cis rs9903692 0.954 rs9909933 ENSG00000278765.1 RP5-890E16.5 4.51 8.95e-06 0.00241 0.31 0.24 Pulse pressure; chr17:48202870 chr17:48066704~48067293:- LIHC cis rs9903692 0.909 rs2325885 ENSG00000278765.1 RP5-890E16.5 4.51 8.95e-06 0.00241 0.31 0.24 Pulse pressure; chr17:48213013 chr17:48066704~48067293:- LIHC cis rs2688482 0.512 rs3103953 ENSG00000185485.13 SDHAP1 -4.51 8.95e-06 0.00241 -0.27 -0.24 Lung disease severity in cystic fibrosis; chr3:195793726 chr3:195959748~195990318:- LIHC cis rs4578769 0.959 rs9945114 ENSG00000265943.1 RP11-739L10.1 4.51 8.96e-06 0.00241 0.3 0.24 Eosinophil percentage of white cells; chr18:22884044 chr18:22699481~22933764:- LIHC cis rs2880765 0.545 rs11631739 ENSG00000259630.2 CTD-2262B20.1 -4.51 8.96e-06 0.00241 -0.33 -0.24 Coronary artery disease; chr15:85469347 chr15:85415228~85415633:+ LIHC cis rs2348418 0.765 rs4931734 ENSG00000247934.4 RP11-967K21.1 -4.51 8.96e-06 0.00241 -0.21 -0.24 Lung function (FEV1);Lung function (FVC); chr12:28196661 chr12:28163298~28190738:- LIHC cis rs11096990 0.634 rs1057807 ENSG00000249685.1 RP11-360F5.3 -4.51 8.96e-06 0.00241 -0.28 -0.24 Cognitive function; chr4:39287853 chr4:39133913~39135608:+ LIHC cis rs4366055 1 rs4366055 ENSG00000253704.1 RP11-267M23.4 4.51 8.96e-06 0.00241 0.29 0.24 Body mass index; chr8:94495100 chr8:94553722~94569745:+ LIHC cis rs11098499 0.754 rs66900435 ENSG00000245958.5 RP11-33B1.1 -4.51 8.97e-06 0.00241 -0.24 -0.24 Corneal astigmatism; chr4:119328270 chr4:119454791~119552025:+ LIHC cis rs748404 0.578 rs2584701 ENSG00000205771.5 CATSPER2P1 -4.51 8.97e-06 0.00241 -0.28 -0.24 Lung cancer; chr15:43392741 chr15:43726918~43747094:- LIHC cis rs3733589 0.59 rs6849736 ENSG00000250413.1 RP11-448G15.1 4.51 8.98e-06 0.00241 0.4 0.24 Renal overload gout; chr4:9985159 chr4:10006482~10009725:+ LIHC cis rs3733589 0.59 rs6849962 ENSG00000250413.1 RP11-448G15.1 4.51 8.98e-06 0.00241 0.4 0.24 Renal overload gout; chr4:9985279 chr4:10006482~10009725:+ LIHC cis rs4356203 0.525 rs111416579 ENSG00000272034.1 SNORD14A -4.51 8.98e-06 0.00241 -0.25 -0.24 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17227461 chr11:17074654~17074744:- LIHC cis rs79040073 0.53 rs73394357 ENSG00000259531.2 RP11-295H24.3 4.51 8.99e-06 0.00241 0.38 0.24 Lung cancer in ever smokers; chr15:49300314 chr15:49365124~49366685:- LIHC cis rs3812762 0.879 rs10743089 ENSG00000254860.4 TMEM9B-AS1 4.51 8.99e-06 0.00241 0.25 0.24 Hypospadias; chr11:8766621 chr11:8964675~8977527:+ LIHC cis rs875971 0.54 rs736270 ENSG00000224316.1 RP11-479O9.2 4.51 9.01e-06 0.00242 0.24 0.24 Aortic root size; chr7:65963835 chr7:65773620~65802067:+ LIHC cis rs193541 0.632 rs400207 ENSG00000263432.2 RN7SL689P -4.51 9.01e-06 0.00242 -0.37 -0.24 Glucose homeostasis traits; chr5:122982802 chr5:123022487~123022783:- LIHC cis rs763121 0.853 rs138704 ENSG00000273076.1 RP3-508I15.22 4.51 9.01e-06 0.00242 0.26 0.24 Menopause (age at onset); chr22:38737405 chr22:38743495~38743910:+ LIHC cis rs950169 0.544 rs12913702 ENSG00000259295.5 CSPG4P12 4.51 9.02e-06 0.00242 0.33 0.24 Schizophrenia; chr15:84609953 chr15:85191438~85213905:+ LIHC cis rs950169 0.509 rs71395455 ENSG00000259295.5 CSPG4P12 4.51 9.02e-06 0.00242 0.33 0.24 Schizophrenia; chr15:84610573 chr15:85191438~85213905:+ LIHC cis rs11673344 0.526 rs17305823 ENSG00000226686.6 LINC01535 -4.51 9.02e-06 0.00242 -0.36 -0.24 Obesity-related traits; chr19:37644145 chr19:37251912~37265535:+ LIHC cis rs10829156 0.679 rs4747352 ENSG00000240291.1 RP11-499P20.2 4.51 9.03e-06 0.00242 0.37 0.24 Sudden cardiac arrest; chr10:18539734 chr10:18513115~18545651:- LIHC cis rs7224610 1 rs7224610 ENSG00000263096.1 RP11-515O17.2 4.51 9.04e-06 0.00243 0.33 0.24 Urate levels; chr17:55287427 chr17:55271504~55273653:- LIHC cis rs2564921 0.73 rs930122 ENSG00000242142.1 SERBP1P3 4.51 9.04e-06 0.00243 0.31 0.24 Height; chr3:53085313 chr3:53064283~53065091:- LIHC cis rs2976388 0.609 rs2585148 ENSG00000253196.1 RP11-706C16.7 4.51 9.04e-06 0.00243 0.23 0.24 Urinary tract infection frequency; chr8:142714775 chr8:142763116~142766427:+ LIHC cis rs921968 0.565 rs6723334 ENSG00000272555.1 RP11-459I19.1 4.51 9.05e-06 0.00243 0.25 0.24 Mean corpuscular hemoglobin concentration; chr2:218764580 chr2:218818690~218819144:+ LIHC cis rs6901152 0.525 rs1424932 ENSG00000217648.1 RP1-95L4.4 -4.51 9.06e-06 0.00243 -0.28 -0.24 Acute lymphoblastic leukemia (childhood); chr6:143372811 chr6:143342246~143343383:+ LIHC cis rs5758511 0.508 rs28715885 ENSG00000237037.8 NDUFA6-AS1 -4.51 9.06e-06 0.00243 -0.45 -0.24 Birth weight; chr22:42045087 chr22:42090931~42137742:+ LIHC cis rs7429990 0.864 rs11130143 ENSG00000229759.1 MRPS18AP1 -4.51 9.07e-06 0.00243 -0.25 -0.24 Educational attainment (years of education); chr3:47614943 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs6774170 ENSG00000229759.1 MRPS18AP1 -4.51 9.07e-06 0.00243 -0.25 -0.24 Educational attainment (years of education); chr3:47615977 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs1403578 ENSG00000229759.1 MRPS18AP1 -4.51 9.07e-06 0.00243 -0.25 -0.24 Educational attainment (years of education); chr3:47617997 chr3:48256350~48256938:- LIHC cis rs7429990 0.833 rs883661 ENSG00000229759.1 MRPS18AP1 -4.51 9.07e-06 0.00243 -0.25 -0.24 Educational attainment (years of education); chr3:47618611 chr3:48256350~48256938:- LIHC cis rs7429990 0.833 rs870622 ENSG00000229759.1 MRPS18AP1 -4.51 9.07e-06 0.00243 -0.25 -0.24 Educational attainment (years of education); chr3:47618683 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs868255 ENSG00000229759.1 MRPS18AP1 -4.51 9.07e-06 0.00243 -0.25 -0.24 Educational attainment (years of education); chr3:47619074 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs4858842 ENSG00000229759.1 MRPS18AP1 -4.51 9.07e-06 0.00243 -0.25 -0.24 Educational attainment (years of education); chr3:47619574 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs11130144 ENSG00000229759.1 MRPS18AP1 -4.51 9.07e-06 0.00243 -0.25 -0.24 Educational attainment (years of education); chr3:47626444 chr3:48256350~48256938:- LIHC cis rs2075423 1 rs2075423 ENSG00000274895.1 RP11-478J18.2 4.51 9.07e-06 0.00243 0.27 0.24 Type 2 diabetes; chr1:213981376 chr1:213983793~213986419:- LIHC cis rs916888 0.738 rs199515 ENSG00000274883.1 Metazoa_SRP 4.51 9.07e-06 0.00243 0.35 0.24 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:45931806~45932083:+ LIHC cis rs3733589 0.59 rs16892449 ENSG00000250413.1 RP11-448G15.1 4.51 9.07e-06 0.00243 0.38 0.24 Renal overload gout; chr4:10036967 chr4:10006482~10009725:+ LIHC cis rs3733589 0.744 rs55668232 ENSG00000250413.1 RP11-448G15.1 4.51 9.07e-06 0.00243 0.38 0.24 Renal overload gout; chr4:10038538 chr4:10006482~10009725:+ LIHC cis rs3733589 0.744 rs16892474 ENSG00000250413.1 RP11-448G15.1 4.51 9.07e-06 0.00243 0.38 0.24 Renal overload gout; chr4:10038596 chr4:10006482~10009725:+ LIHC cis rs3733589 0.744 rs10516196 ENSG00000250413.1 RP11-448G15.1 4.51 9.07e-06 0.00243 0.38 0.24 Renal overload gout; chr4:10039341 chr4:10006482~10009725:+ LIHC cis rs7246657 0.943 rs7408563 ENSG00000276846.1 CTD-3220F14.3 4.51 9.07e-06 0.00243 0.31 0.24 Coronary artery calcification; chr19:37317683 chr19:37314868~37315620:- LIHC cis rs2243480 1 rs313809 ENSG00000230295.1 RP11-458F8.2 -4.51 9.07e-06 0.00243 -0.25 -0.24 Diabetic kidney disease; chr7:66034996 chr7:66880708~66882981:+ LIHC cis rs4639966 0.569 rs603486 ENSG00000255422.1 AP002954.4 -4.51 9.08e-06 0.00244 -0.28 -0.24 Systemic lupus erythematosus; chr11:118716638 chr11:118704607~118750263:+ LIHC cis rs17772222 0.917 rs1950806 ENSG00000258789.1 RP11-507K2.3 -4.51 9.08e-06 0.00244 -0.29 -0.24 Coronary artery calcification; chr14:88774412 chr14:88551597~88552493:+ LIHC cis rs7546 0.504 rs2015319 ENSG00000267077.1 RP11-127I20.5 -4.51 9.08e-06 0.00244 -0.25 -0.24 Cancer; chr16:4886279 chr16:4795265~4796532:- LIHC cis rs3733589 0.661 rs12511989 ENSG00000250413.1 RP11-448G15.1 4.51 9.08e-06 0.00244 0.42 0.24 Renal overload gout; chr4:10050034 chr4:10006482~10009725:+ LIHC cis rs9487094 0.961 rs3778477 ENSG00000260273.1 RP11-425D10.10 4.51 9.08e-06 0.00244 0.28 0.24 Height; chr6:109454855 chr6:109382795~109383666:+ LIHC cis rs12571093 0.773 rs7895164 ENSG00000233590.1 RP11-153K11.3 -4.51 9.09e-06 0.00244 -0.35 -0.24 Optic nerve measurement (disc area); chr10:68225658 chr10:68233251~68242379:- LIHC cis rs2243480 1 rs313813 ENSG00000230295.1 RP11-458F8.2 -4.51 9.09e-06 0.00244 -0.25 -0.24 Diabetic kidney disease; chr7:66038513 chr7:66880708~66882981:+ LIHC cis rs2739330 0.752 rs2330634 ENSG00000206090.4 AP000350.7 4.51 9.09e-06 0.00244 0.28 0.24 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908608 chr22:23939998~23942798:+ LIHC cis rs72675573 0.675 rs1331860 ENSG00000235612.1 RP1-158P9.1 -4.51 9.1e-06 0.00244 -0.31 -0.24 Monocyte count; chr1:56165771 chr1:56145721~56155224:+ LIHC cis rs7412746 0.552 rs4970980 ENSG00000231073.1 RP11-316M1.3 4.51 9.11e-06 0.00244 0.24 0.24 Melanoma; chr1:150892516 chr1:150973123~150975534:+ LIHC cis rs12478296 1 rs56387669 ENSG00000261186.2 RP11-341N2.1 -4.51 9.11e-06 0.00244 -0.34 -0.24 Obesity-related traits; chr2:242101738 chr2:242087351~242088457:- LIHC cis rs8028182 0.636 rs4486847 ENSG00000260269.4 CTD-2323K18.1 -4.51 9.11e-06 0.00244 -0.3 -0.24 Sudden cardiac arrest; chr15:75436190 chr15:75527150~75601205:- LIHC cis rs8028182 0.636 rs4886703 ENSG00000260269.4 CTD-2323K18.1 -4.51 9.11e-06 0.00244 -0.3 -0.24 Sudden cardiac arrest; chr15:75438025 chr15:75527150~75601205:- LIHC cis rs960902 0.713 rs7557408 ENSG00000213553.4 RPLP0P6 -4.5 9.12e-06 0.00245 -0.2 -0.24 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37515158 chr2:38481851~38482804:+ LIHC cis rs4218 0.701 rs56375269 ENSG00000277144.1 RP11-59H7.4 -4.5 9.13e-06 0.00245 -0.26 -0.24 Social communication problems; chr15:59137741 chr15:59115547~59116089:- LIHC cis rs11971779 0.68 rs7779900 ENSG00000273391.1 RP11-634H22.1 4.5 9.13e-06 0.00245 0.21 0.24 Diisocyanate-induced asthma; chr7:139398241 chr7:139359032~139359566:- LIHC cis rs3733589 1 rs35933067 ENSG00000250413.1 RP11-448G15.1 4.5 9.14e-06 0.00245 0.42 0.24 Renal overload gout; chr4:9998884 chr4:10006482~10009725:+ LIHC cis rs7712401 0.584 rs4836382 ENSG00000263432.2 RN7SL689P 4.5 9.15e-06 0.00245 0.33 0.24 Mean platelet volume; chr5:123040946 chr5:123022487~123022783:- LIHC cis rs9896933 0.778 rs80112422 ENSG00000263063.1 RP11-388C12.1 -4.5 9.16e-06 0.00246 -0.33 -0.24 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82869843 chr17:82713908~82716255:- LIHC cis rs9896933 0.775 rs79299098 ENSG00000263063.1 RP11-388C12.1 -4.5 9.16e-06 0.00246 -0.33 -0.24 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82873068 chr17:82713908~82716255:- LIHC cis rs2836974 0.897 rs2836927 ENSG00000255568.3 BRWD1-AS2 4.5 9.16e-06 0.00246 0.27 0.24 Cognitive function; chr21:39171290 chr21:39313935~39314962:+ LIHC cis rs2836974 0.899 rs8127087 ENSG00000255568.3 BRWD1-AS2 4.5 9.16e-06 0.00246 0.27 0.24 Cognitive function; chr21:39172576 chr21:39313935~39314962:+ LIHC cis rs2836974 0.897 rs2836932 ENSG00000255568.3 BRWD1-AS2 4.5 9.16e-06 0.00246 0.27 0.24 Cognitive function; chr21:39174791 chr21:39313935~39314962:+ LIHC cis rs16958440 0.867 rs12386076 ENSG00000267724.1 RP11-49K24.8 4.5 9.17e-06 0.00246 0.37 0.24 Sitting height ratio; chr18:47146969 chr18:47105946~47108062:+ LIHC cis rs67311347 0.866 rs11712426 ENSG00000223797.4 ENTPD3-AS1 4.5 9.18e-06 0.00246 0.2 0.24 Renal cell carcinoma; chr3:40288831 chr3:40313802~40453329:- LIHC cis rs875971 0.66 rs801193 ENSG00000273024.4 INTS4P2 4.5 9.19e-06 0.00246 0.26 0.24 Aortic root size; chr7:66565625 chr7:65647864~65715661:+ LIHC cis rs4356975 0.697 rs66666893 ENSG00000196472.4 RP13-644M16.4 4.5 9.2e-06 0.00246 0.26 0.24 Obesity-related traits; chr4:69133393 chr4:69181660~69182372:+ LIHC cis rs7923609 0.967 rs6479896 ENSG00000232075.1 MRPL35P2 -4.5 9.2e-06 0.00246 -0.26 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63367072 chr10:63634317~63634827:- LIHC cis rs10761750 1 rs10761750 ENSG00000232075.1 MRPL35P2 -4.5 9.2e-06 0.00246 -0.26 -0.24 Vascular endothelial growth factor levels; chr10:63368859 chr10:63634317~63634827:- LIHC cis rs4834770 0.792 rs6823331 ENSG00000245958.5 RP11-33B1.1 -4.5 9.2e-06 0.00246 -0.24 -0.24 Blood protein levels; chr4:119259635 chr4:119454791~119552025:+ LIHC cis rs2337406 0.866 rs7153964 ENSG00000274576.2 IGHV2-70 -4.5 9.2e-06 0.00247 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106790480 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs2301536 ENSG00000274576.2 IGHV2-70 -4.5 9.2e-06 0.00247 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106790636 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs7144369 ENSG00000274576.2 IGHV2-70 -4.5 9.2e-06 0.00247 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106793065 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs78525520 ENSG00000274576.2 IGHV2-70 -4.5 9.2e-06 0.00247 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106795643 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs7140974 ENSG00000274576.2 IGHV2-70 -4.5 9.2e-06 0.00247 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106795976 chr14:106770577~106771020:- LIHC cis rs10129255 0.646 rs55995061 ENSG00000274576.2 IGHV2-70 -4.5 9.2e-06 0.00247 -0.25 -0.24 Kawasaki disease; chr14:106799309 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs76871148 ENSG00000274576.2 IGHV2-70 -4.5 9.2e-06 0.00247 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106799722 chr14:106770577~106771020:- LIHC cis rs2337406 0.866 rs61521632 ENSG00000274576.2 IGHV2-70 -4.5 9.2e-06 0.00247 -0.25 -0.24 Alzheimer's disease (late onset); chr14:106801091 chr14:106770577~106771020:- LIHC cis rs10129255 0.833 rs61997797 ENSG00000211970.3 IGHV4-61 -4.5 9.21e-06 0.00247 -0.18 -0.24 Kawasaki disease; chr14:106815190 chr14:106639119~106639657:- LIHC cis rs7208859 0.673 rs9898858 ENSG00000266490.1 CTD-2349P21.9 4.5 9.21e-06 0.00247 0.3 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829193 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs55658077 ENSG00000266490.1 CTD-2349P21.9 4.5 9.21e-06 0.00247 0.3 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829501 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9899692 ENSG00000266490.1 CTD-2349P21.9 4.5 9.21e-06 0.00247 0.3 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829921 chr17:30792372~30792833:+ LIHC cis rs13392177 0.637 rs61041183 ENSG00000261338.2 RP11-378A13.1 4.5 9.21e-06 0.00247 0.25 0.24 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218191657 chr2:218255319~218257366:+ LIHC cis rs67311347 0.826 rs9863679 ENSG00000223797.4 ENTPD3-AS1 4.5 9.21e-06 0.00247 0.2 0.24 Renal cell carcinoma; chr3:40398123 chr3:40313802~40453329:- LIHC cis rs67311347 0.911 rs9863737 ENSG00000223797.4 ENTPD3-AS1 4.5 9.21e-06 0.00247 0.2 0.24 Renal cell carcinoma; chr3:40398345 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs9875245 ENSG00000223797.4 ENTPD3-AS1 4.5 9.21e-06 0.00247 0.2 0.24 Renal cell carcinoma; chr3:40400789 chr3:40313802~40453329:- LIHC cis rs58785573 0.624 rs2126526 ENSG00000231160.8 KLF3-AS1 -4.5 9.21e-06 0.00247 -0.21 -0.24 Lymphocyte percentage of white cells; chr4:38617068 chr4:38612701~38664883:- LIHC cis rs7688540 0.771 rs4549329 ENSG00000275426.1 CH17-262A2.1 4.5 9.21e-06 0.00247 0.3 0.24 Facial morphology (factor 6, height of vermillion lower lip); chr4:245996 chr4:149738~150317:+ LIHC cis rs638893 0.636 rs6421569 ENSG00000278376.1 RP11-158I9.8 -4.5 9.22e-06 0.00247 -0.44 -0.24 Vitiligo; chr11:118785066 chr11:118791254~118793137:+ LIHC cis rs10853057 1 rs10853057 ENSG00000214174.7 AMZ2P1 4.5 9.22e-06 0.00247 0.44 0.24 White matter microstructure (global fractional anisotropy); chr17:65001905 chr17:64966550~64975576:- LIHC cis rs7246657 0.943 rs8109038 ENSG00000276846.1 CTD-3220F14.3 -4.5 9.23e-06 0.00247 -0.32 -0.24 Coronary artery calcification; chr19:37524807 chr19:37314868~37315620:- LIHC cis rs11098499 0.954 rs59866101 ENSG00000245958.5 RP11-33B1.1 -4.5 9.23e-06 0.00247 -0.25 -0.24 Corneal astigmatism; chr4:119375436 chr4:119454791~119552025:+ LIHC cis rs10800713 0.954 rs6667081 ENSG00000260088.1 RP11-92G12.3 -4.5 9.24e-06 0.00247 -0.33 -0.24 Tandem gait; chr1:200593366 chr1:200669507~200694250:+ LIHC cis rs1061377 0.585 rs3733271 ENSG00000249685.1 RP11-360F5.3 4.5 9.25e-06 0.00248 0.29 0.24 Uric acid levels; chr4:39047948 chr4:39133913~39135608:+ LIHC cis rs67311347 0.822 rs9826847 ENSG00000223797.4 ENTPD3-AS1 4.5 9.25e-06 0.00248 0.2 0.24 Renal cell carcinoma; chr3:40303821 chr3:40313802~40453329:- LIHC cis rs10129255 0.744 rs28517388 ENSG00000223648.3 IGHV3-64 4.5 9.26e-06 0.00248 0.18 0.24 Kawasaki disease; chr14:106704323 chr14:106643132~106658258:- LIHC cis rs6061231 0.571 rs482010 ENSG00000273619.1 RP5-908M14.9 4.5 9.26e-06 0.00248 0.19 0.24 Colorectal cancer; chr20:62352495 chr20:62386303~62386970:- LIHC cis rs2243480 1 rs1499614 ENSG00000230295.1 RP11-458F8.2 -4.5 9.26e-06 0.00248 -0.25 -0.24 Diabetic kidney disease; chr7:66265811 chr7:66880708~66882981:+ LIHC cis rs3096299 0.838 rs3102384 ENSG00000261118.1 RP11-104N10.1 4.5 9.27e-06 0.00248 0.24 0.24 Multiple myeloma (IgH translocation); chr16:89345253 chr16:89492017~89504460:- LIHC cis rs6802315 0.604 rs9863103 ENSG00000272087.1 RP11-379F4.7 -4.5 9.27e-06 0.00248 -0.27 -0.24 Periodontitis (CDC/AAP); chr3:158746014 chr3:158693120~158693768:- LIHC cis rs4713118 0.513 rs149955 ENSG00000219392.1 RP1-265C24.5 -4.5 9.28e-06 0.00248 -0.32 -0.24 Parkinson's disease; chr6:28068447 chr6:28115628~28116551:+ LIHC cis rs748404 0.631 rs7163288 ENSG00000205771.5 CATSPER2P1 -4.5 9.28e-06 0.00248 -0.28 -0.24 Lung cancer; chr15:43379157 chr15:43726918~43747094:- LIHC cis rs1061377 0.585 rs12648581 ENSG00000249685.1 RP11-360F5.3 4.5 9.28e-06 0.00248 0.29 0.24 Uric acid levels; chr4:39054024 chr4:39133913~39135608:+ LIHC cis rs10991814 0.557 rs77696699 ENSG00000273381.1 RP11-305L7.7 4.5 9.29e-06 0.00248 0.27 0.24 Neutrophil percentage of granulocytes; chr9:91235591 chr9:91206175~91210299:- LIHC cis rs7208859 0.524 rs73988172 ENSG00000266490.1 CTD-2349P21.9 4.5 9.29e-06 0.00249 0.3 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759314 chr17:30792372~30792833:+ LIHC cis rs11671005 0.735 rs56292587 ENSG00000269473.1 CTD-2619J13.19 4.5 9.29e-06 0.00249 0.4 0.24 Mean platelet volume; chr19:58407699 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs56290606 ENSG00000269473.1 CTD-2619J13.19 4.5 9.29e-06 0.00249 0.4 0.24 Mean platelet volume; chr19:58407953 chr19:58440448~58445849:+ LIHC cis rs11671005 0.651 rs11878203 ENSG00000269473.1 CTD-2619J13.19 4.5 9.29e-06 0.00249 0.4 0.24 Mean platelet volume; chr19:58408683 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs11878198 ENSG00000269473.1 CTD-2619J13.19 4.5 9.29e-06 0.00249 0.4 0.24 Mean platelet volume; chr19:58408935 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs11666716 ENSG00000269473.1 CTD-2619J13.19 4.5 9.29e-06 0.00249 0.4 0.24 Mean platelet volume; chr19:58409585 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs34511020 ENSG00000269473.1 CTD-2619J13.19 4.5 9.29e-06 0.00249 0.4 0.24 Mean platelet volume; chr19:58409929 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs11666303 ENSG00000269473.1 CTD-2619J13.19 4.5 9.29e-06 0.00249 0.4 0.24 Mean platelet volume; chr19:58411135 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs34152946 ENSG00000269473.1 CTD-2619J13.19 4.5 9.29e-06 0.00249 0.4 0.24 Mean platelet volume; chr19:58411896 chr19:58440448~58445849:+ LIHC cis rs6802315 0.573 rs7635993 ENSG00000272087.1 RP11-379F4.7 4.5 9.3e-06 0.00249 0.27 0.24 Periodontitis (CDC/AAP); chr3:158742187 chr3:158693120~158693768:- LIHC cis rs30380 1 rs246454 ENSG00000272109.1 CTD-2260A17.3 -4.5 9.3e-06 0.00249 -0.29 -0.24 Cerebrospinal fluid biomarker levels; chr5:96787561 chr5:96804353~96806105:+ LIHC cis rs30380 0.922 rs246453 ENSG00000272109.1 CTD-2260A17.3 -4.5 9.3e-06 0.00249 -0.29 -0.24 Cerebrospinal fluid biomarker levels; chr5:96787633 chr5:96804353~96806105:+ LIHC cis rs11603023 0.625 rs633683 ENSG00000255422.1 AP002954.4 -4.5 9.3e-06 0.00249 -0.27 -0.24 Cholesterol, total; chr11:118634025 chr11:118704607~118750263:+ LIHC cis rs875971 0.545 rs2279757 ENSG00000273142.1 RP11-458F8.4 4.5 9.31e-06 0.00249 0.23 0.24 Aortic root size; chr7:66363676 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs11766183 ENSG00000273142.1 RP11-458F8.4 4.5 9.31e-06 0.00249 0.23 0.24 Aortic root size; chr7:66374173 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs1065265 ENSG00000273142.1 RP11-458F8.4 4.5 9.31e-06 0.00249 0.23 0.24 Aortic root size; chr7:66376216 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs7811204 ENSG00000273142.1 RP11-458F8.4 4.5 9.31e-06 0.00249 0.23 0.24 Aortic root size; chr7:66387213 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs4718348 ENSG00000273142.1 RP11-458F8.4 4.5 9.32e-06 0.00249 0.23 0.24 Aortic root size; chr7:66441589 chr7:66902857~66906297:+ LIHC cis rs11098499 0.866 rs7665125 ENSG00000260091.1 RP11-33B1.4 -4.5 9.32e-06 0.00249 -0.16 -0.24 Corneal astigmatism; chr4:119480924 chr4:119409333~119410233:+ LIHC cis rs10771431 0.935 rs1117735 ENSG00000111788.10 RP11-22B23.1 4.5 9.32e-06 0.00249 0.21 0.24 Breast size; chr12:9220132 chr12:9277235~9313241:+ LIHC cis rs11673344 0.9 rs11671112 ENSG00000226686.6 LINC01535 4.5 9.32e-06 0.00249 0.37 0.24 Obesity-related traits; chr19:37169384 chr19:37251912~37265535:+ LIHC cis rs465969 1 rs465969 ENSG00000255389.1 C6orf3 -4.5 9.33e-06 0.00249 -0.37 -0.24 Psoriasis; chr6:111334327 chr6:111599875~111602295:+ LIHC cis rs7208859 0.778 rs6505219 ENSG00000263531.1 RP13-753N3.1 4.5 9.33e-06 0.0025 0.31 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30938603 chr17:30863921~30864940:- LIHC cis rs1558001 0.87 rs4732409 ENSG00000230196.1 DDX43P3 -4.5 9.35e-06 0.0025 -0.25 -0.24 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81808557 chr7:81610884~81611326:- LIHC cis rs1558001 0.87 rs4732410 ENSG00000230196.1 DDX43P3 -4.5 9.35e-06 0.0025 -0.25 -0.24 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81808559 chr7:81610884~81611326:- LIHC cis rs73186030 0.764 rs66508963 ENSG00000272758.4 RP11-299J3.8 4.5 9.35e-06 0.0025 0.44 0.24 Serum parathyroid hormone levels; chr3:122365682 chr3:122416207~122443180:+ LIHC cis rs7809950 0.954 rs12673675 ENSG00000238832.1 snoU109 -4.5 9.36e-06 0.0025 -0.29 -0.24 Coronary artery disease; chr7:107472775 chr7:107603363~107603507:+ LIHC cis rs2243480 1 rs427044 ENSG00000230295.1 RP11-458F8.2 -4.5 9.37e-06 0.0025 -0.24 -0.24 Diabetic kidney disease; chr7:66043558 chr7:66880708~66882981:+ LIHC cis rs7208859 0.573 rs73267873 ENSG00000266490.1 CTD-2349P21.9 4.5 9.37e-06 0.0025 0.29 0.24 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741439 chr17:30792372~30792833:+ LIHC cis rs17826219 0.561 rs4085382 ENSG00000266490.1 CTD-2349P21.9 4.5 9.37e-06 0.0025 0.29 0.24 Body mass index; chr17:30744184 chr17:30792372~30792833:+ LIHC cis rs6433895 0.71 rs11692625 ENSG00000236153.1 AC104076.3 -4.5 9.39e-06 0.00251 -0.33 -0.24 Lymphocyte counts; chr2:181150757 chr2:180979427~180980090:- LIHC cis rs7119038 0.629 rs10892272 ENSG00000255239.1 AP002954.6 -4.5 9.39e-06 0.00251 -0.32 -0.24 Sjögren's syndrome; chr11:118731998 chr11:118688039~118690600:- LIHC cis rs61160187 0.505 rs4235482 ENSG00000272308.1 RP11-231G3.1 -4.5 9.4e-06 0.00251 -0.28 -0.24 Educational attainment (years of education);Educational attainment (college completion); chr5:60797785 chr5:60866457~60866935:- LIHC cis rs2243480 1 rs2462569 ENSG00000228409.4 CCT6P1 -4.5 9.4e-06 0.00251 -0.25 -0.24 Diabetic kidney disease; chr7:66009859 chr7:65751142~65763354:+ LIHC cis rs6997458 0.742 rs13269441 ENSG00000253549.4 RP11-317J10.2 4.5 9.4e-06 0.00251 0.26 0.24 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85418406 chr8:85441851~85464915:- LIHC cis rs6903823 0.508 rs1150721 ENSG00000204709.4 LINC01556 4.5 9.41e-06 0.00251 0.26 0.24 Pulmonary function; chr6:28287263 chr6:28943877~28944537:+ LIHC cis rs1005277 0.579 rs1780116 ENSG00000275858.1 RP11-291L22.8 4.5 9.41e-06 0.00251 0.26 0.24 Extrinsic epigenetic age acceleration; chr10:38237693 chr10:38450738~38451069:- LIHC cis rs11098499 0.754 rs9991959 ENSG00000260091.1 RP11-33B1.4 4.5 9.43e-06 0.00252 0.17 0.24 Corneal astigmatism; chr4:119332618 chr4:119409333~119410233:+ LIHC cis rs11673344 0.864 rs79407399 ENSG00000226686.6 LINC01535 4.5 9.43e-06 0.00252 0.37 0.24 Obesity-related traits; chr19:37000004 chr19:37251912~37265535:+ LIHC cis rs12478296 0.892 rs60042638 ENSG00000261186.2 RP11-341N2.1 -4.5 9.44e-06 0.00252 -0.34 -0.24 Obesity-related traits; chr2:242096556 chr2:242087351~242088457:- LIHC cis rs12478296 1 rs12474070 ENSG00000261186.2 RP11-341N2.1 -4.5 9.44e-06 0.00252 -0.34 -0.24 Obesity-related traits; chr2:242097587 chr2:242087351~242088457:- LIHC cis rs12478296 1 rs56102931 ENSG00000261186.2 RP11-341N2.1 -4.5 9.44e-06 0.00252 -0.34 -0.24 Obesity-related traits; chr2:242097785 chr2:242087351~242088457:- LIHC cis rs12478296 1 rs55732177 ENSG00000261186.2 RP11-341N2.1 -4.5 9.44e-06 0.00252 -0.34 -0.24 Obesity-related traits; chr2:242097855 chr2:242087351~242088457:- LIHC cis rs12478296 1 rs55758933 ENSG00000261186.2 RP11-341N2.1 -4.5 9.44e-06 0.00252 -0.34 -0.24 Obesity-related traits; chr2:242098138 chr2:242087351~242088457:- LIHC cis rs12478296 1 rs55717005 ENSG00000261186.2 RP11-341N2.1 -4.5 9.44e-06 0.00252 -0.34 -0.24 Obesity-related traits; chr2:242098920 chr2:242087351~242088457:- LIHC cis rs12478296 1 rs55814222 ENSG00000261186.2 RP11-341N2.1 -4.5 9.44e-06 0.00252 -0.34 -0.24 Obesity-related traits; chr2:242099015 chr2:242087351~242088457:- LIHC cis rs6445975 0.666 rs12489103 ENSG00000272360.1 RP11-359I18.5 4.5 9.45e-06 0.00252 0.31 0.24 Systemic lupus erythematosus; chr3:58387440 chr3:58490830~58491291:- LIHC cis rs11669181 1 rs11669181 ENSG00000267147.2 CTC-548K16.1 4.5 9.46e-06 0.00252 0.29 0.24 Conotruncal heart defects (maternal effects); chr19:14334326 chr19:14333743~14343916:+ LIHC cis rs11971779 0.938 rs11981688 ENSG00000273391.1 RP11-634H22.1 4.5 9.46e-06 0.00253 0.23 0.24 Diisocyanate-induced asthma; chr7:139404149 chr7:139359032~139359566:- LIHC cis rs1577917 0.958 rs10944168 ENSG00000234155.1 RP11-30P6.6 4.5 9.47e-06 0.00253 0.31 0.24 Response to antipsychotic treatment; chr6:85970438 chr6:85387219~85390186:- LIHC cis rs7915414 0.951 rs68157779 ENSG00000230338.1 MTND4P19 4.5 9.48e-06 0.00253 0.25 0.24 Clopidogrel active metabolite levels; chr10:94672932 chr10:94774156~94774633:- LIHC cis rs875971 0.522 rs34973832 ENSG00000224316.1 RP11-479O9.2 4.5 9.48e-06 0.00253 0.24 0.24 Aortic root size; chr7:65931217 chr7:65773620~65802067:+ LIHC cis rs417065 0.516 rs7548511 ENSG00000227634.1 RP11-431K24.3 -4.5 9.48e-06 0.00253 -0.28 -0.24 Psoriasis; chr1:8207453 chr1:8208672~8215210:+ LIHC cis rs17270561 0.887 rs12201170 ENSG00000216436.2 HIST1H2APS1 -4.5 9.5e-06 0.00253 -0.37 -0.24 Iron status biomarkers; chr6:25866019 chr6:25732497~25732827:+ LIHC cis rs11098499 0.909 rs1546502 ENSG00000245958.5 RP11-33B1.1 -4.5 9.5e-06 0.00254 -0.25 -0.24 Corneal astigmatism; chr4:119314743 chr4:119454791~119552025:+ LIHC cis rs9487094 0.961 rs1546980 ENSG00000260273.1 RP11-425D10.10 4.5 9.5e-06 0.00254 0.28 0.24 Height; chr6:109452743 chr6:109382795~109383666:+ LIHC cis rs875971 0.522 rs6960048 ENSG00000224316.1 RP11-479O9.2 4.5 9.5e-06 0.00254 0.24 0.24 Aortic root size; chr7:65943052 chr7:65773620~65802067:+ LIHC cis rs5756813 0.811 rs4396807 ENSG00000233360.4 Z83844.1 4.5 9.51e-06 0.00254 0.29 0.24 Optic cup area;Vertical cup-disc ratio; chr22:37742372 chr22:37641832~37658377:- LIHC cis rs11971779 0.68 rs10274480 ENSG00000273391.1 RP11-634H22.1 4.5 9.51e-06 0.00254 0.21 0.24 Diisocyanate-induced asthma; chr7:139367682 chr7:139359032~139359566:- LIHC cis rs10262624 0.967 rs2390848 ENSG00000234286.1 AC006026.13 -4.5 9.51e-06 0.00254 -0.26 -0.24 Schizophrenia; chr7:23872755 chr7:23680195~23680786:- LIHC cis rs10262624 0.967 rs7792734 ENSG00000234286.1 AC006026.13 -4.5 9.51e-06 0.00254 -0.26 -0.24 Schizophrenia; chr7:23876429 chr7:23680195~23680786:- LIHC cis rs875971 0.522 rs1880556 ENSG00000224316.1 RP11-479O9.2 4.5 9.52e-06 0.00254 0.24 0.24 Aortic root size; chr7:65967557 chr7:65773620~65802067:+ LIHC cis rs11098499 0.69 rs34818745 ENSG00000245958.5 RP11-33B1.1 -4.5 9.53e-06 0.00254 -0.25 -0.24 Corneal astigmatism; chr4:119335900 chr4:119454791~119552025:+ LIHC cis rs2842992 0.715 rs2277073 ENSG00000237927.1 RP3-393E18.2 -4.5 9.53e-06 0.00254 -0.29 -0.24 Age-related macular degeneration (geographic atrophy); chr6:159761717 chr6:159586955~159589169:- LIHC cis rs11637445 0.603 rs1478941 ENSG00000260657.2 RP11-315D16.4 -4.49 9.56e-06 0.00255 -0.33 -0.24 Posterior cortical atrophy and Alzheimer's disease; chr15:67834803 chr15:68267792~68277994:- LIHC cis rs957448 1 rs1992370 ENSG00000253704.1 RP11-267M23.4 4.49 9.57e-06 0.00255 0.29 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94546466 chr8:94553722~94569745:+ LIHC cis rs11971779 0.68 rs2355786 ENSG00000273391.1 RP11-634H22.1 -4.49 9.57e-06 0.00255 -0.21 -0.24 Diisocyanate-induced asthma; chr7:139380876 chr7:139359032~139359566:- LIHC cis rs2739330 0.796 rs5760097 ENSG00000206090.4 AP000350.7 4.49 9.59e-06 0.00256 0.28 0.24 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23939998~23942798:+ LIHC cis rs160451 0.966 rs160427 ENSG00000251136.7 RP11-37B2.1 4.49 9.6e-06 0.00256 0.21 0.24 Leprosy; chr8:89659156 chr8:89609409~89757727:- LIHC cis rs2439831 0.702 rs9989313 ENSG00000275601.1 AC011330.13 -4.49 9.61e-06 0.00256 -0.35 -0.24 Lung cancer in ever smokers; chr15:43860619 chr15:43642389~43643023:- LIHC cis rs3733589 1 rs16891923 ENSG00000250413.1 RP11-448G15.1 4.49 9.61e-06 0.00256 0.43 0.24 Renal overload gout; chr4:9995037 chr4:10006482~10009725:+ LIHC cis rs643506 1 rs647080 ENSG00000254990.4 RP11-108O10.2 4.49 9.61e-06 0.00256 0.26 0.24 Breast cancer; chr11:111738450 chr11:111768668~111778350:- LIHC cis rs950169 0.544 rs2036949 ENSG00000225151.9 GOLGA2P7 -4.49 9.62e-06 0.00256 -0.3 -0.24 Schizophrenia; chr15:84620374 chr15:84199311~84230136:- LIHC cis rs7811142 0.83 rs28495773 ENSG00000242294.5 STAG3L5P 4.49 9.62e-06 0.00256 0.26 0.24 Platelet count; chr7:100345960 chr7:100336079~100351900:+ LIHC cis rs9595908 0.865 rs497255 ENSG00000212293.1 SNORA16 -4.49 9.62e-06 0.00256 -0.29 -0.24 Body mass index; chr13:32424754 chr13:32420390~32420516:- LIHC cis rs11098499 0.863 rs6534139 ENSG00000260091.1 RP11-33B1.4 4.49 9.62e-06 0.00257 0.17 0.24 Corneal astigmatism; chr4:119528301 chr4:119409333~119410233:+ LIHC cis rs11668505 0.965 rs12985683 ENSG00000259108.2 CTD-3098H1.2 4.49 9.62e-06 0.00257 0.3 0.24 Lung function (FVC); chr19:47836597 chr19:47863483~47865341:- LIHC cis rs9368481 0.554 rs2754603 ENSG00000241549.7 GUSBP2 -4.49 9.62e-06 0.00257 -0.25 -0.24 Autism spectrum disorder or schizophrenia; chr6:26997360 chr6:26871484~26956554:- LIHC cis rs9368481 0.761 rs9357028 ENSG00000241549.7 GUSBP2 -4.49 9.62e-06 0.00257 -0.25 -0.24 Autism spectrum disorder or schizophrenia; chr6:26999445 chr6:26871484~26956554:- LIHC cis rs11971779 0.793 rs11772447 ENSG00000273391.1 RP11-634H22.1 4.49 9.63e-06 0.00257 0.22 0.24 Diisocyanate-induced asthma; chr7:139348843 chr7:139359032~139359566:- LIHC cis rs227275 0.554 rs223422 ENSG00000246560.2 RP11-10L12.4 4.49 9.64e-06 0.00257 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102805616 chr4:102828055~102844075:+ LIHC cis rs2439831 0.717 rs28495368 ENSG00000166763.7 STRCP1 4.49 9.64e-06 0.00257 0.37 0.24 Lung cancer in ever smokers; chr15:43603444 chr15:43699488~43718184:- LIHC cis rs2243480 1 rs313807 ENSG00000228409.4 CCT6P1 4.49 9.64e-06 0.00257 0.25 0.24 Diabetic kidney disease; chr7:66034494 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs313808 ENSG00000228409.4 CCT6P1 4.49 9.64e-06 0.00257 0.25 0.24 Diabetic kidney disease; chr7:66034886 chr7:65751142~65763354:+ LIHC cis rs28475163 0.958 rs7395116 ENSG00000251661.3 RP11-326C3.11 4.49 9.65e-06 0.00257 0.32 0.24 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr11:324880 chr11:318640~325631:+ LIHC cis rs763512 0.504 rs58201617 ENSG00000276054.1 RP11-378E13.3 4.49 9.67e-06 0.00257 0.29 0.24 3-hydroxypropylmercapturic acid levels in smokers; chr17:37505345 chr17:37386886~37387926:+ LIHC cis rs2072510 0.932 rs10859999 ENSG00000257715.1 RP11-256L6.2 4.49 9.67e-06 0.00258 0.24 0.24 Metabolite levels (small molecules and protein measures); chr12:95997556 chr12:96025323~96027971:+ LIHC cis rs6142102 0.651 rs6059692 ENSG00000276073.1 RP5-1125A11.7 4.49 9.68e-06 0.00258 0.27 0.24 Skin pigmentation; chr20:34158397 chr20:33985617~33988989:- LIHC cis rs11971779 0.648 rs4732367 ENSG00000273391.1 RP11-634H22.1 4.49 9.68e-06 0.00258 0.21 0.24 Diisocyanate-induced asthma; chr7:139343356 chr7:139359032~139359566:- LIHC cis rs12554020 0.892 rs6479494 ENSG00000227603.1 RP11-165J3.6 -4.49 9.68e-06 0.00258 -0.32 -0.24 Schizophrenia; chr9:93568217 chr9:93435332~93437121:- LIHC cis rs9487094 0.961 rs752262 ENSG00000260273.1 RP11-425D10.10 4.49 9.68e-06 0.00258 0.28 0.24 Height; chr6:109449796 chr6:109382795~109383666:+ LIHC cis rs2032366 0.63 rs7235404 ENSG00000267279.1 RP11-879F14.2 4.49 9.69e-06 0.00258 0.29 0.24 Obesity-related traits; chr18:61628753 chr18:61585746~61606916:- LIHC cis rs2337406 1 rs7145100 ENSG00000274576.2 IGHV2-70 -4.49 9.69e-06 0.00258 -0.28 -0.24 Alzheimer's disease (late onset); chr14:106704673 chr14:106770577~106771020:- LIHC cis rs72675573 0.821 rs12563043 ENSG00000235612.1 RP1-158P9.1 -4.49 9.71e-06 0.00258 -0.32 -0.24 Monocyte count; chr1:56107650 chr1:56145721~56155224:+ LIHC cis rs7809950 0.906 rs2395907 ENSG00000238832.1 snoU109 4.49 9.71e-06 0.00258 0.29 0.24 Coronary artery disease; chr7:107612859 chr7:107603363~107603507:+ LIHC cis rs11722228 0.549 rs73212828 ENSG00000261490.1 RP11-448G15.3 4.49 9.72e-06 0.00259 0.31 0.24 Urate levels;Serum uric acid levels;Gout; chr4:10077132 chr4:10068089~10073019:- LIHC cis rs11722228 0.549 rs73212830 ENSG00000261490.1 RP11-448G15.3 4.49 9.72e-06 0.00259 0.31 0.24 Urate levels;Serum uric acid levels;Gout; chr4:10077135 chr4:10068089~10073019:- LIHC cis rs7246657 0.943 rs10415024 ENSG00000276846.1 CTD-3220F14.3 4.49 9.72e-06 0.00259 0.31 0.24 Coronary artery calcification; chr19:37323822 chr19:37314868~37315620:- LIHC cis rs17826219 0.714 rs11650821 ENSG00000266490.1 CTD-2349P21.9 4.49 9.72e-06 0.00259 0.3 0.24 Body mass index; chr17:30641132 chr17:30792372~30792833:+ LIHC cis rs3733589 0.59 rs6822023 ENSG00000250413.1 RP11-448G15.1 4.49 9.72e-06 0.00259 0.38 0.24 Renal overload gout; chr4:10050970 chr4:10006482~10009725:+ LIHC cis rs3733589 0.59 rs6837659 ENSG00000250413.1 RP11-448G15.1 4.49 9.72e-06 0.00259 0.38 0.24 Renal overload gout; chr4:10050986 chr4:10006482~10009725:+ LIHC cis rs7044106 0.791 rs4837793 ENSG00000238181.2 AHCYP2 -4.49 9.73e-06 0.00259 -0.27 -0.24 Hip circumference adjusted for BMI; chr9:120721343 chr9:120720673~120721972:+ LIHC cis rs7809950 1 rs2520265 ENSG00000238832.1 snoU109 -4.49 9.73e-06 0.00259 -0.29 -0.24 Coronary artery disease; chr7:107540786 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2712191 ENSG00000238832.1 snoU109 -4.49 9.73e-06 0.00259 -0.29 -0.24 Coronary artery disease; chr7:107542279 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs10267907 ENSG00000238832.1 snoU109 -4.49 9.73e-06 0.00259 -0.29 -0.24 Coronary artery disease; chr7:107544021 chr7:107603363~107603507:+ LIHC cis rs2243480 1 rs778729 ENSG00000230295.1 RP11-458F8.2 -4.49 9.74e-06 0.00259 -0.25 -0.24 Diabetic kidney disease; chr7:66359432 chr7:66880708~66882981:+ LIHC cis rs2243480 0.901 rs778687 ENSG00000230295.1 RP11-458F8.2 -4.49 9.74e-06 0.00259 -0.25 -0.24 Diabetic kidney disease; chr7:66370832 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs778679 ENSG00000230295.1 RP11-458F8.2 -4.49 9.74e-06 0.00259 -0.25 -0.24 Diabetic kidney disease; chr7:66375924 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs778704 ENSG00000230295.1 RP11-458F8.2 -4.49 9.74e-06 0.00259 -0.25 -0.24 Diabetic kidney disease; chr7:66398480 chr7:66880708~66882981:+ LIHC cis rs2243480 0.901 rs778693 ENSG00000230295.1 RP11-458F8.2 -4.49 9.74e-06 0.00259 -0.25 -0.24 Diabetic kidney disease; chr7:66407358 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs778691 ENSG00000230295.1 RP11-458F8.2 -4.49 9.74e-06 0.00259 -0.25 -0.24 Diabetic kidney disease; chr7:66408105 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs13235972 ENSG00000230295.1 RP11-458F8.2 -4.49 9.74e-06 0.00259 -0.25 -0.24 Diabetic kidney disease; chr7:66418618 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs34192067 ENSG00000230295.1 RP11-458F8.2 -4.49 9.74e-06 0.00259 -0.25 -0.24 Diabetic kidney disease; chr7:66422670 chr7:66880708~66882981:+ LIHC cis rs4650994 0.789 rs2811300 ENSG00000273384.1 RP5-1098D14.1 -4.49 9.75e-06 0.00259 -0.28 -0.24 HDL cholesterol;HDL cholesterol levels; chr1:178621259 chr1:178651706~178652282:+ LIHC cis rs4650994 0.816 rs1074896 ENSG00000273384.1 RP5-1098D14.1 -4.49 9.75e-06 0.00259 -0.28 -0.24 HDL cholesterol;HDL cholesterol levels; chr1:178622055 chr1:178651706~178652282:+ LIHC cis rs875971 0.522 rs7784623 ENSG00000224316.1 RP11-479O9.2 4.49 9.75e-06 0.00259 0.24 0.24 Aortic root size; chr7:65930047 chr7:65773620~65802067:+ LIHC cis rs7811142 0.83 rs6948685 ENSG00000242294.5 STAG3L5P 4.49 9.75e-06 0.00259 0.26 0.24 Platelet count; chr7:100372565 chr7:100336079~100351900:+ LIHC cis rs7811142 0.83 rs73401450 ENSG00000242294.5 STAG3L5P 4.49 9.75e-06 0.00259 0.26 0.24 Platelet count; chr7:100384236 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs28490152 ENSG00000242294.5 STAG3L5P 4.49 9.76e-06 0.00259 0.27 0.24 Platelet count; chr7:100423359 chr7:100336079~100351900:+ LIHC cis rs7811142 0.943 rs28660238 ENSG00000242294.5 STAG3L5P 4.49 9.76e-06 0.00259 0.27 0.24 Platelet count; chr7:100425685 chr7:100336079~100351900:+ LIHC cis rs875971 0.638 rs10249404 ENSG00000273024.4 INTS4P2 4.49 9.76e-06 0.0026 0.26 0.24 Aortic root size; chr7:66581737 chr7:65647864~65715661:+ LIHC cis rs17818399 0.547 rs12997164 ENSG00000239332.4 LINC01119 -4.49 9.76e-06 0.0026 -0.33 -0.24 Height; chr2:46531607 chr2:46816697~46859007:+ LIHC cis rs10129255 0.5 rs7159033 ENSG00000223648.3 IGHV3-64 4.49 9.77e-06 0.0026 0.17 0.24 Kawasaki disease; chr14:106701709 chr14:106643132~106658258:- LIHC cis rs12478296 1 rs56136197 ENSG00000261186.2 RP11-341N2.1 -4.49 9.77e-06 0.0026 -0.34 -0.24 Obesity-related traits; chr2:242101726 chr2:242087351~242088457:- LIHC cis rs9595908 0.9 rs731413 ENSG00000212293.1 SNORA16 4.49 9.77e-06 0.0026 0.27 0.24 Body mass index; chr13:32601519 chr13:32420390~32420516:- LIHC cis rs2348418 0.733 rs9651832 ENSG00000247934.4 RP11-967K21.1 -4.49 9.77e-06 0.0026 -0.21 -0.24 Lung function (FEV1);Lung function (FVC); chr12:28242489 chr12:28163298~28190738:- LIHC cis rs7734985 0.772 rs10045777 ENSG00000250551.1 RP11-254I22.1 -4.49 9.77e-06 0.0026 -0.3 -0.24 IgG glycosylation; chr5:96096049 chr5:96050115~96215519:+ LIHC cis rs7637701 0.773 rs9859058 ENSG00000243926.1 TIPARP-AS1 4.49 9.77e-06 0.0026 0.21 0.24 Breast cancer; chr3:156795028 chr3:156671862~156674378:- LIHC cis rs17270561 0.887 rs717551 ENSG00000216436.2 HIST1H2APS1 -4.49 9.77e-06 0.0026 -0.37 -0.24 Iron status biomarkers; chr6:25855396 chr6:25732497~25732827:+ LIHC cis rs2015599 0.56 rs11050147 ENSG00000275476.1 RP11-996F15.4 -4.49 9.79e-06 0.0026 -0.3 -0.24 Platelet count;Mean platelet volume; chr12:29242746 chr12:29277397~29277882:- LIHC cis rs42490 0.789 rs416324 ENSG00000251136.7 RP11-37B2.1 4.49 9.8e-06 0.0026 0.2 0.24 Leprosy; chr8:89803007 chr8:89609409~89757727:- LIHC cis rs12701220 0.894 rs8591 ENSG00000229043.2 AC091729.9 -4.49 9.8e-06 0.00261 -0.33 -0.24 Bronchopulmonary dysplasia; chr7:997163 chr7:1160374~1165267:+ LIHC cis rs1729407 0.625 rs2727789 ENSG00000236267.1 AP006216.5 4.49 9.82e-06 0.00261 0.22 0.24 Apolipoprotein A-IV levels; chr11:116826171 chr11:116813204~116814003:- LIHC cis rs9549367 0.789 rs9549365 ENSG00000269125.1 RP11-98F14.11 4.49 9.82e-06 0.00261 0.27 0.24 Platelet distribution width; chr13:113253077 chr13:113165002~113165183:- LIHC cis rs11064881 1 rs11064881 ENSG00000278344.1 RP11-18C24.8 4.49 9.82e-06 0.00261 0.65 0.24 Inflammatory bowel disease;Ulcerative colitis; chr12:119709120 chr12:120500735~120501090:- LIHC cis rs7193541 0.965 rs7199068 ENSG00000261079.1 RP11-252A24.3 4.49 9.83e-06 0.00261 0.26 0.24 Multiple myeloma; chr16:74664365 chr16:74367462~74369826:+ LIHC cis rs2274273 0.87 rs8013713 ENSG00000258413.1 RP11-665C16.6 4.49 9.83e-06 0.00261 0.28 0.24 Protein biomarker; chr14:55374534 chr14:55262767~55272075:- LIHC cis rs919433 0.927 rs1429412 ENSG00000231621.1 AC013264.2 4.49 9.83e-06 0.00261 0.22 0.24 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197326170 chr2:197197991~197199273:+ LIHC cis rs919433 0.927 rs3843857 ENSG00000231621.1 AC013264.2 4.49 9.83e-06 0.00261 0.22 0.24 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197331241 chr2:197197991~197199273:+ LIHC cis rs6745190 0.557 rs34504038 ENSG00000236153.1 AC104076.3 -4.49 9.83e-06 0.00261 -0.33 -0.24 White blood cell count; chr2:181128227 chr2:180979427~180980090:- LIHC cis rs2243480 1 rs7804223 ENSG00000230295.1 RP11-458F8.2 4.49 9.85e-06 0.00262 0.25 0.24 Diabetic kidney disease; chr7:66199572 chr7:66880708~66882981:+ LIHC cis rs2932538 0.922 rs12125361 ENSG00000225075.1 RP11-426L16.3 4.49 9.85e-06 0.00262 0.3 0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112602157 chr1:112693688~112696621:- LIHC cis rs6433895 0.677 rs11688120 ENSG00000236153.1 AC104076.3 -4.49 9.87e-06 0.00262 -0.33 -0.24 Lymphocyte counts; chr2:181133223 chr2:180979427~180980090:- LIHC cis rs6433895 0.677 rs35725888 ENSG00000236153.1 AC104076.3 -4.49 9.87e-06 0.00262 -0.33 -0.24 Lymphocyte counts; chr2:181133900 chr2:180979427~180980090:- LIHC cis rs6433895 0.677 rs35076700 ENSG00000236153.1 AC104076.3 -4.49 9.87e-06 0.00262 -0.33 -0.24 Lymphocyte counts; chr2:181134597 chr2:180979427~180980090:- LIHC cis rs6433895 0.677 rs72887083 ENSG00000236153.1 AC104076.3 -4.49 9.87e-06 0.00262 -0.33 -0.24 Lymphocyte counts; chr2:181134803 chr2:180979427~180980090:- LIHC cis rs9525927 0.57 rs9533797 ENSG00000230731.2 RP11-478K15.6 4.49 9.87e-06 0.00262 0.27 0.24 Dupuytren's disease; chr13:44225232 chr13:44234118~44243192:- LIHC cis rs4218 1 rs4218 ENSG00000277144.1 RP11-59H7.4 -4.49 9.88e-06 0.00262 -0.26 -0.24 Social communication problems; chr15:59136459 chr15:59115547~59116089:- LIHC cis rs11089937 0.626 rs5757011 ENSG00000211639.2 IGLV4-60 4.49 9.88e-06 0.00262 0.2 0.24 Periodontitis (PAL4Q3); chr22:22135336 chr22:22162199~22162681:+ LIHC cis rs9595908 0.931 rs55645971 ENSG00000212293.1 SNORA16 4.49 9.88e-06 0.00262 0.27 0.24 Body mass index; chr13:32615452 chr13:32420390~32420516:- LIHC cis rs7615952 0.512 rs2979336 ENSG00000171084.14 FAM86JP 4.49 9.89e-06 0.00263 0.36 0.24 Blood pressure (smoking interaction); chr3:125638626 chr3:125916620~125930024:+ LIHC cis rs2439831 0.681 rs7168940 ENSG00000166763.7 STRCP1 4.49 9.89e-06 0.00263 0.33 0.24 Lung cancer in ever smokers; chr15:43341136 chr15:43699488~43718184:- LIHC cis rs1062177 1 rs2915887 ENSG00000253921.1 CTB-113P19.3 -4.49 9.89e-06 0.00263 -0.28 -0.24 Preschool internalizing problems; chr5:151825943 chr5:151753992~151767247:+ LIHC cis rs3858145 0.506 rs10762224 ENSG00000233590.1 RP11-153K11.3 4.49 9.89e-06 0.00263 0.31 0.24 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68326556 chr10:68233251~68242379:- LIHC cis rs2243480 1 rs4718317 ENSG00000230295.1 RP11-458F8.2 4.49 9.89e-06 0.00263 0.24 0.24 Diabetic kidney disease; chr7:66183914 chr7:66880708~66882981:+ LIHC cis rs7826238 0.72 rs12546760 ENSG00000253893.2 FAM85B 4.49 9.9e-06 0.00263 0.3 0.24 Systolic blood pressure; chr8:8517326 chr8:8167819~8226614:- LIHC cis rs11098499 0.863 rs1010740 ENSG00000260091.1 RP11-33B1.4 4.49 9.9e-06 0.00263 0.17 0.24 Corneal astigmatism; chr4:119542254 chr4:119409333~119410233:+ LIHC cis rs2976388 0.609 rs2717601 ENSG00000253741.1 CTD-2292P10.4 -4.49 9.9e-06 0.00263 -0.27 -0.24 Urinary tract infection frequency; chr8:142726506 chr8:142702252~142726973:- LIHC cis rs9992667 0.91 rs10019144 ENSG00000231160.8 KLF3-AS1 4.49 9.9e-06 0.00263 0.29 0.24 Eosinophil percentage of granulocytes; chr4:38684784 chr4:38612701~38664883:- LIHC cis rs8028182 0.636 rs7166737 ENSG00000260269.4 CTD-2323K18.1 -4.49 9.9e-06 0.00263 -0.3 -0.24 Sudden cardiac arrest; chr15:75390172 chr15:75527150~75601205:- LIHC cis rs11673344 0.838 rs112401881 ENSG00000226686.6 LINC01535 4.49 9.91e-06 0.00263 0.37 0.24 Obesity-related traits; chr19:37156092 chr19:37251912~37265535:+ LIHC cis rs11098499 0.863 rs1383532 ENSG00000260091.1 RP11-33B1.4 4.49 9.92e-06 0.00263 0.17 0.24 Corneal astigmatism; chr4:119513249 chr4:119409333~119410233:+ LIHC cis rs2243480 0.901 rs34807232 ENSG00000230295.1 RP11-458F8.2 -4.49 9.92e-06 0.00263 -0.25 -0.24 Diabetic kidney disease; chr7:66500146 chr7:66880708~66882981:+ LIHC cis rs2243480 0.901 rs35823062 ENSG00000230295.1 RP11-458F8.2 -4.49 9.92e-06 0.00263 -0.25 -0.24 Diabetic kidney disease; chr7:66500834 chr7:66880708~66882981:+ LIHC cis rs950169 0.922 rs17531523 ENSG00000259295.5 CSPG4P12 4.49 9.92e-06 0.00263 0.33 0.24 Schizophrenia; chr15:84589218 chr15:85191438~85213905:+ LIHC cis rs10129255 0.957 rs10136817 ENSG00000211970.3 IGHV4-61 -4.49 9.92e-06 0.00263 -0.19 -0.24 Kawasaki disease; chr14:106787730 chr14:106639119~106639657:- LIHC cis rs9595908 0.897 rs12429688 ENSG00000212293.1 SNORA16 4.49 9.92e-06 0.00263 0.28 0.24 Body mass index; chr13:32572075 chr13:32420390~32420516:- LIHC cis rs73186030 0.92 rs73186050 ENSG00000272758.4 RP11-299J3.8 4.49 9.95e-06 0.00264 0.45 0.24 Serum parathyroid hormone levels; chr3:122321081 chr3:122416207~122443180:+ LIHC cis rs73186030 0.92 rs73186053 ENSG00000272758.4 RP11-299J3.8 4.49 9.95e-06 0.00264 0.45 0.24 Serum parathyroid hormone levels; chr3:122322009 chr3:122416207~122443180:+ LIHC cis rs7615952 0.605 rs11708269 ENSG00000171084.14 FAM86JP 4.49 9.95e-06 0.00264 0.56 0.24 Blood pressure (smoking interaction); chr3:125613306 chr3:125916620~125930024:+ LIHC cis rs7412746 0.611 rs1889741 ENSG00000231073.1 RP11-316M1.3 4.49 9.95e-06 0.00264 0.23 0.24 Melanoma; chr1:150896569 chr1:150973123~150975534:+ LIHC cis rs7412746 0.611 rs66847267 ENSG00000231073.1 RP11-316M1.3 4.49 9.95e-06 0.00264 0.23 0.24 Melanoma; chr1:150902697 chr1:150973123~150975534:+ LIHC cis rs11098499 0.954 rs28572238 ENSG00000260091.1 RP11-33B1.4 -4.49 9.95e-06 0.00264 -0.17 -0.24 Corneal astigmatism; chr4:119395531 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs28714195 ENSG00000260091.1 RP11-33B1.4 -4.49 9.95e-06 0.00264 -0.17 -0.24 Corneal astigmatism; chr4:119395795 chr4:119409333~119410233:+ LIHC cis rs4965006 0.915 rs7969545 ENSG00000273568.1 RP11-417L19.6 4.49 9.96e-06 0.00264 0.3 0.24 Posterior cortical atrophy and Alzheimer's disease; chr12:131934612 chr12:131934642~131934928:+ LIHC cis rs1865760 0.516 rs9379818 ENSG00000216436.2 HIST1H2APS1 -4.49 9.96e-06 0.00264 -0.27 -0.24 Height; chr6:26022978 chr6:25732497~25732827:+ LIHC cis rs5769765 0.72 rs138820 ENSG00000278869.1 CITF22-49E9.3 4.48 9.97e-06 0.00265 0.33 0.24 Schizophrenia; chr22:49770430 chr22:49933198~49934074:- LIHC cis rs2932538 0.961 rs6537746 ENSG00000225075.1 RP11-426L16.3 -4.48 9.97e-06 0.00265 -0.3 -0.24 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112620907 chr1:112693688~112696621:- LIHC cis rs9675120 0.781 rs7212152 ENSG00000262006.1 RP11-700H6.4 -4.48 9.98e-06 0.00265 -0.26 -0.24 Cerebrospinal fluid biomarker levels; chr17:50838870 chr17:50909637~50910232:- LIHC cis rs9675120 0.672 rs7225619 ENSG00000262006.1 RP11-700H6.4 -4.48 9.98e-06 0.00265 -0.26 -0.24 Cerebrospinal fluid biomarker levels; chr17:50838889 chr17:50909637~50910232:- LIHC cis rs3733589 1 rs34644460 ENSG00000250413.1 RP11-448G15.1 4.48 9.98e-06 0.00265 0.42 0.24 Renal overload gout; chr4:10016015 chr4:10006482~10009725:+ LIHC cis rs3733589 1 rs35271694 ENSG00000250413.1 RP11-448G15.1 4.48 9.98e-06 0.00265 0.42 0.24 Renal overload gout; chr4:10016214 chr4:10006482~10009725:+ LIHC cis rs875971 0.545 rs6969224 ENSG00000273142.1 RP11-458F8.4 4.48 9.98e-06 0.00265 0.23 0.24 Aortic root size; chr7:66370011 chr7:66902857~66906297:+ LIHC cis rs2337406 1 rs11161002 ENSG00000274576.2 IGHV2-70 -4.48 9.99e-06 0.00265 -0.27 -0.24 Alzheimer's disease (late onset); chr14:106702202 chr14:106770577~106771020:- LIHC cis rs9527 0.545 rs35756290 ENSG00000236937.2 PTGES3P4 4.48 1e-05 0.00265 0.36 0.24 Arsenic metabolism; chr10:102825815 chr10:102845595~102845950:+ LIHC cis rs1075232 1 rs12437749 ENSG00000270055.1 CTD-3092A11.2 -4.48 1e-05 0.00265 -0.46 -0.24 Survival in colorectal cancer (non-distant metastatic); chr15:31357685 chr15:30487963~30490313:+ LIHC cis rs1075232 1 rs12439239 ENSG00000270055.1 CTD-3092A11.2 -4.48 1e-05 0.00265 -0.46 -0.24 Survival in colorectal cancer (non-distant metastatic); chr15:31359515 chr15:30487963~30490313:+ LIHC cis rs11096990 0.634 rs2276888 ENSG00000249685.1 RP11-360F5.3 -4.48 1e-05 0.00265 -0.28 -0.24 Cognitive function; chr4:39278287 chr4:39133913~39135608:+ LIHC cis rs6480314 0.831 rs17538164 ENSG00000233590.1 RP11-153K11.3 4.48 1e-05 0.00265 0.35 0.24 Optic nerve measurement (disc area); chr10:68215920 chr10:68233251~68242379:- LIHC cis rs901683 0.702 rs78034568 ENSG00000230869.1 CTGLF10P -4.48 1e-05 0.00265 -0.53 -0.24 Mean corpuscular volume;Red blood cell traits; chr10:45654132 chr10:45678692~45700532:+ LIHC cis rs3931020 0.548 rs969435 ENSG00000272864.1 RP11-17E13.2 4.48 1e-05 0.00265 0.35 0.24 Resistin levels; chr1:74808182 chr1:74698769~74699333:- LIHC cis rs9388451 0.626 rs3799708 ENSG00000237742.5 RP11-624M8.1 -4.48 1e-05 0.00265 -0.22 -0.24 Brugada syndrome; chr6:125757384 chr6:125578558~125749190:- LIHC cis rs2284219 0.964 rs255098 ENSG00000196295.10 AC005154.6 -4.48 1e-05 0.00265 -0.17 -0.24 Type 2 diabetes; chr7:30687711 chr7:30516309~30594809:- LIHC cis rs6921919 0.848 rs9468350 ENSG00000216901.1 AL022393.7 4.48 1e-05 0.00265 0.3 0.24 Autism spectrum disorder or schizophrenia; chr6:28351330 chr6:28176188~28176674:+ LIHC cis rs597539 0.652 rs496616 ENSG00000250508.1 RP11-757G1.6 -4.48 1e-05 0.00266 -0.35 -0.24 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68905332 chr11:68870664~68874542:+ LIHC cis rs3733589 0.59 rs3733590 ENSG00000250413.1 RP11-448G15.1 4.48 1e-05 0.00266 0.4 0.24 Renal overload gout; chr4:9985602 chr4:10006482~10009725:+ LIHC cis rs921968 0.565 rs2272188 ENSG00000272555.1 RP11-459I19.1 4.48 1e-05 0.00266 0.25 0.24 Mean corpuscular hemoglobin concentration; chr2:218747559 chr2:218818690~218819144:+ LIHC cis rs13083990 0.881 rs13085674 ENSG00000272758.4 RP11-299J3.8 -4.48 1e-05 0.00266 -0.25 -0.24 Cardiac Troponin-T levels; chr3:122292504 chr3:122416207~122443180:+ LIHC cis rs13083990 0.881 rs13085498 ENSG00000272758.4 RP11-299J3.8 4.48 1e-05 0.00266 0.25 0.24 Cardiac Troponin-T levels; chr3:122292516 chr3:122416207~122443180:+ LIHC cis rs2439831 0.85 rs3736180 ENSG00000166763.7 STRCP1 4.48 1e-05 0.00266 0.36 0.24 Lung cancer in ever smokers; chr15:43814426 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs28684672 ENSG00000166763.7 STRCP1 4.48 1e-05 0.00266 0.36 0.24 Lung cancer in ever smokers; chr15:43815464 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs12440573 ENSG00000166763.7 STRCP1 4.48 1e-05 0.00266 0.36 0.24 Lung cancer in ever smokers; chr15:43816799 chr15:43699488~43718184:- LIHC cis rs748404 0.631 rs8042688 ENSG00000205771.5 CATSPER2P1 -4.48 1e-05 0.00266 -0.28 -0.24 Lung cancer; chr15:43346327 chr15:43726918~43747094:- LIHC cis rs748404 0.631 rs4296223 ENSG00000205771.5 CATSPER2P1 -4.48 1e-05 0.00266 -0.28 -0.24 Lung cancer; chr15:43353048 chr15:43726918~43747094:- LIHC cis rs748404 0.631 rs6493084 ENSG00000205771.5 CATSPER2P1 -4.48 1e-05 0.00266 -0.28 -0.24 Lung cancer; chr15:43355429 chr15:43726918~43747094:- LIHC cis rs748404 0.631 rs12905772 ENSG00000205771.5 CATSPER2P1 -4.48 1e-05 0.00266 -0.28 -0.24 Lung cancer; chr15:43356246 chr15:43726918~43747094:- LIHC cis rs748404 0.676 rs4401024 ENSG00000205771.5 CATSPER2P1 -4.48 1e-05 0.00266 -0.28 -0.24 Lung cancer; chr15:43358137 chr15:43726918~43747094:- LIHC cis rs748404 0.631 rs6493086 ENSG00000205771.5 CATSPER2P1 -4.48 1e-05 0.00266 -0.28 -0.24 Lung cancer; chr15:43363196 chr15:43726918~43747094:- LIHC cis rs79349575 0.783 rs903567 ENSG00000248278.1 SUMO2P17 4.48 1e-05 0.00266 0.29 0.24 Type 2 diabetes; chr17:48902956 chr17:48874860~48908983:- LIHC cis rs3782123 0.514 rs11246007 ENSG00000277290.1 RP11-326C3.16 -4.48 1e-05 0.00266 -0.28 -0.24 Red cell distribution width;Glycated hemoglobin levels; chr11:221584 chr11:243099~243483:- LIHC cis rs12280210 0.557 rs11216225 ENSG00000254851.1 RP11-109L13.1 4.48 1e-05 0.00266 0.37 0.24 Lobe attachment (rater-scored or self-reported); chr11:117007298 chr11:117135528~117138582:+ LIHC cis rs79349575 0.783 rs62075818 ENSG00000248278.1 SUMO2P17 4.48 1e-05 0.00266 0.29 0.24 Type 2 diabetes; chr17:48904965 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs9912829 ENSG00000248278.1 SUMO2P17 4.48 1e-05 0.00266 0.29 0.24 Type 2 diabetes; chr17:48905387 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs62075820 ENSG00000248278.1 SUMO2P17 4.48 1e-05 0.00266 0.29 0.24 Type 2 diabetes; chr17:48905809 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs4294857 ENSG00000248278.1 SUMO2P17 4.48 1e-05 0.00266 0.29 0.24 Type 2 diabetes; chr17:48906029 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs61576918 ENSG00000248278.1 SUMO2P17 4.48 1e-05 0.00266 0.29 0.24 Type 2 diabetes; chr17:48908231 chr17:48874860~48908983:- LIHC cis rs79349575 0.729 rs62075824 ENSG00000248278.1 SUMO2P17 4.48 1e-05 0.00266 0.29 0.24 Type 2 diabetes; chr17:48909317 chr17:48874860~48908983:- LIHC cis rs7945705 0.935 rs1883098 ENSG00000254860.4 TMEM9B-AS1 4.48 1.01e-05 0.00267 0.23 0.24 Hemoglobin concentration; chr11:8869047 chr11:8964675~8977527:+ LIHC cis rs2243480 1 rs4149468 ENSG00000230295.1 RP11-458F8.2 -4.48 1.01e-05 0.00267 -0.24 -0.24 Diabetic kidney disease; chr7:66360703 chr7:66880708~66882981:+ LIHC cis rs748404 0.697 rs1814323 ENSG00000166763.7 STRCP1 -4.48 1.01e-05 0.00267 -0.29 -0.24 Lung cancer; chr15:43271039 chr15:43699488~43718184:- LIHC cis rs1075232 0.826 rs12437800 ENSG00000270055.1 CTD-3092A11.2 -4.48 1.01e-05 0.00267 -0.46 -0.24 Survival in colorectal cancer (non-distant metastatic); chr15:31379229 chr15:30487963~30490313:+ LIHC cis rs948562 0.947 rs75708979 ENSG00000280010.1 AP001350.4 4.48 1.01e-05 0.00267 0.43 0.24 Lymphoma; chr11:58662312 chr11:58627435~58628528:+ LIHC cis rs948562 0.947 rs78629620 ENSG00000280010.1 AP001350.4 4.48 1.01e-05 0.00267 0.43 0.24 Lymphoma; chr11:58662329 chr11:58627435~58628528:+ LIHC cis rs7044106 0.791 rs4837792 ENSG00000238181.2 AHCYP2 -4.48 1.01e-05 0.00267 -0.27 -0.24 Hip circumference adjusted for BMI; chr9:120721281 chr9:120720673~120721972:+ LIHC cis rs7044106 0.791 rs10985000 ENSG00000238181.2 AHCYP2 -4.48 1.01e-05 0.00267 -0.27 -0.24 Hip circumference adjusted for BMI; chr9:120721837 chr9:120720673~120721972:+ LIHC cis rs673078 0.615 rs73222058 ENSG00000275759.1 RP11-131L12.3 -4.48 1.01e-05 0.00267 -0.3 -0.24 Glucose homeostasis traits; chr12:118221066 chr12:118428281~118428870:+ LIHC cis rs11096990 0.634 rs11736790 ENSG00000249207.1 RP11-360F5.1 -4.48 1.01e-05 0.00267 -0.24 -0.24 Cognitive function; chr4:39254704 chr4:39112677~39126818:- LIHC cis rs2976388 0.692 rs2978983 ENSG00000253196.1 RP11-706C16.7 4.48 1.01e-05 0.00267 0.23 0.24 Urinary tract infection frequency; chr8:142684424 chr8:142763116~142766427:+ LIHC cis rs1865760 0.566 rs9348706 ENSG00000216436.2 HIST1H2APS1 -4.48 1.01e-05 0.00267 -0.28 -0.24 Height; chr6:26065253 chr6:25732497~25732827:+ LIHC cis rs2562456 0.617 rs34203148 ENSG00000268555.1 RP11-678G14.3 4.48 1.01e-05 0.00267 0.31 0.24 Pain; chr19:21590743 chr19:21570822~21587322:- LIHC cis rs7809950 1 rs6976607 ENSG00000238832.1 snoU109 4.48 1.01e-05 0.00268 0.29 0.24 Coronary artery disease; chr7:107582956 chr7:107603363~107603507:+ LIHC cis rs7412746 0.611 rs11204747 ENSG00000231073.1 RP11-316M1.3 -4.48 1.01e-05 0.00268 -0.23 -0.24 Melanoma; chr1:150954676 chr1:150973123~150975534:+ LIHC cis rs11671005 0.735 rs3826684 ENSG00000269473.1 CTD-2619J13.19 4.48 1.01e-05 0.00268 0.39 0.24 Mean platelet volume; chr19:58407338 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs3826683 ENSG00000269473.1 CTD-2619J13.19 4.48 1.01e-05 0.00268 0.39 0.24 Mean platelet volume; chr19:58407366 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs3826682 ENSG00000269473.1 CTD-2619J13.19 4.48 1.01e-05 0.00268 0.39 0.24 Mean platelet volume; chr19:58407381 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs3826681 ENSG00000269473.1 CTD-2619J13.19 4.48 1.01e-05 0.00268 0.39 0.24 Mean platelet volume; chr19:58407397 chr19:58440448~58445849:+ LIHC cis rs2836974 0.897 rs7280375 ENSG00000255568.3 BRWD1-AS2 -4.48 1.01e-05 0.00268 -0.27 -0.24 Cognitive function; chr21:39180482 chr21:39313935~39314962:+ LIHC cis rs9399135 0.743 rs7745098 ENSG00000232876.1 CTA-212D2.2 -4.48 1.01e-05 0.00268 -0.27 -0.24 Red blood cell count; chr6:135093866 chr6:135055033~135060550:+ LIHC cis rs1005277 0.602 rs1831315 ENSG00000276805.1 RP11-291L22.6 4.48 1.01e-05 0.00268 0.29 0.24 Extrinsic epigenetic age acceleration; chr10:38184425 chr10:38451030~38451785:+ LIHC cis rs3733589 0.59 rs73100621 ENSG00000250413.1 RP11-448G15.1 4.48 1.01e-05 0.00268 0.41 0.24 Renal overload gout; chr4:9984715 chr4:10006482~10009725:+ LIHC cis rs875971 0.66 rs7807944 ENSG00000273024.4 INTS4P2 4.48 1.01e-05 0.00268 0.26 0.24 Aortic root size; chr7:66622208 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs10950036 ENSG00000273142.1 RP11-458F8.4 4.48 1.01e-05 0.00268 0.23 0.24 Aortic root size; chr7:66353241 chr7:66902857~66906297:+ LIHC cis rs16958440 0.867 rs79420880 ENSG00000267724.1 RP11-49K24.8 4.48 1.01e-05 0.00268 0.37 0.24 Sitting height ratio; chr18:47137316 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs78720782 ENSG00000267724.1 RP11-49K24.8 4.48 1.01e-05 0.00268 0.37 0.24 Sitting height ratio; chr18:47137644 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs79231363 ENSG00000267724.1 RP11-49K24.8 4.48 1.01e-05 0.00268 0.37 0.24 Sitting height ratio; chr18:47138716 chr18:47105946~47108062:+ LIHC cis rs76297747 1 rs76297747 ENSG00000267724.1 RP11-49K24.8 4.48 1.01e-05 0.00268 0.37 0.24 Response to paliperidone in schizophrenia (Multivariate); chr18:47139286 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs78854354 ENSG00000267724.1 RP11-49K24.8 4.48 1.01e-05 0.00268 0.37 0.24 Sitting height ratio; chr18:47140553 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs79078752 ENSG00000267724.1 RP11-49K24.8 4.48 1.01e-05 0.00268 0.37 0.24 Sitting height ratio; chr18:47141091 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs61689863 ENSG00000267724.1 RP11-49K24.8 4.48 1.01e-05 0.00268 0.37 0.24 Sitting height ratio; chr18:47142786 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs80064497 ENSG00000267724.1 RP11-49K24.8 4.48 1.01e-05 0.00268 0.37 0.24 Sitting height ratio; chr18:47143282 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs78547658 ENSG00000267724.1 RP11-49K24.8 4.48 1.01e-05 0.00268 0.37 0.24 Sitting height ratio; chr18:47143481 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs12386092 ENSG00000267724.1 RP11-49K24.8 4.48 1.01e-05 0.00268 0.37 0.24 Sitting height ratio; chr18:47145687 chr18:47105946~47108062:+ LIHC cis rs12157904 1 rs3761443 ENSG00000233360.4 Z83844.1 4.48 1.02e-05 0.00269 0.49 0.24 Response to anti-depressant treatment in major depressive disorder; chr22:37607228 chr22:37641832~37658377:- LIHC cis rs12157904 1 rs6000840 ENSG00000233360.4 Z83844.1 4.48 1.02e-05 0.00269 0.49 0.24 Response to anti-depressant treatment in major depressive disorder; chr22:37608637 chr22:37641832~37658377:- LIHC cis rs10991814 0.557 rs76379507 ENSG00000273381.1 RP11-305L7.7 4.48 1.02e-05 0.00269 0.27 0.24 Neutrophil percentage of granulocytes; chr9:91232926 chr9:91206175~91210299:- LIHC cis rs10510102 0.872 rs11200292 ENSG00000226864.1 ATE1-AS1 4.48 1.02e-05 0.00269 0.4 0.24 Breast cancer; chr10:121967383 chr10:121928312~121951965:+ LIHC cis rs1729407 0.632 rs2071523 ENSG00000236267.1 AP006216.5 4.48 1.02e-05 0.00269 0.22 0.24 Apolipoprotein A-IV levels; chr11:116826628 chr11:116813204~116814003:- LIHC cis rs7914558 0.505 rs12260436 ENSG00000236937.2 PTGES3P4 4.48 1.02e-05 0.00269 0.29 0.24 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102981357 chr10:102845595~102845950:+ LIHC cis rs901683 1 rs17157919 ENSG00000230869.1 CTGLF10P 4.48 1.02e-05 0.00269 0.55 0.24 Mean corpuscular volume;Red blood cell traits; chr10:45548644 chr10:45678692~45700532:+ LIHC cis rs8024893 0.764 rs7178760 ENSG00000270055.1 CTD-3092A11.2 4.48 1.02e-05 0.00269 0.34 0.24 Red cell distribution width; chr15:31239170 chr15:30487963~30490313:+ LIHC cis rs1247318 0.853 rs1247325 ENSG00000243831.1 RP1-81D8.4 4.48 1.02e-05 0.00269 0.33 0.24 Aging; chr6:160907638 chr6:160666228~160676523:- LIHC cis rs79349575 0.783 rs832410 ENSG00000248278.1 SUMO2P17 4.48 1.02e-05 0.00269 0.29 0.24 Type 2 diabetes; chr17:48895503 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs318095 ENSG00000248278.1 SUMO2P17 4.48 1.02e-05 0.00269 0.29 0.24 Type 2 diabetes; chr17:48897372 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs318096 ENSG00000248278.1 SUMO2P17 4.48 1.02e-05 0.00269 0.29 0.24 Type 2 diabetes; chr17:48898008 chr17:48874860~48908983:- LIHC cis rs79349575 0.777 rs28517720 ENSG00000248278.1 SUMO2P17 4.48 1.02e-05 0.00269 0.29 0.24 Type 2 diabetes; chr17:48899394 chr17:48874860~48908983:- LIHC cis rs79349575 0.756 rs2643361 ENSG00000248278.1 SUMO2P17 4.48 1.02e-05 0.00269 0.29 0.24 Type 2 diabetes; chr17:48900100 chr17:48874860~48908983:- LIHC cis rs79349575 0.749 rs2546491 ENSG00000248278.1 SUMO2P17 4.48 1.02e-05 0.00269 0.29 0.24 Type 2 diabetes; chr17:48900554 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs962272 ENSG00000248278.1 SUMO2P17 4.48 1.02e-05 0.00269 0.29 0.24 Type 2 diabetes; chr17:48900921 chr17:48874860~48908983:- LIHC cis rs62355901 0.509 rs10461615 ENSG00000271828.1 CTD-2310F14.1 4.48 1.02e-05 0.00269 0.47 0.24 Breast cancer; chr5:56715913 chr5:56927874~56929573:+ LIHC cis rs734999 0.545 rs7368072 ENSG00000225931.3 RP3-395M20.7 4.48 1.02e-05 0.00269 0.25 0.24 Ulcerative colitis; chr1:2624686 chr1:2566410~2569888:+ LIHC cis rs75920871 0.688 rs55703909 ENSG00000254851.1 RP11-109L13.1 -4.48 1.02e-05 0.00269 -0.47 -0.24 Subjective well-being; chr11:117114150 chr11:117135528~117138582:+ LIHC cis rs6951245 0.554 rs11544331 ENSG00000229043.2 AC091729.9 -4.48 1.02e-05 0.00269 -0.43 -0.24 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1091775 chr7:1160374~1165267:+ LIHC cis rs950169 0.58 rs11635597 ENSG00000225151.9 GOLGA2P7 -4.48 1.02e-05 0.0027 -0.3 -0.24 Schizophrenia; chr15:84622468 chr15:84199311~84230136:- LIHC cis rs1577917 0.958 rs12208227 ENSG00000234155.1 RP11-30P6.6 4.48 1.02e-05 0.0027 0.31 0.24 Response to antipsychotic treatment; chr6:85961226 chr6:85387219~85390186:- LIHC cis rs4578769 0.765 rs35151054 ENSG00000266850.1 RP11-370A5.1 -4.48 1.02e-05 0.0027 -0.28 -0.24 Eosinophil percentage of white cells; chr18:22818375 chr18:22723491~22907721:- LIHC cis rs4578769 0.765 rs72882153 ENSG00000266850.1 RP11-370A5.1 -4.48 1.02e-05 0.0027 -0.28 -0.24 Eosinophil percentage of white cells; chr18:22823275 chr18:22723491~22907721:- LIHC cis rs957448 1 rs2381885 ENSG00000253704.1 RP11-267M23.4 4.48 1.02e-05 0.0027 0.29 0.24 Nonsyndromic cleft lip with cleft palate; chr8:94499974 chr8:94553722~94569745:+ LIHC cis rs875971 0.66 rs79009421 ENSG00000273024.4 INTS4P2 4.48 1.02e-05 0.00271 0.26 0.24 Aortic root size; chr7:66603522 chr7:65647864~65715661:+ LIHC cis rs875971 0.66 rs6460308 ENSG00000273024.4 INTS4P2 4.48 1.02e-05 0.00271 0.26 0.24 Aortic root size; chr7:66619753 chr7:65647864~65715661:+ LIHC cis rs8040855 0.69 rs8041189 ENSG00000259295.5 CSPG4P12 -4.48 1.03e-05 0.00271 -0.37 -0.24 Bulimia nervosa; chr15:85143096 chr15:85191438~85213905:+ LIHC cis rs1005277 0.579 rs1780130 ENSG00000276805.1 RP11-291L22.6 4.48 1.03e-05 0.00271 0.29 0.24 Extrinsic epigenetic age acceleration; chr10:38196450 chr10:38451030~38451785:+ LIHC cis rs17711722 0.727 rs2658585 ENSG00000224316.1 RP11-479O9.2 4.48 1.03e-05 0.00271 0.24 0.24 Calcium levels; chr7:65996954 chr7:65773620~65802067:+ LIHC cis rs2274273 0.624 rs67386901 ENSG00000258413.1 RP11-665C16.6 -4.48 1.03e-05 0.00271 -0.29 -0.24 Protein biomarker; chr14:55290646 chr14:55262767~55272075:- LIHC cis rs2274273 0.624 rs7140628 ENSG00000258413.1 RP11-665C16.6 -4.48 1.03e-05 0.00271 -0.29 -0.24 Protein biomarker; chr14:55293963 chr14:55262767~55272075:- LIHC cis rs2274273 0.624 rs7154796 ENSG00000258413.1 RP11-665C16.6 -4.48 1.03e-05 0.00271 -0.29 -0.24 Protein biomarker; chr14:55304740 chr14:55262767~55272075:- LIHC cis rs2274273 0.624 rs7159824 ENSG00000258413.1 RP11-665C16.6 -4.48 1.03e-05 0.00271 -0.29 -0.24 Protein biomarker; chr14:55305818 chr14:55262767~55272075:- LIHC cis rs2274273 0.624 rs10129505 ENSG00000258413.1 RP11-665C16.6 -4.48 1.03e-05 0.00271 -0.29 -0.24 Protein biomarker; chr14:55309657 chr14:55262767~55272075:- LIHC cis rs2274273 0.624 rs68138420 ENSG00000258413.1 RP11-665C16.6 -4.48 1.03e-05 0.00271 -0.29 -0.24 Protein biomarker; chr14:55311249 chr14:55262767~55272075:- LIHC cis rs2274273 0.624 rs4580079 ENSG00000258413.1 RP11-665C16.6 -4.48 1.03e-05 0.00271 -0.29 -0.24 Protein biomarker; chr14:55313648 chr14:55262767~55272075:- LIHC cis rs2274273 0.6 rs35112084 ENSG00000258413.1 RP11-665C16.6 -4.48 1.03e-05 0.00271 -0.29 -0.24 Protein biomarker; chr14:55314382 chr14:55262767~55272075:- LIHC cis rs2836974 0.897 rs12481860 ENSG00000255568.3 BRWD1-AS2 4.48 1.03e-05 0.00271 0.27 0.24 Cognitive function; chr21:39165910 chr21:39313935~39314962:+ LIHC cis rs2836974 0.863 rs6517519 ENSG00000255568.3 BRWD1-AS2 4.48 1.03e-05 0.00271 0.27 0.24 Cognitive function; chr21:39168319 chr21:39313935~39314962:+ LIHC cis rs7637701 0.713 rs9867857 ENSG00000243926.1 TIPARP-AS1 4.48 1.03e-05 0.00271 0.21 0.24 Breast cancer; chr3:156773371 chr3:156671862~156674378:- LIHC cis rs2929278 0.617 rs694461 ENSG00000275601.1 AC011330.13 4.48 1.03e-05 0.00271 0.29 0.24 Schizophrenia; chr15:43803865 chr15:43642389~43643023:- LIHC cis rs2998286 0.862 rs2998285 ENSG00000254635.4 WAC-AS1 4.48 1.03e-05 0.00271 0.28 0.24 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28504310 chr10:28522652~28532743:- LIHC cis rs2998286 0.862 rs4237390 ENSG00000254635.4 WAC-AS1 -4.48 1.03e-05 0.00271 -0.28 -0.24 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28504497 chr10:28522652~28532743:- LIHC cis rs9467711 0.591 rs6940007 ENSG00000216436.2 HIST1H2APS1 4.48 1.03e-05 0.00271 0.61 0.24 Autism spectrum disorder or schizophrenia; chr6:25931729 chr6:25732497~25732827:+ LIHC cis rs875971 0.522 rs4718285 ENSG00000224316.1 RP11-479O9.2 4.48 1.03e-05 0.00271 0.24 0.24 Aortic root size; chr7:65827018 chr7:65773620~65802067:+ LIHC cis rs17711722 0.64 rs13237956 ENSG00000224316.1 RP11-479O9.2 4.48 1.03e-05 0.00271 0.24 0.24 Calcium levels; chr7:65853042 chr7:65773620~65802067:+ LIHC cis rs875971 0.516 rs6945322 ENSG00000224316.1 RP11-479O9.2 4.48 1.03e-05 0.00271 0.24 0.24 Aortic root size; chr7:65871069 chr7:65773620~65802067:+ LIHC cis rs17711722 0.701 rs4467826 ENSG00000224316.1 RP11-479O9.2 4.48 1.03e-05 0.00271 0.24 0.24 Calcium levels; chr7:65903721 chr7:65773620~65802067:+ LIHC cis rs683257 0.636 rs17070386 ENSG00000234147.1 RP3-460G2.2 4.48 1.03e-05 0.00272 0.38 0.24 Facial emotion recognition (angry faces); chr6:140850424 chr6:140845958~140852924:- LIHC cis rs8040855 0.627 rs11637512 ENSG00000259295.5 CSPG4P12 4.48 1.03e-05 0.00272 0.37 0.24 Bulimia nervosa; chr15:85105528 chr15:85191438~85213905:+ LIHC cis rs8040855 0.627 rs17541051 ENSG00000259295.5 CSPG4P12 4.48 1.03e-05 0.00272 0.37 0.24 Bulimia nervosa; chr15:85106122 chr15:85191438~85213905:+ LIHC cis rs8040855 0.627 rs35668291 ENSG00000259295.5 CSPG4P12 4.48 1.03e-05 0.00272 0.37 0.24 Bulimia nervosa; chr15:85109582 chr15:85191438~85213905:+ LIHC cis rs7923609 1 rs10822163 ENSG00000232075.1 MRPL35P2 -4.48 1.03e-05 0.00272 -0.26 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63364338 chr10:63634317~63634827:- LIHC cis rs17711722 0.727 rs1880555 ENSG00000224316.1 RP11-479O9.2 4.48 1.03e-05 0.00272 0.24 0.24 Calcium levels; chr7:65967580 chr7:65773620~65802067:+ LIHC cis rs2337406 1 rs17113257 ENSG00000274576.2 IGHV2-70 -4.48 1.03e-05 0.00272 -0.26 -0.24 Alzheimer's disease (late onset); chr14:106679574 chr14:106770577~106771020:- LIHC cis rs2337406 1 rs1961901 ENSG00000274576.2 IGHV2-70 -4.48 1.03e-05 0.00272 -0.26 -0.24 Alzheimer's disease (late onset); chr14:106680856 chr14:106770577~106771020:- LIHC cis rs875971 0.66 rs10950044 ENSG00000273024.4 INTS4P2 4.48 1.03e-05 0.00272 0.26 0.24 Aortic root size; chr7:66577989 chr7:65647864~65715661:+ LIHC cis rs1400745 0.729 rs28472856 ENSG00000258738.1 RP11-73E17.2 4.48 1.03e-05 0.00272 0.29 0.24 Monocyte count; chr14:34862951 chr14:34874343~34876459:+ LIHC cis rs5742933 0.817 rs4667297 ENSG00000253559.1 OSGEPL1-AS1 4.48 1.03e-05 0.00272 0.31 0.24 Ferritin levels; chr2:189664270 chr2:189762704~189765556:+ LIHC cis rs2565722 0.665 rs2465854 ENSG00000243831.1 RP1-81D8.4 -4.48 1.03e-05 0.00273 -0.32 -0.24 Blood protein levels; chr6:160889878 chr6:160666228~160676523:- LIHC cis rs1577917 0.958 rs11756615 ENSG00000234155.1 RP11-30P6.6 4.48 1.03e-05 0.00273 0.31 0.24 Response to antipsychotic treatment; chr6:85970117 chr6:85387219~85390186:- LIHC cis rs875971 0.545 rs12670811 ENSG00000228409.4 CCT6P1 -4.48 1.03e-05 0.00273 -0.2 -0.24 Aortic root size; chr7:66358032 chr7:65751142~65763354:+ LIHC cis rs921968 0.565 rs608047 ENSG00000272555.1 RP11-459I19.1 4.48 1.03e-05 0.00273 0.25 0.24 Mean corpuscular hemoglobin concentration; chr2:218751187 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs692049 ENSG00000272555.1 RP11-459I19.1 -4.48 1.03e-05 0.00273 -0.25 -0.24 Mean corpuscular hemoglobin concentration; chr2:218758055 chr2:218818690~218819144:+ LIHC cis rs7607369 0.719 rs690882 ENSG00000272555.1 RP11-459I19.1 -4.48 1.03e-05 0.00273 -0.25 -0.24 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218775897 chr2:218818690~218819144:+ LIHC cis rs7923609 1 rs10822161 ENSG00000232075.1 MRPL35P2 -4.48 1.04e-05 0.00273 -0.26 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63358443 chr10:63634317~63634827:- LIHC cis rs13315871 1 rs9862969 ENSG00000272182.1 RP11-802O23.3 4.48 1.04e-05 0.00273 0.58 0.24 Cholesterol, total; chr3:58356190 chr3:58428255~58428815:+ LIHC cis rs13315871 1 rs11715445 ENSG00000272182.1 RP11-802O23.3 4.48 1.04e-05 0.00273 0.58 0.24 Cholesterol, total; chr3:58358161 chr3:58428255~58428815:+ LIHC cis rs3812762 0.871 rs11603335 ENSG00000254860.4 TMEM9B-AS1 -4.48 1.04e-05 0.00274 -0.25 -0.24 Hypospadias; chr11:8788297 chr11:8964675~8977527:+ LIHC cis rs901683 0.85 rs112997714 ENSG00000230869.1 CTGLF10P -4.48 1.04e-05 0.00274 -0.5 -0.24 Mean corpuscular volume;Red blood cell traits; chr10:45601768 chr10:45678692~45700532:+ LIHC cis rs2439831 0.85 rs16950562 ENSG00000275601.1 AC011330.13 -4.48 1.04e-05 0.00274 -0.35 -0.24 Lung cancer in ever smokers; chr15:43744166 chr15:43642389~43643023:- LIHC cis rs734999 0.545 rs4648565 ENSG00000225931.3 RP3-395M20.7 -4.48 1.04e-05 0.00274 -0.25 -0.24 Ulcerative colitis; chr1:2638584 chr1:2566410~2569888:+ LIHC cis rs4561483 0.801 rs33631 ENSG00000261560.1 RP11-166B2.3 -4.48 1.04e-05 0.00274 -0.26 -0.24 Testicular germ cell tumor; chr16:11901530 chr16:11881075~11882569:- LIHC cis rs2877649 1 rs2332352 ENSG00000258744.1 RP11-80A15.1 4.48 1.04e-05 0.00274 0.45 0.24 Smooth-surface caries; chr14:24484774 chr14:24501594~24508688:+ LIHC cis rs2877649 1 rs2877649 ENSG00000258744.1 RP11-80A15.1 4.48 1.04e-05 0.00274 0.45 0.24 Smooth-surface caries; chr14:24484796 chr14:24501594~24508688:+ LIHC cis rs9992667 0.955 rs11096953 ENSG00000231160.8 KLF3-AS1 -4.48 1.04e-05 0.00274 -0.32 -0.24 Eosinophil percentage of granulocytes; chr4:38642171 chr4:38612701~38664883:- LIHC cis rs9992667 0.955 rs1491199 ENSG00000231160.8 KLF3-AS1 4.48 1.04e-05 0.00274 0.32 0.24 Eosinophil percentage of granulocytes; chr4:38641393 chr4:38612701~38664883:- LIHC cis rs9992667 0.955 rs9992076 ENSG00000231160.8 KLF3-AS1 4.48 1.04e-05 0.00274 0.32 0.24 Eosinophil percentage of granulocytes; chr4:38643046 chr4:38612701~38664883:- LIHC cis rs9992667 0.955 rs28664852 ENSG00000231160.8 KLF3-AS1 4.48 1.04e-05 0.00274 0.32 0.24 Eosinophil percentage of granulocytes; chr4:38644479 chr4:38612701~38664883:- LIHC cis rs17214007 0.877 rs4541094 ENSG00000263335.1 AF001548.5 -4.48 1.04e-05 0.00274 -0.3 -0.24 Cognitive function; chr16:15776878 chr16:15726674~15732993:+ LIHC cis rs1558001 0.84 rs10435298 ENSG00000230196.1 DDX43P3 -4.48 1.04e-05 0.00274 -0.25 -0.24 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81800792 chr7:81610884~81611326:- LIHC cis rs1558001 0.84 rs17155517 ENSG00000230196.1 DDX43P3 -4.48 1.04e-05 0.00274 -0.25 -0.24 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81801380 chr7:81610884~81611326:- LIHC cis rs1558001 0.87 rs9332389 ENSG00000230196.1 DDX43P3 -4.48 1.04e-05 0.00274 -0.25 -0.24 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81802463 chr7:81610884~81611326:- LIHC cis rs1558001 0.87 rs35555877 ENSG00000230196.1 DDX43P3 -4.48 1.04e-05 0.00274 -0.25 -0.24 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81809611 chr7:81610884~81611326:- LIHC cis rs6977955 1 rs740122 ENSG00000234336.5 JAZF1-AS1 -4.47 1.04e-05 0.00275 -0.34 -0.24 Allergic disease (asthma, hay fever or eczema); chr7:28126823 chr7:28180322~28243917:+ LIHC cis rs10129255 0.646 rs55995061 ENSG00000211970.3 IGHV4-61 -4.47 1.04e-05 0.00275 -0.18 -0.24 Kawasaki disease; chr14:106799309 chr14:106639119~106639657:- LIHC cis rs4650994 0.623 rs12121188 ENSG00000213057.5 C1orf220 -4.47 1.04e-05 0.00275 -0.2 -0.24 HDL cholesterol;HDL cholesterol levels; chr1:178653364 chr1:178542752~178548889:+ LIHC cis rs2274273 0.624 rs7157308 ENSG00000258413.1 RP11-665C16.6 -4.47 1.04e-05 0.00275 -0.29 -0.24 Protein biomarker; chr14:55315325 chr14:55262767~55272075:- LIHC cis rs62355901 0.83 rs12653202 ENSG00000271828.1 CTD-2310F14.1 4.47 1.05e-05 0.00275 0.36 0.24 Breast cancer; chr5:56721091 chr5:56927874~56929573:+ LIHC cis rs227275 0.554 rs149576 ENSG00000246560.2 RP11-10L12.4 4.47 1.05e-05 0.00275 0.27 0.24 Allergic disease (asthma, hay fever or eczema); chr4:102811411 chr4:102828055~102844075:+ LIHC cis rs72675573 0.925 rs1304824 ENSG00000235612.1 RP1-158P9.1 -4.47 1.05e-05 0.00276 -0.31 -0.24 Monocyte count; chr1:56158342 chr1:56145721~56155224:+ LIHC cis rs2494250 0.542 rs4269772 ENSG00000231434.1 RP11-144L1.8 -4.47 1.05e-05 0.00276 -0.29 -0.24 Select biomarker traits; chr1:159320871 chr1:158523672~158525838:+ LIHC cis rs58785573 0.624 rs337605 ENSG00000231160.8 KLF3-AS1 -4.47 1.05e-05 0.00276 -0.22 -0.24 Lymphocyte percentage of white cells; chr4:38646132 chr4:38612701~38664883:- LIHC cis rs67311347 1 rs73076035 ENSG00000223797.4 ENTPD3-AS1 4.47 1.05e-05 0.00276 0.19 0.24 Renal cell carcinoma; chr3:40398390 chr3:40313802~40453329:- LIHC cis rs79349575 0.783 rs4793991 ENSG00000248278.1 SUMO2P17 4.47 1.05e-05 0.00276 0.29 0.24 Type 2 diabetes; chr17:48924439 chr17:48874860~48908983:- LIHC cis rs79349575 0.715 rs62075844 ENSG00000248278.1 SUMO2P17 4.47 1.05e-05 0.00276 0.29 0.24 Type 2 diabetes; chr17:48925027 chr17:48874860~48908983:- LIHC cis rs79349575 0.749 rs957557 ENSG00000248278.1 SUMO2P17 4.47 1.05e-05 0.00276 0.29 0.24 Type 2 diabetes; chr17:48925859 chr17:48874860~48908983:- LIHC cis rs79349575 0.749 rs12601672 ENSG00000248278.1 SUMO2P17 4.47 1.05e-05 0.00276 0.29 0.24 Type 2 diabetes; chr17:48929131 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs17635252 ENSG00000248278.1 SUMO2P17 4.47 1.05e-05 0.00276 0.29 0.24 Type 2 diabetes; chr17:48929588 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs56046215 ENSG00000248278.1 SUMO2P17 4.47 1.05e-05 0.00276 0.29 0.24 Type 2 diabetes; chr17:48931395 chr17:48874860~48908983:- LIHC cis rs1558001 0.87 rs62465439 ENSG00000230196.1 DDX43P3 -4.47 1.05e-05 0.00276 -0.25 -0.24 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81806289 chr7:81610884~81611326:- LIHC cis rs748404 0.631 rs11070399 ENSG00000205771.5 CATSPER2P1 -4.47 1.05e-05 0.00276 -0.28 -0.24 Lung cancer; chr15:43354149 chr15:43726918~43747094:- LIHC cis rs1558001 0.87 rs2194752 ENSG00000230196.1 DDX43P3 -4.47 1.05e-05 0.00276 -0.25 -0.24 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81803802 chr7:81610884~81611326:- LIHC cis rs9992667 0.955 rs66709517 ENSG00000231160.8 KLF3-AS1 4.47 1.05e-05 0.00276 0.32 0.24 Eosinophil percentage of granulocytes; chr4:38647772 chr4:38612701~38664883:- LIHC cis rs9992667 0.955 rs6858772 ENSG00000231160.8 KLF3-AS1 4.47 1.05e-05 0.00276 0.32 0.24 Eosinophil percentage of granulocytes; chr4:38649382 chr4:38612701~38664883:- LIHC cis rs9527 1 rs9527 ENSG00000236937.2 PTGES3P4 4.47 1.05e-05 0.00276 0.36 0.24 Arsenic metabolism; chr10:102863821 chr10:102845595~102845950:+ LIHC cis rs9843304 0.624 rs13061914 ENSG00000244503.1 RP11-278L15.6 4.47 1.05e-05 0.00276 0.24 0.24 Gallstone disease; chr3:149484345 chr3:149494660~149495995:+ LIHC cis rs9843304 0.529 rs61382471 ENSG00000244503.1 RP11-278L15.6 4.47 1.05e-05 0.00276 0.24 0.24 Gallstone disease; chr3:149484373 chr3:149494660~149495995:+ LIHC cis rs2274273 0.84 rs10150760 ENSG00000258413.1 RP11-665C16.6 4.47 1.05e-05 0.00276 0.28 0.24 Protein biomarker; chr14:55354830 chr14:55262767~55272075:- LIHC cis rs3733589 1 rs13118801 ENSG00000250413.1 RP11-448G15.1 4.47 1.05e-05 0.00277 0.42 0.24 Renal overload gout; chr4:9996192 chr4:10006482~10009725:+ LIHC cis rs2842992 0.789 rs10945635 ENSG00000237927.1 RP3-393E18.2 -4.47 1.05e-05 0.00277 -0.29 -0.24 Age-related macular degeneration (geographic atrophy); chr6:159793455 chr6:159586955~159589169:- LIHC cis rs11098499 0.954 rs1546505 ENSG00000245958.5 RP11-33B1.1 -4.47 1.05e-05 0.00277 -0.25 -0.24 Corneal astigmatism; chr4:119320069 chr4:119454791~119552025:+ LIHC cis rs9304742 0.962 rs1044467 ENSG00000213801.4 ZNF816-ZNF321P 4.47 1.05e-05 0.00277 0.23 0.24 Psoriasis; chr19:52949516 chr19:52927135~52942601:- LIHC cis rs1005277 0.579 rs1780121 ENSG00000275858.1 RP11-291L22.8 4.47 1.05e-05 0.00277 0.26 0.24 Extrinsic epigenetic age acceleration; chr10:38240509 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1780122 ENSG00000275858.1 RP11-291L22.8 4.47 1.05e-05 0.00277 0.26 0.24 Extrinsic epigenetic age acceleration; chr10:38240581 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1780145 ENSG00000275858.1 RP11-291L22.8 4.47 1.05e-05 0.00277 0.26 0.24 Extrinsic epigenetic age acceleration; chr10:38248142 chr10:38450738~38451069:- LIHC cis rs79349575 0.749 rs1057902 ENSG00000248278.1 SUMO2P17 4.47 1.05e-05 0.00277 0.29 0.24 Type 2 diabetes; chr17:48928226 chr17:48874860~48908983:- LIHC cis rs7923609 0.902 rs10822158 ENSG00000232075.1 MRPL35P2 -4.47 1.06e-05 0.00277 -0.26 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63334623 chr10:63634317~63634827:- LIHC cis rs7923609 0.846 rs10740115 ENSG00000232075.1 MRPL35P2 -4.47 1.06e-05 0.00277 -0.26 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63335230 chr10:63634317~63634827:- LIHC cis rs7923609 0.846 rs10740116 ENSG00000232075.1 MRPL35P2 -4.47 1.06e-05 0.00277 -0.26 -0.24 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63335232 chr10:63634317~63634827:- LIHC cis rs9318086 0.935 rs9553083 ENSG00000205861.10 C1QTNF9B-AS1 4.47 1.06e-05 0.00277 0.26 0.24 Myopia (pathological); chr13:23867386 chr13:23888889~23897263:+ LIHC cis rs1400745 0.756 rs799683 ENSG00000258738.1 RP11-73E17.2 4.47 1.06e-05 0.00278 0.29 0.24 Monocyte count; chr14:34880030 chr14:34874343~34876459:+ LIHC cis rs11971779 0.68 rs7805824 ENSG00000273391.1 RP11-634H22.1 -4.47 1.06e-05 0.00278 -0.21 -0.24 Diisocyanate-induced asthma; chr7:139426423 chr7:139359032~139359566:- LIHC cis rs7587476 0.643 rs6714373 ENSG00000229267.2 AC072062.1 -4.47 1.06e-05 0.00278 -0.3 -0.24 Neuroblastoma; chr2:214854290 chr2:214810229~214963274:+ LIHC cis rs875971 0.522 rs4718286 ENSG00000224316.1 RP11-479O9.2 4.47 1.06e-05 0.00278 0.24 0.24 Aortic root size; chr7:65827777 chr7:65773620~65802067:+ LIHC cis rs17711722 0.585 rs6942660 ENSG00000224316.1 RP11-479O9.2 4.47 1.06e-05 0.00278 0.24 0.24 Calcium levels; chr7:65837419 chr7:65773620~65802067:+ LIHC cis rs17711722 0.701 rs55773927 ENSG00000224316.1 RP11-479O9.2 4.47 1.06e-05 0.00278 0.24 0.24 Calcium levels; chr7:65872915 chr7:65773620~65802067:+ LIHC cis rs17711722 0.727 rs35850374 ENSG00000224316.1 RP11-479O9.2 4.47 1.06e-05 0.00278 0.24 0.24 Calcium levels; chr7:65892789 chr7:65773620~65802067:+ LIHC cis rs7224610 0.966 rs3794748 ENSG00000263096.1 RP11-515O17.2 4.47 1.06e-05 0.00278 0.34 0.24 Urate levels; chr17:55287811 chr17:55271504~55273653:- LIHC cis rs10871290 0.881 rs3863439 ENSG00000261079.1 RP11-252A24.3 -4.47 1.06e-05 0.00278 -0.27 -0.24 Breast cancer; chr16:74436746 chr16:74367462~74369826:+ LIHC cis rs875971 0.66 rs2013222 ENSG00000273024.4 INTS4P2 4.47 1.06e-05 0.00278 0.26 0.24 Aortic root size; chr7:66570949 chr7:65647864~65715661:+ LIHC cis rs79349575 0.783 rs9747646 ENSG00000248278.1 SUMO2P17 4.47 1.06e-05 0.00278 0.29 0.24 Type 2 diabetes; chr17:48939520 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs62075852 ENSG00000248278.1 SUMO2P17 4.47 1.06e-05 0.00278 0.29 0.24 Type 2 diabetes; chr17:48939814 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs12601858 ENSG00000248278.1 SUMO2P17 4.47 1.06e-05 0.00278 0.29 0.24 Type 2 diabetes; chr17:48940115 chr17:48874860~48908983:- LIHC cis rs79349575 0.749 rs8182364 ENSG00000248278.1 SUMO2P17 4.47 1.06e-05 0.00278 0.29 0.24 Type 2 diabetes; chr17:48940663 chr17:48874860~48908983:- LIHC cis rs79349575 0.681 rs56080003 ENSG00000248278.1 SUMO2P17 4.47 1.06e-05 0.00278 0.29 0.24 Type 2 diabetes; chr17:48941687 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs4793995 ENSG00000248278.1 SUMO2P17 4.47 1.06e-05 0.00278 0.29 0.24 Type 2 diabetes; chr17:48942037 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs4793996 ENSG00000248278.1 SUMO2P17 4.47 1.06e-05 0.00278 0.29 0.24 Type 2 diabetes; chr17:48942235 chr17:48874860~48908983:- LIHC cis rs79349575 0.715 rs4793997 ENSG00000248278.1 SUMO2P17 4.47 1.06e-05 0.00278 0.29 0.24 Type 2 diabetes; chr17:48942310 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs4793998 ENSG00000248278.1 SUMO2P17 4.47 1.06e-05 0.00278 0.29 0.24 Type 2 diabetes; chr17:48942537 chr17:48874860~48908983:- LIHC cis rs79349575 0.749 rs2270574 ENSG00000248278.1 SUMO2P17 4.47 1.06e-05 0.00278 0.29 0.24 Type 2 diabetes; chr17:48944908 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs4794000 ENSG00000248278.1 SUMO2P17 4.47 1.06e-05 0.00278 0.29 0.24 Type 2 diabetes; chr17:48945393 chr17:48874860~48908983:- LIHC cis rs1318937 1 rs3821639 ENSG00000224660.1 SH3BP5-AS1 4.47 1.06e-05 0.00278 0.23 0.24 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15264159 chr3:15254184~15264493:+ LIHC cis rs2348418 0.639 rs10459087 ENSG00000247934.4 RP11-967K21.1 4.47 1.06e-05 0.00278 0.22 0.24 Lung function (FEV1);Lung function (FVC); chr12:28115904 chr12:28163298~28190738:- LIHC cis rs1352413 0.881 rs2299269 ENSG00000275834.1 RP11-440E5.1 -4.47 1.06e-05 0.00278 -0.31 -0.24 Knee osteoarthritis; chr7:95990065 chr7:96306810~96306874:+ LIHC cis rs17711722 0.653 rs2460421 ENSG00000237310.1 GS1-124K5.4 -4.47 1.06e-05 0.00278 -0.22 -0.24 Calcium levels; chr7:66026136 chr7:66493706~66495474:+ LIHC cis rs67311347 1 rs73076046 ENSG00000223797.4 ENTPD3-AS1 4.47 1.06e-05 0.00278 0.19 0.24 Renal cell carcinoma; chr3:40406233 chr3:40313802~40453329:- LIHC cis rs3758785 0.737 rs12270338 ENSG00000255893.1 RP11-685N10.1 4.47 1.06e-05 0.00278 0.27 0.24 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94414298 chr11:94472908~94473570:- LIHC cis rs2439831 0.85 rs12441861 ENSG00000275601.1 AC011330.13 -4.47 1.06e-05 0.00278 -0.35 -0.24 Lung cancer in ever smokers; chr15:43768685 chr15:43642389~43643023:- LIHC cis rs2072510 0.593 rs2660892 ENSG00000257715.1 RP11-256L6.2 -4.47 1.06e-05 0.00278 -0.37 -0.23 Metabolite levels (small molecules and protein measures); chr12:96027200 chr12:96025323~96027971:+ LIHC cis rs11779988 0.545 rs431961 ENSG00000253671.1 RP11-806O11.1 -4.47 1.06e-05 0.00279 -0.31 -0.23 Breast cancer; chr8:17928695 chr8:17808941~17820868:+ LIHC cis rs10129255 0.833 rs7156689 ENSG00000211970.3 IGHV4-61 -4.47 1.06e-05 0.00279 -0.18 -0.23 Kawasaki disease; chr14:106816039 chr14:106639119~106639657:- LIHC cis rs651907 0.535 rs13084113 ENSG00000244119.1 PDCL3P4 4.47 1.06e-05 0.00279 0.24 0.23 Colorectal cancer; chr3:101815195 chr3:101712472~101713191:+ LIHC cis rs1400745 0.756 rs799682 ENSG00000258738.1 RP11-73E17.2 4.47 1.06e-05 0.00279 0.29 0.23 Monocyte count; chr14:34880778 chr14:34874343~34876459:+ LIHC cis rs11971779 0.941 rs74299967 ENSG00000273391.1 RP11-634H22.1 4.47 1.06e-05 0.00279 0.23 0.23 Diisocyanate-induced asthma; chr7:139359023 chr7:139359032~139359566:- LIHC cis rs11971779 0.646 rs58682779 ENSG00000273391.1 RP11-634H22.1 4.47 1.06e-05 0.00279 0.23 0.23 Diisocyanate-induced asthma; chr7:139399966 chr7:139359032~139359566:- LIHC cis rs755249 1 rs4660303 ENSG00000182109.6 RP11-69E11.4 4.47 1.06e-05 0.00279 0.34 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39594801 chr1:39522280~39546187:- LIHC cis rs2439831 0.867 rs2614811 ENSG00000166763.7 STRCP1 4.47 1.06e-05 0.00279 0.37 0.23 Lung cancer in ever smokers; chr15:43621289 chr15:43699488~43718184:- LIHC cis rs9318086 0.776 rs1326130 ENSG00000205861.10 C1QTNF9B-AS1 -4.47 1.06e-05 0.00279 -0.26 -0.23 Myopia (pathological); chr13:23873525 chr13:23888889~23897263:+ LIHC cis rs960902 0.592 rs7588494 ENSG00000213553.4 RPLP0P6 -4.47 1.06e-05 0.00279 -0.19 -0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37509738 chr2:38481851~38482804:+ LIHC cis rs875971 0.505 rs1167386 ENSG00000224316.1 RP11-479O9.2 -4.47 1.06e-05 0.00279 -0.24 -0.23 Aortic root size; chr7:66048109 chr7:65773620~65802067:+ LIHC cis rs875971 0.505 rs1167385 ENSG00000224316.1 RP11-479O9.2 -4.47 1.06e-05 0.00279 -0.24 -0.23 Aortic root size; chr7:66048321 chr7:65773620~65802067:+ LIHC cis rs9487094 0.961 rs12193493 ENSG00000260273.1 RP11-425D10.10 4.47 1.06e-05 0.00279 0.28 0.23 Height; chr6:109371573 chr6:109382795~109383666:+ LIHC cis rs748404 0.631 rs2412781 ENSG00000166763.7 STRCP1 -4.47 1.07e-05 0.0028 -0.29 -0.23 Lung cancer; chr15:43375702 chr15:43699488~43718184:- LIHC cis rs5758659 0.633 rs762995 ENSG00000227370.1 RP4-669P10.19 -4.47 1.07e-05 0.0028 -0.26 -0.23 Cognitive function; chr22:42276118 chr22:42132543~42132998:+ LIHC cis rs11671005 0.735 rs11671591 ENSG00000269473.1 CTD-2619J13.19 -4.47 1.07e-05 0.0028 -0.39 -0.23 Mean platelet volume; chr19:58406970 chr19:58440448~58445849:+ LIHC cis rs160451 1 rs160424 ENSG00000251136.7 RP11-37B2.1 4.47 1.07e-05 0.0028 0.21 0.23 Leprosy; chr8:89658452 chr8:89609409~89757727:- LIHC cis rs709400 0.859 rs942863 ENSG00000258534.1 CTD-2134A5.4 4.47 1.07e-05 0.0028 0.36 0.23 Body mass index; chr14:103554931 chr14:103854366~103880111:- LIHC cis rs2790457 0.917 rs1265831 ENSG00000254635.4 WAC-AS1 -4.47 1.07e-05 0.0028 -0.22 -0.23 Multiple myeloma; chr10:28623921 chr10:28522652~28532743:- LIHC cis rs6085948 0.861 rs2224055 ENSG00000228888.1 LINC01428 -4.47 1.07e-05 0.0028 -0.39 -0.23 Interleukin-10 levels; chr20:7253521 chr20:7146467~7254202:- LIHC cis rs748404 0.697 rs473554 ENSG00000166763.7 STRCP1 4.47 1.07e-05 0.0028 0.3 0.23 Lung cancer; chr15:43276009 chr15:43699488~43718184:- LIHC cis rs748404 0.697 rs530683 ENSG00000166763.7 STRCP1 -4.47 1.07e-05 0.0028 -0.3 -0.23 Lung cancer; chr15:43276801 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs28524541 ENSG00000275601.1 AC011330.13 -4.47 1.07e-05 0.0028 -0.34 -0.23 Lung cancer in ever smokers; chr15:43832633 chr15:43642389~43643023:- LIHC cis rs1062177 1 rs2016409 ENSG00000253921.1 CTB-113P19.3 4.47 1.07e-05 0.00281 0.27 0.23 Preschool internalizing problems; chr5:151746763 chr5:151753992~151767247:+ LIHC cis rs9318086 0.904 rs9580769 ENSG00000205861.10 C1QTNF9B-AS1 4.47 1.07e-05 0.00281 0.26 0.23 Myopia (pathological); chr13:23865585 chr13:23888889~23897263:+ LIHC cis rs10080237 0.564 rs2490232 ENSG00000272129.1 RP11-250B2.6 -4.47 1.07e-05 0.00281 -0.23 -0.23 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr6:80105085 chr6:80355424~80356859:+ LIHC cis rs9525927 0.521 rs4942298 ENSG00000230731.2 RP11-478K15.6 4.47 1.07e-05 0.00281 0.27 0.23 Dupuytren's disease; chr13:44224486 chr13:44234118~44243192:- LIHC cis rs202072 1 rs202070 ENSG00000215022.6 RP1-257A7.4 -4.47 1.07e-05 0.00281 -0.25 -0.23 HIV-1 viral setpoint; chr6:13267706 chr6:13264861~13295586:- LIHC cis rs2980436 1 rs2980436 ENSG00000253426.4 RP11-10A14.4 -4.47 1.07e-05 0.00281 -0.34 -0.23 Schizophrenia; chr8:8234503 chr8:9151742~9168136:+ LIHC cis rs2243480 1 rs73142162 ENSG00000230295.1 RP11-458F8.2 -4.47 1.07e-05 0.00281 -0.25 -0.23 Diabetic kidney disease; chr7:65909309 chr7:66880708~66882981:+ LIHC cis rs755249 0.567 rs4660603 ENSG00000182109.6 RP11-69E11.4 -4.47 1.07e-05 0.00281 -0.31 -0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39270662 chr1:39522280~39546187:- LIHC cis rs2348418 0.733 rs1904386 ENSG00000247934.4 RP11-967K21.1 -4.47 1.07e-05 0.00281 -0.21 -0.23 Lung function (FEV1);Lung function (FVC); chr12:28202321 chr12:28163298~28190738:- LIHC cis rs7809950 0.911 rs7778250 ENSG00000238832.1 snoU109 4.47 1.07e-05 0.00281 0.29 0.23 Coronary artery disease; chr7:107584120 chr7:107603363~107603507:+ LIHC cis rs734999 0.566 rs12748729 ENSG00000225931.3 RP3-395M20.7 -4.47 1.07e-05 0.00281 -0.25 -0.23 Ulcerative colitis; chr1:2627301 chr1:2566410~2569888:+ LIHC cis rs734999 0.545 rs12730932 ENSG00000225931.3 RP3-395M20.7 -4.47 1.07e-05 0.00281 -0.25 -0.23 Ulcerative colitis; chr1:2628150 chr1:2566410~2569888:+ LIHC cis rs2439831 0.85 rs28590651 ENSG00000275601.1 AC011330.13 -4.47 1.07e-05 0.00281 -0.35 -0.23 Lung cancer in ever smokers; chr15:43820818 chr15:43642389~43643023:- LIHC cis rs9318086 0.935 rs9652080 ENSG00000205861.10 C1QTNF9B-AS1 4.47 1.07e-05 0.00281 0.26 0.23 Myopia (pathological); chr13:23861287 chr13:23888889~23897263:+ LIHC cis rs9318086 0.935 rs9652081 ENSG00000205861.10 C1QTNF9B-AS1 4.47 1.07e-05 0.00281 0.26 0.23 Myopia (pathological); chr13:23861371 chr13:23888889~23897263:+ LIHC cis rs11098499 0.863 rs10018280 ENSG00000245958.5 RP11-33B1.1 -4.47 1.07e-05 0.00281 -0.25 -0.23 Corneal astigmatism; chr4:119556984 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs6534141 ENSG00000245958.5 RP11-33B1.1 -4.47 1.07e-05 0.00281 -0.25 -0.23 Corneal astigmatism; chr4:119564068 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs2127823 ENSG00000245958.5 RP11-33B1.1 -4.47 1.07e-05 0.00281 -0.25 -0.23 Corneal astigmatism; chr4:119564515 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs3775858 ENSG00000245958.5 RP11-33B1.1 -4.47 1.07e-05 0.00281 -0.25 -0.23 Corneal astigmatism; chr4:119564873 chr4:119454791~119552025:+ LIHC cis rs17711722 0.503 rs453835 ENSG00000273024.4 INTS4P2 4.47 1.07e-05 0.00282 0.25 0.23 Calcium levels; chr7:66046172 chr7:65647864~65715661:+ LIHC cis rs11098499 0.863 rs3736115 ENSG00000260091.1 RP11-33B1.4 4.47 1.07e-05 0.00282 0.17 0.23 Corneal astigmatism; chr4:119567548 chr4:119409333~119410233:+ LIHC cis rs7923609 1 rs7070296 ENSG00000232075.1 MRPL35P2 -4.47 1.07e-05 0.00282 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63310678 chr10:63634317~63634827:- LIHC cis rs4578769 0.729 rs72882140 ENSG00000266850.1 RP11-370A5.1 -4.47 1.08e-05 0.00282 -0.28 -0.23 Eosinophil percentage of white cells; chr18:22805952 chr18:22723491~22907721:- LIHC cis rs72627509 0.638 rs1608165 ENSG00000269949.1 RP11-738E22.3 4.47 1.08e-05 0.00282 0.31 0.23 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57028551 chr4:56960927~56961373:- LIHC cis rs2320952 0.874 rs11078853 ENSG00000263400.5 TMEM220-AS1 -4.47 1.08e-05 0.00282 -0.25 -0.23 Gut microbiome composition (winter); chr17:10588844 chr17:10729777~10815164:+ LIHC cis rs673078 0.66 rs7136216 ENSG00000275759.1 RP11-131L12.3 -4.47 1.08e-05 0.00282 -0.29 -0.23 Glucose homeostasis traits; chr12:118170475 chr12:118428281~118428870:+ LIHC cis rs10078 0.898 rs2241598 ENSG00000221990.4 EXOC3-AS1 -4.47 1.08e-05 0.00282 -0.23 -0.23 Fat distribution (HIV); chr5:438449 chr5:441498~443160:- LIHC cis rs9595908 0.965 rs8000071 ENSG00000212293.1 SNORA16 4.47 1.08e-05 0.00282 0.27 0.23 Body mass index; chr13:32551236 chr13:32420390~32420516:- LIHC cis rs9595908 0.965 rs7984903 ENSG00000212293.1 SNORA16 4.47 1.08e-05 0.00282 0.27 0.23 Body mass index; chr13:32552002 chr13:32420390~32420516:- LIHC cis rs9595908 0.965 rs7318297 ENSG00000212293.1 SNORA16 4.47 1.08e-05 0.00282 0.27 0.23 Body mass index; chr13:32563835 chr13:32420390~32420516:- LIHC cis rs9595908 0.9 rs7994229 ENSG00000212293.1 SNORA16 4.47 1.08e-05 0.00283 0.27 0.23 Body mass index; chr13:32586568 chr13:32420390~32420516:- LIHC cis rs7714584 0.793 rs35707106 ENSG00000197083.10 ZNF300P1 4.47 1.08e-05 0.00283 0.36 0.23 Crohn's disease; chr5:150845815 chr5:150930645~150946289:- LIHC cis rs7169304 0.531 rs59356430 ENSG00000259531.2 RP11-295H24.3 4.47 1.08e-05 0.00283 0.38 0.23 Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma; chr15:49324835 chr15:49365124~49366685:- LIHC cis rs7712401 0.765 rs10079941 ENSG00000263432.2 RN7SL689P 4.47 1.08e-05 0.00283 0.31 0.23 Mean platelet volume; chr5:123045668 chr5:123022487~123022783:- LIHC cis rs2072510 0.722 rs2247330 ENSG00000257878.1 RP11-256L6.3 4.47 1.08e-05 0.00283 0.2 0.23 Metabolite levels (small molecules and protein measures); chr12:96030344 chr12:95996521~96011489:+ LIHC cis rs7429990 0.864 rs12492915 ENSG00000229759.1 MRPS18AP1 -4.47 1.08e-05 0.00283 -0.24 -0.23 Educational attainment (years of education); chr3:47636545 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs12636863 ENSG00000229759.1 MRPS18AP1 -4.47 1.08e-05 0.00283 -0.24 -0.23 Educational attainment (years of education); chr3:47638629 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs7613934 ENSG00000229759.1 MRPS18AP1 -4.47 1.08e-05 0.00283 -0.24 -0.23 Educational attainment (years of education); chr3:47640681 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs7621236 ENSG00000229759.1 MRPS18AP1 -4.47 1.08e-05 0.00283 -0.24 -0.23 Educational attainment (years of education); chr3:47646677 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs7624474 ENSG00000229759.1 MRPS18AP1 -4.47 1.08e-05 0.00283 -0.24 -0.23 Educational attainment (years of education); chr3:47647786 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs4858846 ENSG00000229759.1 MRPS18AP1 -4.47 1.08e-05 0.00283 -0.24 -0.23 Educational attainment (years of education); chr3:47654591 chr3:48256350~48256938:- LIHC cis rs7429990 0.803 rs13081356 ENSG00000229759.1 MRPS18AP1 -4.47 1.08e-05 0.00283 -0.24 -0.23 Educational attainment (years of education); chr3:47660067 chr3:48256350~48256938:- LIHC cis rs7429990 0.803 rs11130145 ENSG00000229759.1 MRPS18AP1 -4.47 1.08e-05 0.00283 -0.24 -0.23 Educational attainment (years of education); chr3:47661780 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs2140335 ENSG00000229759.1 MRPS18AP1 -4.47 1.08e-05 0.00283 -0.24 -0.23 Educational attainment (years of education); chr3:47663625 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs11130146 ENSG00000229759.1 MRPS18AP1 -4.47 1.08e-05 0.00283 -0.24 -0.23 Educational attainment (years of education); chr3:47666322 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs12633604 ENSG00000229759.1 MRPS18AP1 -4.47 1.08e-05 0.00283 -0.24 -0.23 Educational attainment (years of education); chr3:47673308 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs6772301 ENSG00000229759.1 MRPS18AP1 -4.47 1.08e-05 0.00283 -0.24 -0.23 Educational attainment (years of education); chr3:47682366 chr3:48256350~48256938:- LIHC cis rs875971 0.545 rs10261710 ENSG00000273142.1 RP11-458F8.4 4.47 1.08e-05 0.00283 0.23 0.23 Aortic root size; chr7:66249202 chr7:66902857~66906297:+ LIHC cis rs13083990 0.919 rs3792289 ENSG00000272758.4 RP11-299J3.8 4.47 1.08e-05 0.00283 0.26 0.23 Cardiac Troponin-T levels; chr3:122274753 chr3:122416207~122443180:+ LIHC cis rs9992667 0.955 rs12331049 ENSG00000231160.8 KLF3-AS1 4.47 1.08e-05 0.00283 0.32 0.23 Eosinophil percentage of granulocytes; chr4:38654151 chr4:38612701~38664883:- LIHC cis rs901683 0.702 rs74940001 ENSG00000230869.1 CTGLF10P -4.47 1.08e-05 0.00283 -0.52 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45648846 chr10:45678692~45700532:+ LIHC cis rs734999 0.545 rs28690427 ENSG00000225931.3 RP3-395M20.7 -4.47 1.08e-05 0.00283 -0.25 -0.23 Ulcerative colitis; chr1:2640384 chr1:2566410~2569888:+ LIHC cis rs2877649 0.51 rs10083368 ENSG00000258744.1 RP11-80A15.1 -4.47 1.08e-05 0.00283 -0.43 -0.23 Smooth-surface caries; chr14:24438978 chr14:24501594~24508688:+ LIHC cis rs2877649 0.51 rs10083369 ENSG00000258744.1 RP11-80A15.1 -4.47 1.08e-05 0.00283 -0.43 -0.23 Smooth-surface caries; chr14:24439005 chr14:24501594~24508688:+ LIHC cis rs730566 0.64 rs6442112 ENSG00000229759.1 MRPS18AP1 4.47 1.08e-05 0.00283 0.25 0.23 Prion diseases; chr3:48274544 chr3:48256350~48256938:- LIHC cis rs61160187 0.51 rs10076679 ENSG00000272308.1 RP11-231G3.1 -4.47 1.08e-05 0.00283 -0.28 -0.23 Educational attainment (years of education);Educational attainment (college completion); chr5:60795124 chr5:60866457~60866935:- LIHC cis rs61160187 0.527 rs10076742 ENSG00000272308.1 RP11-231G3.1 -4.47 1.08e-05 0.00283 -0.28 -0.23 Educational attainment (years of education);Educational attainment (college completion); chr5:60795219 chr5:60866457~60866935:- LIHC cis rs61160187 0.527 rs6890201 ENSG00000272308.1 RP11-231G3.1 -4.47 1.08e-05 0.00283 -0.28 -0.23 Educational attainment (years of education);Educational attainment (college completion); chr5:60795365 chr5:60866457~60866935:- LIHC cis rs61160187 0.51 rs6875456 ENSG00000272308.1 RP11-231G3.1 -4.47 1.08e-05 0.00283 -0.28 -0.23 Educational attainment (years of education);Educational attainment (college completion); chr5:60795503 chr5:60866457~60866935:- LIHC cis rs61160187 0.51 rs6894750 ENSG00000272308.1 RP11-231G3.1 -4.47 1.08e-05 0.00283 -0.28 -0.23 Educational attainment (years of education);Educational attainment (college completion); chr5:60795729 chr5:60866457~60866935:- LIHC cis rs61160187 0.51 rs6876335 ENSG00000272308.1 RP11-231G3.1 -4.47 1.08e-05 0.00283 -0.28 -0.23 Educational attainment (years of education);Educational attainment (college completion); chr5:60795991 chr5:60866457~60866935:- LIHC cis rs61160187 0.51 rs6449501 ENSG00000272308.1 RP11-231G3.1 -4.47 1.08e-05 0.00283 -0.28 -0.23 Educational attainment (years of education);Educational attainment (college completion); chr5:60796860 chr5:60866457~60866935:- LIHC cis rs9675120 0.675 rs7214434 ENSG00000262006.1 RP11-700H6.4 -4.47 1.08e-05 0.00283 -0.26 -0.23 Cerebrospinal fluid biomarker levels; chr17:50849904 chr17:50909637~50910232:- LIHC cis rs9675120 0.675 rs7214603 ENSG00000262006.1 RP11-700H6.4 -4.47 1.08e-05 0.00283 -0.26 -0.23 Cerebrospinal fluid biomarker levels; chr17:50850021 chr17:50909637~50910232:- LIHC cis rs2439831 0.702 rs2467402 ENSG00000275601.1 AC011330.13 4.47 1.08e-05 0.00283 0.33 0.23 Lung cancer in ever smokers; chr15:43732292 chr15:43642389~43643023:- LIHC cis rs77204473 0.549 rs12280210 ENSG00000254851.1 RP11-109L13.1 4.47 1.08e-05 0.00284 0.37 0.23 Sum eosinophil basophil counts;Eosinophil counts; chr11:117069733 chr11:117135528~117138582:+ LIHC cis rs79040073 0.53 rs73396206 ENSG00000259531.2 RP11-295H24.3 4.47 1.08e-05 0.00284 0.38 0.23 Lung cancer in ever smokers; chr15:49323632 chr15:49365124~49366685:- LIHC cis rs17301013 0.932 rs1653632 ENSG00000227373.4 RP11-160H22.5 -4.47 1.08e-05 0.00284 -0.28 -0.23 Systemic lupus erythematosus; chr1:174786459 chr1:174115300~174160004:- LIHC cis rs780096 0.565 rs8179252 ENSG00000234072.1 AC074117.10 -4.47 1.08e-05 0.00284 -0.22 -0.23 Total body bone mineral density; chr2:27523965 chr2:27356246~27367622:+ LIHC cis rs6688613 0.685 rs4657613 ENSG00000225171.2 DUTP6 -4.47 1.09e-05 0.00284 -0.26 -0.23 Refractive astigmatism; chr1:166901641 chr1:166868748~166869209:+ LIHC cis rs11098499 0.697 rs11941899 ENSG00000260091.1 RP11-33B1.4 -4.47 1.09e-05 0.00284 -0.17 -0.23 Corneal astigmatism; chr4:119461603 chr4:119409333~119410233:+ LIHC cis rs11098499 0.821 rs28665282 ENSG00000260091.1 RP11-33B1.4 -4.47 1.09e-05 0.00284 -0.17 -0.23 Corneal astigmatism; chr4:119463031 chr4:119409333~119410233:+ LIHC cis rs11098499 0.738 rs10026493 ENSG00000260091.1 RP11-33B1.4 -4.47 1.09e-05 0.00284 -0.17 -0.23 Corneal astigmatism; chr4:119463039 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs7681214 ENSG00000260091.1 RP11-33B1.4 -4.47 1.09e-05 0.00284 -0.17 -0.23 Corneal astigmatism; chr4:119464165 chr4:119409333~119410233:+ LIHC cis rs11098499 0.908 rs71614449 ENSG00000260091.1 RP11-33B1.4 -4.47 1.09e-05 0.00284 -0.17 -0.23 Corneal astigmatism; chr4:119465900 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs35063680 ENSG00000260091.1 RP11-33B1.4 -4.47 1.09e-05 0.00284 -0.17 -0.23 Corneal astigmatism; chr4:119465947 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs34858317 ENSG00000260091.1 RP11-33B1.4 -4.47 1.09e-05 0.00284 -0.17 -0.23 Corneal astigmatism; chr4:119465955 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs17046116 ENSG00000260091.1 RP11-33B1.4 -4.47 1.09e-05 0.00284 -0.17 -0.23 Corneal astigmatism; chr4:119466104 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs17046118 ENSG00000260091.1 RP11-33B1.4 -4.47 1.09e-05 0.00284 -0.17 -0.23 Corneal astigmatism; chr4:119466341 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs7654587 ENSG00000260091.1 RP11-33B1.4 -4.47 1.09e-05 0.00284 -0.17 -0.23 Corneal astigmatism; chr4:119467251 chr4:119409333~119410233:+ LIHC cis rs4453827 1 rs28675949 ENSG00000271916.1 RP11-884K10.6 4.47 1.09e-05 0.00284 0.49 0.23 Blood protein levels; chr3:53708376 chr3:53797764~53798019:- LIHC cis rs710913 0.816 rs1180341 ENSG00000182109.6 RP11-69E11.4 -4.47 1.09e-05 0.00284 -0.23 -0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39527136 chr1:39522280~39546187:- LIHC cis rs11098499 0.618 rs28491261 ENSG00000245958.5 RP11-33B1.1 -4.47 1.09e-05 0.00284 -0.25 -0.23 Corneal astigmatism; chr4:119373745 chr4:119454791~119552025:+ LIHC cis rs734999 0.545 rs10797441 ENSG00000225931.3 RP3-395M20.7 4.47 1.09e-05 0.00285 0.25 0.23 Ulcerative colitis; chr1:2620221 chr1:2566410~2569888:+ LIHC cis rs7811142 1 rs7783159 ENSG00000242294.5 STAG3L5P 4.47 1.09e-05 0.00285 0.26 0.23 Platelet count; chr7:100419831 chr7:100336079~100351900:+ LIHC cis rs10833905 1 rs10833877 ENSG00000246225.5 RP11-17A1.3 -4.47 1.09e-05 0.00285 -0.31 -0.23 Sudden cardiac arrest; chr11:22988269 chr11:22829380~22945393:+ LIHC cis rs17214007 0.877 rs4482303 ENSG00000263335.1 AF001548.5 -4.47 1.09e-05 0.00285 -0.3 -0.23 Cognitive function; chr16:15777020 chr16:15726674~15732993:+ LIHC cis rs5769707 0.935 rs1109320 ENSG00000235111.1 RP1-29C18.8 -4.47 1.09e-05 0.00285 -0.27 -0.23 Monocyte percentage of white cells;Monocyte count; chr22:49595458 chr22:49612657~49615716:- LIHC cis rs5769707 0.839 rs73176988 ENSG00000235111.1 RP1-29C18.8 -4.47 1.09e-05 0.00285 -0.27 -0.23 Monocyte percentage of white cells;Monocyte count; chr22:49596001 chr22:49612657~49615716:- LIHC cis rs2310173 0.898 rs4851533 ENSG00000281162.1 LINC01127 -4.47 1.09e-05 0.00285 -0.26 -0.23 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:102035208 chr2:101962056~101987167:+ LIHC cis rs6887276 0.538 rs35897671 ENSG00000245937.6 LINC01184 -4.46 1.09e-05 0.00285 -0.28 -0.23 Height; chr5:128014053 chr5:127940426~128083172:- LIHC cis rs11671005 0.695 rs8106061 ENSG00000269473.1 CTD-2619J13.19 4.46 1.09e-05 0.00285 0.39 0.23 Mean platelet volume; chr19:58406623 chr19:58440448~58445849:+ LIHC cis rs2439831 0.867 rs2260160 ENSG00000275601.1 AC011330.13 -4.46 1.09e-05 0.00285 -0.35 -0.23 Lung cancer in ever smokers; chr15:43603445 chr15:43642389~43643023:- LIHC cis rs172166 0.694 rs203876 ENSG00000216901.1 AL022393.7 4.46 1.09e-05 0.00285 0.3 0.23 Cardiac Troponin-T levels; chr6:28078895 chr6:28176188~28176674:+ LIHC cis rs1075232 0.655 rs80220087 ENSG00000270055.1 CTD-3092A11.2 -4.46 1.09e-05 0.00285 -0.46 -0.23 Survival in colorectal cancer (non-distant metastatic); chr15:31263614 chr15:30487963~30490313:+ LIHC cis rs227275 0.554 rs223399 ENSG00000246560.2 RP11-10L12.4 4.46 1.09e-05 0.00285 0.26 0.23 Allergic disease (asthma, hay fever or eczema); chr4:102820800 chr4:102828055~102844075:+ LIHC cis rs12554020 0.582 rs12552323 ENSG00000227603.1 RP11-165J3.6 -4.46 1.09e-05 0.00286 -0.4 -0.23 Schizophrenia; chr9:93680532 chr9:93435332~93437121:- LIHC cis rs2243480 1 rs313807 ENSG00000230295.1 RP11-458F8.2 -4.46 1.09e-05 0.00286 -0.24 -0.23 Diabetic kidney disease; chr7:66034494 chr7:66880708~66882981:+ LIHC cis rs2243480 0.901 rs313808 ENSG00000230295.1 RP11-458F8.2 -4.46 1.09e-05 0.00286 -0.24 -0.23 Diabetic kidney disease; chr7:66034886 chr7:66880708~66882981:+ LIHC cis rs9400467 0.528 rs456865 ENSG00000271789.1 RP5-1112D6.7 -4.46 1.09e-05 0.00286 -0.23 -0.23 Amino acid levels;Blood metabolite levels; chr6:111311725 chr6:111297126~111298510:+ LIHC cis rs30380 1 rs469758 ENSG00000272109.1 CTD-2260A17.3 -4.46 1.09e-05 0.00286 -0.29 -0.23 Cerebrospinal fluid biomarker levels; chr5:96786011 chr5:96804353~96806105:+ LIHC cis rs30380 1 rs30379 ENSG00000272109.1 CTD-2260A17.3 -4.46 1.09e-05 0.00286 -0.29 -0.23 Cerebrospinal fluid biomarker levels; chr5:96786556 chr5:96804353~96806105:+ LIHC cis rs30380 1 rs30380 ENSG00000272109.1 CTD-2260A17.3 -4.46 1.09e-05 0.00286 -0.29 -0.23 Cerebrospinal fluid biomarker levels; chr5:96786577 chr5:96804353~96806105:+ LIHC cis rs4453827 1 rs10510765 ENSG00000271916.1 RP11-884K10.6 -4.46 1.09e-05 0.00286 -0.45 -0.23 Blood protein levels; chr3:53712179 chr3:53797764~53798019:- LIHC cis rs2276314 0.857 rs59649576 ENSG00000278986.1 RP11-723J4.3 -4.46 1.09e-05 0.00286 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:36036112 chr18:35972151~35973916:+ LIHC cis rs748404 0.631 rs2412781 ENSG00000205771.5 CATSPER2P1 4.46 1.1e-05 0.00286 0.28 0.23 Lung cancer; chr15:43375702 chr15:43726918~43747094:- LIHC cis rs875971 0.522 rs1968127 ENSG00000273024.4 INTS4P2 4.46 1.1e-05 0.00287 0.26 0.23 Aortic root size; chr7:66591816 chr7:65647864~65715661:+ LIHC cis rs7809950 0.953 rs2520263 ENSG00000238832.1 snoU109 -4.46 1.1e-05 0.00287 -0.28 -0.23 Coronary artery disease; chr7:107538674 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2520264 ENSG00000238832.1 snoU109 -4.46 1.1e-05 0.00287 -0.28 -0.23 Coronary artery disease; chr7:107538899 chr7:107603363~107603507:+ LIHC cis rs7809950 0.773 rs62483722 ENSG00000238832.1 snoU109 -4.46 1.1e-05 0.00287 -0.28 -0.23 Coronary artery disease; chr7:107545904 chr7:107603363~107603507:+ LIHC cis rs7809950 0.906 rs62483723 ENSG00000238832.1 snoU109 -4.46 1.1e-05 0.00287 -0.28 -0.23 Coronary artery disease; chr7:107545913 chr7:107603363~107603507:+ LIHC cis rs7809950 0.953 rs2520267 ENSG00000238832.1 snoU109 -4.46 1.1e-05 0.00287 -0.28 -0.23 Coronary artery disease; chr7:107547052 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2712214 ENSG00000238832.1 snoU109 -4.46 1.1e-05 0.00287 -0.28 -0.23 Coronary artery disease; chr7:107547586 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2712215 ENSG00000238832.1 snoU109 -4.46 1.1e-05 0.00287 -0.28 -0.23 Coronary artery disease; chr7:107547762 chr7:107603363~107603507:+ LIHC cis rs11098499 0.954 rs1022145 ENSG00000245958.5 RP11-33B1.1 -4.46 1.1e-05 0.00287 -0.25 -0.23 Corneal astigmatism; chr4:119309824 chr4:119454791~119552025:+ LIHC cis rs11098499 0.954 rs11722872 ENSG00000245958.5 RP11-33B1.1 -4.46 1.1e-05 0.00287 -0.25 -0.23 Corneal astigmatism; chr4:119311875 chr4:119454791~119552025:+ LIHC cis rs9341808 0.527 rs2505946 ENSG00000272129.1 RP11-250B2.6 4.46 1.1e-05 0.00287 0.23 0.23 Sitting height ratio; chr6:80100966 chr6:80355424~80356859:+ LIHC cis rs17818399 0.888 rs2346419 ENSG00000279254.1 RP11-536C12.1 -4.46 1.1e-05 0.00287 -0.29 -0.23 Height; chr2:46617930 chr2:46668870~46670778:+ LIHC cis rs9487094 0.922 rs6916579 ENSG00000260273.1 RP11-425D10.10 4.46 1.1e-05 0.00287 0.28 0.23 Height; chr6:109530435 chr6:109382795~109383666:+ LIHC cis rs73186030 1 rs5008830 ENSG00000272758.4 RP11-299J3.8 4.46 1.1e-05 0.00287 0.44 0.23 Serum parathyroid hormone levels; chr3:122311615 chr3:122416207~122443180:+ LIHC cis rs13083990 0.747 rs6438720 ENSG00000272758.4 RP11-299J3.8 -4.46 1.1e-05 0.00287 -0.26 -0.23 Cardiac Troponin-T levels; chr3:122298385 chr3:122416207~122443180:+ LIHC cis rs7193541 0.826 rs56143602 ENSG00000262904.1 TMPOP2 -4.46 1.1e-05 0.00287 -0.2 -0.23 Multiple myeloma; chr16:74660794 chr16:74667506~74668706:+ LIHC cis rs4650994 0.789 rs2761471 ENSG00000273384.1 RP5-1098D14.1 -4.46 1.1e-05 0.00287 -0.28 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178630213 chr1:178651706~178652282:+ LIHC cis rs9425766 0.626 rs6691053 ENSG00000200674.1 RN7SKP160 4.46 1.1e-05 0.00288 0.28 0.23 Life satisfaction; chr1:173899817 chr1:173791548~173791887:+ LIHC cis rs1577917 0.958 rs2121594 ENSG00000234155.1 RP11-30P6.6 4.46 1.1e-05 0.00288 0.31 0.23 Response to antipsychotic treatment; chr6:85867136 chr6:85387219~85390186:- LIHC cis rs11722228 0.522 rs881641 ENSG00000261490.1 RP11-448G15.3 4.46 1.1e-05 0.00288 0.32 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10132123 chr4:10068089~10073019:- LIHC cis rs9595908 0.965 rs9595893 ENSG00000212293.1 SNORA16 4.46 1.1e-05 0.00288 0.27 0.23 Body mass index; chr13:32601656 chr13:32420390~32420516:- LIHC cis rs4694744 0.576 rs13116232 ENSG00000264696.1 AC108078.1 -4.46 1.1e-05 0.00288 -0.35 -0.23 Bacteremia; chr4:69492807 chr4:69479331~69479434:+ LIHC cis rs67311347 1 rs954589 ENSG00000223797.4 ENTPD3-AS1 4.46 1.1e-05 0.00288 0.19 0.23 Renal cell carcinoma; chr3:40403054 chr3:40313802~40453329:- LIHC cis rs1023500 0.505 rs134887 ENSG00000205702.9 CYP2D7 4.46 1.11e-05 0.00289 0.24 0.23 Schizophrenia; chr22:42278233 chr22:42140203~42144577:- LIHC cis rs2836974 0.583 rs2410124 ENSG00000255568.3 BRWD1-AS2 -4.46 1.11e-05 0.00289 -0.2 -0.23 Cognitive function; chr21:39332834 chr21:39313935~39314962:+ LIHC cis rs72675573 0.821 rs1331857 ENSG00000235612.1 RP1-158P9.1 -4.46 1.11e-05 0.00289 -0.32 -0.23 Monocyte count; chr1:56108494 chr1:56145721~56155224:+ LIHC cis rs2243480 1 rs313809 ENSG00000228409.4 CCT6P1 4.46 1.11e-05 0.00289 0.25 0.23 Diabetic kidney disease; chr7:66034996 chr7:65751142~65763354:+ LIHC cis rs4660456 0.504 rs587963 ENSG00000237899.1 RP4-739H11.3 4.46 1.11e-05 0.0029 0.32 0.23 Platelet count; chr1:40640045 chr1:40669089~40687588:- LIHC cis rs904251 0.6 rs11756241 ENSG00000204110.6 RP1-153P14.8 -4.46 1.11e-05 0.0029 -0.29 -0.23 Cognitive performance; chr6:37477325 chr6:37507348~37535616:+ LIHC cis rs10129255 0.719 rs7156660 ENSG00000211970.3 IGHV4-61 -4.46 1.11e-05 0.0029 -0.18 -0.23 Kawasaki disease; chr14:106673171 chr14:106639119~106639657:- LIHC cis rs3091242 0.933 rs35497030 ENSG00000224183.1 SDHDP6 4.46 1.11e-05 0.0029 0.27 0.23 Erythrocyte sedimentation rate; chr1:25456575 chr1:25294164~25294643:- LIHC cis rs1005277 0.579 rs1740737 ENSG00000275858.1 RP11-291L22.8 4.46 1.11e-05 0.0029 0.26 0.23 Extrinsic epigenetic age acceleration; chr10:38210437 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2749616 ENSG00000275858.1 RP11-291L22.8 4.46 1.11e-05 0.0029 0.26 0.23 Extrinsic epigenetic age acceleration; chr10:38222065 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1780146 ENSG00000275858.1 RP11-291L22.8 4.46 1.11e-05 0.0029 0.26 0.23 Extrinsic epigenetic age acceleration; chr10:38228946 chr10:38450738~38451069:- LIHC cis rs2836974 0.831 rs34294410 ENSG00000255568.3 BRWD1-AS2 4.46 1.11e-05 0.0029 0.27 0.23 Cognitive function; chr21:39183234 chr21:39313935~39314962:+ LIHC cis rs2439831 0.681 rs484846 ENSG00000166763.7 STRCP1 4.46 1.11e-05 0.0029 0.32 0.23 Lung cancer in ever smokers; chr15:43308605 chr15:43699488~43718184:- LIHC cis rs755249 0.883 rs12035330 ENSG00000182109.6 RP11-69E11.4 4.46 1.11e-05 0.00291 0.26 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39535388 chr1:39522280~39546187:- LIHC cis rs875971 0.502 rs2465121 ENSG00000228409.4 CCT6P1 4.46 1.11e-05 0.00291 0.2 0.23 Aortic root size; chr7:66156017 chr7:65751142~65763354:+ LIHC cis rs4938303 0.718 rs10892020 ENSG00000254851.1 RP11-109L13.1 -4.46 1.11e-05 0.00291 -0.29 -0.23 Triglycerides; chr11:116718936 chr11:117135528~117138582:+ LIHC cis rs643506 0.774 rs11214033 ENSG00000254990.4 RP11-108O10.2 -4.46 1.11e-05 0.00291 -0.25 -0.23 Breast cancer; chr11:111898978 chr11:111768668~111778350:- LIHC cis rs957448 1 rs10956915 ENSG00000253704.1 RP11-267M23.4 4.46 1.12e-05 0.00291 0.29 0.23 Nonsyndromic cleft lip with cleft palate; chr8:94502362 chr8:94553722~94569745:+ LIHC cis rs2439831 0.85 rs28509275 ENSG00000275601.1 AC011330.13 -4.46 1.12e-05 0.00291 -0.36 -0.23 Lung cancer in ever smokers; chr15:43805907 chr15:43642389~43643023:- LIHC cis rs2243480 1 rs1723270 ENSG00000230295.1 RP11-458F8.2 -4.46 1.12e-05 0.00291 -0.25 -0.23 Diabetic kidney disease; chr7:66004843 chr7:66880708~66882981:+ LIHC cis rs2276314 0.857 rs28791905 ENSG00000278986.1 RP11-723J4.3 -4.46 1.12e-05 0.00291 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:36022250 chr18:35972151~35973916:+ LIHC cis rs2836974 0.897 rs2836929 ENSG00000255568.3 BRWD1-AS2 4.46 1.12e-05 0.00291 0.27 0.23 Cognitive function; chr21:39171885 chr21:39313935~39314962:+ LIHC cis rs2842992 0.789 rs9355748 ENSG00000237927.1 RP3-393E18.2 -4.46 1.12e-05 0.00291 -0.28 -0.23 Age-related macular degeneration (geographic atrophy); chr6:159773850 chr6:159586955~159589169:- LIHC cis rs7702057 0.53 rs7728055 ENSG00000271918.1 CTD-2287O16.5 4.46 1.12e-05 0.00291 0.32 0.23 Amyotrophic lateral sclerosis; chr5:116078170 chr5:116083807~116085416:- LIHC cis rs12554020 0.786 rs12551314 ENSG00000227603.1 RP11-165J3.6 4.46 1.12e-05 0.00291 0.33 0.23 Schizophrenia; chr9:93617515 chr9:93435332~93437121:- LIHC cis rs1062177 1 rs62377945 ENSG00000253921.1 CTB-113P19.3 -4.46 1.12e-05 0.00292 -0.27 -0.23 Preschool internalizing problems; chr5:151828443 chr5:151753992~151767247:+ LIHC cis rs1062177 1 rs12515762 ENSG00000253921.1 CTB-113P19.3 -4.46 1.12e-05 0.00292 -0.27 -0.23 Preschool internalizing problems; chr5:151830361 chr5:151753992~151767247:+ LIHC cis rs7709377 0.516 rs73257286 ENSG00000271918.1 CTD-2287O16.5 4.46 1.12e-05 0.00292 0.28 0.23 Metabolite levels (X-11787); chr5:116200654 chr5:116083807~116085416:- LIHC cis rs11098499 0.863 rs11947234 ENSG00000245958.5 RP11-33B1.1 -4.46 1.12e-05 0.00292 -0.25 -0.23 Corneal astigmatism; chr4:119553704 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs11933966 ENSG00000245958.5 RP11-33B1.1 -4.46 1.12e-05 0.00292 -0.25 -0.23 Corneal astigmatism; chr4:119555560 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs36040693 ENSG00000245958.5 RP11-33B1.1 -4.46 1.12e-05 0.00292 -0.25 -0.23 Corneal astigmatism; chr4:119556461 chr4:119454791~119552025:+ LIHC cis rs1577917 1 rs12201735 ENSG00000234155.1 RP11-30P6.6 4.46 1.12e-05 0.00292 0.31 0.23 Response to antipsychotic treatment; chr6:85947221 chr6:85387219~85390186:- LIHC cis rs12554020 1 rs4552973 ENSG00000227603.1 RP11-165J3.6 4.46 1.12e-05 0.00292 0.31 0.23 Schizophrenia; chr9:93539437 chr9:93435332~93437121:- LIHC cis rs853679 0.882 rs9461432 ENSG00000219392.1 RP1-265C24.5 -4.46 1.12e-05 0.00292 -0.44 -0.23 Depression; chr6:28119105 chr6:28115628~28116551:+ LIHC cis rs853679 0.882 rs4713139 ENSG00000219392.1 RP1-265C24.5 -4.46 1.12e-05 0.00292 -0.44 -0.23 Depression; chr6:28124907 chr6:28115628~28116551:+ LIHC cis rs4578769 0.694 rs72882142 ENSG00000266850.1 RP11-370A5.1 -4.46 1.12e-05 0.00292 -0.28 -0.23 Eosinophil percentage of white cells; chr18:22806755 chr18:22723491~22907721:- LIHC cis rs6565180 0.888 rs8060853 ENSG00000183604.13 SMG1P5 4.46 1.12e-05 0.00292 0.25 0.23 Tonsillectomy; chr16:30392537 chr16:30267553~30335374:- LIHC cis rs2337406 1 rs74090714 ENSG00000274576.2 IGHV2-70 -4.46 1.12e-05 0.00292 -0.26 -0.23 Alzheimer's disease (late onset); chr14:106691225 chr14:106770577~106771020:- LIHC cis rs11079159 0.651 rs2287223 ENSG00000263096.1 RP11-515O17.2 4.46 1.12e-05 0.00293 0.3 0.23 QRS duration; chr17:55315491 chr17:55271504~55273653:- LIHC cis rs748404 0.578 rs507178 ENSG00000166763.7 STRCP1 4.46 1.12e-05 0.00293 0.29 0.23 Lung cancer; chr15:43317937 chr15:43699488~43718184:- LIHC cis rs11098499 0.863 rs1552092 ENSG00000245958.5 RP11-33B1.1 -4.46 1.12e-05 0.00293 -0.25 -0.23 Corneal astigmatism; chr4:119567341 chr4:119454791~119552025:+ LIHC cis rs1558001 0.87 rs2216951 ENSG00000230196.1 DDX43P3 -4.46 1.12e-05 0.00293 -0.25 -0.23 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81804008 chr7:81610884~81611326:- LIHC cis rs10510102 0.808 rs11200296 ENSG00000226864.1 ATE1-AS1 4.46 1.13e-05 0.00293 0.41 0.23 Breast cancer; chr10:121971956 chr10:121928312~121951965:+ LIHC cis rs950169 0.58 rs17532346 ENSG00000225151.9 GOLGA2P7 -4.46 1.13e-05 0.00293 -0.29 -0.23 Schizophrenia; chr15:84628264 chr15:84199311~84230136:- LIHC cis rs2283831 0.536 rs9608503 ENSG00000213707.2 HMGB1P10 -4.46 1.13e-05 0.00293 -0.28 -0.23 Anti-saccade response; chr22:26561505 chr22:26560526~26561088:+ LIHC cis rs2283831 0.56 rs9613212 ENSG00000213707.2 HMGB1P10 -4.46 1.13e-05 0.00293 -0.28 -0.23 Anti-saccade response; chr22:26561808 chr22:26560526~26561088:+ LIHC cis rs2283831 0.56 rs9613213 ENSG00000213707.2 HMGB1P10 -4.46 1.13e-05 0.00293 -0.28 -0.23 Anti-saccade response; chr22:26562138 chr22:26560526~26561088:+ LIHC cis rs2283831 0.58 rs9608504 ENSG00000213707.2 HMGB1P10 -4.46 1.13e-05 0.00293 -0.28 -0.23 Anti-saccade response; chr22:26562216 chr22:26560526~26561088:+ LIHC cis rs2283831 0.56 rs9608505 ENSG00000213707.2 HMGB1P10 -4.46 1.13e-05 0.00293 -0.28 -0.23 Anti-saccade response; chr22:26562352 chr22:26560526~26561088:+ LIHC cis rs2283831 0.56 rs9613214 ENSG00000213707.2 HMGB1P10 -4.46 1.13e-05 0.00293 -0.28 -0.23 Anti-saccade response; chr22:26562376 chr22:26560526~26561088:+ LIHC cis rs79349575 0.783 rs58591767 ENSG00000248278.1 SUMO2P17 4.46 1.13e-05 0.00293 0.29 0.23 Type 2 diabetes; chr17:48948714 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs59270107 ENSG00000248278.1 SUMO2P17 4.46 1.13e-05 0.00293 0.29 0.23 Type 2 diabetes; chr17:48948823 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs62078370 ENSG00000248278.1 SUMO2P17 4.46 1.13e-05 0.00293 0.29 0.23 Type 2 diabetes; chr17:48949474 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs11079844 ENSG00000248278.1 SUMO2P17 4.46 1.13e-05 0.00293 0.29 0.23 Type 2 diabetes; chr17:48950972 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs62078372 ENSG00000248278.1 SUMO2P17 4.46 1.13e-05 0.00293 0.29 0.23 Type 2 diabetes; chr17:48951627 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs12602933 ENSG00000248278.1 SUMO2P17 4.46 1.13e-05 0.00293 0.29 0.23 Type 2 diabetes; chr17:48951918 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs4794003 ENSG00000248278.1 SUMO2P17 4.46 1.13e-05 0.00293 0.29 0.23 Type 2 diabetes; chr17:48952542 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs12602746 ENSG00000248278.1 SUMO2P17 4.46 1.13e-05 0.00293 0.29 0.23 Type 2 diabetes; chr17:48954379 chr17:48874860~48908983:- LIHC cis rs699371 0.507 rs10149538 ENSG00000270000.1 RP3-449M8.9 4.46 1.13e-05 0.00293 0.27 0.23 Height; chr14:74458694 chr14:74471930~74472360:- LIHC cis rs11098499 0.78 rs7680914 ENSG00000260091.1 RP11-33B1.4 -4.46 1.13e-05 0.00294 -0.17 -0.23 Corneal astigmatism; chr4:119641898 chr4:119409333~119410233:+ LIHC cis rs875971 0.505 rs2462573 ENSG00000224316.1 RP11-479O9.2 -4.46 1.13e-05 0.00294 -0.23 -0.23 Aortic root size; chr7:66042405 chr7:65773620~65802067:+ LIHC cis rs11098499 0.575 rs907204 ENSG00000260091.1 RP11-33B1.4 -4.46 1.13e-05 0.00294 -0.17 -0.23 Corneal astigmatism; chr4:119317499 chr4:119409333~119410233:+ LIHC cis rs11098499 0.575 rs907205 ENSG00000260091.1 RP11-33B1.4 -4.46 1.13e-05 0.00294 -0.17 -0.23 Corneal astigmatism; chr4:119317509 chr4:119409333~119410233:+ LIHC cis rs17301013 0.9 rs1793300 ENSG00000227373.4 RP11-160H22.5 -4.46 1.13e-05 0.00294 -0.29 -0.23 Systemic lupus erythematosus; chr1:174768559 chr1:174115300~174160004:- LIHC cis rs11098499 0.863 rs3775854 ENSG00000245958.5 RP11-33B1.1 -4.46 1.13e-05 0.00294 -0.25 -0.23 Corneal astigmatism; chr4:119550816 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs6853998 ENSG00000245958.5 RP11-33B1.1 -4.46 1.13e-05 0.00294 -0.25 -0.23 Corneal astigmatism; chr4:119554705 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs6858777 ENSG00000245958.5 RP11-33B1.1 -4.46 1.13e-05 0.00294 -0.25 -0.23 Corneal astigmatism; chr4:119554811 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs11731756 ENSG00000245958.5 RP11-33B1.1 -4.46 1.13e-05 0.00294 -0.25 -0.23 Corneal astigmatism; chr4:119557541 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs34308924 ENSG00000245958.5 RP11-33B1.1 -4.46 1.13e-05 0.00294 -0.25 -0.23 Corneal astigmatism; chr4:119560276 chr4:119454791~119552025:+ LIHC cis rs11098499 0.863 rs2170276 ENSG00000245958.5 RP11-33B1.1 -4.46 1.13e-05 0.00294 -0.25 -0.23 Corneal astigmatism; chr4:119564669 chr4:119454791~119552025:+ LIHC cis rs7809950 1 rs2894475 ENSG00000238832.1 snoU109 -4.46 1.13e-05 0.00294 -0.27 -0.23 Coronary artery disease; chr7:107622113 chr7:107603363~107603507:+ LIHC cis rs7637701 0.713 rs9818780 ENSG00000243926.1 TIPARP-AS1 4.46 1.13e-05 0.00294 0.21 0.23 Breast cancer; chr3:156774969 chr3:156671862~156674378:- LIHC cis rs7637701 0.713 rs9878566 ENSG00000243926.1 TIPARP-AS1 4.46 1.13e-05 0.00294 0.21 0.23 Breast cancer; chr3:156775424 chr3:156671862~156674378:- LIHC cis rs11098499 0.863 rs2306456 ENSG00000245958.5 RP11-33B1.1 -4.46 1.13e-05 0.00294 -0.25 -0.23 Corneal astigmatism; chr4:119551267 chr4:119454791~119552025:+ LIHC cis rs10829156 0.699 rs7911922 ENSG00000225527.1 RP11-383B4.4 -4.46 1.13e-05 0.00294 -0.37 -0.23 Sudden cardiac arrest; chr10:18542768 chr10:18531849~18533336:- LIHC cis rs9595908 0.965 rs4941612 ENSG00000212293.1 SNORA16 4.46 1.13e-05 0.00294 0.28 0.23 Body mass index; chr13:32549791 chr13:32420390~32420516:- LIHC cis rs9843304 0.501 rs34540967 ENSG00000244503.1 RP11-278L15.6 4.46 1.13e-05 0.00295 0.24 0.23 Gallstone disease; chr3:149486594 chr3:149494660~149495995:+ LIHC cis rs6921919 0.848 rs9468350 ENSG00000204709.4 LINC01556 4.46 1.13e-05 0.00295 0.29 0.23 Autism spectrum disorder or schizophrenia; chr6:28351330 chr6:28943877~28944537:+ LIHC cis rs12134133 1 rs7518565 ENSG00000274245.1 RP11-357P18.2 4.46 1.13e-05 0.00295 0.35 0.23 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207246998 chr1:207372559~207373252:+ LIHC cis rs2276314 0.857 rs28651028 ENSG00000278986.1 RP11-723J4.3 -4.46 1.13e-05 0.00295 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:36058947 chr18:35972151~35973916:+ LIHC cis rs11951515 0.508 rs1366410 ENSG00000248240.1 RP11-159F24.5 -4.46 1.13e-05 0.00295 -0.29 -0.23 Metabolite levels (X-11787); chr5:43601508 chr5:43515274~43525310:+ LIHC cis rs11096990 0.634 rs4975001 ENSG00000249207.1 RP11-360F5.1 4.46 1.13e-05 0.00295 0.24 0.23 Cognitive function; chr4:39264844 chr4:39112677~39126818:- LIHC cis rs748404 0.697 rs1095389 ENSG00000166763.7 STRCP1 4.46 1.13e-05 0.00295 0.29 0.23 Lung cancer; chr15:43274473 chr15:43699488~43718184:- LIHC cis rs1318937 1 rs2046725 ENSG00000224660.1 SH3BP5-AS1 4.46 1.14e-05 0.00295 0.23 0.23 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15253651 chr3:15254184~15264493:+ LIHC cis rs10129255 0.5 rs2105991 ENSG00000211972.2 IGHV3-66 4.46 1.14e-05 0.00295 0.17 0.23 Kawasaki disease; chr14:106682022 chr14:106675017~106675544:- LIHC cis rs202072 1 rs202072 ENSG00000215022.6 RP1-257A7.4 4.46 1.14e-05 0.00296 0.25 0.23 HIV-1 viral setpoint; chr6:13267979 chr6:13264861~13295586:- LIHC cis rs8064024 1 rs8064024 ENSG00000267077.1 RP11-127I20.5 -4.46 1.14e-05 0.00296 -0.23 -0.23 Cancer; chr16:4805278 chr16:4795265~4796532:- LIHC cis rs4561483 0.667 rs3743590 ENSG00000261560.1 RP11-166B2.3 -4.46 1.14e-05 0.00296 -0.25 -0.23 Testicular germ cell tumor; chr16:11836480 chr16:11881075~11882569:- LIHC cis rs7412746 0.658 rs4970988 ENSG00000231073.1 RP11-316M1.3 -4.46 1.14e-05 0.00296 -0.23 -0.23 Melanoma; chr1:150977586 chr1:150973123~150975534:+ LIHC cis rs875971 0.66 rs10215132 ENSG00000273024.4 INTS4P2 4.46 1.14e-05 0.00296 0.26 0.23 Aortic root size; chr7:66589419 chr7:65647864~65715661:+ LIHC cis rs11064837 0.525 rs739422 ENSG00000248636.5 RP11-768F21.1 4.46 1.14e-05 0.00296 0.38 0.23 Schizophrenia; chr12:119604701 chr12:119387987~119668079:- LIHC cis rs72675573 0.821 rs1412216 ENSG00000235612.1 RP1-158P9.1 -4.46 1.14e-05 0.00296 -0.31 -0.23 Monocyte count; chr1:56100245 chr1:56145721~56155224:+ LIHC cis rs1075232 0.579 rs58156651 ENSG00000270055.1 CTD-3092A11.2 -4.46 1.14e-05 0.00296 -0.44 -0.23 Survival in colorectal cancer (non-distant metastatic); chr15:31456864 chr15:30487963~30490313:+ LIHC cis rs11098499 0.78 rs12504773 ENSG00000260091.1 RP11-33B1.4 -4.46 1.14e-05 0.00296 -0.17 -0.23 Corneal astigmatism; chr4:119640994 chr4:119409333~119410233:+ LIHC cis rs1247318 0.856 rs2465871 ENSG00000243831.1 RP1-81D8.4 4.46 1.14e-05 0.00296 0.31 0.23 Aging; chr6:160900556 chr6:160666228~160676523:- LIHC cis rs6480314 0.522 rs10740294 ENSG00000233590.1 RP11-153K11.3 4.45 1.14e-05 0.00296 0.36 0.23 Optic nerve measurement (disc area); chr10:68301595 chr10:68233251~68242379:- LIHC cis rs17826219 0.636 rs4055314 ENSG00000266490.1 CTD-2349P21.9 4.45 1.14e-05 0.00296 0.3 0.23 Body mass index; chr17:30752751 chr17:30792372~30792833:+ LIHC cis rs79349575 0.783 rs28409394 ENSG00000248278.1 SUMO2P17 4.45 1.14e-05 0.00296 0.29 0.23 Type 2 diabetes; chr17:48920756 chr17:48874860~48908983:- LIHC cis rs7615952 0.512 rs2922175 ENSG00000171084.14 FAM86JP 4.45 1.14e-05 0.00296 0.36 0.23 Blood pressure (smoking interaction); chr3:125642516 chr3:125916620~125930024:+ LIHC cis rs7615952 0.512 rs2979351 ENSG00000171084.14 FAM86JP 4.45 1.14e-05 0.00296 0.36 0.23 Blood pressure (smoking interaction); chr3:125644755 chr3:125916620~125930024:+ LIHC cis rs4862307 0.836 rs6829678 ENSG00000250726.1 RP11-616K6.1 -4.45 1.14e-05 0.00296 -0.25 -0.23 Serum dimethylarginine levels (asymmetric/symetric ratio); chr4:184080478 chr4:184072403~184073039:+ LIHC cis rs875971 0.505 rs1723275 ENSG00000224316.1 RP11-479O9.2 -4.45 1.14e-05 0.00296 -0.23 -0.23 Aortic root size; chr7:66039646 chr7:65773620~65802067:+ LIHC cis rs2749592 0.513 rs9417249 ENSG00000263064.2 RP11-291L22.7 -4.45 1.14e-05 0.00297 -0.24 -0.23 Age-related hearing impairment (SNP x SNP interaction); chr10:37548227 chr10:38448689~38448949:+ LIHC cis rs9807989 0.507 rs1420105 ENSG00000234389.1 AC007278.3 4.45 1.14e-05 0.00297 0.25 0.23 Asthma; chr2:102418659 chr2:102438713~102440475:+ LIHC cis rs12478296 0.901 rs7420176 ENSG00000261186.2 RP11-341N2.1 -4.45 1.14e-05 0.00297 -0.31 -0.23 Obesity-related traits; chr2:242063126 chr2:242087351~242088457:- LIHC cis rs73186030 0.764 rs2332179 ENSG00000272758.4 RP11-299J3.8 4.45 1.14e-05 0.00297 0.44 0.23 Serum parathyroid hormone levels; chr3:122360583 chr3:122416207~122443180:+ LIHC cis rs875971 0.545 rs1796219 ENSG00000237310.1 GS1-124K5.4 -4.45 1.14e-05 0.00297 -0.23 -0.23 Aortic root size; chr7:66645977 chr7:66493706~66495474:+ LIHC cis rs11722228 0.522 rs77691548 ENSG00000261490.1 RP11-448G15.3 4.45 1.14e-05 0.00297 0.31 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10134491 chr4:10068089~10073019:- LIHC cis rs10771431 1 rs11611670 ENSG00000111788.10 RP11-22B23.1 4.45 1.14e-05 0.00297 0.21 0.23 Breast size; chr12:9232939 chr12:9277235~9313241:+ LIHC cis rs7811142 1 rs6975729 ENSG00000242294.5 STAG3L5P 4.45 1.14e-05 0.00297 0.28 0.23 Platelet count; chr7:100430564 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs1073 ENSG00000242294.5 STAG3L5P 4.45 1.14e-05 0.00297 0.28 0.23 Platelet count; chr7:100433989 chr7:100336079~100351900:+ LIHC cis rs7811142 0.887 rs4074838 ENSG00000242294.5 STAG3L5P 4.45 1.14e-05 0.00297 0.28 0.23 Platelet count; chr7:100435042 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs11764818 ENSG00000242294.5 STAG3L5P 4.45 1.14e-05 0.00297 0.28 0.23 Platelet count; chr7:100445432 chr7:100336079~100351900:+ LIHC cis rs12554020 0.581 rs4255201 ENSG00000227603.1 RP11-165J3.6 4.45 1.14e-05 0.00298 0.38 0.23 Schizophrenia; chr9:93401055 chr9:93435332~93437121:- LIHC cis rs67311347 0.866 rs2371183 ENSG00000223797.4 ENTPD3-AS1 -4.45 1.14e-05 0.00298 -0.19 -0.23 Renal cell carcinoma; chr3:40292756 chr3:40313802~40453329:- LIHC cis rs11971779 0.68 rs17691238 ENSG00000273391.1 RP11-634H22.1 -4.45 1.15e-05 0.00298 -0.21 -0.23 Diisocyanate-induced asthma; chr7:139367538 chr7:139359032~139359566:- LIHC cis rs748404 0.601 rs502157 ENSG00000205771.5 CATSPER2P1 4.45 1.15e-05 0.00298 0.29 0.23 Lung cancer; chr15:43236375 chr15:43726918~43747094:- LIHC cis rs7734985 0.728 rs6556904 ENSG00000250551.1 RP11-254I22.1 -4.45 1.15e-05 0.00298 -0.29 -0.23 IgG glycosylation; chr5:96159933 chr5:96050115~96215519:+ LIHC cis rs9353324 1 rs9444356 ENSG00000203875.9 SNHG5 -4.45 1.15e-05 0.00298 -0.51 -0.23 Interferon gamma-induced protein 10 levels; chr6:85651200 chr6:85660950~85678736:- LIHC cis rs6545883 0.525 rs1621048 ENSG00000271889.1 RP11-493E12.1 -4.45 1.15e-05 0.00298 -0.27 -0.23 Tuberculosis; chr2:61137081 chr2:61151433~61162105:- LIHC cis rs17772222 0.876 rs12587598 ENSG00000258789.1 RP11-507K2.3 -4.45 1.15e-05 0.00298 -0.28 -0.23 Coronary artery calcification; chr14:88729474 chr14:88551597~88552493:+ LIHC cis rs79349575 0.783 rs17708633 ENSG00000248278.1 SUMO2P17 4.45 1.15e-05 0.00298 0.29 0.23 Type 2 diabetes; chr17:48934258 chr17:48874860~48908983:- LIHC cis rs10262624 0.935 rs8180700 ENSG00000234286.1 AC006026.13 -4.45 1.15e-05 0.00298 -0.26 -0.23 Schizophrenia; chr7:23870323 chr7:23680195~23680786:- LIHC cis rs10833905 1 rs10766991 ENSG00000246225.5 RP11-17A1.3 -4.45 1.15e-05 0.00298 -0.31 -0.23 Sudden cardiac arrest; chr11:22987325 chr11:22829380~22945393:+ LIHC cis rs9595908 0.929 rs34916533 ENSG00000212293.1 SNORA16 4.45 1.15e-05 0.00298 0.29 0.23 Body mass index; chr13:32500537 chr13:32420390~32420516:- LIHC cis rs72675573 0.925 rs706405 ENSG00000235612.1 RP1-158P9.1 -4.45 1.15e-05 0.00298 -0.3 -0.23 Monocyte count; chr1:56162133 chr1:56145721~56155224:+ LIHC cis rs61160187 0.51 rs4482855 ENSG00000272308.1 RP11-231G3.1 -4.45 1.15e-05 0.00298 -0.28 -0.23 Educational attainment (years of education);Educational attainment (college completion); chr5:60800670 chr5:60866457~60866935:- LIHC cis rs7809950 0.954 rs2520243 ENSG00000238832.1 snoU109 -4.45 1.15e-05 0.00298 -0.28 -0.23 Coronary artery disease; chr7:107496528 chr7:107603363~107603507:+ LIHC cis rs7809950 0.954 rs2520245 ENSG00000238832.1 snoU109 -4.45 1.15e-05 0.00298 -0.28 -0.23 Coronary artery disease; chr7:107496983 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2250414 ENSG00000238832.1 snoU109 -4.45 1.15e-05 0.00298 -0.28 -0.23 Coronary artery disease; chr7:107500542 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2712200 ENSG00000238832.1 snoU109 -4.45 1.15e-05 0.00298 -0.28 -0.23 Coronary artery disease; chr7:107501990 chr7:107603363~107603507:+ LIHC cis rs7809950 0.953 rs3094383 ENSG00000238832.1 snoU109 -4.45 1.15e-05 0.00298 -0.28 -0.23 Coronary artery disease; chr7:107502719 chr7:107603363~107603507:+ LIHC cis rs7809950 0.954 rs2520247 ENSG00000238832.1 snoU109 -4.45 1.15e-05 0.00298 -0.28 -0.23 Coronary artery disease; chr7:107503501 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2712201 ENSG00000238832.1 snoU109 -4.45 1.15e-05 0.00298 -0.28 -0.23 Coronary artery disease; chr7:107505119 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2520249 ENSG00000238832.1 snoU109 -4.45 1.15e-05 0.00298 -0.28 -0.23 Coronary artery disease; chr7:107506303 chr7:107603363~107603507:+ LIHC cis rs6565180 0.926 rs4787643 ENSG00000183604.13 SMG1P5 4.45 1.15e-05 0.00298 0.25 0.23 Tonsillectomy; chr16:30382339 chr16:30267553~30335374:- LIHC cis rs6565180 0.926 rs4788409 ENSG00000183604.13 SMG1P5 4.45 1.15e-05 0.00298 0.25 0.23 Tonsillectomy; chr16:30382450 chr16:30267553~30335374:- LIHC cis rs13083990 0.919 rs10934578 ENSG00000272758.4 RP11-299J3.8 -4.45 1.15e-05 0.00299 -0.25 -0.23 Cardiac Troponin-T levels; chr3:122258435 chr3:122416207~122443180:+ LIHC cis rs6997458 0.652 rs7827051 ENSG00000253549.4 RP11-317J10.2 4.45 1.15e-05 0.00299 0.26 0.23 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85425619 chr8:85441851~85464915:- LIHC cis rs113084984 0.642 rs35417544 ENSG00000271952.1 RP11-245G13.2 -4.45 1.15e-05 0.00299 -0.29 -0.23 Breast cancer; chr2:11540277 chr2:10878269~10885118:+ LIHC cis rs7714584 1 rs10058943 ENSG00000197083.10 ZNF300P1 4.45 1.15e-05 0.00299 0.36 0.23 Crohn's disease; chr5:150847024 chr5:150930645~150946289:- LIHC cis rs4356975 0.899 rs7677996 ENSG00000250919.1 RP11-813N20.3 -4.45 1.15e-05 0.00299 -0.24 -0.23 Obesity-related traits; chr4:69075473 chr4:69027831~69044578:+ LIHC cis rs7923609 1 rs10761742 ENSG00000232075.1 MRPL35P2 -4.45 1.15e-05 0.00299 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63325288 chr10:63634317~63634827:- LIHC cis rs61041384 1 rs4759367 ENSG00000256092.2 RP13-942N8.1 -4.45 1.15e-05 0.00299 -0.37 -0.23 Schizophrenia; chr12:123171997 chr12:123363868~123366113:+ LIHC cis rs1865760 0.566 rs2051544 ENSG00000216436.2 HIST1H2APS1 -4.45 1.15e-05 0.003 -0.27 -0.23 Height; chr6:26070865 chr6:25732497~25732827:+ LIHC cis rs11951515 0.509 rs12521249 ENSG00000248240.1 RP11-159F24.5 4.45 1.16e-05 0.003 0.29 0.23 Metabolite levels (X-11787); chr5:43558527 chr5:43515274~43525310:+ LIHC cis rs4356975 0.83 rs7435274 ENSG00000250919.1 RP11-813N20.3 -4.45 1.16e-05 0.003 -0.24 -0.23 Obesity-related traits; chr4:69050281 chr4:69027831~69044578:+ LIHC cis rs4356975 0.83 rs7438808 ENSG00000250919.1 RP11-813N20.3 -4.45 1.16e-05 0.003 -0.24 -0.23 Obesity-related traits; chr4:69050666 chr4:69027831~69044578:+ LIHC cis rs2932538 1 rs2932538 ENSG00000225075.1 RP11-426L16.3 -4.45 1.16e-05 0.003 -0.3 -0.23 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112673921 chr1:112693688~112696621:- LIHC cis rs651907 0.535 rs11707250 ENSG00000244119.1 PDCL3P4 -4.45 1.16e-05 0.003 -0.25 -0.23 Colorectal cancer; chr3:101790527 chr3:101712472~101713191:+ LIHC cis rs77204473 0.744 rs2306472 ENSG00000254851.1 RP11-109L13.1 4.45 1.16e-05 0.003 0.43 0.23 Sum eosinophil basophil counts;Eosinophil counts; chr11:117187346 chr11:117135528~117138582:+ LIHC cis rs77204473 0.744 rs3213459 ENSG00000254851.1 RP11-109L13.1 4.45 1.16e-05 0.003 0.43 0.23 Sum eosinophil basophil counts;Eosinophil counts; chr11:117191773 chr11:117135528~117138582:+ LIHC cis rs77204473 0.744 rs3781985 ENSG00000254851.1 RP11-109L13.1 4.45 1.16e-05 0.003 0.43 0.23 Sum eosinophil basophil counts;Eosinophil counts; chr11:117194350 chr11:117135528~117138582:+ LIHC cis rs77204473 0.744 rs11606480 ENSG00000254851.1 RP11-109L13.1 4.45 1.16e-05 0.003 0.43 0.23 Sum eosinophil basophil counts;Eosinophil counts; chr11:117194817 chr11:117135528~117138582:+ LIHC cis rs3733585 0.683 rs13112015 ENSG00000250413.1 RP11-448G15.1 4.45 1.16e-05 0.003 0.3 0.23 Cleft plate (environmental tobacco smoke interaction); chr4:9932172 chr4:10006482~10009725:+ LIHC cis rs3733585 0.66 rs13122290 ENSG00000250413.1 RP11-448G15.1 4.45 1.16e-05 0.003 0.3 0.23 Cleft plate (environmental tobacco smoke interaction); chr4:9932208 chr4:10006482~10009725:+ LIHC cis rs11096990 0.634 rs2839765 ENSG00000249685.1 RP11-360F5.3 -4.45 1.16e-05 0.00301 -0.28 -0.23 Cognitive function; chr4:39293933 chr4:39133913~39135608:+ LIHC cis rs13083990 0.919 rs3804590 ENSG00000272758.4 RP11-299J3.8 4.45 1.16e-05 0.00301 0.26 0.23 Cardiac Troponin-T levels; chr3:122259226 chr3:122416207~122443180:+ LIHC cis rs950169 0.58 rs11630887 ENSG00000225151.9 GOLGA2P7 -4.45 1.16e-05 0.00301 -0.29 -0.23 Schizophrenia; chr15:84649784 chr15:84199311~84230136:- LIHC cis rs803923 0.56 rs811688 ENSG00000230894.1 RP11-67K19.3 4.45 1.16e-05 0.00301 0.3 0.23 Lung function (FEV1/FVC); chr9:116648461 chr9:116568449~116586328:+ LIHC cis rs2919917 0.628 rs979564 ENSG00000254352.1 RP11-578O24.2 4.45 1.16e-05 0.00301 0.35 0.23 Lymphocyte counts; chr8:78663924 chr8:78723796~78724136:- LIHC cis rs172166 0.694 rs203876 ENSG00000219392.1 RP1-265C24.5 -4.45 1.16e-05 0.00301 -0.31 -0.23 Cardiac Troponin-T levels; chr6:28078895 chr6:28115628~28116551:+ LIHC cis rs17711722 0.74 rs7809991 ENSG00000224316.1 RP11-479O9.2 4.45 1.16e-05 0.00301 0.24 0.23 Calcium levels; chr7:65941231 chr7:65773620~65802067:+ LIHC cis rs11673344 0.75 rs78241494 ENSG00000226686.6 LINC01535 4.45 1.16e-05 0.00301 0.37 0.23 Obesity-related traits; chr19:37158846 chr19:37251912~37265535:+ LIHC cis rs11673344 0.838 rs111827672 ENSG00000226686.6 LINC01535 4.45 1.16e-05 0.00301 0.37 0.23 Obesity-related traits; chr19:37158964 chr19:37251912~37265535:+ LIHC cis rs7615952 0.599 rs66532274 ENSG00000171084.14 FAM86JP 4.45 1.16e-05 0.00302 0.36 0.23 Blood pressure (smoking interaction); chr3:126013002 chr3:125916620~125930024:+ LIHC cis rs417065 1 rs11588420 ENSG00000227634.1 RP11-431K24.3 -4.45 1.16e-05 0.00302 -0.31 -0.23 Psoriasis; chr1:8200696 chr1:8208672~8215210:+ LIHC cis rs10829156 0.625 rs7082235 ENSG00000240291.1 RP11-499P20.2 4.45 1.16e-05 0.00302 0.35 0.23 Sudden cardiac arrest; chr10:18536765 chr10:18513115~18545651:- LIHC cis rs7923609 0.87 rs10822156 ENSG00000232075.1 MRPL35P2 -4.45 1.16e-05 0.00302 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63320967 chr10:63634317~63634827:- LIHC cis rs734999 0.505 rs4648659 ENSG00000225931.3 RP3-395M20.7 -4.45 1.17e-05 0.00302 -0.25 -0.23 Ulcerative colitis; chr1:2629464 chr1:2566410~2569888:+ LIHC cis rs734999 0.545 rs28532547 ENSG00000225931.3 RP3-395M20.7 -4.45 1.17e-05 0.00302 -0.25 -0.23 Ulcerative colitis; chr1:2629847 chr1:2566410~2569888:+ LIHC cis rs2929278 0.561 rs2927071 ENSG00000275601.1 AC011330.13 -4.45 1.17e-05 0.00302 -0.29 -0.23 Schizophrenia; chr15:43626883 chr15:43642389~43643023:- LIHC cis rs30380 1 rs30378 ENSG00000272109.1 CTD-2260A17.3 -4.45 1.17e-05 0.00302 -0.29 -0.23 Cerebrospinal fluid biomarker levels; chr5:96786290 chr5:96804353~96806105:+ LIHC cis rs17301013 0.9 rs1754351 ENSG00000227373.4 RP11-160H22.5 -4.45 1.17e-05 0.00302 -0.29 -0.23 Systemic lupus erythematosus; chr1:174762458 chr1:174115300~174160004:- LIHC cis rs901683 1 rs9422653 ENSG00000230869.1 CTGLF10P 4.45 1.17e-05 0.00302 0.54 0.23 Mean corpuscular volume;Red blood cell traits; chr10:45553470 chr10:45678692~45700532:+ LIHC cis rs6700559 0.81 rs7529962 ENSG00000260088.1 RP11-92G12.3 -4.45 1.17e-05 0.00303 -0.29 -0.23 Coronary artery disease; chr1:200627849 chr1:200669507~200694250:+ LIHC cis rs3812762 0.917 rs10743087 ENSG00000254860.4 TMEM9B-AS1 -4.45 1.17e-05 0.00303 -0.24 -0.23 Hypospadias; chr11:8764511 chr11:8964675~8977527:+ LIHC cis rs7945705 0.818 rs2742552 ENSG00000254860.4 TMEM9B-AS1 4.45 1.17e-05 0.00304 0.23 0.23 Hemoglobin concentration; chr11:8855305 chr11:8964675~8977527:+ LIHC cis rs651907 0.557 rs13099674 ENSG00000244119.1 PDCL3P4 4.45 1.17e-05 0.00304 0.24 0.23 Colorectal cancer; chr3:101770785 chr3:101712472~101713191:+ LIHC cis rs2836974 0.899 rs35774464 ENSG00000255568.3 BRWD1-AS2 4.45 1.17e-05 0.00304 0.27 0.23 Cognitive function; chr21:39208243 chr21:39313935~39314962:+ LIHC cis rs875971 0.545 rs67397473 ENSG00000228409.4 CCT6P1 -4.45 1.17e-05 0.00304 -0.2 -0.23 Aortic root size; chr7:66168318 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs10950027 ENSG00000228409.4 CCT6P1 -4.45 1.17e-05 0.00304 -0.2 -0.23 Aortic root size; chr7:66169164 chr7:65751142~65763354:+ LIHC cis rs7637701 0.773 rs4098 ENSG00000243926.1 TIPARP-AS1 4.45 1.17e-05 0.00304 0.21 0.23 Breast cancer; chr3:156783274 chr3:156671862~156674378:- LIHC cis rs7637701 0.773 rs7623691 ENSG00000243926.1 TIPARP-AS1 -4.45 1.17e-05 0.00304 -0.21 -0.23 Breast cancer; chr3:156790921 chr3:156671862~156674378:- LIHC cis rs921968 0.591 rs3731877 ENSG00000272555.1 RP11-459I19.1 -4.45 1.17e-05 0.00304 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218737776 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs7562426 ENSG00000272555.1 RP11-459I19.1 -4.45 1.17e-05 0.00304 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218740395 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs1079177 ENSG00000272555.1 RP11-459I19.1 -4.45 1.17e-05 0.00304 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218741206 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs755112 ENSG00000272555.1 RP11-459I19.1 -4.45 1.17e-05 0.00304 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218741329 chr2:218818690~218819144:+ LIHC cis rs1075232 1 rs56396205 ENSG00000270055.1 CTD-3092A11.2 -4.45 1.17e-05 0.00304 -0.46 -0.23 Survival in colorectal cancer (non-distant metastatic); chr15:31386182 chr15:30487963~30490313:+ LIHC cis rs763121 0.853 rs1056610 ENSG00000273076.1 RP3-508I15.22 -4.45 1.17e-05 0.00304 -0.26 -0.23 Menopause (age at onset); chr22:38684073 chr22:38743495~38743910:+ LIHC cis rs10262624 0.935 rs4722283 ENSG00000234286.1 AC006026.13 4.45 1.18e-05 0.00304 0.26 0.23 Schizophrenia; chr7:23866595 chr7:23680195~23680786:- LIHC cis rs875971 0.545 rs73142265 ENSG00000228409.4 CCT6P1 -4.45 1.18e-05 0.00305 -0.2 -0.23 Aortic root size; chr7:66234510 chr7:65751142~65763354:+ LIHC cis rs17270561 1 rs17270561 ENSG00000272810.1 U91328.22 4.45 1.18e-05 0.00305 0.3 0.23 Iron status biomarkers; chr6:25820211 chr6:26013241~26013757:+ LIHC cis rs9595908 0.9 rs1324414 ENSG00000212293.1 SNORA16 4.45 1.18e-05 0.00305 0.27 0.23 Body mass index; chr13:32600088 chr13:32420390~32420516:- LIHC cis rs4356975 0.83 rs10012607 ENSG00000250919.1 RP11-813N20.3 -4.45 1.18e-05 0.00305 -0.24 -0.23 Obesity-related traits; chr4:69048866 chr4:69027831~69044578:+ LIHC cis rs2836974 0.897 rs8132295 ENSG00000255568.3 BRWD1-AS2 -4.45 1.18e-05 0.00305 -0.26 -0.23 Cognitive function; chr21:39155848 chr21:39313935~39314962:+ LIHC cis rs71520386 0.632 rs1474349 ENSG00000228649.7 AC005682.5 -4.45 1.18e-05 0.00305 -0.31 -0.23 Fibrinogen levels; chr7:22814146 chr7:22854178~22861579:+ LIHC cis rs9595908 0.965 rs12323094 ENSG00000212293.1 SNORA16 4.45 1.18e-05 0.00305 0.28 0.23 Body mass index; chr13:32569227 chr13:32420390~32420516:- LIHC cis rs9595908 0.965 rs12323101 ENSG00000212293.1 SNORA16 4.45 1.18e-05 0.00305 0.28 0.23 Body mass index; chr13:32569269 chr13:32420390~32420516:- LIHC cis rs9595908 0.965 rs1123462 ENSG00000212293.1 SNORA16 4.45 1.18e-05 0.00305 0.28 0.23 Body mass index; chr13:32571325 chr13:32420390~32420516:- LIHC cis rs728616 0.614 rs35193855 ENSG00000225484.5 NUTM2B-AS1 -4.45 1.18e-05 0.00305 -0.43 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80028739 chr10:79663088~79826594:- LIHC cis rs67311347 0.911 rs6776044 ENSG00000223797.4 ENTPD3-AS1 4.45 1.18e-05 0.00306 0.19 0.23 Renal cell carcinoma; chr3:40336012 chr3:40313802~40453329:- LIHC cis rs67311347 0.955 rs6764102 ENSG00000223797.4 ENTPD3-AS1 4.45 1.18e-05 0.00306 0.19 0.23 Renal cell carcinoma; chr3:40336662 chr3:40313802~40453329:- LIHC cis rs7208859 0.673 rs4131618 ENSG00000266490.1 CTD-2349P21.9 4.45 1.18e-05 0.00306 0.3 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30877783 chr17:30792372~30792833:+ LIHC cis rs9487094 0.848 rs7372 ENSG00000260273.1 RP11-425D10.10 4.45 1.18e-05 0.00306 0.28 0.23 Height; chr6:109366911 chr6:109382795~109383666:+ LIHC cis rs7923609 0.936 rs4405189 ENSG00000232075.1 MRPL35P2 -4.45 1.18e-05 0.00306 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63254175 chr10:63634317~63634827:- LIHC cis rs17270561 0.636 rs2070642 ENSG00000216436.2 HIST1H2APS1 -4.45 1.18e-05 0.00306 -0.28 -0.23 Iron status biomarkers; chr6:25830984 chr6:25732497~25732827:+ LIHC cis rs7714584 0.826 rs12655654 ENSG00000197083.10 ZNF300P1 4.45 1.18e-05 0.00306 0.38 0.23 Crohn's disease; chr5:150794733 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs74955473 ENSG00000197083.10 ZNF300P1 4.45 1.18e-05 0.00306 0.38 0.23 Crohn's disease; chr5:150794996 chr5:150930645~150946289:- LIHC cis rs7714584 1 rs79780973 ENSG00000197083.10 ZNF300P1 4.45 1.18e-05 0.00306 0.38 0.23 Crohn's disease; chr5:150795248 chr5:150930645~150946289:- LIHC cis rs960902 0.747 rs62135565 ENSG00000213553.4 RPLP0P6 4.45 1.18e-05 0.00306 0.19 0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37490364 chr2:38481851~38482804:+ LIHC cis rs7119038 0.865 rs7117261 ENSG00000255239.1 AP002954.6 4.45 1.18e-05 0.00306 0.35 0.23 Sjögren's syndrome; chr11:118870448 chr11:118688039~118690600:- LIHC cis rs240993 0.812 rs9374262 ENSG00000271789.1 RP5-1112D6.7 4.45 1.18e-05 0.00306 0.28 0.23 Inflammatory skin disease;Psoriasis; chr6:111553772 chr6:111297126~111298510:+ LIHC cis rs2929278 0.589 rs7174732 ENSG00000275601.1 AC011330.13 4.45 1.18e-05 0.00306 0.29 0.23 Schizophrenia; chr15:43746265 chr15:43642389~43643023:- LIHC cis rs748404 0.604 rs2278857 ENSG00000166763.7 STRCP1 4.45 1.18e-05 0.00306 0.28 0.23 Lung cancer; chr15:43340351 chr15:43699488~43718184:- LIHC cis rs8040855 0.627 rs4843019 ENSG00000259295.5 CSPG4P12 -4.45 1.19e-05 0.00307 -0.36 -0.23 Bulimia nervosa; chr15:85101228 chr15:85191438~85213905:+ LIHC cis rs7615952 0.599 rs2270986 ENSG00000171084.14 FAM86JP 4.45 1.19e-05 0.00307 0.37 0.23 Blood pressure (smoking interaction); chr3:125982256 chr3:125916620~125930024:+ LIHC cis rs7615952 0.599 rs12496921 ENSG00000171084.14 FAM86JP 4.45 1.19e-05 0.00307 0.37 0.23 Blood pressure (smoking interaction); chr3:125983105 chr3:125916620~125930024:+ LIHC cis rs755249 0.509 rs710913 ENSG00000182109.6 RP11-69E11.4 -4.45 1.19e-05 0.00307 -0.24 -0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39524254 chr1:39522280~39546187:- LIHC cis rs55794721 0.543 rs1293260 ENSG00000261349.1 RP3-465N24.5 -4.45 1.19e-05 0.00308 -0.23 -0.23 Mean corpuscular volume;Plateletcrit; chr1:25382613 chr1:25266102~25267136:- LIHC cis rs3733589 0.59 rs12642537 ENSG00000250413.1 RP11-448G15.1 4.44 1.19e-05 0.00308 0.38 0.23 Renal overload gout; chr4:10035997 chr4:10006482~10009725:+ LIHC cis rs200986 1 rs200986 ENSG00000216901.1 AL022393.7 4.44 1.19e-05 0.00308 0.3 0.23 Autism spectrum disorder or schizophrenia; chr6:27856988 chr6:28176188~28176674:+ LIHC cis rs921968 0.565 rs7599568 ENSG00000272555.1 RP11-459I19.1 -4.44 1.19e-05 0.00308 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218743096 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs3755045 ENSG00000272555.1 RP11-459I19.1 -4.44 1.19e-05 0.00308 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218744439 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs2037622 ENSG00000272555.1 RP11-459I19.1 -4.44 1.19e-05 0.00308 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218744717 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs2272191 ENSG00000272555.1 RP11-459I19.1 -4.44 1.19e-05 0.00308 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218745053 chr2:218818690~218819144:+ LIHC cis rs7607369 0.714 rs2272190 ENSG00000272555.1 RP11-459I19.1 -4.44 1.19e-05 0.00308 -0.25 -0.23 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218745272 chr2:218818690~218819144:+ LIHC cis rs9487094 0.885 rs1358997 ENSG00000260273.1 RP11-425D10.10 4.44 1.19e-05 0.00308 0.28 0.23 Height; chr6:109380457 chr6:109382795~109383666:+ LIHC cis rs9487094 0.885 rs3799839 ENSG00000260273.1 RP11-425D10.10 4.44 1.19e-05 0.00308 0.28 0.23 Height; chr6:109380990 chr6:109382795~109383666:+ LIHC cis rs172166 0.694 rs536704 ENSG00000219392.1 RP1-265C24.5 -4.44 1.19e-05 0.00309 -0.31 -0.23 Cardiac Troponin-T levels; chr6:28124825 chr6:28115628~28116551:+ LIHC cis rs929596 0.793 rs2602376 ENSG00000233445.1 RPL17P11 4.44 1.19e-05 0.00309 0.34 0.23 Total bilirubin levels in HIV-1 infection; chr2:233673405 chr2:233721522~233722065:- LIHC cis rs172166 0.543 rs1150691 ENSG00000204709.4 LINC01556 4.44 1.2e-05 0.00309 0.26 0.23 Cardiac Troponin-T levels; chr6:28200255 chr6:28943877~28944537:+ LIHC cis rs638893 0.636 rs1784295 ENSG00000278376.1 RP11-158I9.8 -4.44 1.2e-05 0.00309 -0.44 -0.23 Vitiligo; chr11:118790223 chr11:118791254~118793137:+ LIHC cis rs638893 0.578 rs1790188 ENSG00000278376.1 RP11-158I9.8 -4.44 1.2e-05 0.00309 -0.44 -0.23 Vitiligo; chr11:118790346 chr11:118791254~118793137:+ LIHC cis rs10829156 0.786 rs7093907 ENSG00000240291.1 RP11-499P20.2 4.44 1.2e-05 0.00309 0.38 0.23 Sudden cardiac arrest; chr10:18587225 chr10:18513115~18545651:- LIHC cis rs160451 0.934 rs160422 ENSG00000251136.7 RP11-37B2.1 4.44 1.2e-05 0.0031 0.21 0.23 Leprosy; chr8:89657610 chr8:89609409~89757727:- LIHC cis rs11096990 0.634 rs6531702 ENSG00000249685.1 RP11-360F5.3 4.44 1.2e-05 0.0031 0.28 0.23 Cognitive function; chr4:39273774 chr4:39133913~39135608:+ LIHC cis rs2243480 0.706 rs34466769 ENSG00000230295.1 RP11-458F8.2 -4.44 1.2e-05 0.0031 -0.22 -0.23 Diabetic kidney disease; chr7:65988305 chr7:66880708~66882981:+ LIHC cis rs6903823 0.508 rs1150718 ENSG00000204709.4 LINC01556 4.44 1.2e-05 0.0031 0.26 0.23 Pulmonary function; chr6:28289170 chr6:28943877~28944537:+ LIHC cis rs6903823 0.508 rs1233660 ENSG00000204709.4 LINC01556 4.44 1.2e-05 0.0031 0.26 0.23 Pulmonary function; chr6:28292472 chr6:28943877~28944537:+ LIHC cis rs17270561 0.779 rs78589800 ENSG00000216436.2 HIST1H2APS1 -4.44 1.2e-05 0.0031 -0.36 -0.23 Iron status biomarkers; chr6:25883272 chr6:25732497~25732827:+ LIHC cis rs2929278 0.562 rs8033846 ENSG00000275601.1 AC011330.13 4.44 1.2e-05 0.0031 0.29 0.23 Schizophrenia; chr15:43743165 chr15:43642389~43643023:- LIHC cis rs4578769 0.959 rs11082184 ENSG00000265943.1 RP11-739L10.1 4.44 1.2e-05 0.0031 0.3 0.23 Eosinophil percentage of white cells; chr18:22872288 chr18:22699481~22933764:- LIHC cis rs4578769 0.959 rs12964817 ENSG00000265943.1 RP11-739L10.1 4.44 1.2e-05 0.0031 0.3 0.23 Eosinophil percentage of white cells; chr18:22876657 chr18:22699481~22933764:- LIHC cis rs763512 0.504 rs11652399 ENSG00000276054.1 RP11-378E13.3 4.44 1.2e-05 0.0031 0.3 0.23 3-hydroxypropylmercapturic acid levels in smokers; chr17:37509679 chr17:37386886~37387926:+ LIHC cis rs11951515 0.508 rs7706431 ENSG00000248240.1 RP11-159F24.5 -4.44 1.2e-05 0.0031 -0.29 -0.23 Metabolite levels (X-11787); chr5:43582321 chr5:43515274~43525310:+ LIHC cis rs11951515 0.508 rs6898866 ENSG00000248240.1 RP11-159F24.5 -4.44 1.2e-05 0.0031 -0.29 -0.23 Metabolite levels (X-11787); chr5:43586273 chr5:43515274~43525310:+ LIHC cis rs733592 0.524 rs10875727 ENSG00000240399.1 RP1-228P16.1 -4.44 1.2e-05 0.0031 -0.22 -0.23 Plateletcrit; chr12:48032360 chr12:48054813~48055591:- LIHC cis rs9467603 0.925 rs1892253 ENSG00000216436.2 HIST1H2APS1 4.44 1.2e-05 0.0031 0.51 0.23 Intelligence (multi-trait analysis); chr6:25782086 chr6:25732497~25732827:+ LIHC cis rs2439831 0.702 rs16977724 ENSG00000275601.1 AC011330.13 -4.44 1.2e-05 0.00311 -0.35 -0.23 Lung cancer in ever smokers; chr15:43859101 chr15:43642389~43643023:- LIHC cis rs6683071 1 rs6683071 ENSG00000272750.1 RP11-378J18.8 -4.44 1.2e-05 0.00311 -0.29 -0.23 Cognitive performance; chr1:222750009 chr1:222658867~222661512:- LIHC cis rs6445975 0.572 rs6768547 ENSG00000272360.1 RP11-359I18.5 -4.44 1.2e-05 0.00311 -0.32 -0.23 Systemic lupus erythematosus; chr3:58449242 chr3:58490830~58491291:- LIHC cis rs4862307 0.836 rs4507404 ENSG00000250726.1 RP11-616K6.1 -4.44 1.2e-05 0.00311 -0.25 -0.23 Serum dimethylarginine levels (asymmetric/symetric ratio); chr4:184082614 chr4:184072403~184073039:+ LIHC cis rs202072 0.725 rs202071 ENSG00000215022.6 RP1-257A7.4 -4.44 1.2e-05 0.00311 -0.25 -0.23 HIV-1 viral setpoint; chr6:13267926 chr6:13264861~13295586:- LIHC cis rs11603023 0.967 rs4245184 ENSG00000255422.1 AP002954.4 4.44 1.2e-05 0.00311 0.26 0.23 Cholesterol, total; chr11:118639844 chr11:118704607~118750263:+ LIHC cis rs8177376 0.906 rs522486 ENSG00000254905.1 RP11-712L6.7 4.44 1.21e-05 0.00311 0.36 0.23 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126190054 chr11:126292922~126294254:- LIHC cis rs950169 0.922 rs11638445 ENSG00000259295.5 CSPG4P12 4.44 1.21e-05 0.00311 0.33 0.23 Schizophrenia; chr15:84594463 chr15:85191438~85213905:+ LIHC cis rs6545883 0.525 rs2049747 ENSG00000271889.1 RP11-493E12.1 -4.44 1.21e-05 0.00311 -0.28 -0.23 Tuberculosis; chr2:61137019 chr2:61151433~61162105:- LIHC cis rs2749097 0.825 rs6670731 ENSG00000244256.3 RN7SL130P -4.44 1.21e-05 0.00311 -0.28 -0.23 Alcohol consumption (transferrin glycosylation); chr1:63657487 chr1:63655743~63656047:+ LIHC cis rs4650994 0.524 rs2761465 ENSG00000273384.1 RP5-1098D14.1 -4.44 1.21e-05 0.00311 -0.29 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178610269 chr1:178651706~178652282:+ LIHC cis rs10256972 0.524 rs6945202 ENSG00000199023.2 MIR339 -4.44 1.21e-05 0.00312 -0.27 -0.23 Endometriosis;Longevity; chr7:1076922 chr7:1022935~1023045:- LIHC cis rs11098499 0.754 rs1849457 ENSG00000260091.1 RP11-33B1.4 -4.44 1.21e-05 0.00312 -0.17 -0.23 Corneal astigmatism; chr4:119333200 chr4:119409333~119410233:+ LIHC cis rs7945705 0.902 rs2568059 ENSG00000254860.4 TMEM9B-AS1 4.44 1.21e-05 0.00312 0.23 0.23 Hemoglobin concentration; chr11:8862614 chr11:8964675~8977527:+ LIHC cis rs7945705 0.875 rs2653616 ENSG00000254860.4 TMEM9B-AS1 4.44 1.21e-05 0.00312 0.23 0.23 Hemoglobin concentration; chr11:8864345 chr11:8964675~8977527:+ LIHC cis rs7945705 0.935 rs2568061 ENSG00000254860.4 TMEM9B-AS1 4.44 1.21e-05 0.00312 0.23 0.23 Hemoglobin concentration; chr11:8864713 chr11:8964675~8977527:+ LIHC cis rs12554020 0.686 rs12553775 ENSG00000227603.1 RP11-165J3.6 4.44 1.21e-05 0.00312 0.42 0.23 Schizophrenia; chr9:93630107 chr9:93435332~93437121:- LIHC cis rs7508 0.511 rs438818 ENSG00000253671.1 RP11-806O11.1 -4.44 1.21e-05 0.00313 -0.28 -0.23 Atrial fibrillation; chr8:18042052 chr8:17808941~17820868:+ LIHC cis rs1865760 0.622 rs9295685 ENSG00000216436.2 HIST1H2APS1 -4.44 1.21e-05 0.00313 -0.27 -0.23 Height; chr6:26071497 chr6:25732497~25732827:+ LIHC cis rs2688482 0.557 rs3103952 ENSG00000207650.1 MIR570 4.44 1.21e-05 0.00313 0.3 0.23 Lung disease severity in cystic fibrosis; chr3:195795819 chr3:195699401~195699497:+ LIHC cis rs2739330 0.76 rs5751761 ENSG00000099984.9 GSTT2 4.44 1.21e-05 0.00313 0.28 0.23 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23980123~23983911:+ LIHC cis rs17711722 0.522 rs62469933 ENSG00000226002.1 RP11-460N20.5 4.44 1.21e-05 0.00313 0.25 0.23 Calcium levels; chr7:65800652 chr7:65084103~65100232:+ LIHC cis rs11096990 0.634 rs60016848 ENSG00000249685.1 RP11-360F5.3 -4.44 1.21e-05 0.00313 -0.28 -0.23 Cognitive function; chr4:39281436 chr4:39133913~39135608:+ LIHC cis rs11096990 0.577 rs6830736 ENSG00000249685.1 RP11-360F5.3 -4.44 1.21e-05 0.00313 -0.28 -0.23 Cognitive function; chr4:39281467 chr4:39133913~39135608:+ LIHC cis rs11096990 0.634 rs6854358 ENSG00000249685.1 RP11-360F5.3 -4.44 1.21e-05 0.00313 -0.28 -0.23 Cognitive function; chr4:39281492 chr4:39133913~39135608:+ LIHC cis rs9675120 0.638 rs8079519 ENSG00000262006.1 RP11-700H6.4 -4.44 1.21e-05 0.00313 -0.26 -0.23 Cerebrospinal fluid biomarker levels; chr17:50855456 chr17:50909637~50910232:- LIHC cis rs9675120 0.638 rs9910819 ENSG00000262006.1 RP11-700H6.4 -4.44 1.21e-05 0.00313 -0.26 -0.23 Cerebrospinal fluid biomarker levels; chr17:50855845 chr17:50909637~50910232:- LIHC cis rs1062177 1 rs12654573 ENSG00000253921.1 CTB-113P19.3 -4.44 1.21e-05 0.00313 -0.27 -0.23 Preschool internalizing problems; chr5:151827912 chr5:151753992~151767247:+ LIHC cis rs950169 1 rs11638297 ENSG00000259728.4 LINC00933 4.44 1.22e-05 0.00314 0.36 0.23 Schizophrenia; chr15:84113665 chr15:84570649~84580175:+ LIHC cis rs2337406 1 rs11850600 ENSG00000274576.2 IGHV2-70 -4.44 1.22e-05 0.00314 -0.27 -0.23 Alzheimer's disease (late onset); chr14:106670765 chr14:106770577~106771020:- LIHC cis rs901683 0.85 rs73291121 ENSG00000230869.1 CTGLF10P -4.44 1.22e-05 0.00314 -0.56 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45601956 chr10:45678692~45700532:+ LIHC cis rs748404 0.578 rs478028 ENSG00000205771.5 CATSPER2P1 -4.44 1.22e-05 0.00314 -0.28 -0.23 Lung cancer; chr15:43318574 chr15:43726918~43747094:- LIHC cis rs748404 0.578 rs552701 ENSG00000205771.5 CATSPER2P1 -4.44 1.22e-05 0.00314 -0.28 -0.23 Lung cancer; chr15:43321612 chr15:43726918~43747094:- LIHC cis rs748404 0.578 rs573615 ENSG00000205771.5 CATSPER2P1 -4.44 1.22e-05 0.00314 -0.28 -0.23 Lung cancer; chr15:43322083 chr15:43726918~43747094:- LIHC cis rs79349575 0.783 rs4399576 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48932473 chr17:48874860~48908983:- LIHC cis rs79349575 0.687 rs12602179 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48932672 chr17:48874860~48908983:- LIHC cis rs875971 0.545 rs11767262 ENSG00000273142.1 RP11-458F8.4 4.44 1.22e-05 0.00315 0.22 0.23 Aortic root size; chr7:66302237 chr7:66902857~66906297:+ LIHC cis rs11089937 0.857 rs5750580 ENSG00000211639.2 IGLV4-60 4.44 1.22e-05 0.00315 0.23 0.23 Periodontitis (PAL4Q3); chr22:22137471 chr22:22162199~22162681:+ LIHC cis rs763121 0.853 rs10135 ENSG00000273076.1 RP3-508I15.22 -4.44 1.22e-05 0.00315 -0.26 -0.23 Menopause (age at onset); chr22:38686169 chr22:38743495~38743910:+ LIHC cis rs763121 0.785 rs5750646 ENSG00000273076.1 RP3-508I15.22 4.44 1.22e-05 0.00315 0.26 0.23 Menopause (age at onset); chr22:38617825 chr22:38743495~38743910:+ LIHC cis rs10129255 0.957 rs10136560 ENSG00000211970.3 IGHV4-61 -4.44 1.22e-05 0.00315 -0.19 -0.23 Kawasaki disease; chr14:106787630 chr14:106639119~106639657:- LIHC cis rs1075232 1 rs72722861 ENSG00000270055.1 CTD-3092A11.2 -4.44 1.22e-05 0.00315 -0.46 -0.23 Survival in colorectal cancer (non-distant metastatic); chr15:31412085 chr15:30487963~30490313:+ LIHC cis rs1075232 0.826 rs12438813 ENSG00000270055.1 CTD-3092A11.2 -4.44 1.22e-05 0.00315 -0.46 -0.23 Survival in colorectal cancer (non-distant metastatic); chr15:31413710 chr15:30487963~30490313:+ LIHC cis rs1075232 1 rs34959140 ENSG00000270055.1 CTD-3092A11.2 -4.44 1.22e-05 0.00315 -0.46 -0.23 Survival in colorectal cancer (non-distant metastatic); chr15:31433020 chr15:30487963~30490313:+ LIHC cis rs79349575 0.749 rs46521 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48911167 chr17:48874860~48908983:- LIHC cis rs79349575 0.749 rs318093 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48911992 chr17:48874860~48908983:- LIHC cis rs79349575 0.745 rs170319 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48914169 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs318090 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48914390 chr17:48874860~48908983:- LIHC cis rs79349575 0.721 rs3744608 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48915871 chr17:48874860~48908983:- LIHC cis rs79349575 0.651 rs4378658 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48916008 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs12453374 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48917484 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs12453394 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48917608 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs62075838 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48919070 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs62075839 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48919072 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs4255820 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48919221 chr17:48874860~48908983:- LIHC cis rs79349575 0.811 rs12601072 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48920636 chr17:48874860~48908983:- LIHC cis rs79349575 0.749 rs58838744 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48921540 chr17:48874860~48908983:- LIHC cis rs79349575 0.811 rs60708039 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48922011 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs55771415 ENSG00000248278.1 SUMO2P17 4.44 1.22e-05 0.00315 0.29 0.23 Type 2 diabetes; chr17:48922575 chr17:48874860~48908983:- LIHC cis rs77204473 0.744 rs2269399 ENSG00000254851.1 RP11-109L13.1 4.44 1.22e-05 0.00315 0.42 0.23 Sum eosinophil basophil counts;Eosinophil counts; chr11:117195637 chr11:117135528~117138582:+ LIHC cis rs9326248 0.501 rs4938351 ENSG00000236267.1 AP006216.5 4.44 1.22e-05 0.00315 0.24 0.23 Blood protein levels; chr11:117151636 chr11:116813204~116814003:- LIHC cis rs9834975 0.967 rs9823467 ENSG00000272758.4 RP11-299J3.8 -4.44 1.22e-05 0.00315 -0.26 -0.23 Diastolic blood pressure; chr3:122403245 chr3:122416207~122443180:+ LIHC cis rs4650994 0.524 rs1998544 ENSG00000273384.1 RP5-1098D14.1 -4.44 1.23e-05 0.00316 -0.29 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178636141 chr1:178651706~178652282:+ LIHC cis rs2274273 0.773 rs10147765 ENSG00000258413.1 RP11-665C16.6 -4.44 1.23e-05 0.00316 -0.28 -0.23 Protein biomarker; chr14:55361108 chr14:55262767~55272075:- LIHC cis rs6600671 0.899 rs2319971 ENSG00000227082.1 CH17-437K3.1 -4.44 1.23e-05 0.00316 -0.31 -0.23 Hip geometry; chr1:121485184 chr1:121396754~121463129:+ LIHC cis rs10829156 0.699 rs7911922 ENSG00000240291.1 RP11-499P20.2 4.44 1.23e-05 0.00316 0.35 0.23 Sudden cardiac arrest; chr10:18542768 chr10:18513115~18545651:- LIHC cis rs7809950 0.954 rs2520241 ENSG00000238832.1 snoU109 -4.44 1.23e-05 0.00316 -0.29 -0.23 Coronary artery disease; chr7:107494998 chr7:107603363~107603507:+ LIHC cis rs7809950 0.954 rs2520242 ENSG00000238832.1 snoU109 4.44 1.23e-05 0.00316 0.29 0.23 Coronary artery disease; chr7:107495875 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs17154077 ENSG00000238832.1 snoU109 4.44 1.23e-05 0.00316 0.28 0.23 Coronary artery disease; chr7:107437496 chr7:107603363~107603507:+ LIHC cis rs2739330 0.828 rs5751770 ENSG00000206090.4 AP000350.7 4.44 1.23e-05 0.00316 0.27 0.23 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23939998~23942798:+ LIHC cis rs875971 0.545 rs2707851 ENSG00000273142.1 RP11-458F8.4 -4.44 1.23e-05 0.00317 -0.22 -0.23 Aortic root size; chr7:66624178 chr7:66902857~66906297:+ LIHC cis rs7811142 1 rs1000215 ENSG00000242294.5 STAG3L5P 4.44 1.23e-05 0.00317 0.25 0.23 Platelet count; chr7:100406920 chr7:100336079~100351900:+ LIHC cis rs8005677 0.828 rs35085068 ENSG00000279656.1 RP11-298I3.6 4.44 1.23e-05 0.00317 0.26 0.23 Cognitive ability (multi-trait analysis); chr14:22940700 chr14:23023083~23024217:- LIHC cis rs8005677 0.828 rs57822749 ENSG00000279656.1 RP11-298I3.6 4.44 1.23e-05 0.00317 0.26 0.23 Cognitive ability (multi-trait analysis); chr14:22940758 chr14:23023083~23024217:- LIHC cis rs8005677 0.828 rs4981451 ENSG00000279656.1 RP11-298I3.6 4.44 1.23e-05 0.00317 0.26 0.23 Cognitive ability (multi-trait analysis); chr14:22941072 chr14:23023083~23024217:- LIHC cis rs8005677 0.798 rs4536383 ENSG00000279656.1 RP11-298I3.6 4.44 1.23e-05 0.00317 0.26 0.23 Cognitive ability (multi-trait analysis); chr14:22941717 chr14:23023083~23024217:- LIHC cis rs8005677 0.828 rs34584578 ENSG00000279656.1 RP11-298I3.6 4.44 1.23e-05 0.00317 0.26 0.23 Cognitive ability (multi-trait analysis); chr14:22942481 chr14:23023083~23024217:- LIHC cis rs8005677 0.828 rs8016027 ENSG00000279656.1 RP11-298I3.6 4.44 1.23e-05 0.00317 0.26 0.23 Cognitive ability (multi-trait analysis); chr14:22950944 chr14:23023083~23024217:- LIHC cis rs11971779 0.838 rs58074268 ENSG00000273391.1 RP11-634H22.1 4.44 1.23e-05 0.00317 0.21 0.23 Diisocyanate-induced asthma; chr7:139424179 chr7:139359032~139359566:- LIHC cis rs7923609 0.934 rs10822153 ENSG00000232075.1 MRPL35P2 -4.44 1.23e-05 0.00317 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63297053 chr10:63634317~63634827:- LIHC cis rs7546 0.504 rs2075636 ENSG00000267077.1 RP11-127I20.5 -4.44 1.23e-05 0.00317 -0.24 -0.23 Cancer; chr16:4888320 chr16:4795265~4796532:- LIHC cis rs10129255 0.5 rs2027903 ENSG00000223648.3 IGHV3-64 4.44 1.23e-05 0.00317 0.17 0.23 Kawasaki disease; chr14:106807047 chr14:106643132~106658258:- LIHC cis rs3733589 0.744 rs13135351 ENSG00000250413.1 RP11-448G15.1 4.44 1.23e-05 0.00317 0.38 0.23 Renal overload gout; chr4:10031901 chr4:10006482~10009725:+ LIHC cis rs901683 0.571 rs7898761 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45614085 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs77637903 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45614661 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs41301625 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45615591 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs77592696 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45616087 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs74699241 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45616268 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs75205426 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45616583 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs76251295 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45616763 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs77337258 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45617343 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs76974099 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45622334 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs78628569 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45624952 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs77820027 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45627820 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs76608282 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45627863 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs79353548 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45628673 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs112121507 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45628891 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs79180351 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45630238 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs74482366 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45631441 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs76549378 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45632385 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs75085022 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45633821 chr10:45678692~45700532:+ LIHC cis rs901683 0.571 rs77407875 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45634138 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs113009703 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45634407 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs77820794 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45634720 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs76612219 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45635258 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs79180736 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45637045 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs74895607 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45638171 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs78230012 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45638760 chr10:45678692~45700532:+ LIHC cis rs901683 0.571 rs79050563 ENSG00000230869.1 CTGLF10P -4.44 1.23e-05 0.00317 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45639532 chr10:45678692~45700532:+ LIHC cis rs950169 0.656 rs748455 ENSG00000259295.5 CSPG4P12 4.44 1.23e-05 0.00317 0.33 0.23 Schizophrenia; chr15:84606344 chr15:85191438~85213905:+ LIHC cis rs62388641 0.813 rs55821127 ENSG00000272279.1 RP11-157J24.2 4.44 1.23e-05 0.00317 0.47 0.23 Daytime sleep phenotypes; chr6:1550635 chr6:1528364~1528911:- LIHC cis rs62388641 0.813 rs62390562 ENSG00000272279.1 RP11-157J24.2 4.44 1.23e-05 0.00317 0.47 0.23 Daytime sleep phenotypes; chr6:1551467 chr6:1528364~1528911:- LIHC cis rs62388641 0.813 rs34114087 ENSG00000272279.1 RP11-157J24.2 4.44 1.23e-05 0.00317 0.47 0.23 Daytime sleep phenotypes; chr6:1553203 chr6:1528364~1528911:- LIHC cis rs11098499 0.908 rs28559989 ENSG00000260091.1 RP11-33B1.4 -4.44 1.23e-05 0.00318 -0.17 -0.23 Corneal astigmatism; chr4:119465472 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs28632018 ENSG00000260091.1 RP11-33B1.4 -4.44 1.23e-05 0.00318 -0.17 -0.23 Corneal astigmatism; chr4:119465575 chr4:119409333~119410233:+ LIHC cis rs4718428 0.576 rs12698546 ENSG00000230295.1 RP11-458F8.2 -4.44 1.23e-05 0.00318 -0.2 -0.23 Corneal structure; chr7:66801919 chr7:66880708~66882981:+ LIHC cis rs8064024 0.676 rs2075467 ENSG00000267077.1 RP11-127I20.5 -4.44 1.24e-05 0.00318 -0.23 -0.23 Cancer; chr16:4823241 chr16:4795265~4796532:- LIHC cis rs12744310 0.526 rs11209858 ENSG00000235358.1 RP11-399E6.1 -4.44 1.24e-05 0.00318 -0.3 -0.23 Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability; chr1:41316522 chr1:41242373~41284861:+ LIHC cis rs7429990 0.864 rs13063042 ENSG00000229759.1 MRPS18AP1 -4.44 1.24e-05 0.00318 -0.24 -0.23 Educational attainment (years of education); chr3:47683825 chr3:48256350~48256938:- LIHC cis rs17711722 0.522 rs6957759 ENSG00000226002.1 RP11-460N20.5 4.44 1.24e-05 0.00318 0.25 0.23 Calcium levels; chr7:65806798 chr7:65084103~65100232:+ LIHC cis rs643506 0.845 rs2850245 ENSG00000254990.4 RP11-108O10.2 4.44 1.24e-05 0.00318 0.25 0.23 Breast cancer; chr11:111890014 chr11:111768668~111778350:- LIHC cis rs16917919 0.688 rs11007642 ENSG00000225527.1 RP11-383B4.4 -4.44 1.24e-05 0.00318 -0.32 -0.23 Brain structure (hippocampal volume); chr10:18915313 chr10:18531849~18533336:- LIHC cis rs6997458 0.785 rs6996345 ENSG00000253549.4 RP11-317J10.2 4.44 1.24e-05 0.00318 0.26 0.23 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85418846 chr8:85441851~85464915:- LIHC cis rs6997458 0.774 rs6984619 ENSG00000253549.4 RP11-317J10.2 4.44 1.24e-05 0.00318 0.26 0.23 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85419149 chr8:85441851~85464915:- LIHC cis rs734999 0.545 rs7368105 ENSG00000225931.3 RP3-395M20.7 4.44 1.24e-05 0.00318 0.25 0.23 Ulcerative colitis; chr1:2625109 chr1:2566410~2569888:+ LIHC cis rs734999 0.545 rs7364820 ENSG00000225931.3 RP3-395M20.7 4.44 1.24e-05 0.00318 0.25 0.23 Ulcerative colitis; chr1:2625270 chr1:2566410~2569888:+ LIHC cis rs1062753 0.527 rs62240998 ENSG00000237037.8 NDUFA6-AS1 -4.44 1.24e-05 0.00319 -0.33 -0.23 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41958697 chr22:42090931~42137742:+ LIHC cis rs9992667 0.911 rs12332031 ENSG00000231160.8 KLF3-AS1 4.44 1.24e-05 0.00319 0.32 0.23 Eosinophil percentage of granulocytes; chr4:38651881 chr4:38612701~38664883:- LIHC cis rs734999 0.588 rs6668149 ENSG00000225931.3 RP3-395M20.7 -4.44 1.24e-05 0.00319 -0.25 -0.23 Ulcerative colitis; chr1:2626869 chr1:2566410~2569888:+ LIHC cis rs2060793 0.519 rs1403247 ENSG00000251991.1 RNU7-49P -4.44 1.24e-05 0.00319 -0.26 -0.23 Vitamin D levels; chr11:14611024 chr11:14478892~14478953:+ LIHC cis rs11971779 0.648 rs59791374 ENSG00000273391.1 RP11-634H22.1 4.44 1.24e-05 0.00319 0.21 0.23 Diisocyanate-induced asthma; chr7:139432216 chr7:139359032~139359566:- LIHC cis rs11971779 0.59 rs59602547 ENSG00000273391.1 RP11-634H22.1 4.44 1.24e-05 0.00319 0.21 0.23 Diisocyanate-induced asthma; chr7:139432277 chr7:139359032~139359566:- LIHC cis rs5758511 0.514 rs5751240 ENSG00000205702.9 CYP2D7 4.44 1.24e-05 0.00319 0.28 0.23 Birth weight; chr22:42199252 chr22:42140203~42144577:- LIHC cis rs61160187 0.527 rs6449500 ENSG00000272308.1 RP11-231G3.1 -4.44 1.24e-05 0.00319 -0.28 -0.23 Educational attainment (years of education);Educational attainment (college completion); chr5:60788076 chr5:60866457~60866935:- LIHC cis rs748404 0.697 rs555001 ENSG00000166763.7 STRCP1 4.43 1.24e-05 0.00319 0.29 0.23 Lung cancer; chr15:43253530 chr15:43699488~43718184:- LIHC cis rs17818399 0.781 rs4952837 ENSG00000279254.1 RP11-536C12.1 -4.43 1.24e-05 0.0032 -0.29 -0.23 Height; chr2:46638595 chr2:46668870~46670778:+ LIHC cis rs17818399 0.781 rs6746598 ENSG00000279254.1 RP11-536C12.1 -4.43 1.24e-05 0.0032 -0.29 -0.23 Height; chr2:46638634 chr2:46668870~46670778:+ LIHC cis rs7709377 0.516 rs73257302 ENSG00000271918.1 CTD-2287O16.5 4.43 1.24e-05 0.0032 0.28 0.23 Metabolite levels (X-11787); chr5:116207391 chr5:116083807~116085416:- LIHC cis rs17711722 0.565 rs73372653 ENSG00000273024.4 INTS4P2 -4.43 1.24e-05 0.0032 -0.25 -0.23 Calcium levels; chr7:65977808 chr7:65647864~65715661:+ LIHC cis rs62355901 0.739 rs61055995 ENSG00000271828.1 CTD-2310F14.1 4.43 1.25e-05 0.0032 0.36 0.23 Breast cancer; chr5:56723237 chr5:56927874~56929573:+ LIHC cis rs889312 0.532 rs16886165 ENSG00000271828.1 CTD-2310F14.1 4.43 1.25e-05 0.0032 0.36 0.23 Breast cancer (early onset);Breast cancer; chr5:56727256 chr5:56927874~56929573:+ LIHC cis rs2735413 0.56 rs73562716 ENSG00000276007.1 RP11-358L22.3 4.43 1.25e-05 0.0032 0.29 0.23 Systolic blood pressure (alcohol consumption interaction); chr16:78092518 chr16:78123243~78124332:+ LIHC cis rs11603023 0.967 rs644273 ENSG00000255422.1 AP002954.4 4.43 1.25e-05 0.0032 0.26 0.23 Cholesterol, total; chr11:118640634 chr11:118704607~118750263:+ LIHC cis rs11603023 0.967 rs654423 ENSG00000255422.1 AP002954.4 4.43 1.25e-05 0.0032 0.26 0.23 Cholesterol, total; chr11:118641039 chr11:118704607~118750263:+ LIHC cis rs11951515 0.508 rs7705166 ENSG00000248240.1 RP11-159F24.5 -4.43 1.25e-05 0.00321 -0.29 -0.23 Metabolite levels (X-11787); chr5:43587346 chr5:43515274~43525310:+ LIHC cis rs7216064 0.589 rs8072723 ENSG00000278740.1 RP11-147L13.14 -4.43 1.25e-05 0.00321 -0.28 -0.23 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68060854 chr17:68188547~68189165:+ LIHC cis rs860295 0.775 rs1749410 ENSG00000203761.5 MSTO2P 4.43 1.25e-05 0.00321 0.2 0.23 Body mass index; chr1:155874274 chr1:155745829~155750137:+ LIHC cis rs1075232 1 rs12438318 ENSG00000270055.1 CTD-3092A11.2 -4.43 1.25e-05 0.00321 -0.46 -0.23 Survival in colorectal cancer (non-distant metastatic); chr15:31388242 chr15:30487963~30490313:+ LIHC cis rs7809950 0.678 rs17153981 ENSG00000238832.1 snoU109 -4.43 1.25e-05 0.00321 -0.3 -0.23 Coronary artery disease; chr7:107281661 chr7:107603363~107603507:+ LIHC cis rs2836974 0.863 rs12483216 ENSG00000255568.3 BRWD1-AS2 4.43 1.25e-05 0.00321 0.26 0.23 Cognitive function; chr21:39167688 chr21:39313935~39314962:+ LIHC cis rs7568498 0.517 rs197261 ENSG00000227403.1 AC009299.3 4.43 1.25e-05 0.00321 0.3 0.23 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161048312 chr2:161244739~161249050:+ LIHC cis rs2842992 0.747 rs9365095 ENSG00000237927.1 RP3-393E18.2 -4.43 1.25e-05 0.00322 -0.28 -0.23 Age-related macular degeneration (geographic atrophy); chr6:159771896 chr6:159586955~159589169:- LIHC cis rs2842992 0.789 rs7758895 ENSG00000237927.1 RP3-393E18.2 -4.43 1.25e-05 0.00322 -0.28 -0.23 Age-related macular degeneration (geographic atrophy); chr6:159772433 chr6:159586955~159589169:- LIHC cis rs2842992 0.789 rs4276525 ENSG00000237927.1 RP3-393E18.2 -4.43 1.25e-05 0.00322 -0.28 -0.23 Age-related macular degeneration (geographic atrophy); chr6:159772580 chr6:159586955~159589169:- LIHC cis rs728616 0.867 rs61859022 ENSG00000225484.5 NUTM2B-AS1 -4.43 1.25e-05 0.00322 -0.52 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80101043 chr10:79663088~79826594:- LIHC cis rs763512 0.504 rs853216 ENSG00000276054.1 RP11-378E13.3 4.43 1.25e-05 0.00322 0.3 0.23 3-hydroxypropylmercapturic acid levels in smokers; chr17:37502902 chr17:37386886~37387926:+ LIHC cis rs7412746 0.524 rs58304714 ENSG00000231073.1 RP11-316M1.3 4.43 1.25e-05 0.00322 0.24 0.23 Melanoma; chr1:150859085 chr1:150973123~150975534:+ LIHC cis rs4356975 0.932 rs7657426 ENSG00000250919.1 RP11-813N20.3 -4.43 1.25e-05 0.00322 -0.23 -0.23 Obesity-related traits; chr4:69079291 chr4:69027831~69044578:+ LIHC cis rs1577917 0.958 rs11755048 ENSG00000234155.1 RP11-30P6.6 4.43 1.25e-05 0.00322 0.32 0.23 Response to antipsychotic treatment; chr6:85804616 chr6:85387219~85390186:- LIHC cis rs172166 0.694 rs203877 ENSG00000219392.1 RP1-265C24.5 -4.43 1.25e-05 0.00322 -0.31 -0.23 Cardiac Troponin-T levels; chr6:28080846 chr6:28115628~28116551:+ LIHC cis rs7208859 0.623 rs383436 ENSG00000266490.1 CTD-2349P21.9 4.43 1.25e-05 0.00322 0.3 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30632161 chr17:30792372~30792833:+ LIHC cis rs9388451 0.626 rs1935983 ENSG00000237742.5 RP11-624M8.1 -4.43 1.26e-05 0.00322 -0.22 -0.23 Brugada syndrome; chr6:125747768 chr6:125578558~125749190:- LIHC cis rs9388451 0.626 rs1343116 ENSG00000237742.5 RP11-624M8.1 -4.43 1.26e-05 0.00322 -0.22 -0.23 Brugada syndrome; chr6:125748556 chr6:125578558~125749190:- LIHC cis rs9388451 0.626 rs1343115 ENSG00000237742.5 RP11-624M8.1 -4.43 1.26e-05 0.00322 -0.22 -0.23 Brugada syndrome; chr6:125748671 chr6:125578558~125749190:- LIHC cis rs9388451 0.626 rs2875881 ENSG00000237742.5 RP11-624M8.1 -4.43 1.26e-05 0.00322 -0.22 -0.23 Brugada syndrome; chr6:125751707 chr6:125578558~125749190:- LIHC cis rs748404 0.578 rs507178 ENSG00000205771.5 CATSPER2P1 -4.43 1.26e-05 0.00322 -0.28 -0.23 Lung cancer; chr15:43317937 chr15:43726918~43747094:- LIHC cis rs875971 0.522 rs4502988 ENSG00000224316.1 RP11-479O9.2 4.43 1.26e-05 0.00323 0.24 0.23 Aortic root size; chr7:65832759 chr7:65773620~65802067:+ LIHC cis rs875971 0.522 rs2008188 ENSG00000224316.1 RP11-479O9.2 4.43 1.26e-05 0.00323 0.24 0.23 Aortic root size; chr7:65964026 chr7:65773620~65802067:+ LIHC cis rs734999 0.588 rs876938 ENSG00000225931.3 RP3-395M20.7 4.43 1.26e-05 0.00323 0.25 0.23 Ulcerative colitis; chr1:2591773 chr1:2566410~2569888:+ LIHC cis rs734999 0.588 rs745368 ENSG00000225931.3 RP3-395M20.7 4.43 1.26e-05 0.00323 0.25 0.23 Ulcerative colitis; chr1:2592766 chr1:2566410~2569888:+ LIHC cis rs734999 0.566 rs10752747 ENSG00000225931.3 RP3-395M20.7 4.43 1.26e-05 0.00323 0.25 0.23 Ulcerative colitis; chr1:2593476 chr1:2566410~2569888:+ LIHC cis rs11676348 0.751 rs6715591 ENSG00000261338.2 RP11-378A13.1 -4.43 1.26e-05 0.00323 -0.26 -0.23 Ulcerative colitis; chr2:218155148 chr2:218255319~218257366:+ LIHC cis rs921968 0.565 rs7603709 ENSG00000272555.1 RP11-459I19.1 -4.43 1.26e-05 0.00323 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218777878 chr2:218818690~218819144:+ LIHC cis rs2284219 0.929 rs12533248 ENSG00000196295.10 AC005154.6 -4.43 1.26e-05 0.00323 -0.17 -0.23 Type 2 diabetes; chr7:30678973 chr7:30516309~30594809:- LIHC cis rs73086581 0.645 rs2103659 ENSG00000229539.1 RP11-119B16.2 -4.43 1.26e-05 0.00323 -0.25 -0.23 Response to antidepressants in depression; chr20:4001925 chr20:3888239~3888868:- LIHC cis rs7208859 0.673 rs11656845 ENSG00000266490.1 CTD-2349P21.9 4.43 1.26e-05 0.00323 0.3 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30879146 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11657662 ENSG00000266490.1 CTD-2349P21.9 -4.43 1.26e-05 0.00323 -0.29 -0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749329 chr17:30792372~30792833:+ LIHC cis rs875971 0.545 rs4718325 ENSG00000228409.4 CCT6P1 -4.43 1.26e-05 0.00324 -0.19 -0.23 Aortic root size; chr7:66215323 chr7:65751142~65763354:+ LIHC cis rs9675120 0.747 rs4366750 ENSG00000262006.1 RP11-700H6.4 -4.43 1.26e-05 0.00324 -0.25 -0.23 Cerebrospinal fluid biomarker levels; chr17:50843073 chr17:50909637~50910232:- LIHC cis rs9675120 0.747 rs4306561 ENSG00000262006.1 RP11-700H6.4 -4.43 1.26e-05 0.00324 -0.25 -0.23 Cerebrospinal fluid biomarker levels; chr17:50843194 chr17:50909637~50910232:- LIHC cis rs2337406 0.925 rs873534 ENSG00000274576.2 IGHV2-70 -4.43 1.26e-05 0.00324 -0.27 -0.23 Alzheimer's disease (late onset); chr14:106667423 chr14:106770577~106771020:- LIHC cis rs9532669 0.89 rs2324738 ENSG00000168852.11 TPTE2P5 4.43 1.26e-05 0.00324 0.25 0.23 Cervical cancer; chr13:40925242 chr13:40822296~40921749:- LIHC cis rs9532669 0.963 rs2324739 ENSG00000168852.11 TPTE2P5 4.43 1.26e-05 0.00324 0.25 0.23 Cervical cancer; chr13:40925479 chr13:40822296~40921749:- LIHC cis rs42490 0.528 rs7004089 ENSG00000251136.7 RP11-37B2.1 4.43 1.26e-05 0.00324 0.2 0.23 Leprosy; chr8:89688329 chr8:89609409~89757727:- LIHC cis rs4578769 0.765 rs998184 ENSG00000266850.1 RP11-370A5.1 -4.43 1.26e-05 0.00324 -0.28 -0.23 Eosinophil percentage of white cells; chr18:22925006 chr18:22723491~22907721:- LIHC cis rs4578769 0.765 rs4800440 ENSG00000266850.1 RP11-370A5.1 -4.43 1.26e-05 0.00324 -0.28 -0.23 Eosinophil percentage of white cells; chr18:22928158 chr18:22723491~22907721:- LIHC cis rs17711722 0.523 rs313812 ENSG00000226002.1 RP11-460N20.5 -4.43 1.26e-05 0.00324 -0.24 -0.23 Calcium levels; chr7:66040056 chr7:65084103~65100232:+ LIHC cis rs1223397 1 rs1223402 ENSG00000215022.6 RP1-257A7.4 -4.43 1.26e-05 0.00324 -0.27 -0.23 Blood pressure; chr6:13271408 chr6:13264861~13295586:- LIHC cis rs7208859 0.673 rs11657270 ENSG00000266490.1 CTD-2349P21.9 4.43 1.26e-05 0.00324 0.3 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887369 chr17:30792372~30792833:+ LIHC cis rs17301013 0.932 rs1754349 ENSG00000227373.4 RP11-160H22.5 -4.43 1.26e-05 0.00324 -0.28 -0.23 Systemic lupus erythematosus; chr1:174837663 chr1:174115300~174160004:- LIHC cis rs2929278 0.561 rs3099045 ENSG00000275601.1 AC011330.13 -4.43 1.26e-05 0.00324 -0.29 -0.23 Schizophrenia; chr15:43631757 chr15:43642389~43643023:- LIHC cis rs2726040 0.902 rs33957528 ENSG00000259982.1 CDC37P1 -4.43 1.26e-05 0.00324 -0.25 -0.23 Hip circumference; chr16:28296619 chr16:28700294~28701540:- LIHC cis rs2439831 0.85 rs3742982 ENSG00000166763.7 STRCP1 4.43 1.26e-05 0.00324 0.36 0.23 Lung cancer in ever smokers; chr15:43884483 chr15:43699488~43718184:- LIHC cis rs7246657 0.943 rs4801803 ENSG00000276846.1 CTD-3220F14.3 -4.43 1.26e-05 0.00324 -0.3 -0.23 Coronary artery calcification; chr19:37476021 chr19:37314868~37315620:- LIHC cis rs2948294 0.545 rs11776397 ENSG00000173295.6 FAM86B3P 4.43 1.27e-05 0.00325 0.29 0.23 Red cell distribution width; chr8:8257639 chr8:8228595~8244865:+ LIHC cis rs1160985 0.967 rs741780 ENSG00000214855.8 APOC1P1 -4.43 1.27e-05 0.00325 -0.28 -0.23 C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels; chr19:44901174 chr19:44926804~44931386:+ LIHC cis rs11216126 1 rs11216126 ENSG00000254851.1 RP11-109L13.1 4.43 1.27e-05 0.00325 0.33 0.23 HDL cholesterol; chr11:116746524 chr11:117135528~117138582:+ LIHC cis rs2439831 0.867 rs2927072 ENSG00000166763.7 STRCP1 4.43 1.27e-05 0.00325 0.36 0.23 Lung cancer in ever smokers; chr15:43630200 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs2920781 ENSG00000166763.7 STRCP1 4.43 1.27e-05 0.00325 0.36 0.23 Lung cancer in ever smokers; chr15:43632484 chr15:43699488~43718184:- LIHC cis rs2439831 0.764 rs2447193 ENSG00000166763.7 STRCP1 4.43 1.27e-05 0.00325 0.36 0.23 Lung cancer in ever smokers; chr15:43637535 chr15:43699488~43718184:- LIHC cis rs651907 0.557 rs11712748 ENSG00000244119.1 PDCL3P4 4.43 1.27e-05 0.00325 0.24 0.23 Colorectal cancer; chr3:101664718 chr3:101712472~101713191:+ LIHC cis rs651907 0.557 rs7651406 ENSG00000244119.1 PDCL3P4 4.43 1.27e-05 0.00325 0.24 0.23 Colorectal cancer; chr3:101674452 chr3:101712472~101713191:+ LIHC cis rs875971 0.545 rs6950988 ENSG00000273142.1 RP11-458F8.4 4.43 1.27e-05 0.00325 0.22 0.23 Aortic root size; chr7:66511428 chr7:66902857~66906297:+ LIHC cis rs4834770 1 rs6823963 ENSG00000245958.5 RP11-33B1.1 -4.43 1.27e-05 0.00325 -0.22 -0.23 Blood protein levels; chr4:119321009 chr4:119454791~119552025:+ LIHC cis rs4834770 1 rs4834771 ENSG00000245958.5 RP11-33B1.1 -4.43 1.27e-05 0.00325 -0.22 -0.23 Blood protein levels; chr4:119321617 chr4:119454791~119552025:+ LIHC cis rs4834770 1 rs1397613 ENSG00000245958.5 RP11-33B1.1 -4.43 1.27e-05 0.00325 -0.22 -0.23 Blood protein levels; chr4:119321774 chr4:119454791~119552025:+ LIHC cis rs4834770 1 rs6857641 ENSG00000245958.5 RP11-33B1.1 -4.43 1.27e-05 0.00325 -0.22 -0.23 Blood protein levels; chr4:119322356 chr4:119454791~119552025:+ LIHC cis rs4834770 1 rs2282688 ENSG00000245958.5 RP11-33B1.1 -4.43 1.27e-05 0.00325 -0.22 -0.23 Blood protein levels; chr4:119322567 chr4:119454791~119552025:+ LIHC cis rs2439831 0.867 rs2470134 ENSG00000275601.1 AC011330.13 4.43 1.27e-05 0.00325 0.34 0.23 Lung cancer in ever smokers; chr15:43557688 chr15:43642389~43643023:- LIHC cis rs13083990 0.919 rs13095172 ENSG00000272758.4 RP11-299J3.8 4.43 1.27e-05 0.00325 0.25 0.23 Cardiac Troponin-T levels; chr3:122271410 chr3:122416207~122443180:+ LIHC cis rs1165668 0.755 rs10735390 ENSG00000257327.1 RP11-650K20.3 4.43 1.27e-05 0.00325 0.27 0.23 Coronary heart disease (SNP X SNP interaction); chr12:103917953 chr12:103841451~103844664:+ LIHC cis rs3733589 0.744 rs59234705 ENSG00000250413.1 RP11-448G15.1 4.43 1.27e-05 0.00325 0.37 0.23 Renal overload gout; chr4:10025121 chr4:10006482~10009725:+ LIHC cis rs755249 1 rs4660293 ENSG00000182109.6 RP11-69E11.4 -4.43 1.27e-05 0.00325 -0.31 -0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39562508 chr1:39522280~39546187:- LIHC cis rs7809950 1 rs2395883 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107449225 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs4727681 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107455699 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs7782057 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107458432 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs67982599 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107459659 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs28714607 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107465808 chr7:107603363~107603507:+ LIHC cis rs7809950 0.953 rs28687365 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107466267 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs3801954 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107476603 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs10251808 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107480008 chr7:107603363~107603507:+ LIHC cis rs7809950 0.954 rs2712193 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107485440 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2520277 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107489789 chr7:107603363~107603507:+ LIHC cis rs7809950 0.953 rs2237670 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107491040 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2237672 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107491118 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2237673 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107491135 chr7:107603363~107603507:+ LIHC cis rs7809950 0.911 rs1015411 ENSG00000238832.1 snoU109 -4.43 1.27e-05 0.00325 -0.28 -0.23 Coronary artery disease; chr7:107495167 chr7:107603363~107603507:+ LIHC cis rs7208859 0.673 rs9903862 ENSG00000266490.1 CTD-2349P21.9 4.43 1.27e-05 0.00325 0.31 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30879415 chr17:30792372~30792833:+ LIHC cis rs2348418 0.701 rs1463570 ENSG00000247934.4 RP11-967K21.1 -4.43 1.27e-05 0.00325 -0.21 -0.23 Lung function (FEV1);Lung function (FVC); chr12:28156095 chr12:28163298~28190738:- LIHC cis rs6569038 0.557 rs9374777 ENSG00000253194.1 RP11-351A11.1 -4.43 1.27e-05 0.00326 -0.31 -0.23 Epstein-Barr virus copy number in lymphoblastoid cell lines; chr6:119056334 chr6:118934785~119031541:+ LIHC cis rs6439153 0.933 rs7648877 ENSG00000231305.3 RP11-723O4.2 4.43 1.27e-05 0.00326 0.26 0.23 Pneumococcal bacteremia; chr3:128991137 chr3:128861313~128871540:- LIHC cis rs7208859 0.673 rs2433 ENSG00000266490.1 CTD-2349P21.9 4.43 1.27e-05 0.00326 0.3 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30899210 chr17:30792372~30792833:+ LIHC cis rs11951515 0.508 rs6860493 ENSG00000248240.1 RP11-159F24.5 -4.43 1.27e-05 0.00326 -0.29 -0.23 Metabolite levels (X-11787); chr5:43602611 chr5:43515274~43525310:+ LIHC cis rs1030877 0.515 rs3828300 ENSG00000235319.1 AC012360.4 4.43 1.27e-05 0.00326 0.33 0.23 Obesity-related traits; chr2:105284650 chr2:105324210~105330529:+ LIHC cis rs901683 0.571 rs73292811 ENSG00000230869.1 CTGLF10P -4.43 1.27e-05 0.00326 -0.49 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45618673 chr10:45678692~45700532:+ LIHC cis rs73186030 0.92 rs73186057 ENSG00000272758.4 RP11-299J3.8 4.43 1.27e-05 0.00326 0.44 0.23 Serum parathyroid hormone levels; chr3:122325058 chr3:122416207~122443180:+ LIHC cis rs3812762 0.868 rs7934519 ENSG00000254860.4 TMEM9B-AS1 -4.43 1.27e-05 0.00326 -0.25 -0.23 Hypospadias; chr11:8770434 chr11:8964675~8977527:+ LIHC cis rs9487094 0.848 rs1322816 ENSG00000260273.1 RP11-425D10.10 4.43 1.27e-05 0.00326 0.28 0.23 Height; chr6:109382524 chr6:109382795~109383666:+ LIHC cis rs2036707 0.744 rs9555412 ENSG00000277246.1 RP11-153I24.4 -4.43 1.27e-05 0.00326 -0.46 -0.23 Obesity-related traits; chr13:107826853 chr13:108267320~108267734:+ LIHC cis rs12478296 1 rs73007140 ENSG00000261186.2 RP11-341N2.1 -4.43 1.27e-05 0.00326 -0.31 -0.23 Obesity-related traits; chr2:242068605 chr2:242087351~242088457:- LIHC cis rs755249 0.958 rs2068663 ENSG00000182109.6 RP11-69E11.4 4.43 1.27e-05 0.00327 0.32 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39572899 chr1:39522280~39546187:- LIHC cis rs11668505 0.965 rs12463238 ENSG00000259108.2 CTD-3098H1.2 4.43 1.27e-05 0.00327 0.3 0.23 Lung function (FVC); chr19:47842526 chr19:47863483~47865341:- LIHC cis rs11668505 1 rs11666203 ENSG00000259108.2 CTD-3098H1.2 4.43 1.27e-05 0.00327 0.3 0.23 Lung function (FVC); chr19:47842684 chr19:47863483~47865341:- LIHC cis rs6997458 0.742 rs3758076 ENSG00000253549.4 RP11-317J10.2 4.43 1.28e-05 0.00327 0.25 0.23 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85463306 chr8:85441851~85464915:- LIHC cis rs1160985 0.967 rs760136 ENSG00000214855.8 APOC1P1 -4.43 1.28e-05 0.00327 -0.28 -0.23 C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels; chr19:44900601 chr19:44926804~44931386:+ LIHC cis rs6439153 0.743 rs71331685 ENSG00000231305.3 RP11-723O4.2 4.43 1.28e-05 0.00327 0.26 0.23 Pneumococcal bacteremia; chr3:128992582 chr3:128861313~128871540:- LIHC cis rs11690935 0.61 rs59844139 ENSG00000228389.1 AC068039.4 -4.43 1.28e-05 0.00327 -0.28 -0.23 Schizophrenia; chr2:171875473 chr2:171773482~171775844:+ LIHC cis rs9595908 0.655 rs56080053 ENSG00000212293.1 SNORA16 4.43 1.28e-05 0.00328 0.27 0.23 Body mass index; chr13:32720045 chr13:32420390~32420516:- LIHC cis rs929596 0.793 rs2741046 ENSG00000233445.1 RPL17P11 4.43 1.28e-05 0.00329 0.34 0.23 Total bilirubin levels in HIV-1 infection; chr2:233671603 chr2:233721522~233722065:- LIHC cis rs7208859 0.673 rs12103759 ENSG00000266490.1 CTD-2349P21.9 4.43 1.28e-05 0.00329 0.3 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908669 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs59029591 ENSG00000266490.1 CTD-2349P21.9 4.43 1.28e-05 0.00329 0.3 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908728 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs73265633 ENSG00000266490.1 CTD-2349P21.9 4.43 1.28e-05 0.00329 0.3 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30909288 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9913782 ENSG00000266490.1 CTD-2349P21.9 4.43 1.28e-05 0.00329 0.3 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910366 chr17:30792372~30792833:+ LIHC cis rs651907 0.557 rs35850993 ENSG00000244119.1 PDCL3P4 4.43 1.28e-05 0.00329 0.24 0.23 Colorectal cancer; chr3:101718589 chr3:101712472~101713191:+ LIHC cis rs3733585 0.682 rs13124563 ENSG00000250413.1 RP11-448G15.1 -4.43 1.28e-05 0.00329 -0.3 -0.23 Cleft plate (environmental tobacco smoke interaction); chr4:9925929 chr4:10006482~10009725:+ LIHC cis rs9992667 0.955 rs7654470 ENSG00000231160.8 KLF3-AS1 4.43 1.28e-05 0.00329 0.32 0.23 Eosinophil percentage of granulocytes; chr4:38634608 chr4:38612701~38664883:- LIHC cis rs9992667 0.955 rs12499028 ENSG00000231160.8 KLF3-AS1 4.43 1.28e-05 0.00329 0.32 0.23 Eosinophil percentage of granulocytes; chr4:38638087 chr4:38612701~38664883:- LIHC cis rs9992667 0.955 rs28491682 ENSG00000231160.8 KLF3-AS1 4.43 1.28e-05 0.00329 0.32 0.23 Eosinophil percentage of granulocytes; chr4:38639268 chr4:38612701~38664883:- LIHC cis rs9992667 0.826 rs7656708 ENSG00000231160.8 KLF3-AS1 4.43 1.28e-05 0.00329 0.32 0.23 Eosinophil percentage of granulocytes; chr4:38640041 chr4:38612701~38664883:- LIHC cis rs9992667 0.744 rs7657152 ENSG00000231160.8 KLF3-AS1 4.43 1.28e-05 0.00329 0.32 0.23 Eosinophil percentage of granulocytes; chr4:38640315 chr4:38612701~38664883:- LIHC cis rs72675573 0.852 rs6703713 ENSG00000235612.1 RP1-158P9.1 -4.43 1.28e-05 0.00329 -0.31 -0.23 Monocyte count; chr1:56151289 chr1:56145721~56155224:+ LIHC cis rs3015497 0.616 rs3825571 ENSG00000269906.1 RP11-248J18.2 4.43 1.28e-05 0.00329 0.29 0.23 Mean platelet volume; chr14:50585400 chr14:50662511~50663178:- LIHC cis rs4834770 1 rs4834770 ENSG00000245958.5 RP11-33B1.1 -4.43 1.29e-05 0.00329 -0.22 -0.23 Blood protein levels; chr4:119320694 chr4:119454791~119552025:+ LIHC cis rs643506 1 rs4936675 ENSG00000254990.4 RP11-108O10.2 4.43 1.29e-05 0.00329 0.26 0.23 Breast cancer; chr11:111752364 chr11:111768668~111778350:- LIHC cis rs6430585 0.528 rs309161 ENSG00000231890.6 DARS-AS1 4.43 1.29e-05 0.00329 0.32 0.23 Corneal structure; chr2:135931179 chr2:135985176~136022593:+ LIHC cis rs8028182 0.636 rs10152155 ENSG00000260269.4 CTD-2323K18.1 -4.43 1.29e-05 0.00329 -0.3 -0.23 Sudden cardiac arrest; chr15:75409213 chr15:75527150~75601205:- LIHC cis rs9527 0.662 rs4919686 ENSG00000236937.2 PTGES3P4 4.43 1.29e-05 0.00329 0.35 0.23 Arsenic metabolism; chr10:102832492 chr10:102845595~102845950:+ LIHC cis rs812925 0.515 rs1177308 ENSG00000212978.6 AC016747.3 -4.43 1.29e-05 0.0033 -0.25 -0.23 Immature fraction of reticulocytes; chr2:61160119 chr2:61141592~61144969:- LIHC cis rs881375 0.678 rs3761846 ENSG00000226752.6 PSMD5-AS1 -4.43 1.29e-05 0.0033 -0.24 -0.23 Rheumatoid arthritis; chr9:120927319 chr9:120824828~120854385:+ LIHC cis rs2243480 1 rs1039664 ENSG00000228409.4 CCT6P1 4.43 1.29e-05 0.0033 0.25 0.23 Diabetic kidney disease; chr7:65984729 chr7:65751142~65763354:+ LIHC cis rs7412746 0.611 rs4970985 ENSG00000231073.1 RP11-316M1.3 -4.43 1.29e-05 0.0033 -0.23 -0.23 Melanoma; chr1:150914966 chr1:150973123~150975534:+ LIHC cis rs2976388 0.609 rs2585153 ENSG00000253741.1 CTD-2292P10.4 -4.43 1.29e-05 0.0033 -0.27 -0.23 Urinary tract infection frequency; chr8:142703927 chr8:142702252~142726973:- LIHC cis rs2439831 0.702 rs8033995 ENSG00000275601.1 AC011330.13 -4.43 1.29e-05 0.0033 -0.33 -0.23 Lung cancer in ever smokers; chr15:43721311 chr15:43642389~43643023:- LIHC cis rs9646944 0.519 rs1041973 ENSG00000234389.1 AC007278.3 -4.43 1.29e-05 0.0033 -0.26 -0.23 Blood protein levels; chr2:102339008 chr2:102438713~102440475:+ LIHC cis rs1030877 0.557 rs2278501 ENSG00000235319.1 AC012360.4 4.43 1.29e-05 0.0033 0.28 0.23 Obesity-related traits; chr2:105363049 chr2:105324210~105330529:+ LIHC cis rs9467711 0.591 rs6903228 ENSG00000216436.2 HIST1H2APS1 4.43 1.29e-05 0.0033 0.56 0.23 Autism spectrum disorder or schizophrenia; chr6:25902819 chr6:25732497~25732827:+ LIHC cis rs9467711 0.591 rs9461222 ENSG00000216436.2 HIST1H2APS1 4.43 1.29e-05 0.0033 0.56 0.23 Autism spectrum disorder or schizophrenia; chr6:25904883 chr6:25732497~25732827:+ LIHC cis rs9467711 0.591 rs9467635 ENSG00000216436.2 HIST1H2APS1 4.43 1.29e-05 0.0033 0.56 0.23 Autism spectrum disorder or schizophrenia; chr6:25908938 chr6:25732497~25732827:+ LIHC cis rs73198271 0.751 rs617813 ENSG00000253893.2 FAM85B 4.43 1.29e-05 0.0033 0.29 0.23 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8778378 chr8:8167819~8226614:- LIHC cis rs812925 0.553 rs1177307 ENSG00000212978.6 AC016747.3 -4.43 1.29e-05 0.00331 -0.25 -0.23 Immature fraction of reticulocytes; chr2:61160253 chr2:61141592~61144969:- LIHC cis rs4578769 0.959 rs3851819 ENSG00000265943.1 RP11-739L10.1 4.43 1.29e-05 0.00331 0.3 0.23 Eosinophil percentage of white cells; chr18:22881321 chr18:22699481~22933764:- LIHC cis rs4578769 0.959 rs3851820 ENSG00000265943.1 RP11-739L10.1 4.43 1.29e-05 0.00331 0.3 0.23 Eosinophil percentage of white cells; chr18:22881359 chr18:22699481~22933764:- LIHC cis rs4578769 0.918 rs3851821 ENSG00000265943.1 RP11-739L10.1 4.43 1.29e-05 0.00331 0.3 0.23 Eosinophil percentage of white cells; chr18:22882492 chr18:22699481~22933764:- LIHC cis rs17270561 0.514 rs10946805 ENSG00000216436.2 HIST1H2APS1 -4.43 1.29e-05 0.00331 -0.36 -0.23 Iron status biomarkers; chr6:26077663 chr6:25732497~25732827:+ LIHC cis rs2348418 0.703 rs10843122 ENSG00000247934.4 RP11-967K21.1 -4.43 1.29e-05 0.00331 -0.21 -0.23 Lung function (FEV1);Lung function (FVC); chr12:28174153 chr12:28163298~28190738:- LIHC cis rs2348418 0.765 rs2078016 ENSG00000247934.4 RP11-967K21.1 -4.43 1.29e-05 0.00331 -0.21 -0.23 Lung function (FEV1);Lung function (FVC); chr12:28180174 chr12:28163298~28190738:- LIHC cis rs2735413 0.914 rs2707604 ENSG00000276007.1 RP11-358L22.3 -4.43 1.3e-05 0.00331 -0.27 -0.23 Systolic blood pressure (alcohol consumption interaction); chr16:78020956 chr16:78123243~78124332:+ LIHC cis rs7726839 0.54 rs72703079 ENSG00000271781.1 CTD-2589H19.6 -4.43 1.3e-05 0.00331 -0.35 -0.23 Obesity-related traits; chr5:595058 chr5:675826~676616:+ LIHC cis rs7726839 0.54 rs61580655 ENSG00000271781.1 CTD-2589H19.6 -4.43 1.3e-05 0.00331 -0.35 -0.23 Obesity-related traits; chr5:597449 chr5:675826~676616:+ LIHC cis rs7726839 0.54 rs57306627 ENSG00000271781.1 CTD-2589H19.6 -4.43 1.3e-05 0.00331 -0.35 -0.23 Obesity-related traits; chr5:597528 chr5:675826~676616:+ LIHC cis rs748404 0.578 rs510108 ENSG00000166763.7 STRCP1 4.43 1.3e-05 0.00331 0.29 0.23 Lung cancer; chr15:43313241 chr15:43699488~43718184:- LIHC cis rs1165668 0.727 rs2722176 ENSG00000257327.1 RP11-650K20.3 4.43 1.3e-05 0.00331 0.27 0.23 Coronary heart disease (SNP X SNP interaction); chr12:103920165 chr12:103841451~103844664:+ LIHC cis rs1165668 0.785 rs2583223 ENSG00000257327.1 RP11-650K20.3 4.43 1.3e-05 0.00331 0.27 0.23 Coronary heart disease (SNP X SNP interaction); chr12:103923063 chr12:103841451~103844664:+ LIHC cis rs867371 0.717 rs3858954 ENSG00000259429.4 UBE2Q2P2 -4.43 1.3e-05 0.00331 -0.23 -0.23 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82265693 chr15:82355142~82420075:+ LIHC cis rs7945705 0.846 rs2742540 ENSG00000254860.4 TMEM9B-AS1 -4.42 1.3e-05 0.00332 -0.23 -0.23 Hemoglobin concentration; chr11:8877981 chr11:8964675~8977527:+ LIHC cis rs7546 0.504 rs2075637 ENSG00000267077.1 RP11-127I20.5 -4.42 1.3e-05 0.00332 -0.24 -0.23 Cancer; chr16:4888279 chr16:4795265~4796532:- LIHC cis rs7615952 0.512 rs4679430 ENSG00000171084.14 FAM86JP 4.42 1.3e-05 0.00332 0.35 0.23 Blood pressure (smoking interaction); chr3:125639049 chr3:125916620~125930024:+ LIHC cis rs7615952 0.512 rs34651730 ENSG00000171084.14 FAM86JP 4.42 1.3e-05 0.00332 0.35 0.23 Blood pressure (smoking interaction); chr3:125639796 chr3:125916620~125930024:+ LIHC cis rs7615952 0.512 rs2979334 ENSG00000171084.14 FAM86JP 4.42 1.3e-05 0.00332 0.35 0.23 Blood pressure (smoking interaction); chr3:125639980 chr3:125916620~125930024:+ LIHC cis rs7615952 0.512 rs11929125 ENSG00000171084.14 FAM86JP 4.42 1.3e-05 0.00332 0.35 0.23 Blood pressure (smoking interaction); chr3:125640599 chr3:125916620~125930024:+ LIHC cis rs7615952 0.512 rs11921452 ENSG00000171084.14 FAM86JP 4.42 1.3e-05 0.00332 0.35 0.23 Blood pressure (smoking interaction); chr3:125640906 chr3:125916620~125930024:+ LIHC cis rs7945705 0.747 rs2568045 ENSG00000254860.4 TMEM9B-AS1 4.42 1.3e-05 0.00332 0.23 0.23 Hemoglobin concentration; chr11:8982513 chr11:8964675~8977527:+ LIHC cis rs10129255 0.957 rs2013423 ENSG00000223648.3 IGHV3-64 4.42 1.3e-05 0.00332 0.18 0.23 Kawasaki disease; chr14:106690675 chr14:106643132~106658258:- LIHC cis rs10129255 0.957 rs56134540 ENSG00000223648.3 IGHV3-64 4.42 1.3e-05 0.00332 0.18 0.23 Kawasaki disease; chr14:106691290 chr14:106643132~106658258:- LIHC cis rs4650994 0.517 rs2761473 ENSG00000273384.1 RP5-1098D14.1 -4.42 1.3e-05 0.00332 -0.28 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178640623 chr1:178651706~178652282:+ LIHC cis rs921968 0.529 rs6729341 ENSG00000272555.1 RP11-459I19.1 -4.42 1.3e-05 0.00332 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218746711 chr2:218818690~218819144:+ LIHC cis rs2562456 0.724 rs58001930 ENSG00000268555.1 RP11-678G14.3 4.42 1.3e-05 0.00332 0.29 0.23 Pain; chr19:21560061 chr19:21570822~21587322:- LIHC cis rs2562456 0.754 rs55771551 ENSG00000268555.1 RP11-678G14.3 4.42 1.3e-05 0.00332 0.29 0.23 Pain; chr19:21563578 chr19:21570822~21587322:- LIHC cis rs2562456 0.561 rs12610883 ENSG00000268555.1 RP11-678G14.3 4.42 1.3e-05 0.00332 0.29 0.23 Pain; chr19:21567257 chr19:21570822~21587322:- LIHC cis rs2562456 0.837 rs11085462 ENSG00000268555.1 RP11-678G14.3 4.42 1.3e-05 0.00332 0.29 0.23 Pain; chr19:21567449 chr19:21570822~21587322:- LIHC cis rs2562456 0.793 rs7259708 ENSG00000268555.1 RP11-678G14.3 4.42 1.3e-05 0.00332 0.29 0.23 Pain; chr19:21567846 chr19:21570822~21587322:- LIHC cis rs703842 0.616 rs10783850 ENSG00000270039.1 RP11-571M6.17 -4.42 1.3e-05 0.00332 -0.34 -0.23 Multiple sclerosis; chr12:57835594 chr12:57803838~57804415:+ LIHC cis rs56205728 0.582 rs1869901 ENSG00000273855.1 RP11-133K1.12 4.42 1.3e-05 0.00333 0.26 0.23 Schizophrenia; chr15:40303426 chr15:40285468~40285909:- LIHC cis rs3091242 0.933 rs909833 ENSG00000224183.1 SDHDP6 -4.42 1.3e-05 0.00333 -0.27 -0.23 Erythrocyte sedimentation rate; chr1:25427649 chr1:25294164~25294643:- LIHC cis rs6439153 0.933 rs9822511 ENSG00000231305.3 RP11-723O4.2 4.42 1.3e-05 0.00333 0.26 0.23 Pneumococcal bacteremia; chr3:128986724 chr3:128861313~128871540:- LIHC cis rs6745190 0.906 rs1829365 ENSG00000236153.1 AC104076.3 4.42 1.3e-05 0.00333 0.34 0.23 White blood cell count; chr2:181020894 chr2:180979427~180980090:- LIHC cis rs11233413 0.874 rs11233440 ENSG00000246067.6 RAB30-AS1 4.42 1.3e-05 0.00333 0.32 0.23 Economic and political preferences (feminism/equality); chr11:83047195 chr11:83072066~83106719:+ LIHC cis rs9368481 0.761 rs9348746 ENSG00000241549.7 GUSBP2 -4.42 1.31e-05 0.00333 -0.24 -0.23 Autism spectrum disorder or schizophrenia; chr6:27002578 chr6:26871484~26956554:- LIHC cis rs9368481 0.761 rs9379952 ENSG00000241549.7 GUSBP2 -4.42 1.31e-05 0.00333 -0.24 -0.23 Autism spectrum disorder or schizophrenia; chr6:27020121 chr6:26871484~26956554:- LIHC cis rs4356975 0.83 rs10012215 ENSG00000250919.1 RP11-813N20.3 -4.42 1.31e-05 0.00333 -0.23 -0.23 Obesity-related traits; chr4:69048448 chr4:69027831~69044578:+ LIHC cis rs4356975 0.83 rs10012240 ENSG00000250919.1 RP11-813N20.3 -4.42 1.31e-05 0.00333 -0.23 -0.23 Obesity-related traits; chr4:69048519 chr4:69027831~69044578:+ LIHC cis rs11096990 0.634 rs11096988 ENSG00000249207.1 RP11-360F5.1 -4.42 1.31e-05 0.00333 -0.23 -0.23 Cognitive function; chr4:39264081 chr4:39112677~39126818:- LIHC cis rs1558001 0.84 rs17155560 ENSG00000230196.1 DDX43P3 -4.42 1.31e-05 0.00334 -0.25 -0.23 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81837426 chr7:81610884~81611326:- LIHC cis rs9896933 0.832 rs79103992 ENSG00000263063.1 RP11-388C12.1 -4.42 1.31e-05 0.00334 -0.33 -0.23 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82897607 chr17:82713908~82716255:- LIHC cis rs2276314 1 rs56050783 ENSG00000278986.1 RP11-723J4.3 -4.42 1.31e-05 0.00334 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:35973828 chr18:35972151~35973916:+ LIHC cis rs2276314 1 rs58054756 ENSG00000278986.1 RP11-723J4.3 -4.42 1.31e-05 0.00334 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:35974090 chr18:35972151~35973916:+ LIHC cis rs2276314 1 rs1540042 ENSG00000278986.1 RP11-723J4.3 -4.42 1.31e-05 0.00334 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:35975273 chr18:35972151~35973916:+ LIHC cis rs4453827 1 rs35657034 ENSG00000271916.1 RP11-884K10.6 4.42 1.31e-05 0.00334 0.48 0.23 Blood protein levels; chr3:53708773 chr3:53797764~53798019:- LIHC cis rs875971 0.638 rs6460305 ENSG00000273024.4 INTS4P2 4.42 1.31e-05 0.00334 0.26 0.23 Aortic root size; chr7:66595421 chr7:65647864~65715661:+ LIHC cis rs875971 0.66 rs10272357 ENSG00000273024.4 INTS4P2 4.42 1.31e-05 0.00334 0.26 0.23 Aortic root size; chr7:66598087 chr7:65647864~65715661:+ LIHC cis rs11098499 0.909 rs7681978 ENSG00000260091.1 RP11-33B1.4 -4.42 1.31e-05 0.00334 -0.17 -0.23 Corneal astigmatism; chr4:119462620 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs13134665 ENSG00000260091.1 RP11-33B1.4 -4.42 1.31e-05 0.00334 -0.17 -0.23 Corneal astigmatism; chr4:119505275 chr4:119409333~119410233:+ LIHC cis rs7587476 1 rs3768707 ENSG00000229267.2 AC072062.1 -4.42 1.31e-05 0.00335 -0.3 -0.23 Neuroblastoma; chr2:214780411 chr2:214810229~214963274:+ LIHC cis rs2337406 0.85 rs75196489 ENSG00000274576.2 IGHV2-70 -4.42 1.31e-05 0.00335 -0.27 -0.23 Alzheimer's disease (late onset); chr14:106699438 chr14:106770577~106771020:- LIHC cis rs2284219 0.964 rs255097 ENSG00000196295.10 AC005154.6 -4.42 1.31e-05 0.00335 -0.17 -0.23 Type 2 diabetes; chr7:30687343 chr7:30516309~30594809:- LIHC cis rs7923609 1 rs7073746 ENSG00000232075.1 MRPL35P2 -4.42 1.32e-05 0.00336 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63144311 chr10:63634317~63634827:- LIHC cis rs875971 0.522 rs10807697 ENSG00000224316.1 RP11-479O9.2 4.42 1.32e-05 0.00336 0.24 0.23 Aortic root size; chr7:65951183 chr7:65773620~65802067:+ LIHC cis rs79349575 0.715 rs55724082 ENSG00000248278.1 SUMO2P17 4.42 1.32e-05 0.00336 0.29 0.23 Type 2 diabetes; chr17:48940517 chr17:48874860~48908983:- LIHC cis rs3091242 0.933 rs28530483 ENSG00000224183.1 SDHDP6 -4.42 1.32e-05 0.00336 -0.27 -0.23 Erythrocyte sedimentation rate; chr1:25414356 chr1:25294164~25294643:- LIHC cis rs3845817 0.868 rs702938 ENSG00000281920.1 RP11-418H16.1 4.42 1.32e-05 0.00337 0.28 0.23 Bipolar disorder; chr2:65520308 chr2:65623272~65628424:+ LIHC cis rs7923609 1 rs7923609 ENSG00000232075.1 MRPL35P2 -4.42 1.32e-05 0.00337 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63374062 chr10:63634317~63634827:- LIHC cis rs812925 0.511 rs11886950 ENSG00000212978.6 AC016747.3 -4.42 1.32e-05 0.00337 -0.25 -0.23 Immature fraction of reticulocytes; chr2:61172182 chr2:61141592~61144969:- LIHC cis rs11723261 0.513 rs2353623 ENSG00000211553.1 AC253576.2 -4.42 1.32e-05 0.00337 -0.24 -0.23 Immune response to smallpox vaccine (IL-6); chr4:95673 chr4:136461~136568:+ LIHC cis rs921968 0.565 rs7573999 ENSG00000272555.1 RP11-459I19.1 -4.42 1.32e-05 0.00337 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218736669 chr2:218818690~218819144:+ LIHC cis rs2439831 0.867 rs3101443 ENSG00000166763.7 STRCP1 4.42 1.32e-05 0.00337 0.36 0.23 Lung cancer in ever smokers; chr15:43620174 chr15:43699488~43718184:- LIHC cis rs2929278 0.588 rs1975364 ENSG00000166763.7 STRCP1 4.42 1.32e-05 0.00337 0.31 0.23 Schizophrenia; chr15:43857991 chr15:43699488~43718184:- LIHC cis rs734999 0.545 rs28568531 ENSG00000225931.3 RP3-395M20.7 4.42 1.32e-05 0.00338 0.25 0.23 Ulcerative colitis; chr1:2624201 chr1:2566410~2569888:+ LIHC cis rs2919917 0.955 rs1441850 ENSG00000254352.1 RP11-578O24.2 -4.42 1.33e-05 0.00338 -0.33 -0.23 Lymphocyte counts; chr8:78745431 chr8:78723796~78724136:- LIHC cis rs12701220 0.894 rs34712249 ENSG00000229043.2 AC091729.9 -4.42 1.33e-05 0.00338 -0.33 -0.23 Bronchopulmonary dysplasia; chr7:996998 chr7:1160374~1165267:+ LIHC cis rs755249 0.917 rs61781393 ENSG00000182109.6 RP11-69E11.4 4.42 1.33e-05 0.00338 0.33 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39622092 chr1:39522280~39546187:- LIHC cis rs79349575 0.783 rs2088139 ENSG00000248278.1 SUMO2P17 4.42 1.33e-05 0.00338 0.29 0.23 Type 2 diabetes; chr17:48922748 chr17:48874860~48908983:- LIHC cis rs8031584 1 rs8031584 ENSG00000270015.1 RP11-540B6.6 -4.42 1.33e-05 0.00338 -0.3 -0.23 Huntington's disease progression; chr15:30995140 chr15:30926514~30928407:+ LIHC cis rs4578769 0.765 rs12458947 ENSG00000266850.1 RP11-370A5.1 -4.42 1.33e-05 0.00338 -0.28 -0.23 Eosinophil percentage of white cells; chr18:22856655 chr18:22723491~22907721:- LIHC cis rs4578769 0.729 rs12454969 ENSG00000266850.1 RP11-370A5.1 -4.42 1.33e-05 0.00338 -0.28 -0.23 Eosinophil percentage of white cells; chr18:22893042 chr18:22723491~22907721:- LIHC cis rs2283831 0.524 rs9613210 ENSG00000213707.2 HMGB1P10 -4.42 1.33e-05 0.00338 -0.28 -0.23 Anti-saccade response; chr22:26560529 chr22:26560526~26561088:+ LIHC cis rs3733589 0.59 rs4502681 ENSG00000250413.1 RP11-448G15.1 -4.42 1.33e-05 0.00338 -0.41 -0.23 Renal overload gout; chr4:9988548 chr4:10006482~10009725:+ LIHC cis rs3733589 0.744 rs6820616 ENSG00000250413.1 RP11-448G15.1 4.42 1.33e-05 0.00339 0.37 0.23 Renal overload gout; chr4:10028452 chr4:10006482~10009725:+ LIHC cis rs2976388 0.609 rs2717550 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.33e-05 0.00339 -0.27 -0.23 Urinary tract infection frequency; chr8:142706390 chr8:142702252~142726973:- LIHC cis rs160451 1 rs160446 ENSG00000251136.7 RP11-37B2.1 4.42 1.33e-05 0.00339 0.21 0.23 Leprosy; chr8:89647035 chr8:89609409~89757727:- LIHC cis rs2243480 1 rs1964692 ENSG00000230295.1 RP11-458F8.2 -4.42 1.33e-05 0.00339 -0.25 -0.23 Diabetic kidney disease; chr7:65989196 chr7:66880708~66882981:+ LIHC cis rs2243480 0.901 rs2456483 ENSG00000230295.1 RP11-458F8.2 -4.42 1.33e-05 0.00339 -0.25 -0.23 Diabetic kidney disease; chr7:65996588 chr7:66880708~66882981:+ LIHC cis rs2243480 0.901 rs2949697 ENSG00000230295.1 RP11-458F8.2 -4.42 1.33e-05 0.00339 -0.25 -0.23 Diabetic kidney disease; chr7:65999249 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1701750 ENSG00000230295.1 RP11-458F8.2 -4.42 1.33e-05 0.00339 -0.25 -0.23 Diabetic kidney disease; chr7:66002158 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1701758 ENSG00000230295.1 RP11-458F8.2 -4.42 1.33e-05 0.00339 -0.25 -0.23 Diabetic kidney disease; chr7:66005214 chr7:66880708~66882981:+ LIHC cis rs2243480 0.901 rs1701759 ENSG00000230295.1 RP11-458F8.2 -4.42 1.33e-05 0.00339 -0.25 -0.23 Diabetic kidney disease; chr7:66005945 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs13247184 ENSG00000230295.1 RP11-458F8.2 -4.42 1.33e-05 0.00339 -0.25 -0.23 Diabetic kidney disease; chr7:65893941 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs35283677 ENSG00000230295.1 RP11-458F8.2 -4.42 1.33e-05 0.00339 -0.25 -0.23 Diabetic kidney disease; chr7:65894246 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs35421653 ENSG00000230295.1 RP11-458F8.2 -4.42 1.33e-05 0.00339 -0.25 -0.23 Diabetic kidney disease; chr7:65898442 chr7:66880708~66882981:+ LIHC cis rs3733589 0.59 rs16892420 ENSG00000250413.1 RP11-448G15.1 4.42 1.33e-05 0.00339 0.37 0.23 Renal overload gout; chr4:10034091 chr4:10006482~10009725:+ LIHC cis rs3733589 0.59 rs3822250 ENSG00000250413.1 RP11-448G15.1 4.42 1.33e-05 0.00339 0.37 0.23 Renal overload gout; chr4:10035006 chr4:10006482~10009725:+ LIHC cis rs11233413 0.874 rs17504704 ENSG00000246067.6 RAB30-AS1 4.42 1.33e-05 0.00339 0.32 0.23 Economic and political preferences (feminism/equality); chr11:83034485 chr11:83072066~83106719:+ LIHC cis rs11064837 0.504 rs7310148 ENSG00000248636.5 RP11-768F21.1 4.42 1.33e-05 0.00339 0.37 0.23 Schizophrenia; chr12:119615925 chr12:119387987~119668079:- LIHC cis rs4879656 0.5 rs12553806 ENSG00000236184.1 TCEA1P4 -4.42 1.33e-05 0.0034 -0.37 -0.23 Menopause (age at onset); chr9:33083374 chr9:32979560~32980403:- LIHC cis rs9843304 0.529 rs4681510 ENSG00000244503.1 RP11-278L15.6 4.42 1.33e-05 0.0034 0.23 0.23 Gallstone disease; chr3:149483786 chr3:149494660~149495995:+ LIHC cis rs9843304 0.529 rs4681511 ENSG00000244503.1 RP11-278L15.6 4.42 1.33e-05 0.0034 0.23 0.23 Gallstone disease; chr3:149483792 chr3:149494660~149495995:+ LIHC cis rs1865760 0.516 rs9358903 ENSG00000216436.2 HIST1H2APS1 -4.42 1.33e-05 0.0034 -0.27 -0.23 Height; chr6:26061721 chr6:25732497~25732827:+ LIHC cis rs1865760 0.516 rs9393683 ENSG00000216436.2 HIST1H2APS1 -4.42 1.33e-05 0.0034 -0.27 -0.23 Height; chr6:26065970 chr6:25732497~25732827:+ LIHC cis rs921968 0.565 rs7594046 ENSG00000272555.1 RP11-459I19.1 4.42 1.34e-05 0.0034 0.25 0.23 Mean corpuscular hemoglobin concentration; chr2:218759447 chr2:218818690~218819144:+ LIHC cis rs5742933 0.711 rs12693551 ENSG00000253559.1 OSGEPL1-AS1 4.42 1.34e-05 0.0034 0.31 0.23 Ferritin levels; chr2:189664505 chr2:189762704~189765556:+ LIHC cis rs4578769 0.765 rs3844226 ENSG00000266850.1 RP11-370A5.1 -4.42 1.34e-05 0.0034 -0.28 -0.23 Eosinophil percentage of white cells; chr18:22866817 chr18:22723491~22907721:- LIHC cis rs8031584 0.679 rs34017474 ENSG00000270055.1 CTD-3092A11.2 -4.42 1.34e-05 0.0034 -0.27 -0.23 Huntington's disease progression; chr15:30938408 chr15:30487963~30490313:+ LIHC cis rs2842992 0.789 rs4235925 ENSG00000237927.1 RP3-393E18.2 -4.42 1.34e-05 0.0034 -0.28 -0.23 Age-related macular degeneration (geographic atrophy); chr6:159781828 chr6:159586955~159589169:- LIHC cis rs17826219 0.568 rs2626985 ENSG00000266490.1 CTD-2349P21.9 4.42 1.34e-05 0.0034 0.29 0.23 Body mass index; chr17:30750419 chr17:30792372~30792833:+ LIHC cis rs7208859 0.573 rs8078656 ENSG00000266490.1 CTD-2349P21.9 4.42 1.34e-05 0.0034 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753953 chr17:30792372~30792833:+ LIHC cis rs8028182 0.636 rs4564532 ENSG00000260269.4 CTD-2323K18.1 -4.42 1.34e-05 0.00341 -0.29 -0.23 Sudden cardiac arrest; chr15:75413955 chr15:75527150~75601205:- LIHC cis rs9487094 0.922 rs11153181 ENSG00000260273.1 RP11-425D10.10 4.42 1.34e-05 0.00341 0.28 0.23 Height; chr6:109428824 chr6:109382795~109383666:+ LIHC cis rs2439831 0.85 rs28564774 ENSG00000275601.1 AC011330.13 -4.42 1.34e-05 0.00341 -0.34 -0.23 Lung cancer in ever smokers; chr15:43833277 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs28513374 ENSG00000275601.1 AC011330.13 -4.42 1.34e-05 0.00341 -0.34 -0.23 Lung cancer in ever smokers; chr15:43833297 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs12441984 ENSG00000275601.1 AC011330.13 -4.42 1.34e-05 0.00341 -0.34 -0.23 Lung cancer in ever smokers; chr15:43834087 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs7169322 ENSG00000275601.1 AC011330.13 -4.42 1.34e-05 0.00341 -0.34 -0.23 Lung cancer in ever smokers; chr15:43838816 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs28707214 ENSG00000275601.1 AC011330.13 -4.42 1.34e-05 0.00341 -0.34 -0.23 Lung cancer in ever smokers; chr15:43839425 chr15:43642389~43643023:- LIHC cis rs2565722 0.583 rs2465875 ENSG00000243831.1 RP1-81D8.4 4.42 1.34e-05 0.00341 0.31 0.23 Blood protein levels; chr6:160877372 chr6:160666228~160676523:- LIHC cis rs2565722 0.583 rs2465874 ENSG00000243831.1 RP1-81D8.4 4.42 1.34e-05 0.00341 0.31 0.23 Blood protein levels; chr6:160877560 chr6:160666228~160676523:- LIHC cis rs1015362 0.503 rs1883708 ENSG00000276073.1 RP5-1125A11.7 -4.42 1.34e-05 0.00341 -0.3 -0.23 Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling; chr20:33924107 chr20:33985617~33988989:- LIHC cis rs13113518 0.812 rs12500601 ENSG00000249700.7 SRD5A3-AS1 4.42 1.34e-05 0.00341 0.27 0.23 Height; chr4:55451489 chr4:55363971~55395847:- LIHC cis rs881375 0.678 rs10739581 ENSG00000226752.6 PSMD5-AS1 -4.42 1.34e-05 0.00341 -0.24 -0.23 Rheumatoid arthritis; chr9:120934593 chr9:120824828~120854385:+ LIHC cis rs10833905 1 rs28776242 ENSG00000246225.5 RP11-17A1.3 -4.42 1.34e-05 0.00341 -0.3 -0.23 Sudden cardiac arrest; chr11:22986516 chr11:22829380~22945393:+ LIHC cis rs2310173 0.966 rs10185424 ENSG00000281162.1 LINC01127 -4.42 1.34e-05 0.00341 -0.24 -0.23 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:102046427 chr2:101962056~101987167:+ LIHC cis rs1247318 1 rs1247313 ENSG00000243831.1 RP1-81D8.4 4.42 1.34e-05 0.00341 0.33 0.23 Aging; chr6:160914988 chr6:160666228~160676523:- LIHC cis rs3733589 0.59 rs12499734 ENSG00000250413.1 RP11-448G15.1 -4.42 1.34e-05 0.00341 -0.38 -0.23 Renal overload gout; chr4:10050137 chr4:10006482~10009725:+ LIHC cis rs2072510 1 rs2660897 ENSG00000257715.1 RP11-256L6.2 -4.42 1.34e-05 0.00341 -0.24 -0.23 Metabolite levels (small molecules and protein measures); chr12:96031654 chr12:96025323~96027971:+ LIHC cis rs1865760 0.566 rs2858993 ENSG00000216436.2 HIST1H2APS1 -4.42 1.34e-05 0.00342 -0.27 -0.23 Height; chr6:26087628 chr6:25732497~25732827:+ LIHC cis rs597539 0.652 rs646586 ENSG00000250508.1 RP11-757G1.6 4.42 1.34e-05 0.00342 0.35 0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68914185 chr11:68870664~68874542:+ LIHC cis rs2439831 0.85 rs7183809 ENSG00000275601.1 AC011330.13 -4.42 1.34e-05 0.00342 -0.34 -0.23 Lung cancer in ever smokers; chr15:43828670 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs3759790 ENSG00000275601.1 AC011330.13 -4.42 1.34e-05 0.00342 -0.34 -0.23 Lung cancer in ever smokers; chr15:43828832 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs68079546 ENSG00000275601.1 AC011330.13 -4.42 1.34e-05 0.00342 -0.34 -0.23 Lung cancer in ever smokers; chr15:43844759 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs56909447 ENSG00000275601.1 AC011330.13 -4.42 1.34e-05 0.00342 -0.34 -0.23 Lung cancer in ever smokers; chr15:43845420 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs28476182 ENSG00000275601.1 AC011330.13 -4.42 1.34e-05 0.00342 -0.34 -0.23 Lung cancer in ever smokers; chr15:43847445 chr15:43642389~43643023:- LIHC cis rs2439831 0.85 rs28696802 ENSG00000275601.1 AC011330.13 -4.42 1.34e-05 0.00342 -0.34 -0.23 Lung cancer in ever smokers; chr15:43848197 chr15:43642389~43643023:- LIHC cis rs9467711 0.591 rs34525648 ENSG00000216436.2 HIST1H2APS1 4.42 1.34e-05 0.00342 0.56 0.23 Autism spectrum disorder or schizophrenia; chr6:25914625 chr6:25732497~25732827:+ LIHC cis rs1165668 0.755 rs2583283 ENSG00000257327.1 RP11-650K20.3 4.42 1.34e-05 0.00342 0.27 0.23 Coronary heart disease (SNP X SNP interaction); chr12:103919865 chr12:103841451~103844664:+ LIHC cis rs3893377 0.848 rs11933202 ENSG00000214846.4 RP11-115L11.1 4.42 1.35e-05 0.00342 0.29 0.23 Current cigarettes per day in chronic obstructive pulmonary disease; chr4:15742905 chr4:15730962~15731627:- LIHC cis rs1247318 1 rs1247362 ENSG00000243831.1 RP1-81D8.4 4.42 1.35e-05 0.00342 0.33 0.23 Aging; chr6:160921628 chr6:160666228~160676523:- LIHC cis rs1247318 0.901 rs1247364 ENSG00000243831.1 RP1-81D8.4 4.42 1.35e-05 0.00342 0.33 0.23 Aging; chr6:160921706 chr6:160666228~160676523:- LIHC cis rs748404 0.578 rs478028 ENSG00000166763.7 STRCP1 4.42 1.35e-05 0.00342 0.29 0.23 Lung cancer; chr15:43318574 chr15:43699488~43718184:- LIHC cis rs748404 0.578 rs552701 ENSG00000166763.7 STRCP1 4.42 1.35e-05 0.00342 0.29 0.23 Lung cancer; chr15:43321612 chr15:43699488~43718184:- LIHC cis rs748404 0.578 rs573615 ENSG00000166763.7 STRCP1 4.42 1.35e-05 0.00342 0.29 0.23 Lung cancer; chr15:43322083 chr15:43699488~43718184:- LIHC cis rs7759633 0.502 rs9458005 ENSG00000224477.4 RP1-81D8.3 4.42 1.35e-05 0.00342 0.32 0.23 Triglycerides; chr6:160697545 chr6:160698288~160700632:+ LIHC cis rs950169 0.58 rs2271431 ENSG00000259728.4 LINC00933 4.42 1.35e-05 0.00342 0.33 0.23 Schizophrenia; chr15:84646233 chr15:84570649~84580175:+ LIHC cis rs6723226 0.679 rs116617324 ENSG00000276334.1 AL133243.1 -4.42 1.35e-05 0.00342 -0.25 -0.23 Intelligence (multi-trait analysis); chr2:32397641 chr2:32521927~32523547:+ LIHC cis rs9595908 1 rs9595908 ENSG00000212293.1 SNORA16 4.42 1.35e-05 0.00342 0.27 0.23 Body mass index; chr13:32610151 chr13:32420390~32420516:- LIHC cis rs7809950 1 rs2520268 ENSG00000238832.1 snoU109 -4.42 1.35e-05 0.00342 -0.28 -0.23 Coronary artery disease; chr7:107550716 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2520269 ENSG00000238832.1 snoU109 -4.42 1.35e-05 0.00342 -0.28 -0.23 Coronary artery disease; chr7:107550882 chr7:107603363~107603507:+ LIHC cis rs2976388 0.609 rs2717605 ENSG00000253196.1 RP11-706C16.7 4.42 1.35e-05 0.00343 0.23 0.23 Urinary tract infection frequency; chr8:142719597 chr8:142763116~142766427:+ LIHC cis rs651907 0.557 rs11924013 ENSG00000244119.1 PDCL3P4 4.42 1.35e-05 0.00343 0.24 0.23 Colorectal cancer; chr3:101647854 chr3:101712472~101713191:+ LIHC cis rs12209785 1 rs10485422 ENSG00000231769.2 RP1-8B1.4 4.42 1.35e-05 0.00343 0.34 0.23 Survival in pancreatic cancer; chr6:45521455 chr6:46097093~46129706:- LIHC cis rs67311347 0.956 rs11714871 ENSG00000223797.4 ENTPD3-AS1 4.42 1.35e-05 0.00343 0.19 0.23 Renal cell carcinoma; chr3:40387447 chr3:40313802~40453329:- LIHC cis rs11098499 0.754 rs17049949 ENSG00000260091.1 RP11-33B1.4 -4.42 1.35e-05 0.00343 -0.16 -0.23 Corneal astigmatism; chr4:119334135 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs7689729 ENSG00000260091.1 RP11-33B1.4 -4.42 1.35e-05 0.00343 -0.16 -0.23 Corneal astigmatism; chr4:119335037 chr4:119409333~119410233:+ LIHC cis rs10028773 0.7 rs7690338 ENSG00000260091.1 RP11-33B1.4 -4.42 1.35e-05 0.00343 -0.16 -0.23 Educational attainment; chr4:119335313 chr4:119409333~119410233:+ LIHC cis rs11098499 0.865 rs3956464 ENSG00000260091.1 RP11-33B1.4 -4.42 1.35e-05 0.00343 -0.16 -0.23 Corneal astigmatism; chr4:119335609 chr4:119409333~119410233:+ LIHC cis rs11098499 0.619 rs28502463 ENSG00000260091.1 RP11-33B1.4 -4.42 1.35e-05 0.00343 -0.16 -0.23 Corneal astigmatism; chr4:119335868 chr4:119409333~119410233:+ LIHC cis rs11098499 0.648 rs2002047 ENSG00000260091.1 RP11-33B1.4 -4.42 1.35e-05 0.00343 -0.16 -0.23 Corneal astigmatism; chr4:119336073 chr4:119409333~119410233:+ LIHC cis rs11098499 0.775 rs2002049 ENSG00000260091.1 RP11-33B1.4 -4.42 1.35e-05 0.00343 -0.16 -0.23 Corneal astigmatism; chr4:119336262 chr4:119409333~119410233:+ LIHC cis rs1396485 0.66 rs6874747 ENSG00000271918.1 CTD-2287O16.5 4.42 1.35e-05 0.00343 0.28 0.23 Inflammatory biomarkers; chr5:116196852 chr5:116083807~116085416:- LIHC cis rs875971 0.545 rs1638735 ENSG00000273142.1 RP11-458F8.4 4.42 1.35e-05 0.00343 0.23 0.23 Aortic root size; chr7:66630751 chr7:66902857~66906297:+ LIHC cis rs4948102 0.69 rs35844144 ENSG00000226278.1 PSPHP1 -4.42 1.35e-05 0.00343 -0.27 -0.23 Plasma homocysteine levels (post-methionine load test); chr7:55982832 chr7:55764797~55773288:+ LIHC cis rs2976388 0.609 rs2572904 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.35e-05 0.00343 -0.27 -0.23 Urinary tract infection frequency; chr8:142710775 chr8:142702252~142726973:- LIHC cis rs2976388 0.609 rs2585150 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.35e-05 0.00343 -0.27 -0.23 Urinary tract infection frequency; chr8:142711251 chr8:142702252~142726973:- LIHC cis rs6480314 0.711 rs61854659 ENSG00000233590.1 RP11-153K11.3 -4.42 1.35e-05 0.00344 -0.39 -0.23 Optic nerve measurement (disc area); chr10:68182967 chr10:68233251~68242379:- LIHC cis rs1400745 0.729 rs1741196 ENSG00000258738.1 RP11-73E17.2 4.42 1.35e-05 0.00344 0.29 0.23 Monocyte count; chr14:34877814 chr14:34874343~34876459:+ LIHC cis rs2243480 1 rs313814 ENSG00000230295.1 RP11-458F8.2 -4.42 1.35e-05 0.00344 -0.24 -0.23 Diabetic kidney disease; chr7:66038306 chr7:66880708~66882981:+ LIHC cis rs12701220 0.69 rs10243973 ENSG00000229043.2 AC091729.9 -4.42 1.35e-05 0.00344 -0.32 -0.23 Bronchopulmonary dysplasia; chr7:1025347 chr7:1160374~1165267:+ LIHC cis rs12216125 0.554 rs6942196 ENSG00000216436.2 HIST1H2APS1 -4.42 1.36e-05 0.00344 -0.27 -0.23 Iron status biomarkers; chr6:26072576 chr6:25732497~25732827:+ LIHC cis rs7923609 0.934 rs2893919 ENSG00000232075.1 MRPL35P2 -4.42 1.36e-05 0.00344 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63375018 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs2393966 ENSG00000232075.1 MRPL35P2 -4.42 1.36e-05 0.00344 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63375054 chr10:63634317~63634827:- LIHC cis rs7923609 1 rs4310508 ENSG00000232075.1 MRPL35P2 -4.42 1.36e-05 0.00344 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63378813 chr10:63634317~63634827:- LIHC cis rs7923609 1 rs7910927 ENSG00000232075.1 MRPL35P2 -4.42 1.36e-05 0.00344 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63379150 chr10:63634317~63634827:- LIHC cis rs2976388 0.609 rs2263092 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.36e-05 0.00344 -0.27 -0.23 Urinary tract infection frequency; chr8:142708548 chr8:142702252~142726973:- LIHC cis rs2976388 0.609 rs1594999 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.36e-05 0.00344 -0.27 -0.23 Urinary tract infection frequency; chr8:142709156 chr8:142702252~142726973:- LIHC cis rs960902 0.592 rs10199137 ENSG00000213553.4 RPLP0P6 -4.42 1.36e-05 0.00344 -0.19 -0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37508238 chr2:38481851~38482804:+ LIHC cis rs17818399 0.815 rs35837037 ENSG00000279254.1 RP11-536C12.1 -4.41 1.36e-05 0.00344 -0.29 -0.23 Height; chr2:46634161 chr2:46668870~46670778:+ LIHC cis rs8040855 0.627 rs62019482 ENSG00000259295.5 CSPG4P12 4.41 1.36e-05 0.00344 0.37 0.23 Bulimia nervosa; chr15:85071796 chr15:85191438~85213905:+ LIHC cis rs950880 0.593 rs887971 ENSG00000234389.1 AC007278.3 -4.41 1.36e-05 0.00344 -0.23 -0.23 Serum protein levels (sST2); chr2:102424707 chr2:102438713~102440475:+ LIHC cis rs617219 0.698 rs10514159 ENSG00000251675.1 CTC-458I2.2 4.41 1.36e-05 0.00345 0.26 0.23 Betaine levels in individuals undergoing cardiac evaluation; chr5:79300221 chr5:80128361~80143883:+ LIHC cis rs7923609 1 rs10761723 ENSG00000232075.1 MRPL35P2 -4.41 1.36e-05 0.00345 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63195821 chr10:63634317~63634827:- LIHC cis rs7923609 1 rs4379723 ENSG00000232075.1 MRPL35P2 -4.41 1.36e-05 0.00345 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63203689 chr10:63634317~63634827:- LIHC cis rs7923609 1 rs10822149 ENSG00000232075.1 MRPL35P2 -4.41 1.36e-05 0.00345 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63227652 chr10:63634317~63634827:- LIHC cis rs7923609 1 rs10761727 ENSG00000232075.1 MRPL35P2 -4.41 1.36e-05 0.00345 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63235733 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs10761729 ENSG00000232075.1 MRPL35P2 -4.41 1.36e-05 0.00345 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63235844 chr10:63634317~63634827:- LIHC cis rs7923609 1 rs4399232 ENSG00000232075.1 MRPL35P2 -4.41 1.36e-05 0.00345 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63239730 chr10:63634317~63634827:- LIHC cis rs4660456 0.504 rs587064 ENSG00000237899.1 RP4-739H11.3 4.41 1.36e-05 0.00345 0.32 0.23 Platelet count; chr1:40640238 chr1:40669089~40687588:- LIHC cis rs7193541 0.694 rs3896277 ENSG00000261079.1 RP11-252A24.3 4.41 1.36e-05 0.00345 0.26 0.23 Multiple myeloma; chr16:74446796 chr16:74367462~74369826:+ LIHC cis rs2337406 1 rs17113276 ENSG00000274576.2 IGHV2-70 4.41 1.36e-05 0.00345 0.26 0.23 Alzheimer's disease (late onset); chr14:106683485 chr14:106770577~106771020:- LIHC cis rs2562456 0.682 rs11085464 ENSG00000268555.1 RP11-678G14.3 4.41 1.36e-05 0.00345 0.29 0.23 Pain; chr19:21568976 chr19:21570822~21587322:- LIHC cis rs10129255 0.957 rs17113284 ENSG00000211970.3 IGHV4-61 4.41 1.36e-05 0.00346 0.18 0.23 Kawasaki disease; chr14:106684476 chr14:106639119~106639657:- LIHC cis rs7246657 1 rs1529957 ENSG00000276846.1 CTD-3220F14.3 4.41 1.36e-05 0.00346 0.29 0.23 Coronary artery calcification; chr19:37248899 chr19:37314868~37315620:- LIHC cis rs7208859 0.573 rs216442 ENSG00000266490.1 CTD-2349P21.9 4.41 1.36e-05 0.00346 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604179 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs216445 ENSG00000266490.1 CTD-2349P21.9 4.41 1.36e-05 0.00346 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30606558 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs216446 ENSG00000266490.1 CTD-2349P21.9 4.41 1.36e-05 0.00346 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30606700 chr17:30792372~30792833:+ LIHC cis rs617219 0.66 rs7705607 ENSG00000251675.1 CTC-458I2.2 4.41 1.36e-05 0.00346 0.26 0.23 Betaine levels in individuals undergoing cardiac evaluation; chr5:79313890 chr5:80128361~80143883:+ LIHC cis rs2015599 0.56 rs3948497 ENSG00000275476.1 RP11-996F15.4 -4.41 1.36e-05 0.00346 -0.29 -0.23 Platelet count;Mean platelet volume; chr12:29247552 chr12:29277397~29277882:- LIHC cis rs5756813 0.661 rs2285178 ENSG00000233360.4 Z83844.1 4.41 1.36e-05 0.00346 0.29 0.23 Optic cup area;Vertical cup-disc ratio; chr22:37809982 chr22:37641832~37658377:- LIHC cis rs921968 0.565 rs6708192 ENSG00000272555.1 RP11-459I19.1 -4.41 1.36e-05 0.00346 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218727504 chr2:218818690~218819144:+ LIHC cis rs9595908 0.758 rs9591219 ENSG00000212293.1 SNORA16 4.41 1.36e-05 0.00346 0.26 0.23 Body mass index; chr13:32653020 chr13:32420390~32420516:- LIHC cis rs9595908 0.758 rs9591220 ENSG00000212293.1 SNORA16 4.41 1.36e-05 0.00346 0.26 0.23 Body mass index; chr13:32653059 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs9591226 ENSG00000212293.1 SNORA16 4.41 1.36e-05 0.00346 0.26 0.23 Body mass index; chr13:32655322 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs7335546 ENSG00000212293.1 SNORA16 4.41 1.36e-05 0.00346 0.26 0.23 Body mass index; chr13:32658197 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs9591228 ENSG00000212293.1 SNORA16 4.41 1.36e-05 0.00346 0.26 0.23 Body mass index; chr13:32658632 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs9596051 ENSG00000212293.1 SNORA16 4.41 1.36e-05 0.00346 0.26 0.23 Body mass index; chr13:32666528 chr13:32420390~32420516:- LIHC cis rs9890032 0.52 rs2321926 ENSG00000266490.1 CTD-2349P21.9 4.41 1.36e-05 0.00346 0.22 0.23 Hip circumference adjusted for BMI; chr17:30714534 chr17:30792372~30792833:+ LIHC cis rs2998286 0.723 rs332139 ENSG00000254635.4 WAC-AS1 -4.41 1.36e-05 0.00346 -0.3 -0.23 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28570150 chr10:28522652~28532743:- LIHC cis rs72675573 0.852 rs12125786 ENSG00000235612.1 RP1-158P9.1 -4.41 1.36e-05 0.00346 -0.3 -0.23 Monocyte count; chr1:56151040 chr1:56145721~56155224:+ LIHC cis rs7923609 0.936 rs10822160 ENSG00000232075.1 MRPL35P2 -4.41 1.36e-05 0.00346 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63353036 chr10:63634317~63634827:- LIHC cis rs2276314 1 rs4799835 ENSG00000278986.1 RP11-723J4.3 -4.41 1.36e-05 0.00346 -0.29 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:35991305 chr18:35972151~35973916:+ LIHC cis rs7709377 0.516 rs13362436 ENSG00000271918.1 CTD-2287O16.5 4.41 1.36e-05 0.00346 0.27 0.23 Metabolite levels (X-11787); chr5:116207285 chr5:116083807~116085416:- LIHC cis rs11098499 0.754 rs28643450 ENSG00000260091.1 RP11-33B1.4 -4.41 1.37e-05 0.00346 -0.16 -0.23 Corneal astigmatism; chr4:119324087 chr4:119409333~119410233:+ LIHC cis rs2932538 0.922 rs12750023 ENSG00000225075.1 RP11-426L16.3 4.41 1.37e-05 0.00346 0.3 0.23 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112575707 chr1:112693688~112696621:- LIHC cis rs2932538 0.922 rs12137107 ENSG00000225075.1 RP11-426L16.3 4.41 1.37e-05 0.00346 0.3 0.23 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112584815 chr1:112693688~112696621:- LIHC cis rs2932538 0.922 rs12758377 ENSG00000225075.1 RP11-426L16.3 4.41 1.37e-05 0.00346 0.3 0.23 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112594599 chr1:112693688~112696621:- LIHC cis rs2348418 0.702 rs10843116 ENSG00000247934.4 RP11-967K21.1 -4.41 1.37e-05 0.00346 -0.21 -0.23 Lung function (FEV1);Lung function (FVC); chr12:28162248 chr12:28163298~28190738:- LIHC cis rs2842992 0.83 rs2758313 ENSG00000237927.1 RP3-393E18.2 -4.41 1.37e-05 0.00346 -0.29 -0.23 Age-related macular degeneration (geographic atrophy); chr6:159733067 chr6:159586955~159589169:- LIHC cis rs812925 0.533 rs35507645 ENSG00000212978.6 AC016747.3 -4.41 1.37e-05 0.00346 -0.25 -0.23 Immature fraction of reticulocytes; chr2:61169631 chr2:61141592~61144969:- LIHC cis rs4834770 1 rs10034579 ENSG00000245958.5 RP11-33B1.1 -4.41 1.37e-05 0.00347 -0.22 -0.23 Blood protein levels; chr4:119322874 chr4:119454791~119552025:+ LIHC cis rs2834188 0.924 rs2040107 ENSG00000272659.1 AP000295.10 4.41 1.37e-05 0.00347 0.33 0.23 Narcolepsy; chr21:33303657 chr21:33309491~33310181:+ LIHC cis rs17373728 1 rs17373728 ENSG00000249395.2 CASC9 -4.41 1.37e-05 0.00347 -0.25 -0.23 Diabetic kidney disease; chr8:75313281 chr8:75223404~75324741:- LIHC cis rs6903823 0.508 rs1150724 ENSG00000204709.4 LINC01556 4.41 1.37e-05 0.00347 0.26 0.23 Pulmonary function; chr6:28282459 chr6:28943877~28944537:+ LIHC cis rs7714584 1 rs73282209 ENSG00000197083.10 ZNF300P1 4.41 1.37e-05 0.00347 0.37 0.23 Crohn's disease; chr5:150795397 chr5:150930645~150946289:- LIHC cis rs2976388 0.609 rs2585149 ENSG00000253741.1 CTD-2292P10.4 -4.41 1.37e-05 0.00347 -0.27 -0.23 Urinary tract infection frequency; chr8:142711902 chr8:142702252~142726973:- LIHC cis rs72675573 0.788 rs12137066 ENSG00000235612.1 RP1-158P9.1 -4.41 1.37e-05 0.00348 -0.3 -0.23 Monocyte count; chr1:56065183 chr1:56145721~56155224:+ LIHC cis rs5769707 0.521 rs6009810 ENSG00000235111.1 RP1-29C18.8 -4.41 1.37e-05 0.00348 -0.28 -0.23 Monocyte percentage of white cells;Monocyte count; chr22:49665892 chr22:49612657~49615716:- LIHC cis rs11098499 0.954 rs7437420 ENSG00000260091.1 RP11-33B1.4 -4.41 1.37e-05 0.00348 -0.17 -0.23 Corneal astigmatism; chr4:119391748 chr4:119409333~119410233:+ LIHC cis rs1577917 0.958 rs12199832 ENSG00000234155.1 RP11-30P6.6 4.41 1.37e-05 0.00348 0.31 0.23 Response to antipsychotic treatment; chr6:85943030 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs12207374 ENSG00000234155.1 RP11-30P6.6 4.41 1.37e-05 0.00348 0.31 0.23 Response to antipsychotic treatment; chr6:85946927 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs12213740 ENSG00000234155.1 RP11-30P6.6 4.41 1.37e-05 0.00348 0.31 0.23 Response to antipsychotic treatment; chr6:85947015 chr6:85387219~85390186:- LIHC cis rs6745190 0.512 rs35482602 ENSG00000236153.1 AC104076.3 -4.41 1.37e-05 0.00348 -0.32 -0.23 White blood cell count; chr2:181130594 chr2:180979427~180980090:- LIHC cis rs17711722 0.565 rs4717276 ENSG00000226002.1 RP11-460N20.5 4.41 1.37e-05 0.00348 0.25 0.23 Calcium levels; chr7:65829754 chr7:65084103~65100232:+ LIHC cis rs17301013 0.932 rs1653626 ENSG00000227373.4 RP11-160H22.5 -4.41 1.37e-05 0.00348 -0.29 -0.23 Systemic lupus erythematosus; chr1:174770348 chr1:174115300~174160004:- LIHC cis rs7208859 0.623 rs7219361 ENSG00000266490.1 CTD-2349P21.9 4.41 1.37e-05 0.00348 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753375 chr17:30792372~30792833:+ LIHC cis rs61160187 0.51 rs10072745 ENSG00000272308.1 RP11-231G3.1 -4.41 1.38e-05 0.00348 -0.28 -0.23 Educational attainment (years of education);Educational attainment (college completion); chr5:60787448 chr5:60866457~60866935:- LIHC cis rs227275 0.554 rs223382 ENSG00000246560.2 RP11-10L12.4 4.41 1.38e-05 0.00348 0.26 0.23 Allergic disease (asthma, hay fever or eczema); chr4:102831145 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223377 ENSG00000246560.2 RP11-10L12.4 4.41 1.38e-05 0.00348 0.26 0.23 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102834919 chr4:102828055~102844075:+ LIHC cis rs875971 0.545 rs801199 ENSG00000273142.1 RP11-458F8.4 -4.41 1.38e-05 0.00348 -0.22 -0.23 Aortic root size; chr7:66560286 chr7:66902857~66906297:+ LIHC cis rs875971 0.545 rs1638724 ENSG00000273142.1 RP11-458F8.4 -4.41 1.38e-05 0.00348 -0.22 -0.23 Aortic root size; chr7:66575494 chr7:66902857~66906297:+ LIHC cis rs2337406 0.925 rs76288499 ENSG00000274576.2 IGHV2-70 -4.41 1.38e-05 0.00349 -0.26 -0.23 Alzheimer's disease (late onset); chr14:106686309 chr14:106770577~106771020:- LIHC cis rs1865760 0.566 rs9379825 ENSG00000216436.2 HIST1H2APS1 -4.41 1.38e-05 0.00349 -0.27 -0.23 Height; chr6:26083643 chr6:25732497~25732827:+ LIHC cis rs1865760 0.566 rs9467672 ENSG00000216436.2 HIST1H2APS1 -4.41 1.38e-05 0.00349 -0.27 -0.23 Height; chr6:26083676 chr6:25732497~25732827:+ LIHC cis rs1865760 0.566 rs9295688 ENSG00000216436.2 HIST1H2APS1 -4.41 1.38e-05 0.00349 -0.27 -0.23 Height; chr6:26083989 chr6:25732497~25732827:+ LIHC cis rs950880 0.593 rs887972 ENSG00000234389.1 AC007278.3 -4.41 1.38e-05 0.00349 -0.23 -0.23 Serum protein levels (sST2); chr2:102424485 chr2:102438713~102440475:+ LIHC cis rs2275906 1 rs2275906 ENSG00000216436.2 HIST1H2APS1 4.41 1.38e-05 0.00349 0.45 0.23 Urate levels in lean individuals; chr6:25773581 chr6:25732497~25732827:+ LIHC cis rs2275906 1 rs72843517 ENSG00000216436.2 HIST1H2APS1 4.41 1.38e-05 0.00349 0.45 0.23 Urate levels in lean individuals; chr6:25773785 chr6:25732497~25732827:+ LIHC cis rs11673344 0.668 rs7248693 ENSG00000226686.6 LINC01535 4.41 1.38e-05 0.0035 0.35 0.23 Obesity-related traits; chr19:36991864 chr19:37251912~37265535:+ LIHC cis rs17826219 0.568 rs11658027 ENSG00000266490.1 CTD-2349P21.9 -4.41 1.38e-05 0.0035 -0.29 -0.23 Body mass index; chr17:30767864 chr17:30792372~30792833:+ LIHC cis rs763121 0.853 rs6001175 ENSG00000273076.1 RP3-508I15.22 4.41 1.38e-05 0.0035 0.26 0.23 Menopause (age at onset); chr22:38622329 chr22:38743495~38743910:+ LIHC cis rs733592 0.524 rs10875726 ENSG00000240399.1 RP1-228P16.1 -4.41 1.38e-05 0.0035 -0.22 -0.23 Plateletcrit; chr12:48032209 chr12:48054813~48055591:- LIHC cis rs651907 0.557 rs7645391 ENSG00000244119.1 PDCL3P4 4.41 1.38e-05 0.0035 0.24 0.23 Colorectal cancer; chr3:101642662 chr3:101712472~101713191:+ LIHC cis rs7662987 0.793 rs78790289 ENSG00000272777.1 RP11-571L19.8 4.41 1.38e-05 0.0035 0.51 0.23 Smoking initiation; chr4:99066736 chr4:99067256~99068125:- LIHC cis rs67311347 1 rs17078916 ENSG00000223797.4 ENTPD3-AS1 4.41 1.39e-05 0.0035 0.19 0.23 Renal cell carcinoma; chr3:40403947 chr3:40313802~40453329:- LIHC cis rs6085948 0.861 rs6054847 ENSG00000228888.1 LINC01428 -4.41 1.39e-05 0.00351 -0.42 -0.23 Interleukin-10 levels; chr20:7249794 chr20:7146467~7254202:- LIHC cis rs6085948 0.861 rs11908494 ENSG00000228888.1 LINC01428 -4.41 1.39e-05 0.00351 -0.42 -0.23 Interleukin-10 levels; chr20:7250266 chr20:7146467~7254202:- LIHC cis rs7412746 0.658 rs11582281 ENSG00000231073.1 RP11-316M1.3 4.41 1.39e-05 0.00351 0.24 0.23 Melanoma; chr1:150854355 chr1:150973123~150975534:+ LIHC cis rs7809950 1 rs987391 ENSG00000238832.1 snoU109 -4.41 1.39e-05 0.00351 -0.28 -0.23 Coronary artery disease; chr7:107460349 chr7:107603363~107603507:+ LIHC cis rs875971 0.66 rs12698534 ENSG00000273024.4 INTS4P2 -4.41 1.39e-05 0.00351 -0.26 -0.23 Aortic root size; chr7:66521858 chr7:65647864~65715661:+ LIHC cis rs875971 0.66 rs62465434 ENSG00000273024.4 INTS4P2 -4.41 1.39e-05 0.00351 -0.26 -0.23 Aortic root size; chr7:66540165 chr7:65647864~65715661:+ LIHC cis rs875971 0.66 rs13224319 ENSG00000273024.4 INTS4P2 -4.41 1.39e-05 0.00351 -0.26 -0.23 Aortic root size; chr7:66542376 chr7:65647864~65715661:+ LIHC cis rs875971 0.66 rs801217 ENSG00000273024.4 INTS4P2 4.41 1.39e-05 0.00351 0.26 0.23 Aortic root size; chr7:66545590 chr7:65647864~65715661:+ LIHC cis rs875971 0.638 rs801216 ENSG00000273024.4 INTS4P2 4.41 1.39e-05 0.00351 0.26 0.23 Aortic root size; chr7:66546680 chr7:65647864~65715661:+ LIHC cis rs875971 0.66 rs801211 ENSG00000273024.4 INTS4P2 4.41 1.39e-05 0.00351 0.26 0.23 Aortic root size; chr7:66550702 chr7:65647864~65715661:+ LIHC cis rs875971 0.638 rs801205 ENSG00000273024.4 INTS4P2 4.41 1.39e-05 0.00351 0.26 0.23 Aortic root size; chr7:66557157 chr7:65647864~65715661:+ LIHC cis rs875971 0.617 rs810400 ENSG00000273024.4 INTS4P2 4.41 1.39e-05 0.00351 0.26 0.23 Aortic root size; chr7:66557902 chr7:65647864~65715661:+ LIHC cis rs875971 0.638 rs3898855 ENSG00000273024.4 INTS4P2 4.41 1.39e-05 0.00351 0.26 0.23 Aortic root size; chr7:66571411 chr7:65647864~65715661:+ LIHC cis rs875971 0.638 rs10278816 ENSG00000273024.4 INTS4P2 4.41 1.39e-05 0.00351 0.26 0.23 Aortic root size; chr7:66572000 chr7:65647864~65715661:+ LIHC cis rs875971 0.66 rs10281080 ENSG00000273024.4 INTS4P2 4.41 1.39e-05 0.00351 0.26 0.23 Aortic root size; chr7:66577454 chr7:65647864~65715661:+ LIHC cis rs2072438 0.503 rs2146838 ENSG00000226752.6 PSMD5-AS1 4.41 1.39e-05 0.00352 0.24 0.23 Rheumatoid arthritis; chr9:121114027 chr9:120824828~120854385:+ LIHC cis rs2033711 0.503 rs7254299 ENSG00000269473.1 CTD-2619J13.19 4.41 1.39e-05 0.00352 0.27 0.23 Uric acid clearance; chr19:58373598 chr19:58440448~58445849:+ LIHC cis rs7131987 0.903 rs7308125 ENSG00000275476.1 RP11-996F15.4 -4.41 1.39e-05 0.00352 -0.27 -0.23 QT interval; chr12:29272278 chr12:29277397~29277882:- LIHC cis rs921968 0.565 rs11896209 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218734545 chr2:218818690~218819144:+ LIHC cis rs227275 0.524 rs223423 ENSG00000246560.2 RP11-10L12.4 4.41 1.39e-05 0.00352 0.26 0.23 Allergic disease (asthma, hay fever or eczema); chr4:102804737 chr4:102828055~102844075:+ LIHC cis rs921968 0.565 rs4674329 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218730784 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs4674330 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218730987 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs6436069 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218732462 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs6436070 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218733237 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs6436071 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218733318 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs6761437 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218733369 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs6436072 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218733372 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs6757772 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218753774 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs3770220 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218754827 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs3770219 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218755043 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs3821035 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218755500 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs13412324 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218755798 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs7599365 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218755843 chr2:218818690~218819144:+ LIHC cis rs921968 0.54 rs7582329 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218756186 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs12611632 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218756535 chr2:218818690~218819144:+ LIHC cis rs7607369 0.719 rs12613545 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218758781 chr2:218818690~218819144:+ LIHC cis rs7607369 0.719 rs7567622 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218759826 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs35358516 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218761000 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs1529382 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218761766 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs7605055 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218762327 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs62191658 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218765571 chr2:218818690~218819144:+ LIHC cis rs921968 0.519 rs62191659 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218765787 chr2:218818690~218819144:+ LIHC cis rs921968 0.521 rs56923478 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218773816 chr2:218818690~218819144:+ LIHC cis rs7607369 0.718 rs6727147 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218774301 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs6436082 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218774707 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs6436083 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218774996 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs6436084 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218775059 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs6745700 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218775139 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs6436086 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218775402 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs7599945 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218776805 chr2:218818690~218819144:+ LIHC cis rs597539 0.615 rs629426 ENSG00000250508.1 RP11-757G1.6 -4.41 1.39e-05 0.00352 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68903636 chr11:68870664~68874542:+ LIHC cis rs7945705 0.935 rs2568062 ENSG00000254860.4 TMEM9B-AS1 4.41 1.39e-05 0.00352 0.23 0.23 Hemoglobin concentration; chr11:8866398 chr11:8964675~8977527:+ LIHC cis rs921968 0.565 rs6436081 ENSG00000272555.1 RP11-459I19.1 -4.41 1.39e-05 0.00352 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218773161 chr2:218818690~218819144:+ LIHC cis rs2276314 1 rs2298715 ENSG00000278986.1 RP11-723J4.3 -4.41 1.4e-05 0.00352 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:35972462 chr18:35972151~35973916:+ LIHC cis rs2276314 1 rs4573997 ENSG00000278986.1 RP11-723J4.3 -4.41 1.4e-05 0.00352 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:35972605 chr18:35972151~35973916:+ LIHC cis rs8064024 0.681 rs1395602 ENSG00000267077.1 RP11-127I20.5 4.41 1.4e-05 0.00352 0.24 0.23 Cancer; chr16:4861238 chr16:4795265~4796532:- LIHC cis rs1577917 1 rs12196037 ENSG00000234155.1 RP11-30P6.6 4.41 1.4e-05 0.00353 0.31 0.23 Response to antipsychotic treatment; chr6:85984913 chr6:85387219~85390186:- LIHC cis rs11079159 1 rs10445344 ENSG00000263096.1 RP11-515O17.2 4.41 1.4e-05 0.00353 0.32 0.23 QRS duration; chr17:55290427 chr17:55271504~55273653:- LIHC cis rs2072510 0.722 rs2540496 ENSG00000257878.1 RP11-256L6.3 -4.41 1.4e-05 0.00353 -0.2 -0.23 Metabolite levels (small molecules and protein measures); chr12:96012725 chr12:95996521~96011489:+ LIHC cis rs2072510 0.722 rs2540495 ENSG00000257878.1 RP11-256L6.3 -4.41 1.4e-05 0.00353 -0.2 -0.23 Metabolite levels (small molecules and protein measures); chr12:96012945 chr12:95996521~96011489:+ LIHC cis rs638893 1 rs28827279 ENSG00000255239.1 AP002954.6 4.41 1.4e-05 0.00353 0.38 0.23 Vitiligo; chr11:118830054 chr11:118688039~118690600:- LIHC cis rs227275 0.554 rs223424 ENSG00000246560.2 RP11-10L12.4 4.41 1.4e-05 0.00353 0.26 0.23 Allergic disease (asthma, hay fever or eczema); chr4:102804177 chr4:102828055~102844075:+ LIHC cis rs875971 0.545 rs1267814 ENSG00000273142.1 RP11-458F8.4 -4.41 1.4e-05 0.00353 -0.22 -0.23 Aortic root size; chr7:66579422 chr7:66902857~66906297:+ LIHC cis rs916888 0.647 rs199524 ENSG00000260075.1 NSFP1 -4.41 1.4e-05 0.00353 -0.29 -0.23 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:46372855~46487141:+ LIHC cis rs960902 0.747 rs17020823 ENSG00000213553.4 RPLP0P6 4.41 1.4e-05 0.00353 0.19 0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37489925 chr2:38481851~38482804:+ LIHC cis rs709400 0.93 rs28513222 ENSG00000258534.1 CTD-2134A5.4 4.41 1.4e-05 0.00353 0.36 0.23 Body mass index; chr14:103561732 chr14:103854366~103880111:- LIHC cis rs3091242 0.933 rs61775174 ENSG00000224183.1 SDHDP6 4.41 1.4e-05 0.00353 0.27 0.23 Erythrocyte sedimentation rate; chr1:25460822 chr1:25294164~25294643:- LIHC cis rs904251 0.861 rs1757183 ENSG00000204110.6 RP1-153P14.8 4.41 1.4e-05 0.00353 0.29 0.23 Cognitive performance; chr6:37517014 chr6:37507348~37535616:+ LIHC cis rs1223397 1 rs1223399 ENSG00000215022.6 RP1-257A7.4 -4.41 1.4e-05 0.00353 -0.27 -0.23 Blood pressure; chr6:13270988 chr6:13264861~13295586:- LIHC cis rs4356975 0.798 rs4694588 ENSG00000250919.1 RP11-813N20.3 4.41 1.4e-05 0.00353 0.23 0.23 Obesity-related traits; chr4:69044664 chr4:69027831~69044578:+ LIHC cis rs4356975 0.83 rs7693166 ENSG00000250919.1 RP11-813N20.3 4.41 1.4e-05 0.00353 0.23 0.23 Obesity-related traits; chr4:69044866 chr4:69027831~69044578:+ LIHC cis rs4356975 0.83 rs6422321 ENSG00000250919.1 RP11-813N20.3 4.41 1.4e-05 0.00353 0.23 0.23 Obesity-related traits; chr4:69044911 chr4:69027831~69044578:+ LIHC cis rs748404 0.723 rs512431 ENSG00000166763.7 STRCP1 -4.41 1.4e-05 0.00353 -0.28 -0.23 Lung cancer; chr15:43249741 chr15:43699488~43718184:- LIHC cis rs1247318 1 rs1781546 ENSG00000243831.1 RP1-81D8.4 4.41 1.4e-05 0.00354 0.33 0.23 Aging; chr6:160915375 chr6:160666228~160676523:- LIHC cis rs1247318 1 rs1663025 ENSG00000243831.1 RP1-81D8.4 4.41 1.4e-05 0.00354 0.33 0.23 Aging; chr6:160915377 chr6:160666228~160676523:- LIHC cis rs1247318 1 rs1247310 ENSG00000243831.1 RP1-81D8.4 4.41 1.4e-05 0.00354 0.33 0.23 Aging; chr6:160915496 chr6:160666228~160676523:- LIHC cis rs1247318 0.853 rs1247309 ENSG00000243831.1 RP1-81D8.4 4.41 1.4e-05 0.00354 0.33 0.23 Aging; chr6:160915604 chr6:160666228~160676523:- LIHC cis rs10912872 0.634 rs10912842 ENSG00000231424.2 RP1-45C12.1 4.41 1.4e-05 0.00354 0.25 0.23 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr1:171365688 chr1:171247580~171251794:- LIHC cis rs11637445 0.603 rs7183168 ENSG00000260657.2 RP11-315D16.4 -4.41 1.4e-05 0.00354 -0.32 -0.23 Posterior cortical atrophy and Alzheimer's disease; chr15:67829145 chr15:68267792~68277994:- LIHC cis rs755249 0.917 rs61232586 ENSG00000182109.6 RP11-69E11.4 4.41 1.4e-05 0.00354 0.33 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39620685 chr1:39522280~39546187:- LIHC cis rs875971 0.545 rs2420456 ENSG00000273142.1 RP11-458F8.4 4.41 1.4e-05 0.00354 0.22 0.23 Aortic root size; chr7:66280619 chr7:66902857~66906297:+ LIHC cis rs6439153 0.933 rs11711812 ENSG00000231305.3 RP11-723O4.2 4.41 1.4e-05 0.00354 0.25 0.23 Pneumococcal bacteremia; chr3:128989711 chr3:128861313~128871540:- LIHC cis rs728616 0.867 rs61858980 ENSG00000225484.5 NUTM2B-AS1 -4.41 1.4e-05 0.00354 -0.51 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80056862 chr10:79663088~79826594:- LIHC cis rs728616 0.867 rs2152550 ENSG00000225484.5 NUTM2B-AS1 -4.41 1.4e-05 0.00354 -0.51 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80058753 chr10:79663088~79826594:- LIHC cis rs875971 0.545 rs10261710 ENSG00000228409.4 CCT6P1 -4.41 1.41e-05 0.00354 -0.2 -0.23 Aortic root size; chr7:66249202 chr7:65751142~65763354:+ LIHC cis rs858239 0.862 rs1728292 ENSG00000226816.2 AC005082.12 4.41 1.41e-05 0.00355 0.29 0.23 Cerebrospinal fluid biomarker levels; chr7:23223855 chr7:23206013~23208045:+ LIHC cis rs5758511 0.689 rs17478227 ENSG00000237037.8 NDUFA6-AS1 4.41 1.41e-05 0.00355 0.47 0.23 Birth weight; chr22:42258321 chr22:42090931~42137742:+ LIHC cis rs4925386 1 rs4925389 ENSG00000273619.1 RP5-908M14.9 4.41 1.41e-05 0.00355 0.19 0.23 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62347456 chr20:62386303~62386970:- LIHC cis rs4650994 0.816 rs2811301 ENSG00000213057.5 C1orf220 -4.41 1.41e-05 0.00355 -0.19 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178625061 chr1:178542752~178548889:+ LIHC cis rs1005277 0.691 rs2474558 ENSG00000099251.13 HSD17B7P2 -4.41 1.41e-05 0.00355 -0.28 -0.23 Extrinsic epigenetic age acceleration; chr10:38197213 chr10:38356380~38378505:+ LIHC cis rs7129556 0.69 rs648601 ENSG00000254459.1 RP11-91P24.7 4.41 1.41e-05 0.00355 0.38 0.23 Weight loss (gastric bypass surgery); chr11:77875864 chr11:77829654~77872262:- LIHC cis rs11648785 0.777 rs4433810 ENSG00000221819.5 GAS8-AS1 -4.41 1.41e-05 0.00355 -0.32 -0.23 Tanning; chr16:90032058 chr16:90028908~90029367:- LIHC cis rs11098499 0.644 rs10009566 ENSG00000245958.5 RP11-33B1.1 -4.41 1.41e-05 0.00355 -0.24 -0.23 Corneal astigmatism; chr4:119637453 chr4:119454791~119552025:+ LIHC cis rs2274273 0.804 rs28428911 ENSG00000258413.1 RP11-665C16.6 -4.41 1.41e-05 0.00356 -0.28 -0.23 Protein biomarker; chr14:55376878 chr14:55262767~55272075:- LIHC cis rs2274273 0.805 rs28660594 ENSG00000258413.1 RP11-665C16.6 -4.41 1.41e-05 0.00356 -0.28 -0.23 Protein biomarker; chr14:55379456 chr14:55262767~55272075:- LIHC cis rs42490 0.716 rs40636 ENSG00000251136.7 RP11-37B2.1 -4.41 1.41e-05 0.00356 -0.2 -0.23 Leprosy; chr8:89809079 chr8:89609409~89757727:- LIHC cis rs1865760 0.532 rs2794719 ENSG00000216436.2 HIST1H2APS1 -4.41 1.41e-05 0.00356 -0.27 -0.23 Height; chr6:26088662 chr6:25732497~25732827:+ LIHC cis rs11098499 0.754 rs10212714 ENSG00000260091.1 RP11-33B1.4 -4.41 1.41e-05 0.00356 -0.16 -0.23 Corneal astigmatism; chr4:119333147 chr4:119409333~119410233:+ LIHC cis rs11971779 0.941 rs1127424 ENSG00000273391.1 RP11-634H22.1 4.41 1.41e-05 0.00356 0.22 0.23 Diisocyanate-induced asthma; chr7:139422914 chr7:139359032~139359566:- LIHC cis rs13083990 0.959 rs10934583 ENSG00000272758.4 RP11-299J3.8 4.41 1.41e-05 0.00356 0.25 0.23 Cardiac Troponin-T levels; chr3:122294557 chr3:122416207~122443180:+ LIHC cis rs13083990 0.92 rs13061521 ENSG00000272758.4 RP11-299J3.8 4.41 1.41e-05 0.00356 0.25 0.23 Cardiac Troponin-T levels; chr3:122295835 chr3:122416207~122443180:+ LIHC cis rs1005277 0.577 rs4934906 ENSG00000099251.13 HSD17B7P2 4.41 1.41e-05 0.00356 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:37726100 chr10:38356380~38378505:+ LIHC cis rs2015599 0.623 rs10843385 ENSG00000275476.1 RP11-996F15.4 -4.41 1.41e-05 0.00356 -0.29 -0.23 Platelet count;Mean platelet volume; chr12:29323100 chr12:29277397~29277882:- LIHC cis rs2015599 0.601 rs17715086 ENSG00000275476.1 RP11-996F15.4 -4.41 1.41e-05 0.00356 -0.29 -0.23 Platelet count;Mean platelet volume; chr12:29329073 chr12:29277397~29277882:- LIHC cis rs4834770 1 rs4336213 ENSG00000245958.5 RP11-33B1.1 -4.41 1.41e-05 0.00356 -0.22 -0.23 Blood protein levels; chr4:119315314 chr4:119454791~119552025:+ LIHC cis rs1823913 1 rs1823913 ENSG00000227542.1 AC092614.2 4.41 1.41e-05 0.00356 0.24 0.23 Obesity-related traits; chr2:191253321 chr2:191229165~191246172:- LIHC cis rs651907 0.557 rs13066768 ENSG00000244119.1 PDCL3P4 -4.41 1.41e-05 0.00357 -0.24 -0.23 Colorectal cancer; chr3:101768076 chr3:101712472~101713191:+ LIHC cis rs2836974 0.533 rs4817999 ENSG00000255568.3 BRWD1-AS2 -4.41 1.42e-05 0.00357 -0.2 -0.23 Cognitive function; chr21:39182429 chr21:39313935~39314962:+ LIHC cis rs6480314 0.831 rs1900007 ENSG00000233590.1 RP11-153K11.3 -4.41 1.42e-05 0.00357 -0.34 -0.23 Optic nerve measurement (disc area); chr10:68218018 chr10:68233251~68242379:- LIHC cis rs11971779 0.666 rs6467847 ENSG00000273391.1 RP11-634H22.1 4.4 1.42e-05 0.00357 0.21 0.23 Diisocyanate-induced asthma; chr7:139394690 chr7:139359032~139359566:- LIHC cis rs2976388 0.647 rs2585138 ENSG00000253741.1 CTD-2292P10.4 -4.4 1.42e-05 0.00357 -0.26 -0.23 Urinary tract infection frequency; chr8:142727533 chr8:142702252~142726973:- LIHC cis rs755249 0.958 rs61781370 ENSG00000182109.6 RP11-69E11.4 4.4 1.42e-05 0.00357 0.33 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39579628 chr1:39522280~39546187:- LIHC cis rs812925 0.533 rs60997156 ENSG00000212978.6 AC016747.3 -4.4 1.42e-05 0.00357 -0.25 -0.23 Immature fraction of reticulocytes; chr2:61169404 chr2:61141592~61144969:- LIHC cis rs881375 0.678 rs10818488 ENSG00000226752.6 PSMD5-AS1 -4.4 1.42e-05 0.00357 -0.24 -0.23 Rheumatoid arthritis; chr9:120942809 chr9:120824828~120854385:+ LIHC cis rs812925 0.512 rs1177309 ENSG00000271889.1 RP11-493E12.1 4.4 1.42e-05 0.00357 0.27 0.23 Immature fraction of reticulocytes; chr2:61158113 chr2:61151433~61162105:- LIHC cis rs960902 0.592 rs10865125 ENSG00000213553.4 RPLP0P6 -4.4 1.42e-05 0.00357 -0.19 -0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37510740 chr2:38481851~38482804:+ LIHC cis rs6802315 0.575 rs57932243 ENSG00000272087.1 RP11-379F4.7 4.4 1.42e-05 0.00358 0.27 0.23 Periodontitis (CDC/AAP); chr3:158754187 chr3:158693120~158693768:- LIHC cis rs7923609 1 rs4595427 ENSG00000232075.1 MRPL35P2 -4.4 1.42e-05 0.00358 -0.26 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63253184 chr10:63634317~63634827:- LIHC cis rs2581828 0.656 rs2581800 ENSG00000242142.1 SERBP1P3 4.4 1.42e-05 0.00358 0.27 0.23 Crohn's disease; chr3:53075336 chr3:53064283~53065091:- LIHC cis rs7937890 0.559 rs1116739 ENSG00000251991.1 RNU7-49P 4.4 1.42e-05 0.00358 0.25 0.23 Mitochondrial DNA levels; chr11:14467636 chr11:14478892~14478953:+ LIHC cis rs748404 0.66 rs509306 ENSG00000166763.7 STRCP1 4.4 1.42e-05 0.00358 0.28 0.23 Lung cancer; chr15:43422973 chr15:43699488~43718184:- LIHC cis rs1165668 0.816 rs1866072 ENSG00000257327.1 RP11-650K20.3 4.4 1.42e-05 0.00358 0.27 0.23 Coronary heart disease (SNP X SNP interaction); chr12:103916928 chr12:103841451~103844664:+ LIHC cis rs3733585 0.683 rs6449140 ENSG00000250413.1 RP11-448G15.1 4.4 1.42e-05 0.00358 0.3 0.23 Cleft plate (environmental tobacco smoke interaction); chr4:9934813 chr4:10006482~10009725:+ LIHC cis rs3091242 0.933 rs34933589 ENSG00000224183.1 SDHDP6 4.4 1.42e-05 0.00358 0.27 0.23 Erythrocyte sedimentation rate; chr1:25461707 chr1:25294164~25294643:- LIHC cis rs11098499 0.909 rs73842633 ENSG00000260091.1 RP11-33B1.4 -4.4 1.42e-05 0.00358 -0.17 -0.23 Corneal astigmatism; chr4:119454309 chr4:119409333~119410233:+ LIHC cis rs6964833 0.786 rs35633336 ENSG00000277053.3 GTF2IP1 -4.4 1.42e-05 0.00358 -0.28 -0.23 Menarche (age at onset); chr7:74643961 chr7:75185385~75237696:- LIHC cis rs6964833 0.935 rs34630792 ENSG00000277053.3 GTF2IP1 -4.4 1.42e-05 0.00358 -0.28 -0.23 Menarche (age at onset); chr7:74646869 chr7:75185385~75237696:- LIHC cis rs6565180 1 rs11863150 ENSG00000183604.13 SMG1P5 4.4 1.42e-05 0.00359 0.23 0.23 Tonsillectomy; chr16:30374182 chr16:30267553~30335374:- LIHC cis rs6801605 0.743 rs1025689 ENSG00000271916.1 RP11-884K10.6 -4.4 1.42e-05 0.00359 -0.3 -0.23 Blood protein levels; chr3:53849695 chr3:53797764~53798019:- LIHC cis rs6745190 0.953 rs12989967 ENSG00000236153.1 AC104076.3 -4.4 1.43e-05 0.00359 -0.35 -0.23 White blood cell count; chr2:181040627 chr2:180979427~180980090:- LIHC cis rs13287066 0.692 rs7031032 ENSG00000227603.1 RP11-165J3.6 4.4 1.43e-05 0.00359 0.27 0.23 Intelligence (multi-trait analysis); chr9:93412186 chr9:93435332~93437121:- LIHC cis rs10262624 0.935 rs6966641 ENSG00000234286.1 AC006026.13 -4.4 1.43e-05 0.00359 -0.26 -0.23 Schizophrenia; chr7:23866979 chr7:23680195~23680786:- LIHC cis rs901683 0.702 rs76551593 ENSG00000230869.1 CTGLF10P -4.4 1.43e-05 0.00359 -0.52 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45615533 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs76831684 ENSG00000230869.1 CTGLF10P -4.4 1.43e-05 0.00359 -0.52 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45620584 chr10:45678692~45700532:+ LIHC cis rs12554020 0.892 rs76488437 ENSG00000227603.1 RP11-165J3.6 4.4 1.43e-05 0.00359 0.33 0.23 Schizophrenia; chr9:93605514 chr9:93435332~93437121:- LIHC cis rs12554020 0.681 rs80062429 ENSG00000227603.1 RP11-165J3.6 4.4 1.43e-05 0.00359 0.33 0.23 Schizophrenia; chr9:93608830 chr9:93435332~93437121:- LIHC cis rs2060793 0.712 rs10832290 ENSG00000251991.1 RNU7-49P 4.4 1.43e-05 0.00359 0.26 0.23 Vitamin D levels; chr11:14650684 chr11:14478892~14478953:+ LIHC cis rs2060793 0.774 rs1403249 ENSG00000251991.1 RNU7-49P 4.4 1.43e-05 0.00359 0.26 0.23 Vitamin D levels; chr11:14651438 chr11:14478892~14478953:+ LIHC cis rs2060793 0.741 rs7119073 ENSG00000251991.1 RNU7-49P 4.4 1.43e-05 0.00359 0.26 0.23 Vitamin D levels; chr11:14669416 chr11:14478892~14478953:+ LIHC cis rs2060793 0.741 rs4344519 ENSG00000251991.1 RNU7-49P 4.4 1.43e-05 0.00359 0.26 0.23 Vitamin D levels; chr11:14701347 chr11:14478892~14478953:+ LIHC cis rs2060793 0.712 rs11023310 ENSG00000251991.1 RNU7-49P 4.4 1.43e-05 0.00359 0.26 0.23 Vitamin D levels; chr11:14703717 chr11:14478892~14478953:+ LIHC cis rs3091242 0.933 rs926438 ENSG00000224183.1 SDHDP6 -4.4 1.43e-05 0.00359 -0.26 -0.23 Erythrocyte sedimentation rate; chr1:25427147 chr1:25294164~25294643:- LIHC cis rs10262624 1 rs2023786 ENSG00000234286.1 AC006026.13 -4.4 1.43e-05 0.00359 -0.26 -0.23 Schizophrenia; chr7:23875534 chr7:23680195~23680786:- LIHC cis rs10262624 1 rs9769098 ENSG00000234286.1 AC006026.13 -4.4 1.43e-05 0.00359 -0.26 -0.23 Schizophrenia; chr7:23877113 chr7:23680195~23680786:- LIHC cis rs10262624 0.967 rs12333669 ENSG00000234286.1 AC006026.13 -4.4 1.43e-05 0.00359 -0.26 -0.23 Schizophrenia; chr7:23877267 chr7:23680195~23680786:- LIHC cis rs10262624 0.935 rs10487596 ENSG00000234286.1 AC006026.13 -4.4 1.43e-05 0.00359 -0.26 -0.23 Schizophrenia; chr7:23877458 chr7:23680195~23680786:- LIHC cis rs10262624 1 rs10950973 ENSG00000234286.1 AC006026.13 -4.4 1.43e-05 0.00359 -0.26 -0.23 Schizophrenia; chr7:23877658 chr7:23680195~23680786:- LIHC cis rs10262624 1 rs10950974 ENSG00000234286.1 AC006026.13 -4.4 1.43e-05 0.00359 -0.26 -0.23 Schizophrenia; chr7:23877661 chr7:23680195~23680786:- LIHC cis rs10262624 1 rs10950975 ENSG00000234286.1 AC006026.13 -4.4 1.43e-05 0.00359 -0.26 -0.23 Schizophrenia; chr7:23877861 chr7:23680195~23680786:- LIHC cis rs10262624 0.967 rs13244145 ENSG00000234286.1 AC006026.13 -4.4 1.43e-05 0.00359 -0.26 -0.23 Schizophrenia; chr7:23878123 chr7:23680195~23680786:- LIHC cis rs10262624 1 rs13244265 ENSG00000234286.1 AC006026.13 -4.4 1.43e-05 0.00359 -0.26 -0.23 Schizophrenia; chr7:23878284 chr7:23680195~23680786:- LIHC cis rs11971779 0.941 rs6954453 ENSG00000273391.1 RP11-634H22.1 4.4 1.43e-05 0.0036 0.22 0.23 Diisocyanate-induced asthma; chr7:139347048 chr7:139359032~139359566:- LIHC cis rs11971779 0.941 rs4732368 ENSG00000273391.1 RP11-634H22.1 4.4 1.43e-05 0.0036 0.22 0.23 Diisocyanate-induced asthma; chr7:139349461 chr7:139359032~139359566:- LIHC cis rs960902 0.818 rs60691585 ENSG00000213553.4 RPLP0P6 4.4 1.43e-05 0.0036 0.19 0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37487285 chr2:38481851~38482804:+ LIHC cis rs1062177 0.724 rs2915828 ENSG00000253921.1 CTB-113P19.3 4.4 1.43e-05 0.0036 0.27 0.23 Preschool internalizing problems; chr5:151738560 chr5:151753992~151767247:+ LIHC cis rs1062177 0.724 rs2964590 ENSG00000253921.1 CTB-113P19.3 4.4 1.43e-05 0.0036 0.27 0.23 Preschool internalizing problems; chr5:151738585 chr5:151753992~151767247:+ LIHC cis rs11096990 0.634 rs6531703 ENSG00000249685.1 RP11-360F5.3 -4.4 1.43e-05 0.0036 -0.27 -0.23 Cognitive function; chr4:39281786 chr4:39133913~39135608:+ LIHC cis rs3738443 0.868 rs56029850 ENSG00000259865.1 RP11-488L18.10 4.4 1.43e-05 0.0036 0.21 0.23 Alcohol dependence; chr1:247201027 chr1:247187281~247188526:- LIHC cis rs3738443 0.868 rs55643126 ENSG00000259865.1 RP11-488L18.10 4.4 1.43e-05 0.0036 0.21 0.23 Alcohol dependence; chr1:247201042 chr1:247187281~247188526:- LIHC cis rs2243480 1 rs464895 ENSG00000230295.1 RP11-458F8.2 -4.4 1.43e-05 0.00361 -0.24 -0.23 Diabetic kidney disease; chr7:66062119 chr7:66880708~66882981:+ LIHC cis rs763121 0.853 rs5750677 ENSG00000273076.1 RP3-508I15.22 4.4 1.43e-05 0.00361 0.27 0.23 Menopause (age at onset); chr22:38751710 chr22:38743495~38743910:+ LIHC cis rs7849270 0.959 rs9408986 ENSG00000268707.1 RP11-247A12.7 4.4 1.44e-05 0.00361 0.27 0.23 Blood metabolite ratios; chr9:129126156 chr9:129170434~129170940:+ LIHC cis rs1015362 0.504 rs6059552 ENSG00000276073.1 RP5-1125A11.7 -4.4 1.44e-05 0.00361 -0.3 -0.23 Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling; chr20:33923820 chr20:33985617~33988989:- LIHC cis rs2072510 0.593 rs2540499 ENSG00000257878.1 RP11-256L6.3 4.4 1.44e-05 0.00361 0.3 0.23 Metabolite levels (small molecules and protein measures); chr12:96006091 chr12:95996521~96011489:+ LIHC cis rs1075232 1 rs9672214 ENSG00000270055.1 CTD-3092A11.2 -4.4 1.44e-05 0.00361 -0.45 -0.23 Survival in colorectal cancer (non-distant metastatic); chr15:31385572 chr15:30487963~30490313:+ LIHC cis rs9896933 0.623 rs77166830 ENSG00000263063.1 RP11-388C12.1 -4.4 1.44e-05 0.00362 -0.33 -0.23 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82875649 chr17:82713908~82716255:- LIHC cis rs875971 0.545 rs73142245 ENSG00000228409.4 CCT6P1 -4.4 1.44e-05 0.00362 -0.19 -0.23 Aortic root size; chr7:66226662 chr7:65751142~65763354:+ LIHC cis rs227275 0.554 rs223363 ENSG00000246560.2 RP11-10L12.4 4.4 1.44e-05 0.00362 0.26 0.23 Allergic disease (asthma, hay fever or eczema); chr4:102846182 chr4:102828055~102844075:+ LIHC cis rs763121 0.853 rs6001214 ENSG00000273076.1 RP3-508I15.22 4.4 1.44e-05 0.00362 0.27 0.23 Menopause (age at onset); chr22:38753150 chr22:38743495~38743910:+ LIHC cis rs2834655 0.861 rs11088296 ENSG00000237945.6 LINC00649 -4.4 1.44e-05 0.00362 -0.43 -0.23 Immune response to smallpox vaccine (IL-6); chr21:34865249 chr21:33915534~33977691:+ LIHC cis rs7208859 0.673 rs9911989 ENSG00000266490.1 CTD-2349P21.9 -4.4 1.44e-05 0.00362 -0.29 -0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910684 chr17:30792372~30792833:+ LIHC cis rs1865760 0.566 rs1539183 ENSG00000216436.2 HIST1H2APS1 -4.4 1.44e-05 0.00362 -0.27 -0.23 Height; chr6:26074823 chr6:25732497~25732827:+ LIHC cis rs1865760 0.566 rs9295686 ENSG00000216436.2 HIST1H2APS1 -4.4 1.44e-05 0.00362 -0.27 -0.23 Height; chr6:26081755 chr6:25732497~25732827:+ LIHC cis rs1865760 0.532 rs9295687 ENSG00000216436.2 HIST1H2APS1 -4.4 1.44e-05 0.00362 -0.27 -0.23 Height; chr6:26082482 chr6:25732497~25732827:+ LIHC cis rs1865760 0.566 rs4529296 ENSG00000216436.2 HIST1H2APS1 -4.4 1.44e-05 0.00362 -0.27 -0.23 Height; chr6:26082907 chr6:25732497~25732827:+ LIHC cis rs1865760 0.566 rs1971509 ENSG00000216436.2 HIST1H2APS1 -4.4 1.44e-05 0.00362 -0.27 -0.23 Height; chr6:26085549 chr6:25732497~25732827:+ LIHC cis rs1865760 0.532 rs2006736 ENSG00000216436.2 HIST1H2APS1 -4.4 1.44e-05 0.00362 -0.27 -0.23 Height; chr6:26085789 chr6:25732497~25732827:+ LIHC cis rs1865760 0.566 rs1800702 ENSG00000216436.2 HIST1H2APS1 -4.4 1.44e-05 0.00362 -0.27 -0.23 Height; chr6:26086235 chr6:25732497~25732827:+ LIHC cis rs1865760 0.566 rs2794720 ENSG00000216436.2 HIST1H2APS1 -4.4 1.44e-05 0.00362 -0.27 -0.23 Height; chr6:26086974 chr6:25732497~25732827:+ LIHC cis rs2276314 0.947 rs16967319 ENSG00000278986.1 RP11-723J4.3 -4.4 1.44e-05 0.00363 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:35993562 chr18:35972151~35973916:+ LIHC cis rs7809950 1 rs2057837 ENSG00000238832.1 snoU109 4.4 1.44e-05 0.00363 0.28 0.23 Coronary artery disease; chr7:107582280 chr7:107603363~107603507:+ LIHC cis rs7044106 0.791 rs10985001 ENSG00000238181.2 AHCYP2 -4.4 1.45e-05 0.00363 -0.27 -0.23 Hip circumference adjusted for BMI; chr9:120721954 chr9:120720673~120721972:+ LIHC cis rs7208859 0.573 rs7223803 ENSG00000266490.1 CTD-2349P21.9 4.4 1.45e-05 0.00363 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750175 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs55814012 ENSG00000266490.1 CTD-2349P21.9 4.4 1.45e-05 0.00363 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750679 chr17:30792372~30792833:+ LIHC cis rs17826219 0.5 rs2449749 ENSG00000266490.1 CTD-2349P21.9 4.4 1.45e-05 0.00363 0.29 0.23 Body mass index; chr17:30751280 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9894709 ENSG00000266490.1 CTD-2349P21.9 4.4 1.45e-05 0.00363 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751436 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9896603 ENSG00000266490.1 CTD-2349P21.9 4.4 1.45e-05 0.00363 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751494 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs8080882 ENSG00000266490.1 CTD-2349P21.9 4.4 1.45e-05 0.00363 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30754128 chr17:30792372~30792833:+ LIHC cis rs8040855 0.576 rs62022527 ENSG00000259295.5 CSPG4P12 4.4 1.45e-05 0.00363 0.36 0.23 Bulimia nervosa; chr15:84988022 chr15:85191438~85213905:+ LIHC cis rs11098499 0.779 rs28495013 ENSG00000260091.1 RP11-33B1.4 -4.4 1.45e-05 0.00364 -0.17 -0.23 Corneal astigmatism; chr4:119454676 chr4:119409333~119410233:+ LIHC cis rs2834288 0.5 rs766425 ENSG00000237945.6 LINC00649 4.4 1.45e-05 0.00364 0.3 0.23 Gut microbiota (bacterial taxa); chr21:33962264 chr21:33915534~33977691:+ LIHC cis rs651907 0.557 rs17347644 ENSG00000244119.1 PDCL3P4 4.4 1.45e-05 0.00364 0.24 0.23 Colorectal cancer; chr3:101828889 chr3:101712472~101713191:+ LIHC cis rs2834188 0.669 rs1467845 ENSG00000272659.1 AP000295.10 -4.4 1.45e-05 0.00364 -0.32 -0.23 Narcolepsy; chr21:33294071 chr21:33309491~33310181:+ LIHC cis rs9326248 0.52 rs2735183 ENSG00000236267.1 AP006216.5 4.4 1.45e-05 0.00364 0.24 0.23 Blood protein levels; chr11:117144479 chr11:116813204~116814003:- LIHC cis rs3015497 0.586 rs12587821 ENSG00000269906.1 RP11-248J18.2 4.4 1.45e-05 0.00364 0.29 0.23 Mean platelet volume; chr14:50625836 chr14:50662511~50663178:- LIHC cis rs3015497 0.586 rs12587842 ENSG00000269906.1 RP11-248J18.2 4.4 1.45e-05 0.00364 0.29 0.23 Mean platelet volume; chr14:50625844 chr14:50662511~50663178:- LIHC cis rs12478296 0.786 rs6721704 ENSG00000261186.2 RP11-341N2.1 -4.4 1.45e-05 0.00364 -0.31 -0.23 Obesity-related traits; chr2:242052772 chr2:242087351~242088457:- LIHC cis rs2562456 0.876 rs11085467 ENSG00000268555.1 RP11-678G14.3 4.4 1.45e-05 0.00364 0.29 0.23 Pain; chr19:21569041 chr19:21570822~21587322:- LIHC cis rs8091660 0.929 rs4939780 ENSG00000278983.1 RP11-426J5.3 4.4 1.45e-05 0.00364 0.34 0.23 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48568873 chr18:48564795~48568342:+ LIHC cis rs17711722 0.522 rs4642526 ENSG00000226002.1 RP11-460N20.5 4.4 1.45e-05 0.00364 0.25 0.23 Calcium levels; chr7:65751755 chr7:65084103~65100232:+ LIHC cis rs367615 0.506 rs2914684 ENSG00000249476.1 CTD-2587M2.1 -4.4 1.45e-05 0.00364 -0.27 -0.23 Colorectal cancer (SNP x SNP interaction); chr5:109439409 chr5:109237120~109326369:- LIHC cis rs2581828 0.646 rs9757079 ENSG00000242142.1 SERBP1P3 -4.4 1.45e-05 0.00365 -0.3 -0.23 Crohn's disease; chr3:53121142 chr3:53064283~53065091:- LIHC cis rs2243480 0.522 rs12698511 ENSG00000230295.1 RP11-458F8.2 -4.4 1.45e-05 0.00365 -0.26 -0.23 Diabetic kidney disease; chr7:66009932 chr7:66880708~66882981:+ LIHC cis rs783540 0.521 rs28719490 ENSG00000278603.1 RP13-608F4.5 4.4 1.45e-05 0.00365 0.31 0.23 Schizophrenia; chr15:82720688 chr15:82472203~82472426:+ LIHC cis rs11098499 0.908 rs28499576 ENSG00000260091.1 RP11-33B1.4 -4.4 1.45e-05 0.00365 -0.17 -0.23 Corneal astigmatism; chr4:119465522 chr4:119409333~119410233:+ LIHC cis rs6442522 1 rs6778562 ENSG00000249786.6 EAF1-AS1 4.4 1.45e-05 0.00365 0.27 0.23 Uric acid levels; chr3:15441268 chr3:15436171~15455940:- LIHC cis rs960902 0.71 rs2192943 ENSG00000213553.4 RPLP0P6 -4.4 1.45e-05 0.00365 -0.19 -0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37504317 chr2:38481851~38482804:+ LIHC cis rs227275 0.554 rs223371 ENSG00000246560.2 RP11-10L12.4 4.4 1.45e-05 0.00365 0.26 0.23 Allergic disease (asthma, hay fever or eczema); chr4:102838032 chr4:102828055~102844075:+ LIHC cis rs7809950 1 rs2066735 ENSG00000238832.1 snoU109 -4.4 1.46e-05 0.00366 -0.28 -0.23 Coronary artery disease; chr7:107548274 chr7:107603363~107603507:+ LIHC cis rs2337406 1 rs79452530 ENSG00000274576.2 IGHV2-70 -4.4 1.46e-05 0.00366 -0.26 -0.23 Alzheimer's disease (late onset); chr14:106699992 chr14:106770577~106771020:- LIHC cis rs2337406 0.85 rs4774179 ENSG00000274576.2 IGHV2-70 -4.4 1.46e-05 0.00366 -0.26 -0.23 Alzheimer's disease (late onset); chr14:106700837 chr14:106770577~106771020:- LIHC cis rs901683 0.85 rs73291122 ENSG00000230869.1 CTGLF10P -4.4 1.46e-05 0.00366 -0.55 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45603955 chr10:45678692~45700532:+ LIHC cis rs597539 0.652 rs513359 ENSG00000250508.1 RP11-757G1.6 4.4 1.46e-05 0.00366 0.35 0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68902028 chr11:68870664~68874542:+ LIHC cis rs2739330 0.828 rs2877178 ENSG00000206090.4 AP000350.7 4.4 1.46e-05 0.00366 0.27 0.23 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23939998~23942798:+ LIHC cis rs330048 0.545 rs11774353 ENSG00000254340.1 RP11-10A14.3 4.4 1.46e-05 0.00366 0.22 0.23 Systemic lupus erythematosus; chr8:9295617 chr8:9141424~9145435:+ LIHC cis rs150992 0.507 rs377731 ENSG00000248489.1 CTD-2007H13.3 4.4 1.46e-05 0.00367 0.31 0.23 Body mass index; chr5:98996535 chr5:98929171~98995013:+ LIHC cis rs748404 0.697 rs564946 ENSG00000166763.7 STRCP1 4.4 1.46e-05 0.00367 0.29 0.23 Lung cancer; chr15:43264074 chr15:43699488~43718184:- LIHC cis rs748404 0.723 rs565658 ENSG00000166763.7 STRCP1 4.4 1.46e-05 0.00367 0.29 0.23 Lung cancer; chr15:43264109 chr15:43699488~43718184:- LIHC cis rs748404 0.697 rs579651 ENSG00000166763.7 STRCP1 4.4 1.46e-05 0.00367 0.29 0.23 Lung cancer; chr15:43266178 chr15:43699488~43718184:- LIHC cis rs748404 0.697 rs473016 ENSG00000166763.7 STRCP1 4.4 1.46e-05 0.00367 0.29 0.23 Lung cancer; chr15:43266625 chr15:43699488~43718184:- LIHC cis rs56205728 0.606 rs2898991 ENSG00000273855.1 RP11-133K1.12 4.4 1.46e-05 0.00367 0.26 0.23 Schizophrenia; chr15:40304367 chr15:40285468~40285909:- LIHC cis rs56205728 0.606 rs3784398 ENSG00000273855.1 RP11-133K1.12 4.4 1.46e-05 0.00367 0.26 0.23 Schizophrenia; chr15:40304665 chr15:40285468~40285909:- LIHC cis rs2439831 0.85 rs7179388 ENSG00000275601.1 AC011330.13 -4.4 1.47e-05 0.00368 -0.34 -0.23 Lung cancer in ever smokers; chr15:43831747 chr15:43642389~43643023:- LIHC cis rs2337406 1 rs11849532 ENSG00000274576.2 IGHV2-70 -4.4 1.47e-05 0.00368 -0.26 -0.23 Alzheimer's disease (late onset); chr14:106669877 chr14:106770577~106771020:- LIHC cis rs4356975 0.768 rs4518318 ENSG00000250919.1 RP11-813N20.3 4.4 1.47e-05 0.00368 0.23 0.23 Obesity-related traits; chr4:69045479 chr4:69027831~69044578:+ LIHC cis rs4356975 0.83 rs4351079 ENSG00000250919.1 RP11-813N20.3 4.4 1.47e-05 0.00368 0.23 0.23 Obesity-related traits; chr4:69045631 chr4:69027831~69044578:+ LIHC cis rs4356975 0.798 rs4607293 ENSG00000250919.1 RP11-813N20.3 4.4 1.47e-05 0.00368 0.23 0.23 Obesity-related traits; chr4:69045714 chr4:69027831~69044578:+ LIHC cis rs338389 0.542 rs8036189 ENSG00000260657.2 RP11-315D16.4 -4.4 1.47e-05 0.00368 -0.38 -0.23 Survival in rectal cancer; chr15:68000614 chr15:68267792~68277994:- LIHC cis rs2348418 0.864 rs7957495 ENSG00000247934.4 RP11-967K21.1 -4.4 1.47e-05 0.00369 -0.21 -0.23 Lung function (FEV1);Lung function (FVC); chr12:28564522 chr12:28163298~28190738:- LIHC cis rs752590 0.806 rs874898 ENSG00000274877.1 RP11-65I12.1 -4.4 1.47e-05 0.00369 -0.3 -0.23 Mucinous ovarian carcinoma; chr2:113216619 chr2:113237595~113240825:+ LIHC cis rs2976388 0.632 rs2585139 ENSG00000253196.1 RP11-706C16.7 4.4 1.47e-05 0.00369 0.23 0.23 Urinary tract infection frequency; chr8:142726757 chr8:142763116~142766427:+ LIHC cis rs11121022 0.601 rs707455 ENSG00000269925.1 RP3-467L1.6 4.4 1.47e-05 0.00369 0.22 0.23 Morning vs. evening chronotype; chr1:7765251 chr1:7776383~7776775:+ LIHC cis rs3091242 0.933 rs1534954 ENSG00000224183.1 SDHDP6 -4.4 1.47e-05 0.00369 -0.26 -0.23 Erythrocyte sedimentation rate; chr1:25435433 chr1:25294164~25294643:- LIHC cis rs9896933 0.832 rs77512810 ENSG00000263063.1 RP11-388C12.1 -4.4 1.47e-05 0.0037 -0.32 -0.23 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82846713 chr17:82713908~82716255:- LIHC cis rs9896933 0.832 rs75552659 ENSG00000263063.1 RP11-388C12.1 -4.4 1.47e-05 0.0037 -0.32 -0.23 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82846754 chr17:82713908~82716255:- LIHC cis rs113084984 0.718 rs7568108 ENSG00000271952.1 RP11-245G13.2 -4.4 1.47e-05 0.0037 -0.28 -0.23 Breast cancer; chr2:11543198 chr2:10878269~10885118:+ LIHC cis rs16858210 0.607 rs953419 ENSG00000234371.6 RPSAP31 -4.4 1.47e-05 0.0037 -0.31 -0.23 Menopause (age at onset); chr3:183868095 chr3:183884924~183888449:+ LIHC cis rs7809950 1 rs2520271 ENSG00000238832.1 snoU109 -4.4 1.47e-05 0.0037 -0.28 -0.23 Coronary artery disease; chr7:107554504 chr7:107603363~107603507:+ LIHC cis rs3733589 0.744 rs35782952 ENSG00000250413.1 RP11-448G15.1 4.4 1.47e-05 0.0037 0.37 0.23 Renal overload gout; chr4:10044471 chr4:10006482~10009725:+ LIHC cis rs3733589 0.744 rs35334203 ENSG00000250413.1 RP11-448G15.1 4.4 1.47e-05 0.0037 0.37 0.23 Renal overload gout; chr4:10044547 chr4:10006482~10009725:+ LIHC cis rs10129255 0.5 rs10143242 ENSG00000211972.2 IGHV3-66 4.4 1.47e-05 0.0037 0.17 0.23 Kawasaki disease; chr14:106681814 chr14:106675017~106675544:- LIHC cis rs58950470 0.927 rs1205259 ENSG00000265874.1 MIR4489 4.4 1.48e-05 0.0037 0.34 0.23 Schizophrenia; chr11:65625224 chr11:65649192~65649253:+ LIHC cis rs75920871 0.541 rs76690043 ENSG00000254851.1 RP11-109L13.1 -4.4 1.48e-05 0.0037 -0.47 -0.23 Subjective well-being; chr11:116930813 chr11:117135528~117138582:+ LIHC cis rs2276314 0.857 rs9304155 ENSG00000278986.1 RP11-723J4.3 -4.4 1.48e-05 0.0037 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:36005747 chr18:35972151~35973916:+ LIHC cis rs6504622 0.72 rs4968304 ENSG00000262879.4 RP11-156P1.3 -4.4 1.48e-05 0.0037 -0.24 -0.23 Orofacial clefts; chr17:47063235 chr17:46984045~47100323:- LIHC cis rs9992667 0.955 rs6855993 ENSG00000231160.8 KLF3-AS1 4.4 1.48e-05 0.0037 0.31 0.23 Eosinophil percentage of granulocytes; chr4:38607291 chr4:38612701~38664883:- LIHC cis rs9650657 0.547 rs11250099 ENSG00000255394.4 C8orf49 4.4 1.48e-05 0.00371 0.29 0.23 Neuroticism; chr8:10961147 chr8:11761256~11763223:+ LIHC cis rs9595908 0.929 rs7328939 ENSG00000212293.1 SNORA16 4.4 1.48e-05 0.00371 0.27 0.23 Body mass index; chr13:32552711 chr13:32420390~32420516:- LIHC cis rs6822297 0.522 rs7700108 ENSG00000240005.4 RP11-293A21.1 4.4 1.48e-05 0.00371 0.27 0.23 Obesity-related traits; chr4:26967785 chr4:26859806~26860599:- LIHC cis rs901683 0.702 rs76041951 ENSG00000230869.1 CTGLF10P -4.39 1.48e-05 0.00371 -0.61 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45609715 chr10:45678692~45700532:+ LIHC cis rs7809950 1 rs2237676 ENSG00000238832.1 snoU109 -4.39 1.48e-05 0.00371 -0.28 -0.23 Coronary artery disease; chr7:107557634 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs2253146 ENSG00000238832.1 snoU109 -4.39 1.48e-05 0.00371 -0.28 -0.23 Coronary artery disease; chr7:107559874 chr7:107603363~107603507:+ LIHC cis rs7809950 0.953 rs2253271 ENSG00000238832.1 snoU109 -4.39 1.48e-05 0.00371 -0.28 -0.23 Coronary artery disease; chr7:107560807 chr7:107603363~107603507:+ LIHC cis rs11722228 0.521 rs12501336 ENSG00000261490.1 RP11-448G15.3 4.39 1.48e-05 0.00371 0.31 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10135727 chr4:10068089~10073019:- LIHC cis rs9487094 0.961 rs3778475 ENSG00000260273.1 RP11-425D10.10 4.39 1.48e-05 0.00372 0.28 0.23 Height; chr6:109375003 chr6:109382795~109383666:+ LIHC cis rs9595908 0.785 rs7326809 ENSG00000212293.1 SNORA16 4.39 1.48e-05 0.00372 0.26 0.23 Body mass index; chr13:32662135 chr13:32420390~32420516:- LIHC cis rs2717559 0.561 rs7841267 ENSG00000253196.1 RP11-706C16.7 -4.39 1.48e-05 0.00372 -0.26 -0.23 Urinary tract infection frequency; chr8:142800267 chr8:142763116~142766427:+ LIHC cis rs11690935 0.632 rs2292816 ENSG00000228389.1 AC068039.4 -4.39 1.49e-05 0.00372 -0.28 -0.23 Schizophrenia; chr2:171730204 chr2:171773482~171775844:+ LIHC cis rs9467711 0.538 rs9467632 ENSG00000216436.2 HIST1H2APS1 4.39 1.49e-05 0.00372 0.56 0.23 Autism spectrum disorder or schizophrenia; chr6:25889478 chr6:25732497~25732827:+ LIHC cis rs2739330 0.828 rs2154593 ENSG00000206090.4 AP000350.7 4.39 1.49e-05 0.00372 0.27 0.23 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23939998~23942798:+ LIHC cis rs6480314 0.764 rs7898034 ENSG00000233590.1 RP11-153K11.3 4.39 1.49e-05 0.00372 0.33 0.23 Optic nerve measurement (disc area); chr10:68217859 chr10:68233251~68242379:- LIHC cis rs950169 0.881 rs72750843 ENSG00000259728.4 LINC00933 4.39 1.49e-05 0.00372 0.35 0.23 Schizophrenia; chr15:84592552 chr15:84570649~84580175:+ LIHC cis rs9807989 0.507 rs2287033 ENSG00000234389.1 AC007278.3 -4.39 1.49e-05 0.00372 -0.25 -0.23 Asthma; chr2:102394777 chr2:102438713~102440475:+ LIHC cis rs72675573 0.925 rs72675569 ENSG00000235612.1 RP1-158P9.1 -4.39 1.49e-05 0.00373 -0.3 -0.23 Monocyte count; chr1:56160903 chr1:56145721~56155224:+ LIHC cis rs748404 0.578 rs576557 ENSG00000166763.7 STRCP1 4.39 1.49e-05 0.00373 0.28 0.23 Lung cancer; chr15:43305539 chr15:43699488~43718184:- LIHC cis rs748404 0.697 rs475261 ENSG00000166763.7 STRCP1 4.39 1.49e-05 0.00373 0.29 0.23 Lung cancer; chr15:43254258 chr15:43699488~43718184:- LIHC cis rs881375 0.715 rs7858209 ENSG00000226752.6 PSMD5-AS1 -4.39 1.49e-05 0.00373 -0.23 -0.23 Rheumatoid arthritis; chr9:120883482 chr9:120824828~120854385:+ LIHC cis rs881375 0.715 rs10760119 ENSG00000226752.6 PSMD5-AS1 -4.39 1.49e-05 0.00373 -0.23 -0.23 Rheumatoid arthritis; chr9:120883782 chr9:120824828~120854385:+ LIHC cis rs2790457 0.958 rs2532744 ENSG00000254635.4 WAC-AS1 -4.39 1.49e-05 0.00373 -0.22 -0.23 Multiple myeloma; chr10:28613689 chr10:28522652~28532743:- LIHC cis rs9595908 0.869 rs7337687 ENSG00000212293.1 SNORA16 -4.39 1.49e-05 0.00374 -0.26 -0.23 Body mass index; chr13:32595560 chr13:32420390~32420516:- LIHC cis rs180358 0.568 rs1268353 ENSG00000254851.1 RP11-109L13.1 4.39 1.49e-05 0.00374 0.3 0.23 Multiple sclerosis (severity); chr11:116768976 chr11:117135528~117138582:+ LIHC cis rs7412746 0.658 rs897815 ENSG00000231073.1 RP11-316M1.3 -4.39 1.49e-05 0.00374 -0.23 -0.23 Melanoma; chr1:150906625 chr1:150973123~150975534:+ LIHC cis rs227275 0.554 rs223381 ENSG00000246560.2 RP11-10L12.4 4.39 1.49e-05 0.00374 0.26 0.23 Allergic disease (asthma, hay fever or eczema); chr4:102832578 chr4:102828055~102844075:+ LIHC cis rs875971 0.545 rs1547529 ENSG00000273142.1 RP11-458F8.4 4.39 1.49e-05 0.00374 0.22 0.23 Aortic root size; chr7:66258859 chr7:66902857~66906297:+ LIHC cis rs2243480 1 rs73150014 ENSG00000228409.4 CCT6P1 4.39 1.49e-05 0.00374 0.25 0.23 Diabetic kidney disease; chr7:65985932 chr7:65751142~65763354:+ LIHC cis rs812925 0.512 rs1729674 ENSG00000212978.6 AC016747.3 -4.39 1.49e-05 0.00374 -0.25 -0.23 Immature fraction of reticulocytes; chr2:61162602 chr2:61141592~61144969:- LIHC cis rs7176527 1 rs3762169 ENSG00000229212.6 RP11-561C5.4 4.39 1.5e-05 0.00374 0.26 0.23 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84598728 chr15:85205440~85234795:- LIHC cis rs6546886 0.536 rs7589197 ENSG00000217702.2 RP11-287D1.4 4.39 1.5e-05 0.00375 0.27 0.23 Dialysis-related mortality; chr2:74095342 chr2:74130583~74135395:+ LIHC cis rs638893 1 rs638893 ENSG00000255239.1 AP002954.6 4.39 1.5e-05 0.00375 0.38 0.23 Vitiligo; chr11:118827828 chr11:118688039~118690600:- LIHC cis rs11098499 0.789 rs10212719 ENSG00000260091.1 RP11-33B1.4 -4.39 1.5e-05 0.00375 -0.16 -0.23 Corneal astigmatism; chr4:119333282 chr4:119409333~119410233:+ LIHC cis rs1062177 0.502 rs10463321 ENSG00000213433.5 RPLP1P6 -4.39 1.5e-05 0.00375 -0.25 -0.23 Preschool internalizing problems; chr5:151944344 chr5:151765859~151766378:- LIHC cis rs11089937 0.597 rs5757007 ENSG00000211639.2 IGLV4-60 4.39 1.5e-05 0.00375 0.2 0.23 Periodontitis (PAL4Q3); chr22:22135167 chr22:22162199~22162681:+ LIHC cis rs523522 0.571 rs11065120 ENSG00000278344.1 RP11-18C24.8 4.39 1.5e-05 0.00375 0.29 0.23 High light scatter reticulocyte count; chr12:120437653 chr12:120500735~120501090:- LIHC cis rs4356975 1 rs4356975 ENSG00000250919.1 RP11-813N20.3 -4.39 1.5e-05 0.00375 -0.24 -0.23 Obesity-related traits; chr4:69106745 chr4:69027831~69044578:+ LIHC cis rs11098499 0.754 rs878376 ENSG00000260091.1 RP11-33B1.4 -4.39 1.5e-05 0.00376 -0.16 -0.23 Corneal astigmatism; chr4:119316547 chr4:119409333~119410233:+ LIHC cis rs9368481 0.761 rs9357030 ENSG00000241549.7 GUSBP2 -4.39 1.5e-05 0.00376 -0.24 -0.23 Autism spectrum disorder or schizophrenia; chr6:27017247 chr6:26871484~26956554:- LIHC cis rs338389 0.542 rs7494835 ENSG00000260657.2 RP11-315D16.4 -4.39 1.5e-05 0.00376 -0.37 -0.23 Survival in rectal cancer; chr15:68001993 chr15:68267792~68277994:- LIHC cis rs2564921 0.73 rs62255897 ENSG00000242142.1 SERBP1P3 -4.39 1.5e-05 0.00376 -0.31 -0.23 Height; chr3:53029854 chr3:53064283~53065091:- LIHC cis rs11098499 0.754 rs938056 ENSG00000260091.1 RP11-33B1.4 -4.39 1.5e-05 0.00376 -0.16 -0.23 Corneal astigmatism; chr4:119316298 chr4:119409333~119410233:+ LIHC cis rs11098499 0.722 rs10006192 ENSG00000245958.5 RP11-33B1.1 -4.39 1.5e-05 0.00376 -0.23 -0.23 Corneal astigmatism; chr4:119341867 chr4:119454791~119552025:+ LIHC cis rs10129255 0.957 rs4387509 ENSG00000223648.3 IGHV3-64 4.39 1.51e-05 0.00377 0.18 0.23 Kawasaki disease; chr14:106704386 chr14:106643132~106658258:- LIHC cis rs3733589 0.744 rs36036984 ENSG00000250413.1 RP11-448G15.1 4.39 1.51e-05 0.00377 0.37 0.23 Renal overload gout; chr4:10042008 chr4:10006482~10009725:+ LIHC cis rs7119038 0.818 rs4936444 ENSG00000255239.1 AP002954.6 4.39 1.51e-05 0.00377 0.34 0.23 Sjögren's syndrome; chr11:118872629 chr11:118688039~118690600:- LIHC cis rs734999 0.572 rs2985857 ENSG00000225931.3 RP3-395M20.7 -4.39 1.51e-05 0.00377 -0.24 -0.23 Ulcerative colitis; chr1:2601185 chr1:2566410~2569888:+ LIHC cis rs7412746 0.634 rs72704658 ENSG00000231073.1 RP11-316M1.3 4.39 1.51e-05 0.00377 0.24 0.23 Melanoma; chr1:150860534 chr1:150973123~150975534:+ LIHC cis rs7829975 0.514 rs2979151 ENSG00000253981.4 ALG1L13P -4.39 1.51e-05 0.00377 -0.27 -0.23 Mood instability; chr8:8400509 chr8:8236003~8244667:- LIHC cis rs13083990 0.959 rs1472621 ENSG00000272758.4 RP11-299J3.8 4.39 1.51e-05 0.00377 0.25 0.23 Cardiac Troponin-T levels; chr3:122293879 chr3:122416207~122443180:+ LIHC cis rs13083990 0.959 rs10934582 ENSG00000272758.4 RP11-299J3.8 4.39 1.51e-05 0.00377 0.25 0.23 Cardiac Troponin-T levels; chr3:122294507 chr3:122416207~122443180:+ LIHC cis rs7208859 0.573 rs73267829 ENSG00000266490.1 CTD-2349P21.9 4.39 1.51e-05 0.00377 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30676921 chr17:30792372~30792833:+ LIHC cis rs7615952 0.558 rs7641353 ENSG00000171084.14 FAM86JP 4.39 1.51e-05 0.00378 0.35 0.23 Blood pressure (smoking interaction); chr3:125621035 chr3:125916620~125930024:+ LIHC cis rs597539 0.652 rs478647 ENSG00000250508.1 RP11-757G1.6 -4.39 1.51e-05 0.00378 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68932956 chr11:68870664~68874542:+ LIHC cis rs3733589 1 rs16868271 ENSG00000250413.1 RP11-448G15.1 4.39 1.51e-05 0.00378 0.41 0.23 Renal overload gout; chr4:9987423 chr4:10006482~10009725:+ LIHC cis rs11676348 0.808 rs61700947 ENSG00000261338.2 RP11-378A13.1 4.39 1.51e-05 0.00378 0.25 0.23 Ulcerative colitis; chr2:218181448 chr2:218255319~218257366:+ LIHC cis rs1318937 1 rs3773469 ENSG00000224660.1 SH3BP5-AS1 4.39 1.51e-05 0.00378 0.21 0.23 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15266733 chr3:15254184~15264493:+ LIHC cis rs1005277 0.579 rs1780137 ENSG00000275858.1 RP11-291L22.8 4.39 1.52e-05 0.00379 0.26 0.23 Extrinsic epigenetic age acceleration; chr10:38212547 chr10:38450738~38451069:- LIHC cis rs2243480 0.908 rs4718273 ENSG00000228409.4 CCT6P1 -4.39 1.52e-05 0.00379 -0.25 -0.23 Diabetic kidney disease; chr7:65751112 chr7:65751142~65763354:+ LIHC cis rs10829156 0.755 rs10732437 ENSG00000240291.1 RP11-499P20.2 4.39 1.52e-05 0.00379 0.36 0.23 Sudden cardiac arrest; chr10:18626973 chr10:18513115~18545651:- LIHC cis rs950169 0.656 rs748455 ENSG00000225151.9 GOLGA2P7 -4.39 1.52e-05 0.00379 -0.3 -0.23 Schizophrenia; chr15:84606344 chr15:84199311~84230136:- LIHC cis rs7429990 0.833 rs2293226 ENSG00000229759.1 MRPS18AP1 4.39 1.52e-05 0.00379 0.24 0.23 Educational attainment (years of education); chr3:47585292 chr3:48256350~48256938:- LIHC cis rs651907 0.557 rs2318090 ENSG00000244119.1 PDCL3P4 4.39 1.52e-05 0.00379 0.24 0.23 Colorectal cancer; chr3:101756089 chr3:101712472~101713191:+ LIHC cis rs7811142 0.83 rs6945952 ENSG00000242294.5 STAG3L5P 4.39 1.52e-05 0.00379 0.25 0.23 Platelet count; chr7:100384152 chr7:100336079~100351900:+ LIHC cis rs7811142 0.83 rs73401451 ENSG00000242294.5 STAG3L5P 4.39 1.52e-05 0.00379 0.25 0.23 Platelet count; chr7:100384272 chr7:100336079~100351900:+ LIHC cis rs6445975 0.715 rs6769100 ENSG00000272360.1 RP11-359I18.5 4.39 1.52e-05 0.00379 0.27 0.23 Systemic lupus erythematosus; chr3:58274272 chr3:58490830~58491291:- LIHC cis rs1823913 0.927 rs35339956 ENSG00000227542.1 AC092614.2 4.39 1.52e-05 0.00379 0.24 0.23 Obesity-related traits; chr2:191261668 chr2:191229165~191246172:- LIHC cis rs1823913 0.927 rs56209234 ENSG00000227542.1 AC092614.2 4.39 1.52e-05 0.00379 0.24 0.23 Obesity-related traits; chr2:191261748 chr2:191229165~191246172:- LIHC cis rs55726902 1 rs73107980 ENSG00000276691.1 RP5-1057I20.5 4.39 1.52e-05 0.00379 0.44 0.23 Allergic disease (asthma, hay fever or eczema); chr12:47793818 chr12:47788426~47788971:+ LIHC cis rs6480314 0.831 rs11813125 ENSG00000233590.1 RP11-153K11.3 4.39 1.52e-05 0.00379 0.34 0.23 Optic nerve measurement (disc area); chr10:68215276 chr10:68233251~68242379:- LIHC cis rs950881 0.932 rs72823619 ENSG00000234389.1 AC007278.3 4.39 1.52e-05 0.00379 0.31 0.23 Allergy; chr2:102308155 chr2:102438713~102440475:+ LIHC cis rs7829975 0.56 rs17154599 ENSG00000173295.6 FAM86B3P -4.39 1.52e-05 0.00379 -0.31 -0.23 Mood instability; chr8:8693908 chr8:8228595~8244865:+ LIHC cis rs4578769 0.765 rs72882147 ENSG00000266850.1 RP11-370A5.1 -4.39 1.52e-05 0.0038 -0.28 -0.23 Eosinophil percentage of white cells; chr18:22816590 chr18:22723491~22907721:- LIHC cis rs4650994 0.505 rs2811291 ENSG00000273384.1 RP5-1098D14.1 -4.39 1.52e-05 0.0038 -0.29 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178605082 chr1:178651706~178652282:+ LIHC cis rs4578769 0.788 rs12962334 ENSG00000265943.1 RP11-739L10.1 4.39 1.52e-05 0.0038 0.28 0.23 Eosinophil percentage of white cells; chr18:22897971 chr18:22699481~22933764:- LIHC cis rs12478296 0.786 rs13409307 ENSG00000261186.2 RP11-341N2.1 -4.39 1.52e-05 0.0038 -0.3 -0.23 Obesity-related traits; chr2:242053348 chr2:242087351~242088457:- LIHC cis rs5769707 0.967 rs763126 ENSG00000235111.1 RP1-29C18.8 4.39 1.52e-05 0.0038 0.26 0.23 Monocyte percentage of white cells;Monocyte count; chr22:49594926 chr22:49612657~49615716:- LIHC cis rs651907 0.557 rs34947019 ENSG00000244119.1 PDCL3P4 4.39 1.52e-05 0.0038 0.24 0.23 Colorectal cancer; chr3:101813391 chr3:101712472~101713191:+ LIHC cis rs11722228 0.508 rs9732 ENSG00000261490.1 RP11-448G15.3 4.39 1.52e-05 0.0038 0.3 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10075034 chr4:10068089~10073019:- LIHC cis rs12291225 0.839 rs4757244 ENSG00000251991.1 RNU7-49P -4.39 1.52e-05 0.00381 -0.24 -0.23 Sense of smell; chr11:14237109 chr11:14478892~14478953:+ LIHC cis rs2739330 0.828 rs5760108 ENSG00000206090.4 AP000350.7 4.39 1.52e-05 0.00381 0.27 0.23 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23939998~23942798:+ LIHC cis rs2439831 0.867 rs11856184 ENSG00000166763.7 STRCP1 4.39 1.52e-05 0.00381 0.36 0.23 Lung cancer in ever smokers; chr15:43626964 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs2447211 ENSG00000166763.7 STRCP1 4.39 1.52e-05 0.00381 0.36 0.23 Lung cancer in ever smokers; chr15:43644153 chr15:43699488~43718184:- LIHC cis rs2439831 0.571 rs2470121 ENSG00000166763.7 STRCP1 4.39 1.52e-05 0.00381 0.36 0.23 Lung cancer in ever smokers; chr15:43645420 chr15:43699488~43718184:- LIHC cis rs4244255 1 rs17116149 ENSG00000260461.1 RP11-541N10.3 -4.39 1.53e-05 0.00381 -0.39 -0.23 Differentiated thyroid cancer; chr10:103928292 chr10:103877374~103879761:- LIHC cis rs8005677 0.798 rs4982711 ENSG00000257285.4 RP11-298I3.1 4.39 1.53e-05 0.00381 0.23 0.23 Cognitive ability (multi-trait analysis); chr14:22929781 chr14:22929609~22955562:+ LIHC cis rs4650994 0.507 rs2811312 ENSG00000273384.1 RP5-1098D14.1 -4.39 1.53e-05 0.00381 -0.29 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178648468 chr1:178651706~178652282:+ LIHC cis rs11971779 0.941 rs7800795 ENSG00000273391.1 RP11-634H22.1 4.39 1.53e-05 0.00381 0.22 0.23 Diisocyanate-induced asthma; chr7:139395602 chr7:139359032~139359566:- LIHC cis rs5742933 0.857 rs7571089 ENSG00000253559.1 OSGEPL1-AS1 4.39 1.53e-05 0.00381 0.31 0.23 Ferritin levels; chr2:189697067 chr2:189762704~189765556:+ LIHC cis rs1275468 0.798 rs10879928 ENSG00000257497.2 RP11-585P4.5 4.39 1.53e-05 0.00381 0.31 0.23 Polycystic ovary syndrome; chr12:75531996 chr12:75483454~75489820:- LIHC cis rs4718428 1 rs12534637 ENSG00000273142.1 RP11-458F8.4 -4.39 1.53e-05 0.00381 -0.23 -0.23 Corneal structure; chr7:66862667 chr7:66902857~66906297:+ LIHC cis rs7615952 0.599 rs6803160 ENSG00000171084.14 FAM86JP 4.39 1.53e-05 0.00382 0.36 0.23 Blood pressure (smoking interaction); chr3:125990711 chr3:125916620~125930024:+ LIHC cis rs950169 0.881 rs72750843 ENSG00000259295.5 CSPG4P12 4.39 1.53e-05 0.00382 0.33 0.23 Schizophrenia; chr15:84592552 chr15:85191438~85213905:+ LIHC cis rs7702057 0.53 rs3087831 ENSG00000271918.1 CTD-2287O16.5 4.39 1.53e-05 0.00383 0.32 0.23 Amyotrophic lateral sclerosis; chr5:116084901 chr5:116083807~116085416:- LIHC cis rs3091242 0.967 rs665372 ENSG00000224183.1 SDHDP6 -4.39 1.53e-05 0.00383 -0.26 -0.23 Erythrocyte sedimentation rate; chr1:25392744 chr1:25294164~25294643:- LIHC cis rs3733589 0.744 rs3775941 ENSG00000250413.1 RP11-448G15.1 4.39 1.54e-05 0.00383 0.37 0.23 Renal overload gout; chr4:10023469 chr4:10006482~10009725:+ LIHC cis rs2439831 0.85 rs2957637 ENSG00000166763.7 STRCP1 4.39 1.54e-05 0.00383 0.36 0.23 Lung cancer in ever smokers; chr15:43658920 chr15:43699488~43718184:- LIHC cis rs11668505 1 rs12974951 ENSG00000259108.2 CTD-3098H1.2 4.39 1.54e-05 0.00383 0.3 0.23 Lung function (FVC); chr19:47842671 chr19:47863483~47865341:- LIHC cis rs2976388 0.506 rs2572902 ENSG00000253741.1 CTD-2292P10.4 -4.39 1.54e-05 0.00384 -0.27 -0.23 Urinary tract infection frequency; chr8:142709969 chr8:142702252~142726973:- LIHC cis rs4578769 0.918 rs8089471 ENSG00000265943.1 RP11-739L10.1 4.39 1.54e-05 0.00384 0.29 0.23 Eosinophil percentage of white cells; chr18:22892994 chr18:22699481~22933764:- LIHC cis rs2243480 1 rs2243480 ENSG00000226824.5 RP4-756H11.3 -4.39 1.54e-05 0.00384 -0.38 -0.23 Diabetic kidney disease; chr7:66134209 chr7:66654538~66669855:+ LIHC cis rs2929278 0.588 rs688009 ENSG00000166763.7 STRCP1 4.39 1.54e-05 0.00384 0.3 0.23 Schizophrenia; chr15:43864104 chr15:43699488~43718184:- LIHC cis rs58749629 1 rs73128528 ENSG00000269549.2 RP3-461P17.10 4.39 1.54e-05 0.00384 0.58 0.23 Abdominal aortic aneurysm; chr20:45953548 chr20:45445431~45448580:+ LIHC cis rs7119038 0.818 rs4936441 ENSG00000255239.1 AP002954.6 4.39 1.54e-05 0.00384 0.34 0.23 Sjögren's syndrome; chr11:118854951 chr11:118688039~118690600:- LIHC cis rs7119038 0.865 rs10892299 ENSG00000255239.1 AP002954.6 -4.39 1.54e-05 0.00384 -0.34 -0.23 Sjögren's syndrome; chr11:118856134 chr11:118688039~118690600:- LIHC cis rs10790268 1 rs10790268 ENSG00000255239.1 AP002954.6 4.39 1.54e-05 0.00384 0.34 0.23 Rheumatoid arthritis; chr11:118858682 chr11:118688039~118690600:- LIHC cis rs7119038 0.73 rs10790269 ENSG00000255239.1 AP002954.6 4.39 1.54e-05 0.00384 0.34 0.23 Sjögren's syndrome; chr11:118858747 chr11:118688039~118690600:- LIHC cis rs11671005 0.695 rs11673069 ENSG00000269473.1 CTD-2619J13.19 4.39 1.54e-05 0.00384 0.39 0.23 Mean platelet volume; chr19:58423551 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs12981875 ENSG00000269473.1 CTD-2619J13.19 4.39 1.54e-05 0.00384 0.39 0.23 Mean platelet volume; chr19:58423763 chr19:58440448~58445849:+ LIHC cis rs3738443 0.817 rs6698690 ENSG00000259865.1 RP11-488L18.10 4.39 1.54e-05 0.00384 0.21 0.23 Alcohol dependence; chr1:247199176 chr1:247187281~247188526:- LIHC cis rs3738443 0.868 rs7551871 ENSG00000259865.1 RP11-488L18.10 4.39 1.54e-05 0.00384 0.21 0.23 Alcohol dependence; chr1:247199888 chr1:247187281~247188526:- LIHC cis rs11098499 0.615 rs28551750 ENSG00000245958.5 RP11-33B1.1 -4.39 1.54e-05 0.00385 -0.23 -0.23 Corneal astigmatism; chr4:119343746 chr4:119454791~119552025:+ LIHC cis rs11098499 0.691 rs9995716 ENSG00000245958.5 RP11-33B1.1 -4.39 1.54e-05 0.00385 -0.23 -0.23 Corneal astigmatism; chr4:119343841 chr4:119454791~119552025:+ LIHC cis rs7412746 0.622 rs72704654 ENSG00000231073.1 RP11-316M1.3 4.39 1.54e-05 0.00385 0.24 0.23 Melanoma; chr1:150853934 chr1:150973123~150975534:+ LIHC cis rs7176527 1 rs7176527 ENSG00000189136.7 UBE2Q2P1 -4.38 1.55e-05 0.00385 -0.2 -0.23 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84597563 chr15:84526781~84571216:- LIHC cis rs172166 0.694 rs1631552 ENSG00000219392.1 RP1-265C24.5 -4.38 1.55e-05 0.00386 -0.3 -0.23 Cardiac Troponin-T levels; chr6:28121921 chr6:28115628~28116551:+ LIHC cis rs853679 0.825 rs8180562 ENSG00000219392.1 RP1-265C24.5 -4.38 1.55e-05 0.00386 -0.44 -0.23 Depression; chr6:28173682 chr6:28115628~28116551:+ LIHC cis rs853679 0.882 rs9380064 ENSG00000219392.1 RP1-265C24.5 -4.38 1.55e-05 0.00386 -0.44 -0.23 Depression; chr6:28175340 chr6:28115628~28116551:+ LIHC cis rs1729407 0.814 rs2071521 ENSG00000236267.1 AP006216.5 -4.38 1.55e-05 0.00387 -0.22 -0.23 Apolipoprotein A-IV levels; chr11:116827132 chr11:116813204~116814003:- LIHC cis rs597539 0.652 rs668576 ENSG00000250508.1 RP11-757G1.6 -4.38 1.55e-05 0.00387 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68900740 chr11:68870664~68874542:+ LIHC cis rs948562 1 rs3829218 ENSG00000280010.1 AP001350.4 4.38 1.55e-05 0.00387 0.41 0.23 Lymphoma; chr11:58563836 chr11:58627435~58628528:+ LIHC cis rs7702057 0.53 rs3087832 ENSG00000271918.1 CTD-2287O16.5 4.38 1.55e-05 0.00387 0.32 0.23 Amyotrophic lateral sclerosis; chr5:116084931 chr5:116083807~116085416:- LIHC cis rs7702057 0.53 rs74583480 ENSG00000271918.1 CTD-2287O16.5 4.38 1.55e-05 0.00387 0.32 0.23 Amyotrophic lateral sclerosis; chr5:116085200 chr5:116083807~116085416:- LIHC cis rs7702057 0.53 rs73780832 ENSG00000271918.1 CTD-2287O16.5 4.38 1.55e-05 0.00387 0.32 0.23 Amyotrophic lateral sclerosis; chr5:116085208 chr5:116083807~116085416:- LIHC cis rs529413 0.57 rs524607 ENSG00000259237.1 RP11-209E8.1 4.38 1.56e-05 0.00387 0.32 0.23 Itch intensity from mosquito bite adjusted by bite size; chr15:53244544 chr15:53116365~53129698:+ LIHC cis rs11098499 0.82 rs13128602 ENSG00000260091.1 RP11-33B1.4 4.38 1.56e-05 0.00387 0.17 0.23 Corneal astigmatism; chr4:119538211 chr4:119409333~119410233:+ LIHC cis rs12478296 0.901 rs67423532 ENSG00000261186.2 RP11-341N2.1 -4.38 1.56e-05 0.00387 -0.31 -0.23 Obesity-related traits; chr2:242062568 chr2:242087351~242088457:- LIHC cis rs12478296 0.901 rs67951957 ENSG00000261186.2 RP11-341N2.1 -4.38 1.56e-05 0.00387 -0.31 -0.23 Obesity-related traits; chr2:242062750 chr2:242087351~242088457:- LIHC cis rs12478296 0.792 rs3924263 ENSG00000261186.2 RP11-341N2.1 -4.38 1.56e-05 0.00387 -0.31 -0.23 Obesity-related traits; chr2:242063016 chr2:242087351~242088457:- LIHC cis rs12478296 1 rs7420157 ENSG00000261186.2 RP11-341N2.1 -4.38 1.56e-05 0.00387 -0.31 -0.23 Obesity-related traits; chr2:242063053 chr2:242087351~242088457:- LIHC cis rs1865760 0.566 rs3752419 ENSG00000216436.2 HIST1H2APS1 -4.38 1.56e-05 0.00388 -0.27 -0.23 Height; chr6:26027205 chr6:25732497~25732827:+ LIHC cis rs904251 0.62 rs883372 ENSG00000204110.6 RP1-153P14.8 -4.38 1.56e-05 0.00388 -0.3 -0.23 Cognitive performance; chr6:37509829 chr6:37507348~37535616:+ LIHC cis rs748404 0.697 rs531910 ENSG00000166763.7 STRCP1 4.38 1.56e-05 0.00388 0.29 0.23 Lung cancer; chr15:43268409 chr15:43699488~43718184:- LIHC cis rs748404 0.697 rs491804 ENSG00000166763.7 STRCP1 4.38 1.56e-05 0.00388 0.29 0.23 Lung cancer; chr15:43268627 chr15:43699488~43718184:- LIHC cis rs748404 0.697 rs492743 ENSG00000166763.7 STRCP1 4.38 1.56e-05 0.00388 0.29 0.23 Lung cancer; chr15:43268747 chr15:43699488~43718184:- LIHC cis rs948562 0.895 rs11229537 ENSG00000280010.1 AP001350.4 4.38 1.56e-05 0.00388 0.41 0.23 Lymphoma; chr11:58585392 chr11:58627435~58628528:+ LIHC cis rs17270561 0.636 rs1185977 ENSG00000216436.2 HIST1H2APS1 -4.38 1.56e-05 0.00388 -0.28 -0.23 Iron status biomarkers; chr6:25828826 chr6:25732497~25732827:+ LIHC cis rs1247318 1 rs1247365 ENSG00000243831.1 RP1-81D8.4 4.38 1.56e-05 0.00388 0.33 0.23 Aging; chr6:160921896 chr6:160666228~160676523:- LIHC cis rs9595908 0.865 rs499966 ENSG00000212293.1 SNORA16 -4.38 1.56e-05 0.00389 -0.27 -0.23 Body mass index; chr13:32424473 chr13:32420390~32420516:- LIHC cis rs9595908 1 rs9591165 ENSG00000212293.1 SNORA16 4.38 1.56e-05 0.00389 0.26 0.23 Body mass index; chr13:32611016 chr13:32420390~32420516:- LIHC cis rs950169 0.922 rs11633534 ENSG00000259295.5 CSPG4P12 4.38 1.56e-05 0.00389 0.32 0.23 Schizophrenia; chr15:84581411 chr15:85191438~85213905:+ LIHC cis rs8028182 0.636 rs4462560 ENSG00000260269.4 CTD-2323K18.1 4.38 1.56e-05 0.00389 0.3 0.23 Sudden cardiac arrest; chr15:75355623 chr15:75527150~75601205:- LIHC cis rs9807989 0.507 rs2041739 ENSG00000234389.1 AC007278.3 -4.38 1.56e-05 0.00389 -0.25 -0.23 Asthma; chr2:102377873 chr2:102438713~102440475:+ LIHC cis rs1400745 0.718 rs799681 ENSG00000258738.1 RP11-73E17.2 4.38 1.56e-05 0.00389 0.29 0.23 Monocyte count; chr14:34881373 chr14:34874343~34876459:+ LIHC cis rs6480314 0.708 rs11812723 ENSG00000233590.1 RP11-153K11.3 -4.38 1.56e-05 0.00389 -0.36 -0.23 Optic nerve measurement (disc area); chr10:68215014 chr10:68233251~68242379:- LIHC cis rs417065 1 rs12745477 ENSG00000227634.1 RP11-431K24.3 -4.38 1.56e-05 0.00389 -0.31 -0.23 Psoriasis; chr1:8204397 chr1:8208672~8215210:+ LIHC cis rs12478296 0.901 rs7423119 ENSG00000261186.2 RP11-341N2.1 -4.38 1.56e-05 0.00389 -0.31 -0.23 Obesity-related traits; chr2:242063337 chr2:242087351~242088457:- LIHC cis rs2739330 0.828 rs4822451 ENSG00000206090.4 AP000350.7 4.38 1.56e-05 0.00389 0.27 0.23 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23939998~23942798:+ LIHC cis rs921968 0.619 rs1554623 ENSG00000272555.1 RP11-459I19.1 -4.38 1.56e-05 0.00389 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218741454 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs1554622 ENSG00000272555.1 RP11-459I19.1 -4.38 1.56e-05 0.00389 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218741495 chr2:218818690~218819144:+ LIHC cis rs1577917 1 rs10455456 ENSG00000234155.1 RP11-30P6.6 4.38 1.56e-05 0.00389 0.3 0.23 Response to antipsychotic treatment; chr6:85960604 chr6:85387219~85390186:- LIHC cis rs860295 0.665 rs11264367 ENSG00000203761.5 MSTO2P -4.38 1.57e-05 0.00389 -0.19 -0.23 Body mass index; chr1:155367547 chr1:155745829~155750137:+ LIHC cis rs1075265 0.563 rs2542588 ENSG00000272156.1 RP11-477N3.1 4.38 1.57e-05 0.00389 0.28 0.23 Chronotype;Morning vs. evening chronotype; chr2:53791787 chr2:54082554~54085066:+ LIHC cis rs9595908 0.965 rs35193668 ENSG00000212293.1 SNORA16 4.38 1.57e-05 0.0039 0.28 0.23 Body mass index; chr13:32518792 chr13:32420390~32420516:- LIHC cis rs9595908 0.965 rs2239748 ENSG00000212293.1 SNORA16 4.38 1.57e-05 0.0039 0.28 0.23 Body mass index; chr13:32527680 chr13:32420390~32420516:- LIHC cis rs6901152 0.525 rs2216918 ENSG00000217648.1 RP1-95L4.4 -4.38 1.57e-05 0.0039 -0.28 -0.23 Acute lymphoblastic leukemia (childhood); chr6:143368254 chr6:143342246~143343383:+ LIHC cis rs11148252 0.904 rs7321964 ENSG00000278238.1 RP11-245D16.4 -4.38 1.57e-05 0.0039 -0.22 -0.23 Lewy body disease; chr13:52466687 chr13:52454775~52455331:- LIHC cis rs4694744 0.576 rs13145834 ENSG00000264696.1 AC108078.1 4.38 1.57e-05 0.0039 0.34 0.23 Bacteremia; chr4:69493350 chr4:69479331~69479434:+ LIHC cis rs4694744 0.576 rs10518061 ENSG00000264696.1 AC108078.1 4.38 1.57e-05 0.0039 0.34 0.23 Bacteremia; chr4:69493442 chr4:69479331~69479434:+ LIHC cis rs7945705 0.818 rs1988708 ENSG00000254860.4 TMEM9B-AS1 4.38 1.57e-05 0.0039 0.23 0.23 Hemoglobin concentration; chr11:8861346 chr11:8964675~8977527:+ LIHC cis rs5742933 0.857 rs13021611 ENSG00000253559.1 OSGEPL1-AS1 4.38 1.57e-05 0.0039 0.31 0.23 Ferritin levels; chr2:189700038 chr2:189762704~189765556:+ LIHC cis rs6545883 0.524 rs778159 ENSG00000271889.1 RP11-493E12.1 -4.38 1.57e-05 0.0039 -0.28 -0.23 Tuberculosis; chr2:61329609 chr2:61151433~61162105:- LIHC cis rs494453 0.922 rs531692 ENSG00000227811.2 FAM212B-AS1 -4.38 1.57e-05 0.0039 -0.25 -0.23 Osteoporosis-related phenotypes; chr1:111691954 chr1:111739841~111747798:+ LIHC cis rs9675120 0.708 rs9893135 ENSG00000262006.1 RP11-700H6.4 -4.38 1.57e-05 0.0039 -0.26 -0.23 Cerebrospinal fluid biomarker levels; chr17:50844519 chr17:50909637~50910232:- LIHC cis rs929596 0.639 rs2070959 ENSG00000233445.1 RPL17P11 4.38 1.57e-05 0.0039 0.26 0.23 Total bilirubin levels in HIV-1 infection; chr2:233693545 chr2:233721522~233722065:- LIHC cis rs17711722 1 rs17711722 ENSG00000224316.1 RP11-479O9.2 -4.38 1.57e-05 0.0039 -0.23 -0.23 Calcium levels; chr7:65806210 chr7:65773620~65802067:+ LIHC cis rs17711722 0.675 rs6947132 ENSG00000224316.1 RP11-479O9.2 -4.38 1.57e-05 0.0039 -0.23 -0.23 Calcium levels; chr7:65808508 chr7:65773620~65802067:+ LIHC cis rs2836974 0.583 rs9636957 ENSG00000255568.3 BRWD1-AS2 -4.38 1.57e-05 0.0039 -0.19 -0.23 Cognitive function; chr21:39333921 chr21:39313935~39314962:+ LIHC cis rs9843304 0.529 rs4681512 ENSG00000244503.1 RP11-278L15.6 4.38 1.57e-05 0.00391 0.23 0.23 Gallstone disease; chr3:149485654 chr3:149494660~149495995:+ LIHC cis rs9807989 0.507 rs4851004 ENSG00000234389.1 AC007278.3 -4.38 1.57e-05 0.00391 -0.25 -0.23 Asthma; chr2:102393077 chr2:102438713~102440475:+ LIHC cis rs9595908 0.965 rs9591180 ENSG00000212293.1 SNORA16 4.38 1.57e-05 0.00391 0.27 0.23 Body mass index; chr13:32622864 chr13:32420390~32420516:- LIHC cis rs17270561 0.723 rs12192635 ENSG00000216436.2 HIST1H2APS1 -4.38 1.57e-05 0.00391 -0.35 -0.23 Iron status biomarkers; chr6:25880679 chr6:25732497~25732827:+ LIHC cis rs11722228 0.521 rs56403947 ENSG00000261490.1 RP11-448G15.3 4.38 1.57e-05 0.00391 0.31 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10110905 chr4:10068089~10073019:- LIHC cis rs10262624 1 rs2023787 ENSG00000234286.1 AC006026.13 -4.38 1.57e-05 0.00391 -0.26 -0.23 Schizophrenia; chr7:23875521 chr7:23680195~23680786:- LIHC cis rs10262624 1 rs17347505 ENSG00000234286.1 AC006026.13 -4.38 1.57e-05 0.00391 -0.26 -0.23 Schizophrenia; chr7:23875664 chr7:23680195~23680786:- LIHC cis rs10262624 1 rs12671624 ENSG00000234286.1 AC006026.13 -4.38 1.57e-05 0.00391 -0.26 -0.23 Schizophrenia; chr7:23875794 chr7:23680195~23680786:- LIHC cis rs10262624 1 rs12671584 ENSG00000234286.1 AC006026.13 -4.38 1.57e-05 0.00391 -0.26 -0.23 Schizophrenia; chr7:23875803 chr7:23680195~23680786:- LIHC cis rs10262624 1 rs10262624 ENSG00000234286.1 AC006026.13 -4.38 1.57e-05 0.00391 -0.26 -0.23 Schizophrenia; chr7:23876057 chr7:23680195~23680786:- LIHC cis rs11098499 0.863 rs7678400 ENSG00000260091.1 RP11-33B1.4 -4.38 1.57e-05 0.00391 -0.17 -0.23 Corneal astigmatism; chr4:119540802 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs1480936 ENSG00000260091.1 RP11-33B1.4 -4.38 1.57e-05 0.00391 -0.17 -0.23 Corneal astigmatism; chr4:119541706 chr4:119409333~119410233:+ LIHC cis rs9595908 0.931 rs9595628 ENSG00000212293.1 SNORA16 4.38 1.58e-05 0.00391 0.27 0.23 Body mass index; chr13:32491021 chr13:32420390~32420516:- LIHC cis rs7811142 1 rs6979335 ENSG00000242294.5 STAG3L5P 4.38 1.58e-05 0.00392 0.28 0.23 Platelet count; chr7:100492237 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs73405353 ENSG00000242294.5 STAG3L5P 4.38 1.58e-05 0.00392 0.28 0.23 Platelet count; chr7:100493592 chr7:100336079~100351900:+ LIHC cis rs2274273 0.624 rs11848575 ENSG00000258413.1 RP11-665C16.6 -4.38 1.58e-05 0.00392 -0.29 -0.23 Protein biomarker; chr14:55289070 chr14:55262767~55272075:- LIHC cis rs35934224 0.891 rs12158214 ENSG00000232926.1 AC000078.5 4.38 1.58e-05 0.00392 0.31 0.23 Glaucoma (primary open-angle); chr22:19884168 chr22:19887289~19887970:+ LIHC cis rs5742933 0.857 rs12471217 ENSG00000253559.1 OSGEPL1-AS1 4.38 1.58e-05 0.00392 0.3 0.23 Ferritin levels; chr2:189707337 chr2:189762704~189765556:+ LIHC cis rs597539 0.652 rs514833 ENSG00000250508.1 RP11-757G1.6 -4.38 1.58e-05 0.00393 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68890266 chr11:68870664~68874542:+ LIHC cis rs597539 0.652 rs488363 ENSG00000250508.1 RP11-757G1.6 -4.38 1.58e-05 0.00393 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68890830 chr11:68870664~68874542:+ LIHC cis rs597539 0.652 rs660614 ENSG00000250508.1 RP11-757G1.6 -4.38 1.58e-05 0.00393 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68892020 chr11:68870664~68874542:+ LIHC cis rs875971 0.619 rs12533585 ENSG00000273024.4 INTS4P2 -4.38 1.58e-05 0.00393 -0.26 -0.23 Aortic root size; chr7:66519618 chr7:65647864~65715661:+ LIHC cis rs875971 0.66 rs28698552 ENSG00000273024.4 INTS4P2 -4.38 1.58e-05 0.00393 -0.26 -0.23 Aortic root size; chr7:66540031 chr7:65647864~65715661:+ LIHC cis rs875971 0.66 rs801192 ENSG00000273024.4 INTS4P2 4.38 1.58e-05 0.00393 0.26 0.23 Aortic root size; chr7:66566965 chr7:65647864~65715661:+ LIHC cis rs875971 0.66 rs801190 ENSG00000273024.4 INTS4P2 4.38 1.58e-05 0.00393 0.26 0.23 Aortic root size; chr7:66568046 chr7:65647864~65715661:+ LIHC cis rs875971 0.66 rs3857686 ENSG00000273024.4 INTS4P2 4.38 1.58e-05 0.00393 0.26 0.23 Aortic root size; chr7:66571204 chr7:65647864~65715661:+ LIHC cis rs6964833 0.935 rs34762099 ENSG00000277053.3 GTF2IP1 -4.38 1.58e-05 0.00393 -0.28 -0.23 Menarche (age at onset); chr7:74636378 chr7:75185385~75237696:- LIHC cis rs5769707 0.542 rs739242 ENSG00000235111.1 RP1-29C18.8 -4.38 1.58e-05 0.00393 -0.28 -0.23 Monocyte percentage of white cells;Monocyte count; chr22:49663468 chr22:49612657~49615716:- LIHC cis rs5769707 0.521 rs7285764 ENSG00000235111.1 RP1-29C18.8 -4.38 1.58e-05 0.00393 -0.28 -0.23 Monocyte percentage of white cells;Monocyte count; chr22:49664913 chr22:49612657~49615716:- LIHC cis rs5769707 0.521 rs9616715 ENSG00000235111.1 RP1-29C18.8 -4.38 1.58e-05 0.00393 -0.28 -0.23 Monocyte percentage of white cells;Monocyte count; chr22:49664934 chr22:49612657~49615716:- LIHC cis rs5769707 0.521 rs6009805 ENSG00000235111.1 RP1-29C18.8 -4.38 1.58e-05 0.00393 -0.28 -0.23 Monocyte percentage of white cells;Monocyte count; chr22:49665067 chr22:49612657~49615716:- LIHC cis rs5769707 0.521 rs6009807 ENSG00000235111.1 RP1-29C18.8 -4.38 1.58e-05 0.00393 -0.28 -0.23 Monocyte percentage of white cells;Monocyte count; chr22:49665274 chr22:49612657~49615716:- LIHC cis rs803923 0.585 rs803914 ENSG00000230894.1 RP11-67K19.3 -4.38 1.58e-05 0.00393 -0.3 -0.23 Lung function (FEV1/FVC); chr9:116654425 chr9:116568449~116586328:+ LIHC cis rs2274273 0.87 rs10139000 ENSG00000258413.1 RP11-665C16.6 -4.38 1.58e-05 0.00393 -0.27 -0.23 Protein biomarker; chr14:55383158 chr14:55262767~55272075:- LIHC cis rs651907 0.535 rs13059470 ENSG00000244119.1 PDCL3P4 -4.38 1.58e-05 0.00393 -0.24 -0.23 Colorectal cancer; chr3:101705956 chr3:101712472~101713191:+ LIHC cis rs10829156 0.898 rs4748504 ENSG00000240291.1 RP11-499P20.2 4.38 1.58e-05 0.00393 0.36 0.23 Sudden cardiac arrest; chr10:18651868 chr10:18513115~18545651:- LIHC cis rs11668505 1 rs12982537 ENSG00000259108.2 CTD-3098H1.2 4.38 1.59e-05 0.00394 0.29 0.23 Lung function (FVC); chr19:47842073 chr19:47863483~47865341:- LIHC cis rs921968 0.565 rs7595901 ENSG00000272555.1 RP11-459I19.1 -4.38 1.59e-05 0.00394 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218742208 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs2272189 ENSG00000272555.1 RP11-459I19.1 -4.38 1.59e-05 0.00394 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218745599 chr2:218818690~218819144:+ LIHC cis rs7474896 0.583 rs11011346 ENSG00000263064.2 RP11-291L22.7 4.38 1.59e-05 0.00394 0.28 0.23 Obesity (extreme); chr10:37720555 chr10:38448689~38448949:+ LIHC cis rs172166 0.694 rs203893 ENSG00000219392.1 RP1-265C24.5 -4.38 1.59e-05 0.00394 -0.3 -0.23 Cardiac Troponin-T levels; chr6:28094288 chr6:28115628~28116551:+ LIHC cis rs172166 0.652 rs476167 ENSG00000219392.1 RP1-265C24.5 -4.38 1.59e-05 0.00394 -0.3 -0.23 Cardiac Troponin-T levels; chr6:28098110 chr6:28115628~28116551:+ LIHC cis rs172166 0.694 rs203892 ENSG00000219392.1 RP1-265C24.5 -4.38 1.59e-05 0.00394 -0.3 -0.23 Cardiac Troponin-T levels; chr6:28099418 chr6:28115628~28116551:+ LIHC cis rs172166 0.694 rs188105 ENSG00000219392.1 RP1-265C24.5 -4.38 1.59e-05 0.00394 -0.3 -0.23 Cardiac Troponin-T levels; chr6:28103615 chr6:28115628~28116551:+ LIHC cis rs803923 0.56 rs811458 ENSG00000230894.1 RP11-67K19.3 -4.38 1.59e-05 0.00394 -0.29 -0.23 Lung function (FEV1/FVC); chr9:116642992 chr9:116568449~116586328:+ LIHC cis rs7615952 0.599 rs2333408 ENSG00000171084.14 FAM86JP 4.38 1.59e-05 0.00394 0.35 0.23 Blood pressure (smoking interaction); chr3:126013255 chr3:125916620~125930024:+ LIHC cis rs6487679 1 rs6487679 ENSG00000111788.10 RP11-22B23.1 4.38 1.59e-05 0.00394 0.28 0.23 Non-alcoholic fatty liver disease histology (AST); chr12:9218736 chr12:9277235~9313241:+ LIHC cis rs1075265 0.575 rs2692531 ENSG00000272156.1 RP11-477N3.1 -4.38 1.59e-05 0.00394 -0.28 -0.23 Chronotype;Morning vs. evening chronotype; chr2:53776640 chr2:54082554~54085066:+ LIHC cis rs9595908 1 rs9595905 ENSG00000212293.1 SNORA16 4.38 1.59e-05 0.00395 0.26 0.23 Body mass index; chr13:32609266 chr13:32420390~32420516:- LIHC cis rs16958440 1 rs61316646 ENSG00000267724.1 RP11-49K24.8 4.38 1.59e-05 0.00395 0.36 0.23 Sitting height ratio; chr18:47084299 chr18:47105946~47108062:+ LIHC cis rs10262624 0.564 rs58051142 ENSG00000234286.1 AC006026.13 -4.38 1.59e-05 0.00395 -0.26 -0.23 Schizophrenia; chr7:23866047 chr7:23680195~23680786:- LIHC cis rs7809950 1 rs10243340 ENSG00000238832.1 snoU109 -4.38 1.59e-05 0.00395 -0.28 -0.23 Coronary artery disease; chr7:107450510 chr7:107603363~107603507:+ LIHC cis rs13315871 0.615 rs7618604 ENSG00000272182.1 RP11-802O23.3 4.38 1.59e-05 0.00395 0.46 0.23 Cholesterol, total; chr3:58372058 chr3:58428255~58428815:+ LIHC cis rs2562456 0.792 rs2562398 ENSG00000268555.1 RP11-678G14.3 -4.38 1.59e-05 0.00395 -0.29 -0.23 Pain; chr19:21540147 chr19:21570822~21587322:- LIHC cis rs921968 0.565 rs13408305 ENSG00000272555.1 RP11-459I19.1 -4.38 1.59e-05 0.00395 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218763460 chr2:218818690~218819144:+ LIHC cis rs921968 0.528 rs13382651 ENSG00000272555.1 RP11-459I19.1 -4.38 1.59e-05 0.00395 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218763468 chr2:218818690~218819144:+ LIHC cis rs2717559 0.522 rs10956987 ENSG00000253196.1 RP11-706C16.7 -4.38 1.59e-05 0.00396 -0.25 -0.23 Urinary tract infection frequency; chr8:142805197 chr8:142763116~142766427:+ LIHC cis rs2243480 0.522 rs431168 ENSG00000230295.1 RP11-458F8.2 -4.38 1.59e-05 0.00396 -0.26 -0.23 Diabetic kidney disease; chr7:66046617 chr7:66880708~66882981:+ LIHC cis rs1275468 0.798 rs1275474 ENSG00000257497.2 RP11-585P4.5 -4.38 1.6e-05 0.00396 -0.31 -0.23 Polycystic ovary syndrome; chr12:75525870 chr12:75483454~75489820:- LIHC cis rs2348418 0.765 rs6487665 ENSG00000247934.4 RP11-967K21.1 4.38 1.6e-05 0.00396 0.2 0.23 Lung function (FEV1);Lung function (FVC); chr12:28177726 chr12:28163298~28190738:- LIHC cis rs7412746 0.588 rs10305664 ENSG00000231073.1 RP11-316M1.3 4.38 1.6e-05 0.00396 0.24 0.23 Melanoma; chr1:150867210 chr1:150973123~150975534:+ LIHC cis rs11098499 0.754 rs878372 ENSG00000260091.1 RP11-33B1.4 -4.38 1.6e-05 0.00396 -0.16 -0.23 Corneal astigmatism; chr4:119317625 chr4:119409333~119410233:+ LIHC cis rs113084984 0.634 rs7582396 ENSG00000271952.1 RP11-245G13.2 4.38 1.6e-05 0.00396 0.29 0.23 Breast cancer; chr2:11524223 chr2:10878269~10885118:+ LIHC cis rs2439831 0.85 rs8032649 ENSG00000275601.1 AC011330.13 4.38 1.6e-05 0.00397 0.34 0.23 Lung cancer in ever smokers; chr15:43842724 chr15:43642389~43643023:- LIHC cis rs853679 0.882 rs9468300 ENSG00000219392.1 RP1-265C24.5 -4.38 1.6e-05 0.00397 -0.44 -0.23 Depression; chr6:28159062 chr6:28115628~28116551:+ LIHC cis rs8028182 0.549 rs4886696 ENSG00000260269.4 CTD-2323K18.1 4.38 1.6e-05 0.00397 0.29 0.23 Sudden cardiac arrest; chr15:75372229 chr15:75527150~75601205:- LIHC cis rs7894407 0.76 rs1163072 ENSG00000236937.2 PTGES3P4 -4.38 1.6e-05 0.00397 -0.26 -0.23 White matter hyperintensity burden; chr10:103264621 chr10:102845595~102845950:+ LIHC cis rs4650994 0.789 rs2476559 ENSG00000213057.5 C1orf220 -4.38 1.6e-05 0.00397 -0.19 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178623784 chr1:178542752~178548889:+ LIHC cis rs673078 0.607 rs59594854 ENSG00000275759.1 RP11-131L12.3 -4.38 1.6e-05 0.00397 -0.27 -0.23 Glucose homeostasis traits; chr12:118374000 chr12:118428281~118428870:+ LIHC cis rs4578769 0.879 rs7243408 ENSG00000266850.1 RP11-370A5.1 4.38 1.6e-05 0.00397 0.27 0.23 Eosinophil percentage of white cells; chr18:22861647 chr18:22723491~22907721:- LIHC cis rs9573567 0.609 rs9565164 ENSG00000261553.4 RP11-29G8.3 -4.38 1.6e-05 0.00398 -0.4 -0.23 Red blood cell count;Mean corpuscular volume; chr13:75465240 chr13:75549773~75807120:+ LIHC cis rs9457247 0.935 rs427824 ENSG00000227598.1 RP1-167A14.2 -4.38 1.61e-05 0.00398 -0.25 -0.23 Crohn's disease; chr6:166990430 chr6:166969626~166999065:- LIHC cis rs2998286 0.723 rs332191 ENSG00000254635.4 WAC-AS1 -4.38 1.61e-05 0.00398 -0.3 -0.23 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28632196 chr10:28522652~28532743:- LIHC cis rs2312236 0.714 rs10918573 ENSG00000225171.2 DUTP6 4.38 1.61e-05 0.00399 0.3 0.23 Post-traumatic stress disorder; chr1:166749647 chr1:166868748~166869209:+ LIHC cis rs11098499 0.82 rs28578366 ENSG00000260091.1 RP11-33B1.4 4.38 1.61e-05 0.00399 0.16 0.23 Corneal astigmatism; chr4:119615750 chr4:119409333~119410233:+ LIHC cis rs7587476 0.906 rs2734674 ENSG00000229267.2 AC072062.1 4.38 1.61e-05 0.00399 0.3 0.23 Neuroblastoma; chr2:214794171 chr2:214810229~214963274:+ LIHC cis rs189798 0.807 rs330909 ENSG00000254340.1 RP11-10A14.3 4.38 1.61e-05 0.00399 0.25 0.23 Myopia (pathological); chr8:9137877 chr8:9141424~9145435:+ LIHC cis rs2301573 1 rs2301573 ENSG00000251474.5 RPL32P3 4.38 1.61e-05 0.00399 0.25 0.23 Hip circumference; chr3:129587076 chr3:129382922~129399655:- LIHC cis rs919433 0.927 rs13032495 ENSG00000231621.1 AC013264.2 4.38 1.61e-05 0.004 0.21 0.23 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197324622 chr2:197197991~197199273:+ LIHC cis rs4650994 0.816 rs2761470 ENSG00000273384.1 RP5-1098D14.1 -4.38 1.61e-05 0.004 -0.27 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178626898 chr1:178651706~178652282:+ LIHC cis rs6893782 0.887 rs6596075 ENSG00000233006.5 AC034220.3 4.38 1.61e-05 0.004 0.33 0.23 Acylcarnitine levels; chr5:132406536 chr5:132311285~132369916:- LIHC cis rs228614 0.51 rs223438 ENSG00000246560.2 RP11-10L12.4 -4.38 1.61e-05 0.004 -0.26 -0.23 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798584 chr4:102828055~102844075:+ LIHC cis rs1223397 0.651 rs402705 ENSG00000215022.6 RP1-257A7.4 -4.37 1.62e-05 0.004 -0.24 -0.23 Blood pressure; chr6:13296207 chr6:13264861~13295586:- LIHC cis rs3812762 0.879 rs4929910 ENSG00000254860.4 TMEM9B-AS1 -4.37 1.62e-05 0.004 -0.24 -0.23 Hypospadias; chr11:8763322 chr11:8964675~8977527:+ LIHC cis rs2976388 0.609 rs2257796 ENSG00000253741.1 CTD-2292P10.4 -4.37 1.62e-05 0.004 -0.26 -0.23 Urinary tract infection frequency; chr8:142727249 chr8:142702252~142726973:- LIHC cis rs948562 1 rs79475579 ENSG00000280010.1 AP001350.4 4.37 1.62e-05 0.00401 0.4 0.23 Lymphoma; chr11:58528427 chr11:58627435~58628528:+ LIHC cis rs948562 1 rs111901203 ENSG00000280010.1 AP001350.4 4.37 1.62e-05 0.00401 0.4 0.23 Lymphoma; chr11:58530069 chr11:58627435~58628528:+ LIHC cis rs55894132 1 rs55894132 ENSG00000279656.1 RP11-298I3.6 4.37 1.62e-05 0.00401 0.25 0.23 Intelligence (multi-trait analysis); chr14:22939628 chr14:23023083~23024217:- LIHC cis rs921968 0.565 rs7580147 ENSG00000272555.1 RP11-459I19.1 -4.37 1.62e-05 0.00401 -0.25 -0.23 Mean corpuscular hemoglobin concentration; chr2:218778313 chr2:218818690~218819144:+ LIHC cis rs7615952 0.599 rs12486459 ENSG00000171084.14 FAM86JP 4.37 1.62e-05 0.00401 0.37 0.23 Blood pressure (smoking interaction); chr3:126022622 chr3:125916620~125930024:+ LIHC cis rs7615952 0.599 rs67575510 ENSG00000171084.14 FAM86JP 4.37 1.62e-05 0.00401 0.37 0.23 Blood pressure (smoking interaction); chr3:126023512 chr3:125916620~125930024:+ LIHC cis rs9595908 0.931 rs9595617 ENSG00000212293.1 SNORA16 4.37 1.62e-05 0.00401 0.27 0.23 Body mass index; chr13:32483208 chr13:32420390~32420516:- LIHC cis rs9595908 0.895 rs9591012 ENSG00000212293.1 SNORA16 4.37 1.62e-05 0.00401 0.27 0.23 Body mass index; chr13:32484196 chr13:32420390~32420516:- LIHC cis rs13083990 0.919 rs3749208 ENSG00000272758.4 RP11-299J3.8 4.37 1.62e-05 0.00401 0.25 0.23 Cardiac Troponin-T levels; chr3:122261437 chr3:122416207~122443180:+ LIHC cis rs2243480 1 rs2462569 ENSG00000230295.1 RP11-458F8.2 4.37 1.62e-05 0.00401 0.24 0.23 Diabetic kidney disease; chr7:66009859 chr7:66880708~66882981:+ LIHC cis rs748404 0.578 rs2278856 ENSG00000166763.7 STRCP1 4.37 1.62e-05 0.00401 0.28 0.23 Lung cancer; chr15:43339158 chr15:43699488~43718184:- LIHC cis rs2976388 0.609 rs2572907 ENSG00000253196.1 RP11-706C16.7 4.37 1.62e-05 0.00402 0.22 0.23 Urinary tract infection frequency; chr8:142720520 chr8:142763116~142766427:+ LIHC cis rs2976388 0.609 rs2572908 ENSG00000253196.1 RP11-706C16.7 4.37 1.62e-05 0.00402 0.22 0.23 Urinary tract infection frequency; chr8:142721218 chr8:142763116~142766427:+ LIHC cis rs2976388 0.609 rs2717602 ENSG00000253196.1 RP11-706C16.7 4.37 1.62e-05 0.00402 0.22 0.23 Urinary tract infection frequency; chr8:142724265 chr8:142763116~142766427:+ LIHC cis rs11098499 0.569 rs10023641 ENSG00000245958.5 RP11-33B1.1 -4.37 1.62e-05 0.00402 -0.22 -0.23 Corneal astigmatism; chr4:119337255 chr4:119454791~119552025:+ LIHC cis rs7811142 1 rs67040465 ENSG00000242294.5 STAG3L5P 4.37 1.62e-05 0.00402 0.28 0.23 Platelet count; chr7:100485455 chr7:100336079~100351900:+ LIHC cis rs4578769 1 rs4578769 ENSG00000265943.1 RP11-739L10.1 4.37 1.62e-05 0.00402 0.29 0.23 Eosinophil percentage of white cells; chr18:22815141 chr18:22699481~22933764:- LIHC cis rs11603023 0.967 rs494560 ENSG00000255422.1 AP002954.4 4.37 1.62e-05 0.00402 0.25 0.23 Cholesterol, total; chr11:118650844 chr11:118704607~118750263:+ LIHC cis rs1577917 1 rs68171315 ENSG00000234155.1 RP11-30P6.6 4.37 1.63e-05 0.00402 0.3 0.23 Response to antipsychotic treatment; chr6:85997682 chr6:85387219~85390186:- LIHC cis rs1865760 0.516 rs9295684 ENSG00000216436.2 HIST1H2APS1 -4.37 1.63e-05 0.00403 -0.27 -0.23 Height; chr6:26069441 chr6:25732497~25732827:+ LIHC cis rs9595908 0.965 rs9337 ENSG00000212293.1 SNORA16 4.37 1.63e-05 0.00403 0.28 0.23 Body mass index; chr13:32517104 chr13:32420390~32420516:- LIHC cis rs7829975 0.511 rs2976902 ENSG00000253893.2 FAM85B -4.37 1.63e-05 0.00403 -0.31 -0.23 Mood instability; chr8:8483595 chr8:8167819~8226614:- LIHC cis rs2564921 0.765 rs2581799 ENSG00000242142.1 SERBP1P3 -4.37 1.63e-05 0.00403 -0.27 -0.23 Height; chr3:53074760 chr3:53064283~53065091:- LIHC cis rs7208859 0.673 rs17826219 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834827 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs61223749 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30836729 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs3764420 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30837136 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs3764421 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30840635 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11651858 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30843700 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs36056619 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30845266 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9909497 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30846210 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs11080135 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30849463 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9894876 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30855002 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs60020217 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30858036 chr17:30792372~30792833:+ LIHC cis rs7208859 0.573 rs73277974 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862851 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs73277978 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30864431 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11657391 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30867269 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs58089675 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869746 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs73263755 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30871954 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9899349 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30873104 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11652358 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30878462 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9891179 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881142 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9891413 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881191 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs73263776 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30884313 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11650271 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30886925 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9889968 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30893110 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs61348930 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30894745 chr17:30792372~30792833:+ LIHC cis rs7208859 0.614 rs28758251 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896294 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9899943 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896907 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs11080138 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30897524 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs73265612 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30898965 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs11658435 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30901543 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs73265624 ENSG00000266490.1 CTD-2349P21.9 4.37 1.63e-05 0.00403 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905048 chr17:30792372~30792833:+ LIHC cis rs1223397 1 rs1223403 ENSG00000215022.6 RP1-257A7.4 -4.37 1.63e-05 0.00403 -0.27 -0.23 Blood pressure; chr6:13271580 chr6:13264861~13295586:- LIHC cis rs11951515 0.508 rs10065689 ENSG00000248240.1 RP11-159F24.5 -4.37 1.63e-05 0.00404 -0.29 -0.23 Metabolite levels (X-11787); chr5:43604156 chr5:43515274~43525310:+ LIHC cis rs3733589 0.744 rs57897925 ENSG00000250413.1 RP11-448G15.1 4.37 1.63e-05 0.00404 0.37 0.23 Renal overload gout; chr4:10051657 chr4:10006482~10009725:+ LIHC cis rs73086581 0.592 rs2300217 ENSG00000229539.1 RP11-119B16.2 4.37 1.63e-05 0.00404 0.25 0.23 Response to antidepressants in depression; chr20:3957928 chr20:3888239~3888868:- LIHC cis rs899997 1 rs12899940 ENSG00000261143.1 ADAMTS7P3 -4.37 1.64e-05 0.00404 -0.27 -0.23 Coronary artery disease or large artery stroke; chr15:78709357 chr15:77976042~77993057:+ LIHC cis rs3743772 0.5 rs11866060 ENSG00000279722.1 RP11-44F14.6 4.37 1.64e-05 0.00404 0.3 0.23 Depressive symptoms (SSRI exposure interaction); chr16:53394937 chr16:53487607~53489943:- LIHC cis rs10129255 0.872 rs10133674 ENSG00000223648.3 IGHV3-64 4.37 1.64e-05 0.00404 0.17 0.23 Kawasaki disease; chr14:106692788 chr14:106643132~106658258:- LIHC cis rs67311347 1 rs72861689 ENSG00000223797.4 ENTPD3-AS1 4.37 1.64e-05 0.00404 0.19 0.23 Renal cell carcinoma; chr3:40394399 chr3:40313802~40453329:- LIHC cis rs1799949 1 rs8176126 ENSG00000267681.1 CTD-3199J23.6 4.37 1.64e-05 0.00405 0.22 0.23 Menopause (age at onset); chr17:43107032 chr17:43144956~43145255:+ LIHC cis rs7811142 1 rs11763414 ENSG00000242294.5 STAG3L5P 4.37 1.64e-05 0.00405 0.27 0.23 Platelet count; chr7:100419221 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs67163493 ENSG00000242294.5 STAG3L5P 4.37 1.64e-05 0.00405 0.27 0.23 Platelet count; chr7:100426215 chr7:100336079~100351900:+ LIHC cis rs2243480 1 rs1638734 ENSG00000232546.1 RP11-458F8.1 -4.37 1.64e-05 0.00405 -0.26 -0.23 Diabetic kidney disease; chr7:66632552 chr7:66848496~66858136:+ LIHC cis rs875971 0.545 rs73376401 ENSG00000228409.4 CCT6P1 -4.37 1.64e-05 0.00405 -0.19 -0.23 Aortic root size; chr7:66174841 chr7:65751142~65763354:+ LIHC cis rs1816213 1 rs16859180 ENSG00000273466.1 RP11-548H3.1 4.37 1.64e-05 0.00406 0.34 0.23 Diastolic blood pressure; chr2:218688745 chr2:218633256~218634014:- LIHC cis rs12935418 0.83 rs12448368 ENSG00000261061.1 RP11-303E16.2 4.37 1.64e-05 0.00406 0.34 0.23 Mean corpuscular volume; chr16:81011342 chr16:81030770~81031485:+ LIHC cis rs2243480 1 rs6460260 ENSG00000228409.4 CCT6P1 -4.37 1.64e-05 0.00406 -0.25 -0.23 Diabetic kidney disease; chr7:65750468 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs6460261 ENSG00000228409.4 CCT6P1 -4.37 1.64e-05 0.00406 -0.25 -0.23 Diabetic kidney disease; chr7:65750593 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs4718270 ENSG00000228409.4 CCT6P1 4.37 1.64e-05 0.00406 0.25 0.23 Diabetic kidney disease; chr7:65737415 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs2900904 ENSG00000228409.4 CCT6P1 4.37 1.64e-05 0.00406 0.25 0.23 Diabetic kidney disease; chr7:65739282 chr7:65751142~65763354:+ LIHC cis rs6940638 0.662 rs7759694 ENSG00000216901.1 AL022393.7 4.37 1.64e-05 0.00406 0.32 0.23 Intelligence (multi-trait analysis); chr6:27273177 chr6:28176188~28176674:+ LIHC cis rs11096990 0.634 rs6531703 ENSG00000249207.1 RP11-360F5.1 4.37 1.64e-05 0.00406 0.23 0.23 Cognitive function; chr4:39281786 chr4:39112677~39126818:- LIHC cis rs9834975 0.967 rs6768280 ENSG00000272758.4 RP11-299J3.8 4.37 1.64e-05 0.00406 0.25 0.23 Diastolic blood pressure; chr3:122406205 chr3:122416207~122443180:+ LIHC cis rs11676348 0.808 rs1008563 ENSG00000261338.2 RP11-378A13.1 -4.37 1.65e-05 0.00406 -0.25 -0.23 Ulcerative colitis; chr2:218162165 chr2:218255319~218257366:+ LIHC cis rs17826219 0.706 rs9905827 ENSG00000266490.1 CTD-2349P21.9 4.37 1.65e-05 0.00407 0.29 0.23 Body mass index; chr17:30865150 chr17:30792372~30792833:+ LIHC cis rs11233413 0.874 rs5018628 ENSG00000246067.6 RAB30-AS1 4.37 1.65e-05 0.00407 0.32 0.23 Economic and political preferences (feminism/equality); chr11:83041195 chr11:83072066~83106719:+ LIHC cis rs17301013 0.869 rs3133270 ENSG00000227373.4 RP11-160H22.5 -4.37 1.65e-05 0.00407 -0.28 -0.23 Systemic lupus erythematosus; chr1:174819547 chr1:174115300~174160004:- LIHC cis rs2739330 0.828 rs5760098 ENSG00000206090.4 AP000350.7 4.37 1.65e-05 0.00407 0.27 0.23 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23939998~23942798:+ LIHC cis rs3812762 0.912 rs10769954 ENSG00000254860.4 TMEM9B-AS1 -4.37 1.65e-05 0.00407 -0.25 -0.23 Hypospadias; chr11:8762166 chr11:8964675~8977527:+ LIHC cis rs4356203 0.519 rs214097 ENSG00000260196.1 RP1-239B22.5 -4.37 1.65e-05 0.00407 -0.28 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17269952 chr11:17380649~17383531:+ LIHC cis rs748404 0.66 rs690446 ENSG00000166763.7 STRCP1 4.37 1.65e-05 0.00407 0.28 0.23 Lung cancer; chr15:43469066 chr15:43699488~43718184:- LIHC cis rs748404 0.66 rs518288 ENSG00000166763.7 STRCP1 4.37 1.65e-05 0.00407 0.28 0.23 Lung cancer; chr15:43471801 chr15:43699488~43718184:- LIHC cis rs748404 0.66 rs690472 ENSG00000166763.7 STRCP1 4.37 1.65e-05 0.00407 0.28 0.23 Lung cancer; chr15:43472170 chr15:43699488~43718184:- LIHC cis rs748404 0.631 rs560191 ENSG00000166763.7 STRCP1 4.37 1.65e-05 0.00407 0.28 0.23 Lung cancer; chr15:43475576 chr15:43699488~43718184:- LIHC cis rs2581828 0.646 rs9867023 ENSG00000242142.1 SERBP1P3 4.37 1.65e-05 0.00407 0.3 0.23 Crohn's disease; chr3:53126116 chr3:53064283~53065091:- LIHC cis rs8040855 0.627 rs12905036 ENSG00000259295.5 CSPG4P12 4.37 1.65e-05 0.00407 0.36 0.23 Bulimia nervosa; chr15:85094557 chr15:85191438~85213905:+ LIHC cis rs8040855 0.627 rs12913859 ENSG00000259295.5 CSPG4P12 4.37 1.65e-05 0.00407 0.36 0.23 Bulimia nervosa; chr15:85095187 chr15:85191438~85213905:+ LIHC cis rs9353324 1 rs7745560 ENSG00000203875.9 SNHG5 4.37 1.65e-05 0.00408 0.45 0.23 Interferon gamma-induced protein 10 levels; chr6:85579203 chr6:85660950~85678736:- LIHC cis rs11098499 0.754 rs7672594 ENSG00000260091.1 RP11-33B1.4 -4.37 1.65e-05 0.00408 -0.16 -0.23 Corneal astigmatism; chr4:119327388 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs7672778 ENSG00000260091.1 RP11-33B1.4 -4.37 1.65e-05 0.00408 -0.16 -0.23 Corneal astigmatism; chr4:119327430 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs12513083 ENSG00000260091.1 RP11-33B1.4 -4.37 1.65e-05 0.00408 -0.16 -0.23 Corneal astigmatism; chr4:119328457 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs12509621 ENSG00000260091.1 RP11-33B1.4 -4.37 1.65e-05 0.00408 -0.16 -0.23 Corneal astigmatism; chr4:119328505 chr4:119409333~119410233:+ LIHC cis rs75920871 0.688 rs1473326 ENSG00000254851.1 RP11-109L13.1 -4.37 1.65e-05 0.00408 -0.48 -0.23 Subjective well-being; chr11:116952956 chr11:117135528~117138582:+ LIHC cis rs11096990 0.656 rs2066786 ENSG00000249685.1 RP11-360F5.3 4.37 1.65e-05 0.00408 0.28 0.23 Cognitive function; chr4:39300409 chr4:39133913~39135608:+ LIHC cis rs2276314 0.802 rs58906216 ENSG00000278986.1 RP11-723J4.3 -4.37 1.66e-05 0.00408 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:36050334 chr18:35972151~35973916:+ LIHC cis rs3733589 1 rs13106922 ENSG00000250413.1 RP11-448G15.1 4.37 1.66e-05 0.00409 0.37 0.23 Renal overload gout; chr4:10020135 chr4:10006482~10009725:+ LIHC cis rs3733589 0.744 rs13114106 ENSG00000250413.1 RP11-448G15.1 4.37 1.66e-05 0.00409 0.37 0.23 Renal overload gout; chr4:10020501 chr4:10006482~10009725:+ LIHC cis rs3733589 0.744 rs3756234 ENSG00000250413.1 RP11-448G15.1 4.37 1.66e-05 0.00409 0.37 0.23 Renal overload gout; chr4:10020850 chr4:10006482~10009725:+ LIHC cis rs9341808 0.527 rs7453746 ENSG00000272129.1 RP11-250B2.6 4.37 1.66e-05 0.00409 0.22 0.23 Sitting height ratio; chr6:80100296 chr6:80355424~80356859:+ LIHC cis rs748404 0.66 rs2602141 ENSG00000166763.7 STRCP1 4.37 1.66e-05 0.00409 0.28 0.23 Lung cancer; chr15:43432448 chr15:43699488~43718184:- LIHC cis rs901683 0.702 rs4326742 ENSG00000230869.1 CTGLF10P -4.37 1.66e-05 0.00409 -0.55 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45607788 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs4576771 ENSG00000230869.1 CTGLF10P -4.37 1.66e-05 0.00409 -0.55 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45607790 chr10:45678692~45700532:+ LIHC cis rs765787 0.53 rs12323957 ENSG00000259520.4 CTD-2651B20.3 -4.37 1.66e-05 0.0041 -0.27 -0.23 Uric acid levels; chr15:45198575 chr15:45251580~45279251:- LIHC cis rs4578769 0.918 rs9957390 ENSG00000265943.1 RP11-739L10.1 4.37 1.66e-05 0.0041 0.29 0.23 Eosinophil percentage of white cells; chr18:22840421 chr18:22699481~22933764:- LIHC cis rs11098499 0.863 rs2306457 ENSG00000245958.5 RP11-33B1.1 -4.37 1.66e-05 0.0041 -0.24 -0.23 Corneal astigmatism; chr4:119551684 chr4:119454791~119552025:+ LIHC cis rs5770917 1 rs5770924 ENSG00000273272.1 CTA-384D8.34 4.37 1.66e-05 0.0041 0.34 0.23 Narcolepsy; chr22:50586113 chr22:50542650~50543011:+ LIHC cis rs11096990 0.634 rs2381371 ENSG00000249207.1 RP11-360F5.1 -4.37 1.66e-05 0.0041 -0.23 -0.23 Cognitive function; chr4:39271414 chr4:39112677~39126818:- LIHC cis rs2749097 0.825 rs35477997 ENSG00000244256.3 RN7SL130P -4.37 1.66e-05 0.0041 -0.27 -0.23 Alcohol consumption (transferrin glycosylation); chr1:63656834 chr1:63655743~63656047:+ LIHC cis rs11096990 0.634 rs10010352 ENSG00000249207.1 RP11-360F5.1 -4.37 1.66e-05 0.0041 -0.24 -0.23 Cognitive function; chr4:39240657 chr4:39112677~39126818:- LIHC cis rs7937890 0.505 rs1403248 ENSG00000251991.1 RNU7-49P 4.37 1.66e-05 0.0041 0.26 0.23 Mitochondrial DNA levels; chr11:14657471 chr11:14478892~14478953:+ LIHC cis rs6504622 0.721 rs8077021 ENSG00000262879.4 RP11-156P1.3 -4.37 1.67e-05 0.0041 -0.24 -0.23 Orofacial clefts; chr17:47061937 chr17:46984045~47100323:- LIHC cis rs9487094 0.885 rs12524273 ENSG00000260273.1 RP11-425D10.10 4.37 1.67e-05 0.00411 0.27 0.23 Height; chr6:109395761 chr6:109382795~109383666:+ LIHC cis rs755249 0.567 rs61779308 ENSG00000182109.6 RP11-69E11.4 4.37 1.67e-05 0.00411 0.32 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39472585 chr1:39522280~39546187:- LIHC cis rs9467711 0.584 rs34391493 ENSG00000216436.2 HIST1H2APS1 4.37 1.67e-05 0.00411 0.55 0.23 Autism spectrum disorder or schizophrenia; chr6:26022420 chr6:25732497~25732827:+ LIHC cis rs651907 0.535 rs9830943 ENSG00000244119.1 PDCL3P4 4.37 1.67e-05 0.00411 0.24 0.23 Colorectal cancer; chr3:101710055 chr3:101712472~101713191:+ LIHC cis rs783540 0.5 rs7178459 ENSG00000278603.1 RP13-608F4.5 4.37 1.67e-05 0.00411 0.31 0.23 Schizophrenia; chr15:82729632 chr15:82472203~82472426:+ LIHC cis rs7743045 0.625 rs9387628 ENSG00000253194.1 RP11-351A11.1 -4.37 1.67e-05 0.00411 -0.31 -0.23 Mean platelet volume; chr6:119031853 chr6:118934785~119031541:+ LIHC cis rs7809950 1 rs4730245 ENSG00000238832.1 snoU109 -4.37 1.67e-05 0.00412 -0.28 -0.23 Coronary artery disease; chr7:107446849 chr7:107603363~107603507:+ LIHC cis rs6445975 0.612 rs6763103 ENSG00000272360.1 RP11-359I18.5 4.37 1.67e-05 0.00412 0.32 0.23 Systemic lupus erythematosus; chr3:58451618 chr3:58490830~58491291:- LIHC cis rs9304742 0.962 rs12459008 ENSG00000213801.4 ZNF816-ZNF321P -4.37 1.67e-05 0.00413 -0.23 -0.23 Psoriasis; chr19:52951536 chr19:52927135~52942601:- LIHC cis rs8040855 0.658 rs11634877 ENSG00000259295.5 CSPG4P12 4.37 1.67e-05 0.00413 0.36 0.23 Bulimia nervosa; chr15:85068246 chr15:85191438~85213905:+ LIHC cis rs8040855 0.627 rs11632175 ENSG00000259295.5 CSPG4P12 4.37 1.67e-05 0.00413 0.36 0.23 Bulimia nervosa; chr15:85068449 chr15:85191438~85213905:+ LIHC cis rs8040855 0.627 rs11631548 ENSG00000259295.5 CSPG4P12 4.37 1.67e-05 0.00413 0.36 0.23 Bulimia nervosa; chr15:85076017 chr15:85191438~85213905:+ LIHC cis rs4660214 0.724 rs3931300 ENSG00000182109.6 RP11-69E11.4 -4.37 1.68e-05 0.00413 -0.25 -0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39195175 chr1:39522280~39546187:- LIHC cis rs6442522 0.772 rs2278961 ENSG00000249786.6 EAF1-AS1 4.37 1.68e-05 0.00413 0.26 0.23 Uric acid levels; chr3:15451300 chr3:15436171~15455940:- LIHC cis rs1865760 0.516 rs9393684 ENSG00000216436.2 HIST1H2APS1 -4.37 1.68e-05 0.00413 -0.27 -0.23 Height; chr6:26075303 chr6:25732497~25732827:+ LIHC cis rs1400745 0.718 rs1200414 ENSG00000258738.1 RP11-73E17.2 4.37 1.68e-05 0.00413 0.28 0.23 Monocyte count; chr14:34861687 chr14:34874343~34876459:+ LIHC cis rs524281 0.731 rs2452682 ENSG00000255320.1 RP11-755F10.1 4.37 1.68e-05 0.00414 0.3 0.23 Electroencephalogram traits; chr11:66045138 chr11:66244840~66246239:- LIHC cis rs6903823 0.508 rs1150726 ENSG00000204709.4 LINC01556 4.37 1.68e-05 0.00414 0.25 0.23 Pulmonary function; chr6:28275265 chr6:28943877~28944537:+ LIHC cis rs13217239 0.646 rs11756275 ENSG00000241549.7 GUSBP2 -4.37 1.68e-05 0.00414 -0.24 -0.23 Schizophrenia; chr6:27039334 chr6:26871484~26956554:- LIHC cis rs10028773 0.7 rs7671797 ENSG00000260091.1 RP11-33B1.4 -4.37 1.68e-05 0.00414 -0.16 -0.23 Educational attainment; chr4:119327002 chr4:119409333~119410233:+ LIHC cis rs193541 0.564 rs62377434 ENSG00000263432.2 RN7SL689P -4.37 1.68e-05 0.00414 -0.37 -0.23 Glucose homeostasis traits; chr5:123004874 chr5:123022487~123022783:- LIHC cis rs1115240 0.891 rs17111488 ENSG00000257842.4 NOVA1-AS1 4.37 1.68e-05 0.00414 0.21 0.23 Educational attainment (years of education); chr14:26638054 chr14:26598412~26806467:+ LIHC cis rs734999 0.545 rs10752748 ENSG00000225931.3 RP3-395M20.7 4.37 1.68e-05 0.00415 0.24 0.23 Ulcerative colitis; chr1:2613201 chr1:2566410~2569888:+ LIHC cis rs763121 0.853 rs6001173 ENSG00000273076.1 RP3-508I15.22 4.37 1.68e-05 0.00415 0.26 0.23 Menopause (age at onset); chr22:38619297 chr22:38743495~38743910:+ LIHC cis rs7208859 0.623 rs7219712 ENSG00000266490.1 CTD-2349P21.9 4.37 1.68e-05 0.00415 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753552 chr17:30792372~30792833:+ LIHC cis rs11098499 0.644 rs34835603 ENSG00000260091.1 RP11-33B1.4 -4.37 1.69e-05 0.00415 -0.16 -0.23 Corneal astigmatism; chr4:119632273 chr4:119409333~119410233:+ LIHC cis rs5758511 0.689 rs17002947 ENSG00000237037.8 NDUFA6-AS1 4.37 1.69e-05 0.00415 0.44 0.23 Birth weight; chr22:42292526 chr22:42090931~42137742:+ LIHC cis rs193541 0.632 rs34486978 ENSG00000263432.2 RN7SL689P -4.37 1.69e-05 0.00415 -0.36 -0.23 Glucose homeostasis traits; chr5:122976848 chr5:123022487~123022783:- LIHC cis rs7702057 0.53 rs56953556 ENSG00000271918.1 CTD-2287O16.5 4.36 1.69e-05 0.00416 0.31 0.23 Amyotrophic lateral sclerosis; chr5:116076903 chr5:116083807~116085416:- LIHC cis rs763121 0.819 rs5757160 ENSG00000273076.1 RP3-508I15.22 4.36 1.69e-05 0.00416 0.26 0.23 Menopause (age at onset); chr22:38593641 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs5757166 ENSG00000273076.1 RP3-508I15.22 4.36 1.69e-05 0.00416 0.26 0.23 Menopause (age at onset); chr22:38599380 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs1569716 ENSG00000273076.1 RP3-508I15.22 4.36 1.69e-05 0.00416 0.26 0.23 Menopause (age at onset); chr22:38602514 chr22:38743495~38743910:+ LIHC cis rs763121 0.819 rs5757169 ENSG00000273076.1 RP3-508I15.22 4.36 1.69e-05 0.00416 0.26 0.23 Menopause (age at onset); chr22:38607490 chr22:38743495~38743910:+ LIHC cis rs686320 0.748 rs673753 ENSG00000245532.5 NEAT1 -4.36 1.69e-05 0.00416 -0.32 -0.23 Hip circumference adjusted for BMI; chr11:65438546 chr11:65422774~65445540:+ LIHC cis rs9675120 0.675 rs4586493 ENSG00000262006.1 RP11-700H6.4 -4.36 1.69e-05 0.00416 -0.25 -0.23 Cerebrospinal fluid biomarker levels; chr17:50847104 chr17:50909637~50910232:- LIHC cis rs7662987 0.793 rs28730602 ENSG00000272777.1 RP11-571L19.8 4.36 1.69e-05 0.00416 0.54 0.23 Smoking initiation; chr4:99080531 chr4:99067256~99068125:- LIHC cis rs6921919 0.789 rs13210258 ENSG00000216901.1 AL022393.7 4.36 1.69e-05 0.00416 0.29 0.23 Autism spectrum disorder or schizophrenia; chr6:28340894 chr6:28176188~28176674:+ LIHC cis rs3845817 0.67 rs840787 ENSG00000281920.1 RP11-418H16.1 -4.36 1.69e-05 0.00416 -0.27 -0.23 Bipolar disorder; chr2:65548756 chr2:65623272~65628424:+ LIHC cis rs1075265 0.597 rs10490471 ENSG00000272156.1 RP11-477N3.1 -4.36 1.69e-05 0.00416 -0.28 -0.23 Chronotype;Morning vs. evening chronotype; chr2:53769446 chr2:54082554~54085066:+ LIHC cis rs10181042 0.514 rs1177289 ENSG00000271889.1 RP11-493E12.1 4.36 1.69e-05 0.00417 0.27 0.23 Crohn's disease; chr2:61126121 chr2:61151433~61162105:- LIHC cis rs6723226 0.572 rs176411 ENSG00000276334.1 AL133243.1 4.36 1.69e-05 0.00417 0.25 0.23 Intelligence (multi-trait analysis); chr2:32418460 chr2:32521927~32523547:+ LIHC cis rs3733589 0.744 rs13142273 ENSG00000250413.1 RP11-448G15.1 4.36 1.7e-05 0.00418 0.37 0.23 Renal overload gout; chr4:9940335 chr4:10006482~10009725:+ LIHC cis rs2439831 0.717 rs690170 ENSG00000275601.1 AC011330.13 -4.36 1.7e-05 0.00418 -0.35 -0.23 Lung cancer in ever smokers; chr15:43518224 chr15:43642389~43643023:- LIHC cis rs11096990 0.593 rs6531700 ENSG00000249207.1 RP11-360F5.1 4.36 1.7e-05 0.00418 0.23 0.23 Cognitive function; chr4:39269265 chr4:39112677~39126818:- LIHC cis rs11733284 0.515 rs7667425 ENSG00000259959.1 RP11-121C2.2 -4.36 1.7e-05 0.00418 -0.22 -0.23 Gout;Renal underexcretion gout; chr4:48014453 chr4:47840122~47844339:- LIHC cis rs11096990 0.656 rs2123028 ENSG00000249685.1 RP11-360F5.3 -4.36 1.7e-05 0.00418 -0.27 -0.23 Cognitive function; chr4:39301859 chr4:39133913~39135608:+ LIHC cis rs4578769 0.959 rs3851816 ENSG00000266850.1 RP11-370A5.1 4.36 1.7e-05 0.00418 0.27 0.23 Eosinophil percentage of white cells; chr18:22866880 chr18:22723491~22907721:- LIHC cis rs7587476 1 rs2121285 ENSG00000229267.2 AC072062.1 4.36 1.7e-05 0.00418 0.3 0.23 Neuroblastoma; chr2:214791444 chr2:214810229~214963274:+ LIHC cis rs2564921 0.765 rs35333155 ENSG00000242142.1 SERBP1P3 4.36 1.7e-05 0.00418 0.27 0.23 Height; chr3:53073764 chr3:53064283~53065091:- LIHC cis rs6445975 1 rs7653734 ENSG00000272360.1 RP11-359I18.5 4.36 1.7e-05 0.00419 0.29 0.23 Systemic lupus erythematosus; chr3:58387158 chr3:58490830~58491291:- LIHC cis rs2243480 0.522 rs778717 ENSG00000230295.1 RP11-458F8.2 -4.36 1.7e-05 0.00419 -0.26 -0.23 Diabetic kidney disease; chr7:66383164 chr7:66880708~66882981:+ LIHC cis rs875971 0.545 rs316305 ENSG00000228409.4 CCT6P1 4.36 1.7e-05 0.00419 0.19 0.23 Aortic root size; chr7:66152984 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs316306 ENSG00000228409.4 CCT6P1 4.36 1.7e-05 0.00419 0.19 0.23 Aortic root size; chr7:66153687 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs10950025 ENSG00000228409.4 CCT6P1 -4.36 1.7e-05 0.00419 -0.19 -0.23 Aortic root size; chr7:66158946 chr7:65751142~65763354:+ LIHC cis rs875971 0.52 rs12666485 ENSG00000228409.4 CCT6P1 -4.36 1.7e-05 0.00419 -0.19 -0.23 Aortic root size; chr7:66160135 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs67688847 ENSG00000228409.4 CCT6P1 -4.36 1.7e-05 0.00419 -0.19 -0.23 Aortic root size; chr7:66161064 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs12673308 ENSG00000228409.4 CCT6P1 -4.36 1.7e-05 0.00419 -0.19 -0.23 Aortic root size; chr7:66166374 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs6460281 ENSG00000228409.4 CCT6P1 -4.36 1.71e-05 0.00419 -0.19 -0.23 Aortic root size; chr7:66216128 chr7:65751142~65763354:+ LIHC cis rs1865760 0.551 rs9461230 ENSG00000216436.2 HIST1H2APS1 -4.36 1.71e-05 0.00419 -0.27 -0.23 Height; chr6:26019012 chr6:25732497~25732827:+ LIHC cis rs11098499 0.789 rs9991166 ENSG00000260091.1 RP11-33B1.4 -4.36 1.71e-05 0.0042 -0.16 -0.23 Corneal astigmatism; chr4:119316696 chr4:119409333~119410233:+ LIHC cis rs11098499 0.708 rs10005237 ENSG00000260091.1 RP11-33B1.4 -4.36 1.71e-05 0.0042 -0.16 -0.23 Corneal astigmatism; chr4:119316742 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs10213267 ENSG00000260091.1 RP11-33B1.4 -4.36 1.71e-05 0.0042 -0.16 -0.23 Corneal astigmatism; chr4:119317919 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs10212775 ENSG00000260091.1 RP11-33B1.4 -4.36 1.71e-05 0.0042 -0.16 -0.23 Corneal astigmatism; chr4:119318089 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs11732087 ENSG00000260091.1 RP11-33B1.4 -4.36 1.71e-05 0.0042 -0.16 -0.23 Corneal astigmatism; chr4:119318676 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs2964 ENSG00000260091.1 RP11-33B1.4 -4.36 1.71e-05 0.0042 -0.16 -0.23 Corneal astigmatism; chr4:119318976 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs1511025 ENSG00000260091.1 RP11-33B1.4 -4.36 1.71e-05 0.0042 -0.16 -0.23 Corneal astigmatism; chr4:119319083 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs12510269 ENSG00000260091.1 RP11-33B1.4 -4.36 1.71e-05 0.0042 -0.16 -0.23 Corneal astigmatism; chr4:119320491 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs12506610 ENSG00000260091.1 RP11-33B1.4 -4.36 1.71e-05 0.0042 -0.16 -0.23 Corneal astigmatism; chr4:119320504 chr4:119409333~119410233:+ LIHC cis rs11098499 0.743 rs10003567 ENSG00000260091.1 RP11-33B1.4 -4.36 1.71e-05 0.0042 -0.16 -0.23 Corneal astigmatism; chr4:119320519 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs10006259 ENSG00000260091.1 RP11-33B1.4 -4.36 1.71e-05 0.0042 -0.16 -0.23 Corneal astigmatism; chr4:119320990 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs28652763 ENSG00000260091.1 RP11-33B1.4 -4.36 1.71e-05 0.0042 -0.16 -0.23 Corneal astigmatism; chr4:119321157 chr4:119409333~119410233:+ LIHC cis rs10262624 1 rs10238070 ENSG00000234286.1 AC006026.13 -4.36 1.71e-05 0.0042 -0.26 -0.23 Schizophrenia; chr7:23870172 chr7:23680195~23680786:- LIHC cis rs11690935 0.632 rs9789538 ENSG00000228389.1 AC068039.4 -4.36 1.71e-05 0.0042 -0.27 -0.23 Schizophrenia; chr2:171761964 chr2:171773482~171775844:+ LIHC cis rs853679 0.882 rs3757188 ENSG00000219392.1 RP1-265C24.5 -4.36 1.71e-05 0.0042 -0.44 -0.23 Depression; chr6:28139579 chr6:28115628~28116551:+ LIHC cis rs8040855 0.575 rs12912860 ENSG00000259295.5 CSPG4P12 4.36 1.71e-05 0.0042 0.37 0.23 Bulimia nervosa; chr15:85030267 chr15:85191438~85213905:+ LIHC cis rs901683 0.85 rs79022473 ENSG00000230869.1 CTGLF10P -4.36 1.71e-05 0.0042 -0.58 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45606320 chr10:45678692~45700532:+ LIHC cis rs6558530 0.897 rs10481354 ENSG00000253982.1 CTD-2336O2.1 -4.36 1.71e-05 0.0042 -0.29 -0.23 Systolic blood pressure; chr8:1755864 chr8:1761990~1764502:- LIHC cis rs6802315 0.604 rs2364927 ENSG00000272087.1 RP11-379F4.7 4.36 1.71e-05 0.00421 0.26 0.23 Periodontitis (CDC/AAP); chr3:158760066 chr3:158693120~158693768:- LIHC cis rs7893279 0.543 rs11597737 ENSG00000225527.1 RP11-383B4.4 4.36 1.71e-05 0.00421 0.32 0.23 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18670162 chr10:18531849~18533336:- LIHC cis rs6982751 0.673 rs4841464 ENSG00000255310.2 AF131215.2 -4.36 1.71e-05 0.00421 -0.35 -0.23 Asthma and hay fever; chr8:10949721 chr8:11107788~11109726:- LIHC cis rs9675120 1 rs7207028 ENSG00000262006.1 RP11-700H6.4 4.36 1.71e-05 0.00421 0.24 0.23 Cerebrospinal fluid biomarker levels; chr17:50838691 chr17:50909637~50910232:- LIHC cis rs638893 0.636 rs7119702 ENSG00000278376.1 RP11-158I9.8 -4.36 1.71e-05 0.00421 -0.41 -0.23 Vitiligo; chr11:118736985 chr11:118791254~118793137:+ LIHC cis rs2744375 1 rs2744373 ENSG00000261189.1 RP3-512B11.3 4.36 1.71e-05 0.00421 0.4 0.23 Resting heart rate; chr6:7554294 chr6:7540451~7541338:- LIHC cis rs11098499 0.82 rs13122709 ENSG00000260091.1 RP11-33B1.4 -4.36 1.72e-05 0.00421 -0.17 -0.23 Corneal astigmatism; chr4:119634201 chr4:119409333~119410233:+ LIHC cis rs2842992 0.747 rs1547093 ENSG00000237927.1 RP3-393E18.2 -4.36 1.72e-05 0.00421 -0.28 -0.23 Age-related macular degeneration (geographic atrophy); chr6:159784959 chr6:159586955~159589169:- LIHC cis rs2036707 0.744 rs9555413 ENSG00000277246.1 RP11-153I24.4 -4.36 1.72e-05 0.00422 -0.45 -0.23 Obesity-related traits; chr13:107828388 chr13:108267320~108267734:+ LIHC cis rs7044106 0.791 rs4836829 ENSG00000238181.2 AHCYP2 -4.36 1.72e-05 0.00422 -0.26 -0.23 Hip circumference adjusted for BMI; chr9:120720469 chr9:120720673~120721972:+ LIHC cis rs763121 0.853 rs138705 ENSG00000273076.1 RP3-508I15.22 4.36 1.72e-05 0.00422 0.26 0.23 Menopause (age at onset); chr22:38737798 chr22:38743495~38743910:+ LIHC cis rs2274273 0.624 rs10143136 ENSG00000258413.1 RP11-665C16.6 -4.36 1.72e-05 0.00422 -0.29 -0.23 Protein biomarker; chr14:55276810 chr14:55262767~55272075:- LIHC cis rs6445975 0.666 rs12635366 ENSG00000272360.1 RP11-359I18.5 -4.36 1.72e-05 0.00422 -0.3 -0.23 Systemic lupus erythematosus; chr3:58412739 chr3:58490830~58491291:- LIHC cis rs9876781 1 rs1459242 ENSG00000229759.1 MRPS18AP1 -4.36 1.72e-05 0.00423 -0.24 -0.23 Longevity; chr3:48372047 chr3:48256350~48256938:- LIHC cis rs5756813 0.661 rs2246503 ENSG00000233360.4 Z83844.1 4.36 1.72e-05 0.00423 0.29 0.23 Optic cup area;Vertical cup-disc ratio; chr22:37808533 chr22:37641832~37658377:- LIHC cis rs5756813 0.661 rs5995500 ENSG00000233360.4 Z83844.1 4.36 1.72e-05 0.00423 0.29 0.23 Optic cup area;Vertical cup-disc ratio; chr22:37808633 chr22:37641832~37658377:- LIHC cis rs1558001 0.84 rs12707460 ENSG00000230196.1 DDX43P3 -4.36 1.72e-05 0.00423 -0.24 -0.23 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81816773 chr7:81610884~81611326:- LIHC cis rs960902 0.869 rs6735123 ENSG00000213553.4 RPLP0P6 -4.36 1.72e-05 0.00423 -0.19 -0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37508721 chr2:38481851~38482804:+ LIHC cis rs6442522 0.809 rs2290537 ENSG00000249786.6 EAF1-AS1 4.36 1.72e-05 0.00423 0.27 0.23 Uric acid levels; chr3:15414210 chr3:15436171~15455940:- LIHC cis rs11722228 0.549 rs3796818 ENSG00000261490.1 RP11-448G15.3 4.36 1.72e-05 0.00423 0.31 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10096352 chr4:10068089~10073019:- LIHC cis rs921968 0.541 rs933995 ENSG00000272555.1 RP11-459I19.1 -4.36 1.73e-05 0.00424 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218785995 chr2:218818690~218819144:+ LIHC cis rs9890032 0.532 rs1808257 ENSG00000266490.1 CTD-2349P21.9 4.36 1.73e-05 0.00424 0.21 0.23 Hip circumference adjusted for BMI; chr17:30712948 chr17:30792372~30792833:+ LIHC cis rs12936587 0.535 rs8065154 ENSG00000223979.2 SMCR2 -4.36 1.73e-05 0.00424 -0.3 -0.23 Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference; chr17:17711633 chr17:17674026~17677688:- LIHC cis rs1577917 0.917 rs35283633 ENSG00000234155.1 RP11-30P6.6 4.36 1.73e-05 0.00424 0.3 0.23 Response to antipsychotic treatment; chr6:85981069 chr6:85387219~85390186:- LIHC cis rs12216125 0.549 rs9358905 ENSG00000216436.2 HIST1H2APS1 -4.36 1.73e-05 0.00424 -0.27 -0.23 Iron status biomarkers; chr6:26077611 chr6:25732497~25732827:+ LIHC cis rs113084984 0.718 rs12994182 ENSG00000271952.1 RP11-245G13.2 -4.36 1.73e-05 0.00424 -0.28 -0.23 Breast cancer; chr2:11543772 chr2:10878269~10885118:+ LIHC cis rs5756813 0.635 rs11089856 ENSG00000233360.4 Z83844.1 4.36 1.73e-05 0.00424 0.28 0.23 Optic cup area;Vertical cup-disc ratio; chr22:37809777 chr22:37641832~37658377:- LIHC cis rs11098499 0.754 rs1511017 ENSG00000260091.1 RP11-33B1.4 -4.36 1.73e-05 0.00424 -0.16 -0.23 Corneal astigmatism; chr4:119329650 chr4:119409333~119410233:+ LIHC cis rs11098499 0.789 rs12498994 ENSG00000260091.1 RP11-33B1.4 -4.36 1.73e-05 0.00424 -0.16 -0.23 Corneal astigmatism; chr4:119329663 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs12507565 ENSG00000260091.1 RP11-33B1.4 -4.36 1.73e-05 0.00424 -0.16 -0.23 Corneal astigmatism; chr4:119329966 chr4:119409333~119410233:+ LIHC cis rs11098499 0.826 rs12511640 ENSG00000260091.1 RP11-33B1.4 -4.36 1.73e-05 0.00424 -0.16 -0.23 Corneal astigmatism; chr4:119330093 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs1980026 ENSG00000260091.1 RP11-33B1.4 -4.36 1.73e-05 0.00424 -0.16 -0.23 Corneal astigmatism; chr4:119330488 chr4:119409333~119410233:+ LIHC cis rs11648785 0.777 rs3785183 ENSG00000221819.5 GAS8-AS1 -4.36 1.73e-05 0.00424 -0.31 -0.23 Tanning; chr16:90029153 chr16:90028908~90029367:- LIHC cis rs244293 0.831 rs7207057 ENSG00000275710.1 RP11-257O5.4 -4.36 1.73e-05 0.00425 -0.24 -0.23 Menarche (age at onset); chr17:55095607 chr17:54964474~54964679:+ LIHC cis rs11779988 0.545 rs436506 ENSG00000253671.1 RP11-806O11.1 4.36 1.73e-05 0.00425 0.31 0.23 Breast cancer; chr8:17940734 chr8:17808941~17820868:+ LIHC cis rs2276314 0.857 rs6507157 ENSG00000278986.1 RP11-723J4.3 -4.36 1.73e-05 0.00425 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:36051740 chr18:35972151~35973916:+ LIHC cis rs1876905 0.539 rs240969 ENSG00000271789.1 RP5-1112D6.7 4.36 1.73e-05 0.00425 0.27 0.23 Mean corpuscular hemoglobin; chr6:111314605 chr6:111297126~111298510:+ LIHC cis rs957448 1 rs56716157 ENSG00000253704.1 RP11-267M23.4 4.36 1.73e-05 0.00425 0.29 0.23 Nonsyndromic cleft lip with cleft palate; chr8:94530644 chr8:94553722~94569745:+ LIHC cis rs709400 0.93 rs61996717 ENSG00000258534.1 CTD-2134A5.4 4.36 1.73e-05 0.00425 0.34 0.23 Body mass index; chr14:103582234 chr14:103854366~103880111:- LIHC cis rs11098499 0.754 rs9999724 ENSG00000260091.1 RP11-33B1.4 -4.36 1.73e-05 0.00425 -0.16 -0.23 Corneal astigmatism; chr4:119318789 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs714899 ENSG00000260091.1 RP11-33B1.4 -4.36 1.73e-05 0.00425 -0.16 -0.23 Corneal astigmatism; chr4:119321880 chr4:119409333~119410233:+ LIHC cis rs2274273 0.87 rs3783652 ENSG00000258413.1 RP11-665C16.6 -4.36 1.73e-05 0.00425 -0.27 -0.23 Protein biomarker; chr14:55387490 chr14:55262767~55272075:- LIHC cis rs1318937 0.915 rs78365740 ENSG00000224660.1 SH3BP5-AS1 4.36 1.74e-05 0.00426 0.23 0.23 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15258339 chr3:15254184~15264493:+ LIHC cis rs2274273 0.624 rs10146637 ENSG00000258413.1 RP11-665C16.6 -4.36 1.74e-05 0.00426 -0.28 -0.23 Protein biomarker; chr14:55278092 chr14:55262767~55272075:- LIHC cis rs2274273 0.624 rs7155954 ENSG00000258413.1 RP11-665C16.6 -4.36 1.74e-05 0.00426 -0.28 -0.23 Protein biomarker; chr14:55284225 chr14:55262767~55272075:- LIHC cis rs6430585 0.528 rs2278682 ENSG00000231890.6 DARS-AS1 -4.36 1.74e-05 0.00426 -0.31 -0.23 Corneal structure; chr2:135985573 chr2:135985176~136022593:+ LIHC cis rs11671005 0.693 rs11669665 ENSG00000269473.1 CTD-2619J13.19 4.36 1.74e-05 0.00427 0.39 0.23 Mean platelet volume; chr19:58420518 chr19:58440448~58445849:+ LIHC cis rs11671005 0.693 rs11084542 ENSG00000269473.1 CTD-2619J13.19 4.36 1.74e-05 0.00427 0.39 0.23 Mean platelet volume; chr19:58420732 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs11084543 ENSG00000269473.1 CTD-2619J13.19 4.36 1.74e-05 0.00427 0.39 0.23 Mean platelet volume; chr19:58421334 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs11881000 ENSG00000269473.1 CTD-2619J13.19 4.36 1.74e-05 0.00427 0.39 0.23 Mean platelet volume; chr19:58421421 chr19:58440448~58445849:+ LIHC cis rs875971 0.545 rs10950029 ENSG00000228409.4 CCT6P1 -4.36 1.74e-05 0.00427 -0.19 -0.23 Aortic root size; chr7:66169334 chr7:65751142~65763354:+ LIHC cis rs11637445 0.627 rs4776988 ENSG00000260657.2 RP11-315D16.4 -4.36 1.74e-05 0.00427 -0.32 -0.23 Posterior cortical atrophy and Alzheimer's disease; chr15:67831813 chr15:68267792~68277994:- LIHC cis rs12468226 0.938 rs10166594 ENSG00000273456.1 RP11-686O6.2 4.36 1.74e-05 0.00427 0.31 0.23 Urate levels; chr2:202250262 chr2:202374932~202375604:- LIHC cis rs17270561 0.609 rs1165181 ENSG00000216436.2 HIST1H2APS1 -4.36 1.74e-05 0.00427 -0.28 -0.23 Iron status biomarkers; chr6:25825162 chr6:25732497~25732827:+ LIHC cis rs1420585 0.932 rs4785155 ENSG00000260769.1 RP11-491F9.5 4.36 1.74e-05 0.00428 0.29 0.23 Pursuit maintenance gain; chr16:48969867 chr16:49337167~49338993:+ LIHC cis rs1558001 0.84 rs2367739 ENSG00000230196.1 DDX43P3 4.36 1.75e-05 0.00428 0.24 0.23 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81829036 chr7:81610884~81611326:- LIHC cis rs55794721 0.509 rs873308 ENSG00000261349.1 RP3-465N24.5 4.36 1.75e-05 0.00429 0.22 0.23 Mean corpuscular volume;Plateletcrit; chr1:25432164 chr1:25266102~25267136:- LIHC cis rs6142102 0.961 rs8119937 ENSG00000275784.1 RP5-1125A11.6 -4.36 1.75e-05 0.00429 -0.26 -0.23 Skin pigmentation; chr20:34057745 chr20:33989480~33991818:- LIHC cis rs7208859 0.673 rs999796 ENSG00000264538.5 SUZ12P1 -4.36 1.75e-05 0.00429 -0.23 -0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832386 chr17:30709299~30790908:+ LIHC cis rs11722228 0.508 rs3796826 ENSG00000261490.1 RP11-448G15.3 4.36 1.75e-05 0.00429 0.3 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10091104 chr4:10068089~10073019:- LIHC cis rs11722228 0.508 rs3796825 ENSG00000261490.1 RP11-448G15.3 4.36 1.75e-05 0.00429 0.3 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10091255 chr4:10068089~10073019:- LIHC cis rs875971 0.545 rs316316 ENSG00000228409.4 CCT6P1 4.36 1.75e-05 0.0043 0.19 0.23 Aortic root size; chr7:66149270 chr7:65751142~65763354:+ LIHC cis rs8040855 0.627 rs11630697 ENSG00000259295.5 CSPG4P12 4.36 1.75e-05 0.0043 0.36 0.23 Bulimia nervosa; chr15:85063214 chr15:85191438~85213905:+ LIHC cis rs8040855 0.627 rs4980357 ENSG00000259295.5 CSPG4P12 4.36 1.75e-05 0.0043 0.36 0.23 Bulimia nervosa; chr15:85064878 chr15:85191438~85213905:+ LIHC cis rs8040855 0.627 rs4980356 ENSG00000259295.5 CSPG4P12 4.36 1.75e-05 0.0043 0.36 0.23 Bulimia nervosa; chr15:85064901 chr15:85191438~85213905:+ LIHC cis rs617219 0.819 rs1870058 ENSG00000251675.1 CTC-458I2.2 -4.36 1.75e-05 0.0043 -0.26 -0.23 Betaine levels in individuals undergoing cardiac evaluation; chr5:79297335 chr5:80128361~80143883:+ LIHC cis rs950169 0.58 rs2271431 ENSG00000225151.9 GOLGA2P7 -4.36 1.76e-05 0.0043 -0.29 -0.23 Schizophrenia; chr15:84646233 chr15:84199311~84230136:- LIHC cis rs12216125 0.801 rs56107510 ENSG00000216436.2 HIST1H2APS1 -4.36 1.76e-05 0.0043 -0.31 -0.23 Iron status biomarkers; chr6:25987208 chr6:25732497~25732827:+ LIHC cis rs5769707 0.967 rs17182154 ENSG00000235111.1 RP1-29C18.8 -4.36 1.76e-05 0.0043 -0.27 -0.23 Monocyte percentage of white cells;Monocyte count; chr22:49596822 chr22:49612657~49615716:- LIHC cis rs6480314 0.831 rs2166221 ENSG00000233590.1 RP11-153K11.3 4.36 1.76e-05 0.0043 0.33 0.23 Optic nerve measurement (disc area); chr10:68222541 chr10:68233251~68242379:- LIHC cis rs12220777 1 rs11201799 ENSG00000230091.5 TMEM254-AS1 -4.36 1.76e-05 0.0043 -0.29 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80122198 chr10:80046860~80078912:- LIHC cis rs10829156 0.66 rs10764587 ENSG00000240291.1 RP11-499P20.2 4.36 1.76e-05 0.00431 0.35 0.23 Sudden cardiac arrest; chr10:18548901 chr10:18513115~18545651:- LIHC cis rs763121 0.853 rs138716 ENSG00000273076.1 RP3-508I15.22 4.36 1.76e-05 0.00431 0.27 0.23 Menopause (age at onset); chr22:38750522 chr22:38743495~38743910:+ LIHC cis rs529413 0.57 rs500895 ENSG00000259237.1 RP11-209E8.1 4.36 1.76e-05 0.00431 0.32 0.23 Itch intensity from mosquito bite adjusted by bite size; chr15:53243478 chr15:53116365~53129698:+ LIHC cis rs6558530 0.692 rs6558522 ENSG00000253982.1 CTD-2336O2.1 -4.36 1.76e-05 0.00431 -0.31 -0.23 Systolic blood pressure; chr8:1754204 chr8:1761990~1764502:- LIHC cis rs2877649 0.793 rs118096303 ENSG00000258744.1 RP11-80A15.1 -4.36 1.76e-05 0.00431 -0.48 -0.23 Smooth-surface caries; chr14:24483328 chr14:24501594~24508688:+ LIHC cis rs11098499 0.754 rs17595608 ENSG00000260091.1 RP11-33B1.4 -4.35 1.76e-05 0.00431 -0.16 -0.23 Corneal astigmatism; chr4:119329351 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs1980027 ENSG00000260091.1 RP11-33B1.4 -4.35 1.76e-05 0.00431 -0.16 -0.23 Corneal astigmatism; chr4:119330422 chr4:119409333~119410233:+ LIHC cis rs6480314 0.831 rs6480317 ENSG00000233590.1 RP11-153K11.3 4.35 1.76e-05 0.00431 0.33 0.23 Optic nerve measurement (disc area); chr10:68216837 chr10:68233251~68242379:- LIHC cis rs4925386 1 rs2151512 ENSG00000226332.2 RP11-157P1.4 -4.35 1.76e-05 0.00431 -0.24 -0.23 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62338439 chr20:62305432~62306325:- LIHC cis rs2739330 0.828 rs5760099 ENSG00000206090.4 AP000350.7 4.35 1.76e-05 0.00431 0.27 0.23 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23939998~23942798:+ LIHC cis rs11098499 0.754 rs2036857 ENSG00000260091.1 RP11-33B1.4 -4.35 1.76e-05 0.00432 -0.16 -0.23 Corneal astigmatism; chr4:119328085 chr4:119409333~119410233:+ LIHC cis rs5758511 0.508 rs2413667 ENSG00000237037.8 NDUFA6-AS1 -4.35 1.77e-05 0.00433 -0.43 -0.23 Birth weight; chr22:42076233 chr22:42090931~42137742:+ LIHC cis rs4694744 0.576 rs4554145 ENSG00000264696.1 AC108078.1 4.35 1.77e-05 0.00434 0.34 0.23 Bacteremia; chr4:69485570 chr4:69479331~69479434:+ LIHC cis rs673078 0.66 rs17586342 ENSG00000275409.1 RP11-131L12.4 -4.35 1.77e-05 0.00434 -0.28 -0.23 Glucose homeostasis traits; chr12:118162399 chr12:118430147~118430699:+ LIHC cis rs11216126 0.524 rs61905084 ENSG00000254851.1 RP11-109L13.1 4.35 1.77e-05 0.00434 0.32 0.23 HDL cholesterol; chr11:116739578 chr11:117135528~117138582:+ LIHC cis rs11722228 0.508 rs3822246 ENSG00000261490.1 RP11-448G15.3 4.35 1.77e-05 0.00434 0.31 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10093074 chr4:10068089~10073019:- LIHC cis rs11722228 0.549 rs73212853 ENSG00000261490.1 RP11-448G15.3 4.35 1.77e-05 0.00434 0.31 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10094606 chr4:10068089~10073019:- LIHC cis rs1577917 1 rs12190604 ENSG00000234155.1 RP11-30P6.6 4.35 1.77e-05 0.00434 0.3 0.23 Response to antipsychotic treatment; chr6:86006497 chr6:85387219~85390186:- LIHC cis rs172166 0.516 rs1225715 ENSG00000204709.4 LINC01556 -4.35 1.77e-05 0.00434 -0.25 -0.23 Cardiac Troponin-T levels; chr6:28145595 chr6:28943877~28944537:+ LIHC cis rs73198271 0.74 rs1039912 ENSG00000253893.2 FAM85B 4.35 1.77e-05 0.00434 0.38 0.23 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8790719 chr8:8167819~8226614:- LIHC cis rs6085948 1 rs6085948 ENSG00000228888.1 LINC01428 4.35 1.77e-05 0.00434 0.31 0.23 Interleukin-10 levels; chr20:7252703 chr20:7146467~7254202:- LIHC cis rs875971 0.545 rs1796217 ENSG00000273142.1 RP11-458F8.4 -4.35 1.78e-05 0.00434 -0.22 -0.23 Aortic root size; chr7:66620931 chr7:66902857~66906297:+ LIHC cis rs651907 0.535 rs34743741 ENSG00000244119.1 PDCL3P4 4.35 1.78e-05 0.00434 0.24 0.23 Colorectal cancer; chr3:101813604 chr3:101712472~101713191:+ LIHC cis rs1062177 1 rs17804178 ENSG00000253921.1 CTB-113P19.3 -4.35 1.78e-05 0.00434 -0.27 -0.23 Preschool internalizing problems; chr5:151818168 chr5:151753992~151767247:+ LIHC cis rs7702057 0.53 rs17138841 ENSG00000271918.1 CTD-2287O16.5 4.35 1.78e-05 0.00435 0.31 0.23 Amyotrophic lateral sclerosis; chr5:116077109 chr5:116083807~116085416:- LIHC cis rs2072510 0.683 rs2246973 ENSG00000257878.1 RP11-256L6.3 -4.35 1.78e-05 0.00435 -0.2 -0.23 Metabolite levels (small molecules and protein measures); chr12:96034097 chr12:95996521~96011489:+ LIHC cis rs2072510 0.683 rs2246972 ENSG00000257878.1 RP11-256L6.3 -4.35 1.78e-05 0.00435 -0.2 -0.23 Metabolite levels (small molecules and protein measures); chr12:96034111 chr12:95996521~96011489:+ LIHC cis rs7709377 0.516 rs7726794 ENSG00000271918.1 CTD-2287O16.5 4.35 1.78e-05 0.00435 0.28 0.23 Metabolite levels (X-11787); chr5:116130293 chr5:116083807~116085416:- LIHC cis rs9896933 0.778 rs80243549 ENSG00000263063.1 RP11-388C12.1 -4.35 1.78e-05 0.00436 -0.33 -0.23 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82863609 chr17:82713908~82716255:- LIHC cis rs228614 0.51 rs223397 ENSG00000246560.2 RP11-10L12.4 4.35 1.78e-05 0.00436 0.25 0.23 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102821494 chr4:102828055~102844075:+ LIHC cis rs17826219 0.636 rs7221463 ENSG00000266490.1 CTD-2349P21.9 4.35 1.78e-05 0.00436 0.29 0.23 Body mass index; chr17:30753533 chr17:30792372~30792833:+ LIHC cis rs875971 0.502 rs6460311 ENSG00000273024.4 INTS4P2 4.35 1.78e-05 0.00436 0.26 0.23 Aortic root size; chr7:66646886 chr7:65647864~65715661:+ LIHC cis rs1400745 0.756 rs3783316 ENSG00000258738.1 RP11-73E17.2 4.35 1.78e-05 0.00436 0.28 0.23 Monocyte count; chr14:34867986 chr14:34874343~34876459:+ LIHC cis rs6430585 0.528 rs3098102 ENSG00000231890.6 DARS-AS1 -4.35 1.79e-05 0.00436 -0.31 -0.23 Corneal structure; chr2:135897263 chr2:135985176~136022593:+ LIHC cis rs11671005 0.735 rs12986387 ENSG00000269473.1 CTD-2619J13.19 4.35 1.79e-05 0.00437 0.38 0.23 Mean platelet volume; chr19:58415848 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs11667723 ENSG00000269473.1 CTD-2619J13.19 4.35 1.79e-05 0.00437 0.38 0.23 Mean platelet volume; chr19:58416122 chr19:58440448~58445849:+ LIHC cis rs11671005 0.693 rs11668757 ENSG00000269473.1 CTD-2619J13.19 4.35 1.79e-05 0.00437 0.38 0.23 Mean platelet volume; chr19:58416932 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs11668789 ENSG00000269473.1 CTD-2619J13.19 4.35 1.79e-05 0.00437 0.38 0.23 Mean platelet volume; chr19:58416942 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs35652377 ENSG00000269473.1 CTD-2619J13.19 4.35 1.79e-05 0.00437 0.38 0.23 Mean platelet volume; chr19:58417833 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs3764532 ENSG00000269473.1 CTD-2619J13.19 4.35 1.79e-05 0.00437 0.38 0.23 Mean platelet volume; chr19:58417855 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs3088284 ENSG00000269473.1 CTD-2619J13.19 4.35 1.79e-05 0.00437 0.38 0.23 Mean platelet volume; chr19:58418060 chr19:58440448~58445849:+ LIHC cis rs11671005 0.735 rs12981649 ENSG00000269473.1 CTD-2619J13.19 4.35 1.79e-05 0.00437 0.38 0.23 Mean platelet volume; chr19:58418676 chr19:58440448~58445849:+ LIHC cis rs7923609 1 rs1935 ENSG00000232075.1 MRPL35P2 -4.35 1.79e-05 0.00437 -0.25 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63168063 chr10:63634317~63634827:- LIHC cis rs2976388 0.609 rs2572899 ENSG00000253741.1 CTD-2292P10.4 -4.35 1.79e-05 0.00437 -0.26 -0.23 Urinary tract infection frequency; chr8:142704131 chr8:142702252~142726973:- LIHC cis rs12478296 1 rs6739247 ENSG00000261186.2 RP11-341N2.1 -4.35 1.79e-05 0.00437 -0.33 -0.23 Obesity-related traits; chr2:242097038 chr2:242087351~242088457:- LIHC cis rs6893782 0.887 rs274552 ENSG00000233006.5 AC034220.3 4.35 1.79e-05 0.00437 0.32 0.23 Acylcarnitine levels; chr5:132391654 chr5:132311285~132369916:- LIHC cis rs950169 0.58 rs11636189 ENSG00000225151.9 GOLGA2P7 -4.35 1.79e-05 0.00437 -0.29 -0.23 Schizophrenia; chr15:84650323 chr15:84199311~84230136:- LIHC cis rs1061377 1 rs7685468 ENSG00000249685.1 RP11-360F5.3 4.35 1.79e-05 0.00437 0.27 0.23 Uric acid levels; chr4:39116649 chr4:39133913~39135608:+ LIHC cis rs17818399 0.781 rs13024534 ENSG00000279254.1 RP11-536C12.1 -4.35 1.79e-05 0.00437 -0.28 -0.23 Height; chr2:46632247 chr2:46668870~46670778:+ LIHC cis rs17818399 0.675 rs35949012 ENSG00000279254.1 RP11-536C12.1 -4.35 1.79e-05 0.00437 -0.28 -0.23 Height; chr2:46633262 chr2:46668870~46670778:+ LIHC cis rs17818399 0.815 rs17768018 ENSG00000279254.1 RP11-536C12.1 -4.35 1.79e-05 0.00437 -0.28 -0.23 Height; chr2:46634872 chr2:46668870~46670778:+ LIHC cis rs7412746 0.658 rs6660845 ENSG00000231073.1 RP11-316M1.3 4.35 1.79e-05 0.00437 0.24 0.23 Melanoma; chr1:150868590 chr1:150973123~150975534:+ LIHC cis rs7712401 0.765 rs4349713 ENSG00000263432.2 RN7SL689P 4.35 1.79e-05 0.00438 0.3 0.23 Mean platelet volume; chr5:123055931 chr5:123022487~123022783:- LIHC cis rs10266483 0.654 rs6962076 ENSG00000164669.11 INTS4P1 4.35 1.79e-05 0.00438 0.36 0.23 Response to statin therapy; chr7:64559214 chr7:65141225~65234216:+ LIHC cis rs2448490 0.642 rs507859 ENSG00000265874.1 MIR4489 4.35 1.79e-05 0.00438 0.29 0.23 Platelet count; chr11:65704511 chr11:65649192~65649253:+ LIHC cis rs4578769 0.765 rs11082173 ENSG00000266850.1 RP11-370A5.1 -4.35 1.79e-05 0.00438 -0.28 -0.23 Eosinophil percentage of white cells; chr18:22858048 chr18:22723491~22907721:- LIHC cis rs4713118 0.513 rs149972 ENSG00000219392.1 RP1-265C24.5 -4.35 1.79e-05 0.00438 -0.31 -0.23 Parkinson's disease; chr6:28015449 chr6:28115628~28116551:+ LIHC cis rs4713118 0.513 rs149975 ENSG00000219392.1 RP1-265C24.5 -4.35 1.79e-05 0.00438 -0.31 -0.23 Parkinson's disease; chr6:28018562 chr6:28115628~28116551:+ LIHC cis rs2273788 0.793 rs34492085 ENSG00000204173.9 LRRC37A5P 4.35 1.79e-05 0.00438 0.38 0.23 Monocyte count; chr9:111584381 chr9:111602831~111631289:- LIHC cis rs1400745 0.756 rs3783314 ENSG00000258738.1 RP11-73E17.2 4.35 1.79e-05 0.00438 0.28 0.23 Monocyte count; chr14:34868178 chr14:34874343~34876459:+ LIHC cis rs5756813 0.661 rs11703407 ENSG00000233360.4 Z83844.1 4.35 1.8e-05 0.00439 0.29 0.23 Optic cup area;Vertical cup-disc ratio; chr22:37804117 chr22:37641832~37658377:- LIHC cis rs8040855 0.627 rs11634975 ENSG00000259295.5 CSPG4P12 4.35 1.8e-05 0.00439 0.36 0.23 Bulimia nervosa; chr15:85063247 chr15:85191438~85213905:+ LIHC cis rs7809950 1 rs2712189 ENSG00000238832.1 snoU109 -4.35 1.8e-05 0.00439 -0.28 -0.23 Coronary artery disease; chr7:107555302 chr7:107603363~107603507:+ LIHC cis rs11722228 0.549 rs41268389 ENSG00000261490.1 RP11-448G15.3 4.35 1.8e-05 0.00439 0.3 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10097653 chr4:10068089~10073019:- LIHC cis rs11722228 0.521 rs62288520 ENSG00000261490.1 RP11-448G15.3 4.35 1.8e-05 0.00439 0.3 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10098050 chr4:10068089~10073019:- LIHC cis rs11722228 0.549 rs62288521 ENSG00000261490.1 RP11-448G15.3 4.35 1.8e-05 0.00439 0.3 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10098148 chr4:10068089~10073019:- LIHC cis rs11098499 0.779 rs10011097 ENSG00000260091.1 RP11-33B1.4 -4.35 1.8e-05 0.00439 -0.17 -0.23 Corneal astigmatism; chr4:119389204 chr4:119409333~119410233:+ LIHC cis rs5756813 0.635 rs12160750 ENSG00000233360.4 Z83844.1 4.35 1.8e-05 0.00439 0.29 0.23 Optic cup area;Vertical cup-disc ratio; chr22:37803047 chr22:37641832~37658377:- LIHC cis rs9322193 0.607 rs6557165 ENSG00000223701.3 RAET1E-AS1 -4.35 1.8e-05 0.0044 -0.27 -0.23 Lung cancer; chr6:149906883 chr6:149884431~149919508:+ LIHC cis rs9834975 0.935 rs6798997 ENSG00000272758.4 RP11-299J3.8 -4.35 1.8e-05 0.0044 -0.26 -0.23 Diastolic blood pressure; chr3:122355857 chr3:122416207~122443180:+ LIHC cis rs9304742 0.962 rs1808106 ENSG00000213801.4 ZNF816-ZNF321P 4.35 1.8e-05 0.0044 0.23 0.23 Psoriasis; chr19:52949691 chr19:52927135~52942601:- LIHC cis rs9907295 0.818 rs4796112 ENSG00000270871.1 AC015849.19 -4.35 1.8e-05 0.0044 -0.24 -0.23 Fibroblast growth factor basic levels; chr17:35831722 chr17:35816717~35830293:- LIHC cis rs1003645 1 rs8075916 ENSG00000278690.1 RP11-104J23.2 4.35 1.8e-05 0.0044 0.27 0.23 Blood protein levels; chr17:36016808 chr17:36012504~36012891:+ LIHC cis rs6997458 0.869 rs11261474 ENSG00000253549.4 RP11-317J10.2 4.35 1.8e-05 0.0044 0.25 0.23 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85382421 chr8:85441851~85464915:- LIHC cis rs9450351 0.744 rs9450299 ENSG00000203875.9 SNHG5 -4.35 1.81e-05 0.00441 -0.55 -0.23 Interferon gamma-induced protein 10 levels; chr6:85562103 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs6930543 ENSG00000203875.9 SNHG5 -4.35 1.81e-05 0.00441 -0.55 -0.23 Interferon gamma-induced protein 10 levels; chr6:85562658 chr6:85660950~85678736:- LIHC cis rs6442522 0.78 rs13068150 ENSG00000249786.6 EAF1-AS1 4.35 1.81e-05 0.00441 0.27 0.23 Uric acid levels; chr3:15397434 chr3:15436171~15455940:- LIHC cis rs6442522 0.78 rs13095978 ENSG00000249786.6 EAF1-AS1 4.35 1.81e-05 0.00441 0.27 0.23 Uric acid levels; chr3:15399603 chr3:15436171~15455940:- LIHC cis rs728616 0.867 rs41302709 ENSG00000225484.5 NUTM2B-AS1 -4.35 1.81e-05 0.00441 -0.5 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80047522 chr10:79663088~79826594:- LIHC cis rs2276314 0.947 rs4799831 ENSG00000278986.1 RP11-723J4.3 -4.35 1.81e-05 0.00441 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:35974812 chr18:35972151~35973916:+ LIHC cis rs7811142 0.83 rs75636500 ENSG00000242294.5 STAG3L5P 4.35 1.81e-05 0.00441 0.26 0.23 Platelet count; chr7:100350034 chr7:100336079~100351900:+ LIHC cis rs597539 0.69 rs647661 ENSG00000250508.1 RP11-757G1.6 -4.35 1.81e-05 0.00441 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68858407 chr11:68870664~68874542:+ LIHC cis rs3096299 0.781 rs2965819 ENSG00000261118.1 RP11-104N10.1 -4.35 1.81e-05 0.00441 -0.23 -0.23 Multiple myeloma (IgH translocation); chr16:89434622 chr16:89492017~89504460:- LIHC cis rs10129255 1 rs8010605 ENSG00000223648.3 IGHV3-64 4.35 1.81e-05 0.00441 0.17 0.23 Kawasaki disease; chr14:106678742 chr14:106643132~106658258:- LIHC cis rs597539 0.69 rs552517 ENSG00000250508.1 RP11-757G1.6 -4.35 1.81e-05 0.00441 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68857818 chr11:68870664~68874542:+ LIHC cis rs597539 0.69 rs578791 ENSG00000250508.1 RP11-757G1.6 -4.35 1.81e-05 0.00441 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68858341 chr11:68870664~68874542:+ LIHC cis rs11098499 0.644 rs2389880 ENSG00000260091.1 RP11-33B1.4 -4.35 1.81e-05 0.00441 -0.16 -0.23 Corneal astigmatism; chr4:119638715 chr4:119409333~119410233:+ LIHC cis rs11671005 0.735 rs11670871 ENSG00000269473.1 CTD-2619J13.19 -4.35 1.81e-05 0.00442 -0.38 -0.23 Mean platelet volume; chr19:58429147 chr19:58440448~58445849:+ LIHC cis rs6085948 1 rs4815987 ENSG00000228888.1 LINC01428 4.35 1.81e-05 0.00442 0.31 0.23 Interleukin-10 levels; chr20:7259968 chr20:7146467~7254202:- LIHC cis rs6085948 0.953 rs6117725 ENSG00000228888.1 LINC01428 4.35 1.81e-05 0.00442 0.31 0.23 Interleukin-10 levels; chr20:7262362 chr20:7146467~7254202:- LIHC cis rs597539 0.731 rs664229 ENSG00000250508.1 RP11-757G1.6 -4.35 1.81e-05 0.00442 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68857015 chr11:68870664~68874542:+ LIHC cis rs651907 0.535 rs36060163 ENSG00000244119.1 PDCL3P4 4.35 1.81e-05 0.00442 0.24 0.23 Colorectal cancer; chr3:101642119 chr3:101712472~101713191:+ LIHC cis rs9573567 0.609 rs79938109 ENSG00000261553.4 RP11-29G8.3 -4.35 1.81e-05 0.00442 -0.4 -0.23 Red blood cell count;Mean corpuscular volume; chr13:75467476 chr13:75549773~75807120:+ LIHC cis rs812925 0.855 rs777592 ENSG00000212978.6 AC016747.3 -4.35 1.81e-05 0.00442 -0.26 -0.23 Immature fraction of reticulocytes; chr2:61191208 chr2:61141592~61144969:- LIHC cis rs7508 0.511 rs208025 ENSG00000253671.1 RP11-806O11.1 -4.35 1.81e-05 0.00442 -0.29 -0.23 Atrial fibrillation; chr8:18020661 chr8:17808941~17820868:+ LIHC cis rs2243480 1 rs160643 ENSG00000230295.1 RP11-458F8.2 -4.35 1.81e-05 0.00442 -0.23 -0.23 Diabetic kidney disease; chr7:66093235 chr7:66880708~66882981:+ LIHC cis rs755249 0.567 rs72661961 ENSG00000182109.6 RP11-69E11.4 4.35 1.81e-05 0.00442 0.3 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39366096 chr1:39522280~39546187:- LIHC cis rs755249 0.532 rs61779277 ENSG00000182109.6 RP11-69E11.4 4.35 1.81e-05 0.00442 0.3 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39367863 chr1:39522280~39546187:- LIHC cis rs755249 0.532 rs61779278 ENSG00000182109.6 RP11-69E11.4 4.35 1.81e-05 0.00442 0.3 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39368945 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs2296172 ENSG00000182109.6 RP11-69E11.4 4.35 1.81e-05 0.00442 0.3 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39370145 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs61779279 ENSG00000182109.6 RP11-69E11.4 4.35 1.81e-05 0.00442 0.3 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39371430 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs76111861 ENSG00000182109.6 RP11-69E11.4 4.35 1.81e-05 0.00442 0.3 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39377018 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs72661965 ENSG00000182109.6 RP11-69E11.4 4.35 1.81e-05 0.00442 0.3 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39380918 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs6668369 ENSG00000182109.6 RP11-69E11.4 4.35 1.81e-05 0.00442 0.3 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39382675 chr1:39522280~39546187:- LIHC cis rs1577917 1 rs12215037 ENSG00000234155.1 RP11-30P6.6 4.35 1.82e-05 0.00443 0.3 0.23 Response to antipsychotic treatment; chr6:86017913 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs1337850 ENSG00000234155.1 RP11-30P6.6 4.35 1.82e-05 0.00443 0.3 0.23 Response to antipsychotic treatment; chr6:86019385 chr6:85387219~85390186:- LIHC cis rs11098499 0.615 rs28850368 ENSG00000260091.1 RP11-33B1.4 -4.35 1.82e-05 0.00443 -0.16 -0.23 Corneal astigmatism; chr4:119633158 chr4:119409333~119410233:+ LIHC cis rs11098499 0.644 rs28787668 ENSG00000260091.1 RP11-33B1.4 -4.35 1.82e-05 0.00443 -0.16 -0.23 Corneal astigmatism; chr4:119633532 chr4:119409333~119410233:+ LIHC cis rs5758659 0.679 rs134870 ENSG00000227370.1 RP4-669P10.19 -4.35 1.82e-05 0.00443 -0.25 -0.23 Cognitive function; chr22:42256311 chr22:42132543~42132998:+ LIHC cis rs7824557 0.583 rs2736306 ENSG00000255394.4 C8orf49 4.35 1.82e-05 0.00443 0.31 0.23 Retinal vascular caliber; chr8:11382253 chr8:11761256~11763223:+ LIHC cis rs3096299 0.781 rs2170839 ENSG00000261118.1 RP11-104N10.1 4.35 1.82e-05 0.00443 0.23 0.23 Multiple myeloma (IgH translocation); chr16:89343044 chr16:89492017~89504460:- LIHC cis rs11098499 0.754 rs2036860 ENSG00000260091.1 RP11-33B1.4 -4.35 1.82e-05 0.00443 -0.16 -0.23 Corneal astigmatism; chr4:119327779 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs2036856 ENSG00000260091.1 RP11-33B1.4 -4.35 1.82e-05 0.00443 -0.16 -0.23 Corneal astigmatism; chr4:119328133 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs4443261 ENSG00000260091.1 RP11-33B1.4 -4.35 1.82e-05 0.00443 -0.16 -0.23 Corneal astigmatism; chr4:119328146 chr4:119409333~119410233:+ LIHC cis rs748404 0.578 rs2278856 ENSG00000205771.5 CATSPER2P1 -4.35 1.82e-05 0.00443 -0.27 -0.23 Lung cancer; chr15:43339158 chr15:43726918~43747094:- LIHC cis rs4713118 0.539 rs200951 ENSG00000216901.1 AL022393.7 4.35 1.82e-05 0.00444 0.29 0.23 Parkinson's disease; chr6:27868152 chr6:28176188~28176674:+ LIHC cis rs1003645 1 rs9908216 ENSG00000278690.1 RP11-104J23.2 4.35 1.82e-05 0.00444 0.27 0.23 Blood protein levels; chr17:36018981 chr17:36012504~36012891:+ LIHC cis rs12304921 0.683 rs73103154 ENSG00000277201.1 AC087884.1 4.35 1.82e-05 0.00445 0.27 0.23 Type 2 diabetes; chr12:51074729 chr12:51049921~51050025:+ LIHC cis rs2877649 1 rs78804957 ENSG00000258744.1 RP11-80A15.1 -4.35 1.82e-05 0.00445 -0.45 -0.23 Smooth-surface caries; chr14:24479999 chr14:24501594~24508688:+ LIHC cis rs2877649 1 rs1951137 ENSG00000258744.1 RP11-80A15.1 -4.35 1.82e-05 0.00445 -0.45 -0.23 Smooth-surface caries; chr14:24481497 chr14:24501594~24508688:+ LIHC cis rs875971 0.619 rs2302918 ENSG00000273024.4 INTS4P2 -4.35 1.82e-05 0.00445 -0.25 -0.23 Aortic root size; chr7:66535945 chr7:65647864~65715661:+ LIHC cis rs7915414 0.951 rs2094296 ENSG00000230338.1 MTND4P19 4.35 1.82e-05 0.00445 0.24 0.23 Clopidogrel active metabolite levels; chr10:94663648 chr10:94774156~94774633:- LIHC cis rs1577917 1 rs12205336 ENSG00000234155.1 RP11-30P6.6 4.35 1.83e-05 0.00445 0.3 0.23 Response to antipsychotic treatment; chr6:86012649 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs12209127 ENSG00000234155.1 RP11-30P6.6 4.35 1.83e-05 0.00445 0.3 0.23 Response to antipsychotic treatment; chr6:86014709 chr6:85387219~85390186:- LIHC cis rs6439153 0.933 rs34193129 ENSG00000231305.3 RP11-723O4.2 4.35 1.83e-05 0.00445 0.25 0.23 Pneumococcal bacteremia; chr3:128972564 chr3:128861313~128871540:- LIHC cis rs7809950 0.954 rs62482543 ENSG00000238832.1 snoU109 -4.35 1.83e-05 0.00445 -0.28 -0.23 Coronary artery disease; chr7:107440211 chr7:107603363~107603507:+ LIHC cis rs7809950 1 rs1544336 ENSG00000238832.1 snoU109 -4.35 1.83e-05 0.00445 -0.28 -0.23 Coronary artery disease; chr7:107441970 chr7:107603363~107603507:+ LIHC cis rs853679 0.76 rs9468317 ENSG00000219392.1 RP1-265C24.5 -4.35 1.83e-05 0.00445 -0.35 -0.23 Depression; chr6:28230678 chr6:28115628~28116551:+ LIHC cis rs7811142 1 rs74460138 ENSG00000242294.5 STAG3L5P 4.35 1.83e-05 0.00445 0.28 0.23 Platelet count; chr7:100429716 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs4989959 ENSG00000242294.5 STAG3L5P 4.35 1.83e-05 0.00445 0.28 0.23 Platelet count; chr7:100434665 chr7:100336079~100351900:+ LIHC cis rs2280018 0.526 rs2941257 ENSG00000188599.16 NPIPP1 -4.35 1.83e-05 0.00446 -0.21 -0.23 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15072588 chr16:15104312~15123498:- LIHC cis rs4988958 0.525 rs3771159 ENSG00000234389.1 AC007278.3 4.35 1.83e-05 0.00446 0.25 0.23 Asthma (childhood onset); chr2:102388498 chr2:102438713~102440475:+ LIHC cis rs9807989 0.501 rs11903946 ENSG00000234389.1 AC007278.3 4.35 1.83e-05 0.00446 0.25 0.23 Asthma; chr2:102388870 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs6706002 ENSG00000234389.1 AC007278.3 4.35 1.83e-05 0.00446 0.25 0.23 Asthma; chr2:102389644 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs6749014 ENSG00000234389.1 AC007278.3 4.35 1.83e-05 0.00446 0.25 0.23 Asthma; chr2:102389988 chr2:102438713~102440475:+ LIHC cis rs4988958 0.565 rs12712146 ENSG00000234389.1 AC007278.3 4.35 1.83e-05 0.00446 0.25 0.23 Asthma (childhood onset); chr2:102392254 chr2:102438713~102440475:+ LIHC cis rs11971779 0.838 rs11764161 ENSG00000273391.1 RP11-634H22.1 4.35 1.83e-05 0.00447 0.21 0.23 Diisocyanate-induced asthma; chr7:139430452 chr7:139359032~139359566:- LIHC cis rs950881 0.866 rs72823628 ENSG00000234389.1 AC007278.3 4.35 1.83e-05 0.00447 0.3 0.23 Allergy; chr2:102312157 chr2:102438713~102440475:+ LIHC cis rs7615952 0.599 rs60847438 ENSG00000171084.14 FAM86JP 4.35 1.83e-05 0.00447 0.37 0.23 Blood pressure (smoking interaction); chr3:126027162 chr3:125916620~125930024:+ LIHC cis rs7809950 0.906 rs2253269 ENSG00000238832.1 snoU109 -4.35 1.83e-05 0.00447 -0.28 -0.23 Coronary artery disease; chr7:107560669 chr7:107603363~107603507:+ LIHC cis rs8005677 0.798 rs4982711 ENSG00000279656.1 RP11-298I3.6 4.35 1.84e-05 0.00447 0.26 0.23 Cognitive ability (multi-trait analysis); chr14:22929781 chr14:23023083~23024217:- LIHC cis rs28475163 1 rs28475163 ENSG00000251661.3 RP11-326C3.11 -4.35 1.84e-05 0.00447 -0.32 -0.23 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes; chr11:327143 chr11:318640~325631:+ LIHC cis rs7712401 0.502 rs30066 ENSG00000263432.2 RN7SL689P 4.34 1.84e-05 0.00448 0.36 0.23 Mean platelet volume; chr5:122958007 chr5:123022487~123022783:- LIHC cis rs11098499 0.955 rs7685268 ENSG00000260091.1 RP11-33B1.4 -4.34 1.84e-05 0.00448 -0.17 -0.23 Corneal astigmatism; chr4:119241033 chr4:119409333~119410233:+ LIHC cis rs12478296 0.681 rs6598999 ENSG00000261186.2 RP11-341N2.1 -4.34 1.84e-05 0.00448 -0.3 -0.23 Obesity-related traits; chr2:242052254 chr2:242087351~242088457:- LIHC cis rs11096990 0.634 rs7666632 ENSG00000249207.1 RP11-360F5.1 -4.34 1.84e-05 0.00448 -0.24 -0.23 Cognitive function; chr4:39238568 chr4:39112677~39126818:- LIHC cis rs2932538 0.961 rs6537747 ENSG00000225075.1 RP11-426L16.3 -4.34 1.84e-05 0.00448 -0.28 -0.23 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112636975 chr1:112693688~112696621:- LIHC cis rs3733585 0.654 rs4447863 ENSG00000250413.1 RP11-448G15.1 4.34 1.84e-05 0.00448 0.3 0.23 Cleft plate (environmental tobacco smoke interaction); chr4:9937345 chr4:10006482~10009725:+ LIHC cis rs6142102 0.923 rs6059586 ENSG00000275784.1 RP5-1125A11.6 -4.34 1.84e-05 0.00448 -0.26 -0.23 Skin pigmentation; chr20:33952695 chr20:33989480~33991818:- LIHC cis rs9807989 0.507 rs6745614 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102374753 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs6758936 ENSG00000234389.1 AC007278.3 -4.34 1.84e-05 0.00448 -0.25 -0.23 Asthma; chr2:102374909 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs10208196 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102379885 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs7584093 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102381261 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs3213732 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102381819 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs10204757 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102382514 chr2:102438713~102440475:+ LIHC cis rs9807989 0.524 rs7591246 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102382943 chr2:102438713~102440475:+ LIHC cis rs4988958 0.565 rs6760621 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma (childhood onset); chr2:102383492 chr2:102438713~102440475:+ LIHC cis rs4988958 0.527 rs11465641 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma (childhood onset); chr2:102384408 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs6710528 ENSG00000234389.1 AC007278.3 -4.34 1.84e-05 0.00448 -0.25 -0.23 Asthma; chr2:102399682 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs1420096 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102394452 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs1420094 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102399227 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs4851571 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102402540 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs4851572 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102402571 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs1035129 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102403325 chr2:102438713~102440475:+ LIHC cis rs9807989 0.524 rs2110662 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102403679 chr2:102438713~102440475:+ LIHC cis rs9807989 0.524 rs7594402 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102404807 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs6710034 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma; chr2:102407218 chr2:102438713~102440475:+ LIHC cis rs4988958 0.584 rs7589142 ENSG00000234389.1 AC007278.3 4.34 1.84e-05 0.00448 0.25 0.23 Asthma (childhood onset); chr2:102408200 chr2:102438713~102440475:+ LIHC cis rs2015599 0.623 rs2288128 ENSG00000275476.1 RP11-996F15.4 4.34 1.84e-05 0.00448 0.29 0.23 Platelet count;Mean platelet volume; chr12:29316054 chr12:29277397~29277882:- LIHC cis rs2015599 0.584 rs2288129 ENSG00000275476.1 RP11-996F15.4 4.34 1.84e-05 0.00448 0.29 0.23 Platelet count;Mean platelet volume; chr12:29316355 chr12:29277397~29277882:- LIHC cis rs6445975 0.617 rs60962024 ENSG00000272360.1 RP11-359I18.5 4.34 1.84e-05 0.00449 0.3 0.23 Systemic lupus erythematosus; chr3:58404485 chr3:58490830~58491291:- LIHC cis rs921968 0.565 rs6436073 ENSG00000272555.1 RP11-459I19.1 -4.34 1.85e-05 0.00449 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218753514 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs12612395 ENSG00000272555.1 RP11-459I19.1 -4.34 1.85e-05 0.00449 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218756919 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs13408427 ENSG00000272555.1 RP11-459I19.1 -4.34 1.85e-05 0.00449 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218763666 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs35189512 ENSG00000272555.1 RP11-459I19.1 -4.34 1.85e-05 0.00449 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218764036 chr2:218818690~218819144:+ LIHC cis rs709400 0.827 rs2274269 ENSG00000258534.1 CTD-2134A5.4 4.34 1.85e-05 0.00449 0.35 0.23 Body mass index; chr14:103562909 chr14:103854366~103880111:- LIHC cis rs2735413 0.958 rs2735401 ENSG00000276007.1 RP11-358L22.3 4.34 1.85e-05 0.00449 0.26 0.23 Systolic blood pressure (alcohol consumption interaction); chr16:78023206 chr16:78123243~78124332:+ LIHC cis rs1865760 0.566 rs9366634 ENSG00000216436.2 HIST1H2APS1 -4.34 1.85e-05 0.0045 -0.26 -0.23 Height; chr6:26072168 chr6:25732497~25732827:+ LIHC cis rs6442522 0.809 rs6805196 ENSG00000249786.6 EAF1-AS1 4.34 1.85e-05 0.0045 0.27 0.23 Uric acid levels; chr3:15410471 chr3:15436171~15455940:- LIHC cis rs10829156 0.66 rs4338439 ENSG00000240291.1 RP11-499P20.2 4.34 1.85e-05 0.0045 0.37 0.23 Sudden cardiac arrest; chr10:18594220 chr10:18513115~18545651:- LIHC cis rs11098499 0.754 rs66900435 ENSG00000260091.1 RP11-33B1.4 -4.34 1.85e-05 0.0045 -0.16 -0.23 Corneal astigmatism; chr4:119328270 chr4:119409333~119410233:+ LIHC cis rs524281 1 rs565198 ENSG00000255320.1 RP11-755F10.1 -4.34 1.85e-05 0.0045 -0.27 -0.23 Electroencephalogram traits; chr11:66146037 chr11:66244840~66246239:- LIHC cis rs1075232 1 rs67634762 ENSG00000270055.1 CTD-3092A11.2 -4.34 1.86e-05 0.00451 -0.44 -0.23 Survival in colorectal cancer (non-distant metastatic); chr15:31455852 chr15:30487963~30490313:+ LIHC cis rs709400 0.93 rs57447494 ENSG00000258534.1 CTD-2134A5.4 4.34 1.86e-05 0.00451 0.35 0.23 Body mass index; chr14:103568232 chr14:103854366~103880111:- LIHC cis rs2976388 0.609 rs2585152 ENSG00000253741.1 CTD-2292P10.4 -4.34 1.86e-05 0.00451 -0.26 -0.23 Urinary tract infection frequency; chr8:142704796 chr8:142702252~142726973:- LIHC cis rs3733589 0.744 rs2240723 ENSG00000250413.1 RP11-448G15.1 4.34 1.86e-05 0.00452 0.36 0.23 Renal overload gout; chr4:10019527 chr4:10006482~10009725:+ LIHC cis rs9457247 1 rs404222 ENSG00000227598.1 RP1-167A14.2 -4.34 1.86e-05 0.00452 -0.24 -0.23 Crohn's disease; chr6:166988662 chr6:166969626~166999065:- LIHC cis rs2060793 0.519 rs10766187 ENSG00000251991.1 RNU7-49P 4.34 1.86e-05 0.00452 0.25 0.23 Vitamin D levels; chr11:14603836 chr11:14478892~14478953:+ LIHC cis rs2348418 0.864 rs7960369 ENSG00000247934.4 RP11-967K21.1 4.34 1.86e-05 0.00452 0.21 0.23 Lung function (FEV1);Lung function (FVC); chr12:28561569 chr12:28163298~28190738:- LIHC cis rs921968 0.565 rs1078803 ENSG00000272555.1 RP11-459I19.1 4.34 1.86e-05 0.00452 0.24 0.23 Mean corpuscular hemoglobin concentration; chr2:218741815 chr2:218818690~218819144:+ LIHC cis rs11233413 0.874 rs4943870 ENSG00000246067.6 RAB30-AS1 4.34 1.86e-05 0.00452 0.31 0.23 Economic and political preferences (feminism/equality); chr11:83042198 chr11:83072066~83106719:+ LIHC cis rs921968 0.565 rs1541777 ENSG00000272555.1 RP11-459I19.1 -4.34 1.86e-05 0.00453 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218722568 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs4672897 ENSG00000272555.1 RP11-459I19.1 -4.34 1.86e-05 0.00453 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218723411 chr2:218818690~218819144:+ LIHC cis rs921968 0.591 rs6717107 ENSG00000272555.1 RP11-459I19.1 -4.34 1.86e-05 0.00453 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218723974 chr2:218818690~218819144:+ LIHC cis rs921968 0.528 rs35695178 ENSG00000272555.1 RP11-459I19.1 -4.34 1.86e-05 0.00453 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218724441 chr2:218818690~218819144:+ LIHC cis rs921968 0.528 rs13022583 ENSG00000272555.1 RP11-459I19.1 -4.34 1.86e-05 0.00453 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218724452 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs35594672 ENSG00000272555.1 RP11-459I19.1 -4.34 1.86e-05 0.00453 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218724557 chr2:218818690~218819144:+ LIHC cis rs921968 0.565 rs12694439 ENSG00000272555.1 RP11-459I19.1 -4.34 1.86e-05 0.00453 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218726148 chr2:218818690~218819144:+ LIHC cis rs901683 0.85 rs12098366 ENSG00000230869.1 CTGLF10P -4.34 1.86e-05 0.00453 -0.58 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45596168 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs80174235 ENSG00000230869.1 CTGLF10P -4.34 1.86e-05 0.00453 -0.58 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45596370 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs75402959 ENSG00000230869.1 CTGLF10P -4.34 1.86e-05 0.00453 -0.58 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45597359 chr10:45678692~45700532:+ LIHC cis rs193541 0.632 rs119449 ENSG00000263432.2 RN7SL689P 4.34 1.86e-05 0.00453 0.36 0.23 Glucose homeostasis traits; chr5:122948046 chr5:123022487~123022783:- LIHC cis rs12549025 0.782 rs11781222 ENSG00000253390.1 CTC-756D1.2 -4.34 1.86e-05 0.00453 -0.27 -0.23 Reticulocyte fraction of red cells; chr8:23532058 chr8:23458601~23484971:+ LIHC cis rs2842992 0.789 rs4709370 ENSG00000237927.1 RP3-393E18.2 -4.34 1.86e-05 0.00453 -0.28 -0.23 Age-related macular degeneration (geographic atrophy); chr6:159789029 chr6:159586955~159589169:- LIHC cis rs6480314 0.711 rs61857176 ENSG00000233590.1 RP11-153K11.3 -4.34 1.87e-05 0.00453 -0.38 -0.23 Optic nerve measurement (disc area); chr10:68186207 chr10:68233251~68242379:- LIHC cis rs2739330 0.828 rs5760102 ENSG00000206090.4 AP000350.7 4.34 1.87e-05 0.00453 0.27 0.23 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23939998~23942798:+ LIHC cis rs1729407 0.814 rs2542051 ENSG00000236267.1 AP006216.5 -4.34 1.87e-05 0.00453 -0.22 -0.23 Apolipoprotein A-IV levels; chr11:116827022 chr11:116813204~116814003:- LIHC cis rs2976388 0.669 rs2976391 ENSG00000253196.1 RP11-706C16.7 4.34 1.87e-05 0.00454 0.22 0.23 Urinary tract infection frequency; chr8:142681306 chr8:142763116~142766427:+ LIHC cis rs7487637 0.529 rs56389811 ENSG00000276691.1 RP5-1057I20.5 4.34 1.87e-05 0.00454 0.41 0.23 Mononucleosis; chr12:47811575 chr12:47788426~47788971:+ LIHC cis rs11673344 0.864 rs1533736 ENSG00000226686.6 LINC01535 4.34 1.87e-05 0.00454 0.36 0.23 Obesity-related traits; chr19:37164074 chr19:37251912~37265535:+ LIHC cis rs709400 0.894 rs61996721 ENSG00000258534.1 CTD-2134A5.4 4.34 1.87e-05 0.00454 0.34 0.23 Body mass index; chr14:103595015 chr14:103854366~103880111:- LIHC cis rs3733589 1 rs36058283 ENSG00000250413.1 RP11-448G15.1 4.34 1.87e-05 0.00454 0.41 0.23 Renal overload gout; chr4:10006888 chr4:10006482~10009725:+ LIHC cis rs3733589 1 rs67968745 ENSG00000250413.1 RP11-448G15.1 4.34 1.87e-05 0.00454 0.41 0.23 Renal overload gout; chr4:10007125 chr4:10006482~10009725:+ LIHC cis rs11668505 1 rs12462534 ENSG00000259108.2 CTD-3098H1.2 4.34 1.87e-05 0.00454 0.29 0.23 Lung function (FVC); chr19:47841313 chr19:47863483~47865341:- LIHC cis rs11096990 0.593 rs1026235 ENSG00000249207.1 RP11-360F5.1 -4.34 1.87e-05 0.00454 -0.23 -0.23 Cognitive function; chr4:39226629 chr4:39112677~39126818:- LIHC cis rs2274273 0.87 rs2016931 ENSG00000258413.1 RP11-665C16.6 -4.34 1.87e-05 0.00455 -0.27 -0.23 Protein biomarker; chr14:55375614 chr14:55262767~55272075:- LIHC cis rs11096990 0.634 rs1451818 ENSG00000249207.1 RP11-360F5.1 -4.34 1.87e-05 0.00455 -0.23 -0.23 Cognitive function; chr4:39257151 chr4:39112677~39126818:- LIHC cis rs597539 0.652 rs482172 ENSG00000250508.1 RP11-757G1.6 -4.34 1.87e-05 0.00455 -0.34 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68900969 chr11:68870664~68874542:+ LIHC cis rs748404 0.631 rs7163288 ENSG00000166763.7 STRCP1 4.34 1.87e-05 0.00455 0.28 0.23 Lung cancer; chr15:43379157 chr15:43699488~43718184:- LIHC cis rs748404 0.66 rs693510 ENSG00000166763.7 STRCP1 4.34 1.88e-05 0.00455 0.28 0.23 Lung cancer; chr15:43422427 chr15:43699488~43718184:- LIHC cis rs748404 0.66 rs690512 ENSG00000166763.7 STRCP1 4.34 1.88e-05 0.00455 0.28 0.23 Lung cancer; chr15:43425480 chr15:43699488~43718184:- LIHC cis rs748404 0.66 rs542898 ENSG00000166763.7 STRCP1 4.34 1.88e-05 0.00455 0.28 0.23 Lung cancer; chr15:43427194 chr15:43699488~43718184:- LIHC cis rs748404 0.66 rs2249952 ENSG00000166763.7 STRCP1 4.34 1.88e-05 0.00455 0.28 0.23 Lung cancer; chr15:43428335 chr15:43699488~43718184:- LIHC cis rs2836974 0.897 rs68090597 ENSG00000255568.3 BRWD1-AS2 4.34 1.88e-05 0.00456 0.26 0.23 Cognitive function; chr21:39163707 chr21:39313935~39314962:+ LIHC cis rs858239 0.932 rs1624451 ENSG00000226816.2 AC005082.12 -4.34 1.88e-05 0.00456 -0.31 -0.23 Cerebrospinal fluid biomarker levels; chr7:23222816 chr7:23206013~23208045:+ LIHC cis rs2836974 0.549 rs34160989 ENSG00000255568.3 BRWD1-AS2 4.34 1.88e-05 0.00456 0.34 0.23 Cognitive function; chr21:39182192 chr21:39313935~39314962:+ LIHC cis rs7702057 0.53 rs17138848 ENSG00000271918.1 CTD-2287O16.5 4.34 1.88e-05 0.00456 0.31 0.23 Amyotrophic lateral sclerosis; chr5:116083606 chr5:116083807~116085416:- LIHC cis rs2932538 0.922 rs999923 ENSG00000225075.1 RP11-426L16.3 4.34 1.88e-05 0.00456 0.3 0.23 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112567926 chr1:112693688~112696621:- LIHC cis rs2932538 0.922 rs6690169 ENSG00000225075.1 RP11-426L16.3 4.34 1.88e-05 0.00456 0.3 0.23 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112572352 chr1:112693688~112696621:- LIHC cis rs3091242 0.804 rs631133 ENSG00000224183.1 SDHDP6 -4.34 1.88e-05 0.00457 -0.26 -0.23 Erythrocyte sedimentation rate; chr1:25397655 chr1:25294164~25294643:- LIHC cis rs494453 0.922 rs476515 ENSG00000227811.2 FAM212B-AS1 -4.34 1.88e-05 0.00457 -0.25 -0.23 Osteoporosis-related phenotypes; chr1:111672454 chr1:111739841~111747798:+ LIHC cis rs4578769 0.842 rs8093152 ENSG00000266850.1 RP11-370A5.1 4.34 1.88e-05 0.00457 0.27 0.23 Eosinophil percentage of white cells; chr18:22867925 chr18:22723491~22907721:- LIHC cis rs11098499 0.82 rs28535956 ENSG00000260091.1 RP11-33B1.4 4.34 1.88e-05 0.00457 0.16 0.23 Corneal astigmatism; chr4:119615703 chr4:119409333~119410233:+ LIHC cis rs2348418 0.733 rs7955080 ENSG00000247934.4 RP11-967K21.1 -4.34 1.88e-05 0.00457 -0.21 -0.23 Lung function (FEV1);Lung function (FVC); chr12:28153972 chr12:28163298~28190738:- LIHC cis rs2348418 0.733 rs12229219 ENSG00000247934.4 RP11-967K21.1 -4.34 1.88e-05 0.00457 -0.21 -0.23 Lung function (FEV1);Lung function (FVC); chr12:28158414 chr12:28163298~28190738:- LIHC cis rs921968 0.541 rs933994 ENSG00000272555.1 RP11-459I19.1 -4.34 1.88e-05 0.00457 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218785893 chr2:218818690~218819144:+ LIHC cis rs2243480 1 rs1964692 ENSG00000228409.4 CCT6P1 4.34 1.88e-05 0.00457 0.25 0.23 Diabetic kidney disease; chr7:65989196 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs2456483 ENSG00000228409.4 CCT6P1 4.34 1.88e-05 0.00457 0.25 0.23 Diabetic kidney disease; chr7:65996588 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs2949697 ENSG00000228409.4 CCT6P1 4.34 1.88e-05 0.00457 0.25 0.23 Diabetic kidney disease; chr7:65999249 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1701750 ENSG00000228409.4 CCT6P1 4.34 1.88e-05 0.00457 0.25 0.23 Diabetic kidney disease; chr7:66002158 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1701758 ENSG00000228409.4 CCT6P1 4.34 1.88e-05 0.00457 0.25 0.23 Diabetic kidney disease; chr7:66005214 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs1701759 ENSG00000228409.4 CCT6P1 4.34 1.88e-05 0.00457 0.25 0.23 Diabetic kidney disease; chr7:66005945 chr7:65751142~65763354:+ LIHC cis rs11779988 0.545 rs397096 ENSG00000253671.1 RP11-806O11.1 4.34 1.89e-05 0.00457 0.3 0.23 Breast cancer; chr8:17941339 chr8:17808941~17820868:+ LIHC cis rs1023500 0.505 rs134874 ENSG00000205702.9 CYP2D7 4.34 1.89e-05 0.00457 0.23 0.23 Schizophrenia; chr22:42265138 chr22:42140203~42144577:- LIHC cis rs1799949 1 rs8070085 ENSG00000267681.1 CTD-3199J23.6 4.34 1.89e-05 0.00457 0.22 0.23 Menopause (age at onset); chr17:43189967 chr17:43144956~43145255:+ LIHC cis rs9487094 0.961 rs9487100 ENSG00000260273.1 RP11-425D10.10 4.34 1.89e-05 0.00458 0.28 0.23 Height; chr6:109429207 chr6:109382795~109383666:+ LIHC cis rs11096990 0.634 rs2381372 ENSG00000249207.1 RP11-360F5.1 -4.34 1.89e-05 0.00458 -0.23 -0.23 Cognitive function; chr4:39271471 chr4:39112677~39126818:- LIHC cis rs9532669 0.926 rs7799 ENSG00000239827.7 SUGT1P3 -4.34 1.89e-05 0.00458 -0.29 -0.23 Cervical cancer; chr13:40958916 chr13:40908159~40921774:- LIHC cis rs2243480 1 rs6966322 ENSG00000230295.1 RP11-458F8.2 4.34 1.89e-05 0.00459 0.24 0.23 Diabetic kidney disease; chr7:66181767 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs4145008 ENSG00000230295.1 RP11-458F8.2 4.34 1.89e-05 0.00459 0.24 0.23 Diabetic kidney disease; chr7:66182524 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs4718315 ENSG00000230295.1 RP11-458F8.2 4.34 1.89e-05 0.00459 0.24 0.23 Diabetic kidney disease; chr7:66183554 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs4718316 ENSG00000230295.1 RP11-458F8.2 4.34 1.89e-05 0.00459 0.24 0.23 Diabetic kidney disease; chr7:66183744 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs1873494 ENSG00000230295.1 RP11-458F8.2 4.34 1.89e-05 0.00459 0.24 0.23 Diabetic kidney disease; chr7:66184912 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs6959002 ENSG00000230295.1 RP11-458F8.2 4.34 1.89e-05 0.00459 0.24 0.23 Diabetic kidney disease; chr7:66185509 chr7:66880708~66882981:+ LIHC cis rs748404 0.578 rs2012467 ENSG00000166763.7 STRCP1 4.34 1.9e-05 0.0046 0.28 0.23 Lung cancer; chr15:43398367 chr15:43699488~43718184:- LIHC cis rs11096990 0.634 rs2381371 ENSG00000249685.1 RP11-360F5.3 4.34 1.9e-05 0.0046 0.27 0.23 Cognitive function; chr4:39271414 chr4:39133913~39135608:+ LIHC cis rs7915414 0.802 rs12762067 ENSG00000230338.1 MTND4P19 4.34 1.9e-05 0.0046 0.24 0.23 Clopidogrel active metabolite levels; chr10:94638576 chr10:94774156~94774633:- LIHC cis rs875971 0.545 rs73142233 ENSG00000228409.4 CCT6P1 -4.34 1.9e-05 0.0046 -0.19 -0.23 Aortic root size; chr7:66221293 chr7:65751142~65763354:+ LIHC cis rs2072510 0.569 rs2540488 ENSG00000257715.1 RP11-256L6.2 -4.34 1.9e-05 0.00461 -0.32 -0.23 Metabolite levels (small molecules and protein measures); chr12:96032967 chr12:96025323~96027971:+ LIHC cis rs9595908 0.931 rs35555940 ENSG00000212293.1 SNORA16 4.34 1.9e-05 0.00461 0.27 0.23 Body mass index; chr13:32492975 chr13:32420390~32420516:- LIHC cis rs11079159 0.606 rs876720 ENSG00000263096.1 RP11-515O17.2 -4.34 1.9e-05 0.00461 -0.3 -0.23 QRS duration; chr17:55289154 chr17:55271504~55273653:- LIHC cis rs56046484 0.75 rs12900078 ENSG00000259630.2 CTD-2262B20.1 -4.34 1.9e-05 0.00461 -0.47 -0.23 Testicular germ cell tumor; chr15:84980738 chr15:85415228~85415633:+ LIHC cis rs2564921 0.693 rs2581798 ENSG00000242142.1 SERBP1P3 4.34 1.9e-05 0.00461 0.3 0.23 Height; chr3:53073584 chr3:53064283~53065091:- LIHC cis rs6442522 0.809 rs12494163 ENSG00000249786.6 EAF1-AS1 4.34 1.91e-05 0.00461 0.26 0.23 Uric acid levels; chr3:15382327 chr3:15436171~15455940:- LIHC cis rs3733589 1 rs13117275 ENSG00000250413.1 RP11-448G15.1 4.34 1.91e-05 0.00461 0.42 0.23 Renal overload gout; chr4:10006618 chr4:10006482~10009725:+ LIHC cis rs9487094 0.961 rs11153175 ENSG00000260273.1 RP11-425D10.10 4.34 1.91e-05 0.00462 0.27 0.23 Height; chr6:109361318 chr6:109382795~109383666:+ LIHC cis rs2243480 1 rs2420171 ENSG00000230295.1 RP11-458F8.2 4.34 1.91e-05 0.00462 0.24 0.23 Diabetic kidney disease; chr7:66172773 chr7:66880708~66882981:+ LIHC cis rs875971 0.545 rs67775320 ENSG00000228409.4 CCT6P1 -4.34 1.91e-05 0.00462 -0.19 -0.23 Aortic root size; chr7:66193792 chr7:65751142~65763354:+ LIHC cis rs244293 0.868 rs12453779 ENSG00000275710.1 RP11-257O5.4 -4.34 1.91e-05 0.00462 -0.24 -0.23 Menarche (age at onset); chr17:55094748 chr17:54964474~54964679:+ LIHC cis rs244293 0.831 rs7209029 ENSG00000275710.1 RP11-257O5.4 -4.34 1.91e-05 0.00462 -0.24 -0.23 Menarche (age at onset); chr17:55095685 chr17:54964474~54964679:+ LIHC cis rs1223397 0.938 rs3734878 ENSG00000215022.6 RP1-257A7.4 -4.34 1.91e-05 0.00462 -0.31 -0.23 Blood pressure; chr6:13288618 chr6:13264861~13295586:- LIHC cis rs8040855 0.597 rs12902942 ENSG00000259295.5 CSPG4P12 4.34 1.91e-05 0.00462 0.36 0.23 Bulimia nervosa; chr15:85041573 chr15:85191438~85213905:+ LIHC cis rs748404 0.66 rs689767 ENSG00000166763.7 STRCP1 4.34 1.91e-05 0.00462 0.28 0.23 Lung cancer; chr15:43429879 chr15:43699488~43718184:- LIHC cis rs748404 0.66 rs2439845 ENSG00000166763.7 STRCP1 4.34 1.91e-05 0.00462 0.28 0.23 Lung cancer; chr15:43430412 chr15:43699488~43718184:- LIHC cis rs748404 0.631 rs2467745 ENSG00000166763.7 STRCP1 4.34 1.91e-05 0.00462 0.28 0.23 Lung cancer; chr15:43430544 chr15:43699488~43718184:- LIHC cis rs748404 0.66 rs2439846 ENSG00000166763.7 STRCP1 4.34 1.91e-05 0.00462 0.28 0.23 Lung cancer; chr15:43448772 chr15:43699488~43718184:- LIHC cis rs748404 0.66 rs2467741 ENSG00000166763.7 STRCP1 4.34 1.91e-05 0.00462 0.28 0.23 Lung cancer; chr15:43450428 chr15:43699488~43718184:- LIHC cis rs4561483 0.801 rs33637 ENSG00000261560.1 RP11-166B2.3 -4.34 1.91e-05 0.00463 -0.26 -0.23 Testicular germ cell tumor; chr16:11896018 chr16:11881075~11882569:- LIHC cis rs11098499 0.697 rs28655325 ENSG00000260091.1 RP11-33B1.4 -4.34 1.91e-05 0.00463 -0.16 -0.23 Corneal astigmatism; chr4:119451844 chr4:119409333~119410233:+ LIHC cis rs7567389 0.51 rs1473623 ENSG00000236682.1 AC068282.3 4.34 1.91e-05 0.00463 0.33 0.23 Self-rated health; chr2:127438644 chr2:127389130~127400580:+ LIHC cis rs2060793 0.519 rs7931378 ENSG00000251991.1 RNU7-49P 4.34 1.91e-05 0.00463 0.25 0.23 Vitamin D levels; chr11:14592869 chr11:14478892~14478953:+ LIHC cis rs17711722 0.565 rs4275112 ENSG00000226002.1 RP11-460N20.5 -4.34 1.91e-05 0.00463 -0.24 -0.23 Calcium levels; chr7:65733651 chr7:65084103~65100232:+ LIHC cis rs1075265 0.62 rs2542584 ENSG00000272156.1 RP11-477N3.1 -4.34 1.91e-05 0.00463 -0.27 -0.23 Chronotype;Morning vs. evening chronotype; chr2:53782707 chr2:54082554~54085066:+ LIHC cis rs860295 0.775 rs822505 ENSG00000203761.5 MSTO2P 4.34 1.91e-05 0.00463 0.19 0.23 Body mass index; chr1:155876737 chr1:155745829~155750137:+ LIHC cis rs860295 0.775 rs822509 ENSG00000203761.5 MSTO2P 4.34 1.91e-05 0.00463 0.19 0.23 Body mass index; chr1:155881020 chr1:155745829~155750137:+ LIHC cis rs2072510 0.722 rs763874 ENSG00000257878.1 RP11-256L6.3 -4.34 1.91e-05 0.00463 -0.2 -0.23 Metabolite levels (small molecules and protein measures); chr12:96026435 chr12:95996521~96011489:+ LIHC cis rs1577917 1 rs12216203 ENSG00000234155.1 RP11-30P6.6 4.34 1.92e-05 0.00463 0.3 0.23 Response to antipsychotic treatment; chr6:85965583 chr6:85387219~85390186:- LIHC cis rs10129255 0.957 rs10132367 ENSG00000223648.3 IGHV3-64 4.34 1.92e-05 0.00464 0.17 0.23 Kawasaki disease; chr14:106690981 chr14:106643132~106658258:- LIHC cis rs6545883 0.507 rs12617371 ENSG00000271889.1 RP11-493E12.1 -4.34 1.92e-05 0.00464 -0.27 -0.23 Tuberculosis; chr2:61341999 chr2:61151433~61162105:- LIHC cis rs11098499 0.863 rs3822190 ENSG00000260091.1 RP11-33B1.4 -4.34 1.92e-05 0.00464 -0.17 -0.23 Corneal astigmatism; chr4:119506943 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs3822191 ENSG00000260091.1 RP11-33B1.4 -4.34 1.92e-05 0.00464 -0.17 -0.23 Corneal astigmatism; chr4:119506946 chr4:119409333~119410233:+ LIHC cis rs2243480 1 rs709607 ENSG00000232546.1 RP11-458F8.1 4.34 1.92e-05 0.00464 0.26 0.23 Diabetic kidney disease; chr7:65984554 chr7:66848496~66858136:+ LIHC cis rs496547 0.756 rs562059 ENSG00000255422.1 AP002954.4 -4.34 1.92e-05 0.00464 -0.28 -0.23 Hip minimal joint space width; chr11:118731349 chr11:118704607~118750263:+ LIHC cis rs3812762 0.917 rs905289 ENSG00000254860.4 TMEM9B-AS1 -4.34 1.92e-05 0.00464 -0.24 -0.23 Hypospadias; chr11:8732005 chr11:8964675~8977527:+ LIHC cis rs1577917 0.958 rs11756510 ENSG00000234155.1 RP11-30P6.6 4.33 1.92e-05 0.00465 0.3 0.23 Response to antipsychotic treatment; chr6:85990076 chr6:85387219~85390186:- LIHC cis rs7615952 0.599 rs6779141 ENSG00000171084.14 FAM86JP 4.33 1.92e-05 0.00465 0.35 0.23 Blood pressure (smoking interaction); chr3:125991152 chr3:125916620~125930024:+ LIHC cis rs1555322 0.53 rs2297789 ENSG00000279253.1 RP4-614O4.13 -4.33 1.92e-05 0.00465 -0.3 -0.23 Attention deficit hyperactivity disorder; chr20:35279445 chr20:35262727~35264187:- LIHC cis rs9457247 0.756 rs2345572 ENSG00000227598.1 RP1-167A14.2 -4.33 1.92e-05 0.00466 -0.24 -0.23 Crohn's disease; chr6:166989953 chr6:166969626~166999065:- LIHC cis rs1499614 1 rs1267817 ENSG00000232546.1 RP11-458F8.1 -4.33 1.93e-05 0.00466 -0.26 -0.23 Gout; chr7:66645053 chr7:66848496~66858136:+ LIHC cis rs116139393 0.54 rs13224907 ENSG00000187953.9 PMS2CL -4.33 1.93e-05 0.00466 -0.24 -0.23 Alzheimer's disease (APOE e4 interaction); chr7:6734261 chr7:6710128~6753862:+ LIHC cis rs1577917 1 rs12664335 ENSG00000234155.1 RP11-30P6.6 -4.33 1.93e-05 0.00466 -0.29 -0.23 Response to antipsychotic treatment; chr6:85888056 chr6:85387219~85390186:- LIHC cis rs9341808 1 rs9341808 ENSG00000272129.1 RP11-250B2.6 4.33 1.93e-05 0.00466 0.23 0.23 Sitting height ratio; chr6:80243540 chr6:80355424~80356859:+ LIHC cis rs2337406 1 rs4774172 ENSG00000274576.2 IGHV2-70 -4.33 1.93e-05 0.00467 -0.25 -0.23 Alzheimer's disease (late onset); chr14:106681320 chr14:106770577~106771020:- LIHC cis rs2337406 1 rs4774173 ENSG00000274576.2 IGHV2-70 -4.33 1.93e-05 0.00467 -0.25 -0.23 Alzheimer's disease (late onset); chr14:106682029 chr14:106770577~106771020:- LIHC cis rs193541 0.593 rs246309 ENSG00000263432.2 RN7SL689P 4.33 1.93e-05 0.00467 0.37 0.23 Glucose homeostasis traits; chr5:122934024 chr5:123022487~123022783:- LIHC cis rs1729407 0.709 rs2098453 ENSG00000236267.1 AP006216.5 4.33 1.93e-05 0.00467 0.22 0.23 Apolipoprotein A-IV levels; chr11:116825964 chr11:116813204~116814003:- LIHC cis rs10129255 0.957 rs12590735 ENSG00000211970.3 IGHV4-61 -4.33 1.93e-05 0.00468 -0.18 -0.23 Kawasaki disease; chr14:106779660 chr14:106639119~106639657:- LIHC cis rs7615952 0.641 rs6438951 ENSG00000171084.14 FAM86JP 4.33 1.93e-05 0.00468 0.36 0.23 Blood pressure (smoking interaction); chr3:125978156 chr3:125916620~125930024:+ LIHC cis rs2274273 0.837 rs8008119 ENSG00000258413.1 RP11-665C16.6 -4.33 1.94e-05 0.00468 -0.27 -0.23 Protein biomarker; chr14:55364510 chr14:55262767~55272075:- LIHC cis rs169313 0.556 rs7220819 ENSG00000264016.2 CTC-297N7.9 -4.33 1.94e-05 0.00468 -0.28 -0.23 Relative hand skill in reading disability; chr17:10663157 chr17:10741267~10769016:- LIHC cis rs367615 0.704 rs4320313 ENSG00000249476.1 CTD-2587M2.1 4.33 1.94e-05 0.00468 0.27 0.23 Colorectal cancer (SNP x SNP interaction); chr5:109492986 chr5:109237120~109326369:- LIHC cis rs1823913 1 rs6749232 ENSG00000227542.1 AC092614.2 -4.33 1.94e-05 0.00469 -0.23 -0.23 Obesity-related traits; chr2:191250326 chr2:191229165~191246172:- LIHC cis rs8028182 0.636 rs7175852 ENSG00000260269.4 CTD-2323K18.1 -4.33 1.94e-05 0.00469 -0.29 -0.23 Sudden cardiac arrest; chr15:75402194 chr15:75527150~75601205:- LIHC cis rs709400 0.93 rs2274268 ENSG00000258534.1 CTD-2134A5.4 4.33 1.94e-05 0.00469 0.35 0.23 Body mass index; chr14:103563041 chr14:103854366~103880111:- LIHC cis rs7429990 0.52 rs78838427 ENSG00000229759.1 MRPS18AP1 -4.33 1.94e-05 0.00469 -0.24 -0.23 Educational attainment (years of education); chr3:47595561 chr3:48256350~48256938:- LIHC cis rs2524005 1 rs2524005 ENSG00000272236.1 XXbac-BPG170G13.32 -4.33 1.94e-05 0.00469 -0.31 -0.23 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29751965~29752207:- LIHC cis rs4862307 0.836 rs11132220 ENSG00000250726.1 RP11-616K6.1 -4.33 1.94e-05 0.00469 -0.25 -0.23 Serum dimethylarginine levels (asymmetric/symetric ratio); chr4:184076094 chr4:184072403~184073039:+ LIHC cis rs4934494 0.689 rs11185895 ENSG00000232936.4 RP11-80H5.2 -4.33 1.94e-05 0.0047 -0.26 -0.23 Red blood cell count; chr10:89817482 chr10:89645282~89650667:+ LIHC cis rs831571 0.636 rs56228642 ENSG00000280620.1 SCAANT1 4.33 1.94e-05 0.0047 0.34 0.23 Type 2 diabetes; chr3:64090083 chr3:63911518~63911772:- LIHC cis rs9652601 0.959 rs2058531 ENSG00000274038.1 RP11-66H6.4 -4.33 1.94e-05 0.0047 -0.29 -0.23 Systemic lupus erythematosus; chr16:11078252 chr16:11056556~11057034:+ LIHC cis rs1005277 0.522 rs289650 ENSG00000099251.13 HSD17B7P2 4.33 1.94e-05 0.0047 0.25 0.23 Extrinsic epigenetic age acceleration; chr10:37686577 chr10:38356380~38378505:+ LIHC cis rs113084984 0.538 rs11686574 ENSG00000271952.1 RP11-245G13.2 -4.33 1.95e-05 0.0047 -0.26 -0.23 Breast cancer; chr2:11543881 chr2:10878269~10885118:+ LIHC cis rs734999 0.588 rs2985859 ENSG00000225931.3 RP3-395M20.7 -4.33 1.95e-05 0.0047 -0.24 -0.23 Ulcerative colitis; chr1:2600977 chr1:2566410~2569888:+ LIHC cis rs734999 0.588 rs3001837 ENSG00000225931.3 RP3-395M20.7 -4.33 1.95e-05 0.0047 -0.24 -0.23 Ulcerative colitis; chr1:2601067 chr1:2566410~2569888:+ LIHC cis rs734999 0.55 rs2985855 ENSG00000225931.3 RP3-395M20.7 -4.33 1.95e-05 0.0047 -0.24 -0.23 Ulcerative colitis; chr1:2599933 chr1:2566410~2569888:+ LIHC cis rs734999 0.588 rs6689711 ENSG00000225931.3 RP3-395M20.7 -4.33 1.95e-05 0.0047 -0.24 -0.23 Ulcerative colitis; chr1:2600028 chr1:2566410~2569888:+ LIHC cis rs2836974 0.932 rs73221193 ENSG00000255568.3 BRWD1-AS2 4.33 1.95e-05 0.0047 0.26 0.23 Cognitive function; chr21:39182767 chr21:39313935~39314962:+ LIHC cis rs755249 0.917 rs61781392 ENSG00000182109.6 RP11-69E11.4 4.33 1.95e-05 0.0047 0.33 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39617969 chr1:39522280~39546187:- LIHC cis rs17711722 0.528 rs73138179 ENSG00000273024.4 INTS4P2 -4.33 1.95e-05 0.0047 -0.24 -0.23 Calcium levels; chr7:65829495 chr7:65647864~65715661:+ LIHC cis rs7915414 0.951 rs2104543 ENSG00000230338.1 MTND4P19 4.33 1.95e-05 0.00471 0.24 0.23 Clopidogrel active metabolite levels; chr10:94670214 chr10:94774156~94774633:- LIHC cis rs2243480 0.706 rs6460257 ENSG00000164669.11 INTS4P1 4.33 1.95e-05 0.00471 0.35 0.23 Diabetic kidney disease; chr7:65731813 chr7:65141225~65234216:+ LIHC cis rs9675120 0.638 rs7216662 ENSG00000262006.1 RP11-700H6.4 -4.33 1.95e-05 0.00471 -0.26 -0.23 Cerebrospinal fluid biomarker levels; chr17:50859850 chr17:50909637~50910232:- LIHC cis rs9549367 0.756 rs3861723 ENSG00000269125.1 RP11-98F14.11 -4.33 1.95e-05 0.00471 -0.26 -0.23 Platelet distribution width; chr13:113256612 chr13:113165002~113165183:- LIHC cis rs1555322 0.505 rs639763 ENSG00000279253.1 RP4-614O4.13 -4.33 1.95e-05 0.00471 -0.31 -0.23 Attention deficit hyperactivity disorder; chr20:35274101 chr20:35262727~35264187:- LIHC cis rs3812762 0.912 rs10769953 ENSG00000254860.4 TMEM9B-AS1 -4.33 1.95e-05 0.00471 -0.25 -0.23 Hypospadias; chr11:8756805 chr11:8964675~8977527:+ LIHC cis rs1005277 0.579 rs1740732 ENSG00000099251.13 HSD17B7P2 4.33 1.95e-05 0.00471 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38202457 chr10:38356380~38378505:+ LIHC cis rs172166 0.611 rs203883 ENSG00000219392.1 RP1-265C24.5 -4.33 1.95e-05 0.00471 -0.3 -0.23 Cardiac Troponin-T levels; chr6:28110578 chr6:28115628~28116551:+ LIHC cis rs172166 0.611 rs203882 ENSG00000219392.1 RP1-265C24.5 -4.33 1.95e-05 0.00471 -0.3 -0.23 Cardiac Troponin-T levels; chr6:28110724 chr6:28115628~28116551:+ LIHC cis rs172166 0.694 rs1770131 ENSG00000219392.1 RP1-265C24.5 -4.33 1.95e-05 0.00471 -0.3 -0.23 Cardiac Troponin-T levels; chr6:28118635 chr6:28115628~28116551:+ LIHC cis rs2284219 0.894 rs1076291 ENSG00000196295.10 AC005154.6 -4.33 1.95e-05 0.00471 -0.16 -0.23 Type 2 diabetes; chr7:30672979 chr7:30516309~30594809:- LIHC cis rs2284219 0.894 rs1076292 ENSG00000196295.10 AC005154.6 -4.33 1.95e-05 0.00471 -0.16 -0.23 Type 2 diabetes; chr7:30673085 chr7:30516309~30594809:- LIHC cis rs2284219 0.894 rs2251002 ENSG00000196295.10 AC005154.6 -4.33 1.95e-05 0.00471 -0.16 -0.23 Type 2 diabetes; chr7:30673228 chr7:30516309~30594809:- LIHC cis rs7119038 0.865 rs7951740 ENSG00000255239.1 AP002954.6 4.33 1.95e-05 0.00472 0.34 0.23 Sjögren's syndrome; chr11:118869709 chr11:118688039~118690600:- LIHC cis rs709400 0.894 rs10143293 ENSG00000258534.1 CTD-2134A5.4 4.33 1.96e-05 0.00472 0.34 0.23 Body mass index; chr14:103596677 chr14:103854366~103880111:- LIHC cis rs1865760 0.532 rs1061482 ENSG00000216436.2 HIST1H2APS1 -4.33 1.96e-05 0.00472 -0.27 -0.23 Height; chr6:26086471 chr6:25732497~25732827:+ LIHC cis rs6504622 0.702 rs11079747 ENSG00000262879.4 RP11-156P1.3 -4.33 1.96e-05 0.00472 -0.25 -0.23 Orofacial clefts; chr17:47001484 chr17:46984045~47100323:- LIHC cis rs7208859 0.673 rs1347360 ENSG00000266490.1 CTD-2349P21.9 4.33 1.96e-05 0.00473 0.28 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587514 chr17:30792372~30792833:+ LIHC cis rs734999 0.545 rs4648356 ENSG00000225931.3 RP3-395M20.7 4.33 1.96e-05 0.00473 0.24 0.23 Ulcerative colitis; chr1:2792599 chr1:2566410~2569888:+ LIHC cis rs11098499 0.644 rs7676296 ENSG00000260091.1 RP11-33B1.4 -4.33 1.96e-05 0.00473 -0.16 -0.23 Corneal astigmatism; chr4:119634532 chr4:119409333~119410233:+ LIHC cis rs4834770 1 rs878375 ENSG00000245958.5 RP11-33B1.1 -4.33 1.97e-05 0.00474 -0.22 -0.23 Blood protein levels; chr4:119316419 chr4:119454791~119552025:+ LIHC cis rs160451 1 rs160451 ENSG00000251136.7 RP11-37B2.1 4.33 1.97e-05 0.00475 0.21 0.23 Leprosy; chr8:89650713 chr8:89609409~89757727:- LIHC cis rs4925386 1 rs4925386 ENSG00000273619.1 RP5-908M14.9 -4.33 1.97e-05 0.00475 -0.18 -0.23 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62345988 chr20:62386303~62386970:- LIHC cis rs11722228 0.549 rs2241488 ENSG00000261490.1 RP11-448G15.3 4.33 1.97e-05 0.00475 0.31 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10099507 chr4:10068089~10073019:- LIHC cis rs948562 0.74 rs12361770 ENSG00000280010.1 AP001350.4 4.33 1.97e-05 0.00475 0.41 0.23 Lymphoma; chr11:58666759 chr11:58627435~58628528:+ LIHC cis rs7665090 0.714 rs5026475 ENSG00000248971.2 KRT8P46 -4.33 1.97e-05 0.00475 -0.23 -0.23 Primary biliary cholangitis; chr4:102633664 chr4:102728746~102730171:- LIHC cis rs2439831 0.85 rs28413704 ENSG00000275601.1 AC011330.13 -4.33 1.97e-05 0.00475 -0.33 -0.23 Lung cancer in ever smokers; chr15:43856229 chr15:43642389~43643023:- LIHC cis rs7208859 0.673 rs73277967 ENSG00000266490.1 CTD-2349P21.9 4.33 1.97e-05 0.00475 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30857148 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs2269915 ENSG00000266490.1 CTD-2349P21.9 4.33 1.97e-05 0.00475 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906326 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs2269916 ENSG00000266490.1 CTD-2349P21.9 4.33 1.97e-05 0.00475 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906745 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs11649765 ENSG00000266490.1 CTD-2349P21.9 4.33 1.97e-05 0.00475 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906870 chr17:30792372~30792833:+ LIHC cis rs4650994 0.623 rs7534394 ENSG00000213057.5 C1orf220 -4.33 1.97e-05 0.00475 -0.2 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178653625 chr1:178542752~178548889:+ LIHC cis rs10129255 0.518 rs10150460 ENSG00000211972.2 IGHV3-66 -4.33 1.97e-05 0.00475 -0.17 -0.23 Kawasaki disease; chr14:106677179 chr14:106675017~106675544:- LIHC cis rs9595908 0.865 rs743760 ENSG00000212293.1 SNORA16 -4.33 1.97e-05 0.00476 -0.29 -0.23 Body mass index; chr13:32496990 chr13:32420390~32420516:- LIHC cis rs79349575 0.87 rs12941262 ENSG00000248278.1 SUMO2P17 4.33 1.97e-05 0.00476 0.28 0.23 Type 2 diabetes; chr17:48889675 chr17:48874860~48908983:- LIHC cis rs79349575 0.778 rs12950328 ENSG00000248278.1 SUMO2P17 4.33 1.97e-05 0.00476 0.28 0.23 Type 2 diabetes; chr17:48889699 chr17:48874860~48908983:- LIHC cis rs10028773 0.515 rs9994651 ENSG00000245958.5 RP11-33B1.1 -4.33 1.97e-05 0.00476 -0.23 -0.23 Educational attainment; chr4:119666648 chr4:119454791~119552025:+ LIHC cis rs5758511 0.689 rs55906806 ENSG00000237037.8 NDUFA6-AS1 -4.33 1.97e-05 0.00476 -0.47 -0.23 Birth weight; chr22:42248465 chr22:42090931~42137742:+ LIHC cis rs1062753 0.527 rs2187959 ENSG00000237037.8 NDUFA6-AS1 -4.33 1.97e-05 0.00476 -0.32 -0.23 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41951840 chr22:42090931~42137742:+ LIHC cis rs12655019 0.92 rs7725377 ENSG00000271828.1 CTD-2310F14.1 -4.33 1.98e-05 0.00476 -0.41 -0.23 Breast cancer (early onset); chr5:56960769 chr5:56927874~56929573:+ LIHC cis rs72634501 0.568 rs6679564 ENSG00000182109.6 RP11-69E11.4 -4.33 1.98e-05 0.00476 -0.24 -0.23 HDL cholesterol; chr1:39151408 chr1:39522280~39546187:- LIHC cis rs948562 1 rs12365551 ENSG00000280010.1 AP001350.4 4.33 1.98e-05 0.00477 0.4 0.23 Lymphoma; chr11:58590895 chr11:58627435~58628528:+ LIHC cis rs950880 0.71 rs11123928 ENSG00000234389.1 AC007278.3 -4.33 1.98e-05 0.00477 -0.23 -0.23 Serum protein levels (sST2); chr2:102444826 chr2:102438713~102440475:+ LIHC cis rs11098499 0.57 rs6832740 ENSG00000260091.1 RP11-33B1.4 -4.33 1.98e-05 0.00477 -0.16 -0.23 Corneal astigmatism; chr4:119624981 chr4:119409333~119410233:+ LIHC cis rs11098499 0.644 rs6855918 ENSG00000260091.1 RP11-33B1.4 -4.33 1.98e-05 0.00477 -0.16 -0.23 Corneal astigmatism; chr4:119625144 chr4:119409333~119410233:+ LIHC cis rs2836974 0.8 rs73221174 ENSG00000255568.3 BRWD1-AS2 4.33 1.98e-05 0.00477 0.26 0.23 Cognitive function; chr21:39169013 chr21:39313935~39314962:+ LIHC cis rs11668505 1 rs12985570 ENSG00000259108.2 CTD-3098H1.2 4.33 1.98e-05 0.00477 0.29 0.23 Lung function (FVC); chr19:47845683 chr19:47863483~47865341:- LIHC cis rs6430585 0.528 rs309166 ENSG00000231890.6 DARS-AS1 -4.33 1.98e-05 0.00477 -0.31 -0.23 Corneal structure; chr2:135909917 chr2:135985176~136022593:+ LIHC cis rs6430585 0.591 rs309170 ENSG00000231890.6 DARS-AS1 -4.33 1.98e-05 0.00477 -0.31 -0.23 Corneal structure; chr2:135915205 chr2:135985176~136022593:+ LIHC cis rs11098499 0.691 rs9996644 ENSG00000260091.1 RP11-33B1.4 -4.33 1.98e-05 0.00477 -0.16 -0.23 Corneal astigmatism; chr4:119317722 chr4:119409333~119410233:+ LIHC cis rs11098499 0.691 rs9996494 ENSG00000260091.1 RP11-33B1.4 -4.33 1.98e-05 0.00477 -0.16 -0.23 Corneal astigmatism; chr4:119317725 chr4:119409333~119410233:+ LIHC cis rs812925 0.512 rs1177309 ENSG00000212978.6 AC016747.3 -4.33 1.98e-05 0.00477 -0.25 -0.23 Immature fraction of reticulocytes; chr2:61158113 chr2:61141592~61144969:- LIHC cis rs921968 0.565 rs4674328 ENSG00000272555.1 RP11-459I19.1 -4.33 1.98e-05 0.00478 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218728480 chr2:218818690~218819144:+ LIHC cis rs875971 0.505 rs6955582 ENSG00000224316.1 RP11-479O9.2 4.33 1.98e-05 0.00478 0.23 0.23 Aortic root size; chr7:65966699 chr7:65773620~65802067:+ LIHC cis rs10991814 0.557 rs79342869 ENSG00000273381.1 RP11-305L7.7 4.33 1.98e-05 0.00478 0.26 0.23 Neutrophil percentage of granulocytes; chr9:91225500 chr9:91206175~91210299:- LIHC cis rs2243480 1 rs1546059 ENSG00000230295.1 RP11-458F8.2 4.33 1.98e-05 0.00478 0.24 0.23 Diabetic kidney disease; chr7:66189722 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs6958289 ENSG00000230295.1 RP11-458F8.2 4.33 1.98e-05 0.00478 0.24 0.23 Diabetic kidney disease; chr7:66192124 chr7:66880708~66882981:+ LIHC cis rs7945705 0.692 rs11042149 ENSG00000254860.4 TMEM9B-AS1 4.33 1.98e-05 0.00478 0.22 0.23 Hemoglobin concentration; chr11:8989190 chr11:8964675~8977527:+ LIHC cis rs7712401 0.623 rs7723798 ENSG00000263432.2 RN7SL689P 4.33 1.99e-05 0.00479 0.31 0.23 Mean platelet volume; chr5:123034022 chr5:123022487~123022783:- LIHC cis rs1062177 0.694 rs2915816 ENSG00000253921.1 CTB-113P19.3 4.33 1.99e-05 0.00479 0.25 0.23 Preschool internalizing problems; chr5:151736296 chr5:151753992~151767247:+ LIHC cis rs6445975 0.617 rs4470539 ENSG00000272360.1 RP11-359I18.5 4.33 1.99e-05 0.00479 0.3 0.23 Systemic lupus erythematosus; chr3:58418759 chr3:58490830~58491291:- LIHC cis rs6445975 0.666 rs9822328 ENSG00000272360.1 RP11-359I18.5 4.33 1.99e-05 0.00479 0.3 0.23 Systemic lupus erythematosus; chr3:58422110 chr3:58490830~58491291:- LIHC cis rs6445975 0.666 rs6767291 ENSG00000272360.1 RP11-359I18.5 4.33 1.99e-05 0.00479 0.3 0.23 Systemic lupus erythematosus; chr3:58423183 chr3:58490830~58491291:- LIHC cis rs11690935 0.632 rs6723259 ENSG00000228389.1 AC068039.4 -4.33 1.99e-05 0.00479 -0.27 -0.23 Schizophrenia; chr2:171766017 chr2:171773482~171775844:+ LIHC cis rs4356203 0.87 rs10832748 ENSG00000260196.1 RP1-239B22.5 -4.33 1.99e-05 0.00479 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17230184 chr11:17380649~17383531:+ LIHC cis rs2072510 0.932 rs2070614 ENSG00000257878.1 RP11-256L6.3 -4.33 1.99e-05 0.00479 -0.21 -0.23 Metabolite levels (small molecules and protein measures); chr12:95996558 chr12:95996521~96011489:+ LIHC cis rs11098499 0.754 rs1546503 ENSG00000260091.1 RP11-33B1.4 -4.33 1.99e-05 0.0048 -0.16 -0.23 Corneal astigmatism; chr4:119320012 chr4:119409333~119410233:+ LIHC cis rs11098499 0.708 rs1546506 ENSG00000260091.1 RP11-33B1.4 -4.33 1.99e-05 0.0048 -0.16 -0.23 Corneal astigmatism; chr4:119320085 chr4:119409333~119410233:+ LIHC cis rs11722228 0.549 rs73212863 ENSG00000261490.1 RP11-448G15.3 4.33 1.99e-05 0.0048 0.31 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10102549 chr4:10068089~10073019:- LIHC cis rs11722228 0.508 rs73212864 ENSG00000261490.1 RP11-448G15.3 4.33 1.99e-05 0.0048 0.31 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10102567 chr4:10068089~10073019:- LIHC cis rs673078 0.607 rs61943369 ENSG00000275759.1 RP11-131L12.3 -4.33 1.99e-05 0.0048 -0.28 -0.23 Glucose homeostasis traits; chr12:118368145 chr12:118428281~118428870:+ LIHC cis rs948562 0.947 rs1938601 ENSG00000280010.1 AP001350.4 4.33 2e-05 0.0048 0.41 0.23 Lymphoma; chr11:58646988 chr11:58627435~58628528:+ LIHC cis rs7429990 0.864 rs7631950 ENSG00000229759.1 MRPS18AP1 -4.33 2e-05 0.00481 -0.24 -0.23 Educational attainment (years of education); chr3:47591865 chr3:48256350~48256938:- LIHC cis rs7429990 0.833 rs11716582 ENSG00000229759.1 MRPS18AP1 -4.33 2e-05 0.00481 -0.24 -0.23 Educational attainment (years of education); chr3:47592269 chr3:48256350~48256938:- LIHC cis rs7429990 0.833 rs4858801 ENSG00000229759.1 MRPS18AP1 -4.33 2e-05 0.00481 -0.24 -0.23 Educational attainment (years of education); chr3:47599432 chr3:48256350~48256938:- LIHC cis rs7429990 0.864 rs61620099 ENSG00000229759.1 MRPS18AP1 -4.33 2e-05 0.00481 -0.24 -0.23 Educational attainment (years of education); chr3:47600755 chr3:48256350~48256938:- LIHC cis rs16858210 0.874 rs55666767 ENSG00000234371.6 RPSAP31 4.33 2e-05 0.00481 0.3 0.23 Menopause (age at onset); chr3:183855447 chr3:183884924~183888449:+ LIHC cis rs17376456 0.877 rs12716460 ENSG00000251023.1 RP11-549J18.1 -4.33 2e-05 0.00481 -0.48 -0.23 Diabetic retinopathy; chr5:94081028 chr5:93860669~93863825:- LIHC cis rs2832191 0.511 rs7278227 ENSG00000176054.6 RPL23P2 -4.33 2e-05 0.00481 -0.26 -0.23 Dental caries; chr21:29110386 chr21:28997613~28998033:- LIHC cis rs77204473 0.744 rs2170317 ENSG00000254851.1 RP11-109L13.1 4.33 2e-05 0.00481 0.42 0.23 Sum eosinophil basophil counts;Eosinophil counts; chr11:117200024 chr11:117135528~117138582:+ LIHC cis rs7945705 0.747 rs11042150 ENSG00000254860.4 TMEM9B-AS1 4.33 2e-05 0.00481 0.22 0.23 Hemoglobin concentration; chr11:8989272 chr11:8964675~8977527:+ LIHC cis rs7615952 0.534 rs1503072 ENSG00000171084.14 FAM86JP 4.33 2e-05 0.00481 0.37 0.23 Blood pressure (smoking interaction); chr3:126035848 chr3:125916620~125930024:+ LIHC cis rs7615952 0.599 rs7631268 ENSG00000171084.14 FAM86JP 4.33 2e-05 0.00481 0.37 0.23 Blood pressure (smoking interaction); chr3:126036821 chr3:125916620~125930024:+ LIHC cis rs9457247 1 rs444988 ENSG00000227598.1 RP1-167A14.2 -4.33 2e-05 0.00482 -0.24 -0.23 Crohn's disease; chr6:166976186 chr6:166969626~166999065:- LIHC cis rs9457247 1 rs408080 ENSG00000227598.1 RP1-167A14.2 -4.33 2e-05 0.00482 -0.24 -0.23 Crohn's disease; chr6:166979034 chr6:166969626~166999065:- LIHC cis rs7894407 0.76 rs4917386 ENSG00000236937.2 PTGES3P4 -4.33 2e-05 0.00482 -0.27 -0.23 White matter hyperintensity burden; chr10:103247771 chr10:102845595~102845950:+ LIHC cis rs2243480 1 rs59794892 ENSG00000230295.1 RP11-458F8.2 -4.32 2e-05 0.00482 -0.24 -0.23 Diabetic kidney disease; chr7:65950886 chr7:66880708~66882981:+ LIHC cis rs2243480 0.803 rs36004293 ENSG00000230295.1 RP11-458F8.2 -4.32 2e-05 0.00482 -0.24 -0.23 Diabetic kidney disease; chr7:65951525 chr7:66880708~66882981:+ LIHC cis rs2243480 0.803 rs35268390 ENSG00000230295.1 RP11-458F8.2 -4.32 2e-05 0.00482 -0.24 -0.23 Diabetic kidney disease; chr7:65951549 chr7:66880708~66882981:+ LIHC cis rs11096990 0.634 rs746678 ENSG00000249685.1 RP11-360F5.3 -4.32 2.01e-05 0.00482 -0.27 -0.23 Cognitive function; chr4:39279035 chr4:39133913~39135608:+ LIHC cis rs7208859 0.614 rs73265646 ENSG00000266490.1 CTD-2349P21.9 4.32 2.01e-05 0.00482 0.28 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917005 chr17:30792372~30792833:+ LIHC cis rs2599510 0.811 rs2710615 ENSG00000276334.1 AL133243.1 4.32 2.01e-05 0.00483 0.26 0.23 Interleukin-18 levels; chr2:32566155 chr2:32521927~32523547:+ LIHC cis rs755249 0.567 rs4660214 ENSG00000182109.6 RP11-69E11.4 4.32 2.01e-05 0.00483 0.29 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39265878 chr1:39522280~39546187:- LIHC cis rs12681366 0.839 rs2931632 ENSG00000253704.1 RP11-267M23.4 4.32 2.01e-05 0.00483 0.26 0.23 Nonsyndromic cleft lip with cleft palate; chr8:94406560 chr8:94553722~94569745:+ LIHC cis rs3204270 0.684 rs57405099 ENSG00000281517.1 Metazoa_SRP -4.32 2.01e-05 0.00483 -0.43 -0.23 Dental caries; chr17:81670035 chr17:81718849~81719095:- LIHC cis rs734999 0.588 rs2843401 ENSG00000225931.3 RP3-395M20.7 -4.32 2.01e-05 0.00483 -0.24 -0.23 Ulcerative colitis; chr1:2596694 chr1:2566410~2569888:+ LIHC cis rs748404 0.697 rs471122 ENSG00000166763.7 STRCP1 -4.32 2.01e-05 0.00483 -0.28 -0.23 Lung cancer; chr15:43266376 chr15:43699488~43718184:- LIHC cis rs10129255 0.701 rs2005643 ENSG00000223648.3 IGHV3-64 4.32 2.01e-05 0.00484 0.16 0.23 Kawasaki disease; chr14:106676288 chr14:106643132~106658258:- LIHC cis rs9527 0.615 rs4919685 ENSG00000236937.2 PTGES3P4 4.32 2.01e-05 0.00484 0.34 0.23 Arsenic metabolism; chr10:102827605 chr10:102845595~102845950:+ LIHC cis rs728616 0.867 rs55835350 ENSG00000225484.5 NUTM2B-AS1 -4.32 2.01e-05 0.00484 -0.52 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80041972 chr10:79663088~79826594:- LIHC cis rs728616 0.867 rs79904324 ENSG00000225484.5 NUTM2B-AS1 -4.32 2.01e-05 0.00484 -0.52 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80044932 chr10:79663088~79826594:- LIHC cis rs728616 0.867 rs41297151 ENSG00000225484.5 NUTM2B-AS1 -4.32 2.01e-05 0.00484 -0.52 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80047411 chr10:79663088~79826594:- LIHC cis rs728616 0.867 rs17096197 ENSG00000225484.5 NUTM2B-AS1 -4.32 2.01e-05 0.00484 -0.52 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80048428 chr10:79663088~79826594:- LIHC cis rs6504622 0.721 rs7215903 ENSG00000262879.4 RP11-156P1.3 -4.32 2.02e-05 0.00485 -0.24 -0.23 Orofacial clefts; chr17:47097100 chr17:46984045~47100323:- LIHC cis rs2581828 0.646 rs9861233 ENSG00000242142.1 SERBP1P3 -4.32 2.02e-05 0.00485 -0.3 -0.23 Crohn's disease; chr3:53124815 chr3:53064283~53065091:- LIHC cis rs734999 0.588 rs2764848 ENSG00000225931.3 RP3-395M20.7 -4.32 2.02e-05 0.00485 -0.24 -0.23 Ulcerative colitis; chr1:2599255 chr1:2566410~2569888:+ LIHC cis rs2797160 0.904 rs2326292 ENSG00000237742.5 RP11-624M8.1 -4.32 2.02e-05 0.00485 -0.23 -0.23 Endometrial cancer; chr6:125678528 chr6:125578558~125749190:- LIHC cis rs67311347 1 rs9848083 ENSG00000223797.4 ENTPD3-AS1 -4.32 2.02e-05 0.00485 -0.18 -0.23 Renal cell carcinoma; chr3:40425488 chr3:40313802~40453329:- LIHC cis rs9843304 0.529 rs72996050 ENSG00000244503.1 RP11-278L15.6 4.32 2.02e-05 0.00485 0.23 0.23 Gallstone disease; chr3:149484846 chr3:149494660~149495995:+ LIHC cis rs2998286 1 rs2998286 ENSG00000254635.4 WAC-AS1 -4.32 2.02e-05 0.00485 -0.24 -0.23 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28491444 chr10:28522652~28532743:- LIHC cis rs75920871 0.614 rs117287138 ENSG00000254851.1 RP11-109L13.1 -4.32 2.02e-05 0.00485 -0.48 -0.23 Subjective well-being; chr11:116924163 chr11:117135528~117138582:+ LIHC cis rs6569038 0.557 rs9401118 ENSG00000253194.1 RP11-351A11.1 -4.32 2.02e-05 0.00485 -0.29 -0.23 Epstein-Barr virus copy number in lymphoblastoid cell lines; chr6:119053584 chr6:118934785~119031541:+ LIHC cis rs3091242 0.9 rs669063 ENSG00000261349.1 RP3-465N24.5 -4.32 2.02e-05 0.00486 -0.22 -0.23 Erythrocyte sedimentation rate; chr1:25394663 chr1:25266102~25267136:- LIHC cis rs4650994 1 rs4077194 ENSG00000273384.1 RP5-1098D14.1 -4.32 2.02e-05 0.00486 -0.26 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178564697 chr1:178651706~178652282:+ LIHC cis rs11098499 0.909 rs11723757 ENSG00000260091.1 RP11-33B1.4 -4.32 2.02e-05 0.00486 -0.17 -0.23 Corneal astigmatism; chr4:119378514 chr4:119409333~119410233:+ LIHC cis rs2276314 0.802 rs9963714 ENSG00000278986.1 RP11-723J4.3 -4.32 2.02e-05 0.00486 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:36012093 chr18:35972151~35973916:+ LIHC cis rs2276314 0.802 rs4799838 ENSG00000278986.1 RP11-723J4.3 -4.32 2.02e-05 0.00486 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:36017567 chr18:35972151~35973916:+ LIHC cis rs2276314 0.748 rs4799839 ENSG00000278986.1 RP11-723J4.3 -4.32 2.02e-05 0.00486 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:36017568 chr18:35972151~35973916:+ LIHC cis rs2276314 0.857 rs28375959 ENSG00000278986.1 RP11-723J4.3 -4.32 2.02e-05 0.00486 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:36021571 chr18:35972151~35973916:+ LIHC cis rs11096990 0.634 rs12651217 ENSG00000249207.1 RP11-360F5.1 -4.32 2.03e-05 0.00487 -0.23 -0.23 Cognitive function; chr4:39271964 chr4:39112677~39126818:- LIHC cis rs11098499 0.865 rs11098513 ENSG00000260091.1 RP11-33B1.4 -4.32 2.03e-05 0.00487 -0.17 -0.23 Corneal astigmatism; chr4:119394920 chr4:119409333~119410233:+ LIHC cis rs1160985 1 rs1160985 ENSG00000214855.8 APOC1P1 -4.32 2.03e-05 0.00487 -0.27 -0.23 C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels; chr19:44900155 chr19:44926804~44931386:+ LIHC cis rs8024893 1 rs6493544 ENSG00000270055.1 CTD-3092A11.2 4.32 2.03e-05 0.00487 0.32 0.23 Red cell distribution width; chr15:31245356 chr15:30487963~30490313:+ LIHC cis rs2412819 0.599 rs2470120 ENSG00000275601.1 AC011330.13 -4.32 2.03e-05 0.00488 -0.28 -0.23 Lung cancer; chr15:43636872 chr15:43642389~43643023:- LIHC cis rs67311347 0.713 rs9861194 ENSG00000223797.4 ENTPD3-AS1 4.32 2.03e-05 0.00488 0.19 0.23 Renal cell carcinoma; chr3:40267734 chr3:40313802~40453329:- LIHC cis rs2243480 1 rs466983 ENSG00000232546.1 RP11-458F8.1 -4.32 2.03e-05 0.00488 -0.25 -0.23 Diabetic kidney disease; chr7:66055509 chr7:66848496~66858136:+ LIHC cis rs950169 0.58 rs35516100 ENSG00000225151.9 GOLGA2P7 -4.32 2.04e-05 0.00489 -0.29 -0.23 Schizophrenia; chr15:84652199 chr15:84199311~84230136:- LIHC cis rs950169 0.58 rs62021208 ENSG00000225151.9 GOLGA2P7 -4.32 2.04e-05 0.00489 -0.29 -0.23 Schizophrenia; chr15:84653013 chr15:84199311~84230136:- LIHC cis rs948562 1 rs76435840 ENSG00000280010.1 AP001350.4 4.32 2.04e-05 0.00489 0.4 0.23 Lymphoma; chr11:58518508 chr11:58627435~58628528:+ LIHC cis rs193541 0.545 rs12518979 ENSG00000263432.2 RN7SL689P -4.32 2.04e-05 0.00489 -0.35 -0.23 Glucose homeostasis traits; chr5:122846092 chr5:123022487~123022783:- LIHC cis rs2337406 0.925 rs873533 ENSG00000274576.2 IGHV2-70 -4.32 2.04e-05 0.00489 -0.26 -0.23 Alzheimer's disease (late onset); chr14:106667442 chr14:106770577~106771020:- LIHC cis rs11096990 0.6 rs6835337 ENSG00000249685.1 RP11-360F5.3 -4.32 2.04e-05 0.00489 -0.27 -0.23 Cognitive function; chr4:39281189 chr4:39133913~39135608:+ LIHC cis rs524281 0.682 rs34274349 ENSG00000255320.1 RP11-755F10.1 -4.32 2.04e-05 0.00489 -0.32 -0.23 Electroencephalogram traits; chr11:66030595 chr11:66244840~66246239:- LIHC cis rs524281 0.731 rs730787 ENSG00000255320.1 RP11-755F10.1 -4.32 2.04e-05 0.00489 -0.32 -0.23 Electroencephalogram traits; chr11:66031488 chr11:66244840~66246239:- LIHC cis rs748404 0.631 rs7167882 ENSG00000166763.7 STRCP1 4.32 2.04e-05 0.00489 0.28 0.23 Lung cancer; chr15:43386465 chr15:43699488~43718184:- LIHC cis rs11098499 0.863 rs13136462 ENSG00000260091.1 RP11-33B1.4 -4.32 2.04e-05 0.00489 -0.16 -0.23 Corneal astigmatism; chr4:119622018 chr4:119409333~119410233:+ LIHC cis rs28829049 0.57 rs12060125 ENSG00000270728.1 RP4-657E11.10 4.32 2.04e-05 0.0049 0.21 0.23 QRS duration in Tripanosoma cruzi seropositivity; chr1:19064614 chr1:19297080~19297903:+ LIHC cis rs875971 0.545 rs2460427 ENSG00000228409.4 CCT6P1 4.32 2.04e-05 0.0049 0.19 0.23 Aortic root size; chr7:66154218 chr7:65751142~65763354:+ LIHC cis rs7809950 0.678 rs7803151 ENSG00000238832.1 snoU109 -4.32 2.04e-05 0.0049 -0.29 -0.23 Coronary artery disease; chr7:107293801 chr7:107603363~107603507:+ LIHC cis rs2688482 0.557 rs3103952 ENSG00000185485.13 SDHAP1 4.32 2.04e-05 0.0049 0.26 0.23 Lung disease severity in cystic fibrosis; chr3:195795819 chr3:195959748~195990318:- LIHC cis rs12478296 0.901 rs6731775 ENSG00000261186.2 RP11-341N2.1 -4.32 2.04e-05 0.0049 -0.31 -0.23 Obesity-related traits; chr2:242057292 chr2:242087351~242088457:- LIHC cis rs11096990 0.855 rs2566172 ENSG00000249207.1 RP11-360F5.1 4.32 2.04e-05 0.0049 0.26 0.23 Cognitive function; chr4:39150943 chr4:39112677~39126818:- LIHC cis rs960902 0.818 rs4353628 ENSG00000213553.4 RPLP0P6 -4.32 2.04e-05 0.0049 -0.19 -0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37512369 chr2:38481851~38482804:+ LIHC cis rs3015497 0.616 rs6572678 ENSG00000269906.1 RP11-248J18.2 4.32 2.05e-05 0.00491 0.28 0.23 Mean platelet volume; chr14:50623397 chr14:50662511~50663178:- LIHC cis rs3015497 0.616 rs4901044 ENSG00000269906.1 RP11-248J18.2 4.32 2.05e-05 0.00491 0.28 0.23 Mean platelet volume; chr14:50623577 chr14:50662511~50663178:- LIHC cis rs2929278 0.589 rs2411284 ENSG00000275601.1 AC011330.13 4.32 2.05e-05 0.00491 0.28 0.23 Schizophrenia; chr15:43746701 chr15:43642389~43643023:- LIHC cis rs960902 0.592 rs4503968 ENSG00000213553.4 RPLP0P6 -4.32 2.05e-05 0.00491 -0.19 -0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37507073 chr2:38481851~38482804:+ LIHC cis rs4356203 0.875 rs11024136 ENSG00000260196.1 RP1-239B22.5 -4.32 2.05e-05 0.00491 -0.28 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17042850 chr11:17380649~17383531:+ LIHC cis rs831571 1 rs17069791 ENSG00000280620.1 SCAANT1 4.32 2.05e-05 0.00491 0.36 0.23 Type 2 diabetes; chr3:64066603 chr3:63911518~63911772:- LIHC cis rs7044106 0.762 rs13291660 ENSG00000238181.2 AHCYP2 -4.32 2.05e-05 0.00491 -0.26 -0.23 Hip circumference adjusted for BMI; chr9:120630470 chr9:120720673~120721972:+ LIHC cis rs8028182 0.537 rs4371118 ENSG00000260269.4 CTD-2323K18.1 -4.32 2.05e-05 0.00491 -0.37 -0.23 Sudden cardiac arrest; chr15:75606549 chr15:75527150~75601205:- LIHC cis rs2717559 0.542 rs34147336 ENSG00000253196.1 RP11-706C16.7 -4.32 2.05e-05 0.00491 -0.26 -0.23 Urinary tract infection frequency; chr8:142803453 chr8:142763116~142766427:+ LIHC cis rs11098499 0.722 rs28713555 ENSG00000260091.1 RP11-33B1.4 -4.32 2.05e-05 0.00491 -0.16 -0.23 Corneal astigmatism; chr4:119330840 chr4:119409333~119410233:+ LIHC cis rs11098499 0.743 rs11098501 ENSG00000260091.1 RP11-33B1.4 -4.32 2.05e-05 0.00491 -0.16 -0.23 Corneal astigmatism; chr4:119330862 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs11098502 ENSG00000260091.1 RP11-33B1.4 -4.32 2.05e-05 0.00491 -0.16 -0.23 Corneal astigmatism; chr4:119330908 chr4:119409333~119410233:+ LIHC cis rs11098499 0.708 rs11732686 ENSG00000260091.1 RP11-33B1.4 -4.32 2.05e-05 0.00491 -0.16 -0.23 Corneal astigmatism; chr4:119331175 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs11724409 ENSG00000260091.1 RP11-33B1.4 -4.32 2.05e-05 0.00491 -0.16 -0.23 Corneal astigmatism; chr4:119331206 chr4:119409333~119410233:+ LIHC cis rs4988958 0.565 rs6732138 ENSG00000234389.1 AC007278.3 4.32 2.05e-05 0.00492 0.25 0.23 Asthma (childhood onset); chr2:102393202 chr2:102438713~102440475:+ LIHC cis rs960902 0.592 rs4450582 ENSG00000213553.4 RPLP0P6 -4.32 2.05e-05 0.00492 -0.19 -0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37506998 chr2:38481851~38482804:+ LIHC cis rs2243480 1 rs4718334 ENSG00000230295.1 RP11-458F8.2 4.32 2.05e-05 0.00492 0.23 0.23 Diabetic kidney disease; chr7:66324467 chr7:66880708~66882981:+ LIHC cis rs417065 1 rs72635712 ENSG00000227634.1 RP11-431K24.3 -4.32 2.06e-05 0.00493 -0.31 -0.23 Psoriasis; chr1:8199415 chr1:8208672~8215210:+ LIHC cis rs1005277 0.579 rs2103938 ENSG00000099251.13 HSD17B7P2 4.32 2.06e-05 0.00493 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38205070 chr10:38356380~38378505:+ LIHC cis rs9595908 0.645 rs7983065 ENSG00000212293.1 SNORA16 4.32 2.06e-05 0.00493 0.27 0.23 Body mass index; chr13:32806648 chr13:32420390~32420516:- LIHC cis rs858239 1 rs166663 ENSG00000226816.2 AC005082.12 4.32 2.06e-05 0.00493 0.3 0.23 Cerebrospinal fluid biomarker levels; chr7:23277123 chr7:23206013~23208045:+ LIHC cis rs9388451 0.626 rs3734637 ENSG00000237742.5 RP11-624M8.1 -4.32 2.06e-05 0.00493 -0.21 -0.23 Brugada syndrome; chr6:125760173 chr6:125578558~125749190:- LIHC cis rs875971 0.964 rs6945019 ENSG00000237310.1 GS1-124K5.4 4.32 2.06e-05 0.00493 0.2 0.23 Aortic root size; chr7:66457471 chr7:66493706~66495474:+ LIHC cis rs2032447 0.61 rs189911 ENSG00000242387.1 HIST1H2APS2 4.32 2.06e-05 0.00494 0.29 0.23 Intelligence (multi-trait analysis); chr6:25965714 chr6:25882026~25882395:- LIHC cis rs748404 0.66 rs2467742 ENSG00000166763.7 STRCP1 4.32 2.06e-05 0.00494 0.28 0.23 Lung cancer; chr15:43458039 chr15:43699488~43718184:- LIHC cis rs748404 0.69 rs2244981 ENSG00000166763.7 STRCP1 4.32 2.06e-05 0.00494 0.28 0.23 Lung cancer; chr15:43460553 chr15:43699488~43718184:- LIHC cis rs10129255 0.957 rs10138532 ENSG00000211970.3 IGHV4-61 -4.32 2.06e-05 0.00494 -0.18 -0.23 Kawasaki disease; chr14:106803901 chr14:106639119~106639657:- LIHC cis rs9457247 0.967 rs1794696 ENSG00000227598.1 RP1-167A14.2 -4.32 2.07e-05 0.00495 -0.24 -0.23 Crohn's disease; chr6:166982686 chr6:166969626~166999065:- LIHC cis rs1928295 0.786 rs957512 ENSG00000233569.1 RP11-500B12.1 4.32 2.07e-05 0.00495 0.24 0.23 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117643427 chr9:117648606~117657027:+ LIHC cis rs673078 0.607 rs2036314 ENSG00000275759.1 RP11-131L12.3 -4.32 2.07e-05 0.00495 -0.28 -0.23 Glucose homeostasis traits; chr12:118367132 chr12:118428281~118428870:+ LIHC cis rs6471393 0.861 rs2976372 ENSG00000253848.1 RP11-10N23.5 -4.32 2.07e-05 0.00495 -0.25 -0.23 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93690797 chr8:93741193~93744534:+ LIHC cis rs1499614 1 rs1267818 ENSG00000232546.1 RP11-458F8.1 -4.32 2.07e-05 0.00495 -0.26 -0.23 Gout; chr7:66642037 chr7:66848496~66858136:+ LIHC cis rs13287066 0.669 rs10992728 ENSG00000227603.1 RP11-165J3.6 4.32 2.07e-05 0.00495 0.25 0.23 Intelligence (multi-trait analysis); chr9:93416386 chr9:93435332~93437121:- LIHC cis rs189798 0.738 rs330908 ENSG00000254340.1 RP11-10A14.3 4.32 2.07e-05 0.00495 0.23 0.23 Myopia (pathological); chr8:9137656 chr8:9141424~9145435:+ LIHC cis rs2276314 1 rs9304153 ENSG00000278986.1 RP11-723J4.3 -4.32 2.07e-05 0.00496 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:35982187 chr18:35972151~35973916:+ LIHC cis rs2276314 1 rs9304154 ENSG00000278986.1 RP11-723J4.3 -4.32 2.07e-05 0.00496 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:35982264 chr18:35972151~35973916:+ LIHC cis rs61041384 0.661 rs3759111 ENSG00000256092.2 RP13-942N8.1 4.32 2.07e-05 0.00496 0.35 0.23 Schizophrenia; chr12:123203227 chr12:123363868~123366113:+ LIHC cis rs703842 1 rs2069502 ENSG00000270039.1 RP11-571M6.17 4.32 2.07e-05 0.00496 0.33 0.23 Multiple sclerosis; chr12:57750882 chr12:57803838~57804415:+ LIHC cis rs2581828 0.541 rs2115781 ENSG00000242142.1 SERBP1P3 4.32 2.07e-05 0.00496 0.26 0.23 Crohn's disease; chr3:53097813 chr3:53064283~53065091:- LIHC cis rs3812762 0.917 rs2873297 ENSG00000254860.4 TMEM9B-AS1 -4.32 2.07e-05 0.00496 -0.24 -0.23 Hypospadias; chr11:8769680 chr11:8964675~8977527:+ LIHC cis rs11098499 0.82 rs6829903 ENSG00000260091.1 RP11-33B1.4 -4.32 2.07e-05 0.00496 -0.16 -0.23 Corneal astigmatism; chr4:119585729 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs7669520 ENSG00000260091.1 RP11-33B1.4 -4.32 2.07e-05 0.00496 -0.16 -0.23 Corneal astigmatism; chr4:119594123 chr4:119409333~119410233:+ LIHC cis rs1075265 0.633 rs3731967 ENSG00000233266.1 HMGB1P31 -4.32 2.07e-05 0.00496 -0.27 -0.23 Chronotype;Morning vs. evening chronotype; chr2:53975311 chr2:54051334~54051760:+ LIHC cis rs1799949 0.965 rs8176161 ENSG00000267681.1 CTD-3199J23.6 -4.32 2.08e-05 0.00497 -0.22 -0.23 Menopause (age at onset); chr17:43089373 chr17:43144956~43145255:+ LIHC cis rs1799949 0.894 rs8176160 ENSG00000267681.1 CTD-3199J23.6 -4.32 2.08e-05 0.00497 -0.22 -0.23 Menopause (age at onset); chr17:43089486 chr17:43144956~43145255:+ LIHC cis rs7412746 0.658 rs10305714 ENSG00000231073.1 RP11-316M1.3 -4.32 2.08e-05 0.00497 -0.22 -0.23 Melanoma; chr1:150828179 chr1:150973123~150975534:+ LIHC cis rs11064837 0.504 rs7310536 ENSG00000248636.5 RP11-768F21.1 4.32 2.08e-05 0.00497 0.35 0.23 Schizophrenia; chr12:119616268 chr12:119387987~119668079:- LIHC cis rs11064837 0.504 rs7972445 ENSG00000248636.5 RP11-768F21.1 4.32 2.08e-05 0.00497 0.35 0.23 Schizophrenia; chr12:119617604 chr12:119387987~119668079:- LIHC cis rs13315871 1 rs9850717 ENSG00000272182.1 RP11-802O23.3 4.32 2.08e-05 0.00497 0.53 0.23 Cholesterol, total; chr3:58366148 chr3:58428255~58428815:+ LIHC cis rs1501911 0.588 rs709389 ENSG00000248489.1 CTD-2007H13.3 4.32 2.08e-05 0.00497 0.34 0.23 Lung function (FEV1/FVC); chr5:98994011 chr5:98929171~98995013:+ LIHC cis rs7044106 0.718 rs1981021 ENSG00000238181.2 AHCYP2 -4.32 2.08e-05 0.00497 -0.26 -0.23 Hip circumference adjusted for BMI; chr9:120626115 chr9:120720673~120721972:+ LIHC cis rs7044106 0.734 rs1981020 ENSG00000238181.2 AHCYP2 -4.32 2.08e-05 0.00497 -0.26 -0.23 Hip circumference adjusted for BMI; chr9:120626186 chr9:120720673~120721972:+ LIHC cis rs60733400 0.782 rs4648564 ENSG00000225931.3 RP3-395M20.7 -4.32 2.08e-05 0.00497 -0.24 -0.23 Multiple sclerosis; chr1:2630730 chr1:2566410~2569888:+ LIHC cis rs1005277 0.557 rs2983338 ENSG00000099251.13 HSD17B7P2 4.32 2.08e-05 0.00498 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38261806 chr10:38356380~38378505:+ LIHC cis rs881375 0.678 rs1930782 ENSG00000226752.6 PSMD5-AS1 -4.32 2.08e-05 0.00498 -0.23 -0.23 Rheumatoid arthritis; chr9:120925627 chr9:120824828~120854385:+ LIHC cis rs8064024 0.87 rs6500635 ENSG00000267077.1 RP11-127I20.5 4.32 2.08e-05 0.00498 0.23 0.23 Cancer; chr16:4817564 chr16:4795265~4796532:- LIHC cis rs9450351 0.744 rs9362247 ENSG00000203875.9 SNHG5 -4.32 2.08e-05 0.00498 -0.48 -0.23 Interferon gamma-induced protein 10 levels; chr6:85822546 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs6913958 ENSG00000203875.9 SNHG5 -4.32 2.08e-05 0.00498 -0.48 -0.23 Interferon gamma-induced protein 10 levels; chr6:85825481 chr6:85660950~85678736:- LIHC cis rs6439153 0.967 rs61480393 ENSG00000231305.3 RP11-723O4.2 4.32 2.09e-05 0.00498 0.25 0.23 Pneumococcal bacteremia; chr3:128980916 chr3:128861313~128871540:- LIHC cis rs6439153 1 rs6439153 ENSG00000231305.3 RP11-723O4.2 4.32 2.09e-05 0.00498 0.25 0.23 Pneumococcal bacteremia; chr3:128982287 chr3:128861313~128871540:- LIHC cis rs1005277 0.563 rs2505215 ENSG00000275858.1 RP11-291L22.8 4.32 2.09e-05 0.00499 0.25 0.23 Extrinsic epigenetic age acceleration; chr10:38192345 chr10:38450738~38451069:- LIHC cis rs1005277 0.563 rs2505216 ENSG00000275858.1 RP11-291L22.8 4.32 2.09e-05 0.00499 0.25 0.23 Extrinsic epigenetic age acceleration; chr10:38193902 chr10:38450738~38451069:- LIHC cis rs1005277 0.563 rs2800550 ENSG00000275858.1 RP11-291L22.8 4.32 2.09e-05 0.00499 0.25 0.23 Extrinsic epigenetic age acceleration; chr10:38194001 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2749612 ENSG00000275858.1 RP11-291L22.8 4.32 2.09e-05 0.00499 0.25 0.23 Extrinsic epigenetic age acceleration; chr10:38199682 chr10:38450738~38451069:- LIHC cis rs1400745 0.812 rs72678789 ENSG00000258738.1 RP11-73E17.2 -4.32 2.09e-05 0.00499 -0.28 -0.23 Monocyte count; chr14:34878995 chr14:34874343~34876459:+ LIHC cis rs10822145 1 rs10822145 ENSG00000232075.1 MRPL35P2 -4.32 2.09e-05 0.00499 -0.25 -0.23 Triglycerides; chr10:63174788 chr10:63634317~63634827:- LIHC cis rs2276314 0.857 rs28431958 ENSG00000278986.1 RP11-723J4.3 -4.32 2.09e-05 0.00499 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:35998438 chr18:35972151~35973916:+ LIHC cis rs7580658 0.545 rs59318157 ENSG00000236682.1 AC068282.3 -4.32 2.09e-05 0.00499 -0.28 -0.23 Protein C levels; chr2:127192498 chr2:127389130~127400580:+ LIHC cis rs7702057 0.53 rs17138850 ENSG00000271918.1 CTD-2287O16.5 4.32 2.09e-05 0.005 0.31 0.23 Amyotrophic lateral sclerosis; chr5:116085317 chr5:116083807~116085416:- LIHC cis rs6723226 0.638 rs6543657 ENSG00000276334.1 AL133243.1 4.31 2.09e-05 0.005 0.25 0.23 Intelligence (multi-trait analysis); chr2:32480017 chr2:32521927~32523547:+ LIHC cis rs901683 1 rs9422651 ENSG00000230869.1 CTGLF10P -4.31 2.09e-05 0.005 -0.53 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45552008 chr10:45678692~45700532:+ LIHC cis rs948562 1 rs948562 ENSG00000280010.1 AP001350.4 4.31 2.09e-05 0.005 0.39 0.23 Lymphoma; chr11:58580292 chr11:58627435~58628528:+ LIHC cis rs7208859 0.623 rs9912440 ENSG00000266490.1 CTD-2349P21.9 4.31 2.09e-05 0.005 0.28 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30821754 chr17:30792372~30792833:+ LIHC cis rs2976388 0.609 rs2244152 ENSG00000253741.1 CTD-2292P10.4 -4.31 2.09e-05 0.005 -0.26 -0.23 Urinary tract infection frequency; chr8:142703467 chr8:142702252~142726973:- LIHC cis rs2524005 1 rs2524005 ENSG00000228078.1 HLA-U -4.31 2.1e-05 0.005 -0.31 -0.23 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29934101~29934286:+ LIHC cis rs7193541 0.826 rs56143602 ENSG00000261079.1 RP11-252A24.3 4.31 2.1e-05 0.005 0.25 0.23 Multiple myeloma; chr16:74660794 chr16:74367462~74369826:+ LIHC cis rs11098499 0.754 rs12711071 ENSG00000260091.1 RP11-33B1.4 -4.31 2.1e-05 0.00501 -0.16 -0.23 Corneal astigmatism; chr4:119319779 chr4:119409333~119410233:+ LIHC cis rs6921919 0.638 rs7772827 ENSG00000204709.4 LINC01556 4.31 2.1e-05 0.00501 0.26 0.23 Autism spectrum disorder or schizophrenia; chr6:28333366 chr6:28943877~28944537:+ LIHC cis rs1144713 0.6 rs2683489 ENSG00000276115.1 RP11-817I4.2 -4.31 2.1e-05 0.00501 -0.24 -0.23 Obesity-related traits; chr12:32098247 chr12:32352349~32354144:+ LIHC cis rs7044106 0.762 rs7044226 ENSG00000238181.2 AHCYP2 -4.31 2.1e-05 0.00501 -0.26 -0.23 Hip circumference adjusted for BMI; chr9:120704050 chr9:120720673~120721972:+ LIHC cis rs734999 0.588 rs2843402 ENSG00000225931.3 RP3-395M20.7 -4.31 2.1e-05 0.00501 -0.24 -0.23 Ulcerative colitis; chr1:2597243 chr1:2566410~2569888:+ LIHC cis rs734999 0.588 rs2764842 ENSG00000225931.3 RP3-395M20.7 -4.31 2.1e-05 0.00501 -0.24 -0.23 Ulcerative colitis; chr1:2597753 chr1:2566410~2569888:+ LIHC cis rs9595908 0.622 rs7983267 ENSG00000212293.1 SNORA16 4.31 2.1e-05 0.00501 0.26 0.23 Body mass index; chr13:32806767 chr13:32420390~32420516:- LIHC cis rs2276314 1 rs2298716 ENSG00000278986.1 RP11-723J4.3 -4.31 2.1e-05 0.00501 -0.28 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:35972635 chr18:35972151~35973916:+ LIHC cis rs9595908 0.965 rs11840502 ENSG00000212293.1 SNORA16 4.31 2.1e-05 0.00502 0.26 0.23 Body mass index; chr13:32624572 chr13:32420390~32420516:- LIHC cis rs2739330 0.685 rs4822453 ENSG00000206090.4 AP000350.7 4.31 2.1e-05 0.00502 0.27 0.23 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23939998~23942798:+ LIHC cis rs494453 0.885 rs496296 ENSG00000227811.2 FAM212B-AS1 -4.31 2.1e-05 0.00502 -0.26 -0.23 Osteoporosis-related phenotypes; chr1:111682034 chr1:111739841~111747798:+ LIHC cis rs494453 0.883 rs1099800 ENSG00000227811.2 FAM212B-AS1 -4.31 2.1e-05 0.00502 -0.26 -0.23 Osteoporosis-related phenotypes; chr1:111682961 chr1:111739841~111747798:+ LIHC cis rs2877649 0.793 rs3814810 ENSG00000258744.1 RP11-80A15.1 -4.31 2.1e-05 0.00502 -0.47 -0.23 Smooth-surface caries; chr14:24439189 chr14:24501594~24508688:+ LIHC cis rs901683 1 rs71496622 ENSG00000230869.1 CTGLF10P -4.31 2.11e-05 0.00503 -0.55 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45586140 chr10:45678692~45700532:+ LIHC cis rs11098499 0.71 rs4145952 ENSG00000260091.1 RP11-33B1.4 -4.31 2.11e-05 0.00503 -0.16 -0.23 Corneal astigmatism; chr4:119234651 chr4:119409333~119410233:+ LIHC cis rs734999 0.588 rs2843404 ENSG00000225931.3 RP3-395M20.7 -4.31 2.11e-05 0.00503 -0.24 -0.23 Ulcerative colitis; chr1:2599119 chr1:2566410~2569888:+ LIHC cis rs17818399 0.926 rs7590693 ENSG00000279254.1 RP11-536C12.1 -4.31 2.11e-05 0.00503 -0.28 -0.23 Height; chr2:46596853 chr2:46668870~46670778:+ LIHC cis rs2243480 1 rs2420170 ENSG00000230295.1 RP11-458F8.2 4.31 2.11e-05 0.00503 0.24 0.23 Diabetic kidney disease; chr7:66191066 chr7:66880708~66882981:+ LIHC cis rs5756813 0.688 rs5995498 ENSG00000233360.4 Z83844.1 4.31 2.11e-05 0.00503 0.28 0.23 Optic cup area;Vertical cup-disc ratio; chr22:37800566 chr22:37641832~37658377:- LIHC cis rs5756813 0.661 rs7286550 ENSG00000233360.4 Z83844.1 4.31 2.11e-05 0.00503 0.28 0.23 Optic cup area;Vertical cup-disc ratio; chr22:37800753 chr22:37641832~37658377:- LIHC cis rs7119038 0.818 rs715412 ENSG00000255239.1 AP002954.6 -4.31 2.11e-05 0.00503 -0.33 -0.23 Sjögren's syndrome; chr11:118813901 chr11:118688039~118690600:- LIHC cis rs755249 0.701 rs1180342 ENSG00000182109.6 RP11-69E11.4 -4.31 2.11e-05 0.00504 -0.23 -0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39527206 chr1:39522280~39546187:- LIHC cis rs1799949 0.896 rs35908185 ENSG00000267681.1 CTD-3199J23.6 -4.31 2.11e-05 0.00504 -0.22 -0.23 Menopause (age at onset); chr17:43103094 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs8176130 ENSG00000267681.1 CTD-3199J23.6 -4.31 2.11e-05 0.00504 -0.22 -0.23 Menopause (age at onset); chr17:43106026 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs8176120 ENSG00000267681.1 CTD-3199J23.6 -4.31 2.11e-05 0.00504 -0.22 -0.23 Menopause (age at onset); chr17:43109216 chr17:43144956~43145255:+ LIHC cis rs7131987 1 rs7131987 ENSG00000257176.2 RP11-996F15.2 -4.31 2.11e-05 0.00504 -0.26 -0.23 QT interval; chr12:29253555 chr12:29280418~29317848:- LIHC cis rs11098499 0.863 rs59732491 ENSG00000260091.1 RP11-33B1.4 -4.31 2.11e-05 0.00504 -0.16 -0.23 Corneal astigmatism; chr4:119568433 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs11723090 ENSG00000260091.1 RP11-33B1.4 -4.31 2.11e-05 0.00504 -0.16 -0.23 Corneal astigmatism; chr4:119569437 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs11098532 ENSG00000260091.1 RP11-33B1.4 -4.31 2.11e-05 0.00504 -0.16 -0.23 Corneal astigmatism; chr4:119569571 chr4:119409333~119410233:+ LIHC cis rs1005277 0.522 rs9418276 ENSG00000099251.13 HSD17B7P2 4.31 2.11e-05 0.00504 0.26 0.23 Extrinsic epigenetic age acceleration; chr10:37651188 chr10:38356380~38378505:+ LIHC cis rs1005277 0.522 rs7072977 ENSG00000099251.13 HSD17B7P2 4.31 2.11e-05 0.00504 0.26 0.23 Extrinsic epigenetic age acceleration; chr10:37651512 chr10:38356380~38378505:+ LIHC cis rs13113518 0.812 rs11945371 ENSG00000249700.7 SRD5A3-AS1 4.31 2.11e-05 0.00504 0.26 0.23 Height; chr4:55409063 chr4:55363971~55395847:- LIHC cis rs11951515 0.508 rs10059993 ENSG00000248240.1 RP11-159F24.5 -4.31 2.11e-05 0.00504 -0.28 -0.23 Metabolite levels (X-11787); chr5:43598250 chr5:43515274~43525310:+ LIHC cis rs7208859 0.623 rs122898 ENSG00000264538.5 SUZ12P1 4.31 2.11e-05 0.00504 0.23 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30578236 chr17:30709299~30790908:+ LIHC cis rs2439831 0.85 rs3816792 ENSG00000166763.7 STRCP1 -4.31 2.12e-05 0.00505 -0.33 -0.23 Lung cancer in ever smokers; chr15:43824788 chr15:43699488~43718184:- LIHC cis rs73193808 0.639 rs2832248 ENSG00000212479.2 U3 4.31 2.12e-05 0.00505 0.26 0.23 Coronary artery disease; chr21:29184660 chr21:29180425~29180639:- LIHC cis rs79349575 0.721 rs9904645 ENSG00000248278.1 SUMO2P17 4.31 2.12e-05 0.00505 0.28 0.23 Type 2 diabetes; chr17:48892303 chr17:48874860~48908983:- LIHC cis rs7129556 0.69 rs695046 ENSG00000254459.1 RP11-91P24.7 4.31 2.12e-05 0.00506 0.38 0.23 Weight loss (gastric bypass surgery); chr11:77883308 chr11:77829654~77872262:- LIHC cis rs9467711 0.651 rs2237228 ENSG00000216436.2 HIST1H2APS1 4.31 2.12e-05 0.00506 0.6 0.23 Autism spectrum disorder or schizophrenia; chr6:26104402 chr6:25732497~25732827:+ LIHC cis rs9467711 0.722 rs35825164 ENSG00000216436.2 HIST1H2APS1 4.31 2.12e-05 0.00506 0.6 0.23 Autism spectrum disorder or schizophrenia; chr6:26117176 chr6:25732497~25732827:+ LIHC cis rs9467711 0.651 rs13206443 ENSG00000216436.2 HIST1H2APS1 4.31 2.12e-05 0.00506 0.6 0.23 Autism spectrum disorder or schizophrenia; chr6:26119017 chr6:25732497~25732827:+ LIHC cis rs4792901 0.659 rs8073121 ENSG00000267747.1 RP11-392O1.4 -4.31 2.12e-05 0.00506 -0.27 -0.23 Dupuytren's disease; chr17:43465554 chr17:43544785~43610338:+ LIHC cis rs2072510 0.722 rs2540489 ENSG00000257878.1 RP11-256L6.3 -4.31 2.12e-05 0.00506 -0.2 -0.23 Metabolite levels (small molecules and protein measures); chr12:96032724 chr12:95996521~96011489:+ LIHC cis rs2072510 0.683 rs2246990 ENSG00000257878.1 RP11-256L6.3 -4.31 2.12e-05 0.00506 -0.2 -0.23 Metabolite levels (small molecules and protein measures); chr12:96033524 chr12:95996521~96011489:+ LIHC cis rs10262624 0.967 rs35988560 ENSG00000234286.1 AC006026.13 -4.31 2.12e-05 0.00506 -0.26 -0.23 Schizophrenia; chr7:23878561 chr7:23680195~23680786:- LIHC cis rs860295 0.58 rs12032720 ENSG00000203761.5 MSTO2P -4.31 2.12e-05 0.00506 -0.19 -0.23 Body mass index; chr1:155305169 chr1:155745829~155750137:+ LIHC cis rs11096990 0.634 rs745642 ENSG00000249685.1 RP11-360F5.3 -4.31 2.12e-05 0.00506 -0.27 -0.23 Cognitive function; chr4:39279642 chr4:39133913~39135608:+ LIHC cis rs11096990 0.634 rs2086752 ENSG00000249685.1 RP11-360F5.3 -4.31 2.12e-05 0.00506 -0.27 -0.23 Cognitive function; chr4:39280486 chr4:39133913~39135608:+ LIHC cis rs11096990 0.594 rs2381373 ENSG00000249685.1 RP11-360F5.3 -4.31 2.12e-05 0.00506 -0.27 -0.23 Cognitive function; chr4:39280683 chr4:39133913~39135608:+ LIHC cis rs11096990 0.634 rs6531704 ENSG00000249685.1 RP11-360F5.3 -4.31 2.12e-05 0.00506 -0.27 -0.23 Cognitive function; chr4:39282126 chr4:39133913~39135608:+ LIHC cis rs11096990 0.634 rs7659894 ENSG00000249685.1 RP11-360F5.3 -4.31 2.12e-05 0.00506 -0.27 -0.23 Cognitive function; chr4:39282815 chr4:39133913~39135608:+ LIHC cis rs916888 0.647 rs199523 ENSG00000260075.1 NSFP1 -4.31 2.12e-05 0.00506 -0.28 -0.23 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:46372855~46487141:+ LIHC cis rs7474896 0.583 rs10764144 ENSG00000263064.2 RP11-291L22.7 4.31 2.13e-05 0.00507 0.27 0.23 Obesity (extreme); chr10:37686804 chr10:38448689~38448949:+ LIHC cis rs1015362 0.581 rs4911373 ENSG00000276073.1 RP5-1125A11.7 -4.31 2.13e-05 0.00507 -0.29 -0.23 Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling; chr20:33920952 chr20:33985617~33988989:- LIHC cis rs1015362 0.54 rs2378026 ENSG00000276073.1 RP5-1125A11.7 -4.31 2.13e-05 0.00507 -0.29 -0.23 Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling; chr20:33921845 chr20:33985617~33988989:- LIHC cis rs4700393 0.967 rs921897 ENSG00000272308.1 RP11-231G3.1 -4.31 2.13e-05 0.00507 -0.27 -0.23 Intelligence (multi-trait analysis); chr5:60793310 chr5:60866457~60866935:- LIHC cis rs11874381 0.582 rs8093891 ENSG00000267322.2 SNHG22 4.31 2.13e-05 0.00507 0.27 0.23 C-reactive protein levels or HDL-cholesterol levels (pleiotropy); chr18:49680213 chr18:49814023~49851059:+ LIHC cis rs2281636 0.798 rs3184991 ENSG00000233690.1 EBAG9P1 -4.31 2.13e-05 0.00507 -0.23 -0.23 Obesity-related traits; chr10:99755559 chr10:99697407~99697949:- LIHC cis rs10801727 0.597 rs4658174 ENSG00000225492.5 GBP1P1 -4.31 2.13e-05 0.00507 -0.22 -0.23 Parental extreme longevity (95 years and older); chr1:89446540 chr1:89407679~89426243:+ LIHC cis rs10801727 0.597 rs1599152 ENSG00000225492.5 GBP1P1 -4.31 2.13e-05 0.00507 -0.22 -0.23 Parental extreme longevity (95 years and older); chr1:89448737 chr1:89407679~89426243:+ LIHC cis rs55794721 0.509 rs11249248 ENSG00000224183.1 SDHDP6 -4.31 2.13e-05 0.00508 -0.26 -0.23 Mean corpuscular volume;Plateletcrit; chr1:25426560 chr1:25294164~25294643:- LIHC cis rs875971 0.545 rs7783889 ENSG00000273142.1 RP11-458F8.4 4.31 2.13e-05 0.00508 0.22 0.23 Aortic root size; chr7:66283366 chr7:66902857~66906297:+ LIHC cis rs901683 1 rs9422655 ENSG00000230869.1 CTGLF10P -4.31 2.13e-05 0.00508 -0.54 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45555960 chr10:45678692~45700532:+ LIHC cis rs748404 0.66 rs2444251 ENSG00000166763.7 STRCP1 4.31 2.13e-05 0.00508 0.28 0.23 Lung cancer; chr15:43496397 chr15:43699488~43718184:- LIHC cis rs748404 0.66 rs548704 ENSG00000166763.7 STRCP1 4.31 2.13e-05 0.00508 0.28 0.23 Lung cancer; chr15:43499508 chr15:43699488~43718184:- LIHC cis rs11971779 0.68 rs4732379 ENSG00000273391.1 RP11-634H22.1 4.31 2.13e-05 0.00508 0.21 0.23 Diisocyanate-induced asthma; chr7:139438068 chr7:139359032~139359566:- LIHC cis rs7726839 0.54 rs3792720 ENSG00000271781.1 CTD-2589H19.6 -4.31 2.14e-05 0.00509 -0.34 -0.23 Obesity-related traits; chr5:642913 chr5:675826~676616:+ LIHC cis rs2253762 0.54 rs10887037 ENSG00000276742.1 RP11-500G22.4 4.31 2.14e-05 0.00509 0.36 0.23 Breast cancer; chr10:121997572 chr10:121956782~121957098:+ LIHC cis rs10129255 1 rs4612959 ENSG00000224373.3 IGHV4-59 4.31 2.14e-05 0.00509 0.18 0.23 Kawasaki disease; chr14:106767055 chr14:106627249~106627825:- LIHC cis rs244293 0.831 rs12453699 ENSG00000275710.1 RP11-257O5.4 -4.31 2.14e-05 0.00509 -0.24 -0.23 Menarche (age at onset); chr17:55094485 chr17:54964474~54964679:+ LIHC cis rs2276314 0.857 rs28530656 ENSG00000278986.1 RP11-723J4.3 4.31 2.14e-05 0.0051 0.27 0.23 Endometriosis;Drug-induced torsades de pointes; chr18:36008737 chr18:35972151~35973916:+ LIHC cis rs2749592 0.531 rs1208559 ENSG00000276805.1 RP11-291L22.6 -4.31 2.14e-05 0.0051 -0.27 -0.23 Age-related hearing impairment (SNP x SNP interaction); chr10:37932442 chr10:38451030~38451785:+ LIHC cis rs2808510 0.756 rs6427827 ENSG00000230623.2 RP11-469A15.2 4.31 2.14e-05 0.0051 0.26 0.23 Myopia; chr1:200429259 chr1:200473920~200478293:+ LIHC cis rs4356975 0.932 rs4694611 ENSG00000250919.1 RP11-813N20.3 -4.31 2.14e-05 0.0051 -0.22 -0.23 Obesity-related traits; chr4:69079387 chr4:69027831~69044578:+ LIHC cis rs812925 0.559 rs2600667 ENSG00000212978.6 AC016747.3 -4.31 2.14e-05 0.0051 -0.25 -0.23 Immature fraction of reticulocytes; chr2:61177796 chr2:61141592~61144969:- LIHC cis rs5742933 0.857 rs10931430 ENSG00000253559.1 OSGEPL1-AS1 4.31 2.14e-05 0.0051 0.31 0.23 Ferritin levels; chr2:189677460 chr2:189762704~189765556:+ LIHC cis rs5742933 0.817 rs11679767 ENSG00000253559.1 OSGEPL1-AS1 4.31 2.14e-05 0.0051 0.31 0.23 Ferritin levels; chr2:189681574 chr2:189762704~189765556:+ LIHC cis rs2932538 0.885 rs6693880 ENSG00000225075.1 RP11-426L16.3 4.31 2.15e-05 0.00511 0.29 0.23 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112567639 chr1:112693688~112696621:- LIHC cis rs10912872 0.672 rs7516677 ENSG00000231424.2 RP1-45C12.1 4.31 2.15e-05 0.00511 0.24 0.23 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr1:171372697 chr1:171247580~171251794:- LIHC cis rs651907 0.557 rs12629954 ENSG00000244119.1 PDCL3P4 4.31 2.15e-05 0.00511 0.23 0.23 Colorectal cancer; chr3:101641779 chr3:101712472~101713191:+ LIHC cis rs8040855 0.603 rs10520585 ENSG00000259295.5 CSPG4P12 -4.31 2.15e-05 0.00511 -0.37 -0.23 Bulimia nervosa; chr15:85118275 chr15:85191438~85213905:+ LIHC cis rs193541 0.556 rs30024 ENSG00000263432.2 RN7SL689P 4.31 2.15e-05 0.00511 0.36 0.23 Glucose homeostasis traits; chr5:122949465 chr5:123022487~123022783:- LIHC cis rs193541 0.632 rs30023 ENSG00000263432.2 RN7SL689P 4.31 2.15e-05 0.00511 0.36 0.23 Glucose homeostasis traits; chr5:122949604 chr5:123022487~123022783:- LIHC cis rs10129255 0.879 rs7160512 ENSG00000211970.3 IGHV4-61 -4.31 2.15e-05 0.00511 -0.17 -0.23 Kawasaki disease; chr14:106694574 chr14:106639119~106639657:- LIHC cis rs10129255 0.879 rs7159157 ENSG00000211970.3 IGHV4-61 -4.31 2.15e-05 0.00511 -0.17 -0.23 Kawasaki disease; chr14:106694578 chr14:106639119~106639657:- LIHC cis rs6480314 0.522 rs10762212 ENSG00000233590.1 RP11-153K11.3 4.31 2.15e-05 0.00511 0.36 0.23 Optic nerve measurement (disc area); chr10:68295190 chr10:68233251~68242379:- LIHC cis rs5756813 0.661 rs6000898 ENSG00000233360.4 Z83844.1 4.31 2.15e-05 0.00512 0.28 0.23 Optic cup area;Vertical cup-disc ratio; chr22:37806392 chr22:37641832~37658377:- LIHC cis rs5756813 0.635 rs6000899 ENSG00000233360.4 Z83844.1 4.31 2.15e-05 0.00512 0.28 0.23 Optic cup area;Vertical cup-disc ratio; chr22:37807789 chr22:37641832~37658377:- LIHC cis rs4561483 0.831 rs2018199 ENSG00000261560.1 RP11-166B2.3 -4.31 2.15e-05 0.00512 -0.25 -0.23 Testicular germ cell tumor; chr16:11847111 chr16:11881075~11882569:- LIHC cis rs295490 0.748 rs17494356 ENSG00000272656.1 RP11-219D15.3 4.31 2.15e-05 0.00512 0.68 0.23 PR interval in Tripanosoma cruzi seropositivity; chr3:139465126 chr3:139349024~139349371:- LIHC cis rs651907 0.557 rs62284198 ENSG00000244119.1 PDCL3P4 4.31 2.15e-05 0.00512 0.23 0.23 Colorectal cancer; chr3:101755855 chr3:101712472~101713191:+ LIHC cis rs4718428 1 rs1830070 ENSG00000273142.1 RP11-458F8.4 -4.31 2.15e-05 0.00512 -0.22 -0.23 Corneal structure; chr7:66884684 chr7:66902857~66906297:+ LIHC cis rs1005277 0.529 rs1780125 ENSG00000099251.13 HSD17B7P2 4.31 2.15e-05 0.00512 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38242448 chr10:38356380~38378505:+ LIHC cis rs1005277 0.502 rs2800484 ENSG00000099251.13 HSD17B7P2 4.31 2.15e-05 0.00512 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38253487 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2800485 ENSG00000099251.13 HSD17B7P2 4.31 2.15e-05 0.00512 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38253660 chr10:38356380~38378505:+ LIHC cis rs2337406 0.714 rs7152055 ENSG00000274576.2 IGHV2-70 -4.31 2.16e-05 0.00513 -0.25 -0.23 Alzheimer's disease (late onset); chr14:106818996 chr14:106770577~106771020:- LIHC cis rs12946454 0.727 rs4792858 ENSG00000267288.2 RP13-890H12.2 -4.31 2.16e-05 0.00513 -0.25 -0.23 Systolic blood pressure; chr17:45167333 chr17:45168800~45171584:- LIHC cis rs734999 0.545 rs6666430 ENSG00000225931.3 RP3-395M20.7 4.31 2.16e-05 0.00513 0.24 0.23 Ulcerative colitis; chr1:2782407 chr1:2566410~2569888:+ LIHC cis rs11096990 0.576 rs2008679 ENSG00000249207.1 RP11-360F5.1 4.31 2.16e-05 0.00513 0.23 0.23 Cognitive function; chr4:39266385 chr4:39112677~39126818:- LIHC cis rs875971 0.545 rs17138156 ENSG00000228409.4 CCT6P1 -4.31 2.16e-05 0.00514 -0.19 -0.23 Aortic root size; chr7:66249708 chr7:65751142~65763354:+ LIHC cis rs11098499 0.644 rs3806808 ENSG00000260091.1 RP11-33B1.4 -4.31 2.16e-05 0.00514 -0.16 -0.23 Corneal astigmatism; chr4:119629930 chr4:119409333~119410233:+ LIHC cis rs8040855 0.627 rs12909971 ENSG00000259295.5 CSPG4P12 4.31 2.16e-05 0.00514 0.35 0.23 Bulimia nervosa; chr15:85045767 chr15:85191438~85213905:+ LIHC cis rs6500637 0.631 rs12921187 ENSG00000267077.1 RP11-127I20.5 -4.31 2.16e-05 0.00514 -0.24 -0.23 Cancer; chr16:4893018 chr16:4795265~4796532:- LIHC cis rs11096990 0.634 rs2276888 ENSG00000249207.1 RP11-360F5.1 4.31 2.16e-05 0.00514 0.23 0.23 Cognitive function; chr4:39278287 chr4:39112677~39126818:- LIHC cis rs9322193 0.607 rs9383941 ENSG00000216906.2 RP11-350J20.9 -4.31 2.16e-05 0.00514 -0.24 -0.23 Lung cancer; chr6:149912100 chr6:149904243~149906418:+ LIHC cis rs77204473 0.655 rs11216183 ENSG00000254851.1 RP11-109L13.1 4.31 2.16e-05 0.00514 0.43 0.23 Sum eosinophil basophil counts;Eosinophil counts; chr11:116910829 chr11:117135528~117138582:+ LIHC cis rs11098499 0.644 rs7693919 ENSG00000260091.1 RP11-33B1.4 -4.31 2.17e-05 0.00515 -0.16 -0.23 Corneal astigmatism; chr4:119619416 chr4:119409333~119410233:+ LIHC cis rs875971 0.545 rs1796222 ENSG00000273142.1 RP11-458F8.4 -4.31 2.17e-05 0.00515 -0.21 -0.23 Aortic root size; chr7:66592167 chr7:66902857~66906297:+ LIHC cis rs55794721 0.509 rs2375313 ENSG00000261349.1 RP3-465N24.5 -4.31 2.17e-05 0.00515 -0.22 -0.23 Mean corpuscular volume;Plateletcrit; chr1:25421744 chr1:25266102~25267136:- LIHC cis rs748404 0.66 rs690012 ENSG00000166763.7 STRCP1 4.31 2.17e-05 0.00515 0.28 0.23 Lung cancer; chr15:43427557 chr15:43699488~43718184:- LIHC cis rs11098499 0.863 rs13140391 ENSG00000260091.1 RP11-33B1.4 -4.31 2.17e-05 0.00516 -0.16 -0.23 Corneal astigmatism; chr4:119582282 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs13140409 ENSG00000260091.1 RP11-33B1.4 -4.31 2.17e-05 0.00516 -0.16 -0.23 Corneal astigmatism; chr4:119582305 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs6833334 ENSG00000260091.1 RP11-33B1.4 -4.31 2.17e-05 0.00516 -0.16 -0.23 Corneal astigmatism; chr4:119583072 chr4:119409333~119410233:+ LIHC cis rs6445975 0.666 rs11710823 ENSG00000272360.1 RP11-359I18.5 4.31 2.17e-05 0.00516 0.3 0.23 Systemic lupus erythematosus; chr3:58410766 chr3:58490830~58491291:- LIHC cis rs11233413 0.829 rs11233422 ENSG00000246067.6 RAB30-AS1 -4.31 2.17e-05 0.00516 -0.3 -0.23 Economic and political preferences (feminism/equality); chr11:83019480 chr11:83072066~83106719:+ LIHC cis rs1799949 1 rs8176103 ENSG00000267681.1 CTD-3199J23.6 -4.31 2.18e-05 0.00517 -0.22 -0.23 Menopause (age at onset); chr17:43115033 chr17:43144956~43145255:+ LIHC cis rs960902 0.561 rs4517954 ENSG00000213553.4 RPLP0P6 -4.31 2.18e-05 0.00517 -0.19 -0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37507278 chr2:38481851~38482804:+ LIHC cis rs10129255 0.957 rs17113284 ENSG00000223648.3 IGHV3-64 -4.31 2.18e-05 0.00517 -0.17 -0.23 Kawasaki disease; chr14:106684476 chr14:106643132~106658258:- LIHC cis rs11722228 0.522 rs7681250 ENSG00000261490.1 RP11-448G15.3 4.31 2.18e-05 0.00518 0.29 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10131389 chr4:10068089~10073019:- LIHC cis rs11722228 0.522 rs7662229 ENSG00000261490.1 RP11-448G15.3 4.31 2.18e-05 0.00518 0.29 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10131390 chr4:10068089~10073019:- LIHC cis rs10262624 0.967 rs10229233 ENSG00000234286.1 AC006026.13 -4.31 2.18e-05 0.00518 -0.25 -0.23 Schizophrenia; chr7:23867900 chr7:23680195~23680786:- LIHC cis rs10262624 1 rs10245161 ENSG00000234286.1 AC006026.13 -4.31 2.18e-05 0.00518 -0.25 -0.23 Schizophrenia; chr7:23868073 chr7:23680195~23680786:- LIHC cis rs6901152 0.508 rs1424926 ENSG00000217648.1 RP1-95L4.4 -4.31 2.18e-05 0.00518 -0.27 -0.23 Acute lymphoblastic leukemia (childhood); chr6:143366538 chr6:143342246~143343383:+ LIHC cis rs7119038 0.865 rs4936443 ENSG00000255239.1 AP002954.6 4.31 2.18e-05 0.00518 0.33 0.23 Sjögren's syndrome; chr11:118870155 chr11:118688039~118690600:- LIHC cis rs11098499 0.863 rs11098531 ENSG00000260091.1 RP11-33B1.4 -4.31 2.18e-05 0.00518 -0.16 -0.23 Corneal astigmatism; chr4:119543846 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs28718422 ENSG00000260091.1 RP11-33B1.4 -4.31 2.18e-05 0.00518 -0.16 -0.23 Corneal astigmatism; chr4:119545149 chr4:119409333~119410233:+ LIHC cis rs11098499 0.818 rs12498599 ENSG00000260091.1 RP11-33B1.4 -4.31 2.18e-05 0.00518 -0.16 -0.23 Corneal astigmatism; chr4:119547348 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs10009626 ENSG00000260091.1 RP11-33B1.4 -4.31 2.18e-05 0.00518 -0.16 -0.23 Corneal astigmatism; chr4:119548850 chr4:119409333~119410233:+ LIHC cis rs41313321 0.541 rs1468648 ENSG00000272696.1 RP11-339B21.13 -4.3 2.18e-05 0.00519 -0.3 -0.23 Coenzyme Q10 levels; chr9:128295706 chr9:128316337~128316909:+ LIHC cis rs9876781 1 rs898225 ENSG00000229759.1 MRPS18AP1 -4.3 2.18e-05 0.00519 -0.24 -0.23 Longevity; chr3:48371689 chr3:48256350~48256938:- LIHC cis rs75920871 0.764 rs74428560 ENSG00000254851.1 RP11-109L13.1 -4.3 2.19e-05 0.00519 -0.46 -0.23 Subjective well-being; chr11:117119266 chr11:117135528~117138582:+ LIHC cis rs2749592 0.611 rs176888 ENSG00000263064.2 RP11-291L22.7 4.3 2.19e-05 0.00519 0.24 0.23 Age-related hearing impairment (SNP x SNP interaction); chr10:38117233 chr10:38448689~38448949:+ LIHC cis rs1577917 1 rs10944170 ENSG00000234155.1 RP11-30P6.6 4.3 2.19e-05 0.0052 0.3 0.23 Response to antipsychotic treatment; chr6:85975751 chr6:85387219~85390186:- LIHC cis rs6504622 0.539 rs4968248 ENSG00000263766.4 RP11-580I16.2 4.3 2.19e-05 0.0052 0.26 0.23 Orofacial clefts; chr17:46915762 chr17:47603860~47649420:- LIHC cis rs9457247 1 rs398278 ENSG00000227598.1 RP1-167A14.2 -4.3 2.19e-05 0.0052 -0.24 -0.23 Crohn's disease; chr6:166974681 chr6:166969626~166999065:- LIHC cis rs11971779 0.941 rs7802779 ENSG00000273391.1 RP11-634H22.1 4.3 2.19e-05 0.0052 0.22 0.23 Diisocyanate-induced asthma; chr7:139437833 chr7:139359032~139359566:- LIHC cis rs4713118 0.513 rs149989 ENSG00000219392.1 RP1-265C24.5 -4.3 2.19e-05 0.0052 -0.3 -0.23 Parkinson's disease; chr6:28030406 chr6:28115628~28116551:+ LIHC cis rs4713118 0.513 rs149941 ENSG00000219392.1 RP1-265C24.5 -4.3 2.19e-05 0.0052 -0.3 -0.23 Parkinson's disease; chr6:28033255 chr6:28115628~28116551:+ LIHC cis rs4713118 0.513 rs149942 ENSG00000219392.1 RP1-265C24.5 -4.3 2.19e-05 0.0052 -0.3 -0.23 Parkinson's disease; chr6:28033832 chr6:28115628~28116551:+ LIHC cis rs4713118 0.513 rs149944 ENSG00000219392.1 RP1-265C24.5 -4.3 2.19e-05 0.0052 -0.3 -0.23 Parkinson's disease; chr6:28035040 chr6:28115628~28116551:+ LIHC cis rs4713118 0.513 rs149945 ENSG00000219392.1 RP1-265C24.5 -4.3 2.19e-05 0.0052 -0.3 -0.23 Parkinson's disease; chr6:28035075 chr6:28115628~28116551:+ LIHC cis rs1005277 0.579 rs932538 ENSG00000276805.1 RP11-291L22.6 4.3 2.19e-05 0.0052 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38092386 chr10:38451030~38451785:+ LIHC cis rs1005277 0.541 rs2472177 ENSG00000276805.1 RP11-291L22.6 4.3 2.19e-05 0.0052 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38095087 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2472178 ENSG00000276805.1 RP11-291L22.6 4.3 2.19e-05 0.0052 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38095822 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474572 ENSG00000276805.1 RP11-291L22.6 4.3 2.19e-05 0.0052 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38096388 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2505198 ENSG00000276805.1 RP11-291L22.6 4.3 2.19e-05 0.0052 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38104255 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2008449 ENSG00000276805.1 RP11-291L22.6 -4.3 2.19e-05 0.0052 -0.27 -0.23 Extrinsic epigenetic age acceleration; chr10:38125276 chr10:38451030~38451785:+ LIHC cis rs56080343 0.515 rs73222056 ENSG00000275409.1 RP11-131L12.4 -4.3 2.19e-05 0.0052 -0.31 -0.23 Neuroticism; chr12:118215875 chr12:118430147~118430699:+ LIHC cis rs6480314 0.831 rs7080267 ENSG00000233590.1 RP11-153K11.3 -4.3 2.19e-05 0.0052 -0.32 -0.23 Optic nerve measurement (disc area); chr10:68220993 chr10:68233251~68242379:- LIHC cis rs673078 0.66 rs61945176 ENSG00000275409.1 RP11-131L12.4 -4.3 2.19e-05 0.0052 -0.28 -0.23 Glucose homeostasis traits; chr12:118204735 chr12:118430147~118430699:+ LIHC cis rs7985 0.935 rs4280 ENSG00000244625.4 MIATNB 4.3 2.19e-05 0.00521 0.25 0.23 Electroencephalogram traits; chr22:26671082 chr22:26672767~26780207:+ LIHC cis rs1023500 1 rs6002552 ENSG00000237037.8 NDUFA6-AS1 -4.3 2.19e-05 0.00521 -0.31 -0.23 Schizophrenia; chr22:41942347 chr22:42090931~42137742:+ LIHC cis rs6142102 0.961 rs6059587 ENSG00000275784.1 RP5-1125A11.6 -4.3 2.2e-05 0.00521 -0.26 -0.23 Skin pigmentation; chr20:33955120 chr20:33989480~33991818:- LIHC cis rs4578769 0.879 rs12963622 ENSG00000266850.1 RP11-370A5.1 4.3 2.2e-05 0.00521 0.26 0.23 Eosinophil percentage of white cells; chr18:22859594 chr18:22723491~22907721:- LIHC cis rs4578769 0.879 rs7241050 ENSG00000266850.1 RP11-370A5.1 4.3 2.2e-05 0.00521 0.26 0.23 Eosinophil percentage of white cells; chr18:22860300 chr18:22723491~22907721:- LIHC cis rs1023500 0.505 rs134878 ENSG00000205702.9 CYP2D7 4.3 2.2e-05 0.00521 0.23 0.23 Schizophrenia; chr22:42267868 chr22:42140203~42144577:- LIHC cis rs2735413 0.958 rs7192416 ENSG00000276007.1 RP11-358L22.3 -4.3 2.2e-05 0.00521 -0.26 -0.23 Systolic blood pressure (alcohol consumption interaction); chr16:78029246 chr16:78123243~78124332:+ LIHC cis rs4356975 0.932 rs4694612 ENSG00000250919.1 RP11-813N20.3 -4.3 2.2e-05 0.00521 -0.22 -0.23 Obesity-related traits; chr4:69079446 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs56879009 ENSG00000250919.1 RP11-813N20.3 -4.3 2.2e-05 0.00521 -0.22 -0.23 Obesity-related traits; chr4:69079589 chr4:69027831~69044578:+ LIHC cis rs3812762 0.843 rs2292046 ENSG00000254860.4 TMEM9B-AS1 -4.3 2.2e-05 0.00521 -0.24 -0.23 Hypospadias; chr11:8785632 chr11:8964675~8977527:+ LIHC cis rs2243480 1 rs1723270 ENSG00000228409.4 CCT6P1 4.3 2.2e-05 0.00521 0.25 0.23 Diabetic kidney disease; chr7:66004843 chr7:65751142~65763354:+ LIHC cis rs7208859 0.562 rs11650923 ENSG00000266490.1 CTD-2349P21.9 4.3 2.2e-05 0.00521 0.28 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30681149 chr17:30792372~30792833:+ LIHC cis rs6472235 0.681 rs34174890 ENSG00000272010.1 CTD-3025N20.3 -4.3 2.2e-05 0.00521 -0.31 -0.23 Plateletcrit;Myopia (pathological); chr8:65954892 chr8:65591850~65592472:- LIHC cis rs6472235 0.681 rs67768803 ENSG00000272010.1 CTD-3025N20.3 -4.3 2.2e-05 0.00521 -0.31 -0.23 Plateletcrit;Myopia (pathological); chr8:65955957 chr8:65591850~65592472:- LIHC cis rs6472235 0.681 rs66644630 ENSG00000272010.1 CTD-3025N20.3 -4.3 2.2e-05 0.00521 -0.31 -0.23 Plateletcrit;Myopia (pathological); chr8:65956483 chr8:65591850~65592472:- LIHC cis rs9450351 0.744 rs9450313 ENSG00000203875.9 SNHG5 -4.3 2.2e-05 0.00522 -0.48 -0.23 Interferon gamma-induced protein 10 levels; chr6:85684419 chr6:85660950~85678736:- LIHC cis rs9353324 1 rs9351066 ENSG00000203875.9 SNHG5 -4.3 2.2e-05 0.00522 -0.48 -0.23 Interferon gamma-induced protein 10 levels; chr6:85689099 chr6:85660950~85678736:- LIHC cis rs1223397 0.938 rs35511719 ENSG00000215022.6 RP1-257A7.4 -4.3 2.2e-05 0.00522 -0.3 -0.23 Blood pressure; chr6:13282210 chr6:13264861~13295586:- LIHC cis rs7923609 1 rs2393969 ENSG00000232075.1 MRPL35P2 -4.3 2.2e-05 0.00522 -0.25 -0.23 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63380680 chr10:63634317~63634827:- LIHC cis rs709400 0.93 rs57447494 ENSG00000269958.1 RP11-73M18.8 4.3 2.2e-05 0.00522 0.31 0.23 Body mass index; chr14:103568232 chr14:103696353~103697163:+ LIHC cis rs42490 0.576 rs388866 ENSG00000251136.7 RP11-37B2.1 -4.3 2.2e-05 0.00522 -0.2 -0.23 Leprosy; chr8:89856604 chr8:89609409~89757727:- LIHC cis rs1577917 0.883 rs2782263 ENSG00000234155.1 RP11-30P6.6 4.3 2.2e-05 0.00522 0.28 0.23 Response to antipsychotic treatment; chr6:86081589 chr6:85387219~85390186:- LIHC cis rs2243480 1 rs316327 ENSG00000230295.1 RP11-458F8.2 4.3 2.2e-05 0.00522 0.24 0.23 Diabetic kidney disease; chr7:66144214 chr7:66880708~66882981:+ LIHC cis rs7412746 0.634 rs7521592 ENSG00000231073.1 RP11-316M1.3 4.3 2.2e-05 0.00522 0.24 0.23 Melanoma; chr1:150849215 chr1:150973123~150975534:+ LIHC cis rs6430585 0.528 rs309113 ENSG00000231890.6 DARS-AS1 -4.3 2.2e-05 0.00522 -0.31 -0.23 Corneal structure; chr2:135979890 chr2:135985176~136022593:+ LIHC cis rs2274273 0.624 rs11158034 ENSG00000258413.1 RP11-665C16.6 -4.3 2.2e-05 0.00523 -0.28 -0.23 Protein biomarker; chr14:55286842 chr14:55262767~55272075:- LIHC cis rs2274273 0.624 rs11848456 ENSG00000258413.1 RP11-665C16.6 -4.3 2.2e-05 0.00523 -0.28 -0.23 Protein biomarker; chr14:55288674 chr14:55262767~55272075:- LIHC cis rs6430585 0.528 rs309133 ENSG00000231890.6 DARS-AS1 -4.3 2.2e-05 0.00523 -0.31 -0.23 Corneal structure; chr2:135994272 chr2:135985176~136022593:+ LIHC cis rs2243480 1 rs34970380 ENSG00000228409.4 CCT6P1 4.3 2.2e-05 0.00523 0.25 0.23 Diabetic kidney disease; chr7:65966506 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs73148097 ENSG00000228409.4 CCT6P1 4.3 2.2e-05 0.00523 0.25 0.23 Diabetic kidney disease; chr7:65966800 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs906134 ENSG00000228409.4 CCT6P1 4.3 2.2e-05 0.00523 0.25 0.23 Diabetic kidney disease; chr7:65979301 chr7:65751142~65763354:+ LIHC cis rs2948294 0.588 rs12544596 ENSG00000253981.4 ALG1L13P 4.3 2.2e-05 0.00523 0.26 0.23 Red cell distribution width; chr8:8258824 chr8:8236003~8244667:- LIHC cis rs9353324 1 rs7771366 ENSG00000203875.9 SNHG5 -4.3 2.2e-05 0.00523 -0.48 -0.23 Interferon gamma-induced protein 10 levels; chr6:85582193 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs6902638 ENSG00000203875.9 SNHG5 -4.3 2.2e-05 0.00523 -0.48 -0.23 Interferon gamma-induced protein 10 levels; chr6:85608881 chr6:85660950~85678736:- LIHC cis rs748404 0.69 rs2467737 ENSG00000166763.7 STRCP1 4.3 2.21e-05 0.00523 0.28 0.23 Lung cancer; chr15:43444990 chr15:43699488~43718184:- LIHC cis rs2797160 0.904 rs1739370 ENSG00000237742.5 RP11-624M8.1 4.3 2.21e-05 0.00524 0.23 0.23 Endometrial cancer; chr6:125690085 chr6:125578558~125749190:- LIHC cis rs2744375 0.6 rs2008748 ENSG00000261189.1 RP3-512B11.3 4.3 2.21e-05 0.00524 0.29 0.23 Resting heart rate; chr6:7551445 chr6:7540451~7541338:- LIHC cis rs1799949 1 rs3950989 ENSG00000267681.1 CTD-3199J23.6 -4.3 2.21e-05 0.00524 -0.22 -0.23 Menopause (age at onset); chr17:43085936 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs2070834 ENSG00000267681.1 CTD-3199J23.6 -4.3 2.21e-05 0.00524 -0.22 -0.23 Menopause (age at onset); chr17:43090268 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs16942 ENSG00000267681.1 CTD-3199J23.6 -4.3 2.21e-05 0.00524 -0.22 -0.23 Menopause (age at onset); chr17:43091983 chr17:43144956~43145255:+ LIHC cis rs11690935 0.632 rs1607254 ENSG00000228389.1 AC068039.4 -4.3 2.21e-05 0.00524 -0.28 -0.23 Schizophrenia; chr2:171770042 chr2:171773482~171775844:+ LIHC cis rs12701220 0.947 rs1007765 ENSG00000229043.2 AC091729.9 -4.3 2.21e-05 0.00524 -0.33 -0.23 Bronchopulmonary dysplasia; chr7:993169 chr7:1160374~1165267:+ LIHC cis rs2276314 0.857 rs3737474 ENSG00000278986.1 RP11-723J4.3 -4.3 2.22e-05 0.00525 -0.27 -0.23 Endometriosis;Drug-induced torsades de pointes; chr18:36033632 chr18:35972151~35973916:+ LIHC cis rs2439831 0.867 rs45585139 ENSG00000166763.7 STRCP1 4.3 2.22e-05 0.00525 0.37 0.23 Lung cancer in ever smokers; chr15:43408229 chr15:43699488~43718184:- LIHC cis rs12304921 0.683 rs56060103 ENSG00000277201.1 AC087884.1 4.3 2.22e-05 0.00525 0.27 0.23 Type 2 diabetes; chr12:51058879 chr12:51049921~51050025:+ LIHC cis rs3812762 0.879 rs1079452 ENSG00000254860.4 TMEM9B-AS1 4.3 2.22e-05 0.00525 0.24 0.23 Hypospadias; chr11:8757625 chr11:8964675~8977527:+ LIHC cis rs950169 0.65 rs12902052 ENSG00000259295.5 CSPG4P12 4.3 2.22e-05 0.00525 0.32 0.23 Schizophrenia; chr15:84582607 chr15:85191438~85213905:+ LIHC cis rs193541 0.593 rs30042 ENSG00000263432.2 RN7SL689P 4.3 2.22e-05 0.00525 0.36 0.23 Glucose homeostasis traits; chr5:122936946 chr5:123022487~123022783:- LIHC cis rs4356975 0.932 rs7662632 ENSG00000250919.1 RP11-813N20.3 -4.3 2.22e-05 0.00526 -0.22 -0.23 Obesity-related traits; chr4:69062256 chr4:69027831~69044578:+ LIHC cis rs10510102 0.748 rs11200297 ENSG00000226864.1 ATE1-AS1 4.3 2.22e-05 0.00526 0.39 0.23 Breast cancer; chr10:121972916 chr10:121928312~121951965:+ LIHC cis rs11098499 0.826 rs4472123 ENSG00000260091.1 RP11-33B1.4 -4.3 2.22e-05 0.00526 -0.16 -0.23 Corneal astigmatism; chr4:119315475 chr4:119409333~119410233:+ LIHC cis rs3758785 0.679 rs11819857 ENSG00000255893.1 RP11-685N10.1 -4.3 2.22e-05 0.00526 -0.27 -0.23 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94495070 chr11:94472908~94473570:- LIHC cis rs1062177 1 rs12518722 ENSG00000253921.1 CTB-113P19.3 -4.3 2.22e-05 0.00526 -0.27 -0.23 Preschool internalizing problems; chr5:151851899 chr5:151753992~151767247:+ LIHC cis rs875971 0.545 rs1909508 ENSG00000273142.1 RP11-458F8.4 4.3 2.22e-05 0.00526 0.22 0.23 Aortic root size; chr7:66301366 chr7:66902857~66906297:+ LIHC cis rs1115240 0.685 rs1950409 ENSG00000257842.4 NOVA1-AS1 4.3 2.22e-05 0.00526 0.23 0.23 Educational attainment (years of education); chr14:26594861 chr14:26598412~26806467:+ LIHC cis rs11098499 0.955 rs1397608 ENSG00000260091.1 RP11-33B1.4 -4.3 2.23e-05 0.00527 -0.17 -0.23 Corneal astigmatism; chr4:119240589 chr4:119409333~119410233:+ LIHC cis rs11098499 0.955 rs7684942 ENSG00000260091.1 RP11-33B1.4 -4.3 2.23e-05 0.00527 -0.17 -0.23 Corneal astigmatism; chr4:119241046 chr4:119409333~119410233:+ LIHC cis rs11098499 0.779 rs7699346 ENSG00000260091.1 RP11-33B1.4 -4.3 2.23e-05 0.00527 -0.16 -0.23 Corneal astigmatism; chr4:119389387 chr4:119409333~119410233:+ LIHC cis rs2274273 0.624 rs7152390 ENSG00000258413.1 RP11-665C16.6 -4.3 2.23e-05 0.00527 -0.28 -0.23 Protein biomarker; chr14:55344983 chr14:55262767~55272075:- LIHC cis rs2274273 0.588 rs9919923 ENSG00000258413.1 RP11-665C16.6 -4.3 2.23e-05 0.00527 -0.28 -0.23 Protein biomarker; chr14:55347181 chr14:55262767~55272075:- LIHC cis rs2274273 0.588 rs9919932 ENSG00000258413.1 RP11-665C16.6 -4.3 2.23e-05 0.00527 -0.28 -0.23 Protein biomarker; chr14:55347362 chr14:55262767~55272075:- LIHC cis rs17818399 0.633 rs2242033 ENSG00000279254.1 RP11-536C12.1 -4.3 2.23e-05 0.00527 -0.27 -0.23 Height; chr2:46615271 chr2:46668870~46670778:+ LIHC cis rs27434 0.605 rs1230366 ENSG00000272109.1 CTD-2260A17.3 -4.3 2.23e-05 0.00527 -0.31 -0.23 Ankylosing spondylitis; chr5:96859577 chr5:96804353~96806105:+ LIHC cis rs72627509 0.638 rs12648928 ENSG00000269949.1 RP11-738E22.3 4.3 2.23e-05 0.00527 0.32 0.23 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57036340 chr4:56960927~56961373:- LIHC cis rs734999 0.588 rs10910099 ENSG00000225931.3 RP3-395M20.7 -4.3 2.23e-05 0.00527 -0.24 -0.23 Ulcerative colitis; chr1:2602113 chr1:2566410~2569888:+ LIHC cis rs1247318 0.806 rs638141 ENSG00000243831.1 RP1-81D8.4 4.3 2.23e-05 0.00527 0.33 0.23 Aging; chr6:160940856 chr6:160666228~160676523:- LIHC cis rs113084984 0.597 rs10803739 ENSG00000271952.1 RP11-245G13.2 -4.3 2.23e-05 0.00527 -0.29 -0.23 Breast cancer; chr2:11527501 chr2:10878269~10885118:+ LIHC cis rs6142102 0.602 rs4911396 ENSG00000275784.1 RP5-1125A11.6 -4.3 2.23e-05 0.00527 -0.24 -0.23 Skin pigmentation; chr20:33992139 chr20:33989480~33991818:- LIHC cis rs948562 0.947 rs76985515 ENSG00000280010.1 AP001350.4 4.3 2.23e-05 0.00527 0.41 0.23 Lymphoma; chr11:58604321 chr11:58627435~58628528:+ LIHC cis rs948562 0.947 rs7482383 ENSG00000280010.1 AP001350.4 4.3 2.23e-05 0.00527 0.41 0.23 Lymphoma; chr11:58602225 chr11:58627435~58628528:+ LIHC cis rs948562 0.947 rs78176302 ENSG00000280010.1 AP001350.4 4.3 2.23e-05 0.00527 0.41 0.23 Lymphoma; chr11:58615176 chr11:58627435~58628528:+ LIHC cis rs948562 0.947 rs11541682 ENSG00000280010.1 AP001350.4 4.3 2.23e-05 0.00527 0.41 0.23 Lymphoma; chr11:58618279 chr11:58627435~58628528:+ LIHC cis rs79349575 0.594 rs1985785 ENSG00000248278.1 SUMO2P17 4.3 2.23e-05 0.00528 0.28 0.23 Type 2 diabetes; chr17:48890426 chr17:48874860~48908983:- LIHC cis rs79349575 0.685 rs1124829 ENSG00000248278.1 SUMO2P17 4.3 2.23e-05 0.00528 0.28 0.23 Type 2 diabetes; chr17:48890435 chr17:48874860~48908983:- LIHC cis rs79349575 0.721 rs1008834 ENSG00000248278.1 SUMO2P17 4.3 2.23e-05 0.00528 0.28 0.23 Type 2 diabetes; chr17:48890646 chr17:48874860~48908983:- LIHC cis rs597539 0.652 rs559032 ENSG00000250508.1 RP11-757G1.6 -4.3 2.23e-05 0.00528 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68943379 chr11:68870664~68874542:+ LIHC cis rs1501911 0.611 rs10041261 ENSG00000248489.1 CTD-2007H13.3 -4.3 2.23e-05 0.00528 -0.34 -0.23 Lung function (FEV1/FVC); chr5:99023435 chr5:98929171~98995013:+ LIHC cis rs893363 0.559 rs877484 ENSG00000271916.1 RP11-884K10.6 4.3 2.23e-05 0.00528 0.29 0.23 Axial length; chr3:53812897 chr3:53797764~53798019:- LIHC cis rs11098499 0.82 rs28578366 ENSG00000245958.5 RP11-33B1.1 4.3 2.23e-05 0.00528 0.23 0.23 Corneal astigmatism; chr4:119615750 chr4:119454791~119552025:+ LIHC cis rs12946454 0.668 rs4792867 ENSG00000267288.2 RP13-890H12.2 -4.3 2.23e-05 0.00528 -0.25 -0.23 Systolic blood pressure; chr17:45172077 chr17:45168800~45171584:- LIHC cis rs12946454 0.621 rs11651809 ENSG00000267288.2 RP13-890H12.2 -4.3 2.23e-05 0.00528 -0.25 -0.23 Systolic blood pressure; chr17:45178314 chr17:45168800~45171584:- LIHC cis rs4356203 0.783 rs7113964 ENSG00000260196.1 RP1-239B22.5 -4.3 2.24e-05 0.00529 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17234374 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs11024208 ENSG00000260196.1 RP1-239B22.5 -4.3 2.24e-05 0.00529 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17238432 chr11:17380649~17383531:+ LIHC cis rs4356203 0.678 rs1125737 ENSG00000260196.1 RP1-239B22.5 -4.3 2.24e-05 0.00529 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17242386 chr11:17380649~17383531:+ LIHC cis rs11779988 0.545 rs439374 ENSG00000253671.1 RP11-806O11.1 -4.3 2.24e-05 0.00529 -0.29 -0.23 Breast cancer; chr8:17929309 chr8:17808941~17820868:+ LIHC cis rs4578769 0.959 rs3911557 ENSG00000265943.1 RP11-739L10.1 -4.3 2.24e-05 0.00529 -0.28 -0.23 Eosinophil percentage of white cells; chr18:22892600 chr18:22699481~22933764:- LIHC cis rs9640161 0.83 rs6722 ENSG00000261305.1 RP4-584D14.7 4.3 2.24e-05 0.00529 0.27 0.23 Blood protein levels;Circulating chemerin levels; chr7:150371844 chr7:150341771~150342607:+ LIHC cis rs597539 0.69 rs608810 ENSG00000250508.1 RP11-757G1.6 -4.3 2.24e-05 0.00529 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68856650 chr11:68870664~68874542:+ LIHC cis rs3812762 0.912 rs11042058 ENSG00000254860.4 TMEM9B-AS1 4.3 2.24e-05 0.00529 0.26 0.23 Hypospadias; chr11:8742268 chr11:8964675~8977527:+ LIHC cis rs9675120 0.742 rs9905568 ENSG00000262006.1 RP11-700H6.4 -4.3 2.24e-05 0.0053 -0.25 -0.23 Cerebrospinal fluid biomarker levels; chr17:50842718 chr17:50909637~50910232:- LIHC cis rs12478296 0.901 rs9653611 ENSG00000261186.2 RP11-341N2.1 -4.3 2.25e-05 0.00531 -0.3 -0.23 Obesity-related traits; chr2:242064805 chr2:242087351~242088457:- LIHC cis rs12478296 0.818 rs57194240 ENSG00000261186.2 RP11-341N2.1 -4.3 2.25e-05 0.00531 -0.3 -0.23 Obesity-related traits; chr2:242069394 chr2:242087351~242088457:- LIHC cis rs11096990 0.634 rs6852967 ENSG00000249685.1 RP11-360F5.3 -4.3 2.25e-05 0.00531 -0.27 -0.23 Cognitive function; chr4:39281526 chr4:39133913~39135608:+ LIHC cis rs60733400 0.5 rs72644697 ENSG00000225931.3 RP3-395M20.7 4.3 2.25e-05 0.00531 0.24 0.23 Multiple sclerosis; chr1:2602166 chr1:2566410~2569888:+ LIHC cis rs7726839 0.54 rs4957080 ENSG00000271781.1 CTD-2589H19.6 4.3 2.25e-05 0.00531 0.35 0.23 Obesity-related traits; chr5:644437 chr5:675826~676616:+ LIHC cis rs1799949 1 rs8176145 ENSG00000267681.1 CTD-3199J23.6 -4.3 2.25e-05 0.00531 -0.22 -0.23 Menopause (age at onset); chr17:43097077 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs8176140 ENSG00000267681.1 CTD-3199J23.6 -4.3 2.25e-05 0.00531 -0.22 -0.23 Menopause (age at onset); chr17:43099629 chr17:43144956~43145255:+ LIHC cis rs17818399 1 rs17818399 ENSG00000279254.1 RP11-536C12.1 -4.3 2.25e-05 0.00531 -0.27 -0.23 Height; chr2:46598887 chr2:46668870~46670778:+ LIHC cis rs901683 1 rs9422657 ENSG00000230869.1 CTGLF10P -4.3 2.25e-05 0.00531 -0.54 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45557613 chr10:45678692~45700532:+ LIHC cis rs948562 0.947 rs17489568 ENSG00000280010.1 AP001350.4 4.3 2.25e-05 0.00532 0.41 0.23 Lymphoma; chr11:58622534 chr11:58627435~58628528:+ LIHC cis rs494453 0.922 rs2473843 ENSG00000227811.2 FAM212B-AS1 -4.3 2.25e-05 0.00532 -0.26 -0.23 Osteoporosis-related phenotypes; chr1:111698035 chr1:111739841~111747798:+ LIHC cis rs494453 0.845 rs2477427 ENSG00000227811.2 FAM212B-AS1 -4.3 2.25e-05 0.00532 -0.26 -0.23 Osteoporosis-related phenotypes; chr1:111698072 chr1:111739841~111747798:+ LIHC cis rs6439153 0.967 rs9821769 ENSG00000231305.3 RP11-723O4.2 4.3 2.25e-05 0.00532 0.25 0.23 Pneumococcal bacteremia; chr3:129007423 chr3:128861313~128871540:- LIHC cis rs2243480 1 rs709607 ENSG00000230295.1 RP11-458F8.2 4.3 2.25e-05 0.00532 0.24 0.23 Diabetic kidney disease; chr7:65984554 chr7:66880708~66882981:+ LIHC cis rs8040855 0.547 rs17611171 ENSG00000259295.5 CSPG4P12 4.3 2.25e-05 0.00532 0.36 0.23 Bulimia nervosa; chr15:85029468 chr15:85191438~85213905:+ LIHC cis rs2929278 0.617 rs693919 ENSG00000166763.7 STRCP1 -4.3 2.25e-05 0.00532 -0.29 -0.23 Schizophrenia; chr15:43810130 chr15:43699488~43718184:- LIHC cis rs67478160 0.643 rs6575997 ENSG00000258534.1 CTD-2134A5.4 4.3 2.25e-05 0.00532 0.24 0.23 Schizophrenia; chr14:103762209 chr14:103854366~103880111:- LIHC cis rs794185 0.652 rs2633844 ENSG00000231249.1 ITPR1-AS1 -4.3 2.26e-05 0.00532 -0.24 -0.23 Multiple sclerosis--Brain Glutamate Levels; chr3:4470207 chr3:4490891~4493163:- LIHC cis rs1005277 0.579 rs1621040 ENSG00000099251.13 HSD17B7P2 4.3 2.26e-05 0.00533 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38208304 chr10:38356380~38378505:+ LIHC cis rs901683 1 rs9422652 ENSG00000230869.1 CTGLF10P -4.3 2.26e-05 0.00533 -0.54 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45552486 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs9422441 ENSG00000230869.1 CTGLF10P -4.3 2.26e-05 0.00533 -0.54 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45552605 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs9422442 ENSG00000230869.1 CTGLF10P -4.3 2.26e-05 0.00533 -0.54 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45552630 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs17157928 ENSG00000230869.1 CTGLF10P -4.3 2.26e-05 0.00533 -0.54 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45552781 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs77649955 ENSG00000230869.1 CTGLF10P -4.3 2.26e-05 0.00533 -0.54 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45555241 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs74874679 ENSG00000230869.1 CTGLF10P -4.3 2.26e-05 0.00533 -0.54 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45555285 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs9422654 ENSG00000230869.1 CTGLF10P -4.3 2.26e-05 0.00533 -0.54 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45555953 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs17451208 ENSG00000230869.1 CTGLF10P -4.3 2.26e-05 0.00533 -0.54 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45556457 chr10:45678692~45700532:+ LIHC cis rs116139393 0.561 rs62439737 ENSG00000187953.9 PMS2CL -4.3 2.26e-05 0.00533 -0.23 -0.23 Alzheimer's disease (APOE e4 interaction); chr7:6740179 chr7:6710128~6753862:+ LIHC cis rs2280018 0.526 rs1510148 ENSG00000188599.16 NPIPP1 -4.3 2.26e-05 0.00533 -0.2 -0.23 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15073522 chr16:15104312~15123498:- LIHC cis rs6500637 0.57 rs1049205 ENSG00000267077.1 RP11-127I20.5 -4.3 2.26e-05 0.00533 -0.24 -0.23 Cancer; chr16:4892098 chr16:4795265~4796532:- LIHC cis rs2439831 0.717 rs2447198 ENSG00000275601.1 AC011330.13 -4.3 2.26e-05 0.00533 -0.34 -0.23 Lung cancer in ever smokers; chr15:43602920 chr15:43642389~43643023:- LIHC cis rs763121 0.626 rs5750643 ENSG00000273076.1 RP3-508I15.22 4.3 2.26e-05 0.00534 0.25 0.23 Menopause (age at onset); chr22:38613012 chr22:38743495~38743910:+ LIHC cis rs9937943 0.512 rs13335886 ENSG00000261079.1 RP11-252A24.3 -4.3 2.26e-05 0.00534 -0.28 -0.23 Neutrophil percentage of white cells; chr16:74543263 chr16:74367462~74369826:+ LIHC cis rs2300206 1 rs2300206 ENSG00000275784.1 RP5-1125A11.6 -4.3 2.26e-05 0.00534 -0.26 -0.23 Cancer (pleiotropy);Cancer; chr20:34002002 chr20:33989480~33991818:- LIHC cis rs2581828 1 rs2581828 ENSG00000242142.1 SERBP1P3 4.3 2.26e-05 0.00534 0.26 0.23 Crohn's disease; chr3:53099133 chr3:53064283~53065091:- LIHC cis rs710865 0.527 rs2275403 ENSG00000270728.1 RP4-657E11.10 4.3 2.27e-05 0.00534 0.21 0.23 Brain structure; chr1:19231219 chr1:19297080~19297903:+ LIHC cis rs8040855 0.597 rs994989 ENSG00000259295.5 CSPG4P12 4.3 2.27e-05 0.00534 0.35 0.23 Bulimia nervosa; chr15:85117485 chr15:85191438~85213905:+ LIHC cis rs2599510 0.748 rs6718214 ENSG00000276334.1 AL133243.1 -4.3 2.27e-05 0.00534 -0.26 -0.23 Interleukin-18 levels; chr2:32325416 chr2:32521927~32523547:+ LIHC cis rs734999 0.545 rs6666788 ENSG00000225931.3 RP3-395M20.7 -4.3 2.27e-05 0.00535 -0.24 -0.23 Ulcerative colitis; chr1:2636061 chr1:2566410~2569888:+ LIHC cis rs9640161 0.83 rs3735165 ENSG00000261305.1 RP4-584D14.7 4.3 2.27e-05 0.00535 0.27 0.23 Blood protein levels;Circulating chemerin levels; chr7:150371282 chr7:150341771~150342607:+ LIHC cis rs2243480 1 rs937108 ENSG00000230295.1 RP11-458F8.2 -4.3 2.27e-05 0.00535 -0.24 -0.23 Diabetic kidney disease; chr7:65963465 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs35542501 ENSG00000230295.1 RP11-458F8.2 -4.3 2.27e-05 0.00535 -0.24 -0.23 Diabetic kidney disease; chr7:65966228 chr7:66880708~66882981:+ LIHC cis rs2243480 0.711 rs1626926 ENSG00000230295.1 RP11-458F8.2 -4.3 2.27e-05 0.00535 -0.24 -0.23 Diabetic kidney disease; chr7:65970805 chr7:66880708~66882981:+ LIHC cis rs2243480 0.708 rs781141 ENSG00000230295.1 RP11-458F8.2 -4.3 2.27e-05 0.00535 -0.24 -0.23 Diabetic kidney disease; chr7:65973566 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs781142 ENSG00000230295.1 RP11-458F8.2 -4.3 2.27e-05 0.00535 -0.24 -0.23 Diabetic kidney disease; chr7:65973791 chr7:66880708~66882981:+ LIHC cis rs12887734 0.524 rs4900599 ENSG00000258534.1 CTD-2134A5.4 -4.3 2.27e-05 0.00535 -0.25 -0.23 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103817107 chr14:103854366~103880111:- LIHC cis rs597539 0.652 rs602805 ENSG00000250508.1 RP11-757G1.6 -4.3 2.27e-05 0.00535 -0.34 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68894608 chr11:68870664~68874542:+ LIHC cis rs597539 0.652 rs602364 ENSG00000250508.1 RP11-757G1.6 -4.3 2.27e-05 0.00535 -0.34 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68894699 chr11:68870664~68874542:+ LIHC cis rs11648785 0.81 rs4354938 ENSG00000221819.5 GAS8-AS1 -4.3 2.27e-05 0.00535 -0.31 -0.23 Tanning; chr16:90032420 chr16:90028908~90029367:- LIHC cis rs2284219 1 rs2284219 ENSG00000196295.10 AC005154.6 -4.3 2.27e-05 0.00535 -0.16 -0.23 Type 2 diabetes; chr7:30674820 chr7:30516309~30594809:- LIHC cis rs2284219 0.964 rs733453 ENSG00000196295.10 AC005154.6 -4.3 2.27e-05 0.00535 -0.16 -0.23 Type 2 diabetes; chr7:30675157 chr7:30516309~30594809:- LIHC cis rs2932538 0.961 rs3013441 ENSG00000225075.1 RP11-426L16.3 -4.3 2.27e-05 0.00536 -0.29 -0.23 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112649983 chr1:112693688~112696621:- LIHC cis rs860295 0.58 rs6672284 ENSG00000203761.5 MSTO2P -4.3 2.27e-05 0.00536 -0.19 -0.23 Body mass index; chr1:155308172 chr1:155745829~155750137:+ LIHC cis rs36093924 0.646 rs5996094 ENSG00000227370.1 RP4-669P10.19 4.3 2.27e-05 0.00536 0.27 0.23 Intelligence; chr22:41951056 chr22:42132543~42132998:+ LIHC cis rs3020736 0.5 rs11090076 ENSG00000205702.9 CYP2D7 -4.3 2.27e-05 0.00536 -0.26 -0.23 Autism spectrum disorder or schizophrenia; chr22:42118186 chr22:42140203~42144577:- LIHC cis rs2790457 0.958 rs2790444 ENSG00000254635.4 WAC-AS1 -4.3 2.28e-05 0.00537 -0.21 -0.23 Multiple myeloma; chr10:28536760 chr10:28522652~28532743:- LIHC cis rs617219 0.819 rs4704552 ENSG00000251675.1 CTC-458I2.2 4.3 2.28e-05 0.00537 0.26 0.23 Betaine levels in individuals undergoing cardiac evaluation; chr5:79284545 chr5:80128361~80143883:+ LIHC cis rs9640161 0.789 rs3735172 ENSG00000261305.1 RP4-584D14.7 -4.3 2.28e-05 0.00537 -0.27 -0.23 Blood protein levels;Circulating chemerin levels; chr7:150331869 chr7:150341771~150342607:+ LIHC cis rs748404 0.69 rs1079309 ENSG00000166763.7 STRCP1 4.3 2.28e-05 0.00537 0.28 0.23 Lung cancer; chr15:43490966 chr15:43699488~43718184:- LIHC cis rs748404 0.69 rs2924369 ENSG00000166763.7 STRCP1 -4.3 2.28e-05 0.00537 -0.28 -0.23 Lung cancer; chr15:43485787 chr15:43699488~43718184:- LIHC cis rs172166 0.694 rs203884 ENSG00000219392.1 RP1-265C24.5 -4.3 2.28e-05 0.00537 -0.29 -0.23 Cardiac Troponin-T levels; chr6:28109596 chr6:28115628~28116551:+ LIHC cis rs11671005 0.651 rs10402325 ENSG00000269473.1 CTD-2619J13.19 4.29 2.28e-05 0.00537 0.39 0.23 Mean platelet volume; chr19:58402140 chr19:58440448~58445849:+ LIHC cis rs875971 0.54 rs781152 ENSG00000224316.1 RP11-479O9.2 4.29 2.28e-05 0.00537 0.23 0.23 Aortic root size; chr7:66014585 chr7:65773620~65802067:+ LIHC cis rs1062177 1 rs41494545 ENSG00000253921.1 CTB-113P19.3 4.29 2.28e-05 0.00537 0.26 0.23 Preschool internalizing problems; chr5:151855533 chr5:151753992~151767247:+ LIHC cis rs11148252 0.904 rs9536079 ENSG00000278238.1 RP11-245D16.4 -4.29 2.28e-05 0.00537 -0.21 -0.23 Lewy body disease; chr13:52456430 chr13:52454775~52455331:- LIHC cis rs9532669 0.963 rs1056835 ENSG00000168852.11 TPTE2P5 4.29 2.28e-05 0.00537 0.25 0.23 Cervical cancer; chr13:40932585 chr13:40822296~40921749:- LIHC cis rs1062177 1 rs892006 ENSG00000253921.1 CTB-113P19.3 -4.29 2.28e-05 0.00538 -0.25 -0.23 Preschool internalizing problems; chr5:151801329 chr5:151753992~151767247:+ LIHC cis rs901683 0.85 rs78990676 ENSG00000230869.1 CTGLF10P -4.29 2.28e-05 0.00538 -0.56 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45606277 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs112114291 ENSG00000230869.1 CTGLF10P -4.29 2.28e-05 0.00538 -0.56 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45606562 chr10:45678692~45700532:+ LIHC cis rs875971 0.502 rs1796227 ENSG00000273142.1 RP11-458F8.4 -4.29 2.28e-05 0.00538 -0.21 -0.23 Aortic root size; chr7:66622032 chr7:66902857~66906297:+ LIHC cis rs748404 0.66 rs694725 ENSG00000166763.7 STRCP1 4.29 2.29e-05 0.00539 0.28 0.23 Lung cancer; chr15:43464012 chr15:43699488~43718184:- LIHC cis rs12157904 0.744 rs13055343 ENSG00000233360.4 Z83844.1 4.29 2.29e-05 0.00539 0.47 0.23 Response to anti-depressant treatment in major depressive disorder; chr22:37609137 chr22:37641832~37658377:- LIHC cis rs2439831 0.867 rs2447208 ENSG00000166763.7 STRCP1 4.29 2.29e-05 0.00539 0.34 0.23 Lung cancer in ever smokers; chr15:43641697 chr15:43699488~43718184:- LIHC cis rs875971 0.522 rs1917563 ENSG00000224316.1 RP11-479O9.2 -4.29 2.29e-05 0.00539 -0.23 -0.23 Aortic root size; chr7:65950660 chr7:65773620~65802067:+ LIHC cis rs2739330 0.929 rs5751775 ENSG00000206090.4 AP000350.7 4.29 2.29e-05 0.00539 0.26 0.23 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23939998~23942798:+ LIHC cis rs67311347 1 rs9874006 ENSG00000223797.4 ENTPD3-AS1 4.29 2.29e-05 0.00539 0.18 0.23 Renal cell carcinoma; chr3:40430105 chr3:40313802~40453329:- LIHC cis rs67311347 0.955 rs60554147 ENSG00000223797.4 ENTPD3-AS1 4.29 2.29e-05 0.00539 0.18 0.23 Renal cell carcinoma; chr3:40431012 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs34762643 ENSG00000223797.4 ENTPD3-AS1 4.29 2.29e-05 0.00539 0.18 0.23 Renal cell carcinoma; chr3:40433942 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs9841335 ENSG00000223797.4 ENTPD3-AS1 4.29 2.29e-05 0.00539 0.18 0.23 Renal cell carcinoma; chr3:40434367 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs28434528 ENSG00000223797.4 ENTPD3-AS1 4.29 2.29e-05 0.00539 0.18 0.23 Renal cell carcinoma; chr3:40443402 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs11716675 ENSG00000223797.4 ENTPD3-AS1 4.29 2.29e-05 0.00539 0.18 0.23 Renal cell carcinoma; chr3:40443789 chr3:40313802~40453329:- LIHC cis rs8064024 0.87 rs930854 ENSG00000267077.1 RP11-127I20.5 4.29 2.29e-05 0.0054 0.22 0.23 Cancer; chr16:4814100 chr16:4795265~4796532:- LIHC cis rs2439831 0.85 rs7169988 ENSG00000275601.1 AC011330.13 -4.29 2.29e-05 0.0054 -0.33 -0.23 Lung cancer in ever smokers; chr15:43768237 chr15:43642389~43643023:- LIHC cis rs875971 0.545 rs73378304 ENSG00000228409.4 CCT6P1 -4.29 2.29e-05 0.0054 -0.19 -0.23 Aortic root size; chr7:66175760 chr7:65751142~65763354:+ LIHC cis rs2797160 0.837 rs1739364 ENSG00000237742.5 RP11-624M8.1 -4.29 2.29e-05 0.0054 -0.23 -0.23 Endometrial cancer; chr6:125701237 chr6:125578558~125749190:- LIHC cis rs875971 0.545 rs6969224 ENSG00000273024.4 INTS4P2 -4.29 2.29e-05 0.0054 -0.26 -0.23 Aortic root size; chr7:66370011 chr7:65647864~65715661:+ LIHC cis rs7131987 0.903 rs11050153 ENSG00000257176.2 RP11-996F15.2 -4.29 2.3e-05 0.0054 -0.26 -0.23 QT interval; chr12:29252215 chr12:29280418~29317848:- LIHC cis rs1247318 1 rs1247363 ENSG00000243831.1 RP1-81D8.4 4.29 2.3e-05 0.00541 0.36 0.23 Aging; chr6:160921658 chr6:160666228~160676523:- LIHC cis rs1200821 0.529 rs2505707 ENSG00000263064.2 RP11-291L22.7 4.29 2.3e-05 0.00541 0.24 0.23 Hemostatic factors and hematological phenotypes; chr10:37512326 chr10:38448689~38448949:+ LIHC cis rs7709377 0.597 rs57484726 ENSG00000271918.1 CTD-2287O16.5 4.29 2.3e-05 0.00541 0.27 0.23 Metabolite levels (X-11787); chr5:116178348 chr5:116083807~116085416:- LIHC cis rs1005277 0.54 rs1814077 ENSG00000099251.13 HSD17B7P2 4.29 2.3e-05 0.00541 0.26 0.23 Extrinsic epigenetic age acceleration; chr10:37703090 chr10:38356380~38378505:+ LIHC cis rs748404 0.578 rs512628 ENSG00000166763.7 STRCP1 4.29 2.3e-05 0.00541 0.28 0.23 Lung cancer; chr15:43326536 chr15:43699488~43718184:- LIHC cis rs7615952 0.688 rs12485622 ENSG00000171084.14 FAM86JP 4.29 2.3e-05 0.00541 0.35 0.23 Blood pressure (smoking interaction); chr3:125991896 chr3:125916620~125930024:+ LIHC cis rs4356203 0.87 rs10741724 ENSG00000260196.1 RP1-239B22.5 -4.29 2.3e-05 0.00541 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17231604 chr11:17380649~17383531:+ LIHC cis rs11098499 0.863 rs3775841 ENSG00000260091.1 RP11-33B1.4 -4.29 2.3e-05 0.00541 -0.16 -0.23 Corneal astigmatism; chr4:119504622 chr4:119409333~119410233:+ LIHC cis rs46522 0.585 rs79049364 ENSG00000248278.1 SUMO2P17 4.29 2.3e-05 0.00542 0.28 0.23 Coronary heart disease; chr17:48937629 chr17:48874860~48908983:- LIHC cis rs79349575 0.811 rs80032154 ENSG00000248278.1 SUMO2P17 4.29 2.3e-05 0.00542 0.28 0.23 Type 2 diabetes; chr17:48937630 chr17:48874860~48908983:- LIHC cis rs651907 0.535 rs58658478 ENSG00000244119.1 PDCL3P4 4.29 2.3e-05 0.00542 0.24 0.23 Colorectal cancer; chr3:101792823 chr3:101712472~101713191:+ LIHC cis rs417065 0.516 rs11121129 ENSG00000227634.1 RP11-431K24.3 4.29 2.3e-05 0.00542 0.28 0.23 Psoriasis; chr1:8208035 chr1:8208672~8215210:+ LIHC cis rs875971 0.545 rs7787063 ENSG00000228409.4 CCT6P1 -4.29 2.3e-05 0.00542 -0.19 -0.23 Aortic root size; chr7:66164012 chr7:65751142~65763354:+ LIHC cis rs494453 0.922 rs498787 ENSG00000227811.2 FAM212B-AS1 -4.29 2.31e-05 0.00542 -0.25 -0.23 Osteoporosis-related phenotypes; chr1:111690722 chr1:111739841~111747798:+ LIHC cis rs11722228 0.522 rs2241468 ENSG00000261490.1 RP11-448G15.3 4.29 2.31e-05 0.00543 0.31 0.23 Urate levels;Serum uric acid levels;Gout; chr4:10112281 chr4:10068089~10073019:- LIHC cis rs7712401 0.601 rs246285 ENSG00000263432.2 RN7SL689P -4.29 2.31e-05 0.00543 -0.33 -0.23 Mean platelet volume; chr5:122909273 chr5:123022487~123022783:- LIHC cis rs13083990 0.8 rs13061727 ENSG00000272758.4 RP11-299J3.8 4.29 2.31e-05 0.00543 0.25 0.23 Cardiac Troponin-T levels; chr3:122288504 chr3:122416207~122443180:+ LIHC cis rs2919917 0.628 rs1021157 ENSG00000254352.1 RP11-578O24.2 4.29 2.31e-05 0.00543 0.33 0.23 Lymphocyte counts; chr8:78662938 chr8:78723796~78724136:- LIHC cis rs11098499 1 rs13435802 ENSG00000260091.1 RP11-33B1.4 4.29 2.31e-05 0.00543 0.17 0.23 Corneal astigmatism; chr4:119256805 chr4:119409333~119410233:+ LIHC cis rs17027258 0.609 rs4851005 ENSG00000234389.1 AC007278.3 -4.29 2.31e-05 0.00543 -0.22 -0.23 White blood cell types; chr2:102395092 chr2:102438713~102440475:+ LIHC cis rs2284219 1 rs2267715 ENSG00000196295.10 AC005154.6 -4.29 2.31e-05 0.00544 -0.16 -0.23 Type 2 diabetes; chr7:30676471 chr7:30516309~30594809:- LIHC cis rs2070488 0.965 rs2284819 ENSG00000229589.1 ACVR2B-AS1 4.29 2.31e-05 0.00544 0.26 0.23 Electrocardiographic conduction measures; chr3:38515670 chr3:38451027~38454820:- LIHC cis rs11098499 0.754 rs7672372 ENSG00000260091.1 RP11-33B1.4 -4.29 2.31e-05 0.00544 -0.16 -0.23 Corneal astigmatism; chr4:119327251 chr4:119409333~119410233:+ LIHC cis rs916888 0.821 rs199513 ENSG00000274883.1 Metazoa_SRP 4.29 2.32e-05 0.00544 0.34 0.23 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:45931806~45932083:+ LIHC cis rs7893279 0.505 rs7904949 ENSG00000225527.1 RP11-383B4.4 4.29 2.32e-05 0.00544 0.32 0.23 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18624533 chr10:18531849~18533336:- LIHC cis rs7893279 0.505 rs4468242 ENSG00000225527.1 RP11-383B4.4 4.29 2.32e-05 0.00544 0.32 0.23 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18633730 chr10:18531849~18533336:- LIHC cis rs12931792 0.72 rs12102320 ENSG00000183604.13 SMG1P5 4.29 2.32e-05 0.00545 0.22 0.23 Tonsillectomy; chr16:30167195 chr16:30267553~30335374:- LIHC cis rs9368481 0.761 rs4358615 ENSG00000241549.7 GUSBP2 4.29 2.32e-05 0.00545 0.23 0.23 Autism spectrum disorder or schizophrenia; chr6:27030788 chr6:26871484~26956554:- LIHC cis rs7809950 0.862 rs62482502 ENSG00000238832.1 snoU109 -4.29 2.32e-05 0.00545 -0.28 -0.23 Coronary artery disease; chr7:107347365 chr7:107603363~107603507:+ LIHC cis rs11098499 0.863 rs6835635 ENSG00000260091.1 RP11-33B1.4 -4.29 2.32e-05 0.00545 -0.16 -0.23 Corneal astigmatism; chr4:119537712 chr4:119409333~119410233:+ LIHC cis rs6480314 0.831 rs10740287 ENSG00000233590.1 RP11-153K11.3 4.29 2.32e-05 0.00545 0.33 0.23 Optic nerve measurement (disc area); chr10:68214133 chr10:68233251~68242379:- LIHC cis rs3733589 0.744 rs13148476 ENSG00000250413.1 RP11-448G15.1 4.29 2.32e-05 0.00546 0.36 0.23 Renal overload gout; chr4:10023774 chr4:10006482~10009725:+ LIHC cis rs1005277 0.54 rs2474598 ENSG00000276805.1 RP11-291L22.6 -4.29 2.32e-05 0.00546 -0.27 -0.23 Extrinsic epigenetic age acceleration; chr10:38141368 chr10:38451030~38451785:+ LIHC cis rs2790457 0.874 rs2790446 ENSG00000254635.4 WAC-AS1 -4.29 2.32e-05 0.00546 -0.22 -0.23 Multiple myeloma; chr10:28512101 chr10:28522652~28532743:- LIHC cis rs6745190 0.953 rs4667005 ENSG00000236153.1 AC104076.3 -4.29 2.32e-05 0.00546 -0.29 -0.23 White blood cell count; chr2:180997852 chr2:180979427~180980090:- LIHC cis rs11098499 0.754 rs4107728 ENSG00000260091.1 RP11-33B1.4 -4.29 2.32e-05 0.00546 -0.16 -0.23 Corneal astigmatism; chr4:119332755 chr4:119409333~119410233:+ LIHC cis rs4845875 0.513 rs198397 ENSG00000242349.4 NPPA-AS1 -4.29 2.33e-05 0.00546 -0.23 -0.23 Midregional pro atrial natriuretic peptide levels; chr1:11823275 chr1:11841017~11848079:+ LIHC cis rs960902 0.714 rs10198396 ENSG00000213553.4 RPLP0P6 -4.29 2.33e-05 0.00546 -0.19 -0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37514999 chr2:38481851~38482804:+ LIHC cis rs55794721 0.509 rs2982358 ENSG00000224183.1 SDHDP6 -4.29 2.33e-05 0.00547 -0.26 -0.23 Mean corpuscular volume;Plateletcrit; chr1:25418713 chr1:25294164~25294643:- LIHC cis rs10801727 0.597 rs7534759 ENSG00000225492.5 GBP1P1 -4.29 2.33e-05 0.00547 -0.22 -0.23 Parental extreme longevity (95 years and older); chr1:89447069 chr1:89407679~89426243:+ LIHC cis rs10801727 0.597 rs9427980 ENSG00000225492.5 GBP1P1 -4.29 2.33e-05 0.00547 -0.22 -0.23 Parental extreme longevity (95 years and older); chr1:89447849 chr1:89407679~89426243:+ LIHC cis rs950880 0.71 rs11123927 ENSG00000234389.1 AC007278.3 -4.29 2.33e-05 0.00547 -0.23 -0.23 Serum protein levels (sST2); chr2:102442343 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs10490203 ENSG00000234389.1 AC007278.3 -4.29 2.33e-05 0.00547 -0.23 -0.23 Serum protein levels (sST2); chr2:102442777 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs4851583 ENSG00000234389.1 AC007278.3 -4.29 2.33e-05 0.00547 -0.23 -0.23 Serum protein levels (sST2); chr2:102443840 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs11694360 ENSG00000234389.1 AC007278.3 -4.29 2.33e-05 0.00547 -0.23 -0.23 Serum protein levels (sST2); chr2:102444687 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs7597017 ENSG00000234389.1 AC007278.3 -4.29 2.33e-05 0.00547 -0.23 -0.23 Serum protein levels (sST2); chr2:102445656 chr2:102438713~102440475:+ LIHC cis rs160451 0.966 rs160423 ENSG00000251136.7 RP11-37B2.1 4.29 2.33e-05 0.00547 0.2 0.23 Leprosy; chr8:89658395 chr8:89609409~89757727:- LIHC cis rs2658782 0.789 rs2658776 ENSG00000279684.1 RP11-755E23.2 -4.29 2.33e-05 0.00547 -0.39 -0.23 Pulmonary function decline; chr11:93414761 chr11:93286629~93288903:- LIHC cis rs10262624 1 rs17347692 ENSG00000234286.1 AC006026.13 -4.29 2.33e-05 0.00548 -0.25 -0.23 Schizophrenia; chr7:23878748 chr7:23680195~23680786:- LIHC cis rs11098499 0.789 rs1980024 ENSG00000260091.1 RP11-33B1.4 -4.29 2.33e-05 0.00548 -0.16 -0.23 Corneal astigmatism; chr4:119331892 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs34425882 ENSG00000260091.1 RP11-33B1.4 -4.29 2.33e-05 0.00548 -0.16 -0.23 Corneal astigmatism; chr4:119332022 chr4:119409333~119410233:+ LIHC cis rs703842 0.616 rs1875125 ENSG00000270039.1 RP11-571M6.17 -4.29 2.33e-05 0.00548 -0.33 -0.23 Multiple sclerosis; chr12:57833458 chr12:57803838~57804415:+ LIHC cis rs9876781 1 rs9815103 ENSG00000229759.1 MRPS18AP1 4.29 2.34e-05 0.00548 0.24 0.23 Longevity; chr3:48372725 chr3:48256350~48256938:- LIHC cis rs6445975 0.666 rs6773099 ENSG00000272360.1 RP11-359I18.5 4.29 2.34e-05 0.00548 0.3 0.23 Systemic lupus erythematosus; chr3:58417725 chr3:58490830~58491291:- LIHC cis rs6445975 0.578 rs6782218 ENSG00000272360.1 RP11-359I18.5 4.29 2.34e-05 0.00548 0.3 0.23 Systemic lupus erythematosus; chr3:58423038 chr3:58490830~58491291:- LIHC cis rs10129255 0.957 rs8005468 ENSG00000223648.3 IGHV3-64 4.29 2.34e-05 0.00549 0.17 0.23 Kawasaki disease; chr14:106686431 chr14:106643132~106658258:- LIHC cis rs11098499 0.954 rs4309825 ENSG00000260091.1 RP11-33B1.4 4.29 2.34e-05 0.00549 0.16 0.23 Corneal astigmatism; chr4:119393726 chr4:119409333~119410233:+ LIHC cis rs950169 0.922 rs4586394 ENSG00000225151.9 GOLGA2P7 4.29 2.34e-05 0.00549 0.3 0.23 Schizophrenia; chr15:84153633 chr15:84199311~84230136:- LIHC cis rs11148252 0.904 rs3892337 ENSG00000278238.1 RP11-245D16.4 -4.29 2.34e-05 0.00549 -0.22 -0.23 Lewy body disease; chr13:52455350 chr13:52454775~52455331:- LIHC cis rs875971 0.545 rs12671152 ENSG00000273142.1 RP11-458F8.4 4.29 2.34e-05 0.00549 0.23 0.23 Aortic root size; chr7:66311140 chr7:66902857~66906297:+ LIHC cis rs11874381 0.582 rs8083571 ENSG00000267322.2 SNHG22 4.29 2.34e-05 0.00549 0.27 0.23 C-reactive protein levels or HDL-cholesterol levels (pleiotropy); chr18:49691751 chr18:49814023~49851059:+ LIHC cis rs2072510 0.722 rs2660895 ENSG00000257878.1 RP11-256L6.3 -4.29 2.34e-05 0.00549 -0.2 -0.23 Metabolite levels (small molecules and protein measures); chr12:96029669 chr12:95996521~96011489:+ LIHC cis rs2243480 1 rs56291018 ENSG00000228409.4 CCT6P1 4.29 2.34e-05 0.0055 0.25 0.23 Diabetic kidney disease; chr7:65925352 chr7:65751142~65763354:+ LIHC cis rs7129556 0.737 rs10899404 ENSG00000254459.1 RP11-91P24.7 4.29 2.34e-05 0.0055 0.37 0.23 Weight loss (gastric bypass surgery); chr11:77751747 chr11:77829654~77872262:- LIHC cis rs9516 0.544 rs681179 ENSG00000254974.1 RP11-702H23.2 4.29 2.34e-05 0.0055 0.24 0.23 Facial morphology (factor 15, philtrum width); chr11:74475791 chr11:74485580~74486051:- LIHC cis rs10853057 0.541 rs11656396 ENSG00000214174.7 AMZ2P1 4.29 2.34e-05 0.0055 0.46 0.23 White matter microstructure (global fractional anisotropy); chr17:65049958 chr17:64966550~64975576:- LIHC cis rs9952991 0.941 rs9952749 ENSG00000260302.1 RP11-973H7.1 -4.29 2.35e-05 0.0055 -0.34 -0.23 Inflammatory skin disease; chr18:12780457 chr18:12774651~12775923:- LIHC cis rs9952991 0.943 rs9952753 ENSG00000260302.1 RP11-973H7.1 -4.29 2.35e-05 0.0055 -0.34 -0.23 Inflammatory skin disease; chr18:12780464 chr18:12774651~12775923:- LIHC cis rs9952991 1 rs9952991 ENSG00000260302.1 RP11-973H7.1 -4.29 2.35e-05 0.0055 -0.34 -0.23 Inflammatory skin disease; chr18:12780465 chr18:12774651~12775923:- LIHC cis rs13217239 0.646 rs10456352 ENSG00000241549.7 GUSBP2 4.29 2.35e-05 0.0055 0.23 0.23 Schizophrenia; chr6:27022579 chr6:26871484~26956554:- LIHC cis rs13217239 0.646 rs4583981 ENSG00000241549.7 GUSBP2 4.29 2.35e-05 0.0055 0.23 0.23 Schizophrenia; chr6:27024244 chr6:26871484~26956554:- LIHC cis rs4578769 0.879 rs7244549 ENSG00000266850.1 RP11-370A5.1 4.29 2.35e-05 0.0055 0.26 0.23 Eosinophil percentage of white cells; chr18:22866052 chr18:22723491~22907721:- LIHC cis rs875971 0.502 rs11769702 ENSG00000273024.4 INTS4P2 -4.29 2.35e-05 0.00551 -0.26 -0.23 Aortic root size; chr7:66255529 chr7:65647864~65715661:+ LIHC cis rs2243480 1 rs160633 ENSG00000228409.4 CCT6P1 4.29 2.35e-05 0.00551 0.24 0.23 Diabetic kidney disease; chr7:66063241 chr7:65751142~65763354:+ LIHC cis rs9907295 1 rs9908011 ENSG00000270871.1 AC015849.19 4.29 2.35e-05 0.00551 0.24 0.23 Fibroblast growth factor basic levels; chr17:35908371 chr17:35816717~35830293:- LIHC cis rs1005277 0.579 rs1780139 ENSG00000099251.13 HSD17B7P2 4.29 2.35e-05 0.00551 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38214090 chr10:38356380~38378505:+ LIHC cis rs4356975 0.932 rs72852450 ENSG00000250919.1 RP11-813N20.3 -4.29 2.35e-05 0.00551 -0.23 -0.23 Obesity-related traits; chr4:69079704 chr4:69027831~69044578:+ LIHC cis rs12478296 0.892 rs11893879 ENSG00000261186.2 RP11-341N2.1 -4.29 2.35e-05 0.00552 -0.3 -0.23 Obesity-related traits; chr2:242068260 chr2:242087351~242088457:- LIHC cis rs2717559 0.522 rs35816096 ENSG00000253196.1 RP11-706C16.7 -4.29 2.35e-05 0.00552 -0.25 -0.23 Urinary tract infection frequency; chr8:142803522 chr8:142763116~142766427:+ LIHC cis rs11098499 0.954 rs6857105 ENSG00000260091.1 RP11-33B1.4 -4.29 2.35e-05 0.00552 -0.17 -0.23 Corneal astigmatism; chr4:119301143 chr4:119409333~119410233:+ LIHC cis rs1023500 0.505 rs2143139 ENSG00000205702.9 CYP2D7 4.29 2.35e-05 0.00552 0.23 0.23 Schizophrenia; chr22:42218395 chr22:42140203~42144577:- LIHC cis rs11064837 0.504 rs7311445 ENSG00000248636.5 RP11-768F21.1 4.29 2.35e-05 0.00552 0.35 0.23 Schizophrenia; chr12:119616292 chr12:119387987~119668079:- LIHC cis rs4713118 0.513 rs149897 ENSG00000219392.1 RP1-265C24.5 -4.29 2.35e-05 0.00552 -0.3 -0.23 Parkinson's disease; chr6:28038872 chr6:28115628~28116551:+ LIHC cis rs4713118 0.513 rs156734 ENSG00000219392.1 RP1-265C24.5 -4.29 2.35e-05 0.00552 -0.3 -0.23 Parkinson's disease; chr6:28039579 chr6:28115628~28116551:+ LIHC cis rs2439831 0.681 rs2278859 ENSG00000166763.7 STRCP1 4.29 2.35e-05 0.00552 0.31 0.23 Lung cancer in ever smokers; chr15:43340762 chr15:43699488~43718184:- LIHC cis rs2243480 1 rs9769882 ENSG00000230295.1 RP11-458F8.2 4.29 2.36e-05 0.00553 0.24 0.23 Diabetic kidney disease; chr7:66177938 chr7:66880708~66882981:+ LIHC cis rs7412746 0.611 rs7532045 ENSG00000231073.1 RP11-316M1.3 4.29 2.36e-05 0.00553 0.23 0.23 Melanoma; chr1:150849371 chr1:150973123~150975534:+ LIHC cis rs875971 0.545 rs316328 ENSG00000228409.4 CCT6P1 4.29 2.36e-05 0.00553 0.18 0.23 Aortic root size; chr7:66143851 chr7:65751142~65763354:+ LIHC cis rs26528 0.584 rs153103 ENSG00000259982.1 CDC37P1 -4.29 2.36e-05 0.00553 -0.24 -0.23 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr16:28517302 chr16:28700294~28701540:- LIHC cis rs9952991 0.883 rs2847293 ENSG00000260302.1 RP11-973H7.1 -4.29 2.36e-05 0.00553 -0.33 -0.23 Inflammatory skin disease; chr18:12782449 chr18:12774651~12775923:- LIHC cis rs10129255 0.518 rs12590732 ENSG00000211972.2 IGHV3-66 -4.29 2.36e-05 0.00554 -0.17 -0.23 Kawasaki disease; chr14:106779612 chr14:106675017~106675544:- LIHC cis rs1075232 1 rs72722829 ENSG00000270055.1 CTD-3092A11.2 -4.29 2.36e-05 0.00554 -0.44 -0.23 Survival in colorectal cancer (non-distant metastatic); chr15:31346911 chr15:30487963~30490313:+ LIHC cis rs1075232 1 rs16956707 ENSG00000270055.1 CTD-3092A11.2 -4.29 2.36e-05 0.00554 -0.44 -0.23 Survival in colorectal cancer (non-distant metastatic); chr15:31349430 chr15:30487963~30490313:+ LIHC cis rs7615952 0.599 rs16834938 ENSG00000171084.14 FAM86JP 4.29 2.36e-05 0.00554 0.35 0.23 Blood pressure (smoking interaction); chr3:125987203 chr3:125916620~125930024:+ LIHC cis rs17711722 0.727 rs781151 ENSG00000224316.1 RP11-479O9.2 4.29 2.37e-05 0.00554 0.23 0.23 Calcium levels; chr7:66014891 chr7:65773620~65802067:+ LIHC cis rs948562 1 rs11229535 ENSG00000280010.1 AP001350.4 4.29 2.37e-05 0.00554 0.4 0.23 Lymphoma; chr11:58580913 chr11:58627435~58628528:+ LIHC cis rs11098499 0.779 rs80242894 ENSG00000260091.1 RP11-33B1.4 -4.29 2.37e-05 0.00554 -0.16 -0.23 Corneal astigmatism; chr4:119454597 chr4:119409333~119410233:+ LIHC cis rs10985070 0.504 rs2296077 ENSG00000226752.6 PSMD5-AS1 -4.29 2.37e-05 0.00554 -0.24 -0.23 Rheumatoid arthritis; chr9:121182665 chr9:120824828~120854385:+ LIHC cis rs9516 0.544 rs664679 ENSG00000254974.1 RP11-702H23.2 4.29 2.37e-05 0.00554 0.24 0.23 Facial morphology (factor 15, philtrum width); chr11:74475254 chr11:74485580~74486051:- LIHC cis rs10510102 0.872 rs11200267 ENSG00000273891.1 RP11-500G22.5 4.29 2.37e-05 0.00555 0.31 0.23 Breast cancer; chr10:121929851 chr10:121965764~121967700:+ LIHC cis rs4650994 0.544 rs2811306 ENSG00000273384.1 RP5-1098D14.1 -4.29 2.37e-05 0.00555 -0.28 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178630113 chr1:178651706~178652282:+ LIHC cis rs7508 0.511 rs371922 ENSG00000253671.1 RP11-806O11.1 -4.29 2.37e-05 0.00555 -0.28 -0.23 Atrial fibrillation; chr8:18042494 chr8:17808941~17820868:+ LIHC cis rs2015599 0.623 rs12581107 ENSG00000275476.1 RP11-996F15.4 -4.29 2.37e-05 0.00555 -0.29 -0.23 Platelet count;Mean platelet volume; chr12:29352358 chr12:29277397~29277882:- LIHC cis rs11767557 1 rs56402156 ENSG00000229153.4 EPHA1-AS1 4.29 2.37e-05 0.00555 0.35 0.23 Alzheimer's disease (late onset); chr7:143406388 chr7:143407813~143523449:+ LIHC cis rs3812762 0.879 rs3844099 ENSG00000254860.4 TMEM9B-AS1 -4.29 2.37e-05 0.00555 -0.24 -0.23 Hypospadias; chr11:8786705 chr11:8964675~8977527:+ LIHC cis rs10129255 0.957 rs8009948 ENSG00000211970.3 IGHV4-61 -4.29 2.37e-05 0.00555 -0.18 -0.23 Kawasaki disease; chr14:106805607 chr14:106639119~106639657:- LIHC cis rs11098499 0.863 rs6534139 ENSG00000245958.5 RP11-33B1.1 4.29 2.37e-05 0.00556 0.24 0.23 Corneal astigmatism; chr4:119528301 chr4:119454791~119552025:+ LIHC cis rs3812762 0.957 rs6484008 ENSG00000254860.4 TMEM9B-AS1 -4.29 2.37e-05 0.00556 -0.24 -0.23 Hypospadias; chr11:8732601 chr11:8964675~8977527:+ LIHC cis rs11710088 0.634 rs13095959 ENSG00000244503.1 RP11-278L15.6 4.29 2.38e-05 0.00556 0.24 0.23 QRS duration; chr3:149489409 chr3:149494660~149495995:+ LIHC cis rs17270561 0.609 rs1165208 ENSG00000216436.2 HIST1H2APS1 -4.29 2.38e-05 0.00556 -0.28 -0.23 Iron status biomarkers; chr6:25803676 chr6:25732497~25732827:+ LIHC cis rs5769707 0.521 rs5769719 ENSG00000235111.1 RP1-29C18.8 -4.29 2.38e-05 0.00556 -0.27 -0.23 Monocyte percentage of white cells;Monocyte count; chr22:49668453 chr22:49612657~49615716:- LIHC cis rs5769707 0.521 rs5769720 ENSG00000235111.1 RP1-29C18.8 -4.29 2.38e-05 0.00556 -0.27 -0.23 Monocyte percentage of white cells;Monocyte count; chr22:49668485 chr22:49612657~49615716:- LIHC cis rs5769707 0.521 rs5770633 ENSG00000235111.1 RP1-29C18.8 -4.29 2.38e-05 0.00556 -0.27 -0.23 Monocyte percentage of white cells;Monocyte count; chr22:49668779 chr22:49612657~49615716:- LIHC cis rs4073416 0.712 rs12586842 ENSG00000276116.2 FUT8-AS1 4.29 2.38e-05 0.00557 0.27 0.23 N-glycan levels; chr14:65678304 chr14:65411170~65412690:- LIHC cis rs875971 0.545 rs17138149 ENSG00000228409.4 CCT6P1 -4.29 2.38e-05 0.00557 -0.19 -0.23 Aortic root size; chr7:66228193 chr7:65751142~65763354:+ LIHC cis rs75920871 0.764 rs76136280 ENSG00000254851.1 RP11-109L13.1 -4.28 2.38e-05 0.00557 -0.46 -0.23 Subjective well-being; chr11:116917775 chr11:117135528~117138582:+ LIHC cis rs10129255 0.576 rs2157616 ENSG00000211972.2 IGHV3-66 4.28 2.38e-05 0.00557 0.17 0.23 Kawasaki disease; chr14:106767802 chr14:106675017~106675544:- LIHC cis rs3096299 0.754 rs3096296 ENSG00000261118.1 RP11-104N10.1 4.28 2.38e-05 0.00557 0.23 0.23 Multiple myeloma (IgH translocation); chr16:89344602 chr16:89492017~89504460:- LIHC cis rs13217239 0.574 rs9366680 ENSG00000241549.7 GUSBP2 4.28 2.38e-05 0.00558 0.23 0.23 Schizophrenia; chr6:27038344 chr6:26871484~26956554:- LIHC cis rs6921919 0.789 rs13210258 ENSG00000204709.4 LINC01556 4.28 2.38e-05 0.00558 0.28 0.23 Autism spectrum disorder or schizophrenia; chr6:28340894 chr6:28943877~28944537:+ LIHC cis rs17270561 0.779 rs17271767 ENSG00000216436.2 HIST1H2APS1 -4.28 2.38e-05 0.00558 -0.34 -0.23 Iron status biomarkers; chr6:25886693 chr6:25732497~25732827:+ LIHC cis rs755249 0.567 rs61783378 ENSG00000182109.6 RP11-69E11.4 4.28 2.38e-05 0.00558 0.3 0.23 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39311487 chr1:39522280~39546187:- LIHC cis rs2284219 0.964 rs2284218 ENSG00000196295.10 AC005154.6 -4.28 2.38e-05 0.00558 -0.17 -0.23 Type 2 diabetes; chr7:30674717 chr7:30516309~30594809:- LIHC cis rs55794721 0.509 rs6699896 ENSG00000261349.1 RP3-465N24.5 -4.28 2.38e-05 0.00558 -0.22 -0.23 Mean corpuscular volume;Plateletcrit; chr1:25436411 chr1:25266102~25267136:- LIHC cis rs597539 0.652 rs516425 ENSG00000250508.1 RP11-757G1.6 -4.28 2.38e-05 0.00558 -0.36 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68948206 chr11:68870664~68874542:+ LIHC cis rs11096990 0.855 rs2566184 ENSG00000249207.1 RP11-360F5.1 4.28 2.39e-05 0.00558 0.26 0.23 Cognitive function; chr4:39162700 chr4:39112677~39126818:- LIHC cis rs2243480 0.901 rs57126451 ENSG00000230295.1 RP11-458F8.2 -4.28 2.39e-05 0.00559 -0.24 -0.23 Diabetic kidney disease; chr7:65951319 chr7:66880708~66882981:+ LIHC cis rs7811142 0.83 rs7341507 ENSG00000242294.5 STAG3L5P 4.28 2.39e-05 0.00559 0.24 0.23 Platelet count; chr7:100353692 chr7:100336079~100351900:+ LIHC cis rs2015599 0.54 rs12301475 ENSG00000275476.1 RP11-996F15.4 4.28 2.39e-05 0.00559 0.28 0.23 Platelet count;Mean platelet volume; chr12:29253144 chr12:29277397~29277882:- LIHC cis rs787274 0.543 rs4978509 ENSG00000271631.1 RP11-408O19.5 4.28 2.39e-05 0.00559 0.36 0.23 Age-related hearing impairment (SNP x SNP interaction); chr9:112873361 chr9:112885158~112885767:+ LIHC cis rs875971 0.545 rs316324 ENSG00000228409.4 CCT6P1 4.28 2.39e-05 0.00559 0.19 0.23 Aortic root size; chr7:66145627 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs316323 ENSG00000228409.4 CCT6P1 4.28 2.39e-05 0.00559 0.19 0.23 Aortic root size; chr7:66146002 chr7:65751142~65763354:+ LIHC cis rs79349575 0.783 rs4793992 ENSG00000248278.1 SUMO2P17 4.28 2.39e-05 0.00559 0.28 0.23 Type 2 diabetes; chr17:48930845 chr17:48874860~48908983:- LIHC cis rs2658782 0.756 rs2658777 ENSG00000279684.1 RP11-755E23.2 -4.28 2.39e-05 0.00559 -0.39 -0.23 Pulmonary function decline; chr11:93415257 chr11:93286629~93288903:- LIHC cis rs11098499 0.739 rs10031033 ENSG00000245958.5 RP11-33B1.1 -4.28 2.39e-05 0.0056 -0.22 -0.23 Corneal astigmatism; chr4:119230297 chr4:119454791~119552025:+ LIHC cis rs9341808 0.905 rs9343977 ENSG00000272129.1 RP11-250B2.6 4.28 2.4e-05 0.0056 0.23 0.23 Sitting height ratio; chr6:80257284 chr6:80355424~80356859:+ LIHC cis rs2348418 0.864 rs2175464 ENSG00000247934.4 RP11-967K21.1 -4.28 2.4e-05 0.0056 -0.2 -0.23 Lung function (FEV1);Lung function (FVC); chr12:28564178 chr12:28163298~28190738:- LIHC cis rs948562 0.895 rs7484263 ENSG00000280010.1 AP001350.4 4.28 2.4e-05 0.0056 0.39 0.23 Lymphoma; chr11:58608080 chr11:58627435~58628528:+ LIHC cis rs651907 0.535 rs35810977 ENSG00000244119.1 PDCL3P4 4.28 2.4e-05 0.0056 0.23 0.23 Colorectal cancer; chr3:101812536 chr3:101712472~101713191:+ LIHC cis rs2439831 0.85 rs16965120 ENSG00000166763.7 STRCP1 4.28 2.4e-05 0.00561 0.35 0.23 Lung cancer in ever smokers; chr15:43808144 chr15:43699488~43718184:- LIHC cis rs2744375 0.6 rs2744362 ENSG00000261189.1 RP3-512B11.3 4.28 2.4e-05 0.00561 0.29 0.23 Resting heart rate; chr6:7550975 chr6:7540451~7541338:- LIHC cis rs2243480 1 rs937108 ENSG00000228409.4 CCT6P1 4.28 2.4e-05 0.00561 0.24 0.23 Diabetic kidney disease; chr7:65963465 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs35542501 ENSG00000228409.4 CCT6P1 4.28 2.4e-05 0.00561 0.24 0.23 Diabetic kidney disease; chr7:65966228 chr7:65751142~65763354:+ LIHC cis rs2243480 0.711 rs1626926 ENSG00000228409.4 CCT6P1 4.28 2.4e-05 0.00561 0.24 0.23 Diabetic kidney disease; chr7:65970805 chr7:65751142~65763354:+ LIHC cis rs2243480 0.708 rs781141 ENSG00000228409.4 CCT6P1 4.28 2.4e-05 0.00561 0.24 0.23 Diabetic kidney disease; chr7:65973566 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs781142 ENSG00000228409.4 CCT6P1 4.28 2.4e-05 0.00561 0.24 0.23 Diabetic kidney disease; chr7:65973791 chr7:65751142~65763354:+ LIHC cis rs17711722 0.503 rs453835 ENSG00000237310.1 GS1-124K5.4 -4.28 2.4e-05 0.00561 -0.2 -0.23 Calcium levels; chr7:66046172 chr7:66493706~66495474:+ LIHC cis rs12681366 0.919 rs13248829 ENSG00000253704.1 RP11-267M23.4 4.28 2.4e-05 0.00561 0.26 0.23 Nonsyndromic cleft lip with cleft palate; chr8:94476750 chr8:94553722~94569745:+ LIHC cis rs11247230 0.901 rs2411841 ENSG00000270127.2 RP11-526I2.5 4.28 2.4e-05 0.00561 0.27 0.23 Optic cup area; chr15:100652046 chr15:100547765~100550153:- LIHC cis rs709400 0.93 rs10134399 ENSG00000258534.1 CTD-2134A5.4 4.28 2.41e-05 0.00562 0.34 0.23 Body mass index; chr14:103617120 chr14:103854366~103880111:- LIHC cis rs4925386 0.959 rs4925385 ENSG00000226332.2 RP11-157P1.4 -4.28 2.41e-05 0.00562 -0.23 -0.23 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62345568 chr20:62305432~62306325:- LIHC cis rs4925386 0.921 rs11204472 ENSG00000226332.2 RP11-157P1.4 -4.28 2.41e-05 0.00562 -0.23 -0.23 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62345831 chr20:62305432~62306325:- LIHC cis rs4713118 0.662 rs4713120 ENSG00000216901.1 AL022393.7 4.28 2.41e-05 0.00562 0.25 0.23 Parkinson's disease; chr6:27754056 chr6:28176188~28176674:+ LIHC cis rs9652601 0.845 rs7184615 ENSG00000274038.1 RP11-66H6.4 -4.28 2.41e-05 0.00562 -0.27 -0.23 Systemic lupus erythematosus; chr16:11071685 chr16:11056556~11057034:+ LIHC cis rs5742933 0.762 rs2033746 ENSG00000253559.1 OSGEPL1-AS1 4.28 2.41e-05 0.00562 0.29 0.23 Ferritin levels; chr2:189734726 chr2:189762704~189765556:+ LIHC cis rs6480314 0.711 rs61857177 ENSG00000233590.1 RP11-153K11.3 -4.28 2.41e-05 0.00562 -0.38 -0.23 Optic nerve measurement (disc area); chr10:68187015 chr10:68233251~68242379:- LIHC cis rs2310173 0.575 rs4851527 ENSG00000281162.1 LINC01127 4.28 2.41e-05 0.00563 0.24 0.23 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:102005914 chr2:101962056~101987167:+ LIHC cis rs4561483 0.832 rs171656 ENSG00000261560.1 RP11-166B2.3 -4.28 2.41e-05 0.00563 -0.25 -0.23 Testicular germ cell tumor; chr16:11859310 chr16:11881075~11882569:- LIHC cis rs2243480 1 rs13247184 ENSG00000228409.4 CCT6P1 4.28 2.41e-05 0.00563 0.25 0.23 Diabetic kidney disease; chr7:65893941 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs35283677 ENSG00000228409.4 CCT6P1 4.28 2.41e-05 0.00563 0.25 0.23 Diabetic kidney disease; chr7:65894246 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs35421653 ENSG00000228409.4 CCT6P1 4.28 2.41e-05 0.00563 0.25 0.23 Diabetic kidney disease; chr7:65898442 chr7:65751142~65763354:+ LIHC cis rs11064837 0.55 rs11064849 ENSG00000248636.5 RP11-768F21.1 4.28 2.41e-05 0.00563 0.39 0.23 Schizophrenia; chr12:119616782 chr12:119387987~119668079:- LIHC cis rs2274273 0.84 rs28493647 ENSG00000258413.1 RP11-665C16.6 -4.28 2.42e-05 0.00564 -0.26 -0.23 Protein biomarker; chr14:55357745 chr14:55262767~55272075:- LIHC cis rs2274273 0.84 rs17674463 ENSG00000258413.1 RP11-665C16.6 -4.28 2.42e-05 0.00564 -0.26 -0.23 Protein biomarker; chr14:55358145 chr14:55262767~55272075:- LIHC cis rs673078 0.615 rs73222058 ENSG00000275409.1 RP11-131L12.4 -4.28 2.42e-05 0.00564 -0.28 -0.23 Glucose homeostasis traits; chr12:118221066 chr12:118430147~118430699:+ LIHC cis rs950881 0.932 rs72823632 ENSG00000234389.1 AC007278.3 4.28 2.42e-05 0.00564 0.3 0.23 Allergy; chr2:102315074 chr2:102438713~102440475:+ LIHC cis rs950881 0.932 rs72823635 ENSG00000234389.1 AC007278.3 4.28 2.42e-05 0.00564 0.3 0.23 Allergy; chr2:102315152 chr2:102438713~102440475:+ LIHC cis rs950881 1 rs950881 ENSG00000234389.1 AC007278.3 4.28 2.42e-05 0.00564 0.3 0.23 Allergy; chr2:102316052 chr2:102438713~102440475:+ LIHC cis rs950881 0.932 rs10179458 ENSG00000234389.1 AC007278.3 4.28 2.42e-05 0.00564 0.3 0.23 Allergy; chr2:102318514 chr2:102438713~102440475:+ LIHC cis rs673078 0.607 rs17512763 ENSG00000275759.1 RP11-131L12.3 -4.28 2.42e-05 0.00564 -0.44 -0.23 Glucose homeostasis traits; chr12:118400974 chr12:118428281~118428870:+ LIHC cis rs9595908 0.931 rs7998440 ENSG00000212293.1 SNORA16 4.28 2.42e-05 0.00564 0.26 0.23 Body mass index; chr13:32551069 chr13:32420390~32420516:- LIHC cis rs9595908 0.965 rs7991314 ENSG00000212293.1 SNORA16 4.28 2.42e-05 0.00564 0.26 0.23 Body mass index; chr13:32551937 chr13:32420390~32420516:- LIHC cis rs9595908 0.965 rs7328733 ENSG00000212293.1 SNORA16 4.28 2.42e-05 0.00564 0.26 0.23 Body mass index; chr13:32552600 chr13:32420390~32420516:- LIHC cis rs2060793 0.741 rs10741653 ENSG00000251991.1 RNU7-49P 4.28 2.42e-05 0.00564 0.25 0.23 Vitamin D levels; chr11:14683294 chr11:14478892~14478953:+ LIHC cis rs9400467 0.528 rs465796 ENSG00000271789.1 RP5-1112D6.7 -4.28 2.42e-05 0.00564 -0.22 -0.23 Amino acid levels;Blood metabolite levels; chr6:111298522 chr6:111297126~111298510:+ LIHC cis rs2739330 0.828 rs4822454 ENSG00000206090.4 AP000350.7 4.28 2.42e-05 0.00565 0.27 0.23 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23939998~23942798:+ LIHC cis rs2333021 0.78 rs2243596 ENSG00000259015.1 RP11-109N23.6 -4.28 2.42e-05 0.00565 -0.27 -0.23 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72961952 chr14:72960595~72961993:+ LIHC cis rs4938303 0.633 rs567209 ENSG00000254851.1 RP11-109L13.1 4.28 2.42e-05 0.00565 0.31 0.23 Triglycerides; chr11:116664111 chr11:117135528~117138582:+ LIHC cis rs75920871 0.688 rs77320801 ENSG00000254851.1 RP11-109L13.1 -4.28 2.42e-05 0.00565 -0.47 -0.23 Subjective well-being; chr11:116965633 chr11:117135528~117138582:+ LIHC cis rs2749592 0.55 rs7917262 ENSG00000276805.1 RP11-291L22.6 -4.28 2.42e-05 0.00565 -0.27 -0.23 Age-related hearing impairment (SNP x SNP interaction); chr10:37585674 chr10:38451030~38451785:+ LIHC cis rs2749592 0.55 rs9733309 ENSG00000276805.1 RP11-291L22.6 -4.28 2.42e-05 0.00565 -0.27 -0.23 Age-related hearing impairment (SNP x SNP interaction); chr10:37593477 chr10:38451030~38451785:+ LIHC cis rs2749592 0.55 rs7081464 ENSG00000276805.1 RP11-291L22.6 -4.28 2.42e-05 0.00565 -0.27 -0.23 Age-related hearing impairment (SNP x SNP interaction); chr10:37595009 chr10:38451030~38451785:+ LIHC cis rs2749592 0.531 rs994804 ENSG00000276805.1 RP11-291L22.6 -4.28 2.42e-05 0.00565 -0.27 -0.23 Age-related hearing impairment (SNP x SNP interaction); chr10:37611212 chr10:38451030~38451785:+ LIHC cis rs7726839 0.54 rs12517638 ENSG00000271781.1 CTD-2589H19.6 -4.28 2.42e-05 0.00565 -0.34 -0.23 Obesity-related traits; chr5:645369 chr5:675826~676616:+ LIHC cis rs7726839 0.54 rs4957081 ENSG00000271781.1 CTD-2589H19.6 -4.28 2.42e-05 0.00565 -0.34 -0.23 Obesity-related traits; chr5:646303 chr5:675826~676616:+ LIHC cis rs7726839 0.54 rs72705097 ENSG00000271781.1 CTD-2589H19.6 -4.28 2.42e-05 0.00565 -0.34 -0.23 Obesity-related traits; chr5:654952 chr5:675826~676616:+ LIHC cis rs10129255 0.5 rs1024350 ENSG00000211972.2 IGHV3-66 4.28 2.43e-05 0.00565 0.17 0.23 Kawasaki disease; chr14:106685105 chr14:106675017~106675544:- LIHC cis rs10129255 0.518 rs7143784 ENSG00000211972.2 IGHV3-66 4.28 2.43e-05 0.00565 0.17 0.23 Kawasaki disease; chr14:106687277 chr14:106675017~106675544:- LIHC cis rs228614 0.51 rs223378 ENSG00000246560.2 RP11-10L12.4 4.28 2.43e-05 0.00566 0.26 0.23 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102833488 chr4:102828055~102844075:+ LIHC cis rs2842992 0.789 rs2295901 ENSG00000237927.1 RP3-393E18.2 -4.28 2.43e-05 0.00566 -0.27 -0.23 Age-related macular degeneration (geographic atrophy); chr6:159780263 chr6:159586955~159589169:- LIHC cis rs2842992 0.789 rs3818300 ENSG00000237927.1 RP3-393E18.2 -4.28 2.43e-05 0.00566 -0.27 -0.23 Age-related macular degeneration (geographic atrophy); chr6:159780645 chr6:159586955~159589169:- LIHC cis rs2744375 0.6 rs2078438 ENSG00000261189.1 RP3-512B11.3 4.28 2.43e-05 0.00566 0.29 0.23 Resting heart rate; chr6:7552996 chr6:7540451~7541338:- LIHC cis rs597539 0.652 rs11603827 ENSG00000250508.1 RP11-757G1.6 -4.28 2.43e-05 0.00566 -0.35 -0.23 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68951752 chr11:68870664~68874542:+ LIHC cis rs2599510 0.783 rs2710626 ENSG00000276334.1 AL133243.1 4.28 2.43e-05 0.00566 0.25 0.23 Interleukin-18 levels; chr2:32533687 chr2:32521927~32523547:+ LIHC cis rs4660456 0.913 rs12743517 ENSG00000237899.1 RP4-739H11.3 4.28 2.43e-05 0.00566 0.3 0.23 Platelet count; chr1:40759682 chr1:40669089~40687588:- LIHC cis rs6545883 0.507 rs2123111 ENSG00000271889.1 RP11-493E12.1 -4.28 2.43e-05 0.00566 -0.27 -0.23 Tuberculosis; chr2:61223319 chr2:61151433~61162105:- LIHC cis rs9952991 0.527 rs2847259 ENSG00000260302.1 RP11-973H7.1 -4.28 2.43e-05 0.00566 -0.29 -0.23 Inflammatory skin disease; chr18:12775822 chr18:12774651~12775923:- LIHC cis rs1499614 1 rs34250985 ENSG00000230295.1 RP11-458F8.2 -4.28 2.43e-05 0.00567 -0.26 -0.23 Gout; chr7:66696075 chr7:66880708~66882981:+ LIHC cis rs2717559 0.542 rs2717590 ENSG00000253196.1 RP11-706C16.7 -4.28 2.43e-05 0.00567 -0.25 -0.23 Urinary tract infection frequency; chr8:142819296 chr8:142763116~142766427:+ LIHC cis rs875971 0.545 rs1796219 ENSG00000273024.4 INTS4P2 4.28 2.43e-05 0.00567 0.26 0.23 Aortic root size; chr7:66645977 chr7:65647864~65715661:+ LIHC cis rs1577917 1 rs12207610 ENSG00000234155.1 RP11-30P6.6 4.28 2.43e-05 0.00567 0.29 0.23 Response to antipsychotic treatment; chr6:85978298 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs12203457 ENSG00000234155.1 RP11-30P6.6 4.28 2.43e-05 0.00567 0.29 0.23 Response to antipsychotic treatment; chr6:85979559 chr6:85387219~85390186:- LIHC cis rs160451 1 rs160449 ENSG00000251136.7 RP11-37B2.1 4.28 2.44e-05 0.00568 0.21 0.23 Leprosy; chr8:89648287 chr8:89609409~89757727:- LIHC cis rs13217239 0.646 rs35691005 ENSG00000241549.7 GUSBP2 4.28 2.44e-05 0.00568 0.23 0.23 Schizophrenia; chr6:27004291 chr6:26871484~26956554:- LIHC cis rs13217239 0.646 rs10946891 ENSG00000241549.7 GUSBP2 4.28 2.44e-05 0.00568 0.23 0.23 Schizophrenia; chr6:27005436 chr6:26871484~26956554:- LIHC cis rs13217239 0.646 rs12201393 ENSG00000241549.7 GUSBP2 4.28 2.44e-05 0.00568 0.23 0.23 Schizophrenia; chr6:27007911 chr6:26871484~26956554:- LIHC cis rs13217239 0.646 rs12209886 ENSG00000241549.7 GUSBP2 4.28 2.44e-05 0.00568 0.23 0.23 Schizophrenia; chr6:27016978 chr6:26871484~26956554:- LIHC cis rs6940638 0.531 rs12211984 ENSG00000241549.7 GUSBP2 4.28 2.44e-05 0.00568 0.23 0.23 Intelligence (multi-trait analysis); chr6:27018275 chr6:26871484~26956554:- LIHC cis rs13217239 0.646 rs10456351 ENSG00000241549.7 GUSBP2 4.28 2.44e-05 0.00568 0.23 0.23 Schizophrenia; chr6:27019013 chr6:26871484~26956554:- LIHC cis rs651907 0.535 rs11711903 ENSG00000244119.1 PDCL3P4 4.28 2.44e-05 0.00568 0.23 0.23 Colorectal cancer; chr3:101781904 chr3:101712472~101713191:+ LIHC cis rs12571093 0.773 rs3740588 ENSG00000233590.1 RP11-153K11.3 4.28 2.44e-05 0.00568 0.34 0.23 Optic nerve measurement (disc area); chr10:68261079 chr10:68233251~68242379:- LIHC cis rs27434 0.605 rs2351012 ENSG00000272109.1 CTD-2260A17.3 -4.28 2.44e-05 0.00568 -0.3 -0.23 Ankylosing spondylitis; chr5:96856044 chr5:96804353~96806105:+ LIHC cis rs919433 0.889 rs10931782 ENSG00000231621.1 AC013264.2 4.28 2.44e-05 0.00568 0.21 0.23 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197346855 chr2:197197991~197199273:+ LIHC cis rs904251 1 rs904251 ENSG00000204110.6 RP1-153P14.8 -4.28 2.44e-05 0.00569 -0.27 -0.23 Cognitive performance; chr6:37483920 chr6:37507348~37535616:+ LIHC cis rs875971 0.545 rs4441996 ENSG00000228409.4 CCT6P1 4.28 2.44e-05 0.00569 0.19 0.23 Aortic root size; chr7:66123233 chr7:65751142~65763354:+ LIHC cis rs6445975 0.666 rs3922713 ENSG00000272360.1 RP11-359I18.5 4.28 2.44e-05 0.00569 0.3 0.23 Systemic lupus erythematosus; chr3:58398061 chr3:58490830~58491291:- LIHC cis rs27434 0.615 rs61112531 ENSG00000272109.1 CTD-2260A17.3 4.28 2.44e-05 0.00569 0.3 0.23 Ankylosing spondylitis; chr5:96856117 chr5:96804353~96806105:+ LIHC cis rs7208859 0.673 rs9889755 ENSG00000266490.1 CTD-2349P21.9 -4.28 2.44e-05 0.00569 -0.27 -0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30907487 chr17:30792372~30792833:+ LIHC cis rs10829156 0.741 rs9731044 ENSG00000240291.1 RP11-499P20.2 4.28 2.45e-05 0.0057 0.37 0.23 Sudden cardiac arrest; chr10:18605356 chr10:18513115~18545651:- LIHC cis rs10829156 0.538 rs61840846 ENSG00000240291.1 RP11-499P20.2 4.28 2.45e-05 0.0057 0.37 0.23 Sudden cardiac arrest; chr10:18606393 chr10:18513115~18545651:- LIHC cis rs524281 0.692 rs2302884 ENSG00000255320.1 RP11-755F10.1 4.28 2.45e-05 0.0057 0.32 0.23 Electroencephalogram traits; chr11:66056613 chr11:66244840~66246239:- LIHC cis rs524281 0.647 rs2302883 ENSG00000255320.1 RP11-755F10.1 4.28 2.45e-05 0.0057 0.32 0.23 Electroencephalogram traits; chr11:66057523 chr11:66244840~66246239:- LIHC cis rs948562 0.947 rs7481388 ENSG00000280010.1 AP001350.4 4.28 2.45e-05 0.0057 0.38 0.23 Lymphoma; chr11:58592143 chr11:58627435~58628528:+ LIHC cis rs1005277 0.579 rs1740735 ENSG00000099251.13 HSD17B7P2 4.28 2.45e-05 0.0057 0.27 0.23 Extrinsic epigenetic age acceleration; chr10:38208849 chr10:38356380~38378505:+ LIHC cis rs3812762 0.917 rs11042066 ENSG00000254860.4 TMEM9B-AS1 -4.28 2.45e-05 0.0057 -0.23 -0.23 Hypospadias; chr11:8788013 chr11:8964675~8977527:+ LIHC cis rs6088765 0.596 rs7280 ENSG00000126005.14 MMP24-AS1 -4.28 2.45e-05 0.0057 -0.29 -0.23 Ulcerative colitis; chr20:35276681 chr20:35216462~35278131:- LIHC cis rs6480314 0.711 rs78671884 ENSG00000233590.1 RP11-153K11.3 -4.28 2.45e-05 0.0057 -0.38 -0.23 Optic nerve measurement (disc area); chr10:68192669 chr10:68233251~68242379:- LIHC cis rs6480314 0.711 rs61857181 ENSG00000233590.1 RP11-153K11.3 -4.28 2.45e-05 0.0057 -0.38 -0.23 Optic nerve measurement (disc area); chr10:68193771 chr10:68233251~68242379:- LIHC cis rs7208859 0.673 rs73263785 ENSG00000266490.1 CTD-2349P21.9 4.28 2.45e-05 0.0057 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887790 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs55904046 ENSG00000266490.1 CTD-2349P21.9 4.28 2.45e-05 0.0057 0.29 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888373 chr17:30792372~30792833:+ LIHC cis rs5756813 0.661 rs2071910 ENSG00000233360.4 Z83844.1 4.28 2.45e-05 0.00571 0.28 0.23 Optic cup area;Vertical cup-disc ratio; chr22:37808252 chr22:37641832~37658377:- LIHC cis rs160451 0.966 rs160450 ENSG00000251136.7 RP11-37B2.1 4.28 2.45e-05 0.00571 0.21 0.23 Leprosy; chr8:89650354 chr8:89609409~89757727:- LIHC cis rs73198271 0.855 rs57301822 ENSG00000253893.2 FAM85B 4.28 2.45e-05 0.00571 0.35 0.23 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8751132 chr8:8167819~8226614:- LIHC cis rs960902 0.818 rs58694726 ENSG00000213553.4 RPLP0P6 4.28 2.45e-05 0.00571 0.19 0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37491553 chr2:38481851~38482804:+ LIHC cis rs7586604 0.608 rs2115600 ENSG00000230393.1 AC092667.2 4.28 2.45e-05 0.00571 0.29 0.23 Cannabis dependence symptom count; chr2:99781169 chr2:100104919~100107504:+ LIHC cis rs2749592 0.611 rs2505199 ENSG00000263064.2 RP11-291L22.7 4.28 2.46e-05 0.00572 0.24 0.23 Age-related hearing impairment (SNP x SNP interaction); chr10:38103529 chr10:38448689~38448949:+ LIHC cis rs2749592 0.588 rs2505192 ENSG00000263064.2 RP11-291L22.7 4.28 2.46e-05 0.00572 0.24 0.23 Age-related hearing impairment (SNP x SNP interaction); chr10:38106095 chr10:38448689~38448949:+ LIHC cis rs524281 0.954 rs549187 ENSG00000255320.1 RP11-755F10.1 4.28 2.46e-05 0.00572 0.27 0.23 Electroencephalogram traits; chr11:66131160 chr11:66244840~66246239:- LIHC cis rs4845875 0.514 rs198392 ENSG00000242349.4 NPPA-AS1 -4.28 2.46e-05 0.00572 -0.23 -0.23 Midregional pro atrial natriuretic peptide levels; chr1:11819105 chr1:11841017~11848079:+ LIHC cis rs9450351 0.546 rs9344550 ENSG00000203875.9 SNHG5 -4.28 2.46e-05 0.00572 -0.48 -0.23 Interferon gamma-induced protein 10 levels; chr6:85829000 chr6:85660950~85678736:- LIHC cis rs11767557 1 rs11763230 ENSG00000229153.4 EPHA1-AS1 4.28 2.46e-05 0.00572 0.35 0.23 Alzheimer's disease (late onset); chr7:143411748 chr7:143407813~143523449:+ LIHC cis rs921968 0.54 rs6746040 ENSG00000272555.1 RP11-459I19.1 -4.28 2.46e-05 0.00572 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218724167 chr2:218818690~218819144:+ LIHC cis rs2153535 0.967 rs10484750 ENSG00000230939.1 RP11-314C16.1 4.28 2.46e-05 0.00573 0.26 0.23 Motion sickness; chr6:8378376 chr6:8784178~8785445:+ LIHC cis rs12908161 1 rs12908161 ENSG00000225151.9 GOLGA2P7 -4.28 2.46e-05 0.00573 -0.29 -0.23 Schizophrenia; chr15:84664594 chr15:84199311~84230136:- LIHC cis rs9675120 0.638 rs4626 ENSG00000262006.1 RP11-700H6.4 -4.28 2.46e-05 0.00573 -0.24 -0.23 Cerebrospinal fluid biomarker levels; chr17:50863061 chr17:50909637~50910232:- LIHC cis rs7702057 0.53 rs7703978 ENSG00000271918.1 CTD-2287O16.5 4.28 2.46e-05 0.00573 0.31 0.23 Amyotrophic lateral sclerosis; chr5:116085951 chr5:116083807~116085416:- LIHC cis rs9843304 0.585 rs9842139 ENSG00000244503.1 RP11-278L15.6 -4.28 2.46e-05 0.00573 -0.28 -0.23 Gallstone disease; chr3:149489730 chr3:149494660~149495995:+ LIHC cis rs12701220 0.842 rs10236293 ENSG00000229043.2 AC091729.9 -4.28 2.47e-05 0.00574 -0.33 -0.23 Bronchopulmonary dysplasia; chr7:993001 chr7:1160374~1165267:+ LIHC cis rs67311347 0.955 rs4974067 ENSG00000223797.4 ENTPD3-AS1 4.28 2.47e-05 0.00574 0.18 0.23 Renal cell carcinoma; chr3:40333060 chr3:40313802~40453329:- LIHC cis rs11096990 0.964 rs16988409 ENSG00000249685.1 RP11-360F5.3 4.28 2.47e-05 0.00574 0.3 0.23 Cognitive function; chr4:39267730 chr4:39133913~39135608:+ LIHC cis rs1005277 0.505 rs7917943 ENSG00000275858.1 RP11-291L22.8 -4.28 2.47e-05 0.00574 -0.25 -0.23 Extrinsic epigenetic age acceleration; chr10:37906883 chr10:38450738~38451069:- LIHC cis rs4845875 0.53 rs4846048 ENSG00000242349.4 NPPA-AS1 -4.28 2.47e-05 0.00574 -0.26 -0.23 Midregional pro atrial natriuretic peptide levels; chr1:11786195 chr1:11841017~11848079:+ LIHC cis rs2562456 0.652 rs4809145 ENSG00000268555.1 RP11-678G14.3 4.28 2.47e-05 0.00574 0.3 0.23 Pain; chr19:21597907 chr19:21570822~21587322:- LIHC cis rs651907 0.535 rs17347156 ENSG00000244119.1 PDCL3P4 4.28 2.47e-05 0.00574 0.24 0.23 Colorectal cancer; chr3:101785830 chr3:101712472~101713191:+ LIHC cis rs867371 0.722 rs8033050 ENSG00000259429.4 UBE2Q2P2 -4.28 2.47e-05 0.00575 -0.22 -0.23 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82269648 chr15:82355142~82420075:+ LIHC cis rs2032447 0.736 rs115810 ENSG00000242387.1 HIST1H2APS2 4.28 2.47e-05 0.00575 0.3 0.23 Intelligence (multi-trait analysis); chr6:25975655 chr6:25882026~25882395:- LIHC cis rs2280018 0.526 rs2966128 ENSG00000188599.16 NPIPP1 -4.28 2.47e-05 0.00575 -0.21 -0.23 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059532 chr16:15104312~15123498:- LIHC cis rs10871290 0.881 rs11649338 ENSG00000261079.1 RP11-252A24.3 -4.28 2.47e-05 0.00575 -0.25 -0.23 Breast cancer; chr16:74437522 chr16:74367462~74369826:+ LIHC cis rs2439831 0.85 rs11856795 ENSG00000166763.7 STRCP1 4.28 2.47e-05 0.00575 0.35 0.23 Lung cancer in ever smokers; chr15:43868384 chr15:43699488~43718184:- LIHC cis rs4578769 0.959 rs9955664 ENSG00000265943.1 RP11-739L10.1 4.28 2.47e-05 0.00575 0.29 0.23 Eosinophil percentage of white cells; chr18:22901330 chr18:22699481~22933764:- LIHC cis rs7508 0.511 rs2237853 ENSG00000253671.1 RP11-806O11.1 -4.28 2.47e-05 0.00575 -0.3 -0.23 Atrial fibrillation; chr8:18020371 chr8:17808941~17820868:+ LIHC cis rs10129255 0.957 rs28887506 ENSG00000211970.3 IGHV4-61 -4.28 2.47e-05 0.00575 -0.18 -0.23 Kawasaki disease; chr14:106785589 chr14:106639119~106639657:- LIHC cis rs7208859 0.573 rs216443 ENSG00000266490.1 CTD-2349P21.9 4.28 2.47e-05 0.00575 0.27 0.23 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604853 chr17:30792372~30792833:+ LIHC cis rs881375 0.678 rs2269060 ENSG00000226752.6 PSMD5-AS1 -4.28 2.47e-05 0.00575 -0.23 -0.23 Rheumatoid arthritis; chr9:120921291 chr9:120824828~120854385:+ LIHC cis rs494453 0.845 rs523650 ENSG00000227811.2 FAM212B-AS1 -4.28 2.48e-05 0.00576 -0.25 -0.23 Osteoporosis-related phenotypes; chr1:111699642 chr1:111739841~111747798:+ LIHC cis rs9595908 0.785 rs12428283 ENSG00000212293.1 SNORA16 4.28 2.48e-05 0.00577 0.25 0.23 Body mass index; chr13:32653775 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs9596035 ENSG00000212293.1 SNORA16 4.28 2.48e-05 0.00577 0.25 0.23 Body mass index; chr13:32654803 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs4942791 ENSG00000212293.1 SNORA16 4.28 2.48e-05 0.00577 0.25 0.23 Body mass index; chr13:32663085 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs9591230 ENSG00000212293.1 SNORA16 4.28 2.48e-05 0.00577 0.25 0.23 Body mass index; chr13:32663944 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs2874282 ENSG00000212293.1 SNORA16 4.28 2.48e-05 0.00577 0.25 0.23 Body mass index; chr13:32665876 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs9596057 ENSG00000212293.1 SNORA16 4.28 2.48e-05 0.00577 0.25 0.23 Body mass index; chr13:32669831 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs9596059 ENSG00000212293.1 SNORA16 4.28 2.48e-05 0.00577 0.25 0.23 Body mass index; chr13:32670145 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs9596060 ENSG00000212293.1 SNORA16 4.28 2.48e-05 0.00577 0.25 0.23 Body mass index; chr13:32670467 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs7317147 ENSG00000212293.1 SNORA16 4.28 2.48e-05 0.00577 0.25 0.23 Body mass index; chr13:32670838 chr13:32420390~32420516:- LIHC cis rs244293 0.965 rs244352 ENSG00000275710.1 RP11-257O5.4 -4.28 2.48e-05 0.00577 -0.25 -0.23 Menarche (age at onset); chr17:55118117 chr17:54964474~54964679:+ LIHC cis rs9303401 0.555 rs8073699 ENSG00000265415.1 CTD-2510F5.4 4.28 2.48e-05 0.00577 0.16 0.23 Cognitive test performance; chr17:59158956 chr17:59202677~59203829:- LIHC cis rs901683 0.85 rs60791882 ENSG00000230869.1 CTGLF10P -4.28 2.48e-05 0.00577 -0.52 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45604590 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs73291195 ENSG00000230869.1 CTGLF10P -4.28 2.48e-05 0.00577 -0.52 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45605573 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs73291198 ENSG00000230869.1 CTGLF10P -4.28 2.48e-05 0.00577 -0.52 -0.23 Mean corpuscular volume;Red blood cell traits; chr10:45605638 chr10:45678692~45700532:+ LIHC cis rs7412746 0.658 rs72704652 ENSG00000231073.1 RP11-316M1.3 4.28 2.48e-05 0.00577 0.24 0.23 Melanoma; chr1:150846994 chr1:150973123~150975534:+ LIHC cis rs11971779 0.68 rs11768023 ENSG00000273391.1 RP11-634H22.1 4.28 2.48e-05 0.00577 0.2 0.23 Diisocyanate-induced asthma; chr7:139369649 chr7:139359032~139359566:- LIHC cis rs11233413 0.874 rs4515990 ENSG00000246067.6 RAB30-AS1 4.27 2.48e-05 0.00577 0.31 0.23 Economic and political preferences (feminism/equality); chr11:83041420 chr11:83072066~83106719:+ LIHC cis rs921968 0.565 rs3731876 ENSG00000272555.1 RP11-459I19.1 -4.27 2.48e-05 0.00577 -0.24 -0.23 Mean corpuscular hemoglobin concentration; chr2:218738096 chr2:218818690~218819144:+ LIHC cis rs17711722 0.51 rs11767457 ENSG00000273024.4 INTS4P2 -4.27 2.49e-05 0.00578 -0.24 -0.23 Calcium levels; chr7:65825628 chr7:65647864~65715661:+ LIHC cis rs11098499 1 rs11098500 ENSG00000260091.1 RP11-33B1.4 -4.27 2.49e-05 0.00578 -0.16 -0.23 Corneal astigmatism; chr4:119298084 chr4:119409333~119410233:+ LIHC cis rs2072510 0.569 rs61937880 ENSG00000257878.1 RP11-256L6.3 -4.27 2.49e-05 0.00578 -0.3 -0.23 Metabolite levels (small molecules and protein measures); chr12:95997089 chr12:95996521~96011489:+ LIHC cis rs73086581 0.524 rs2253977 ENSG00000229539.1 RP11-119B16.2 -4.27 2.49e-05 0.00579 -0.24 -0.23 Response to antidepressants in depression; chr20:3958493 chr20:3888239~3888868:- LIHC cis rs11168351 0.517 rs10875754 ENSG00000240399.1 RP1-228P16.1 4.27 2.49e-05 0.00579 0.22 0.23 Bipolar disorder and schizophrenia; chr12:48164139 chr12:48054813~48055591:- LIHC cis rs2072510 0.722 rs2247323 ENSG00000257878.1 RP11-256L6.3 -4.27 2.49e-05 0.00579 -0.19 -0.23 Metabolite levels (small molecules and protein measures); chr12:96030478 chr12:95996521~96011489:+ LIHC cis rs2072510 0.722 rs2247313 ENSG00000257878.1 RP11-256L6.3 -4.27 2.49e-05 0.00579 -0.19 -0.23 Metabolite levels (small molecules and protein measures); chr12:96030669 chr12:95996521~96011489:+ LIHC cis rs2072510 0.722 rs2247309 ENSG00000257878.1 RP11-256L6.3 -4.27 2.49e-05 0.00579 -0.19 -0.23 Metabolite levels (small molecules and protein measures); chr12:96030764 chr12:95996521~96011489:+ LIHC cis rs2072510 0.75 rs2660898 ENSG00000257878.1 RP11-256L6.3 -4.27 2.49e-05 0.00579 -0.19 -0.23 Metabolite levels (small molecules and protein measures); chr12:96032219 chr12:95996521~96011489:+ LIHC cis rs172166 0.769 rs149965 ENSG00000216901.1 AL022393.7 4.27 2.49e-05 0.00579 0.29 0.23 Cardiac Troponin-T levels; chr6:28050911 chr6:28176188~28176674:+ LIHC cis rs4356203 0.87 rs214922 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17215576 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs214921 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17215914 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs214918 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17218302 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs214915 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17220226 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs214914 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17220345 chr11:17380649~17383531:+ LIHC cis rs4356203 0.84 rs214911 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17220691 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs214910 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17221242 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs214909 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17221731 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs603618 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17224815 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs618331 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17225789 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs7949699 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17226161 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs10832745 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17228128 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs11024204 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17228258 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs10832746 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17228406 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs10832747 ENSG00000260196.1 RP1-239B22.5 -4.27 2.5e-05 0.0058 -0.27 -0.23 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17228472 chr11:17380649~17383531:+ LIHC cis rs9595908 0.965 rs9595795 ENSG00000212293.1 SNORA16 4.27 2.5e-05 0.0058 0.27 0.23 Body mass index; chr13:32548658 chr13:32420390~32420516:- LIHC cis rs10262624 0.901 rs6966655 ENSG00000234286.1 AC006026.13 -4.27 2.5e-05 0.0058 -0.25 -0.23 Schizophrenia; chr7:23867010 chr7:23680195~23680786:- LIHC cis rs960902 0.747 rs6724538 ENSG00000213553.4 RPLP0P6 -4.27 2.5e-05 0.00581 -0.18 -0.23 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37500875 chr2:38481851~38482804:+ LIHC cis rs2243480 0.711 rs2420172 ENSG00000230295.1 RP11-458F8.2 4.27 2.5e-05 0.00581 0.24 0.23 Diabetic kidney disease; chr7:66170354 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs6974723 ENSG00000230295.1 RP11-458F8.2 4.27 2.5e-05 0.00581 0.24 0.23 Diabetic kidney disease; chr7:66172952 chr7:66880708~66882981:+ LIHC cis rs875971 0.545 rs73146609 ENSG00000273024.4 INTS4P2 -4.27 2.5e-05 0.00581 -0.26 -0.23 Aortic root size; chr7:66302477 chr7:65647864~65715661:+ LIHC cis rs11098499 0.909 rs11723839 ENSG00000260091.1 RP11-33B1.4 -4.27 2.5e-05 0.00581 -0.16 -0.23 Corneal astigmatism; chr4:119378518 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs12506546 ENSG00000260091.1 RP11-33B1.4 -4.27 2.5e-05 0.00581 -0.16 -0.23 Corneal astigmatism; chr4:119380463 chr4:119409333~119410233:+ LIHC cis rs7129556 0.69 rs947841 ENSG00000254459.1 RP11-91P24.7 4.27 2.5e-05 0.00582 0.37 0.23 Weight loss (gastric bypass surgery); chr11:77881863 chr11:77829654~77872262:- LIHC cis rs4845875 0.559 rs4846047 ENSG00000242349.4 NPPA-AS1 4.27 2.5e-05 0.00582 0.26 0.23 Midregional pro atrial natriuretic peptide levels; chr1:11783575 chr1:11841017~11848079:+ LIHC cis rs11098499 0.863 rs3775843 ENSG00000260091.1 RP11-33B1.4 -4.27 2.51e-05 0.00582 -0.16 -0.23 Corneal astigmatism; chr4:119506689 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs3775844 ENSG00000260091.1 RP11-33B1.4 -4.27 2.51e-05 0.00582 -0.16 -0.23 Corneal astigmatism; chr4:119506878 chr4:119409333~119410233:+ LIHC cis rs6480314 0.519 rs3998872 ENSG00000233590.1 RP11-153K11.3 -4.27 2.51e-05 0.00582 -0.37 -0.23 Optic nerve measurement (disc area); chr10:68184845 chr10:68233251~68242379:- LIHC cis rs4356975 0.509 rs5014975 ENSG00000196472.4 RP13-644M16.4 4.27 2.51e-05 0.00582 0.25 0.23 Obesity-related traits; chr4:69130244 chr4:69181660~69182372:+ LIHC cis rs4356975 0.867 rs6600869 ENSG00000250919.1 RP11-813N20.3 -4.27 2.51e-05 0.00583 -0.22 -0.23 Obesity-related traits; chr4:69075937 chr4:69027831~69044578:+ LIHC cis rs4356975 0.836 rs6600870 ENSG00000250919.1 RP11-813N20.3 -4.27 2.51e-05 0.00583 -0.22 -0.23 Obesity-related traits; chr4:69075944 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs7442394 ENSG00000250919.1 RP11-813N20.3 -4.27 2.51e-05 0.00583 -0.22 -0.23 Obesity-related traits; chr4:69076309 chr4:69027831~69044578:+ LIHC cis rs2072510 0.593 rs2247304 ENSG00000257715.1 RP11-256L6.2 -4.27 2.51e-05 0.00583 -0.31 -0.23 Metabolite levels (small molecules and protein measures); chr12:96030887 chr12:96025323~96027971:+ LIHC cis rs638893 0.578 rs500254 ENSG00000255422.1 AP002954.4 4.27 2.51e-05 0.00583 0.5 0.23 Vitiligo; chr11:118808071 chr11:118704607~118750263:+ LIHC cis rs709400 0.832 rs55864158 ENSG00000258534.1 CTD-2134A5.4 4.27 2.51e-05 0.00583 0.34 0.23 Body mass index; chr14:103602242 chr14:103854366~103880111:- LIHC cis rs7246657 0.714 rs12972195 ENSG00000276846.1 CTD-3220F14.3 4.27 2.51e-05 0.00583 0.28 0.23 Coronary artery calcification; chr19:37261603 chr19:37314868~37315620:- LIHC cis rs244293 0.76 rs12945393 ENSG00000275710.1 RP11-257O5.4 4.27 2.51e-05 0.00583 0.25 0.23 Menarche (age at onset); chr17:54967882 chr17:54964474~54964679:+ LIHC cis rs113084984 0.718 rs1865574 ENSG00000271952.1 RP11-245G13.2 -4.27 2.52e-05 0.00584 -0.28 -0.23 Breast cancer; chr2:11541312 chr2:10878269~10885118:+ LIHC cis rs8005677 0.828 rs12437151 ENSG00000279656.1 RP11-298I3.6 4.27 2.52e-05 0.00584 0.25 0.23 Cognitive ability (multi-trait analysis); chr14:22903704 chr14:23023083~23024217:- LIHC cis rs3733589 0.744 rs2276963 ENSG00000250413.1 RP11-448G15.1 4.27 2.52e-05 0.00584 0.36 0.23 Renal overload gout; chr4:10021215 chr4:10006482~10009725:+ LIHC cis rs17713451 0.593 rs74882587 ENSG00000204894.4 RP11-208G20.2 4.27 2.52e-05 0.00584 0.46 0.23 Interleukin-4 levels; chr7:151581002 chr7:152367171~152367260:+ LIHC cis rs6439153 0.933 rs6799008 ENSG00000231305.3 RP11-723O4.2 4.27 2.52e-05 0.00584 0.25 0.23 Pneumococcal bacteremia; chr3:128998544 chr3:128861313~128871540:- LIHC cis rs709400 0.643 rs11621777 ENSG00000258534.1 CTD-2134A5.4 4.27 2.52e-05 0.00585 0.34 0.23 Body mass index; chr14:103605753 chr14:103854366~103880111:- LIHC cis rs42490 0.934 rs218947 ENSG00000251136.7 RP11-37B2.1 4.27 2.52e-05 0.00585 0.2 0.23 Leprosy; chr8:89705148 chr8:89609409~89757727:- LIHC cis rs4713118 0.513 rs149954 ENSG00000216901.1 AL022393.7 4.27 2.52e-05 0.00585 0.29 0.23 Parkinson's disease; chr6:28067468 chr6:28176188~28176674:+ LIHC cis rs2072510 0.722 rs2540490 ENSG00000257878.1 RP11-256L6.3 -4.27 2.52e-05 0.00585 -0.2 -0.23 Metabolite levels (small molecules and protein measures); chr12:96032494 chr12:95996521~96011489:+ LIHC cis rs160451 0.966 rs2101854 ENSG00000251136.7 RP11-37B2.1 4.27 2.52e-05 0.00585 0.2 0.23 Leprosy; chr8:89663517 chr8:89609409~89757727:- LIHC cis rs2658782 0.906 rs2658791 ENSG00000279684.1 RP11-755E23.2 -4.27 2.52e-05 0.00585 -0.39 -0.23 Pulmonary function decline; chr11:93465817 chr11:93286629~93288903:- LIHC cis rs5760092 0.572 rs738806 ENSG00000206090.4 AP000350.7 4.27 2.52e-05 0.00585 0.3 0.23 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23939998~23942798:+ LIHC cis rs6901152 0.525 rs1424927 ENSG00000217648.1 RP1-95L4.4 -4.27 2.52e-05 0.00585 -0.27 -0.23 Acute lymphoblastic leukemia (childhood); chr6:143367996 chr6:143342246~143343383:+ LIHC cis rs2243480 1 rs78803505 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65917585 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs34933526 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65918212 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs34577383 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65920739 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs6949812 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65922114 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs6970243 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65923503 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs7794661 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65924743 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs7795242 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65925107 chr7:66880708~66882981:+ LIHC cis rs2243480 0.708 rs35310401 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65925372 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs35058610 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65925938 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs2177703 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65926730 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs35432774 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65928032 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs56985706 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65929575 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs60683927 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65929781 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs58062456 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65929865 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs34529418 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65938222 chr7:66880708~66882981:+ LIHC cis rs2243480 0.901 rs35087093 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65940221 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs35046236 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65943626 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs36068983 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65944004 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs68189316 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65944182 chr7:66880708~66882981:+ LIHC cis rs2243480 0.803 rs34804747 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65947955 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs11538349 ENSG00000230295.1 RP11-458F8.2 -4.27 2.53e-05 0.00586 -0.24 -0.23 Diabetic kidney disease; chr7:65956884 chr7:66880708~66882981:+ LIHC cis rs2243480 0.831 rs7806717 ENSG00000230295.1 RP11-458F8.2 4.27 2.53e-05 0.00586 0.24 0.23 Diabetic kidney disease; chr7:65928187 chr7:66880708~66882981:+ LIHC cis rs4650994 0.524 rs2476558 ENSG00000273384.1 RP5-1098D14.1 -4.27 2.53e-05 0.00586 -0.28 -0.23 HDL cholesterol;HDL cholesterol levels; chr1:178611818 chr1:178651706~178652282:+ LIHC cis rs1075232 0.655 rs28451043 ENSG00000270055.1 CTD-3092A11.2 -4.27 2.53e-05 0.00586 -0.44 -0.23 Survival in colorectal cancer (non-distant metastatic); chr15:31295359 chr15:30487963~30490313:+ LIHC cis rs11971779 0.68 rs10273527 ENSG00000273391.1 RP11-634H22.1 -4.27 2.53e-05 0.00586 -0.18 -0.23 Diisocyanate-induced asthma; chr7:139351852 chr7:139359032~139359566:- LIHC cis rs728616 0.717 rs111403425 ENSG00000225484.5 NUTM2B-AS1 -4.27 2.53e-05 0.00586 -0.49 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80060786 chr10:79663088~79826594:- LIHC cis rs728616 0.867 rs78131725 ENSG00000225484.5 NUTM2B-AS1 -4.27 2.53e-05 0.00586 -0.49 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80061163 chr10:79663088~79826594:- LIHC cis rs728616 0.867 rs12411407 ENSG00000225484.5 NUTM2B-AS1 -4.27 2.53e-05 0.00586 -0.49 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80068475 chr10:79663088~79826594:- LIHC cis rs728616 0.867 rs61859008 ENSG00000225484.5 NUTM2B-AS1 -4.27 2.53e-05 0.00586 -0.49 -0.23 Chronic obstructive pulmonary disease-related biomarkers; chr10:80071955 chr10:79663088~79826594:- LIHC cis rs1876905 0.539 rs240962 ENSG00000271789.1 RP5-1112D6.7 4.27 2.53e-05 0.00587 0.26 0.22 Mean corpuscular hemoglobin; chr6:111321243 chr6:111297126~111298510:+ LIHC cis rs1075265 0.875 rs12616212 ENSG00000233266.1 HMGB1P31 4.27 2.53e-05 0.00587 0.34 0.22 Chronotype;Morning vs. evening chronotype; chr2:54039109 chr2:54051334~54051760:+ LIHC cis rs4604234 0.573 rs11961361 ENSG00000272129.1 RP11-250B2.6 -4.27 2.53e-05 0.00587 -0.35 -0.22 Cancer; chr6:80294840 chr6:80355424~80356859:+ LIHC cis rs4604234 0.541 rs11963917 ENSG00000272129.1 RP11-250B2.6 -4.27 2.53e-05 0.00587 -0.35 -0.22 Cancer; chr6:80294843 chr6:80355424~80356859:+ LIHC cis rs9549367 1 rs9549367 ENSG00000269125.1 RP11-98F14.11 -4.27 2.53e-05 0.00587 -0.26 -0.22 Platelet distribution width; chr13:113257218 chr13:113165002~113165183:- LIHC cis rs2749592 0.588 rs2504144 ENSG00000263064.2 RP11-291L22.7 4.27 2.53e-05 0.00587 0.24 0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:38094597 chr10:38448689~38448949:+ LIHC cis rs7809950 1 rs2293658 ENSG00000238832.1 snoU109 -4.27 2.53e-05 0.00587 -0.27 -0.22 Coronary artery disease; chr7:107630122 chr7:107603363~107603507:+ LIHC cis rs10129255 0.957 rs12590667 ENSG00000223648.3 IGHV3-64 -4.27 2.54e-05 0.00588 -0.17 -0.22 Kawasaki disease; chr14:106779223 chr14:106643132~106658258:- LIHC cis rs603446 0.541 rs59854309 ENSG00000254851.1 RP11-109L13.1 4.27 2.54e-05 0.00589 0.29 0.22 Triglycerides; chr11:116696047 chr11:117135528~117138582:+ LIHC cis rs5742933 0.817 rs2033870 ENSG00000253559.1 OSGEPL1-AS1 -4.27 2.54e-05 0.00589 -0.29 -0.22 Ferritin levels; chr2:189739104 chr2:189762704~189765556:+ LIHC cis rs7809950 0.798 rs2701687 ENSG00000238832.1 snoU109 4.27 2.54e-05 0.00589 0.25 0.22 Coronary artery disease; chr7:107664183 chr7:107603363~107603507:+ LIHC cis rs709400 0.894 rs56017123 ENSG00000258534.1 CTD-2134A5.4 4.27 2.55e-05 0.0059 0.34 0.22 Body mass index; chr14:103608940 chr14:103854366~103880111:- LIHC cis rs6565180 0.962 rs6565182 ENSG00000183604.13 SMG1P5 -4.27 2.55e-05 0.0059 -0.25 -0.22 Tonsillectomy; chr16:30363060 chr16:30267553~30335374:- LIHC cis rs3845817 0.868 rs702891 ENSG00000281920.1 RP11-418H16.1 4.27 2.55e-05 0.0059 0.27 0.22 Bipolar disorder; chr2:65531316 chr2:65623272~65628424:+ LIHC cis rs7811142 1 rs66632384 ENSG00000242294.5 STAG3L5P 4.27 2.55e-05 0.0059 0.26 0.22 Platelet count; chr7:100421281 chr7:100336079~100351900:+ LIHC cis rs7811142 0.943 rs73403312 ENSG00000242294.5 STAG3L5P 4.27 2.55e-05 0.0059 0.26 0.22 Platelet count; chr7:100426530 chr7:100336079~100351900:+ LIHC cis rs8177253 0.665 rs6774822 ENSG00000244062.1 RP11-404G16.2 4.27 2.55e-05 0.0059 0.22 0.22 Iron status biomarkers; chr3:133723168 chr3:133760300~133762363:+ LIHC cis rs3758785 0.679 rs13447595 ENSG00000255893.1 RP11-685N10.1 -4.27 2.55e-05 0.0059 -0.26 -0.22 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94489524 chr11:94472908~94473570:- LIHC cis rs13217239 0.646 rs10946897 ENSG00000241549.7 GUSBP2 4.27 2.55e-05 0.00591 0.23 0.22 Schizophrenia; chr6:27027472 chr6:26871484~26956554:- LIHC cis rs950880 0.71 rs55645612 ENSG00000234389.1 AC007278.3 -4.27 2.55e-05 0.00591 -0.22 -0.22 Serum protein levels (sST2); chr2:102439201 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs56166614 ENSG00000234389.1 AC007278.3 -4.27 2.55e-05 0.00591 -0.22 -0.22 Serum protein levels (sST2); chr2:102439636 chr2:102438713~102440475:+ LIHC cis rs2276314 0.857 rs62101376 ENSG00000278986.1 RP11-723J4.3 -4.27 2.55e-05 0.00591 -0.27 -0.22 Endometriosis;Drug-induced torsades de pointes; chr18:36002992 chr18:35972151~35973916:+ LIHC cis rs13083990 0.881 rs12635478 ENSG00000272758.4 RP11-299J3.8 4.27 2.55e-05 0.00591 0.24 0.22 Cardiac Troponin-T levels; chr3:122289706 chr3:122416207~122443180:+ LIHC cis rs3845817 0.832 rs702883 ENSG00000281920.1 RP11-418H16.1 -4.27 2.55e-05 0.00591 -0.27 -0.22 Bipolar disorder; chr2:65524951 chr2:65623272~65628424:+ LIHC cis rs3845817 0.838 rs702886 ENSG00000281920.1 RP11-418H16.1 -4.27 2.55e-05 0.00591 -0.27 -0.22 Bipolar disorder; chr2:65526176 chr2:65623272~65628424:+ LIHC cis rs4578769 0.959 rs6507323 ENSG00000266850.1 RP11-370A5.1 -4.27 2.56e-05 0.00592 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22846715 chr18:22723491~22907721:- LIHC cis rs1865760 0.516 rs10807007 ENSG00000216436.2 HIST1H2APS1 -4.27 2.56e-05 0.00592 -0.26 -0.22 Height; chr6:26048703 chr6:25732497~25732827:+ LIHC cis rs1865760 0.516 rs9379819 ENSG00000216436.2 HIST1H2APS1 -4.27 2.56e-05 0.00592 -0.26 -0.22 Height; chr6:26049591 chr6:25732497~25732827:+ LIHC cis rs9527 0.59 rs12355120 ENSG00000236937.2 PTGES3P4 4.27 2.56e-05 0.00592 0.29 0.22 Arsenic metabolism; chr10:103092409 chr10:102845595~102845950:+ LIHC cis rs1075265 0.518 rs13414393 ENSG00000272156.1 RP11-477N3.1 -4.27 2.56e-05 0.00592 -0.27 -0.22 Chronotype;Morning vs. evening chronotype; chr2:54048025 chr2:54082554~54085066:+ LIHC cis rs3812762 0.871 rs2173999 ENSG00000254860.4 TMEM9B-AS1 -4.27 2.56e-05 0.00593 -0.24 -0.22 Hypospadias; chr11:8756530 chr11:8964675~8977527:+ LIHC cis rs6921919 0.789 rs1119211 ENSG00000204709.4 LINC01556 -4.27 2.56e-05 0.00593 -0.28 -0.22 Autism spectrum disorder or schizophrenia; chr6:28341359 chr6:28943877~28944537:+ LIHC cis rs4578769 0.879 rs7235234 ENSG00000266850.1 RP11-370A5.1 4.27 2.56e-05 0.00593 0.26 0.22 Eosinophil percentage of white cells; chr18:22864239 chr18:22723491~22907721:- LIHC cis rs4578769 0.879 rs9950650 ENSG00000266850.1 RP11-370A5.1 4.27 2.56e-05 0.00593 0.26 0.22 Eosinophil percentage of white cells; chr18:22864537 chr18:22723491~22907721:- LIHC cis rs4578769 0.733 rs7226388 ENSG00000266850.1 RP11-370A5.1 4.27 2.56e-05 0.00593 0.26 0.22 Eosinophil percentage of white cells; chr18:22865371 chr18:22723491~22907721:- LIHC cis rs67311347 1 rs6795475 ENSG00000223797.4 ENTPD3-AS1 4.27 2.57e-05 0.00594 0.18 0.22 Renal cell carcinoma; chr3:40447790 chr3:40313802~40453329:- LIHC cis rs11121022 0.965 rs11121021 ENSG00000269925.1 RP3-467L1.6 -4.27 2.57e-05 0.00594 -0.23 -0.22 Morning vs. evening chronotype; chr1:7775639 chr1:7776383~7776775:+ LIHC cis rs2074193 1 rs2074193 ENSG00000257906.1 RP1-90J4.1 -4.27 2.57e-05 0.00594 -0.29 -0.22 Migraine with aura; chr12:47377646 chr12:47415008~47420179:+ LIHC cis rs748404 0.66 rs493377 ENSG00000166763.7 STRCP1 4.27 2.57e-05 0.00594 0.28 0.22 Lung cancer; chr15:43481269 chr15:43699488~43718184:- LIHC cis rs4578769 0.959 rs4800137 ENSG00000265943.1 RP11-739L10.1 4.27 2.57e-05 0.00594 0.29 0.22 Eosinophil percentage of white cells; chr18:22899721 chr18:22699481~22933764:- LIHC cis rs12887734 0.546 rs66676135 ENSG00000258534.1 CTD-2134A5.4 -4.27 2.57e-05 0.00594 -0.25 -0.22 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103805167 chr14:103854366~103880111:- LIHC cis rs7615952 0.641 rs4422257 ENSG00000171084.14 FAM86JP 4.27 2.57e-05 0.00595 0.36 0.22 Blood pressure (smoking interaction); chr3:126055520 chr3:125916620~125930024:+ LIHC cis rs9400467 0.528 rs56827 ENSG00000271789.1 RP5-1112D6.7 -4.27 2.57e-05 0.00595 -0.22 -0.22 Amino acid levels;Blood metabolite levels; chr6:111302000 chr6:111297126~111298510:+ LIHC cis rs4578769 0.959 rs3851819 ENSG00000266850.1 RP11-370A5.1 4.27 2.57e-05 0.00595 0.26 0.22 Eosinophil percentage of white cells; chr18:22881321 chr18:22723491~22907721:- LIHC cis rs4578769 0.959 rs3851820 ENSG00000266850.1 RP11-370A5.1 4.27 2.57e-05 0.00595 0.26 0.22 Eosinophil percentage of white cells; chr18:22881359 chr18:22723491~22907721:- LIHC cis rs4578769 0.918 rs3851821 ENSG00000266850.1 RP11-370A5.1 4.27 2.57e-05 0.00595 0.26 0.22 Eosinophil percentage of white cells; chr18:22882492 chr18:22723491~22907721:- LIHC cis rs950881 0.932 rs72823621 ENSG00000234389.1 AC007278.3 4.27 2.57e-05 0.00595 0.3 0.22 Allergy; chr2:102308975 chr2:102438713~102440475:+ LIHC cis rs9595908 0.827 rs9595885 ENSG00000212293.1 SNORA16 4.27 2.57e-05 0.00595 0.26 0.22 Body mass index; chr13:32593913 chr13:32420390~32420516:- LIHC cis rs9368481 0.761 rs6918835 ENSG00000241549.7 GUSBP2 -4.27 2.57e-05 0.00595 -0.24 -0.22 Autism spectrum disorder or schizophrenia; chr6:27050048 chr6:26871484~26956554:- LIHC cis rs13043901 0.539 rs6097480 ENSG00000197670.6 RP4-724E16.2 -4.27 2.57e-05 0.00595 -0.22 -0.22 Type 2 diabetes (age of onset); chr20:53560021 chr20:53552770~53575863:+ LIHC cis rs5742933 0.725 rs1132360 ENSG00000253559.1 OSGEPL1-AS1 4.27 2.57e-05 0.00596 0.3 0.22 Ferritin levels; chr2:189661498 chr2:189762704~189765556:+ LIHC cis rs7615952 0.599 rs7652883 ENSG00000171084.14 FAM86JP 4.27 2.58e-05 0.00596 0.35 0.22 Blood pressure (smoking interaction); chr3:125989134 chr3:125916620~125930024:+ LIHC cis rs1223397 0.938 rs9381884 ENSG00000215022.6 RP1-257A7.4 -4.27 2.58e-05 0.00597 -0.27 -0.22 Blood pressure; chr6:13278556 chr6:13264861~13295586:- LIHC cis rs11971779 0.68 rs7785903 ENSG00000273391.1 RP11-634H22.1 4.27 2.58e-05 0.00597 0.2 0.22 Diisocyanate-induced asthma; chr7:139437897 chr7:139359032~139359566:- LIHC cis rs9457247 0.935 rs9348211 ENSG00000227598.1 RP1-167A14.2 4.27 2.58e-05 0.00597 0.24 0.22 Crohn's disease; chr6:166961685 chr6:166969626~166999065:- LIHC cis rs6920364 1 rs6920364 ENSG00000227598.1 RP1-167A14.2 4.27 2.58e-05 0.00597 0.24 0.22 Lung cancer; chr6:166962978 chr6:166969626~166999065:- LIHC cis rs9457247 1 rs2769352 ENSG00000227598.1 RP1-167A14.2 4.27 2.58e-05 0.00597 0.24 0.22 Crohn's disease; chr6:166965131 chr6:166969626~166999065:- LIHC cis rs2998286 0.723 rs332189 ENSG00000254635.4 WAC-AS1 -4.27 2.58e-05 0.00597 -0.28 -0.22 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28628292 chr10:28522652~28532743:- LIHC cis rs4578769 0.959 rs9945114 ENSG00000266850.1 RP11-370A5.1 4.27 2.58e-05 0.00598 0.26 0.22 Eosinophil percentage of white cells; chr18:22884044 chr18:22723491~22907721:- LIHC cis rs17818399 0.708 rs1531133 ENSG00000279254.1 RP11-536C12.1 -4.27 2.59e-05 0.00598 -0.26 -0.22 Height; chr2:46616492 chr2:46668870~46670778:+ LIHC cis rs7989332 1 rs7989332 ENSG00000275964.1 RP11-61K9.3 -4.27 2.59e-05 0.00598 -0.3 -0.22 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20476436 chr13:19863858~19865048:+ LIHC cis rs3812762 0.879 rs10769959 ENSG00000254860.4 TMEM9B-AS1 -4.27 2.59e-05 0.00598 -0.25 -0.22 Hypospadias; chr11:8797286 chr11:8964675~8977527:+ LIHC cis rs6504622 0.755 rs34038545 ENSG00000262879.4 RP11-156P1.3 -4.27 2.59e-05 0.00598 -0.24 -0.22 Orofacial clefts; chr17:47067541 chr17:46984045~47100323:- LIHC cis rs4578769 1 rs4578769 ENSG00000266850.1 RP11-370A5.1 4.27 2.59e-05 0.00598 0.26 0.22 Eosinophil percentage of white cells; chr18:22815141 chr18:22723491~22907721:- LIHC cis rs9368481 0.672 rs3931463 ENSG00000241549.7 GUSBP2 4.26 2.59e-05 0.00599 0.24 0.22 Autism spectrum disorder or schizophrenia; chr6:26972018 chr6:26871484~26956554:- LIHC cis rs7811142 1 rs11771241 ENSG00000242294.5 STAG3L5P 4.26 2.59e-05 0.00599 0.25 0.22 Platelet count; chr7:100397162 chr7:100336079~100351900:+ LIHC cis rs13217239 0.646 rs6937880 ENSG00000241549.7 GUSBP2 4.26 2.59e-05 0.00599 0.23 0.22 Schizophrenia; chr6:27032457 chr6:26871484~26956554:- LIHC cis rs13217239 0.621 rs12527231 ENSG00000241549.7 GUSBP2 4.26 2.59e-05 0.00599 0.23 0.22 Schizophrenia; chr6:27033509 chr6:26871484~26956554:- LIHC cis rs13217239 0.646 rs12523820 ENSG00000241549.7 GUSBP2 4.26 2.59e-05 0.00599 0.23 0.22 Schizophrenia; chr6:27033723 chr6:26871484~26956554:- LIHC cis rs73086581 0.568 rs6084541 ENSG00000229539.1 RP11-119B16.2 -4.26 2.59e-05 0.00599 -0.24 -0.22 Response to antidepressants in depression; chr20:3982084 chr20:3888239~3888868:- LIHC cis rs4578769 0.918 rs9957390 ENSG00000266850.1 RP11-370A5.1 4.26 2.59e-05 0.00599 0.26 0.22 Eosinophil percentage of white cells; chr18:22840421 chr18:22723491~22907721:- LIHC cis rs11096990 0.656 rs7693837 ENSG00000249685.1 RP11-360F5.3 4.26 2.59e-05 0.00599 0.27 0.22 Cognitive function; chr4:39301481 chr4:39133913~39135608:+ LIHC cis rs6545883 0.507 rs34668697 ENSG00000271889.1 RP11-493E12.1 -4.26 2.59e-05 0.00599 -0.27 -0.22 Tuberculosis; chr2:61341214 chr2:61151433~61162105:- LIHC cis rs3812762 0.871 rs10734637 ENSG00000254860.4 TMEM9B-AS1 -4.26 2.59e-05 0.00599 -0.24 -0.22 Hypospadias; chr11:8766678 chr11:8964675~8977527:+ LIHC cis rs2581828 0.656 rs2336723 ENSG00000242142.1 SERBP1P3 4.26 2.59e-05 0.00599 0.26 0.22 Crohn's disease; chr3:53072031 chr3:53064283~53065091:- LIHC cis rs2115630 0.936 rs11073663 ENSG00000259295.5 CSPG4P12 -4.26 2.59e-05 0.00599 -0.26 -0.22 P wave terminal force; chr15:84717037 chr15:85191438~85213905:+ LIHC cis rs7811142 0.83 rs11765869 ENSG00000242294.5 STAG3L5P 4.26 2.59e-05 0.00599 0.25 0.22 Platelet count; chr7:100367166 chr7:100336079~100351900:+ LIHC cis rs4218 0.597 rs4775114 ENSG00000277144.1 RP11-59H7.4 -4.26 2.6e-05 0.006 -0.25 -0.22 Social communication problems; chr15:59059635 chr15:59115547~59116089:- LIHC cis rs6745190 0.557 rs13011738 ENSG00000236153.1 AC104076.3 -4.26 2.6e-05 0.006 -0.32 -0.22 White blood cell count; chr2:181121015 chr2:180979427~180980090:- LIHC cis rs2072438 0.503 rs10739590 ENSG00000226752.6 PSMD5-AS1 -4.26 2.6e-05 0.00601 -0.23 -0.22 Rheumatoid arthritis; chr9:121109203 chr9:120824828~120854385:+ LIHC cis rs11098499 0.909 rs28884220 ENSG00000260091.1 RP11-33B1.4 -4.26 2.6e-05 0.00601 -0.16 -0.22 Corneal astigmatism; chr4:119386056 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs28793658 ENSG00000260091.1 RP11-33B1.4 -4.26 2.6e-05 0.00601 -0.16 -0.22 Corneal astigmatism; chr4:119386059 chr4:119409333~119410233:+ LIHC cis rs875971 0.522 rs781144 ENSG00000273024.4 INTS4P2 -4.26 2.6e-05 0.00601 -0.27 -0.22 Aortic root size; chr7:65975357 chr7:65647864~65715661:+ LIHC cis rs858239 0.932 rs1637190 ENSG00000226816.2 AC005082.12 4.26 2.6e-05 0.00601 0.29 0.22 Cerebrospinal fluid biomarker levels; chr7:23229446 chr7:23206013~23208045:+ LIHC cis rs4356975 0.932 rs4694604 ENSG00000250919.1 RP11-813N20.3 -4.26 2.6e-05 0.00601 -0.22 -0.22 Obesity-related traits; chr4:69072745 chr4:69027831~69044578:+ LIHC cis rs193541 0.632 rs30063 ENSG00000263432.2 RN7SL689P 4.26 2.61e-05 0.00602 0.35 0.22 Glucose homeostasis traits; chr5:122959998 chr5:123022487~123022783:- LIHC cis rs2243480 1 rs34136756 ENSG00000230295.1 RP11-458F8.2 -4.26 2.61e-05 0.00602 -0.24 -0.22 Diabetic kidney disease; chr7:65916269 chr7:66880708~66882981:+ LIHC cis rs1823913 0.895 rs10931491 ENSG00000227542.1 AC092614.2 -4.26 2.61e-05 0.00602 -0.23 -0.22 Obesity-related traits; chr2:191256087 chr2:191229165~191246172:- LIHC cis rs1823913 1 rs11681777 ENSG00000227542.1 AC092614.2 -4.26 2.61e-05 0.00602 -0.23 -0.22 Obesity-related traits; chr2:191256741 chr2:191229165~191246172:- LIHC cis rs1062753 0.527 rs6519296 ENSG00000237037.8 NDUFA6-AS1 -4.26 2.61e-05 0.00602 -0.32 -0.22 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41952598 chr22:42090931~42137742:+ LIHC cis rs12887734 0.569 rs66953418 ENSG00000258534.1 CTD-2134A5.4 -4.26 2.61e-05 0.00603 -0.25 -0.22 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103805133 chr14:103854366~103880111:- LIHC cis rs10833905 1 rs10833895 ENSG00000246225.5 RP11-17A1.3 -4.26 2.61e-05 0.00603 -0.29 -0.22 Sudden cardiac arrest; chr11:23006951 chr11:22829380~22945393:+ LIHC cis rs6903823 0.508 rs1778484 ENSG00000204709.4 LINC01556 4.26 2.61e-05 0.00603 0.25 0.22 Pulmonary function; chr6:28273021 chr6:28943877~28944537:+ LIHC cis rs7893279 0.505 rs7072624 ENSG00000225527.1 RP11-383B4.4 4.26 2.61e-05 0.00603 0.32 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18670865 chr10:18531849~18533336:- LIHC cis rs9595908 0.931 rs9315167 ENSG00000212293.1 SNORA16 4.26 2.62e-05 0.00604 0.27 0.22 Body mass index; chr13:32495051 chr13:32420390~32420516:- LIHC cis rs703842 0.616 rs10877024 ENSG00000270039.1 RP11-571M6.17 -4.26 2.62e-05 0.00604 -0.33 -0.22 Multiple sclerosis; chr12:57832926 chr12:57803838~57804415:+ LIHC cis rs9368481 0.729 rs9379948 ENSG00000241549.7 GUSBP2 4.26 2.62e-05 0.00605 0.24 0.22 Autism spectrum disorder or schizophrenia; chr6:26977004 chr6:26871484~26956554:- LIHC cis rs709400 0.859 rs7693 ENSG00000258534.1 CTD-2134A5.4 4.26 2.62e-05 0.00605 0.34 0.22 Body mass index; chr14:103557367 chr14:103854366~103880111:- LIHC cis rs950169 0.65 rs12902052 ENSG00000259728.4 LINC00933 4.26 2.62e-05 0.00605 0.33 0.22 Schizophrenia; chr15:84582607 chr15:84570649~84580175:+ LIHC cis rs4561483 0.801 rs33649 ENSG00000261560.1 RP11-166B2.3 -4.26 2.62e-05 0.00605 -0.26 -0.22 Testicular germ cell tumor; chr16:11885751 chr16:11881075~11882569:- LIHC cis rs1558001 1 rs1558001 ENSG00000230196.1 DDX43P3 4.26 2.63e-05 0.00606 0.24 0.22 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81777764 chr7:81610884~81611326:- LIHC cis rs748404 0.66 rs2467738 ENSG00000166763.7 STRCP1 4.26 2.63e-05 0.00606 0.28 0.22 Lung cancer; chr15:43447738 chr15:43699488~43718184:- LIHC cis rs367615 0.506 rs2963013 ENSG00000249476.1 CTD-2587M2.1 -4.26 2.63e-05 0.00606 -0.26 -0.22 Colorectal cancer (SNP x SNP interaction); chr5:109440110 chr5:109237120~109326369:- LIHC cis rs12478296 1 rs12478296 ENSG00000261186.2 RP11-341N2.1 4.26 2.63e-05 0.00606 0.31 0.22 Obesity-related traits; chr2:242106609 chr2:242087351~242088457:- LIHC cis rs11098499 0.779 rs6815934 ENSG00000260091.1 RP11-33B1.4 -4.26 2.63e-05 0.00607 -0.15 -0.22 Corneal astigmatism; chr4:119346155 chr4:119409333~119410233:+ LIHC cis rs9595908 0.568 rs4942923 ENSG00000212293.1 SNORA16 4.26 2.63e-05 0.00607 0.26 0.22 Body mass index; chr13:32806887 chr13:32420390~32420516:- LIHC cis rs481331 0.932 rs210228 ENSG00000185904.10 LINC00839 -4.26 2.63e-05 0.00607 -0.42 -0.22 Systemic juvenile idiopathic arthritis; chr10:42507610 chr10:42475543~42495336:+ LIHC cis rs699371 0.507 rs10149787 ENSG00000270000.1 RP3-449M8.9 -4.26 2.63e-05 0.00608 -0.26 -0.22 Height; chr14:74458749 chr14:74471930~74472360:- LIHC cis rs9527 0.615 rs10883781 ENSG00000236937.2 PTGES3P4 4.26 2.64e-05 0.00608 0.34 0.22 Arsenic metabolism; chr10:102821373 chr10:102845595~102845950:+ LIHC cis rs11951515 0.508 rs67261887 ENSG00000248240.1 RP11-159F24.5 -4.26 2.64e-05 0.00608 -0.28 -0.22 Metabolite levels (X-11787); chr5:43612339 chr5:43515274~43525310:+ LIHC cis rs4650994 0.544 rs2476560 ENSG00000273384.1 RP5-1098D14.1 -4.26 2.64e-05 0.00609 -0.28 -0.22 HDL cholesterol;HDL cholesterol levels; chr1:178625784 chr1:178651706~178652282:+ LIHC cis rs748404 0.604 rs2278857 ENSG00000205771.5 CATSPER2P1 -4.26 2.64e-05 0.00609 -0.27 -0.22 Lung cancer; chr15:43340351 chr15:43726918~43747094:- LIHC cis rs6445975 0.617 rs13071422 ENSG00000272360.1 RP11-359I18.5 4.26 2.64e-05 0.00609 0.29 0.22 Systemic lupus erythematosus; chr3:58413086 chr3:58490830~58491291:- LIHC cis rs2790457 0.793 rs2153302 ENSG00000254635.4 WAC-AS1 -4.26 2.64e-05 0.00609 -0.21 -0.22 Multiple myeloma; chr10:28529607 chr10:28522652~28532743:- LIHC cis rs7474896 0.616 rs2505239 ENSG00000120555.12 SEPT7P9 4.26 2.64e-05 0.00609 0.33 0.22 Obesity (extreme); chr10:38151837 chr10:38383069~38402916:- LIHC cis rs2032447 0.839 rs199751 ENSG00000242387.1 HIST1H2APS2 4.26 2.64e-05 0.0061 0.29 0.22 Intelligence (multi-trait analysis); chr6:26015355 chr6:25882026~25882395:- LIHC cis rs617219 0.819 rs6889156 ENSG00000251675.1 CTC-458I2.2 4.26 2.64e-05 0.0061 0.26 0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79301096 chr5:80128361~80143883:+ LIHC cis rs617219 0.819 rs6889383 ENSG00000251675.1 CTC-458I2.2 4.26 2.64e-05 0.0061 0.26 0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79301235 chr5:80128361~80143883:+ LIHC cis rs617219 0.819 rs7711939 ENSG00000251675.1 CTC-458I2.2 4.26 2.64e-05 0.0061 0.26 0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79303696 chr5:80128361~80143883:+ LIHC cis rs71007656 1 rs71007656 ENSG00000099251.13 HSD17B7P2 4.26 2.65e-05 0.0061 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:37681922 chr10:38356380~38378505:+ LIHC cis rs9487094 0.961 rs1358998 ENSG00000260273.1 RP11-425D10.10 -4.26 2.65e-05 0.0061 -0.27 -0.22 Height; chr6:109380015 chr6:109382795~109383666:+ LIHC cis rs3812762 0.868 rs7952335 ENSG00000254860.4 TMEM9B-AS1 -4.26 2.65e-05 0.0061 -0.24 -0.22 Hypospadias; chr11:8732484 chr11:8964675~8977527:+ LIHC cis rs17214007 0.877 rs11075281 ENSG00000263335.1 AF001548.5 -4.26 2.65e-05 0.0061 -0.29 -0.22 Cognitive function; chr16:15780585 chr16:15726674~15732993:+ LIHC cis rs12701220 0.817 rs59471534 ENSG00000229043.2 AC091729.9 -4.26 2.65e-05 0.00611 -0.3 -0.22 Bronchopulmonary dysplasia; chr7:1045588 chr7:1160374~1165267:+ LIHC cis rs9318086 0.901 rs7336730 ENSG00000205861.10 C1QTNF9B-AS1 4.26 2.65e-05 0.00611 0.25 0.22 Myopia (pathological); chr13:23877965 chr13:23888889~23897263:+ LIHC cis rs11096990 0.613 rs6829660 ENSG00000249207.1 RP11-360F5.1 -4.26 2.65e-05 0.00611 -0.22 -0.22 Cognitive function; chr4:39280943 chr4:39112677~39126818:- LIHC cis rs5742933 0.857 rs2289226 ENSG00000253559.1 OSGEPL1-AS1 -4.26 2.65e-05 0.00611 -0.29 -0.22 Ferritin levels; chr2:189661479 chr2:189762704~189765556:+ LIHC cis rs1023500 0.505 rs134891 ENSG00000226450.2 CYP2D8P 4.26 2.65e-05 0.00611 0.25 0.22 Schizophrenia; chr22:42279876 chr22:42149886~42155001:- LIHC cis rs1577917 1 rs10455158 ENSG00000234155.1 RP11-30P6.6 4.26 2.65e-05 0.00611 0.29 0.22 Response to antipsychotic treatment; chr6:85963107 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs34106666 ENSG00000234155.1 RP11-30P6.6 4.26 2.65e-05 0.00611 0.29 0.22 Response to antipsychotic treatment; chr6:85966540 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs1337844 ENSG00000234155.1 RP11-30P6.6 4.26 2.65e-05 0.00611 0.29 0.22 Response to antipsychotic treatment; chr6:85967555 chr6:85387219~85390186:- LIHC cis rs11098499 1 rs10029750 ENSG00000260091.1 RP11-33B1.4 -4.26 2.65e-05 0.00611 -0.17 -0.22 Corneal astigmatism; chr4:119251388 chr4:119409333~119410233:+ LIHC cis rs42490 0.51 rs13278061 ENSG00000251136.7 RP11-37B2.1 -4.26 2.65e-05 0.00611 -0.2 -0.22 Leprosy; chr8:89686032 chr8:89609409~89757727:- LIHC cis rs10262624 1 rs7792262 ENSG00000234286.1 AC006026.13 4.26 2.65e-05 0.00612 0.25 0.22 Schizophrenia; chr7:23876124 chr7:23680195~23680786:- LIHC cis rs2015599 0.645 rs12578931 ENSG00000275476.1 RP11-996F15.4 -4.26 2.65e-05 0.00612 -0.29 -0.22 Platelet count;Mean platelet volume; chr12:29358608 chr12:29277397~29277882:- LIHC cis rs2015599 0.623 rs4931174 ENSG00000275476.1 RP11-996F15.4 -4.26 2.65e-05 0.00612 -0.29 -0.22 Platelet count;Mean platelet volume; chr12:29360545 chr12:29277397~29277882:- LIHC cis rs709400 0.77 rs7142883 ENSG00000258534.1 CTD-2134A5.4 4.26 2.65e-05 0.00612 0.34 0.22 Body mass index; chr14:103600308 chr14:103854366~103880111:- LIHC cis rs875971 0.54 rs35510581 ENSG00000273024.4 INTS4P2 4.26 2.66e-05 0.00612 0.26 0.22 Aortic root size; chr7:66113790 chr7:65647864~65715661:+ LIHC cis rs1023500 1 rs6002554 ENSG00000237037.8 NDUFA6-AS1 -4.26 2.66e-05 0.00613 -0.31 -0.22 Schizophrenia; chr22:41943091 chr22:42090931~42137742:+ LIHC cis rs17270561 0.525 rs10484432 ENSG00000216436.2 HIST1H2APS1 -4.26 2.66e-05 0.00613 -0.35 -0.22 Iron status biomarkers; chr6:26008648 chr6:25732497~25732827:+ LIHC cis rs1499614 1 rs2659913 ENSG00000275400.1 RP4-756H11.5 4.26 2.66e-05 0.00613 0.3 0.22 Gout; chr7:66692349 chr7:66553805~66554199:- LIHC cis rs1499614 1 rs2707840 ENSG00000275400.1 RP4-756H11.5 4.26 2.66e-05 0.00613 0.3 0.22 Gout; chr7:66693028 chr7:66553805~66554199:- LIHC cis rs1499614 1 rs2659911 ENSG00000275400.1 RP4-756H11.5 4.26 2.66e-05 0.00613 0.3 0.22 Gout; chr7:66693433 chr7:66553805~66554199:- LIHC cis rs1499614 1 rs2707838 ENSG00000275400.1 RP4-756H11.5 4.26 2.66e-05 0.00613 0.3 0.22 Gout; chr7:66694214 chr7:66553805~66554199:- LIHC cis rs1499614 1 rs60326618 ENSG00000275400.1 RP4-756H11.5 4.26 2.66e-05 0.00613 0.3 0.22 Gout; chr7:66701371 chr7:66553805~66554199:- LIHC cis rs1499614 1 rs2707830 ENSG00000275400.1 RP4-756H11.5 4.26 2.66e-05 0.00613 0.3 0.22 Gout; chr7:66702658 chr7:66553805~66554199:- LIHC cis rs1499614 1 rs2707828 ENSG00000275400.1 RP4-756H11.5 4.26 2.66e-05 0.00613 0.3 0.22 Gout; chr7:66706390 chr7:66553805~66554199:- LIHC cis rs1499614 0.803 rs1922723 ENSG00000275400.1 RP4-756H11.5 4.26 2.66e-05 0.00613 0.3 0.22 Gout; chr7:66710076 chr7:66553805~66554199:- LIHC cis rs1499614 1 rs2659903 ENSG00000275400.1 RP4-756H11.5 4.26 2.66e-05 0.00613 0.3 0.22 Gout; chr7:66715944 chr7:66553805~66554199:- LIHC cis rs1499614 1 rs2141924 ENSG00000275400.1 RP4-756H11.5 4.26 2.66e-05 0.00613 0.3 0.22 Gout; chr7:66721259 chr7:66553805~66554199:- LIHC cis rs2280018 0.526 rs2966129 ENSG00000188599.16 NPIPP1 4.26 2.66e-05 0.00614 0.2 0.22 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059070 chr16:15104312~15123498:- LIHC cis rs113084984 0.718 rs7568223 ENSG00000271952.1 RP11-245G13.2 -4.26 2.67e-05 0.00614 -0.28 -0.22 Breast cancer; chr2:11543297 chr2:10878269~10885118:+ LIHC cis rs113084984 0.718 rs7558961 ENSG00000271952.1 RP11-245G13.2 -4.26 2.67e-05 0.00614 -0.28 -0.22 Breast cancer; chr2:11543324 chr2:10878269~10885118:+ LIHC cis rs113084984 0.718 rs7609384 ENSG00000271952.1 RP11-245G13.2 -4.26 2.67e-05 0.00614 -0.28 -0.22 Breast cancer; chr2:11543505 chr2:10878269~10885118:+ LIHC cis rs4578769 0.879 rs3863524 ENSG00000266850.1 RP11-370A5.1 4.26 2.67e-05 0.00614 0.26 0.22 Eosinophil percentage of white cells; chr18:22881319 chr18:22723491~22907721:- LIHC cis rs2243480 1 rs34702770 ENSG00000228409.4 CCT6P1 4.26 2.67e-05 0.00614 0.24 0.22 Diabetic kidney disease; chr7:65879836 chr7:65751142~65763354:+ LIHC cis rs2243480 0.803 rs35480979 ENSG00000228409.4 CCT6P1 4.26 2.67e-05 0.00614 0.24 0.22 Diabetic kidney disease; chr7:65892097 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs34637256 ENSG00000228409.4 CCT6P1 4.26 2.67e-05 0.00614 0.24 0.22 Diabetic kidney disease; chr7:65895144 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs35391607 ENSG00000228409.4 CCT6P1 4.26 2.67e-05 0.00614 0.24 0.22 Diabetic kidney disease; chr7:65895842 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs13220979 ENSG00000228409.4 CCT6P1 4.26 2.67e-05 0.00614 0.24 0.22 Diabetic kidney disease; chr7:65898217 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs34974928 ENSG00000228409.4 CCT6P1 4.26 2.67e-05 0.00614 0.24 0.22 Diabetic kidney disease; chr7:65899019 chr7:65751142~65763354:+ LIHC cis rs1005277 0.579 rs1780133 ENSG00000099251.13 HSD17B7P2 4.26 2.67e-05 0.00614 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:38210581 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs1780136 ENSG00000099251.13 HSD17B7P2 4.26 2.67e-05 0.00614 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:38212525 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs1780138 ENSG00000099251.13 HSD17B7P2 4.26 2.67e-05 0.00614 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:38212726 chr10:38356380~38378505:+ LIHC cis rs1005277 0.602 rs1780141 ENSG00000099251.13 HSD17B7P2 4.26 2.67e-05 0.00614 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:38215371 chr10:38356380~38378505:+ LIHC cis rs1005277 0.541 rs1740741 ENSG00000099251.13 HSD17B7P2 4.26 2.67e-05 0.00614 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:38226406 chr10:38356380~38378505:+ LIHC cis rs1005277 0.528 rs2057228 ENSG00000099251.13 HSD17B7P2 4.26 2.67e-05 0.00614 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:38226838 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs1740742 ENSG00000099251.13 HSD17B7P2 4.26 2.67e-05 0.00614 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:38229932 chr10:38356380~38378505:+ LIHC cis rs1005277 0.602 rs1740743 ENSG00000099251.13 HSD17B7P2 4.26 2.67e-05 0.00614 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:38230294 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs1740745 ENSG00000099251.13 HSD17B7P2 4.26 2.67e-05 0.00614 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:38231128 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs1740747 ENSG00000099251.13 HSD17B7P2 4.26 2.67e-05 0.00614 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:38231537 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs1740749 ENSG00000099251.13 HSD17B7P2 4.26 2.67e-05 0.00614 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:38232718 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs1780115 ENSG00000099251.13 HSD17B7P2 4.26 2.67e-05 0.00614 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:38235845 chr10:38356380~38378505:+ LIHC cis rs3916 0.794 rs10431384 ENSG00000277423.1 RP11-173P15.9 -4.26 2.67e-05 0.00614 -0.25 -0.22 Urinary metabolites (H-NMR features); chr12:120689544 chr12:120703867~120704282:+ LIHC cis rs3738443 0.868 rs61840048 ENSG00000259865.1 RP11-488L18.10 4.26 2.67e-05 0.00614 0.21 0.22 Alcohol dependence; chr1:247199829 chr1:247187281~247188526:- LIHC cis rs2749592 0.55 rs7917262 ENSG00000275858.1 RP11-291L22.8 -4.26 2.67e-05 0.00614 -0.25 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37585674 chr10:38450738~38451069:- LIHC cis rs2749592 0.55 rs9733309 ENSG00000275858.1 RP11-291L22.8 -4.26 2.67e-05 0.00614 -0.25 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37593477 chr10:38450738~38451069:- LIHC cis rs2749592 0.55 rs7081464 ENSG00000275858.1 RP11-291L22.8 -4.26 2.67e-05 0.00614 -0.25 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37595009 chr10:38450738~38451069:- LIHC cis rs2749592 0.531 rs994804 ENSG00000275858.1 RP11-291L22.8 -4.26 2.67e-05 0.00614 -0.25 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37611212 chr10:38450738~38451069:- LIHC cis rs11096990 0.613 rs2060805 ENSG00000249207.1 RP11-360F5.1 -4.26 2.67e-05 0.00614 -0.23 -0.22 Cognitive function; chr4:39232788 chr4:39112677~39126818:- LIHC cis rs11096990 0.634 rs17431358 ENSG00000249685.1 RP11-360F5.3 -4.26 2.67e-05 0.00615 -0.27 -0.22 Cognitive function; chr4:39275676 chr4:39133913~39135608:+ LIHC cis rs2278034 0.578 rs881753 ENSG00000229178.1 AC069513.4 4.26 2.67e-05 0.00615 0.24 0.22 Bronchopulmonary dysplasia; chr3:195879899 chr3:195655565~195657927:- LIHC cis rs1075232 0.826 rs16956738 ENSG00000270055.1 CTD-3092A11.2 4.26 2.67e-05 0.00615 0.4 0.22 Survival in colorectal cancer (non-distant metastatic); chr15:31444028 chr15:30487963~30490313:+ LIHC cis rs3091242 0.866 rs11249249 ENSG00000261349.1 RP3-465N24.5 -4.26 2.67e-05 0.00615 -0.22 -0.22 Erythrocyte sedimentation rate; chr1:25431643 chr1:25266102~25267136:- LIHC cis rs11098499 0.675 rs11098534 ENSG00000260091.1 RP11-33B1.4 -4.26 2.67e-05 0.00615 -0.16 -0.22 Corneal astigmatism; chr4:119635617 chr4:119409333~119410233:+ LIHC cis rs1023500 0.505 rs134887 ENSG00000226450.2 CYP2D8P 4.26 2.67e-05 0.00615 0.25 0.22 Schizophrenia; chr22:42278233 chr22:42149886~42155001:- LIHC cis rs875971 1 rs3981131 ENSG00000237310.1 GS1-124K5.4 4.26 2.67e-05 0.00615 0.2 0.22 Aortic root size; chr7:66486690 chr7:66493706~66495474:+ LIHC cis rs1005277 0.505 rs1208689 ENSG00000275858.1 RP11-291L22.8 4.26 2.67e-05 0.00615 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37808847 chr10:38450738~38451069:- LIHC cis rs11096990 0.634 rs12651217 ENSG00000249685.1 RP11-360F5.3 4.26 2.68e-05 0.00616 0.27 0.22 Cognitive function; chr4:39271964 chr4:39133913~39135608:+ LIHC cis rs2842992 0.692 rs9347342 ENSG00000237927.1 RP3-393E18.2 -4.26 2.68e-05 0.00616 -0.26 -0.22 Age-related macular degeneration (geographic atrophy); chr6:159772097 chr6:159586955~159589169:- LIHC cis rs6545883 0.507 rs2442025 ENSG00000271889.1 RP11-493E12.1 -4.26 2.68e-05 0.00616 -0.27 -0.22 Tuberculosis; chr2:61344310 chr2:61151433~61162105:- LIHC cis rs6545883 0.524 rs2593631 ENSG00000271889.1 RP11-493E12.1 -4.26 2.68e-05 0.00616 -0.27 -0.22 Tuberculosis; chr2:61345151 chr2:61151433~61162105:- LIHC cis rs6545883 0.542 rs2593628 ENSG00000271889.1 RP11-493E12.1 -4.26 2.68e-05 0.00616 -0.27 -0.22 Tuberculosis; chr2:61346152 chr2:61151433~61162105:- LIHC cis rs875971 0.545 rs2173571 ENSG00000273024.4 INTS4P2 -4.26 2.68e-05 0.00616 -0.26 -0.22 Aortic root size; chr7:66305392 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs11770063 ENSG00000273024.4 INTS4P2 -4.26 2.68e-05 0.00616 -0.26 -0.22 Aortic root size; chr7:66318029 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs3936065 ENSG00000273024.4 INTS4P2 -4.26 2.68e-05 0.00616 -0.26 -0.22 Aortic root size; chr7:66325577 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs4718335 ENSG00000273024.4 INTS4P2 -4.26 2.68e-05 0.00616 -0.26 -0.22 Aortic root size; chr7:66339619 chr7:65647864~65715661:+ LIHC cis rs11098499 0.779 rs7674500 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119382438 chr4:119409333~119410233:+ LIHC cis rs11098499 0.865 rs4507344 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119386330 chr4:119409333~119410233:+ LIHC cis rs11098499 0.697 rs4373140 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119386543 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs13113483 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119387884 chr4:119409333~119410233:+ LIHC cis rs11098499 0.542 rs10440343 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119388632 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs28668716 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119388720 chr4:119409333~119410233:+ LIHC cis rs11098499 0.542 rs7677836 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119389483 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs10002083 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119389997 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs10024844 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119390373 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs4345162 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119391804 chr4:119409333~119410233:+ LIHC cis rs11098499 0.657 rs4463052 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119392103 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs13151285 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119393586 chr4:119409333~119410233:+ LIHC cis rs2439831 0.618 rs999026 ENSG00000166763.7 STRCP1 4.26 2.68e-05 0.00616 0.31 0.22 Lung cancer in ever smokers; chr15:43398017 chr15:43699488~43718184:- LIHC cis rs673078 0.607 rs4442583 ENSG00000275409.1 RP11-131L12.4 -4.26 2.68e-05 0.00616 -0.28 -0.22 Glucose homeostasis traits; chr12:118367914 chr12:118430147~118430699:+ LIHC cis rs673078 0.607 rs61943370 ENSG00000275409.1 RP11-131L12.4 -4.26 2.68e-05 0.00616 -0.28 -0.22 Glucose homeostasis traits; chr12:118369469 chr12:118430147~118430699:+ LIHC cis rs673078 0.607 rs61943371 ENSG00000275409.1 RP11-131L12.4 -4.26 2.68e-05 0.00616 -0.28 -0.22 Glucose homeostasis traits; chr12:118369600 chr12:118430147~118430699:+ LIHC cis rs11098499 0.863 rs7664986 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119508797 chr4:119409333~119410233:+ LIHC cis rs11098499 0.818 rs10008791 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119510314 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs11736416 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119510506 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs3775845 ENSG00000260091.1 RP11-33B1.4 -4.26 2.68e-05 0.00616 -0.16 -0.22 Corneal astigmatism; chr4:119511292 chr4:119409333~119410233:+ LIHC cis rs9595908 0.606 rs4942922 ENSG00000212293.1 SNORA16 4.26 2.68e-05 0.00616 0.26 0.22 Body mass index; chr13:32806832 chr13:32420390~32420516:- LIHC cis rs11671005 0.693 rs34023391 ENSG00000269473.1 CTD-2619J13.19 4.26 2.68e-05 0.00616 0.39 0.22 Mean platelet volume; chr19:58402001 chr19:58440448~58445849:+ LIHC cis rs11671005 0.693 rs11666928 ENSG00000269473.1 CTD-2619J13.19 4.26 2.68e-05 0.00616 0.39 0.22 Mean platelet volume; chr19:58402864 chr19:58440448~58445849:+ LIHC cis rs1005277 0.505 rs7099777 ENSG00000275858.1 RP11-291L22.8 -4.26 2.68e-05 0.00616 -0.25 -0.22 Extrinsic epigenetic age acceleration; chr10:37894641 chr10:38450738~38451069:- LIHC cis rs2243480 1 rs56016656 ENSG00000228409.4 CCT6P1 4.26 2.68e-05 0.00616 0.25 0.22 Diabetic kidney disease; chr7:65918494 chr7:65751142~65763354:+ LIHC cis rs2243480 0.803 rs55700941 ENSG00000228409.4 CCT6P1 4.26 2.68e-05 0.00616 0.25 0.22 Diabetic kidney disease; chr7:65924813 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs36033484 ENSG00000228409.4 CCT6P1 4.26 2.68e-05 0.00616 0.25 0.22 Diabetic kidney disease; chr7:65925571 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs34193460 ENSG00000228409.4 CCT6P1 4.26 2.68e-05 0.00616 0.25 0.22 Diabetic kidney disease; chr7:65928123 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs34560516 ENSG00000228409.4 CCT6P1 4.26 2.68e-05 0.00616 0.25 0.22 Diabetic kidney disease; chr7:65939105 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs57057549 ENSG00000228409.4 CCT6P1 4.26 2.68e-05 0.00616 0.25 0.22 Diabetic kidney disease; chr7:65940751 chr7:65751142~65763354:+ LIHC cis rs2243480 0.808 rs12698508 ENSG00000228409.4 CCT6P1 4.26 2.68e-05 0.00616 0.25 0.22 Diabetic kidney disease; chr7:65946971 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs2961102 ENSG00000228409.4 CCT6P1 4.26 2.68e-05 0.00616 0.25 0.22 Diabetic kidney disease; chr7:65959671 chr7:65751142~65763354:+ LIHC cis rs1077773 0.509 rs2123745 ENSG00000237773.4 AC003075.4 -4.26 2.68e-05 0.00616 -0.28 -0.22 Ulcerative colitis;Inflammatory bowel disease; chr7:17401458 chr7:17279834~17299357:- LIHC cis rs950169 0.922 rs11633534 ENSG00000259728.4 LINC00933 4.26 2.68e-05 0.00616 0.33 0.22 Schizophrenia; chr15:84581411 chr15:84570649~84580175:+ LIHC cis rs7809950 0.798 rs2701684 ENSG00000238832.1 snoU109 4.26 2.68e-05 0.00617 0.25 0.22 Coronary artery disease; chr7:107659082 chr7:107603363~107603507:+ LIHC cis rs2998286 0.637 rs332113 ENSG00000254635.4 WAC-AS1 -4.26 2.69e-05 0.00617 -0.28 -0.22 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28634806 chr10:28522652~28532743:- LIHC cis rs11098499 0.955 rs6815725 ENSG00000260091.1 RP11-33B1.4 -4.26 2.69e-05 0.00617 -0.17 -0.22 Corneal astigmatism; chr4:119237255 chr4:119409333~119410233:+ LIHC cis rs11098499 0.955 rs1551 ENSG00000260091.1 RP11-33B1.4 -4.26 2.69e-05 0.00617 -0.17 -0.22 Corneal astigmatism; chr4:119237345 chr4:119409333~119410233:+ LIHC cis rs11098499 0.955 rs11931312 ENSG00000260091.1 RP11-33B1.4 -4.26 2.69e-05 0.00617 -0.17 -0.22 Corneal astigmatism; chr4:119237868 chr4:119409333~119410233:+ LIHC cis rs2581828 0.646 rs9878875 ENSG00000242142.1 SERBP1P3 -4.26 2.69e-05 0.00618 -0.29 -0.22 Crohn's disease; chr3:53122851 chr3:53064283~53065091:- LIHC cis rs2581828 0.646 rs12630819 ENSG00000242142.1 SERBP1P3 -4.26 2.69e-05 0.00618 -0.29 -0.22 Crohn's disease; chr3:53123286 chr3:53064283~53065091:- LIHC cis rs2581828 0.646 rs12638996 ENSG00000242142.1 SERBP1P3 -4.26 2.69e-05 0.00618 -0.29 -0.22 Crohn's disease; chr3:53123530 chr3:53064283~53065091:- LIHC cis rs12478296 0.581 rs56142391 ENSG00000261186.2 RP11-341N2.1 -4.26 2.69e-05 0.00618 -0.29 -0.22 Obesity-related traits; chr2:242050097 chr2:242087351~242088457:- LIHC cis rs9907295 1 rs11650409 ENSG00000270871.1 AC015849.19 -4.26 2.69e-05 0.00619 -0.23 -0.22 Fibroblast growth factor basic levels; chr17:35907949 chr17:35816717~35830293:- LIHC cis rs60733400 0.818 rs10909839 ENSG00000225931.3 RP3-395M20.7 4.26 2.69e-05 0.00619 0.24 0.22 Multiple sclerosis; chr1:2791865 chr1:2566410~2569888:+ LIHC cis rs6442522 1 rs9847430 ENSG00000249786.6 EAF1-AS1 4.26 2.7e-05 0.00619 0.25 0.22 Uric acid levels; chr3:15408133 chr3:15436171~15455940:- LIHC cis rs6442522 1 rs13075694 ENSG00000249786.6 EAF1-AS1 4.26 2.7e-05 0.00619 0.25 0.22 Uric acid levels; chr3:15408893 chr3:15436171~15455940:- LIHC cis rs6442522 1 rs13075773 ENSG00000249786.6 EAF1-AS1 4.26 2.7e-05 0.00619 0.25 0.22 Uric acid levels; chr3:15409062 chr3:15436171~15455940:- LIHC cis rs10129255 0.957 rs1024349 ENSG00000223648.3 IGHV3-64 4.26 2.7e-05 0.0062 0.17 0.22 Kawasaki disease; chr14:106689997 chr14:106643132~106658258:- LIHC cis rs8040855 0.52 rs67613323 ENSG00000259295.5 CSPG4P12 4.26 2.7e-05 0.0062 0.36 0.22 Bulimia nervosa; chr15:84986541 chr15:85191438~85213905:+ LIHC cis rs8040855 0.52 rs11629962 ENSG00000259295.5 CSPG4P12 4.26 2.7e-05 0.0062 0.36 0.22 Bulimia nervosa; chr15:84986797 chr15:85191438~85213905:+ LIHC cis rs11096990 0.656 rs3733284 ENSG00000249685.1 RP11-360F5.3 -4.26 2.7e-05 0.0062 -0.27 -0.22 Cognitive function; chr4:39299714 chr4:39133913~39135608:+ LIHC cis rs72675573 0.821 rs41533449 ENSG00000235612.1 RP1-158P9.1 -4.26 2.7e-05 0.0062 -0.29 -0.22 Monocyte count; chr1:56065750 chr1:56145721~56155224:+ LIHC cis rs763121 0.853 rs2267395 ENSG00000273076.1 RP3-508I15.22 4.26 2.7e-05 0.0062 0.25 0.22 Menopause (age at onset); chr22:38717898 chr22:38743495~38743910:+ LIHC cis rs4356975 0.692 rs7691361 ENSG00000250919.1 RP11-813N20.3 -4.26 2.7e-05 0.0062 -0.22 -0.22 Obesity-related traits; chr4:69077628 chr4:69027831~69044578:+ LIHC cis rs4356975 0.72 rs7691362 ENSG00000250919.1 RP11-813N20.3 -4.26 2.7e-05 0.0062 -0.22 -0.22 Obesity-related traits; chr4:69077631 chr4:69027831~69044578:+ LIHC cis rs9304742 0.962 rs12461778 ENSG00000213801.4 ZNF816-ZNF321P 4.26 2.7e-05 0.00621 0.22 0.22 Psoriasis; chr19:52951710 chr19:52927135~52942601:- LIHC cis rs9304742 0.962 rs12461796 ENSG00000213801.4 ZNF816-ZNF321P 4.26 2.7e-05 0.00621 0.22 0.22 Psoriasis; chr19:52951835 chr19:52927135~52942601:- LIHC cis rs9304742 0.962 rs12150933 ENSG00000213801.4 ZNF816-ZNF321P 4.26 2.7e-05 0.00621 0.22 0.22 Psoriasis; chr19:52951968 chr19:52927135~52942601:- LIHC cis rs2842992 0.789 rs7765490 ENSG00000237927.1 RP3-393E18.2 -4.26 2.7e-05 0.00621 -0.27 -0.22 Age-related macular degeneration (geographic atrophy); chr6:159783294 chr6:159586955~159589169:- LIHC cis rs17376456 0.877 rs10476601 ENSG00000251023.1 RP11-549J18.1 -4.25 2.7e-05 0.00621 -0.48 -0.22 Diabetic retinopathy; chr5:94066817 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs7728736 ENSG00000251023.1 RP11-549J18.1 -4.25 2.7e-05 0.00621 -0.48 -0.22 Diabetic retinopathy; chr5:94068572 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs12153788 ENSG00000251023.1 RP11-549J18.1 -4.25 2.7e-05 0.00621 -0.48 -0.22 Diabetic retinopathy; chr5:94069732 chr5:93860669~93863825:- LIHC cis rs17376456 0.809 rs12152763 ENSG00000251023.1 RP11-549J18.1 -4.25 2.7e-05 0.00621 -0.48 -0.22 Diabetic retinopathy; chr5:94069804 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10072592 ENSG00000251023.1 RP11-549J18.1 -4.25 2.7e-05 0.00621 -0.48 -0.22 Diabetic retinopathy; chr5:94070284 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10044139 ENSG00000251023.1 RP11-549J18.1 -4.25 2.7e-05 0.00621 -0.48 -0.22 Diabetic retinopathy; chr5:94072098 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10514380 ENSG00000251023.1 RP11-549J18.1 -4.25 2.7e-05 0.00621 -0.48 -0.22 Diabetic retinopathy; chr5:94073665 chr5:93860669~93863825:- LIHC cis rs6442522 1 rs11918807 ENSG00000249786.6 EAF1-AS1 4.25 2.7e-05 0.00621 0.25 0.22 Uric acid levels; chr3:15404770 chr3:15436171~15455940:- LIHC cis rs11098499 1 rs28374891 ENSG00000260091.1 RP11-33B1.4 -4.25 2.7e-05 0.00621 -0.17 -0.22 Corneal astigmatism; chr4:119262395 chr4:119409333~119410233:+ LIHC cis rs1023500 0.505 rs134885 ENSG00000226450.2 CYP2D8P 4.25 2.7e-05 0.00621 0.24 0.22 Schizophrenia; chr22:42277805 chr22:42149886~42155001:- LIHC cis rs6430585 0.528 rs309122 ENSG00000231890.6 DARS-AS1 -4.25 2.71e-05 0.00621 -0.31 -0.22 Corneal structure; chr2:136004283 chr2:135985176~136022593:+ LIHC cis rs875971 0.545 rs10950036 ENSG00000273024.4 INTS4P2 -4.25 2.71e-05 0.00621 -0.26 -0.22 Aortic root size; chr7:66353241 chr7:65647864~65715661:+ LIHC cis rs901683 1 rs36074276 ENSG00000230869.1 CTGLF10P -4.25 2.71e-05 0.00621 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45560293 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs77651228 ENSG00000230869.1 CTGLF10P -4.25 2.71e-05 0.00621 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45560681 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs9422658 ENSG00000230869.1 CTGLF10P -4.25 2.71e-05 0.00621 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45564219 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35934513 ENSG00000230869.1 CTGLF10P -4.25 2.71e-05 0.00621 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45564333 chr10:45678692~45700532:+ LIHC cis rs763121 0.819 rs138700 ENSG00000273076.1 RP3-508I15.22 4.25 2.71e-05 0.00621 0.25 0.22 Menopause (age at onset); chr22:38733994 chr22:38743495~38743910:+ LIHC cis rs651907 0.535 rs61396602 ENSG00000244119.1 PDCL3P4 4.25 2.71e-05 0.00622 0.23 0.22 Colorectal cancer; chr3:101790202 chr3:101712472~101713191:+ LIHC cis rs6442522 0.898 rs2219251 ENSG00000249786.6 EAF1-AS1 4.25 2.71e-05 0.00622 0.25 0.22 Uric acid levels; chr3:15387661 chr3:15436171~15455940:- LIHC cis rs11064837 0.56 rs7952841 ENSG00000248636.5 RP11-768F21.1 4.25 2.71e-05 0.00622 0.38 0.22 Schizophrenia; chr12:119620349 chr12:119387987~119668079:- LIHC cis rs2998286 0.723 rs332151 ENSG00000254635.4 WAC-AS1 -4.25 2.71e-05 0.00622 -0.28 -0.22 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28585331 chr10:28522652~28532743:- LIHC cis rs2276314 0.857 rs28379448 ENSG00000278986.1 RP11-723J4.3 -4.25 2.71e-05 0.00622 -0.27 -0.22 Endometriosis;Drug-induced torsades de pointes; chr18:36024401 chr18:35972151~35973916:+ LIHC cis rs6048205 0.881 rs945982 ENSG00000259974.2 LINC00261 4.25 2.71e-05 0.00623 0.32 0.22 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22553503 chr20:22547671~22578642:- LIHC cis rs9322193 0.607 rs10457852 ENSG00000216906.2 RP11-350J20.9 4.25 2.71e-05 0.00623 0.24 0.22 Lung cancer; chr6:149880584 chr6:149904243~149906418:+ LIHC cis rs11763147 1 rs11763147 ENSG00000224316.1 RP11-479O9.2 -4.25 2.71e-05 0.00623 -0.23 -0.22 Corneal structure; chr7:65861834 chr7:65773620~65802067:+ LIHC cis rs9467711 0.651 rs72834677 ENSG00000216436.2 HIST1H2APS1 4.25 2.72e-05 0.00623 0.6 0.22 Autism spectrum disorder or schizophrenia; chr6:26106376 chr6:25732497~25732827:+ LIHC cis rs9467711 0.651 rs13200797 ENSG00000216436.2 HIST1H2APS1 4.25 2.72e-05 0.00623 0.6 0.22 Autism spectrum disorder or schizophrenia; chr6:26122729 chr6:25732497~25732827:+ LIHC cis rs2243480 1 rs67728539 ENSG00000230295.1 RP11-458F8.2 -4.25 2.72e-05 0.00624 -0.24 -0.22 Diabetic kidney disease; chr7:65913137 chr7:66880708~66882981:+ LIHC cis rs651907 0.557 rs3094295 ENSG00000244119.1 PDCL3P4 4.25 2.72e-05 0.00624 0.23 0.22 Colorectal cancer; chr3:101683151 chr3:101712472~101713191:+ LIHC cis rs9640161 0.83 rs3757425 ENSG00000261305.1 RP4-584D14.7 4.25 2.72e-05 0.00625 0.27 0.22 Blood protein levels;Circulating chemerin levels; chr7:150370551 chr7:150341771~150342607:+ LIHC cis rs9640161 0.83 rs3757424 ENSG00000261305.1 RP4-584D14.7 4.25 2.72e-05 0.00625 0.27 0.22 Blood protein levels;Circulating chemerin levels; chr7:150370590 chr7:150341771~150342607:+ LIHC cis rs6921919 0.697 rs758398 ENSG00000204709.4 LINC01556 4.25 2.72e-05 0.00625 0.25 0.22 Autism spectrum disorder or schizophrenia; chr6:28352897 chr6:28943877~28944537:+ LIHC cis rs2243480 1 rs73142162 ENSG00000228409.4 CCT6P1 4.25 2.73e-05 0.00626 0.25 0.22 Diabetic kidney disease; chr7:65909309 chr7:65751142~65763354:+ LIHC cis rs1023500 1 rs6002548 ENSG00000237037.8 NDUFA6-AS1 -4.25 2.73e-05 0.00626 -0.31 -0.22 Schizophrenia; chr22:41941036 chr22:42090931~42137742:+ LIHC cis rs1115240 0.947 rs56303656 ENSG00000257842.4 NOVA1-AS1 4.25 2.73e-05 0.00626 0.21 0.22 Educational attainment (years of education); chr14:26638715 chr14:26598412~26806467:+ LIHC cis rs875971 0.545 rs10950036 ENSG00000228409.4 CCT6P1 -4.25 2.73e-05 0.00626 -0.19 -0.22 Aortic root size; chr7:66353241 chr7:65751142~65763354:+ LIHC cis rs2739330 0.892 rs5751776 ENSG00000206090.4 AP000350.7 4.25 2.73e-05 0.00627 0.26 0.22 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23939998~23942798:+ LIHC cis rs12554020 0.892 rs75625893 ENSG00000227603.1 RP11-165J3.6 4.25 2.73e-05 0.00627 0.32 0.22 Schizophrenia; chr9:93605006 chr9:93435332~93437121:- LIHC cis rs42490 0.51 rs218890 ENSG00000251136.7 RP11-37B2.1 -4.25 2.73e-05 0.00627 -0.19 -0.22 Leprosy; chr8:89680848 chr8:89609409~89757727:- LIHC cis rs4356975 0.806 rs12648808 ENSG00000250919.1 RP11-813N20.3 -4.25 2.74e-05 0.00627 -0.22 -0.22 Obesity-related traits; chr4:69075351 chr4:69027831~69044578:+ LIHC cis rs13242816 1 rs3807995 ENSG00000279086.1 RP11-667F14.1 4.25 2.74e-05 0.00627 0.4 0.22 P wave duration; chr7:116557922 chr7:116209234~116211511:- LIHC cis rs6472235 0.681 rs4129057 ENSG00000272010.1 CTD-3025N20.3 -4.25 2.74e-05 0.00627 -0.31 -0.22 Plateletcrit;Myopia (pathological); chr8:65943911 chr8:65591850~65592472:- LIHC cis rs9646944 0.578 rs13418548 ENSG00000234389.1 AC007278.3 4.25 2.74e-05 0.00628 0.3 0.22 Blood protein levels; chr2:102300779 chr2:102438713~102440475:+ LIHC cis rs6745190 0.861 rs7349232 ENSG00000236153.1 AC104076.3 -4.25 2.74e-05 0.00629 -0.32 -0.22 White blood cell count; chr2:181088627 chr2:180979427~180980090:- LIHC cis rs12931792 0.712 rs56399904 ENSG00000183604.13 SMG1P5 4.25 2.75e-05 0.00629 0.2 0.22 Tonsillectomy; chr16:30154862 chr16:30267553~30335374:- LIHC cis rs11098499 0.698 rs4422403 ENSG00000245958.5 RP11-33B1.1 -4.25 2.75e-05 0.00629 -0.22 -0.22 Corneal astigmatism; chr4:119337039 chr4:119454791~119552025:+ LIHC cis rs6951245 0.507 rs11976805 ENSG00000229043.2 AC091729.9 -4.25 2.75e-05 0.0063 -0.31 -0.22 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1099080 chr7:1160374~1165267:+ LIHC cis rs10129255 0.5 rs4774008 ENSG00000211972.2 IGHV3-66 4.25 2.75e-05 0.0063 0.17 0.22 Kawasaki disease; chr14:106681273 chr14:106675017~106675544:- LIHC cis rs11148252 0.904 rs7990581 ENSG00000278238.1 RP11-245D16.4 -4.25 2.75e-05 0.0063 -0.21 -0.22 Lewy body disease; chr13:52445298 chr13:52454775~52455331:- LIHC cis rs651907 0.535 rs11919389 ENSG00000244119.1 PDCL3P4 4.25 2.75e-05 0.0063 0.23 0.22 Colorectal cancer; chr3:101705614 chr3:101712472~101713191:+ LIHC cis rs651907 0.514 rs55654108 ENSG00000244119.1 PDCL3P4 4.25 2.75e-05 0.0063 0.23 0.22 Colorectal cancer; chr3:101706859 chr3:101712472~101713191:+ LIHC cis rs673078 0.66 rs73205531 ENSG00000275759.1 RP11-131L12.3 -4.25 2.75e-05 0.0063 -0.45 -0.22 Glucose homeostasis traits; chr12:118282063 chr12:118428281~118428870:+ LIHC cis rs6430585 0.528 rs309119 ENSG00000231890.6 DARS-AS1 -4.25 2.75e-05 0.0063 -0.31 -0.22 Corneal structure; chr2:135952802 chr2:135985176~136022593:+ LIHC cis rs2060793 0.519 rs10832285 ENSG00000251991.1 RNU7-49P 4.25 2.75e-05 0.00631 0.25 0.22 Vitamin D levels; chr11:14628031 chr11:14478892~14478953:+ LIHC cis rs2929278 0.617 rs4617832 ENSG00000275601.1 AC011330.13 4.25 2.75e-05 0.00631 0.28 0.22 Schizophrenia; chr15:43738381 chr15:43642389~43643023:- LIHC cis rs763121 0.853 rs5750671 ENSG00000273076.1 RP3-508I15.22 4.25 2.75e-05 0.00631 0.25 0.22 Menopause (age at onset); chr22:38698614 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs926299 ENSG00000273076.1 RP3-508I15.22 4.25 2.75e-05 0.00631 0.25 0.22 Menopause (age at onset); chr22:38699693 chr22:38743495~38743910:+ LIHC cis rs763121 0.785 rs6001203 ENSG00000273076.1 RP3-508I15.22 4.25 2.75e-05 0.00631 0.25 0.22 Menopause (age at onset); chr22:38703597 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs6001204 ENSG00000273076.1 RP3-508I15.22 4.25 2.75e-05 0.00631 0.25 0.22 Menopause (age at onset); chr22:38704234 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs2267393 ENSG00000273076.1 RP3-508I15.22 4.25 2.75e-05 0.00631 0.25 0.22 Menopause (age at onset); chr22:38705614 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs2267394 ENSG00000273076.1 RP3-508I15.22 4.25 2.75e-05 0.00631 0.25 0.22 Menopause (age at onset); chr22:38705628 chr22:38743495~38743910:+ LIHC cis rs651907 0.557 rs2303474 ENSG00000244119.1 PDCL3P4 4.25 2.76e-05 0.00631 0.23 0.22 Colorectal cancer; chr3:101653055 chr3:101712472~101713191:+ LIHC cis rs4578769 0.729 rs16973538 ENSG00000266850.1 RP11-370A5.1 4.25 2.76e-05 0.00631 0.27 0.22 Eosinophil percentage of white cells; chr18:22899823 chr18:22723491~22907721:- LIHC cis rs651907 0.557 rs59596156 ENSG00000244119.1 PDCL3P4 4.25 2.76e-05 0.00632 0.23 0.22 Colorectal cancer; chr3:101675373 chr3:101712472~101713191:+ LIHC cis rs7246657 1 rs7246657 ENSG00000276846.1 CTD-3220F14.3 -4.25 2.76e-05 0.00632 -0.27 -0.22 Coronary artery calcification; chr19:37256206 chr19:37314868~37315620:- LIHC cis rs2739330 0.796 rs1006771 ENSG00000250470.1 AP000351.3 4.25 2.76e-05 0.00632 0.26 0.22 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23976904~23977585:- LIHC cis rs4266144 1 rs4561781 ENSG00000241770.1 RP11-555M1.3 4.25 2.76e-05 0.00632 0.26 0.22 Coronary artery disease; chr3:157135154 chr3:157163452~157169133:+ LIHC cis rs11216126 1 rs34637368 ENSG00000254851.1 RP11-109L13.1 4.25 2.76e-05 0.00632 0.35 0.22 HDL cholesterol; chr11:116748889 chr11:117135528~117138582:+ LIHC cis rs901683 1 rs34011467 ENSG00000230869.1 CTGLF10P -4.25 2.76e-05 0.00632 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45564310 chr10:45678692~45700532:+ LIHC cis rs2243480 1 rs34136756 ENSG00000232546.1 RP11-458F8.1 -4.25 2.76e-05 0.00632 -0.25 -0.22 Diabetic kidney disease; chr7:65916269 chr7:66848496~66858136:+ LIHC cis rs752590 0.943 rs13407583 ENSG00000189223.12 PAX8-AS1 -4.25 2.76e-05 0.00632 -0.36 -0.22 Mucinous ovarian carcinoma; chr2:113210163 chr2:113211522~113276581:+ LIHC cis rs4356203 0.87 rs10766381 ENSG00000260196.1 RP1-239B22.5 -4.25 2.76e-05 0.00632 -0.27 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17235498 chr11:17380649~17383531:+ LIHC cis rs7615952 0.641 rs12488180 ENSG00000171084.14 FAM86JP 4.25 2.76e-05 0.00632 0.36 0.22 Blood pressure (smoking interaction); chr3:126063393 chr3:125916620~125930024:+ LIHC cis rs202072 0.725 rs445590 ENSG00000215022.6 RP1-257A7.4 -4.25 2.76e-05 0.00633 -0.25 -0.22 HIV-1 viral setpoint; chr6:13280632 chr6:13264861~13295586:- LIHC cis rs1577917 1 rs1018184 ENSG00000234155.1 RP11-30P6.6 -4.25 2.76e-05 0.00633 -0.29 -0.22 Response to antipsychotic treatment; chr6:85938757 chr6:85387219~85390186:- LIHC cis rs8177253 0.763 rs6797713 ENSG00000244062.1 RP11-404G16.2 4.25 2.76e-05 0.00633 0.22 0.22 Iron status biomarkers; chr3:133755988 chr3:133760300~133762363:+ LIHC cis rs6442522 0.966 rs6792128 ENSG00000249786.6 EAF1-AS1 4.25 2.77e-05 0.00633 0.25 0.22 Uric acid levels; chr3:15417350 chr3:15436171~15455940:- LIHC cis rs1865760 0.566 rs9358904 ENSG00000216436.2 HIST1H2APS1 -4.25 2.77e-05 0.00633 -0.26 -0.22 Height; chr6:26068338 chr6:25732497~25732827:+ LIHC cis rs7487637 0.529 rs11168245 ENSG00000276691.1 RP5-1057I20.5 4.25 2.77e-05 0.00633 0.4 0.22 Mononucleosis; chr12:47810716 chr12:47788426~47788971:+ LIHC cis rs10262624 1 rs17347733 ENSG00000234286.1 AC006026.13 -4.25 2.77e-05 0.00634 -0.25 -0.22 Schizophrenia; chr7:23878891 chr7:23680195~23680786:- LIHC cis rs9527 0.59 rs3861984 ENSG00000236937.2 PTGES3P4 4.25 2.77e-05 0.00634 0.28 0.22 Arsenic metabolism; chr10:103157223 chr10:102845595~102845950:+ LIHC cis rs1555322 0.872 rs2425046 ENSG00000126005.14 MMP24-AS1 -4.25 2.77e-05 0.00634 -0.45 -0.22 Attention deficit hyperactivity disorder; chr20:35283858 chr20:35216462~35278131:- LIHC cis rs2439831 1 rs2439850 ENSG00000166763.7 STRCP1 4.25 2.77e-05 0.00634 0.32 0.22 Lung cancer in ever smokers; chr15:43492656 chr15:43699488~43718184:- LIHC cis rs683257 1 rs117661682 ENSG00000234147.1 RP3-460G2.2 -4.25 2.77e-05 0.00634 -0.42 -0.22 Facial emotion recognition (angry faces); chr6:140832838 chr6:140845958~140852924:- LIHC cis rs7208859 0.623 rs56378576 ENSG00000266490.1 CTD-2349P21.9 4.25 2.77e-05 0.00634 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30683102 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs35916850 ENSG00000266490.1 CTD-2349P21.9 4.25 2.77e-05 0.00634 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30684155 chr17:30792372~30792833:+ LIHC cis rs3020736 0.5 rs11090076 ENSG00000226450.2 CYP2D8P -4.25 2.77e-05 0.00634 -0.28 -0.22 Autism spectrum disorder or schizophrenia; chr22:42118186 chr22:42149886~42155001:- LIHC cis rs2361718 0.967 rs2361719 ENSG00000261978.1 CTD-2529O21.2 -4.25 2.77e-05 0.00634 -0.24 -0.22 Yeast infection; chr17:80129604 chr17:80023894~80026107:+ LIHC cis rs42490 0.528 rs1032516 ENSG00000251136.7 RP11-37B2.1 4.25 2.77e-05 0.00635 0.19 0.22 Leprosy; chr8:89670055 chr8:89609409~89757727:- LIHC cis rs7894407 0.76 rs1163085 ENSG00000236937.2 PTGES3P4 4.25 2.78e-05 0.00635 0.27 0.22 White matter hyperintensity burden; chr10:103279484 chr10:102845595~102845950:+ LIHC cis rs5742933 0.857 rs1437891 ENSG00000253559.1 OSGEPL1-AS1 -4.25 2.78e-05 0.00635 -0.3 -0.22 Ferritin levels; chr2:189697982 chr2:189762704~189765556:+ LIHC cis rs7119038 0.865 rs4938573 ENSG00000255239.1 AP002954.6 4.25 2.78e-05 0.00635 0.33 0.22 Sjögren's syndrome; chr11:118871133 chr11:118688039~118690600:- LIHC cis rs875971 0.545 rs2279757 ENSG00000273024.4 INTS4P2 -4.25 2.78e-05 0.00635 -0.26 -0.22 Aortic root size; chr7:66363676 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs11766183 ENSG00000273024.4 INTS4P2 -4.25 2.78e-05 0.00635 -0.26 -0.22 Aortic root size; chr7:66374173 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs1065265 ENSG00000273024.4 INTS4P2 -4.25 2.78e-05 0.00635 -0.26 -0.22 Aortic root size; chr7:66376216 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs7811204 ENSG00000273024.4 INTS4P2 -4.25 2.78e-05 0.00635 -0.26 -0.22 Aortic root size; chr7:66387213 chr7:65647864~65715661:+ LIHC cis rs11098499 0.909 rs79026312 ENSG00000260091.1 RP11-33B1.4 -4.25 2.78e-05 0.00635 -0.16 -0.22 Corneal astigmatism; chr4:119519522 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs35111518 ENSG00000260091.1 RP11-33B1.4 -4.25 2.78e-05 0.00635 -0.16 -0.22 Corneal astigmatism; chr4:119519527 chr4:119409333~119410233:+ LIHC cis rs2581828 0.656 rs4687701 ENSG00000242142.1 SERBP1P3 -4.25 2.78e-05 0.00635 -0.25 -0.22 Crohn's disease; chr3:53087260 chr3:53064283~53065091:- LIHC cis rs2348418 0.864 rs7977817 ENSG00000247934.4 RP11-967K21.1 4.25 2.78e-05 0.00636 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28562549 chr12:28163298~28190738:- LIHC cis rs2348418 0.831 rs7977525 ENSG00000247934.4 RP11-967K21.1 4.25 2.78e-05 0.00636 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28562584 chr12:28163298~28190738:- LIHC cis rs2348418 0.864 rs7977850 ENSG00000247934.4 RP11-967K21.1 4.25 2.78e-05 0.00636 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28562715 chr12:28163298~28190738:- LIHC cis rs2348418 0.864 rs11609924 ENSG00000247934.4 RP11-967K21.1 4.25 2.78e-05 0.00636 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28563197 chr12:28163298~28190738:- LIHC cis rs2348418 0.864 rs7968563 ENSG00000247934.4 RP11-967K21.1 4.25 2.78e-05 0.00636 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28563844 chr12:28163298~28190738:- LIHC cis rs2348418 0.864 rs2137072 ENSG00000247934.4 RP11-967K21.1 4.25 2.78e-05 0.00636 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28563872 chr12:28163298~28190738:- LIHC cis rs3733589 0.744 rs13122112 ENSG00000250413.1 RP11-448G15.1 4.25 2.78e-05 0.00636 0.36 0.22 Renal overload gout; chr4:10019780 chr4:10006482~10009725:+ LIHC cis rs4948102 0.731 rs4948099 ENSG00000226278.1 PSPHP1 4.25 2.78e-05 0.00636 0.25 0.22 Plasma homocysteine levels (post-methionine load test); chr7:56004557 chr7:55764797~55773288:+ LIHC cis rs7587476 0.954 rs3768708 ENSG00000229267.2 AC072062.1 4.25 2.78e-05 0.00636 0.29 0.22 Neuroblastoma; chr2:214780322 chr2:214810229~214963274:+ LIHC cis rs3772760 0.744 rs3772764 ENSG00000240622.1 RPL7P15 -4.25 2.78e-05 0.00636 -0.42 -0.22 Amyotrophic lateral sclerosis; chr3:124481954 chr3:124151960~124153063:- LIHC cis rs2688482 0.557 rs2550236 ENSG00000185485.13 SDHAP1 4.25 2.78e-05 0.00637 0.25 0.22 Lung disease severity in cystic fibrosis; chr3:195795450 chr3:195959748~195990318:- LIHC cis rs2581828 0.656 rs2163167 ENSG00000242142.1 SERBP1P3 4.25 2.78e-05 0.00637 0.26 0.22 Crohn's disease; chr3:53097756 chr3:53064283~53065091:- LIHC cis rs202072 0.769 rs445591 ENSG00000215022.6 RP1-257A7.4 -4.25 2.79e-05 0.00637 -0.25 -0.22 HIV-1 viral setpoint; chr6:13280634 chr6:13264861~13295586:- LIHC cis rs748404 0.578 rs576557 ENSG00000205771.5 CATSPER2P1 -4.25 2.79e-05 0.00637 -0.27 -0.22 Lung cancer; chr15:43305539 chr15:43726918~43747094:- LIHC cis rs113084984 0.538 rs12994384 ENSG00000271952.1 RP11-245G13.2 -4.25 2.79e-05 0.00637 -0.25 -0.22 Breast cancer; chr2:11543839 chr2:10878269~10885118:+ LIHC cis rs867371 0.762 rs1846910 ENSG00000259429.4 UBE2Q2P2 -4.25 2.79e-05 0.00637 -0.22 -0.22 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82279439 chr15:82355142~82420075:+ LIHC cis rs9907295 0.681 rs9912284 ENSG00000270871.1 AC015849.19 4.25 2.79e-05 0.00637 0.24 0.22 Fibroblast growth factor basic levels; chr17:35906638 chr17:35816717~35830293:- LIHC cis rs7429990 0.864 rs12497826 ENSG00000229759.1 MRPS18AP1 -4.25 2.79e-05 0.00638 -0.24 -0.22 Educational attainment (years of education); chr3:47628059 chr3:48256350~48256938:- LIHC cis rs11710088 0.74 rs13069729 ENSG00000244503.1 RP11-278L15.6 -4.25 2.79e-05 0.00638 -0.28 -0.22 QRS duration; chr3:149473092 chr3:149494660~149495995:+ LIHC cis rs7044106 0.762 rs10984974 ENSG00000238181.2 AHCYP2 -4.25 2.79e-05 0.00639 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120659278 chr9:120720673~120721972:+ LIHC cis rs6901152 0.525 rs1424930 ENSG00000217648.1 RP1-95L4.4 -4.25 2.8e-05 0.00639 -0.27 -0.22 Acute lymphoblastic leukemia (childhood); chr6:143371223 chr6:143342246~143343383:+ LIHC cis rs6901152 0.525 rs4645437 ENSG00000217648.1 RP1-95L4.4 -4.25 2.8e-05 0.00639 -0.27 -0.22 Acute lymphoblastic leukemia (childhood); chr6:143371531 chr6:143342246~143343383:+ LIHC cis rs1023500 0.505 rs134874 ENSG00000226450.2 CYP2D8P 4.25 2.8e-05 0.00639 0.24 0.22 Schizophrenia; chr22:42265138 chr22:42149886~42155001:- LIHC cis rs7811142 0.83 rs6965458 ENSG00000242294.5 STAG3L5P 4.25 2.8e-05 0.00639 0.25 0.22 Platelet count; chr7:100375779 chr7:100336079~100351900:+ LIHC cis rs651907 0.535 rs34263427 ENSG00000244119.1 PDCL3P4 4.25 2.8e-05 0.00639 0.23 0.22 Colorectal cancer; chr3:101788961 chr3:101712472~101713191:+ LIHC cis rs6565180 1 rs12930787 ENSG00000183604.13 SMG1P5 -4.25 2.8e-05 0.00639 -0.24 -0.22 Tonsillectomy; chr16:30369982 chr16:30267553~30335374:- LIHC cis rs2243480 0.706 rs34466769 ENSG00000164669.11 INTS4P1 4.25 2.8e-05 0.0064 0.35 0.22 Diabetic kidney disease; chr7:65988305 chr7:65141225~65234216:+ LIHC cis rs2744375 0.6 rs2237102 ENSG00000261189.1 RP3-512B11.3 4.25 2.8e-05 0.0064 0.28 0.22 Resting heart rate; chr6:7551912 chr6:7540451~7541338:- LIHC cis rs17507216 0.628 rs17158396 ENSG00000278603.1 RP13-608F4.5 4.25 2.8e-05 0.0064 0.43 0.22 Excessive daytime sleepiness; chr15:82615688 chr15:82472203~82472426:+ LIHC cis rs9652601 0.879 rs9926367 ENSG00000274038.1 RP11-66H6.4 -4.25 2.8e-05 0.0064 -0.28 -0.22 Systemic lupus erythematosus; chr16:10999322 chr16:11056556~11057034:+ LIHC cis rs7615952 0.599 rs67566088 ENSG00000171084.14 FAM86JP 4.25 2.8e-05 0.0064 0.36 0.22 Blood pressure (smoking interaction); chr3:126050130 chr3:125916620~125930024:+ LIHC cis rs7615952 0.641 rs12495947 ENSG00000171084.14 FAM86JP 4.25 2.8e-05 0.0064 0.36 0.22 Blood pressure (smoking interaction); chr3:126052855 chr3:125916620~125930024:+ LIHC cis rs7615952 0.641 rs6805074 ENSG00000171084.14 FAM86JP 4.25 2.8e-05 0.0064 0.36 0.22 Blood pressure (smoking interaction); chr3:126053431 chr3:125916620~125930024:+ LIHC cis rs7615952 0.641 rs66520539 ENSG00000171084.14 FAM86JP 4.25 2.8e-05 0.0064 0.36 0.22 Blood pressure (smoking interaction); chr3:126061531 chr3:125916620~125930024:+ LIHC cis rs4356203 0.87 rs214926 ENSG00000260196.1 RP1-239B22.5 -4.25 2.8e-05 0.0064 -0.27 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17210255 chr11:17380649~17383531:+ LIHC cis rs2276314 0.857 rs9960670 ENSG00000278986.1 RP11-723J4.3 -4.25 2.8e-05 0.0064 -0.27 -0.22 Endometriosis;Drug-induced torsades de pointes; chr18:35997749 chr18:35972151~35973916:+ LIHC cis rs17507216 0.628 rs8028130 ENSG00000278603.1 RP13-608F4.5 4.25 2.8e-05 0.0064 0.45 0.22 Excessive daytime sleepiness; chr15:82734974 chr15:82472203~82472426:+ LIHC cis rs1876905 0.539 rs240969 ENSG00000272356.1 RP5-1112D6.8 4.25 2.8e-05 0.0064 0.21 0.22 Mean corpuscular hemoglobin; chr6:111314605 chr6:111309203~111313517:+ LIHC cis rs617219 0.819 rs6453434 ENSG00000251675.1 CTC-458I2.2 4.25 2.8e-05 0.0064 0.26 0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79274396 chr5:80128361~80143883:+ LIHC cis rs881375 0.702 rs3761847 ENSG00000226752.6 PSMD5-AS1 -4.25 2.81e-05 0.00641 -0.23 -0.22 Rheumatoid arthritis; chr9:120927961 chr9:120824828~120854385:+ LIHC cis rs673078 0.607 rs17440893 ENSG00000275759.1 RP11-131L12.3 -4.25 2.81e-05 0.00641 -0.45 -0.22 Glucose homeostasis traits; chr12:118362532 chr12:118428281~118428870:+ LIHC cis rs651907 0.557 rs11925001 ENSG00000244119.1 PDCL3P4 4.25 2.81e-05 0.00641 0.23 0.22 Colorectal cancer; chr3:101655122 chr3:101712472~101713191:+ LIHC cis rs651907 0.557 rs3806653 ENSG00000244119.1 PDCL3P4 4.25 2.81e-05 0.00641 0.23 0.22 Colorectal cancer; chr3:101678128 chr3:101712472~101713191:+ LIHC cis rs651907 0.557 rs1056579 ENSG00000244119.1 PDCL3P4 4.25 2.81e-05 0.00641 0.23 0.22 Colorectal cancer; chr3:101679033 chr3:101712472~101713191:+ LIHC cis rs17345786 0.511 rs1138818 ENSG00000244119.1 PDCL3P4 4.25 2.81e-05 0.00641 0.23 0.22 Colonoscopy-negative controls vs population controls; chr3:101680739 chr3:101712472~101713191:+ LIHC cis rs3010562 1 rs3010562 ENSG00000216966.1 RP11-568A7.1 -4.25 2.81e-05 0.00642 -0.23 -0.22 Gut microbiome composition (summer and winter); chr6:167351763 chr6:167208631~167208897:- LIHC cis rs4938303 0.671 rs2008915 ENSG00000236267.1 AP006216.5 4.25 2.81e-05 0.00642 0.23 0.22 Triglycerides; chr11:116732418 chr11:116813204~116814003:- LIHC cis rs1200821 0.559 rs9418267 ENSG00000263064.2 RP11-291L22.7 -4.25 2.81e-05 0.00642 -0.23 -0.22 Hemostatic factors and hematological phenotypes; chr10:37531023 chr10:38448689~38448949:+ LIHC cis rs75920871 0.688 rs7109876 ENSG00000254851.1 RP11-109L13.1 -4.25 2.81e-05 0.00642 -0.43 -0.22 Subjective well-being; chr11:116977932 chr11:117135528~117138582:+ LIHC cis rs4356975 0.932 rs4400060 ENSG00000250919.1 RP11-813N20.3 -4.25 2.81e-05 0.00642 -0.22 -0.22 Obesity-related traits; chr4:69071215 chr4:69027831~69044578:+ LIHC cis rs12701220 0.894 rs2141274 ENSG00000229043.2 AC091729.9 -4.25 2.81e-05 0.00642 -0.31 -0.22 Bronchopulmonary dysplasia; chr7:995081 chr7:1160374~1165267:+ LIHC cis rs12701220 0.817 rs1058727 ENSG00000229043.2 AC091729.9 -4.25 2.81e-05 0.00642 -0.3 -0.22 Bronchopulmonary dysplasia; chr7:1047459 chr7:1160374~1165267:+ LIHC cis rs7129556 0.645 rs598071 ENSG00000254459.1 RP11-91P24.7 4.25 2.81e-05 0.00642 0.36 0.22 Weight loss (gastric bypass surgery); chr11:77849606 chr11:77829654~77872262:- LIHC cis rs7129556 0.69 rs12285765 ENSG00000254459.1 RP11-91P24.7 4.25 2.81e-05 0.00642 0.36 0.22 Weight loss (gastric bypass surgery); chr11:77857989 chr11:77829654~77872262:- LIHC cis rs7129556 0.728 rs628668 ENSG00000254459.1 RP11-91P24.7 4.25 2.81e-05 0.00642 0.36 0.22 Weight loss (gastric bypass surgery); chr11:77866448 chr11:77829654~77872262:- LIHC cis rs7129556 0.69 rs588217 ENSG00000254459.1 RP11-91P24.7 -4.25 2.81e-05 0.00642 -0.36 -0.22 Weight loss (gastric bypass surgery); chr11:77872330 chr11:77829654~77872262:- LIHC cis rs2348418 1 rs2348418 ENSG00000247934.4 RP11-967K21.1 4.25 2.81e-05 0.00643 0.21 0.22 Lung function (FEV1);Lung function (FVC); chr12:28536581 chr12:28163298~28190738:- LIHC cis rs4972806 0.739 rs10834 ENSG00000226363.3 HAGLROS -4.25 2.82e-05 0.00643 -0.29 -0.22 IgG glycosylation; chr2:176177359 chr2:176177717~176179008:+ LIHC cis rs1501911 0.611 rs7712408 ENSG00000248489.1 CTD-2007H13.3 -4.25 2.82e-05 0.00643 -0.34 -0.22 Lung function (FEV1/FVC); chr5:99020633 chr5:98929171~98995013:+ LIHC cis rs7429990 0.833 rs3755637 ENSG00000229759.1 MRPS18AP1 -4.24 2.82e-05 0.00644 -0.24 -0.22 Educational attainment (years of education); chr3:47580720 chr3:48256350~48256938:- LIHC cis rs9457247 1 rs364451 ENSG00000227598.1 RP1-167A14.2 -4.24 2.82e-05 0.00644 -0.24 -0.22 Crohn's disease; chr6:166971268 chr6:166969626~166999065:- LIHC cis rs11096990 0.855 rs1820939 ENSG00000249207.1 RP11-360F5.1 4.24 2.82e-05 0.00644 0.26 0.22 Cognitive function; chr4:39170115 chr4:39112677~39126818:- LIHC cis rs734999 0.524 rs4648448 ENSG00000225931.3 RP3-395M20.7 4.24 2.82e-05 0.00644 0.24 0.22 Ulcerative colitis; chr1:2779144 chr1:2566410~2569888:+ LIHC cis rs2274273 0.967 rs8013027 ENSG00000258413.1 RP11-665C16.6 -4.24 2.82e-05 0.00644 -0.26 -0.22 Protein biomarker; chr14:55144222 chr14:55262767~55272075:- LIHC cis rs12931792 0.846 rs9924308 ENSG00000183604.13 SMG1P5 -4.24 2.83e-05 0.00645 -0.22 -0.22 Tonsillectomy; chr16:30143419 chr16:30267553~30335374:- LIHC cis rs875971 0.571 rs78668714 ENSG00000228409.4 CCT6P1 -4.24 2.83e-05 0.00645 -0.19 -0.22 Aortic root size; chr7:66474464 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs73150604 ENSG00000228409.4 CCT6P1 -4.24 2.83e-05 0.00645 -0.19 -0.22 Aortic root size; chr7:66480545 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs7810213 ENSG00000228409.4 CCT6P1 -4.24 2.83e-05 0.00645 -0.19 -0.22 Aortic root size; chr7:66481592 chr7:65751142~65763354:+ LIHC cis rs4713118 0.513 rs149955 ENSG00000216901.1 AL022393.7 4.24 2.83e-05 0.00645 0.29 0.22 Parkinson's disease; chr6:28068447 chr6:28176188~28176674:+ LIHC cis rs1075232 0.655 rs77987193 ENSG00000270055.1 CTD-3092A11.2 -4.24 2.83e-05 0.00645 -0.44 -0.22 Survival in colorectal cancer (non-distant metastatic); chr15:31296055 chr15:30487963~30490313:+ LIHC cis rs763121 0.853 rs5750633 ENSG00000273076.1 RP3-508I15.22 4.24 2.83e-05 0.00646 0.25 0.22 Menopause (age at onset); chr22:38597462 chr22:38743495~38743910:+ LIHC cis rs4694744 0.576 rs41297373 ENSG00000264696.1 AC108078.1 4.24 2.83e-05 0.00646 0.33 0.22 Bacteremia; chr4:69491476 chr4:69479331~69479434:+ LIHC cis rs4694744 0.576 rs41297371 ENSG00000264696.1 AC108078.1 4.24 2.83e-05 0.00646 0.33 0.22 Bacteremia; chr4:69491511 chr4:69479331~69479434:+ LIHC cis rs4694744 0.576 rs41297367 ENSG00000264696.1 AC108078.1 4.24 2.83e-05 0.00646 0.33 0.22 Bacteremia; chr4:69491851 chr4:69479331~69479434:+ LIHC cis rs4694744 0.576 rs13139888 ENSG00000264696.1 AC108078.1 4.24 2.83e-05 0.00646 0.33 0.22 Bacteremia; chr4:69492158 chr4:69479331~69479434:+ LIHC cis rs734999 0.566 rs6424092 ENSG00000225931.3 RP3-395M20.7 -4.24 2.83e-05 0.00646 -0.24 -0.22 Ulcerative colitis; chr1:2601460 chr1:2566410~2569888:+ LIHC cis rs734999 0.588 rs10910098 ENSG00000225931.3 RP3-395M20.7 4.24 2.83e-05 0.00646 0.24 0.22 Ulcerative colitis; chr1:2601811 chr1:2566410~2569888:+ LIHC cis rs734999 0.588 rs60520190 ENSG00000225931.3 RP3-395M20.7 4.24 2.83e-05 0.00646 0.24 0.22 Ulcerative colitis; chr1:2602267 chr1:2566410~2569888:+ LIHC cis rs9907295 0.748 rs78672421 ENSG00000270871.1 AC015849.19 4.24 2.83e-05 0.00646 0.24 0.22 Fibroblast growth factor basic levels; chr17:35837325 chr17:35816717~35830293:- LIHC cis rs6439153 0.933 rs1871951 ENSG00000231305.3 RP11-723O4.2 4.24 2.84e-05 0.00646 0.25 0.22 Pneumococcal bacteremia; chr3:129001644 chr3:128861313~128871540:- LIHC cis rs6439153 0.933 rs6769662 ENSG00000231305.3 RP11-723O4.2 4.24 2.84e-05 0.00646 0.25 0.22 Pneumococcal bacteremia; chr3:129002467 chr3:128861313~128871540:- LIHC cis rs6439153 0.967 rs12695512 ENSG00000231305.3 RP11-723O4.2 4.24 2.84e-05 0.00646 0.25 0.22 Pneumococcal bacteremia; chr3:129003239 chr3:128861313~128871540:- LIHC cis rs6439153 0.967 rs12695513 ENSG00000231305.3 RP11-723O4.2 4.24 2.84e-05 0.00646 0.25 0.22 Pneumococcal bacteremia; chr3:129003469 chr3:128861313~128871540:- LIHC cis rs11098499 0.913 rs10010696 ENSG00000260091.1 RP11-33B1.4 -4.24 2.84e-05 0.00646 -0.17 -0.22 Corneal astigmatism; chr4:119243148 chr4:119409333~119410233:+ LIHC cis rs12908161 0.683 rs12903256 ENSG00000259295.5 CSPG4P12 4.24 2.84e-05 0.00647 0.28 0.22 Schizophrenia; chr15:84764910 chr15:85191438~85213905:+ LIHC cis rs11096990 0.593 rs35937374 ENSG00000249207.1 RP11-360F5.1 -4.24 2.84e-05 0.00647 -0.23 -0.22 Cognitive function; chr4:39184735 chr4:39112677~39126818:- LIHC cis rs11096990 0.574 rs34070258 ENSG00000249207.1 RP11-360F5.1 -4.24 2.84e-05 0.00647 -0.23 -0.22 Cognitive function; chr4:39188132 chr4:39112677~39126818:- LIHC cis rs11096990 0.613 rs6840578 ENSG00000249207.1 RP11-360F5.1 -4.24 2.84e-05 0.00647 -0.23 -0.22 Cognitive function; chr4:39206996 chr4:39112677~39126818:- LIHC cis rs734999 0.588 rs4648653 ENSG00000225931.3 RP3-395M20.7 4.24 2.84e-05 0.00647 0.24 0.22 Ulcerative colitis; chr1:2604456 chr1:2566410~2569888:+ LIHC cis rs17270561 0.723 rs12213243 ENSG00000216436.2 HIST1H2APS1 -4.24 2.84e-05 0.00648 -0.35 -0.22 Iron status biomarkers; chr6:25889880 chr6:25732497~25732827:+ LIHC cis rs6061231 0.544 rs2427314 ENSG00000226332.2 RP11-157P1.4 4.24 2.84e-05 0.00648 0.25 0.22 Colorectal cancer; chr20:62398610 chr20:62305432~62306325:- LIHC cis rs752590 0.887 rs68090726 ENSG00000189223.12 PAX8-AS1 -4.24 2.84e-05 0.00648 -0.36 -0.22 Mucinous ovarian carcinoma; chr2:113205258 chr2:113211522~113276581:+ LIHC cis rs4913250 0.514 rs7133322 ENSG00000273824.1 RP11-81H14.1 -4.24 2.84e-05 0.00648 -0.28 -0.22 Amyotrophic lateral sclerosis (C9orf72 mutation interaction); chr12:67541047 chr12:68426331~68427737:- LIHC cis rs4578769 0.836 rs3844227 ENSG00000265943.1 RP11-739L10.1 4.24 2.84e-05 0.00648 0.28 0.22 Eosinophil percentage of white cells; chr18:22871067 chr18:22699481~22933764:- LIHC cis rs7044106 0.708 rs10984992 ENSG00000238181.2 AHCYP2 -4.24 2.85e-05 0.00649 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120711138 chr9:120720673~120721972:+ LIHC cis rs4356975 0.932 rs4400061 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69071281 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs4446390 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69071328 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs7434389 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69071698 chr4:69027831~69044578:+ LIHC cis rs4356975 0.896 rs58496756 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69072070 chr4:69027831~69044578:+ LIHC cis rs4356975 0.599 rs7660019 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69072135 chr4:69027831~69044578:+ LIHC cis rs4356975 0.574 rs7660021 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69072143 chr4:69027831~69044578:+ LIHC cis rs4356975 0.549 rs7687692 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69072154 chr4:69027831~69044578:+ LIHC cis rs4356975 0.899 rs7687725 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69072229 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs4516791 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69072402 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs4694605 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69072777 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs4694607 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69073025 chr4:69027831~69044578:+ LIHC cis rs4356975 0.899 rs4410590 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69073381 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs4611997 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69073429 chr4:69027831~69044578:+ LIHC cis rs4356975 0.899 rs4412058 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69073715 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs7436912 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69074077 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs72852416 ENSG00000250919.1 RP11-813N20.3 -4.24 2.85e-05 0.00649 -0.22 -0.22 Obesity-related traits; chr4:69075085 chr4:69027831~69044578:+ LIHC cis rs6430585 0.528 rs6711493 ENSG00000231890.6 DARS-AS1 -4.24 2.85e-05 0.00649 -0.3 -0.22 Corneal structure; chr2:135934983 chr2:135985176~136022593:+ LIHC cis rs1005277 0.505 rs13503 ENSG00000275858.1 RP11-291L22.8 -4.24 2.85e-05 0.0065 -0.24 -0.22 Extrinsic epigenetic age acceleration; chr10:37950915 chr10:38450738~38451069:- LIHC cis rs1005277 0.505 rs7069702 ENSG00000275858.1 RP11-291L22.8 -4.24 2.85e-05 0.0065 -0.24 -0.22 Extrinsic epigenetic age acceleration; chr10:37958431 chr10:38450738~38451069:- LIHC cis rs960902 0.713 rs6757678 ENSG00000213553.4 RPLP0P6 4.24 2.85e-05 0.0065 0.18 0.22 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37496467 chr2:38481851~38482804:+ LIHC cis rs10510102 0.872 rs7907815 ENSG00000226864.1 ATE1-AS1 4.24 2.85e-05 0.0065 0.38 0.22 Breast cancer; chr10:121965951 chr10:121928312~121951965:+ LIHC cis rs11098499 0.697 rs4560394 ENSG00000260091.1 RP11-33B1.4 -4.24 2.85e-05 0.0065 -0.16 -0.22 Corneal astigmatism; chr4:119392280 chr4:119409333~119410233:+ LIHC cis rs1405130 0.935 rs2386495 ENSG00000224287.2 MSL3P1 4.24 2.85e-05 0.0065 0.26 0.22 Coronary artery disease; chr2:234667576 chr2:233865437~233868444:- LIHC cis rs10129255 0.912 rs61997792 ENSG00000211970.3 IGHV4-61 -4.24 2.86e-05 0.0065 -0.18 -0.22 Kawasaki disease; chr14:106799304 chr14:106639119~106639657:- LIHC cis rs6504622 0.755 rs4074249 ENSG00000262879.4 RP11-156P1.3 -4.24 2.86e-05 0.00651 -0.23 -0.22 Orofacial clefts; chr17:47072043 chr17:46984045~47100323:- LIHC cis rs6430585 0.528 rs309165 ENSG00000231890.6 DARS-AS1 -4.24 2.86e-05 0.00651 -0.3 -0.22 Corneal structure; chr2:135909731 chr2:135985176~136022593:+ LIHC cis rs6430585 0.528 rs309158 ENSG00000231890.6 DARS-AS1 -4.24 2.86e-05 0.00651 -0.3 -0.22 Corneal structure; chr2:135922964 chr2:135985176~136022593:+ LIHC cis rs4578769 0.765 rs10432158 ENSG00000266850.1 RP11-370A5.1 -4.24 2.86e-05 0.00651 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22826406 chr18:22723491~22907721:- LIHC cis rs4578769 0.765 rs10432159 ENSG00000266850.1 RP11-370A5.1 -4.24 2.86e-05 0.00651 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22826596 chr18:22723491~22907721:- LIHC cis rs4578769 0.765 rs16972382 ENSG00000266850.1 RP11-370A5.1 -4.24 2.86e-05 0.00651 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22831403 chr18:22723491~22907721:- LIHC cis rs4926298 0.89 rs1017180 ENSG00000228887.3 EEF1DP1 4.24 2.86e-05 0.00652 0.2 0.22 Bipolar disorder; chr19:13083958 chr19:14070342~14071237:+ LIHC cis rs3733589 1 rs12646380 ENSG00000250413.1 RP11-448G15.1 4.24 2.86e-05 0.00652 0.4 0.22 Renal overload gout; chr4:9989878 chr4:10006482~10009725:+ LIHC cis rs6445975 0.572 rs4320076 ENSG00000272360.1 RP11-359I18.5 4.24 2.87e-05 0.00653 0.3 0.22 Systemic lupus erythematosus; chr3:58419557 chr3:58490830~58491291:- LIHC cis rs2790457 0.518 rs2993984 ENSG00000254635.4 WAC-AS1 -4.24 2.87e-05 0.00653 -0.21 -0.22 Multiple myeloma; chr10:28509727 chr10:28522652~28532743:- LIHC cis rs11096990 0.634 rs12648082 ENSG00000249685.1 RP11-360F5.3 -4.24 2.87e-05 0.00653 -0.27 -0.22 Cognitive function; chr4:39278104 chr4:39133913~39135608:+ LIHC cis rs524281 1 rs547087 ENSG00000255320.1 RP11-755F10.1 -4.24 2.87e-05 0.00653 -0.26 -0.22 Electroencephalogram traits; chr11:66078793 chr11:66244840~66246239:- LIHC cis rs755249 0.567 rs41270807 ENSG00000182109.6 RP11-69E11.4 4.24 2.87e-05 0.00653 0.29 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39336143 chr1:39522280~39546187:- LIHC cis rs755249 0.53 rs16826087 ENSG00000182109.6 RP11-69E11.4 4.24 2.87e-05 0.00653 0.29 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39346846 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs3754346 ENSG00000182109.6 RP11-69E11.4 4.24 2.87e-05 0.00653 0.29 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39349288 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs16826093 ENSG00000182109.6 RP11-69E11.4 4.24 2.87e-05 0.00653 0.29 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39349471 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs41270811 ENSG00000182109.6 RP11-69E11.4 4.24 2.87e-05 0.00653 0.29 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39349672 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs61779274 ENSG00000182109.6 RP11-69E11.4 4.24 2.87e-05 0.00653 0.29 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39351269 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs17264671 ENSG00000182109.6 RP11-69E11.4 4.24 2.87e-05 0.00653 0.29 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39352380 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs4660690 ENSG00000182109.6 RP11-69E11.4 4.24 2.87e-05 0.00653 0.29 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39353831 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs61779275 ENSG00000182109.6 RP11-69E11.4 4.24 2.87e-05 0.00653 0.29 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39354638 chr1:39522280~39546187:- LIHC cis rs4650994 0.816 rs2761470 ENSG00000213057.5 C1orf220 -4.24 2.87e-05 0.00653 -0.19 -0.22 HDL cholesterol;HDL cholesterol levels; chr1:178626898 chr1:178542752~178548889:+ LIHC cis rs7182621 0.546 rs12906587 ENSG00000182397.13 DNM1P46 -4.24 2.87e-05 0.00654 -0.29 -0.22 Colonoscopy-negative controls vs population controls; chr15:99837114 chr15:99790156~99806927:- LIHC cis rs6430585 0.591 rs309118 ENSG00000231890.6 DARS-AS1 -4.24 2.87e-05 0.00654 -0.3 -0.22 Corneal structure; chr2:135988654 chr2:135985176~136022593:+ LIHC cis rs1005277 0.602 rs1831315 ENSG00000275858.1 RP11-291L22.8 4.24 2.88e-05 0.00655 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:38184425 chr10:38450738~38451069:- LIHC cis rs901683 1 rs9422440 ENSG00000230869.1 CTGLF10P -4.24 2.88e-05 0.00655 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45549677 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs78363416 ENSG00000230869.1 CTGLF10P -4.24 2.88e-05 0.00655 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45550686 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34138033 ENSG00000230869.1 CTGLF10P -4.24 2.88e-05 0.00655 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45551064 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35036712 ENSG00000230869.1 CTGLF10P -4.24 2.88e-05 0.00655 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45551262 chr10:45678692~45700532:+ LIHC cis rs7937890 0.599 rs2597204 ENSG00000251991.1 RNU7-49P 4.24 2.88e-05 0.00655 0.25 0.22 Mitochondrial DNA levels; chr11:14459471 chr11:14478892~14478953:+ LIHC cis rs7474896 0.583 rs11011341 ENSG00000263064.2 RP11-291L22.7 4.24 2.88e-05 0.00655 0.27 0.22 Obesity (extreme); chr10:37709572 chr10:38448689~38448949:+ LIHC cis rs7474896 0.609 rs1830612 ENSG00000263064.2 RP11-291L22.7 4.24 2.88e-05 0.00655 0.27 0.22 Obesity (extreme); chr10:37710955 chr10:38448689~38448949:+ LIHC cis rs3845817 0.868 rs702942 ENSG00000281920.1 RP11-418H16.1 -4.24 2.88e-05 0.00655 -0.27 -0.22 Bipolar disorder; chr2:65529831 chr2:65623272~65628424:+ LIHC cis rs3845817 0.832 rs702945 ENSG00000281920.1 RP11-418H16.1 -4.24 2.88e-05 0.00655 -0.27 -0.22 Bipolar disorder; chr2:65534098 chr2:65623272~65628424:+ LIHC cis rs3845817 0.868 rs702896 ENSG00000281920.1 RP11-418H16.1 -4.24 2.88e-05 0.00655 -0.27 -0.22 Bipolar disorder; chr2:65535089 chr2:65623272~65628424:+ LIHC cis rs6142102 0.602 rs10485503 ENSG00000275784.1 RP5-1125A11.6 -4.24 2.88e-05 0.00655 -0.24 -0.22 Skin pigmentation; chr20:33970036 chr20:33989480~33991818:- LIHC cis rs901683 1 rs71496610 ENSG00000230869.1 CTGLF10P -4.24 2.88e-05 0.00655 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45526198 chr10:45678692~45700532:+ LIHC cis rs10129255 0.719 rs7156660 ENSG00000223648.3 IGHV3-64 4.24 2.88e-05 0.00655 0.16 0.22 Kawasaki disease; chr14:106673171 chr14:106643132~106658258:- LIHC cis rs6445975 0.666 rs4681844 ENSG00000272360.1 RP11-359I18.5 -4.24 2.88e-05 0.00655 -0.31 -0.22 Systemic lupus erythematosus; chr3:58346719 chr3:58490830~58491291:- LIHC cis rs6480314 0.831 rs6480316 ENSG00000233590.1 RP11-153K11.3 4.24 2.88e-05 0.00656 0.33 0.22 Optic nerve measurement (disc area); chr10:68212943 chr10:68233251~68242379:- LIHC cis rs6480314 0.831 rs7071208 ENSG00000233590.1 RP11-153K11.3 4.24 2.88e-05 0.00656 0.33 0.22 Optic nerve measurement (disc area); chr10:68213350 chr10:68233251~68242379:- LIHC cis rs9450351 0.744 rs9450294 ENSG00000203875.9 SNHG5 -4.24 2.88e-05 0.00656 -0.44 -0.22 Interferon gamma-induced protein 10 levels; chr6:85540712 chr6:85660950~85678736:- LIHC cis rs11098499 0.644 rs10012252 ENSG00000260091.1 RP11-33B1.4 -4.24 2.88e-05 0.00656 -0.16 -0.22 Corneal astigmatism; chr4:119637984 chr4:119409333~119410233:+ LIHC cis rs17214007 0.877 rs11644832 ENSG00000263335.1 AF001548.5 -4.24 2.89e-05 0.00657 -0.29 -0.22 Cognitive function; chr16:15778891 chr16:15726674~15732993:+ LIHC cis rs17214007 0.877 rs11645883 ENSG00000263335.1 AF001548.5 -4.24 2.89e-05 0.00657 -0.29 -0.22 Cognitive function; chr16:15778950 chr16:15726674~15732993:+ LIHC cis rs651907 0.535 rs4342086 ENSG00000244119.1 PDCL3P4 4.24 2.89e-05 0.00657 0.23 0.22 Colorectal cancer; chr3:101784921 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs34648996 ENSG00000244119.1 PDCL3P4 4.24 2.89e-05 0.00657 0.23 0.22 Colorectal cancer; chr3:101792358 chr3:101712472~101713191:+ LIHC cis rs2032447 0.869 rs2230655 ENSG00000242387.1 HIST1H2APS2 -4.24 2.89e-05 0.00657 -0.29 -0.22 Intelligence (multi-trait analysis); chr6:26033278 chr6:25882026~25882395:- LIHC cis rs9807989 0.507 rs3732124 ENSG00000234389.1 AC007278.3 -4.24 2.89e-05 0.00658 -0.25 -0.22 Asthma; chr2:102401592 chr2:102438713~102440475:+ LIHC cis rs7044106 0.762 rs12003646 ENSG00000238181.2 AHCYP2 -4.24 2.89e-05 0.00658 -0.26 -0.22 Hip circumference adjusted for BMI; chr9:120708343 chr9:120720673~120721972:+ LIHC cis rs9322193 0.607 rs6557165 ENSG00000216906.2 RP11-350J20.9 -4.24 2.89e-05 0.00658 -0.23 -0.22 Lung cancer; chr6:149906883 chr6:149904243~149906418:+ LIHC cis rs11098499 0.661 rs10015965 ENSG00000260091.1 RP11-33B1.4 -4.24 2.89e-05 0.00658 -0.15 -0.22 Corneal astigmatism; chr4:119347082 chr4:119409333~119410233:+ LIHC cis rs4713118 0.513 rs149962 ENSG00000216901.1 AL022393.7 4.24 2.89e-05 0.00658 0.29 0.22 Parkinson's disease; chr6:28048140 chr6:28176188~28176674:+ LIHC cis rs4713118 0.513 rs9368547 ENSG00000216901.1 AL022393.7 4.24 2.89e-05 0.00658 0.29 0.22 Parkinson's disease; chr6:28060289 chr6:28176188~28176674:+ LIHC cis rs4713118 0.513 rs183244 ENSG00000216901.1 AL022393.7 4.24 2.89e-05 0.00658 0.29 0.22 Parkinson's disease; chr6:28064060 chr6:28176188~28176674:+ LIHC cis rs4713118 0.513 rs149950 ENSG00000216901.1 AL022393.7 4.24 2.89e-05 0.00658 0.29 0.22 Parkinson's disease; chr6:28065261 chr6:28176188~28176674:+ LIHC cis rs4713118 0.513 rs149951 ENSG00000216901.1 AL022393.7 4.24 2.89e-05 0.00658 0.29 0.22 Parkinson's disease; chr6:28065309 chr6:28176188~28176674:+ LIHC cis rs2120243 0.504 rs114107407 ENSG00000244515.1 KRT18P34 -4.24 2.9e-05 0.00658 -0.21 -0.22 Hepatocellular carcinoma in hepatitis B infection; chr3:157344846 chr3:157162663~157163932:- LIHC cis rs4713118 0.513 rs1225591 ENSG00000216901.1 AL022393.7 4.24 2.9e-05 0.00658 0.29 0.22 Parkinson's disease; chr6:28180974 chr6:28176188~28176674:+ LIHC cis rs7208859 0.673 rs56846352 ENSG00000266490.1 CTD-2349P21.9 4.24 2.9e-05 0.00658 0.27 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792170 chr17:30792372~30792833:+ LIHC cis rs10829156 0.796 rs6482567 ENSG00000240291.1 RP11-499P20.2 4.24 2.9e-05 0.00659 0.35 0.22 Sudden cardiac arrest; chr10:18625860 chr10:18513115~18545651:- LIHC cis rs960902 0.747 rs62135566 ENSG00000213553.4 RPLP0P6 4.24 2.9e-05 0.00659 0.18 0.22 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37491787 chr2:38481851~38482804:+ LIHC cis rs2243480 1 rs34136756 ENSG00000228409.4 CCT6P1 4.24 2.9e-05 0.00659 0.24 0.22 Diabetic kidney disease; chr7:65916269 chr7:65751142~65763354:+ LIHC cis rs4073416 0.691 rs10483785 ENSG00000276116.2 FUT8-AS1 4.24 2.9e-05 0.00659 0.27 0.22 N-glycan levels; chr14:65752799 chr14:65411170~65412690:- LIHC cis rs2739330 0.892 rs4822455 ENSG00000206090.4 AP000350.7 4.24 2.9e-05 0.00659 0.26 0.22 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23939998~23942798:+ LIHC cis rs2838568 0.967 rs2838569 ENSG00000277352.1 KB-68A7.2 -4.24 2.9e-05 0.00659 -0.26 -0.22 Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals; chr21:44478340 chr21:44494874~44495519:+ LIHC cis rs13113518 0.729 rs13120134 ENSG00000249700.7 SRD5A3-AS1 4.24 2.9e-05 0.00659 0.27 0.22 Height; chr4:55415153 chr4:55363971~55395847:- LIHC cis rs4561483 0.799 rs33635 ENSG00000261560.1 RP11-166B2.3 -4.24 2.9e-05 0.00659 -0.24 -0.22 Testicular germ cell tumor; chr16:11898087 chr16:11881075~11882569:- LIHC cis rs73186030 0.92 rs73186048 ENSG00000272758.4 RP11-299J3.8 4.24 2.9e-05 0.00659 0.43 0.22 Serum parathyroid hormone levels; chr3:122316515 chr3:122416207~122443180:+ LIHC cis rs1023500 1 rs1023499 ENSG00000237037.8 NDUFA6-AS1 -4.24 2.9e-05 0.00659 -0.31 -0.22 Schizophrenia; chr22:41944578 chr22:42090931~42137742:+ LIHC cis rs950880 0.71 rs17027179 ENSG00000234389.1 AC007278.3 -4.24 2.9e-05 0.0066 -0.22 -0.22 Serum protein levels (sST2); chr2:102440699 chr2:102438713~102440475:+ LIHC cis rs597539 0.689 rs596874 ENSG00000250508.1 RP11-757G1.6 4.24 2.9e-05 0.0066 0.32 0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68863406 chr11:68870664~68874542:+ LIHC cis rs11096990 0.613 rs35391082 ENSG00000249207.1 RP11-360F5.1 -4.24 2.91e-05 0.00661 -0.23 -0.22 Cognitive function; chr4:39191033 chr4:39112677~39126818:- LIHC cis rs11096990 0.613 rs4974990 ENSG00000249207.1 RP11-360F5.1 -4.24 2.91e-05 0.00661 -0.23 -0.22 Cognitive function; chr4:39191645 chr4:39112677~39126818:- LIHC cis rs875971 0.577 rs35072105 ENSG00000273024.4 INTS4P2 4.24 2.91e-05 0.00661 0.26 0.22 Aortic root size; chr7:66144830 chr7:65647864~65715661:+ LIHC cis rs763121 0.853 rs5757253 ENSG00000273076.1 RP3-508I15.22 4.24 2.91e-05 0.00661 0.25 0.22 Menopause (age at onset); chr22:38708315 chr22:38743495~38743910:+ LIHC cis rs950169 0.541 rs10795 ENSG00000225151.9 GOLGA2P7 -4.24 2.91e-05 0.00661 -0.28 -0.22 Schizophrenia; chr15:84634066 chr15:84199311~84230136:- LIHC cis rs950169 0.58 rs36126054 ENSG00000225151.9 GOLGA2P7 -4.24 2.91e-05 0.00661 -0.28 -0.22 Schizophrenia; chr15:84634492 chr15:84199311~84230136:- LIHC cis rs11098499 0.535 rs7671759 ENSG00000260091.1 RP11-33B1.4 -4.24 2.91e-05 0.00662 -0.16 -0.22 Corneal astigmatism; chr4:119326939 chr4:119409333~119410233:+ LIHC cis rs4578769 0.959 rs3863525 ENSG00000265943.1 RP11-739L10.1 4.24 2.91e-05 0.00662 0.28 0.22 Eosinophil percentage of white cells; chr18:22898714 chr18:22699481~22933764:- LIHC cis rs3758785 0.565 rs598645 ENSG00000255893.1 RP11-685N10.1 4.24 2.91e-05 0.00662 0.23 0.22 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94338579 chr11:94472908~94473570:- LIHC cis rs9907295 0.818 rs4796115 ENSG00000270871.1 AC015849.19 4.24 2.92e-05 0.00662 0.24 0.22 Fibroblast growth factor basic levels; chr17:35841315 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs78905197 ENSG00000270871.1 AC015849.19 4.24 2.92e-05 0.00662 0.24 0.22 Fibroblast growth factor basic levels; chr17:35850189 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs3760326 ENSG00000270871.1 AC015849.19 4.24 2.92e-05 0.00662 0.24 0.22 Fibroblast growth factor basic levels; chr17:35853493 chr17:35816717~35830293:- LIHC cis rs2310173 0.575 rs13022757 ENSG00000281162.1 LINC01127 -4.24 2.92e-05 0.00662 -0.24 -0.22 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:101997084 chr2:101962056~101987167:+ LIHC cis rs960902 0.747 rs2216117 ENSG00000213553.4 RPLP0P6 4.24 2.92e-05 0.00663 0.18 0.22 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37496025 chr2:38481851~38482804:+ LIHC cis rs6504622 0.755 rs12938690 ENSG00000262879.4 RP11-156P1.3 -4.24 2.92e-05 0.00663 -0.24 -0.22 Orofacial clefts; chr17:46997999 chr17:46984045~47100323:- LIHC cis rs10129255 1 rs10134517 ENSG00000224373.3 IGHV4-59 4.24 2.92e-05 0.00663 0.18 0.22 Kawasaki disease; chr14:106718498 chr14:106627249~106627825:- LIHC cis rs172166 0.694 rs1225716 ENSG00000216901.1 AL022393.7 4.24 2.92e-05 0.00663 0.29 0.22 Cardiac Troponin-T levels; chr6:28145968 chr6:28176188~28176674:+ LIHC cis rs4713118 0.512 rs2622319 ENSG00000216901.1 AL022393.7 4.24 2.92e-05 0.00663 0.29 0.22 Parkinson's disease; chr6:28152623 chr6:28176188~28176674:+ LIHC cis rs172166 0.694 rs1150666 ENSG00000216901.1 AL022393.7 4.24 2.92e-05 0.00663 0.29 0.22 Cardiac Troponin-T levels; chr6:28156150 chr6:28176188~28176674:+ LIHC cis rs7580658 0.521 rs2404535 ENSG00000236682.1 AC068282.3 4.24 2.92e-05 0.00663 0.28 0.22 Protein C levels; chr2:127190133 chr2:127389130~127400580:+ LIHC cis rs524281 1 rs475805 ENSG00000255320.1 RP11-755F10.1 -4.24 2.92e-05 0.00663 -0.26 -0.22 Electroencephalogram traits; chr11:66081267 chr11:66244840~66246239:- LIHC cis rs77204473 1 rs77204473 ENSG00000254851.1 RP11-109L13.1 4.24 2.92e-05 0.00663 0.52 0.22 Sum eosinophil basophil counts;Eosinophil counts; chr11:116934348 chr11:117135528~117138582:+ LIHC cis rs2253762 0.54 rs10887036 ENSG00000276742.1 RP11-500G22.4 4.24 2.92e-05 0.00663 0.36 0.22 Breast cancer; chr10:121997570 chr10:121956782~121957098:+ LIHC cis rs494453 0.922 rs2477428 ENSG00000227811.2 FAM212B-AS1 -4.24 2.92e-05 0.00663 -0.25 -0.22 Osteoporosis-related phenotypes; chr1:111671634 chr1:111739841~111747798:+ LIHC cis rs9527 0.59 rs10509766 ENSG00000236937.2 PTGES3P4 4.24 2.92e-05 0.00663 0.28 0.22 Arsenic metabolism; chr10:103166577 chr10:102845595~102845950:+ LIHC cis rs9527 0.64 rs35195396 ENSG00000236937.2 PTGES3P4 4.24 2.92e-05 0.00663 0.28 0.22 Arsenic metabolism; chr10:103169013 chr10:102845595~102845950:+ LIHC cis rs9527 0.614 rs11191589 ENSG00000236937.2 PTGES3P4 4.24 2.92e-05 0.00663 0.28 0.22 Arsenic metabolism; chr10:103170625 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs3740386 ENSG00000236937.2 PTGES3P4 4.24 2.92e-05 0.00663 0.28 0.22 Arsenic metabolism; chr10:103171294 chr10:102845595~102845950:+ LIHC cis rs1005277 0.579 rs1780130 ENSG00000275858.1 RP11-291L22.8 4.24 2.92e-05 0.00664 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:38196450 chr10:38450738~38451069:- LIHC cis rs2060793 0.552 rs939968 ENSG00000251991.1 RNU7-49P 4.24 2.92e-05 0.00664 0.25 0.22 Vitamin D levels; chr11:14608134 chr11:14478892~14478953:+ LIHC cis rs228614 0.51 rs150893 ENSG00000246560.2 RP11-10L12.4 -4.24 2.93e-05 0.00665 -0.25 -0.22 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102817075 chr4:102828055~102844075:+ LIHC cis rs228614 0.51 rs223452 ENSG00000246560.2 RP11-10L12.4 4.24 2.93e-05 0.00665 0.26 0.22 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102790277 chr4:102828055~102844075:+ LIHC cis rs10129255 0.5 rs4774189 ENSG00000211972.2 IGHV3-66 4.24 2.93e-05 0.00666 0.16 0.22 Kawasaki disease; chr14:106768275 chr14:106675017~106675544:- LIHC cis rs733592 0.507 rs10875739 ENSG00000240399.1 RP1-228P16.1 4.24 2.93e-05 0.00666 0.22 0.22 Plateletcrit; chr12:48087136 chr12:48054813~48055591:- LIHC cis rs2348418 0.831 rs7296538 ENSG00000247934.4 RP11-967K21.1 -4.24 2.93e-05 0.00666 -0.21 -0.22 Lung function (FEV1);Lung function (FVC); chr12:28558850 chr12:28163298~28190738:- LIHC cis rs8005677 0.828 rs2295682 ENSG00000279656.1 RP11-298I3.6 4.24 2.94e-05 0.00666 0.25 0.22 Cognitive ability (multi-trait analysis); chr14:22905653 chr14:23023083~23024217:- LIHC cis rs11690935 0.655 rs1028127 ENSG00000228389.1 AC068039.4 -4.24 2.94e-05 0.00666 -0.27 -0.22 Schizophrenia; chr2:171673526 chr2:171773482~171775844:+ LIHC cis rs10028773 0.6 rs4001390 ENSG00000260091.1 RP11-33B1.4 -4.24 2.94e-05 0.00667 -0.15 -0.22 Educational attainment; chr4:119344628 chr4:119409333~119410233:+ LIHC cis rs11098499 0.691 rs2136911 ENSG00000260091.1 RP11-33B1.4 -4.24 2.94e-05 0.00667 -0.15 -0.22 Corneal astigmatism; chr4:119344704 chr4:119409333~119410233:+ LIHC cis rs10028773 0.568 rs6838457 ENSG00000260091.1 RP11-33B1.4 -4.24 2.94e-05 0.00667 -0.15 -0.22 Educational attainment; chr4:119346212 chr4:119409333~119410233:+ LIHC cis rs11098499 0.535 rs10005542 ENSG00000260091.1 RP11-33B1.4 -4.24 2.94e-05 0.00667 -0.15 -0.22 Corneal astigmatism; chr4:119347147 chr4:119409333~119410233:+ LIHC cis rs17270561 0.562 rs74293932 ENSG00000216436.2 HIST1H2APS1 -4.24 2.94e-05 0.00667 -0.34 -0.22 Iron status biomarkers; chr6:26014583 chr6:25732497~25732827:+ LIHC cis rs2243480 1 rs78803505 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65917585 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs34933526 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65918212 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs34577383 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65920739 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs6949812 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65922114 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs6970243 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65923503 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs7794661 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65924743 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs7795242 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65925107 chr7:65751142~65763354:+ LIHC cis rs2243480 0.708 rs35310401 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65925372 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs35058610 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65925938 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs2177703 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65926730 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs35432774 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65928032 chr7:65751142~65763354:+ LIHC cis rs2243480 0.831 rs7806717 ENSG00000228409.4 CCT6P1 -4.24 2.94e-05 0.00667 -0.24 -0.22 Diabetic kidney disease; chr7:65928187 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs56985706 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65929575 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs60683927 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65929781 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs58062456 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65929865 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs34529418 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65938222 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs35087093 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65940221 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs35046236 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65943626 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs36068983 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65944004 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs68189316 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65944182 chr7:65751142~65763354:+ LIHC cis rs2243480 0.803 rs34804747 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65947955 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs11538349 ENSG00000228409.4 CCT6P1 4.24 2.94e-05 0.00667 0.24 0.22 Diabetic kidney disease; chr7:65956884 chr7:65751142~65763354:+ LIHC cis rs7121538 0.756 rs1966615 ENSG00000251991.1 RNU7-49P -4.24 2.94e-05 0.00667 -0.32 -0.22 HDL cholesterol; chr11:14403354 chr11:14478892~14478953:+ LIHC cis rs875971 0.545 rs6979636 ENSG00000273024.4 INTS4P2 -4.24 2.94e-05 0.00667 -0.25 -0.22 Aortic root size; chr7:66276638 chr7:65647864~65715661:+ LIHC cis rs55966801 0.68 rs17655730 ENSG00000279672.1 CMB9-55F22.1 4.24 2.94e-05 0.00667 0.35 0.22 Plateletcrit; chr11:270715 chr11:779617~780755:+ LIHC cis rs2243480 1 rs73142166 ENSG00000232546.1 RP11-458F8.1 -4.24 2.94e-05 0.00667 -0.26 -0.22 Diabetic kidney disease; chr7:65910845 chr7:66848496~66858136:+ LIHC cis rs7429990 0.864 rs4274776 ENSG00000229759.1 MRPS18AP1 4.24 2.94e-05 0.00667 0.24 0.22 Educational attainment (years of education); chr3:47605868 chr3:48256350~48256938:- LIHC cis rs748404 0.631 rs6493083 ENSG00000166763.7 STRCP1 4.23 2.94e-05 0.00667 0.27 0.22 Lung cancer; chr15:43345787 chr15:43699488~43718184:- LIHC cis rs11064837 0.523 rs1978107 ENSG00000248636.5 RP11-768F21.1 4.23 2.94e-05 0.00667 0.38 0.22 Schizophrenia; chr12:119663909 chr12:119387987~119668079:- LIHC cis rs2072510 0.569 rs7134860 ENSG00000257878.1 RP11-256L6.3 -4.23 2.94e-05 0.00668 -0.29 -0.22 Metabolite levels (small molecules and protein measures); chr12:95996580 chr12:95996521~96011489:+ LIHC cis rs2072510 0.569 rs7134975 ENSG00000257878.1 RP11-256L6.3 -4.23 2.94e-05 0.00668 -0.29 -0.22 Metabolite levels (small molecules and protein measures); chr12:95996642 chr12:95996521~96011489:+ LIHC cis rs2072510 0.569 rs7306086 ENSG00000257878.1 RP11-256L6.3 -4.23 2.94e-05 0.00668 -0.29 -0.22 Metabolite levels (small molecules and protein measures); chr12:95996724 chr12:95996521~96011489:+ LIHC cis rs3204270 0.639 rs62080199 ENSG00000281517.1 Metazoa_SRP -4.23 2.95e-05 0.00668 -0.43 -0.22 Dental caries; chr17:81660876 chr17:81718849~81719095:- LIHC cis rs338389 0.542 rs7182139 ENSG00000260657.2 RP11-315D16.4 -4.23 2.95e-05 0.00668 -0.36 -0.22 Survival in rectal cancer; chr15:67993116 chr15:68267792~68277994:- LIHC cis rs3204270 0.714 rs7189 ENSG00000281517.1 Metazoa_SRP -4.23 2.95e-05 0.00668 -0.42 -0.22 Dental caries; chr17:81701867 chr17:81718849~81719095:- LIHC cis rs651907 0.557 rs34376498 ENSG00000244119.1 PDCL3P4 4.23 2.95e-05 0.00669 0.23 0.22 Colorectal cancer; chr3:101761312 chr3:101712472~101713191:+ LIHC cis rs6471393 0.861 rs2976374 ENSG00000253848.1 RP11-10N23.5 4.23 2.95e-05 0.0067 0.24 0.22 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93691945 chr8:93741193~93744534:+ LIHC cis rs812925 0.784 rs1177304 ENSG00000212978.6 AC016747.3 -4.23 2.96e-05 0.0067 -0.25 -0.22 Immature fraction of reticulocytes; chr2:61161029 chr2:61141592~61144969:- LIHC cis rs6822297 0.504 rs9291487 ENSG00000240005.4 RP11-293A21.1 4.23 2.96e-05 0.0067 0.26 0.22 Obesity-related traits; chr4:26965862 chr4:26859806~26860599:- LIHC cis rs901683 1 rs71494793 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45489644 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs71494794 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45489836 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs71515355 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45489908 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34415465 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45490132 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12768131 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45491000 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12763205 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45491047 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35187216 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45491172 chr10:45678692~45700532:+ LIHC cis rs901683 0.681 rs71494795 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45492297 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs34019727 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45492303 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs75712637 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45492744 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs78220003 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45492900 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35303148 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45493806 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12764652 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45496530 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12778980 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45498763 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34081402 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45498979 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs35081812 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45500341 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71494797 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45502010 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35326978 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45502264 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34879733 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45502313 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35918870 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45502830 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71494798 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45503532 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35394192 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45505313 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12764485 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45507139 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71494800 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45507506 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12773463 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45508183 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35172875 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45508712 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71494802 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45510176 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71496603 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45510201 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35294227 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45511350 chr10:45678692~45700532:+ LIHC cis rs35993099 1 rs35993099 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular hemoglobin;Red blood cell count; chr10:45511519 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71496605 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45514370 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71496606 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45514650 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs71496607 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45514868 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35504302 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45515057 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12772485 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45515973 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs115391636 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45516597 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12781186 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45517990 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12779198 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45518099 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12762495 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45518167 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs17157880 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45519040 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35131026 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45519311 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs17157884 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45520494 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71496608 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45521684 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs78913745 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45524463 chr10:45678692~45700532:+ LIHC cis rs901683 0.867 rs17157885 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45524646 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs17157887 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45524900 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71496609 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45525583 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs36070535 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45526790 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12764693 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45527879 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35902429 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45528887 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34897497 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45529229 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs76805415 ENSG00000230869.1 CTGLF10P -4.23 2.96e-05 0.0067 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45530715 chr10:45678692~45700532:+ LIHC cis rs7208859 0.673 rs216410 ENSG00000266490.1 CTD-2349P21.9 -4.23 2.96e-05 0.0067 -0.27 -0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576813 chr17:30792372~30792833:+ LIHC cis rs6504622 0.677 rs12949446 ENSG00000262879.4 RP11-156P1.3 -4.23 2.96e-05 0.0067 -0.24 -0.22 Orofacial clefts; chr17:46994311 chr17:46984045~47100323:- LIHC cis rs6504622 0.693 rs12952596 ENSG00000262879.4 RP11-156P1.3 -4.23 2.96e-05 0.0067 -0.24 -0.22 Orofacial clefts; chr17:46994319 chr17:46984045~47100323:- LIHC cis rs6480314 0.831 rs7904069 ENSG00000233590.1 RP11-153K11.3 -4.23 2.96e-05 0.0067 -0.32 -0.22 Optic nerve measurement (disc area); chr10:68220436 chr10:68233251~68242379:- LIHC cis rs11079159 0.917 rs12452367 ENSG00000263096.1 RP11-515O17.2 4.23 2.96e-05 0.00671 0.3 0.22 QRS duration; chr17:55297249 chr17:55271504~55273653:- LIHC cis rs1577917 1 rs955196 ENSG00000234155.1 RP11-30P6.6 -4.23 2.96e-05 0.00671 -0.29 -0.22 Response to antipsychotic treatment; chr6:86020233 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs11755864 ENSG00000234155.1 RP11-30P6.6 4.23 2.97e-05 0.00671 0.28 0.22 Response to antipsychotic treatment; chr6:85982073 chr6:85387219~85390186:- LIHC cis rs638893 0.947 rs1170396 ENSG00000255239.1 AP002954.6 4.23 2.97e-05 0.00672 0.38 0.22 Vitiligo; chr11:118833108 chr11:118688039~118690600:- LIHC cis rs9652601 0.959 rs12925642 ENSG00000274038.1 RP11-66H6.4 -4.23 2.97e-05 0.00672 -0.27 -0.22 Systemic lupus erythematosus; chr16:11077745 chr16:11056556~11057034:+ LIHC cis rs6480314 0.764 rs2394462 ENSG00000233590.1 RP11-153K11.3 4.23 2.97e-05 0.00672 0.31 0.22 Optic nerve measurement (disc area); chr10:68221986 chr10:68233251~68242379:- LIHC cis rs651907 0.535 rs1460097 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101778725 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs17412601 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101780431 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs11717638 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101786624 chr3:101712472~101713191:+ LIHC cis rs651907 0.514 rs11706494 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101790631 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs34063583 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101791104 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs34161138 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101791544 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs11714444 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101794838 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs12631513 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101798632 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs13094911 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101800177 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs11712309 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101800253 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs35799195 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101803083 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs13094753 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101806238 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs11716558 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101809637 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs12633089 ENSG00000244119.1 PDCL3P4 4.23 2.97e-05 0.00672 0.23 0.22 Colorectal cancer; chr3:101809919 chr3:101712472~101713191:+ LIHC cis rs812925 0.537 rs10208769 ENSG00000271889.1 RP11-493E12.1 -4.23 2.97e-05 0.00673 -0.27 -0.22 Immature fraction of reticulocytes; chr2:61378479 chr2:61151433~61162105:- LIHC cis rs4578769 0.879 rs7244549 ENSG00000265943.1 RP11-739L10.1 4.23 2.98e-05 0.00673 0.28 0.22 Eosinophil percentage of white cells; chr18:22866052 chr18:22699481~22933764:- LIHC cis rs2274273 0.967 rs10147667 ENSG00000258413.1 RP11-665C16.6 4.23 2.98e-05 0.00674 0.26 0.22 Protein biomarker; chr14:55104131 chr14:55262767~55272075:- LIHC cis rs193541 0.617 rs2045628 ENSG00000263432.2 RN7SL689P 4.23 2.98e-05 0.00674 0.36 0.22 Glucose homeostasis traits; chr5:122759459 chr5:123022487~123022783:- LIHC cis rs950880 0.677 rs4851585 ENSG00000234389.1 AC007278.3 -4.23 2.98e-05 0.00674 -0.22 -0.22 Serum protein levels (sST2); chr2:102446294 chr2:102438713~102440475:+ LIHC cis rs8005677 0.77 rs56180741 ENSG00000279656.1 RP11-298I3.6 4.23 2.98e-05 0.00674 0.25 0.22 Cognitive ability (multi-trait analysis); chr14:22908037 chr14:23023083~23024217:- LIHC cis rs8005677 0.828 rs3794452 ENSG00000279656.1 RP11-298I3.6 4.23 2.98e-05 0.00674 0.25 0.22 Cognitive ability (multi-trait analysis); chr14:22917473 chr14:23023083~23024217:- LIHC cis rs8005677 0.828 rs4981450 ENSG00000279656.1 RP11-298I3.6 4.23 2.98e-05 0.00674 0.25 0.22 Cognitive ability (multi-trait analysis); chr14:22920095 chr14:23023083~23024217:- LIHC cis rs2540513 0.643 rs34573 ENSG00000241556.1 RP11-490G8.1 -4.23 2.98e-05 0.00674 -0.24 -0.22 Small intestine neuroendocrine tumor; chr12:96129926 chr12:95467397~95467861:- LIHC cis rs673078 0.66 rs17619932 ENSG00000275759.1 RP11-131L12.3 -4.23 2.98e-05 0.00675 -0.28 -0.22 Glucose homeostasis traits; chr12:118352228 chr12:118428281~118428870:+ LIHC cis rs2243480 0.901 rs73142137 ENSG00000232546.1 RP11-458F8.1 -4.23 2.98e-05 0.00675 -0.26 -0.22 Diabetic kidney disease; chr7:65878455 chr7:66848496~66858136:+ LIHC cis rs3204270 0.639 rs11871678 ENSG00000281517.1 Metazoa_SRP -4.23 2.98e-05 0.00675 -0.41 -0.22 Dental caries; chr17:81687255 chr17:81718849~81719095:- LIHC cis rs11096990 0.855 rs6855008 ENSG00000249207.1 RP11-360F5.1 4.23 2.98e-05 0.00675 0.26 0.22 Cognitive function; chr4:39172006 chr4:39112677~39126818:- LIHC cis rs11690935 0.632 rs11690807 ENSG00000228389.1 AC068039.4 -4.23 2.98e-05 0.00675 -0.26 -0.22 Schizophrenia; chr2:171771610 chr2:171773482~171775844:+ LIHC cis rs2598107 0.601 rs13240429 ENSG00000211698.2 TRGV4 -4.23 2.99e-05 0.00675 -0.26 -0.22 Dupuytren's disease; chr7:37921233 chr7:38353715~38354517:- LIHC cis rs6439153 0.933 rs900381 ENSG00000231305.3 RP11-723O4.2 4.23 2.99e-05 0.00675 0.25 0.22 Pneumococcal bacteremia; chr3:128994612 chr3:128861313~128871540:- LIHC cis rs11733284 0.63 rs2048157 ENSG00000259959.1 RP11-121C2.2 -4.23 2.99e-05 0.00676 -0.21 -0.22 Gout;Renal underexcretion gout; chr4:48021329 chr4:47840122~47844339:- LIHC cis rs2253762 0.507 rs10159998 ENSG00000276742.1 RP11-500G22.4 4.23 2.99e-05 0.00676 0.36 0.22 Breast cancer; chr10:121994550 chr10:121956782~121957098:+ LIHC cis rs2253762 0.54 rs11200311 ENSG00000276742.1 RP11-500G22.4 4.23 2.99e-05 0.00676 0.36 0.22 Breast cancer; chr10:121995094 chr10:121956782~121957098:+ LIHC cis rs2253762 0.54 rs79069897 ENSG00000276742.1 RP11-500G22.4 4.23 2.99e-05 0.00676 0.36 0.22 Breast cancer; chr10:121995680 chr10:121956782~121957098:+ LIHC cis rs2253762 0.54 rs77032313 ENSG00000276742.1 RP11-500G22.4 4.23 2.99e-05 0.00676 0.36 0.22 Breast cancer; chr10:121995687 chr10:121956782~121957098:+ LIHC cis rs2253762 0.54 rs4752631 ENSG00000276742.1 RP11-500G22.4 4.23 2.99e-05 0.00676 0.36 0.22 Breast cancer; chr10:121996442 chr10:121956782~121957098:+ LIHC cis rs2253762 0.54 rs11200313 ENSG00000276742.1 RP11-500G22.4 4.23 2.99e-05 0.00676 0.36 0.22 Breast cancer; chr10:121996523 chr10:121956782~121957098:+ LIHC cis rs2439831 1 rs471229 ENSG00000166763.7 STRCP1 4.23 2.99e-05 0.00676 0.31 0.22 Lung cancer in ever smokers; chr15:43441796 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs2439841 ENSG00000166763.7 STRCP1 4.23 2.99e-05 0.00676 0.31 0.22 Lung cancer in ever smokers; chr15:43442551 chr15:43699488~43718184:- LIHC cis rs9368481 0.761 rs3931464 ENSG00000241549.7 GUSBP2 4.23 2.99e-05 0.00676 0.24 0.22 Autism spectrum disorder or schizophrenia; chr6:26972077 chr6:26871484~26956554:- LIHC cis rs113084984 0.718 rs12620490 ENSG00000271952.1 RP11-245G13.2 -4.23 2.99e-05 0.00676 -0.27 -0.22 Breast cancer; chr2:11542670 chr2:10878269~10885118:+ LIHC cis rs11096990 0.613 rs12643415 ENSG00000249207.1 RP11-360F5.1 4.23 2.99e-05 0.00677 0.22 0.22 Cognitive function; chr4:39270375 chr4:39112677~39126818:- LIHC cis rs6951245 0.554 rs10246354 ENSG00000229043.2 AC091729.9 -4.23 3e-05 0.00677 -0.41 -0.22 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1092820 chr7:1160374~1165267:+ LIHC cis rs17834679 1 rs17834679 ENSG00000243680.1 RPL37P23 -4.23 3e-05 0.00677 -0.19 -0.22 Alopecia areata; chr19:51766834 chr19:52143043~52143336:+ LIHC cis rs7474896 0.616 rs1985260 ENSG00000263064.2 RP11-291L22.7 4.23 3e-05 0.00677 0.3 0.22 Obesity (extreme); chr10:38145162 chr10:38448689~38448949:+ LIHC cis rs12887734 0.546 rs12885509 ENSG00000258534.1 CTD-2134A5.4 -4.23 3e-05 0.00677 -0.25 -0.22 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103806988 chr14:103854366~103880111:- LIHC cis rs2919917 0.628 rs894222 ENSG00000254352.1 RP11-578O24.2 -4.23 3e-05 0.00677 -0.34 -0.22 Lymphocyte counts; chr8:78737034 chr8:78723796~78724136:- LIHC cis rs673078 0.66 rs17512574 ENSG00000275759.1 RP11-131L12.3 -4.23 3e-05 0.00677 -0.41 -0.22 Glucose homeostasis traits; chr12:118350198 chr12:118428281~118428870:+ LIHC cis rs11779988 0.501 rs3760 ENSG00000253671.1 RP11-806O11.1 -4.23 3e-05 0.00678 -0.28 -0.22 Breast cancer; chr8:18028836 chr8:17808941~17820868:+ LIHC cis rs763121 0.853 rs2284073 ENSG00000273076.1 RP3-508I15.22 4.23 3e-05 0.00678 0.25 0.22 Menopause (age at onset); chr22:38709943 chr22:38743495~38743910:+ LIHC cis rs1115240 0.947 rs56150758 ENSG00000257842.4 NOVA1-AS1 4.23 3e-05 0.00678 0.2 0.22 Educational attainment (years of education); chr14:26636268 chr14:26598412~26806467:+ LIHC cis rs11098499 0.618 rs6858383 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119375617 chr4:119409333~119410233:+ LIHC cis rs11098499 0.697 rs6832410 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119375645 chr4:119409333~119410233:+ LIHC cis rs11098499 0.865 rs1112817 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119376645 chr4:119409333~119410233:+ LIHC cis rs11098499 0.779 rs10016060 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119377257 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs10005644 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119377322 chr4:119409333~119410233:+ LIHC cis rs11098499 0.697 rs10016448 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119377690 chr4:119409333~119410233:+ LIHC cis rs11098499 0.657 rs9996569 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119377849 chr4:119409333~119410233:+ LIHC cis rs11098499 0.908 rs11729050 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119378911 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs28429722 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119378938 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs10014845 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119379922 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs34868248 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119521275 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs3733525 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119525893 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs3775847 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119526487 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs3775848 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119526569 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs10013305 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119529269 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs3775849 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119529753 chr4:119409333~119410233:+ LIHC cis rs11098499 0.818 rs7688802 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119530513 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs7695620 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119531621 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs12502389 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119533036 chr4:119409333~119410233:+ LIHC cis rs11098499 0.821 rs3775852 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119533401 chr4:119409333~119410233:+ LIHC cis rs11098499 0.82 rs6534140 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119534156 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs7657849 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119534339 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs10034450 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119534494 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs1480939 ENSG00000260091.1 RP11-33B1.4 -4.23 3e-05 0.00678 -0.16 -0.22 Corneal astigmatism; chr4:119535772 chr4:119409333~119410233:+ LIHC cis rs4356975 0.932 rs7692377 ENSG00000250919.1 RP11-813N20.3 -4.23 3.01e-05 0.00679 -0.22 -0.22 Obesity-related traits; chr4:69078113 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs61612343 ENSG00000250919.1 RP11-813N20.3 -4.23 3.01e-05 0.00679 -0.22 -0.22 Obesity-related traits; chr4:69078247 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs7679418 ENSG00000250919.1 RP11-813N20.3 -4.23 3.01e-05 0.00679 -0.22 -0.22 Obesity-related traits; chr4:69078533 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs7680156 ENSG00000250919.1 RP11-813N20.3 -4.23 3.01e-05 0.00679 -0.22 -0.22 Obesity-related traits; chr4:69078868 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs7698430 ENSG00000250919.1 RP11-813N20.3 -4.23 3.01e-05 0.00679 -0.22 -0.22 Obesity-related traits; chr4:69078897 chr4:69027831~69044578:+ LIHC cis rs4713118 0.513 rs202908 ENSG00000219392.1 RP1-265C24.5 -4.23 3.01e-05 0.00679 -0.3 -0.22 Parkinson's disease; chr6:28043773 chr6:28115628~28116551:+ LIHC cis rs3020736 0.5 rs8138678 ENSG00000205702.9 CYP2D7 -4.23 3.01e-05 0.00679 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42120225 chr22:42140203~42144577:- LIHC cis rs4694744 1 rs4694744 ENSG00000264696.1 AC108078.1 -4.23 3.01e-05 0.00679 -0.3 -0.22 Bacteremia; chr4:69460938 chr4:69479331~69479434:+ LIHC cis rs4650994 0.789 rs2811300 ENSG00000213057.5 C1orf220 -4.23 3.01e-05 0.00679 -0.19 -0.22 HDL cholesterol;HDL cholesterol levels; chr1:178621259 chr1:178542752~178548889:+ LIHC cis rs4650994 0.816 rs1074896 ENSG00000213057.5 C1orf220 -4.23 3.01e-05 0.00679 -0.19 -0.22 HDL cholesterol;HDL cholesterol levels; chr1:178622055 chr1:178542752~178548889:+ LIHC cis rs17772222 0.874 rs61984746 ENSG00000258789.1 RP11-507K2.3 -4.23 3.01e-05 0.0068 -0.26 -0.22 Coronary artery calcification; chr14:88668136 chr14:88551597~88552493:+ LIHC cis rs17711722 0.523 rs365896 ENSG00000226002.1 RP11-460N20.5 -4.23 3.01e-05 0.0068 -0.23 -0.22 Calcium levels; chr7:66045710 chr7:65084103~65100232:+ LIHC cis rs6700559 0.81 rs10399615 ENSG00000260088.1 RP11-92G12.3 4.23 3.01e-05 0.0068 0.28 0.22 Coronary artery disease; chr1:200626145 chr1:200669507~200694250:+ LIHC cis rs755249 1 rs755249 ENSG00000182109.6 RP11-69E11.4 4.23 3.01e-05 0.0068 0.29 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39529402 chr1:39522280~39546187:- LIHC cis rs10833905 1 rs12420168 ENSG00000246225.5 RP11-17A1.3 -4.23 3.01e-05 0.0068 -0.29 -0.22 Sudden cardiac arrest; chr11:23002244 chr11:22829380~22945393:+ LIHC cis rs10833905 1 rs11026893 ENSG00000246225.5 RP11-17A1.3 -4.23 3.01e-05 0.0068 -0.29 -0.22 Sudden cardiac arrest; chr11:23002690 chr11:22829380~22945393:+ LIHC cis rs10833905 1 rs7932620 ENSG00000246225.5 RP11-17A1.3 -4.23 3.01e-05 0.0068 -0.29 -0.22 Sudden cardiac arrest; chr11:23003174 chr11:22829380~22945393:+ LIHC cis rs7182621 0.512 rs12903892 ENSG00000182397.13 DNM1P46 4.23 3.01e-05 0.0068 0.31 0.22 Colonoscopy-negative controls vs population controls; chr15:99869662 chr15:99790156~99806927:- LIHC cis rs755249 0.588 rs6665948 ENSG00000182109.6 RP11-69E11.4 -4.23 3.02e-05 0.00681 -0.23 -0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39478508 chr1:39522280~39546187:- LIHC cis rs960902 0.747 rs13412538 ENSG00000213553.4 RPLP0P6 4.23 3.02e-05 0.00681 0.18 0.22 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37497480 chr2:38481851~38482804:+ LIHC cis rs3015497 0.789 rs11621971 ENSG00000269906.1 RP11-248J18.2 -4.23 3.02e-05 0.00682 -0.28 -0.22 Mean platelet volume; chr14:50657809 chr14:50662511~50663178:- LIHC cis rs3015497 0.789 rs923908 ENSG00000269906.1 RP11-248J18.2 4.23 3.02e-05 0.00682 0.28 0.22 Mean platelet volume; chr14:50656877 chr14:50662511~50663178:- LIHC cis rs11098499 0.863 rs10030660 ENSG00000260091.1 RP11-33B1.4 -4.23 3.02e-05 0.00682 -0.16 -0.22 Corneal astigmatism; chr4:119515549 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs13149407 ENSG00000260091.1 RP11-33B1.4 -4.23 3.02e-05 0.00682 -0.16 -0.22 Corneal astigmatism; chr4:119516670 chr4:119409333~119410233:+ LIHC cis rs11096990 0.613 rs7690414 ENSG00000249207.1 RP11-360F5.1 -4.23 3.02e-05 0.00682 -0.23 -0.22 Cognitive function; chr4:39210669 chr4:39112677~39126818:- LIHC cis rs11096990 0.593 rs7685619 ENSG00000249207.1 RP11-360F5.1 -4.23 3.02e-05 0.00682 -0.23 -0.22 Cognitive function; chr4:39211779 chr4:39112677~39126818:- LIHC cis rs75920871 0.764 rs4938338 ENSG00000254851.1 RP11-109L13.1 -4.23 3.02e-05 0.00682 -0.45 -0.22 Subjective well-being; chr11:117102178 chr11:117135528~117138582:+ LIHC cis rs617219 0.746 rs7724909 ENSG00000251675.1 CTC-458I2.2 -4.23 3.02e-05 0.00682 -0.26 -0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79263809 chr5:80128361~80143883:+ LIHC cis rs734999 0.588 rs3748819 ENSG00000225931.3 RP3-395M20.7 4.23 3.02e-05 0.00682 0.24 0.22 Ulcerative colitis; chr1:2593527 chr1:2566410~2569888:+ LIHC cis rs6545883 0.524 rs7561697 ENSG00000271889.1 RP11-493E12.1 -4.23 3.03e-05 0.00683 -0.27 -0.22 Tuberculosis; chr2:61292030 chr2:61151433~61162105:- LIHC cis rs9527 0.59 rs10883839 ENSG00000236937.2 PTGES3P4 4.23 3.03e-05 0.00683 0.29 0.22 Arsenic metabolism; chr10:103160584 chr10:102845595~102845950:+ LIHC cis rs9595908 0.606 rs4942925 ENSG00000212293.1 SNORA16 4.23 3.03e-05 0.00683 0.26 0.22 Body mass index; chr13:32807106 chr13:32420390~32420516:- LIHC cis rs904251 0.58 rs62408367 ENSG00000204110.6 RP1-153P14.8 -4.23 3.03e-05 0.00683 -0.27 -0.22 Cognitive performance; chr6:37477037 chr6:37507348~37535616:+ LIHC cis rs2929278 0.617 rs12908467 ENSG00000275601.1 AC011330.13 4.23 3.03e-05 0.00684 0.28 0.22 Schizophrenia; chr15:43755232 chr15:43642389~43643023:- LIHC cis rs6445975 0.666 rs4613423 ENSG00000272360.1 RP11-359I18.5 -4.23 3.03e-05 0.00684 -0.31 -0.22 Systemic lupus erythematosus; chr3:58355841 chr3:58490830~58491291:- LIHC cis rs12931792 0.712 rs2887799 ENSG00000183604.13 SMG1P5 4.23 3.03e-05 0.00684 0.2 0.22 Tonsillectomy; chr16:30152512 chr16:30267553~30335374:- LIHC cis rs2929278 0.617 rs663214 ENSG00000275601.1 AC011330.13 4.23 3.03e-05 0.00684 0.26 0.22 Schizophrenia; chr15:43821584 chr15:43642389~43643023:- LIHC cis rs901683 1 rs12766550 ENSG00000230869.1 CTGLF10P -4.23 3.03e-05 0.00684 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45515907 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12775527 ENSG00000230869.1 CTGLF10P -4.23 3.03e-05 0.00684 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45529542 chr10:45678692~45700532:+ LIHC cis rs6745190 0.953 rs6704750 ENSG00000236153.1 AC104076.3 4.23 3.04e-05 0.00685 0.3 0.22 White blood cell count; chr2:180964847 chr2:180979427~180980090:- LIHC cis rs6545883 0.542 rs10177225 ENSG00000271889.1 RP11-493E12.1 -4.23 3.04e-05 0.00685 -0.27 -0.22 Tuberculosis; chr2:61367363 chr2:61151433~61162105:- LIHC cis rs6545883 0.507 rs62149712 ENSG00000271889.1 RP11-493E12.1 -4.23 3.04e-05 0.00685 -0.27 -0.22 Tuberculosis; chr2:61374137 chr2:61151433~61162105:- LIHC cis rs9457247 0.935 rs2149093 ENSG00000227598.1 RP1-167A14.2 4.23 3.04e-05 0.00685 0.24 0.22 Crohn's disease; chr6:166959557 chr6:166969626~166999065:- LIHC cis rs9907295 0.818 rs4796109 ENSG00000270871.1 AC015849.19 4.23 3.04e-05 0.00685 0.23 0.22 Fibroblast growth factor basic levels; chr17:35811904 chr17:35816717~35830293:- LIHC cis rs4650994 0.623 rs2248666 ENSG00000273384.1 RP5-1098D14.1 -4.23 3.04e-05 0.00685 -0.27 -0.22 HDL cholesterol;HDL cholesterol levels; chr1:178651466 chr1:178651706~178652282:+ LIHC cis rs6442522 1 rs6762167 ENSG00000249786.6 EAF1-AS1 -4.23 3.04e-05 0.00685 -0.25 -0.22 Uric acid levels; chr3:15403530 chr3:15436171~15455940:- LIHC cis rs3091242 0.9 rs1811832 ENSG00000261349.1 RP3-465N24.5 -4.23 3.04e-05 0.00685 -0.22 -0.22 Erythrocyte sedimentation rate; chr1:25427074 chr1:25266102~25267136:- LIHC cis rs901683 1 rs71494792 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45487601 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35632234 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45487931 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs36070902 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45488529 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34195613 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45534926 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35824277 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45535029 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs12765244 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45536593 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71496612 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45537057 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71496613 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45537125 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs17157898 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45541761 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs36054203 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45542413 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12776291 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45543059 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12781506 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45543254 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs12774453 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45543473 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34309840 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45543913 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs36109121 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45544063 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35034867 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45544117 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs75595592 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45544482 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs9422439 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45545025 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs9422650 ENSG00000230869.1 CTGLF10P -4.23 3.04e-05 0.00685 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45550313 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12779976 ENSG00000230869.1 CTGLF10P 4.23 3.04e-05 0.00685 0.54 0.22 Mean corpuscular volume;Red blood cell traits; chr10:45547484 chr10:45678692~45700532:+ LIHC cis rs2283792 0.765 rs2266966 ENSG00000224086.5 LL22NC03-86G7.1 -4.23 3.04e-05 0.00685 -0.23 -0.22 Multiple sclerosis; chr22:21767265 chr22:21938293~21977632:+ LIHC cis rs17464492 0.593 rs12541832 ENSG00000246228.5 CASC8 4.23 3.04e-05 0.00685 0.25 0.22 Prostate-specific antigen levels (conditioned on lead SNPs); chr8:127340926 chr8:127289817~127482139:- LIHC cis rs755249 0.567 rs61779284 ENSG00000182109.6 RP11-69E11.4 4.23 3.04e-05 0.00686 0.29 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39389505 chr1:39522280~39546187:- LIHC cis rs13113518 0.776 rs13124436 ENSG00000249700.7 SRD5A3-AS1 4.23 3.04e-05 0.00686 0.26 0.22 Height; chr4:55502504 chr4:55363971~55395847:- LIHC cis rs13113518 0.783 rs6843997 ENSG00000249700.7 SRD5A3-AS1 4.23 3.04e-05 0.00686 0.26 0.22 Height; chr4:55508982 chr4:55363971~55395847:- LIHC cis rs13113518 0.783 rs12508367 ENSG00000249700.7 SRD5A3-AS1 4.23 3.04e-05 0.00686 0.26 0.22 Height; chr4:55509442 chr4:55363971~55395847:- LIHC cis rs13113518 0.812 rs2272073 ENSG00000249700.7 SRD5A3-AS1 4.23 3.04e-05 0.00686 0.26 0.22 Height; chr4:55510177 chr4:55363971~55395847:- LIHC cis rs6964833 1 rs34324835 ENSG00000277053.3 GTF2IP1 -4.23 3.04e-05 0.00686 -0.29 -0.22 Menarche (age at onset); chr7:74717986 chr7:75185385~75237696:- LIHC cis rs6832769 1 rs6554286 ENSG00000272969.1 RP11-528I4.2 -4.23 3.04e-05 0.00686 -0.27 -0.22 Personality dimensions; chr4:55534137 chr4:55547112~55547889:+ LIHC cis rs2070488 0.965 rs2051215 ENSG00000229589.1 ACVR2B-AS1 -4.23 3.04e-05 0.00686 -0.25 -0.22 Electrocardiographic conduction measures; chr3:38518854 chr3:38451027~38454820:- LIHC cis rs748404 0.631 rs6493083 ENSG00000205771.5 CATSPER2P1 -4.23 3.05e-05 0.00686 -0.26 -0.22 Lung cancer; chr15:43345787 chr15:43726918~43747094:- LIHC cis rs9906944 0.707 rs4794019 ENSG00000248278.1 SUMO2P17 -4.23 3.05e-05 0.00686 -0.36 -0.22 Intelligence (multi-trait analysis);Body fat percentage; chr17:49029928 chr17:48874860~48908983:- LIHC cis rs8177253 0.665 rs9869535 ENSG00000244062.1 RP11-404G16.2 4.23 3.05e-05 0.00687 0.22 0.22 Iron status biomarkers; chr3:133732737 chr3:133760300~133762363:+ LIHC cis rs2932538 0.922 rs11102508 ENSG00000225075.1 RP11-426L16.3 4.23 3.05e-05 0.00687 0.28 0.22 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112598553 chr1:112693688~112696621:- LIHC cis rs2932538 0.922 rs6537745 ENSG00000225075.1 RP11-426L16.3 4.23 3.05e-05 0.00687 0.28 0.22 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112611458 chr1:112693688~112696621:- LIHC cis rs617219 0.787 rs12189006 ENSG00000251675.1 CTC-458I2.2 -4.23 3.05e-05 0.00687 -0.25 -0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79243849 chr5:80128361~80143883:+ LIHC cis rs7615952 0.576 rs66671308 ENSG00000171084.14 FAM86JP 4.23 3.05e-05 0.00688 0.36 0.22 Blood pressure (smoking interaction); chr3:126074683 chr3:125916620~125930024:+ LIHC cis rs2739330 0.828 rs2186366 ENSG00000206090.4 AP000350.7 -4.23 3.05e-05 0.00688 -0.26 -0.22 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23939998~23942798:+ LIHC cis rs6142102 0.961 rs2300204 ENSG00000275784.1 RP5-1125A11.6 -4.23 3.05e-05 0.00688 -0.25 -0.22 Skin pigmentation; chr20:34000967 chr20:33989480~33991818:- LIHC cis rs2070488 1 rs1002676 ENSG00000229589.1 ACVR2B-AS1 -4.23 3.06e-05 0.00689 -0.25 -0.22 Electrocardiographic conduction measures; chr3:38403441 chr3:38451027~38454820:- LIHC cis rs73193808 0.614 rs2832251 ENSG00000212479.2 U3 4.23 3.06e-05 0.0069 0.26 0.22 Coronary artery disease; chr21:29187231 chr21:29180425~29180639:- LIHC cis rs12157904 1 rs13055987 ENSG00000233360.4 Z83844.1 4.23 3.06e-05 0.0069 0.47 0.22 Response to anti-depressant treatment in major depressive disorder; chr22:37609434 chr22:37641832~37658377:- LIHC cis rs950169 1 rs1818950 ENSG00000259728.4 LINC00933 4.23 3.07e-05 0.0069 0.36 0.22 Schizophrenia; chr15:84053769 chr15:84570649~84580175:+ LIHC cis rs367615 0.506 rs2963021 ENSG00000249476.1 CTD-2587M2.1 4.23 3.07e-05 0.0069 0.26 0.22 Colorectal cancer (SNP x SNP interaction); chr5:109464664 chr5:109237120~109326369:- LIHC cis rs10853057 0.717 rs58524282 ENSG00000214174.7 AMZ2P1 4.23 3.07e-05 0.00691 0.52 0.22 White matter microstructure (global fractional anisotropy); chr17:65060479 chr17:64966550~64975576:- LIHC cis rs2749592 0.513 rs1208708 ENSG00000276805.1 RP11-291L22.6 4.23 3.07e-05 0.00691 0.27 0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37796648 chr10:38451030~38451785:+ LIHC cis rs5758511 0.689 rs45441993 ENSG00000237037.8 NDUFA6-AS1 -4.23 3.07e-05 0.00691 -0.44 -0.22 Birth weight; chr22:42075734 chr22:42090931~42137742:+ LIHC cis rs7129556 0.701 rs10899399 ENSG00000254459.1 RP11-91P24.7 4.22 3.07e-05 0.00691 0.38 0.22 Weight loss (gastric bypass surgery); chr11:77698787 chr11:77829654~77872262:- LIHC cis rs7893279 0.505 rs7919487 ENSG00000225527.1 RP11-383B4.4 4.22 3.07e-05 0.00691 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18579870 chr10:18531849~18533336:- LIHC cis rs4578769 0.959 rs4800430 ENSG00000265943.1 RP11-739L10.1 4.22 3.07e-05 0.00691 0.28 0.22 Eosinophil percentage of white cells; chr18:22803299 chr18:22699481~22933764:- LIHC cis rs11148252 0.904 rs9568734 ENSG00000278238.1 RP11-245D16.4 -4.22 3.07e-05 0.00692 -0.21 -0.22 Lewy body disease; chr13:52430087 chr13:52454775~52455331:- LIHC cis rs3738443 0.868 rs6660351 ENSG00000259865.1 RP11-488L18.10 4.22 3.07e-05 0.00692 0.22 0.22 Alcohol dependence; chr1:247184526 chr1:247187281~247188526:- LIHC cis rs651907 0.557 rs62284199 ENSG00000244119.1 PDCL3P4 4.22 3.08e-05 0.00692 0.23 0.22 Colorectal cancer; chr3:101759687 chr3:101712472~101713191:+ LIHC cis rs7811142 0.83 rs705866 ENSG00000242294.5 STAG3L5P 4.22 3.08e-05 0.00692 0.25 0.22 Platelet count; chr7:100367662 chr7:100336079~100351900:+ LIHC cis rs2581828 0.646 rs6769931 ENSG00000242142.1 SERBP1P3 -4.22 3.08e-05 0.00692 -0.29 -0.22 Crohn's disease; chr3:53126177 chr3:53064283~53065091:- LIHC cis rs2581828 0.646 rs6809973 ENSG00000242142.1 SERBP1P3 -4.22 3.08e-05 0.00692 -0.29 -0.22 Crohn's disease; chr3:53126200 chr3:53064283~53065091:- LIHC cis rs2581828 0.608 rs6769944 ENSG00000242142.1 SERBP1P3 -4.22 3.08e-05 0.00692 -0.29 -0.22 Crohn's disease; chr3:53126227 chr3:53064283~53065091:- LIHC cis rs2581828 0.646 rs9858469 ENSG00000242142.1 SERBP1P3 -4.22 3.08e-05 0.00692 -0.29 -0.22 Crohn's disease; chr3:53128390 chr3:53064283~53065091:- LIHC cis rs2581828 0.646 rs9820324 ENSG00000242142.1 SERBP1P3 -4.22 3.08e-05 0.00692 -0.29 -0.22 Crohn's disease; chr3:53128429 chr3:53064283~53065091:- LIHC cis rs7923609 0.875 rs10761741 ENSG00000232075.1 MRPL35P2 -4.22 3.08e-05 0.00692 -0.25 -0.22 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63306426 chr10:63634317~63634827:- LIHC cis rs673078 0.66 rs16948234 ENSG00000275759.1 RP11-131L12.3 4.22 3.08e-05 0.00693 0.42 0.22 Glucose homeostasis traits; chr12:118282464 chr12:118428281~118428870:+ LIHC cis rs10028773 0.666 rs12498657 ENSG00000245958.5 RP11-33B1.1 -4.22 3.08e-05 0.00693 -0.22 -0.22 Educational attainment; chr4:119341711 chr4:119454791~119552025:+ LIHC cis rs8005677 0.649 rs11629120 ENSG00000257285.4 RP11-298I3.1 -4.22 3.08e-05 0.00693 -0.23 -0.22 Cognitive ability (multi-trait analysis); chr14:22989248 chr14:22929609~22955562:+ LIHC cis rs6445975 0.666 rs4553989 ENSG00000272360.1 RP11-359I18.5 4.22 3.08e-05 0.00694 0.3 0.22 Systemic lupus erythematosus; chr3:58395393 chr3:58490830~58491291:- LIHC cis rs11233413 0.874 rs12422142 ENSG00000246067.6 RAB30-AS1 4.22 3.09e-05 0.00694 0.3 0.22 Economic and political preferences (feminism/equality); chr11:83043119 chr11:83072066~83106719:+ LIHC cis rs9675120 0.821 rs7207294 ENSG00000262006.1 RP11-700H6.4 -4.22 3.09e-05 0.00694 -0.24 -0.22 Cerebrospinal fluid biomarker levels; chr17:50838483 chr17:50909637~50910232:- LIHC cis rs875971 0.929 rs4122249 ENSG00000237310.1 GS1-124K5.4 4.22 3.09e-05 0.00694 0.2 0.22 Aortic root size; chr7:66455949 chr7:66493706~66495474:+ LIHC cis rs1865760 0.625 rs9393681 ENSG00000216436.2 HIST1H2APS1 -4.22 3.09e-05 0.00695 -0.25 -0.22 Height; chr6:26008032 chr6:25732497~25732827:+ LIHC cis rs42490 0.528 rs1040327 ENSG00000251136.7 RP11-37B2.1 4.22 3.09e-05 0.00695 0.19 0.22 Leprosy; chr8:89669585 chr8:89609409~89757727:- LIHC cis rs42490 0.528 rs2840206 ENSG00000251136.7 RP11-37B2.1 4.22 3.09e-05 0.00695 0.19 0.22 Leprosy; chr8:89670184 chr8:89609409~89757727:- LIHC cis rs932287 0.536 rs10840160 ENSG00000254860.4 TMEM9B-AS1 4.22 3.09e-05 0.00695 0.22 0.22 Colonoscopy-negative controls vs population controls; chr11:9031989 chr11:8964675~8977527:+ LIHC cis rs1223397 0.938 rs17767967 ENSG00000215022.6 RP1-257A7.4 -4.22 3.09e-05 0.00696 -0.29 -0.22 Blood pressure; chr6:13281835 chr6:13264861~13295586:- LIHC cis rs4845875 0.626 rs4845882 ENSG00000242349.4 NPPA-AS1 4.22 3.09e-05 0.00696 0.24 0.22 Midregional pro atrial natriuretic peptide levels; chr1:11783110 chr1:11841017~11848079:+ LIHC cis rs11098499 0.644 rs17517414 ENSG00000245958.5 RP11-33B1.1 -4.22 3.1e-05 0.00696 -0.22 -0.22 Corneal astigmatism; chr4:119340946 chr4:119454791~119552025:+ LIHC cis rs2243480 1 rs4718269 ENSG00000228409.4 CCT6P1 -4.22 3.1e-05 0.00696 -0.24 -0.22 Diabetic kidney disease; chr7:65735810 chr7:65751142~65763354:+ LIHC cis rs2348418 0.966 rs7316797 ENSG00000247934.4 RP11-967K21.1 4.22 3.1e-05 0.00696 0.21 0.22 Lung function (FEV1);Lung function (FVC); chr12:28529776 chr12:28163298~28190738:- LIHC cis rs6480314 0.831 rs10733840 ENSG00000233590.1 RP11-153K11.3 4.22 3.1e-05 0.00697 0.3 0.22 Optic nerve measurement (disc area); chr10:68220464 chr10:68233251~68242379:- LIHC cis rs12701220 0.522 rs868833 ENSG00000229043.2 AC091729.9 -4.22 3.1e-05 0.00697 -0.28 -0.22 Bronchopulmonary dysplasia; chr7:1015337 chr7:1160374~1165267:+ LIHC cis rs901683 1 rs901683 ENSG00000230869.1 CTGLF10P -4.22 3.1e-05 0.00698 -0.52 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45470974 chr10:45678692~45700532:+ LIHC cis rs638893 0.842 rs480791 ENSG00000255239.1 AP002954.6 4.22 3.1e-05 0.00698 0.4 0.22 Vitiligo; chr11:118833546 chr11:118688039~118690600:- LIHC cis rs4925386 1 rs6121990 ENSG00000226332.2 RP11-157P1.4 -4.22 3.1e-05 0.00698 -0.23 -0.22 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62344207 chr20:62305432~62306325:- LIHC cis rs12468226 0.689 rs73989733 ENSG00000272966.1 RP11-686O6.1 4.22 3.11e-05 0.00698 0.39 0.22 Urate levels; chr2:202115241 chr2:202336739~202337200:+ LIHC cis rs4561483 0.798 rs33629 ENSG00000261560.1 RP11-166B2.3 -4.22 3.11e-05 0.00698 -0.24 -0.22 Testicular germ cell tumor; chr16:11903633 chr16:11881075~11882569:- LIHC cis rs4356975 0.932 rs4694610 ENSG00000250919.1 RP11-813N20.3 -4.22 3.11e-05 0.00698 -0.22 -0.22 Obesity-related traits; chr4:69079224 chr4:69027831~69044578:+ LIHC cis rs4356203 0.87 rs2171615 ENSG00000260196.1 RP1-239B22.5 -4.22 3.11e-05 0.00698 -0.27 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17231094 chr11:17380649~17383531:+ LIHC cis rs2564921 0.704 rs56058643 ENSG00000242142.1 SERBP1P3 -4.22 3.11e-05 0.00699 -0.3 -0.22 Height; chr3:53093751 chr3:53064283~53065091:- LIHC cis rs2439831 0.618 rs8023508 ENSG00000275601.1 AC011330.13 4.22 3.11e-05 0.00699 0.32 0.22 Lung cancer in ever smokers; chr15:43883905 chr15:43642389~43643023:- LIHC cis rs11098499 0.554 rs2175381 ENSG00000260091.1 RP11-33B1.4 -4.22 3.11e-05 0.00699 -0.15 -0.22 Corneal astigmatism; chr4:119344812 chr4:119409333~119410233:+ LIHC cis rs4578769 0.765 rs55762801 ENSG00000266850.1 RP11-370A5.1 -4.22 3.11e-05 0.00699 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22807096 chr18:22723491~22907721:- LIHC cis rs244293 0.801 rs2541241 ENSG00000275710.1 RP11-257O5.4 -4.22 3.12e-05 0.00701 -0.24 -0.22 Menarche (age at onset); chr17:54995632 chr17:54964474~54964679:+ LIHC cis rs2274273 0.588 rs9323285 ENSG00000258413.1 RP11-665C16.6 4.22 3.12e-05 0.00701 0.27 0.22 Protein biomarker; chr14:55397111 chr14:55262767~55272075:- LIHC cis rs72675573 0.852 rs72675552 ENSG00000235612.1 RP1-158P9.1 -4.22 3.12e-05 0.00701 -0.29 -0.22 Monocyte count; chr1:56138851 chr1:56145721~56155224:+ LIHC cis rs950880 0.71 rs2287035 ENSG00000234389.1 AC007278.3 -4.22 3.13e-05 0.00703 -0.23 -0.22 Serum protein levels (sST2); chr2:102394070 chr2:102438713~102440475:+ LIHC cis rs9450351 0.744 rs7749600 ENSG00000203875.9 SNHG5 -4.22 3.13e-05 0.00704 -0.49 -0.22 Interferon gamma-induced protein 10 levels; chr6:85624372 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs9344538 ENSG00000203875.9 SNHG5 -4.22 3.13e-05 0.00704 -0.49 -0.22 Interferon gamma-induced protein 10 levels; chr6:85625243 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs9450307 ENSG00000203875.9 SNHG5 -4.22 3.13e-05 0.00704 -0.49 -0.22 Interferon gamma-induced protein 10 levels; chr6:85634633 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs9450309 ENSG00000203875.9 SNHG5 -4.22 3.13e-05 0.00704 -0.49 -0.22 Interferon gamma-induced protein 10 levels; chr6:85639025 chr6:85660950~85678736:- LIHC cis rs2598107 0.601 rs71546608 ENSG00000211698.2 TRGV4 -4.22 3.13e-05 0.00704 -0.27 -0.22 Dupuytren's disease; chr7:37900850 chr7:38353715~38354517:- LIHC cis rs1115240 0.947 rs1010727 ENSG00000257842.4 NOVA1-AS1 -4.22 3.14e-05 0.00704 -0.21 -0.22 Educational attainment (years of education); chr14:26647971 chr14:26598412~26806467:+ LIHC cis rs2283792 0.646 rs9610317 ENSG00000224086.5 LL22NC03-86G7.1 -4.22 3.14e-05 0.00704 -0.24 -0.22 Multiple sclerosis; chr22:21785601 chr22:21938293~21977632:+ LIHC cis rs2998286 0.723 rs332162 ENSG00000254635.4 WAC-AS1 -4.22 3.14e-05 0.00705 -0.28 -0.22 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28599960 chr10:28522652~28532743:- LIHC cis rs6445975 1 rs6445975 ENSG00000272360.1 RP11-359I18.5 4.22 3.14e-05 0.00705 0.28 0.22 Systemic lupus erythematosus; chr3:58384450 chr3:58490830~58491291:- LIHC cis rs3204270 0.639 rs7216239 ENSG00000281517.1 Metazoa_SRP -4.22 3.14e-05 0.00705 -0.41 -0.22 Dental caries; chr17:81693157 chr17:81718849~81719095:- LIHC cis rs2243480 1 rs35825738 ENSG00000232546.1 RP11-458F8.1 -4.22 3.14e-05 0.00705 -0.25 -0.22 Diabetic kidney disease; chr7:65853040 chr7:66848496~66858136:+ LIHC cis rs10262624 0.935 rs6955884 ENSG00000234286.1 AC006026.13 -4.22 3.14e-05 0.00705 -0.25 -0.22 Schizophrenia; chr7:23865654 chr7:23680195~23680786:- LIHC cis rs10262624 0.901 rs6977550 ENSG00000234286.1 AC006026.13 -4.22 3.14e-05 0.00705 -0.25 -0.22 Schizophrenia; chr7:23865825 chr7:23680195~23680786:- LIHC cis rs11096990 0.656 rs6531709 ENSG00000249685.1 RP11-360F5.3 -4.22 3.14e-05 0.00705 -0.27 -0.22 Cognitive function; chr4:39300629 chr4:39133913~39135608:+ LIHC cis rs30380 0.688 rs27524 ENSG00000272109.1 CTD-2260A17.3 -4.22 3.14e-05 0.00705 -0.29 -0.22 Cerebrospinal fluid biomarker levels; chr5:96766240 chr5:96804353~96806105:+ LIHC cis rs938554 0.513 rs3733588 ENSG00000250413.1 RP11-448G15.1 4.22 3.14e-05 0.00705 0.3 0.22 Blood metabolite levels; chr4:9995679 chr4:10006482~10009725:+ LIHC cis rs748404 0.578 rs510108 ENSG00000205771.5 CATSPER2P1 -4.22 3.15e-05 0.00706 -0.27 -0.22 Lung cancer; chr15:43313241 chr15:43726918~43747094:- LIHC cis rs524281 0.692 rs11227395 ENSG00000255320.1 RP11-755F10.1 4.22 3.15e-05 0.00706 0.32 0.22 Electroencephalogram traits; chr11:66062166 chr11:66244840~66246239:- LIHC cis rs8024893 0.764 rs8035110 ENSG00000270055.1 CTD-3092A11.2 4.22 3.15e-05 0.00706 0.33 0.22 Red cell distribution width; chr15:31241884 chr15:30487963~30490313:+ LIHC cis rs8024893 0.764 rs8036245 ENSG00000270055.1 CTD-3092A11.2 4.22 3.15e-05 0.00706 0.33 0.22 Red cell distribution width; chr15:31242211 chr15:30487963~30490313:+ LIHC cis rs6860806 0.507 rs2631372 ENSG00000263597.1 MIR3936 4.22 3.15e-05 0.00707 0.24 0.22 Breast cancer; chr5:132367886 chr5:132365490~132365599:- LIHC cis rs2072510 0.966 rs11108372 ENSG00000257715.1 RP11-256L6.2 -4.22 3.15e-05 0.00707 -0.23 -0.22 Metabolite levels (small molecules and protein measures); chr12:96000739 chr12:96025323~96027971:+ LIHC cis rs2439831 1 rs690436 ENSG00000166763.7 STRCP1 4.22 3.15e-05 0.00707 0.31 0.22 Lung cancer in ever smokers; chr15:43469007 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs2264239 ENSG00000166763.7 STRCP1 4.22 3.15e-05 0.00707 0.31 0.22 Lung cancer in ever smokers; chr15:43473335 chr15:43699488~43718184:- LIHC cis rs812925 0.512 rs7558954 ENSG00000212978.6 AC016747.3 -4.22 3.15e-05 0.00707 -0.24 -0.22 Immature fraction of reticulocytes; chr2:61157771 chr2:61141592~61144969:- LIHC cis rs6901152 0.561 rs1424929 ENSG00000217648.1 RP1-95L4.4 -4.22 3.15e-05 0.00707 -0.26 -0.22 Acute lymphoblastic leukemia (childhood); chr6:143371109 chr6:143342246~143343383:+ LIHC cis rs7712401 0.601 rs152039 ENSG00000263432.2 RN7SL689P 4.22 3.15e-05 0.00708 0.33 0.22 Mean platelet volume; chr5:122884970 chr5:123022487~123022783:- LIHC cis rs2842992 0.513 rs7759086 ENSG00000237927.1 RP3-393E18.2 -4.22 3.15e-05 0.00708 -0.26 -0.22 Age-related macular degeneration (geographic atrophy); chr6:159772821 chr6:159586955~159589169:- LIHC cis rs11096990 0.634 rs3733287 ENSG00000249207.1 RP11-360F5.1 -4.22 3.15e-05 0.00708 -0.22 -0.22 Cognitive function; chr4:39215732 chr4:39112677~39126818:- LIHC cis rs2015599 0.56 rs11050147 ENSG00000257176.2 RP11-996F15.2 -4.22 3.16e-05 0.00708 -0.28 -0.22 Platelet count;Mean platelet volume; chr12:29242746 chr12:29280418~29317848:- LIHC cis rs950880 0.71 rs2287034 ENSG00000234389.1 AC007278.3 4.22 3.16e-05 0.00708 0.23 0.22 Serum protein levels (sST2); chr2:102394128 chr2:102438713~102440475:+ LIHC cis rs7809950 1 rs10276604 ENSG00000238832.1 snoU109 4.22 3.16e-05 0.00709 0.26 0.22 Coronary artery disease; chr7:107576293 chr7:107603363~107603507:+ LIHC cis rs11098499 0.599 rs3864142 ENSG00000260091.1 RP11-33B1.4 -4.22 3.16e-05 0.00709 -0.15 -0.22 Corneal astigmatism; chr4:119345036 chr4:119409333~119410233:+ LIHC cis rs11098499 0.605 rs6833140 ENSG00000260091.1 RP11-33B1.4 -4.22 3.16e-05 0.00709 -0.15 -0.22 Corneal astigmatism; chr4:119345667 chr4:119409333~119410233:+ LIHC cis rs1223397 0.651 rs202021 ENSG00000215022.6 RP1-257A7.4 -4.22 3.16e-05 0.00709 -0.24 -0.22 Blood pressure; chr6:13302609 chr6:13264861~13295586:- LIHC cis rs12887734 0.524 rs17791722 ENSG00000258534.1 CTD-2134A5.4 -4.22 3.16e-05 0.00709 -0.25 -0.22 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103819873 chr14:103854366~103880111:- LIHC cis rs4925386 0.959 rs4925385 ENSG00000273619.1 RP5-908M14.9 4.22 3.16e-05 0.00709 0.18 0.22 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62345568 chr20:62386303~62386970:- LIHC cis rs4925386 0.921 rs11204472 ENSG00000273619.1 RP5-908M14.9 4.22 3.16e-05 0.00709 0.18 0.22 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62345831 chr20:62386303~62386970:- LIHC cis rs2348418 0.639 rs11049350 ENSG00000247934.4 RP11-967K21.1 -4.22 3.16e-05 0.00709 -0.2 -0.22 Lung function (FEV1);Lung function (FVC); chr12:28113042 chr12:28163298~28190738:- LIHC cis rs4578769 0.879 rs7243408 ENSG00000265943.1 RP11-739L10.1 4.22 3.16e-05 0.0071 0.28 0.22 Eosinophil percentage of white cells; chr18:22861647 chr18:22699481~22933764:- LIHC cis rs9527 0.59 rs2281877 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103106305 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs10786738 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103109694 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs1807298 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103110461 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs2182348 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103112927 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs1926037 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103118253 chr10:102845595~102845950:+ LIHC cis rs9527 0.567 rs6584539 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103119645 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs2148200 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103120090 chr10:102845595~102845950:+ LIHC cis rs9527 0.614 rs2153774 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103121278 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs10883834 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103121645 chr10:102845595~102845950:+ LIHC cis rs9527 0.545 rs7915816 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103121993 chr10:102845595~102845950:+ LIHC cis rs9527 0.568 rs1926036 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103124055 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs1541213 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103125573 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs10883836 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103131441 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs11191572 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103133380 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs12415199 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103135779 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs34104646 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103136321 chr10:102845595~102845950:+ LIHC cis rs9527 0.567 rs11191573 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103137059 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs11191578 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103142580 chr10:102845595~102845950:+ LIHC cis rs9527 0.641 rs34130454 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103143881 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs7897663 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103145847 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs12775302 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103151599 chr10:102845595~102845950:+ LIHC cis rs9527 0.59 rs12414232 ENSG00000236937.2 PTGES3P4 4.22 3.16e-05 0.0071 0.28 0.22 Arsenic metabolism; chr10:103154734 chr10:102845595~102845950:+ LIHC cis rs2739330 0.652 rs2000469 ENSG00000228039.3 KB-1125A3.10 4.22 3.17e-05 0.0071 0.27 0.22 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23963780~23964374:+ LIHC cis rs1023500 0.573 rs6002592 ENSG00000205702.9 CYP2D7 -4.22 3.17e-05 0.0071 -0.25 -0.22 Schizophrenia; chr22:42080750 chr22:42140203~42144577:- LIHC cis rs10833905 1 rs1465521 ENSG00000246225.5 RP11-17A1.3 -4.22 3.17e-05 0.0071 -0.29 -0.22 Sudden cardiac arrest; chr11:23010880 chr11:22829380~22945393:+ LIHC cis rs11098499 0.955 rs13129661 ENSG00000260091.1 RP11-33B1.4 -4.22 3.17e-05 0.00711 -0.17 -0.22 Corneal astigmatism; chr4:119231754 chr4:119409333~119410233:+ LIHC cis rs4925386 0.625 rs3810550 ENSG00000226332.2 RP11-157P1.4 4.22 3.17e-05 0.00711 0.27 0.22 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62337061 chr20:62305432~62306325:- LIHC cis rs2072438 0.503 rs4837810 ENSG00000226752.6 PSMD5-AS1 -4.22 3.17e-05 0.00711 -0.23 -0.22 Rheumatoid arthritis; chr9:121118921 chr9:120824828~120854385:+ LIHC cis rs9525927 0.553 rs2773283 ENSG00000227258.4 SMIM2-AS1 -4.22 3.17e-05 0.00711 -0.24 -0.22 Dupuytren's disease; chr13:44225727 chr13:44110451~44240517:+ LIHC cis rs1005277 0.522 rs289643 ENSG00000275858.1 RP11-291L22.8 4.22 3.17e-05 0.00711 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:37652566 chr10:38450738~38451069:- LIHC cis rs1799949 1 rs8176109 ENSG00000267681.1 CTD-3199J23.6 -4.22 3.17e-05 0.00711 -0.22 -0.22 Menopause (age at onset); chr17:43113759 chr17:43144956~43145255:+ LIHC cis rs1799949 0.896 rs8176098 ENSG00000267681.1 CTD-3199J23.6 -4.22 3.17e-05 0.00711 -0.22 -0.22 Menopause (age at onset); chr17:43116189 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs11656097 ENSG00000267681.1 CTD-3199J23.6 -4.22 3.17e-05 0.00711 -0.22 -0.22 Menopause (age at onset); chr17:43138596 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs2292595 ENSG00000267681.1 CTD-3199J23.6 -4.22 3.17e-05 0.00711 -0.22 -0.22 Menopause (age at onset); chr17:43138657 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs11658754 ENSG00000267681.1 CTD-3199J23.6 -4.22 3.17e-05 0.00711 -0.22 -0.22 Menopause (age at onset); chr17:43140722 chr17:43144956~43145255:+ LIHC cis rs10129255 0.957 rs10142918 ENSG00000211970.3 IGHV4-61 -4.22 3.17e-05 0.00711 -0.18 -0.22 Kawasaki disease; chr14:106782206 chr14:106639119~106639657:- LIHC cis rs10129255 0.957 rs10142859 ENSG00000211970.3 IGHV4-61 -4.22 3.17e-05 0.00711 -0.18 -0.22 Kawasaki disease; chr14:106782238 chr14:106639119~106639657:- LIHC cis rs10028773 0.515 rs9994488 ENSG00000245958.5 RP11-33B1.1 -4.22 3.17e-05 0.00711 -0.22 -0.22 Educational attainment; chr4:119666626 chr4:119454791~119552025:+ LIHC cis rs7044106 0.791 rs4617229 ENSG00000238181.2 AHCYP2 -4.22 3.17e-05 0.00712 -0.26 -0.22 Hip circumference adjusted for BMI; chr9:120718418 chr9:120720673~120721972:+ LIHC cis rs17818399 0.962 rs7565274 ENSG00000279254.1 RP11-536C12.1 -4.22 3.18e-05 0.00712 -0.28 -0.22 Height; chr2:46614722 chr2:46668870~46670778:+ LIHC cis rs7208859 0.614 rs216412 ENSG00000266490.1 CTD-2349P21.9 -4.22 3.18e-05 0.00712 -0.26 -0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576376 chr17:30792372~30792833:+ LIHC cis rs6921919 0.789 rs1119211 ENSG00000216901.1 AL022393.7 -4.22 3.18e-05 0.00712 -0.28 -0.22 Autism spectrum disorder or schizophrenia; chr6:28341359 chr6:28176188~28176674:+ LIHC cis rs921968 0.565 rs6704575 ENSG00000272555.1 RP11-459I19.1 4.22 3.18e-05 0.00712 0.24 0.22 Mean corpuscular hemoglobin concentration; chr2:218724871 chr2:218818690~218819144:+ LIHC cis rs919433 0.89 rs979020 ENSG00000231621.1 AC013264.2 4.22 3.18e-05 0.00712 0.2 0.22 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197305025 chr2:197197991~197199273:+ LIHC cis rs2439831 0.764 rs12324584 ENSG00000166763.7 STRCP1 4.22 3.18e-05 0.00712 0.31 0.22 Lung cancer in ever smokers; chr15:43391248 chr15:43699488~43718184:- LIHC cis rs2337406 1 rs10459466 ENSG00000274576.2 IGHV2-70 -4.22 3.18e-05 0.00713 -0.26 -0.22 Alzheimer's disease (late onset); chr14:106689255 chr14:106770577~106771020:- LIHC cis rs8177253 0.665 rs9869257 ENSG00000244062.1 RP11-404G16.2 4.22 3.18e-05 0.00713 0.22 0.22 Iron status biomarkers; chr3:133732568 chr3:133760300~133762363:+ LIHC cis rs8177253 0.665 rs9831392 ENSG00000244062.1 RP11-404G16.2 4.22 3.18e-05 0.00713 0.22 0.22 Iron status biomarkers; chr3:133732629 chr3:133760300~133762363:+ LIHC cis rs2070488 1 rs13058903 ENSG00000229589.1 ACVR2B-AS1 -4.22 3.18e-05 0.00713 -0.25 -0.22 Electrocardiographic conduction measures; chr3:38471874 chr3:38451027~38454820:- LIHC cis rs597539 0.652 rs544370 ENSG00000250508.1 RP11-757G1.6 -4.22 3.18e-05 0.00713 -0.32 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68885764 chr11:68870664~68874542:+ LIHC cis rs9907295 1 rs9908525 ENSG00000270871.1 AC015849.19 4.22 3.19e-05 0.00714 0.24 0.22 Fibroblast growth factor basic levels; chr17:35908605 chr17:35816717~35830293:- LIHC cis rs7208859 0.673 rs78799101 ENSG00000266490.1 CTD-2349P21.9 4.22 3.19e-05 0.00714 0.29 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888142 chr17:30792372~30792833:+ LIHC cis rs950881 0.799 rs72823669 ENSG00000234389.1 AC007278.3 4.22 3.19e-05 0.00714 0.3 0.22 Allergy; chr2:102365573 chr2:102438713~102440475:+ LIHC cis rs17214007 0.877 rs2075515 ENSG00000263335.1 AF001548.5 -4.22 3.19e-05 0.00714 -0.29 -0.22 Cognitive function; chr16:15778462 chr16:15726674~15732993:+ LIHC cis rs2243480 0.908 rs55876148 ENSG00000232546.1 RP11-458F8.1 -4.22 3.19e-05 0.00714 -0.25 -0.22 Diabetic kidney disease; chr7:65914813 chr7:66848496~66858136:+ LIHC cis rs7635879 0.702 rs4687494 ENSG00000230102.6 RP11-407B7.1 -4.22 3.19e-05 0.00715 -0.21 -0.22 Breastfeeding duration; chr3:194010581 chr3:194005259~194070970:- LIHC cis rs875971 0.545 rs6460298 ENSG00000228409.4 CCT6P1 -4.22 3.19e-05 0.00715 -0.19 -0.22 Aortic root size; chr7:66442783 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs35459055 ENSG00000228409.4 CCT6P1 -4.22 3.19e-05 0.00715 -0.19 -0.22 Aortic root size; chr7:66479399 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs75577046 ENSG00000228409.4 CCT6P1 -4.22 3.19e-05 0.00715 -0.19 -0.22 Aortic root size; chr7:66493729 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs3735147 ENSG00000228409.4 CCT6P1 -4.22 3.19e-05 0.00715 -0.19 -0.22 Aortic root size; chr7:66505541 chr7:65751142~65763354:+ LIHC cis rs893363 0.522 rs2241807 ENSG00000271916.1 RP11-884K10.6 -4.22 3.19e-05 0.00715 -0.27 -0.22 Axial length; chr3:53823131 chr3:53797764~53798019:- LIHC cis rs7044106 0.791 rs2416797 ENSG00000238181.2 AHCYP2 -4.22 3.19e-05 0.00715 -0.26 -0.22 Hip circumference adjusted for BMI; chr9:120718322 chr9:120720673~120721972:+ LIHC cis rs7044106 0.791 rs2416798 ENSG00000238181.2 AHCYP2 -4.22 3.19e-05 0.00715 -0.26 -0.22 Hip circumference adjusted for BMI; chr9:120718325 chr9:120720673~120721972:+ LIHC cis rs2998286 0.636 rs2772436 ENSG00000254635.4 WAC-AS1 -4.22 3.19e-05 0.00715 -0.27 -0.22 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28644655 chr10:28522652~28532743:- LIHC cis rs6700559 0.683 rs7548530 ENSG00000260088.1 RP11-92G12.3 -4.22 3.19e-05 0.00715 -0.28 -0.22 Coronary artery disease; chr1:200687904 chr1:200669507~200694250:+ LIHC cis rs6700559 0.683 rs7526136 ENSG00000260088.1 RP11-92G12.3 -4.22 3.19e-05 0.00715 -0.28 -0.22 Coronary artery disease; chr1:200687911 chr1:200669507~200694250:+ LIHC cis rs6700559 0.733 rs7526265 ENSG00000260088.1 RP11-92G12.3 -4.22 3.19e-05 0.00715 -0.28 -0.22 Coronary artery disease; chr1:200687916 chr1:200669507~200694250:+ LIHC cis rs853679 0.628 rs9368560 ENSG00000219392.1 RP1-265C24.5 -4.22 3.19e-05 0.00715 -0.36 -0.22 Depression; chr6:28192182 chr6:28115628~28116551:+ LIHC cis rs9952991 0.941 rs2542151 ENSG00000260302.1 RP11-973H7.1 -4.22 3.2e-05 0.00716 -0.33 -0.22 Inflammatory skin disease; chr18:12779948 chr18:12774651~12775923:- LIHC cis rs875971 1 rs4717292 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66430611 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs2420591 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66447394 chr7:66493706~66495474:+ LIHC cis rs875971 0.895 rs10755833 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66448930 chr7:66493706~66495474:+ LIHC cis rs875971 0.964 rs12668936 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66449417 chr7:66493706~66495474:+ LIHC cis rs875971 0.895 rs1833495 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66456608 chr7:66493706~66495474:+ LIHC cis rs875971 0.964 rs6945032 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66457499 chr7:66493706~66495474:+ LIHC cis rs875971 0.929 rs12673810 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66458866 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs35149210 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66464938 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs6961155 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66468308 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs7789768 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66473993 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs1363055 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66478288 chr7:66493706~66495474:+ LIHC cis rs875971 0.964 rs9691480 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66479319 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs7789554 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66481051 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs4717300 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66482393 chr7:66493706~66495474:+ LIHC cis rs875971 0.895 rs1974769 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66485627 chr7:66493706~66495474:+ LIHC cis rs875971 0.895 rs6460300 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66487937 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs7803416 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66489212 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs1981799 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66490572 chr7:66493706~66495474:+ LIHC cis rs875971 0.964 rs2277911 ENSG00000237310.1 GS1-124K5.4 4.22 3.2e-05 0.00716 0.2 0.22 Aortic root size; chr7:66493638 chr7:66493706~66495474:+ LIHC cis rs3795324 0.793 rs60294056 ENSG00000227741.1 RP11-536C5.7 -4.22 3.2e-05 0.00716 -0.31 -0.22 Microalbuminuria; chr1:160661318 chr1:160202199~160208869:- LIHC cis rs2274273 1 rs7160110 ENSG00000258413.1 RP11-665C16.6 -4.22 3.2e-05 0.00716 -0.26 -0.22 Protein biomarker; chr14:55127917 chr14:55262767~55272075:- LIHC cis rs1075232 1 rs66581165 ENSG00000270055.1 CTD-3092A11.2 -4.22 3.2e-05 0.00716 -0.43 -0.22 Survival in colorectal cancer (non-distant metastatic); chr15:31451564 chr15:30487963~30490313:+ LIHC cis rs1075265 0.54 rs2542587 ENSG00000272156.1 RP11-477N3.1 -4.22 3.2e-05 0.00716 -0.27 -0.22 Chronotype;Morning vs. evening chronotype; chr2:53788839 chr2:54082554~54085066:+ LIHC cis rs1075265 0.563 rs2692537 ENSG00000272156.1 RP11-477N3.1 -4.22 3.2e-05 0.00716 -0.27 -0.22 Chronotype;Morning vs. evening chronotype; chr2:53788840 chr2:54082554~54085066:+ LIHC cis rs7937890 0.572 rs2597202 ENSG00000251991.1 RNU7-49P 4.21 3.2e-05 0.00717 0.25 0.22 Mitochondrial DNA levels; chr11:14463099 chr11:14478892~14478953:+ LIHC cis rs7809950 1 rs7793613 ENSG00000238832.1 snoU109 -4.21 3.2e-05 0.00717 -0.26 -0.22 Coronary artery disease; chr7:107610039 chr7:107603363~107603507:+ LIHC cis rs11098499 0.908 rs1002152 ENSG00000260091.1 RP11-33B1.4 -4.21 3.2e-05 0.00717 -0.16 -0.22 Corneal astigmatism; chr4:119352232 chr4:119409333~119410233:+ LIHC cis rs1405130 0.869 rs12995365 ENSG00000224287.2 MSL3P1 4.21 3.2e-05 0.00717 0.27 0.22 Coronary artery disease; chr2:234657059 chr2:233865437~233868444:- LIHC cis rs12157904 1 rs5995478 ENSG00000233360.4 Z83844.1 4.21 3.2e-05 0.00717 0.47 0.22 Response to anti-depressant treatment in major depressive disorder; chr22:37604461 chr22:37641832~37658377:- LIHC cis rs6439153 0.933 rs810952 ENSG00000231305.3 RP11-723O4.2 4.21 3.2e-05 0.00717 0.24 0.22 Pneumococcal bacteremia; chr3:128967062 chr3:128861313~128871540:- LIHC cis rs11098499 1 rs35643470 ENSG00000260091.1 RP11-33B1.4 -4.21 3.21e-05 0.00718 -0.16 -0.22 Corneal astigmatism; chr4:119263793 chr4:119409333~119410233:+ LIHC cis rs11971779 0.68 rs73154134 ENSG00000273391.1 RP11-634H22.1 4.21 3.21e-05 0.00718 0.22 0.22 Diisocyanate-induced asthma; chr7:139355205 chr7:139359032~139359566:- LIHC cis rs6445975 0.915 rs11130633 ENSG00000272360.1 RP11-359I18.5 4.21 3.21e-05 0.00718 0.27 0.22 Systemic lupus erythematosus; chr3:58385065 chr3:58490830~58491291:- LIHC cis rs950169 0.58 rs4603535 ENSG00000225151.9 GOLGA2P7 -4.21 3.21e-05 0.00718 -0.28 -0.22 Schizophrenia; chr15:84630641 chr15:84199311~84230136:- LIHC cis rs2439831 0.867 rs2447196 ENSG00000166763.7 STRCP1 -4.21 3.21e-05 0.00718 -0.34 -0.22 Lung cancer in ever smokers; chr15:43601620 chr15:43699488~43718184:- LIHC cis rs12701220 0.817 rs7798459 ENSG00000229043.2 AC091729.9 -4.21 3.21e-05 0.00719 -0.3 -0.22 Bronchopulmonary dysplasia; chr7:1048329 chr7:1160374~1165267:+ LIHC cis rs7208859 0.573 rs8078182 ENSG00000266490.1 CTD-2349P21.9 4.21 3.21e-05 0.00719 0.27 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822646 chr17:30792372~30792833:+ LIHC cis rs6504622 0.755 rs11079750 ENSG00000262879.4 RP11-156P1.3 -4.21 3.21e-05 0.00719 -0.23 -0.22 Orofacial clefts; chr17:47072149 chr17:46984045~47100323:- LIHC cis rs2439831 1 rs9920763 ENSG00000205771.5 CATSPER2P1 -4.21 3.21e-05 0.00719 -0.37 -0.22 Lung cancer in ever smokers; chr15:43468310 chr15:43726918~43747094:- LIHC cis rs673078 0.66 rs2280711 ENSG00000275409.1 RP11-131L12.4 -4.21 3.21e-05 0.00719 -0.28 -0.22 Glucose homeostasis traits; chr12:118212149 chr12:118430147~118430699:+ LIHC cis rs794185 0.714 rs2633860 ENSG00000231249.1 ITPR1-AS1 -4.21 3.21e-05 0.00719 -0.25 -0.22 Multiple sclerosis--Brain Glutamate Levels; chr3:4457662 chr3:4490891~4493163:- LIHC cis rs6061231 0.556 rs6121571 ENSG00000226332.2 RP11-157P1.4 4.21 3.21e-05 0.00719 0.25 0.22 Colorectal cancer; chr20:62402267 chr20:62305432~62306325:- LIHC cis rs875971 0.83 rs587360 ENSG00000232559.3 GS1-124K5.12 4.21 3.22e-05 0.00719 0.18 0.22 Aortic root size; chr7:66057711 chr7:66554588~66576923:- LIHC cis rs193541 0.53 rs9327272 ENSG00000263432.2 RN7SL689P 4.21 3.22e-05 0.0072 0.33 0.22 Glucose homeostasis traits; chr5:122737853 chr5:123022487~123022783:- LIHC cis rs9467711 0.591 rs68149500 ENSG00000216436.2 HIST1H2APS1 4.21 3.22e-05 0.0072 0.58 0.22 Autism spectrum disorder or schizophrenia; chr6:26111043 chr6:25732497~25732827:+ LIHC cis rs169313 0.556 rs7220819 ENSG00000263400.5 TMEM220-AS1 -4.21 3.22e-05 0.0072 -0.27 -0.22 Relative hand skill in reading disability; chr17:10663157 chr17:10729777~10815164:+ LIHC cis rs3096299 0.781 rs3102381 ENSG00000261118.1 RP11-104N10.1 4.21 3.22e-05 0.00721 0.22 0.22 Multiple myeloma (IgH translocation); chr16:89343312 chr16:89492017~89504460:- LIHC cis rs295490 0.667 rs78684868 ENSG00000272656.1 RP11-219D15.3 4.21 3.22e-05 0.00721 0.65 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139485651 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs74636199 ENSG00000272656.1 RP11-219D15.3 4.21 3.22e-05 0.00721 0.65 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139493679 chr3:139349024~139349371:- LIHC cis rs673078 0.607 rs11068926 ENSG00000275409.1 RP11-131L12.4 -4.21 3.22e-05 0.00721 -0.28 -0.22 Glucose homeostasis traits; chr12:118367320 chr12:118430147~118430699:+ LIHC cis rs2998286 0.597 rs1272396 ENSG00000254635.4 WAC-AS1 -4.21 3.22e-05 0.00721 -0.27 -0.22 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28643416 chr10:28522652~28532743:- LIHC cis rs9487094 0.744 rs11964533 ENSG00000260273.1 RP11-425D10.10 4.21 3.22e-05 0.00721 0.31 0.22 Height; chr6:109737797 chr6:109382795~109383666:+ LIHC cis rs8177376 0.581 rs512577 ENSG00000254905.1 RP11-712L6.7 -4.21 3.22e-05 0.00721 -0.24 -0.22 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126222046 chr11:126292922~126294254:- LIHC cis rs875971 0.545 rs73376394 ENSG00000228409.4 CCT6P1 -4.21 3.22e-05 0.00721 -0.18 -0.22 Aortic root size; chr7:66172694 chr7:65751142~65763354:+ LIHC cis rs6545883 0.524 rs811871 ENSG00000271889.1 RP11-493E12.1 -4.21 3.23e-05 0.00721 -0.27 -0.22 Tuberculosis; chr2:61350814 chr2:61151433~61162105:- LIHC cis rs11079159 0.637 rs4147524 ENSG00000263096.1 RP11-515O17.2 4.21 3.23e-05 0.00721 0.39 0.22 QRS duration; chr17:55274249 chr17:55271504~55273653:- LIHC cis rs2562456 0.876 rs11085465 ENSG00000268555.1 RP11-678G14.3 -4.21 3.23e-05 0.00721 -0.28 -0.22 Pain; chr19:21568988 chr19:21570822~21587322:- LIHC cis rs7714584 0.793 rs11949375 ENSG00000197083.10 ZNF300P1 4.21 3.23e-05 0.00722 0.35 0.22 Crohn's disease; chr5:150823418 chr5:150930645~150946289:- LIHC cis rs11690935 0.632 rs34242651 ENSG00000228389.1 AC068039.4 -4.21 3.23e-05 0.00722 -0.26 -0.22 Schizophrenia; chr2:171697489 chr2:171773482~171775844:+ LIHC cis rs9450351 0.744 rs7744309 ENSG00000203875.9 SNHG5 -4.21 3.23e-05 0.00723 -0.47 -0.22 Interferon gamma-induced protein 10 levels; chr6:85556764 chr6:85660950~85678736:- LIHC cis rs5758511 0.689 rs62240864 ENSG00000237037.8 NDUFA6-AS1 -4.21 3.23e-05 0.00723 -0.46 -0.22 Birth weight; chr22:42167883 chr22:42090931~42137742:+ LIHC cis rs1075265 0.587 rs2949811 ENSG00000272156.1 RP11-477N3.1 -4.21 3.23e-05 0.00723 -0.27 -0.22 Chronotype;Morning vs. evening chronotype; chr2:53797028 chr2:54082554~54085066:+ LIHC cis rs1115240 0.898 rs11159911 ENSG00000257842.4 NOVA1-AS1 -4.21 3.24e-05 0.00723 -0.21 -0.22 Educational attainment (years of education); chr14:26594193 chr14:26598412~26806467:+ LIHC cis rs4356975 0.932 rs7654272 ENSG00000250919.1 RP11-813N20.3 -4.21 3.24e-05 0.00724 -0.22 -0.22 Obesity-related traits; chr4:69074144 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs6600867 ENSG00000250919.1 RP11-813N20.3 -4.21 3.24e-05 0.00724 -0.22 -0.22 Obesity-related traits; chr4:69074157 chr4:69027831~69044578:+ LIHC cis rs938554 0.513 rs1014290 ENSG00000250413.1 RP11-448G15.1 -4.21 3.24e-05 0.00724 -0.3 -0.22 Blood metabolite levels; chr4:10000237 chr4:10006482~10009725:+ LIHC cis rs11098499 0.863 rs3822192 ENSG00000260091.1 RP11-33B1.4 -4.21 3.24e-05 0.00724 -0.16 -0.22 Corneal astigmatism; chr4:119524565 chr4:119409333~119410233:+ LIHC cis rs948562 0.947 rs7945889 ENSG00000280010.1 AP001350.4 4.21 3.24e-05 0.00724 0.39 0.22 Lymphoma; chr11:58609262 chr11:58627435~58628528:+ LIHC cis rs7474896 0.559 rs10740949 ENSG00000263064.2 RP11-291L22.7 4.21 3.24e-05 0.00724 0.27 0.22 Obesity (extreme); chr10:37689507 chr10:38448689~38448949:+ LIHC cis rs7474896 0.609 rs11011336 ENSG00000263064.2 RP11-291L22.7 4.21 3.24e-05 0.00724 0.27 0.22 Obesity (extreme); chr10:37696388 chr10:38448689~38448949:+ LIHC cis rs7474896 0.583 rs4934898 ENSG00000263064.2 RP11-291L22.7 4.21 3.24e-05 0.00724 0.27 0.22 Obesity (extreme); chr10:37701467 chr10:38448689~38448949:+ LIHC cis rs17774123 0.901 rs79373064 ENSG00000257808.1 RP11-1136G11.8 4.21 3.24e-05 0.00724 0.4 0.22 Diastolic blood pressure; chr12:53867904 chr12:53159586~53161000:+ LIHC cis rs6997458 0.742 rs7841178 ENSG00000253549.4 RP11-317J10.2 -4.21 3.24e-05 0.00725 -0.24 -0.22 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85425690 chr8:85441851~85464915:- LIHC cis rs755249 0.588 rs2275767 ENSG00000182109.6 RP11-69E11.4 -4.21 3.24e-05 0.00725 -0.23 -0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39479625 chr1:39522280~39546187:- LIHC cis rs7208859 0.623 rs58908911 ENSG00000266490.1 CTD-2349P21.9 4.21 3.24e-05 0.00725 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917540 chr17:30792372~30792833:+ LIHC cis rs7246657 1 rs6508710 ENSG00000276846.1 CTD-3220F14.3 4.21 3.24e-05 0.00725 0.27 0.22 Coronary artery calcification; chr19:37258984 chr19:37314868~37315620:- LIHC cis rs875971 0.895 rs12698520 ENSG00000237310.1 GS1-124K5.4 4.21 3.25e-05 0.00725 0.2 0.22 Aortic root size; chr7:66453720 chr7:66493706~66495474:+ LIHC cis rs7044106 0.762 rs10818471 ENSG00000238181.2 AHCYP2 -4.21 3.25e-05 0.00725 -0.26 -0.22 Hip circumference adjusted for BMI; chr9:120631767 chr9:120720673~120721972:+ LIHC cis rs2744375 0.6 rs2744372 ENSG00000261189.1 RP3-512B11.3 -4.21 3.25e-05 0.00725 -0.27 -0.22 Resting heart rate; chr6:7554233 chr6:7540451~7541338:- LIHC cis rs12908161 0.959 rs17598603 ENSG00000225151.9 GOLGA2P7 4.21 3.25e-05 0.00726 0.28 0.22 Schizophrenia; chr15:84656980 chr15:84199311~84230136:- LIHC cis rs755249 0.567 rs61779306 ENSG00000182109.6 RP11-69E11.4 4.21 3.25e-05 0.00726 0.31 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39456754 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs41270821 ENSG00000182109.6 RP11-69E11.4 4.21 3.25e-05 0.00726 0.31 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39458060 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs2296175 ENSG00000182109.6 RP11-69E11.4 4.21 3.25e-05 0.00726 0.31 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39458726 chr1:39522280~39546187:- LIHC cis rs1005277 0.691 rs2474558 ENSG00000120555.12 SEPT7P9 -4.21 3.25e-05 0.00727 -0.27 -0.22 Extrinsic epigenetic age acceleration; chr10:38197213 chr10:38383069~38402916:- LIHC cis rs673078 0.66 rs11068917 ENSG00000275759.1 RP11-131L12.3 -4.21 3.25e-05 0.00727 -0.28 -0.22 Glucose homeostasis traits; chr12:118353315 chr12:118428281~118428870:+ LIHC cis rs4578769 0.959 rs9961893 ENSG00000265943.1 RP11-739L10.1 4.21 3.25e-05 0.00727 0.28 0.22 Eosinophil percentage of white cells; chr18:22849805 chr18:22699481~22933764:- LIHC cis rs4578769 0.959 rs11082169 ENSG00000265943.1 RP11-739L10.1 4.21 3.25e-05 0.00727 0.28 0.22 Eosinophil percentage of white cells; chr18:22850034 chr18:22699481~22933764:- LIHC cis rs4578769 0.959 rs2100191 ENSG00000265943.1 RP11-739L10.1 4.21 3.25e-05 0.00727 0.28 0.22 Eosinophil percentage of white cells; chr18:22851428 chr18:22699481~22933764:- LIHC cis rs4578769 0.959 rs2100190 ENSG00000265943.1 RP11-739L10.1 4.21 3.25e-05 0.00727 0.28 0.22 Eosinophil percentage of white cells; chr18:22851857 chr18:22699481~22933764:- LIHC cis rs72675573 0.852 rs12145789 ENSG00000235612.1 RP1-158P9.1 -4.21 3.26e-05 0.00727 -0.29 -0.22 Monocyte count; chr1:56141397 chr1:56145721~56155224:+ LIHC cis rs72675573 0.852 rs72675557 ENSG00000235612.1 RP1-158P9.1 -4.21 3.26e-05 0.00727 -0.29 -0.22 Monocyte count; chr1:56142821 chr1:56145721~56155224:+ LIHC cis rs72675573 0.852 rs12118277 ENSG00000235612.1 RP1-158P9.1 -4.21 3.26e-05 0.00727 -0.29 -0.22 Monocyte count; chr1:56143624 chr1:56145721~56155224:+ LIHC cis rs72675573 0.852 rs12142826 ENSG00000235612.1 RP1-158P9.1 -4.21 3.26e-05 0.00727 -0.29 -0.22 Monocyte count; chr1:56146214 chr1:56145721~56155224:+ LIHC cis rs6723226 0.65 rs6729952 ENSG00000276334.1 AL133243.1 4.21 3.26e-05 0.00728 0.24 0.22 Intelligence (multi-trait analysis); chr2:32539855 chr2:32521927~32523547:+ LIHC cis rs1577917 1 rs12215903 ENSG00000234155.1 RP11-30P6.6 4.21 3.26e-05 0.00728 0.29 0.22 Response to antipsychotic treatment; chr6:85965310 chr6:85387219~85390186:- LIHC cis rs11098499 0.863 rs9884402 ENSG00000260091.1 RP11-33B1.4 -4.21 3.26e-05 0.00728 -0.16 -0.22 Corneal astigmatism; chr4:119568827 chr4:119409333~119410233:+ LIHC cis rs11098499 0.731 rs9995026 ENSG00000260091.1 RP11-33B1.4 -4.21 3.26e-05 0.00728 -0.16 -0.22 Corneal astigmatism; chr4:119569344 chr4:119409333~119410233:+ LIHC cis rs2581828 0.965 rs2581829 ENSG00000242142.1 SERBP1P3 -4.21 3.26e-05 0.00728 -0.25 -0.22 Crohn's disease; chr3:53099510 chr3:53064283~53065091:- LIHC cis rs2658782 0.951 rs117384439 ENSG00000279684.1 RP11-755E23.2 4.21 3.26e-05 0.00728 0.38 0.22 Pulmonary function decline; chr11:93378312 chr11:93286629~93288903:- LIHC cis rs8024893 1 rs8038787 ENSG00000270055.1 CTD-3092A11.2 4.21 3.26e-05 0.00728 0.31 0.22 Red cell distribution width; chr15:31246171 chr15:30487963~30490313:+ LIHC cis rs193541 0.632 rs30036 ENSG00000263432.2 RN7SL689P 4.21 3.26e-05 0.00728 0.35 0.22 Glucose homeostasis traits; chr5:122942565 chr5:123022487~123022783:- LIHC cis rs709400 0.859 rs7154948 ENSG00000258534.1 CTD-2134A5.4 4.21 3.26e-05 0.00728 0.34 0.22 Body mass index; chr14:103556607 chr14:103854366~103880111:- LIHC cis rs17772222 0.876 rs12436982 ENSG00000258789.1 RP11-507K2.3 -4.21 3.26e-05 0.00728 -0.26 -0.22 Coronary artery calcification; chr14:88689862 chr14:88551597~88552493:+ LIHC cis rs2581828 0.646 rs3796351 ENSG00000242142.1 SERBP1P3 4.21 3.26e-05 0.00728 0.29 0.22 Crohn's disease; chr3:53122049 chr3:53064283~53065091:- LIHC cis rs9807989 0.507 rs3755266 ENSG00000234389.1 AC007278.3 4.21 3.26e-05 0.00728 0.24 0.22 Asthma; chr2:102426252 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs2110659 ENSG00000234389.1 AC007278.3 4.21 3.26e-05 0.00728 0.24 0.22 Asthma; chr2:102427407 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs7605284 ENSG00000234389.1 AC007278.3 4.21 3.26e-05 0.00728 0.24 0.22 Asthma; chr2:102427715 chr2:102438713~102440475:+ LIHC cis rs4988958 0.584 rs12712149 ENSG00000234389.1 AC007278.3 4.21 3.26e-05 0.00728 0.24 0.22 Asthma (childhood onset); chr2:102428733 chr2:102438713~102440475:+ LIHC cis rs4988958 0.584 rs7559845 ENSG00000234389.1 AC007278.3 4.21 3.26e-05 0.00728 0.24 0.22 Asthma (childhood onset); chr2:102429754 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs6755905 ENSG00000234389.1 AC007278.3 4.21 3.26e-05 0.00728 0.24 0.22 Asthma; chr2:102431747 chr2:102438713~102440475:+ LIHC cis rs4988958 0.527 rs6756161 ENSG00000234389.1 AC007278.3 4.21 3.26e-05 0.00728 0.24 0.22 Asthma (childhood onset); chr2:102431957 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs6726985 ENSG00000234389.1 AC007278.3 4.21 3.26e-05 0.00728 0.24 0.22 Asthma; chr2:102432120 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs2310300 ENSG00000234389.1 AC007278.3 4.21 3.26e-05 0.00728 0.24 0.22 Asthma; chr2:102432614 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs7581119 ENSG00000234389.1 AC007278.3 4.21 3.26e-05 0.00728 0.24 0.22 Asthma; chr2:102433405 chr2:102438713~102440475:+ LIHC cis rs4925386 1 rs6089351 ENSG00000226332.2 RP11-157P1.4 -4.21 3.26e-05 0.00729 -0.23 -0.22 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62341097 chr20:62305432~62306325:- LIHC cis rs4925386 0.959 rs6121989 ENSG00000226332.2 RP11-157P1.4 -4.21 3.26e-05 0.00729 -0.23 -0.22 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62341657 chr20:62305432~62306325:- LIHC cis rs10833905 0.941 rs11026897 ENSG00000246225.5 RP11-17A1.3 -4.21 3.27e-05 0.00729 -0.29 -0.22 Sudden cardiac arrest; chr11:23005501 chr11:22829380~22945393:+ LIHC cis rs6442522 1 rs6442522 ENSG00000249786.6 EAF1-AS1 4.21 3.27e-05 0.00729 0.25 0.22 Uric acid levels; chr3:15399049 chr3:15436171~15455940:- LIHC cis rs763512 0.504 rs1051838 ENSG00000276054.1 RP11-378E13.3 4.21 3.27e-05 0.00729 0.28 0.22 3-hydroxypropylmercapturic acid levels in smokers; chr17:37510731 chr17:37386886~37387926:+ LIHC cis rs7412746 0.658 rs7526489 ENSG00000231073.1 RP11-316M1.3 4.21 3.27e-05 0.0073 0.23 0.22 Melanoma; chr1:150753762 chr1:150973123~150975534:+ LIHC cis rs11096990 0.855 rs4974986 ENSG00000249207.1 RP11-360F5.1 4.21 3.27e-05 0.0073 0.25 0.22 Cognitive function; chr4:39165308 chr4:39112677~39126818:- LIHC cis rs9595908 0.785 rs9596032 ENSG00000212293.1 SNORA16 4.21 3.27e-05 0.0073 0.25 0.22 Body mass index; chr13:32654708 chr13:32420390~32420516:- LIHC cis rs9595908 0.746 rs2301393 ENSG00000212293.1 SNORA16 4.21 3.27e-05 0.0073 0.25 0.22 Body mass index; chr13:32658298 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs7985656 ENSG00000212293.1 SNORA16 4.21 3.27e-05 0.0073 0.25 0.22 Body mass index; chr13:32664414 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs9596056 ENSG00000212293.1 SNORA16 4.21 3.27e-05 0.0073 0.25 0.22 Body mass index; chr13:32669402 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs3783267 ENSG00000212293.1 SNORA16 4.21 3.27e-05 0.0073 0.25 0.22 Body mass index; chr13:32670719 chr13:32420390~32420516:- LIHC cis rs9303401 0.703 rs8077052 ENSG00000265415.1 CTD-2510F5.4 4.21 3.28e-05 0.00731 0.16 0.22 Cognitive test performance; chr17:59131560 chr17:59202677~59203829:- LIHC cis rs2749592 0.918 rs1208653 ENSG00000263064.2 RP11-291L22.7 -4.21 3.28e-05 0.00731 -0.24 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37964898 chr10:38448689~38448949:+ LIHC cis rs2120243 0.533 rs1500921 ENSG00000244515.1 KRT18P34 -4.21 3.28e-05 0.00731 -0.21 -0.22 Hepatocellular carcinoma in hepatitis B infection; chr3:157337638 chr3:157162663~157163932:- LIHC cis rs2120243 0.533 rs62278578 ENSG00000244515.1 KRT18P34 -4.21 3.28e-05 0.00731 -0.21 -0.22 Hepatocellular carcinoma in hepatitis B infection; chr3:157338078 chr3:157162663~157163932:- LIHC cis rs651907 0.557 rs34624546 ENSG00000244119.1 PDCL3P4 4.21 3.28e-05 0.00731 0.23 0.22 Colorectal cancer; chr3:101655382 chr3:101712472~101713191:+ LIHC cis rs11096990 0.634 rs12648793 ENSG00000249207.1 RP11-360F5.1 4.21 3.28e-05 0.00732 0.22 0.22 Cognitive function; chr4:39284473 chr4:39112677~39126818:- LIHC cis rs673078 0.66 rs11068891 ENSG00000275759.1 RP11-131L12.3 4.21 3.28e-05 0.00732 0.29 0.22 Glucose homeostasis traits; chr12:118259814 chr12:118428281~118428870:+ LIHC cis rs2562456 0.837 rs62110205 ENSG00000268555.1 RP11-678G14.3 4.21 3.28e-05 0.00732 0.29 0.22 Pain; chr19:21577269 chr19:21570822~21587322:- LIHC cis rs603446 0.703 rs1263151 ENSG00000254851.1 RP11-109L13.1 -4.21 3.28e-05 0.00732 -0.26 -0.22 Triglycerides; chr11:116770312 chr11:117135528~117138582:+ LIHC cis rs160451 0.966 rs183363 ENSG00000251136.7 RP11-37B2.1 4.21 3.28e-05 0.00732 0.21 0.22 Leprosy; chr8:89665951 chr8:89609409~89757727:- LIHC cis rs2919917 0.628 rs1036751 ENSG00000254352.1 RP11-578O24.2 -4.21 3.29e-05 0.00733 -0.34 -0.22 Lymphocyte counts; chr8:78729671 chr8:78723796~78724136:- LIHC cis rs7208859 0.673 rs11654331 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30837999 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs73277964 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30852183 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs11652409 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30855689 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9896095 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30860479 chr17:30792372~30792833:+ LIHC cis rs7208859 0.573 rs58920731 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30864728 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs73277984 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869115 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs73277986 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869179 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs12103588 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30870442 chr17:30792372~30792833:+ LIHC cis rs7208859 0.614 rs9914534 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30875646 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs11658344 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30880727 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs9900144 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881371 chr17:30792372~30792833:+ LIHC cis rs7208859 0.573 rs11656121 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887025 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs11650973 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887027 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs56085216 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30890216 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs11650305 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902343 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs11654914 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902406 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9914271 ENSG00000266490.1 CTD-2349P21.9 4.21 3.29e-05 0.00733 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905607 chr17:30792372~30792833:+ LIHC cis rs2911132 0.62 rs1065407 ENSG00000248734.2 CTD-2260A17.1 4.21 3.29e-05 0.00733 0.3 0.22 Urate levels (BMI interaction); chr5:96776379 chr5:96784777~96785999:+ LIHC cis rs7044106 0.791 rs2416799 ENSG00000238181.2 AHCYP2 -4.21 3.29e-05 0.00733 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120718588 chr9:120720673~120721972:+ LIHC cis rs7044106 0.791 rs10984998 ENSG00000238181.2 AHCYP2 -4.21 3.29e-05 0.00733 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120719238 chr9:120720673~120721972:+ LIHC cis rs1005277 0.579 rs932538 ENSG00000275858.1 RP11-291L22.8 4.21 3.29e-05 0.00733 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:38092386 chr10:38450738~38451069:- LIHC cis rs1005277 0.541 rs2472177 ENSG00000275858.1 RP11-291L22.8 4.21 3.29e-05 0.00733 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:38095087 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2472178 ENSG00000275858.1 RP11-291L22.8 4.21 3.29e-05 0.00733 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:38095822 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474572 ENSG00000275858.1 RP11-291L22.8 4.21 3.29e-05 0.00733 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:38096388 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2505198 ENSG00000275858.1 RP11-291L22.8 4.21 3.29e-05 0.00733 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:38104255 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2008449 ENSG00000275858.1 RP11-291L22.8 -4.21 3.29e-05 0.00733 -0.24 -0.22 Extrinsic epigenetic age acceleration; chr10:38125276 chr10:38450738~38451069:- LIHC cis rs2932538 0.961 rs6690292 ENSG00000225075.1 RP11-426L16.3 -4.21 3.29e-05 0.00733 -0.28 -0.22 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112645797 chr1:112693688~112696621:- LIHC cis rs11098499 0.955 rs56386062 ENSG00000260091.1 RP11-33B1.4 -4.21 3.29e-05 0.00733 -0.17 -0.22 Corneal astigmatism; chr4:119233980 chr4:119409333~119410233:+ LIHC cis rs11098499 0.955 rs4145951 ENSG00000260091.1 RP11-33B1.4 -4.21 3.29e-05 0.00733 -0.17 -0.22 Corneal astigmatism; chr4:119234662 chr4:119409333~119410233:+ LIHC cis rs11098499 0.955 rs35916640 ENSG00000260091.1 RP11-33B1.4 -4.21 3.29e-05 0.00733 -0.17 -0.22 Corneal astigmatism; chr4:119234697 chr4:119409333~119410233:+ LIHC cis rs11098499 0.955 rs13113112 ENSG00000260091.1 RP11-33B1.4 -4.21 3.29e-05 0.00733 -0.17 -0.22 Corneal astigmatism; chr4:119234885 chr4:119409333~119410233:+ LIHC cis rs11676348 0.71 rs11894169 ENSG00000261338.2 RP11-378A13.1 4.21 3.29e-05 0.00733 0.24 0.22 Ulcerative colitis; chr2:218182123 chr2:218255319~218257366:+ LIHC cis rs763121 0.819 rs5757161 ENSG00000273076.1 RP3-508I15.22 4.21 3.29e-05 0.00733 0.25 0.22 Menopause (age at onset); chr22:38594657 chr22:38743495~38743910:+ LIHC cis rs763121 0.925 rs5757165 ENSG00000273076.1 RP3-508I15.22 4.21 3.29e-05 0.00733 0.25 0.22 Menopause (age at onset); chr22:38598572 chr22:38743495~38743910:+ LIHC cis rs763121 0.925 rs4821797 ENSG00000273076.1 RP3-508I15.22 4.21 3.29e-05 0.00733 0.25 0.22 Menopause (age at onset); chr22:38620177 chr22:38743495~38743910:+ LIHC cis rs2243480 0.908 rs55876148 ENSG00000228409.4 CCT6P1 4.21 3.29e-05 0.00734 0.24 0.22 Diabetic kidney disease; chr7:65914813 chr7:65751142~65763354:+ LIHC cis rs7044106 0.718 rs1960421 ENSG00000238181.2 AHCYP2 -4.21 3.29e-05 0.00734 -0.26 -0.22 Hip circumference adjusted for BMI; chr9:120632616 chr9:120720673~120721972:+ LIHC cis rs75920871 0.544 rs76868258 ENSG00000254851.1 RP11-109L13.1 -4.21 3.3e-05 0.00734 -0.45 -0.22 Subjective well-being; chr11:117122576 chr11:117135528~117138582:+ LIHC cis rs4356203 0.87 rs7937176 ENSG00000260196.1 RP1-239B22.5 -4.21 3.3e-05 0.00734 -0.26 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17258198 chr11:17380649~17383531:+ LIHC cis rs1005277 0.505 rs7917943 ENSG00000276805.1 RP11-291L22.6 -4.21 3.3e-05 0.00734 -0.27 -0.22 Extrinsic epigenetic age acceleration; chr10:37906883 chr10:38451030~38451785:+ LIHC cis rs12681287 0.608 rs13270090 ENSG00000254088.1 SLC2A3P4 -4.21 3.3e-05 0.00734 -0.27 -0.22 Caudate activity during reward; chr8:86541069 chr8:86503591~86505061:+ LIHC cis rs1823913 1 rs1454749 ENSG00000227542.1 AC092614.2 4.21 3.3e-05 0.00734 0.23 0.22 Obesity-related traits; chr2:191240909 chr2:191229165~191246172:- LIHC cis rs10510102 0.872 rs11814703 ENSG00000273891.1 RP11-500G22.5 4.21 3.3e-05 0.00734 0.3 0.22 Breast cancer; chr10:121964774 chr10:121965764~121967700:+ LIHC cis rs2333021 0.689 rs2535901 ENSG00000259015.1 RP11-109N23.6 -4.21 3.3e-05 0.00734 -0.26 -0.22 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72965734 chr14:72960595~72961993:+ LIHC cis rs13068223 0.905 rs344027 ENSG00000243926.1 TIPARP-AS1 -4.21 3.3e-05 0.00735 -0.23 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr3:156750604 chr3:156671862~156674378:- LIHC cis rs7811142 1 rs60257855 ENSG00000242294.5 STAG3L5P 4.21 3.3e-05 0.00735 0.27 0.22 Platelet count; chr7:100429157 chr7:100336079~100351900:+ LIHC cis rs597539 0.652 rs622082 ENSG00000250508.1 RP11-757G1.6 -4.21 3.3e-05 0.00735 -0.35 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68936491 chr11:68870664~68874542:+ LIHC cis rs597539 0.652 rs546382 ENSG00000250508.1 RP11-757G1.6 -4.21 3.3e-05 0.00735 -0.35 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68936796 chr11:68870664~68874542:+ LIHC cis rs597539 0.652 rs569777 ENSG00000250508.1 RP11-757G1.6 -4.21 3.3e-05 0.00735 -0.35 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68939380 chr11:68870664~68874542:+ LIHC cis rs1023500 0.505 rs134891 ENSG00000205702.9 CYP2D7 4.21 3.3e-05 0.00735 0.22 0.22 Schizophrenia; chr22:42279876 chr22:42140203~42144577:- LIHC cis rs6449502 0.858 rs6894795 ENSG00000272308.1 RP11-231G3.1 -4.21 3.3e-05 0.00736 -0.33 -0.22 Mean platelet volume; chr5:60825535 chr5:60866457~60866935:- LIHC cis rs6449502 0.858 rs4410607 ENSG00000272308.1 RP11-231G3.1 -4.21 3.3e-05 0.00736 -0.33 -0.22 Mean platelet volume; chr5:60830439 chr5:60866457~60866935:- LIHC cis rs11096990 0.613 rs35391082 ENSG00000249685.1 RP11-360F5.3 4.21 3.31e-05 0.00736 0.27 0.22 Cognitive function; chr4:39191033 chr4:39133913~39135608:+ LIHC cis rs11096990 0.613 rs4974990 ENSG00000249685.1 RP11-360F5.3 4.21 3.31e-05 0.00736 0.27 0.22 Cognitive function; chr4:39191645 chr4:39133913~39135608:+ LIHC cis rs9450351 0.744 rs9450295 ENSG00000203875.9 SNHG5 -4.21 3.31e-05 0.00737 -0.47 -0.22 Interferon gamma-induced protein 10 levels; chr6:85548156 chr6:85660950~85678736:- LIHC cis rs1023500 1 rs1047997 ENSG00000237037.8 NDUFA6-AS1 -4.21 3.31e-05 0.00737 -0.31 -0.22 Schizophrenia; chr22:41938949 chr22:42090931~42137742:+ LIHC cis rs6445975 0.666 rs4075152 ENSG00000272360.1 RP11-359I18.5 -4.21 3.31e-05 0.00737 -0.29 -0.22 Systemic lupus erythematosus; chr3:58399467 chr3:58490830~58491291:- LIHC cis rs4356203 0.87 rs7925692 ENSG00000260196.1 RP1-239B22.5 4.21 3.31e-05 0.00737 0.27 0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17249575 chr11:17380649~17383531:+ LIHC cis rs2439831 0.85 rs28564774 ENSG00000166763.7 STRCP1 4.21 3.32e-05 0.00738 0.34 0.22 Lung cancer in ever smokers; chr15:43833277 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs28513374 ENSG00000166763.7 STRCP1 4.21 3.32e-05 0.00738 0.34 0.22 Lung cancer in ever smokers; chr15:43833297 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs12441984 ENSG00000166763.7 STRCP1 4.21 3.32e-05 0.00738 0.34 0.22 Lung cancer in ever smokers; chr15:43834087 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs7169322 ENSG00000166763.7 STRCP1 4.21 3.32e-05 0.00738 0.34 0.22 Lung cancer in ever smokers; chr15:43838816 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs28707214 ENSG00000166763.7 STRCP1 4.21 3.32e-05 0.00738 0.34 0.22 Lung cancer in ever smokers; chr15:43839425 chr15:43699488~43718184:- LIHC cis rs9876781 1 rs7630741 ENSG00000229759.1 MRPS18AP1 4.21 3.32e-05 0.00738 0.23 0.22 Longevity; chr3:48378233 chr3:48256350~48256938:- LIHC cis rs875971 0.8 rs427557 ENSG00000232559.3 GS1-124K5.12 4.21 3.32e-05 0.00738 0.18 0.22 Aortic root size; chr7:66054263 chr7:66554588~66576923:- LIHC cis rs11971779 0.638 rs77668044 ENSG00000273391.1 RP11-634H22.1 4.21 3.32e-05 0.00738 0.22 0.22 Diisocyanate-induced asthma; chr7:139426339 chr7:139359032~139359566:- LIHC cis rs17214007 0.877 rs2075514 ENSG00000263335.1 AF001548.5 -4.21 3.32e-05 0.00738 -0.29 -0.22 Cognitive function; chr16:15778752 chr16:15726674~15732993:+ LIHC cis rs34375054 0.553 rs12581512 ENSG00000279233.1 RP11-158L12.4 4.21 3.32e-05 0.00739 0.2 0.22 Post bronchodilator FEV1/FVC ratio; chr12:125137716 chr12:125138245~125141711:+ LIHC cis rs673078 0.66 rs7136216 ENSG00000275409.1 RP11-131L12.4 -4.21 3.32e-05 0.00739 -0.27 -0.22 Glucose homeostasis traits; chr12:118170475 chr12:118430147~118430699:+ LIHC cis rs2243480 1 rs67728539 ENSG00000232546.1 RP11-458F8.1 -4.21 3.32e-05 0.00739 -0.25 -0.22 Diabetic kidney disease; chr7:65913137 chr7:66848496~66858136:+ LIHC cis rs597539 0.652 rs507520 ENSG00000250508.1 RP11-757G1.6 -4.21 3.32e-05 0.00739 -0.34 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68898586 chr11:68870664~68874542:+ LIHC cis rs494453 0.922 rs484495 ENSG00000227811.2 FAM212B-AS1 -4.21 3.32e-05 0.00739 -0.25 -0.22 Osteoporosis-related phenotypes; chr1:111693680 chr1:111739841~111747798:+ LIHC cis rs960902 1 rs960902 ENSG00000213553.4 RPLP0P6 4.21 3.33e-05 0.0074 0.18 0.22 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37504522 chr2:38481851~38482804:+ LIHC cis rs4578769 0.959 rs4800430 ENSG00000266850.1 RP11-370A5.1 4.21 3.33e-05 0.0074 0.26 0.22 Eosinophil percentage of white cells; chr18:22803299 chr18:22723491~22907721:- LIHC cis rs10833905 0.756 rs4923046 ENSG00000246225.5 RP11-17A1.3 -4.21 3.33e-05 0.0074 -0.3 -0.22 Sudden cardiac arrest; chr11:22969127 chr11:22829380~22945393:+ LIHC cis rs62445005 1 rs62445005 ENSG00000211698.2 TRGV4 4.21 3.33e-05 0.0074 0.25 0.22 Shingles; chr7:38346957 chr7:38353715~38354517:- LIHC cis rs1115240 0.947 rs4297616 ENSG00000257842.4 NOVA1-AS1 -4.21 3.33e-05 0.0074 -0.21 -0.22 Educational attainment (years of education); chr14:26643673 chr14:26598412~26806467:+ LIHC cis rs244293 0.862 rs11079146 ENSG00000275710.1 RP11-257O5.4 -4.21 3.33e-05 0.0074 -0.24 -0.22 Menarche (age at onset); chr17:55016761 chr17:54964474~54964679:+ LIHC cis rs13113518 0.812 rs13140173 ENSG00000249700.7 SRD5A3-AS1 4.21 3.33e-05 0.0074 0.26 0.22 Height; chr4:55527164 chr4:55363971~55395847:- LIHC cis rs244293 0.831 rs2111097 ENSG00000275710.1 RP11-257O5.4 -4.21 3.33e-05 0.00741 -0.24 -0.22 Menarche (age at onset); chr17:55013113 chr17:54964474~54964679:+ LIHC cis rs3091242 0.967 rs3093614 ENSG00000224183.1 SDHDP6 4.21 3.33e-05 0.00741 0.25 0.22 Erythrocyte sedimentation rate; chr1:25351353 chr1:25294164~25294643:- LIHC cis rs3091242 0.967 rs1053438 ENSG00000224183.1 SDHDP6 4.21 3.33e-05 0.00741 0.25 0.22 Erythrocyte sedimentation rate; chr1:25361410 chr1:25294164~25294643:- LIHC cis rs5742933 0.857 rs893784 ENSG00000253559.1 OSGEPL1-AS1 -4.21 3.34e-05 0.00742 -0.29 -0.22 Ferritin levels; chr2:189671557 chr2:189762704~189765556:+ LIHC cis rs28829049 0.597 rs2296107 ENSG00000270728.1 RP4-657E11.10 -4.2 3.34e-05 0.00742 -0.2 -0.22 QRS duration in Tripanosoma cruzi seropositivity; chr1:19150155 chr1:19297080~19297903:+ LIHC cis rs11671005 0.651 rs35117909 ENSG00000269473.1 CTD-2619J13.19 4.2 3.34e-05 0.00742 0.39 0.22 Mean platelet volume; chr19:58401539 chr19:58440448~58445849:+ LIHC cis rs7915414 0.951 rs1998591 ENSG00000230338.1 MTND4P19 4.2 3.34e-05 0.00742 0.23 0.22 Clopidogrel active metabolite levels; chr10:94648221 chr10:94774156~94774633:- LIHC cis rs7915414 0.901 rs1998590 ENSG00000230338.1 MTND4P19 4.2 3.34e-05 0.00742 0.23 0.22 Clopidogrel active metabolite levels; chr10:94648248 chr10:94774156~94774633:- LIHC cis rs7826238 0.623 rs2976893 ENSG00000253893.2 FAM85B 4.2 3.34e-05 0.00743 0.29 0.22 Systolic blood pressure; chr8:8480709 chr8:8167819~8226614:- LIHC cis rs3091242 0.933 rs28633797 ENSG00000224183.1 SDHDP6 -4.2 3.34e-05 0.00743 -0.26 -0.22 Erythrocyte sedimentation rate; chr1:25415138 chr1:25294164~25294643:- LIHC cis rs548181 0.736 rs543389 ENSG00000254671.2 STT3A-AS1 -4.2 3.34e-05 0.00743 -0.41 -0.22 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr11:125594946 chr11:125570284~125592568:- LIHC cis rs901683 1 rs35047800 ENSG00000230869.1 CTGLF10P -4.2 3.34e-05 0.00743 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45593599 chr10:45678692~45700532:+ LIHC cis rs4356203 0.87 rs214919 ENSG00000260196.1 RP1-239B22.5 -4.2 3.35e-05 0.00743 -0.26 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17217157 chr11:17380649~17383531:+ LIHC cis rs4356203 0.87 rs214916 ENSG00000260196.1 RP1-239B22.5 -4.2 3.35e-05 0.00743 -0.26 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17220102 chr11:17380649~17383531:+ LIHC cis rs1075265 0.633 rs7564912 ENSG00000233266.1 HMGB1P31 4.2 3.35e-05 0.00744 0.27 0.22 Chronotype;Morning vs. evening chronotype; chr2:53995048 chr2:54051334~54051760:+ LIHC cis rs11098499 0.954 rs59866101 ENSG00000260091.1 RP11-33B1.4 -4.2 3.35e-05 0.00744 -0.16 -0.22 Corneal astigmatism; chr4:119375436 chr4:119409333~119410233:+ LIHC cis rs244293 0.801 rs11655949 ENSG00000275710.1 RP11-257O5.4 -4.2 3.35e-05 0.00744 -0.24 -0.22 Menarche (age at onset); chr17:55092522 chr17:54964474~54964679:+ LIHC cis rs1577917 1 rs10944169 ENSG00000234155.1 RP11-30P6.6 4.2 3.35e-05 0.00744 0.28 0.22 Response to antipsychotic treatment; chr6:85973318 chr6:85387219~85390186:- LIHC cis rs1023500 0.505 rs134901 ENSG00000226450.2 CYP2D8P 4.2 3.35e-05 0.00745 0.25 0.22 Schizophrenia; chr22:42287514 chr22:42149886~42155001:- LIHC cis rs2735413 0.914 rs1922608 ENSG00000276007.1 RP11-358L22.3 -4.2 3.35e-05 0.00745 -0.26 -0.22 Systolic blood pressure (alcohol consumption interaction); chr16:78031242 chr16:78123243~78124332:+ LIHC cis rs9326248 0.515 rs2727793 ENSG00000280143.1 AP000892.6 4.2 3.35e-05 0.00745 0.25 0.22 Blood protein levels; chr11:116812658 chr11:117204967~117210292:+ LIHC cis rs4356203 0.905 rs7939750 ENSG00000260196.1 RP1-239B22.5 -4.2 3.35e-05 0.00745 -0.27 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17058208 chr11:17380649~17383531:+ LIHC cis rs2337406 1 rs17112416 ENSG00000274576.2 IGHV2-70 4.2 3.35e-05 0.00745 0.24 0.22 Alzheimer's disease (late onset); chr14:106686773 chr14:106770577~106771020:- LIHC cis rs2243480 1 rs313814 ENSG00000228409.4 CCT6P1 4.2 3.35e-05 0.00745 0.24 0.22 Diabetic kidney disease; chr7:66038306 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs6460276 ENSG00000228409.4 CCT6P1 -4.2 3.35e-05 0.00745 -0.18 -0.22 Aortic root size; chr7:66182290 chr7:65751142~65763354:+ LIHC cis rs8005677 0.828 rs12589539 ENSG00000257285.4 RP11-298I3.1 4.2 3.35e-05 0.00745 0.22 0.22 Cognitive ability (multi-trait analysis); chr14:22927471 chr14:22929609~22955562:+ LIHC cis rs875971 0.545 rs6950988 ENSG00000228409.4 CCT6P1 -4.2 3.35e-05 0.00745 -0.19 -0.22 Aortic root size; chr7:66511428 chr7:65751142~65763354:+ LIHC cis rs787274 0.543 rs10116897 ENSG00000271631.1 RP11-408O19.5 4.2 3.36e-05 0.00745 0.35 0.22 Age-related hearing impairment (SNP x SNP interaction); chr9:112871199 chr9:112885158~112885767:+ LIHC cis rs11096990 0.634 rs3733287 ENSG00000249685.1 RP11-360F5.3 4.2 3.36e-05 0.00746 0.27 0.22 Cognitive function; chr4:39215732 chr4:39133913~39135608:+ LIHC cis rs10829156 0.699 rs10764584 ENSG00000240291.1 RP11-499P20.2 -4.2 3.36e-05 0.00746 -0.34 -0.22 Sudden cardiac arrest; chr10:18546396 chr10:18513115~18545651:- LIHC cis rs9907295 1 rs9913488 ENSG00000270871.1 AC015849.19 4.2 3.36e-05 0.00746 0.23 0.22 Fibroblast growth factor basic levels; chr17:35906447 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9912571 ENSG00000270871.1 AC015849.19 4.2 3.36e-05 0.00746 0.23 0.22 Fibroblast growth factor basic levels; chr17:35906782 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9912793 ENSG00000270871.1 AC015849.19 4.2 3.36e-05 0.00746 0.23 0.22 Fibroblast growth factor basic levels; chr17:35906867 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs11655533 ENSG00000270871.1 AC015849.19 4.2 3.36e-05 0.00746 0.23 0.22 Fibroblast growth factor basic levels; chr17:35908002 chr17:35816717~35830293:- LIHC cis rs2243480 1 rs35820085 ENSG00000228409.4 CCT6P1 4.2 3.36e-05 0.00746 0.24 0.22 Diabetic kidney disease; chr7:65977771 chr7:65751142~65763354:+ LIHC cis rs11733284 0.962 rs4694879 ENSG00000259959.1 RP11-121C2.2 4.2 3.36e-05 0.00746 0.2 0.22 Gout;Renal underexcretion gout; chr4:48030339 chr4:47840122~47844339:- LIHC cis rs12589282 1 rs12589282 ENSG00000257285.4 RP11-298I3.1 -4.2 3.36e-05 0.00747 -0.21 -0.22 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs); chr14:22468664 chr14:22929609~22955562:+ LIHC cis rs1075265 0.87 rs1363062 ENSG00000233266.1 HMGB1P31 4.2 3.37e-05 0.00747 0.27 0.22 Chronotype;Morning vs. evening chronotype; chr2:54054625 chr2:54051334~54051760:+ LIHC cis rs2929278 0.617 rs3087657 ENSG00000275601.1 AC011330.13 -4.2 3.37e-05 0.00747 -0.26 -0.22 Schizophrenia; chr15:43771661 chr15:43642389~43643023:- LIHC cis rs7246657 1 rs35398388 ENSG00000276846.1 CTD-3220F14.3 4.2 3.37e-05 0.00747 0.29 0.22 Coronary artery calcification; chr19:37249456 chr19:37314868~37315620:- LIHC cis rs7246657 1 rs7247672 ENSG00000276846.1 CTD-3220F14.3 4.2 3.37e-05 0.00747 0.29 0.22 Coronary artery calcification; chr19:37253026 chr19:37314868~37315620:- LIHC cis rs7246657 1 rs8110011 ENSG00000276846.1 CTD-3220F14.3 4.2 3.37e-05 0.00747 0.29 0.22 Coronary artery calcification; chr19:37254911 chr19:37314868~37315620:- LIHC cis rs2299116 1 rs2299116 ENSG00000225264.3 ZNRF2P2 -4.2 3.37e-05 0.00748 -0.25 -0.22 Serum thyroid-stimulating hormone levels; chr7:28775622 chr7:29598795~29685255:- LIHC cis rs875971 1 rs2077593 ENSG00000237310.1 GS1-124K5.4 4.2 3.37e-05 0.00748 0.2 0.22 Aortic root size; chr7:66427543 chr7:66493706~66495474:+ LIHC cis rs1005277 0.638 rs1005278 ENSG00000263064.2 RP11-291L22.7 -4.2 3.37e-05 0.00748 -0.23 -0.22 Extrinsic epigenetic age acceleration; chr10:37929820 chr10:38448689~38448949:+ LIHC cis rs2243480 1 rs55895244 ENSG00000230295.1 RP11-458F8.2 -4.2 3.37e-05 0.00748 -0.23 -0.22 Diabetic kidney disease; chr7:65922691 chr7:66880708~66882981:+ LIHC cis rs755249 0.565 rs722357 ENSG00000182109.6 RP11-69E11.4 -4.2 3.37e-05 0.00748 -0.23 -0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39479096 chr1:39522280~39546187:- LIHC cis rs748404 0.578 rs512628 ENSG00000205771.5 CATSPER2P1 -4.2 3.37e-05 0.00749 -0.26 -0.22 Lung cancer; chr15:43326536 chr15:43726918~43747094:- LIHC cis rs7945705 0.905 rs2568054 ENSG00000254860.4 TMEM9B-AS1 4.2 3.37e-05 0.00749 0.22 0.22 Hemoglobin concentration; chr11:8854482 chr11:8964675~8977527:+ LIHC cis rs7945705 0.935 rs2653593 ENSG00000254860.4 TMEM9B-AS1 4.2 3.37e-05 0.00749 0.22 0.22 Hemoglobin concentration; chr11:8855770 chr11:8964675~8977527:+ LIHC cis rs7915414 0.756 rs1010570 ENSG00000230338.1 MTND4P19 4.2 3.37e-05 0.00749 0.23 0.22 Clopidogrel active metabolite levels; chr10:94686875 chr10:94774156~94774633:- LIHC cis rs2439831 0.681 rs524527 ENSG00000166763.7 STRCP1 -4.2 3.37e-05 0.00749 -0.31 -0.22 Lung cancer in ever smokers; chr15:43306918 chr15:43699488~43718184:- LIHC cis rs1115240 0.685 rs56777534 ENSG00000257842.4 NOVA1-AS1 4.2 3.37e-05 0.00749 0.22 0.22 Educational attainment (years of education); chr14:26627899 chr14:26598412~26806467:+ LIHC cis rs6442522 0.809 rs749845 ENSG00000249786.6 EAF1-AS1 4.2 3.38e-05 0.00749 0.24 0.22 Uric acid levels; chr3:15422811 chr3:15436171~15455940:- LIHC cis rs9326248 0.581 rs7120515 ENSG00000280143.1 AP000892.6 4.2 3.38e-05 0.00749 0.26 0.22 Blood protein levels; chr11:117121210 chr11:117204967~117210292:+ LIHC cis rs27434 0.605 rs152468 ENSG00000272109.1 CTD-2260A17.3 -4.2 3.38e-05 0.00749 -0.3 -0.22 Ankylosing spondylitis; chr5:96831833 chr5:96804353~96806105:+ LIHC cis rs7806994 1 rs7806994 ENSG00000226278.1 PSPHP1 -4.2 3.38e-05 0.0075 -0.42 -0.22 PR interval in Tripanosoma cruzi seropositivity; chr7:56071812 chr7:55764797~55773288:+ LIHC cis rs295490 0.748 rs77016755 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139392125 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs61034702 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139395105 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs115177972 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139410696 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs77876369 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139412070 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs77131232 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139415468 chr3:139349024~139349371:- LIHC cis rs295490 0.588 rs75694829 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139416582 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs76520271 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139422441 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs77343695 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139430617 chr3:139349024~139349371:- LIHC cis rs295490 0.667 rs79661321 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139434762 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs77036655 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139436231 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs75472377 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139439365 chr3:139349024~139349371:- LIHC cis rs295490 0.667 rs76728176 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139441574 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs76522909 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139444006 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs61680644 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139455729 chr3:139349024~139349371:- LIHC cis rs295490 0.667 rs79829464 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139456842 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs77347345 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139459863 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs17560106 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139461388 chr3:139349024~139349371:- LIHC cis rs295490 0.667 rs2289350 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139462436 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs80323892 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139464658 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs3772876 ENSG00000272656.1 RP11-219D15.3 4.2 3.38e-05 0.0075 0.66 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139469035 chr3:139349024~139349371:- LIHC cis rs2598107 0.601 rs3807194 ENSG00000211698.2 TRGV4 -4.2 3.38e-05 0.0075 -0.26 -0.22 Dupuytren's disease; chr7:37912789 chr7:38353715~38354517:- LIHC cis rs8177253 0.763 rs12769 ENSG00000244062.1 RP11-404G16.2 4.2 3.39e-05 0.00751 0.22 0.22 Iron status biomarkers; chr3:133755484 chr3:133760300~133762363:+ LIHC cis rs57502260 0.834 rs3736228 ENSG00000212093.1 AP000807.1 -4.2 3.39e-05 0.00751 -0.28 -0.22 Total body bone mineral density (age 45-60); chr11:68433827 chr11:68506083~68506166:- LIHC cis rs7246657 0.941 rs10418729 ENSG00000276846.1 CTD-3220F14.3 4.2 3.39e-05 0.00751 0.29 0.22 Coronary artery calcification; chr19:37246163 chr19:37314868~37315620:- LIHC cis rs1075265 0.588 rs1477258 ENSG00000233266.1 HMGB1P31 4.2 3.39e-05 0.00751 0.26 0.22 Chronotype;Morning vs. evening chronotype; chr2:54000031 chr2:54051334~54051760:+ LIHC cis rs35343117 1 rs35343117 ENSG00000259630.2 CTD-2262B20.1 -4.2 3.39e-05 0.00752 -0.32 -0.22 Psoriasis; chr15:85535884 chr15:85415228~85415633:+ LIHC cis rs12681366 0.801 rs12549544 ENSG00000253704.1 RP11-267M23.4 4.2 3.39e-05 0.00753 0.26 0.22 Nonsyndromic cleft lip with cleft palate; chr8:94471329 chr8:94553722~94569745:+ LIHC cis rs6921919 0.697 rs12180820 ENSG00000204709.4 LINC01556 -4.2 3.39e-05 0.00753 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr6:28348701 chr6:28943877~28944537:+ LIHC cis rs9807989 0.507 rs10439410 ENSG00000234389.1 AC007278.3 -4.2 3.4e-05 0.00753 -0.24 -0.22 Asthma; chr2:102374328 chr2:102438713~102440475:+ LIHC cis rs1900005 0.519 rs2894061 ENSG00000233590.1 RP11-153K11.3 -4.2 3.4e-05 0.00754 -0.32 -0.22 Vertical cup-disc ratio; chr10:68191152 chr10:68233251~68242379:- LIHC cis rs881375 0.9 rs2241003 ENSG00000226752.6 PSMD5-AS1 -4.2 3.4e-05 0.00754 -0.22 -0.22 Rheumatoid arthritis; chr9:120904499 chr9:120824828~120854385:+ LIHC cis rs11098499 0.863 rs12498539 ENSG00000260091.1 RP11-33B1.4 -4.2 3.4e-05 0.00754 -0.16 -0.22 Corneal astigmatism; chr4:119547215 chr4:119409333~119410233:+ LIHC cis rs9907295 0.901 rs9898132 ENSG00000270871.1 AC015849.19 4.2 3.4e-05 0.00754 0.24 0.22 Fibroblast growth factor basic levels; chr17:35869187 chr17:35816717~35830293:- LIHC cis rs11690935 0.632 rs62184165 ENSG00000228389.1 AC068039.4 -4.2 3.4e-05 0.00754 -0.26 -0.22 Schizophrenia; chr2:171701818 chr2:171773482~171775844:+ LIHC cis rs853679 0.824 rs34712084 ENSG00000219392.1 RP1-265C24.5 -4.2 3.41e-05 0.00755 -0.42 -0.22 Depression; chr6:28076050 chr6:28115628~28116551:+ LIHC cis rs853679 0.824 rs1321505 ENSG00000219392.1 RP1-265C24.5 -4.2 3.41e-05 0.00755 -0.42 -0.22 Depression; chr6:28085045 chr6:28115628~28116551:+ LIHC cis rs853679 0.882 rs9468287 ENSG00000219392.1 RP1-265C24.5 -4.2 3.41e-05 0.00755 -0.42 -0.22 Depression; chr6:28111963 chr6:28115628~28116551:+ LIHC cis rs524281 1 rs524281 ENSG00000255320.1 RP11-755F10.1 -4.2 3.41e-05 0.00755 -0.26 -0.22 Electroencephalogram traits; chr11:66119191 chr11:66244840~66246239:- LIHC cis rs72634501 0.517 rs7522362 ENSG00000182109.6 RP11-69E11.4 -4.2 3.41e-05 0.00755 -0.23 -0.22 HDL cholesterol; chr1:39139419 chr1:39522280~39546187:- LIHC cis rs2932538 0.922 rs12143068 ENSG00000225075.1 RP11-426L16.3 4.2 3.41e-05 0.00756 0.28 0.22 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112595488 chr1:112693688~112696621:- LIHC cis rs673078 0.607 rs11068906 ENSG00000275759.1 RP11-131L12.3 -4.2 3.41e-05 0.00756 -0.28 -0.22 Glucose homeostasis traits; chr12:118315098 chr12:118428281~118428870:+ LIHC cis rs7580658 0.545 rs12477559 ENSG00000236682.1 AC068282.3 -4.2 3.41e-05 0.00756 -0.27 -0.22 Protein C levels; chr2:127194221 chr2:127389130~127400580:+ LIHC cis rs2439831 0.867 rs3809481 ENSG00000166763.7 STRCP1 4.2 3.41e-05 0.00756 0.36 0.22 Lung cancer in ever smokers; chr15:43370631 chr15:43699488~43718184:- LIHC cis rs2070488 1 rs2268753 ENSG00000229589.1 ACVR2B-AS1 4.2 3.42e-05 0.00757 0.25 0.22 Electrocardiographic conduction measures; chr3:38458698 chr3:38451027~38454820:- LIHC cis rs2070488 1 rs2268757 ENSG00000229589.1 ACVR2B-AS1 4.2 3.42e-05 0.00757 0.25 0.22 Electrocardiographic conduction measures; chr3:38464362 chr3:38451027~38454820:- LIHC cis rs2070488 1 rs2276540 ENSG00000229589.1 ACVR2B-AS1 4.2 3.42e-05 0.00757 0.25 0.22 Electrocardiographic conduction measures; chr3:38471016 chr3:38451027~38454820:- LIHC cis rs2070488 1 rs2268758 ENSG00000229589.1 ACVR2B-AS1 4.2 3.42e-05 0.00757 0.25 0.22 Electrocardiographic conduction measures; chr3:38472558 chr3:38451027~38454820:- LIHC cis rs17270561 1 rs12211184 ENSG00000216436.2 HIST1H2APS1 -4.2 3.42e-05 0.00757 -0.34 -0.22 Iron status biomarkers; chr6:25823546 chr6:25732497~25732827:+ LIHC cis rs17270561 1 rs79867288 ENSG00000216436.2 HIST1H2APS1 -4.2 3.42e-05 0.00757 -0.34 -0.22 Iron status biomarkers; chr6:25828188 chr6:25732497~25732827:+ LIHC cis rs17270561 1 rs12200962 ENSG00000216436.2 HIST1H2APS1 -4.2 3.42e-05 0.00757 -0.34 -0.22 Iron status biomarkers; chr6:25828758 chr6:25732497~25732827:+ LIHC cis rs6545883 0.507 rs4672427 ENSG00000271889.1 RP11-493E12.1 -4.2 3.42e-05 0.00757 -0.27 -0.22 Tuberculosis; chr2:61242115 chr2:61151433~61162105:- LIHC cis rs2243480 1 rs313803 ENSG00000232546.1 RP11-458F8.1 -4.2 3.42e-05 0.00758 -0.25 -0.22 Diabetic kidney disease; chr7:66049744 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs313802 ENSG00000232546.1 RP11-458F8.1 -4.2 3.42e-05 0.00758 -0.25 -0.22 Diabetic kidney disease; chr7:66051386 chr7:66848496~66858136:+ LIHC cis rs2243480 0.803 rs403089 ENSG00000232546.1 RP11-458F8.1 -4.2 3.42e-05 0.00758 -0.25 -0.22 Diabetic kidney disease; chr7:66052736 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs458291 ENSG00000232546.1 RP11-458F8.1 -4.2 3.42e-05 0.00758 -0.25 -0.22 Diabetic kidney disease; chr7:66055492 chr7:66848496~66858136:+ LIHC cis rs11098499 0.863 rs1383533 ENSG00000260091.1 RP11-33B1.4 -4.2 3.42e-05 0.00758 -0.16 -0.22 Corneal astigmatism; chr4:119513421 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs2291185 ENSG00000260091.1 RP11-33B1.4 -4.2 3.42e-05 0.00758 -0.16 -0.22 Corneal astigmatism; chr4:119513678 chr4:119409333~119410233:+ LIHC cis rs2032447 0.772 rs199754 ENSG00000242387.1 HIST1H2APS2 4.2 3.42e-05 0.00758 0.29 0.22 Intelligence (multi-trait analysis); chr6:25992081 chr6:25882026~25882395:- LIHC cis rs7714584 1 rs75294883 ENSG00000197083.10 ZNF300P1 4.2 3.42e-05 0.00758 0.39 0.22 Crohn's disease; chr5:150816941 chr5:150930645~150946289:- LIHC cis rs12549025 0.536 rs9644075 ENSG00000253390.1 CTC-756D1.2 -4.2 3.42e-05 0.00758 -0.27 -0.22 Reticulocyte fraction of red cells; chr8:23502448 chr8:23458601~23484971:+ LIHC cis rs1729407 0.706 rs595049 ENSG00000236267.1 AP006216.5 4.2 3.42e-05 0.00758 0.21 0.22 Apolipoprotein A-IV levels; chr11:116828729 chr11:116813204~116814003:- LIHC cis rs27434 0.602 rs2927620 ENSG00000272109.1 CTD-2260A17.3 -4.2 3.43e-05 0.00759 -0.3 -0.22 Ankylosing spondylitis; chr5:96845594 chr5:96804353~96806105:+ LIHC cis rs10829156 0.898 rs10741120 ENSG00000240291.1 RP11-499P20.2 4.2 3.43e-05 0.00759 0.36 0.22 Sudden cardiac arrest; chr10:18641063 chr10:18513115~18545651:- LIHC cis rs7121538 0.756 rs12421378 ENSG00000251991.1 RNU7-49P -4.2 3.43e-05 0.00759 -0.32 -0.22 HDL cholesterol; chr11:14402689 chr11:14478892~14478953:+ LIHC cis rs2299116 1 rs13233430 ENSG00000225264.3 ZNRF2P2 -4.2 3.43e-05 0.00759 -0.25 -0.22 Serum thyroid-stimulating hormone levels; chr7:28777807 chr7:29598795~29685255:- LIHC cis rs2299116 1 rs35341608 ENSG00000225264.3 ZNRF2P2 -4.2 3.43e-05 0.00759 -0.25 -0.22 Serum thyroid-stimulating hormone levels; chr7:28777894 chr7:29598795~29685255:- LIHC cis rs2299116 1 rs34399011 ENSG00000225264.3 ZNRF2P2 -4.2 3.43e-05 0.00759 -0.25 -0.22 Serum thyroid-stimulating hormone levels; chr7:28777991 chr7:29598795~29685255:- LIHC cis rs11098499 1 rs3749591 ENSG00000260091.1 RP11-33B1.4 -4.2 3.44e-05 0.0076 -0.16 -0.22 Corneal astigmatism; chr4:119292875 chr4:119409333~119410233:+ LIHC cis rs1075265 0.62 rs10192626 ENSG00000272156.1 RP11-477N3.1 -4.2 3.44e-05 0.0076 -0.27 -0.22 Chronotype;Morning vs. evening chronotype; chr2:53760885 chr2:54082554~54085066:+ LIHC cis rs9907295 0.901 rs4795095 ENSG00000270871.1 AC015849.19 4.2 3.44e-05 0.00762 0.23 0.22 Fibroblast growth factor basic levels; chr17:35870296 chr17:35816717~35830293:- LIHC cis rs2797160 0.904 rs1418637 ENSG00000237742.5 RP11-624M8.1 -4.2 3.45e-05 0.00762 -0.23 -0.22 Endometrial cancer; chr6:125671407 chr6:125578558~125749190:- LIHC cis rs7044106 0.762 rs10760115 ENSG00000238181.2 AHCYP2 -4.2 3.45e-05 0.00762 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120714674 chr9:120720673~120721972:+ LIHC cis rs2243480 1 rs12698509 ENSG00000228409.4 CCT6P1 4.2 3.45e-05 0.00763 0.24 0.22 Diabetic kidney disease; chr7:65953889 chr7:65751142~65763354:+ LIHC cis rs9322193 0.566 rs3922947 ENSG00000216906.2 RP11-350J20.9 -4.2 3.45e-05 0.00763 -0.25 -0.22 Lung cancer; chr6:149924856 chr6:149904243~149906418:+ LIHC cis rs7726839 0.54 rs72703078 ENSG00000271781.1 CTD-2589H19.6 -4.2 3.45e-05 0.00763 -0.34 -0.22 Obesity-related traits; chr5:594872 chr5:675826~676616:+ LIHC cis rs7726839 0.54 rs72703083 ENSG00000271781.1 CTD-2589H19.6 -4.2 3.45e-05 0.00763 -0.34 -0.22 Obesity-related traits; chr5:595250 chr5:675826~676616:+ LIHC cis rs7726839 0.54 rs55929359 ENSG00000271781.1 CTD-2589H19.6 -4.2 3.45e-05 0.00763 -0.34 -0.22 Obesity-related traits; chr5:595841 chr5:675826~676616:+ LIHC cis rs7726839 0.54 rs58599998 ENSG00000271781.1 CTD-2589H19.6 -4.2 3.45e-05 0.00763 -0.34 -0.22 Obesity-related traits; chr5:595972 chr5:675826~676616:+ LIHC cis rs7726839 0.507 rs56282020 ENSG00000271781.1 CTD-2589H19.6 -4.2 3.45e-05 0.00763 -0.34 -0.22 Obesity-related traits; chr5:596586 chr5:675826~676616:+ LIHC cis rs7726839 0.507 rs60068988 ENSG00000271781.1 CTD-2589H19.6 -4.2 3.45e-05 0.00763 -0.34 -0.22 Obesity-related traits; chr5:597553 chr5:675826~676616:+ LIHC cis rs57221529 0.709 rs72703090 ENSG00000271781.1 CTD-2589H19.6 -4.2 3.45e-05 0.00763 -0.34 -0.22 Lung disease severity in cystic fibrosis; chr5:598199 chr5:675826~676616:+ LIHC cis rs6565180 0.888 rs12921440 ENSG00000183604.13 SMG1P5 4.2 3.46e-05 0.00764 0.23 0.22 Tonsillectomy; chr16:30397444 chr16:30267553~30335374:- LIHC cis rs6723226 0.721 rs3769600 ENSG00000276334.1 AL133243.1 -4.2 3.46e-05 0.00765 -0.24 -0.22 Intelligence (multi-trait analysis); chr2:32391811 chr2:32521927~32523547:+ LIHC cis rs1062177 0.756 rs2964588 ENSG00000253921.1 CTB-113P19.3 4.2 3.46e-05 0.00765 0.26 0.22 Preschool internalizing problems; chr5:151738825 chr5:151753992~151767247:+ LIHC cis rs11096990 0.593 rs35937374 ENSG00000249685.1 RP11-360F5.3 4.2 3.46e-05 0.00765 0.27 0.22 Cognitive function; chr4:39184735 chr4:39133913~39135608:+ LIHC cis rs11096990 0.574 rs34070258 ENSG00000249685.1 RP11-360F5.3 4.2 3.46e-05 0.00765 0.27 0.22 Cognitive function; chr4:39188132 chr4:39133913~39135608:+ LIHC cis rs11096990 0.613 rs6840578 ENSG00000249685.1 RP11-360F5.3 4.2 3.46e-05 0.00765 0.27 0.22 Cognitive function; chr4:39206996 chr4:39133913~39135608:+ LIHC cis rs3845817 0.703 rs702919 ENSG00000281920.1 RP11-418H16.1 -4.2 3.46e-05 0.00765 -0.26 -0.22 Bipolar disorder; chr2:65545157 chr2:65623272~65628424:+ LIHC cis rs9450351 0.744 rs9450304 ENSG00000203875.9 SNHG5 -4.2 3.47e-05 0.00766 -0.49 -0.22 Interferon gamma-induced protein 10 levels; chr6:85620141 chr6:85660950~85678736:- LIHC cis rs7474896 0.583 rs10827817 ENSG00000263064.2 RP11-291L22.7 4.2 3.47e-05 0.00766 0.27 0.22 Obesity (extreme); chr10:37709046 chr10:38448689~38448949:+ LIHC cis rs7309 0.622 rs4664396 ENSG00000227403.1 AC009299.3 4.2 3.47e-05 0.00766 0.26 0.22 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161045139 chr2:161244739~161249050:+ LIHC cis rs2015599 0.56 rs3948497 ENSG00000257176.2 RP11-996F15.2 -4.2 3.47e-05 0.00766 -0.27 -0.22 Platelet count;Mean platelet volume; chr12:29247552 chr12:29280418~29317848:- LIHC cis rs7829975 0.742 rs1533058 ENSG00000253893.2 FAM85B -4.2 3.47e-05 0.00767 -0.26 -0.22 Mood instability; chr8:8827680 chr8:8167819~8226614:- LIHC cis rs651907 0.557 rs17411983 ENSG00000244119.1 PDCL3P4 -4.2 3.47e-05 0.00767 -0.23 -0.22 Colorectal cancer; chr3:101680282 chr3:101712472~101713191:+ LIHC cis rs10875746 0.587 rs9788082 ENSG00000240399.1 RP1-228P16.1 -4.2 3.47e-05 0.00767 -0.27 -0.22 Longevity (90 years and older); chr12:48358273 chr12:48054813~48055591:- LIHC cis rs11096990 1 rs11096990 ENSG00000249685.1 RP11-360F5.3 4.2 3.47e-05 0.00767 0.3 0.22 Cognitive function; chr4:39285329 chr4:39133913~39135608:+ LIHC cis rs12887734 0.546 rs4906376 ENSG00000258534.1 CTD-2134A5.4 -4.2 3.47e-05 0.00767 -0.25 -0.22 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103805828 chr14:103854366~103880111:- LIHC cis rs1799949 1 rs33926631 ENSG00000267681.1 CTD-3199J23.6 -4.2 3.47e-05 0.00767 -0.21 -0.22 Menopause (age at onset); chr17:43152446 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs1960605 ENSG00000267681.1 CTD-3199J23.6 -4.2 3.47e-05 0.00767 -0.21 -0.22 Menopause (age at onset); chr17:43153380 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs2037076 ENSG00000267681.1 CTD-3199J23.6 -4.2 3.47e-05 0.00767 -0.21 -0.22 Menopause (age at onset); chr17:43153866 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs12950779 ENSG00000267681.1 CTD-3199J23.6 -4.2 3.47e-05 0.00767 -0.21 -0.22 Menopause (age at onset); chr17:43154506 chr17:43144956~43145255:+ LIHC cis rs1799949 0.929 rs12937015 ENSG00000267681.1 CTD-3199J23.6 -4.2 3.47e-05 0.00767 -0.21 -0.22 Menopause (age at onset); chr17:43155456 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs4340367 ENSG00000267681.1 CTD-3199J23.6 -4.2 3.47e-05 0.00767 -0.21 -0.22 Menopause (age at onset); chr17:43155755 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs4792981 ENSG00000267681.1 CTD-3199J23.6 -4.2 3.47e-05 0.00767 -0.21 -0.22 Menopause (age at onset); chr17:43156257 chr17:43144956~43145255:+ LIHC cis rs17774123 0.901 rs17712839 ENSG00000257808.1 RP11-1136G11.8 4.2 3.48e-05 0.00768 0.41 0.22 Diastolic blood pressure; chr12:53866962 chr12:53159586~53161000:+ LIHC cis rs597539 0.652 rs592697 ENSG00000250508.1 RP11-757G1.6 -4.2 3.48e-05 0.00768 -0.33 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68882596 chr11:68870664~68874542:+ LIHC cis rs597539 0.652 rs654071 ENSG00000250508.1 RP11-757G1.6 -4.2 3.48e-05 0.00768 -0.33 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68885964 chr11:68870664~68874542:+ LIHC cis rs8005677 0.77 rs56180741 ENSG00000257285.4 RP11-298I3.1 4.2 3.48e-05 0.00768 0.22 0.22 Cognitive ability (multi-trait analysis); chr14:22908037 chr14:22929609~22955562:+ LIHC cis rs8005677 0.828 rs3794452 ENSG00000257285.4 RP11-298I3.1 4.2 3.48e-05 0.00768 0.22 0.22 Cognitive ability (multi-trait analysis); chr14:22917473 chr14:22929609~22955562:+ LIHC cis rs8005677 0.828 rs4981450 ENSG00000257285.4 RP11-298I3.1 4.2 3.48e-05 0.00768 0.22 0.22 Cognitive ability (multi-trait analysis); chr14:22920095 chr14:22929609~22955562:+ LIHC cis rs4650994 0.816 rs2811304 ENSG00000273384.1 RP5-1098D14.1 -4.2 3.48e-05 0.00768 -0.25 -0.22 HDL cholesterol;HDL cholesterol levels; chr1:178627659 chr1:178651706~178652282:+ LIHC cis rs7893279 0.505 rs7923480 ENSG00000225527.1 RP11-383B4.4 4.19 3.48e-05 0.00769 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18616736 chr10:18531849~18533336:- LIHC cis rs9368481 0.729 rs10946881 ENSG00000241549.7 GUSBP2 4.19 3.48e-05 0.00769 0.24 0.22 Autism spectrum disorder or schizophrenia; chr6:26946832 chr6:26871484~26956554:- LIHC cis rs11098499 1 rs12506395 ENSG00000260091.1 RP11-33B1.4 -4.19 3.48e-05 0.00769 -0.16 -0.22 Corneal astigmatism; chr4:119263939 chr4:119409333~119410233:+ LIHC cis rs10829156 0.898 rs7923072 ENSG00000225527.1 RP11-383B4.4 -4.19 3.49e-05 0.00769 -0.36 -0.22 Sudden cardiac arrest; chr10:18649305 chr10:18531849~18533336:- LIHC cis rs4925386 1 rs4925382 ENSG00000226332.2 RP11-157P1.4 -4.19 3.49e-05 0.0077 -0.23 -0.22 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62343486 chr20:62305432~62306325:- LIHC cis rs801193 0.548 rs2659904 ENSG00000237310.1 GS1-124K5.4 4.19 3.49e-05 0.0077 0.2 0.22 Aortic root size; chr7:66713615 chr7:66493706~66495474:+ LIHC cis rs9487094 0.961 rs11153180 ENSG00000260273.1 RP11-425D10.10 4.19 3.49e-05 0.0077 0.27 0.22 Height; chr6:109423238 chr6:109382795~109383666:+ LIHC cis rs6430585 0.528 rs309120 ENSG00000231890.6 DARS-AS1 -4.19 3.49e-05 0.0077 -0.3 -0.22 Corneal structure; chr2:135951217 chr2:135985176~136022593:+ LIHC cis rs6430585 0.528 rs3112496 ENSG00000231890.6 DARS-AS1 -4.19 3.49e-05 0.0077 -0.3 -0.22 Corneal structure; chr2:135953494 chr2:135985176~136022593:+ LIHC cis rs16958440 1 rs62096471 ENSG00000267724.1 RP11-49K24.8 4.19 3.49e-05 0.0077 0.34 0.22 Sitting height ratio; chr18:47117443 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs4609941 ENSG00000267724.1 RP11-49K24.8 4.19 3.49e-05 0.0077 0.34 0.22 Sitting height ratio; chr18:47119120 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs57928699 ENSG00000267724.1 RP11-49K24.8 4.19 3.49e-05 0.0077 0.34 0.22 Sitting height ratio; chr18:47119222 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs60854219 ENSG00000267724.1 RP11-49K24.8 4.19 3.49e-05 0.0077 0.34 0.22 Sitting height ratio; chr18:47120293 chr18:47105946~47108062:+ LIHC cis rs10829156 0.898 rs6482565 ENSG00000225527.1 RP11-383B4.4 -4.19 3.49e-05 0.0077 -0.36 -0.22 Sudden cardiac arrest; chr10:18611664 chr10:18531849~18533336:- LIHC cis rs9527 1 rs12416687 ENSG00000236937.2 PTGES3P4 4.19 3.49e-05 0.0077 0.34 0.22 Arsenic metabolism; chr10:102869254 chr10:102845595~102845950:+ LIHC cis rs10129255 0.879 rs7160512 ENSG00000223648.3 IGHV3-64 4.19 3.49e-05 0.00771 0.16 0.22 Kawasaki disease; chr14:106694574 chr14:106643132~106658258:- LIHC cis rs10129255 0.879 rs7159157 ENSG00000223648.3 IGHV3-64 4.19 3.49e-05 0.00771 0.16 0.22 Kawasaki disease; chr14:106694578 chr14:106643132~106658258:- LIHC cis rs931127 0.595 rs11227248 ENSG00000265874.1 MIR4489 4.19 3.5e-05 0.00771 0.35 0.22 Systemic lupus erythematosus; chr11:65660707 chr11:65649192~65649253:+ LIHC cis rs7429990 0.774 rs3772402 ENSG00000229759.1 MRPS18AP1 -4.19 3.5e-05 0.00771 -0.24 -0.22 Educational attainment (years of education); chr3:47574661 chr3:48256350~48256938:- LIHC cis rs9675120 0.638 rs8071494 ENSG00000262006.1 RP11-700H6.4 4.19 3.5e-05 0.00772 0.24 0.22 Cerebrospinal fluid biomarker levels; chr17:50850488 chr17:50909637~50910232:- LIHC cis rs6545883 0.503 rs1665272 ENSG00000271889.1 RP11-493E12.1 4.19 3.5e-05 0.00772 0.26 0.22 Tuberculosis; chr2:61152151 chr2:61151433~61162105:- LIHC cis rs7937890 0.532 rs2575833 ENSG00000251991.1 RNU7-49P 4.19 3.5e-05 0.00773 0.24 0.22 Mitochondrial DNA levels; chr11:14470959 chr11:14478892~14478953:+ LIHC cis rs6479901 0.501 rs4414112 ENSG00000232075.1 MRPL35P2 -4.19 3.5e-05 0.00773 -0.25 -0.22 Intelligence (multi-trait analysis); chr10:63115786 chr10:63634317~63634827:- LIHC cis rs2562456 0.876 rs62110163 ENSG00000268555.1 RP11-678G14.3 4.19 3.5e-05 0.00773 0.28 0.22 Pain; chr19:21546020 chr19:21570822~21587322:- LIHC cis rs2562456 0.761 rs35008138 ENSG00000268555.1 RP11-678G14.3 4.19 3.5e-05 0.00773 0.28 0.22 Pain; chr19:21548822 chr19:21570822~21587322:- LIHC cis rs2562456 0.833 rs2681388 ENSG00000268555.1 RP11-678G14.3 4.19 3.5e-05 0.00773 0.28 0.22 Pain; chr19:21549451 chr19:21570822~21587322:- LIHC cis rs2562456 0.876 rs2681370 ENSG00000268555.1 RP11-678G14.3 4.19 3.5e-05 0.00773 0.28 0.22 Pain; chr19:21554036 chr19:21570822~21587322:- LIHC cis rs2562456 0.876 rs11668606 ENSG00000268555.1 RP11-678G14.3 4.19 3.5e-05 0.00773 0.28 0.22 Pain; chr19:21554618 chr19:21570822~21587322:- LIHC cis rs2562456 0.876 rs2681395 ENSG00000268555.1 RP11-678G14.3 4.19 3.5e-05 0.00773 0.28 0.22 Pain; chr19:21555338 chr19:21570822~21587322:- LIHC cis rs1115240 0.947 rs7154726 ENSG00000257842.4 NOVA1-AS1 -4.19 3.51e-05 0.00773 -0.21 -0.22 Educational attainment (years of education); chr14:26649170 chr14:26598412~26806467:+ LIHC cis rs651907 0.513 rs34963630 ENSG00000244119.1 PDCL3P4 4.19 3.51e-05 0.00773 0.23 0.22 Colorectal cancer; chr3:101785973 chr3:101712472~101713191:+ LIHC cis rs77204473 0.744 rs2046149 ENSG00000254851.1 RP11-109L13.1 4.19 3.51e-05 0.00773 0.4 0.22 Sum eosinophil basophil counts;Eosinophil counts; chr11:117183993 chr11:117135528~117138582:+ LIHC cis rs2276314 0.857 rs28396546 ENSG00000278986.1 RP11-723J4.3 -4.19 3.51e-05 0.00774 -0.27 -0.22 Endometriosis;Drug-induced torsades de pointes; chr18:36059061 chr18:35972151~35973916:+ LIHC cis rs11096990 0.656 rs7686161 ENSG00000249207.1 RP11-360F5.1 4.19 3.51e-05 0.00774 0.22 0.22 Cognitive function; chr4:39283201 chr4:39112677~39126818:- LIHC cis rs11096990 0.593 rs7662880 ENSG00000249207.1 RP11-360F5.1 4.19 3.51e-05 0.00774 0.22 0.22 Cognitive function; chr4:39283604 chr4:39112677~39126818:- LIHC cis rs2439831 0.85 rs16977798 ENSG00000275601.1 AC011330.13 -4.19 3.51e-05 0.00774 -0.32 -0.22 Lung cancer in ever smokers; chr15:43859750 chr15:43642389~43643023:- LIHC cis rs2072510 0.932 rs10859999 ENSG00000257878.1 RP11-256L6.3 4.19 3.52e-05 0.00776 0.2 0.22 Metabolite levels (small molecules and protein measures); chr12:95997556 chr12:95996521~96011489:+ LIHC cis rs7044106 0.791 rs7036196 ENSG00000238181.2 AHCYP2 -4.19 3.52e-05 0.00776 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120717179 chr9:120720673~120721972:+ LIHC cis rs7044106 0.791 rs3904196 ENSG00000238181.2 AHCYP2 -4.19 3.52e-05 0.00776 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120718091 chr9:120720673~120721972:+ LIHC cis rs2762353 0.776 rs1165190 ENSG00000242387.1 HIST1H2APS2 4.19 3.52e-05 0.00776 0.25 0.22 Blood metabolite levels; chr6:25847791 chr6:25882026~25882395:- LIHC cis rs17772222 0.876 rs12586348 ENSG00000258789.1 RP11-507K2.3 -4.19 3.53e-05 0.00777 -0.26 -0.22 Coronary artery calcification; chr14:88643523 chr14:88551597~88552493:+ LIHC cis rs7044106 0.791 rs7036766 ENSG00000238181.2 AHCYP2 -4.19 3.53e-05 0.00777 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120717343 chr9:120720673~120721972:+ LIHC cis rs2749592 0.531 rs10764134 ENSG00000275858.1 RP11-291L22.8 -4.19 3.53e-05 0.00777 -0.24 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37567732 chr10:38450738~38451069:- LIHC cis rs875971 1 rs709597 ENSG00000237310.1 GS1-124K5.4 -4.19 3.53e-05 0.00777 -0.19 -0.22 Aortic root size; chr7:66360996 chr7:66493706~66495474:+ LIHC cis rs9467711 0.591 rs10484433 ENSG00000216436.2 HIST1H2APS1 4.19 3.53e-05 0.00778 0.54 0.22 Autism spectrum disorder or schizophrenia; chr6:26030264 chr6:25732497~25732827:+ LIHC cis rs79349575 0.721 rs4794004 ENSG00000248278.1 SUMO2P17 4.19 3.53e-05 0.00778 0.28 0.22 Type 2 diabetes; chr17:48961109 chr17:48874860~48908983:- LIHC cis rs9907295 0.818 rs11658222 ENSG00000270871.1 AC015849.19 4.19 3.53e-05 0.00778 0.23 0.22 Fibroblast growth factor basic levels; chr17:35825092 chr17:35816717~35830293:- LIHC cis rs7615952 0.546 rs16836896 ENSG00000171084.14 FAM86JP 4.19 3.53e-05 0.00778 0.37 0.22 Blood pressure (smoking interaction); chr3:125592418 chr3:125916620~125930024:+ LIHC cis rs5769707 0.933 rs2157444 ENSG00000235111.1 RP1-29C18.8 -4.19 3.54e-05 0.00779 -0.26 -0.22 Monocyte percentage of white cells;Monocyte count; chr22:49600644 chr22:49612657~49615716:- LIHC cis rs2015599 0.54 rs12301475 ENSG00000257176.2 RP11-996F15.2 4.19 3.54e-05 0.00779 0.27 0.22 Platelet count;Mean platelet volume; chr12:29253144 chr12:29280418~29317848:- LIHC cis rs1075265 0.508 rs12621225 ENSG00000272156.1 RP11-477N3.1 -4.19 3.54e-05 0.00779 -0.27 -0.22 Chronotype;Morning vs. evening chronotype; chr2:53710040 chr2:54082554~54085066:+ LIHC cis rs11096990 0.634 rs2381372 ENSG00000249685.1 RP11-360F5.3 4.19 3.54e-05 0.00779 0.26 0.22 Cognitive function; chr4:39271471 chr4:39133913~39135608:+ LIHC cis rs9457247 0.602 rs12208359 ENSG00000227598.1 RP1-167A14.2 -4.19 3.54e-05 0.00779 -0.24 -0.22 Crohn's disease; chr6:167044967 chr6:166969626~166999065:- LIHC cis rs7937890 0.598 rs10734225 ENSG00000251991.1 RNU7-49P 4.19 3.54e-05 0.0078 0.25 0.22 Mitochondrial DNA levels; chr11:14421448 chr11:14478892~14478953:+ LIHC cis rs2688482 0.557 rs2550236 ENSG00000207650.1 MIR570 4.19 3.54e-05 0.0078 0.28 0.22 Lung disease severity in cystic fibrosis; chr3:195795450 chr3:195699401~195699497:+ LIHC cis rs9368481 0.761 rs7775041 ENSG00000241549.7 GUSBP2 -4.19 3.54e-05 0.0078 -0.23 -0.22 Autism spectrum disorder or schizophrenia; chr6:27041733 chr6:26871484~26956554:- LIHC cis rs9527 0.544 rs3781280 ENSG00000236937.2 PTGES3P4 4.19 3.54e-05 0.0078 0.28 0.22 Arsenic metabolism; chr10:103104086 chr10:102845595~102845950:+ LIHC cis rs4650994 0.816 rs2811303 ENSG00000213057.5 C1orf220 -4.19 3.54e-05 0.00781 -0.18 -0.22 HDL cholesterol;HDL cholesterol levels; chr1:178626511 chr1:178542752~178548889:+ LIHC cis rs524281 1 rs472518 ENSG00000255320.1 RP11-755F10.1 -4.19 3.55e-05 0.00782 -0.26 -0.22 Electroencephalogram traits; chr11:66084431 chr11:66244840~66246239:- LIHC cis rs10829156 0.699 rs1917209 ENSG00000240291.1 RP11-499P20.2 4.19 3.55e-05 0.00782 0.34 0.22 Sudden cardiac arrest; chr10:18543631 chr10:18513115~18545651:- LIHC cis rs4938303 0.633 rs12801136 ENSG00000254851.1 RP11-109L13.1 4.19 3.55e-05 0.00782 0.31 0.22 Triglycerides; chr11:116677632 chr11:117135528~117138582:+ LIHC cis rs4938303 0.633 rs35963862 ENSG00000254851.1 RP11-109L13.1 4.19 3.55e-05 0.00782 0.31 0.22 Triglycerides; chr11:116679180 chr11:117135528~117138582:+ LIHC cis rs4938303 0.671 rs35352977 ENSG00000254851.1 RP11-109L13.1 4.19 3.55e-05 0.00782 0.31 0.22 Triglycerides; chr11:116681756 chr11:117135528~117138582:+ LIHC cis rs2283792 0.765 rs5999749 ENSG00000224086.5 LL22NC03-86G7.1 4.19 3.55e-05 0.00782 0.23 0.22 Multiple sclerosis; chr22:21833371 chr22:21938293~21977632:+ LIHC cis rs4578769 0.959 rs11082184 ENSG00000266850.1 RP11-370A5.1 4.19 3.55e-05 0.00782 0.26 0.22 Eosinophil percentage of white cells; chr18:22872288 chr18:22723491~22907721:- LIHC cis rs4578769 0.959 rs12964817 ENSG00000266850.1 RP11-370A5.1 4.19 3.55e-05 0.00782 0.26 0.22 Eosinophil percentage of white cells; chr18:22876657 chr18:22723491~22907721:- LIHC cis rs960902 0.592 rs7571760 ENSG00000213553.4 RPLP0P6 -4.19 3.55e-05 0.00782 -0.18 -0.22 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37515615 chr2:38481851~38482804:+ LIHC cis rs755249 0.529 rs4660732 ENSG00000182109.6 RP11-69E11.4 4.19 3.55e-05 0.00782 0.29 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39397543 chr1:39522280~39546187:- LIHC cis rs875971 0.545 rs6970498 ENSG00000228409.4 CCT6P1 -4.19 3.55e-05 0.00782 -0.19 -0.22 Aortic root size; chr7:66275908 chr7:65751142~65763354:+ LIHC cis rs6545883 0.524 rs2694619 ENSG00000271889.1 RP11-493E12.1 -4.19 3.55e-05 0.00782 -0.26 -0.22 Tuberculosis; chr2:61309766 chr2:61151433~61162105:- LIHC cis rs8064024 0.649 rs9934930 ENSG00000267077.1 RP11-127I20.5 4.19 3.55e-05 0.00782 0.23 0.22 Cancer; chr16:4852037 chr16:4795265~4796532:- LIHC cis rs875971 0.502 rs11769702 ENSG00000228409.4 CCT6P1 -4.19 3.55e-05 0.00782 -0.19 -0.22 Aortic root size; chr7:66255529 chr7:65751142~65763354:+ LIHC cis rs6832769 1 rs9312662 ENSG00000272969.1 RP11-528I4.2 -4.19 3.56e-05 0.00783 -0.26 -0.22 Personality dimensions; chr4:55520204 chr4:55547112~55547889:+ LIHC cis rs67311347 0.568 rs9864544 ENSG00000223797.4 ENTPD3-AS1 4.19 3.56e-05 0.00783 0.18 0.22 Renal cell carcinoma; chr3:40294713 chr3:40313802~40453329:- LIHC cis rs67311347 0.544 rs9864664 ENSG00000223797.4 ENTPD3-AS1 4.19 3.56e-05 0.00783 0.18 0.22 Renal cell carcinoma; chr3:40294735 chr3:40313802~40453329:- LIHC cis rs67311347 0.544 rs13062243 ENSG00000223797.4 ENTPD3-AS1 4.19 3.56e-05 0.00783 0.18 0.22 Renal cell carcinoma; chr3:40295298 chr3:40313802~40453329:- LIHC cis rs67311347 0.544 rs35112505 ENSG00000223797.4 ENTPD3-AS1 4.19 3.56e-05 0.00783 0.18 0.22 Renal cell carcinoma; chr3:40295584 chr3:40313802~40453329:- LIHC cis rs67311347 0.544 rs12054197 ENSG00000223797.4 ENTPD3-AS1 4.19 3.56e-05 0.00783 0.18 0.22 Renal cell carcinoma; chr3:40296071 chr3:40313802~40453329:- LIHC cis rs67311347 0.544 rs67533651 ENSG00000223797.4 ENTPD3-AS1 4.19 3.56e-05 0.00783 0.18 0.22 Renal cell carcinoma; chr3:40296876 chr3:40313802~40453329:- LIHC cis rs67311347 0.544 rs4974047 ENSG00000223797.4 ENTPD3-AS1 4.19 3.56e-05 0.00783 0.18 0.22 Renal cell carcinoma; chr3:40298162 chr3:40313802~40453329:- LIHC cis rs67311347 0.544 rs9814779 ENSG00000223797.4 ENTPD3-AS1 4.19 3.56e-05 0.00783 0.18 0.22 Renal cell carcinoma; chr3:40298940 chr3:40313802~40453329:- LIHC cis rs948562 0.947 rs2298607 ENSG00000280010.1 AP001350.4 4.19 3.56e-05 0.00783 0.38 0.22 Lymphoma; chr11:58637026 chr11:58627435~58628528:+ LIHC cis rs7208859 0.673 rs999797 ENSG00000266490.1 CTD-2349P21.9 4.19 3.56e-05 0.00783 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832311 chr17:30792372~30792833:+ LIHC cis rs4713118 0.513 rs149958 ENSG00000216901.1 AL022393.7 4.19 3.56e-05 0.00783 0.29 0.22 Parkinson's disease; chr6:28045839 chr6:28176188~28176674:+ LIHC cis rs4713118 0.513 rs149959 ENSG00000216901.1 AL022393.7 4.19 3.56e-05 0.00783 0.29 0.22 Parkinson's disease; chr6:28046076 chr6:28176188~28176674:+ LIHC cis rs4713118 0.513 rs156738 ENSG00000216901.1 AL022393.7 4.19 3.56e-05 0.00783 0.29 0.22 Parkinson's disease; chr6:28046247 chr6:28176188~28176674:+ LIHC cis rs2348418 0.864 rs2137071 ENSG00000247934.4 RP11-967K21.1 4.19 3.56e-05 0.00783 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28563797 chr12:28163298~28190738:- LIHC cis rs9595908 0.785 rs9591236 ENSG00000212293.1 SNORA16 4.19 3.56e-05 0.00784 0.25 0.22 Body mass index; chr13:32671667 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs6561499 ENSG00000212293.1 SNORA16 4.19 3.56e-05 0.00784 0.25 0.22 Body mass index; chr13:32681075 chr13:32420390~32420516:- LIHC cis rs7216064 0.636 rs4638 ENSG00000278740.1 RP11-147L13.14 -4.19 3.56e-05 0.00784 -0.26 -0.22 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68043234 chr17:68188547~68189165:+ LIHC cis rs7216064 0.601 rs35453056 ENSG00000278740.1 RP11-147L13.14 -4.19 3.56e-05 0.00784 -0.26 -0.22 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68043552 chr17:68188547~68189165:+ LIHC cis rs7216064 0.628 rs62084702 ENSG00000278740.1 RP11-147L13.14 -4.19 3.56e-05 0.00784 -0.26 -0.22 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68047041 chr17:68188547~68189165:+ LIHC cis rs2877649 0.793 rs75612696 ENSG00000258744.1 RP11-80A15.1 -4.19 3.57e-05 0.00784 -0.45 -0.22 Smooth-surface caries; chr14:24499862 chr14:24501594~24508688:+ LIHC cis rs160451 1 rs160448 ENSG00000251136.7 RP11-37B2.1 4.19 3.57e-05 0.00784 0.21 0.22 Leprosy; chr8:89647622 chr8:89609409~89757727:- LIHC cis rs193541 0.642 rs42538 ENSG00000263432.2 RN7SL689P 4.19 3.57e-05 0.00785 0.35 0.22 Glucose homeostasis traits; chr5:122956657 chr5:123022487~123022783:- LIHC cis rs193541 0.632 rs39821 ENSG00000263432.2 RN7SL689P 4.19 3.57e-05 0.00785 0.35 0.22 Glucose homeostasis traits; chr5:122959777 chr5:123022487~123022783:- LIHC cis rs673078 0.66 rs61945219 ENSG00000275409.1 RP11-131L12.4 -4.19 3.57e-05 0.00785 -0.27 -0.22 Glucose homeostasis traits; chr12:118272916 chr12:118430147~118430699:+ LIHC cis rs1928295 0.786 rs7032255 ENSG00000233569.1 RP11-500B12.1 4.19 3.57e-05 0.00785 0.23 0.22 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117637809 chr9:117648606~117657027:+ LIHC cis rs686320 0.748 rs580933 ENSG00000245532.5 NEAT1 -4.19 3.57e-05 0.00786 -0.33 -0.22 Hip circumference adjusted for BMI; chr11:65429413 chr11:65422774~65445540:+ LIHC cis rs13287066 0.692 rs10992723 ENSG00000227603.1 RP11-165J3.6 4.19 3.57e-05 0.00786 0.25 0.22 Intelligence (multi-trait analysis); chr9:93407016 chr9:93435332~93437121:- LIHC cis rs4578769 0.722 rs55943912 ENSG00000266850.1 RP11-370A5.1 -4.19 3.57e-05 0.00786 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22938388 chr18:22723491~22907721:- LIHC cis rs7580658 0.534 rs2089109 ENSG00000236682.1 AC068282.3 -4.19 3.58e-05 0.00787 -0.27 -0.22 Protein C levels; chr2:127193882 chr2:127389130~127400580:+ LIHC cis rs9807989 0.507 rs1592459 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00787 0.24 0.22 Asthma; chr2:102415109 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs1592458 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00787 0.24 0.22 Asthma; chr2:102415289 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs2160201 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00787 0.24 0.22 Asthma; chr2:102417501 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs1833174 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00787 0.24 0.22 Asthma; chr2:102418383 chr2:102438713~102440475:+ LIHC cis rs7587476 0.689 rs10498025 ENSG00000229267.2 AC072062.1 -4.19 3.58e-05 0.00787 -0.28 -0.22 Neuroblastoma; chr2:214884532 chr2:214810229~214963274:+ LIHC cis rs72627509 0.638 rs12642622 ENSG00000269949.1 RP11-738E22.3 4.19 3.58e-05 0.00787 0.32 0.22 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57036110 chr4:56960927~56961373:- LIHC cis rs2735413 0.914 rs2262658 ENSG00000276007.1 RP11-358L22.3 -4.19 3.58e-05 0.00787 -0.25 -0.22 Systolic blood pressure (alcohol consumption interaction); chr16:78026370 chr16:78123243~78124332:+ LIHC cis rs734999 0.545 rs9970196 ENSG00000225931.3 RP3-395M20.7 -4.19 3.58e-05 0.00787 -0.24 -0.22 Ulcerative colitis; chr1:2642639 chr1:2566410~2569888:+ LIHC cis rs3764021 1 rs7977720 ENSG00000256673.1 RP11-599J14.2 -4.19 3.58e-05 0.00787 -0.21 -0.22 Type 1 diabetes; chr12:9713753 chr12:9398355~9414851:- LIHC cis rs2348418 0.669 rs7959641 ENSG00000247934.4 RP11-967K21.1 4.19 3.58e-05 0.00787 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28237267 chr12:28163298~28190738:- LIHC cis rs673078 0.607 rs56080343 ENSG00000275759.1 RP11-131L12.3 -4.19 3.58e-05 0.00787 -0.28 -0.22 Glucose homeostasis traits; chr12:118439113 chr12:118428281~118428870:+ LIHC cis rs603446 1 rs1145208 ENSG00000254851.1 RP11-109L13.1 -4.19 3.58e-05 0.00788 -0.28 -0.22 Triglycerides; chr11:116767269 chr11:117135528~117138582:+ LIHC cis rs1005277 0.505 rs7099777 ENSG00000276805.1 RP11-291L22.6 -4.19 3.58e-05 0.00788 -0.27 -0.22 Extrinsic epigenetic age acceleration; chr10:37894641 chr10:38451030~38451785:+ LIHC cis rs2243480 1 rs67728539 ENSG00000228409.4 CCT6P1 4.19 3.58e-05 0.00788 0.24 0.22 Diabetic kidney disease; chr7:65913137 chr7:65751142~65763354:+ LIHC cis rs8177253 0.665 rs12493887 ENSG00000244062.1 RP11-404G16.2 4.19 3.58e-05 0.00788 0.22 0.22 Iron status biomarkers; chr3:133721893 chr3:133760300~133762363:+ LIHC cis rs9807989 0.507 rs2293224 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00788 0.24 0.22 Asthma; chr2:102419319 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs6743516 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00788 0.24 0.22 Asthma; chr2:102419875 chr2:102438713~102440475:+ LIHC cis rs4988958 0.565 rs1420100 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00788 0.24 0.22 Asthma (childhood onset); chr2:102420542 chr2:102438713~102440475:+ LIHC cis rs4988958 0.527 rs3771155 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00788 0.24 0.22 Asthma (childhood onset); chr2:102421366 chr2:102438713~102440475:+ LIHC cis rs4988958 0.565 rs10206291 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00788 0.24 0.22 Asthma (childhood onset); chr2:102422403 chr2:102438713~102440475:+ LIHC cis rs4988958 0.565 rs885088 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00788 0.24 0.22 Asthma (childhood onset); chr2:102422584 chr2:102438713~102440475:+ LIHC cis rs4988958 0.565 rs3771154 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00788 0.24 0.22 Asthma (childhood onset); chr2:102422900 chr2:102438713~102440475:+ LIHC cis rs9807989 0.524 rs6759479 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00788 0.24 0.22 Asthma; chr2:102423587 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs6543133 ENSG00000234389.1 AC007278.3 4.19 3.58e-05 0.00788 0.24 0.22 Asthma; chr2:102423717 chr2:102438713~102440475:+ LIHC cis rs6061231 0.654 rs2427322 ENSG00000226332.2 RP11-157P1.4 4.19 3.59e-05 0.00788 0.24 0.22 Colorectal cancer; chr20:62404314 chr20:62305432~62306325:- LIHC cis rs7937890 0.531 rs2575828 ENSG00000251991.1 RNU7-49P 4.19 3.59e-05 0.00788 0.24 0.22 Mitochondrial DNA levels; chr11:14462646 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2575829 ENSG00000251991.1 RNU7-49P 4.19 3.59e-05 0.00788 0.24 0.22 Mitochondrial DNA levels; chr11:14463475 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2597201 ENSG00000251991.1 RNU7-49P 4.19 3.59e-05 0.00788 0.24 0.22 Mitochondrial DNA levels; chr11:14463858 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2597200 ENSG00000251991.1 RNU7-49P 4.19 3.59e-05 0.00788 0.24 0.22 Mitochondrial DNA levels; chr11:14464054 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2575830 ENSG00000251991.1 RNU7-49P 4.19 3.59e-05 0.00788 0.24 0.22 Mitochondrial DNA levels; chr11:14464056 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2575831 ENSG00000251991.1 RNU7-49P 4.19 3.59e-05 0.00788 0.24 0.22 Mitochondrial DNA levels; chr11:14464648 chr11:14478892~14478953:+ LIHC cis rs7937890 0.532 rs2575832 ENSG00000251991.1 RNU7-49P 4.19 3.59e-05 0.00788 0.24 0.22 Mitochondrial DNA levels; chr11:14467264 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2597197 ENSG00000251991.1 RNU7-49P 4.19 3.59e-05 0.00788 0.24 0.22 Mitochondrial DNA levels; chr11:14468286 chr11:14478892~14478953:+ LIHC cis rs11098499 0.644 rs10009566 ENSG00000260091.1 RP11-33B1.4 -4.19 3.59e-05 0.00789 -0.16 -0.22 Corneal astigmatism; chr4:119637453 chr4:119409333~119410233:+ LIHC cis rs1005277 0.505 rs1208689 ENSG00000276805.1 RP11-291L22.6 4.19 3.59e-05 0.00789 0.27 0.22 Extrinsic epigenetic age acceleration; chr10:37808847 chr10:38451030~38451785:+ LIHC cis rs1005277 0.522 rs289648 ENSG00000099251.13 HSD17B7P2 4.19 3.59e-05 0.00789 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:37682909 chr10:38356380~38378505:+ LIHC cis rs2581828 0.965 rs4337632 ENSG00000242142.1 SERBP1P3 4.19 3.59e-05 0.00789 0.25 0.22 Crohn's disease; chr3:53103295 chr3:53064283~53065091:- LIHC cis rs5758659 0.716 rs2143138 ENSG00000227370.1 RP4-669P10.19 -4.19 3.59e-05 0.00789 -0.24 -0.22 Cognitive function; chr22:42222334 chr22:42132543~42132998:+ LIHC cis rs4578769 0.765 rs1609463 ENSG00000266850.1 RP11-370A5.1 -4.19 3.59e-05 0.00789 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22824144 chr18:22723491~22907721:- LIHC cis rs2060793 0.741 rs4757268 ENSG00000251991.1 RNU7-49P 4.19 3.59e-05 0.00789 0.25 0.22 Vitamin D levels; chr11:14789216 chr11:14478892~14478953:+ LIHC cis rs11098499 0.955 rs35197422 ENSG00000260091.1 RP11-33B1.4 -4.19 3.59e-05 0.0079 -0.16 -0.22 Corneal astigmatism; chr4:119248159 chr4:119409333~119410233:+ LIHC cis rs11098499 0.955 rs1511015 ENSG00000260091.1 RP11-33B1.4 -4.19 3.59e-05 0.0079 -0.16 -0.22 Corneal astigmatism; chr4:119249318 chr4:119409333~119410233:+ LIHC cis rs2348418 0.864 rs1343859 ENSG00000247934.4 RP11-967K21.1 4.19 3.6e-05 0.0079 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28559537 chr12:28163298~28190738:- LIHC cis rs524281 0.731 rs1125078 ENSG00000255320.1 RP11-755F10.1 -4.19 3.6e-05 0.0079 -0.31 -0.22 Electroencephalogram traits; chr11:66042404 chr11:66244840~66246239:- LIHC cis rs198389 0.589 rs12404124 ENSG00000242349.4 NPPA-AS1 -4.19 3.6e-05 0.0079 -0.23 -0.22 B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome; chr1:11813812 chr1:11841017~11848079:+ LIHC cis rs9992667 0.955 rs922334 ENSG00000231160.8 KLF3-AS1 4.19 3.6e-05 0.0079 0.29 0.22 Eosinophil percentage of granulocytes; chr4:38615137 chr4:38612701~38664883:- LIHC cis rs8177253 0.574 rs6775042 ENSG00000244062.1 RP11-404G16.2 4.19 3.6e-05 0.0079 0.22 0.22 Iron status biomarkers; chr3:133723401 chr3:133760300~133762363:+ LIHC cis rs2439831 0.85 rs61390361 ENSG00000166763.7 STRCP1 4.19 3.6e-05 0.00791 0.35 0.22 Lung cancer in ever smokers; chr15:43867644 chr15:43699488~43718184:- LIHC cis rs1501911 0.611 rs2221268 ENSG00000248489.1 CTD-2007H13.3 -4.19 3.6e-05 0.00791 -0.33 -0.22 Lung function (FEV1/FVC); chr5:99021711 chr5:98929171~98995013:+ LIHC cis rs1023500 0.505 rs134899 ENSG00000226450.2 CYP2D8P 4.19 3.6e-05 0.00791 0.25 0.22 Schizophrenia; chr22:42287024 chr22:42149886~42155001:- LIHC cis rs244293 0.795 rs11079150 ENSG00000275710.1 RP11-257O5.4 -4.19 3.6e-05 0.00791 -0.24 -0.22 Menarche (age at onset); chr17:55017700 chr17:54964474~54964679:+ LIHC cis rs7131987 0.834 rs11050167 ENSG00000275476.1 RP11-996F15.4 -4.19 3.61e-05 0.00792 -0.27 -0.22 QT interval; chr12:29273454 chr12:29277397~29277882:- LIHC cis rs5742933 0.762 rs12992061 ENSG00000253559.1 OSGEPL1-AS1 4.19 3.61e-05 0.00792 0.29 0.22 Ferritin levels; chr2:189736026 chr2:189762704~189765556:+ LIHC cis rs417065 1 rs417065 ENSG00000227634.1 RP11-431K24.3 -4.19 3.61e-05 0.00792 -0.3 -0.22 Psoriasis; chr1:8204052 chr1:8208672~8215210:+ LIHC cis rs597539 0.652 rs674654 ENSG00000250508.1 RP11-757G1.6 -4.19 3.61e-05 0.00792 -0.34 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68931294 chr11:68870664~68874542:+ LIHC cis rs597539 0.616 rs513476 ENSG00000250508.1 RP11-757G1.6 -4.19 3.61e-05 0.00792 -0.34 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68931528 chr11:68870664~68874542:+ LIHC cis rs9675120 0.963 rs7225019 ENSG00000262006.1 RP11-700H6.4 -4.19 3.61e-05 0.00792 -0.23 -0.22 Cerebrospinal fluid biomarker levels; chr17:50838518 chr17:50909637~50910232:- LIHC cis rs2929278 0.589 rs11638972 ENSG00000275601.1 AC011330.13 4.19 3.61e-05 0.00793 0.26 0.22 Schizophrenia; chr15:43782493 chr15:43642389~43643023:- LIHC cis rs2274273 0.624 rs8015211 ENSG00000258413.1 RP11-665C16.6 -4.19 3.61e-05 0.00793 -0.27 -0.22 Protein biomarker; chr14:55374729 chr14:55262767~55272075:- LIHC cis rs1823913 1 rs10445782 ENSG00000227542.1 AC092614.2 -4.19 3.61e-05 0.00793 -0.23 -0.22 Obesity-related traits; chr2:191236639 chr2:191229165~191246172:- LIHC cis rs1823913 1 rs4853561 ENSG00000227542.1 AC092614.2 -4.19 3.61e-05 0.00793 -0.23 -0.22 Obesity-related traits; chr2:191242980 chr2:191229165~191246172:- LIHC cis rs4879656 0.593 rs13297493 ENSG00000225693.1 LAGE3P1 4.19 3.61e-05 0.00793 0.28 0.22 Menopause (age at onset); chr9:33049603 chr9:33019682~33020165:- LIHC cis rs1823913 1 rs6704784 ENSG00000227542.1 AC092614.2 -4.19 3.61e-05 0.00793 -0.23 -0.22 Obesity-related traits; chr2:191244832 chr2:191229165~191246172:- LIHC cis rs2243480 1 rs1618893 ENSG00000232546.1 RP11-458F8.1 -4.19 3.61e-05 0.00793 -0.23 -0.22 Diabetic kidney disease; chr7:66631132 chr7:66848496~66858136:+ LIHC cis rs6997458 0.935 rs7824715 ENSG00000253549.4 RP11-317J10.2 4.19 3.62e-05 0.00793 0.24 0.22 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85366148 chr8:85441851~85464915:- LIHC cis rs10829156 0.607 rs7908550 ENSG00000240291.1 RP11-499P20.2 4.19 3.62e-05 0.00794 0.36 0.22 Sudden cardiac arrest; chr10:18573282 chr10:18513115~18545651:- LIHC cis rs921968 0.565 rs6733892 ENSG00000272555.1 RP11-459I19.1 -4.19 3.62e-05 0.00794 -0.23 -0.22 Mean corpuscular hemoglobin concentration; chr2:218751279 chr2:218818690~218819144:+ LIHC cis rs3204270 0.759 rs8065104 ENSG00000281517.1 Metazoa_SRP -4.19 3.62e-05 0.00794 -0.41 -0.22 Dental caries; chr17:81705575 chr17:81718849~81719095:- LIHC cis rs2243480 1 rs427044 ENSG00000228409.4 CCT6P1 4.19 3.62e-05 0.00794 0.23 0.22 Diabetic kidney disease; chr7:66043558 chr7:65751142~65763354:+ LIHC cis rs17772222 0.837 rs57118463 ENSG00000258789.1 RP11-507K2.3 -4.19 3.62e-05 0.00794 -0.26 -0.22 Coronary artery calcification; chr14:88665822 chr14:88551597~88552493:+ LIHC cis rs7800244 0.848 rs62447755 ENSG00000146666.5 LINC00525 -4.19 3.62e-05 0.00794 -0.35 -0.22 Hepatitis C induced liver fibrosis; chr7:47750564 chr7:47761476~47766772:+ LIHC cis rs2658782 1 rs2605585 ENSG00000279684.1 RP11-755E23.2 -4.19 3.62e-05 0.00794 -0.38 -0.22 Pulmonary function decline; chr11:93438696 chr11:93286629~93288903:- LIHC cis rs6430585 0.528 rs660002 ENSG00000231890.6 DARS-AS1 -4.19 3.62e-05 0.00794 -0.3 -0.22 Corneal structure; chr2:135965934 chr2:135985176~136022593:+ LIHC cis rs6496667 0.509 rs2253419 ENSG00000213471.7 TTLL13P 4.19 3.62e-05 0.00794 0.29 0.22 Rheumatoid arthritis; chr15:90402643 chr15:90249530~90265482:+ LIHC cis rs67311347 0.713 rs4974018 ENSG00000223797.4 ENTPD3-AS1 4.19 3.62e-05 0.00795 0.18 0.22 Renal cell carcinoma; chr3:40265928 chr3:40313802~40453329:- LIHC cis rs12931792 0.782 rs6565176 ENSG00000183604.13 SMG1P5 4.19 3.62e-05 0.00795 0.22 0.22 Tonsillectomy; chr16:30163605 chr16:30267553~30335374:- LIHC cis rs1223397 0.651 rs449727 ENSG00000215022.6 RP1-257A7.4 -4.19 3.62e-05 0.00795 -0.23 -0.22 Blood pressure; chr6:13296078 chr6:13264861~13295586:- LIHC cis rs6801605 0.743 rs4687751 ENSG00000271916.1 RP11-884K10.6 -4.19 3.63e-05 0.00795 -0.29 -0.22 Blood protein levels; chr3:53849883 chr3:53797764~53798019:- LIHC cis rs932287 0.505 rs2742536 ENSG00000254860.4 TMEM9B-AS1 4.19 3.63e-05 0.00796 0.21 0.22 Colonoscopy-negative controls vs population controls; chr11:8888269 chr11:8964675~8977527:+ LIHC cis rs9907295 0.71 rs9894083 ENSG00000270871.1 AC015849.19 4.19 3.63e-05 0.00796 0.23 0.22 Fibroblast growth factor basic levels; chr17:35842151 chr17:35816717~35830293:- LIHC cis rs17772222 0.636 rs77528165 ENSG00000258789.1 RP11-507K2.3 -4.18 3.63e-05 0.00796 -0.27 -0.22 Coronary artery calcification; chr14:88794249 chr14:88551597~88552493:+ LIHC cis rs6471393 0.964 rs2914941 ENSG00000253848.1 RP11-10N23.5 4.18 3.63e-05 0.00796 0.25 0.22 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93716983 chr8:93741193~93744534:+ LIHC cis rs11098499 0.739 rs10031033 ENSG00000260091.1 RP11-33B1.4 -4.18 3.64e-05 0.00797 -0.15 -0.22 Corneal astigmatism; chr4:119230297 chr4:119409333~119410233:+ LIHC cis rs8059260 0.935 rs9928255 ENSG00000274038.1 RP11-66H6.4 -4.18 3.64e-05 0.00797 -0.29 -0.22 Alcohol consumption over the past year; chr16:11027408 chr16:11056556~11057034:+ LIHC cis rs728616 0.867 rs56123058 ENSG00000225484.5 NUTM2B-AS1 -4.18 3.64e-05 0.00798 -0.5 -0.22 Chronic obstructive pulmonary disease-related biomarkers; chr10:80051316 chr10:79663088~79826594:- LIHC cis rs4713118 0.513 rs156739 ENSG00000216901.1 AL022393.7 4.18 3.64e-05 0.00798 0.29 0.22 Parkinson's disease; chr6:28045632 chr6:28176188~28176674:+ LIHC cis rs73186030 1 rs73186044 ENSG00000272758.4 RP11-299J3.8 4.18 3.64e-05 0.00798 0.42 0.22 Serum parathyroid hormone levels; chr3:122309629 chr3:122416207~122443180:+ LIHC cis rs73186030 1 rs55838400 ENSG00000272758.4 RP11-299J3.8 4.18 3.64e-05 0.00798 0.42 0.22 Serum parathyroid hormone levels; chr3:122313446 chr3:122416207~122443180:+ LIHC cis rs73186030 0.92 rs73186059 ENSG00000272758.4 RP11-299J3.8 4.18 3.64e-05 0.00798 0.42 0.22 Serum parathyroid hormone levels; chr3:122332336 chr3:122416207~122443180:+ LIHC cis rs73186030 0.92 rs73186060 ENSG00000272758.4 RP11-299J3.8 4.18 3.64e-05 0.00798 0.42 0.22 Serum parathyroid hormone levels; chr3:122333507 chr3:122416207~122443180:+ LIHC cis rs2243480 1 rs316329 ENSG00000230295.1 RP11-458F8.2 -4.18 3.64e-05 0.00798 -0.23 -0.22 Diabetic kidney disease; chr7:66143429 chr7:66880708~66882981:+ LIHC cis rs603446 0.55 rs1787698 ENSG00000254851.1 RP11-109L13.1 4.18 3.64e-05 0.00799 0.29 0.22 Triglycerides; chr11:116693846 chr11:117135528~117138582:+ LIHC cis rs150992 0.53 rs2927646 ENSG00000248489.1 CTD-2007H13.3 4.18 3.64e-05 0.00799 0.29 0.22 Body mass index; chr5:98989462 chr5:98929171~98995013:+ LIHC cis rs912057 1 rs912057 ENSG00000261211.1 RP1-80N2.3 -4.18 3.64e-05 0.00799 -0.22 -0.22 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index; chr6:6736698 chr6:6680309~6683633:- LIHC cis rs6565180 0.888 rs13333093 ENSG00000183604.13 SMG1P5 4.18 3.65e-05 0.00799 0.23 0.22 Tonsillectomy; chr16:30395948 chr16:30267553~30335374:- LIHC cis rs2243480 0.901 rs57126451 ENSG00000228409.4 CCT6P1 4.18 3.65e-05 0.00799 0.24 0.22 Diabetic kidney disease; chr7:65951319 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs801199 ENSG00000228409.4 CCT6P1 4.18 3.65e-05 0.00799 0.18 0.22 Aortic root size; chr7:66560286 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs1638724 ENSG00000228409.4 CCT6P1 4.18 3.65e-05 0.00799 0.18 0.22 Aortic root size; chr7:66575494 chr7:65751142~65763354:+ LIHC cis rs7811142 1 rs67315960 ENSG00000242294.5 STAG3L5P 4.18 3.65e-05 0.008 0.25 0.22 Platelet count; chr7:100417501 chr7:100336079~100351900:+ LIHC cis rs957448 1 rs1023767 ENSG00000253704.1 RP11-267M23.4 4.18 3.65e-05 0.008 0.27 0.22 Nonsyndromic cleft lip with cleft palate; chr8:94518741 chr8:94553722~94569745:+ LIHC cis rs7809950 0.862 rs58391518 ENSG00000238832.1 snoU109 -4.18 3.65e-05 0.008 -0.27 -0.22 Coronary artery disease; chr7:107390342 chr7:107603363~107603507:+ LIHC cis rs6439153 0.933 rs2630262 ENSG00000231305.3 RP11-723O4.2 -4.18 3.65e-05 0.008 -0.24 -0.22 Pneumococcal bacteremia; chr3:128958255 chr3:128861313~128871540:- LIHC cis rs12468226 0.689 rs17656903 ENSG00000272966.1 RP11-686O6.1 -4.18 3.65e-05 0.008 -0.39 -0.22 Urate levels; chr2:202106312 chr2:202336739~202337200:+ LIHC cis rs673078 0.571 rs61945220 ENSG00000275759.1 RP11-131L12.3 -4.18 3.65e-05 0.008 -0.45 -0.22 Glucose homeostasis traits; chr12:118272924 chr12:118428281~118428870:+ LIHC cis rs673078 0.571 rs61945221 ENSG00000275759.1 RP11-131L12.3 -4.18 3.65e-05 0.008 -0.45 -0.22 Glucose homeostasis traits; chr12:118272926 chr12:118428281~118428870:+ LIHC cis rs4144027 0.904 rs10438244 ENSG00000258534.1 CTD-2134A5.4 4.18 3.65e-05 0.008 0.25 0.22 Blood metabolite levels; chr14:103879848 chr14:103854366~103880111:- LIHC cis rs6700559 0.81 rs10919990 ENSG00000260088.1 RP11-92G12.3 -4.18 3.65e-05 0.008 -0.28 -0.22 Coronary artery disease; chr1:200627076 chr1:200669507~200694250:+ LIHC cis rs2286503 0.839 rs4722188 ENSG00000228649.7 AC005682.5 4.18 3.65e-05 0.00801 0.26 0.22 Fibrinogen; chr7:22820592 chr7:22854178~22861579:+ LIHC cis rs11671005 0.611 rs36090113 ENSG00000269473.1 CTD-2619J13.19 4.18 3.65e-05 0.00801 0.39 0.22 Mean platelet volume; chr19:58401017 chr19:58440448~58445849:+ LIHC cis rs728616 0.867 rs7906286 ENSG00000225484.5 NUTM2B-AS1 -4.18 3.66e-05 0.00801 -0.46 -0.22 Chronic obstructive pulmonary disease-related biomarkers; chr10:80074279 chr10:79663088~79826594:- LIHC cis rs4578769 0.765 rs9949825 ENSG00000266850.1 RP11-370A5.1 -4.18 3.66e-05 0.00801 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22806055 chr18:22723491~22907721:- LIHC cis rs202072 1 rs202077 ENSG00000215022.6 RP1-257A7.4 -4.18 3.66e-05 0.00802 -0.25 -0.22 HIV-1 viral setpoint; chr6:13271206 chr6:13264861~13295586:- LIHC cis rs597539 0.652 rs673821 ENSG00000250508.1 RP11-757G1.6 -4.18 3.66e-05 0.00802 -0.34 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68911250 chr11:68870664~68874542:+ LIHC cis rs244293 0.864 rs244374 ENSG00000275710.1 RP11-257O5.4 -4.18 3.66e-05 0.00802 -0.24 -0.22 Menarche (age at onset); chr17:55106393 chr17:54964474~54964679:+ LIHC cis rs1005277 0.522 rs9417256 ENSG00000099251.13 HSD17B7P2 4.18 3.66e-05 0.00802 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:37688062 chr10:38356380~38378505:+ LIHC cis rs2462686 1 rs2462686 ENSG00000272556.1 RP11-638I8.1 4.18 3.66e-05 0.00803 0.32 0.22 Major depressive disorder; chr7:45942861 chr7:45814602~45815263:+ LIHC cis rs1115240 0.947 rs11623268 ENSG00000257842.4 NOVA1-AS1 -4.18 3.67e-05 0.00803 -0.21 -0.22 Educational attainment (years of education); chr14:26636263 chr14:26598412~26806467:+ LIHC cis rs1115240 0.947 rs11627577 ENSG00000257842.4 NOVA1-AS1 -4.18 3.67e-05 0.00803 -0.21 -0.22 Educational attainment (years of education); chr14:26636355 chr14:26598412~26806467:+ LIHC cis rs62355901 0.8 rs7709971 ENSG00000271828.1 CTD-2310F14.1 4.18 3.67e-05 0.00803 0.35 0.22 Breast cancer; chr5:56711512 chr5:56927874~56929573:+ LIHC cis rs950880 0.71 rs17027006 ENSG00000234389.1 AC007278.3 4.18 3.67e-05 0.00803 0.23 0.22 Serum protein levels (sST2); chr2:102348872 chr2:102438713~102440475:+ LIHC cis rs2744375 0.544 rs2744365 ENSG00000261189.1 RP3-512B11.3 4.18 3.67e-05 0.00804 0.28 0.22 Resting heart rate; chr6:7551787 chr6:7540451~7541338:- LIHC cis rs2253762 0.54 rs79547192 ENSG00000276742.1 RP11-500G22.4 4.18 3.67e-05 0.00804 0.36 0.22 Breast cancer; chr10:121998664 chr10:121956782~121957098:+ LIHC cis rs8064029 0.655 rs77468976 ENSG00000267077.1 RP11-127I20.5 4.18 3.67e-05 0.00804 0.29 0.22 Cancer; chr16:4819249 chr16:4795265~4796532:- LIHC cis rs7246657 0.765 rs10402455 ENSG00000276846.1 CTD-3220F14.3 4.18 3.67e-05 0.00804 0.31 0.22 Coronary artery calcification; chr19:37237805 chr19:37314868~37315620:- LIHC cis rs2598107 0.568 rs4723717 ENSG00000211698.2 TRGV4 -4.18 3.68e-05 0.00805 -0.26 -0.22 Dupuytren's disease; chr7:37929206 chr7:38353715~38354517:- LIHC cis rs1876905 0.539 rs240962 ENSG00000272356.1 RP5-1112D6.8 4.18 3.68e-05 0.00805 0.21 0.22 Mean corpuscular hemoglobin; chr6:111321243 chr6:111309203~111313517:+ LIHC cis rs9876781 1 rs2885510 ENSG00000229759.1 MRPS18AP1 -4.18 3.68e-05 0.00805 -0.23 -0.22 Longevity; chr3:48376736 chr3:48256350~48256938:- LIHC cis rs7893279 0.505 rs12766105 ENSG00000225527.1 RP11-383B4.4 4.18 3.68e-05 0.00805 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18584296 chr10:18531849~18533336:- LIHC cis rs79349575 0.716 rs46522 ENSG00000248278.1 SUMO2P17 4.18 3.68e-05 0.00805 0.28 0.22 Type 2 diabetes; chr17:48911235 chr17:48874860~48908983:- LIHC cis rs9565309 0.579 rs9634731 ENSG00000274898.1 AC001226.7 4.18 3.68e-05 0.00806 0.38 0.22 Morning vs. evening chronotype; chr13:77022696 chr13:77027944~77028482:+ LIHC cis rs950169 0.922 rs11638445 ENSG00000259728.4 LINC00933 4.18 3.68e-05 0.00806 0.33 0.22 Schizophrenia; chr15:84594463 chr15:84570649~84580175:+ LIHC cis rs728616 0.867 rs1537835 ENSG00000225484.5 NUTM2B-AS1 -4.18 3.68e-05 0.00806 -0.46 -0.22 Chronic obstructive pulmonary disease-related biomarkers; chr10:80070396 chr10:79663088~79826594:- LIHC cis rs160451 0.933 rs2088198 ENSG00000251136.7 RP11-37B2.1 4.18 3.68e-05 0.00806 0.2 0.22 Leprosy; chr8:89678693 chr8:89609409~89757727:- LIHC cis rs2880765 0.566 rs17553249 ENSG00000259630.2 CTD-2262B20.1 -4.18 3.68e-05 0.00806 -0.32 -0.22 Coronary artery disease; chr15:85463463 chr15:85415228~85415633:+ LIHC cis rs10833905 1 rs11026880 ENSG00000246225.5 RP11-17A1.3 -4.18 3.68e-05 0.00806 -0.29 -0.22 Sudden cardiac arrest; chr11:22994273 chr11:22829380~22945393:+ LIHC cis rs7412746 0.658 rs12068264 ENSG00000231073.1 RP11-316M1.3 4.18 3.68e-05 0.00806 0.23 0.22 Melanoma; chr1:150754853 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs2230061 ENSG00000231073.1 RP11-316M1.3 4.18 3.68e-05 0.00806 0.23 0.22 Melanoma; chr1:150755063 chr1:150973123~150975534:+ LIHC cis rs2744375 0.6 rs2237104 ENSG00000261189.1 RP3-512B11.3 -4.18 3.69e-05 0.00807 -0.27 -0.22 Resting heart rate; chr6:7551939 chr6:7540451~7541338:- LIHC cis rs9527 0.83 rs10883790 ENSG00000236937.2 PTGES3P4 4.18 3.69e-05 0.00807 0.29 0.22 Arsenic metabolism; chr10:102881198 chr10:102845595~102845950:+ LIHC cis rs9527 0.83 rs11191440 ENSG00000236937.2 PTGES3P4 4.18 3.69e-05 0.00807 0.29 0.22 Arsenic metabolism; chr10:102881754 chr10:102845595~102845950:+ LIHC cis rs9527 0.83 rs11191442 ENSG00000236937.2 PTGES3P4 4.18 3.69e-05 0.00807 0.29 0.22 Arsenic metabolism; chr10:102883839 chr10:102845595~102845950:+ LIHC cis rs9527 0.83 rs12249194 ENSG00000236937.2 PTGES3P4 4.18 3.69e-05 0.00807 0.29 0.22 Arsenic metabolism; chr10:102883941 chr10:102845595~102845950:+ LIHC cis rs3091242 0.967 rs3093614 ENSG00000261349.1 RP3-465N24.5 4.18 3.69e-05 0.00807 0.21 0.22 Erythrocyte sedimentation rate; chr1:25351353 chr1:25266102~25267136:- LIHC cis rs3091242 0.967 rs1053438 ENSG00000261349.1 RP3-465N24.5 4.18 3.69e-05 0.00807 0.21 0.22 Erythrocyte sedimentation rate; chr1:25361410 chr1:25266102~25267136:- LIHC cis rs6723108 0.517 rs1530555 ENSG00000224043.6 CCNT2-AS1 -4.18 3.69e-05 0.00807 -0.31 -0.22 Type 2 diabetes; chr2:134842169 chr2:134735464~134918710:- LIHC cis rs875971 0.571 rs160641 ENSG00000228409.4 CCT6P1 4.18 3.69e-05 0.00807 0.19 0.22 Aortic root size; chr7:66112359 chr7:65751142~65763354:+ LIHC cis rs2390582 0.564 rs74472546 ENSG00000231613.1 RP5-943J3.1 4.18 3.69e-05 0.00808 0.45 0.22 Coronary artery calcification; chr1:90304318 chr1:89788914~89790492:+ LIHC cis rs2390582 0.607 rs4658152 ENSG00000231613.1 RP5-943J3.1 4.18 3.69e-05 0.00808 0.45 0.22 Coronary artery calcification; chr1:90305596 chr1:89788914~89790492:+ LIHC cis rs11098499 0.691 rs10010355 ENSG00000245958.5 RP11-33B1.1 -4.18 3.69e-05 0.00808 -0.22 -0.22 Corneal astigmatism; chr4:119339888 chr4:119454791~119552025:+ LIHC cis rs11098499 0.691 rs9307471 ENSG00000245958.5 RP11-33B1.1 -4.18 3.69e-05 0.00808 -0.22 -0.22 Corneal astigmatism; chr4:119340107 chr4:119454791~119552025:+ LIHC cis rs11690935 0.632 rs12998411 ENSG00000228389.1 AC068039.4 -4.18 3.69e-05 0.00808 -0.27 -0.22 Schizophrenia; chr2:171674197 chr2:171773482~171775844:+ LIHC cis rs151234 0.676 rs151320 ENSG00000259982.1 CDC37P1 4.18 3.69e-05 0.00808 0.5 0.22 Platelet distribution width; chr16:28557357 chr16:28700294~28701540:- LIHC cis rs7044106 0.762 rs1411158 ENSG00000238181.2 AHCYP2 -4.18 3.69e-05 0.00808 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120702526 chr9:120720673~120721972:+ LIHC cis rs8064024 0.619 rs9935080 ENSG00000267077.1 RP11-127I20.5 4.18 3.69e-05 0.00808 0.23 0.22 Cancer; chr16:4852206 chr16:4795265~4796532:- LIHC cis rs12157904 1 rs35103516 ENSG00000233360.4 Z83844.1 4.18 3.69e-05 0.00808 0.47 0.22 Response to anti-depressant treatment in major depressive disorder; chr22:37605741 chr22:37641832~37658377:- LIHC cis rs12157904 1 rs71317058 ENSG00000233360.4 Z83844.1 4.18 3.69e-05 0.00808 0.47 0.22 Response to anti-depressant treatment in major depressive disorder; chr22:37605821 chr22:37641832~37658377:- LIHC cis rs7474896 0.507 rs2474555 ENSG00000120555.12 SEPT7P9 4.18 3.69e-05 0.00808 0.32 0.22 Obesity (extreme); chr10:38176292 chr10:38383069~38402916:- LIHC cis rs2243480 1 rs3885839 ENSG00000228409.4 CCT6P1 4.18 3.69e-05 0.00808 0.24 0.22 Diabetic kidney disease; chr7:65825416 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs3813708 ENSG00000228409.4 CCT6P1 4.18 3.69e-05 0.00808 0.24 0.22 Diabetic kidney disease; chr7:65840645 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs73142122 ENSG00000228409.4 CCT6P1 4.18 3.69e-05 0.00808 0.24 0.22 Diabetic kidney disease; chr7:65846311 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs73142137 ENSG00000228409.4 CCT6P1 4.18 3.69e-05 0.00808 0.24 0.22 Diabetic kidney disease; chr7:65878455 chr7:65751142~65763354:+ LIHC cis rs10129255 0.957 rs10136781 ENSG00000211970.3 IGHV4-61 -4.18 3.7e-05 0.00808 -0.17 -0.22 Kawasaki disease; chr14:106780451 chr14:106639119~106639657:- LIHC cis rs481331 0.866 rs34920187 ENSG00000185904.10 LINC00839 4.18 3.7e-05 0.00809 0.41 0.22 Systemic juvenile idiopathic arthritis; chr10:42497070 chr10:42475543~42495336:+ LIHC cis rs7131987 0.675 rs3847678 ENSG00000257176.2 RP11-996F15.2 4.18 3.7e-05 0.00809 0.25 0.22 QT interval; chr12:29398627 chr12:29280418~29317848:- LIHC cis rs10129255 0.957 rs4387509 ENSG00000224373.3 IGHV4-59 4.18 3.7e-05 0.00809 0.18 0.22 Kawasaki disease; chr14:106704386 chr14:106627249~106627825:- LIHC cis rs1005277 0.505 rs7917943 ENSG00000099251.13 HSD17B7P2 -4.18 3.7e-05 0.0081 -0.26 -0.22 Extrinsic epigenetic age acceleration; chr10:37906883 chr10:38356380~38378505:+ LIHC cis rs2439831 1 rs2439831 ENSG00000166763.7 STRCP1 4.18 3.7e-05 0.0081 0.31 0.22 Lung cancer in ever smokers; chr15:43492277 chr15:43699488~43718184:- LIHC cis rs875971 0.895 rs4718349 ENSG00000237310.1 GS1-124K5.4 4.18 3.7e-05 0.0081 0.2 0.22 Aortic root size; chr7:66444024 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs2042133 ENSG00000237310.1 GS1-124K5.4 4.18 3.7e-05 0.0081 0.2 0.22 Aortic root size; chr7:66466935 chr7:66493706~66495474:+ LIHC cis rs875971 0.964 rs2161065 ENSG00000237310.1 GS1-124K5.4 4.18 3.7e-05 0.0081 0.2 0.22 Aortic root size; chr7:66467918 chr7:66493706~66495474:+ LIHC cis rs875971 0.862 rs12698521 ENSG00000237310.1 GS1-124K5.4 4.18 3.7e-05 0.0081 0.2 0.22 Aortic root size; chr7:66474502 chr7:66493706~66495474:+ LIHC cis rs7208859 0.673 rs11656462 ENSG00000266490.1 CTD-2349P21.9 4.18 3.7e-05 0.0081 0.28 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30833682 chr17:30792372~30792833:+ LIHC cis rs2524005 1 rs2524005 ENSG00000229390.1 MICD -4.18 3.7e-05 0.0081 -0.28 -0.22 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29970801~29972464:- LIHC cis rs853679 0.545 rs35949109 ENSG00000204709.4 LINC01556 4.18 3.71e-05 0.0081 0.38 0.22 Depression; chr6:28058148 chr6:28943877~28944537:+ LIHC cis rs718433 0.717 rs12893255 ENSG00000258441.1 LINC00641 -4.18 3.71e-05 0.0081 -0.2 -0.22 Intraocular pressure; chr14:21773162 chr14:21200079~21206900:- LIHC cis rs11098499 0.954 rs6820115 ENSG00000260091.1 RP11-33B1.4 -4.18 3.71e-05 0.00811 -0.15 -0.22 Corneal astigmatism; chr4:119477027 chr4:119409333~119410233:+ LIHC cis rs2274273 0.588 rs17675223 ENSG00000258413.1 RP11-665C16.6 -4.18 3.71e-05 0.00811 -0.27 -0.22 Protein biomarker; chr14:55395518 chr14:55262767~55272075:- LIHC cis rs17774123 0.851 rs17775712 ENSG00000257808.1 RP11-1136G11.8 4.18 3.71e-05 0.00812 0.41 0.22 Diastolic blood pressure; chr12:53892581 chr12:53159586~53161000:+ LIHC cis rs10262624 1 rs11767124 ENSG00000234286.1 AC006026.13 -4.18 3.72e-05 0.00812 -0.25 -0.22 Schizophrenia; chr7:23879461 chr7:23680195~23680786:- LIHC cis rs113835537 0.866 rs59566349 ENSG00000255517.5 CTD-3074O7.5 -4.18 3.72e-05 0.00812 -0.39 -0.22 Airway imaging phenotypes; chr11:66598523 chr11:66473490~66480233:- LIHC cis rs113835537 0.935 rs1127145 ENSG00000255517.5 CTD-3074O7.5 -4.18 3.72e-05 0.00812 -0.39 -0.22 Airway imaging phenotypes; chr11:66605834 chr11:66473490~66480233:- LIHC cis rs3091242 0.933 rs9438904 ENSG00000224183.1 SDHDP6 -4.18 3.72e-05 0.00813 -0.25 -0.22 Erythrocyte sedimentation rate; chr1:25430369 chr1:25294164~25294643:- LIHC cis rs763121 0.962 rs138703 ENSG00000273076.1 RP3-508I15.22 4.18 3.72e-05 0.00813 0.24 0.22 Menopause (age at onset); chr22:38736743 chr22:38743495~38743910:+ LIHC cis rs1005277 0.579 rs2472183 ENSG00000276805.1 RP11-291L22.6 4.18 3.73e-05 0.00814 0.27 0.22 Extrinsic epigenetic age acceleration; chr10:38103567 chr10:38451030~38451785:+ LIHC cis rs7989332 0.925 rs9506494 ENSG00000275964.1 RP11-61K9.3 -4.18 3.73e-05 0.00814 -0.25 -0.22 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20473719 chr13:19863858~19865048:+ LIHC cis rs4578769 0.879 rs12963622 ENSG00000265943.1 RP11-739L10.1 4.18 3.73e-05 0.00814 0.28 0.22 Eosinophil percentage of white cells; chr18:22859594 chr18:22699481~22933764:- LIHC cis rs4578769 0.879 rs7241050 ENSG00000265943.1 RP11-739L10.1 4.18 3.73e-05 0.00814 0.28 0.22 Eosinophil percentage of white cells; chr18:22860300 chr18:22699481~22933764:- LIHC cis rs2929278 0.617 rs693919 ENSG00000275601.1 AC011330.13 4.18 3.73e-05 0.00814 0.27 0.22 Schizophrenia; chr15:43810130 chr15:43642389~43643023:- LIHC cis rs3772760 1 rs3755672 ENSG00000240622.1 RPL7P15 -4.18 3.73e-05 0.00814 -0.41 -0.22 Amyotrophic lateral sclerosis; chr3:124447661 chr3:124151960~124153063:- LIHC cis rs2348418 0.733 rs2169754 ENSG00000247934.4 RP11-967K21.1 -4.18 3.73e-05 0.00815 -0.19 -0.22 Lung function (FEV1);Lung function (FVC); chr12:28187712 chr12:28163298~28190738:- LIHC cis rs62246343 0.605 rs7650141 ENSG00000206573.7 THUMPD3-AS1 -4.18 3.73e-05 0.00815 -0.25 -0.22 Fibrinogen levels; chr3:9407726 chr3:9349689~9398579:- LIHC cis rs17376456 0.825 rs13156202 ENSG00000251023.1 RP11-549J18.1 4.18 3.73e-05 0.00815 0.45 0.22 Diabetic retinopathy; chr5:93822015 chr5:93860669~93863825:- LIHC cis rs950169 0.92 rs2135551 ENSG00000259728.4 LINC00933 4.18 3.73e-05 0.00815 0.36 0.22 Schizophrenia; chr15:84039099 chr15:84570649~84580175:+ LIHC cis rs950169 1 rs12902672 ENSG00000259728.4 LINC00933 4.18 3.73e-05 0.00815 0.36 0.22 Schizophrenia; chr15:84048234 chr15:84570649~84580175:+ LIHC cis rs950169 1 rs12903820 ENSG00000259728.4 LINC00933 4.18 3.73e-05 0.00815 0.36 0.22 Schizophrenia; chr15:84055068 chr15:84570649~84580175:+ LIHC cis rs950169 0.919 rs12915589 ENSG00000259728.4 LINC00933 4.18 3.73e-05 0.00815 0.36 0.22 Schizophrenia; chr15:84065712 chr15:84570649~84580175:+ LIHC cis rs950169 0.959 rs66801143 ENSG00000259728.4 LINC00933 4.18 3.73e-05 0.00815 0.36 0.22 Schizophrenia; chr15:84067905 chr15:84570649~84580175:+ LIHC cis rs950169 1 rs35648189 ENSG00000259728.4 LINC00933 4.18 3.73e-05 0.00815 0.36 0.22 Schizophrenia; chr15:84071996 chr15:84570649~84580175:+ LIHC cis rs950169 0.92 rs17300048 ENSG00000259728.4 LINC00933 4.18 3.73e-05 0.00815 0.36 0.22 Schizophrenia; chr15:84080725 chr15:84570649~84580175:+ LIHC cis rs950169 1 rs1848093 ENSG00000259728.4 LINC00933 4.18 3.73e-05 0.00815 0.36 0.22 Schizophrenia; chr15:84086775 chr15:84570649~84580175:+ LIHC cis rs950169 1 rs12915234 ENSG00000259728.4 LINC00933 4.18 3.73e-05 0.00815 0.36 0.22 Schizophrenia; chr15:84089549 chr15:84570649~84580175:+ LIHC cis rs950169 1 rs34751999 ENSG00000259728.4 LINC00933 4.18 3.73e-05 0.00815 0.36 0.22 Schizophrenia; chr15:84089667 chr15:84570649~84580175:+ LIHC cis rs950169 0.919 rs17300292 ENSG00000259728.4 LINC00933 4.18 3.73e-05 0.00815 0.36 0.22 Schizophrenia; chr15:84093816 chr15:84570649~84580175:+ LIHC cis rs1577917 0.959 rs34258068 ENSG00000234155.1 RP11-30P6.6 4.18 3.73e-05 0.00815 0.29 0.22 Response to antipsychotic treatment; chr6:85969731 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs884841 ENSG00000234155.1 RP11-30P6.6 4.18 3.73e-05 0.00815 0.29 0.22 Response to antipsychotic treatment; chr6:85970582 chr6:85387219~85390186:- LIHC cis rs1577917 0.958 rs884842 ENSG00000234155.1 RP11-30P6.6 4.18 3.73e-05 0.00815 0.29 0.22 Response to antipsychotic treatment; chr6:85970679 chr6:85387219~85390186:- LIHC cis rs901683 1 rs12773263 ENSG00000230869.1 CTGLF10P -4.18 3.73e-05 0.00816 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45488898 chr10:45678692~45700532:+ LIHC cis rs1577917 0.958 rs11758508 ENSG00000234155.1 RP11-30P6.6 -4.18 3.74e-05 0.00816 -0.28 -0.22 Response to antipsychotic treatment; chr6:85797160 chr6:85387219~85390186:- LIHC cis rs11096990 0.634 rs12648082 ENSG00000249207.1 RP11-360F5.1 4.18 3.74e-05 0.00817 0.22 0.22 Cognitive function; chr4:39278104 chr4:39112677~39126818:- LIHC cis rs7044106 0.791 rs10984995 ENSG00000238181.2 AHCYP2 -4.18 3.74e-05 0.00817 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120716932 chr9:120720673~120721972:+ LIHC cis rs2834188 0.889 rs2040108 ENSG00000272659.1 AP000295.10 -4.18 3.74e-05 0.00817 -0.32 -0.22 Narcolepsy; chr21:33303853 chr21:33309491~33310181:+ LIHC cis rs4356203 0.818 rs214927 ENSG00000260196.1 RP1-239B22.5 -4.18 3.74e-05 0.00817 -0.26 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17209698 chr11:17380649~17383531:+ LIHC cis rs2274273 1 rs1009977 ENSG00000258413.1 RP11-665C16.6 -4.18 3.74e-05 0.00817 -0.26 -0.22 Protein biomarker; chr14:55136284 chr14:55262767~55272075:- LIHC cis rs4356975 0.83 rs6422322 ENSG00000250919.1 RP11-813N20.3 -4.18 3.74e-05 0.00818 -0.22 -0.22 Obesity-related traits; chr4:69055571 chr4:69027831~69044578:+ LIHC cis rs2070488 0.965 rs6805386 ENSG00000229589.1 ACVR2B-AS1 -4.18 3.75e-05 0.00818 -0.25 -0.22 Electrocardiographic conduction measures; chr3:38516430 chr3:38451027~38454820:- LIHC cis rs2070488 0.965 rs6599209 ENSG00000229589.1 ACVR2B-AS1 -4.18 3.75e-05 0.00818 -0.25 -0.22 Electrocardiographic conduction measures; chr3:38516706 chr3:38451027~38454820:- LIHC cis rs4578769 0.765 rs1609464 ENSG00000266850.1 RP11-370A5.1 -4.18 3.75e-05 0.00818 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22844191 chr18:22723491~22907721:- LIHC cis rs17818399 0.735 rs11894342 ENSG00000279254.1 RP11-536C12.1 -4.18 3.75e-05 0.00818 -0.25 -0.22 Height; chr2:46609300 chr2:46668870~46670778:+ LIHC cis rs417065 1 rs72635711 ENSG00000227634.1 RP11-431K24.3 -4.18 3.75e-05 0.00818 -0.3 -0.22 Psoriasis; chr1:8199243 chr1:8208672~8215210:+ LIHC cis rs1065852 0.906 rs9611734 ENSG00000205702.9 CYP2D7 4.18 3.75e-05 0.00818 0.26 0.22 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42106066 chr22:42140203~42144577:- LIHC cis rs7474896 0.583 rs34185758 ENSG00000263064.2 RP11-291L22.7 4.18 3.75e-05 0.00818 0.27 0.22 Obesity (extreme); chr10:37701926 chr10:38448689~38448949:+ LIHC cis rs17270561 0.562 rs74293932 ENSG00000272810.1 U91328.22 -4.18 3.75e-05 0.00819 -0.29 -0.22 Iron status biomarkers; chr6:26014583 chr6:26013241~26013757:+ LIHC cis rs6445975 0.666 rs4681680 ENSG00000272360.1 RP11-359I18.5 -4.18 3.75e-05 0.00819 -0.3 -0.22 Systemic lupus erythematosus; chr3:58346490 chr3:58490830~58491291:- LIHC cis rs6445975 0.666 rs9817356 ENSG00000272360.1 RP11-359I18.5 -4.18 3.75e-05 0.00819 -0.3 -0.22 Systemic lupus erythematosus; chr3:58349846 chr3:58490830~58491291:- LIHC cis rs2790457 0.958 rs2790454 ENSG00000254635.4 WAC-AS1 -4.18 3.76e-05 0.00819 -0.21 -0.22 Multiple myeloma; chr10:28553103 chr10:28522652~28532743:- LIHC cis rs2790457 0.958 rs2790455 ENSG00000254635.4 WAC-AS1 -4.18 3.76e-05 0.00819 -0.21 -0.22 Multiple myeloma; chr10:28558148 chr10:28522652~28532743:- LIHC cis rs2032447 0.869 rs199752 ENSG00000242387.1 HIST1H2APS2 4.18 3.76e-05 0.0082 0.28 0.22 Intelligence (multi-trait analysis); chr6:26012647 chr6:25882026~25882395:- LIHC cis rs524281 0.814 rs2270448 ENSG00000255320.1 RP11-755F10.1 4.18 3.76e-05 0.0082 0.32 0.22 Electroencephalogram traits; chr11:66068460 chr11:66244840~66246239:- LIHC cis rs17774123 0.901 rs2366134 ENSG00000257808.1 RP11-1136G11.8 4.18 3.76e-05 0.0082 0.41 0.22 Diastolic blood pressure; chr12:53875183 chr12:53159586~53161000:+ LIHC cis rs7923609 0.875 rs10740118 ENSG00000232075.1 MRPL35P2 4.18 3.76e-05 0.0082 0.25 0.22 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63341447 chr10:63634317~63634827:- LIHC cis rs7893279 0.505 rs4748497 ENSG00000225527.1 RP11-383B4.4 4.18 3.76e-05 0.0082 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18618105 chr10:18531849~18533336:- LIHC cis rs2439831 0.681 rs825739 ENSG00000166763.7 STRCP1 4.18 3.76e-05 0.0082 0.3 0.22 Lung cancer in ever smokers; chr15:43300230 chr15:43699488~43718184:- LIHC cis rs2348418 0.864 rs7978086 ENSG00000247934.4 RP11-967K21.1 4.18 3.76e-05 0.0082 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28562761 chr12:28163298~28190738:- LIHC cis rs6700559 0.873 rs7526031 ENSG00000260088.1 RP11-92G12.3 -4.18 3.76e-05 0.0082 -0.28 -0.22 Coronary artery disease; chr1:200695174 chr1:200669507~200694250:+ LIHC cis rs3020736 0.519 rs5996116 ENSG00000205702.9 CYP2D7 -4.18 3.76e-05 0.00821 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42121488 chr22:42140203~42144577:- LIHC cis rs3091242 0.836 rs34997029 ENSG00000224183.1 SDHDP6 4.18 3.76e-05 0.00821 0.25 0.22 Erythrocyte sedimentation rate; chr1:25457332 chr1:25294164~25294643:- LIHC cis rs55794721 0.509 rs12027135 ENSG00000224183.1 SDHDP6 -4.18 3.76e-05 0.00821 -0.25 -0.22 Mean corpuscular volume;Plateletcrit; chr1:25449242 chr1:25294164~25294643:- LIHC cis rs295490 0.831 rs3772871 ENSG00000272656.1 RP11-219D15.3 -4.18 3.77e-05 0.00821 -0.6 -0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139522774 chr3:139349024~139349371:- LIHC cis rs804280 0.662 rs11784693 ENSG00000255394.4 C8orf49 -4.18 3.77e-05 0.00821 -0.31 -0.22 Myopia (pathological); chr8:11753165 chr8:11761256~11763223:+ LIHC cis rs2072510 0.593 rs2540498 ENSG00000257878.1 RP11-256L6.3 -4.18 3.77e-05 0.00822 -0.28 -0.22 Metabolite levels (small molecules and protein measures); chr12:96006791 chr12:95996521~96011489:+ LIHC cis rs1874124 0.577 rs2807880 ENSG00000238078.1 LINC01352 4.18 3.77e-05 0.00822 0.4 0.22 Cholesterol, total; chr1:220869661 chr1:220829255~220832429:+ LIHC cis rs17772222 0.917 rs61986670 ENSG00000258789.1 RP11-507K2.3 -4.18 3.77e-05 0.00822 -0.26 -0.22 Coronary artery calcification; chr14:88730875 chr14:88551597~88552493:+ LIHC cis rs17818399 0.815 rs17819022 ENSG00000279254.1 RP11-536C12.1 -4.18 3.77e-05 0.00822 -0.28 -0.22 Height; chr2:46623432 chr2:46668870~46670778:+ LIHC cis rs860295 0.871 rs34632540 ENSG00000203761.5 MSTO2P 4.18 3.77e-05 0.00822 0.18 0.22 Body mass index; chr1:155642406 chr1:155745829~155750137:+ LIHC cis rs2749592 0.531 rs10764134 ENSG00000276805.1 RP11-291L22.6 -4.18 3.77e-05 0.00823 -0.26 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37567732 chr10:38451030~38451785:+ LIHC cis rs2243480 1 rs160633 ENSG00000230295.1 RP11-458F8.2 -4.18 3.78e-05 0.00823 -0.23 -0.22 Diabetic kidney disease; chr7:66063241 chr7:66880708~66882981:+ LIHC cis rs11098499 0.863 rs1480940 ENSG00000260091.1 RP11-33B1.4 -4.18 3.78e-05 0.00824 -0.16 -0.22 Corneal astigmatism; chr4:119536527 chr4:119409333~119410233:+ LIHC cis rs875971 0.545 rs12670811 ENSG00000273142.1 RP11-458F8.4 4.18 3.78e-05 0.00824 0.21 0.22 Aortic root size; chr7:66358032 chr7:66902857~66906297:+ LIHC cis rs2276314 0.857 rs62101379 ENSG00000278986.1 RP11-723J4.3 -4.18 3.78e-05 0.00824 -0.27 -0.22 Endometriosis;Drug-induced torsades de pointes; chr18:36004939 chr18:35972151~35973916:+ LIHC cis rs7208859 0.673 rs11652370 ENSG00000266490.1 CTD-2349P21.9 4.18 3.78e-05 0.00825 0.27 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770205 chr17:30792372~30792833:+ LIHC cis rs2439831 1 rs2253708 ENSG00000166763.7 STRCP1 4.17 3.79e-05 0.00825 0.31 0.22 Lung cancer in ever smokers; chr15:43505075 chr15:43699488~43718184:- LIHC cis rs875971 0.895 rs7788984 ENSG00000237310.1 GS1-124K5.4 4.17 3.79e-05 0.00825 0.2 0.22 Aortic root size; chr7:66450629 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs1981798 ENSG00000237310.1 GS1-124K5.4 4.17 3.79e-05 0.00825 0.2 0.22 Aortic root size; chr7:66489916 chr7:66493706~66495474:+ LIHC cis rs2598107 0.601 rs6968647 ENSG00000211698.2 TRGV4 -4.17 3.79e-05 0.00825 -0.26 -0.22 Dupuytren's disease; chr7:37923320 chr7:38353715~38354517:- LIHC cis rs13113518 0.783 rs2171618 ENSG00000249700.7 SRD5A3-AS1 4.17 3.79e-05 0.00825 0.26 0.22 Height; chr4:55564241 chr4:55363971~55395847:- LIHC cis rs10129255 0.518 rs2006284 ENSG00000211972.2 IGHV3-66 4.17 3.79e-05 0.00826 0.16 0.22 Kawasaki disease; chr14:106676185 chr14:106675017~106675544:- LIHC cis rs17772222 0.917 rs12434935 ENSG00000258789.1 RP11-507K2.3 -4.17 3.79e-05 0.00826 -0.26 -0.22 Coronary artery calcification; chr14:88645449 chr14:88551597~88552493:+ LIHC cis rs193541 0.632 rs1460040 ENSG00000263432.2 RN7SL689P 4.17 3.79e-05 0.00826 0.35 0.22 Glucose homeostasis traits; chr5:122769537 chr5:123022487~123022783:- LIHC cis rs4356203 0.87 rs10832751 ENSG00000260196.1 RP1-239B22.5 -4.17 3.8e-05 0.00827 -0.26 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17252469 chr11:17380649~17383531:+ LIHC cis rs9487094 1 rs10872032 ENSG00000260273.1 RP11-425D10.10 4.17 3.8e-05 0.00827 0.25 0.22 Height; chr6:109355573 chr6:109382795~109383666:+ LIHC cis rs2243480 1 rs313813 ENSG00000232546.1 RP11-458F8.1 -4.17 3.8e-05 0.00827 -0.24 -0.22 Diabetic kidney disease; chr7:66038513 chr7:66848496~66858136:+ LIHC cis rs1799949 0.93 rs33968979 ENSG00000267681.1 CTD-3199J23.6 -4.17 3.8e-05 0.00827 -0.21 -0.22 Menopause (age at onset); chr17:43145975 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs12952790 ENSG00000267681.1 CTD-3199J23.6 -4.17 3.8e-05 0.00827 -0.21 -0.22 Menopause (age at onset); chr17:43147590 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs12950607 ENSG00000267681.1 CTD-3199J23.6 -4.17 3.8e-05 0.00827 -0.21 -0.22 Menopause (age at onset); chr17:43147911 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs11079056 ENSG00000267681.1 CTD-3199J23.6 -4.17 3.8e-05 0.00827 -0.21 -0.22 Menopause (age at onset); chr17:43148782 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs12936816 ENSG00000267681.1 CTD-3199J23.6 -4.17 3.8e-05 0.00827 -0.21 -0.22 Menopause (age at onset); chr17:43149692 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs35521261 ENSG00000267681.1 CTD-3199J23.6 -4.17 3.8e-05 0.00827 -0.21 -0.22 Menopause (age at onset); chr17:43161595 chr17:43144956~43145255:+ LIHC cis rs1799949 0.896 rs33933393 ENSG00000267681.1 CTD-3199J23.6 -4.17 3.8e-05 0.00827 -0.21 -0.22 Menopause (age at onset); chr17:43165415 chr17:43144956~43145255:+ LIHC cis rs62388641 0.539 rs56016631 ENSG00000272279.1 RP11-157J24.2 4.17 3.8e-05 0.00828 0.3 0.22 Daytime sleep phenotypes; chr6:1542340 chr6:1528364~1528911:- LIHC cis rs62388641 0.539 rs56304710 ENSG00000272279.1 RP11-157J24.2 4.17 3.8e-05 0.00828 0.3 0.22 Daytime sleep phenotypes; chr6:1542341 chr6:1528364~1528911:- LIHC cis rs12681287 0.64 rs10086340 ENSG00000254088.1 SLC2A3P4 4.17 3.8e-05 0.00828 0.25 0.22 Caudate activity during reward; chr8:86434560 chr8:86503591~86505061:+ LIHC cis rs6597981 0.675 rs4963120 ENSG00000255284.1 AP006621.5 -4.17 3.8e-05 0.00828 -0.24 -0.22 Breast cancer; chr11:825777 chr11:777578~784297:+ LIHC cis rs2243480 1 rs73142166 ENSG00000228409.4 CCT6P1 4.17 3.8e-05 0.00829 0.24 0.22 Diabetic kidney disease; chr7:65910845 chr7:65751142~65763354:+ LIHC cis rs72634501 0.542 rs2134472 ENSG00000182109.6 RP11-69E11.4 -4.17 3.81e-05 0.00829 -0.23 -0.22 HDL cholesterol; chr1:39137542 chr1:39522280~39546187:- LIHC cis rs2243480 1 rs10807702 ENSG00000230295.1 RP11-458F8.2 -4.17 3.81e-05 0.00829 -0.23 -0.22 Diabetic kidney disease; chr7:66302856 chr7:66880708~66882981:+ LIHC cis rs748404 0.631 rs28702649 ENSG00000205771.5 CATSPER2P1 -4.17 3.81e-05 0.00829 -0.27 -0.22 Lung cancer; chr15:43356431 chr15:43726918~43747094:- LIHC cis rs858239 1 rs156407 ENSG00000226816.2 AC005082.12 4.17 3.81e-05 0.00829 0.28 0.22 Cerebrospinal fluid biomarker levels; chr7:23276020 chr7:23206013~23208045:+ LIHC cis rs7216064 0.655 rs8078543 ENSG00000278740.1 RP11-147L13.14 -4.17 3.81e-05 0.00829 -0.26 -0.22 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68041135 chr17:68188547~68189165:+ LIHC cis rs7216064 0.636 rs62084696 ENSG00000278740.1 RP11-147L13.14 -4.17 3.81e-05 0.00829 -0.26 -0.22 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68042065 chr17:68188547~68189165:+ LIHC cis rs6700559 0.873 rs6427840 ENSG00000260088.1 RP11-92G12.3 -4.17 3.81e-05 0.00829 -0.28 -0.22 Coronary artery disease; chr1:200685659 chr1:200669507~200694250:+ LIHC cis rs7474896 0.583 rs10827818 ENSG00000263064.2 RP11-291L22.7 4.17 3.81e-05 0.0083 0.26 0.22 Obesity (extreme); chr10:37711928 chr10:38448689~38448949:+ LIHC cis rs7474896 0.583 rs7071147 ENSG00000263064.2 RP11-291L22.7 4.17 3.81e-05 0.0083 0.26 0.22 Obesity (extreme); chr10:37714448 chr10:38448689~38448949:+ LIHC cis rs7474896 0.583 rs10740950 ENSG00000263064.2 RP11-291L22.7 4.17 3.81e-05 0.0083 0.26 0.22 Obesity (extreme); chr10:37714568 chr10:38448689~38448949:+ LIHC cis rs7474896 0.583 rs11011347 ENSG00000263064.2 RP11-291L22.7 4.17 3.81e-05 0.0083 0.26 0.22 Obesity (extreme); chr10:37730336 chr10:38448689~38448949:+ LIHC cis rs9843304 0.528 rs9860963 ENSG00000244503.1 RP11-278L15.6 -4.17 3.81e-05 0.0083 -0.28 -0.22 Gallstone disease; chr3:149479678 chr3:149494660~149495995:+ LIHC cis rs10129255 0.913 rs28861466 ENSG00000224373.3 IGHV4-59 4.17 3.82e-05 0.00831 0.18 0.22 Kawasaki disease; chr14:106718572 chr14:106627249~106627825:- LIHC cis rs9525916 0.967 rs9533775 ENSG00000230731.2 RP11-478K15.6 -4.17 3.82e-05 0.00831 -0.25 -0.22 Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction); chr13:44123820 chr13:44234118~44243192:- LIHC cis rs13113518 0.738 rs6849883 ENSG00000249700.7 SRD5A3-AS1 4.17 3.82e-05 0.00831 0.25 0.22 Height; chr4:55387515 chr4:55363971~55395847:- LIHC cis rs1729407 0.649 rs2849176 ENSG00000236267.1 AP006216.5 -4.17 3.82e-05 0.00831 -0.21 -0.22 Apolipoprotein A-IV levels; chr11:116826205 chr11:116813204~116814003:- LIHC cis rs9450351 0.744 rs9362248 ENSG00000203875.9 SNHG5 -4.17 3.82e-05 0.00831 -0.47 -0.22 Interferon gamma-induced protein 10 levels; chr6:85847249 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs9342047 ENSG00000203875.9 SNHG5 -4.17 3.82e-05 0.00831 -0.47 -0.22 Interferon gamma-induced protein 10 levels; chr6:85869115 chr6:85660950~85678736:- LIHC cis rs4650994 0.816 rs2209169 ENSG00000213057.5 C1orf220 -4.17 3.82e-05 0.00831 -0.18 -0.22 HDL cholesterol;HDL cholesterol levels; chr1:178632357 chr1:178542752~178548889:+ LIHC cis rs2072438 0.503 rs1323474 ENSG00000226752.6 PSMD5-AS1 -4.17 3.82e-05 0.00832 -0.23 -0.22 Rheumatoid arthritis; chr9:121090581 chr9:120824828~120854385:+ LIHC cis rs11098499 0.955 rs1511018 ENSG00000260091.1 RP11-33B1.4 -4.17 3.82e-05 0.00832 -0.16 -0.22 Corneal astigmatism; chr4:119240425 chr4:119409333~119410233:+ LIHC cis rs6142102 0.602 rs4911395 ENSG00000275784.1 RP5-1125A11.6 -4.17 3.83e-05 0.00832 -0.24 -0.22 Skin pigmentation; chr20:33992095 chr20:33989480~33991818:- LIHC cis rs787274 0.543 rs1324930 ENSG00000271631.1 RP11-408O19.5 -4.17 3.83e-05 0.00833 -0.34 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr9:112872359 chr9:112885158~112885767:+ LIHC cis rs5758511 0.514 rs5758580 ENSG00000205702.9 CYP2D7 4.17 3.83e-05 0.00833 0.26 0.22 Birth weight; chr22:42097871 chr22:42140203~42144577:- LIHC cis rs4650994 0.905 rs12753251 ENSG00000273384.1 RP5-1098D14.1 4.17 3.83e-05 0.00834 0.27 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178560763 chr1:178651706~178652282:+ LIHC cis rs7809950 1 rs986994 ENSG00000238832.1 snoU109 -4.17 3.83e-05 0.00834 -0.26 -0.22 Coronary artery disease; chr7:107463670 chr7:107603363~107603507:+ LIHC cis rs75920871 0.764 rs17120347 ENSG00000254851.1 RP11-109L13.1 -4.17 3.83e-05 0.00834 -0.46 -0.22 Subjective well-being; chr11:117125823 chr11:117135528~117138582:+ LIHC cis rs8041227 0.525 rs4304986 ENSG00000259772.5 RP11-16E12.2 4.17 3.84e-05 0.00834 0.3 0.22 Eosinophilic esophagitis; chr15:31226833 chr15:31221999~31230838:- LIHC cis rs4148008 0.564 rs6501769 ENSG00000267250.1 RP11-118B18.2 -4.17 3.84e-05 0.00835 -0.29 -0.22 HDL cholesterol; chr17:68823677 chr17:68793549~68797822:- LIHC cis rs8064024 0.625 rs960006 ENSG00000267077.1 RP11-127I20.5 4.17 3.84e-05 0.00835 0.23 0.22 Cancer; chr16:4861194 chr16:4795265~4796532:- LIHC cis rs1062177 0.855 rs6884630 ENSG00000253921.1 CTB-113P19.3 -4.17 3.84e-05 0.00835 -0.24 -0.22 Preschool internalizing problems; chr5:151889436 chr5:151753992~151767247:+ LIHC cis rs710913 0.738 rs755247 ENSG00000182109.6 RP11-69E11.4 -4.17 3.84e-05 0.00835 -0.22 -0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39528873 chr1:39522280~39546187:- LIHC cis rs4578769 0.729 rs12456875 ENSG00000266850.1 RP11-370A5.1 -4.17 3.84e-05 0.00835 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22830208 chr18:22723491~22907721:- LIHC cis rs4578769 0.765 rs67551099 ENSG00000266850.1 RP11-370A5.1 -4.17 3.84e-05 0.00835 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22831167 chr18:22723491~22907721:- LIHC cis rs4578769 0.765 rs12455548 ENSG00000266850.1 RP11-370A5.1 -4.17 3.84e-05 0.00835 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22831514 chr18:22723491~22907721:- LIHC cis rs2762353 0.562 rs1165206 ENSG00000242387.1 HIST1H2APS2 4.17 3.84e-05 0.00835 0.25 0.22 Blood metabolite levels; chr6:25867338 chr6:25882026~25882395:- LIHC cis rs7208859 0.673 rs7211776 ENSG00000266490.1 CTD-2349P21.9 4.17 3.84e-05 0.00835 0.27 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793178 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs9912122 ENSG00000266490.1 CTD-2349P21.9 4.17 3.84e-05 0.00835 0.27 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813698 chr17:30792372~30792833:+ LIHC cis rs2797160 1 rs6904069 ENSG00000237742.5 RP11-624M8.1 -4.17 3.84e-05 0.00836 -0.21 -0.22 Endometrial cancer; chr6:125673988 chr6:125578558~125749190:- LIHC cis rs11098499 0.955 rs13114751 ENSG00000260091.1 RP11-33B1.4 -4.17 3.84e-05 0.00836 -0.16 -0.22 Corneal astigmatism; chr4:119235462 chr4:119409333~119410233:+ LIHC cis rs11098499 0.913 rs35271032 ENSG00000260091.1 RP11-33B1.4 -4.17 3.84e-05 0.00836 -0.16 -0.22 Corneal astigmatism; chr4:119235504 chr4:119409333~119410233:+ LIHC cis rs3812762 0.833 rs35670750 ENSG00000254860.4 TMEM9B-AS1 4.17 3.84e-05 0.00836 0.26 0.22 Hypospadias; chr11:8760897 chr11:8964675~8977527:+ LIHC cis rs17464492 0.569 rs687279 ENSG00000246228.5 CASC8 -4.17 3.84e-05 0.00836 -0.25 -0.22 Prostate-specific antigen levels (conditioned on lead SNPs); chr8:127332379 chr8:127289817~127482139:- LIHC cis rs11098499 1 rs11098499 ENSG00000260091.1 RP11-33B1.4 -4.17 3.85e-05 0.00836 -0.16 -0.22 Corneal astigmatism; chr4:119266456 chr4:119409333~119410233:+ LIHC cis rs2243480 0.708 rs13242216 ENSG00000232546.1 RP11-458F8.1 -4.17 3.85e-05 0.00836 -0.25 -0.22 Diabetic kidney disease; chr7:66433290 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs67536397 ENSG00000232546.1 RP11-458F8.1 -4.17 3.85e-05 0.00836 -0.25 -0.22 Diabetic kidney disease; chr7:66482930 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs58669269 ENSG00000232546.1 RP11-458F8.1 -4.17 3.85e-05 0.00836 -0.25 -0.22 Diabetic kidney disease; chr7:66486966 chr7:66848496~66858136:+ LIHC cis rs12887734 0.524 rs722637 ENSG00000258534.1 CTD-2134A5.4 4.17 3.85e-05 0.00837 0.24 0.22 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103795386 chr14:103854366~103880111:- LIHC cis rs67311347 1 rs12638199 ENSG00000223797.4 ENTPD3-AS1 4.17 3.85e-05 0.00837 0.17 0.22 Renal cell carcinoma; chr3:40433794 chr3:40313802~40453329:- LIHC cis rs2274273 1 rs6573006 ENSG00000258413.1 RP11-665C16.6 -4.17 3.85e-05 0.00837 -0.25 -0.22 Protein biomarker; chr14:55143714 chr14:55262767~55272075:- LIHC cis rs6445975 0.666 rs4518147 ENSG00000272360.1 RP11-359I18.5 4.17 3.85e-05 0.00837 0.29 0.22 Systemic lupus erythematosus; chr3:58407847 chr3:58490830~58491291:- LIHC cis rs6445975 0.578 rs6772652 ENSG00000272360.1 RP11-359I18.5 4.17 3.85e-05 0.00837 0.29 0.22 Systemic lupus erythematosus; chr3:58420966 chr3:58490830~58491291:- LIHC cis rs6445975 0.572 rs12485999 ENSG00000272360.1 RP11-359I18.5 4.17 3.85e-05 0.00837 0.29 0.22 Systemic lupus erythematosus; chr3:58424036 chr3:58490830~58491291:- LIHC cis rs2274273 0.564 rs3783649 ENSG00000258413.1 RP11-665C16.6 -4.17 3.86e-05 0.00838 -0.27 -0.22 Protein biomarker; chr14:55367692 chr14:55262767~55272075:- LIHC cis rs7044106 0.762 rs1886337 ENSG00000238181.2 AHCYP2 -4.17 3.86e-05 0.00839 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120681498 chr9:120720673~120721972:+ LIHC cis rs7044106 0.762 rs3904197 ENSG00000238181.2 AHCYP2 -4.17 3.86e-05 0.00839 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120718100 chr9:120720673~120721972:+ LIHC cis rs673078 0.615 rs56324376 ENSG00000275759.1 RP11-131L12.3 -4.17 3.86e-05 0.00839 -0.26 -0.22 Glucose homeostasis traits; chr12:118372134 chr12:118428281~118428870:+ LIHC cis rs9532669 0.926 rs2875421 ENSG00000168852.11 TPTE2P5 4.17 3.86e-05 0.00839 0.25 0.22 Cervical cancer; chr13:40936536 chr13:40822296~40921749:- LIHC cis rs755249 0.567 rs72661927 ENSG00000182109.6 RP11-69E11.4 4.17 3.86e-05 0.00839 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39209650 chr1:39522280~39546187:- LIHC cis rs10129255 0.53 rs11624912 ENSG00000211972.2 IGHV3-66 4.17 3.86e-05 0.00839 0.16 0.22 Kawasaki disease; chr14:106673891 chr14:106675017~106675544:- LIHC cis rs734999 0.87 rs2147905 ENSG00000225931.3 RP3-395M20.7 -4.17 3.86e-05 0.00839 -0.24 -0.22 Ulcerative colitis; chr1:2551482 chr1:2566410~2569888:+ LIHC cis rs7044106 0.708 rs10760113 ENSG00000238181.2 AHCYP2 -4.17 3.86e-05 0.00839 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120711772 chr9:120720673~120721972:+ LIHC cis rs6545883 0.507 rs6545855 ENSG00000271889.1 RP11-493E12.1 -4.17 3.86e-05 0.0084 -0.26 -0.22 Tuberculosis; chr2:61305725 chr2:61151433~61162105:- LIHC cis rs1823913 1 rs10445783 ENSG00000227542.1 AC092614.2 -4.17 3.86e-05 0.0084 -0.23 -0.22 Obesity-related traits; chr2:191236772 chr2:191229165~191246172:- LIHC cis rs60432013 0.584 rs3764167 ENSG00000279656.1 RP11-298I3.6 4.17 3.87e-05 0.0084 0.43 0.22 Red cell distribution width; chr14:23050766 chr14:23023083~23024217:- LIHC cis rs67311347 0.544 rs6769627 ENSG00000223797.4 ENTPD3-AS1 4.17 3.87e-05 0.0084 0.18 0.22 Renal cell carcinoma; chr3:40286354 chr3:40313802~40453329:- LIHC cis rs11216126 0.556 rs1893460 ENSG00000254851.1 RP11-109L13.1 4.17 3.87e-05 0.0084 0.3 0.22 HDL cholesterol; chr11:116732961 chr11:117135528~117138582:+ LIHC cis rs1799949 0.965 rs8176193 ENSG00000267681.1 CTD-3199J23.6 -4.17 3.87e-05 0.0084 -0.21 -0.22 Menopause (age at onset); chr17:43079499 chr17:43144956~43145255:+ LIHC cis rs287982 1 rs287977 ENSG00000269973.1 RP11-95D17.1 4.17 3.87e-05 0.00841 0.21 0.22 Nonsyndromic cleft lip with cleft palate; chr2:9829889 chr2:9936360~9939590:+ LIHC cis rs10829156 0.755 rs10732437 ENSG00000225527.1 RP11-383B4.4 -4.17 3.87e-05 0.00841 -0.36 -0.22 Sudden cardiac arrest; chr10:18626973 chr10:18531849~18533336:- LIHC cis rs9907295 0.71 rs4796113 ENSG00000270871.1 AC015849.19 4.17 3.87e-05 0.00841 0.24 0.22 Fibroblast growth factor basic levels; chr17:35832562 chr17:35816717~35830293:- LIHC cis rs9907295 0.818 rs4796114 ENSG00000270871.1 AC015849.19 4.17 3.87e-05 0.00841 0.24 0.22 Fibroblast growth factor basic levels; chr17:35832653 chr17:35816717~35830293:- LIHC cis rs9907295 0.818 rs3785764 ENSG00000270871.1 AC015849.19 4.17 3.87e-05 0.00841 0.24 0.22 Fibroblast growth factor basic levels; chr17:35833760 chr17:35816717~35830293:- LIHC cis rs62355901 0.8 rs10461612 ENSG00000271828.1 CTD-2310F14.1 4.17 3.87e-05 0.00841 0.34 0.22 Breast cancer; chr5:56708004 chr5:56927874~56929573:+ LIHC cis rs7182621 0.512 rs34151878 ENSG00000182397.13 DNM1P46 4.17 3.87e-05 0.00841 0.3 0.22 Colonoscopy-negative controls vs population controls; chr15:99869179 chr15:99790156~99806927:- LIHC cis rs2070488 0.965 rs2154778 ENSG00000229589.1 ACVR2B-AS1 -4.17 3.87e-05 0.00841 -0.25 -0.22 Electrocardiographic conduction measures; chr3:38512148 chr3:38451027~38454820:- LIHC cis rs2253762 0.54 rs7358186 ENSG00000276742.1 RP11-500G22.4 4.17 3.87e-05 0.00841 0.36 0.22 Breast cancer; chr10:122000816 chr10:121956782~121957098:+ LIHC cis rs1075265 0.61 rs6746965 ENSG00000233266.1 HMGB1P31 4.17 3.88e-05 0.00842 0.26 0.22 Chronotype;Morning vs. evening chronotype; chr2:53996388 chr2:54051334~54051760:+ LIHC cis rs2658782 0.951 rs72972357 ENSG00000279684.1 RP11-755E23.2 4.17 3.88e-05 0.00842 0.38 0.22 Pulmonary function decline; chr11:93385674 chr11:93286629~93288903:- LIHC cis rs875971 0.545 rs1267814 ENSG00000228409.4 CCT6P1 4.17 3.88e-05 0.00843 0.18 0.22 Aortic root size; chr7:66579422 chr7:65751142~65763354:+ LIHC cis rs113084984 0.684 rs4669745 ENSG00000271952.1 RP11-245G13.2 -4.17 3.88e-05 0.00843 -0.27 -0.22 Breast cancer; chr2:11541446 chr2:10878269~10885118:+ LIHC cis rs6142102 0.961 rs4911392 ENSG00000275784.1 RP5-1125A11.6 -4.17 3.88e-05 0.00843 -0.25 -0.22 Skin pigmentation; chr20:33982712 chr20:33989480~33991818:- LIHC cis rs6142102 0.961 rs4911393 ENSG00000275784.1 RP5-1125A11.6 -4.17 3.88e-05 0.00843 -0.25 -0.22 Skin pigmentation; chr20:33983120 chr20:33989480~33991818:- LIHC cis rs893363 0.522 rs2241808 ENSG00000271916.1 RP11-884K10.6 -4.17 3.89e-05 0.00844 -0.27 -0.22 Axial length; chr3:53822626 chr3:53797764~53798019:- LIHC cis rs9640161 0.789 rs10952250 ENSG00000261305.1 RP4-584D14.7 4.17 3.89e-05 0.00844 0.26 0.22 Blood protein levels;Circulating chemerin levels; chr7:150328877 chr7:150341771~150342607:+ LIHC cis rs9341808 1 rs1359239 ENSG00000272129.1 RP11-250B2.6 4.17 3.89e-05 0.00845 0.23 0.22 Sitting height ratio; chr6:80246429 chr6:80355424~80356859:+ LIHC cis rs2494250 0.542 rs12140039 ENSG00000231434.1 RP11-144L1.8 -4.17 3.89e-05 0.00845 -0.27 -0.22 Select biomarker traits; chr1:159359410 chr1:158523672~158525838:+ LIHC cis rs8005677 0.611 rs11624528 ENSG00000257285.4 RP11-298I3.1 4.17 3.89e-05 0.00845 0.22 0.22 Cognitive ability (multi-trait analysis); chr14:22989947 chr14:22929609~22955562:+ LIHC cis rs860295 0.58 rs10908461 ENSG00000203761.5 MSTO2P -4.17 3.89e-05 0.00845 -0.19 -0.22 Body mass index; chr1:155305936 chr1:155745829~155750137:+ LIHC cis rs67311347 1 rs9842564 ENSG00000223797.4 ENTPD3-AS1 -4.17 3.89e-05 0.00845 -0.17 -0.22 Renal cell carcinoma; chr3:40364319 chr3:40313802~40453329:- LIHC cis rs6430585 0.528 rs309142 ENSG00000231890.6 DARS-AS1 -4.17 3.89e-05 0.00845 -0.3 -0.22 Corneal structure; chr2:135957754 chr2:135985176~136022593:+ LIHC cis rs710913 0.816 rs1727098 ENSG00000182109.6 RP11-69E11.4 -4.17 3.9e-05 0.00846 -0.22 -0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39523655 chr1:39522280~39546187:- LIHC cis rs2072510 0.966 rs1990611 ENSG00000257715.1 RP11-256L6.2 -4.17 3.9e-05 0.00846 -0.22 -0.22 Metabolite levels (small molecules and protein measures); chr12:96020206 chr12:96025323~96027971:+ LIHC cis rs875971 0.522 rs1880556 ENSG00000273024.4 INTS4P2 -4.17 3.9e-05 0.00846 -0.26 -0.22 Aortic root size; chr7:65967557 chr7:65647864~65715661:+ LIHC cis rs172166 0.694 rs2791332 ENSG00000216901.1 AL022393.7 4.17 3.9e-05 0.00846 0.28 0.22 Cardiac Troponin-T levels; chr6:28141010 chr6:28176188~28176674:+ LIHC cis rs763121 0.853 rs4821798 ENSG00000273076.1 RP3-508I15.22 4.17 3.9e-05 0.00846 0.24 0.22 Menopause (age at onset); chr22:38625160 chr22:38743495~38743910:+ LIHC cis rs10761256 0.835 rs10992841 ENSG00000227603.1 RP11-165J3.6 4.17 3.9e-05 0.00847 0.26 0.22 Itch intensity from mosquito bite adjusted by bite size; chr9:93667833 chr9:93435332~93437121:- LIHC cis rs16958440 1 rs62096476 ENSG00000267724.1 RP11-49K24.8 4.17 3.9e-05 0.00847 0.34 0.22 Sitting height ratio; chr18:47132250 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs62096478 ENSG00000267724.1 RP11-49K24.8 4.17 3.9e-05 0.00847 0.34 0.22 Sitting height ratio; chr18:47136038 chr18:47105946~47108062:+ LIHC cis rs11603023 0.804 rs527619 ENSG00000255422.1 AP002954.4 4.17 3.9e-05 0.00847 0.25 0.22 Cholesterol, total; chr11:118692577 chr11:118704607~118750263:+ LIHC cis rs9992667 0.956 rs73232890 ENSG00000231160.8 KLF3-AS1 4.17 3.9e-05 0.00847 0.31 0.22 Eosinophil percentage of granulocytes; chr4:38683420 chr4:38612701~38664883:- LIHC cis rs9652601 0.779 rs7203793 ENSG00000274038.1 RP11-66H6.4 -4.17 3.9e-05 0.00847 -0.27 -0.22 Systemic lupus erythematosus; chr16:11088277 chr16:11056556~11057034:+ LIHC cis rs2243480 1 rs383402 ENSG00000230295.1 RP11-458F8.2 4.17 3.91e-05 0.00848 0.23 0.22 Diabetic kidney disease; chr7:66121666 chr7:66880708~66882981:+ LIHC cis rs7246657 0.941 rs12982333 ENSG00000276846.1 CTD-3220F14.3 4.17 3.91e-05 0.00848 0.29 0.22 Coronary artery calcification; chr19:37303822 chr19:37314868~37315620:- LIHC cis rs7246657 1 rs10426297 ENSG00000276846.1 CTD-3220F14.3 4.17 3.91e-05 0.00848 0.29 0.22 Coronary artery calcification; chr19:37307471 chr19:37314868~37315620:- LIHC cis rs7246657 1 rs1823061 ENSG00000276846.1 CTD-3220F14.3 4.17 3.91e-05 0.00848 0.29 0.22 Coronary artery calcification; chr19:37309724 chr19:37314868~37315620:- LIHC cis rs875971 1 rs6460296 ENSG00000237310.1 GS1-124K5.4 4.17 3.91e-05 0.00848 0.2 0.22 Aortic root size; chr7:66430152 chr7:66493706~66495474:+ LIHC cis rs9595908 0.785 rs9596058 ENSG00000212293.1 SNORA16 4.17 3.91e-05 0.00848 0.25 0.22 Body mass index; chr13:32669938 chr13:32420390~32420516:- LIHC cis rs12681287 0.64 rs7841690 ENSG00000254088.1 SLC2A3P4 -4.17 3.91e-05 0.00849 -0.26 -0.22 Caudate activity during reward; chr8:86353130 chr8:86503591~86505061:+ LIHC cis rs6921919 0.789 rs6456814 ENSG00000204709.4 LINC01556 4.17 3.91e-05 0.00849 0.27 0.22 Autism spectrum disorder or schizophrenia; chr6:28338035 chr6:28943877~28944537:+ LIHC cis rs3733589 1 rs3756231 ENSG00000250413.1 RP11-448G15.1 -4.17 3.91e-05 0.00849 -0.38 -0.22 Renal overload gout; chr4:10023920 chr4:10006482~10009725:+ LIHC cis rs2598107 0.601 rs71546610 ENSG00000211698.2 TRGV4 -4.17 3.91e-05 0.00849 -0.26 -0.22 Dupuytren's disease; chr7:37916793 chr7:38353715~38354517:- LIHC cis rs2598107 0.601 rs35850626 ENSG00000211698.2 TRGV4 -4.17 3.91e-05 0.00849 -0.26 -0.22 Dupuytren's disease; chr7:37918865 chr7:38353715~38354517:- LIHC cis rs7811142 1 rs11771419 ENSG00000242294.5 STAG3L5P 4.17 3.92e-05 0.0085 0.25 0.22 Platelet count; chr7:100390780 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs76913697 ENSG00000242294.5 STAG3L5P 4.17 3.92e-05 0.0085 0.25 0.22 Platelet count; chr7:100405149 chr7:100336079~100351900:+ LIHC cis rs7044106 0.791 rs10984994 ENSG00000238181.2 AHCYP2 4.17 3.92e-05 0.0085 0.25 0.22 Hip circumference adjusted for BMI; chr9:120716491 chr9:120720673~120721972:+ LIHC cis rs2439831 0.85 rs8032649 ENSG00000166763.7 STRCP1 -4.17 3.92e-05 0.00851 -0.34 -0.22 Lung cancer in ever smokers; chr15:43842724 chr15:43699488~43718184:- LIHC cis rs10129255 0.956 rs10137268 ENSG00000223648.3 IGHV3-64 4.17 3.92e-05 0.00851 0.17 0.22 Kawasaki disease; chr14:106697402 chr14:106643132~106658258:- LIHC cis rs2243480 1 rs59794892 ENSG00000232546.1 RP11-458F8.1 -4.17 3.93e-05 0.00852 -0.25 -0.22 Diabetic kidney disease; chr7:65950886 chr7:66848496~66858136:+ LIHC cis rs2243480 0.803 rs36004293 ENSG00000232546.1 RP11-458F8.1 -4.17 3.93e-05 0.00852 -0.25 -0.22 Diabetic kidney disease; chr7:65951525 chr7:66848496~66858136:+ LIHC cis rs2243480 0.803 rs35268390 ENSG00000232546.1 RP11-458F8.1 -4.17 3.93e-05 0.00852 -0.25 -0.22 Diabetic kidney disease; chr7:65951549 chr7:66848496~66858136:+ LIHC cis rs1247318 0.507 rs1247330 ENSG00000243831.1 RP1-81D8.4 4.17 3.93e-05 0.00852 0.28 0.22 Aging; chr6:160905618 chr6:160666228~160676523:- LIHC cis rs6445975 0.666 rs4390943 ENSG00000272360.1 RP11-359I18.5 -4.17 3.93e-05 0.00852 -0.29 -0.22 Systemic lupus erythematosus; chr3:58390912 chr3:58490830~58491291:- LIHC cis rs638893 1 rs649338 ENSG00000255239.1 AP002954.6 4.17 3.93e-05 0.00852 0.38 0.22 Vitiligo; chr11:118834945 chr11:118688039~118690600:- LIHC cis rs7829975 0.871 rs777709 ENSG00000253893.2 FAM85B 4.17 3.93e-05 0.00852 0.26 0.22 Mood instability; chr8:8726362 chr8:8167819~8226614:- LIHC cis rs4561483 0.549 rs154149 ENSG00000261560.1 RP11-166B2.3 -4.17 3.93e-05 0.00852 -0.25 -0.22 Testicular germ cell tumor; chr16:11862261 chr16:11881075~11882569:- LIHC cis rs7044106 0.762 rs7357638 ENSG00000238181.2 AHCYP2 -4.17 3.93e-05 0.00853 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120626926 chr9:120720673~120721972:+ LIHC cis rs6445975 0.666 rs57621305 ENSG00000272360.1 RP11-359I18.5 -4.17 3.94e-05 0.00854 -0.3 -0.22 Systemic lupus erythematosus; chr3:58361017 chr3:58490830~58491291:- LIHC cis rs6445975 0.666 rs4681683 ENSG00000272360.1 RP11-359I18.5 -4.17 3.94e-05 0.00854 -0.3 -0.22 Systemic lupus erythematosus; chr3:58361958 chr3:58490830~58491291:- LIHC cis rs2274273 0.588 rs7154831 ENSG00000258413.1 RP11-665C16.6 -4.17 3.94e-05 0.00854 -0.27 -0.22 Protein biomarker; chr14:55357247 chr14:55262767~55272075:- LIHC cis rs494453 0.922 rs480578 ENSG00000227811.2 FAM212B-AS1 -4.17 3.94e-05 0.00854 -0.25 -0.22 Osteoporosis-related phenotypes; chr1:111709839 chr1:111739841~111747798:+ LIHC cis rs853679 0.76 rs2299029 ENSG00000219392.1 RP1-265C24.5 -4.17 3.94e-05 0.00854 -0.34 -0.22 Depression; chr6:28231053 chr6:28115628~28116551:+ LIHC cis rs853679 0.76 rs11962305 ENSG00000219392.1 RP1-265C24.5 -4.17 3.94e-05 0.00854 -0.34 -0.22 Depression; chr6:28232159 chr6:28115628~28116551:+ LIHC cis rs1115240 0.947 rs8010856 ENSG00000257842.4 NOVA1-AS1 -4.17 3.94e-05 0.00855 -0.2 -0.22 Educational attainment (years of education); chr14:26639592 chr14:26598412~26806467:+ LIHC cis rs4148323 1 rs4148323 ENSG00000228445.1 UGT1A2P -4.17 3.94e-05 0.00855 -0.28 -0.22 Bilirubin levels; chr2:233760498 chr2:233747214~233748079:+ LIHC cis rs9487094 0.626 rs2025148 ENSG00000260273.1 RP11-425D10.10 4.17 3.94e-05 0.00855 0.26 0.22 Height; chr6:109706740 chr6:109382795~109383666:+ LIHC cis rs3812762 0.879 rs3763920 ENSG00000254860.4 TMEM9B-AS1 4.17 3.95e-05 0.00855 0.23 0.22 Hypospadias; chr11:8787040 chr11:8964675~8977527:+ LIHC cis rs6700559 0.81 rs10919991 ENSG00000260088.1 RP11-92G12.3 -4.16 3.95e-05 0.00855 -0.28 -0.22 Coronary artery disease; chr1:200627217 chr1:200669507~200694250:+ LIHC cis rs8091660 0.929 rs12606093 ENSG00000278983.1 RP11-426J5.3 4.16 3.95e-05 0.00856 0.3 0.22 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48550924 chr18:48564795~48568342:+ LIHC cis rs9450351 0.744 rs35510369 ENSG00000203875.9 SNHG5 -4.16 3.95e-05 0.00856 -0.48 -0.22 Interferon gamma-induced protein 10 levels; chr6:85556411 chr6:85660950~85678736:- LIHC cis rs9400467 0.528 rs6933627 ENSG00000271789.1 RP5-1112D6.7 -4.16 3.95e-05 0.00856 -0.21 -0.22 Amino acid levels;Blood metabolite levels; chr6:111279606 chr6:111297126~111298510:+ LIHC cis rs7937890 0.559 rs2034480 ENSG00000251991.1 RNU7-49P 4.16 3.95e-05 0.00857 0.24 0.22 Mitochondrial DNA levels; chr11:14445377 chr11:14478892~14478953:+ LIHC cis rs11096990 0.855 rs75746161 ENSG00000249207.1 RP11-360F5.1 4.16 3.95e-05 0.00857 0.25 0.22 Cognitive function; chr4:39167481 chr4:39112677~39126818:- LIHC cis rs7937890 0.504 rs2575847 ENSG00000251991.1 RNU7-49P 4.16 3.95e-05 0.00857 0.24 0.22 Mitochondrial DNA levels; chr11:14449626 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2575825 ENSG00000251991.1 RNU7-49P 4.16 3.95e-05 0.00857 0.24 0.22 Mitochondrial DNA levels; chr11:14450550 chr11:14478892~14478953:+ LIHC cis rs7937890 0.532 rs2575827 ENSG00000251991.1 RNU7-49P 4.16 3.95e-05 0.00857 0.24 0.22 Mitochondrial DNA levels; chr11:14453969 chr11:14478892~14478953:+ LIHC cis rs7937890 0.532 rs2256884 ENSG00000251991.1 RNU7-49P 4.16 3.95e-05 0.00857 0.24 0.22 Mitochondrial DNA levels; chr11:14454856 chr11:14478892~14478953:+ LIHC cis rs7937890 0.559 rs2597206 ENSG00000251991.1 RNU7-49P 4.16 3.95e-05 0.00857 0.24 0.22 Mitochondrial DNA levels; chr11:14455992 chr11:14478892~14478953:+ LIHC cis rs673078 0.607 rs17440956 ENSG00000275759.1 RP11-131L12.3 4.16 3.95e-05 0.00857 0.45 0.22 Glucose homeostasis traits; chr12:118394639 chr12:118428281~118428870:+ LIHC cis rs11676348 0.805 rs12694428 ENSG00000261338.2 RP11-378A13.1 -4.16 3.96e-05 0.00857 -0.24 -0.22 Ulcerative colitis; chr2:218094097 chr2:218255319~218257366:+ LIHC cis rs7474896 0.583 rs12776092 ENSG00000263064.2 RP11-291L22.7 4.16 3.96e-05 0.00857 0.26 0.22 Obesity (extreme); chr10:37726867 chr10:38448689~38448949:+ LIHC cis rs9992667 0.91 rs28681431 ENSG00000231160.8 KLF3-AS1 4.16 3.96e-05 0.00858 0.28 0.22 Eosinophil percentage of granulocytes; chr4:38686307 chr4:38612701~38664883:- LIHC cis rs9807989 0.507 rs10203558 ENSG00000234389.1 AC007278.3 4.16 3.96e-05 0.00858 0.24 0.22 Asthma; chr2:102411180 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs10200952 ENSG00000234389.1 AC007278.3 4.16 3.96e-05 0.00858 0.24 0.22 Asthma; chr2:102411191 chr2:102438713~102440475:+ LIHC cis rs4988958 0.548 rs6543127 ENSG00000234389.1 AC007278.3 4.16 3.96e-05 0.00858 0.24 0.22 Asthma (childhood onset); chr2:102411841 chr2:102438713~102440475:+ LIHC cis rs9807989 0.524 rs4851576 ENSG00000234389.1 AC007278.3 4.16 3.96e-05 0.00858 0.24 0.22 Asthma; chr2:102412435 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs4851577 ENSG00000234389.1 AC007278.3 4.16 3.96e-05 0.00858 0.24 0.22 Asthma; chr2:102412461 chr2:102438713~102440475:+ LIHC cis rs9807989 0.507 rs4851579 ENSG00000234389.1 AC007278.3 4.16 3.96e-05 0.00858 0.24 0.22 Asthma; chr2:102412524 chr2:102438713~102440475:+ LIHC cis rs2439831 0.681 rs3742971 ENSG00000166763.7 STRCP1 -4.16 3.96e-05 0.00858 -0.3 -0.22 Lung cancer in ever smokers; chr15:43330718 chr15:43699488~43718184:- LIHC cis rs8007846 0.539 rs67957534 ENSG00000276116.2 FUT8-AS1 4.16 3.96e-05 0.00858 0.27 0.22 Multiple sclerosis--Brain Glutamate Levels; chr14:65657867 chr14:65411170~65412690:- LIHC cis rs2310173 0.575 rs757918 ENSG00000281162.1 LINC01127 -4.16 3.96e-05 0.00858 -0.23 -0.22 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:101996837 chr2:101962056~101987167:+ LIHC cis rs12681287 0.605 rs6471296 ENSG00000254088.1 SLC2A3P4 -4.16 3.96e-05 0.00858 -0.26 -0.22 Caudate activity during reward; chr8:86362425 chr8:86503591~86505061:+ LIHC cis rs2439831 0.867 rs12443102 ENSG00000166763.7 STRCP1 4.16 3.96e-05 0.00858 0.34 0.22 Lung cancer in ever smokers; chr15:43639905 chr15:43699488~43718184:- LIHC cis rs72675573 0.852 rs1331859 ENSG00000235612.1 RP1-158P9.1 -4.16 3.96e-05 0.00858 -0.29 -0.22 Monocyte count; chr1:56128439 chr1:56145721~56155224:+ LIHC cis rs763121 0.819 rs5750629 ENSG00000273076.1 RP3-508I15.22 4.16 3.96e-05 0.00859 0.25 0.22 Menopause (age at onset); chr22:38589060 chr22:38743495~38743910:+ LIHC cis rs7893279 0.505 rs12785031 ENSG00000225527.1 RP11-383B4.4 4.16 3.97e-05 0.00859 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18611240 chr10:18531849~18533336:- LIHC cis rs948562 0.947 rs2186381 ENSG00000280010.1 AP001350.4 4.16 3.97e-05 0.00859 0.36 0.22 Lymphoma; chr11:58630320 chr11:58627435~58628528:+ LIHC cis rs11096990 0.634 rs1451818 ENSG00000249685.1 RP11-360F5.3 4.16 3.97e-05 0.00859 0.26 0.22 Cognitive function; chr4:39257151 chr4:39133913~39135608:+ LIHC cis rs2581828 0.965 rs35783750 ENSG00000242142.1 SERBP1P3 4.16 3.97e-05 0.0086 0.25 0.22 Crohn's disease; chr3:53100847 chr3:53064283~53065091:- LIHC cis rs2581828 0.965 rs34454739 ENSG00000242142.1 SERBP1P3 4.16 3.97e-05 0.0086 0.25 0.22 Crohn's disease; chr3:53100955 chr3:53064283~53065091:- LIHC cis rs2581828 0.965 rs2564961 ENSG00000242142.1 SERBP1P3 4.16 3.97e-05 0.0086 0.25 0.22 Crohn's disease; chr3:53102445 chr3:53064283~53065091:- LIHC cis rs11096990 0.613 rs4974996 ENSG00000249207.1 RP11-360F5.1 -4.16 3.97e-05 0.0086 -0.22 -0.22 Cognitive function; chr4:39225928 chr4:39112677~39126818:- LIHC cis rs6832769 0.961 rs6824955 ENSG00000272969.1 RP11-528I4.2 4.16 3.97e-05 0.0086 0.26 0.22 Personality dimensions; chr4:55450969 chr4:55547112~55547889:+ LIHC cis rs113835537 0.935 rs79106199 ENSG00000255517.5 CTD-3074O7.5 -4.16 3.97e-05 0.0086 -0.38 -0.22 Airway imaging phenotypes; chr11:66653047 chr11:66473490~66480233:- LIHC cis rs113835537 0.935 rs117131621 ENSG00000255517.5 CTD-3074O7.5 -4.16 3.97e-05 0.0086 -0.38 -0.22 Airway imaging phenotypes; chr11:66654863 chr11:66473490~66480233:- LIHC cis rs113835537 0.935 rs57043177 ENSG00000255517.5 CTD-3074O7.5 -4.16 3.97e-05 0.0086 -0.38 -0.22 Airway imaging phenotypes; chr11:66655676 chr11:66473490~66480233:- LIHC cis rs2243480 1 rs35820085 ENSG00000232546.1 RP11-458F8.1 -4.16 3.97e-05 0.0086 -0.25 -0.22 Diabetic kidney disease; chr7:65977771 chr7:66848496~66858136:+ LIHC cis rs7829975 0.511 rs2976902 ENSG00000253981.4 ALG1L13P 4.16 3.97e-05 0.0086 0.29 0.22 Mood instability; chr8:8483595 chr8:8236003~8244667:- LIHC cis rs4682868 0.611 rs734969 ENSG00000273328.4 RP11-141M3.6 4.16 3.98e-05 0.00861 0.22 0.22 Monocyte percentage of white cells; chr3:42876414 chr3:42809414~42908105:+ LIHC cis rs950169 1 rs12916348 ENSG00000259728.4 LINC00933 4.16 3.98e-05 0.00861 0.35 0.22 Schizophrenia; chr15:84096775 chr15:84570649~84580175:+ LIHC cis rs6500637 0.86 rs11644917 ENSG00000267077.1 RP11-127I20.5 -4.16 3.98e-05 0.00861 -0.24 -0.22 Cancer; chr16:4890386 chr16:4795265~4796532:- LIHC cis rs950169 0.959 rs12902070 ENSG00000259728.4 LINC00933 4.16 3.98e-05 0.00861 0.35 0.22 Schizophrenia; chr15:84124806 chr15:84570649~84580175:+ LIHC cis rs67311347 0.568 rs57287242 ENSG00000223797.4 ENTPD3-AS1 4.16 3.98e-05 0.00861 0.18 0.22 Renal cell carcinoma; chr3:40294047 chr3:40313802~40453329:- LIHC cis rs7474896 0.561 rs2474603 ENSG00000120555.12 SEPT7P9 4.16 3.98e-05 0.00861 0.32 0.22 Obesity (extreme); chr10:38156754 chr10:38383069~38402916:- LIHC cis rs9353324 1 rs9353324 ENSG00000203875.9 SNHG5 -4.16 3.98e-05 0.00862 -0.48 -0.22 Interferon gamma-induced protein 10 levels; chr6:85653156 chr6:85660950~85678736:- LIHC cis rs1510272 0.515 rs6807235 ENSG00000243926.1 TIPARP-AS1 -4.16 3.98e-05 0.00862 -0.25 -0.22 Testicular germ cell tumor; chr3:156623812 chr3:156671862~156674378:- LIHC cis rs1062177 0.756 rs2915827 ENSG00000253921.1 CTB-113P19.3 4.16 3.98e-05 0.00862 0.25 0.22 Preschool internalizing problems; chr5:151740144 chr5:151753992~151767247:+ LIHC cis rs66887589 0.807 rs7694483 ENSG00000260091.1 RP11-33B1.4 -4.16 3.98e-05 0.00862 -0.14 -0.22 Diastolic blood pressure; chr4:119484774 chr4:119409333~119410233:+ LIHC cis rs9652601 0.843 rs7204643 ENSG00000274038.1 RP11-66H6.4 4.16 3.98e-05 0.00862 0.28 0.22 Systemic lupus erythematosus; chr16:11073746 chr16:11056556~11057034:+ LIHC cis rs7246657 1 rs12709812 ENSG00000276846.1 CTD-3220F14.3 -4.16 3.99e-05 0.00863 -0.29 -0.22 Coronary artery calcification; chr19:37303948 chr19:37314868~37315620:- LIHC cis rs6700559 0.873 rs7524025 ENSG00000260088.1 RP11-92G12.3 -4.16 3.99e-05 0.00863 -0.28 -0.22 Coronary artery disease; chr1:200687859 chr1:200669507~200694250:+ LIHC cis rs60733400 0.667 rs4385650 ENSG00000225931.3 RP3-395M20.7 4.16 3.99e-05 0.00863 0.24 0.22 Multiple sclerosis; chr1:2568459 chr1:2566410~2569888:+ LIHC cis rs2998286 0.723 rs1034087 ENSG00000254635.4 WAC-AS1 -4.16 3.99e-05 0.00863 -0.27 -0.22 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28643143 chr10:28522652~28532743:- LIHC cis rs2564921 0.73 rs56386026 ENSG00000242142.1 SERBP1P3 -4.16 3.99e-05 0.00863 -0.3 -0.22 Height; chr3:53080524 chr3:53064283~53065091:- LIHC cis rs1115240 0.898 rs2332816 ENSG00000257842.4 NOVA1-AS1 -4.16 3.99e-05 0.00863 -0.2 -0.22 Educational attainment (years of education); chr14:26635642 chr14:26598412~26806467:+ LIHC cis rs2717559 0.542 rs11777634 ENSG00000253196.1 RP11-706C16.7 -4.16 3.99e-05 0.00864 -0.24 -0.22 Urinary tract infection frequency; chr8:142806541 chr8:142763116~142766427:+ LIHC cis rs42490 0.868 rs1605997 ENSG00000251136.7 RP11-37B2.1 4.16 3.99e-05 0.00864 0.19 0.22 Leprosy; chr8:89655885 chr8:89609409~89757727:- LIHC cis rs338389 0.542 rs12594726 ENSG00000260657.2 RP11-315D16.4 -4.16 3.99e-05 0.00864 -0.36 -0.22 Survival in rectal cancer; chr15:67994440 chr15:68267792~68277994:- LIHC cis rs11673344 0.698 rs56161518 ENSG00000226686.6 LINC01535 4.16 3.99e-05 0.00864 0.34 0.22 Obesity-related traits; chr19:36978555 chr19:37251912~37265535:+ LIHC cis rs9322193 0.607 rs9371228 ENSG00000216906.2 RP11-350J20.9 -4.16 3.99e-05 0.00864 -0.25 -0.22 Lung cancer; chr6:149921977 chr6:149904243~149906418:+ LIHC cis rs79349575 0.716 rs595767 ENSG00000248278.1 SUMO2P17 4.16 4e-05 0.00864 0.27 0.22 Type 2 diabetes; chr17:48880625 chr17:48874860~48908983:- LIHC cis rs875971 0.929 rs34406470 ENSG00000237310.1 GS1-124K5.4 4.16 4e-05 0.00864 0.2 0.22 Aortic root size; chr7:66464969 chr7:66493706~66495474:+ LIHC cis rs803923 0.52 rs35910339 ENSG00000230894.1 RP11-67K19.3 -4.16 4e-05 0.00865 -0.28 -0.22 Lung function (FEV1/FVC); chr9:116632085 chr9:116568449~116586328:+ LIHC cis rs7121538 0.756 rs76613195 ENSG00000251991.1 RNU7-49P -4.16 4e-05 0.00865 -0.31 -0.22 HDL cholesterol; chr11:14405856 chr11:14478892~14478953:+ LIHC cis rs3091242 0.933 rs4649084 ENSG00000224183.1 SDHDP6 -4.16 4e-05 0.00866 -0.25 -0.22 Erythrocyte sedimentation rate; chr1:25426126 chr1:25294164~25294643:- LIHC cis rs867371 1 rs13380317 ENSG00000259429.4 UBE2Q2P2 4.16 4e-05 0.00866 0.21 0.22 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82214449 chr15:82355142~82420075:+ LIHC cis rs11745587 0.539 rs6897597 ENSG00000233006.5 AC034220.3 4.16 4e-05 0.00866 0.24 0.22 Asthma; chr5:132407773 chr5:132311285~132369916:- LIHC cis rs921968 0.565 rs2059717 ENSG00000272555.1 RP11-459I19.1 -4.16 4e-05 0.00866 -0.24 -0.22 Mean corpuscular hemoglobin concentration; chr2:218735593 chr2:218818690~218819144:+ LIHC cis rs875971 0.545 rs1796222 ENSG00000273024.4 INTS4P2 4.16 4e-05 0.00866 0.25 0.22 Aortic root size; chr7:66592167 chr7:65647864~65715661:+ LIHC cis rs1005277 0.505 rs10827835 ENSG00000275858.1 RP11-291L22.8 -4.16 4.01e-05 0.00866 -0.24 -0.22 Extrinsic epigenetic age acceleration; chr10:37861781 chr10:38450738~38451069:- LIHC cis rs9876781 1 rs4858817 ENSG00000229759.1 MRPS18AP1 -4.16 4.01e-05 0.00866 -0.23 -0.22 Longevity; chr3:48375266 chr3:48256350~48256938:- LIHC cis rs4578769 0.918 rs8089471 ENSG00000266850.1 RP11-370A5.1 4.16 4.01e-05 0.00867 0.26 0.22 Eosinophil percentage of white cells; chr18:22892994 chr18:22723491~22907721:- LIHC cis rs875971 0.502 rs1796227 ENSG00000273024.4 INTS4P2 4.16 4.01e-05 0.00867 0.25 0.22 Aortic root size; chr7:66622032 chr7:65647864~65715661:+ LIHC cis rs7665090 1 rs3733202 ENSG00000246560.2 RP11-10L12.4 4.16 4.01e-05 0.00867 0.26 0.22 Primary biliary cholangitis; chr4:102635704 chr4:102828055~102844075:+ LIHC cis rs7615952 0.543 rs4645102 ENSG00000171084.14 FAM86JP 4.16 4.01e-05 0.00867 0.34 0.22 Blood pressure (smoking interaction); chr3:125705597 chr3:125916620~125930024:+ LIHC cis rs2658782 0.951 rs72972364 ENSG00000279684.1 RP11-755E23.2 4.16 4.02e-05 0.00868 0.39 0.22 Pulmonary function decline; chr11:93388962 chr11:93286629~93288903:- LIHC cis rs453301 0.506 rs686189 ENSG00000253893.2 FAM85B 4.16 4.02e-05 0.00868 0.25 0.22 Joint mobility (Beighton score); chr8:8766127 chr8:8167819~8226614:- LIHC cis rs11722228 0.508 rs61335146 ENSG00000261490.1 RP11-448G15.3 4.16 4.02e-05 0.00868 0.28 0.22 Urate levels;Serum uric acid levels;Gout; chr4:10129169 chr4:10068089~10073019:- LIHC cis rs16958440 1 rs62096474 ENSG00000267724.1 RP11-49K24.8 4.16 4.02e-05 0.00868 0.34 0.22 Sitting height ratio; chr18:47121133 chr18:47105946~47108062:+ LIHC cis rs16958440 0.737 rs16958699 ENSG00000267724.1 RP11-49K24.8 4.16 4.02e-05 0.00868 0.34 0.22 Sitting height ratio; chr18:47128475 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs16958701 ENSG00000267724.1 RP11-49K24.8 4.16 4.02e-05 0.00868 0.34 0.22 Sitting height ratio; chr18:47128870 chr18:47105946~47108062:+ LIHC cis rs8064024 0.676 rs9926458 ENSG00000267077.1 RP11-127I20.5 4.16 4.02e-05 0.00869 0.22 0.22 Cancer; chr16:4822627 chr16:4795265~4796532:- LIHC cis rs1223397 1 rs1223397 ENSG00000215022.6 RP1-257A7.4 -4.16 4.02e-05 0.00869 -0.24 -0.22 Blood pressure; chr6:13270713 chr6:13264861~13295586:- LIHC cis rs7688540 0.665 rs11731933 ENSG00000275426.1 CH17-262A2.1 4.16 4.02e-05 0.00869 0.28 0.22 Facial morphology (factor 6, height of vermillion lower lip); chr4:245370 chr4:149738~150317:+ LIHC cis rs10129255 0.5 rs2027902 ENSG00000211972.2 IGHV3-66 4.16 4.02e-05 0.00869 0.16 0.22 Kawasaki disease; chr14:106807157 chr14:106675017~106675544:- LIHC cis rs7129556 0.621 rs663674 ENSG00000254459.1 RP11-91P24.7 4.16 4.02e-05 0.00869 0.35 0.22 Weight loss (gastric bypass surgery); chr11:77881476 chr11:77829654~77872262:- LIHC cis rs417065 1 rs12140347 ENSG00000227634.1 RP11-431K24.3 -4.16 4.03e-05 0.0087 -0.29 -0.22 Psoriasis; chr1:8200139 chr1:8208672~8215210:+ LIHC cis rs9652601 0.959 rs11865121 ENSG00000274038.1 RP11-66H6.4 -4.16 4.03e-05 0.0087 -0.27 -0.22 Systemic lupus erythematosus; chr16:11072831 chr16:11056556~11057034:+ LIHC cis rs3758785 0.623 rs75164831 ENSG00000255893.1 RP11-685N10.1 -4.16 4.03e-05 0.0087 -0.27 -0.22 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94410667 chr11:94472908~94473570:- LIHC cis rs3758785 0.562 rs79850307 ENSG00000255893.1 RP11-685N10.1 -4.16 4.03e-05 0.0087 -0.27 -0.22 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94411859 chr11:94472908~94473570:- LIHC cis rs2790457 0.958 rs2532742 ENSG00000254635.4 WAC-AS1 -4.16 4.03e-05 0.0087 -0.21 -0.22 Multiple myeloma; chr10:28578291 chr10:28522652~28532743:- LIHC cis rs875971 0.502 rs1796227 ENSG00000228409.4 CCT6P1 4.16 4.03e-05 0.0087 0.18 0.22 Aortic root size; chr7:66622032 chr7:65751142~65763354:+ LIHC cis rs7688540 0.739 rs11729659 ENSG00000275426.1 CH17-262A2.1 4.16 4.03e-05 0.00871 0.28 0.22 Facial morphology (factor 6, height of vermillion lower lip); chr4:243495 chr4:149738~150317:+ LIHC cis rs780096 0.526 rs11682621 ENSG00000234072.1 AC074117.10 -4.16 4.03e-05 0.00871 -0.21 -0.22 Total body bone mineral density; chr2:27526802 chr2:27356246~27367622:+ LIHC cis rs597539 0.652 rs513615 ENSG00000250508.1 RP11-757G1.6 -4.16 4.03e-05 0.00871 -0.34 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68938036 chr11:68870664~68874542:+ LIHC cis rs1115240 0.947 rs11159938 ENSG00000257842.4 NOVA1-AS1 -4.16 4.03e-05 0.00871 -0.2 -0.22 Educational attainment (years of education); chr14:26637780 chr14:26598412~26806467:+ LIHC cis rs1115240 0.898 rs10134225 ENSG00000257842.4 NOVA1-AS1 -4.16 4.03e-05 0.00871 -0.2 -0.22 Educational attainment (years of education); chr14:26574517 chr14:26598412~26806467:+ LIHC cis rs1115240 0.898 rs2017442 ENSG00000257842.4 NOVA1-AS1 -4.16 4.03e-05 0.00871 -0.2 -0.22 Educational attainment (years of education); chr14:26576572 chr14:26598412~26806467:+ LIHC cis rs1115240 0.853 rs11159900 ENSG00000257842.4 NOVA1-AS1 -4.16 4.03e-05 0.00871 -0.2 -0.22 Educational attainment (years of education); chr14:26582164 chr14:26598412~26806467:+ LIHC cis rs6433895 0.71 rs7581267 ENSG00000236153.1 AC104076.3 -4.16 4.04e-05 0.00872 -0.32 -0.22 Lymphocyte counts; chr2:181143574 chr2:180979427~180980090:- LIHC cis rs42490 0.51 rs4961157 ENSG00000251136.7 RP11-37B2.1 -4.16 4.04e-05 0.00872 -0.19 -0.22 Leprosy; chr8:89684800 chr8:89609409~89757727:- LIHC cis rs2072510 0.569 rs61937881 ENSG00000257878.1 RP11-256L6.3 -4.16 4.04e-05 0.00872 -0.29 -0.22 Metabolite levels (small molecules and protein measures); chr12:95999809 chr12:95996521~96011489:+ LIHC cis rs2072510 0.569 rs17677343 ENSG00000257878.1 RP11-256L6.3 -4.16 4.04e-05 0.00872 -0.29 -0.22 Metabolite levels (small molecules and protein measures); chr12:96003303 chr12:95996521~96011489:+ LIHC cis rs1115240 0.731 rs12587726 ENSG00000257842.4 NOVA1-AS1 -4.16 4.04e-05 0.00872 -0.2 -0.22 Educational attainment (years of education); chr14:26587118 chr14:26598412~26806467:+ LIHC cis rs1115240 0.898 rs9323839 ENSG00000257842.4 NOVA1-AS1 -4.16 4.04e-05 0.00872 -0.2 -0.22 Educational attainment (years of education); chr14:26587583 chr14:26598412~26806467:+ LIHC cis rs2243480 1 rs34815098 ENSG00000228409.4 CCT6P1 4.16 4.04e-05 0.00872 0.24 0.22 Diabetic kidney disease; chr7:65827267 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs4548056 ENSG00000228409.4 CCT6P1 4.16 4.04e-05 0.00872 0.24 0.22 Diabetic kidney disease; chr7:65833886 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs7456042 ENSG00000228409.4 CCT6P1 4.16 4.04e-05 0.00872 0.24 0.22 Diabetic kidney disease; chr7:65834791 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs35735127 ENSG00000228409.4 CCT6P1 4.16 4.04e-05 0.00872 0.24 0.22 Diabetic kidney disease; chr7:65835436 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs35256305 ENSG00000228409.4 CCT6P1 4.16 4.04e-05 0.00872 0.24 0.22 Diabetic kidney disease; chr7:65841418 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs73142121 ENSG00000228409.4 CCT6P1 4.16 4.04e-05 0.00872 0.24 0.22 Diabetic kidney disease; chr7:65846219 chr7:65751142~65763354:+ LIHC cis rs2243480 0.803 rs34004500 ENSG00000228409.4 CCT6P1 4.16 4.04e-05 0.00872 0.24 0.22 Diabetic kidney disease; chr7:65847191 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs35825738 ENSG00000228409.4 CCT6P1 4.16 4.04e-05 0.00872 0.24 0.22 Diabetic kidney disease; chr7:65853040 chr7:65751142~65763354:+ LIHC cis rs2070488 0.931 rs6599212 ENSG00000229589.1 ACVR2B-AS1 -4.16 4.04e-05 0.00873 -0.25 -0.22 Electrocardiographic conduction measures; chr3:38517415 chr3:38451027~38454820:- LIHC cis rs72627509 0.587 rs17087401 ENSG00000269949.1 RP11-738E22.3 4.16 4.04e-05 0.00873 0.31 0.22 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:57034989 chr4:56960927~56961373:- LIHC cis rs2243480 1 rs55895244 ENSG00000228409.4 CCT6P1 4.16 4.05e-05 0.00873 0.24 0.22 Diabetic kidney disease; chr7:65922691 chr7:65751142~65763354:+ LIHC cis rs1223397 0.938 rs13205692 ENSG00000215022.6 RP1-257A7.4 -4.16 4.05e-05 0.00873 -0.29 -0.22 Blood pressure; chr6:13291328 chr6:13264861~13295586:- LIHC cis rs4873772 0.834 rs7842068 ENSG00000253608.1 RP11-770E5.1 4.16 4.05e-05 0.00874 0.25 0.22 Lobe attachment (rater-scored or self-reported); chr8:47670402 chr8:48551567~48698510:+ LIHC cis rs3743772 0.5 rs8045574 ENSG00000279722.1 RP11-44F14.6 -4.16 4.05e-05 0.00874 -0.29 -0.22 Depressive symptoms (SSRI exposure interaction); chr16:53395293 chr16:53487607~53489943:- LIHC cis rs755249 0.567 rs61779309 ENSG00000182109.6 RP11-69E11.4 4.16 4.05e-05 0.00874 0.3 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39474827 chr1:39522280~39546187:- LIHC cis rs2015599 0.563 rs11050168 ENSG00000275476.1 RP11-996F15.4 4.16 4.05e-05 0.00874 0.27 0.22 Platelet count;Mean platelet volume; chr12:29273760 chr12:29277397~29277882:- LIHC cis rs1005277 0.522 rs7090858 ENSG00000099251.13 HSD17B7P2 -4.16 4.05e-05 0.00874 -0.25 -0.22 Extrinsic epigenetic age acceleration; chr10:37714742 chr10:38356380~38378505:+ LIHC cis rs10262624 0.967 rs13235406 ENSG00000234286.1 AC006026.13 -4.16 4.05e-05 0.00875 -0.25 -0.22 Schizophrenia; chr7:23879212 chr7:23680195~23680786:- LIHC cis rs17818399 1 rs62136864 ENSG00000279254.1 RP11-536C12.1 -4.16 4.05e-05 0.00875 -0.26 -0.22 Height; chr2:46601985 chr2:46668870~46670778:+ LIHC cis rs3020736 0.5 rs1801311 ENSG00000205702.9 CYP2D7 -4.16 4.05e-05 0.00875 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42090719 chr22:42140203~42144577:- LIHC cis rs67311347 0.544 rs2278930 ENSG00000223797.4 ENTPD3-AS1 4.16 4.05e-05 0.00875 0.18 0.22 Renal cell carcinoma; chr3:40309601 chr3:40313802~40453329:- LIHC cis rs950169 0.58 rs11636189 ENSG00000259728.4 LINC00933 4.16 4.05e-05 0.00875 0.31 0.22 Schizophrenia; chr15:84650323 chr15:84570649~84580175:+ LIHC cis rs9532669 0.963 rs1056824 ENSG00000168852.11 TPTE2P5 4.16 4.06e-05 0.00875 0.24 0.22 Cervical cancer; chr13:40932748 chr13:40822296~40921749:- LIHC cis rs4713118 0.539 rs200967 ENSG00000216901.1 AL022393.7 4.16 4.06e-05 0.00876 0.29 0.22 Parkinson's disease; chr6:27894349 chr6:28176188~28176674:+ LIHC cis rs1876905 0.539 rs240958 ENSG00000271789.1 RP5-1112D6.7 4.16 4.06e-05 0.00876 0.25 0.22 Mean corpuscular hemoglobin; chr6:111298449 chr6:111297126~111298510:+ LIHC cis rs1077773 0.531 rs11766278 ENSG00000237773.4 AC003075.4 -4.16 4.06e-05 0.00876 -0.27 -0.22 Ulcerative colitis;Inflammatory bowel disease; chr7:17410907 chr7:17279834~17299357:- LIHC cis rs3015497 0.763 rs2934689 ENSG00000269906.1 RP11-248J18.2 4.16 4.06e-05 0.00876 0.28 0.22 Mean platelet volume; chr14:50651609 chr14:50662511~50663178:- LIHC cis rs67311347 0.544 rs6762121 ENSG00000223797.4 ENTPD3-AS1 4.16 4.07e-05 0.00877 0.18 0.22 Renal cell carcinoma; chr3:40313822 chr3:40313802~40453329:- LIHC cis rs67311347 0.544 rs6787516 ENSG00000223797.4 ENTPD3-AS1 4.16 4.07e-05 0.00877 0.18 0.22 Renal cell carcinoma; chr3:40314125 chr3:40313802~40453329:- LIHC cis rs3812762 0.833 rs3850933 ENSG00000254860.4 TMEM9B-AS1 -4.16 4.07e-05 0.00878 -0.23 -0.22 Hypospadias; chr11:8779588 chr11:8964675~8977527:+ LIHC cis rs875971 0.545 rs66594357 ENSG00000273024.4 INTS4P2 -4.16 4.07e-05 0.00878 -0.25 -0.22 Aortic root size; chr7:66327797 chr7:65647864~65715661:+ LIHC cis rs10262624 0.935 rs6955725 ENSG00000234286.1 AC006026.13 -4.16 4.07e-05 0.00878 -0.25 -0.22 Schizophrenia; chr7:23865523 chr7:23680195~23680786:- LIHC cis rs12468226 0.689 rs60584169 ENSG00000272966.1 RP11-686O6.1 4.16 4.07e-05 0.00879 0.39 0.22 Urate levels; chr2:202111695 chr2:202336739~202337200:+ LIHC cis rs4356203 0.87 rs7342262 ENSG00000260196.1 RP1-239B22.5 -4.16 4.08e-05 0.00879 -0.26 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17264260 chr11:17380649~17383531:+ LIHC cis rs10857712 0.754 rs2297031 ENSG00000214279.11 SCART1 -4.16 4.08e-05 0.00879 -0.27 -0.22 Systemic lupus erythematosus; chr10:133419150 chr10:133453928~133523558:+ LIHC cis rs875971 0.545 rs2420456 ENSG00000273024.4 INTS4P2 -4.16 4.08e-05 0.00879 -0.25 -0.22 Aortic root size; chr7:66280619 chr7:65647864~65715661:+ LIHC cis rs9303401 0.734 rs8073316 ENSG00000265415.1 CTD-2510F5.4 -4.16 4.08e-05 0.0088 -0.15 -0.22 Cognitive test performance; chr17:59134020 chr17:59202677~59203829:- LIHC cis rs3822625 0.541 rs10042998 ENSG00000271828.1 CTD-2310F14.1 4.16 4.08e-05 0.0088 0.42 0.22 Breast cancer (early onset); chr5:56909472 chr5:56927874~56929573:+ LIHC cis rs673078 0.607 rs6490177 ENSG00000275409.1 RP11-131L12.4 -4.16 4.08e-05 0.0088 -0.27 -0.22 Glucose homeostasis traits; chr12:118358280 chr12:118430147~118430699:+ LIHC cis rs6547741 1 rs4666009 ENSG00000234072.1 AC074117.10 4.16 4.08e-05 0.00881 0.2 0.22 Oral cavity cancer; chr2:27635125 chr2:27356246~27367622:+ LIHC cis rs651907 0.557 rs13081846 ENSG00000244119.1 PDCL3P4 4.16 4.09e-05 0.00881 0.23 0.22 Colorectal cancer; chr3:101664477 chr3:101712472~101713191:+ LIHC cis rs651907 0.557 rs11711079 ENSG00000244119.1 PDCL3P4 4.16 4.09e-05 0.00881 0.23 0.22 Colorectal cancer; chr3:101668074 chr3:101712472~101713191:+ LIHC cis rs17345786 0.511 rs13061565 ENSG00000244119.1 PDCL3P4 4.16 4.09e-05 0.00881 0.23 0.22 Colonoscopy-negative controls vs population controls; chr3:101673426 chr3:101712472~101713191:+ LIHC cis rs651907 0.557 rs7651404 ENSG00000244119.1 PDCL3P4 4.16 4.09e-05 0.00881 0.23 0.22 Colorectal cancer; chr3:101674450 chr3:101712472~101713191:+ LIHC cis rs4578769 0.765 rs35998712 ENSG00000265943.1 RP11-739L10.1 -4.16 4.09e-05 0.00881 -0.29 -0.22 Eosinophil percentage of white cells; chr18:22873654 chr18:22699481~22933764:- LIHC cis rs9341808 0.905 rs3805903 ENSG00000272129.1 RP11-250B2.6 4.16 4.09e-05 0.00881 0.22 0.22 Sitting height ratio; chr6:80266112 chr6:80355424~80356859:+ LIHC cis rs7412746 0.611 rs2256355 ENSG00000231073.1 RP11-316M1.3 4.16 4.09e-05 0.00881 0.22 0.22 Melanoma; chr1:150839318 chr1:150973123~150975534:+ LIHC cis rs11098499 0.913 rs11098496 ENSG00000260091.1 RP11-33B1.4 -4.16 4.09e-05 0.00882 -0.16 -0.22 Corneal astigmatism; chr4:119246311 chr4:119409333~119410233:+ LIHC cis rs1115240 0.812 rs7156412 ENSG00000257842.4 NOVA1-AS1 -4.16 4.09e-05 0.00882 -0.2 -0.22 Educational attainment (years of education); chr14:26574623 chr14:26598412~26806467:+ LIHC cis rs1023500 0.505 rs134878 ENSG00000226450.2 CYP2D8P 4.16 4.09e-05 0.00882 0.24 0.22 Schizophrenia; chr22:42267868 chr22:42149886~42155001:- LIHC cis rs12209785 1 rs12209785 ENSG00000231769.2 RP1-8B1.4 4.16 4.09e-05 0.00882 0.34 0.22 Survival in pancreatic cancer; chr6:45538385 chr6:46097093~46129706:- LIHC cis rs6445975 0.688 rs2271633 ENSG00000272360.1 RP11-359I18.5 -4.16 4.09e-05 0.00882 -0.25 -0.22 Systemic lupus erythematosus; chr3:58274346 chr3:58490830~58491291:- LIHC cis rs2283831 0.506 rs9613209 ENSG00000213707.2 HMGB1P10 -4.16 4.09e-05 0.00882 -0.27 -0.22 Anti-saccade response; chr22:26560426 chr22:26560526~26561088:+ LIHC cis rs1005277 0.522 rs11011343 ENSG00000099251.13 HSD17B7P2 4.16 4.1e-05 0.00882 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37713770 chr10:38356380~38378505:+ LIHC cis rs61160187 0.51 rs10057395 ENSG00000272308.1 RP11-231G3.1 -4.16 4.1e-05 0.00882 -0.27 -0.22 Educational attainment (years of education);Educational attainment (college completion); chr5:60792967 chr5:60866457~60866935:- LIHC cis rs9876781 1 rs725309 ENSG00000229759.1 MRPS18AP1 -4.16 4.1e-05 0.00883 -0.23 -0.22 Longevity; chr3:48377218 chr3:48256350~48256938:- LIHC cis rs9907295 0.901 rs9907121 ENSG00000270871.1 AC015849.19 4.16 4.1e-05 0.00883 0.23 0.22 Fibroblast growth factor basic levels; chr17:35849074 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs4796118 ENSG00000270871.1 AC015849.19 4.16 4.1e-05 0.00883 0.23 0.22 Fibroblast growth factor basic levels; chr17:35858804 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs9914401 ENSG00000270871.1 AC015849.19 4.16 4.1e-05 0.00883 0.23 0.22 Fibroblast growth factor basic levels; chr17:35861810 chr17:35816717~35830293:- LIHC cis rs12157904 1 rs12160480 ENSG00000233360.4 Z83844.1 4.16 4.1e-05 0.00883 0.47 0.22 Response to anti-depressant treatment in major depressive disorder; chr22:37602224 chr22:37641832~37658377:- LIHC cis rs11096990 0.613 rs9997015 ENSG00000249207.1 RP11-360F5.1 4.16 4.1e-05 0.00884 0.22 0.22 Cognitive function; chr4:39222677 chr4:39112677~39126818:- LIHC cis rs3845817 0.838 rs697150 ENSG00000281920.1 RP11-418H16.1 -4.16 4.1e-05 0.00884 -0.26 -0.22 Bipolar disorder; chr2:65522950 chr2:65623272~65628424:+ LIHC cis rs8005677 0.798 rs61977741 ENSG00000257285.4 RP11-298I3.1 4.16 4.1e-05 0.00884 0.22 0.22 Cognitive ability (multi-trait analysis); chr14:22931770 chr14:22929609~22955562:+ LIHC cis rs529413 0.57 rs553000 ENSG00000259237.1 RP11-209E8.1 4.16 4.11e-05 0.00884 0.3 0.22 Itch intensity from mosquito bite adjusted by bite size; chr15:53242389 chr15:53116365~53129698:+ LIHC cis rs8005677 0.828 rs2295680 ENSG00000257285.4 RP11-298I3.1 -4.16 4.11e-05 0.00884 -0.22 -0.22 Cognitive ability (multi-trait analysis); chr14:22905226 chr14:22929609~22955562:+ LIHC cis rs875971 1 rs7781698 ENSG00000237310.1 GS1-124K5.4 4.16 4.11e-05 0.00884 0.2 0.22 Aortic root size; chr7:66431325 chr7:66493706~66495474:+ LIHC cis rs1062177 0.756 rs2964589 ENSG00000253921.1 CTB-113P19.3 4.16 4.11e-05 0.00885 0.25 0.22 Preschool internalizing problems; chr5:151738628 chr5:151753992~151767247:+ LIHC cis rs1115240 0.898 rs12323384 ENSG00000257842.4 NOVA1-AS1 4.16 4.11e-05 0.00885 0.2 0.22 Educational attainment (years of education); chr14:26588286 chr14:26598412~26806467:+ LIHC cis rs67311347 0.956 rs12633446 ENSG00000223797.4 ENTPD3-AS1 -4.16 4.11e-05 0.00886 -0.18 -0.22 Renal cell carcinoma; chr3:40464170 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs7617989 ENSG00000223797.4 ENTPD3-AS1 -4.16 4.11e-05 0.00886 -0.18 -0.22 Renal cell carcinoma; chr3:40470972 chr3:40313802~40453329:- LIHC cis rs28829049 0.536 rs12405382 ENSG00000270728.1 RP4-657E11.10 -4.16 4.11e-05 0.00886 -0.21 -0.22 QRS duration in Tripanosoma cruzi seropositivity; chr1:19222487 chr1:19297080~19297903:+ LIHC cis rs651907 0.557 rs56291106 ENSG00000244119.1 PDCL3P4 4.16 4.11e-05 0.00886 0.23 0.22 Colorectal cancer; chr3:101658630 chr3:101712472~101713191:+ LIHC cis rs2283792 0.624 rs2876981 ENSG00000224086.5 LL22NC03-86G7.1 -4.15 4.12e-05 0.00886 -0.24 -0.22 Multiple sclerosis; chr22:21851322 chr22:21938293~21977632:+ LIHC cis rs41369048 0.858 rs2807866 ENSG00000272823.1 RP11-295M18.6 -4.15 4.12e-05 0.00886 -0.36 -0.22 Eosinophil counts;Sum eosinophil basophil counts; chr1:220907587 chr1:220828676~220829211:- LIHC cis rs6504622 0.693 rs12950276 ENSG00000262879.4 RP11-156P1.3 -4.15 4.12e-05 0.00886 -0.23 -0.22 Orofacial clefts; chr17:47095819 chr17:46984045~47100323:- LIHC cis rs6504622 0.755 rs12950699 ENSG00000262879.4 RP11-156P1.3 -4.15 4.12e-05 0.00886 -0.23 -0.22 Orofacial clefts; chr17:47096296 chr17:46984045~47100323:- LIHC cis rs6504622 0.748 rs7215573 ENSG00000262879.4 RP11-156P1.3 -4.15 4.12e-05 0.00886 -0.23 -0.22 Orofacial clefts; chr17:47096887 chr17:46984045~47100323:- LIHC cis rs801193 0.591 rs9986881 ENSG00000237310.1 GS1-124K5.4 4.15 4.12e-05 0.00887 0.19 0.22 Aortic root size; chr7:66708053 chr7:66493706~66495474:+ LIHC cis rs1005277 0.54 rs289638 ENSG00000099251.13 HSD17B7P2 4.15 4.12e-05 0.00887 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:37634803 chr10:38356380~38378505:+ LIHC cis rs1005277 0.54 rs7903942 ENSG00000099251.13 HSD17B7P2 -4.15 4.12e-05 0.00887 -0.26 -0.22 Extrinsic epigenetic age acceleration; chr10:37640348 chr10:38356380~38378505:+ LIHC cis rs9907295 0.605 rs11652192 ENSG00000270871.1 AC015849.19 4.15 4.12e-05 0.00887 0.23 0.22 Fibroblast growth factor basic levels; chr17:35833174 chr17:35816717~35830293:- LIHC cis rs11098499 0.644 rs10050092 ENSG00000260091.1 RP11-33B1.4 -4.15 4.12e-05 0.00887 -0.15 -0.22 Corneal astigmatism; chr4:119610930 chr4:119409333~119410233:+ LIHC cis rs4713118 0.539 rs200988 ENSG00000216901.1 AL022393.7 4.15 4.12e-05 0.00887 0.28 0.22 Parkinson's disease; chr6:27851575 chr6:28176188~28176674:+ LIHC cis rs7396835 0.5 rs5092 ENSG00000280143.1 AP000892.6 4.15 4.13e-05 0.00888 0.27 0.22 Quantitative traits; chr11:116822748 chr11:117204967~117210292:+ LIHC cis rs8005677 0.649 rs11629120 ENSG00000279656.1 RP11-298I3.6 -4.15 4.13e-05 0.00888 -0.25 -0.22 Cognitive ability (multi-trait analysis); chr14:22989248 chr14:23023083~23024217:- LIHC cis rs2877649 0.793 rs75089419 ENSG00000258744.1 RP11-80A15.1 -4.15 4.13e-05 0.00889 -0.45 -0.22 Smooth-surface caries; chr14:24505850 chr14:24501594~24508688:+ LIHC cis rs2877649 0.793 rs2073335 ENSG00000258744.1 RP11-80A15.1 -4.15 4.13e-05 0.00889 -0.45 -0.22 Smooth-surface caries; chr14:24505955 chr14:24501594~24508688:+ LIHC cis rs617219 0.819 rs72766705 ENSG00000251675.1 CTC-458I2.2 -4.15 4.13e-05 0.00889 -0.25 -0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79266177 chr5:80128361~80143883:+ LIHC cis rs617219 0.819 rs2607140 ENSG00000251675.1 CTC-458I2.2 -4.15 4.13e-05 0.00889 -0.25 -0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79267404 chr5:80128361~80143883:+ LIHC cis rs9400467 0.528 rs10872066 ENSG00000271789.1 RP5-1112D6.7 -4.15 4.13e-05 0.00889 -0.21 -0.22 Amino acid levels;Blood metabolite levels; chr6:111272408 chr6:111297126~111298510:+ LIHC cis rs703842 0.642 rs10876994 ENSG00000270039.1 RP11-571M6.17 -4.15 4.13e-05 0.00889 -0.31 -0.22 Multiple sclerosis; chr12:57670954 chr12:57803838~57804415:+ LIHC cis rs5758659 0.716 rs5758661 ENSG00000227370.1 RP4-669P10.19 -4.15 4.13e-05 0.0089 -0.24 -0.22 Cognitive function; chr22:42228439 chr22:42132543~42132998:+ LIHC cis rs2598107 0.601 rs1975641 ENSG00000211698.2 TRGV4 -4.15 4.13e-05 0.0089 -0.26 -0.22 Dupuytren's disease; chr7:37923748 chr7:38353715~38354517:- LIHC cis rs2598107 0.601 rs3734952 ENSG00000211698.2 TRGV4 -4.15 4.13e-05 0.0089 -0.26 -0.22 Dupuytren's disease; chr7:37925563 chr7:38353715~38354517:- LIHC cis rs2749592 0.531 rs10764134 ENSG00000099251.13 HSD17B7P2 -4.15 4.13e-05 0.0089 -0.25 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37567732 chr10:38356380~38378505:+ LIHC cis rs2274273 0.588 rs7155054 ENSG00000258413.1 RP11-665C16.6 -4.15 4.14e-05 0.0089 -0.27 -0.22 Protein biomarker; chr14:55283944 chr14:55262767~55272075:- LIHC cis rs2836974 0.965 rs9941894 ENSG00000255568.3 BRWD1-AS2 4.15 4.14e-05 0.0089 0.25 0.22 Cognitive function; chr21:39262132 chr21:39313935~39314962:+ LIHC cis rs1023500 0.505 rs134886 ENSG00000226450.2 CYP2D8P -4.15 4.14e-05 0.0089 -0.24 -0.22 Schizophrenia; chr22:42277850 chr22:42149886~42155001:- LIHC cis rs4682868 0.611 rs7614670 ENSG00000273328.4 RP11-141M3.6 4.15 4.14e-05 0.0089 0.22 0.22 Monocyte percentage of white cells; chr3:42879906 chr3:42809414~42908105:+ LIHC cis rs4682868 0.581 rs7630617 ENSG00000273328.4 RP11-141M3.6 4.15 4.14e-05 0.0089 0.22 0.22 Monocyte percentage of white cells; chr3:42880157 chr3:42809414~42908105:+ LIHC cis rs2790457 0.958 rs1265829 ENSG00000254635.4 WAC-AS1 -4.15 4.14e-05 0.0089 -0.21 -0.22 Multiple myeloma; chr10:28622374 chr10:28522652~28532743:- LIHC cis rs2348418 0.864 rs7304776 ENSG00000247934.4 RP11-967K21.1 4.15 4.14e-05 0.0089 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28560634 chr12:28163298~28190738:- LIHC cis rs2348418 0.864 rs11049714 ENSG00000247934.4 RP11-967K21.1 4.15 4.14e-05 0.0089 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28561162 chr12:28163298~28190738:- LIHC cis rs9929218 0.551 rs2296408 ENSG00000260459.2 FTLP14 -4.15 4.14e-05 0.00891 -0.25 -0.22 Colorectal cancer; chr16:68679920 chr16:68822587~68823070:+ LIHC cis rs16858210 0.647 rs67397446 ENSG00000234371.6 RPSAP31 4.15 4.14e-05 0.00891 0.32 0.22 Menopause (age at onset); chr3:183900355 chr3:183884924~183888449:+ LIHC cis rs2115630 0.936 rs6496318 ENSG00000259295.5 CSPG4P12 -4.15 4.14e-05 0.00891 -0.26 -0.22 P wave terminal force; chr15:84671998 chr15:85191438~85213905:+ LIHC cis rs2115630 0.902 rs8023276 ENSG00000259295.5 CSPG4P12 -4.15 4.14e-05 0.00891 -0.26 -0.22 P wave terminal force; chr15:84676407 chr15:85191438~85213905:+ LIHC cis rs1005277 0.505 rs200935 ENSG00000275858.1 RP11-291L22.8 4.15 4.14e-05 0.00891 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:37843882 chr10:38450738~38451069:- LIHC cis rs1005277 0.505 rs200936 ENSG00000275858.1 RP11-291L22.8 4.15 4.14e-05 0.00891 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:37846007 chr10:38450738~38451069:- LIHC cis rs1005277 0.505 rs200937 ENSG00000275858.1 RP11-291L22.8 4.15 4.14e-05 0.00891 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:37846844 chr10:38450738~38451069:- LIHC cis rs11767557 1 rs11762262 ENSG00000229153.4 EPHA1-AS1 4.15 4.14e-05 0.00891 0.34 0.22 Alzheimer's disease (late onset); chr7:143410783 chr7:143407813~143523449:+ LIHC cis rs2243480 1 rs437889 ENSG00000228409.4 CCT6P1 4.15 4.14e-05 0.00891 0.23 0.22 Diabetic kidney disease; chr7:66044247 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs402418 ENSG00000228409.4 CCT6P1 4.15 4.14e-05 0.00891 0.23 0.22 Diabetic kidney disease; chr7:66044482 chr7:65751142~65763354:+ LIHC cis rs2243480 0.803 rs423187 ENSG00000228409.4 CCT6P1 4.15 4.14e-05 0.00891 0.23 0.22 Diabetic kidney disease; chr7:66044512 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs431318 ENSG00000228409.4 CCT6P1 4.15 4.14e-05 0.00891 0.23 0.22 Diabetic kidney disease; chr7:66046610 chr7:65751142~65763354:+ LIHC cis rs794185 0.652 rs2819584 ENSG00000231249.1 ITPR1-AS1 -4.15 4.14e-05 0.00891 -0.24 -0.22 Multiple sclerosis--Brain Glutamate Levels; chr3:4470566 chr3:4490891~4493163:- LIHC cis rs75920871 0.609 rs11216187 ENSG00000254851.1 RP11-109L13.1 -4.15 4.15e-05 0.00891 -0.43 -0.22 Subjective well-being; chr11:116916432 chr11:117135528~117138582:+ LIHC cis rs1023500 1 rs1023500 ENSG00000237037.8 NDUFA6-AS1 4.15 4.15e-05 0.00892 0.29 0.22 Schizophrenia; chr22:41944840 chr22:42090931~42137742:+ LIHC cis rs617219 0.819 rs2607145 ENSG00000251675.1 CTC-458I2.2 -4.15 4.15e-05 0.00892 -0.25 -0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79256577 chr5:80128361~80143883:+ LIHC cis rs617219 0.819 rs2591389 ENSG00000251675.1 CTC-458I2.2 -4.15 4.15e-05 0.00892 -0.25 -0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79259385 chr5:80128361~80143883:+ LIHC cis rs13113518 0.812 rs2035691 ENSG00000249700.7 SRD5A3-AS1 4.15 4.15e-05 0.00892 0.26 0.22 Height; chr4:55529786 chr4:55363971~55395847:- LIHC cis rs919433 0.929 rs4850788 ENSG00000231621.1 AC013264.2 4.15 4.15e-05 0.00892 0.2 0.22 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197318216 chr2:197197991~197199273:+ LIHC cis rs2153535 0.935 rs11243254 ENSG00000230939.1 RP11-314C16.1 4.15 4.15e-05 0.00893 0.25 0.22 Motion sickness; chr6:8381009 chr6:8784178~8785445:+ LIHC cis rs7615952 0.641 rs7632497 ENSG00000171084.14 FAM86JP 4.15 4.15e-05 0.00893 0.36 0.22 Blood pressure (smoking interaction); chr3:126064243 chr3:125916620~125930024:+ LIHC cis rs7615952 0.641 rs12487875 ENSG00000171084.14 FAM86JP 4.15 4.15e-05 0.00893 0.36 0.22 Blood pressure (smoking interaction); chr3:126068381 chr3:125916620~125930024:+ LIHC cis rs1005277 0.505 rs200910 ENSG00000275858.1 RP11-291L22.8 4.15 4.15e-05 0.00893 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:37819248 chr10:38450738~38451069:- LIHC cis rs875971 0.545 rs75840613 ENSG00000273024.4 INTS4P2 -4.15 4.16e-05 0.00894 -0.25 -0.22 Aortic root size; chr7:66376399 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs73148639 ENSG00000273024.4 INTS4P2 -4.15 4.16e-05 0.00894 -0.25 -0.22 Aortic root size; chr7:66390342 chr7:65647864~65715661:+ LIHC cis rs77204473 0.744 rs2301174 ENSG00000254851.1 RP11-109L13.1 4.15 4.16e-05 0.00894 0.41 0.22 Sum eosinophil basophil counts;Eosinophil counts; chr11:117192993 chr11:117135528~117138582:+ LIHC cis rs17818399 0.781 rs12105006 ENSG00000239332.4 LINC01119 4.15 4.16e-05 0.00895 0.3 0.22 Height; chr2:46635447 chr2:46816697~46859007:+ LIHC cis rs62246343 0.516 rs2251166 ENSG00000206573.7 THUMPD3-AS1 4.15 4.17e-05 0.00895 0.25 0.22 Fibrinogen levels; chr3:9400053 chr3:9349689~9398579:- LIHC cis rs72675573 0.852 rs778121 ENSG00000235612.1 RP1-158P9.1 -4.15 4.17e-05 0.00895 -0.28 -0.22 Monocyte count; chr1:56154596 chr1:56145721~56155224:+ LIHC cis rs2749097 0.696 rs12129559 ENSG00000244256.3 RN7SL130P -4.15 4.17e-05 0.00895 -0.28 -0.22 Alcohol consumption (transferrin glycosylation); chr1:63680890 chr1:63655743~63656047:+ LIHC cis rs8177253 0.665 rs10935074 ENSG00000244062.1 RP11-404G16.2 4.15 4.17e-05 0.00896 0.22 0.22 Iron status biomarkers; chr3:133722848 chr3:133760300~133762363:+ LIHC cis rs875971 0.545 rs73146609 ENSG00000228409.4 CCT6P1 -4.15 4.17e-05 0.00896 -0.18 -0.22 Aortic root size; chr7:66302477 chr7:65751142~65763354:+ LIHC cis rs1577917 1 rs34581302 ENSG00000234155.1 RP11-30P6.6 4.15 4.17e-05 0.00896 0.29 0.22 Response to antipsychotic treatment; chr6:85996230 chr6:85387219~85390186:- LIHC cis rs3091242 0.933 rs35148262 ENSG00000261349.1 RP3-465N24.5 -4.15 4.17e-05 0.00896 -0.22 -0.22 Erythrocyte sedimentation rate; chr1:25440132 chr1:25266102~25267136:- LIHC cis rs340849 0.901 rs340841 ENSG00000274895.1 RP11-478J18.2 4.15 4.17e-05 0.00896 0.23 0.22 Alzheimer's disease; chr1:213951127 chr1:213983793~213986419:- LIHC cis rs734999 0.545 rs10797436 ENSG00000225931.3 RP3-395M20.7 4.15 4.17e-05 0.00896 0.23 0.22 Ulcerative colitis; chr1:2606910 chr1:2566410~2569888:+ LIHC cis rs9595908 0.931 rs9591001 ENSG00000212293.1 SNORA16 -4.15 4.17e-05 0.00896 -0.25 -0.22 Body mass index; chr13:32468733 chr13:32420390~32420516:- LIHC cis rs1005277 0.505 rs200939 ENSG00000275858.1 RP11-291L22.8 4.15 4.17e-05 0.00897 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:37850555 chr10:38450738~38451069:- LIHC cis rs2283792 0.646 rs7292584 ENSG00000224086.5 LL22NC03-86G7.1 -4.15 4.17e-05 0.00897 -0.24 -0.22 Multiple sclerosis; chr22:21768458 chr22:21938293~21977632:+ LIHC cis rs1005277 0.505 rs719569 ENSG00000275858.1 RP11-291L22.8 -4.15 4.17e-05 0.00897 -0.24 -0.22 Extrinsic epigenetic age acceleration; chr10:37865487 chr10:38450738~38451069:- LIHC cis rs1005277 0.522 rs200943 ENSG00000275858.1 RP11-291L22.8 4.15 4.17e-05 0.00897 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:37859802 chr10:38450738~38451069:- LIHC cis rs7131987 0.675 rs1436322 ENSG00000257176.2 RP11-996F15.2 4.15 4.18e-05 0.00897 0.24 0.22 QT interval; chr12:29401872 chr12:29280418~29317848:- LIHC cis rs860295 0.871 rs6688636 ENSG00000203761.5 MSTO2P 4.15 4.18e-05 0.00897 0.17 0.22 Body mass index; chr1:155509106 chr1:155745829~155750137:+ LIHC cis rs6700559 0.742 rs10399790 ENSG00000260088.1 RP11-92G12.3 -4.15 4.18e-05 0.00897 -0.28 -0.22 Coronary artery disease; chr1:200626241 chr1:200669507~200694250:+ LIHC cis rs2877649 0.623 rs4555074 ENSG00000258744.1 RP11-80A15.1 -4.15 4.18e-05 0.00898 -0.45 -0.22 Smooth-surface caries; chr14:24503136 chr14:24501594~24508688:+ LIHC cis rs901683 1 rs35968565 ENSG00000230869.1 CTGLF10P -4.15 4.18e-05 0.00899 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45580748 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs75820736 ENSG00000230869.1 CTGLF10P -4.15 4.18e-05 0.00899 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45580788 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71496621 ENSG00000230869.1 CTGLF10P -4.15 4.18e-05 0.00899 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45580900 chr10:45678692~45700532:+ LIHC cis rs2243480 1 rs59794892 ENSG00000228409.4 CCT6P1 4.15 4.18e-05 0.00899 0.24 0.22 Diabetic kidney disease; chr7:65950886 chr7:65751142~65763354:+ LIHC cis rs2243480 0.803 rs36004293 ENSG00000228409.4 CCT6P1 4.15 4.18e-05 0.00899 0.24 0.22 Diabetic kidney disease; chr7:65951525 chr7:65751142~65763354:+ LIHC cis rs2243480 0.803 rs35268390 ENSG00000228409.4 CCT6P1 4.15 4.18e-05 0.00899 0.24 0.22 Diabetic kidney disease; chr7:65951549 chr7:65751142~65763354:+ LIHC cis rs755249 0.753 rs72663529 ENSG00000182109.6 RP11-69E11.4 4.15 4.19e-05 0.00899 0.22 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39557684 chr1:39522280~39546187:- LIHC cis rs6921919 0.697 rs6942030 ENSG00000204709.4 LINC01556 4.15 4.19e-05 0.00899 0.25 0.22 Autism spectrum disorder or schizophrenia; chr6:28348181 chr6:28943877~28944537:+ LIHC cis rs7586970 0.583 rs35935664 ENSG00000224063.4 AC007319.1 4.15 4.19e-05 0.009 0.33 0.22 Coronary heart disease; chr2:187531609 chr2:187003220~187554663:+ LIHC cis rs7586970 0.583 rs34893125 ENSG00000224063.4 AC007319.1 4.15 4.19e-05 0.009 0.33 0.22 Coronary heart disease; chr2:187532612 chr2:187003220~187554663:+ LIHC cis rs7760535 0.735 rs240974 ENSG00000271789.1 RP5-1112D6.7 -4.15 4.19e-05 0.009 -0.21 -0.22 Metabolic traits; chr6:111328113 chr6:111297126~111298510:+ LIHC cis rs11671005 0.735 rs12977592 ENSG00000269473.1 CTD-2619J13.19 4.15 4.2e-05 0.00902 0.34 0.22 Mean platelet volume; chr19:58449689 chr19:58440448~58445849:+ LIHC cis rs4356975 0.932 rs12648830 ENSG00000250919.1 RP11-813N20.3 4.15 4.2e-05 0.00902 0.22 0.22 Obesity-related traits; chr4:69075436 chr4:69027831~69044578:+ LIHC cis rs673078 0.66 rs7974718 ENSG00000275409.1 RP11-131L12.4 -4.15 4.2e-05 0.00902 -0.28 -0.22 Glucose homeostasis traits; chr12:118243258 chr12:118430147~118430699:+ LIHC cis rs4938303 0.633 rs12799441 ENSG00000254851.1 RP11-109L13.1 4.15 4.21e-05 0.00904 0.31 0.22 Triglycerides; chr11:116687799 chr11:117135528~117138582:+ LIHC cis rs3020736 0.5 rs2413669 ENSG00000226450.2 CYP2D8P -4.15 4.21e-05 0.00904 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42111744 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs6002618 ENSG00000226450.2 CYP2D8P -4.15 4.21e-05 0.00904 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42111855 chr22:42149886~42155001:- LIHC cis rs1023500 0.551 rs61665536 ENSG00000226450.2 CYP2D8P -4.15 4.21e-05 0.00904 -0.27 -0.22 Schizophrenia; chr22:42116609 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs2413672 ENSG00000226450.2 CYP2D8P -4.15 4.21e-05 0.00904 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42117257 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs6002623 ENSG00000226450.2 CYP2D8P -4.15 4.21e-05 0.00904 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42117757 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs764481 ENSG00000226450.2 CYP2D8P -4.15 4.21e-05 0.00904 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42122422 chr22:42149886~42155001:- LIHC cis rs7893279 0.505 rs4748499 ENSG00000225527.1 RP11-383B4.4 4.15 4.21e-05 0.00904 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18621441 chr10:18531849~18533336:- LIHC cis rs7893279 0.505 rs12769425 ENSG00000225527.1 RP11-383B4.4 4.15 4.21e-05 0.00904 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18622185 chr10:18531849~18533336:- LIHC cis rs6142102 0.602 rs2268079 ENSG00000275784.1 RP5-1125A11.6 -4.15 4.22e-05 0.00904 -0.23 -0.22 Skin pigmentation; chr20:34008944 chr20:33989480~33991818:- LIHC cis rs10129255 0.957 rs7493713 ENSG00000211970.3 IGHV4-61 -4.15 4.22e-05 0.00905 -0.17 -0.22 Kawasaki disease; chr14:106783685 chr14:106639119~106639657:- LIHC cis rs10129255 0.912 rs35468694 ENSG00000211970.3 IGHV4-61 -4.15 4.22e-05 0.00905 -0.17 -0.22 Kawasaki disease; chr14:106784199 chr14:106639119~106639657:- LIHC cis rs10129255 0.957 rs8019272 ENSG00000211970.3 IGHV4-61 -4.15 4.22e-05 0.00905 -0.17 -0.22 Kawasaki disease; chr14:106784709 chr14:106639119~106639657:- LIHC cis rs113084984 0.718 rs4669747 ENSG00000271952.1 RP11-245G13.2 -4.15 4.22e-05 0.00905 -0.27 -0.22 Breast cancer; chr2:11544189 chr2:10878269~10885118:+ LIHC cis rs2243480 1 rs12698509 ENSG00000232546.1 RP11-458F8.1 -4.15 4.22e-05 0.00905 -0.24 -0.22 Diabetic kidney disease; chr7:65953889 chr7:66848496~66858136:+ LIHC cis rs2744375 0.6 rs874646 ENSG00000261189.1 RP3-512B11.3 4.15 4.22e-05 0.00905 0.28 0.22 Resting heart rate; chr6:7550458 chr6:7540451~7541338:- LIHC cis rs17772222 0.917 rs58984912 ENSG00000258789.1 RP11-507K2.3 -4.15 4.22e-05 0.00905 -0.26 -0.22 Coronary artery calcification; chr14:88698172 chr14:88551597~88552493:+ LIHC cis rs2243480 1 rs437889 ENSG00000232546.1 RP11-458F8.1 -4.15 4.22e-05 0.00906 -0.24 -0.22 Diabetic kidney disease; chr7:66044247 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs402418 ENSG00000232546.1 RP11-458F8.1 -4.15 4.22e-05 0.00906 -0.24 -0.22 Diabetic kidney disease; chr7:66044482 chr7:66848496~66858136:+ LIHC cis rs2243480 0.803 rs423187 ENSG00000232546.1 RP11-458F8.1 -4.15 4.22e-05 0.00906 -0.24 -0.22 Diabetic kidney disease; chr7:66044512 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs431318 ENSG00000232546.1 RP11-458F8.1 -4.15 4.22e-05 0.00906 -0.24 -0.22 Diabetic kidney disease; chr7:66046610 chr7:66848496~66858136:+ LIHC cis rs4578769 0.836 rs3936488 ENSG00000266850.1 RP11-370A5.1 4.15 4.22e-05 0.00906 0.26 0.22 Eosinophil percentage of white cells; chr18:22874459 chr18:22723491~22907721:- LIHC cis rs2299116 1 rs34276478 ENSG00000225264.3 ZNRF2P2 -4.15 4.22e-05 0.00906 -0.25 -0.22 Serum thyroid-stimulating hormone levels; chr7:28776481 chr7:29598795~29685255:- LIHC cis rs11096990 0.634 rs7666632 ENSG00000249685.1 RP11-360F5.3 4.15 4.23e-05 0.00906 0.27 0.22 Cognitive function; chr4:39238568 chr4:39133913~39135608:+ LIHC cis rs4578769 0.879 rs3863524 ENSG00000265943.1 RP11-739L10.1 4.15 4.23e-05 0.00906 0.28 0.22 Eosinophil percentage of white cells; chr18:22881319 chr18:22699481~22933764:- LIHC cis rs244293 0.831 rs11079147 ENSG00000275710.1 RP11-257O5.4 -4.15 4.23e-05 0.00906 -0.23 -0.22 Menarche (age at onset); chr17:55017393 chr17:54964474~54964679:+ LIHC cis rs244293 0.831 rs11079149 ENSG00000275710.1 RP11-257O5.4 -4.15 4.23e-05 0.00906 -0.23 -0.22 Menarche (age at onset); chr17:55017685 chr17:54964474~54964679:+ LIHC cis rs244293 0.795 rs11079151 ENSG00000275710.1 RP11-257O5.4 -4.15 4.23e-05 0.00906 -0.23 -0.22 Menarche (age at onset); chr17:55018005 chr17:54964474~54964679:+ LIHC cis rs11098499 0.863 rs9997631 ENSG00000260091.1 RP11-33B1.4 -4.15 4.23e-05 0.00906 -0.16 -0.22 Corneal astigmatism; chr4:119548840 chr4:119409333~119410233:+ LIHC cis rs3020736 0.5 rs4147641 ENSG00000205702.9 CYP2D7 -4.15 4.23e-05 0.00906 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42086498 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs4147640 ENSG00000205702.9 CYP2D7 -4.15 4.23e-05 0.00906 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42089288 chr22:42140203~42144577:- LIHC cis rs1023500 0.507 rs6002600 ENSG00000205702.9 CYP2D7 -4.15 4.23e-05 0.00906 -0.25 -0.22 Schizophrenia; chr22:42092902 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs6002601 ENSG00000205702.9 CYP2D7 -4.15 4.23e-05 0.00906 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42093054 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs6002604 ENSG00000205702.9 CYP2D7 -4.15 4.23e-05 0.00906 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42097077 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs5996109 ENSG00000205702.9 CYP2D7 -4.15 4.23e-05 0.00906 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42097094 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs5996110 ENSG00000205702.9 CYP2D7 -4.15 4.23e-05 0.00906 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42097763 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs9620026 ENSG00000205702.9 CYP2D7 -4.15 4.23e-05 0.00906 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42102574 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs28791586 ENSG00000205702.9 CYP2D7 -4.15 4.23e-05 0.00906 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42104479 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs2839708 ENSG00000205702.9 CYP2D7 -4.15 4.23e-05 0.00906 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42104741 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs6519306 ENSG00000205702.9 CYP2D7 -4.15 4.23e-05 0.00906 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42105213 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs6002614 ENSG00000205702.9 CYP2D7 -4.15 4.23e-05 0.00906 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42105798 chr22:42140203~42144577:- LIHC cis rs4453827 0.563 rs10510766 ENSG00000271916.1 RP11-884K10.6 4.15 4.23e-05 0.00906 0.49 0.22 Blood protein levels; chr3:53777314 chr3:53797764~53798019:- LIHC cis rs9652601 0.779 rs725613 ENSG00000274038.1 RP11-66H6.4 -4.15 4.23e-05 0.00907 -0.26 -0.22 Systemic lupus erythematosus; chr16:11075826 chr16:11056556~11057034:+ LIHC cis rs524281 0.692 rs2452681 ENSG00000255320.1 RP11-755F10.1 -4.15 4.23e-05 0.00908 -0.27 -0.22 Electroencephalogram traits; chr11:66047371 chr11:66244840~66246239:- LIHC cis rs2243480 0.708 rs35825036 ENSG00000232546.1 RP11-458F8.1 -4.15 4.24e-05 0.00908 -0.25 -0.22 Diabetic kidney disease; chr7:66521515 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs13237037 ENSG00000232546.1 RP11-458F8.1 -4.15 4.24e-05 0.00908 -0.25 -0.22 Diabetic kidney disease; chr7:66532895 chr7:66848496~66858136:+ LIHC cis rs2243480 0.901 rs13237344 ENSG00000232546.1 RP11-458F8.1 -4.15 4.24e-05 0.00908 -0.25 -0.22 Diabetic kidney disease; chr7:66557269 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1796228 ENSG00000232546.1 RP11-458F8.1 -4.15 4.24e-05 0.00908 -0.25 -0.22 Diabetic kidney disease; chr7:66568097 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1267820 ENSG00000232546.1 RP11-458F8.1 -4.15 4.24e-05 0.00908 -0.25 -0.22 Diabetic kidney disease; chr7:66585308 chr7:66848496~66858136:+ LIHC cis rs10129255 0.957 rs12590799 ENSG00000211970.3 IGHV4-61 -4.15 4.24e-05 0.00908 -0.17 -0.22 Kawasaki disease; chr14:106779713 chr14:106639119~106639657:- LIHC cis rs11096990 0.613 rs4974995 ENSG00000249207.1 RP11-360F5.1 4.15 4.24e-05 0.00908 0.22 0.22 Cognitive function; chr4:39216503 chr4:39112677~39126818:- LIHC cis rs11096990 0.634 rs10010352 ENSG00000249685.1 RP11-360F5.3 4.15 4.24e-05 0.00909 0.27 0.22 Cognitive function; chr4:39240657 chr4:39133913~39135608:+ LIHC cis rs1062177 0.756 rs2915826 ENSG00000253921.1 CTB-113P19.3 4.15 4.24e-05 0.00909 0.25 0.22 Preschool internalizing problems; chr5:151740402 chr5:151753992~151767247:+ LIHC cis rs1062177 0.756 rs2964587 ENSG00000253921.1 CTB-113P19.3 4.15 4.24e-05 0.00909 0.25 0.22 Preschool internalizing problems; chr5:151740411 chr5:151753992~151767247:+ LIHC cis rs6545883 0.507 rs10169662 ENSG00000271889.1 RP11-493E12.1 -4.15 4.24e-05 0.00909 -0.26 -0.22 Tuberculosis; chr2:61280801 chr2:61151433~61162105:- LIHC cis rs66887589 0.807 rs13134517 ENSG00000260091.1 RP11-33B1.4 -4.15 4.24e-05 0.00909 -0.14 -0.22 Diastolic blood pressure; chr4:119484107 chr4:119409333~119410233:+ LIHC cis rs66887589 0.837 rs6534135 ENSG00000260091.1 RP11-33B1.4 -4.15 4.24e-05 0.00909 -0.14 -0.22 Diastolic blood pressure; chr4:119485147 chr4:119409333~119410233:+ LIHC cis rs673078 0.607 rs61943369 ENSG00000275409.1 RP11-131L12.4 -4.15 4.25e-05 0.00909 -0.27 -0.22 Glucose homeostasis traits; chr12:118368145 chr12:118430147~118430699:+ LIHC cis rs1005277 0.505 rs13503 ENSG00000099251.13 HSD17B7P2 -4.15 4.25e-05 0.0091 -0.25 -0.22 Extrinsic epigenetic age acceleration; chr10:37950915 chr10:38356380~38378505:+ LIHC cis rs1005277 0.505 rs7069702 ENSG00000099251.13 HSD17B7P2 -4.15 4.25e-05 0.0091 -0.25 -0.22 Extrinsic epigenetic age acceleration; chr10:37958431 chr10:38356380~38378505:+ LIHC cis rs4356975 0.83 rs6600868 ENSG00000250919.1 RP11-813N20.3 -4.15 4.25e-05 0.0091 -0.22 -0.22 Obesity-related traits; chr4:69075923 chr4:69027831~69044578:+ LIHC cis rs11098499 0.913 rs12186259 ENSG00000245958.5 RP11-33B1.1 -4.15 4.25e-05 0.0091 -0.24 -0.22 Corneal astigmatism; chr4:119230884 chr4:119454791~119552025:+ LIHC cis rs3845817 0.801 rs2438102 ENSG00000281920.1 RP11-418H16.1 -4.15 4.25e-05 0.0091 -0.26 -0.22 Bipolar disorder; chr2:65530223 chr2:65623272~65628424:+ LIHC cis rs875971 0.545 rs2420612 ENSG00000228409.4 CCT6P1 -4.15 4.25e-05 0.0091 -0.18 -0.22 Aortic root size; chr7:66536825 chr7:65751142~65763354:+ LIHC cis rs13113518 0.756 rs7658446 ENSG00000249700.7 SRD5A3-AS1 4.15 4.25e-05 0.0091 0.26 0.22 Height; chr4:55495262 chr4:55363971~55395847:- LIHC cis rs11763353 0.593 rs6969348 ENSG00000235828.5 RPL36AP26 -4.15 4.25e-05 0.0091 -0.21 -0.22 Blood trace element (Zn levels); chr7:15571007 chr7:15701435~15701752:- LIHC cis rs2739330 0.796 rs2154594 ENSG00000206090.4 AP000350.7 -4.15 4.25e-05 0.00911 -0.26 -0.22 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23939998~23942798:+ LIHC cis rs6449502 1 rs6869332 ENSG00000272308.1 RP11-231G3.1 4.15 4.25e-05 0.00911 0.32 0.22 Mean platelet volume; chr5:60833534 chr5:60866457~60866935:- LIHC cis rs9652601 0.779 rs9929994 ENSG00000274038.1 RP11-66H6.4 -4.15 4.25e-05 0.00911 -0.27 -0.22 Systemic lupus erythematosus; chr16:11084388 chr16:11056556~11057034:+ LIHC cis rs11651753 0.613 rs3096 ENSG00000264920.1 RP11-6N17.4 -4.15 4.25e-05 0.00911 -0.23 -0.22 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47952066 chr17:47891255~47895812:- LIHC cis rs2276314 1 rs62101367 ENSG00000278986.1 RP11-723J4.3 -4.15 4.26e-05 0.00912 -0.27 -0.22 Endometriosis;Drug-induced torsades de pointes; chr18:35970921 chr18:35972151~35973916:+ LIHC cis rs5742933 0.744 rs13002216 ENSG00000253559.1 OSGEPL1-AS1 4.15 4.26e-05 0.00912 0.28 0.22 Ferritin levels; chr2:189746358 chr2:189762704~189765556:+ LIHC cis rs17270561 0.525 rs10484432 ENSG00000272810.1 U91328.22 -4.15 4.26e-05 0.00912 -0.28 -0.22 Iron status biomarkers; chr6:26008648 chr6:26013241~26013757:+ LIHC cis rs524281 0.731 rs12576969 ENSG00000255320.1 RP11-755F10.1 -4.15 4.26e-05 0.00913 -0.31 -0.22 Electroencephalogram traits; chr11:66035007 chr11:66244840~66246239:- LIHC cis rs1223397 0.651 rs641758 ENSG00000215022.6 RP1-257A7.4 -4.15 4.26e-05 0.00913 -0.23 -0.22 Blood pressure; chr6:13300270 chr6:13264861~13295586:- LIHC cis rs901683 1 rs78661209 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45579491 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12766764 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45584065 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35070150 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45584385 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs76469200 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45584585 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs79490183 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45584793 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35183191 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45585169 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34163035 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45585271 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12779637 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45585648 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12772102 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45585653 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35183751 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45585910 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34516867 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45586289 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35049879 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45586296 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs36102549 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45586595 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs4442500 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45587050 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35916836 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45587068 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12763285 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45587421 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71499567 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45588508 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35506889 ENSG00000230869.1 CTGLF10P -4.15 4.26e-05 0.00913 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45589189 chr10:45678692~45700532:+ LIHC cis rs10129255 0.913 rs10140943 ENSG00000224373.3 IGHV4-59 4.15 4.27e-05 0.00913 0.18 0.22 Kawasaki disease; chr14:106767441 chr14:106627249~106627825:- LIHC cis rs287982 1 rs287982 ENSG00000269973.1 RP11-95D17.1 4.15 4.27e-05 0.00913 0.2 0.22 Nonsyndromic cleft lip with cleft palate; chr2:9832313 chr2:9936360~9939590:+ LIHC cis rs524281 1 rs527897 ENSG00000255320.1 RP11-755F10.1 4.15 4.27e-05 0.00914 0.26 0.22 Electroencephalogram traits; chr11:66133306 chr11:66244840~66246239:- LIHC cis rs295490 0.748 rs80175427 ENSG00000272656.1 RP11-219D15.3 4.15 4.27e-05 0.00914 0.63 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139498904 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs17494482 ENSG00000272656.1 RP11-219D15.3 4.15 4.27e-05 0.00914 0.63 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139499028 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs2882080 ENSG00000272656.1 RP11-219D15.3 4.15 4.27e-05 0.00914 0.63 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139499109 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs2882081 ENSG00000272656.1 RP11-219D15.3 4.15 4.27e-05 0.00914 0.63 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139499427 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs7428398 ENSG00000272656.1 RP11-219D15.3 4.15 4.27e-05 0.00914 0.63 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139499687 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs77398474 ENSG00000272656.1 RP11-219D15.3 4.15 4.27e-05 0.00914 0.63 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139502307 chr3:139349024~139349371:- LIHC cis rs2790457 0.917 rs2790462 ENSG00000254635.4 WAC-AS1 -4.15 4.27e-05 0.00914 -0.21 -0.22 Multiple myeloma; chr10:28584273 chr10:28522652~28532743:- LIHC cis rs2348418 0.864 rs7304540 ENSG00000247934.4 RP11-967K21.1 4.15 4.27e-05 0.00915 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28560489 chr12:28163298~28190738:- LIHC cis rs7893279 0.505 rs11812341 ENSG00000225527.1 RP11-383B4.4 4.15 4.28e-05 0.00915 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18607994 chr10:18531849~18533336:- LIHC cis rs2581828 0.646 rs28501212 ENSG00000242142.1 SERBP1P3 -4.15 4.28e-05 0.00916 -0.29 -0.22 Crohn's disease; chr3:53129041 chr3:53064283~53065091:- LIHC cis rs72675573 0.852 rs12133795 ENSG00000235612.1 RP1-158P9.1 -4.15 4.28e-05 0.00916 -0.29 -0.22 Monocyte count; chr1:56126545 chr1:56145721~56155224:+ LIHC cis rs10129255 0.5 rs8011115 ENSG00000211972.2 IGHV3-66 4.15 4.28e-05 0.00916 0.16 0.22 Kawasaki disease; chr14:106786292 chr14:106675017~106675544:- LIHC cis rs10912872 0.531 rs12407579 ENSG00000231424.2 RP1-45C12.1 4.15 4.29e-05 0.00917 0.23 0.22 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr1:171371553 chr1:171247580~171251794:- LIHC cis rs66887589 0.774 rs9307477 ENSG00000260091.1 RP11-33B1.4 -4.14 4.29e-05 0.00917 -0.14 -0.22 Diastolic blood pressure; chr4:119500654 chr4:119409333~119410233:+ LIHC cis rs9300255 0.596 rs10773002 ENSG00000256092.2 RP13-942N8.1 -4.14 4.29e-05 0.00918 -0.26 -0.22 Neutrophil percentage of white cells; chr12:123262414 chr12:123363868~123366113:+ LIHC cis rs2749592 0.918 rs4934590 ENSG00000263064.2 RP11-291L22.7 -4.14 4.3e-05 0.00919 -0.24 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37588641 chr10:38448689~38448949:+ LIHC cis rs901683 1 rs71496623 ENSG00000230869.1 CTGLF10P -4.14 4.3e-05 0.00919 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45590418 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71496624 ENSG00000230869.1 CTGLF10P -4.14 4.3e-05 0.00919 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45590501 chr10:45678692~45700532:+ LIHC cis rs901683 0.867 rs34144887 ENSG00000230869.1 CTGLF10P -4.14 4.3e-05 0.00919 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45590945 chr10:45678692~45700532:+ LIHC cis rs901683 0.867 rs71496625 ENSG00000230869.1 CTGLF10P -4.14 4.3e-05 0.00919 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45591201 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs36100685 ENSG00000230869.1 CTGLF10P -4.14 4.3e-05 0.00919 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45591406 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34574958 ENSG00000230869.1 CTGLF10P -4.14 4.3e-05 0.00919 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45591592 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12779005 ENSG00000230869.1 CTGLF10P -4.14 4.3e-05 0.00919 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45591926 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34539215 ENSG00000230869.1 CTGLF10P -4.14 4.3e-05 0.00919 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45591930 chr10:45678692~45700532:+ LIHC cis rs7615952 0.546 rs2979307 ENSG00000171084.14 FAM86JP -4.14 4.3e-05 0.0092 -0.37 -0.22 Blood pressure (smoking interaction); chr3:125590730 chr3:125916620~125930024:+ LIHC cis rs9487094 0.961 rs7773095 ENSG00000260273.1 RP11-425D10.10 -4.14 4.31e-05 0.0092 -0.26 -0.22 Height; chr6:109405874 chr6:109382795~109383666:+ LIHC cis rs2281636 0.723 rs1128642 ENSG00000233690.1 EBAG9P1 4.14 4.31e-05 0.0092 0.22 0.22 Obesity-related traits; chr10:99711938 chr10:99697407~99697949:- LIHC cis rs301901 0.664 rs4504403 ENSG00000250155.1 CTD-2353F22.1 4.14 4.31e-05 0.0092 0.21 0.22 Height; chr5:37481330 chr5:36666214~36725195:- LIHC cis rs73193808 0.639 rs7277858 ENSG00000212479.2 U3 4.14 4.31e-05 0.0092 0.25 0.22 Coronary artery disease; chr21:29180556 chr21:29180425~29180639:- LIHC cis rs11668505 0.965 rs12981169 ENSG00000259108.2 CTD-3098H1.2 4.14 4.31e-05 0.00921 0.28 0.22 Lung function (FVC); chr19:47848623 chr19:47863483~47865341:- LIHC cis rs2790457 0.958 rs2532741 ENSG00000254635.4 WAC-AS1 -4.14 4.31e-05 0.00921 -0.21 -0.22 Multiple myeloma; chr10:28574879 chr10:28522652~28532743:- LIHC cis rs2070488 0.931 rs7630012 ENSG00000229589.1 ACVR2B-AS1 -4.14 4.31e-05 0.00921 -0.25 -0.22 Electrocardiographic conduction measures; chr3:38510759 chr3:38451027~38454820:- LIHC cis rs3096299 0.685 rs4785571 ENSG00000261118.1 RP11-104N10.1 4.14 4.32e-05 0.00922 0.2 0.22 Multiple myeloma (IgH translocation); chr16:89498761 chr16:89492017~89504460:- LIHC cis rs4356203 0.905 rs7938820 ENSG00000260196.1 RP1-239B22.5 4.14 4.32e-05 0.00922 0.26 0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17055905 chr11:17380649~17383531:+ LIHC cis rs3020736 0.519 rs5996116 ENSG00000226450.2 CYP2D8P -4.14 4.32e-05 0.00922 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42121488 chr22:42149886~42155001:- LIHC cis rs12554020 0.892 rs75678521 ENSG00000227603.1 RP11-165J3.6 4.14 4.32e-05 0.00922 0.31 0.22 Schizophrenia; chr9:93600744 chr9:93435332~93437121:- LIHC cis rs755249 0.567 rs61782157 ENSG00000182109.6 RP11-69E11.4 4.14 4.32e-05 0.00922 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39297217 chr1:39522280~39546187:- LIHC cis rs7893279 0.505 rs11815228 ENSG00000225527.1 RP11-383B4.4 4.14 4.32e-05 0.00923 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18590899 chr10:18531849~18533336:- LIHC cis rs938554 0.513 rs4529048 ENSG00000250413.1 RP11-448G15.1 -4.14 4.33e-05 0.00923 -0.3 -0.22 Blood metabolite levels; chr4:9995488 chr4:10006482~10009725:+ LIHC cis rs244293 0.657 rs4829 ENSG00000275710.1 RP11-257O5.4 4.14 4.33e-05 0.00923 0.25 0.22 Menarche (age at onset); chr17:54961954 chr17:54964474~54964679:+ LIHC cis rs244293 0.73 rs3213757 ENSG00000275710.1 RP11-257O5.4 4.14 4.33e-05 0.00923 0.25 0.22 Menarche (age at onset); chr17:54964496 chr17:54964474~54964679:+ LIHC cis rs1577917 1 rs1999852 ENSG00000234155.1 RP11-30P6.6 4.14 4.33e-05 0.00924 0.28 0.22 Response to antipsychotic treatment; chr6:85996020 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs35797755 ENSG00000234155.1 RP11-30P6.6 4.14 4.33e-05 0.00924 0.28 0.22 Response to antipsychotic treatment; chr6:85996836 chr6:85387219~85390186:- LIHC cis rs9896933 0.723 rs7224189 ENSG00000263063.1 RP11-388C12.1 -4.14 4.33e-05 0.00924 -0.29 -0.22 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82824351 chr17:82713908~82716255:- LIHC cis rs12554020 0.892 rs12555047 ENSG00000227603.1 RP11-165J3.6 4.14 4.33e-05 0.00924 0.29 0.22 Schizophrenia; chr9:93424208 chr9:93435332~93437121:- LIHC cis rs9907295 0.581 rs4251751 ENSG00000270871.1 AC015849.19 4.14 4.33e-05 0.00924 0.23 0.22 Fibroblast growth factor basic levels; chr17:35823733 chr17:35816717~35830293:- LIHC cis rs9907295 0.748 rs4251752 ENSG00000270871.1 AC015849.19 4.14 4.33e-05 0.00924 0.23 0.22 Fibroblast growth factor basic levels; chr17:35823900 chr17:35816717~35830293:- LIHC cis rs7044106 0.762 rs10739570 ENSG00000238181.2 AHCYP2 -4.14 4.33e-05 0.00924 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120618944 chr9:120720673~120721972:+ LIHC cis rs1247318 1 rs1247319 ENSG00000243831.1 RP1-81D8.4 4.14 4.33e-05 0.00924 0.3 0.22 Aging; chr6:160912828 chr6:160666228~160676523:- LIHC cis rs748404 0.587 rs690276 ENSG00000166763.7 STRCP1 4.14 4.33e-05 0.00925 0.27 0.22 Lung cancer; chr15:43412360 chr15:43699488~43718184:- LIHC cis rs1005277 0.522 rs289649 ENSG00000099251.13 HSD17B7P2 4.14 4.34e-05 0.00925 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37686456 chr10:38356380~38378505:+ LIHC cis rs673078 0.66 rs61946063 ENSG00000275759.1 RP11-131L12.3 -4.14 4.34e-05 0.00926 -0.27 -0.22 Glucose homeostasis traits; chr12:118294448 chr12:118428281~118428870:+ LIHC cis rs9976767 0.637 rs11909930 ENSG00000225218.1 AP001628.6 -4.14 4.34e-05 0.00926 -0.21 -0.22 Type 1 diabetes; chr21:42402091 chr21:42831040~42836477:- LIHC cis rs3809863 0.602 rs6504833 ENSG00000228782.6 CTD-2026D20.3 4.14 4.34e-05 0.00926 0.25 0.22 Glaucoma (primary open-angle); chr17:47318721 chr17:47450568~47492492:- LIHC cis rs6445975 0.666 rs9311674 ENSG00000272360.1 RP11-359I18.5 4.14 4.34e-05 0.00926 0.29 0.22 Systemic lupus erythematosus; chr3:58404975 chr3:58490830~58491291:- LIHC cis rs804280 0.525 rs1004712 ENSG00000255394.4 C8orf49 4.14 4.34e-05 0.00926 0.26 0.22 Myopia (pathological); chr8:11764784 chr8:11761256~11763223:+ LIHC cis rs950880 0.71 rs56043441 ENSG00000234389.1 AC007278.3 -4.14 4.34e-05 0.00926 -0.22 -0.22 Serum protein levels (sST2); chr2:102470923 chr2:102438713~102440475:+ LIHC cis rs921968 0.565 rs7586384 ENSG00000272555.1 RP11-459I19.1 -4.14 4.34e-05 0.00926 -0.23 -0.22 Mean corpuscular hemoglobin concentration; chr2:218718174 chr2:218818690~218819144:+ LIHC cis rs340849 0.617 rs17710847 ENSG00000274895.1 RP11-478J18.2 -4.14 4.34e-05 0.00927 -0.25 -0.22 Alzheimer's disease; chr1:213929776 chr1:213983793~213986419:- LIHC cis rs7044106 0.762 rs1158554 ENSG00000238181.2 AHCYP2 -4.14 4.34e-05 0.00927 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120638620 chr9:120720673~120721972:+ LIHC cis rs755249 0.565 rs12138051 ENSG00000182109.6 RP11-69E11.4 -4.14 4.34e-05 0.00927 -0.22 -0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39482552 chr1:39522280~39546187:- LIHC cis rs755249 0.564 rs6691194 ENSG00000182109.6 RP11-69E11.4 -4.14 4.34e-05 0.00927 -0.22 -0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39483069 chr1:39522280~39546187:- LIHC cis rs3809863 0.646 rs9899121 ENSG00000228782.6 CTD-2026D20.3 4.14 4.35e-05 0.00928 0.25 0.22 Glaucoma (primary open-angle); chr17:47317778 chr17:47450568~47492492:- LIHC cis rs875971 0.545 rs11767262 ENSG00000273024.4 INTS4P2 -4.14 4.35e-05 0.00928 -0.25 -0.22 Aortic root size; chr7:66302237 chr7:65647864~65715661:+ LIHC cis rs4356203 0.811 rs214920 ENSG00000260196.1 RP1-239B22.5 -4.14 4.35e-05 0.00928 -0.26 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17216402 chr11:17380649~17383531:+ LIHC cis rs1823913 1 rs11691372 ENSG00000227542.1 AC092614.2 -4.14 4.35e-05 0.00928 -0.23 -0.22 Obesity-related traits; chr2:191249952 chr2:191229165~191246172:- LIHC cis rs1075265 0.704 rs10084374 ENSG00000272156.1 RP11-477N3.1 -4.14 4.35e-05 0.00929 -0.25 -0.22 Chronotype;Morning vs. evening chronotype; chr2:54022175 chr2:54082554~54085066:+ LIHC cis rs950169 0.58 rs35516100 ENSG00000259728.4 LINC00933 4.14 4.36e-05 0.0093 0.31 0.22 Schizophrenia; chr15:84652199 chr15:84570649~84580175:+ LIHC cis rs950169 0.58 rs62021208 ENSG00000259728.4 LINC00933 4.14 4.36e-05 0.0093 0.31 0.22 Schizophrenia; chr15:84653013 chr15:84570649~84580175:+ LIHC cis rs7560272 0.538 rs2001436 ENSG00000204872.3 NAT8B -4.14 4.36e-05 0.0093 -0.3 -0.22 Schizophrenia; chr2:73701838 chr2:73700576~73701340:- LIHC cis rs651907 0.557 rs13069443 ENSG00000244119.1 PDCL3P4 4.14 4.36e-05 0.0093 0.23 0.22 Colorectal cancer; chr3:101654461 chr3:101712472~101713191:+ LIHC cis rs2243480 1 rs56291018 ENSG00000232546.1 RP11-458F8.1 -4.14 4.36e-05 0.00931 -0.25 -0.22 Diabetic kidney disease; chr7:65925352 chr7:66848496~66858136:+ LIHC cis rs2744375 0.6 rs2744371 ENSG00000261189.1 RP3-512B11.3 4.14 4.37e-05 0.00931 0.27 0.22 Resting heart rate; chr6:7553941 chr6:7540451~7541338:- LIHC cis rs2744375 0.6 rs2744368 ENSG00000261189.1 RP3-512B11.3 4.14 4.37e-05 0.00931 0.28 0.22 Resting heart rate; chr6:7553157 chr6:7540451~7541338:- LIHC cis rs2744375 0.6 rs2744369 ENSG00000261189.1 RP3-512B11.3 4.14 4.37e-05 0.00931 0.28 0.22 Resting heart rate; chr6:7553237 chr6:7540451~7541338:- LIHC cis rs12554020 0.582 rs2001609 ENSG00000227603.1 RP11-165J3.6 4.14 4.37e-05 0.00931 0.38 0.22 Schizophrenia; chr9:93633081 chr9:93435332~93437121:- LIHC cis rs875971 0.545 rs1796226 ENSG00000228409.4 CCT6P1 -4.14 4.37e-05 0.00932 -0.18 -0.22 Aortic root size; chr7:66622723 chr7:65751142~65763354:+ LIHC cis rs875971 0.54 rs35510581 ENSG00000164669.11 INTS4P1 4.14 4.38e-05 0.00933 0.3 0.22 Aortic root size; chr7:66113790 chr7:65141225~65234216:+ LIHC cis rs11098499 0.954 rs12505469 ENSG00000260091.1 RP11-33B1.4 -4.14 4.38e-05 0.00933 -0.16 -0.22 Corneal astigmatism; chr4:119328430 chr4:119409333~119410233:+ LIHC cis rs1153858 1 rs9783731 ENSG00000259433.2 CTD-2651B20.4 4.14 4.38e-05 0.00934 0.29 0.22 Homoarginine levels; chr15:45350686 chr15:45330209~45332634:- LIHC cis rs6504622 0.755 rs12942936 ENSG00000262879.4 RP11-156P1.3 -4.14 4.38e-05 0.00934 -0.23 -0.22 Orofacial clefts; chr17:47075062 chr17:46984045~47100323:- LIHC cis rs17023223 0.537 rs17023185 ENSG00000231365.4 RP11-418J17.1 -4.14 4.38e-05 0.00934 -0.26 -0.22 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119068164 chr1:119140396~119275973:+ LIHC cis rs2762353 0.603 rs9393670 ENSG00000242387.1 HIST1H2APS2 -4.14 4.38e-05 0.00934 -0.25 -0.22 Blood metabolite levels; chr6:25788833 chr6:25882026~25882395:- LIHC cis rs2274273 0.588 rs58296156 ENSG00000258413.1 RP11-665C16.6 -4.14 4.39e-05 0.00934 -0.27 -0.22 Protein biomarker; chr14:55361609 chr14:55262767~55272075:- LIHC cis rs2274273 0.588 rs7158791 ENSG00000258413.1 RP11-665C16.6 -4.14 4.39e-05 0.00934 -0.27 -0.22 Protein biomarker; chr14:55361889 chr14:55262767~55272075:- LIHC cis rs2274273 0.588 rs11158037 ENSG00000258413.1 RP11-665C16.6 -4.14 4.39e-05 0.00934 -0.27 -0.22 Protein biomarker; chr14:55365434 chr14:55262767~55272075:- LIHC cis rs56080343 0.515 rs73222056 ENSG00000275759.1 RP11-131L12.3 -4.14 4.39e-05 0.00934 -0.31 -0.22 Neuroticism; chr12:118215875 chr12:118428281~118428870:+ LIHC cis rs11098499 0.863 rs7699064 ENSG00000260091.1 RP11-33B1.4 4.14 4.39e-05 0.00934 0.16 0.22 Corneal astigmatism; chr4:119507154 chr4:119409333~119410233:+ LIHC cis rs2735413 0.918 rs7197254 ENSG00000276007.1 RP11-358L22.3 -4.14 4.39e-05 0.00934 -0.25 -0.22 Systolic blood pressure (alcohol consumption interaction); chr16:78029456 chr16:78123243~78124332:+ LIHC cis rs17818399 0.548 rs1989720 ENSG00000239332.4 LINC01119 -4.14 4.39e-05 0.00935 -0.29 -0.22 Height; chr2:46627225 chr2:46816697~46859007:+ LIHC cis rs12291225 0.883 rs1864658 ENSG00000251991.1 RNU7-49P -4.14 4.39e-05 0.00935 -0.23 -0.22 Sense of smell; chr11:14234898 chr11:14478892~14478953:+ LIHC cis rs17772222 0.917 rs17188207 ENSG00000258789.1 RP11-507K2.3 -4.14 4.39e-05 0.00935 -0.26 -0.22 Coronary artery calcification; chr14:88699579 chr14:88551597~88552493:+ LIHC cis rs3812762 0.879 rs10769952 ENSG00000254860.4 TMEM9B-AS1 -4.14 4.39e-05 0.00935 -0.23 -0.22 Hypospadias; chr11:8755153 chr11:8964675~8977527:+ LIHC cis rs755249 0.567 rs61779285 ENSG00000182109.6 RP11-69E11.4 4.14 4.39e-05 0.00935 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39401383 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs3768301 ENSG00000182109.6 RP11-69E11.4 4.14 4.39e-05 0.00935 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39405121 chr1:39522280~39546187:- LIHC cis rs10510102 0.872 rs116521083 ENSG00000273891.1 RP11-500G22.5 4.14 4.39e-05 0.00936 0.29 0.22 Breast cancer; chr10:121950611 chr10:121965764~121967700:+ LIHC cis rs10510102 0.748 rs4589226 ENSG00000273891.1 RP11-500G22.5 4.14 4.39e-05 0.00936 0.29 0.22 Breast cancer; chr10:121951073 chr10:121965764~121967700:+ LIHC cis rs10510102 0.81 rs34738294 ENSG00000273891.1 RP11-500G22.5 4.14 4.39e-05 0.00936 0.29 0.22 Breast cancer; chr10:121951357 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs12258234 ENSG00000273891.1 RP11-500G22.5 4.14 4.39e-05 0.00936 0.29 0.22 Breast cancer; chr10:121952828 chr10:121965764~121967700:+ LIHC cis rs10510102 0.515 rs11200285 ENSG00000273891.1 RP11-500G22.5 4.14 4.39e-05 0.00936 0.29 0.22 Breast cancer; chr10:121953931 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs75831447 ENSG00000273891.1 RP11-500G22.5 4.14 4.39e-05 0.00936 0.29 0.22 Breast cancer; chr10:121953963 chr10:121965764~121967700:+ LIHC cis rs10510102 0.63 rs79960726 ENSG00000273891.1 RP11-500G22.5 4.14 4.39e-05 0.00936 0.29 0.22 Breast cancer; chr10:121954358 chr10:121965764~121967700:+ LIHC cis rs7811142 0.83 rs7792525 ENSG00000242294.5 STAG3L5P 4.14 4.4e-05 0.00936 0.24 0.22 Platelet count; chr7:100374499 chr7:100336079~100351900:+ LIHC cis rs4266144 1 rs4266144 ENSG00000243176.4 RP11-550I24.2 -4.14 4.4e-05 0.00937 -0.28 -0.22 Coronary artery disease; chr3:157134803 chr3:157175223~157381265:+ LIHC cis rs7474896 0.583 rs12783272 ENSG00000263064.2 RP11-291L22.7 4.14 4.4e-05 0.00937 0.26 0.22 Obesity (extreme); chr10:37735957 chr10:38448689~38448949:+ LIHC cis rs709400 0.859 rs942863 ENSG00000258914.1 CTD-2134A5.3 4.14 4.4e-05 0.00937 0.32 0.22 Body mass index; chr14:103554931 chr14:103875055~103877478:+ LIHC cis rs7412746 0.563 rs3768013 ENSG00000231073.1 RP11-316M1.3 4.14 4.4e-05 0.00937 0.22 0.22 Melanoma; chr1:150842935 chr1:150973123~150975534:+ LIHC cis rs6442522 0.737 rs905640 ENSG00000249786.6 EAF1-AS1 4.14 4.4e-05 0.00937 0.25 0.22 Uric acid levels; chr3:15454333 chr3:15436171~15455940:- LIHC cis rs5742933 0.744 rs12693557 ENSG00000253559.1 OSGEPL1-AS1 4.14 4.4e-05 0.00937 0.29 0.22 Ferritin levels; chr2:189726211 chr2:189762704~189765556:+ LIHC cis rs5742933 0.817 rs13035966 ENSG00000253559.1 OSGEPL1-AS1 4.14 4.4e-05 0.00937 0.29 0.22 Ferritin levels; chr2:189726507 chr2:189762704~189765556:+ LIHC cis rs7893279 0.505 rs2171922 ENSG00000225527.1 RP11-383B4.4 4.14 4.4e-05 0.00937 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18646977 chr10:18531849~18533336:- LIHC cis rs597539 0.652 rs553875 ENSG00000250508.1 RP11-757G1.6 -4.14 4.4e-05 0.00937 -0.34 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68927676 chr11:68870664~68874542:+ LIHC cis rs2390582 0.607 rs34627995 ENSG00000231613.1 RP5-943J3.1 4.14 4.41e-05 0.00938 0.45 0.22 Coronary artery calcification; chr1:90302369 chr1:89788914~89790492:+ LIHC cis rs960902 0.648 rs11124584 ENSG00000213553.4 RPLP0P6 4.14 4.41e-05 0.00938 0.18 0.22 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37484714 chr2:38481851~38482804:+ LIHC cis rs960902 0.648 rs11124585 ENSG00000213553.4 RPLP0P6 4.14 4.41e-05 0.00938 0.18 0.22 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37484749 chr2:38481851~38482804:+ LIHC cis rs67311347 0.544 rs6599088 ENSG00000223797.4 ENTPD3-AS1 4.14 4.41e-05 0.00938 0.18 0.22 Renal cell carcinoma; chr3:40287797 chr3:40313802~40453329:- LIHC cis rs67311347 0.544 rs4974040 ENSG00000223797.4 ENTPD3-AS1 4.14 4.41e-05 0.00938 0.18 0.22 Renal cell carcinoma; chr3:40289568 chr3:40313802~40453329:- LIHC cis rs67311347 0.544 rs9877105 ENSG00000223797.4 ENTPD3-AS1 4.14 4.41e-05 0.00938 0.18 0.22 Renal cell carcinoma; chr3:40291875 chr3:40313802~40453329:- LIHC cis rs2348418 0.864 rs6487689 ENSG00000247934.4 RP11-967K21.1 4.14 4.41e-05 0.00938 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28560101 chr12:28163298~28190738:- LIHC cis rs11733284 0.894 rs321630 ENSG00000259959.1 RP11-121C2.2 4.14 4.41e-05 0.00939 0.2 0.22 Gout;Renal underexcretion gout; chr4:48016153 chr4:47840122~47844339:- LIHC cis rs11733284 0.963 rs321631 ENSG00000259959.1 RP11-121C2.2 4.14 4.41e-05 0.00939 0.2 0.22 Gout;Renal underexcretion gout; chr4:48016212 chr4:47840122~47844339:- LIHC cis rs875971 0.545 rs6969224 ENSG00000228409.4 CCT6P1 -4.14 4.41e-05 0.00939 -0.18 -0.22 Aortic root size; chr7:66370011 chr7:65751142~65763354:+ LIHC cis rs2749592 0.55 rs10764135 ENSG00000275858.1 RP11-291L22.8 -4.14 4.41e-05 0.00939 -0.24 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37577917 chr10:38450738~38451069:- LIHC cis rs2749592 0.55 rs12255038 ENSG00000275858.1 RP11-291L22.8 -4.14 4.41e-05 0.00939 -0.24 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37580404 chr10:38450738~38451069:- LIHC cis rs2749592 0.505 rs7915670 ENSG00000275858.1 RP11-291L22.8 -4.14 4.41e-05 0.00939 -0.24 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37581284 chr10:38450738~38451069:- LIHC cis rs1115240 0.785 rs12588828 ENSG00000257842.4 NOVA1-AS1 -4.14 4.41e-05 0.00939 -0.2 -0.22 Educational attainment (years of education); chr14:26594587 chr14:26598412~26806467:+ LIHC cis rs8005677 0.828 rs12437151 ENSG00000257285.4 RP11-298I3.1 4.14 4.42e-05 0.0094 0.22 0.22 Cognitive ability (multi-trait analysis); chr14:22903704 chr14:22929609~22955562:+ LIHC cis rs2243480 1 rs73142162 ENSG00000232546.1 RP11-458F8.1 -4.14 4.42e-05 0.0094 -0.25 -0.22 Diabetic kidney disease; chr7:65909309 chr7:66848496~66858136:+ LIHC cis rs10510102 0.872 rs12240306 ENSG00000273891.1 RP11-500G22.5 4.14 4.42e-05 0.0094 0.29 0.22 Breast cancer; chr10:121963391 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs12240308 ENSG00000273891.1 RP11-500G22.5 4.14 4.42e-05 0.0094 0.29 0.22 Breast cancer; chr10:121963407 chr10:121965764~121967700:+ LIHC cis rs10129255 1 rs10129319 ENSG00000224373.3 IGHV4-59 4.14 4.42e-05 0.0094 0.17 0.22 Kawasaki disease; chr14:106767996 chr14:106627249~106627825:- LIHC cis rs4356975 0.83 rs4235114 ENSG00000250919.1 RP11-813N20.3 -4.14 4.42e-05 0.00941 -0.22 -0.22 Obesity-related traits; chr4:69056953 chr4:69027831~69044578:+ LIHC cis rs6445975 0.666 rs11130629 ENSG00000272360.1 RP11-359I18.5 4.14 4.43e-05 0.00941 0.3 0.22 Systemic lupus erythematosus; chr3:58366872 chr3:58490830~58491291:- LIHC cis rs6445975 0.572 rs7642018 ENSG00000272360.1 RP11-359I18.5 4.14 4.43e-05 0.00941 0.3 0.22 Systemic lupus erythematosus; chr3:58367536 chr3:58490830~58491291:- LIHC cis rs6445975 0.666 rs9867320 ENSG00000272360.1 RP11-359I18.5 4.14 4.43e-05 0.00941 0.3 0.22 Systemic lupus erythematosus; chr3:58369546 chr3:58490830~58491291:- LIHC cis rs2274273 0.624 rs7150763 ENSG00000258413.1 RP11-665C16.6 -4.14 4.43e-05 0.00941 -0.27 -0.22 Protein biomarker; chr14:55373083 chr14:55262767~55272075:- LIHC cis rs260461 0.92 rs79259289 ENSG00000268516.2 CTD-3138B18.5 -4.14 4.43e-05 0.00941 -0.23 -0.22 Attention deficit hyperactivity disorder; chr19:58240891 chr19:58257270~58278808:- LIHC cis rs524281 0.731 rs9326365 ENSG00000255320.1 RP11-755F10.1 -4.14 4.43e-05 0.00942 -0.3 -0.22 Electroencephalogram traits; chr11:66040414 chr11:66244840~66246239:- LIHC cis rs4356975 0.83 rs6600865 ENSG00000250919.1 RP11-813N20.3 -4.14 4.43e-05 0.00943 -0.22 -0.22 Obesity-related traits; chr4:69057904 chr4:69027831~69044578:+ LIHC cis rs2762353 0.718 rs1165207 ENSG00000242387.1 HIST1H2APS2 4.14 4.43e-05 0.00943 0.25 0.22 Blood metabolite levels; chr6:25865038 chr6:25882026~25882395:- LIHC cis rs673078 0.66 rs76842574 ENSG00000275759.1 RP11-131L12.3 -4.14 4.43e-05 0.00943 -0.26 -0.22 Glucose homeostasis traits; chr12:118371789 chr12:118428281~118428870:+ LIHC cis rs2036707 1 rs58806855 ENSG00000277246.1 RP11-153I24.4 -4.14 4.43e-05 0.00943 -0.39 -0.22 Obesity-related traits; chr13:107831721 chr13:108267320~108267734:+ LIHC cis rs901683 1 rs12761573 ENSG00000230869.1 CTGLF10P -4.14 4.44e-05 0.00943 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45584069 chr10:45678692~45700532:+ LIHC cis rs919433 0.927 rs6759834 ENSG00000231621.1 AC013264.2 4.14 4.44e-05 0.00943 0.2 0.22 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197340136 chr2:197197991~197199273:+ LIHC cis rs875971 0.545 rs2279757 ENSG00000228409.4 CCT6P1 -4.14 4.44e-05 0.00943 -0.18 -0.22 Aortic root size; chr7:66363676 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs11766183 ENSG00000228409.4 CCT6P1 -4.14 4.44e-05 0.00943 -0.18 -0.22 Aortic root size; chr7:66374173 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs1065265 ENSG00000228409.4 CCT6P1 -4.14 4.44e-05 0.00943 -0.18 -0.22 Aortic root size; chr7:66376216 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs7811204 ENSG00000228409.4 CCT6P1 -4.14 4.44e-05 0.00943 -0.18 -0.22 Aortic root size; chr7:66387213 chr7:65751142~65763354:+ LIHC cis rs5769707 0.967 rs5769698 ENSG00000279345.1 RP3-522J7.7 -4.14 4.44e-05 0.00944 -0.19 -0.22 Monocyte percentage of white cells;Monocyte count; chr22:49604058 chr22:49805452~49807208:+ LIHC cis rs11098499 1 rs13116504 ENSG00000260091.1 RP11-33B1.4 -4.14 4.44e-05 0.00944 -0.16 -0.22 Corneal astigmatism; chr4:119288257 chr4:119409333~119410233:+ LIHC cis rs858239 0.932 rs858272 ENSG00000226816.2 AC005082.12 4.14 4.44e-05 0.00944 0.27 0.22 Cerebrospinal fluid biomarker levels; chr7:23237166 chr7:23206013~23208045:+ LIHC cis rs1165668 0.816 rs1866069 ENSG00000257327.1 RP11-650K20.3 -4.14 4.44e-05 0.00944 -0.25 -0.22 Coronary heart disease (SNP X SNP interaction); chr12:103916767 chr12:103841451~103844664:+ LIHC cis rs10761256 0.835 rs10761255 ENSG00000227603.1 RP11-165J3.6 4.14 4.44e-05 0.00944 0.26 0.22 Itch intensity from mosquito bite adjusted by bite size; chr9:93670902 chr9:93435332~93437121:- LIHC cis rs1115240 0.947 rs7140993 ENSG00000257842.4 NOVA1-AS1 4.14 4.44e-05 0.00944 0.2 0.22 Educational attainment (years of education); chr14:26637960 chr14:26598412~26806467:+ LIHC cis rs42490 0.727 rs42481 ENSG00000251136.7 RP11-37B2.1 4.14 4.45e-05 0.00945 0.18 0.22 Leprosy; chr8:89825486 chr8:89609409~89757727:- LIHC cis rs9595908 0.746 rs7985640 ENSG00000212293.1 SNORA16 4.14 4.45e-05 0.00946 0.25 0.22 Body mass index; chr13:32698228 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs9591252 ENSG00000212293.1 SNORA16 4.14 4.45e-05 0.00946 0.25 0.22 Body mass index; chr13:32698297 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs9596083 ENSG00000212293.1 SNORA16 4.14 4.45e-05 0.00946 0.25 0.22 Body mass index; chr13:32700494 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs4942829 ENSG00000212293.1 SNORA16 4.14 4.45e-05 0.00946 0.25 0.22 Body mass index; chr13:32708994 chr13:32420390~32420516:- LIHC cis rs734999 0.545 rs10910105 ENSG00000225931.3 RP3-395M20.7 4.14 4.45e-05 0.00946 0.23 0.22 Ulcerative colitis; chr1:2606770 chr1:2566410~2569888:+ LIHC cis rs734999 0.545 rs10910106 ENSG00000225931.3 RP3-395M20.7 4.14 4.45e-05 0.00946 0.23 0.22 Ulcerative colitis; chr1:2607447 chr1:2566410~2569888:+ LIHC cis rs6433895 0.677 rs34825850 ENSG00000236153.1 AC104076.3 -4.14 4.45e-05 0.00946 -0.31 -0.22 Lymphocyte counts; chr2:181140599 chr2:180979427~180980090:- LIHC cis rs11676348 0.808 rs12694430 ENSG00000261338.2 RP11-378A13.1 -4.14 4.46e-05 0.00946 -0.24 -0.22 Ulcerative colitis; chr2:218151076 chr2:218255319~218257366:+ LIHC cis rs17376456 0.877 rs12109629 ENSG00000251023.1 RP11-549J18.1 -4.14 4.46e-05 0.00947 -0.46 -0.22 Diabetic retinopathy; chr5:94023997 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs12153501 ENSG00000251023.1 RP11-549J18.1 -4.14 4.46e-05 0.00947 -0.46 -0.22 Diabetic retinopathy; chr5:94025161 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs12153506 ENSG00000251023.1 RP11-549J18.1 -4.14 4.46e-05 0.00947 -0.46 -0.22 Diabetic retinopathy; chr5:94025248 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10078194 ENSG00000251023.1 RP11-549J18.1 -4.14 4.46e-05 0.00947 -0.46 -0.22 Diabetic retinopathy; chr5:94028605 chr5:93860669~93863825:- LIHC cis rs6496044 0.507 rs410522 ENSG00000259630.2 CTD-2262B20.1 4.14 4.46e-05 0.00947 0.23 0.22 Interstitial lung disease; chr15:85663813 chr15:85415228~85415633:+ LIHC cis rs73198271 0.813 rs56007835 ENSG00000253893.2 FAM85B 4.14 4.46e-05 0.00947 0.34 0.22 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8752516 chr8:8167819~8226614:- LIHC cis rs8177253 0.665 rs12639304 ENSG00000244062.1 RP11-404G16.2 4.14 4.46e-05 0.00947 0.22 0.22 Iron status biomarkers; chr3:133722750 chr3:133760300~133762363:+ LIHC cis rs6745190 0.512 rs13026070 ENSG00000236153.1 AC104076.3 -4.14 4.46e-05 0.00947 -0.31 -0.22 White blood cell count; chr2:181126695 chr2:180979427~180980090:- LIHC cis rs6745190 0.557 rs13031518 ENSG00000236153.1 AC104076.3 -4.14 4.46e-05 0.00947 -0.31 -0.22 White blood cell count; chr2:181127032 chr2:180979427~180980090:- LIHC cis rs867371 0.762 rs12905578 ENSG00000259429.4 UBE2Q2P2 4.14 4.46e-05 0.00948 0.21 0.22 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82288923 chr15:82355142~82420075:+ LIHC cis rs4356975 0.83 rs4235113 ENSG00000250919.1 RP11-813N20.3 -4.14 4.46e-05 0.00948 -0.22 -0.22 Obesity-related traits; chr4:69056739 chr4:69027831~69044578:+ LIHC cis rs4578769 0.765 rs11662489 ENSG00000266850.1 RP11-370A5.1 -4.14 4.46e-05 0.00948 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22816959 chr18:22723491~22907721:- LIHC cis rs13113518 0.812 rs3805153 ENSG00000249700.7 SRD5A3-AS1 4.14 4.46e-05 0.00948 0.26 0.22 Height; chr4:55493557 chr4:55363971~55395847:- LIHC cis rs4650994 0.524 rs2811299 ENSG00000273384.1 RP5-1098D14.1 -4.14 4.47e-05 0.00948 -0.27 -0.22 HDL cholesterol;HDL cholesterol levels; chr1:178617242 chr1:178651706~178652282:+ LIHC cis rs1023500 0.529 rs133375 ENSG00000205702.9 CYP2D7 4.14 4.47e-05 0.00948 0.25 0.22 Schizophrenia; chr22:42070505 chr22:42140203~42144577:- LIHC cis rs11098499 0.954 rs10006877 ENSG00000260091.1 RP11-33B1.4 -4.14 4.47e-05 0.00948 -0.16 -0.22 Corneal astigmatism; chr4:119321638 chr4:119409333~119410233:+ LIHC cis rs2243480 0.803 rs36127118 ENSG00000228409.4 CCT6P1 4.14 4.47e-05 0.00948 0.23 0.22 Diabetic kidney disease; chr7:66100518 chr7:65751142~65763354:+ LIHC cis rs2877649 0.793 rs74780198 ENSG00000258744.1 RP11-80A15.1 -4.14 4.47e-05 0.00949 -0.45 -0.22 Smooth-surface caries; chr14:24498714 chr14:24501594~24508688:+ LIHC cis rs12931792 0.712 rs4787495 ENSG00000183604.13 SMG1P5 -4.14 4.47e-05 0.00949 -0.19 -0.22 Tonsillectomy; chr16:30154404 chr16:30267553~30335374:- LIHC cis rs1823913 1 rs1840377 ENSG00000227542.1 AC092614.2 -4.13 4.47e-05 0.00949 -0.22 -0.22 Obesity-related traits; chr2:191257992 chr2:191229165~191246172:- LIHC cis rs1823913 1 rs4853564 ENSG00000227542.1 AC092614.2 -4.13 4.47e-05 0.00949 -0.22 -0.22 Obesity-related traits; chr2:191258939 chr2:191229165~191246172:- LIHC cis rs1823913 1 rs4853565 ENSG00000227542.1 AC092614.2 -4.13 4.47e-05 0.00949 -0.22 -0.22 Obesity-related traits; chr2:191259020 chr2:191229165~191246172:- LIHC cis rs1823913 1 rs4853462 ENSG00000227542.1 AC092614.2 -4.13 4.47e-05 0.00949 -0.22 -0.22 Obesity-related traits; chr2:191259078 chr2:191229165~191246172:- LIHC cis rs6061231 0.583 rs2427313 ENSG00000226332.2 RP11-157P1.4 4.13 4.47e-05 0.00949 0.25 0.22 Colorectal cancer; chr20:62395619 chr20:62305432~62306325:- LIHC cis rs13242816 1 rs3807993 ENSG00000279086.1 RP11-667F14.1 4.13 4.47e-05 0.00949 0.38 0.22 P wave duration; chr7:116557518 chr7:116209234~116211511:- LIHC cis rs4925386 1 rs6121990 ENSG00000273619.1 RP5-908M14.9 4.13 4.47e-05 0.00949 0.18 0.22 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62344207 chr20:62386303~62386970:- LIHC cis rs901683 0.867 rs35003524 ENSG00000230869.1 CTGLF10P -4.13 4.47e-05 0.00949 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45591333 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs78766622 ENSG00000230869.1 CTGLF10P -4.13 4.47e-05 0.00949 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45592071 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34618850 ENSG00000230869.1 CTGLF10P -4.13 4.47e-05 0.00949 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45592415 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35670420 ENSG00000230869.1 CTGLF10P -4.13 4.47e-05 0.00949 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45592604 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs36053776 ENSG00000230869.1 CTGLF10P -4.13 4.47e-05 0.00949 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45592697 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35713143 ENSG00000230869.1 CTGLF10P -4.13 4.47e-05 0.00949 -0.54 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45592711 chr10:45678692~45700532:+ LIHC cis rs7923609 0.934 rs10761756 ENSG00000232075.1 MRPL35P2 -4.13 4.47e-05 0.00949 -0.24 -0.22 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63412568 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs10761758 ENSG00000232075.1 MRPL35P2 -4.13 4.47e-05 0.00949 -0.24 -0.22 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63412987 chr10:63634317~63634827:- LIHC cis rs7923609 0.967 rs7909269 ENSG00000232075.1 MRPL35P2 -4.13 4.47e-05 0.00949 -0.24 -0.22 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63418006 chr10:63634317~63634827:- LIHC cis rs12280210 0.557 rs12284696 ENSG00000254851.1 RP11-109L13.1 4.13 4.48e-05 0.0095 0.34 0.22 Lobe attachment (rater-scored or self-reported); chr11:117008803 chr11:117135528~117138582:+ LIHC cis rs6471393 0.964 rs12056877 ENSG00000253848.1 RP11-10N23.5 -4.13 4.48e-05 0.0095 -0.24 -0.22 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93710234 chr8:93741193~93744534:+ LIHC cis rs8177253 0.634 rs6798547 ENSG00000244062.1 RP11-404G16.2 4.13 4.48e-05 0.0095 0.21 0.22 Iron status biomarkers; chr3:133729655 chr3:133760300~133762363:+ LIHC cis rs8177253 0.665 rs7646118 ENSG00000244062.1 RP11-404G16.2 4.13 4.48e-05 0.0095 0.21 0.22 Iron status biomarkers; chr3:133731195 chr3:133760300~133762363:+ LIHC cis rs2286503 0.839 rs4722189 ENSG00000228649.7 AC005682.5 4.13 4.48e-05 0.0095 0.25 0.22 Fibrinogen; chr7:22820855 chr7:22854178~22861579:+ LIHC cis rs9527 0.615 rs11191401 ENSG00000236937.2 PTGES3P4 4.13 4.48e-05 0.0095 0.33 0.22 Arsenic metabolism; chr10:102813646 chr10:102845595~102845950:+ LIHC cis rs11676348 0.838 rs17844697 ENSG00000261338.2 RP11-378A13.1 -4.13 4.48e-05 0.0095 -0.23 -0.22 Ulcerative colitis; chr2:218134532 chr2:218255319~218257366:+ LIHC cis rs1799949 0.931 rs34410138 ENSG00000267681.1 CTD-3199J23.6 -4.13 4.48e-05 0.0095 -0.21 -0.22 Menopause (age at onset); chr17:43127753 chr17:43144956~43145255:+ LIHC cis rs11096990 0.613 rs4974996 ENSG00000249685.1 RP11-360F5.3 4.13 4.48e-05 0.0095 0.27 0.22 Cognitive function; chr4:39225928 chr4:39133913~39135608:+ LIHC cis rs17818399 0.653 rs34050156 ENSG00000239332.4 LINC01119 -4.13 4.48e-05 0.0095 -0.31 -0.22 Height; chr2:46550507 chr2:46816697~46859007:+ LIHC cis rs617219 0.819 rs2591387 ENSG00000251675.1 CTC-458I2.2 -4.13 4.48e-05 0.00951 -0.25 -0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79262602 chr5:80128361~80143883:+ LIHC cis rs7568498 0.759 rs6728594 ENSG00000235724.7 AC009299.2 4.13 4.49e-05 0.00952 0.29 0.22 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161011641 chr2:161222785~161308303:- LIHC cis rs56205728 0.606 rs3784397 ENSG00000273855.1 RP11-133K1.12 4.13 4.49e-05 0.00952 0.24 0.22 Schizophrenia; chr15:40304643 chr15:40285468~40285909:- LIHC cis rs4561483 0.801 rs251723 ENSG00000261560.1 RP11-166B2.3 -4.13 4.5e-05 0.00953 -0.25 -0.22 Testicular germ cell tumor; chr16:11859223 chr16:11881075~11882569:- LIHC cis rs3020736 0.5 rs2413669 ENSG00000205702.9 CYP2D7 -4.13 4.5e-05 0.00953 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42111744 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs6002618 ENSG00000205702.9 CYP2D7 -4.13 4.5e-05 0.00953 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42111855 chr22:42140203~42144577:- LIHC cis rs1023500 0.551 rs61665536 ENSG00000205702.9 CYP2D7 -4.13 4.5e-05 0.00953 -0.25 -0.22 Schizophrenia; chr22:42116609 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs2413672 ENSG00000205702.9 CYP2D7 -4.13 4.5e-05 0.00953 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42117257 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs6002623 ENSG00000205702.9 CYP2D7 -4.13 4.5e-05 0.00953 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42117757 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs764481 ENSG00000205702.9 CYP2D7 -4.13 4.5e-05 0.00953 -0.25 -0.22 Autism spectrum disorder or schizophrenia; chr22:42122422 chr22:42140203~42144577:- LIHC cis rs7044106 0.791 rs10984997 ENSG00000238181.2 AHCYP2 -4.13 4.5e-05 0.00953 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120718928 chr9:120720673~120721972:+ LIHC cis rs7615952 0.641 rs7618515 ENSG00000171084.14 FAM86JP 4.13 4.5e-05 0.00953 0.35 0.22 Blood pressure (smoking interaction); chr3:126071735 chr3:125916620~125930024:+ LIHC cis rs1223397 0.651 rs2439537 ENSG00000215022.6 RP1-257A7.4 -4.13 4.5e-05 0.00954 -0.24 -0.22 Blood pressure; chr6:13307592 chr6:13264861~13295586:- LIHC cis rs603446 0.84 rs180329 ENSG00000254851.1 RP11-109L13.1 -4.13 4.5e-05 0.00954 -0.27 -0.22 Triglycerides; chr11:116752242 chr11:117135528~117138582:+ LIHC cis rs1005277 0.522 rs1208767 ENSG00000099251.13 HSD17B7P2 4.13 4.5e-05 0.00954 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37753367 chr10:38356380~38378505:+ LIHC cis rs1876905 0.539 rs240958 ENSG00000272356.1 RP5-1112D6.8 4.13 4.5e-05 0.00954 0.2 0.22 Mean corpuscular hemoglobin; chr6:111298449 chr6:111309203~111313517:+ LIHC cis rs193541 0.501 rs3943379 ENSG00000263432.2 RN7SL689P 4.13 4.5e-05 0.00954 0.33 0.22 Glucose homeostasis traits; chr5:122720442 chr5:123022487~123022783:- LIHC cis rs193541 0.502 rs2061511 ENSG00000263432.2 RN7SL689P 4.13 4.5e-05 0.00954 0.33 0.22 Glucose homeostasis traits; chr5:122721032 chr5:123022487~123022783:- LIHC cis rs73193808 0.614 rs9976839 ENSG00000212479.2 U3 4.13 4.51e-05 0.00954 0.25 0.22 Coronary artery disease; chr21:29190389 chr21:29180425~29180639:- LIHC cis rs4650994 0.623 rs12121188 ENSG00000273384.1 RP5-1098D14.1 -4.13 4.51e-05 0.00955 -0.27 -0.22 HDL cholesterol;HDL cholesterol levels; chr1:178653364 chr1:178651706~178652282:+ LIHC cis rs1400745 0.756 rs10136352 ENSG00000258738.1 RP11-73E17.2 4.13 4.51e-05 0.00955 0.27 0.22 Monocyte count; chr14:34865349 chr14:34874343~34876459:+ LIHC cis rs7044106 0.762 rs10491783 ENSG00000238181.2 AHCYP2 -4.13 4.51e-05 0.00955 -0.24 -0.22 Hip circumference adjusted for BMI; chr9:120687877 chr9:120720673~120721972:+ LIHC cis rs7044106 0.762 rs966397 ENSG00000238181.2 AHCYP2 -4.13 4.51e-05 0.00955 -0.24 -0.22 Hip circumference adjusted for BMI; chr9:120691034 chr9:120720673~120721972:+ LIHC cis rs12157904 1 rs12157904 ENSG00000233360.4 Z83844.1 -4.13 4.51e-05 0.00955 -0.42 -0.22 Response to anti-depressant treatment in major depressive disorder; chr22:37586005 chr22:37641832~37658377:- LIHC cis rs4578769 0.879 rs7235234 ENSG00000265943.1 RP11-739L10.1 4.13 4.51e-05 0.00955 0.28 0.22 Eosinophil percentage of white cells; chr18:22864239 chr18:22699481~22933764:- LIHC cis rs4578769 0.879 rs9950650 ENSG00000265943.1 RP11-739L10.1 4.13 4.51e-05 0.00955 0.28 0.22 Eosinophil percentage of white cells; chr18:22864537 chr18:22699481~22933764:- LIHC cis rs4578769 0.733 rs7226388 ENSG00000265943.1 RP11-739L10.1 4.13 4.51e-05 0.00955 0.28 0.22 Eosinophil percentage of white cells; chr18:22865371 chr18:22699481~22933764:- LIHC cis rs734999 0.505 rs60687045 ENSG00000225931.3 RP3-395M20.7 4.13 4.51e-05 0.00955 0.23 0.22 Ulcerative colitis; chr1:2608164 chr1:2566410~2569888:+ LIHC cis rs2243480 0.803 rs13224048 ENSG00000232546.1 RP11-458F8.1 -4.13 4.51e-05 0.00956 -0.25 -0.22 Diabetic kidney disease; chr7:66528779 chr7:66848496~66858136:+ LIHC cis rs960902 0.747 rs7593333 ENSG00000213553.4 RPLP0P6 4.13 4.51e-05 0.00956 0.18 0.22 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37498569 chr2:38481851~38482804:+ LIHC cis rs6997458 0.839 rs1390712 ENSG00000253549.4 RP11-317J10.2 4.13 4.51e-05 0.00956 0.24 0.22 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85395020 chr8:85441851~85464915:- LIHC cis rs6472235 0.656 rs11995784 ENSG00000272010.1 CTD-3025N20.3 -4.13 4.52e-05 0.00956 -0.3 -0.22 Plateletcrit;Myopia (pathological); chr8:65967906 chr8:65591850~65592472:- LIHC cis rs6472235 0.656 rs11993927 ENSG00000272010.1 CTD-3025N20.3 -4.13 4.52e-05 0.00956 -0.3 -0.22 Plateletcrit;Myopia (pathological); chr8:65969407 chr8:65591850~65592472:- LIHC cis rs6472235 0.656 rs11994927 ENSG00000272010.1 CTD-3025N20.3 -4.13 4.52e-05 0.00956 -0.3 -0.22 Plateletcrit;Myopia (pathological); chr8:65970615 chr8:65591850~65592472:- LIHC cis rs6472235 0.609 rs11985589 ENSG00000272010.1 CTD-3025N20.3 -4.13 4.52e-05 0.00956 -0.3 -0.22 Plateletcrit;Myopia (pathological); chr8:65972076 chr8:65591850~65592472:- LIHC cis rs6496667 0.557 rs2601203 ENSG00000213471.7 TTLL13P 4.13 4.52e-05 0.00956 0.29 0.22 Rheumatoid arthritis; chr15:90414897 chr15:90249530~90265482:+ LIHC cis rs2494250 0.542 rs11265174 ENSG00000231434.1 RP11-144L1.8 -4.13 4.52e-05 0.00956 -0.26 -0.22 Select biomarker traits; chr1:159350569 chr1:158523672~158525838:+ LIHC cis rs3002131 0.736 rs2936027 ENSG00000225265.1 TAF1A-AS1 -4.13 4.52e-05 0.00956 -0.32 -0.22 Interleukin-10 levels; chr1:222588974 chr1:222589825~222593032:+ LIHC cis rs2281636 0.723 rs11190255 ENSG00000233690.1 EBAG9P1 4.13 4.52e-05 0.00956 0.22 0.22 Obesity-related traits; chr10:99714742 chr10:99697407~99697949:- LIHC cis rs2348418 0.733 rs10771414 ENSG00000247934.4 RP11-967K21.1 4.13 4.52e-05 0.00956 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28241369 chr12:28163298~28190738:- LIHC cis rs193541 0.632 rs173481 ENSG00000263432.2 RN7SL689P 4.13 4.52e-05 0.00957 0.35 0.22 Glucose homeostasis traits; chr5:122918857 chr5:123022487~123022783:- LIHC cis rs1823913 1 rs7574570 ENSG00000227542.1 AC092614.2 -4.13 4.52e-05 0.00957 -0.23 -0.22 Obesity-related traits; chr2:191233790 chr2:191229165~191246172:- LIHC cis rs6449502 1 rs6889730 ENSG00000272308.1 RP11-231G3.1 -4.13 4.52e-05 0.00957 -0.33 -0.22 Mean platelet volume; chr5:60825270 chr5:60866457~60866935:- LIHC cis rs3015497 0.616 rs7152874 ENSG00000269906.1 RP11-248J18.2 4.13 4.52e-05 0.00957 0.27 0.22 Mean platelet volume; chr14:50579322 chr14:50662511~50663178:- LIHC cis rs9652601 0.959 rs7198621 ENSG00000274038.1 RP11-66H6.4 -4.13 4.52e-05 0.00958 -0.27 -0.22 Systemic lupus erythematosus; chr16:11073601 chr16:11056556~11057034:+ LIHC cis rs6832769 1 rs7667849 ENSG00000272969.1 RP11-528I4.2 -4.13 4.52e-05 0.00958 -0.26 -0.22 Personality dimensions; chr4:55522032 chr4:55547112~55547889:+ LIHC cis rs6745190 0.748 rs6735373 ENSG00000236153.1 AC104076.3 4.13 4.52e-05 0.00958 0.29 0.22 White blood cell count; chr2:181065907 chr2:180979427~180980090:- LIHC cis rs1005277 0.505 rs13503 ENSG00000276805.1 RP11-291L22.6 -4.13 4.52e-05 0.00958 -0.26 -0.22 Extrinsic epigenetic age acceleration; chr10:37950915 chr10:38451030~38451785:+ LIHC cis rs1005277 0.505 rs7069702 ENSG00000276805.1 RP11-291L22.6 -4.13 4.52e-05 0.00958 -0.26 -0.22 Extrinsic epigenetic age acceleration; chr10:37958431 chr10:38451030~38451785:+ LIHC cis rs11722228 0.522 rs73212880 ENSG00000261490.1 RP11-448G15.3 4.13 4.52e-05 0.00958 0.29 0.22 Urate levels;Serum uric acid levels;Gout; chr4:10114068 chr4:10068089~10073019:- LIHC cis rs10129255 1 rs10129255 ENSG00000224373.3 IGHV4-59 -4.13 4.52e-05 0.00958 -0.17 -0.22 Kawasaki disease; chr14:106767970 chr14:106627249~106627825:- LIHC cis rs7412746 0.621 rs72704656 ENSG00000231073.1 RP11-316M1.3 4.13 4.53e-05 0.00958 0.23 0.22 Melanoma; chr1:150855831 chr1:150973123~150975534:+ LIHC cis rs17711722 1 rs17711722 ENSG00000273024.4 INTS4P2 4.13 4.53e-05 0.00958 0.26 0.22 Calcium levels; chr7:65806210 chr7:65647864~65715661:+ LIHC cis rs17711722 0.675 rs6947132 ENSG00000273024.4 INTS4P2 4.13 4.53e-05 0.00958 0.26 0.22 Calcium levels; chr7:65808508 chr7:65647864~65715661:+ LIHC cis rs6545883 0.56 rs11677775 ENSG00000271889.1 RP11-493E12.1 -4.13 4.53e-05 0.00958 -0.26 -0.22 Tuberculosis; chr2:61275975 chr2:61151433~61162105:- LIHC cis rs11098499 0.722 rs7673476 ENSG00000260091.1 RP11-33B1.4 -4.13 4.53e-05 0.00958 -0.15 -0.22 Corneal astigmatism; chr4:119327528 chr4:119409333~119410233:+ LIHC cis rs651907 0.514 rs12636046 ENSG00000244119.1 PDCL3P4 4.13 4.53e-05 0.00959 0.23 0.22 Colorectal cancer; chr3:101715604 chr3:101712472~101713191:+ LIHC cis rs12468226 0.689 rs73989731 ENSG00000272966.1 RP11-686O6.1 4.13 4.53e-05 0.00959 0.39 0.22 Urate levels; chr2:202109309 chr2:202336739~202337200:+ LIHC cis rs529413 0.641 rs1520413 ENSG00000259237.1 RP11-209E8.1 4.13 4.53e-05 0.00959 0.3 0.22 Itch intensity from mosquito bite adjusted by bite size; chr15:53239216 chr15:53116365~53129698:+ LIHC cis rs6921919 0.638 rs1416920 ENSG00000204709.4 LINC01556 4.13 4.53e-05 0.0096 0.24 0.22 Autism spectrum disorder or schizophrenia; chr6:28335007 chr6:28943877~28944537:+ LIHC cis rs6921919 0.525 rs1361386 ENSG00000204709.4 LINC01556 4.13 4.53e-05 0.0096 0.24 0.22 Autism spectrum disorder or schizophrenia; chr6:28337827 chr6:28943877~28944537:+ LIHC cis rs6921919 0.638 rs6456815 ENSG00000204709.4 LINC01556 4.13 4.53e-05 0.0096 0.24 0.22 Autism spectrum disorder or schizophrenia; chr6:28338360 chr6:28943877~28944537:+ LIHC cis rs6921919 0.638 rs2108926 ENSG00000204709.4 LINC01556 4.13 4.53e-05 0.0096 0.24 0.22 Autism spectrum disorder or schizophrenia; chr6:28340970 chr6:28943877~28944537:+ LIHC cis rs6430585 0.528 rs6743537 ENSG00000231890.6 DARS-AS1 -4.13 4.54e-05 0.0096 -0.32 -0.22 Corneal structure; chr2:135945031 chr2:135985176~136022593:+ LIHC cis rs10771431 1 rs10771431 ENSG00000111788.10 RP11-22B23.1 4.13 4.54e-05 0.0096 0.2 0.22 Breast size; chr12:9228263 chr12:9277235~9313241:+ LIHC cis rs11096990 0.634 rs11736790 ENSG00000249685.1 RP11-360F5.3 4.13 4.54e-05 0.0096 0.26 0.22 Cognitive function; chr4:39254704 chr4:39133913~39135608:+ LIHC cis rs2562456 0.917 rs2681377 ENSG00000268555.1 RP11-678G14.3 -4.13 4.54e-05 0.0096 -0.28 -0.22 Pain; chr19:21533718 chr19:21570822~21587322:- LIHC cis rs6433895 0.677 rs6716261 ENSG00000236153.1 AC104076.3 -4.13 4.54e-05 0.0096 -0.29 -0.22 Lymphocyte counts; chr2:181166505 chr2:180979427~180980090:- LIHC cis rs757081 0.676 rs567033 ENSG00000272034.1 SNORD14A -4.13 4.54e-05 0.00961 -0.23 -0.22 Systolic blood pressure; chr11:17185463 chr11:17074654~17074744:- LIHC cis rs757081 0.676 rs677042 ENSG00000272034.1 SNORD14A -4.13 4.54e-05 0.00961 -0.23 -0.22 Systolic blood pressure; chr11:17185533 chr11:17074654~17074744:- LIHC cis rs1023500 1 rs9620001 ENSG00000237037.8 NDUFA6-AS1 -4.13 4.54e-05 0.00961 -0.3 -0.22 Schizophrenia; chr22:41934225 chr22:42090931~42137742:+ LIHC cis rs3845817 0.733 rs702906 ENSG00000281920.1 RP11-418H16.1 -4.13 4.55e-05 0.00962 -0.25 -0.22 Bipolar disorder; chr2:65539745 chr2:65623272~65628424:+ LIHC cis rs7044106 0.708 rs920745 ENSG00000238181.2 AHCYP2 -4.13 4.55e-05 0.00962 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120667665 chr9:120720673~120721972:+ LIHC cis rs7044106 0.734 rs10491784 ENSG00000238181.2 AHCYP2 -4.13 4.55e-05 0.00962 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120670011 chr9:120720673~120721972:+ LIHC cis rs11096990 0.634 rs11096988 ENSG00000249685.1 RP11-360F5.3 4.13 4.55e-05 0.00963 0.26 0.22 Cognitive function; chr4:39264081 chr4:39133913~39135608:+ LIHC cis rs9400467 0.528 rs459403 ENSG00000271789.1 RP5-1112D6.7 -4.13 4.55e-05 0.00963 -0.21 -0.22 Amino acid levels;Blood metabolite levels; chr6:111332674 chr6:111297126~111298510:+ LIHC cis rs875971 0.545 rs7783889 ENSG00000273024.4 INTS4P2 -4.13 4.55e-05 0.00963 -0.25 -0.22 Aortic root size; chr7:66283366 chr7:65647864~65715661:+ LIHC cis rs2243480 1 rs34970380 ENSG00000232546.1 RP11-458F8.1 -4.13 4.55e-05 0.00963 -0.25 -0.22 Diabetic kidney disease; chr7:65966506 chr7:66848496~66858136:+ LIHC cis rs2243480 0.901 rs73148097 ENSG00000232546.1 RP11-458F8.1 -4.13 4.55e-05 0.00963 -0.25 -0.22 Diabetic kidney disease; chr7:65966800 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs906134 ENSG00000232546.1 RP11-458F8.1 -4.13 4.55e-05 0.00963 -0.25 -0.22 Diabetic kidney disease; chr7:65979301 chr7:66848496~66858136:+ LIHC cis rs2439831 0.85 rs9944216 ENSG00000166763.7 STRCP1 -4.13 4.55e-05 0.00963 -0.34 -0.22 Lung cancer in ever smokers; chr15:43868575 chr15:43699488~43718184:- LIHC cis rs11098499 0.863 rs3822194 ENSG00000260091.1 RP11-33B1.4 -4.13 4.55e-05 0.00963 -0.16 -0.22 Corneal astigmatism; chr4:119550493 chr4:119409333~119410233:+ LIHC cis rs7044106 0.762 rs1547268 ENSG00000238181.2 AHCYP2 -4.13 4.56e-05 0.00963 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120646410 chr9:120720673~120721972:+ LIHC cis rs7044106 0.762 rs1547267 ENSG00000238181.2 AHCYP2 -4.13 4.56e-05 0.00963 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120646458 chr9:120720673~120721972:+ LIHC cis rs7044106 0.762 rs4142158 ENSG00000238181.2 AHCYP2 -4.13 4.56e-05 0.00963 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120648541 chr9:120720673~120721972:+ LIHC cis rs11098499 0.863 rs17050695 ENSG00000260091.1 RP11-33B1.4 -4.13 4.56e-05 0.00964 -0.15 -0.22 Corneal astigmatism; chr4:119568372 chr4:119409333~119410233:+ LIHC cis rs11722228 0.522 rs1109472 ENSG00000261490.1 RP11-448G15.3 4.13 4.56e-05 0.00964 0.28 0.22 Urate levels;Serum uric acid levels;Gout; chr4:10132824 chr4:10068089~10073019:- LIHC cis rs673078 0.607 rs4766899 ENSG00000275759.1 RP11-131L12.3 -4.13 4.56e-05 0.00964 -0.26 -0.22 Glucose homeostasis traits; chr12:118374888 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs10850967 ENSG00000275759.1 RP11-131L12.3 -4.13 4.56e-05 0.00964 -0.26 -0.22 Glucose homeostasis traits; chr12:118380072 chr12:118428281~118428870:+ LIHC cis rs11064837 0.504 rs7973772 ENSG00000248636.5 RP11-768F21.1 -4.13 4.56e-05 0.00964 -0.35 -0.22 Schizophrenia; chr12:119648932 chr12:119387987~119668079:- LIHC cis rs7586970 0.549 rs13035938 ENSG00000224063.4 AC007319.1 4.13 4.56e-05 0.00964 0.34 0.22 Coronary heart disease; chr2:187525385 chr2:187003220~187554663:+ LIHC cis rs73198271 0.74 rs10092720 ENSG00000253893.2 FAM85B 4.13 4.56e-05 0.00964 0.32 0.22 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8791607 chr8:8167819~8226614:- LIHC cis rs12304921 0.748 rs17125258 ENSG00000277201.1 AC087884.1 4.13 4.56e-05 0.00965 0.26 0.22 Type 2 diabetes; chr12:51051896 chr12:51049921~51050025:+ LIHC cis rs4561483 0.831 rs2075158 ENSG00000261560.1 RP11-166B2.3 4.13 4.56e-05 0.00965 0.24 0.22 Testicular germ cell tumor; chr16:11851374 chr16:11881075~11882569:- LIHC cis rs6048205 0.764 rs1203868 ENSG00000259974.2 LINC00261 4.13 4.57e-05 0.00965 0.33 0.22 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22551374 chr20:22547671~22578642:- LIHC cis rs7945705 0.774 rs6486060 ENSG00000254860.4 TMEM9B-AS1 -4.13 4.57e-05 0.00965 -0.22 -0.22 Hemoglobin concentration; chr11:9003083 chr11:8964675~8977527:+ LIHC cis rs9640161 0.702 rs11765692 ENSG00000261305.1 RP4-584D14.7 4.13 4.57e-05 0.00965 0.26 0.22 Blood protein levels;Circulating chemerin levels; chr7:150329478 chr7:150341771~150342607:+ LIHC cis rs7615952 0.599 rs12485717 ENSG00000171084.14 FAM86JP -4.13 4.57e-05 0.00966 -0.34 -0.22 Blood pressure (smoking interaction); chr3:125988232 chr3:125916620~125930024:+ LIHC cis rs4713118 0.614 rs9468209 ENSG00000216901.1 AL022393.7 4.13 4.57e-05 0.00966 0.24 0.22 Parkinson's disease; chr6:27726642 chr6:28176188~28176674:+ LIHC cis rs17818399 0.89 rs34544165 ENSG00000279254.1 RP11-536C12.1 -4.13 4.57e-05 0.00966 -0.26 -0.22 Height; chr2:46609767 chr2:46668870~46670778:+ LIHC cis rs763121 0.853 rs2076028 ENSG00000273076.1 RP3-508I15.22 4.13 4.57e-05 0.00966 0.25 0.22 Menopause (age at onset); chr22:38754445 chr22:38743495~38743910:+ LIHC cis rs875971 0.545 rs1796226 ENSG00000273024.4 INTS4P2 -4.13 4.57e-05 0.00966 -0.25 -0.22 Aortic root size; chr7:66622723 chr7:65647864~65715661:+ LIHC cis rs11096990 0.821 rs2711991 ENSG00000249207.1 RP11-360F5.1 4.13 4.57e-05 0.00966 0.25 0.22 Cognitive function; chr4:39149733 chr4:39112677~39126818:- LIHC cis rs9890032 0.581 rs62070592 ENSG00000266490.1 CTD-2349P21.9 4.13 4.57e-05 0.00966 0.21 0.22 Hip circumference adjusted for BMI; chr17:30695531 chr17:30792372~30792833:+ LIHC cis rs11098499 0.954 rs878373 ENSG00000260091.1 RP11-33B1.4 -4.13 4.58e-05 0.00967 -0.16 -0.22 Corneal astigmatism; chr4:119316329 chr4:119409333~119410233:+ LIHC cis rs950880 0.668 rs3732126 ENSG00000234389.1 AC007278.3 -4.13 4.58e-05 0.00967 -0.22 -0.22 Serum protein levels (sST2); chr2:102397502 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs3732125 ENSG00000234389.1 AC007278.3 -4.13 4.58e-05 0.00967 -0.22 -0.22 Serum protein levels (sST2); chr2:102397503 chr2:102438713~102440475:+ LIHC cis rs2243480 0.615 rs34363376 ENSG00000232546.1 RP11-458F8.1 -4.13 4.58e-05 0.00967 -0.25 -0.22 Diabetic kidney disease; chr7:66474549 chr7:66848496~66858136:+ LIHC cis rs4925386 1 rs4925382 ENSG00000273619.1 RP5-908M14.9 4.13 4.58e-05 0.00967 0.18 0.22 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62343486 chr20:62386303~62386970:- LIHC cis rs1005277 0.54 rs2474598 ENSG00000275858.1 RP11-291L22.8 -4.13 4.58e-05 0.00967 -0.24 -0.22 Extrinsic epigenetic age acceleration; chr10:38141368 chr10:38450738~38451069:- LIHC cis rs6433895 0.71 rs56692685 ENSG00000236153.1 AC104076.3 -4.13 4.58e-05 0.00968 -0.28 -0.22 Lymphocyte counts; chr2:181147366 chr2:180979427~180980090:- LIHC cis rs2598107 0.601 rs7807170 ENSG00000211698.2 TRGV4 -4.13 4.58e-05 0.00968 -0.27 -0.22 Dupuytren's disease; chr7:37894980 chr7:38353715~38354517:- LIHC cis rs638893 0.636 rs493720 ENSG00000278376.1 RP11-158I9.8 -4.13 4.59e-05 0.00969 -0.39 -0.22 Vitiligo; chr11:118733969 chr11:118791254~118793137:+ LIHC cis rs638893 0.636 rs526850 ENSG00000278376.1 RP11-158I9.8 -4.13 4.59e-05 0.00969 -0.39 -0.22 Vitiligo; chr11:118734418 chr11:118791254~118793137:+ LIHC cis rs2243480 1 rs13310597 ENSG00000232546.1 RP11-458F8.1 -4.13 4.59e-05 0.00969 -0.25 -0.22 Diabetic kidney disease; chr7:66133553 chr7:66848496~66858136:+ LIHC cis rs6456156 0.586 rs1358883 ENSG00000227598.1 RP1-167A14.2 4.13 4.59e-05 0.00969 0.22 0.22 Primary biliary cholangitis; chr6:167053945 chr6:166969626~166999065:- LIHC cis rs6921919 0.638 rs9468344 ENSG00000204709.4 LINC01556 4.13 4.6e-05 0.0097 0.25 0.22 Autism spectrum disorder or schizophrenia; chr6:28341792 chr6:28943877~28944537:+ LIHC cis rs2562456 0.917 rs2681376 ENSG00000268555.1 RP11-678G14.3 -4.13 4.6e-05 0.00971 -0.28 -0.22 Pain; chr19:21532723 chr19:21570822~21587322:- LIHC cis rs295490 0.748 rs58234450 ENSG00000272656.1 RP11-219D15.3 4.13 4.6e-05 0.00971 0.62 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139481465 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs114423015 ENSG00000272656.1 RP11-219D15.3 4.13 4.6e-05 0.00971 0.62 0.22 PR interval in Tripanosoma cruzi seropositivity; chr3:139488980 chr3:139349024~139349371:- LIHC cis rs904251 0.861 rs914349 ENSG00000204110.6 RP1-153P14.8 -4.13 4.6e-05 0.00971 -0.27 -0.22 Cognitive performance; chr6:37516939 chr6:37507348~37535616:+ LIHC cis rs17774123 0.901 rs11830203 ENSG00000257808.1 RP11-1136G11.8 4.13 4.6e-05 0.00972 0.4 0.22 Diastolic blood pressure; chr12:53870638 chr12:53159586~53161000:+ LIHC cis rs4356975 0.83 rs4481286 ENSG00000250919.1 RP11-813N20.3 -4.13 4.6e-05 0.00972 -0.22 -0.22 Obesity-related traits; chr4:69056631 chr4:69027831~69044578:+ LIHC cis rs4356975 0.83 rs4583828 ENSG00000250919.1 RP11-813N20.3 -4.13 4.6e-05 0.00972 -0.22 -0.22 Obesity-related traits; chr4:69056669 chr4:69027831~69044578:+ LIHC cis rs10129255 0.957 rs8022165 ENSG00000211970.3 IGHV4-61 -4.13 4.6e-05 0.00972 -0.17 -0.22 Kawasaki disease; chr14:106781682 chr14:106639119~106639657:- LIHC cis rs10129255 0.917 rs8022493 ENSG00000211970.3 IGHV4-61 -4.13 4.6e-05 0.00972 -0.17 -0.22 Kawasaki disease; chr14:106781820 chr14:106639119~106639657:- LIHC cis rs2361701 0.636 rs1982244 ENSG00000275479.1 RP11-334C17.6 4.13 4.6e-05 0.00972 0.22 0.22 IgG glycosylation; chr17:80095149 chr17:80149627~80149798:+ LIHC cis rs673078 0.607 rs7967900 ENSG00000275759.1 RP11-131L12.3 4.13 4.61e-05 0.00972 0.43 0.22 Glucose homeostasis traits; chr12:118381902 chr12:118428281~118428870:+ LIHC cis rs2299116 0.962 rs62442194 ENSG00000225264.3 ZNRF2P2 -4.13 4.61e-05 0.00972 -0.25 -0.22 Serum thyroid-stimulating hormone levels; chr7:28776584 chr7:29598795~29685255:- LIHC cis rs2299116 0.962 rs62442195 ENSG00000225264.3 ZNRF2P2 -4.13 4.61e-05 0.00972 -0.25 -0.22 Serum thyroid-stimulating hormone levels; chr7:28776890 chr7:29598795~29685255:- LIHC cis rs2439831 0.681 rs1549523 ENSG00000166763.7 STRCP1 4.13 4.61e-05 0.00972 0.3 0.22 Lung cancer in ever smokers; chr15:43331991 chr15:43699488~43718184:- LIHC cis rs2439831 0.681 rs1549525 ENSG00000166763.7 STRCP1 4.13 4.61e-05 0.00972 0.3 0.22 Lung cancer in ever smokers; chr15:43335657 chr15:43699488~43718184:- LIHC cis rs1005277 0.505 rs7099777 ENSG00000099251.13 HSD17B7P2 -4.13 4.61e-05 0.00972 -0.25 -0.22 Extrinsic epigenetic age acceleration; chr10:37894641 chr10:38356380~38378505:+ LIHC cis rs597539 0.617 rs672853 ENSG00000250508.1 RP11-757G1.6 -4.13 4.61e-05 0.00973 -0.34 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68868894 chr11:68870664~68874542:+ LIHC cis rs651907 0.514 rs12636047 ENSG00000244119.1 PDCL3P4 4.13 4.61e-05 0.00974 0.23 0.22 Colorectal cancer; chr3:101715605 chr3:101712472~101713191:+ LIHC cis rs651907 0.557 rs7612283 ENSG00000244119.1 PDCL3P4 4.13 4.61e-05 0.00974 0.23 0.22 Colorectal cancer; chr3:101716075 chr3:101712472~101713191:+ LIHC cis rs651907 0.557 rs34457525 ENSG00000244119.1 PDCL3P4 4.13 4.61e-05 0.00974 0.23 0.22 Colorectal cancer; chr3:101716381 chr3:101712472~101713191:+ LIHC cis rs4938303 0.633 rs61906081 ENSG00000254851.1 RP11-109L13.1 4.13 4.62e-05 0.00974 0.31 0.22 Triglycerides; chr11:116666342 chr11:117135528~117138582:+ LIHC cis rs4073416 0.712 rs2411351 ENSG00000276116.2 FUT8-AS1 4.13 4.62e-05 0.00974 0.26 0.22 N-glycan levels; chr14:65704823 chr14:65411170~65412690:- LIHC cis rs9906944 0.933 rs12945020 ENSG00000248278.1 SUMO2P17 -4.13 4.62e-05 0.00975 -0.37 -0.22 Intelligence (multi-trait analysis);Body fat percentage; chr17:49005413 chr17:48874860~48908983:- LIHC cis rs7712401 0.715 rs13163098 ENSG00000263432.2 RN7SL689P -4.13 4.62e-05 0.00975 -0.31 -0.22 Mean platelet volume; chr5:123010841 chr5:123022487~123022783:- LIHC cis rs7712401 0.715 rs13164161 ENSG00000263432.2 RN7SL689P -4.13 4.62e-05 0.00975 -0.31 -0.22 Mean platelet volume; chr5:123011202 chr5:123022487~123022783:- LIHC cis rs7712401 0.715 rs401226 ENSG00000263432.2 RN7SL689P -4.13 4.62e-05 0.00975 -0.31 -0.22 Mean platelet volume; chr5:123012031 chr5:123022487~123022783:- LIHC cis rs7712401 0.715 rs395981 ENSG00000263432.2 RN7SL689P -4.13 4.62e-05 0.00975 -0.31 -0.22 Mean platelet volume; chr5:123012216 chr5:123022487~123022783:- LIHC cis rs7712401 0.715 rs424247 ENSG00000263432.2 RN7SL689P -4.13 4.62e-05 0.00975 -0.31 -0.22 Mean platelet volume; chr5:123012298 chr5:123022487~123022783:- LIHC cis rs7712401 0.715 rs424262 ENSG00000263432.2 RN7SL689P -4.13 4.62e-05 0.00975 -0.31 -0.22 Mean platelet volume; chr5:123012317 chr5:123022487~123022783:- LIHC cis rs7208859 0.673 rs11655623 ENSG00000266490.1 CTD-2349P21.9 4.13 4.62e-05 0.00976 0.27 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30835155 chr17:30792372~30792833:+ LIHC cis rs7208859 0.573 rs73277960 ENSG00000266490.1 CTD-2349P21.9 4.13 4.62e-05 0.00976 0.27 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30850423 chr17:30792372~30792833:+ LIHC cis rs7208859 0.623 rs73263788 ENSG00000266490.1 CTD-2349P21.9 4.13 4.62e-05 0.00976 0.27 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889472 chr17:30792372~30792833:+ LIHC cis rs7208859 0.673 rs12949860 ENSG00000266490.1 CTD-2349P21.9 4.13 4.62e-05 0.00976 0.27 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896014 chr17:30792372~30792833:+ LIHC cis rs875971 0.545 rs2420456 ENSG00000228409.4 CCT6P1 -4.13 4.63e-05 0.00976 -0.18 -0.22 Aortic root size; chr7:66280619 chr7:65751142~65763354:+ LIHC cis rs67311347 0.544 rs1454492 ENSG00000223797.4 ENTPD3-AS1 4.13 4.63e-05 0.00977 0.18 0.22 Renal cell carcinoma; chr3:40311393 chr3:40313802~40453329:- LIHC cis rs2072510 1 rs2072512 ENSG00000257715.1 RP11-256L6.2 -4.13 4.63e-05 0.00977 -0.22 -0.22 Metabolite levels (small molecules and protein measures); chr12:96015198 chr12:96025323~96027971:+ LIHC cis rs2072510 1 rs1978331 ENSG00000257715.1 RP11-256L6.2 -4.13 4.63e-05 0.00977 -0.22 -0.22 Metabolite levels (small molecules and protein measures); chr12:96015423 chr12:96025323~96027971:+ LIHC cis rs4578769 0.918 rs8085287 ENSG00000265943.1 RP11-739L10.1 4.13 4.63e-05 0.00977 0.27 0.22 Eosinophil percentage of white cells; chr18:22884208 chr18:22699481~22933764:- LIHC cis rs2243480 1 rs56016656 ENSG00000232546.1 RP11-458F8.1 -4.13 4.63e-05 0.00977 -0.25 -0.22 Diabetic kidney disease; chr7:65918494 chr7:66848496~66858136:+ LIHC cis rs2243480 0.803 rs55700941 ENSG00000232546.1 RP11-458F8.1 -4.13 4.63e-05 0.00977 -0.25 -0.22 Diabetic kidney disease; chr7:65924813 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs36033484 ENSG00000232546.1 RP11-458F8.1 -4.13 4.63e-05 0.00977 -0.25 -0.22 Diabetic kidney disease; chr7:65925571 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs34193460 ENSG00000232546.1 RP11-458F8.1 -4.13 4.63e-05 0.00977 -0.25 -0.22 Diabetic kidney disease; chr7:65928123 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs34560516 ENSG00000232546.1 RP11-458F8.1 -4.13 4.63e-05 0.00977 -0.25 -0.22 Diabetic kidney disease; chr7:65939105 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs57057549 ENSG00000232546.1 RP11-458F8.1 -4.13 4.63e-05 0.00977 -0.25 -0.22 Diabetic kidney disease; chr7:65940751 chr7:66848496~66858136:+ LIHC cis rs2243480 0.808 rs12698508 ENSG00000232546.1 RP11-458F8.1 -4.13 4.63e-05 0.00977 -0.25 -0.22 Diabetic kidney disease; chr7:65946971 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs2961102 ENSG00000232546.1 RP11-458F8.1 -4.13 4.63e-05 0.00977 -0.25 -0.22 Diabetic kidney disease; chr7:65959671 chr7:66848496~66858136:+ LIHC cis rs11690935 0.632 rs34531723 ENSG00000228389.1 AC068039.4 -4.13 4.64e-05 0.00978 -0.26 -0.22 Schizophrenia; chr2:171707584 chr2:171773482~171775844:+ LIHC cis rs4578769 0.836 rs3936488 ENSG00000265943.1 RP11-739L10.1 4.13 4.64e-05 0.00978 0.28 0.22 Eosinophil percentage of white cells; chr18:22874459 chr18:22699481~22933764:- LIHC cis rs1005277 0.505 rs1208689 ENSG00000099251.13 HSD17B7P2 4.13 4.64e-05 0.00978 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37808847 chr10:38356380~38378505:+ LIHC cis rs11098499 1 rs6837898 ENSG00000260091.1 RP11-33B1.4 -4.13 4.64e-05 0.00979 -0.16 -0.22 Corneal astigmatism; chr4:119257999 chr4:119409333~119410233:+ LIHC cis rs803903 0.883 rs1090025 ENSG00000230894.1 RP11-67K19.3 -4.13 4.64e-05 0.00979 -0.28 -0.22 Breast cancer; chr9:116677596 chr9:116568449~116586328:+ LIHC cis rs5758511 0.68 rs5758698 ENSG00000237037.8 NDUFA6-AS1 -4.13 4.64e-05 0.00979 -0.28 -0.22 Birth weight; chr22:42288812 chr22:42090931~42137742:+ LIHC cis rs6496044 0.507 rs2467096 ENSG00000259630.2 CTD-2262B20.1 4.13 4.64e-05 0.00979 0.23 0.22 Interstitial lung disease; chr15:85667447 chr15:85415228~85415633:+ LIHC cis rs6545883 0.507 rs12478192 ENSG00000271889.1 RP11-493E12.1 -4.13 4.64e-05 0.00979 -0.26 -0.22 Tuberculosis; chr2:61364040 chr2:61151433~61162105:- LIHC cis rs6545883 0.524 rs12992614 ENSG00000271889.1 RP11-493E12.1 -4.13 4.64e-05 0.00979 -0.26 -0.22 Tuberculosis; chr2:61365941 chr2:61151433~61162105:- LIHC cis rs1577917 1 rs12216328 ENSG00000234155.1 RP11-30P6.6 4.13 4.65e-05 0.00979 0.29 0.22 Response to antipsychotic treatment; chr6:85993700 chr6:85387219~85390186:- LIHC cis rs812925 0.537 rs778146 ENSG00000271889.1 RP11-493E12.1 -4.13 4.65e-05 0.0098 -0.26 -0.22 Immature fraction of reticulocytes; chr2:61379340 chr2:61151433~61162105:- LIHC cis rs812925 0.537 rs778153 ENSG00000271889.1 RP11-493E12.1 -4.13 4.65e-05 0.0098 -0.26 -0.22 Immature fraction of reticulocytes; chr2:61381517 chr2:61151433~61162105:- LIHC cis rs17214007 0.778 rs17213271 ENSG00000263335.1 AF001548.5 -4.13 4.65e-05 0.0098 -0.32 -0.22 Cognitive function; chr16:15770487 chr16:15726674~15732993:+ LIHC cis rs73183643 0.666 rs2690943 ENSG00000239486.1 RP11-163E9.1 4.13 4.65e-05 0.0098 0.29 0.22 Basal cell carcinoma; chr7:101759452 chr7:102380465~102382737:- LIHC cis rs12681287 0.64 rs13253296 ENSG00000254088.1 SLC2A3P4 4.13 4.65e-05 0.0098 0.25 0.22 Caudate activity during reward; chr8:86436016 chr8:86503591~86505061:+ LIHC cis rs12681287 0.604 rs34227066 ENSG00000254088.1 SLC2A3P4 4.13 4.65e-05 0.0098 0.25 0.22 Caudate activity during reward; chr8:86437137 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs34794500 ENSG00000254088.1 SLC2A3P4 4.13 4.65e-05 0.0098 0.25 0.22 Caudate activity during reward; chr8:86437766 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs7833049 ENSG00000254088.1 SLC2A3P4 -4.13 4.65e-05 0.0098 -0.25 -0.22 Caudate activity during reward; chr8:86433669 chr8:86503591~86505061:+ LIHC cis rs957448 1 rs2381882 ENSG00000253704.1 RP11-267M23.4 4.13 4.65e-05 0.00981 0.27 0.22 Nonsyndromic cleft lip with cleft palate; chr8:94535496 chr8:94553722~94569745:+ LIHC cis rs2348418 0.765 rs11049381 ENSG00000247934.4 RP11-967K21.1 -4.13 4.65e-05 0.00981 -0.2 -0.22 Lung function (FEV1);Lung function (FVC); chr12:28162107 chr12:28163298~28190738:- LIHC cis rs2348418 0.765 rs10843117 ENSG00000247934.4 RP11-967K21.1 -4.13 4.65e-05 0.00981 -0.2 -0.22 Lung function (FEV1);Lung function (FVC); chr12:28162457 chr12:28163298~28190738:- LIHC cis rs2348418 0.765 rs7954851 ENSG00000247934.4 RP11-967K21.1 -4.13 4.65e-05 0.00981 -0.2 -0.22 Lung function (FEV1);Lung function (FVC); chr12:28162909 chr12:28163298~28190738:- LIHC cis rs2348418 0.765 rs7954877 ENSG00000247934.4 RP11-967K21.1 -4.13 4.65e-05 0.00981 -0.2 -0.22 Lung function (FEV1);Lung function (FVC); chr12:28163008 chr12:28163298~28190738:- LIHC cis rs2348418 0.765 rs10843118 ENSG00000247934.4 RP11-967K21.1 -4.13 4.65e-05 0.00981 -0.2 -0.22 Lung function (FEV1);Lung function (FVC); chr12:28164396 chr12:28163298~28190738:- LIHC cis rs2348418 0.966 rs1527578 ENSG00000247934.4 RP11-967K21.1 4.13 4.65e-05 0.00981 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28536903 chr12:28163298~28190738:- LIHC cis rs2348418 0.966 rs16932891 ENSG00000247934.4 RP11-967K21.1 4.13 4.65e-05 0.00981 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28537055 chr12:28163298~28190738:- LIHC cis rs2348418 0.966 rs2881910 ENSG00000247934.4 RP11-967K21.1 4.13 4.65e-05 0.00981 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28544459 chr12:28163298~28190738:- LIHC cis rs2243480 1 rs73150014 ENSG00000232546.1 RP11-458F8.1 -4.13 4.65e-05 0.00981 -0.25 -0.22 Diabetic kidney disease; chr7:65985932 chr7:66848496~66858136:+ LIHC cis rs9450351 0.744 rs6913147 ENSG00000203875.9 SNHG5 -4.13 4.66e-05 0.00981 -0.45 -0.22 Interferon gamma-induced protein 10 levels; chr6:85800641 chr6:85660950~85678736:- LIHC cis rs881375 0.526 rs1930785 ENSG00000226752.6 PSMD5-AS1 -4.13 4.66e-05 0.00981 -0.22 -0.22 Rheumatoid arthritis; chr9:120928959 chr9:120824828~120854385:+ LIHC cis rs2808510 0.826 rs36003362 ENSG00000230623.2 RP11-469A15.2 -4.13 4.66e-05 0.00981 -0.25 -0.22 Myopia; chr1:200397960 chr1:200473920~200478293:+ LIHC cis rs10510102 0.872 rs12246728 ENSG00000273891.1 RP11-500G22.5 4.13 4.66e-05 0.00982 0.29 0.22 Breast cancer; chr10:121966618 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs12261371 ENSG00000273891.1 RP11-500G22.5 4.13 4.66e-05 0.00982 0.29 0.22 Breast cancer; chr10:121966686 chr10:121965764~121967700:+ LIHC cis rs10510102 0.808 rs17102804 ENSG00000273891.1 RP11-500G22.5 4.13 4.66e-05 0.00982 0.29 0.22 Breast cancer; chr10:121968365 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs12265369 ENSG00000273891.1 RP11-500G22.5 4.13 4.66e-05 0.00982 0.29 0.22 Breast cancer; chr10:121968455 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs12265542 ENSG00000273891.1 RP11-500G22.5 4.13 4.66e-05 0.00982 0.29 0.22 Breast cancer; chr10:121968740 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs11200293 ENSG00000273891.1 RP11-500G22.5 4.13 4.66e-05 0.00982 0.29 0.22 Breast cancer; chr10:121969195 chr10:121965764~121967700:+ LIHC cis rs11148252 0.846 rs8001624 ENSG00000278238.1 RP11-245D16.4 -4.12 4.66e-05 0.00982 -0.21 -0.22 Lewy body disease; chr13:52428860 chr13:52454775~52455331:- LIHC cis rs6048205 0.892 rs1203889 ENSG00000259974.2 LINC00261 -4.12 4.66e-05 0.00983 -0.31 -0.22 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22566283 chr20:22547671~22578642:- LIHC cis rs2243480 1 rs937108 ENSG00000232546.1 RP11-458F8.1 -4.12 4.66e-05 0.00983 -0.24 -0.22 Diabetic kidney disease; chr7:65963465 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs35542501 ENSG00000232546.1 RP11-458F8.1 -4.12 4.66e-05 0.00983 -0.24 -0.22 Diabetic kidney disease; chr7:65966228 chr7:66848496~66858136:+ LIHC cis rs2243480 0.711 rs1626926 ENSG00000232546.1 RP11-458F8.1 -4.12 4.66e-05 0.00983 -0.24 -0.22 Diabetic kidney disease; chr7:65970805 chr7:66848496~66858136:+ LIHC cis rs2243480 0.708 rs781141 ENSG00000232546.1 RP11-458F8.1 -4.12 4.66e-05 0.00983 -0.24 -0.22 Diabetic kidney disease; chr7:65973566 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs781142 ENSG00000232546.1 RP11-458F8.1 -4.12 4.66e-05 0.00983 -0.24 -0.22 Diabetic kidney disease; chr7:65973791 chr7:66848496~66858136:+ LIHC cis rs113835537 0.935 rs75863187 ENSG00000255517.5 CTD-3074O7.5 -4.12 4.67e-05 0.00983 -0.38 -0.22 Airway imaging phenotypes; chr11:66675990 chr11:66473490~66480233:- LIHC cis rs9595908 0.785 rs60088097 ENSG00000212293.1 SNORA16 4.12 4.67e-05 0.00983 0.25 0.22 Body mass index; chr13:32678043 chr13:32420390~32420516:- LIHC cis rs7246657 0.941 rs7259618 ENSG00000276846.1 CTD-3220F14.3 4.12 4.67e-05 0.00983 0.29 0.22 Coronary artery calcification; chr19:37259817 chr19:37314868~37315620:- LIHC cis rs73186030 0.841 rs112779893 ENSG00000272758.4 RP11-299J3.8 4.12 4.67e-05 0.00984 0.41 0.22 Serum parathyroid hormone levels; chr3:122334433 chr3:122416207~122443180:+ LIHC cis rs73186030 0.92 rs55784797 ENSG00000272758.4 RP11-299J3.8 4.12 4.67e-05 0.00984 0.41 0.22 Serum parathyroid hormone levels; chr3:122335788 chr3:122416207~122443180:+ LIHC cis rs4144027 0.904 rs10438244 ENSG00000258914.1 CTD-2134A5.3 4.12 4.67e-05 0.00984 0.23 0.22 Blood metabolite levels; chr14:103879848 chr14:103875055~103877478:+ LIHC cis rs1005277 0.522 rs9418276 ENSG00000276805.1 RP11-291L22.6 4.12 4.67e-05 0.00984 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:37651188 chr10:38451030~38451785:+ LIHC cis rs1005277 0.522 rs7072977 ENSG00000276805.1 RP11-291L22.6 4.12 4.67e-05 0.00984 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:37651512 chr10:38451030~38451785:+ LIHC cis rs4865169 0.967 rs10023088 ENSG00000269949.1 RP11-738E22.3 4.12 4.67e-05 0.00984 0.27 0.22 Breast cancer; chr4:57018269 chr4:56960927~56961373:- LIHC cis rs11690935 0.655 rs12052995 ENSG00000228389.1 AC068039.4 -4.12 4.68e-05 0.00985 -0.26 -0.22 Schizophrenia; chr2:171680702 chr2:171773482~171775844:+ LIHC cis rs244293 0.701 rs4793784 ENSG00000275710.1 RP11-257O5.4 4.12 4.68e-05 0.00986 0.25 0.22 Menarche (age at onset); chr17:54961069 chr17:54964474~54964679:+ LIHC cis rs4578769 0.959 rs3911557 ENSG00000266850.1 RP11-370A5.1 -4.12 4.68e-05 0.00986 -0.25 -0.22 Eosinophil percentage of white cells; chr18:22892600 chr18:22723491~22907721:- LIHC cis rs1799949 1 rs8176220 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.68e-05 0.00986 -0.21 -0.22 Menopause (age at onset); chr17:43070445 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs1799966 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.68e-05 0.00986 -0.21 -0.22 Menopause (age at onset); chr17:43071077 chr17:43144956~43145255:+ LIHC cis rs6480314 0.711 rs16925246 ENSG00000233590.1 RP11-153K11.3 4.12 4.68e-05 0.00986 0.36 0.22 Optic nerve measurement (disc area); chr10:68188569 chr10:68233251~68242379:- LIHC cis rs7208859 0.673 rs2470251 ENSG00000266490.1 CTD-2349P21.9 4.12 4.68e-05 0.00986 0.27 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30768043 chr17:30792372~30792833:+ LIHC cis rs7042864 0.506 rs989820 ENSG00000225531.1 RP11-196I18.3 4.12 4.68e-05 0.00986 0.3 0.22 Tonometry; chr9:108114562 chr9:107116829~107117557:+ LIHC cis rs67311347 0.544 rs9821440 ENSG00000223797.4 ENTPD3-AS1 4.12 4.69e-05 0.00986 0.18 0.22 Renal cell carcinoma; chr3:40300856 chr3:40313802~40453329:- LIHC cis rs67311347 0.544 rs13098483 ENSG00000223797.4 ENTPD3-AS1 4.12 4.69e-05 0.00986 0.18 0.22 Renal cell carcinoma; chr3:40301252 chr3:40313802~40453329:- LIHC cis rs67311347 0.544 rs9868700 ENSG00000223797.4 ENTPD3-AS1 4.12 4.69e-05 0.00986 0.18 0.22 Renal cell carcinoma; chr3:40303917 chr3:40313802~40453329:- LIHC cis rs4356975 0.83 rs4413468 ENSG00000250919.1 RP11-813N20.3 -4.12 4.69e-05 0.00987 -0.22 -0.22 Obesity-related traits; chr4:69061845 chr4:69027831~69044578:+ LIHC cis rs1075232 1 rs1075232 ENSG00000270055.1 CTD-3092A11.2 -4.12 4.69e-05 0.00987 -0.42 -0.22 Survival in colorectal cancer (non-distant metastatic); chr15:31449013 chr15:30487963~30490313:+ LIHC cis rs2243480 0.901 rs778732 ENSG00000232546.1 RP11-458F8.1 -4.12 4.69e-05 0.00987 -0.24 -0.22 Diabetic kidney disease; chr7:66357373 chr7:66848496~66858136:+ LIHC cis rs1577917 1 rs12212733 ENSG00000234155.1 RP11-30P6.6 4.12 4.69e-05 0.00987 0.28 0.22 Response to antipsychotic treatment; chr6:86016295 chr6:85387219~85390186:- LIHC cis rs9527 0.59 rs7067663 ENSG00000236937.2 PTGES3P4 4.12 4.69e-05 0.00987 0.28 0.22 Arsenic metabolism; chr10:103123893 chr10:102845595~102845950:+ LIHC cis rs2179367 0.632 rs6920383 ENSG00000231760.4 RP11-350J20.5 4.12 4.69e-05 0.00988 0.35 0.22 Dupuytren's disease; chr6:149356361 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs11155645 ENSG00000231760.4 RP11-350J20.5 4.12 4.69e-05 0.00988 0.35 0.22 Dupuytren's disease; chr6:149360056 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs9498332 ENSG00000231760.4 RP11-350J20.5 4.12 4.69e-05 0.00988 0.35 0.22 Dupuytren's disease; chr6:149367490 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs9498333 ENSG00000231760.4 RP11-350J20.5 4.12 4.69e-05 0.00988 0.35 0.22 Dupuytren's disease; chr6:149368196 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs9498334 ENSG00000231760.4 RP11-350J20.5 4.12 4.69e-05 0.00988 0.35 0.22 Dupuytren's disease; chr6:149370902 chr6:149796151~149826294:- LIHC cis rs6445975 0.956 rs7612923 ENSG00000272360.1 RP11-359I18.5 4.12 4.69e-05 0.00988 0.27 0.22 Systemic lupus erythematosus; chr3:58388706 chr3:58490830~58491291:- LIHC cis rs734999 0.545 rs41300092 ENSG00000225931.3 RP3-395M20.7 4.12 4.69e-05 0.00988 0.23 0.22 Ulcerative colitis; chr1:2606399 chr1:2566410~2569888:+ LIHC cis rs875971 0.83 rs427575 ENSG00000232559.3 GS1-124K5.12 4.12 4.69e-05 0.00988 0.18 0.22 Aortic root size; chr7:66054232 chr7:66554588~66576923:- LIHC cis rs7829975 0.514 rs2976929 ENSG00000253981.4 ALG1L13P 4.12 4.69e-05 0.00988 0.25 0.22 Mood instability; chr8:8401202 chr8:8236003~8244667:- LIHC cis rs1023500 0.573 rs8135801 ENSG00000205702.9 CYP2D7 -4.12 4.7e-05 0.00988 -0.25 -0.22 Schizophrenia; chr22:42079564 chr22:42140203~42144577:- LIHC cis rs6480314 0.636 rs10509298 ENSG00000233590.1 RP11-153K11.3 -4.12 4.7e-05 0.00989 -0.36 -0.22 Optic nerve measurement (disc area); chr10:68176982 chr10:68233251~68242379:- LIHC cis rs651907 0.514 rs10936744 ENSG00000244119.1 PDCL3P4 4.12 4.7e-05 0.00989 0.23 0.22 Colorectal cancer; chr3:101714596 chr3:101712472~101713191:+ LIHC cis rs950880 0.71 rs55742125 ENSG00000234389.1 AC007278.3 -4.12 4.7e-05 0.00989 -0.22 -0.22 Serum protein levels (sST2); chr2:102403322 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs55883125 ENSG00000234389.1 AC007278.3 -4.12 4.7e-05 0.00989 -0.22 -0.22 Serum protein levels (sST2); chr2:102407871 chr2:102438713~102440475:+ LIHC cis rs950880 0.645 rs4851006 ENSG00000234389.1 AC007278.3 -4.12 4.7e-05 0.00989 -0.22 -0.22 Serum protein levels (sST2); chr2:102408278 chr2:102438713~102440475:+ LIHC cis rs17270561 0.562 rs12199626 ENSG00000216436.2 HIST1H2APS1 -4.12 4.7e-05 0.0099 -0.34 -0.22 Iron status biomarkers; chr6:26013376 chr6:25732497~25732827:+ LIHC cis rs801193 0.548 rs2659904 ENSG00000232559.3 GS1-124K5.12 4.12 4.7e-05 0.0099 0.17 0.22 Aortic root size; chr7:66713615 chr7:66554588~66576923:- LIHC cis rs7923609 0.846 rs7896518 ENSG00000232075.1 MRPL35P2 -4.12 4.7e-05 0.0099 -0.24 -0.22 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63344740 chr10:63634317~63634827:- LIHC cis rs7412746 0.658 rs1027699 ENSG00000231073.1 RP11-316M1.3 4.12 4.71e-05 0.0099 0.22 0.22 Melanoma; chr1:150839236 chr1:150973123~150975534:+ LIHC cis rs1075265 0.73 rs6713088 ENSG00000272156.1 RP11-477N3.1 -4.12 4.71e-05 0.00991 -0.25 -0.22 Chronotype;Morning vs. evening chronotype; chr2:54118332 chr2:54082554~54085066:+ LIHC cis rs9896933 0.708 rs9908751 ENSG00000263063.1 RP11-388C12.1 4.12 4.71e-05 0.00991 0.27 0.22 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82833954 chr17:82713908~82716255:- LIHC cis rs75920871 0.589 rs2306473 ENSG00000254851.1 RP11-109L13.1 -4.12 4.71e-05 0.00991 -0.41 -0.22 Subjective well-being; chr11:117227236 chr11:117135528~117138582:+ LIHC cis rs804280 1 rs804280 ENSG00000255495.1 AC145124.2 4.12 4.71e-05 0.00991 0.28 0.22 Myopia (pathological); chr8:11755189 chr8:12194467~12196280:+ LIHC cis rs734999 0.505 rs4073285 ENSG00000225931.3 RP3-395M20.7 4.12 4.71e-05 0.00991 0.23 0.22 Ulcerative colitis; chr1:2608357 chr1:2566410~2569888:+ LIHC cis rs1799949 1 rs16941 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.71e-05 0.00991 -0.21 -0.22 Menopause (age at onset); chr17:43092418 chr17:43144956~43145255:+ LIHC cis rs638893 0.636 rs2186781 ENSG00000278376.1 RP11-158I9.8 -4.12 4.72e-05 0.00992 -0.39 -0.22 Vitiligo; chr11:118734738 chr11:118791254~118793137:+ LIHC cis rs7809950 0.678 rs2107317 ENSG00000238832.1 snoU109 -4.12 4.72e-05 0.00992 -0.28 -0.22 Coronary artery disease; chr7:107259240 chr7:107603363~107603507:+ LIHC cis rs875971 0.545 rs1796226 ENSG00000273142.1 RP11-458F8.4 4.12 4.72e-05 0.00992 0.21 0.22 Aortic root size; chr7:66622723 chr7:66902857~66906297:+ LIHC cis rs11096990 0.613 rs7690414 ENSG00000249685.1 RP11-360F5.3 4.12 4.72e-05 0.00992 0.26 0.22 Cognitive function; chr4:39210669 chr4:39133913~39135608:+ LIHC cis rs11096990 0.593 rs7685619 ENSG00000249685.1 RP11-360F5.3 4.12 4.72e-05 0.00992 0.26 0.22 Cognitive function; chr4:39211779 chr4:39133913~39135608:+ LIHC cis rs2439831 0.681 rs11858152 ENSG00000166763.7 STRCP1 4.12 4.72e-05 0.00993 0.3 0.22 Lung cancer in ever smokers; chr15:43341998 chr15:43699488~43718184:- LIHC cis rs2562456 0.652 rs62110214 ENSG00000268555.1 RP11-678G14.3 4.12 4.72e-05 0.00993 0.29 0.22 Pain; chr19:21592406 chr19:21570822~21587322:- LIHC cis rs2299116 1 rs35910392 ENSG00000225264.3 ZNRF2P2 4.12 4.73e-05 0.00994 0.25 0.22 Serum thyroid-stimulating hormone levels; chr7:28778195 chr7:29598795~29685255:- LIHC cis rs1577917 1 rs7760207 ENSG00000234155.1 RP11-30P6.6 4.12 4.73e-05 0.00994 0.28 0.22 Response to antipsychotic treatment; chr6:86011982 chr6:85387219~85390186:- LIHC cis rs860295 0.871 rs6696888 ENSG00000203761.5 MSTO2P 4.12 4.73e-05 0.00994 0.18 0.22 Body mass index; chr1:155539091 chr1:155745829~155750137:+ LIHC cis rs597539 0.552 rs6591360 ENSG00000250508.1 RP11-757G1.6 -4.12 4.73e-05 0.00994 -0.34 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68951200 chr11:68870664~68874542:+ LIHC cis rs13287066 0.692 rs2184255 ENSG00000227603.1 RP11-165J3.6 -4.12 4.73e-05 0.00995 -0.25 -0.22 Intelligence (multi-trait analysis); chr9:93413921 chr9:93435332~93437121:- LIHC cis rs875971 0.528 rs801213 ENSG00000228409.4 CCT6P1 4.12 4.73e-05 0.00995 0.18 0.22 Aortic root size; chr7:66549931 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs801212 ENSG00000228409.4 CCT6P1 4.12 4.73e-05 0.00995 0.18 0.22 Aortic root size; chr7:66550643 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs73152714 ENSG00000228409.4 CCT6P1 -4.12 4.73e-05 0.00995 -0.18 -0.22 Aortic root size; chr7:66534641 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs4718364 ENSG00000228409.4 CCT6P1 -4.12 4.73e-05 0.00995 -0.18 -0.22 Aortic root size; chr7:66536353 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs6961853 ENSG00000228409.4 CCT6P1 -4.12 4.73e-05 0.00995 -0.18 -0.22 Aortic root size; chr7:66537035 chr7:65751142~65763354:+ LIHC cis rs1799949 1 rs33946455 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.73e-05 0.00995 -0.21 -0.22 Menopause (age at onset); chr17:43169829 chr17:43144956~43145255:+ LIHC cis rs3015497 0.648 rs10144512 ENSG00000269906.1 RP11-248J18.2 4.12 4.74e-05 0.00996 0.27 0.22 Mean platelet volume; chr14:50615553 chr14:50662511~50663178:- LIHC cis rs763121 0.853 rs6519120 ENSG00000273076.1 RP3-508I15.22 -4.12 4.74e-05 0.00996 -0.26 -0.22 Menopause (age at onset); chr22:38595388 chr22:38743495~38743910:+ LIHC cis rs10833905 0.775 rs10833889 ENSG00000246225.5 RP11-17A1.3 -4.12 4.74e-05 0.00996 -0.28 -0.22 Sudden cardiac arrest; chr11:23001805 chr11:22829380~22945393:+ LIHC cis rs858239 0.965 rs156429 ENSG00000226816.2 AC005082.12 4.12 4.74e-05 0.00996 0.27 0.22 Cerebrospinal fluid biomarker levels; chr7:23266401 chr7:23206013~23208045:+ LIHC cis rs1005277 0.579 rs2472183 ENSG00000275858.1 RP11-291L22.8 4.12 4.74e-05 0.00996 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:38103567 chr10:38450738~38451069:- LIHC cis rs3015497 0.616 rs10131107 ENSG00000269906.1 RP11-248J18.2 4.12 4.74e-05 0.00997 0.27 0.22 Mean platelet volume; chr14:50595737 chr14:50662511~50663178:- LIHC cis rs9652601 0.881 rs11860603 ENSG00000274038.1 RP11-66H6.4 -4.12 4.74e-05 0.00997 -0.27 -0.22 Systemic lupus erythematosus; chr16:11071160 chr16:11056556~11057034:+ LIHC cis rs734999 0.545 rs3890745 ENSG00000225931.3 RP3-395M20.7 -4.12 4.75e-05 0.00997 -0.23 -0.22 Ulcerative colitis; chr1:2622185 chr1:2566410~2569888:+ LIHC cis rs801193 0.613 rs2016325 ENSG00000273142.1 RP11-458F8.4 4.12 4.75e-05 0.00997 0.23 0.22 Aortic root size; chr7:66858513 chr7:66902857~66906297:+ LIHC cis rs8005677 0.741 rs1043675 ENSG00000257285.4 RP11-298I3.1 -4.12 4.75e-05 0.00997 -0.22 -0.22 Cognitive ability (multi-trait analysis); chr14:22987106 chr14:22929609~22955562:+ LIHC cis rs748404 0.631 rs28702649 ENSG00000166763.7 STRCP1 4.12 4.75e-05 0.00998 0.27 0.22 Lung cancer; chr15:43356431 chr15:43699488~43718184:- LIHC cis rs597539 0.652 rs627731 ENSG00000250508.1 RP11-757G1.6 -4.12 4.75e-05 0.00998 -0.34 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68931195 chr11:68870664~68874542:+ LIHC cis rs8040855 0.627 rs17540307 ENSG00000259295.5 CSPG4P12 4.12 4.75e-05 0.00998 0.34 0.22 Bulimia nervosa; chr15:85090614 chr15:85191438~85213905:+ LIHC cis rs6545883 0.524 rs17482440 ENSG00000271889.1 RP11-493E12.1 -4.12 4.75e-05 0.00998 -0.26 -0.22 Tuberculosis; chr2:61321722 chr2:61151433~61162105:- LIHC cis rs875971 0.545 rs2173571 ENSG00000228409.4 CCT6P1 -4.12 4.75e-05 0.00998 -0.18 -0.22 Aortic root size; chr7:66305392 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs11770063 ENSG00000228409.4 CCT6P1 -4.12 4.75e-05 0.00998 -0.18 -0.22 Aortic root size; chr7:66318029 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs3936065 ENSG00000228409.4 CCT6P1 -4.12 4.75e-05 0.00998 -0.18 -0.22 Aortic root size; chr7:66325577 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs4718335 ENSG00000228409.4 CCT6P1 -4.12 4.75e-05 0.00998 -0.18 -0.22 Aortic root size; chr7:66339619 chr7:65751142~65763354:+ LIHC cis rs3020736 0.5 rs1801311 ENSG00000226450.2 CYP2D8P -4.12 4.75e-05 0.00998 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42090719 chr22:42149886~42155001:- LIHC cis rs7809950 0.834 rs2712199 ENSG00000238832.1 snoU109 -4.12 4.76e-05 0.00999 -0.27 -0.22 Coronary artery disease; chr7:107499794 chr7:107603363~107603507:+ LIHC cis rs10129255 1 rs10141557 ENSG00000224373.3 IGHV4-59 4.12 4.76e-05 0.00999 0.18 0.22 Kawasaki disease; chr14:106767990 chr14:106627249~106627825:- LIHC cis rs57675369 1 rs57675369 ENSG00000251000.1 AC008592.3 4.12 4.76e-05 0.00999 0.37 0.22 Immature fraction of reticulocytes; chr5:95826714 chr5:95834424~95835046:- LIHC cis rs3015497 0.753 rs4643225 ENSG00000269906.1 RP11-248J18.2 4.12 4.76e-05 0.00999 0.28 0.22 Mean platelet volume; chr14:50655487 chr14:50662511~50663178:- LIHC cis rs2581828 0.609 rs73088342 ENSG00000242142.1 SERBP1P3 -4.12 4.76e-05 0.00999 -0.28 -0.22 Crohn's disease; chr3:53117648 chr3:53064283~53065091:- LIHC cis rs2581828 0.646 rs6783748 ENSG00000242142.1 SERBP1P3 -4.12 4.76e-05 0.00999 -0.28 -0.22 Crohn's disease; chr3:53119415 chr3:53064283~53065091:- LIHC cis rs2243480 1 rs12698509 ENSG00000230295.1 RP11-458F8.2 -4.12 4.76e-05 0.00999 -0.23 -0.22 Diabetic kidney disease; chr7:65953889 chr7:66880708~66882981:+ LIHC cis rs763121 0.925 rs17032 ENSG00000273076.1 RP3-508I15.22 4.12 4.76e-05 0.01 0.23 0.22 Menopause (age at onset); chr22:38734838 chr22:38743495~38743910:+ LIHC cis rs57502260 0.704 rs72936570 ENSG00000212093.1 AP000807.1 4.12 4.76e-05 0.01 0.3 0.22 Total body bone mineral density (age 45-60); chr11:68539671 chr11:68506083~68506166:- LIHC cis rs11690935 0.731 rs10930491 ENSG00000228389.1 AC068039.4 -4.12 4.76e-05 0.01 -0.26 -0.22 Schizophrenia; chr2:171713314 chr2:171773482~171775844:+ LIHC cis rs7586604 0.608 rs10204617 ENSG00000230393.1 AC092667.2 4.12 4.76e-05 0.01 0.28 0.22 Cannabis dependence symptom count; chr2:99789291 chr2:100104919~100107504:+ LIHC cis rs7586604 0.608 rs62147565 ENSG00000230393.1 AC092667.2 4.12 4.76e-05 0.01 0.28 0.22 Cannabis dependence symptom count; chr2:99792258 chr2:100104919~100107504:+ LIHC cis rs7586604 0.608 rs2309650 ENSG00000230393.1 AC092667.2 4.12 4.76e-05 0.01 0.28 0.22 Cannabis dependence symptom count; chr2:99792312 chr2:100104919~100107504:+ LIHC cis rs950169 0.96 rs35159785 ENSG00000225151.9 GOLGA2P7 -4.12 4.77e-05 0.01 -0.3 -0.22 Schizophrenia; chr15:84135262 chr15:84199311~84230136:- LIHC cis rs1799949 1 rs35668327 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.77e-05 0.01 -0.21 -0.22 Menopause (age at onset); chr17:43121078 chr17:43144956~43145255:+ LIHC cis rs12554020 1 rs12335532 ENSG00000227603.1 RP11-165J3.6 4.12 4.77e-05 0.01 0.26 0.22 Schizophrenia; chr9:93431673 chr9:93435332~93437121:- LIHC cis rs9907295 0.901 rs4251729 ENSG00000270871.1 AC015849.19 4.12 4.77e-05 0.01 0.23 0.22 Fibroblast growth factor basic levels; chr17:35818348 chr17:35816717~35830293:- LIHC cis rs929596 0.793 rs2741044 ENSG00000233445.1 RPL17P11 4.12 4.77e-05 0.01 0.32 0.22 Total bilirubin levels in HIV-1 infection; chr2:233670722 chr2:233721522~233722065:- LIHC cis rs4650994 1 rs10913568 ENSG00000273384.1 RP5-1098D14.1 4.12 4.77e-05 0.01 0.27 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178544276 chr1:178651706~178652282:+ LIHC cis rs2243480 0.831 rs7806717 ENSG00000232546.1 RP11-458F8.1 4.12 4.77e-05 0.01 0.24 0.22 Diabetic kidney disease; chr7:65928187 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs78803505 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65917585 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs34933526 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65918212 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs34577383 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65920739 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs6949812 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65922114 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs6970243 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65923503 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs7794661 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65924743 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs7795242 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65925107 chr7:66848496~66858136:+ LIHC cis rs2243480 0.708 rs35310401 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65925372 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs35058610 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65925938 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs2177703 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65926730 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs35432774 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65928032 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs56985706 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65929575 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs60683927 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65929781 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs58062456 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65929865 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs34529418 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65938222 chr7:66848496~66858136:+ LIHC cis rs2243480 0.901 rs35087093 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65940221 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs35046236 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65943626 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs36068983 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65944004 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs68189316 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65944182 chr7:66848496~66858136:+ LIHC cis rs2243480 0.803 rs34804747 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65947955 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs11538349 ENSG00000232546.1 RP11-458F8.1 -4.12 4.77e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:65956884 chr7:66848496~66858136:+ LIHC cis rs3812762 0.879 rs10743088 ENSG00000254860.4 TMEM9B-AS1 -4.12 4.77e-05 0.01 -0.23 -0.22 Hypospadias; chr11:8766073 chr11:8964675~8977527:+ LIHC cis rs4650994 1 rs10798615 ENSG00000273384.1 RP5-1098D14.1 4.12 4.78e-05 0.01 0.27 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178544760 chr1:178651706~178652282:+ LIHC cis rs2070488 0.965 rs1065800 ENSG00000229589.1 ACVR2B-AS1 -4.12 4.78e-05 0.01 -0.25 -0.22 Electrocardiographic conduction measures; chr3:38524989 chr3:38451027~38454820:- LIHC cis rs6480314 0.831 rs6480318 ENSG00000233590.1 RP11-153K11.3 -4.12 4.78e-05 0.01 -0.3 -0.22 Optic nerve measurement (disc area); chr10:68224348 chr10:68233251~68242379:- LIHC cis rs4266144 0.558 rs4680339 ENSG00000244515.1 KRT18P34 4.12 4.78e-05 0.01 0.21 0.22 Coronary artery disease; chr3:157117630 chr3:157162663~157163932:- LIHC cis rs2877649 0.793 rs79461934 ENSG00000258744.1 RP11-80A15.1 -4.12 4.78e-05 0.01 -0.45 -0.22 Smooth-surface caries; chr14:24485438 chr14:24501594~24508688:+ LIHC cis rs2877649 0.793 rs112628162 ENSG00000258744.1 RP11-80A15.1 -4.12 4.78e-05 0.01 -0.45 -0.22 Smooth-surface caries; chr14:24491459 chr14:24501594~24508688:+ LIHC cis rs2877649 0.793 rs76857510 ENSG00000258744.1 RP11-80A15.1 -4.12 4.78e-05 0.01 -0.45 -0.22 Smooth-surface caries; chr14:24498552 chr14:24501594~24508688:+ LIHC cis rs11098499 0.644 rs3986377 ENSG00000245958.5 RP11-33B1.1 -4.12 4.78e-05 0.01 -0.21 -0.22 Corneal astigmatism; chr4:119339115 chr4:119454791~119552025:+ LIHC cis rs10028773 0.556 rs4473640 ENSG00000245958.5 RP11-33B1.1 -4.12 4.78e-05 0.01 -0.21 -0.22 Educational attainment; chr4:119339282 chr4:119454791~119552025:+ LIHC cis rs2842992 0.724 rs9365097 ENSG00000237927.1 RP3-393E18.2 -4.12 4.78e-05 0.01 -0.26 -0.22 Age-related macular degeneration (geographic atrophy); chr6:159790227 chr6:159586955~159589169:- LIHC cis rs1799949 1 rs67060599 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.78e-05 0.01 -0.21 -0.22 Menopause (age at onset); chr17:43103085 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs8176133 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.78e-05 0.01 -0.21 -0.22 Menopause (age at onset); chr17:43105441 chr17:43144956~43145255:+ LIHC cis rs7474896 0.616 rs2474561 ENSG00000120555.12 SEPT7P9 4.12 4.78e-05 0.01 0.29 0.22 Obesity (extreme); chr10:38084616 chr10:38383069~38402916:- LIHC cis rs6433895 0.71 rs34467063 ENSG00000236153.1 AC104076.3 -4.12 4.79e-05 0.01 -0.32 -0.22 Lymphocyte counts; chr2:181149252 chr2:180979427~180980090:- LIHC cis rs2243480 1 rs2533288 ENSG00000232546.1 RP11-458F8.1 -4.12 4.79e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:66591724 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs2707844 ENSG00000232546.1 RP11-458F8.1 -4.12 4.79e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:66594522 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1796220 ENSG00000232546.1 RP11-458F8.1 -4.12 4.79e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:66597113 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs2707831 ENSG00000232546.1 RP11-458F8.1 -4.12 4.79e-05 0.01 -0.24 -0.22 Diabetic kidney disease; chr7:66597524 chr7:66848496~66858136:+ LIHC cis rs4970988 0.607 rs7548516 ENSG00000231073.1 RP11-316M1.3 -4.12 4.79e-05 0.01 -0.23 -0.22 Urate levels; chr1:151007805 chr1:150973123~150975534:+ LIHC cis rs617219 0.889 rs1316776 ENSG00000251675.1 CTC-458I2.2 -4.12 4.79e-05 0.01 -0.24 -0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79134784 chr5:80128361~80143883:+ LIHC cis rs617219 0.889 rs10042338 ENSG00000251675.1 CTC-458I2.2 -4.12 4.79e-05 0.01 -0.24 -0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79135254 chr5:80128361~80143883:+ LIHC cis rs1223397 0.938 rs34505804 ENSG00000215022.6 RP1-257A7.4 -4.12 4.79e-05 0.01 -0.29 -0.22 Blood pressure; chr6:13292282 chr6:13264861~13295586:- LIHC cis rs9527 0.59 rs10786741 ENSG00000236937.2 PTGES3P4 4.12 4.79e-05 0.01 0.28 0.22 Arsenic metabolism; chr10:103179425 chr10:102845595~102845950:+ LIHC cis rs950169 1 rs79318564 ENSG00000259728.4 LINC00933 4.12 4.79e-05 0.01 0.35 0.22 Schizophrenia; chr15:84117398 chr15:84570649~84580175:+ LIHC cis rs950169 1 rs1911155 ENSG00000259728.4 LINC00933 4.12 4.79e-05 0.01 0.35 0.22 Schizophrenia; chr15:84118883 chr15:84570649~84580175:+ LIHC cis rs11098499 0.863 rs58452170 ENSG00000260091.1 RP11-33B1.4 -4.12 4.79e-05 0.01 -0.16 -0.22 Corneal astigmatism; chr4:119538519 chr4:119409333~119410233:+ LIHC cis rs2439831 0.867 rs2260160 ENSG00000166763.7 STRCP1 4.12 4.79e-05 0.01 0.34 0.22 Lung cancer in ever smokers; chr15:43603445 chr15:43699488~43718184:- LIHC cis rs160451 0.899 rs218918 ENSG00000251136.7 RP11-37B2.1 -4.12 4.79e-05 0.0101 -0.2 -0.22 Leprosy; chr8:89690153 chr8:89609409~89757727:- LIHC cis rs6472235 0.656 rs72650541 ENSG00000272010.1 CTD-3025N20.3 -4.12 4.8e-05 0.0101 -0.3 -0.22 Plateletcrit;Myopia (pathological); chr8:65966056 chr8:65591850~65592472:- LIHC cis rs6472235 0.656 rs62506593 ENSG00000272010.1 CTD-3025N20.3 -4.12 4.8e-05 0.0101 -0.3 -0.22 Plateletcrit;Myopia (pathological); chr8:65966114 chr8:65591850~65592472:- LIHC cis rs6472235 0.656 rs16932382 ENSG00000272010.1 CTD-3025N20.3 -4.12 4.8e-05 0.0101 -0.3 -0.22 Plateletcrit;Myopia (pathological); chr8:65966241 chr8:65591850~65592472:- LIHC cis rs7811142 0.943 rs3900792 ENSG00000242294.5 STAG3L5P 4.12 4.8e-05 0.0101 0.24 0.22 Platelet count; chr7:100406954 chr7:100336079~100351900:+ LIHC cis rs1223397 0.702 rs13191897 ENSG00000215022.6 RP1-257A7.4 -4.12 4.8e-05 0.0101 -0.29 -0.22 Blood pressure; chr6:13288196 chr6:13264861~13295586:- LIHC cis rs4578769 0.765 rs11082147 ENSG00000266850.1 RP11-370A5.1 -4.12 4.8e-05 0.0101 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22806559 chr18:22723491~22907721:- LIHC cis rs1799949 1 rs33994002 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.8e-05 0.0101 -0.21 -0.22 Menopause (age at onset); chr17:43176801 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs33920795 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.8e-05 0.0101 -0.21 -0.22 Menopause (age at onset); chr17:43176993 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs33918839 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.8e-05 0.0101 -0.21 -0.22 Menopause (age at onset); chr17:43177155 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs11653231 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.8e-05 0.0101 -0.21 -0.22 Menopause (age at onset); chr17:43179443 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs1399323 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.8e-05 0.0101 -0.21 -0.22 Menopause (age at onset); chr17:43180313 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs35954893 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.8e-05 0.0101 -0.21 -0.22 Menopause (age at onset); chr17:43181769 chr17:43144956~43145255:+ LIHC cis rs1799949 0.93 rs4445938 ENSG00000267681.1 CTD-3199J23.6 -4.12 4.8e-05 0.0101 -0.21 -0.22 Menopause (age at onset); chr17:43185883 chr17:43144956~43145255:+ LIHC cis rs2243480 1 rs313832 ENSG00000232546.1 RP11-458F8.1 -4.12 4.8e-05 0.0101 -0.24 -0.22 Diabetic kidney disease; chr7:66085904 chr7:66848496~66858136:+ LIHC cis rs2320952 0.874 rs11078853 ENSG00000264016.2 CTC-297N7.9 -4.12 4.81e-05 0.0101 -0.23 -0.22 Gut microbiome composition (winter); chr17:10588844 chr17:10741267~10769016:- LIHC cis rs4578769 0.765 rs16972427 ENSG00000266850.1 RP11-370A5.1 -4.12 4.81e-05 0.0101 -0.26 -0.22 Eosinophil percentage of white cells; chr18:22833393 chr18:22723491~22907721:- LIHC cis rs703842 0.616 rs10783851 ENSG00000270039.1 RP11-571M6.17 4.12 4.81e-05 0.0101 0.31 0.22 Multiple sclerosis; chr12:57837372 chr12:57803838~57804415:+ LIHC cis rs603446 0.586 rs1787690 ENSG00000254851.1 RP11-109L13.1 4.12 4.81e-05 0.0101 0.28 0.22 Triglycerides; chr11:116697800 chr11:117135528~117138582:+ LIHC cis rs603446 0.586 rs947986 ENSG00000254851.1 RP11-109L13.1 4.12 4.81e-05 0.0101 0.28 0.22 Triglycerides; chr11:116698488 chr11:117135528~117138582:+ LIHC cis rs481331 0.741 rs7072200 ENSG00000185904.10 LINC00839 4.12 4.81e-05 0.0101 0.4 0.22 Systemic juvenile idiopathic arthritis; chr10:42657970 chr10:42475543~42495336:+ LIHC cis rs6442522 0.809 rs13081119 ENSG00000249786.6 EAF1-AS1 -4.12 4.81e-05 0.0101 -0.25 -0.22 Uric acid levels; chr3:15409514 chr3:15436171~15455940:- LIHC cis rs734999 0.588 rs2260976 ENSG00000225931.3 RP3-395M20.7 -4.12 4.81e-05 0.0101 -0.23 -0.22 Ulcerative colitis; chr1:2596239 chr1:2566410~2569888:+ LIHC cis rs10833905 1 rs77438393 ENSG00000246225.5 RP11-17A1.3 -4.12 4.82e-05 0.0101 -0.28 -0.22 Sudden cardiac arrest; chr11:22991177 chr11:22829380~22945393:+ LIHC cis rs160451 0.966 rs28374917 ENSG00000251136.7 RP11-37B2.1 4.12 4.82e-05 0.0101 0.19 0.22 Leprosy; chr8:89666525 chr8:89609409~89757727:- LIHC cis rs2739330 0.753 rs4822452 ENSG00000206090.4 AP000350.7 4.12 4.82e-05 0.0101 0.26 0.22 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23939998~23942798:+ LIHC cis rs9907295 0.688 rs4572457 ENSG00000270871.1 AC015849.19 4.12 4.82e-05 0.0101 0.23 0.22 Fibroblast growth factor basic levels; chr17:35813645 chr17:35816717~35830293:- LIHC cis rs2243480 0.803 rs35480979 ENSG00000230295.1 RP11-458F8.2 -4.12 4.82e-05 0.0101 -0.23 -0.22 Diabetic kidney disease; chr7:65892097 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs34637256 ENSG00000230295.1 RP11-458F8.2 -4.12 4.82e-05 0.0101 -0.23 -0.22 Diabetic kidney disease; chr7:65895144 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs35391607 ENSG00000230295.1 RP11-458F8.2 -4.12 4.82e-05 0.0101 -0.23 -0.22 Diabetic kidney disease; chr7:65895842 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs13220979 ENSG00000230295.1 RP11-458F8.2 -4.12 4.82e-05 0.0101 -0.23 -0.22 Diabetic kidney disease; chr7:65898217 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs34974928 ENSG00000230295.1 RP11-458F8.2 -4.12 4.82e-05 0.0101 -0.23 -0.22 Diabetic kidney disease; chr7:65899019 chr7:66880708~66882981:+ LIHC cis rs3015497 0.789 rs10133849 ENSG00000269906.1 RP11-248J18.2 4.12 4.82e-05 0.0101 0.28 0.22 Mean platelet volume; chr14:50654982 chr14:50662511~50663178:- LIHC cis rs6496667 0.509 rs2657948 ENSG00000213471.7 TTLL13P 4.12 4.82e-05 0.0101 0.28 0.22 Rheumatoid arthritis; chr15:90405385 chr15:90249530~90265482:+ LIHC cis rs7923609 0.818 rs10822159 ENSG00000232075.1 MRPL35P2 -4.12 4.82e-05 0.0101 -0.24 -0.22 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63336490 chr10:63634317~63634827:- LIHC cis rs4561483 0.801 rs8061189 ENSG00000261560.1 RP11-166B2.3 4.12 4.82e-05 0.0101 0.25 0.22 Testicular germ cell tumor; chr16:11857892 chr16:11881075~11882569:- LIHC cis rs16958440 1 rs60422392 ENSG00000267724.1 RP11-49K24.8 4.12 4.82e-05 0.0101 0.33 0.22 Sitting height ratio; chr18:47095102 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs2289130 ENSG00000267724.1 RP11-49K24.8 4.12 4.82e-05 0.0101 0.33 0.22 Sitting height ratio; chr18:47100259 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs62096463 ENSG00000267724.1 RP11-49K24.8 4.12 4.82e-05 0.0101 0.33 0.22 Sitting height ratio; chr18:47102557 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs62096464 ENSG00000267724.1 RP11-49K24.8 4.12 4.82e-05 0.0101 0.33 0.22 Sitting height ratio; chr18:47102836 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs16958440 ENSG00000267724.1 RP11-49K24.8 4.12 4.82e-05 0.0101 0.33 0.22 Sitting height ratio; chr18:47106513 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs75800624 ENSG00000267724.1 RP11-49K24.8 4.12 4.82e-05 0.0101 0.33 0.22 Sitting height ratio; chr18:47107234 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs62096466 ENSG00000267724.1 RP11-49K24.8 4.12 4.82e-05 0.0101 0.33 0.22 Sitting height ratio; chr18:47109800 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs76594057 ENSG00000267724.1 RP11-49K24.8 4.12 4.82e-05 0.0101 0.33 0.22 Sitting height ratio; chr18:47110901 chr18:47105946~47108062:+ LIHC cis rs6921919 0.789 rs6456814 ENSG00000216901.1 AL022393.7 4.12 4.82e-05 0.0101 0.27 0.22 Autism spectrum disorder or schizophrenia; chr6:28338035 chr6:28176188~28176674:+ LIHC cis rs755249 0.567 rs113214136 ENSG00000182109.6 RP11-69E11.4 4.12 4.83e-05 0.0101 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39408867 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs3768302 ENSG00000182109.6 RP11-69E11.4 4.12 4.83e-05 0.0101 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39414647 chr1:39522280~39546187:- LIHC cis rs755249 0.532 rs17343193 ENSG00000182109.6 RP11-69E11.4 4.12 4.83e-05 0.0101 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39415796 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs61779300 ENSG00000182109.6 RP11-69E11.4 4.12 4.83e-05 0.0101 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39420091 chr1:39522280~39546187:- LIHC cis rs9487094 0.922 rs9885646 ENSG00000260273.1 RP11-425D10.10 4.12 4.83e-05 0.0101 0.26 0.22 Height; chr6:109421257 chr6:109382795~109383666:+ LIHC cis rs4604234 0.708 rs11966262 ENSG00000272129.1 RP11-250B2.6 -4.12 4.83e-05 0.0101 -0.34 -0.22 Cancer; chr6:80294867 chr6:80355424~80356859:+ LIHC cis rs77972916 0.614 rs80323638 ENSG00000234936.1 AC010883.5 4.12 4.83e-05 0.0101 0.47 0.22 Granulocyte percentage of myeloid white cells; chr2:43242476 chr2:43229573~43233394:+ LIHC cis rs950880 0.71 rs3732123 ENSG00000234389.1 AC007278.3 -4.12 4.83e-05 0.0101 -0.22 -0.22 Serum protein levels (sST2); chr2:102401617 chr2:102438713~102440475:+ LIHC cis rs6893782 0.83 rs274553 ENSG00000233006.5 AC034220.3 -4.12 4.83e-05 0.0101 -0.3 -0.22 Acylcarnitine levels; chr5:132390140 chr5:132311285~132369916:- LIHC cis rs10129255 0.957 rs12590667 ENSG00000211970.3 IGHV4-61 4.12 4.83e-05 0.0101 0.17 0.22 Kawasaki disease; chr14:106779223 chr14:106639119~106639657:- LIHC cis rs10833905 1 rs112686297 ENSG00000246225.5 RP11-17A1.3 -4.12 4.83e-05 0.0101 -0.28 -0.22 Sudden cardiac arrest; chr11:23001448 chr11:22829380~22945393:+ LIHC cis rs2115630 0.936 rs8033459 ENSG00000259295.5 CSPG4P12 -4.12 4.84e-05 0.0101 -0.26 -0.22 P wave terminal force; chr15:84710027 chr15:85191438~85213905:+ LIHC cis rs875971 0.545 rs1909508 ENSG00000273024.4 INTS4P2 -4.12 4.84e-05 0.0101 -0.25 -0.22 Aortic root size; chr7:66301366 chr7:65647864~65715661:+ LIHC cis rs13113518 0.812 rs2035692 ENSG00000249700.7 SRD5A3-AS1 4.12 4.84e-05 0.0101 0.25 0.22 Height; chr4:55528801 chr4:55363971~55395847:- LIHC cis rs13113518 0.812 rs4507426 ENSG00000249700.7 SRD5A3-AS1 4.12 4.84e-05 0.0101 0.25 0.22 Height; chr4:55529387 chr4:55363971~55395847:- LIHC cis rs1247318 1 rs1247302 ENSG00000243831.1 RP1-81D8.4 4.12 4.84e-05 0.0101 0.31 0.22 Aging; chr6:160925412 chr6:160666228~160676523:- LIHC cis rs1005277 0.522 rs9418276 ENSG00000275858.1 RP11-291L22.8 4.12 4.84e-05 0.0101 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:37651188 chr10:38450738~38451069:- LIHC cis rs1005277 0.522 rs7072977 ENSG00000275858.1 RP11-291L22.8 4.12 4.84e-05 0.0101 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:37651512 chr10:38450738~38451069:- LIHC cis rs4650994 1 rs4650994 ENSG00000273384.1 RP5-1098D14.1 -4.12 4.84e-05 0.0101 -0.26 -0.22 HDL cholesterol;HDL cholesterol levels; chr1:178546177 chr1:178651706~178652282:+ LIHC cis rs11098499 0.909 rs28555550 ENSG00000260091.1 RP11-33B1.4 -4.12 4.84e-05 0.0101 -0.16 -0.22 Corneal astigmatism; chr4:119289885 chr4:119409333~119410233:+ LIHC cis rs11098499 1 rs28419773 ENSG00000260091.1 RP11-33B1.4 -4.12 4.84e-05 0.0101 -0.16 -0.22 Corneal astigmatism; chr4:119289906 chr4:119409333~119410233:+ LIHC cis rs11098499 1 rs11726229 ENSG00000260091.1 RP11-33B1.4 -4.12 4.84e-05 0.0101 -0.16 -0.22 Corneal astigmatism; chr4:119290425 chr4:119409333~119410233:+ LIHC cis rs853679 0.76 rs9393910 ENSG00000219392.1 RP1-265C24.5 -4.12 4.84e-05 0.0101 -0.34 -0.22 Depression; chr6:28240414 chr6:28115628~28116551:+ LIHC cis rs853679 0.76 rs9368563 ENSG00000219392.1 RP1-265C24.5 -4.12 4.84e-05 0.0101 -0.34 -0.22 Depression; chr6:28240780 chr6:28115628~28116551:+ LIHC cis rs853679 0.76 rs9295768 ENSG00000219392.1 RP1-265C24.5 -4.12 4.84e-05 0.0101 -0.34 -0.22 Depression; chr6:28241324 chr6:28115628~28116551:+ LIHC cis rs853679 0.699 rs9468318 ENSG00000219392.1 RP1-265C24.5 -4.12 4.84e-05 0.0101 -0.34 -0.22 Depression; chr6:28241753 chr6:28115628~28116551:+ LIHC cis rs853679 0.76 rs9357067 ENSG00000219392.1 RP1-265C24.5 -4.12 4.84e-05 0.0101 -0.34 -0.22 Depression; chr6:28242515 chr6:28115628~28116551:+ LIHC cis rs7809950 0.678 rs2237665 ENSG00000238832.1 snoU109 -4.12 4.85e-05 0.0101 -0.28 -0.22 Coronary artery disease; chr7:107266553 chr7:107603363~107603507:+ LIHC cis rs10871290 1 rs11149710 ENSG00000261079.1 RP11-252A24.3 -4.12 4.85e-05 0.0101 -0.25 -0.22 Breast cancer; chr16:74438648 chr16:74367462~74369826:+ LIHC cis rs6710529 1 rs6710529 ENSG00000272555.1 RP11-459I19.1 -4.12 4.85e-05 0.0101 -0.23 -0.22 Lobe attachment (rater-scored or self-reported); chr2:218780830 chr2:218818690~218819144:+ LIHC cis rs2749592 0.55 rs4934881 ENSG00000275858.1 RP11-291L22.8 -4.12 4.85e-05 0.0101 -0.24 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37625418 chr10:38450738~38451069:- LIHC cis rs2976388 0.59 rs3736011 ENSG00000253196.1 RP11-706C16.7 -4.12 4.85e-05 0.0101 -0.22 -0.22 Urinary tract infection frequency; chr8:142736371 chr8:142763116~142766427:+ LIHC cis rs2976388 0.59 rs7828042 ENSG00000253196.1 RP11-706C16.7 -4.12 4.85e-05 0.0101 -0.22 -0.22 Urinary tract infection frequency; chr8:142737965 chr8:142763116~142766427:+ LIHC cis rs2976388 0.59 rs10110970 ENSG00000253196.1 RP11-706C16.7 -4.12 4.85e-05 0.0101 -0.22 -0.22 Urinary tract infection frequency; chr8:142738992 chr8:142763116~142766427:+ LIHC cis rs6679677 0.543 rs1230680 ENSG00000232450.1 RP4-730K3.3 -4.12 4.85e-05 0.0101 -0.29 -0.22 Rheumatoid arthritis;Monokine induced by gamma interferon levels;Type 1 diabetes;Hypothyroidism;Systemic lupus erythematosus;Pediatric autoimmune diseases;Crohn's disease;Antineutrophil cytoplasmic antibody-associated vasculitis; chr1:113754148 chr1:113698884~113699631:- LIHC cis rs7712401 0.601 rs34126945 ENSG00000263432.2 RN7SL689P -4.12 4.85e-05 0.0101 -0.32 -0.22 Mean platelet volume; chr5:122994034 chr5:123022487~123022783:- LIHC cis rs6142102 0.58 rs761233 ENSG00000275784.1 RP5-1125A11.6 -4.12 4.85e-05 0.0102 -0.23 -0.22 Skin pigmentation; chr20:33981080 chr20:33989480~33991818:- LIHC cis rs6997458 0.874 rs13252971 ENSG00000253549.4 RP11-317J10.2 4.12 4.85e-05 0.0102 0.23 0.22 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85357055 chr8:85441851~85464915:- LIHC cis rs2070488 0.965 rs2051216 ENSG00000229589.1 ACVR2B-AS1 -4.12 4.85e-05 0.0102 -0.25 -0.22 Electrocardiographic conduction measures; chr3:38520797 chr3:38451027~38454820:- LIHC cis rs41341749 0.831 rs854684 ENSG00000275944.1 RP11-104J23.1 -4.12 4.86e-05 0.0102 -0.21 -0.22 Blood protein levels; chr17:35985179 chr17:36001419~36011618:+ LIHC cis rs7412746 0.611 rs4319334 ENSG00000231073.1 RP11-316M1.3 4.11 4.86e-05 0.0102 0.22 0.22 Melanoma; chr1:150794346 chr1:150973123~150975534:+ LIHC cis rs13217239 0.646 rs10946898 ENSG00000241549.7 GUSBP2 4.11 4.86e-05 0.0102 0.22 0.22 Schizophrenia; chr6:27036105 chr6:26871484~26956554:- LIHC cis rs13217239 0.646 rs12527111 ENSG00000241549.7 GUSBP2 4.11 4.86e-05 0.0102 0.22 0.22 Schizophrenia; chr6:27038696 chr6:26871484~26956554:- LIHC cis rs6456156 0.586 rs9459862 ENSG00000227598.1 RP1-167A14.2 4.11 4.86e-05 0.0102 0.23 0.22 Primary biliary cholangitis; chr6:167073523 chr6:166969626~166999065:- LIHC cis rs67311347 0.544 rs1902073 ENSG00000223797.4 ENTPD3-AS1 4.11 4.86e-05 0.0102 0.18 0.22 Renal cell carcinoma; chr3:40292006 chr3:40313802~40453329:- LIHC cis rs11096990 0.634 rs4975001 ENSG00000249685.1 RP11-360F5.3 -4.11 4.86e-05 0.0102 -0.26 -0.22 Cognitive function; chr4:39264844 chr4:39133913~39135608:+ LIHC cis rs11096990 0.656 rs6531710 ENSG00000249685.1 RP11-360F5.3 -4.11 4.87e-05 0.0102 -0.26 -0.22 Cognitive function; chr4:39300658 chr4:39133913~39135608:+ LIHC cis rs2749592 0.55 rs10764135 ENSG00000276805.1 RP11-291L22.6 -4.11 4.87e-05 0.0102 -0.26 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37577917 chr10:38451030~38451785:+ LIHC cis rs2749592 0.55 rs12255038 ENSG00000276805.1 RP11-291L22.6 -4.11 4.87e-05 0.0102 -0.26 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37580404 chr10:38451030~38451785:+ LIHC cis rs2749592 0.505 rs7915670 ENSG00000276805.1 RP11-291L22.6 -4.11 4.87e-05 0.0102 -0.26 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37581284 chr10:38451030~38451785:+ LIHC cis rs7208859 0.623 rs122898 ENSG00000266490.1 CTD-2349P21.9 -4.11 4.87e-05 0.0102 -0.27 -0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30578236 chr17:30792372~30792833:+ LIHC cis rs901683 1 rs34268168 ENSG00000230869.1 CTGLF10P -4.11 4.87e-05 0.0102 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45493078 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12774690 ENSG00000230869.1 CTGLF10P -4.11 4.87e-05 0.0102 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45494297 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71499566 ENSG00000230869.1 CTGLF10P -4.11 4.87e-05 0.0102 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45500567 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71494799 ENSG00000230869.1 CTGLF10P -4.11 4.87e-05 0.0102 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45507408 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71496611 ENSG00000230869.1 CTGLF10P -4.11 4.87e-05 0.0102 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45526284 chr10:45678692~45700532:+ LIHC cis rs7916410 0.505 rs11595406 ENSG00000233590.1 RP11-153K11.3 -4.11 4.87e-05 0.0102 -0.31 -0.22 Optic disc area; chr10:68185542 chr10:68233251~68242379:- LIHC cis rs34787248 1 rs34787248 ENSG00000219392.1 RP1-265C24.5 -4.11 4.87e-05 0.0102 -0.34 -0.22 Autism spectrum disorder or schizophrenia; chr6:28230108 chr6:28115628~28116551:+ LIHC cis rs1577917 1 rs34281561 ENSG00000234155.1 RP11-30P6.6 4.11 4.87e-05 0.0102 0.28 0.22 Response to antipsychotic treatment; chr6:85992154 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs35419329 ENSG00000234155.1 RP11-30P6.6 4.11 4.87e-05 0.0102 0.28 0.22 Response to antipsychotic treatment; chr6:85992573 chr6:85387219~85390186:- LIHC cis rs2439831 1 rs689596 ENSG00000166763.7 STRCP1 4.11 4.87e-05 0.0102 0.3 0.22 Lung cancer in ever smokers; chr15:43469519 chr15:43699488~43718184:- LIHC cis rs11098499 0.82 rs11737395 ENSG00000260091.1 RP11-33B1.4 -4.11 4.88e-05 0.0102 -0.16 -0.22 Corneal astigmatism; chr4:119599549 chr4:119409333~119410233:+ LIHC cis rs13315871 0.585 rs12107189 ENSG00000272182.1 RP11-802O23.3 4.11 4.88e-05 0.0102 0.42 0.22 Cholesterol, total; chr3:58363295 chr3:58428255~58428815:+ LIHC cis rs864537 0.618 rs2988277 ENSG00000273160.1 RP11-104L21.3 -4.11 4.88e-05 0.0102 -0.3 -0.22 Celiac disease or Rheumatoid arthritis;Celiac disease; chr1:167462115 chr1:167457742~167459891:- LIHC cis rs11096990 0.855 rs2566168 ENSG00000249207.1 RP11-360F5.1 4.11 4.88e-05 0.0102 0.25 0.22 Cognitive function; chr4:39150053 chr4:39112677~39126818:- LIHC cis rs6433895 0.677 rs72888919 ENSG00000236153.1 AC104076.3 -4.11 4.89e-05 0.0102 -0.28 -0.22 Lymphocyte counts; chr2:181162274 chr2:180979427~180980090:- LIHC cis rs11098499 1 rs6849889 ENSG00000260091.1 RP11-33B1.4 -4.11 4.89e-05 0.0102 -0.16 -0.22 Corneal astigmatism; chr4:119265193 chr4:119409333~119410233:+ LIHC cis rs960902 1 rs2192944 ENSG00000213553.4 RPLP0P6 4.11 4.89e-05 0.0102 0.18 0.22 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37504151 chr2:38481851~38482804:+ LIHC cis rs7607369 0.58 rs7568196 ENSG00000272555.1 RP11-459I19.1 -4.11 4.89e-05 0.0102 -0.25 -0.22 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218787650 chr2:218818690~218819144:+ LIHC cis rs2286503 0.65 rs1990279 ENSG00000226329.2 AC005682.6 4.11 4.89e-05 0.0102 0.26 0.22 Fibrinogen; chr7:22851123 chr7:22863874~22881350:- LIHC cis rs2439831 0.681 rs28653441 ENSG00000166763.7 STRCP1 4.11 4.89e-05 0.0102 0.3 0.22 Lung cancer in ever smokers; chr15:43385064 chr15:43699488~43718184:- LIHC cis rs1322639 0.614 rs4708414 ENSG00000261039.2 RP11-417E7.2 -4.11 4.89e-05 0.0102 -0.22 -0.22 Pulse pressure; chr6:169174049 chr6:169175304~169182740:- LIHC cis rs919433 0.889 rs12472355 ENSG00000231621.1 AC013264.2 4.11 4.89e-05 0.0102 0.2 0.22 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197341116 chr2:197197991~197199273:+ LIHC cis rs4650994 1 rs4511075 ENSG00000273384.1 RP5-1098D14.1 4.11 4.9e-05 0.0102 0.27 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178549501 chr1:178651706~178652282:+ LIHC cis rs4650994 1 rs12138541 ENSG00000273384.1 RP5-1098D14.1 4.11 4.9e-05 0.0102 0.27 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178549572 chr1:178651706~178652282:+ LIHC cis rs1799949 1 rs4793194 ENSG00000267681.1 CTD-3199J23.6 -4.11 4.9e-05 0.0102 -0.21 -0.22 Menopause (age at onset); chr17:43066316 chr17:43144956~43145255:+ LIHC cis rs12681287 0.64 rs7007855 ENSG00000254088.1 SLC2A3P4 -4.11 4.9e-05 0.0102 -0.25 -0.22 Caudate activity during reward; chr8:86417262 chr8:86503591~86505061:+ LIHC cis rs12681287 0.57 rs10956830 ENSG00000254088.1 SLC2A3P4 -4.11 4.9e-05 0.0102 -0.25 -0.22 Caudate activity during reward; chr8:86418254 chr8:86503591~86505061:+ LIHC cis rs12681287 0.604 rs28378899 ENSG00000254088.1 SLC2A3P4 -4.11 4.9e-05 0.0102 -0.25 -0.22 Caudate activity during reward; chr8:86422271 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs10098356 ENSG00000254088.1 SLC2A3P4 -4.11 4.9e-05 0.0102 -0.25 -0.22 Caudate activity during reward; chr8:86430438 chr8:86503591~86505061:+ LIHC cis rs2283792 0.819 rs2266965 ENSG00000224086.5 LL22NC03-86G7.1 -4.11 4.9e-05 0.0102 -0.22 -0.22 Multiple sclerosis; chr22:21766866 chr22:21938293~21977632:+ LIHC cis rs7580658 0.545 rs885275 ENSG00000236682.1 AC068282.3 -4.11 4.9e-05 0.0102 -0.27 -0.22 Protein C levels; chr2:127193519 chr2:127389130~127400580:+ LIHC cis rs9907295 0.748 rs4795091 ENSG00000270871.1 AC015849.19 4.11 4.9e-05 0.0102 0.23 0.22 Fibroblast growth factor basic levels; chr17:35814874 chr17:35816717~35830293:- LIHC cis rs9907295 0.71 rs4795092 ENSG00000270871.1 AC015849.19 4.11 4.9e-05 0.0102 0.23 0.22 Fibroblast growth factor basic levels; chr17:35814967 chr17:35816717~35830293:- LIHC cis rs752590 0.774 rs6755077 ENSG00000189223.12 PAX8-AS1 -4.11 4.9e-05 0.0102 -0.35 -0.22 Mucinous ovarian carcinoma; chr2:113195931 chr2:113211522~113276581:+ LIHC cis rs752590 0.887 rs7603621 ENSG00000189223.12 PAX8-AS1 -4.11 4.9e-05 0.0102 -0.35 -0.22 Mucinous ovarian carcinoma; chr2:113196407 chr2:113211522~113276581:+ LIHC cis rs2470135 1 rs2470135 ENSG00000275601.1 AC011330.13 -4.11 4.91e-05 0.0102 -0.26 -0.22 Diastolic blood pressure; chr15:43703591 chr15:43642389~43643023:- LIHC cis rs6142102 0.602 rs4911399 ENSG00000275784.1 RP5-1125A11.6 -4.11 4.91e-05 0.0103 -0.23 -0.22 Skin pigmentation; chr20:34035612 chr20:33989480~33991818:- LIHC cis rs5758659 0.729 rs134866 ENSG00000227370.1 RP4-669P10.19 -4.11 4.91e-05 0.0103 -0.24 -0.22 Cognitive function; chr22:42254657 chr22:42132543~42132998:+ LIHC cis rs5742933 0.857 rs11685425 ENSG00000253559.1 OSGEPL1-AS1 4.11 4.91e-05 0.0103 0.28 0.22 Ferritin levels; chr2:189747977 chr2:189762704~189765556:+ LIHC cis rs7811142 0.83 rs76798830 ENSG00000242294.5 STAG3L5P 4.11 4.92e-05 0.0103 0.25 0.22 Platelet count; chr7:100355205 chr7:100336079~100351900:+ LIHC cis rs7811142 0.775 rs6946768 ENSG00000242294.5 STAG3L5P 4.11 4.92e-05 0.0103 0.25 0.22 Platelet count; chr7:100356770 chr7:100336079~100351900:+ LIHC cis rs11098499 0.722 rs1814814 ENSG00000260091.1 RP11-33B1.4 -4.11 4.92e-05 0.0103 -0.15 -0.22 Corneal astigmatism; chr4:119336969 chr4:119409333~119410233:+ LIHC cis rs7923609 0.812 rs10822155 ENSG00000232075.1 MRPL35P2 -4.11 4.92e-05 0.0103 -0.24 -0.22 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63311455 chr10:63634317~63634827:- LIHC cis rs2439831 1 rs561863 ENSG00000166763.7 STRCP1 4.11 4.92e-05 0.0103 0.3 0.22 Lung cancer in ever smokers; chr15:43469154 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs689616 ENSG00000166763.7 STRCP1 4.11 4.92e-05 0.0103 0.3 0.22 Lung cancer in ever smokers; chr15:43469703 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs689647 ENSG00000166763.7 STRCP1 4.11 4.92e-05 0.0103 0.3 0.22 Lung cancer in ever smokers; chr15:43469998 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs2251538 ENSG00000166763.7 STRCP1 4.11 4.92e-05 0.0103 0.3 0.22 Lung cancer in ever smokers; chr15:43475011 chr15:43699488~43718184:- LIHC cis rs2494250 0.542 rs9782926 ENSG00000231434.1 RP11-144L1.8 -4.11 4.92e-05 0.0103 -0.26 -0.22 Select biomarker traits; chr1:159353602 chr1:158523672~158525838:+ LIHC cis rs748404 0.697 rs574065 ENSG00000205771.5 CATSPER2P1 4.11 4.92e-05 0.0103 0.26 0.22 Lung cancer; chr15:43258457 chr15:43726918~43747094:- LIHC cis rs860295 0.871 rs11582072 ENSG00000203761.5 MSTO2P 4.11 4.92e-05 0.0103 0.18 0.22 Body mass index; chr1:155507779 chr1:155745829~155750137:+ LIHC cis rs7726839 0.54 rs72703087 ENSG00000271781.1 CTD-2589H19.6 -4.11 4.92e-05 0.0103 -0.33 -0.22 Obesity-related traits; chr5:597914 chr5:675826~676616:+ LIHC cis rs8177253 0.606 rs6787177 ENSG00000244062.1 RP11-404G16.2 4.11 4.93e-05 0.0103 0.21 0.22 Iron status biomarkers; chr3:133731876 chr3:133760300~133762363:+ LIHC cis rs8064024 0.65 rs8056889 ENSG00000267077.1 RP11-127I20.5 4.11 4.93e-05 0.0103 0.22 0.22 Cancer; chr16:4853242 chr16:4795265~4796532:- LIHC cis rs2904804 0.792 rs2904795 ENSG00000224251.5 RP11-499O7.7 4.11 4.93e-05 0.0103 0.28 0.22 Economic and political preferences (immigration/crime); chr10:4962125 chr10:4995488~4997380:+ LIHC cis rs524281 0.731 rs2430979 ENSG00000255320.1 RP11-755F10.1 -4.11 4.93e-05 0.0103 -0.28 -0.22 Electroencephalogram traits; chr11:66045912 chr11:66244840~66246239:- LIHC cis rs11089937 0.963 rs2073454 ENSG00000211639.2 IGLV4-60 4.11 4.93e-05 0.0103 0.19 0.22 Periodontitis (PAL4Q3); chr22:22163086 chr22:22162199~22162681:+ LIHC cis rs7429990 1 rs1665982 ENSG00000229759.1 MRPS18AP1 -4.11 4.93e-05 0.0103 -0.28 -0.22 Educational attainment (years of education); chr3:47863589 chr3:48256350~48256938:- LIHC cis rs4713118 0.513 rs202908 ENSG00000216901.1 AL022393.7 4.11 4.93e-05 0.0103 0.28 0.22 Parkinson's disease; chr6:28043773 chr6:28176188~28176674:+ LIHC cis rs4650994 1 rs12138561 ENSG00000273384.1 RP5-1098D14.1 4.11 4.93e-05 0.0103 0.27 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178549649 chr1:178651706~178652282:+ LIHC cis rs875971 0.528 rs801213 ENSG00000224316.1 RP11-479O9.2 -4.11 4.93e-05 0.0103 -0.21 -0.22 Aortic root size; chr7:66549931 chr7:65773620~65802067:+ LIHC cis rs875971 0.545 rs801212 ENSG00000224316.1 RP11-479O9.2 -4.11 4.93e-05 0.0103 -0.21 -0.22 Aortic root size; chr7:66550643 chr7:65773620~65802067:+ LIHC cis rs875971 0.545 rs73152714 ENSG00000224316.1 RP11-479O9.2 4.11 4.93e-05 0.0103 0.21 0.22 Aortic root size; chr7:66534641 chr7:65773620~65802067:+ LIHC cis rs875971 0.545 rs4718364 ENSG00000224316.1 RP11-479O9.2 4.11 4.93e-05 0.0103 0.21 0.22 Aortic root size; chr7:66536353 chr7:65773620~65802067:+ LIHC cis rs875971 0.545 rs6961853 ENSG00000224316.1 RP11-479O9.2 4.11 4.93e-05 0.0103 0.21 0.22 Aortic root size; chr7:66537035 chr7:65773620~65802067:+ LIHC cis rs1005277 0.54 rs2145487 ENSG00000099251.13 HSD17B7P2 4.11 4.93e-05 0.0103 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37721149 chr10:38356380~38378505:+ LIHC cis rs1005277 0.54 rs4934907 ENSG00000099251.13 HSD17B7P2 4.11 4.93e-05 0.0103 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37726302 chr10:38356380~38378505:+ LIHC cis rs1005277 0.54 rs11011351 ENSG00000099251.13 HSD17B7P2 4.11 4.93e-05 0.0103 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37741597 chr10:38356380~38378505:+ LIHC cis rs6471393 0.964 rs2914942 ENSG00000253848.1 RP11-10N23.5 -4.11 4.94e-05 0.0103 -0.24 -0.22 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93714189 chr8:93741193~93744534:+ LIHC cis rs858239 0.669 rs10950940 ENSG00000226816.2 AC005082.12 -4.11 4.94e-05 0.0103 -0.26 -0.22 Cerebrospinal fluid biomarker levels; chr7:23157197 chr7:23206013~23208045:+ LIHC cis rs9675120 0.925 rs3803884 ENSG00000262006.1 RP11-700H6.4 -4.11 4.94e-05 0.0103 -0.23 -0.22 Cerebrospinal fluid biomarker levels; chr17:50841678 chr17:50909637~50910232:- LIHC cis rs7937890 1 rs6486190 ENSG00000251991.1 RNU7-49P 4.11 4.95e-05 0.0103 0.23 0.22 Mitochondrial DNA levels; chr11:14379670 chr11:14478892~14478953:+ LIHC cis rs1757171 0.534 rs2797793 ENSG00000204110.6 RP1-153P14.8 4.11 4.95e-05 0.0103 0.25 0.22 Cognitive performance; chr6:37509486 chr6:37507348~37535616:+ LIHC cis rs1577917 1 rs12207305 ENSG00000234155.1 RP11-30P6.6 4.11 4.95e-05 0.0103 0.28 0.22 Response to antipsychotic treatment; chr6:86013784 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs12199784 ENSG00000234155.1 RP11-30P6.6 4.11 4.95e-05 0.0103 0.28 0.22 Response to antipsychotic treatment; chr6:86017090 chr6:85387219~85390186:- LIHC cis rs3015497 0.753 rs12881776 ENSG00000269906.1 RP11-248J18.2 4.11 4.95e-05 0.0103 0.28 0.22 Mean platelet volume; chr14:50669612 chr14:50662511~50663178:- LIHC cis rs1023500 1 rs10154646 ENSG00000237037.8 NDUFA6-AS1 -4.11 4.95e-05 0.0103 -0.3 -0.22 Schizophrenia; chr22:41935405 chr22:42090931~42137742:+ LIHC cis rs6700559 0.815 rs12141497 ENSG00000260088.1 RP11-92G12.3 -4.11 4.95e-05 0.0103 -0.28 -0.22 Coronary artery disease; chr1:200693389 chr1:200669507~200694250:+ LIHC cis rs6700559 0.873 rs12126708 ENSG00000260088.1 RP11-92G12.3 -4.11 4.95e-05 0.0103 -0.28 -0.22 Coronary artery disease; chr1:200693397 chr1:200669507~200694250:+ LIHC cis rs6700559 0.873 rs10920008 ENSG00000260088.1 RP11-92G12.3 -4.11 4.95e-05 0.0103 -0.28 -0.22 Coronary artery disease; chr1:200694546 chr1:200669507~200694250:+ LIHC cis rs7121538 0.551 rs12421455 ENSG00000251991.1 RNU7-49P -4.11 4.96e-05 0.0103 -0.35 -0.22 HDL cholesterol; chr11:14511995 chr11:14478892~14478953:+ LIHC cis rs1223397 0.651 rs453877 ENSG00000215022.6 RP1-257A7.4 -4.11 4.96e-05 0.0103 -0.23 -0.22 Blood pressure; chr6:13297231 chr6:13264861~13295586:- LIHC cis rs16958440 1 rs16958432 ENSG00000267724.1 RP11-49K24.8 4.11 4.96e-05 0.0103 0.33 0.22 Sitting height ratio; chr18:47105402 chr18:47105946~47108062:+ LIHC cis rs12936587 0.935 rs12449964 ENSG00000223979.2 SMCR2 -4.11 4.96e-05 0.0103 -0.26 -0.22 Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference; chr17:17641390 chr17:17674026~17677688:- LIHC cis rs11148252 0.669 rs4884320 ENSG00000278238.1 RP11-245D16.4 -4.11 4.96e-05 0.0103 -0.21 -0.22 Lewy body disease; chr13:52432779 chr13:52454775~52455331:- LIHC cis rs2439831 0.681 rs7175434 ENSG00000166763.7 STRCP1 4.11 4.96e-05 0.0104 0.3 0.22 Lung cancer in ever smokers; chr15:43336344 chr15:43699488~43718184:- LIHC cis rs2243480 1 rs55895244 ENSG00000232546.1 RP11-458F8.1 -4.11 4.96e-05 0.0104 -0.24 -0.22 Diabetic kidney disease; chr7:65922691 chr7:66848496~66858136:+ LIHC cis rs2283831 0.524 rs2187862 ENSG00000213707.2 HMGB1P10 -4.11 4.97e-05 0.0104 -0.27 -0.22 Anti-saccade response; chr22:26559320 chr22:26560526~26561088:+ LIHC cis rs73081554 0.505 rs2063644 ENSG00000272360.1 RP11-359I18.5 -4.11 4.97e-05 0.0104 -0.31 -0.22 Rheumatoid arthritis; chr3:58345215 chr3:58490830~58491291:- LIHC cis rs6445975 0.666 rs13077234 ENSG00000272360.1 RP11-359I18.5 4.11 4.97e-05 0.0104 0.3 0.22 Systemic lupus erythematosus; chr3:58450978 chr3:58490830~58491291:- LIHC cis rs4356975 0.932 rs60814050 ENSG00000250919.1 RP11-813N20.3 -4.11 4.97e-05 0.0104 -0.22 -0.22 Obesity-related traits; chr4:69063770 chr4:69027831~69044578:+ LIHC cis rs3015497 0.616 rs34061700 ENSG00000269906.1 RP11-248J18.2 4.11 4.97e-05 0.0104 0.27 0.22 Mean platelet volume; chr14:50618142 chr14:50662511~50663178:- LIHC cis rs3091242 0.867 rs602052 ENSG00000261349.1 RP3-465N24.5 -4.11 4.98e-05 0.0104 -0.21 -0.22 Erythrocyte sedimentation rate; chr1:25395715 chr1:25266102~25267136:- LIHC cis rs2243480 0.901 rs57126451 ENSG00000232546.1 RP11-458F8.1 -4.11 4.98e-05 0.0104 -0.24 -0.22 Diabetic kidney disease; chr7:65951319 chr7:66848496~66858136:+ LIHC cis rs7811142 0.943 rs10241492 ENSG00000242294.5 STAG3L5P 4.11 4.98e-05 0.0104 0.24 0.22 Platelet count; chr7:100397190 chr7:100336079~100351900:+ LIHC cis rs1075265 0.563 rs2692536 ENSG00000272156.1 RP11-477N3.1 -4.11 4.98e-05 0.0104 -0.26 -0.22 Chronotype;Morning vs. evening chronotype; chr2:53788266 chr2:54082554~54085066:+ LIHC cis rs3091242 0.728 rs706845 ENSG00000224183.1 SDHDP6 -4.11 4.98e-05 0.0104 -0.25 -0.22 Erythrocyte sedimentation rate; chr1:25404222 chr1:25294164~25294643:- LIHC cis rs1577917 0.917 rs35038582 ENSG00000234155.1 RP11-30P6.6 4.11 4.98e-05 0.0104 0.28 0.22 Response to antipsychotic treatment; chr6:86011587 chr6:85387219~85390186:- LIHC cis rs10857712 0.754 rs1052582 ENSG00000214279.11 SCART1 -4.11 4.98e-05 0.0104 -0.27 -0.22 Systemic lupus erythematosus; chr10:133420336 chr10:133453928~133523558:+ LIHC cis rs1577917 1 rs12199516 ENSG00000234155.1 RP11-30P6.6 4.11 4.98e-05 0.0104 0.28 0.22 Response to antipsychotic treatment; chr6:86016503 chr6:85387219~85390186:- LIHC cis rs950169 0.58 rs11633762 ENSG00000259728.4 LINC00933 4.11 4.99e-05 0.0104 0.32 0.22 Schizophrenia; chr15:84643921 chr15:84570649~84580175:+ LIHC cis rs67311347 0.911 rs6773917 ENSG00000223797.4 ENTPD3-AS1 4.11 4.99e-05 0.0104 0.17 0.22 Renal cell carcinoma; chr3:40427763 chr3:40313802~40453329:- LIHC cis rs2179367 0.613 rs12207047 ENSG00000231760.4 RP11-350J20.5 4.11 4.99e-05 0.0104 0.35 0.22 Dupuytren's disease; chr6:149423496 chr6:149796151~149826294:- LIHC cis rs2179367 0.613 rs12207261 ENSG00000231760.4 RP11-350J20.5 4.11 4.99e-05 0.0104 0.35 0.22 Dupuytren's disease; chr6:149423722 chr6:149796151~149826294:- LIHC cis rs7989332 0.89 rs4770042 ENSG00000275964.1 RP11-61K9.3 -4.11 4.99e-05 0.0104 -0.26 -0.22 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20480765 chr13:19863858~19865048:+ LIHC cis rs987724 0.515 rs1574980 ENSG00000243926.1 TIPARP-AS1 4.11 4.99e-05 0.0104 0.24 0.22 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156917639 chr3:156671862~156674378:- LIHC cis rs987724 0.501 rs2321293 ENSG00000243926.1 TIPARP-AS1 4.11 4.99e-05 0.0104 0.24 0.22 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156931311 chr3:156671862~156674378:- LIHC cis rs2243480 1 rs313831 ENSG00000230295.1 RP11-458F8.2 -4.11 4.99e-05 0.0104 -0.23 -0.22 Diabetic kidney disease; chr7:66086239 chr7:66880708~66882981:+ LIHC cis rs901683 1 rs71494791 ENSG00000230869.1 CTGLF10P -4.11 4.99e-05 0.0104 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45482883 chr10:45678692~45700532:+ LIHC cis rs17818399 0.612 rs4952834 ENSG00000239332.4 LINC01119 -4.11 5e-05 0.0104 -0.3 -0.22 Height; chr2:46550323 chr2:46816697~46859007:+ LIHC cis rs2919917 0.628 rs2583759 ENSG00000254352.1 RP11-578O24.2 -4.11 5e-05 0.0104 -0.33 -0.22 Lymphocyte counts; chr8:78732729 chr8:78723796~78724136:- LIHC cis rs2919917 0.628 rs2583778 ENSG00000254352.1 RP11-578O24.2 -4.11 5e-05 0.0104 -0.33 -0.22 Lymphocyte counts; chr8:78738906 chr8:78723796~78724136:- LIHC cis rs11096990 0.634 rs7654501 ENSG00000249207.1 RP11-360F5.1 4.11 5e-05 0.0104 0.22 0.22 Cognitive function; chr4:39282364 chr4:39112677~39126818:- LIHC cis rs875971 0.545 rs75840613 ENSG00000228409.4 CCT6P1 -4.11 5e-05 0.0104 -0.18 -0.22 Aortic root size; chr7:66376399 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs73148639 ENSG00000228409.4 CCT6P1 -4.11 5e-05 0.0104 -0.18 -0.22 Aortic root size; chr7:66390342 chr7:65751142~65763354:+ LIHC cis rs1799949 1 rs16940 ENSG00000267681.1 CTD-3199J23.6 -4.11 5.01e-05 0.0104 -0.21 -0.22 Menopause (age at onset); chr17:43093220 chr17:43144956~43145255:+ LIHC cis rs6439153 0.901 rs2630263 ENSG00000231305.3 RP11-723O4.2 4.11 5.01e-05 0.0104 0.24 0.22 Pneumococcal bacteremia; chr3:128969475 chr3:128861313~128871540:- LIHC cis rs11096990 0.634 rs4975002 ENSG00000249207.1 RP11-360F5.1 4.11 5.01e-05 0.0104 0.21 0.22 Cognitive function; chr4:39286733 chr4:39112677~39126818:- LIHC cis rs113084984 0.718 rs4669744 ENSG00000271952.1 RP11-245G13.2 -4.11 5.01e-05 0.0104 -0.27 -0.22 Breast cancer; chr2:11541442 chr2:10878269~10885118:+ LIHC cis rs4578769 0.649 rs6507433 ENSG00000265943.1 RP11-739L10.1 4.11 5.01e-05 0.0104 0.28 0.22 Eosinophil percentage of white cells; chr18:23011784 chr18:22699481~22933764:- LIHC cis rs2564921 0.73 rs58492539 ENSG00000242142.1 SERBP1P3 -4.11 5.01e-05 0.0104 -0.3 -0.22 Height; chr3:53052712 chr3:53064283~53065091:- LIHC cis rs1223397 0.938 rs35549743 ENSG00000215022.6 RP1-257A7.4 -4.11 5.01e-05 0.0104 -0.29 -0.22 Blood pressure; chr6:13294122 chr6:13264861~13295586:- LIHC cis rs17711722 0.653 rs2460421 ENSG00000236529.1 RP13-254B10.1 -4.11 5.01e-05 0.0104 -0.21 -0.22 Calcium levels; chr7:66026136 chr7:65840212~65840596:+ LIHC cis rs6504622 0.721 rs11079748 ENSG00000262879.4 RP11-156P1.3 -4.11 5.01e-05 0.0104 -0.23 -0.22 Orofacial clefts; chr17:47055097 chr17:46984045~47100323:- LIHC cis rs7809950 0.678 rs62483640 ENSG00000238832.1 snoU109 -4.11 5.02e-05 0.0104 -0.28 -0.22 Coronary artery disease; chr7:107259769 chr7:107603363~107603507:+ LIHC cis rs7809950 0.678 rs62483641 ENSG00000238832.1 snoU109 -4.11 5.02e-05 0.0104 -0.28 -0.22 Coronary artery disease; chr7:107261296 chr7:107603363~107603507:+ LIHC cis rs7809950 0.678 rs2395869 ENSG00000238832.1 snoU109 -4.11 5.02e-05 0.0105 -0.28 -0.22 Coronary artery disease; chr7:107299653 chr7:107603363~107603507:+ LIHC cis rs6445975 0.666 rs6793328 ENSG00000272360.1 RP11-359I18.5 4.11 5.02e-05 0.0105 0.29 0.22 Systemic lupus erythematosus; chr3:58429145 chr3:58490830~58491291:- LIHC cis rs4925386 1 rs6089351 ENSG00000273619.1 RP5-908M14.9 4.11 5.03e-05 0.0105 0.17 0.22 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62341097 chr20:62386303~62386970:- LIHC cis rs4925386 0.959 rs6121989 ENSG00000273619.1 RP5-908M14.9 4.11 5.03e-05 0.0105 0.17 0.22 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62341657 chr20:62386303~62386970:- LIHC cis rs748404 0.631 rs8042688 ENSG00000166763.7 STRCP1 4.11 5.03e-05 0.0105 0.27 0.22 Lung cancer; chr15:43346327 chr15:43699488~43718184:- LIHC cis rs748404 0.631 rs4296223 ENSG00000166763.7 STRCP1 4.11 5.03e-05 0.0105 0.27 0.22 Lung cancer; chr15:43353048 chr15:43699488~43718184:- LIHC cis rs748404 0.631 rs6493084 ENSG00000166763.7 STRCP1 4.11 5.03e-05 0.0105 0.27 0.22 Lung cancer; chr15:43355429 chr15:43699488~43718184:- LIHC cis rs748404 0.631 rs12905772 ENSG00000166763.7 STRCP1 4.11 5.03e-05 0.0105 0.27 0.22 Lung cancer; chr15:43356246 chr15:43699488~43718184:- LIHC cis rs748404 0.676 rs4401024 ENSG00000166763.7 STRCP1 4.11 5.03e-05 0.0105 0.27 0.22 Lung cancer; chr15:43358137 chr15:43699488~43718184:- LIHC cis rs748404 0.631 rs6493086 ENSG00000166763.7 STRCP1 4.11 5.03e-05 0.0105 0.27 0.22 Lung cancer; chr15:43363196 chr15:43699488~43718184:- LIHC cis rs6048205 0.764 rs6082743 ENSG00000259974.2 LINC00261 4.11 5.03e-05 0.0105 0.34 0.22 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22545748 chr20:22547671~22578642:- LIHC cis rs73193808 0.639 rs2832241 ENSG00000212479.2 U3 4.11 5.03e-05 0.0105 0.25 0.22 Coronary artery disease; chr21:29179715 chr21:29180425~29180639:- LIHC cis rs17772222 0.874 rs78077739 ENSG00000258789.1 RP11-507K2.3 -4.11 5.03e-05 0.0105 -0.26 -0.22 Coronary artery calcification; chr14:88741176 chr14:88551597~88552493:+ LIHC cis rs9467711 0.591 rs7748167 ENSG00000216436.2 HIST1H2APS1 4.11 5.03e-05 0.0105 0.49 0.22 Autism spectrum disorder or schizophrenia; chr6:25904424 chr6:25732497~25732827:+ LIHC cis rs4988958 0.565 rs1035125 ENSG00000234389.1 AC007278.3 4.11 5.03e-05 0.0105 0.24 0.22 Asthma (childhood onset); chr2:102417379 chr2:102438713~102440475:+ LIHC cis rs2581828 0.618 rs9824325 ENSG00000242142.1 SERBP1P3 -4.11 5.03e-05 0.0105 -0.29 -0.22 Crohn's disease; chr3:53132494 chr3:53064283~53065091:- LIHC cis rs17214007 0.877 rs10852376 ENSG00000263335.1 AF001548.5 4.11 5.04e-05 0.0105 0.28 0.22 Cognitive function; chr16:15778216 chr16:15726674~15732993:+ LIHC cis rs7044106 0.762 rs10984972 ENSG00000238181.2 AHCYP2 -4.11 5.04e-05 0.0105 -0.25 -0.22 Hip circumference adjusted for BMI; chr9:120647586 chr9:120720673~120721972:+ LIHC cis rs1577917 1 rs12190598 ENSG00000234155.1 RP11-30P6.6 4.11 5.04e-05 0.0105 0.29 0.22 Response to antipsychotic treatment; chr6:85976356 chr6:85387219~85390186:- LIHC cis rs4938303 0.633 rs12800436 ENSG00000254851.1 RP11-109L13.1 4.11 5.04e-05 0.0105 0.32 0.22 Triglycerides; chr11:116688086 chr11:117135528~117138582:+ LIHC cis rs9322193 0.607 rs4870078 ENSG00000268592.3 RAET1E-AS1 -4.11 5.04e-05 0.0105 -0.29 -0.22 Lung cancer; chr6:149880676 chr6:149863494~149919507:+ LIHC cis rs13113518 0.841 rs7699867 ENSG00000249700.7 SRD5A3-AS1 4.11 5.04e-05 0.0105 0.25 0.22 Height; chr4:55483718 chr4:55363971~55395847:- LIHC cis rs6048205 0.773 rs1203871 ENSG00000259974.2 LINC00261 -4.11 5.05e-05 0.0105 -0.32 -0.22 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22555042 chr20:22547671~22578642:- LIHC cis rs2243480 0.522 rs1638736 ENSG00000230295.1 RP11-458F8.2 -4.11 5.05e-05 0.0105 -0.25 -0.22 Diabetic kidney disease; chr7:66627321 chr7:66880708~66882981:+ LIHC cis rs748404 0.66 rs690367 ENSG00000166763.7 STRCP1 -4.11 5.05e-05 0.0105 -0.27 -0.22 Lung cancer; chr15:43456106 chr15:43699488~43718184:- LIHC cis rs11585357 0.671 rs2501776 ENSG00000186301.8 MST1P2 4.11 5.05e-05 0.0105 0.31 0.22 Hair shape; chr1:17292784 chr1:16645622~16650289:+ LIHC cis rs938554 0.513 rs3775948 ENSG00000250413.1 RP11-448G15.1 -4.11 5.05e-05 0.0105 -0.3 -0.22 Blood metabolite levels; chr4:9993558 chr4:10006482~10009725:+ LIHC cis rs10129255 0.913 rs28861466 ENSG00000211972.2 IGHV3-66 4.11 5.05e-05 0.0105 0.18 0.22 Kawasaki disease; chr14:106718572 chr14:106675017~106675544:- LIHC cis rs2658782 0.547 rs10765602 ENSG00000279684.1 RP11-755E23.2 -4.11 5.06e-05 0.0105 -0.31 -0.22 Pulmonary function decline; chr11:93314999 chr11:93286629~93288903:- LIHC cis rs1799810 0.523 rs11683986 ENSG00000231731.6 AC010976.2 4.11 5.06e-05 0.0105 0.21 0.22 Self-rated health; chr2:127438822 chr2:127455394~127514623:+ LIHC cis rs9907295 0.901 rs9898152 ENSG00000270871.1 AC015849.19 4.11 5.06e-05 0.0105 0.23 0.22 Fibroblast growth factor basic levels; chr17:35869211 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs78023535 ENSG00000270871.1 AC015849.19 4.11 5.06e-05 0.0105 0.23 0.22 Fibroblast growth factor basic levels; chr17:35869598 chr17:35816717~35830293:- LIHC cis rs2274459 0.545 rs72896150 ENSG00000224557.6 HLA-DPB2 -4.11 5.06e-05 0.0105 -0.42 -0.22 Obesity (extreme); chr6:33825319 chr6:33112451~33129084:+ LIHC cis rs17772222 0.917 rs17260380 ENSG00000258789.1 RP11-507K2.3 -4.11 5.06e-05 0.0105 -0.26 -0.22 Coronary artery calcification; chr14:88682142 chr14:88551597~88552493:+ LIHC cis rs755249 0.567 rs3818806 ENSG00000182109.6 RP11-69E11.4 4.1 5.06e-05 0.0105 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39282599 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs41270799 ENSG00000182109.6 RP11-69E11.4 4.1 5.06e-05 0.0105 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39282990 chr1:39522280~39546187:- LIHC cis rs13113518 0.783 rs11133389 ENSG00000249700.7 SRD5A3-AS1 4.1 5.06e-05 0.0105 0.25 0.22 Height; chr4:55486718 chr4:55363971~55395847:- LIHC cis rs673078 0.607 rs2036314 ENSG00000275409.1 RP11-131L12.4 -4.1 5.07e-05 0.0105 -0.27 -0.22 Glucose homeostasis traits; chr12:118367132 chr12:118430147~118430699:+ LIHC cis rs6745190 0.953 rs13029368 ENSG00000236153.1 AC104076.3 -4.1 5.07e-05 0.0105 -0.32 -0.22 White blood cell count; chr2:180993441 chr2:180979427~180980090:- LIHC cis rs950169 0.544 rs2036949 ENSG00000259728.4 LINC00933 4.1 5.07e-05 0.0105 0.31 0.22 Schizophrenia; chr15:84620374 chr15:84570649~84580175:+ LIHC cis rs17270561 0.609 rs1165211 ENSG00000216436.2 HIST1H2APS1 -4.1 5.07e-05 0.0105 -0.26 -0.22 Iron status biomarkers; chr6:25800694 chr6:25732497~25732827:+ LIHC cis rs4578769 0.765 rs1584428 ENSG00000266850.1 RP11-370A5.1 4.1 5.08e-05 0.0105 0.25 0.22 Eosinophil percentage of white cells; chr18:22807886 chr18:22723491~22907721:- LIHC cis rs7809950 0.768 rs62482493 ENSG00000238832.1 snoU109 -4.1 5.08e-05 0.0105 -0.28 -0.22 Coronary artery disease; chr7:107311134 chr7:107603363~107603507:+ LIHC cis rs4356975 0.83 rs7666894 ENSG00000250919.1 RP11-813N20.3 -4.1 5.08e-05 0.0105 -0.21 -0.22 Obesity-related traits; chr4:69078780 chr4:69027831~69044578:+ LIHC cis rs338389 0.591 rs8037902 ENSG00000260657.2 RP11-315D16.4 4.1 5.08e-05 0.0105 0.27 0.22 Survival in rectal cancer; chr15:67988365 chr15:68267792~68277994:- LIHC cis rs1799949 0.93 rs66499067 ENSG00000267681.1 CTD-3199J23.6 -4.1 5.08e-05 0.0105 -0.21 -0.22 Menopause (age at onset); chr17:43096467 chr17:43144956~43145255:+ LIHC cis rs987724 0.515 rs344073 ENSG00000243926.1 TIPARP-AS1 -4.1 5.08e-05 0.0105 -0.25 -0.22 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156829224 chr3:156671862~156674378:- LIHC cis rs11096990 0.634 rs6852967 ENSG00000249207.1 RP11-360F5.1 4.1 5.08e-05 0.0105 0.22 0.22 Cognitive function; chr4:39281526 chr4:39112677~39126818:- LIHC cis rs6061231 0.518 rs639836 ENSG00000226332.2 RP11-157P1.4 -4.1 5.09e-05 0.0106 -0.22 -0.22 Colorectal cancer; chr20:62351167 chr20:62305432~62306325:- LIHC cis rs10129255 1 rs11621409 ENSG00000211970.3 IGHV4-61 -4.1 5.09e-05 0.0106 -0.17 -0.22 Kawasaki disease; chr14:106695603 chr14:106639119~106639657:- LIHC cis rs2599510 0.811 rs176413 ENSG00000276334.1 AL133243.1 -4.1 5.09e-05 0.0106 -0.24 -0.22 Interleukin-18 levels; chr2:32421779 chr2:32521927~32523547:+ LIHC cis rs6700559 0.873 rs7542840 ENSG00000260088.1 RP11-92G12.3 -4.1 5.09e-05 0.0106 -0.28 -0.22 Coronary artery disease; chr1:200686558 chr1:200669507~200694250:+ LIHC cis rs6700559 0.873 rs7526482 ENSG00000260088.1 RP11-92G12.3 -4.1 5.09e-05 0.0106 -0.28 -0.22 Coronary artery disease; chr1:200688310 chr1:200669507~200694250:+ LIHC cis rs6700559 0.873 rs7526853 ENSG00000260088.1 RP11-92G12.3 -4.1 5.09e-05 0.0106 -0.28 -0.22 Coronary artery disease; chr1:200688529 chr1:200669507~200694250:+ LIHC cis rs6700559 0.844 rs61825137 ENSG00000260088.1 RP11-92G12.3 -4.1 5.09e-05 0.0106 -0.28 -0.22 Coronary artery disease; chr1:200689267 chr1:200669507~200694250:+ LIHC cis rs6700559 0.873 rs7545177 ENSG00000260088.1 RP11-92G12.3 -4.1 5.09e-05 0.0106 -0.28 -0.22 Coronary artery disease; chr1:200690727 chr1:200669507~200694250:+ LIHC cis rs6700559 0.873 rs7539646 ENSG00000260088.1 RP11-92G12.3 -4.1 5.09e-05 0.0106 -0.28 -0.22 Coronary artery disease; chr1:200692534 chr1:200669507~200694250:+ LIHC cis rs6700559 0.873 rs7519383 ENSG00000260088.1 RP11-92G12.3 -4.1 5.09e-05 0.0106 -0.28 -0.22 Coronary artery disease; chr1:200692968 chr1:200669507~200694250:+ LIHC cis rs17464492 0.593 rs61044379 ENSG00000246228.5 CASC8 4.1 5.09e-05 0.0106 0.24 0.22 Prostate-specific antigen levels (conditioned on lead SNPs); chr8:127339709 chr8:127289817~127482139:- LIHC cis rs17464492 0.593 rs28759353 ENSG00000246228.5 CASC8 4.1 5.09e-05 0.0106 0.24 0.22 Prostate-specific antigen levels (conditioned on lead SNPs); chr8:127340118 chr8:127289817~127482139:- LIHC cis rs9952991 0.941 rs2014857 ENSG00000260302.1 RP11-973H7.1 -4.1 5.09e-05 0.0106 -0.32 -0.22 Inflammatory skin disease; chr18:12774327 chr18:12774651~12775923:- LIHC cis rs9952991 0.883 rs2847260 ENSG00000260302.1 RP11-973H7.1 -4.1 5.09e-05 0.0106 -0.32 -0.22 Inflammatory skin disease; chr18:12775592 chr18:12774651~12775923:- LIHC cis rs9952991 0.883 rs2542147 ENSG00000260302.1 RP11-973H7.1 -4.1 5.09e-05 0.0106 -0.32 -0.22 Inflammatory skin disease; chr18:12775852 chr18:12774651~12775923:- LIHC cis rs481331 0.866 rs11499095 ENSG00000185904.10 LINC00839 4.1 5.09e-05 0.0106 0.4 0.22 Systemic juvenile idiopathic arthritis; chr10:42488077 chr10:42475543~42495336:+ LIHC cis rs481331 0.866 rs1855450 ENSG00000185904.10 LINC00839 4.1 5.09e-05 0.0106 0.4 0.22 Systemic juvenile idiopathic arthritis; chr10:42488259 chr10:42475543~42495336:+ LIHC cis rs13113518 0.812 rs2048564 ENSG00000249700.7 SRD5A3-AS1 4.1 5.09e-05 0.0106 0.25 0.22 Height; chr4:55407965 chr4:55363971~55395847:- LIHC cis rs2762353 0.718 rs1165160 ENSG00000242387.1 HIST1H2APS2 4.1 5.1e-05 0.0106 0.25 0.22 Blood metabolite levels; chr6:25864228 chr6:25882026~25882395:- LIHC cis rs12908161 0.959 rs17534709 ENSG00000259728.4 LINC00933 4.1 5.1e-05 0.0106 0.31 0.22 Schizophrenia; chr15:84771166 chr15:84570649~84580175:+ LIHC cis rs2286503 0.809 rs4719716 ENSG00000228649.7 AC005682.5 4.1 5.1e-05 0.0106 0.25 0.22 Fibrinogen; chr7:22821750 chr7:22854178~22861579:+ LIHC cis rs2286503 0.78 rs981792 ENSG00000228649.7 AC005682.5 4.1 5.1e-05 0.0106 0.25 0.22 Fibrinogen; chr7:22822020 chr7:22854178~22861579:+ LIHC cis rs2286503 0.839 rs2270108 ENSG00000228649.7 AC005682.5 4.1 5.1e-05 0.0106 0.25 0.22 Fibrinogen; chr7:22822512 chr7:22854178~22861579:+ LIHC cis rs2286503 0.839 rs2270107 ENSG00000228649.7 AC005682.5 4.1 5.1e-05 0.0106 0.25 0.22 Fibrinogen; chr7:22822564 chr7:22854178~22861579:+ LIHC cis rs10129255 0.957 rs12589190 ENSG00000211970.3 IGHV4-61 -4.1 5.11e-05 0.0106 -0.17 -0.22 Kawasaki disease; chr14:106783079 chr14:106639119~106639657:- LIHC cis rs3091242 0.809 rs660129 ENSG00000224183.1 SDHDP6 -4.1 5.11e-05 0.0106 -0.25 -0.22 Erythrocyte sedimentation rate; chr1:25400947 chr1:25294164~25294643:- LIHC cis rs7989332 0.662 rs9552200 ENSG00000275964.1 RP11-61K9.3 4.1 5.11e-05 0.0106 0.27 0.22 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20487462 chr13:19863858~19865048:+ LIHC cis rs2665103 0.61 rs56398167 ENSG00000259429.4 UBE2Q2P2 -4.1 5.11e-05 0.0106 -0.23 -0.22 Intelligence (multi-trait analysis); chr15:82237482 chr15:82355142~82420075:+ LIHC cis rs875971 0.522 rs1701760 ENSG00000273024.4 INTS4P2 -4.1 5.11e-05 0.0106 -0.26 -0.22 Aortic root size; chr7:66008701 chr7:65647864~65715661:+ LIHC cis rs4266144 0.544 rs13080798 ENSG00000244515.1 KRT18P34 -4.1 5.11e-05 0.0106 -0.21 -0.22 Coronary artery disease; chr3:157114612 chr3:157162663~157163932:- LIHC cis rs72739697 0.892 rs72739688 ENSG00000231084.2 CTA-253N17.1 -4.1 5.11e-05 0.0106 -0.41 -0.22 Itch intensity from mosquito bite adjusted by bite size; chr1:185034239 chr1:185171335~185171710:- LIHC cis rs2439831 1 rs527921 ENSG00000275601.1 AC011330.13 4.1 5.12e-05 0.0106 0.31 0.22 Lung cancer in ever smokers; chr15:43478218 chr15:43642389~43643023:- LIHC cis rs2581828 0.965 rs2581830 ENSG00000242142.1 SERBP1P3 4.1 5.12e-05 0.0106 0.25 0.22 Crohn's disease; chr3:53100082 chr3:53064283~53065091:- LIHC cis rs11148252 0.846 rs7323666 ENSG00000278238.1 RP11-245D16.4 -4.1 5.12e-05 0.0106 -0.21 -0.22 Lewy body disease; chr13:52431923 chr13:52454775~52455331:- LIHC cis rs7429990 0.833 rs3755638 ENSG00000229759.1 MRPS18AP1 -4.1 5.12e-05 0.0106 -0.23 -0.22 Educational attainment (years of education); chr3:47580841 chr3:48256350~48256938:- LIHC cis rs10510102 0.872 rs12259144 ENSG00000273891.1 RP11-500G22.5 4.1 5.12e-05 0.0106 0.29 0.22 Breast cancer; chr10:121965433 chr10:121965764~121967700:+ LIHC cis rs3204270 0.639 rs62080213 ENSG00000281517.1 Metazoa_SRP -4.1 5.12e-05 0.0106 -0.42 -0.22 Dental caries; chr17:81675501 chr17:81718849~81719095:- LIHC cis rs72634501 0.54 rs16826036 ENSG00000182109.6 RP11-69E11.4 4.1 5.12e-05 0.0106 0.28 0.22 HDL cholesterol; chr1:39292127 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs16826038 ENSG00000182109.6 RP11-69E11.4 4.1 5.12e-05 0.0106 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39292962 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs41270803 ENSG00000182109.6 RP11-69E11.4 4.1 5.12e-05 0.0106 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39300369 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs61783376 ENSG00000182109.6 RP11-69E11.4 4.1 5.12e-05 0.0106 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39303328 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs4660636 ENSG00000182109.6 RP11-69E11.4 4.1 5.12e-05 0.0106 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39304555 chr1:39522280~39546187:- LIHC cis rs7915414 0.951 rs1326837 ENSG00000230338.1 MTND4P19 -4.1 5.12e-05 0.0106 -0.22 -0.22 Clopidogrel active metabolite levels; chr10:94626449 chr10:94774156~94774633:- LIHC cis rs1530530 0.881 rs17081048 ENSG00000253771.4 TPTE2P1 -4.1 5.13e-05 0.0106 -0.46 -0.22 Obesity-related traits; chr13:24692250 chr13:24924677~24968487:- LIHC cis rs1005277 0.505 rs10827835 ENSG00000099251.13 HSD17B7P2 -4.1 5.13e-05 0.0106 -0.25 -0.22 Extrinsic epigenetic age acceleration; chr10:37861781 chr10:38356380~38378505:+ LIHC cis rs7985 1 rs1894720 ENSG00000244625.4 MIATNB 4.1 5.13e-05 0.0106 0.24 0.22 Electroencephalogram traits; chr22:26671261 chr22:26672767~26780207:+ LIHC cis rs7985 0.967 rs73163299 ENSG00000244625.4 MIATNB 4.1 5.13e-05 0.0106 0.24 0.22 Electroencephalogram traits; chr22:26671680 chr22:26672767~26780207:+ LIHC cis rs2286503 0.839 rs2270105 ENSG00000228649.7 AC005682.5 4.1 5.13e-05 0.0106 0.25 0.22 Fibrinogen; chr7:22822848 chr7:22854178~22861579:+ LIHC cis rs2286503 0.839 rs2270103 ENSG00000228649.7 AC005682.5 4.1 5.13e-05 0.0106 0.25 0.22 Fibrinogen; chr7:22823103 chr7:22854178~22861579:+ LIHC cis rs2286503 0.839 rs10276099 ENSG00000228649.7 AC005682.5 4.1 5.13e-05 0.0106 0.25 0.22 Fibrinogen; chr7:22823331 chr7:22854178~22861579:+ LIHC cis rs17772222 0.876 rs61983303 ENSG00000258789.1 RP11-507K2.3 -4.1 5.13e-05 0.0106 -0.26 -0.22 Coronary artery calcification; chr14:88764459 chr14:88551597~88552493:+ LIHC cis rs17772222 0.917 rs2224333 ENSG00000258789.1 RP11-507K2.3 -4.1 5.13e-05 0.0106 -0.26 -0.22 Coronary artery calcification; chr14:88768748 chr14:88551597~88552493:+ LIHC cis rs17772222 0.917 rs12590826 ENSG00000258789.1 RP11-507K2.3 -4.1 5.13e-05 0.0106 -0.26 -0.22 Coronary artery calcification; chr14:88769357 chr14:88551597~88552493:+ LIHC cis rs9876781 1 rs7653691 ENSG00000229759.1 MRPS18AP1 -4.1 5.14e-05 0.0106 -0.23 -0.22 Longevity; chr3:48378199 chr3:48256350~48256938:- LIHC cis rs6433895 0.677 rs111242075 ENSG00000236153.1 AC104076.3 -4.1 5.14e-05 0.0106 -0.28 -0.22 Lymphocyte counts; chr2:181162212 chr2:180979427~180980090:- LIHC cis rs7129556 0.69 rs24356 ENSG00000254459.1 RP11-91P24.7 4.1 5.14e-05 0.0106 0.35 0.22 Weight loss (gastric bypass surgery); chr11:77856482 chr11:77829654~77872262:- LIHC cis rs7131987 0.903 rs67517901 ENSG00000275476.1 RP11-996F15.4 -4.1 5.14e-05 0.0106 -0.25 -0.22 QT interval; chr12:29268413 chr12:29277397~29277882:- LIHC cis rs7131987 0.903 rs6487796 ENSG00000275476.1 RP11-996F15.4 -4.1 5.14e-05 0.0106 -0.25 -0.22 QT interval; chr12:29269831 chr12:29277397~29277882:- LIHC cis rs1075265 0.633 rs28653587 ENSG00000233266.1 HMGB1P31 4.1 5.14e-05 0.0106 0.26 0.22 Chronotype;Morning vs. evening chronotype; chr2:53992435 chr2:54051334~54051760:+ LIHC cis rs12681287 0.64 rs4587306 ENSG00000254088.1 SLC2A3P4 -4.1 5.14e-05 0.0106 -0.26 -0.22 Caudate activity during reward; chr8:86373282 chr8:86503591~86505061:+ LIHC cis rs875971 0.545 rs2707851 ENSG00000273024.4 INTS4P2 4.1 5.14e-05 0.0106 0.25 0.22 Aortic root size; chr7:66624178 chr7:65647864~65715661:+ LIHC cis rs4253772 1 rs4253766 ENSG00000260708.1 CTA-29F11.1 4.1 5.14e-05 0.0107 0.44 0.22 Cholesterol, total;LDL cholesterol; chr22:46228008 chr22:46761894~46762563:- LIHC cis rs938554 0.513 rs11943372 ENSG00000250413.1 RP11-448G15.1 -4.1 5.14e-05 0.0107 -0.29 -0.22 Blood metabolite levels; chr4:9997722 chr4:10006482~10009725:+ LIHC cis rs316274 1 rs316274 ENSG00000273384.1 RP5-1098D14.1 4.1 5.14e-05 0.0107 0.26 0.22 Immune response to smallpox vaccine (IL-6); chr1:178173073 chr1:178651706~178652282:+ LIHC cis rs2581828 0.618 rs7615099 ENSG00000242142.1 SERBP1P3 -4.1 5.15e-05 0.0107 -0.28 -0.22 Crohn's disease; chr3:53109885 chr3:53064283~53065091:- LIHC cis rs481331 0.866 rs12259795 ENSG00000185904.10 LINC00839 4.1 5.15e-05 0.0107 0.41 0.22 Systemic juvenile idiopathic arthritis; chr10:42488627 chr10:42475543~42495336:+ LIHC cis rs7893279 0.505 rs12778992 ENSG00000225527.1 RP11-383B4.4 4.1 5.15e-05 0.0107 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18611218 chr10:18531849~18533336:- LIHC cis rs10829156 0.738 rs4748502 ENSG00000225527.1 RP11-383B4.4 -4.1 5.15e-05 0.0107 -0.34 -0.22 Sudden cardiac arrest; chr10:18647032 chr10:18531849~18533336:- LIHC cis rs7131987 0.903 rs1035604 ENSG00000275476.1 RP11-996F15.4 -4.1 5.16e-05 0.0107 -0.25 -0.22 QT interval; chr12:29240169 chr12:29277397~29277882:- LIHC cis rs904251 0.772 rs2776906 ENSG00000204110.6 RP1-153P14.8 -4.1 5.16e-05 0.0107 -0.27 -0.22 Cognitive performance; chr6:37463981 chr6:37507348~37535616:+ LIHC cis rs7688540 0.723 rs80316648 ENSG00000275426.1 CH17-262A2.1 4.1 5.16e-05 0.0107 0.27 0.22 Facial morphology (factor 6, height of vermillion lower lip); chr4:238426 chr4:149738~150317:+ LIHC cis rs2070488 0.965 rs1870915 ENSG00000229589.1 ACVR2B-AS1 4.1 5.17e-05 0.0107 0.25 0.22 Electrocardiographic conduction measures; chr3:38452737 chr3:38451027~38454820:- LIHC cis rs2070488 0.965 rs3749386 ENSG00000229589.1 ACVR2B-AS1 4.1 5.17e-05 0.0107 0.25 0.22 Electrocardiographic conduction measures; chr3:38454574 chr3:38451027~38454820:- LIHC cis rs2243480 0.803 rs36127118 ENSG00000230295.1 RP11-458F8.2 -4.1 5.17e-05 0.0107 -0.22 -0.22 Diabetic kidney disease; chr7:66100518 chr7:66880708~66882981:+ LIHC cis rs1023500 0.573 rs1807494 ENSG00000205702.9 CYP2D7 -4.1 5.17e-05 0.0107 -0.24 -0.22 Schizophrenia; chr22:42078134 chr22:42140203~42144577:- LIHC cis rs1023500 0.573 rs133370 ENSG00000205702.9 CYP2D7 4.1 5.17e-05 0.0107 0.24 0.22 Schizophrenia; chr22:42069256 chr22:42140203~42144577:- LIHC cis rs73198271 0.74 rs10092600 ENSG00000253893.2 FAM85B 4.1 5.17e-05 0.0107 0.33 0.22 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8791513 chr8:8167819~8226614:- LIHC cis rs73198271 0.74 rs10105690 ENSG00000253893.2 FAM85B 4.1 5.17e-05 0.0107 0.33 0.22 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8791722 chr8:8167819~8226614:- LIHC cis rs2439831 0.681 rs7176849 ENSG00000166763.7 STRCP1 4.1 5.17e-05 0.0107 0.3 0.22 Lung cancer in ever smokers; chr15:43389229 chr15:43699488~43718184:- LIHC cis rs4578769 0.959 rs9961893 ENSG00000266850.1 RP11-370A5.1 4.1 5.17e-05 0.0107 0.25 0.22 Eosinophil percentage of white cells; chr18:22849805 chr18:22723491~22907721:- LIHC cis rs4578769 0.959 rs11082169 ENSG00000266850.1 RP11-370A5.1 4.1 5.17e-05 0.0107 0.25 0.22 Eosinophil percentage of white cells; chr18:22850034 chr18:22723491~22907721:- LIHC cis rs4578769 0.959 rs2100191 ENSG00000266850.1 RP11-370A5.1 4.1 5.17e-05 0.0107 0.25 0.22 Eosinophil percentage of white cells; chr18:22851428 chr18:22723491~22907721:- LIHC cis rs4578769 0.959 rs2100190 ENSG00000266850.1 RP11-370A5.1 4.1 5.17e-05 0.0107 0.25 0.22 Eosinophil percentage of white cells; chr18:22851857 chr18:22723491~22907721:- LIHC cis rs3015497 0.586 rs7144714 ENSG00000269906.1 RP11-248J18.2 4.1 5.17e-05 0.0107 0.27 0.22 Mean platelet volume; chr14:50611867 chr14:50662511~50663178:- LIHC cis rs875971 0.54 rs736270 ENSG00000273024.4 INTS4P2 -4.1 5.18e-05 0.0107 -0.26 -0.22 Aortic root size; chr7:65963835 chr7:65647864~65715661:+ LIHC cis rs3812762 0.879 rs4929934 ENSG00000254860.4 TMEM9B-AS1 -4.1 5.18e-05 0.0107 -0.23 -0.22 Hypospadias; chr11:8756242 chr11:8964675~8977527:+ LIHC cis rs2072510 1 rs2540492 ENSG00000257715.1 RP11-256L6.2 -4.1 5.18e-05 0.0107 -0.22 -0.22 Metabolite levels (small molecules and protein measures); chr12:96023881 chr12:96025323~96027971:+ LIHC cis rs875971 0.545 rs1547529 ENSG00000228409.4 CCT6P1 -4.1 5.18e-05 0.0107 -0.18 -0.22 Aortic root size; chr7:66258859 chr7:65751142~65763354:+ LIHC cis rs73193808 0.639 rs9984810 ENSG00000212479.2 U3 4.1 5.18e-05 0.0107 0.25 0.22 Coronary artery disease; chr21:29181059 chr21:29180425~29180639:- LIHC cis rs73193808 0.614 rs4817274 ENSG00000212479.2 U3 4.1 5.18e-05 0.0107 0.25 0.22 Coronary artery disease; chr21:29181296 chr21:29180425~29180639:- LIHC cis rs73193808 0.639 rs9976274 ENSG00000212479.2 U3 4.1 5.18e-05 0.0107 0.25 0.22 Coronary artery disease; chr21:29181615 chr21:29180425~29180639:- LIHC cis rs73193808 0.59 rs2832244 ENSG00000212479.2 U3 4.1 5.18e-05 0.0107 0.25 0.22 Coronary artery disease; chr21:29181713 chr21:29180425~29180639:- LIHC cis rs17826219 0.568 rs59858012 ENSG00000266490.1 CTD-2349P21.9 4.1 5.18e-05 0.0107 0.29 0.22 Body mass index; chr17:30751564 chr17:30792372~30792833:+ LIHC cis rs11096990 0.593 rs1026235 ENSG00000249685.1 RP11-360F5.3 4.1 5.18e-05 0.0107 0.26 0.22 Cognitive function; chr4:39226629 chr4:39133913~39135608:+ LIHC cis rs3020736 0.5 rs4147641 ENSG00000226450.2 CYP2D8P -4.1 5.19e-05 0.0107 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42086498 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs4147640 ENSG00000226450.2 CYP2D8P -4.1 5.19e-05 0.0107 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42089288 chr22:42149886~42155001:- LIHC cis rs1023500 0.507 rs6002600 ENSG00000226450.2 CYP2D8P -4.1 5.19e-05 0.0107 -0.27 -0.22 Schizophrenia; chr22:42092902 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs6002601 ENSG00000226450.2 CYP2D8P -4.1 5.19e-05 0.0107 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42093054 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs6002604 ENSG00000226450.2 CYP2D8P -4.1 5.19e-05 0.0107 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42097077 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs5996109 ENSG00000226450.2 CYP2D8P -4.1 5.19e-05 0.0107 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42097094 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs5996110 ENSG00000226450.2 CYP2D8P -4.1 5.19e-05 0.0107 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42097763 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs9620026 ENSG00000226450.2 CYP2D8P -4.1 5.19e-05 0.0107 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42102574 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs28791586 ENSG00000226450.2 CYP2D8P -4.1 5.19e-05 0.0107 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42104479 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs2839708 ENSG00000226450.2 CYP2D8P -4.1 5.19e-05 0.0107 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42104741 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs6519306 ENSG00000226450.2 CYP2D8P -4.1 5.19e-05 0.0107 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42105213 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs6002614 ENSG00000226450.2 CYP2D8P -4.1 5.19e-05 0.0107 -0.27 -0.22 Autism spectrum disorder or schizophrenia; chr22:42105798 chr22:42149886~42155001:- LIHC cis rs2348418 0.639 rs2347595 ENSG00000247934.4 RP11-967K21.1 -4.1 5.19e-05 0.0107 -0.2 -0.22 Lung function (FEV1);Lung function (FVC); chr12:28109947 chr12:28163298~28190738:- LIHC cis rs7665090 0.806 rs434644 ENSG00000246560.2 RP11-10L12.4 -4.1 5.19e-05 0.0107 -0.25 -0.22 Primary biliary cholangitis; chr4:102662032 chr4:102828055~102844075:+ LIHC cis rs7665090 0.806 rs413967 ENSG00000246560.2 RP11-10L12.4 -4.1 5.19e-05 0.0107 -0.25 -0.22 Primary biliary cholangitis; chr4:102662039 chr4:102828055~102844075:+ LIHC cis rs7665090 0.806 rs404574 ENSG00000246560.2 RP11-10L12.4 -4.1 5.19e-05 0.0107 -0.25 -0.22 Primary biliary cholangitis; chr4:102662051 chr4:102828055~102844075:+ LIHC cis rs2243480 1 rs422164 ENSG00000230295.1 RP11-458F8.2 -4.1 5.19e-05 0.0107 -0.22 -0.22 Diabetic kidney disease; chr7:66121618 chr7:66880708~66882981:+ LIHC cis rs4713118 0.662 rs149969 ENSG00000219891.2 ZSCAN12P1 4.1 5.19e-05 0.0107 0.3 0.22 Parkinson's disease; chr6:28009959 chr6:28091154~28093664:+ LIHC cis rs17023223 0.537 rs7525871 ENSG00000231365.4 RP11-418J17.1 -4.1 5.19e-05 0.0107 -0.26 -0.22 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119079271 chr1:119140396~119275973:+ LIHC cis rs875971 0.545 rs7783889 ENSG00000228409.4 CCT6P1 -4.1 5.19e-05 0.0107 -0.18 -0.22 Aortic root size; chr7:66283366 chr7:65751142~65763354:+ LIHC cis rs9367716 0.912 rs9382695 ENSG00000215190.7 LINC00680 -4.1 5.19e-05 0.0107 -0.24 -0.22 Coronary artery disease; chr6:57245256 chr6:57946074~57961501:- LIHC cis rs9457247 1 rs2757042 ENSG00000227598.1 RP1-167A14.2 4.1 5.2e-05 0.0107 0.23 0.22 Crohn's disease; chr6:166957746 chr6:166969626~166999065:- LIHC cis rs951005 0.808 rs28524729 ENSG00000281491.1 DNAJB5-AS1 -4.1 5.2e-05 0.0107 -0.41 -0.22 Rheumatoid arthritis; chr9:34712322 chr9:34985410~34989379:- LIHC cis rs2439831 0.85 rs9944216 ENSG00000275601.1 AC011330.13 4.1 5.2e-05 0.0108 0.32 0.22 Lung cancer in ever smokers; chr15:43868575 chr15:43642389~43643023:- LIHC cis rs2072510 0.569 rs7970524 ENSG00000257878.1 RP11-256L6.3 -4.1 5.2e-05 0.0108 -0.27 -0.22 Metabolite levels (small molecules and protein measures); chr12:95996374 chr12:95996521~96011489:+ LIHC cis rs6545883 0.718 rs2694624 ENSG00000271889.1 RP11-493E12.1 4.1 5.21e-05 0.0108 0.26 0.22 Tuberculosis; chr2:61445178 chr2:61151433~61162105:- LIHC cis rs10801727 0.521 rs9428027 ENSG00000225492.5 GBP1P1 4.1 5.21e-05 0.0108 0.21 0.22 Parental extreme longevity (95 years and older); chr1:89438986 chr1:89407679~89426243:+ LIHC cis rs16958440 1 rs60228288 ENSG00000267724.1 RP11-49K24.8 4.1 5.21e-05 0.0108 0.33 0.22 Sitting height ratio; chr18:47114041 chr18:47105946~47108062:+ LIHC cis rs951005 0.808 rs12348592 ENSG00000281491.1 DNAJB5-AS1 -4.1 5.21e-05 0.0108 -0.44 -0.22 Rheumatoid arthritis; chr9:34711835 chr9:34985410~34989379:- LIHC cis rs2243480 1 rs1723270 ENSG00000232546.1 RP11-458F8.1 -4.1 5.21e-05 0.0108 -0.25 -0.22 Diabetic kidney disease; chr7:66004843 chr7:66848496~66858136:+ LIHC cis rs4879656 0.593 rs7041702 ENSG00000225693.1 LAGE3P1 4.1 5.22e-05 0.0108 0.28 0.22 Menopause (age at onset); chr9:33053432 chr9:33019682~33020165:- LIHC cis rs13113518 0.557 rs13142096 ENSG00000249700.7 SRD5A3-AS1 4.1 5.22e-05 0.0108 0.26 0.22 Height; chr4:55566291 chr4:55363971~55395847:- LIHC cis rs2274273 1 rs8011834 ENSG00000258413.1 RP11-665C16.6 -4.1 5.22e-05 0.0108 -0.25 -0.22 Protein biomarker; chr14:55159259 chr14:55262767~55272075:- LIHC cis rs2243480 1 rs465359 ENSG00000230295.1 RP11-458F8.2 -4.1 5.22e-05 0.0108 -0.22 -0.22 Diabetic kidney disease; chr7:66093177 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs462853 ENSG00000230295.1 RP11-458F8.2 -4.1 5.22e-05 0.0108 -0.22 -0.22 Diabetic kidney disease; chr7:66093180 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs160644 ENSG00000230295.1 RP11-458F8.2 -4.1 5.22e-05 0.0108 -0.22 -0.22 Diabetic kidney disease; chr7:66093199 chr7:66880708~66882981:+ LIHC cis rs73198271 0.586 rs3789850 ENSG00000253893.2 FAM85B 4.1 5.22e-05 0.0108 0.31 0.22 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8829335 chr8:8167819~8226614:- LIHC cis rs2283792 0.74 rs8140258 ENSG00000224086.5 LL22NC03-86G7.1 -4.1 5.22e-05 0.0108 -0.23 -0.22 Multiple sclerosis; chr22:21755545 chr22:21938293~21977632:+ LIHC cis rs7208859 0.673 rs28588622 ENSG00000266490.1 CTD-2349P21.9 4.1 5.22e-05 0.0108 0.27 0.22 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30918681 chr17:30792372~30792833:+ LIHC cis rs2919917 0.628 rs9298314 ENSG00000254352.1 RP11-578O24.2 4.1 5.22e-05 0.0108 0.3 0.22 Lymphocyte counts; chr8:78660874 chr8:78723796~78724136:- LIHC cis rs7811142 1 rs7783550 ENSG00000242294.5 STAG3L5P -4.1 5.23e-05 0.0108 -0.24 -0.22 Platelet count; chr7:100390182 chr7:100336079~100351900:+ LIHC cis rs2348418 0.864 rs11049716 ENSG00000247934.4 RP11-967K21.1 4.1 5.23e-05 0.0108 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28564713 chr12:28163298~28190738:- LIHC cis rs2348418 0.864 rs7136843 ENSG00000247934.4 RP11-967K21.1 4.1 5.23e-05 0.0108 0.2 0.22 Lung function (FEV1);Lung function (FVC); chr12:28564875 chr12:28163298~28190738:- LIHC cis rs11096990 0.855 rs2566183 ENSG00000249207.1 RP11-360F5.1 4.1 5.23e-05 0.0108 0.25 0.22 Cognitive function; chr4:39162288 chr4:39112677~39126818:- LIHC cis rs755249 0.756 rs72637908 ENSG00000182109.6 RP11-69E11.4 4.1 5.24e-05 0.0108 0.23 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39557375 chr1:39522280~39546187:- LIHC cis rs9527 0.615 rs2152915 ENSG00000236937.2 PTGES3P4 4.1 5.24e-05 0.0108 0.27 0.22 Arsenic metabolism; chr10:102931975 chr10:102845595~102845950:+ LIHC cis rs9595908 0.568 rs4942926 ENSG00000212293.1 SNORA16 4.1 5.24e-05 0.0108 0.25 0.22 Body mass index; chr13:32807204 chr13:32420390~32420516:- LIHC cis rs10510102 0.872 rs11200292 ENSG00000273891.1 RP11-500G22.5 4.1 5.24e-05 0.0108 0.29 0.22 Breast cancer; chr10:121967383 chr10:121965764~121967700:+ LIHC cis rs858239 0.676 rs274032 ENSG00000226816.2 AC005082.12 4.1 5.24e-05 0.0108 0.27 0.22 Cerebrospinal fluid biomarker levels; chr7:23334940 chr7:23206013~23208045:+ LIHC cis rs73193808 0.614 rs2245023 ENSG00000212479.2 U3 4.1 5.24e-05 0.0108 0.25 0.22 Coronary artery disease; chr21:29174539 chr21:29180425~29180639:- LIHC cis rs617219 0.853 rs3829809 ENSG00000251675.1 CTC-458I2.2 4.1 5.24e-05 0.0108 0.24 0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79227709 chr5:80128361~80143883:+ LIHC cis rs734999 0.566 rs4648563 ENSG00000225931.3 RP3-395M20.7 4.1 5.24e-05 0.0108 0.23 0.22 Ulcerative colitis; chr1:2604563 chr1:2566410~2569888:+ LIHC cis rs4266144 0.544 rs7340627 ENSG00000244515.1 KRT18P34 -4.1 5.24e-05 0.0108 -0.21 -0.22 Coronary artery disease; chr3:157114604 chr3:157162663~157163932:- LIHC cis rs2070488 0.965 rs6599206 ENSG00000229589.1 ACVR2B-AS1 -4.1 5.25e-05 0.0108 -0.25 -0.22 Electrocardiographic conduction measures; chr3:38503858 chr3:38451027~38454820:- LIHC cis rs3738443 1 rs3738443 ENSG00000259865.1 RP11-488L18.10 -4.1 5.25e-05 0.0108 -0.22 -0.22 Alcohol dependence; chr1:247184887 chr1:247187281~247188526:- LIHC cis rs6545883 0.562 rs777588 ENSG00000271889.1 RP11-493E12.1 4.1 5.25e-05 0.0108 0.26 0.22 Tuberculosis; chr2:61199685 chr2:61151433~61162105:- LIHC cis rs10833905 1 rs3909703 ENSG00000246225.5 RP11-17A1.3 -4.1 5.25e-05 0.0108 -0.28 -0.22 Sudden cardiac arrest; chr11:22999094 chr11:22829380~22945393:+ LIHC cis rs7580658 0.509 rs12477653 ENSG00000236682.1 AC068282.3 -4.1 5.25e-05 0.0108 -0.27 -0.22 Protein C levels; chr2:127194505 chr2:127389130~127400580:+ LIHC cis rs904251 0.772 rs1224127 ENSG00000204110.6 RP1-153P14.8 -4.1 5.26e-05 0.0109 -0.27 -0.22 Cognitive performance; chr6:37449780 chr6:37507348~37535616:+ LIHC cis rs1823913 1 rs4853562 ENSG00000227542.1 AC092614.2 -4.1 5.26e-05 0.0109 -0.22 -0.22 Obesity-related traits; chr2:191253696 chr2:191229165~191246172:- LIHC cis rs1823913 1 rs4853461 ENSG00000227542.1 AC092614.2 -4.1 5.26e-05 0.0109 -0.22 -0.22 Obesity-related traits; chr2:191254572 chr2:191229165~191246172:- LIHC cis rs1823913 1 rs4853563 ENSG00000227542.1 AC092614.2 -4.1 5.26e-05 0.0109 -0.22 -0.22 Obesity-related traits; chr2:191254808 chr2:191229165~191246172:- LIHC cis rs11098499 0.615 rs28551750 ENSG00000260091.1 RP11-33B1.4 -4.1 5.26e-05 0.0109 -0.15 -0.22 Corneal astigmatism; chr4:119343746 chr4:119409333~119410233:+ LIHC cis rs11098499 0.691 rs9995716 ENSG00000260091.1 RP11-33B1.4 -4.1 5.26e-05 0.0109 -0.15 -0.22 Corneal astigmatism; chr4:119343841 chr4:119409333~119410233:+ LIHC cis rs7193541 0.694 rs3896277 ENSG00000262904.1 TMPOP2 -4.1 5.26e-05 0.0109 -0.19 -0.22 Multiple myeloma; chr16:74446796 chr16:74667506~74668706:+ LIHC cis rs673078 0.571 rs7963464 ENSG00000275409.1 RP11-131L12.4 -4.1 5.26e-05 0.0109 -0.28 -0.22 Glucose homeostasis traits; chr12:118264924 chr12:118430147~118430699:+ LIHC cis rs2299116 0.886 rs2237351 ENSG00000225264.3 ZNRF2P2 -4.1 5.27e-05 0.0109 -0.24 -0.22 Serum thyroid-stimulating hormone levels; chr7:28748640 chr7:29598795~29685255:- LIHC cis rs7044106 0.762 rs1324473 ENSG00000238181.2 AHCYP2 4.1 5.27e-05 0.0109 0.24 0.22 Hip circumference adjusted for BMI; chr9:120642332 chr9:120720673~120721972:+ LIHC cis rs748404 0.631 rs11070399 ENSG00000166763.7 STRCP1 4.1 5.27e-05 0.0109 0.27 0.22 Lung cancer; chr15:43354149 chr15:43699488~43718184:- LIHC cis rs6517329 0.674 rs1543655 ENSG00000231106.2 LINC01436 4.1 5.27e-05 0.0109 0.24 0.22 Schizophrenia; chr21:36111076 chr21:36005338~36007838:+ LIHC cis rs2665103 0.61 rs1972460 ENSG00000259429.4 UBE2Q2P2 -4.1 5.27e-05 0.0109 -0.22 -0.22 Intelligence (multi-trait analysis); chr15:82238289 chr15:82355142~82420075:+ LIHC cis rs1005277 0.505 rs200939 ENSG00000099251.13 HSD17B7P2 4.1 5.27e-05 0.0109 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37850555 chr10:38356380~38378505:+ LIHC cis rs860295 0.702 rs11264366 ENSG00000203761.5 MSTO2P -4.09 5.28e-05 0.0109 -0.18 -0.22 Body mass index; chr1:155365620 chr1:155745829~155750137:+ LIHC cis rs603446 0.55 rs1784118 ENSG00000254851.1 RP11-109L13.1 4.09 5.28e-05 0.0109 0.28 0.22 Triglycerides; chr11:116694339 chr11:117135528~117138582:+ LIHC cis rs172166 0.694 rs9295760 ENSG00000216901.1 AL022393.7 4.09 5.28e-05 0.0109 0.28 0.22 Cardiac Troponin-T levels; chr6:28179607 chr6:28176188~28176674:+ LIHC cis rs1005277 0.505 rs200910 ENSG00000099251.13 HSD17B7P2 4.09 5.28e-05 0.0109 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37819248 chr10:38356380~38378505:+ LIHC cis rs1005277 0.522 rs200943 ENSG00000099251.13 HSD17B7P2 4.09 5.29e-05 0.0109 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37859802 chr10:38356380~38378505:+ LIHC cis rs1005277 0.505 rs719569 ENSG00000099251.13 HSD17B7P2 -4.09 5.29e-05 0.0109 -0.25 -0.22 Extrinsic epigenetic age acceleration; chr10:37865487 chr10:38356380~38378505:+ LIHC cis rs7182621 0.546 rs11635811 ENSG00000182397.13 DNM1P46 4.09 5.29e-05 0.0109 0.29 0.22 Colonoscopy-negative controls vs population controls; chr15:99839918 chr15:99790156~99806927:- LIHC cis rs1005277 0.505 rs200935 ENSG00000099251.13 HSD17B7P2 4.09 5.29e-05 0.0109 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37843882 chr10:38356380~38378505:+ LIHC cis rs1005277 0.505 rs200936 ENSG00000099251.13 HSD17B7P2 4.09 5.29e-05 0.0109 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37846007 chr10:38356380~38378505:+ LIHC cis rs1005277 0.505 rs200937 ENSG00000099251.13 HSD17B7P2 4.09 5.29e-05 0.0109 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:37846844 chr10:38356380~38378505:+ LIHC cis rs4650994 0.967 rs4650998 ENSG00000273384.1 RP5-1098D14.1 4.09 5.3e-05 0.0109 0.26 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178562715 chr1:178651706~178652282:+ LIHC cis rs4819852 0.958 rs2238792 ENSG00000215493.3 XXbac-B562F10.11 -4.09 5.3e-05 0.0109 -0.18 -0.22 Pulse pressure; chr22:19995690 chr22:20450122~20451824:+ LIHC cis rs703842 0.642 rs73123375 ENSG00000270039.1 RP11-571M6.17 -4.09 5.3e-05 0.0109 -0.31 -0.22 Multiple sclerosis; chr12:57669881 chr12:57803838~57804415:+ LIHC cis rs66887589 0.837 rs7661498 ENSG00000260091.1 RP11-33B1.4 -4.09 5.3e-05 0.0109 -0.14 -0.22 Diastolic blood pressure; chr4:119486953 chr4:119409333~119410233:+ LIHC cis rs2980436 1 rs2980436 ENSG00000254340.1 RP11-10A14.3 -4.09 5.3e-05 0.0109 -0.23 -0.22 Schizophrenia; chr8:8234503 chr8:9141424~9145435:+ LIHC cis rs2243480 1 rs465359 ENSG00000228409.4 CCT6P1 4.09 5.3e-05 0.0109 0.23 0.22 Diabetic kidney disease; chr7:66093177 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs462853 ENSG00000228409.4 CCT6P1 4.09 5.3e-05 0.0109 0.23 0.22 Diabetic kidney disease; chr7:66093180 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs160644 ENSG00000228409.4 CCT6P1 4.09 5.3e-05 0.0109 0.23 0.22 Diabetic kidney disease; chr7:66093199 chr7:65751142~65763354:+ LIHC cis rs6832769 1 rs7670225 ENSG00000272969.1 RP11-528I4.2 4.09 5.31e-05 0.0109 0.26 0.22 Personality dimensions; chr4:55501851 chr4:55547112~55547889:+ LIHC cis rs6832769 0.925 rs3817444 ENSG00000272969.1 RP11-528I4.2 4.09 5.31e-05 0.0109 0.26 0.22 Personality dimensions; chr4:55509814 chr4:55547112~55547889:+ LIHC cis rs6832769 0.826 rs10462035 ENSG00000272969.1 RP11-528I4.2 4.09 5.31e-05 0.0109 0.26 0.22 Personality dimensions; chr4:55513011 chr4:55547112~55547889:+ LIHC cis rs6832769 0.961 rs2177127 ENSG00000272969.1 RP11-528I4.2 4.09 5.31e-05 0.0109 0.26 0.22 Personality dimensions; chr4:55513792 chr4:55547112~55547889:+ LIHC cis rs950169 1 rs950169 ENSG00000259728.4 LINC00933 4.09 5.31e-05 0.0109 0.35 0.22 Schizophrenia; chr15:84037709 chr15:84570649~84580175:+ LIHC cis rs12681366 0.801 rs12682524 ENSG00000253704.1 RP11-267M23.4 4.09 5.31e-05 0.0109 0.25 0.22 Nonsyndromic cleft lip with cleft palate; chr8:94472071 chr8:94553722~94569745:+ LIHC cis rs2070488 0.932 rs1841776 ENSG00000229589.1 ACVR2B-AS1 4.09 5.32e-05 0.0109 0.25 0.22 Electrocardiographic conduction measures; chr3:38439236 chr3:38451027~38454820:- LIHC cis rs2070488 1 rs1841777 ENSG00000229589.1 ACVR2B-AS1 4.09 5.32e-05 0.0109 0.25 0.22 Electrocardiographic conduction measures; chr3:38443328 chr3:38451027~38454820:- LIHC cis rs2070488 0.965 rs13093640 ENSG00000229589.1 ACVR2B-AS1 4.09 5.32e-05 0.0109 0.25 0.22 Electrocardiographic conduction measures; chr3:38445685 chr3:38451027~38454820:- LIHC cis rs2070488 1 rs7373816 ENSG00000229589.1 ACVR2B-AS1 4.09 5.32e-05 0.0109 0.25 0.22 Electrocardiographic conduction measures; chr3:38448952 chr3:38451027~38454820:- LIHC cis rs2070488 1 rs13079757 ENSG00000229589.1 ACVR2B-AS1 4.09 5.32e-05 0.0109 0.25 0.22 Electrocardiographic conduction measures; chr3:38449953 chr3:38451027~38454820:- LIHC cis rs2070488 0.965 rs2366123 ENSG00000229589.1 ACVR2B-AS1 4.09 5.32e-05 0.0109 0.25 0.22 Electrocardiographic conduction measures; chr3:38451662 chr3:38451027~38454820:- LIHC cis rs2070488 1 rs3792527 ENSG00000229589.1 ACVR2B-AS1 4.09 5.32e-05 0.0109 0.25 0.22 Electrocardiographic conduction measures; chr3:38451721 chr3:38451027~38454820:- LIHC cis rs2070488 0.965 rs3762788 ENSG00000229589.1 ACVR2B-AS1 4.09 5.32e-05 0.0109 0.25 0.22 Electrocardiographic conduction measures; chr3:38452361 chr3:38451027~38454820:- LIHC cis rs2070488 1 rs762317 ENSG00000229589.1 ACVR2B-AS1 4.09 5.32e-05 0.0109 0.25 0.22 Electrocardiographic conduction measures; chr3:38456168 chr3:38451027~38454820:- LIHC cis rs6452524 0.71 rs7708124 ENSG00000271862.1 RP11-343L5.2 4.09 5.32e-05 0.011 0.25 0.22 Hypertension (SNP x SNP interaction); chr5:83132035 chr5:83049376~83050964:- LIHC cis rs13113518 0.812 rs6825774 ENSG00000249700.7 SRD5A3-AS1 4.09 5.32e-05 0.011 0.25 0.22 Height; chr4:55491150 chr4:55363971~55395847:- LIHC cis rs11098499 0.722 rs10006192 ENSG00000260091.1 RP11-33B1.4 -4.09 5.32e-05 0.011 -0.15 -0.22 Corneal astigmatism; chr4:119341867 chr4:119409333~119410233:+ LIHC cis rs1023500 0.551 rs133371 ENSG00000205702.9 CYP2D7 4.09 5.32e-05 0.011 0.24 0.22 Schizophrenia; chr22:42069570 chr22:42140203~42144577:- LIHC cis rs1023500 0.573 rs133374 ENSG00000205702.9 CYP2D7 4.09 5.32e-05 0.011 0.24 0.22 Schizophrenia; chr22:42069937 chr22:42140203~42144577:- LIHC cis rs1023500 0.573 rs133378 ENSG00000205702.9 CYP2D7 4.09 5.32e-05 0.011 0.24 0.22 Schizophrenia; chr22:42071691 chr22:42140203~42144577:- LIHC cis rs1023500 0.573 rs133382 ENSG00000205702.9 CYP2D7 4.09 5.32e-05 0.011 0.24 0.22 Schizophrenia; chr22:42075770 chr22:42140203~42144577:- LIHC cis rs875971 0.545 rs1796217 ENSG00000273024.4 INTS4P2 4.09 5.32e-05 0.011 0.24 0.22 Aortic root size; chr7:66620931 chr7:65647864~65715661:+ LIHC cis rs4650994 0.967 rs4650992 ENSG00000273384.1 RP5-1098D14.1 4.09 5.32e-05 0.011 0.26 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178546000 chr1:178651706~178652282:+ LIHC cis rs4650994 1 rs4650993 ENSG00000273384.1 RP5-1098D14.1 4.09 5.32e-05 0.011 0.26 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178546052 chr1:178651706~178652282:+ LIHC cis rs4650994 0.935 rs12039531 ENSG00000273384.1 RP5-1098D14.1 4.09 5.32e-05 0.011 0.26 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178546477 chr1:178651706~178652282:+ LIHC cis rs4650994 1 rs10798616 ENSG00000273384.1 RP5-1098D14.1 4.09 5.32e-05 0.011 0.26 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178546507 chr1:178651706~178652282:+ LIHC cis rs755249 0.567 rs4660543 ENSG00000182109.6 RP11-69E11.4 4.09 5.32e-05 0.011 0.27 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39213318 chr1:39522280~39546187:- LIHC cis rs2744375 1 rs2744375 ENSG00000261189.1 RP3-512B11.3 4.09 5.32e-05 0.011 0.37 0.22 Resting heart rate; chr6:7554606 chr6:7540451~7541338:- LIHC cis rs1577917 1 rs36096931 ENSG00000234155.1 RP11-30P6.6 4.09 5.33e-05 0.011 0.28 0.22 Response to antipsychotic treatment; chr6:85983416 chr6:85387219~85390186:- LIHC cis rs9652601 0.959 rs9934969 ENSG00000274038.1 RP11-66H6.4 -4.09 5.33e-05 0.011 -0.27 -0.22 Systemic lupus erythematosus; chr16:11072145 chr16:11056556~11057034:+ LIHC cis rs13113518 0.812 rs4864996 ENSG00000249700.7 SRD5A3-AS1 4.09 5.33e-05 0.011 0.25 0.22 Height; chr4:55452921 chr4:55363971~55395847:- LIHC cis rs73198271 0.74 rs10105920 ENSG00000253893.2 FAM85B -4.09 5.33e-05 0.011 -0.31 -0.22 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8791227 chr8:8167819~8226614:- LIHC cis rs11690935 0.632 rs17581284 ENSG00000228389.1 AC068039.4 -4.09 5.33e-05 0.011 -0.26 -0.22 Schizophrenia; chr2:171802866 chr2:171773482~171775844:+ LIHC cis rs9952991 0.941 rs7237497 ENSG00000260302.1 RP11-973H7.1 -4.09 5.33e-05 0.011 -0.32 -0.22 Inflammatory skin disease; chr18:12777326 chr18:12774651~12775923:- LIHC cis rs9952991 0.882 rs2847274 ENSG00000260302.1 RP11-973H7.1 -4.09 5.33e-05 0.011 -0.32 -0.22 Inflammatory skin disease; chr18:12777604 chr18:12774651~12775923:- LIHC cis rs12946454 0.696 rs4792819 ENSG00000267288.2 RP13-890H12.2 -4.09 5.33e-05 0.011 -0.24 -0.22 Systolic blood pressure; chr17:45170590 chr17:45168800~45171584:- LIHC cis rs6545883 0.929 rs6705235 ENSG00000271889.1 RP11-493E12.1 4.09 5.34e-05 0.011 0.26 0.22 Tuberculosis; chr2:61486445 chr2:61151433~61162105:- LIHC cis rs950880 0.71 rs17027230 ENSG00000234389.1 AC007278.3 -4.09 5.34e-05 0.011 -0.22 -0.22 Serum protein levels (sST2); chr2:102462870 chr2:102438713~102440475:+ LIHC cis rs6942407 0.64 rs4728690 ENSG00000224046.1 AC005076.5 -4.09 5.34e-05 0.011 -0.2 -0.22 Food allergy; chr7:87224688 chr7:87151423~87152420:- LIHC cis rs597539 0.616 rs631001 ENSG00000250508.1 RP11-757G1.6 -4.09 5.34e-05 0.011 -0.34 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68875506 chr11:68870664~68874542:+ LIHC cis rs3845817 0.808 rs702895 ENSG00000281920.1 RP11-418H16.1 -4.09 5.34e-05 0.011 -0.26 -0.22 Bipolar disorder; chr2:65534933 chr2:65623272~65628424:+ LIHC cis rs875971 0.545 rs1638735 ENSG00000228409.4 CCT6P1 -4.09 5.34e-05 0.011 -0.19 -0.22 Aortic root size; chr7:66630751 chr7:65751142~65763354:+ LIHC cis rs11096990 0.634 rs746678 ENSG00000249207.1 RP11-360F5.1 4.09 5.34e-05 0.011 0.21 0.22 Cognitive function; chr4:39279035 chr4:39112677~39126818:- LIHC cis rs875971 0.522 rs4718286 ENSG00000273024.4 INTS4P2 -4.09 5.34e-05 0.011 -0.26 -0.22 Aortic root size; chr7:65827777 chr7:65647864~65715661:+ LIHC cis rs17711722 0.585 rs6942660 ENSG00000273024.4 INTS4P2 -4.09 5.34e-05 0.011 -0.26 -0.22 Calcium levels; chr7:65837419 chr7:65647864~65715661:+ LIHC cis rs17711722 0.701 rs55773927 ENSG00000273024.4 INTS4P2 -4.09 5.34e-05 0.011 -0.26 -0.22 Calcium levels; chr7:65872915 chr7:65647864~65715661:+ LIHC cis rs17711722 0.727 rs35850374 ENSG00000273024.4 INTS4P2 -4.09 5.34e-05 0.011 -0.26 -0.22 Calcium levels; chr7:65892789 chr7:65647864~65715661:+ LIHC cis rs597539 0.615 rs583182 ENSG00000250508.1 RP11-757G1.6 -4.09 5.34e-05 0.011 -0.32 -0.22 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68911166 chr11:68870664~68874542:+ LIHC cis rs2494250 0.542 rs12041803 ENSG00000231434.1 RP11-144L1.8 -4.09 5.34e-05 0.011 -0.27 -0.22 Select biomarker traits; chr1:159341817 chr1:158523672~158525838:+ LIHC cis rs2243480 1 rs13247184 ENSG00000232546.1 RP11-458F8.1 -4.09 5.34e-05 0.011 -0.25 -0.22 Diabetic kidney disease; chr7:65893941 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs35283677 ENSG00000232546.1 RP11-458F8.1 -4.09 5.34e-05 0.011 -0.25 -0.22 Diabetic kidney disease; chr7:65894246 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs35421653 ENSG00000232546.1 RP11-458F8.1 -4.09 5.34e-05 0.011 -0.25 -0.22 Diabetic kidney disease; chr7:65898442 chr7:66848496~66858136:+ LIHC cis rs10857712 0.754 rs2297032 ENSG00000214279.11 SCART1 -4.09 5.34e-05 0.011 -0.27 -0.22 Systemic lupus erythematosus; chr10:133421076 chr10:133453928~133523558:+ LIHC cis rs4792901 0.722 rs12603085 ENSG00000267747.1 RP11-392O1.4 -4.09 5.35e-05 0.011 -0.25 -0.22 Dupuytren's disease; chr17:43468479 chr17:43544785~43610338:+ LIHC cis rs113835537 0.935 rs117480267 ENSG00000255517.5 CTD-3074O7.5 -4.09 5.35e-05 0.011 -0.38 -0.22 Airway imaging phenotypes; chr11:66631125 chr11:66473490~66480233:- LIHC cis rs864745 0.967 rs1635852 ENSG00000234336.5 JAZF1-AS1 4.09 5.35e-05 0.011 0.29 0.22 Crohn's disease;Type 2 diabetes; chr7:28149792 chr7:28180322~28243917:+ LIHC cis rs763121 0.853 rs4821810 ENSG00000273076.1 RP3-508I15.22 4.09 5.35e-05 0.011 0.24 0.22 Menopause (age at onset); chr22:38676093 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs5757234 ENSG00000273076.1 RP3-508I15.22 4.09 5.35e-05 0.011 0.24 0.22 Menopause (age at onset); chr22:38676681 chr22:38743495~38743910:+ LIHC cis rs340849 0.967 rs340868 ENSG00000274895.1 RP11-478J18.2 4.09 5.35e-05 0.011 0.23 0.22 Alzheimer's disease; chr1:213955877 chr1:213983793~213986419:- LIHC cis rs7893279 0.505 rs4748496 ENSG00000225527.1 RP11-383B4.4 4.09 5.36e-05 0.011 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18618028 chr10:18531849~18533336:- LIHC cis rs951005 0.808 rs10972207 ENSG00000281491.1 DNAJB5-AS1 4.09 5.36e-05 0.011 0.39 0.22 Rheumatoid arthritis; chr9:34713751 chr9:34985410~34989379:- LIHC cis rs13113518 0.812 rs12500456 ENSG00000249700.7 SRD5A3-AS1 4.09 5.36e-05 0.011 0.25 0.22 Height; chr4:55561053 chr4:55363971~55395847:- LIHC cis rs6496667 0.533 rs886491 ENSG00000213471.7 TTLL13P 4.09 5.37e-05 0.011 0.28 0.22 Rheumatoid arthritis; chr15:90449983 chr15:90249530~90265482:+ LIHC cis rs3812762 0.826 rs2292045 ENSG00000254860.4 TMEM9B-AS1 4.09 5.37e-05 0.011 0.25 0.22 Hypospadias; chr11:8785162 chr11:8964675~8977527:+ LIHC cis rs11096990 0.819 rs2711992 ENSG00000249207.1 RP11-360F5.1 4.09 5.37e-05 0.011 0.25 0.22 Cognitive function; chr4:39148651 chr4:39112677~39126818:- LIHC cis rs4561483 0.832 rs33645 ENSG00000261560.1 RP11-166B2.3 -4.09 5.37e-05 0.011 -0.25 -0.22 Testicular germ cell tumor; chr16:11891344 chr16:11881075~11882569:- LIHC cis rs1075265 0.621 rs2542593 ENSG00000272156.1 RP11-477N3.1 -4.09 5.38e-05 0.0111 -0.26 -0.22 Chronotype;Morning vs. evening chronotype; chr2:53804299 chr2:54082554~54085066:+ LIHC cis rs875971 0.545 rs66594357 ENSG00000228409.4 CCT6P1 -4.09 5.38e-05 0.0111 -0.18 -0.22 Aortic root size; chr7:66327797 chr7:65751142~65763354:+ LIHC cis rs950169 0.656 rs748455 ENSG00000259728.4 LINC00933 4.09 5.38e-05 0.0111 0.32 0.22 Schizophrenia; chr15:84606344 chr15:84570649~84580175:+ LIHC cis rs11098499 0.909 rs1546504 ENSG00000260091.1 RP11-33B1.4 -4.09 5.38e-05 0.0111 -0.16 -0.22 Corneal astigmatism; chr4:119320024 chr4:119409333~119410233:+ LIHC cis rs875971 0.545 rs6970498 ENSG00000273024.4 INTS4P2 -4.09 5.38e-05 0.0111 -0.25 -0.22 Aortic root size; chr7:66275908 chr7:65647864~65715661:+ LIHC cis rs13113518 0.812 rs56055342 ENSG00000249700.7 SRD5A3-AS1 4.09 5.38e-05 0.0111 0.25 0.22 Height; chr4:55540928 chr4:55363971~55395847:- LIHC cis rs7617773 0.817 rs6801801 ENSG00000228638.1 FCF1P2 -4.09 5.38e-05 0.0111 -0.24 -0.22 Coronary artery disease; chr3:48284943 chr3:48290793~48291375:- LIHC cis rs6832769 1 rs4865008 ENSG00000272969.1 RP11-528I4.2 -4.09 5.38e-05 0.0111 -0.26 -0.22 Personality dimensions; chr4:55544688 chr4:55547112~55547889:+ LIHC cis rs11763353 0.627 rs6948002 ENSG00000235828.5 RPL36AP26 -4.09 5.38e-05 0.0111 -0.21 -0.22 Blood trace element (Zn levels); chr7:15574487 chr7:15701435~15701752:- LIHC cis rs603446 0.55 rs1784119 ENSG00000254851.1 RP11-109L13.1 4.09 5.38e-05 0.0111 0.28 0.22 Triglycerides; chr11:116692089 chr11:117135528~117138582:+ LIHC cis rs9992667 0.91 rs4535339 ENSG00000231160.8 KLF3-AS1 4.09 5.38e-05 0.0111 0.28 0.22 Eosinophil percentage of granulocytes; chr4:38687607 chr4:38612701~38664883:- LIHC cis rs9807989 0.524 rs6543126 ENSG00000234389.1 AC007278.3 4.09 5.38e-05 0.0111 0.24 0.22 Asthma; chr2:102410644 chr2:102438713~102440475:+ LIHC cis rs1577917 0.876 rs1582126 ENSG00000234155.1 RP11-30P6.6 4.09 5.39e-05 0.0111 0.29 0.22 Response to antipsychotic treatment; chr6:85987487 chr6:85387219~85390186:- LIHC cis rs2243480 1 rs316307 ENSG00000228409.4 CCT6P1 4.09 5.39e-05 0.0111 0.23 0.22 Diabetic kidney disease; chr7:66105184 chr7:65751142~65763354:+ LIHC cis rs16958440 1 rs62096469 ENSG00000267724.1 RP11-49K24.8 4.09 5.39e-05 0.0111 0.33 0.22 Sitting height ratio; chr18:47111927 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs62096470 ENSG00000267724.1 RP11-49K24.8 4.09 5.39e-05 0.0111 0.33 0.22 Sitting height ratio; chr18:47115095 chr18:47105946~47108062:+ LIHC cis rs9675120 0.747 rs9303565 ENSG00000262006.1 RP11-700H6.4 -4.09 5.4e-05 0.0111 -0.23 -0.22 Cerebrospinal fluid biomarker levels; chr17:50843432 chr17:50909637~50910232:- LIHC cis rs7923609 0.846 rs7073753 ENSG00000232075.1 MRPL35P2 -4.09 5.4e-05 0.0111 -0.24 -0.22 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63303060 chr10:63634317~63634827:- LIHC cis rs1005277 0.522 rs289645 ENSG00000275858.1 RP11-291L22.8 4.09 5.4e-05 0.0111 0.24 0.22 Extrinsic epigenetic age acceleration; chr10:37654714 chr10:38450738~38451069:- LIHC cis rs4763555 1 rs4763555 ENSG00000256667.5 KLRAP1 4.09 5.4e-05 0.0111 0.19 0.22 Cognitive function; chr12:10568857 chr12:10588063~10599669:- LIHC cis rs11841001 0.556 rs17065026 ENSG00000261105.4 LMO7-AS1 4.09 5.4e-05 0.0111 0.43 0.22 Corneal astigmatism; chr13:75779020 chr13:75604700~75635994:- LIHC cis rs75920871 0.61 rs888246 ENSG00000254851.1 RP11-109L13.1 -4.09 5.4e-05 0.0111 -0.47 -0.22 Subjective well-being; chr11:116853516 chr11:117135528~117138582:+ LIHC cis rs4925386 0.681 rs2427295 ENSG00000273619.1 RP5-908M14.9 -4.09 5.4e-05 0.0111 -0.2 -0.22 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62352375 chr20:62386303~62386970:- LIHC cis rs72675573 0.821 rs7547019 ENSG00000235612.1 RP1-158P9.1 -4.09 5.4e-05 0.0111 -0.3 -0.22 Monocyte count; chr1:56060374 chr1:56145721~56155224:+ LIHC cis rs7615952 0.512 rs4234285 ENSG00000171084.14 FAM86JP 4.09 5.4e-05 0.0111 0.33 0.22 Blood pressure (smoking interaction); chr3:125685633 chr3:125916620~125930024:+ LIHC cis rs7615952 0.546 rs2976733 ENSG00000171084.14 FAM86JP 4.09 5.4e-05 0.0111 0.33 0.22 Blood pressure (smoking interaction); chr3:125695294 chr3:125916620~125930024:+ LIHC cis rs4879656 0.545 rs1537254 ENSG00000225693.1 LAGE3P1 4.09 5.4e-05 0.0111 0.27 0.22 Menopause (age at onset); chr9:33004341 chr9:33019682~33020165:- LIHC cis rs875971 0.505 rs2462573 ENSG00000273024.4 INTS4P2 4.09 5.41e-05 0.0111 0.25 0.22 Aortic root size; chr7:66042405 chr7:65647864~65715661:+ LIHC cis rs7338174 0.655 rs9316535 ENSG00000236778.6 INTS6-AS1 4.09 5.41e-05 0.0111 0.42 0.22 Mitochondrial DNA levels; chr13:51329329 chr13:51452367~51552364:+ LIHC cis rs74233809 0.636 rs284851 ENSG00000236937.2 PTGES3P4 4.09 5.41e-05 0.0111 0.29 0.22 Birth weight; chr10:102818774 chr10:102845595~102845950:+ LIHC cis rs6545883 0.524 rs4599092 ENSG00000271889.1 RP11-493E12.1 -4.09 5.41e-05 0.0111 -0.26 -0.22 Tuberculosis; chr2:61271833 chr2:61151433~61162105:- LIHC cis rs6545883 0.524 rs12713435 ENSG00000271889.1 RP11-493E12.1 -4.09 5.41e-05 0.0111 -0.26 -0.22 Tuberculosis; chr2:61272654 chr2:61151433~61162105:- LIHC cis rs2581828 0.646 rs13433700 ENSG00000242142.1 SERBP1P3 -4.09 5.41e-05 0.0111 -0.28 -0.22 Crohn's disease; chr3:53113870 chr3:53064283~53065091:- LIHC cis rs2562456 0.833 rs2562507 ENSG00000268555.1 RP11-678G14.3 -4.09 5.41e-05 0.0111 -0.27 -0.22 Pain; chr19:21543535 chr19:21570822~21587322:- LIHC cis rs17270561 0.666 rs1937129 ENSG00000216436.2 HIST1H2APS1 -4.09 5.42e-05 0.0111 -0.25 -0.22 Iron status biomarkers; chr6:25788904 chr6:25732497~25732827:+ LIHC cis rs3779195 0.584 rs1688605 ENSG00000272950.1 RP11-307C18.1 -4.09 5.42e-05 0.0111 -0.33 -0.22 Sex hormone-binding globulin levels; chr7:98410534 chr7:98322853~98323430:+ LIHC cis rs8005677 0.828 rs2295682 ENSG00000257285.4 RP11-298I3.1 4.09 5.42e-05 0.0111 0.22 0.22 Cognitive ability (multi-trait analysis); chr14:22905653 chr14:22929609~22955562:+ LIHC cis rs9595908 0.869 rs7983457 ENSG00000212293.1 SNORA16 -4.09 5.42e-05 0.0111 -0.25 -0.22 Body mass index; chr13:32631797 chr13:32420390~32420516:- LIHC cis rs4578769 0.765 rs35151054 ENSG00000265943.1 RP11-739L10.1 -4.09 5.42e-05 0.0111 -0.28 -0.22 Eosinophil percentage of white cells; chr18:22818375 chr18:22699481~22933764:- LIHC cis rs4578769 0.765 rs72882153 ENSG00000265943.1 RP11-739L10.1 -4.09 5.42e-05 0.0111 -0.28 -0.22 Eosinophil percentage of white cells; chr18:22823275 chr18:22699481~22933764:- LIHC cis rs950027 1 rs950027 ENSG00000259433.2 CTD-2651B20.4 4.09 5.43e-05 0.0111 0.31 0.22 Response to fenofibrate (adiponectin levels); chr15:45508837 chr15:45330209~45332634:- LIHC cis rs2243480 1 rs427044 ENSG00000232546.1 RP11-458F8.1 -4.09 5.43e-05 0.0111 -0.24 -0.22 Diabetic kidney disease; chr7:66043558 chr7:66848496~66858136:+ LIHC cis rs11096990 0.634 rs745642 ENSG00000249207.1 RP11-360F5.1 4.09 5.43e-05 0.0111 0.21 0.22 Cognitive function; chr4:39279642 chr4:39112677~39126818:- LIHC cis rs11096990 0.634 rs2086752 ENSG00000249207.1 RP11-360F5.1 4.09 5.43e-05 0.0111 0.21 0.22 Cognitive function; chr4:39280486 chr4:39112677~39126818:- LIHC cis rs11096990 0.594 rs2381373 ENSG00000249207.1 RP11-360F5.1 4.09 5.43e-05 0.0111 0.21 0.22 Cognitive function; chr4:39280683 chr4:39112677~39126818:- LIHC cis rs11096990 0.634 rs6531704 ENSG00000249207.1 RP11-360F5.1 4.09 5.43e-05 0.0111 0.21 0.22 Cognitive function; chr4:39282126 chr4:39112677~39126818:- LIHC cis rs11096990 0.634 rs7659894 ENSG00000249207.1 RP11-360F5.1 4.09 5.43e-05 0.0111 0.21 0.22 Cognitive function; chr4:39282815 chr4:39112677~39126818:- LIHC cis rs2243480 1 rs160642 ENSG00000228409.4 CCT6P1 4.09 5.43e-05 0.0111 0.23 0.22 Diabetic kidney disease; chr7:66093386 chr7:65751142~65763354:+ LIHC cis rs2243480 0.614 rs34032527 ENSG00000228409.4 CCT6P1 4.09 5.43e-05 0.0111 0.23 0.22 Diabetic kidney disease; chr7:66100154 chr7:65751142~65763354:+ LIHC cis rs17711722 0.583 rs10085415 ENSG00000273024.4 INTS4P2 4.09 5.43e-05 0.0111 0.26 0.22 Calcium levels; chr7:65628655 chr7:65647864~65715661:+ LIHC cis rs755249 0.567 rs112672438 ENSG00000182109.6 RP11-69E11.4 4.09 5.43e-05 0.0111 0.27 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39181115 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs16825921 ENSG00000182109.6 RP11-69E11.4 4.09 5.43e-05 0.0111 0.27 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39183526 chr1:39522280~39546187:- LIHC cis rs673078 0.607 rs61946067 ENSG00000275759.1 RP11-131L12.3 -4.09 5.43e-05 0.0111 -0.43 -0.22 Glucose homeostasis traits; chr12:118303152 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs61946068 ENSG00000275759.1 RP11-131L12.3 -4.09 5.43e-05 0.0111 -0.43 -0.22 Glucose homeostasis traits; chr12:118305861 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs7307393 ENSG00000275759.1 RP11-131L12.3 -4.09 5.43e-05 0.0111 -0.43 -0.22 Glucose homeostasis traits; chr12:118308537 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs17440669 ENSG00000275759.1 RP11-131L12.3 -4.09 5.43e-05 0.0111 -0.43 -0.22 Glucose homeostasis traits; chr12:118310397 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs7309671 ENSG00000275759.1 RP11-131L12.3 -4.09 5.43e-05 0.0111 -0.43 -0.22 Glucose homeostasis traits; chr12:118313188 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs17512525 ENSG00000275759.1 RP11-131L12.3 -4.09 5.43e-05 0.0111 -0.43 -0.22 Glucose homeostasis traits; chr12:118315467 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs17440774 ENSG00000275759.1 RP11-131L12.3 -4.09 5.43e-05 0.0111 -0.43 -0.22 Glucose homeostasis traits; chr12:118316155 chr12:118428281~118428870:+ LIHC cis rs433598 0.753 rs163274 ENSG00000260201.2 RP11-143N13.2 4.09 5.43e-05 0.0111 0.22 0.22 Schizophrenia; chr16:20661013 chr16:20580999~20586640:+ LIHC cis rs7989332 0.89 rs35891640 ENSG00000275964.1 RP11-61K9.3 -4.09 5.43e-05 0.0111 -0.24 -0.22 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20476035 chr13:19863858~19865048:+ LIHC cis rs875971 0.545 rs11767262 ENSG00000228409.4 CCT6P1 -4.09 5.43e-05 0.0111 -0.18 -0.22 Aortic root size; chr7:66302237 chr7:65751142~65763354:+ LIHC cis rs875971 0.545 rs801199 ENSG00000224316.1 RP11-479O9.2 -4.09 5.43e-05 0.0111 -0.21 -0.22 Aortic root size; chr7:66560286 chr7:65773620~65802067:+ LIHC cis rs875971 0.545 rs1638724 ENSG00000224316.1 RP11-479O9.2 -4.09 5.43e-05 0.0111 -0.21 -0.22 Aortic root size; chr7:66575494 chr7:65773620~65802067:+ LIHC cis rs6449502 0.92 rs158926 ENSG00000272308.1 RP11-231G3.1 -4.09 5.44e-05 0.0112 -0.29 -0.22 Mean platelet volume; chr5:60955380 chr5:60866457~60866935:- LIHC cis rs11673344 0.801 rs17707446 ENSG00000226686.6 LINC01535 -4.09 5.44e-05 0.0112 -0.33 -0.22 Obesity-related traits; chr19:37092140 chr19:37251912~37265535:+ LIHC cis rs11671005 0.695 rs12972898 ENSG00000269473.1 CTD-2619J13.19 4.09 5.44e-05 0.0112 0.37 0.22 Mean platelet volume; chr19:58445521 chr19:58440448~58445849:+ LIHC cis rs10829156 0.66 rs7918933 ENSG00000240291.1 RP11-499P20.2 4.09 5.45e-05 0.0112 0.33 0.22 Sudden cardiac arrest; chr10:18517434 chr10:18513115~18545651:- LIHC cis rs17774123 0.851 rs12425339 ENSG00000257808.1 RP11-1136G11.8 4.09 5.45e-05 0.0112 0.4 0.22 Diastolic blood pressure; chr12:53882713 chr12:53159586~53161000:+ LIHC cis rs17774123 0.851 rs79275870 ENSG00000257808.1 RP11-1136G11.8 4.09 5.45e-05 0.0112 0.4 0.22 Diastolic blood pressure; chr12:53890227 chr12:53159586~53161000:+ LIHC cis rs2439831 0.681 rs999047 ENSG00000166763.7 STRCP1 4.09 5.45e-05 0.0112 0.3 0.22 Lung cancer in ever smokers; chr15:43396718 chr15:43699488~43718184:- LIHC cis rs2439831 0.614 rs2467733 ENSG00000166763.7 STRCP1 4.09 5.45e-05 0.0112 0.3 0.22 Lung cancer in ever smokers; chr15:43401130 chr15:43699488~43718184:- LIHC cis rs2439831 0.681 rs2444036 ENSG00000166763.7 STRCP1 4.09 5.45e-05 0.0112 0.3 0.22 Lung cancer in ever smokers; chr15:43401910 chr15:43699488~43718184:- LIHC cis rs193541 0.53 rs2045626 ENSG00000263432.2 RN7SL689P 4.09 5.45e-05 0.0112 0.31 0.22 Glucose homeostasis traits; chr5:122745558 chr5:123022487~123022783:- LIHC cis rs6471393 0.964 rs2976366 ENSG00000253848.1 RP11-10N23.5 -4.09 5.45e-05 0.0112 -0.23 -0.22 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93708829 chr8:93741193~93744534:+ LIHC cis rs11096990 0.6 rs6835337 ENSG00000249207.1 RP11-360F5.1 4.09 5.45e-05 0.0112 0.21 0.22 Cognitive function; chr4:39281189 chr4:39112677~39126818:- LIHC cis rs2439831 0.681 rs540388 ENSG00000166763.7 STRCP1 4.09 5.46e-05 0.0112 0.3 0.22 Lung cancer in ever smokers; chr15:43314296 chr15:43699488~43718184:- LIHC cis rs17711722 0.701 rs781145 ENSG00000273024.4 INTS4P2 -4.09 5.46e-05 0.0112 -0.26 -0.22 Calcium levels; chr7:65975383 chr7:65647864~65715661:+ LIHC cis rs2333021 0.689 rs2998006 ENSG00000259015.1 RP11-109N23.6 -4.09 5.46e-05 0.0112 -0.26 -0.22 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72962406 chr14:72960595~72961993:+ LIHC cis rs2333021 0.689 rs8010674 ENSG00000259015.1 RP11-109N23.6 -4.09 5.46e-05 0.0112 -0.26 -0.22 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72962458 chr14:72960595~72961993:+ LIHC cis rs763121 0.853 rs1043441 ENSG00000273076.1 RP3-508I15.22 4.09 5.47e-05 0.0112 0.24 0.22 Menopause (age at onset); chr22:38734959 chr22:38743495~38743910:+ LIHC cis rs2015599 0.563 rs11050168 ENSG00000257176.2 RP11-996F15.2 4.09 5.48e-05 0.0112 0.27 0.22 Platelet count;Mean platelet volume; chr12:29273760 chr12:29280418~29317848:- LIHC cis rs960902 0.818 rs2192942 ENSG00000213553.4 RPLP0P6 -4.09 5.48e-05 0.0112 -0.18 -0.22 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37504350 chr2:38481851~38482804:+ LIHC cis rs6449502 1 rs6871557 ENSG00000272308.1 RP11-231G3.1 -4.09 5.48e-05 0.0112 -0.32 -0.22 Mean platelet volume; chr5:60821679 chr5:60866457~60866935:- LIHC cis rs938554 0.578 rs7663032 ENSG00000250413.1 RP11-448G15.1 -4.09 5.48e-05 0.0112 -0.29 -0.22 Blood metabolite levels; chr4:9992214 chr4:10006482~10009725:+ LIHC cis rs7607369 0.714 rs4674338 ENSG00000272555.1 RP11-459I19.1 4.09 5.48e-05 0.0112 0.25 0.22 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218782764 chr2:218818690~218819144:+ LIHC cis rs72675573 0.852 rs11206747 ENSG00000235612.1 RP1-158P9.1 -4.09 5.49e-05 0.0112 -0.28 -0.22 Monocyte count; chr1:56140977 chr1:56145721~56155224:+ LIHC cis rs1005277 0.563 rs2505215 ENSG00000099251.13 HSD17B7P2 4.09 5.49e-05 0.0112 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:38192345 chr10:38356380~38378505:+ LIHC cis rs1005277 0.563 rs2505216 ENSG00000099251.13 HSD17B7P2 4.09 5.49e-05 0.0112 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:38193902 chr10:38356380~38378505:+ LIHC cis rs1005277 0.563 rs2800550 ENSG00000099251.13 HSD17B7P2 4.09 5.49e-05 0.0112 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:38194001 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2749612 ENSG00000099251.13 HSD17B7P2 4.09 5.49e-05 0.0112 0.25 0.22 Extrinsic epigenetic age acceleration; chr10:38199682 chr10:38356380~38378505:+ LIHC cis rs10833905 1 rs12421624 ENSG00000246225.5 RP11-17A1.3 -4.09 5.49e-05 0.0113 -0.28 -0.22 Sudden cardiac arrest; chr11:22994882 chr11:22829380~22945393:+ LIHC cis rs7587476 0.505 rs777323 ENSG00000229267.2 AC072062.1 4.09 5.49e-05 0.0113 0.27 0.22 Neuroblastoma; chr2:214873761 chr2:214810229~214963274:+ LIHC cis rs3738443 0.645 rs55768801 ENSG00000259865.1 RP11-488L18.10 4.09 5.49e-05 0.0113 0.18 0.22 Alcohol dependence; chr1:247199688 chr1:247187281~247188526:- LIHC cis rs6471393 0.964 rs2914944 ENSG00000253848.1 RP11-10N23.5 -4.09 5.49e-05 0.0113 -0.23 -0.22 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93711815 chr8:93741193~93744534:+ LIHC cis rs713477 1 rs8014526 ENSG00000258413.1 RP11-665C16.6 4.08 5.5e-05 0.0113 0.24 0.22 Pediatric bone mineral content (femoral neck); chr14:55418336 chr14:55262767~55272075:- LIHC cis rs7811142 1 rs67471932 ENSG00000242294.5 STAG3L5P 4.08 5.5e-05 0.0113 0.25 0.22 Platelet count; chr7:100412362 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs73161759 ENSG00000242294.5 STAG3L5P 4.08 5.5e-05 0.0113 0.25 0.22 Platelet count; chr7:100412371 chr7:100336079~100351900:+ LIHC cis rs12157904 1 rs6000841 ENSG00000233360.4 Z83844.1 4.08 5.5e-05 0.0113 0.44 0.22 Response to anti-depressant treatment in major depressive disorder; chr22:37609930 chr22:37641832~37658377:- LIHC cis rs12157904 1 rs5995482 ENSG00000233360.4 Z83844.1 4.08 5.5e-05 0.0113 0.44 0.22 Response to anti-depressant treatment in major depressive disorder; chr22:37610374 chr22:37641832~37658377:- LIHC cis rs4578769 0.879 rs11659315 ENSG00000266850.1 RP11-370A5.1 -4.08 5.5e-05 0.0113 -0.25 -0.22 Eosinophil percentage of white cells; chr18:22836405 chr18:22723491~22907721:- LIHC cis rs4578769 0.879 rs11659384 ENSG00000266850.1 RP11-370A5.1 -4.08 5.5e-05 0.0113 -0.25 -0.22 Eosinophil percentage of white cells; chr18:22836662 chr18:22723491~22907721:- LIHC cis rs7989332 0.925 rs7329649 ENSG00000275964.1 RP11-61K9.3 -4.08 5.5e-05 0.0113 -0.24 -0.22 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20475948 chr13:19863858~19865048:+ LIHC cis rs1665050 0.842 rs1665049 ENSG00000259250.1 RP11-50C13.1 -4.08 5.5e-05 0.0113 -0.22 -0.22 Atopic dermatitis; chr15:58998453 chr15:58587507~58591676:+ LIHC cis rs1075265 0.587 rs2542585 ENSG00000272156.1 RP11-477N3.1 -4.08 5.51e-05 0.0113 -0.26 -0.22 Chronotype;Morning vs. evening chronotype; chr2:53786407 chr2:54082554~54085066:+ LIHC cis rs7989332 0.925 rs6490585 ENSG00000275964.1 RP11-61K9.3 -4.08 5.51e-05 0.0113 -0.25 -0.22 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20478159 chr13:19863858~19865048:+ LIHC cis rs72829446 0.53 rs72827503 ENSG00000263316.1 RP11-530N7.3 4.08 5.51e-05 0.0113 0.44 0.22 Androgen levels; chr17:7467949 chr17:6954098~6978960:- LIHC cis rs10129255 0.957 rs11847726 ENSG00000211970.3 IGHV4-61 -4.08 5.51e-05 0.0113 -0.17 -0.22 Kawasaki disease; chr14:106779116 chr14:106639119~106639657:- LIHC cis rs4578769 0.765 rs57308197 ENSG00000266850.1 RP11-370A5.1 -4.08 5.51e-05 0.0113 -0.25 -0.22 Eosinophil percentage of white cells; chr18:22874272 chr18:22723491~22907721:- LIHC cis rs4578769 0.765 rs61311054 ENSG00000266850.1 RP11-370A5.1 -4.08 5.51e-05 0.0113 -0.25 -0.22 Eosinophil percentage of white cells; chr18:22906406 chr18:22723491~22907721:- LIHC cis rs4578769 0.765 rs10502430 ENSG00000266850.1 RP11-370A5.1 -4.08 5.51e-05 0.0113 -0.25 -0.22 Eosinophil percentage of white cells; chr18:22916946 chr18:22723491~22907721:- LIHC cis rs4578769 0.681 rs72887615 ENSG00000266850.1 RP11-370A5.1 -4.08 5.51e-05 0.0113 -0.25 -0.22 Eosinophil percentage of white cells; chr18:22928638 chr18:22723491~22907721:- LIHC cis rs4578769 0.765 rs898000 ENSG00000266850.1 RP11-370A5.1 -4.08 5.51e-05 0.0113 -0.25 -0.22 Eosinophil percentage of white cells; chr18:22929109 chr18:22723491~22907721:- LIHC cis rs1200821 0.529 rs4934856 ENSG00000263064.2 RP11-291L22.7 -4.08 5.51e-05 0.0113 -0.23 -0.22 Hemostatic factors and hematological phenotypes; chr10:37518919 chr10:38448689~38448949:+ LIHC cis rs950880 0.71 rs1135354 ENSG00000234389.1 AC007278.3 -4.08 5.51e-05 0.0113 -0.22 -0.22 Serum protein levels (sST2); chr2:102397842 chr2:102438713~102440475:+ LIHC cis rs673078 0.607 rs11068919 ENSG00000275409.1 RP11-131L12.4 -4.08 5.51e-05 0.0113 -0.27 -0.22 Glucose homeostasis traits; chr12:118354925 chr12:118430147~118430699:+ LIHC cis rs4694744 0.576 rs13151870 ENSG00000264696.1 AC108078.1 4.08 5.51e-05 0.0113 0.33 0.22 Bacteremia; chr4:69490285 chr4:69479331~69479434:+ LIHC cis rs193541 0.632 rs6878609 ENSG00000263432.2 RN7SL689P 4.08 5.51e-05 0.0113 0.35 0.22 Glucose homeostasis traits; chr5:122759854 chr5:123022487~123022783:- LIHC cis rs10510102 0.872 rs11200277 ENSG00000273891.1 RP11-500G22.5 4.08 5.52e-05 0.0113 0.28 0.22 Breast cancer; chr10:121944295 chr10:121965764~121967700:+ LIHC cis rs7131987 0.903 rs1991114 ENSG00000275476.1 RP11-996F15.4 -4.08 5.52e-05 0.0113 -0.25 -0.22 QT interval; chr12:29239149 chr12:29277397~29277882:- LIHC cis rs901683 1 rs12779204 ENSG00000230869.1 CTGLF10P -4.08 5.52e-05 0.0113 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45568807 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34670342 ENSG00000230869.1 CTGLF10P -4.08 5.52e-05 0.0113 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45570714 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71496619 ENSG00000230869.1 CTGLF10P -4.08 5.52e-05 0.0113 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45572647 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs113862353 ENSG00000230869.1 CTGLF10P -4.08 5.52e-05 0.0113 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45573138 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35001302 ENSG00000230869.1 CTGLF10P -4.08 5.52e-05 0.0113 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45573488 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35585999 ENSG00000230869.1 CTGLF10P -4.08 5.52e-05 0.0113 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45574711 chr10:45678692~45700532:+ LIHC cis rs901683 0.702 rs34176769 ENSG00000230869.1 CTGLF10P -4.08 5.52e-05 0.0113 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45575579 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs35150810 ENSG00000230869.1 CTGLF10P -4.08 5.52e-05 0.0113 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45575694 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs74411575 ENSG00000230869.1 CTGLF10P -4.08 5.52e-05 0.0113 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45576519 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs79752400 ENSG00000230869.1 CTGLF10P -4.08 5.52e-05 0.0113 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45576640 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71496620 ENSG00000230869.1 CTGLF10P -4.08 5.52e-05 0.0113 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45578881 chr10:45678692~45700532:+ LIHC cis rs950880 0.71 rs11123929 ENSG00000234389.1 AC007278.3 -4.08 5.52e-05 0.0113 -0.21 -0.22 Serum protein levels (sST2); chr2:102450683 chr2:102438713~102440475:+ LIHC cis rs2739330 0.929 rs5751777 ENSG00000206090.4 AP000350.7 4.08 5.52e-05 0.0113 0.25 0.22 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23939998~23942798:+ LIHC cis rs6061231 0.631 rs2427317 ENSG00000226332.2 RP11-157P1.4 4.08 5.52e-05 0.0113 0.23 0.22 Colorectal cancer; chr20:62400669 chr20:62305432~62306325:- LIHC cis rs6061231 0.631 rs2427318 ENSG00000226332.2 RP11-157P1.4 4.08 5.52e-05 0.0113 0.23 0.22 Colorectal cancer; chr20:62400671 chr20:62305432~62306325:- LIHC cis rs755249 0.567 rs2018212 ENSG00000182109.6 RP11-69E11.4 4.08 5.52e-05 0.0113 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39439916 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs4660751 ENSG00000182109.6 RP11-69E11.4 4.08 5.52e-05 0.0113 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39440201 chr1:39522280~39546187:- LIHC cis rs2790457 1 rs2790457 ENSG00000254635.4 WAC-AS1 -4.08 5.52e-05 0.0113 -0.2 -0.22 Multiple myeloma; chr10:28567890 chr10:28522652~28532743:- LIHC cis rs638893 1 rs113641235 ENSG00000255239.1 AP002954.6 -4.08 5.52e-05 0.0113 -0.49 -0.22 Vitiligo; chr11:118829555 chr11:118688039~118690600:- LIHC cis rs7726839 0.574 rs12522955 ENSG00000271781.1 CTD-2589H19.6 -4.08 5.53e-05 0.0113 -0.33 -0.22 Obesity-related traits; chr5:639116 chr5:675826~676616:+ LIHC cis rs7937890 0.559 rs2597208 ENSG00000251991.1 RNU7-49P 4.08 5.53e-05 0.0113 0.23 0.22 Mitochondrial DNA levels; chr11:14450783 chr11:14478892~14478953:+ LIHC cis rs6600671 0.934 rs67718113 ENSG00000227082.1 CH17-437K3.1 4.08 5.53e-05 0.0113 0.3 0.22 Hip geometry; chr1:121497112 chr1:121396754~121463129:+ LIHC cis rs6445975 0.617 rs6762478 ENSG00000272360.1 RP11-359I18.5 4.08 5.53e-05 0.0113 0.29 0.22 Systemic lupus erythematosus; chr3:58418084 chr3:58490830~58491291:- LIHC cis rs6893782 0.887 rs274548 ENSG00000233006.5 AC034220.3 -4.08 5.53e-05 0.0113 -0.3 -0.22 Acylcarnitine levels; chr5:132395115 chr5:132311285~132369916:- LIHC cis rs6893782 0.83 rs2897160 ENSG00000233006.5 AC034220.3 -4.08 5.53e-05 0.0113 -0.3 -0.22 Acylcarnitine levels; chr5:132405806 chr5:132311285~132369916:- LIHC cis rs8002861 0.87 rs9567293 ENSG00000274001.1 RP11-5G9.5 4.08 5.53e-05 0.0113 0.25 0.22 Leprosy; chr13:43873107 chr13:43877715~43878163:- LIHC cis rs17772222 0.917 rs61983300 ENSG00000258789.1 RP11-507K2.3 -4.08 5.53e-05 0.0113 -0.26 -0.22 Coronary artery calcification; chr14:88754047 chr14:88551597~88552493:+ LIHC cis rs17772222 0.876 rs78068036 ENSG00000258789.1 RP11-507K2.3 -4.08 5.53e-05 0.0113 -0.26 -0.22 Coronary artery calcification; chr14:88754817 chr14:88551597~88552493:+ LIHC cis rs244293 0.965 rs11079153 ENSG00000275710.1 RP11-257O5.4 -4.08 5.53e-05 0.0113 -0.23 -0.22 Menarche (age at onset); chr17:55098662 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs7224560 ENSG00000275710.1 RP11-257O5.4 -4.08 5.53e-05 0.0113 -0.23 -0.22 Menarche (age at onset); chr17:55099178 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs2529507 ENSG00000275710.1 RP11-257O5.4 -4.08 5.53e-05 0.0113 -0.23 -0.22 Menarche (age at onset); chr17:55103911 chr17:54964474~54964679:+ LIHC cis rs244293 0.894 rs244372 ENSG00000275710.1 RP11-257O5.4 -4.08 5.53e-05 0.0113 -0.23 -0.22 Menarche (age at onset); chr17:55107851 chr17:54964474~54964679:+ LIHC cis rs244293 0.929 rs244371 ENSG00000275710.1 RP11-257O5.4 -4.08 5.53e-05 0.0113 -0.23 -0.22 Menarche (age at onset); chr17:55107864 chr17:54964474~54964679:+ LIHC cis rs244293 0.931 rs244370 ENSG00000275710.1 RP11-257O5.4 -4.08 5.53e-05 0.0113 -0.23 -0.22 Menarche (age at onset); chr17:55107906 chr17:54964474~54964679:+ LIHC cis rs244293 0.929 rs181728 ENSG00000275710.1 RP11-257O5.4 -4.08 5.53e-05 0.0113 -0.23 -0.22 Menarche (age at onset); chr17:55108442 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244369 ENSG00000275710.1 RP11-257O5.4 -4.08 5.53e-05 0.0113 -0.23 -0.22 Menarche (age at onset); chr17:55108700 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244368 ENSG00000275710.1 RP11-257O5.4 4.08 5.53e-05 0.0113 0.23 0.22 Menarche (age at onset); chr17:55109176 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244366 ENSG00000275710.1 RP11-257O5.4 4.08 5.53e-05 0.0113 0.23 0.22 Menarche (age at onset); chr17:55109939 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244365 ENSG00000275710.1 RP11-257O5.4 4.08 5.53e-05 0.0113 0.23 0.22 Menarche (age at onset); chr17:55110040 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244363 ENSG00000275710.1 RP11-257O5.4 4.08 5.53e-05 0.0113 0.23 0.22 Menarche (age at onset); chr17:55111532 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244356 ENSG00000275710.1 RP11-257O5.4 4.08 5.53e-05 0.0113 0.23 0.22 Menarche (age at onset); chr17:55116448 chr17:54964474~54964679:+ LIHC cis rs244293 0.899 rs244355 ENSG00000275710.1 RP11-257O5.4 4.08 5.53e-05 0.0113 0.23 0.22 Menarche (age at onset); chr17:55116724 chr17:54964474~54964679:+ LIHC cis rs13315871 0.615 rs7625655 ENSG00000272182.1 RP11-802O23.3 -4.08 5.54e-05 0.0113 -0.4 -0.22 Cholesterol, total; chr3:58351996 chr3:58428255~58428815:+ LIHC cis rs763121 0.925 rs9611008 ENSG00000273076.1 RP3-508I15.22 4.08 5.54e-05 0.0113 0.24 0.22 Menopause (age at onset); chr22:38702782 chr22:38743495~38743910:+ LIHC cis rs7580658 0.521 rs35577992 ENSG00000236682.1 AC068282.3 -4.08 5.55e-05 0.0114 -0.26 -0.22 Protein C levels; chr2:127183748 chr2:127389130~127400580:+ LIHC cis rs987724 0.515 rs453219 ENSG00000243926.1 TIPARP-AS1 4.08 5.55e-05 0.0114 0.24 0.22 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156856463 chr3:156671862~156674378:- LIHC cis rs11673344 0.683 rs11668615 ENSG00000226686.6 LINC01535 4.08 5.55e-05 0.0114 0.36 0.22 Obesity-related traits; chr19:37063632 chr19:37251912~37265535:+ LIHC cis rs6700559 0.815 rs7526365 ENSG00000260088.1 RP11-92G12.3 -4.08 5.56e-05 0.0114 -0.27 -0.22 Coronary artery disease; chr1:200688020 chr1:200669507~200694250:+ LIHC cis rs6142102 0.961 rs2377957 ENSG00000275784.1 RP5-1125A11.6 -4.08 5.56e-05 0.0114 -0.25 -0.22 Skin pigmentation; chr20:33966667 chr20:33989480~33991818:- LIHC cis rs17818399 0.62 rs1080871 ENSG00000239332.4 LINC01119 -4.08 5.56e-05 0.0114 -0.28 -0.22 Height; chr2:46627569 chr2:46816697~46859007:+ LIHC cis rs17818399 0.62 rs7598578 ENSG00000239332.4 LINC01119 -4.08 5.56e-05 0.0114 -0.28 -0.22 Height; chr2:46629946 chr2:46816697~46859007:+ LIHC cis rs17818399 0.62 rs1598517 ENSG00000239332.4 LINC01119 -4.08 5.56e-05 0.0114 -0.28 -0.22 Height; chr2:46630262 chr2:46816697~46859007:+ LIHC cis rs17818399 0.62 rs6739397 ENSG00000239332.4 LINC01119 -4.08 5.56e-05 0.0114 -0.28 -0.22 Height; chr2:46631182 chr2:46816697~46859007:+ LIHC cis rs4650994 1 rs4650994 ENSG00000213057.5 C1orf220 -4.08 5.56e-05 0.0114 -0.18 -0.22 HDL cholesterol;HDL cholesterol levels; chr1:178546177 chr1:178542752~178548889:+ LIHC cis rs4650994 0.967 rs4650992 ENSG00000213057.5 C1orf220 4.08 5.56e-05 0.0114 0.19 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178546000 chr1:178542752~178548889:+ LIHC cis rs4650994 1 rs4650993 ENSG00000213057.5 C1orf220 4.08 5.56e-05 0.0114 0.19 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178546052 chr1:178542752~178548889:+ LIHC cis rs4650994 0.935 rs12039531 ENSG00000213057.5 C1orf220 4.08 5.56e-05 0.0114 0.19 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178546477 chr1:178542752~178548889:+ LIHC cis rs4650994 1 rs10798616 ENSG00000213057.5 C1orf220 4.08 5.56e-05 0.0114 0.19 0.22 HDL cholesterol;HDL cholesterol levels; chr1:178546507 chr1:178542752~178548889:+ LIHC cis rs2243480 1 rs34702770 ENSG00000232546.1 RP11-458F8.1 -4.08 5.57e-05 0.0114 -0.24 -0.22 Diabetic kidney disease; chr7:65879836 chr7:66848496~66858136:+ LIHC cis rs2243480 0.803 rs35480979 ENSG00000232546.1 RP11-458F8.1 -4.08 5.57e-05 0.0114 -0.24 -0.22 Diabetic kidney disease; chr7:65892097 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs34637256 ENSG00000232546.1 RP11-458F8.1 -4.08 5.57e-05 0.0114 -0.24 -0.22 Diabetic kidney disease; chr7:65895144 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs35391607 ENSG00000232546.1 RP11-458F8.1 -4.08 5.57e-05 0.0114 -0.24 -0.22 Diabetic kidney disease; chr7:65895842 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs13220979 ENSG00000232546.1 RP11-458F8.1 -4.08 5.57e-05 0.0114 -0.24 -0.22 Diabetic kidney disease; chr7:65898217 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs34974928 ENSG00000232546.1 RP11-458F8.1 -4.08 5.57e-05 0.0114 -0.24 -0.22 Diabetic kidney disease; chr7:65899019 chr7:66848496~66858136:+ LIHC cis rs7726839 0.54 rs72703095 ENSG00000271781.1 CTD-2589H19.6 -4.08 5.57e-05 0.0114 -0.33 -0.22 Obesity-related traits; chr5:601674 chr5:675826~676616:+ LIHC cis rs755249 0.567 rs72637906 ENSG00000182109.6 RP11-69E11.4 4.08 5.57e-05 0.0114 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39242630 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs67886352 ENSG00000182109.6 RP11-69E11.4 4.08 5.57e-05 0.0114 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39243031 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs66727439 ENSG00000182109.6 RP11-69E11.4 4.08 5.57e-05 0.0114 0.28 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39246258 chr1:39522280~39546187:- LIHC cis rs9309711 0.621 rs12993215 ENSG00000225234.1 TRAPPC12-AS1 -4.08 5.57e-05 0.0114 -0.2 -0.22 Neurofibrillary tangles; chr2:3469956 chr2:3481242~3482409:- LIHC cis rs9304742 0.924 rs8111196 ENSG00000213801.4 ZNF816-ZNF321P 4.08 5.57e-05 0.0114 0.22 0.22 Psoriasis; chr19:52953970 chr19:52927135~52942601:- LIHC cis rs9304742 0.888 rs8111514 ENSG00000213801.4 ZNF816-ZNF321P 4.08 5.57e-05 0.0114 0.22 0.22 Psoriasis; chr19:52953993 chr19:52927135~52942601:- LIHC cis rs9304742 0.888 rs8112137 ENSG00000213801.4 ZNF816-ZNF321P 4.08 5.57e-05 0.0114 0.22 0.22 Psoriasis; chr19:52954002 chr19:52927135~52942601:- LIHC cis rs7083 0.967 rs558590 ENSG00000254851.1 RP11-109L13.1 4.08 5.58e-05 0.0114 0.31 0.22 Blood protein levels; chr11:117268405 chr11:117135528~117138582:+ LIHC cis rs889014 1 rs12517986 ENSG00000204758.6 CTC-308K20.1 4.08 5.58e-05 0.0114 0.31 0.22 Height; chr5:173568157 chr5:172954786~172959392:- LIHC cis rs4891159 0.79 rs17059379 ENSG00000265778.2 RP11-17M16.2 4.08 5.58e-05 0.0114 0.25 0.22 Longevity; chr18:76448360 chr18:76491652~76493918:+ LIHC cis rs6480314 1 rs6480314 ENSG00000233590.1 RP11-153K11.3 4.08 5.58e-05 0.0114 0.32 0.22 Optic nerve measurement (disc area); chr10:68207690 chr10:68233251~68242379:- LIHC cis rs2808510 1 rs2808500 ENSG00000230623.2 RP11-469A15.2 -4.08 5.58e-05 0.0114 -0.25 -0.22 Myopia; chr1:200361351 chr1:200473920~200478293:+ LIHC cis rs929596 0.563 rs1105879 ENSG00000233445.1 RPL17P11 4.08 5.58e-05 0.0114 0.23 0.22 Total bilirubin levels in HIV-1 infection; chr2:233693556 chr2:233721522~233722065:- LIHC cis rs7615952 0.599 rs1875683 ENSG00000171084.14 FAM86JP 4.08 5.58e-05 0.0114 0.34 0.22 Blood pressure (smoking interaction); chr3:126013638 chr3:125916620~125930024:+ LIHC cis rs244293 0.965 rs12453615 ENSG00000275710.1 RP11-257O5.4 -4.08 5.58e-05 0.0114 -0.23 -0.22 Menarche (age at onset); chr17:55100148 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs2628326 ENSG00000275710.1 RP11-257O5.4 -4.08 5.58e-05 0.0114 -0.23 -0.22 Menarche (age at onset); chr17:55100922 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs2787504 ENSG00000275710.1 RP11-257O5.4 -4.08 5.58e-05 0.0114 -0.23 -0.22 Menarche (age at onset); chr17:55100980 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244364 ENSG00000275710.1 RP11-257O5.4 4.08 5.58e-05 0.0114 0.23 0.22 Menarche (age at onset); chr17:55110919 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244360 ENSG00000275710.1 RP11-257O5.4 4.08 5.58e-05 0.0114 0.23 0.22 Menarche (age at onset); chr17:55114342 chr17:54964474~54964679:+ LIHC cis rs6860806 0.507 rs272878 ENSG00000263597.1 MIR3936 -4.08 5.59e-05 0.0114 -0.24 -0.22 Breast cancer; chr5:132336076 chr5:132365490~132365599:- LIHC cis rs7617480 0.61 rs4955420 ENSG00000270441.1 RP11-694I15.7 -4.08 5.59e-05 0.0114 -0.31 -0.22 Menarche (age at onset);Subjective well-being (multi-trait analysis); chr3:49171432 chr3:49140086~49160851:- LIHC cis rs113835537 0.935 rs11550057 ENSG00000255517.5 CTD-3074O7.5 -4.08 5.59e-05 0.0114 -0.38 -0.22 Airway imaging phenotypes; chr11:66625409 chr11:66473490~66480233:- LIHC cis rs113835537 0.935 rs15969 ENSG00000255517.5 CTD-3074O7.5 -4.08 5.59e-05 0.0114 -0.38 -0.22 Airway imaging phenotypes; chr11:66626916 chr11:66473490~66480233:- LIHC cis rs55794721 0.509 rs12027110 ENSG00000224183.1 SDHDP6 -4.08 5.59e-05 0.0114 -0.25 -0.22 Mean corpuscular volume;Plateletcrit; chr1:25449191 chr1:25294164~25294643:- LIHC cis rs9527 0.615 rs11191489 ENSG00000236937.2 PTGES3P4 4.08 5.59e-05 0.0114 0.27 0.22 Arsenic metabolism; chr10:102980811 chr10:102845595~102845950:+ LIHC cis rs13113518 0.812 rs13140590 ENSG00000249700.7 SRD5A3-AS1 4.08 5.59e-05 0.0114 0.25 0.22 Height; chr4:55548666 chr4:55363971~55395847:- LIHC cis rs2599510 0.811 rs2754523 ENSG00000276334.1 AL133243.1 4.08 5.59e-05 0.0114 0.24 0.22 Interleukin-18 levels; chr2:32612043 chr2:32521927~32523547:+ LIHC cis rs643506 0.845 rs762550 ENSG00000254990.4 RP11-108O10.2 4.08 5.6e-05 0.0114 0.24 0.22 Breast cancer; chr11:111912376 chr11:111768668~111778350:- LIHC cis rs9595908 0.709 rs56347753 ENSG00000212293.1 SNORA16 4.08 5.6e-05 0.0114 0.25 0.22 Body mass index; chr13:32721685 chr13:32420390~32420516:- LIHC cis rs9595908 0.669 rs9596149 ENSG00000212293.1 SNORA16 4.08 5.6e-05 0.0114 0.25 0.22 Body mass index; chr13:32722533 chr13:32420390~32420516:- LIHC cis rs9595908 0.709 rs4281583 ENSG00000212293.1 SNORA16 4.08 5.6e-05 0.0114 0.25 0.22 Body mass index; chr13:32722781 chr13:32420390~32420516:- LIHC cis rs9595908 0.686 rs9596155 ENSG00000212293.1 SNORA16 4.08 5.6e-05 0.0114 0.25 0.22 Body mass index; chr13:32724002 chr13:32420390~32420516:- LIHC cis rs9595908 0.709 rs7322827 ENSG00000212293.1 SNORA16 4.08 5.6e-05 0.0114 0.25 0.22 Body mass index; chr13:32724396 chr13:32420390~32420516:- LIHC cis rs9595908 0.629 rs9596156 ENSG00000212293.1 SNORA16 4.08 5.6e-05 0.0114 0.25 0.22 Body mass index; chr13:32724977 chr13:32420390~32420516:- LIHC cis rs9595908 0.669 rs7319787 ENSG00000212293.1 SNORA16 4.08 5.6e-05 0.0114 0.25 0.22 Body mass index; chr13:32728320 chr13:32420390~32420516:- LIHC cis rs9595908 0.669 rs7331529 ENSG00000212293.1 SNORA16 4.08 5.6e-05 0.0114 0.25 0.22 Body mass index; chr13:32728409 chr13:32420390~32420516:- LIHC cis rs755249 0.529 rs3768299 ENSG00000182109.6 RP11-69E11.4 4.08 5.6e-05 0.0114 0.27 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39391520 chr1:39522280~39546187:- LIHC cis rs6832769 1 rs10016506 ENSG00000272969.1 RP11-528I4.2 -4.08 5.6e-05 0.0114 -0.26 -0.22 Personality dimensions; chr4:55530507 chr4:55547112~55547889:+ LIHC cis rs2658782 0.507 rs4457713 ENSG00000279684.1 RP11-755E23.2 -4.08 5.6e-05 0.0114 -0.31 -0.22 Pulmonary function decline; chr11:93304264 chr11:93286629~93288903:- LIHC cis rs2836974 0.545 rs8128901 ENSG00000255568.3 BRWD1-AS2 4.08 5.6e-05 0.0114 0.2 0.22 Cognitive function; chr21:39338493 chr21:39313935~39314962:+ LIHC cis rs10080237 0.564 rs2490224 ENSG00000272129.1 RP11-250B2.6 4.08 5.6e-05 0.0114 0.21 0.22 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr6:80100116 chr6:80355424~80356859:+ LIHC cis rs1799949 0.896 rs8176086 ENSG00000267681.1 CTD-3199J23.6 -4.08 5.61e-05 0.0114 -0.21 -0.22 Menopause (age at onset); chr17:43122761 chr17:43144956~43145255:+ LIHC cis rs9326248 0.59 rs2542063 ENSG00000280143.1 AP000892.6 4.08 5.61e-05 0.0114 0.24 0.22 Blood protein levels; chr11:116814051 chr11:117204967~117210292:+ LIHC cis rs4561483 0.801 rs33643 ENSG00000261560.1 RP11-166B2.3 -4.08 5.61e-05 0.0115 -0.25 -0.22 Testicular germ cell tumor; chr16:11892292 chr16:11881075~11882569:- LIHC cis rs755249 0.762 rs1775654 ENSG00000182109.6 RP11-69E11.4 4.08 5.61e-05 0.0115 0.23 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39484408 chr1:39522280~39546187:- LIHC cis rs2790457 0.958 rs2772431 ENSG00000254635.4 WAC-AS1 -4.08 5.61e-05 0.0115 -0.2 -0.22 Multiple myeloma; chr10:28601231 chr10:28522652~28532743:- LIHC cis rs1005277 0.505 rs10827835 ENSG00000276805.1 RP11-291L22.6 -4.08 5.61e-05 0.0115 -0.26 -0.22 Extrinsic epigenetic age acceleration; chr10:37861781 chr10:38451030~38451785:+ LIHC cis rs12468226 1 rs76021735 ENSG00000272966.1 RP11-686O6.1 4.08 5.61e-05 0.0115 0.36 0.22 Urate levels; chr2:202511476 chr2:202336739~202337200:+ LIHC cis rs12468226 1 rs57080353 ENSG00000272966.1 RP11-686O6.1 4.08 5.61e-05 0.0115 0.36 0.22 Urate levels; chr2:202511824 chr2:202336739~202337200:+ LIHC cis rs12468226 0.81 rs3736578 ENSG00000272966.1 RP11-686O6.1 4.08 5.61e-05 0.0115 0.36 0.22 Urate levels; chr2:202519989 chr2:202336739~202337200:+ LIHC cis rs12468226 1 rs116439150 ENSG00000272966.1 RP11-686O6.1 4.08 5.61e-05 0.0115 0.36 0.22 Urate levels; chr2:202523814 chr2:202336739~202337200:+ LIHC cis rs12468226 1 rs12467409 ENSG00000272966.1 RP11-686O6.1 4.08 5.61e-05 0.0115 0.36 0.22 Urate levels; chr2:202529625 chr2:202336739~202337200:+ LIHC cis rs17270561 0.562 rs12199626 ENSG00000272810.1 U91328.22 -4.08 5.62e-05 0.0115 -0.28 -0.22 Iron status biomarkers; chr6:26013376 chr6:26013241~26013757:+ LIHC cis rs7412746 0.658 rs3768016 ENSG00000231073.1 RP11-316M1.3 4.08 5.62e-05 0.0115 0.22 0.22 Melanoma; chr1:150837443 chr1:150973123~150975534:+ LIHC cis rs9400467 0.528 rs11153280 ENSG00000271789.1 RP5-1112D6.7 -4.08 5.62e-05 0.0115 -0.21 -0.22 Amino acid levels;Blood metabolite levels; chr6:111268090 chr6:111297126~111298510:+ LIHC cis rs3758785 0.623 rs77241189 ENSG00000255893.1 RP11-685N10.1 -4.08 5.62e-05 0.0115 -0.26 -0.22 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94410151 chr11:94472908~94473570:- LIHC cis rs11098499 0.569 rs10023641 ENSG00000260091.1 RP11-33B1.4 -4.08 5.62e-05 0.0115 -0.14 -0.22 Corneal astigmatism; chr4:119337255 chr4:119409333~119410233:+ LIHC cis rs17834679 0.957 rs59546961 ENSG00000243680.1 RPL37P23 -4.08 5.62e-05 0.0115 -0.19 -0.22 Alopecia areata; chr19:51766957 chr19:52143043~52143336:+ LIHC cis rs901683 0.85 rs12778143 ENSG00000230869.1 CTGLF10P -4.08 5.62e-05 0.0115 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45568092 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12776336 ENSG00000230869.1 CTGLF10P -4.08 5.62e-05 0.0115 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45568463 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs33997730 ENSG00000230869.1 CTGLF10P -4.08 5.62e-05 0.0115 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45572665 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35639934 ENSG00000230869.1 CTGLF10P -4.08 5.62e-05 0.0115 -0.53 -0.22 Mean corpuscular volume;Red blood cell traits; chr10:45575179 chr10:45678692~45700532:+ LIHC cis rs67311347 1 rs897117 ENSG00000223797.4 ENTPD3-AS1 -4.08 5.62e-05 0.0115 -0.17 -0.22 Renal cell carcinoma; chr3:40395803 chr3:40313802~40453329:- LIHC cis rs2439831 0.85 rs11856795 ENSG00000275601.1 AC011330.13 -4.08 5.62e-05 0.0115 -0.32 -0.22 Lung cancer in ever smokers; chr15:43868384 chr15:43642389~43643023:- LIHC cis rs950880 0.71 rs17027258 ENSG00000234389.1 AC007278.3 -4.08 5.63e-05 0.0115 -0.21 -0.22 Serum protein levels (sST2); chr2:102475081 chr2:102438713~102440475:+ LIHC cis rs3015497 0.616 rs1494181 ENSG00000269906.1 RP11-248J18.2 4.08 5.64e-05 0.0115 0.27 0.22 Mean platelet volume; chr14:50589882 chr14:50662511~50663178:- LIHC cis rs812925 0.511 rs11886950 ENSG00000271889.1 RP11-493E12.1 4.08 5.64e-05 0.0115 0.25 0.22 Immature fraction of reticulocytes; chr2:61172182 chr2:61151433~61162105:- LIHC cis rs875971 0.522 rs7784623 ENSG00000273024.4 INTS4P2 -4.08 5.64e-05 0.0115 -0.26 -0.22 Aortic root size; chr7:65930047 chr7:65647864~65715661:+ LIHC cis rs10995505 0.589 rs1553789 ENSG00000232075.1 MRPL35P2 4.08 5.64e-05 0.0115 0.24 0.22 Intelligence (multi-trait analysis); chr10:63119469 chr10:63634317~63634827:- LIHC cis rs10871290 0.551 rs3863435 ENSG00000214331.7 RP11-252A24.2 -4.08 5.64e-05 0.0115 -0.18 -0.22 Breast cancer; chr16:74431498 chr16:74332402~74368240:- LIHC cis rs12210905 0.92 rs9393802 ENSG00000216901.1 AL022393.7 4.08 5.65e-05 0.0115 0.36 0.22 Hip circumference adjusted for BMI; chr6:27275326 chr6:28176188~28176674:+ LIHC cis rs42490 0.868 rs1605996 ENSG00000251136.7 RP11-37B2.1 4.08 5.65e-05 0.0115 0.19 0.22 Leprosy; chr8:89655674 chr8:89609409~89757727:- LIHC cis rs803923 0.585 rs803931 ENSG00000230894.1 RP11-67K19.3 -4.08 5.65e-05 0.0115 -0.27 -0.22 Lung function (FEV1/FVC); chr9:116696405 chr9:116568449~116586328:+ LIHC cis rs1223397 0.651 rs202023 ENSG00000215022.6 RP1-257A7.4 -4.08 5.65e-05 0.0115 -0.23 -0.22 Blood pressure; chr6:13304426 chr6:13264861~13295586:- LIHC cis rs3015497 0.526 rs10136630 ENSG00000269906.1 RP11-248J18.2 4.08 5.66e-05 0.0115 0.26 0.22 Mean platelet volume; chr14:50579756 chr14:50662511~50663178:- LIHC cis rs11247230 1 rs11247230 ENSG00000270127.2 RP11-526I2.5 4.08 5.66e-05 0.0115 0.24 0.22 Optic cup area; chr15:100656800 chr15:100547765~100550153:- LIHC cis rs10857712 0.95 rs11101744 ENSG00000214279.11 SCART1 -4.08 5.66e-05 0.0115 -0.26 -0.22 Systemic lupus erythematosus; chr10:133412537 chr10:133453928~133523558:+ LIHC cis rs10510102 0.808 rs11200296 ENSG00000273891.1 RP11-500G22.5 4.08 5.66e-05 0.0115 0.3 0.22 Breast cancer; chr10:121971956 chr10:121965764~121967700:+ LIHC cis rs8005677 0.828 rs712486 ENSG00000257285.4 RP11-298I3.1 4.08 5.67e-05 0.0115 0.22 0.22 Cognitive ability (multi-trait analysis); chr14:22955832 chr14:22929609~22955562:+ LIHC cis rs57502260 0.704 rs72936599 ENSG00000212093.1 AP000807.1 4.08 5.67e-05 0.0115 0.29 0.22 Total body bone mineral density (age 45-60); chr11:68552937 chr11:68506083~68506166:- LIHC cis rs3015497 0.789 rs1389652 ENSG00000269906.1 RP11-248J18.2 4.08 5.67e-05 0.0116 0.27 0.22 Mean platelet volume; chr14:50658522 chr14:50662511~50663178:- LIHC cis rs6860806 0.507 rs2631369 ENSG00000263597.1 MIR3936 -4.08 5.67e-05 0.0116 -0.23 -0.22 Breast cancer; chr5:132369574 chr5:132365490~132365599:- LIHC cis rs274567 0.501 rs2631368 ENSG00000263597.1 MIR3936 -4.08 5.67e-05 0.0116 -0.23 -0.22 Blood metabolite levels; chr5:132369605 chr5:132365490~132365599:- LIHC cis rs12468226 1 rs2350809 ENSG00000272966.1 RP11-686O6.1 4.08 5.67e-05 0.0116 0.35 0.22 Urate levels; chr2:202464210 chr2:202336739~202337200:+ LIHC cis rs801193 0.613 rs2659900 ENSG00000237310.1 GS1-124K5.4 4.08 5.67e-05 0.0116 0.19 0.22 Aortic root size; chr7:66719456 chr7:66493706~66495474:+ LIHC cis rs651907 0.557 rs36002990 ENSG00000244119.1 PDCL3P4 4.08 5.68e-05 0.0116 0.22 0.22 Colorectal cancer; chr3:101719018 chr3:101712472~101713191:+ LIHC cis rs651907 0.557 rs11720745 ENSG00000244119.1 PDCL3P4 4.08 5.68e-05 0.0116 0.22 0.22 Colorectal cancer; chr3:101722846 chr3:101712472~101713191:+ LIHC cis rs651907 0.557 rs35117343 ENSG00000244119.1 PDCL3P4 4.08 5.68e-05 0.0116 0.22 0.22 Colorectal cancer; chr3:101726282 chr3:101712472~101713191:+ LIHC cis rs651907 0.557 rs11914318 ENSG00000244119.1 PDCL3P4 4.08 5.68e-05 0.0116 0.22 0.22 Colorectal cancer; chr3:101735014 chr3:101712472~101713191:+ LIHC cis rs651907 0.557 rs1031710 ENSG00000244119.1 PDCL3P4 4.08 5.68e-05 0.0116 0.22 0.22 Colorectal cancer; chr3:101745051 chr3:101712472~101713191:+ LIHC cis rs651907 0.535 rs13065944 ENSG00000244119.1 PDCL3P4 4.08 5.68e-05 0.0116 0.22 0.22 Colorectal cancer; chr3:101754244 chr3:101712472~101713191:+ LIHC cis rs57502260 0.573 rs11228294 ENSG00000212093.1 AP000807.1 4.08 5.68e-05 0.0116 0.25 0.22 Total body bone mineral density (age 45-60); chr11:68621099 chr11:68506083~68506166:- LIHC cis rs11671005 0.656 rs11672609 ENSG00000269473.1 CTD-2619J13.19 4.08 5.68e-05 0.0116 0.4 0.22 Mean platelet volume; chr19:58495557 chr19:58440448~58445849:+ LIHC cis rs1799949 1 rs8176234 ENSG00000267681.1 CTD-3199J23.6 -4.08 5.68e-05 0.0116 -0.21 -0.22 Menopause (age at onset); chr17:43067763 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs8176233 ENSG00000267681.1 CTD-3199J23.6 -4.08 5.68e-05 0.0116 -0.21 -0.22 Menopause (age at onset); chr17:43067787 chr17:43144956~43145255:+ LIHC cis rs9952991 0.883 rs2542148 ENSG00000260302.1 RP11-973H7.1 -4.08 5.68e-05 0.0116 -0.32 -0.22 Inflammatory skin disease; chr18:12777574 chr18:12774651~12775923:- LIHC cis rs10985070 0.507 rs12551347 ENSG00000226752.6 PSMD5-AS1 -4.08 5.68e-05 0.0116 -0.23 -0.22 Rheumatoid arthritis; chr9:121174316 chr9:120824828~120854385:+ LIHC cis rs617219 0.746 rs2591391 ENSG00000251675.1 CTC-458I2.2 -4.08 5.68e-05 0.0116 -0.25 -0.22 Betaine levels in individuals undergoing cardiac evaluation; chr5:79250632 chr5:80128361~80143883:+ LIHC cis rs11696277 0.518 rs6044739 ENSG00000232333.1 RPS27AP2 -4.08 5.69e-05 0.0116 -0.3 -0.22 Gut microbiome composition (summer); chr20:17335297 chr20:17516843~17517307:+ LIHC cis rs9326248 0.574 rs1263173 ENSG00000280143.1 AP000892.6 4.08 5.69e-05 0.0116 0.24 0.22 Blood protein levels; chr11:116810292 chr11:117204967~117210292:+ LIHC cis rs2243480 1 rs313831 ENSG00000228409.4 CCT6P1 4.08 5.69e-05 0.0116 0.23 0.22 Diabetic kidney disease; chr7:66086239 chr7:65751142~65763354:+ LIHC cis rs860295 0.836 rs35615695 ENSG00000203761.5 MSTO2P 4.08 5.69e-05 0.0116 0.17 0.22 Body mass index; chr1:155531223 chr1:155745829~155750137:+ LIHC cis rs1005277 0.505 rs200939 ENSG00000276805.1 RP11-291L22.6 4.08 5.69e-05 0.0116 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:37850555 chr10:38451030~38451785:+ LIHC cis rs11874381 0.582 rs6507943 ENSG00000267322.2 SNHG22 4.08 5.69e-05 0.0116 0.25 0.22 C-reactive protein levels or HDL-cholesterol levels (pleiotropy); chr18:49686717 chr18:49814023~49851059:+ LIHC cis rs7119038 0.818 rs10892294 ENSG00000255239.1 AP002954.6 4.08 5.7e-05 0.0116 0.3 0.22 Sjögren's syndrome; chr11:118796648 chr11:118688039~118690600:- LIHC cis rs1005277 0.505 rs200935 ENSG00000276805.1 RP11-291L22.6 4.08 5.7e-05 0.0116 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:37843882 chr10:38451030~38451785:+ LIHC cis rs1005277 0.505 rs200936 ENSG00000276805.1 RP11-291L22.6 4.08 5.7e-05 0.0116 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:37846007 chr10:38451030~38451785:+ LIHC cis rs1005277 0.505 rs200937 ENSG00000276805.1 RP11-291L22.6 4.08 5.7e-05 0.0116 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:37846844 chr10:38451030~38451785:+ LIHC cis rs417065 1 rs11588819 ENSG00000227634.1 RP11-431K24.3 -4.08 5.7e-05 0.0116 -0.28 -0.22 Psoriasis; chr1:8200885 chr1:8208672~8215210:+ LIHC cis rs748404 0.631 rs3809482 ENSG00000166763.7 STRCP1 4.08 5.7e-05 0.0116 0.27 0.22 Lung cancer; chr15:43369604 chr15:43699488~43718184:- LIHC cis rs11121022 1 rs11121022 ENSG00000269925.1 RP3-467L1.6 -4.08 5.7e-05 0.0116 -0.22 -0.22 Morning vs. evening chronotype; chr1:7776599 chr1:7776383~7776775:+ LIHC cis rs8032158 0.502 rs2136385 ENSG00000279145.1 RP11-547D13.1 4.08 5.7e-05 0.0116 0.22 0.22 Keloid; chr15:55943047 chr15:55171972~55178175:- LIHC cis rs4694744 0.538 rs13111134 ENSG00000264696.1 AC108078.1 4.08 5.7e-05 0.0116 0.32 0.22 Bacteremia; chr4:69489093 chr4:69479331~69479434:+ LIHC cis rs1023500 0.505 rs134889 ENSG00000226450.2 CYP2D8P 4.08 5.71e-05 0.0116 0.24 0.22 Schizophrenia; chr22:42278344 chr22:42149886~42155001:- LIHC cis rs10510102 0.516 rs10159589 ENSG00000276742.1 RP11-500G22.4 4.08 5.71e-05 0.0116 0.36 0.22 Breast cancer; chr10:121986659 chr10:121956782~121957098:+ LIHC cis rs904251 0.965 rs62406516 ENSG00000204110.6 RP1-153P14.8 -4.08 5.71e-05 0.0116 -0.26 -0.22 Cognitive performance; chr6:37471588 chr6:37507348~37535616:+ LIHC cis rs1075265 0.692 rs805358 ENSG00000233266.1 HMGB1P31 4.08 5.71e-05 0.0116 0.27 0.22 Chronotype;Morning vs. evening chronotype; chr2:53934885 chr2:54051334~54051760:+ LIHC cis rs1499614 0.803 rs1796229 ENSG00000232546.1 RP11-458F8.1 -4.08 5.71e-05 0.0116 -0.24 -0.22 Gout; chr7:66654674 chr7:66848496~66858136:+ LIHC cis rs1499614 0.901 rs3936 ENSG00000232546.1 RP11-458F8.1 -4.08 5.71e-05 0.0116 -0.24 -0.22 Gout; chr7:66661502 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs160642 ENSG00000230295.1 RP11-458F8.2 -4.08 5.71e-05 0.0116 -0.22 -0.22 Diabetic kidney disease; chr7:66093386 chr7:66880708~66882981:+ LIHC cis rs2243480 0.614 rs34032527 ENSG00000230295.1 RP11-458F8.2 -4.08 5.71e-05 0.0116 -0.22 -0.22 Diabetic kidney disease; chr7:66100154 chr7:66880708~66882981:+ LIHC cis rs801193 0.66 rs2659914 ENSG00000237310.1 GS1-124K5.4 4.08 5.71e-05 0.0116 0.19 0.22 Aortic root size; chr7:66691927 chr7:66493706~66495474:+ LIHC cis rs933688 1 rs12651840 ENSG00000281357.1 ARRDC3-AS1 4.08 5.71e-05 0.0116 0.27 0.22 Smoking behavior; chr5:91433775 chr5:91380349~91439085:+ LIHC cis rs933688 1 rs2052553 ENSG00000281357.1 ARRDC3-AS1 4.08 5.71e-05 0.0116 0.27 0.22 Smoking behavior; chr5:91434089 chr5:91380349~91439085:+ LIHC cis rs638893 0.853 rs4938549 ENSG00000255239.1 AP002954.6 4.08 5.71e-05 0.0116 0.37 0.22 Vitiligo; chr11:118830888 chr11:118688039~118690600:- LIHC cis rs638893 0.898 rs530646 ENSG00000255239.1 AP002954.6 4.08 5.71e-05 0.0116 0.37 0.22 Vitiligo; chr11:118830959 chr11:118688039~118690600:- LIHC cis rs638893 0.947 rs12808822 ENSG00000255239.1 AP002954.6 4.08 5.71e-05 0.0116 0.37 0.22 Vitiligo; chr11:118831560 chr11:118688039~118690600:- LIHC cis rs875971 0.545 rs1796217 ENSG00000228409.4 CCT6P1 4.08 5.71e-05 0.0116 0.18 0.22 Aortic root size; chr7:66620931 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs160655 ENSG00000228409.4 CCT6P1 4.08 5.71e-05 0.0116 0.23 0.22 Diabetic kidney disease; chr7:66068227 chr7:65751142~65763354:+ LIHC cis rs2919917 0.628 rs9643739 ENSG00000254352.1 RP11-578O24.2 4.08 5.71e-05 0.0116 0.32 0.22 Lymphocyte counts; chr8:78679535 chr8:78723796~78724136:- LIHC cis rs2919917 0.628 rs2170732 ENSG00000254352.1 RP11-578O24.2 4.08 5.71e-05 0.0116 0.32 0.22 Lymphocyte counts; chr8:78684261 chr8:78723796~78724136:- LIHC cis rs7615952 0.599 rs6766327 ENSG00000171084.14 FAM86JP 4.08 5.71e-05 0.0116 0.34 0.22 Blood pressure (smoking interaction); chr3:126004834 chr3:125916620~125930024:+ LIHC cis rs1005277 0.505 rs200910 ENSG00000276805.1 RP11-291L22.6 4.08 5.72e-05 0.0116 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:37819248 chr10:38451030~38451785:+ LIHC cis rs2283792 0.765 rs8139376 ENSG00000224086.5 LL22NC03-86G7.1 -4.08 5.72e-05 0.0116 -0.22 -0.22 Multiple sclerosis; chr22:21755307 chr22:21938293~21977632:+ LIHC cis rs2598107 0.601 rs3807612 ENSG00000211698.2 TRGV4 -4.07 5.73e-05 0.0117 -0.25 -0.22 Dupuytren's disease; chr7:37918169 chr7:38353715~38354517:- LIHC cis rs1005277 0.505 rs719569 ENSG00000276805.1 RP11-291L22.6 -4.07 5.73e-05 0.0117 -0.26 -0.22 Extrinsic epigenetic age acceleration; chr10:37865487 chr10:38451030~38451785:+ LIHC cis rs1005277 0.522 rs200943 ENSG00000276805.1 RP11-291L22.6 4.07 5.73e-05 0.0117 0.26 0.22 Extrinsic epigenetic age acceleration; chr10:37859802 chr10:38451030~38451785:+ LIHC cis rs748404 0.588 rs506120 ENSG00000166763.7 STRCP1 4.07 5.73e-05 0.0117 0.27 0.22 Lung cancer; chr15:43509826 chr15:43699488~43718184:- LIHC cis rs11096990 0.855 rs2711989 ENSG00000249207.1 RP11-360F5.1 4.07 5.73e-05 0.0117 0.25 0.22 Cognitive function; chr4:39150416 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2566169 ENSG00000249207.1 RP11-360F5.1 4.07 5.73e-05 0.0117 0.25 0.22 Cognitive function; chr4:39150420 chr4:39112677~39126818:- LIHC cis rs10829156 0.796 rs6482567 ENSG00000225527.1 RP11-383B4.4 -4.07 5.73e-05 0.0117 -0.36 -0.22 Sudden cardiac arrest; chr10:18625860 chr10:18531849~18533336:- LIHC cis rs11673344 0.536 rs62108291 ENSG00000226686.6 LINC01535 4.07 5.73e-05 0.0117 0.3 0.22 Obesity-related traits; chr19:37659457 chr19:37251912~37265535:+ LIHC cis rs5758511 0.514 rs5751221 ENSG00000205702.9 CYP2D7 4.07 5.73e-05 0.0117 0.25 0.22 Birth weight; chr22:42120362 chr22:42140203~42144577:- LIHC cis rs7811142 1 rs11761725 ENSG00000242294.5 STAG3L5P 4.07 5.74e-05 0.0117 0.27 0.22 Platelet count; chr7:100442192 chr7:100336079~100351900:+ LIHC cis rs7811142 1 rs2406255 ENSG00000242294.5 STAG3L5P 4.07 5.74e-05 0.0117 0.27 0.22 Platelet count; chr7:100456067 chr7:100336079~100351900:+ LIHC cis rs603446 0.56 rs1240781 ENSG00000254851.1 RP11-109L13.1 4.07 5.74e-05 0.0117 0.28 0.22 Triglycerides; chr11:116704101 chr11:117135528~117138582:+ LIHC cis rs7131987 0.903 rs11050161 ENSG00000275476.1 RP11-996F15.4 -4.07 5.74e-05 0.0117 -0.25 -0.22 QT interval; chr12:29267116 chr12:29277397~29277882:- LIHC cis rs7131987 0.903 rs11050162 ENSG00000275476.1 RP11-996F15.4 -4.07 5.74e-05 0.0117 -0.25 -0.22 QT interval; chr12:29267121 chr12:29277397~29277882:- LIHC cis rs55966801 0.853 rs505404 ENSG00000277290.1 RP11-326C3.16 -4.07 5.74e-05 0.0117 -0.26 -0.22 Plateletcrit; chr11:243268 chr11:243099~243483:- LIHC cis rs6504622 0.755 rs12939753 ENSG00000262879.4 RP11-156P1.3 -4.07 5.74e-05 0.0117 -0.23 -0.22 Orofacial clefts; chr17:47104133 chr17:46984045~47100323:- LIHC cis rs7893279 0.505 rs2130531 ENSG00000225527.1 RP11-383B4.4 4.07 5.74e-05 0.0117 0.3 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18658450 chr10:18531849~18533336:- LIHC cis rs7893279 0.505 rs11015435 ENSG00000225527.1 RP11-383B4.4 4.07 5.74e-05 0.0117 0.3 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18659143 chr10:18531849~18533336:- LIHC cis rs9906944 0.898 rs9909861 ENSG00000248278.1 SUMO2P17 -4.07 5.74e-05 0.0117 -0.37 -0.22 Intelligence (multi-trait analysis);Body fat percentage; chr17:49002054 chr17:48874860~48908983:- LIHC cis rs3733589 0.744 rs3775939 ENSG00000250413.1 RP11-448G15.1 4.07 5.74e-05 0.0117 0.35 0.22 Renal overload gout; chr4:10023672 chr4:10006482~10009725:+ LIHC cis rs904251 0.772 rs10692 ENSG00000204110.6 RP1-153P14.8 -4.07 5.74e-05 0.0117 -0.26 -0.22 Cognitive performance; chr6:37483138 chr6:37507348~37535616:+ LIHC cis rs6452524 1 rs11958314 ENSG00000271862.1 RP11-343L5.2 4.07 5.74e-05 0.0117 0.25 0.22 Hypertension (SNP x SNP interaction); chr5:83132929 chr5:83049376~83050964:- LIHC cis rs6452524 0.686 rs6452517 ENSG00000271862.1 RP11-343L5.2 4.07 5.74e-05 0.0117 0.25 0.22 Hypertension (SNP x SNP interaction); chr5:83133041 chr5:83049376~83050964:- LIHC cis rs4578769 0.802 rs66816194 ENSG00000266850.1 RP11-370A5.1 -4.07 5.75e-05 0.0117 -0.25 -0.22 Eosinophil percentage of white cells; chr18:22895554 chr18:22723491~22907721:- LIHC cis rs853679 0.766 rs9368561 ENSG00000219392.1 RP1-265C24.5 -4.07 5.75e-05 0.0117 -0.41 -0.22 Depression; chr6:28200565 chr6:28115628~28116551:+ LIHC cis rs7923609 0.846 rs9787438 ENSG00000232075.1 MRPL35P2 -4.07 5.75e-05 0.0117 -0.24 -0.22 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63278270 chr10:63634317~63634827:- LIHC cis rs12681366 0.881 rs3019149 ENSG00000253704.1 RP11-267M23.4 4.07 5.75e-05 0.0117 0.26 0.22 Nonsyndromic cleft lip with cleft palate; chr8:94418351 chr8:94553722~94569745:+ LIHC cis rs10833905 1 rs57275726 ENSG00000246225.5 RP11-17A1.3 -4.07 5.75e-05 0.0117 -0.27 -0.22 Sudden cardiac arrest; chr11:23024166 chr11:22829380~22945393:+ LIHC cis rs1874124 0.577 rs2807872 ENSG00000238078.1 LINC01352 -4.07 5.75e-05 0.0117 -0.36 -0.22 Cholesterol, total; chr1:220866908 chr1:220829255~220832429:+ LIHC cis rs6445975 0.667 rs2037123 ENSG00000272360.1 RP11-359I18.5 -4.07 5.75e-05 0.0117 -0.25 -0.22 Systemic lupus erythematosus; chr3:58253466 chr3:58490830~58491291:- LIHC cis rs6445975 0.575 rs7614726 ENSG00000272360.1 RP11-359I18.5 -4.07 5.75e-05 0.0117 -0.25 -0.22 Systemic lupus erythematosus; chr3:58257562 chr3:58490830~58491291:- LIHC cis rs6445975 0.667 rs34532954 ENSG00000272360.1 RP11-359I18.5 -4.07 5.75e-05 0.0117 -0.25 -0.22 Systemic lupus erythematosus; chr3:58257867 chr3:58490830~58491291:- LIHC cis rs4356203 0.905 rs7927240 ENSG00000260196.1 RP1-239B22.5 -4.07 5.76e-05 0.0117 -0.26 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17056681 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs7946165 ENSG00000260196.1 RP1-239B22.5 -4.07 5.76e-05 0.0117 -0.26 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17057080 chr11:17380649~17383531:+ LIHC cis rs4356203 0.875 rs7939614 ENSG00000260196.1 RP1-239B22.5 -4.07 5.76e-05 0.0117 -0.26 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17058073 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs9919600 ENSG00000260196.1 RP1-239B22.5 -4.07 5.76e-05 0.0117 -0.26 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17058198 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs9919540 ENSG00000260196.1 RP1-239B22.5 -4.07 5.76e-05 0.0117 -0.26 -0.22 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17058786 chr11:17380649~17383531:+ LIHC cis rs13113518 0.812 rs6830409 ENSG00000249700.7 SRD5A3-AS1 4.07 5.76e-05 0.0117 0.25 0.22 Height; chr4:55522229 chr4:55363971~55395847:- LIHC cis rs794185 0.592 rs304078 ENSG00000231249.1 ITPR1-AS1 -4.07 5.76e-05 0.0117 -0.24 -0.22 Multiple sclerosis--Brain Glutamate Levels; chr3:4491474 chr3:4490891~4493163:- LIHC cis rs11098499 0.691 rs17009144 ENSG00000245958.5 RP11-33B1.1 4.07 5.76e-05 0.0117 0.21 0.22 Corneal astigmatism; chr4:119349640 chr4:119454791~119552025:+ LIHC cis rs694739 1 rs499425 ENSG00000236935.1 AP003774.1 -4.07 5.76e-05 0.0117 -0.23 -0.22 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64338457 chr11:64325050~64329504:- LIHC cis rs4578769 0.765 rs8091950 ENSG00000266850.1 RP11-370A5.1 4.07 5.76e-05 0.0117 0.25 0.22 Eosinophil percentage of white cells; chr18:22859136 chr18:22723491~22907721:- LIHC cis rs7893279 0.505 rs12766314 ENSG00000225527.1 RP11-383B4.4 4.07 5.76e-05 0.0117 0.31 0.22 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18584361 chr10:18531849~18533336:- LIHC cis rs1928295 0.786 rs10983720 ENSG00000233569.1 RP11-500B12.1 4.07 5.76e-05 0.0117 0.22 0.22 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117625209 chr9:117648606~117657027:+ LIHC cis rs1928295 0.75 rs10818054 ENSG00000233569.1 RP11-500B12.1 4.07 5.76e-05 0.0117 0.22 0.22 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117625739 chr9:117648606~117657027:+ LIHC cis rs55794721 0.509 rs873308 ENSG00000224183.1 SDHDP6 4.07 5.77e-05 0.0117 0.25 0.22 Mean corpuscular volume;Plateletcrit; chr1:25432164 chr1:25294164~25294643:- LIHC cis rs11671005 0.656 rs55652736 ENSG00000269473.1 CTD-2619J13.19 4.07 5.77e-05 0.0117 0.4 0.22 Mean platelet volume; chr19:58496199 chr19:58440448~58445849:+ LIHC cis rs11098499 0.863 rs10004484 ENSG00000260091.1 RP11-33B1.4 -4.07 5.77e-05 0.0117 -0.16 -0.22 Corneal astigmatism; chr4:119521273 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs1155576 ENSG00000260091.1 RP11-33B1.4 -4.07 5.77e-05 0.0117 -0.16 -0.22 Corneal astigmatism; chr4:119529004 chr4:119409333~119410233:+ LIHC cis rs3015497 0.626 rs7150204 ENSG00000269906.1 RP11-248J18.2 4.07 5.77e-05 0.0117 0.28 0.22 Mean platelet volume; chr14:50670637 chr14:50662511~50663178:- LIHC cis rs72675573 0.852 rs1757915 ENSG00000235612.1 RP1-158P9.1 -4.07 5.77e-05 0.0117 -0.28 -0.22 Monocyte count; chr1:56150137 chr1:56145721~56155224:+ LIHC cis rs11690935 0.61 rs3770458 ENSG00000228389.1 AC068039.4 -4.07 5.78e-05 0.0117 -0.26 -0.22 Schizophrenia; chr2:171794777 chr2:171773482~171775844:+ LIHC cis rs2762353 0.776 rs942379 ENSG00000242387.1 HIST1H2APS2 4.07 5.78e-05 0.0117 0.25 0.22 Blood metabolite levels; chr6:25849392 chr6:25882026~25882395:- LIHC cis rs6061231 0.631 rs927133 ENSG00000226332.2 RP11-157P1.4 4.07 5.78e-05 0.0117 0.23 0.22 Colorectal cancer; chr20:62397053 chr20:62305432~62306325:- LIHC cis rs9652601 0.959 rs12919083 ENSG00000274038.1 RP11-66H6.4 4.07 5.78e-05 0.0117 0.26 0.22 Systemic lupus erythematosus; chr16:11095073 chr16:11056556~11057034:+ LIHC cis rs494453 1 rs494453 ENSG00000227811.2 FAM212B-AS1 -4.07 5.79e-05 0.0118 -0.24 -0.22 Osteoporosis-related phenotypes; chr1:111649500 chr1:111739841~111747798:+ LIHC cis rs1558001 0.84 rs11760903 ENSG00000230196.1 DDX43P3 -4.07 5.79e-05 0.0118 -0.23 -0.22 Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect); chr7:81833131 chr7:81610884~81611326:- LIHC cis rs17270561 0.514 rs10946805 ENSG00000272810.1 U91328.22 -4.07 5.79e-05 0.0118 -0.28 -0.22 Iron status biomarkers; chr6:26077663 chr6:26013241~26013757:+ LIHC cis rs11098499 0.909 rs1546502 ENSG00000260091.1 RP11-33B1.4 -4.07 5.79e-05 0.0118 -0.16 -0.22 Corneal astigmatism; chr4:119314743 chr4:119409333~119410233:+ LIHC cis rs10129255 0.828 rs10140989 ENSG00000211970.3 IGHV4-61 -4.07 5.79e-05 0.0118 -0.17 -0.22 Kawasaki disease; chr14:106668657 chr14:106639119~106639657:- LIHC cis rs79349575 0.783 rs2112617 ENSG00000248278.1 SUMO2P17 4.07 5.79e-05 0.0118 0.27 0.22 Type 2 diabetes; chr17:48899763 chr17:48874860~48908983:- LIHC cis rs2179367 0.632 rs9498344 ENSG00000231760.4 RP11-350J20.5 4.07 5.79e-05 0.0118 0.35 0.22 Dupuytren's disease; chr6:149401053 chr6:149796151~149826294:- LIHC cis rs755249 0.567 rs66531516 ENSG00000182109.6 RP11-69E11.4 4.07 5.79e-05 0.0118 0.27 0.22 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39163390 chr1:39522280~39546187:- LIHC cis rs7726839 0.54 rs12520279 ENSG00000271781.1 CTD-2589H19.6 -4.07 5.8e-05 0.0118 -0.33 -0.22 Obesity-related traits; chr5:657176 chr5:675826~676616:+ LIHC cis rs7726839 0.54 rs4957083 ENSG00000271781.1 CTD-2589H19.6 -4.07 5.8e-05 0.0118 -0.33 -0.22 Obesity-related traits; chr5:659228 chr5:675826~676616:+ LIHC cis rs6901152 0.525 rs6570557 ENSG00000217648.1 RP1-95L4.4 -4.07 5.8e-05 0.0118 -0.25 -0.22 Acute lymphoblastic leukemia (childhood); chr6:143370470 chr6:143342246~143343383:+ LIHC cis rs2885805 0.596 rs343763 ENSG00000259834.1 RP11-284N8.3 -4.07 5.8e-05 0.0118 -0.18 -0.22 Cytomegalovirus antibody response; chr1:110810039 chr1:110653560~110657040:- LIHC cis rs7712401 0.601 rs454617 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122986232 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs386602 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122986262 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs442427 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122986570 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs436546 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122987095 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs397731 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122987264 chr5:123022487~123022783:- LIHC cis rs7712401 0.58 rs35902490 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122987703 chr5:123022487~123022783:- LIHC cis rs7712401 0.562 rs383638 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122988983 chr5:123022487~123022783:- LIHC cis rs7712401 0.562 rs62377399 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122988984 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs415534 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122989606 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs442911 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122989856 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs425573 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122990313 chr5:123022487~123022783:- LIHC cis rs7712401 0.562 rs364723 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122990769 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs35847506 ENSG00000263432.2 RN7SL689P -4.07 5.81e-05 0.0118 -0.31 -0.22 Mean platelet volume; chr5:122991413 chr5:123022487~123022783:- LIHC cis rs8037137 0.731 rs78029804 ENSG00000258725.1 PRC1-AS1 -4.07 5.81e-05 0.0118 -0.28 -0.22 Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr15:90995690 chr15:90966345~90988624:+ LIHC cis rs2749592 0.55 rs10764135 ENSG00000099251.13 HSD17B7P2 -4.07 5.81e-05 0.0118 -0.25 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37577917 chr10:38356380~38378505:+ LIHC cis rs2749592 0.55 rs12255038 ENSG00000099251.13 HSD17B7P2 -4.07 5.81e-05 0.0118 -0.25 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37580404 chr10:38356380~38378505:+ LIHC cis rs2749592 0.505 rs7915670 ENSG00000099251.13 HSD17B7P2 -4.07 5.81e-05 0.0118 -0.25 -0.22 Age-related hearing impairment (SNP x SNP interaction); chr10:37581284 chr10:38356380~38378505:+ LIHC cis rs1799949 1 rs2271574 ENSG00000267681.1 CTD-3199J23.6 -4.07 5.81e-05 0.0118 -0.21 -0.22 Menopause (age at onset); chr17:43175631 chr17:43144956~43145255:+ LIHC cis rs2243480 1 rs316307 ENSG00000230295.1 RP11-458F8.2 -4.07 5.81e-05 0.0118 -0.22 -0.22 Diabetic kidney disease; chr7:66105184 chr7:66880708~66882981:+ LIHC cis rs6442522 0.933 rs6442518 ENSG00000249786.6 EAF1-AS1 4.07 5.81e-05 0.0118 0.24 0.22 Uric acid levels; chr3:15380543 chr3:15436171~15455940:- LIHC cis rs7829975 0.84 rs572366 ENSG00000253893.2 FAM85B -4.07 5.81e-05 0.0118 -0.25 -0.22 Mood instability; chr8:8721284 chr8:8167819~8226614:- LIHC cis rs6472235 0.632 rs11985554 ENSG00000272010.1 CTD-3025N20.3 -4.07 5.81e-05 0.0118 -0.31 -0.22 Plateletcrit;Myopia (pathological); chr8:65972004 chr8:65591850~65592472:- LIHC cis rs831571 0.653 rs73120967 ENSG00000280620.1 SCAANT1 4.07 5.82e-05 0.0118 0.32 0.21 Type 2 diabetes; chr3:64084696 chr3:63911518~63911772:- LIHC cis rs7917772 0.503 rs11191347 ENSG00000236937.2 PTGES3P4 -4.07 5.82e-05 0.0118 -0.29 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102591860 chr10:102845595~102845950:+ LIHC cis rs2762353 0.718 rs1747550 ENSG00000242387.1 HIST1H2APS2 4.07 5.82e-05 0.0118 0.25 0.21 Blood metabolite levels; chr6:25851305 chr6:25882026~25882395:- LIHC cis rs5769707 0.749 rs7286706 ENSG00000235111.1 RP1-29C18.8 -4.07 5.82e-05 0.0118 -0.25 -0.21 Monocyte percentage of white cells;Monocyte count; chr22:49664698 chr22:49612657~49615716:- LIHC cis rs2613514 1 rs16970811 ENSG00000204277.1 RP11-219G17.4 4.07 5.82e-05 0.0118 0.32 0.21 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78095099 chr17:78261349~78278492:- LIHC cis rs7915414 0.901 rs34870400 ENSG00000230338.1 MTND4P19 4.07 5.82e-05 0.0118 0.23 0.21 Clopidogrel active metabolite levels; chr10:94675066 chr10:94774156~94774633:- LIHC cis rs11096990 0.613 rs4974995 ENSG00000249685.1 RP11-360F5.3 -4.07 5.82e-05 0.0118 -0.25 -0.21 Cognitive function; chr4:39216503 chr4:39133913~39135608:+ LIHC cis rs11733284 0.894 rs321628 ENSG00000259959.1 RP11-121C2.2 4.07 5.83e-05 0.0118 0.2 0.21 Gout;Renal underexcretion gout; chr4:48014858 chr4:47840122~47844339:- LIHC cis rs2243480 1 rs313831 ENSG00000232546.1 RP11-458F8.1 -4.07 5.83e-05 0.0118 -0.24 -0.21 Diabetic kidney disease; chr7:66086239 chr7:66848496~66858136:+ LIHC cis rs244293 0.831 rs12450607 ENSG00000275710.1 RP11-257O5.4 -4.07 5.83e-05 0.0118 -0.23 -0.21 Menarche (age at onset); chr17:55049894 chr17:54964474~54964679:+ LIHC cis rs4925386 0.681 rs2427294 ENSG00000273619.1 RP5-908M14.9 -4.07 5.83e-05 0.0118 -0.2 -0.21 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62352201 chr20:62386303~62386970:- LIHC cis rs11651753 0.636 rs4794332 ENSG00000264920.1 RP11-6N17.4 -4.07 5.83e-05 0.0118 -0.22 -0.21 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47963201 chr17:47891255~47895812:- LIHC cis rs3091242 0.933 rs35148262 ENSG00000224183.1 SDHDP6 -4.07 5.83e-05 0.0118 -0.25 -0.21 Erythrocyte sedimentation rate; chr1:25440132 chr1:25294164~25294643:- LIHC cis rs7989332 0.89 rs4770040 ENSG00000275964.1 RP11-61K9.3 -4.07 5.83e-05 0.0118 -0.24 -0.21 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20474349 chr13:19863858~19865048:+ LIHC cis rs597539 0.552 rs6591361 ENSG00000250508.1 RP11-757G1.6 -4.07 5.83e-05 0.0118 -0.33 -0.21 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68951815 chr11:68870664~68874542:+ LIHC cis rs4934494 0.834 rs3740033 ENSG00000232936.4 RP11-80H5.2 -4.07 5.83e-05 0.0118 -0.23 -0.21 Red blood cell count; chr10:89634639 chr10:89645282~89650667:+ LIHC cis rs2274273 0.967 rs2094102 ENSG00000258413.1 RP11-665C16.6 -4.07 5.84e-05 0.0118 -0.25 -0.21 Protein biomarker; chr14:55124380 chr14:55262767~55272075:- LIHC cis rs9595908 0.785 rs7328827 ENSG00000212293.1 SNORA16 4.07 5.84e-05 0.0118 0.24 0.21 Body mass index; chr13:32686650 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs3858846 ENSG00000212293.1 SNORA16 4.07 5.84e-05 0.0118 0.24 0.21 Body mass index; chr13:32687408 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs7981925 ENSG00000212293.1 SNORA16 4.07 5.84e-05 0.0118 0.24 0.21 Body mass index; chr13:32693706 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs9596081 ENSG00000212293.1 SNORA16 4.07 5.84e-05 0.0118 0.24 0.21 Body mass index; chr13:32698405 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs7326314 ENSG00000212293.1 SNORA16 4.07 5.84e-05 0.0118 0.24 0.21 Body mass index; chr13:32706422 chr13:32420390~32420516:- LIHC cis rs10829156 0.898 rs7095666 ENSG00000225527.1 RP11-383B4.4 4.07 5.84e-05 0.0118 0.33 0.21 Sudden cardiac arrest; chr10:18650538 chr10:18531849~18533336:- LIHC cis rs7809950 0.815 rs62482495 ENSG00000238832.1 snoU109 -4.07 5.84e-05 0.0118 -0.28 -0.21 Coronary artery disease; chr7:107324564 chr7:107603363~107603507:+ LIHC cis rs2919917 0.666 rs10957898 ENSG00000254352.1 RP11-578O24.2 -4.07 5.84e-05 0.0118 -0.32 -0.21 Lymphocyte counts; chr8:78705078 chr8:78723796~78724136:- LIHC cis rs10510102 0.748 rs11200297 ENSG00000273891.1 RP11-500G22.5 4.07 5.84e-05 0.0118 0.29 0.21 Breast cancer; chr10:121972916 chr10:121965764~121967700:+ LIHC cis rs6445975 0.617 rs11130641 ENSG00000272360.1 RP11-359I18.5 4.07 5.84e-05 0.0118 0.28 0.21 Systemic lupus erythematosus; chr3:58432202 chr3:58490830~58491291:- LIHC cis rs2282930 0.874 rs2299156 ENSG00000228897.1 CTD-2021A8.2 -4.07 5.84e-05 0.0119 -0.29 -0.21 Bone mineral density; chr7:50696707 chr7:51386363~51387101:- LIHC cis rs12681287 0.64 rs7832493 ENSG00000254088.1 SLC2A3P4 -4.07 5.85e-05 0.0119 -0.25 -0.21 Caudate activity during reward; chr8:86359304 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs7816275 ENSG00000254088.1 SLC2A3P4 -4.07 5.85e-05 0.0119 -0.25 -0.21 Caudate activity during reward; chr8:86361175 chr8:86503591~86505061:+ LIHC cis rs13113518 0.729 rs11133377 ENSG00000249700.7 SRD5A3-AS1 4.07 5.85e-05 0.0119 0.26 0.21 Height; chr4:55413708 chr4:55363971~55395847:- LIHC cis rs6142102 0.602 rs2300209 ENSG00000275784.1 RP5-1125A11.6 -4.07 5.85e-05 0.0119 -0.23 -0.21 Skin pigmentation; chr20:34055294 chr20:33989480~33991818:- LIHC cis rs763121 0.925 rs4821815 ENSG00000273076.1 RP3-508I15.22 4.07 5.85e-05 0.0119 0.24 0.21 Menopause (age at onset); chr22:38709702 chr22:38743495~38743910:+ LIHC cis rs3204270 0.53 rs57707013 ENSG00000281517.1 Metazoa_SRP -4.07 5.85e-05 0.0119 -0.39 -0.21 Dental caries; chr17:81668251 chr17:81718849~81719095:- LIHC cis rs8177253 0.665 rs11921527 ENSG00000244062.1 RP11-404G16.2 4.07 5.85e-05 0.0119 0.21 0.21 Iron status biomarkers; chr3:133722323 chr3:133760300~133762363:+ LIHC cis rs13315871 0.615 rs6793358 ENSG00000272182.1 RP11-802O23.3 4.07 5.86e-05 0.0119 0.41 0.21 Cholesterol, total; chr3:58370727 chr3:58428255~58428815:+ LIHC cis rs4650994 1 rs4354501 ENSG00000273384.1 RP5-1098D14.1 4.07 5.86e-05 0.0119 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178555461 chr1:178651706~178652282:+ LIHC cis rs4650994 0.967 rs6681043 ENSG00000273384.1 RP5-1098D14.1 4.07 5.86e-05 0.0119 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178556822 chr1:178651706~178652282:+ LIHC cis rs4650994 0.625 rs6681348 ENSG00000273384.1 RP5-1098D14.1 4.07 5.86e-05 0.0119 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178557136 chr1:178651706~178652282:+ LIHC cis rs4650994 0.625 rs6681354 ENSG00000273384.1 RP5-1098D14.1 4.07 5.86e-05 0.0119 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178557144 chr1:178651706~178652282:+ LIHC cis rs4650994 1 rs10913571 ENSG00000273384.1 RP5-1098D14.1 4.07 5.86e-05 0.0119 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178557513 chr1:178651706~178652282:+ LIHC cis rs4650994 1 rs10913572 ENSG00000273384.1 RP5-1098D14.1 4.07 5.86e-05 0.0119 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178557583 chr1:178651706~178652282:+ LIHC cis rs4650994 0.935 rs4652306 ENSG00000273384.1 RP5-1098D14.1 4.07 5.86e-05 0.0119 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178559071 chr1:178651706~178652282:+ LIHC cis rs4650994 1 rs6660445 ENSG00000273384.1 RP5-1098D14.1 4.07 5.86e-05 0.0119 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178559736 chr1:178651706~178652282:+ LIHC cis rs2243480 0.803 rs160649 ENSG00000228409.4 CCT6P1 4.07 5.86e-05 0.0119 0.23 0.21 Diabetic kidney disease; chr7:66078212 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs160648 ENSG00000228409.4 CCT6P1 4.07 5.86e-05 0.0119 0.23 0.21 Diabetic kidney disease; chr7:66078397 chr7:65751142~65763354:+ LIHC cis rs2274273 1 rs61508494 ENSG00000258413.1 RP11-665C16.6 -4.07 5.87e-05 0.0119 -0.25 -0.21 Protein biomarker; chr14:55120579 chr14:55262767~55272075:- LIHC cis rs9907295 1 rs9303693 ENSG00000270871.1 AC015849.19 4.07 5.87e-05 0.0119 0.23 0.21 Fibroblast growth factor basic levels; chr17:35913595 chr17:35816717~35830293:- LIHC cis rs4660214 0.568 rs967530 ENSG00000182109.6 RP11-69E11.4 -4.07 5.87e-05 0.0119 -0.23 -0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39130465 chr1:39522280~39546187:- LIHC cis rs801193 0.66 rs974239 ENSG00000232559.3 GS1-124K5.12 4.07 5.87e-05 0.0119 0.17 0.21 Aortic root size; chr7:66748504 chr7:66554588~66576923:- LIHC cis rs10510102 0.872 rs12246693 ENSG00000273891.1 RP11-500G22.5 4.07 5.87e-05 0.0119 0.28 0.21 Breast cancer; chr10:121957373 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs12248806 ENSG00000273891.1 RP11-500G22.5 4.07 5.87e-05 0.0119 0.28 0.21 Breast cancer; chr10:121958638 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs12255832 ENSG00000273891.1 RP11-500G22.5 4.07 5.87e-05 0.0119 0.28 0.21 Breast cancer; chr10:121958762 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs12247367 ENSG00000273891.1 RP11-500G22.5 4.07 5.87e-05 0.0119 0.28 0.21 Breast cancer; chr10:121961556 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs10887032 ENSG00000273891.1 RP11-500G22.5 -4.07 5.87e-05 0.0119 -0.28 -0.21 Breast cancer; chr10:121955887 chr10:121965764~121967700:+ LIHC cis rs11098499 0.874 rs13139045 ENSG00000260091.1 RP11-33B1.4 -4.07 5.88e-05 0.0119 -0.15 -0.21 Corneal astigmatism; chr4:119247433 chr4:119409333~119410233:+ LIHC cis rs2253762 0.54 rs10887037 ENSG00000226864.1 ATE1-AS1 4.07 5.88e-05 0.0119 0.36 0.21 Breast cancer; chr10:121997572 chr10:121928312~121951965:+ LIHC cis rs35099186 0.583 rs12290068 ENSG00000255062.1 RP11-712L6.5 -4.07 5.88e-05 0.0119 -0.28 -0.21 Coronary artery disease; chr11:126391669 chr11:126294298~126304318:- LIHC cis rs55966801 0.898 rs551419 ENSG00000277290.1 RP11-326C3.16 -4.07 5.88e-05 0.0119 -0.26 -0.21 Plateletcrit; chr11:240844 chr11:243099~243483:- LIHC cis rs755249 0.567 rs16826000 ENSG00000182109.6 RP11-69E11.4 4.07 5.88e-05 0.0119 0.28 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39248188 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs16826009 ENSG00000182109.6 RP11-69E11.4 4.07 5.88e-05 0.0119 0.28 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39251230 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs4660208 ENSG00000182109.6 RP11-69E11.4 4.07 5.88e-05 0.0119 0.28 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39256542 chr1:39522280~39546187:- LIHC cis rs2735413 0.958 rs11150034 ENSG00000276007.1 RP11-358L22.3 -4.07 5.89e-05 0.0119 -0.25 -0.21 Systolic blood pressure (alcohol consumption interaction); chr16:78032472 chr16:78123243~78124332:+ LIHC cis rs2735413 0.914 rs12448754 ENSG00000276007.1 RP11-358L22.3 -4.07 5.89e-05 0.0119 -0.25 -0.21 Systolic blood pressure (alcohol consumption interaction); chr16:78032850 chr16:78123243~78124332:+ LIHC cis rs13242816 1 rs62469031 ENSG00000279086.1 RP11-667F14.1 4.07 5.89e-05 0.0119 0.38 0.21 P wave duration; chr7:116555787 chr7:116209234~116211511:- LIHC cis rs2842992 0.724 rs15982 ENSG00000237927.1 RP3-393E18.2 -4.07 5.89e-05 0.0119 -0.25 -0.21 Age-related macular degeneration (geographic atrophy); chr6:159778655 chr6:159586955~159589169:- LIHC cis rs617219 0.726 rs3733893 ENSG00000251675.1 CTC-458I2.2 -4.07 5.9e-05 0.0119 -0.24 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79236835 chr5:80128361~80143883:+ LIHC cis rs11977715 0.538 rs43063 ENSG00000233942.1 AC004012.1 -4.07 5.9e-05 0.0119 -0.3 -0.21 Middle childhood and early adolescence aggressive behavior; chr7:95480475 chr7:95471835~95473998:+ LIHC cis rs11096990 0.855 rs2566173 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39151111 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2711988 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39151128 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2043102 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39151292 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2711986 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39152258 chr4:39112677~39126818:- LIHC cis rs11096990 0.75 rs2465242 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39153796 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2465243 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39154036 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2566176 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39154373 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2566178 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39155194 chr4:39112677~39126818:- LIHC cis rs11096990 0.819 rs2435528 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39155916 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2711933 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39156090 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2566179 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39156413 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2566180 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39157381 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2566181 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39157987 chr4:39112677~39126818:- LIHC cis rs11096990 0.819 rs2381225 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39158915 chr4:39112677~39126818:- LIHC cis rs11096990 0.819 rs1367297 ENSG00000249207.1 RP11-360F5.1 4.07 5.9e-05 0.0119 0.25 0.21 Cognitive function; chr4:39159614 chr4:39112677~39126818:- LIHC cis rs11971779 0.941 rs28395455 ENSG00000273391.1 RP11-634H22.1 4.07 5.9e-05 0.0119 0.23 0.21 Diisocyanate-induced asthma; chr7:139351240 chr7:139359032~139359566:- LIHC cis rs6445975 1 rs2176082 ENSG00000272360.1 RP11-359I18.5 -4.07 5.91e-05 0.012 -0.28 -0.21 Systemic lupus erythematosus; chr3:58345459 chr3:58490830~58491291:- LIHC cis rs295490 0.748 rs78681436 ENSG00000272656.1 RP11-219D15.3 4.07 5.91e-05 0.012 0.6 0.21 PR interval in Tripanosoma cruzi seropositivity; chr3:139510715 chr3:139349024~139349371:- LIHC cis rs295490 0.748 rs79854429 ENSG00000272656.1 RP11-219D15.3 4.07 5.91e-05 0.012 0.6 0.21 PR interval in Tripanosoma cruzi seropositivity; chr3:139512550 chr3:139349024~139349371:- LIHC cis rs244293 0.965 rs244357 ENSG00000275710.1 RP11-257O5.4 4.07 5.91e-05 0.012 0.23 0.21 Menarche (age at onset); chr17:55115820 chr17:54964474~54964679:+ LIHC cis rs6832769 1 rs35767091 ENSG00000272969.1 RP11-528I4.2 4.07 5.91e-05 0.012 0.26 0.21 Personality dimensions; chr4:55480556 chr4:55547112~55547889:+ LIHC cis rs2749592 0.55 rs4934881 ENSG00000276805.1 RP11-291L22.6 -4.07 5.92e-05 0.012 -0.26 -0.21 Age-related hearing impairment (SNP x SNP interaction); chr10:37625418 chr10:38451030~38451785:+ LIHC cis rs7809950 0.954 rs2712229 ENSG00000238832.1 snoU109 4.07 5.92e-05 0.012 0.24 0.21 Coronary artery disease; chr7:107654881 chr7:107603363~107603507:+ LIHC cis rs193541 0.632 rs430069 ENSG00000263432.2 RN7SL689P 4.07 5.92e-05 0.012 0.35 0.21 Glucose homeostasis traits; chr5:122927656 chr5:123022487~123022783:- LIHC cis rs1023500 0.529 rs133375 ENSG00000226450.2 CYP2D8P 4.07 5.92e-05 0.012 0.26 0.21 Schizophrenia; chr22:42070505 chr22:42149886~42155001:- LIHC cis rs2439831 0.681 rs484029 ENSG00000166763.7 STRCP1 4.07 5.92e-05 0.012 0.29 0.21 Lung cancer in ever smokers; chr15:43327362 chr15:43699488~43718184:- LIHC cis rs6436017 0.589 rs1424918 ENSG00000199121.3 MIR26B 4.07 5.92e-05 0.012 0.25 0.21 Breast cancer; chr2:217876772 chr2:218402637~218402746:+ LIHC cis rs4919694 1 rs12268849 ENSG00000236937.2 PTGES3P4 4.07 5.92e-05 0.012 0.39 0.21 Arsenic metabolism; chr10:102977925 chr10:102845595~102845950:+ LIHC cis rs6832769 1 rs28670674 ENSG00000272969.1 RP11-528I4.2 -4.07 5.92e-05 0.012 -0.26 -0.21 Personality dimensions; chr4:55540936 chr4:55547112~55547889:+ LIHC cis rs2243480 1 rs2257790 ENSG00000230295.1 RP11-458F8.2 -4.07 5.92e-05 0.012 -0.23 -0.21 Diabetic kidney disease; chr7:66135463 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs316332 ENSG00000230295.1 RP11-458F8.2 -4.07 5.92e-05 0.012 -0.23 -0.21 Diabetic kidney disease; chr7:66139312 chr7:66880708~66882981:+ LIHC cis rs17270561 0.887 rs12201170 ENSG00000272810.1 U91328.22 -4.07 5.93e-05 0.012 -0.29 -0.21 Iron status biomarkers; chr6:25866019 chr6:26013241~26013757:+ LIHC cis rs755249 0.532 rs2296173 ENSG00000182109.6 RP11-69E11.4 4.07 5.94e-05 0.012 0.28 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39447679 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs3118014 ENSG00000182109.6 RP11-69E11.4 4.07 5.94e-05 0.012 0.28 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39448418 chr1:39522280~39546187:- LIHC cis rs7937890 0.967 rs963212 ENSG00000251991.1 RNU7-49P -4.07 5.94e-05 0.012 -0.23 -0.21 Mitochondrial DNA levels; chr11:14303186 chr11:14478892~14478953:+ LIHC cis rs7937890 1 rs2970334 ENSG00000251991.1 RNU7-49P -4.07 5.94e-05 0.012 -0.23 -0.21 Mitochondrial DNA levels; chr11:14307809 chr11:14478892~14478953:+ LIHC cis rs2739330 0.734 rs2000467 ENSG00000206090.4 AP000350.7 -4.07 5.94e-05 0.012 -0.25 -0.21 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23939998~23942798:+ LIHC cis rs6997458 0.785 rs1389247 ENSG00000253549.4 RP11-317J10.2 4.07 5.94e-05 0.012 0.24 0.21 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85410354 chr8:85441851~85464915:- LIHC cis rs694739 1 rs1783521 ENSG00000236935.1 AP003774.1 4.07 5.95e-05 0.012 0.23 0.21 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64338819 chr11:64325050~64329504:- LIHC cis rs1023500 0.573 rs8135801 ENSG00000226450.2 CYP2D8P -4.07 5.95e-05 0.012 -0.26 -0.21 Schizophrenia; chr22:42079564 chr22:42149886~42155001:- LIHC cis rs2243480 1 rs160646 ENSG00000228409.4 CCT6P1 4.07 5.95e-05 0.012 0.23 0.21 Diabetic kidney disease; chr7:66091293 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1039664 ENSG00000232546.1 RP11-458F8.1 -4.07 5.95e-05 0.012 -0.24 -0.21 Diabetic kidney disease; chr7:65984729 chr7:66848496~66858136:+ LIHC cis rs4578769 0.722 rs72887683 ENSG00000265943.1 RP11-739L10.1 -4.07 5.96e-05 0.012 -0.28 -0.21 Eosinophil percentage of white cells; chr18:22981366 chr18:22699481~22933764:- LIHC cis rs1799949 0.93 rs3765640 ENSG00000267681.1 CTD-3199J23.6 -4.07 5.96e-05 0.012 -0.21 -0.21 Menopause (age at onset); chr17:43124230 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs8176077 ENSG00000267681.1 CTD-3199J23.6 -4.07 5.96e-05 0.012 -0.21 -0.21 Menopause (age at onset); chr17:43124331 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs11655505 ENSG00000267681.1 CTD-3199J23.6 -4.07 5.96e-05 0.012 -0.21 -0.21 Menopause (age at onset); chr17:43126360 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs4793204 ENSG00000267681.1 CTD-3199J23.6 -4.07 5.96e-05 0.012 -0.21 -0.21 Menopause (age at onset); chr17:43127281 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs12947782 ENSG00000267681.1 CTD-3199J23.6 -4.07 5.96e-05 0.012 -0.21 -0.21 Menopause (age at onset); chr17:43127865 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs33945274 ENSG00000267681.1 CTD-3199J23.6 -4.07 5.96e-05 0.012 -0.21 -0.21 Menopause (age at onset); chr17:43128056 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs11653069 ENSG00000267681.1 CTD-3199J23.6 -4.07 5.96e-05 0.012 -0.21 -0.21 Menopause (age at onset); chr17:43131360 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs2175957 ENSG00000267681.1 CTD-3199J23.6 -4.07 5.96e-05 0.012 -0.21 -0.21 Menopause (age at onset); chr17:43134805 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs33988650 ENSG00000267681.1 CTD-3199J23.6 -4.07 5.96e-05 0.012 -0.21 -0.21 Menopause (age at onset); chr17:43135863 chr17:43144956~43145255:+ LIHC cis rs6977955 0.627 rs1513275 ENSG00000234336.5 JAZF1-AS1 4.07 5.96e-05 0.0121 0.32 0.21 Allergic disease (asthma, hay fever or eczema); chr7:28219614 chr7:28180322~28243917:+ LIHC cis rs11651753 0.613 rs4793732 ENSG00000264920.1 RP11-6N17.4 -4.06 5.97e-05 0.0121 -0.22 -0.21 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47956488 chr17:47891255~47895812:- LIHC cis rs7712401 0.601 rs28892 ENSG00000263432.2 RN7SL689P -4.06 5.97e-05 0.0121 -0.32 -0.21 Mean platelet volume; chr5:122948131 chr5:123022487~123022783:- LIHC cis rs17774123 0.901 rs2590706 ENSG00000257808.1 RP11-1136G11.8 4.06 5.97e-05 0.0121 0.39 0.21 Diastolic blood pressure; chr12:53876492 chr12:53159586~53161000:+ LIHC cis rs7893279 0.505 rs3740104 ENSG00000225527.1 RP11-383B4.4 4.06 5.97e-05 0.0121 0.31 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18648793 chr10:18531849~18533336:- LIHC cis rs2790457 0.958 rs2807754 ENSG00000254635.4 WAC-AS1 -4.06 5.97e-05 0.0121 -0.2 -0.21 Multiple myeloma; chr10:28598263 chr10:28522652~28532743:- LIHC cis rs2790457 0.958 rs2772432 ENSG00000254635.4 WAC-AS1 -4.06 5.97e-05 0.0121 -0.2 -0.21 Multiple myeloma; chr10:28605366 chr10:28522652~28532743:- LIHC cis rs950169 1 rs35297609 ENSG00000259728.4 LINC00933 4.06 5.98e-05 0.0121 0.34 0.21 Schizophrenia; chr15:84104144 chr15:84570649~84580175:+ LIHC cis rs950169 1 rs62026530 ENSG00000259728.4 LINC00933 4.06 5.98e-05 0.0121 0.34 0.21 Schizophrenia; chr15:84107088 chr15:84570649~84580175:+ LIHC cis rs950169 1 rs11638394 ENSG00000259728.4 LINC00933 4.06 5.98e-05 0.0121 0.34 0.21 Schizophrenia; chr15:84110176 chr15:84570649~84580175:+ LIHC cis rs950169 1 rs35658069 ENSG00000259728.4 LINC00933 4.06 5.98e-05 0.0121 0.34 0.21 Schizophrenia; chr15:84111394 chr15:84570649~84580175:+ LIHC cis rs801193 0.636 rs10233806 ENSG00000232559.3 GS1-124K5.12 -4.06 5.98e-05 0.0121 -0.17 -0.21 Aortic root size; chr7:66653261 chr7:66554588~66576923:- LIHC cis rs7412746 0.503 rs72704639 ENSG00000231073.1 RP11-316M1.3 4.06 5.98e-05 0.0121 0.21 0.21 Melanoma; chr1:150825859 chr1:150973123~150975534:+ LIHC cis rs7208859 0.673 rs11651802 ENSG00000266490.1 CTD-2349P21.9 4.06 5.98e-05 0.0121 0.28 0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832642 chr17:30792372~30792833:+ LIHC cis rs10857712 1 rs10857712 ENSG00000214279.11 SCART1 -4.06 5.98e-05 0.0121 -0.26 -0.21 Systemic lupus erythematosus; chr10:133412162 chr10:133453928~133523558:+ LIHC cis rs673078 0.66 rs9943819 ENSG00000275759.1 RP11-131L12.3 -4.06 5.99e-05 0.0121 -0.26 -0.21 Glucose homeostasis traits; chr12:118298917 chr12:118428281~118428870:+ LIHC cis rs8064024 0.508 rs2037912 ENSG00000267077.1 RP11-127I20.5 -4.06 5.99e-05 0.0121 -0.22 -0.21 Cancer; chr16:4883938 chr16:4795265~4796532:- LIHC cis rs16902947 0.592 rs4869655 ENSG00000245711.2 NADK2-AS1 4.06 5.99e-05 0.0121 0.18 0.21 Serum tamsulosin hydrochloride concentration; chr5:36350739 chr5:36221055~36221902:+ LIHC cis rs6745190 0.906 rs6706565 ENSG00000236153.1 AC104076.3 4.06 5.99e-05 0.0121 0.29 0.21 White blood cell count; chr2:181065685 chr2:180979427~180980090:- LIHC cis rs4218 0.648 rs12441973 ENSG00000277144.1 RP11-59H7.4 -4.06 5.99e-05 0.0121 -0.24 -0.21 Social communication problems; chr15:59057016 chr15:59115547~59116089:- LIHC cis rs1005277 0.522 rs289649 ENSG00000275858.1 RP11-291L22.8 4.06 5.99e-05 0.0121 0.24 0.21 Extrinsic epigenetic age acceleration; chr10:37686456 chr10:38450738~38451069:- LIHC cis rs6142102 0.923 rs2268078 ENSG00000275784.1 RP5-1125A11.6 -4.06 5.99e-05 0.0121 -0.25 -0.21 Skin pigmentation; chr20:34008898 chr20:33989480~33991818:- LIHC cis rs2976388 0.566 rs6998746 ENSG00000253741.1 CTD-2292P10.4 -4.06 6e-05 0.0121 -0.26 -0.21 Urinary tract infection frequency; chr8:142721038 chr8:142702252~142726973:- LIHC cis rs6700559 0.873 rs7542210 ENSG00000260088.1 RP11-92G12.3 -4.06 6e-05 0.0121 -0.27 -0.21 Coronary artery disease; chr1:200693087 chr1:200669507~200694250:+ LIHC cis rs7893279 0.505 rs7897159 ENSG00000225527.1 RP11-383B4.4 4.06 6e-05 0.0121 0.31 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18642651 chr10:18531849~18533336:- LIHC cis rs794185 0.653 rs2819586 ENSG00000231249.1 ITPR1-AS1 -4.06 6e-05 0.0121 -0.23 -0.21 Multiple sclerosis--Brain Glutamate Levels; chr3:4470108 chr3:4490891~4493163:- LIHC cis rs794185 0.686 rs2633843 ENSG00000231249.1 ITPR1-AS1 -4.06 6e-05 0.0121 -0.23 -0.21 Multiple sclerosis--Brain Glutamate Levels; chr3:4470109 chr3:4490891~4493163:- LIHC cis rs950169 0.58 rs1061737 ENSG00000225151.9 GOLGA2P7 -4.06 6.01e-05 0.0121 -0.28 -0.21 Schizophrenia; chr15:84640559 chr15:84199311~84230136:- LIHC cis rs66887589 0.775 rs6843229 ENSG00000260091.1 RP11-33B1.4 -4.06 6.01e-05 0.0121 -0.14 -0.21 Diastolic blood pressure; chr4:119502932 chr4:119409333~119410233:+ LIHC cis rs3738443 0.83 rs6684181 ENSG00000259865.1 RP11-488L18.10 4.06 6.01e-05 0.0121 0.22 0.21 Alcohol dependence; chr1:247184669 chr1:247187281~247188526:- LIHC cis rs11098499 0.865 rs28634456 ENSG00000260091.1 RP11-33B1.4 -4.06 6.01e-05 0.0121 -0.16 -0.21 Corneal astigmatism; chr4:119454623 chr4:119409333~119410233:+ LIHC cis rs11098499 0.909 rs78332141 ENSG00000260091.1 RP11-33B1.4 -4.06 6.01e-05 0.0121 -0.16 -0.21 Corneal astigmatism; chr4:119454627 chr4:119409333~119410233:+ LIHC cis rs3015497 0.616 rs1389650 ENSG00000269906.1 RP11-248J18.2 4.06 6.01e-05 0.0121 0.27 0.21 Mean platelet volume; chr14:50614731 chr14:50662511~50663178:- LIHC cis rs2976388 0.609 rs2585153 ENSG00000253196.1 RP11-706C16.7 4.06 6.01e-05 0.0121 0.2 0.21 Urinary tract infection frequency; chr8:142703927 chr8:142763116~142766427:+ LIHC cis rs1223397 0.702 rs1223400 ENSG00000215022.6 RP1-257A7.4 -4.06 6.02e-05 0.0122 -0.25 -0.21 Blood pressure; chr6:13271010 chr6:13264861~13295586:- LIHC cis rs9595908 0.869 rs55880225 ENSG00000212293.1 SNORA16 4.06 6.02e-05 0.0122 0.25 0.21 Body mass index; chr13:32616733 chr13:32420390~32420516:- LIHC cis rs4578769 0.729 rs72882140 ENSG00000265943.1 RP11-739L10.1 -4.06 6.02e-05 0.0122 -0.28 -0.21 Eosinophil percentage of white cells; chr18:22805952 chr18:22699481~22933764:- LIHC cis rs2274273 0.624 rs8014477 ENSG00000258413.1 RP11-665C16.6 4.06 6.03e-05 0.0122 0.26 0.21 Protein biomarker; chr14:55374759 chr14:55262767~55272075:- LIHC cis rs6445975 0.667 rs6445963 ENSG00000272360.1 RP11-359I18.5 -4.06 6.03e-05 0.0122 -0.25 -0.21 Systemic lupus erythematosus; chr3:58248752 chr3:58490830~58491291:- LIHC cis rs6445975 0.667 rs2292676 ENSG00000272360.1 RP11-359I18.5 -4.06 6.03e-05 0.0122 -0.25 -0.21 Systemic lupus erythematosus; chr3:58250201 chr3:58490830~58491291:- LIHC cis rs7923609 0.846 rs7098181 ENSG00000232075.1 MRPL35P2 -4.06 6.03e-05 0.0122 -0.24 -0.21 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63267383 chr10:63634317~63634827:- LIHC cis rs7923609 0.846 rs10761731 ENSG00000232075.1 MRPL35P2 -4.06 6.03e-05 0.0122 -0.24 -0.21 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63267850 chr10:63634317~63634827:- LIHC cis rs617219 0.553 rs114964313 ENSG00000251675.1 CTC-458I2.2 -4.06 6.03e-05 0.0122 -0.24 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79137749 chr5:80128361~80143883:+ LIHC cis rs4578769 0.694 rs72882142 ENSG00000265943.1 RP11-739L10.1 -4.06 6.03e-05 0.0122 -0.28 -0.21 Eosinophil percentage of white cells; chr18:22806755 chr18:22699481~22933764:- LIHC cis rs734999 0.588 rs11585048 ENSG00000225931.3 RP3-395M20.7 4.06 6.03e-05 0.0122 0.23 0.21 Ulcerative colitis; chr1:2602648 chr1:2566410~2569888:+ LIHC cis rs6433895 0.677 rs11693055 ENSG00000236153.1 AC104076.3 -4.06 6.03e-05 0.0122 -0.28 -0.21 Lymphocyte counts; chr2:181168567 chr2:180979427~180980090:- LIHC cis rs13113518 0.812 rs1522114 ENSG00000249700.7 SRD5A3-AS1 4.06 6.04e-05 0.0122 0.25 0.21 Height; chr4:55489895 chr4:55363971~55395847:- LIHC cis rs2658782 0.789 rs2658775 ENSG00000279684.1 RP11-755E23.2 -4.06 6.04e-05 0.0122 -0.36 -0.21 Pulmonary function decline; chr11:93393633 chr11:93286629~93288903:- LIHC cis rs2658782 0.789 rs2658773 ENSG00000279684.1 RP11-755E23.2 -4.06 6.04e-05 0.0122 -0.36 -0.21 Pulmonary function decline; chr11:93393748 chr11:93286629~93288903:- LIHC cis rs2439831 0.85 rs28524541 ENSG00000166763.7 STRCP1 4.06 6.04e-05 0.0122 0.33 0.21 Lung cancer in ever smokers; chr15:43832633 chr15:43699488~43718184:- LIHC cis rs17376456 0.877 rs13165147 ENSG00000251023.1 RP11-549J18.1 -4.06 6.04e-05 0.0122 -0.45 -0.21 Diabetic retinopathy; chr5:94086509 chr5:93860669~93863825:- LIHC cis rs4578769 0.765 rs12456384 ENSG00000266850.1 RP11-370A5.1 -4.06 6.04e-05 0.0122 -0.25 -0.21 Eosinophil percentage of white cells; chr18:22841032 chr18:22723491~22907721:- LIHC cis rs1005277 0.522 rs1208681 ENSG00000099251.13 HSD17B7P2 4.06 6.04e-05 0.0122 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37804047 chr10:38356380~38378505:+ LIHC cis rs4650994 0.789 rs2761471 ENSG00000213057.5 C1orf220 -4.06 6.04e-05 0.0122 -0.18 -0.21 HDL cholesterol;HDL cholesterol levels; chr1:178630213 chr1:178542752~178548889:+ LIHC cis rs2598107 0.601 rs1014938 ENSG00000211698.2 TRGV4 -4.06 6.04e-05 0.0122 -0.25 -0.21 Dupuytren's disease; chr7:37901550 chr7:38353715~38354517:- LIHC cis rs875971 0.545 rs1796219 ENSG00000228409.4 CCT6P1 4.06 6.04e-05 0.0122 0.19 0.21 Aortic root size; chr7:66645977 chr7:65751142~65763354:+ LIHC cis rs9843304 0.528 rs12488126 ENSG00000244503.1 RP11-278L15.6 -4.06 6.04e-05 0.0122 -0.27 -0.21 Gallstone disease; chr3:149474889 chr3:149494660~149495995:+ LIHC cis rs1008953 0.95 rs1548227 ENSG00000227477.1 STK4-AS1 4.06 6.04e-05 0.0122 0.22 0.21 Psoriasis; chr20:45354870 chr20:44963794~44966402:- LIHC cis rs3015497 0.789 rs2934688 ENSG00000269906.1 RP11-248J18.2 4.06 6.05e-05 0.0122 0.27 0.21 Mean platelet volume; chr14:50645642 chr14:50662511~50663178:- LIHC cis rs2243480 1 rs160639 ENSG00000228409.4 CCT6P1 4.06 6.05e-05 0.0122 0.23 0.21 Diabetic kidney disease; chr7:66115000 chr7:65751142~65763354:+ LIHC cis rs2581828 0.608 rs9830353 ENSG00000242142.1 SERBP1P3 -4.06 6.05e-05 0.0122 -0.29 -0.21 Crohn's disease; chr3:53129937 chr3:53064283~53065091:- LIHC cis rs67311347 0.544 rs6804545 ENSG00000223797.4 ENTPD3-AS1 4.06 6.05e-05 0.0122 0.18 0.21 Renal cell carcinoma; chr3:40312549 chr3:40313802~40453329:- LIHC cis rs901683 0.85 rs112297763 ENSG00000230869.1 CTGLF10P -4.06 6.05e-05 0.0122 -0.46 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45573988 chr10:45678692~45700532:+ LIHC cis rs2243480 1 rs383402 ENSG00000232546.1 RP11-458F8.1 4.06 6.05e-05 0.0122 0.24 0.21 Diabetic kidney disease; chr7:66121666 chr7:66848496~66858136:+ LIHC cis rs17774123 0.901 rs1596370 ENSG00000257808.1 RP11-1136G11.8 -4.06 6.05e-05 0.0122 -0.39 -0.21 Diastolic blood pressure; chr12:53881482 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs182714 ENSG00000257808.1 RP11-1136G11.8 -4.06 6.05e-05 0.0122 -0.39 -0.21 Diastolic blood pressure; chr12:53887178 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2590713 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53869758 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2254753 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53870550 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2254752 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53870569 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2586701 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53872176 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2254525 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53872629 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2586702 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53872761 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2586703 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53872783 chr12:53159586~53161000:+ LIHC cis rs17774123 0.851 rs2586704 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53872836 chr12:53159586~53161000:+ LIHC cis rs17774123 0.755 rs34613738 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53872862 chr12:53159586~53161000:+ LIHC cis rs17774123 0.755 rs2586705 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53872957 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs1899664 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53873362 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2699929 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53873702 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2254397 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53873920 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2699927 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53875794 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2577862 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53876470 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2590707 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53877648 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs117359066 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53879488 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2590708 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53880331 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs1073061 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53880625 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs182713 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53880840 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2590711 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53882945 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs324267 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53883199 chr12:53159586~53161000:+ LIHC cis rs17774123 0.851 rs324268 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53883336 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs324269 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53883577 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs324270 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53884323 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs2247520 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53884642 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs324271 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53885533 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs324272 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53886487 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs188962 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53887408 chr12:53159586~53161000:+ LIHC cis rs17774123 0.901 rs167776 ENSG00000257808.1 RP11-1136G11.8 4.06 6.05e-05 0.0122 0.39 0.21 Diastolic blood pressure; chr12:53887797 chr12:53159586~53161000:+ LIHC cis rs6142102 0.602 rs6142069 ENSG00000275784.1 RP5-1125A11.6 -4.06 6.05e-05 0.0122 -0.23 -0.21 Skin pigmentation; chr20:33972736 chr20:33989480~33991818:- LIHC cis rs58785573 1 rs58785573 ENSG00000231160.8 KLF3-AS1 -4.06 6.06e-05 0.0122 -0.19 -0.21 Lymphocyte percentage of white cells; chr4:38652152 chr4:38612701~38664883:- LIHC cis rs950880 0.71 rs4851570 ENSG00000234389.1 AC007278.3 -4.06 6.06e-05 0.0122 -0.22 -0.21 Serum protein levels (sST2); chr2:102389927 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs17027060 ENSG00000234389.1 AC007278.3 -4.06 6.06e-05 0.0122 -0.22 -0.21 Serum protein levels (sST2); chr2:102391107 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs66919607 ENSG00000234389.1 AC007278.3 -4.06 6.06e-05 0.0122 -0.22 -0.21 Serum protein levels (sST2); chr2:102392509 chr2:102438713~102440475:+ LIHC cis rs2243480 1 rs313832 ENSG00000230295.1 RP11-458F8.2 -4.06 6.07e-05 0.0122 -0.23 -0.21 Diabetic kidney disease; chr7:66085904 chr7:66880708~66882981:+ LIHC cis rs4767841 0.625 rs12302281 ENSG00000248636.5 RP11-768F21.1 -4.06 6.07e-05 0.0122 -0.27 -0.21 Urgency urinary incontinence; chr12:119800693 chr12:119387987~119668079:- LIHC cis rs755249 0.567 rs16825939 ENSG00000182109.6 RP11-69E11.4 4.06 6.07e-05 0.0122 0.27 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39196836 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs16825942 ENSG00000182109.6 RP11-69E11.4 4.06 6.07e-05 0.0122 0.27 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39196946 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs72661925 ENSG00000182109.6 RP11-69E11.4 4.06 6.07e-05 0.0122 0.27 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39203865 chr1:39522280~39546187:- LIHC cis rs919433 0.889 rs6711624 ENSG00000231621.1 AC013264.2 4.06 6.07e-05 0.0122 0.2 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197342883 chr2:197197991~197199273:+ LIHC cis rs919433 0.889 rs12693816 ENSG00000231621.1 AC013264.2 4.06 6.07e-05 0.0122 0.2 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197343696 chr2:197197991~197199273:+ LIHC cis rs11096990 0.855 rs56275407 ENSG00000249207.1 RP11-360F5.1 4.06 6.07e-05 0.0122 0.25 0.21 Cognitive function; chr4:39177224 chr4:39112677~39126818:- LIHC cis rs6600233 0.77 rs7185768 ENSG00000268836.1 LA16c-OS12.2 4.06 6.07e-05 0.0122 0.25 0.21 High light scatter reticulocyte percentage of red cells; chr16:115782 chr16:185748~186294:- LIHC cis rs10129255 1 rs10129407 ENSG00000224373.3 IGHV4-59 4.06 6.07e-05 0.0122 0.17 0.21 Kawasaki disease; chr14:106767956 chr14:106627249~106627825:- LIHC cis rs8077577 0.747 rs12449313 ENSG00000260647.1 RP1-178F10.1 4.06 6.07e-05 0.0122 0.27 0.21 Obesity-related traits; chr17:18317696 chr17:18268080~18268828:+ LIHC cis rs10078 0.51 rs2278248 ENSG00000248925.1 CTD-2083E4.6 4.06 6.08e-05 0.0122 0.26 0.21 Fat distribution (HIV); chr5:469455 chr5:269858~271516:- LIHC cis rs10871290 0.801 rs3851726 ENSG00000261079.1 RP11-252A24.3 -4.06 6.08e-05 0.0122 -0.25 -0.21 Breast cancer; chr16:74437746 chr16:74367462~74369826:+ LIHC cis rs2562456 0.958 rs2562508 ENSG00000268555.1 RP11-678G14.3 -4.06 6.08e-05 0.0122 -0.27 -0.21 Pain; chr19:21543479 chr19:21570822~21587322:- LIHC cis rs6887276 0.504 rs1003136 ENSG00000245937.6 LINC01184 4.06 6.08e-05 0.0122 0.25 0.21 Height; chr5:128012123 chr5:127940426~128083172:- LIHC cis rs3002131 0.688 rs2936040 ENSG00000225265.1 TAF1A-AS1 -4.06 6.08e-05 0.0122 -0.29 -0.21 Interleukin-10 levels; chr1:222590319 chr1:222589825~222593032:+ LIHC cis rs7115242 1 rs7115242 ENSG00000280143.1 AP000892.6 -4.06 6.08e-05 0.0122 -0.31 -0.21 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117037567 chr11:117204967~117210292:+ LIHC cis rs1267303 0.798 rs1267302 ENSG00000227857.2 RP4-533D7.5 4.06 6.08e-05 0.0123 0.29 0.21 Monobrow; chr1:46524873 chr1:46134531~46139081:+ LIHC cis rs6479901 0.501 rs7084396 ENSG00000232075.1 MRPL35P2 -4.06 6.08e-05 0.0123 -0.24 -0.21 Intelligence (multi-trait analysis); chr10:63116965 chr10:63634317~63634827:- LIHC cis rs17772222 0.917 rs7157149 ENSG00000258789.1 RP11-507K2.3 -4.06 6.09e-05 0.0123 -0.26 -0.21 Coronary artery calcification; chr14:88765501 chr14:88551597~88552493:+ LIHC cis rs6449502 0.748 rs1445292 ENSG00000272308.1 RP11-231G3.1 -4.06 6.09e-05 0.0123 -0.3 -0.21 Mean platelet volume; chr5:60824295 chr5:60866457~60866935:- LIHC cis rs2598107 0.601 rs4720265 ENSG00000211698.2 TRGV4 -4.06 6.09e-05 0.0123 -0.25 -0.21 Dupuytren's disease; chr7:37905144 chr7:38353715~38354517:- LIHC cis rs6061231 0.597 rs624313 ENSG00000226332.2 RP11-157P1.4 -4.06 6.09e-05 0.0123 -0.22 -0.21 Colorectal cancer; chr20:62352356 chr20:62305432~62306325:- LIHC cis rs686320 1 rs72643572 ENSG00000245532.5 NEAT1 4.06 6.09e-05 0.0123 0.29 0.21 Hip circumference adjusted for BMI; chr11:65483496 chr11:65422774~65445540:+ LIHC cis rs9907295 1 rs11653051 ENSG00000270871.1 AC015849.19 4.06 6.09e-05 0.0123 0.23 0.21 Fibroblast growth factor basic levels; chr17:35909166 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs11653016 ENSG00000270871.1 AC015849.19 4.06 6.09e-05 0.0123 0.23 0.21 Fibroblast growth factor basic levels; chr17:35909756 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9889977 ENSG00000270871.1 AC015849.19 4.06 6.09e-05 0.0123 0.23 0.21 Fibroblast growth factor basic levels; chr17:35910691 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9894799 ENSG00000270871.1 AC015849.19 4.06 6.09e-05 0.0123 0.23 0.21 Fibroblast growth factor basic levels; chr17:35911085 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9903590 ENSG00000270871.1 AC015849.19 4.06 6.09e-05 0.0123 0.23 0.21 Fibroblast growth factor basic levels; chr17:35911286 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9897665 ENSG00000270871.1 AC015849.19 4.06 6.09e-05 0.0123 0.23 0.21 Fibroblast growth factor basic levels; chr17:35911595 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9912049 ENSG00000270871.1 AC015849.19 4.06 6.09e-05 0.0123 0.23 0.21 Fibroblast growth factor basic levels; chr17:35912530 chr17:35816717~35830293:- LIHC cis rs9595908 0.536 rs73452706 ENSG00000212293.1 SNORA16 4.06 6.09e-05 0.0123 0.24 0.21 Body mass index; chr13:32718155 chr13:32420390~32420516:- LIHC cis rs11098499 0.955 rs35434465 ENSG00000260091.1 RP11-33B1.4 -4.06 6.09e-05 0.0123 -0.16 -0.21 Corneal astigmatism; chr4:119248223 chr4:119409333~119410233:+ LIHC cis rs11676348 0.774 rs11683524 ENSG00000261338.2 RP11-378A13.1 -4.06 6.1e-05 0.0123 -0.23 -0.21 Ulcerative colitis; chr2:218119881 chr2:218255319~218257366:+ LIHC cis rs7726839 0.54 rs72705030 ENSG00000271781.1 CTD-2589H19.6 -4.06 6.1e-05 0.0123 -0.33 -0.21 Obesity-related traits; chr5:645447 chr5:675826~676616:+ LIHC cis rs7412746 0.658 rs2275235 ENSG00000231073.1 RP11-316M1.3 4.06 6.11e-05 0.0123 0.22 0.21 Melanoma; chr1:150757803 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs11204723 ENSG00000231073.1 RP11-316M1.3 4.06 6.11e-05 0.0123 0.22 0.21 Melanoma; chr1:150759142 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs4537557 ENSG00000231073.1 RP11-316M1.3 4.06 6.11e-05 0.0123 0.22 0.21 Melanoma; chr1:150761960 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs2864869 ENSG00000231073.1 RP11-316M1.3 4.06 6.11e-05 0.0123 0.22 0.21 Melanoma; chr1:150762179 chr1:150973123~150975534:+ LIHC cis rs7412746 0.634 rs3754212 ENSG00000231073.1 RP11-316M1.3 4.06 6.11e-05 0.0123 0.22 0.21 Melanoma; chr1:150765724 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs6657388 ENSG00000231073.1 RP11-316M1.3 4.06 6.11e-05 0.0123 0.22 0.21 Melanoma; chr1:150776310 chr1:150973123~150975534:+ LIHC cis rs11096990 0.634 rs17431358 ENSG00000249207.1 RP11-360F5.1 4.06 6.11e-05 0.0123 0.21 0.21 Cognitive function; chr4:39275676 chr4:39112677~39126818:- LIHC cis rs71520386 0.561 rs10274260 ENSG00000228649.7 AC005682.5 -4.06 6.12e-05 0.0123 -0.26 -0.21 Fibrinogen levels; chr7:22805227 chr7:22854178~22861579:+ LIHC cis rs617219 0.889 rs1627316 ENSG00000251675.1 CTC-458I2.2 -4.06 6.12e-05 0.0123 -0.24 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79136621 chr5:80128361~80143883:+ LIHC cis rs617219 0.892 rs1717566 ENSG00000251675.1 CTC-458I2.2 -4.06 6.12e-05 0.0123 -0.24 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79136785 chr5:80128361~80143883:+ LIHC cis rs9675120 0.817 rs11079937 ENSG00000262006.1 RP11-700H6.4 -4.06 6.12e-05 0.0123 -0.23 -0.21 Cerebrospinal fluid biomarker levels; chr17:50853604 chr17:50909637~50910232:- LIHC cis rs72675573 0.821 rs1331854 ENSG00000235612.1 RP1-158P9.1 -4.06 6.12e-05 0.0123 -0.3 -0.21 Monocyte count; chr1:56058879 chr1:56145721~56155224:+ LIHC cis rs67311347 0.544 rs9833640 ENSG00000223797.4 ENTPD3-AS1 4.06 6.13e-05 0.0123 0.18 0.21 Renal cell carcinoma; chr3:40313450 chr3:40313802~40453329:- LIHC cis rs2564921 0.73 rs62255895 ENSG00000242142.1 SERBP1P3 -4.06 6.13e-05 0.0123 -0.29 -0.21 Height; chr3:53027969 chr3:53064283~53065091:- LIHC cis rs2564921 0.73 rs62255898 ENSG00000242142.1 SERBP1P3 -4.06 6.13e-05 0.0123 -0.29 -0.21 Height; chr3:53029908 chr3:53064283~53065091:- LIHC cis rs57502260 0.573 rs12291008 ENSG00000212093.1 AP000807.1 4.06 6.13e-05 0.0123 0.24 0.21 Total body bone mineral density (age 45-60); chr11:68621604 chr11:68506083~68506166:- LIHC cis rs17376456 0.877 rs10061080 ENSG00000251023.1 RP11-549J18.1 -4.06 6.14e-05 0.0123 -0.45 -0.21 Diabetic retinopathy; chr5:94084854 chr5:93860669~93863825:- LIHC cis rs9595908 0.544 rs7328213 ENSG00000212293.1 SNORA16 4.06 6.14e-05 0.0123 0.26 0.21 Body mass index; chr13:32803692 chr13:32420390~32420516:- LIHC cis rs9467773 0.804 rs2073526 ENSG00000241549.7 GUSBP2 -4.06 6.14e-05 0.0123 -0.22 -0.21 Intelligence (multi-trait analysis); chr6:26374430 chr6:26871484~26956554:- LIHC cis rs10510102 0.516 rs10887034 ENSG00000226864.1 ATE1-AS1 4.06 6.14e-05 0.0123 0.38 0.21 Breast cancer; chr10:121973996 chr10:121928312~121951965:+ LIHC cis rs1005277 0.579 rs1780121 ENSG00000099251.13 HSD17B7P2 4.06 6.14e-05 0.0123 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38240509 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs1780122 ENSG00000099251.13 HSD17B7P2 4.06 6.14e-05 0.0123 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38240581 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs1780145 ENSG00000099251.13 HSD17B7P2 4.06 6.14e-05 0.0123 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38248142 chr10:38356380~38378505:+ LIHC cis rs1023500 0.505 rs134885 ENSG00000205702.9 CYP2D7 4.06 6.14e-05 0.0123 0.22 0.21 Schizophrenia; chr22:42277805 chr22:42140203~42144577:- LIHC cis rs17464492 0.592 rs13270266 ENSG00000246228.5 CASC8 4.06 6.14e-05 0.0123 0.24 0.21 Prostate-specific antigen levels (conditioned on lead SNPs); chr8:127341840 chr8:127289817~127482139:- LIHC cis rs7722022 0.961 rs58870274 ENSG00000253428.1 CTB-43E15.2 4.06 6.15e-05 0.0124 0.22 0.21 Adiponectin levels; chr5:173521529 chr5:173689459~173705849:+ LIHC cis rs7617773 0.817 rs9837228 ENSG00000228638.1 FCF1P2 4.06 6.16e-05 0.0124 0.24 0.21 Coronary artery disease; chr3:48282976 chr3:48290793~48291375:- LIHC cis rs875971 0.522 rs1917563 ENSG00000273024.4 INTS4P2 4.06 6.16e-05 0.0124 0.26 0.21 Aortic root size; chr7:65950660 chr7:65647864~65715661:+ LIHC cis rs4578769 0.765 rs60721147 ENSG00000266850.1 RP11-370A5.1 -4.06 6.16e-05 0.0124 -0.25 -0.21 Eosinophil percentage of white cells; chr18:22848569 chr18:22723491~22907721:- LIHC cis rs481331 0.611 rs12264895 ENSG00000185904.10 LINC00839 4.06 6.16e-05 0.0124 0.4 0.21 Systemic juvenile idiopathic arthritis; chr10:42695001 chr10:42475543~42495336:+ LIHC cis rs481331 0.741 rs7088389 ENSG00000185904.10 LINC00839 4.06 6.16e-05 0.0124 0.4 0.21 Systemic juvenile idiopathic arthritis; chr10:42695806 chr10:42475543~42495336:+ LIHC cis rs481331 0.741 rs7099013 ENSG00000185904.10 LINC00839 4.06 6.16e-05 0.0124 0.4 0.21 Systemic juvenile idiopathic arthritis; chr10:42696291 chr10:42475543~42495336:+ LIHC cis rs9652601 0.919 rs12924729 ENSG00000274038.1 RP11-66H6.4 -4.06 6.17e-05 0.0124 -0.26 -0.21 Systemic lupus erythematosus; chr16:11093926 chr16:11056556~11057034:+ LIHC cis rs9640161 0.83 rs3757423 ENSG00000261305.1 RP4-584D14.7 -4.06 6.17e-05 0.0124 -0.25 -0.21 Blood protein levels;Circulating chemerin levels; chr7:150370625 chr7:150341771~150342607:+ LIHC cis rs617219 0.889 rs36177073 ENSG00000251675.1 CTC-458I2.2 -4.06 6.17e-05 0.0124 -0.24 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79136934 chr5:80128361~80143883:+ LIHC cis rs597539 0.616 rs473997 ENSG00000250508.1 RP11-757G1.6 -4.06 6.17e-05 0.0124 -0.33 -0.21 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68872013 chr11:68870664~68874542:+ LIHC cis rs7044106 0.762 rs10760107 ENSG00000238181.2 AHCYP2 -4.06 6.17e-05 0.0124 -0.24 -0.21 Hip circumference adjusted for BMI; chr9:120621352 chr9:120720673~120721972:+ LIHC cis rs11098499 0.863 rs3822195 ENSG00000260091.1 RP11-33B1.4 -4.06 6.17e-05 0.0124 -0.15 -0.21 Corneal astigmatism; chr4:119550505 chr4:119409333~119410233:+ LIHC cis rs763121 0.853 rs2235230 ENSG00000273076.1 RP3-508I15.22 -4.06 6.18e-05 0.0124 -0.26 -0.21 Menopause (age at onset); chr22:38728462 chr22:38743495~38743910:+ LIHC cis rs17818399 0.645 rs35870739 ENSG00000239332.4 LINC01119 -4.06 6.18e-05 0.0124 -0.31 -0.21 Height; chr2:46557092 chr2:46816697~46859007:+ LIHC cis rs4650994 0.544 rs2476561 ENSG00000273384.1 RP5-1098D14.1 4.06 6.18e-05 0.0124 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178650765 chr1:178651706~178652282:+ LIHC cis rs11098499 0.865 rs10213221 ENSG00000260091.1 RP11-33B1.4 -4.06 6.18e-05 0.0124 -0.15 -0.21 Corneal astigmatism; chr4:119334771 chr4:119409333~119410233:+ LIHC cis rs6430585 0.528 rs3099429 ENSG00000231890.6 DARS-AS1 -4.06 6.18e-05 0.0124 -0.3 -0.21 Corneal structure; chr2:135898012 chr2:135985176~136022593:+ LIHC cis rs17818399 0.817 rs17767994 ENSG00000279254.1 RP11-536C12.1 4.06 6.18e-05 0.0124 0.27 0.21 Height; chr2:46632940 chr2:46668870~46670778:+ LIHC cis rs6472827 0.794 rs4439117 ENSG00000253983.2 RP1-16A9.1 4.06 6.18e-05 0.0124 0.27 0.21 Uterine fibroids; chr8:74207475 chr8:74199396~74208441:+ LIHC cis rs6832769 0.961 rs28790098 ENSG00000272969.1 RP11-528I4.2 -4.06 6.19e-05 0.0124 -0.25 -0.21 Personality dimensions; chr4:55531942 chr4:55547112~55547889:+ LIHC cis rs244293 0.795 rs12940239 ENSG00000275710.1 RP11-257O5.4 4.06 6.19e-05 0.0124 0.24 0.21 Menarche (age at onset); chr17:54991569 chr17:54964474~54964679:+ LIHC cis rs3091242 0.9 rs669063 ENSG00000224183.1 SDHDP6 -4.06 6.19e-05 0.0124 -0.25 -0.21 Erythrocyte sedimentation rate; chr1:25394663 chr1:25294164~25294643:- LIHC cis rs13113518 0.812 rs4865003 ENSG00000249700.7 SRD5A3-AS1 4.06 6.19e-05 0.0124 0.25 0.21 Height; chr4:55514802 chr4:55363971~55395847:- LIHC cis rs13113518 0.756 rs12510275 ENSG00000249700.7 SRD5A3-AS1 4.06 6.19e-05 0.0124 0.25 0.21 Height; chr4:55516548 chr4:55363971~55395847:- LIHC cis rs13113518 0.812 rs12510327 ENSG00000249700.7 SRD5A3-AS1 4.06 6.19e-05 0.0124 0.25 0.21 Height; chr4:55516744 chr4:55363971~55395847:- LIHC cis rs13113518 0.812 rs11939580 ENSG00000249700.7 SRD5A3-AS1 4.06 6.19e-05 0.0124 0.25 0.21 Height; chr4:55517185 chr4:55363971~55395847:- LIHC cis rs2032447 0.702 rs199753 ENSG00000242387.1 HIST1H2APS2 4.06 6.19e-05 0.0124 0.28 0.21 Intelligence (multi-trait analysis); chr6:26001660 chr6:25882026~25882395:- LIHC cis rs1876905 0.539 rs457497 ENSG00000272356.1 RP5-1112D6.8 4.06 6.19e-05 0.0124 0.2 0.21 Mean corpuscular hemoglobin; chr6:111301346 chr6:111309203~111313517:+ LIHC cis rs11098499 0.863 rs1552095 ENSG00000260091.1 RP11-33B1.4 -4.06 6.2e-05 0.0124 -0.16 -0.21 Corneal astigmatism; chr4:119539151 chr4:119409333~119410233:+ LIHC cis rs56046484 0.703 rs116893322 ENSG00000259630.2 CTD-2262B20.1 -4.06 6.2e-05 0.0124 -0.42 -0.21 Testicular germ cell tumor; chr15:84981397 chr15:85415228~85415633:+ LIHC cis rs57221529 0.608 rs11749927 ENSG00000271781.1 CTD-2589H19.6 -4.06 6.2e-05 0.0124 -0.3 -0.21 Lung disease severity in cystic fibrosis; chr5:668727 chr5:675826~676616:+ LIHC cis rs244293 0.965 rs244311 ENSG00000275710.1 RP11-257O5.4 4.06 6.2e-05 0.0125 0.23 0.21 Menarche (age at onset); chr17:55135442 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244312 ENSG00000275710.1 RP11-257O5.4 4.06 6.2e-05 0.0125 0.23 0.21 Menarche (age at onset); chr17:55135836 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244313 ENSG00000275710.1 RP11-257O5.4 4.06 6.2e-05 0.0125 0.23 0.21 Menarche (age at onset); chr17:55136971 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244314 ENSG00000275710.1 RP11-257O5.4 4.06 6.2e-05 0.0125 0.23 0.21 Menarche (age at onset); chr17:55137156 chr17:54964474~54964679:+ LIHC cis rs763121 0.719 rs138699 ENSG00000273076.1 RP3-508I15.22 4.06 6.2e-05 0.0125 0.25 0.21 Menopause (age at onset); chr22:38733703 chr22:38743495~38743910:+ LIHC cis rs3761847 0.5 rs7037673 ENSG00000226752.6 PSMD5-AS1 -4.06 6.21e-05 0.0125 -0.22 -0.21 Rheumatoid arthritis; chr9:120978206 chr9:120824828~120854385:+ LIHC cis rs12145833 0.538 rs10926977 ENSG00000253326.2 RP11-261C10.7 -4.06 6.21e-05 0.0125 -0.44 -0.21 Obesity (early onset extreme); chr1:243248065 chr1:243054861~243056394:- LIHC cis rs2948294 0.588 rs4840913 ENSG00000173295.6 FAM86B3P 4.06 6.21e-05 0.0125 0.26 0.21 Red cell distribution width; chr8:8259384 chr8:8228595~8244865:+ LIHC cis rs2243480 0.901 rs778730 ENSG00000232546.1 RP11-458F8.1 -4.06 6.21e-05 0.0125 -0.24 -0.21 Diabetic kidney disease; chr7:66358338 chr7:66848496~66858136:+ LIHC cis rs11098499 0.913 rs67073020 ENSG00000260091.1 RP11-33B1.4 -4.05 6.21e-05 0.0125 -0.16 -0.21 Corneal astigmatism; chr4:119231402 chr4:119409333~119410233:+ LIHC cis rs673078 0.66 rs16948197 ENSG00000275759.1 RP11-131L12.3 4.05 6.21e-05 0.0125 0.4 0.21 Glucose homeostasis traits; chr12:118239135 chr12:118428281~118428870:+ LIHC cis rs3015497 0.789 rs3015496 ENSG00000269906.1 RP11-248J18.2 4.05 6.22e-05 0.0125 0.27 0.21 Mean platelet volume; chr14:50647333 chr14:50662511~50663178:- LIHC cis rs2439831 1 rs2444032 ENSG00000166763.7 STRCP1 4.05 6.22e-05 0.0125 0.3 0.21 Lung cancer in ever smokers; chr15:43463148 chr15:43699488~43718184:- LIHC cis rs57502260 0.679 rs72936524 ENSG00000212093.1 AP000807.1 4.05 6.22e-05 0.0125 0.29 0.21 Total body bone mineral density (age 45-60); chr11:68508430 chr11:68506083~68506166:- LIHC cis rs2717559 0.542 rs11774823 ENSG00000253196.1 RP11-706C16.7 -4.05 6.22e-05 0.0125 -0.24 -0.21 Urinary tract infection frequency; chr8:142806152 chr8:142763116~142766427:+ LIHC cis rs787274 0.543 rs62576453 ENSG00000271631.1 RP11-408O19.5 4.05 6.22e-05 0.0125 0.35 0.21 Age-related hearing impairment (SNP x SNP interaction); chr9:112867641 chr9:112885158~112885767:+ LIHC cis rs11096990 0.855 rs2711935 ENSG00000249207.1 RP11-360F5.1 4.05 6.22e-05 0.0125 0.25 0.21 Cognitive function; chr4:39160837 chr4:39112677~39126818:- LIHC cis rs10829156 0.898 rs7095666 ENSG00000240291.1 RP11-499P20.2 -4.05 6.23e-05 0.0125 -0.32 -0.21 Sudden cardiac arrest; chr10:18650538 chr10:18513115~18545651:- LIHC cis rs1499614 0.901 rs2178742 ENSG00000275400.1 RP4-756H11.5 4.05 6.23e-05 0.0125 0.29 0.21 Gout; chr7:66732812 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs160639 ENSG00000230295.1 RP11-458F8.2 -4.05 6.23e-05 0.0125 -0.22 -0.21 Diabetic kidney disease; chr7:66115000 chr7:66880708~66882981:+ LIHC cis rs7985 1 rs3752603 ENSG00000244625.4 MIATNB 4.05 6.23e-05 0.0125 0.23 0.21 Electroencephalogram traits; chr22:26668531 chr22:26672767~26780207:+ LIHC cis rs7985 1 rs7985 ENSG00000244625.4 MIATNB 4.05 6.23e-05 0.0125 0.23 0.21 Electroencephalogram traits; chr22:26670572 chr22:26672767~26780207:+ LIHC cis rs2120243 0.533 rs1392798 ENSG00000244515.1 KRT18P34 4.05 6.23e-05 0.0125 0.2 0.21 Hepatocellular carcinoma in hepatitis B infection; chr3:157338498 chr3:157162663~157163932:- LIHC cis rs6893782 0.945 rs7705826 ENSG00000233006.5 AC034220.3 -4.05 6.23e-05 0.0125 -0.3 -0.21 Acylcarnitine levels; chr5:132396764 chr5:132311285~132369916:- LIHC cis rs6893782 1 rs6893782 ENSG00000233006.5 AC034220.3 -4.05 6.23e-05 0.0125 -0.3 -0.21 Acylcarnitine levels; chr5:132403741 chr5:132311285~132369916:- LIHC cis rs6893782 0.945 rs2405522 ENSG00000233006.5 AC034220.3 -4.05 6.23e-05 0.0125 -0.3 -0.21 Acylcarnitine levels; chr5:132406004 chr5:132311285~132369916:- LIHC cis rs11637445 0.677 rs3784713 ENSG00000260657.2 RP11-315D16.4 -4.05 6.23e-05 0.0125 -0.3 -0.21 Posterior cortical atrophy and Alzheimer's disease; chr15:67780675 chr15:68267792~68277994:- LIHC cis rs11637445 0.677 rs12441598 ENSG00000260657.2 RP11-315D16.4 -4.05 6.23e-05 0.0125 -0.3 -0.21 Posterior cortical atrophy and Alzheimer's disease; chr15:67780867 chr15:68267792~68277994:- LIHC cis rs6832769 0.961 rs11735267 ENSG00000272969.1 RP11-528I4.2 4.05 6.23e-05 0.0125 0.26 0.21 Personality dimensions; chr4:55481120 chr4:55547112~55547889:+ LIHC cis rs3845817 0.671 rs840785 ENSG00000281920.1 RP11-418H16.1 -4.05 6.24e-05 0.0125 -0.25 -0.21 Bipolar disorder; chr2:65541842 chr2:65623272~65628424:+ LIHC cis rs3845817 0.703 rs702915 ENSG00000281920.1 RP11-418H16.1 -4.05 6.24e-05 0.0125 -0.25 -0.21 Bipolar disorder; chr2:65543462 chr2:65623272~65628424:+ LIHC cis rs3845817 0.703 rs1673458 ENSG00000281920.1 RP11-418H16.1 -4.05 6.24e-05 0.0125 -0.25 -0.21 Bipolar disorder; chr2:65544512 chr2:65623272~65628424:+ LIHC cis rs2976388 0.669 rs2585135 ENSG00000253196.1 RP11-706C16.7 -4.05 6.24e-05 0.0125 -0.22 -0.21 Urinary tract infection frequency; chr8:142732775 chr8:142763116~142766427:+ LIHC cis rs875971 0.505 rs1723275 ENSG00000273024.4 INTS4P2 4.05 6.24e-05 0.0125 0.25 0.21 Aortic root size; chr7:66039646 chr7:65647864~65715661:+ LIHC cis rs3091242 0.933 rs11802413 ENSG00000261349.1 RP3-465N24.5 4.05 6.24e-05 0.0125 0.21 0.21 Erythrocyte sedimentation rate; chr1:25434429 chr1:25266102~25267136:- LIHC cis rs11010290 0.639 rs17511194 ENSG00000269952.1 RP11-324I22.3 -4.05 6.24e-05 0.0125 -0.35 -0.21 Antineutrophil cytoplasmic antibody-associated vasculitis; chr10:35747852 chr10:35210416~35210750:+ LIHC cis rs8026198 0.929 rs3743006 ENSG00000260571.1 BNIP3P5 -4.05 6.24e-05 0.0125 -0.3 -0.21 Fibrinogen levels; chr15:42353570 chr15:42313687~42314386:+ LIHC cis rs27434 0.66 rs26493 ENSG00000272109.1 CTD-2260A17.3 -4.05 6.25e-05 0.0125 -0.29 -0.21 Ankylosing spondylitis; chr5:96819615 chr5:96804353~96806105:+ LIHC cis rs4650994 1 rs17361251 ENSG00000213057.5 C1orf220 4.05 6.25e-05 0.0125 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178551442 chr1:178542752~178548889:+ LIHC cis rs4650994 1 rs17276527 ENSG00000213057.5 C1orf220 4.05 6.25e-05 0.0125 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178551545 chr1:178542752~178548889:+ LIHC cis rs9303401 0.632 rs7222087 ENSG00000265415.1 CTD-2510F5.4 4.05 6.25e-05 0.0125 0.15 0.21 Cognitive test performance; chr17:59144258 chr17:59202677~59203829:- LIHC cis rs6500637 0.591 rs2075466 ENSG00000267077.1 RP11-127I20.5 4.05 6.25e-05 0.0125 0.24 0.21 Cancer; chr16:4822969 chr16:4795265~4796532:- LIHC cis rs13287066 0.692 rs7020852 ENSG00000227603.1 RP11-165J3.6 4.05 6.25e-05 0.0125 0.25 0.21 Intelligence (multi-trait analysis); chr9:93400978 chr9:93435332~93437121:- LIHC cis rs858239 0.636 rs28706766 ENSG00000226816.2 AC005082.12 4.05 6.25e-05 0.0125 0.25 0.21 Cerebrospinal fluid biomarker levels; chr7:23130215 chr7:23206013~23208045:+ LIHC cis rs638893 0.898 rs587816 ENSG00000255239.1 AP002954.6 4.05 6.25e-05 0.0125 0.47 0.21 Vitiligo; chr11:118819162 chr11:118688039~118690600:- LIHC cis rs638893 0.898 rs577121 ENSG00000255239.1 AP002954.6 4.05 6.25e-05 0.0125 0.47 0.21 Vitiligo; chr11:118819841 chr11:118688039~118690600:- LIHC cis rs202072 1 rs202074 ENSG00000215022.6 RP1-257A7.4 -4.05 6.26e-05 0.0125 -0.25 -0.21 HIV-1 viral setpoint; chr6:13269131 chr6:13264861~13295586:- LIHC cis rs938554 0.513 rs3775947 ENSG00000250413.1 RP11-448G15.1 -4.05 6.26e-05 0.0126 -0.3 -0.21 Blood metabolite levels; chr4:9993616 chr4:10006482~10009725:+ LIHC cis rs11098499 0.955 rs11944880 ENSG00000260091.1 RP11-33B1.4 4.05 6.26e-05 0.0126 0.16 0.21 Corneal astigmatism; chr4:119238179 chr4:119409333~119410233:+ LIHC cis rs7412746 0.566 rs2864871 ENSG00000231073.1 RP11-316M1.3 4.05 6.26e-05 0.0126 0.22 0.21 Melanoma; chr1:150794488 chr1:150973123~150975534:+ LIHC cis rs295490 0.748 rs2289348 ENSG00000272656.1 RP11-219D15.3 4.05 6.26e-05 0.0126 0.61 0.21 PR interval in Tripanosoma cruzi seropositivity; chr3:139445424 chr3:139349024~139349371:- LIHC cis rs17818399 0.89 rs34752561 ENSG00000279254.1 RP11-536C12.1 -4.05 6.27e-05 0.0126 -0.27 -0.21 Height; chr2:46623011 chr2:46668870~46670778:+ LIHC cis rs6732160 0.691 rs6728147 ENSG00000272702.1 RP11-44N22.3 -4.05 6.27e-05 0.0126 -0.24 -0.21 Intelligence (multi-trait analysis); chr2:73196362 chr2:73113018~73115907:+ LIHC cis rs755249 0.567 rs1126313 ENSG00000182109.6 RP11-69E11.4 -4.05 6.27e-05 0.0126 -0.27 -0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39174072 chr1:39522280~39546187:- LIHC cis rs1799949 1 rs8074136 ENSG00000267681.1 CTD-3199J23.6 -4.05 6.27e-05 0.0126 -0.21 -0.21 Menopause (age at onset); chr17:43190296 chr17:43144956~43145255:+ LIHC cis rs6964833 1 rs17515241 ENSG00000277053.3 GTF2IP1 4.05 6.28e-05 0.0126 0.27 0.21 Menarche (age at onset); chr7:74717695 chr7:75185385~75237696:- LIHC cis rs10510102 0.516 rs10219133 ENSG00000276742.1 RP11-500G22.4 4.05 6.28e-05 0.0126 0.36 0.21 Breast cancer; chr10:121987898 chr10:121956782~121957098:+ LIHC cis rs1799949 1 rs11652332 ENSG00000267681.1 CTD-3199J23.6 -4.05 6.28e-05 0.0126 -0.21 -0.21 Menopause (age at onset); chr17:43143472 chr17:43144956~43145255:+ LIHC cis rs9467603 0.925 rs1892251 ENSG00000216436.2 HIST1H2APS1 -4.05 6.28e-05 0.0126 -0.48 -0.21 Intelligence (multi-trait analysis); chr6:25769121 chr6:25732497~25732827:+ LIHC cis rs9467603 0.858 rs1937126 ENSG00000216436.2 HIST1H2APS1 -4.05 6.28e-05 0.0126 -0.48 -0.21 Intelligence (multi-trait analysis); chr6:25769380 chr6:25732497~25732827:+ LIHC cis rs3768716 0.5 rs777329 ENSG00000229267.2 AC072062.1 4.05 6.28e-05 0.0126 0.27 0.21 Neuroblastoma; chr2:214877871 chr2:214810229~214963274:+ LIHC cis rs7617480 0.61 rs10865954 ENSG00000270441.1 RP11-694I15.7 -4.05 6.28e-05 0.0126 -0.31 -0.21 Menarche (age at onset);Subjective well-being (multi-trait analysis); chr3:49174556 chr3:49140086~49160851:- LIHC cis rs4834770 0.765 rs1511016 ENSG00000245958.5 RP11-33B1.1 -4.05 6.28e-05 0.0126 -0.21 -0.21 Blood protein levels; chr4:119249200 chr4:119454791~119552025:+ LIHC cis rs10829156 0.773 rs7909552 ENSG00000225527.1 RP11-383B4.4 -4.05 6.28e-05 0.0126 -0.34 -0.21 Sudden cardiac arrest; chr10:18620407 chr10:18531849~18533336:- LIHC cis rs4578769 0.918 rs4800138 ENSG00000265943.1 RP11-739L10.1 -4.05 6.29e-05 0.0126 -0.27 -0.21 Eosinophil percentage of white cells; chr18:22934334 chr18:22699481~22933764:- LIHC cis rs6997458 0.904 rs725605 ENSG00000253549.4 RP11-317J10.2 4.05 6.29e-05 0.0126 0.24 0.21 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85354657 chr8:85441851~85464915:- LIHC cis rs6997458 0.904 rs1532424 ENSG00000253549.4 RP11-317J10.2 4.05 6.29e-05 0.0126 0.24 0.21 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85355963 chr8:85441851~85464915:- LIHC cis rs13113518 0.812 rs4865001 ENSG00000249700.7 SRD5A3-AS1 4.05 6.29e-05 0.0126 0.25 0.21 Height; chr4:55490176 chr4:55363971~55395847:- LIHC cis rs13113518 0.812 rs4864543 ENSG00000249700.7 SRD5A3-AS1 4.05 6.29e-05 0.0126 0.25 0.21 Height; chr4:55490228 chr4:55363971~55395847:- LIHC cis rs950880 0.71 rs3771150 ENSG00000234389.1 AC007278.3 -4.05 6.29e-05 0.0126 -0.22 -0.21 Serum protein levels (sST2); chr2:102444391 chr2:102438713~102440475:+ LIHC cis rs7811142 1 rs7794485 ENSG00000242294.5 STAG3L5P 4.05 6.3e-05 0.0126 0.27 0.21 Platelet count; chr7:100471313 chr7:100336079~100351900:+ LIHC cis rs875971 0.545 rs1267814 ENSG00000224316.1 RP11-479O9.2 -4.05 6.3e-05 0.0126 -0.2 -0.21 Aortic root size; chr7:66579422 chr7:65773620~65802067:+ LIHC cis rs9341808 0.6 rs590641 ENSG00000272129.1 RP11-250B2.6 4.05 6.3e-05 0.0126 0.23 0.21 Sitting height ratio; chr6:80256766 chr6:80355424~80356859:+ LIHC cis rs12468226 1 rs11899836 ENSG00000272966.1 RP11-686O6.1 4.05 6.3e-05 0.0126 0.36 0.21 Urate levels; chr2:202371316 chr2:202336739~202337200:+ LIHC cis rs2448490 0.642 rs573589 ENSG00000265874.1 MIR4489 4.05 6.3e-05 0.0126 0.27 0.21 Platelet count; chr11:65716510 chr11:65649192~65649253:+ LIHC cis rs12681287 0.64 rs7846090 ENSG00000254088.1 SLC2A3P4 4.05 6.3e-05 0.0126 0.25 0.21 Caudate activity during reward; chr8:86455495 chr8:86503591~86505061:+ LIHC cis rs8177876 0.749 rs12927828 ENSG00000261061.1 RP11-303E16.2 -4.05 6.3e-05 0.0126 -0.29 -0.21 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81057019 chr16:81030770~81031485:+ LIHC cis rs2439831 1 rs2584726 ENSG00000166763.7 STRCP1 4.05 6.3e-05 0.0126 0.3 0.21 Lung cancer in ever smokers; chr15:43423184 chr15:43699488~43718184:- LIHC cis rs67311347 0.524 rs7649168 ENSG00000223797.4 ENTPD3-AS1 4.05 6.31e-05 0.0126 0.18 0.21 Renal cell carcinoma; chr3:40314667 chr3:40313802~40453329:- LIHC cis rs11637445 0.677 rs1564278 ENSG00000260657.2 RP11-315D16.4 -4.05 6.31e-05 0.0126 -0.3 -0.21 Posterior cortical atrophy and Alzheimer's disease; chr15:67815050 chr15:68267792~68277994:- LIHC cis rs2070488 0.965 rs2366119 ENSG00000229589.1 ACVR2B-AS1 4.05 6.31e-05 0.0126 0.24 0.21 Electrocardiographic conduction measures; chr3:38442962 chr3:38451027~38454820:- LIHC cis rs9952991 0.941 rs2847278 ENSG00000260302.1 RP11-973H7.1 -4.05 6.31e-05 0.0126 -0.32 -0.21 Inflammatory skin disease; chr18:12778716 chr18:12774651~12775923:- LIHC cis rs9952991 0.941 rs2542149 ENSG00000260302.1 RP11-973H7.1 -4.05 6.31e-05 0.0126 -0.32 -0.21 Inflammatory skin disease; chr18:12779019 chr18:12774651~12775923:- LIHC cis rs9952991 0.941 rs2847280 ENSG00000260302.1 RP11-973H7.1 -4.05 6.31e-05 0.0126 -0.32 -0.21 Inflammatory skin disease; chr18:12779343 chr18:12774651~12775923:- LIHC cis rs9952991 0.941 rs2542150 ENSG00000260302.1 RP11-973H7.1 -4.05 6.31e-05 0.0126 -0.32 -0.21 Inflammatory skin disease; chr18:12779764 chr18:12774651~12775923:- LIHC cis rs703842 0.928 rs724834 ENSG00000270039.1 RP11-571M6.17 -4.05 6.31e-05 0.0126 -0.3 -0.21 Multiple sclerosis; chr12:57786633 chr12:57803838~57804415:+ LIHC cis rs10510102 0.516 rs2420976 ENSG00000276742.1 RP11-500G22.4 -4.05 6.32e-05 0.0127 -0.35 -0.21 Breast cancer; chr10:121986932 chr10:121956782~121957098:+ LIHC cis rs4561483 0.798 rs456325 ENSG00000261560.1 RP11-166B2.3 -4.05 6.32e-05 0.0127 -0.24 -0.21 Testicular germ cell tumor; chr16:11918705 chr16:11881075~11882569:- LIHC cis rs901683 1 rs10508896 ENSG00000230869.1 CTGLF10P -4.05 6.32e-05 0.0127 -0.5 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45535195 chr10:45678692~45700532:+ LIHC cis rs4356975 0.932 rs4694602 ENSG00000250919.1 RP11-813N20.3 -4.05 6.32e-05 0.0127 -0.21 -0.21 Obesity-related traits; chr4:69070955 chr4:69027831~69044578:+ LIHC cis rs7829975 0.626 rs907183 ENSG00000253981.4 ALG1L13P -4.05 6.33e-05 0.0127 -0.25 -0.21 Mood instability; chr8:8872251 chr8:8236003~8244667:- LIHC cis rs987724 0.515 rs9870137 ENSG00000243926.1 TIPARP-AS1 4.05 6.33e-05 0.0127 0.24 0.21 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156898867 chr3:156671862~156674378:- LIHC cis rs3733589 1 rs16891926 ENSG00000250413.1 RP11-448G15.1 4.05 6.34e-05 0.0127 0.43 0.21 Renal overload gout; chr4:9995228 chr4:10006482~10009725:+ LIHC cis rs12681287 0.608 rs13273338 ENSG00000254088.1 SLC2A3P4 4.05 6.34e-05 0.0127 0.25 0.21 Caudate activity during reward; chr8:86441132 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs13258126 ENSG00000254088.1 SLC2A3P4 4.05 6.34e-05 0.0127 0.25 0.21 Caudate activity during reward; chr8:86441149 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs13256765 ENSG00000254088.1 SLC2A3P4 4.05 6.34e-05 0.0127 0.25 0.21 Caudate activity during reward; chr8:86445604 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs12678720 ENSG00000254088.1 SLC2A3P4 4.05 6.34e-05 0.0127 0.25 0.21 Caudate activity during reward; chr8:86445700 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs13253261 ENSG00000254088.1 SLC2A3P4 4.05 6.34e-05 0.0127 0.25 0.21 Caudate activity during reward; chr8:86446271 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs13253515 ENSG00000254088.1 SLC2A3P4 4.05 6.34e-05 0.0127 0.25 0.21 Caudate activity during reward; chr8:86446367 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs12541793 ENSG00000254088.1 SLC2A3P4 4.05 6.34e-05 0.0127 0.25 0.21 Caudate activity during reward; chr8:86450329 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs12679811 ENSG00000254088.1 SLC2A3P4 4.05 6.34e-05 0.0127 0.25 0.21 Caudate activity during reward; chr8:86453141 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs13264364 ENSG00000254088.1 SLC2A3P4 4.05 6.34e-05 0.0127 0.25 0.21 Caudate activity during reward; chr8:86454156 chr8:86503591~86505061:+ LIHC cis rs1789 0.503 rs13133213 ENSG00000273133.1 RP11-799M12.2 -4.05 6.34e-05 0.0127 -0.27 -0.21 Blood protein levels; chr4:15645171 chr4:15563698~15564253:- LIHC cis rs2274273 0.624 rs72717738 ENSG00000258413.1 RP11-665C16.6 -4.05 6.34e-05 0.0127 -0.26 -0.21 Protein biomarker; chr14:55376043 chr14:55262767~55272075:- LIHC cis rs1577917 1 rs11758849 ENSG00000234155.1 RP11-30P6.6 4.05 6.34e-05 0.0127 0.28 0.21 Response to antipsychotic treatment; chr6:85998544 chr6:85387219~85390186:- LIHC cis rs2348418 0.932 rs7968515 ENSG00000247934.4 RP11-967K21.1 4.05 6.34e-05 0.0127 0.2 0.21 Lung function (FEV1);Lung function (FVC); chr12:28542914 chr12:28163298~28190738:- LIHC cis rs1499614 1 rs1882655 ENSG00000275400.1 RP4-756H11.5 -4.05 6.35e-05 0.0127 -0.29 -0.21 Gout; chr7:66682070 chr7:66553805~66554199:- LIHC cis rs1499614 0.831 rs3800822 ENSG00000275400.1 RP4-756H11.5 -4.05 6.35e-05 0.0127 -0.29 -0.21 Gout; chr7:66682162 chr7:66553805~66554199:- LIHC cis rs1499614 1 rs1638731 ENSG00000275400.1 RP4-756H11.5 4.05 6.35e-05 0.0127 0.29 0.21 Gout; chr7:66679692 chr7:66553805~66554199:- LIHC cis rs2564921 0.73 rs2253675 ENSG00000242142.1 SERBP1P3 -4.05 6.35e-05 0.0127 -0.28 -0.21 Height; chr3:53085518 chr3:53064283~53065091:- LIHC cis rs7044106 0.762 rs7024046 ENSG00000238181.2 AHCYP2 -4.05 6.36e-05 0.0127 -0.24 -0.21 Hip circumference adjusted for BMI; chr9:120656900 chr9:120720673~120721972:+ LIHC cis rs10943724 0.799 rs6913206 ENSG00000272129.1 RP11-250B2.6 4.05 6.36e-05 0.0127 0.24 0.21 Thiazide-induced adverse metabolic effects in hypertensive patients; chr6:80472345 chr6:80355424~80356859:+ LIHC cis rs3015497 0.616 rs11157759 ENSG00000269906.1 RP11-248J18.2 4.05 6.36e-05 0.0127 0.27 0.21 Mean platelet volume; chr14:50620545 chr14:50662511~50663178:- LIHC cis rs2439831 0.702 rs495175 ENSG00000166763.7 STRCP1 4.05 6.36e-05 0.0127 0.3 0.21 Lung cancer in ever smokers; chr15:43506486 chr15:43699488~43718184:- LIHC cis rs2243480 0.908 rs2460431 ENSG00000232546.1 RP11-458F8.1 4.05 6.36e-05 0.0127 0.24 0.21 Diabetic kidney disease; chr7:66157859 chr7:66848496~66858136:+ LIHC cis rs2243480 0.711 rs2460426 ENSG00000232546.1 RP11-458F8.1 4.05 6.36e-05 0.0127 0.24 0.21 Diabetic kidney disease; chr7:66158142 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs4718309 ENSG00000232546.1 RP11-458F8.1 4.05 6.36e-05 0.0127 0.24 0.21 Diabetic kidney disease; chr7:66162777 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs6460274 ENSG00000232546.1 RP11-458F8.1 4.05 6.36e-05 0.0127 0.24 0.21 Diabetic kidney disease; chr7:66163497 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs7787230 ENSG00000232546.1 RP11-458F8.1 4.05 6.36e-05 0.0127 0.24 0.21 Diabetic kidney disease; chr7:66164112 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs316317 ENSG00000232546.1 RP11-458F8.1 -4.05 6.36e-05 0.0127 -0.24 -0.21 Diabetic kidney disease; chr7:66148650 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs316304 ENSG00000232546.1 RP11-458F8.1 -4.05 6.36e-05 0.0127 -0.24 -0.21 Diabetic kidney disease; chr7:66151907 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs2465120 ENSG00000232546.1 RP11-458F8.1 -4.05 6.36e-05 0.0127 -0.24 -0.21 Diabetic kidney disease; chr7:66155987 chr7:66848496~66858136:+ LIHC cis rs11763353 0.627 rs6951635 ENSG00000235828.5 RPL36AP26 -4.05 6.37e-05 0.0127 -0.21 -0.21 Blood trace element (Zn levels); chr7:15571071 chr7:15701435~15701752:- LIHC cis rs16958440 1 rs62096468 ENSG00000267724.1 RP11-49K24.8 4.05 6.37e-05 0.0127 0.33 0.21 Sitting height ratio; chr18:47111195 chr18:47105946~47108062:+ LIHC cis rs11148252 0.846 rs4886077 ENSG00000278238.1 RP11-245D16.4 -4.05 6.37e-05 0.0127 -0.2 -0.21 Lewy body disease; chr13:52424562 chr13:52454775~52455331:- LIHC cis rs911186 0.812 rs3800316 ENSG00000216901.1 AL022393.7 4.05 6.37e-05 0.0127 0.35 0.21 Autism spectrum disorder or schizophrenia; chr6:27288323 chr6:28176188~28176674:+ LIHC cis rs1799949 0.965 rs33925201 ENSG00000267681.1 CTD-3199J23.6 -4.05 6.38e-05 0.0128 -0.21 -0.21 Menopause (age at onset); chr17:43128665 chr17:43144956~43145255:+ LIHC cis rs5758511 0.514 rs5751211 ENSG00000205702.9 CYP2D7 4.05 6.38e-05 0.0128 0.25 0.21 Birth weight; chr22:42090052 chr22:42140203~42144577:- LIHC cis rs5758511 0.514 rs3985938 ENSG00000205702.9 CYP2D7 4.05 6.38e-05 0.0128 0.25 0.21 Birth weight; chr22:42115723 chr22:42140203~42144577:- LIHC cis rs5758511 0.514 rs5758586 ENSG00000205702.9 CYP2D7 4.05 6.38e-05 0.0128 0.25 0.21 Birth weight; chr22:42121467 chr22:42140203~42144577:- LIHC cis rs5758511 0.514 rs5751222 ENSG00000205702.9 CYP2D7 4.05 6.38e-05 0.0128 0.25 0.21 Birth weight; chr22:42121918 chr22:42140203~42144577:- LIHC cis rs875971 0.522 rs6960048 ENSG00000273024.4 INTS4P2 -4.05 6.38e-05 0.0128 -0.25 -0.21 Aortic root size; chr7:65943052 chr7:65647864~65715661:+ LIHC cis rs7915414 0.951 rs749744 ENSG00000230338.1 MTND4P19 4.05 6.38e-05 0.0128 0.23 0.21 Clopidogrel active metabolite levels; chr10:94646838 chr10:94774156~94774633:- LIHC cis rs4578769 0.959 rs9955664 ENSG00000266850.1 RP11-370A5.1 4.05 6.38e-05 0.0128 0.25 0.21 Eosinophil percentage of white cells; chr18:22901330 chr18:22723491~22907721:- LIHC cis rs42490 1 rs43134 ENSG00000251136.7 RP11-37B2.1 4.05 6.38e-05 0.0128 0.19 0.21 Leprosy; chr8:89775732 chr8:89609409~89757727:- LIHC cis rs1075265 0.744 rs10203576 ENSG00000233266.1 HMGB1P31 4.05 6.38e-05 0.0128 0.26 0.21 Chronotype;Morning vs. evening chronotype; chr2:54060939 chr2:54051334~54051760:+ LIHC cis rs2658782 0.951 rs2608215 ENSG00000279684.1 RP11-755E23.2 -4.05 6.39e-05 0.0128 -0.38 -0.21 Pulmonary function decline; chr11:93415651 chr11:93286629~93288903:- LIHC cis rs4578769 0.918 rs8085287 ENSG00000266850.1 RP11-370A5.1 4.05 6.39e-05 0.0128 0.25 0.21 Eosinophil percentage of white cells; chr18:22884208 chr18:22723491~22907721:- LIHC cis rs9527 0.615 rs10883804 ENSG00000236937.2 PTGES3P4 4.05 6.39e-05 0.0128 0.27 0.21 Arsenic metabolism; chr10:102946763 chr10:102845595~102845950:+ LIHC cis rs72634501 0.517 rs6684217 ENSG00000182109.6 RP11-69E11.4 -4.05 6.39e-05 0.0128 -0.23 -0.21 HDL cholesterol; chr1:39121606 chr1:39522280~39546187:- LIHC cis rs12681287 0.57 rs4961188 ENSG00000254088.1 SLC2A3P4 -4.05 6.39e-05 0.0128 -0.25 -0.21 Caudate activity during reward; chr8:86370804 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs4490816 ENSG00000254088.1 SLC2A3P4 -4.05 6.39e-05 0.0128 -0.25 -0.21 Caudate activity during reward; chr8:86372709 chr8:86503591~86505061:+ LIHC cis rs433598 0.964 rs234279 ENSG00000260201.2 RP11-143N13.2 4.05 6.39e-05 0.0128 0.22 0.21 Schizophrenia; chr16:20677307 chr16:20580999~20586640:+ LIHC cis rs2070488 1 rs13072809 ENSG00000229589.1 ACVR2B-AS1 4.05 6.4e-05 0.0128 0.24 0.21 Electrocardiographic conduction measures; chr3:38426680 chr3:38451027~38454820:- LIHC cis rs1075265 0.527 rs10167891 ENSG00000233266.1 HMGB1P31 4.05 6.4e-05 0.0128 0.26 0.21 Chronotype;Morning vs. evening chronotype; chr2:54003658 chr2:54051334~54051760:+ LIHC cis rs651907 0.557 rs2288272 ENSG00000244119.1 PDCL3P4 4.05 6.4e-05 0.0128 0.22 0.21 Colorectal cancer; chr3:101659632 chr3:101712472~101713191:+ LIHC cis rs8177876 0.749 rs11865207 ENSG00000261061.1 RP11-303E16.2 -4.05 6.4e-05 0.0128 -0.29 -0.21 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81056055 chr16:81030770~81031485:+ LIHC cis rs12681287 0.64 rs67123356 ENSG00000254088.1 SLC2A3P4 4.05 6.41e-05 0.0128 0.25 0.21 Caudate activity during reward; chr8:86441763 chr8:86503591~86505061:+ LIHC cis rs7923609 0.905 rs7088799 ENSG00000232075.1 MRPL35P2 -4.05 6.41e-05 0.0128 -0.24 -0.21 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63256414 chr10:63634317~63634827:- LIHC cis rs7923609 0.756 rs7080386 ENSG00000232075.1 MRPL35P2 -4.05 6.41e-05 0.0128 -0.24 -0.21 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63288546 chr10:63634317~63634827:- LIHC cis rs7923609 0.778 rs7075195 ENSG00000232075.1 MRPL35P2 -4.05 6.41e-05 0.0128 -0.24 -0.21 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63290899 chr10:63634317~63634827:- LIHC cis rs1115240 0.898 rs1245196 ENSG00000257842.4 NOVA1-AS1 -4.05 6.41e-05 0.0128 -0.2 -0.21 Educational attainment (years of education); chr14:26565476 chr14:26598412~26806467:+ LIHC cis rs1115240 0.853 rs1951073 ENSG00000257842.4 NOVA1-AS1 -4.05 6.41e-05 0.0128 -0.2 -0.21 Educational attainment (years of education); chr14:26565906 chr14:26598412~26806467:+ LIHC cis rs1115240 0.898 rs178159 ENSG00000257842.4 NOVA1-AS1 -4.05 6.41e-05 0.0128 -0.2 -0.21 Educational attainment (years of education); chr14:26567912 chr14:26598412~26806467:+ LIHC cis rs1577917 0.958 rs13207354 ENSG00000234155.1 RP11-30P6.6 4.05 6.41e-05 0.0128 0.28 0.21 Response to antipsychotic treatment; chr6:85990545 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs12204365 ENSG00000234155.1 RP11-30P6.6 4.05 6.41e-05 0.0128 0.28 0.21 Response to antipsychotic treatment; chr6:85990814 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs12663651 ENSG00000234155.1 RP11-30P6.6 4.05 6.41e-05 0.0128 0.28 0.21 Response to antipsychotic treatment; chr6:85991937 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs34852683 ENSG00000234155.1 RP11-30P6.6 4.05 6.41e-05 0.0128 0.28 0.21 Response to antipsychotic treatment; chr6:85992612 chr6:85387219~85390186:- LIHC cis rs1577917 1 rs6936048 ENSG00000234155.1 RP11-30P6.6 4.05 6.41e-05 0.0128 0.28 0.21 Response to antipsychotic treatment; chr6:85992890 chr6:85387219~85390186:- LIHC cis rs55966801 0.786 rs72865316 ENSG00000279672.1 CMB9-55F22.1 4.05 6.41e-05 0.0128 0.36 0.21 Plateletcrit; chr11:247028 chr11:779617~780755:+ LIHC cis rs9595908 0.965 rs9595903 ENSG00000212293.1 SNORA16 4.05 6.41e-05 0.0128 0.25 0.21 Body mass index; chr13:32608003 chr13:32420390~32420516:- LIHC cis rs72675573 0.852 rs1331858 ENSG00000235612.1 RP1-158P9.1 -4.05 6.41e-05 0.0128 -0.28 -0.21 Monocyte count; chr1:56113658 chr1:56145721~56155224:+ LIHC cis rs72675573 0.852 rs12119549 ENSG00000235612.1 RP1-158P9.1 -4.05 6.41e-05 0.0128 -0.28 -0.21 Monocyte count; chr1:56115063 chr1:56145721~56155224:+ LIHC cis rs55794721 0.509 rs7554255 ENSG00000224183.1 SDHDP6 -4.05 6.42e-05 0.0128 -0.25 -0.21 Mean corpuscular volume;Plateletcrit; chr1:25451615 chr1:25294164~25294643:- LIHC cis rs55794721 0.509 rs4649085 ENSG00000224183.1 SDHDP6 -4.05 6.42e-05 0.0128 -0.25 -0.21 Mean corpuscular volume;Plateletcrit; chr1:25452341 chr1:25294164~25294643:- LIHC cis rs4650994 1 rs4076205 ENSG00000273384.1 RP5-1098D14.1 4.05 6.42e-05 0.0128 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178565022 chr1:178651706~178652282:+ LIHC cis rs2658782 0.547 rs4344448 ENSG00000279684.1 RP11-755E23.2 -4.05 6.42e-05 0.0128 -0.31 -0.21 Pulmonary function decline; chr11:93313881 chr11:93286629~93288903:- LIHC cis rs9527 0.615 rs3897401 ENSG00000236937.2 PTGES3P4 4.05 6.42e-05 0.0128 0.27 0.21 Arsenic metabolism; chr10:102936622 chr10:102845595~102845950:+ LIHC cis rs9527 0.615 rs36045108 ENSG00000236937.2 PTGES3P4 4.05 6.42e-05 0.0128 0.27 0.21 Arsenic metabolism; chr10:102938172 chr10:102845595~102845950:+ LIHC cis rs9527 0.615 rs7917295 ENSG00000236937.2 PTGES3P4 4.05 6.42e-05 0.0128 0.27 0.21 Arsenic metabolism; chr10:102941430 chr10:102845595~102845950:+ LIHC cis rs9527 0.568 rs12772775 ENSG00000236937.2 PTGES3P4 4.05 6.42e-05 0.0128 0.27 0.21 Arsenic metabolism; chr10:102943242 chr10:102845595~102845950:+ LIHC cis rs8059260 0.696 rs2110354 ENSG00000274038.1 RP11-66H6.4 -4.05 6.43e-05 0.0128 -0.26 -0.21 Alcohol consumption over the past year; chr16:11013635 chr16:11056556~11057034:+ LIHC cis rs9341808 0.667 rs806783 ENSG00000272129.1 RP11-250B2.6 -4.05 6.43e-05 0.0128 -0.22 -0.21 Sitting height ratio; chr6:80233226 chr6:80355424~80356859:+ LIHC cis rs9457247 0.602 rs10484530 ENSG00000227598.1 RP1-167A14.2 -4.05 6.43e-05 0.0128 -0.23 -0.21 Crohn's disease; chr6:167048074 chr6:166969626~166999065:- LIHC cis rs1005277 0.522 rs289643 ENSG00000276805.1 RP11-291L22.6 4.05 6.43e-05 0.0128 0.26 0.21 Extrinsic epigenetic age acceleration; chr10:37652566 chr10:38451030~38451785:+ LIHC cis rs13434995 0.537 rs7340797 ENSG00000273257.1 RP11-177J6.1 4.05 6.43e-05 0.0128 0.33 0.21 Adiponectin levels; chr4:55363681 chr4:55387949~55388271:+ LIHC cis rs7647973 0.58 rs4955432 ENSG00000270441.1 RP11-694I15.7 -4.05 6.44e-05 0.0129 -0.3 -0.21 Menarche (age at onset); chr3:49229339 chr3:49140086~49160851:- LIHC cis rs7647973 0.6 rs11920267 ENSG00000270441.1 RP11-694I15.7 -4.05 6.44e-05 0.0129 -0.3 -0.21 Menarche (age at onset); chr3:49238531 chr3:49140086~49160851:- LIHC cis rs11690935 0.589 rs2271758 ENSG00000228389.1 AC068039.4 -4.05 6.44e-05 0.0129 -0.27 -0.21 Schizophrenia; chr2:171844647 chr2:171773482~171775844:+ LIHC cis rs2439831 0.717 rs2447198 ENSG00000166763.7 STRCP1 4.05 6.44e-05 0.0129 0.34 0.21 Lung cancer in ever smokers; chr15:43602920 chr15:43699488~43718184:- LIHC cis rs9633402 0.697 rs4925735 ENSG00000259865.1 RP11-488L18.10 4.05 6.44e-05 0.0129 0.26 0.21 Systemic juvenile idiopathic arthritis; chr1:247837017 chr1:247187281~247188526:- LIHC cis rs6504622 0.755 rs34774205 ENSG00000262879.4 RP11-156P1.3 -4.05 6.45e-05 0.0129 -0.23 -0.21 Orofacial clefts; chr17:47083453 chr17:46984045~47100323:- LIHC cis rs673078 0.66 rs12229607 ENSG00000275759.1 RP11-131L12.3 -4.05 6.45e-05 0.0129 -0.27 -0.21 Glucose homeostasis traits; chr12:118338333 chr12:118428281~118428870:+ LIHC cis rs1005277 0.522 rs1208684 ENSG00000099251.13 HSD17B7P2 4.05 6.45e-05 0.0129 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37805008 chr10:38356380~38378505:+ LIHC cis rs2439831 0.85 rs558656 ENSG00000166763.7 STRCP1 4.05 6.46e-05 0.0129 0.3 0.21 Lung cancer in ever smokers; chr15:43431316 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs2467739 ENSG00000166763.7 STRCP1 4.05 6.46e-05 0.0129 0.3 0.21 Lung cancer in ever smokers; chr15:43447998 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs2245790 ENSG00000166763.7 STRCP1 4.05 6.46e-05 0.0129 0.3 0.21 Lung cancer in ever smokers; chr15:43452259 chr15:43699488~43718184:- LIHC cis rs6061231 0.571 rs482010 ENSG00000226332.2 RP11-157P1.4 -4.05 6.46e-05 0.0129 -0.22 -0.21 Colorectal cancer; chr20:62352495 chr20:62305432~62306325:- LIHC cis rs6142102 0.923 rs6059635 ENSG00000275784.1 RP5-1125A11.6 -4.05 6.46e-05 0.0129 -0.25 -0.21 Skin pigmentation; chr20:34025687 chr20:33989480~33991818:- LIHC cis rs1005277 0.54 rs1987431 ENSG00000099251.13 HSD17B7P2 4.05 6.46e-05 0.0129 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37699959 chr10:38356380~38378505:+ LIHC cis rs4925386 0.759 rs2427293 ENSG00000226332.2 RP11-157P1.4 -4.05 6.46e-05 0.0129 -0.25 -0.21 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62350803 chr20:62305432~62306325:- LIHC cis rs4356203 0.87 rs7936310 ENSG00000260196.1 RP1-239B22.5 4.05 6.46e-05 0.0129 0.26 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17248741 chr11:17380649~17383531:+ LIHC cis rs11673344 0.502 rs62108306 ENSG00000226686.6 LINC01535 4.05 6.47e-05 0.0129 0.3 0.21 Obesity-related traits; chr19:37691789 chr19:37251912~37265535:+ LIHC cis rs11673344 0.536 rs7259272 ENSG00000226686.6 LINC01535 4.05 6.47e-05 0.0129 0.3 0.21 Obesity-related traits; chr19:37692214 chr19:37251912~37265535:+ LIHC cis rs7712401 0.601 rs418229 ENSG00000263432.2 RN7SL689P -4.05 6.47e-05 0.0129 -0.31 -0.21 Mean platelet volume; chr5:123005969 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs374403 ENSG00000263432.2 RN7SL689P -4.05 6.47e-05 0.0129 -0.31 -0.21 Mean platelet volume; chr5:123006018 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs446782 ENSG00000263432.2 RN7SL689P -4.05 6.47e-05 0.0129 -0.31 -0.21 Mean platelet volume; chr5:123006173 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs417268 ENSG00000263432.2 RN7SL689P -4.05 6.47e-05 0.0129 -0.31 -0.21 Mean platelet volume; chr5:123009317 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs398142 ENSG00000263432.2 RN7SL689P -4.05 6.47e-05 0.0129 -0.31 -0.21 Mean platelet volume; chr5:123009881 chr5:123022487~123022783:- LIHC cis rs7712401 0.58 rs383262 ENSG00000263432.2 RN7SL689P -4.05 6.47e-05 0.0129 -0.31 -0.21 Mean platelet volume; chr5:123009989 chr5:123022487~123022783:- LIHC cis rs11096990 0.855 rs2566170 ENSG00000249207.1 RP11-360F5.1 4.05 6.47e-05 0.0129 0.25 0.21 Cognitive function; chr4:39150757 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2566177 ENSG00000249207.1 RP11-360F5.1 4.05 6.47e-05 0.0129 0.25 0.21 Cognitive function; chr4:39154558 chr4:39112677~39126818:- LIHC cis rs11096990 0.855 rs2711934 ENSG00000249207.1 RP11-360F5.1 4.05 6.47e-05 0.0129 0.25 0.21 Cognitive function; chr4:39156254 chr4:39112677~39126818:- LIHC cis rs6142102 0.961 rs1007090 ENSG00000275784.1 RP5-1125A11.6 -4.05 6.47e-05 0.0129 -0.25 -0.21 Skin pigmentation; chr20:33995065 chr20:33989480~33991818:- LIHC cis rs6142102 0.923 rs2284377 ENSG00000275784.1 RP5-1125A11.6 -4.05 6.47e-05 0.0129 -0.25 -0.21 Skin pigmentation; chr20:33998876 chr20:33989480~33991818:- LIHC cis rs6142102 0.961 rs2284378 ENSG00000275784.1 RP5-1125A11.6 -4.05 6.47e-05 0.0129 -0.25 -0.21 Skin pigmentation; chr20:34000289 chr20:33989480~33991818:- LIHC cis rs6142102 0.961 rs2284379 ENSG00000275784.1 RP5-1125A11.6 -4.05 6.47e-05 0.0129 -0.25 -0.21 Skin pigmentation; chr20:34006836 chr20:33989480~33991818:- LIHC cis rs6142102 0.961 rs2268080 ENSG00000275784.1 RP5-1125A11.6 -4.05 6.47e-05 0.0129 -0.25 -0.21 Skin pigmentation; chr20:34009910 chr20:33989480~33991818:- LIHC cis rs4682868 0.581 rs6774801 ENSG00000273328.4 RP11-141M3.6 -4.04 6.47e-05 0.0129 -0.21 -0.21 Monocyte percentage of white cells; chr3:42882284 chr3:42809414~42908105:+ LIHC cis rs651907 0.557 rs11917682 ENSG00000244119.1 PDCL3P4 4.04 6.48e-05 0.0129 0.22 0.21 Colorectal cancer; chr3:101636583 chr3:101712472~101713191:+ LIHC cis rs651907 0.557 rs12629658 ENSG00000244119.1 PDCL3P4 4.04 6.48e-05 0.0129 0.22 0.21 Colorectal cancer; chr3:101637691 chr3:101712472~101713191:+ LIHC cis rs875971 0.505 rs1167386 ENSG00000273024.4 INTS4P2 4.04 6.48e-05 0.0129 0.25 0.21 Aortic root size; chr7:66048109 chr7:65647864~65715661:+ LIHC cis rs875971 0.505 rs1167385 ENSG00000273024.4 INTS4P2 4.04 6.48e-05 0.0129 0.25 0.21 Aortic root size; chr7:66048321 chr7:65647864~65715661:+ LIHC cis rs7208859 0.673 rs9895684 ENSG00000266490.1 CTD-2349P21.9 4.04 6.48e-05 0.0129 0.27 0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30915582 chr17:30792372~30792833:+ LIHC cis rs875971 0.545 rs13311962 ENSG00000228409.4 CCT6P1 4.04 6.49e-05 0.0129 0.18 0.21 Aortic root size; chr7:66603142 chr7:65751142~65763354:+ LIHC cis rs794185 0.714 rs2633861 ENSG00000231249.1 ITPR1-AS1 -4.04 6.49e-05 0.0129 -0.24 -0.21 Multiple sclerosis--Brain Glutamate Levels; chr3:4457864 chr3:4490891~4493163:- LIHC cis rs875971 0.662 rs448725 ENSG00000232559.3 GS1-124K5.12 4.04 6.49e-05 0.0129 0.17 0.21 Aortic root size; chr7:66049641 chr7:66554588~66576923:- LIHC cis rs875971 0.658 rs432667 ENSG00000232559.3 GS1-124K5.12 4.04 6.49e-05 0.0129 0.17 0.21 Aortic root size; chr7:66049646 chr7:66554588~66576923:- LIHC cis rs1555322 0.556 rs7272884 ENSG00000279253.1 RP4-614O4.13 -4.04 6.49e-05 0.0129 -0.29 -0.21 Attention deficit hyperactivity disorder; chr20:35295212 chr20:35262727~35264187:- LIHC cis rs2348418 0.639 rs10459086 ENSG00000247934.4 RP11-967K21.1 -4.04 6.5e-05 0.013 -0.2 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28115511 chr12:28163298~28190738:- LIHC cis rs11779988 0.516 rs426498 ENSG00000253671.1 RP11-806O11.1 -4.04 6.5e-05 0.013 -0.26 -0.21 Breast cancer; chr8:18039649 chr8:17808941~17820868:+ LIHC cis rs6686842 0.562 rs213769 ENSG00000235358.1 RP11-399E6.1 4.04 6.5e-05 0.013 0.25 0.21 Height; chr1:41149686 chr1:41242373~41284861:+ LIHC cis rs3015497 0.616 rs7154131 ENSG00000269906.1 RP11-248J18.2 4.04 6.5e-05 0.013 0.26 0.21 Mean platelet volume; chr14:50579808 chr14:50662511~50663178:- LIHC cis rs10912872 0.564 rs11807475 ENSG00000231424.2 RP1-45C12.1 4.04 6.5e-05 0.013 0.23 0.21 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr1:171371960 chr1:171247580~171251794:- LIHC cis rs10510102 0.516 rs10437506 ENSG00000276742.1 RP11-500G22.4 4.04 6.5e-05 0.013 0.35 0.21 Breast cancer; chr10:121984011 chr10:121956782~121957098:+ LIHC cis rs10510102 0.516 rs74461504 ENSG00000276742.1 RP11-500G22.4 4.04 6.5e-05 0.013 0.35 0.21 Breast cancer; chr10:121986077 chr10:121956782~121957098:+ LIHC cis rs10510102 0.516 rs61071865 ENSG00000276742.1 RP11-500G22.4 4.04 6.5e-05 0.013 0.35 0.21 Breast cancer; chr10:121986236 chr10:121956782~121957098:+ LIHC cis rs2736340 0.539 rs9644687 ENSG00000255310.2 AF131215.2 -4.04 6.51e-05 0.013 -0.18 -0.21 Systemic lupus erythematosus;Systemic lupus erythematosus or rheumatoid arthritis;Kawasaki disease;Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis; chr8:11465516 chr8:11107788~11109726:- LIHC cis rs6439153 0.839 rs2624901 ENSG00000231305.3 RP11-723O4.2 -4.04 6.51e-05 0.013 -0.22 -0.21 Pneumococcal bacteremia; chr3:128958345 chr3:128861313~128871540:- LIHC cis rs55966801 0.68 rs6541 ENSG00000279672.1 CMB9-55F22.1 4.04 6.51e-05 0.013 0.35 0.21 Plateletcrit; chr11:252851 chr11:779617~780755:+ LIHC cis rs1023500 0.551 rs133371 ENSG00000226450.2 CYP2D8P 4.04 6.51e-05 0.013 0.26 0.21 Schizophrenia; chr22:42069570 chr22:42149886~42155001:- LIHC cis rs1023500 0.573 rs133374 ENSG00000226450.2 CYP2D8P 4.04 6.51e-05 0.013 0.26 0.21 Schizophrenia; chr22:42069937 chr22:42149886~42155001:- LIHC cis rs1023500 0.573 rs133378 ENSG00000226450.2 CYP2D8P 4.04 6.51e-05 0.013 0.26 0.21 Schizophrenia; chr22:42071691 chr22:42149886~42155001:- LIHC cis rs1023500 0.573 rs133382 ENSG00000226450.2 CYP2D8P 4.04 6.51e-05 0.013 0.26 0.21 Schizophrenia; chr22:42075770 chr22:42149886~42155001:- LIHC cis rs8060686 0.516 rs1971546 ENSG00000261469.1 RP11-96D1.6 -4.04 6.52e-05 0.013 -0.25 -0.21 HDL cholesterol;Metabolic syndrome; chr16:68246990 chr16:68236845~68237667:- LIHC cis rs8060686 0.516 rs73612297 ENSG00000261469.1 RP11-96D1.6 -4.04 6.52e-05 0.013 -0.25 -0.21 HDL cholesterol;Metabolic syndrome; chr16:68250851 chr16:68236845~68237667:- LIHC cis rs7208859 0.673 rs79541516 ENSG00000266490.1 CTD-2349P21.9 4.04 6.52e-05 0.013 0.27 0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913565 chr17:30792372~30792833:+ LIHC cis rs1443267 0.935 rs7210267 ENSG00000265542.4 RP11-60A24.3 -4.04 6.52e-05 0.013 -0.33 -0.21 Obstetric antiphospholipid syndrome; chr17:57848208 chr17:57771946~57834749:- LIHC cis rs7044106 0.762 rs4837789 ENSG00000238181.2 AHCYP2 -4.04 6.53e-05 0.013 -0.24 -0.21 Hip circumference adjusted for BMI; chr9:120663978 chr9:120720673~120721972:+ LIHC cis rs14027 0.512 rs4871528 ENSG00000279347.1 RP11-85I17.2 4.04 6.53e-05 0.013 0.21 0.21 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119700371 chr8:119838736~119840385:- LIHC cis rs1005277 0.579 rs1780116 ENSG00000099251.13 HSD17B7P2 4.04 6.53e-05 0.013 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38237693 chr10:38356380~38378505:+ LIHC cis rs2337406 0.925 rs34064152 ENSG00000274576.2 IGHV2-70 -4.04 6.53e-05 0.013 -0.27 -0.21 Alzheimer's disease (late onset); chr14:106700364 chr14:106770577~106771020:- LIHC cis rs3808502 0.527 rs2736374 ENSG00000255495.1 AC145124.2 -4.04 6.54e-05 0.013 -0.28 -0.21 Neuroticism; chr8:11256319 chr8:12194467~12196280:+ LIHC cis rs2797160 1 rs2211418 ENSG00000237742.5 RP11-624M8.1 -4.04 6.54e-05 0.013 -0.21 -0.21 Endometrial cancer; chr6:125674357 chr6:125578558~125749190:- LIHC cis rs1106684 1 rs1106683 ENSG00000233559.1 AC016831.7 4.04 6.54e-05 0.013 0.37 0.21 Body mass index; chr7:131768766 chr7:130853720~130928649:+ LIHC cis rs11098499 0.954 rs1546505 ENSG00000260091.1 RP11-33B1.4 -4.04 6.54e-05 0.013 -0.16 -0.21 Corneal astigmatism; chr4:119320069 chr4:119409333~119410233:+ LIHC cis rs6997458 0.742 rs9969643 ENSG00000253549.4 RP11-317J10.2 4.04 6.54e-05 0.013 0.23 0.21 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85453758 chr8:85441851~85464915:- LIHC cis rs1005277 0.579 rs1614236 ENSG00000099251.13 HSD17B7P2 4.04 6.55e-05 0.013 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38214068 chr10:38356380~38378505:+ LIHC cis rs7224610 0.931 rs7223342 ENSG00000263096.1 RP11-515O17.2 4.04 6.55e-05 0.013 0.31 0.21 Urate levels; chr17:55292233 chr17:55271504~55273653:- LIHC cis rs2439831 0.867 rs2584702 ENSG00000166763.7 STRCP1 4.04 6.55e-05 0.013 0.3 0.21 Lung cancer in ever smokers; chr15:43392716 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs2243434 ENSG00000166763.7 STRCP1 4.04 6.55e-05 0.013 0.3 0.21 Lung cancer in ever smokers; chr15:43397669 chr15:43699488~43718184:- LIHC cis rs3015497 0.789 rs3015500 ENSG00000269906.1 RP11-248J18.2 4.04 6.55e-05 0.013 0.27 0.21 Mean platelet volume; chr14:50642159 chr14:50662511~50663178:- LIHC cis rs638893 0.717 rs622690 ENSG00000255239.1 AP002954.6 4.04 6.56e-05 0.0131 0.37 0.21 Vitiligo; chr11:118833556 chr11:118688039~118690600:- LIHC cis rs7945705 0.818 rs4929916 ENSG00000254860.4 TMEM9B-AS1 -4.04 6.56e-05 0.0131 -0.21 -0.21 Hemoglobin concentration; chr11:8803449 chr11:8964675~8977527:+ LIHC cis rs8177876 0.822 rs16954582 ENSG00000261061.1 RP11-303E16.2 -4.04 6.56e-05 0.0131 -0.3 -0.21 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080552 chr16:81030770~81031485:+ LIHC cis rs6745190 0.906 rs13019038 ENSG00000236153.1 AC104076.3 -4.04 6.56e-05 0.0131 -0.28 -0.21 White blood cell count; chr2:181082907 chr2:180979427~180980090:- LIHC cis rs295490 0.667 rs75356853 ENSG00000272656.1 RP11-219D15.3 4.04 6.56e-05 0.0131 0.62 0.21 PR interval in Tripanosoma cruzi seropositivity; chr3:139324055 chr3:139349024~139349371:- LIHC cis rs9487094 0.922 rs2236582 ENSG00000260273.1 RP11-425D10.10 -4.04 6.56e-05 0.0131 -0.25 -0.21 Height; chr6:109444615 chr6:109382795~109383666:+ LIHC cis rs17376456 0.877 rs66696214 ENSG00000251023.1 RP11-549J18.1 -4.04 6.56e-05 0.0131 -0.45 -0.21 Diabetic retinopathy; chr5:94088828 chr5:93860669~93863825:- LIHC cis rs17376456 0.778 rs10440717 ENSG00000251023.1 RP11-549J18.1 -4.04 6.56e-05 0.0131 -0.45 -0.21 Diabetic retinopathy; chr5:94089147 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs9314095 ENSG00000251023.1 RP11-549J18.1 -4.04 6.56e-05 0.0131 -0.45 -0.21 Diabetic retinopathy; chr5:94089790 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10064520 ENSG00000251023.1 RP11-549J18.1 -4.04 6.56e-05 0.0131 -0.45 -0.21 Diabetic retinopathy; chr5:94091653 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs55832164 ENSG00000251023.1 RP11-549J18.1 -4.04 6.56e-05 0.0131 -0.45 -0.21 Diabetic retinopathy; chr5:94100874 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs17315943 ENSG00000251023.1 RP11-549J18.1 -4.04 6.56e-05 0.0131 -0.45 -0.21 Diabetic retinopathy; chr5:94107125 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs34184666 ENSG00000251023.1 RP11-549J18.1 -4.04 6.56e-05 0.0131 -0.45 -0.21 Diabetic retinopathy; chr5:94108879 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs28633397 ENSG00000251023.1 RP11-549J18.1 -4.04 6.56e-05 0.0131 -0.45 -0.21 Diabetic retinopathy; chr5:94111343 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs9314099 ENSG00000251023.1 RP11-549J18.1 -4.04 6.56e-05 0.0131 -0.45 -0.21 Diabetic retinopathy; chr5:94111670 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs9314100 ENSG00000251023.1 RP11-549J18.1 -4.04 6.56e-05 0.0131 -0.45 -0.21 Diabetic retinopathy; chr5:94111689 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10059230 ENSG00000251023.1 RP11-549J18.1 -4.04 6.56e-05 0.0131 -0.45 -0.21 Diabetic retinopathy; chr5:94114642 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10070390 ENSG00000251023.1 RP11-549J18.1 -4.04 6.56e-05 0.0131 -0.45 -0.21 Diabetic retinopathy; chr5:94116640 chr5:93860669~93863825:- LIHC cis rs4356203 0.87 rs1979603 ENSG00000260196.1 RP1-239B22.5 -4.04 6.57e-05 0.0131 -0.25 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17261839 chr11:17380649~17383531:+ LIHC cis rs4964805 0.802 rs11111778 ENSG00000257681.1 RP11-341G23.4 4.04 6.57e-05 0.0131 0.22 0.21 Attention deficit hyperactivity disorder; chr12:103791653 chr12:103746315~103768858:- LIHC cis rs11098499 0.78 rs7692994 ENSG00000260091.1 RP11-33B1.4 -4.04 6.57e-05 0.0131 -0.15 -0.21 Corneal astigmatism; chr4:119506334 chr4:119409333~119410233:+ LIHC cis rs950880 0.71 rs55927292 ENSG00000234389.1 AC007278.3 -4.04 6.58e-05 0.0131 -0.22 -0.21 Serum protein levels (sST2); chr2:102348401 chr2:102438713~102440475:+ LIHC cis rs2120243 0.647 rs60676003 ENSG00000244515.1 KRT18P34 -4.04 6.58e-05 0.0131 -0.21 -0.21 Hepatocellular carcinoma in hepatitis B infection; chr3:157430150 chr3:157162663~157163932:- LIHC cis rs8060686 0.516 rs2290700 ENSG00000261469.1 RP11-96D1.6 -4.04 6.58e-05 0.0131 -0.25 -0.21 HDL cholesterol;Metabolic syndrome; chr16:68255080 chr16:68236845~68237667:- LIHC cis rs8060686 0.516 rs2290699 ENSG00000261469.1 RP11-96D1.6 -4.04 6.58e-05 0.0131 -0.25 -0.21 HDL cholesterol;Metabolic syndrome; chr16:68255156 chr16:68236845~68237667:- LIHC cis rs8060686 0.516 rs8062085 ENSG00000261469.1 RP11-96D1.6 -4.04 6.58e-05 0.0131 -0.25 -0.21 HDL cholesterol;Metabolic syndrome; chr16:68255410 chr16:68236845~68237667:- LIHC cis rs12908161 0.959 rs2175567 ENSG00000259728.4 LINC00933 4.04 6.58e-05 0.0131 0.31 0.21 Schizophrenia; chr15:84657715 chr15:84570649~84580175:+ LIHC cis rs2562456 0.874 rs2562408 ENSG00000268555.1 RP11-678G14.3 -4.04 6.58e-05 0.0131 -0.27 -0.21 Pain; chr19:21527079 chr19:21570822~21587322:- LIHC cis rs2598107 0.532 rs7807193 ENSG00000211698.2 TRGV4 -4.04 6.58e-05 0.0131 -0.25 -0.21 Dupuytren's disease; chr7:37895071 chr7:38353715~38354517:- LIHC cis rs11096990 0.613 rs2060805 ENSG00000249685.1 RP11-360F5.3 4.04 6.58e-05 0.0131 0.26 0.21 Cognitive function; chr4:39232788 chr4:39133913~39135608:+ LIHC cis rs673078 0.66 rs6490175 ENSG00000275759.1 RP11-131L12.3 -4.04 6.58e-05 0.0131 -0.26 -0.21 Glucose homeostasis traits; chr12:118293559 chr12:118428281~118428870:+ LIHC cis rs55966801 0.68 rs72882962 ENSG00000279672.1 CMB9-55F22.1 4.04 6.58e-05 0.0131 0.36 0.21 Plateletcrit; chr11:269129 chr11:779617~780755:+ LIHC cis rs3761847 0.593 rs1468673 ENSG00000226752.6 PSMD5-AS1 -4.04 6.58e-05 0.0131 -0.22 -0.21 Rheumatoid arthritis; chr9:121047612 chr9:120824828~120854385:+ LIHC cis rs950880 0.71 rs4140785 ENSG00000234389.1 AC007278.3 -4.04 6.58e-05 0.0131 -0.21 -0.21 Serum protein levels (sST2); chr2:102472057 chr2:102438713~102440475:+ LIHC cis rs6430585 0.528 rs309159 ENSG00000231890.6 DARS-AS1 -4.04 6.59e-05 0.0131 -0.3 -0.21 Corneal structure; chr2:135927370 chr2:135985176~136022593:+ LIHC cis rs4965006 1 rs4965006 ENSG00000273568.1 RP11-417L19.6 4.04 6.59e-05 0.0131 0.27 0.21 Posterior cortical atrophy and Alzheimer's disease; chr12:131934988 chr12:131934642~131934928:+ LIHC cis rs5769765 1 rs761879 ENSG00000278869.1 CITF22-49E9.3 -4.04 6.59e-05 0.0131 -0.33 -0.21 Schizophrenia; chr22:49847562 chr22:49933198~49934074:- LIHC cis rs9807989 0.507 rs1420097 ENSG00000234389.1 AC007278.3 -4.04 6.59e-05 0.0131 -0.23 -0.21 Asthma; chr2:102392894 chr2:102438713~102440475:+ LIHC cis rs916888 0.61 rs142167 ENSG00000260075.1 NSFP1 -4.04 6.59e-05 0.0131 -0.26 -0.21 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:46372855~46487141:+ LIHC cis rs9976767 0.608 rs11909987 ENSG00000225218.1 AP001628.6 -4.04 6.6e-05 0.0131 -0.21 -0.21 Type 1 diabetes; chr21:42402293 chr21:42831040~42836477:- LIHC cis rs5770917 1 rs5770911 ENSG00000273272.1 CTA-384D8.34 4.04 6.6e-05 0.0131 0.31 0.21 Narcolepsy; chr22:50572812 chr22:50542650~50543011:+ LIHC cis rs950880 0.71 rs12905 ENSG00000234389.1 AC007278.3 -4.04 6.6e-05 0.0131 -0.22 -0.21 Serum protein levels (sST2); chr2:102343547 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs3821204 ENSG00000234389.1 AC007278.3 -4.04 6.6e-05 0.0131 -0.22 -0.21 Serum protein levels (sST2); chr2:102343821 chr2:102438713~102440475:+ LIHC cis rs2072510 0.9 rs2110762 ENSG00000257715.1 RP11-256L6.2 -4.04 6.6e-05 0.0131 -0.22 -0.21 Metabolite levels (small molecules and protein measures); chr12:96008756 chr12:96025323~96027971:+ LIHC cis rs2439831 0.681 rs478104 ENSG00000166763.7 STRCP1 4.04 6.6e-05 0.0131 0.29 0.21 Lung cancer in ever smokers; chr15:43302702 chr15:43699488~43718184:- LIHC cis rs7083 0.935 rs2509211 ENSG00000254851.1 RP11-109L13.1 4.04 6.6e-05 0.0131 0.31 0.21 Blood protein levels; chr11:117266917 chr11:117135528~117138582:+ LIHC cis rs7083 1 rs524085 ENSG00000254851.1 RP11-109L13.1 4.04 6.6e-05 0.0131 0.31 0.21 Blood protein levels; chr11:117266931 chr11:117135528~117138582:+ LIHC cis rs6480314 0.656 rs2394459 ENSG00000233590.1 RP11-153K11.3 -4.04 6.6e-05 0.0131 -0.29 -0.21 Optic nerve measurement (disc area); chr10:68221679 chr10:68233251~68242379:- LIHC cis rs12468226 0.689 rs17651413 ENSG00000272966.1 RP11-686O6.1 4.04 6.6e-05 0.0131 0.38 0.21 Urate levels; chr2:202104086 chr2:202336739~202337200:+ LIHC cis rs160451 0.966 rs1603289 ENSG00000251136.7 RP11-37B2.1 4.04 6.6e-05 0.0131 0.19 0.21 Leprosy; chr8:89655405 chr8:89609409~89757727:- LIHC cis rs2283792 0.74 rs8138075 ENSG00000224086.5 LL22NC03-86G7.1 -4.04 6.61e-05 0.0131 -0.22 -0.21 Multiple sclerosis; chr22:21755092 chr22:21938293~21977632:+ LIHC cis rs16958440 1 rs2289132 ENSG00000267724.1 RP11-49K24.8 4.04 6.61e-05 0.0131 0.33 0.21 Sitting height ratio; chr18:47075921 chr18:47105946~47108062:+ LIHC cis rs16958440 1 rs2289131 ENSG00000267724.1 RP11-49K24.8 4.04 6.61e-05 0.0131 0.33 0.21 Sitting height ratio; chr18:47076493 chr18:47105946~47108062:+ LIHC cis rs11676348 0.774 rs13397673 ENSG00000261338.2 RP11-378A13.1 -4.04 6.61e-05 0.0131 -0.23 -0.21 Ulcerative colitis; chr2:218183059 chr2:218255319~218257366:+ LIHC cis rs13217239 0.646 rs4269366 ENSG00000241549.7 GUSBP2 4.04 6.61e-05 0.0131 0.22 0.21 Schizophrenia; chr6:27048634 chr6:26871484~26956554:- LIHC cis rs2658782 0.901 rs10466368 ENSG00000279684.1 RP11-755E23.2 -4.04 6.61e-05 0.0131 -0.39 -0.21 Pulmonary function decline; chr11:93496590 chr11:93286629~93288903:- LIHC cis rs73081554 0.505 rs7626442 ENSG00000272360.1 RP11-359I18.5 -4.04 6.61e-05 0.0132 -0.29 -0.21 Rheumatoid arthritis; chr3:58352985 chr3:58490830~58491291:- LIHC cis rs4218 0.597 rs62002544 ENSG00000277144.1 RP11-59H7.4 -4.04 6.62e-05 0.0132 -0.24 -0.21 Social communication problems; chr15:59066663 chr15:59115547~59116089:- LIHC cis rs9595908 0.785 rs9596109 ENSG00000212293.1 SNORA16 4.04 6.62e-05 0.0132 0.24 0.21 Body mass index; chr13:32712611 chr13:32420390~32420516:- LIHC cis rs794185 0.657 rs2633846 ENSG00000231249.1 ITPR1-AS1 -4.04 6.62e-05 0.0132 -0.23 -0.21 Multiple sclerosis--Brain Glutamate Levels; chr3:4471781 chr3:4490891~4493163:- LIHC cis rs4356975 0.83 rs3922514 ENSG00000250919.1 RP11-813N20.3 -4.04 6.62e-05 0.0132 -0.21 -0.21 Obesity-related traits; chr4:69060905 chr4:69027831~69044578:+ LIHC cis rs4356975 0.83 rs28775401 ENSG00000250919.1 RP11-813N20.3 -4.04 6.62e-05 0.0132 -0.21 -0.21 Obesity-related traits; chr4:69060999 chr4:69027831~69044578:+ LIHC cis rs2836974 0.867 rs77959119 ENSG00000255568.3 BRWD1-AS2 4.04 6.63e-05 0.0132 0.24 0.21 Cognitive function; chr21:39170842 chr21:39313935~39314962:+ LIHC cis rs2598107 0.505 rs10435156 ENSG00000211698.2 TRGV4 -4.04 6.63e-05 0.0132 -0.25 -0.21 Dupuytren's disease; chr7:37896128 chr7:38353715~38354517:- LIHC cis rs1005277 0.683 rs7923868 ENSG00000275858.1 RP11-291L22.8 4.04 6.63e-05 0.0132 0.24 0.21 Extrinsic epigenetic age acceleration; chr10:37700838 chr10:38450738~38451069:- LIHC cis rs11690935 0.632 rs35854151 ENSG00000228389.1 AC068039.4 -4.04 6.63e-05 0.0132 -0.26 -0.21 Schizophrenia; chr2:171800929 chr2:171773482~171775844:+ LIHC cis rs709400 0.859 rs7693 ENSG00000258914.1 CTD-2134A5.3 4.04 6.63e-05 0.0132 0.31 0.21 Body mass index; chr14:103557367 chr14:103875055~103877478:+ LIHC cis rs4356203 0.87 rs214901 ENSG00000260196.1 RP1-239B22.5 4.04 6.64e-05 0.0132 0.25 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17206181 chr11:17380649~17383531:+ LIHC cis rs2998286 0.678 rs1755205 ENSG00000254635.4 WAC-AS1 -4.04 6.64e-05 0.0132 -0.26 -0.21 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28644828 chr10:28522652~28532743:- LIHC cis rs1062753 0.731 rs11090065 ENSG00000237037.8 NDUFA6-AS1 -4.04 6.64e-05 0.0132 -0.29 -0.21 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41988167 chr22:42090931~42137742:+ LIHC cis rs7945705 0.747 rs1980428 ENSG00000254860.4 TMEM9B-AS1 -4.04 6.64e-05 0.0132 -0.21 -0.21 Hemoglobin concentration; chr11:8988950 chr11:8964675~8977527:+ LIHC cis rs10857712 0.703 rs12253520 ENSG00000214279.11 SCART1 -4.04 6.65e-05 0.0132 -0.26 -0.21 Systemic lupus erythematosus; chr10:133421817 chr10:133453928~133523558:+ LIHC cis rs10857712 0.703 rs1056521 ENSG00000214279.11 SCART1 -4.04 6.65e-05 0.0132 -0.26 -0.21 Systemic lupus erythematosus; chr10:133422386 chr10:133453928~133523558:+ LIHC cis rs4356203 0.875 rs7125607 ENSG00000260196.1 RP1-239B22.5 -4.04 6.65e-05 0.0132 -0.26 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17074603 chr11:17380649~17383531:+ LIHC cis rs2948294 0.588 rs12544596 ENSG00000173295.6 FAM86B3P 4.04 6.65e-05 0.0132 0.27 0.21 Red cell distribution width; chr8:8258824 chr8:8228595~8244865:+ LIHC cis rs11673344 0.864 rs79927931 ENSG00000226686.6 LINC01535 4.04 6.65e-05 0.0132 0.29 0.21 Obesity-related traits; chr19:37012241 chr19:37251912~37265535:+ LIHC cis rs2243480 1 rs313832 ENSG00000228409.4 CCT6P1 4.04 6.65e-05 0.0132 0.23 0.21 Diabetic kidney disease; chr7:66085904 chr7:65751142~65763354:+ LIHC cis rs673078 0.66 rs17619932 ENSG00000275409.1 RP11-131L12.4 -4.04 6.66e-05 0.0132 -0.26 -0.21 Glucose homeostasis traits; chr12:118352228 chr12:118430147~118430699:+ LIHC cis rs17270561 0.666 rs12209856 ENSG00000216436.2 HIST1H2APS1 -4.04 6.66e-05 0.0132 -0.25 -0.21 Iron status biomarkers; chr6:25793445 chr6:25732497~25732827:+ LIHC cis rs755249 0.567 rs67020650 ENSG00000182109.6 RP11-69E11.4 4.04 6.66e-05 0.0132 0.27 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39202343 chr1:39522280~39546187:- LIHC cis rs1115240 0.853 rs10129655 ENSG00000257842.4 NOVA1-AS1 4.04 6.66e-05 0.0132 0.2 0.21 Educational attainment (years of education); chr14:26569709 chr14:26598412~26806467:+ LIHC cis rs2739330 0.731 rs4822450 ENSG00000228039.3 KB-1125A3.10 4.04 6.66e-05 0.0132 0.26 0.21 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23963780~23964374:+ LIHC cis rs2243480 1 rs1964692 ENSG00000232546.1 RP11-458F8.1 -4.04 6.66e-05 0.0132 -0.24 -0.21 Diabetic kidney disease; chr7:65989196 chr7:66848496~66858136:+ LIHC cis rs2243480 0.901 rs2456483 ENSG00000232546.1 RP11-458F8.1 -4.04 6.66e-05 0.0132 -0.24 -0.21 Diabetic kidney disease; chr7:65996588 chr7:66848496~66858136:+ LIHC cis rs2243480 0.901 rs2949697 ENSG00000232546.1 RP11-458F8.1 -4.04 6.66e-05 0.0132 -0.24 -0.21 Diabetic kidney disease; chr7:65999249 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1701750 ENSG00000232546.1 RP11-458F8.1 -4.04 6.66e-05 0.0132 -0.24 -0.21 Diabetic kidney disease; chr7:66002158 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1701758 ENSG00000232546.1 RP11-458F8.1 -4.04 6.66e-05 0.0132 -0.24 -0.21 Diabetic kidney disease; chr7:66005214 chr7:66848496~66858136:+ LIHC cis rs2243480 0.901 rs1701759 ENSG00000232546.1 RP11-458F8.1 -4.04 6.66e-05 0.0132 -0.24 -0.21 Diabetic kidney disease; chr7:66005945 chr7:66848496~66858136:+ LIHC cis rs1023500 0.505 rs134886 ENSG00000205702.9 CYP2D7 -4.04 6.66e-05 0.0132 -0.21 -0.21 Schizophrenia; chr22:42277850 chr22:42140203~42144577:- LIHC cis rs2980439 0.525 rs2980508 ENSG00000173295.6 FAM86B3P 4.04 6.66e-05 0.0132 0.27 0.21 Neuroticism; chr8:8314210 chr8:8228595~8244865:+ LIHC cis rs2598107 0.601 rs17171212 ENSG00000211698.2 TRGV4 4.04 6.66e-05 0.0132 0.25 0.21 Dupuytren's disease; chr7:37925363 chr7:38353715~38354517:- LIHC cis rs673078 0.66 rs11068908 ENSG00000275759.1 RP11-131L12.3 -4.04 6.66e-05 0.0132 -0.27 -0.21 Glucose homeostasis traits; chr12:118327265 chr12:118428281~118428870:+ LIHC cis rs3020736 0.5 rs8138678 ENSG00000226450.2 CYP2D8P -4.04 6.66e-05 0.0132 -0.26 -0.21 Autism spectrum disorder or schizophrenia; chr22:42120225 chr22:42149886~42155001:- LIHC cis rs244293 0.899 rs8080876 ENSG00000275710.1 RP11-257O5.4 -4.04 6.66e-05 0.0132 -0.23 -0.21 Menarche (age at onset); chr17:55097906 chr17:54964474~54964679:+ LIHC cis rs4218 0.681 rs12913177 ENSG00000277144.1 RP11-59H7.4 4.04 6.66e-05 0.0132 0.23 0.21 Social communication problems; chr15:59066273 chr15:59115547~59116089:- LIHC cis rs10129255 0.957 rs8005468 ENSG00000211970.3 IGHV4-61 -4.04 6.67e-05 0.0132 -0.17 -0.21 Kawasaki disease; chr14:106686431 chr14:106639119~106639657:- LIHC cis rs3091242 1 rs3091242 ENSG00000224183.1 SDHDP6 -4.04 6.67e-05 0.0132 -0.24 -0.21 Erythrocyte sedimentation rate; chr1:25348294 chr1:25294164~25294643:- LIHC cis rs638893 0.947 rs515707 ENSG00000255239.1 AP002954.6 4.04 6.67e-05 0.0132 0.46 0.21 Vitiligo; chr11:118814772 chr11:118688039~118690600:- LIHC cis rs7893279 0.505 rs12770851 ENSG00000225527.1 RP11-383B4.4 4.04 6.68e-05 0.0133 0.3 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18584223 chr10:18531849~18533336:- LIHC cis rs875971 0.545 rs12670811 ENSG00000273024.4 INTS4P2 -4.04 6.68e-05 0.0133 -0.24 -0.21 Aortic root size; chr7:66358032 chr7:65647864~65715661:+ LIHC cis rs10829156 0.898 rs4748504 ENSG00000225527.1 RP11-383B4.4 -4.04 6.68e-05 0.0133 -0.35 -0.21 Sudden cardiac arrest; chr10:18651868 chr10:18531849~18533336:- LIHC cis rs9992667 0.91 rs17428945 ENSG00000231160.8 KLF3-AS1 4.04 6.68e-05 0.0133 0.27 0.21 Eosinophil percentage of granulocytes; chr4:38688124 chr4:38612701~38664883:- LIHC cis rs2599510 0.811 rs2710628 ENSG00000276334.1 AL133243.1 4.04 6.69e-05 0.0133 0.24 0.21 Interleukin-18 levels; chr2:32533286 chr2:32521927~32523547:+ LIHC cis rs5769707 0.967 rs5769698 ENSG00000235111.1 RP1-29C18.8 -4.04 6.69e-05 0.0133 -0.24 -0.21 Monocyte percentage of white cells;Monocyte count; chr22:49604058 chr22:49612657~49615716:- LIHC cis rs13113518 0.812 rs12648271 ENSG00000249700.7 SRD5A3-AS1 4.04 6.69e-05 0.0133 0.26 0.21 Height; chr4:55501955 chr4:55363971~55395847:- LIHC cis rs2790457 0.958 rs2772433 ENSG00000254635.4 WAC-AS1 4.04 6.69e-05 0.0133 0.2 0.21 Multiple myeloma; chr10:28607017 chr10:28522652~28532743:- LIHC cis rs6822297 0.608 rs12331333 ENSG00000240005.4 RP11-293A21.1 -4.04 6.69e-05 0.0133 -0.24 -0.21 Obesity-related traits; chr4:26907458 chr4:26859806~26860599:- LIHC cis rs2348418 0.639 rs61301264 ENSG00000247934.4 RP11-967K21.1 -4.04 6.69e-05 0.0133 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28112922 chr12:28163298~28190738:- LIHC cis rs2929278 0.588 rs1975364 ENSG00000275601.1 AC011330.13 -4.04 6.69e-05 0.0133 -0.27 -0.21 Schizophrenia; chr15:43857991 chr15:43642389~43643023:- LIHC cis rs673078 0.66 rs56708462 ENSG00000275759.1 RP11-131L12.3 -4.04 6.69e-05 0.0133 -0.41 -0.21 Glucose homeostasis traits; chr12:118284135 chr12:118428281~118428870:+ LIHC cis rs858239 1 rs858239 ENSG00000226816.2 AC005082.12 4.04 6.7e-05 0.0133 0.27 0.21 Cerebrospinal fluid biomarker levels; chr7:23246696 chr7:23206013~23208045:+ LIHC cis rs2762353 0.718 rs1184804 ENSG00000242387.1 HIST1H2APS2 4.04 6.7e-05 0.0133 0.24 0.21 Blood metabolite levels; chr6:25867998 chr6:25882026~25882395:- LIHC cis rs858239 1 rs199351 ENSG00000226816.2 AC005082.12 4.04 6.7e-05 0.0133 0.27 0.21 Cerebrospinal fluid biomarker levels; chr7:23260430 chr7:23206013~23208045:+ LIHC cis rs12478296 0.685 rs12473450 ENSG00000261186.2 RP11-341N2.1 -4.04 6.7e-05 0.0133 -0.28 -0.21 Obesity-related traits; chr2:242049595 chr2:242087351~242088457:- LIHC cis rs11603023 0.772 rs540800 ENSG00000255422.1 AP002954.4 -4.04 6.7e-05 0.0133 -0.24 -0.21 Cholesterol, total; chr11:118694942 chr11:118704607~118750263:+ LIHC cis rs2581828 0.632 rs73088322 ENSG00000242142.1 SERBP1P3 -4.04 6.7e-05 0.0133 -0.28 -0.21 Crohn's disease; chr3:53107500 chr3:53064283~53065091:- LIHC cis rs2581828 0.659 rs73088327 ENSG00000242142.1 SERBP1P3 -4.04 6.7e-05 0.0133 -0.28 -0.21 Crohn's disease; chr3:53107533 chr3:53064283~53065091:- LIHC cis rs2581828 0.659 rs4282053 ENSG00000242142.1 SERBP1P3 -4.04 6.7e-05 0.0133 -0.28 -0.21 Crohn's disease; chr3:53107949 chr3:53064283~53065091:- LIHC cis rs638893 1 rs73005500 ENSG00000255239.1 AP002954.6 -4.04 6.7e-05 0.0133 -0.48 -0.21 Vitiligo; chr11:118826666 chr11:118688039~118690600:- LIHC cis rs2072510 1 rs2072510 ENSG00000257715.1 RP11-256L6.2 4.04 6.71e-05 0.0133 0.22 0.21 Metabolite levels (small molecules and protein measures); chr12:96009421 chr12:96025323~96027971:+ LIHC cis rs643506 0.934 rs4936690 ENSG00000254990.4 RP11-108O10.2 4.04 6.71e-05 0.0133 0.23 0.21 Breast cancer; chr11:111776191 chr11:111768668~111778350:- LIHC cis rs6142102 0.961 rs4911389 ENSG00000275784.1 RP5-1125A11.6 -4.04 6.71e-05 0.0133 -0.25 -0.21 Skin pigmentation; chr20:33977235 chr20:33989480~33991818:- LIHC cis rs2439831 0.867 rs3213990 ENSG00000166763.7 STRCP1 4.04 6.72e-05 0.0133 0.3 0.21 Lung cancer in ever smokers; chr15:43378028 chr15:43699488~43718184:- LIHC cis rs860295 0.729 rs4971072 ENSG00000203761.5 MSTO2P 4.04 6.72e-05 0.0133 0.18 0.21 Body mass index; chr1:155304078 chr1:155745829~155750137:+ LIHC cis rs2976388 0.566 rs4736373 ENSG00000253741.1 CTD-2292P10.4 4.04 6.72e-05 0.0133 0.27 0.21 Urinary tract infection frequency; chr8:142710939 chr8:142702252~142726973:- LIHC cis rs2749097 1 rs2749097 ENSG00000244256.3 RN7SL130P -4.04 6.72e-05 0.0133 -0.28 -0.21 Alcohol consumption (transferrin glycosylation); chr1:63661797 chr1:63655743~63656047:+ LIHC cis rs904251 0.965 rs1317563 ENSG00000204110.6 RP1-153P14.8 -4.04 6.72e-05 0.0133 -0.25 -0.21 Cognitive performance; chr6:37484078 chr6:37507348~37535616:+ LIHC cis rs2276314 0.793 rs77590522 ENSG00000278986.1 RP11-723J4.3 -4.04 6.72e-05 0.0133 -0.27 -0.21 Endometriosis;Drug-induced torsades de pointes; chr18:36049447 chr18:35972151~35973916:+ LIHC cis rs4650994 0.623 rs7534394 ENSG00000273384.1 RP5-1098D14.1 -4.04 6.72e-05 0.0133 -0.26 -0.21 HDL cholesterol;HDL cholesterol levels; chr1:178653625 chr1:178651706~178652282:+ LIHC cis rs951005 0.808 rs16931797 ENSG00000281491.1 DNAJB5-AS1 -4.04 6.72e-05 0.0133 -0.4 -0.21 Rheumatoid arthritis; chr9:34712761 chr9:34985410~34989379:- LIHC cis rs2299116 1 rs4722848 ENSG00000225264.3 ZNRF2P2 -4.04 6.73e-05 0.0133 -0.23 -0.21 Serum thyroid-stimulating hormone levels; chr7:28779832 chr7:29598795~29685255:- LIHC cis rs4578769 0.959 rs9947011 ENSG00000266850.1 RP11-370A5.1 -4.04 6.73e-05 0.0133 -0.25 -0.21 Eosinophil percentage of white cells; chr18:22840446 chr18:22723491~22907721:- LIHC cis rs7688540 0.771 rs2353605 ENSG00000275426.1 CH17-262A2.1 4.04 6.73e-05 0.0133 0.27 0.21 Facial morphology (factor 6, height of vermillion lower lip); chr4:225749 chr4:149738~150317:+ LIHC cis rs734999 0.566 rs10797435 ENSG00000225931.3 RP3-395M20.7 4.04 6.73e-05 0.0133 0.23 0.21 Ulcerative colitis; chr1:2603362 chr1:2566410~2569888:+ LIHC cis rs3812762 0.871 rs3862352 ENSG00000254860.4 TMEM9B-AS1 4.04 6.73e-05 0.0133 0.25 0.21 Hypospadias; chr11:8796473 chr11:8964675~8977527:+ LIHC cis rs2564921 0.73 rs73079924 ENSG00000242142.1 SERBP1P3 -4.04 6.74e-05 0.0133 -0.29 -0.21 Height; chr3:53034139 chr3:53064283~53065091:- LIHC cis rs17711722 0.727 rs2658585 ENSG00000273024.4 INTS4P2 -4.04 6.74e-05 0.0134 -0.25 -0.21 Calcium levels; chr7:65996954 chr7:65647864~65715661:+ LIHC cis rs9565309 0.579 rs76251632 ENSG00000274898.1 AC001226.7 -4.04 6.74e-05 0.0134 -0.37 -0.21 Morning vs. evening chronotype; chr13:77010273 chr13:77027944~77028482:+ LIHC cis rs9565309 0.579 rs8002862 ENSG00000274898.1 AC001226.7 -4.04 6.74e-05 0.0134 -0.37 -0.21 Morning vs. evening chronotype; chr13:77010293 chr13:77027944~77028482:+ LIHC cis rs4356975 0.527 rs60423649 ENSG00000196472.4 RP13-644M16.4 4.03 6.74e-05 0.0134 0.24 0.21 Obesity-related traits; chr4:69127952 chr4:69181660~69182372:+ LIHC cis rs6589219 0.566 rs2001754 ENSG00000196167.8 COLCA1 -4.03 6.74e-05 0.0134 -0.27 -0.21 Colorectal cancer; chr11:111254787 chr11:111290787~111305045:- LIHC cis rs4578769 0.729 rs12456891 ENSG00000266850.1 RP11-370A5.1 -4.03 6.75e-05 0.0134 -0.25 -0.21 Eosinophil percentage of white cells; chr18:22830243 chr18:22723491~22907721:- LIHC cis rs919433 0.963 rs6738836 ENSG00000231621.1 AC013264.2 4.03 6.75e-05 0.0134 0.19 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197317708 chr2:197197991~197199273:+ LIHC cis rs6487679 1 rs1017302 ENSG00000111788.10 RP11-22B23.1 4.03 6.76e-05 0.0134 0.26 0.21 Non-alcoholic fatty liver disease histology (AST); chr12:9214806 chr12:9277235~9313241:+ LIHC cis rs6487679 1 rs10734765 ENSG00000111788.10 RP11-22B23.1 4.03 6.76e-05 0.0134 0.26 0.21 Non-alcoholic fatty liver disease histology (AST); chr12:9216789 chr12:9277235~9313241:+ LIHC cis rs617219 0.889 rs1717567 ENSG00000251675.1 CTC-458I2.2 4.03 6.76e-05 0.0134 0.23 0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79139939 chr5:80128361~80143883:+ LIHC cis rs734999 0.588 rs4648562 ENSG00000225931.3 RP3-395M20.7 4.03 6.76e-05 0.0134 0.23 0.21 Ulcerative colitis; chr1:2604174 chr1:2566410~2569888:+ LIHC cis rs9368481 0.645 rs10456350 ENSG00000241549.7 GUSBP2 4.03 6.76e-05 0.0134 0.22 0.21 Autism spectrum disorder or schizophrenia; chr6:27007802 chr6:26871484~26956554:- LIHC cis rs17711722 0.565 rs73372653 ENSG00000236529.1 RP13-254B10.1 4.03 6.76e-05 0.0134 0.2 0.21 Calcium levels; chr7:65977808 chr7:65840212~65840596:+ LIHC cis rs2276314 0.857 rs28540805 ENSG00000278986.1 RP11-723J4.3 -4.03 6.76e-05 0.0134 -0.26 -0.21 Endometriosis;Drug-induced torsades de pointes; chr18:36062012 chr18:35972151~35973916:+ LIHC cis rs748404 0.646 rs2253268 ENSG00000166763.7 STRCP1 4.03 6.76e-05 0.0134 0.27 0.21 Lung cancer; chr15:43508770 chr15:43699488~43718184:- LIHC cis rs2598107 0.601 rs2167268 ENSG00000211698.2 TRGV4 -4.03 6.76e-05 0.0134 -0.25 -0.21 Dupuytren's disease; chr7:37902926 chr7:38353715~38354517:- LIHC cis rs960902 1 rs10204024 ENSG00000213553.4 RPLP0P6 -4.03 6.77e-05 0.0134 -0.17 -0.21 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37504886 chr2:38481851~38482804:+ LIHC cis rs4578769 0.959 rs4800137 ENSG00000266850.1 RP11-370A5.1 4.03 6.77e-05 0.0134 0.25 0.21 Eosinophil percentage of white cells; chr18:22899721 chr18:22723491~22907721:- LIHC cis rs41313321 0.541 rs4637952 ENSG00000272696.1 RP11-339B21.13 4.03 6.77e-05 0.0134 0.28 0.21 Coenzyme Q10 levels; chr9:128297978 chr9:128316337~128316909:+ LIHC cis rs748404 0.578 rs4547312 ENSG00000205771.5 CATSPER2P1 -4.03 6.77e-05 0.0134 -0.25 -0.21 Lung cancer; chr15:43339940 chr15:43726918~43747094:- LIHC cis rs2749097 0.735 rs12127151 ENSG00000244256.3 RN7SL130P -4.03 6.77e-05 0.0134 -0.27 -0.21 Alcohol consumption (transferrin glycosylation); chr1:63684028 chr1:63655743~63656047:+ LIHC cis rs875971 0.577 rs34888281 ENSG00000164669.11 INTS4P1 4.03 6.77e-05 0.0134 0.31 0.21 Aortic root size; chr7:66120784 chr7:65141225~65234216:+ LIHC cis rs35934224 0.891 rs13054713 ENSG00000232926.1 AC000078.5 4.03 6.77e-05 0.0134 0.3 0.21 Glaucoma (primary open-angle); chr22:19880391 chr22:19887289~19887970:+ LIHC cis rs35934224 0.891 rs33997573 ENSG00000232926.1 AC000078.5 4.03 6.77e-05 0.0134 0.3 0.21 Glaucoma (primary open-angle); chr22:19881428 chr22:19887289~19887970:+ LIHC cis rs938554 0.513 rs3775946 ENSG00000250413.1 RP11-448G15.1 -4.03 6.77e-05 0.0134 -0.3 -0.21 Blood metabolite levels; chr4:9993632 chr4:10006482~10009725:+ LIHC cis rs4073416 0.712 rs11627184 ENSG00000276116.2 FUT8-AS1 4.03 6.77e-05 0.0134 0.26 0.21 N-glycan levels; chr14:65654725 chr14:65411170~65412690:- LIHC cis rs9309711 0.623 rs4641971 ENSG00000225234.1 TRAPPC12-AS1 4.03 6.78e-05 0.0134 0.19 0.21 Neurofibrillary tangles; chr2:3478086 chr2:3481242~3482409:- LIHC cis rs2976388 0.566 rs2585141 ENSG00000253741.1 CTD-2292P10.4 4.03 6.78e-05 0.0134 0.27 0.21 Urinary tract infection frequency; chr8:142724925 chr8:142702252~142726973:- LIHC cis rs9304742 0.54 rs10416138 ENSG00000213801.4 ZNF816-ZNF321P 4.03 6.78e-05 0.0134 0.23 0.21 Psoriasis; chr19:52961899 chr19:52927135~52942601:- LIHC cis rs2658782 0.951 rs2608214 ENSG00000279684.1 RP11-755E23.2 -4.03 6.79e-05 0.0134 -0.37 -0.21 Pulmonary function decline; chr11:93415499 chr11:93286629~93288903:- LIHC cis rs2228479 0.681 rs3212346 ENSG00000261253.2 AC137932.6 4.03 6.79e-05 0.0134 0.3 0.21 Skin colour saturation; chr16:89915950 chr16:89321133~89325110:+ LIHC cis rs7083 1 rs512188 ENSG00000254851.1 RP11-109L13.1 -4.03 6.79e-05 0.0134 -0.3 -0.21 Blood protein levels; chr11:117255994 chr11:117135528~117138582:+ LIHC cis rs75920871 0.614 rs10892045 ENSG00000254851.1 RP11-109L13.1 -4.03 6.79e-05 0.0134 -0.43 -0.21 Subjective well-being; chr11:116914108 chr11:117135528~117138582:+ LIHC cis rs4356203 0.905 rs7107283 ENSG00000260196.1 RP1-239B22.5 4.03 6.79e-05 0.0134 0.26 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17067856 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs11024148 ENSG00000260196.1 RP1-239B22.5 -4.03 6.79e-05 0.0134 -0.26 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17074512 chr11:17380649~17383531:+ LIHC cis rs929596 0.674 rs2602374 ENSG00000233445.1 RPL17P11 4.03 6.79e-05 0.0134 0.31 0.21 Total bilirubin levels in HIV-1 infection; chr2:233660318 chr2:233721522~233722065:- LIHC cis rs2274273 0.6 rs10131730 ENSG00000258413.1 RP11-665C16.6 -4.03 6.79e-05 0.0134 -0.26 -0.21 Protein biomarker; chr14:55373374 chr14:55262767~55272075:- LIHC cis rs2274273 0.624 rs12050123 ENSG00000258413.1 RP11-665C16.6 -4.03 6.79e-05 0.0134 -0.26 -0.21 Protein biomarker; chr14:55373668 chr14:55262767~55272075:- LIHC cis rs2274273 0.624 rs10132453 ENSG00000258413.1 RP11-665C16.6 -4.03 6.79e-05 0.0134 -0.26 -0.21 Protein biomarker; chr14:55374133 chr14:55262767~55272075:- LIHC cis rs7989332 0.961 rs4770039 ENSG00000275964.1 RP11-61K9.3 -4.03 6.79e-05 0.0134 -0.24 -0.21 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20474285 chr13:19863858~19865048:+ LIHC cis rs2749097 1 rs4643 ENSG00000244256.3 RN7SL130P -4.03 6.8e-05 0.0134 -0.27 -0.21 Alcohol consumption (transferrin glycosylation); chr1:63659768 chr1:63655743~63656047:+ LIHC cis rs2581828 0.659 rs9845352 ENSG00000242142.1 SERBP1P3 -4.03 6.8e-05 0.0135 -0.28 -0.21 Crohn's disease; chr3:53108205 chr3:53064283~53065091:- LIHC cis rs2581828 0.659 rs9845484 ENSG00000242142.1 SERBP1P3 -4.03 6.8e-05 0.0135 -0.28 -0.21 Crohn's disease; chr3:53108240 chr3:53064283~53065091:- LIHC cis rs617219 0.889 rs10942885 ENSG00000251675.1 CTC-458I2.2 -4.03 6.8e-05 0.0135 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79140950 chr5:80128361~80143883:+ LIHC cis rs1799949 1 rs4793229 ENSG00000267681.1 CTD-3199J23.6 4.03 6.8e-05 0.0135 0.21 0.21 Menopause (age at onset); chr17:43340966 chr17:43144956~43145255:+ LIHC cis rs417065 1 rs11587140 ENSG00000227634.1 RP11-431K24.3 -4.03 6.8e-05 0.0135 -0.28 -0.21 Psoriasis; chr1:8200774 chr1:8208672~8215210:+ LIHC cis rs7915414 1 rs7915414 ENSG00000230338.1 MTND4P19 4.03 6.8e-05 0.0135 0.22 0.21 Clopidogrel active metabolite levels; chr10:94839753 chr10:94774156~94774633:- LIHC cis rs2243480 1 rs6966322 ENSG00000232546.1 RP11-458F8.1 4.03 6.81e-05 0.0135 0.24 0.21 Diabetic kidney disease; chr7:66181767 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs4145008 ENSG00000232546.1 RP11-458F8.1 4.03 6.81e-05 0.0135 0.24 0.21 Diabetic kidney disease; chr7:66182524 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs4718315 ENSG00000232546.1 RP11-458F8.1 4.03 6.81e-05 0.0135 0.24 0.21 Diabetic kidney disease; chr7:66183554 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs4718316 ENSG00000232546.1 RP11-458F8.1 4.03 6.81e-05 0.0135 0.24 0.21 Diabetic kidney disease; chr7:66183744 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1873494 ENSG00000232546.1 RP11-458F8.1 4.03 6.81e-05 0.0135 0.24 0.21 Diabetic kidney disease; chr7:66184912 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs6959002 ENSG00000232546.1 RP11-458F8.1 4.03 6.81e-05 0.0135 0.24 0.21 Diabetic kidney disease; chr7:66185509 chr7:66848496~66858136:+ LIHC cis rs881375 0.715 rs10818482 ENSG00000226752.6 PSMD5-AS1 4.03 6.81e-05 0.0135 0.22 0.21 Rheumatoid arthritis; chr9:120885807 chr9:120824828~120854385:+ LIHC cis rs11098499 1 rs58601355 ENSG00000260091.1 RP11-33B1.4 -4.03 6.81e-05 0.0135 -0.16 -0.21 Corneal astigmatism; chr4:119265212 chr4:119409333~119410233:+ LIHC cis rs4356203 0.905 rs6486352 ENSG00000260196.1 RP1-239B22.5 4.03 6.81e-05 0.0135 0.25 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17150823 chr11:17380649~17383531:+ LIHC cis rs2439831 0.85 rs61390361 ENSG00000275601.1 AC011330.13 -4.03 6.81e-05 0.0135 -0.32 -0.21 Lung cancer in ever smokers; chr15:43867644 chr15:43642389~43643023:- LIHC cis rs713477 1 rs8010013 ENSG00000258413.1 RP11-665C16.6 4.03 6.82e-05 0.0135 0.24 0.21 Pediatric bone mineral content (femoral neck); chr14:55418110 chr14:55262767~55272075:- LIHC cis rs11977715 0.521 rs1476516 ENSG00000233942.1 AC004012.1 -4.03 6.82e-05 0.0135 -0.31 -0.21 Middle childhood and early adolescence aggressive behavior; chr7:95489898 chr7:95471835~95473998:+ LIHC cis rs709400 0.93 rs2274268 ENSG00000269958.1 RP11-73M18.8 4.03 6.82e-05 0.0135 0.29 0.21 Body mass index; chr14:103563041 chr14:103696353~103697163:+ LIHC cis rs617219 0.819 rs10074882 ENSG00000251675.1 CTC-458I2.2 -4.03 6.82e-05 0.0135 -0.24 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79307040 chr5:80128361~80143883:+ LIHC cis rs4148008 0.589 rs6501788 ENSG00000267250.1 RP11-118B18.2 -4.03 6.82e-05 0.0135 -0.26 -0.21 HDL cholesterol; chr17:68840429 chr17:68793549~68797822:- LIHC cis rs2243480 1 rs313814 ENSG00000232546.1 RP11-458F8.1 -4.03 6.82e-05 0.0135 -0.24 -0.21 Diabetic kidney disease; chr7:66038306 chr7:66848496~66858136:+ LIHC cis rs7412746 0.658 rs57818453 ENSG00000231073.1 RP11-316M1.3 4.03 6.82e-05 0.0135 0.22 0.21 Melanoma; chr1:150790663 chr1:150973123~150975534:+ LIHC cis rs4356975 0.899 rs72501227 ENSG00000250919.1 RP11-813N20.3 -4.03 6.83e-05 0.0135 -0.21 -0.21 Obesity-related traits; chr4:69069866 chr4:69027831~69044578:+ LIHC cis rs12209785 0.955 rs4714857 ENSG00000231769.2 RP1-8B1.4 4.03 6.83e-05 0.0135 0.34 0.21 Survival in pancreatic cancer; chr6:45525936 chr6:46097093~46129706:- LIHC cis rs12209785 1 rs11756145 ENSG00000231769.2 RP1-8B1.4 4.03 6.83e-05 0.0135 0.34 0.21 Survival in pancreatic cancer; chr6:45532529 chr6:46097093~46129706:- LIHC cis rs3824488 0.599 rs16909856 ENSG00000237857.2 RP11-435O5.2 -4.03 6.83e-05 0.0135 -0.28 -0.21 Neuroticism; chr9:95442211 chr9:95414834~95426796:- LIHC cis rs1005277 0.579 rs1780137 ENSG00000099251.13 HSD17B7P2 4.03 6.84e-05 0.0135 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38212547 chr10:38356380~38378505:+ LIHC cis rs1494950 1 rs28520420 ENSG00000214846.4 RP11-115L11.1 -4.03 6.84e-05 0.0135 -0.43 -0.21 Political ideology; chr4:15005995 chr4:15730962~15731627:- LIHC cis rs1494950 1 rs79121288 ENSG00000214846.4 RP11-115L11.1 -4.03 6.84e-05 0.0135 -0.43 -0.21 Political ideology; chr4:15011246 chr4:15730962~15731627:- LIHC cis rs1494950 1 rs12512141 ENSG00000214846.4 RP11-115L11.1 -4.03 6.84e-05 0.0135 -0.43 -0.21 Political ideology; chr4:15011737 chr4:15730962~15731627:- LIHC cis rs11125080 1 rs11125079 ENSG00000239332.4 LINC01119 -4.03 6.84e-05 0.0135 -0.29 -0.21 Anti-saccade response;Anti-saccade error rate in psychotic disorders; chr2:46505076 chr2:46816697~46859007:+ LIHC cis rs72829446 0.53 rs8075007 ENSG00000263316.1 RP11-530N7.3 4.03 6.84e-05 0.0135 0.44 0.21 Androgen levels; chr17:7471188 chr17:6954098~6978960:- LIHC cis rs7044106 0.762 rs10760110 ENSG00000238181.2 AHCYP2 4.03 6.85e-05 0.0135 0.24 0.21 Hip circumference adjusted for BMI; chr9:120650285 chr9:120720673~120721972:+ LIHC cis rs1577917 0.652 rs75593931 ENSG00000234155.1 RP11-30P6.6 4.03 6.85e-05 0.0135 0.28 0.21 Response to antipsychotic treatment; chr6:86009821 chr6:85387219~85390186:- LIHC cis rs1577917 0.959 rs12201739 ENSG00000234155.1 RP11-30P6.6 4.03 6.85e-05 0.0135 0.28 0.21 Response to antipsychotic treatment; chr6:86011021 chr6:85387219~85390186:- LIHC cis rs901683 1 rs34793991 ENSG00000230869.1 CTGLF10P -4.03 6.85e-05 0.0135 -0.53 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45585142 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs36052429 ENSG00000230869.1 CTGLF10P -4.03 6.85e-05 0.0135 -0.53 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45586897 chr10:45678692~45700532:+ LIHC cis rs9450351 1 rs7774219 ENSG00000203875.9 SNHG5 -4.03 6.85e-05 0.0135 -0.46 -0.21 Interferon gamma-induced protein 10 levels; chr6:85908837 chr6:85660950~85678736:- LIHC cis rs11096990 0.855 rs1597722 ENSG00000249207.1 RP11-360F5.1 -4.03 6.85e-05 0.0135 -0.25 -0.21 Cognitive function; chr4:39173255 chr4:39112677~39126818:- LIHC cis rs10761256 0.835 rs3750362 ENSG00000227603.1 RP11-165J3.6 4.03 6.85e-05 0.0135 0.25 0.21 Itch intensity from mosquito bite adjusted by bite size; chr9:93669577 chr9:93435332~93437121:- LIHC cis rs2839186 0.934 rs4819221 ENSG00000215424.8 MCM3AP-AS1 4.03 6.86e-05 0.0135 0.17 0.21 Testicular germ cell tumor; chr21:46275503 chr21:46229217~46259390:+ LIHC cis rs3772760 1 rs2289839 ENSG00000240622.1 RPL7P15 -4.03 6.86e-05 0.0136 -0.41 -0.21 Amyotrophic lateral sclerosis; chr3:124462607 chr3:124151960~124153063:- LIHC cis rs7246657 0.943 rs34603719 ENSG00000276846.1 CTD-3220F14.3 4.03 6.86e-05 0.0136 0.28 0.21 Coronary artery calcification; chr19:37303626 chr19:37314868~37315620:- LIHC cis rs7246657 0.941 rs67293224 ENSG00000276846.1 CTD-3220F14.3 4.03 6.86e-05 0.0136 0.28 0.21 Coronary artery calcification; chr19:37312346 chr19:37314868~37315620:- LIHC cis rs858239 0.896 rs1637192 ENSG00000226816.2 AC005082.12 4.03 6.87e-05 0.0136 0.29 0.21 Cerebrospinal fluid biomarker levels; chr7:23220895 chr7:23206013~23208045:+ LIHC cis rs8060686 0.516 rs11075670 ENSG00000261469.1 RP11-96D1.6 -4.03 6.87e-05 0.0136 -0.25 -0.21 HDL cholesterol;Metabolic syndrome; chr16:68254490 chr16:68236845~68237667:- LIHC cis rs4927850 0.521 rs4927679 ENSG00000272792.1 RP11-141C7.4 4.03 6.87e-05 0.0136 0.22 0.21 Pancreatic cancer; chr3:195931489 chr3:195639990~195640460:+ LIHC cis rs1928295 0.786 rs28693508 ENSG00000233569.1 RP11-500B12.1 4.03 6.87e-05 0.0136 0.22 0.21 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117599140 chr9:117648606~117657027:+ LIHC cis rs1062753 0.7 rs58874647 ENSG00000237037.8 NDUFA6-AS1 -4.03 6.88e-05 0.0136 -0.3 -0.21 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41990265 chr22:42090931~42137742:+ LIHC cis rs7712401 0.601 rs154502 ENSG00000263432.2 RN7SL689P 4.03 6.88e-05 0.0136 0.31 0.21 Mean platelet volume; chr5:122871351 chr5:123022487~123022783:- LIHC cis rs9527 0.615 rs7096452 ENSG00000236937.2 PTGES3P4 4.03 6.88e-05 0.0136 0.27 0.21 Arsenic metabolism; chr10:102976806 chr10:102845595~102845950:+ LIHC cis rs9527 0.615 rs7080462 ENSG00000236937.2 PTGES3P4 4.03 6.88e-05 0.0136 0.27 0.21 Arsenic metabolism; chr10:102976942 chr10:102845595~102845950:+ LIHC cis rs950880 0.71 rs10490204 ENSG00000234389.1 AC007278.3 -4.03 6.89e-05 0.0136 -0.21 -0.21 Serum protein levels (sST2); chr2:102440074 chr2:102438713~102440475:+ LIHC cis rs1003719 0.68 rs3737540 ENSG00000272948.2 AP001412.1 -4.03 6.89e-05 0.0136 -0.24 -0.21 Eye color traits; chr21:37150966 chr21:37267784~37268497:+ LIHC cis rs17772222 0.917 rs1956406 ENSG00000258789.1 RP11-507K2.3 -4.03 6.89e-05 0.0136 -0.26 -0.21 Coronary artery calcification; chr14:88749711 chr14:88551597~88552493:+ LIHC cis rs4356975 0.527 rs57102579 ENSG00000196472.4 RP13-644M16.4 4.03 6.89e-05 0.0136 0.23 0.21 Obesity-related traits; chr4:69125476 chr4:69181660~69182372:+ LIHC cis rs4356975 0.527 rs4385139 ENSG00000196472.4 RP13-644M16.4 4.03 6.89e-05 0.0136 0.23 0.21 Obesity-related traits; chr4:69125911 chr4:69181660~69182372:+ LIHC cis rs4356975 0.527 rs4694645 ENSG00000196472.4 RP13-644M16.4 4.03 6.89e-05 0.0136 0.23 0.21 Obesity-related traits; chr4:69127200 chr4:69181660~69182372:+ LIHC cis rs858239 0.67 rs3807452 ENSG00000226816.2 AC005082.12 -4.03 6.89e-05 0.0136 -0.25 -0.21 Cerebrospinal fluid biomarker levels; chr7:23122462 chr7:23206013~23208045:+ LIHC cis rs2439831 1 rs28666488 ENSG00000166763.7 STRCP1 4.03 6.89e-05 0.0136 0.3 0.21 Lung cancer in ever smokers; chr15:43448892 chr15:43699488~43718184:- LIHC cis rs2243480 1 rs422164 ENSG00000232546.1 RP11-458F8.1 -4.03 6.9e-05 0.0136 -0.24 -0.21 Diabetic kidney disease; chr7:66121618 chr7:66848496~66858136:+ LIHC cis rs901683 1 rs35626777 ENSG00000230869.1 CTGLF10P -4.03 6.9e-05 0.0136 -0.53 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45592719 chr10:45678692~45700532:+ LIHC cis rs113835537 0.935 rs3867133 ENSG00000255517.5 CTD-3074O7.5 4.03 6.9e-05 0.0136 0.36 0.21 Airway imaging phenotypes; chr11:66684491 chr11:66473490~66480233:- LIHC cis rs2439831 0.867 rs2412778 ENSG00000166763.7 STRCP1 4.03 6.9e-05 0.0136 0.3 0.21 Lung cancer in ever smokers; chr15:43368784 chr15:43699488~43718184:- LIHC cis rs860295 0.65 rs2993207 ENSG00000203761.5 MSTO2P 4.03 6.9e-05 0.0136 0.18 0.21 Body mass index; chr1:155903523 chr1:155745829~155750137:+ LIHC cis rs950880 0.744 rs3771156 ENSG00000234389.1 AC007278.3 -4.03 6.91e-05 0.0136 -0.22 -0.21 Serum protein levels (sST2); chr2:102420217 chr2:102438713~102440475:+ LIHC cis rs7617773 0.817 rs4131362 ENSG00000228638.1 FCF1P2 -4.03 6.92e-05 0.0136 -0.24 -0.21 Coronary artery disease; chr3:48287546 chr3:48290793~48291375:- LIHC cis rs10883723 0.773 rs1326193 ENSG00000236937.2 PTGES3P4 -4.03 6.92e-05 0.0136 -0.29 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102511917 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs10883729 ENSG00000236937.2 PTGES3P4 -4.03 6.92e-05 0.0136 -0.29 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102514186 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs913025 ENSG00000236937.2 PTGES3P4 -4.03 6.92e-05 0.0136 -0.29 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102516286 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs17782574 ENSG00000236937.2 PTGES3P4 -4.03 6.92e-05 0.0136 -0.29 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102519637 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs1409311 ENSG00000236937.2 PTGES3P4 -4.03 6.92e-05 0.0136 -0.29 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102522403 chr10:102845595~102845950:+ LIHC cis rs787274 0.543 rs10114623 ENSG00000271631.1 RP11-408O19.5 4.03 6.92e-05 0.0137 0.34 0.21 Age-related hearing impairment (SNP x SNP interaction); chr9:112869080 chr9:112885158~112885767:+ LIHC cis rs651907 0.535 rs2290859 ENSG00000244119.1 PDCL3P4 4.03 6.92e-05 0.0137 0.22 0.21 Colorectal cancer; chr3:101806781 chr3:101712472~101713191:+ LIHC cis rs1729407 0.586 rs1729408 ENSG00000254851.1 RP11-109L13.1 -4.03 6.92e-05 0.0137 -0.26 -0.21 Apolipoprotein A-IV levels; chr11:116804102 chr11:117135528~117138582:+ LIHC cis rs11148252 0.904 rs9568732 ENSG00000278238.1 RP11-245D16.4 4.03 6.92e-05 0.0137 0.2 0.21 Lewy body disease; chr13:52419277 chr13:52454775~52455331:- LIHC cis rs6832769 1 rs6853192 ENSG00000272969.1 RP11-528I4.2 -4.03 6.92e-05 0.0137 -0.26 -0.21 Personality dimensions; chr4:55543087 chr4:55547112~55547889:+ LIHC cis rs1075265 0.633 rs10183655 ENSG00000233266.1 HMGB1P31 4.03 6.93e-05 0.0137 0.26 0.21 Chronotype;Morning vs. evening chronotype; chr2:53983644 chr2:54051334~54051760:+ LIHC cis rs72634501 0.517 rs10788925 ENSG00000182109.6 RP11-69E11.4 -4.03 6.93e-05 0.0137 -0.23 -0.21 HDL cholesterol; chr1:39128430 chr1:39522280~39546187:- LIHC cis rs7923609 0.875 rs10822143 ENSG00000232075.1 MRPL35P2 -4.03 6.93e-05 0.0137 -0.24 -0.21 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63128096 chr10:63634317~63634827:- LIHC cis rs17774123 0.851 rs12427309 ENSG00000257808.1 RP11-1136G11.8 4.03 6.93e-05 0.0137 0.39 0.21 Diastolic blood pressure; chr12:53898364 chr12:53159586~53161000:+ LIHC cis rs244293 0.831 rs1948000 ENSG00000275710.1 RP11-257O5.4 -4.03 6.93e-05 0.0137 -0.23 -0.21 Menarche (age at onset); chr17:55070355 chr17:54964474~54964679:+ LIHC cis rs2658782 0.547 rs4753453 ENSG00000279684.1 RP11-755E23.2 -4.03 6.93e-05 0.0137 -0.3 -0.21 Pulmonary function decline; chr11:93308008 chr11:93286629~93288903:- LIHC cis rs9652601 0.959 rs12928537 ENSG00000274038.1 RP11-66H6.4 -4.03 6.93e-05 0.0137 -0.26 -0.21 Systemic lupus erythematosus; chr16:11097543 chr16:11056556~11057034:+ LIHC cis rs13287066 0.692 rs10761225 ENSG00000227603.1 RP11-165J3.6 4.03 6.94e-05 0.0137 0.24 0.21 Intelligence (multi-trait analysis); chr9:93404358 chr9:93435332~93437121:- LIHC cis rs13287066 0.692 rs4563950 ENSG00000227603.1 RP11-165J3.6 4.03 6.94e-05 0.0137 0.24 0.21 Intelligence (multi-trait analysis); chr9:93405359 chr9:93435332~93437121:- LIHC cis rs6569038 0.502 rs2051056 ENSG00000253194.1 RP11-351A11.1 -4.03 6.94e-05 0.0137 -0.28 -0.21 Epstein-Barr virus copy number in lymphoblastoid cell lines; chr6:118978418 chr6:118934785~119031541:+ LIHC cis rs4356203 0.905 rs11821773 ENSG00000260196.1 RP1-239B22.5 -4.03 6.94e-05 0.0137 -0.26 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17095807 chr11:17380649~17383531:+ LIHC cis rs755249 0.567 rs4660546 ENSG00000182109.6 RP11-69E11.4 4.03 6.94e-05 0.0137 0.27 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39213730 chr1:39522280~39546187:- LIHC cis rs4578769 0.722 rs55943912 ENSG00000265943.1 RP11-739L10.1 -4.03 6.94e-05 0.0137 -0.28 -0.21 Eosinophil percentage of white cells; chr18:22938388 chr18:22699481~22933764:- LIHC cis rs2036707 0.744 rs76569829 ENSG00000277246.1 RP11-153I24.4 -4.03 6.94e-05 0.0137 -0.43 -0.21 Obesity-related traits; chr13:107849537 chr13:108267320~108267734:+ LIHC cis rs10510102 0.516 rs10159759 ENSG00000276742.1 RP11-500G22.4 4.03 6.94e-05 0.0137 0.35 0.21 Breast cancer; chr10:121986533 chr10:121956782~121957098:+ LIHC cis rs1799949 1 rs4793197 ENSG00000267681.1 CTD-3199J23.6 -4.03 6.94e-05 0.0137 -0.21 -0.21 Menopause (age at onset); chr17:43079885 chr17:43144956~43145255:+ LIHC cis rs8077577 0.689 rs62072515 ENSG00000260647.1 RP1-178F10.1 4.03 6.94e-05 0.0137 0.27 0.21 Obesity-related traits; chr17:18310121 chr17:18268080~18268828:+ LIHC cis rs2658782 0.901 rs2605611 ENSG00000279684.1 RP11-755E23.2 -4.03 6.94e-05 0.0137 -0.38 -0.21 Pulmonary function decline; chr11:93496153 chr11:93286629~93288903:- LIHC cis rs6832769 1 rs9998146 ENSG00000272969.1 RP11-528I4.2 -4.03 6.95e-05 0.0137 -0.25 -0.21 Personality dimensions; chr4:55531810 chr4:55547112~55547889:+ LIHC cis rs853679 0.599 rs149990 ENSG00000219891.2 ZSCAN12P1 4.03 6.95e-05 0.0137 0.38 0.21 Depression; chr6:28030480 chr6:28091154~28093664:+ LIHC cis rs853679 0.599 rs149943 ENSG00000219891.2 ZSCAN12P1 4.03 6.95e-05 0.0137 0.38 0.21 Depression; chr6:28034610 chr6:28091154~28093664:+ LIHC cis rs9450351 0.744 rs6923017 ENSG00000203875.9 SNHG5 -4.03 6.95e-05 0.0137 -0.45 -0.21 Interferon gamma-induced protein 10 levels; chr6:85592619 chr6:85660950~85678736:- LIHC cis rs9353324 1 rs7775788 ENSG00000203875.9 SNHG5 -4.03 6.95e-05 0.0137 -0.45 -0.21 Interferon gamma-induced protein 10 levels; chr6:85595761 chr6:85660950~85678736:- LIHC cis rs950169 0.92 rs12915390 ENSG00000259728.4 LINC00933 4.03 6.95e-05 0.0137 0.34 0.21 Schizophrenia; chr15:84123317 chr15:84570649~84580175:+ LIHC cis rs2790457 0.874 rs1265840 ENSG00000254635.4 WAC-AS1 -4.03 6.96e-05 0.0137 -0.2 -0.21 Multiple myeloma; chr10:28630712 chr10:28522652~28532743:- LIHC cis rs703842 1 rs11172333 ENSG00000270039.1 RP11-571M6.17 -4.03 6.96e-05 0.0137 -0.3 -0.21 Multiple sclerosis; chr12:57776552 chr12:57803838~57804415:+ LIHC cis rs4218 0.597 rs12438962 ENSG00000277144.1 RP11-59H7.4 -4.03 6.96e-05 0.0137 -0.24 -0.21 Social communication problems; chr15:59065694 chr15:59115547~59116089:- LIHC cis rs6430585 0.528 rs614193 ENSG00000231890.6 DARS-AS1 -4.03 6.96e-05 0.0137 -0.3 -0.21 Corneal structure; chr2:135896355 chr2:135985176~136022593:+ LIHC cis rs7893279 0.505 rs7089083 ENSG00000225527.1 RP11-383B4.4 4.03 6.97e-05 0.0137 0.3 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18623473 chr10:18531849~18533336:- LIHC cis rs3204270 0.714 rs8074828 ENSG00000281517.1 Metazoa_SRP -4.03 6.97e-05 0.0137 -0.39 -0.21 Dental caries; chr17:81690106 chr17:81718849~81719095:- LIHC cis rs801193 0.613 rs2659900 ENSG00000232559.3 GS1-124K5.12 4.03 6.97e-05 0.0137 0.17 0.21 Aortic root size; chr7:66719456 chr7:66554588~66576923:- LIHC cis rs3812762 0.843 rs10732515 ENSG00000254860.4 TMEM9B-AS1 -4.03 6.97e-05 0.0137 -0.23 -0.21 Hypospadias; chr11:8780243 chr11:8964675~8977527:+ LIHC cis rs11096990 0.634 rs3733281 ENSG00000249685.1 RP11-360F5.3 -4.03 6.97e-05 0.0137 -0.25 -0.21 Cognitive function; chr4:39270293 chr4:39133913~39135608:+ LIHC cis rs2243480 1 rs160646 ENSG00000230295.1 RP11-458F8.2 -4.03 6.97e-05 0.0137 -0.22 -0.21 Diabetic kidney disease; chr7:66091293 chr7:66880708~66882981:+ LIHC cis rs950880 0.614 rs60038017 ENSG00000234389.1 AC007278.3 -4.03 6.97e-05 0.0137 -0.21 -0.21 Serum protein levels (sST2); chr2:102459541 chr2:102438713~102440475:+ LIHC cis rs13113518 0.783 rs7690837 ENSG00000249700.7 SRD5A3-AS1 4.03 6.97e-05 0.0137 0.25 0.21 Height; chr4:55575856 chr4:55363971~55395847:- LIHC cis rs6504622 0.537 rs1662596 ENSG00000263766.4 RP11-580I16.2 -4.03 6.97e-05 0.0137 -0.25 -0.21 Orofacial clefts; chr17:46915752 chr17:47603860~47649420:- LIHC cis rs17818399 0.547 rs62134736 ENSG00000239332.4 LINC01119 -4.03 6.97e-05 0.0137 -0.31 -0.21 Height; chr2:46539307 chr2:46816697~46859007:+ LIHC cis rs4356975 0.932 rs4694159 ENSG00000250919.1 RP11-813N20.3 -4.03 6.97e-05 0.0137 -0.21 -0.21 Obesity-related traits; chr4:69068460 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs4694597 ENSG00000250919.1 RP11-813N20.3 -4.03 6.97e-05 0.0137 -0.21 -0.21 Obesity-related traits; chr4:69068643 chr4:69027831~69044578:+ LIHC cis rs4356975 0.899 rs4694160 ENSG00000250919.1 RP11-813N20.3 -4.03 6.97e-05 0.0137 -0.21 -0.21 Obesity-related traits; chr4:69068755 chr4:69027831~69044578:+ LIHC cis rs4356975 0.899 rs7439419 ENSG00000250919.1 RP11-813N20.3 -4.03 6.97e-05 0.0137 -0.21 -0.21 Obesity-related traits; chr4:69069090 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs7658748 ENSG00000250919.1 RP11-813N20.3 -4.03 6.97e-05 0.0137 -0.21 -0.21 Obesity-related traits; chr4:69069219 chr4:69027831~69044578:+ LIHC cis rs4356975 0.899 rs7687336 ENSG00000250919.1 RP11-813N20.3 -4.03 6.97e-05 0.0137 -0.21 -0.21 Obesity-related traits; chr4:69069397 chr4:69027831~69044578:+ LIHC cis rs4356975 0.899 rs7659138 ENSG00000250919.1 RP11-813N20.3 -4.03 6.97e-05 0.0137 -0.21 -0.21 Obesity-related traits; chr4:69069420 chr4:69027831~69044578:+ LIHC cis rs4356975 0.932 rs7674600 ENSG00000250919.1 RP11-813N20.3 -4.03 6.97e-05 0.0137 -0.21 -0.21 Obesity-related traits; chr4:69069614 chr4:69027831~69044578:+ LIHC cis rs1005277 0.577 rs4934906 ENSG00000275858.1 RP11-291L22.8 4.03 6.98e-05 0.0137 0.23 0.21 Extrinsic epigenetic age acceleration; chr10:37726100 chr10:38450738~38451069:- LIHC cis rs591584 0.728 rs649973 ENSG00000255893.1 RP11-685N10.1 -4.03 6.98e-05 0.0137 -0.21 -0.21 Macrophage Migration Inhibitory Factor levels; chr11:94600708 chr11:94472908~94473570:- LIHC cis rs11098499 0.908 rs2017057 ENSG00000260091.1 RP11-33B1.4 -4.03 6.98e-05 0.0137 -0.15 -0.21 Corneal astigmatism; chr4:119336556 chr4:119409333~119410233:+ LIHC cis rs17711722 0.583 rs11768292 ENSG00000273024.4 INTS4P2 4.03 6.98e-05 0.0138 0.27 0.21 Calcium levels; chr7:66009814 chr7:65647864~65715661:+ LIHC cis rs1005277 0.54 rs289638 ENSG00000276805.1 RP11-291L22.6 4.03 6.98e-05 0.0138 0.26 0.21 Extrinsic epigenetic age acceleration; chr10:37634803 chr10:38451030~38451785:+ LIHC cis rs1005277 0.54 rs7903942 ENSG00000276805.1 RP11-291L22.6 -4.03 6.98e-05 0.0138 -0.26 -0.21 Extrinsic epigenetic age acceleration; chr10:37640348 chr10:38451030~38451785:+ LIHC cis rs287982 1 rs287979 ENSG00000269973.1 RP11-95D17.1 4.03 6.98e-05 0.0138 0.2 0.21 Nonsyndromic cleft lip with cleft palate; chr2:9830838 chr2:9936360~9939590:+ LIHC cis rs287982 1 rs287980 ENSG00000269973.1 RP11-95D17.1 4.03 6.98e-05 0.0138 0.2 0.21 Nonsyndromic cleft lip with cleft palate; chr2:9831237 chr2:9936360~9939590:+ LIHC cis rs597539 0.652 rs686390 ENSG00000250508.1 RP11-757G1.6 -4.03 6.99e-05 0.0138 -0.32 -0.21 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68888609 chr11:68870664~68874542:+ LIHC cis rs17023223 0.537 rs6662165 ENSG00000231365.4 RP11-418J17.1 -4.03 6.99e-05 0.0138 -0.25 -0.21 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119071448 chr1:119140396~119275973:+ LIHC cis rs2439831 0.867 rs2470134 ENSG00000166763.7 STRCP1 -4.03 6.99e-05 0.0138 -0.33 -0.21 Lung cancer in ever smokers; chr15:43557688 chr15:43699488~43718184:- LIHC cis rs853679 0.76 rs967005 ENSG00000219392.1 RP1-265C24.5 -4.03 6.99e-05 0.0138 -0.33 -0.21 Depression; chr6:28242910 chr6:28115628~28116551:+ LIHC cis rs6452524 0.686 rs6452518 ENSG00000271862.1 RP11-343L5.2 4.03 6.99e-05 0.0138 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83133043 chr5:83049376~83050964:- LIHC cis rs17373728 0.71 rs2221810 ENSG00000249395.2 CASC9 4.03 6.99e-05 0.0138 0.23 0.21 Diabetic kidney disease; chr8:75309233 chr8:75223404~75324741:- LIHC cis rs1499614 1 rs2707832 ENSG00000232546.1 RP11-458F8.1 -4.03 6.99e-05 0.0138 -0.23 -0.21 Gout; chr7:66671562 chr7:66848496~66858136:+ LIHC cis rs1023500 0.505 rs134888 ENSG00000226450.2 CYP2D8P 4.03 6.99e-05 0.0138 0.23 0.21 Schizophrenia; chr22:42278275 chr22:42149886~42155001:- LIHC cis rs7809950 0.817 rs17154091 ENSG00000238832.1 snoU109 -4.03 7e-05 0.0138 -0.27 -0.21 Coronary artery disease; chr7:107444345 chr7:107603363~107603507:+ LIHC cis rs6600671 0.934 rs11249431 ENSG00000227082.1 CH17-437K3.1 4.03 7e-05 0.0138 0.29 0.21 Hip geometry; chr1:121544405 chr1:121396754~121463129:+ LIHC cis rs1015362 0.503 rs4911371 ENSG00000276073.1 RP5-1125A11.7 -4.03 7e-05 0.0138 -0.27 -0.21 Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling; chr20:33904096 chr20:33985617~33988989:- LIHC cis rs9595908 0.671 rs12428598 ENSG00000212293.1 SNORA16 4.03 7e-05 0.0138 0.24 0.21 Body mass index; chr13:32684839 chr13:32420390~32420516:- LIHC cis rs673078 0.66 rs6490173 ENSG00000275759.1 RP11-131L12.3 -4.03 7e-05 0.0138 -0.26 -0.21 Glucose homeostasis traits; chr12:118278637 chr12:118428281~118428870:+ LIHC cis rs673078 0.571 rs17440823 ENSG00000275759.1 RP11-131L12.3 -4.03 7.01e-05 0.0138 -0.43 -0.21 Glucose homeostasis traits; chr12:118353023 chr12:118428281~118428870:+ LIHC cis rs2562456 0.874 rs2562417 ENSG00000268555.1 RP11-678G14.3 -4.03 7.01e-05 0.0138 -0.27 -0.21 Pain; chr19:21528400 chr19:21570822~21587322:- LIHC cis rs2562456 0.917 rs2562466 ENSG00000268555.1 RP11-678G14.3 -4.03 7.01e-05 0.0138 -0.27 -0.21 Pain; chr19:21531402 chr19:21570822~21587322:- LIHC cis rs2562456 0.917 rs2562468 ENSG00000268555.1 RP11-678G14.3 -4.03 7.01e-05 0.0138 -0.27 -0.21 Pain; chr19:21532048 chr19:21570822~21587322:- LIHC cis rs2562456 0.917 rs2562471 ENSG00000268555.1 RP11-678G14.3 -4.03 7.01e-05 0.0138 -0.27 -0.21 Pain; chr19:21533017 chr19:21570822~21587322:- LIHC cis rs858239 0.669 rs1618339 ENSG00000226816.2 AC005082.12 4.03 7.01e-05 0.0138 0.26 0.21 Cerebrospinal fluid biomarker levels; chr7:23190155 chr7:23206013~23208045:+ LIHC cis rs1003719 0.591 rs2835633 ENSG00000272948.2 AP001412.1 -4.03 7.01e-05 0.0138 -0.23 -0.21 Eye color traits; chr21:37152719 chr21:37267784~37268497:+ LIHC cis rs6745190 0.953 rs4346343 ENSG00000236153.1 AC104076.3 4.03 7.01e-05 0.0138 0.28 0.21 White blood cell count; chr2:181002320 chr2:180979427~180980090:- LIHC cis rs4561483 0.801 rs33637 ENSG00000261216.1 RP11-166B2.5 -4.03 7.01e-05 0.0138 -0.23 -0.21 Testicular germ cell tumor; chr16:11896018 chr16:11908208~11908916:+ LIHC cis rs2117029 0.5 rs3741619 ENSG00000281789.1 Y_RNA -4.03 7.01e-05 0.0138 -0.23 -0.21 Intelligence (multi-trait analysis); chr12:48995693 chr12:48927939~48928033:- LIHC cis rs847851 0.798 rs2177381 ENSG00000276712.1 MIR7111 -4.03 7.02e-05 0.0138 -0.22 -0.21 Colonoscopy-negative controls vs population controls; chr6:35009598 chr6:35470508~35470579:+ LIHC cis rs244293 0.931 rs244354 ENSG00000275710.1 RP11-257O5.4 4.03 7.02e-05 0.0138 0.23 0.21 Menarche (age at onset); chr17:55116781 chr17:54964474~54964679:+ LIHC cis rs66486766 1 rs66486766 ENSG00000225151.9 GOLGA2P7 -4.02 7.02e-05 0.0138 -0.3 -0.21 Bipolar disorder lithium response (categorical) or schizophrenia; chr15:84137308 chr15:84199311~84230136:- LIHC cis rs2337406 0.714 rs7145254 ENSG00000274576.2 IGHV2-70 -4.02 7.02e-05 0.0138 -0.23 -0.21 Alzheimer's disease (late onset); chr14:106817783 chr14:106770577~106771020:- LIHC cis rs7915414 0.951 rs12772169 ENSG00000230338.1 MTND4P19 4.02 7.03e-05 0.0138 0.22 0.21 Clopidogrel active metabolite levels; chr10:94645572 chr10:94774156~94774633:- LIHC cis rs10129255 0.957 rs8009073 ENSG00000211970.3 IGHV4-61 -4.02 7.03e-05 0.0138 -0.17 -0.21 Kawasaki disease; chr14:106777278 chr14:106639119~106639657:- LIHC cis rs2032447 0.802 rs199755 ENSG00000242387.1 HIST1H2APS2 4.02 7.03e-05 0.0138 0.28 0.21 Intelligence (multi-trait analysis); chr6:25990139 chr6:25882026~25882395:- LIHC cis rs4086116 0.526 rs2104162 ENSG00000230338.1 MTND4P19 4.02 7.03e-05 0.0138 0.21 0.21 Warfarin maintenance dose; chr10:94876348 chr10:94774156~94774633:- LIHC cis rs12772169 0.502 rs4608002 ENSG00000230338.1 MTND4P19 4.02 7.03e-05 0.0138 0.21 0.21 Acenocoumarol maintenance dosage; chr10:94880345 chr10:94774156~94774633:- LIHC cis rs801193 0.66 rs2659914 ENSG00000232559.3 GS1-124K5.12 4.02 7.03e-05 0.0138 0.17 0.21 Aortic root size; chr7:66691927 chr7:66554588~66576923:- LIHC cis rs13113518 0.783 rs12510400 ENSG00000249700.7 SRD5A3-AS1 4.02 7.04e-05 0.0138 0.25 0.21 Height; chr4:55577294 chr4:55363971~55395847:- LIHC cis rs13113518 0.783 rs13111128 ENSG00000249700.7 SRD5A3-AS1 4.02 7.04e-05 0.0138 0.25 0.21 Height; chr4:55578154 chr4:55363971~55395847:- LIHC cis rs748404 0.723 rs573169 ENSG00000205771.5 CATSPER2P1 -4.02 7.04e-05 0.0139 -0.26 -0.21 Lung cancer; chr15:43258383 chr15:43726918~43747094:- LIHC cis rs748404 0.697 rs524547 ENSG00000205771.5 CATSPER2P1 -4.02 7.04e-05 0.0139 -0.26 -0.21 Lung cancer; chr15:43258825 chr15:43726918~43747094:- LIHC cis rs4356203 0.905 rs17472886 ENSG00000260196.1 RP1-239B22.5 -4.02 7.04e-05 0.0139 -0.26 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17064620 chr11:17380649~17383531:+ LIHC cis rs763121 0.853 rs1013338 ENSG00000273076.1 RP3-508I15.22 4.02 7.04e-05 0.0139 0.24 0.21 Menopause (age at onset); chr22:38578149 chr22:38743495~38743910:+ LIHC cis rs950880 0.71 rs11693955 ENSG00000234389.1 AC007278.3 -4.02 7.05e-05 0.0139 -0.22 -0.21 Serum protein levels (sST2); chr2:102412705 chr2:102438713~102440475:+ LIHC cis rs875971 0.545 rs1638735 ENSG00000273024.4 INTS4P2 -4.02 7.05e-05 0.0139 -0.25 -0.21 Aortic root size; chr7:66630751 chr7:65647864~65715661:+ LIHC cis rs1799949 0.965 rs8176087 ENSG00000267681.1 CTD-3199J23.6 -4.02 7.06e-05 0.0139 -0.21 -0.21 Menopause (age at onset); chr17:43118649 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs8176083 ENSG00000267681.1 CTD-3199J23.6 -4.02 7.06e-05 0.0139 -0.21 -0.21 Menopause (age at onset); chr17:43123134 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs11657835 ENSG00000267681.1 CTD-3199J23.6 -4.02 7.06e-05 0.0139 -0.21 -0.21 Menopause (age at onset); chr17:43139936 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs1135214 ENSG00000267681.1 CTD-3199J23.6 -4.02 7.06e-05 0.0139 -0.21 -0.21 Menopause (age at onset); chr17:43140306 chr17:43144956~43145255:+ LIHC cis rs12157904 1 rs6000815 ENSG00000233360.4 Z83844.1 4.02 7.06e-05 0.0139 0.42 0.21 Response to anti-depressant treatment in major depressive disorder; chr22:37585856 chr22:37641832~37658377:- LIHC cis rs4578769 0.959 rs9947011 ENSG00000265943.1 RP11-739L10.1 -4.02 7.06e-05 0.0139 -0.27 -0.21 Eosinophil percentage of white cells; chr18:22840446 chr18:22699481~22933764:- LIHC cis rs4578769 0.765 rs998184 ENSG00000265943.1 RP11-739L10.1 -4.02 7.06e-05 0.0139 -0.28 -0.21 Eosinophil percentage of white cells; chr18:22925006 chr18:22699481~22933764:- LIHC cis rs4578769 0.765 rs4800440 ENSG00000265943.1 RP11-739L10.1 -4.02 7.06e-05 0.0139 -0.28 -0.21 Eosinophil percentage of white cells; chr18:22928158 chr18:22699481~22933764:- LIHC cis rs4938303 0.633 rs35681250 ENSG00000254851.1 RP11-109L13.1 4.02 7.06e-05 0.0139 0.29 0.21 Triglycerides; chr11:116684670 chr11:117135528~117138582:+ LIHC cis rs13217239 0.646 rs4403259 ENSG00000241549.7 GUSBP2 4.02 7.06e-05 0.0139 0.22 0.21 Schizophrenia; chr6:27029838 chr6:26871484~26956554:- LIHC cis rs6142102 0.961 rs2284386 ENSG00000275784.1 RP5-1125A11.6 -4.02 7.07e-05 0.0139 -0.24 -0.21 Skin pigmentation; chr20:34056590 chr20:33989480~33991818:- LIHC cis rs2281636 0.723 rs11190245 ENSG00000233690.1 EBAG9P1 4.02 7.07e-05 0.0139 0.22 0.21 Obesity-related traits; chr10:99691502 chr10:99697407~99697949:- LIHC cis rs9907295 0.901 rs4796120 ENSG00000270871.1 AC015849.19 -4.02 7.07e-05 0.0139 -0.22 -0.21 Fibroblast growth factor basic levels; chr17:35873887 chr17:35816717~35830293:- LIHC cis rs2932538 0.922 rs6673930 ENSG00000225075.1 RP11-426L16.3 4.02 7.07e-05 0.0139 0.27 0.21 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112562265 chr1:112693688~112696621:- LIHC cis rs4578769 0.765 rs72882147 ENSG00000265943.1 RP11-739L10.1 -4.02 7.07e-05 0.0139 -0.28 -0.21 Eosinophil percentage of white cells; chr18:22816590 chr18:22699481~22933764:- LIHC cis rs875971 0.545 rs4718348 ENSG00000228409.4 CCT6P1 -4.02 7.07e-05 0.0139 -0.18 -0.21 Aortic root size; chr7:66441589 chr7:65751142~65763354:+ LIHC cis rs7809950 0.817 rs2253833 ENSG00000238832.1 snoU109 4.02 7.07e-05 0.0139 0.27 0.21 Coronary artery disease; chr7:107565224 chr7:107603363~107603507:+ LIHC cis rs948562 0.69 rs11229425 ENSG00000280010.1 AP001350.4 -4.02 7.07e-05 0.0139 -0.37 -0.21 Lymphoma; chr11:58411114 chr11:58627435~58628528:+ LIHC cis rs7734985 0.775 rs4357059 ENSG00000250551.1 RP11-254I22.1 -4.02 7.07e-05 0.0139 -0.24 -0.21 IgG glycosylation; chr5:96173022 chr5:96050115~96215519:+ LIHC cis rs1115240 0.754 rs178171 ENSG00000257842.4 NOVA1-AS1 -4.02 7.08e-05 0.0139 -0.2 -0.21 Educational attainment (years of education); chr14:26544635 chr14:26598412~26806467:+ LIHC cis rs10761256 0.835 rs7873003 ENSG00000227603.1 RP11-165J3.6 4.02 7.08e-05 0.0139 0.25 0.21 Itch intensity from mosquito bite adjusted by bite size; chr9:93630663 chr9:93435332~93437121:- LIHC cis rs244293 0.965 rs244362 ENSG00000275710.1 RP11-257O5.4 4.02 7.08e-05 0.0139 0.23 0.21 Menarche (age at onset); chr17:55111556 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs171513 ENSG00000275710.1 RP11-257O5.4 4.02 7.08e-05 0.0139 0.23 0.21 Menarche (age at onset); chr17:55113065 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244361 ENSG00000275710.1 RP11-257O5.4 4.02 7.08e-05 0.0139 0.23 0.21 Menarche (age at onset); chr17:55113995 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs8068337 ENSG00000275710.1 RP11-257O5.4 -4.02 7.08e-05 0.0139 -0.23 -0.21 Menarche (age at onset); chr17:55100538 chr17:54964474~54964679:+ LIHC cis rs72675573 0.578 rs6659982 ENSG00000235612.1 RP1-158P9.1 -4.02 7.08e-05 0.0139 -0.28 -0.21 Monocyte count; chr1:56109624 chr1:56145721~56155224:+ LIHC cis rs4683346 0.731 rs760193 ENSG00000273328.4 RP11-141M3.6 -4.02 7.08e-05 0.0139 -0.23 -0.21 Granulocyte percentage of myeloid white cells; chr3:42876805 chr3:42809414~42908105:+ LIHC cis rs4253772 0.938 rs41427746 ENSG00000260708.1 CTA-29F11.1 4.02 7.08e-05 0.0139 0.42 0.21 Cholesterol, total;LDL cholesterol; chr22:46241342 chr22:46761894~46762563:- LIHC cis rs2115630 0.967 rs11073731 ENSG00000189136.7 UBE2Q2P1 -4.02 7.08e-05 0.0139 -0.17 -0.21 P wave terminal force; chr15:84811882 chr15:84526781~84571216:- LIHC cis rs9500256 0.967 rs1012500 ENSG00000215190.7 LINC00680 -4.02 7.08e-05 0.0139 -0.22 -0.21 Eosinophilic esophagitis (pediatric); chr6:57978391 chr6:57946074~57961501:- LIHC cis rs4803480 0.543 rs7257282 ENSG00000267107.5 PCAT19 4.02 7.08e-05 0.0139 0.27 0.21 Schizophrenia; chr19:41536585 chr19:41454169~41500649:- LIHC cis rs3020736 0.5 rs6002597 ENSG00000205702.9 CYP2D7 -4.02 7.08e-05 0.0139 -0.25 -0.21 Autism spectrum disorder or schizophrenia; chr22:42092156 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs7292241 ENSG00000205702.9 CYP2D7 -4.02 7.08e-05 0.0139 -0.25 -0.21 Autism spectrum disorder or schizophrenia; chr22:42096059 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs6002603 ENSG00000205702.9 CYP2D7 -4.02 7.08e-05 0.0139 -0.25 -0.21 Autism spectrum disorder or schizophrenia; chr22:42096358 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs5996111 ENSG00000205702.9 CYP2D7 -4.02 7.08e-05 0.0139 -0.25 -0.21 Autism spectrum disorder or schizophrenia; chr22:42097898 chr22:42140203~42144577:- LIHC cis rs11098499 1 rs7659194 ENSG00000260091.1 RP11-33B1.4 -4.02 7.09e-05 0.0139 -0.15 -0.21 Corneal astigmatism; chr4:119285992 chr4:119409333~119410233:+ LIHC cis rs1062177 0.855 rs919263 ENSG00000253921.1 CTB-113P19.3 -4.02 7.09e-05 0.0139 -0.22 -0.21 Preschool internalizing problems; chr5:151886292 chr5:151753992~151767247:+ LIHC cis rs2120243 0.647 rs9289983 ENSG00000244515.1 KRT18P34 -4.02 7.09e-05 0.0139 -0.21 -0.21 Hepatocellular carcinoma in hepatitis B infection; chr3:157428216 chr3:157162663~157163932:- LIHC cis rs10129255 1 rs11627342 ENSG00000211972.2 IGHV3-66 4.02 7.09e-05 0.0139 0.17 0.21 Kawasaki disease; chr14:106675823 chr14:106675017~106675544:- LIHC cis rs10991814 0.546 rs10991837 ENSG00000273381.1 RP11-305L7.7 4.02 7.09e-05 0.0139 0.23 0.21 Neutrophil percentage of granulocytes; chr9:91237559 chr9:91206175~91210299:- LIHC cis rs11233413 0.874 rs11233443 ENSG00000246067.6 RAB30-AS1 4.02 7.09e-05 0.0139 0.29 0.21 Economic and political preferences (feminism/equality); chr11:83060764 chr11:83072066~83106719:+ LIHC cis rs11233413 0.834 rs11233444 ENSG00000246067.6 RAB30-AS1 4.02 7.09e-05 0.0139 0.29 0.21 Economic and political preferences (feminism/equality); chr11:83060852 chr11:83072066~83106719:+ LIHC cis rs7893279 0.543 rs7099423 ENSG00000225527.1 RP11-383B4.4 4.02 7.1e-05 0.0139 0.3 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18623773 chr10:18531849~18533336:- LIHC cis rs1318937 1 rs1318937 ENSG00000224660.1 SH3BP5-AS1 -4.02 7.1e-05 0.0139 -0.19 -0.21 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15253857 chr3:15254184~15264493:+ LIHC cis rs338389 0.542 rs62002423 ENSG00000260657.2 RP11-315D16.4 4.02 7.1e-05 0.0139 0.35 0.21 Survival in rectal cancer; chr15:67976709 chr15:68267792~68277994:- LIHC cis rs3091242 1 rs9689 ENSG00000261349.1 RP3-465N24.5 -4.02 7.1e-05 0.0139 -0.2 -0.21 Erythrocyte sedimentation rate; chr1:25361785 chr1:25266102~25267136:- LIHC cis rs2348418 0.579 rs2126896 ENSG00000247934.4 RP11-967K21.1 -4.02 7.1e-05 0.0139 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28239701 chr12:28163298~28190738:- LIHC cis rs7193541 0.965 rs4402594 ENSG00000261079.1 RP11-252A24.3 4.02 7.1e-05 0.014 0.23 0.21 Multiple myeloma; chr16:74667462 chr16:74367462~74369826:+ LIHC cis rs55794721 0.509 rs6699896 ENSG00000224183.1 SDHDP6 -4.02 7.1e-05 0.014 -0.25 -0.21 Mean corpuscular volume;Plateletcrit; chr1:25436411 chr1:25294164~25294643:- LIHC cis rs6547741 1 rs6547741 ENSG00000234072.1 AC074117.10 4.02 7.11e-05 0.014 0.2 0.21 Oral cavity cancer; chr2:27633057 chr2:27356246~27367622:+ LIHC cis rs6442522 0.867 rs12637268 ENSG00000249786.6 EAF1-AS1 4.02 7.11e-05 0.014 0.25 0.21 Uric acid levels; chr3:15458741 chr3:15436171~15455940:- LIHC cis rs6723226 0.708 rs2710627 ENSG00000276334.1 AL133243.1 4.02 7.11e-05 0.014 0.24 0.21 Intelligence (multi-trait analysis); chr2:32533560 chr2:32521927~32523547:+ LIHC cis rs1115240 0.853 rs61986523 ENSG00000257842.4 NOVA1-AS1 4.02 7.12e-05 0.014 0.2 0.21 Educational attainment (years of education); chr14:26541423 chr14:26598412~26806467:+ LIHC cis rs875971 0.545 rs12671152 ENSG00000273024.4 INTS4P2 -4.02 7.12e-05 0.014 -0.25 -0.21 Aortic root size; chr7:66311140 chr7:65647864~65715661:+ LIHC cis rs3809863 0.602 rs2317677 ENSG00000228782.6 CTD-2026D20.3 4.02 7.13e-05 0.014 0.24 0.21 Glaucoma (primary open-angle); chr17:47316041 chr17:47450568~47492492:- LIHC cis rs703842 0.616 rs7489290 ENSG00000270039.1 RP11-571M6.17 -4.02 7.13e-05 0.014 -0.3 -0.21 Multiple sclerosis; chr12:57834805 chr12:57803838~57804415:+ LIHC cis rs7917772 0.503 rs1536308 ENSG00000236937.2 PTGES3P4 -4.02 7.13e-05 0.014 -0.29 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102529020 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs11191320 ENSG00000236937.2 PTGES3P4 -4.02 7.13e-05 0.014 -0.29 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102533637 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs11191321 ENSG00000236937.2 PTGES3P4 -4.02 7.13e-05 0.014 -0.29 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102533655 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs7896841 ENSG00000236937.2 PTGES3P4 -4.02 7.13e-05 0.014 -0.29 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102534908 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs6584510 ENSG00000236937.2 PTGES3P4 -4.02 7.13e-05 0.014 -0.29 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102540111 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs7096072 ENSG00000236937.2 PTGES3P4 -4.02 7.13e-05 0.014 -0.29 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102540219 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs56219824 ENSG00000236937.2 PTGES3P4 -4.02 7.13e-05 0.014 -0.29 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102542580 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs56397707 ENSG00000236937.2 PTGES3P4 -4.02 7.13e-05 0.014 -0.29 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102542936 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs11191325 ENSG00000236937.2 PTGES3P4 -4.02 7.13e-05 0.014 -0.29 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102543176 chr10:102845595~102845950:+ LIHC cis rs6430585 0.583 rs76097170 ENSG00000231890.6 DARS-AS1 -4.02 7.13e-05 0.014 -0.3 -0.21 Corneal structure; chr2:135835928 chr2:135985176~136022593:+ LIHC cis rs113084984 0.718 rs10929754 ENSG00000271952.1 RP11-245G13.2 -4.02 7.13e-05 0.014 -0.26 -0.21 Breast cancer; chr2:11542948 chr2:10878269~10885118:+ LIHC cis rs11098499 0.722 rs17595727 ENSG00000245958.5 RP11-33B1.1 4.02 7.13e-05 0.014 0.21 0.21 Corneal astigmatism; chr4:119340919 chr4:119454791~119552025:+ LIHC cis rs11098499 0.866 rs11098506 ENSG00000245958.5 RP11-33B1.1 -4.02 7.13e-05 0.014 -0.22 -0.21 Corneal astigmatism; chr4:119363816 chr4:119454791~119552025:+ LIHC cis rs7688540 0.771 rs7669892 ENSG00000275426.1 CH17-262A2.1 -4.02 7.14e-05 0.014 -0.22 -0.21 Facial morphology (factor 6, height of vermillion lower lip); chr4:315464 chr4:149738~150317:+ LIHC cis rs10262624 0.967 rs2188845 ENSG00000234286.1 AC006026.13 -4.02 7.14e-05 0.014 -0.24 -0.21 Schizophrenia; chr7:23882391 chr7:23680195~23680786:- LIHC cis rs1023500 1 rs3752591 ENSG00000237037.8 NDUFA6-AS1 -4.02 7.14e-05 0.014 -0.29 -0.21 Schizophrenia; chr22:41943512 chr22:42090931~42137742:+ LIHC cis rs9450351 0.744 rs7764843 ENSG00000203875.9 SNHG5 -4.02 7.15e-05 0.014 -0.46 -0.21 Interferon gamma-induced protein 10 levels; chr6:85903875 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs7752222 ENSG00000203875.9 SNHG5 -4.02 7.15e-05 0.014 -0.46 -0.21 Interferon gamma-induced protein 10 levels; chr6:85913874 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs7738777 ENSG00000203875.9 SNHG5 -4.02 7.15e-05 0.014 -0.46 -0.21 Interferon gamma-induced protein 10 levels; chr6:85923468 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs6912150 ENSG00000203875.9 SNHG5 -4.02 7.15e-05 0.014 -0.46 -0.21 Interferon gamma-induced protein 10 levels; chr6:85925291 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs9444371 ENSG00000203875.9 SNHG5 -4.02 7.15e-05 0.014 -0.46 -0.21 Interferon gamma-induced protein 10 levels; chr6:85950676 chr6:85660950~85678736:- LIHC cis rs9353324 1 rs58334368 ENSG00000203875.9 SNHG5 -4.02 7.15e-05 0.014 -0.46 -0.21 Interferon gamma-induced protein 10 levels; chr6:85971591 chr6:85660950~85678736:- LIHC cis rs2120243 0.647 rs1456099 ENSG00000244515.1 KRT18P34 4.02 7.15e-05 0.014 0.2 0.21 Hepatocellular carcinoma in hepatitis B infection; chr3:157428518 chr3:157162663~157163932:- LIHC cis rs11098499 0.722 rs10025925 ENSG00000245958.5 RP11-33B1.1 -4.02 7.15e-05 0.014 -0.21 -0.21 Corneal astigmatism; chr4:119350589 chr4:119454791~119552025:+ LIHC cis rs11098499 0.731 rs10015579 ENSG00000245958.5 RP11-33B1.1 -4.02 7.15e-05 0.014 -0.21 -0.21 Corneal astigmatism; chr4:119350647 chr4:119454791~119552025:+ LIHC cis rs6471393 1 rs6997642 ENSG00000253848.1 RP11-10N23.5 -4.02 7.15e-05 0.014 -0.23 -0.21 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93703737 chr8:93741193~93744534:+ LIHC cis rs1023500 0.505 rs134901 ENSG00000205702.9 CYP2D7 4.02 7.16e-05 0.014 0.22 0.21 Schizophrenia; chr22:42287514 chr22:42140203~42144577:- LIHC cis rs2564921 0.704 rs62253606 ENSG00000242142.1 SERBP1P3 -4.02 7.16e-05 0.014 -0.29 -0.21 Height; chr3:52949886 chr3:53064283~53065091:- LIHC cis rs7731783 1 rs7731783 ENSG00000246596.5 RP11-1277A3.2 4.02 7.16e-05 0.014 0.22 0.21 Methadone dose in opioid dependence; chr5:177633311 chr5:177619059~177672209:- LIHC cis rs1499614 1 rs2659913 ENSG00000228409.4 CCT6P1 4.02 7.16e-05 0.014 0.23 0.21 Gout; chr7:66692349 chr7:65751142~65763354:+ LIHC cis rs1499614 1 rs2707840 ENSG00000228409.4 CCT6P1 4.02 7.16e-05 0.014 0.23 0.21 Gout; chr7:66693028 chr7:65751142~65763354:+ LIHC cis rs1499614 1 rs2659911 ENSG00000228409.4 CCT6P1 4.02 7.16e-05 0.014 0.23 0.21 Gout; chr7:66693433 chr7:65751142~65763354:+ LIHC cis rs1499614 1 rs2707838 ENSG00000228409.4 CCT6P1 4.02 7.16e-05 0.014 0.23 0.21 Gout; chr7:66694214 chr7:65751142~65763354:+ LIHC cis rs1499614 1 rs60326618 ENSG00000228409.4 CCT6P1 4.02 7.16e-05 0.014 0.23 0.21 Gout; chr7:66701371 chr7:65751142~65763354:+ LIHC cis rs1499614 1 rs2707830 ENSG00000228409.4 CCT6P1 4.02 7.16e-05 0.014 0.23 0.21 Gout; chr7:66702658 chr7:65751142~65763354:+ LIHC cis rs1499614 1 rs2707828 ENSG00000228409.4 CCT6P1 4.02 7.16e-05 0.014 0.23 0.21 Gout; chr7:66706390 chr7:65751142~65763354:+ LIHC cis rs1499614 0.803 rs1922723 ENSG00000228409.4 CCT6P1 4.02 7.16e-05 0.014 0.23 0.21 Gout; chr7:66710076 chr7:65751142~65763354:+ LIHC cis rs1499614 1 rs2659903 ENSG00000228409.4 CCT6P1 4.02 7.16e-05 0.014 0.23 0.21 Gout; chr7:66715944 chr7:65751142~65763354:+ LIHC cis rs1499614 1 rs2141924 ENSG00000228409.4 CCT6P1 4.02 7.16e-05 0.014 0.23 0.21 Gout; chr7:66721259 chr7:65751142~65763354:+ LIHC cis rs9595908 0.785 rs9315177 ENSG00000212293.1 SNORA16 4.02 7.16e-05 0.014 0.24 0.21 Body mass index; chr13:32696214 chr13:32420390~32420516:- LIHC cis rs12681287 0.64 rs13267782 ENSG00000254088.1 SLC2A3P4 4.02 7.17e-05 0.0141 0.25 0.21 Caudate activity during reward; chr8:86469658 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs7830480 ENSG00000254088.1 SLC2A3P4 -4.02 7.17e-05 0.0141 -0.25 -0.21 Caudate activity during reward; chr8:86390908 chr8:86503591~86505061:+ LIHC cis rs12681287 0.604 rs6471316 ENSG00000254088.1 SLC2A3P4 -4.02 7.17e-05 0.0141 -0.25 -0.21 Caudate activity during reward; chr8:86391358 chr8:86503591~86505061:+ LIHC cis rs6471393 1 rs6471393 ENSG00000253848.1 RP11-10N23.5 -4.02 7.17e-05 0.0141 -0.23 -0.21 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93703063 chr8:93741193~93744534:+ LIHC cis rs12681287 0.64 rs10086340 ENSG00000254231.1 CTD-2284J15.1 4.02 7.17e-05 0.0141 0.21 0.21 Caudate activity during reward; chr8:86434560 chr8:86333274~86343314:- LIHC cis rs950880 0.677 rs17027087 ENSG00000234389.1 AC007278.3 -4.02 7.18e-05 0.0141 -0.21 -0.21 Serum protein levels (sST2); chr2:102399458 chr2:102438713~102440475:+ LIHC cis rs2838568 0.967 rs34672935 ENSG00000277352.1 KB-68A7.2 -4.02 7.18e-05 0.0141 -0.25 -0.21 Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals; chr21:44478073 chr21:44494874~44495519:+ LIHC cis rs2243480 0.803 rs160649 ENSG00000230295.1 RP11-458F8.2 -4.02 7.19e-05 0.0141 -0.22 -0.21 Diabetic kidney disease; chr7:66078212 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs160648 ENSG00000230295.1 RP11-458F8.2 -4.02 7.19e-05 0.0141 -0.22 -0.21 Diabetic kidney disease; chr7:66078397 chr7:66880708~66882981:+ LIHC cis rs7568498 1 rs13004784 ENSG00000235724.7 AC009299.2 -4.02 7.19e-05 0.0141 -0.27 -0.21 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161022320 chr2:161222785~161308303:- LIHC cis rs3204270 0.516 rs62077189 ENSG00000281517.1 Metazoa_SRP -4.02 7.19e-05 0.0141 -0.37 -0.21 Dental caries; chr17:81706058 chr17:81718849~81719095:- LIHC cis rs7726839 0.54 rs72705102 ENSG00000271781.1 CTD-2589H19.6 -4.02 7.19e-05 0.0141 -0.32 -0.21 Obesity-related traits; chr5:659322 chr5:675826~676616:+ LIHC cis rs2015599 0.623 rs10843385 ENSG00000257176.2 RP11-996F15.2 -4.02 7.19e-05 0.0141 -0.26 -0.21 Platelet count;Mean platelet volume; chr12:29323100 chr12:29280418~29317848:- LIHC cis rs2015599 0.601 rs17715086 ENSG00000257176.2 RP11-996F15.2 -4.02 7.19e-05 0.0141 -0.26 -0.21 Platelet count;Mean platelet volume; chr12:29329073 chr12:29280418~29317848:- LIHC cis rs6048205 1 rs1203875 ENSG00000259974.2 LINC00261 -4.02 7.19e-05 0.0141 -0.29 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22559683 chr20:22547671~22578642:- LIHC cis rs6048205 1 rs1203877 ENSG00000259974.2 LINC00261 -4.02 7.19e-05 0.0141 -0.29 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22560838 chr20:22547671~22578642:- LIHC cis rs6048205 1 rs1203879 ENSG00000259974.2 LINC00261 -4.02 7.19e-05 0.0141 -0.29 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22561178 chr20:22547671~22578642:- LIHC cis rs6048205 1 rs1203880 ENSG00000259974.2 LINC00261 -4.02 7.19e-05 0.0141 -0.29 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22561385 chr20:22547671~22578642:- LIHC cis rs6048205 1 rs1203881 ENSG00000259974.2 LINC00261 -4.02 7.19e-05 0.0141 -0.29 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22561883 chr20:22547671~22578642:- LIHC cis rs6048205 1 rs1203883 ENSG00000259974.2 LINC00261 -4.02 7.19e-05 0.0141 -0.29 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22563008 chr20:22547671~22578642:- LIHC cis rs8077577 0.689 rs16961114 ENSG00000260647.1 RP1-178F10.1 4.02 7.2e-05 0.0141 0.27 0.21 Obesity-related traits; chr17:18312025 chr17:18268080~18268828:+ LIHC cis rs8077577 0.747 rs62072537 ENSG00000260647.1 RP1-178F10.1 4.02 7.2e-05 0.0141 0.27 0.21 Obesity-related traits; chr17:18312786 chr17:18268080~18268828:+ LIHC cis rs950880 0.71 rs11678975 ENSG00000234389.1 AC007278.3 -4.02 7.2e-05 0.0141 -0.21 -0.21 Serum protein levels (sST2); chr2:102427279 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs56331791 ENSG00000234389.1 AC007278.3 -4.02 7.2e-05 0.0141 -0.21 -0.21 Serum protein levels (sST2); chr2:102431697 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs11681718 ENSG00000234389.1 AC007278.3 -4.02 7.2e-05 0.0141 -0.21 -0.21 Serum protein levels (sST2); chr2:102434684 chr2:102438713~102440475:+ LIHC cis rs10857712 0.754 rs7921041 ENSG00000214279.11 SCART1 -4.02 7.21e-05 0.0141 -0.26 -0.21 Systemic lupus erythematosus; chr10:133415735 chr10:133453928~133523558:+ LIHC cis rs2253762 0.507 rs10159998 ENSG00000226864.1 ATE1-AS1 4.02 7.21e-05 0.0141 0.35 0.21 Breast cancer; chr10:121994550 chr10:121928312~121951965:+ LIHC cis rs2253762 0.54 rs11200311 ENSG00000226864.1 ATE1-AS1 4.02 7.21e-05 0.0141 0.35 0.21 Breast cancer; chr10:121995094 chr10:121928312~121951965:+ LIHC cis rs2253762 0.54 rs79069897 ENSG00000226864.1 ATE1-AS1 4.02 7.21e-05 0.0141 0.35 0.21 Breast cancer; chr10:121995680 chr10:121928312~121951965:+ LIHC cis rs2253762 0.54 rs77032313 ENSG00000226864.1 ATE1-AS1 4.02 7.21e-05 0.0141 0.35 0.21 Breast cancer; chr10:121995687 chr10:121928312~121951965:+ LIHC cis rs2253762 0.54 rs4752631 ENSG00000226864.1 ATE1-AS1 4.02 7.21e-05 0.0141 0.35 0.21 Breast cancer; chr10:121996442 chr10:121928312~121951965:+ LIHC cis rs2253762 0.54 rs11200313 ENSG00000226864.1 ATE1-AS1 4.02 7.21e-05 0.0141 0.35 0.21 Breast cancer; chr10:121996523 chr10:121928312~121951965:+ LIHC cis rs1405130 0.869 rs13020275 ENSG00000224287.2 MSL3P1 4.02 7.21e-05 0.0141 0.25 0.21 Coronary artery disease; chr2:234657455 chr2:233865437~233868444:- LIHC cis rs4682868 0.611 rs2888271 ENSG00000273328.4 RP11-141M3.6 4.02 7.22e-05 0.0141 0.22 0.21 Monocyte percentage of white cells; chr3:42873384 chr3:42809414~42908105:+ LIHC cis rs62246343 0.605 rs9832810 ENSG00000206573.7 THUMPD3-AS1 -4.02 7.22e-05 0.0141 -0.24 -0.21 Fibrinogen levels; chr3:9424095 chr3:9349689~9398579:- LIHC cis rs4873772 0.735 rs4608108 ENSG00000253608.1 RP11-770E5.1 4.02 7.22e-05 0.0141 0.23 0.21 Lobe attachment (rater-scored or self-reported); chr8:47602961 chr8:48551567~48698510:+ LIHC cis rs6142102 0.625 rs4911381 ENSG00000275784.1 RP5-1125A11.6 4.02 7.22e-05 0.0141 0.22 0.21 Skin pigmentation; chr20:33962539 chr20:33989480~33991818:- LIHC cis rs4578769 0.765 rs12458947 ENSG00000265943.1 RP11-739L10.1 -4.02 7.22e-05 0.0141 -0.28 -0.21 Eosinophil percentage of white cells; chr18:22856655 chr18:22699481~22933764:- LIHC cis rs4578769 0.729 rs12454969 ENSG00000265943.1 RP11-739L10.1 -4.02 7.22e-05 0.0141 -0.28 -0.21 Eosinophil percentage of white cells; chr18:22893042 chr18:22699481~22933764:- LIHC cis rs9876781 0.874 rs56298324 ENSG00000229759.1 MRPS18AP1 -4.02 7.22e-05 0.0141 -0.22 -0.21 Longevity; chr3:48393626 chr3:48256350~48256938:- LIHC cis rs6471393 0.964 rs2914953 ENSG00000253848.1 RP11-10N23.5 4.02 7.22e-05 0.0141 0.23 0.21 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93730122 chr8:93741193~93744534:+ LIHC cis rs17711722 0.51 rs11767457 ENSG00000237310.1 GS1-124K5.4 4.02 7.24e-05 0.0142 0.19 0.21 Calcium levels; chr7:65825628 chr7:66493706~66495474:+ LIHC cis rs4938303 0.633 rs17092638 ENSG00000254851.1 RP11-109L13.1 4.02 7.24e-05 0.0142 0.29 0.21 Triglycerides; chr11:116685520 chr11:117135528~117138582:+ LIHC cis rs10857712 0.754 rs2297033 ENSG00000214279.11 SCART1 -4.02 7.24e-05 0.0142 -0.26 -0.21 Systemic lupus erythematosus; chr10:133421344 chr10:133453928~133523558:+ LIHC cis rs755249 0.545 rs12037073 ENSG00000182109.6 RP11-69E11.4 -4.02 7.24e-05 0.0142 -0.27 -0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39581225 chr1:39522280~39546187:- LIHC cis rs9565309 0.579 rs9573978 ENSG00000274898.1 AC001226.7 -4.02 7.24e-05 0.0142 -0.37 -0.21 Morning vs. evening chronotype; chr13:77015121 chr13:77027944~77028482:+ LIHC cis rs12304921 0.683 rs17125346 ENSG00000277201.1 AC087884.1 -4.02 7.25e-05 0.0142 -0.25 -0.21 Type 2 diabetes; chr12:51077369 chr12:51049921~51050025:+ LIHC cis rs12681287 0.64 rs6471314 ENSG00000254088.1 SLC2A3P4 -4.02 7.25e-05 0.0142 -0.25 -0.21 Caudate activity during reward; chr8:86388230 chr8:86503591~86505061:+ LIHC cis rs7712401 0.601 rs36180885 ENSG00000263432.2 RN7SL689P -4.02 7.25e-05 0.0142 -0.33 -0.21 Mean platelet volume; chr5:123020708 chr5:123022487~123022783:- LIHC cis rs2439831 0.681 rs1095386 ENSG00000166763.7 STRCP1 4.02 7.25e-05 0.0142 0.29 0.21 Lung cancer in ever smokers; chr15:43317311 chr15:43699488~43718184:- LIHC cis rs2115630 0.846 rs8024538 ENSG00000259295.5 CSPG4P12 -4.02 7.26e-05 0.0142 -0.26 -0.21 P wave terminal force; chr15:84825188 chr15:85191438~85213905:+ LIHC cis rs6449502 0.925 rs35006499 ENSG00000272308.1 RP11-231G3.1 -4.02 7.26e-05 0.0142 -0.32 -0.21 Mean platelet volume; chr5:60816122 chr5:60866457~60866935:- LIHC cis rs763121 0.962 rs138711 ENSG00000273076.1 RP3-508I15.22 4.02 7.27e-05 0.0142 0.27 0.21 Menopause (age at onset); chr22:38743908 chr22:38743495~38743910:+ LIHC cis rs4266144 0.569 rs729257 ENSG00000244515.1 KRT18P34 -4.02 7.27e-05 0.0142 -0.21 -0.21 Coronary artery disease; chr3:157111034 chr3:157162663~157163932:- LIHC cis rs4948102 0.655 rs4947533 ENSG00000226278.1 PSPHP1 -4.02 7.27e-05 0.0142 -0.25 -0.21 Plasma homocysteine levels (post-methionine load test); chr7:56003589 chr7:55764797~55773288:+ LIHC cis rs7829975 0.56 rs17154599 ENSG00000253981.4 ALG1L13P -4.02 7.27e-05 0.0142 -0.27 -0.21 Mood instability; chr8:8693908 chr8:8236003~8244667:- LIHC cis rs919433 0.854 rs13013049 ENSG00000231621.1 AC013264.2 4.02 7.27e-05 0.0142 0.2 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197343940 chr2:197197991~197199273:+ LIHC cis rs66887589 0.777 rs4643791 ENSG00000260091.1 RP11-33B1.4 4.02 7.28e-05 0.0142 0.14 0.21 Diastolic blood pressure; chr4:119344464 chr4:119409333~119410233:+ LIHC cis rs13113518 0.756 rs11939652 ENSG00000249700.7 SRD5A3-AS1 4.02 7.28e-05 0.0142 0.25 0.21 Height; chr4:55532542 chr4:55363971~55395847:- LIHC cis rs308971 0.635 rs310761 ENSG00000225026.1 AC091492.2 4.02 7.28e-05 0.0142 0.58 0.21 Fasting blood insulin (BMI interaction); chr3:12179929 chr3:12328003~12328274:+ LIHC cis rs933688 1 rs10474353 ENSG00000281357.1 ARRDC3-AS1 4.02 7.28e-05 0.0142 0.26 0.21 Smoking behavior; chr5:91436468 chr5:91380349~91439085:+ LIHC cis rs1344653 0.738 rs13006791 ENSG00000236204.4 LINC01376 -4.02 7.28e-05 0.0142 -0.25 -0.21 Pulse pressure; chr2:19560885 chr2:18986451~19346748:- LIHC cis rs4578769 0.649 rs6507433 ENSG00000266850.1 RP11-370A5.1 4.02 7.29e-05 0.0143 0.25 0.21 Eosinophil percentage of white cells; chr18:23011784 chr18:22723491~22907721:- LIHC cis rs17818399 0.62 rs3087822 ENSG00000239332.4 LINC01119 4.02 7.29e-05 0.0143 0.28 0.21 Height; chr2:46624894 chr2:46816697~46859007:+ LIHC cis rs2439831 0.85 rs8042868 ENSG00000166763.7 STRCP1 4.02 7.29e-05 0.0143 0.34 0.21 Lung cancer in ever smokers; chr15:43647444 chr15:43699488~43718184:- LIHC cis rs498872 1 rs498872 ENSG00000255422.1 AP002954.4 -4.02 7.29e-05 0.0143 -0.27 -0.21 Glioma; chr11:118606652 chr11:118704607~118750263:+ LIHC cis rs1499614 1 rs2707832 ENSG00000228409.4 CCT6P1 4.02 7.3e-05 0.0143 0.22 0.21 Gout; chr7:66671562 chr7:65751142~65763354:+ LIHC cis rs7712401 0.623 rs426877 ENSG00000263432.2 RN7SL689P -4.02 7.3e-05 0.0143 -0.31 -0.21 Mean platelet volume; chr5:122978940 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs34233716 ENSG00000263432.2 RN7SL689P -4.02 7.3e-05 0.0143 -0.31 -0.21 Mean platelet volume; chr5:122980670 chr5:123022487~123022783:- LIHC cis rs7712401 0.54 rs416763 ENSG00000263432.2 RN7SL689P -4.02 7.3e-05 0.0143 -0.31 -0.21 Mean platelet volume; chr5:122981546 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs35339188 ENSG00000263432.2 RN7SL689P -4.02 7.3e-05 0.0143 -0.31 -0.21 Mean platelet volume; chr5:122981990 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs36099390 ENSG00000263432.2 RN7SL689P -4.02 7.3e-05 0.0143 -0.31 -0.21 Mean platelet volume; chr5:122982024 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs35157167 ENSG00000263432.2 RN7SL689P -4.02 7.3e-05 0.0143 -0.31 -0.21 Mean platelet volume; chr5:122982506 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs396941 ENSG00000263432.2 RN7SL689P -4.02 7.3e-05 0.0143 -0.31 -0.21 Mean platelet volume; chr5:122982570 chr5:123022487~123022783:- LIHC cis rs7712401 0.58 rs439739 ENSG00000263432.2 RN7SL689P -4.02 7.3e-05 0.0143 -0.31 -0.21 Mean platelet volume; chr5:122982726 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs371604 ENSG00000263432.2 RN7SL689P -4.02 7.3e-05 0.0143 -0.31 -0.21 Mean platelet volume; chr5:122982737 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs385547 ENSG00000263432.2 RN7SL689P -4.02 7.3e-05 0.0143 -0.31 -0.21 Mean platelet volume; chr5:122986138 chr5:123022487~123022783:- LIHC cis rs189798 0.592 rs10111263 ENSG00000253893.2 FAM85B 4.02 7.3e-05 0.0143 0.24 0.21 Myopia (pathological); chr8:9111923 chr8:8167819~8226614:- LIHC cis rs2243480 1 rs4718334 ENSG00000232546.1 RP11-458F8.1 4.02 7.3e-05 0.0143 0.23 0.21 Diabetic kidney disease; chr7:66324467 chr7:66848496~66858136:+ LIHC cis rs617219 0.889 rs1664551 ENSG00000251675.1 CTC-458I2.2 -4.02 7.31e-05 0.0143 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79144273 chr5:80128361~80143883:+ LIHC cis rs2015599 0.623 rs1072724 ENSG00000275476.1 RP11-996F15.4 4.02 7.31e-05 0.0143 0.27 0.21 Platelet count;Mean platelet volume; chr12:29289205 chr12:29277397~29277882:- LIHC cis rs2015599 0.623 rs7358667 ENSG00000275476.1 RP11-996F15.4 4.02 7.31e-05 0.0143 0.27 0.21 Platelet count;Mean platelet volume; chr12:29290236 chr12:29277397~29277882:- LIHC cis rs2015599 0.623 rs3782505 ENSG00000275476.1 RP11-996F15.4 4.02 7.31e-05 0.0143 0.27 0.21 Platelet count;Mean platelet volume; chr12:29292236 chr12:29277397~29277882:- LIHC cis rs1816213 0.744 rs73992536 ENSG00000273466.1 RP11-548H3.1 -4.01 7.31e-05 0.0143 -0.33 -0.21 Diastolic blood pressure; chr2:218628620 chr2:218633256~218634014:- LIHC cis rs617219 0.853 rs4704546 ENSG00000251675.1 CTC-458I2.2 4.01 7.31e-05 0.0143 0.23 0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79224908 chr5:80128361~80143883:+ LIHC cis rs2564921 0.73 rs6781896 ENSG00000242142.1 SERBP1P3 -4.01 7.32e-05 0.0143 -0.3 -0.21 Height; chr3:53047596 chr3:53064283~53065091:- LIHC cis rs17270561 0.609 rs1185976 ENSG00000216436.2 HIST1H2APS1 4.01 7.32e-05 0.0143 0.25 0.21 Iron status biomarkers; chr6:25822135 chr6:25732497~25732827:+ LIHC cis rs9906944 0.707 rs12942084 ENSG00000248278.1 SUMO2P17 -4.01 7.32e-05 0.0143 -0.35 -0.21 Intelligence (multi-trait analysis);Body fat percentage; chr17:49037030 chr17:48874860~48908983:- LIHC cis rs9906944 0.707 rs729003 ENSG00000248278.1 SUMO2P17 -4.01 7.32e-05 0.0143 -0.35 -0.21 Intelligence (multi-trait analysis);Body fat percentage; chr17:49040413 chr17:48874860~48908983:- LIHC cis rs3738443 1 rs56340510 ENSG00000259865.1 RP11-488L18.10 4.01 7.32e-05 0.0143 0.23 0.21 Alcohol dependence; chr1:247208707 chr1:247187281~247188526:- LIHC cis rs2564921 0.704 rs12053904 ENSG00000242142.1 SERBP1P3 -4.01 7.32e-05 0.0143 -0.28 -0.21 Height; chr3:52991821 chr3:53064283~53065091:- LIHC cis rs2564921 0.679 rs2115779 ENSG00000242142.1 SERBP1P3 -4.01 7.32e-05 0.0143 -0.28 -0.21 Height; chr3:52992698 chr3:53064283~53065091:- LIHC cis rs12681287 0.547 rs13261956 ENSG00000254088.1 SLC2A3P4 4.01 7.32e-05 0.0143 0.25 0.21 Caudate activity during reward; chr8:86466536 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs71502658 ENSG00000254088.1 SLC2A3P4 4.01 7.32e-05 0.0143 0.25 0.21 Caudate activity during reward; chr8:86466556 chr8:86503591~86505061:+ LIHC cis rs673078 0.66 rs7962185 ENSG00000275759.1 RP11-131L12.3 -4.01 7.32e-05 0.0143 -0.41 -0.21 Glucose homeostasis traits; chr12:118287842 chr12:118428281~118428870:+ LIHC cis rs6142102 0.602 rs1054534 ENSG00000275784.1 RP5-1125A11.6 -4.01 7.33e-05 0.0143 -0.23 -0.21 Skin pigmentation; chr20:34017521 chr20:33989480~33991818:- LIHC cis rs3015497 0.967 rs3015483 ENSG00000269906.1 RP11-248J18.2 4.01 7.33e-05 0.0143 0.27 0.21 Mean platelet volume; chr14:50670756 chr14:50662511~50663178:- LIHC cis rs12681287 0.605 rs2976181 ENSG00000254088.1 SLC2A3P4 4.01 7.33e-05 0.0143 0.25 0.21 Caudate activity during reward; chr8:86332241 chr8:86503591~86505061:+ LIHC cis rs12468226 0.872 rs1061157 ENSG00000272966.1 RP11-686O6.1 4.01 7.33e-05 0.0143 0.37 0.21 Urate levels; chr2:202556476 chr2:202336739~202337200:+ LIHC cis rs3091242 0.967 rs3091240 ENSG00000224183.1 SDHDP6 -4.01 7.34e-05 0.0143 -0.24 -0.21 Erythrocyte sedimentation rate; chr1:25350444 chr1:25294164~25294643:- LIHC cis rs4578769 0.918 rs4800138 ENSG00000266850.1 RP11-370A5.1 -4.01 7.34e-05 0.0143 -0.25 -0.21 Eosinophil percentage of white cells; chr18:22934334 chr18:22723491~22907721:- LIHC cis rs9595908 0.965 rs9595877 ENSG00000212293.1 SNORA16 4.01 7.34e-05 0.0143 0.25 0.21 Body mass index; chr13:32589512 chr13:32420390~32420516:- LIHC cis rs1005277 0.579 rs1740737 ENSG00000099251.13 HSD17B7P2 4.01 7.35e-05 0.0143 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38210437 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2749616 ENSG00000099251.13 HSD17B7P2 4.01 7.35e-05 0.0143 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38222065 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs1780146 ENSG00000099251.13 HSD17B7P2 4.01 7.35e-05 0.0143 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38228946 chr10:38356380~38378505:+ LIHC cis rs11651753 0.636 rs4793737 ENSG00000264920.1 RP11-6N17.4 -4.01 7.35e-05 0.0143 -0.22 -0.21 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47964891 chr17:47891255~47895812:- LIHC cis rs2243480 0.901 rs34807232 ENSG00000232546.1 RP11-458F8.1 -4.01 7.35e-05 0.0144 -0.24 -0.21 Diabetic kidney disease; chr7:66500146 chr7:66848496~66858136:+ LIHC cis rs2243480 0.901 rs35823062 ENSG00000232546.1 RP11-458F8.1 -4.01 7.35e-05 0.0144 -0.24 -0.21 Diabetic kidney disease; chr7:66500834 chr7:66848496~66858136:+ LIHC cis rs4682868 0.583 rs10865925 ENSG00000273328.4 RP11-141M3.6 4.01 7.35e-05 0.0144 0.22 0.21 Monocyte percentage of white cells; chr3:42872118 chr3:42809414~42908105:+ LIHC cis rs7726839 0.574 rs11134148 ENSG00000271781.1 CTD-2589H19.6 -4.01 7.35e-05 0.0144 -0.32 -0.21 Obesity-related traits; chr5:636992 chr5:675826~676616:+ LIHC cis rs4865169 0.934 rs12650737 ENSG00000269949.1 RP11-738E22.3 -4.01 7.35e-05 0.0144 -0.26 -0.21 Breast cancer; chr4:57026309 chr4:56960927~56961373:- LIHC cis rs9304742 0.573 rs10415950 ENSG00000213801.4 ZNF816-ZNF321P 4.01 7.35e-05 0.0144 0.22 0.21 Psoriasis; chr19:52961847 chr19:52927135~52942601:- LIHC cis rs9595908 0.733 rs9591282 ENSG00000212293.1 SNORA16 4.01 7.36e-05 0.0144 0.24 0.21 Body mass index; chr13:32725844 chr13:32420390~32420516:- LIHC cis rs7412746 0.611 rs3768018 ENSG00000231073.1 RP11-316M1.3 4.01 7.36e-05 0.0144 0.22 0.21 Melanoma; chr1:150751271 chr1:150973123~150975534:+ LIHC cis rs7809950 0.53 rs111865019 ENSG00000238832.1 snoU109 -4.01 7.36e-05 0.0144 -0.28 -0.21 Coronary artery disease; chr7:107171801 chr7:107603363~107603507:+ LIHC cis rs2243480 0.764 rs2460423 ENSG00000230295.1 RP11-458F8.2 -4.01 7.37e-05 0.0144 -0.22 -0.21 Diabetic kidney disease; chr7:66136229 chr7:66880708~66882981:+ LIHC cis rs2281636 0.723 rs11190246 ENSG00000233690.1 EBAG9P1 4.01 7.37e-05 0.0144 0.21 0.21 Obesity-related traits; chr10:99691854 chr10:99697407~99697949:- LIHC cis rs2281636 0.723 rs2150916 ENSG00000233690.1 EBAG9P1 4.01 7.37e-05 0.0144 0.21 0.21 Obesity-related traits; chr10:99692737 chr10:99697407~99697949:- LIHC cis rs2599510 0.783 rs2710630 ENSG00000276334.1 AL133243.1 -4.01 7.37e-05 0.0144 -0.24 -0.21 Interleukin-18 levels; chr2:32540930 chr2:32521927~32523547:+ LIHC cis rs9450351 0.744 rs9351072 ENSG00000203875.9 SNHG5 -4.01 7.37e-05 0.0144 -0.46 -0.21 Interferon gamma-induced protein 10 levels; chr6:85917611 chr6:85660950~85678736:- LIHC cis rs875971 0.545 rs1909508 ENSG00000224316.1 RP11-479O9.2 4.01 7.37e-05 0.0144 0.2 0.21 Aortic root size; chr7:66301366 chr7:65773620~65802067:+ LIHC cis rs6471393 0.964 rs2914940 ENSG00000253848.1 RP11-10N23.5 4.01 7.38e-05 0.0144 0.23 0.21 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93719598 chr8:93741193~93744534:+ LIHC cis rs72627509 0.523 rs9637714 ENSG00000269949.1 RP11-738E22.3 -4.01 7.38e-05 0.0144 -0.27 -0.21 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56865280 chr4:56960927~56961373:- LIHC cis rs673078 0.607 rs61943385 ENSG00000275759.1 RP11-131L12.3 -4.01 7.38e-05 0.0144 -0.42 -0.21 Glucose homeostasis traits; chr12:118370339 chr12:118428281~118428870:+ LIHC cis rs6048205 1 rs6048196 ENSG00000259974.2 LINC00261 -4.01 7.38e-05 0.0144 -0.32 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22565548 chr20:22547671~22578642:- LIHC cis rs9525927 0.553 rs2773283 ENSG00000230731.2 RP11-478K15.6 -4.01 7.38e-05 0.0144 -0.23 -0.21 Dupuytren's disease; chr13:44225727 chr13:44234118~44243192:- LIHC cis rs72675573 0.852 rs6681705 ENSG00000235612.1 RP1-158P9.1 -4.01 7.39e-05 0.0144 -0.28 -0.21 Monocyte count; chr1:56117306 chr1:56145721~56155224:+ LIHC cis rs9565309 0.579 rs12431286 ENSG00000274898.1 AC001226.7 -4.01 7.39e-05 0.0144 -0.37 -0.21 Morning vs. evening chronotype; chr13:77011297 chr13:77027944~77028482:+ LIHC cis rs9565309 0.579 rs75343734 ENSG00000274898.1 AC001226.7 -4.01 7.39e-05 0.0144 -0.37 -0.21 Morning vs. evening chronotype; chr13:77011857 chr13:77027944~77028482:+ LIHC cis rs9565309 0.579 rs79325097 ENSG00000274898.1 AC001226.7 -4.01 7.39e-05 0.0144 -0.37 -0.21 Morning vs. evening chronotype; chr13:77013105 chr13:77027944~77028482:+ LIHC cis rs9565309 0.579 rs76924563 ENSG00000274898.1 AC001226.7 -4.01 7.39e-05 0.0144 -0.37 -0.21 Morning vs. evening chronotype; chr13:77013814 chr13:77027944~77028482:+ LIHC cis rs9565309 0.579 rs75065210 ENSG00000274898.1 AC001226.7 -4.01 7.39e-05 0.0144 -0.37 -0.21 Morning vs. evening chronotype; chr13:77014356 chr13:77027944~77028482:+ LIHC cis rs9565309 0.579 rs76803135 ENSG00000274898.1 AC001226.7 -4.01 7.39e-05 0.0144 -0.37 -0.21 Morning vs. evening chronotype; chr13:77014444 chr13:77027944~77028482:+ LIHC cis rs3761847 0.5 rs10760132 ENSG00000226752.6 PSMD5-AS1 -4.01 7.39e-05 0.0144 -0.22 -0.21 Rheumatoid arthritis; chr9:120977715 chr9:120824828~120854385:+ LIHC cis rs673078 0.607 rs56157623 ENSG00000275759.1 RP11-131L12.3 -4.01 7.39e-05 0.0144 -0.42 -0.21 Glucose homeostasis traits; chr12:118388162 chr12:118428281~118428870:+ LIHC cis rs755249 0.567 rs60323161 ENSG00000182109.6 RP11-69E11.4 4.01 7.4e-05 0.0144 0.28 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39244787 chr1:39522280~39546187:- LIHC cis rs703842 1 rs3825079 ENSG00000270039.1 RP11-571M6.17 -4.01 7.4e-05 0.0144 -0.3 -0.21 Multiple sclerosis; chr12:57809571 chr12:57803838~57804415:+ LIHC cis rs17818399 0.788 rs17818315 ENSG00000279254.1 RP11-536C12.1 -4.01 7.4e-05 0.0144 -0.27 -0.21 Height; chr2:46591853 chr2:46668870~46670778:+ LIHC cis rs7734985 0.698 rs28757605 ENSG00000250551.1 RP11-254I22.1 4.01 7.4e-05 0.0144 0.24 0.21 IgG glycosylation; chr5:96179252 chr5:96050115~96215519:+ LIHC cis rs2439831 0.85 rs28413704 ENSG00000166763.7 STRCP1 4.01 7.4e-05 0.0144 0.33 0.21 Lung cancer in ever smokers; chr15:43856229 chr15:43699488~43718184:- LIHC cis rs453301 0.686 rs6601280 ENSG00000253426.4 RP11-10A14.4 4.01 7.4e-05 0.0144 0.33 0.21 Joint mobility (Beighton score); chr8:9051726 chr8:9151742~9168136:+ LIHC cis rs11098499 0.913 rs68128210 ENSG00000260091.1 RP11-33B1.4 -4.01 7.4e-05 0.0144 -0.15 -0.21 Corneal astigmatism; chr4:119216664 chr4:119409333~119410233:+ LIHC cis rs2281636 0.691 rs11190218 ENSG00000233690.1 EBAG9P1 4.01 7.4e-05 0.0144 0.22 0.21 Obesity-related traits; chr10:99650305 chr10:99697407~99697949:- LIHC cis rs683257 1 rs11758771 ENSG00000234147.1 RP3-460G2.2 -4.01 7.4e-05 0.0144 -0.39 -0.21 Facial emotion recognition (angry faces); chr6:140841644 chr6:140845958~140852924:- LIHC cis rs683257 1 rs72988196 ENSG00000234147.1 RP3-460G2.2 -4.01 7.4e-05 0.0144 -0.39 -0.21 Facial emotion recognition (angry faces); chr6:140841728 chr6:140845958~140852924:- LIHC cis rs2439831 0.85 rs7181039 ENSG00000166763.7 STRCP1 4.01 7.41e-05 0.0145 0.34 0.21 Lung cancer in ever smokers; chr15:43886914 chr15:43699488~43718184:- LIHC cis rs77972916 0.517 rs17406126 ENSG00000234936.1 AC010883.5 4.01 7.41e-05 0.0145 0.38 0.21 Granulocyte percentage of myeloid white cells; chr2:43319493 chr2:43229573~43233394:+ LIHC cis rs9896933 0.83 rs607544 ENSG00000263063.1 RP11-388C12.1 -4.01 7.41e-05 0.0145 -0.28 -0.21 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82810884 chr17:82713908~82716255:- LIHC cis rs11098499 0.913 rs56122576 ENSG00000260091.1 RP11-33B1.4 -4.01 7.41e-05 0.0145 -0.15 -0.21 Corneal astigmatism; chr4:119208181 chr4:119409333~119410233:+ LIHC cis rs11098499 0.913 rs13126596 ENSG00000260091.1 RP11-33B1.4 -4.01 7.41e-05 0.0145 -0.15 -0.21 Corneal astigmatism; chr4:119219574 chr4:119409333~119410233:+ LIHC cis rs73193808 0.639 rs2832242 ENSG00000212479.2 U3 4.01 7.41e-05 0.0145 0.25 0.21 Coronary artery disease; chr21:29179864 chr21:29180425~29180639:- LIHC cis rs4792901 0.765 rs12600416 ENSG00000267747.1 RP11-392O1.4 -4.01 7.41e-05 0.0145 -0.25 -0.21 Dupuytren's disease; chr17:43469190 chr17:43544785~43610338:+ LIHC cis rs2439831 1 rs2467743 ENSG00000166763.7 STRCP1 4.01 7.42e-05 0.0145 0.3 0.21 Lung cancer in ever smokers; chr15:43458148 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs2245176 ENSG00000166763.7 STRCP1 4.01 7.42e-05 0.0145 0.3 0.21 Lung cancer in ever smokers; chr15:43458564 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs2245054 ENSG00000166763.7 STRCP1 4.01 7.42e-05 0.0145 0.3 0.21 Lung cancer in ever smokers; chr15:43459711 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs2264876 ENSG00000166763.7 STRCP1 4.01 7.42e-05 0.0145 0.3 0.21 Lung cancer in ever smokers; chr15:43465221 chr15:43699488~43718184:- LIHC cis rs11096990 0.634 rs17754 ENSG00000249207.1 RP11-360F5.1 -4.01 7.43e-05 0.0145 -0.21 -0.21 Cognitive function; chr4:39287688 chr4:39112677~39126818:- LIHC cis rs193541 0.632 rs1903260 ENSG00000263432.2 RN7SL689P 4.01 7.43e-05 0.0145 0.34 0.21 Glucose homeostasis traits; chr5:122799493 chr5:123022487~123022783:- LIHC cis rs1061377 0.513 rs2566163 ENSG00000249685.1 RP11-360F5.3 4.01 7.43e-05 0.0145 0.32 0.21 Uric acid levels; chr4:39128345 chr4:39133913~39135608:+ LIHC cis rs853679 0.527 rs9461443 ENSG00000219392.1 RP1-265C24.5 -4.01 7.44e-05 0.0145 -0.31 -0.21 Depression; chr6:28226851 chr6:28115628~28116551:+ LIHC cis rs6445975 0.667 rs6772264 ENSG00000272360.1 RP11-359I18.5 -4.01 7.44e-05 0.0145 -0.25 -0.21 Systemic lupus erythematosus; chr3:58247214 chr3:58490830~58491291:- LIHC cis rs2312236 0.714 rs12566009 ENSG00000225171.2 DUTP6 -4.01 7.44e-05 0.0145 -0.28 -0.21 Post-traumatic stress disorder; chr1:166752048 chr1:166868748~166869209:+ LIHC cis rs2312236 0.714 rs12566727 ENSG00000225171.2 DUTP6 -4.01 7.44e-05 0.0145 -0.28 -0.21 Post-traumatic stress disorder; chr1:166753917 chr1:166868748~166869209:+ LIHC cis rs193541 0.586 rs11241662 ENSG00000263432.2 RN7SL689P -4.01 7.44e-05 0.0145 -0.34 -0.21 Glucose homeostasis traits; chr5:122846280 chr5:123022487~123022783:- LIHC cis rs2842992 0.724 rs4709368 ENSG00000237927.1 RP3-393E18.2 4.01 7.44e-05 0.0145 0.24 0.21 Age-related macular degeneration (geographic atrophy); chr6:159783095 chr6:159586955~159589169:- LIHC cis rs73193808 0.639 rs2832237 ENSG00000212479.2 U3 4.01 7.44e-05 0.0145 0.25 0.21 Coronary artery disease; chr21:29175362 chr21:29180425~29180639:- LIHC cis rs1799949 1 rs34942571 ENSG00000267681.1 CTD-3199J23.6 -4.01 7.45e-05 0.0145 -0.21 -0.21 Menopause (age at onset); chr17:43121362 chr17:43144956~43145255:+ LIHC cis rs9595908 0.785 rs9591261 ENSG00000212293.1 SNORA16 4.01 7.45e-05 0.0145 0.24 0.21 Body mass index; chr13:32710989 chr13:32420390~32420516:- LIHC cis rs1499614 1 rs1267818 ENSG00000228409.4 CCT6P1 4.01 7.45e-05 0.0145 0.23 0.21 Gout; chr7:66642037 chr7:65751142~65763354:+ LIHC cis rs1499614 1 rs2707832 ENSG00000275400.1 RP4-756H11.5 4.01 7.45e-05 0.0145 0.27 0.21 Gout; chr7:66671562 chr7:66553805~66554199:- LIHC cis rs763121 0.853 rs4821816 ENSG00000273076.1 RP3-508I15.22 4.01 7.45e-05 0.0145 0.24 0.21 Menopause (age at onset); chr22:38717129 chr22:38743495~38743910:+ LIHC cis rs4453827 1 rs35414202 ENSG00000271916.1 RP11-884K10.6 4.01 7.46e-05 0.0145 0.42 0.21 Blood protein levels; chr3:53712757 chr3:53797764~53798019:- LIHC cis rs7044106 0.762 rs4837790 ENSG00000238181.2 AHCYP2 -4.01 7.46e-05 0.0145 -0.24 -0.21 Hip circumference adjusted for BMI; chr9:120684047 chr9:120720673~120721972:+ LIHC cis rs801193 0.66 rs1962050 ENSG00000232559.3 GS1-124K5.12 -4.01 7.46e-05 0.0145 -0.16 -0.21 Aortic root size; chr7:66775021 chr7:66554588~66576923:- LIHC cis rs2439831 0.85 rs12442297 ENSG00000166763.7 STRCP1 4.01 7.46e-05 0.0145 0.34 0.21 Lung cancer in ever smokers; chr15:43876272 chr15:43699488~43718184:- LIHC cis rs2243480 1 rs4718317 ENSG00000232546.1 RP11-458F8.1 4.01 7.46e-05 0.0145 0.23 0.21 Diabetic kidney disease; chr7:66183914 chr7:66848496~66858136:+ LIHC cis rs2439831 0.702 rs9989313 ENSG00000166763.7 STRCP1 4.01 7.47e-05 0.0145 0.33 0.21 Lung cancer in ever smokers; chr15:43860619 chr15:43699488~43718184:- LIHC cis rs2036707 0.546 rs16971278 ENSG00000277246.1 RP11-153I24.4 -4.01 7.47e-05 0.0146 -0.43 -0.21 Obesity-related traits; chr13:107842631 chr13:108267320~108267734:+ LIHC cis rs17774123 0.851 rs79543293 ENSG00000257808.1 RP11-1136G11.8 4.01 7.47e-05 0.0146 0.39 0.21 Diastolic blood pressure; chr12:53899497 chr12:53159586~53161000:+ LIHC cis rs4713118 0.513 rs149989 ENSG00000216901.1 AL022393.7 4.01 7.47e-05 0.0146 0.28 0.21 Parkinson's disease; chr6:28030406 chr6:28176188~28176674:+ LIHC cis rs4713118 0.513 rs149941 ENSG00000216901.1 AL022393.7 4.01 7.47e-05 0.0146 0.28 0.21 Parkinson's disease; chr6:28033255 chr6:28176188~28176674:+ LIHC cis rs4713118 0.513 rs149942 ENSG00000216901.1 AL022393.7 4.01 7.47e-05 0.0146 0.28 0.21 Parkinson's disease; chr6:28033832 chr6:28176188~28176674:+ LIHC cis rs4713118 0.513 rs149944 ENSG00000216901.1 AL022393.7 4.01 7.47e-05 0.0146 0.28 0.21 Parkinson's disease; chr6:28035040 chr6:28176188~28176674:+ LIHC cis rs4713118 0.513 rs149945 ENSG00000216901.1 AL022393.7 4.01 7.47e-05 0.0146 0.28 0.21 Parkinson's disease; chr6:28035075 chr6:28176188~28176674:+ LIHC cis rs8177876 0.749 rs10459872 ENSG00000261061.1 RP11-303E16.2 4.01 7.47e-05 0.0146 0.3 0.21 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81061346 chr16:81030770~81031485:+ LIHC cis rs7945705 0.875 rs10769947 ENSG00000254860.4 TMEM9B-AS1 -4.01 7.49e-05 0.0146 -0.21 -0.21 Hemoglobin concentration; chr11:8736567 chr11:8964675~8977527:+ LIHC cis rs2581828 0.618 rs9838517 ENSG00000242142.1 SERBP1P3 -4.01 7.49e-05 0.0146 -0.28 -0.21 Crohn's disease; chr3:53110347 chr3:53064283~53065091:- LIHC cis rs7688540 0.723 rs7687112 ENSG00000275426.1 CH17-262A2.1 4.01 7.49e-05 0.0146 0.26 0.21 Facial morphology (factor 6, height of vermillion lower lip); chr4:249767 chr4:149738~150317:+ LIHC cis rs7809950 0.53 rs34021916 ENSG00000238832.1 snoU109 -4.01 7.49e-05 0.0146 -0.27 -0.21 Coronary artery disease; chr7:107177456 chr7:107603363~107603507:+ LIHC cis rs794185 0.625 rs1844123 ENSG00000231249.1 ITPR1-AS1 -4.01 7.49e-05 0.0146 -0.23 -0.21 Multiple sclerosis--Brain Glutamate Levels; chr3:4471177 chr3:4490891~4493163:- LIHC cis rs673078 0.66 rs61943524 ENSG00000275759.1 RP11-131L12.3 -4.01 7.49e-05 0.0146 -0.43 -0.21 Glucose homeostasis traits; chr12:118151530 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs17440315 ENSG00000275759.1 RP11-131L12.3 -4.01 7.49e-05 0.0146 -0.43 -0.21 Glucose homeostasis traits; chr12:118158819 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs73220119 ENSG00000275759.1 RP11-131L12.3 -4.01 7.49e-05 0.0146 -0.43 -0.21 Glucose homeostasis traits; chr12:118159864 chr12:118428281~118428870:+ LIHC cis rs287982 1 rs56154233 ENSG00000269973.1 RP11-95D17.1 -4.01 7.49e-05 0.0146 -0.2 -0.21 Nonsyndromic cleft lip with cleft palate; chr2:9829098 chr2:9936360~9939590:+ LIHC cis rs950169 0.922 rs4842939 ENSG00000225151.9 GOLGA2P7 4.01 7.49e-05 0.0146 0.26 0.21 Schizophrenia; chr15:84159214 chr15:84199311~84230136:- LIHC cis rs338389 0.521 rs8031161 ENSG00000260657.2 RP11-315D16.4 -4.01 7.49e-05 0.0146 -0.35 -0.21 Survival in rectal cancer; chr15:67990789 chr15:68267792~68277994:- LIHC cis rs3790268 0.53 rs3790261 ENSG00000273148.1 RP5-1068E13.7 4.01 7.5e-05 0.0146 0.21 0.21 Matrix metalloproteinase levels; chr20:19580020 chr20:18794529~18796067:+ LIHC cis rs3812762 0.833 rs10500705 ENSG00000254860.4 TMEM9B-AS1 4.01 7.5e-05 0.0146 0.24 0.21 Hypospadias; chr11:8783714 chr11:8964675~8977527:+ LIHC cis rs57502260 0.704 rs17149179 ENSG00000212093.1 AP000807.1 4.01 7.5e-05 0.0146 0.28 0.21 Total body bone mineral density (age 45-60); chr11:68584254 chr11:68506083~68506166:- LIHC cis rs7560272 0.512 rs12998980 ENSG00000204872.3 NAT8B -4.01 7.5e-05 0.0146 -0.29 -0.21 Schizophrenia; chr2:73703599 chr2:73700576~73701340:- LIHC cis rs73183643 0.666 rs2529196 ENSG00000239486.1 RP11-163E9.1 -4.01 7.51e-05 0.0146 -0.28 -0.21 Basal cell carcinoma; chr7:101759916 chr7:102380465~102382737:- LIHC cis rs1023500 0.956 rs1894713 ENSG00000237037.8 NDUFA6-AS1 -4.01 7.51e-05 0.0146 -0.29 -0.21 Schizophrenia; chr22:41939617 chr22:42090931~42137742:+ LIHC cis rs4713118 0.513 rs200971 ENSG00000216901.1 AL022393.7 4.01 7.51e-05 0.0146 0.27 0.21 Parkinson's disease; chr6:27891126 chr6:28176188~28176674:+ LIHC cis rs7208859 0.673 rs216411 ENSG00000266490.1 CTD-2349P21.9 -4.01 7.51e-05 0.0146 -0.26 -0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576475 chr17:30792372~30792833:+ LIHC cis rs2243480 1 rs160634 ENSG00000275400.1 RP4-756H11.5 -4.01 7.51e-05 0.0146 -0.27 -0.21 Diabetic kidney disease; chr7:66063677 chr7:66553805~66554199:- LIHC cis rs7709377 0.516 rs10519444 ENSG00000271918.1 CTD-2287O16.5 4.01 7.52e-05 0.0146 0.25 0.21 Metabolite levels (X-11787); chr5:116137726 chr5:116083807~116085416:- LIHC cis rs3204270 0.543 rs34034499 ENSG00000281517.1 Metazoa_SRP -4.01 7.52e-05 0.0146 -0.38 -0.21 Dental caries; chr17:81671538 chr17:81718849~81719095:- LIHC cis rs8060598 1 rs3135503 ENSG00000275155.1 CTD-2595P9.4 4.01 7.52e-05 0.0146 0.25 0.21 Leprosy; chr16:50757339 chr16:49847018~49847632:- LIHC cis rs2946504 0.501 rs2977092 ENSG00000251468.2 RP11-369K16.1 -4.01 7.52e-05 0.0146 -0.22 -0.21 Type 2 diabetes; chr8:12949867 chr8:12958387~12962200:+ LIHC cis rs1005277 0.529 rs1780125 ENSG00000120555.12 SEPT7P9 4.01 7.52e-05 0.0146 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38242448 chr10:38383069~38402916:- LIHC cis rs1005277 0.502 rs2800484 ENSG00000120555.12 SEPT7P9 4.01 7.52e-05 0.0146 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38253487 chr10:38383069~38402916:- LIHC cis rs1005277 0.579 rs2800485 ENSG00000120555.12 SEPT7P9 4.01 7.52e-05 0.0146 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38253660 chr10:38383069~38402916:- LIHC cis rs950776 0.518 rs4887063 ENSG00000261762.1 RP11-650L12.2 -4.01 7.52e-05 0.0146 -0.28 -0.21 Sudden cardiac arrest; chr15:78547373 chr15:78589123~78591276:- LIHC cis rs6504622 0.755 rs7219544 ENSG00000262879.4 RP11-156P1.3 -4.01 7.53e-05 0.0146 -0.22 -0.21 Orofacial clefts; chr17:47089562 chr17:46984045~47100323:- LIHC cis rs3733589 0.59 rs34707376 ENSG00000250413.1 RP11-448G15.1 4.01 7.53e-05 0.0147 0.37 0.21 Renal overload gout; chr4:9977277 chr4:10006482~10009725:+ LIHC cis rs875971 0.545 rs2707851 ENSG00000228409.4 CCT6P1 4.01 7.53e-05 0.0147 0.18 0.21 Aortic root size; chr7:66624178 chr7:65751142~65763354:+ LIHC cis rs6545883 0.56 rs11677776 ENSG00000271889.1 RP11-493E12.1 -4.01 7.53e-05 0.0147 -0.25 -0.21 Tuberculosis; chr2:61275978 chr2:61151433~61162105:- LIHC cis rs7250849 0.79 rs7259861 ENSG00000273837.1 LLNLR-470E3.1 -4.01 7.53e-05 0.0147 -0.45 -0.21 Blood protein levels; chr19:51657490 chr19:51639478~51639931:- LIHC cis rs7917772 0.503 rs7899576 ENSG00000236937.2 PTGES3P4 -4.01 7.53e-05 0.0147 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102547747 chr10:102845595~102845950:+ LIHC cis rs4356203 0.87 rs7935219 ENSG00000260196.1 RP1-239B22.5 4.01 7.53e-05 0.0147 0.25 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17146640 chr11:17380649~17383531:+ LIHC cis rs7826238 0.566 rs2945886 ENSG00000173295.6 FAM86B3P 4.01 7.53e-05 0.0147 0.26 0.21 Systolic blood pressure; chr8:8290748 chr8:8228595~8244865:+ LIHC cis rs9595908 0.63 rs4057297 ENSG00000212293.1 SNORA16 4.01 7.54e-05 0.0147 0.25 0.21 Body mass index; chr13:32731612 chr13:32420390~32420516:- LIHC cis rs673078 0.66 rs76842574 ENSG00000275409.1 RP11-131L12.4 -4.01 7.54e-05 0.0147 -0.25 -0.21 Glucose homeostasis traits; chr12:118371789 chr12:118430147~118430699:+ LIHC cis rs2834188 0.924 rs6517159 ENSG00000272659.1 AP000295.10 -4.01 7.54e-05 0.0147 -0.31 -0.21 Narcolepsy; chr21:33301095 chr21:33309491~33310181:+ LIHC cis rs2243480 0.708 rs13242216 ENSG00000228409.4 CCT6P1 4.01 7.54e-05 0.0147 0.23 0.21 Diabetic kidney disease; chr7:66433290 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs67536397 ENSG00000228409.4 CCT6P1 4.01 7.54e-05 0.0147 0.23 0.21 Diabetic kidney disease; chr7:66482930 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs58669269 ENSG00000228409.4 CCT6P1 4.01 7.54e-05 0.0147 0.23 0.21 Diabetic kidney disease; chr7:66486966 chr7:65751142~65763354:+ LIHC cis rs673078 0.615 rs61943528 ENSG00000275759.1 RP11-131L12.3 -4.01 7.54e-05 0.0147 -0.43 -0.21 Glucose homeostasis traits; chr12:118163134 chr12:118428281~118428870:+ LIHC cis rs17270561 0.636 rs9393671 ENSG00000216436.2 HIST1H2APS1 4.01 7.54e-05 0.0147 0.26 0.21 Iron status biomarkers; chr6:25788961 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs1179086 ENSG00000216436.2 HIST1H2APS1 -4.01 7.54e-05 0.0147 -0.26 -0.21 Iron status biomarkers; chr6:25791517 chr6:25732497~25732827:+ LIHC cis rs17270561 0.636 rs1165157 ENSG00000216436.2 HIST1H2APS1 -4.01 7.54e-05 0.0147 -0.26 -0.21 Iron status biomarkers; chr6:25792022 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs1165156 ENSG00000216436.2 HIST1H2APS1 -4.01 7.54e-05 0.0147 -0.26 -0.21 Iron status biomarkers; chr6:25792750 chr6:25732497~25732827:+ LIHC cis rs17270561 0.609 rs1165155 ENSG00000216436.2 HIST1H2APS1 -4.01 7.54e-05 0.0147 -0.26 -0.21 Iron status biomarkers; chr6:25795349 chr6:25732497~25732827:+ LIHC cis rs1799949 1 rs8176242 ENSG00000267681.1 CTD-3199J23.6 -4.01 7.54e-05 0.0147 -0.21 -0.21 Menopause (age at onset); chr17:43065857 chr17:43144956~43145255:+ LIHC cis rs7617773 0.817 rs9830016 ENSG00000228638.1 FCF1P2 -4.01 7.55e-05 0.0147 -0.23 -0.21 Coronary artery disease; chr3:48241004 chr3:48290793~48291375:- LIHC cis rs1005277 0.579 rs2472173 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38085710 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2472174 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38086454 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474563 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38087010 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs9418322 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38088368 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs9299760 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38088992 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2023351 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38089886 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474567 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38093564 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2472175 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38093973 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2472176 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38093993 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2983343 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38094404 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474569 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38094563 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2504143 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38094778 chr10:38451030~38451785:+ LIHC cis rs1005277 0.602 rs2504142 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38094865 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474571 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38095711 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2472181 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38097836 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474574 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38098367 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2504140 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38098651 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474575 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38098973 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2472182 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38099937 chr10:38451030~38451785:+ LIHC cis rs1005277 0.541 rs2263163 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38100959 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2021649 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38103194 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2505197 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38104382 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2505196 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38104635 chr10:38451030~38451785:+ LIHC cis rs1005277 0.541 rs2505193 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38105710 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474580 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38109785 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2504148 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38111860 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs176886 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38115046 chr10:38451030~38451785:+ LIHC cis rs1005277 0.557 rs176887 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38117166 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474594 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38137733 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs11011461 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38142499 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs1985707 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38145170 chr10:38451030~38451785:+ LIHC cis rs1005277 0.557 rs1854563 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38146033 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2505237 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38149970 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474599 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38150011 chr10:38451030~38451785:+ LIHC cis rs1005277 0.54 rs2224248 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38162958 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474608 ENSG00000276805.1 RP11-291L22.6 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38168181 chr10:38451030~38451785:+ LIHC cis rs1075265 0.704 rs10181999 ENSG00000272156.1 RP11-477N3.1 -4.01 7.55e-05 0.0147 -0.24 -0.21 Chronotype;Morning vs. evening chronotype; chr2:54025360 chr2:54082554~54085066:+ LIHC cis rs1005277 0.557 rs2983338 ENSG00000120555.12 SEPT7P9 4.01 7.55e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38261806 chr10:38383069~38402916:- LIHC cis rs1023500 1 rs7293091 ENSG00000237037.8 NDUFA6-AS1 -4.01 7.55e-05 0.0147 -0.29 -0.21 Schizophrenia; chr22:41945304 chr22:42090931~42137742:+ LIHC cis rs1005277 0.579 rs2474584 ENSG00000276805.1 RP11-291L22.6 4.01 7.56e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38127461 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs1548255 ENSG00000276805.1 RP11-291L22.6 4.01 7.56e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38128265 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474586 ENSG00000276805.1 RP11-291L22.6 4.01 7.56e-05 0.0147 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38129954 chr10:38451030~38451785:+ LIHC cis rs904251 1 rs12212090 ENSG00000204110.6 RP1-153P14.8 -4.01 7.56e-05 0.0147 -0.25 -0.21 Cognitive performance; chr6:37464032 chr6:37507348~37535616:+ LIHC cis rs11098499 0.955 rs1511019 ENSG00000260091.1 RP11-33B1.4 -4.01 7.56e-05 0.0147 -0.16 -0.21 Corneal astigmatism; chr4:119244852 chr4:119409333~119410233:+ LIHC cis rs11098499 0.698 rs4422403 ENSG00000260091.1 RP11-33B1.4 -4.01 7.56e-05 0.0147 -0.14 -0.21 Corneal astigmatism; chr4:119337039 chr4:119409333~119410233:+ LIHC cis rs2564921 0.73 rs2564922 ENSG00000242142.1 SERBP1P3 4.01 7.56e-05 0.0147 0.28 0.21 Height; chr3:53091453 chr3:53064283~53065091:- LIHC cis rs6832769 1 rs6824057 ENSG00000272969.1 RP11-528I4.2 4.01 7.56e-05 0.0147 0.25 0.21 Personality dimensions; chr4:55501111 chr4:55547112~55547889:+ LIHC cis rs6832769 1 rs12646078 ENSG00000272969.1 RP11-528I4.2 4.01 7.56e-05 0.0147 0.25 0.21 Personality dimensions; chr4:55502037 chr4:55547112~55547889:+ LIHC cis rs6832769 1 rs6837710 ENSG00000272969.1 RP11-528I4.2 4.01 7.56e-05 0.0147 0.25 0.21 Personality dimensions; chr4:55508288 chr4:55547112~55547889:+ LIHC cis rs1816213 0.744 rs35255403 ENSG00000273466.1 RP11-548H3.1 -4.01 7.57e-05 0.0147 -0.33 -0.21 Diastolic blood pressure; chr2:218632556 chr2:218633256~218634014:- LIHC cis rs1005277 0.505 rs10827836 ENSG00000275858.1 RP11-291L22.8 -4.01 7.57e-05 0.0147 -0.23 -0.21 Extrinsic epigenetic age acceleration; chr10:37926513 chr10:38450738~38451069:- LIHC cis rs7849270 0.76 rs1075650 ENSG00000268707.1 RP11-247A12.7 4.01 7.57e-05 0.0147 0.26 0.21 Blood metabolite ratios; chr9:129176634 chr9:129170434~129170940:+ LIHC cis rs11096990 0.634 rs3733281 ENSG00000249207.1 RP11-360F5.1 4.01 7.57e-05 0.0147 0.21 0.21 Cognitive function; chr4:39270293 chr4:39112677~39126818:- LIHC cis rs2299116 0.789 rs62442203 ENSG00000225264.3 ZNRF2P2 -4.01 7.57e-05 0.0147 -0.23 -0.21 Serum thyroid-stimulating hormone levels; chr7:28789636 chr7:29598795~29685255:- LIHC cis rs6496667 0.533 rs7173201 ENSG00000213471.7 TTLL13P 4.01 7.58e-05 0.0147 0.28 0.21 Rheumatoid arthritis; chr15:90447963 chr15:90249530~90265482:+ LIHC cis rs6496667 0.533 rs7172909 ENSG00000213471.7 TTLL13P 4.01 7.58e-05 0.0147 0.28 0.21 Rheumatoid arthritis; chr15:90448184 chr15:90249530~90265482:+ LIHC cis rs67311347 1 rs1119179 ENSG00000223797.4 ENTPD3-AS1 -4.01 7.58e-05 0.0147 -0.17 -0.21 Renal cell carcinoma; chr3:40383438 chr3:40313802~40453329:- LIHC cis rs10510102 0.872 rs12248004 ENSG00000273891.1 RP11-500G22.5 4.01 7.58e-05 0.0147 0.3 0.21 Breast cancer; chr10:121972215 chr10:121965764~121967700:+ LIHC cis rs4561483 0.801 rs33623 ENSG00000261560.1 RP11-166B2.3 4.01 7.58e-05 0.0147 0.24 0.21 Testicular germ cell tumor; chr16:11913578 chr16:11881075~11882569:- LIHC cis rs1928295 0.786 rs10759926 ENSG00000233569.1 RP11-500B12.1 4.01 7.58e-05 0.0147 0.22 0.21 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117603947 chr9:117648606~117657027:+ LIHC cis rs16958440 0.737 rs16950096 ENSG00000267724.1 RP11-49K24.8 4.01 7.58e-05 0.0147 0.45 0.21 Sitting height ratio; chr18:47219175 chr18:47105946~47108062:+ LIHC cis rs12681287 0.64 rs72606633 ENSG00000254088.1 SLC2A3P4 4.01 7.59e-05 0.0147 0.25 0.21 Caudate activity during reward; chr8:86464007 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs61106663 ENSG00000254088.1 SLC2A3P4 4.01 7.59e-05 0.0147 0.25 0.21 Caudate activity during reward; chr8:86464852 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs13252046 ENSG00000254088.1 SLC2A3P4 4.01 7.59e-05 0.0147 0.25 0.21 Caudate activity during reward; chr8:86465522 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs13261901 ENSG00000254088.1 SLC2A3P4 4.01 7.59e-05 0.0147 0.25 0.21 Caudate activity during reward; chr8:86466488 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs7017706 ENSG00000254088.1 SLC2A3P4 4.01 7.59e-05 0.0147 0.25 0.21 Caudate activity during reward; chr8:86468661 chr8:86503591~86505061:+ LIHC cis rs12681287 0.608 rs13272148 ENSG00000254088.1 SLC2A3P4 4.01 7.59e-05 0.0147 0.25 0.21 Caudate activity during reward; chr8:86469624 chr8:86503591~86505061:+ LIHC cis rs12681287 0.608 rs1135451 ENSG00000254088.1 SLC2A3P4 4.01 7.59e-05 0.0147 0.25 0.21 Caudate activity during reward; chr8:86471379 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs13260345 ENSG00000254088.1 SLC2A3P4 4.01 7.59e-05 0.0147 0.25 0.21 Caudate activity during reward; chr8:86471492 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs13282351 ENSG00000254088.1 SLC2A3P4 4.01 7.59e-05 0.0147 0.25 0.21 Caudate activity during reward; chr8:86472440 chr8:86503591~86505061:+ LIHC cis rs11637445 0.677 rs3784716 ENSG00000260657.2 RP11-315D16.4 -4.01 7.59e-05 0.0147 -0.29 -0.21 Posterior cortical atrophy and Alzheimer's disease; chr15:67792112 chr15:68267792~68277994:- LIHC cis rs4713118 0.513 rs149897 ENSG00000216901.1 AL022393.7 4.01 7.6e-05 0.0148 0.28 0.21 Parkinson's disease; chr6:28038872 chr6:28176188~28176674:+ LIHC cis rs4713118 0.513 rs156734 ENSG00000216901.1 AL022393.7 4.01 7.6e-05 0.0148 0.28 0.21 Parkinson's disease; chr6:28039579 chr6:28176188~28176674:+ LIHC cis rs4718428 0.924 rs6971897 ENSG00000273142.1 RP11-458F8.4 -4.01 7.6e-05 0.0148 -0.22 -0.21 Corneal structure; chr7:66947787 chr7:66902857~66906297:+ LIHC cis rs1005277 0.54 rs289638 ENSG00000275858.1 RP11-291L22.8 4.01 7.6e-05 0.0148 0.23 0.21 Extrinsic epigenetic age acceleration; chr10:37634803 chr10:38450738~38451069:- LIHC cis rs1005277 0.54 rs7903942 ENSG00000275858.1 RP11-291L22.8 -4.01 7.6e-05 0.0148 -0.23 -0.21 Extrinsic epigenetic age acceleration; chr10:37640348 chr10:38450738~38451069:- LIHC cis rs2564921 0.704 rs55950520 ENSG00000242142.1 SERBP1P3 -4.01 7.6e-05 0.0148 -0.29 -0.21 Height; chr3:53094335 chr3:53064283~53065091:- LIHC cis rs11098499 0.866 rs12501602 ENSG00000245958.5 RP11-33B1.1 -4.01 7.6e-05 0.0148 -0.22 -0.21 Corneal astigmatism; chr4:119366780 chr4:119454791~119552025:+ LIHC cis rs34421088 0.576 rs2572437 ENSG00000255495.1 AC145124.2 -4.01 7.61e-05 0.0148 -0.29 -0.21 Neuroticism; chr8:11240932 chr8:12194467~12196280:+ LIHC cis rs950880 0.71 rs1474309 ENSG00000234389.1 AC007278.3 -4.01 7.61e-05 0.0148 -0.21 -0.21 Serum protein levels (sST2); chr2:102474542 chr2:102438713~102440475:+ LIHC cis rs4356203 0.905 rs7123301 ENSG00000260196.1 RP1-239B22.5 -4.01 7.61e-05 0.0148 -0.25 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17141880 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs512852 ENSG00000260196.1 RP1-239B22.5 -4.01 7.61e-05 0.0148 -0.25 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17193382 chr11:17380649~17383531:+ LIHC cis rs2243480 0.908 rs2460431 ENSG00000230295.1 RP11-458F8.2 4.01 7.61e-05 0.0148 0.22 0.21 Diabetic kidney disease; chr7:66157859 chr7:66880708~66882981:+ LIHC cis rs2243480 0.711 rs2460426 ENSG00000230295.1 RP11-458F8.2 4.01 7.61e-05 0.0148 0.22 0.21 Diabetic kidney disease; chr7:66158142 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs4718309 ENSG00000230295.1 RP11-458F8.2 4.01 7.61e-05 0.0148 0.22 0.21 Diabetic kidney disease; chr7:66162777 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs6460274 ENSG00000230295.1 RP11-458F8.2 4.01 7.61e-05 0.0148 0.22 0.21 Diabetic kidney disease; chr7:66163497 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs7787230 ENSG00000230295.1 RP11-458F8.2 4.01 7.61e-05 0.0148 0.22 0.21 Diabetic kidney disease; chr7:66164112 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs316317 ENSG00000230295.1 RP11-458F8.2 -4.01 7.61e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66148650 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs316304 ENSG00000230295.1 RP11-458F8.2 -4.01 7.61e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66151907 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs2465120 ENSG00000230295.1 RP11-458F8.2 -4.01 7.61e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66155987 chr7:66880708~66882981:+ LIHC cis rs17772222 0.917 rs61984736 ENSG00000258789.1 RP11-507K2.3 -4 7.61e-05 0.0148 -0.27 -0.21 Coronary artery calcification; chr14:88626359 chr14:88551597~88552493:+ LIHC cis rs2396442 1 rs4711816 ENSG00000231769.2 RP1-8B1.4 4 7.62e-05 0.0148 0.26 0.21 Left ventricle wall thickness; chr6:45482473 chr6:46097093~46129706:- LIHC cis rs10857712 0.95 rs7906765 ENSG00000214279.11 SCART1 -4 7.62e-05 0.0148 -0.26 -0.21 Systemic lupus erythematosus; chr10:133411956 chr10:133453928~133523558:+ LIHC cis rs748404 0.587 rs9920879 ENSG00000166763.7 STRCP1 4 7.62e-05 0.0148 0.26 0.21 Lung cancer; chr15:43347572 chr15:43699488~43718184:- LIHC cis rs748404 0.631 rs7166812 ENSG00000166763.7 STRCP1 4 7.62e-05 0.0148 0.26 0.21 Lung cancer; chr15:43352562 chr15:43699488~43718184:- LIHC cis rs748404 0.631 rs1133395 ENSG00000166763.7 STRCP1 4 7.62e-05 0.0148 0.26 0.21 Lung cancer; chr15:43358186 chr15:43699488~43718184:- LIHC cis rs481331 0.689 rs210220 ENSG00000185904.10 LINC00839 -4 7.62e-05 0.0148 -0.4 -0.21 Systemic juvenile idiopathic arthritis; chr10:42560213 chr10:42475543~42495336:+ LIHC cis rs1005277 0.579 rs2474568 ENSG00000276805.1 RP11-291L22.6 4 7.63e-05 0.0148 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38094219 chr10:38451030~38451785:+ LIHC cis rs1005277 0.54 rs1814077 ENSG00000275858.1 RP11-291L22.8 4 7.63e-05 0.0148 0.23 0.21 Extrinsic epigenetic age acceleration; chr10:37703090 chr10:38450738~38451069:- LIHC cis rs4792901 0.802 rs2271958 ENSG00000267747.1 RP11-392O1.4 -4 7.63e-05 0.0148 -0.25 -0.21 Dupuytren's disease; chr17:43522015 chr17:43544785~43610338:+ LIHC cis rs10912872 0.672 rs1018392 ENSG00000231424.2 RP1-45C12.1 4 7.63e-05 0.0148 0.22 0.21 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr1:171384725 chr1:171247580~171251794:- LIHC cis rs11686241 0.872 rs284525 ENSG00000241520.1 AC098820.4 -4 7.63e-05 0.0148 -0.25 -0.21 Cancer; chr2:216473196 chr2:216483032~216487196:- LIHC cis rs472265 0.512 rs62119547 ENSG00000269688.1 AC008982.2 4 7.64e-05 0.0148 0.23 0.21 Type 2 diabetes; chr19:39076050 chr19:38844729~38845499:- LIHC cis rs673078 0.615 rs56324376 ENSG00000275409.1 RP11-131L12.4 -4 7.64e-05 0.0148 -0.25 -0.21 Glucose homeostasis traits; chr12:118372134 chr12:118430147~118430699:+ LIHC cis rs2243480 1 rs316313 ENSG00000230295.1 RP11-458F8.2 -4 7.64e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66128561 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs316312 ENSG00000230295.1 RP11-458F8.2 -4 7.64e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66131504 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs419603 ENSG00000230295.1 RP11-458F8.2 -4 7.64e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66132354 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs431076 ENSG00000230295.1 RP11-458F8.2 -4 7.64e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66135333 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs2460422 ENSG00000230295.1 RP11-458F8.2 -4 7.64e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66136518 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs316334 ENSG00000230295.1 RP11-458F8.2 -4 7.64e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66137139 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs316330 ENSG00000230295.1 RP11-458F8.2 -4 7.64e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66140385 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs316326 ENSG00000230295.1 RP11-458F8.2 -4 7.64e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66144466 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs316325 ENSG00000230295.1 RP11-458F8.2 -4 7.64e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66144531 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs316321 ENSG00000230295.1 RP11-458F8.2 -4 7.64e-05 0.0148 -0.22 -0.21 Diabetic kidney disease; chr7:66146626 chr7:66880708~66882981:+ LIHC cis rs763121 0.889 rs4820335 ENSG00000273076.1 RP3-508I15.22 -4 7.64e-05 0.0148 -0.23 -0.21 Menopause (age at onset); chr22:38539922 chr22:38743495~38743910:+ LIHC cis rs948562 0.947 rs73470778 ENSG00000280010.1 AP001350.4 4 7.64e-05 0.0148 0.38 0.21 Lymphoma; chr11:58650594 chr11:58627435~58628528:+ LIHC cis rs57502260 0.573 rs11228295 ENSG00000212093.1 AP000807.1 4 7.64e-05 0.0148 0.24 0.21 Total body bone mineral density (age 45-60); chr11:68621120 chr11:68506083~68506166:- LIHC cis rs113084984 0.718 rs4669746 ENSG00000271952.1 RP11-245G13.2 -4 7.64e-05 0.0148 -0.26 -0.21 Breast cancer; chr2:11541892 chr2:10878269~10885118:+ LIHC cis rs7849270 0.879 rs10760587 ENSG00000268707.1 RP11-247A12.7 4 7.64e-05 0.0148 0.23 0.21 Blood metabolite ratios; chr9:129083737 chr9:129170434~129170940:+ LIHC cis rs7617773 0.779 rs9833309 ENSG00000228638.1 FCF1P2 -4 7.65e-05 0.0148 -0.24 -0.21 Coronary artery disease; chr3:48285960 chr3:48290793~48291375:- LIHC cis rs7617773 0.817 rs9853804 ENSG00000228638.1 FCF1P2 -4 7.65e-05 0.0148 -0.24 -0.21 Coronary artery disease; chr3:48286239 chr3:48290793~48291375:- LIHC cis rs7617773 0.817 rs9834095 ENSG00000228638.1 FCF1P2 -4 7.65e-05 0.0148 -0.24 -0.21 Coronary artery disease; chr3:48286261 chr3:48290793~48291375:- LIHC cis rs875971 0.54 rs4717275 ENSG00000273024.4 INTS4P2 4 7.65e-05 0.0148 0.25 0.21 Aortic root size; chr7:65800193 chr7:65647864~65715661:+ LIHC cis rs7849270 0.801 rs10819475 ENSG00000268707.1 RP11-247A12.7 4 7.65e-05 0.0148 0.25 0.21 Blood metabolite ratios; chr9:129168561 chr9:129170434~129170940:+ LIHC cis rs7849270 0.76 rs419636 ENSG00000268707.1 RP11-247A12.7 4 7.65e-05 0.0148 0.25 0.21 Blood metabolite ratios; chr9:129168998 chr9:129170434~129170940:+ LIHC cis rs2072438 0.505 rs7034074 ENSG00000226752.6 PSMD5-AS1 -4 7.65e-05 0.0148 -0.22 -0.21 Rheumatoid arthritis; chr9:121160751 chr9:120824828~120854385:+ LIHC cis rs703842 0.964 rs2014886 ENSG00000270039.1 RP11-571M6.17 -4 7.66e-05 0.0149 -0.3 -0.21 Multiple sclerosis; chr12:57783654 chr12:57803838~57804415:+ LIHC cis rs703842 1 rs1599932 ENSG00000270039.1 RP11-571M6.17 -4 7.66e-05 0.0149 -0.3 -0.21 Multiple sclerosis; chr12:57784160 chr12:57803838~57804415:+ LIHC cis rs703842 1 rs11172342 ENSG00000270039.1 RP11-571M6.17 -4 7.66e-05 0.0149 -0.3 -0.21 Multiple sclerosis; chr12:57793975 chr12:57803838~57804415:+ LIHC cis rs703842 1 rs11172343 ENSG00000270039.1 RP11-571M6.17 -4 7.66e-05 0.0149 -0.3 -0.21 Multiple sclerosis; chr12:57794374 chr12:57803838~57804415:+ LIHC cis rs703842 1 rs1875124 ENSG00000270039.1 RP11-571M6.17 -4 7.66e-05 0.0149 -0.3 -0.21 Multiple sclerosis; chr12:57803019 chr12:57803838~57804415:+ LIHC cis rs6445975 0.639 rs2037125 ENSG00000272360.1 RP11-359I18.5 -4 7.66e-05 0.0149 -0.25 -0.21 Systemic lupus erythematosus; chr3:58255504 chr3:58490830~58491291:- LIHC cis rs4578769 0.531 rs9957103 ENSG00000266850.1 RP11-370A5.1 4 7.66e-05 0.0149 0.23 0.21 Eosinophil percentage of white cells; chr18:22870172 chr18:22723491~22907721:- LIHC cis rs2243480 0.615 rs34363376 ENSG00000230295.1 RP11-458F8.2 -4 7.66e-05 0.0149 -0.23 -0.21 Diabetic kidney disease; chr7:66474549 chr7:66880708~66882981:+ LIHC cis rs4578769 0.765 rs11082172 ENSG00000266850.1 RP11-370A5.1 -4 7.67e-05 0.0149 -0.25 -0.21 Eosinophil percentage of white cells; chr18:22857866 chr18:22723491~22907721:- LIHC cis rs10510102 0.872 rs7906271 ENSG00000273891.1 RP11-500G22.5 -4 7.67e-05 0.0149 -0.27 -0.21 Breast cancer; chr10:121948207 chr10:121965764~121967700:+ LIHC cis rs3761847 0.593 rs10985140 ENSG00000226752.6 PSMD5-AS1 -4 7.67e-05 0.0149 -0.22 -0.21 Rheumatoid arthritis; chr9:121060559 chr9:120824828~120854385:+ LIHC cis rs7474896 0.616 rs2474561 ENSG00000276805.1 RP11-291L22.6 4 7.67e-05 0.0149 0.3 0.21 Obesity (extreme); chr10:38084616 chr10:38451030~38451785:+ LIHC cis rs10461617 0.541 rs7715822 ENSG00000271828.1 CTD-2310F14.1 4 7.67e-05 0.0149 0.41 0.21 Type 2 diabetes; chr5:56747773 chr5:56927874~56929573:+ LIHC cis rs4218 0.734 rs12912071 ENSG00000277144.1 RP11-59H7.4 -4 7.67e-05 0.0149 -0.23 -0.21 Social communication problems; chr15:59150951 chr15:59115547~59116089:- LIHC cis rs7429990 0.864 rs1464614 ENSG00000229759.1 MRPS18AP1 4 7.68e-05 0.0149 0.22 0.21 Educational attainment (years of education); chr3:47612885 chr3:48256350~48256938:- LIHC cis rs875971 0.545 rs2420612 ENSG00000273024.4 INTS4P2 -4 7.68e-05 0.0149 -0.24 -0.21 Aortic root size; chr7:66536825 chr7:65647864~65715661:+ LIHC cis rs1005277 0.54 rs1814077 ENSG00000276805.1 RP11-291L22.6 4 7.68e-05 0.0149 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37703090 chr10:38451030~38451785:+ LIHC cis rs4578769 0.959 rs3863525 ENSG00000266850.1 RP11-370A5.1 4 7.68e-05 0.0149 0.25 0.21 Eosinophil percentage of white cells; chr18:22898714 chr18:22723491~22907721:- LIHC cis rs2834188 0.737 rs2834179 ENSG00000272659.1 AP000295.10 -4 7.69e-05 0.0149 -0.31 -0.21 Narcolepsy; chr21:33307426 chr21:33309491~33310181:+ LIHC cis rs9896933 0.83 rs113051447 ENSG00000263063.1 RP11-388C12.1 -4 7.69e-05 0.0149 -0.28 -0.21 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82833930 chr17:82713908~82716255:- LIHC cis rs2120243 0.647 rs7632702 ENSG00000244515.1 KRT18P34 -4 7.69e-05 0.0149 -0.2 -0.21 Hepatocellular carcinoma in hepatitis B infection; chr3:157428114 chr3:157162663~157163932:- LIHC cis rs1318937 1 rs8225 ENSG00000224660.1 SH3BP5-AS1 4 7.69e-05 0.0149 0.19 0.21 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15264363 chr3:15254184~15264493:+ LIHC cis rs6472235 0.656 rs11987304 ENSG00000272010.1 CTD-3025N20.3 -4 7.69e-05 0.0149 -0.3 -0.21 Plateletcrit;Myopia (pathological); chr8:65957778 chr8:65591850~65592472:- LIHC cis rs17482078 0.959 rs71630754 ENSG00000248734.2 CTD-2260A17.1 4 7.7e-05 0.0149 0.3 0.21 Behcet's disease;Blood protein levels; chr5:96791235 chr5:96784777~96785999:+ LIHC cis rs42490 0.576 rs432457 ENSG00000251136.7 RP11-37B2.1 -4 7.7e-05 0.0149 -0.19 -0.21 Leprosy; chr8:89853680 chr8:89609409~89757727:- LIHC cis rs17508449 0.819 rs17031795 ENSG00000232450.1 RP4-730K3.3 -4 7.7e-05 0.0149 -0.28 -0.21 Leprosy; chr1:113713206 chr1:113698884~113699631:- LIHC cis rs7811142 1 rs73161762 ENSG00000242294.5 STAG3L5P 4 7.7e-05 0.0149 0.25 0.21 Platelet count; chr7:100417223 chr7:100336079~100351900:+ LIHC cis rs2243480 1 rs160634 ENSG00000232559.3 GS1-124K5.12 -4 7.7e-05 0.0149 -0.21 -0.21 Diabetic kidney disease; chr7:66063677 chr7:66554588~66576923:- LIHC cis rs2276314 1 rs1789513 ENSG00000278986.1 RP11-723J4.3 4 7.71e-05 0.0149 0.26 0.21 Endometriosis;Drug-induced torsades de pointes; chr18:35965667 chr18:35972151~35973916:+ LIHC cis rs1799949 1 rs4793212 ENSG00000267681.1 CTD-3199J23.6 -4 7.71e-05 0.0149 -0.21 -0.21 Menopause (age at onset); chr17:43150733 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs34534709 ENSG00000267681.1 CTD-3199J23.6 -4 7.71e-05 0.0149 -0.21 -0.21 Menopause (age at onset); chr17:43150923 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs34059614 ENSG00000267681.1 CTD-3199J23.6 -4 7.71e-05 0.0149 -0.21 -0.21 Menopause (age at onset); chr17:43151054 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs1973646 ENSG00000267681.1 CTD-3199J23.6 -4 7.71e-05 0.0149 -0.21 -0.21 Menopause (age at onset); chr17:43158478 chr17:43144956~43145255:+ LIHC cis rs6860806 0.507 rs2631362 ENSG00000263597.1 MIR3936 -4 7.71e-05 0.0149 -0.23 -0.21 Breast cancer; chr5:132371601 chr5:132365490~132365599:- LIHC cis rs7809950 0.599 rs2237658 ENSG00000238832.1 snoU109 -4 7.72e-05 0.0149 -0.27 -0.21 Coronary artery disease; chr7:107197421 chr7:107603363~107603507:+ LIHC cis rs7937890 1 rs7937890 ENSG00000251991.1 RNU7-49P 4 7.72e-05 0.0149 0.22 0.21 Mitochondrial DNA levels; chr11:14374939 chr11:14478892~14478953:+ LIHC cis rs17464492 0.593 rs13262406 ENSG00000246228.5 CASC8 4 7.72e-05 0.0149 0.24 0.21 Prostate-specific antigen levels (conditioned on lead SNPs); chr8:127341494 chr8:127289817~127482139:- LIHC cis rs875971 0.522 rs4718285 ENSG00000273024.4 INTS4P2 -4 7.72e-05 0.0149 -0.25 -0.21 Aortic root size; chr7:65827018 chr7:65647864~65715661:+ LIHC cis rs17711722 0.64 rs13237956 ENSG00000273024.4 INTS4P2 -4 7.72e-05 0.0149 -0.25 -0.21 Calcium levels; chr7:65853042 chr7:65647864~65715661:+ LIHC cis rs875971 0.516 rs6945322 ENSG00000273024.4 INTS4P2 -4 7.72e-05 0.0149 -0.25 -0.21 Aortic root size; chr7:65871069 chr7:65647864~65715661:+ LIHC cis rs17711722 0.701 rs4467826 ENSG00000273024.4 INTS4P2 -4 7.72e-05 0.0149 -0.25 -0.21 Calcium levels; chr7:65903721 chr7:65647864~65715661:+ LIHC cis rs12468226 0.938 rs10166594 ENSG00000226261.1 AC064836.3 4 7.72e-05 0.0149 0.32 0.21 Urate levels; chr2:202250262 chr2:202336024~202336727:- LIHC cis rs9368481 0.7 rs6911401 ENSG00000241549.7 GUSBP2 4 7.72e-05 0.0149 0.22 0.21 Autism spectrum disorder or schizophrenia; chr6:26945435 chr6:26871484~26956554:- LIHC cis rs62402013 1 rs62402013 ENSG00000241549.7 GUSBP2 4 7.72e-05 0.0149 0.22 0.21 Schizophrenia; chr6:26947221 chr6:26871484~26956554:- LIHC cis rs4356203 0.905 rs7930058 ENSG00000260196.1 RP1-239B22.5 -4 7.72e-05 0.0149 -0.26 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17045071 chr11:17380649~17383531:+ LIHC cis rs7044106 0.762 rs3903886 ENSG00000238181.2 AHCYP2 4 7.72e-05 0.0149 0.24 0.21 Hip circumference adjusted for BMI; chr9:120621368 chr9:120720673~120721972:+ LIHC cis rs9595908 0.669 rs7983309 ENSG00000212293.1 SNORA16 4 7.72e-05 0.0149 0.24 0.21 Body mass index; chr13:32740254 chr13:32420390~32420516:- LIHC cis rs1023500 1 rs1023498 ENSG00000237037.8 NDUFA6-AS1 -4 7.72e-05 0.0149 -0.29 -0.21 Schizophrenia; chr22:41944565 chr22:42090931~42137742:+ LIHC cis rs2735413 0.874 rs12917942 ENSG00000276007.1 RP11-358L22.3 -4 7.73e-05 0.015 -0.25 -0.21 Systolic blood pressure (alcohol consumption interaction); chr16:78030323 chr16:78123243~78124332:+ LIHC cis rs10129255 0.872 rs10133674 ENSG00000211970.3 IGHV4-61 -4 7.73e-05 0.015 -0.16 -0.21 Kawasaki disease; chr14:106692788 chr14:106639119~106639657:- LIHC cis rs2299116 0.962 rs2299115 ENSG00000225264.3 ZNRF2P2 -4 7.73e-05 0.015 -0.23 -0.21 Serum thyroid-stimulating hormone levels; chr7:28775222 chr7:29598795~29685255:- LIHC cis rs7115242 0.844 rs645258 ENSG00000280143.1 AP000892.6 4 7.73e-05 0.015 0.31 0.21 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116930485 chr11:117204967~117210292:+ LIHC cis rs6504622 0.728 rs7222781 ENSG00000262879.4 RP11-156P1.3 -4 7.74e-05 0.015 -0.23 -0.21 Orofacial clefts; chr17:47100059 chr17:46984045~47100323:- LIHC cis rs3761847 0.622 rs10435888 ENSG00000226752.6 PSMD5-AS1 -4 7.74e-05 0.015 -0.22 -0.21 Rheumatoid arthritis; chr9:121057325 chr9:120824828~120854385:+ LIHC cis rs3761847 0.622 rs1323471 ENSG00000226752.6 PSMD5-AS1 -4 7.74e-05 0.015 -0.22 -0.21 Rheumatoid arthritis; chr9:121064037 chr9:120824828~120854385:+ LIHC cis rs1005277 0.683 rs7923868 ENSG00000099251.13 HSD17B7P2 4 7.74e-05 0.015 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37700838 chr10:38356380~38378505:+ LIHC cis rs854624 0.892 rs7213419 ENSG00000278690.1 RP11-104J23.2 -4 7.74e-05 0.015 -0.46 -0.21 Blood protein levels; chr17:36002262 chr17:36012504~36012891:+ LIHC cis rs11696277 0.54 rs2424077 ENSG00000232333.1 RPS27AP2 -4 7.74e-05 0.015 -0.3 -0.21 Gut microbiome composition (summer); chr20:17335988 chr20:17516843~17517307:+ LIHC cis rs11696277 0.518 rs2424078 ENSG00000232333.1 RPS27AP2 -4 7.74e-05 0.015 -0.3 -0.21 Gut microbiome composition (summer); chr20:17336330 chr20:17516843~17517307:+ LIHC cis rs11696277 0.518 rs2424079 ENSG00000232333.1 RPS27AP2 -4 7.74e-05 0.015 -0.3 -0.21 Gut microbiome composition (summer); chr20:17336479 chr20:17516843~17517307:+ LIHC cis rs11696277 0.518 rs9789830 ENSG00000232333.1 RPS27AP2 -4 7.74e-05 0.015 -0.3 -0.21 Gut microbiome composition (summer); chr20:17338092 chr20:17516843~17517307:+ LIHC cis rs11696277 0.518 rs7509543 ENSG00000232333.1 RPS27AP2 -4 7.74e-05 0.015 -0.3 -0.21 Gut microbiome composition (summer); chr20:17338119 chr20:17516843~17517307:+ LIHC cis rs11696277 0.518 rs6111512 ENSG00000232333.1 RPS27AP2 -4 7.74e-05 0.015 -0.3 -0.21 Gut microbiome composition (summer); chr20:17338263 chr20:17516843~17517307:+ LIHC cis rs11696277 0.518 rs6044744 ENSG00000232333.1 RPS27AP2 4 7.74e-05 0.015 0.3 0.21 Gut microbiome composition (summer); chr20:17338474 chr20:17516843~17517307:+ LIHC cis rs11696277 0.518 rs6075193 ENSG00000232333.1 RPS27AP2 4 7.74e-05 0.015 0.3 0.21 Gut microbiome composition (summer); chr20:17339412 chr20:17516843~17517307:+ LIHC cis rs7208859 0.725 rs9897673 ENSG00000266490.1 CTD-2349P21.9 4 7.75e-05 0.015 0.25 0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916348 chr17:30792372~30792833:+ LIHC cis rs17270561 0.887 rs717551 ENSG00000272810.1 U91328.22 -4 7.75e-05 0.015 -0.28 -0.21 Iron status biomarkers; chr6:25855396 chr6:26013241~26013757:+ LIHC cis rs12468226 0.81 rs77090459 ENSG00000272966.1 RP11-686O6.1 4 7.75e-05 0.015 0.35 0.21 Urate levels; chr2:202542132 chr2:202336739~202337200:+ LIHC cis rs2562456 0.876 rs11085468 ENSG00000268555.1 RP11-678G14.3 4 7.75e-05 0.015 0.27 0.21 Pain; chr19:21569087 chr19:21570822~21587322:- LIHC cis rs6822297 0.517 rs10006403 ENSG00000240005.4 RP11-293A21.1 -4 7.75e-05 0.015 -0.23 -0.21 Obesity-related traits; chr4:26872078 chr4:26859806~26860599:- LIHC cis rs1005277 0.522 rs289647 ENSG00000275858.1 RP11-291L22.8 4 7.75e-05 0.015 0.23 0.21 Extrinsic epigenetic age acceleration; chr10:37679350 chr10:38450738~38451069:- LIHC cis rs748404 0.697 rs555001 ENSG00000205771.5 CATSPER2P1 -4 7.75e-05 0.015 -0.25 -0.21 Lung cancer; chr15:43253530 chr15:43726918~43747094:- LIHC cis rs10028773 0.666 rs12498657 ENSG00000260091.1 RP11-33B1.4 -4 7.75e-05 0.015 -0.14 -0.21 Educational attainment; chr4:119341711 chr4:119409333~119410233:+ LIHC cis rs244293 0.831 rs11654268 ENSG00000275710.1 RP11-257O5.4 -4 7.75e-05 0.015 -0.23 -0.21 Menarche (age at onset); chr17:55073929 chr17:54964474~54964679:+ LIHC cis rs11098499 0.954 rs1022145 ENSG00000260091.1 RP11-33B1.4 -4 7.76e-05 0.015 -0.15 -0.21 Corneal astigmatism; chr4:119309824 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs11722872 ENSG00000260091.1 RP11-33B1.4 -4 7.76e-05 0.015 -0.15 -0.21 Corneal astigmatism; chr4:119311875 chr4:119409333~119410233:+ LIHC cis rs3015497 0.752 rs6572682 ENSG00000269906.1 RP11-248J18.2 4 7.76e-05 0.015 0.26 0.21 Mean platelet volume; chr14:50678082 chr14:50662511~50663178:- LIHC cis rs4964805 0.672 rs4964823 ENSG00000257681.1 RP11-341G23.4 4 7.76e-05 0.015 0.22 0.21 Attention deficit hyperactivity disorder; chr12:103787642 chr12:103746315~103768858:- LIHC cis rs950027 0.967 rs2643718 ENSG00000259433.2 CTD-2651B20.4 -4 7.76e-05 0.015 -0.28 -0.21 Response to fenofibrate (adiponectin levels); chr15:45502464 chr15:45330209~45332634:- LIHC cis rs950169 0.541 rs10795 ENSG00000259728.4 LINC00933 4 7.76e-05 0.015 0.31 0.21 Schizophrenia; chr15:84634066 chr15:84570649~84580175:+ LIHC cis rs950169 0.58 rs36126054 ENSG00000259728.4 LINC00933 4 7.76e-05 0.015 0.31 0.21 Schizophrenia; chr15:84634492 chr15:84570649~84580175:+ LIHC cis rs2744375 0.6 rs2237103 ENSG00000261189.1 RP3-512B11.3 4 7.76e-05 0.015 0.27 0.21 Resting heart rate; chr6:7551929 chr6:7540451~7541338:- LIHC cis rs875971 0.502 rs6460311 ENSG00000228409.4 CCT6P1 4 7.76e-05 0.015 0.18 0.21 Aortic root size; chr7:66646886 chr7:65751142~65763354:+ LIHC cis rs7192392 0.545 rs11150110 ENSG00000260816.2 RP11-319G9.3 4 7.77e-05 0.015 0.2 0.21 Acute graft versus host disease in bone marrow transplantation (recipient effect); chr16:78897782 chr16:78895361~78899644:+ LIHC cis rs2348418 0.864 rs2137073 ENSG00000247934.4 RP11-967K21.1 -4 7.77e-05 0.015 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28564151 chr12:28163298~28190738:- LIHC cis rs2243480 1 rs1723269 ENSG00000275400.1 RP4-756H11.5 4 7.78e-05 0.015 0.28 0.21 Diabetic kidney disease; chr7:66007799 chr7:66553805~66554199:- LIHC cis rs7985 1 rs5761672 ENSG00000244625.4 MIATNB 4 7.78e-05 0.015 0.23 0.21 Electroencephalogram traits; chr22:26673476 chr22:26672767~26780207:+ LIHC cis rs6600671 0.934 rs12060031 ENSG00000227082.1 CH17-437K3.1 4 7.79e-05 0.015 0.29 0.21 Hip geometry; chr1:121501652 chr1:121396754~121463129:+ LIHC cis rs1799949 0.794 rs116409325 ENSG00000267681.1 CTD-3199J23.6 -4 7.79e-05 0.015 -0.21 -0.21 Menopause (age at onset); chr17:43368092 chr17:43144956~43145255:+ LIHC cis rs55794721 0.509 rs7554255 ENSG00000261349.1 RP3-465N24.5 -4 7.79e-05 0.015 -0.21 -0.21 Mean corpuscular volume;Plateletcrit; chr1:25451615 chr1:25266102~25267136:- LIHC cis rs55794721 0.509 rs4649085 ENSG00000261349.1 RP3-465N24.5 -4 7.79e-05 0.015 -0.21 -0.21 Mean corpuscular volume;Plateletcrit; chr1:25452341 chr1:25266102~25267136:- LIHC cis rs17772222 0.636 rs3850390 ENSG00000258789.1 RP11-507K2.3 -4 7.79e-05 0.0151 -0.26 -0.21 Coronary artery calcification; chr14:88829185 chr14:88551597~88552493:+ LIHC cis rs17772222 0.597 rs17700296 ENSG00000258789.1 RP11-507K2.3 -4 7.79e-05 0.0151 -0.26 -0.21 Coronary artery calcification; chr14:88840976 chr14:88551597~88552493:+ LIHC cis rs7923609 0.846 rs7090111 ENSG00000232075.1 MRPL35P2 -4 7.8e-05 0.0151 -0.24 -0.21 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63318234 chr10:63634317~63634827:- LIHC cis rs2070488 0.965 rs7640050 ENSG00000229589.1 ACVR2B-AS1 4 7.8e-05 0.0151 0.24 0.21 Electrocardiographic conduction measures; chr3:38484373 chr3:38451027~38454820:- LIHC cis rs9652601 0.959 rs9931397 ENSG00000274038.1 RP11-66H6.4 -4 7.8e-05 0.0151 -0.27 -0.21 Systemic lupus erythematosus; chr16:11083537 chr16:11056556~11057034:+ LIHC cis rs9652601 0.959 rs12708715 ENSG00000274038.1 RP11-66H6.4 -4 7.8e-05 0.0151 -0.27 -0.21 Systemic lupus erythematosus; chr16:11083967 chr16:11056556~11057034:+ LIHC cis rs2762353 0.718 rs1165205 ENSG00000242387.1 HIST1H2APS2 -4 7.81e-05 0.0151 -0.24 -0.21 Blood metabolite levels; chr6:25870314 chr6:25882026~25882395:- LIHC cis rs703842 1 rs11172335 ENSG00000270039.1 RP11-571M6.17 -4 7.81e-05 0.0151 -0.3 -0.21 Multiple sclerosis; chr12:57781418 chr12:57803838~57804415:+ LIHC cis rs1499614 1 rs1882655 ENSG00000228409.4 CCT6P1 -4 7.81e-05 0.0151 -0.23 -0.21 Gout; chr7:66682070 chr7:65751142~65763354:+ LIHC cis rs1499614 0.831 rs3800822 ENSG00000228409.4 CCT6P1 -4 7.81e-05 0.0151 -0.23 -0.21 Gout; chr7:66682162 chr7:65751142~65763354:+ LIHC cis rs1499614 1 rs1638731 ENSG00000228409.4 CCT6P1 4 7.81e-05 0.0151 0.23 0.21 Gout; chr7:66679692 chr7:65751142~65763354:+ LIHC cis rs950169 1 rs11638297 ENSG00000225151.9 GOLGA2P7 -4 7.81e-05 0.0151 -0.29 -0.21 Schizophrenia; chr15:84113665 chr15:84199311~84230136:- LIHC cis rs67311347 0.544 rs2278927 ENSG00000223797.4 ENTPD3-AS1 4 7.81e-05 0.0151 0.18 0.21 Renal cell carcinoma; chr3:40308956 chr3:40313802~40453329:- LIHC cis rs11096990 0.892 rs11937540 ENSG00000249207.1 RP11-360F5.1 4 7.81e-05 0.0151 0.24 0.21 Cognitive function; chr4:39179897 chr4:39112677~39126818:- LIHC cis rs921968 0.519 rs72966020 ENSG00000272555.1 RP11-459I19.1 -4 7.82e-05 0.0151 -0.25 -0.21 Mean corpuscular hemoglobin concentration; chr2:218777897 chr2:218818690~218819144:+ LIHC cis rs2562456 0.55 rs4809143 ENSG00000268555.1 RP11-678G14.3 4 7.82e-05 0.0151 0.28 0.21 Pain; chr19:21589926 chr19:21570822~21587322:- LIHC cis rs2562456 0.583 rs4809144 ENSG00000268555.1 RP11-678G14.3 4 7.82e-05 0.0151 0.28 0.21 Pain; chr19:21589928 chr19:21570822~21587322:- LIHC cis rs6723108 0.517 rs3739029 ENSG00000224043.6 CCNT2-AS1 -4 7.82e-05 0.0151 -0.29 -0.21 Type 2 diabetes; chr2:134841837 chr2:134735464~134918710:- LIHC cis rs9450351 0.744 rs6906618 ENSG00000203875.9 SNHG5 -4 7.83e-05 0.0151 -0.45 -0.21 Interferon gamma-induced protein 10 levels; chr6:85741719 chr6:85660950~85678736:- LIHC cis rs4763879 0.634 rs12424826 ENSG00000256673.1 RP11-599J14.2 4 7.83e-05 0.0151 0.21 0.21 Type 1 diabetes; chr12:9701981 chr12:9398355~9414851:- LIHC cis rs524281 0.731 rs6591203 ENSG00000255320.1 RP11-755F10.1 -4 7.83e-05 0.0151 -0.3 -0.21 Electroencephalogram traits; chr11:66038758 chr11:66244840~66246239:- LIHC cis rs6600233 0.874 rs11865131 ENSG00000268836.1 LA16c-OS12.2 4 7.83e-05 0.0151 0.25 0.21 High light scatter reticulocyte percentage of red cells; chr16:113668 chr16:185748~186294:- LIHC cis rs17482078 0.959 rs13154629 ENSG00000248734.2 CTD-2260A17.1 4 7.83e-05 0.0151 0.3 0.21 Behcet's disease;Blood protein levels; chr5:96786754 chr5:96784777~96785999:+ LIHC cis rs13113518 0.812 rs13107810 ENSG00000249700.7 SRD5A3-AS1 4 7.84e-05 0.0151 0.25 0.21 Height; chr4:55542243 chr4:55363971~55395847:- LIHC cis rs10129255 0.5 rs9324092 ENSG00000211972.2 IGHV3-66 -4 7.84e-05 0.0151 -0.16 -0.21 Kawasaki disease; chr14:106683806 chr14:106675017~106675544:- LIHC cis rs1799949 0.602 rs8176235 ENSG00000267681.1 CTD-3199J23.6 -4 7.84e-05 0.0151 -0.21 -0.21 Menopause (age at onset); chr17:43067543 chr17:43144956~43145255:+ LIHC cis rs2919917 0.628 rs12544041 ENSG00000254352.1 RP11-578O24.2 -4 7.84e-05 0.0151 -0.33 -0.21 Lymphocyte counts; chr8:78731404 chr8:78723796~78724136:- LIHC cis rs867371 1 rs11855089 ENSG00000259429.4 UBE2Q2P2 -4 7.84e-05 0.0151 -0.2 -0.21 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82154924 chr15:82355142~82420075:+ LIHC cis rs867371 1 rs1174543 ENSG00000259429.4 UBE2Q2P2 4 7.84e-05 0.0151 0.2 0.21 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82155732 chr15:82355142~82420075:+ LIHC cis rs3091242 1 rs9689 ENSG00000224183.1 SDHDP6 -4 7.84e-05 0.0151 -0.24 -0.21 Erythrocyte sedimentation rate; chr1:25361785 chr1:25294164~25294643:- LIHC cis rs11096990 0.892 rs1473364 ENSG00000249207.1 RP11-360F5.1 -4 7.84e-05 0.0151 -0.24 -0.21 Cognitive function; chr4:39211259 chr4:39112677~39126818:- LIHC cis rs6700559 0.873 rs7526367 ENSG00000260088.1 RP11-92G12.3 -4 7.84e-05 0.0151 -0.27 -0.21 Coronary artery disease; chr1:200688025 chr1:200669507~200694250:+ LIHC cis rs8037137 0.915 rs12594752 ENSG00000258725.1 PRC1-AS1 -4 7.85e-05 0.0152 -0.27 -0.21 Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr15:90988765 chr15:90966345~90988624:+ LIHC cis rs11098499 0.909 rs10020034 ENSG00000260091.1 RP11-33B1.4 -4 7.85e-05 0.0152 -0.15 -0.21 Corneal astigmatism; chr4:119373176 chr4:119409333~119410233:+ LIHC cis rs11098499 0.954 rs59394118 ENSG00000260091.1 RP11-33B1.4 -4 7.85e-05 0.0152 -0.15 -0.21 Corneal astigmatism; chr4:119374396 chr4:119409333~119410233:+ LIHC cis rs11098499 0.865 rs9996417 ENSG00000260091.1 RP11-33B1.4 -4 7.85e-05 0.0152 -0.15 -0.21 Corneal astigmatism; chr4:119374707 chr4:119409333~119410233:+ LIHC cis rs12586317 0.62 rs8020370 ENSG00000257307.1 RP11-317N8.4 -4 7.85e-05 0.0152 -0.25 -0.21 Psoriasis; chr14:35112226 chr14:35881001~35881709:+ LIHC cis rs9907295 1 rs9911016 ENSG00000270871.1 AC015849.19 4 7.85e-05 0.0152 0.22 0.21 Fibroblast growth factor basic levels; chr17:35913349 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9912894 ENSG00000270871.1 AC015849.19 4 7.85e-05 0.0152 0.22 0.21 Fibroblast growth factor basic levels; chr17:35913452 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9914468 ENSG00000270871.1 AC015849.19 4 7.85e-05 0.0152 0.22 0.21 Fibroblast growth factor basic levels; chr17:35913727 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9893004 ENSG00000270871.1 AC015849.19 4 7.85e-05 0.0152 0.22 0.21 Fibroblast growth factor basic levels; chr17:35913855 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9899215 ENSG00000270871.1 AC015849.19 4 7.85e-05 0.0152 0.22 0.21 Fibroblast growth factor basic levels; chr17:35914215 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9907145 ENSG00000270871.1 AC015849.19 4 7.85e-05 0.0152 0.22 0.21 Fibroblast growth factor basic levels; chr17:35915237 chr17:35816717~35830293:- LIHC cis rs58749629 1 rs7270354 ENSG00000269549.2 RP3-461P17.10 4 7.86e-05 0.0152 0.41 0.21 Abdominal aortic aneurysm; chr20:45979022 chr20:45445431~45448580:+ LIHC cis rs1077773 0.509 rs6965584 ENSG00000237773.4 AC003075.4 -4 7.86e-05 0.0152 -0.26 -0.21 Ulcerative colitis;Inflammatory bowel disease; chr7:17394681 chr7:17279834~17299357:- LIHC cis rs1075265 0.704 rs9631059 ENSG00000272156.1 RP11-477N3.1 -4 7.86e-05 0.0152 -0.24 -0.21 Chronotype;Morning vs. evening chronotype; chr2:54015160 chr2:54082554~54085066:+ LIHC cis rs1075265 0.73 rs6711105 ENSG00000272156.1 RP11-477N3.1 -4 7.86e-05 0.0152 -0.24 -0.21 Chronotype;Morning vs. evening chronotype; chr2:54017775 chr2:54082554~54085066:+ LIHC cis rs1075265 0.704 rs6711217 ENSG00000272156.1 RP11-477N3.1 -4 7.86e-05 0.0152 -0.24 -0.21 Chronotype;Morning vs. evening chronotype; chr2:54017892 chr2:54082554~54085066:+ LIHC cis rs748404 0.697 rs1814323 ENSG00000205771.5 CATSPER2P1 4 7.86e-05 0.0152 0.26 0.21 Lung cancer; chr15:43271039 chr15:43726918~43747094:- LIHC cis rs11079159 0.959 rs17817857 ENSG00000263096.1 RP11-515O17.2 4 7.86e-05 0.0152 0.29 0.21 QRS duration; chr17:55299581 chr17:55271504~55273653:- LIHC cis rs7620503 0.659 rs11707350 ENSG00000228561.2 RP11-114M1.1 -4 7.87e-05 0.0152 -0.23 -0.21 Corneal structure; chr3:177570055 chr3:177683627~177691250:+ LIHC cis rs950880 0.71 rs11693204 ENSG00000234389.1 AC007278.3 -4 7.87e-05 0.0152 -0.22 -0.21 Serum protein levels (sST2); chr2:102319514 chr2:102438713~102440475:+ LIHC cis rs763121 0.853 rs5750649 ENSG00000273076.1 RP3-508I15.22 4 7.87e-05 0.0152 0.24 0.21 Menopause (age at onset); chr22:38640764 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs6519124 ENSG00000273076.1 RP3-508I15.22 4 7.87e-05 0.0152 0.24 0.21 Menopause (age at onset); chr22:38649094 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs5750652 ENSG00000273076.1 RP3-508I15.22 4 7.87e-05 0.0152 0.24 0.21 Menopause (age at onset); chr22:38652311 chr22:38743495~38743910:+ LIHC cis rs763121 0.814 rs5757212 ENSG00000273076.1 RP3-508I15.22 4 7.87e-05 0.0152 0.24 0.21 Menopause (age at onset); chr22:38657752 chr22:38743495~38743910:+ LIHC cis rs6997458 0.806 rs1496532 ENSG00000253549.4 RP11-317J10.2 -4 7.87e-05 0.0152 -0.22 -0.21 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85341753 chr8:85441851~85464915:- LIHC cis rs17023223 0.537 rs12081585 ENSG00000231365.4 RP11-418J17.1 -4 7.87e-05 0.0152 -0.25 -0.21 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119073333 chr1:119140396~119275973:+ LIHC cis rs1005277 0.522 rs7090858 ENSG00000276805.1 RP11-291L22.6 -4 7.88e-05 0.0152 -0.25 -0.21 Extrinsic epigenetic age acceleration; chr10:37714742 chr10:38451030~38451785:+ LIHC cis rs3204270 0.639 rs6565620 ENSG00000281517.1 Metazoa_SRP -4 7.88e-05 0.0152 -0.39 -0.21 Dental caries; chr17:81691070 chr17:81718849~81719095:- LIHC cis rs7712401 0.601 rs431878 ENSG00000263432.2 RN7SL689P -4 7.88e-05 0.0152 -0.31 -0.21 Mean platelet volume; chr5:122926096 chr5:123022487~123022783:- LIHC cis rs7412746 0.611 rs2864873 ENSG00000231073.1 RP11-316M1.3 4 7.88e-05 0.0152 0.22 0.21 Melanoma; chr1:150841698 chr1:150973123~150975534:+ LIHC cis rs17711722 0.701 rs781143 ENSG00000273024.4 INTS4P2 -4 7.89e-05 0.0152 -0.25 -0.21 Calcium levels; chr7:65974892 chr7:65647864~65715661:+ LIHC cis rs11098499 0.691 rs17009144 ENSG00000260091.1 RP11-33B1.4 4 7.89e-05 0.0152 0.14 0.21 Corneal astigmatism; chr4:119349640 chr4:119409333~119410233:+ LIHC cis rs748404 0.586 rs2584700 ENSG00000166763.7 STRCP1 4 7.89e-05 0.0152 0.27 0.21 Lung cancer; chr15:43393134 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs2467736 ENSG00000166763.7 STRCP1 4 7.89e-05 0.0152 0.3 0.21 Lung cancer in ever smokers; chr15:43492719 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs2444250 ENSG00000166763.7 STRCP1 4 7.89e-05 0.0152 0.3 0.21 Lung cancer in ever smokers; chr15:43492853 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs101094 ENSG00000166763.7 STRCP1 4 7.89e-05 0.0152 0.3 0.21 Lung cancer in ever smokers; chr15:43495124 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs689781 ENSG00000166763.7 STRCP1 4 7.89e-05 0.0152 0.3 0.21 Lung cancer in ever smokers; chr15:43499899 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs2584725 ENSG00000166763.7 STRCP1 4 7.89e-05 0.0152 0.3 0.21 Lung cancer in ever smokers; chr15:43500937 chr15:43699488~43718184:- LIHC cis rs3764400 0.567 rs9890691 ENSG00000278765.1 RP5-890E16.5 -4 7.89e-05 0.0152 -0.32 -0.21 Body mass index; chr17:48115574 chr17:48066704~48067293:- LIHC cis rs673078 0.66 rs61945212 ENSG00000275759.1 RP11-131L12.3 -4 7.89e-05 0.0152 -0.43 -0.21 Glucose homeostasis traits; chr12:118252351 chr12:118428281~118428870:+ LIHC cis rs801193 0.839 rs12534943 ENSG00000224316.1 RP11-479O9.2 -4 7.89e-05 0.0152 -0.19 -0.21 Aortic root size; chr7:66605533 chr7:65773620~65802067:+ LIHC cis rs17121403 0.661 rs12132802 ENSG00000261254.2 RP4-714D9.5 -4 7.89e-05 0.0152 -0.38 -0.21 Pulmonary function decline; chr1:100099903 chr1:100030566~100035637:+ LIHC cis rs1799949 1 rs11653460 ENSG00000267681.1 CTD-3199J23.6 -4 7.89e-05 0.0152 -0.2 -0.21 Menopause (age at onset); chr17:43179289 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs11650913 ENSG00000267681.1 CTD-3199J23.6 -4 7.89e-05 0.0152 -0.2 -0.21 Menopause (age at onset); chr17:43179580 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs12936831 ENSG00000267681.1 CTD-3199J23.6 -4 7.89e-05 0.0152 -0.2 -0.21 Menopause (age at onset); chr17:43179799 chr17:43144956~43145255:+ LIHC cis rs1799949 0.93 rs35292991 ENSG00000267681.1 CTD-3199J23.6 -4 7.89e-05 0.0152 -0.2 -0.21 Menopause (age at onset); chr17:43181999 chr17:43144956~43145255:+ LIHC cis rs7726839 0.507 rs72703100 ENSG00000271781.1 CTD-2589H19.6 -4 7.89e-05 0.0152 -0.32 -0.21 Obesity-related traits; chr5:614176 chr5:675826~676616:+ LIHC cis rs7726839 0.574 rs72705014 ENSG00000271781.1 CTD-2589H19.6 -4 7.89e-05 0.0152 -0.32 -0.21 Obesity-related traits; chr5:619700 chr5:675826~676616:+ LIHC cis rs7726839 0.574 rs72705017 ENSG00000271781.1 CTD-2589H19.6 -4 7.89e-05 0.0152 -0.32 -0.21 Obesity-related traits; chr5:623618 chr5:675826~676616:+ LIHC cis rs3091242 0.934 rs666686 ENSG00000224183.1 SDHDP6 -4 7.89e-05 0.0152 -0.25 -0.21 Erythrocyte sedimentation rate; chr1:25393020 chr1:25294164~25294643:- LIHC cis rs11676348 0.808 rs4674261 ENSG00000261338.2 RP11-378A13.1 -4 7.9e-05 0.0152 -0.23 -0.21 Ulcerative colitis; chr2:218140286 chr2:218255319~218257366:+ LIHC cis rs2749592 0.918 rs11011388 ENSG00000263064.2 RP11-291L22.7 -4 7.9e-05 0.0152 -0.23 -0.21 Age-related hearing impairment (SNP x SNP interaction); chr10:37866282 chr10:38448689~38448949:+ LIHC cis rs34044649 1 rs34044649 ENSG00000214106.6 PAXIP1-AS2 -4 7.9e-05 0.0152 -0.17 -0.21 Triptolide cytotoxicity; chr7:155862999 chr7:154928498~154949908:+ LIHC cis rs6471393 0.964 rs11549490 ENSG00000253848.1 RP11-10N23.5 -4 7.91e-05 0.0152 -0.23 -0.21 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93732822 chr8:93741193~93744534:+ LIHC cis rs524281 0.682 rs6591202 ENSG00000255320.1 RP11-755F10.1 -4 7.91e-05 0.0152 -0.3 -0.21 Electroencephalogram traits; chr11:66038622 chr11:66244840~66246239:- LIHC cis rs801193 0.591 rs2707839 ENSG00000237310.1 GS1-124K5.4 4 7.91e-05 0.0152 0.19 0.21 Aortic root size; chr7:66728097 chr7:66493706~66495474:+ LIHC cis rs801193 0.636 rs2659895 ENSG00000237310.1 GS1-124K5.4 4 7.91e-05 0.0152 0.19 0.21 Aortic root size; chr7:66731484 chr7:66493706~66495474:+ LIHC cis rs4713118 0.55 rs9368527 ENSG00000216901.1 AL022393.7 4 7.91e-05 0.0152 0.24 0.21 Parkinson's disease; chr6:27711666 chr6:28176188~28176674:+ LIHC cis rs77204473 0.744 rs12281009 ENSG00000254851.1 RP11-109L13.1 4 7.91e-05 0.0152 0.37 0.21 Sum eosinophil basophil counts;Eosinophil counts; chr11:117162243 chr11:117135528~117138582:+ LIHC cis rs12586317 0.62 rs17091786 ENSG00000257307.1 RP11-317N8.4 -4 7.91e-05 0.0152 -0.25 -0.21 Psoriasis; chr14:35096650 chr14:35881001~35881709:+ LIHC cis rs4073416 0.712 rs1535173 ENSG00000276116.2 FUT8-AS1 -4 7.91e-05 0.0152 -0.26 -0.21 N-glycan levels; chr14:65732421 chr14:65411170~65412690:- LIHC cis rs4650994 1 rs10798619 ENSG00000273384.1 RP5-1098D14.1 4 7.92e-05 0.0153 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178563382 chr1:178651706~178652282:+ LIHC cis rs2659703 0.933 rs2953119 ENSG00000261159.1 RP11-723O4.9 4 7.92e-05 0.0153 0.27 0.21 Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid); chr3:128455596 chr3:128859716~128860526:- LIHC cis rs1115240 0.636 rs1955813 ENSG00000257842.4 NOVA1-AS1 3.99 7.93e-05 0.0153 0.2 0.21 Educational attainment (years of education); chr14:26645579 chr14:26598412~26806467:+ LIHC cis rs11710088 0.74 rs73152645 ENSG00000244503.1 RP11-278L15.6 3.99 7.93e-05 0.0153 0.28 0.21 QRS duration; chr3:149488309 chr3:149494660~149495995:+ LIHC cis rs17772222 0.917 rs61986671 ENSG00000258789.1 RP11-507K2.3 -3.99 7.93e-05 0.0153 -0.25 -0.21 Coronary artery calcification; chr14:88732917 chr14:88551597~88552493:+ LIHC cis rs7893279 0.505 rs7071300 ENSG00000225527.1 RP11-383B4.4 3.99 7.93e-05 0.0153 0.3 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18594736 chr10:18531849~18533336:- LIHC cis rs7893279 0.505 rs7074644 ENSG00000225527.1 RP11-383B4.4 3.99 7.93e-05 0.0153 0.3 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18594778 chr10:18531849~18533336:- LIHC cis rs10833905 1 rs7934818 ENSG00000246225.5 RP11-17A1.3 -3.99 7.93e-05 0.0153 -0.27 -0.21 Sudden cardiac arrest; chr11:23039003 chr11:22829380~22945393:+ LIHC cis rs17774123 0.851 rs17719188 ENSG00000257808.1 RP11-1136G11.8 -3.99 7.93e-05 0.0153 -0.38 -0.21 Diastolic blood pressure; chr12:53892434 chr12:53159586~53161000:+ LIHC cis rs79349575 0.783 rs12603969 ENSG00000248278.1 SUMO2P17 3.99 7.93e-05 0.0153 0.27 0.21 Type 2 diabetes; chr17:48957057 chr17:48874860~48908983:- LIHC cis rs79349575 0.783 rs12601955 ENSG00000248278.1 SUMO2P17 3.99 7.93e-05 0.0153 0.27 0.21 Type 2 diabetes; chr17:48957058 chr17:48874860~48908983:- LIHC cis rs79349575 0.594 rs62078375 ENSG00000248278.1 SUMO2P17 3.99 7.93e-05 0.0153 0.27 0.21 Type 2 diabetes; chr17:48957612 chr17:48874860~48908983:- LIHC cis rs11098499 0.913 rs10006304 ENSG00000260091.1 RP11-33B1.4 -3.99 7.94e-05 0.0153 -0.15 -0.21 Corneal astigmatism; chr4:119203150 chr4:119409333~119410233:+ LIHC cis rs11647589 0.688 rs28556968 ENSG00000262995.1 CTD-2194A8.2 -3.99 7.94e-05 0.0153 -0.19 -0.21 Blood metabolite levels; chr16:20469357 chr16:20440266~20447000:- LIHC cis rs948562 0.744 rs60998298 ENSG00000280010.1 AP001350.4 3.99 7.94e-05 0.0153 0.38 0.21 Lymphoma; chr11:58534382 chr11:58627435~58628528:+ LIHC cis rs2070488 0.965 rs1984312 ENSG00000229589.1 ACVR2B-AS1 -3.99 7.94e-05 0.0153 -0.24 -0.21 Electrocardiographic conduction measures; chr3:38496975 chr3:38451027~38454820:- LIHC cis rs7712401 0.601 rs390234 ENSG00000263432.2 RN7SL689P -3.99 7.95e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:122995828 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs4555798 ENSG00000263432.2 RN7SL689P -3.99 7.95e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:122996419 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs62377424 ENSG00000263432.2 RN7SL689P -3.99 7.95e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:122996627 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs35699701 ENSG00000263432.2 RN7SL689P -3.99 7.95e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:122998061 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs35256179 ENSG00000263432.2 RN7SL689P -3.99 7.95e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:122998560 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs35858098 ENSG00000263432.2 RN7SL689P -3.99 7.95e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:122998670 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs13155907 ENSG00000263432.2 RN7SL689P -3.99 7.95e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:122998938 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs62377430 ENSG00000263432.2 RN7SL689P -3.99 7.95e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:122998993 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs34348084 ENSG00000263432.2 RN7SL689P -3.99 7.95e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:122999419 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs35334805 ENSG00000263432.2 RN7SL689P -3.99 7.95e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:122999566 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs13164134 ENSG00000263432.2 RN7SL689P -3.99 7.95e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:123002246 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs13185741 ENSG00000263432.2 RN7SL689P -3.99 7.95e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:123002315 chr5:123022487~123022783:- LIHC cis rs617219 0.819 rs72764990 ENSG00000251675.1 CTC-458I2.2 -3.99 7.95e-05 0.0153 -0.24 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79240367 chr5:80128361~80143883:+ LIHC cis rs812925 0.533 rs60997156 ENSG00000271889.1 RP11-493E12.1 3.99 7.95e-05 0.0153 0.25 0.21 Immature fraction of reticulocytes; chr2:61169404 chr2:61151433~61162105:- LIHC cis rs1928295 0.786 rs10983712 ENSG00000233569.1 RP11-500B12.1 3.99 7.95e-05 0.0153 0.22 0.21 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117606458 chr9:117648606~117657027:+ LIHC cis rs2281636 0.723 rs3740078 ENSG00000233690.1 EBAG9P1 3.99 7.95e-05 0.0153 0.21 0.21 Obesity-related traits; chr10:99685834 chr10:99697407~99697949:- LIHC cis rs7712401 0.601 rs35479600 ENSG00000263432.2 RN7SL689P -3.99 7.96e-05 0.0153 -0.31 -0.21 Mean platelet volume; chr5:122988775 chr5:123022487~123022783:- LIHC cis rs10129255 0.744 rs28517388 ENSG00000224373.3 IGHV4-59 3.99 7.96e-05 0.0153 0.17 0.21 Kawasaki disease; chr14:106704323 chr14:106627249~106627825:- LIHC cis rs494453 0.672 rs565522 ENSG00000227811.2 FAM212B-AS1 -3.99 7.96e-05 0.0153 -0.24 -0.21 Osteoporosis-related phenotypes; chr1:111718911 chr1:111739841~111747798:+ LIHC cis rs673078 0.607 rs61943391 ENSG00000275759.1 RP11-131L12.3 -3.99 7.97e-05 0.0153 -0.41 -0.21 Glucose homeostasis traits; chr12:118382603 chr12:118428281~118428870:+ LIHC cis rs9450351 0.744 rs7772723 ENSG00000203875.9 SNHG5 -3.99 7.97e-05 0.0153 -0.45 -0.21 Interferon gamma-induced protein 10 levels; chr6:85913980 chr6:85660950~85678736:- LIHC cis rs2749592 0.918 rs1208653 ENSG00000275858.1 RP11-291L22.8 -3.99 7.97e-05 0.0153 -0.24 -0.21 Age-related hearing impairment (SNP x SNP interaction); chr10:37964898 chr10:38450738~38451069:- LIHC cis rs7726839 0.54 rs7558 ENSG00000271781.1 CTD-2589H19.6 -3.99 7.97e-05 0.0153 -0.32 -0.21 Obesity-related traits; chr5:660376 chr5:675826~676616:+ LIHC cis rs17345786 0.511 rs12639028 ENSG00000244119.1 PDCL3P4 3.99 7.97e-05 0.0153 0.22 0.21 Colonoscopy-negative controls vs population controls; chr3:101627189 chr3:101712472~101713191:+ LIHC cis rs6984305 0.541 rs17716118 ENSG00000253426.4 RP11-10A14.4 3.99 7.98e-05 0.0153 0.42 0.21 Liver enzyme levels (alkaline phosphatase); chr8:9322624 chr8:9151742~9168136:+ LIHC cis rs6142102 0.961 rs6119447 ENSG00000275784.1 RP5-1125A11.6 -3.99 7.98e-05 0.0154 -0.24 -0.21 Skin pigmentation; chr20:34080770 chr20:33989480~33991818:- LIHC cis rs13217239 0.646 rs7451149 ENSG00000241549.7 GUSBP2 -3.99 7.99e-05 0.0154 -0.21 -0.21 Schizophrenia; chr6:27089739 chr6:26871484~26956554:- LIHC cis rs10752881 0.602 rs9425569 ENSG00000224810.1 RP11-538D16.2 -3.99 7.99e-05 0.0154 -0.22 -0.21 Colorectal cancer; chr1:182973067 chr1:182062677~182069253:- LIHC cis rs11010290 0.639 rs752431 ENSG00000269952.1 RP11-324I22.3 3.99 7.99e-05 0.0154 0.33 0.21 Antineutrophil cytoplasmic antibody-associated vasculitis; chr10:35749347 chr10:35210416~35210750:+ LIHC cis rs6545883 0.524 rs2463101 ENSG00000271889.1 RP11-493E12.1 -3.99 8e-05 0.0154 -0.25 -0.21 Tuberculosis; chr2:61347287 chr2:61151433~61162105:- LIHC cis rs7937890 1 rs2970335 ENSG00000251991.1 RNU7-49P 3.99 8e-05 0.0154 0.22 0.21 Mitochondrial DNA levels; chr11:14303855 chr11:14478892~14478953:+ LIHC cis rs2195987 1 rs2195987 ENSG00000268442.1 CTD-2027I19.2 -3.99 8e-05 0.0154 -0.39 -0.21 Testicular germ cell tumor; chr19:23966743 chr19:24162370~24163425:- LIHC cis rs804280 1 rs804280 ENSG00000255394.4 C8orf49 3.99 8e-05 0.0154 0.29 0.21 Myopia (pathological); chr8:11755189 chr8:11761256~11763223:+ LIHC cis rs9513627 0.915 rs7327204 ENSG00000280710.1 RP11-214F16.8 -3.99 8.01e-05 0.0154 -0.29 -0.21 Obesity-related traits; chr13:99474698 chr13:99498524~99501315:+ LIHC cis rs11673344 0.526 rs57654288 ENSG00000226686.6 LINC01535 3.99 8.01e-05 0.0154 0.29 0.21 Obesity-related traits; chr19:37587870 chr19:37251912~37265535:+ LIHC cis rs2348418 0.798 rs11049486 ENSG00000247934.4 RP11-967K21.1 -3.99 8.01e-05 0.0154 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28253224 chr12:28163298~28190738:- LIHC cis rs2060793 0.519 rs2597212 ENSG00000251991.1 RNU7-49P -3.99 8.01e-05 0.0154 -0.23 -0.21 Vitamin D levels; chr11:14560216 chr11:14478892~14478953:+ LIHC cis rs11212260 0.512 rs76580404 ENSG00000261098.1 RP11-819C21.1 3.99 8.01e-05 0.0154 0.37 0.21 IgG glycosylation; chr11:107320287 chr11:107312132~107316271:- LIHC cis rs10833905 1 rs28591594 ENSG00000246225.5 RP11-17A1.3 -3.99 8.02e-05 0.0154 -0.26 -0.21 Sudden cardiac arrest; chr11:23022338 chr11:22829380~22945393:+ LIHC cis rs10833905 1 rs3909702 ENSG00000246225.5 RP11-17A1.3 -3.99 8.02e-05 0.0154 -0.26 -0.21 Sudden cardiac arrest; chr11:23022607 chr11:22829380~22945393:+ LIHC cis rs10833905 1 rs5005787 ENSG00000246225.5 RP11-17A1.3 -3.99 8.02e-05 0.0154 -0.26 -0.21 Sudden cardiac arrest; chr11:23022940 chr11:22829380~22945393:+ LIHC cis rs10833905 1 rs7924512 ENSG00000246225.5 RP11-17A1.3 -3.99 8.02e-05 0.0154 -0.26 -0.21 Sudden cardiac arrest; chr11:23025503 chr11:22829380~22945393:+ LIHC cis rs651907 0.557 rs11710533 ENSG00000244119.1 PDCL3P4 3.99 8.02e-05 0.0154 0.22 0.21 Colorectal cancer; chr3:101632628 chr3:101712472~101713191:+ LIHC cis rs2243480 0.908 rs313822 ENSG00000230295.1 RP11-458F8.2 -3.99 8.03e-05 0.0154 -0.22 -0.21 Diabetic kidney disease; chr7:66108952 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs313820 ENSG00000230295.1 RP11-458F8.2 -3.99 8.03e-05 0.0154 -0.22 -0.21 Diabetic kidney disease; chr7:66109479 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs313824 ENSG00000230295.1 RP11-458F8.2 -3.99 8.03e-05 0.0154 -0.22 -0.21 Diabetic kidney disease; chr7:66116220 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs186378 ENSG00000230295.1 RP11-458F8.2 -3.99 8.03e-05 0.0154 -0.22 -0.21 Diabetic kidney disease; chr7:66117071 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs160637 ENSG00000230295.1 RP11-458F8.2 -3.99 8.03e-05 0.0154 -0.22 -0.21 Diabetic kidney disease; chr7:66119331 chr7:66880708~66882981:+ LIHC cis rs2015599 0.623 rs3782510 ENSG00000275476.1 RP11-996F15.4 3.99 8.03e-05 0.0154 0.25 0.21 Platelet count;Mean platelet volume; chr12:29301176 chr12:29277397~29277882:- LIHC cis rs340849 0.935 rs340847 ENSG00000274895.1 RP11-478J18.2 3.99 8.03e-05 0.0154 0.22 0.21 Alzheimer's disease; chr1:213947603 chr1:213983793~213986419:- LIHC cis rs340849 0.935 rs340846 ENSG00000274895.1 RP11-478J18.2 3.99 8.03e-05 0.0154 0.22 0.21 Alzheimer's disease; chr1:213947753 chr1:213983793~213986419:- LIHC cis rs4819852 0.958 rs2238784 ENSG00000215493.3 XXbac-B562F10.11 -3.99 8.03e-05 0.0154 -0.18 -0.21 Pulse pressure; chr22:19985036 chr22:20450122~20451824:+ LIHC cis rs4819852 0.958 rs2238786 ENSG00000215493.3 XXbac-B562F10.11 -3.99 8.03e-05 0.0154 -0.18 -0.21 Pulse pressure; chr22:19987921 chr22:20450122~20451824:+ LIHC cis rs4819852 0.958 rs2238787 ENSG00000215493.3 XXbac-B562F10.11 -3.99 8.03e-05 0.0154 -0.18 -0.21 Pulse pressure; chr22:19988883 chr22:20450122~20451824:+ LIHC cis rs4819852 0.958 rs9606204 ENSG00000215493.3 XXbac-B562F10.11 -3.99 8.03e-05 0.0154 -0.18 -0.21 Pulse pressure; chr22:19988987 chr22:20450122~20451824:+ LIHC cis rs4819852 0.958 rs756653 ENSG00000215493.3 XXbac-B562F10.11 -3.99 8.03e-05 0.0154 -0.18 -0.21 Pulse pressure; chr22:19989322 chr22:20450122~20451824:+ LIHC cis rs7182621 0.512 rs71403471 ENSG00000182397.13 DNM1P46 3.99 8.03e-05 0.0154 0.29 0.21 Colonoscopy-negative controls vs population controls; chr15:99870656 chr15:99790156~99806927:- LIHC cis rs13113518 0.812 rs11932712 ENSG00000249700.7 SRD5A3-AS1 3.99 8.04e-05 0.0154 0.25 0.21 Height; chr4:55436423 chr4:55363971~55395847:- LIHC cis rs13113518 0.812 rs12501746 ENSG00000249700.7 SRD5A3-AS1 3.99 8.04e-05 0.0154 0.25 0.21 Height; chr4:55437438 chr4:55363971~55395847:- LIHC cis rs2838568 0.967 rs12627610 ENSG00000277352.1 KB-68A7.2 3.99 8.04e-05 0.0154 0.25 0.21 Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals; chr21:44475876 chr21:44494874~44495519:+ LIHC cis rs3091242 0.935 rs3093632 ENSG00000224183.1 SDHDP6 -3.99 8.04e-05 0.0154 -0.24 -0.21 Erythrocyte sedimentation rate; chr1:25357521 chr1:25294164~25294643:- LIHC cis rs6442522 0.772 rs2278962 ENSG00000249786.6 EAF1-AS1 3.99 8.04e-05 0.0154 0.24 0.21 Uric acid levels; chr3:15451279 chr3:15436171~15455940:- LIHC cis rs8037137 0.915 rs60290423 ENSG00000258725.1 PRC1-AS1 -3.99 8.05e-05 0.0155 -0.27 -0.21 Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr15:90986222 chr15:90966345~90988624:+ LIHC cis rs7617773 0.78 rs13090538 ENSG00000228638.1 FCF1P2 -3.99 8.05e-05 0.0155 -0.24 -0.21 Coronary artery disease; chr3:48329279 chr3:48290793~48291375:- LIHC cis rs7617773 0.817 rs9818937 ENSG00000228638.1 FCF1P2 -3.99 8.05e-05 0.0155 -0.23 -0.21 Coronary artery disease; chr3:48283791 chr3:48290793~48291375:- LIHC cis rs2243480 1 rs778729 ENSG00000232546.1 RP11-458F8.1 -3.99 8.05e-05 0.0155 -0.23 -0.21 Diabetic kidney disease; chr7:66359432 chr7:66848496~66858136:+ LIHC cis rs2243480 0.901 rs778687 ENSG00000232546.1 RP11-458F8.1 -3.99 8.05e-05 0.0155 -0.23 -0.21 Diabetic kidney disease; chr7:66370832 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs778679 ENSG00000232546.1 RP11-458F8.1 -3.99 8.05e-05 0.0155 -0.23 -0.21 Diabetic kidney disease; chr7:66375924 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs778704 ENSG00000232546.1 RP11-458F8.1 -3.99 8.05e-05 0.0155 -0.23 -0.21 Diabetic kidney disease; chr7:66398480 chr7:66848496~66858136:+ LIHC cis rs2243480 0.901 rs778693 ENSG00000232546.1 RP11-458F8.1 -3.99 8.05e-05 0.0155 -0.23 -0.21 Diabetic kidney disease; chr7:66407358 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs778691 ENSG00000232546.1 RP11-458F8.1 -3.99 8.05e-05 0.0155 -0.23 -0.21 Diabetic kidney disease; chr7:66408105 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs13235972 ENSG00000232546.1 RP11-458F8.1 -3.99 8.05e-05 0.0155 -0.23 -0.21 Diabetic kidney disease; chr7:66418618 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs34192067 ENSG00000232546.1 RP11-458F8.1 -3.99 8.05e-05 0.0155 -0.23 -0.21 Diabetic kidney disease; chr7:66422670 chr7:66848496~66858136:+ LIHC cis rs17482078 0.918 rs13160231 ENSG00000248734.2 CTD-2260A17.1 3.99 8.05e-05 0.0155 0.31 0.21 Behcet's disease;Blood protein levels; chr5:96818087 chr5:96784777~96785999:+ LIHC cis rs77204473 0.744 rs12419178 ENSG00000254851.1 RP11-109L13.1 3.99 8.07e-05 0.0155 0.38 0.21 Sum eosinophil basophil counts;Eosinophil counts; chr11:117180202 chr11:117135528~117138582:+ LIHC cis rs1247318 0.951 rs1247298 ENSG00000243831.1 RP1-81D8.4 3.99 8.07e-05 0.0155 0.31 0.21 Aging; chr6:160926657 chr6:160666228~160676523:- LIHC cis rs8064024 0.604 rs1049212 ENSG00000267077.1 RP11-127I20.5 -3.99 8.07e-05 0.0155 -0.22 -0.21 Cancer; chr16:4882928 chr16:4795265~4796532:- LIHC cis rs9527 0.615 rs7899622 ENSG00000236937.2 PTGES3P4 3.99 8.07e-05 0.0155 0.26 0.21 Arsenic metabolism; chr10:102967576 chr10:102845595~102845950:+ LIHC cis rs4713118 0.662 rs175954 ENSG00000219891.2 ZSCAN12P1 3.99 8.08e-05 0.0155 0.31 0.21 Parkinson's disease; chr6:28043807 chr6:28091154~28093664:+ LIHC cis rs1062177 0.756 rs2915815 ENSG00000253921.1 CTB-113P19.3 3.99 8.08e-05 0.0155 0.24 0.21 Preschool internalizing problems; chr5:151736322 chr5:151753992~151767247:+ LIHC cis rs2072510 0.966 rs2660896 ENSG00000257715.1 RP11-256L6.2 -3.99 8.09e-05 0.0155 -0.22 -0.21 Metabolite levels (small molecules and protein measures); chr12:96030004 chr12:96025323~96027971:+ LIHC cis rs8026198 0.929 rs2918461 ENSG00000260571.1 BNIP3P5 -3.99 8.09e-05 0.0155 -0.3 -0.21 Fibrinogen levels; chr15:42328283 chr15:42313687~42314386:+ LIHC cis rs12956009 0.518 rs1347343 ENSG00000280212.1 RP11-49K24.3 -3.99 8.1e-05 0.0155 -0.23 -0.21 Educational attainment (years of education); chr18:47292625 chr18:47076117~47076594:+ LIHC cis rs2036707 1 rs2036707 ENSG00000277246.1 RP11-153I24.4 -3.99 8.1e-05 0.0155 -0.37 -0.21 Obesity-related traits; chr13:107832106 chr13:108267320~108267734:+ LIHC cis rs3845817 0.703 rs702904 ENSG00000281920.1 RP11-418H16.1 -3.99 8.1e-05 0.0155 -0.25 -0.21 Bipolar disorder; chr2:65538960 chr2:65623272~65628424:+ LIHC cis rs9341808 0.622 rs682482 ENSG00000272129.1 RP11-250B2.6 -3.99 8.1e-05 0.0155 -0.22 -0.21 Sitting height ratio; chr6:80251422 chr6:80355424~80356859:+ LIHC cis rs6997458 1 rs6997458 ENSG00000253549.4 RP11-317J10.2 3.99 8.1e-05 0.0155 0.24 0.21 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85361801 chr8:85441851~85464915:- LIHC cis rs733175 0.855 rs9291641 ENSG00000250413.1 RP11-448G15.1 -3.99 8.11e-05 0.0156 -0.3 -0.21 Psychosis and Alzheimer's disease; chr4:10005635 chr4:10006482~10009725:+ LIHC cis rs9929218 0.551 rs2296409 ENSG00000260459.2 FTLP14 3.99 8.12e-05 0.0156 0.24 0.21 Colorectal cancer; chr16:68679827 chr16:68822587~68823070:+ LIHC cis rs847851 0.798 rs12212217 ENSG00000276712.1 MIR7111 -3.99 8.12e-05 0.0156 -0.21 -0.21 Colonoscopy-negative controls vs population controls; chr6:35004301 chr6:35470508~35470579:+ LIHC cis rs847851 0.798 rs2140418 ENSG00000276712.1 MIR7111 -3.99 8.12e-05 0.0156 -0.21 -0.21 Colonoscopy-negative controls vs population controls; chr6:35007638 chr6:35470508~35470579:+ LIHC cis rs9400467 0.528 rs17539197 ENSG00000271789.1 RP5-1112D6.7 -3.99 8.12e-05 0.0156 -0.2 -0.21 Amino acid levels;Blood metabolite levels; chr6:111447968 chr6:111297126~111298510:+ LIHC cis rs16895768 0.786 rs71626451 ENSG00000229666.1 MAST4-AS1 -3.99 8.12e-05 0.0156 -0.5 -0.21 Selective IgA deficiency; chr5:66874710 chr5:67001383~67003953:- LIHC cis rs938554 0.513 rs10939650 ENSG00000250413.1 RP11-448G15.1 -3.99 8.13e-05 0.0156 -0.28 -0.21 Blood metabolite levels; chr4:9996816 chr4:10006482~10009725:+ LIHC cis rs10129255 0.5 rs8014529 ENSG00000211972.2 IGHV3-66 3.99 8.13e-05 0.0156 0.16 0.21 Kawasaki disease; chr14:106784065 chr14:106675017~106675544:- LIHC cis rs10129255 0.5 rs12101190 ENSG00000211972.2 IGHV3-66 3.99 8.13e-05 0.0156 0.16 0.21 Kawasaki disease; chr14:106784149 chr14:106675017~106675544:- LIHC cis rs10129255 0.518 rs8004895 ENSG00000211972.2 IGHV3-66 3.99 8.13e-05 0.0156 0.16 0.21 Kawasaki disease; chr14:106785139 chr14:106675017~106675544:- LIHC cis rs858239 0.932 rs199355 ENSG00000226816.2 AC005082.12 3.99 8.13e-05 0.0156 0.28 0.21 Cerebrospinal fluid biomarker levels; chr7:23256914 chr7:23206013~23208045:+ LIHC cis rs17376456 0.877 rs10044066 ENSG00000251023.1 RP11-549J18.1 -3.99 8.13e-05 0.0156 -0.44 -0.21 Diabetic retinopathy; chr5:94101875 chr5:93860669~93863825:- LIHC cis rs244293 0.73 rs9898020 ENSG00000275710.1 RP11-257O5.4 3.99 8.13e-05 0.0156 0.23 0.21 Menarche (age at onset); chr17:54980354 chr17:54964474~54964679:+ LIHC cis rs2239557 0.5 rs7157723 ENSG00000259065.1 RP5-1021I20.1 3.99 8.13e-05 0.0156 0.27 0.21 Common traits (Other); chr14:73999497 chr14:73787360~73803270:+ LIHC cis rs875971 0.522 rs34973832 ENSG00000273024.4 INTS4P2 -3.99 8.13e-05 0.0156 -0.25 -0.21 Aortic root size; chr7:65931217 chr7:65647864~65715661:+ LIHC cis rs4925386 0.681 rs2427296 ENSG00000273619.1 RP5-908M14.9 -3.99 8.14e-05 0.0156 -0.2 -0.21 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62352419 chr20:62386303~62386970:- LIHC cis rs4073416 0.679 rs11622829 ENSG00000276116.2 FUT8-AS1 3.99 8.14e-05 0.0156 0.26 0.21 N-glycan levels; chr14:65725064 chr14:65411170~65412690:- LIHC cis rs6142102 0.961 rs4911390 ENSG00000275784.1 RP5-1125A11.6 -3.99 8.14e-05 0.0156 -0.24 -0.21 Skin pigmentation; chr20:33977401 chr20:33989480~33991818:- LIHC cis rs6142102 0.923 rs6057961 ENSG00000275784.1 RP5-1125A11.6 -3.99 8.14e-05 0.0156 -0.24 -0.21 Skin pigmentation; chr20:33986005 chr20:33989480~33991818:- LIHC cis rs6732160 0.967 rs6760964 ENSG00000272702.1 RP11-44N22.3 3.99 8.14e-05 0.0156 0.23 0.21 Intelligence (multi-trait analysis); chr2:73160258 chr2:73113018~73115907:+ LIHC cis rs8037137 0.915 rs76119208 ENSG00000258725.1 PRC1-AS1 -3.99 8.14e-05 0.0156 -0.27 -0.21 Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr15:90992099 chr15:90966345~90988624:+ LIHC cis rs365302 0.556 rs563553 ENSG00000216480.2 RP3-393E18.1 -3.99 8.14e-05 0.0156 -0.26 -0.21 Coronary heart disease; chr6:159210107 chr6:159526062~159526527:- LIHC cis rs365302 0.556 rs563436 ENSG00000216480.2 RP3-393E18.1 -3.99 8.14e-05 0.0156 -0.26 -0.21 Coronary heart disease; chr6:159210145 chr6:159526062~159526527:- LIHC cis rs494453 0.922 rs486982 ENSG00000227811.2 FAM212B-AS1 -3.99 8.14e-05 0.0156 -0.24 -0.21 Osteoporosis-related phenotypes; chr1:111710492 chr1:111739841~111747798:+ LIHC cis rs4650994 1 rs10913570 ENSG00000273384.1 RP5-1098D14.1 3.99 8.15e-05 0.0156 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178553991 chr1:178651706~178652282:+ LIHC cis rs3809863 0.602 rs7225700 ENSG00000228782.6 CTD-2026D20.3 3.99 8.15e-05 0.0156 0.24 0.21 Glaucoma (primary open-angle); chr17:47314438 chr17:47450568~47492492:- LIHC cis rs4713118 0.629 rs203887 ENSG00000219392.1 RP1-265C24.5 -3.99 8.15e-05 0.0156 -0.32 -0.21 Parkinson's disease; chr6:28053491 chr6:28115628~28116551:+ LIHC cis rs7208859 0.573 rs73267873 ENSG00000264538.5 SUZ12P1 -3.99 8.15e-05 0.0156 -0.21 -0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741439 chr17:30709299~30790908:+ LIHC cis rs17826219 0.561 rs4085382 ENSG00000264538.5 SUZ12P1 -3.99 8.15e-05 0.0156 -0.21 -0.21 Body mass index; chr17:30744184 chr17:30709299~30790908:+ LIHC cis rs295490 0.831 rs57707457 ENSG00000272656.1 RP11-219D15.3 3.99 8.15e-05 0.0156 0.58 0.21 PR interval in Tripanosoma cruzi seropositivity; chr3:139520256 chr3:139349024~139349371:- LIHC cis rs12468226 1 rs7587234 ENSG00000272966.1 RP11-686O6.1 3.99 8.16e-05 0.0156 0.36 0.21 Urate levels; chr2:202351699 chr2:202336739~202337200:+ LIHC cis rs2243480 1 rs1546059 ENSG00000232546.1 RP11-458F8.1 3.99 8.16e-05 0.0156 0.24 0.21 Diabetic kidney disease; chr7:66189722 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs6958289 ENSG00000232546.1 RP11-458F8.1 3.99 8.16e-05 0.0156 0.24 0.21 Diabetic kidney disease; chr7:66192124 chr7:66848496~66858136:+ LIHC cis rs10761256 0.752 rs6479500 ENSG00000227603.1 RP11-165J3.6 3.99 8.16e-05 0.0156 0.24 0.21 Itch intensity from mosquito bite adjusted by bite size; chr9:93645540 chr9:93435332~93437121:- LIHC cis rs73198271 0.74 rs10103163 ENSG00000253893.2 FAM85B 3.99 8.16e-05 0.0156 0.31 0.21 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8793165 chr8:8167819~8226614:- LIHC cis rs73198271 0.599 rs10103169 ENSG00000253893.2 FAM85B 3.99 8.16e-05 0.0156 0.31 0.21 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8793188 chr8:8167819~8226614:- LIHC cis rs73198271 0.7 rs10103282 ENSG00000253893.2 FAM85B 3.99 8.16e-05 0.0156 0.31 0.21 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8793247 chr8:8167819~8226614:- LIHC cis rs1405130 0.869 rs11682735 ENSG00000224287.2 MSL3P1 3.99 8.16e-05 0.0156 0.25 0.21 Coronary artery disease; chr2:234658186 chr2:233865437~233868444:- LIHC cis rs651907 0.557 rs11917569 ENSG00000244119.1 PDCL3P4 3.99 8.16e-05 0.0156 0.22 0.21 Colorectal cancer; chr3:101636219 chr3:101712472~101713191:+ LIHC cis rs3824488 0.599 rs357523 ENSG00000237857.2 RP11-435O5.2 -3.99 8.16e-05 0.0156 -0.3 -0.21 Neuroticism; chr9:95427053 chr9:95414834~95426796:- LIHC cis rs12908161 1 rs17601029 ENSG00000259728.4 LINC00933 3.99 8.17e-05 0.0156 0.3 0.21 Schizophrenia; chr15:84804478 chr15:84570649~84580175:+ LIHC cis rs948562 0.793 rs11229552 ENSG00000280010.1 AP001350.4 3.99 8.17e-05 0.0156 0.39 0.21 Lymphoma; chr11:58633441 chr11:58627435~58628528:+ LIHC cis rs1223397 0.651 rs2439535 ENSG00000215022.6 RP1-257A7.4 -3.99 8.17e-05 0.0156 -0.23 -0.21 Blood pressure; chr6:13305590 chr6:13264861~13295586:- LIHC cis rs2562456 1 rs2359155 ENSG00000268555.1 RP11-678G14.3 -3.99 8.17e-05 0.0157 -0.29 -0.21 Pain; chr19:21489067 chr19:21570822~21587322:- LIHC cis rs673078 0.607 rs17440942 ENSG00000275759.1 RP11-131L12.3 3.99 8.18e-05 0.0157 0.42 0.21 Glucose homeostasis traits; chr12:118394030 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs4767669 ENSG00000275759.1 RP11-131L12.3 -3.99 8.18e-05 0.0157 -0.42 -0.21 Glucose homeostasis traits; chr12:118390651 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs4767670 ENSG00000275759.1 RP11-131L12.3 -3.99 8.18e-05 0.0157 -0.42 -0.21 Glucose homeostasis traits; chr12:118390737 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs950288 ENSG00000275759.1 RP11-131L12.3 -3.99 8.18e-05 0.0157 -0.42 -0.21 Glucose homeostasis traits; chr12:118392201 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs61943399 ENSG00000275759.1 RP11-131L12.3 -3.99 8.18e-05 0.0157 -0.42 -0.21 Glucose homeostasis traits; chr12:118393628 chr12:118428281~118428870:+ LIHC cis rs2299116 0.962 rs2299114 ENSG00000225264.3 ZNRF2P2 -3.99 8.18e-05 0.0157 -0.23 -0.21 Serum thyroid-stimulating hormone levels; chr7:28775183 chr7:29598795~29685255:- LIHC cis rs901683 1 rs12779281 ENSG00000230869.1 CTGLF10P -3.99 8.19e-05 0.0157 -0.51 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45481999 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71499565 ENSG00000230869.1 CTGLF10P -3.99 8.19e-05 0.0157 -0.51 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45482267 chr10:45678692~45700532:+ LIHC cis rs10883723 0.81 rs7090034 ENSG00000236937.2 PTGES3P4 -3.99 8.19e-05 0.0157 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102521398 chr10:102845595~102845950:+ LIHC cis rs17818399 0.574 rs6544907 ENSG00000239332.4 LINC01119 -3.99 8.19e-05 0.0157 -0.27 -0.21 Height; chr2:46641180 chr2:46816697~46859007:+ LIHC cis rs11089937 0.568 rs6001078 ENSG00000211639.2 IGLV4-60 3.99 8.19e-05 0.0157 0.18 0.21 Periodontitis (PAL4Q3); chr22:22134365 chr22:22162199~22162681:+ LIHC cis rs11637445 0.677 rs4386088 ENSG00000260657.2 RP11-315D16.4 -3.99 8.2e-05 0.0157 -0.29 -0.21 Posterior cortical atrophy and Alzheimer's disease; chr15:67816575 chr15:68267792~68277994:- LIHC cis rs11637445 0.64 rs4508380 ENSG00000260657.2 RP11-315D16.4 -3.99 8.2e-05 0.0157 -0.29 -0.21 Posterior cortical atrophy and Alzheimer's disease; chr15:67816711 chr15:68267792~68277994:- LIHC cis rs2749097 1 rs11208263 ENSG00000244256.3 RN7SL130P -3.99 8.2e-05 0.0157 -0.27 -0.21 Alcohol consumption (transferrin glycosylation); chr1:63659259 chr1:63655743~63656047:+ LIHC cis rs1816213 0.744 rs12991539 ENSG00000273466.1 RP11-548H3.1 -3.99 8.21e-05 0.0157 -0.34 -0.21 Diastolic blood pressure; chr2:218563357 chr2:218633256~218634014:- LIHC cis rs1023500 0.573 rs133370 ENSG00000226450.2 CYP2D8P 3.99 8.21e-05 0.0157 0.26 0.21 Schizophrenia; chr22:42069256 chr22:42149886~42155001:- LIHC cis rs1023500 0.573 rs1807494 ENSG00000226450.2 CYP2D8P -3.99 8.21e-05 0.0157 -0.26 -0.21 Schizophrenia; chr22:42078134 chr22:42149886~42155001:- LIHC cis rs228614 0.51 rs223438 ENSG00000248971.2 KRT8P46 3.99 8.21e-05 0.0157 0.21 0.21 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798584 chr4:102728746~102730171:- LIHC cis rs2032447 0.901 rs1540276 ENSG00000242387.1 HIST1H2APS2 3.99 8.22e-05 0.0157 0.27 0.21 Intelligence (multi-trait analysis); chr6:26028591 chr6:25882026~25882395:- LIHC cis rs2070488 1 rs7433707 ENSG00000229589.1 ACVR2B-AS1 3.99 8.22e-05 0.0157 0.24 0.21 Electrocardiographic conduction measures; chr3:38401689 chr3:38451027~38454820:- LIHC cis rs2070488 0.932 rs4678604 ENSG00000229589.1 ACVR2B-AS1 3.99 8.22e-05 0.0157 0.24 0.21 Electrocardiographic conduction measures; chr3:38402782 chr3:38451027~38454820:- LIHC cis rs2439831 1 rs565007 ENSG00000166763.7 STRCP1 3.99 8.22e-05 0.0157 0.29 0.21 Lung cancer in ever smokers; chr15:43424443 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs550239 ENSG00000166763.7 STRCP1 3.99 8.22e-05 0.0157 0.29 0.21 Lung cancer in ever smokers; chr15:43427999 chr15:43699488~43718184:- LIHC cis rs7937890 0.732 rs7946902 ENSG00000251991.1 RNU7-49P -3.99 8.22e-05 0.0157 -0.23 -0.21 Mitochondrial DNA levels; chr11:14251762 chr11:14478892~14478953:+ LIHC cis rs7674212 0.581 rs10516496 ENSG00000248971.2 KRT8P46 -3.99 8.22e-05 0.0157 -0.22 -0.21 Type 2 diabetes; chr4:103021008 chr4:102728746~102730171:- LIHC cis rs13113518 0.812 rs2412648 ENSG00000249700.7 SRD5A3-AS1 3.99 8.22e-05 0.0157 0.25 0.21 Height; chr4:55454900 chr4:55363971~55395847:- LIHC cis rs13113518 0.812 rs12512737 ENSG00000249700.7 SRD5A3-AS1 3.99 8.22e-05 0.0157 0.25 0.21 Height; chr4:55454938 chr4:55363971~55395847:- LIHC cis rs13113518 0.812 rs13125984 ENSG00000249700.7 SRD5A3-AS1 3.99 8.22e-05 0.0157 0.25 0.21 Height; chr4:55455102 chr4:55363971~55395847:- LIHC cis rs4913250 0.514 rs7133322 ENSG00000251301.5 RP11-81H14.2 -3.99 8.22e-05 0.0157 -0.27 -0.21 Amyotrophic lateral sclerosis (C9orf72 mutation interaction); chr12:67541047 chr12:68332888~68451663:- LIHC cis rs7945705 0.846 rs905290 ENSG00000254860.4 TMEM9B-AS1 -3.99 8.23e-05 0.0157 -0.21 -0.21 Hemoglobin concentration; chr11:8732182 chr11:8964675~8977527:+ LIHC cis rs7809950 0.817 rs11535285 ENSG00000238832.1 snoU109 -3.99 8.23e-05 0.0157 -0.27 -0.21 Coronary artery disease; chr7:107503421 chr7:107603363~107603507:+ LIHC cis rs11671005 0.656 rs55928441 ENSG00000269473.1 CTD-2619J13.19 3.99 8.23e-05 0.0157 0.39 0.21 Mean platelet volume; chr19:58498307 chr19:58440448~58445849:+ LIHC cis rs1799949 0.501 rs2343819 ENSG00000267681.1 CTD-3199J23.6 -3.99 8.24e-05 0.0158 -0.21 -0.21 Menopause (age at onset); chr17:43332285 chr17:43144956~43145255:+ LIHC cis rs1799949 0.501 rs35399157 ENSG00000267681.1 CTD-3199J23.6 -3.99 8.24e-05 0.0158 -0.21 -0.21 Menopause (age at onset); chr17:43334234 chr17:43144956~43145255:+ LIHC cis rs1799949 0.602 rs4600503 ENSG00000267681.1 CTD-3199J23.6 -3.99 8.24e-05 0.0158 -0.21 -0.21 Menopause (age at onset); chr17:43336956 chr17:43144956~43145255:+ LIHC cis rs1799949 0.501 rs9675035 ENSG00000267681.1 CTD-3199J23.6 -3.99 8.24e-05 0.0158 -0.21 -0.21 Menopause (age at onset); chr17:43337648 chr17:43144956~43145255:+ LIHC cis rs9450351 0.744 rs7775016 ENSG00000203875.9 SNHG5 -3.99 8.24e-05 0.0158 -0.45 -0.21 Interferon gamma-induced protein 10 levels; chr6:85780196 chr6:85660950~85678736:- LIHC cis rs11096990 0.656 rs2123028 ENSG00000249207.1 RP11-360F5.1 3.99 8.24e-05 0.0158 0.21 0.21 Cognitive function; chr4:39301859 chr4:39112677~39126818:- LIHC cis rs7580658 0.545 rs13001179 ENSG00000236682.1 AC068282.3 -3.99 8.24e-05 0.0158 -0.26 -0.21 Protein C levels; chr2:127194617 chr2:127389130~127400580:+ LIHC cis rs7580658 0.545 rs13001184 ENSG00000236682.1 AC068282.3 -3.99 8.24e-05 0.0158 -0.26 -0.21 Protein C levels; chr2:127194630 chr2:127389130~127400580:+ LIHC cis rs11690935 0.655 rs12997093 ENSG00000228389.1 AC068039.4 -3.99 8.24e-05 0.0158 -0.25 -0.21 Schizophrenia; chr2:171707928 chr2:171773482~171775844:+ LIHC cis rs1247318 1 rs1247317 ENSG00000243831.1 RP1-81D8.4 -3.99 8.24e-05 0.0158 -0.28 -0.21 Aging; chr6:160913382 chr6:160666228~160676523:- LIHC cis rs2337406 1 rs11845269 ENSG00000274576.2 IGHV2-70 -3.99 8.24e-05 0.0158 -0.22 -0.21 Alzheimer's disease (late onset); chr14:106683851 chr14:106770577~106771020:- LIHC cis rs17376456 0.825 rs17314825 ENSG00000251023.1 RP11-549J18.1 -3.99 8.24e-05 0.0158 -0.44 -0.21 Diabetic retinopathy; chr5:93899231 chr5:93860669~93863825:- LIHC cis rs7976059 0.505 rs303795 ENSG00000261586.2 RP11-923I11.6 3.99 8.24e-05 0.0158 0.23 0.21 Urate levels; chr12:51852154 chr12:51817899~51820150:+ LIHC cis rs230529 0.51 rs1120986 ENSG00000230069.3 LRRC37A15P -3.99 8.24e-05 0.0158 -0.19 -0.21 Schizophrenia (treatment resistant); chr4:102515484 chr4:102727274~102730721:- LIHC cis rs875971 0.522 rs709604 ENSG00000273024.4 INTS4P2 3.99 8.25e-05 0.0158 0.25 0.21 Aortic root size; chr7:66032447 chr7:65647864~65715661:+ LIHC cis rs10510102 0.872 rs7907815 ENSG00000273891.1 RP11-500G22.5 3.99 8.25e-05 0.0158 0.28 0.21 Breast cancer; chr10:121965951 chr10:121965764~121967700:+ LIHC cis rs2390582 0.563 rs12735216 ENSG00000231613.1 RP5-943J3.1 3.99 8.25e-05 0.0158 0.44 0.21 Coronary artery calcification; chr1:90296151 chr1:89788914~89790492:+ LIHC cis rs193541 0.632 rs10037044 ENSG00000263432.2 RN7SL689P -3.99 8.25e-05 0.0158 -0.34 -0.21 Glucose homeostasis traits; chr5:122787604 chr5:123022487~123022783:- LIHC cis rs9457247 0.602 rs2157388 ENSG00000227598.1 RP1-167A14.2 -3.99 8.25e-05 0.0158 -0.23 -0.21 Crohn's disease; chr6:167068424 chr6:166969626~166999065:- LIHC cis rs9834975 0.875 rs4678191 ENSG00000272758.4 RP11-299J3.8 -3.99 8.25e-05 0.0158 -0.24 -0.21 Diastolic blood pressure; chr3:122402391 chr3:122416207~122443180:+ LIHC cis rs3020736 0.5 rs6002597 ENSG00000226450.2 CYP2D8P -3.98 8.25e-05 0.0158 -0.26 -0.21 Autism spectrum disorder or schizophrenia; chr22:42092156 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs7292241 ENSG00000226450.2 CYP2D8P -3.98 8.25e-05 0.0158 -0.26 -0.21 Autism spectrum disorder or schizophrenia; chr22:42096059 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs6002603 ENSG00000226450.2 CYP2D8P -3.98 8.25e-05 0.0158 -0.26 -0.21 Autism spectrum disorder or schizophrenia; chr22:42096358 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs5996111 ENSG00000226450.2 CYP2D8P -3.98 8.25e-05 0.0158 -0.26 -0.21 Autism spectrum disorder or schizophrenia; chr22:42097898 chr22:42149886~42155001:- LIHC cis rs2243480 1 rs9769882 ENSG00000232546.1 RP11-458F8.1 3.98 8.25e-05 0.0158 0.24 0.21 Diabetic kidney disease; chr7:66177938 chr7:66848496~66858136:+ LIHC cis rs76878669 0.917 rs10219183 ENSG00000255320.1 RP11-755F10.1 -3.98 8.25e-05 0.0158 -0.28 -0.21 Educational attainment (years of education); chr11:66322561 chr11:66244840~66246239:- LIHC cis rs10857712 0.904 rs7083614 ENSG00000214279.11 SCART1 -3.98 8.25e-05 0.0158 -0.26 -0.21 Systemic lupus erythematosus; chr10:133412732 chr10:133453928~133523558:+ LIHC cis rs16958440 0.867 rs2117373 ENSG00000267724.1 RP11-49K24.8 3.98 8.25e-05 0.0158 0.31 0.21 Sitting height ratio; chr18:47145463 chr18:47105946~47108062:+ LIHC cis rs6471393 0.893 rs2976350 ENSG00000253848.1 RP11-10N23.5 -3.98 8.26e-05 0.0158 -0.23 -0.21 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93716818 chr8:93741193~93744534:+ LIHC cis rs10761256 0.778 rs6479499 ENSG00000227603.1 RP11-165J3.6 3.98 8.26e-05 0.0158 0.24 0.21 Itch intensity from mosquito bite adjusted by bite size; chr9:93643582 chr9:93435332~93437121:- LIHC cis rs287982 1 rs287981 ENSG00000269973.1 RP11-95D17.1 3.98 8.26e-05 0.0158 0.2 0.21 Nonsyndromic cleft lip with cleft palate; chr2:9831433 chr2:9936360~9939590:+ LIHC cis rs1003719 0.68 rs2835630 ENSG00000272948.2 AP001412.1 -3.98 8.27e-05 0.0158 -0.23 -0.21 Eye color traits; chr21:37149542 chr21:37267784~37268497:+ LIHC cis rs1003719 0.68 rs2257091 ENSG00000272948.2 AP001412.1 -3.98 8.27e-05 0.0158 -0.23 -0.21 Eye color traits; chr21:37150318 chr21:37267784~37268497:+ LIHC cis rs6910233 0.682 rs9380369 ENSG00000224557.6 HLA-DPB2 -3.98 8.27e-05 0.0158 -0.22 -0.21 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr6:33563694 chr6:33112451~33129084:+ LIHC cis rs1023500 0.552 rs133368 ENSG00000205702.9 CYP2D7 3.98 8.27e-05 0.0158 0.24 0.21 Schizophrenia; chr22:42067685 chr22:42140203~42144577:- LIHC cis rs11668505 0.897 rs12981676 ENSG00000259108.2 CTD-3098H1.2 3.98 8.28e-05 0.0158 0.27 0.21 Lung function (FVC); chr19:47848797 chr19:47863483~47865341:- LIHC cis rs13113518 0.812 rs12649507 ENSG00000249700.7 SRD5A3-AS1 -3.98 8.28e-05 0.0158 -0.25 -0.21 Height; chr4:55514317 chr4:55363971~55395847:- LIHC cis rs7722022 0.961 rs34574781 ENSG00000253428.1 CTB-43E15.2 3.98 8.28e-05 0.0158 0.23 0.21 Adiponectin levels; chr5:173521060 chr5:173689459~173705849:+ LIHC cis rs2243480 0.708 rs13242216 ENSG00000230295.1 RP11-458F8.2 -3.98 8.28e-05 0.0158 -0.23 -0.21 Diabetic kidney disease; chr7:66433290 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs67536397 ENSG00000230295.1 RP11-458F8.2 -3.98 8.28e-05 0.0158 -0.23 -0.21 Diabetic kidney disease; chr7:66482930 chr7:66880708~66882981:+ LIHC cis rs2243480 1 rs58669269 ENSG00000230295.1 RP11-458F8.2 -3.98 8.28e-05 0.0158 -0.23 -0.21 Diabetic kidney disease; chr7:66486966 chr7:66880708~66882981:+ LIHC cis rs3015497 0.789 rs3015498 ENSG00000269906.1 RP11-248J18.2 3.98 8.28e-05 0.0158 0.27 0.21 Mean platelet volume; chr14:50646106 chr14:50662511~50663178:- LIHC cis rs11098499 0.697 rs35280960 ENSG00000260091.1 RP11-33B1.4 -3.98 8.28e-05 0.0158 -0.15 -0.21 Corneal astigmatism; chr4:119335904 chr4:119409333~119410233:+ LIHC cis rs7580658 0.545 rs885276 ENSG00000236682.1 AC068282.3 -3.98 8.28e-05 0.0158 -0.26 -0.21 Protein C levels; chr2:127193328 chr2:127389130~127400580:+ LIHC cis rs4938303 0.633 rs1960036 ENSG00000254851.1 RP11-109L13.1 3.98 8.28e-05 0.0158 0.29 0.21 Triglycerides; chr11:116676692 chr11:117135528~117138582:+ LIHC cis rs4938303 0.633 rs61906104 ENSG00000254851.1 RP11-109L13.1 3.98 8.28e-05 0.0158 0.29 0.21 Triglycerides; chr11:116679398 chr11:117135528~117138582:+ LIHC cis rs617219 0.55 rs115009495 ENSG00000251675.1 CTC-458I2.2 -3.98 8.28e-05 0.0158 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79138008 chr5:80128361~80143883:+ LIHC cis rs4787491 0.704 rs66467443 ENSG00000250616.2 RP11-455F5.3 3.98 8.29e-05 0.0158 0.21 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30039173 chr16:30096430~30104116:+ LIHC cis rs8077577 0.731 rs11869952 ENSG00000260647.1 RP1-178F10.1 3.98 8.29e-05 0.0158 0.27 0.21 Obesity-related traits; chr17:18318399 chr17:18268080~18268828:+ LIHC cis rs16958440 1 rs11082563 ENSG00000267724.1 RP11-49K24.8 3.98 8.29e-05 0.0158 0.32 0.21 Sitting height ratio; chr18:47132630 chr18:47105946~47108062:+ LIHC cis rs3015497 0.587 rs1353204 ENSG00000269906.1 RP11-248J18.2 3.98 8.3e-05 0.0159 0.26 0.21 Mean platelet volume; chr14:50614797 chr14:50662511~50663178:- LIHC cis rs950880 0.71 rs3771171 ENSG00000234389.1 AC007278.3 -3.98 8.3e-05 0.0159 -0.22 -0.21 Serum protein levels (sST2); chr2:102369490 chr2:102438713~102440475:+ LIHC cis rs7119038 0.818 rs2155433 ENSG00000255422.1 AP002954.4 3.98 8.3e-05 0.0159 0.26 0.21 Sjögren's syndrome; chr11:118742212 chr11:118704607~118750263:+ LIHC cis rs9341808 0.622 rs684283 ENSG00000272129.1 RP11-250B2.6 -3.98 8.3e-05 0.0159 -0.22 -0.21 Sitting height ratio; chr6:80257600 chr6:80355424~80356859:+ LIHC cis rs6504622 0.755 rs4968253 ENSG00000262879.4 RP11-156P1.3 -3.98 8.3e-05 0.0159 -0.22 -0.21 Orofacial clefts; chr17:47093553 chr17:46984045~47100323:- LIHC cis rs4650994 1 rs35810840 ENSG00000273384.1 RP5-1098D14.1 3.98 8.3e-05 0.0159 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178553507 chr1:178651706~178652282:+ LIHC cis rs13113518 0.812 rs7667741 ENSG00000249700.7 SRD5A3-AS1 3.98 8.31e-05 0.0159 0.25 0.21 Height; chr4:55544621 chr4:55363971~55395847:- LIHC cis rs10833905 1 rs11026884 ENSG00000246225.5 RP11-17A1.3 -3.98 8.31e-05 0.0159 -0.27 -0.21 Sudden cardiac arrest; chr11:22997830 chr11:22829380~22945393:+ LIHC cis rs35306767 0.812 rs1013504 ENSG00000229869.1 RP11-363N22.2 -3.98 8.31e-05 0.0159 -0.49 -0.21 Eosinophil percentage of granulocytes; chr10:906876 chr10:933026~942743:+ LIHC cis rs7615952 0.641 rs12491577 ENSG00000171084.14 FAM86JP 3.98 8.32e-05 0.0159 0.33 0.21 Blood pressure (smoking interaction); chr3:126012288 chr3:125916620~125930024:+ LIHC cis rs12681287 0.571 rs10097450 ENSG00000254088.1 SLC2A3P4 -3.98 8.32e-05 0.0159 -0.25 -0.21 Caudate activity during reward; chr8:86346448 chr8:86503591~86505061:+ LIHC cis rs847851 0.652 rs12661991 ENSG00000276712.1 MIR7111 -3.98 8.33e-05 0.0159 -0.21 -0.21 Colonoscopy-negative controls vs population controls; chr6:35010036 chr6:35470508~35470579:+ LIHC cis rs847851 0.798 rs2504168 ENSG00000276712.1 MIR7111 -3.98 8.33e-05 0.0159 -0.21 -0.21 Colonoscopy-negative controls vs population controls; chr6:35010203 chr6:35470508~35470579:+ LIHC cis rs2390582 0.607 rs35791630 ENSG00000231613.1 RP5-943J3.1 3.98 8.33e-05 0.0159 0.42 0.21 Coronary artery calcification; chr1:90313469 chr1:89788914~89790492:+ LIHC cis rs4578769 0.765 rs3844226 ENSG00000265943.1 RP11-739L10.1 -3.98 8.33e-05 0.0159 -0.28 -0.21 Eosinophil percentage of white cells; chr18:22866817 chr18:22699481~22933764:- LIHC cis rs12468226 1 rs112306637 ENSG00000226261.1 AC064836.3 3.98 8.33e-05 0.0159 0.34 0.21 Urate levels; chr2:202334195 chr2:202336024~202336727:- LIHC cis rs12468226 1 rs111252524 ENSG00000226261.1 AC064836.3 3.98 8.33e-05 0.0159 0.34 0.21 Urate levels; chr2:202334465 chr2:202336024~202336727:- LIHC cis rs12468226 1 rs112753638 ENSG00000226261.1 AC064836.3 3.98 8.33e-05 0.0159 0.34 0.21 Urate levels; chr2:202334496 chr2:202336024~202336727:- LIHC cis rs9595908 0.785 rs9652200 ENSG00000212293.1 SNORA16 3.98 8.33e-05 0.0159 0.24 0.21 Body mass index; chr13:32715613 chr13:32420390~32420516:- LIHC cis rs1318937 0.764 rs66813829 ENSG00000224660.1 SH3BP5-AS1 3.98 8.34e-05 0.0159 0.19 0.21 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15202214 chr3:15254184~15264493:+ LIHC cis rs703842 1 rs10747783 ENSG00000270039.1 RP11-571M6.17 -3.98 8.34e-05 0.0159 -0.29 -0.21 Multiple sclerosis; chr12:57782831 chr12:57803838~57804415:+ LIHC cis rs703842 0.964 rs10431552 ENSG00000270039.1 RP11-571M6.17 -3.98 8.34e-05 0.0159 -0.29 -0.21 Multiple sclerosis; chr12:57784365 chr12:57803838~57804415:+ LIHC cis rs709400 0.93 rs28513222 ENSG00000269958.1 RP11-73M18.8 3.98 8.34e-05 0.0159 0.29 0.21 Body mass index; chr14:103561732 chr14:103696353~103697163:+ LIHC cis rs7915414 0.951 rs12772521 ENSG00000230338.1 MTND4P19 3.98 8.35e-05 0.0159 0.22 0.21 Clopidogrel active metabolite levels; chr10:94711753 chr10:94774156~94774633:- LIHC cis rs948562 0.793 rs79170562 ENSG00000280010.1 AP001350.4 3.98 8.35e-05 0.0159 0.39 0.21 Lymphoma; chr11:58604081 chr11:58627435~58628528:+ LIHC cis rs948562 0.793 rs1944051 ENSG00000280010.1 AP001350.4 3.98 8.35e-05 0.0159 0.39 0.21 Lymphoma; chr11:58607820 chr11:58627435~58628528:+ LIHC cis rs948562 0.793 rs1800169 ENSG00000280010.1 AP001350.4 3.98 8.35e-05 0.0159 0.39 0.21 Lymphoma; chr11:58624028 chr11:58627435~58628528:+ LIHC cis rs948562 0.696 rs17568220 ENSG00000280010.1 AP001350.4 3.98 8.35e-05 0.0159 0.39 0.21 Lymphoma; chr11:58627550 chr11:58627435~58628528:+ LIHC cis rs7224610 0.898 rs4299205 ENSG00000263096.1 RP11-515O17.2 3.98 8.35e-05 0.0159 0.31 0.21 Urate levels; chr17:55288785 chr17:55271504~55273653:- LIHC cis rs7726839 0.54 rs11739847 ENSG00000271781.1 CTD-2589H19.6 -3.98 8.35e-05 0.0159 -0.32 -0.21 Obesity-related traits; chr5:609546 chr5:675826~676616:+ LIHC cis rs812925 0.533 rs35507645 ENSG00000271889.1 RP11-493E12.1 3.98 8.35e-05 0.0159 0.25 0.21 Immature fraction of reticulocytes; chr2:61169631 chr2:61151433~61162105:- LIHC cis rs2735413 0.914 rs11150035 ENSG00000276007.1 RP11-358L22.3 -3.98 8.35e-05 0.0159 -0.25 -0.21 Systolic blood pressure (alcohol consumption interaction); chr16:78032552 chr16:78123243~78124332:+ LIHC cis rs11089937 0.568 rs5756988 ENSG00000211639.2 IGLV4-60 -3.98 8.35e-05 0.0159 -0.18 -0.21 Periodontitis (PAL4Q3); chr22:22132397 chr22:22162199~22162681:+ LIHC cis rs72675573 0.852 rs72675539 ENSG00000235612.1 RP1-158P9.1 -3.98 8.35e-05 0.0159 -0.28 -0.21 Monocyte count; chr1:56118641 chr1:56145721~56155224:+ LIHC cis rs2462686 1 rs1534150 ENSG00000272556.1 RP11-638I8.1 3.98 8.35e-05 0.0159 0.32 0.21 Major depressive disorder; chr7:45945691 chr7:45814602~45815263:+ LIHC cis rs17376456 0.877 rs17316137 ENSG00000251023.1 RP11-549J18.1 -3.98 8.36e-05 0.0159 -0.43 -0.21 Diabetic retinopathy; chr5:94120872 chr5:93860669~93863825:- LIHC cis rs4578769 0.879 rs11659315 ENSG00000265943.1 RP11-739L10.1 -3.98 8.36e-05 0.0159 -0.27 -0.21 Eosinophil percentage of white cells; chr18:22836405 chr18:22699481~22933764:- LIHC cis rs4578769 0.879 rs11659384 ENSG00000265943.1 RP11-739L10.1 -3.98 8.36e-05 0.0159 -0.27 -0.21 Eosinophil percentage of white cells; chr18:22836662 chr18:22699481~22933764:- LIHC cis rs3758785 0.697 rs3758789 ENSG00000255893.1 RP11-685N10.1 -3.98 8.36e-05 0.016 -0.26 -0.21 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94399958 chr11:94472908~94473570:- LIHC cis rs6745190 0.953 rs4510177 ENSG00000236153.1 AC104076.3 3.98 8.36e-05 0.016 0.28 0.21 White blood cell count; chr2:180976518 chr2:180979427~180980090:- LIHC cis rs875971 0.545 rs1796222 ENSG00000228409.4 CCT6P1 3.98 8.37e-05 0.016 0.18 0.21 Aortic root size; chr7:66592167 chr7:65751142~65763354:+ LIHC cis rs3845817 0.703 rs702941 ENSG00000281920.1 RP11-418H16.1 -3.98 8.37e-05 0.016 -0.24 -0.21 Bipolar disorder; chr2:65521864 chr2:65623272~65628424:+ LIHC cis rs340849 0.933 rs10746444 ENSG00000274895.1 RP11-478J18.2 3.98 8.37e-05 0.016 0.22 0.21 Alzheimer's disease; chr1:213930938 chr1:213983793~213986419:- LIHC cis rs3758785 0.737 rs79512686 ENSG00000255893.1 RP11-685N10.1 -3.98 8.37e-05 0.016 -0.26 -0.21 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94398331 chr11:94472908~94473570:- LIHC cis rs1499614 1 rs1267817 ENSG00000275400.1 RP4-756H11.5 3.98 8.38e-05 0.016 0.28 0.21 Gout; chr7:66645053 chr7:66553805~66554199:- LIHC cis rs7315621 0.896 rs6421999 ENSG00000279700.1 RP13-554M15.2 3.98 8.38e-05 0.016 0.16 0.21 Longevity; chr12:131595470 chr12:132565071~132566425:+ LIHC cis rs7315621 0.93 rs7316770 ENSG00000279700.1 RP13-554M15.2 3.98 8.38e-05 0.016 0.16 0.21 Longevity; chr12:131595561 chr12:132565071~132566425:+ LIHC cis rs77204473 1 rs79207844 ENSG00000254851.1 RP11-109L13.1 3.98 8.39e-05 0.016 0.48 0.21 Sum eosinophil basophil counts;Eosinophil counts; chr11:116934725 chr11:117135528~117138582:+ LIHC cis rs2932538 0.922 rs6671645 ENSG00000225075.1 RP11-426L16.3 3.98 8.39e-05 0.016 0.26 0.21 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112586506 chr1:112693688~112696621:- LIHC cis rs2932538 0.922 rs6691917 ENSG00000225075.1 RP11-426L16.3 3.98 8.39e-05 0.016 0.26 0.21 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112594421 chr1:112693688~112696621:- LIHC cis rs9487094 0.961 rs11153177 ENSG00000260273.1 RP11-425D10.10 3.98 8.4e-05 0.016 0.25 0.21 Height; chr6:109416225 chr6:109382795~109383666:+ LIHC cis rs79349575 0.756 rs4793605 ENSG00000248278.1 SUMO2P17 3.98 8.4e-05 0.016 0.26 0.21 Type 2 diabetes; chr17:48958507 chr17:48874860~48908983:- LIHC cis rs11098499 0.82 rs28394116 ENSG00000260091.1 RP11-33B1.4 -3.98 8.4e-05 0.016 -0.15 -0.21 Corneal astigmatism; chr4:119603128 chr4:119409333~119410233:+ LIHC cis rs2562456 0.917 rs2681392 ENSG00000268555.1 RP11-678G14.3 -3.98 8.4e-05 0.016 -0.27 -0.21 Pain; chr19:21513185 chr19:21570822~21587322:- LIHC cis rs4650994 1 rs4354501 ENSG00000213057.5 C1orf220 3.98 8.41e-05 0.016 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178555461 chr1:178542752~178548889:+ LIHC cis rs4650994 0.967 rs6681043 ENSG00000213057.5 C1orf220 3.98 8.41e-05 0.016 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178556822 chr1:178542752~178548889:+ LIHC cis rs4650994 0.625 rs6681348 ENSG00000213057.5 C1orf220 3.98 8.41e-05 0.016 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178557136 chr1:178542752~178548889:+ LIHC cis rs4650994 0.625 rs6681354 ENSG00000213057.5 C1orf220 3.98 8.41e-05 0.016 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178557144 chr1:178542752~178548889:+ LIHC cis rs4650994 1 rs10913571 ENSG00000213057.5 C1orf220 3.98 8.41e-05 0.016 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178557513 chr1:178542752~178548889:+ LIHC cis rs4650994 1 rs10913572 ENSG00000213057.5 C1orf220 3.98 8.41e-05 0.016 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178557583 chr1:178542752~178548889:+ LIHC cis rs4650994 0.935 rs4652306 ENSG00000213057.5 C1orf220 3.98 8.41e-05 0.016 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178559071 chr1:178542752~178548889:+ LIHC cis rs4650994 1 rs6660445 ENSG00000213057.5 C1orf220 3.98 8.41e-05 0.016 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178559736 chr1:178542752~178548889:+ LIHC cis rs6860806 0.507 rs273917 ENSG00000263597.1 MIR3936 3.98 8.41e-05 0.016 0.23 0.21 Breast cancer; chr5:132323925 chr5:132365490~132365599:- LIHC cis rs270601 0.913 rs273916 ENSG00000263597.1 MIR3936 3.98 8.41e-05 0.016 0.23 0.21 Acylcarnitine levels; chr5:132324137 chr5:132365490~132365599:- LIHC cis rs6860806 0.507 rs273915 ENSG00000263597.1 MIR3936 3.98 8.41e-05 0.016 0.23 0.21 Breast cancer; chr5:132324426 chr5:132365490~132365599:- LIHC cis rs270601 0.955 rs273911 ENSG00000263597.1 MIR3936 3.98 8.41e-05 0.016 0.23 0.21 Acylcarnitine levels; chr5:132325833 chr5:132365490~132365599:- LIHC cis rs12936587 0.777 rs12951347 ENSG00000223979.2 SMCR2 3.98 8.41e-05 0.016 0.27 0.21 Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference; chr17:17631199 chr17:17674026~17677688:- LIHC cis rs57502260 0.704 rs55975204 ENSG00000212093.1 AP000807.1 3.98 8.41e-05 0.016 0.28 0.21 Total body bone mineral density (age 45-60); chr11:68481656 chr11:68506083~68506166:- LIHC cis rs673078 0.607 rs61943393 ENSG00000275759.1 RP11-131L12.3 -3.98 8.41e-05 0.016 -0.42 -0.21 Glucose homeostasis traits; chr12:118383650 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs73205576 ENSG00000275759.1 RP11-131L12.3 -3.98 8.41e-05 0.016 -0.42 -0.21 Glucose homeostasis traits; chr12:118384268 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs2055534 ENSG00000275759.1 RP11-131L12.3 -3.98 8.41e-05 0.016 -0.42 -0.21 Glucose homeostasis traits; chr12:118386527 chr12:118428281~118428870:+ LIHC cis rs1075232 0.677 rs72714666 ENSG00000270055.1 CTD-3092A11.2 -3.98 8.41e-05 0.016 -0.35 -0.21 Survival in colorectal cancer (non-distant metastatic); chr15:31200023 chr15:30487963~30490313:+ LIHC cis rs1005277 0.579 rs2505194 ENSG00000276805.1 RP11-291L22.6 3.98 8.41e-05 0.016 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38104953 chr10:38451030~38451785:+ LIHC cis rs1799949 1 rs4793215 ENSG00000267681.1 CTD-3199J23.6 -3.98 8.41e-05 0.016 -0.2 -0.21 Menopause (age at onset); chr17:43166915 chr17:43144956~43145255:+ LIHC cis rs41313321 0.541 rs7867338 ENSG00000272696.1 RP11-339B21.13 3.98 8.42e-05 0.016 0.28 0.21 Coenzyme Q10 levels; chr9:128302043 chr9:128316337~128316909:+ LIHC cis rs193541 0.632 rs154512 ENSG00000263432.2 RN7SL689P 3.98 8.42e-05 0.016 0.34 0.21 Glucose homeostasis traits; chr5:122859345 chr5:123022487~123022783:- LIHC cis rs193541 0.555 rs2438151 ENSG00000263432.2 RN7SL689P 3.98 8.42e-05 0.016 0.34 0.21 Glucose homeostasis traits; chr5:122863502 chr5:123022487~123022783:- LIHC cis rs72675573 0.852 rs72675530 ENSG00000235612.1 RP1-158P9.1 -3.98 8.42e-05 0.016 -0.28 -0.21 Monocyte count; chr1:56111674 chr1:56145721~56155224:+ LIHC cis rs12681287 0.64 rs12544463 ENSG00000254088.1 SLC2A3P4 3.98 8.43e-05 0.0161 0.25 0.21 Caudate activity during reward; chr8:86468885 chr8:86503591~86505061:+ LIHC cis rs4453827 1 rs13075639 ENSG00000271916.1 RP11-884K10.6 3.98 8.43e-05 0.0161 0.41 0.21 Blood protein levels; chr3:53713061 chr3:53797764~53798019:- LIHC cis rs7131987 0.903 rs11050152 ENSG00000275476.1 RP11-996F15.4 -3.98 8.43e-05 0.0161 -0.25 -0.21 QT interval; chr12:29251491 chr12:29277397~29277882:- LIHC cis rs2439831 1 rs690002 ENSG00000166763.7 STRCP1 3.98 8.43e-05 0.0161 0.29 0.21 Lung cancer in ever smokers; chr15:43437151 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs537115 ENSG00000166763.7 STRCP1 3.98 8.43e-05 0.0161 0.29 0.21 Lung cancer in ever smokers; chr15:43437750 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs2245908 ENSG00000166763.7 STRCP1 3.98 8.43e-05 0.0161 0.29 0.21 Lung cancer in ever smokers; chr15:43439256 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs2444029 ENSG00000166763.7 STRCP1 3.98 8.43e-05 0.0161 0.29 0.21 Lung cancer in ever smokers; chr15:43445286 chr15:43699488~43718184:- LIHC cis rs2439831 1 rs2467740 ENSG00000166763.7 STRCP1 3.98 8.43e-05 0.0161 0.29 0.21 Lung cancer in ever smokers; chr15:43454594 chr15:43699488~43718184:- LIHC cis rs6745190 0.953 rs4990275 ENSG00000236153.1 AC104076.3 3.98 8.43e-05 0.0161 0.29 0.21 White blood cell count; chr2:181008934 chr2:180979427~180980090:- LIHC cis rs7617773 0.817 rs4131361 ENSG00000228638.1 FCF1P2 -3.98 8.43e-05 0.0161 -0.23 -0.21 Coronary artery disease; chr3:48287322 chr3:48290793~48291375:- LIHC cis rs7617773 0.817 rs6791930 ENSG00000228638.1 FCF1P2 -3.98 8.43e-05 0.0161 -0.23 -0.21 Coronary artery disease; chr3:48288410 chr3:48290793~48291375:- LIHC cis rs7617773 0.817 rs6794644 ENSG00000228638.1 FCF1P2 -3.98 8.43e-05 0.0161 -0.23 -0.21 Coronary artery disease; chr3:48288547 chr3:48290793~48291375:- LIHC cis rs9400467 0.508 rs12211763 ENSG00000271789.1 RP5-1112D6.7 -3.98 8.43e-05 0.0161 -0.21 -0.21 Amino acid levels;Blood metabolite levels; chr6:111465953 chr6:111297126~111298510:+ LIHC cis rs4938303 0.549 rs12420888 ENSG00000254851.1 RP11-109L13.1 3.98 8.43e-05 0.0161 0.26 0.21 Triglycerides; chr11:116693106 chr11:117135528~117138582:+ LIHC cis rs11125080 1 rs11125080 ENSG00000239332.4 LINC01119 -3.98 8.44e-05 0.0161 -0.29 -0.21 Anti-saccade response;Anti-saccade error rate in psychotic disorders; chr2:46505266 chr2:46816697~46859007:+ LIHC cis rs367615 0.506 rs2914680 ENSG00000249476.1 CTD-2587M2.1 -3.98 8.44e-05 0.0161 -0.25 -0.21 Colorectal cancer (SNP x SNP interaction); chr5:109451445 chr5:109237120~109326369:- LIHC cis rs2070488 0.965 rs13079145 ENSG00000229589.1 ACVR2B-AS1 3.98 8.44e-05 0.0161 0.24 0.21 Electrocardiographic conduction measures; chr3:38476501 chr3:38451027~38454820:- LIHC cis rs2243480 1 rs1404147 ENSG00000229886.1 RP5-1132H15.3 3.98 8.44e-05 0.0161 0.3 0.21 Diabetic kidney disease; chr7:65799537 chr7:66025126~66031544:- LIHC cis rs748404 0.697 rs572959 ENSG00000205771.5 CATSPER2P1 -3.98 8.44e-05 0.0161 -0.25 -0.21 Lung cancer; chr15:43258304 chr15:43726918~43747094:- LIHC cis rs748404 0.697 rs554001 ENSG00000205771.5 CATSPER2P1 -3.98 8.44e-05 0.0161 -0.25 -0.21 Lung cancer; chr15:43259721 chr15:43726918~43747094:- LIHC cis rs11710088 0.74 rs13092900 ENSG00000244503.1 RP11-278L15.6 3.98 8.45e-05 0.0161 0.27 0.21 QRS duration; chr3:149473313 chr3:149494660~149495995:+ LIHC cis rs11710088 0.74 rs13076896 ENSG00000244503.1 RP11-278L15.6 3.98 8.45e-05 0.0161 0.27 0.21 QRS duration; chr3:149474494 chr3:149494660~149495995:+ LIHC cis rs3761847 0.622 rs10818498 ENSG00000226752.6 PSMD5-AS1 -3.98 8.45e-05 0.0161 -0.22 -0.21 Rheumatoid arthritis; chr9:121025288 chr9:120824828~120854385:+ LIHC cis rs2348418 0.864 rs2203088 ENSG00000247934.4 RP11-967K21.1 3.98 8.46e-05 0.0161 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28556767 chr12:28163298~28190738:- LIHC cis rs12936587 0.564 rs7208561 ENSG00000223979.2 SMCR2 -3.98 8.46e-05 0.0161 -0.27 -0.21 Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference; chr17:17712214 chr17:17674026~17677688:- LIHC cis rs6142102 0.961 rs1883524 ENSG00000275784.1 RP5-1125A11.6 -3.98 8.46e-05 0.0161 -0.24 -0.21 Skin pigmentation; chr20:34038301 chr20:33989480~33991818:- LIHC cis rs6745190 0.953 rs10171108 ENSG00000236153.1 AC104076.3 3.98 8.46e-05 0.0161 0.29 0.21 White blood cell count; chr2:181046944 chr2:180979427~180980090:- LIHC cis rs6745190 0.953 rs6744130 ENSG00000236153.1 AC104076.3 3.98 8.46e-05 0.0161 0.29 0.21 White blood cell count; chr2:181048088 chr2:180979427~180980090:- LIHC cis rs6745190 0.953 rs6731268 ENSG00000236153.1 AC104076.3 3.98 8.46e-05 0.0161 0.29 0.21 White blood cell count; chr2:181048264 chr2:180979427~180980090:- LIHC cis rs6745190 0.953 rs10171998 ENSG00000236153.1 AC104076.3 3.98 8.46e-05 0.0161 0.29 0.21 White blood cell count; chr2:181054763 chr2:180979427~180980090:- LIHC cis rs6745190 0.953 rs7371639 ENSG00000236153.1 AC104076.3 3.98 8.46e-05 0.0161 0.29 0.21 White blood cell count; chr2:181057272 chr2:180979427~180980090:- LIHC cis rs4073416 0.684 rs11627185 ENSG00000276116.2 FUT8-AS1 3.98 8.47e-05 0.0161 0.25 0.21 N-glycan levels; chr14:65654774 chr14:65411170~65412690:- LIHC cis rs970548 0.954 rs2291429 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total; chr10:45463433 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12769244 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45463937 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs12771275 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45464204 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34731408 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45465572 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs17157832 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45466313 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs17157836 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45468138 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs17157839 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45468329 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71494785 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45469105 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs901682 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45470413 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs901684 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45471180 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs768673 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45471301 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs10508895 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45472320 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs17157852 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45472353 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71494786 ENSG00000230869.1 CTGLF10P -3.98 8.47e-05 0.0161 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45474669 chr10:45678692~45700532:+ LIHC cis rs287982 0.935 rs287978 ENSG00000269973.1 RP11-95D17.1 3.98 8.47e-05 0.0161 0.2 0.21 Nonsyndromic cleft lip with cleft palate; chr2:9830405 chr2:9936360~9939590:+ LIHC cis rs9640161 0.75 rs3735173 ENSG00000261305.1 RP4-584D14.7 3.98 8.47e-05 0.0161 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150323437 chr7:150341771~150342607:+ LIHC cis rs6832769 1 rs3805152 ENSG00000272969.1 RP11-528I4.2 3.98 8.47e-05 0.0161 0.25 0.21 Personality dimensions; chr4:55493491 chr4:55547112~55547889:+ LIHC cis rs6860806 0.507 rs273912 ENSG00000263597.1 MIR3936 -3.98 8.47e-05 0.0161 -0.23 -0.21 Breast cancer; chr5:132325656 chr5:132365490~132365599:- LIHC cis rs11079159 0.5 rs7223165 ENSG00000263096.1 RP11-515O17.2 3.98 8.47e-05 0.0161 0.26 0.21 QRS duration; chr17:55286477 chr17:55271504~55273653:- LIHC cis rs617219 0.927 rs949644 ENSG00000251675.1 CTC-458I2.2 -3.98 8.48e-05 0.0161 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79146528 chr5:80128361~80143883:+ LIHC cis rs6669919 0.553 rs11587632 ENSG00000229832.1 RP11-384C4.2 3.98 8.48e-05 0.0161 0.23 0.21 Intelligence (multi-trait analysis); chr1:211495095 chr1:212357418~212358353:+ LIHC cis rs755249 0.567 rs2036463 ENSG00000182109.6 RP11-69E11.4 3.98 8.48e-05 0.0161 0.27 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39222403 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs2036464 ENSG00000182109.6 RP11-69E11.4 3.98 8.48e-05 0.0161 0.27 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39222570 chr1:39522280~39546187:- LIHC cis rs755249 0.567 rs905381 ENSG00000182109.6 RP11-69E11.4 3.98 8.48e-05 0.0161 0.27 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39222880 chr1:39522280~39546187:- LIHC cis rs17818399 0.749 rs13000560 ENSG00000239332.4 LINC01119 -3.98 8.48e-05 0.0161 -0.31 -0.21 Height; chr2:46563858 chr2:46816697~46859007:+ LIHC cis rs6840360 1 rs4696283 ENSG00000251603.1 RP11-164P12.4 -3.98 8.49e-05 0.0161 -0.19 -0.21 Intelligence (multi-trait analysis); chr4:151659364 chr4:151667224~151670502:+ LIHC cis rs11671005 0.656 rs11671092 ENSG00000269473.1 CTD-2619J13.19 3.98 8.49e-05 0.0161 0.39 0.21 Mean platelet volume; chr19:58497742 chr19:58440448~58445849:+ LIHC cis rs4561483 0.864 rs190461 ENSG00000261560.1 RP11-166B2.3 -3.98 8.5e-05 0.0162 -0.23 -0.21 Testicular germ cell tumor; chr16:11911888 chr16:11881075~11882569:- LIHC cis rs4561483 0.831 rs33621 ENSG00000261560.1 RP11-166B2.3 -3.98 8.5e-05 0.0162 -0.23 -0.21 Testicular germ cell tumor; chr16:11914656 chr16:11881075~11882569:- LIHC cis rs703842 1 rs8181644 ENSG00000270039.1 RP11-571M6.17 -3.98 8.5e-05 0.0162 -0.29 -0.21 Multiple sclerosis; chr12:57779683 chr12:57803838~57804415:+ LIHC cis rs244293 0.765 rs7503269 ENSG00000275710.1 RP11-257O5.4 3.98 8.5e-05 0.0162 0.25 0.21 Menarche (age at onset); chr17:54942351 chr17:54964474~54964679:+ LIHC cis rs1005277 0.602 rs1831315 ENSG00000099251.13 HSD17B7P2 3.98 8.5e-05 0.0162 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38184425 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs932538 ENSG00000099251.13 HSD17B7P2 3.98 8.5e-05 0.0162 0.24 0.21 Extrinsic epigenetic age acceleration; chr10:38092386 chr10:38356380~38378505:+ LIHC cis rs1005277 0.541 rs2472177 ENSG00000099251.13 HSD17B7P2 3.98 8.5e-05 0.0162 0.24 0.21 Extrinsic epigenetic age acceleration; chr10:38095087 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2472178 ENSG00000099251.13 HSD17B7P2 3.98 8.5e-05 0.0162 0.24 0.21 Extrinsic epigenetic age acceleration; chr10:38095822 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474572 ENSG00000099251.13 HSD17B7P2 3.98 8.5e-05 0.0162 0.24 0.21 Extrinsic epigenetic age acceleration; chr10:38096388 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2505198 ENSG00000099251.13 HSD17B7P2 3.98 8.5e-05 0.0162 0.24 0.21 Extrinsic epigenetic age acceleration; chr10:38104255 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2008449 ENSG00000099251.13 HSD17B7P2 -3.98 8.5e-05 0.0162 -0.24 -0.21 Extrinsic epigenetic age acceleration; chr10:38125276 chr10:38356380~38378505:+ LIHC cis rs755249 0.567 rs67408364 ENSG00000182109.6 RP11-69E11.4 3.98 8.5e-05 0.0162 0.27 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39152884 chr1:39522280~39546187:- LIHC cis rs948562 0.947 rs60767173 ENSG00000280010.1 AP001350.4 3.98 8.51e-05 0.0162 0.36 0.21 Lymphoma; chr11:58634074 chr11:58627435~58628528:+ LIHC cis rs9595908 0.629 rs962454 ENSG00000212293.1 SNORA16 3.98 8.51e-05 0.0162 0.24 0.21 Body mass index; chr13:32719131 chr13:32420390~32420516:- LIHC cis rs3091242 0.904 rs6661533 ENSG00000224183.1 SDHDP6 -3.98 8.51e-05 0.0162 -0.24 -0.21 Erythrocyte sedimentation rate; chr1:25445224 chr1:25294164~25294643:- LIHC cis rs55794721 0.509 rs6699113 ENSG00000224183.1 SDHDP6 -3.98 8.51e-05 0.0162 -0.24 -0.21 Mean corpuscular volume;Plateletcrit; chr1:25451252 chr1:25294164~25294643:- LIHC cis rs9976767 0.637 rs2277799 ENSG00000225218.1 AP001628.6 -3.98 8.51e-05 0.0162 -0.2 -0.21 Type 1 diabetes; chr21:42404014 chr21:42831040~42836477:- LIHC cis rs7182621 0.546 rs11632596 ENSG00000182397.13 DNM1P46 3.98 8.51e-05 0.0162 0.28 0.21 Colonoscopy-negative controls vs population controls; chr15:99834385 chr15:99790156~99806927:- LIHC cis rs8177876 0.749 rs12927239 ENSG00000261061.1 RP11-303E16.2 -3.98 8.51e-05 0.0162 -0.28 -0.21 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81053883 chr16:81030770~81031485:+ LIHC cis rs1005277 0.579 rs1780139 ENSG00000120555.12 SEPT7P9 3.98 8.52e-05 0.0162 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38214090 chr10:38383069~38402916:- LIHC cis rs3020736 0.5 rs4147638 ENSG00000205702.9 CYP2D7 -3.98 8.53e-05 0.0162 -0.24 -0.21 Autism spectrum disorder or schizophrenia; chr22:42091896 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs6002605 ENSG00000205702.9 CYP2D7 -3.98 8.53e-05 0.0162 -0.24 -0.21 Autism spectrum disorder or schizophrenia; chr22:42098331 chr22:42140203~42144577:- LIHC cis rs748404 0.697 rs1095389 ENSG00000205771.5 CATSPER2P1 -3.98 8.53e-05 0.0162 -0.26 -0.21 Lung cancer; chr15:43274473 chr15:43726918~43747094:- LIHC cis rs12468226 1 rs79919139 ENSG00000272966.1 RP11-686O6.1 3.98 8.53e-05 0.0162 0.35 0.21 Urate levels; chr2:202382786 chr2:202336739~202337200:+ LIHC cis rs12468226 0.935 rs75597391 ENSG00000272966.1 RP11-686O6.1 3.98 8.53e-05 0.0162 0.35 0.21 Urate levels; chr2:202398850 chr2:202336739~202337200:+ LIHC cis rs12468226 1 rs12472408 ENSG00000272966.1 RP11-686O6.1 3.98 8.53e-05 0.0162 0.35 0.21 Urate levels; chr2:202413973 chr2:202336739~202337200:+ LIHC cis rs12468226 1 rs115170232 ENSG00000272966.1 RP11-686O6.1 3.98 8.53e-05 0.0162 0.35 0.21 Urate levels; chr2:202416790 chr2:202336739~202337200:+ LIHC cis rs12468226 1 rs16839149 ENSG00000272966.1 RP11-686O6.1 3.98 8.53e-05 0.0162 0.35 0.21 Urate levels; chr2:202427621 chr2:202336739~202337200:+ LIHC cis rs12468226 1 rs76528043 ENSG00000272966.1 RP11-686O6.1 3.98 8.53e-05 0.0162 0.35 0.21 Urate levels; chr2:202466116 chr2:202336739~202337200:+ LIHC cis rs12468226 1 rs12468226 ENSG00000272966.1 RP11-686O6.1 3.98 8.53e-05 0.0162 0.35 0.21 Urate levels; chr2:202472278 chr2:202336739~202337200:+ LIHC cis rs12468226 1 rs75040639 ENSG00000272966.1 RP11-686O6.1 3.98 8.53e-05 0.0162 0.35 0.21 Urate levels; chr2:202486973 chr2:202336739~202337200:+ LIHC cis rs12468226 0.872 rs115187557 ENSG00000272966.1 RP11-686O6.1 3.98 8.53e-05 0.0162 0.35 0.21 Urate levels; chr2:202495351 chr2:202336739~202337200:+ LIHC cis rs12468226 1 rs74508472 ENSG00000272966.1 RP11-686O6.1 3.98 8.53e-05 0.0162 0.35 0.21 Urate levels; chr2:202517290 chr2:202336739~202337200:+ LIHC cis rs1005277 0.579 rs176880 ENSG00000276805.1 RP11-291L22.6 -3.98 8.53e-05 0.0162 -0.25 -0.21 Extrinsic epigenetic age acceleration; chr10:38112489 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2505248 ENSG00000276805.1 RP11-291L22.6 3.98 8.53e-05 0.0162 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38170169 chr10:38451030~38451785:+ LIHC cis rs1799949 0.93 rs8176194 ENSG00000267681.1 CTD-3199J23.6 -3.98 8.53e-05 0.0162 -0.2 -0.21 Menopause (age at onset); chr17:43079204 chr17:43144956~43145255:+ LIHC cis rs4561483 0.583 rs9925010 ENSG00000261560.1 RP11-166B2.3 3.98 8.53e-05 0.0162 0.25 0.21 Testicular germ cell tumor; chr16:11862811 chr16:11881075~11882569:- LIHC cis rs17711722 0.583 rs10085415 ENSG00000234338.1 RP11-797H7.1 3.98 8.53e-05 0.0162 0.2 0.21 Calcium levels; chr7:65628655 chr7:64835280~64836882:- LIHC cis rs4938303 0.633 rs77835865 ENSG00000254851.1 RP11-109L13.1 3.98 8.53e-05 0.0162 0.29 0.21 Triglycerides; chr11:116684713 chr11:117135528~117138582:+ LIHC cis rs4925386 1 rs1889201 ENSG00000226332.2 RP11-157P1.4 -3.98 8.53e-05 0.0162 -0.21 -0.21 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62348019 chr20:62305432~62306325:- LIHC cis rs7712401 0.601 rs30026 ENSG00000263432.2 RN7SL689P 3.98 8.53e-05 0.0162 0.31 0.21 Mean platelet volume; chr5:122948873 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs30022 ENSG00000263432.2 RN7SL689P 3.98 8.53e-05 0.0162 0.31 0.21 Mean platelet volume; chr5:122950021 chr5:123022487~123022783:- LIHC cis rs7712401 0.546 rs30021 ENSG00000263432.2 RN7SL689P 3.98 8.53e-05 0.0162 0.31 0.21 Mean platelet volume; chr5:122950199 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs246328 ENSG00000263432.2 RN7SL689P 3.98 8.53e-05 0.0162 0.31 0.21 Mean platelet volume; chr5:122951933 chr5:123022487~123022783:- LIHC cis rs6430553 0.964 rs1530556 ENSG00000224043.6 CCNT2-AS1 -3.98 8.54e-05 0.0162 -0.24 -0.21 Blood metabolite levels; chr2:134842164 chr2:134735464~134918710:- LIHC cis rs1115240 0.853 rs11159880 ENSG00000257842.4 NOVA1-AS1 3.98 8.54e-05 0.0162 0.19 0.21 Educational attainment (years of education); chr14:26547812 chr14:26598412~26806467:+ LIHC cis rs11971779 1 rs75919582 ENSG00000273391.1 RP11-634H22.1 3.98 8.54e-05 0.0162 0.23 0.21 Diisocyanate-induced asthma; chr7:139370173 chr7:139359032~139359566:- LIHC cis rs4148008 0.589 rs11655986 ENSG00000267250.1 RP11-118B18.2 -3.98 8.54e-05 0.0162 -0.27 -0.21 HDL cholesterol; chr17:68828615 chr17:68793549~68797822:- LIHC cis rs673078 0.607 rs7137055 ENSG00000275759.1 RP11-131L12.3 -3.98 8.54e-05 0.0162 -0.42 -0.21 Glucose homeostasis traits; chr12:118395030 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs7137184 ENSG00000275759.1 RP11-131L12.3 -3.98 8.54e-05 0.0162 -0.42 -0.21 Glucose homeostasis traits; chr12:118395163 chr12:118428281~118428870:+ LIHC cis rs673078 0.562 rs4767672 ENSG00000275759.1 RP11-131L12.3 -3.98 8.54e-05 0.0162 -0.42 -0.21 Glucose homeostasis traits; chr12:118397048 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs73205594 ENSG00000275759.1 RP11-131L12.3 -3.98 8.54e-05 0.0162 -0.42 -0.21 Glucose homeostasis traits; chr12:118397168 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs61943400 ENSG00000275759.1 RP11-131L12.3 -3.98 8.54e-05 0.0162 -0.42 -0.21 Glucose homeostasis traits; chr12:118398236 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs61943401 ENSG00000275759.1 RP11-131L12.3 -3.98 8.54e-05 0.0162 -0.42 -0.21 Glucose homeostasis traits; chr12:118398527 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs61943402 ENSG00000275759.1 RP11-131L12.3 -3.98 8.54e-05 0.0162 -0.42 -0.21 Glucose homeostasis traits; chr12:118398808 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs7309484 ENSG00000275759.1 RP11-131L12.3 -3.98 8.54e-05 0.0162 -0.42 -0.21 Glucose homeostasis traits; chr12:118400833 chr12:118428281~118428870:+ LIHC cis rs6860806 0.507 rs273901 ENSG00000263597.1 MIR3936 3.98 8.54e-05 0.0162 0.22 0.21 Breast cancer; chr5:132358667 chr5:132365490~132365599:- LIHC cis rs270601 0.913 rs273899 ENSG00000263597.1 MIR3936 3.98 8.54e-05 0.0162 0.22 0.21 Acylcarnitine levels; chr5:132359485 chr5:132365490~132365599:- LIHC cis rs951005 0.808 rs10124246 ENSG00000281491.1 DNAJB5-AS1 -3.98 8.55e-05 0.0162 -0.39 -0.21 Rheumatoid arthritis; chr9:34713132 chr9:34985410~34989379:- LIHC cis rs951005 0.808 rs10124310 ENSG00000281491.1 DNAJB5-AS1 -3.98 8.55e-05 0.0162 -0.39 -0.21 Rheumatoid arthritis; chr9:34713365 chr9:34985410~34989379:- LIHC cis rs864745 1 rs864745 ENSG00000234336.5 JAZF1-AS1 -3.98 8.55e-05 0.0162 -0.28 -0.21 Crohn's disease;Type 2 diabetes; chr7:28140937 chr7:28180322~28243917:+ LIHC cis rs2836974 0.583 rs8132993 ENSG00000255568.3 BRWD1-AS2 3.98 8.55e-05 0.0162 0.2 0.21 Cognitive function; chr21:39344484 chr21:39313935~39314962:+ LIHC cis rs950169 0.959 rs12902070 ENSG00000225151.9 GOLGA2P7 -3.98 8.55e-05 0.0162 -0.3 -0.21 Schizophrenia; chr15:84124806 chr15:84199311~84230136:- LIHC cis rs794185 0.625 rs304088 ENSG00000231249.1 ITPR1-AS1 -3.98 8.55e-05 0.0162 -0.23 -0.21 Multiple sclerosis--Brain Glutamate Levels; chr3:4479513 chr3:4490891~4493163:- LIHC cis rs597539 0.616 rs10896386 ENSG00000250508.1 RP11-757G1.6 -3.98 8.55e-05 0.0162 -0.33 -0.21 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68955225 chr11:68870664~68874542:+ LIHC cis rs6745190 0.953 rs6433878 ENSG00000236153.1 AC104076.3 3.98 8.56e-05 0.0162 0.29 0.21 White blood cell count; chr2:180973227 chr2:180979427~180980090:- LIHC cis rs6545883 0.899 rs12473030 ENSG00000271889.1 RP11-493E12.1 3.98 8.56e-05 0.0162 0.25 0.21 Tuberculosis; chr2:61493362 chr2:61151433~61162105:- LIHC cis rs2243480 1 rs2420170 ENSG00000232546.1 RP11-458F8.1 3.98 8.56e-05 0.0163 0.23 0.21 Diabetic kidney disease; chr7:66191066 chr7:66848496~66858136:+ LIHC cis rs2462686 0.965 rs1534151 ENSG00000272556.1 RP11-638I8.1 3.98 8.56e-05 0.0163 0.32 0.21 Major depressive disorder; chr7:45945046 chr7:45814602~45815263:+ LIHC cis rs7615952 0.641 rs61048217 ENSG00000171084.14 FAM86JP 3.98 8.56e-05 0.0163 0.34 0.21 Blood pressure (smoking interaction); chr3:126089062 chr3:125916620~125930024:+ LIHC cis rs7615952 0.641 rs60839048 ENSG00000171084.14 FAM86JP 3.98 8.56e-05 0.0163 0.34 0.21 Blood pressure (smoking interaction); chr3:126089095 chr3:125916620~125930024:+ LIHC cis rs7615952 0.641 rs7640158 ENSG00000171084.14 FAM86JP 3.98 8.56e-05 0.0163 0.34 0.21 Blood pressure (smoking interaction); chr3:126089168 chr3:125916620~125930024:+ LIHC cis rs919433 0.929 rs1366836 ENSG00000231621.1 AC013264.2 3.98 8.56e-05 0.0163 0.19 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197307424 chr2:197197991~197199273:+ LIHC cis rs919433 1 rs112572902 ENSG00000231621.1 AC013264.2 3.98 8.56e-05 0.0163 0.19 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197310455 chr2:197197991~197199273:+ LIHC cis rs74233809 0.591 rs284853 ENSG00000236937.2 PTGES3P4 -3.98 8.56e-05 0.0163 -0.29 -0.21 Birth weight; chr10:102814885 chr10:102845595~102845950:+ LIHC cis rs2439831 1 rs2256764 ENSG00000275601.1 AC011330.13 -3.98 8.57e-05 0.0163 -0.31 -0.21 Lung cancer in ever smokers; chr15:43443565 chr15:43642389~43643023:- LIHC cis rs2243480 0.615 rs34363376 ENSG00000228409.4 CCT6P1 3.98 8.57e-05 0.0163 0.23 0.21 Diabetic kidney disease; chr7:66474549 chr7:65751142~65763354:+ LIHC cis rs7726839 0.574 rs12517345 ENSG00000271781.1 CTD-2589H19.6 -3.98 8.57e-05 0.0163 -0.32 -0.21 Obesity-related traits; chr5:628179 chr5:675826~676616:+ LIHC cis rs7726839 0.574 rs11739866 ENSG00000271781.1 CTD-2589H19.6 -3.98 8.57e-05 0.0163 -0.32 -0.21 Obesity-related traits; chr5:636184 chr5:675826~676616:+ LIHC cis rs6452524 1 rs10474094 ENSG00000271862.1 RP11-343L5.2 3.98 8.57e-05 0.0163 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83154678 chr5:83049376~83050964:- LIHC cis rs8072100 0.544 rs9284377 ENSG00000228782.6 CTD-2026D20.3 3.98 8.58e-05 0.0163 0.24 0.21 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47309046 chr17:47450568~47492492:- LIHC cis rs12681287 0.577 rs13257414 ENSG00000254088.1 SLC2A3P4 3.98 8.58e-05 0.0163 0.25 0.21 Caudate activity during reward; chr8:86481909 chr8:86503591~86505061:+ LIHC cis rs12681287 0.609 rs13281414 ENSG00000254088.1 SLC2A3P4 3.98 8.58e-05 0.0163 0.25 0.21 Caudate activity during reward; chr8:86483025 chr8:86503591~86505061:+ LIHC cis rs12681287 0.546 rs12546802 ENSG00000254088.1 SLC2A3P4 3.98 8.58e-05 0.0163 0.25 0.21 Caudate activity during reward; chr8:86487106 chr8:86503591~86505061:+ LIHC cis rs4561483 0.831 rs33648 ENSG00000261560.1 RP11-166B2.3 -3.98 8.58e-05 0.0163 -0.23 -0.21 Testicular germ cell tumor; chr16:11885765 chr16:11881075~11882569:- LIHC cis rs4803480 0.578 rs7252454 ENSG00000267107.5 PCAT19 3.98 8.58e-05 0.0163 0.26 0.21 Schizophrenia; chr19:41527343 chr19:41454169~41500649:- LIHC cis rs9303401 0.646 rs7213269 ENSG00000265415.1 CTD-2510F5.4 3.98 8.58e-05 0.0163 0.15 0.21 Cognitive test performance; chr17:59160435 chr17:59202677~59203829:- LIHC cis rs11096990 0.634 rs6531706 ENSG00000249207.1 RP11-360F5.1 3.98 8.59e-05 0.0163 0.21 0.21 Cognitive function; chr4:39294547 chr4:39112677~39126818:- LIHC cis rs875971 1 rs10215948 ENSG00000237310.1 GS1-124K5.4 -3.97 8.59e-05 0.0163 -0.19 -0.21 Aortic root size; chr7:66282799 chr7:66493706~66495474:+ LIHC cis rs7176527 1 rs7176527 ENSG00000229212.6 RP11-561C5.4 3.97 8.59e-05 0.0163 0.24 0.21 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84597563 chr15:85205440~85234795:- LIHC cis rs3015497 0.594 rs35637875 ENSG00000269906.1 RP11-248J18.2 3.97 8.59e-05 0.0163 0.27 0.21 Mean platelet volume; chr14:50665815 chr14:50662511~50663178:- LIHC cis rs7989332 0.961 rs4770041 ENSG00000275964.1 RP11-61K9.3 -3.97 8.59e-05 0.0163 -0.24 -0.21 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20474430 chr13:19863858~19865048:+ LIHC cis rs748404 0.697 rs475261 ENSG00000205771.5 CATSPER2P1 -3.97 8.59e-05 0.0163 -0.25 -0.21 Lung cancer; chr15:43254258 chr15:43726918~43747094:- LIHC cis rs780096 0.546 rs715326 ENSG00000234072.1 AC074117.10 3.97 8.6e-05 0.0163 0.19 0.21 Total body bone mineral density; chr2:27502894 chr2:27356246~27367622:+ LIHC cis rs6832769 0.922 rs60797008 ENSG00000272969.1 RP11-528I4.2 -3.97 8.6e-05 0.0163 -0.25 -0.21 Personality dimensions; chr4:55522505 chr4:55547112~55547889:+ LIHC cis rs6496667 0.509 rs57962570 ENSG00000213471.7 TTLL13P 3.97 8.6e-05 0.0163 0.28 0.21 Rheumatoid arthritis; chr15:90442364 chr15:90249530~90265482:+ LIHC cis rs950776 0.667 rs57728226 ENSG00000261762.1 RP11-650L12.2 3.97 8.6e-05 0.0163 0.3 0.21 Sudden cardiac arrest; chr15:78637008 chr15:78589123~78591276:- LIHC cis rs1223397 0.651 rs202016 ENSG00000215022.6 RP1-257A7.4 -3.97 8.6e-05 0.0163 -0.22 -0.21 Blood pressure; chr6:13300811 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs202017 ENSG00000215022.6 RP1-257A7.4 -3.97 8.6e-05 0.0163 -0.22 -0.21 Blood pressure; chr6:13300819 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs202018 ENSG00000215022.6 RP1-257A7.4 -3.97 8.6e-05 0.0163 -0.22 -0.21 Blood pressure; chr6:13301270 chr6:13264861~13295586:- LIHC cis rs9907295 0.748 rs55767296 ENSG00000270871.1 AC015849.19 3.97 8.61e-05 0.0163 0.22 0.21 Fibroblast growth factor basic levels; chr17:35850524 chr17:35816717~35830293:- LIHC cis rs17713451 0.593 rs78219774 ENSG00000204894.4 RP11-208G20.2 3.97 8.61e-05 0.0163 0.4 0.21 Interleukin-4 levels; chr7:151581946 chr7:152367171~152367260:+ LIHC cis rs17713451 0.593 rs80311488 ENSG00000204894.4 RP11-208G20.2 3.97 8.61e-05 0.0163 0.4 0.21 Interleukin-4 levels; chr7:151582031 chr7:152367171~152367260:+ LIHC cis rs2283792 0.765 rs9340 ENSG00000224086.5 LL22NC03-86G7.1 -3.97 8.61e-05 0.0163 -0.21 -0.21 Multiple sclerosis; chr22:21761064 chr22:21938293~21977632:+ LIHC cis rs2283792 0.765 rs1063311 ENSG00000224086.5 LL22NC03-86G7.1 -3.97 8.61e-05 0.0163 -0.21 -0.21 Multiple sclerosis; chr22:21762178 chr22:21938293~21977632:+ LIHC cis rs6142102 0.581 rs4911148 ENSG00000275784.1 RP5-1125A11.6 -3.97 8.62e-05 0.0163 -0.23 -0.21 Skin pigmentation; chr20:34080438 chr20:33989480~33991818:- LIHC cis rs1023500 1 rs1023497 ENSG00000237037.8 NDUFA6-AS1 -3.97 8.62e-05 0.0163 -0.28 -0.21 Schizophrenia; chr22:41944504 chr22:42090931~42137742:+ LIHC cis rs1005277 0.522 rs7090858 ENSG00000275858.1 RP11-291L22.8 -3.97 8.62e-05 0.0163 -0.23 -0.21 Extrinsic epigenetic age acceleration; chr10:37714742 chr10:38450738~38451069:- LIHC cis rs10256972 0.786 rs3735686 ENSG00000224079.1 AC091729.7 -3.97 8.62e-05 0.0163 -0.24 -0.21 Endometriosis;Longevity; chr7:1022891 chr7:1074450~1078036:+ LIHC cis rs4650994 1 rs4511075 ENSG00000213057.5 C1orf220 3.97 8.62e-05 0.0164 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178549501 chr1:178542752~178548889:+ LIHC cis rs4650994 1 rs12138541 ENSG00000213057.5 C1orf220 3.97 8.62e-05 0.0164 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178549572 chr1:178542752~178548889:+ LIHC cis rs9595908 0.785 rs2183873 ENSG00000212293.1 SNORA16 3.97 8.62e-05 0.0164 0.24 0.21 Body mass index; chr13:32710508 chr13:32420390~32420516:- LIHC cis rs11079757 0.681 rs34811916 ENSG00000262879.4 RP11-156P1.3 3.97 8.62e-05 0.0164 0.25 0.21 Erythema nodosum in inflammatory bowel disease; chr17:47111431 chr17:46984045~47100323:- LIHC cis rs4964805 0.58 rs1866292 ENSG00000257681.1 RP11-341G23.4 3.97 8.63e-05 0.0164 0.22 0.21 Attention deficit hyperactivity disorder; chr12:103780414 chr12:103746315~103768858:- LIHC cis rs854624 0.892 rs1734954 ENSG00000278690.1 RP11-104J23.2 -3.97 8.63e-05 0.0164 -0.48 -0.21 Blood protein levels; chr17:36010848 chr17:36012504~36012891:+ LIHC cis rs748404 0.697 rs473554 ENSG00000205771.5 CATSPER2P1 -3.97 8.63e-05 0.0164 -0.26 -0.21 Lung cancer; chr15:43276009 chr15:43726918~43747094:- LIHC cis rs748404 0.697 rs530683 ENSG00000205771.5 CATSPER2P1 3.97 8.63e-05 0.0164 0.26 0.21 Lung cancer; chr15:43276801 chr15:43726918~43747094:- LIHC cis rs30380 0.69 rs2216752 ENSG00000272109.1 CTD-2260A17.3 3.97 8.63e-05 0.0164 0.27 0.21 Cerebrospinal fluid biomarker levels; chr5:96849764 chr5:96804353~96806105:+ LIHC cis rs4891159 0.79 rs35516239 ENSG00000265778.2 RP11-17M16.2 -3.97 8.64e-05 0.0164 -0.25 -0.21 Longevity; chr18:76417986 chr18:76491652~76493918:+ LIHC cis rs1530530 0.748 rs12868533 ENSG00000253771.4 TPTE2P1 -3.97 8.64e-05 0.0164 -0.46 -0.21 Obesity-related traits; chr13:24684673 chr13:24924677~24968487:- LIHC cis rs1530530 0.748 rs12860747 ENSG00000253771.4 TPTE2P1 -3.97 8.64e-05 0.0164 -0.46 -0.21 Obesity-related traits; chr13:24684678 chr13:24924677~24968487:- LIHC cis rs889014 1 rs7733195 ENSG00000204758.6 CTC-308K20.1 -3.97 8.64e-05 0.0164 -0.31 -0.21 Height; chr5:173567621 chr5:172954786~172959392:- LIHC cis rs2739330 0.734 rs2000467 ENSG00000228039.3 KB-1125A3.10 -3.97 8.64e-05 0.0164 -0.25 -0.21 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23963780~23964374:+ LIHC cis rs694739 1 rs11231757 ENSG00000236935.1 AP003774.1 3.97 8.65e-05 0.0164 0.23 0.21 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64338845 chr11:64325050~64329504:- LIHC cis rs6445975 0.628 rs7231 ENSG00000272360.1 RP11-359I18.5 -3.97 8.65e-05 0.0164 -0.27 -0.21 Systemic lupus erythematosus; chr3:58427738 chr3:58490830~58491291:- LIHC cis rs597539 0.69 rs635529 ENSG00000250508.1 RP11-757G1.6 -3.97 8.65e-05 0.0164 -0.32 -0.21 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68858826 chr11:68870664~68874542:+ LIHC cis rs6910233 0.793 rs210160 ENSG00000224557.6 HLA-DPB2 -3.97 8.65e-05 0.0164 -0.22 -0.21 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr6:33551931 chr6:33112451~33129084:+ LIHC cis rs950880 0.71 rs66566526 ENSG00000234389.1 AC007278.3 -3.97 8.65e-05 0.0164 -0.21 -0.21 Serum protein levels (sST2); chr2:102431342 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs4851582 ENSG00000234389.1 AC007278.3 -3.97 8.65e-05 0.0164 -0.21 -0.21 Serum protein levels (sST2); chr2:102435098 chr2:102438713~102440475:+ LIHC cis rs2243480 0.711 rs2420172 ENSG00000232546.1 RP11-458F8.1 3.97 8.65e-05 0.0164 0.23 0.21 Diabetic kidney disease; chr7:66170354 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs6974723 ENSG00000232546.1 RP11-458F8.1 3.97 8.65e-05 0.0164 0.23 0.21 Diabetic kidney disease; chr7:66172952 chr7:66848496~66858136:+ LIHC cis rs734999 0.566 rs6664969 ENSG00000225931.3 RP3-395M20.7 3.97 8.65e-05 0.0164 0.22 0.21 Ulcerative colitis; chr1:2603539 chr1:2566410~2569888:+ LIHC cis rs901683 1 rs34383275 ENSG00000230869.1 CTGLF10P -3.97 8.65e-05 0.0164 -0.52 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45577429 chr10:45678692~45700532:+ LIHC cis rs7760535 0.811 rs7764591 ENSG00000271789.1 RP5-1112D6.7 -3.97 8.65e-05 0.0164 -0.21 -0.21 Metabolic traits; chr6:111462211 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs7750792 ENSG00000271789.1 RP5-1112D6.7 -3.97 8.65e-05 0.0164 -0.21 -0.21 Amino acid levels;Blood metabolite levels; chr6:111462556 chr6:111297126~111298510:+ LIHC cis rs1005277 0.579 rs1780133 ENSG00000120555.12 SEPT7P9 3.97 8.66e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38210581 chr10:38383069~38402916:- LIHC cis rs1005277 0.579 rs1780136 ENSG00000120555.12 SEPT7P9 3.97 8.66e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38212525 chr10:38383069~38402916:- LIHC cis rs1005277 0.579 rs1780138 ENSG00000120555.12 SEPT7P9 3.97 8.66e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38212726 chr10:38383069~38402916:- LIHC cis rs1005277 0.602 rs1780141 ENSG00000120555.12 SEPT7P9 3.97 8.66e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38215371 chr10:38383069~38402916:- LIHC cis rs1005277 0.541 rs1740741 ENSG00000120555.12 SEPT7P9 3.97 8.66e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38226406 chr10:38383069~38402916:- LIHC cis rs1005277 0.528 rs2057228 ENSG00000120555.12 SEPT7P9 3.97 8.66e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38226838 chr10:38383069~38402916:- LIHC cis rs1005277 0.579 rs1740742 ENSG00000120555.12 SEPT7P9 3.97 8.66e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38229932 chr10:38383069~38402916:- LIHC cis rs1005277 0.602 rs1740743 ENSG00000120555.12 SEPT7P9 3.97 8.66e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38230294 chr10:38383069~38402916:- LIHC cis rs1005277 0.579 rs1740745 ENSG00000120555.12 SEPT7P9 3.97 8.66e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38231128 chr10:38383069~38402916:- LIHC cis rs1005277 0.579 rs1740747 ENSG00000120555.12 SEPT7P9 3.97 8.66e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38231537 chr10:38383069~38402916:- LIHC cis rs1005277 0.579 rs1740749 ENSG00000120555.12 SEPT7P9 3.97 8.66e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38232718 chr10:38383069~38402916:- LIHC cis rs1005277 0.579 rs1780115 ENSG00000120555.12 SEPT7P9 3.97 8.66e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38235845 chr10:38383069~38402916:- LIHC cis rs17508449 0.819 rs79198040 ENSG00000232450.1 RP4-730K3.3 -3.97 8.66e-05 0.0164 -0.28 -0.21 Leprosy; chr1:113746069 chr1:113698884~113699631:- LIHC cis rs2749592 1 rs2749592 ENSG00000263064.2 RP11-291L22.7 3.97 8.66e-05 0.0164 0.22 0.21 Age-related hearing impairment (SNP x SNP interaction); chr10:37969914 chr10:38448689~38448949:+ LIHC cis rs10833905 1 rs1426849 ENSG00000246225.5 RP11-17A1.3 -3.97 8.66e-05 0.0164 -0.26 -0.21 Sudden cardiac arrest; chr11:23026393 chr11:22829380~22945393:+ LIHC cis rs7809950 0.817 rs2807 ENSG00000238832.1 snoU109 3.97 8.66e-05 0.0164 0.26 0.21 Coronary artery disease; chr7:107620333 chr7:107603363~107603507:+ LIHC cis rs11096990 0.819 rs4974991 ENSG00000249207.1 RP11-360F5.1 3.97 8.66e-05 0.0164 0.24 0.21 Cognitive function; chr4:39193147 chr4:39112677~39126818:- LIHC cis rs11096990 0.892 rs6815686 ENSG00000249207.1 RP11-360F5.1 3.97 8.66e-05 0.0164 0.24 0.21 Cognitive function; chr4:39198171 chr4:39112677~39126818:- LIHC cis rs11098499 0.863 rs10019674 ENSG00000260091.1 RP11-33B1.4 3.97 8.67e-05 0.0164 0.15 0.21 Corneal astigmatism; chr4:119522334 chr4:119409333~119410233:+ LIHC cis rs2439831 0.85 rs524417 ENSG00000166763.7 STRCP1 3.97 8.67e-05 0.0164 0.3 0.21 Lung cancer in ever smokers; chr15:43480176 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs2439832 ENSG00000166763.7 STRCP1 3.97 8.67e-05 0.0164 0.3 0.21 Lung cancer in ever smokers; chr15:43487488 chr15:43699488~43718184:- LIHC cis rs11673344 0.734 rs1234250 ENSG00000226686.6 LINC01535 -3.97 8.67e-05 0.0164 -0.3 -0.21 Obesity-related traits; chr19:37199518 chr19:37251912~37265535:+ LIHC cis rs57502260 0.68 rs55654976 ENSG00000212093.1 AP000807.1 3.97 8.67e-05 0.0164 0.27 0.21 Total body bone mineral density (age 45-60); chr11:68626073 chr11:68506083~68506166:- LIHC cis rs9595908 0.63 rs1929939 ENSG00000212293.1 SNORA16 3.97 8.67e-05 0.0164 0.24 0.21 Body mass index; chr13:32733547 chr13:32420390~32420516:- LIHC cis rs4650994 1 rs17276513 ENSG00000213057.5 C1orf220 -3.97 8.67e-05 0.0164 -0.17 -0.21 HDL cholesterol;HDL cholesterol levels; chr1:178551469 chr1:178542752~178548889:+ LIHC cis rs4650994 1 rs12138561 ENSG00000213057.5 C1orf220 3.97 8.68e-05 0.0164 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178549649 chr1:178542752~178548889:+ LIHC cis rs703842 0.642 rs11536137 ENSG00000270039.1 RP11-571M6.17 -3.97 8.68e-05 0.0164 -0.3 -0.21 Multiple sclerosis; chr12:57662643 chr12:57803838~57804415:+ LIHC cis rs6471393 0.929 rs62525162 ENSG00000253848.1 RP11-10N23.5 3.97 8.68e-05 0.0164 0.23 0.21 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93749654 chr8:93741193~93744534:+ LIHC cis rs794185 0.714 rs2633836 ENSG00000231249.1 ITPR1-AS1 -3.97 8.68e-05 0.0164 -0.23 -0.21 Multiple sclerosis--Brain Glutamate Levels; chr3:4461224 chr3:4490891~4493163:- LIHC cis rs12468226 0.938 rs6435139 ENSG00000226261.1 AC064836.3 -3.97 8.68e-05 0.0164 -0.33 -0.21 Urate levels; chr2:202255145 chr2:202336024~202336727:- LIHC cis rs1005277 0.522 rs11011343 ENSG00000276805.1 RP11-291L22.6 3.97 8.68e-05 0.0164 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37713770 chr10:38451030~38451785:+ LIHC cis rs4657482 0.962 rs10800164 ENSG00000203307.2 RP11-375H19.2 3.97 8.68e-05 0.0164 0.24 0.21 Testicular germ cell tumor; chr1:165889117 chr1:166081183~166087483:+ LIHC cis rs7182948 1 rs12901416 ENSG00000259531.2 RP11-295H24.3 -3.97 8.69e-05 0.0165 -0.31 -0.21 Lung adenocarcinoma; chr15:49574925 chr15:49365124~49366685:- LIHC cis rs7182948 1 rs12902794 ENSG00000259531.2 RP11-295H24.3 -3.97 8.69e-05 0.0165 -0.31 -0.21 Lung adenocarcinoma; chr15:49574951 chr15:49365124~49366685:- LIHC cis rs7129556 0.701 rs4945220 ENSG00000254459.1 RP11-91P24.7 -3.97 8.69e-05 0.0165 -0.34 -0.21 Weight loss (gastric bypass surgery); chr11:77817115 chr11:77829654~77872262:- LIHC cis rs7129556 0.737 rs7951033 ENSG00000254459.1 RP11-91P24.7 -3.97 8.69e-05 0.0165 -0.34 -0.21 Weight loss (gastric bypass surgery); chr11:77823398 chr11:77829654~77872262:- LIHC cis rs7129556 0.737 rs614495 ENSG00000254459.1 RP11-91P24.7 3.97 8.69e-05 0.0165 0.34 0.21 Weight loss (gastric bypass surgery); chr11:77825840 chr11:77829654~77872262:- LIHC cis rs1005277 0.579 rs1740735 ENSG00000120555.12 SEPT7P9 3.97 8.69e-05 0.0165 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38208849 chr10:38383069~38402916:- LIHC cis rs2243480 1 rs316322 ENSG00000230295.1 RP11-458F8.2 -3.97 8.69e-05 0.0165 -0.22 -0.21 Diabetic kidney disease; chr7:66146246 chr7:66880708~66882981:+ LIHC cis rs2390582 0.563 rs12736146 ENSG00000231613.1 RP5-943J3.1 3.97 8.69e-05 0.0165 0.44 0.21 Coronary artery calcification; chr1:90296952 chr1:89788914~89790492:+ LIHC cis rs875971 0.545 rs1909508 ENSG00000228409.4 CCT6P1 -3.97 8.7e-05 0.0165 -0.18 -0.21 Aortic root size; chr7:66301366 chr7:65751142~65763354:+ LIHC cis rs875971 1 rs10244498 ENSG00000232559.3 GS1-124K5.12 3.97 8.7e-05 0.0165 0.16 0.21 Aortic root size; chr7:66651069 chr7:66554588~66576923:- LIHC cis rs9400467 0.528 rs7752361 ENSG00000271789.1 RP5-1112D6.7 -3.97 8.7e-05 0.0165 -0.21 -0.21 Amino acid levels;Blood metabolite levels; chr6:111459502 chr6:111297126~111298510:+ LIHC cis rs1799949 0.93 rs3092987 ENSG00000267681.1 CTD-3199J23.6 -3.97 8.71e-05 0.0165 -0.2 -0.21 Menopause (age at onset); chr17:43070706 chr17:43144956~43145255:+ LIHC cis rs755249 1 rs17513135 ENSG00000182109.6 RP11-69E11.4 3.97 8.71e-05 0.0165 0.29 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39570014 chr1:39522280~39546187:- LIHC cis rs6832769 0.961 rs13138697 ENSG00000272969.1 RP11-528I4.2 3.97 8.71e-05 0.0165 0.25 0.21 Personality dimensions; chr4:55497142 chr4:55547112~55547889:+ LIHC cis rs858239 1 rs156425 ENSG00000226816.2 AC005082.12 -3.97 8.71e-05 0.0165 -0.26 -0.21 Cerebrospinal fluid biomarker levels; chr7:23269500 chr7:23206013~23208045:+ LIHC cis rs4787491 0.729 rs4788215 ENSG00000250616.2 RP11-455F5.3 3.97 8.71e-05 0.0165 0.21 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30036609 chr16:30096430~30104116:+ LIHC cis rs2243480 1 rs34703416 ENSG00000228409.4 CCT6P1 3.97 8.72e-05 0.0165 0.23 0.21 Diabetic kidney disease; chr7:65835655 chr7:65751142~65763354:+ LIHC cis rs244293 0.76 rs1990673 ENSG00000275710.1 RP11-257O5.4 3.97 8.72e-05 0.0165 0.23 0.21 Menarche (age at onset); chr17:54972664 chr17:54964474~54964679:+ LIHC cis rs11733284 0.55 rs62300320 ENSG00000259959.1 RP11-121C2.2 -3.97 8.72e-05 0.0165 -0.2 -0.21 Gout;Renal underexcretion gout; chr4:48025932 chr4:47840122~47844339:- LIHC cis rs12935418 1 rs2602431 ENSG00000261061.1 RP11-303E16.2 3.97 8.72e-05 0.0165 0.26 0.21 Mean corpuscular volume; chr16:81037092 chr16:81030770~81031485:+ LIHC cis rs7712401 0.715 rs6880480 ENSG00000263432.2 RN7SL689P -3.97 8.73e-05 0.0165 -0.3 -0.21 Mean platelet volume; chr5:123019031 chr5:123022487~123022783:- LIHC cis rs6142102 0.923 rs4911383 ENSG00000275784.1 RP5-1125A11.6 -3.97 8.73e-05 0.0165 -0.24 -0.21 Skin pigmentation; chr20:33967973 chr20:33989480~33991818:- LIHC cis rs2439831 0.85 rs544122 ENSG00000275601.1 AC011330.13 -3.97 8.73e-05 0.0165 -0.31 -0.21 Lung cancer in ever smokers; chr15:43483534 chr15:43642389~43643023:- LIHC cis rs11098499 0.644 rs17517414 ENSG00000260091.1 RP11-33B1.4 -3.97 8.73e-05 0.0165 -0.14 -0.21 Corneal astigmatism; chr4:119340946 chr4:119409333~119410233:+ LIHC cis rs4713118 0.513 rs149972 ENSG00000216901.1 AL022393.7 3.97 8.74e-05 0.0165 0.27 0.21 Parkinson's disease; chr6:28015449 chr6:28176188~28176674:+ LIHC cis rs4713118 0.513 rs149975 ENSG00000216901.1 AL022393.7 3.97 8.74e-05 0.0165 0.27 0.21 Parkinson's disease; chr6:28018562 chr6:28176188~28176674:+ LIHC cis rs2070488 0.965 rs4679060 ENSG00000229589.1 ACVR2B-AS1 -3.97 8.74e-05 0.0165 -0.24 -0.21 Electrocardiographic conduction measures; chr3:38494770 chr3:38451027~38454820:- LIHC cis rs2070488 0.965 rs13097628 ENSG00000229589.1 ACVR2B-AS1 3.97 8.74e-05 0.0165 0.24 0.21 Electrocardiographic conduction measures; chr3:38479665 chr3:38451027~38454820:- LIHC cis rs2070488 0.965 rs4679053 ENSG00000229589.1 ACVR2B-AS1 3.97 8.74e-05 0.0165 0.24 0.21 Electrocardiographic conduction measures; chr3:38482004 chr3:38451027~38454820:- LIHC cis rs2070488 0.965 rs1046048 ENSG00000229589.1 ACVR2B-AS1 3.97 8.74e-05 0.0165 0.24 0.21 Electrocardiographic conduction measures; chr3:38483251 chr3:38451027~38454820:- LIHC cis rs2070488 0.965 rs7642472 ENSG00000229589.1 ACVR2B-AS1 3.97 8.74e-05 0.0165 0.24 0.21 Electrocardiographic conduction measures; chr3:38484076 chr3:38451027~38454820:- LIHC cis rs2070488 0.93 rs928813 ENSG00000229589.1 ACVR2B-AS1 3.97 8.74e-05 0.0165 0.24 0.21 Electrocardiographic conduction measures; chr3:38487046 chr3:38451027~38454820:- LIHC cis rs8077577 0.689 rs16961133 ENSG00000260647.1 RP1-178F10.1 3.97 8.74e-05 0.0165 0.27 0.21 Obesity-related traits; chr17:18320234 chr17:18268080~18268828:+ LIHC cis rs7121538 0.551 rs16930448 ENSG00000251991.1 RNU7-49P -3.97 8.74e-05 0.0165 -0.31 -0.21 HDL cholesterol; chr11:14702166 chr11:14478892~14478953:+ LIHC cis rs2623384 0.555 rs35410350 ENSG00000249274.1 PDLIM1P4 3.97 8.74e-05 0.0165 0.28 0.21 Superior frontal gyrus grey matter volume; chr3:99328300 chr3:98782188~98783193:+ LIHC cis rs3761847 0.651 rs1323472 ENSG00000226752.6 PSMD5-AS1 -3.97 8.75e-05 0.0165 -0.22 -0.21 Rheumatoid arthritis; chr9:121064057 chr9:120824828~120854385:+ LIHC cis rs6832769 0.961 rs7684810 ENSG00000272969.1 RP11-528I4.2 3.97 8.75e-05 0.0165 0.25 0.21 Personality dimensions; chr4:55486627 chr4:55547112~55547889:+ LIHC cis rs950169 0.519 rs7237 ENSG00000259728.4 LINC00933 3.97 8.75e-05 0.0165 0.3 0.21 Schizophrenia; chr15:84643346 chr15:84570649~84580175:+ LIHC cis rs673078 0.607 rs56080343 ENSG00000275409.1 RP11-131L12.4 -3.97 8.75e-05 0.0165 -0.26 -0.21 Glucose homeostasis traits; chr12:118439113 chr12:118430147~118430699:+ LIHC cis rs6860806 0.507 rs272854 ENSG00000263597.1 MIR3936 3.97 8.75e-05 0.0166 0.22 0.21 Breast cancer; chr5:132352324 chr5:132365490~132365599:- LIHC cis rs673078 0.607 rs16948230 ENSG00000275759.1 RP11-131L12.3 -3.97 8.76e-05 0.0166 -0.39 -0.21 Glucose homeostasis traits; chr12:118277086 chr12:118428281~118428870:+ LIHC cis rs875971 0.965 rs7794930 ENSG00000237310.1 GS1-124K5.4 -3.97 8.76e-05 0.0166 -0.19 -0.21 Aortic root size; chr7:66313559 chr7:66493706~66495474:+ LIHC cis rs950881 0.601 rs11465705 ENSG00000234389.1 AC007278.3 3.97 8.76e-05 0.0166 0.27 0.21 Allergy; chr2:102442350 chr2:102438713~102440475:+ LIHC cis rs7688540 0.74 rs28784663 ENSG00000275426.1 CH17-262A2.1 3.97 8.76e-05 0.0166 0.25 0.21 Facial morphology (factor 6, height of vermillion lower lip); chr4:293257 chr4:149738~150317:+ LIHC cis rs13113518 0.729 rs12641881 ENSG00000249700.7 SRD5A3-AS1 3.97 8.77e-05 0.0166 0.25 0.21 Height; chr4:55401306 chr4:55363971~55395847:- LIHC cis rs9487094 0.961 rs9480948 ENSG00000260273.1 RP11-425D10.10 3.97 8.77e-05 0.0166 0.25 0.21 Height; chr6:109407148 chr6:109382795~109383666:+ LIHC cis rs7412746 0.611 rs10788794 ENSG00000231073.1 RP11-316M1.3 3.97 8.77e-05 0.0166 0.21 0.21 Melanoma; chr1:150756200 chr1:150973123~150975534:+ LIHC cis rs7412746 0.611 rs10888391 ENSG00000231073.1 RP11-316M1.3 3.97 8.77e-05 0.0166 0.21 0.21 Melanoma; chr1:150757507 chr1:150973123~150975534:+ LIHC cis rs2976388 0.566 rs13250661 ENSG00000253741.1 CTD-2292P10.4 3.97 8.77e-05 0.0166 0.27 0.21 Urinary tract infection frequency; chr8:142722716 chr8:142702252~142726973:- LIHC cis rs13434995 0.537 rs6554275 ENSG00000273257.1 RP11-177J6.1 3.97 8.77e-05 0.0166 0.33 0.21 Adiponectin levels; chr4:55362981 chr4:55387949~55388271:+ LIHC cis rs2243480 0.908 rs55876148 ENSG00000226002.1 RP11-460N20.5 -3.97 8.77e-05 0.0166 -0.31 -0.21 Diabetic kidney disease; chr7:65914813 chr7:65084103~65100232:+ LIHC cis rs2348418 0.765 rs10843119 ENSG00000247934.4 RP11-967K21.1 -3.97 8.77e-05 0.0166 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28164675 chr12:28163298~28190738:- LIHC cis rs2348418 0.765 rs10843120 ENSG00000247934.4 RP11-967K21.1 -3.97 8.77e-05 0.0166 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28165881 chr12:28163298~28190738:- LIHC cis rs13028485 1 rs13015247 ENSG00000236449.1 AC018890.6 -3.97 8.78e-05 0.0166 -0.34 -0.21 Multiple myeloma (IgH translocation); chr2:173645683 chr2:174547141~174774827:+ LIHC cis rs13028485 1 rs13033812 ENSG00000236449.1 AC018890.6 -3.97 8.78e-05 0.0166 -0.34 -0.21 Multiple myeloma (IgH translocation); chr2:173646345 chr2:174547141~174774827:+ LIHC cis rs7119038 0.607 rs12365699 ENSG00000255239.1 AP002954.6 -3.97 8.78e-05 0.0166 -0.38 -0.21 Sjögren's syndrome; chr11:118872577 chr11:118688039~118690600:- LIHC cis rs76878669 0.917 rs10444359 ENSG00000255320.1 RP11-755F10.1 3.97 8.79e-05 0.0166 0.28 0.21 Educational attainment (years of education); chr11:66335336 chr11:66244840~66246239:- LIHC cis rs673078 0.607 rs61943388 ENSG00000275759.1 RP11-131L12.3 -3.97 8.79e-05 0.0166 -0.42 -0.21 Glucose homeostasis traits; chr12:118374590 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs61943389 ENSG00000275759.1 RP11-131L12.3 -3.97 8.79e-05 0.0166 -0.42 -0.21 Glucose homeostasis traits; chr12:118377467 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs7299040 ENSG00000275759.1 RP11-131L12.3 -3.97 8.79e-05 0.0166 -0.42 -0.21 Glucose homeostasis traits; chr12:118380660 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs7968011 ENSG00000275759.1 RP11-131L12.3 -3.97 8.79e-05 0.0166 -0.42 -0.21 Glucose homeostasis traits; chr12:118382001 chr12:118428281~118428870:+ LIHC cis rs75920871 0.609 rs11216180 ENSG00000254851.1 RP11-109L13.1 -3.97 8.79e-05 0.0166 -0.43 -0.21 Subjective well-being; chr11:116902662 chr11:117135528~117138582:+ LIHC cis rs12586317 0.62 rs8021414 ENSG00000257307.1 RP11-317N8.4 -3.97 8.79e-05 0.0166 -0.25 -0.21 Psoriasis; chr14:35112274 chr14:35881001~35881709:+ LIHC cis rs688181 1 rs688181 ENSG00000271265.1 RP11-230C9.4 3.97 8.79e-05 0.0166 0.25 0.21 Platelet distribution width; chr6:157671606 chr6:156774217~156774662:- LIHC cis rs17818399 0.533 rs13420857 ENSG00000239332.4 LINC01119 3.97 8.79e-05 0.0166 0.28 0.21 Height; chr2:46570866 chr2:46816697~46859007:+ LIHC cis rs757081 0.648 rs7108316 ENSG00000272034.1 SNORD14A -3.97 8.79e-05 0.0166 -0.22 -0.21 Systolic blood pressure; chr11:17253488 chr11:17074654~17074744:- LIHC cis rs6452524 1 rs10069402 ENSG00000271862.1 RP11-343L5.2 3.97 8.79e-05 0.0166 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83133776 chr5:83049376~83050964:- LIHC cis rs11098499 0.691 rs12510133 ENSG00000260091.1 RP11-33B1.4 -3.97 8.8e-05 0.0166 -0.14 -0.21 Corneal astigmatism; chr4:119350189 chr4:119409333~119410233:+ LIHC cis rs11098499 0.754 rs12506487 ENSG00000260091.1 RP11-33B1.4 -3.97 8.8e-05 0.0166 -0.14 -0.21 Corneal astigmatism; chr4:119350206 chr4:119409333~119410233:+ LIHC cis rs11098499 0.691 rs12502524 ENSG00000260091.1 RP11-33B1.4 -3.97 8.8e-05 0.0166 -0.14 -0.21 Corneal astigmatism; chr4:119350259 chr4:119409333~119410233:+ LIHC cis rs11098499 0.691 rs28396837 ENSG00000260091.1 RP11-33B1.4 -3.97 8.8e-05 0.0166 -0.14 -0.21 Corneal astigmatism; chr4:119350386 chr4:119409333~119410233:+ LIHC cis rs11098499 0.629 rs28369518 ENSG00000260091.1 RP11-33B1.4 -3.97 8.8e-05 0.0166 -0.14 -0.21 Corneal astigmatism; chr4:119350475 chr4:119409333~119410233:+ LIHC cis rs34044649 0.84 rs1616634 ENSG00000214106.6 PAXIP1-AS2 3.97 8.8e-05 0.0166 0.17 0.21 Triptolide cytotoxicity; chr7:155860384 chr7:154928498~154949908:+ LIHC cis rs5770917 1 rs5770922 ENSG00000273272.1 CTA-384D8.34 3.97 8.8e-05 0.0166 0.31 0.21 Narcolepsy; chr22:50584979 chr22:50542650~50543011:+ LIHC cis rs2762353 0.808 rs1165150 ENSG00000242387.1 HIST1H2APS2 3.97 8.8e-05 0.0166 0.24 0.21 Blood metabolite levels; chr6:25841804 chr6:25882026~25882395:- LIHC cis rs3812762 0.833 rs10500707 ENSG00000254860.4 TMEM9B-AS1 -3.97 8.8e-05 0.0166 -0.24 -0.21 Hypospadias; chr11:8796033 chr11:8964675~8977527:+ LIHC cis rs2658782 0.901 rs11604909 ENSG00000279684.1 RP11-755E23.2 -3.97 8.8e-05 0.0166 -0.36 -0.21 Pulmonary function decline; chr11:93485189 chr11:93286629~93288903:- LIHC cis rs4218 0.648 rs58087223 ENSG00000277144.1 RP11-59H7.4 -3.97 8.81e-05 0.0166 -0.24 -0.21 Social communication problems; chr15:59075132 chr15:59115547~59116089:- LIHC cis rs2348418 0.966 rs11049694 ENSG00000247934.4 RP11-967K21.1 3.97 8.81e-05 0.0166 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28527925 chr12:28163298~28190738:- LIHC cis rs6732160 0.691 rs7599223 ENSG00000272702.1 RP11-44N22.3 3.97 8.81e-05 0.0166 0.23 0.21 Intelligence (multi-trait analysis); chr2:73199975 chr2:73113018~73115907:+ LIHC cis rs1405130 0.869 rs12995348 ENSG00000224287.2 MSL3P1 3.97 8.81e-05 0.0166 0.25 0.21 Coronary artery disease; chr2:234656853 chr2:233865437~233868444:- LIHC cis rs1405130 0.869 rs13019592 ENSG00000224287.2 MSL3P1 3.97 8.81e-05 0.0166 0.25 0.21 Coronary artery disease; chr2:234657116 chr2:233865437~233868444:- LIHC cis rs1405130 0.869 rs13018244 ENSG00000224287.2 MSL3P1 3.97 8.81e-05 0.0166 0.25 0.21 Coronary artery disease; chr2:234657155 chr2:233865437~233868444:- LIHC cis rs1405130 0.869 rs11681332 ENSG00000224287.2 MSL3P1 3.97 8.81e-05 0.0166 0.25 0.21 Coronary artery disease; chr2:234657616 chr2:233865437~233868444:- LIHC cis rs1405130 0.869 rs12990323 ENSG00000224287.2 MSL3P1 3.97 8.81e-05 0.0166 0.25 0.21 Coronary artery disease; chr2:234663375 chr2:233865437~233868444:- LIHC cis rs1405130 0.869 rs13016360 ENSG00000224287.2 MSL3P1 3.97 8.81e-05 0.0166 0.25 0.21 Coronary artery disease; chr2:234663460 chr2:233865437~233868444:- LIHC cis rs1405130 0.727 rs4233610 ENSG00000224287.2 MSL3P1 3.97 8.81e-05 0.0166 0.25 0.21 Coronary artery disease; chr2:234664401 chr2:233865437~233868444:- LIHC cis rs6704644 0.51 rs10153744 ENSG00000222001.2 AC106876.2 3.97 8.82e-05 0.0167 0.33 0.21 Bilirubin levels; chr2:233372083 chr2:233012614~233015885:+ LIHC cis rs6745190 0.953 rs6433879 ENSG00000236153.1 AC104076.3 3.97 8.82e-05 0.0167 0.28 0.21 White blood cell count; chr2:180990735 chr2:180979427~180980090:- LIHC cis rs55726902 1 rs55726902 ENSG00000276691.1 RP5-1057I20.5 3.97 8.82e-05 0.0167 0.37 0.21 Allergic disease (asthma, hay fever or eczema); chr12:47803199 chr12:47788426~47788971:+ LIHC cis rs7809950 0.723 rs62483633 ENSG00000238832.1 snoU109 -3.97 8.82e-05 0.0167 -0.27 -0.21 Coronary artery disease; chr7:107236199 chr7:107603363~107603507:+ LIHC cis rs673078 0.607 rs4766899 ENSG00000275409.1 RP11-131L12.4 -3.97 8.82e-05 0.0167 -0.25 -0.21 Glucose homeostasis traits; chr12:118374888 chr12:118430147~118430699:+ LIHC cis rs673078 0.607 rs10850967 ENSG00000275409.1 RP11-131L12.4 -3.97 8.82e-05 0.0167 -0.25 -0.21 Glucose homeostasis traits; chr12:118380072 chr12:118430147~118430699:+ LIHC cis rs1005277 0.579 rs1780130 ENSG00000099251.13 HSD17B7P2 3.97 8.83e-05 0.0167 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38196450 chr10:38356380~38378505:+ LIHC cis rs1799949 1 rs1060915 ENSG00000267681.1 CTD-3199J23.6 -3.97 8.84e-05 0.0167 -0.2 -0.21 Menopause (age at onset); chr17:43082453 chr17:43144956~43145255:+ LIHC cis rs4964805 0.626 rs4964827 ENSG00000257681.1 RP11-341G23.4 3.97 8.84e-05 0.0167 0.22 0.21 Attention deficit hyperactivity disorder; chr12:103783303 chr12:103746315~103768858:- LIHC cis rs2179367 0.959 rs9373589 ENSG00000231760.4 RP11-350J20.5 3.97 8.84e-05 0.0167 0.27 0.21 Dupuytren's disease; chr6:149386152 chr6:149796151~149826294:- LIHC cis rs12586317 0.62 rs10145433 ENSG00000257307.1 RP11-317N8.4 -3.97 8.84e-05 0.0167 -0.25 -0.21 Psoriasis; chr14:35114127 chr14:35881001~35881709:+ LIHC cis rs6452524 1 rs2126990 ENSG00000271862.1 RP11-343L5.2 3.97 8.84e-05 0.0167 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83161351 chr5:83049376~83050964:- LIHC cis rs7809950 0.678 rs3801966 ENSG00000238832.1 snoU109 -3.97 8.84e-05 0.0167 -0.28 -0.21 Coronary artery disease; chr7:107184135 chr7:107603363~107603507:+ LIHC cis rs7829975 0.688 rs7817376 ENSG00000173295.6 FAM86B3P -3.97 8.85e-05 0.0167 -0.27 -0.21 Mood instability; chr8:8523020 chr8:8228595~8244865:+ LIHC cis rs539096 0.54 rs37452 ENSG00000237950.1 RP11-7O11.3 3.97 8.86e-05 0.0167 0.22 0.21 Intelligence (multi-trait analysis); chr1:43831901 chr1:43944370~43946551:- LIHC cis rs9457247 0.602 rs9457262 ENSG00000227598.1 RP1-167A14.2 -3.97 8.86e-05 0.0167 -0.23 -0.21 Crohn's disease; chr6:167060197 chr6:166969626~166999065:- LIHC cis rs7586604 0.608 rs9967704 ENSG00000230393.1 AC092667.2 3.97 8.86e-05 0.0167 0.27 0.21 Cannabis dependence symptom count; chr2:99784887 chr2:100104919~100107504:+ LIHC cis rs9341808 0.667 rs583426 ENSG00000272129.1 RP11-250B2.6 -3.97 8.86e-05 0.0167 -0.21 -0.21 Sitting height ratio; chr6:80236970 chr6:80355424~80356859:+ LIHC cis rs875971 0.571 rs78668714 ENSG00000273024.4 INTS4P2 -3.97 8.86e-05 0.0167 -0.24 -0.21 Aortic root size; chr7:66474464 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs73150604 ENSG00000273024.4 INTS4P2 -3.97 8.86e-05 0.0167 -0.24 -0.21 Aortic root size; chr7:66480545 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs7810213 ENSG00000273024.4 INTS4P2 -3.97 8.86e-05 0.0167 -0.24 -0.21 Aortic root size; chr7:66481592 chr7:65647864~65715661:+ LIHC cis rs794185 0.625 rs304090 ENSG00000231249.1 ITPR1-AS1 3.97 8.86e-05 0.0167 0.23 0.21 Multiple sclerosis--Brain Glutamate Levels; chr3:4478183 chr3:4490891~4493163:- LIHC cis rs4561483 0.549 rs33657 ENSG00000261560.1 RP11-166B2.3 -3.97 8.86e-05 0.0167 -0.24 -0.21 Testicular germ cell tumor; chr16:11875867 chr16:11881075~11882569:- LIHC cis rs1420585 0.932 rs4785155 ENSG00000260614.1 RP11-491F9.1 3.97 8.86e-05 0.0167 0.3 0.21 Pursuit maintenance gain; chr16:48969867 chr16:49287430~49290227:+ LIHC cis rs875971 0.545 rs1267814 ENSG00000273024.4 INTS4P2 3.97 8.87e-05 0.0167 0.24 0.21 Aortic root size; chr7:66579422 chr7:65647864~65715661:+ LIHC cis rs3204270 0.81 rs8077959 ENSG00000281517.1 Metazoa_SRP -3.97 8.87e-05 0.0167 -0.39 -0.21 Dental caries; chr17:81703092 chr17:81718849~81719095:- LIHC cis rs2390582 0.607 rs12407088 ENSG00000231613.1 RP5-943J3.1 3.97 8.87e-05 0.0167 0.42 0.21 Coronary artery calcification; chr1:90311302 chr1:89788914~89790492:+ LIHC cis rs3738443 1 rs61839991 ENSG00000259865.1 RP11-488L18.10 3.97 8.88e-05 0.0167 0.22 0.21 Alcohol dependence; chr1:247186284 chr1:247187281~247188526:- LIHC cis rs3738443 0.953 rs56065612 ENSG00000259865.1 RP11-488L18.10 3.97 8.88e-05 0.0167 0.22 0.21 Alcohol dependence; chr1:247194812 chr1:247187281~247188526:- LIHC cis rs875971 0.545 rs6950988 ENSG00000224316.1 RP11-479O9.2 3.97 8.88e-05 0.0168 0.2 0.21 Aortic root size; chr7:66511428 chr7:65773620~65802067:+ LIHC cis rs7129556 0.701 rs4322421 ENSG00000254459.1 RP11-91P24.7 3.97 8.88e-05 0.0168 0.35 0.21 Weight loss (gastric bypass surgery); chr11:77748349 chr11:77829654~77872262:- LIHC cis rs28829049 0.536 rs2073106 ENSG00000270728.1 RP4-657E11.10 -3.97 8.88e-05 0.0168 -0.2 -0.21 QRS duration in Tripanosoma cruzi seropositivity; chr1:19222849 chr1:19297080~19297903:+ LIHC cis rs6745190 0.953 rs4595925 ENSG00000236153.1 AC104076.3 3.97 8.88e-05 0.0168 0.28 0.21 White blood cell count; chr2:180979589 chr2:180979427~180980090:- LIHC cis rs950169 0.58 rs4603535 ENSG00000259728.4 LINC00933 3.97 8.89e-05 0.0168 0.3 0.21 Schizophrenia; chr15:84630641 chr15:84570649~84580175:+ LIHC cis rs864745 0.967 rs849133 ENSG00000234336.5 JAZF1-AS1 3.97 8.89e-05 0.0168 0.28 0.21 Crohn's disease;Type 2 diabetes; chr7:28152661 chr7:28180322~28243917:+ LIHC cis rs864745 0.967 rs860262 ENSG00000234336.5 JAZF1-AS1 3.97 8.89e-05 0.0168 0.28 0.21 Crohn's disease;Type 2 diabetes; chr7:28154778 chr7:28180322~28243917:+ LIHC cis rs864745 0.967 rs849134 ENSG00000234336.5 JAZF1-AS1 3.97 8.89e-05 0.0168 0.28 0.21 Crohn's disease;Type 2 diabetes; chr7:28156603 chr7:28180322~28243917:+ LIHC cis rs10761256 0.806 rs2001994 ENSG00000227603.1 RP11-165J3.6 3.97 8.89e-05 0.0168 0.24 0.21 Itch intensity from mosquito bite adjusted by bite size; chr9:93631567 chr9:93435332~93437121:- LIHC cis rs912057 0.932 rs1294406 ENSG00000261211.1 RP1-80N2.3 3.97 8.89e-05 0.0168 0.22 0.21 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index; chr6:6737504 chr6:6680309~6683633:- LIHC cis rs4538475 0.858 rs4320134 ENSG00000214846.4 RP11-115L11.1 3.97 8.89e-05 0.0168 0.3 0.21 Parkinson's disease; chr4:15737805 chr4:15730962~15731627:- LIHC cis rs67311347 0.544 rs9864601 ENSG00000223797.4 ENTPD3-AS1 3.97 8.89e-05 0.0168 0.17 0.21 Renal cell carcinoma; chr3:40303827 chr3:40313802~40453329:- LIHC cis rs4356203 0.792 rs620241 ENSG00000260196.1 RP1-239B22.5 -3.97 8.9e-05 0.0168 -0.25 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17175343 chr11:17380649~17383531:+ LIHC cis rs7809950 0.817 rs34325395 ENSG00000238832.1 snoU109 -3.97 8.9e-05 0.0168 -0.27 -0.21 Coronary artery disease; chr7:107473363 chr7:107603363~107603507:+ LIHC cis rs79578553 0.702 rs10129166 ENSG00000258667.1 HIF1A-AS2 3.97 8.9e-05 0.0168 0.31 0.21 Red wine liking; chr14:61133722 chr14:61715558~61751097:- LIHC cis rs1223397 0.651 rs488297 ENSG00000215022.6 RP1-257A7.4 -3.97 8.9e-05 0.0168 -0.22 -0.21 Blood pressure; chr6:13300264 chr6:13264861~13295586:- LIHC cis rs4561483 0.801 rs33619 ENSG00000261560.1 RP11-166B2.3 -3.97 8.9e-05 0.0168 -0.24 -0.21 Testicular germ cell tumor; chr16:11915084 chr16:11881075~11882569:- LIHC cis rs1223397 0.53 rs2458313 ENSG00000215022.6 RP1-257A7.4 -3.97 8.91e-05 0.0168 -0.22 -0.21 Blood pressure; chr6:13309557 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs2496140 ENSG00000215022.6 RP1-257A7.4 -3.97 8.91e-05 0.0168 -0.22 -0.21 Blood pressure; chr6:13309663 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs2458312 ENSG00000215022.6 RP1-257A7.4 -3.97 8.91e-05 0.0168 -0.22 -0.21 Blood pressure; chr6:13309757 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs2458311 ENSG00000215022.6 RP1-257A7.4 -3.97 8.91e-05 0.0168 -0.22 -0.21 Blood pressure; chr6:13309780 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs2458310 ENSG00000215022.6 RP1-257A7.4 -3.97 8.91e-05 0.0168 -0.22 -0.21 Blood pressure; chr6:13310076 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs2439541 ENSG00000215022.6 RP1-257A7.4 -3.97 8.91e-05 0.0168 -0.22 -0.21 Blood pressure; chr6:13310335 chr6:13264861~13295586:- LIHC cis rs1003719 0.614 rs1053808 ENSG00000272948.2 AP001412.1 -3.97 8.92e-05 0.0168 -0.23 -0.21 Eye color traits; chr21:37153056 chr21:37267784~37268497:+ LIHC cis rs1005277 0.54 rs2474598 ENSG00000099251.13 HSD17B7P2 -3.97 8.92e-05 0.0168 -0.24 -0.21 Extrinsic epigenetic age acceleration; chr10:38141368 chr10:38356380~38378505:+ LIHC cis rs113084984 0.816 rs4669749 ENSG00000271952.1 RP11-245G13.2 3.97 8.92e-05 0.0168 0.28 0.21 Breast cancer; chr2:11552538 chr2:10878269~10885118:+ LIHC cis rs7726839 0.54 rs3749615 ENSG00000271781.1 CTD-2589H19.6 -3.97 8.93e-05 0.0168 -0.32 -0.21 Obesity-related traits; chr5:601370 chr5:675826~676616:+ LIHC cis rs7760535 0.826 rs3777905 ENSG00000271789.1 RP5-1112D6.7 -3.96 8.94e-05 0.0169 -0.21 -0.21 Metabolic traits; chr6:111549385 chr6:111297126~111298510:+ LIHC cis rs7726839 0.54 rs3749618 ENSG00000271781.1 CTD-2589H19.6 -3.96 8.94e-05 0.0169 -0.32 -0.21 Obesity-related traits; chr5:602535 chr5:675826~676616:+ LIHC cis rs748404 0.697 rs530188 ENSG00000205771.5 CATSPER2P1 -3.96 8.94e-05 0.0169 -0.25 -0.21 Lung cancer; chr15:43253116 chr15:43726918~43747094:- LIHC cis rs12692119 0.649 rs6431194 ENSG00000272789.1 RP11-286H15.1 3.96 8.95e-05 0.0169 0.49 0.21 Pelvic organ prolapse (moderate/severe); chr2:126877103 chr2:127625997~127626848:- LIHC cis rs79349575 0.756 rs937301 ENSG00000248278.1 SUMO2P17 -3.96 8.95e-05 0.0169 -0.26 -0.21 Type 2 diabetes; chr17:48968914 chr17:48874860~48908983:- LIHC cis rs79349575 0.756 rs3848460 ENSG00000248278.1 SUMO2P17 -3.96 8.95e-05 0.0169 -0.26 -0.21 Type 2 diabetes; chr17:48969752 chr17:48874860~48908983:- LIHC cis rs10883723 0.81 rs3740406 ENSG00000236937.2 PTGES3P4 -3.96 8.95e-05 0.0169 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102513032 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs10748824 ENSG00000236937.2 PTGES3P4 -3.96 8.95e-05 0.0169 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102514709 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs7094751 ENSG00000236937.2 PTGES3P4 -3.96 8.95e-05 0.0169 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102515061 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs1884929 ENSG00000236937.2 PTGES3P4 -3.96 8.95e-05 0.0169 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102515661 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs7912901 ENSG00000236937.2 PTGES3P4 -3.96 8.95e-05 0.0169 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102517683 chr10:102845595~102845950:+ LIHC cis rs3862030 0.503 rs10786673 ENSG00000236937.2 PTGES3P4 -3.96 8.95e-05 0.0169 -0.28 -0.21 Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction); chr10:102520780 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs7090276 ENSG00000236937.2 PTGES3P4 -3.96 8.95e-05 0.0169 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102521482 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs1409310 ENSG00000236937.2 PTGES3P4 -3.96 8.95e-05 0.0169 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102522508 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs7074343 ENSG00000236937.2 PTGES3P4 -3.96 8.95e-05 0.0169 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102523408 chr10:102845595~102845950:+ LIHC cis rs673078 0.66 rs7965350 ENSG00000275759.1 RP11-131L12.3 -3.96 8.95e-05 0.0169 -0.41 -0.21 Glucose homeostasis traits; chr12:118266710 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs17433217 ENSG00000275759.1 RP11-131L12.3 -3.96 8.95e-05 0.0169 -0.41 -0.21 Glucose homeostasis traits; chr12:118269076 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs73205526 ENSG00000275759.1 RP11-131L12.3 -3.96 8.95e-05 0.0169 -0.41 -0.21 Glucose homeostasis traits; chr12:118273172 chr12:118428281~118428870:+ LIHC cis rs673078 0.571 rs7954330 ENSG00000275759.1 RP11-131L12.3 -3.96 8.95e-05 0.0169 -0.41 -0.21 Glucose homeostasis traits; chr12:118275284 chr12:118428281~118428870:+ LIHC cis rs7893279 0.505 rs4748498 ENSG00000225527.1 RP11-383B4.4 3.96 8.96e-05 0.0169 0.3 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18618124 chr10:18531849~18533336:- LIHC cis rs494003 1 rs11227284 ENSG00000265874.1 MIR4489 3.96 8.96e-05 0.0169 0.35 0.21 Systemic lupus erythematosus; chr11:65735753 chr11:65649192~65649253:+ LIHC cis rs494003 1 rs72922733 ENSG00000265874.1 MIR4489 3.96 8.96e-05 0.0169 0.35 0.21 Systemic lupus erythematosus; chr11:65753275 chr11:65649192~65649253:+ LIHC cis rs193541 0.632 rs246276 ENSG00000263432.2 RN7SL689P 3.96 8.96e-05 0.0169 0.34 0.21 Glucose homeostasis traits; chr5:122904262 chr5:123022487~123022783:- LIHC cis rs2531992 1 rs2531992 ENSG00000262185.1 RP11-462G12.1 -3.96 8.96e-05 0.0169 -0.37 -0.21 Waist circumference; chr16:3971733 chr16:3947609~3950444:- LIHC cis rs1405130 0.869 rs884064 ENSG00000224287.2 MSL3P1 3.96 8.97e-05 0.0169 0.25 0.21 Coronary artery disease; chr2:234661897 chr2:233865437~233868444:- LIHC cis rs1405130 0.839 rs13009399 ENSG00000224287.2 MSL3P1 3.96 8.97e-05 0.0169 0.25 0.21 Coronary artery disease; chr2:234662584 chr2:233865437~233868444:- LIHC cis rs1405130 0.781 rs13009798 ENSG00000224287.2 MSL3P1 3.96 8.97e-05 0.0169 0.25 0.21 Coronary artery disease; chr2:234662721 chr2:233865437~233868444:- LIHC cis rs1405130 0.835 rs2892049 ENSG00000224287.2 MSL3P1 3.96 8.97e-05 0.0169 0.25 0.21 Coronary artery disease; chr2:234663259 chr2:233865437~233868444:- LIHC cis rs1405130 0.802 rs2892048 ENSG00000224287.2 MSL3P1 3.96 8.97e-05 0.0169 0.25 0.21 Coronary artery disease; chr2:234663260 chr2:233865437~233868444:- LIHC cis rs1405130 0.869 rs4663466 ENSG00000224287.2 MSL3P1 3.96 8.97e-05 0.0169 0.25 0.21 Coronary artery disease; chr2:234664559 chr2:233865437~233868444:- LIHC cis rs2274273 0.624 rs8014540 ENSG00000258413.1 RP11-665C16.6 -3.96 8.97e-05 0.0169 -0.26 -0.21 Protein biomarker; chr14:55374970 chr14:55262767~55272075:- LIHC cis rs12681366 0.881 rs3019155 ENSG00000253704.1 RP11-267M23.4 3.96 8.97e-05 0.0169 0.24 0.21 Nonsyndromic cleft lip with cleft palate; chr8:94405359 chr8:94553722~94569745:+ LIHC cis rs417065 0.703 rs425371 ENSG00000227634.1 RP11-431K24.3 -3.96 8.97e-05 0.0169 -0.24 -0.21 Psoriasis; chr1:8212466 chr1:8208672~8215210:+ LIHC cis rs7665090 0.967 rs6533022 ENSG00000230069.3 LRRC37A15P -3.96 8.97e-05 0.0169 -0.2 -0.21 Primary biliary cholangitis; chr4:102637794 chr4:102727274~102730721:- LIHC cis rs6061231 0.631 rs2427310 ENSG00000226332.2 RP11-157P1.4 3.96 8.97e-05 0.0169 0.22 0.21 Colorectal cancer; chr20:62394873 chr20:62305432~62306325:- LIHC cis rs919433 0.929 rs7592511 ENSG00000231621.1 AC013264.2 3.96 8.97e-05 0.0169 0.19 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197313250 chr2:197197991~197199273:+ LIHC cis rs1799949 1 rs4793190 ENSG00000267681.1 CTD-3199J23.6 -3.96 8.98e-05 0.0169 -0.2 -0.21 Menopause (age at onset); chr17:43048092 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs8176297 ENSG00000267681.1 CTD-3199J23.6 -3.96 8.98e-05 0.0169 -0.2 -0.21 Menopause (age at onset); chr17:43051308 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs8176296 ENSG00000267681.1 CTD-3199J23.6 -3.96 8.98e-05 0.0169 -0.2 -0.21 Menopause (age at onset); chr17:43051574 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs4793191 ENSG00000267681.1 CTD-3199J23.6 -3.96 8.98e-05 0.0169 -0.2 -0.21 Menopause (age at onset); chr17:43052360 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs4793192 ENSG00000267681.1 CTD-3199J23.6 -3.96 8.98e-05 0.0169 -0.2 -0.21 Menopause (age at onset); chr17:43052373 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs8176289 ENSG00000267681.1 CTD-3199J23.6 -3.96 8.98e-05 0.0169 -0.2 -0.21 Menopause (age at onset); chr17:43054039 chr17:43144956~43145255:+ LIHC cis rs12468226 0.873 rs6761131 ENSG00000226261.1 AC064836.3 -3.96 8.98e-05 0.0169 -0.33 -0.21 Urate levels; chr2:202237675 chr2:202336024~202336727:- LIHC cis rs12586317 0.553 rs78124218 ENSG00000257307.1 RP11-317N8.4 -3.96 8.98e-05 0.0169 -0.25 -0.21 Psoriasis; chr14:35101400 chr14:35881001~35881709:+ LIHC cis rs1247318 1 rs1247322 ENSG00000243831.1 RP1-81D8.4 -3.96 8.98e-05 0.0169 -0.3 -0.21 Aging; chr6:160909620 chr6:160666228~160676523:- LIHC cis rs1928295 0.786 rs7038943 ENSG00000233569.1 RP11-500B12.1 3.96 8.99e-05 0.0169 0.22 0.21 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117614900 chr9:117648606~117657027:+ LIHC cis rs79349575 0.756 rs2291726 ENSG00000248278.1 SUMO2P17 -3.96 8.99e-05 0.0169 -0.26 -0.21 Type 2 diabetes; chr17:48961892 chr17:48874860~48908983:- LIHC cis rs7617773 0.78 rs71323396 ENSG00000228638.1 FCF1P2 -3.96 8.99e-05 0.0169 -0.24 -0.21 Coronary artery disease; chr3:48333244 chr3:48290793~48291375:- LIHC cis rs4356203 0.87 rs214900 ENSG00000260196.1 RP1-239B22.5 3.96 9e-05 0.0169 0.25 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17206215 chr11:17380649~17383531:+ LIHC cis rs1005277 0.579 rs2505240 ENSG00000276805.1 RP11-291L22.6 3.96 9e-05 0.0169 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38153491 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2505241 ENSG00000276805.1 RP11-291L22.6 3.96 9e-05 0.0169 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38153493 chr10:38451030~38451785:+ LIHC cis rs891378 0.837 rs11120688 ENSG00000274245.1 RP11-357P18.2 3.96 9e-05 0.0169 0.27 0.21 Spherical equivalent (joint analysis main effects and education interaction); chr1:207312770 chr1:207372559~207373252:+ LIHC cis rs10129255 0.913 rs10140943 ENSG00000211972.2 IGHV3-66 3.96 9e-05 0.0169 0.17 0.21 Kawasaki disease; chr14:106767441 chr14:106675017~106675544:- LIHC cis rs7182948 1 rs12902107 ENSG00000259531.2 RP11-295H24.3 -3.96 9e-05 0.0169 -0.31 -0.21 Lung adenocarcinoma; chr15:49575126 chr15:49365124~49366685:- LIHC cis rs9890032 0.618 rs55872374 ENSG00000266490.1 CTD-2349P21.9 3.96 9e-05 0.0169 0.2 0.21 Hip circumference adjusted for BMI; chr17:30822863 chr17:30792372~30792833:+ LIHC cis rs6430585 0.583 rs11886852 ENSG00000231890.6 DARS-AS1 -3.96 9.01e-05 0.0169 -0.3 -0.21 Corneal structure; chr2:135831809 chr2:135985176~136022593:+ LIHC cis rs13217239 0.646 rs7768407 ENSG00000241549.7 GUSBP2 3.96 9.01e-05 0.017 0.21 0.21 Schizophrenia; chr6:27049016 chr6:26871484~26956554:- LIHC cis rs6997458 0.785 rs7016369 ENSG00000253549.4 RP11-317J10.2 -3.96 9.01e-05 0.017 -0.24 -0.21 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85456040 chr8:85441851~85464915:- LIHC cis rs6832769 0.922 rs6825994 ENSG00000272969.1 RP11-528I4.2 -3.96 9.01e-05 0.017 -0.25 -0.21 Personality dimensions; chr4:55524244 chr4:55547112~55547889:+ LIHC cis rs2919917 0.628 rs11776243 ENSG00000254352.1 RP11-578O24.2 3.96 9.02e-05 0.017 0.32 0.21 Lymphocyte counts; chr8:78648848 chr8:78723796~78724136:- LIHC cis rs2919917 0.628 rs10110524 ENSG00000254352.1 RP11-578O24.2 3.96 9.02e-05 0.017 0.32 0.21 Lymphocyte counts; chr8:78648871 chr8:78723796~78724136:- LIHC cis rs703842 1 rs10877015 ENSG00000270039.1 RP11-571M6.17 -3.96 9.02e-05 0.017 -0.3 -0.21 Multiple sclerosis; chr12:57774005 chr12:57803838~57804415:+ LIHC cis rs5770917 1 rs2269382 ENSG00000273272.1 CTA-384D8.34 3.96 9.02e-05 0.017 0.31 0.21 Narcolepsy; chr22:50580482 chr22:50542650~50543011:+ LIHC cis rs7826238 0.623 rs2976893 ENSG00000253981.4 ALG1L13P -3.96 9.03e-05 0.017 -0.27 -0.21 Systolic blood pressure; chr8:8480709 chr8:8236003~8244667:- LIHC cis rs6723108 0.603 rs10187990 ENSG00000224043.6 CCNT2-AS1 -3.96 9.03e-05 0.017 -0.29 -0.21 Type 2 diabetes; chr2:134939987 chr2:134735464~134918710:- LIHC cis rs2348418 0.966 rs11049695 ENSG00000247934.4 RP11-967K21.1 3.96 9.04e-05 0.017 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28527934 chr12:28163298~28190738:- LIHC cis rs4650994 1 rs4650995 ENSG00000213057.5 C1orf220 3.96 9.04e-05 0.017 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178548181 chr1:178542752~178548889:+ LIHC cis rs17197037 0.545 rs8010980 ENSG00000240954.1 RPL4P1 -3.96 9.04e-05 0.017 -0.21 -0.21 Bipolar disorder; chr14:21318343 chr14:21750269~21751546:+ LIHC cis rs17197037 0.545 rs7147689 ENSG00000240954.1 RPL4P1 -3.96 9.04e-05 0.017 -0.21 -0.21 Bipolar disorder; chr14:21318697 chr14:21750269~21751546:+ LIHC cis rs10760158 0.51 rs7020643 ENSG00000226752.6 PSMD5-AS1 -3.96 9.04e-05 0.017 -0.21 -0.21 Pulse pressure; chr9:121099578 chr9:120824828~120854385:+ LIHC cis rs7412746 0.658 rs10305704 ENSG00000231073.1 RP11-316M1.3 3.96 9.04e-05 0.017 0.21 0.21 Melanoma; chr1:150831953 chr1:150973123~150975534:+ LIHC cis rs853679 0.599 rs156743 ENSG00000219891.2 ZSCAN12P1 3.96 9.05e-05 0.017 0.38 0.21 Depression; chr6:27999311 chr6:28091154~28093664:+ LIHC cis rs4650994 1 rs10798617 ENSG00000213057.5 C1orf220 3.96 9.05e-05 0.017 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178546671 chr1:178542752~178548889:+ LIHC cis rs6142102 0.602 rs4911402 ENSG00000275784.1 RP5-1125A11.6 -3.96 9.05e-05 0.017 -0.23 -0.21 Skin pigmentation; chr20:34079839 chr20:33989480~33991818:- LIHC cis rs1223397 0.689 rs2439539 ENSG00000215022.6 RP1-257A7.4 -3.96 9.05e-05 0.017 -0.22 -0.21 Blood pressure; chr6:13308601 chr6:13264861~13295586:- LIHC cis rs1223397 0.589 rs2439540 ENSG00000215022.6 RP1-257A7.4 -3.96 9.05e-05 0.017 -0.22 -0.21 Blood pressure; chr6:13309110 chr6:13264861~13295586:- LIHC cis rs1061377 0.513 rs6840214 ENSG00000249685.1 RP11-360F5.3 -3.96 9.06e-05 0.017 -0.31 -0.21 Uric acid levels; chr4:39118999 chr4:39133913~39135608:+ LIHC cis rs11696277 0.518 rs6080641 ENSG00000232333.1 RPS27AP2 3.96 9.06e-05 0.017 0.29 0.21 Gut microbiome composition (summer); chr20:17340158 chr20:17516843~17517307:+ LIHC cis rs6471393 0.964 rs16916186 ENSG00000253848.1 RP11-10N23.5 3.96 9.06e-05 0.017 0.23 0.21 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93733158 chr8:93741193~93744534:+ LIHC cis rs7917772 0.503 rs7078435 ENSG00000236937.2 PTGES3P4 -3.96 9.07e-05 0.017 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102545009 chr10:102845595~102845950:+ LIHC cis rs4970988 0.787 rs1532770 ENSG00000231073.1 RP11-316M1.3 3.96 9.07e-05 0.017 0.21 0.21 Urate levels; chr1:150752859 chr1:150973123~150975534:+ LIHC cis rs2115630 0.905 rs1975277 ENSG00000259295.5 CSPG4P12 -3.96 9.07e-05 0.0171 -0.24 -0.21 P wave terminal force; chr15:84786327 chr15:85191438~85213905:+ LIHC cis rs17264034 0.861 rs55713652 ENSG00000250786.1 SNHG18 3.96 9.08e-05 0.0171 0.28 0.21 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9557010 chr5:9546200~9550609:+ LIHC cis rs9652601 0.879 rs8062322 ENSG00000274038.1 RP11-66H6.4 -3.96 9.08e-05 0.0171 -0.27 -0.21 Systemic lupus erythematosus; chr16:10998462 chr16:11056556~11057034:+ LIHC cis rs3020736 0.5 rs8143153 ENSG00000205702.9 CYP2D7 -3.96 9.09e-05 0.0171 -0.24 -0.21 Autism spectrum disorder or schizophrenia; chr22:42119633 chr22:42140203~42144577:- LIHC cis rs11096990 0.821 rs76235093 ENSG00000249685.1 RP11-360F5.3 -3.96 9.09e-05 0.0171 -0.28 -0.21 Cognitive function; chr4:39281157 chr4:39133913~39135608:+ LIHC cis rs3093024 0.595 rs4412174 ENSG00000227598.1 RP1-167A14.2 -3.96 9.09e-05 0.0171 -0.23 -0.21 Rheumatoid arthritis; chr6:167062578 chr6:166969626~166999065:- LIHC cis rs3093024 0.595 rs4458654 ENSG00000227598.1 RP1-167A14.2 -3.96 9.09e-05 0.0171 -0.23 -0.21 Rheumatoid arthritis; chr6:167062580 chr6:166969626~166999065:- LIHC cis rs2074193 0.627 rs215387 ENSG00000257906.1 RP1-90J4.1 3.96 9.09e-05 0.0171 0.29 0.21 Migraine with aura; chr12:47369890 chr12:47415008~47420179:+ LIHC cis rs13113518 0.683 rs9761521 ENSG00000249700.7 SRD5A3-AS1 3.96 9.09e-05 0.0171 0.23 0.21 Height; chr4:55363436 chr4:55363971~55395847:- LIHC cis rs113835537 0.935 rs76228630 ENSG00000255517.5 CTD-3074O7.5 -3.96 9.1e-05 0.0171 -0.37 -0.21 Airway imaging phenotypes; chr11:66691205 chr11:66473490~66480233:- LIHC cis rs113835537 0.935 rs79496339 ENSG00000255517.5 CTD-3074O7.5 -3.96 9.1e-05 0.0171 -0.37 -0.21 Airway imaging phenotypes; chr11:66700298 chr11:66473490~66480233:- LIHC cis rs7083 0.716 rs574603 ENSG00000254851.1 RP11-109L13.1 3.96 9.1e-05 0.0171 0.31 0.21 Blood protein levels; chr11:117307025 chr11:117135528~117138582:+ LIHC cis rs4578769 0.765 rs11082173 ENSG00000265943.1 RP11-739L10.1 -3.96 9.1e-05 0.0171 -0.27 -0.21 Eosinophil percentage of white cells; chr18:22858048 chr18:22699481~22933764:- LIHC cis rs2462686 0.965 rs1525831 ENSG00000272556.1 RP11-638I8.1 -3.96 9.11e-05 0.0171 -0.32 -0.21 Major depressive disorder; chr7:45954810 chr7:45814602~45815263:+ LIHC cis rs244293 0.672 rs9901526 ENSG00000275710.1 RP11-257O5.4 3.96 9.11e-05 0.0171 0.22 0.21 Menarche (age at onset); chr17:54935018 chr17:54964474~54964679:+ LIHC cis rs11089937 1 rs6001121 ENSG00000211639.2 IGLV4-60 3.96 9.11e-05 0.0171 0.18 0.21 Periodontitis (PAL4Q3); chr22:22149505 chr22:22162199~22162681:+ LIHC cis rs10833905 1 rs10833905 ENSG00000246225.5 RP11-17A1.3 3.96 9.12e-05 0.0171 0.26 0.21 Sudden cardiac arrest; chr11:23023046 chr11:22829380~22945393:+ LIHC cis rs17376456 0.877 rs9314092 ENSG00000251023.1 RP11-549J18.1 -3.96 9.12e-05 0.0171 -0.44 -0.21 Diabetic retinopathy; chr5:93990657 chr5:93860669~93863825:- LIHC cis rs244293 0.931 rs173408 ENSG00000275710.1 RP11-257O5.4 3.96 9.12e-05 0.0171 0.23 0.21 Menarche (age at onset); chr17:55125031 chr17:54964474~54964679:+ LIHC cis rs244293 0.931 rs2628323 ENSG00000275710.1 RP11-257O5.4 3.96 9.12e-05 0.0171 0.23 0.21 Menarche (age at onset); chr17:55125736 chr17:54964474~54964679:+ LIHC cis rs193541 0.632 rs7729834 ENSG00000263432.2 RN7SL689P 3.96 9.12e-05 0.0171 0.34 0.21 Glucose homeostasis traits; chr5:122786464 chr5:123022487~123022783:- LIHC cis rs11733284 0.894 rs11722463 ENSG00000259959.1 RP11-121C2.2 3.96 9.12e-05 0.0171 0.19 0.21 Gout;Renal underexcretion gout; chr4:48036699 chr4:47840122~47844339:- LIHC cis rs11733284 0.928 rs11736427 ENSG00000259959.1 RP11-121C2.2 3.96 9.12e-05 0.0171 0.19 0.21 Gout;Renal underexcretion gout; chr4:48037885 chr4:47840122~47844339:- LIHC cis rs244293 0.931 rs244349 ENSG00000275710.1 RP11-257O5.4 3.96 9.13e-05 0.0171 0.23 0.21 Menarche (age at onset); chr17:55118808 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244346 ENSG00000275710.1 RP11-257O5.4 3.96 9.13e-05 0.0171 0.23 0.21 Menarche (age at onset); chr17:55119022 chr17:54964474~54964679:+ LIHC cis rs244293 0.899 rs244344 ENSG00000275710.1 RP11-257O5.4 3.96 9.13e-05 0.0171 0.23 0.21 Menarche (age at onset); chr17:55119637 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244343 ENSG00000275710.1 RP11-257O5.4 3.96 9.13e-05 0.0171 0.23 0.21 Menarche (age at onset); chr17:55120251 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244341 ENSG00000275710.1 RP11-257O5.4 3.96 9.13e-05 0.0171 0.23 0.21 Menarche (age at onset); chr17:55121561 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244340 ENSG00000275710.1 RP11-257O5.4 3.96 9.13e-05 0.0171 0.23 0.21 Menarche (age at onset); chr17:55121984 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244339 ENSG00000275710.1 RP11-257O5.4 3.96 9.13e-05 0.0171 0.23 0.21 Menarche (age at onset); chr17:55122753 chr17:54964474~54964679:+ LIHC cis rs4453827 1 rs2359204 ENSG00000271916.1 RP11-884K10.6 3.96 9.13e-05 0.0171 0.43 0.21 Blood protein levels; chr3:53715713 chr3:53797764~53798019:- LIHC cis rs9907295 1 rs9889274 ENSG00000270871.1 AC015849.19 3.96 9.13e-05 0.0171 0.22 0.21 Fibroblast growth factor basic levels; chr17:35910397 chr17:35816717~35830293:- LIHC cis rs11096990 0.892 rs1901404 ENSG00000249207.1 RP11-360F5.1 3.96 9.13e-05 0.0171 0.24 0.21 Cognitive function; chr4:39210990 chr4:39112677~39126818:- LIHC cis rs17711722 0.523 rs365896 ENSG00000236529.1 RP13-254B10.1 -3.96 9.13e-05 0.0171 -0.19 -0.21 Calcium levels; chr7:66045710 chr7:65840212~65840596:+ LIHC cis rs11148252 0.774 rs6561666 ENSG00000278238.1 RP11-245D16.4 -3.96 9.14e-05 0.0171 -0.2 -0.21 Lewy body disease; chr13:52355910 chr13:52454775~52455331:- LIHC cis rs651907 0.557 rs7651721 ENSG00000244119.1 PDCL3P4 3.96 9.14e-05 0.0172 0.22 0.21 Colorectal cancer; chr3:101674739 chr3:101712472~101713191:+ LIHC cis rs7829975 0.606 rs11776838 ENSG00000253893.2 FAM85B 3.96 9.14e-05 0.0172 0.25 0.21 Mood instability; chr8:8937291 chr8:8167819~8226614:- LIHC cis rs12586317 0.62 rs76293361 ENSG00000257307.1 RP11-317N8.4 -3.96 9.14e-05 0.0172 -0.25 -0.21 Psoriasis; chr14:35101683 chr14:35881001~35881709:+ LIHC cis rs172166 0.694 rs9295760 ENSG00000219392.1 RP1-265C24.5 -3.96 9.14e-05 0.0172 -0.28 -0.21 Cardiac Troponin-T levels; chr6:28179607 chr6:28115628~28116551:+ LIHC cis rs16958440 0.581 rs12386097 ENSG00000267724.1 RP11-49K24.8 3.96 9.15e-05 0.0172 0.29 0.21 Sitting height ratio; chr18:47146897 chr18:47105946~47108062:+ LIHC cis rs11048434 0.518 rs7311267 ENSG00000257027.1 RP11-705C15.3 3.96 9.15e-05 0.0172 0.19 0.21 Sjögren's syndrome; chr12:9026082 chr12:9658567~9662085:+ LIHC cis rs131777 0.577 rs131748 ENSG00000272940.1 CTA-384D8.33 -3.96 9.15e-05 0.0172 -0.27 -0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586408 chr22:50597152~50597599:+ LIHC cis rs17818399 0.962 rs2122715 ENSG00000279254.1 RP11-536C12.1 -3.96 9.15e-05 0.0172 -0.26 -0.21 Height; chr2:46618710 chr2:46668870~46670778:+ LIHC cis rs7917772 0.503 rs10883732 ENSG00000236937.2 PTGES3P4 -3.96 9.15e-05 0.0172 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102533704 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs10748825 ENSG00000236937.2 PTGES3P4 -3.96 9.15e-05 0.0172 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102533852 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs7893155 ENSG00000236937.2 PTGES3P4 -3.96 9.15e-05 0.0172 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102534471 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs7914389 ENSG00000236937.2 PTGES3P4 -3.96 9.15e-05 0.0172 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102535645 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs7915589 ENSG00000236937.2 PTGES3P4 -3.96 9.15e-05 0.0172 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102539507 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs7100753 ENSG00000236937.2 PTGES3P4 -3.96 9.15e-05 0.0172 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102541222 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs11191326 ENSG00000236937.2 PTGES3P4 -3.96 9.15e-05 0.0172 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102543202 chr10:102845595~102845950:+ LIHC cis rs4763879 0.634 rs11052582 ENSG00000256673.1 RP11-599J14.2 3.96 9.15e-05 0.0172 0.2 0.21 Type 1 diabetes; chr12:9706714 chr12:9398355~9414851:- LIHC cis rs1075265 0.554 rs10168293 ENSG00000233266.1 HMGB1P31 3.96 9.16e-05 0.0172 0.25 0.21 Chronotype;Morning vs. evening chronotype; chr2:53973793 chr2:54051334~54051760:+ LIHC cis rs1075265 0.567 rs66773232 ENSG00000233266.1 HMGB1P31 3.96 9.16e-05 0.0172 0.25 0.21 Chronotype;Morning vs. evening chronotype; chr2:53973970 chr2:54051334~54051760:+ LIHC cis rs889014 1 rs6885032 ENSG00000204758.6 CTC-308K20.1 -3.96 9.16e-05 0.0172 -0.31 -0.21 Height; chr5:173556276 chr5:172954786~172959392:- LIHC cis rs891378 0.876 rs1367067 ENSG00000274245.1 RP11-357P18.2 3.96 9.17e-05 0.0172 0.26 0.21 Spherical equivalent (joint analysis main effects and education interaction); chr1:207269019 chr1:207372559~207373252:+ LIHC cis rs6496044 0.507 rs62022863 ENSG00000259630.2 CTD-2262B20.1 3.96 9.17e-05 0.0172 0.22 0.21 Interstitial lung disease; chr15:85618822 chr15:85415228~85415633:+ LIHC cis rs10510102 0.872 rs28586586 ENSG00000273891.1 RP11-500G22.5 3.96 9.17e-05 0.0172 0.28 0.21 Breast cancer; chr10:121950228 chr10:121965764~121967700:+ LIHC cis rs6700559 0.74 rs4437908 ENSG00000260088.1 RP11-92G12.3 3.96 9.17e-05 0.0172 0.29 0.21 Coronary artery disease; chr1:200679311 chr1:200669507~200694250:+ LIHC cis rs9341808 0.6 rs668329 ENSG00000272129.1 RP11-250B2.6 -3.96 9.18e-05 0.0172 -0.22 -0.21 Sitting height ratio; chr6:80258861 chr6:80355424~80356859:+ LIHC cis rs8177876 0.749 rs2549896 ENSG00000261061.1 RP11-303E16.2 3.96 9.18e-05 0.0172 0.27 0.21 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81054334 chr16:81030770~81031485:+ LIHC cis rs11096990 0.656 rs9993224 ENSG00000249207.1 RP11-360F5.1 3.96 9.18e-05 0.0172 0.21 0.21 Cognitive function; chr4:39298578 chr4:39112677~39126818:- LIHC cis rs673078 0.607 rs59594854 ENSG00000275409.1 RP11-131L12.4 -3.96 9.18e-05 0.0172 -0.25 -0.21 Glucose homeostasis traits; chr12:118374000 chr12:118430147~118430699:+ LIHC cis rs9457247 0.561 rs916331 ENSG00000227598.1 RP1-167A14.2 -3.96 9.19e-05 0.0172 -0.23 -0.21 Crohn's disease; chr6:167057071 chr6:166969626~166999065:- LIHC cis rs9457247 0.602 rs13204839 ENSG00000227598.1 RP1-167A14.2 -3.96 9.19e-05 0.0172 -0.23 -0.21 Crohn's disease; chr6:167057631 chr6:166969626~166999065:- LIHC cis rs9457247 0.602 rs6456152 ENSG00000227598.1 RP1-167A14.2 -3.96 9.19e-05 0.0172 -0.23 -0.21 Crohn's disease; chr6:167058574 chr6:166969626~166999065:- LIHC cis rs7937890 0.505 rs4403769 ENSG00000251991.1 RNU7-49P 3.96 9.19e-05 0.0172 0.23 0.21 Mitochondrial DNA levels; chr11:14428630 chr11:14478892~14478953:+ LIHC cis rs919433 0.963 rs4850430 ENSG00000231621.1 AC013264.2 3.96 9.19e-05 0.0172 0.19 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197318072 chr2:197197991~197199273:+ LIHC cis rs919433 0.963 rs10166569 ENSG00000231621.1 AC013264.2 3.96 9.19e-05 0.0172 0.19 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197318715 chr2:197197991~197199273:+ LIHC cis rs12478296 0.792 rs6740738 ENSG00000261186.2 RP11-341N2.1 -3.96 9.19e-05 0.0172 -0.27 -0.21 Obesity-related traits; chr2:242065217 chr2:242087351~242088457:- LIHC cis rs4578769 0.649 rs72889626 ENSG00000265943.1 RP11-739L10.1 -3.96 9.19e-05 0.0172 -0.27 -0.21 Eosinophil percentage of white cells; chr18:23006282 chr18:22699481~22933764:- LIHC cis rs7083 1 rs644215 ENSG00000254851.1 RP11-109L13.1 3.96 9.2e-05 0.0172 0.3 0.21 Blood protein levels; chr11:117275202 chr11:117135528~117138582:+ LIHC cis rs673078 0.607 rs6490177 ENSG00000275759.1 RP11-131L12.3 -3.96 9.2e-05 0.0172 -0.26 -0.21 Glucose homeostasis traits; chr12:118358280 chr12:118428281~118428870:+ LIHC cis rs13434995 0.589 rs496055 ENSG00000273257.1 RP11-177J6.1 -3.96 9.2e-05 0.0172 -0.33 -0.21 Adiponectin levels; chr4:55383670 chr4:55387949~55388271:+ LIHC cis rs244293 0.931 rs244345 ENSG00000275710.1 RP11-257O5.4 3.96 9.2e-05 0.0173 0.23 0.21 Menarche (age at onset); chr17:55119616 chr17:54964474~54964679:+ LIHC cis rs6832769 1 rs17085889 ENSG00000272969.1 RP11-528I4.2 -3.96 9.2e-05 0.0173 -0.25 -0.21 Personality dimensions; chr4:55535948 chr4:55547112~55547889:+ LIHC cis rs6832769 1 rs10005989 ENSG00000272969.1 RP11-528I4.2 -3.96 9.2e-05 0.0173 -0.25 -0.21 Personality dimensions; chr4:55539039 chr4:55547112~55547889:+ LIHC cis rs61237505 1 rs61237505 ENSG00000260711.2 RP11-747H7.3 3.96 9.21e-05 0.0173 0.28 0.21 Mean platelet volume; chr14:91779639 chr14:91752856~91759798:- LIHC cis rs6545883 0.929 rs55806663 ENSG00000271889.1 RP11-493E12.1 3.96 9.21e-05 0.0173 0.25 0.21 Tuberculosis; chr2:61513352 chr2:61151433~61162105:- LIHC cis rs9527 0.83 rs3740392 ENSG00000236937.2 PTGES3P4 3.96 9.21e-05 0.0173 0.27 0.21 Arsenic metabolism; chr10:102877098 chr10:102845595~102845950:+ LIHC cis rs4356203 0.905 rs7946010 ENSG00000260196.1 RP1-239B22.5 3.96 9.21e-05 0.0173 0.25 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17154510 chr11:17380649~17383531:+ LIHC cis rs6545883 0.507 rs4411680 ENSG00000271889.1 RP11-493E12.1 -3.96 9.21e-05 0.0173 -0.25 -0.21 Tuberculosis; chr2:61356970 chr2:61151433~61162105:- LIHC cis rs2564921 0.73 rs2564939 ENSG00000242142.1 SERBP1P3 3.96 9.22e-05 0.0173 0.28 0.21 Height; chr3:53072864 chr3:53064283~53065091:- LIHC cis rs2070488 0.965 rs35553573 ENSG00000229589.1 ACVR2B-AS1 3.96 9.22e-05 0.0173 0.24 0.21 Electrocardiographic conduction measures; chr3:38399948 chr3:38451027~38454820:- LIHC cis rs603446 0.55 rs3017229 ENSG00000254851.1 RP11-109L13.1 3.96 9.23e-05 0.0173 0.27 0.21 Triglycerides; chr11:116690251 chr11:117135528~117138582:+ LIHC cis rs801193 0.66 rs4610622 ENSG00000232559.3 GS1-124K5.12 3.96 9.23e-05 0.0173 0.16 0.21 Aortic root size; chr7:66759510 chr7:66554588~66576923:- LIHC cis rs801193 0.66 rs10950049 ENSG00000232559.3 GS1-124K5.12 3.96 9.23e-05 0.0173 0.16 0.21 Aortic root size; chr7:66765873 chr7:66554588~66576923:- LIHC cis rs6832769 1 rs6812042 ENSG00000272969.1 RP11-528I4.2 3.96 9.23e-05 0.0173 0.25 0.21 Personality dimensions; chr4:55529912 chr4:55547112~55547889:+ LIHC cis rs710913 0.618 rs6587 ENSG00000182109.6 RP11-69E11.4 3.96 9.23e-05 0.0173 0.21 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39624273 chr1:39522280~39546187:- LIHC cis rs365302 0.556 rs558804 ENSG00000216480.2 RP3-393E18.1 3.96 9.23e-05 0.0173 0.25 0.21 Coronary heart disease; chr6:159226422 chr6:159526062~159526527:- LIHC cis rs9527 0.569 rs10786730 ENSG00000236937.2 PTGES3P4 3.96 9.23e-05 0.0173 0.26 0.21 Arsenic metabolism; chr10:102964443 chr10:102845595~102845950:+ LIHC cis rs9527 0.615 rs1556960 ENSG00000236937.2 PTGES3P4 3.96 9.23e-05 0.0173 0.26 0.21 Arsenic metabolism; chr10:102966916 chr10:102845595~102845950:+ LIHC cis rs2070488 0.93 rs2370840 ENSG00000229589.1 ACVR2B-AS1 3.96 9.24e-05 0.0173 0.23 0.21 Electrocardiographic conduction measures; chr3:38488334 chr3:38451027~38454820:- LIHC cis rs6430585 0.528 rs309172 ENSG00000231890.6 DARS-AS1 -3.96 9.24e-05 0.0173 -0.29 -0.21 Corneal structure; chr2:135916458 chr2:135985176~136022593:+ LIHC cis rs7560272 0.538 rs2012574 ENSG00000204872.3 NAT8B -3.96 9.25e-05 0.0173 -0.28 -0.21 Schizophrenia; chr2:73701239 chr2:73700576~73701340:- LIHC cis rs528808 1 rs528808 ENSG00000279170.1 RP1-199J3.6 3.96 9.25e-05 0.0173 0.4 0.21 Age-related hearing impairment; chr6:99656413 chr6:99587611~99589898:+ LIHC cis rs9527 0.64 rs7089061 ENSG00000236937.2 PTGES3P4 3.96 9.25e-05 0.0173 0.26 0.21 Arsenic metabolism; chr10:102963258 chr10:102845595~102845950:+ LIHC cis rs9527 0.615 rs7089065 ENSG00000236937.2 PTGES3P4 3.96 9.25e-05 0.0173 0.26 0.21 Arsenic metabolism; chr10:102963265 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs746552 ENSG00000236937.2 PTGES3P4 -3.96 9.25e-05 0.0173 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102582744 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs11191342 ENSG00000236937.2 PTGES3P4 -3.96 9.25e-05 0.0173 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102584693 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs7068535 ENSG00000236937.2 PTGES3P4 -3.96 9.25e-05 0.0173 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102589370 chr10:102845595~102845950:+ LIHC cis rs2439831 1 rs2601014 ENSG00000275601.1 AC011330.13 -3.96 9.25e-05 0.0173 -0.31 -0.21 Lung cancer in ever smokers; chr15:43463815 chr15:43642389~43643023:- LIHC cis rs2070488 0.965 rs2284820 ENSG00000229589.1 ACVR2B-AS1 -3.96 9.26e-05 0.0173 -0.24 -0.21 Electrocardiographic conduction measures; chr3:38521088 chr3:38451027~38454820:- LIHC cis rs3738443 1 rs61840059 ENSG00000259865.1 RP11-488L18.10 3.96 9.26e-05 0.0173 0.23 0.21 Alcohol dependence; chr1:247207676 chr1:247187281~247188526:- LIHC cis rs3738443 1 rs75028588 ENSG00000259865.1 RP11-488L18.10 3.96 9.26e-05 0.0173 0.23 0.21 Alcohol dependence; chr1:247208350 chr1:247187281~247188526:- LIHC cis rs17197037 0.545 rs3748357 ENSG00000240954.1 RPL4P1 3.96 9.26e-05 0.0173 0.2 0.21 Bipolar disorder; chr14:21317631 chr14:21750269~21751546:+ LIHC cis rs11977715 0.538 rs3801916 ENSG00000233942.1 AC004012.1 3.96 9.26e-05 0.0173 0.3 0.21 Middle childhood and early adolescence aggressive behavior; chr7:95491707 chr7:95471835~95473998:+ LIHC cis rs9595908 0.709 rs9596222 ENSG00000212293.1 SNORA16 3.96 9.26e-05 0.0173 0.24 0.21 Body mass index; chr13:32767679 chr13:32420390~32420516:- LIHC cis rs801193 0.66 rs1016265 ENSG00000232559.3 GS1-124K5.12 3.96 9.27e-05 0.0173 0.16 0.21 Aortic root size; chr7:66749580 chr7:66554588~66576923:- LIHC cis rs597539 0.58 rs7935851 ENSG00000250508.1 RP11-757G1.6 -3.96 9.27e-05 0.0174 -0.34 -0.21 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68963653 chr11:68870664~68874542:+ LIHC cis rs2253762 0.54 rs10887036 ENSG00000226864.1 ATE1-AS1 3.96 9.27e-05 0.0174 0.35 0.21 Breast cancer; chr10:121997570 chr10:121928312~121951965:+ LIHC cis rs2243480 1 rs4149468 ENSG00000232546.1 RP11-458F8.1 -3.96 9.27e-05 0.0174 -0.23 -0.21 Diabetic kidney disease; chr7:66360703 chr7:66848496~66858136:+ LIHC cis rs2581828 0.58 rs6799837 ENSG00000242142.1 SERBP1P3 -3.96 9.27e-05 0.0174 -0.28 -0.21 Crohn's disease; chr3:53133838 chr3:53064283~53065091:- LIHC cis rs2581828 0.58 rs57514626 ENSG00000242142.1 SERBP1P3 -3.96 9.27e-05 0.0174 -0.28 -0.21 Crohn's disease; chr3:53135286 chr3:53064283~53065091:- LIHC cis rs2581828 0.58 rs61296683 ENSG00000242142.1 SERBP1P3 -3.96 9.27e-05 0.0174 -0.28 -0.21 Crohn's disease; chr3:53135307 chr3:53064283~53065091:- LIHC cis rs2581828 0.58 rs9867590 ENSG00000242142.1 SERBP1P3 -3.96 9.27e-05 0.0174 -0.28 -0.21 Crohn's disease; chr3:53135635 chr3:53064283~53065091:- LIHC cis rs2581828 0.58 rs9834111 ENSG00000242142.1 SERBP1P3 -3.96 9.27e-05 0.0174 -0.28 -0.21 Crohn's disease; chr3:53136028 chr3:53064283~53065091:- LIHC cis rs2581828 0.58 rs9817467 ENSG00000242142.1 SERBP1P3 -3.96 9.27e-05 0.0174 -0.28 -0.21 Crohn's disease; chr3:53136609 chr3:53064283~53065091:- LIHC cis rs7546 0.505 rs760118 ENSG00000267077.1 RP11-127I20.5 -3.96 9.28e-05 0.0174 -0.22 -0.21 Cancer; chr16:4890993 chr16:4795265~4796532:- LIHC cis rs763121 0.886 rs1013339 ENSG00000273076.1 RP3-508I15.22 3.96 9.28e-05 0.0174 0.23 0.21 Menopause (age at onset); chr22:38578675 chr22:38743495~38743910:+ LIHC cis rs1023500 0.506 rs6002625 ENSG00000205702.9 CYP2D7 -3.96 9.28e-05 0.0174 -0.24 -0.21 Schizophrenia; chr22:42121685 chr22:42140203~42144577:- LIHC cis rs116139393 0.611 rs7792579 ENSG00000187953.9 PMS2CL -3.96 9.28e-05 0.0174 -0.22 -0.21 Alzheimer's disease (APOE e4 interaction); chr7:6725962 chr7:6710128~6753862:+ LIHC cis rs848490 0.674 rs6971555 ENSG00000214293.7 APTR 3.96 9.29e-05 0.0174 0.25 0.21 Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine); chr7:77777422 chr7:77657660~77696265:- LIHC cis rs2070488 1 rs34258593 ENSG00000229589.1 ACVR2B-AS1 3.96 9.29e-05 0.0174 0.24 0.21 Electrocardiographic conduction measures; chr3:38423074 chr3:38451027~38454820:- LIHC cis rs1577917 0.876 rs12190735 ENSG00000234155.1 RP11-30P6.6 3.96 9.29e-05 0.0174 0.27 0.21 Response to antipsychotic treatment; chr6:85976749 chr6:85387219~85390186:- LIHC cis rs13113518 0.812 rs13116035 ENSG00000249700.7 SRD5A3-AS1 3.96 9.29e-05 0.0174 0.24 0.21 Height; chr4:55561218 chr4:55363971~55395847:- LIHC cis rs2665103 0.632 rs3902959 ENSG00000259429.4 UBE2Q2P2 -3.96 9.29e-05 0.0174 -0.22 -0.21 Intelligence (multi-trait analysis); chr15:82252586 chr15:82355142~82420075:+ LIHC cis rs11096990 0.855 rs2711990 ENSG00000249685.1 RP11-360F5.3 -3.96 9.29e-05 0.0174 -0.28 -0.21 Cognitive function; chr4:39150116 chr4:39133913~39135608:+ LIHC cis rs16902947 0.592 rs61537490 ENSG00000245711.2 NADK2-AS1 3.96 9.29e-05 0.0174 0.18 0.21 Serum tamsulosin hydrochloride concentration; chr5:36347225 chr5:36221055~36221902:+ LIHC cis rs2599510 0.84 rs466146 ENSG00000276334.1 AL133243.1 3.96 9.29e-05 0.0174 0.23 0.21 Interleukin-18 levels; chr2:32314167 chr2:32521927~32523547:+ LIHC cis rs3204270 0.639 rs62077183 ENSG00000281517.1 Metazoa_SRP -3.96 9.29e-05 0.0174 -0.39 -0.21 Dental caries; chr17:81691910 chr17:81718849~81719095:- LIHC cis rs9595908 0.709 rs7318563 ENSG00000212293.1 SNORA16 3.96 9.29e-05 0.0174 0.24 0.21 Body mass index; chr13:32749348 chr13:32420390~32420516:- LIHC cis rs2032447 0.831 rs9467664 ENSG00000242387.1 HIST1H2APS2 3.96 9.29e-05 0.0174 0.27 0.21 Intelligence (multi-trait analysis); chr6:26021585 chr6:25882026~25882395:- LIHC cis rs7119038 0.818 rs10892279 ENSG00000255422.1 AP002954.4 3.96 9.3e-05 0.0174 0.26 0.21 Sjögren's syndrome; chr11:118741072 chr11:118704607~118750263:+ LIHC cis rs7726839 0.574 rs72707007 ENSG00000271781.1 CTD-2589H19.6 -3.96 9.3e-05 0.0174 -0.32 -0.21 Obesity-related traits; chr5:661741 chr5:675826~676616:+ LIHC cis rs12468226 1 rs7565875 ENSG00000272966.1 RP11-686O6.1 3.96 9.3e-05 0.0174 0.34 0.21 Urate levels; chr2:202516412 chr2:202336739~202337200:+ LIHC cis rs2581828 0.618 rs9828221 ENSG00000242142.1 SERBP1P3 -3.96 9.3e-05 0.0174 -0.28 -0.21 Crohn's disease; chr3:53132643 chr3:53064283~53065091:- LIHC cis rs17772222 0.917 rs61986664 ENSG00000258789.1 RP11-507K2.3 -3.96 9.3e-05 0.0174 -0.25 -0.21 Coronary artery calcification; chr14:88711251 chr14:88551597~88552493:+ LIHC cis rs17772222 0.876 rs61986665 ENSG00000258789.1 RP11-507K2.3 -3.96 9.3e-05 0.0174 -0.25 -0.21 Coronary artery calcification; chr14:88711354 chr14:88551597~88552493:+ LIHC cis rs17772222 0.917 rs8018755 ENSG00000258789.1 RP11-507K2.3 -3.96 9.3e-05 0.0174 -0.25 -0.21 Coronary artery calcification; chr14:88714249 chr14:88551597~88552493:+ LIHC cis rs17772222 0.917 rs8018630 ENSG00000258789.1 RP11-507K2.3 -3.96 9.3e-05 0.0174 -0.25 -0.21 Coronary artery calcification; chr14:88714250 chr14:88551597~88552493:+ LIHC cis rs17772222 0.917 rs8020072 ENSG00000258789.1 RP11-507K2.3 -3.96 9.3e-05 0.0174 -0.25 -0.21 Coronary artery calcification; chr14:88714332 chr14:88551597~88552493:+ LIHC cis rs17772222 0.917 rs17260408 ENSG00000258789.1 RP11-507K2.3 -3.96 9.3e-05 0.0174 -0.25 -0.21 Coronary artery calcification; chr14:88715464 chr14:88551597~88552493:+ LIHC cis rs17772222 0.917 rs12589982 ENSG00000258789.1 RP11-507K2.3 -3.96 9.3e-05 0.0174 -0.25 -0.21 Coronary artery calcification; chr14:88716861 chr14:88551597~88552493:+ LIHC cis rs17772222 0.917 rs8021690 ENSG00000258789.1 RP11-507K2.3 -3.96 9.3e-05 0.0174 -0.25 -0.21 Coronary artery calcification; chr14:88717806 chr14:88551597~88552493:+ LIHC cis rs13113518 0.783 rs11943206 ENSG00000249700.7 SRD5A3-AS1 3.96 9.3e-05 0.0174 0.24 0.21 Height; chr4:55570843 chr4:55363971~55395847:- LIHC cis rs6496044 0.507 rs1471455 ENSG00000259630.2 CTD-2262B20.1 3.96 9.31e-05 0.0174 0.22 0.21 Interstitial lung disease; chr15:85611496 chr15:85415228~85415633:+ LIHC cis rs2439831 0.681 rs825739 ENSG00000205771.5 CATSPER2P1 -3.95 9.31e-05 0.0174 -0.28 -0.21 Lung cancer in ever smokers; chr15:43300230 chr15:43726918~43747094:- LIHC cis rs10895987 0.83 rs12292693 ENSG00000254614.2 AP003068.23 -3.95 9.31e-05 0.0174 -0.37 -0.21 Blood protein levels; chr11:65169248 chr11:65177606~65181834:- LIHC cis rs7893279 0.505 rs12780652 ENSG00000225527.1 RP11-383B4.4 3.95 9.31e-05 0.0174 0.3 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18652685 chr10:18531849~18533336:- LIHC cis rs801193 0.839 rs12534943 ENSG00000273024.4 INTS4P2 3.95 9.31e-05 0.0174 0.23 0.21 Aortic root size; chr7:66605533 chr7:65647864~65715661:+ LIHC cis rs71520386 0.583 rs28799344 ENSG00000228649.7 AC005682.5 -3.95 9.31e-05 0.0174 -0.26 -0.21 Fibrinogen levels; chr7:22805647 chr7:22854178~22861579:+ LIHC cis rs2348418 0.864 rs7312339 ENSG00000247934.4 RP11-967K21.1 3.95 9.31e-05 0.0174 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28558751 chr12:28163298~28190738:- LIHC cis rs17711722 0.583 rs10085415 ENSG00000237310.1 GS1-124K5.4 -3.95 9.31e-05 0.0174 -0.21 -0.21 Calcium levels; chr7:65628655 chr7:66493706~66495474:+ LIHC cis rs7989332 0.698 rs9315620 ENSG00000275964.1 RP11-61K9.3 3.95 9.32e-05 0.0174 0.26 0.21 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20486906 chr13:19863858~19865048:+ LIHC cis rs7989332 0.698 rs9315621 ENSG00000275964.1 RP11-61K9.3 3.95 9.32e-05 0.0174 0.26 0.21 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20486914 chr13:19863858~19865048:+ LIHC cis rs11148252 0.846 rs13431 ENSG00000278238.1 RP11-245D16.4 -3.95 9.32e-05 0.0174 -0.2 -0.21 Lewy body disease; chr13:52413342 chr13:52454775~52455331:- LIHC cis rs1023500 0.552 rs5758566 ENSG00000205702.9 CYP2D7 3.95 9.32e-05 0.0174 0.24 0.21 Schizophrenia; chr22:42058350 chr22:42140203~42144577:- LIHC cis rs950169 0.58 rs11635597 ENSG00000259728.4 LINC00933 3.95 9.32e-05 0.0174 0.3 0.21 Schizophrenia; chr15:84622468 chr15:84570649~84580175:+ LIHC cis rs11676348 0.772 rs12471105 ENSG00000261338.2 RP11-378A13.1 -3.95 9.32e-05 0.0174 -0.22 -0.21 Ulcerative colitis; chr2:218085486 chr2:218255319~218257366:+ LIHC cis rs875971 0.965 rs9969301 ENSG00000237310.1 GS1-124K5.4 -3.95 9.32e-05 0.0174 -0.19 -0.21 Aortic root size; chr7:66316668 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs6460292 ENSG00000237310.1 GS1-124K5.4 -3.95 9.32e-05 0.0174 -0.19 -0.21 Aortic root size; chr7:66345088 chr7:66493706~66495474:+ LIHC cis rs12586317 0.62 rs2295104 ENSG00000257307.1 RP11-317N8.4 3.95 9.32e-05 0.0174 0.25 0.21 Psoriasis; chr14:35110721 chr14:35881001~35881709:+ LIHC cis rs7989332 0.925 rs7324189 ENSG00000275964.1 RP11-61K9.3 -3.95 9.32e-05 0.0174 -0.24 -0.21 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20476037 chr13:19863858~19865048:+ LIHC cis rs2115630 0.967 rs10438428 ENSG00000259295.5 CSPG4P12 -3.95 9.32e-05 0.0174 -0.24 -0.21 P wave terminal force; chr15:84787514 chr15:85191438~85213905:+ LIHC cis rs244293 0.73 rs9303362 ENSG00000275710.1 RP11-257O5.4 3.95 9.33e-05 0.0174 0.23 0.21 Menarche (age at onset); chr17:54985192 chr17:54964474~54964679:+ LIHC cis rs4578769 0.722 rs5013130 ENSG00000266850.1 RP11-370A5.1 -3.95 9.33e-05 0.0174 -0.25 -0.21 Eosinophil percentage of white cells; chr18:22945388 chr18:22723491~22907721:- LIHC cis rs1115240 0.785 rs17111369 ENSG00000257842.4 NOVA1-AS1 3.95 9.33e-05 0.0174 0.19 0.21 Educational attainment (years of education); chr14:26552441 chr14:26598412~26806467:+ LIHC cis rs2253762 0.507 rs10159582 ENSG00000226864.1 ATE1-AS1 3.95 9.34e-05 0.0174 0.35 0.21 Breast cancer; chr10:121993110 chr10:121928312~121951965:+ LIHC cis rs2253762 0.507 rs10159583 ENSG00000226864.1 ATE1-AS1 3.95 9.34e-05 0.0174 0.35 0.21 Breast cancer; chr10:121993154 chr10:121928312~121951965:+ LIHC cis rs2253762 0.507 rs75383663 ENSG00000226864.1 ATE1-AS1 3.95 9.34e-05 0.0174 0.35 0.21 Breast cancer; chr10:121993340 chr10:121928312~121951965:+ LIHC cis rs733175 0.855 rs9291640 ENSG00000250413.1 RP11-448G15.1 -3.95 9.34e-05 0.0175 -0.3 -0.21 Psychosis and Alzheimer's disease; chr4:10005462 chr4:10006482~10009725:+ LIHC cis rs1494950 1 rs10013449 ENSG00000214846.4 RP11-115L11.1 -3.95 9.34e-05 0.0175 -0.44 -0.21 Political ideology; chr4:15067965 chr4:15730962~15731627:- LIHC cis rs1494950 1 rs7661362 ENSG00000214846.4 RP11-115L11.1 -3.95 9.34e-05 0.0175 -0.44 -0.21 Political ideology; chr4:15076118 chr4:15730962~15731627:- LIHC cis rs1494950 0.661 rs72491263 ENSG00000214846.4 RP11-115L11.1 -3.95 9.34e-05 0.0175 -0.44 -0.21 Political ideology; chr4:15078976 chr4:15730962~15731627:- LIHC cis rs11647589 0.735 rs2221448 ENSG00000262995.1 CTD-2194A8.2 -3.95 9.34e-05 0.0175 -0.19 -0.21 Blood metabolite levels; chr16:20473548 chr16:20440266~20447000:- LIHC cis rs193541 0.53 rs1466371 ENSG00000263432.2 RN7SL689P 3.95 9.34e-05 0.0175 0.32 0.21 Glucose homeostasis traits; chr5:122748093 chr5:123022487~123022783:- LIHC cis rs2599510 0.811 rs176410 ENSG00000276334.1 AL133243.1 -3.95 9.34e-05 0.0175 -0.23 -0.21 Interleukin-18 levels; chr2:32418369 chr2:32521927~32523547:+ LIHC cis rs2839186 0.708 rs6518285 ENSG00000215447.6 BX322557.10 -3.95 9.34e-05 0.0175 -0.18 -0.21 Testicular germ cell tumor; chr21:46224753 chr21:45288052~45291738:+ LIHC cis rs1075265 0.584 rs10164409 ENSG00000233266.1 HMGB1P31 3.95 9.34e-05 0.0175 0.26 0.21 Chronotype;Morning vs. evening chronotype; chr2:53940867 chr2:54051334~54051760:+ LIHC cis rs7702057 0.53 rs17138834 ENSG00000272265.1 CTD-2287O16.4 -3.95 9.34e-05 0.0175 -0.33 -0.21 Amyotrophic lateral sclerosis; chr5:116076625 chr5:116078110~116078570:- LIHC cis rs6048205 1 rs1203876 ENSG00000259974.2 LINC00261 -3.95 9.34e-05 0.0175 -0.29 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22560277 chr20:22547671~22578642:- LIHC cis rs6048205 1 rs1203884 ENSG00000259974.2 LINC00261 -3.95 9.34e-05 0.0175 -0.29 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22563062 chr20:22547671~22578642:- LIHC cis rs6048205 1 rs1203886 ENSG00000259974.2 LINC00261 -3.95 9.34e-05 0.0175 -0.29 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22563877 chr20:22547671~22578642:- LIHC cis rs6048205 1 rs2471 ENSG00000259974.2 LINC00261 -3.95 9.34e-05 0.0175 -0.29 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22564111 chr20:22547671~22578642:- LIHC cis rs8060598 0.966 rs2066851 ENSG00000275155.1 CTD-2595P9.4 -3.95 9.34e-05 0.0175 -0.24 -0.21 Leprosy; chr16:50765018 chr16:49847018~49847632:- LIHC cis rs2070488 0.965 rs7433277 ENSG00000229589.1 ACVR2B-AS1 3.95 9.35e-05 0.0175 0.24 0.21 Electrocardiographic conduction measures; chr3:38488327 chr3:38451027~38454820:- LIHC cis rs1075265 0.692 rs805361 ENSG00000233266.1 HMGB1P31 3.95 9.35e-05 0.0175 0.26 0.21 Chronotype;Morning vs. evening chronotype; chr2:53938709 chr2:54051334~54051760:+ LIHC cis rs2243480 1 rs2420171 ENSG00000232546.1 RP11-458F8.1 3.95 9.36e-05 0.0175 0.23 0.21 Diabetic kidney disease; chr7:66172773 chr7:66848496~66858136:+ LIHC cis rs6452524 1 rs2126988 ENSG00000271862.1 RP11-343L5.2 3.95 9.36e-05 0.0175 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83146496 chr5:83049376~83050964:- LIHC cis rs12468226 0.873 rs2350358 ENSG00000226261.1 AC064836.3 -3.95 9.36e-05 0.0175 -0.33 -0.21 Urate levels; chr2:202199771 chr2:202336024~202336727:- LIHC cis rs3091242 0.904 rs6661533 ENSG00000261349.1 RP3-465N24.5 -3.95 9.36e-05 0.0175 -0.2 -0.21 Erythrocyte sedimentation rate; chr1:25445224 chr1:25266102~25267136:- LIHC cis rs55794721 0.509 rs6699113 ENSG00000261349.1 RP3-465N24.5 -3.95 9.36e-05 0.0175 -0.2 -0.21 Mean corpuscular volume;Plateletcrit; chr1:25451252 chr1:25266102~25267136:- LIHC cis rs858239 0.896 rs1637193 ENSG00000226816.2 AC005082.12 3.95 9.36e-05 0.0175 0.27 0.21 Cerebrospinal fluid biomarker levels; chr7:23220632 chr7:23206013~23208045:+ LIHC cis rs4453827 1 rs35377175 ENSG00000271916.1 RP11-884K10.6 3.95 9.36e-05 0.0175 0.41 0.21 Blood protein levels; chr3:53713590 chr3:53797764~53798019:- LIHC cis rs4453827 1 rs13092344 ENSG00000271916.1 RP11-884K10.6 3.95 9.36e-05 0.0175 0.41 0.21 Blood protein levels; chr3:53713889 chr3:53797764~53798019:- LIHC cis rs9487094 0.644 rs13201430 ENSG00000260273.1 RP11-425D10.10 3.95 9.36e-05 0.0175 0.24 0.21 Height; chr6:109634847 chr6:109382795~109383666:+ LIHC cis rs3015497 0.934 rs2934691 ENSG00000269906.1 RP11-248J18.2 3.95 9.37e-05 0.0175 0.26 0.21 Mean platelet volume; chr14:50654615 chr14:50662511~50663178:- LIHC cis rs4218 0.597 rs12442301 ENSG00000277144.1 RP11-59H7.4 -3.95 9.37e-05 0.0175 -0.23 -0.21 Social communication problems; chr15:59065968 chr15:59115547~59116089:- LIHC cis rs7665090 1 rs735404 ENSG00000230069.3 LRRC37A15P -3.95 9.37e-05 0.0175 -0.2 -0.21 Primary biliary cholangitis; chr4:102632508 chr4:102727274~102730721:- LIHC cis rs1499614 1 rs1267817 ENSG00000228409.4 CCT6P1 3.95 9.38e-05 0.0175 0.23 0.21 Gout; chr7:66645053 chr7:65751142~65763354:+ LIHC cis rs2299116 0.785 rs4719950 ENSG00000225264.3 ZNRF2P2 -3.95 9.38e-05 0.0175 -0.24 -0.21 Serum thyroid-stimulating hormone levels; chr7:28753349 chr7:29598795~29685255:- LIHC cis rs11096990 0.855 rs2711990 ENSG00000249207.1 RP11-360F5.1 3.95 9.38e-05 0.0175 0.24 0.21 Cognitive function; chr4:39150116 chr4:39112677~39126818:- LIHC cis rs6951245 0.554 rs2070118 ENSG00000229043.2 AC091729.9 -3.95 9.38e-05 0.0175 -0.4 -0.21 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1092869 chr7:1160374~1165267:+ LIHC cis rs1799949 1 rs11649954 ENSG00000267681.1 CTD-3199J23.6 -3.95 9.39e-05 0.0175 -0.2 -0.21 Menopause (age at onset); chr17:43342667 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs1824889 ENSG00000267681.1 CTD-3199J23.6 -3.95 9.39e-05 0.0175 -0.2 -0.21 Menopause (age at onset); chr17:43344508 chr17:43144956~43145255:+ LIHC cis rs10761256 0.806 rs6479501 ENSG00000227603.1 RP11-165J3.6 3.95 9.39e-05 0.0175 0.24 0.21 Itch intensity from mosquito bite adjusted by bite size; chr9:93646621 chr9:93435332~93437121:- LIHC cis rs11009175 0.799 rs2457703 ENSG00000273038.2 RP11-479G22.8 -3.95 9.39e-05 0.0175 -0.24 -0.21 Depression (quantitative trait); chr10:33050611 chr10:32887255~32889311:- LIHC cis rs11009175 0.746 rs2756023 ENSG00000273038.2 RP11-479G22.8 -3.95 9.39e-05 0.0175 -0.24 -0.21 Depression (quantitative trait); chr10:33050726 chr10:32887255~32889311:- LIHC cis rs11009175 0.799 rs2756022 ENSG00000273038.2 RP11-479G22.8 -3.95 9.39e-05 0.0175 -0.24 -0.21 Depression (quantitative trait); chr10:33051028 chr10:32887255~32889311:- LIHC cis rs2976388 0.59 rs13254346 ENSG00000253196.1 RP11-706C16.7 -3.95 9.39e-05 0.0175 -0.22 -0.21 Urinary tract infection frequency; chr8:142742445 chr8:142763116~142766427:+ LIHC cis rs2976388 0.59 rs3758082 ENSG00000253196.1 RP11-706C16.7 -3.95 9.39e-05 0.0175 -0.22 -0.21 Urinary tract infection frequency; chr8:142743065 chr8:142763116~142766427:+ LIHC cis rs1635 0.826 rs1233710 ENSG00000216901.1 AL022393.7 3.95 9.39e-05 0.0175 0.32 0.21 Schizophrenia; chr6:28247668 chr6:28176188~28176674:+ LIHC cis rs4650994 1 rs4650995 ENSG00000273384.1 RP5-1098D14.1 3.95 9.39e-05 0.0175 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178548181 chr1:178651706~178652282:+ LIHC cis rs780096 0.565 rs13022659 ENSG00000234072.1 AC074117.10 -3.95 9.39e-05 0.0175 -0.2 -0.21 Total body bone mineral density; chr2:27520763 chr2:27356246~27367622:+ LIHC cis rs858239 0.863 rs274054 ENSG00000226816.2 AC005082.12 3.95 9.4e-05 0.0175 0.26 0.21 Cerebrospinal fluid biomarker levels; chr7:23350848 chr7:23206013~23208045:+ LIHC cis rs801193 0.591 rs9986881 ENSG00000228409.4 CCT6P1 -3.95 9.4e-05 0.0175 -0.16 -0.21 Aortic root size; chr7:66708053 chr7:65751142~65763354:+ LIHC cis rs244293 0.931 rs244351 ENSG00000275710.1 RP11-257O5.4 3.95 9.41e-05 0.0176 0.23 0.21 Menarche (age at onset); chr17:55118205 chr17:54964474~54964679:+ LIHC cis rs9929218 0.581 rs7203337 ENSG00000260459.2 FTLP14 3.95 9.41e-05 0.0176 0.23 0.21 Colorectal cancer; chr16:68740897 chr16:68822587~68823070:+ LIHC cis rs9487094 1 rs12197114 ENSG00000260273.1 RP11-425D10.10 3.95 9.41e-05 0.0176 0.25 0.21 Height; chr6:109414295 chr6:109382795~109383666:+ LIHC cis rs6545883 0.929 rs3821222 ENSG00000271889.1 RP11-493E12.1 3.95 9.41e-05 0.0176 0.25 0.21 Tuberculosis; chr2:61486391 chr2:61151433~61162105:- LIHC cis rs6558530 0.836 rs7461159 ENSG00000253982.1 CTD-2336O2.1 3.95 9.42e-05 0.0176 0.27 0.21 Systolic blood pressure; chr8:1768450 chr8:1761990~1764502:- LIHC cis rs7015630 0.738 rs11785163 ENSG00000251136.7 RP11-37B2.1 -3.95 9.42e-05 0.0176 -0.22 -0.21 Inflammatory bowel disease;Crohn's disease; chr8:89857181 chr8:89609409~89757727:- LIHC cis rs801193 0.66 rs974239 ENSG00000237310.1 GS1-124K5.4 3.95 9.42e-05 0.0176 0.18 0.21 Aortic root size; chr7:66748504 chr7:66493706~66495474:+ LIHC cis rs7809950 0.773 rs9791733 ENSG00000238832.1 snoU109 -3.95 9.42e-05 0.0176 -0.27 -0.21 Coronary artery disease; chr7:107401285 chr7:107603363~107603507:+ LIHC cis rs2598107 0.542 rs6965395 ENSG00000211698.2 TRGV4 -3.95 9.42e-05 0.0176 -0.25 -0.21 Dupuytren's disease; chr7:37910513 chr7:38353715~38354517:- LIHC cis rs2243480 1 rs313803 ENSG00000228409.4 CCT6P1 3.95 9.42e-05 0.0176 0.22 0.21 Diabetic kidney disease; chr7:66049744 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs313802 ENSG00000228409.4 CCT6P1 3.95 9.42e-05 0.0176 0.22 0.21 Diabetic kidney disease; chr7:66051386 chr7:65751142~65763354:+ LIHC cis rs2243480 0.803 rs403089 ENSG00000228409.4 CCT6P1 3.95 9.42e-05 0.0176 0.22 0.21 Diabetic kidney disease; chr7:66052736 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs458291 ENSG00000228409.4 CCT6P1 3.95 9.42e-05 0.0176 0.22 0.21 Diabetic kidney disease; chr7:66055492 chr7:65751142~65763354:+ LIHC cis rs950169 1 rs12916348 ENSG00000225151.9 GOLGA2P7 -3.95 9.42e-05 0.0176 -0.29 -0.21 Schizophrenia; chr15:84096775 chr15:84199311~84230136:- LIHC cis rs6723226 0.521 rs1991626 ENSG00000276334.1 AL133243.1 -3.95 9.43e-05 0.0176 -0.24 -0.21 Intelligence (multi-trait analysis); chr2:32377382 chr2:32521927~32523547:+ LIHC cis rs7412746 0.611 rs4509581 ENSG00000231073.1 RP11-316M1.3 3.95 9.43e-05 0.0176 0.21 0.21 Melanoma; chr1:150801989 chr1:150973123~150975534:+ LIHC cis rs673078 0.66 rs11068910 ENSG00000275759.1 RP11-131L12.3 -3.95 9.43e-05 0.0176 -0.25 -0.21 Glucose homeostasis traits; chr12:118336076 chr12:118428281~118428870:+ LIHC cis rs234043 1 rs234043 ENSG00000223387.5 RP11-408H1.3 3.95 9.44e-05 0.0176 0.23 0.21 Renal cell carcinoma; chr3:172595577 chr3:172560888~172595607:- LIHC cis rs12817211 0.549 rs7398567 ENSG00000272368.2 RP4-605O3.4 3.95 9.44e-05 0.0176 0.23 0.21 Colorectal or endometrial cancer; chr12:50157375 chr12:50112197~50165618:+ LIHC cis rs12817211 0.549 rs10783338 ENSG00000272368.2 RP4-605O3.4 3.95 9.44e-05 0.0176 0.23 0.21 Colorectal or endometrial cancer; chr12:50158746 chr12:50112197~50165618:+ LIHC cis rs1005277 0.522 rs289648 ENSG00000275858.1 RP11-291L22.8 3.95 9.44e-05 0.0176 0.23 0.21 Extrinsic epigenetic age acceleration; chr10:37682909 chr10:38450738~38451069:- LIHC cis rs57502260 0.704 rs12286536 ENSG00000212093.1 AP000807.1 3.95 9.44e-05 0.0176 0.28 0.21 Total body bone mineral density (age 45-60); chr11:68522766 chr11:68506083~68506166:- LIHC cis rs867371 0.502 rs2047679 ENSG00000259429.4 UBE2Q2P2 -3.95 9.44e-05 0.0176 -0.22 -0.21 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82239540 chr15:82355142~82420075:+ LIHC cis rs867371 0.502 rs7176926 ENSG00000259429.4 UBE2Q2P2 -3.95 9.44e-05 0.0176 -0.22 -0.21 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82245753 chr15:82355142~82420075:+ LIHC cis rs4650994 1 rs10798617 ENSG00000273384.1 RP5-1098D14.1 3.95 9.45e-05 0.0176 0.26 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178546671 chr1:178651706~178652282:+ LIHC cis rs3096299 0.606 rs4785573 ENSG00000274627.1 RP11-104N10.2 3.95 9.46e-05 0.0176 0.23 0.21 Multiple myeloma (IgH translocation); chr16:89498995 chr16:89516797~89522217:+ LIHC cis rs4237845 0.537 rs1599931 ENSG00000270039.1 RP11-571M6.17 -3.95 9.46e-05 0.0176 -0.3 -0.21 Intelligence (multi-trait analysis); chr12:57865067 chr12:57803838~57804415:+ LIHC cis rs8087799 0.894 rs12967225 ENSG00000273232.1 RP11-370A5.2 3.95 9.47e-05 0.0177 0.24 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22682331 chr18:22882825~22883357:- LIHC cis rs12157904 1 rs12158020 ENSG00000233360.4 Z83844.1 3.95 9.47e-05 0.0177 0.4 0.21 Response to anti-depressant treatment in major depressive disorder; chr22:37586050 chr22:37641832~37658377:- LIHC cis rs13287066 0.74 rs10761223 ENSG00000227603.1 RP11-165J3.6 3.95 9.47e-05 0.0177 0.23 0.21 Intelligence (multi-trait analysis); chr9:93404028 chr9:93435332~93437121:- LIHC cis rs11098499 0.691 rs10010355 ENSG00000260091.1 RP11-33B1.4 -3.95 9.47e-05 0.0177 -0.14 -0.21 Corneal astigmatism; chr4:119339888 chr4:119409333~119410233:+ LIHC cis rs11098499 0.691 rs9307471 ENSG00000260091.1 RP11-33B1.4 -3.95 9.47e-05 0.0177 -0.14 -0.21 Corneal astigmatism; chr4:119340107 chr4:119409333~119410233:+ LIHC cis rs2834655 0.773 rs35068491 ENSG00000237945.6 LINC00649 -3.95 9.47e-05 0.0177 -0.42 -0.21 Immune response to smallpox vaccine (IL-6); chr21:34866010 chr21:33915534~33977691:+ LIHC cis rs6445975 0.617 rs9859048 ENSG00000272360.1 RP11-359I18.5 3.95 9.47e-05 0.0177 0.28 0.21 Systemic lupus erythematosus; chr3:58434691 chr3:58490830~58491291:- LIHC cis rs11098499 0.604 rs2389886 ENSG00000260091.1 RP11-33B1.4 -3.95 9.48e-05 0.0177 -0.15 -0.21 Corneal astigmatism; chr4:119649267 chr4:119409333~119410233:+ LIHC cis rs1494950 0.661 rs1908446 ENSG00000214846.4 RP11-115L11.1 -3.95 9.48e-05 0.0177 -0.42 -0.21 Political ideology; chr4:15001160 chr4:15730962~15731627:- LIHC cis rs757081 0.669 rs542274 ENSG00000272034.1 SNORD14A -3.95 9.48e-05 0.0177 -0.22 -0.21 Systolic blood pressure; chr11:17185886 chr11:17074654~17074744:- LIHC cis rs7176527 1 rs3762169 ENSG00000189136.7 UBE2Q2P1 -3.95 9.48e-05 0.0177 -0.17 -0.21 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84598728 chr15:84526781~84571216:- LIHC cis rs6430585 0.528 rs309152 ENSG00000231890.6 DARS-AS1 3.95 9.48e-05 0.0177 0.29 0.21 Corneal structure; chr2:135899682 chr2:135985176~136022593:+ LIHC cis rs4845875 0.514 rs198393 ENSG00000242349.4 NPPA-AS1 -3.95 9.48e-05 0.0177 -0.22 -0.21 Midregional pro atrial natriuretic peptide levels; chr1:11819628 chr1:11841017~11848079:+ LIHC cis rs67311347 1 rs9332450 ENSG00000223797.4 ENTPD3-AS1 -3.95 9.48e-05 0.0177 -0.17 -0.21 Renal cell carcinoma; chr3:40416550 chr3:40313802~40453329:- LIHC cis rs1023500 0.573 rs133381 ENSG00000205702.9 CYP2D7 3.95 9.48e-05 0.0177 0.24 0.21 Schizophrenia; chr22:42074604 chr22:42140203~42144577:- LIHC cis rs1062177 0.901 rs1549622 ENSG00000253921.1 CTB-113P19.3 -3.95 9.48e-05 0.0177 -0.24 -0.21 Preschool internalizing problems; chr5:151886488 chr5:151753992~151767247:+ LIHC cis rs11096990 0.656 rs4580661 ENSG00000249207.1 RP11-360F5.1 3.95 9.49e-05 0.0177 0.21 0.21 Cognitive function; chr4:39294730 chr4:39112677~39126818:- LIHC cis rs2880765 0.525 rs35899940 ENSG00000259295.5 CSPG4P12 3.95 9.49e-05 0.0177 0.29 0.21 Coronary artery disease; chr15:85510466 chr15:85191438~85213905:+ LIHC cis rs71007656 1 rs71007656 ENSG00000275858.1 RP11-291L22.8 3.95 9.49e-05 0.0177 0.23 0.21 Extrinsic epigenetic age acceleration; chr10:37681922 chr10:38450738~38451069:- LIHC cis rs524281 0.731 rs6591201 ENSG00000255320.1 RP11-755F10.1 -3.95 9.49e-05 0.0177 -0.3 -0.21 Electroencephalogram traits; chr11:66038499 chr11:66244840~66246239:- LIHC cis rs337161 0.719 rs10863562 ENSG00000272823.1 RP11-295M18.6 3.95 9.5e-05 0.0177 0.25 0.21 Response to antipsychotic therapy (extrapyramidal side effects); chr1:220755813 chr1:220828676~220829211:- LIHC cis rs950776 0.745 rs36045869 ENSG00000261762.1 RP11-650L12.2 3.95 9.5e-05 0.0177 0.3 0.21 Sudden cardiac arrest; chr15:78637156 chr15:78589123~78591276:- LIHC cis rs7945705 0.791 rs6484484 ENSG00000254860.4 TMEM9B-AS1 -3.95 9.5e-05 0.0177 -0.21 -0.21 Hemoglobin concentration; chr11:8795659 chr11:8964675~8977527:+ LIHC cis rs11098499 0.865 rs11722183 ENSG00000260091.1 RP11-33B1.4 -3.95 9.5e-05 0.0177 -0.15 -0.21 Corneal astigmatism; chr4:119359442 chr4:119409333~119410233:+ LIHC cis rs709400 0.827 rs2274269 ENSG00000269958.1 RP11-73M18.8 3.95 9.5e-05 0.0177 0.28 0.21 Body mass index; chr14:103562909 chr14:103696353~103697163:+ LIHC cis rs10829156 0.732 rs7100884 ENSG00000240291.1 RP11-499P20.2 3.95 9.5e-05 0.0177 0.34 0.21 Sudden cardiac arrest; chr10:18523768 chr10:18513115~18545651:- LIHC cis rs12468226 1 rs76284304 ENSG00000272966.1 RP11-686O6.1 3.95 9.51e-05 0.0177 0.35 0.21 Urate levels; chr2:202427116 chr2:202336739~202337200:+ LIHC cis rs71520386 0.583 rs35322907 ENSG00000228649.7 AC005682.5 -3.95 9.51e-05 0.0177 -0.26 -0.21 Fibrinogen levels; chr7:22806592 chr7:22854178~22861579:+ LIHC cis rs12908161 0.92 rs35758837 ENSG00000259728.4 LINC00933 3.95 9.51e-05 0.0177 0.3 0.21 Schizophrenia; chr15:84768151 chr15:84570649~84580175:+ LIHC cis rs1005277 0.565 rs2474565 ENSG00000099251.13 HSD17B7P2 3.95 9.51e-05 0.0177 0.24 0.21 Extrinsic epigenetic age acceleration; chr10:38091900 chr10:38356380~38378505:+ LIHC cis rs6504622 0.702 rs3851798 ENSG00000262879.4 RP11-156P1.3 3.95 9.51e-05 0.0177 0.22 0.21 Orofacial clefts; chr17:46988901 chr17:46984045~47100323:- LIHC cis rs2253762 0.507 rs4752630 ENSG00000226864.1 ATE1-AS1 3.95 9.52e-05 0.0177 0.34 0.21 Breast cancer; chr10:121991440 chr10:121928312~121951965:+ LIHC cis rs763121 0.925 rs5750654 ENSG00000273076.1 RP3-508I15.22 3.95 9.52e-05 0.0177 0.23 0.21 Menopause (age at onset); chr22:38655423 chr22:38743495~38743910:+ LIHC cis rs12817211 0.502 rs1554844 ENSG00000272368.2 RP4-605O3.4 -3.95 9.52e-05 0.0177 -0.23 -0.21 Colorectal or endometrial cancer; chr12:50120582 chr12:50112197~50165618:+ LIHC cis rs7712401 0.601 rs404442 ENSG00000263432.2 RN7SL689P -3.95 9.53e-05 0.0177 -0.31 -0.21 Mean platelet volume; chr5:123009236 chr5:123022487~123022783:- LIHC cis rs7829975 0.659 rs4382480 ENSG00000254340.1 RP11-10A14.3 3.95 9.53e-05 0.0177 0.21 0.21 Mood instability; chr8:8863963 chr8:9141424~9145435:+ LIHC cis rs4948102 0.731 rs10229446 ENSG00000226278.1 PSPHP1 3.95 9.53e-05 0.0177 0.25 0.21 Plasma homocysteine levels (post-methionine load test); chr7:55996569 chr7:55764797~55773288:+ LIHC cis rs6445975 0.666 rs2070662 ENSG00000272360.1 RP11-359I18.5 3.95 9.53e-05 0.0178 0.27 0.21 Systemic lupus erythematosus; chr3:58429863 chr3:58490830~58491291:- LIHC cis rs7587476 0.548 rs35982594 ENSG00000229267.2 AC072062.1 -3.95 9.53e-05 0.0178 -0.3 -0.21 Neuroblastoma; chr2:214841351 chr2:214810229~214963274:+ LIHC cis rs9640161 0.783 rs1132261 ENSG00000261305.1 RP4-584D14.7 3.95 9.54e-05 0.0178 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150362898 chr7:150341771~150342607:+ LIHC cis rs3772760 1 rs3772760 ENSG00000240622.1 RPL7P15 -3.95 9.54e-05 0.0178 -0.4 -0.21 Amyotrophic lateral sclerosis; chr3:124453403 chr3:124151960~124153063:- LIHC cis rs9640161 0.789 rs1464751 ENSG00000261305.1 RP4-584D14.7 3.95 9.54e-05 0.0178 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150324193 chr7:150341771~150342607:+ LIHC cis rs2932538 0.883 rs6701351 ENSG00000225075.1 RP11-426L16.3 3.95 9.54e-05 0.0178 0.26 0.21 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112596574 chr1:112693688~112696621:- LIHC cis rs748404 0.697 rs493177 ENSG00000205771.5 CATSPER2P1 -3.95 9.54e-05 0.0178 -0.25 -0.21 Lung cancer; chr15:43251060 chr15:43726918~43747094:- LIHC cis rs9527 0.615 rs10883811 ENSG00000236937.2 PTGES3P4 3.95 9.54e-05 0.0178 0.26 0.21 Arsenic metabolism; chr10:102967522 chr10:102845595~102845950:+ LIHC cis rs5770917 1 rs2269381 ENSG00000273272.1 CTA-384D8.34 3.95 9.54e-05 0.0178 0.31 0.21 Narcolepsy; chr22:50581640 chr22:50542650~50543011:+ LIHC cis rs1405130 0.869 rs11687171 ENSG00000224287.2 MSL3P1 3.95 9.55e-05 0.0178 0.25 0.21 Coronary artery disease; chr2:234657868 chr2:233865437~233868444:- LIHC cis rs794185 0.625 rs2259801 ENSG00000231249.1 ITPR1-AS1 -3.95 9.55e-05 0.0178 -0.22 -0.21 Multiple sclerosis--Brain Glutamate Levels; chr3:4471859 chr3:4490891~4493163:- LIHC cis rs875971 0.545 rs6950988 ENSG00000273024.4 INTS4P2 -3.95 9.56e-05 0.0178 -0.24 -0.21 Aortic root size; chr7:66511428 chr7:65647864~65715661:+ LIHC cis rs1922291 0.546 rs12473710 ENSG00000281162.1 LINC01127 3.95 9.56e-05 0.0178 0.22 0.21 Blood protein levels; chr2:102224519 chr2:101962056~101987167:+ LIHC cis rs1922291 0.528 rs12472862 ENSG00000281162.1 LINC01127 3.95 9.56e-05 0.0178 0.22 0.21 Blood protein levels; chr2:102224534 chr2:101962056~101987167:+ LIHC cis rs7224610 0.932 rs10852974 ENSG00000263096.1 RP11-515O17.2 3.95 9.56e-05 0.0178 0.31 0.21 Urate levels; chr17:55295205 chr17:55271504~55273653:- LIHC cis rs7044106 0.762 rs1158553 ENSG00000238181.2 AHCYP2 -3.95 9.56e-05 0.0178 -0.24 -0.21 Hip circumference adjusted for BMI; chr9:120638696 chr9:120720673~120721972:+ LIHC cis rs2739330 0.652 rs2000469 ENSG00000206090.4 AP000350.7 3.95 9.56e-05 0.0178 0.25 0.21 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23939998~23942798:+ LIHC cis rs6142102 0.961 rs4911385 ENSG00000275784.1 RP5-1125A11.6 -3.95 9.57e-05 0.0178 -0.24 -0.21 Skin pigmentation; chr20:33970787 chr20:33989480~33991818:- LIHC cis rs4650994 0.905 rs12753251 ENSG00000213057.5 C1orf220 3.95 9.57e-05 0.0178 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178560763 chr1:178542752~178548889:+ LIHC cis rs11671005 0.656 rs73066226 ENSG00000269473.1 CTD-2619J13.19 3.95 9.57e-05 0.0178 0.39 0.21 Mean platelet volume; chr19:58496846 chr19:58440448~58445849:+ LIHC cis rs2932538 0.961 rs4839257 ENSG00000225075.1 RP11-426L16.3 -3.95 9.57e-05 0.0178 -0.26 -0.21 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112676766 chr1:112693688~112696621:- LIHC cis rs875971 0.965 rs10267430 ENSG00000237310.1 GS1-124K5.4 -3.95 9.58e-05 0.0178 -0.18 -0.21 Aortic root size; chr7:66278036 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs10257427 ENSG00000237310.1 GS1-124K5.4 -3.95 9.58e-05 0.0178 -0.18 -0.21 Aortic root size; chr7:66278221 chr7:66493706~66495474:+ LIHC cis rs875971 0.964 rs55748098 ENSG00000237310.1 GS1-124K5.4 -3.95 9.58e-05 0.0178 -0.18 -0.21 Aortic root size; chr7:66298631 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs1796226 ENSG00000224316.1 RP11-479O9.2 3.95 9.58e-05 0.0178 0.2 0.21 Aortic root size; chr7:66622723 chr7:65773620~65802067:+ LIHC cis rs10991814 0.623 rs74660460 ENSG00000273381.1 RP11-305L7.7 3.95 9.58e-05 0.0178 0.25 0.21 Neutrophil percentage of granulocytes; chr9:91192530 chr9:91206175~91210299:- LIHC cis rs7829975 0.56 rs17154599 ENSG00000233609.3 RP11-62H7.2 -3.95 9.58e-05 0.0178 -0.25 -0.21 Mood instability; chr8:8693908 chr8:8961200~8979025:+ LIHC cis rs1115240 0.678 rs1951074 ENSG00000257842.4 NOVA1-AS1 3.95 9.58e-05 0.0178 0.19 0.21 Educational attainment (years of education); chr14:26561001 chr14:26598412~26806467:+ LIHC cis rs9906944 0.545 rs2088140 ENSG00000251461.3 RP11-501C14.6 3.95 9.58e-05 0.0178 0.25 0.21 Intelligence (multi-trait analysis);Body fat percentage; chr17:49017237 chr17:49004731~49013725:- LIHC cis rs7688540 0.771 rs77078697 ENSG00000275426.1 CH17-262A2.1 3.95 9.59e-05 0.0178 0.26 0.21 Facial morphology (factor 6, height of vermillion lower lip); chr4:258259 chr4:149738~150317:+ LIHC cis rs7688540 0.771 rs61795006 ENSG00000275426.1 CH17-262A2.1 3.95 9.59e-05 0.0178 0.26 0.21 Facial morphology (factor 6, height of vermillion lower lip); chr4:259812 chr4:149738~150317:+ LIHC cis rs7688540 0.771 rs61795007 ENSG00000275426.1 CH17-262A2.1 3.95 9.59e-05 0.0178 0.26 0.21 Facial morphology (factor 6, height of vermillion lower lip); chr4:261475 chr4:149738~150317:+ LIHC cis rs9595908 0.9 rs61947058 ENSG00000212293.1 SNORA16 3.95 9.59e-05 0.0178 0.24 0.21 Body mass index; chr13:32617419 chr13:32420390~32420516:- LIHC cis rs11098499 0.691 rs12510133 ENSG00000245958.5 RP11-33B1.1 -3.95 9.59e-05 0.0178 -0.2 -0.21 Corneal astigmatism; chr4:119350189 chr4:119454791~119552025:+ LIHC cis rs11098499 0.754 rs12506487 ENSG00000245958.5 RP11-33B1.1 -3.95 9.59e-05 0.0178 -0.2 -0.21 Corneal astigmatism; chr4:119350206 chr4:119454791~119552025:+ LIHC cis rs11098499 0.691 rs12502524 ENSG00000245958.5 RP11-33B1.1 -3.95 9.59e-05 0.0178 -0.2 -0.21 Corneal astigmatism; chr4:119350259 chr4:119454791~119552025:+ LIHC cis rs11098499 0.691 rs28396837 ENSG00000245958.5 RP11-33B1.1 -3.95 9.59e-05 0.0178 -0.2 -0.21 Corneal astigmatism; chr4:119350386 chr4:119454791~119552025:+ LIHC cis rs11098499 0.629 rs28369518 ENSG00000245958.5 RP11-33B1.1 -3.95 9.59e-05 0.0178 -0.2 -0.21 Corneal astigmatism; chr4:119350475 chr4:119454791~119552025:+ LIHC cis rs951005 0.808 rs10972208 ENSG00000281491.1 DNAJB5-AS1 3.95 9.59e-05 0.0178 0.39 0.21 Rheumatoid arthritis; chr9:34714362 chr9:34985410~34989379:- LIHC cis rs2439831 0.571 rs689883 ENSG00000166763.7 STRCP1 3.95 9.6e-05 0.0178 0.29 0.21 Lung cancer in ever smokers; chr15:43520398 chr15:43699488~43718184:- LIHC cis rs4148008 0.589 rs10512519 ENSG00000267250.1 RP11-118B18.2 -3.95 9.6e-05 0.0179 -0.27 -0.21 HDL cholesterol; chr17:68835579 chr17:68793549~68797822:- LIHC cis rs673078 0.66 rs61945224 ENSG00000275759.1 RP11-131L12.3 -3.95 9.6e-05 0.0179 -0.45 -0.21 Glucose homeostasis traits; chr12:118288623 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs61945225 ENSG00000275759.1 RP11-131L12.3 -3.95 9.6e-05 0.0179 -0.45 -0.21 Glucose homeostasis traits; chr12:118288960 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs61946064 ENSG00000275759.1 RP11-131L12.3 -3.95 9.6e-05 0.0179 -0.45 -0.21 Glucose homeostasis traits; chr12:118294495 chr12:118428281~118428870:+ LIHC cis rs6472827 0.904 rs6986922 ENSG00000253983.2 RP1-16A9.1 3.95 9.6e-05 0.0179 0.3 0.21 Uterine fibroids; chr8:74208158 chr8:74199396~74208441:+ LIHC cis rs2439831 0.681 rs540031 ENSG00000166763.7 STRCP1 3.95 9.6e-05 0.0179 0.29 0.21 Lung cancer in ever smokers; chr15:43316657 chr15:43699488~43718184:- LIHC cis rs3733589 1 rs35110076 ENSG00000250413.1 RP11-448G15.1 3.95 9.6e-05 0.0179 0.34 0.21 Renal overload gout; chr4:9965169 chr4:10006482~10009725:+ LIHC cis rs57221529 0.713 rs12521091 ENSG00000271781.1 CTD-2589H19.6 -3.95 9.6e-05 0.0179 -0.33 -0.21 Lung disease severity in cystic fibrosis; chr5:590595 chr5:675826~676616:+ LIHC cis rs6142102 0.625 rs6142068 ENSG00000275784.1 RP5-1125A11.6 3.95 9.61e-05 0.0179 0.22 0.21 Skin pigmentation; chr20:33969366 chr20:33989480~33991818:- LIHC cis rs1799949 1 rs3092994 ENSG00000267681.1 CTD-3199J23.6 -3.95 9.61e-05 0.0179 -0.2 -0.21 Menopause (age at onset); chr17:43063808 chr17:43144956~43145255:+ LIHC cis rs1367117 0.789 rs1367113 ENSG00000233005.1 AC067959.1 -3.95 9.61e-05 0.0179 -0.25 -0.21 LDL cholesterol;Cholesterol, total;LDL cholesterol levels;Total cholesterol levels;Lipid metabolism phenotypes; chr2:21072960 chr2:21221175~21970959:+ LIHC cis rs7829975 0.564 rs2921060 ENSG00000253981.4 ALG1L13P -3.95 9.61e-05 0.0179 -0.27 -0.21 Mood instability; chr8:8460307 chr8:8236003~8244667:- LIHC cis rs34044649 1 rs1731847 ENSG00000214106.6 PAXIP1-AS2 3.95 9.61e-05 0.0179 0.16 0.21 Triptolide cytotoxicity; chr7:155862828 chr7:154928498~154949908:+ LIHC cis rs6745190 0.953 rs9808318 ENSG00000236153.1 AC104076.3 3.95 9.62e-05 0.0179 0.28 0.21 White blood cell count; chr2:181025478 chr2:180979427~180980090:- LIHC cis rs17197037 0.545 rs8009616 ENSG00000240954.1 RPL4P1 -3.95 9.62e-05 0.0179 -0.21 -0.21 Bipolar disorder; chr14:21318241 chr14:21750269~21751546:+ LIHC cis rs4650994 1 rs17276513 ENSG00000273384.1 RP5-1098D14.1 -3.95 9.62e-05 0.0179 -0.24 -0.21 HDL cholesterol;HDL cholesterol levels; chr1:178551469 chr1:178651706~178652282:+ LIHC cis rs1023500 0.505 rs134889 ENSG00000205702.9 CYP2D7 3.95 9.63e-05 0.0179 0.21 0.21 Schizophrenia; chr22:42278344 chr22:42140203~42144577:- LIHC cis rs9450351 0.744 rs111533912 ENSG00000203875.9 SNHG5 -3.95 9.63e-05 0.0179 -0.46 -0.21 Interferon gamma-induced protein 10 levels; chr6:85622231 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs9450308 ENSG00000203875.9 SNHG5 -3.95 9.63e-05 0.0179 -0.46 -0.21 Interferon gamma-induced protein 10 levels; chr6:85638820 chr6:85660950~85678736:- LIHC cis rs6496667 0.532 rs2601207 ENSG00000213471.7 TTLL13P -3.95 9.63e-05 0.0179 -0.27 -0.21 Rheumatoid arthritis; chr15:90420310 chr15:90249530~90265482:+ LIHC cis rs4792901 0.765 rs34778116 ENSG00000267747.1 RP11-392O1.4 -3.95 9.63e-05 0.0179 -0.24 -0.21 Dupuytren's disease; chr17:43462330 chr17:43544785~43610338:+ LIHC cis rs4792901 0.722 rs7220615 ENSG00000267747.1 RP11-392O1.4 -3.95 9.63e-05 0.0179 -0.24 -0.21 Dupuytren's disease; chr17:43463276 chr17:43544785~43610338:+ LIHC cis rs17772222 0.917 rs61986669 ENSG00000258789.1 RP11-507K2.3 -3.95 9.63e-05 0.0179 -0.25 -0.21 Coronary artery calcification; chr14:88727121 chr14:88551597~88552493:+ LIHC cis rs6430585 0.583 rs9636213 ENSG00000231890.6 DARS-AS1 3.95 9.64e-05 0.0179 0.29 0.21 Corneal structure; chr2:135831708 chr2:135985176~136022593:+ LIHC cis rs10829156 0.732 rs10828834 ENSG00000240291.1 RP11-499P20.2 3.95 9.64e-05 0.0179 0.34 0.21 Sudden cardiac arrest; chr10:18523505 chr10:18513115~18545651:- LIHC cis rs3764021 0.527 rs3764022 ENSG00000256673.1 RP11-599J14.2 -3.95 9.64e-05 0.0179 -0.22 -0.21 Type 1 diabetes; chr12:9680928 chr12:9398355~9414851:- LIHC cis rs2243480 1 rs313813 ENSG00000228409.4 CCT6P1 3.95 9.64e-05 0.0179 0.22 0.21 Diabetic kidney disease; chr7:66038513 chr7:65751142~65763354:+ LIHC cis rs916888 0.821 rs199499 ENSG00000274883.1 Metazoa_SRP -3.95 9.64e-05 0.0179 -0.38 -0.21 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788132 chr17:45931806~45932083:+ LIHC cis rs11098499 0.82 rs2389885 ENSG00000260091.1 RP11-33B1.4 -3.95 9.64e-05 0.0179 -0.15 -0.21 Corneal astigmatism; chr4:119612776 chr4:119409333~119410233:+ LIHC cis rs2494250 0.542 rs4402126 ENSG00000231434.1 RP11-144L1.8 -3.95 9.64e-05 0.0179 -0.25 -0.21 Select biomarker traits; chr1:159356328 chr1:158523672~158525838:+ LIHC cis rs8087799 0.965 rs35945038 ENSG00000273232.1 RP11-370A5.2 3.95 9.65e-05 0.0179 0.24 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22665285 chr18:22882825~22883357:- LIHC cis rs10129255 0.957 rs2007467 ENSG00000224373.3 IGHV4-59 -3.95 9.65e-05 0.0179 -0.17 -0.21 Kawasaki disease; chr14:106771605 chr14:106627249~106627825:- LIHC cis rs875971 1 rs6958271 ENSG00000237310.1 GS1-124K5.4 3.95 9.65e-05 0.0179 0.19 0.21 Aortic root size; chr7:66514344 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs6958277 ENSG00000237310.1 GS1-124K5.4 3.95 9.65e-05 0.0179 0.19 0.21 Aortic root size; chr7:66514362 chr7:66493706~66495474:+ LIHC cis rs6832769 1 rs10002541 ENSG00000272969.1 RP11-528I4.2 -3.95 9.65e-05 0.0179 -0.25 -0.21 Personality dimensions; chr4:55528844 chr4:55547112~55547889:+ LIHC cis rs34220720 0.892 rs35349559 ENSG00000267013.4 CTD-2171N6.1 3.95 9.65e-05 0.0179 0.28 0.21 Neuroticism; chr18:55098522 chr18:55105904~55124306:- LIHC cis rs2243480 1 rs4718333 ENSG00000232546.1 RP11-458F8.1 3.95 9.65e-05 0.0179 0.23 0.21 Diabetic kidney disease; chr7:66307771 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs7792391 ENSG00000232546.1 RP11-458F8.1 3.95 9.65e-05 0.0179 0.23 0.21 Diabetic kidney disease; chr7:66308442 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs10247526 ENSG00000232546.1 RP11-458F8.1 3.95 9.65e-05 0.0179 0.23 0.21 Diabetic kidney disease; chr7:66315709 chr7:66848496~66858136:+ LIHC cis rs2243480 0.908 rs1532573 ENSG00000232546.1 RP11-458F8.1 3.95 9.65e-05 0.0179 0.23 0.21 Diabetic kidney disease; chr7:66333815 chr7:66848496~66858136:+ LIHC cis rs8087799 0.894 rs3018320 ENSG00000273232.1 RP11-370A5.2 -3.95 9.65e-05 0.0179 -0.24 -0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22705797 chr18:22882825~22883357:- LIHC cis rs7508 0.546 rs382752 ENSG00000253671.1 RP11-806O11.1 3.95 9.66e-05 0.0179 0.25 0.21 Atrial fibrillation; chr8:18040874 chr8:17808941~17820868:+ LIHC cis rs41272086 0.636 rs1652507 ENSG00000243831.1 RP1-81D8.4 3.95 9.66e-05 0.0179 0.27 0.21 Monokine induced by gamma interferon levels; chr6:160661429 chr6:160666228~160676523:- LIHC cis rs7923609 0.846 rs10761739 ENSG00000232075.1 MRPL35P2 3.95 9.66e-05 0.0179 0.23 0.21 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63302248 chr10:63634317~63634827:- LIHC cis rs4792901 0.722 rs12601849 ENSG00000267747.1 RP11-392O1.4 -3.95 9.66e-05 0.0179 -0.24 -0.21 Dupuytren's disease; chr17:43468920 chr17:43544785~43610338:+ LIHC cis rs6910233 0.793 rs210170 ENSG00000224557.6 HLA-DPB2 -3.95 9.67e-05 0.018 -0.22 -0.21 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr6:33557903 chr6:33112451~33129084:+ LIHC cis rs4787951 0.754 rs6498012 ENSG00000274092.1 CTD-3203P2.3 -3.95 9.67e-05 0.018 -0.21 -0.21 Eosinophil percentage of white cells; chr16:27320653 chr16:27313387~27314101:- LIHC cis rs703842 1 rs3782130 ENSG00000270039.1 RP11-571M6.17 -3.95 9.67e-05 0.018 -0.3 -0.21 Multiple sclerosis; chr12:57768115 chr12:57803838~57804415:+ LIHC cis rs703842 1 rs10877012 ENSG00000270039.1 RP11-571M6.17 -3.95 9.67e-05 0.018 -0.3 -0.21 Multiple sclerosis; chr12:57768302 chr12:57803838~57804415:+ LIHC cis rs6480314 0.711 rs11815154 ENSG00000233590.1 RP11-153K11.3 -3.95 9.67e-05 0.018 -0.36 -0.21 Optic nerve measurement (disc area); chr10:68194544 chr10:68233251~68242379:- LIHC cis rs7953249 0.807 rs2393791 ENSG00000241388.4 HNF1A-AS1 3.95 9.68e-05 0.018 0.21 0.21 N-glycan levels;Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr12:120986153 chr12:120941728~120980965:- LIHC cis rs17428076 0.514 rs3821095 ENSG00000228389.1 AC068039.4 3.95 9.68e-05 0.018 0.25 0.21 Myopia; chr2:171827496 chr2:171773482~171775844:+ LIHC cis rs55794721 0.509 rs909834 ENSG00000224183.1 SDHDP6 -3.94 9.69e-05 0.018 -0.24 -0.21 Mean corpuscular volume;Plateletcrit; chr1:25431505 chr1:25294164~25294643:- LIHC cis rs2439831 1 rs689826 ENSG00000166763.7 STRCP1 3.94 9.69e-05 0.018 0.29 0.21 Lung cancer in ever smokers; chr15:43457718 chr15:43699488~43718184:- LIHC cis rs2179367 0.632 rs10155766 ENSG00000231760.4 RP11-350J20.5 3.94 9.69e-05 0.018 0.34 0.21 Dupuytren's disease; chr6:149364577 chr6:149796151~149826294:- LIHC cis rs2274273 0.624 rs3783651 ENSG00000258413.1 RP11-665C16.6 -3.94 9.69e-05 0.018 -0.26 -0.21 Protein biomarker; chr14:55384255 chr14:55262767~55272075:- LIHC cis rs9652601 0.677 rs35732840 ENSG00000274038.1 RP11-66H6.4 -3.94 9.69e-05 0.018 -0.26 -0.21 Systemic lupus erythematosus; chr16:11134498 chr16:11056556~11057034:+ LIHC cis rs11079159 0.959 rs3794752 ENSG00000263096.1 RP11-515O17.2 3.94 9.69e-05 0.018 0.29 0.21 QRS duration; chr17:55305468 chr17:55271504~55273653:- LIHC cis rs2243480 1 rs160655 ENSG00000230295.1 RP11-458F8.2 -3.94 9.7e-05 0.018 -0.22 -0.21 Diabetic kidney disease; chr7:66068227 chr7:66880708~66882981:+ LIHC cis rs2070488 1 rs13089394 ENSG00000229589.1 ACVR2B-AS1 3.94 9.7e-05 0.018 0.24 0.21 Electrocardiographic conduction measures; chr3:38404818 chr3:38451027~38454820:- LIHC cis rs6442522 0.606 rs3274 ENSG00000249786.6 EAF1-AS1 3.94 9.7e-05 0.018 0.24 0.21 Uric acid levels; chr3:15450249 chr3:15436171~15455940:- LIHC cis rs6442522 0.606 rs3846128 ENSG00000249786.6 EAF1-AS1 3.94 9.7e-05 0.018 0.24 0.21 Uric acid levels; chr3:15450643 chr3:15436171~15455940:- LIHC cis rs1005277 0.522 rs9417256 ENSG00000275858.1 RP11-291L22.8 3.94 9.7e-05 0.018 0.23 0.21 Extrinsic epigenetic age acceleration; chr10:37688062 chr10:38450738~38451069:- LIHC cis rs2348418 0.864 rs6487687 ENSG00000247934.4 RP11-967K21.1 3.94 9.71e-05 0.018 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28558230 chr12:28163298~28190738:- LIHC cis rs3761847 0.622 rs4837807 ENSG00000226752.6 PSMD5-AS1 -3.94 9.71e-05 0.018 -0.22 -0.21 Rheumatoid arthritis; chr9:121029727 chr9:120824828~120854385:+ LIHC cis rs8040855 0.825 rs3964197 ENSG00000259295.5 CSPG4P12 3.94 9.71e-05 0.018 0.3 0.21 Bulimia nervosa; chr15:85178681 chr15:85191438~85213905:+ LIHC cis rs8177876 0.749 rs2970076 ENSG00000261061.1 RP11-303E16.2 -3.94 9.71e-05 0.018 -0.27 -0.21 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81056211 chr16:81030770~81031485:+ LIHC cis rs2439831 0.85 rs7179388 ENSG00000166763.7 STRCP1 3.94 9.71e-05 0.018 0.32 0.21 Lung cancer in ever smokers; chr15:43831747 chr15:43699488~43718184:- LIHC cis rs2070488 0.965 rs3762791 ENSG00000229589.1 ACVR2B-AS1 -3.94 9.72e-05 0.018 -0.24 -0.21 Electrocardiographic conduction measures; chr3:38527337 chr3:38451027~38454820:- LIHC cis rs2749097 1 rs8294 ENSG00000244256.3 RN7SL130P -3.94 9.72e-05 0.018 -0.27 -0.21 Alcohol consumption (transferrin glycosylation); chr1:63659697 chr1:63655743~63656047:+ LIHC cis rs1405130 0.869 rs11688577 ENSG00000224287.2 MSL3P1 3.94 9.72e-05 0.018 0.25 0.21 Coronary artery disease; chr2:234658406 chr2:233865437~233868444:- LIHC cis rs1405130 0.839 rs1405132 ENSG00000224287.2 MSL3P1 3.94 9.72e-05 0.018 0.25 0.21 Coronary artery disease; chr2:234658816 chr2:233865437~233868444:- LIHC cis rs1405130 0.869 rs13001109 ENSG00000224287.2 MSL3P1 3.94 9.72e-05 0.018 0.25 0.21 Coronary artery disease; chr2:234661002 chr2:233865437~233868444:- LIHC cis rs1405130 0.839 rs11693749 ENSG00000224287.2 MSL3P1 3.94 9.72e-05 0.018 0.25 0.21 Coronary artery disease; chr2:234661247 chr2:233865437~233868444:- LIHC cis rs7712401 0.601 rs30027 ENSG00000263432.2 RN7SL689P 3.94 9.72e-05 0.018 0.3 0.21 Mean platelet volume; chr5:122947695 chr5:123022487~123022783:- LIHC cis rs4650994 0.967 rs4650998 ENSG00000213057.5 C1orf220 3.94 9.73e-05 0.018 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178562715 chr1:178542752~178548889:+ LIHC cis rs42490 0.664 rs39767 ENSG00000251136.7 RP11-37B2.1 -3.94 9.73e-05 0.018 -0.18 -0.21 Leprosy; chr8:89807770 chr8:89609409~89757727:- LIHC cis rs757081 0.648 rs12276859 ENSG00000272034.1 SNORD14A -3.94 9.73e-05 0.018 -0.22 -0.21 Systolic blood pressure; chr11:17255418 chr11:17074654~17074744:- LIHC cis rs10129255 0.957 rs10140904 ENSG00000211970.3 IGHV4-61 -3.94 9.73e-05 0.018 -0.17 -0.21 Kawasaki disease; chr14:106776558 chr14:106639119~106639657:- LIHC cis rs6545883 0.602 rs11125871 ENSG00000271889.1 RP11-493E12.1 -3.94 9.73e-05 0.0181 -0.26 -0.21 Tuberculosis; chr2:61242991 chr2:61151433~61162105:- LIHC cis rs875971 1 rs6945843 ENSG00000237310.1 GS1-124K5.4 -3.94 9.74e-05 0.0181 -0.18 -0.21 Aortic root size; chr7:66269796 chr7:66493706~66495474:+ LIHC cis rs2070488 0.965 rs35091896 ENSG00000229589.1 ACVR2B-AS1 3.94 9.74e-05 0.0181 0.24 0.21 Electrocardiographic conduction measures; chr3:38401829 chr3:38451027~38454820:- LIHC cis rs4356203 0.905 rs214940 ENSG00000260196.1 RP1-239B22.5 -3.94 9.74e-05 0.0181 -0.25 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17165308 chr11:17380649~17383531:+ LIHC cis rs853679 0.599 rs149949 ENSG00000204709.4 LINC01556 3.94 9.74e-05 0.0181 0.36 0.21 Depression; chr6:28043738 chr6:28943877~28944537:+ LIHC cis rs933688 1 rs6865495 ENSG00000281357.1 ARRDC3-AS1 3.94 9.75e-05 0.0181 0.26 0.21 Smoking behavior; chr5:91450607 chr5:91380349~91439085:+ LIHC cis rs1062753 0.731 rs11914200 ENSG00000237037.8 NDUFA6-AS1 -3.94 9.75e-05 0.0181 -0.29 -0.21 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:41982066 chr22:42090931~42137742:+ LIHC cis rs2749592 0.55 rs7917262 ENSG00000099251.13 HSD17B7P2 -3.94 9.75e-05 0.0181 -0.24 -0.21 Age-related hearing impairment (SNP x SNP interaction); chr10:37585674 chr10:38356380~38378505:+ LIHC cis rs2749592 0.55 rs9733309 ENSG00000099251.13 HSD17B7P2 -3.94 9.75e-05 0.0181 -0.24 -0.21 Age-related hearing impairment (SNP x SNP interaction); chr10:37593477 chr10:38356380~38378505:+ LIHC cis rs2749592 0.55 rs7081464 ENSG00000099251.13 HSD17B7P2 -3.94 9.75e-05 0.0181 -0.24 -0.21 Age-related hearing impairment (SNP x SNP interaction); chr10:37595009 chr10:38356380~38378505:+ LIHC cis rs2749592 0.531 rs994804 ENSG00000099251.13 HSD17B7P2 -3.94 9.75e-05 0.0181 -0.24 -0.21 Age-related hearing impairment (SNP x SNP interaction); chr10:37611212 chr10:38356380~38378505:+ LIHC cis rs10129255 0.5 rs59939897 ENSG00000211972.2 IGHV3-66 3.94 9.76e-05 0.0181 0.16 0.21 Kawasaki disease; chr14:106783414 chr14:106675017~106675544:- LIHC cis rs4891159 0.756 rs55763305 ENSG00000265778.2 RP11-17M16.2 -3.94 9.76e-05 0.0181 -0.25 -0.21 Longevity; chr18:76449293 chr18:76491652~76493918:+ LIHC cis rs4561483 0.545 rs9927446 ENSG00000261560.1 RP11-166B2.3 3.94 9.76e-05 0.0181 0.24 0.21 Testicular germ cell tumor; chr16:11863307 chr16:11881075~11882569:- LIHC cis rs9565309 0.579 rs9573976 ENSG00000274898.1 AC001226.7 -3.94 9.76e-05 0.0181 -0.38 -0.21 Morning vs. evening chronotype; chr13:77008384 chr13:77027944~77028482:+ LIHC cis rs9565309 0.579 rs76391359 ENSG00000274898.1 AC001226.7 -3.94 9.76e-05 0.0181 -0.38 -0.21 Morning vs. evening chronotype; chr13:77008573 chr13:77027944~77028482:+ LIHC cis rs2032366 1 rs2032366 ENSG00000267279.1 RP11-879F14.2 -3.94 9.76e-05 0.0181 -0.24 -0.21 Obesity-related traits; chr18:61599138 chr18:61585746~61606916:- LIHC cis rs2032366 0.967 rs6650736 ENSG00000267279.1 RP11-879F14.2 -3.94 9.76e-05 0.0181 -0.24 -0.21 Obesity-related traits; chr18:61601711 chr18:61585746~61606916:- LIHC cis rs2032366 0.967 rs9965804 ENSG00000267279.1 RP11-879F14.2 -3.94 9.76e-05 0.0181 -0.24 -0.21 Obesity-related traits; chr18:61602021 chr18:61585746~61606916:- LIHC cis rs4266144 0.558 rs34696078 ENSG00000244515.1 KRT18P34 -3.94 9.76e-05 0.0181 -0.21 -0.21 Coronary artery disease; chr3:157114875 chr3:157162663~157163932:- LIHC cis rs4266144 0.558 rs7623382 ENSG00000244515.1 KRT18P34 -3.94 9.76e-05 0.0181 -0.21 -0.21 Coronary artery disease; chr3:157115105 chr3:157162663~157163932:- LIHC cis rs9876781 1 rs6442119 ENSG00000229759.1 MRPS18AP1 3.94 9.76e-05 0.0181 0.22 0.21 Longevity; chr3:48398713 chr3:48256350~48256938:- LIHC cis rs12586317 0.62 rs17103042 ENSG00000257307.1 RP11-317N8.4 -3.94 9.76e-05 0.0181 -0.25 -0.21 Psoriasis; chr14:35106222 chr14:35881001~35881709:+ LIHC cis rs9527 0.59 rs3781282 ENSG00000236937.2 PTGES3P4 -3.94 9.76e-05 0.0181 -0.26 -0.21 Arsenic metabolism; chr10:103092662 chr10:102845595~102845950:+ LIHC cis rs8064024 0.513 rs1049207 ENSG00000267077.1 RP11-127I20.5 -3.94 9.77e-05 0.0181 -0.22 -0.21 Cancer; chr16:4884563 chr16:4795265~4796532:- LIHC cis rs950169 0.92 rs12915390 ENSG00000225151.9 GOLGA2P7 -3.94 9.77e-05 0.0181 -0.3 -0.21 Schizophrenia; chr15:84123317 chr15:84199311~84230136:- LIHC cis rs4578769 0.797 rs9304261 ENSG00000265943.1 RP11-739L10.1 -3.94 9.77e-05 0.0181 -0.26 -0.21 Eosinophil percentage of white cells; chr18:23026633 chr18:22699481~22933764:- LIHC cis rs801193 0.636 rs10233806 ENSG00000237310.1 GS1-124K5.4 -3.94 9.78e-05 0.0181 -0.18 -0.21 Aortic root size; chr7:66653261 chr7:66493706~66495474:+ LIHC cis rs8077577 0.747 rs62072541 ENSG00000260647.1 RP1-178F10.1 3.94 9.78e-05 0.0181 0.26 0.21 Obesity-related traits; chr17:18323385 chr17:18268080~18268828:+ LIHC cis rs12209785 0.774 rs7755257 ENSG00000231769.2 RP1-8B1.4 3.94 9.78e-05 0.0181 0.3 0.21 Survival in pancreatic cancer; chr6:45522555 chr6:46097093~46129706:- LIHC cis rs11096990 0.634 rs6829064 ENSG00000249207.1 RP11-360F5.1 3.94 9.78e-05 0.0181 0.21 0.21 Cognitive function; chr4:39290192 chr4:39112677~39126818:- LIHC cis rs17221829 0.932 rs7924841 ENSG00000280367.1 RP11-121L10.2 3.94 9.78e-05 0.0181 0.24 0.21 Anxiety in major depressive disorder; chr11:89727116 chr11:90223153~90226538:+ LIHC cis rs1005277 0.505 rs10827836 ENSG00000276805.1 RP11-291L22.6 -3.94 9.78e-05 0.0181 -0.25 -0.21 Extrinsic epigenetic age acceleration; chr10:37926513 chr10:38451030~38451785:+ LIHC cis rs9595908 0.645 rs4942924 ENSG00000212293.1 SNORA16 3.94 9.78e-05 0.0181 0.24 0.21 Body mass index; chr13:32806987 chr13:32420390~32420516:- LIHC cis rs16958440 0.737 rs12327081 ENSG00000267724.1 RP11-49K24.8 3.94 9.78e-05 0.0181 0.44 0.21 Sitting height ratio; chr18:47218051 chr18:47105946~47108062:+ LIHC cis rs6545883 0.524 rs2694618 ENSG00000271889.1 RP11-493E12.1 3.94 9.79e-05 0.0181 0.25 0.21 Tuberculosis; chr2:61309849 chr2:61151433~61162105:- LIHC cis rs1344653 0.738 rs59991730 ENSG00000236204.4 LINC01376 -3.94 9.79e-05 0.0181 -0.25 -0.21 Pulse pressure; chr2:19550417 chr2:18986451~19346748:- LIHC cis rs17711722 0.583 rs11768292 ENSG00000224316.1 RP11-479O9.2 -3.94 9.79e-05 0.0181 -0.23 -0.21 Calcium levels; chr7:66009814 chr7:65773620~65802067:+ LIHC cis rs1075265 0.73 rs11893270 ENSG00000272156.1 RP11-477N3.1 -3.94 9.8e-05 0.0181 -0.24 -0.21 Chronotype;Morning vs. evening chronotype; chr2:54019828 chr2:54082554~54085066:+ LIHC cis rs1799949 1 rs12944430 ENSG00000267681.1 CTD-3199J23.6 -3.94 9.8e-05 0.0181 -0.2 -0.21 Menopause (age at onset); chr17:43178803 chr17:43144956~43145255:+ LIHC cis rs950880 0.71 rs17027255 ENSG00000234389.1 AC007278.3 -3.94 9.81e-05 0.0182 -0.21 -0.21 Serum protein levels (sST2); chr2:102473668 chr2:102438713~102440475:+ LIHC cis rs9640161 0.663 rs1916932 ENSG00000261305.1 RP4-584D14.7 3.94 9.81e-05 0.0182 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150324555 chr7:150341771~150342607:+ LIHC cis rs9640161 0.789 rs60283368 ENSG00000261305.1 RP4-584D14.7 3.94 9.81e-05 0.0182 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150326169 chr7:150341771~150342607:+ LIHC cis rs9640161 0.75 rs59211922 ENSG00000261305.1 RP4-584D14.7 3.94 9.81e-05 0.0182 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150326701 chr7:150341771~150342607:+ LIHC cis rs801193 0.66 rs2659897 ENSG00000237310.1 GS1-124K5.4 -3.94 9.82e-05 0.0182 -0.18 -0.21 Aortic root size; chr7:66722728 chr7:66493706~66495474:+ LIHC cis rs2439831 1 rs2254321 ENSG00000166763.7 STRCP1 3.94 9.82e-05 0.0182 0.3 0.21 Lung cancer in ever smokers; chr15:43415344 chr15:43699488~43718184:- LIHC cis rs9640161 0.711 rs60268791 ENSG00000261305.1 RP4-584D14.7 3.94 9.82e-05 0.0182 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150326711 chr7:150341771~150342607:+ LIHC cis rs6700559 0.74 rs10919997 ENSG00000260088.1 RP11-92G12.3 3.94 9.82e-05 0.0182 0.29 0.21 Coronary artery disease; chr1:200677522 chr1:200669507~200694250:+ LIHC cis rs6700559 0.74 rs4072551 ENSG00000260088.1 RP11-92G12.3 3.94 9.82e-05 0.0182 0.29 0.21 Coronary artery disease; chr1:200679993 chr1:200669507~200694250:+ LIHC cis rs6700559 0.74 rs4072554 ENSG00000260088.1 RP11-92G12.3 3.94 9.82e-05 0.0182 0.29 0.21 Coronary artery disease; chr1:200680238 chr1:200669507~200694250:+ LIHC cis rs6700559 0.74 rs10919999 ENSG00000260088.1 RP11-92G12.3 3.94 9.82e-05 0.0182 0.29 0.21 Coronary artery disease; chr1:200680631 chr1:200669507~200694250:+ LIHC cis rs17772222 0.636 rs10484010 ENSG00000258789.1 RP11-507K2.3 -3.94 9.82e-05 0.0182 -0.25 -0.21 Coronary artery calcification; chr14:88831944 chr14:88551597~88552493:+ LIHC cis rs9487094 0.813 rs6920962 ENSG00000260273.1 RP11-425D10.10 3.94 9.82e-05 0.0182 0.24 0.21 Height; chr6:109403287 chr6:109382795~109383666:+ LIHC cis rs4865169 1 rs4865169 ENSG00000269949.1 RP11-738E22.3 -3.94 9.82e-05 0.0182 -0.26 -0.21 Breast cancer; chr4:57013626 chr4:56960927~56961373:- LIHC cis rs4073416 0.712 rs12888212 ENSG00000276116.2 FUT8-AS1 3.94 9.83e-05 0.0182 0.26 0.21 N-glycan levels; chr14:65733740 chr14:65411170~65412690:- LIHC cis rs4073416 0.712 rs927004 ENSG00000276116.2 FUT8-AS1 3.94 9.83e-05 0.0182 0.26 0.21 N-glycan levels; chr14:65734193 chr14:65411170~65412690:- LIHC cis rs1405130 1 rs4663459 ENSG00000224287.2 MSL3P1 3.94 9.83e-05 0.0182 0.25 0.21 Coronary artery disease; chr2:234654783 chr2:233865437~233868444:- LIHC cis rs539096 0.54 rs3011217 ENSG00000237950.1 RP11-7O11.3 -3.94 9.83e-05 0.0182 -0.22 -0.21 Intelligence (multi-trait analysis); chr1:43837594 chr1:43944370~43946551:- LIHC cis rs55794721 0.509 rs12027110 ENSG00000261349.1 RP3-465N24.5 -3.94 9.83e-05 0.0182 -0.2 -0.21 Mean corpuscular volume;Plateletcrit; chr1:25449191 chr1:25266102~25267136:- LIHC cis rs1530530 0.748 rs41305040 ENSG00000253771.4 TPTE2P1 -3.94 9.84e-05 0.0182 -0.46 -0.21 Obesity-related traits; chr13:24689401 chr13:24924677~24968487:- LIHC cis rs4561483 0.645 rs2192645 ENSG00000261560.1 RP11-166B2.3 -3.94 9.84e-05 0.0182 -0.24 -0.21 Testicular germ cell tumor; chr16:11834162 chr16:11881075~11882569:- LIHC cis rs4356203 0.87 rs12286505 ENSG00000260196.1 RP1-239B22.5 3.94 9.85e-05 0.0182 0.25 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17142178 chr11:17380649~17383531:+ LIHC cis rs7129556 0.737 rs537811 ENSG00000254459.1 RP11-91P24.7 3.94 9.85e-05 0.0182 0.34 0.21 Weight loss (gastric bypass surgery); chr11:77757043 chr11:77829654~77872262:- LIHC cis rs2439831 0.867 rs496584 ENSG00000166763.7 STRCP1 3.94 9.85e-05 0.0182 0.3 0.21 Lung cancer in ever smokers; chr15:43539725 chr15:43699488~43718184:- LIHC cis rs295490 0.667 rs80284522 ENSG00000272656.1 RP11-219D15.3 3.94 9.85e-05 0.0182 0.59 0.21 PR interval in Tripanosoma cruzi seropositivity; chr3:139316346 chr3:139349024~139349371:- LIHC cis rs4356203 0.905 rs214937 ENSG00000260196.1 RP1-239B22.5 3.94 9.86e-05 0.0182 0.25 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17168005 chr11:17380649~17383531:+ LIHC cis rs6445975 0.619 rs112015230 ENSG00000272360.1 RP11-359I18.5 -3.94 9.86e-05 0.0182 -0.25 -0.21 Systemic lupus erythematosus; chr3:58276477 chr3:58490830~58491291:- LIHC cis rs17818399 0.716 rs62134741 ENSG00000239332.4 LINC01119 -3.94 9.86e-05 0.0182 -0.31 -0.21 Height; chr2:46555050 chr2:46816697~46859007:+ LIHC cis rs1115240 0.898 rs1245198 ENSG00000257842.4 NOVA1-AS1 -3.94 9.86e-05 0.0182 -0.19 -0.21 Educational attainment (years of education); chr14:26535522 chr14:26598412~26806467:+ LIHC cis rs66486766 1 rs66486766 ENSG00000259728.4 LINC00933 3.94 9.86e-05 0.0182 0.33 0.21 Bipolar disorder lithium response (categorical) or schizophrenia; chr15:84137308 chr15:84570649~84580175:+ LIHC cis rs13315871 0.929 rs7628038 ENSG00000272182.1 RP11-802O23.3 3.94 9.86e-05 0.0182 0.49 0.21 Cholesterol, total; chr3:58328086 chr3:58428255~58428815:+ LIHC cis rs6048205 0.657 rs2021680 ENSG00000259974.2 LINC00261 3.94 9.87e-05 0.0182 0.32 0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22548114 chr20:22547671~22578642:- LIHC cis rs4763879 0.634 rs61915473 ENSG00000256673.1 RP11-599J14.2 3.94 9.87e-05 0.0182 0.2 0.21 Type 1 diabetes; chr12:9705282 chr12:9398355~9414851:- LIHC cis rs875971 0.929 rs6970860 ENSG00000237310.1 GS1-124K5.4 3.94 9.87e-05 0.0183 0.18 0.21 Aortic root size; chr7:66511647 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs6957199 ENSG00000237310.1 GS1-124K5.4 3.94 9.87e-05 0.0183 0.18 0.21 Aortic root size; chr7:66513532 chr7:66493706~66495474:+ LIHC cis rs4787491 0.704 rs35605010 ENSG00000250616.2 RP11-455F5.3 3.94 9.87e-05 0.0183 0.21 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30022107 chr16:30096430~30104116:+ LIHC cis rs4787491 0.729 rs4238960 ENSG00000250616.2 RP11-455F5.3 3.94 9.87e-05 0.0183 0.21 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30027327 chr16:30096430~30104116:+ LIHC cis rs2658782 0.901 rs11601056 ENSG00000279684.1 RP11-755E23.2 3.94 9.87e-05 0.0183 0.38 0.21 Pulmonary function decline; chr11:93495995 chr11:93286629~93288903:- LIHC cis rs881375 0.967 rs1930778 ENSG00000226752.6 PSMD5-AS1 -3.94 9.88e-05 0.0183 -0.23 -0.21 Rheumatoid arthritis; chr9:120879091 chr9:120824828~120854385:+ LIHC cis rs1396626 0.855 rs6684598 ENSG00000230427.1 RP11-313A24.1 3.94 9.88e-05 0.0183 0.33 0.21 Diabetic kidney disease; chr1:95512268 chr1:95061596~95067545:+ LIHC cis rs1005277 0.54 rs2145487 ENSG00000276805.1 RP11-291L22.6 3.94 9.88e-05 0.0183 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37721149 chr10:38451030~38451785:+ LIHC cis rs1005277 0.54 rs4934907 ENSG00000276805.1 RP11-291L22.6 3.94 9.88e-05 0.0183 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37726302 chr10:38451030~38451785:+ LIHC cis rs1005277 0.54 rs11011351 ENSG00000276805.1 RP11-291L22.6 3.94 9.88e-05 0.0183 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37741597 chr10:38451030~38451785:+ LIHC cis rs7688540 0.713 rs12511388 ENSG00000275426.1 CH17-262A2.1 3.94 9.89e-05 0.0183 0.25 0.21 Facial morphology (factor 6, height of vermillion lower lip); chr4:303758 chr4:149738~150317:+ LIHC cis rs13434995 0.589 rs499110 ENSG00000273257.1 RP11-177J6.1 -3.94 9.89e-05 0.0183 -0.32 -0.21 Adiponectin levels; chr4:55381628 chr4:55387949~55388271:+ LIHC cis rs1499614 1 rs1267818 ENSG00000275400.1 RP4-756H11.5 3.94 9.89e-05 0.0183 0.28 0.21 Gout; chr7:66642037 chr7:66553805~66554199:- LIHC cis rs9450351 0.744 rs9344559 ENSG00000203875.9 SNHG5 -3.94 9.89e-05 0.0183 -0.45 -0.21 Interferon gamma-induced protein 10 levels; chr6:86012192 chr6:85660950~85678736:- LIHC cis rs4356975 0.795 rs4694599 ENSG00000250919.1 RP11-813N20.3 -3.94 9.89e-05 0.0183 -0.21 -0.21 Obesity-related traits; chr4:69070858 chr4:69027831~69044578:+ LIHC cis rs875971 0.508 rs10242423 ENSG00000224316.1 RP11-479O9.2 -3.94 9.89e-05 0.0183 -0.19 -0.21 Aortic root size; chr7:66594188 chr7:65773620~65802067:+ LIHC cis rs875971 0.508 rs10253883 ENSG00000224316.1 RP11-479O9.2 -3.94 9.89e-05 0.0183 -0.19 -0.21 Aortic root size; chr7:66596151 chr7:65773620~65802067:+ LIHC cis rs1874124 0.577 rs2807872 ENSG00000257551.1 HLX-AS1 -3.94 9.89e-05 0.0183 -0.33 -0.21 Cholesterol, total; chr1:220866908 chr1:220832763~220880140:- LIHC cis rs2911132 0.511 rs7063 ENSG00000248734.2 CTD-2260A17.1 3.94 9.9e-05 0.0183 0.29 0.21 Urate levels (BMI interaction); chr5:96774507 chr5:96784777~96785999:+ LIHC cis rs6723108 0.627 rs1374292 ENSG00000224043.6 CCNT2-AS1 -3.94 9.9e-05 0.0183 -0.29 -0.21 Type 2 diabetes; chr2:134896598 chr2:134735464~134918710:- LIHC cis rs2115630 1 rs8037423 ENSG00000189136.7 UBE2Q2P1 -3.94 9.9e-05 0.0183 -0.17 -0.21 P wave terminal force; chr15:84812263 chr15:84526781~84571216:- LIHC cis rs6142102 0.602 rs932388 ENSG00000275784.1 RP5-1125A11.6 -3.94 9.9e-05 0.0183 -0.22 -0.21 Skin pigmentation; chr20:34069572 chr20:33989480~33991818:- LIHC cis rs7914558 0.646 rs10883799 ENSG00000236937.2 PTGES3P4 3.94 9.9e-05 0.0183 0.26 0.21 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102903553 chr10:102845595~102845950:+ LIHC cis rs7182948 1 rs11070707 ENSG00000259531.2 RP11-295H24.3 -3.94 9.91e-05 0.0183 -0.31 -0.21 Lung adenocarcinoma; chr15:49567438 chr15:49365124~49366685:- LIHC cis rs7083 0.653 rs573442 ENSG00000254851.1 RP11-109L13.1 3.94 9.92e-05 0.0183 0.31 0.21 Blood protein levels; chr11:117307204 chr11:117135528~117138582:+ LIHC cis rs2564921 0.73 rs73082047 ENSG00000242142.1 SERBP1P3 -3.94 9.92e-05 0.0183 -0.28 -0.21 Height; chr3:53070344 chr3:53064283~53065091:- LIHC cis rs703842 0.963 rs2291617 ENSG00000270039.1 RP11-571M6.17 -3.94 9.92e-05 0.0183 -0.29 -0.21 Multiple sclerosis; chr12:57772620 chr12:57803838~57804415:+ LIHC cis rs10752881 1 rs10797802 ENSG00000224468.3 RP11-181K3.4 3.94 9.92e-05 0.0183 0.17 0.21 Colorectal cancer; chr1:183004023 chr1:183138402~183141282:- LIHC cis rs9303401 0.646 rs7217845 ENSG00000265415.1 CTD-2510F5.4 3.94 9.92e-05 0.0183 0.14 0.21 Cognitive test performance; chr17:59159539 chr17:59202677~59203829:- LIHC cis rs7809950 0.678 rs2301801 ENSG00000238832.1 snoU109 -3.94 9.93e-05 0.0184 -0.27 -0.21 Coronary artery disease; chr7:107230301 chr7:107603363~107603507:+ LIHC cis rs7712401 0.691 rs62377436 ENSG00000263432.2 RN7SL689P -3.94 9.94e-05 0.0184 -0.31 -0.21 Mean platelet volume; chr5:123018007 chr5:123022487~123022783:- LIHC cis rs6745190 0.906 rs12621277 ENSG00000236153.1 AC104076.3 3.94 9.94e-05 0.0184 0.29 0.21 White blood cell count; chr2:180966460 chr2:180979427~180980090:- LIHC cis rs9951150 0.557 rs34220720 ENSG00000267013.4 CTD-2171N6.1 3.94 9.94e-05 0.0184 0.28 0.21 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55127853 chr18:55105904~55124306:- LIHC cis rs950880 0.71 rs56117144 ENSG00000234389.1 AC007278.3 -3.94 9.94e-05 0.0184 -0.21 -0.21 Serum protein levels (sST2); chr2:102458191 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs57081652 ENSG00000234389.1 AC007278.3 -3.94 9.94e-05 0.0184 -0.21 -0.21 Serum protein levels (sST2); chr2:102458921 chr2:102438713~102440475:+ LIHC cis rs7119038 0.818 rs73003215 ENSG00000255422.1 AP002954.4 3.94 9.94e-05 0.0184 0.26 0.21 Sjögren's syndrome; chr11:118778803 chr11:118704607~118750263:+ LIHC cis rs7726839 0.54 rs7434 ENSG00000271781.1 CTD-2589H19.6 3.94 9.94e-05 0.0184 0.32 0.21 Obesity-related traits; chr5:660689 chr5:675826~676616:+ LIHC cis rs10851478 0.692 rs62010017 ENSG00000276593.1 RP11-295H24.5 3.94 9.94e-05 0.0184 0.23 0.21 Oral cavity cancer; chr15:49525667 chr15:49353485~49354034:+ LIHC cis rs763512 0.532 rs1416 ENSG00000276054.1 RP11-378E13.3 3.94 9.95e-05 0.0184 0.27 0.21 3-hydroxypropylmercapturic acid levels in smokers; chr17:37534709 chr17:37386886~37387926:+ LIHC cis rs7665090 0.87 rs228615 ENSG00000246560.2 RP11-10L12.4 -3.94 9.95e-05 0.0184 -0.24 -0.21 Primary biliary cholangitis; chr4:102658303 chr4:102828055~102844075:+ LIHC cis rs2149150 0.673 rs115520991 ENSG00000229950.1 TFAP2A-AS1 -3.94 9.95e-05 0.0184 -0.46 -0.21 Male-pattern baldness; chr6:9615840 chr6:10409340~10416446:+ LIHC cis rs6464929 0.744 rs73160314 ENSG00000281189.1 GHET1 3.94 9.95e-05 0.0184 0.32 0.21 Pediatric bone mineral content (hip); chr7:148991439 chr7:148987527~148989432:+ LIHC cis rs2274273 0.624 rs67412516 ENSG00000258413.1 RP11-665C16.6 -3.94 9.95e-05 0.0184 -0.26 -0.21 Protein biomarker; chr14:55386519 chr14:55262767~55272075:- LIHC cis rs1115240 0.785 rs1950412 ENSG00000257842.4 NOVA1-AS1 3.94 9.95e-05 0.0184 0.19 0.21 Educational attainment (years of education); chr14:26582134 chr14:26598412~26806467:+ LIHC cis rs10883723 0.81 rs10786669 ENSG00000236937.2 PTGES3P4 -3.94 9.95e-05 0.0184 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102496337 chr10:102845595~102845950:+ LIHC cis rs748404 0.556 rs574856 ENSG00000205771.5 CATSPER2P1 3.94 9.96e-05 0.0184 0.26 0.21 Lung cancer; chr15:43168636 chr15:43726918~43747094:- LIHC cis rs748404 0.697 rs475227 ENSG00000205771.5 CATSPER2P1 -3.94 9.96e-05 0.0184 -0.25 -0.21 Lung cancer; chr15:43254248 chr15:43726918~43747094:- LIHC cis rs9527 0.615 rs10883810 ENSG00000236937.2 PTGES3P4 3.94 9.96e-05 0.0184 0.26 0.21 Arsenic metabolism; chr10:102967467 chr10:102845595~102845950:+ LIHC cis rs6142102 0.923 rs4911394 ENSG00000275784.1 RP5-1125A11.6 -3.94 9.96e-05 0.0184 -0.24 -0.21 Skin pigmentation; chr20:33989521 chr20:33989480~33991818:- LIHC cis rs2880765 0.525 rs35899940 ENSG00000259630.2 CTD-2262B20.1 -3.94 9.97e-05 0.0184 -0.29 -0.21 Coronary artery disease; chr15:85510466 chr15:85415228~85415633:+ LIHC cis rs6048205 1 rs2277763 ENSG00000259974.2 LINC00261 -3.94 9.97e-05 0.0184 -0.32 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22567656 chr20:22547671~22578642:- LIHC cis rs2439831 0.681 rs1095386 ENSG00000205771.5 CATSPER2P1 -3.94 9.97e-05 0.0184 -0.28 -0.21 Lung cancer in ever smokers; chr15:43317311 chr15:43726918~43747094:- LIHC cis rs6142102 0.961 rs1319363 ENSG00000275784.1 RP5-1125A11.6 -3.94 9.97e-05 0.0184 -0.24 -0.21 Skin pigmentation; chr20:33954070 chr20:33989480~33991818:- LIHC cis rs617219 0.853 rs1664552 ENSG00000251675.1 CTC-458I2.2 -3.94 9.97e-05 0.0184 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79142669 chr5:80128361~80143883:+ LIHC cis rs617219 0.889 rs1533760 ENSG00000251675.1 CTC-458I2.2 -3.94 9.97e-05 0.0184 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79143114 chr5:80128361~80143883:+ LIHC cis rs4578769 0.569 rs12966840 ENSG00000266850.1 RP11-370A5.1 -3.94 9.97e-05 0.0184 -0.22 -0.21 Eosinophil percentage of white cells; chr18:22856911 chr18:22723491~22907721:- LIHC cis rs853679 0.599 rs149949 ENSG00000219891.2 ZSCAN12P1 3.94 9.97e-05 0.0184 0.37 0.21 Depression; chr6:28043738 chr6:28091154~28093664:+ LIHC cis rs1115240 0.841 rs11851681 ENSG00000257842.4 NOVA1-AS1 3.94 9.97e-05 0.0184 0.19 0.21 Educational attainment (years of education); chr14:26586827 chr14:26598412~26806467:+ LIHC cis rs7809950 0.678 rs77395658 ENSG00000238832.1 snoU109 -3.94 9.97e-05 0.0184 -0.27 -0.21 Coronary artery disease; chr7:107360206 chr7:107603363~107603507:+ LIHC cis rs12468226 0.938 rs3843338 ENSG00000226261.1 AC064836.3 -3.94 9.98e-05 0.0184 -0.33 -0.21 Urate levels; chr2:202246102 chr2:202336024~202336727:- LIHC cis rs2439831 0.681 rs498837 ENSG00000166763.7 STRCP1 3.94 9.98e-05 0.0184 0.29 0.21 Lung cancer in ever smokers; chr15:43315826 chr15:43699488~43718184:- LIHC cis rs11089937 0.597 rs5757005 ENSG00000211639.2 IGLV4-60 3.94 9.98e-05 0.0184 0.18 0.21 Periodontitis (PAL4Q3); chr22:22134775 chr22:22162199~22162681:+ LIHC cis rs4787491 0.729 rs12446378 ENSG00000250616.2 RP11-455F5.3 3.94 9.98e-05 0.0184 0.2 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30031789 chr16:30096430~30104116:+ LIHC cis rs7789940 0.904 rs73140040 ENSG00000205485.12 AC004980.7 -3.94 9.98e-05 0.0184 -0.22 -0.21 Multiple sclerosis; chr7:76306923 chr7:76549360~76627982:+ LIHC cis rs10471753 0.901 rs2078396 ENSG00000248359.1 CTC-537E7.2 -3.94 9.98e-05 0.0184 -0.26 -0.21 Hip minimal joint space width; chr5:68538416 chr5:68531690~68533530:- LIHC cis rs4578769 0.55 rs4800435 ENSG00000266850.1 RP11-370A5.1 3.94 9.99e-05 0.0184 0.22 0.21 Eosinophil percentage of white cells; chr18:22862923 chr18:22723491~22907721:- LIHC cis rs673078 0.607 rs11068906 ENSG00000275409.1 RP11-131L12.4 -3.94 9.99e-05 0.0184 -0.26 -0.21 Glucose homeostasis traits; chr12:118315098 chr12:118430147~118430699:+ LIHC cis rs1555322 0.872 rs6579227 ENSG00000126005.14 MMP24-AS1 -3.94 1e-04 0.0185 -0.43 -0.21 Attention deficit hyperactivity disorder; chr20:35291403 chr20:35216462~35278131:- LIHC cis rs11676348 0.772 rs6738953 ENSG00000261338.2 RP11-378A13.1 -3.94 1e-04 0.0185 -0.22 -0.21 Ulcerative colitis; chr2:218085313 chr2:218255319~218257366:+ LIHC cis rs193541 0.632 rs2407402 ENSG00000263432.2 RN7SL689P 3.94 1e-04 0.0185 0.33 0.21 Glucose homeostasis traits; chr5:122771410 chr5:123022487~123022783:- LIHC cis rs1499614 0.803 rs1796229 ENSG00000228409.4 CCT6P1 3.94 1e-04 0.0185 0.23 0.21 Gout; chr7:66654674 chr7:65751142~65763354:+ LIHC cis rs1499614 0.901 rs3936 ENSG00000228409.4 CCT6P1 3.94 1e-04 0.0185 0.23 0.21 Gout; chr7:66661502 chr7:65751142~65763354:+ LIHC cis rs9425766 0.679 rs7552939 ENSG00000200674.1 RN7SKP160 3.94 1e-04 0.0185 0.24 0.21 Life satisfaction; chr1:173798305 chr1:173791548~173791887:+ LIHC cis rs904251 0.772 rs2252920 ENSG00000204110.6 RP1-153P14.8 -3.94 1e-04 0.0185 -0.26 -0.21 Cognitive performance; chr6:37450551 chr6:37507348~37535616:+ LIHC cis rs1005277 0.522 rs1208767 ENSG00000276805.1 RP11-291L22.6 3.94 1e-04 0.0185 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37753367 chr10:38451030~38451785:+ LIHC cis rs4218 0.597 rs10431762 ENSG00000277144.1 RP11-59H7.4 -3.94 1e-04 0.0185 -0.23 -0.21 Social communication problems; chr15:59066330 chr15:59115547~59116089:- LIHC cis rs2462686 1 rs788765 ENSG00000272556.1 RP11-638I8.1 3.94 1e-04 0.0185 0.32 0.21 Major depressive disorder; chr7:45957386 chr7:45814602~45815263:+ LIHC cis rs2880765 0.546 rs11637726 ENSG00000259630.2 CTD-2262B20.1 3.94 1e-04 0.0185 0.3 0.21 Coronary artery disease; chr15:85516040 chr15:85415228~85415633:+ LIHC cis rs1062177 0.855 rs62395861 ENSG00000253921.1 CTB-113P19.3 -3.94 1e-04 0.0185 -0.24 -0.21 Preschool internalizing problems; chr5:151889709 chr5:151753992~151767247:+ LIHC cis rs17772222 0.917 rs2145120 ENSG00000258789.1 RP11-507K2.3 -3.94 1e-04 0.0185 -0.25 -0.21 Coronary artery calcification; chr14:88777699 chr14:88551597~88552493:+ LIHC cis rs6471393 0.964 rs7001808 ENSG00000253848.1 RP11-10N23.5 3.94 1e-04 0.0185 0.23 0.21 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93725043 chr8:93741193~93744534:+ LIHC cis rs4713118 0.539 rs510987 ENSG00000216901.1 AL022393.7 3.94 0.000101 0.0185 0.27 0.21 Parkinson's disease; chr6:27879739 chr6:28176188~28176674:+ LIHC cis rs7722022 0.961 rs11746603 ENSG00000253428.1 CTB-43E15.2 3.94 0.000101 0.0185 0.22 0.21 Adiponectin levels; chr5:173523441 chr5:173689459~173705849:+ LIHC cis rs6745190 0.862 rs10187842 ENSG00000236153.1 AC104076.3 3.94 0.000101 0.0185 0.28 0.21 White blood cell count; chr2:181034788 chr2:180979427~180980090:- LIHC cis rs7044106 0.762 rs966396 ENSG00000238181.2 AHCYP2 -3.94 0.000101 0.0185 -0.24 -0.21 Hip circumference adjusted for BMI; chr9:120691003 chr9:120720673~120721972:+ LIHC cis rs875971 1 rs3735148 ENSG00000237310.1 GS1-124K5.4 3.94 0.000101 0.0185 0.18 0.21 Aortic root size; chr7:66506022 chr7:66493706~66495474:+ LIHC cis rs12681366 0.881 rs12674614 ENSG00000253704.1 RP11-267M23.4 3.94 0.000101 0.0185 0.24 0.21 Nonsyndromic cleft lip with cleft palate; chr8:94396605 chr8:94553722~94569745:+ LIHC cis rs12681366 0.881 rs2931631 ENSG00000253704.1 RP11-267M23.4 3.94 0.000101 0.0185 0.24 0.21 Nonsyndromic cleft lip with cleft palate; chr8:94401415 chr8:94553722~94569745:+ LIHC cis rs12681287 0.64 rs8635 ENSG00000254088.1 SLC2A3P4 3.94 0.000101 0.0185 0.24 0.21 Caudate activity during reward; chr8:86467581 chr8:86503591~86505061:+ LIHC cis rs12908161 0.959 rs61074241 ENSG00000259728.4 LINC00933 3.94 0.000101 0.0185 0.31 0.21 Schizophrenia; chr15:84790165 chr15:84570649~84580175:+ LIHC cis rs57502260 0.704 rs2186937 ENSG00000212093.1 AP000807.1 3.94 0.000101 0.0186 0.27 0.21 Total body bone mineral density (age 45-60); chr11:68489379 chr11:68506083~68506166:- LIHC cis rs1075265 0.68 rs6715488 ENSG00000272156.1 RP11-477N3.1 -3.94 0.000101 0.0186 -0.24 -0.21 Chronotype;Morning vs. evening chronotype; chr2:54004130 chr2:54082554~54085066:+ LIHC cis rs3204270 0.759 rs8066217 ENSG00000281517.1 Metazoa_SRP -3.94 0.000101 0.0186 -0.39 -0.21 Dental caries; chr17:81705585 chr17:81718849~81719095:- LIHC cis rs9595908 0.609 rs733487 ENSG00000212293.1 SNORA16 3.94 0.000101 0.0186 0.24 0.21 Body mass index; chr13:32741068 chr13:32420390~32420516:- LIHC cis rs4787951 0.754 rs6498011 ENSG00000274092.1 CTD-3203P2.3 3.93 0.000101 0.0186 0.21 0.21 Eosinophil percentage of white cells; chr16:27320573 chr16:27313387~27314101:- LIHC cis rs11733284 1 rs13142905 ENSG00000259959.1 RP11-121C2.2 3.93 0.000101 0.0186 0.19 0.21 Gout;Renal underexcretion gout; chr4:48023281 chr4:47840122~47844339:- LIHC cis rs2581828 0.632 rs891369 ENSG00000242142.1 SERBP1P3 -3.93 0.000101 0.0186 -0.29 -0.21 Crohn's disease; chr3:53102535 chr3:53064283~53065091:- LIHC cis rs10129255 0.5 rs7157975 ENSG00000211972.2 IGHV3-66 3.93 0.000101 0.0186 0.16 0.21 Kawasaki disease; chr14:106804049 chr14:106675017~106675544:- LIHC cis rs12468226 0.935 rs113188021 ENSG00000226261.1 AC064836.3 3.93 0.000101 0.0186 0.34 0.21 Urate levels; chr2:202336237 chr2:202336024~202336727:- LIHC cis rs12468226 1 rs6731027 ENSG00000226261.1 AC064836.3 3.93 0.000101 0.0186 0.34 0.21 Urate levels; chr2:202337443 chr2:202336024~202336727:- LIHC cis rs875971 0.545 rs7783889 ENSG00000224316.1 RP11-479O9.2 3.93 0.000101 0.0186 0.2 0.21 Aortic root size; chr7:66283366 chr7:65773620~65802067:+ LIHC cis rs6496044 0.507 rs7175731 ENSG00000259630.2 CTD-2262B20.1 3.93 0.000101 0.0186 0.22 0.21 Interstitial lung disease; chr15:85611115 chr15:85415228~85415633:+ LIHC cis rs2919917 0.578 rs11783804 ENSG00000254352.1 RP11-578O24.2 3.93 0.000101 0.0186 0.31 0.21 Lymphocyte counts; chr8:78652776 chr8:78723796~78724136:- LIHC cis rs17376456 0.825 rs36042718 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000101 0.0186 -0.44 -0.21 Diabetic retinopathy; chr5:93845291 chr5:93860669~93863825:- LIHC cis rs17376456 0.757 rs10066431 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000101 0.0186 -0.44 -0.21 Diabetic retinopathy; chr5:93862498 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs6877030 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000101 0.0186 -0.44 -0.21 Diabetic retinopathy; chr5:93866135 chr5:93860669~93863825:- LIHC cis rs17376456 0.757 rs6859757 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000101 0.0186 -0.44 -0.21 Diabetic retinopathy; chr5:93870336 chr5:93860669~93863825:- LIHC cis rs5770917 1 rs5770917 ENSG00000273272.1 CTA-384D8.34 3.93 0.000101 0.0186 0.3 0.21 Narcolepsy; chr22:50578924 chr22:50542650~50543011:+ LIHC cis rs875971 0.545 rs1547529 ENSG00000273024.4 INTS4P2 -3.93 0.000101 0.0186 -0.24 -0.21 Aortic root size; chr7:66258859 chr7:65647864~65715661:+ LIHC cis rs9450351 0.744 rs9444353 ENSG00000203875.9 SNHG5 -3.93 0.000101 0.0186 -0.44 -0.21 Interferon gamma-induced protein 10 levels; chr6:85566986 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs9351063 ENSG00000203875.9 SNHG5 -3.93 0.000101 0.0186 -0.44 -0.21 Interferon gamma-induced protein 10 levels; chr6:85567123 chr6:85660950~85678736:- LIHC cis rs2072510 0.966 rs11108372 ENSG00000257878.1 RP11-256L6.3 -3.93 0.000101 0.0186 -0.19 -0.21 Metabolite levels (small molecules and protein measures); chr12:96000739 chr12:95996521~96011489:+ LIHC cis rs801193 0.844 rs732465 ENSG00000273024.4 INTS4P2 -3.93 0.000101 0.0186 -0.22 -0.21 Aortic root size; chr7:66533463 chr7:65647864~65715661:+ LIHC cis rs7915414 0.951 rs66883721 ENSG00000230338.1 MTND4P19 3.93 0.000101 0.0186 0.21 0.21 Clopidogrel active metabolite levels; chr10:94842037 chr10:94774156~94774633:- LIHC cis rs1405130 0.869 rs11687004 ENSG00000224287.2 MSL3P1 3.93 0.000101 0.0186 0.25 0.21 Coronary artery disease; chr2:234657499 chr2:233865437~233868444:- LIHC cis rs7044106 0.762 rs1867254 ENSG00000238181.2 AHCYP2 -3.93 0.000101 0.0186 -0.24 -0.21 Hip circumference adjusted for BMI; chr9:120666800 chr9:120720673~120721972:+ LIHC cis rs8060598 0.745 rs8045009 ENSG00000275155.1 CTD-2595P9.4 -3.93 0.000101 0.0186 -0.25 -0.21 Leprosy; chr16:50702030 chr16:49847018~49847632:- LIHC cis rs2390582 0.563 rs12405570 ENSG00000231613.1 RP5-943J3.1 3.93 0.000101 0.0186 0.43 0.21 Coronary artery calcification; chr1:90246813 chr1:89788914~89790492:+ LIHC cis rs2390582 0.563 rs35814759 ENSG00000231613.1 RP5-943J3.1 3.93 0.000101 0.0186 0.43 0.21 Coronary artery calcification; chr1:90247471 chr1:89788914~89790492:+ LIHC cis rs9890032 0.57 rs8068504 ENSG00000266490.1 CTD-2349P21.9 3.93 0.000101 0.0186 0.2 0.21 Hip circumference adjusted for BMI; chr17:30785052 chr17:30792372~30792833:+ LIHC cis rs8077577 0.747 rs62072540 ENSG00000260647.1 RP1-178F10.1 3.93 0.000101 0.0186 0.26 0.21 Obesity-related traits; chr17:18321914 chr17:18268080~18268828:+ LIHC cis rs9400467 0.528 rs240954 ENSG00000271789.1 RP5-1112D6.7 -3.93 0.000101 0.0186 -0.2 -0.21 Amino acid levels;Blood metabolite levels; chr6:111338619 chr6:111297126~111298510:+ LIHC cis rs62184315 0.638 rs12475694 ENSG00000273240.1 RP11-455J20.3 3.93 0.000101 0.0186 0.24 0.21 Alcohol dependence (age at onset); chr2:189907882 chr2:189763859~189764456:- LIHC cis rs12468226 0.938 rs116601501 ENSG00000226261.1 AC064836.3 3.93 0.000101 0.0186 0.34 0.21 Urate levels; chr2:202274567 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs76658848 ENSG00000226261.1 AC064836.3 3.93 0.000101 0.0186 0.34 0.21 Urate levels; chr2:202275548 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs74454549 ENSG00000226261.1 AC064836.3 3.93 0.000101 0.0186 0.34 0.21 Urate levels; chr2:202288044 chr2:202336024~202336727:- LIHC cis rs3204270 0.714 rs7503307 ENSG00000281517.1 Metazoa_SRP -3.93 0.000101 0.0187 -0.39 -0.21 Dental caries; chr17:81707899 chr17:81718849~81719095:- LIHC cis rs7115242 0.858 rs6589592 ENSG00000280143.1 AP000892.6 3.93 0.000101 0.0187 0.32 0.21 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117087191 chr11:117204967~117210292:+ LIHC cis rs42490 1 rs405734 ENSG00000251136.7 RP11-37B2.1 -3.93 0.000101 0.0187 -0.18 -0.21 Leprosy; chr8:89756211 chr8:89609409~89757727:- LIHC cis rs10883723 0.81 rs7072351 ENSG00000236937.2 PTGES3P4 -3.93 0.000101 0.0187 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102505290 chr10:102845595~102845950:+ LIHC cis rs11977715 0.538 rs43067 ENSG00000233942.1 AC004012.1 -3.93 0.000101 0.0187 -0.3 -0.21 Middle childhood and early adolescence aggressive behavior; chr7:95485392 chr7:95471835~95473998:+ LIHC cis rs9400467 0.528 rs462432 ENSG00000271789.1 RP5-1112D6.7 -3.93 0.000101 0.0187 -0.2 -0.21 Amino acid levels;Blood metabolite levels; chr6:111338552 chr6:111297126~111298510:+ LIHC cis rs7760535 0.931 rs466923 ENSG00000271789.1 RP5-1112D6.7 -3.93 0.000101 0.0187 -0.2 -0.21 Metabolic traits; chr6:111341774 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs1623806 ENSG00000271789.1 RP5-1112D6.7 -3.93 0.000101 0.0187 -0.2 -0.21 Amino acid levels;Blood metabolite levels; chr6:111343868 chr6:111297126~111298510:+ LIHC cis rs1802575 0.675 rs10167227 ENSG00000272606.1 RP11-554J4.1 3.93 0.000101 0.0187 0.39 0.21 Childhood ear infection; chr2:55777646 chr2:55617909~55618373:+ LIHC cis rs710913 0.745 rs1180334 ENSG00000182109.6 RP11-69E11.4 -3.93 0.000101 0.0187 -0.21 -0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39555972 chr1:39522280~39546187:- LIHC cis rs2439831 1 rs7173487 ENSG00000275601.1 AC011330.13 -3.93 0.000101 0.0187 -0.3 -0.21 Lung cancer in ever smokers; chr15:43458041 chr15:43642389~43643023:- LIHC cis rs12468226 0.873 rs60722019 ENSG00000226261.1 AC064836.3 3.93 0.000102 0.0187 0.34 0.21 Urate levels; chr2:202282060 chr2:202336024~202336727:- LIHC cis rs7893279 0.505 rs12772009 ENSG00000225527.1 RP11-383B4.4 3.93 0.000102 0.0187 0.3 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18607599 chr10:18531849~18533336:- LIHC cis rs847851 0.798 rs10947536 ENSG00000276712.1 MIR7111 3.93 0.000102 0.0187 0.21 0.21 Colonoscopy-negative controls vs population controls; chr6:35008216 chr6:35470508~35470579:+ LIHC cis rs16958440 0.581 rs56395942 ENSG00000267724.1 RP11-49K24.8 3.93 0.000102 0.0187 0.28 0.21 Sitting height ratio; chr18:47145928 chr18:47105946~47108062:+ LIHC cis rs12586317 0.534 rs1568200 ENSG00000258738.1 RP11-73E17.2 3.93 0.000102 0.0187 0.28 0.21 Psoriasis; chr14:34950386 chr14:34874343~34876459:+ LIHC cis rs295490 0.667 rs78259171 ENSG00000272656.1 RP11-219D15.3 3.93 0.000102 0.0187 0.6 0.21 PR interval in Tripanosoma cruzi seropositivity; chr3:139323866 chr3:139349024~139349371:- LIHC cis rs812925 0.784 rs6735081 ENSG00000212978.6 AC016747.3 3.93 0.000102 0.0187 0.24 0.21 Immature fraction of reticulocytes; chr2:61233582 chr2:61141592~61144969:- LIHC cis rs2562456 0.755 rs1879234 ENSG00000268555.1 RP11-678G14.3 -3.93 0.000102 0.0187 -0.26 -0.21 Pain; chr19:21521677 chr19:21570822~21587322:- LIHC cis rs875971 0.964 rs6978429 ENSG00000237310.1 GS1-124K5.4 3.93 0.000102 0.0187 0.18 0.21 Aortic root size; chr7:66494889 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs4718357 ENSG00000237310.1 GS1-124K5.4 3.93 0.000102 0.0187 0.18 0.21 Aortic root size; chr7:66495891 chr7:66493706~66495474:+ LIHC cis rs875971 0.929 rs12535036 ENSG00000237310.1 GS1-124K5.4 3.93 0.000102 0.0187 0.18 0.21 Aortic root size; chr7:66499076 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs12532998 ENSG00000237310.1 GS1-124K5.4 3.93 0.000102 0.0187 0.18 0.21 Aortic root size; chr7:66502472 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs6970030 ENSG00000237310.1 GS1-124K5.4 3.93 0.000102 0.0187 0.18 0.21 Aortic root size; chr7:66503692 chr7:66493706~66495474:+ LIHC cis rs875971 0.928 rs6970357 ENSG00000237310.1 GS1-124K5.4 3.93 0.000102 0.0187 0.18 0.21 Aortic root size; chr7:66503891 chr7:66493706~66495474:+ LIHC cis rs9635231 1 rs9635231 ENSG00000258413.1 RP11-665C16.6 3.93 0.000102 0.0187 0.23 0.21 Pediatric bone mineral density (femoral neck); chr14:55420985 chr14:55262767~55272075:- LIHC cis rs340849 0.844 rs340864 ENSG00000274895.1 RP11-478J18.2 -3.93 0.000102 0.0187 -0.21 -0.21 Alzheimer's disease; chr1:213958028 chr1:213983793~213986419:- LIHC cis rs35099186 0.583 rs12280645 ENSG00000255062.1 RP11-712L6.5 -3.93 0.000102 0.0187 -0.25 -0.21 Coronary artery disease; chr11:126393990 chr11:126294298~126304318:- LIHC cis rs2243480 1 rs160652 ENSG00000230295.1 RP11-458F8.2 -3.93 0.000102 0.0187 -0.22 -0.21 Diabetic kidney disease; chr7:66073444 chr7:66880708~66882981:+ LIHC cis rs673078 0.66 rs17512407 ENSG00000275759.1 RP11-131L12.3 -3.93 0.000102 0.0187 -0.45 -0.21 Glucose homeostasis traits; chr12:118292705 chr12:118428281~118428870:+ LIHC cis rs11096990 0.656 rs7693837 ENSG00000249207.1 RP11-360F5.1 -3.93 0.000102 0.0187 -0.21 -0.21 Cognitive function; chr4:39301481 chr4:39112677~39126818:- LIHC cis rs160451 0.934 rs160453 ENSG00000251136.7 RP11-37B2.1 3.93 0.000102 0.0187 0.19 0.21 Leprosy; chr8:89652326 chr8:89609409~89757727:- LIHC cis rs6452524 1 rs1382368 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83155256 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs1382366 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83156352 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs1382364 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83156677 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs1382363 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83156753 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs11741897 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83157246 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs13358361 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83160237 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs10076000 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83161629 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs6452528 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83162560 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs6864479 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83166421 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs13436667 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83168948 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs7726564 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83170274 chr5:83049376~83050964:- LIHC cis rs2299116 0.962 rs11514759 ENSG00000225264.3 ZNRF2P2 -3.93 0.000102 0.0187 -0.24 -0.21 Serum thyroid-stimulating hormone levels; chr7:28784678 chr7:29598795~29685255:- LIHC cis rs6452524 1 rs10076271 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83133875 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs10076274 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83133908 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs10061521 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83133936 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs7733151 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83134655 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs7733330 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83134774 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs7733354 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83134859 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs4634330 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83134963 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs2386238 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83135266 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs2386239 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83135339 chr5:83049376~83050964:- LIHC cis rs6452524 0.934 rs7700253 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83135510 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs10067439 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83136274 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs7710900 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0187 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83137201 chr5:83049376~83050964:- LIHC cis rs7607369 0.679 rs6751527 ENSG00000272555.1 RP11-459I19.1 3.93 0.000102 0.0187 0.24 0.21 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218766242 chr2:218818690~218819144:+ LIHC cis rs2842992 0.672 rs7738253 ENSG00000237927.1 RP3-393E18.2 -3.93 0.000102 0.0187 -0.26 -0.21 Age-related macular degeneration (geographic atrophy); chr6:159772885 chr6:159586955~159589169:- LIHC cis rs7712401 0.58 rs10066632 ENSG00000263432.2 RN7SL689P 3.93 0.000102 0.0187 0.32 0.21 Mean platelet volume; chr5:123028988 chr5:123022487~123022783:- LIHC cis rs7712401 0.58 rs10076327 ENSG00000263432.2 RN7SL689P 3.93 0.000102 0.0187 0.32 0.21 Mean platelet volume; chr5:123031652 chr5:123022487~123022783:- LIHC cis rs12586317 0.534 rs2273157 ENSG00000258738.1 RP11-73E17.2 3.93 0.000102 0.0188 0.27 0.21 Psoriasis; chr14:34969630 chr14:34874343~34876459:+ LIHC cis rs742731 0.553 rs34913842 ENSG00000179935.8 LINC00652 -3.93 0.000102 0.0188 -0.22 -0.21 Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction); chr20:18899482 chr20:18786065~18794335:- LIHC cis rs6142102 0.625 rs4911384 ENSG00000275784.1 RP5-1125A11.6 -3.93 0.000102 0.0188 -0.22 -0.21 Skin pigmentation; chr20:33968001 chr20:33989480~33991818:- LIHC cis rs6442522 0.568 rs3773461 ENSG00000249786.6 EAF1-AS1 3.93 0.000102 0.0188 0.25 0.21 Uric acid levels; chr3:15453151 chr3:15436171~15455940:- LIHC cis rs7208859 0.673 rs75142521 ENSG00000266490.1 CTD-2349P21.9 3.93 0.000102 0.0188 0.26 0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913519 chr17:30792372~30792833:+ LIHC cis rs794185 0.714 rs711633 ENSG00000231249.1 ITPR1-AS1 3.93 0.000102 0.0188 0.23 0.21 Multiple sclerosis--Brain Glutamate Levels; chr3:4449577 chr3:4490891~4493163:- LIHC cis rs5742933 0.779 rs1899025 ENSG00000253559.1 OSGEPL1-AS1 3.93 0.000102 0.0188 0.27 0.21 Ferritin levels; chr2:189784856 chr2:189762704~189765556:+ LIHC cis rs2243480 1 rs316318 ENSG00000232546.1 RP11-458F8.1 -3.93 0.000102 0.0188 -0.23 -0.21 Diabetic kidney disease; chr7:66147917 chr7:66848496~66858136:+ LIHC cis rs2032447 0.901 rs2213284 ENSG00000242387.1 HIST1H2APS2 3.93 0.000102 0.0188 0.27 0.21 Intelligence (multi-trait analysis); chr6:26031640 chr6:25882026~25882395:- LIHC cis rs1799949 1 rs8176202 ENSG00000267681.1 CTD-3199J23.6 -3.93 0.000102 0.0188 -0.2 -0.21 Menopause (age at onset); chr17:43078211 chr17:43144956~43145255:+ LIHC cis rs6452524 0.618 rs1478487 ENSG00000271862.1 RP11-343L5.2 3.93 0.000102 0.0188 0.25 0.21 Hypertension (SNP x SNP interaction); chr5:83080900 chr5:83049376~83050964:- LIHC cis rs5742933 0.817 rs1233265 ENSG00000253559.1 OSGEPL1-AS1 -3.93 0.000103 0.0188 -0.27 -0.21 Ferritin levels; chr2:189796390 chr2:189762704~189765556:+ LIHC cis rs9876781 1 rs2362452 ENSG00000229759.1 MRPS18AP1 -3.93 0.000103 0.0188 -0.22 -0.21 Longevity; chr3:48376724 chr3:48256350~48256938:- LIHC cis rs4718428 0.96 rs6460317 ENSG00000273142.1 RP11-458F8.4 -3.93 0.000103 0.0188 -0.21 -0.21 Corneal structure; chr7:66925268 chr7:66902857~66906297:+ LIHC cis rs7945705 0.776 rs11042069 ENSG00000254860.4 TMEM9B-AS1 -3.93 0.000103 0.0189 -0.21 -0.21 Hemoglobin concentration; chr11:8795768 chr11:8964675~8977527:+ LIHC cis rs867371 0.502 rs1846908 ENSG00000259429.4 UBE2Q2P2 -3.93 0.000103 0.0189 -0.22 -0.21 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82230185 chr15:82355142~82420075:+ LIHC cis rs2665103 0.655 rs1501367 ENSG00000259429.4 UBE2Q2P2 -3.93 0.000103 0.0189 -0.22 -0.21 Intelligence (multi-trait analysis); chr15:82230475 chr15:82355142~82420075:+ LIHC cis rs9640161 0.789 rs1464752 ENSG00000261305.1 RP4-584D14.7 3.93 0.000103 0.0189 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150324195 chr7:150341771~150342607:+ LIHC cis rs9640161 0.789 rs1464753 ENSG00000261305.1 RP4-584D14.7 3.93 0.000103 0.0189 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150324261 chr7:150341771~150342607:+ LIHC cis rs9640161 0.75 rs1983440 ENSG00000261305.1 RP4-584D14.7 3.93 0.000103 0.0189 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150326852 chr7:150341771~150342607:+ LIHC cis rs9952991 0.941 rs34920518 ENSG00000260302.1 RP11-973H7.1 3.93 0.000103 0.0189 0.31 0.21 Inflammatory skin disease; chr18:12783087 chr18:12774651~12775923:- LIHC cis rs2018683 0.649 rs221193 ENSG00000272568.4 CTB-113D17.1 3.93 0.000103 0.0189 0.26 0.21 Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer; chr7:28976168 chr7:28979967~29013367:+ LIHC cis rs12209785 0.774 rs6458446 ENSG00000231769.2 RP1-8B1.4 3.93 0.000103 0.0189 0.3 0.21 Survival in pancreatic cancer; chr6:45532733 chr6:46097093~46129706:- LIHC cis rs6832769 1 rs1522108 ENSG00000272969.1 RP11-528I4.2 3.93 0.000103 0.0189 0.25 0.21 Personality dimensions; chr4:55514566 chr4:55547112~55547889:+ LIHC cis rs10129255 0.957 rs8014696 ENSG00000224373.3 IGHV4-59 -3.93 0.000103 0.0189 -0.17 -0.21 Kawasaki disease; chr14:106769752 chr14:106627249~106627825:- LIHC cis rs3733589 1 rs16891489 ENSG00000250413.1 RP11-448G15.1 3.93 0.000103 0.0189 0.34 0.21 Renal overload gout; chr4:9965690 chr4:10006482~10009725:+ LIHC cis rs2806356 1 rs2798641 ENSG00000203801.7 LINC00222 3.93 0.000103 0.0189 0.27 0.21 Chronic obstructive pulmonary disease; chr6:108946847 chr6:108751654~108769942:+ LIHC cis rs6723108 0.517 rs1530557 ENSG00000224043.6 CCNT2-AS1 3.93 0.000103 0.0189 0.24 0.21 Type 2 diabetes; chr2:134849309 chr2:134735464~134918710:- LIHC cis rs755249 0.53 rs66848709 ENSG00000182109.6 RP11-69E11.4 3.93 0.000103 0.0189 0.26 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39146885 chr1:39522280~39546187:- LIHC cis rs72675573 0.852 rs72675531 ENSG00000235612.1 RP1-158P9.1 -3.93 0.000103 0.0189 -0.28 -0.21 Monocyte count; chr1:56111740 chr1:56145721~56155224:+ LIHC cis rs6456156 0.792 rs7775443 ENSG00000227598.1 RP1-167A14.2 3.93 0.000103 0.0189 0.21 0.21 Primary biliary cholangitis; chr6:167099764 chr6:166969626~166999065:- LIHC cis rs1023500 0.573 rs2269524 ENSG00000205702.9 CYP2D7 -3.93 0.000103 0.0189 -0.23 -0.21 Schizophrenia; chr22:42079699 chr22:42140203~42144577:- LIHC cis rs2243480 1 rs316307 ENSG00000232546.1 RP11-458F8.1 -3.93 0.000103 0.0189 -0.23 -0.21 Diabetic kidney disease; chr7:66105184 chr7:66848496~66858136:+ LIHC cis rs7789940 0.817 rs6946310 ENSG00000205485.12 AC004980.7 -3.93 0.000103 0.0189 -0.21 -0.21 Multiple sclerosis; chr7:76306782 chr7:76549360~76627982:+ LIHC cis rs7129556 0.69 rs687037 ENSG00000254459.1 RP11-91P24.7 3.93 0.000103 0.0189 0.35 0.21 Weight loss (gastric bypass surgery); chr11:77885058 chr11:77829654~77872262:- LIHC cis rs9595908 0.709 rs9285093 ENSG00000212293.1 SNORA16 3.93 0.000103 0.0189 0.24 0.21 Body mass index; chr13:32745500 chr13:32420390~32420516:- LIHC cis rs17376456 0.825 rs35496867 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93884694 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs12153021 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93738207 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs13165400 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93755721 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs13182631 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93779995 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs10038828 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93788350 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs10038831 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93788409 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs17372615 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93789062 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs17372649 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93790390 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs17372725 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93799882 chr5:93860669~93863825:- LIHC cis rs17376456 0.757 rs1031424 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93804000 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs28418572 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93808455 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs13357713 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93809717 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs13164315 ENSG00000251023.1 RP11-549J18.1 -3.93 0.000103 0.0189 -0.44 -0.21 Diabetic retinopathy; chr5:93811715 chr5:93860669~93863825:- LIHC cis rs4443100 0.67 rs9608071 ENSG00000234353.2 AP000347.4 -3.93 0.000103 0.0189 -0.24 -0.21 Serum parathyroid hormone levels; chr22:23065939 chr22:23638492~23640762:- LIHC cis rs172166 0.694 rs2791332 ENSG00000219392.1 RP1-265C24.5 -3.93 0.000103 0.0189 -0.28 -0.21 Cardiac Troponin-T levels; chr6:28141010 chr6:28115628~28116551:+ LIHC cis rs2243480 0.908 rs313822 ENSG00000228409.4 CCT6P1 3.93 0.000103 0.0189 0.22 0.21 Diabetic kidney disease; chr7:66108952 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs313820 ENSG00000228409.4 CCT6P1 3.93 0.000103 0.0189 0.22 0.21 Diabetic kidney disease; chr7:66109479 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs313824 ENSG00000228409.4 CCT6P1 3.93 0.000103 0.0189 0.22 0.21 Diabetic kidney disease; chr7:66116220 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs186378 ENSG00000228409.4 CCT6P1 3.93 0.000103 0.0189 0.22 0.21 Diabetic kidney disease; chr7:66117071 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs160637 ENSG00000228409.4 CCT6P1 3.93 0.000103 0.0189 0.22 0.21 Diabetic kidney disease; chr7:66119331 chr7:65751142~65763354:+ LIHC cis rs673078 0.66 rs117091919 ENSG00000275759.1 RP11-131L12.3 -3.93 0.000103 0.0189 -0.46 -0.21 Glucose homeostasis traits; chr12:118273228 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs7314987 ENSG00000275759.1 RP11-131L12.3 -3.93 0.000103 0.0189 -0.46 -0.21 Glucose homeostasis traits; chr12:118274072 chr12:118428281~118428870:+ LIHC cis rs6723108 0.604 rs2322251 ENSG00000224043.6 CCNT2-AS1 -3.93 0.000103 0.019 -0.29 -0.21 Type 2 diabetes; chr2:134913732 chr2:134735464~134918710:- LIHC cis rs6723108 0.603 rs62168891 ENSG00000224043.6 CCNT2-AS1 -3.93 0.000103 0.019 -0.29 -0.21 Type 2 diabetes; chr2:134914617 chr2:134735464~134918710:- LIHC cis rs2070488 0.965 rs9877282 ENSG00000229589.1 ACVR2B-AS1 -3.93 0.000103 0.019 -0.23 -0.21 Electrocardiographic conduction measures; chr3:38499961 chr3:38451027~38454820:- LIHC cis rs9595908 0.792 rs61947055 ENSG00000212293.1 SNORA16 3.93 0.000103 0.019 0.24 0.21 Body mass index; chr13:32614414 chr13:32420390~32420516:- LIHC cis rs2838568 0.967 rs2838571 ENSG00000277352.1 KB-68A7.2 -3.93 0.000103 0.019 -0.24 -0.21 Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals; chr21:44478486 chr21:44494874~44495519:+ LIHC cis rs7809950 0.678 rs13230144 ENSG00000238832.1 snoU109 -3.93 0.000103 0.019 -0.27 -0.21 Coronary artery disease; chr7:107268727 chr7:107603363~107603507:+ LIHC cis rs6142102 0.602 rs2268086 ENSG00000275784.1 RP5-1125A11.6 3.93 0.000103 0.019 0.22 0.21 Skin pigmentation; chr20:34060932 chr20:33989480~33991818:- LIHC cis rs7722022 0.961 rs11748850 ENSG00000253428.1 CTB-43E15.2 3.93 0.000103 0.019 0.22 0.21 Adiponectin levels; chr5:173521018 chr5:173689459~173705849:+ LIHC cis rs2015599 0.623 rs2288128 ENSG00000257176.2 RP11-996F15.2 3.93 0.000104 0.019 0.26 0.21 Platelet count;Mean platelet volume; chr12:29316054 chr12:29280418~29317848:- LIHC cis rs2015599 0.584 rs2288129 ENSG00000257176.2 RP11-996F15.2 3.93 0.000104 0.019 0.26 0.21 Platelet count;Mean platelet volume; chr12:29316355 chr12:29280418~29317848:- LIHC cis rs11096990 0.593 rs6531700 ENSG00000249685.1 RP11-360F5.3 -3.93 0.000104 0.019 -0.25 -0.21 Cognitive function; chr4:39269265 chr4:39133913~39135608:+ LIHC cis rs6600671 1 rs2319969 ENSG00000227082.1 CH17-437K3.1 -3.93 0.000104 0.019 -0.28 -0.21 Hip geometry; chr1:121465481 chr1:121396754~121463129:+ LIHC cis rs8177253 0.763 rs8177224 ENSG00000244062.1 RP11-404G16.2 -3.93 0.000104 0.019 -0.21 -0.21 Iron status biomarkers; chr3:133755159 chr3:133760300~133762363:+ LIHC cis rs7674212 0.581 rs13150953 ENSG00000248971.2 KRT8P46 -3.93 0.000104 0.019 -0.22 -0.21 Type 2 diabetes; chr4:103021341 chr4:102728746~102730171:- LIHC cis rs7674212 0.556 rs13151569 ENSG00000248971.2 KRT8P46 -3.93 0.000104 0.019 -0.22 -0.21 Type 2 diabetes; chr4:103021633 chr4:102728746~102730171:- LIHC cis rs4578769 0.569 rs12955131 ENSG00000266850.1 RP11-370A5.1 -3.93 0.000104 0.019 -0.23 -0.21 Eosinophil percentage of white cells; chr18:22900424 chr18:22723491~22907721:- LIHC cis rs755249 0.727 rs2242500 ENSG00000182109.6 RP11-69E11.4 3.93 0.000104 0.019 0.22 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39572230 chr1:39522280~39546187:- LIHC cis rs755249 0.727 rs16826349 ENSG00000182109.6 RP11-69E11.4 3.93 0.000104 0.019 0.22 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39573264 chr1:39522280~39546187:- LIHC cis rs7617773 0.78 rs11706277 ENSG00000228638.1 FCF1P2 -3.93 0.000104 0.019 -0.24 -0.21 Coronary artery disease; chr3:48318943 chr3:48290793~48291375:- LIHC cis rs7131987 0.874 rs10843366 ENSG00000275476.1 RP11-996F15.4 -3.93 0.000104 0.019 -0.24 -0.21 QT interval; chr12:29254970 chr12:29277397~29277882:- LIHC cis rs7131987 0.845 rs2042511 ENSG00000275476.1 RP11-996F15.4 -3.93 0.000104 0.019 -0.24 -0.21 QT interval; chr12:29255847 chr12:29277397~29277882:- LIHC cis rs7131987 0.903 rs10843371 ENSG00000275476.1 RP11-996F15.4 -3.93 0.000104 0.019 -0.24 -0.21 QT interval; chr12:29261299 chr12:29277397~29277882:- LIHC cis rs11733284 1 rs13140968 ENSG00000259959.1 RP11-121C2.2 3.93 0.000104 0.019 0.19 0.21 Gout;Renal underexcretion gout; chr4:48023078 chr4:47840122~47844339:- LIHC cis rs12550612 0.83 rs10111172 ENSG00000253616.4 RP11-875O11.3 -3.93 0.000104 0.019 -0.24 -0.21 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23111578 chr8:23071377~23074488:- LIHC cis rs4427176 0.765 rs11249943 ENSG00000272267.2 RP11-375N15.2 3.93 0.000104 0.019 0.3 0.21 Mosquito bite size; chr8:9750353 chr8:9555144~9556520:- LIHC cis rs7119038 0.818 rs6589685 ENSG00000255422.1 AP002954.4 3.93 0.000104 0.019 0.26 0.21 Sjögren's syndrome; chr11:118741488 chr11:118704607~118750263:+ LIHC cis rs11096990 0.656 rs3796513 ENSG00000249207.1 RP11-360F5.1 3.93 0.000104 0.019 0.21 0.21 Cognitive function; chr4:39289462 chr4:39112677~39126818:- LIHC cis rs11096990 0.656 rs2123027 ENSG00000249207.1 RP11-360F5.1 3.93 0.000104 0.019 0.21 0.21 Cognitive function; chr4:39289493 chr4:39112677~39126818:- LIHC cis rs11096990 0.634 rs10029074 ENSG00000249207.1 RP11-360F5.1 3.93 0.000104 0.019 0.21 0.21 Cognitive function; chr4:39290882 chr4:39112677~39126818:- LIHC cis rs11096990 0.634 rs1564710 ENSG00000249207.1 RP11-360F5.1 3.93 0.000104 0.019 0.21 0.21 Cognitive function; chr4:39291178 chr4:39112677~39126818:- LIHC cis rs11096990 0.634 rs6815855 ENSG00000249207.1 RP11-360F5.1 3.93 0.000104 0.019 0.21 0.21 Cognitive function; chr4:39294926 chr4:39112677~39126818:- LIHC cis rs7734985 0.598 rs7714279 ENSG00000250551.1 RP11-254I22.1 3.93 0.000104 0.019 0.23 0.21 IgG glycosylation; chr5:96191679 chr5:96050115~96215519:+ LIHC cis rs34375054 0.525 rs1080910 ENSG00000279233.1 RP11-158L12.4 3.93 0.000104 0.019 0.18 0.21 Post bronchodilator FEV1/FVC ratio; chr12:125123946 chr12:125138245~125141711:+ LIHC cis rs638893 0.636 rs61901411 ENSG00000255422.1 AP002954.4 3.93 0.000104 0.019 0.49 0.21 Vitiligo; chr11:118794615 chr11:118704607~118750263:+ LIHC cis rs757081 0.648 rs1488933 ENSG00000272034.1 SNORD14A -3.93 0.000104 0.019 -0.22 -0.21 Systolic blood pressure; chr11:17245482 chr11:17074654~17074744:- LIHC cis rs67311347 1 rs28491638 ENSG00000223797.4 ENTPD3-AS1 3.93 0.000104 0.0191 0.17 0.21 Renal cell carcinoma; chr3:40454772 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs28536038 ENSG00000223797.4 ENTPD3-AS1 3.93 0.000104 0.0191 0.17 0.21 Renal cell carcinoma; chr3:40454891 chr3:40313802~40453329:- LIHC cis rs67311347 0.955 rs2085114 ENSG00000223797.4 ENTPD3-AS1 3.93 0.000104 0.0191 0.17 0.21 Renal cell carcinoma; chr3:40455946 chr3:40313802~40453329:- LIHC cis rs2283792 0.691 rs11913721 ENSG00000224086.5 LL22NC03-86G7.1 -3.93 0.000104 0.0191 -0.21 -0.21 Multiple sclerosis; chr22:21855846 chr22:21938293~21977632:+ LIHC cis rs11098499 0.722 rs10025925 ENSG00000260091.1 RP11-33B1.4 -3.93 0.000104 0.0191 -0.14 -0.21 Corneal astigmatism; chr4:119350589 chr4:119409333~119410233:+ LIHC cis rs11098499 0.731 rs10015579 ENSG00000260091.1 RP11-33B1.4 -3.93 0.000104 0.0191 -0.14 -0.21 Corneal astigmatism; chr4:119350647 chr4:119409333~119410233:+ LIHC cis rs7412746 0.658 rs10305711 ENSG00000231073.1 RP11-316M1.3 3.93 0.000104 0.0191 0.21 0.21 Melanoma; chr1:150830520 chr1:150973123~150975534:+ LIHC cis rs7826238 0.539 rs2945891 ENSG00000173295.6 FAM86B3P 3.93 0.000104 0.0191 0.27 0.21 Systolic blood pressure; chr8:8297953 chr8:8228595~8244865:+ LIHC cis rs9640161 0.83 rs17173681 ENSG00000261305.1 RP4-584D14.7 -3.93 0.000104 0.0191 -0.25 -0.21 Blood protein levels;Circulating chemerin levels; chr7:150362325 chr7:150341771~150342607:+ LIHC cis rs7131987 0.903 rs2194518 ENSG00000275476.1 RP11-996F15.4 -3.93 0.000104 0.0191 -0.25 -0.21 QT interval; chr12:29266527 chr12:29277397~29277882:- LIHC cis rs794185 0.598 rs304087 ENSG00000231249.1 ITPR1-AS1 -3.93 0.000104 0.0191 -0.23 -0.21 Multiple sclerosis--Brain Glutamate Levels; chr3:4479955 chr3:4490891~4493163:- LIHC cis rs617219 0.889 rs1717560 ENSG00000251675.1 CTC-458I2.2 -3.93 0.000104 0.0191 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79142920 chr5:80128361~80143883:+ LIHC cis rs617219 0.889 rs1717565 ENSG00000251675.1 CTC-458I2.2 -3.93 0.000104 0.0191 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79144546 chr5:80128361~80143883:+ LIHC cis rs734999 0.588 rs78506337 ENSG00000225931.3 RP3-395M20.7 3.93 0.000104 0.0191 0.22 0.21 Ulcerative colitis; chr1:2605656 chr1:2566410~2569888:+ LIHC cis rs6504622 0.577 rs197915 ENSG00000263766.4 RP11-580I16.2 -3.93 0.000104 0.0191 -0.24 -0.21 Orofacial clefts; chr17:46913156 chr17:47603860~47649420:- LIHC cis rs875971 1 rs12698523 ENSG00000237310.1 GS1-124K5.4 3.93 0.000104 0.0191 0.18 0.21 Aortic root size; chr7:66503126 chr7:66493706~66495474:+ LIHC cis rs2933343 0.621 rs4927921 ENSG00000261159.1 RP11-723O4.9 -3.93 0.000104 0.0191 -0.26 -0.21 IgG glycosylation; chr3:128850025 chr3:128859716~128860526:- LIHC cis rs2283792 0.646 rs9610271 ENSG00000224086.5 LL22NC03-86G7.1 -3.93 0.000104 0.0191 -0.23 -0.21 Multiple sclerosis; chr22:21758238 chr22:21938293~21977632:+ LIHC cis rs3758785 0.737 rs3758786 ENSG00000255893.1 RP11-685N10.1 -3.93 0.000104 0.0191 -0.25 -0.21 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94399118 chr11:94472908~94473570:- LIHC cis rs7617773 0.743 rs71323397 ENSG00000228638.1 FCF1P2 -3.93 0.000104 0.0191 -0.24 -0.21 Coronary artery disease; chr3:48333384 chr3:48290793~48291375:- LIHC cis rs42490 1 rs40452 ENSG00000251136.7 RP11-37B2.1 -3.93 0.000104 0.0191 -0.18 -0.21 Leprosy; chr8:89765931 chr8:89609409~89757727:- LIHC cis rs42490 0.966 rs39503 ENSG00000251136.7 RP11-37B2.1 -3.93 0.000104 0.0191 -0.18 -0.21 Leprosy; chr8:89767579 chr8:89609409~89757727:- LIHC cis rs2070488 0.965 rs6796845 ENSG00000229589.1 ACVR2B-AS1 -3.93 0.000105 0.0191 -0.24 -0.21 Electrocardiographic conduction measures; chr3:38526280 chr3:38451027~38454820:- LIHC cis rs10883723 0.81 rs10748823 ENSG00000236937.2 PTGES3P4 -3.93 0.000105 0.0191 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102514708 chr10:102845595~102845950:+ LIHC cis rs12209785 0.681 rs6911664 ENSG00000231769.2 RP1-8B1.4 3.93 0.000105 0.0191 0.3 0.21 Survival in pancreatic cancer; chr6:45521193 chr6:46097093~46129706:- LIHC cis rs3845817 0.966 rs13028180 ENSG00000237979.1 AC007389.1 -3.93 0.000105 0.0191 -0.23 -0.21 Bipolar disorder; chr2:65536906 chr2:65500993~65502138:- LIHC cis rs7216064 0.636 rs4638 ENSG00000265055.1 AC145343.2 -3.93 0.000105 0.0191 -0.21 -0.21 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68043234 chr17:68096046~68101474:- LIHC cis rs7216064 0.601 rs35453056 ENSG00000265055.1 AC145343.2 -3.93 0.000105 0.0191 -0.21 -0.21 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68043552 chr17:68096046~68101474:- LIHC cis rs7216064 0.628 rs62084702 ENSG00000265055.1 AC145343.2 -3.93 0.000105 0.0191 -0.21 -0.21 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68047041 chr17:68096046~68101474:- LIHC cis rs7182948 1 rs8034473 ENSG00000259531.2 RP11-295H24.3 -3.93 0.000105 0.0192 -0.31 -0.21 Lung adenocarcinoma; chr15:49537443 chr15:49365124~49366685:- LIHC cis rs7182948 1 rs967892 ENSG00000259531.2 RP11-295H24.3 -3.93 0.000105 0.0192 -0.31 -0.21 Lung adenocarcinoma; chr15:49540056 chr15:49365124~49366685:- LIHC cis rs7182948 0.958 rs1848286 ENSG00000259531.2 RP11-295H24.3 -3.93 0.000105 0.0192 -0.31 -0.21 Lung adenocarcinoma; chr15:49545346 chr15:49365124~49366685:- LIHC cis rs7182948 1 rs11070705 ENSG00000259531.2 RP11-295H24.3 -3.93 0.000105 0.0192 -0.31 -0.21 Lung adenocarcinoma; chr15:49551454 chr15:49365124~49366685:- LIHC cis rs7182948 1 rs2413963 ENSG00000259531.2 RP11-295H24.3 -3.93 0.000105 0.0192 -0.31 -0.21 Lung adenocarcinoma; chr15:49555934 chr15:49365124~49366685:- LIHC cis rs7182948 1 rs1395900 ENSG00000259531.2 RP11-295H24.3 -3.93 0.000105 0.0192 -0.31 -0.21 Lung adenocarcinoma; chr15:49557400 chr15:49365124~49366685:- LIHC cis rs9976767 0.608 rs2277797 ENSG00000225218.1 AP001628.6 -3.93 0.000105 0.0192 -0.2 -0.21 Type 1 diabetes; chr21:42403801 chr21:42831040~42836477:- LIHC cis rs2439831 0.867 rs6493082 ENSG00000166763.7 STRCP1 3.93 0.000105 0.0192 0.29 0.21 Lung cancer in ever smokers; chr15:43342610 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs8041132 ENSG00000166763.7 STRCP1 3.93 0.000105 0.0192 0.29 0.21 Lung cancer in ever smokers; chr15:43342938 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs7170489 ENSG00000166763.7 STRCP1 3.93 0.000105 0.0192 0.29 0.21 Lung cancer in ever smokers; chr15:43344453 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs16957627 ENSG00000166763.7 STRCP1 3.93 0.000105 0.0192 0.29 0.21 Lung cancer in ever smokers; chr15:43350459 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs16957630 ENSG00000166763.7 STRCP1 3.93 0.000105 0.0192 0.29 0.21 Lung cancer in ever smokers; chr15:43350582 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs16957632 ENSG00000166763.7 STRCP1 3.93 0.000105 0.0192 0.29 0.21 Lung cancer in ever smokers; chr15:43350699 chr15:43699488~43718184:- LIHC cis rs2439831 0.717 rs7165471 ENSG00000166763.7 STRCP1 3.93 0.000105 0.0192 0.29 0.21 Lung cancer in ever smokers; chr15:43352590 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs6493085 ENSG00000166763.7 STRCP1 3.93 0.000105 0.0192 0.29 0.21 Lung cancer in ever smokers; chr15:43361984 chr15:43699488~43718184:- LIHC cis rs2348418 0.767 rs1478332 ENSG00000247934.4 RP11-967K21.1 -3.93 0.000105 0.0192 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28255432 chr12:28163298~28190738:- LIHC cis rs11098499 0.866 rs3756156 ENSG00000260091.1 RP11-33B1.4 -3.93 0.000105 0.0192 -0.15 -0.21 Corneal astigmatism; chr4:119603686 chr4:119409333~119410233:+ LIHC cis rs4903214 0.895 rs1548767 ENSG00000273565.1 CTD-3075F15.1 3.92 0.000105 0.0192 0.27 0.21 Inflammatory bowel disease; chr14:74228254 chr14:75176929~75177418:+ LIHC cis rs8077577 0.747 rs57697650 ENSG00000260647.1 RP1-178F10.1 3.92 0.000105 0.0192 0.26 0.21 Obesity-related traits; chr17:18321381 chr17:18268080~18268828:+ LIHC cis rs803903 0.57 rs12005639 ENSG00000230894.1 RP11-67K19.3 3.92 0.000105 0.0192 0.29 0.21 Breast cancer; chr9:116476477 chr9:116568449~116586328:+ LIHC cis rs11148252 0.846 rs7985262 ENSG00000278238.1 RP11-245D16.4 -3.92 0.000105 0.0192 -0.2 -0.21 Lewy body disease; chr13:52423026 chr13:52454775~52455331:- LIHC cis rs72634501 0.531 rs67758468 ENSG00000182109.6 RP11-69E11.4 3.92 0.000105 0.0192 0.24 0.21 HDL cholesterol; chr1:39156916 chr1:39522280~39546187:- LIHC cis rs12817211 0.502 rs12369049 ENSG00000272368.2 RP4-605O3.4 -3.92 0.000105 0.0192 -0.23 -0.21 Colorectal or endometrial cancer; chr12:50116679 chr12:50112197~50165618:+ LIHC cis rs7182948 1 rs967893 ENSG00000259531.2 RP11-295H24.3 -3.92 0.000105 0.0192 -0.31 -0.21 Lung adenocarcinoma; chr15:49540071 chr15:49365124~49366685:- LIHC cis rs763121 0.853 rs138702 ENSG00000273076.1 RP3-508I15.22 -3.92 0.000105 0.0192 -0.23 -0.21 Menopause (age at onset); chr22:38736596 chr22:38743495~38743910:+ LIHC cis rs3096299 0.606 rs8052103 ENSG00000274627.1 RP11-104N10.2 -3.92 0.000105 0.0192 -0.23 -0.21 Multiple myeloma (IgH translocation); chr16:89474835 chr16:89516797~89522217:+ LIHC cis rs11096990 0.634 rs10019594 ENSG00000249207.1 RP11-360F5.1 3.92 0.000105 0.0192 0.21 0.21 Cognitive function; chr4:39287127 chr4:39112677~39126818:- LIHC cis rs2599510 0.744 rs4952212 ENSG00000276334.1 AL133243.1 -3.92 0.000105 0.0192 -0.24 -0.21 Interleukin-18 levels; chr2:32393425 chr2:32521927~32523547:+ LIHC cis rs919433 0.817 rs10931780 ENSG00000231621.1 AC013264.2 3.92 0.000105 0.0192 0.19 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197310573 chr2:197197991~197199273:+ LIHC cis rs4561483 0.801 rs33660 ENSG00000261216.1 RP11-166B2.5 -3.92 0.000105 0.0192 -0.23 -0.21 Testicular germ cell tumor; chr16:11868001 chr16:11908208~11908916:+ LIHC cis rs2439831 0.867 rs4075674 ENSG00000166763.7 STRCP1 3.92 0.000105 0.0192 0.29 0.21 Lung cancer in ever smokers; chr15:43358032 chr15:43699488~43718184:- LIHC cis rs13242816 1 rs1049334 ENSG00000279086.1 RP11-667F14.1 -3.92 0.000105 0.0192 -0.35 -0.21 P wave duration; chr7:116560326 chr7:116209234~116211511:- LIHC cis rs4819852 0.958 rs9606203 ENSG00000215493.3 XXbac-B562F10.11 -3.92 0.000105 0.0192 -0.18 -0.21 Pulse pressure; chr22:19984595 chr22:20450122~20451824:+ LIHC cis rs6600671 1 rs6600671 ENSG00000227082.1 CH17-437K3.1 3.92 0.000105 0.0192 0.28 0.21 Hip geometry; chr1:121458637 chr1:121396754~121463129:+ LIHC cis rs17482078 0.959 rs35983588 ENSG00000248734.2 CTD-2260A17.1 3.92 0.000105 0.0192 0.29 0.21 Behcet's disease;Blood protein levels; chr5:96787726 chr5:96784777~96785999:+ LIHC cis rs17482078 0.959 rs13170045 ENSG00000248734.2 CTD-2260A17.1 3.92 0.000105 0.0192 0.29 0.21 Behcet's disease;Blood protein levels; chr5:96790082 chr5:96784777~96785999:+ LIHC cis rs17482078 0.959 rs2287987 ENSG00000248734.2 CTD-2260A17.1 3.92 0.000105 0.0192 0.29 0.21 Behcet's disease;Blood protein levels; chr5:96793832 chr5:96784777~96785999:+ LIHC cis rs17482078 0.959 rs13168673 ENSG00000248734.2 CTD-2260A17.1 3.92 0.000105 0.0192 0.29 0.21 Behcet's disease;Blood protein levels; chr5:96794486 chr5:96784777~96785999:+ LIHC cis rs17482078 0.959 rs13173167 ENSG00000248734.2 CTD-2260A17.1 3.92 0.000105 0.0192 0.29 0.21 Behcet's disease;Blood protein levels; chr5:96795780 chr5:96784777~96785999:+ LIHC cis rs2032366 1 rs1894095 ENSG00000267279.1 RP11-879F14.2 -3.92 0.000105 0.0193 -0.24 -0.21 Obesity-related traits; chr18:61605988 chr18:61585746~61606916:- LIHC cis rs4938303 0.549 rs12291024 ENSG00000254851.1 RP11-109L13.1 3.92 0.000105 0.0193 0.25 0.21 Triglycerides; chr11:116689951 chr11:117135528~117138582:+ LIHC cis rs4873772 0.735 rs16928696 ENSG00000253608.1 RP11-770E5.1 3.92 0.000105 0.0193 0.22 0.21 Lobe attachment (rater-scored or self-reported); chr8:47612438 chr8:48551567~48698510:+ LIHC cis rs1799949 0.965 rs11651623 ENSG00000267681.1 CTD-3199J23.6 -3.92 0.000105 0.0193 -0.2 -0.21 Menopause (age at onset); chr17:43177830 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs11657883 ENSG00000267681.1 CTD-3199J23.6 -3.92 0.000105 0.0193 -0.2 -0.21 Menopause (age at onset); chr17:43178007 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs11656945 ENSG00000267681.1 CTD-3199J23.6 -3.92 0.000105 0.0193 -0.2 -0.21 Menopause (age at onset); chr17:43178248 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs11658499 ENSG00000267681.1 CTD-3199J23.6 -3.92 0.000105 0.0193 -0.2 -0.21 Menopause (age at onset); chr17:43182732 chr17:43144956~43145255:+ LIHC cis rs1223397 0.651 rs2496142 ENSG00000215022.6 RP1-257A7.4 3.92 0.000105 0.0193 0.22 0.21 Blood pressure; chr6:13311562 chr6:13264861~13295586:- LIHC cis rs2976388 0.609 rs2585152 ENSG00000253196.1 RP11-706C16.7 3.92 0.000105 0.0193 0.2 0.21 Urinary tract infection frequency; chr8:142704796 chr8:142763116~142766427:+ LIHC cis rs6456156 0.846 rs7774396 ENSG00000227598.1 RP1-167A14.2 -3.92 0.000105 0.0193 -0.21 -0.21 Primary biliary cholangitis; chr6:167106298 chr6:166969626~166999065:- LIHC cis rs7131987 0.903 rs2194519 ENSG00000275476.1 RP11-996F15.4 3.92 0.000105 0.0193 0.24 0.21 QT interval; chr12:29270650 chr12:29277397~29277882:- LIHC cis rs6893782 1 rs274550 ENSG00000233006.5 AC034220.3 -3.92 0.000105 0.0193 -0.28 -0.21 Acylcarnitine levels; chr5:132393020 chr5:132311285~132369916:- LIHC cis rs6142102 0.625 rs2050208 ENSG00000275784.1 RP5-1125A11.6 -3.92 0.000105 0.0193 -0.22 -0.21 Skin pigmentation; chr20:33955767 chr20:33989480~33991818:- LIHC cis rs1930961 0.558 rs5996951 ENSG00000100058.11 CRYBB2P1 3.92 0.000105 0.0193 0.42 0.21 Bipolar disorder with mood-incongruent psychosis; chr22:25529032 chr22:25448105~25520854:+ LIHC cis rs9976767 0.646 rs876497 ENSG00000225218.1 AP001628.6 -3.92 0.000105 0.0193 -0.21 -0.21 Type 1 diabetes; chr21:42421796 chr21:42831040~42836477:- LIHC cis rs6557876 0.615 rs4872393 ENSG00000228451.3 SDAD1P1 -3.92 0.000105 0.0193 -0.24 -0.21 Systolic blood pressure; chr8:26060195 chr8:26379259~26382953:- LIHC cis rs2836974 0.583 rs2776306 ENSG00000255568.3 BRWD1-AS2 3.92 0.000105 0.0193 0.19 0.21 Cognitive function; chr21:39341828 chr21:39313935~39314962:+ LIHC cis rs2836974 0.545 rs3167757 ENSG00000255568.3 BRWD1-AS2 3.92 0.000105 0.0193 0.19 0.21 Cognitive function; chr21:39342552 chr21:39313935~39314962:+ LIHC cis rs17774123 0.851 rs78378006 ENSG00000257808.1 RP11-1136G11.8 3.92 0.000105 0.0193 0.39 0.21 Diastolic blood pressure; chr12:53894771 chr12:53159586~53161000:+ LIHC cis rs1023500 0.551 rs133379 ENSG00000205702.9 CYP2D7 3.92 0.000105 0.0193 0.24 0.21 Schizophrenia; chr22:42072531 chr22:42140203~42144577:- LIHC cis rs1816213 0.744 rs3821043 ENSG00000273466.1 RP11-548H3.1 -3.92 0.000105 0.0193 -0.33 -0.21 Diastolic blood pressure; chr2:218562768 chr2:218633256~218634014:- LIHC cis rs2439831 0.867 rs933941 ENSG00000166763.7 STRCP1 3.92 0.000105 0.0193 0.29 0.21 Lung cancer in ever smokers; chr15:43340028 chr15:43699488~43718184:- LIHC cis rs56046484 0.75 rs62022525 ENSG00000259630.2 CTD-2262B20.1 -3.92 0.000106 0.0193 -0.41 -0.21 Testicular germ cell tumor; chr15:84980447 chr15:85415228~85415633:+ LIHC cis rs56046484 0.62 rs34585903 ENSG00000259630.2 CTD-2262B20.1 -3.92 0.000106 0.0193 -0.41 -0.21 Testicular germ cell tumor; chr15:84984893 chr15:85415228~85415633:+ LIHC cis rs1577917 1 rs13217384 ENSG00000234155.1 RP11-30P6.6 3.92 0.000106 0.0193 0.28 0.21 Response to antipsychotic treatment; chr6:86010282 chr6:85387219~85390186:- LIHC cis rs61542988 0.57 rs62448268 ENSG00000226816.2 AC005082.12 -3.92 0.000106 0.0193 -0.28 -0.21 Fibrinogen levels; chr7:22789845 chr7:23206013~23208045:+ LIHC cis rs7726839 0.54 rs3762951 ENSG00000271781.1 CTD-2589H19.6 -3.92 0.000106 0.0193 -0.32 -0.21 Obesity-related traits; chr5:662498 chr5:675826~676616:+ LIHC cis rs673078 0.66 rs73205551 ENSG00000275759.1 RP11-131L12.3 -3.92 0.000106 0.0193 -0.25 -0.21 Glucose homeostasis traits; chr12:118330808 chr12:118428281~118428870:+ LIHC cis rs1005277 0.522 rs289649 ENSG00000276805.1 RP11-291L22.6 3.92 0.000106 0.0193 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37686456 chr10:38451030~38451785:+ LIHC cis rs10129255 1 rs8010605 ENSG00000211972.2 IGHV3-66 3.92 0.000106 0.0193 0.17 0.21 Kawasaki disease; chr14:106678742 chr14:106675017~106675544:- LIHC cis rs13113518 1 rs13132420 ENSG00000223305.1 RN7SKP30 -3.92 0.000106 0.0193 -0.24 -0.21 Height; chr4:55526646 chr4:55540502~55540835:- LIHC cis rs7333764 0.793 rs4943125 ENSG00000234535.1 RP11-37L2.1 -3.92 0.000106 0.0193 -0.33 -0.21 CTACK levels; chr13:33642958 chr13:33610967~33611522:+ LIHC cis rs17711722 0.653 rs2460421 ENSG00000164669.11 INTS4P1 3.92 0.000106 0.0193 0.27 0.21 Calcium levels; chr7:66026136 chr7:65141225~65234216:+ LIHC cis rs1876905 0.539 rs457497 ENSG00000271789.1 RP5-1112D6.7 3.92 0.000106 0.0193 0.24 0.21 Mean corpuscular hemoglobin; chr6:111301346 chr6:111297126~111298510:+ LIHC cis rs7734985 0.587 rs6882897 ENSG00000250551.1 RP11-254I22.1 -3.92 0.000106 0.0193 -0.23 -0.21 IgG glycosylation; chr5:96256022 chr5:96050115~96215519:+ LIHC cis rs73193808 0.614 rs2832255 ENSG00000212479.2 U3 -3.92 0.000106 0.0193 -0.25 -0.21 Coronary artery disease; chr21:29191846 chr21:29180425~29180639:- LIHC cis rs950169 1 rs35297609 ENSG00000225151.9 GOLGA2P7 -3.92 0.000106 0.0193 -0.29 -0.21 Schizophrenia; chr15:84104144 chr15:84199311~84230136:- LIHC cis rs950169 1 rs62026530 ENSG00000225151.9 GOLGA2P7 -3.92 0.000106 0.0193 -0.29 -0.21 Schizophrenia; chr15:84107088 chr15:84199311~84230136:- LIHC cis rs950169 1 rs11638394 ENSG00000225151.9 GOLGA2P7 -3.92 0.000106 0.0193 -0.29 -0.21 Schizophrenia; chr15:84110176 chr15:84199311~84230136:- LIHC cis rs950169 1 rs35658069 ENSG00000225151.9 GOLGA2P7 -3.92 0.000106 0.0193 -0.29 -0.21 Schizophrenia; chr15:84111394 chr15:84199311~84230136:- LIHC cis rs7917772 0.503 rs2031602 ENSG00000236937.2 PTGES3P4 -3.92 0.000106 0.0193 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102548198 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs2031601 ENSG00000236937.2 PTGES3P4 -3.92 0.000106 0.0193 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102548307 chr10:102845595~102845950:+ LIHC cis rs9807989 0.571 rs10208293 ENSG00000234389.1 AC007278.3 3.92 0.000106 0.0193 0.23 0.21 Asthma; chr2:102349850 chr2:102438713~102440475:+ LIHC cis rs524281 0.731 rs10896075 ENSG00000255320.1 RP11-755F10.1 -3.92 0.000106 0.0193 -0.29 -0.21 Electroencephalogram traits; chr11:66024742 chr11:66244840~66246239:- LIHC cis rs1023500 0.505 rs134888 ENSG00000205702.9 CYP2D7 3.92 0.000106 0.0193 0.21 0.21 Schizophrenia; chr22:42278275 chr22:42140203~42144577:- LIHC cis rs9890032 0.618 rs1979507 ENSG00000266490.1 CTD-2349P21.9 3.92 0.000106 0.0193 0.2 0.21 Hip circumference adjusted for BMI; chr17:30811002 chr17:30792372~30792833:+ LIHC cis rs4218 0.648 rs2289895 ENSG00000277144.1 RP11-59H7.4 -3.92 0.000106 0.0193 -0.23 -0.21 Social communication problems; chr15:59089570 chr15:59115547~59116089:- LIHC cis rs853679 1 rs6901575 ENSG00000204709.4 LINC01556 3.92 0.000106 0.0193 0.35 0.21 Depression; chr6:28283207 chr6:28943877~28944537:+ LIHC cis rs11096990 0.576 rs2008679 ENSG00000249685.1 RP11-360F5.3 -3.92 0.000106 0.0194 -0.25 -0.21 Cognitive function; chr4:39266385 chr4:39133913~39135608:+ LIHC cis rs8087799 0.931 rs7239677 ENSG00000273232.1 RP11-370A5.2 -3.92 0.000106 0.0194 -0.23 -0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22703458 chr18:22882825~22883357:- LIHC cis rs9640161 0.789 rs2159234 ENSG00000261305.1 RP4-584D14.7 3.92 0.000106 0.0194 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150323333 chr7:150341771~150342607:+ LIHC cis rs9640161 0.702 rs3735175 ENSG00000261305.1 RP4-584D14.7 3.92 0.000106 0.0194 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150323368 chr7:150341771~150342607:+ LIHC cis rs4650994 1 rs35810840 ENSG00000213057.5 C1orf220 3.92 0.000106 0.0194 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178553507 chr1:178542752~178548889:+ LIHC cis rs875971 0.867 rs13227219 ENSG00000237310.1 GS1-124K5.4 3.92 0.000106 0.0194 0.19 0.21 Aortic root size; chr7:66379075 chr7:66493706~66495474:+ LIHC cis rs12681366 0.763 rs3019277 ENSG00000253704.1 RP11-267M23.4 3.92 0.000106 0.0194 0.25 0.21 Nonsyndromic cleft lip with cleft palate; chr8:94428195 chr8:94553722~94569745:+ LIHC cis rs12681366 0.839 rs3019278 ENSG00000253704.1 RP11-267M23.4 3.92 0.000106 0.0194 0.25 0.21 Nonsyndromic cleft lip with cleft palate; chr8:94434339 chr8:94553722~94569745:+ LIHC cis rs12681366 0.761 rs2930963 ENSG00000253704.1 RP11-267M23.4 3.92 0.000106 0.0194 0.25 0.21 Nonsyndromic cleft lip with cleft palate; chr8:94434892 chr8:94553722~94569745:+ LIHC cis rs12681366 0.839 rs2930964 ENSG00000253704.1 RP11-267M23.4 3.92 0.000106 0.0194 0.25 0.21 Nonsyndromic cleft lip with cleft palate; chr8:94435906 chr8:94553722~94569745:+ LIHC cis rs7849270 1 rs7037163 ENSG00000268707.1 RP11-247A12.7 -3.92 0.000106 0.0194 -0.22 -0.21 Blood metabolite ratios; chr9:129132061 chr9:129170434~129170940:+ LIHC cis rs7809950 0.817 rs2237678 ENSG00000238832.1 snoU109 -3.92 0.000106 0.0194 -0.27 -0.21 Coronary artery disease; chr7:107562820 chr7:107603363~107603507:+ LIHC cis rs7208859 0.673 rs7211776 ENSG00000264538.5 SUZ12P1 -3.92 0.000106 0.0194 -0.21 -0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793178 chr17:30709299~30790908:+ LIHC cis rs7208859 0.673 rs9912122 ENSG00000264538.5 SUZ12P1 -3.92 0.000106 0.0194 -0.21 -0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813698 chr17:30709299~30790908:+ LIHC cis rs1799922 0.725 rs1318256 ENSG00000273270.1 RP11-212P7.2 3.92 0.000106 0.0194 0.27 0.21 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr7:128777959 chr7:128524016~128531069:- LIHC cis rs2243480 0.764 rs2460423 ENSG00000232546.1 RP11-458F8.1 -3.92 0.000106 0.0194 -0.23 -0.21 Diabetic kidney disease; chr7:66136229 chr7:66848496~66858136:+ LIHC cis rs4787491 0.729 rs11150584 ENSG00000250616.2 RP11-455F5.3 3.92 0.000106 0.0194 0.2 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30028357 chr16:30096430~30104116:+ LIHC cis rs11710088 0.74 rs4408826 ENSG00000244503.1 RP11-278L15.6 3.92 0.000107 0.0194 0.27 0.21 QRS duration; chr3:149468838 chr3:149494660~149495995:+ LIHC cis rs2070488 0.965 rs9829192 ENSG00000229589.1 ACVR2B-AS1 -3.92 0.000107 0.0194 -0.24 -0.21 Electrocardiographic conduction measures; chr3:38527972 chr3:38451027~38454820:- LIHC cis rs4845875 0.534 rs6541003 ENSG00000242349.4 NPPA-AS1 3.92 0.000107 0.0194 0.22 0.21 Midregional pro atrial natriuretic peptide levels; chr1:11795810 chr1:11841017~11848079:+ LIHC cis rs3845817 0.868 rs702890 ENSG00000281920.1 RP11-418H16.1 3.92 0.000107 0.0194 0.24 0.21 Bipolar disorder; chr2:65530517 chr2:65623272~65628424:+ LIHC cis rs2253762 0.507 rs12264894 ENSG00000226864.1 ATE1-AS1 3.92 0.000107 0.0195 0.35 0.21 Breast cancer; chr10:121992087 chr10:121928312~121951965:+ LIHC cis rs5742933 0.817 rs5742938 ENSG00000253559.1 OSGEPL1-AS1 3.92 0.000107 0.0195 0.27 0.21 Ferritin levels; chr2:189785232 chr2:189762704~189765556:+ LIHC cis rs2744375 0.6 rs2744370 ENSG00000261189.1 RP3-512B11.3 3.92 0.000107 0.0195 0.26 0.21 Resting heart rate; chr6:7553763 chr6:7540451~7541338:- LIHC cis rs11098499 0.954 rs10017371 ENSG00000260091.1 RP11-33B1.4 -3.92 0.000107 0.0195 -0.15 -0.21 Corneal astigmatism; chr4:119372621 chr4:119409333~119410233:+ LIHC cis rs9640161 0.789 rs4554381 ENSG00000261305.1 RP4-584D14.7 3.92 0.000107 0.0195 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150328478 chr7:150341771~150342607:+ LIHC cis rs244293 0.73 rs12951898 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.23 0.21 Menarche (age at onset); chr17:54958241 chr17:54964474~54964679:+ LIHC cis rs6471393 0.964 rs2914959 ENSG00000253848.1 RP11-10N23.5 3.92 0.000107 0.0195 0.24 0.21 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93727117 chr8:93741193~93744534:+ LIHC cis rs481331 0.799 rs3928822 ENSG00000185904.10 LINC00839 3.92 0.000107 0.0195 0.41 0.21 Systemic juvenile idiopathic arthritis; chr10:42471984 chr10:42475543~42495336:+ LIHC cis rs8067287 0.634 rs11652811 ENSG00000205312.7 KRT17P4 3.92 0.000107 0.0195 0.35 0.21 Diabetic kidney disease; chr17:16939857 chr17:16847635~16852777:- LIHC cis rs960902 0.764 rs1113496 ENSG00000213553.4 RPLP0P6 -3.92 0.000107 0.0195 -0.17 -0.21 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37505712 chr2:38481851~38482804:+ LIHC cis rs2243480 1 rs316329 ENSG00000232546.1 RP11-458F8.1 -3.92 0.000107 0.0195 -0.23 -0.21 Diabetic kidney disease; chr7:66143429 chr7:66848496~66858136:+ LIHC cis rs1816213 0.744 rs3731869 ENSG00000273466.1 RP11-548H3.1 -3.92 0.000107 0.0195 -0.32 -0.21 Diastolic blood pressure; chr2:218632325 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs6728701 ENSG00000273466.1 RP11-548H3.1 -3.92 0.000107 0.0195 -0.32 -0.21 Diastolic blood pressure; chr2:218637431 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs1803383 ENSG00000273466.1 RP11-548H3.1 -3.92 0.000107 0.0195 -0.32 -0.21 Diastolic blood pressure; chr2:218638390 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs6736648 ENSG00000273466.1 RP11-548H3.1 -3.92 0.000107 0.0195 -0.32 -0.21 Diastolic blood pressure; chr2:218639420 chr2:218633256~218634014:- LIHC cis rs6545883 0.501 rs935860 ENSG00000271889.1 RP11-493E12.1 3.92 0.000107 0.0195 0.24 0.21 Tuberculosis; chr2:61179426 chr2:61151433~61162105:- LIHC cis rs1555322 0.872 rs2425048 ENSG00000126005.14 MMP24-AS1 -3.92 0.000107 0.0195 -0.42 -0.21 Attention deficit hyperactivity disorder; chr20:35284920 chr20:35216462~35278131:- LIHC cis rs948562 0.793 rs79869893 ENSG00000280010.1 AP001350.4 3.92 0.000107 0.0195 0.38 0.21 Lymphoma; chr11:58514409 chr11:58627435~58628528:+ LIHC cis rs2070488 0.804 rs2268755 ENSG00000229589.1 ACVR2B-AS1 -3.92 0.000107 0.0195 -0.22 -0.21 Electrocardiographic conduction measures; chr3:38460425 chr3:38451027~38454820:- LIHC cis rs10129255 0.5 rs2105989 ENSG00000211972.2 IGHV3-66 3.92 0.000107 0.0195 0.16 0.21 Kawasaki disease; chr14:106682199 chr14:106675017~106675544:- LIHC cis rs591584 0.839 rs7120907 ENSG00000255893.1 RP11-685N10.1 -3.92 0.000107 0.0195 -0.21 -0.21 Macrophage Migration Inhibitory Factor levels; chr11:94593814 chr11:94472908~94473570:- LIHC cis rs9675120 1 rs9675120 ENSG00000262006.1 RP11-700H6.4 3.92 0.000107 0.0195 0.22 0.21 Cerebrospinal fluid biomarker levels; chr17:50839972 chr17:50909637~50910232:- LIHC cis rs1823913 1 rs12623832 ENSG00000227542.1 AC092614.2 -3.92 0.000107 0.0195 -0.21 -0.21 Obesity-related traits; chr2:191260918 chr2:191229165~191246172:- LIHC cis rs6547741 1 rs4666007 ENSG00000234072.1 AC074117.10 3.92 0.000107 0.0195 0.19 0.21 Oral cavity cancer; chr2:27633628 chr2:27356246~27367622:+ LIHC cis rs6547741 1 rs1528402 ENSG00000234072.1 AC074117.10 3.92 0.000107 0.0195 0.19 0.21 Oral cavity cancer; chr2:27634650 chr2:27356246~27367622:+ LIHC cis rs7246657 0.525 rs10405238 ENSG00000225975.5 LINC01534 3.92 0.000107 0.0195 0.33 0.21 Coronary artery calcification; chr19:36997153 chr19:36685440~36687449:- LIHC cis rs193541 0.632 rs154503 ENSG00000263432.2 RN7SL689P 3.92 0.000107 0.0195 0.33 0.21 Glucose homeostasis traits; chr5:122868804 chr5:123022487~123022783:- LIHC cis rs1598856 1 rs11934404 ENSG00000230069.3 LRRC37A15P -3.92 0.000107 0.0195 -0.18 -0.21 Primary biliary cholangitis; chr4:102516444 chr4:102727274~102730721:- LIHC cis rs244293 0.931 rs2058026 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55127398 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs2058027 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55127498 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs2529505 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55129447 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs2628320 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55130632 chr17:54964474~54964679:+ LIHC cis rs244293 0.868 rs2787490 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55130690 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs2628318 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55132951 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs2787482 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55133413 chr17:54964474~54964679:+ LIHC cis rs244293 0.868 rs171510 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55134166 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244307 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55134352 chr17:54964474~54964679:+ LIHC cis rs244293 0.931 rs244308 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55134692 chr17:54964474~54964679:+ LIHC cis rs244293 0.899 rs244309 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55134732 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs2529508 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55135211 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs244310 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55135294 chr17:54964474~54964679:+ LIHC cis rs875971 0.545 rs12671152 ENSG00000228409.4 CCT6P1 -3.92 0.000107 0.0195 -0.18 -0.21 Aortic root size; chr7:66311140 chr7:65751142~65763354:+ LIHC cis rs597539 0.552 rs10896384 ENSG00000250508.1 RP11-757G1.6 3.92 0.000107 0.0195 0.32 0.21 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68952542 chr11:68870664~68874542:+ LIHC cis rs1494950 1 rs7661252 ENSG00000214846.4 RP11-115L11.1 -3.92 0.000107 0.0195 -0.42 -0.21 Political ideology; chr4:14980365 chr4:15730962~15731627:- LIHC cis rs4938303 0.633 rs528806 ENSG00000254851.1 RP11-109L13.1 3.92 0.000107 0.0195 0.3 0.21 Triglycerides; chr11:116659197 chr11:117135528~117138582:+ LIHC cis rs9400467 0.508 rs11153283 ENSG00000271789.1 RP5-1112D6.7 -3.92 0.000107 0.0195 -0.2 -0.21 Amino acid levels;Blood metabolite levels; chr6:111275940 chr6:111297126~111298510:+ LIHC cis rs6723108 0.603 rs12469411 ENSG00000224043.6 CCNT2-AS1 -3.92 0.000107 0.0195 -0.29 -0.21 Type 2 diabetes; chr2:134906986 chr2:134735464~134918710:- LIHC cis rs6723108 0.592 rs10928523 ENSG00000224043.6 CCNT2-AS1 -3.92 0.000107 0.0195 -0.29 -0.21 Type 2 diabetes; chr2:134907891 chr2:134735464~134918710:- LIHC cis rs6723108 0.603 rs6733130 ENSG00000224043.6 CCNT2-AS1 -3.92 0.000107 0.0195 -0.29 -0.21 Type 2 diabetes; chr2:134908983 chr2:134735464~134918710:- LIHC cis rs6723108 0.627 rs1374288 ENSG00000224043.6 CCNT2-AS1 -3.92 0.000107 0.0195 -0.29 -0.21 Type 2 diabetes; chr2:134909483 chr2:134735464~134918710:- LIHC cis rs6723108 0.627 rs1374287 ENSG00000224043.6 CCNT2-AS1 -3.92 0.000107 0.0195 -0.29 -0.21 Type 2 diabetes; chr2:134909631 chr2:134735464~134918710:- LIHC cis rs757081 0.648 rs7108315 ENSG00000272034.1 SNORD14A -3.92 0.000107 0.0195 -0.22 -0.21 Systolic blood pressure; chr11:17245617 chr11:17074654~17074744:- LIHC cis rs10510102 0.872 rs7916008 ENSG00000273891.1 RP11-500G22.5 3.92 0.000107 0.0195 0.27 0.21 Breast cancer; chr10:121943578 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs7916380 ENSG00000273891.1 RP11-500G22.5 3.92 0.000107 0.0195 0.27 0.21 Breast cancer; chr10:121943773 chr10:121965764~121967700:+ LIHC cis rs10510102 0.808 rs7920024 ENSG00000273891.1 RP11-500G22.5 3.92 0.000107 0.0195 0.27 0.21 Breast cancer; chr10:121944063 chr10:121965764~121967700:+ LIHC cis rs6504622 0.702 rs3851796 ENSG00000262879.4 RP11-156P1.3 -3.92 0.000107 0.0195 -0.22 -0.21 Orofacial clefts; chr17:46983809 chr17:46984045~47100323:- LIHC cis rs17772222 0.917 rs57889459 ENSG00000258789.1 RP11-507K2.3 -3.92 0.000107 0.0195 -0.25 -0.21 Coronary artery calcification; chr14:88770820 chr14:88551597~88552493:+ LIHC cis rs17772222 0.917 rs58550317 ENSG00000258789.1 RP11-507K2.3 -3.92 0.000107 0.0195 -0.25 -0.21 Coronary artery calcification; chr14:88775243 chr14:88551597~88552493:+ LIHC cis rs17772222 0.917 rs61982733 ENSG00000258789.1 RP11-507K2.3 -3.92 0.000107 0.0195 -0.25 -0.21 Coronary artery calcification; chr14:88776244 chr14:88551597~88552493:+ LIHC cis rs2243480 1 rs316329 ENSG00000228409.4 CCT6P1 3.92 0.000107 0.0195 0.22 0.21 Diabetic kidney disease; chr7:66143429 chr7:65751142~65763354:+ LIHC cis rs4919694 1 rs4919694 ENSG00000236937.2 PTGES3P4 3.92 0.000107 0.0195 0.38 0.21 Arsenic metabolism; chr10:102939221 chr10:102845595~102845950:+ LIHC cis rs13113518 0.812 rs11945371 ENSG00000223305.1 RN7SKP30 3.92 0.000107 0.0195 0.25 0.21 Height; chr4:55409063 chr4:55540502~55540835:- LIHC cis rs950880 0.645 rs11679889 ENSG00000234389.1 AC007278.3 -3.92 0.000107 0.0195 -0.21 -0.21 Serum protein levels (sST2); chr2:102324549 chr2:102438713~102440475:+ LIHC cis rs42490 1 rs402886 ENSG00000251136.7 RP11-37B2.1 -3.92 0.000107 0.0195 -0.18 -0.21 Leprosy; chr8:89760272 chr8:89609409~89757727:- LIHC cis rs42490 0.966 rs39500 ENSG00000251136.7 RP11-37B2.1 -3.92 0.000107 0.0195 -0.18 -0.21 Leprosy; chr8:89760437 chr8:89609409~89757727:- LIHC cis rs42490 0.966 rs39761 ENSG00000251136.7 RP11-37B2.1 -3.92 0.000107 0.0195 -0.18 -0.21 Leprosy; chr8:89760692 chr8:89609409~89757727:- LIHC cis rs42490 0.934 rs43225 ENSG00000251136.7 RP11-37B2.1 -3.92 0.000107 0.0195 -0.18 -0.21 Leprosy; chr8:89760776 chr8:89609409~89757727:- LIHC cis rs244293 0.965 rs2170943 ENSG00000275710.1 RP11-257O5.4 3.92 0.000107 0.0195 0.22 0.21 Menarche (age at onset); chr17:55132144 chr17:54964474~54964679:+ LIHC cis rs1799949 1 rs35956818 ENSG00000267681.1 CTD-3199J23.6 -3.92 0.000107 0.0195 -0.2 -0.21 Menopause (age at onset); chr17:43345617 chr17:43144956~43145255:+ LIHC cis rs1799949 0.93 rs4584865 ENSG00000267681.1 CTD-3199J23.6 -3.92 0.000107 0.0195 -0.2 -0.21 Menopause (age at onset); chr17:43347551 chr17:43144956~43145255:+ LIHC cis rs10129255 0.5 rs8004923 ENSG00000211972.2 IGHV3-66 3.92 0.000107 0.0195 0.16 0.21 Kawasaki disease; chr14:106785926 chr14:106675017~106675544:- LIHC cis rs9300255 0.596 rs1568427 ENSG00000256092.2 RP13-942N8.1 3.92 0.000107 0.0195 0.26 0.21 Neutrophil percentage of white cells; chr12:123254131 chr12:123363868~123366113:+ LIHC cis rs7121538 0.756 rs61884006 ENSG00000251991.1 RNU7-49P -3.92 0.000107 0.0196 -0.28 -0.21 HDL cholesterol; chr11:14385566 chr11:14478892~14478953:+ LIHC cis rs748404 0.65 rs556851 ENSG00000205771.5 CATSPER2P1 -3.92 0.000107 0.0196 -0.25 -0.21 Lung cancer; chr15:43279021 chr15:43726918~43747094:- LIHC cis rs748404 0.697 rs567357 ENSG00000205771.5 CATSPER2P1 -3.92 0.000107 0.0196 -0.25 -0.21 Lung cancer; chr15:43279192 chr15:43726918~43747094:- LIHC cis rs2562456 1 rs2562456 ENSG00000268555.1 RP11-678G14.3 3.92 0.000107 0.0196 0.26 0.21 Pain; chr19:21483408 chr19:21570822~21587322:- LIHC cis rs61542988 0.57 rs62448267 ENSG00000226816.2 AC005082.12 -3.92 0.000107 0.0196 -0.27 -0.21 Fibrinogen levels; chr7:22782882 chr7:23206013~23208045:+ LIHC cis rs2179367 0.632 rs7349921 ENSG00000231760.4 RP11-350J20.5 3.92 0.000108 0.0196 0.34 0.21 Dupuytren's disease; chr6:149392727 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs60153446 ENSG00000231760.4 RP11-350J20.5 3.92 0.000108 0.0196 0.34 0.21 Dupuytren's disease; chr6:149393186 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs61259243 ENSG00000231760.4 RP11-350J20.5 3.92 0.000108 0.0196 0.34 0.21 Dupuytren's disease; chr6:149393457 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs62426115 ENSG00000231760.4 RP11-350J20.5 3.92 0.000108 0.0196 0.34 0.21 Dupuytren's disease; chr6:149393718 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs68080376 ENSG00000231760.4 RP11-350J20.5 3.92 0.000108 0.0196 0.34 0.21 Dupuytren's disease; chr6:149393873 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs763590 ENSG00000231760.4 RP11-350J20.5 3.92 0.000108 0.0196 0.34 0.21 Dupuytren's disease; chr6:149398831 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs17506789 ENSG00000231760.4 RP11-350J20.5 3.92 0.000108 0.0196 0.34 0.21 Dupuytren's disease; chr6:149399710 chr6:149796151~149826294:- LIHC cis rs2179367 0.586 rs34097428 ENSG00000231760.4 RP11-350J20.5 3.92 0.000108 0.0196 0.34 0.21 Dupuytren's disease; chr6:149399822 chr6:149796151~149826294:- LIHC cis rs17711722 0.528 rs73138179 ENSG00000237310.1 GS1-124K5.4 3.92 0.000108 0.0196 0.18 0.21 Calcium levels; chr7:65829495 chr7:66493706~66495474:+ LIHC cis rs4650994 1 rs10913568 ENSG00000213057.5 C1orf220 3.92 0.000108 0.0196 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178544276 chr1:178542752~178548889:+ LIHC cis rs66887589 0.967 rs1480933 ENSG00000260091.1 RP11-33B1.4 -3.92 0.000108 0.0196 -0.14 -0.21 Diastolic blood pressure; chr4:119512093 chr4:119409333~119410233:+ LIHC cis rs1816213 0.744 rs59341668 ENSG00000273466.1 RP11-548H3.1 -3.92 0.000108 0.0196 -0.33 -0.21 Diastolic blood pressure; chr2:218623314 chr2:218633256~218634014:- LIHC cis rs6061231 0.546 rs482220 ENSG00000226332.2 RP11-157P1.4 -3.92 0.000108 0.0196 -0.22 -0.21 Colorectal cancer; chr20:62352426 chr20:62305432~62306325:- LIHC cis rs7131987 0.834 rs1989478 ENSG00000275476.1 RP11-996F15.4 -3.92 0.000108 0.0196 -0.24 -0.21 QT interval; chr12:29289296 chr12:29277397~29277882:- LIHC cis rs2348418 0.864 rs7314984 ENSG00000247934.4 RP11-967K21.1 3.92 0.000108 0.0196 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28557936 chr12:28163298~28190738:- LIHC cis rs7712401 0.601 rs246268 ENSG00000263432.2 RN7SL689P 3.92 0.000108 0.0196 0.3 0.21 Mean platelet volume; chr5:122920647 chr5:123022487~123022783:- LIHC cis rs17774123 0.901 rs1816829 ENSG00000257808.1 RP11-1136G11.8 3.92 0.000108 0.0196 0.38 0.21 Diastolic blood pressure; chr12:53873209 chr12:53159586~53161000:+ LIHC cis rs2195987 0.668 rs4533408 ENSG00000268442.1 CTD-2027I19.2 3.92 0.000108 0.0196 0.39 0.21 Testicular germ cell tumor; chr19:23971002 chr19:24162370~24163425:- LIHC cis rs875971 1 rs6956179 ENSG00000237310.1 GS1-124K5.4 -3.92 0.000108 0.0196 -0.18 -0.21 Aortic root size; chr7:66341672 chr7:66493706~66495474:+ LIHC cis rs1799949 1 rs12951869 ENSG00000267681.1 CTD-3199J23.6 -3.92 0.000108 0.0196 -0.2 -0.21 Menopause (age at onset); chr17:43035550 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs11654452 ENSG00000267681.1 CTD-3199J23.6 -3.92 0.000108 0.0196 -0.2 -0.21 Menopause (age at onset); chr17:43037366 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs4793189 ENSG00000267681.1 CTD-3199J23.6 -3.92 0.000108 0.0196 -0.2 -0.21 Menopause (age at onset); chr17:43038698 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs11657053 ENSG00000267681.1 CTD-3199J23.6 -3.92 0.000108 0.0196 -0.2 -0.21 Menopause (age at onset); chr17:43039112 chr17:43144956~43145255:+ LIHC cis rs4650994 1 rs10798615 ENSG00000213057.5 C1orf220 3.92 0.000108 0.0196 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178544760 chr1:178542752~178548889:+ LIHC cis rs1494950 0.661 rs2702521 ENSG00000214846.4 RP11-115L11.1 -3.92 0.000108 0.0196 -0.41 -0.21 Political ideology; chr4:15015517 chr4:15730962~15731627:- LIHC cis rs9326248 0.603 rs7396061 ENSG00000280143.1 AP000892.6 3.92 0.000108 0.0196 0.24 0.21 Blood protein levels; chr11:116880158 chr11:117204967~117210292:+ LIHC cis rs617219 0.746 rs56246109 ENSG00000251675.1 CTC-458I2.2 -3.92 0.000108 0.0196 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79219375 chr5:80128361~80143883:+ LIHC cis rs617219 0.853 rs58150362 ENSG00000251675.1 CTC-458I2.2 -3.92 0.000108 0.0196 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79223715 chr5:80128361~80143883:+ LIHC cis rs617219 0.853 rs4703773 ENSG00000251675.1 CTC-458I2.2 -3.92 0.000108 0.0196 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79224733 chr5:80128361~80143883:+ LIHC cis rs617219 0.853 rs13355606 ENSG00000251675.1 CTC-458I2.2 -3.92 0.000108 0.0196 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79226536 chr5:80128361~80143883:+ LIHC cis rs617219 0.853 rs10078815 ENSG00000251675.1 CTC-458I2.2 -3.92 0.000108 0.0196 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79227072 chr5:80128361~80143883:+ LIHC cis rs9843304 0.5 rs34358037 ENSG00000244503.1 RP11-278L15.6 3.92 0.000108 0.0196 0.21 0.21 Gallstone disease; chr3:149483497 chr3:149494660~149495995:+ LIHC cis rs6452524 0.618 rs4266384 ENSG00000271862.1 RP11-343L5.2 3.92 0.000108 0.0196 0.25 0.21 Hypertension (SNP x SNP interaction); chr5:83080872 chr5:83049376~83050964:- LIHC cis rs17376456 0.877 rs17083462 ENSG00000251023.1 RP11-549J18.1 -3.92 0.000108 0.0197 -0.43 -0.21 Diabetic retinopathy; chr5:94126696 chr5:93860669~93863825:- LIHC cis rs7809950 0.655 rs4730220 ENSG00000238832.1 snoU109 -3.92 0.000108 0.0197 -0.25 -0.21 Coronary artery disease; chr7:107168611 chr7:107603363~107603507:+ LIHC cis rs2919917 0.59 rs2919919 ENSG00000254352.1 RP11-578O24.2 -3.92 0.000108 0.0197 -0.32 -0.21 Lymphocyte counts; chr8:78745274 chr8:78723796~78724136:- LIHC cis rs12681366 0.881 rs3019145 ENSG00000253704.1 RP11-267M23.4 3.92 0.000108 0.0197 0.24 0.21 Nonsyndromic cleft lip with cleft palate; chr8:94401324 chr8:94553722~94569745:+ LIHC cis rs4787491 0.729 rs8043883 ENSG00000250616.2 RP11-455F5.3 3.92 0.000108 0.0197 0.2 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30033260 chr16:30096430~30104116:+ LIHC cis rs4787491 0.765 rs8054507 ENSG00000250616.2 RP11-455F5.3 3.92 0.000108 0.0197 0.2 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30034721 chr16:30096430~30104116:+ LIHC cis rs4787491 0.765 rs4788216 ENSG00000250616.2 RP11-455F5.3 3.92 0.000108 0.0197 0.2 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30036756 chr16:30096430~30104116:+ LIHC cis rs1023500 0.551 rs2854837 ENSG00000205702.9 CYP2D7 3.92 0.000108 0.0197 0.24 0.21 Schizophrenia; chr22:42062477 chr22:42140203~42144577:- LIHC cis rs11098499 0.863 rs6858592 ENSG00000260091.1 RP11-33B1.4 -3.92 0.000108 0.0197 -0.15 -0.21 Corneal astigmatism; chr4:119537537 chr4:119409333~119410233:+ LIHC cis rs10256972 0.684 rs4724039 ENSG00000199023.2 MIR339 -3.92 0.000108 0.0197 -0.23 -0.21 Endometriosis;Longevity; chr7:1071997 chr7:1022935~1023045:- LIHC cis rs4356203 0.905 rs214906 ENSG00000260196.1 RP1-239B22.5 3.92 0.000108 0.0197 0.25 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17159793 chr11:17380649~17383531:+ LIHC cis rs919433 0.963 rs4850786 ENSG00000231621.1 AC013264.2 -3.92 0.000108 0.0197 -0.19 -0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197313884 chr2:197197991~197199273:+ LIHC cis rs6860806 0.507 rs272892 ENSG00000263597.1 MIR3936 3.92 0.000108 0.0197 0.22 0.21 Breast cancer; chr5:132328656 chr5:132365490~132365599:- LIHC cis rs6860806 0.507 rs272891 ENSG00000263597.1 MIR3936 3.92 0.000108 0.0197 0.22 0.21 Breast cancer; chr5:132328701 chr5:132365490~132365599:- LIHC cis rs6860806 0.531 rs272888 ENSG00000263597.1 MIR3936 3.92 0.000108 0.0197 0.22 0.21 Breast cancer; chr5:132329730 chr5:132365490~132365599:- LIHC cis rs12936587 0.777 rs12942708 ENSG00000223979.2 SMCR2 -3.92 0.000108 0.0197 -0.27 -0.21 Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference; chr17:17624697 chr17:17674026~17677688:- LIHC cis rs11733284 0.63 rs7690405 ENSG00000259959.1 RP11-121C2.2 -3.92 0.000108 0.0197 -0.2 -0.21 Gout;Renal underexcretion gout; chr4:48028739 chr4:47840122~47844339:- LIHC cis rs875971 0.545 rs75840613 ENSG00000224316.1 RP11-479O9.2 3.92 0.000108 0.0197 0.2 0.21 Aortic root size; chr7:66376399 chr7:65773620~65802067:+ LIHC cis rs875971 0.545 rs73148639 ENSG00000224316.1 RP11-479O9.2 3.92 0.000108 0.0197 0.2 0.21 Aortic root size; chr7:66390342 chr7:65773620~65802067:+ LIHC cis rs6997458 0.967 rs13273654 ENSG00000253549.4 RP11-317J10.2 3.92 0.000108 0.0197 0.23 0.21 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85374328 chr8:85441851~85464915:- LIHC cis rs7917772 0.502 rs10748827 ENSG00000236937.2 PTGES3P4 -3.92 0.000109 0.0197 -0.28 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102608579 chr10:102845595~102845950:+ LIHC cis rs1005277 0.579 rs1621040 ENSG00000120555.12 SEPT7P9 3.92 0.000109 0.0197 0.24 0.21 Extrinsic epigenetic age acceleration; chr10:38208304 chr10:38383069~38402916:- LIHC cis rs6700559 0.74 rs11582610 ENSG00000260088.1 RP11-92G12.3 3.92 0.000109 0.0197 0.29 0.21 Coronary artery disease; chr1:200675973 chr1:200669507~200694250:+ LIHC cis rs6700559 0.654 rs12061556 ENSG00000260088.1 RP11-92G12.3 3.92 0.000109 0.0197 0.29 0.21 Coronary artery disease; chr1:200681111 chr1:200669507~200694250:+ LIHC cis rs17818399 0.684 rs62134759 ENSG00000239332.4 LINC01119 -3.92 0.000109 0.0197 -0.31 -0.21 Height; chr2:46564710 chr2:46816697~46859007:+ LIHC cis rs9876781 1 rs6784322 ENSG00000229759.1 MRPS18AP1 3.92 0.000109 0.0197 0.21 0.21 Longevity; chr3:48380745 chr3:48256350~48256938:- LIHC cis rs1318937 0.764 rs9864422 ENSG00000224660.1 SH3BP5-AS1 3.92 0.000109 0.0197 0.19 0.21 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15185745 chr3:15254184~15264493:+ LIHC cis rs7893279 0.543 rs7093454 ENSG00000225527.1 RP11-383B4.4 3.92 0.000109 0.0197 0.29 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18597751 chr10:18531849~18533336:- LIHC cis rs2919917 0.628 rs2717540 ENSG00000254352.1 RP11-578O24.2 3.92 0.000109 0.0197 0.31 0.21 Lymphocyte counts; chr8:78710128 chr8:78723796~78724136:- LIHC cis rs2072510 1 rs2660897 ENSG00000257878.1 RP11-256L6.3 -3.92 0.000109 0.0198 -0.18 -0.21 Metabolite levels (small molecules and protein measures); chr12:96031654 chr12:95996521~96011489:+ LIHC cis rs57502260 0.704 rs60538784 ENSG00000212093.1 AP000807.1 3.92 0.000109 0.0198 0.27 0.21 Total body bone mineral density (age 45-60); chr11:68619267 chr11:68506083~68506166:- LIHC cis rs11651753 0.689 rs2525107 ENSG00000264920.1 RP11-6N17.4 3.92 0.000109 0.0198 0.21 0.21 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47964038 chr17:47891255~47895812:- LIHC cis rs6048205 0.657 rs2021681 ENSG00000259974.2 LINC00261 3.92 0.000109 0.0198 0.32 0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22548121 chr20:22547671~22578642:- LIHC cis rs875971 0.666 rs13242072 ENSG00000273024.4 INTS4P2 3.92 0.000109 0.0198 0.24 0.21 Aortic root size; chr7:66301001 chr7:65647864~65715661:+ LIHC cis rs6142102 0.923 rs3787230 ENSG00000275784.1 RP5-1125A11.6 -3.92 0.000109 0.0198 -0.23 -0.21 Skin pigmentation; chr20:34052466 chr20:33989480~33991818:- LIHC cis rs12681366 0.663 rs4735294 ENSG00000253704.1 RP11-267M23.4 3.92 0.000109 0.0198 0.23 0.21 Nonsyndromic cleft lip with cleft palate; chr8:94478313 chr8:94553722~94569745:+ LIHC cis rs4356203 0.875 rs214935 ENSG00000260196.1 RP1-239B22.5 -3.91 0.000109 0.0198 -0.25 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17171575 chr11:17380649~17383531:+ LIHC cis rs3204270 0.673 rs62077190 ENSG00000281517.1 Metazoa_SRP -3.91 0.000109 0.0198 -0.4 -0.21 Dental caries; chr17:81709079 chr17:81718849~81719095:- LIHC cis rs757081 0.648 rs214923 ENSG00000272034.1 SNORD14A -3.91 0.000109 0.0198 -0.22 -0.21 Systolic blood pressure; chr11:17215533 chr11:17074654~17074744:- LIHC cis rs9527 0.615 rs11191485 ENSG00000236937.2 PTGES3P4 3.91 0.000109 0.0198 0.26 0.21 Arsenic metabolism; chr10:102970059 chr10:102845595~102845950:+ LIHC cis rs11096990 0.656 rs2066786 ENSG00000249207.1 RP11-360F5.1 -3.91 0.000109 0.0198 -0.21 -0.21 Cognitive function; chr4:39300409 chr4:39112677~39126818:- LIHC cis rs2390582 0.563 rs71666251 ENSG00000231613.1 RP5-943J3.1 3.91 0.000109 0.0198 0.43 0.21 Coronary artery calcification; chr1:90277796 chr1:89788914~89790492:+ LIHC cis rs1023500 0.573 rs4822088 ENSG00000205702.9 CYP2D7 3.91 0.000109 0.0198 0.23 0.21 Schizophrenia; chr22:42074585 chr22:42140203~42144577:- LIHC cis rs9876781 1 rs9864371 ENSG00000229759.1 MRPS18AP1 3.91 0.000109 0.0198 0.22 0.21 Longevity; chr3:48385276 chr3:48256350~48256938:- LIHC cis rs9876781 1 rs11712561 ENSG00000229759.1 MRPS18AP1 3.91 0.000109 0.0198 0.22 0.21 Longevity; chr3:48393807 chr3:48256350~48256938:- LIHC cis rs2581828 0.608 rs9868263 ENSG00000242142.1 SERBP1P3 -3.91 0.000109 0.0198 -0.28 -0.21 Crohn's disease; chr3:53130078 chr3:53064283~53065091:- LIHC cis rs4903214 0.895 rs11621800 ENSG00000273565.1 CTD-3075F15.1 3.91 0.000109 0.0198 0.26 0.21 Inflammatory bowel disease; chr14:74230050 chr14:75176929~75177418:+ LIHC cis rs7989332 0.857 rs9506495 ENSG00000275964.1 RP11-61K9.3 -3.91 0.000109 0.0198 -0.24 -0.21 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20480851 chr13:19863858~19865048:+ LIHC cis rs9595908 0.746 rs9596075 ENSG00000212293.1 SNORA16 3.91 0.000109 0.0198 0.24 0.21 Body mass index; chr13:32692147 chr13:32420390~32420516:- LIHC cis rs1075265 0.73 rs7597188 ENSG00000272156.1 RP11-477N3.1 -3.91 0.000109 0.0198 -0.24 -0.21 Chronotype;Morning vs. evening chronotype; chr2:54014732 chr2:54082554~54085066:+ LIHC cis rs1075265 0.73 rs7597189 ENSG00000272156.1 RP11-477N3.1 -3.91 0.000109 0.0198 -0.24 -0.21 Chronotype;Morning vs. evening chronotype; chr2:54014733 chr2:54082554~54085066:+ LIHC cis rs2243480 1 rs2257790 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000109 0.0198 -0.23 -0.21 Diabetic kidney disease; chr7:66135463 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs316332 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000109 0.0198 -0.23 -0.21 Diabetic kidney disease; chr7:66139312 chr7:66848496~66858136:+ LIHC cis rs7829975 0.688 rs7817376 ENSG00000253893.2 FAM85B 3.91 0.000109 0.0198 0.25 0.21 Mood instability; chr8:8523020 chr8:8167819~8226614:- LIHC cis rs12468226 0.689 rs17656903 ENSG00000273456.1 RP11-686O6.2 -3.91 0.000109 0.0199 -0.32 -0.21 Urate levels; chr2:202106312 chr2:202374932~202375604:- LIHC cis rs6723108 0.627 rs2166480 ENSG00000224043.6 CCNT2-AS1 3.91 0.000109 0.0199 0.28 0.21 Type 2 diabetes; chr2:134879768 chr2:134735464~134918710:- LIHC cis rs6600233 0.874 rs11248850 ENSG00000268836.1 LA16c-OS12.2 3.91 0.000109 0.0199 0.24 0.21 High light scatter reticulocyte percentage of red cells; chr16:113599 chr16:185748~186294:- LIHC cis rs4925386 0.819 rs2890083 ENSG00000273619.1 RP5-908M14.9 3.91 0.00011 0.0199 0.17 0.21 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62336902 chr20:62386303~62386970:- LIHC cis rs73198271 0.681 rs35457364 ENSG00000253893.2 FAM85B 3.91 0.00011 0.0199 0.32 0.21 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8792280 chr8:8167819~8226614:- LIHC cis rs73198271 0.641 rs34473848 ENSG00000253893.2 FAM85B 3.91 0.00011 0.0199 0.32 0.21 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8792327 chr8:8167819~8226614:- LIHC cis rs73198271 0.601 rs11997731 ENSG00000253893.2 FAM85B 3.91 0.00011 0.0199 0.32 0.21 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8792338 chr8:8167819~8226614:- LIHC cis rs73198271 0.681 rs11987924 ENSG00000253893.2 FAM85B 3.91 0.00011 0.0199 0.32 0.21 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8792462 chr8:8167819~8226614:- LIHC cis rs8067287 0.688 rs11652843 ENSG00000205312.7 KRT17P4 3.91 0.00011 0.0199 0.35 0.21 Diabetic kidney disease; chr17:16939936 chr17:16847635~16852777:- LIHC cis rs950880 0.71 rs12469506 ENSG00000234389.1 AC007278.3 -3.91 0.00011 0.0199 -0.21 -0.21 Serum protein levels (sST2); chr2:102349411 chr2:102438713~102440475:+ LIHC cis rs2243480 1 rs316313 ENSG00000232546.1 RP11-458F8.1 -3.91 0.00011 0.0199 -0.23 -0.21 Diabetic kidney disease; chr7:66128561 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs316312 ENSG00000232546.1 RP11-458F8.1 -3.91 0.00011 0.0199 -0.23 -0.21 Diabetic kidney disease; chr7:66131504 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs419603 ENSG00000232546.1 RP11-458F8.1 -3.91 0.00011 0.0199 -0.23 -0.21 Diabetic kidney disease; chr7:66132354 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs431076 ENSG00000232546.1 RP11-458F8.1 -3.91 0.00011 0.0199 -0.23 -0.21 Diabetic kidney disease; chr7:66135333 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs2460422 ENSG00000232546.1 RP11-458F8.1 -3.91 0.00011 0.0199 -0.23 -0.21 Diabetic kidney disease; chr7:66136518 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs316334 ENSG00000232546.1 RP11-458F8.1 -3.91 0.00011 0.0199 -0.23 -0.21 Diabetic kidney disease; chr7:66137139 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs316330 ENSG00000232546.1 RP11-458F8.1 -3.91 0.00011 0.0199 -0.23 -0.21 Diabetic kidney disease; chr7:66140385 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs316326 ENSG00000232546.1 RP11-458F8.1 -3.91 0.00011 0.0199 -0.23 -0.21 Diabetic kidney disease; chr7:66144466 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs316325 ENSG00000232546.1 RP11-458F8.1 -3.91 0.00011 0.0199 -0.23 -0.21 Diabetic kidney disease; chr7:66144531 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs316321 ENSG00000232546.1 RP11-458F8.1 -3.91 0.00011 0.0199 -0.23 -0.21 Diabetic kidney disease; chr7:66146626 chr7:66848496~66858136:+ LIHC cis rs10129255 1 rs10141557 ENSG00000211972.2 IGHV3-66 3.91 0.00011 0.0199 0.17 0.21 Kawasaki disease; chr14:106767990 chr14:106675017~106675544:- LIHC cis rs244293 0.899 rs2787489 ENSG00000275710.1 RP11-257O5.4 3.91 0.00011 0.0199 0.22 0.21 Menarche (age at onset); chr17:55130775 chr17:54964474~54964679:+ LIHC cis rs244293 0.965 rs2787488 ENSG00000275710.1 RP11-257O5.4 3.91 0.00011 0.0199 0.22 0.21 Menarche (age at onset); chr17:55130790 chr17:54964474~54964679:+ LIHC cis rs748404 0.56 rs1869258 ENSG00000166763.7 STRCP1 3.91 0.00011 0.0199 0.26 0.21 Lung cancer; chr15:43511423 chr15:43699488~43718184:- LIHC cis rs748404 0.56 rs529611 ENSG00000166763.7 STRCP1 3.91 0.00011 0.0199 0.26 0.21 Lung cancer; chr15:43513790 chr15:43699488~43718184:- LIHC cis rs365302 0.556 rs576185 ENSG00000216480.2 RP3-393E18.1 -3.91 0.00011 0.0199 -0.25 -0.21 Coronary heart disease; chr6:159215346 chr6:159526062~159526527:- LIHC cis rs365302 0.556 rs605647 ENSG00000216480.2 RP3-393E18.1 -3.91 0.00011 0.0199 -0.25 -0.21 Coronary heart disease; chr6:159215793 chr6:159526062~159526527:- LIHC cis rs12304921 0.683 rs17125286 ENSG00000277201.1 AC087884.1 3.91 0.00011 0.0199 0.24 0.21 Type 2 diabetes; chr12:51060427 chr12:51049921~51050025:+ LIHC cis rs7665090 0.714 rs5026475 ENSG00000230069.3 LRRC37A15P -3.91 0.00011 0.0199 -0.19 -0.21 Primary biliary cholangitis; chr4:102633664 chr4:102727274~102730721:- LIHC cis rs4356203 0.905 rs594034 ENSG00000260196.1 RP1-239B22.5 -3.91 0.00011 0.0199 -0.25 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17200833 chr11:17380649~17383531:+ LIHC cis rs10833905 1 rs10833904 ENSG00000246225.5 RP11-17A1.3 3.91 0.00011 0.0199 0.26 0.21 Sudden cardiac arrest; chr11:23018465 chr11:22829380~22945393:+ LIHC cis rs17373728 0.739 rs6472896 ENSG00000249395.2 CASC9 3.91 0.00011 0.0199 0.23 0.21 Diabetic kidney disease; chr8:75278080 chr8:75223404~75324741:- LIHC cis rs1005277 0.579 rs2505257 ENSG00000276805.1 RP11-291L22.6 3.91 0.00011 0.0199 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38083736 chr10:38451030~38451785:+ LIHC cis rs2749592 0.918 rs4934590 ENSG00000275858.1 RP11-291L22.8 -3.91 0.00011 0.0199 -0.24 -0.21 Age-related hearing impairment (SNP x SNP interaction); chr10:37588641 chr10:38450738~38451069:- LIHC cis rs1023500 0.573 rs133381 ENSG00000226450.2 CYP2D8P 3.91 0.00011 0.0199 0.26 0.21 Schizophrenia; chr22:42074604 chr22:42149886~42155001:- LIHC cis rs7474896 0.616 rs1985260 ENSG00000120555.12 SEPT7P9 3.91 0.00011 0.0199 0.31 0.21 Obesity (extreme); chr10:38145162 chr10:38383069~38402916:- LIHC cis rs9976767 0.637 rs9325635 ENSG00000225218.1 AP001628.6 -3.91 0.00011 0.0199 -0.2 -0.21 Type 1 diabetes; chr21:42403180 chr21:42831040~42836477:- LIHC cis rs8040855 0.52 rs11629963 ENSG00000259295.5 CSPG4P12 -3.91 0.00011 0.0199 -0.32 -0.21 Bulimia nervosa; chr15:84986808 chr15:85191438~85213905:+ LIHC cis rs10129255 0.5 rs7159033 ENSG00000211972.2 IGHV3-66 3.91 0.00011 0.0199 0.15 0.21 Kawasaki disease; chr14:106701709 chr14:106675017~106675544:- LIHC cis rs340849 1 rs340849 ENSG00000274895.1 RP11-478J18.2 3.91 0.00011 0.0199 0.22 0.21 Alzheimer's disease; chr1:213944747 chr1:213983793~213986419:- LIHC cis rs12701220 0.522 rs12334290 ENSG00000229043.2 AC091729.9 -3.91 0.00011 0.0199 -0.26 -0.21 Bronchopulmonary dysplasia; chr7:1014881 chr7:1160374~1165267:+ LIHC cis rs6442522 0.606 rs12633820 ENSG00000249786.6 EAF1-AS1 3.91 0.00011 0.0199 0.24 0.21 Uric acid levels; chr3:15452495 chr3:15436171~15455940:- LIHC cis rs617219 0.889 rs1622238 ENSG00000251675.1 CTC-458I2.2 -3.91 0.00011 0.02 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79141517 chr5:80128361~80143883:+ LIHC cis rs55794721 0.543 rs1293260 ENSG00000224183.1 SDHDP6 -3.91 0.00011 0.02 -0.24 -0.21 Mean corpuscular volume;Plateletcrit; chr1:25382613 chr1:25294164~25294643:- LIHC cis rs7044106 0.762 rs1470307 ENSG00000238181.2 AHCYP2 -3.91 0.00011 0.02 -0.23 -0.21 Hip circumference adjusted for BMI; chr9:120670761 chr9:120720673~120721972:+ LIHC cis rs4787491 0.729 rs4788213 ENSG00000250616.2 RP11-455F5.3 3.91 0.00011 0.02 0.2 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30023203 chr16:30096430~30104116:+ LIHC cis rs4787491 0.679 rs7204852 ENSG00000250616.2 RP11-455F5.3 3.91 0.00011 0.02 0.2 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30028857 chr16:30096430~30104116:+ LIHC cis rs2885805 0.56 rs343822 ENSG00000259834.1 RP11-284N8.3 -3.91 0.00011 0.02 -0.18 -0.21 Cytomegalovirus antibody response; chr1:110800660 chr1:110653560~110657040:- LIHC cis rs11089937 0.597 rs9619794 ENSG00000211639.2 IGLV4-60 3.91 0.00011 0.02 0.18 0.21 Periodontitis (PAL4Q3); chr22:22132999 chr22:22162199~22162681:+ LIHC cis rs8040855 0.624 rs12903975 ENSG00000259295.5 CSPG4P12 3.91 0.00011 0.02 0.28 0.21 Bulimia nervosa; chr15:85006004 chr15:85191438~85213905:+ LIHC cis rs6910233 0.793 rs210158 ENSG00000224557.6 HLA-DPB2 -3.91 0.00011 0.02 -0.21 -0.21 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr6:33551531 chr6:33112451~33129084:+ LIHC cis rs6452524 1 rs62374373 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83137389 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs10043018 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83138498 chr5:83049376~83050964:- LIHC cis rs6452524 0.935 rs10037501 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83138722 chr5:83049376~83050964:- LIHC cis rs6452524 0.904 rs6452525 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83138752 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs7716931 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83138856 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs7721416 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83139174 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs6882220 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83139715 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs6452526 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83140992 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs6452527 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83141021 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs10055844 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83141276 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs10077862 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83141322 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs10474093 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83141612 chr5:83049376~83050964:- LIHC cis rs6452524 0.935 rs10473868 ENSG00000271862.1 RP11-343L5.2 3.91 0.00011 0.02 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83141628 chr5:83049376~83050964:- LIHC cis rs7665090 1 rs909349 ENSG00000230069.3 LRRC37A15P 3.91 0.00011 0.02 0.19 0.21 Primary biliary cholangitis; chr4:102635159 chr4:102727274~102730721:- LIHC cis rs1005277 0.522 rs289647 ENSG00000276805.1 RP11-291L22.6 3.91 0.000111 0.02 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37679350 chr10:38451030~38451785:+ LIHC cis rs1005277 0.522 rs11011343 ENSG00000275858.1 RP11-291L22.8 3.91 0.000111 0.02 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:37713770 chr10:38450738~38451069:- LIHC cis rs2286503 0.752 rs6461669 ENSG00000228649.7 AC005682.5 3.91 0.000111 0.02 0.23 0.21 Fibrinogen; chr7:22818447 chr7:22854178~22861579:+ LIHC cis rs73193808 0.666 rs7276548 ENSG00000212479.2 U3 3.91 0.000111 0.02 0.24 0.21 Coronary artery disease; chr21:29180518 chr21:29180425~29180639:- LIHC cis rs840616 0.933 rs13411274 ENSG00000224063.4 AC007319.1 3.91 0.000111 0.02 0.3 0.21 Coronary heart disease;Coronary artery disease; chr2:187371273 chr2:187003220~187554663:+ LIHC cis rs4964805 0.626 rs869993 ENSG00000257681.1 RP11-341G23.4 3.91 0.000111 0.02 0.22 0.21 Attention deficit hyperactivity disorder; chr12:103781360 chr12:103746315~103768858:- LIHC cis rs76878669 1 rs76878669 ENSG00000255320.1 RP11-755F10.1 3.91 0.000111 0.02 0.27 0.21 Educational attainment (years of education); chr11:66325096 chr11:66244840~66246239:- LIHC cis rs61472021 1 rs61472021 ENSG00000216436.2 HIST1H2APS1 3.91 0.000111 0.02 0.42 0.21 Autism spectrum disorder or schizophrenia; chr6:26089797 chr6:25732497~25732827:+ LIHC cis rs2036225 0.967 rs1813801 ENSG00000227825.4 SLC9A7P1 -3.91 0.000111 0.02 -0.22 -0.21 Amyotrophic lateral sclerosis (age of onset); chr12:98795044 chr12:98453835~98457145:- LIHC cis rs1005277 0.579 rs2474587 ENSG00000276805.1 RP11-291L22.6 3.91 0.000111 0.02 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38131738 chr10:38451030~38451785:+ LIHC cis rs1005277 0.579 rs2474588 ENSG00000276805.1 RP11-291L22.6 3.91 0.000111 0.02 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:38131942 chr10:38451030~38451785:+ LIHC cis rs10256972 0.967 rs1881122 ENSG00000199023.2 MIR339 -3.91 0.000111 0.02 -0.23 -0.21 Endometriosis;Longevity; chr7:1001310 chr7:1022935~1023045:- LIHC cis rs17376456 0.877 rs10060462 ENSG00000251023.1 RP11-549J18.1 -3.91 0.000111 0.02 -0.43 -0.21 Diabetic retinopathy; chr5:94119368 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10059630 ENSG00000251023.1 RP11-549J18.1 -3.91 0.000111 0.02 -0.43 -0.21 Diabetic retinopathy; chr5:94124102 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10213956 ENSG00000251023.1 RP11-549J18.1 -3.91 0.000111 0.02 -0.43 -0.21 Diabetic retinopathy; chr5:94125134 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs9314101 ENSG00000251023.1 RP11-549J18.1 -3.91 0.000111 0.02 -0.43 -0.21 Diabetic retinopathy; chr5:94125888 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10476526 ENSG00000251023.1 RP11-549J18.1 -3.91 0.000111 0.02 -0.43 -0.21 Diabetic retinopathy; chr5:94126211 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs17083460 ENSG00000251023.1 RP11-549J18.1 -3.91 0.000111 0.02 -0.43 -0.21 Diabetic retinopathy; chr5:94126649 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10073039 ENSG00000251023.1 RP11-549J18.1 -3.91 0.000111 0.02 -0.43 -0.21 Diabetic retinopathy; chr5:94132004 chr5:93860669~93863825:- LIHC cis rs193541 0.632 rs6595413 ENSG00000263432.2 RN7SL689P 3.91 0.000111 0.02 0.33 0.21 Glucose homeostasis traits; chr5:122821254 chr5:123022487~123022783:- LIHC cis rs193541 0.632 rs1363200 ENSG00000263432.2 RN7SL689P 3.91 0.000111 0.02 0.33 0.21 Glucose homeostasis traits; chr5:122828107 chr5:123022487~123022783:- LIHC cis rs193541 0.593 rs1035372 ENSG00000263432.2 RN7SL689P 3.91 0.000111 0.02 0.33 0.21 Glucose homeostasis traits; chr5:122833753 chr5:123022487~123022783:- LIHC cis rs6723108 0.627 rs4954187 ENSG00000224043.6 CCNT2-AS1 -3.91 0.000111 0.02 -0.29 -0.21 Type 2 diabetes; chr2:134842848 chr2:134735464~134918710:- LIHC cis rs9652601 0.959 rs9652582 ENSG00000274038.1 RP11-66H6.4 -3.91 0.000111 0.0201 -0.26 -0.21 Systemic lupus erythematosus; chr16:11080707 chr16:11056556~11057034:+ LIHC cis rs9652601 0.959 rs2041670 ENSG00000274038.1 RP11-66H6.4 -3.91 0.000111 0.0201 -0.26 -0.21 Systemic lupus erythematosus; chr16:11080795 chr16:11056556~11057034:+ LIHC cis rs3020736 0.5 rs6002616 ENSG00000205702.9 CYP2D7 -3.91 0.000111 0.0201 -0.24 -0.21 Autism spectrum disorder or schizophrenia; chr22:42108675 chr22:42140203~42144577:- LIHC cis rs3020736 0.5 rs7364293 ENSG00000205702.9 CYP2D7 -3.91 0.000111 0.0201 -0.24 -0.21 Autism spectrum disorder or schizophrenia; chr22:42110366 chr22:42140203~42144577:- LIHC cis rs8026198 0.929 rs7166785 ENSG00000260571.1 BNIP3P5 -3.91 0.000111 0.0201 -0.29 -0.21 Fibrinogen levels; chr15:42370455 chr15:42313687~42314386:+ LIHC cis rs6893782 0.887 rs274551 ENSG00000233006.5 AC034220.3 -3.91 0.000111 0.0201 -0.28 -0.21 Acylcarnitine levels; chr5:132391988 chr5:132311285~132369916:- LIHC cis rs2980439 0.87 rs2945230 ENSG00000253981.4 ALG1L13P 3.91 0.000111 0.0201 0.26 0.21 Neuroticism; chr8:8252414 chr8:8236003~8244667:- LIHC cis rs7176527 0.5 rs895571 ENSG00000230373.7 GOLGA6L5P 3.91 0.000111 0.0201 0.21 0.21 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84573922 chr15:84507885~84516814:- LIHC cis rs8087799 0.894 rs12961222 ENSG00000273232.1 RP11-370A5.2 3.91 0.000111 0.0201 0.24 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22688325 chr18:22882825~22883357:- LIHC cis rs2253762 0.507 rs4752630 ENSG00000276742.1 RP11-500G22.4 3.91 0.000111 0.0201 0.33 0.21 Breast cancer; chr10:121991440 chr10:121956782~121957098:+ LIHC cis rs2348418 0.733 rs11049508 ENSG00000247934.4 RP11-967K21.1 3.91 0.000111 0.0201 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28289633 chr12:28163298~28190738:- LIHC cis rs1005277 0.522 rs289645 ENSG00000276805.1 RP11-291L22.6 3.91 0.000111 0.0201 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37654714 chr10:38451030~38451785:+ LIHC cis rs7811142 1 rs7803454 ENSG00000242294.5 STAG3L5P 3.91 0.000111 0.0201 0.24 0.21 Platelet count; chr7:100393925 chr7:100336079~100351900:+ LIHC cis rs7811142 0.943 rs11769886 ENSG00000242294.5 STAG3L5P 3.91 0.000111 0.0201 0.24 0.21 Platelet count; chr7:100400984 chr7:100336079~100351900:+ LIHC cis rs7811142 0.887 rs35111986 ENSG00000242294.5 STAG3L5P 3.91 0.000111 0.0201 0.24 0.21 Platelet count; chr7:100402651 chr7:100336079~100351900:+ LIHC cis rs9527 0.615 rs12248123 ENSG00000236937.2 PTGES3P4 3.91 0.000111 0.0201 0.26 0.21 Arsenic metabolism; chr10:102975609 chr10:102845595~102845950:+ LIHC cis rs2658782 0.789 rs2259633 ENSG00000279684.1 RP11-755E23.2 -3.91 0.000111 0.0201 -0.35 -0.21 Pulmonary function decline; chr11:93408414 chr11:93286629~93288903:- LIHC cis rs7712401 0.601 rs30067 ENSG00000263432.2 RN7SL689P 3.91 0.000111 0.0201 0.3 0.21 Mean platelet volume; chr5:122957973 chr5:123022487~123022783:- LIHC cis rs1005277 0.54 rs2145487 ENSG00000275858.1 RP11-291L22.8 3.91 0.000111 0.0201 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:37721149 chr10:38450738~38451069:- LIHC cis rs1005277 0.54 rs4934907 ENSG00000275858.1 RP11-291L22.8 3.91 0.000111 0.0201 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:37726302 chr10:38450738~38451069:- LIHC cis rs1005277 0.54 rs11011351 ENSG00000275858.1 RP11-291L22.8 3.91 0.000111 0.0201 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:37741597 chr10:38450738~38451069:- LIHC cis rs2243480 1 rs160639 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000111 0.0201 -0.23 -0.21 Diabetic kidney disease; chr7:66115000 chr7:66848496~66858136:+ LIHC cis rs7809950 0.723 rs62483634 ENSG00000238832.1 snoU109 -3.91 0.000111 0.0201 -0.26 -0.21 Coronary artery disease; chr7:107238071 chr7:107603363~107603507:+ LIHC cis rs559928 0.606 rs61083753 ENSG00000236935.1 AP003774.1 3.91 0.000111 0.0201 0.28 0.21 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64125193 chr11:64325050~64329504:- LIHC cis rs6723226 0.593 rs176401 ENSG00000276334.1 AL133243.1 -3.91 0.000111 0.0201 -0.23 -0.21 Intelligence (multi-trait analysis); chr2:32411443 chr2:32521927~32523547:+ LIHC cis rs7560272 0.512 rs12998980 ENSG00000273245.1 RP11-434P11.2 -3.91 0.000111 0.0201 -0.25 -0.21 Schizophrenia; chr2:73703599 chr2:73750256~73750786:- LIHC cis rs617219 0.853 rs57587638 ENSG00000251675.1 CTC-458I2.2 -3.91 0.000111 0.0201 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79217344 chr5:80128361~80143883:+ LIHC cis rs748404 0.697 rs501884 ENSG00000205771.5 CATSPER2P1 -3.91 0.000111 0.0201 -0.25 -0.21 Lung cancer; chr15:43261784 chr15:43726918~43747094:- LIHC cis rs748404 0.697 rs504417 ENSG00000205771.5 CATSPER2P1 -3.91 0.000111 0.0201 -0.25 -0.21 Lung cancer; chr15:43262028 chr15:43726918~43747094:- LIHC cis rs1501138 0.547 rs317856 ENSG00000263327.5 TAPT1-AS1 3.91 0.000111 0.0201 0.28 0.21 Systemic juvenile idiopathic arthritis; chr4:16159942 chr4:16226685~16320140:+ LIHC cis rs1075265 0.626 rs805320 ENSG00000233266.1 HMGB1P31 3.91 0.000111 0.0202 0.26 0.21 Chronotype;Morning vs. evening chronotype; chr2:53911305 chr2:54051334~54051760:+ LIHC cis rs1499614 1 rs1882655 ENSG00000232546.1 RP11-458F8.1 3.91 0.000111 0.0202 0.23 0.21 Gout; chr7:66682070 chr7:66848496~66858136:+ LIHC cis rs1499614 0.831 rs3800822 ENSG00000232546.1 RP11-458F8.1 3.91 0.000111 0.0202 0.23 0.21 Gout; chr7:66682162 chr7:66848496~66858136:+ LIHC cis rs1499614 1 rs1638731 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000111 0.0202 -0.23 -0.21 Gout; chr7:66679692 chr7:66848496~66858136:+ LIHC cis rs11977715 0.521 rs6465466 ENSG00000233942.1 AC004012.1 -3.91 0.000112 0.0202 -0.3 -0.21 Middle childhood and early adolescence aggressive behavior; chr7:95502275 chr7:95471835~95473998:+ LIHC cis rs11096990 0.656 rs3733284 ENSG00000249207.1 RP11-360F5.1 3.91 0.000112 0.0202 0.21 0.21 Cognitive function; chr4:39299714 chr4:39112677~39126818:- LIHC cis rs11148252 0.624 rs6561682 ENSG00000278238.1 RP11-245D16.4 3.91 0.000112 0.0202 0.2 0.21 Lewy body disease; chr13:52692162 chr13:52454775~52455331:- LIHC cis rs2243480 0.908 rs313822 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000112 0.0202 -0.23 -0.21 Diabetic kidney disease; chr7:66108952 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs313820 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000112 0.0202 -0.23 -0.21 Diabetic kidney disease; chr7:66109479 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs313824 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000112 0.0202 -0.23 -0.21 Diabetic kidney disease; chr7:66116220 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs186378 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000112 0.0202 -0.23 -0.21 Diabetic kidney disease; chr7:66117071 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs160637 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000112 0.0202 -0.23 -0.21 Diabetic kidney disease; chr7:66119331 chr7:66848496~66858136:+ LIHC cis rs7914558 0.646 rs1046778 ENSG00000236937.2 PTGES3P4 3.91 0.000112 0.0202 0.26 0.21 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102901727 chr10:102845595~102845950:+ LIHC cis rs7914558 0.646 rs11191459 ENSG00000236937.2 PTGES3P4 3.91 0.000112 0.0202 0.26 0.21 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102902361 chr10:102845595~102845950:+ LIHC cis rs597539 0.652 rs636049 ENSG00000250508.1 RP11-757G1.6 -3.91 0.000112 0.0202 -0.3 -0.21 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68899730 chr11:68870664~68874542:+ LIHC cis rs7915414 0.663 rs35476215 ENSG00000230338.1 MTND4P19 3.91 0.000112 0.0202 0.23 0.21 Clopidogrel active metabolite levels; chr10:94810172 chr10:94774156~94774633:- LIHC cis rs4873772 0.735 rs4873395 ENSG00000253608.1 RP11-770E5.1 -3.91 0.000112 0.0202 -0.23 -0.21 Lobe attachment (rater-scored or self-reported); chr8:47594066 chr8:48551567~48698510:+ LIHC cis rs17197037 0.545 rs17792617 ENSG00000240954.1 RPL4P1 -3.91 0.000112 0.0202 -0.2 -0.21 Bipolar disorder; chr14:21315725 chr14:21750269~21751546:+ LIHC cis rs7617773 0.779 rs77957078 ENSG00000228638.1 FCF1P2 -3.91 0.000112 0.0202 -0.24 -0.21 Coronary artery disease; chr3:48289796 chr3:48290793~48291375:- LIHC cis rs7712401 0.601 rs246322 ENSG00000263432.2 RN7SL689P -3.91 0.000112 0.0202 -0.3 -0.21 Mean platelet volume; chr5:122971574 chr5:123022487~123022783:- LIHC cis rs2243480 1 rs73142166 ENSG00000226002.1 RP11-460N20.5 -3.91 0.000112 0.0202 -0.31 -0.21 Diabetic kidney disease; chr7:65910845 chr7:65084103~65100232:+ LIHC cis rs17482078 1 rs17482078 ENSG00000248734.2 CTD-2260A17.1 3.91 0.000112 0.0202 0.3 0.21 Behcet's disease;Blood protein levels; chr5:96783162 chr5:96784777~96785999:+ LIHC cis rs7893279 0.505 rs7075135 ENSG00000225527.1 RP11-383B4.4 3.91 0.000112 0.0202 0.3 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18595123 chr10:18531849~18533336:- LIHC cis rs316274 0.855 rs178397 ENSG00000273384.1 RP5-1098D14.1 -3.91 0.000112 0.0202 -0.26 -0.21 Immune response to smallpox vaccine (IL-6); chr1:178212419 chr1:178651706~178652282:+ LIHC cis rs2439831 0.681 rs956391 ENSG00000166763.7 STRCP1 -3.91 0.000112 0.0202 -0.29 -0.21 Lung cancer in ever smokers; chr15:43325295 chr15:43699488~43718184:- LIHC cis rs4763879 0.634 rs61915472 ENSG00000256673.1 RP11-599J14.2 3.91 0.000112 0.0202 0.2 0.21 Type 1 diabetes; chr12:9700995 chr12:9398355~9414851:- LIHC cis rs2243480 0.803 rs36127118 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000112 0.0202 -0.23 -0.21 Diabetic kidney disease; chr7:66100518 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1499614 ENSG00000228409.4 CCT6P1 3.91 0.000112 0.0202 0.22 0.21 Diabetic kidney disease; chr7:66265811 chr7:65751142~65763354:+ LIHC cis rs752590 1 rs752590 ENSG00000189223.12 PAX8-AS1 -3.91 0.000112 0.0202 -0.32 -0.21 Mucinous ovarian carcinoma; chr2:113215368 chr2:113211522~113276581:+ LIHC cis rs11123170 0.529 rs35606997 ENSG00000189223.12 PAX8-AS1 -3.91 0.000112 0.0202 -0.36 -0.21 Renal function-related traits (BUN); chr2:113215773 chr2:113211522~113276581:+ LIHC cis rs2275906 0.557 rs56392519 ENSG00000216436.2 HIST1H2APS1 3.91 0.000112 0.0202 0.32 0.21 Urate levels in lean individuals; chr6:25885943 chr6:25732497~25732827:+ LIHC cis rs617219 0.889 rs56064275 ENSG00000251675.1 CTC-458I2.2 -3.91 0.000112 0.0202 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79141129 chr5:80128361~80143883:+ LIHC cis rs3204270 0.684 rs62080212 ENSG00000281517.1 Metazoa_SRP -3.91 0.000112 0.0202 -0.4 -0.21 Dental caries; chr17:81675470 chr17:81718849~81719095:- LIHC cis rs1816213 0.744 rs12989709 ENSG00000273466.1 RP11-548H3.1 3.91 0.000112 0.0202 0.33 0.21 Diastolic blood pressure; chr2:218575705 chr2:218633256~218634014:- LIHC cis rs7809950 0.678 rs7788330 ENSG00000238832.1 snoU109 -3.91 0.000112 0.0202 -0.26 -0.21 Coronary artery disease; chr7:107345203 chr7:107603363~107603507:+ LIHC cis rs7809950 0.678 rs7788271 ENSG00000238832.1 snoU109 -3.91 0.000112 0.0202 -0.26 -0.21 Coronary artery disease; chr7:107345428 chr7:107603363~107603507:+ LIHC cis rs10761256 0.806 rs7024028 ENSG00000227603.1 RP11-165J3.6 -3.91 0.000112 0.0202 -0.24 -0.21 Itch intensity from mosquito bite adjusted by bite size; chr9:93632740 chr9:93435332~93437121:- LIHC cis rs2243480 1 rs466983 ENSG00000228409.4 CCT6P1 3.91 0.000112 0.0202 0.22 0.21 Diabetic kidney disease; chr7:66055509 chr7:65751142~65763354:+ LIHC cis rs3812762 0.957 rs10160684 ENSG00000254860.4 TMEM9B-AS1 -3.91 0.000112 0.0202 -0.22 -0.21 Hypospadias; chr11:8753872 chr11:8964675~8977527:+ LIHC cis rs4578769 0.765 rs1609464 ENSG00000265943.1 RP11-739L10.1 -3.91 0.000112 0.0202 -0.27 -0.21 Eosinophil percentage of white cells; chr18:22844191 chr18:22699481~22933764:- LIHC cis rs9652601 0.959 rs741172 ENSG00000274038.1 RP11-66H6.4 -3.91 0.000112 0.0203 -0.26 -0.21 Systemic lupus erythematosus; chr16:11106941 chr16:11056556~11057034:+ LIHC cis rs7849270 1 rs2254230 ENSG00000268707.1 RP11-247A12.7 3.91 0.000112 0.0203 0.22 0.21 Blood metabolite ratios; chr9:129142898 chr9:129170434~129170940:+ LIHC cis rs875971 0.545 rs73152714 ENSG00000273024.4 INTS4P2 -3.91 0.000112 0.0203 -0.23 -0.21 Aortic root size; chr7:66534641 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs4718364 ENSG00000273024.4 INTS4P2 -3.91 0.000112 0.0203 -0.23 -0.21 Aortic root size; chr7:66536353 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs6961853 ENSG00000273024.4 INTS4P2 -3.91 0.000112 0.0203 -0.23 -0.21 Aortic root size; chr7:66537035 chr7:65647864~65715661:+ LIHC cis rs875971 0.528 rs801213 ENSG00000273024.4 INTS4P2 3.91 0.000112 0.0203 0.23 0.21 Aortic root size; chr7:66549931 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs801212 ENSG00000273024.4 INTS4P2 3.91 0.000112 0.0203 0.23 0.21 Aortic root size; chr7:66550643 chr7:65647864~65715661:+ LIHC cis rs2243480 0.901 rs12530490 ENSG00000232546.1 RP11-458F8.1 3.91 0.000112 0.0203 0.23 0.21 Diabetic kidney disease; chr7:66226660 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs7778911 ENSG00000232546.1 RP11-458F8.1 3.91 0.000112 0.0203 0.23 0.21 Diabetic kidney disease; chr7:66229519 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1979823 ENSG00000232546.1 RP11-458F8.1 3.91 0.000112 0.0203 0.23 0.21 Diabetic kidney disease; chr7:66239626 chr7:66848496~66858136:+ LIHC cis rs12956009 0.518 rs4458096 ENSG00000280212.1 RP11-49K24.3 3.91 0.000112 0.0203 0.22 0.21 Educational attainment (years of education); chr18:47293184 chr18:47076117~47076594:+ LIHC cis rs6545883 0.507 rs59981505 ENSG00000271889.1 RP11-493E12.1 -3.91 0.000112 0.0203 -0.25 -0.21 Tuberculosis; chr2:61353394 chr2:61151433~61162105:- LIHC cis rs2299116 1 rs4722849 ENSG00000225264.3 ZNRF2P2 -3.91 0.000112 0.0203 -0.22 -0.21 Serum thyroid-stimulating hormone levels; chr7:28781137 chr7:29598795~29685255:- LIHC cis rs2299116 0.924 rs35159971 ENSG00000225264.3 ZNRF2P2 -3.91 0.000112 0.0203 -0.22 -0.21 Serum thyroid-stimulating hormone levels; chr7:28781305 chr7:29598795~29685255:- LIHC cis rs2299116 0.522 rs34382884 ENSG00000225264.3 ZNRF2P2 -3.91 0.000112 0.0203 -0.22 -0.21 Serum thyroid-stimulating hormone levels; chr7:28781938 chr7:29598795~29685255:- LIHC cis rs651907 0.557 rs13077925 ENSG00000244119.1 PDCL3P4 3.91 0.000112 0.0203 0.22 0.21 Colorectal cancer; chr3:101769337 chr3:101712472~101713191:+ LIHC cis rs240993 0.812 rs459809 ENSG00000255389.1 C6orf3 -3.91 0.000112 0.0203 -0.24 -0.21 Inflammatory skin disease;Psoriasis; chr6:111331964 chr6:111599875~111602295:+ LIHC cis rs748404 0.697 rs493444 ENSG00000205771.5 CATSPER2P1 -3.91 0.000112 0.0203 -0.25 -0.21 Lung cancer; chr15:43274272 chr15:43726918~43747094:- LIHC cis rs4578769 0.722 rs1010801 ENSG00000265943.1 RP11-739L10.1 3.91 0.000112 0.0203 0.26 0.21 Eosinophil percentage of white cells; chr18:23027435 chr18:22699481~22933764:- LIHC cis rs638893 0.527 rs7933859 ENSG00000278376.1 RP11-158I9.8 -3.91 0.000112 0.0203 -0.38 -0.21 Vitiligo; chr11:118791336 chr11:118791254~118793137:+ LIHC cis rs638893 0.578 rs4508234 ENSG00000278376.1 RP11-158I9.8 -3.91 0.000112 0.0203 -0.38 -0.21 Vitiligo; chr11:118791494 chr11:118791254~118793137:+ LIHC cis rs638893 0.578 rs5006102 ENSG00000278376.1 RP11-158I9.8 -3.91 0.000112 0.0203 -0.38 -0.21 Vitiligo; chr11:118791631 chr11:118791254~118793137:+ LIHC cis rs17772222 0.917 rs17188228 ENSG00000258789.1 RP11-507K2.3 -3.91 0.000112 0.0203 -0.25 -0.21 Coronary artery calcification; chr14:88738921 chr14:88551597~88552493:+ LIHC cis rs4792901 0.918 rs76798487 ENSG00000279602.1 CTD-3014M21.1 -3.91 0.000112 0.0203 -0.24 -0.21 Dupuytren's disease; chr17:43556023 chr17:43360041~43361361:- LIHC cis rs6545883 0.655 rs11893880 ENSG00000271889.1 RP11-493E12.1 3.91 0.000112 0.0203 0.25 0.21 Tuberculosis; chr2:61194884 chr2:61151433~61162105:- LIHC cis rs11733284 1 rs321622 ENSG00000259959.1 RP11-121C2.2 3.91 0.000112 0.0203 0.19 0.21 Gout;Renal underexcretion gout; chr4:48022363 chr4:47840122~47844339:- LIHC cis rs4144027 0.791 rs66473563 ENSG00000258534.1 CTD-2134A5.4 -3.91 0.000113 0.0203 -0.23 -0.21 Blood metabolite levels; chr14:103895534 chr14:103854366~103880111:- LIHC cis rs9640161 0.659 rs7781827 ENSG00000261305.1 RP4-584D14.7 3.91 0.000113 0.0203 0.25 0.21 Blood protein levels;Circulating chemerin levels; chr7:150311769 chr7:150341771~150342607:+ LIHC cis rs4948102 0.731 rs4689 ENSG00000226278.1 PSPHP1 -3.91 0.000113 0.0203 -0.24 -0.21 Plasma homocysteine levels (post-methionine load test); chr7:55999323 chr7:55764797~55773288:+ LIHC cis rs6723108 0.627 rs3814358 ENSG00000224043.6 CCNT2-AS1 -3.91 0.000113 0.0203 -0.28 -0.21 Type 2 diabetes; chr2:134866438 chr2:134735464~134918710:- LIHC cis rs10129255 0.5 rs11628999 ENSG00000211972.2 IGHV3-66 3.91 0.000113 0.0203 0.15 0.21 Kawasaki disease; chr14:106800208 chr14:106675017~106675544:- LIHC cis rs10027350 0.765 rs6838393 ENSG00000281501.1 SEPSECS-AS1 3.91 0.000113 0.0203 0.25 0.21 Childhood ear infection; chr4:25172629 chr4:25160641~25201440:+ LIHC cis rs2243480 1 rs313809 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000113 0.0203 -0.23 -0.21 Diabetic kidney disease; chr7:66034996 chr7:66848496~66858136:+ LIHC cis rs244293 0.673 rs12944690 ENSG00000275710.1 RP11-257O5.4 3.91 0.000113 0.0203 0.24 0.21 Menarche (age at onset); chr17:54952253 chr17:54964474~54964679:+ LIHC cis rs9595908 0.709 rs17594677 ENSG00000212293.1 SNORA16 3.91 0.000113 0.0204 0.24 0.21 Body mass index; chr13:32734875 chr13:32420390~32420516:- LIHC cis rs6142102 0.961 rs6088355 ENSG00000275784.1 RP5-1125A11.6 -3.91 0.000113 0.0204 -0.24 -0.21 Skin pigmentation; chr20:33958081 chr20:33989480~33991818:- LIHC cis rs6142102 0.961 rs6057957 ENSG00000275784.1 RP5-1125A11.6 -3.91 0.000113 0.0204 -0.24 -0.21 Skin pigmentation; chr20:33962052 chr20:33989480~33991818:- LIHC cis rs11096990 0.634 rs2839765 ENSG00000249207.1 RP11-360F5.1 3.91 0.000113 0.0204 0.21 0.21 Cognitive function; chr4:39293933 chr4:39112677~39126818:- LIHC cis rs763121 0.853 rs5750627 ENSG00000273076.1 RP3-508I15.22 3.91 0.000113 0.0204 0.23 0.21 Menopause (age at onset); chr22:38586316 chr22:38743495~38743910:+ LIHC cis rs4332428 1 rs4268415 ENSG00000224251.5 RP11-499O7.7 3.91 0.000113 0.0204 0.41 0.21 Height; chr10:4941398 chr10:4995488~4997380:+ LIHC cis rs17818399 0.597 rs12104572 ENSG00000239332.4 LINC01119 -3.91 0.000113 0.0204 -0.27 -0.21 Height; chr2:46635327 chr2:46816697~46859007:+ LIHC cis rs8087799 0.894 rs2385660 ENSG00000273232.1 RP11-370A5.2 3.91 0.000113 0.0204 0.24 0.21 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22675029 chr18:22882825~22883357:- LIHC cis rs617219 0.89 rs10060869 ENSG00000251675.1 CTC-458I2.2 -3.91 0.000113 0.0204 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79194156 chr5:80128361~80143883:+ LIHC cis rs617219 0.817 rs72764978 ENSG00000251675.1 CTC-458I2.2 -3.91 0.000113 0.0204 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79196017 chr5:80128361~80143883:+ LIHC cis rs617219 0.89 rs72764981 ENSG00000251675.1 CTC-458I2.2 -3.91 0.000113 0.0204 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79198180 chr5:80128361~80143883:+ LIHC cis rs1816213 0.744 rs13026613 ENSG00000273466.1 RP11-548H3.1 -3.91 0.000113 0.0204 -0.33 -0.21 Diastolic blood pressure; chr2:218621221 chr2:218633256~218634014:- LIHC cis rs79040073 0.607 rs17400706 ENSG00000259531.2 RP11-295H24.3 3.91 0.000113 0.0204 0.4 0.21 Lung cancer in ever smokers; chr15:49455148 chr15:49365124~49366685:- LIHC cis rs748404 0.556 rs7166467 ENSG00000205771.5 CATSPER2P1 3.91 0.000113 0.0204 0.26 0.21 Lung cancer; chr15:43148324 chr15:43726918~43747094:- LIHC cis rs3096299 0.606 rs4785674 ENSG00000274627.1 RP11-104N10.2 3.91 0.000113 0.0204 0.23 0.21 Multiple myeloma (IgH translocation); chr16:89470205 chr16:89516797~89522217:+ LIHC cis rs4915737 0.569 rs6673795 ENSG00000270742.1 RP4-802A10.1 -3.91 0.000113 0.0204 -0.32 -0.21 Bipolar disorder; chr1:61358046 chr1:61124733~61125202:+ LIHC cis rs728616 0.764 rs12413678 ENSG00000225484.5 NUTM2B-AS1 -3.91 0.000113 0.0204 -0.47 -0.21 Chronic obstructive pulmonary disease-related biomarkers; chr10:79927343 chr10:79663088~79826594:- LIHC cis rs875971 0.929 rs10950041 ENSG00000237310.1 GS1-124K5.4 3.91 0.000113 0.0204 0.18 0.21 Aortic root size; chr7:66508888 chr7:66493706~66495474:+ LIHC cis rs1023500 0.573 rs133377 ENSG00000205702.9 CYP2D7 3.91 0.000113 0.0204 0.23 0.21 Schizophrenia; chr22:42070946 chr22:42140203~42144577:- LIHC cis rs11098499 0.604 rs12642411 ENSG00000260091.1 RP11-33B1.4 -3.91 0.000113 0.0204 -0.15 -0.21 Corneal astigmatism; chr4:119659370 chr4:119409333~119410233:+ LIHC cis rs6732160 0.657 rs10171459 ENSG00000272702.1 RP11-44N22.3 3.91 0.000113 0.0204 0.23 0.21 Intelligence (multi-trait analysis); chr2:73207600 chr2:73113018~73115907:+ LIHC cis rs2032366 1 rs10439023 ENSG00000267279.1 RP11-879F14.2 -3.91 0.000113 0.0204 -0.24 -0.21 Obesity-related traits; chr18:61597073 chr18:61585746~61606916:- LIHC cis rs2243480 1 rs6964245 ENSG00000232546.1 RP11-458F8.1 3.91 0.000113 0.0204 0.23 0.21 Diabetic kidney disease; chr7:66253730 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs6964530 ENSG00000232546.1 RP11-458F8.1 3.91 0.000113 0.0204 0.23 0.21 Diabetic kidney disease; chr7:66253864 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs10807701 ENSG00000232546.1 RP11-458F8.1 3.91 0.000113 0.0204 0.23 0.21 Diabetic kidney disease; chr7:66259699 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1499613 ENSG00000232546.1 RP11-458F8.1 3.91 0.000113 0.0204 0.23 0.21 Diabetic kidney disease; chr7:66265873 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1553174 ENSG00000232546.1 RP11-458F8.1 3.91 0.000113 0.0204 0.23 0.21 Diabetic kidney disease; chr7:66266207 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs10950032 ENSG00000232546.1 RP11-458F8.1 3.91 0.000113 0.0204 0.23 0.21 Diabetic kidney disease; chr7:66273604 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1392104 ENSG00000232546.1 RP11-458F8.1 3.91 0.000113 0.0204 0.23 0.21 Diabetic kidney disease; chr7:66294120 chr7:66848496~66858136:+ LIHC cis rs7893279 0.505 rs12767923 ENSG00000225527.1 RP11-383B4.4 3.91 0.000113 0.0204 0.3 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18618822 chr10:18531849~18533336:- LIHC cis rs7617773 0.78 rs35411187 ENSG00000228638.1 FCF1P2 -3.91 0.000113 0.0204 -0.24 -0.21 Coronary artery disease; chr3:48318527 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs11714176 ENSG00000228638.1 FCF1P2 -3.91 0.000113 0.0204 -0.24 -0.21 Coronary artery disease; chr3:48319372 chr3:48290793~48291375:- LIHC cis rs6142102 0.538 rs6142058 ENSG00000275784.1 RP5-1125A11.6 -3.91 0.000114 0.0205 -0.22 -0.21 Skin pigmentation; chr20:33954995 chr20:33989480~33991818:- LIHC cis rs6142102 0.502 rs58393429 ENSG00000275784.1 RP5-1125A11.6 -3.91 0.000114 0.0205 -0.22 -0.21 Skin pigmentation; chr20:33957996 chr20:33989480~33991818:- LIHC cis rs6142102 0.602 rs4911380 ENSG00000275784.1 RP5-1125A11.6 -3.91 0.000114 0.0205 -0.22 -0.21 Skin pigmentation; chr20:33958418 chr20:33989480~33991818:- LIHC cis rs6142102 0.625 rs4911138 ENSG00000275784.1 RP5-1125A11.6 -3.91 0.000114 0.0205 -0.22 -0.21 Skin pigmentation; chr20:33959893 chr20:33989480~33991818:- LIHC cis rs6142102 0.625 rs4243974 ENSG00000275784.1 RP5-1125A11.6 -3.91 0.000114 0.0205 -0.22 -0.21 Skin pigmentation; chr20:33960062 chr20:33989480~33991818:- LIHC cis rs2243480 1 rs781150 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000114 0.0205 -0.23 -0.21 Diabetic kidney disease; chr7:66015986 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs313798 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000114 0.0205 -0.23 -0.21 Diabetic kidney disease; chr7:66028044 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs35396113 ENSG00000232546.1 RP11-458F8.1 -3.91 0.000114 0.0205 -0.23 -0.21 Diabetic kidney disease; chr7:66030474 chr7:66848496~66858136:+ LIHC cis rs4578769 0.959 rs7226652 ENSG00000265943.1 RP11-739L10.1 3.91 0.000114 0.0205 0.26 0.21 Eosinophil percentage of white cells; chr18:22904043 chr18:22699481~22933764:- LIHC cis rs3845817 0.832 rs702950 ENSG00000281920.1 RP11-418H16.1 -3.9 0.000114 0.0205 -0.25 -0.21 Bipolar disorder; chr2:65537776 chr2:65623272~65628424:+ LIHC cis rs7989332 1 rs4769117 ENSG00000275964.1 RP11-61K9.3 -3.9 0.000114 0.0205 -0.28 -0.21 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20480585 chr13:19863858~19865048:+ LIHC cis rs17774123 0.805 rs79915059 ENSG00000257808.1 RP11-1136G11.8 3.9 0.000114 0.0205 0.39 0.21 Diastolic blood pressure; chr12:53903014 chr12:53159586~53161000:+ LIHC cis rs7722022 0.961 rs2052507 ENSG00000253428.1 CTB-43E15.2 3.9 0.000114 0.0205 0.22 0.21 Adiponectin levels; chr5:173519293 chr5:173689459~173705849:+ LIHC cis rs4356203 0.905 rs6486354 ENSG00000260196.1 RP1-239B22.5 -3.9 0.000114 0.0205 -0.25 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17178561 chr11:17380649~17383531:+ LIHC cis rs1023500 1 rs6002548 ENSG00000227370.1 RP4-669P10.19 3.9 0.000114 0.0205 0.27 0.21 Schizophrenia; chr22:41941036 chr22:42132543~42132998:+ LIHC cis rs4650994 1 rs10798619 ENSG00000213057.5 C1orf220 3.9 0.000114 0.0205 0.18 0.21 HDL cholesterol;HDL cholesterol levels; chr1:178563382 chr1:178542752~178548889:+ LIHC cis rs2036707 0.744 rs79922539 ENSG00000277246.1 RP11-153I24.4 -3.9 0.000114 0.0205 -0.43 -0.21 Obesity-related traits; chr13:107823845 chr13:108267320~108267734:+ LIHC cis rs17264034 0.861 rs11749803 ENSG00000250786.1 SNHG18 3.9 0.000114 0.0205 0.27 0.21 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9553456 chr5:9546200~9550609:+ LIHC cis rs17264034 0.861 rs56344213 ENSG00000250786.1 SNHG18 3.9 0.000114 0.0205 0.27 0.21 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9553756 chr5:9546200~9550609:+ LIHC cis rs7688540 0.771 rs11737268 ENSG00000275426.1 CH17-262A2.1 3.9 0.000114 0.0205 0.25 0.21 Facial morphology (factor 6, height of vermillion lower lip); chr4:230663 chr4:149738~150317:+ LIHC cis rs7688540 0.771 rs11726829 ENSG00000275426.1 CH17-262A2.1 3.9 0.000114 0.0205 0.25 0.21 Facial morphology (factor 6, height of vermillion lower lip); chr4:231159 chr4:149738~150317:+ LIHC cis rs1005277 0.579 rs2103938 ENSG00000120555.12 SEPT7P9 3.9 0.000114 0.0205 0.24 0.21 Extrinsic epigenetic age acceleration; chr10:38205070 chr10:38383069~38402916:- LIHC cis rs7915414 0.951 rs7912099 ENSG00000230338.1 MTND4P19 3.9 0.000114 0.0205 0.22 0.21 Clopidogrel active metabolite levels; chr10:94750932 chr10:94774156~94774633:- LIHC cis rs2243480 1 rs160642 ENSG00000232546.1 RP11-458F8.1 -3.9 0.000114 0.0205 -0.23 -0.21 Diabetic kidney disease; chr7:66093386 chr7:66848496~66858136:+ LIHC cis rs2243480 0.614 rs34032527 ENSG00000232546.1 RP11-458F8.1 -3.9 0.000114 0.0205 -0.23 -0.21 Diabetic kidney disease; chr7:66100154 chr7:66848496~66858136:+ LIHC cis rs4561483 0.801 rs33640 ENSG00000261560.1 RP11-166B2.3 -3.9 0.000114 0.0205 -0.24 -0.21 Testicular germ cell tumor; chr16:11893017 chr16:11881075~11882569:- LIHC cis rs465969 0.793 rs34288099 ENSG00000255389.1 C6orf3 -3.9 0.000114 0.0205 -0.4 -0.21 Psoriasis; chr6:111424034 chr6:111599875~111602295:+ LIHC cis rs2749097 1 rs11208259 ENSG00000244256.3 RN7SL130P -3.9 0.000114 0.0205 -0.27 -0.21 Alcohol consumption (transferrin glycosylation); chr1:63657549 chr1:63655743~63656047:+ LIHC cis rs4787491 0.729 rs11544328 ENSG00000250616.2 RP11-455F5.3 3.9 0.000114 0.0205 0.2 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30025807 chr16:30096430~30104116:+ LIHC cis rs11148252 0.967 rs4286007 ENSG00000278238.1 RP11-245D16.4 -3.9 0.000114 0.0205 -0.2 -0.21 Lewy body disease; chr13:52448383 chr13:52454775~52455331:- LIHC cis rs10080237 0.564 rs2490230 ENSG00000272129.1 RP11-250B2.6 3.9 0.000114 0.0205 0.2 0.21 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr6:80102747 chr6:80355424~80356859:+ LIHC cis rs875971 0.867 rs1002053 ENSG00000237310.1 GS1-124K5.4 -3.9 0.000114 0.0205 -0.18 -0.21 Aortic root size; chr7:66333558 chr7:66493706~66495474:+ LIHC cis rs2383378 0.714 rs11626702 ENSG00000258474.1 RP11-187E13.1 3.9 0.000114 0.0205 0.27 0.21 Anorexia nervosa; chr14:32810003 chr14:31944853~31950382:+ LIHC cis rs6745190 0.953 rs4366861 ENSG00000236153.1 AC104076.3 -3.9 0.000114 0.0205 -0.28 -0.21 White blood cell count; chr2:180988301 chr2:180979427~180980090:- LIHC cis rs12817211 0.502 rs59262224 ENSG00000272368.2 RP4-605O3.4 -3.9 0.000114 0.0205 -0.23 -0.21 Colorectal or endometrial cancer; chr12:50117164 chr12:50112197~50165618:+ LIHC cis rs12817211 0.502 rs7135322 ENSG00000272368.2 RP4-605O3.4 -3.9 0.000114 0.0205 -0.23 -0.21 Colorectal or endometrial cancer; chr12:50118065 chr12:50112197~50165618:+ LIHC cis rs11098499 0.644 rs3986377 ENSG00000260091.1 RP11-33B1.4 -3.9 0.000114 0.0205 -0.14 -0.21 Corneal astigmatism; chr4:119339115 chr4:119409333~119410233:+ LIHC cis rs10028773 0.556 rs4473640 ENSG00000260091.1 RP11-33B1.4 -3.9 0.000114 0.0205 -0.14 -0.21 Educational attainment; chr4:119339282 chr4:119409333~119410233:+ LIHC cis rs62435770 0.615 rs2224645 ENSG00000224417.2 RP11-503C24.6 -3.9 0.000114 0.0205 -0.38 -0.21 Loneliness; chr6:169109705 chr6:168298069~168302114:- LIHC cis rs9300255 0.539 rs1969355 ENSG00000256092.2 RP13-942N8.1 3.9 0.000114 0.0205 0.25 0.21 Neutrophil percentage of white cells; chr12:123257514 chr12:123363868~123366113:+ LIHC cis rs9300255 0.596 rs10734900 ENSG00000256092.2 RP13-942N8.1 3.9 0.000114 0.0205 0.25 0.21 Neutrophil percentage of white cells; chr12:123258898 chr12:123363868~123366113:+ LIHC cis rs9300255 0.596 rs10734901 ENSG00000256092.2 RP13-942N8.1 3.9 0.000114 0.0205 0.25 0.21 Neutrophil percentage of white cells; chr12:123258900 chr12:123363868~123366113:+ LIHC cis rs9300255 0.596 rs10732573 ENSG00000256092.2 RP13-942N8.1 3.9 0.000114 0.0205 0.25 0.21 Neutrophil percentage of white cells; chr12:123259336 chr12:123363868~123366113:+ LIHC cis rs2348418 0.67 rs4035202 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000114 0.0205 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28118015 chr12:28163298~28190738:- LIHC cis rs2348418 0.67 rs1824919 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000114 0.0205 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28118449 chr12:28163298~28190738:- LIHC cis rs2348418 0.67 rs899504 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000114 0.0205 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28118723 chr12:28163298~28190738:- LIHC cis rs4792901 0.759 rs12948043 ENSG00000267747.1 RP11-392O1.4 -3.9 0.000114 0.0205 -0.24 -0.21 Dupuytren's disease; chr17:43538462 chr17:43544785~43610338:+ LIHC cis rs6860806 0.531 rs272887 ENSG00000263597.1 MIR3936 3.9 0.000114 0.0205 0.22 0.21 Breast cancer; chr5:132330020 chr5:132365490~132365599:- LIHC cis rs274567 0.55 rs272885 ENSG00000263597.1 MIR3936 3.9 0.000114 0.0205 0.22 0.21 Blood metabolite levels; chr5:132332043 chr5:132365490~132365599:- LIHC cis rs6860806 0.507 rs272883 ENSG00000263597.1 MIR3936 3.9 0.000114 0.0205 0.22 0.21 Breast cancer; chr5:132333005 chr5:132365490~132365599:- LIHC cis rs6860806 0.507 rs272882 ENSG00000263597.1 MIR3936 3.9 0.000114 0.0205 0.22 0.21 Breast cancer; chr5:132333468 chr5:132365490~132365599:- LIHC cis rs6860806 0.507 rs272880 ENSG00000263597.1 MIR3936 3.9 0.000114 0.0205 0.22 0.21 Breast cancer; chr5:132334485 chr5:132365490~132365599:- LIHC cis rs703842 0.616 rs4760332 ENSG00000270039.1 RP11-571M6.17 3.9 0.000114 0.0205 0.3 0.21 Multiple sclerosis; chr12:57828889 chr12:57803838~57804415:+ LIHC cis rs1499614 0.901 rs2178742 ENSG00000232546.1 RP11-458F8.1 -3.9 0.000114 0.0205 -0.23 -0.21 Gout; chr7:66732812 chr7:66848496~66858136:+ LIHC cis rs160451 0.966 rs160447 ENSG00000251136.7 RP11-37B2.1 3.9 0.000114 0.0206 0.19 0.21 Leprosy; chr8:89647432 chr8:89609409~89757727:- LIHC cis rs13113518 0.783 rs34534635 ENSG00000249700.7 SRD5A3-AS1 3.9 0.000114 0.0206 0.24 0.21 Height; chr4:55573424 chr4:55363971~55395847:- LIHC cis rs13315871 0.929 rs9857333 ENSG00000272182.1 RP11-802O23.3 3.9 0.000114 0.0206 0.51 0.21 Cholesterol, total; chr3:58307824 chr3:58428255~58428815:+ LIHC cis rs13315871 0.79 rs28502788 ENSG00000272182.1 RP11-802O23.3 3.9 0.000114 0.0206 0.51 0.21 Cholesterol, total; chr3:58310481 chr3:58428255~58428815:+ LIHC cis rs11089937 0.54 rs9622920 ENSG00000211639.2 IGLV4-60 -3.9 0.000114 0.0206 -0.18 -0.21 Periodontitis (PAL4Q3); chr22:22133024 chr22:22162199~22162681:+ LIHC cis rs6560517 0.56 rs2490573 ENSG00000219149.4 RP11-214N16.2 3.9 0.000114 0.0206 0.22 0.21 Dialysis-related mortality; chr9:76374612 chr9:76549282~76549771:- LIHC cis rs1062177 0.855 rs6896664 ENSG00000253921.1 CTB-113P19.3 -3.9 0.000114 0.0206 -0.23 -0.21 Preschool internalizing problems; chr5:151885713 chr5:151753992~151767247:+ LIHC cis rs803923 0.585 rs803901 ENSG00000230894.1 RP11-67K19.3 -3.9 0.000114 0.0206 -0.27 -0.21 Lung function (FEV1/FVC); chr9:116673882 chr9:116568449~116586328:+ LIHC cis rs17772222 0.917 rs12588535 ENSG00000258789.1 RP11-507K2.3 -3.9 0.000114 0.0206 -0.25 -0.21 Coronary artery calcification; chr14:88781900 chr14:88551597~88552493:+ LIHC cis rs1862618 0.641 rs252893 ENSG00000271828.1 CTD-2310F14.1 3.9 0.000114 0.0206 0.28 0.21 Initial pursuit acceleration; chr5:56928887 chr5:56927874~56929573:+ LIHC cis rs1862618 0.671 rs173763 ENSG00000271828.1 CTD-2310F14.1 3.9 0.000114 0.0206 0.28 0.21 Initial pursuit acceleration; chr5:56929591 chr5:56927874~56929573:+ LIHC cis rs1862618 0.62 rs189695 ENSG00000271828.1 CTD-2310F14.1 3.9 0.000114 0.0206 0.28 0.21 Initial pursuit acceleration; chr5:56929942 chr5:56927874~56929573:+ LIHC cis rs1862618 0.613 rs252889 ENSG00000271828.1 CTD-2310F14.1 3.9 0.000114 0.0206 0.28 0.21 Initial pursuit acceleration; chr5:56931242 chr5:56927874~56929573:+ LIHC cis rs234043 0.515 rs4894566 ENSG00000223387.5 RP11-408H1.3 -3.9 0.000114 0.0206 -0.24 -0.21 Renal cell carcinoma; chr3:172589688 chr3:172560888~172595607:- LIHC cis rs6496667 0.533 rs2074583 ENSG00000213471.7 TTLL13P 3.9 0.000114 0.0206 0.27 0.21 Rheumatoid arthritis; chr15:90465960 chr15:90249530~90265482:+ LIHC cis rs9303401 0.646 rs7342863 ENSG00000265415.1 CTD-2510F5.4 3.9 0.000114 0.0206 0.14 0.21 Cognitive test performance; chr17:59149649 chr17:59202677~59203829:- LIHC cis rs2310173 1 rs2310173 ENSG00000281162.1 LINC01127 -3.9 0.000114 0.0206 -0.21 -0.21 Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr2:102047167 chr2:101962056~101987167:+ LIHC cis rs6700559 0.81 rs2809344 ENSG00000260088.1 RP11-92G12.3 3.9 0.000114 0.0206 0.26 0.21 Coronary artery disease; chr1:200627478 chr1:200669507~200694250:+ LIHC cis rs1816213 0.744 rs35935245 ENSG00000273466.1 RP11-548H3.1 -3.9 0.000115 0.0206 -0.33 -0.21 Diastolic blood pressure; chr2:218540399 chr2:218633256~218634014:- LIHC cis rs801193 0.591 rs2707839 ENSG00000232559.3 GS1-124K5.12 3.9 0.000115 0.0206 0.16 0.21 Aortic root size; chr7:66728097 chr7:66554588~66576923:- LIHC cis rs801193 0.636 rs2659895 ENSG00000232559.3 GS1-124K5.12 3.9 0.000115 0.0206 0.16 0.21 Aortic root size; chr7:66731484 chr7:66554588~66576923:- LIHC cis rs17818399 0.926 rs35682608 ENSG00000239332.4 LINC01119 -3.9 0.000115 0.0206 -0.3 -0.21 Height; chr2:46609403 chr2:46816697~46859007:+ LIHC cis rs1075265 0.669 rs805330 ENSG00000233266.1 HMGB1P31 3.9 0.000115 0.0206 0.26 0.21 Chronotype;Morning vs. evening chronotype; chr2:53921194 chr2:54051334~54051760:+ LIHC cis rs1499614 0.803 rs1796229 ENSG00000275400.1 RP4-756H11.5 3.9 0.000115 0.0206 0.28 0.21 Gout; chr7:66654674 chr7:66553805~66554199:- LIHC cis rs1499614 0.901 rs3936 ENSG00000275400.1 RP4-756H11.5 3.9 0.000115 0.0206 0.28 0.21 Gout; chr7:66661502 chr7:66553805~66554199:- LIHC cis rs9640161 0.789 rs3735174 ENSG00000261305.1 RP4-584D14.7 3.9 0.000115 0.0206 0.24 0.21 Blood protein levels;Circulating chemerin levels; chr7:150323400 chr7:150341771~150342607:+ LIHC cis rs13315871 0.929 rs13080508 ENSG00000272182.1 RP11-802O23.3 3.9 0.000115 0.0206 0.51 0.21 Cholesterol, total; chr3:58314389 chr3:58428255~58428815:+ LIHC cis rs13315871 0.929 rs17059171 ENSG00000272182.1 RP11-802O23.3 3.9 0.000115 0.0206 0.51 0.21 Cholesterol, total; chr3:58316859 chr3:58428255~58428815:+ LIHC cis rs1816213 0.744 rs71415849 ENSG00000273466.1 RP11-548H3.1 -3.9 0.000115 0.0206 -0.33 -0.21 Diastolic blood pressure; chr2:218615163 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs114354238 ENSG00000273466.1 RP11-548H3.1 -3.9 0.000115 0.0206 -0.33 -0.21 Diastolic blood pressure; chr2:218616625 chr2:218633256~218634014:- LIHC cis rs6700559 0.74 rs4387211 ENSG00000260088.1 RP11-92G12.3 -3.9 0.000115 0.0206 -0.28 -0.21 Coronary artery disease; chr1:200676810 chr1:200669507~200694250:+ LIHC cis rs875971 0.545 rs17138156 ENSG00000224316.1 RP11-479O9.2 3.9 0.000115 0.0206 0.2 0.21 Aortic root size; chr7:66249708 chr7:65773620~65802067:+ LIHC cis rs2919917 0.628 rs2717544 ENSG00000254352.1 RP11-578O24.2 -3.9 0.000115 0.0206 -0.3 -0.21 Lymphocyte counts; chr8:78724307 chr8:78723796~78724136:- LIHC cis rs42490 0.716 rs40638 ENSG00000251136.7 RP11-37B2.1 -3.9 0.000115 0.0206 -0.18 -0.21 Leprosy; chr8:89815824 chr8:89609409~89757727:- LIHC cis rs42490 0.716 rs370282 ENSG00000251136.7 RP11-37B2.1 -3.9 0.000115 0.0206 -0.18 -0.21 Leprosy; chr8:89816117 chr8:89609409~89757727:- LIHC cis rs8005677 0.798 rs4982713 ENSG00000257285.4 RP11-298I3.1 3.9 0.000115 0.0206 0.21 0.21 Cognitive ability (multi-trait analysis); chr14:22934893 chr14:22929609~22955562:+ LIHC cis rs8005677 0.798 rs35615180 ENSG00000257285.4 RP11-298I3.1 3.9 0.000115 0.0206 0.21 0.21 Cognitive ability (multi-trait analysis); chr14:22935180 chr14:22929609~22955562:+ LIHC cis rs244293 0.965 rs2628324 ENSG00000275710.1 RP11-257O5.4 3.9 0.000115 0.0207 0.22 0.21 Menarche (age at onset); chr17:55125616 chr17:54964474~54964679:+ LIHC cis rs1802575 0.61 rs13404167 ENSG00000272606.1 RP11-554J4.1 3.9 0.000115 0.0207 0.39 0.21 Childhood ear infection; chr2:55770441 chr2:55617909~55618373:+ LIHC cis rs6969780 0.915 rs12666919 ENSG00000233429.8 HOTAIRM1 -3.9 0.000115 0.0207 -0.29 -0.21 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27149879 chr7:27095647~27100265:+ LIHC cis rs9646944 0.501 rs10174323 ENSG00000234389.1 AC007278.3 3.9 0.000115 0.0207 0.26 0.21 Blood protein levels; chr2:102396321 chr2:102438713~102440475:+ LIHC cis rs9646944 0.501 rs3732127 ENSG00000234389.1 AC007278.3 3.9 0.000115 0.0207 0.26 0.21 Blood protein levels; chr2:102397290 chr2:102438713~102440475:+ LIHC cis rs12935418 0.55 rs35595567 ENSG00000261061.1 RP11-303E16.2 -3.9 0.000115 0.0207 -0.27 -0.21 Mean corpuscular volume; chr16:80999761 chr16:81030770~81031485:+ LIHC cis rs7119038 0.818 rs7942535 ENSG00000255422.1 AP002954.4 -3.9 0.000115 0.0207 -0.26 -0.21 Sjögren's syndrome; chr11:118810755 chr11:118704607~118750263:+ LIHC cis rs273909 0.622 rs2662314 ENSG00000233006.5 AC034220.3 -3.9 0.000115 0.0207 -0.28 -0.21 Coronary artery disease; chr5:132289476 chr5:132311285~132369916:- LIHC cis rs2581828 0.618 rs1560332 ENSG00000242142.1 SERBP1P3 3.9 0.000115 0.0207 0.27 0.21 Crohn's disease; chr3:53130787 chr3:53064283~53065091:- LIHC cis rs11212260 0.655 rs76734158 ENSG00000261098.1 RP11-819C21.1 3.9 0.000115 0.0207 0.36 0.21 IgG glycosylation; chr11:107333791 chr11:107312132~107316271:- LIHC cis rs6832769 1 rs28582059 ENSG00000272969.1 RP11-528I4.2 -3.9 0.000115 0.0207 -0.25 -0.21 Personality dimensions; chr4:55542237 chr4:55547112~55547889:+ LIHC cis rs9400467 0.528 rs9689727 ENSG00000271789.1 RP5-1112D6.7 -3.9 0.000115 0.0207 -0.2 -0.21 Amino acid levels;Blood metabolite levels; chr6:111475360 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs12214380 ENSG00000271789.1 RP5-1112D6.7 -3.9 0.000115 0.0207 -0.2 -0.21 Amino acid levels;Blood metabolite levels; chr6:111475734 chr6:111297126~111298510:+ LIHC cis rs9400467 0.508 rs61269242 ENSG00000271789.1 RP5-1112D6.7 -3.9 0.000115 0.0207 -0.2 -0.21 Amino acid levels;Blood metabolite levels; chr6:111481856 chr6:111297126~111298510:+ LIHC cis rs7712401 0.601 rs34707663 ENSG00000263432.2 RN7SL689P -3.9 0.000115 0.0207 -0.3 -0.21 Mean platelet volume; chr5:122984768 chr5:123022487~123022783:- LIHC cis rs3091242 0.933 rs28530483 ENSG00000261349.1 RP3-465N24.5 -3.9 0.000115 0.0207 -0.2 -0.21 Erythrocyte sedimentation rate; chr1:25414356 chr1:25266102~25267136:- LIHC cis rs1510272 0.515 rs6762762 ENSG00000243926.1 TIPARP-AS1 -3.9 0.000115 0.0207 -0.23 -0.21 Testicular germ cell tumor; chr3:156625194 chr3:156671862~156674378:- LIHC cis rs2179367 0.632 rs12154153 ENSG00000231760.4 RP11-350J20.5 3.9 0.000115 0.0207 0.33 0.21 Dupuytren's disease; chr6:149401686 chr6:149796151~149826294:- LIHC cis rs6471393 0.929 rs4464937 ENSG00000253848.1 RP11-10N23.5 3.9 0.000115 0.0207 0.22 0.21 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93744689 chr8:93741193~93744534:+ LIHC cis rs1062753 0.771 rs5751245 ENSG00000205702.9 CYP2D7 3.9 0.000115 0.0207 0.22 0.21 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42224934 chr22:42140203~42144577:- LIHC cis rs4218 0.513 rs17302142 ENSG00000277144.1 RP11-59H7.4 -3.9 0.000115 0.0207 -0.22 -0.21 Social communication problems; chr15:59053813 chr15:59115547~59116089:- LIHC cis rs4218 0.528 rs57557135 ENSG00000277144.1 RP11-59H7.4 -3.9 0.000115 0.0207 -0.22 -0.21 Social communication problems; chr15:59054018 chr15:59115547~59116089:- LIHC cis rs1665050 0.571 rs1446238 ENSG00000277144.1 RP11-59H7.4 -3.9 0.000115 0.0207 -0.22 -0.21 Atopic dermatitis; chr15:59055558 chr15:59115547~59116089:- LIHC cis rs17772222 0.917 rs11159868 ENSG00000258789.1 RP11-507K2.3 -3.9 0.000115 0.0207 -0.25 -0.21 Coronary artery calcification; chr14:88760528 chr14:88551597~88552493:+ LIHC cis rs1023500 0.573 rs13057094 ENSG00000205702.9 CYP2D7 3.9 0.000115 0.0207 0.24 0.21 Schizophrenia; chr22:42074313 chr22:42140203~42144577:- LIHC cis rs9368481 0.678 rs62402024 ENSG00000241549.7 GUSBP2 3.9 0.000115 0.0207 0.22 0.21 Autism spectrum disorder or schizophrenia; chr6:26956197 chr6:26871484~26956554:- LIHC cis rs7617773 0.78 rs11710257 ENSG00000228638.1 FCF1P2 -3.9 0.000115 0.0207 -0.24 -0.21 Coronary artery disease; chr3:48331724 chr3:48290793~48291375:- LIHC cis rs7617773 0.707 rs13061269 ENSG00000228638.1 FCF1P2 -3.9 0.000115 0.0207 -0.24 -0.21 Coronary artery disease; chr3:48331853 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs71323395 ENSG00000228638.1 FCF1P2 -3.9 0.000115 0.0207 -0.24 -0.21 Coronary artery disease; chr3:48332587 chr3:48290793~48291375:- LIHC cis rs9640161 0.789 rs34311995 ENSG00000261305.1 RP4-584D14.7 3.9 0.000115 0.0207 0.24 0.21 Blood protein levels;Circulating chemerin levels; chr7:150362166 chr7:150341771~150342607:+ LIHC cis rs2243480 1 rs410128 ENSG00000230295.1 RP11-458F8.2 -3.9 0.000115 0.0207 -0.23 -0.21 Diabetic kidney disease; chr7:66138186 chr7:66880708~66882981:+ LIHC cis rs4682868 0.552 rs6771233 ENSG00000273328.4 RP11-141M3.6 3.9 0.000115 0.0207 0.21 0.21 Monocyte percentage of white cells; chr3:42881205 chr3:42809414~42908105:+ LIHC cis rs79040073 0.911 rs11638981 ENSG00000259531.2 RP11-295H24.3 3.9 0.000115 0.0207 0.31 0.21 Lung cancer in ever smokers; chr15:49029332 chr15:49365124~49366685:- LIHC cis rs4694744 0.54 rs7684949 ENSG00000264696.1 AC108078.1 3.9 0.000115 0.0207 0.32 0.21 Bacteremia; chr4:69445938 chr4:69479331~69479434:+ LIHC cis rs875971 1 rs2087647 ENSG00000237310.1 GS1-124K5.4 -3.9 0.000116 0.0208 -0.19 -0.21 Aortic root size; chr7:66128201 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs6958484 ENSG00000237310.1 GS1-124K5.4 -3.9 0.000116 0.0208 -0.19 -0.21 Aortic root size; chr7:66134459 chr7:66493706~66495474:+ LIHC cis rs875971 0.545 rs13311962 ENSG00000224316.1 RP11-479O9.2 -3.9 0.000116 0.0208 -0.2 -0.21 Aortic root size; chr7:66603142 chr7:65773620~65802067:+ LIHC cis rs4578769 0.569 rs12605806 ENSG00000266850.1 RP11-370A5.1 3.9 0.000116 0.0208 0.22 0.21 Eosinophil percentage of white cells; chr18:22882093 chr18:22723491~22907721:- LIHC cis rs3204270 0.759 rs8071492 ENSG00000281517.1 Metazoa_SRP -3.9 0.000116 0.0208 -0.4 -0.21 Dental caries; chr17:81715620 chr17:81718849~81719095:- LIHC cis rs4792901 0.729 rs12603059 ENSG00000267747.1 RP11-392O1.4 -3.9 0.000116 0.0208 -0.24 -0.21 Dupuytren's disease; chr17:43461078 chr17:43544785~43610338:+ LIHC cis rs8005677 0.741 rs1043675 ENSG00000279656.1 RP11-298I3.6 -3.9 0.000116 0.0208 -0.23 -0.21 Cognitive ability (multi-trait analysis); chr14:22987106 chr14:23023083~23024217:- LIHC cis rs1799949 1 rs12944458 ENSG00000267681.1 CTD-3199J23.6 -3.9 0.000116 0.0208 -0.2 -0.21 Menopause (age at onset); chr17:43028755 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs36036395 ENSG00000267681.1 CTD-3199J23.6 -3.9 0.000116 0.0208 -0.2 -0.21 Menopause (age at onset); chr17:43029280 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs72829113 ENSG00000267681.1 CTD-3199J23.6 -3.9 0.000116 0.0208 -0.2 -0.21 Menopause (age at onset); chr17:43029818 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs11653253 ENSG00000267681.1 CTD-3199J23.6 -3.9 0.000116 0.0208 -0.2 -0.21 Menopause (age at onset); chr17:43030645 chr17:43144956~43145255:+ LIHC cis rs193541 0.593 rs154517 ENSG00000263432.2 RN7SL689P 3.9 0.000116 0.0208 0.33 0.21 Glucose homeostasis traits; chr5:122854130 chr5:123022487~123022783:- LIHC cis rs193541 0.632 rs152038 ENSG00000263432.2 RN7SL689P 3.9 0.000116 0.0208 0.33 0.21 Glucose homeostasis traits; chr5:122860151 chr5:123022487~123022783:- LIHC cis rs2564921 0.704 rs62255931 ENSG00000242142.1 SERBP1P3 -3.9 0.000116 0.0208 -0.29 -0.21 Height; chr3:53097932 chr3:53064283~53065091:- LIHC cis rs2439831 0.85 rs16977798 ENSG00000166763.7 STRCP1 3.9 0.000116 0.0208 0.31 0.21 Lung cancer in ever smokers; chr15:43859750 chr15:43699488~43718184:- LIHC cis rs4578769 0.722 rs72887683 ENSG00000266850.1 RP11-370A5.1 -3.9 0.000116 0.0208 -0.24 -0.21 Eosinophil percentage of white cells; chr18:22981366 chr18:22723491~22907721:- LIHC cis rs1318937 0.764 rs60977744 ENSG00000224660.1 SH3BP5-AS1 3.9 0.000116 0.0208 0.19 0.21 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15198464 chr3:15254184~15264493:+ LIHC cis rs1318937 0.764 rs58837640 ENSG00000224660.1 SH3BP5-AS1 3.9 0.000116 0.0208 0.19 0.21 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15199139 chr3:15254184~15264493:+ LIHC cis rs2439831 0.867 rs12323999 ENSG00000166763.7 STRCP1 3.9 0.000116 0.0208 0.29 0.21 Lung cancer in ever smokers; chr15:43390917 chr15:43699488~43718184:- LIHC cis rs3204270 0.639 rs11867543 ENSG00000281517.1 Metazoa_SRP -3.9 0.000116 0.0208 -0.39 -0.21 Dental caries; chr17:81688016 chr17:81718849~81719095:- LIHC cis rs2598107 0.601 rs11983934 ENSG00000211698.2 TRGV4 -3.9 0.000116 0.0208 -0.25 -0.21 Dupuytren's disease; chr7:37895366 chr7:38353715~38354517:- LIHC cis rs6480314 1 rs61854764 ENSG00000233590.1 RP11-153K11.3 -3.9 0.000116 0.0208 -0.33 -0.21 Optic nerve measurement (disc area); chr10:68205718 chr10:68233251~68242379:- LIHC cis rs8054556 0.647 rs4788211 ENSG00000250616.2 RP11-455F5.3 3.9 0.000116 0.0208 0.2 0.21 Autism spectrum disorder or schizophrenia; chr16:30004244 chr16:30096430~30104116:+ LIHC cis rs591584 0.617 rs608972 ENSG00000255893.1 RP11-685N10.1 3.9 0.000116 0.0209 0.21 0.21 Macrophage Migration Inhibitory Factor levels; chr11:94602964 chr11:94472908~94473570:- LIHC cis rs858239 1 rs858240 ENSG00000226816.2 AC005082.12 3.9 0.000116 0.0209 0.26 0.21 Cerebrospinal fluid biomarker levels; chr7:23244618 chr7:23206013~23208045:+ LIHC cis rs875971 0.964 rs60193905 ENSG00000237310.1 GS1-124K5.4 3.9 0.000116 0.0209 0.18 0.21 Aortic root size; chr7:66506273 chr7:66493706~66495474:+ LIHC cis rs2243480 1 rs1723269 ENSG00000232546.1 RP11-458F8.1 -3.9 0.000116 0.0209 -0.23 -0.21 Diabetic kidney disease; chr7:66007799 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs464895 ENSG00000228409.4 CCT6P1 3.9 0.000116 0.0209 0.22 0.21 Diabetic kidney disease; chr7:66062119 chr7:65751142~65763354:+ LIHC cis rs803903 0.605 rs34513895 ENSG00000230894.1 RP11-67K19.3 3.9 0.000116 0.0209 0.28 0.21 Breast cancer; chr9:116491699 chr9:116568449~116586328:+ LIHC cis rs1115240 0.898 rs1950411 ENSG00000257842.4 NOVA1-AS1 3.9 0.000116 0.0209 0.19 0.21 Educational attainment (years of education); chr14:26582292 chr14:26598412~26806467:+ LIHC cis rs875971 0.83 rs4718358 ENSG00000237310.1 GS1-124K5.4 3.9 0.000116 0.0209 0.18 0.21 Aortic root size; chr7:66508681 chr7:66493706~66495474:+ LIHC cis rs6433895 0.677 rs11692430 ENSG00000236153.1 AC104076.3 -3.9 0.000116 0.0209 -0.28 -0.21 Lymphocyte counts; chr2:181171344 chr2:180979427~180980090:- LIHC cis rs10129255 0.957 rs11846893 ENSG00000211970.3 IGHV4-61 -3.9 0.000116 0.0209 -0.16 -0.21 Kawasaki disease; chr14:106779068 chr14:106639119~106639657:- LIHC cis rs875971 0.545 rs2420456 ENSG00000224316.1 RP11-479O9.2 3.9 0.000116 0.0209 0.2 0.21 Aortic root size; chr7:66280619 chr7:65773620~65802067:+ LIHC cis rs12681287 0.64 rs7460342 ENSG00000254088.1 SLC2A3P4 3.9 0.000116 0.0209 0.24 0.21 Caudate activity during reward; chr8:86462908 chr8:86503591~86505061:+ LIHC cis rs803923 0.585 rs803903 ENSG00000230894.1 RP11-67K19.3 -3.9 0.000116 0.0209 -0.27 -0.21 Lung function (FEV1/FVC); chr9:116672011 chr9:116568449~116586328:+ LIHC cis rs12908161 1 rs36033486 ENSG00000259728.4 LINC00933 3.9 0.000117 0.0209 0.29 0.21 Schizophrenia; chr15:84776461 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs12908549 ENSG00000259728.4 LINC00933 3.9 0.000117 0.0209 0.29 0.21 Schizophrenia; chr15:84779120 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs12903134 ENSG00000259728.4 LINC00933 3.9 0.000117 0.0209 0.29 0.21 Schizophrenia; chr15:84794468 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs35726233 ENSG00000259728.4 LINC00933 3.9 0.000117 0.0209 0.29 0.21 Schizophrenia; chr15:84794569 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs35960805 ENSG00000259728.4 LINC00933 3.9 0.000117 0.0209 0.29 0.21 Schizophrenia; chr15:84800749 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs12912388 ENSG00000259728.4 LINC00933 3.9 0.000117 0.0209 0.29 0.21 Schizophrenia; chr15:84801319 chr15:84570649~84580175:+ LIHC cis rs6597981 0.604 rs7945912 ENSG00000255142.1 AP006621.6 3.9 0.000117 0.0209 0.18 0.21 Breast cancer; chr11:750849 chr11:781645~782105:+ LIHC cis rs7246657 0.525 rs10401417 ENSG00000225975.5 LINC01534 3.9 0.000117 0.0209 0.33 0.21 Coronary artery calcification; chr19:36976638 chr19:36685440~36687449:- LIHC cis rs7246657 0.525 rs997516 ENSG00000225975.5 LINC01534 3.9 0.000117 0.0209 0.33 0.21 Coronary artery calcification; chr19:36983362 chr19:36685440~36687449:- LIHC cis rs7246657 0.525 rs10410594 ENSG00000225975.5 LINC01534 3.9 0.000117 0.0209 0.33 0.21 Coronary artery calcification; chr19:36986856 chr19:36685440~36687449:- LIHC cis rs2070488 1 rs6772046 ENSG00000229589.1 ACVR2B-AS1 3.9 0.000117 0.0209 0.24 0.21 Electrocardiographic conduction measures; chr3:38438169 chr3:38451027~38454820:- LIHC cis rs2070488 0.965 rs7372386 ENSG00000229589.1 ACVR2B-AS1 3.9 0.000117 0.0209 0.24 0.21 Electrocardiographic conduction measures; chr3:38442684 chr3:38451027~38454820:- LIHC cis rs67311347 1 rs4973997 ENSG00000223797.4 ENTPD3-AS1 3.9 0.000117 0.0209 0.16 0.21 Renal cell carcinoma; chr3:40418654 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs13324109 ENSG00000223797.4 ENTPD3-AS1 3.9 0.000117 0.0209 0.16 0.21 Renal cell carcinoma; chr3:40419276 chr3:40313802~40453329:- LIHC cis rs4938303 0.718 rs3212282 ENSG00000236267.1 AP006216.5 3.9 0.000117 0.0209 0.21 0.21 Triglycerides; chr11:116731229 chr11:116813204~116814003:- LIHC cis rs9400467 0.528 rs10872067 ENSG00000271789.1 RP5-1112D6.7 -3.9 0.000117 0.0209 -0.2 -0.21 Amino acid levels;Blood metabolite levels; chr6:111467188 chr6:111297126~111298510:+ LIHC cis rs710913 0.691 rs1180351 ENSG00000182109.6 RP11-69E11.4 -3.9 0.000117 0.0209 -0.2 -0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39541605 chr1:39522280~39546187:- LIHC cis rs710913 0.717 rs1180352 ENSG00000182109.6 RP11-69E11.4 -3.9 0.000117 0.0209 -0.2 -0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39542157 chr1:39522280~39546187:- LIHC cis rs7647973 0.58 rs2117938 ENSG00000270441.1 RP11-694I15.7 3.9 0.000117 0.0209 0.29 0.21 Menarche (age at onset); chr3:49226417 chr3:49140086~49160851:- LIHC cis rs524281 0.731 rs7931167 ENSG00000255320.1 RP11-755F10.1 -3.9 0.000117 0.0209 -0.29 -0.21 Electroencephalogram traits; chr11:66036279 chr11:66244840~66246239:- LIHC cis rs524281 0.638 rs4261293 ENSG00000255320.1 RP11-755F10.1 -3.9 0.000117 0.0209 -0.29 -0.21 Electroencephalogram traits; chr11:66037664 chr11:66244840~66246239:- LIHC cis rs17818399 0.62 rs6544906 ENSG00000239332.4 LINC01119 -3.9 0.000117 0.0209 -0.27 -0.21 Height; chr2:46636733 chr2:46816697~46859007:+ LIHC cis rs950169 0.519 rs7237 ENSG00000225151.9 GOLGA2P7 -3.9 0.000117 0.0209 -0.26 -0.21 Schizophrenia; chr15:84643346 chr15:84199311~84230136:- LIHC cis rs2439831 0.717 rs9806227 ENSG00000166763.7 STRCP1 3.9 0.000117 0.0209 0.29 0.21 Lung cancer in ever smokers; chr15:43387917 chr15:43699488~43718184:- LIHC cis rs4713118 0.662 rs156744 ENSG00000219891.2 ZSCAN12P1 3.9 0.000117 0.0209 0.3 0.21 Parkinson's disease; chr6:27999496 chr6:28091154~28093664:+ LIHC cis rs4713118 0.662 rs149946 ENSG00000219891.2 ZSCAN12P1 -3.9 0.000117 0.0209 -0.3 -0.21 Parkinson's disease; chr6:28002253 chr6:28091154~28093664:+ LIHC cis rs4713118 0.662 rs149947 ENSG00000219891.2 ZSCAN12P1 3.9 0.000117 0.0209 0.3 0.21 Parkinson's disease; chr6:28004655 chr6:28091154~28093664:+ LIHC cis rs875971 0.895 rs3857684 ENSG00000237310.1 GS1-124K5.4 3.9 0.000117 0.0209 0.18 0.21 Aortic root size; chr7:66473171 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs12533997 ENSG00000237310.1 GS1-124K5.4 3.9 0.000117 0.0209 0.18 0.21 Aortic root size; chr7:66500390 chr7:66493706~66495474:+ LIHC cis rs6732160 1 rs6732160 ENSG00000272702.1 RP11-44N22.3 3.9 0.000117 0.0209 0.23 0.21 Intelligence (multi-trait analysis); chr2:73160100 chr2:73113018~73115907:+ LIHC cis rs812925 0.784 rs7588041 ENSG00000212978.6 AC016747.3 3.9 0.000117 0.0209 0.24 0.21 Immature fraction of reticulocytes; chr2:61234277 chr2:61141592~61144969:- LIHC cis rs7121538 0.551 rs73412605 ENSG00000251991.1 RNU7-49P -3.9 0.000117 0.0209 -0.33 -0.21 HDL cholesterol; chr11:14654445 chr11:14478892~14478953:+ LIHC cis rs7121538 0.551 rs73412619 ENSG00000251991.1 RNU7-49P -3.9 0.000117 0.0209 -0.33 -0.21 HDL cholesterol; chr11:14688716 chr11:14478892~14478953:+ LIHC cis rs7121538 0.551 rs73412620 ENSG00000251991.1 RNU7-49P -3.9 0.000117 0.0209 -0.33 -0.21 HDL cholesterol; chr11:14688771 chr11:14478892~14478953:+ LIHC cis rs2337406 0.714 rs8022729 ENSG00000274576.2 IGHV2-70 3.9 0.000117 0.0209 0.22 0.21 Alzheimer's disease (late onset); chr14:106816928 chr14:106770577~106771020:- LIHC cis rs921968 0.545 rs2433738 ENSG00000272555.1 RP11-459I19.1 -3.9 0.000117 0.0209 -0.23 -0.21 Mean corpuscular hemoglobin concentration; chr2:218686313 chr2:218818690~218819144:+ LIHC cis rs921968 0.607 rs2465100 ENSG00000272555.1 RP11-459I19.1 -3.9 0.000117 0.0209 -0.23 -0.21 Mean corpuscular hemoglobin concentration; chr2:218686321 chr2:218818690~218819144:+ LIHC cis rs757081 0.648 rs11024223 ENSG00000272034.1 SNORD14A 3.9 0.000117 0.021 0.21 0.21 Systolic blood pressure; chr11:17256146 chr11:17074654~17074744:- LIHC cis rs2980436 1 rs2980436 ENSG00000253893.2 FAM85B 3.9 0.000117 0.021 0.26 0.21 Schizophrenia; chr8:8234503 chr8:8167819~8226614:- LIHC cis rs12681366 0.881 rs3019150 ENSG00000253704.1 RP11-267M23.4 3.9 0.000117 0.021 0.24 0.21 Nonsyndromic cleft lip with cleft palate; chr8:94420055 chr8:94553722~94569745:+ LIHC cis rs1555322 0.53 rs2250205 ENSG00000279253.1 RP4-614O4.13 -3.9 0.000117 0.021 -0.28 -0.21 Attention deficit hyperactivity disorder; chr20:35280121 chr20:35262727~35264187:- LIHC cis rs3749237 0.595 rs3870338 ENSG00000226913.1 BSN-AS2 -3.9 0.000117 0.021 -0.27 -0.21 Resting heart rate; chr3:49519618 chr3:49549306~49554366:- LIHC cis rs11098499 0.913 rs12186259 ENSG00000260091.1 RP11-33B1.4 -3.9 0.000117 0.021 -0.15 -0.21 Corneal astigmatism; chr4:119230884 chr4:119409333~119410233:+ LIHC cis rs9906944 0.678 rs56015440 ENSG00000248278.1 SUMO2P17 -3.9 0.000117 0.021 -0.34 -0.21 Intelligence (multi-trait analysis);Body fat percentage; chr17:49059269 chr17:48874860~48908983:- LIHC cis rs4862307 0.623 rs11730046 ENSG00000250726.1 RP11-616K6.1 3.9 0.000117 0.021 0.23 0.21 Serum dimethylarginine levels (asymmetric/symetric ratio); chr4:184067092 chr4:184072403~184073039:+ LIHC cis rs42490 1 rs40545 ENSG00000251136.7 RP11-37B2.1 -3.9 0.000117 0.021 -0.18 -0.21 Leprosy; chr8:89777483 chr8:89609409~89757727:- LIHC cis rs8024893 1 rs7180114 ENSG00000270055.1 CTD-3092A11.2 3.9 0.000117 0.021 0.29 0.21 Red cell distribution width; chr15:31247976 chr15:30487963~30490313:+ LIHC cis rs8054556 0.647 rs11649149 ENSG00000250616.2 RP11-455F5.3 3.9 0.000117 0.021 0.2 0.21 Autism spectrum disorder or schizophrenia; chr16:29997323 chr16:30096430~30104116:+ LIHC cis rs875971 0.508 rs10950045 ENSG00000273024.4 INTS4P2 3.9 0.000117 0.021 0.22 0.21 Aortic root size; chr7:66601386 chr7:65647864~65715661:+ LIHC cis rs801193 0.839 rs6968619 ENSG00000273024.4 INTS4P2 3.9 0.000117 0.021 0.22 0.21 Aortic root size; chr7:66603880 chr7:65647864~65715661:+ LIHC cis rs9640161 0.742 rs2108852 ENSG00000261305.1 RP4-584D14.7 3.9 0.000117 0.021 0.24 0.21 Blood protein levels;Circulating chemerin levels; chr7:150322539 chr7:150341771~150342607:+ LIHC cis rs9640161 0.742 rs2108851 ENSG00000261305.1 RP4-584D14.7 3.9 0.000117 0.021 0.24 0.21 Blood protein levels;Circulating chemerin levels; chr7:150322545 chr7:150341771~150342607:+ LIHC cis rs12681287 0.64 rs12549332 ENSG00000254088.1 SLC2A3P4 3.9 0.000117 0.021 0.24 0.21 Caudate activity during reward; chr8:86341163 chr8:86503591~86505061:+ LIHC cis rs3015497 0.789 rs3015502 ENSG00000269906.1 RP11-248J18.2 3.9 0.000117 0.021 0.26 0.21 Mean platelet volume; chr14:50641709 chr14:50662511~50663178:- LIHC cis rs710913 0.717 rs1180349 ENSG00000182109.6 RP11-69E11.4 -3.9 0.000117 0.021 -0.2 -0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39540380 chr1:39522280~39546187:- LIHC cis rs812925 0.537 rs2463097 ENSG00000271889.1 RP11-493E12.1 -3.9 0.000117 0.021 -0.25 -0.21 Immature fraction of reticulocytes; chr2:61387166 chr2:61151433~61162105:- LIHC cis rs812925 0.537 rs10865324 ENSG00000271889.1 RP11-493E12.1 -3.9 0.000117 0.021 -0.25 -0.21 Immature fraction of reticulocytes; chr2:61394172 chr2:61151433~61162105:- LIHC cis rs879620 1 rs879620 ENSG00000262888.1 RP11-462G12.2 3.9 0.000117 0.021 0.26 0.21 Hip circumference;Body mass index; chr16:3965728 chr16:3931217~3946305:- LIHC cis rs138249 0.505 rs138218 ENSG00000273253.2 RP3-402G11.26 -3.9 0.000117 0.021 -0.23 -0.21 Gestational age at birth in labor-initiated deliveries (child effect); chr22:50109129 chr22:50199090~50200837:- LIHC cis rs801193 0.805 rs12532355 ENSG00000273024.4 INTS4P2 3.9 0.000117 0.021 0.22 0.21 Aortic root size; chr7:66605597 chr7:65647864~65715661:+ LIHC cis rs16958440 0.541 rs11876448 ENSG00000267724.1 RP11-49K24.8 3.9 0.000117 0.021 0.28 0.21 Sitting height ratio; chr18:47118159 chr18:47105946~47108062:+ LIHC cis rs1005277 0.522 rs1208767 ENSG00000275858.1 RP11-291L22.8 3.9 0.000117 0.021 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:37753367 chr10:38450738~38451069:- LIHC cis rs703842 0.616 rs870392 ENSG00000270039.1 RP11-571M6.17 -3.9 0.000117 0.021 -0.3 -0.21 Multiple sclerosis; chr12:57825390 chr12:57803838~57804415:+ LIHC cis rs7829975 0.711 rs12682352 ENSG00000253893.2 FAM85B -3.9 0.000118 0.021 -0.24 -0.21 Mood instability; chr8:8788736 chr8:8167819~8226614:- LIHC cis rs4891159 0.79 rs17059325 ENSG00000265778.2 RP11-17M16.2 -3.9 0.000118 0.021 -0.26 -0.21 Longevity; chr18:76407611 chr18:76491652~76493918:+ LIHC cis rs2948294 0.588 rs4840913 ENSG00000253981.4 ALG1L13P 3.9 0.000118 0.021 0.24 0.21 Red cell distribution width; chr8:8259384 chr8:8236003~8244667:- LIHC cis rs1075265 0.87 rs6724389 ENSG00000233266.1 HMGB1P31 3.9 0.000118 0.021 0.31 0.21 Chronotype;Morning vs. evening chronotype; chr2:53985698 chr2:54051334~54051760:+ LIHC cis rs617219 0.853 rs7448481 ENSG00000251675.1 CTC-458I2.2 -3.9 0.000118 0.021 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79211587 chr5:80128361~80143883:+ LIHC cis rs875971 0.522 rs4502988 ENSG00000273024.4 INTS4P2 -3.9 0.000118 0.021 -0.25 -0.21 Aortic root size; chr7:65832759 chr7:65647864~65715661:+ LIHC cis rs875971 0.522 rs2008188 ENSG00000273024.4 INTS4P2 -3.9 0.000118 0.021 -0.25 -0.21 Aortic root size; chr7:65964026 chr7:65647864~65715661:+ LIHC cis rs950169 0.96 rs35159785 ENSG00000259728.4 LINC00933 3.9 0.000118 0.021 0.33 0.21 Schizophrenia; chr15:84135262 chr15:84570649~84580175:+ LIHC cis rs6504622 0.545 rs10853087 ENSG00000263766.4 RP11-580I16.2 3.9 0.000118 0.0211 0.24 0.21 Orofacial clefts; chr17:46928746 chr17:47603860~47649420:- LIHC cis rs1062177 1 rs62394155 ENSG00000253921.1 CTB-113P19.3 -3.9 0.000118 0.0211 -0.24 -0.21 Preschool internalizing problems; chr5:151868508 chr5:151753992~151767247:+ LIHC cis rs1062177 1 rs12653926 ENSG00000253921.1 CTB-113P19.3 -3.9 0.000118 0.0211 -0.24 -0.21 Preschool internalizing problems; chr5:151870687 chr5:151753992~151767247:+ LIHC cis rs2911132 0.564 rs1057569 ENSG00000248734.2 CTD-2260A17.1 3.9 0.000118 0.0211 0.29 0.21 Urate levels (BMI interaction); chr5:96773906 chr5:96784777~96785999:+ LIHC cis rs2911132 0.511 rs3198304 ENSG00000248734.2 CTD-2260A17.1 3.9 0.000118 0.0211 0.29 0.21 Urate levels (BMI interaction); chr5:96775524 chr5:96784777~96785999:+ LIHC cis rs2911132 0.511 rs13160562 ENSG00000248734.2 CTD-2260A17.1 3.9 0.000118 0.0211 0.29 0.21 Urate levels (BMI interaction); chr5:96775667 chr5:96784777~96785999:+ LIHC cis rs9652601 0.779 rs11648679 ENSG00000274038.1 RP11-66H6.4 -3.9 0.000118 0.0211 -0.25 -0.21 Systemic lupus erythematosus; chr16:11082127 chr16:11056556~11057034:+ LIHC cis rs1023500 0.551 rs133355 ENSG00000205702.9 CYP2D7 3.9 0.000118 0.0211 0.23 0.21 Schizophrenia; chr22:42044281 chr22:42140203~42144577:- LIHC cis rs875971 1 rs7792762 ENSG00000237310.1 GS1-124K5.4 3.9 0.000118 0.0211 0.18 0.21 Aortic root size; chr7:66539151 chr7:66493706~66495474:+ LIHC cis rs933688 1 rs60513756 ENSG00000281357.1 ARRDC3-AS1 3.9 0.000118 0.0211 0.26 0.21 Smoking behavior; chr5:91431875 chr5:91380349~91439085:+ LIHC cis rs6142102 0.961 rs6120487 ENSG00000275784.1 RP5-1125A11.6 -3.9 0.000118 0.0211 -0.23 -0.21 Skin pigmentation; chr20:34034802 chr20:33989480~33991818:- LIHC cis rs11647589 0.687 rs12598584 ENSG00000262995.1 CTD-2194A8.2 3.9 0.000118 0.0211 0.19 0.21 Blood metabolite levels; chr16:20476785 chr16:20440266~20447000:- LIHC cis rs3015497 0.789 rs7147956 ENSG00000269906.1 RP11-248J18.2 3.9 0.000118 0.0211 0.26 0.21 Mean platelet volume; chr14:50675887 chr14:50662511~50663178:- LIHC cis rs7182621 0.509 rs12917012 ENSG00000182397.13 DNM1P46 3.9 0.000118 0.0211 0.25 0.21 Colonoscopy-negative controls vs population controls; chr15:99868778 chr15:99790156~99806927:- LIHC cis rs6723108 0.604 rs6430551 ENSG00000224043.6 CCNT2-AS1 -3.9 0.000118 0.0211 -0.29 -0.21 Type 2 diabetes; chr2:134863986 chr2:134735464~134918710:- LIHC cis rs9907295 1 rs9891064 ENSG00000270871.1 AC015849.19 3.9 0.000118 0.0211 0.22 0.21 Fibroblast growth factor basic levels; chr17:35913045 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs9899870 ENSG00000270871.1 AC015849.19 3.9 0.000118 0.0211 0.22 0.21 Fibroblast growth factor basic levels; chr17:35914438 chr17:35816717~35830293:- LIHC cis rs10779751 1 rs1010447 ENSG00000226849.1 RP4-635E18.7 3.9 0.000118 0.0211 0.23 0.21 Body mass index; chr1:11209739 chr1:11068471~11073097:+ LIHC cis rs864537 0.618 rs2995089 ENSG00000273160.1 RP11-104L21.3 3.9 0.000118 0.0211 0.28 0.21 Celiac disease or Rheumatoid arthritis;Celiac disease; chr1:167461956 chr1:167457742~167459891:- LIHC cis rs757081 0.578 rs7109536 ENSG00000272034.1 SNORD14A -3.9 0.000118 0.0211 -0.22 -0.21 Systolic blood pressure; chr11:17233965 chr11:17074654~17074744:- LIHC cis rs9300255 0.596 rs7304782 ENSG00000256092.2 RP13-942N8.1 -3.9 0.000118 0.0211 -0.25 -0.21 Neutrophil percentage of white cells; chr12:123234897 chr12:123363868~123366113:+ LIHC cis rs6545883 0.63 rs12998475 ENSG00000271889.1 RP11-493E12.1 -3.9 0.000118 0.0211 -0.25 -0.21 Tuberculosis; chr2:61210352 chr2:61151433~61162105:- LIHC cis rs73193808 0.614 rs11088112 ENSG00000212479.2 U3 3.9 0.000118 0.0211 0.24 0.21 Coronary artery disease; chr21:29193915 chr21:29180425~29180639:- LIHC cis rs944990 0.576 rs7040832 ENSG00000227603.1 RP11-165J3.6 3.89 0.000118 0.0211 0.22 0.21 Body mass index; chr9:93436508 chr9:93435332~93437121:- LIHC cis rs2439831 0.681 rs3742969 ENSG00000166763.7 STRCP1 3.89 0.000118 0.0211 0.28 0.21 Lung cancer in ever smokers; chr15:43329749 chr15:43699488~43718184:- LIHC cis rs7712401 0.562 rs30073 ENSG00000263432.2 RN7SL689P 3.89 0.000118 0.0211 0.3 0.21 Mean platelet volume; chr5:122954814 chr5:123022487~123022783:- LIHC cis rs2283792 0.765 rs9607285 ENSG00000224086.5 LL22NC03-86G7.1 -3.89 0.000118 0.0211 -0.21 -0.21 Multiple sclerosis; chr22:21808704 chr22:21938293~21977632:+ LIHC cis rs801193 1 rs13239306 ENSG00000224316.1 RP11-479O9.2 -3.89 0.000118 0.0211 -0.19 -0.21 Aortic root size; chr7:66671030 chr7:65773620~65802067:+ LIHC cis rs77204473 0.744 rs11606672 ENSG00000254851.1 RP11-109L13.1 3.89 0.000118 0.0211 0.38 0.21 Sum eosinophil basophil counts;Eosinophil counts; chr11:117185343 chr11:117135528~117138582:+ LIHC cis rs1062177 0.756 rs2915817 ENSG00000253921.1 CTB-113P19.3 3.89 0.000118 0.0212 0.24 0.21 Preschool internalizing problems; chr5:151735956 chr5:151753992~151767247:+ LIHC cis rs17508449 0.732 rs75746385 ENSG00000232450.1 RP4-730K3.3 -3.89 0.000118 0.0212 -0.28 -0.21 Leprosy; chr1:113758270 chr1:113698884~113699631:- LIHC cis rs921968 0.613 rs1427445 ENSG00000272555.1 RP11-459I19.1 -3.89 0.000118 0.0212 -0.23 -0.21 Mean corpuscular hemoglobin concentration; chr2:218690850 chr2:218818690~218819144:+ LIHC cis rs67981189 0.896 rs12100737 ENSG00000274818.1 RP1-292L20.3 -3.89 0.000118 0.0212 -0.24 -0.21 Schizophrenia; chr14:71004383 chr14:70906657~70907111:- LIHC cis rs12817211 0.549 rs6580728 ENSG00000272368.2 RP4-605O3.4 -3.89 0.000119 0.0212 -0.23 -0.21 Colorectal or endometrial cancer; chr12:50147344 chr12:50112197~50165618:+ LIHC cis rs6997458 0.785 rs1389245 ENSG00000253549.4 RP11-317J10.2 -3.89 0.000119 0.0212 -0.23 -0.21 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85440159 chr8:85441851~85464915:- LIHC cis rs10888838 0.652 rs11577661 ENSG00000198711.5 SSBP3-AS1 3.89 0.000119 0.0212 0.29 0.21 Mitochondrial DNA levels; chr1:54227863 chr1:54236440~54239063:+ LIHC cis rs11096990 0.634 rs11947159 ENSG00000249207.1 RP11-360F5.1 3.89 0.000119 0.0212 0.2 0.21 Cognitive function; chr4:39286900 chr4:39112677~39126818:- LIHC cis rs4578769 0.959 rs4800439 ENSG00000266850.1 RP11-370A5.1 3.89 0.000119 0.0212 0.24 0.21 Eosinophil percentage of white cells; chr18:22920492 chr18:22723491~22907721:- LIHC cis rs6860806 0.507 rs270608 ENSG00000263597.1 MIR3936 3.89 0.000119 0.0212 0.22 0.21 Breast cancer; chr5:132312713 chr5:132365490~132365599:- LIHC cis rs2299116 0.962 rs56389942 ENSG00000225264.3 ZNRF2P2 -3.89 0.000119 0.0212 -0.22 -0.21 Serum thyroid-stimulating hormone levels; chr7:28773941 chr7:29598795~29685255:- LIHC cis rs2299116 0.962 rs34805069 ENSG00000225264.3 ZNRF2P2 -3.89 0.000119 0.0212 -0.22 -0.21 Serum thyroid-stimulating hormone levels; chr7:28773960 chr7:29598795~29685255:- LIHC cis rs2299116 0.962 rs757979 ENSG00000225264.3 ZNRF2P2 -3.89 0.000119 0.0212 -0.22 -0.21 Serum thyroid-stimulating hormone levels; chr7:28774055 chr7:29598795~29685255:- LIHC cis rs12586317 0.534 rs28384418 ENSG00000257307.1 RP11-317N8.4 -3.89 0.000119 0.0212 -0.23 -0.21 Psoriasis; chr14:34982920 chr14:35881001~35881709:+ LIHC cis rs57502260 0.79 rs7129320 ENSG00000212093.1 AP000807.1 3.89 0.000119 0.0212 0.27 0.21 Total body bone mineral density (age 45-60); chr11:68620752 chr11:68506083~68506166:- LIHC cis rs1421334 0.781 rs11778607 ENSG00000271869.1 RP11-51J9.5 3.89 0.000119 0.0212 0.22 0.21 Intelligence (multi-trait analysis); chr8:30982052 chr8:30155830~30156232:- LIHC cis rs9747201 0.963 rs11077982 ENSG00000279692.1 RP11-1055B8.1 3.89 0.000119 0.0212 0.36 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82189501 chr17:81395609~81397144:- LIHC cis rs9747201 0.862 rs57596657 ENSG00000279692.1 RP11-1055B8.1 3.89 0.000119 0.0212 0.36 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82190102 chr17:81395609~81397144:- LIHC cis rs9747201 1 rs58119191 ENSG00000279692.1 RP11-1055B8.1 3.89 0.000119 0.0212 0.36 0.21 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82197453 chr17:81395609~81397144:- LIHC cis rs950169 0.92 rs11637666 ENSG00000259728.4 LINC00933 3.89 0.000119 0.0212 0.35 0.21 Schizophrenia; chr15:84035122 chr15:84570649~84580175:+ LIHC cis rs10510102 0.872 rs12244199 ENSG00000226864.1 ATE1-AS1 3.89 0.000119 0.0212 0.36 0.21 Breast cancer; chr10:121965117 chr10:121928312~121951965:+ LIHC cis rs11710088 0.599 rs4681509 ENSG00000244503.1 RP11-278L15.6 3.89 0.000119 0.0212 0.21 0.21 QRS duration; chr3:149483657 chr3:149494660~149495995:+ LIHC cis rs10510102 0.623 rs10159856 ENSG00000276742.1 RP11-500G22.4 3.89 0.000119 0.0212 0.34 0.21 Breast cancer; chr10:121988292 chr10:121956782~121957098:+ LIHC cis rs2838568 0.967 rs2838570 ENSG00000277352.1 KB-68A7.2 -3.89 0.000119 0.0213 -0.24 -0.21 Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals; chr21:44478351 chr21:44494874~44495519:+ LIHC cis rs6504622 0.702 rs3851799 ENSG00000262879.4 RP11-156P1.3 -3.89 0.000119 0.0213 -0.22 -0.21 Orofacial clefts; chr17:46989122 chr17:46984045~47100323:- LIHC cis rs904251 0.772 rs756202 ENSG00000204110.6 RP1-153P14.8 -3.89 0.000119 0.0213 -0.25 -0.21 Cognitive performance; chr6:37492574 chr6:37507348~37535616:+ LIHC cis rs7722022 0.961 rs1422772 ENSG00000253428.1 CTB-43E15.2 3.89 0.000119 0.0213 0.22 0.21 Adiponectin levels; chr5:173515456 chr5:173689459~173705849:+ LIHC cis rs7809950 0.817 rs3779495 ENSG00000238832.1 snoU109 3.89 0.000119 0.0213 0.26 0.21 Coronary artery disease; chr7:107609815 chr7:107603363~107603507:+ LIHC cis rs8024893 1 rs8024893 ENSG00000270055.1 CTD-3092A11.2 3.89 0.000119 0.0213 0.29 0.21 Red cell distribution width; chr15:31248786 chr15:30487963~30490313:+ LIHC cis rs2462686 1 rs2462327 ENSG00000272556.1 RP11-638I8.1 3.89 0.000119 0.0213 0.31 0.21 Major depressive disorder; chr7:45953440 chr7:45814602~45815263:+ LIHC cis rs2337406 0.714 rs7150993 ENSG00000274576.2 IGHV2-70 -3.89 0.000119 0.0213 -0.22 -0.21 Alzheimer's disease (late onset); chr14:106818515 chr14:106770577~106771020:- LIHC cis rs6560039 1 rs6560039 ENSG00000214888.2 XXyac-YM21GA2.7 -3.89 0.000119 0.0213 -0.21 -0.21 Gait variability; chr9:87860031 chr9:87857015~87859399:- LIHC cis rs10975870 0.847 rs7038154 ENSG00000236924.1 RP11-390F4.6 -3.89 0.000119 0.0213 -0.32 -0.21 Body mass index; chr9:6930415 chr9:6645956~6670635:+ LIHC cis rs17264034 1 rs414829 ENSG00000250786.1 SNHG18 3.89 0.000119 0.0213 0.27 0.21 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9552413 chr5:9546200~9550609:+ LIHC cis rs17774123 0.851 rs11831387 ENSG00000257808.1 RP11-1136G11.8 3.89 0.000119 0.0213 0.38 0.21 Diastolic blood pressure; chr12:53895122 chr12:53159586~53161000:+ LIHC cis rs17774123 0.851 rs11170750 ENSG00000257808.1 RP11-1136G11.8 3.89 0.000119 0.0213 0.38 0.21 Diastolic blood pressure; chr12:53895182 chr12:53159586~53161000:+ LIHC cis rs17774123 0.851 rs76631718 ENSG00000257808.1 RP11-1136G11.8 3.89 0.000119 0.0213 0.38 0.21 Diastolic blood pressure; chr12:53895597 chr12:53159586~53161000:+ LIHC cis rs17774123 0.851 rs80076481 ENSG00000257808.1 RP11-1136G11.8 3.89 0.000119 0.0213 0.38 0.21 Diastolic blood pressure; chr12:53896101 chr12:53159586~53161000:+ LIHC cis rs17774123 0.851 rs78540414 ENSG00000257808.1 RP11-1136G11.8 3.89 0.000119 0.0213 0.38 0.21 Diastolic blood pressure; chr12:53896113 chr12:53159586~53161000:+ LIHC cis rs17774123 0.851 rs12426544 ENSG00000257808.1 RP11-1136G11.8 3.89 0.000119 0.0213 0.38 0.21 Diastolic blood pressure; chr12:53896298 chr12:53159586~53161000:+ LIHC cis rs17774123 0.851 rs12423932 ENSG00000257808.1 RP11-1136G11.8 3.89 0.000119 0.0213 0.38 0.21 Diastolic blood pressure; chr12:53896706 chr12:53159586~53161000:+ LIHC cis rs17774123 0.851 rs10506326 ENSG00000257808.1 RP11-1136G11.8 3.89 0.000119 0.0213 0.38 0.21 Diastolic blood pressure; chr12:53896982 chr12:53159586~53161000:+ LIHC cis rs17774123 0.851 rs113100961 ENSG00000257808.1 RP11-1136G11.8 3.89 0.000119 0.0213 0.38 0.21 Diastolic blood pressure; chr12:53899107 chr12:53159586~53161000:+ LIHC cis rs6142102 0.961 rs1555075 ENSG00000275784.1 RP5-1125A11.6 -3.89 0.000119 0.0213 -0.24 -0.21 Skin pigmentation; chr20:34022595 chr20:33989480~33991818:- LIHC cis rs12209785 0.774 rs7772562 ENSG00000231769.2 RP1-8B1.4 3.89 0.000119 0.0213 0.29 0.21 Survival in pancreatic cancer; chr6:45518759 chr6:46097093~46129706:- LIHC cis rs422249 0.819 rs174608 ENSG00000252361.1 RNU6-118P -3.89 0.000119 0.0213 -0.3 -0.21 Trans fatty acid levels; chr11:61860012 chr11:62815966~62816067:- LIHC cis rs422249 0.819 rs174611 ENSG00000252361.1 RNU6-118P -3.89 0.000119 0.0213 -0.3 -0.21 Trans fatty acid levels; chr11:61860409 chr11:62815966~62816067:- LIHC cis rs1005277 0.579 rs176838 ENSG00000276805.1 RP11-291L22.6 -3.89 0.000119 0.0213 -0.25 -0.21 Extrinsic epigenetic age acceleration; chr10:38082971 chr10:38451030~38451785:+ LIHC cis rs11123170 0.529 rs1015755 ENSG00000189223.12 PAX8-AS1 -3.89 0.000119 0.0213 -0.36 -0.21 Renal function-related traits (BUN); chr2:113210730 chr2:113211522~113276581:+ LIHC cis rs2439831 0.681 rs825740 ENSG00000205771.5 CATSPER2P1 -3.89 0.00012 0.0213 -0.28 -0.21 Lung cancer in ever smokers; chr15:43300210 chr15:43726918~43747094:- LIHC cis rs2070488 0.965 rs7373828 ENSG00000229589.1 ACVR2B-AS1 3.89 0.00012 0.0214 0.23 0.21 Electrocardiographic conduction measures; chr3:38482820 chr3:38451027~38454820:- LIHC cis rs67311347 0.955 rs73078170 ENSG00000223797.4 ENTPD3-AS1 3.89 0.00012 0.0214 0.17 0.21 Renal cell carcinoma; chr3:40442456 chr3:40313802~40453329:- LIHC cis rs7722022 0.961 rs6877950 ENSG00000253428.1 CTB-43E15.2 3.89 0.00012 0.0214 0.21 0.21 Adiponectin levels; chr5:173522574 chr5:173689459~173705849:+ LIHC cis rs5743030 1 rs5743208 ENSG00000253559.1 OSGEPL1-AS1 3.89 0.00012 0.0214 0.34 0.21 Subcutaneous adipose tissue; chr2:189878322 chr2:189762704~189765556:+ LIHC cis rs12908161 0.96 rs62019463 ENSG00000259728.4 LINC00933 3.89 0.00012 0.0214 0.29 0.21 Schizophrenia; chr15:84744856 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs62019464 ENSG00000259728.4 LINC00933 3.89 0.00012 0.0214 0.29 0.21 Schizophrenia; chr15:84751238 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs12910012 ENSG00000259728.4 LINC00933 3.89 0.00012 0.0214 0.29 0.21 Schizophrenia; chr15:84755431 chr15:84570649~84580175:+ LIHC cis rs11089937 0.597 rs6001072 ENSG00000211639.2 IGLV4-60 3.89 0.00012 0.0214 0.18 0.21 Periodontitis (PAL4Q3); chr22:22133629 chr22:22162199~22162681:+ LIHC cis rs11089937 0.512 rs6001073 ENSG00000211639.2 IGLV4-60 3.89 0.00012 0.0214 0.18 0.21 Periodontitis (PAL4Q3); chr22:22133650 chr22:22162199~22162681:+ LIHC cis rs9876781 1 rs725310 ENSG00000229759.1 MRPS18AP1 -3.89 0.00012 0.0214 -0.21 -0.21 Longevity; chr3:48377081 chr3:48256350~48256938:- LIHC cis rs8111500 0.793 rs8103121 ENSG00000232871.7 SEC1P -3.89 0.00012 0.0214 -0.25 -0.21 Elevated serum carcinoembryonic antigen levels; chr19:48654881 chr19:48638071~48682245:+ LIHC cis rs11733284 1 rs13125949 ENSG00000259959.1 RP11-121C2.2 3.89 0.00012 0.0214 0.19 0.21 Gout;Renal underexcretion gout; chr4:48024543 chr4:47840122~47844339:- LIHC cis rs3015497 0.789 rs2356457 ENSG00000269906.1 RP11-248J18.2 3.89 0.00012 0.0214 0.26 0.21 Mean platelet volume; chr14:50650145 chr14:50662511~50663178:- LIHC cis rs7224610 0.702 rs3829578 ENSG00000263096.1 RP11-515O17.2 3.89 0.00012 0.0214 0.28 0.21 Urate levels; chr17:55304149 chr17:55271504~55273653:- LIHC cis rs10510102 0.516 rs12244921 ENSG00000276742.1 RP11-500G22.4 3.89 0.00012 0.0214 0.32 0.21 Breast cancer; chr10:121990342 chr10:121956782~121957098:+ LIHC cis rs2253762 0.507 rs10159582 ENSG00000276742.1 RP11-500G22.4 3.89 0.00012 0.0214 0.33 0.21 Breast cancer; chr10:121993110 chr10:121956782~121957098:+ LIHC cis rs2253762 0.507 rs10159583 ENSG00000276742.1 RP11-500G22.4 3.89 0.00012 0.0214 0.33 0.21 Breast cancer; chr10:121993154 chr10:121956782~121957098:+ LIHC cis rs2253762 0.507 rs75383663 ENSG00000276742.1 RP11-500G22.4 3.89 0.00012 0.0214 0.33 0.21 Breast cancer; chr10:121993340 chr10:121956782~121957098:+ LIHC cis rs3761847 0.508 rs4837813 ENSG00000226752.6 PSMD5-AS1 -3.89 0.00012 0.0214 -0.25 -0.21 Rheumatoid arthritis; chr9:121172185 chr9:120824828~120854385:+ LIHC cis rs2070488 0.965 rs1058945 ENSG00000229589.1 ACVR2B-AS1 -3.89 0.00012 0.0214 -0.24 -0.21 Electrocardiographic conduction measures; chr3:38491020 chr3:38451027~38454820:- LIHC cis rs4925386 0.681 rs2427294 ENSG00000226332.2 RP11-157P1.4 3.89 0.00012 0.0214 0.24 0.21 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62352201 chr20:62305432~62306325:- LIHC cis rs17711722 0.727 rs1880555 ENSG00000273024.4 INTS4P2 -3.89 0.00012 0.0214 -0.25 -0.21 Calcium levels; chr7:65967580 chr7:65647864~65715661:+ LIHC cis rs8177253 0.53 rs8177177 ENSG00000244062.1 RP11-404G16.2 3.89 0.00012 0.0214 0.2 0.21 Iron status biomarkers; chr3:133744351 chr3:133760300~133762363:+ LIHC cis rs10883723 0.81 rs10786671 ENSG00000236937.2 PTGES3P4 -3.89 0.00012 0.0214 -0.27 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102511546 chr10:102845595~102845950:+ LIHC cis rs16958440 0.867 rs16948928 ENSG00000267724.1 RP11-49K24.8 3.89 0.00012 0.0214 0.31 0.21 Sitting height ratio; chr18:47149450 chr18:47105946~47108062:+ LIHC cis rs4356975 0.563 rs6858558 ENSG00000250919.1 RP11-813N20.3 -3.89 0.00012 0.0214 -0.21 -0.21 Obesity-related traits; chr4:69103825 chr4:69027831~69044578:+ LIHC cis rs2253762 0.54 rs79547192 ENSG00000226864.1 ATE1-AS1 3.89 0.00012 0.0214 0.35 0.21 Breast cancer; chr10:121998664 chr10:121928312~121951965:+ LIHC cis rs9527 0.615 rs9733635 ENSG00000236937.2 PTGES3P4 3.89 0.00012 0.0214 0.26 0.21 Arsenic metabolism; chr10:102952183 chr10:102845595~102845950:+ LIHC cis rs643506 0.874 rs634983 ENSG00000230911.1 PPIHP1 -3.89 0.00012 0.0214 -0.27 -0.21 Breast cancer; chr11:111876703 chr11:112029858~112030367:- LIHC cis rs62246343 0.605 rs9842540 ENSG00000206573.7 THUMPD3-AS1 -3.89 0.00012 0.0215 -0.24 -0.21 Fibrinogen levels; chr3:9399389 chr3:9349689~9398579:- LIHC cis rs453301 0.506 rs686189 ENSG00000173295.6 FAM86B3P -3.89 0.00012 0.0215 -0.26 -0.21 Joint mobility (Beighton score); chr8:8766127 chr8:8228595~8244865:+ LIHC cis rs2348418 0.966 rs7136139 ENSG00000247934.4 RP11-967K21.1 3.89 0.000121 0.0215 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28531087 chr12:28163298~28190738:- LIHC cis rs2348418 0.966 rs4144964 ENSG00000247934.4 RP11-967K21.1 3.89 0.000121 0.0215 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28531249 chr12:28163298~28190738:- LIHC cis rs673078 0.607 rs61943392 ENSG00000275759.1 RP11-131L12.3 -3.89 0.000121 0.0215 -0.41 -0.21 Glucose homeostasis traits; chr12:118382618 chr12:118428281~118428870:+ LIHC cis rs848490 0.674 rs17807185 ENSG00000214293.7 APTR 3.89 0.000121 0.0215 0.24 0.21 Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine); chr7:77678978 chr7:77657660~77696265:- LIHC cis rs172166 0.637 rs1233691 ENSG00000219392.1 RP1-265C24.5 -3.89 0.000121 0.0215 -0.27 -0.21 Cardiac Troponin-T levels; chr6:28186119 chr6:28115628~28116551:+ LIHC cis rs5769707 0.777 rs739243 ENSG00000235111.1 RP1-29C18.8 -3.89 0.000121 0.0215 -0.24 -0.21 Monocyte percentage of white cells;Monocyte count; chr22:49663563 chr22:49612657~49615716:- LIHC cis rs2179367 0.959 rs652807 ENSG00000231760.4 RP11-350J20.5 -3.89 0.000121 0.0215 -0.26 -0.21 Dupuytren's disease; chr6:149416359 chr6:149796151~149826294:- LIHC cis rs8177253 0.666 rs8177197 ENSG00000244062.1 RP11-404G16.2 3.89 0.000121 0.0215 0.21 0.21 Iron status biomarkers; chr3:133750686 chr3:133760300~133762363:+ LIHC cis rs9409565 1 rs9409567 ENSG00000231806.2 PCAT7 3.89 0.000121 0.0215 0.25 0.21 Colorectal cancer (alcohol consumption interaction); chr9:94490223 chr9:94555069~94568127:+ LIHC cis rs17482078 0.959 rs13185488 ENSG00000248734.2 CTD-2260A17.1 3.89 0.000121 0.0215 0.3 0.21 Behcet's disease;Blood protein levels; chr5:96785480 chr5:96784777~96785999:+ LIHC cis rs17482078 0.959 rs13186739 ENSG00000248734.2 CTD-2260A17.1 3.89 0.000121 0.0215 0.3 0.21 Behcet's disease;Blood protein levels; chr5:96785539 chr5:96784777~96785999:+ LIHC cis rs13315871 0.929 rs34676912 ENSG00000272182.1 RP11-802O23.3 3.89 0.000121 0.0215 0.49 0.21 Cholesterol, total; chr3:58334571 chr3:58428255~58428815:+ LIHC cis rs8054556 0.633 rs12928610 ENSG00000250616.2 RP11-455F5.3 3.89 0.000121 0.0215 0.2 0.21 Autism spectrum disorder or schizophrenia; chr16:30004701 chr16:30096430~30104116:+ LIHC cis rs10829156 0.732 rs7075678 ENSG00000225527.1 RP11-383B4.4 -3.89 0.000121 0.0215 -0.34 -0.21 Sudden cardiac arrest; chr10:18585174 chr10:18531849~18533336:- LIHC cis rs2439831 0.85 rs67541383 ENSG00000166763.7 STRCP1 3.89 0.000121 0.0215 0.36 0.21 Lung cancer in ever smokers; chr15:43880350 chr15:43699488~43718184:- LIHC cis rs9527 0.59 rs3781281 ENSG00000236937.2 PTGES3P4 -3.89 0.000121 0.0215 -0.26 -0.21 Arsenic metabolism; chr10:103092891 chr10:102845595~102845950:+ LIHC cis rs1223397 0.651 rs2458309 ENSG00000215022.6 RP1-257A7.4 -3.89 0.000121 0.0215 -0.22 -0.21 Blood pressure; chr6:13311854 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs2439543 ENSG00000215022.6 RP1-257A7.4 -3.89 0.000121 0.0215 -0.22 -0.21 Blood pressure; chr6:13311921 chr6:13264861~13295586:- LIHC cis rs4578769 0.55 rs11082182 ENSG00000266850.1 RP11-370A5.1 3.89 0.000121 0.0216 0.22 0.21 Eosinophil percentage of white cells; chr18:22872136 chr18:22723491~22907721:- LIHC cis rs4578769 0.531 rs11082183 ENSG00000266850.1 RP11-370A5.1 3.89 0.000121 0.0216 0.22 0.21 Eosinophil percentage of white cells; chr18:22872137 chr18:22723491~22907721:- LIHC cis rs812925 0.762 rs3213951 ENSG00000212978.6 AC016747.3 -3.89 0.000121 0.0216 -0.24 -0.21 Immature fraction of reticulocytes; chr2:61395116 chr2:61141592~61144969:- LIHC cis rs1003719 0.715 rs1981432 ENSG00000272948.2 AP001412.1 -3.89 0.000121 0.0216 -0.23 -0.21 Eye color traits; chr21:37169054 chr21:37267784~37268497:+ LIHC cis rs6504622 0.667 rs11653589 ENSG00000262879.4 RP11-156P1.3 -3.89 0.000121 0.0216 -0.22 -0.21 Orofacial clefts; chr17:46990299 chr17:46984045~47100323:- LIHC cis rs6504622 0.634 rs8068715 ENSG00000262879.4 RP11-156P1.3 -3.89 0.000121 0.0216 -0.22 -0.21 Orofacial clefts; chr17:46991022 chr17:46984045~47100323:- LIHC cis rs6504622 0.514 rs60611133 ENSG00000262879.4 RP11-156P1.3 -3.89 0.000121 0.0216 -0.22 -0.21 Orofacial clefts; chr17:46993027 chr17:46984045~47100323:- LIHC cis rs11676348 0.772 rs7422358 ENSG00000261338.2 RP11-378A13.1 -3.89 0.000121 0.0216 -0.22 -0.21 Ulcerative colitis; chr2:218088055 chr2:218255319~218257366:+ LIHC cis rs2564921 0.666 rs62253656 ENSG00000242142.1 SERBP1P3 -3.89 0.000121 0.0216 -0.27 -0.21 Height; chr3:52989412 chr3:53064283~53065091:- LIHC cis rs2462686 1 rs809298 ENSG00000272556.1 RP11-638I8.1 3.89 0.000121 0.0216 0.31 0.21 Major depressive disorder; chr7:45958745 chr7:45814602~45815263:+ LIHC cis rs2439831 0.867 rs2447196 ENSG00000275601.1 AC011330.13 3.89 0.000121 0.0216 0.3 0.21 Lung cancer in ever smokers; chr15:43601620 chr15:43642389~43643023:- LIHC cis rs812925 0.519 rs2463099 ENSG00000271889.1 RP11-493E12.1 -3.89 0.000121 0.0216 -0.25 -0.21 Immature fraction of reticulocytes; chr2:61391176 chr2:61151433~61162105:- LIHC cis rs1322639 0.571 rs13204417 ENSG00000229214.1 LINC00242 3.89 0.000121 0.0216 0.24 0.21 Pulse pressure; chr6:169175260 chr6:169788790~169798825:- LIHC cis rs763121 0.925 rs1043312 ENSG00000273076.1 RP3-508I15.22 3.89 0.000121 0.0216 0.22 0.21 Menopause (age at onset); chr22:38735722 chr22:38743495~38743910:+ LIHC cis rs1065852 0.51 rs5751247 ENSG00000205702.9 CYP2D7 3.89 0.000121 0.0216 0.23 0.21 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42237048 chr22:42140203~42144577:- LIHC cis rs6421571 0.564 rs11216972 ENSG00000255422.1 AP002954.4 3.89 0.000121 0.0216 0.28 0.21 Primary biliary cholangitis; chr11:118715117 chr11:118704607~118750263:+ LIHC cis rs1499614 0.901 rs2178742 ENSG00000228409.4 CCT6P1 3.89 0.000121 0.0216 0.23 0.21 Gout; chr7:66732812 chr7:65751142~65763354:+ LIHC cis rs7953249 0.807 rs7970695 ENSG00000241388.4 HNF1A-AS1 -3.89 0.000121 0.0216 -0.21 -0.21 N-glycan levels;Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr12:120985573 chr12:120941728~120980965:- LIHC cis rs7953249 0.807 rs2393775 ENSG00000241388.4 HNF1A-AS1 -3.89 0.000121 0.0216 -0.21 -0.21 N-glycan levels;Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr12:120986771 chr12:120941728~120980965:- LIHC cis rs2333021 0.711 rs34518714 ENSG00000259015.1 RP11-109N23.6 3.89 0.000121 0.0216 0.25 0.21 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72992601 chr14:72960595~72961993:+ LIHC cis rs748404 0.697 rs531910 ENSG00000205771.5 CATSPER2P1 -3.89 0.000121 0.0216 -0.25 -0.21 Lung cancer; chr15:43268409 chr15:43726918~43747094:- LIHC cis rs748404 0.697 rs491804 ENSG00000205771.5 CATSPER2P1 -3.89 0.000121 0.0216 -0.25 -0.21 Lung cancer; chr15:43268627 chr15:43726918~43747094:- LIHC cis rs748404 0.697 rs492743 ENSG00000205771.5 CATSPER2P1 -3.89 0.000121 0.0216 -0.25 -0.21 Lung cancer; chr15:43268747 chr15:43726918~43747094:- LIHC cis rs2348418 0.67 rs10843098 ENSG00000247934.4 RP11-967K21.1 -3.89 0.000121 0.0216 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28116709 chr12:28163298~28190738:- LIHC cis rs539096 0.54 rs3011219 ENSG00000237950.1 RP11-7O11.3 3.89 0.000121 0.0216 0.22 0.21 Intelligence (multi-trait analysis); chr1:43840448 chr1:43944370~43946551:- LIHC cis rs6832769 1 rs28463765 ENSG00000272969.1 RP11-528I4.2 -3.89 0.000121 0.0216 -0.25 -0.21 Personality dimensions; chr4:55546267 chr4:55547112~55547889:+ LIHC cis rs8005677 1 rs1956880 ENSG00000279656.1 RP11-298I3.6 3.89 0.000121 0.0216 0.23 0.21 Cognitive ability (multi-trait analysis); chr14:22924798 chr14:23023083~23024217:- LIHC cis rs2070488 1 rs17733640 ENSG00000229589.1 ACVR2B-AS1 3.89 0.000121 0.0216 0.24 0.21 Electrocardiographic conduction measures; chr3:38405251 chr3:38451027~38454820:- LIHC cis rs12681287 0.64 rs6992287 ENSG00000254088.1 SLC2A3P4 -3.89 0.000121 0.0216 -0.24 -0.21 Caudate activity during reward; chr8:86406731 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs6992944 ENSG00000254088.1 SLC2A3P4 -3.89 0.000121 0.0216 -0.24 -0.21 Caudate activity during reward; chr8:86407079 chr8:86503591~86505061:+ LIHC cis rs10851478 0.74 rs11070697 ENSG00000276593.1 RP11-295H24.5 3.89 0.000122 0.0216 0.23 0.21 Oral cavity cancer; chr15:49500833 chr15:49353485~49354034:+ LIHC cis rs10851478 0.692 rs7169799 ENSG00000276593.1 RP11-295H24.5 3.89 0.000122 0.0216 0.23 0.21 Oral cavity cancer; chr15:49501823 chr15:49353485~49354034:+ LIHC cis rs1031391 0.716 rs10772416 ENSG00000247157.5 LINC01252 -3.89 0.000122 0.0217 -0.35 -0.21 Bitter taste perception; chr12:11017488 chr12:11548030~11590369:+ LIHC cis rs950880 0.71 rs11683700 ENSG00000234389.1 AC007278.3 -3.89 0.000122 0.0217 -0.22 -0.21 Serum protein levels (sST2); chr2:102380345 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs56258475 ENSG00000234389.1 AC007278.3 -3.89 0.000122 0.0217 -0.22 -0.21 Serum protein levels (sST2); chr2:102382852 chr2:102438713~102440475:+ LIHC cis rs6142102 0.625 rs6142062 ENSG00000275784.1 RP5-1125A11.6 -3.89 0.000122 0.0217 -0.22 -0.21 Skin pigmentation; chr20:33960706 chr20:33989480~33991818:- LIHC cis rs6142102 0.625 rs6141432 ENSG00000275784.1 RP5-1125A11.6 -3.89 0.000122 0.0217 -0.22 -0.21 Skin pigmentation; chr20:33960791 chr20:33989480~33991818:- LIHC cis rs6142102 0.602 rs6141433 ENSG00000275784.1 RP5-1125A11.6 -3.89 0.000122 0.0217 -0.22 -0.21 Skin pigmentation; chr20:33961056 chr20:33989480~33991818:- LIHC cis rs6142102 0.58 rs4911139 ENSG00000275784.1 RP5-1125A11.6 -3.89 0.000122 0.0217 -0.22 -0.21 Skin pigmentation; chr20:33963729 chr20:33989480~33991818:- LIHC cis rs6142102 0.625 rs1883707 ENSG00000275784.1 RP5-1125A11.6 3.89 0.000122 0.0217 0.22 0.21 Skin pigmentation; chr20:33964781 chr20:33989480~33991818:- LIHC cis rs6142102 0.625 rs1883706 ENSG00000275784.1 RP5-1125A11.6 -3.89 0.000122 0.0217 -0.22 -0.21 Skin pigmentation; chr20:33965071 chr20:33989480~33991818:- LIHC cis rs6142102 0.625 rs1883705 ENSG00000275784.1 RP5-1125A11.6 -3.89 0.000122 0.0217 -0.22 -0.21 Skin pigmentation; chr20:33965072 chr20:33989480~33991818:- LIHC cis rs244293 0.73 rs2332314 ENSG00000275710.1 RP11-257O5.4 3.89 0.000122 0.0217 0.24 0.21 Menarche (age at onset); chr17:54955646 chr17:54964474~54964679:+ LIHC cis rs6061231 0.675 rs755726 ENSG00000226332.2 RP11-157P1.4 3.89 0.000122 0.0217 0.22 0.21 Colorectal cancer; chr20:62387568 chr20:62305432~62306325:- LIHC cis rs867371 0.519 rs1566560 ENSG00000259429.4 UBE2Q2P2 -3.89 0.000122 0.0217 -0.22 -0.21 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82232116 chr15:82355142~82420075:+ LIHC cis rs867371 0.519 rs1566559 ENSG00000259429.4 UBE2Q2P2 -3.89 0.000122 0.0217 -0.22 -0.21 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82232120 chr15:82355142~82420075:+ LIHC cis rs2564921 0.704 rs57916015 ENSG00000242142.1 SERBP1P3 -3.89 0.000122 0.0217 -0.28 -0.21 Height; chr3:52971094 chr3:53064283~53065091:- LIHC cis rs11148252 0.846 rs1056335 ENSG00000278238.1 RP11-245D16.4 -3.89 0.000122 0.0217 -0.2 -0.21 Lewy body disease; chr13:52415728 chr13:52454775~52455331:- LIHC cis rs1005277 0.522 rs289648 ENSG00000276805.1 RP11-291L22.6 3.89 0.000122 0.0217 0.25 0.21 Extrinsic epigenetic age acceleration; chr10:37682909 chr10:38451030~38451785:+ LIHC cis rs1922291 0.546 rs35139442 ENSG00000281162.1 LINC01127 3.89 0.000122 0.0217 0.22 0.21 Blood protein levels; chr2:102225186 chr2:101962056~101987167:+ LIHC cis rs17818399 0.926 rs1824050 ENSG00000279254.1 RP11-536C12.1 -3.89 0.000122 0.0217 -0.26 -0.21 Height; chr2:46612338 chr2:46668870~46670778:+ LIHC cis rs17818399 0.926 rs1378764 ENSG00000279254.1 RP11-536C12.1 -3.89 0.000122 0.0217 -0.26 -0.21 Height; chr2:46612542 chr2:46668870~46670778:+ LIHC cis rs6910233 0.793 rs210156 ENSG00000224557.6 HLA-DPB2 -3.89 0.000122 0.0217 -0.22 -0.21 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr6:33549585 chr6:33112451~33129084:+ LIHC cis rs7665090 1 rs4586937 ENSG00000246560.2 RP11-10L12.4 -3.89 0.000122 0.0217 -0.24 -0.21 Primary biliary cholangitis; chr4:102635305 chr4:102828055~102844075:+ LIHC cis rs6828577 0.862 rs298995 ENSG00000269893.5 SNHG8 3.89 0.000122 0.0217 0.21 0.21 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118704118 chr4:118278709~118279823:+ LIHC cis rs733175 0.855 rs10018666 ENSG00000250413.1 RP11-448G15.1 -3.89 0.000122 0.0217 -0.29 -0.21 Psychosis and Alzheimer's disease; chr4:10003181 chr4:10006482~10009725:+ LIHC cis rs4925386 0.681 rs2427295 ENSG00000226332.2 RP11-157P1.4 3.89 0.000122 0.0217 0.24 0.21 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62352375 chr20:62305432~62306325:- LIHC cis rs2919917 0.628 rs10111658 ENSG00000254352.1 RP11-578O24.2 3.89 0.000122 0.0217 0.3 0.21 Lymphocyte counts; chr8:78652834 chr8:78723796~78724136:- LIHC cis rs2919917 0.59 rs10098472 ENSG00000254352.1 RP11-578O24.2 3.89 0.000122 0.0217 0.3 0.21 Lymphocyte counts; chr8:78652955 chr8:78723796~78724136:- LIHC cis rs2919917 0.628 rs13251931 ENSG00000254352.1 RP11-578O24.2 3.89 0.000122 0.0217 0.3 0.21 Lymphocyte counts; chr8:78653990 chr8:78723796~78724136:- LIHC cis rs2919917 0.628 rs1351742 ENSG00000254352.1 RP11-578O24.2 3.89 0.000122 0.0217 0.3 0.21 Lymphocyte counts; chr8:78655823 chr8:78723796~78724136:- LIHC cis rs2919917 0.666 rs982032 ENSG00000254352.1 RP11-578O24.2 3.89 0.000122 0.0217 0.3 0.21 Lymphocyte counts; chr8:78655825 chr8:78723796~78724136:- LIHC cis rs12908161 1 rs58416181 ENSG00000259728.4 LINC00933 3.89 0.000122 0.0217 0.3 0.21 Schizophrenia; chr15:84721230 chr15:84570649~84580175:+ LIHC cis rs4803480 0.63 rs16975338 ENSG00000270164.1 LINC01480 3.89 0.000122 0.0217 0.41 0.21 Schizophrenia; chr19:41551655 chr19:41535183~41536904:+ LIHC cis rs28829049 0.536 rs2073105 ENSG00000270728.1 RP4-657E11.10 -3.89 0.000122 0.0217 -0.2 -0.21 QRS duration in Tripanosoma cruzi seropositivity; chr1:19223370 chr1:19297080~19297903:+ LIHC cis rs17482078 0.959 rs10062964 ENSG00000248734.2 CTD-2260A17.1 3.89 0.000122 0.0217 0.29 0.21 Behcet's disease;Blood protein levels; chr5:96803363 chr5:96784777~96785999:+ LIHC cis rs6445975 0.715 rs3773007 ENSG00000272360.1 RP11-359I18.5 -3.89 0.000122 0.0218 -0.24 -0.21 Systemic lupus erythematosus; chr3:58283839 chr3:58490830~58491291:- LIHC cis rs7617773 0.746 rs11713476 ENSG00000228638.1 FCF1P2 -3.89 0.000122 0.0218 -0.22 -0.21 Coronary artery disease; chr3:48333944 chr3:48290793~48291375:- LIHC cis rs1198872 0.563 rs1686497 ENSG00000272275.1 RP11-791G15.2 -3.89 0.000122 0.0218 -0.25 -0.21 Cardiac Troponin-T levels; chr2:10821058 chr2:10767875~10770058:- LIHC cis rs67478160 0.643 rs11628332 ENSG00000258534.1 CTD-2134A5.4 -3.89 0.000122 0.0218 -0.22 -0.21 Schizophrenia; chr14:103774804 chr14:103854366~103880111:- LIHC cis rs8054556 0.647 rs11863174 ENSG00000250616.2 RP11-455F5.3 3.89 0.000122 0.0218 0.2 0.21 Autism spectrum disorder or schizophrenia; chr16:30008054 chr16:30096430~30104116:+ LIHC cis rs699371 0.507 rs10149538 ENSG00000259005.1 RP3-449M8.6 3.89 0.000122 0.0218 0.25 0.21 Height; chr14:74458694 chr14:74474007~74474864:- LIHC cis rs2581828 0.646 rs2564944 ENSG00000242142.1 SERBP1P3 3.89 0.000122 0.0218 0.26 0.21 Crohn's disease; chr3:53114439 chr3:53064283~53065091:- LIHC cis rs10761256 0.835 rs1806458 ENSG00000227603.1 RP11-165J3.6 3.89 0.000123 0.0218 0.24 0.21 Itch intensity from mosquito bite adjusted by bite size; chr9:93634049 chr9:93435332~93437121:- LIHC cis rs131777 0.545 rs131759 ENSG00000205559.3 CHKB-AS1 -3.89 0.000123 0.0218 -0.22 -0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50577052 chr22:50583026~50583877:+ LIHC cis rs6496044 0.963 rs11853972 ENSG00000259630.2 CTD-2262B20.1 -3.89 0.000123 0.0218 -0.22 -0.21 Interstitial lung disease; chr15:85519209 chr15:85415228~85415633:+ LIHC cis rs6496044 1 rs6496044 ENSG00000259630.2 CTD-2262B20.1 -3.89 0.000123 0.0218 -0.22 -0.21 Interstitial lung disease; chr15:85524075 chr15:85415228~85415633:+ LIHC cis rs3015497 0.789 rs8003372 ENSG00000269906.1 RP11-248J18.2 3.89 0.000123 0.0218 0.26 0.21 Mean platelet volume; chr14:50635633 chr14:50662511~50663178:- LIHC cis rs8064024 0.538 rs11076854 ENSG00000267077.1 RP11-127I20.5 -3.89 0.000123 0.0218 -0.21 -0.21 Cancer; chr16:4879268 chr16:4795265~4796532:- LIHC cis rs79349575 0.783 rs15563 ENSG00000248278.1 SUMO2P17 3.89 0.000123 0.0218 0.25 0.21 Type 2 diabetes; chr17:48927831 chr17:48874860~48908983:- LIHC cis rs6142102 0.625 rs6142061 ENSG00000275784.1 RP5-1125A11.6 -3.89 0.000123 0.0218 -0.22 -0.21 Skin pigmentation; chr20:33960529 chr20:33989480~33991818:- LIHC cis rs6723226 0.557 rs62136260 ENSG00000276334.1 AL133243.1 -3.89 0.000123 0.0218 -0.24 -0.21 Intelligence (multi-trait analysis); chr2:32350379 chr2:32521927~32523547:+ LIHC cis rs9595908 0.709 rs7322668 ENSG00000212293.1 SNORA16 3.89 0.000123 0.0218 0.24 0.21 Body mass index; chr13:32780298 chr13:32420390~32420516:- LIHC cis rs9595908 0.709 rs7318610 ENSG00000212293.1 SNORA16 3.89 0.000123 0.0218 0.24 0.21 Body mass index; chr13:32781912 chr13:32420390~32420516:- LIHC cis rs17818399 0.749 rs4142759 ENSG00000239332.4 LINC01119 -3.89 0.000123 0.0218 -0.3 -0.21 Height; chr2:46556751 chr2:46816697~46859007:+ LIHC cis rs12681287 0.64 rs28561640 ENSG00000254088.1 SLC2A3P4 -3.89 0.000123 0.0218 -0.24 -0.21 Caudate activity during reward; chr8:86413409 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs10095498 ENSG00000254088.1 SLC2A3P4 -3.89 0.000123 0.0218 -0.24 -0.21 Caudate activity during reward; chr8:86413422 chr8:86503591~86505061:+ LIHC cis rs1075265 0.836 rs1421622 ENSG00000233266.1 HMGB1P31 -3.88 0.000123 0.0218 -0.25 -0.21 Chronotype;Morning vs. evening chronotype; chr2:54062644 chr2:54051334~54051760:+ LIHC cis rs875971 0.545 rs2707851 ENSG00000224316.1 RP11-479O9.2 -3.88 0.000123 0.0218 -0.2 -0.21 Aortic root size; chr7:66624178 chr7:65773620~65802067:+ LIHC cis rs1405130 0.839 rs13018428 ENSG00000224287.2 MSL3P1 3.88 0.000123 0.0218 0.25 0.21 Coronary artery disease; chr2:234657247 chr2:233865437~233868444:- LIHC cis rs1405130 0.839 rs13018439 ENSG00000224287.2 MSL3P1 3.88 0.000123 0.0218 0.25 0.21 Coronary artery disease; chr2:234657268 chr2:233865437~233868444:- LIHC cis rs13028485 1 rs635675 ENSG00000236449.1 AC018890.6 -3.88 0.000123 0.0218 -0.33 -0.21 Multiple myeloma (IgH translocation); chr2:173642624 chr2:174547141~174774827:+ LIHC cis rs683257 0.929 rs72990119 ENSG00000234147.1 RP3-460G2.2 -3.88 0.000123 0.0218 -0.38 -0.21 Facial emotion recognition (angry faces); chr6:140848009 chr6:140845958~140852924:- LIHC cis rs17818399 0.926 rs35682608 ENSG00000279254.1 RP11-536C12.1 -3.88 0.000123 0.0218 -0.26 -0.21 Height; chr2:46609403 chr2:46668870~46670778:+ LIHC cis rs875971 0.545 rs801199 ENSG00000273024.4 INTS4P2 3.88 0.000123 0.0218 0.23 0.21 Aortic root size; chr7:66560286 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs1638724 ENSG00000273024.4 INTS4P2 3.88 0.000123 0.0218 0.23 0.21 Aortic root size; chr7:66575494 chr7:65647864~65715661:+ LIHC cis rs2797160 1 rs2797160 ENSG00000237742.5 RP11-624M8.1 3.88 0.000123 0.0218 0.21 0.21 Endometrial cancer; chr6:125688970 chr6:125578558~125749190:- LIHC cis rs2797160 0.967 rs2797162 ENSG00000237742.5 RP11-624M8.1 3.88 0.000123 0.0218 0.21 0.21 Endometrial cancer; chr6:125690235 chr6:125578558~125749190:- LIHC cis rs3862030 0.503 rs6584505 ENSG00000236937.2 PTGES3P4 -3.88 0.000123 0.0218 -0.28 -0.21 Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction); chr10:102494655 chr10:102845595~102845950:+ LIHC cis rs10883723 0.738 rs715438 ENSG00000236937.2 PTGES3P4 -3.88 0.000123 0.0218 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102498546 chr10:102845595~102845950:+ LIHC cis rs2274273 0.529 rs10131562 ENSG00000258413.1 RP11-665C16.6 -3.88 0.000123 0.0219 -0.25 -0.21 Protein biomarker; chr14:55380297 chr14:55262767~55272075:- LIHC cis rs6456156 0.819 rs7765739 ENSG00000227598.1 RP1-167A14.2 -3.88 0.000123 0.0219 -0.21 -0.21 Primary biliary cholangitis; chr6:167104984 chr6:166969626~166999065:- LIHC cis rs2253762 0.507 rs11200310 ENSG00000276742.1 RP11-500G22.4 3.88 0.000123 0.0219 0.32 0.21 Breast cancer; chr10:121989944 chr10:121956782~121957098:+ LIHC cis rs812925 0.892 rs4672440 ENSG00000212978.6 AC016747.3 3.88 0.000123 0.0219 0.24 0.21 Immature fraction of reticulocytes; chr2:61389518 chr2:61141592~61144969:- LIHC cis rs1005277 0.579 rs2474568 ENSG00000275858.1 RP11-291L22.8 3.88 0.000123 0.0219 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38094219 chr10:38450738~38451069:- LIHC cis rs9976767 0.637 rs2156309 ENSG00000225218.1 AP001628.6 -3.88 0.000123 0.0219 -0.2 -0.21 Type 1 diabetes; chr21:42404420 chr21:42831040~42836477:- LIHC cis rs9976767 0.608 rs9784208 ENSG00000225218.1 AP001628.6 -3.88 0.000123 0.0219 -0.2 -0.21 Type 1 diabetes; chr21:42404877 chr21:42831040~42836477:- LIHC cis rs244293 0.801 rs7225949 ENSG00000275710.1 RP11-257O5.4 -3.88 0.000123 0.0219 -0.22 -0.21 Menarche (age at onset); chr17:55019410 chr17:54964474~54964679:+ LIHC cis rs10129255 0.536 rs10142951 ENSG00000211972.2 IGHV3-66 3.88 0.000123 0.0219 0.15 0.21 Kawasaki disease; chr14:106782337 chr14:106675017~106675544:- LIHC cis rs1075232 0.655 rs66501706 ENSG00000270055.1 CTD-3092A11.2 -3.88 0.000123 0.0219 -0.42 -0.21 Survival in colorectal cancer (non-distant metastatic); chr15:31336855 chr15:30487963~30490313:+ LIHC cis rs7246657 1 rs34544865 ENSG00000276846.1 CTD-3220F14.3 3.88 0.000123 0.0219 0.29 0.21 Coronary artery calcification; chr19:37310340 chr19:37314868~37315620:- LIHC cis rs6723108 0.604 rs1374291 ENSG00000224043.6 CCNT2-AS1 -3.88 0.000123 0.0219 -0.28 -0.21 Type 2 diabetes; chr2:134896768 chr2:134735464~134918710:- LIHC cis rs6704644 0.511 rs55983182 ENSG00000222001.2 AC106876.2 3.88 0.000123 0.0219 0.32 0.21 Bilirubin levels; chr2:233369123 chr2:233012614~233015885:+ LIHC cis rs12586317 0.534 rs28384418 ENSG00000258738.1 RP11-73E17.2 3.88 0.000123 0.0219 0.27 0.21 Psoriasis; chr14:34982920 chr14:34874343~34876459:+ LIHC cis rs73193808 0.59 rs9981735 ENSG00000212479.2 U3 3.88 0.000123 0.0219 0.24 0.21 Coronary artery disease; chr21:29195543 chr21:29180425~29180639:- LIHC cis rs73193808 0.59 rs9982010 ENSG00000212479.2 U3 3.88 0.000123 0.0219 0.24 0.21 Coronary artery disease; chr21:29195855 chr21:29180425~29180639:- LIHC cis rs481331 0.643 rs210285 ENSG00000185904.10 LINC00839 -3.88 0.000124 0.0219 -0.38 -0.21 Systemic juvenile idiopathic arthritis; chr10:42583900 chr10:42475543~42495336:+ LIHC cis rs7560272 0.538 rs35767294 ENSG00000273245.1 RP11-434P11.2 -3.88 0.000124 0.0219 -0.25 -0.21 Schizophrenia; chr2:73695707 chr2:73750256~73750786:- LIHC cis rs7560272 0.502 rs13013228 ENSG00000273245.1 RP11-434P11.2 -3.88 0.000124 0.0219 -0.25 -0.21 Schizophrenia; chr2:73698089 chr2:73750256~73750786:- LIHC cis rs10129255 0.5 rs8022547 ENSG00000211972.2 IGHV3-66 3.88 0.000124 0.0219 0.15 0.21 Kawasaki disease; chr14:106781985 chr14:106675017~106675544:- LIHC cis rs12681287 0.571 rs13254675 ENSG00000254088.1 SLC2A3P4 3.88 0.000124 0.0219 0.24 0.21 Caudate activity during reward; chr8:86341365 chr8:86503591~86505061:+ LIHC cis rs12681287 0.605 rs13262672 ENSG00000254088.1 SLC2A3P4 3.88 0.000124 0.0219 0.24 0.21 Caudate activity during reward; chr8:86343583 chr8:86503591~86505061:+ LIHC cis rs6456156 0.792 rs9366089 ENSG00000227598.1 RP1-167A14.2 -3.88 0.000124 0.0219 -0.21 -0.21 Primary biliary cholangitis; chr6:167099408 chr6:166969626~166999065:- LIHC cis rs1816213 0.744 rs114456768 ENSG00000273466.1 RP11-548H3.1 -3.88 0.000124 0.0219 -0.33 -0.21 Diastolic blood pressure; chr2:218447383 chr2:218633256~218634014:- LIHC cis rs4218 0.648 rs12442134 ENSG00000277144.1 RP11-59H7.4 -3.88 0.000124 0.0219 -0.23 -0.21 Social communication problems; chr15:59074478 chr15:59115547~59116089:- LIHC cis rs2562456 0.92 rs2650784 ENSG00000268555.1 RP11-678G14.3 -3.88 0.000124 0.022 -0.26 -0.21 Pain; chr19:21483795 chr19:21570822~21587322:- LIHC cis rs2243480 1 rs465359 ENSG00000232546.1 RP11-458F8.1 -3.88 0.000124 0.022 -0.23 -0.21 Diabetic kidney disease; chr7:66093177 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs462853 ENSG00000232546.1 RP11-458F8.1 -3.88 0.000124 0.022 -0.23 -0.21 Diabetic kidney disease; chr7:66093180 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs160644 ENSG00000232546.1 RP11-458F8.1 -3.88 0.000124 0.022 -0.23 -0.21 Diabetic kidney disease; chr7:66093199 chr7:66848496~66858136:+ LIHC cis rs950880 0.645 rs56044378 ENSG00000234389.1 AC007278.3 -3.88 0.000124 0.022 -0.2 -0.21 Serum protein levels (sST2); chr2:102448907 chr2:102438713~102440475:+ LIHC cis rs10761256 0.806 rs2398851 ENSG00000227603.1 RP11-165J3.6 3.88 0.000124 0.022 0.24 0.21 Itch intensity from mosquito bite adjusted by bite size; chr9:93636226 chr9:93435332~93437121:- LIHC cis rs950880 0.71 rs3771172 ENSG00000234389.1 AC007278.3 -3.88 0.000124 0.022 -0.22 -0.21 Serum protein levels (sST2); chr2:102369352 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs2160202 ENSG00000234389.1 AC007278.3 -3.88 0.000124 0.022 -0.22 -0.21 Serum protein levels (sST2); chr2:102369694 chr2:102438713~102440475:+ LIHC cis rs1405130 0.9 rs35282172 ENSG00000224287.2 MSL3P1 3.88 0.000124 0.022 0.24 0.21 Coronary artery disease; chr2:234679286 chr2:233865437~233868444:- LIHC cis rs597539 0.652 rs514296 ENSG00000250508.1 RP11-757G1.6 -3.88 0.000124 0.022 -0.3 -0.21 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68886714 chr11:68870664~68874542:+ LIHC cis rs11098499 0.954 rs2389803 ENSG00000260091.1 RP11-33B1.4 3.88 0.000124 0.022 0.15 0.21 Corneal astigmatism; chr4:119472356 chr4:119409333~119410233:+ LIHC cis rs2348418 0.703 rs12368149 ENSG00000247934.4 RP11-967K21.1 -3.88 0.000124 0.022 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28168625 chr12:28163298~28190738:- LIHC cis rs966423 0.55 rs2618147 ENSG00000232485.2 AC098820.3 3.88 0.000124 0.022 0.18 0.21 Thyroid cancer; chr2:217437415 chr2:216479030~216498761:- LIHC cis rs17711722 0.74 rs7809991 ENSG00000273024.4 INTS4P2 -3.88 0.000124 0.022 -0.25 -0.21 Calcium levels; chr7:65941231 chr7:65647864~65715661:+ LIHC cis rs1115240 0.604 rs1955848 ENSG00000257842.4 NOVA1-AS1 -3.88 0.000124 0.022 -0.2 -0.21 Educational attainment (years of education); chr14:26667614 chr14:26598412~26806467:+ LIHC cis rs7208859 0.673 rs3816780 ENSG00000266490.1 CTD-2349P21.9 3.88 0.000124 0.022 0.26 0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834340 chr17:30792372~30792833:+ LIHC cis rs6547705 0.748 rs13010845 ENSG00000266931.1 RP11-1252D15.1 -3.88 0.000124 0.022 -0.37 -0.21 Progressive supranuclear palsy; chr2:86662353 chr2:87055658~87055800:- LIHC cis rs10129255 1 rs8012033 ENSG00000211972.2 IGHV3-66 3.88 0.000124 0.022 0.16 0.21 Kawasaki disease; chr14:106678854 chr14:106675017~106675544:- LIHC cis rs4148008 0.589 rs12602875 ENSG00000267250.1 RP11-118B18.2 -3.88 0.000124 0.022 -0.26 -0.21 HDL cholesterol; chr17:68836002 chr17:68793549~68797822:- LIHC cis rs481331 0.866 rs210222 ENSG00000185904.10 LINC00839 3.88 0.000124 0.022 0.39 0.21 Systemic juvenile idiopathic arthritis; chr10:42561628 chr10:42475543~42495336:+ LIHC cis rs7722022 0.961 rs754312 ENSG00000253428.1 CTB-43E15.2 3.88 0.000124 0.022 0.21 0.21 Adiponectin levels; chr5:173524514 chr5:173689459~173705849:+ LIHC cis rs7722022 0.922 rs11747823 ENSG00000253428.1 CTB-43E15.2 3.88 0.000124 0.022 0.21 0.21 Adiponectin levels; chr5:173525378 chr5:173689459~173705849:+ LIHC cis rs1115240 0.841 rs1245199 ENSG00000257842.4 NOVA1-AS1 -3.88 0.000124 0.022 -0.19 -0.21 Educational attainment (years of education); chr14:26524752 chr14:26598412~26806467:+ LIHC cis rs875971 0.545 rs11767262 ENSG00000224316.1 RP11-479O9.2 3.88 0.000124 0.022 0.2 0.21 Aortic root size; chr7:66302237 chr7:65773620~65802067:+ LIHC cis rs17818399 0.926 rs1824050 ENSG00000239332.4 LINC01119 -3.88 0.000124 0.022 -0.3 -0.21 Height; chr2:46612338 chr2:46816697~46859007:+ LIHC cis rs17818399 0.926 rs1378764 ENSG00000239332.4 LINC01119 -3.88 0.000124 0.022 -0.3 -0.21 Height; chr2:46612542 chr2:46816697~46859007:+ LIHC cis rs4964805 0.626 rs11111771 ENSG00000257681.1 RP11-341G23.4 -3.88 0.000124 0.022 -0.21 -0.21 Attention deficit hyperactivity disorder; chr12:103785493 chr12:103746315~103768858:- LIHC cis rs2929278 0.546 rs686666 ENSG00000275601.1 AC011330.13 -3.88 0.000124 0.022 -0.26 -0.21 Schizophrenia; chr15:43869352 chr15:43642389~43643023:- LIHC cis rs193541 0.632 rs4835896 ENSG00000263432.2 RN7SL689P -3.88 0.000124 0.022 -0.32 -0.21 Glucose homeostasis traits; chr5:122785545 chr5:123022487~123022783:- LIHC cis rs2072510 0.593 rs2540497 ENSG00000257878.1 RP11-256L6.3 -3.88 0.000124 0.022 -0.28 -0.21 Metabolite levels (small molecules and protein measures); chr12:96010497 chr12:95996521~96011489:+ LIHC cis rs950880 0.71 rs17026974 ENSG00000234389.1 AC007278.3 3.88 0.000124 0.022 0.21 0.21 Serum protein levels (sST2); chr2:102335900 chr2:102438713~102440475:+ LIHC cis rs2302464 1 rs10939631 ENSG00000214846.4 RP11-115L11.1 3.88 0.000124 0.0221 0.38 0.21 Cerebrospinal fluid biomarker levels; chr4:15656946 chr4:15730962~15731627:- LIHC cis rs2439831 0.867 rs28729853 ENSG00000166763.7 STRCP1 3.88 0.000124 0.0221 0.29 0.21 Lung cancer in ever smokers; chr15:43381482 chr15:43699488~43718184:- LIHC cis rs8002861 0.664 rs1466005 ENSG00000274001.1 RP11-5G9.5 3.88 0.000124 0.0221 0.22 0.21 Leprosy; chr13:43850074 chr13:43877715~43878163:- LIHC cis rs4578769 0.649 rs72889626 ENSG00000266850.1 RP11-370A5.1 -3.88 0.000124 0.0221 -0.25 -0.21 Eosinophil percentage of white cells; chr18:23006282 chr18:22723491~22907721:- LIHC cis rs27434 0.605 rs12659825 ENSG00000272109.1 CTD-2260A17.3 3.88 0.000124 0.0221 0.28 0.21 Ankylosing spondylitis; chr5:96852380 chr5:96804353~96806105:+ LIHC cis rs6471393 0.964 rs2914952 ENSG00000253848.1 RP11-10N23.5 3.88 0.000125 0.0221 0.23 0.21 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93729524 chr8:93741193~93744534:+ LIHC cis rs2348418 0.831 rs7137119 ENSG00000247934.4 RP11-967K21.1 3.88 0.000125 0.0221 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28565058 chr12:28163298~28190738:- LIHC cis rs875971 0.522 rs10807697 ENSG00000273024.4 INTS4P2 -3.88 0.000125 0.0221 -0.25 -0.21 Aortic root size; chr7:65951183 chr7:65647864~65715661:+ LIHC cis rs748404 0.697 rs564946 ENSG00000205771.5 CATSPER2P1 -3.88 0.000125 0.0221 -0.25 -0.21 Lung cancer; chr15:43264074 chr15:43726918~43747094:- LIHC cis rs748404 0.723 rs565658 ENSG00000205771.5 CATSPER2P1 -3.88 0.000125 0.0221 -0.25 -0.21 Lung cancer; chr15:43264109 chr15:43726918~43747094:- LIHC cis rs748404 0.697 rs579651 ENSG00000205771.5 CATSPER2P1 -3.88 0.000125 0.0221 -0.25 -0.21 Lung cancer; chr15:43266178 chr15:43726918~43747094:- LIHC cis rs748404 0.697 rs473016 ENSG00000205771.5 CATSPER2P1 -3.88 0.000125 0.0221 -0.25 -0.21 Lung cancer; chr15:43266625 chr15:43726918~43747094:- LIHC cis rs6452524 1 rs6452520 ENSG00000271862.1 RP11-343L5.2 3.88 0.000125 0.0221 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83133452 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs6452521 ENSG00000271862.1 RP11-343L5.2 3.88 0.000125 0.0221 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83133453 chr5:83049376~83050964:- LIHC cis rs6452524 0.935 rs6452522 ENSG00000271862.1 RP11-343L5.2 3.88 0.000125 0.0221 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83133471 chr5:83049376~83050964:- LIHC cis rs7893279 0.505 rs2228645 ENSG00000225527.1 RP11-383B4.4 3.88 0.000125 0.0221 0.29 0.21 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18539442 chr10:18531849~18533336:- LIHC cis rs2243480 1 rs316318 ENSG00000230295.1 RP11-458F8.2 -3.88 0.000125 0.0221 -0.22 -0.21 Diabetic kidney disease; chr7:66147917 chr7:66880708~66882981:+ LIHC cis rs17508449 0.819 rs4839000 ENSG00000232450.1 RP4-730K3.3 -3.88 0.000125 0.0221 -0.27 -0.21 Leprosy; chr1:113737513 chr1:113698884~113699631:- LIHC cis rs17508449 0.819 rs78394484 ENSG00000232450.1 RP4-730K3.3 -3.88 0.000125 0.0221 -0.27 -0.21 Leprosy; chr1:113740136 chr1:113698884~113699631:- LIHC cis rs867371 0.502 rs28610286 ENSG00000259429.4 UBE2Q2P2 -3.88 0.000125 0.0221 -0.22 -0.21 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82233314 chr15:82355142~82420075:+ LIHC cis rs6545883 0.929 rs9679557 ENSG00000271889.1 RP11-493E12.1 3.88 0.000125 0.0221 0.25 0.21 Tuberculosis; chr2:61482214 chr2:61151433~61162105:- LIHC cis rs2348418 0.864 rs6487688 ENSG00000247934.4 RP11-967K21.1 -3.88 0.000125 0.0221 -0.19 -0.21 Lung function (FEV1);Lung function (FVC); chr12:28558278 chr12:28163298~28190738:- LIHC cis rs2836974 0.583 rs2735307 ENSG00000255568.3 BRWD1-AS2 3.88 0.000125 0.0221 0.19 0.21 Cognitive function; chr21:39341432 chr21:39313935~39314962:+ LIHC cis rs62246343 0.605 rs34665459 ENSG00000206573.7 THUMPD3-AS1 -3.88 0.000125 0.0221 -0.24 -0.21 Fibrinogen levels; chr3:9423041 chr3:9349689~9398579:- LIHC cis rs10129255 0.5 rs8006888 ENSG00000211972.2 IGHV3-66 3.88 0.000125 0.0221 0.15 0.21 Kawasaki disease; chr14:106782219 chr14:106675017~106675544:- LIHC cis rs11696277 0.518 rs6080642 ENSG00000232333.1 RPS27AP2 -3.88 0.000125 0.0221 -0.29 -0.21 Gut microbiome composition (summer); chr20:17340268 chr20:17516843~17517307:+ LIHC cis rs2348418 0.801 rs7298379 ENSG00000247934.4 RP11-967K21.1 3.88 0.000125 0.0221 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28270541 chr12:28163298~28190738:- LIHC cis rs801193 0.591 rs4506088 ENSG00000232559.3 GS1-124K5.12 -3.88 0.000125 0.0221 -0.16 -0.21 Aortic root size; chr7:66670470 chr7:66554588~66576923:- LIHC cis rs11613048 0.897 rs7976723 ENSG00000245614.3 DDX11-AS1 3.88 0.000125 0.0221 0.19 0.21 Major depressive disorder; chr12:30176590 chr12:31020763~31073847:- LIHC cis rs2243480 0.522 rs431168 ENSG00000232546.1 RP11-458F8.1 -3.88 0.000125 0.0221 -0.25 -0.21 Diabetic kidney disease; chr7:66046617 chr7:66848496~66858136:+ LIHC cis rs2581828 0.58 rs9872260 ENSG00000242142.1 SERBP1P3 -3.88 0.000125 0.0221 -0.27 -0.21 Crohn's disease; chr3:53136158 chr3:53064283~53065091:- LIHC cis rs6142102 0.961 rs2268089 ENSG00000275784.1 RP5-1125A11.6 -3.88 0.000125 0.0221 -0.23 -0.21 Skin pigmentation; chr20:34079492 chr20:33989480~33991818:- LIHC cis rs76878669 0.917 rs10896110 ENSG00000255320.1 RP11-755F10.1 3.88 0.000125 0.0221 0.27 0.21 Educational attainment (years of education); chr11:66334507 chr11:66244840~66246239:- LIHC cis rs172166 0.637 rs1225592 ENSG00000219392.1 RP1-265C24.5 -3.88 0.000125 0.0221 -0.27 -0.21 Cardiac Troponin-T levels; chr6:28182464 chr6:28115628~28116551:+ LIHC cis rs172166 0.637 rs1225595 ENSG00000219392.1 RP1-265C24.5 -3.88 0.000125 0.0221 -0.27 -0.21 Cardiac Troponin-T levels; chr6:28183562 chr6:28115628~28116551:+ LIHC cis rs9896933 0.732 rs590886 ENSG00000263063.1 RP11-388C12.1 3.88 0.000125 0.0221 0.27 0.21 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82809474 chr17:82713908~82716255:- LIHC cis rs7412746 0.658 rs17660092 ENSG00000231073.1 RP11-316M1.3 3.88 0.000125 0.0221 0.21 0.21 Melanoma; chr1:150825272 chr1:150973123~150975534:+ LIHC cis rs7412746 0.658 rs2089082 ENSG00000231073.1 RP11-316M1.3 3.88 0.000125 0.0221 0.21 0.21 Melanoma; chr1:150827614 chr1:150973123~150975534:+ LIHC cis rs9896933 0.83 rs8074277 ENSG00000263063.1 RP11-388C12.1 -3.88 0.000125 0.0221 -0.27 -0.21 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82831752 chr17:82713908~82716255:- LIHC cis rs7607369 0.58 rs17573724 ENSG00000272555.1 RP11-459I19.1 -3.88 0.000125 0.0221 -0.24 -0.21 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218787418 chr2:218818690~218819144:+ LIHC cis rs7607369 0.58 rs17573731 ENSG00000272555.1 RP11-459I19.1 -3.88 0.000125 0.0221 -0.24 -0.21 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218787430 chr2:218818690~218819144:+ LIHC cis rs1799949 1 rs2037075 ENSG00000267681.1 CTD-3199J23.6 -3.88 0.000125 0.0222 -0.2 -0.21 Menopause (age at onset); chr17:43153809 chr17:43144956~43145255:+ LIHC cis rs172166 0.637 rs1225597 ENSG00000219392.1 RP1-265C24.5 -3.88 0.000125 0.0222 -0.27 -0.21 Cardiac Troponin-T levels; chr6:28194309 chr6:28115628~28116551:+ LIHC cis rs172166 0.637 rs1071893 ENSG00000219392.1 RP1-265C24.5 -3.88 0.000125 0.0222 -0.27 -0.21 Cardiac Troponin-T levels; chr6:28199857 chr6:28115628~28116551:+ LIHC cis rs10883723 0.81 rs2296585 ENSG00000236937.2 PTGES3P4 -3.88 0.000125 0.0222 -0.28 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102485792 chr10:102845595~102845950:+ LIHC cis rs10129255 0.5 rs34326748 ENSG00000211972.2 IGHV3-66 3.88 0.000125 0.0222 0.15 0.21 Kawasaki disease; chr14:106782523 chr14:106675017~106675544:- LIHC cis rs10129255 0.5 rs10143385 ENSG00000211972.2 IGHV3-66 3.88 0.000125 0.0222 0.15 0.21 Kawasaki disease; chr14:106782559 chr14:106675017~106675544:- LIHC cis rs12681287 0.64 rs6471309 ENSG00000254088.1 SLC2A3P4 3.88 0.000125 0.0222 0.24 0.21 Caudate activity during reward; chr8:86375531 chr8:86503591~86505061:+ LIHC cis rs7129556 0.737 rs72949616 ENSG00000254459.1 RP11-91P24.7 3.88 0.000125 0.0222 0.35 0.21 Weight loss (gastric bypass surgery); chr11:77753325 chr11:77829654~77872262:- LIHC cis rs7129556 0.737 rs72949618 ENSG00000254459.1 RP11-91P24.7 3.88 0.000125 0.0222 0.35 0.21 Weight loss (gastric bypass surgery); chr11:77753485 chr11:77829654~77872262:- LIHC cis rs7129556 0.737 rs56218634 ENSG00000254459.1 RP11-91P24.7 3.88 0.000125 0.0222 0.35 0.21 Weight loss (gastric bypass surgery); chr11:77753789 chr11:77829654~77872262:- LIHC cis rs12468226 1 rs116635509 ENSG00000272966.1 RP11-686O6.1 3.88 0.000125 0.0222 0.34 0.21 Urate levels; chr2:202460027 chr2:202336739~202337200:+ LIHC cis rs763121 0.657 rs5995603 ENSG00000228274.3 RP3-508I15.9 -3.88 0.000125 0.0222 -0.24 -0.21 Menopause (age at onset); chr22:38644728 chr22:38667585~38681820:- LIHC cis rs2658782 0.789 rs3020076 ENSG00000279684.1 RP11-755E23.2 -3.88 0.000125 0.0222 -0.34 -0.21 Pulmonary function decline; chr11:93407892 chr11:93286629~93288903:- LIHC cis rs6142102 0.602 rs4911145 ENSG00000275784.1 RP5-1125A11.6 3.88 0.000125 0.0222 0.22 0.21 Skin pigmentation; chr20:34027417 chr20:33989480~33991818:- LIHC cis rs74233809 0.901 rs4409766 ENSG00000236937.2 PTGES3P4 3.88 0.000125 0.0222 0.32 0.21 Birth weight; chr10:102856906 chr10:102845595~102845950:+ LIHC cis rs966423 0.55 rs2568176 ENSG00000232485.2 AC098820.3 3.88 0.000125 0.0222 0.19 0.21 Thyroid cancer; chr2:217439235 chr2:216479030~216498761:- LIHC cis rs2243480 1 rs316322 ENSG00000232546.1 RP11-458F8.1 -3.88 0.000125 0.0222 -0.23 -0.21 Diabetic kidney disease; chr7:66146246 chr7:66848496~66858136:+ LIHC cis rs7976059 0.505 rs303795 ENSG00000259887.1 RP11-923I11.5 3.88 0.000125 0.0222 0.25 0.21 Urate levels; chr12:51852154 chr12:51848223~51852729:+ LIHC cis rs2243480 1 rs1404147 ENSG00000232559.3 GS1-124K5.12 3.88 0.000126 0.0222 0.22 0.21 Diabetic kidney disease; chr7:65799537 chr7:66554588~66576923:- LIHC cis rs6951245 0.58 rs10257426 ENSG00000229043.2 AC091729.9 -3.88 0.000126 0.0222 -0.29 -0.21 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1174058 chr7:1160374~1165267:+ LIHC cis rs1799922 0.693 rs339090 ENSG00000273270.1 RP11-212P7.2 3.88 0.000126 0.0222 0.26 0.21 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr7:128782473 chr7:128524016~128531069:- LIHC cis rs6832769 1 rs4580704 ENSG00000272969.1 RP11-528I4.2 -3.88 0.000126 0.0222 -0.24 -0.21 Personality dimensions; chr4:55460540 chr4:55547112~55547889:+ LIHC cis rs728616 0.717 rs17098169 ENSG00000225484.5 NUTM2B-AS1 3.88 0.000126 0.0222 0.46 0.21 Chronic obstructive pulmonary disease-related biomarkers; chr10:80056378 chr10:79663088~79826594:- LIHC cis rs12817211 0.549 rs7972465 ENSG00000272368.2 RP4-605O3.4 3.88 0.000126 0.0222 0.23 0.21 Colorectal or endometrial cancer; chr12:50152342 chr12:50112197~50165618:+ LIHC cis rs638893 1 rs583905 ENSG00000255239.1 AP002954.6 3.88 0.000126 0.0222 0.45 0.21 Vitiligo; chr11:118825199 chr11:118688039~118690600:- LIHC cis rs2562456 0.874 rs9304986 ENSG00000268555.1 RP11-678G14.3 -3.88 0.000126 0.0222 -0.26 -0.21 Pain; chr19:21499260 chr19:21570822~21587322:- LIHC cis rs2562456 0.917 rs2650805 ENSG00000268555.1 RP11-678G14.3 -3.88 0.000126 0.0222 -0.26 -0.21 Pain; chr19:21505137 chr19:21570822~21587322:- LIHC cis rs2562456 0.917 rs10420016 ENSG00000268555.1 RP11-678G14.3 -3.88 0.000126 0.0222 -0.26 -0.21 Pain; chr19:21505800 chr19:21570822~21587322:- LIHC cis rs2562456 0.917 rs2681389 ENSG00000268555.1 RP11-678G14.3 -3.88 0.000126 0.0222 -0.26 -0.21 Pain; chr19:21509773 chr19:21570822~21587322:- LIHC cis rs2562456 0.917 rs6511256 ENSG00000268555.1 RP11-678G14.3 -3.88 0.000126 0.0222 -0.26 -0.21 Pain; chr19:21510513 chr19:21570822~21587322:- LIHC cis rs6997458 0.713 rs703 ENSG00000253549.4 RP11-317J10.2 3.88 0.000126 0.0222 0.23 0.21 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85477174 chr8:85441851~85464915:- LIHC cis rs950169 0.544 rs12913702 ENSG00000259728.4 LINC00933 3.88 0.000126 0.0222 0.3 0.21 Schizophrenia; chr15:84609953 chr15:84570649~84580175:+ LIHC cis rs950169 0.509 rs71395455 ENSG00000259728.4 LINC00933 3.88 0.000126 0.0222 0.3 0.21 Schizophrenia; chr15:84610573 chr15:84570649~84580175:+ LIHC cis rs6142102 0.625 rs9753690 ENSG00000275784.1 RP5-1125A11.6 -3.88 0.000126 0.0223 -0.22 -0.21 Skin pigmentation; chr20:33952995 chr20:33989480~33991818:- LIHC cis rs6142102 0.625 rs7263727 ENSG00000275784.1 RP5-1125A11.6 -3.88 0.000126 0.0223 -0.22 -0.21 Skin pigmentation; chr20:33953133 chr20:33989480~33991818:- LIHC cis rs6142102 0.625 rs6142056 ENSG00000275784.1 RP5-1125A11.6 -3.88 0.000126 0.0223 -0.22 -0.21 Skin pigmentation; chr20:33953349 chr20:33989480~33991818:- LIHC cis rs2448490 0.642 rs535111 ENSG00000265874.1 MIR4489 3.88 0.000126 0.0223 0.26 0.21 Platelet count; chr11:65717866 chr11:65649192~65649253:+ LIHC cis rs12468226 1 rs7597469 ENSG00000226261.1 AC064836.3 3.88 0.000126 0.0223 0.33 0.21 Urate levels; chr2:202329547 chr2:202336024~202336727:- LIHC cis rs12468226 1 rs113877751 ENSG00000226261.1 AC064836.3 3.88 0.000126 0.0223 0.33 0.21 Urate levels; chr2:202329998 chr2:202336024~202336727:- LIHC cis rs12468226 0.935 rs113021930 ENSG00000226261.1 AC064836.3 3.88 0.000126 0.0223 0.33 0.21 Urate levels; chr2:202330448 chr2:202336024~202336727:- LIHC cis rs12468226 1 rs113491584 ENSG00000226261.1 AC064836.3 3.88 0.000126 0.0223 0.33 0.21 Urate levels; chr2:202331724 chr2:202336024~202336727:- LIHC cis rs287982 0.932 rs9973577 ENSG00000269973.1 RP11-95D17.1 -3.88 0.000126 0.0223 -0.19 -0.21 Nonsyndromic cleft lip with cleft palate; chr2:9820574 chr2:9936360~9939590:+ LIHC cis rs6452524 1 rs11740478 ENSG00000271862.1 RP11-343L5.2 3.88 0.000126 0.0223 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83150567 chr5:83049376~83050964:- LIHC cis rs2070488 0.965 rs2126534 ENSG00000229589.1 ACVR2B-AS1 3.88 0.000126 0.0223 0.24 0.21 Electrocardiographic conduction measures; chr3:38403674 chr3:38451027~38454820:- LIHC cis rs4356203 0.905 rs1989405 ENSG00000260196.1 RP1-239B22.5 3.88 0.000126 0.0223 0.24 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17163272 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs214939 ENSG00000260196.1 RP1-239B22.5 3.88 0.000126 0.0223 0.24 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17165992 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs214936 ENSG00000260196.1 RP1-239B22.5 3.88 0.000126 0.0223 0.24 0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17169472 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs621246 ENSG00000260196.1 RP1-239B22.5 -3.88 0.000126 0.0223 -0.24 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17182218 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs635802 ENSG00000260196.1 RP1-239B22.5 -3.88 0.000126 0.0223 -0.24 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17183246 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs662711 ENSG00000260196.1 RP1-239B22.5 -3.88 0.000126 0.0223 -0.24 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17184641 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs598946 ENSG00000260196.1 RP1-239B22.5 -3.88 0.000126 0.0223 -0.24 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17187540 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs545773 ENSG00000260196.1 RP1-239B22.5 -3.88 0.000126 0.0223 -0.24 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17192089 chr11:17380649~17383531:+ LIHC cis rs4356203 0.792 rs677540 ENSG00000260196.1 RP1-239B22.5 -3.88 0.000126 0.0223 -0.24 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17192212 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs511119 ENSG00000260196.1 RP1-239B22.5 -3.88 0.000126 0.0223 -0.24 -0.21 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17193570 chr11:17380649~17383531:+ LIHC cis rs7560272 0.538 rs4852975 ENSG00000273245.1 RP11-434P11.2 -3.88 0.000126 0.0223 -0.25 -0.21 Schizophrenia; chr2:73705338 chr2:73750256~73750786:- LIHC cis rs6500602 0.702 rs2304634 ENSG00000278700.1 Metazoa_SRP 3.88 0.000126 0.0223 0.25 0.21 Schizophrenia; chr16:4450543 chr16:4658851~4659151:+ LIHC cis rs1005277 0.577 rs4934906 ENSG00000276805.1 RP11-291L22.6 3.88 0.000126 0.0223 0.24 0.21 Extrinsic epigenetic age acceleration; chr10:37726100 chr10:38451030~38451785:+ LIHC cis rs875971 0.577 rs34888281 ENSG00000273024.4 INTS4P2 3.88 0.000126 0.0223 0.25 0.21 Aortic root size; chr7:66120784 chr7:65647864~65715661:+ LIHC cis rs2070488 1 rs36006749 ENSG00000229589.1 ACVR2B-AS1 3.88 0.000126 0.0223 0.23 0.21 Electrocardiographic conduction measures; chr3:38401821 chr3:38451027~38454820:- LIHC cis rs7917772 0.503 rs11191330 ENSG00000236937.2 PTGES3P4 -3.88 0.000126 0.0223 -0.27 -0.21 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102546403 chr10:102845595~102845950:+ LIHC cis rs853679 0.882 rs4713140 ENSG00000219392.1 RP1-265C24.5 -3.88 0.000126 0.0223 -0.38 -0.21 Depression; chr6:28129415 chr6:28115628~28116551:+ LIHC cis rs4683346 0.731 rs35807837 ENSG00000273328.4 RP11-141M3.6 3.88 0.000126 0.0223 0.22 0.21 Granulocyte percentage of myeloid white cells; chr3:42878743 chr3:42809414~42908105:+ LIHC cis rs12908161 0.959 rs1051168 ENSG00000259728.4 LINC00933 3.88 0.000126 0.0223 0.3 0.21 Schizophrenia; chr15:84657289 chr15:84570649~84580175:+ LIHC cis rs875971 0.505 rs6955582 ENSG00000273024.4 INTS4P2 -3.88 0.000126 0.0223 -0.24 -0.21 Aortic root size; chr7:65966699 chr7:65647864~65715661:+ LIHC cis rs6452524 0.618 rs10051445 ENSG00000271862.1 RP11-343L5.2 3.88 0.000126 0.0223 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83060280 chr5:83049376~83050964:- LIHC cis rs6452524 0.618 rs6452504 ENSG00000271862.1 RP11-343L5.2 3.88 0.000126 0.0223 0.24 0.21 Hypertension (SNP x SNP interaction); chr5:83074625 chr5:83049376~83050964:- LIHC cis rs8059260 0.877 rs6498146 ENSG00000274038.1 RP11-66H6.4 3.88 0.000126 0.0223 0.26 0.21 Alcohol consumption over the past year; chr16:11012850 chr16:11056556~11057034:+ LIHC cis rs11098403 0.753 rs10031919 ENSG00000260404.2 RP11-384K6.6 3.88 0.000126 0.0224 0.14 0.21 Schizophrenia; chr4:117838073 chr4:118591773~118633729:+ LIHC cis rs9300255 0.596 rs1727331 ENSG00000256092.2 RP13-942N8.1 -3.88 0.000127 0.0224 -0.25 -0.21 Neutrophil percentage of white cells; chr12:123234332 chr12:123363868~123366113:+ LIHC cis rs2462686 1 rs2965071 ENSG00000272556.1 RP11-638I8.1 -3.88 0.000127 0.0224 -0.31 -0.21 Major depressive disorder; chr7:45961783 chr7:45814602~45815263:+ LIHC cis rs2462686 0.932 rs2471557 ENSG00000272556.1 RP11-638I8.1 3.88 0.000127 0.0224 0.31 0.21 Major depressive disorder; chr7:45960996 chr7:45814602~45815263:+ LIHC cis rs2462686 1 rs1525828 ENSG00000272556.1 RP11-638I8.1 3.88 0.000127 0.0224 0.31 0.21 Major depressive disorder; chr7:45962479 chr7:45814602~45815263:+ LIHC cis rs2348418 0.966 rs7315631 ENSG00000247934.4 RP11-967K21.1 3.88 0.000127 0.0224 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28545311 chr12:28163298~28190738:- LIHC cis rs2348418 0.966 rs7316351 ENSG00000247934.4 RP11-967K21.1 3.88 0.000127 0.0224 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28545595 chr12:28163298~28190738:- LIHC cis rs948562 0.69 rs11229391 ENSG00000280010.1 AP001350.4 3.88 0.000127 0.0224 0.36 0.21 Lymphoma; chr11:58382503 chr11:58627435~58628528:+ LIHC cis rs4787491 0.704 rs67218159 ENSG00000250616.2 RP11-455F5.3 3.88 0.000127 0.0224 0.2 0.21 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30039184 chr16:30096430~30104116:+ LIHC cis rs5742933 0.817 rs6738042 ENSG00000253559.1 OSGEPL1-AS1 3.88 0.000127 0.0224 0.27 0.21 Ferritin levels; chr2:189776958 chr2:189762704~189765556:+ LIHC cis rs1799949 0.965 rs11650132 ENSG00000267681.1 CTD-3199J23.6 -3.88 0.000127 0.0224 -0.2 -0.21 Menopause (age at onset); chr17:43174070 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs11654731 ENSG00000267681.1 CTD-3199J23.6 -3.88 0.000127 0.0224 -0.2 -0.21 Menopause (age at onset); chr17:43174923 chr17:43144956~43145255:+ LIHC cis rs1405130 0.967 rs3956012 ENSG00000224287.2 MSL3P1 3.88 0.000127 0.0224 0.24 0.21 Coronary artery disease; chr2:234662928 chr2:233865437~233868444:- LIHC cis rs1665050 0.901 rs1665051 ENSG00000259250.1 RP11-50C13.1 3.88 0.000127 0.0224 0.2 0.21 Atopic dermatitis; chr15:59003025 chr15:58587507~58591676:+ LIHC cis rs6951245 0.744 rs10265758 ENSG00000229043.2 AC091729.9 -3.88 0.000127 0.0224 -0.4 -0.21 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1132882 chr7:1160374~1165267:+ LIHC cis rs4925386 0.84 rs6142738 ENSG00000226332.2 RP11-157P1.4 -3.88 0.000127 0.0224 -0.24 -0.21 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62344904 chr20:62305432~62306325:- LIHC cis rs966423 0.55 rs2618148 ENSG00000232485.2 AC098820.3 3.88 0.000127 0.0224 0.19 0.21 Thyroid cancer; chr2:217439383 chr2:216479030~216498761:- LIHC cis rs801193 0.66 rs1962050 ENSG00000237310.1 GS1-124K5.4 -3.88 0.000127 0.0224 -0.18 -0.21 Aortic root size; chr7:66775021 chr7:66493706~66495474:+ LIHC cis rs9906944 0.864 rs9902512 ENSG00000248278.1 SUMO2P17 -3.88 0.000127 0.0224 -0.34 -0.21 Intelligence (multi-trait analysis);Body fat percentage; chr17:49016912 chr17:48874860~48908983:- LIHC cis rs803903 0.57 rs13284925 ENSG00000230894.1 RP11-67K19.3 3.88 0.000127 0.0224 0.28 0.21 Breast cancer; chr9:116478549 chr9:116568449~116586328:+ LIHC cis rs10975870 0.847 rs7022938 ENSG00000236924.1 RP11-390F4.6 -3.88 0.000127 0.0224 -0.32 -0.21 Body mass index; chr9:6930297 chr9:6645956~6670635:+ LIHC cis rs17713451 0.593 rs75885547 ENSG00000204894.4 RP11-208G20.2 3.88 0.000127 0.0224 0.38 0.21 Interleukin-4 levels; chr7:151582032 chr7:152367171~152367260:+ LIHC cis rs6048205 0.764 rs1203867 ENSG00000259974.2 LINC00261 -3.88 0.000127 0.0224 -0.32 -0.21 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22550503 chr20:22547671~22578642:- LIHC cis rs1061377 0.513 rs2711994 ENSG00000249685.1 RP11-360F5.3 -3.88 0.000127 0.0224 -0.29 -0.21 Uric acid levels; chr4:39148121 chr4:39133913~39135608:+ LIHC cis rs7208859 0.725 rs9891656 ENSG00000266490.1 CTD-2349P21.9 3.88 0.000127 0.0224 0.24 0.21 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916337 chr17:30792372~30792833:+ LIHC cis rs853679 1 rs11965538 ENSG00000219392.1 RP1-265C24.5 -3.88 0.000127 0.0224 -0.36 -0.21 Depression; chr6:28272137 chr6:28115628~28116551:+ LIHC cis rs853679 0.882 rs2743555 ENSG00000219392.1 RP1-265C24.5 -3.88 0.000127 0.0224 -0.36 -0.21 Depression; chr6:28273304 chr6:28115628~28116551:+ LIHC cis rs853679 1 rs1419183 ENSG00000219392.1 RP1-265C24.5 -3.88 0.000127 0.0224 -0.36 -0.21 Depression; chr6:28275017 chr6:28115628~28116551:+ LIHC cis rs7121538 0.551 rs73412615 ENSG00000251991.1 RNU7-49P -3.88 0.000127 0.0224 -0.33 -0.21 HDL cholesterol; chr11:14659498 chr11:14478892~14478953:+ LIHC cis rs2348418 0.639 rs41505151 ENSG00000247934.4 RP11-967K21.1 3.88 0.000127 0.0224 0.19 0.21 Lung function (FEV1);Lung function (FVC); chr12:28112651 chr12:28163298~28190738:- LIHC cis rs1005277 0.579 rs2474584 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0224 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38127461 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1548255 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0224 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38128265 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474586 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0224 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38129954 chr10:38450738~38451069:- LIHC cis rs17376456 0.825 rs10051878 ENSG00000251023.1 RP11-549J18.1 -3.88 0.000127 0.0224 -0.43 -0.21 Diabetic retinopathy; chr5:93728458 chr5:93860669~93863825:- LIHC cis rs597539 0.518 rs35093305 ENSG00000250508.1 RP11-757G1.6 -3.88 0.000127 0.0224 -0.34 -0.21 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68963260 chr11:68870664~68874542:+ LIHC cis rs7607369 0.714 rs55900247 ENSG00000272555.1 RP11-459I19.1 -3.88 0.000127 0.0225 -0.24 -0.21 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218753985 chr2:218818690~218819144:+ LIHC cis rs7607369 0.714 rs4674334 ENSG00000272555.1 RP11-459I19.1 -3.88 0.000127 0.0225 -0.24 -0.21 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218758088 chr2:218818690~218819144:+ LIHC cis rs338389 0.521 rs338381 ENSG00000260657.2 RP11-315D16.4 -3.88 0.000127 0.0225 -0.27 -0.21 Survival in rectal cancer; chr15:67951850 chr15:68267792~68277994:- LIHC cis rs11841001 0.556 rs12859043 ENSG00000261105.4 LMO7-AS1 -3.88 0.000127 0.0225 -0.42 -0.21 Corneal astigmatism; chr13:75769362 chr13:75604700~75635994:- LIHC cis rs11123170 0.503 rs28679654 ENSG00000189223.12 PAX8-AS1 -3.88 0.000127 0.0225 -0.35 -0.21 Renal function-related traits (BUN); chr2:113210040 chr2:113211522~113276581:+ LIHC cis rs34375054 0.526 rs4412800 ENSG00000279233.1 RP11-158L12.4 -3.88 0.000127 0.0225 -0.19 -0.21 Post bronchodilator FEV1/FVC ratio; chr12:125190196 chr12:125138245~125141711:+ LIHC cis rs6723226 0.842 rs2754522 ENSG00000276334.1 AL133243.1 3.88 0.000127 0.0225 0.23 0.21 Intelligence (multi-trait analysis); chr2:32576190 chr2:32521927~32523547:+ LIHC cis rs10883723 0.81 rs6584504 ENSG00000236937.2 PTGES3P4 -3.88 0.000127 0.0225 -0.27 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102493750 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs7069356 ENSG00000236937.2 PTGES3P4 -3.88 0.000127 0.0225 -0.27 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102494602 chr10:102845595~102845950:+ LIHC cis rs3862030 0.503 rs6584506 ENSG00000236937.2 PTGES3P4 -3.88 0.000127 0.0225 -0.27 -0.21 Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction); chr10:102494671 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs6584507 ENSG00000236937.2 PTGES3P4 -3.88 0.000127 0.0225 -0.27 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102494866 chr10:102845595~102845950:+ LIHC cis rs10883723 0.773 rs11191303 ENSG00000236937.2 PTGES3P4 -3.88 0.000127 0.0225 -0.27 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102495401 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs11191304 ENSG00000236937.2 PTGES3P4 -3.88 0.000127 0.0225 -0.27 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102495527 chr10:102845595~102845950:+ LIHC cis rs10883723 0.773 rs715439 ENSG00000236937.2 PTGES3P4 -3.88 0.000127 0.0225 -0.27 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102498052 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs6584508 ENSG00000236937.2 PTGES3P4 -3.88 0.000127 0.0225 -0.27 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102498810 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs7093028 ENSG00000236937.2 PTGES3P4 -3.88 0.000127 0.0225 -0.27 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102499660 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs2296590 ENSG00000236937.2 PTGES3P4 -3.88 0.000127 0.0225 -0.27 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102502871 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs3818470 ENSG00000236937.2 PTGES3P4 -3.88 0.000127 0.0225 -0.27 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102503918 chr10:102845595~102845950:+ LIHC cis rs10883723 0.847 rs3808934 ENSG00000236937.2 PTGES3P4 -3.88 0.000127 0.0225 -0.27 -0.21 Allergic disease (asthma, hay fever or eczema); chr10:102504523 chr10:102845595~102845950:+ LIHC cis rs12468226 0.938 rs57571703 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202281997 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs78928733 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202283787 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs116109808 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202287356 chr2:202336024~202336727:- LIHC cis rs12468226 0.873 rs78175596 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202287993 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs56684065 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202289528 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs1474001 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202290230 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs76664732 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202296298 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs16841867 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202303512 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs79117531 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202307690 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs16839065 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202308774 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs115418918 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202315145 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs114922024 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202315958 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs77261109 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202316233 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs12466003 ENSG00000226261.1 AC064836.3 3.88 0.000127 0.0225 0.33 0.21 Urate levels; chr2:202317317 chr2:202336024~202336727:- LIHC cis rs17711722 0.523 rs313812 ENSG00000236529.1 RP13-254B10.1 -3.88 0.000127 0.0225 -0.19 -0.21 Calcium levels; chr7:66040056 chr7:65840212~65840596:+ LIHC cis rs2790457 0.792 rs1265830 ENSG00000254635.4 WAC-AS1 3.88 0.000127 0.0225 0.2 0.21 Multiple myeloma; chr10:28623294 chr10:28522652~28532743:- LIHC cis rs901683 1 rs35750365 ENSG00000230869.1 CTGLF10P -3.88 0.000127 0.0225 -0.49 -0.21 Mean corpuscular volume;Red blood cell traits; chr10:45517695 chr10:45678692~45700532:+ LIHC cis rs6142102 0.625 rs4012234 ENSG00000275784.1 RP5-1125A11.6 -3.88 0.000127 0.0225 -0.22 -0.21 Skin pigmentation; chr20:33965241 chr20:33989480~33991818:- LIHC cis rs6142102 0.649 rs4911382 ENSG00000275784.1 RP5-1125A11.6 -3.88 0.000127 0.0225 -0.22 -0.21 Skin pigmentation; chr20:33965289 chr20:33989480~33991818:- LIHC cis rs6142102 0.625 rs6141436 ENSG00000275784.1 RP5-1125A11.6 -3.88 0.000127 0.0225 -0.22 -0.21 Skin pigmentation; chr20:33966765 chr20:33989480~33991818:- LIHC cis rs10129255 0.744 rs28517388 ENSG00000211972.2 IGHV3-66 3.88 0.000127 0.0225 0.17 0.21 Kawasaki disease; chr14:106704323 chr14:106675017~106675544:- LIHC cis rs193541 0.632 rs26370 ENSG00000263432.2 RN7SL689P 3.88 0.000127 0.0225 0.33 0.21 Glucose homeostasis traits; chr5:122899497 chr5:123022487~123022783:- LIHC cis rs7131987 0.903 rs10843367 ENSG00000275476.1 RP11-996F15.4 -3.88 0.000127 0.0225 -0.24 -0.21 QT interval; chr12:29255447 chr12:29277397~29277882:- LIHC cis rs7131987 0.903 rs7302129 ENSG00000275476.1 RP11-996F15.4 -3.88 0.000127 0.0225 -0.24 -0.21 QT interval; chr12:29262347 chr12:29277397~29277882:- LIHC cis rs1922291 0.546 rs12476585 ENSG00000281162.1 LINC01127 3.88 0.000127 0.0225 0.21 0.21 Blood protein levels; chr2:102224685 chr2:101962056~101987167:+ LIHC cis rs1922291 0.528 rs34778121 ENSG00000281162.1 LINC01127 3.88 0.000127 0.0225 0.21 0.21 Blood protein levels; chr2:102225107 chr2:101962056~101987167:+ LIHC cis rs11977715 0.538 rs10248407 ENSG00000233942.1 AC004012.1 -3.88 0.000127 0.0225 -0.29 -0.21 Middle childhood and early adolescence aggressive behavior; chr7:95499441 chr7:95471835~95473998:+ LIHC cis rs1005277 0.579 rs2472173 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38085710 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2472174 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38086454 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474563 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38087010 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs9418322 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38088368 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs9299760 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38088992 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2023351 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38089886 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474567 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38093564 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2472175 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38093973 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2472176 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38093993 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2983343 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38094404 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474569 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38094563 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2504143 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38094778 chr10:38450738~38451069:- LIHC cis rs1005277 0.602 rs2504142 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38094865 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474571 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38095711 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2472181 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38097836 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474574 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38098367 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2504140 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38098651 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474575 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38098973 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2472182 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38099937 chr10:38450738~38451069:- LIHC cis rs1005277 0.541 rs2263163 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38100959 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2021649 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38103194 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2505197 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38104382 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2505196 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38104635 chr10:38450738~38451069:- LIHC cis rs1005277 0.541 rs2505193 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38105710 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474580 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38109785 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2504148 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38111860 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs176886 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38115046 chr10:38450738~38451069:- LIHC cis rs1005277 0.557 rs176887 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38117166 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474594 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38137733 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs11011461 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38142499 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs1985707 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38145170 chr10:38450738~38451069:- LIHC cis rs1005277 0.557 rs1854563 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38146033 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2505237 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38149970 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474599 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38150011 chr10:38450738~38451069:- LIHC cis rs1005277 0.54 rs2224248 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38162958 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474608 ENSG00000275858.1 RP11-291L22.8 3.88 0.000127 0.0225 0.22 0.21 Extrinsic epigenetic age acceleration; chr10:38168181 chr10:38450738~38451069:- LIHC cis rs7734985 0.622 rs4869270 ENSG00000250551.1 RP11-254I22.1 3.88 0.000127 0.0225 0.23 0.21 IgG glycosylation; chr5:96188291 chr5:96050115~96215519:+ LIHC cis rs2439831 1 rs690263 ENSG00000166763.7 STRCP1 3.88 0.000127 0.0225 0.29 0.21 Lung cancer in ever smokers; chr15:43412267 chr15:43699488~43718184:- LIHC cis rs11098499 0.604 rs2389882 ENSG00000260091.1 RP11-33B1.4 -3.88 0.000127 0.0225 -0.14 -0.21 Corneal astigmatism; chr4:119645578 chr4:119409333~119410233:+ LIHC cis rs4561483 0.801 rs40311 ENSG00000261560.1 RP11-166B2.3 3.88 0.000128 0.0225 0.23 0.21 Testicular germ cell tumor; chr16:11869333 chr16:11881075~11882569:- LIHC cis rs860295 0.615 rs656737 ENSG00000203761.5 MSTO2P 3.88 0.000128 0.0225 0.17 0.21 Body mass index; chr1:155908104 chr1:155745829~155750137:+ LIHC cis rs860295 0.614 rs639398 ENSG00000203761.5 MSTO2P 3.88 0.000128 0.0225 0.17 0.21 Body mass index; chr1:155920447 chr1:155745829~155750137:+ LIHC cis rs860295 0.65 rs488079 ENSG00000203761.5 MSTO2P 3.88 0.000128 0.0225 0.17 0.21 Body mass index; chr1:155920790 chr1:155745829~155750137:+ LIHC cis rs860295 0.65 rs625658 ENSG00000203761.5 MSTO2P 3.88 0.000128 0.0225 0.17 0.21 Body mass index; chr1:155921254 chr1:155745829~155750137:+ LIHC cis rs4925386 1 rs4925389 ENSG00000226332.2 RP11-157P1.4 -3.88 0.000128 0.0225 -0.21 -0.21 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62347456 chr20:62305432~62306325:- LIHC cis rs4873772 0.735 rs6989917 ENSG00000253608.1 RP11-770E5.1 3.88 0.000128 0.0225 0.22 0.21 Lobe attachment (rater-scored or self-reported); chr8:47614197 chr8:48551567~48698510:+ LIHC cis rs4266144 0.581 rs1806867 ENSG00000244515.1 KRT18P34 -3.88 0.000128 0.0225 -0.21 -0.21 Coronary artery disease; chr3:157110513 chr3:157162663~157163932:- LIHC cis rs860295 0.729 rs11264369 ENSG00000203761.5 MSTO2P 3.88 0.000128 0.0225 0.17 0.21 Body mass index; chr1:155390039 chr1:155745829~155750137:+ LIHC cis rs6504622 0.702 rs2316758 ENSG00000262879.4 RP11-156P1.3 -3.88 0.000128 0.0225 -0.22 -0.21 Orofacial clefts; chr17:46988999 chr17:46984045~47100323:- LIHC cis rs4938303 0.718 rs10892023 ENSG00000236267.1 AP006216.5 3.88 0.000128 0.0225 0.21 0.21 Triglycerides; chr11:116727532 chr11:116813204~116814003:- LIHC cis rs13113518 0.812 rs6849474 ENSG00000249700.7 SRD5A3-AS1 3.88 0.000128 0.0225 0.24 0.21 Height; chr4:55452295 chr4:55363971~55395847:- LIHC cis rs860295 0.836 rs6684889 ENSG00000203761.5 MSTO2P 3.88 0.000128 0.0225 0.17 0.21 Body mass index; chr1:155457271 chr1:155745829~155750137:+ LIHC cis rs10895987 0.955 rs7113761 ENSG00000254614.2 AP003068.23 3.87 0.000128 0.0225 0.37 0.21 Blood protein levels; chr11:65159251 chr11:65177606~65181834:- LIHC cis rs6496667 0.533 rs2589949 ENSG00000213471.7 TTLL13P 3.87 0.000128 0.0225 0.26 0.21 Rheumatoid arthritis; chr15:90411783 chr15:90249530~90265482:+ LIHC cis rs8005677 0.828 rs35085068 ENSG00000257285.4 RP11-298I3.1 3.87 0.000128 0.0225 0.21 0.21 Cognitive ability (multi-trait analysis); chr14:22940700 chr14:22929609~22955562:+ LIHC cis rs8005677 0.828 rs57822749 ENSG00000257285.4 RP11-298I3.1 3.87 0.000128 0.0225 0.21 0.21 Cognitive ability (multi-trait analysis); chr14:22940758 chr14:22929609~22955562:+ LIHC cis rs8005677 0.828 rs4981451 ENSG00000257285.4 RP11-298I3.1 3.87 0.000128 0.0225 0.21 0.21 Cognitive ability (multi-trait analysis); chr14:22941072 chr14:22929609~22955562:+ LIHC cis rs8005677 0.798 rs4536383 ENSG00000257285.4 RP11-298I3.1 3.87 0.000128 0.0225 0.21 0.21 Cognitive ability (multi-trait analysis); chr14:22941717 chr14:22929609~22955562:+ LIHC cis rs8005677 0.828 rs34584578 ENSG00000257285.4 RP11-298I3.1 3.87 0.000128 0.0225 0.21 0.21 Cognitive ability (multi-trait analysis); chr14:22942481 chr14:22929609~22955562:+ LIHC cis rs8005677 0.828 rs8016027 ENSG00000257285.4 RP11-298I3.1 3.87 0.000128 0.0225 0.21 0.21 Cognitive ability (multi-trait analysis); chr14:22950944 chr14:22929609~22955562:+ LIHC cis rs17264034 0.821 rs60322708 ENSG00000250786.1 SNHG18 3.87 0.000128 0.0225 0.26 0.21 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9555837 chr5:9546200~9550609:+ LIHC cis rs617219 0.889 rs1915705 ENSG00000251675.1 CTC-458I2.2 -3.87 0.000128 0.0225 -0.23 -0.21 Betaine levels in individuals undergoing cardiac evaluation; chr5:79140366 chr5:80128361~80143883:+ LIHC cis rs11696277 0.507 rs12480658 ENSG00000232333.1 RPS27AP2 -3.87 0.000128 0.0225 -0.29 -0.21 Gut microbiome composition (summer); chr20:17335225 chr20:17516843~17517307:+ LIHC cis rs6860806 0.507 rs2631371 ENSG00000263597.1 MIR3936 -3.87 0.000128 0.0225 -0.22 -0.21 Breast cancer; chr5:132367999 chr5:132365490~132365599:- LIHC cis rs6832769 0.922 rs28726308 ENSG00000272969.1 RP11-528I4.2 3.87 0.000128 0.0226 0.24 0.21 Personality dimensions; chr4:55368239 chr4:55547112~55547889:+ LIHC cis rs11009175 0.929 rs6481825 ENSG00000273038.2 RP11-479G22.8 -3.87 0.000128 0.0226 -0.24 -0.21 Depression (quantitative trait); chr10:33050595 chr10:32887255~32889311:- LIHC cis rs12908161 0.959 rs34028043 ENSG00000259728.4 LINC00933 3.87 0.000128 0.0226 0.3 0.21 Schizophrenia; chr15:84688354 chr15:84570649~84580175:+ LIHC cis rs12908161 0.959 rs34784022 ENSG00000259728.4 LINC00933 3.87 0.000128 0.0226 0.3 0.21 Schizophrenia; chr15:84688675 chr15:84570649~84580175:+ LIHC cis rs12908161 0.959 rs12908699 ENSG00000259728.4 LINC00933 3.87 0.000128 0.0226 0.3 0.21 Schizophrenia; chr15:84697172 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs35316992 ENSG00000259728.4 LINC00933 3.87 0.000128 0.0226 0.3 0.21 Schizophrenia; chr15:84704902 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs4643294 ENSG00000259728.4 LINC00933 3.87 0.000128 0.0226 0.3 0.21 Schizophrenia; chr15:84707022 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs62021219 ENSG00000259728.4 LINC00933 3.87 0.000128 0.0226 0.3 0.21 Schizophrenia; chr15:84712928 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs34900908 ENSG00000259728.4 LINC00933 3.87 0.000128 0.0226 0.3 0.21 Schizophrenia; chr15:84714368 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs35524990 ENSG00000259728.4 LINC00933 3.87 0.000128 0.0226 0.3 0.21 Schizophrenia; chr15:84714972 chr15:84570649~84580175:+ LIHC cis rs1823913 1 rs4853568 ENSG00000227542.1 AC092614.2 -3.87 0.000128 0.0226 -0.21 -0.21 Obesity-related traits; chr2:191261464 chr2:191229165~191246172:- LIHC cis rs2333021 0.62 rs2002033 ENSG00000259015.1 RP11-109N23.6 -3.87 0.000128 0.0226 -0.25 -0.21 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72968648 chr14:72960595~72961993:+ LIHC cis rs9487094 0.961 rs12528822 ENSG00000260273.1 RP11-425D10.10 3.87 0.000128 0.0226 0.24 0.21 Height; chr6:109340338 chr6:109382795~109383666:+ LIHC cis rs6545883 0.895 rs2442029 ENSG00000271889.1 RP11-493E12.1 3.87 0.000128 0.0226 0.25 0.21 Tuberculosis; chr2:61452417 chr2:61151433~61162105:- LIHC cis rs6545883 0.929 rs2256615 ENSG00000271889.1 RP11-493E12.1 3.87 0.000128 0.0226 0.25 0.21 Tuberculosis; chr2:61452759 chr2:61151433~61162105:- LIHC cis rs10129255 1 rs10134517 ENSG00000211972.2 IGHV3-66 3.87 0.000128 0.0226 0.17 0.21 Kawasaki disease; chr14:106718498 chr14:106675017~106675544:- LIHC cis rs4654783 1 rs4654783 ENSG00000218510.5 LINC00339 3.87 0.000128 0.0226 0.21 0.21 Endometriosis; chr1:22113027 chr1:22025188~22031223:+ LIHC cis rs858239 0.899 rs858271 ENSG00000226816.2 AC005082.12 3.87 0.000128 0.0226 0.26 0.21 Cerebrospinal fluid biomarker levels; chr7:23238664 chr7:23206013~23208045:+ LIHC cis rs8054556 0.539 rs12596543 ENSG00000250616.2 RP11-455F5.3 3.87 0.000128 0.0226 0.2 0.21 Autism spectrum disorder or schizophrenia; chr16:30017814 chr16:30096430~30104116:+ LIHC cis rs5756813 0.661 rs2285177 ENSG00000233360.4 Z83844.1 3.87 0.000128 0.0226 0.25 0.21 Optic cup area;Vertical cup-disc ratio; chr22:37809887 chr22:37641832~37658377:- LIHC cis rs1799922 0.693 rs339086 ENSG00000273270.1 RP11-212P7.2 3.87 0.000128 0.0226 0.26 0.21 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr7:128783563 chr7:128524016~128531069:- LIHC cis rs7760535 0.763 rs9487666 ENSG00000271789.1 RP5-1112D6.7 -3.87 0.000128 0.0226 -0.2 -0.21 Metabolic traits; chr6:111547821 chr6:111297126~111298510:+ LIHC cis rs2665103 0.589 rs3858953 ENSG00000259429.4 UBE2Q2P2 -3.87 0.000128 0.0226 -0.22 -0.21 Intelligence (multi-trait analysis); chr15:82238049 chr15:82355142~82420075:+ LIHC cis rs42490 0.966 rs39505 ENSG00000251136.7 RP11-37B2.1 -3.87 0.000128 0.0226 -0.18 -0.21 Leprosy; chr8:89779838 chr8:89609409~89757727:- LIHC cis rs42490 1 rs39506 ENSG00000251136.7 RP11-37B2.1 -3.87 0.000128 0.0226 -0.18 -0.21 Leprosy; chr8:89779899 chr8:89609409~89757727:- LIHC cis rs10256972 0.869 rs4720158 ENSG00000199023.2 MIR339 -3.87 0.000128 0.0226 -0.23 -0.21 Endometriosis;Longevity; chr7:1000689 chr7:1022935~1023045:- LIHC cis rs794185 0.681 rs901870 ENSG00000231249.1 ITPR1-AS1 3.87 0.000129 0.0226 0.22 0.21 Multiple sclerosis--Brain Glutamate Levels; chr3:4469418 chr3:4490891~4493163:- LIHC cis rs1023500 0.596 rs5751204 ENSG00000205702.9 CYP2D7 3.87 0.000129 0.0226 0.23 0.2 Schizophrenia; chr22:42037797 chr22:42140203~42144577:- LIHC cis rs10774547 0.758 rs11065108 ENSG00000278344.1 RP11-18C24.8 -3.87 0.000129 0.0227 -0.25 -0.2 Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);Reading disability or specific language impairment (pleiotropy); chr12:120425681 chr12:120500735~120501090:- LIHC cis rs12368653 1 rs12371356 ENSG00000270039.1 RP11-571M6.17 3.87 0.000129 0.0227 0.28 0.2 Multiple sclerosis; chr12:57741637 chr12:57803838~57804415:+ LIHC cis rs7560272 0.512 rs4530394 ENSG00000273245.1 RP11-434P11.2 -3.87 0.000129 0.0227 -0.25 -0.2 Schizophrenia; chr2:73702523 chr2:73750256~73750786:- LIHC cis rs7826238 0.539 rs2945891 ENSG00000253981.4 ALG1L13P 3.87 0.000129 0.0227 0.25 0.2 Systolic blood pressure; chr8:8297953 chr8:8236003~8244667:- LIHC cis rs948562 0.69 rs17473544 ENSG00000280010.1 AP001350.4 3.87 0.000129 0.0227 0.35 0.2 Lymphoma; chr11:58388994 chr11:58627435~58628528:+ LIHC cis rs34375054 0.525 rs7133006 ENSG00000279233.1 RP11-158L12.4 3.87 0.000129 0.0227 0.18 0.2 Post bronchodilator FEV1/FVC ratio; chr12:125121577 chr12:125138245~125141711:+ LIHC cis rs34375054 0.525 rs7133864 ENSG00000279233.1 RP11-158L12.4 3.87 0.000129 0.0227 0.18 0.2 Post bronchodilator FEV1/FVC ratio; chr12:125121634 chr12:125138245~125141711:+ LIHC cis rs881375 1 rs6478486 ENSG00000226752.6 PSMD5-AS1 -3.87 0.000129 0.0227 -0.23 -0.2 Rheumatoid arthritis; chr9:120893051 chr9:120824828~120854385:+ LIHC cis rs1799949 0.965 rs33961729 ENSG00000267681.1 CTD-3199J23.6 -3.87 0.000129 0.0227 -0.2 -0.2 Menopause (age at onset); chr17:43135907 chr17:43144956~43145255:+ LIHC cis rs1939012 0.686 rs7946781 ENSG00000281655.1 RP11-817J15.3 -3.87 0.000129 0.0227 -0.28 -0.2 Epilepsy; chr11:102728068 chr11:102681310~102683913:+ LIHC cis rs6442522 0.933 rs7622657 ENSG00000249786.6 EAF1-AS1 -3.87 0.000129 0.0227 -0.23 -0.2 Uric acid levels; chr3:15370385 chr3:15436171~15455940:- LIHC cis rs11089937 0.597 rs6001076 ENSG00000211639.2 IGLV4-60 3.87 0.000129 0.0227 0.18 0.2 Periodontitis (PAL4Q3); chr22:22133873 chr22:22162199~22162681:+ LIHC cis rs11089937 0.597 rs5995560 ENSG00000211639.2 IGLV4-60 3.87 0.000129 0.0227 0.18 0.2 Periodontitis (PAL4Q3); chr22:22133989 chr22:22162199~22162681:+ LIHC cis rs1223397 0.651 rs2496148 ENSG00000215022.6 RP1-257A7.4 -3.87 0.000129 0.0227 -0.22 -0.2 Blood pressure; chr6:13313321 chr6:13264861~13295586:- LIHC cis rs748404 0.697 rs498227 ENSG00000205771.5 CATSPER2P1 -3.87 0.000129 0.0227 -0.25 -0.2 Lung cancer; chr15:43280854 chr15:43726918~43747094:- LIHC cis rs875971 1 rs4718307 ENSG00000237310.1 GS1-124K5.4 -3.87 0.000129 0.0227 -0.18 -0.2 Aortic root size; chr7:66146001 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs7801282 ENSG00000237310.1 GS1-124K5.4 -3.87 0.000129 0.0227 -0.18 -0.2 Aortic root size; chr7:66148700 chr7:66493706~66495474:+ LIHC cis rs7580658 0.545 rs13006847 ENSG00000236682.1 AC068282.3 3.87 0.000129 0.0227 0.25 0.2 Protein C levels; chr2:127194687 chr2:127389130~127400580:+ LIHC cis rs875971 0.54 rs1723268 ENSG00000273024.4 INTS4P2 -3.87 0.000129 0.0227 -0.24 -0.2 Aortic root size; chr7:66008093 chr7:65647864~65715661:+ LIHC cis rs12908161 1 rs12911736 ENSG00000225151.9 GOLGA2P7 -3.87 0.000129 0.0227 -0.26 -0.2 Schizophrenia; chr15:84696777 chr15:84199311~84230136:- LIHC cis rs1799949 1 rs35330014 ENSG00000267681.1 CTD-3199J23.6 -3.87 0.000129 0.0227 -0.2 -0.2 Menopause (age at onset); chr17:43060530 chr17:43144956~43145255:+ LIHC cis rs6452524 1 rs6868817 ENSG00000271862.1 RP11-343L5.2 3.87 0.000129 0.0227 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83142287 chr5:83049376~83050964:- LIHC cis rs6452524 0.967 rs10042018 ENSG00000271862.1 RP11-343L5.2 3.87 0.000129 0.0227 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83142490 chr5:83049376~83050964:- LIHC cis rs6452524 0.967 rs10036418 ENSG00000271862.1 RP11-343L5.2 3.87 0.000129 0.0227 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83142493 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs10055948 ENSG00000271862.1 RP11-343L5.2 3.87 0.000129 0.0227 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83143437 chr5:83049376~83050964:- LIHC cis rs2439831 0.681 rs28594657 ENSG00000166763.7 STRCP1 3.87 0.000129 0.0227 0.37 0.2 Lung cancer in ever smokers; chr15:43296690 chr15:43699488~43718184:- LIHC cis rs853679 0.882 rs9393908 ENSG00000219891.2 ZSCAN12P1 3.87 0.000129 0.0227 0.4 0.2 Depression; chr6:28223052 chr6:28091154~28093664:+ LIHC cis rs853679 0.882 rs9366717 ENSG00000219891.2 ZSCAN12P1 3.87 0.000129 0.0227 0.4 0.2 Depression; chr6:28223279 chr6:28091154~28093664:+ LIHC cis rs8054556 0.647 rs4787488 ENSG00000250616.2 RP11-455F5.3 -3.87 0.000129 0.0227 -0.2 -0.2 Autism spectrum disorder or schizophrenia; chr16:29984482 chr16:30096430~30104116:+ LIHC cis rs699371 0.55 rs11851117 ENSG00000270000.1 RP3-449M8.9 3.87 0.000129 0.0227 0.24 0.2 Height; chr14:74454856 chr14:74471930~74472360:- LIHC cis rs875971 0.522 rs1617484 ENSG00000273024.4 INTS4P2 -3.87 0.000129 0.0227 -0.24 -0.2 Aortic root size; chr7:65998108 chr7:65647864~65715661:+ LIHC cis rs6547705 0.777 rs4832307 ENSG00000231259.4 AC125232.1 -3.87 0.000129 0.0228 -0.38 -0.2 Progressive supranuclear palsy; chr2:86682915 chr2:87031815~87053069:- LIHC cis rs6547705 0.581 rs1400032 ENSG00000231259.4 AC125232.1 -3.87 0.000129 0.0228 -0.38 -0.2 Progressive supranuclear palsy; chr2:86696060 chr2:87031815~87053069:- LIHC cis rs6832769 1 rs1522110 ENSG00000272969.1 RP11-528I4.2 3.87 0.000129 0.0228 0.24 0.2 Personality dimensions; chr4:55514116 chr4:55547112~55547889:+ LIHC cis rs867371 0.892 rs4344697 ENSG00000259429.4 UBE2Q2P2 -3.87 0.000129 0.0228 -0.2 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82252873 chr15:82355142~82420075:+ LIHC cis rs11098499 0.863 rs11947234 ENSG00000260091.1 RP11-33B1.4 -3.87 0.000129 0.0228 -0.15 -0.2 Corneal astigmatism; chr4:119553704 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs11933966 ENSG00000260091.1 RP11-33B1.4 -3.87 0.000129 0.0228 -0.15 -0.2 Corneal astigmatism; chr4:119555560 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs36040693 ENSG00000260091.1 RP11-33B1.4 -3.87 0.000129 0.0228 -0.15 -0.2 Corneal astigmatism; chr4:119556461 chr4:119409333~119410233:+ LIHC cis rs10256972 0.967 rs7799110 ENSG00000199023.2 MIR339 -3.87 0.000129 0.0228 -0.23 -0.2 Endometriosis;Longevity; chr7:999429 chr7:1022935~1023045:- LIHC cis rs17713451 0.593 rs17643028 ENSG00000204894.4 RP11-208G20.2 3.87 0.00013 0.0228 0.38 0.2 Interleukin-4 levels; chr7:151583401 chr7:152367171~152367260:+ LIHC cis rs854624 0.892 rs1719194 ENSG00000278690.1 RP11-104J23.2 -3.87 0.00013 0.0228 -0.41 -0.2 Blood protein levels; chr17:36009014 chr17:36012504~36012891:+ LIHC cis rs2361718 0.568 rs1042397 ENSG00000261978.1 CTD-2529O21.2 3.87 0.00013 0.0228 0.23 0.2 Yeast infection; chr17:80118264 chr17:80023894~80026107:+ LIHC cis rs539096 0.566 rs3011220 ENSG00000237950.1 RP11-7O11.3 3.87 0.00013 0.0228 0.21 0.2 Intelligence (multi-trait analysis); chr1:43843195 chr1:43944370~43946551:- LIHC cis rs1799922 0.693 rs1688931 ENSG00000273270.1 RP11-212P7.2 3.87 0.00013 0.0228 0.26 0.2 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr7:128781728 chr7:128524016~128531069:- LIHC cis rs1065852 0.51 rs5758666 ENSG00000205702.9 CYP2D7 3.87 0.00013 0.0228 0.22 0.2 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42236827 chr22:42140203~42144577:- LIHC cis rs4927850 0.723 rs7630825 ENSG00000207650.1 MIR570 3.87 0.00013 0.0228 0.22 0.2 Pancreatic cancer; chr3:196026869 chr3:195699401~195699497:+ LIHC cis rs7712401 0.601 rs27976 ENSG00000263432.2 RN7SL689P -3.87 0.00013 0.0228 -0.3 -0.2 Mean platelet volume; chr5:122870765 chr5:123022487~123022783:- LIHC cis rs2348418 0.832 rs1032391 ENSG00000247934.4 RP11-967K21.1 3.87 0.00013 0.0228 0.19 0.2 Lung function (FEV1);Lung function (FVC); chr12:28383775 chr12:28163298~28190738:- LIHC cis rs597539 0.652 rs667989 ENSG00000250508.1 RP11-757G1.6 -3.87 0.00013 0.0228 -0.32 -0.2 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr11:68918308 chr11:68870664~68874542:+ LIHC cis rs875971 0.545 rs6460298 ENSG00000273024.4 INTS4P2 -3.87 0.00013 0.0228 -0.23 -0.2 Aortic root size; chr7:66442783 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs35459055 ENSG00000273024.4 INTS4P2 -3.87 0.00013 0.0228 -0.23 -0.2 Aortic root size; chr7:66479399 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs75577046 ENSG00000273024.4 INTS4P2 -3.87 0.00013 0.0228 -0.23 -0.2 Aortic root size; chr7:66493729 chr7:65647864~65715661:+ LIHC cis rs875971 0.545 rs3735147 ENSG00000273024.4 INTS4P2 -3.87 0.00013 0.0228 -0.23 -0.2 Aortic root size; chr7:66505541 chr7:65647864~65715661:+ LIHC cis rs10895987 0.955 rs11227136 ENSG00000254614.2 AP003068.23 3.87 0.00013 0.0228 0.38 0.2 Blood protein levels; chr11:65164493 chr11:65177606~65181834:- LIHC cis rs57221529 0.766 rs72703070 ENSG00000271781.1 CTD-2589H19.6 -3.87 0.00013 0.0228 -0.31 -0.2 Lung disease severity in cystic fibrosis; chr5:590343 chr5:675826~676616:+ LIHC cis rs57221529 0.713 rs72703072 ENSG00000271781.1 CTD-2589H19.6 -3.87 0.00013 0.0228 -0.31 -0.2 Lung disease severity in cystic fibrosis; chr5:590511 chr5:675826~676616:+ LIHC cis rs57221529 0.713 rs12522724 ENSG00000271781.1 CTD-2589H19.6 -3.87 0.00013 0.0228 -0.31 -0.2 Lung disease severity in cystic fibrosis; chr5:590627 chr5:675826~676616:+ LIHC cis rs57221529 0.713 rs56328416 ENSG00000271781.1 CTD-2589H19.6 -3.87 0.00013 0.0228 -0.31 -0.2 Lung disease severity in cystic fibrosis; chr5:591023 chr5:675826~676616:+ LIHC cis rs1075265 0.587 rs2949812 ENSG00000272156.1 RP11-477N3.1 -3.87 0.00013 0.0228 -0.25 -0.2 Chronotype;Morning vs. evening chronotype; chr2:53797190 chr2:54082554~54085066:+ LIHC cis rs748404 0.556 rs10851414 ENSG00000205771.5 CATSPER2P1 3.87 0.00013 0.0228 0.25 0.2 Lung cancer; chr15:43141734 chr15:43726918~43747094:- LIHC cis rs6723108 0.627 rs7589297 ENSG00000224043.6 CCNT2-AS1 -3.87 0.00013 0.0228 -0.28 -0.2 Type 2 diabetes; chr2:134894829 chr2:134735464~134918710:- LIHC cis rs686320 0.748 rs481335 ENSG00000245532.5 NEAT1 3.87 0.00013 0.0228 0.3 0.2 Hip circumference adjusted for BMI; chr11:65439998 chr11:65422774~65445540:+ LIHC cis rs1003719 0.628 rs2835635 ENSG00000272948.2 AP001412.1 -3.87 0.00013 0.0228 -0.22 -0.2 Eye color traits; chr21:37156565 chr21:37267784~37268497:+ LIHC cis rs904251 0.772 rs1812186 ENSG00000204110.6 RP1-153P14.8 -3.87 0.00013 0.0228 -0.25 -0.2 Cognitive performance; chr6:37498140 chr6:37507348~37535616:+ LIHC cis rs172166 0.637 rs1225592 ENSG00000216901.1 AL022393.7 3.87 0.00013 0.0228 0.26 0.2 Cardiac Troponin-T levels; chr6:28182464 chr6:28176188~28176674:+ LIHC cis rs172166 0.637 rs1225595 ENSG00000216901.1 AL022393.7 3.87 0.00013 0.0228 0.26 0.2 Cardiac Troponin-T levels; chr6:28183562 chr6:28176188~28176674:+ LIHC cis rs875971 0.508 rs6947808 ENSG00000224316.1 RP11-479O9.2 -3.87 0.00013 0.0228 -0.19 -0.2 Aortic root size; chr7:66580095 chr7:65773620~65802067:+ LIHC cis rs3091242 0.933 rs12402120 ENSG00000224183.1 SDHDP6 -3.87 0.00013 0.0228 -0.23 -0.2 Erythrocyte sedimentation rate; chr1:25425141 chr1:25294164~25294643:- LIHC cis rs11096990 0.928 rs2008681 ENSG00000249685.1 RP11-360F5.3 -3.87 0.00013 0.0228 -0.28 -0.2 Cognitive function; chr4:39266396 chr4:39133913~39135608:+ LIHC cis rs4523957 0.748 rs12603592 ENSG00000262333.1 HNRNPA1P16 3.87 0.00013 0.0228 0.16 0.2 Schizophrenia;Autism spectrum disorder or schizophrenia; chr17:2216524 chr17:2306761~2307715:+ LIHC cis rs2312236 0.759 rs12742287 ENSG00000225171.2 DUTP6 -3.87 0.00013 0.0228 -0.27 -0.2 Post-traumatic stress disorder; chr1:166755601 chr1:166868748~166869209:+ LIHC cis rs11613048 0.897 rs12423411 ENSG00000245614.3 DDX11-AS1 3.87 0.00013 0.0228 0.18 0.2 Major depressive disorder; chr12:30174868 chr12:31020763~31073847:- LIHC cis rs7182621 0.639 rs1561047 ENSG00000182397.13 DNM1P46 3.87 0.00013 0.0229 0.28 0.2 Colonoscopy-negative controls vs population controls; chr15:99874606 chr15:99790156~99806927:- LIHC cis rs6445975 0.715 rs3773006 ENSG00000272360.1 RP11-359I18.5 -3.87 0.00013 0.0229 -0.24 -0.2 Systemic lupus erythematosus; chr3:58283812 chr3:58490830~58491291:- LIHC cis rs12468226 0.752 rs79058237 ENSG00000272966.1 RP11-686O6.1 3.87 0.00013 0.0229 0.36 0.2 Urate levels; chr2:202140247 chr2:202336739~202337200:+ LIHC cis rs812925 0.502 rs778150 ENSG00000271889.1 RP11-493E12.1 -3.87 0.00013 0.0229 -0.24 -0.2 Immature fraction of reticulocytes; chr2:61381237 chr2:61151433~61162105:- LIHC cis rs11039131 1 rs11039131 ENSG00000247675.5 LRP4-AS1 3.87 0.00013 0.0229 0.26 0.2 Schizophrenia; chr11:47210487 chr11:46846412~46874396:+ LIHC cis rs9450351 0.744 rs9353319 ENSG00000203875.9 SNHG5 -3.87 0.00013 0.0229 -0.45 -0.2 Interferon gamma-induced protein 10 levels; chr6:85522825 chr6:85660950~85678736:- LIHC cis rs7712401 0.584 rs30037 ENSG00000263432.2 RN7SL689P 3.87 0.00013 0.0229 0.3 0.2 Mean platelet volume; chr5:122942295 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs30035 ENSG00000263432.2 RN7SL689P 3.87 0.00013 0.0229 0.3 0.2 Mean platelet volume; chr5:122942850 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs246306 ENSG00000263432.2 RN7SL689P 3.87 0.00013 0.0229 0.3 0.2 Mean platelet volume; chr5:122943523 chr5:123022487~123022783:- LIHC cis rs7712401 0.562 rs2927639 ENSG00000263432.2 RN7SL689P 3.87 0.00013 0.0229 0.3 0.2 Mean platelet volume; chr5:122943971 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs246274 ENSG00000263432.2 RN7SL689P 3.87 0.00013 0.0229 0.3 0.2 Mean platelet volume; chr5:122945108 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs246273 ENSG00000263432.2 RN7SL689P 3.87 0.00013 0.0229 0.3 0.2 Mean platelet volume; chr5:122945280 chr5:123022487~123022783:- LIHC cis rs12468226 1 rs77435512 ENSG00000226261.1 AC064836.3 3.87 0.00013 0.0229 0.32 0.2 Urate levels; chr2:202334165 chr2:202336024~202336727:- LIHC cis rs2243480 1 rs316331 ENSG00000232546.1 RP11-458F8.1 3.87 0.00013 0.0229 0.23 0.2 Diabetic kidney disease; chr7:66139635 chr7:66848496~66858136:+ LIHC cis rs591584 0.621 rs593690 ENSG00000255893.1 RP11-685N10.1 -3.87 0.00013 0.0229 -0.21 -0.2 Macrophage Migration Inhibitory Factor levels; chr11:94604054 chr11:94472908~94473570:- LIHC cis rs4218 0.597 rs12438111 ENSG00000277144.1 RP11-59H7.4 -3.87 0.00013 0.0229 -0.22 -0.2 Social communication problems; chr15:59057540 chr15:59115547~59116089:- LIHC cis rs6142102 0.961 rs1055857 ENSG00000275784.1 RP5-1125A11.6 -3.87 0.000131 0.0229 -0.23 -0.2 Skin pigmentation; chr20:34026067 chr20:33989480~33991818:- LIHC cis rs7560272 0.538 rs2001436 ENSG00000273245.1 RP11-434P11.2 -3.87 0.000131 0.0229 -0.25 -0.2 Schizophrenia; chr2:73701838 chr2:73750256~73750786:- LIHC cis rs11841001 0.556 rs1470273 ENSG00000261105.4 LMO7-AS1 -3.87 0.000131 0.0229 -0.42 -0.2 Corneal astigmatism; chr13:75768241 chr13:75604700~75635994:- LIHC cis rs4650994 0.544 rs2761469 ENSG00000273384.1 RP5-1098D14.1 -3.87 0.000131 0.0229 -0.25 -0.2 HDL cholesterol;HDL cholesterol levels; chr1:178621503 chr1:178651706~178652282:+ LIHC cis rs11216126 0.643 rs11602073 ENSG00000254851.1 RP11-109L13.1 3.87 0.000131 0.0229 0.33 0.2 HDL cholesterol; chr11:116776142 chr11:117135528~117138582:+ LIHC cis rs875971 0.508 rs10242423 ENSG00000273024.4 INTS4P2 3.87 0.000131 0.0229 0.22 0.2 Aortic root size; chr7:66594188 chr7:65647864~65715661:+ LIHC cis rs875971 0.508 rs10253883 ENSG00000273024.4 INTS4P2 3.87 0.000131 0.0229 0.22 0.2 Aortic root size; chr7:66596151 chr7:65647864~65715661:+ LIHC cis rs71007656 1 rs71007656 ENSG00000276805.1 RP11-291L22.6 3.87 0.000131 0.0229 0.25 0.2 Extrinsic epigenetic age acceleration; chr10:37681922 chr10:38451030~38451785:+ LIHC cis rs1930961 0.558 rs12160908 ENSG00000100058.11 CRYBB2P1 3.87 0.000131 0.0229 0.41 0.2 Bipolar disorder with mood-incongruent psychosis; chr22:25532653 chr22:25448105~25520854:+ LIHC cis rs755249 0.53 rs4660475 ENSG00000182109.6 RP11-69E11.4 3.87 0.000131 0.0229 0.26 0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39146568 chr1:39522280~39546187:- LIHC cis rs6452524 1 rs9293334 ENSG00000271862.1 RP11-343L5.2 3.87 0.000131 0.0229 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83156984 chr5:83049376~83050964:- LIHC cis rs2333021 0.801 rs4903086 ENSG00000259015.1 RP11-109N23.6 3.87 0.000131 0.0229 0.24 0.2 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72995605 chr14:72960595~72961993:+ LIHC cis rs4925386 0.84 rs6143036 ENSG00000226332.2 RP11-157P1.4 3.87 0.000131 0.0229 0.24 0.2 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62346665 chr20:62305432~62306325:- LIHC cis rs6452524 1 rs9986131 ENSG00000271862.1 RP11-343L5.2 3.87 0.000131 0.0229 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83149037 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs4591730 ENSG00000271862.1 RP11-343L5.2 3.87 0.000131 0.0229 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83151983 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs1031902 ENSG00000271862.1 RP11-343L5.2 3.87 0.000131 0.0229 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83152308 chr5:83049376~83050964:- LIHC cis rs11098499 0.738 rs28687057 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119359657 chr4:119454791~119552025:+ LIHC cis rs11098499 0.775 rs67281037 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119360002 chr4:119454791~119552025:+ LIHC cis rs10028773 0.506 rs12374346 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Educational attainment; chr4:119360550 chr4:119454791~119552025:+ LIHC cis rs11098499 0.775 rs10021601 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119361408 chr4:119454791~119552025:+ LIHC cis rs11098499 0.866 rs6857892 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119361541 chr4:119454791~119552025:+ LIHC cis rs11098499 0.909 rs28581362 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119362393 chr4:119454791~119552025:+ LIHC cis rs11098499 0.82 rs12503082 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119363162 chr4:119454791~119552025:+ LIHC cis rs11098499 0.866 rs12499602 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119363232 chr4:119454791~119552025:+ LIHC cis rs11098499 0.774 rs11098505 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119363472 chr4:119454791~119552025:+ LIHC cis rs11098499 0.866 rs13105020 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119364533 chr4:119454791~119552025:+ LIHC cis rs11098499 0.866 rs6824111 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119364813 chr4:119454791~119552025:+ LIHC cis rs11098499 0.779 rs10857066 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119365441 chr4:119454791~119552025:+ LIHC cis rs11098499 0.775 rs10029303 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119365600 chr4:119454791~119552025:+ LIHC cis rs11098499 0.866 rs9995136 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119365690 chr4:119454791~119552025:+ LIHC cis rs11098499 0.866 rs13125526 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119366864 chr4:119454791~119552025:+ LIHC cis rs11098499 0.866 rs12513310 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119366884 chr4:119454791~119552025:+ LIHC cis rs11098499 0.564 rs11098507 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119367131 chr4:119454791~119552025:+ LIHC cis rs11098499 0.866 rs12510451 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119367988 chr4:119454791~119552025:+ LIHC cis rs11098499 0.774 rs73842616 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119369528 chr4:119454791~119552025:+ LIHC cis rs11098499 0.645 rs72676059 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119369673 chr4:119454791~119552025:+ LIHC cis rs11098499 0.569 rs55845118 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119369758 chr4:119454791~119552025:+ LIHC cis rs11098499 0.866 rs7677068 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119370549 chr4:119454791~119552025:+ LIHC cis rs11098499 0.866 rs9991221 ENSG00000245958.5 RP11-33B1.1 -3.87 0.000131 0.0229 -0.21 -0.2 Corneal astigmatism; chr4:119370952 chr4:119454791~119552025:+ LIHC cis rs950169 0.58 rs17532346 ENSG00000259728.4 LINC00933 3.87 0.000131 0.023 0.29 0.2 Schizophrenia; chr15:84628264 chr15:84570649~84580175:+ LIHC cis rs481331 0.5 rs210260 ENSG00000185904.10 LINC00839 -3.87 0.000131 0.023 -0.38 -0.2 Systemic juvenile idiopathic arthritis; chr10:42542439 chr10:42475543~42495336:+ LIHC cis rs481331 0.676 rs210267 ENSG00000185904.10 LINC00839 -3.87 0.000131 0.023 -0.38 -0.2 Systemic juvenile idiopathic arthritis; chr10:42552510 chr10:42475543~42495336:+ LIHC cis rs481331 0.866 rs210221 ENSG00000185904.10 LINC00839 -3.87 0.000131 0.023 -0.38 -0.2 Systemic juvenile idiopathic arthritis; chr10:42561182 chr10:42475543~42495336:+ LIHC cis rs1061377 0.513 rs2566162 ENSG00000249685.1 RP11-360F5.3 3.87 0.000131 0.023 0.3 0.2 Uric acid levels; chr4:39126453 chr4:39133913~39135608:+ LIHC cis rs448720 0.684 rs2448134 ENSG00000260657.2 RP11-315D16.4 -3.87 0.000131 0.023 -0.24 -0.2 Cognitive performance; chr15:67930702 chr15:68267792~68277994:- LIHC cis rs875971 0.54 rs781152 ENSG00000237310.1 GS1-124K5.4 3.87 0.000131 0.023 0.21 0.2 Aortic root size; chr7:66014585 chr7:66493706~66495474:+ LIHC cis rs11696277 0.951 rs6034795 ENSG00000232333.1 RPS27AP2 3.87 0.000131 0.023 0.34 0.2 Gut microbiome composition (summer); chr20:17312689 chr20:17516843~17517307:+ LIHC cis rs11096990 0.634 rs60016848 ENSG00000249207.1 RP11-360F5.1 3.87 0.000131 0.023 0.2 0.2 Cognitive function; chr4:39281436 chr4:39112677~39126818:- LIHC cis rs11096990 0.577 rs6830736 ENSG00000249207.1 RP11-360F5.1 3.87 0.000131 0.023 0.2 0.2 Cognitive function; chr4:39281467 chr4:39112677~39126818:- LIHC cis rs11096990 0.634 rs6854358 ENSG00000249207.1 RP11-360F5.1 3.87 0.000131 0.023 0.2 0.2 Cognitive function; chr4:39281492 chr4:39112677~39126818:- LIHC cis rs12817211 0.549 rs7138945 ENSG00000272368.2 RP4-605O3.4 -3.87 0.000131 0.023 -0.23 -0.2 Colorectal or endometrial cancer; chr12:50145636 chr12:50112197~50165618:+ LIHC cis rs12209785 0.727 rs13207392 ENSG00000231769.2 RP1-8B1.4 3.87 0.000131 0.023 0.3 0.2 Survival in pancreatic cancer; chr6:45528719 chr6:46097093~46129706:- LIHC cis rs12962334 0.57 rs4800434 ENSG00000266850.1 RP11-370A5.1 3.87 0.000131 0.023 0.22 0.2 Breast cancer; chr18:22848311 chr18:22723491~22907721:- LIHC cis rs4144027 0.904 rs10438243 ENSG00000258534.1 CTD-2134A5.4 3.87 0.000131 0.023 0.23 0.2 Blood metabolite levels; chr14:103879485 chr14:103854366~103880111:- LIHC cis rs12589282 1 rs3751466 ENSG00000257285.4 RP11-298I3.1 -3.87 0.000131 0.023 -0.2 -0.2 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs); chr14:22468499 chr14:22929609~22955562:+ LIHC cis rs10129255 0.83 rs61997609 ENSG00000211970.3 IGHV4-61 -3.87 0.000131 0.023 -0.16 -0.2 Kawasaki disease; chr14:106692376 chr14:106639119~106639657:- LIHC cis rs67311347 1 rs2085115 ENSG00000223797.4 ENTPD3-AS1 3.87 0.000131 0.023 0.17 0.2 Renal cell carcinoma; chr3:40456049 chr3:40313802~40453329:- LIHC cis rs11096990 0.964 rs11096987 ENSG00000249207.1 RP11-360F5.1 3.87 0.000131 0.023 0.24 0.2 Cognitive function; chr4:39257570 chr4:39112677~39126818:- LIHC cis rs6545883 0.965 rs2305156 ENSG00000271889.1 RP11-493E12.1 3.87 0.000131 0.023 0.24 0.2 Tuberculosis; chr2:61502133 chr2:61151433~61162105:- LIHC cis rs4578769 0.55 rs9949333 ENSG00000266850.1 RP11-370A5.1 3.87 0.000132 0.023 0.22 0.2 Eosinophil percentage of white cells; chr18:22815080 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs9962620 ENSG00000266850.1 RP11-370A5.1 3.87 0.000132 0.023 0.22 0.2 Eosinophil percentage of white cells; chr18:22815811 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs4800433 ENSG00000266850.1 RP11-370A5.1 3.87 0.000132 0.023 0.22 0.2 Eosinophil percentage of white cells; chr18:22816691 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs11082155 ENSG00000266850.1 RP11-370A5.1 3.87 0.000132 0.023 0.22 0.2 Eosinophil percentage of white cells; chr18:22824527 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs4289091 ENSG00000266850.1 RP11-370A5.1 3.87 0.000132 0.023 0.22 0.2 Eosinophil percentage of white cells; chr18:22825856 chr18:22723491~22907721:- LIHC cis rs4578769 0.589 rs12606787 ENSG00000266850.1 RP11-370A5.1 3.87 0.000132 0.023 0.22 0.2 Eosinophil percentage of white cells; chr18:22830392 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs12956367 ENSG00000266850.1 RP11-370A5.1 3.87 0.000132 0.023 0.22 0.2 Eosinophil percentage of white cells; chr18:22833742 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs1448769 ENSG00000266850.1 RP11-370A5.1 3.87 0.000132 0.023 0.22 0.2 Eosinophil percentage of white cells; chr18:22838322 chr18:22723491~22907721:- LIHC cis rs2228479 0.681 rs62052184 ENSG00000261253.2 AC137932.6 3.87 0.000132 0.023 0.29 0.2 Skin colour saturation; chr16:89900809 chr16:89321133~89325110:+ LIHC cis rs2228479 0.681 rs10153196 ENSG00000261253.2 AC137932.6 3.87 0.000132 0.023 0.29 0.2 Skin colour saturation; chr16:89900989 chr16:89321133~89325110:+ LIHC cis rs55726902 1 rs73107993 ENSG00000276691.1 RP5-1057I20.5 3.87 0.000132 0.023 0.36 0.2 Allergic disease (asthma, hay fever or eczema); chr12:47802090 chr12:47788426~47788971:+ LIHC cis rs4218 0.517 rs2899640 ENSG00000277144.1 RP11-59H7.4 -3.87 0.000132 0.023 -0.23 -0.2 Social communication problems; chr15:59060281 chr15:59115547~59116089:- LIHC cis rs875971 0.54 rs781152 ENSG00000273024.4 INTS4P2 -3.87 0.000132 0.023 -0.25 -0.2 Aortic root size; chr7:66014585 chr7:65647864~65715661:+ LIHC cis rs2439831 0.541 rs12440854 ENSG00000166763.7 STRCP1 3.87 0.000132 0.023 0.36 0.2 Lung cancer in ever smokers; chr15:43318474 chr15:43699488~43718184:- LIHC cis rs1075265 0.756 rs3821081 ENSG00000272156.1 RP11-477N3.1 3.87 0.000132 0.023 0.24 0.2 Chronotype;Morning vs. evening chronotype; chr2:53738252 chr2:54082554~54085066:+ LIHC cis rs2998286 0.678 rs332114 ENSG00000254635.4 WAC-AS1 3.87 0.000132 0.023 0.25 0.2 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28636772 chr10:28522652~28532743:- LIHC cis rs4650994 1 rs10913570 ENSG00000213057.5 C1orf220 3.87 0.000132 0.023 0.18 0.2 HDL cholesterol;HDL cholesterol levels; chr1:178553991 chr1:178542752~178548889:+ LIHC cis rs12681287 0.752 rs13277670 ENSG00000254088.1 SLC2A3P4 3.87 0.000132 0.023 0.25 0.2 Caudate activity during reward; chr8:86247691 chr8:86503591~86505061:+ LIHC cis rs10833905 1 rs12279454 ENSG00000246225.5 RP11-17A1.3 -3.87 0.000132 0.023 -0.25 -0.2 Sudden cardiac arrest; chr11:23020769 chr11:22829380~22945393:+ LIHC cis rs875971 1 rs55962648 ENSG00000237310.1 GS1-124K5.4 -3.87 0.000132 0.023 -0.18 -0.2 Aortic root size; chr7:66160764 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs2420168 ENSG00000237310.1 GS1-124K5.4 -3.87 0.000132 0.023 -0.18 -0.2 Aortic root size; chr7:66165644 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs11974219 ENSG00000237310.1 GS1-124K5.4 -3.87 0.000132 0.023 -0.18 -0.2 Aortic root size; chr7:66182423 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs1565531 ENSG00000237310.1 GS1-124K5.4 -3.87 0.000132 0.023 -0.18 -0.2 Aortic root size; chr7:66198126 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs6963646 ENSG00000237310.1 GS1-124K5.4 -3.87 0.000132 0.023 -0.18 -0.2 Aortic root size; chr7:66220780 chr7:66493706~66495474:+ LIHC cis rs875971 0.965 rs28682868 ENSG00000237310.1 GS1-124K5.4 -3.87 0.000132 0.023 -0.18 -0.2 Aortic root size; chr7:66224822 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs9986696 ENSG00000237310.1 GS1-124K5.4 -3.87 0.000132 0.023 -0.18 -0.2 Aortic root size; chr7:66239589 chr7:66493706~66495474:+ LIHC cis rs3764021 0.527 rs2114870 ENSG00000256673.1 RP11-599J14.2 -3.87 0.000132 0.023 -0.21 -0.2 Type 1 diabetes; chr12:9670544 chr12:9398355~9414851:- LIHC cis rs6142102 0.961 rs6059596 ENSG00000275784.1 RP5-1125A11.6 -3.87 0.000132 0.0231 -0.24 -0.2 Skin pigmentation; chr20:33969313 chr20:33989480~33991818:- LIHC cis rs6142102 0.961 rs6088360 ENSG00000275784.1 RP5-1125A11.6 -3.87 0.000132 0.0231 -0.24 -0.2 Skin pigmentation; chr20:33969383 chr20:33989480~33991818:- LIHC cis rs2599510 0.703 rs762023 ENSG00000276334.1 AL133243.1 3.87 0.000132 0.0231 0.24 0.2 Interleukin-18 levels; chr2:32488103 chr2:32521927~32523547:+ LIHC cis rs6142102 0.58 rs9753679 ENSG00000275784.1 RP5-1125A11.6 -3.87 0.000132 0.0231 -0.22 -0.2 Skin pigmentation; chr20:33953054 chr20:33989480~33991818:- LIHC cis rs4356203 0.905 rs651513 ENSG00000260196.1 RP1-239B22.5 -3.87 0.000132 0.0231 -0.25 -0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17177781 chr11:17380649~17383531:+ LIHC cis rs3015497 0.616 rs4901043 ENSG00000269906.1 RP11-248J18.2 -3.87 0.000132 0.0231 -0.25 -0.2 Mean platelet volume; chr14:50616876 chr14:50662511~50663178:- LIHC cis rs6001482 0.638 rs5757569 ENSG00000234630.1 LL22NC03-2H8.4 3.87 0.000132 0.0231 0.16 0.2 Diastolic blood pressure; chr22:22230282 chr22:22293733~22294794:+ LIHC cis rs2179367 0.537 rs12192159 ENSG00000231760.4 RP11-350J20.5 3.87 0.000132 0.0231 0.39 0.2 Dupuytren's disease; chr6:149445969 chr6:149796151~149826294:- LIHC cis rs12209785 1 rs12195878 ENSG00000231769.2 RP1-8B1.4 3.87 0.000132 0.0231 0.33 0.2 Survival in pancreatic cancer; chr6:45523016 chr6:46097093~46129706:- LIHC cis rs7044106 0.762 rs7849566 ENSG00000238181.2 AHCYP2 -3.87 0.000132 0.0231 -0.23 -0.2 Hip circumference adjusted for BMI; chr9:120698491 chr9:120720673~120721972:+ LIHC cis rs2070488 1 rs7373805 ENSG00000229589.1 ACVR2B-AS1 3.87 0.000132 0.0231 0.23 0.2 Electrocardiographic conduction measures; chr3:38413948 chr3:38451027~38454820:- LIHC cis rs2070488 1 rs13074160 ENSG00000229589.1 ACVR2B-AS1 3.87 0.000132 0.0231 0.23 0.2 Electrocardiographic conduction measures; chr3:38414159 chr3:38451027~38454820:- LIHC cis rs2070488 1 rs13074025 ENSG00000229589.1 ACVR2B-AS1 3.87 0.000132 0.0231 0.23 0.2 Electrocardiographic conduction measures; chr3:38414213 chr3:38451027~38454820:- LIHC cis rs2070488 1 rs4147024 ENSG00000229589.1 ACVR2B-AS1 3.87 0.000132 0.0231 0.23 0.2 Electrocardiographic conduction measures; chr3:38415173 chr3:38451027~38454820:- LIHC cis rs4792901 0.722 rs35714338 ENSG00000267747.1 RP11-392O1.4 -3.87 0.000132 0.0231 -0.24 -0.2 Dupuytren's disease; chr17:43536845 chr17:43544785~43610338:+ LIHC cis rs1405130 1 rs6721496 ENSG00000224287.2 MSL3P1 3.87 0.000132 0.0231 0.24 0.2 Coronary artery disease; chr2:234655989 chr2:233865437~233868444:- LIHC cis rs1405130 0.967 rs12989429 ENSG00000224287.2 MSL3P1 3.87 0.000132 0.0231 0.24 0.2 Coronary artery disease; chr2:234662909 chr2:233865437~233868444:- LIHC cis rs4787491 0.729 rs3814878 ENSG00000250616.2 RP11-455F5.3 3.87 0.000132 0.0231 0.2 0.2 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30030645 chr16:30096430~30104116:+ LIHC cis rs10510102 0.516 rs2420976 ENSG00000226864.1 ATE1-AS1 -3.87 0.000132 0.0231 -0.34 -0.2 Breast cancer; chr10:121986932 chr10:121928312~121951965:+ LIHC cis rs1005277 0.579 rs2505257 ENSG00000275858.1 RP11-291L22.8 3.87 0.000132 0.0231 0.22 0.2 Extrinsic epigenetic age acceleration; chr10:38083736 chr10:38450738~38451069:- LIHC cis rs2439831 1 rs1814538 ENSG00000166763.7 STRCP1 -3.87 0.000132 0.0231 -0.29 -0.2 Lung cancer in ever smokers; chr15:43467576 chr15:43699488~43718184:- LIHC cis rs67311347 1 rs6762251 ENSG00000223797.4 ENTPD3-AS1 -3.87 0.000132 0.0231 -0.17 -0.2 Renal cell carcinoma; chr3:40489645 chr3:40313802~40453329:- LIHC cis rs8060686 0.516 rs9938020 ENSG00000261469.1 RP11-96D1.6 -3.87 0.000132 0.0231 -0.24 -0.2 HDL cholesterol;Metabolic syndrome; chr16:68217881 chr16:68236845~68237667:- LIHC cis rs8060686 0.516 rs13339471 ENSG00000261469.1 RP11-96D1.6 -3.87 0.000132 0.0231 -0.24 -0.2 HDL cholesterol;Metabolic syndrome; chr16:68219105 chr16:68236845~68237667:- LIHC cis rs1223397 0.651 rs202019 ENSG00000215022.6 RP1-257A7.4 -3.87 0.000132 0.0231 -0.21 -0.2 Blood pressure; chr6:13301558 chr6:13264861~13295586:- LIHC cis rs875971 0.66 rs10215132 ENSG00000224316.1 RP11-479O9.2 -3.87 0.000132 0.0231 -0.19 -0.2 Aortic root size; chr7:66589419 chr7:65773620~65802067:+ LIHC cis rs559928 0.606 rs12419038 ENSG00000236935.1 AP003774.1 3.87 0.000132 0.0231 0.28 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64145264 chr11:64325050~64329504:- LIHC cis rs11710088 0.711 rs35884523 ENSG00000244503.1 RP11-278L15.6 3.87 0.000132 0.0231 0.26 0.2 QRS duration; chr3:149470430 chr3:149494660~149495995:+ LIHC cis rs2403083 0.505 rs10106970 ENSG00000253549.4 RP11-317J10.2 3.87 0.000132 0.0231 0.23 0.2 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85225831 chr8:85441851~85464915:- LIHC cis rs9303401 0.646 rs8067682 ENSG00000265415.1 CTD-2510F5.4 3.87 0.000132 0.0231 0.14 0.2 Cognitive test performance; chr17:59142030 chr17:59202677~59203829:- LIHC cis rs709400 0.859 rs7154948 ENSG00000258914.1 CTD-2134A5.3 3.87 0.000132 0.0231 0.3 0.2 Body mass index; chr14:103556607 chr14:103875055~103877478:+ LIHC cis rs3749237 0.576 rs4241406 ENSG00000226913.1 BSN-AS2 -3.87 0.000132 0.0231 -0.27 -0.2 Resting heart rate; chr3:49562993 chr3:49549306~49554366:- LIHC cis rs2439831 0.85 rs28858500 ENSG00000166763.7 STRCP1 3.87 0.000133 0.0232 0.32 0.2 Lung cancer in ever smokers; chr15:43864744 chr15:43699488~43718184:- LIHC cis rs11123170 0.529 rs112692022 ENSG00000189223.12 PAX8-AS1 -3.87 0.000133 0.0232 -0.35 -0.2 Renal function-related traits (BUN); chr2:113212605 chr2:113211522~113276581:+ LIHC cis rs287982 0.8 rs9973905 ENSG00000269973.1 RP11-95D17.1 -3.87 0.000133 0.0232 -0.19 -0.2 Nonsyndromic cleft lip with cleft palate; chr2:9820726 chr2:9936360~9939590:+ LIHC cis rs67311347 0.544 rs2123998 ENSG00000223797.4 ENTPD3-AS1 -3.87 0.000133 0.0232 -0.17 -0.2 Renal cell carcinoma; chr3:40317514 chr3:40313802~40453329:- LIHC cis rs3087243 0.56 rs231723 ENSG00000213925.3 NPM1P33 3.87 0.000133 0.0232 0.21 0.2 Rheumatoid arthritis;Type 1 diabetes;Hypothyroidism; chr2:203875058 chr2:203772631~203773502:- LIHC cis rs1799949 0.965 rs4793233 ENSG00000267681.1 CTD-3199J23.6 -3.87 0.000133 0.0232 -0.2 -0.2 Menopause (age at onset); chr17:43358069 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs4793234 ENSG00000267681.1 CTD-3199J23.6 -3.87 0.000133 0.0232 -0.2 -0.2 Menopause (age at onset); chr17:43358815 chr17:43144956~43145255:+ LIHC cis rs875971 0.545 rs2420612 ENSG00000224316.1 RP11-479O9.2 3.87 0.000133 0.0232 0.2 0.2 Aortic root size; chr7:66536825 chr7:65773620~65802067:+ LIHC cis rs2274273 1 rs7142704 ENSG00000258413.1 RP11-665C16.6 -3.87 0.000133 0.0232 -0.24 -0.2 Protein biomarker; chr14:55163885 chr14:55262767~55272075:- LIHC cis rs74181299 0.653 rs2723091 ENSG00000225889.6 AC074289.1 -3.87 0.000133 0.0232 -0.23 -0.2 Pulse pressure; chr2:65074883 chr2:64143239~64252859:+ LIHC cis rs6452524 0.618 rs6452506 ENSG00000271862.1 RP11-343L5.2 3.87 0.000133 0.0232 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83075844 chr5:83049376~83050964:- LIHC cis rs858239 0.712 rs200717 ENSG00000226816.2 AC005082.12 3.87 0.000133 0.0232 0.26 0.2 Cerebrospinal fluid biomarker levels; chr7:23352652 chr7:23206013~23208045:+ LIHC cis rs1816213 0.744 rs35898356 ENSG00000273466.1 RP11-548H3.1 -3.86 0.000133 0.0232 -0.31 -0.2 Diastolic blood pressure; chr2:218560000 chr2:218633256~218634014:- LIHC cis rs794185 0.592 rs304085 ENSG00000231249.1 ITPR1-AS1 -3.86 0.000133 0.0232 -0.22 -0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4480447 chr3:4490891~4493163:- LIHC cis rs1223397 0.938 rs17700321 ENSG00000215022.6 RP1-257A7.4 -3.86 0.000133 0.0232 -0.28 -0.2 Blood pressure; chr6:13280434 chr6:13264861~13295586:- LIHC cis rs11064837 0.523 rs3930004 ENSG00000248636.5 RP11-768F21.1 3.86 0.000133 0.0232 0.35 0.2 Schizophrenia; chr12:119664621 chr12:119387987~119668079:- LIHC cis rs7083 0.935 rs523366 ENSG00000254851.1 RP11-109L13.1 3.86 0.000133 0.0232 0.29 0.2 Blood protein levels; chr11:117248836 chr11:117135528~117138582:+ LIHC cis rs1075265 0.597 rs11694711 ENSG00000233266.1 HMGB1P31 3.86 0.000133 0.0233 0.25 0.2 Chronotype;Morning vs. evening chronotype; chr2:53971924 chr2:54051334~54051760:+ LIHC cis rs9640161 0.83 rs76741564 ENSG00000261305.1 RP4-584D14.7 3.86 0.000133 0.0233 0.24 0.2 Blood protein levels;Circulating chemerin levels; chr7:150362440 chr7:150341771~150342607:+ LIHC cis rs2581828 0.618 rs6784207 ENSG00000242142.1 SERBP1P3 -3.86 0.000133 0.0233 -0.27 -0.2 Crohn's disease; chr3:53133458 chr3:53064283~53065091:- LIHC cis rs1318937 0.679 rs9310471 ENSG00000224660.1 SH3BP5-AS1 3.86 0.000133 0.0233 0.18 0.2 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15195342 chr3:15254184~15264493:+ LIHC cis rs1318937 0.764 rs2129945 ENSG00000224660.1 SH3BP5-AS1 3.86 0.000133 0.0233 0.18 0.2 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15197706 chr3:15254184~15264493:+ LIHC cis rs2253762 0.54 rs10159634 ENSG00000276742.1 RP11-500G22.4 -3.86 0.000133 0.0233 -0.33 -0.2 Breast cancer; chr10:121994520 chr10:121956782~121957098:+ LIHC cis rs12681287 0.64 rs13251006 ENSG00000254088.1 SLC2A3P4 3.86 0.000133 0.0233 0.24 0.2 Caudate activity during reward; chr8:86456876 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs13269259 ENSG00000254088.1 SLC2A3P4 3.86 0.000133 0.0233 0.24 0.2 Caudate activity during reward; chr8:86458224 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs7461413 ENSG00000254088.1 SLC2A3P4 3.86 0.000133 0.0233 0.24 0.2 Caudate activity during reward; chr8:86458749 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs12550142 ENSG00000254088.1 SLC2A3P4 3.86 0.000133 0.0233 0.24 0.2 Caudate activity during reward; chr8:86459632 chr8:86503591~86505061:+ LIHC cis rs748404 0.56 rs2255663 ENSG00000166763.7 STRCP1 -3.86 0.000133 0.0233 -0.25 -0.2 Lung cancer; chr15:43536810 chr15:43699488~43718184:- LIHC cis rs11686241 1 rs11886806 ENSG00000232485.2 AC098820.3 -3.86 0.000133 0.0233 -0.21 -0.2 Cancer; chr2:216424552 chr2:216479030~216498761:- LIHC cis rs4287000 0.647 rs3750361 ENSG00000227603.1 RP11-165J3.6 3.86 0.000133 0.0233 0.23 0.2 Itch intensity from mosquito bite adjusted by bite size; chr9:93669538 chr9:93435332~93437121:- LIHC cis rs944990 0.576 rs10992731 ENSG00000227603.1 RP11-165J3.6 3.86 0.000133 0.0233 0.22 0.2 Body mass index; chr9:93436816 chr9:93435332~93437121:- LIHC cis rs7674212 0.507 rs10516495 ENSG00000248971.2 KRT8P46 -3.86 0.000134 0.0233 -0.22 -0.2 Type 2 diabetes; chr4:102978933 chr4:102728746~102730171:- LIHC cis rs875971 0.508 rs10950045 ENSG00000224316.1 RP11-479O9.2 -3.86 0.000134 0.0233 -0.19 -0.2 Aortic root size; chr7:66601386 chr7:65773620~65802067:+ LIHC cis rs801193 0.839 rs6968619 ENSG00000224316.1 RP11-479O9.2 -3.86 0.000134 0.0233 -0.19 -0.2 Aortic root size; chr7:66603880 chr7:65773620~65802067:+ LIHC cis rs6723108 0.627 rs766270 ENSG00000224043.6 CCNT2-AS1 -3.86 0.000134 0.0233 -0.28 -0.2 Type 2 diabetes; chr2:134909356 chr2:134735464~134918710:- LIHC cis rs1799922 0.693 rs339088 ENSG00000273270.1 RP11-212P7.2 -3.86 0.000134 0.0233 -0.26 -0.2 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr7:128782932 chr7:128524016~128531069:- LIHC cis rs4819852 0.958 rs1034564 ENSG00000215493.3 XXbac-B562F10.11 3.86 0.000134 0.0233 0.17 0.2 Pulse pressure; chr22:19996490 chr22:20450122~20451824:+ LIHC cis rs7607369 0.648 rs17470271 ENSG00000272555.1 RP11-459I19.1 3.86 0.000134 0.0233 0.23 0.2 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218787272 chr2:218818690~218819144:+ LIHC cis rs4218 0.648 rs12442086 ENSG00000277144.1 RP11-59H7.4 -3.86 0.000134 0.0233 -0.23 -0.2 Social communication problems; chr15:59074364 chr15:59115547~59116089:- LIHC cis rs14027 0.843 rs1828238 ENSG00000279347.1 RP11-85I17.2 3.86 0.000134 0.0233 0.2 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119848105 chr8:119838736~119840385:- LIHC cis rs12887734 0.566 rs8548 ENSG00000258534.1 CTD-2134A5.4 -3.86 0.000134 0.0233 -0.23 -0.2 Autism spectrum disorder or schizophrenia;Schizophrenia; chr14:103733243 chr14:103854366~103880111:- LIHC cis rs8054556 0.669 rs9972866 ENSG00000250616.2 RP11-455F5.3 3.86 0.000134 0.0233 0.2 0.2 Autism spectrum disorder or schizophrenia; chr16:30007661 chr16:30096430~30104116:+ LIHC cis rs7176527 0.8 rs56747535 ENSG00000176700.18 SCAND2P 3.86 0.000134 0.0233 0.2 0.2 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84632709 chr15:84631451~84647478:+ LIHC cis rs2072510 0.966 rs1990611 ENSG00000257878.1 RP11-256L6.3 -3.86 0.000134 0.0233 -0.18 -0.2 Metabolite levels (small molecules and protein measures); chr12:96020206 chr12:95996521~96011489:+ LIHC cis rs12468226 0.938 rs77062060 ENSG00000226261.1 AC064836.3 3.86 0.000134 0.0233 0.33 0.2 Urate levels; chr2:202285639 chr2:202336024~202336727:- LIHC cis rs2564921 0.704 rs62253649 ENSG00000242142.1 SERBP1P3 -3.86 0.000134 0.0233 -0.27 -0.2 Height; chr3:52967831 chr3:53064283~53065091:- LIHC cis rs13113518 0.812 rs11133385 ENSG00000249700.7 SRD5A3-AS1 3.86 0.000134 0.0233 0.24 0.2 Height; chr4:55460485 chr4:55363971~55395847:- LIHC cis rs13113518 0.783 rs6843722 ENSG00000249700.7 SRD5A3-AS1 3.86 0.000134 0.0233 0.24 0.2 Height; chr4:55465165 chr4:55363971~55395847:- LIHC cis rs2348418 0.864 rs7295120 ENSG00000247934.4 RP11-967K21.1 3.86 0.000134 0.0233 0.19 0.2 Lung function (FEV1);Lung function (FVC); chr12:28565175 chr12:28163298~28190738:- LIHC cis rs3845817 0.703 rs1673457 ENSG00000281920.1 RP11-418H16.1 -3.86 0.000134 0.0233 -0.24 -0.2 Bipolar disorder; chr2:65544511 chr2:65623272~65628424:+ LIHC cis rs9976767 0.608 rs3746923 ENSG00000225218.1 AP001628.6 -3.86 0.000134 0.0234 -0.2 -0.2 Type 1 diabetes; chr21:42406235 chr21:42831040~42836477:- LIHC cis rs7969148 0.71 rs372201 ENSG00000270130.1 RP11-214K3.23 3.86 0.000134 0.0234 0.31 0.2 Clubfoot; chr12:124118052 chr12:123960717~123961244:- LIHC cis rs1405130 0.967 rs884062 ENSG00000224287.2 MSL3P1 3.86 0.000134 0.0234 0.24 0.2 Coronary artery disease; chr2:234662090 chr2:233865437~233868444:- LIHC cis rs1405130 0.967 rs13009617 ENSG00000224287.2 MSL3P1 3.86 0.000134 0.0234 0.24 0.2 Coronary artery disease; chr2:234662673 chr2:233865437~233868444:- LIHC cis rs1405130 0.933 rs12989408 ENSG00000224287.2 MSL3P1 3.86 0.000134 0.0234 0.24 0.2 Coronary artery disease; chr2:234662887 chr2:233865437~233868444:- LIHC cis rs7688540 0.771 rs61792114 ENSG00000275426.1 CH17-262A2.1 3.86 0.000134 0.0234 0.25 0.2 Facial morphology (factor 6, height of vermillion lower lip); chr4:295350 chr4:149738~150317:+ LIHC cis rs6480314 0.522 rs10047355 ENSG00000233590.1 RP11-153K11.3 -3.86 0.000134 0.0234 -0.35 -0.2 Optic nerve measurement (disc area); chr10:68300321 chr10:68233251~68242379:- LIHC cis rs4682868 0.581 rs4682869 ENSG00000273328.4 RP11-141M3.6 3.86 0.000134 0.0234 0.21 0.2 Monocyte percentage of white cells; chr3:42882472 chr3:42809414~42908105:+ LIHC cis rs9675120 1 rs7225465 ENSG00000262006.1 RP11-700H6.4 3.86 0.000134 0.0234 0.22 0.2 Cerebrospinal fluid biomarker levels; chr17:50838798 chr17:50909637~50910232:- LIHC cis rs194045 0.609 rs252344 ENSG00000273582.1 RP11-426C22.7 -3.86 0.000134 0.0234 -0.36 -0.2 Yu-Zhi constitution type in type 2 diabetes; chr16:29173561 chr16:29225594~29226348:- LIHC cis rs2299116 0.962 rs34820887 ENSG00000225264.3 ZNRF2P2 -3.86 0.000134 0.0234 -0.24 -0.2 Serum thyroid-stimulating hormone levels; chr7:28779596 chr7:29598795~29685255:- LIHC cis rs9457247 0.624 rs9457260 ENSG00000227598.1 RP1-167A14.2 -3.86 0.000134 0.0234 -0.22 -0.2 Crohn's disease; chr6:167053177 chr6:166969626~166999065:- LIHC cis rs860295 0.836 rs1360554 ENSG00000203761.5 MSTO2P 3.86 0.000134 0.0234 0.16 0.2 Body mass index; chr1:155503565 chr1:155745829~155750137:+ LIHC cis rs4578769 0.681 rs6507455 ENSG00000265943.1 RP11-739L10.1 3.86 0.000134 0.0234 0.26 0.2 Eosinophil percentage of white cells; chr18:23032669 chr18:22699481~22933764:- LIHC cis rs172166 0.694 rs1225716 ENSG00000219392.1 RP1-265C24.5 -3.86 0.000134 0.0234 -0.27 -0.2 Cardiac Troponin-T levels; chr6:28145968 chr6:28115628~28116551:+ LIHC cis rs4713118 0.512 rs2622319 ENSG00000219392.1 RP1-265C24.5 -3.86 0.000134 0.0234 -0.27 -0.2 Parkinson's disease; chr6:28152623 chr6:28115628~28116551:+ LIHC cis rs172166 0.694 rs1150666 ENSG00000219392.1 RP1-265C24.5 -3.86 0.000134 0.0234 -0.27 -0.2 Cardiac Troponin-T levels; chr6:28156150 chr6:28115628~28116551:+ LIHC cis rs12468226 0.689 rs17651413 ENSG00000273456.1 RP11-686O6.2 3.86 0.000134 0.0234 0.32 0.2 Urate levels; chr2:202104086 chr2:202374932~202375604:- LIHC cis rs875971 0.508 rs10258739 ENSG00000224316.1 RP11-479O9.2 -3.86 0.000134 0.0234 -0.19 -0.2 Aortic root size; chr7:66597948 chr7:65773620~65802067:+ LIHC cis rs6545883 0.931 rs7557230 ENSG00000271889.1 RP11-493E12.1 3.86 0.000134 0.0234 0.24 0.2 Tuberculosis; chr2:61509517 chr2:61151433~61162105:- LIHC cis rs9906944 0.707 rs9912906 ENSG00000248278.1 SUMO2P17 -3.86 0.000134 0.0234 -0.34 -0.2 Intelligence (multi-trait analysis);Body fat percentage; chr17:49027070 chr17:48874860~48908983:- LIHC cis rs9906944 0.713 rs9899580 ENSG00000248278.1 SUMO2P17 -3.86 0.000134 0.0234 -0.34 -0.2 Intelligence (multi-trait analysis);Body fat percentage; chr17:49029516 chr17:48874860~48908983:- LIHC cis rs9906944 0.707 rs9899931 ENSG00000248278.1 SUMO2P17 -3.86 0.000134 0.0234 -0.34 -0.2 Intelligence (multi-trait analysis);Body fat percentage; chr17:49030920 chr17:48874860~48908983:- LIHC cis rs9906944 0.707 rs4794020 ENSG00000248278.1 SUMO2P17 -3.86 0.000134 0.0234 -0.34 -0.2 Intelligence (multi-trait analysis);Body fat percentage; chr17:49034037 chr17:48874860~48908983:- LIHC cis rs6471393 0.929 rs62525163 ENSG00000253848.1 RP11-10N23.5 3.86 0.000134 0.0234 0.22 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93749824 chr8:93741193~93744534:+ LIHC cis rs8054556 0.669 rs4787491 ENSG00000250616.2 RP11-455F5.3 3.86 0.000134 0.0234 0.2 0.2 Autism spectrum disorder or schizophrenia; chr16:30004016 chr16:30096430~30104116:+ LIHC cis rs875971 0.66 rs10950044 ENSG00000224316.1 RP11-479O9.2 -3.86 0.000134 0.0234 -0.19 -0.2 Aortic root size; chr7:66577989 chr7:65773620~65802067:+ LIHC cis rs6442522 0.606 rs3773459 ENSG00000249786.6 EAF1-AS1 3.86 0.000135 0.0234 0.24 0.2 Uric acid levels; chr3:15454137 chr3:15436171~15455940:- LIHC cis rs6442522 0.606 rs3773458 ENSG00000249786.6 EAF1-AS1 3.86 0.000135 0.0234 0.24 0.2 Uric acid levels; chr3:15454147 chr3:15436171~15455940:- LIHC cis rs3091242 0.9 rs1811832 ENSG00000224183.1 SDHDP6 -3.86 0.000135 0.0234 -0.24 -0.2 Erythrocyte sedimentation rate; chr1:25427074 chr1:25294164~25294643:- LIHC cis rs11105298 0.891 rs10777163 ENSG00000258302.2 RP11-981P6.1 3.86 0.000135 0.0235 0.28 0.2 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89436943 chr12:89561129~89594878:+ LIHC cis rs1061377 0.513 rs2566166 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000135 0.0235 -0.29 -0.2 Uric acid levels; chr4:39148404 chr4:39133913~39135608:+ LIHC cis rs301901 0.766 rs12521993 ENSG00000250155.1 CTD-2353F22.1 3.86 0.000135 0.0235 0.2 0.2 Height; chr5:37488095 chr5:36666214~36725195:- LIHC cis rs9595908 0.709 rs9285092 ENSG00000212293.1 SNORA16 3.86 0.000135 0.0235 0.24 0.2 Body mass index; chr13:32745496 chr13:32420390~32420516:- LIHC cis rs9595908 0.709 rs4942867 ENSG00000212293.1 SNORA16 3.86 0.000135 0.0235 0.24 0.2 Body mass index; chr13:32745916 chr13:32420390~32420516:- LIHC cis rs9457247 0.544 rs6920858 ENSG00000227598.1 RP1-167A14.2 -3.86 0.000135 0.0235 -0.22 -0.2 Crohn's disease; chr6:167051142 chr6:166969626~166999065:- LIHC cis rs9457247 0.602 rs9459854 ENSG00000227598.1 RP1-167A14.2 -3.86 0.000135 0.0235 -0.22 -0.2 Crohn's disease; chr6:167052394 chr6:166969626~166999065:- LIHC cis rs9457247 0.582 rs9459855 ENSG00000227598.1 RP1-167A14.2 -3.86 0.000135 0.0235 -0.22 -0.2 Crohn's disease; chr6:167052662 chr6:166969626~166999065:- LIHC cis rs9457247 0.624 rs17524252 ENSG00000227598.1 RP1-167A14.2 -3.86 0.000135 0.0235 -0.22 -0.2 Crohn's disease; chr6:167053490 chr6:166969626~166999065:- LIHC cis rs4266144 0.544 rs6805781 ENSG00000244515.1 KRT18P34 3.86 0.000135 0.0235 0.2 0.2 Coronary artery disease; chr3:157112780 chr3:157162663~157163932:- LIHC cis rs1115240 0.898 rs178169 ENSG00000257842.4 NOVA1-AS1 -3.86 0.000135 0.0235 -0.19 -0.2 Educational attainment (years of education); chr14:26550038 chr14:26598412~26806467:+ LIHC cis rs7760535 0.757 rs10456875 ENSG00000271789.1 RP5-1112D6.7 -3.86 0.000135 0.0235 -0.2 -0.2 Metabolic traits; chr6:111428522 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs4276544 ENSG00000271789.1 RP5-1112D6.7 -3.86 0.000135 0.0235 -0.2 -0.2 Amino acid levels;Blood metabolite levels; chr6:111438496 chr6:111297126~111298510:+ LIHC cis rs17376456 0.877 rs13169675 ENSG00000251023.1 RP11-549J18.1 -3.86 0.000135 0.0235 -0.43 -0.2 Diabetic retinopathy; chr5:93995579 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs9314093 ENSG00000251023.1 RP11-549J18.1 -3.86 0.000135 0.0235 -0.43 -0.2 Diabetic retinopathy; chr5:93997642 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs13185660 ENSG00000251023.1 RP11-549J18.1 -3.86 0.000135 0.0235 -0.43 -0.2 Diabetic retinopathy; chr5:94000795 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs28575883 ENSG00000251023.1 RP11-549J18.1 -3.86 0.000135 0.0235 -0.43 -0.2 Diabetic retinopathy; chr5:94010330 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10062711 ENSG00000251023.1 RP11-549J18.1 -3.86 0.000135 0.0235 -0.43 -0.2 Diabetic retinopathy; chr5:94012954 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10050465 ENSG00000251023.1 RP11-549J18.1 -3.86 0.000135 0.0235 -0.43 -0.2 Diabetic retinopathy; chr5:94014258 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10066791 ENSG00000251023.1 RP11-549J18.1 -3.86 0.000135 0.0235 -0.43 -0.2 Diabetic retinopathy; chr5:94014550 chr5:93860669~93863825:- LIHC cis rs2659703 0.933 rs12491173 ENSG00000261159.1 RP11-723O4.9 3.86 0.000135 0.0235 0.27 0.2 Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid); chr3:128455336 chr3:128859716~128860526:- LIHC cis rs5742933 0.817 rs1233297 ENSG00000273240.1 RP11-455J20.3 -3.86 0.000135 0.0235 -0.25 -0.2 Ferritin levels; chr2:189829449 chr2:189763859~189764456:- LIHC cis rs244293 0.965 rs2214980 ENSG00000275710.1 RP11-257O5.4 3.86 0.000135 0.0235 0.22 0.2 Menarche (age at onset); chr17:55129700 chr17:54964474~54964679:+ LIHC cis rs244293 0.931 rs2787484 ENSG00000275710.1 RP11-257O5.4 3.86 0.000135 0.0235 0.22 0.2 Menarche (age at onset); chr17:55132759 chr17:54964474~54964679:+ LIHC cis rs244293 1 rs244316 ENSG00000275710.1 RP11-257O5.4 3.86 0.000135 0.0235 0.22 0.2 Menarche (age at onset); chr17:55137862 chr17:54964474~54964679:+ LIHC cis rs11216126 0.554 rs1942478 ENSG00000254851.1 RP11-109L13.1 3.86 0.000135 0.0235 0.33 0.2 HDL cholesterol; chr11:116780747 chr11:117135528~117138582:+ LIHC cis rs10883723 0.81 rs61873733 ENSG00000236937.2 PTGES3P4 -3.86 0.000135 0.0235 -0.27 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102491701 chr10:102845595~102845950:+ LIHC cis rs2919917 0.628 rs6990105 ENSG00000254352.1 RP11-578O24.2 3.86 0.000135 0.0235 0.31 0.2 Lymphocyte counts; chr8:78689652 chr8:78723796~78724136:- LIHC cis rs2439831 0.764 rs12324584 ENSG00000205771.5 CATSPER2P1 -3.86 0.000135 0.0235 -0.28 -0.2 Lung cancer in ever smokers; chr15:43391248 chr15:43726918~43747094:- LIHC cis rs10129255 0.956 rs10137268 ENSG00000211970.3 IGHV4-61 -3.86 0.000135 0.0235 -0.16 -0.2 Kawasaki disease; chr14:106697402 chr14:106639119~106639657:- LIHC cis rs6840360 0.967 rs7695162 ENSG00000251603.1 RP11-164P12.4 -3.86 0.000135 0.0235 -0.18 -0.2 Intelligence (multi-trait analysis); chr4:151589389 chr4:151667224~151670502:+ LIHC cis rs617219 1 rs617219 ENSG00000251675.1 CTC-458I2.2 3.86 0.000135 0.0236 0.22 0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79133771 chr5:80128361~80143883:+ LIHC cis rs36715 1 rs36715 ENSG00000245937.6 LINC01184 3.86 0.000135 0.0236 0.24 0.2 Breast cancer; chr5:128227188 chr5:127940426~128083172:- LIHC cis rs244293 0.931 rs2170942 ENSG00000275710.1 RP11-257O5.4 3.86 0.000135 0.0236 0.22 0.2 Menarche (age at onset); chr17:55132154 chr17:54964474~54964679:+ LIHC cis rs6997458 0.9 rs7000950 ENSG00000253549.4 RP11-317J10.2 3.86 0.000135 0.0236 0.23 0.2 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85395234 chr8:85441851~85464915:- LIHC cis rs10129255 0.912 rs6576227 ENSG00000211970.3 IGHV4-61 -3.86 0.000135 0.0236 -0.16 -0.2 Kawasaki disease; chr14:106778202 chr14:106639119~106639657:- LIHC cis rs1023500 0.505 rs134899 ENSG00000205702.9 CYP2D7 3.86 0.000136 0.0236 0.21 0.2 Schizophrenia; chr22:42287024 chr22:42140203~42144577:- LIHC cis rs2919917 0.628 rs13265305 ENSG00000254352.1 RP11-578O24.2 3.86 0.000136 0.0236 0.3 0.2 Lymphocyte counts; chr8:78656575 chr8:78723796~78724136:- LIHC cis rs2919917 0.628 rs2887482 ENSG00000254352.1 RP11-578O24.2 3.86 0.000136 0.0236 0.3 0.2 Lymphocyte counts; chr8:78659633 chr8:78723796~78724136:- LIHC cis rs2919917 0.628 rs1905364 ENSG00000254352.1 RP11-578O24.2 3.86 0.000136 0.0236 0.3 0.2 Lymphocyte counts; chr8:78660244 chr8:78723796~78724136:- LIHC cis rs3020736 0.5 rs8143153 ENSG00000226450.2 CYP2D8P -3.86 0.000136 0.0236 -0.25 -0.2 Autism spectrum disorder or schizophrenia; chr22:42119633 chr22:42149886~42155001:- LIHC cis rs757081 0.648 rs10766382 ENSG00000272034.1 SNORD14A -3.86 0.000136 0.0236 -0.22 -0.2 Systolic blood pressure; chr11:17252894 chr11:17074654~17074744:- LIHC cis rs757081 0.547 rs11024220 ENSG00000272034.1 SNORD14A -3.86 0.000136 0.0236 -0.22 -0.2 Systolic blood pressure; chr11:17252987 chr11:17074654~17074744:- LIHC cis rs757081 0.579 rs11024221 ENSG00000272034.1 SNORD14A -3.86 0.000136 0.0236 -0.22 -0.2 Systolic blood pressure; chr11:17253003 chr11:17074654~17074744:- LIHC cis rs860295 0.65 rs539602 ENSG00000203761.5 MSTO2P 3.86 0.000136 0.0236 0.17 0.2 Body mass index; chr1:155929229 chr1:155745829~155750137:+ LIHC cis rs860295 0.65 rs4661151 ENSG00000203761.5 MSTO2P 3.86 0.000136 0.0236 0.17 0.2 Body mass index; chr1:155933617 chr1:155745829~155750137:+ LIHC cis rs860295 0.65 rs12024880 ENSG00000203761.5 MSTO2P 3.86 0.000136 0.0236 0.17 0.2 Body mass index; chr1:155939119 chr1:155745829~155750137:+ LIHC cis rs11651753 0.636 rs12602494 ENSG00000264920.1 RP11-6N17.4 -3.86 0.000136 0.0236 -0.21 -0.2 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47960241 chr17:47891255~47895812:- LIHC cis rs7615952 0.546 rs2979306 ENSG00000171084.14 FAM86JP 3.86 0.000136 0.0236 0.34 0.2 Blood pressure (smoking interaction); chr3:125593286 chr3:125916620~125930024:+ LIHC cis rs41341749 0.831 rs854684 ENSG00000278690.1 RP11-104J23.2 -3.86 0.000136 0.0236 -0.24 -0.2 Blood protein levels; chr17:35985179 chr17:36012504~36012891:+ LIHC cis rs7083 0.716 rs687740 ENSG00000254851.1 RP11-109L13.1 -3.86 0.000136 0.0236 -0.3 -0.2 Blood protein levels; chr11:117306887 chr11:117135528~117138582:+ LIHC cis rs11098499 0.866 rs12374244 ENSG00000245958.5 RP11-33B1.1 -3.86 0.000136 0.0236 -0.21 -0.2 Corneal astigmatism; chr4:119360817 chr4:119454791~119552025:+ LIHC cis rs11098499 0.866 rs12374352 ENSG00000245958.5 RP11-33B1.1 -3.86 0.000136 0.0236 -0.21 -0.2 Corneal astigmatism; chr4:119360822 chr4:119454791~119552025:+ LIHC cis rs2919917 0.554 rs2086755 ENSG00000254352.1 RP11-578O24.2 3.86 0.000136 0.0236 0.31 0.2 Lymphocyte counts; chr8:78701809 chr8:78723796~78724136:- LIHC cis rs17270561 0.636 rs1165216 ENSG00000216436.2 HIST1H2APS1 -3.86 0.000136 0.0236 -0.25 -0.2 Iron status biomarkers; chr6:25797743 chr6:25732497~25732827:+ LIHC cis rs8087799 0.894 rs1791736 ENSG00000273232.1 RP11-370A5.2 -3.86 0.000136 0.0236 -0.24 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22697592 chr18:22882825~22883357:- LIHC cis rs3204270 0.639 rs7215738 ENSG00000281517.1 Metazoa_SRP -3.86 0.000136 0.0236 -0.38 -0.2 Dental caries; chr17:81692817 chr17:81718849~81719095:- LIHC cis rs2976388 0.692 rs2978983 ENSG00000253741.1 CTD-2292P10.4 -3.86 0.000136 0.0236 -0.24 -0.2 Urinary tract infection frequency; chr8:142684424 chr8:142702252~142726973:- LIHC cis rs34421088 0.576 rs2572437 ENSG00000255394.4 C8orf49 -3.86 0.000136 0.0237 -0.3 -0.2 Neuroticism; chr8:11240932 chr8:11761256~11763223:+ LIHC cis rs7760535 0.794 rs3851225 ENSG00000271789.1 RP5-1112D6.7 -3.86 0.000136 0.0237 -0.2 -0.2 Metabolic traits; chr6:111503929 chr6:111297126~111298510:+ LIHC cis rs7176527 0.519 rs12148368 ENSG00000230373.7 GOLGA6L5P 3.86 0.000136 0.0237 0.2 0.2 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84563274 chr15:84507885~84516814:- LIHC cis rs673078 0.607 rs17512644 ENSG00000275759.1 RP11-131L12.3 -3.86 0.000136 0.0237 -0.42 -0.2 Glucose homeostasis traits; chr12:118359963 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs17512652 ENSG00000275759.1 RP11-131L12.3 -3.86 0.000136 0.0237 -0.42 -0.2 Glucose homeostasis traits; chr12:118361278 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs61943367 ENSG00000275759.1 RP11-131L12.3 -3.86 0.000136 0.0237 -0.42 -0.2 Glucose homeostasis traits; chr12:118366316 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs61943368 ENSG00000275759.1 RP11-131L12.3 -3.86 0.000136 0.0237 -0.42 -0.2 Glucose homeostasis traits; chr12:118366568 chr12:118428281~118428870:+ LIHC cis rs875971 0.545 rs13311962 ENSG00000273142.1 RP11-458F8.4 -3.86 0.000136 0.0237 -0.2 -0.2 Aortic root size; chr7:66603142 chr7:66902857~66906297:+ LIHC cis rs6600671 0.902 rs2222371 ENSG00000227082.1 CH17-437K3.1 3.86 0.000136 0.0237 0.28 0.2 Hip geometry; chr1:121547320 chr1:121396754~121463129:+ LIHC cis rs9896933 0.83 rs12450046 ENSG00000263063.1 RP11-388C12.1 -3.86 0.000136 0.0237 -0.27 -0.2 Bone mineral accretion in asthma (oral corticosteroid dose interaction); chr17:82832512 chr17:82713908~82716255:- LIHC cis rs10129255 0.957 rs10141052 ENSG00000211970.3 IGHV4-61 -3.86 0.000136 0.0237 -0.16 -0.2 Kawasaki disease; chr14:106776528 chr14:106639119~106639657:- LIHC cis rs10129255 0.957 rs10141009 ENSG00000211970.3 IGHV4-61 -3.86 0.000136 0.0237 -0.16 -0.2 Kawasaki disease; chr14:106776695 chr14:106639119~106639657:- LIHC cis rs6142102 0.961 rs2284389 ENSG00000275784.1 RP5-1125A11.6 -3.86 0.000136 0.0237 -0.23 -0.2 Skin pigmentation; chr20:34069035 chr20:33989480~33991818:- LIHC cis rs1979679 0.842 rs12049916 ENSG00000278733.1 RP11-425D17.1 3.86 0.000136 0.0237 0.28 0.2 Ossification of the posterior longitudinal ligament of the spine; chr12:28207052 chr12:28185625~28186190:- LIHC cis rs67311347 0.635 rs73071706 ENSG00000223797.4 ENTPD3-AS1 3.86 0.000136 0.0237 0.17 0.2 Renal cell carcinoma; chr3:40246699 chr3:40313802~40453329:- LIHC cis rs67311347 0.668 rs73071710 ENSG00000223797.4 ENTPD3-AS1 3.86 0.000136 0.0237 0.17 0.2 Renal cell carcinoma; chr3:40247096 chr3:40313802~40453329:- LIHC cis rs2904804 0.756 rs7100824 ENSG00000224251.5 RP11-499O7.7 3.86 0.000136 0.0237 0.24 0.2 Economic and political preferences (immigration/crime); chr10:4943618 chr10:4995488~4997380:+ LIHC cis rs6723108 0.627 rs62168872 ENSG00000224043.6 CCNT2-AS1 -3.86 0.000136 0.0237 -0.28 -0.2 Type 2 diabetes; chr2:134904177 chr2:134735464~134918710:- LIHC cis rs6723108 0.627 rs4954196 ENSG00000224043.6 CCNT2-AS1 -3.86 0.000136 0.0237 -0.28 -0.2 Type 2 diabetes; chr2:134904446 chr2:134735464~134918710:- LIHC cis rs6723108 0.627 rs4954197 ENSG00000224043.6 CCNT2-AS1 -3.86 0.000136 0.0237 -0.28 -0.2 Type 2 diabetes; chr2:134904674 chr2:134735464~134918710:- LIHC cis rs2842992 0.83 rs1475123 ENSG00000237927.1 RP3-393E18.2 -3.86 0.000136 0.0237 -0.26 -0.2 Age-related macular degeneration (geographic atrophy); chr6:159756975 chr6:159586955~159589169:- LIHC cis rs6452524 1 rs6452519 ENSG00000271862.1 RP11-343L5.2 3.86 0.000136 0.0237 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83133429 chr5:83049376~83050964:- LIHC cis rs17711722 0.727 rs781151 ENSG00000237310.1 GS1-124K5.4 3.86 0.000136 0.0237 0.21 0.2 Calcium levels; chr7:66014891 chr7:66493706~66495474:+ LIHC cis rs287982 1 rs287976 ENSG00000269973.1 RP11-95D17.1 3.86 0.000136 0.0237 0.19 0.2 Nonsyndromic cleft lip with cleft palate; chr2:9829559 chr2:9936360~9939590:+ LIHC cis rs2739330 0.76 rs5751761 ENSG00000228039.3 KB-1125A3.10 -3.86 0.000136 0.0237 -0.25 -0.2 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23963780~23964374:+ LIHC cis rs11651753 0.636 rs4793731 ENSG00000264920.1 RP11-6N17.4 -3.86 0.000136 0.0237 -0.21 -0.2 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47956327 chr17:47891255~47895812:- LIHC cis rs11651753 0.636 rs4793733 ENSG00000264920.1 RP11-6N17.4 -3.86 0.000136 0.0237 -0.21 -0.2 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47956616 chr17:47891255~47895812:- LIHC cis rs9652601 0.719 rs2867880 ENSG00000274038.1 RP11-66H6.4 -3.86 0.000136 0.0237 -0.25 -0.2 Systemic lupus erythematosus; chr16:11138000 chr16:11056556~11057034:+ LIHC cis rs10129255 0.5 rs1974468 ENSG00000211972.2 IGHV3-66 3.86 0.000137 0.0237 0.15 0.2 Kawasaki disease; chr14:106686149 chr14:106675017~106675544:- LIHC cis rs757081 0.648 rs214907 ENSG00000272034.1 SNORD14A -3.86 0.000137 0.0237 -0.22 -0.2 Systolic blood pressure; chr11:17223232 chr11:17074654~17074744:- LIHC cis rs2333021 1 rs4899453 ENSG00000259015.1 RP11-109N23.6 -3.86 0.000137 0.0237 -0.25 -0.2 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:73021883 chr14:72960595~72961993:+ LIHC cis rs6832769 1 rs28572116 ENSG00000272969.1 RP11-528I4.2 -3.86 0.000137 0.0237 -0.24 -0.2 Personality dimensions; chr4:55558177 chr4:55547112~55547889:+ LIHC cis rs2348418 0.831 rs2348416 ENSG00000247934.4 RP11-967K21.1 3.86 0.000137 0.0237 0.19 0.2 Lung function (FEV1);Lung function (FVC); chr12:28556283 chr12:28163298~28190738:- LIHC cis rs2243480 1 rs2257790 ENSG00000228409.4 CCT6P1 3.86 0.000137 0.0237 0.22 0.2 Diabetic kidney disease; chr7:66135463 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs316332 ENSG00000228409.4 CCT6P1 3.86 0.000137 0.0237 0.22 0.2 Diabetic kidney disease; chr7:66139312 chr7:65751142~65763354:+ LIHC cis rs4578769 0.959 rs3898593 ENSG00000265943.1 RP11-739L10.1 3.86 0.000137 0.0237 0.26 0.2 Eosinophil percentage of white cells; chr18:22909074 chr18:22699481~22933764:- LIHC cis rs4578769 0.959 rs1031651 ENSG00000265943.1 RP11-739L10.1 3.86 0.000137 0.0237 0.26 0.2 Eosinophil percentage of white cells; chr18:22915716 chr18:22699481~22933764:- LIHC cis rs4578769 0.959 rs8096389 ENSG00000265943.1 RP11-739L10.1 3.86 0.000137 0.0237 0.26 0.2 Eosinophil percentage of white cells; chr18:22921952 chr18:22699481~22933764:- LIHC cis rs4578769 0.959 rs9949696 ENSG00000265943.1 RP11-739L10.1 3.86 0.000137 0.0237 0.26 0.2 Eosinophil percentage of white cells; chr18:22923688 chr18:22699481~22933764:- LIHC cis rs4578769 0.959 rs930910 ENSG00000265943.1 RP11-739L10.1 3.86 0.000137 0.0237 0.26 0.2 Eosinophil percentage of white cells; chr18:22930178 chr18:22699481~22933764:- LIHC cis rs10129255 0.5 rs7161740 ENSG00000211972.2 IGHV3-66 3.86 0.000137 0.0237 0.15 0.2 Kawasaki disease; chr14:106776119 chr14:106675017~106675544:- LIHC cis rs17376456 0.825 rs66564678 ENSG00000251023.1 RP11-549J18.1 -3.86 0.000137 0.0238 -0.43 -0.2 Diabetic retinopathy; chr5:93830188 chr5:93860669~93863825:- LIHC cis rs2439831 0.867 rs3213991 ENSG00000166763.7 STRCP1 3.86 0.000137 0.0238 0.29 0.2 Lung cancer in ever smokers; chr15:43378082 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs7163245 ENSG00000166763.7 STRCP1 3.86 0.000137 0.0238 0.29 0.2 Lung cancer in ever smokers; chr15:43379096 chr15:43699488~43718184:- LIHC cis rs2015599 0.645 rs12578931 ENSG00000257176.2 RP11-996F15.2 -3.86 0.000137 0.0238 -0.26 -0.2 Platelet count;Mean platelet volume; chr12:29358608 chr12:29280418~29317848:- LIHC cis rs2015599 0.623 rs4931174 ENSG00000257176.2 RP11-996F15.2 -3.86 0.000137 0.0238 -0.26 -0.2 Platelet count;Mean platelet volume; chr12:29360545 chr12:29280418~29317848:- LIHC cis rs10916248 0.788 rs7543027 ENSG00000232628.4 RP11-365O16.3 3.86 0.000137 0.0238 0.26 0.2 QT interval (drug interaction); chr1:224072795 chr1:224208747~224213279:- LIHC cis rs4938303 0.549 rs11216096 ENSG00000254851.1 RP11-109L13.1 3.86 0.000137 0.0238 0.24 0.2 Triglycerides; chr11:116691864 chr11:117135528~117138582:+ LIHC cis rs6745190 0.953 rs6433883 ENSG00000236153.1 AC104076.3 3.86 0.000137 0.0238 0.28 0.2 White blood cell count; chr2:181046155 chr2:180979427~180980090:- LIHC cis rs6449502 0.92 rs158563 ENSG00000272308.1 RP11-231G3.1 -3.86 0.000137 0.0238 -0.29 -0.2 Mean platelet volume; chr5:60959177 chr5:60866457~60866935:- LIHC cis rs11096990 0.855 rs2566173 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39151111 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2711988 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39151128 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2043102 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39151292 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2711986 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39152258 chr4:39133913~39135608:+ LIHC cis rs11096990 0.75 rs2465242 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39153796 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2465243 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39154036 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2566176 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39154373 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2566178 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39155194 chr4:39133913~39135608:+ LIHC cis rs11096990 0.819 rs2435528 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39155916 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2711933 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39156090 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2566179 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39156413 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2566180 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39157381 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2566181 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39157987 chr4:39133913~39135608:+ LIHC cis rs11096990 0.819 rs2381225 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39158915 chr4:39133913~39135608:+ LIHC cis rs11096990 0.819 rs1367297 ENSG00000249685.1 RP11-360F5.3 -3.86 0.000137 0.0238 -0.28 -0.2 Cognitive function; chr4:39159614 chr4:39133913~39135608:+ LIHC cis rs9487605 1 rs9487605 ENSG00000230177.1 RP5-1112D6.4 -3.86 0.000137 0.0238 -0.2 -0.2 Inflammatory skin disease; chr6:111261682 chr6:111277932~111278742:+ LIHC cis rs10752881 1 rs10752885 ENSG00000224468.3 RP11-181K3.4 -3.86 0.000137 0.0238 -0.17 -0.2 Colorectal cancer; chr1:183013743 chr1:183138402~183141282:- LIHC cis rs27434 0.51 rs27038 ENSG00000272109.1 CTD-2260A17.3 -3.86 0.000137 0.0238 -0.28 -0.2 Ankylosing spondylitis; chr5:96777250 chr5:96804353~96806105:+ LIHC cis rs9876781 0.507 rs1824362 ENSG00000229759.1 MRPS18AP1 -3.86 0.000137 0.0238 -0.21 -0.2 Longevity; chr3:48360459 chr3:48256350~48256938:- LIHC cis rs3091242 0.866 rs11249249 ENSG00000224183.1 SDHDP6 -3.86 0.000137 0.0238 -0.23 -0.2 Erythrocyte sedimentation rate; chr1:25431643 chr1:25294164~25294643:- LIHC cis rs1344653 0.738 rs62128262 ENSG00000236204.4 LINC01376 -3.86 0.000137 0.0238 -0.24 -0.2 Pulse pressure; chr2:19551244 chr2:18986451~19346748:- LIHC cis rs2919917 0.617 rs4641056 ENSG00000254352.1 RP11-578O24.2 3.86 0.000137 0.0238 0.3 0.2 Lymphocyte counts; chr8:78670261 chr8:78723796~78724136:- LIHC cis rs2243480 1 rs10807702 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000137 0.0238 -0.23 -0.2 Diabetic kidney disease; chr7:66302856 chr7:66848496~66858136:+ LIHC cis rs6142102 0.961 rs973409 ENSG00000275784.1 RP5-1125A11.6 -3.86 0.000137 0.0238 -0.23 -0.2 Skin pigmentation; chr20:33948558 chr20:33989480~33991818:- LIHC cis rs4578769 0.76 rs7227956 ENSG00000265943.1 RP11-739L10.1 3.86 0.000137 0.0238 0.26 0.2 Eosinophil percentage of white cells; chr18:22933855 chr18:22699481~22933764:- LIHC cis rs4578769 0.842 rs7243256 ENSG00000265943.1 RP11-739L10.1 3.86 0.000137 0.0238 0.26 0.2 Eosinophil percentage of white cells; chr18:22936411 chr18:22699481~22933764:- LIHC cis rs4578769 0.842 rs9966323 ENSG00000265943.1 RP11-739L10.1 3.86 0.000137 0.0238 0.26 0.2 Eosinophil percentage of white cells; chr18:22936418 chr18:22699481~22933764:- LIHC cis rs13434995 0.635 rs1818461 ENSG00000273257.1 RP11-177J6.1 -3.86 0.000137 0.0238 -0.32 -0.2 Adiponectin levels; chr4:55379156 chr4:55387949~55388271:+ LIHC cis rs13434995 0.589 rs861029 ENSG00000273257.1 RP11-177J6.1 -3.86 0.000137 0.0238 -0.32 -0.2 Adiponectin levels; chr4:55379470 chr4:55387949~55388271:+ LIHC cis rs752590 0.887 rs68090726 ENSG00000274877.1 RP11-65I12.1 -3.86 0.000137 0.0238 -0.31 -0.2 Mucinous ovarian carcinoma; chr2:113205258 chr2:113237595~113240825:+ LIHC cis rs713477 0.817 rs55868790 ENSG00000258413.1 RP11-665C16.6 3.86 0.000137 0.0238 0.22 0.2 Pediatric bone mineral content (femoral neck); chr14:55446557 chr14:55262767~55272075:- LIHC cis rs1322639 0.531 rs11751421 ENSG00000229214.1 LINC00242 3.86 0.000137 0.0238 0.24 0.2 Pulse pressure; chr6:169174898 chr6:169788790~169798825:- LIHC cis rs2904804 0.641 rs2904802 ENSG00000224251.5 RP11-499O7.7 3.86 0.000137 0.0238 0.25 0.2 Economic and political preferences (immigration/crime); chr10:4967172 chr10:4995488~4997380:+ LIHC cis rs7208859 0.673 rs999798 ENSG00000266490.1 CTD-2349P21.9 3.86 0.000137 0.0239 0.25 0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831822 chr17:30792372~30792833:+ LIHC cis rs11779988 0.543 rs410445 ENSG00000253671.1 RP11-806O11.1 -3.86 0.000137 0.0239 -0.26 -0.2 Breast cancer; chr8:18024795 chr8:17808941~17820868:+ LIHC cis rs17482078 0.959 rs2013717 ENSG00000248734.2 CTD-2260A17.1 3.86 0.000137 0.0239 0.29 0.2 Behcet's disease;Blood protein levels; chr5:96798472 chr5:96784777~96785999:+ LIHC cis rs17482078 0.918 rs2013671 ENSG00000248734.2 CTD-2260A17.1 3.86 0.000137 0.0239 0.29 0.2 Behcet's disease;Blood protein levels; chr5:96798580 chr5:96784777~96785999:+ LIHC cis rs17482078 0.959 rs2013633 ENSG00000248734.2 CTD-2260A17.1 3.86 0.000137 0.0239 0.29 0.2 Behcet's disease;Blood protein levels; chr5:96798603 chr5:96784777~96785999:+ LIHC cis rs17482078 0.959 rs10074694 ENSG00000248734.2 CTD-2260A17.1 3.86 0.000137 0.0239 0.29 0.2 Behcet's disease;Blood protein levels; chr5:96801437 chr5:96784777~96785999:+ LIHC cis rs17482078 0.959 rs10074708 ENSG00000248734.2 CTD-2260A17.1 3.86 0.000137 0.0239 0.29 0.2 Behcet's disease;Blood protein levels; chr5:96801501 chr5:96784777~96785999:+ LIHC cis rs4561483 0.619 rs12597429 ENSG00000261560.1 RP11-166B2.3 -3.86 0.000137 0.0239 -0.22 -0.2 Testicular germ cell tumor; chr16:11968539 chr16:11881075~11882569:- LIHC cis rs1799949 0.773 rs2137990 ENSG00000267681.1 CTD-3199J23.6 3.86 0.000137 0.0239 0.2 0.2 Menopause (age at onset); chr17:43165879 chr17:43144956~43145255:+ LIHC cis rs7607369 0.58 rs7594289 ENSG00000272555.1 RP11-459I19.1 -3.86 0.000138 0.0239 -0.23 -0.2 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218787563 chr2:218818690~218819144:+ LIHC cis rs67311347 0.549 rs60249586 ENSG00000223797.4 ENTPD3-AS1 3.86 0.000138 0.0239 0.17 0.2 Renal cell carcinoma; chr3:40205168 chr3:40313802~40453329:- LIHC cis rs7945705 0.791 rs7944560 ENSG00000254860.4 TMEM9B-AS1 -3.86 0.000138 0.0239 -0.2 -0.2 Hemoglobin concentration; chr11:8795729 chr11:8964675~8977527:+ LIHC cis rs867371 0.502 rs8025964 ENSG00000259429.4 UBE2Q2P2 -3.86 0.000138 0.0239 -0.21 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82229429 chr15:82355142~82420075:+ LIHC cis rs12468226 1 rs6739198 ENSG00000272966.1 RP11-686O6.1 3.86 0.000138 0.0239 0.33 0.2 Urate levels; chr2:202492273 chr2:202336739~202337200:+ LIHC cis rs1223397 0.651 rs59639740 ENSG00000215022.6 RP1-257A7.4 -3.86 0.000138 0.0239 -0.22 -0.2 Blood pressure; chr6:13310663 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs957175 ENSG00000215022.6 RP1-257A7.4 -3.86 0.000138 0.0239 -0.22 -0.2 Blood pressure; chr6:13311011 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs2919685 ENSG00000215022.6 RP1-257A7.4 -3.86 0.000138 0.0239 -0.22 -0.2 Blood pressure; chr6:13311436 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs2439542 ENSG00000215022.6 RP1-257A7.4 -3.86 0.000138 0.0239 -0.22 -0.2 Blood pressure; chr6:13311591 chr6:13264861~13295586:- LIHC cis rs3749237 0.595 rs1464568 ENSG00000226913.1 BSN-AS2 -3.86 0.000138 0.0239 -0.26 -0.2 Resting heart rate; chr3:49420833 chr3:49549306~49554366:- LIHC cis rs9843304 0.526 rs9850213 ENSG00000244503.1 RP11-278L15.6 -3.86 0.000138 0.0239 -0.26 -0.2 Gallstone disease; chr3:149484803 chr3:149494660~149495995:+ LIHC cis rs12817211 0.502 rs17124432 ENSG00000272368.2 RP4-605O3.4 3.86 0.000138 0.0239 0.23 0.2 Colorectal or endometrial cancer; chr12:50116994 chr12:50112197~50165618:+ LIHC cis rs875971 1 rs937495 ENSG00000237310.1 GS1-124K5.4 -3.86 0.000138 0.0239 -0.18 -0.2 Aortic root size; chr7:66314811 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs2036264 ENSG00000237310.1 GS1-124K5.4 -3.86 0.000138 0.0239 -0.18 -0.2 Aortic root size; chr7:66334917 chr7:66493706~66495474:+ LIHC cis rs2439831 0.681 rs528517 ENSG00000166763.7 STRCP1 3.86 0.000138 0.0239 0.28 0.2 Lung cancer in ever smokers; chr15:43320727 chr15:43699488~43718184:- LIHC cis rs7809950 0.817 rs2712224 ENSG00000238832.1 snoU109 -3.86 0.000138 0.0239 -0.26 -0.2 Coronary artery disease; chr7:107540790 chr7:107603363~107603507:+ LIHC cis rs12908161 1 rs12905057 ENSG00000259728.4 LINC00933 3.86 0.000138 0.024 0.3 0.2 Schizophrenia; chr15:84667534 chr15:84570649~84580175:+ LIHC cis rs4938303 0.549 rs12785772 ENSG00000254851.1 RP11-109L13.1 3.86 0.000138 0.024 0.24 0.2 Triglycerides; chr11:116692892 chr11:117135528~117138582:+ LIHC cis rs7617773 0.78 rs11718350 ENSG00000228638.1 FCF1P2 -3.86 0.000138 0.024 -0.23 -0.2 Coronary artery disease; chr3:48319502 chr3:48290793~48291375:- LIHC cis rs11105298 0.891 rs8181784 ENSG00000258302.2 RP11-981P6.1 3.85 0.000138 0.024 0.27 0.2 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89434814 chr12:89561129~89594878:+ LIHC cis rs12468226 0.873 rs60722019 ENSG00000272966.1 RP11-686O6.1 3.85 0.000138 0.024 0.34 0.2 Urate levels; chr2:202282060 chr2:202336739~202337200:+ LIHC cis rs7617773 0.78 rs13082158 ENSG00000228638.1 FCF1P2 -3.85 0.000138 0.024 -0.23 -0.2 Coronary artery disease; chr3:48330980 chr3:48290793~48291375:- LIHC cis rs7617773 0.676 rs13060020 ENSG00000228638.1 FCF1P2 -3.85 0.000138 0.024 -0.23 -0.2 Coronary artery disease; chr3:48331156 chr3:48290793~48291375:- LIHC cis rs3015497 0.846 rs1565839 ENSG00000269906.1 RP11-248J18.2 3.85 0.000138 0.024 0.25 0.2 Mean platelet volume; chr14:50617307 chr14:50662511~50663178:- LIHC cis rs4865169 0.871 rs9918067 ENSG00000269949.1 RP11-738E22.3 -3.85 0.000139 0.024 -0.25 -0.2 Breast cancer; chr4:57004378 chr4:56960927~56961373:- LIHC cis rs6442522 0.606 rs13093164 ENSG00000249786.6 EAF1-AS1 3.85 0.000139 0.024 0.24 0.2 Uric acid levels; chr3:15452311 chr3:15436171~15455940:- LIHC cis rs1075265 0.605 rs805418 ENSG00000233266.1 HMGB1P31 3.85 0.000139 0.024 0.26 0.2 Chronotype;Morning vs. evening chronotype; chr2:53898634 chr2:54051334~54051760:+ LIHC cis rs6500602 0.702 rs6500605 ENSG00000278700.1 Metazoa_SRP 3.85 0.000139 0.024 0.24 0.2 Schizophrenia; chr16:4452409 chr16:4658851~4659151:+ LIHC cis rs875971 0.522 rs2949690 ENSG00000273024.4 INTS4P2 3.85 0.000139 0.024 0.24 0.2 Aortic root size; chr7:66018255 chr7:65647864~65715661:+ LIHC cis rs4561483 0.771 rs12924398 ENSG00000261560.1 RP11-166B2.3 -3.85 0.000139 0.024 -0.22 -0.2 Testicular germ cell tumor; chr16:11879091 chr16:11881075~11882569:- LIHC cis rs6517329 0.6 rs2835279 ENSG00000231106.2 LINC01436 3.85 0.000139 0.024 0.23 0.2 Schizophrenia; chr21:36112905 chr21:36005338~36007838:+ LIHC cis rs2243480 1 rs7804223 ENSG00000232546.1 RP11-458F8.1 3.85 0.000139 0.024 0.23 0.2 Diabetic kidney disease; chr7:66199572 chr7:66848496~66858136:+ LIHC cis rs4356975 0.563 rs4508963 ENSG00000250919.1 RP11-813N20.3 -3.85 0.000139 0.024 -0.21 -0.2 Obesity-related traits; chr4:69118770 chr4:69027831~69044578:+ LIHC cis rs7849270 0.959 rs2900271 ENSG00000268707.1 RP11-247A12.7 3.85 0.000139 0.024 0.22 0.2 Blood metabolite ratios; chr9:129132655 chr9:129170434~129170940:+ LIHC cis rs4073416 0.712 rs2268961 ENSG00000276116.2 FUT8-AS1 3.85 0.000139 0.0241 0.26 0.2 N-glycan levels; chr14:65680047 chr14:65411170~65412690:- LIHC cis rs4073416 0.746 rs2064694 ENSG00000276116.2 FUT8-AS1 3.85 0.000139 0.0241 0.26 0.2 N-glycan levels; chr14:65681528 chr14:65411170~65412690:- LIHC cis rs4073416 0.657 rs11622271 ENSG00000276116.2 FUT8-AS1 3.85 0.000139 0.0241 0.26 0.2 N-glycan levels; chr14:65682347 chr14:65411170~65412690:- LIHC cis rs4073416 0.746 rs12882200 ENSG00000276116.2 FUT8-AS1 3.85 0.000139 0.0241 0.26 0.2 N-glycan levels; chr14:65691143 chr14:65411170~65412690:- LIHC cis rs4073416 0.712 rs12588838 ENSG00000276116.2 FUT8-AS1 3.85 0.000139 0.0241 0.26 0.2 N-glycan levels; chr14:65695920 chr14:65411170~65412690:- LIHC cis rs2032447 0.933 rs1540275 ENSG00000242387.1 HIST1H2APS2 3.85 0.000139 0.0241 0.26 0.2 Intelligence (multi-trait analysis); chr6:26036248 chr6:25882026~25882395:- LIHC cis rs7893279 0.543 rs34237250 ENSG00000225527.1 RP11-383B4.4 3.85 0.000139 0.0241 0.29 0.2 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18602785 chr10:18531849~18533336:- LIHC cis rs881375 1 rs10760118 ENSG00000226752.6 PSMD5-AS1 -3.85 0.000139 0.0241 -0.22 -0.2 Rheumatoid arthritis; chr9:120879338 chr9:120824828~120854385:+ LIHC cis rs1005277 0.579 rs176838 ENSG00000275858.1 RP11-291L22.8 -3.85 0.000139 0.0241 -0.22 -0.2 Extrinsic epigenetic age acceleration; chr10:38082971 chr10:38450738~38451069:- LIHC cis rs7829975 0.511 rs2976902 ENSG00000173295.6 FAM86B3P 3.85 0.000139 0.0241 0.29 0.2 Mood instability; chr8:8483595 chr8:8228595~8244865:+ LIHC cis rs10510102 0.623 rs10159856 ENSG00000226864.1 ATE1-AS1 3.85 0.000139 0.0241 0.35 0.2 Breast cancer; chr10:121988292 chr10:121928312~121951965:+ LIHC cis rs7726354 0.655 rs16886034 ENSG00000264281.3 CTD-2031P19.4 3.85 0.000139 0.0241 0.41 0.2 Breast cancer (early onset); chr5:56688029 chr5:55944656~55944733:+ LIHC cis rs4925386 0.808 rs1741634 ENSG00000226332.2 RP11-157P1.4 -3.85 0.000139 0.0241 -0.2 -0.2 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62350923 chr20:62305432~62306325:- LIHC cis rs2015599 0.623 rs12581107 ENSG00000257176.2 RP11-996F15.2 -3.85 0.000139 0.0241 -0.26 -0.2 Platelet count;Mean platelet volume; chr12:29352358 chr12:29280418~29317848:- LIHC cis rs933688 1 rs6862125 ENSG00000281357.1 ARRDC3-AS1 3.85 0.000139 0.0241 0.25 0.2 Smoking behavior; chr5:91428781 chr5:91380349~91439085:+ LIHC cis rs673078 0.66 rs61943535 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000139 0.0241 -0.41 -0.2 Glucose homeostasis traits; chr12:118168307 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs76621503 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000139 0.0241 -0.41 -0.2 Glucose homeostasis traits; chr12:118179370 chr12:118428281~118428870:+ LIHC cis rs12900463 0.752 rs12904777 ENSG00000259295.5 CSPG4P12 3.85 0.000139 0.0241 0.25 0.2 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine); chr15:84872514 chr15:85191438~85213905:+ LIHC cis rs4218 0.608 rs34859729 ENSG00000277144.1 RP11-59H7.4 -3.85 0.000139 0.0241 -0.23 -0.2 Social communication problems; chr15:59070117 chr15:59115547~59116089:- LIHC cis rs4218 0.648 rs877269 ENSG00000277144.1 RP11-59H7.4 -3.85 0.000139 0.0241 -0.23 -0.2 Social communication problems; chr15:59081595 chr15:59115547~59116089:- LIHC cis rs4218 0.648 rs35769647 ENSG00000277144.1 RP11-59H7.4 -3.85 0.000139 0.0241 -0.23 -0.2 Social communication problems; chr15:59081670 chr15:59115547~59116089:- LIHC cis rs1862618 0.62 rs2591967 ENSG00000271828.1 CTD-2310F14.1 -3.85 0.000139 0.0241 -0.27 -0.2 Initial pursuit acceleration; chr5:56937724 chr5:56927874~56929573:+ LIHC cis rs919433 0.963 rs1896857 ENSG00000231621.1 AC013264.2 3.85 0.000139 0.0241 0.18 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197299806 chr2:197197991~197199273:+ LIHC cis rs6452524 1 rs17284288 ENSG00000271862.1 RP11-343L5.2 3.85 0.000139 0.0241 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83148997 chr5:83049376~83050964:- LIHC cis rs10895987 0.955 rs12365171 ENSG00000254614.2 AP003068.23 3.85 0.00014 0.0241 0.38 0.2 Blood protein levels; chr11:65161417 chr11:65177606~65181834:- LIHC cis rs17032980 0.744 rs17032976 ENSG00000232046.5 AC007392.3 -3.85 0.00014 0.0242 -0.34 -0.2 Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia; chr2:67075168 chr2:66574030~66730157:+ LIHC cis rs12091564 1 rs12091564 ENSG00000276509.1 CH17-353B19.1 3.85 0.00014 0.0242 0.35 0.2 Coronary heart disease (SNP X SNP interaction); chr1:146039391 chr1:146235806~146237807:+ LIHC cis rs944990 0.557 rs10761237 ENSG00000227603.1 RP11-165J3.6 3.85 0.00014 0.0242 0.21 0.2 Body mass index; chr9:93578535 chr9:93435332~93437121:- LIHC cis rs950880 0.71 rs17027166 ENSG00000234389.1 AC007278.3 -3.85 0.00014 0.0242 -0.21 -0.2 Serum protein levels (sST2); chr2:102438960 chr2:102438713~102440475:+ LIHC cis rs13434995 0.589 rs62306207 ENSG00000273257.1 RP11-177J6.1 -3.85 0.00014 0.0242 -0.32 -0.2 Adiponectin levels; chr4:55384548 chr4:55387949~55388271:+ LIHC cis rs4578769 0.722 rs4265922 ENSG00000266850.1 RP11-370A5.1 -3.85 0.00014 0.0242 -0.23 -0.2 Eosinophil percentage of white cells; chr18:22983169 chr18:22723491~22907721:- LIHC cis rs2015599 0.623 rs1072724 ENSG00000257176.2 RP11-996F15.2 3.85 0.00014 0.0242 0.25 0.2 Platelet count;Mean platelet volume; chr12:29289205 chr12:29280418~29317848:- LIHC cis rs2015599 0.623 rs7358667 ENSG00000257176.2 RP11-996F15.2 3.85 0.00014 0.0242 0.25 0.2 Platelet count;Mean platelet volume; chr12:29290236 chr12:29280418~29317848:- LIHC cis rs2015599 0.623 rs3782505 ENSG00000257176.2 RP11-996F15.2 3.85 0.00014 0.0242 0.25 0.2 Platelet count;Mean platelet volume; chr12:29292236 chr12:29280418~29317848:- LIHC cis rs9595908 0.709 rs3752476 ENSG00000212293.1 SNORA16 -3.85 0.00014 0.0242 -0.23 -0.2 Body mass index; chr13:32770965 chr13:32420390~32420516:- LIHC cis rs1062177 0.95 rs59580263 ENSG00000253921.1 CTB-113P19.3 -3.85 0.00014 0.0242 -0.23 -0.2 Preschool internalizing problems; chr5:151890016 chr5:151753992~151767247:+ LIHC cis rs10975870 0.847 rs10975912 ENSG00000236924.1 RP11-390F4.6 -3.85 0.00014 0.0242 -0.32 -0.2 Body mass index; chr9:6933372 chr9:6645956~6670635:+ LIHC cis rs10975870 0.847 rs10975917 ENSG00000236924.1 RP11-390F4.6 -3.85 0.00014 0.0242 -0.32 -0.2 Body mass index; chr9:6937491 chr9:6645956~6670635:+ LIHC cis rs2253762 0.54 rs7358186 ENSG00000226864.1 ATE1-AS1 3.85 0.00014 0.0242 0.35 0.2 Breast cancer; chr10:122000816 chr10:121928312~121951965:+ LIHC cis rs2179367 0.632 rs12197598 ENSG00000231760.4 RP11-350J20.5 3.85 0.00014 0.0242 0.33 0.2 Dupuytren's disease; chr6:149385418 chr6:149796151~149826294:- LIHC cis rs11096990 0.892 rs11937540 ENSG00000249685.1 RP11-360F5.3 -3.85 0.00014 0.0242 -0.28 -0.2 Cognitive function; chr4:39179897 chr4:39133913~39135608:+ LIHC cis rs7474896 1 rs734512 ENSG00000263064.2 RP11-291L22.7 -3.85 0.00014 0.0242 -0.28 -0.2 Obesity (extreme); chr10:37684144 chr10:38448689~38448949:+ LIHC cis rs9876781 1 rs6442117 ENSG00000229759.1 MRPS18AP1 -3.85 0.00014 0.0242 -0.21 -0.2 Longevity; chr3:48378407 chr3:48256350~48256938:- LIHC cis rs748404 0.697 rs471122 ENSG00000205771.5 CATSPER2P1 3.85 0.00014 0.0243 0.25 0.2 Lung cancer; chr15:43266376 chr15:43726918~43747094:- LIHC cis rs67311347 1 rs66841330 ENSG00000223797.4 ENTPD3-AS1 3.85 0.00014 0.0243 0.17 0.2 Renal cell carcinoma; chr3:40489632 chr3:40313802~40453329:- LIHC cis rs6445975 0.667 rs3773004 ENSG00000272360.1 RP11-359I18.5 -3.85 0.00014 0.0243 -0.24 -0.2 Systemic lupus erythematosus; chr3:58283724 chr3:58490830~58491291:- LIHC cis rs367615 0.66 rs10477972 ENSG00000249476.1 CTD-2587M2.1 3.85 0.00014 0.0243 0.24 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109496250 chr5:109237120~109326369:- LIHC cis rs367615 0.66 rs4632850 ENSG00000249476.1 CTD-2587M2.1 3.85 0.00014 0.0243 0.24 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109497182 chr5:109237120~109326369:- LIHC cis rs4925386 1 rs4925386 ENSG00000226332.2 RP11-157P1.4 3.85 0.00014 0.0243 0.21 0.2 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62345988 chr20:62305432~62306325:- LIHC cis rs2346177 0.554 rs13002880 ENSG00000236824.1 BCYRN1 -3.85 0.00014 0.0243 -0.26 -0.2 HDL cholesterol; chr2:46480990 chr2:47331060~47344517:+ LIHC cis rs2346177 0.554 rs34854267 ENSG00000236824.1 BCYRN1 -3.85 0.00014 0.0243 -0.26 -0.2 HDL cholesterol; chr2:46481403 chr2:47331060~47344517:+ LIHC cis rs2346177 0.554 rs36006825 ENSG00000236824.1 BCYRN1 -3.85 0.00014 0.0243 -0.26 -0.2 HDL cholesterol; chr2:46481806 chr2:47331060~47344517:+ LIHC cis rs2346177 0.519 rs2121698 ENSG00000236824.1 BCYRN1 -3.85 0.00014 0.0243 -0.26 -0.2 HDL cholesterol; chr2:46482432 chr2:47331060~47344517:+ LIHC cis rs801193 0.805 rs12532355 ENSG00000224316.1 RP11-479O9.2 -3.85 0.000141 0.0243 -0.19 -0.2 Aortic root size; chr7:66605597 chr7:65773620~65802067:+ LIHC cis rs11096990 0.964 rs7678689 ENSG00000249685.1 RP11-360F5.3 -3.85 0.000141 0.0243 -0.28 -0.2 Cognitive function; chr4:39261140 chr4:39133913~39135608:+ LIHC cis rs1005277 0.579 rs2505240 ENSG00000099251.13 HSD17B7P2 3.85 0.000141 0.0243 0.24 0.2 Extrinsic epigenetic age acceleration; chr10:38153491 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2505241 ENSG00000099251.13 HSD17B7P2 3.85 0.000141 0.0243 0.24 0.2 Extrinsic epigenetic age acceleration; chr10:38153493 chr10:38356380~38378505:+ LIHC cis rs6452524 1 rs10037872 ENSG00000271862.1 RP11-343L5.2 3.85 0.000141 0.0243 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83144101 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs62374374 ENSG00000271862.1 RP11-343L5.2 3.85 0.000141 0.0243 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83144838 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs1382372 ENSG00000271862.1 RP11-343L5.2 3.85 0.000141 0.0243 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83145237 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs1382371 ENSG00000271862.1 RP11-343L5.2 3.85 0.000141 0.0243 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83145300 chr5:83049376~83050964:- LIHC cis rs6452524 1 rs2386240 ENSG00000271862.1 RP11-343L5.2 3.85 0.000141 0.0243 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83147192 chr5:83049376~83050964:- LIHC cis rs12209785 0.727 rs2031966 ENSG00000231769.2 RP1-8B1.4 3.85 0.000141 0.0243 0.3 0.2 Survival in pancreatic cancer; chr6:45527999 chr6:46097093~46129706:- LIHC cis rs853679 1 rs1679709 ENSG00000204709.4 LINC01556 -3.85 0.000141 0.0243 -0.34 -0.2 Depression; chr6:28260564 chr6:28943877~28944537:+ LIHC cis rs853679 1 rs1778511 ENSG00000204709.4 LINC01556 -3.85 0.000141 0.0243 -0.34 -0.2 Depression; chr6:28261633 chr6:28943877~28944537:+ LIHC cis rs12935418 1 rs62054589 ENSG00000261061.1 RP11-303E16.2 -3.85 0.000141 0.0243 -0.27 -0.2 Mean corpuscular volume; chr16:81035143 chr16:81030770~81031485:+ LIHC cis rs1318937 0.764 rs58768954 ENSG00000224660.1 SH3BP5-AS1 3.85 0.000141 0.0243 0.19 0.2 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15198798 chr3:15254184~15264493:+ LIHC cis rs7617773 0.78 rs7653152 ENSG00000228638.1 FCF1P2 -3.85 0.000141 0.0243 -0.23 -0.2 Coronary artery disease; chr3:48320607 chr3:48290793~48291375:- LIHC cis rs7315621 0.93 rs7297317 ENSG00000279700.1 RP13-554M15.2 3.85 0.000141 0.0243 0.15 0.2 Longevity; chr12:131595814 chr12:132565071~132566425:+ LIHC cis rs1062177 0.855 rs6892117 ENSG00000253921.1 CTB-113P19.3 3.85 0.000141 0.0243 0.23 0.2 Preschool internalizing problems; chr5:151885424 chr5:151753992~151767247:+ LIHC cis rs11763353 0.569 rs9987013 ENSG00000235828.5 RPL36AP26 -3.85 0.000141 0.0244 -0.19 -0.2 Blood trace element (Zn levels); chr7:15568201 chr7:15701435~15701752:- LIHC cis rs8035452 0.857 rs3131604 ENSG00000273674.3 CTD-2378E12.1 3.85 0.000141 0.0244 0.25 0.2 Alzheimer's disease (late onset); chr15:50521842 chr15:50839875~50908599:- LIHC cis rs8035452 0.857 rs3131603 ENSG00000273674.3 CTD-2378E12.1 3.85 0.000141 0.0244 0.25 0.2 Alzheimer's disease (late onset); chr15:50522037 chr15:50839875~50908599:- LIHC cis rs2808510 0.758 rs4317838 ENSG00000230623.2 RP11-469A15.2 3.85 0.000141 0.0244 0.24 0.2 Myopia; chr1:200452318 chr1:200473920~200478293:+ LIHC cis rs7412746 0.611 rs16827671 ENSG00000231073.1 RP11-316M1.3 3.85 0.000141 0.0244 0.21 0.2 Melanoma; chr1:150766283 chr1:150973123~150975534:+ LIHC cis rs7412746 0.611 rs11204726 ENSG00000231073.1 RP11-316M1.3 3.85 0.000141 0.0244 0.21 0.2 Melanoma; chr1:150771016 chr1:150973123~150975534:+ LIHC cis rs7412746 0.553 rs59337856 ENSG00000231073.1 RP11-316M1.3 3.85 0.000141 0.0244 0.21 0.2 Melanoma; chr1:150773930 chr1:150973123~150975534:+ LIHC cis rs7412746 0.611 rs6660084 ENSG00000231073.1 RP11-316M1.3 3.85 0.000141 0.0244 0.21 0.2 Melanoma; chr1:150776327 chr1:150973123~150975534:+ LIHC cis rs7412746 0.611 rs10888394 ENSG00000231073.1 RP11-316M1.3 3.85 0.000141 0.0244 0.21 0.2 Melanoma; chr1:150777437 chr1:150973123~150975534:+ LIHC cis rs1005277 0.579 rs2505194 ENSG00000275858.1 RP11-291L22.8 3.85 0.000141 0.0244 0.22 0.2 Extrinsic epigenetic age acceleration; chr10:38104953 chr10:38450738~38451069:- LIHC cis rs673078 0.607 rs61943404 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000141 0.0244 -0.41 -0.2 Glucose homeostasis traits; chr12:118402062 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs7136676 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000141 0.0244 -0.41 -0.2 Glucose homeostasis traits; chr12:118403605 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs17441033 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000141 0.0244 -0.41 -0.2 Glucose homeostasis traits; chr12:118404101 chr12:118428281~118428870:+ LIHC cis rs673078 0.562 rs61943405 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000141 0.0244 -0.41 -0.2 Glucose homeostasis traits; chr12:118405030 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs61943406 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000141 0.0244 -0.41 -0.2 Glucose homeostasis traits; chr12:118405767 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs17441061 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000141 0.0244 -0.41 -0.2 Glucose homeostasis traits; chr12:118409847 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs17441075 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000141 0.0244 -0.41 -0.2 Glucose homeostasis traits; chr12:118410542 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs965524 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000141 0.0244 -0.41 -0.2 Glucose homeostasis traits; chr12:118412361 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs74685643 ENSG00000275759.1 RP11-131L12.3 -3.85 0.000141 0.0244 -0.41 -0.2 Glucose homeostasis traits; chr12:118412761 chr12:118428281~118428870:+ LIHC cis rs6496667 0.509 rs6496677 ENSG00000213471.7 TTLL13P 3.85 0.000141 0.0244 0.27 0.2 Rheumatoid arthritis; chr15:90447126 chr15:90249530~90265482:+ LIHC cis rs10510102 0.688 rs74570569 ENSG00000273891.1 RP11-500G22.5 3.85 0.000141 0.0244 0.27 0.2 Breast cancer; chr10:121945347 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs7076727 ENSG00000273891.1 RP11-500G22.5 3.85 0.000141 0.0244 0.27 0.2 Breast cancer; chr10:121947000 chr10:121965764~121967700:+ LIHC cis rs10510102 0.745 rs7076882 ENSG00000273891.1 RP11-500G22.5 3.85 0.000141 0.0244 0.27 0.2 Breast cancer; chr10:121947039 chr10:121965764~121967700:+ LIHC cis rs10510102 0.872 rs7077035 ENSG00000273891.1 RP11-500G22.5 3.85 0.000141 0.0244 0.27 0.2 Breast cancer; chr10:121947130 chr10:121965764~121967700:+ LIHC cis rs244293 0.965 rs2529506 ENSG00000275710.1 RP11-257O5.4 3.85 0.000141 0.0244 0.22 0.2 Menarche (age at onset); chr17:55133816 chr17:54964474~54964679:+ LIHC cis rs79040073 0.765 rs7169304 ENSG00000259531.2 RP11-295H24.3 3.85 0.000141 0.0244 0.29 0.2 Lung cancer in ever smokers; chr15:49186829 chr15:49365124~49366685:- LIHC cis rs720475 1 rs720475 ENSG00000204959.4 ARHGEF34P -3.85 0.000141 0.0244 -0.29 -0.2 Breast cancer; chr7:144377836 chr7:144272445~144286966:- LIHC cis rs2361701 0.636 rs1982244 ENSG00000279259.1 RP11-334C17.3 3.85 0.000141 0.0244 0.19 0.2 IgG glycosylation; chr17:80095149 chr17:80147250~80148596:+ LIHC cis rs875971 0.522 rs1968127 ENSG00000224316.1 RP11-479O9.2 -3.85 0.000141 0.0244 -0.19 -0.2 Aortic root size; chr7:66591816 chr7:65773620~65802067:+ LIHC cis rs6163 0.508 rs11191381 ENSG00000236937.2 PTGES3P4 3.85 0.000141 0.0244 0.3 0.2 Waist circumference;Hip circumference; chr10:102733687 chr10:102845595~102845950:+ LIHC cis rs6163 0.54 rs11191385 ENSG00000236937.2 PTGES3P4 3.85 0.000141 0.0244 0.3 0.2 Waist circumference;Hip circumference; chr10:102753292 chr10:102845595~102845950:+ LIHC cis rs6700559 0.654 rs66717951 ENSG00000260088.1 RP11-92G12.3 3.85 0.000141 0.0244 0.26 0.2 Coronary artery disease; chr1:200626437 chr1:200669507~200694250:+ LIHC cis rs9951150 1 rs1011339 ENSG00000267013.4 CTD-2171N6.1 3.85 0.000141 0.0244 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55153832 chr18:55105904~55124306:- LIHC cis rs9951150 1 rs9951150 ENSG00000267013.4 CTD-2171N6.1 3.85 0.000141 0.0244 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55153893 chr18:55105904~55124306:- LIHC cis rs340849 0.967 rs11120231 ENSG00000274895.1 RP11-478J18.2 3.85 0.000141 0.0244 0.21 0.2 Alzheimer's disease; chr1:213936809 chr1:213983793~213986419:- LIHC cis rs875971 0.838 rs2173570 ENSG00000237310.1 GS1-124K5.4 -3.85 0.000142 0.0244 -0.18 -0.2 Aortic root size; chr7:66297976 chr7:66493706~66495474:+ LIHC cis rs12908161 0.92 rs12904605 ENSG00000259728.4 LINC00933 3.85 0.000142 0.0244 0.3 0.2 Schizophrenia; chr15:84658188 chr15:84570649~84580175:+ LIHC cis rs9747201 0.962 rs35051180 ENSG00000279692.1 RP11-1055B8.1 -3.85 0.000142 0.0244 -0.35 -0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82177170 chr17:81395609~81397144:- LIHC cis rs9747201 1 rs56283054 ENSG00000279692.1 RP11-1055B8.1 -3.85 0.000142 0.0244 -0.35 -0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82177450 chr17:81395609~81397144:- LIHC cis rs6832769 1 rs3805157 ENSG00000272969.1 RP11-528I4.2 3.85 0.000142 0.0244 0.24 0.2 Personality dimensions; chr4:55497936 chr4:55547112~55547889:+ LIHC cis rs6832769 1 rs2177129 ENSG00000272969.1 RP11-528I4.2 3.85 0.000142 0.0244 0.24 0.2 Personality dimensions; chr4:55499247 chr4:55547112~55547889:+ LIHC cis rs6832769 0.89 rs1980273 ENSG00000272969.1 RP11-528I4.2 3.85 0.000142 0.0244 0.24 0.2 Personality dimensions; chr4:55501234 chr4:55547112~55547889:+ LIHC cis rs6832769 1 rs6819660 ENSG00000272969.1 RP11-528I4.2 3.85 0.000142 0.0244 0.24 0.2 Personality dimensions; chr4:55508410 chr4:55547112~55547889:+ LIHC cis rs14027 0.921 rs1960438 ENSG00000279347.1 RP11-85I17.2 3.85 0.000142 0.0244 0.2 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119848193 chr8:119838736~119840385:- LIHC cis rs6860806 0.507 rs156322 ENSG00000263597.1 MIR3936 3.85 0.000142 0.0244 0.22 0.2 Breast cancer; chr5:132318232 chr5:132365490~132365599:- LIHC cis rs1115240 0.574 rs17496682 ENSG00000257842.4 NOVA1-AS1 3.85 0.000142 0.0244 0.21 0.2 Educational attainment (years of education); chr14:26450701 chr14:26598412~26806467:+ LIHC cis rs1405130 0.967 rs11674748 ENSG00000224287.2 MSL3P1 3.85 0.000142 0.0244 0.24 0.2 Coronary artery disease; chr2:234660801 chr2:233865437~233868444:- LIHC cis rs10829156 0.786 rs7077786 ENSG00000225527.1 RP11-383B4.4 -3.85 0.000142 0.0245 -0.34 -0.2 Sudden cardiac arrest; chr10:18603453 chr10:18531849~18533336:- LIHC cis rs1816213 0.744 rs34104881 ENSG00000273466.1 RP11-548H3.1 -3.85 0.000142 0.0245 -0.33 -0.2 Diastolic blood pressure; chr2:218487168 chr2:218633256~218634014:- LIHC cis rs10129255 1 rs8012033 ENSG00000211970.3 IGHV4-61 -3.85 0.000142 0.0245 -0.16 -0.2 Kawasaki disease; chr14:106678854 chr14:106639119~106639657:- LIHC cis rs10129255 0.5 rs6576232 ENSG00000211972.2 IGHV3-66 3.85 0.000142 0.0245 0.15 0.2 Kawasaki disease; chr14:106787090 chr14:106675017~106675544:- LIHC cis rs4927850 0.752 rs7624460 ENSG00000207650.1 MIR570 3.85 0.000142 0.0245 0.22 0.2 Pancreatic cancer; chr3:196021659 chr3:195699401~195699497:+ LIHC cis rs950169 0.959 rs12911210 ENSG00000259728.4 LINC00933 3.85 0.000142 0.0245 0.32 0.2 Schizophrenia; chr15:84123331 chr15:84570649~84580175:+ LIHC cis rs875971 0.706 rs1643374 ENSG00000273024.4 INTS4P2 -3.85 0.000142 0.0245 -0.24 -0.2 Aortic root size; chr7:66407695 chr7:65647864~65715661:+ LIHC cis rs4356203 0.905 rs10832743 ENSG00000260196.1 RP1-239B22.5 -3.85 0.000142 0.0245 -0.24 -0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17194933 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs550667 ENSG00000260196.1 RP1-239B22.5 -3.85 0.000142 0.0245 -0.24 -0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17197428 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs656623 ENSG00000260196.1 RP1-239B22.5 -3.85 0.000142 0.0245 -0.24 -0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17197632 chr11:17380649~17383531:+ LIHC cis rs17508449 0.819 rs4589108 ENSG00000232450.1 RP4-730K3.3 -3.85 0.000142 0.0245 -0.27 -0.2 Leprosy; chr1:113717003 chr1:113698884~113699631:- LIHC cis rs1005277 0.565 rs2474565 ENSG00000276805.1 RP11-291L22.6 3.85 0.000142 0.0245 0.25 0.2 Extrinsic epigenetic age acceleration; chr10:38091900 chr10:38451030~38451785:+ LIHC cis rs10129255 0.957 rs6576228 ENSG00000211970.3 IGHV4-61 -3.85 0.000142 0.0245 -0.16 -0.2 Kawasaki disease; chr14:106778401 chr14:106639119~106639657:- LIHC cis rs2274273 0.588 rs2297816 ENSG00000258413.1 RP11-665C16.6 -3.85 0.000142 0.0245 -0.25 -0.2 Protein biomarker; chr14:55366320 chr14:55262767~55272075:- LIHC cis rs803903 0.57 rs56147233 ENSG00000230894.1 RP11-67K19.3 3.85 0.000142 0.0245 0.28 0.2 Breast cancer; chr9:116466145 chr9:116568449~116586328:+ LIHC cis rs2243480 1 rs313807 ENSG00000232546.1 RP11-458F8.1 -3.85 0.000142 0.0245 -0.23 -0.2 Diabetic kidney disease; chr7:66034494 chr7:66848496~66858136:+ LIHC cis rs2243480 0.901 rs313808 ENSG00000232546.1 RP11-458F8.1 -3.85 0.000142 0.0245 -0.23 -0.2 Diabetic kidney disease; chr7:66034886 chr7:66848496~66858136:+ LIHC cis rs17772222 0.876 rs58655091 ENSG00000258789.1 RP11-507K2.3 -3.85 0.000142 0.0245 -0.24 -0.2 Coronary artery calcification; chr14:88748567 chr14:88551597~88552493:+ LIHC cis rs2253762 0.507 rs12264894 ENSG00000276742.1 RP11-500G22.4 3.85 0.000142 0.0245 0.33 0.2 Breast cancer; chr10:121992087 chr10:121956782~121957098:+ LIHC cis rs42490 1 rs447618 ENSG00000251136.7 RP11-37B2.1 -3.85 0.000142 0.0245 -0.18 -0.2 Leprosy; chr8:89773457 chr8:89609409~89757727:- LIHC cis rs6860806 0.507 rs272868 ENSG00000263597.1 MIR3936 3.85 0.000142 0.0245 0.22 0.2 Breast cancer; chr5:132345058 chr5:132365490~132365599:- LIHC cis rs10857712 0.95 rs10857711 ENSG00000214279.11 SCART1 -3.85 0.000142 0.0245 -0.25 -0.2 Systemic lupus erythematosus; chr10:133410555 chr10:133453928~133523558:+ LIHC cis rs987724 0.515 rs344087 ENSG00000243926.1 TIPARP-AS1 3.85 0.000142 0.0245 0.23 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156842608 chr3:156671862~156674378:- LIHC cis rs987724 0.515 rs4680309 ENSG00000243926.1 TIPARP-AS1 3.85 0.000142 0.0245 0.23 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156865807 chr3:156671862~156674378:- LIHC cis rs987724 0.515 rs2874488 ENSG00000243926.1 TIPARP-AS1 3.85 0.000142 0.0245 0.23 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156868027 chr3:156671862~156674378:- LIHC cis rs987724 0.515 rs6765353 ENSG00000243926.1 TIPARP-AS1 3.85 0.000142 0.0245 0.23 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156868755 chr3:156671862~156674378:- LIHC cis rs987724 0.515 rs7638330 ENSG00000243926.1 TIPARP-AS1 3.85 0.000142 0.0245 0.23 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156869976 chr3:156671862~156674378:- LIHC cis rs987724 0.515 rs6441101 ENSG00000243926.1 TIPARP-AS1 3.85 0.000142 0.0245 0.23 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156875409 chr3:156671862~156674378:- LIHC cis rs4578769 0.836 rs3844227 ENSG00000266850.1 RP11-370A5.1 3.85 0.000142 0.0245 0.23 0.2 Eosinophil percentage of white cells; chr18:22871067 chr18:22723491~22907721:- LIHC cis rs9565309 0.579 rs9573977 ENSG00000274898.1 AC001226.7 3.85 0.000142 0.0246 0.34 0.2 Morning vs. evening chronotype; chr13:77012290 chr13:77027944~77028482:+ LIHC cis rs4356203 0.905 rs11024158 ENSG00000260196.1 RP1-239B22.5 3.85 0.000142 0.0246 0.24 0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17103621 chr11:17380649~17383531:+ LIHC cis rs875971 0.508 rs6947808 ENSG00000273024.4 INTS4P2 3.85 0.000142 0.0246 0.22 0.2 Aortic root size; chr7:66580095 chr7:65647864~65715661:+ LIHC cis rs4578769 0.729 rs16973538 ENSG00000265943.1 RP11-739L10.1 3.85 0.000142 0.0246 0.27 0.2 Eosinophil percentage of white cells; chr18:22899823 chr18:22699481~22933764:- LIHC cis rs6723108 0.517 rs6729702 ENSG00000224043.6 CCNT2-AS1 -3.85 0.000143 0.0246 -0.24 -0.2 Type 2 diabetes; chr2:134844586 chr2:134735464~134918710:- LIHC cis rs2243480 1 rs2420171 ENSG00000228409.4 CCT6P1 -3.85 0.000143 0.0246 -0.22 -0.2 Diabetic kidney disease; chr7:66172773 chr7:65751142~65763354:+ LIHC cis rs10256972 0.933 rs35696159 ENSG00000199023.2 MIR339 -3.85 0.000143 0.0246 -0.23 -0.2 Endometriosis;Longevity; chr7:1007558 chr7:1022935~1023045:- LIHC cis rs11105298 0.891 rs11105287 ENSG00000258302.2 RP11-981P6.1 3.85 0.000143 0.0246 0.27 0.2 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89435693 chr12:89561129~89594878:+ LIHC cis rs1005277 0.522 rs1208681 ENSG00000276805.1 RP11-291L22.6 3.85 0.000143 0.0246 0.24 0.2 Extrinsic epigenetic age acceleration; chr10:37804047 chr10:38451030~38451785:+ LIHC cis rs7674212 0.531 rs4698875 ENSG00000248971.2 KRT8P46 -3.85 0.000143 0.0246 -0.21 -0.2 Type 2 diabetes; chr4:103012211 chr4:102728746~102730171:- LIHC cis rs931127 0.719 rs2170082 ENSG00000265874.1 MIR4489 -3.85 0.000143 0.0246 -0.23 -0.2 Systemic lupus erythematosus; chr11:65687324 chr11:65649192~65649253:+ LIHC cis rs1816213 0.744 rs3755040 ENSG00000273466.1 RP11-548H3.1 -3.85 0.000143 0.0246 -0.31 -0.2 Diastolic blood pressure; chr2:218577702 chr2:218633256~218634014:- LIHC cis rs7412746 0.611 rs1889740 ENSG00000231073.1 RP11-316M1.3 3.85 0.000143 0.0246 0.2 0.2 Melanoma; chr1:150827279 chr1:150973123~150975534:+ LIHC cis rs9733 0.519 rs11800855 ENSG00000231073.1 RP11-316M1.3 3.85 0.000143 0.0246 0.2 0.2 Tonsillectomy; chr1:150828519 chr1:150973123~150975534:+ LIHC cis rs6471393 0.929 rs58575315 ENSG00000253848.1 RP11-10N23.5 3.85 0.000143 0.0246 0.22 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93749495 chr8:93741193~93744534:+ LIHC cis rs6471393 0.929 rs62525164 ENSG00000253848.1 RP11-10N23.5 3.85 0.000143 0.0246 0.22 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93750084 chr8:93741193~93744534:+ LIHC cis rs4938303 0.549 rs12785990 ENSG00000254851.1 RP11-109L13.1 3.85 0.000143 0.0246 0.24 0.2 Triglycerides; chr11:116692990 chr11:117135528~117138582:+ LIHC cis rs6860806 0.507 rs270606 ENSG00000263597.1 MIR3936 3.85 0.000143 0.0246 0.22 0.2 Breast cancer; chr5:132315174 chr5:132365490~132365599:- LIHC cis rs643506 0.874 rs4936786 ENSG00000230911.1 PPIHP1 -3.85 0.000143 0.0246 -0.27 -0.2 Breast cancer; chr11:111856504 chr11:112029858~112030367:- LIHC cis rs2836974 0.544 rs8128919 ENSG00000255568.3 BRWD1-AS2 3.85 0.000143 0.0246 0.19 0.2 Cognitive function; chr21:39339936 chr21:39313935~39314962:+ LIHC cis rs2243480 1 rs781157 ENSG00000232546.1 RP11-458F8.1 -3.85 0.000143 0.0246 -0.23 -0.2 Diabetic kidney disease; chr7:66013324 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs781156 ENSG00000232546.1 RP11-458F8.1 -3.85 0.000143 0.0246 -0.23 -0.2 Diabetic kidney disease; chr7:66014154 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs781149 ENSG00000232546.1 RP11-458F8.1 -3.85 0.000143 0.0246 -0.23 -0.2 Diabetic kidney disease; chr7:66016297 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs451396 ENSG00000232546.1 RP11-458F8.1 -3.85 0.000143 0.0246 -0.23 -0.2 Diabetic kidney disease; chr7:66019087 chr7:66848496~66858136:+ LIHC cis rs2243480 0.901 rs58207111 ENSG00000232546.1 RP11-458F8.1 -3.85 0.000143 0.0246 -0.23 -0.2 Diabetic kidney disease; chr7:66021736 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1167613 ENSG00000232546.1 RP11-458F8.1 -3.85 0.000143 0.0246 -0.23 -0.2 Diabetic kidney disease; chr7:66022452 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs1715235 ENSG00000232546.1 RP11-458F8.1 -3.85 0.000143 0.0246 -0.23 -0.2 Diabetic kidney disease; chr7:66023407 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs313799 ENSG00000232546.1 RP11-458F8.1 -3.85 0.000143 0.0246 -0.23 -0.2 Diabetic kidney disease; chr7:66029343 chr7:66848496~66858136:+ LIHC cis rs748404 0.723 rs560134 ENSG00000205771.5 CATSPER2P1 -3.85 0.000143 0.0246 -0.24 -0.2 Lung cancer; chr15:43263501 chr15:43726918~43747094:- LIHC cis rs9595908 0.869 rs7998956 ENSG00000212293.1 SNORA16 3.85 0.000143 0.0246 0.23 0.2 Body mass index; chr13:32622239 chr13:32420390~32420516:- LIHC cis rs7712401 0.601 rs30045 ENSG00000263432.2 RN7SL689P 3.85 0.000143 0.0246 0.29 0.2 Mean platelet volume; chr5:122935924 chr5:123022487~123022783:- LIHC cis rs559928 0.548 rs11231713 ENSG00000236935.1 AP003774.1 3.85 0.000143 0.0246 0.32 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64164377 chr11:64325050~64329504:- LIHC cis rs893363 0.623 rs877483 ENSG00000271916.1 RP11-884K10.6 3.85 0.000143 0.0246 0.28 0.2 Axial length; chr3:53812714 chr3:53797764~53798019:- LIHC cis rs755249 0.565 rs4660846 ENSG00000182109.6 RP11-69E11.4 -3.85 0.000143 0.0246 -0.25 -0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39583839 chr1:39522280~39546187:- LIHC cis rs1799922 0.693 rs339085 ENSG00000273270.1 RP11-212P7.2 3.85 0.000143 0.0247 0.26 0.2 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr7:128783709 chr7:128524016~128531069:- LIHC cis rs367615 0.661 rs9326773 ENSG00000249476.1 CTD-2587M2.1 3.85 0.000143 0.0247 0.24 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109497822 chr5:109237120~109326369:- LIHC cis rs1799949 0.864 rs60309406 ENSG00000267681.1 CTD-3199J23.6 -3.85 0.000143 0.0247 -0.2 -0.2 Menopause (age at onset); chr17:43358297 chr17:43144956~43145255:+ LIHC cis rs1405130 0.967 rs11688510 ENSG00000224287.2 MSL3P1 3.85 0.000143 0.0247 0.24 0.2 Coronary artery disease; chr2:234658308 chr2:233865437~233868444:- LIHC cis rs1405130 0.967 rs1405131 ENSG00000224287.2 MSL3P1 3.85 0.000143 0.0247 0.24 0.2 Coronary artery disease; chr2:234658809 chr2:233865437~233868444:- LIHC cis rs1405130 0.869 rs4663460 ENSG00000224287.2 MSL3P1 3.85 0.000143 0.0247 0.24 0.2 Coronary artery disease; chr2:234659217 chr2:233865437~233868444:- LIHC cis rs1405130 0.967 rs4663461 ENSG00000224287.2 MSL3P1 3.85 0.000143 0.0247 0.24 0.2 Coronary artery disease; chr2:234659847 chr2:233865437~233868444:- LIHC cis rs1405130 0.869 rs55905532 ENSG00000224287.2 MSL3P1 3.85 0.000143 0.0247 0.24 0.2 Coronary artery disease; chr2:234660259 chr2:233865437~233868444:- LIHC cis rs1405130 0.967 rs4663463 ENSG00000224287.2 MSL3P1 3.85 0.000143 0.0247 0.24 0.2 Coronary artery disease; chr2:234660364 chr2:233865437~233868444:- LIHC cis rs1405130 0.869 rs11693175 ENSG00000224287.2 MSL3P1 3.85 0.000143 0.0247 0.24 0.2 Coronary artery disease; chr2:234660798 chr2:233865437~233868444:- LIHC cis rs1405130 0.933 rs11677087 ENSG00000224287.2 MSL3P1 3.85 0.000143 0.0247 0.24 0.2 Coronary artery disease; chr2:234661248 chr2:233865437~233868444:- LIHC cis rs2301573 0.915 rs2285373 ENSG00000251474.5 RPL32P3 3.85 0.000143 0.0247 0.24 0.2 Hip circumference; chr3:129589366 chr3:129382922~129399655:- LIHC cis rs10129255 0.872 rs8015406 ENSG00000211970.3 IGHV4-61 -3.85 0.000143 0.0247 -0.16 -0.2 Kawasaki disease; chr14:106670611 chr14:106639119~106639657:- LIHC cis rs12681287 0.64 rs4961193 ENSG00000254088.1 SLC2A3P4 -3.85 0.000143 0.0247 -0.23 -0.2 Caudate activity during reward; chr8:86473939 chr8:86503591~86505061:+ LIHC cis rs2036707 1 rs2036708 ENSG00000277246.1 RP11-153I24.4 -3.85 0.000143 0.0247 -0.37 -0.2 Obesity-related traits; chr13:107832890 chr13:108267320~108267734:+ LIHC cis rs17345786 1 rs17345528 ENSG00000244119.1 PDCL3P4 -3.85 0.000143 0.0247 -0.22 -0.2 Colonoscopy-negative controls vs population controls; chr3:101575986 chr3:101712472~101713191:+ LIHC cis rs8133974 0.617 rs8128234 ENSG00000234380.1 LINC01426 3.85 0.000143 0.0247 0.37 0.2 Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes; chr21:35098568 chr21:34745757~34784886:+ LIHC cis rs1005277 0.683 rs7923868 ENSG00000276805.1 RP11-291L22.6 3.85 0.000143 0.0247 0.25 0.2 Extrinsic epigenetic age acceleration; chr10:37700838 chr10:38451030~38451785:+ LIHC cis rs4650994 1 rs17361251 ENSG00000273384.1 RP5-1098D14.1 3.85 0.000143 0.0247 0.25 0.2 HDL cholesterol;HDL cholesterol levels; chr1:178551442 chr1:178651706~178652282:+ LIHC cis rs4650994 1 rs17276527 ENSG00000273384.1 RP5-1098D14.1 3.85 0.000143 0.0247 0.25 0.2 HDL cholesterol;HDL cholesterol levels; chr1:178551545 chr1:178651706~178652282:+ LIHC cis rs12681287 0.64 rs7460650 ENSG00000254088.1 SLC2A3P4 3.85 0.000143 0.0247 0.23 0.2 Caudate activity during reward; chr8:86461856 chr8:86503591~86505061:+ LIHC cis rs794185 0.562 rs304095 ENSG00000231249.1 ITPR1-AS1 -3.85 0.000143 0.0247 -0.22 -0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4474856 chr3:4490891~4493163:- LIHC cis rs929596 1 rs929596 ENSG00000233445.1 RPL17P11 3.85 0.000143 0.0247 0.25 0.2 Total bilirubin levels in HIV-1 infection; chr2:233765830 chr2:233721522~233722065:- LIHC cis rs782590 0.574 rs12991445 ENSG00000272606.1 RP11-554J4.1 -3.85 0.000143 0.0247 -0.22 -0.2 Metabolic syndrome; chr2:55448803 chr2:55617909~55618373:+ LIHC cis rs6700559 0.654 rs2809346 ENSG00000260088.1 RP11-92G12.3 3.85 0.000143 0.0247 0.26 0.2 Coronary artery disease; chr1:200627089 chr1:200669507~200694250:+ LIHC cis rs2439831 0.867 rs4583210 ENSG00000166763.7 STRCP1 3.85 0.000143 0.0247 0.29 0.2 Lung cancer in ever smokers; chr15:43368727 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs28461955 ENSG00000166763.7 STRCP1 3.85 0.000143 0.0247 0.29 0.2 Lung cancer in ever smokers; chr15:43369261 chr15:43699488~43718184:- LIHC cis rs3862030 0.5 rs11191327 ENSG00000236937.2 PTGES3P4 -3.85 0.000143 0.0247 -0.27 -0.2 Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction); chr10:102544126 chr10:102845595~102845950:+ LIHC cis rs7917772 0.503 rs11191328 ENSG00000236937.2 PTGES3P4 -3.85 0.000143 0.0247 -0.27 -0.2 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102545428 chr10:102845595~102845950:+ LIHC cis rs858239 0.863 rs274058 ENSG00000226816.2 AC005082.12 3.85 0.000143 0.0247 0.26 0.2 Cerebrospinal fluid biomarker levels; chr7:23351890 chr7:23206013~23208045:+ LIHC cis rs9532669 0.926 rs9525418 ENSG00000176268.5 CYCSP34 -3.85 0.000143 0.0247 -0.23 -0.2 Cervical cancer; chr13:40879081 chr13:40863599~40863902:- LIHC cis rs875971 0.522 rs709604 ENSG00000237310.1 GS1-124K5.4 -3.85 0.000144 0.0247 -0.2 -0.2 Aortic root size; chr7:66032447 chr7:66493706~66495474:+ LIHC cis rs4683346 0.731 rs11923822 ENSG00000273328.4 RP11-141M3.6 3.85 0.000144 0.0247 0.22 0.2 Granulocyte percentage of myeloid white cells; chr3:42880685 chr3:42809414~42908105:+ LIHC cis rs12468226 1 rs16839090 ENSG00000272966.1 RP11-686O6.1 3.85 0.000144 0.0247 0.34 0.2 Urate levels; chr2:202348338 chr2:202336739~202337200:+ LIHC cis rs3811273 1 rs10872997 ENSG00000275552.1 CH17-302M23.1 -3.85 0.000144 0.0247 -0.33 -0.2 Periodontal disease-related phenotypes; chr14:22255085 chr14:22595808~22598946:- LIHC cis rs9906944 0.933 rs4794018 ENSG00000248278.1 SUMO2P17 -3.84 0.000144 0.0247 -0.34 -0.2 Intelligence (multi-trait analysis);Body fat percentage; chr17:49016036 chr17:48874860~48908983:- LIHC cis rs2070488 1 rs4147025 ENSG00000229589.1 ACVR2B-AS1 3.84 0.000144 0.0247 0.23 0.2 Electrocardiographic conduction measures; chr3:38415040 chr3:38451027~38454820:- LIHC cis rs11874381 0.54 rs8084139 ENSG00000267322.2 SNHG22 3.84 0.000144 0.0248 0.24 0.2 C-reactive protein levels or HDL-cholesterol levels (pleiotropy); chr18:49692045 chr18:49814023~49851059:+ LIHC cis rs2243480 1 rs13310597 ENSG00000228409.4 CCT6P1 3.84 0.000144 0.0248 0.22 0.2 Diabetic kidney disease; chr7:66133553 chr7:65751142~65763354:+ LIHC cis rs3738443 0.953 rs61839997 ENSG00000259865.1 RP11-488L18.10 3.84 0.000144 0.0248 0.21 0.2 Alcohol dependence; chr1:247197867 chr1:247187281~247188526:- LIHC cis rs6545883 0.931 rs12713437 ENSG00000271889.1 RP11-493E12.1 3.84 0.000144 0.0248 0.24 0.2 Tuberculosis; chr2:61495769 chr2:61151433~61162105:- LIHC cis rs1494950 1 rs55733122 ENSG00000214846.4 RP11-115L11.1 -3.84 0.000144 0.0248 -0.4 -0.2 Political ideology; chr4:15047158 chr4:15730962~15731627:- LIHC cis rs1494950 1 rs73797791 ENSG00000214846.4 RP11-115L11.1 -3.84 0.000144 0.0248 -0.4 -0.2 Political ideology; chr4:15050110 chr4:15730962~15731627:- LIHC cis rs2880765 0.525 rs2062234 ENSG00000259295.5 CSPG4P12 3.84 0.000144 0.0248 0.28 0.2 Coronary artery disease; chr15:85511259 chr15:85191438~85213905:+ LIHC cis rs6700559 0.967 rs10919992 ENSG00000260088.1 RP11-92G12.3 -3.84 0.000144 0.0248 -0.26 -0.2 Coronary artery disease; chr1:200638338 chr1:200669507~200694250:+ LIHC cis rs12692119 0.649 rs72971140 ENSG00000272789.1 RP11-286H15.1 -3.84 0.000144 0.0248 -0.45 -0.2 Pelvic organ prolapse (moderate/severe); chr2:126874684 chr2:127625997~127626848:- LIHC cis rs12692119 0.649 rs72971143 ENSG00000272789.1 RP11-286H15.1 -3.84 0.000144 0.0248 -0.45 -0.2 Pelvic organ prolapse (moderate/severe); chr2:126874743 chr2:127625997~127626848:- LIHC cis rs901683 0.867 rs35356752 ENSG00000230869.1 CTGLF10P -3.84 0.000144 0.0248 -0.5 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45484658 chr10:45678692~45700532:+ LIHC cis rs12908161 1 rs35630683 ENSG00000225151.9 GOLGA2P7 -3.84 0.000144 0.0248 -0.26 -0.2 Schizophrenia; chr15:84806000 chr15:84199311~84230136:- LIHC cis rs10185424 0.521 rs4851531 ENSG00000281162.1 LINC01127 -3.84 0.000144 0.0248 -0.2 -0.2 Crohn's disease;Ulcerative colitis; chr2:102032147 chr2:101962056~101987167:+ LIHC cis rs7914558 0.646 rs7909286 ENSG00000236937.2 PTGES3P4 3.84 0.000144 0.0248 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102899235 chr10:102845595~102845950:+ LIHC cis rs7914558 0.646 rs7909591 ENSG00000236937.2 PTGES3P4 3.84 0.000144 0.0248 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102899261 chr10:102845595~102845950:+ LIHC cis rs7914558 0.621 rs10786722 ENSG00000236937.2 PTGES3P4 3.84 0.000144 0.0248 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102900311 chr10:102845595~102845950:+ LIHC cis rs2312236 0.714 rs11808386 ENSG00000225171.2 DUTP6 3.84 0.000144 0.0248 0.26 0.2 Post-traumatic stress disorder; chr1:166753153 chr1:166868748~166869209:+ LIHC cis rs12468226 0.938 rs114177656 ENSG00000226261.1 AC064836.3 3.84 0.000144 0.0248 0.33 0.2 Urate levels; chr2:202291596 chr2:202336024~202336727:- LIHC cis rs709400 0.643 rs11621777 ENSG00000258914.1 CTD-2134A5.3 3.84 0.000144 0.0248 0.29 0.2 Body mass index; chr14:103605753 chr14:103875055~103877478:+ LIHC cis rs17135859 0.624 rs57691496 ENSG00000249947.2 XBP1P1 3.84 0.000144 0.0248 0.41 0.2 F-cell distribution; chr5:113705151 chr5:112885094~112885745:+ LIHC cis rs683257 1 rs72988191 ENSG00000234147.1 RP3-460G2.2 -3.84 0.000144 0.0248 -0.39 -0.2 Facial emotion recognition (angry faces); chr6:140838654 chr6:140845958~140852924:- LIHC cis rs9467603 0.925 rs6910549 ENSG00000216436.2 HIST1H2APS1 -3.84 0.000144 0.0248 -0.47 -0.2 Intelligence (multi-trait analysis); chr6:25780583 chr6:25732497~25732827:+ LIHC cis rs709400 0.894 rs56017123 ENSG00000258914.1 CTD-2134A5.3 3.84 0.000144 0.0248 0.29 0.2 Body mass index; chr14:103608940 chr14:103875055~103877478:+ LIHC cis rs4913250 0.854 rs11176777 ENSG00000251301.5 RP11-81H14.2 3.84 0.000144 0.0248 0.22 0.2 Amyotrophic lateral sclerosis (C9orf72 mutation interaction); chr12:67541733 chr12:68332888~68451663:- LIHC cis rs7315621 0.93 rs7300419 ENSG00000279700.1 RP13-554M15.2 3.84 0.000144 0.0248 0.15 0.2 Longevity; chr12:131595813 chr12:132565071~132566425:+ LIHC cis rs7315621 0.965 rs6598193 ENSG00000279700.1 RP13-554M15.2 3.84 0.000144 0.0248 0.15 0.2 Longevity; chr12:131595924 chr12:132565071~132566425:+ LIHC cis rs7315621 0.965 rs6598194 ENSG00000279700.1 RP13-554M15.2 3.84 0.000144 0.0248 0.15 0.2 Longevity; chr12:131596042 chr12:132565071~132566425:+ LIHC cis rs17482078 0.918 rs28513759 ENSG00000248734.2 CTD-2260A17.1 3.84 0.000144 0.0248 0.3 0.2 Behcet's disease;Blood protein levels; chr5:96825366 chr5:96784777~96785999:+ LIHC cis rs3931020 0.772 rs1409785 ENSG00000272864.1 RP11-17E13.2 -3.84 0.000144 0.0248 -0.25 -0.2 Resistin levels; chr1:74782438 chr1:74698769~74699333:- LIHC cis rs950169 1 rs79318564 ENSG00000225151.9 GOLGA2P7 -3.84 0.000145 0.0248 -0.29 -0.2 Schizophrenia; chr15:84117398 chr15:84199311~84230136:- LIHC cis rs950169 1 rs1911155 ENSG00000225151.9 GOLGA2P7 -3.84 0.000145 0.0248 -0.29 -0.2 Schizophrenia; chr15:84118883 chr15:84199311~84230136:- LIHC cis rs2880765 0.546 rs35316253 ENSG00000259630.2 CTD-2262B20.1 -3.84 0.000145 0.0248 -0.29 -0.2 Coronary artery disease; chr15:85522329 chr15:85415228~85415633:+ LIHC cis rs17376456 0.877 rs10057605 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000145 0.0249 -0.43 -0.2 Diabetic retinopathy; chr5:94108245 chr5:93860669~93863825:- LIHC cis rs6840360 1 rs1366909 ENSG00000251603.1 RP11-164P12.4 -3.84 0.000145 0.0249 -0.19 -0.2 Intelligence (multi-trait analysis); chr4:151667269 chr4:151667224~151670502:+ LIHC cis rs1799949 0.965 rs8176323 ENSG00000267681.1 CTD-3199J23.6 -3.84 0.000145 0.0249 -0.2 -0.2 Menopause (age at onset); chr17:43043694 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs8176322 ENSG00000267681.1 CTD-3199J23.6 -3.84 0.000145 0.0249 -0.2 -0.2 Menopause (age at onset); chr17:43043756 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs12516 ENSG00000267681.1 CTD-3199J23.6 -3.84 0.000145 0.0249 -0.2 -0.2 Menopause (age at onset); chr17:43044391 chr17:43144956~43145255:+ LIHC cis rs6452524 1 rs1382369 ENSG00000271862.1 RP11-343L5.2 3.84 0.000145 0.0249 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83145610 chr5:83049376~83050964:- LIHC cis rs617219 0.889 rs10037105 ENSG00000251675.1 CTC-458I2.2 -3.84 0.000145 0.0249 -0.22 -0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79151082 chr5:80128361~80143883:+ LIHC cis rs10833905 1 rs10833906 ENSG00000246225.5 RP11-17A1.3 3.84 0.000145 0.0249 0.25 0.2 Sudden cardiac arrest; chr11:23023828 chr11:22829380~22945393:+ LIHC cis rs867371 1 rs1392976 ENSG00000259429.4 UBE2Q2P2 3.84 0.000145 0.0249 0.19 0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82153834 chr15:82355142~82420075:+ LIHC cis rs875971 0.638 rs10249404 ENSG00000224316.1 RP11-479O9.2 -3.84 0.000145 0.0249 -0.19 -0.2 Aortic root size; chr7:66581737 chr7:65773620~65802067:+ LIHC cis rs801193 0.66 rs4610622 ENSG00000237310.1 GS1-124K5.4 3.84 0.000145 0.0249 0.18 0.2 Aortic root size; chr7:66759510 chr7:66493706~66495474:+ LIHC cis rs801193 0.66 rs10950049 ENSG00000237310.1 GS1-124K5.4 3.84 0.000145 0.0249 0.18 0.2 Aortic root size; chr7:66765873 chr7:66493706~66495474:+ LIHC cis rs11096990 0.892 rs2381349 ENSG00000249207.1 RP11-360F5.1 3.84 0.000145 0.0249 0.23 0.2 Cognitive function; chr4:39210390 chr4:39112677~39126818:- LIHC cis rs7712401 0.601 rs30072 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122956525 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs30069 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122957331 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs187405 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122959300 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs40818 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122959378 chr5:123022487~123022783:- LIHC cis rs7712401 0.562 rs30062 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122960681 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs30060 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122961005 chr5:123022487~123022783:- LIHC cis rs7712401 0.525 rs2910150 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122961050 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs30059 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122961814 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs30058 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122962008 chr5:123022487~123022783:- LIHC cis rs7712401 0.623 rs30057 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122962423 chr5:123022487~123022783:- LIHC cis rs7712401 0.584 rs39820 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122964226 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs30055 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122965384 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs39819 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122965981 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs30054 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122966304 chr5:123022487~123022783:- LIHC cis rs7712401 0.562 rs30053 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122967948 chr5:123022487~123022783:- LIHC cis rs7712401 0.562 rs30052 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122969314 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs30049 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122970402 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs246321 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122972604 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs246320 ENSG00000263432.2 RN7SL689P 3.84 0.000145 0.0249 0.3 0.2 Mean platelet volume; chr5:122972886 chr5:123022487~123022783:- LIHC cis rs16958440 0.541 rs62095459 ENSG00000267724.1 RP11-49K24.8 3.84 0.000145 0.0249 0.27 0.2 Sitting height ratio; chr18:47095011 chr18:47105946~47108062:+ LIHC cis rs16958440 0.541 rs13547 ENSG00000267724.1 RP11-49K24.8 3.84 0.000145 0.0249 0.27 0.2 Sitting height ratio; chr18:47108385 chr18:47105946~47108062:+ LIHC cis rs12681287 0.609 rs13279850 ENSG00000254088.1 SLC2A3P4 3.84 0.000145 0.0249 0.24 0.2 Caudate activity during reward; chr8:86465571 chr8:86503591~86505061:+ LIHC cis rs10129255 0.957 rs4387509 ENSG00000211972.2 IGHV3-66 3.84 0.000145 0.0249 0.17 0.2 Kawasaki disease; chr14:106704386 chr14:106675017~106675544:- LIHC cis rs67311347 0.956 rs4974029 ENSG00000223797.4 ENTPD3-AS1 3.84 0.000145 0.0249 0.16 0.2 Renal cell carcinoma; chr3:40479827 chr3:40313802~40453329:- LIHC cis rs673078 0.607 rs2062519 ENSG00000275759.1 RP11-131L12.3 -3.84 0.000145 0.0249 -0.24 -0.2 Glucose homeostasis traits; chr12:118367577 chr12:118428281~118428870:+ LIHC cis rs6832769 0.961 rs13152650 ENSG00000272969.1 RP11-528I4.2 3.84 0.000145 0.0249 0.24 0.2 Personality dimensions; chr4:55491691 chr4:55547112~55547889:+ LIHC cis rs944990 0.576 rs10821126 ENSG00000227603.1 RP11-165J3.6 3.84 0.000145 0.0249 0.22 0.2 Body mass index; chr9:93436451 chr9:93435332~93437121:- LIHC cis rs1005277 0.522 rs1208684 ENSG00000276805.1 RP11-291L22.6 3.84 0.000145 0.0249 0.24 0.2 Extrinsic epigenetic age acceleration; chr10:37805008 chr10:38451030~38451785:+ LIHC cis rs1023500 0.573 rs6002592 ENSG00000226450.2 CYP2D8P -3.84 0.000145 0.0249 -0.25 -0.2 Schizophrenia; chr22:42080750 chr22:42149886~42155001:- LIHC cis rs4148008 0.589 rs4148011 ENSG00000267250.1 RP11-118B18.2 -3.84 0.000145 0.0249 -0.26 -0.2 HDL cholesterol; chr17:68874776 chr17:68793549~68797822:- LIHC cis rs9747201 0.963 rs4789729 ENSG00000279692.1 RP11-1055B8.1 3.84 0.000145 0.0249 0.35 0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82188213 chr17:81395609~81397144:- LIHC cis rs3020736 0.5 rs6002616 ENSG00000226450.2 CYP2D8P -3.84 0.000145 0.0249 -0.25 -0.2 Autism spectrum disorder or schizophrenia; chr22:42108675 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs7364293 ENSG00000226450.2 CYP2D8P -3.84 0.000145 0.0249 -0.25 -0.2 Autism spectrum disorder or schizophrenia; chr22:42110366 chr22:42149886~42155001:- LIHC cis rs875971 0.558 rs4433015 ENSG00000273024.4 INTS4P2 3.84 0.000145 0.0249 0.24 0.2 Aortic root size; chr7:66174736 chr7:65647864~65715661:+ LIHC cis rs11686241 0.938 rs284550 ENSG00000241520.1 AC098820.4 3.84 0.000145 0.0249 0.23 0.2 Cancer; chr2:216446907 chr2:216483032~216487196:- LIHC cis rs9876781 1 rs11130170 ENSG00000229759.1 MRPS18AP1 3.84 0.000145 0.0249 0.21 0.2 Longevity; chr3:48408490 chr3:48256350~48256938:- LIHC cis rs728616 0.558 rs116434658 ENSG00000225484.5 NUTM2B-AS1 -3.84 0.000145 0.0249 -0.41 -0.2 Chronic obstructive pulmonary disease-related biomarkers; chr10:79994870 chr10:79663088~79826594:- LIHC cis rs4561483 0.734 rs33655 ENSG00000261560.1 RP11-166B2.3 -3.84 0.000145 0.0249 -0.23 -0.2 Testicular germ cell tumor; chr16:11876524 chr16:11881075~11882569:- LIHC cis rs3749237 0.595 rs12489092 ENSG00000270441.1 RP11-694I15.7 -3.84 0.000145 0.0249 -0.29 -0.2 Resting heart rate; chr3:49513481 chr3:49140086~49160851:- LIHC cis rs3749237 0.595 rs3870337 ENSG00000270441.1 RP11-694I15.7 -3.84 0.000145 0.0249 -0.29 -0.2 Resting heart rate; chr3:49519662 chr3:49140086~49160851:- LIHC cis rs1005277 0.54 rs1987431 ENSG00000275858.1 RP11-291L22.8 3.84 0.000145 0.025 0.22 0.2 Extrinsic epigenetic age acceleration; chr10:37699959 chr10:38450738~38451069:- LIHC cis rs709400 0.859 rs7693 ENSG00000269958.1 RP11-73M18.8 3.84 0.000145 0.025 0.27 0.2 Body mass index; chr14:103557367 chr14:103696353~103697163:+ LIHC cis rs34220720 0.894 rs12967831 ENSG00000267013.4 CTD-2171N6.1 3.84 0.000145 0.025 0.27 0.2 Neuroticism; chr18:55118123 chr18:55105904~55124306:- LIHC cis rs2574985 0.738 rs3011770 ENSG00000231345.3 BEND3P1 -3.84 0.000145 0.025 -0.3 -0.2 Subjective well-being; chr10:50511625 chr10:50655967~50660472:+ LIHC cis rs55966801 0.898 rs56312618 ENSG00000277290.1 RP11-326C3.16 -3.84 0.000146 0.025 -0.26 -0.2 Plateletcrit; chr11:237209 chr11:243099~243483:- LIHC cis rs55966801 0.898 rs939915 ENSG00000277290.1 RP11-326C3.16 -3.84 0.000146 0.025 -0.26 -0.2 Plateletcrit; chr11:237737 chr11:243099~243483:- LIHC cis rs55966801 0.842 rs72865313 ENSG00000277290.1 RP11-326C3.16 -3.84 0.000146 0.025 -0.26 -0.2 Plateletcrit; chr11:240754 chr11:243099~243483:- LIHC cis rs6969780 0.778 rs11564055 ENSG00000233429.8 HOTAIRM1 3.84 0.000146 0.025 0.3 0.2 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27105731 chr7:27095647~27100265:+ LIHC cis rs6969780 0.778 rs2428433 ENSG00000233429.8 HOTAIRM1 3.84 0.000146 0.025 0.3 0.2 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27105898 chr7:27095647~27100265:+ LIHC cis rs6433895 0.736 rs11893772 ENSG00000236153.1 AC104076.3 -3.84 0.000146 0.025 -0.27 -0.2 Lymphocyte counts; chr2:181124584 chr2:180979427~180980090:- LIHC cis rs2243480 1 rs781150 ENSG00000275400.1 RP4-756H11.5 3.84 0.000146 0.025 0.27 0.2 Diabetic kidney disease; chr7:66015986 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs313798 ENSG00000275400.1 RP4-756H11.5 3.84 0.000146 0.025 0.27 0.2 Diabetic kidney disease; chr7:66028044 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs35396113 ENSG00000275400.1 RP4-756H11.5 3.84 0.000146 0.025 0.27 0.2 Diabetic kidney disease; chr7:66030474 chr7:66553805~66554199:- LIHC cis rs1115240 0.604 rs1950421 ENSG00000257842.4 NOVA1-AS1 -3.84 0.000146 0.025 -0.19 -0.2 Educational attainment (years of education); chr14:26671686 chr14:26598412~26806467:+ LIHC cis rs2243480 1 rs1723267 ENSG00000232546.1 RP11-458F8.1 -3.84 0.000146 0.025 -0.23 -0.2 Diabetic kidney disease; chr7:66008327 chr7:66848496~66858136:+ LIHC cis rs6442522 0.606 rs3773462 ENSG00000249786.6 EAF1-AS1 3.84 0.000146 0.025 0.24 0.2 Uric acid levels; chr3:15452772 chr3:15436171~15455940:- LIHC cis rs5742933 0.857 rs1233291 ENSG00000253559.1 OSGEPL1-AS1 -3.84 0.000146 0.025 -0.26 -0.2 Ferritin levels; chr2:189826225 chr2:189762704~189765556:+ LIHC cis rs7560272 0.538 rs2012574 ENSG00000273245.1 RP11-434P11.2 -3.84 0.000146 0.025 -0.25 -0.2 Schizophrenia; chr2:73701239 chr2:73750256~73750786:- LIHC cis rs6061231 1 rs11696991 ENSG00000228812.6 LAMA5-AS1 -3.84 0.000146 0.025 -0.25 -0.2 Colorectal cancer; chr20:62384638 chr20:62352995~62356480:+ LIHC cis rs12681287 0.608 rs2953511 ENSG00000254088.1 SLC2A3P4 3.84 0.000146 0.025 0.24 0.2 Caudate activity during reward; chr8:86328641 chr8:86503591~86505061:+ LIHC cis rs12681287 0.647 rs2953510 ENSG00000254088.1 SLC2A3P4 3.84 0.000146 0.025 0.24 0.2 Caudate activity during reward; chr8:86329685 chr8:86503591~86505061:+ LIHC cis rs12681287 0.605 rs2953509 ENSG00000254088.1 SLC2A3P4 3.84 0.000146 0.025 0.24 0.2 Caudate activity during reward; chr8:86330965 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs7816629 ENSG00000254088.1 SLC2A3P4 3.84 0.000146 0.025 0.24 0.2 Caudate activity during reward; chr8:86338559 chr8:86503591~86505061:+ LIHC cis rs12681287 0.64 rs7820234 ENSG00000254088.1 SLC2A3P4 3.84 0.000146 0.025 0.24 0.2 Caudate activity during reward; chr8:86338721 chr8:86503591~86505061:+ LIHC cis rs3764400 0.567 rs8071199 ENSG00000278765.1 RP5-890E16.5 -3.84 0.000146 0.025 -0.31 -0.2 Body mass index; chr17:48117973 chr17:48066704~48067293:- LIHC cis rs11098499 0.588 rs6534149 ENSG00000245958.5 RP11-33B1.1 3.84 0.000146 0.025 0.2 0.2 Corneal astigmatism; chr4:119638137 chr4:119454791~119552025:+ LIHC cis rs8177253 0.965 rs8177260 ENSG00000244062.1 RP11-404G16.2 3.84 0.000146 0.025 0.21 0.2 Iron status biomarkers; chr3:133761614 chr3:133760300~133762363:+ LIHC cis rs4578769 0.76 rs7227956 ENSG00000266850.1 RP11-370A5.1 3.84 0.000146 0.025 0.23 0.2 Eosinophil percentage of white cells; chr18:22933855 chr18:22723491~22907721:- LIHC cis rs4578769 0.842 rs7243256 ENSG00000266850.1 RP11-370A5.1 3.84 0.000146 0.025 0.23 0.2 Eosinophil percentage of white cells; chr18:22936411 chr18:22723491~22907721:- LIHC cis rs4578769 0.842 rs9966323 ENSG00000266850.1 RP11-370A5.1 3.84 0.000146 0.025 0.23 0.2 Eosinophil percentage of white cells; chr18:22936418 chr18:22723491~22907721:- LIHC cis rs6828577 0.819 rs298975 ENSG00000269893.5 SNHG8 3.84 0.000146 0.025 0.21 0.2 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118715240 chr4:118278709~118279823:+ LIHC cis rs9876781 1 rs7651407 ENSG00000229759.1 MRPS18AP1 3.84 0.000146 0.025 0.21 0.2 Longevity; chr3:48402409 chr3:48256350~48256938:- LIHC cis rs494453 0.807 rs2786966 ENSG00000227811.2 FAM212B-AS1 3.84 0.000146 0.025 0.23 0.2 Osteoporosis-related phenotypes; chr1:111638035 chr1:111739841~111747798:+ LIHC cis rs801193 0.66 rs1016265 ENSG00000237310.1 GS1-124K5.4 3.84 0.000146 0.025 0.18 0.2 Aortic root size; chr7:66749580 chr7:66493706~66495474:+ LIHC cis rs10129255 0.785 rs10150044 ENSG00000211970.3 IGHV4-61 -3.84 0.000146 0.025 -0.16 -0.2 Kawasaki disease; chr14:106775695 chr14:106639119~106639657:- LIHC cis rs17376456 0.877 rs7734897 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000146 0.025 -0.43 -0.2 Diabetic retinopathy; chr5:93969697 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs7736620 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000146 0.025 -0.43 -0.2 Diabetic retinopathy; chr5:93970057 chr5:93860669~93863825:- LIHC cis rs17376456 0.809 rs13177800 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000146 0.025 -0.43 -0.2 Diabetic retinopathy; chr5:93971645 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs13173952 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000146 0.025 -0.43 -0.2 Diabetic retinopathy; chr5:93971852 chr5:93860669~93863825:- LIHC cis rs17376456 0.741 rs10036829 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000146 0.025 -0.43 -0.2 Diabetic retinopathy; chr5:93974192 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs35747258 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000146 0.025 -0.43 -0.2 Diabetic retinopathy; chr5:93974424 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs7701974 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000146 0.025 -0.43 -0.2 Diabetic retinopathy; chr5:93975712 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs7701011 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000146 0.025 -0.43 -0.2 Diabetic retinopathy; chr5:93975751 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs34673483 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000146 0.025 -0.43 -0.2 Diabetic retinopathy; chr5:93979374 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10055340 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000146 0.025 -0.43 -0.2 Diabetic retinopathy; chr5:93981939 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs10076052 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000146 0.025 -0.43 -0.2 Diabetic retinopathy; chr5:93982057 chr5:93860669~93863825:- LIHC cis rs7953249 0.807 rs7310409 ENSG00000241388.4 HNF1A-AS1 -3.84 0.000146 0.025 -0.21 -0.2 N-glycan levels;Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr12:120987058 chr12:120941728~120980965:- LIHC cis rs4356975 0.563 rs4694177 ENSG00000250919.1 RP11-813N20.3 -3.84 0.000146 0.025 -0.21 -0.2 Obesity-related traits; chr4:69110141 chr4:69027831~69044578:+ LIHC cis rs950880 0.71 rs2270298 ENSG00000234389.1 AC007278.3 -3.84 0.000146 0.025 -0.21 -0.2 Serum protein levels (sST2); chr2:102375619 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs17027037 ENSG00000234389.1 AC007278.3 -3.84 0.000146 0.025 -0.21 -0.2 Serum protein levels (sST2); chr2:102378424 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs2080289 ENSG00000234389.1 AC007278.3 -3.84 0.000146 0.025 -0.21 -0.2 Serum protein levels (sST2); chr2:102378560 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs3771162 ENSG00000234389.1 AC007278.3 -3.84 0.000146 0.025 -0.21 -0.2 Serum protein levels (sST2); chr2:102380714 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs11465633 ENSG00000234389.1 AC007278.3 -3.84 0.000146 0.025 -0.21 -0.2 Serum protein levels (sST2); chr2:102381273 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs1035130 ENSG00000234389.1 AC007278.3 -3.84 0.000146 0.025 -0.21 -0.2 Serum protein levels (sST2); chr2:102384942 chr2:102438713~102440475:+ LIHC cis rs274567 0.501 rs272856 ENSG00000263597.1 MIR3936 3.84 0.000146 0.0251 0.22 0.2 Blood metabolite levels; chr5:132351388 chr5:132365490~132365599:- LIHC cis rs2439831 0.85 rs7181039 ENSG00000275601.1 AC011330.13 -3.84 0.000146 0.0251 -0.31 -0.2 Lung cancer in ever smokers; chr15:43886914 chr15:43642389~43643023:- LIHC cis rs2797160 0.967 rs2747718 ENSG00000237742.5 RP11-624M8.1 3.84 0.000146 0.0251 0.21 0.2 Endometrial cancer; chr6:125687963 chr6:125578558~125749190:- LIHC cis rs2797160 1 rs2747719 ENSG00000237742.5 RP11-624M8.1 3.84 0.000146 0.0251 0.21 0.2 Endometrial cancer; chr6:125688068 chr6:125578558~125749190:- LIHC cis rs2797160 1 rs2797158 ENSG00000237742.5 RP11-624M8.1 3.84 0.000146 0.0251 0.21 0.2 Endometrial cancer; chr6:125688252 chr6:125578558~125749190:- LIHC cis rs2797160 1 rs2747720 ENSG00000237742.5 RP11-624M8.1 3.84 0.000146 0.0251 0.21 0.2 Endometrial cancer; chr6:125688312 chr6:125578558~125749190:- LIHC cis rs2797160 0.967 rs2797159 ENSG00000237742.5 RP11-624M8.1 3.84 0.000146 0.0251 0.21 0.2 Endometrial cancer; chr6:125688411 chr6:125578558~125749190:- LIHC cis rs2797160 1 rs2747722 ENSG00000237742.5 RP11-624M8.1 3.84 0.000146 0.0251 0.21 0.2 Endometrial cancer; chr6:125688483 chr6:125578558~125749190:- LIHC cis rs10773588 0.642 rs543533 ENSG00000256581.1 NLRP9P -3.84 0.000146 0.0251 -0.27 -0.2 Asthma; chr12:129016085 chr12:129013336~129016663:+ LIHC cis rs6545883 0.929 rs3821222 ENSG00000273302.1 RP11-493E12.2 3.84 0.000146 0.0251 0.22 0.2 Tuberculosis; chr2:61486391 chr2:61199979~61200769:+ LIHC cis rs7044106 0.762 rs10760112 ENSG00000238181.2 AHCYP2 -3.84 0.000146 0.0251 -0.23 -0.2 Hip circumference adjusted for BMI; chr9:120705292 chr9:120720673~120721972:+ LIHC cis rs4925386 0.681 rs2427296 ENSG00000226332.2 RP11-157P1.4 3.84 0.000146 0.0251 0.24 0.2 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62352419 chr20:62305432~62306325:- LIHC cis rs7809950 1 rs2237677 ENSG00000238832.1 snoU109 -3.84 0.000146 0.0251 -0.24 -0.2 Coronary artery disease; chr7:107562057 chr7:107603363~107603507:+ LIHC cis rs875971 0.964 rs778735 ENSG00000237310.1 GS1-124K5.4 3.84 0.000146 0.0251 0.18 0.2 Aortic root size; chr7:66349822 chr7:66493706~66495474:+ LIHC cis rs55966801 0.68 rs72882960 ENSG00000279672.1 CMB9-55F22.1 3.84 0.000146 0.0251 0.34 0.2 Plateletcrit; chr11:268927 chr11:779617~780755:+ LIHC cis rs55966801 0.68 rs17655663 ENSG00000279672.1 CMB9-55F22.1 3.84 0.000146 0.0251 0.34 0.2 Plateletcrit; chr11:268940 chr11:779617~780755:+ LIHC cis rs950169 1 rs1818950 ENSG00000225151.9 GOLGA2P7 -3.84 0.000146 0.0251 -0.29 -0.2 Schizophrenia; chr15:84053769 chr15:84199311~84230136:- LIHC cis rs3768617 0.51 rs10797838 ENSG00000224468.3 RP11-181K3.4 -3.84 0.000146 0.0251 -0.17 -0.2 Fuchs's corneal dystrophy; chr1:183107885 chr1:183138402~183141282:- LIHC cis rs4578769 0.959 rs3898593 ENSG00000266850.1 RP11-370A5.1 3.84 0.000146 0.0251 0.23 0.2 Eosinophil percentage of white cells; chr18:22909074 chr18:22723491~22907721:- LIHC cis rs4578769 0.959 rs1031651 ENSG00000266850.1 RP11-370A5.1 3.84 0.000146 0.0251 0.23 0.2 Eosinophil percentage of white cells; chr18:22915716 chr18:22723491~22907721:- LIHC cis rs4578769 0.959 rs8096389 ENSG00000266850.1 RP11-370A5.1 3.84 0.000146 0.0251 0.23 0.2 Eosinophil percentage of white cells; chr18:22921952 chr18:22723491~22907721:- LIHC cis rs4578769 0.959 rs9949696 ENSG00000266850.1 RP11-370A5.1 3.84 0.000146 0.0251 0.23 0.2 Eosinophil percentage of white cells; chr18:22923688 chr18:22723491~22907721:- LIHC cis rs4578769 0.959 rs930910 ENSG00000266850.1 RP11-370A5.1 3.84 0.000146 0.0251 0.23 0.2 Eosinophil percentage of white cells; chr18:22930178 chr18:22723491~22907721:- LIHC cis rs867371 1 rs13380319 ENSG00000259429.4 UBE2Q2P2 -3.84 0.000147 0.0251 -0.2 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82214526 chr15:82355142~82420075:+ LIHC cis rs3821902 0.501 rs12185962 ENSG00000280620.1 SCAANT1 -3.84 0.000147 0.0251 -0.29 -0.2 Breast cancer; chr3:63711237 chr3:63911518~63911772:- LIHC cis rs3002131 0.604 rs3008644 ENSG00000225265.1 TAF1A-AS1 -3.84 0.000147 0.0251 -0.3 -0.2 Interleukin-10 levels; chr1:222577402 chr1:222589825~222593032:+ LIHC cis rs929596 0.583 rs77070100 ENSG00000233445.1 RPL17P11 3.84 0.000147 0.0251 0.22 0.2 Total bilirubin levels in HIV-1 infection; chr2:233679201 chr2:233721522~233722065:- LIHC cis rs929596 0.556 rs35984508 ENSG00000233445.1 RPL17P11 3.84 0.000147 0.0251 0.22 0.2 Total bilirubin levels in HIV-1 infection; chr2:233679206 chr2:233721522~233722065:- LIHC cis rs1005277 0.579 rs176880 ENSG00000275858.1 RP11-291L22.8 -3.84 0.000147 0.0251 -0.22 -0.2 Extrinsic epigenetic age acceleration; chr10:38112489 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2505248 ENSG00000275858.1 RP11-291L22.8 3.84 0.000147 0.0251 0.22 0.2 Extrinsic epigenetic age acceleration; chr10:38170169 chr10:38450738~38451069:- LIHC cis rs10975870 0.81 rs7031585 ENSG00000236924.1 RP11-390F4.6 -3.84 0.000147 0.0251 -0.32 -0.2 Body mass index; chr9:6932149 chr9:6645956~6670635:+ LIHC cis rs2283792 0.765 rs9610338 ENSG00000224086.5 LL22NC03-86G7.1 3.84 0.000147 0.0251 0.21 0.2 Multiple sclerosis; chr22:21797532 chr22:21938293~21977632:+ LIHC cis rs7208859 0.673 rs2470251 ENSG00000264538.5 SUZ12P1 -3.84 0.000147 0.0251 -0.21 -0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30768043 chr17:30709299~30790908:+ LIHC cis rs867371 1 rs9944197 ENSG00000259429.4 UBE2Q2P2 -3.84 0.000147 0.0251 -0.19 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82158261 chr15:82355142~82420075:+ LIHC cis rs803903 0.57 rs10817890 ENSG00000230894.1 RP11-67K19.3 3.84 0.000147 0.0252 0.27 0.2 Breast cancer; chr9:116429895 chr9:116568449~116586328:+ LIHC cis rs6471393 0.964 rs1051914 ENSG00000253848.1 RP11-10N23.5 3.84 0.000147 0.0252 0.23 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93728838 chr8:93741193~93744534:+ LIHC cis rs548181 0.536 rs503288 ENSG00000254671.2 STT3A-AS1 3.84 0.000147 0.0252 0.31 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr11:125591892 chr11:125570284~125592568:- LIHC cis rs9527 0.59 rs726010 ENSG00000236937.2 PTGES3P4 3.84 0.000147 0.0252 0.26 0.2 Arsenic metabolism; chr10:103082220 chr10:102845595~102845950:+ LIHC cis rs6504622 0.517 rs11656362 ENSG00000263766.4 RP11-580I16.2 -3.84 0.000147 0.0252 -0.24 -0.2 Orofacial clefts; chr17:46958889 chr17:47603860~47649420:- LIHC cis rs12908161 1 rs56864281 ENSG00000259728.4 LINC00933 3.84 0.000147 0.0252 0.3 0.2 Schizophrenia; chr15:84814418 chr15:84570649~84580175:+ LIHC cis rs875971 0.522 rs1617484 ENSG00000237310.1 GS1-124K5.4 3.84 0.000147 0.0252 0.2 0.2 Aortic root size; chr7:65998108 chr7:66493706~66495474:+ LIHC cis rs8059260 0.935 rs7203687 ENSG00000274038.1 RP11-66H6.4 -3.84 0.000147 0.0252 -0.26 -0.2 Alcohol consumption over the past year; chr16:11013063 chr16:11056556~11057034:+ LIHC cis rs7315621 0.965 rs6598195 ENSG00000279700.1 RP13-554M15.2 3.84 0.000147 0.0252 0.15 0.2 Longevity; chr12:131596260 chr12:132565071~132566425:+ LIHC cis rs2581828 0.618 rs6792345 ENSG00000242142.1 SERBP1P3 -3.84 0.000147 0.0252 -0.27 -0.2 Crohn's disease; chr3:53131178 chr3:53064283~53065091:- LIHC cis rs2581828 0.618 rs6792363 ENSG00000242142.1 SERBP1P3 -3.84 0.000147 0.0252 -0.27 -0.2 Crohn's disease; chr3:53131247 chr3:53064283~53065091:- LIHC cis rs2581828 0.618 rs6445565 ENSG00000242142.1 SERBP1P3 -3.84 0.000147 0.0252 -0.27 -0.2 Crohn's disease; chr3:53131448 chr3:53064283~53065091:- LIHC cis rs921968 0.613 rs2556388 ENSG00000272555.1 RP11-459I19.1 -3.84 0.000147 0.0252 -0.23 -0.2 Mean corpuscular hemoglobin concentration; chr2:218676333 chr2:218818690~218819144:+ LIHC cis rs921968 0.613 rs2710250 ENSG00000272555.1 RP11-459I19.1 -3.84 0.000147 0.0252 -0.23 -0.2 Mean corpuscular hemoglobin concentration; chr2:218678554 chr2:218818690~218819144:+ LIHC cis rs921968 0.613 rs2303565 ENSG00000272555.1 RP11-459I19.1 -3.84 0.000147 0.0252 -0.23 -0.2 Mean corpuscular hemoglobin concentration; chr2:218680586 chr2:218818690~218819144:+ LIHC cis rs921968 0.613 rs2912737 ENSG00000272555.1 RP11-459I19.1 -3.84 0.000147 0.0252 -0.23 -0.2 Mean corpuscular hemoglobin concentration; chr2:218681066 chr2:218818690~218819144:+ LIHC cis rs4356203 0.875 rs667984 ENSG00000260196.1 RP1-239B22.5 -3.84 0.000147 0.0252 -0.24 -0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17179219 chr11:17380649~17383531:+ LIHC cis rs1344653 0.738 rs13035812 ENSG00000236204.4 LINC01376 -3.84 0.000147 0.0252 -0.24 -0.2 Pulse pressure; chr2:19564581 chr2:18986451~19346748:- LIHC cis rs10129255 0.957 rs10137980 ENSG00000211970.3 IGHV4-61 -3.84 0.000147 0.0252 -0.16 -0.2 Kawasaki disease; chr14:106775735 chr14:106639119~106639657:- LIHC cis rs3733589 1 rs13127090 ENSG00000250413.1 RP11-448G15.1 3.84 0.000147 0.0252 0.35 0.2 Renal overload gout; chr4:9995592 chr4:10006482~10009725:+ LIHC cis rs8064024 0.65 rs3813749 ENSG00000267077.1 RP11-127I20.5 3.84 0.000147 0.0252 0.21 0.2 Cancer; chr16:4869126 chr16:4795265~4796532:- LIHC cis rs12681366 0.843 rs3019156 ENSG00000253704.1 RP11-267M23.4 3.84 0.000148 0.0253 0.24 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94409552 chr8:94553722~94569745:+ LIHC cis rs12681366 0.843 rs3019147 ENSG00000253704.1 RP11-267M23.4 3.84 0.000148 0.0253 0.24 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94412804 chr8:94553722~94569745:+ LIHC cis rs12681366 0.881 rs2960121 ENSG00000253704.1 RP11-267M23.4 3.84 0.000148 0.0253 0.24 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94417678 chr8:94553722~94569745:+ LIHC cis rs9595908 0.708 rs12429740 ENSG00000212293.1 SNORA16 3.84 0.000148 0.0253 0.23 0.2 Body mass index; chr13:32684928 chr13:32420390~32420516:- LIHC cis rs9595908 0.746 rs9596076 ENSG00000212293.1 SNORA16 3.84 0.000148 0.0253 0.23 0.2 Body mass index; chr13:32693515 chr13:32420390~32420516:- LIHC cis rs9595908 0.746 rs17516171 ENSG00000212293.1 SNORA16 3.84 0.000148 0.0253 0.23 0.2 Body mass index; chr13:32694914 chr13:32420390~32420516:- LIHC cis rs9595908 0.746 rs3848087 ENSG00000212293.1 SNORA16 3.84 0.000148 0.0253 0.23 0.2 Body mass index; chr13:32697637 chr13:32420390~32420516:- LIHC cis rs9595908 0.746 rs1029306 ENSG00000212293.1 SNORA16 3.84 0.000148 0.0253 0.23 0.2 Body mass index; chr13:32707695 chr13:32420390~32420516:- LIHC cis rs2439831 0.867 rs2255440 ENSG00000166763.7 STRCP1 3.84 0.000148 0.0253 0.29 0.2 Lung cancer in ever smokers; chr15:43538269 chr15:43699488~43718184:- LIHC cis rs1912483 0.505 rs3760372 ENSG00000228782.6 CTD-2026D20.3 3.84 0.000148 0.0253 0.26 0.2 Coronary artery disease; chr17:47302636 chr17:47450568~47492492:- LIHC cis rs1405130 1 rs6715142 ENSG00000224287.2 MSL3P1 3.84 0.000148 0.0253 0.24 0.2 Coronary artery disease; chr2:234655658 chr2:233865437~233868444:- LIHC cis rs12681287 0.577 rs11992955 ENSG00000254088.1 SLC2A3P4 -3.84 0.000148 0.0253 -0.24 -0.2 Caudate activity during reward; chr8:86518257 chr8:86503591~86505061:+ LIHC cis rs11651753 0.636 rs35280206 ENSG00000264920.1 RP11-6N17.4 -3.84 0.000148 0.0253 -0.21 -0.2 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47957645 chr17:47891255~47895812:- LIHC cis rs7665090 0.87 rs228613 ENSG00000246560.2 RP11-10L12.4 -3.84 0.000148 0.0253 -0.24 -0.2 Primary biliary cholangitis; chr4:102656308 chr4:102828055~102844075:+ LIHC cis rs854624 0.892 rs1608206 ENSG00000278690.1 RP11-104J23.2 3.84 0.000148 0.0253 0.44 0.2 Blood protein levels; chr17:36009796 chr17:36012504~36012891:+ LIHC cis rs6832769 1 rs3805154 ENSG00000272969.1 RP11-528I4.2 3.84 0.000148 0.0253 0.24 0.2 Personality dimensions; chr4:55497760 chr4:55547112~55547889:+ LIHC cis rs10129255 1 rs9324091 ENSG00000211970.3 IGHV4-61 -3.84 0.000148 0.0253 -0.16 -0.2 Kawasaki disease; chr14:106676625 chr14:106639119~106639657:- LIHC cis rs559928 0.593 rs112275221 ENSG00000236935.1 AP003774.1 3.84 0.000148 0.0253 0.32 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64169522 chr11:64325050~64329504:- LIHC cis rs12468226 0.938 rs80282360 ENSG00000272966.1 RP11-686O6.1 3.84 0.000148 0.0253 0.34 0.2 Urate levels; chr2:202275121 chr2:202336739~202337200:+ LIHC cis rs2932538 0.922 rs7535636 ENSG00000225075.1 RP11-426L16.3 -3.84 0.000148 0.0253 -0.26 -0.2 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112559177 chr1:112693688~112696621:- LIHC cis rs8111500 0.793 rs2892233 ENSG00000232871.7 SEC1P 3.84 0.000148 0.0253 0.25 0.2 Elevated serum carcinoembryonic antigen levels; chr19:48656998 chr19:48638071~48682245:+ LIHC cis rs4218 0.648 rs8042896 ENSG00000277144.1 RP11-59H7.4 -3.84 0.000148 0.0253 -0.22 -0.2 Social communication problems; chr15:59067727 chr15:59115547~59116089:- LIHC cis rs1799949 0.965 rs799912 ENSG00000267681.1 CTD-3199J23.6 -3.84 0.000148 0.0253 -0.2 -0.2 Menopause (age at onset); chr17:43105117 chr17:43144956~43145255:+ LIHC cis rs875971 1 rs6946143 ENSG00000237310.1 GS1-124K5.4 3.84 0.000148 0.0253 0.18 0.2 Aortic root size; chr7:66114735 chr7:66493706~66495474:+ LIHC cis rs7129556 0.815 rs72947625 ENSG00000254459.1 RP11-91P24.7 3.84 0.000148 0.0253 0.35 0.2 Weight loss (gastric bypass surgery); chr11:77688557 chr11:77829654~77872262:- LIHC cis rs2032366 1 rs8088329 ENSG00000267279.1 RP11-879F14.2 -3.84 0.000148 0.0253 -0.24 -0.2 Obesity-related traits; chr18:61595758 chr18:61585746~61606916:- LIHC cis rs11696501 0.792 rs2235584 ENSG00000271984.1 RP3-337O18.9 -3.84 0.000148 0.0253 -0.24 -0.2 Brain structure; chr20:45543797 chr20:45892694~45893419:- LIHC cis rs11696501 0.792 rs2227290 ENSG00000271984.1 RP3-337O18.9 -3.84 0.000148 0.0253 -0.24 -0.2 Brain structure; chr20:45547503 chr20:45892694~45893419:- LIHC cis rs3761847 0.622 rs10818500 ENSG00000226752.6 PSMD5-AS1 3.84 0.000148 0.0253 0.21 0.2 Rheumatoid arthritis; chr9:121048605 chr9:120824828~120854385:+ LIHC cis rs9595908 0.686 rs1015364 ENSG00000212293.1 SNORA16 3.84 0.000148 0.0253 0.23 0.2 Body mass index; chr13:32784455 chr13:32420390~32420516:- LIHC cis rs9595908 0.709 rs7983889 ENSG00000212293.1 SNORA16 3.84 0.000148 0.0253 0.23 0.2 Body mass index; chr13:32785441 chr13:32420390~32420516:- LIHC cis rs8177876 0.749 rs2911159 ENSG00000261061.1 RP11-303E16.2 3.84 0.000148 0.0254 0.27 0.2 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81057653 chr16:81030770~81031485:+ LIHC cis rs1799949 1 rs3092988 ENSG00000267681.1 CTD-3199J23.6 -3.84 0.000148 0.0254 -0.2 -0.2 Menopause (age at onset); chr17:43049685 chr17:43144956~43145255:+ LIHC cis rs55781332 1 rs55781332 ENSG00000277290.1 RP11-326C3.16 -3.84 0.000148 0.0254 -0.26 -0.2 Total body bone mineral density (age 30-45);Total body bone mineral density; chr11:242859 chr11:243099~243483:- LIHC cis rs864537 0.59 rs1214596 ENSG00000273160.1 RP11-104L21.3 -3.84 0.000148 0.0254 -0.28 -0.2 Celiac disease or Rheumatoid arthritis;Celiac disease; chr1:167457933 chr1:167457742~167459891:- LIHC cis rs12681287 0.752 rs9283958 ENSG00000254088.1 SLC2A3P4 3.84 0.000148 0.0254 0.24 0.2 Caudate activity during reward; chr8:86240819 chr8:86503591~86505061:+ LIHC cis rs1023500 0.552 rs133368 ENSG00000226450.2 CYP2D8P 3.84 0.000148 0.0254 0.25 0.2 Schizophrenia; chr22:42067685 chr22:42149886~42155001:- LIHC cis rs8030379 0.811 rs7162542 ENSG00000225151.9 GOLGA2P7 -3.84 0.000149 0.0254 -0.26 -0.2 Waist circumference;Waist circumference adjusted for body mass index; chr15:83845538 chr15:84199311~84230136:- LIHC cis rs10129255 0.912 rs8011090 ENSG00000211972.2 IGHV3-66 3.84 0.000149 0.0254 0.16 0.2 Kawasaki disease; chr14:106678896 chr14:106675017~106675544:- LIHC cis rs11874381 0.54 rs8084172 ENSG00000267322.2 SNHG22 3.84 0.000149 0.0254 0.24 0.2 C-reactive protein levels or HDL-cholesterol levels (pleiotropy); chr18:49692126 chr18:49814023~49851059:+ LIHC cis rs6500602 0.727 rs6500607 ENSG00000278700.1 Metazoa_SRP 3.84 0.000149 0.0254 0.24 0.2 Schizophrenia; chr16:4453630 chr16:4658851~4659151:+ LIHC cis rs6142102 0.812 rs6059574 ENSG00000275784.1 RP5-1125A11.6 3.84 0.000149 0.0254 0.23 0.2 Skin pigmentation; chr20:33935366 chr20:33989480~33991818:- LIHC cis rs4683346 0.731 rs7623543 ENSG00000273328.4 RP11-141M3.6 3.84 0.000149 0.0254 0.22 0.2 Granulocyte percentage of myeloid white cells; chr3:42880135 chr3:42809414~42908105:+ LIHC cis rs950880 0.71 rs3821203 ENSG00000234389.1 AC007278.3 -3.84 0.000149 0.0254 -0.21 -0.2 Serum protein levels (sST2); chr2:102380412 chr2:102438713~102440475:+ LIHC cis rs4144027 0.967 rs72712857 ENSG00000258534.1 CTD-2134A5.4 -3.84 0.000149 0.0254 -0.23 -0.2 Blood metabolite levels; chr14:103896336 chr14:103854366~103880111:- LIHC cis rs12908161 1 rs60957376 ENSG00000259728.4 LINC00933 3.84 0.000149 0.0254 0.29 0.2 Schizophrenia; chr15:84737561 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs11632465 ENSG00000259728.4 LINC00933 3.84 0.000149 0.0254 0.29 0.2 Schizophrenia; chr15:84738814 chr15:84570649~84580175:+ LIHC cis rs12908161 0.96 rs17599989 ENSG00000259728.4 LINC00933 3.84 0.000149 0.0254 0.29 0.2 Schizophrenia; chr15:84742305 chr15:84570649~84580175:+ LIHC cis rs960902 0.738 rs6746868 ENSG00000213553.4 RPLP0P6 -3.84 0.000149 0.0254 -0.16 -0.2 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37502408 chr2:38481851~38482804:+ LIHC cis rs1816213 0.744 rs71415837 ENSG00000273466.1 RP11-548H3.1 -3.84 0.000149 0.0254 -0.33 -0.2 Diastolic blood pressure; chr2:218490229 chr2:218633256~218634014:- LIHC cis rs933688 0.941 rs2887007 ENSG00000281357.1 ARRDC3-AS1 3.84 0.000149 0.0254 0.25 0.2 Smoking behavior; chr5:91444714 chr5:91380349~91439085:+ LIHC cis rs7208859 0.673 rs999797 ENSG00000264538.5 SUZ12P1 -3.84 0.000149 0.0254 -0.22 -0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832311 chr17:30709299~30790908:+ LIHC cis rs12145833 0.748 rs11807162 ENSG00000253326.2 RP11-261C10.7 -3.84 0.000149 0.0254 -0.39 -0.2 Obesity (early onset extreme); chr1:243291378 chr1:243054861~243056394:- LIHC cis rs6452524 0.648 rs27364 ENSG00000271862.1 RP11-343L5.2 3.84 0.000149 0.0254 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83052137 chr5:83049376~83050964:- LIHC cis rs11955398 0.62 rs6449512 ENSG00000272308.1 RP11-231G3.1 -3.84 0.000149 0.0254 -0.21 -0.2 Intelligence (multi-trait analysis); chr5:60938415 chr5:60866457~60866935:- LIHC cis rs1075265 0.836 rs10208233 ENSG00000233266.1 HMGB1P31 3.84 0.000149 0.0254 0.31 0.2 Chronotype;Morning vs. evening chronotype; chr2:54066433 chr2:54051334~54051760:+ LIHC cis rs7760535 0.811 rs1002475 ENSG00000271789.1 RP5-1112D6.7 -3.84 0.000149 0.0255 -0.2 -0.2 Metabolic traits; chr6:111388386 chr6:111297126~111298510:+ LIHC cis rs3087243 0.56 rs231724 ENSG00000213925.3 NPM1P33 3.84 0.000149 0.0255 0.2 0.2 Rheumatoid arthritis;Type 1 diabetes;Hypothyroidism; chr2:203875100 chr2:203772631~203773502:- LIHC cis rs2607426 0.581 rs74746550 ENSG00000276445.1 LLNLR-268E12.1 -3.84 0.000149 0.0255 -0.34 -0.2 Blood protein levels; chr19:40709027 chr19:39812972~39813555:- LIHC cis rs2904804 0.58 rs10128163 ENSG00000224251.5 RP11-499O7.7 3.84 0.000149 0.0255 0.25 0.2 Economic and political preferences (immigration/crime); chr10:4976520 chr10:4995488~4997380:+ LIHC cis rs17376456 0.809 rs10476602 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000149 0.0255 -0.42 -0.2 Diabetic retinopathy; chr5:94109550 chr5:93860669~93863825:- LIHC cis rs17376456 0.877 rs17083455 ENSG00000251023.1 RP11-549J18.1 -3.84 0.000149 0.0255 -0.42 -0.2 Diabetic retinopathy; chr5:94110675 chr5:93860669~93863825:- LIHC cis rs10975870 0.924 rs4567098 ENSG00000236924.1 RP11-390F4.6 -3.84 0.000149 0.0255 -0.33 -0.2 Body mass index; chr9:6866412 chr9:6645956~6670635:+ LIHC cis rs16895768 0.685 rs4700171 ENSG00000229666.1 MAST4-AS1 -3.84 0.000149 0.0255 -0.47 -0.2 Selective IgA deficiency; chr5:66906403 chr5:67001383~67003953:- LIHC cis rs9906944 0.933 rs9906710 ENSG00000248278.1 SUMO2P17 -3.84 0.000149 0.0255 -0.33 -0.2 Intelligence (multi-trait analysis);Body fat percentage; chr17:49013921 chr17:48874860~48908983:- LIHC cis rs12908161 0.96 rs34452033 ENSG00000259728.4 LINC00933 3.84 0.000149 0.0255 0.29 0.2 Schizophrenia; chr15:84678762 chr15:84570649~84580175:+ LIHC cis rs709400 1 rs58133129 ENSG00000258534.1 CTD-2134A5.4 3.84 0.000149 0.0255 0.29 0.2 Body mass index; chr14:103638422 chr14:103854366~103880111:- LIHC cis rs11971779 1 rs11971779 ENSG00000273391.1 RP11-634H22.1 -3.84 0.000149 0.0255 -0.21 -0.2 Diisocyanate-induced asthma; chr7:139355512 chr7:139359032~139359566:- LIHC cis rs10129255 0.957 rs2007467 ENSG00000211970.3 IGHV4-61 3.84 0.000149 0.0255 0.16 0.2 Kawasaki disease; chr14:106771605 chr14:106639119~106639657:- LIHC cis rs8002861 0.664 rs2184882 ENSG00000274001.1 RP11-5G9.5 3.83 0.00015 0.0255 0.22 0.2 Leprosy; chr13:43876210 chr13:43877715~43878163:- LIHC cis rs9300255 0.55 rs10772997 ENSG00000256092.2 RP13-942N8.1 3.83 0.00015 0.0255 0.25 0.2 Neutrophil percentage of white cells; chr12:123235333 chr12:123363868~123366113:+ LIHC cis rs9300255 0.596 rs11057202 ENSG00000256092.2 RP13-942N8.1 3.83 0.00015 0.0255 0.25 0.2 Neutrophil percentage of white cells; chr12:123236228 chr12:123363868~123366113:+ LIHC cis rs9300255 0.566 rs10744150 ENSG00000256092.2 RP13-942N8.1 3.83 0.00015 0.0255 0.25 0.2 Neutrophil percentage of white cells; chr12:123237067 chr12:123363868~123366113:+ LIHC cis rs9300255 0.596 rs11057207 ENSG00000256092.2 RP13-942N8.1 3.83 0.00015 0.0255 0.25 0.2 Neutrophil percentage of white cells; chr12:123246344 chr12:123363868~123366113:+ LIHC cis rs11532322 1 rs11532322 ENSG00000256092.2 RP13-942N8.1 3.83 0.00015 0.0255 0.25 0.2 Schizophrenia; chr12:123246876 chr12:123363868~123366113:+ LIHC cis rs9532669 0.963 rs9532662 ENSG00000168852.11 TPTE2P5 3.83 0.00015 0.0255 0.22 0.2 Cervical cancer; chr13:40926215 chr13:40822296~40921749:- LIHC cis rs9309473 0.5 rs2421664 ENSG00000204872.3 NAT8B -3.83 0.00015 0.0255 -0.26 -0.2 Metabolite levels; chr2:73631754 chr2:73700576~73701340:- LIHC cis rs2564921 0.654 rs73087044 ENSG00000242142.1 SERBP1P3 -3.83 0.00015 0.0255 -0.27 -0.2 Height; chr3:52975027 chr3:53064283~53065091:- LIHC cis rs794185 0.719 rs2633859 ENSG00000231249.1 ITPR1-AS1 -3.83 0.00015 0.0256 -0.22 -0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4455181 chr3:4490891~4493163:- LIHC cis rs9457247 0.765 rs9459836 ENSG00000227598.1 RP1-167A14.2 -3.83 0.00015 0.0256 -0.22 -0.2 Crohn's disease; chr6:167005617 chr6:166969626~166999065:- LIHC cis rs7917772 0.503 rs7087665 ENSG00000236937.2 PTGES3P4 -3.83 0.00015 0.0256 -0.27 -0.2 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102522661 chr10:102845595~102845950:+ LIHC cis rs12145833 0.538 rs61833885 ENSG00000253326.2 RP11-261C10.7 -3.83 0.00015 0.0256 -0.4 -0.2 Obesity (early onset extreme); chr1:243233886 chr1:243054861~243056394:- LIHC cis rs11098403 0.753 rs4834640 ENSG00000260404.2 RP11-384K6.6 3.83 0.00015 0.0256 0.13 0.2 Schizophrenia; chr4:117852204 chr4:118591773~118633729:+ LIHC cis rs6504622 0.577 rs197925 ENSG00000263766.4 RP11-580I16.2 -3.83 0.00015 0.0256 -0.24 -0.2 Orofacial clefts; chr17:46933355 chr17:47603860~47649420:- LIHC cis rs4561483 0.583 rs11645213 ENSG00000261560.1 RP11-166B2.3 3.83 0.00015 0.0256 0.24 0.2 Testicular germ cell tumor; chr16:11849067 chr16:11881075~11882569:- LIHC cis rs1510272 0.515 rs2089735 ENSG00000243926.1 TIPARP-AS1 -3.83 0.00015 0.0256 -0.22 -0.2 Testicular germ cell tumor; chr3:156624763 chr3:156671862~156674378:- LIHC cis rs591584 0.874 rs4753144 ENSG00000255893.1 RP11-685N10.1 -3.83 0.00015 0.0256 -0.2 -0.2 Macrophage Migration Inhibitory Factor levels; chr11:94589520 chr11:94472908~94473570:- LIHC cis rs591584 0.874 rs10831246 ENSG00000255893.1 RP11-685N10.1 -3.83 0.00015 0.0256 -0.2 -0.2 Macrophage Migration Inhibitory Factor levels; chr11:94589529 chr11:94472908~94473570:- LIHC cis rs853679 1 rs2799077 ENSG00000219392.1 RP1-265C24.5 -3.83 0.00015 0.0256 -0.35 -0.2 Depression; chr6:28266819 chr6:28115628~28116551:+ LIHC cis rs7216064 0.655 rs8078543 ENSG00000265055.1 AC145343.2 -3.83 0.00015 0.0256 -0.21 -0.2 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68041135 chr17:68096046~68101474:- LIHC cis rs7216064 0.636 rs62084696 ENSG00000265055.1 AC145343.2 -3.83 0.00015 0.0256 -0.21 -0.2 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68042065 chr17:68096046~68101474:- LIHC cis rs2439831 0.85 rs7183809 ENSG00000166763.7 STRCP1 3.83 0.00015 0.0256 0.31 0.2 Lung cancer in ever smokers; chr15:43828670 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs3759790 ENSG00000166763.7 STRCP1 3.83 0.00015 0.0256 0.31 0.2 Lung cancer in ever smokers; chr15:43828832 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs68079546 ENSG00000166763.7 STRCP1 3.83 0.00015 0.0256 0.31 0.2 Lung cancer in ever smokers; chr15:43844759 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs56909447 ENSG00000166763.7 STRCP1 3.83 0.00015 0.0256 0.31 0.2 Lung cancer in ever smokers; chr15:43845420 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs28476182 ENSG00000166763.7 STRCP1 3.83 0.00015 0.0256 0.31 0.2 Lung cancer in ever smokers; chr15:43847445 chr15:43699488~43718184:- LIHC cis rs2439831 0.85 rs28696802 ENSG00000166763.7 STRCP1 3.83 0.00015 0.0256 0.31 0.2 Lung cancer in ever smokers; chr15:43848197 chr15:43699488~43718184:- LIHC cis rs10857712 0.904 rs36118799 ENSG00000214279.11 SCART1 -3.83 0.00015 0.0256 -0.25 -0.2 Systemic lupus erythematosus; chr10:133408865 chr10:133453928~133523558:+ LIHC cis rs10857712 0.904 rs7918164 ENSG00000214279.11 SCART1 -3.83 0.00015 0.0256 -0.25 -0.2 Systemic lupus erythematosus; chr10:133409819 chr10:133453928~133523558:+ LIHC cis rs10857712 0.784 rs2265639 ENSG00000214279.11 SCART1 3.83 0.00015 0.0256 0.25 0.2 Systemic lupus erythematosus; chr10:133408072 chr10:133453928~133523558:+ LIHC cis rs10857712 0.904 rs2265641 ENSG00000214279.11 SCART1 3.83 0.00015 0.0256 0.25 0.2 Systemic lupus erythematosus; chr10:133408365 chr10:133453928~133523558:+ LIHC cis rs11079757 0.604 rs72823425 ENSG00000262879.4 RP11-156P1.3 3.83 0.00015 0.0256 0.24 0.2 Erythema nodosum in inflammatory bowel disease; chr17:47111303 chr17:46984045~47100323:- LIHC cis rs7129556 0.69 rs668701 ENSG00000254459.1 RP11-91P24.7 3.83 0.00015 0.0256 0.34 0.2 Weight loss (gastric bypass surgery); chr11:77872430 chr11:77829654~77872262:- LIHC cis rs2243480 1 rs6958420 ENSG00000232546.1 RP11-458F8.1 3.83 0.00015 0.0256 0.23 0.2 Diabetic kidney disease; chr7:66286184 chr7:66848496~66858136:+ LIHC cis rs5742933 0.744 rs13009889 ENSG00000253559.1 OSGEPL1-AS1 3.83 0.00015 0.0256 0.27 0.2 Ferritin levels; chr2:189763842 chr2:189762704~189765556:+ LIHC cis rs858239 0.712 rs199650 ENSG00000226816.2 AC005082.12 -3.83 0.00015 0.0256 -0.26 -0.2 Cerebrospinal fluid biomarker levels; chr7:23327570 chr7:23206013~23208045:+ LIHC cis rs6545883 0.929 rs6545877 ENSG00000271889.1 RP11-493E12.1 3.83 0.00015 0.0256 0.24 0.2 Tuberculosis; chr2:61514812 chr2:61151433~61162105:- LIHC cis rs17722688 0.647 rs12657996 ENSG00000248626.1 GAPDHP40 -3.83 0.00015 0.0256 -0.24 -0.2 Interleukin-13 levels; chr5:159477305 chr5:159950493~159951498:- LIHC cis rs11710088 0.74 rs34394409 ENSG00000244503.1 RP11-278L15.6 3.83 0.000151 0.0257 0.27 0.2 QRS duration; chr3:149477439 chr3:149494660~149495995:+ LIHC cis rs709400 0.894 rs10143293 ENSG00000258914.1 CTD-2134A5.3 3.83 0.000151 0.0257 0.29 0.2 Body mass index; chr14:103596677 chr14:103875055~103877478:+ LIHC cis rs2598107 0.542 rs10488617 ENSG00000211698.2 TRGV4 3.83 0.000151 0.0257 0.24 0.2 Dupuytren's disease; chr7:37897431 chr7:38353715~38354517:- LIHC cis rs41313321 0.688 rs73672490 ENSG00000272696.1 RP11-339B21.13 3.83 0.000151 0.0257 0.27 0.2 Coenzyme Q10 levels; chr9:128293454 chr9:128316337~128316909:+ LIHC cis rs673078 0.66 rs6490173 ENSG00000275409.1 RP11-131L12.4 -3.83 0.000151 0.0257 -0.25 -0.2 Glucose homeostasis traits; chr12:118278637 chr12:118430147~118430699:+ LIHC cis rs13113518 0.812 rs12649507 ENSG00000223305.1 RN7SKP30 -3.83 0.000151 0.0257 -0.24 -0.2 Height; chr4:55514317 chr4:55540502~55540835:- LIHC cis rs11690935 0.632 rs12991740 ENSG00000228389.1 AC068039.4 -3.83 0.000151 0.0257 -0.26 -0.2 Schizophrenia; chr2:172021092 chr2:171773482~171775844:+ LIHC cis rs6732160 0.834 rs57456443 ENSG00000272702.1 RP11-44N22.3 3.83 0.000151 0.0257 0.23 0.2 Intelligence (multi-trait analysis); chr2:73139313 chr2:73113018~73115907:+ LIHC cis rs2658782 0.901 rs7116173 ENSG00000279684.1 RP11-755E23.2 3.83 0.000151 0.0257 0.35 0.2 Pulmonary function decline; chr11:93489145 chr11:93286629~93288903:- LIHC cis rs295490 0.667 rs78171819 ENSG00000272656.1 RP11-219D15.3 3.83 0.000151 0.0257 0.58 0.2 PR interval in Tripanosoma cruzi seropositivity; chr3:139316602 chr3:139349024~139349371:- LIHC cis rs7985 0.901 rs6005133 ENSG00000244625.4 MIATNB 3.83 0.000151 0.0257 0.22 0.2 Electroencephalogram traits; chr22:26681021 chr22:26672767~26780207:+ LIHC cis rs1005277 0.579 rs2505240 ENSG00000275858.1 RP11-291L22.8 3.83 0.000151 0.0257 0.22 0.2 Extrinsic epigenetic age acceleration; chr10:38153491 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2505241 ENSG00000275858.1 RP11-291L22.8 3.83 0.000151 0.0257 0.22 0.2 Extrinsic epigenetic age acceleration; chr10:38153493 chr10:38450738~38451069:- LIHC cis rs10883723 0.81 rs2281879 ENSG00000236937.2 PTGES3P4 -3.83 0.000151 0.0257 -0.27 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102509120 chr10:102845595~102845950:+ LIHC cis rs8067287 0.597 rs7223652 ENSG00000175061.16 LRRC75A-AS1 3.83 0.000151 0.0257 0.27 0.2 Diabetic kidney disease; chr17:16961245 chr17:16438822~16478678:+ LIHC cis rs12681287 0.546 rs11539113 ENSG00000254088.1 SLC2A3P4 3.83 0.000151 0.0257 0.24 0.2 Caudate activity during reward; chr8:86484947 chr8:86503591~86505061:+ LIHC cis rs9303401 0.703 rs9911583 ENSG00000265415.1 CTD-2510F5.4 -3.83 0.000151 0.0257 -0.14 -0.2 Cognitive test performance; chr17:59133360 chr17:59202677~59203829:- LIHC cis rs9646944 0.891 rs13027294 ENSG00000234389.1 AC007278.3 3.83 0.000151 0.0257 0.24 0.2 Blood protein levels; chr2:102243614 chr2:102438713~102440475:+ LIHC cis rs244293 0.73 rs11079142 ENSG00000275710.1 RP11-257O5.4 3.83 0.000151 0.0257 0.23 0.2 Menarche (age at onset); chr17:54944594 chr17:54964474~54964679:+ LIHC cis rs5030062 0.531 rs1469859 ENSG00000232233.1 RP11-573D15.2 3.83 0.000151 0.0257 0.25 0.2 Blood protein levels;Plasma renin activity levels;Blood metabolite levels; chr3:186722454 chr3:186810880~186825521:- LIHC cis rs11089937 0.568 rs5756989 ENSG00000211639.2 IGLV4-60 3.83 0.000151 0.0258 0.18 0.2 Periodontitis (PAL4Q3); chr22:22132415 chr22:22162199~22162681:+ LIHC cis rs11098499 0.78 rs10013652 ENSG00000245958.5 RP11-33B1.1 -3.83 0.000151 0.0258 -0.21 -0.2 Corneal astigmatism; chr4:119371101 chr4:119454791~119552025:+ LIHC cis rs7709377 0.516 rs11241379 ENSG00000271918.1 CTD-2287O16.5 3.83 0.000151 0.0258 0.23 0.2 Metabolite levels (X-11787); chr5:116208604 chr5:116083807~116085416:- LIHC cis rs763121 0.889 rs9607557 ENSG00000273076.1 RP3-508I15.22 3.83 0.000151 0.0258 0.22 0.2 Menopause (age at onset); chr22:38644274 chr22:38743495~38743910:+ LIHC cis rs1061377 0.513 rs2712000 ENSG00000249685.1 RP11-360F5.3 3.83 0.000151 0.0258 0.3 0.2 Uric acid levels; chr4:39135462 chr4:39133913~39135608:+ LIHC cis rs12681287 0.604 rs13279589 ENSG00000254088.1 SLC2A3P4 3.83 0.000151 0.0258 0.24 0.2 Caudate activity during reward; chr8:86465494 chr8:86503591~86505061:+ LIHC cis rs340849 0.703 rs1367951 ENSG00000274895.1 RP11-478J18.2 3.83 0.000151 0.0258 0.22 0.2 Alzheimer's disease; chr1:213952170 chr1:213983793~213986419:- LIHC cis rs2562456 0.917 rs2650825 ENSG00000268555.1 RP11-678G14.3 3.83 0.000151 0.0258 0.26 0.2 Pain; chr19:21516423 chr19:21570822~21587322:- LIHC cis rs11676348 0.774 rs57545959 ENSG00000261338.2 RP11-378A13.1 3.83 0.000151 0.0258 0.22 0.2 Ulcerative colitis; chr2:218182995 chr2:218255319~218257366:+ LIHC cis rs2932538 0.922 rs7522110 ENSG00000225075.1 RP11-426L16.3 3.83 0.000151 0.0258 0.26 0.2 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112530292 chr1:112693688~112696621:- LIHC cis rs858239 1 rs156421 ENSG00000226816.2 AC005082.12 3.83 0.000151 0.0258 0.25 0.2 Cerebrospinal fluid biomarker levels; chr7:23272868 chr7:23206013~23208045:+ LIHC cis rs1106684 1 rs10954327 ENSG00000233559.1 AC016831.7 3.83 0.000151 0.0258 0.36 0.2 Body mass index; chr7:131773247 chr7:130853720~130928649:+ LIHC cis rs703842 1 rs10877014 ENSG00000270039.1 RP11-571M6.17 -3.83 0.000152 0.0258 -0.28 -0.2 Multiple sclerosis; chr12:57773878 chr12:57803838~57804415:+ LIHC cis rs7131987 0.801 rs6487804 ENSG00000275476.1 RP11-996F15.4 -3.83 0.000152 0.0258 -0.23 -0.2 QT interval; chr12:29302001 chr12:29277397~29277882:- LIHC cis rs2312236 0.759 rs12758334 ENSG00000225171.2 DUTP6 -3.83 0.000152 0.0258 -0.27 -0.2 Post-traumatic stress disorder; chr1:166758441 chr1:166868748~166869209:+ LIHC cis rs7208859 0.673 rs56846352 ENSG00000264538.5 SUZ12P1 -3.83 0.000152 0.0258 -0.21 -0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792170 chr17:30709299~30790908:+ LIHC cis rs17711722 0.503 rs453835 ENSG00000273142.1 RP11-458F8.4 -3.83 0.000152 0.0258 -0.18 -0.2 Calcium levels; chr7:66046172 chr7:66902857~66906297:+ LIHC cis rs6480314 0.809 rs10509300 ENSG00000233590.1 RP11-153K11.3 -3.83 0.000152 0.0258 -0.32 -0.2 Optic nerve measurement (disc area); chr10:68201078 chr10:68233251~68242379:- LIHC cis rs709400 0.859 rs7154948 ENSG00000269958.1 RP11-73M18.8 3.83 0.000152 0.0258 0.27 0.2 Body mass index; chr14:103556607 chr14:103696353~103697163:+ LIHC cis rs853679 0.513 rs13437444 ENSG00000219891.2 ZSCAN12P1 3.83 0.000152 0.0258 0.34 0.2 Depression; chr6:28103220 chr6:28091154~28093664:+ LIHC cis rs829880 0.57 rs4488248 ENSG00000227825.4 SLC9A7P1 3.83 0.000152 0.0259 0.23 0.2 Colonoscopy-negative controls vs population controls; chr12:98459910 chr12:98453835~98457145:- LIHC cis rs12554020 0.504 rs10992845 ENSG00000227603.1 RP11-165J3.6 3.83 0.000152 0.0259 0.32 0.2 Schizophrenia; chr9:93671148 chr9:93435332~93437121:- LIHC cis rs9595908 0.709 rs9315179 ENSG00000212293.1 SNORA16 3.83 0.000152 0.0259 0.23 0.2 Body mass index; chr13:32773889 chr13:32420390~32420516:- LIHC cis rs858239 0.67 rs6967526 ENSG00000226816.2 AC005082.12 3.83 0.000152 0.0259 0.24 0.2 Cerebrospinal fluid biomarker levels; chr7:23119622 chr7:23206013~23208045:+ LIHC cis rs8037137 1 rs8037137 ENSG00000258725.1 PRC1-AS1 -3.83 0.000152 0.0259 -0.26 -0.2 Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr15:90963407 chr15:90966345~90988624:+ LIHC cis rs2665103 0.61 rs1972460 ENSG00000255769.6 GOLGA2P10 -3.83 0.000152 0.0259 -0.21 -0.2 Intelligence (multi-trait analysis); chr15:82238289 chr15:82472993~82513950:- LIHC cis rs2243480 1 rs2462569 ENSG00000232546.1 RP11-458F8.1 3.83 0.000152 0.0259 0.22 0.2 Diabetic kidney disease; chr7:66009859 chr7:66848496~66858136:+ LIHC cis rs875971 0.505 rs1167386 ENSG00000237310.1 GS1-124K5.4 -3.83 0.000152 0.0259 -0.2 -0.2 Aortic root size; chr7:66048109 chr7:66493706~66495474:+ LIHC cis rs875971 0.505 rs1167385 ENSG00000237310.1 GS1-124K5.4 -3.83 0.000152 0.0259 -0.2 -0.2 Aortic root size; chr7:66048321 chr7:66493706~66495474:+ LIHC cis rs803923 0.585 rs803898 ENSG00000230894.1 RP11-67K19.3 -3.83 0.000152 0.0259 -0.26 -0.2 Lung function (FEV1/FVC); chr9:116679284 chr9:116568449~116586328:+ LIHC cis rs7617773 0.539 rs6779517 ENSG00000229759.1 MRPS18AP1 3.83 0.000152 0.0259 0.23 0.2 Coronary artery disease; chr3:48342898 chr3:48256350~48256938:- LIHC cis rs1799949 1 rs11651341 ENSG00000267681.1 CTD-3199J23.6 -3.83 0.000152 0.0259 -0.2 -0.2 Menopause (age at onset); chr17:43350693 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs34572725 ENSG00000267681.1 CTD-3199J23.6 -3.83 0.000152 0.0259 -0.2 -0.2 Menopause (age at onset); chr17:43351298 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs4534897 ENSG00000267681.1 CTD-3199J23.6 -3.83 0.000152 0.0259 -0.2 -0.2 Menopause (age at onset); chr17:43354440 chr17:43144956~43145255:+ LIHC cis rs10975870 0.812 rs80294608 ENSG00000236924.1 RP11-390F4.6 -3.83 0.000152 0.0259 -0.33 -0.2 Body mass index; chr9:6873823 chr9:6645956~6670635:+ LIHC cis rs10975870 0.924 rs10975868 ENSG00000236924.1 RP11-390F4.6 -3.83 0.000152 0.0259 -0.33 -0.2 Body mass index; chr9:6874035 chr9:6645956~6670635:+ LIHC cis rs10975870 0.924 rs34266958 ENSG00000236924.1 RP11-390F4.6 -3.83 0.000152 0.0259 -0.33 -0.2 Body mass index; chr9:6874618 chr9:6645956~6670635:+ LIHC cis rs10975870 0.924 rs10975869 ENSG00000236924.1 RP11-390F4.6 -3.83 0.000152 0.0259 -0.33 -0.2 Body mass index; chr9:6874688 chr9:6645956~6670635:+ LIHC cis rs10975870 0.887 rs60286758 ENSG00000236924.1 RP11-390F4.6 -3.83 0.000152 0.0259 -0.33 -0.2 Body mass index; chr9:6875085 chr9:6645956~6670635:+ LIHC cis rs10975870 0.924 rs7038892 ENSG00000236924.1 RP11-390F4.6 -3.83 0.000152 0.0259 -0.33 -0.2 Body mass index; chr9:6875197 chr9:6645956~6670635:+ LIHC cis rs1003719 0.591 rs1053984 ENSG00000272948.2 AP001412.1 -3.83 0.000152 0.0259 -0.22 -0.2 Eye color traits; chr21:37201717 chr21:37267784~37268497:+ LIHC cis rs4888671 0.614 rs75165142 ENSG00000261707.1 RP11-264M12.2 3.83 0.000152 0.0259 0.36 0.2 Obesity-related traits; chr16:77741022 chr16:77741468~77743000:- LIHC cis rs4218 0.648 rs34407560 ENSG00000277144.1 RP11-59H7.4 -3.83 0.000152 0.0259 -0.23 -0.2 Social communication problems; chr15:59073397 chr15:59115547~59116089:- LIHC cis rs4218 0.648 rs1074702 ENSG00000277144.1 RP11-59H7.4 -3.83 0.000152 0.0259 -0.23 -0.2 Social communication problems; chr15:59073900 chr15:59115547~59116089:- LIHC cis rs7849270 1 rs6478867 ENSG00000268707.1 RP11-247A12.7 3.83 0.000152 0.0259 0.21 0.2 Blood metabolite ratios; chr9:129141644 chr9:129170434~129170940:+ LIHC cis rs1862618 0.671 rs2591970 ENSG00000271828.1 CTD-2310F14.1 -3.83 0.000153 0.026 -0.27 -0.2 Initial pursuit acceleration; chr5:56936768 chr5:56927874~56929573:+ LIHC cis rs1005277 0.522 rs9417256 ENSG00000276805.1 RP11-291L22.6 3.83 0.000153 0.026 0.24 0.2 Extrinsic epigenetic age acceleration; chr10:37688062 chr10:38451030~38451785:+ LIHC cis rs4713118 0.513 rs1225591 ENSG00000219392.1 RP1-265C24.5 -3.83 0.000153 0.026 -0.27 -0.2 Parkinson's disease; chr6:28180974 chr6:28115628~28116551:+ LIHC cis rs867371 1 rs7181655 ENSG00000259429.4 UBE2Q2P2 -3.83 0.000153 0.026 -0.2 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82163275 chr15:82355142~82420075:+ LIHC cis rs867371 1 rs7180584 ENSG00000259429.4 UBE2Q2P2 -3.83 0.000153 0.026 -0.2 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82163493 chr15:82355142~82420075:+ LIHC cis rs867371 1 rs6495642 ENSG00000259429.4 UBE2Q2P2 -3.83 0.000153 0.026 -0.2 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82165156 chr15:82355142~82420075:+ LIHC cis rs6669919 0.553 rs7546343 ENSG00000229832.1 RP11-384C4.2 3.83 0.000153 0.026 0.22 0.2 Intelligence (multi-trait analysis); chr1:211498459 chr1:212357418~212358353:+ LIHC cis rs2179367 0.632 rs9498336 ENSG00000231760.4 RP11-350J20.5 3.83 0.000153 0.026 0.33 0.2 Dupuytren's disease; chr6:149374208 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs1980774 ENSG00000231760.4 RP11-350J20.5 3.83 0.000153 0.026 0.33 0.2 Dupuytren's disease; chr6:149375030 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs9498337 ENSG00000231760.4 RP11-350J20.5 3.83 0.000153 0.026 0.33 0.2 Dupuytren's disease; chr6:149375970 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs9498338 ENSG00000231760.4 RP11-350J20.5 3.83 0.000153 0.026 0.33 0.2 Dupuytren's disease; chr6:149376428 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs12196656 ENSG00000231760.4 RP11-350J20.5 3.83 0.000153 0.026 0.33 0.2 Dupuytren's disease; chr6:149383104 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs12211570 ENSG00000231760.4 RP11-350J20.5 3.83 0.000153 0.026 0.33 0.2 Dupuytren's disease; chr6:149383616 chr6:149796151~149826294:- LIHC cis rs2179367 0.568 rs11155647 ENSG00000231760.4 RP11-350J20.5 3.83 0.000153 0.026 0.33 0.2 Dupuytren's disease; chr6:149384499 chr6:149796151~149826294:- LIHC cis rs4578769 0.722 rs5013130 ENSG00000265943.1 RP11-739L10.1 -3.83 0.000153 0.026 -0.26 -0.2 Eosinophil percentage of white cells; chr18:22945388 chr18:22699481~22933764:- LIHC cis rs853679 1 rs1679732 ENSG00000219392.1 RP1-265C24.5 3.83 0.000153 0.026 0.35 0.2 Depression; chr6:28253486 chr6:28115628~28116551:+ LIHC cis rs10129255 0.912 rs8011090 ENSG00000211970.3 IGHV4-61 -3.83 0.000153 0.026 -0.16 -0.2 Kawasaki disease; chr14:106678896 chr14:106639119~106639657:- LIHC cis rs2286503 0.901 rs10950922 ENSG00000226329.2 AC005682.6 3.83 0.000153 0.026 0.25 0.2 Fibrinogen; chr7:22814387 chr7:22863874~22881350:- LIHC cis rs2286503 0.966 rs2286507 ENSG00000226329.2 AC005682.6 3.83 0.000153 0.026 0.25 0.2 Fibrinogen; chr7:22815141 chr7:22863874~22881350:- LIHC cis rs2286503 0.901 rs2286505 ENSG00000226329.2 AC005682.6 3.83 0.000153 0.026 0.25 0.2 Fibrinogen; chr7:22815221 chr7:22863874~22881350:- LIHC cis rs4578769 0.959 rs7226652 ENSG00000266850.1 RP11-370A5.1 3.83 0.000153 0.026 0.23 0.2 Eosinophil percentage of white cells; chr18:22904043 chr18:22723491~22907721:- LIHC cis rs2243480 1 rs313813 ENSG00000226002.1 RP11-460N20.5 -3.83 0.000153 0.026 -0.29 -0.2 Diabetic kidney disease; chr7:66038513 chr7:65084103~65100232:+ LIHC cis rs1816213 0.744 rs71415842 ENSG00000273466.1 RP11-548H3.1 -3.83 0.000153 0.026 -0.31 -0.2 Diastolic blood pressure; chr2:218529089 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs35311533 ENSG00000273466.1 RP11-548H3.1 -3.83 0.000153 0.026 -0.31 -0.2 Diastolic blood pressure; chr2:218537502 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs77861966 ENSG00000273466.1 RP11-548H3.1 -3.83 0.000153 0.026 -0.31 -0.2 Diastolic blood pressure; chr2:218556816 chr2:218633256~218634014:- LIHC cis rs9467711 0.538 rs13214169 ENSG00000216436.2 HIST1H2APS1 3.83 0.000153 0.026 0.43 0.2 Autism spectrum disorder or schizophrenia; chr6:25890428 chr6:25732497~25732827:+ LIHC cis rs1344653 0.738 rs17760259 ENSG00000236204.4 LINC01376 -3.83 0.000153 0.026 -0.24 -0.2 Pulse pressure; chr2:19544701 chr2:18986451~19346748:- LIHC cis rs1344653 0.738 rs11888527 ENSG00000236204.4 LINC01376 -3.83 0.000153 0.026 -0.24 -0.2 Pulse pressure; chr2:19545493 chr2:18986451~19346748:- LIHC cis rs1344653 0.738 rs58241593 ENSG00000236204.4 LINC01376 -3.83 0.000153 0.026 -0.24 -0.2 Pulse pressure; chr2:19545686 chr2:18986451~19346748:- LIHC cis rs287982 0.8 rs13429581 ENSG00000269973.1 RP11-95D17.1 -3.83 0.000153 0.026 -0.19 -0.2 Nonsyndromic cleft lip with cleft palate; chr2:9823314 chr2:9936360~9939590:+ LIHC cis rs853679 1 rs7740487 ENSG00000204709.4 LINC01556 3.83 0.000153 0.026 0.35 0.2 Depression; chr6:28248708 chr6:28943877~28944537:+ LIHC cis rs1816213 0.744 rs12989964 ENSG00000273466.1 RP11-548H3.1 -3.83 0.000153 0.026 -0.31 -0.2 Diastolic blood pressure; chr2:218633356 chr2:218633256~218634014:- LIHC cis rs9527 0.59 rs2148198 ENSG00000236937.2 PTGES3P4 -3.83 0.000153 0.0261 -0.26 -0.2 Arsenic metabolism; chr10:103155553 chr10:102845595~102845950:+ LIHC cis rs494453 0.807 rs1324889 ENSG00000227811.2 FAM212B-AS1 3.83 0.000153 0.0261 0.23 0.2 Osteoporosis-related phenotypes; chr1:111641018 chr1:111739841~111747798:+ LIHC cis rs5742933 0.817 rs3816196 ENSG00000253559.1 OSGEPL1-AS1 3.83 0.000153 0.0261 0.26 0.2 Ferritin levels; chr2:189775749 chr2:189762704~189765556:+ LIHC cis rs6456156 0.755 rs4710182 ENSG00000227598.1 RP1-167A14.2 -3.83 0.000153 0.0261 -0.2 -0.2 Primary biliary cholangitis; chr6:167100573 chr6:166969626~166999065:- LIHC cis rs10129255 0.5 rs10131875 ENSG00000211972.2 IGHV3-66 3.83 0.000153 0.0261 0.15 0.2 Kawasaki disease; chr14:106792798 chr14:106675017~106675544:- LIHC cis rs8077577 0.747 rs62072509 ENSG00000260647.1 RP1-178F10.1 3.83 0.000153 0.0261 0.26 0.2 Obesity-related traits; chr17:18279079 chr17:18268080~18268828:+ LIHC cis rs67311347 0.544 rs2887965 ENSG00000223797.4 ENTPD3-AS1 -3.83 0.000154 0.0261 -0.17 -0.2 Renal cell carcinoma; chr3:40292663 chr3:40313802~40453329:- LIHC cis rs12908161 0.959 rs34028043 ENSG00000225151.9 GOLGA2P7 -3.83 0.000154 0.0261 -0.26 -0.2 Schizophrenia; chr15:84688354 chr15:84199311~84230136:- LIHC cis rs12908161 0.959 rs34784022 ENSG00000225151.9 GOLGA2P7 -3.83 0.000154 0.0261 -0.26 -0.2 Schizophrenia; chr15:84688675 chr15:84199311~84230136:- LIHC cis rs12908161 0.959 rs12908699 ENSG00000225151.9 GOLGA2P7 -3.83 0.000154 0.0261 -0.26 -0.2 Schizophrenia; chr15:84697172 chr15:84199311~84230136:- LIHC cis rs12908161 1 rs35316992 ENSG00000225151.9 GOLGA2P7 -3.83 0.000154 0.0261 -0.26 -0.2 Schizophrenia; chr15:84704902 chr15:84199311~84230136:- LIHC cis rs12908161 1 rs4643294 ENSG00000225151.9 GOLGA2P7 -3.83 0.000154 0.0261 -0.26 -0.2 Schizophrenia; chr15:84707022 chr15:84199311~84230136:- LIHC cis rs12908161 1 rs62021219 ENSG00000225151.9 GOLGA2P7 -3.83 0.000154 0.0261 -0.26 -0.2 Schizophrenia; chr15:84712928 chr15:84199311~84230136:- LIHC cis rs12908161 1 rs34900908 ENSG00000225151.9 GOLGA2P7 -3.83 0.000154 0.0261 -0.26 -0.2 Schizophrenia; chr15:84714368 chr15:84199311~84230136:- LIHC cis rs12908161 1 rs35524990 ENSG00000225151.9 GOLGA2P7 -3.83 0.000154 0.0261 -0.26 -0.2 Schizophrenia; chr15:84714972 chr15:84199311~84230136:- LIHC cis rs933688 0.877 rs10474352 ENSG00000281357.1 ARRDC3-AS1 3.83 0.000154 0.0261 0.26 0.2 Smoking behavior; chr5:91436408 chr5:91380349~91439085:+ LIHC cis rs4873772 0.837 rs62539144 ENSG00000253608.1 RP11-770E5.1 3.83 0.000154 0.0261 0.22 0.2 Lobe attachment (rater-scored or self-reported); chr8:47650686 chr8:48551567~48698510:+ LIHC cis rs987724 0.515 rs344079 ENSG00000243926.1 TIPARP-AS1 3.83 0.000154 0.0261 0.23 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156837783 chr3:156671862~156674378:- LIHC cis rs987724 0.515 rs344080 ENSG00000243926.1 TIPARP-AS1 3.83 0.000154 0.0261 0.23 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156837996 chr3:156671862~156674378:- LIHC cis rs987724 0.515 rs344082 ENSG00000243926.1 TIPARP-AS1 3.83 0.000154 0.0261 0.23 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156838290 chr3:156671862~156674378:- LIHC cis rs987724 0.515 rs344084 ENSG00000243926.1 TIPARP-AS1 3.83 0.000154 0.0261 0.23 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156838591 chr3:156671862~156674378:- LIHC cis rs4237845 0.761 rs11172378 ENSG00000270039.1 RP11-571M6.17 -3.83 0.000154 0.0261 -0.28 -0.2 Intelligence (multi-trait analysis); chr12:57904378 chr12:57803838~57804415:+ LIHC cis rs7412746 0.658 rs3768015 ENSG00000231073.1 RP11-316M1.3 3.83 0.000154 0.0261 0.21 0.2 Melanoma; chr1:150840478 chr1:150973123~150975534:+ LIHC cis rs2581828 0.591 rs6445566 ENSG00000242142.1 SERBP1P3 -3.83 0.000154 0.0261 -0.27 -0.2 Crohn's disease; chr3:53131611 chr3:53064283~53065091:- LIHC cis rs2581828 0.618 rs13319872 ENSG00000242142.1 SERBP1P3 -3.83 0.000154 0.0261 -0.27 -0.2 Crohn's disease; chr3:53132082 chr3:53064283~53065091:- LIHC cis rs8072100 0.79 rs11079783 ENSG00000228782.6 CTD-2026D20.3 -3.83 0.000154 0.0261 -0.22 -0.2 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47608650 chr17:47450568~47492492:- LIHC cis rs7015263 0.581 rs1142528 ENSG00000250569.1 NTAN1P2 3.83 0.000154 0.0261 0.23 0.2 Intelligence (multi-trait analysis); chr8:86469071 chr8:86481754~86483002:- LIHC cis rs10461617 0.541 rs860581 ENSG00000271828.1 CTD-2310F14.1 3.83 0.000154 0.0261 0.33 0.2 Type 2 diabetes; chr5:56854710 chr5:56927874~56929573:+ LIHC cis rs55966801 0.898 rs72878047 ENSG00000277290.1 RP11-326C3.16 -3.83 0.000154 0.0261 -0.26 -0.2 Plateletcrit; chr11:229811 chr11:243099~243483:- LIHC cis rs55966801 0.898 rs113919457 ENSG00000277290.1 RP11-326C3.16 -3.83 0.000154 0.0261 -0.26 -0.2 Plateletcrit; chr11:230951 chr11:243099~243483:- LIHC cis rs55966801 0.898 rs11602248 ENSG00000277290.1 RP11-326C3.16 -3.83 0.000154 0.0261 -0.26 -0.2 Plateletcrit; chr11:231305 chr11:243099~243483:- LIHC cis rs55966801 0.841 rs11607019 ENSG00000277290.1 RP11-326C3.16 -3.83 0.000154 0.0261 -0.26 -0.2 Plateletcrit; chr11:234349 chr11:243099~243483:- LIHC cis rs9388451 0.626 rs1268074 ENSG00000237742.5 RP11-624M8.1 -3.83 0.000154 0.0261 -0.19 -0.2 Brugada syndrome; chr6:125786645 chr6:125578558~125749190:- LIHC cis rs6452524 1 rs6452531 ENSG00000271862.1 RP11-343L5.2 3.83 0.000154 0.0261 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83170355 chr5:83049376~83050964:- LIHC cis rs9595908 0.709 rs7319275 ENSG00000212293.1 SNORA16 3.83 0.000154 0.0261 0.23 0.2 Body mass index; chr13:32733280 chr13:32420390~32420516:- LIHC cis rs4356975 0.563 rs6600885 ENSG00000250919.1 RP11-813N20.3 -3.83 0.000154 0.0261 -0.2 -0.2 Obesity-related traits; chr4:69103949 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs6600886 ENSG00000250919.1 RP11-813N20.3 -3.83 0.000154 0.0261 -0.2 -0.2 Obesity-related traits; chr4:69104017 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs6600887 ENSG00000250919.1 RP11-813N20.3 -3.83 0.000154 0.0261 -0.2 -0.2 Obesity-related traits; chr4:69104070 chr4:69027831~69044578:+ LIHC cis rs4356975 0.522 rs6600888 ENSG00000250919.1 RP11-813N20.3 -3.83 0.000154 0.0261 -0.2 -0.2 Obesity-related traits; chr4:69104141 chr4:69027831~69044578:+ LIHC cis rs2243480 1 rs6964245 ENSG00000228409.4 CCT6P1 -3.83 0.000154 0.0261 -0.22 -0.2 Diabetic kidney disease; chr7:66253730 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs6964530 ENSG00000228409.4 CCT6P1 -3.83 0.000154 0.0261 -0.22 -0.2 Diabetic kidney disease; chr7:66253864 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs10807701 ENSG00000228409.4 CCT6P1 -3.83 0.000154 0.0261 -0.22 -0.2 Diabetic kidney disease; chr7:66259699 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1499613 ENSG00000228409.4 CCT6P1 -3.83 0.000154 0.0261 -0.22 -0.2 Diabetic kidney disease; chr7:66265873 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1553174 ENSG00000228409.4 CCT6P1 -3.83 0.000154 0.0261 -0.22 -0.2 Diabetic kidney disease; chr7:66266207 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs10950032 ENSG00000228409.4 CCT6P1 -3.83 0.000154 0.0261 -0.22 -0.2 Diabetic kidney disease; chr7:66273604 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1392104 ENSG00000228409.4 CCT6P1 -3.83 0.000154 0.0261 -0.22 -0.2 Diabetic kidney disease; chr7:66294120 chr7:65751142~65763354:+ LIHC cis rs3931020 0.745 rs10874274 ENSG00000272864.1 RP11-17E13.2 -3.83 0.000154 0.0261 -0.25 -0.2 Resistin levels; chr1:74786450 chr1:74698769~74699333:- LIHC cis rs960902 0.764 rs7582204 ENSG00000213553.4 RPLP0P6 -3.83 0.000154 0.0261 -0.16 -0.2 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37502658 chr2:38481851~38482804:+ LIHC cis rs11096990 0.964 rs3733280 ENSG00000249685.1 RP11-360F5.3 -3.83 0.000154 0.0262 -0.25 -0.2 Cognitive function; chr4:39269921 chr4:39133913~39135608:+ LIHC cis rs12586317 0.62 rs28870452 ENSG00000257307.1 RP11-317N8.4 -3.83 0.000154 0.0262 -0.24 -0.2 Psoriasis; chr14:35067672 chr14:35881001~35881709:+ LIHC cis rs9646944 0.501 rs2075186 ENSG00000234389.1 AC007278.3 3.83 0.000154 0.0262 0.26 0.2 Blood protein levels; chr2:102440791 chr2:102438713~102440475:+ LIHC cis rs12210905 1 rs9379965 ENSG00000216901.1 AL022393.7 3.83 0.000154 0.0262 0.35 0.2 Hip circumference adjusted for BMI; chr6:27259282 chr6:28176188~28176674:+ LIHC cis rs3764021 0.527 rs11052423 ENSG00000256673.1 RP11-599J14.2 3.83 0.000154 0.0262 0.2 0.2 Type 1 diabetes; chr12:9687442 chr12:9398355~9414851:- LIHC cis rs7829975 0.606 rs10112585 ENSG00000254340.1 RP11-10A14.3 -3.83 0.000154 0.0262 -0.2 -0.2 Mood instability; chr8:8937520 chr8:9141424~9145435:+ LIHC cis rs794185 0.747 rs2819566 ENSG00000231249.1 ITPR1-AS1 -3.83 0.000154 0.0262 -0.22 -0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4463958 chr3:4490891~4493163:- LIHC cis rs11613048 0.897 rs12578187 ENSG00000245614.3 DDX11-AS1 -3.83 0.000154 0.0262 -0.18 -0.2 Major depressive disorder; chr12:30171742 chr12:31020763~31073847:- LIHC cis rs1494950 1 rs7675235 ENSG00000214846.4 RP11-115L11.1 -3.83 0.000154 0.0262 -0.43 -0.2 Political ideology; chr4:15061766 chr4:15730962~15731627:- LIHC cis rs1494950 1 rs17309950 ENSG00000214846.4 RP11-115L11.1 -3.83 0.000154 0.0262 -0.43 -0.2 Political ideology; chr4:15072289 chr4:15730962~15731627:- LIHC cis rs10129255 0.744 rs28517388 ENSG00000211970.3 IGHV4-61 -3.83 0.000154 0.0262 -0.17 -0.2 Kawasaki disease; chr14:106704323 chr14:106639119~106639657:- LIHC cis rs591584 0.621 rs489591 ENSG00000255893.1 RP11-685N10.1 -3.83 0.000154 0.0262 -0.2 -0.2 Macrophage Migration Inhibitory Factor levels; chr11:94603265 chr11:94472908~94473570:- LIHC cis rs12468226 0.808 rs73992849 ENSG00000272966.1 RP11-686O6.1 3.83 0.000154 0.0262 0.36 0.2 Urate levels; chr2:202152444 chr2:202336739~202337200:+ LIHC cis rs3893377 1 rs3893377 ENSG00000214846.4 RP11-115L11.1 3.83 0.000154 0.0262 0.26 0.2 Current cigarettes per day in chronic obstructive pulmonary disease; chr4:15740506 chr4:15730962~15731627:- LIHC cis rs2439831 1 rs690316 ENSG00000166763.7 STRCP1 3.83 0.000155 0.0262 0.28 0.2 Lung cancer in ever smokers; chr15:43445682 chr15:43699488~43718184:- LIHC cis rs9341808 0.644 rs62408577 ENSG00000272129.1 RP11-250B2.6 -3.83 0.000155 0.0262 -0.21 -0.2 Sitting height ratio; chr6:80232307 chr6:80355424~80356859:+ LIHC cis rs9341808 0.644 rs76102095 ENSG00000272129.1 RP11-250B2.6 -3.83 0.000155 0.0262 -0.21 -0.2 Sitting height ratio; chr6:80232309 chr6:80355424~80356859:+ LIHC cis rs9341808 0.644 rs59371711 ENSG00000272129.1 RP11-250B2.6 -3.83 0.000155 0.0262 -0.21 -0.2 Sitting height ratio; chr6:80232310 chr6:80355424~80356859:+ LIHC cis rs6545883 0.965 rs11887205 ENSG00000271889.1 RP11-493E12.1 3.83 0.000155 0.0262 0.24 0.2 Tuberculosis; chr2:61547338 chr2:61151433~61162105:- LIHC cis rs875971 1 rs6946143 ENSG00000232559.3 GS1-124K5.12 3.83 0.000155 0.0262 0.16 0.2 Aortic root size; chr7:66114735 chr7:66554588~66576923:- LIHC cis rs13434995 0.513 rs6851971 ENSG00000273257.1 RP11-177J6.1 3.83 0.000155 0.0262 0.32 0.2 Adiponectin levels; chr4:55561897 chr4:55387949~55388271:+ LIHC cis rs6832769 1 rs3736544 ENSG00000272969.1 RP11-528I4.2 3.83 0.000155 0.0262 0.24 0.2 Personality dimensions; chr4:55443825 chr4:55547112~55547889:+ LIHC cis rs11148252 0.669 rs61958050 ENSG00000278238.1 RP11-245D16.4 -3.83 0.000155 0.0263 -0.2 -0.2 Lewy body disease; chr13:52420292 chr13:52454775~52455331:- LIHC cis rs1598856 0.966 rs28573147 ENSG00000230069.3 LRRC37A15P -3.83 0.000155 0.0263 -0.18 -0.2 Primary biliary cholangitis; chr4:102497028 chr4:102727274~102730721:- LIHC cis rs6723108 0.603 rs6430555 ENSG00000224043.6 CCNT2-AS1 -3.83 0.000155 0.0263 -0.28 -0.2 Type 2 diabetes; chr2:134890089 chr2:134735464~134918710:- LIHC cis rs7095607 0.9 rs10823155 ENSG00000233590.1 RP11-153K11.3 3.83 0.000155 0.0263 0.24 0.2 Lung function (FVC); chr10:68190439 chr10:68233251~68242379:- LIHC cis rs7095607 1 rs7900891 ENSG00000233590.1 RP11-153K11.3 3.83 0.000155 0.0263 0.24 0.2 Lung function (FVC); chr10:68193285 chr10:68233251~68242379:- LIHC cis rs7095607 1 rs10998009 ENSG00000233590.1 RP11-153K11.3 3.83 0.000155 0.0263 0.24 0.2 Lung function (FVC); chr10:68193659 chr10:68233251~68242379:- LIHC cis rs6832769 1 rs7677526 ENSG00000272969.1 RP11-528I4.2 3.83 0.000155 0.0263 0.24 0.2 Personality dimensions; chr4:55483741 chr4:55547112~55547889:+ LIHC cis rs367615 0.704 rs6889301 ENSG00000249476.1 CTD-2587M2.1 3.83 0.000155 0.0263 0.24 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109499480 chr5:109237120~109326369:- LIHC cis rs4237845 0.537 rs4237844 ENSG00000270039.1 RP11-571M6.17 3.83 0.000155 0.0263 0.29 0.2 Intelligence (multi-trait analysis); chr12:57874204 chr12:57803838~57804415:+ LIHC cis rs4964805 0.865 rs4964289 ENSG00000257681.1 RP11-341G23.4 3.83 0.000155 0.0263 0.21 0.2 Attention deficit hyperactivity disorder; chr12:103810413 chr12:103746315~103768858:- LIHC cis rs2243480 1 rs67728539 ENSG00000226002.1 RP11-460N20.5 -3.83 0.000155 0.0263 -0.3 -0.2 Diabetic kidney disease; chr7:65913137 chr7:65084103~65100232:+ LIHC cis rs17818399 0.89 rs34752561 ENSG00000239332.4 LINC01119 -3.83 0.000155 0.0263 -0.29 -0.2 Height; chr2:46623011 chr2:46816697~46859007:+ LIHC cis rs6445975 0.715 rs17059125 ENSG00000272360.1 RP11-359I18.5 -3.83 0.000155 0.0263 -0.24 -0.2 Systemic lupus erythematosus; chr3:58283023 chr3:58490830~58491291:- LIHC cis rs7617480 0.519 rs6790914 ENSG00000270441.1 RP11-694I15.7 -3.83 0.000155 0.0263 -0.29 -0.2 Menarche (age at onset);Subjective well-being (multi-trait analysis); chr3:49168885 chr3:49140086~49160851:- LIHC cis rs7915414 0.802 rs34195517 ENSG00000230338.1 MTND4P19 3.83 0.000155 0.0263 0.22 0.2 Clopidogrel active metabolite levels; chr10:94627421 chr10:94774156~94774633:- LIHC cis rs7617773 0.78 rs7645425 ENSG00000228638.1 FCF1P2 -3.83 0.000155 0.0263 -0.23 -0.2 Coronary artery disease; chr3:48320879 chr3:48290793~48291375:- LIHC cis rs7617773 0.743 rs11716371 ENSG00000228638.1 FCF1P2 -3.83 0.000155 0.0263 -0.23 -0.2 Coronary artery disease; chr3:48321260 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs6793223 ENSG00000228638.1 FCF1P2 -3.83 0.000155 0.0263 -0.23 -0.2 Coronary artery disease; chr3:48322611 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs4541431 ENSG00000228638.1 FCF1P2 -3.83 0.000155 0.0263 -0.23 -0.2 Coronary artery disease; chr3:48323728 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs11714944 ENSG00000228638.1 FCF1P2 -3.83 0.000155 0.0263 -0.23 -0.2 Coronary artery disease; chr3:48325481 chr3:48290793~48291375:- LIHC cis rs7617773 0.743 rs13071960 ENSG00000228638.1 FCF1P2 -3.83 0.000155 0.0263 -0.23 -0.2 Coronary artery disease; chr3:48326047 chr3:48290793~48291375:- LIHC cis rs7617773 0.743 rs4632568 ENSG00000228638.1 FCF1P2 -3.83 0.000155 0.0263 -0.23 -0.2 Coronary artery disease; chr3:48326329 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs11130164 ENSG00000228638.1 FCF1P2 -3.83 0.000155 0.0263 -0.23 -0.2 Coronary artery disease; chr3:48327544 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs7653336 ENSG00000228638.1 FCF1P2 -3.83 0.000155 0.0263 -0.23 -0.2 Coronary artery disease; chr3:48327974 chr3:48290793~48291375:- LIHC cis rs7617773 0.747 rs34076262 ENSG00000228638.1 FCF1P2 -3.83 0.000155 0.0263 -0.23 -0.2 Coronary artery disease; chr3:48328926 chr3:48290793~48291375:- LIHC cis rs7586604 0.608 rs10496340 ENSG00000230393.1 AC092667.2 3.83 0.000155 0.0263 0.26 0.2 Cannabis dependence symptom count; chr2:99775847 chr2:100104919~100107504:+ LIHC cis rs12209785 0.911 rs6458444 ENSG00000231769.2 RP1-8B1.4 3.83 0.000155 0.0263 0.29 0.2 Survival in pancreatic cancer; chr6:45522445 chr6:46097093~46129706:- LIHC cis rs8028313 0.731 rs4331293 ENSG00000270964.1 RP11-502I4.3 -3.83 0.000155 0.0263 -0.22 -0.2 Obesity; chr15:67695463 chr15:67541072~67542604:- LIHC cis rs6433895 0.601 rs34405919 ENSG00000236153.1 AC104076.3 -3.83 0.000155 0.0263 -0.28 -0.2 Lymphocyte counts; chr2:181178988 chr2:180979427~180980090:- LIHC cis rs4561483 0.767 rs33633 ENSG00000261560.1 RP11-166B2.3 -3.83 0.000155 0.0263 -0.23 -0.2 Testicular germ cell tumor; chr16:11901000 chr16:11881075~11882569:- LIHC cis rs7712401 0.601 rs246303 ENSG00000263432.2 RN7SL689P 3.83 0.000155 0.0263 0.3 0.2 Mean platelet volume; chr5:122916022 chr5:123022487~123022783:- LIHC cis rs11733284 0.963 rs98270 ENSG00000259959.1 RP11-121C2.2 3.83 0.000155 0.0263 0.19 0.2 Gout;Renal underexcretion gout; chr4:48017306 chr4:47840122~47844339:- LIHC cis rs6840360 0.869 rs55668815 ENSG00000251603.1 RP11-164P12.4 -3.83 0.000155 0.0263 -0.18 -0.2 Intelligence (multi-trait analysis); chr4:151552676 chr4:151667224~151670502:+ LIHC cis rs1115240 0.898 rs178168 ENSG00000257842.4 NOVA1-AS1 -3.83 0.000155 0.0263 -0.19 -0.2 Educational attainment (years of education); chr14:26554591 chr14:26598412~26806467:+ LIHC cis rs881375 1 rs7037140 ENSG00000226752.6 PSMD5-AS1 -3.83 0.000155 0.0263 -0.22 -0.2 Rheumatoid arthritis; chr9:120894049 chr9:120824828~120854385:+ LIHC cis rs12468226 0.873 rs78798541 ENSG00000272966.1 RP11-686O6.1 3.83 0.000155 0.0263 0.35 0.2 Urate levels; chr2:202194708 chr2:202336739~202337200:+ LIHC cis rs6456156 0.792 rs4710181 ENSG00000227598.1 RP1-167A14.2 -3.83 0.000155 0.0263 -0.2 -0.2 Primary biliary cholangitis; chr6:167100510 chr6:166969626~166999065:- LIHC cis rs7560272 0.538 rs13006448 ENSG00000273245.1 RP11-434P11.2 -3.83 0.000155 0.0263 -0.25 -0.2 Schizophrenia; chr2:73697297 chr2:73750256~73750786:- LIHC cis rs917195 0.855 rs2267716 ENSG00000226874.1 AC005154.8 3.82 0.000155 0.0263 0.25 0.2 Type 2 diabetes; chr7:30677027 chr7:30544053~30544431:+ LIHC cis rs17508449 0.819 rs78552134 ENSG00000232450.1 RP4-730K3.3 -3.82 0.000155 0.0263 -0.27 -0.2 Leprosy; chr1:113727044 chr1:113698884~113699631:- LIHC cis rs7560272 0.538 rs12233115 ENSG00000273245.1 RP11-434P11.2 -3.82 0.000155 0.0263 -0.25 -0.2 Schizophrenia; chr2:73704764 chr2:73750256~73750786:- LIHC cis rs7560272 0.538 rs11126414 ENSG00000273245.1 RP11-434P11.2 -3.82 0.000155 0.0263 -0.25 -0.2 Schizophrenia; chr2:73704917 chr2:73750256~73750786:- LIHC cis rs1344653 0.738 rs7561420 ENSG00000236204.4 LINC01376 3.82 0.000155 0.0263 0.24 0.2 Pulse pressure; chr2:19561553 chr2:18986451~19346748:- LIHC cis rs4578769 0.959 rs4800439 ENSG00000265943.1 RP11-739L10.1 3.82 0.000155 0.0263 0.25 0.2 Eosinophil percentage of white cells; chr18:22920492 chr18:22699481~22933764:- LIHC cis rs9890032 1 rs9890032 ENSG00000266490.1 CTD-2349P21.9 -3.82 0.000155 0.0264 -0.18 -0.2 Hip circumference adjusted for BMI; chr17:30838916 chr17:30792372~30792833:+ LIHC cis rs17023223 0.553 rs55696509 ENSG00000231365.4 RP11-418J17.1 -3.82 0.000156 0.0264 -0.29 -0.2 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119144033 chr1:119140396~119275973:+ LIHC cis rs733175 0.855 rs6853437 ENSG00000250413.1 RP11-448G15.1 3.82 0.000156 0.0264 0.29 0.2 Psychosis and Alzheimer's disease; chr4:10003811 chr4:10006482~10009725:+ LIHC cis rs2439831 0.867 rs2278860 ENSG00000166763.7 STRCP1 -3.82 0.000156 0.0264 -0.29 -0.2 Lung cancer in ever smokers; chr15:43366848 chr15:43699488~43718184:- LIHC cis rs755249 0.565 rs3768320 ENSG00000182109.6 RP11-69E11.4 -3.82 0.000156 0.0264 -0.25 -0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39566567 chr1:39522280~39546187:- LIHC cis rs7647973 0.56 rs7638154 ENSG00000270441.1 RP11-694I15.7 -3.82 0.000156 0.0264 -0.29 -0.2 Menarche (age at onset); chr3:49261942 chr3:49140086~49160851:- LIHC cis rs7560272 0.538 rs12233112 ENSG00000273245.1 RP11-434P11.2 -3.82 0.000156 0.0264 -0.25 -0.2 Schizophrenia; chr2:73704637 chr2:73750256~73750786:- LIHC cis rs270601 0.837 rs367805 ENSG00000263597.1 MIR3936 3.82 0.000156 0.0264 0.22 0.2 Acylcarnitine levels; chr5:132365587 chr5:132365490~132365599:- LIHC cis rs79040073 0.911 rs17393193 ENSG00000259531.2 RP11-295H24.3 3.82 0.000156 0.0264 0.31 0.2 Lung cancer in ever smokers; chr15:49039882 chr15:49365124~49366685:- LIHC cis rs7560272 0.538 rs17350056 ENSG00000273245.1 RP11-434P11.2 -3.82 0.000156 0.0264 -0.25 -0.2 Schizophrenia; chr2:73695750 chr2:73750256~73750786:- LIHC cis rs66887589 0.777 rs4643791 ENSG00000245958.5 RP11-33B1.1 3.82 0.000156 0.0264 0.2 0.2 Diastolic blood pressure; chr4:119344464 chr4:119454791~119552025:+ LIHC cis rs42490 0.536 rs366867 ENSG00000251136.7 RP11-37B2.1 -3.82 0.000156 0.0264 -0.17 -0.2 Leprosy; chr8:89851946 chr8:89609409~89757727:- LIHC cis rs42490 0.609 rs367640 ENSG00000251136.7 RP11-37B2.1 -3.82 0.000156 0.0264 -0.17 -0.2 Leprosy; chr8:89852168 chr8:89609409~89757727:- LIHC cis rs2581828 0.618 rs9868406 ENSG00000242142.1 SERBP1P3 -3.82 0.000156 0.0264 -0.27 -0.2 Crohn's disease; chr3:53130177 chr3:53064283~53065091:- LIHC cis rs948562 0.69 rs75365860 ENSG00000280010.1 AP001350.4 3.82 0.000156 0.0264 0.35 0.2 Lymphoma; chr11:58402023 chr11:58627435~58628528:+ LIHC cis rs2562456 0.876 rs7252585 ENSG00000268555.1 RP11-678G14.3 -3.82 0.000156 0.0264 -0.26 -0.2 Pain; chr19:21475141 chr19:21570822~21587322:- LIHC cis rs10833905 1 rs11026883 ENSG00000246225.5 RP11-17A1.3 -3.82 0.000156 0.0264 -0.26 -0.2 Sudden cardiac arrest; chr11:22997005 chr11:22829380~22945393:+ LIHC cis rs9595908 0.709 rs3492 ENSG00000212293.1 SNORA16 3.82 0.000156 0.0264 0.23 0.2 Body mass index; chr13:32775203 chr13:32420390~32420516:- LIHC cis rs9595908 0.709 rs7326102 ENSG00000212293.1 SNORA16 3.82 0.000156 0.0264 0.23 0.2 Body mass index; chr13:32777857 chr13:32420390~32420516:- LIHC cis rs9595908 0.669 rs17516561 ENSG00000212293.1 SNORA16 3.82 0.000156 0.0264 0.23 0.2 Body mass index; chr13:32782063 chr13:32420390~32420516:- LIHC cis rs931127 0.836 rs523029 ENSG00000265874.1 MIR4489 -3.82 0.000156 0.0264 -0.26 -0.2 Systemic lupus erythematosus; chr11:65709016 chr11:65649192~65649253:+ LIHC cis rs10129255 1 rs61997605 ENSG00000211970.3 IGHV4-61 -3.82 0.000156 0.0264 -0.16 -0.2 Kawasaki disease; chr14:106678368 chr14:106639119~106639657:- LIHC cis rs1499614 1 rs2659913 ENSG00000232546.1 RP11-458F8.1 -3.82 0.000156 0.0264 -0.22 -0.2 Gout; chr7:66692349 chr7:66848496~66858136:+ LIHC cis rs1499614 1 rs2707840 ENSG00000232546.1 RP11-458F8.1 -3.82 0.000156 0.0264 -0.22 -0.2 Gout; chr7:66693028 chr7:66848496~66858136:+ LIHC cis rs1499614 1 rs2659911 ENSG00000232546.1 RP11-458F8.1 -3.82 0.000156 0.0264 -0.22 -0.2 Gout; chr7:66693433 chr7:66848496~66858136:+ LIHC cis rs1499614 1 rs2707838 ENSG00000232546.1 RP11-458F8.1 -3.82 0.000156 0.0264 -0.22 -0.2 Gout; chr7:66694214 chr7:66848496~66858136:+ LIHC cis rs1499614 1 rs60326618 ENSG00000232546.1 RP11-458F8.1 -3.82 0.000156 0.0264 -0.22 -0.2 Gout; chr7:66701371 chr7:66848496~66858136:+ LIHC cis rs1499614 1 rs2707830 ENSG00000232546.1 RP11-458F8.1 -3.82 0.000156 0.0264 -0.22 -0.2 Gout; chr7:66702658 chr7:66848496~66858136:+ LIHC cis rs1499614 1 rs2707828 ENSG00000232546.1 RP11-458F8.1 -3.82 0.000156 0.0264 -0.22 -0.2 Gout; chr7:66706390 chr7:66848496~66858136:+ LIHC cis rs1499614 0.803 rs1922723 ENSG00000232546.1 RP11-458F8.1 -3.82 0.000156 0.0264 -0.22 -0.2 Gout; chr7:66710076 chr7:66848496~66858136:+ LIHC cis rs1499614 1 rs2659903 ENSG00000232546.1 RP11-458F8.1 -3.82 0.000156 0.0264 -0.22 -0.2 Gout; chr7:66715944 chr7:66848496~66858136:+ LIHC cis rs1499614 1 rs2141924 ENSG00000232546.1 RP11-458F8.1 -3.82 0.000156 0.0264 -0.22 -0.2 Gout; chr7:66721259 chr7:66848496~66858136:+ LIHC cis rs244293 0.765 rs17817442 ENSG00000275710.1 RP11-257O5.4 -3.82 0.000156 0.0264 -0.22 -0.2 Menarche (age at onset); chr17:55022153 chr17:54964474~54964679:+ LIHC cis rs11710088 0.74 rs11710025 ENSG00000244503.1 RP11-278L15.6 3.82 0.000156 0.0264 0.26 0.2 QRS duration; chr3:149475307 chr3:149494660~149495995:+ LIHC cis rs1267303 0.716 rs942255 ENSG00000227857.2 RP4-533D7.5 -3.82 0.000156 0.0265 -0.27 -0.2 Monobrow; chr1:46524120 chr1:46134531~46139081:+ LIHC cis rs4148008 0.589 rs7219718 ENSG00000267250.1 RP11-118B18.2 -3.82 0.000156 0.0265 -0.26 -0.2 HDL cholesterol; chr17:68830698 chr17:68793549~68797822:- LIHC cis rs4148008 0.589 rs7215620 ENSG00000267250.1 RP11-118B18.2 -3.82 0.000156 0.0265 -0.26 -0.2 HDL cholesterol; chr17:68830708 chr17:68793549~68797822:- LIHC cis rs2243480 1 rs2533288 ENSG00000275400.1 RP4-756H11.5 3.82 0.000156 0.0265 0.27 0.2 Diabetic kidney disease; chr7:66591724 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs2707844 ENSG00000275400.1 RP4-756H11.5 3.82 0.000156 0.0265 0.27 0.2 Diabetic kidney disease; chr7:66594522 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs1796220 ENSG00000275400.1 RP4-756H11.5 3.82 0.000156 0.0265 0.27 0.2 Diabetic kidney disease; chr7:66597113 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs2707831 ENSG00000275400.1 RP4-756H11.5 3.82 0.000156 0.0265 0.27 0.2 Diabetic kidney disease; chr7:66597524 chr7:66553805~66554199:- LIHC cis rs854624 0.892 rs1734961 ENSG00000278690.1 RP11-104J23.2 -3.82 0.000156 0.0265 -0.4 -0.2 Blood protein levels; chr17:36008471 chr17:36012504~36012891:+ LIHC cis rs7917772 0.503 rs7904955 ENSG00000236937.2 PTGES3P4 -3.82 0.000156 0.0265 -0.27 -0.2 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102607335 chr10:102845595~102845950:+ LIHC cis rs7121538 0.551 rs16930332 ENSG00000251991.1 RNU7-49P -3.82 0.000156 0.0265 -0.33 -0.2 HDL cholesterol; chr11:14578392 chr11:14478892~14478953:+ LIHC cis rs11098499 0.863 rs2306456 ENSG00000260091.1 RP11-33B1.4 -3.82 0.000156 0.0265 -0.15 -0.2 Corneal astigmatism; chr4:119551267 chr4:119409333~119410233:+ LIHC cis rs11089937 0.539 rs6001075 ENSG00000211639.2 IGLV4-60 3.82 0.000156 0.0265 0.18 0.2 Periodontitis (PAL4Q3); chr22:22133765 chr22:22162199~22162681:+ LIHC cis rs7914558 0.646 rs7897654 ENSG00000236937.2 PTGES3P4 3.82 0.000156 0.0265 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102902701 chr10:102845595~102845950:+ LIHC cis rs17482078 0.879 rs2124921 ENSG00000248734.2 CTD-2260A17.1 3.82 0.000156 0.0265 0.29 0.2 Behcet's disease;Blood protein levels; chr5:96783635 chr5:96784777~96785999:+ LIHC cis rs7937890 0.559 rs4369365 ENSG00000251991.1 RNU7-49P 3.82 0.000157 0.0265 0.22 0.2 Mitochondrial DNA levels; chr11:14422969 chr11:14478892~14478953:+ LIHC cis rs875971 0.505 rs2462573 ENSG00000237310.1 GS1-124K5.4 -3.82 0.000157 0.0265 -0.2 -0.2 Aortic root size; chr7:66042405 chr7:66493706~66495474:+ LIHC cis rs11096990 0.855 rs2711989 ENSG00000249685.1 RP11-360F5.3 -3.82 0.000157 0.0265 -0.28 -0.2 Cognitive function; chr4:39150416 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2566169 ENSG00000249685.1 RP11-360F5.3 -3.82 0.000157 0.0265 -0.28 -0.2 Cognitive function; chr4:39150420 chr4:39133913~39135608:+ LIHC cis rs2152735 0.569 rs1856047 ENSG00000279778.1 RP11-60A14.1 -3.82 0.000157 0.0265 -0.19 -0.2 Resting heart rate; chr1:87432224 chr1:87805286~87808372:- LIHC cis rs11841001 0.556 rs34083520 ENSG00000261105.4 LMO7-AS1 -3.82 0.000157 0.0265 -0.42 -0.2 Corneal astigmatism; chr13:75775622 chr13:75604700~75635994:- LIHC cis rs1405130 0.967 rs4663155 ENSG00000224287.2 MSL3P1 3.82 0.000157 0.0265 0.24 0.2 Coronary artery disease; chr2:234665381 chr2:233865437~233868444:- LIHC cis rs7712401 0.601 rs30048 ENSG00000263432.2 RN7SL689P 3.82 0.000157 0.0265 0.3 0.2 Mean platelet volume; chr5:122934698 chr5:123022487~123022783:- LIHC cis rs7560272 0.538 rs12233112 ENSG00000204872.3 NAT8B -3.82 0.000157 0.0266 -0.27 -0.2 Schizophrenia; chr2:73704637 chr2:73700576~73701340:- LIHC cis rs2797160 0.935 rs1739372 ENSG00000237742.5 RP11-624M8.1 3.82 0.000157 0.0266 0.21 0.2 Endometrial cancer; chr6:125690179 chr6:125578558~125749190:- LIHC cis rs1005277 0.522 rs1208681 ENSG00000275858.1 RP11-291L22.8 3.82 0.000157 0.0266 0.22 0.2 Extrinsic epigenetic age acceleration; chr10:37804047 chr10:38450738~38451069:- LIHC cis rs6723108 0.603 rs1374289 ENSG00000224043.6 CCNT2-AS1 3.82 0.000157 0.0266 0.28 0.2 Type 2 diabetes; chr2:134936809 chr2:134735464~134918710:- LIHC cis rs3091242 0.9 rs1883427 ENSG00000224183.1 SDHDP6 -3.82 0.000157 0.0266 -0.23 -0.2 Erythrocyte sedimentation rate; chr1:25417977 chr1:25294164~25294643:- LIHC cis rs7560272 0.538 rs6732812 ENSG00000273245.1 RP11-434P11.2 -3.82 0.000157 0.0266 -0.25 -0.2 Schizophrenia; chr2:73695348 chr2:73750256~73750786:- LIHC cis rs718433 0.616 rs10438000 ENSG00000258441.1 LINC00641 -3.82 0.000157 0.0266 -0.2 -0.2 Intraocular pressure; chr14:21741707 chr14:21200079~21206900:- LIHC cis rs67311347 1 rs1004655 ENSG00000223797.4 ENTPD3-AS1 3.82 0.000157 0.0266 0.17 0.2 Renal cell carcinoma; chr3:40448518 chr3:40313802~40453329:- LIHC cis rs41313321 0.736 rs7028431 ENSG00000272696.1 RP11-339B21.13 3.82 0.000157 0.0266 0.27 0.2 Coenzyme Q10 levels; chr9:128293987 chr9:128316337~128316909:+ LIHC cis rs1799949 1 rs12944597 ENSG00000267681.1 CTD-3199J23.6 -3.82 0.000157 0.0266 -0.2 -0.2 Menopause (age at onset); chr17:43035667 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs12942277 ENSG00000267681.1 CTD-3199J23.6 -3.82 0.000157 0.0266 -0.2 -0.2 Menopause (age at onset); chr17:43035957 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs34616041 ENSG00000267681.1 CTD-3199J23.6 -3.82 0.000157 0.0266 -0.2 -0.2 Menopause (age at onset); chr17:43036769 chr17:43144956~43145255:+ LIHC cis rs4561483 0.801 rs33620 ENSG00000261560.1 RP11-166B2.3 -3.82 0.000157 0.0266 -0.23 -0.2 Testicular germ cell tumor; chr16:11914689 chr16:11881075~11882569:- LIHC cis rs694739 0.595 rs11542299 ENSG00000236935.1 AP003774.1 3.82 0.000157 0.0266 0.22 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64371333 chr11:64325050~64329504:- LIHC cis rs1318937 1 rs3773471 ENSG00000224660.1 SH3BP5-AS1 -3.82 0.000157 0.0266 -0.18 -0.2 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15261540 chr3:15254184~15264493:+ LIHC cis rs3764021 0.527 rs10844380 ENSG00000256673.1 RP11-599J14.2 -3.82 0.000157 0.0266 -0.21 -0.2 Type 1 diabetes; chr12:9670678 chr12:9398355~9414851:- LIHC cis rs7315621 0.965 rs6598196 ENSG00000279700.1 RP13-554M15.2 3.82 0.000157 0.0266 0.15 0.2 Longevity; chr12:131596446 chr12:132565071~132566425:+ LIHC cis rs7315621 0.965 rs6598197 ENSG00000279700.1 RP13-554M15.2 3.82 0.000157 0.0266 0.15 0.2 Longevity; chr12:131596465 chr12:132565071~132566425:+ LIHC cis rs2880765 0.527 rs35184622 ENSG00000259630.2 CTD-2262B20.1 -3.82 0.000157 0.0266 -0.29 -0.2 Coronary artery disease; chr15:85529804 chr15:85415228~85415633:+ LIHC cis rs2880765 0.527 rs1483578 ENSG00000259630.2 CTD-2262B20.1 -3.82 0.000157 0.0266 -0.29 -0.2 Coronary artery disease; chr15:85532186 chr15:85415228~85415633:+ LIHC cis rs8005677 1 rs8006409 ENSG00000279656.1 RP11-298I3.6 3.82 0.000157 0.0266 0.23 0.2 Cognitive ability (multi-trait analysis); chr14:22927302 chr14:23023083~23024217:- LIHC cis rs1799949 0.965 rs799917 ENSG00000267681.1 CTD-3199J23.6 -3.82 0.000157 0.0266 -0.2 -0.2 Menopause (age at onset); chr17:43092919 chr17:43144956~43145255:+ LIHC cis rs9450351 0.744 rs9359674 ENSG00000203875.9 SNHG5 3.82 0.000158 0.0266 0.41 0.2 Interferon gamma-induced protein 10 levels; chr6:85996191 chr6:85660950~85678736:- LIHC cis rs17818399 0.735 rs11894342 ENSG00000236824.1 BCYRN1 -3.82 0.000158 0.0266 -0.22 -0.2 Height; chr2:46609300 chr2:47331060~47344517:+ LIHC cis rs6723108 0.581 rs1446525 ENSG00000224043.6 CCNT2-AS1 -3.82 0.000158 0.0267 -0.28 -0.2 Type 2 diabetes; chr2:134880277 chr2:134735464~134918710:- LIHC cis rs694739 0.628 rs645078 ENSG00000236935.1 AP003774.1 3.82 0.000158 0.0267 0.22 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64367826 chr11:64325050~64329504:- LIHC cis rs6745190 0.906 rs6743720 ENSG00000236153.1 AC104076.3 -3.82 0.000158 0.0267 -0.27 -0.2 White blood cell count; chr2:181095771 chr2:180979427~180980090:- LIHC cis rs2976388 0.609 rs2572899 ENSG00000253196.1 RP11-706C16.7 3.82 0.000158 0.0267 0.19 0.2 Urinary tract infection frequency; chr8:142704131 chr8:142763116~142766427:+ LIHC cis rs9906944 0.933 rs35051752 ENSG00000248278.1 SUMO2P17 -3.82 0.000158 0.0267 -0.33 -0.2 Intelligence (multi-trait analysis);Body fat percentage; chr17:49012546 chr17:48874860~48908983:- LIHC cis rs858239 1 rs199357 ENSG00000226816.2 AC005082.12 -3.82 0.000158 0.0267 -0.26 -0.2 Cerebrospinal fluid biomarker levels; chr7:23248690 chr7:23206013~23208045:+ LIHC cis rs867371 0.502 rs3759800 ENSG00000259429.4 UBE2Q2P2 3.82 0.000158 0.0267 0.21 0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82240622 chr15:82355142~82420075:+ LIHC cis rs6828577 0.862 rs298994 ENSG00000269893.5 SNHG8 3.82 0.000158 0.0267 0.21 0.2 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118706098 chr4:118278709~118279823:+ LIHC cis rs1874124 0.778 rs1335920 ENSG00000238078.1 LINC01352 -3.82 0.000158 0.0267 -0.37 -0.2 Cholesterol, total; chr1:220844946 chr1:220829255~220832429:+ LIHC cis rs7044106 0.762 rs1530370 ENSG00000238181.2 AHCYP2 -3.82 0.000158 0.0267 -0.23 -0.2 Hip circumference adjusted for BMI; chr9:120662274 chr9:120720673~120721972:+ LIHC cis rs794185 0.652 rs2819585 ENSG00000231249.1 ITPR1-AS1 -3.82 0.000158 0.0267 -0.22 -0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4470463 chr3:4490891~4493163:- LIHC cis rs2015599 0.623 rs7313552 ENSG00000275476.1 RP11-996F15.4 3.82 0.000158 0.0267 0.25 0.2 Platelet count;Mean platelet volume; chr12:29277302 chr12:29277397~29277882:- LIHC cis rs2015599 0.584 rs7299283 ENSG00000275476.1 RP11-996F15.4 3.82 0.000158 0.0267 0.25 0.2 Platelet count;Mean platelet volume; chr12:29277442 chr12:29277397~29277882:- LIHC cis rs2015599 0.623 rs1006410 ENSG00000275476.1 RP11-996F15.4 3.82 0.000158 0.0267 0.25 0.2 Platelet count;Mean platelet volume; chr12:29282682 chr12:29277397~29277882:- LIHC cis rs2243480 1 rs73142162 ENSG00000226002.1 RP11-460N20.5 -3.82 0.000158 0.0267 -0.3 -0.2 Diabetic kidney disease; chr7:65909309 chr7:65084103~65100232:+ LIHC cis rs3738443 0.868 rs12569042 ENSG00000259865.1 RP11-488L18.10 3.82 0.000158 0.0267 0.19 0.2 Alcohol dependence; chr1:247203078 chr1:247187281~247188526:- LIHC cis rs875971 0.619 rs10278371 ENSG00000224316.1 RP11-479O9.2 -3.82 0.000158 0.0267 -0.2 -0.2 Aortic root size; chr7:66586553 chr7:65773620~65802067:+ LIHC cis rs2179367 0.632 rs9498335 ENSG00000231760.4 RP11-350J20.5 3.82 0.000158 0.0267 0.32 0.2 Dupuytren's disease; chr6:149372648 chr6:149796151~149826294:- LIHC cis rs9487094 0.567 rs13198879 ENSG00000260273.1 RP11-425D10.10 3.82 0.000158 0.0267 0.26 0.2 Height; chr6:109769861 chr6:109382795~109383666:+ LIHC cis rs1023500 0.573 rs2413666 ENSG00000205702.9 CYP2D7 3.82 0.000158 0.0267 0.23 0.2 Schizophrenia; chr22:42063618 chr22:42140203~42144577:- LIHC cis rs4237845 0.537 rs12426201 ENSG00000270039.1 RP11-571M6.17 -3.82 0.000158 0.0267 -0.29 -0.2 Intelligence (multi-trait analysis); chr12:57865969 chr12:57803838~57804415:+ LIHC cis rs2243480 0.803 rs13224048 ENSG00000275400.1 RP4-756H11.5 3.82 0.000158 0.0267 0.27 0.2 Diabetic kidney disease; chr7:66528779 chr7:66553805~66554199:- LIHC cis rs11098499 0.604 rs10022185 ENSG00000260091.1 RP11-33B1.4 -3.82 0.000158 0.0268 -0.15 -0.2 Corneal astigmatism; chr4:119650610 chr4:119409333~119410233:+ LIHC cis rs2243480 1 rs3885839 ENSG00000226002.1 RP11-460N20.5 -3.82 0.000159 0.0268 -0.3 -0.2 Diabetic kidney disease; chr7:65825416 chr7:65084103~65100232:+ LIHC cis rs2243480 0.901 rs3813708 ENSG00000226002.1 RP11-460N20.5 -3.82 0.000159 0.0268 -0.3 -0.2 Diabetic kidney disease; chr7:65840645 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs73142122 ENSG00000226002.1 RP11-460N20.5 -3.82 0.000159 0.0268 -0.3 -0.2 Diabetic kidney disease; chr7:65846311 chr7:65084103~65100232:+ LIHC cis rs2243480 0.901 rs73142137 ENSG00000226002.1 RP11-460N20.5 -3.82 0.000159 0.0268 -0.3 -0.2 Diabetic kidney disease; chr7:65878455 chr7:65084103~65100232:+ LIHC cis rs4660456 0.596 rs1534956 ENSG00000238287.1 RP11-656D10.3 3.82 0.000159 0.0268 0.23 0.2 Platelet count; chr1:40720771 chr1:40493157~40508661:- LIHC cis rs6700559 0.654 rs2809345 ENSG00000260088.1 RP11-92G12.3 3.82 0.000159 0.0268 0.25 0.2 Coronary artery disease; chr1:200627135 chr1:200669507~200694250:+ LIHC cis rs1816213 0.744 rs35485583 ENSG00000273466.1 RP11-548H3.1 -3.82 0.000159 0.0268 -0.32 -0.2 Diastolic blood pressure; chr2:218460536 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs34727952 ENSG00000273466.1 RP11-548H3.1 -3.82 0.000159 0.0268 -0.32 -0.2 Diastolic blood pressure; chr2:218492333 chr2:218633256~218634014:- LIHC cis rs2286503 0.78 rs929464 ENSG00000228649.7 AC005682.5 3.82 0.000159 0.0268 0.23 0.2 Fibrinogen; chr7:22835151 chr7:22854178~22861579:+ LIHC cis rs6832769 0.961 rs11939815 ENSG00000272969.1 RP11-528I4.2 3.82 0.000159 0.0268 0.24 0.2 Personality dimensions; chr4:55492116 chr4:55547112~55547889:+ LIHC cis rs6832769 0.826 rs58894703 ENSG00000272969.1 RP11-528I4.2 3.82 0.000159 0.0268 0.24 0.2 Personality dimensions; chr4:55492371 chr4:55547112~55547889:+ LIHC cis rs12468226 0.938 rs55668474 ENSG00000226261.1 AC064836.3 3.82 0.000159 0.0268 0.32 0.2 Urate levels; chr2:202265559 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs16824590 ENSG00000226261.1 AC064836.3 3.82 0.000159 0.0268 0.32 0.2 Urate levels; chr2:202272624 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs77018809 ENSG00000226261.1 AC064836.3 3.82 0.000159 0.0268 0.32 0.2 Urate levels; chr2:202273166 chr2:202336024~202336727:- LIHC cis rs2395128 0.915 rs7088463 ENSG00000237149.5 ZNF503-AS2 -3.82 0.000159 0.0268 -0.3 -0.2 Ulcerative colitis;Inflammatory bowel disease; chr10:74781576 chr10:75401519~75408982:+ LIHC cis rs4578769 0.569 rs4800431 ENSG00000266850.1 RP11-370A5.1 3.82 0.000159 0.0268 0.22 0.2 Eosinophil percentage of white cells; chr18:22803499 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs1597239 ENSG00000266850.1 RP11-370A5.1 3.82 0.000159 0.0268 0.22 0.2 Eosinophil percentage of white cells; chr18:22805673 chr18:22723491~22907721:- LIHC cis rs6456156 0.792 rs4710178 ENSG00000227598.1 RP1-167A14.2 -3.82 0.000159 0.0268 -0.2 -0.2 Primary biliary cholangitis; chr6:167100044 chr6:166969626~166999065:- LIHC cis rs6456156 0.792 rs4710179 ENSG00000227598.1 RP1-167A14.2 -3.82 0.000159 0.0268 -0.2 -0.2 Primary biliary cholangitis; chr6:167100204 chr6:166969626~166999065:- LIHC cis rs12586317 0.525 rs10144430 ENSG00000258738.1 RP11-73E17.2 3.82 0.000159 0.0268 0.27 0.2 Psoriasis; chr14:34964476 chr14:34874343~34876459:+ LIHC cis rs6545883 0.965 rs6545872 ENSG00000271889.1 RP11-493E12.1 3.82 0.000159 0.0268 0.24 0.2 Tuberculosis; chr2:61497433 chr2:61151433~61162105:- LIHC cis rs6997458 0.576 rs1553016 ENSG00000253549.4 RP11-317J10.2 3.82 0.000159 0.0269 0.21 0.2 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85306169 chr8:85441851~85464915:- LIHC cis rs6452524 1 rs6887846 ENSG00000271862.1 RP11-343L5.2 -3.82 0.000159 0.0269 -0.23 -0.2 Hypertension (SNP x SNP interaction); chr5:83140542 chr5:83049376~83050964:- LIHC cis rs916888 0.61 rs199452 ENSG00000262881.1 RP11-669E14.4 -3.82 0.000159 0.0269 -0.21 -0.2 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:45907670~45910779:- LIHC cis rs2658782 0.724 rs1869914 ENSG00000279684.1 RP11-755E23.2 -3.82 0.000159 0.0269 -0.33 -0.2 Pulmonary function decline; chr11:93379326 chr11:93286629~93288903:- LIHC cis rs340849 1 rs1008431 ENSG00000274895.1 RP11-478J18.2 3.82 0.000159 0.0269 0.22 0.2 Alzheimer's disease; chr1:213935953 chr1:213983793~213986419:- LIHC cis rs7617773 0.746 rs4130995 ENSG00000228638.1 FCF1P2 -3.82 0.000159 0.0269 -0.2 -0.2 Coronary artery disease; chr3:48316765 chr3:48290793~48291375:- LIHC cis rs6452524 1 rs9293332 ENSG00000271862.1 RP11-343L5.2 3.82 0.000159 0.0269 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83141546 chr5:83049376~83050964:- LIHC cis rs6832769 0.885 rs6815516 ENSG00000272969.1 RP11-528I4.2 -3.82 0.000159 0.0269 -0.24 -0.2 Personality dimensions; chr4:55533017 chr4:55547112~55547889:+ LIHC cis rs4879913 0.768 rs2297877 ENSG00000215199.3 YWHAZP6 3.82 0.000159 0.0269 0.19 0.2 Electroencephalogram traits; chr9:35604131 chr9:34922184~34922921:- LIHC cis rs2115630 0.645 rs1107179 ENSG00000259295.5 CSPG4P12 3.82 0.000159 0.0269 0.24 0.2 P wave terminal force; chr15:84655131 chr15:85191438~85213905:+ LIHC cis rs57221529 0.545 rs55955015 ENSG00000271781.1 CTD-2589H19.6 -3.82 0.000159 0.0269 -0.31 -0.2 Lung disease severity in cystic fibrosis; chr5:575067 chr5:675826~676616:+ LIHC cis rs17818399 0.547 rs4953400 ENSG00000239332.4 LINC01119 -3.82 0.000159 0.0269 -0.3 -0.2 Height; chr2:46550069 chr2:46816697~46859007:+ LIHC cis rs921968 0.613 rs1344642 ENSG00000272555.1 RP11-459I19.1 -3.82 0.000159 0.0269 -0.22 -0.2 Mean corpuscular hemoglobin concentration; chr2:218690539 chr2:218818690~218819144:+ LIHC cis rs42490 0.576 rs377897 ENSG00000251136.7 RP11-37B2.1 -3.82 0.000159 0.0269 -0.17 -0.2 Leprosy; chr8:89852734 chr8:89609409~89757727:- LIHC cis rs11098499 0.863 rs1552092 ENSG00000260091.1 RP11-33B1.4 -3.82 0.000159 0.0269 -0.15 -0.2 Corneal astigmatism; chr4:119567341 chr4:119409333~119410233:+ LIHC cis rs481331 0.689 rs10508868 ENSG00000185904.10 LINC00839 3.82 0.000159 0.0269 0.41 0.2 Systemic juvenile idiopathic arthritis; chr10:42729253 chr10:42475543~42495336:+ LIHC cis rs10129255 0.518 rs10136903 ENSG00000211972.2 IGHV3-66 3.82 0.000159 0.0269 0.15 0.2 Kawasaki disease; chr14:106778866 chr14:106675017~106675544:- LIHC cis rs10129255 0.518 rs11847766 ENSG00000211972.2 IGHV3-66 3.82 0.000159 0.0269 0.15 0.2 Kawasaki disease; chr14:106779186 chr14:106675017~106675544:- LIHC cis rs10246939 0.579 rs13232651 ENSG00000228775.6 WEE2-AS1 3.82 0.000159 0.0269 0.24 0.2 Bitter taste perception; chr7:141862624 chr7:141704338~141738346:- LIHC cis rs67311347 1 rs56303661 ENSG00000223797.4 ENTPD3-AS1 3.82 0.000159 0.0269 0.17 0.2 Renal cell carcinoma; chr3:40479287 chr3:40313802~40453329:- LIHC cis rs7712401 0.601 rs30028 ENSG00000263432.2 RN7SL689P 3.82 0.00016 0.0269 0.29 0.2 Mean platelet volume; chr5:122947574 chr5:123022487~123022783:- LIHC cis rs9527 0.615 rs17725614 ENSG00000236937.2 PTGES3P4 3.82 0.00016 0.0269 0.26 0.2 Arsenic metabolism; chr10:102925736 chr10:102845595~102845950:+ LIHC cis rs2243480 1 rs56291018 ENSG00000226002.1 RP11-460N20.5 -3.82 0.00016 0.0269 -0.3 -0.2 Diabetic kidney disease; chr7:65925352 chr7:65084103~65100232:+ LIHC cis rs4792901 0.959 rs12603797 ENSG00000279602.1 CTD-3014M21.1 -3.82 0.00016 0.0269 -0.24 -0.2 Dupuytren's disease; chr17:43553445 chr17:43360041~43361361:- LIHC cis rs919433 0.756 rs7575389 ENSG00000231621.1 AC013264.2 3.82 0.00016 0.027 0.19 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197333765 chr2:197197991~197199273:+ LIHC cis rs73198271 0.74 rs10100066 ENSG00000253893.2 FAM85B 3.82 0.00016 0.027 0.3 0.2 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8792883 chr8:8167819~8226614:- LIHC cis rs73198271 0.74 rs10110711 ENSG00000253893.2 FAM85B 3.82 0.00016 0.027 0.3 0.2 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8792946 chr8:8167819~8226614:- LIHC cis rs748404 0.697 rs505249 ENSG00000205771.5 CATSPER2P1 -3.82 0.00016 0.027 -0.24 -0.2 Lung cancer; chr15:43267762 chr15:43726918~43747094:- LIHC cis rs987724 0.515 rs4315647 ENSG00000243926.1 TIPARP-AS1 3.82 0.00016 0.027 0.22 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156941199 chr3:156671862~156674378:- LIHC cis rs10983238 0.665 rs3747830 ENSG00000230894.1 RP11-67K19.3 -3.82 0.00016 0.027 -0.27 -0.2 Attention deficit hyperactivity disorder; chr9:116423708 chr9:116568449~116586328:+ LIHC cis rs4713118 0.629 rs203890 ENSG00000219891.2 ZSCAN12P1 3.82 0.00016 0.027 0.29 0.2 Parkinson's disease; chr6:28054470 chr6:28091154~28093664:+ LIHC cis rs12573330 1 rs57710486 ENSG00000226688.5 ENTPD1-AS1 3.82 0.00016 0.027 0.24 0.2 Monocyte percentage of white cells; chr10:96711108 chr10:95753206~96090238:- LIHC cis rs4650994 0.571 rs6700047 ENSG00000273384.1 RP5-1098D14.1 -3.82 0.00016 0.027 -0.25 -0.2 HDL cholesterol;HDL cholesterol levels; chr1:178539607 chr1:178651706~178652282:+ LIHC cis rs4650994 0.571 rs6676507 ENSG00000273384.1 RP5-1098D14.1 -3.82 0.00016 0.027 -0.25 -0.2 HDL cholesterol;HDL cholesterol levels; chr1:178539608 chr1:178651706~178652282:+ LIHC cis rs643506 0.845 rs2850245 ENSG00000230911.1 PPIHP1 -3.82 0.00016 0.027 -0.27 -0.2 Breast cancer; chr11:111890014 chr11:112029858~112030367:- LIHC cis rs794185 0.564 rs304080 ENSG00000231249.1 ITPR1-AS1 -3.82 0.00016 0.027 -0.22 -0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4490262 chr3:4490891~4493163:- LIHC cis rs4356203 0.905 rs35933265 ENSG00000260196.1 RP1-239B22.5 -3.82 0.00016 0.027 -0.24 -0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17093707 chr11:17380649~17383531:+ LIHC cis rs4356203 0.875 rs680205 ENSG00000260196.1 RP1-239B22.5 -3.82 0.00016 0.027 -0.24 -0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17186210 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs536628 ENSG00000260196.1 RP1-239B22.5 -3.82 0.00016 0.027 -0.24 -0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17186545 chr11:17380649~17383531:+ LIHC cis rs11098499 0.566 rs7664440 ENSG00000260091.1 RP11-33B1.4 -3.82 0.00016 0.027 -0.15 -0.2 Corneal astigmatism; chr4:119657385 chr4:119409333~119410233:+ LIHC cis rs240993 0.812 rs6568677 ENSG00000230177.1 RP5-1112D6.4 -3.82 0.00016 0.027 -0.22 -0.2 Inflammatory skin disease;Psoriasis; chr6:111392099 chr6:111277932~111278742:+ LIHC cis rs8035452 0.857 rs3098190 ENSG00000273674.3 CTD-2378E12.1 -3.82 0.00016 0.027 -0.25 -0.2 Alzheimer's disease (late onset); chr15:50520702 chr15:50839875~50908599:- LIHC cis rs7712401 0.601 rs246287 ENSG00000263432.2 RN7SL689P 3.82 0.00016 0.027 0.3 0.2 Mean platelet volume; chr5:122909731 chr5:123022487~123022783:- LIHC cis rs6969780 0.778 rs2465276 ENSG00000233429.8 HOTAIRM1 3.82 0.00016 0.027 0.3 0.2 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27106098 chr7:27095647~27100265:+ LIHC cis rs6969780 0.778 rs61384251 ENSG00000233429.8 HOTAIRM1 3.82 0.00016 0.027 0.3 0.2 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27106583 chr7:27095647~27100265:+ LIHC cis rs4148008 0.589 rs8071366 ENSG00000267250.1 RP11-118B18.2 -3.82 0.00016 0.027 -0.26 -0.2 HDL cholesterol; chr17:68829799 chr17:68793549~68797822:- LIHC cis rs7620503 0.613 rs11707809 ENSG00000228561.2 RP11-114M1.1 -3.82 0.00016 0.027 -0.21 -0.2 Corneal structure; chr3:177567542 chr3:177683627~177691250:+ LIHC cis rs7119038 0.774 rs7945144 ENSG00000255422.1 AP002954.4 3.82 0.00016 0.027 0.25 0.2 Sjögren's syndrome; chr11:118738007 chr11:118704607~118750263:+ LIHC cis rs694739 0.657 rs11231770 ENSG00000236935.1 AP003774.1 3.82 0.00016 0.027 0.22 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373153 chr11:64325050~64329504:- LIHC cis rs694739 0.687 rs11231771 ENSG00000236935.1 AP003774.1 3.82 0.00016 0.027 0.22 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373170 chr11:64325050~64329504:- LIHC cis rs694739 0.628 rs10897487 ENSG00000236935.1 AP003774.1 3.82 0.00016 0.027 0.22 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373232 chr11:64325050~64329504:- LIHC cis rs694739 0.654 rs10897488 ENSG00000236935.1 AP003774.1 3.82 0.00016 0.027 0.22 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373334 chr11:64325050~64329504:- LIHC cis rs55894132 1 rs55894132 ENSG00000257285.4 RP11-298I3.1 3.82 0.000161 0.027 0.2 0.2 Intelligence (multi-trait analysis); chr14:22939628 chr14:22929609~22955562:+ LIHC cis rs1075265 0.783 rs805439 ENSG00000272156.1 RP11-477N3.1 -3.82 0.000161 0.0271 -0.23 -0.2 Chronotype;Morning vs. evening chronotype; chr2:53829437 chr2:54082554~54085066:+ LIHC cis rs12908161 1 rs11638290 ENSG00000225151.9 GOLGA2P7 -3.82 0.000161 0.0271 -0.26 -0.2 Schizophrenia; chr15:84684405 chr15:84199311~84230136:- LIHC cis rs10129255 0.912 rs67410411 ENSG00000211970.3 IGHV4-61 -3.82 0.000161 0.0271 -0.16 -0.2 Kawasaki disease; chr14:106680324 chr14:106639119~106639657:- LIHC cis rs4650994 0.593 rs12040058 ENSG00000273384.1 RP5-1098D14.1 -3.82 0.000161 0.0271 -0.25 -0.2 HDL cholesterol;HDL cholesterol levels; chr1:178534422 chr1:178651706~178652282:+ LIHC cis rs4650994 0.593 rs12074085 ENSG00000273384.1 RP5-1098D14.1 -3.82 0.000161 0.0271 -0.25 -0.2 HDL cholesterol;HDL cholesterol levels; chr1:178535028 chr1:178651706~178652282:+ LIHC cis rs17608059 1 rs17608059 ENSG00000236088.8 COX10-AS1 -3.82 0.000161 0.0271 -0.2 -0.2 Temperament; chr17:14007232 chr17:13756478~14069495:- LIHC cis rs1499614 1 rs2659913 ENSG00000232559.3 GS1-124K5.12 3.82 0.000161 0.0271 0.22 0.2 Gout; chr7:66692349 chr7:66554588~66576923:- LIHC cis rs1499614 1 rs2707840 ENSG00000232559.3 GS1-124K5.12 3.82 0.000161 0.0271 0.22 0.2 Gout; chr7:66693028 chr7:66554588~66576923:- LIHC cis rs1499614 1 rs2659911 ENSG00000232559.3 GS1-124K5.12 3.82 0.000161 0.0271 0.22 0.2 Gout; chr7:66693433 chr7:66554588~66576923:- LIHC cis rs1499614 1 rs2707838 ENSG00000232559.3 GS1-124K5.12 3.82 0.000161 0.0271 0.22 0.2 Gout; chr7:66694214 chr7:66554588~66576923:- LIHC cis rs1499614 1 rs60326618 ENSG00000232559.3 GS1-124K5.12 3.82 0.000161 0.0271 0.22 0.2 Gout; chr7:66701371 chr7:66554588~66576923:- LIHC cis rs1499614 1 rs2707830 ENSG00000232559.3 GS1-124K5.12 3.82 0.000161 0.0271 0.22 0.2 Gout; chr7:66702658 chr7:66554588~66576923:- LIHC cis rs1499614 1 rs2707828 ENSG00000232559.3 GS1-124K5.12 3.82 0.000161 0.0271 0.22 0.2 Gout; chr7:66706390 chr7:66554588~66576923:- LIHC cis rs1499614 0.803 rs1922723 ENSG00000232559.3 GS1-124K5.12 3.82 0.000161 0.0271 0.22 0.2 Gout; chr7:66710076 chr7:66554588~66576923:- LIHC cis rs1499614 1 rs2659903 ENSG00000232559.3 GS1-124K5.12 3.82 0.000161 0.0271 0.22 0.2 Gout; chr7:66715944 chr7:66554588~66576923:- LIHC cis rs1499614 1 rs2141924 ENSG00000232559.3 GS1-124K5.12 3.82 0.000161 0.0271 0.22 0.2 Gout; chr7:66721259 chr7:66554588~66576923:- LIHC cis rs6684428 0.536 rs6670350 ENSG00000229871.1 RP4-710M16.1 3.82 0.000161 0.0271 0.31 0.2 Airflow obstruction; chr1:55926133 chr1:56207567~56208456:- LIHC cis rs2932538 0.922 rs3790611 ENSG00000225075.1 RP11-426L16.3 3.82 0.000161 0.0271 0.25 0.2 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112525170 chr1:112693688~112696621:- LIHC cis rs4925386 0.765 rs6142737 ENSG00000226332.2 RP11-157P1.4 3.82 0.000161 0.0271 0.24 0.2 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62344744 chr20:62305432~62306325:- LIHC cis rs4561483 0.801 rs154148 ENSG00000261560.1 RP11-166B2.3 -3.82 0.000161 0.0271 -0.23 -0.2 Testicular germ cell tumor; chr16:11862621 chr16:11881075~11882569:- LIHC cis rs6061231 0.624 rs8668 ENSG00000226332.2 RP11-157P1.4 -3.82 0.000161 0.0271 -0.23 -0.2 Colorectal cancer; chr20:62389008 chr20:62305432~62306325:- LIHC cis rs755249 0.565 rs2695324 ENSG00000182109.6 RP11-69E11.4 3.82 0.000161 0.0271 0.26 0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39587969 chr1:39522280~39546187:- LIHC cis rs8177253 1 rs8177253 ENSG00000244062.1 RP11-404G16.2 -3.82 0.000161 0.0271 -0.21 -0.2 Iron status biomarkers; chr3:133761348 chr3:133760300~133762363:+ LIHC cis rs2120243 0.533 rs34263112 ENSG00000244515.1 KRT18P34 -3.82 0.000161 0.0271 -0.19 -0.2 Hepatocellular carcinoma in hepatitis B infection; chr3:157338259 chr3:157162663~157163932:- LIHC cis rs16958440 0.867 rs12326221 ENSG00000267724.1 RP11-49K24.8 3.82 0.000161 0.0271 0.38 0.2 Sitting height ratio; chr18:47156522 chr18:47105946~47108062:+ LIHC cis rs6480314 0.908 rs7094934 ENSG00000233590.1 RP11-153K11.3 -3.82 0.000161 0.0271 -0.32 -0.2 Optic nerve measurement (disc area); chr10:68203093 chr10:68233251~68242379:- LIHC cis rs6480314 0.908 rs74817543 ENSG00000233590.1 RP11-153K11.3 -3.82 0.000161 0.0271 -0.32 -0.2 Optic nerve measurement (disc area); chr10:68203791 chr10:68233251~68242379:- LIHC cis rs6480314 0.908 rs61854762 ENSG00000233590.1 RP11-153K11.3 -3.82 0.000161 0.0271 -0.32 -0.2 Optic nerve measurement (disc area); chr10:68204891 chr10:68233251~68242379:- LIHC cis rs6480314 0.908 rs61854763 ENSG00000233590.1 RP11-153K11.3 -3.82 0.000161 0.0271 -0.32 -0.2 Optic nerve measurement (disc area); chr10:68205038 chr10:68233251~68242379:- LIHC cis rs56322409 0.561 rs749049 ENSG00000226688.5 ENTPD1-AS1 3.82 0.000161 0.0271 0.19 0.2 Blood metabolite levels; chr10:95616339 chr10:95753206~96090238:- LIHC cis rs7873102 0.702 rs10814634 ENSG00000230188.1 RP11-405L18.4 -3.82 0.000161 0.0271 -0.25 -0.2 Brain structure; chr9:37964851 chr9:37490421~37490893:- LIHC cis rs921968 0.613 rs2303566 ENSG00000272555.1 RP11-459I19.1 -3.82 0.000161 0.0271 -0.22 -0.2 Mean corpuscular hemoglobin concentration; chr2:218693015 chr2:218818690~218819144:+ LIHC cis rs11096990 0.679 rs6531707 ENSG00000249207.1 RP11-360F5.1 3.82 0.000161 0.0271 0.2 0.2 Cognitive function; chr4:39296064 chr4:39112677~39126818:- LIHC cis rs17772222 0.917 rs61984737 ENSG00000258789.1 RP11-507K2.3 -3.82 0.000161 0.0271 -0.24 -0.2 Coronary artery calcification; chr14:88637028 chr14:88551597~88552493:+ LIHC cis rs10129255 0.833 rs61997797 ENSG00000223648.3 IGHV3-64 3.82 0.000161 0.0271 0.15 0.2 Kawasaki disease; chr14:106815190 chr14:106643132~106658258:- LIHC cis rs7209700 0.574 rs3851806 ENSG00000266601.1 RP11-6N17.3 3.82 0.000161 0.0271 0.27 0.2 IgG glycosylation; chr17:47273553 chr17:47929682~47933106:- LIHC cis rs10829156 0.679 rs4748476 ENSG00000240291.1 RP11-499P20.2 3.82 0.000161 0.0271 0.34 0.2 Sudden cardiac arrest; chr10:18503946 chr10:18513115~18545651:- LIHC cis rs2243480 1 rs316327 ENSG00000232546.1 RP11-458F8.1 3.82 0.000161 0.0271 0.23 0.2 Diabetic kidney disease; chr7:66144214 chr7:66848496~66858136:+ LIHC cis rs718433 0.553 rs2141971 ENSG00000258441.1 LINC00641 3.82 0.000161 0.0271 0.24 0.2 Intraocular pressure; chr14:21772593 chr14:21200079~21206900:- LIHC cis rs7867456 0.9 rs12006112 ENSG00000215221.2 UBA52P6 -3.82 0.000161 0.0272 -0.2 -0.2 Axial length; chr9:21042300 chr9:22012155~22012536:+ LIHC cis rs2235573 0.662 rs2076369 ENSG00000233360.4 Z83844.1 -3.82 0.000161 0.0272 -0.26 -0.2 Glioma;Glioblastoma; chr22:38067645 chr22:37641832~37658377:- LIHC cis rs2235573 0.662 rs2076370 ENSG00000233360.4 Z83844.1 -3.82 0.000161 0.0272 -0.26 -0.2 Glioma;Glioblastoma; chr22:38067961 chr22:37641832~37658377:- LIHC cis rs67311347 1 rs73078162 ENSG00000223797.4 ENTPD3-AS1 3.82 0.000161 0.0272 0.16 0.2 Renal cell carcinoma; chr3:40435618 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs73078163 ENSG00000223797.4 ENTPD3-AS1 3.82 0.000161 0.0272 0.16 0.2 Renal cell carcinoma; chr3:40438467 chr3:40313802~40453329:- LIHC cis rs1862618 0.671 rs832531 ENSG00000271828.1 CTD-2310F14.1 3.82 0.000161 0.0272 0.27 0.2 Initial pursuit acceleration; chr5:56932574 chr5:56927874~56929573:+ LIHC cis rs12928939 0.911 rs12919271 ENSG00000263232.2 ATP5A1P3 -3.82 0.000162 0.0272 -0.31 -0.2 Post bronchodilator FEV1; chr16:71758793 chr16:72005037~72006543:- LIHC cis rs7665090 0.528 rs4235405 ENSG00000230069.3 LRRC37A15P -3.81 0.000162 0.0272 -0.18 -0.2 Primary biliary cholangitis; chr4:102595654 chr4:102727274~102730721:- LIHC cis rs9843304 0.528 rs11919764 ENSG00000244503.1 RP11-278L15.6 3.81 0.000162 0.0272 0.26 0.2 Gallstone disease; chr3:149469448 chr3:149494660~149495995:+ LIHC cis rs4578769 0.722 rs55758053 ENSG00000266850.1 RP11-370A5.1 -3.81 0.000162 0.0272 -0.24 -0.2 Eosinophil percentage of white cells; chr18:22958405 chr18:22723491~22907721:- LIHC cis rs12586317 0.62 rs28404080 ENSG00000257307.1 RP11-317N8.4 -3.81 0.000162 0.0272 -0.24 -0.2 Psoriasis; chr14:35070212 chr14:35881001~35881709:+ LIHC cis rs12586317 0.62 rs79832710 ENSG00000257307.1 RP11-317N8.4 -3.81 0.000162 0.0272 -0.24 -0.2 Psoriasis; chr14:35078228 chr14:35881001~35881709:+ LIHC cis rs12586317 0.62 rs12588810 ENSG00000257307.1 RP11-317N8.4 -3.81 0.000162 0.0272 -0.24 -0.2 Psoriasis; chr14:35085278 chr14:35881001~35881709:+ LIHC cis rs2243480 1 rs387676 ENSG00000232546.1 RP11-458F8.1 -3.81 0.000162 0.0272 -0.23 -0.2 Diabetic kidney disease; chr7:66133233 chr7:66848496~66858136:+ LIHC cis rs3105593 0.583 rs3098192 ENSG00000273674.3 CTD-2378E12.1 3.81 0.000162 0.0272 0.24 0.2 QT interval; chr15:50521854 chr15:50839875~50908599:- LIHC cis rs3105593 0.583 rs3098194 ENSG00000273674.3 CTD-2378E12.1 3.81 0.000162 0.0272 0.24 0.2 QT interval; chr15:50522147 chr15:50839875~50908599:- LIHC cis rs3105593 0.583 rs3131602 ENSG00000273674.3 CTD-2378E12.1 3.81 0.000162 0.0272 0.24 0.2 QT interval; chr15:50522472 chr15:50839875~50908599:- LIHC cis rs3105593 0.583 rs3109885 ENSG00000273674.3 CTD-2378E12.1 3.81 0.000162 0.0272 0.24 0.2 QT interval; chr15:50523382 chr15:50839875~50908599:- LIHC cis rs2439831 0.717 rs2470132 ENSG00000166763.7 STRCP1 3.81 0.000162 0.0272 0.28 0.2 Lung cancer in ever smokers; chr15:43543283 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs2251844 ENSG00000166763.7 STRCP1 3.81 0.000162 0.0272 0.28 0.2 Lung cancer in ever smokers; chr15:43544280 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs486301 ENSG00000166763.7 STRCP1 3.81 0.000162 0.0272 0.28 0.2 Lung cancer in ever smokers; chr15:43544751 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs2255051 ENSG00000166763.7 STRCP1 3.81 0.000162 0.0272 0.28 0.2 Lung cancer in ever smokers; chr15:43553963 chr15:43699488~43718184:- LIHC cis rs2564921 0.615 rs56129941 ENSG00000242142.1 SERBP1P3 -3.81 0.000162 0.0272 -0.27 -0.2 Height; chr3:53007328 chr3:53064283~53065091:- LIHC cis rs2564921 0.704 rs56155510 ENSG00000242142.1 SERBP1P3 -3.81 0.000162 0.0272 -0.27 -0.2 Height; chr3:53009621 chr3:53064283~53065091:- LIHC cis rs2564921 0.679 rs12635933 ENSG00000242142.1 SERBP1P3 -3.81 0.000162 0.0272 -0.27 -0.2 Height; chr3:53015087 chr3:53064283~53065091:- LIHC cis rs6745190 0.953 rs4667008 ENSG00000236153.1 AC104076.3 3.81 0.000162 0.0272 0.27 0.2 White blood cell count; chr2:181000876 chr2:180979427~180980090:- LIHC cis rs2564921 0.704 rs2336720 ENSG00000242142.1 SERBP1P3 -3.81 0.000162 0.0272 -0.25 -0.2 Height; chr3:52994045 chr3:53064283~53065091:- LIHC cis rs2564921 0.73 rs56384586 ENSG00000242142.1 SERBP1P3 -3.81 0.000162 0.0272 -0.25 -0.2 Height; chr3:52994990 chr3:53064283~53065091:- LIHC cis rs42490 0.7 rs40250 ENSG00000251136.7 RP11-37B2.1 -3.81 0.000162 0.0273 -0.17 -0.2 Leprosy; chr8:89828779 chr8:89609409~89757727:- LIHC cis rs42490 0.7 rs419890 ENSG00000251136.7 RP11-37B2.1 -3.81 0.000162 0.0273 -0.17 -0.2 Leprosy; chr8:89829012 chr8:89609409~89757727:- LIHC cis rs2032447 0.933 rs4401650 ENSG00000242387.1 HIST1H2APS2 3.81 0.000162 0.0273 0.26 0.2 Intelligence (multi-trait analysis); chr6:26034980 chr6:25882026~25882395:- LIHC cis rs2739330 0.76 rs5760095 ENSG00000228039.3 KB-1125A3.10 3.81 0.000162 0.0273 0.24 0.2 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23963780~23964374:+ LIHC cis rs9747201 0.889 rs4789784 ENSG00000279692.1 RP11-1055B8.1 3.81 0.000162 0.0273 0.35 0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82221337 chr17:81395609~81397144:- LIHC cis rs748404 0.56 rs689797 ENSG00000166763.7 STRCP1 3.81 0.000162 0.0273 0.25 0.2 Lung cancer; chr15:43534359 chr15:43699488~43718184:- LIHC cis rs17221829 0.965 rs10830368 ENSG00000280367.1 RP11-121L10.2 3.81 0.000162 0.0273 0.23 0.2 Anxiety in major depressive disorder; chr11:89726538 chr11:90223153~90226538:+ LIHC cis rs9843304 0.528 rs9880421 ENSG00000244503.1 RP11-278L15.6 -3.81 0.000163 0.0273 -0.26 -0.2 Gallstone disease; chr3:149465572 chr3:149494660~149495995:+ LIHC cis rs6723108 0.627 rs2197579 ENSG00000224043.6 CCNT2-AS1 -3.81 0.000163 0.0273 -0.28 -0.2 Type 2 diabetes; chr2:134887408 chr2:134735464~134918710:- LIHC cis rs1023500 1 rs1047997 ENSG00000227370.1 RP4-669P10.19 3.81 0.000163 0.0273 0.27 0.2 Schizophrenia; chr22:41938949 chr22:42132543~42132998:+ LIHC cis rs2574985 0.54 rs4935712 ENSG00000231345.3 BEND3P1 3.81 0.000163 0.0273 0.23 0.2 Subjective well-being; chr10:50499653 chr10:50655967~50660472:+ LIHC cis rs9527 0.668 rs7092815 ENSG00000236937.2 PTGES3P4 3.81 0.000163 0.0274 0.26 0.2 Arsenic metabolism; chr10:102976588 chr10:102845595~102845950:+ LIHC cis rs6504622 0.557 rs7213526 ENSG00000263766.4 RP11-580I16.2 3.81 0.000163 0.0274 0.23 0.2 Orofacial clefts; chr17:46933791 chr17:47603860~47649420:- LIHC cis rs2243480 1 rs56016656 ENSG00000226002.1 RP11-460N20.5 -3.81 0.000163 0.0274 -0.3 -0.2 Diabetic kidney disease; chr7:65918494 chr7:65084103~65100232:+ LIHC cis rs2243480 0.803 rs55700941 ENSG00000226002.1 RP11-460N20.5 -3.81 0.000163 0.0274 -0.3 -0.2 Diabetic kidney disease; chr7:65924813 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs36033484 ENSG00000226002.1 RP11-460N20.5 -3.81 0.000163 0.0274 -0.3 -0.2 Diabetic kidney disease; chr7:65925571 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs34193460 ENSG00000226002.1 RP11-460N20.5 -3.81 0.000163 0.0274 -0.3 -0.2 Diabetic kidney disease; chr7:65928123 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs34560516 ENSG00000226002.1 RP11-460N20.5 -3.81 0.000163 0.0274 -0.3 -0.2 Diabetic kidney disease; chr7:65939105 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs57057549 ENSG00000226002.1 RP11-460N20.5 -3.81 0.000163 0.0274 -0.3 -0.2 Diabetic kidney disease; chr7:65940751 chr7:65084103~65100232:+ LIHC cis rs2243480 0.808 rs12698508 ENSG00000226002.1 RP11-460N20.5 -3.81 0.000163 0.0274 -0.3 -0.2 Diabetic kidney disease; chr7:65946971 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs2961102 ENSG00000226002.1 RP11-460N20.5 -3.81 0.000163 0.0274 -0.3 -0.2 Diabetic kidney disease; chr7:65959671 chr7:65084103~65100232:+ LIHC cis rs2361718 0.603 rs12951255 ENSG00000261978.1 CTD-2529O21.2 3.81 0.000163 0.0274 0.22 0.2 Yeast infection; chr17:80111798 chr17:80023894~80026107:+ LIHC cis rs1802575 0.675 rs13429677 ENSG00000272606.1 RP11-554J4.1 3.81 0.000163 0.0274 0.38 0.2 Childhood ear infection; chr2:55770413 chr2:55617909~55618373:+ LIHC cis rs875971 1 rs10244498 ENSG00000237310.1 GS1-124K5.4 3.81 0.000163 0.0274 0.18 0.2 Aortic root size; chr7:66651069 chr7:66493706~66495474:+ LIHC cis rs916888 0.773 rs1378358 ENSG00000279685.2 MAPT-IT1 -3.81 0.000163 0.0274 -0.36 -0.2 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45895783~45898798:+ LIHC cis rs11098403 0.753 rs10026808 ENSG00000260404.2 RP11-384K6.6 3.81 0.000163 0.0274 0.13 0.2 Schizophrenia; chr4:117840376 chr4:118591773~118633729:+ LIHC cis rs4356203 0.905 rs7396382 ENSG00000260196.1 RP1-239B22.5 3.81 0.000163 0.0274 0.24 0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17129925 chr11:17380649~17383531:+ LIHC cis rs6545883 0.965 rs3771258 ENSG00000271889.1 RP11-493E12.1 3.81 0.000163 0.0274 0.24 0.2 Tuberculosis; chr2:61537005 chr2:61151433~61162105:- LIHC cis rs3942852 0.703 rs11039513 ENSG00000256897.1 RP11-17G12.2 -3.81 0.000163 0.0274 -0.23 -0.2 Acute lymphoblastic leukemia (childhood); chr11:48085652 chr11:47220218~47221751:- LIHC cis rs7560180 1 rs7560180 ENSG00000189223.12 PAX8-AS1 -3.81 0.000163 0.0274 -0.32 -0.2 Hemoglobin concentration; chr2:113207623 chr2:113211522~113276581:+ LIHC cis rs7809950 0.678 rs7777950 ENSG00000238832.1 snoU109 -3.81 0.000163 0.0274 -0.26 -0.2 Coronary artery disease; chr7:107364227 chr7:107603363~107603507:+ LIHC cis rs2617583 0.509 rs10630 ENSG00000188002.9 RP11-43F13.1 3.81 0.000163 0.0274 0.26 0.2 Breast cancer; chr5:1462605 chr5:1598920~1634005:- LIHC cis rs9951150 0.537 rs35097015 ENSG00000267013.4 CTD-2171N6.1 3.81 0.000163 0.0274 0.27 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55127109 chr18:55105904~55124306:- LIHC cis rs7914558 0.646 rs7100709 ENSG00000236937.2 PTGES3P4 3.81 0.000163 0.0274 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102889972 chr10:102845595~102845950:+ LIHC cis rs2797160 1 rs1935774 ENSG00000237742.5 RP11-624M8.1 3.81 0.000163 0.0274 0.19 0.2 Endometrial cancer; chr6:125675515 chr6:125578558~125749190:- LIHC cis rs1494950 1 rs16891297 ENSG00000214846.4 RP11-115L11.1 -3.81 0.000163 0.0274 -0.41 -0.2 Political ideology; chr4:15032848 chr4:15730962~15731627:- LIHC cis rs1247318 0.806 rs581947 ENSG00000243831.1 RP1-81D8.4 3.81 0.000164 0.0275 0.28 0.2 Aging; chr6:160944597 chr6:160666228~160676523:- LIHC cis rs12935418 1 rs12935418 ENSG00000261061.1 RP11-303E16.2 -3.81 0.000164 0.0275 -0.27 -0.2 Mean corpuscular volume; chr16:81036403 chr16:81030770~81031485:+ LIHC cis rs3813567 0.759 rs12594550 ENSG00000261762.1 RP11-650L12.2 3.81 0.000164 0.0275 0.28 0.2 Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio; chr15:78666695 chr15:78589123~78591276:- LIHC cis rs6565180 0.926 rs8046445 ENSG00000273724.1 RP11-347C12.12 -3.81 0.000164 0.0275 -0.24 -0.2 Tonsillectomy; chr16:30374941 chr16:30336400~30343336:+ LIHC cis rs1635 0.655 rs9368532 ENSG00000216901.1 AL022393.7 3.81 0.000164 0.0275 0.37 0.2 Schizophrenia; chr6:27814232 chr6:28176188~28176674:+ LIHC cis rs2932538 0.922 rs12402469 ENSG00000225075.1 RP11-426L16.3 3.81 0.000164 0.0275 0.26 0.2 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112534003 chr1:112693688~112696621:- LIHC cis rs6860806 0.507 rs270601 ENSG00000263597.1 MIR3936 3.81 0.000164 0.0275 0.22 0.2 Breast cancer; chr5:132321304 chr5:132365490~132365599:- LIHC cis rs4792901 0.592 rs57462570 ENSG00000267747.1 RP11-392O1.4 -3.81 0.000164 0.0275 -0.24 -0.2 Dupuytren's disease; chr17:43530611 chr17:43544785~43610338:+ LIHC cis rs1799949 1 rs4793236 ENSG00000267681.1 CTD-3199J23.6 -3.81 0.000164 0.0275 -0.2 -0.2 Menopause (age at onset); chr17:43359072 chr17:43144956~43145255:+ LIHC cis rs6499755 0.712 rs31110 ENSG00000260135.5 RP11-212I21.2 3.81 0.000164 0.0275 0.23 0.2 Hypospadias; chr16:55344593 chr16:55426797~55462297:- LIHC cis rs1598856 0.966 rs11097788 ENSG00000230069.3 LRRC37A15P -3.81 0.000164 0.0275 -0.18 -0.2 Primary biliary cholangitis; chr4:102486271 chr4:102727274~102730721:- LIHC cis rs8026198 0.929 rs1359003 ENSG00000260571.1 BNIP3P5 -3.81 0.000164 0.0275 -0.29 -0.2 Fibrinogen levels; chr15:42364741 chr15:42313687~42314386:+ LIHC cis rs875971 0.577 rs34888281 ENSG00000237310.1 GS1-124K5.4 -3.81 0.000164 0.0275 -0.21 -0.2 Aortic root size; chr7:66120784 chr7:66493706~66495474:+ LIHC cis rs7192392 0.966 rs8047431 ENSG00000260816.2 RP11-319G9.3 -3.81 0.000164 0.0275 -0.19 -0.2 Acute graft versus host disease in bone marrow transplantation (recipient effect); chr16:78897925 chr16:78895361~78899644:+ LIHC cis rs2243480 0.711 rs2420172 ENSG00000228409.4 CCT6P1 -3.81 0.000164 0.0275 -0.22 -0.2 Diabetic kidney disease; chr7:66170354 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs6974723 ENSG00000228409.4 CCT6P1 -3.81 0.000164 0.0275 -0.22 -0.2 Diabetic kidney disease; chr7:66172952 chr7:65751142~65763354:+ LIHC cis rs6745190 0.906 rs11692072 ENSG00000236153.1 AC104076.3 3.81 0.000164 0.0275 0.27 0.2 White blood cell count; chr2:181037735 chr2:180979427~180980090:- LIHC cis rs2243480 1 rs1499614 ENSG00000275400.1 RP4-756H11.5 3.81 0.000164 0.0276 0.27 0.2 Diabetic kidney disease; chr7:66265811 chr7:66553805~66554199:- LIHC cis rs3020736 0.5 rs4147638 ENSG00000226450.2 CYP2D8P -3.81 0.000164 0.0276 -0.25 -0.2 Autism spectrum disorder or schizophrenia; chr22:42091896 chr22:42149886~42155001:- LIHC cis rs3020736 0.5 rs6002605 ENSG00000226450.2 CYP2D8P -3.81 0.000164 0.0276 -0.25 -0.2 Autism spectrum disorder or schizophrenia; chr22:42098331 chr22:42149886~42155001:- LIHC cis rs3749237 0.595 rs35701831 ENSG00000226913.1 BSN-AS2 -3.81 0.000164 0.0276 -0.26 -0.2 Resting heart rate; chr3:49477567 chr3:49549306~49554366:- LIHC cis rs67601088 1 rs740144 ENSG00000235669.1 AC004593.3 -3.81 0.000164 0.0276 -0.39 -0.2 Pediatric bone mineral density (spine); chr7:29882079 chr7:29199540~29208970:- LIHC cis rs9876781 0.967 rs2885509 ENSG00000229759.1 MRPS18AP1 -3.81 0.000164 0.0276 -0.21 -0.2 Longevity; chr3:48376729 chr3:48256350~48256938:- LIHC cis rs4792901 0.959 rs12103443 ENSG00000279602.1 CTD-3014M21.1 -3.81 0.000164 0.0276 -0.23 -0.2 Dupuytren's disease; chr17:43553890 chr17:43360041~43361361:- LIHC cis rs7617773 0.817 rs936426 ENSG00000228638.1 FCF1P2 -3.81 0.000164 0.0276 -0.22 -0.2 Coronary artery disease; chr3:48173763 chr3:48290793~48291375:- LIHC cis rs1501138 0.506 rs4317201 ENSG00000263327.5 TAPT1-AS1 -3.81 0.000165 0.0276 -0.27 -0.2 Systemic juvenile idiopathic arthritis; chr4:16207396 chr4:16226685~16320140:+ LIHC cis rs12554020 0.786 rs3893381 ENSG00000227603.1 RP11-165J3.6 -3.81 0.000165 0.0276 -0.33 -0.2 Schizophrenia; chr9:93519576 chr9:93435332~93437121:- LIHC cis rs6500637 0.58 rs2660243 ENSG00000267077.1 RP11-127I20.5 -3.81 0.000165 0.0276 -0.22 -0.2 Cancer; chr16:4891396 chr16:4795265~4796532:- LIHC cis rs728616 0.681 rs3862518 ENSG00000225484.5 NUTM2B-AS1 -3.81 0.000165 0.0276 -0.42 -0.2 Chronic obstructive pulmonary disease-related biomarkers; chr10:80158201 chr10:79663088~79826594:- LIHC cis rs3845817 0.675 rs702940 ENSG00000281920.1 RP11-418H16.1 -3.81 0.000165 0.0276 -0.24 -0.2 Bipolar disorder; chr2:65521007 chr2:65623272~65628424:+ LIHC cis rs559928 0.606 rs7941773 ENSG00000236935.1 AP003774.1 3.81 0.000165 0.0276 0.29 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64185287 chr11:64325050~64329504:- LIHC cis rs559928 0.606 rs57021319 ENSG00000236935.1 AP003774.1 3.81 0.000165 0.0276 0.29 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64188630 chr11:64325050~64329504:- LIHC cis rs559928 0.606 rs55970968 ENSG00000236935.1 AP003774.1 3.81 0.000165 0.0276 0.29 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64193961 chr11:64325050~64329504:- LIHC cis rs67311347 1 rs73078158 ENSG00000223797.4 ENTPD3-AS1 3.81 0.000165 0.0276 0.16 0.2 Renal cell carcinoma; chr3:40431076 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs73078164 ENSG00000223797.4 ENTPD3-AS1 3.81 0.000165 0.0276 0.16 0.2 Renal cell carcinoma; chr3:40438798 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs73078169 ENSG00000223797.4 ENTPD3-AS1 3.81 0.000165 0.0276 0.16 0.2 Renal cell carcinoma; chr3:40442307 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs1123019 ENSG00000223797.4 ENTPD3-AS1 3.81 0.000165 0.0276 0.16 0.2 Renal cell carcinoma; chr3:40446789 chr3:40313802~40453329:- LIHC cis rs3733589 0.744 rs75245282 ENSG00000250413.1 RP11-448G15.1 3.81 0.000165 0.0276 0.32 0.2 Renal overload gout; chr4:9950384 chr4:10006482~10009725:+ LIHC cis rs12681366 0.839 rs3019282 ENSG00000253704.1 RP11-267M23.4 3.81 0.000165 0.0276 0.24 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94439898 chr8:94553722~94569745:+ LIHC cis rs875971 1 rs7783613 ENSG00000237310.1 GS1-124K5.4 -3.81 0.000165 0.0276 -0.18 -0.2 Aortic root size; chr7:66340274 chr7:66493706~66495474:+ LIHC cis rs11089937 0.597 rs4821772 ENSG00000211639.2 IGLV4-60 -3.81 0.000165 0.0276 -0.17 -0.2 Periodontitis (PAL4Q3); chr22:22131383 chr22:22162199~22162681:+ LIHC cis rs1003719 0.679 rs2835674 ENSG00000272948.2 AP001412.1 -3.81 0.000165 0.0276 -0.23 -0.2 Eye color traits; chr21:37209221 chr21:37267784~37268497:+ LIHC cis rs11096990 0.855 rs1820939 ENSG00000249685.1 RP11-360F5.3 -3.81 0.000165 0.0276 -0.27 -0.2 Cognitive function; chr4:39170115 chr4:39133913~39135608:+ LIHC cis rs2333021 0.78 rs2806042 ENSG00000259015.1 RP11-109N23.6 -3.81 0.000165 0.0276 -0.24 -0.2 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72947939 chr14:72960595~72961993:+ LIHC cis rs7917772 0.503 rs7093285 ENSG00000236937.2 PTGES3P4 -3.81 0.000165 0.0276 -0.27 -0.2 Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index; chr10:102615058 chr10:102845595~102845950:+ LIHC cis rs10129255 0.5 rs6576225 ENSG00000211972.2 IGHV3-66 3.81 0.000165 0.0276 0.15 0.2 Kawasaki disease; chr14:106778120 chr14:106675017~106675544:- LIHC cis rs10129255 0.5 rs6576226 ENSG00000211972.2 IGHV3-66 3.81 0.000165 0.0276 0.15 0.2 Kawasaki disease; chr14:106778135 chr14:106675017~106675544:- LIHC cis rs4578769 0.569 rs3851822 ENSG00000266850.1 RP11-370A5.1 -3.81 0.000165 0.0277 -0.22 -0.2 Eosinophil percentage of white cells; chr18:22882829 chr18:22723491~22907721:- LIHC cis rs13242816 1 rs12668226 ENSG00000279086.1 RP11-667F14.1 3.81 0.000165 0.0277 0.37 0.2 P wave duration; chr7:116547636 chr7:116209234~116211511:- LIHC cis rs13242816 1 rs2052105 ENSG00000279086.1 RP11-667F14.1 3.81 0.000165 0.0277 0.37 0.2 P wave duration; chr7:116547925 chr7:116209234~116211511:- LIHC cis rs7568498 0.564 rs10490563 ENSG00000235724.7 AC009299.2 3.81 0.000165 0.0277 0.23 0.2 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161057657 chr2:161222785~161308303:- LIHC cis rs7568498 0.564 rs9287807 ENSG00000235724.7 AC009299.2 3.81 0.000165 0.0277 0.23 0.2 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161058850 chr2:161222785~161308303:- LIHC cis rs858239 0.932 rs1728313 ENSG00000226816.2 AC005082.12 3.81 0.000165 0.0277 0.25 0.2 Cerebrospinal fluid biomarker levels; chr7:23231412 chr7:23206013~23208045:+ LIHC cis rs2390582 0.563 rs4658366 ENSG00000231613.1 RP5-943J3.1 3.81 0.000165 0.0277 0.41 0.2 Coronary artery calcification; chr1:90233410 chr1:89788914~89790492:+ LIHC cis rs16902947 0.592 rs56110348 ENSG00000245711.2 NADK2-AS1 3.81 0.000165 0.0277 0.17 0.2 Serum tamsulosin hydrochloride concentration; chr5:36342078 chr5:36221055~36221902:+ LIHC cis rs244293 0.76 rs8069447 ENSG00000275710.1 RP11-257O5.4 3.81 0.000165 0.0277 0.21 0.2 Menarche (age at onset); chr17:54931512 chr17:54964474~54964679:+ LIHC cis rs6430585 0.528 rs309123 ENSG00000231890.6 DARS-AS1 -3.81 0.000165 0.0277 -0.28 -0.2 Corneal structure; chr2:136003605 chr2:135985176~136022593:+ LIHC cis rs1802575 0.675 rs13395798 ENSG00000272606.1 RP11-554J4.1 3.81 0.000165 0.0277 0.37 0.2 Childhood ear infection; chr2:55780501 chr2:55617909~55618373:+ LIHC cis rs916888 0.773 rs169201 ENSG00000279685.2 MAPT-IT1 -3.81 0.000165 0.0277 -0.36 -0.2 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45895783~45898798:+ LIHC cis rs4356203 0.905 rs2052188 ENSG00000260196.1 RP1-239B22.5 3.81 0.000165 0.0277 0.24 0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17105123 chr11:17380649~17383531:+ LIHC cis rs274567 0.501 rs272855 ENSG00000263597.1 MIR3936 3.81 0.000166 0.0277 0.22 0.2 Blood metabolite levels; chr5:132351482 chr5:132365490~132365599:- LIHC cis rs1979679 0.659 rs11049461 ENSG00000278733.1 RP11-425D17.1 3.81 0.000166 0.0277 0.29 0.2 Ossification of the posterior longitudinal ligament of the spine; chr12:28207688 chr12:28185625~28186190:- LIHC cis rs2243480 0.522 rs12698511 ENSG00000228409.4 CCT6P1 3.81 0.000166 0.0277 0.24 0.2 Diabetic kidney disease; chr7:66009932 chr7:65751142~65763354:+ LIHC cis rs4578769 0.84 rs67940971 ENSG00000266850.1 RP11-370A5.1 -3.81 0.000166 0.0277 -0.23 -0.2 Eosinophil percentage of white cells; chr18:22902777 chr18:22723491~22907721:- LIHC cis rs801193 0.569 rs2659893 ENSG00000232559.3 GS1-124K5.12 3.81 0.000166 0.0277 0.16 0.2 Aortic root size; chr7:66735006 chr7:66554588~66576923:- LIHC cis rs801193 0.569 rs2659892 ENSG00000232559.3 GS1-124K5.12 3.81 0.000166 0.0277 0.16 0.2 Aortic root size; chr7:66735318 chr7:66554588~66576923:- LIHC cis rs801193 0.548 rs2659891 ENSG00000232559.3 GS1-124K5.12 3.81 0.000166 0.0277 0.16 0.2 Aortic root size; chr7:66736127 chr7:66554588~66576923:- LIHC cis rs801193 0.569 rs2707847 ENSG00000232559.3 GS1-124K5.12 3.81 0.000166 0.0277 0.16 0.2 Aortic root size; chr7:66737884 chr7:66554588~66576923:- LIHC cis rs801193 0.548 rs7805152 ENSG00000232559.3 GS1-124K5.12 3.81 0.000166 0.0277 0.16 0.2 Aortic root size; chr7:66744266 chr7:66554588~66576923:- LIHC cis rs801193 0.569 rs11761542 ENSG00000232559.3 GS1-124K5.12 3.81 0.000166 0.0277 0.16 0.2 Aortic root size; chr7:66753209 chr7:66554588~66576923:- LIHC cis rs12817211 0.502 rs12819883 ENSG00000272368.2 RP4-605O3.4 -3.81 0.000166 0.0278 -0.23 -0.2 Colorectal or endometrial cancer; chr12:50140005 chr12:50112197~50165618:+ LIHC cis rs2880765 0.546 rs11639291 ENSG00000259630.2 CTD-2262B20.1 -3.81 0.000166 0.0278 -0.29 -0.2 Coronary artery disease; chr15:85520899 chr15:85415228~85415633:+ LIHC cis rs8072100 0.79 rs1962307 ENSG00000228782.6 CTD-2026D20.3 3.81 0.000166 0.0278 0.22 0.2 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47630505 chr17:47450568~47492492:- LIHC cis rs17818399 0.633 rs2242033 ENSG00000239332.4 LINC01119 -3.81 0.000166 0.0278 -0.27 -0.2 Height; chr2:46615271 chr2:46816697~46859007:+ LIHC cis rs12681366 0.881 rs2381793 ENSG00000253704.1 RP11-267M23.4 3.81 0.000166 0.0278 0.23 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94388167 chr8:94553722~94569745:+ LIHC cis rs2518049 0.539 rs1937913 ENSG00000225418.1 AKR1C5P 3.81 0.000166 0.0278 0.21 0.2 Metabolic traits; chr10:5128303 chr10:5122087~5135226:- LIHC cis rs919433 0.963 rs10153881 ENSG00000231621.1 AC013264.2 3.81 0.000166 0.0278 0.18 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197306374 chr2:197197991~197199273:+ LIHC cis rs2613514 1 rs2311439 ENSG00000204277.1 RP11-219G17.4 3.81 0.000166 0.0278 0.31 0.2 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78084005 chr17:78261349~78278492:- LIHC cis rs1115240 0.945 rs6575069 ENSG00000257842.4 NOVA1-AS1 -3.81 0.000166 0.0278 -0.19 -0.2 Educational attainment (years of education); chr14:26602176 chr14:26598412~26806467:+ LIHC cis rs929596 0.728 rs6744284 ENSG00000233445.1 RPL17P11 3.81 0.000166 0.0278 0.24 0.2 Total bilirubin levels in HIV-1 infection; chr2:233716651 chr2:233721522~233722065:- LIHC cis rs2299116 1 rs11762510 ENSG00000225264.3 ZNRF2P2 -3.81 0.000166 0.0278 -0.23 -0.2 Serum thyroid-stimulating hormone levels; chr7:28777469 chr7:29598795~29685255:- LIHC cis rs3798696 0.62 rs2071512 ENSG00000229950.1 TFAP2A-AS1 3.81 0.000166 0.0278 0.29 0.2 Amyotrophic lateral sclerosis (sporadic); chr6:10405121 chr6:10409340~10416446:+ LIHC cis rs3105593 0.542 rs3098186 ENSG00000273674.3 CTD-2378E12.1 3.81 0.000166 0.0278 0.24 0.2 QT interval; chr15:50518424 chr15:50839875~50908599:- LIHC cis rs3105593 0.583 rs3131606 ENSG00000273674.3 CTD-2378E12.1 3.81 0.000166 0.0278 0.24 0.2 QT interval; chr15:50518549 chr15:50839875~50908599:- LIHC cis rs7915414 0.951 rs4362080 ENSG00000230338.1 MTND4P19 3.81 0.000166 0.0278 0.21 0.2 Clopidogrel active metabolite levels; chr10:94777632 chr10:94774156~94774633:- LIHC cis rs4308124 0.708 rs67816163 ENSG00000227992.1 AC108463.2 -3.81 0.000166 0.0278 -0.27 -0.2 Vitiligo; chr2:111205733 chr2:111203964~111206215:- LIHC cis rs10918270 0.71 rs2340723 ENSG00000213075.7 RPL31P11 3.81 0.000166 0.0278 0.22 0.2 Parkinson's disease (age of onset); chr1:161970464 chr1:161683695~161685252:- LIHC cis rs10256972 0.684 rs2363279 ENSG00000199023.2 MIR339 -3.81 0.000166 0.0278 -0.24 -0.2 Endometriosis;Longevity; chr7:1056507 chr7:1022935~1023045:- LIHC cis rs854624 0.792 rs1719199 ENSG00000278690.1 RP11-104J23.2 -3.81 0.000166 0.0278 -0.41 -0.2 Blood protein levels; chr17:36010957 chr17:36012504~36012891:+ LIHC cis rs6545883 0.965 rs778752 ENSG00000273302.1 RP11-493E12.2 3.81 0.000166 0.0278 0.22 0.2 Tuberculosis; chr2:61549767 chr2:61199979~61200769:+ LIHC cis rs847851 0.761 rs10807144 ENSG00000276712.1 MIR7111 -3.81 0.000166 0.0278 -0.21 -0.2 Colonoscopy-negative controls vs population controls; chr6:35004643 chr6:35470508~35470579:+ LIHC cis rs5769707 0.967 rs17182154 ENSG00000279345.1 RP3-522J7.7 -3.81 0.000166 0.0278 -0.18 -0.2 Monocyte percentage of white cells;Monocyte count; chr22:49596822 chr22:49805452~49807208:+ LIHC cis rs4356975 0.563 rs7375178 ENSG00000250919.1 RP11-813N20.3 -3.81 0.000166 0.0278 -0.2 -0.2 Obesity-related traits; chr4:69103961 chr4:69027831~69044578:+ LIHC cis rs1411478 1 rs10753232 ENSG00000243155.1 RP11-46A10.5 3.81 0.000166 0.0278 0.2 0.2 Menopause (age at onset);Progressive supranuclear palsy; chr1:180980990 chr1:180944042~180976482:- LIHC cis rs12681366 0.537 rs10956913 ENSG00000253704.1 RP11-267M23.4 3.81 0.000166 0.0278 0.23 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94471459 chr8:94553722~94569745:+ LIHC cis rs4356203 0.87 rs214925 ENSG00000260196.1 RP1-239B22.5 -3.81 0.000167 0.0279 -0.24 -0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17213037 chr11:17380649~17383531:+ LIHC cis rs4356975 0.563 rs4274916 ENSG00000250919.1 RP11-813N20.3 -3.81 0.000167 0.0279 -0.2 -0.2 Obesity-related traits; chr4:69122660 chr4:69027831~69044578:+ LIHC cis rs9907295 1 rs9901195 ENSG00000270871.1 AC015849.19 3.81 0.000167 0.0279 0.22 0.2 Fibroblast growth factor basic levels; chr17:35915576 chr17:35816717~35830293:- LIHC cis rs9907295 0.786 rs9901418 ENSG00000270871.1 AC015849.19 3.81 0.000167 0.0279 0.22 0.2 Fibroblast growth factor basic levels; chr17:35915699 chr17:35816717~35830293:- LIHC cis rs864537 0.646 rs2995091 ENSG00000273160.1 RP11-104L21.3 3.81 0.000167 0.0279 0.27 0.2 Celiac disease or Rheumatoid arthritis;Celiac disease; chr1:167465040 chr1:167457742~167459891:- LIHC cis rs2243480 1 rs160643 ENSG00000228409.4 CCT6P1 3.81 0.000167 0.0279 0.2 0.2 Diabetic kidney disease; chr7:66093235 chr7:65751142~65763354:+ LIHC cis rs2749097 1 rs12024831 ENSG00000244256.3 RN7SL130P -3.81 0.000167 0.0279 -0.26 -0.2 Alcohol consumption (transferrin glycosylation); chr1:63671796 chr1:63655743~63656047:+ LIHC cis rs7722022 0.961 rs6884670 ENSG00000253428.1 CTB-43E15.2 3.81 0.000167 0.0279 0.21 0.2 Adiponectin levels; chr5:173525924 chr5:173689459~173705849:+ LIHC cis rs4453827 1 rs13076366 ENSG00000271916.1 RP11-884K10.6 -3.81 0.000167 0.0279 -0.38 -0.2 Blood protein levels; chr3:53713347 chr3:53797764~53798019:- LIHC cis rs748404 0.723 rs512431 ENSG00000205771.5 CATSPER2P1 3.81 0.000167 0.0279 0.24 0.2 Lung cancer; chr15:43249741 chr15:43726918~43747094:- LIHC cis rs12210905 1 rs9393796 ENSG00000216901.1 AL022393.7 3.81 0.000167 0.0279 0.34 0.2 Hip circumference adjusted for BMI; chr6:27259186 chr6:28176188~28176674:+ LIHC cis rs9467711 0.538 rs7766531 ENSG00000216436.2 HIST1H2APS1 3.81 0.000167 0.0279 0.43 0.2 Autism spectrum disorder or schizophrenia; chr6:25886349 chr6:25732497~25732827:+ LIHC cis rs9467711 0.538 rs7750960 ENSG00000216436.2 HIST1H2APS1 3.81 0.000167 0.0279 0.43 0.2 Autism spectrum disorder or schizophrenia; chr6:25886989 chr6:25732497~25732827:+ LIHC cis rs938554 0.657 rs7679724 ENSG00000250413.1 RP11-448G15.1 -3.81 0.000167 0.0279 -0.28 -0.2 Blood metabolite levels; chr4:9983752 chr4:10006482~10009725:+ LIHC cis rs4925386 0.559 rs2427291 ENSG00000226332.2 RP11-157P1.4 3.81 0.000167 0.0279 0.25 0.2 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62346268 chr20:62305432~62306325:- LIHC cis rs11096990 0.821 rs2711991 ENSG00000249685.1 RP11-360F5.3 -3.81 0.000167 0.0279 -0.28 -0.2 Cognitive function; chr4:39149733 chr4:39133913~39135608:+ LIHC cis rs2904804 0.641 rs4242782 ENSG00000224251.5 RP11-499O7.7 3.81 0.000167 0.0279 0.25 0.2 Economic and political preferences (immigration/crime); chr10:4973950 chr10:4995488~4997380:+ LIHC cis rs30380 0.69 rs2911139 ENSG00000272109.1 CTD-2260A17.3 -3.81 0.000167 0.0279 -0.25 -0.2 Cerebrospinal fluid biomarker levels; chr5:96843890 chr5:96804353~96806105:+ LIHC cis rs6449502 1 rs4700392 ENSG00000272308.1 RP11-231G3.1 -3.81 0.000167 0.0279 -0.28 -0.2 Mean platelet volume; chr5:60798439 chr5:60866457~60866935:- LIHC cis rs12209785 0.774 rs6905181 ENSG00000231769.2 RP1-8B1.4 3.81 0.000167 0.0279 0.29 0.2 Survival in pancreatic cancer; chr6:45532929 chr6:46097093~46129706:- LIHC cis rs2243480 0.708 rs35825036 ENSG00000275400.1 RP4-756H11.5 3.81 0.000167 0.0279 0.27 0.2 Diabetic kidney disease; chr7:66521515 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs13237037 ENSG00000275400.1 RP4-756H11.5 3.81 0.000167 0.0279 0.27 0.2 Diabetic kidney disease; chr7:66532895 chr7:66553805~66554199:- LIHC cis rs2243480 0.901 rs13237344 ENSG00000275400.1 RP4-756H11.5 3.81 0.000167 0.0279 0.27 0.2 Diabetic kidney disease; chr7:66557269 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs1796228 ENSG00000275400.1 RP4-756H11.5 3.81 0.000167 0.0279 0.27 0.2 Diabetic kidney disease; chr7:66568097 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs1267820 ENSG00000275400.1 RP4-756H11.5 3.81 0.000167 0.0279 0.27 0.2 Diabetic kidney disease; chr7:66585308 chr7:66553805~66554199:- LIHC cis rs853679 1 rs1679709 ENSG00000219392.1 RP1-265C24.5 3.81 0.000167 0.0279 0.35 0.2 Depression; chr6:28260564 chr6:28115628~28116551:+ LIHC cis rs853679 1 rs1778511 ENSG00000219392.1 RP1-265C24.5 3.81 0.000167 0.0279 0.35 0.2 Depression; chr6:28261633 chr6:28115628~28116551:+ LIHC cis rs12681366 0.881 rs12682038 ENSG00000253704.1 RP11-267M23.4 3.81 0.000167 0.0279 0.23 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94393252 chr8:94553722~94569745:+ LIHC cis rs748404 0.56 rs570933 ENSG00000166763.7 STRCP1 3.81 0.000167 0.028 0.25 0.2 Lung cancer; chr15:43531832 chr15:43699488~43718184:- LIHC cis rs12936587 0.811 rs12945496 ENSG00000223979.2 SMCR2 3.81 0.000167 0.028 0.27 0.2 Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference; chr17:17633883 chr17:17674026~17677688:- LIHC cis rs4356975 0.583 rs11936822 ENSG00000250919.1 RP11-813N20.3 -3.81 0.000167 0.028 -0.2 -0.2 Obesity-related traits; chr4:69114229 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs34814736 ENSG00000250919.1 RP11-813N20.3 -3.81 0.000167 0.028 -0.2 -0.2 Obesity-related traits; chr4:69114760 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs11933459 ENSG00000250919.1 RP11-813N20.3 -3.81 0.000167 0.028 -0.2 -0.2 Obesity-related traits; chr4:69116045 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs6600895 ENSG00000250919.1 RP11-813N20.3 -3.81 0.000167 0.028 -0.2 -0.2 Obesity-related traits; chr4:69117694 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs12505466 ENSG00000250919.1 RP11-813N20.3 -3.81 0.000167 0.028 -0.2 -0.2 Obesity-related traits; chr4:69119944 chr4:69027831~69044578:+ LIHC cis rs7809950 0.817 rs58052742 ENSG00000238832.1 snoU109 3.81 0.000167 0.028 0.26 0.2 Coronary artery disease; chr7:107569558 chr7:107603363~107603507:+ LIHC cis rs9322193 0.607 rs4870078 ENSG00000223701.3 RAET1E-AS1 -3.81 0.000167 0.028 -0.25 -0.2 Lung cancer; chr6:149880676 chr6:149884431~149919508:+ LIHC cis rs6669919 0.553 rs7527603 ENSG00000229832.1 RP11-384C4.2 3.81 0.000167 0.028 0.22 0.2 Intelligence (multi-trait analysis); chr1:211494748 chr1:212357418~212358353:+ LIHC cis rs748404 0.56 rs1060939 ENSG00000166763.7 STRCP1 3.81 0.000167 0.028 0.25 0.2 Lung cancer; chr15:43524719 chr15:43699488~43718184:- LIHC cis rs17376456 0.778 rs10476604 ENSG00000251023.1 RP11-549J18.1 -3.81 0.000168 0.028 -0.3 -0.2 Diabetic retinopathy; chr5:94126133 chr5:93860669~93863825:- LIHC cis rs2742417 0.624 rs2673068 ENSG00000244357.3 RN7SL145P 3.81 0.000168 0.028 0.19 0.2 Response to anti-depressant treatment in major depressive disorder; chr3:45727489 chr3:45742675~45742970:+ LIHC cis rs6732160 0.691 rs11886257 ENSG00000272702.1 RP11-44N22.3 3.81 0.000168 0.028 0.23 0.2 Intelligence (multi-trait analysis); chr2:73189745 chr2:73113018~73115907:+ LIHC cis rs6732160 0.691 rs1960233 ENSG00000272702.1 RP11-44N22.3 3.81 0.000168 0.028 0.23 0.2 Intelligence (multi-trait analysis); chr2:73194250 chr2:73113018~73115907:+ LIHC cis rs6732160 0.691 rs2007191 ENSG00000272702.1 RP11-44N22.3 3.81 0.000168 0.028 0.23 0.2 Intelligence (multi-trait analysis); chr2:73194335 chr2:73113018~73115907:+ LIHC cis rs853679 0.599 rs202906 ENSG00000204709.4 LINC01556 -3.81 0.000168 0.028 -0.33 -0.2 Depression; chr6:28043874 chr6:28943877~28944537:+ LIHC cis rs6436017 0.589 rs4674220 ENSG00000199121.3 MIR26B -3.81 0.000168 0.028 -0.23 -0.2 Breast cancer; chr2:217877279 chr2:218402637~218402746:+ LIHC cis rs867371 1 rs7173339 ENSG00000259429.4 UBE2Q2P2 -3.81 0.000168 0.028 -0.19 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82175253 chr15:82355142~82420075:+ LIHC cis rs4308124 0.708 rs56693625 ENSG00000227992.1 AC108463.2 -3.81 0.000168 0.028 -0.27 -0.2 Vitiligo; chr2:111207578 chr2:111203964~111206215:- LIHC cis rs4308124 0.708 rs61358692 ENSG00000227992.1 AC108463.2 -3.81 0.000168 0.028 -0.27 -0.2 Vitiligo; chr2:111207582 chr2:111203964~111206215:- LIHC cis rs9675120 0.925 rs12946082 ENSG00000262006.1 RP11-700H6.4 -3.81 0.000168 0.028 -0.21 -0.2 Cerebrospinal fluid biomarker levels; chr17:50843858 chr17:50909637~50910232:- LIHC cis rs7809950 0.678 rs62482499 ENSG00000238832.1 snoU109 -3.81 0.000168 0.028 -0.26 -0.2 Coronary artery disease; chr7:107334614 chr7:107603363~107603507:+ LIHC cis rs6545883 0.929 rs2121660 ENSG00000271889.1 RP11-493E12.1 -3.81 0.000168 0.028 -0.24 -0.2 Tuberculosis; chr2:61425923 chr2:61151433~61162105:- LIHC cis rs875971 0.545 rs66594357 ENSG00000224316.1 RP11-479O9.2 3.81 0.000168 0.0281 0.19 0.2 Aortic root size; chr7:66327797 chr7:65773620~65802067:+ LIHC cis rs10129255 1 rs9324091 ENSG00000211972.2 IGHV3-66 3.8 0.000168 0.0281 0.16 0.2 Kawasaki disease; chr14:106676625 chr14:106675017~106675544:- LIHC cis rs875971 0.545 rs10950036 ENSG00000224316.1 RP11-479O9.2 3.8 0.000168 0.0281 0.19 0.2 Aortic root size; chr7:66353241 chr7:65773620~65802067:+ LIHC cis rs617219 0.853 rs2364594 ENSG00000251675.1 CTC-458I2.2 -3.8 0.000168 0.0281 -0.22 -0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79158076 chr5:80128361~80143883:+ LIHC cis rs13315871 0.929 rs2056120 ENSG00000272182.1 RP11-802O23.3 3.8 0.000168 0.0281 0.46 0.2 Cholesterol, total; chr3:58323709 chr3:58428255~58428815:+ LIHC cis rs3091242 0.804 rs631133 ENSG00000261349.1 RP3-465N24.5 -3.8 0.000168 0.0281 -0.19 -0.2 Erythrocyte sedimentation rate; chr1:25397655 chr1:25266102~25267136:- LIHC cis rs11159086 0.793 rs9285594 ENSG00000270000.1 RP3-449M8.9 3.8 0.000168 0.0281 0.29 0.2 Advanced glycation end-product levels; chr14:74489253 chr14:74471930~74472360:- LIHC cis rs3931020 0.772 rs11485555 ENSG00000272864.1 RP11-17E13.2 -3.8 0.000168 0.0281 -0.25 -0.2 Resistin levels; chr1:74720825 chr1:74698769~74699333:- LIHC cis rs198389 0.568 rs12406667 ENSG00000242349.4 NPPA-AS1 3.8 0.000168 0.0281 0.21 0.2 B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome; chr1:11813794 chr1:11841017~11848079:+ LIHC cis rs9467773 0.525 rs1535274 ENSG00000261353.1 CTA-14H9.5 -3.8 0.000168 0.0281 -0.23 -0.2 Intelligence (multi-trait analysis); chr6:26520519 chr6:26527063~26527404:+ LIHC cis rs9467773 0.565 rs6925047 ENSG00000261353.1 CTA-14H9.5 -3.8 0.000168 0.0281 -0.23 -0.2 Intelligence (multi-trait analysis); chr6:26521207 chr6:26527063~26527404:+ LIHC cis rs9467773 0.565 rs4343916 ENSG00000261353.1 CTA-14H9.5 -3.8 0.000168 0.0281 -0.23 -0.2 Intelligence (multi-trait analysis); chr6:26522447 chr6:26527063~26527404:+ LIHC cis rs1005277 0.522 rs1208684 ENSG00000275858.1 RP11-291L22.8 3.8 0.000169 0.0281 0.22 0.2 Extrinsic epigenetic age acceleration; chr10:37805008 chr10:38450738~38451069:- LIHC cis rs11613048 0.897 rs7136950 ENSG00000245614.3 DDX11-AS1 3.8 0.000169 0.0281 0.18 0.2 Major depressive disorder; chr12:30168167 chr12:31020763~31073847:- LIHC cis rs846111 1 rs846111 ENSG00000226944.1 RP1-120G22.11 3.8 0.000169 0.0281 0.26 0.2 QT interval; chr1:6219310 chr1:6204840~6205780:- LIHC cis rs1344653 0.738 rs6728887 ENSG00000236204.4 LINC01376 -3.8 0.000169 0.0281 -0.24 -0.2 Pulse pressure; chr2:19564127 chr2:18986451~19346748:- LIHC cis rs4578769 0.642 rs9957007 ENSG00000265943.1 RP11-739L10.1 3.8 0.000169 0.0281 0.26 0.2 Eosinophil percentage of white cells; chr18:23037065 chr18:22699481~22933764:- LIHC cis rs11096990 0.855 rs1597722 ENSG00000249685.1 RP11-360F5.3 3.8 0.000169 0.0282 0.28 0.2 Cognitive function; chr4:39173255 chr4:39133913~39135608:+ LIHC cis rs6828577 0.606 rs441216 ENSG00000281731.1 RP11-384K6.8 -3.8 0.000169 0.0282 -0.29 -0.2 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118709247 chr4:118664087~118685341:- LIHC cis rs10833905 0.877 rs11026924 ENSG00000246225.5 RP11-17A1.3 -3.8 0.000169 0.0282 -0.25 -0.2 Sudden cardiac arrest; chr11:23034626 chr11:22829380~22945393:+ LIHC cis rs17660992 0.716 rs8111426 ENSG00000273837.1 LLNLR-470E3.1 3.8 0.000169 0.0282 0.26 0.2 Blood protein levels; chr19:51662110 chr19:51639478~51639931:- LIHC cis rs4903214 0.895 rs1005740 ENSG00000273565.1 CTD-3075F15.1 3.8 0.000169 0.0282 0.26 0.2 Inflammatory bowel disease; chr14:74228629 chr14:75176929~75177418:+ LIHC cis rs10761256 0.835 rs10821196 ENSG00000227603.1 RP11-165J3.6 3.8 0.000169 0.0282 0.24 0.2 Itch intensity from mosquito bite adjusted by bite size; chr9:93671114 chr9:93435332~93437121:- LIHC cis rs4964805 0.865 rs67825151 ENSG00000257681.1 RP11-341G23.4 3.8 0.000169 0.0282 0.21 0.2 Attention deficit hyperactivity disorder; chr12:103811666 chr12:103746315~103768858:- LIHC cis rs12928939 0.862 rs7197104 ENSG00000263232.2 ATP5A1P3 -3.8 0.000169 0.0282 -0.31 -0.2 Post bronchodilator FEV1; chr16:71760158 chr16:72005037~72006543:- LIHC cis rs494562 0.73 rs9450269 ENSG00000203875.9 SNHG5 3.8 0.000169 0.0282 0.39 0.2 Metabolic traits;Blood metabolite levels; chr6:85404966 chr6:85660950~85678736:- LIHC cis rs2301573 1 rs11708809 ENSG00000251474.5 RPL32P3 3.8 0.000169 0.0282 0.24 0.2 Hip circumference; chr3:129578635 chr3:129382922~129399655:- LIHC cis rs9595908 0.869 rs9595948 ENSG00000212293.1 SNORA16 3.8 0.000169 0.0282 0.23 0.2 Body mass index; chr13:32629519 chr13:32420390~32420516:- LIHC cis rs11089937 0.597 rs5756991 ENSG00000211639.2 IGLV4-60 3.8 0.000169 0.0282 0.18 0.2 Periodontitis (PAL4Q3); chr22:22132541 chr22:22162199~22162681:+ LIHC cis rs172166 0.637 rs1233691 ENSG00000216901.1 AL022393.7 3.8 0.000169 0.0282 0.26 0.2 Cardiac Troponin-T levels; chr6:28186119 chr6:28176188~28176674:+ LIHC cis rs1005277 0.579 rs2474587 ENSG00000275858.1 RP11-291L22.8 3.8 0.000169 0.0282 0.22 0.2 Extrinsic epigenetic age acceleration; chr10:38131738 chr10:38450738~38451069:- LIHC cis rs1005277 0.579 rs2474588 ENSG00000275858.1 RP11-291L22.8 3.8 0.000169 0.0282 0.22 0.2 Extrinsic epigenetic age acceleration; chr10:38131942 chr10:38450738~38451069:- LIHC cis rs1023500 0.506 rs6002625 ENSG00000226450.2 CYP2D8P -3.8 0.000169 0.0282 -0.25 -0.2 Schizophrenia; chr22:42121685 chr22:42149886~42155001:- LIHC cis rs3812762 0.912 rs4929936 ENSG00000254860.4 TMEM9B-AS1 3.8 0.000169 0.0282 0.24 0.2 Hypospadias; chr11:8771075 chr11:8964675~8977527:+ LIHC cis rs6700559 1 rs10800720 ENSG00000260088.1 RP11-92G12.3 -3.8 0.000169 0.0282 -0.26 -0.2 Coronary artery disease; chr1:200679441 chr1:200669507~200694250:+ LIHC cis rs6700559 0.935 rs4072553 ENSG00000260088.1 RP11-92G12.3 -3.8 0.000169 0.0282 -0.26 -0.2 Coronary artery disease; chr1:200680036 chr1:200669507~200694250:+ LIHC cis rs12468226 0.808 rs77251002 ENSG00000273456.1 RP11-686O6.2 3.8 0.000169 0.0282 0.31 0.2 Urate levels; chr2:202150236 chr2:202374932~202375604:- LIHC cis rs5742933 0.652 rs10210345 ENSG00000253559.1 OSGEPL1-AS1 3.8 0.000169 0.0282 0.26 0.2 Ferritin levels; chr2:189754760 chr2:189762704~189765556:+ LIHC cis rs4073416 0.746 rs12883382 ENSG00000276116.2 FUT8-AS1 3.8 0.000169 0.0282 0.26 0.2 N-glycan levels; chr14:65678678 chr14:65411170~65412690:- LIHC cis rs467650 0.782 rs719246 ENSG00000248489.1 CTD-2007H13.3 -3.8 0.000169 0.0282 -0.28 -0.2 Venous thromboembolism (SNP x SNP interaction); chr5:98722220 chr5:98929171~98995013:+ LIHC cis rs6968419 0.585 rs9692117 ENSG00000279086.1 RP11-667F14.1 -3.8 0.000169 0.0282 -0.24 -0.2 Intraocular pressure; chr7:116287905 chr7:116209234~116211511:- LIHC cis rs6442522 0.799 rs4395387 ENSG00000249786.6 EAF1-AS1 3.8 0.000169 0.0282 0.23 0.2 Uric acid levels; chr3:15461548 chr3:15436171~15455940:- LIHC cis rs7722022 0.961 rs17679877 ENSG00000253428.1 CTB-43E15.2 3.8 0.000169 0.0282 0.21 0.2 Adiponectin levels; chr5:173514686 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs6873129 ENSG00000253428.1 CTB-43E15.2 3.8 0.000169 0.0282 0.21 0.2 Adiponectin levels; chr5:173514827 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs996374 ENSG00000253428.1 CTB-43E15.2 3.8 0.000169 0.0282 0.21 0.2 Adiponectin levels; chr5:173514949 chr5:173689459~173705849:+ LIHC cis rs4713118 0.523 rs2179096 ENSG00000216901.1 AL022393.7 3.8 0.000169 0.0282 0.24 0.2 Parkinson's disease; chr6:27698141 chr6:28176188~28176674:+ LIHC cis rs801193 0.527 rs2707837 ENSG00000232559.3 GS1-124K5.12 3.8 0.000169 0.0282 0.16 0.2 Aortic root size; chr7:66716086 chr7:66554588~66576923:- LIHC cis rs481331 0.799 rs58501815 ENSG00000185904.10 LINC00839 3.8 0.000169 0.0282 0.39 0.2 Systemic juvenile idiopathic arthritis; chr10:42475382 chr10:42475543~42495336:+ LIHC cis rs2976388 0.578 rs34956412 ENSG00000253741.1 CTD-2292P10.4 3.8 0.000169 0.0282 0.26 0.2 Urinary tract infection frequency; chr8:142740610 chr8:142702252~142726973:- LIHC cis rs6163 0.508 rs12776506 ENSG00000236937.2 PTGES3P4 3.8 0.000169 0.0283 0.29 0.2 Waist circumference;Hip circumference; chr10:102773071 chr10:102845595~102845950:+ LIHC cis rs524281 0.692 rs10791845 ENSG00000255320.1 RP11-755F10.1 -3.8 0.000169 0.0283 -0.27 -0.2 Electroencephalogram traits; chr11:66066869 chr11:66244840~66246239:- LIHC cis rs10829156 1 rs10829156 ENSG00000240291.1 RP11-499P20.2 3.8 0.00017 0.0283 0.32 0.2 Sudden cardiac arrest; chr10:18661626 chr10:18513115~18545651:- LIHC cis rs748404 0.697 rs546170 ENSG00000205771.5 CATSPER2P1 -3.8 0.00017 0.0283 -0.24 -0.2 Lung cancer; chr15:43272651 chr15:43726918~43747094:- LIHC cis rs2291447 0.618 rs7207047 ENSG00000264070.1 DND1P1 3.8 0.00017 0.0283 0.25 0.2 Economic and political preferences; chr17:45121631 chr17:45585871~45586929:+ LIHC cis rs10129255 0.518 rs8009612 ENSG00000211972.2 IGHV3-66 3.8 0.00017 0.0283 0.15 0.2 Kawasaki disease; chr14:106777510 chr14:106675017~106675544:- LIHC cis rs6745190 0.953 rs7559803 ENSG00000236153.1 AC104076.3 3.8 0.00017 0.0283 0.27 0.2 White blood cell count; chr2:180986450 chr2:180979427~180980090:- LIHC cis rs875971 0.545 rs1547529 ENSG00000224316.1 RP11-479O9.2 3.8 0.00017 0.0283 0.2 0.2 Aortic root size; chr7:66258859 chr7:65773620~65802067:+ LIHC cis rs6832769 1 rs4865010 ENSG00000272969.1 RP11-528I4.2 -3.8 0.00017 0.0283 -0.24 -0.2 Personality dimensions; chr4:55548795 chr4:55547112~55547889:+ LIHC cis rs4356203 0.905 rs615358 ENSG00000260196.1 RP1-239B22.5 -3.8 0.00017 0.0283 -0.24 -0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17188885 chr11:17380649~17383531:+ LIHC cis rs35934224 0.783 rs7288061 ENSG00000232926.1 AC000078.5 3.8 0.00017 0.0283 0.3 0.2 Glaucoma (primary open-angle); chr22:19876716 chr22:19887289~19887970:+ LIHC cis rs35934224 0.783 rs7287073 ENSG00000232926.1 AC000078.5 3.8 0.00017 0.0283 0.3 0.2 Glaucoma (primary open-angle); chr22:19876812 chr22:19887289~19887970:+ LIHC cis rs12681366 0.623 rs10106494 ENSG00000253704.1 RP11-267M23.4 3.8 0.00017 0.0283 0.24 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94471226 chr8:94553722~94569745:+ LIHC cis rs7208859 0.673 rs11652370 ENSG00000264538.5 SUZ12P1 -3.8 0.00017 0.0283 -0.21 -0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770205 chr17:30709299~30790908:+ LIHC cis rs17818399 0.597 rs13385693 ENSG00000239332.4 LINC01119 -3.8 0.00017 0.0283 -0.26 -0.2 Height; chr2:46640019 chr2:46816697~46859007:+ LIHC cis rs2658782 0.756 rs3019205 ENSG00000279684.1 RP11-755E23.2 -3.8 0.00017 0.0284 -0.33 -0.2 Pulmonary function decline; chr11:93376387 chr11:93286629~93288903:- LIHC cis rs733592 0.56 rs61918773 ENSG00000240399.1 RP1-228P16.1 -3.8 0.00017 0.0284 -0.2 -0.2 Plateletcrit; chr12:48027991 chr12:48054813~48055591:- LIHC cis rs9747201 0.963 rs11077983 ENSG00000279692.1 RP11-1055B8.1 3.8 0.00017 0.0284 0.35 0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82227312 chr17:81395609~81397144:- LIHC cis rs6449502 0.702 rs1867597 ENSG00000272308.1 RP11-231G3.1 -3.8 0.00017 0.0284 -0.28 -0.2 Mean platelet volume; chr5:60842003 chr5:60866457~60866935:- LIHC cis rs6449502 0.702 rs13189346 ENSG00000272308.1 RP11-231G3.1 -3.8 0.00017 0.0284 -0.28 -0.2 Mean platelet volume; chr5:60842032 chr5:60866457~60866935:- LIHC cis rs12210905 1 rs9368492 ENSG00000216901.1 AL022393.7 3.8 0.00017 0.0284 0.34 0.2 Hip circumference adjusted for BMI; chr6:27253739 chr6:28176188~28176674:+ LIHC cis rs4763879 0.502 rs11052552 ENSG00000256673.1 RP11-599J14.2 -3.8 0.00017 0.0284 -0.2 -0.2 Type 1 diabetes; chr12:9703362 chr12:9398355~9414851:- LIHC cis rs11613048 0.897 rs12826253 ENSG00000245614.3 DDX11-AS1 3.8 0.00017 0.0284 0.18 0.2 Major depressive disorder; chr12:30170181 chr12:31020763~31073847:- LIHC cis rs12906542 0.544 rs35472584 ENSG00000259792.1 RP11-114H24.6 -3.8 0.00017 0.0284 -0.28 -0.2 Breast cancer; chr15:77974385 chr15:77993405~77995289:+ LIHC cis rs10129255 0.5 rs6576230 ENSG00000211972.2 IGHV3-66 3.8 0.00017 0.0284 0.15 0.2 Kawasaki disease; chr14:106778539 chr14:106675017~106675544:- LIHC cis rs453301 0.653 rs7016139 ENSG00000253893.2 FAM85B 3.8 0.00017 0.0284 0.23 0.2 Joint mobility (Beighton score); chr8:9037960 chr8:8167819~8226614:- LIHC cis rs794185 0.592 rs304079 ENSG00000231249.1 ITPR1-AS1 3.8 0.00017 0.0284 0.22 0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4490785 chr3:4490891~4493163:- LIHC cis rs801193 0.569 rs2659908 ENSG00000232559.3 GS1-124K5.12 3.8 0.00017 0.0284 0.16 0.2 Aortic root size; chr7:66695835 chr7:66554588~66576923:- LIHC cis rs801193 0.569 rs7782587 ENSG00000232559.3 GS1-124K5.12 3.8 0.00017 0.0284 0.16 0.2 Aortic root size; chr7:66701485 chr7:66554588~66576923:- LIHC cis rs801193 0.569 rs4717315 ENSG00000232559.3 GS1-124K5.12 3.8 0.00017 0.0284 0.16 0.2 Aortic root size; chr7:66713338 chr7:66554588~66576923:- LIHC cis rs7712401 0.623 rs30043 ENSG00000263432.2 RN7SL689P 3.8 0.00017 0.0284 0.29 0.2 Mean platelet volume; chr5:122936598 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs185009 ENSG00000263432.2 RN7SL689P 3.8 0.00017 0.0284 0.29 0.2 Mean platelet volume; chr5:122938072 chr5:123022487~123022783:- LIHC cis rs7712401 0.541 rs42537 ENSG00000263432.2 RN7SL689P 3.8 0.00017 0.0284 0.29 0.2 Mean platelet volume; chr5:122938993 chr5:123022487~123022783:- LIHC cis rs7712401 0.58 rs185008 ENSG00000263432.2 RN7SL689P 3.8 0.00017 0.0284 0.29 0.2 Mean platelet volume; chr5:122939039 chr5:123022487~123022783:- LIHC cis rs7712401 0.58 rs30041 ENSG00000263432.2 RN7SL689P 3.8 0.00017 0.0284 0.29 0.2 Mean platelet volume; chr5:122939658 chr5:123022487~123022783:- LIHC cis rs7712401 0.58 rs42536 ENSG00000263432.2 RN7SL689P 3.8 0.00017 0.0284 0.29 0.2 Mean platelet volume; chr5:122940728 chr5:123022487~123022783:- LIHC cis rs617219 0.853 rs55868416 ENSG00000251675.1 CTC-458I2.2 -3.8 0.00017 0.0284 -0.22 -0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79167704 chr5:80128361~80143883:+ LIHC cis rs617219 0.889 rs10942887 ENSG00000251675.1 CTC-458I2.2 -3.8 0.00017 0.0284 -0.22 -0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79168189 chr5:80128361~80143883:+ LIHC cis rs6142618 0.84 rs6119834 ENSG00000235313.1 HM13-IT1 3.8 0.00017 0.0284 0.25 0.2 Inflammatory bowel disease; chr20:32348944 chr20:31563166~31564076:+ LIHC cis rs17741873 1 rs17741873 ENSG00000235316.1 DUSP8P5 3.8 0.000171 0.0284 0.18 0.2 Paclitaxel disposition in epithelial ovarian cancer; chr10:73894042 chr10:73731824~73733638:+ LIHC cis rs853679 1 rs68141011 ENSG00000204709.4 LINC01556 3.8 0.000171 0.0284 0.35 0.2 Depression; chr6:28250019 chr6:28943877~28944537:+ LIHC cis rs853679 1 rs13200462 ENSG00000204709.4 LINC01556 3.8 0.000171 0.0284 0.35 0.2 Depression; chr6:28250421 chr6:28943877~28944537:+ LIHC cis rs10129255 0.957 rs1024349 ENSG00000211970.3 IGHV4-61 -3.8 0.000171 0.0284 -0.16 -0.2 Kawasaki disease; chr14:106689997 chr14:106639119~106639657:- LIHC cis rs11096990 0.964 rs56284364 ENSG00000249685.1 RP11-360F5.3 -3.8 0.000171 0.0284 -0.27 -0.2 Cognitive function; chr4:39255028 chr4:39133913~39135608:+ LIHC cis rs365302 0.597 rs631028 ENSG00000216480.2 RP3-393E18.1 -3.8 0.000171 0.0284 -0.25 -0.2 Coronary heart disease; chr6:159214756 chr6:159526062~159526527:- LIHC cis rs867371 1 rs7166570 ENSG00000259429.4 UBE2Q2P2 -3.8 0.000171 0.0284 -0.19 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82173880 chr15:82355142~82420075:+ LIHC cis rs13217239 0.597 rs9467978 ENSG00000241549.7 GUSBP2 -3.8 0.000171 0.0284 -0.21 -0.2 Schizophrenia; chr6:27056779 chr6:26871484~26956554:- LIHC cis rs2562456 0.917 rs6511253 ENSG00000268555.1 RP11-678G14.3 -3.8 0.000171 0.0284 -0.25 -0.2 Pain; chr19:21495996 chr19:21570822~21587322:- LIHC cis rs62090893 0.656 rs2581655 ENSG00000264247.1 LINC00909 -3.8 0.000171 0.0284 -0.27 -0.2 Anorexia nervosa; chr18:75311188 chr18:74591774~74598508:- LIHC cis rs12681287 0.547 rs11992656 ENSG00000254088.1 SLC2A3P4 -3.8 0.000171 0.0285 -0.24 -0.2 Caudate activity during reward; chr8:86522641 chr8:86503591~86505061:+ LIHC cis rs17373728 0.739 rs7835101 ENSG00000249395.2 CASC9 3.8 0.000171 0.0285 0.22 0.2 Diabetic kidney disease; chr8:75256950 chr8:75223404~75324741:- LIHC cis rs3772760 1 rs9810152 ENSG00000240622.1 RPL7P15 -3.8 0.000171 0.0285 -0.38 -0.2 Amyotrophic lateral sclerosis; chr3:124449881 chr3:124151960~124153063:- LIHC cis rs11686241 0.882 rs2129119 ENSG00000232485.2 AC098820.3 3.8 0.000171 0.0285 0.2 0.2 Cancer; chr2:216464461 chr2:216479030~216498761:- LIHC cis rs8177876 0.686 rs2602402 ENSG00000261061.1 RP11-303E16.2 -3.8 0.000171 0.0285 -0.27 -0.2 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81052725 chr16:81030770~81031485:+ LIHC cis rs9309473 0.519 rs4852950 ENSG00000204872.3 NAT8B -3.8 0.000171 0.0285 -0.26 -0.2 Metabolite levels; chr2:73637543 chr2:73700576~73701340:- LIHC cis rs875971 0.505 rs1723275 ENSG00000237310.1 GS1-124K5.4 -3.8 0.000171 0.0285 -0.2 -0.2 Aortic root size; chr7:66039646 chr7:66493706~66495474:+ LIHC cis rs4683346 0.691 rs12488474 ENSG00000273328.4 RP11-141M3.6 3.8 0.000171 0.0285 0.22 0.2 Granulocyte percentage of myeloid white cells; chr3:42896185 chr3:42809414~42908105:+ LIHC cis rs13113518 0.738 rs6849883 ENSG00000223305.1 RN7SKP30 3.8 0.000171 0.0285 0.23 0.2 Height; chr4:55387515 chr4:55540502~55540835:- LIHC cis rs6452524 0.618 rs1871203 ENSG00000271862.1 RP11-343L5.2 3.8 0.000171 0.0285 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83059567 chr5:83049376~83050964:- LIHC cis rs6452524 0.618 rs7722924 ENSG00000271862.1 RP11-343L5.2 3.8 0.000171 0.0285 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83060223 chr5:83049376~83050964:- LIHC cis rs6452524 0.618 rs6867727 ENSG00000271862.1 RP11-343L5.2 3.8 0.000171 0.0285 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83061333 chr5:83049376~83050964:- LIHC cis rs6452524 0.618 rs7723639 ENSG00000271862.1 RP11-343L5.2 3.8 0.000171 0.0285 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83062610 chr5:83049376~83050964:- LIHC cis rs6452524 0.618 rs2306336 ENSG00000271862.1 RP11-343L5.2 3.8 0.000171 0.0285 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83064964 chr5:83049376~83050964:- LIHC cis rs6452524 0.589 rs6882386 ENSG00000271862.1 RP11-343L5.2 3.8 0.000171 0.0285 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83065555 chr5:83049376~83050964:- LIHC cis rs6452524 0.618 rs6860752 ENSG00000271862.1 RP11-343L5.2 3.8 0.000171 0.0285 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83065587 chr5:83049376~83050964:- LIHC cis rs6452524 0.618 rs3899556 ENSG00000271862.1 RP11-343L5.2 3.8 0.000171 0.0285 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83067862 chr5:83049376~83050964:- LIHC cis rs6452524 0.56 rs6895174 ENSG00000271862.1 RP11-343L5.2 3.8 0.000171 0.0285 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83071606 chr5:83049376~83050964:- LIHC cis rs6452524 0.618 rs6452502 ENSG00000271862.1 RP11-343L5.2 3.8 0.000171 0.0285 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83074578 chr5:83049376~83050964:- LIHC cis rs6452524 0.618 rs6452503 ENSG00000271862.1 RP11-343L5.2 3.8 0.000171 0.0285 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83074596 chr5:83049376~83050964:- LIHC cis rs9532669 0.926 rs7799 ENSG00000176268.5 CYCSP34 3.8 0.000171 0.0285 0.23 0.2 Cervical cancer; chr13:40958916 chr13:40863599~40863902:- LIHC cis rs812925 0.826 rs2694633 ENSG00000212978.6 AC016747.3 3.8 0.000171 0.0285 0.24 0.2 Immature fraction of reticulocytes; chr2:61313507 chr2:61141592~61144969:- LIHC cis rs854624 0.892 rs1734958 ENSG00000278690.1 RP11-104J23.2 3.8 0.000171 0.0285 0.43 0.2 Blood protein levels; chr17:36009521 chr17:36012504~36012891:+ LIHC cis rs1005277 0.603 rs1998062 ENSG00000276805.1 RP11-291L22.6 3.8 0.000171 0.0285 0.24 0.2 Extrinsic epigenetic age acceleration; chr10:38168724 chr10:38451030~38451785:+ LIHC cis rs9906944 0.707 rs11655950 ENSG00000248278.1 SUMO2P17 -3.8 0.000171 0.0285 -0.33 -0.2 Intelligence (multi-trait analysis);Body fat percentage; chr17:49051759 chr17:48874860~48908983:- LIHC cis rs2396442 0.965 rs7756144 ENSG00000231769.2 RP1-8B1.4 3.8 0.000171 0.0285 0.25 0.2 Left ventricle wall thickness; chr6:45485646 chr6:46097093~46129706:- LIHC cis rs7412746 0.611 rs2228099 ENSG00000231073.1 RP11-316M1.3 3.8 0.000171 0.0285 0.19 0.2 Melanoma; chr1:150836413 chr1:150973123~150975534:+ LIHC cis rs12681287 0.517 rs68008113 ENSG00000254088.1 SLC2A3P4 3.8 0.000171 0.0285 0.24 0.2 Caudate activity during reward; chr8:86508665 chr8:86503591~86505061:+ LIHC cis rs1005277 0.505 rs10827836 ENSG00000099251.13 HSD17B7P2 -3.8 0.000171 0.0285 -0.23 -0.2 Extrinsic epigenetic age acceleration; chr10:37926513 chr10:38356380~38378505:+ LIHC cis rs7760535 0.764 rs240994 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000171 0.0285 -0.19 -0.2 Metabolic traits; chr6:111354554 chr6:111297126~111298510:+ LIHC cis rs7760535 0.794 rs463860 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000171 0.0285 -0.19 -0.2 Metabolic traits; chr6:111370518 chr6:111297126~111298510:+ LIHC cis rs516805 0.715 rs11154087 ENSG00000279453.1 RP3-425C14.4 3.8 0.000171 0.0285 0.31 0.2 Lymphocyte counts; chr6:122575484 chr6:122436789~122439223:- LIHC cis rs11722228 0.539 rs62287552 ENSG00000261490.1 RP11-448G15.3 3.8 0.000171 0.0285 0.27 0.2 Urate levels;Serum uric acid levels;Gout; chr4:10151573 chr4:10068089~10073019:- LIHC cis rs13217239 0.646 rs9379956 ENSG00000241549.7 GUSBP2 -3.8 0.000172 0.0285 -0.21 -0.2 Schizophrenia; chr6:27065956 chr6:26871484~26956554:- LIHC cis rs1023500 1 rs10154646 ENSG00000227370.1 RP4-669P10.19 3.8 0.000172 0.0285 0.27 0.2 Schizophrenia; chr22:41935405 chr22:42132543~42132998:+ LIHC cis rs6442522 0.733 rs4143273 ENSG00000249786.6 EAF1-AS1 -3.8 0.000172 0.0285 -0.23 -0.2 Uric acid levels; chr3:15460301 chr3:15436171~15455940:- LIHC cis rs6472827 0.904 rs11996617 ENSG00000253983.2 RP1-16A9.1 -3.8 0.000172 0.0286 -0.27 -0.2 Uterine fibroids; chr8:74208452 chr8:74199396~74208441:+ LIHC cis rs12468226 0.938 rs76501067 ENSG00000226261.1 AC064836.3 3.8 0.000172 0.0286 0.32 0.2 Urate levels; chr2:202318042 chr2:202336024~202336727:- LIHC cis rs1005277 0.565 rs2474565 ENSG00000275858.1 RP11-291L22.8 3.8 0.000172 0.0286 0.22 0.2 Extrinsic epigenetic age acceleration; chr10:38091900 chr10:38450738~38451069:- LIHC cis rs803903 0.57 rs12156498 ENSG00000230894.1 RP11-67K19.3 3.8 0.000172 0.0286 0.26 0.2 Breast cancer; chr9:116463769 chr9:116568449~116586328:+ LIHC cis rs875971 0.619 rs10278371 ENSG00000273024.4 INTS4P2 3.8 0.000172 0.0286 0.23 0.2 Aortic root size; chr7:66586553 chr7:65647864~65715661:+ LIHC cis rs4792901 0.759 rs3179927 ENSG00000267747.1 RP11-392O1.4 -3.8 0.000172 0.0286 -0.24 -0.2 Dupuytren's disease; chr17:43524543 chr17:43544785~43610338:+ LIHC cis rs875971 0.545 rs6460276 ENSG00000224316.1 RP11-479O9.2 3.8 0.000172 0.0286 0.19 0.2 Aortic root size; chr7:66182290 chr7:65773620~65802067:+ LIHC cis rs559928 0.606 rs56311067 ENSG00000236935.1 AP003774.1 3.8 0.000172 0.0286 0.29 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64164135 chr11:64325050~64329504:- LIHC cis rs559928 0.556 rs11607903 ENSG00000236935.1 AP003774.1 3.8 0.000172 0.0286 0.29 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64164668 chr11:64325050~64329504:- LIHC cis rs7121538 0.551 rs16930368 ENSG00000251991.1 RNU7-49P -3.8 0.000172 0.0286 -0.32 -0.2 HDL cholesterol; chr11:14602395 chr11:14478892~14478953:+ LIHC cis rs4073416 0.712 rs1998036 ENSG00000276116.2 FUT8-AS1 3.8 0.000172 0.0286 0.25 0.2 N-glycan levels; chr14:65671481 chr14:65411170~65412690:- LIHC cis rs9400467 0.528 rs455247 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111346596 chr6:111297126~111298510:+ LIHC cis rs7760535 0.811 rs464401 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Metabolic traits; chr6:111347804 chr6:111297126~111298510:+ LIHC cis rs9400467 0.509 rs463854 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111352004 chr6:111297126~111298510:+ LIHC cis rs9400467 0.509 rs463853 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111352008 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs456569 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111353598 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs455335 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111354313 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs465795 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111355240 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs110732 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111358666 chr6:111297126~111298510:+ LIHC cis rs9400467 0.592 rs462493 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111362537 chr6:111297126~111298510:+ LIHC cis rs9400467 0.508 rs456871 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111366447 chr6:111297126~111298510:+ LIHC cis rs7760535 0.811 rs455732 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Metabolic traits; chr6:111374065 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs458486 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111375649 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs455726 ENSG00000271789.1 RP5-1112D6.7 -3.8 0.000172 0.0286 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111378165 chr6:111297126~111298510:+ LIHC cis rs67311347 1 rs6599102 ENSG00000223797.4 ENTPD3-AS1 3.8 0.000172 0.0286 0.16 0.2 Renal cell carcinoma; chr3:40426915 chr3:40313802~40453329:- LIHC cis rs2439831 0.85 rs12442297 ENSG00000275601.1 AC011330.13 -3.8 0.000172 0.0286 -0.31 -0.2 Lung cancer in ever smokers; chr15:43876272 chr15:43642389~43643023:- LIHC cis rs2243480 1 rs387676 ENSG00000230295.1 RP11-458F8.2 -3.8 0.000172 0.0286 -0.21 -0.2 Diabetic kidney disease; chr7:66133233 chr7:66880708~66882981:+ LIHC cis rs1075232 0.51 rs78884938 ENSG00000215302.7 CTD-3092A11.1 -3.8 0.000172 0.0286 -0.38 -0.2 Survival in colorectal cancer (non-distant metastatic); chr15:31218682 chr15:30470779~30507623:+ LIHC cis rs1499614 0.522 rs13247442 ENSG00000273142.1 RP11-458F8.4 -3.8 0.000172 0.0286 -0.3 -0.2 Gout; chr7:66723871 chr7:66902857~66906297:+ LIHC cis rs3738443 0.83 rs58405512 ENSG00000259865.1 RP11-488L18.10 3.8 0.000172 0.0286 0.2 0.2 Alcohol dependence; chr1:247198454 chr1:247187281~247188526:- LIHC cis rs295490 0.667 rs57356584 ENSG00000272656.1 RP11-219D15.3 3.8 0.000172 0.0286 0.54 0.2 PR interval in Tripanosoma cruzi seropositivity; chr3:139319724 chr3:139349024~139349371:- LIHC cis rs11096990 0.855 rs2566168 ENSG00000249685.1 RP11-360F5.3 -3.8 0.000172 0.0286 -0.28 -0.2 Cognitive function; chr4:39150053 chr4:39133913~39135608:+ LIHC cis rs2072510 1 rs2072512 ENSG00000257878.1 RP11-256L6.3 -3.8 0.000172 0.0286 -0.18 -0.2 Metabolite levels (small molecules and protein measures); chr12:96015198 chr12:95996521~96011489:+ LIHC cis rs2072510 1 rs1978331 ENSG00000257878.1 RP11-256L6.3 -3.8 0.000172 0.0286 -0.18 -0.2 Metabolite levels (small molecules and protein measures); chr12:96015423 chr12:95996521~96011489:+ LIHC cis rs1862618 0.671 rs2591956 ENSG00000271828.1 CTD-2310F14.1 -3.8 0.000172 0.0286 -0.27 -0.2 Initial pursuit acceleration; chr5:56948777 chr5:56927874~56929573:+ LIHC cis rs1862618 0.671 rs2591955 ENSG00000271828.1 CTD-2310F14.1 -3.8 0.000172 0.0286 -0.27 -0.2 Initial pursuit acceleration; chr5:56949121 chr5:56927874~56929573:+ LIHC cis rs1862618 0.641 rs2591954 ENSG00000271828.1 CTD-2310F14.1 -3.8 0.000172 0.0286 -0.27 -0.2 Initial pursuit acceleration; chr5:56949217 chr5:56927874~56929573:+ LIHC cis rs1862618 0.671 rs906631 ENSG00000271828.1 CTD-2310F14.1 -3.8 0.000172 0.0286 -0.27 -0.2 Initial pursuit acceleration; chr5:56949976 chr5:56927874~56929573:+ LIHC cis rs4849303 1 rs1017866 ENSG00000224959.1 AC017002.2 3.8 0.000172 0.0286 0.21 0.2 Colorectal cancer (diet interaction); chr2:110973407 chr2:111491943~111494811:- LIHC cis rs853679 1 rs1679732 ENSG00000204709.4 LINC01556 -3.8 0.000172 0.0286 -0.33 -0.2 Depression; chr6:28253486 chr6:28943877~28944537:+ LIHC cis rs17270561 1 rs12211184 ENSG00000272810.1 U91328.22 -3.8 0.000172 0.0286 -0.26 -0.2 Iron status biomarkers; chr6:25823546 chr6:26013241~26013757:+ LIHC cis rs17270561 1 rs79867288 ENSG00000272810.1 U91328.22 -3.8 0.000172 0.0286 -0.26 -0.2 Iron status biomarkers; chr6:25828188 chr6:26013241~26013757:+ LIHC cis rs17270561 1 rs12200962 ENSG00000272810.1 U91328.22 -3.8 0.000172 0.0286 -0.26 -0.2 Iron status biomarkers; chr6:25828758 chr6:26013241~26013757:+ LIHC cis rs794185 0.625 rs2046709 ENSG00000231249.1 ITPR1-AS1 3.8 0.000172 0.0286 0.22 0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4474687 chr3:4490891~4493163:- LIHC cis rs673078 0.66 rs17512609 ENSG00000275759.1 RP11-131L12.3 -3.8 0.000172 0.0286 -0.41 -0.2 Glucose homeostasis traits; chr12:118354072 chr12:118428281~118428870:+ LIHC cis rs9747201 0.926 rs34153075 ENSG00000279692.1 RP11-1055B8.1 -3.8 0.000172 0.0287 -0.35 -0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82177852 chr17:81395609~81397144:- LIHC cis rs9906944 0.707 rs9916472 ENSG00000248278.1 SUMO2P17 -3.8 0.000172 0.0287 -0.34 -0.2 Intelligence (multi-trait analysis);Body fat percentage; chr17:49032636 chr17:48874860~48908983:- LIHC cis rs1923539 0.614 rs1923537 ENSG00000225484.5 NUTM2B-AS1 -3.8 0.000172 0.0287 -0.2 -0.2 Chronic obstructive pulmonary disease-related biomarkers; chr10:79935452 chr10:79663088~79826594:- LIHC cis rs881375 0.967 rs1860823 ENSG00000226752.6 PSMD5-AS1 -3.8 0.000172 0.0287 -0.22 -0.2 Rheumatoid arthritis; chr9:120897026 chr9:120824828~120854385:+ LIHC cis rs881375 0.967 rs1860824 ENSG00000226752.6 PSMD5-AS1 -3.8 0.000172 0.0287 -0.22 -0.2 Rheumatoid arthritis; chr9:120897061 chr9:120824828~120854385:+ LIHC cis rs11613048 0.897 rs2351221 ENSG00000245614.3 DDX11-AS1 3.8 0.000173 0.0287 0.18 0.2 Major depressive disorder; chr12:30182416 chr12:31020763~31073847:- LIHC cis rs1598856 1 rs1598856 ENSG00000230069.3 LRRC37A15P -3.8 0.000173 0.0287 -0.18 -0.2 Primary biliary cholangitis; chr4:102524958 chr4:102727274~102730721:- LIHC cis rs12928939 1 rs12928939 ENSG00000263232.2 ATP5A1P3 -3.8 0.000173 0.0287 -0.31 -0.2 Post bronchodilator FEV1; chr16:71766142 chr16:72005037~72006543:- LIHC cis rs308971 0.711 rs310751 ENSG00000225026.1 AC091492.2 -3.8 0.000173 0.0287 -0.55 -0.2 Fasting blood insulin (BMI interaction); chr3:12232121 chr3:12328003~12328274:+ LIHC cis rs699371 0.507 rs10149787 ENSG00000259005.1 RP3-449M8.6 -3.8 0.000173 0.0287 -0.24 -0.2 Height; chr14:74458749 chr14:74474007~74474864:- LIHC cis rs7474896 1 rs11011339 ENSG00000263064.2 RP11-291L22.7 3.8 0.000173 0.0287 0.28 0.2 Obesity (extreme); chr10:37707418 chr10:38448689~38448949:+ LIHC cis rs13315871 0.654 rs11711261 ENSG00000272182.1 RP11-802O23.3 3.8 0.000173 0.0287 0.38 0.2 Cholesterol, total; chr3:58357969 chr3:58428255~58428815:+ LIHC cis rs193541 0.545 rs112390044 ENSG00000263432.2 RN7SL689P -3.8 0.000173 0.0287 -0.3 -0.2 Glucose homeostasis traits; chr5:122976307 chr5:123022487~123022783:- LIHC cis rs752590 0.774 rs6755077 ENSG00000274877.1 RP11-65I12.1 -3.8 0.000173 0.0287 -0.3 -0.2 Mucinous ovarian carcinoma; chr2:113195931 chr2:113237595~113240825:+ LIHC cis rs752590 0.887 rs7603621 ENSG00000274877.1 RP11-65I12.1 -3.8 0.000173 0.0287 -0.3 -0.2 Mucinous ovarian carcinoma; chr2:113196407 chr2:113237595~113240825:+ LIHC cis rs1115240 0.685 rs1884234 ENSG00000257842.4 NOVA1-AS1 3.8 0.000173 0.0287 0.2 0.2 Educational attainment (years of education); chr14:26612651 chr14:26598412~26806467:+ LIHC cis rs10102392 0.797 rs13276627 ENSG00000253549.4 RP11-317J10.2 3.8 0.000173 0.0287 0.23 0.2 Age-related hearing impairment (SNP x SNP interaction); chr8:85544975 chr8:85441851~85464915:- LIHC cis rs2074409 0.571 rs67499664 ENSG00000276054.1 RP11-378E13.3 3.8 0.000173 0.0287 0.26 0.2 Response to angiotensin II receptor blocker therapy; chr17:37533543 chr17:37386886~37387926:+ LIHC cis rs7560272 0.512 rs13015885 ENSG00000273245.1 RP11-434P11.2 -3.8 0.000173 0.0288 -0.24 -0.2 Schizophrenia; chr2:73693355 chr2:73750256~73750786:- LIHC cis rs1862618 0.671 rs2591968 ENSG00000271828.1 CTD-2310F14.1 3.8 0.000173 0.0288 0.27 0.2 Initial pursuit acceleration; chr5:56937714 chr5:56927874~56929573:+ LIHC cis rs9652601 0.959 rs9746695 ENSG00000274038.1 RP11-66H6.4 3.8 0.000173 0.0288 0.25 0.2 Systemic lupus erythematosus; chr16:11114037 chr16:11056556~11057034:+ LIHC cis rs1223397 0.617 rs957176 ENSG00000215022.6 RP1-257A7.4 -3.8 0.000173 0.0288 -0.21 -0.2 Blood pressure; chr6:13311294 chr6:13264861~13295586:- LIHC cis rs2243480 1 rs160634 ENSG00000230295.1 RP11-458F8.2 3.8 0.000173 0.0288 0.2 0.2 Diabetic kidney disease; chr7:66063677 chr7:66880708~66882981:+ LIHC cis rs193541 0.53 rs6595405 ENSG00000263432.2 RN7SL689P 3.8 0.000173 0.0288 0.31 0.2 Glucose homeostasis traits; chr5:122749050 chr5:123022487~123022783:- LIHC cis rs57502260 0.79 rs7128942 ENSG00000212093.1 AP000807.1 3.8 0.000173 0.0288 0.26 0.2 Total body bone mineral density (age 45-60); chr11:68620516 chr11:68506083~68506166:- LIHC cis rs9425766 0.626 rs6691053 ENSG00000227373.4 RP11-160H22.5 3.8 0.000173 0.0288 0.26 0.2 Life satisfaction; chr1:173899817 chr1:174115300~174160004:- LIHC cis rs4683346 0.731 rs11129983 ENSG00000273328.4 RP11-141M3.6 3.8 0.000173 0.0288 0.22 0.2 Granulocyte percentage of myeloid white cells; chr3:42883191 chr3:42809414~42908105:+ LIHC cis rs548181 0.536 rs503287 ENSG00000254671.2 STT3A-AS1 -3.8 0.000174 0.0288 -0.34 -0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr11:125591893 chr11:125570284~125592568:- LIHC cis rs27434 0.583 rs26653 ENSG00000272109.1 CTD-2260A17.3 -3.8 0.000174 0.0288 -0.24 -0.2 Ankylosing spondylitis; chr5:96803547 chr5:96804353~96806105:+ LIHC cis rs917195 0.906 rs7793837 ENSG00000226874.1 AC005154.8 -3.8 0.000174 0.0288 -0.25 -0.2 Type 2 diabetes; chr7:30687161 chr7:30544053~30544431:+ LIHC cis rs17221829 0.965 rs4553368 ENSG00000280367.1 RP11-121L10.2 3.8 0.000174 0.0288 0.23 0.2 Anxiety in major depressive disorder; chr11:89726574 chr11:90223153~90226538:+ LIHC cis rs6430585 0.583 rs73957037 ENSG00000231890.6 DARS-AS1 -3.8 0.000174 0.0288 -0.29 -0.2 Corneal structure; chr2:135830461 chr2:135985176~136022593:+ LIHC cis rs17376456 0.825 rs6898842 ENSG00000251023.1 RP11-549J18.1 -3.8 0.000174 0.0288 -0.42 -0.2 Diabetic retinopathy; chr5:93877515 chr5:93860669~93863825:- LIHC cis rs5756813 0.668 rs5756805 ENSG00000233360.4 Z83844.1 3.8 0.000174 0.0289 0.24 0.2 Optic cup area;Vertical cup-disc ratio; chr22:37748611 chr22:37641832~37658377:- LIHC cis rs9926296 0.618 rs8058179 ENSG00000275734.1 RP11-368I7.6 -3.8 0.000174 0.0289 -0.26 -0.2 Vitiligo; chr16:89780579 chr16:89684642~89685304:+ LIHC cis rs13217239 0.646 rs62401067 ENSG00000241549.7 GUSBP2 3.8 0.000174 0.0289 0.21 0.2 Schizophrenia; chr6:27050322 chr6:26871484~26956554:- LIHC cis rs4218 0.648 rs10851642 ENSG00000277144.1 RP11-59H7.4 -3.8 0.000174 0.0289 -0.23 -0.2 Social communication problems; chr15:59077909 chr15:59115547~59116089:- LIHC cis rs4218 0.608 rs59282449 ENSG00000277144.1 RP11-59H7.4 -3.8 0.000174 0.0289 -0.23 -0.2 Social communication problems; chr15:59078881 chr15:59115547~59116089:- LIHC cis rs4218 0.648 rs60285686 ENSG00000277144.1 RP11-59H7.4 -3.8 0.000174 0.0289 -0.23 -0.2 Social communication problems; chr15:59079829 chr15:59115547~59116089:- LIHC cis rs4218 0.648 rs60741546 ENSG00000277144.1 RP11-59H7.4 -3.8 0.000174 0.0289 -0.23 -0.2 Social communication problems; chr15:59079831 chr15:59115547~59116089:- LIHC cis rs751728 0.687 rs4711355 ENSG00000204188.6 GGNBP1 3.8 0.000174 0.0289 0.25 0.2 Crohn's disease; chr6:33792129 chr6:33540046~33589026:+ LIHC cis rs7712401 0.715 rs6859163 ENSG00000263432.2 RN7SL689P -3.8 0.000174 0.0289 -0.29 -0.2 Mean platelet volume; chr5:123019225 chr5:123022487~123022783:- LIHC cis rs7712401 0.715 rs385996 ENSG00000263432.2 RN7SL689P -3.8 0.000174 0.0289 -0.29 -0.2 Mean platelet volume; chr5:123019533 chr5:123022487~123022783:- LIHC cis rs7712401 0.715 rs436160 ENSG00000263432.2 RN7SL689P -3.8 0.000174 0.0289 -0.29 -0.2 Mean platelet volume; chr5:123020258 chr5:123022487~123022783:- LIHC cis rs7712401 0.715 rs434789 ENSG00000263432.2 RN7SL689P -3.8 0.000174 0.0289 -0.29 -0.2 Mean platelet volume; chr5:123021615 chr5:123022487~123022783:- LIHC cis rs7712401 0.715 rs1139334 ENSG00000263432.2 RN7SL689P -3.8 0.000174 0.0289 -0.29 -0.2 Mean platelet volume; chr5:123022724 chr5:123022487~123022783:- LIHC cis rs7712401 0.715 rs1062350 ENSG00000263432.2 RN7SL689P -3.8 0.000174 0.0289 -0.29 -0.2 Mean platelet volume; chr5:123022811 chr5:123022487~123022783:- LIHC cis rs7712401 0.678 rs401535 ENSG00000263432.2 RN7SL689P -3.8 0.000174 0.0289 -0.29 -0.2 Mean platelet volume; chr5:123022990 chr5:123022487~123022783:- LIHC cis rs10129255 1 rs61997605 ENSG00000211972.2 IGHV3-66 3.8 0.000174 0.0289 0.16 0.2 Kawasaki disease; chr14:106678368 chr14:106675017~106675544:- LIHC cis rs4561483 0.801 rs33631 ENSG00000261216.1 RP11-166B2.5 -3.8 0.000174 0.0289 -0.22 -0.2 Testicular germ cell tumor; chr16:11901530 chr16:11908208~11908916:+ LIHC cis rs11651753 0.561 rs35336840 ENSG00000264920.1 RP11-6N17.4 -3.8 0.000174 0.0289 -0.2 -0.2 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47888742 chr17:47891255~47895812:- LIHC cis rs11763147 1 rs11763147 ENSG00000273024.4 INTS4P2 3.8 0.000174 0.0289 0.24 0.2 Corneal structure; chr7:65861834 chr7:65647864~65715661:+ LIHC cis rs8005677 1 rs4982709 ENSG00000279656.1 RP11-298I3.6 3.8 0.000174 0.0289 0.23 0.2 Cognitive ability (multi-trait analysis); chr14:22925490 chr14:23023083~23024217:- LIHC cis rs11733284 1 rs11733284 ENSG00000259959.1 RP11-121C2.2 3.8 0.000174 0.0289 0.18 0.2 Gout;Renal underexcretion gout; chr4:48026080 chr4:47840122~47844339:- LIHC cis rs11733284 1 rs13120847 ENSG00000259959.1 RP11-121C2.2 3.8 0.000174 0.0289 0.18 0.2 Gout;Renal underexcretion gout; chr4:48028019 chr4:47840122~47844339:- LIHC cis rs11613048 0.834 rs12582906 ENSG00000245614.3 DDX11-AS1 3.8 0.000174 0.0289 0.18 0.2 Major depressive disorder; chr12:30187069 chr12:31020763~31073847:- LIHC cis rs9303401 0.703 rs9910629 ENSG00000265415.1 CTD-2510F5.4 3.8 0.000174 0.0289 0.14 0.2 Cognitive test performance; chr17:59132940 chr17:59202677~59203829:- LIHC cis rs67311347 1 rs12108041 ENSG00000223797.4 ENTPD3-AS1 3.8 0.000174 0.0289 0.16 0.2 Renal cell carcinoma; chr3:40446044 chr3:40313802~40453329:- LIHC cis rs6442522 0.768 rs3821638 ENSG00000249786.6 EAF1-AS1 3.8 0.000174 0.0289 0.23 0.2 Uric acid levels; chr3:15469537 chr3:15436171~15455940:- LIHC cis rs4073416 0.712 rs6573624 ENSG00000276116.2 FUT8-AS1 3.8 0.000174 0.0289 0.25 0.2 N-glycan levels; chr14:65760167 chr14:65411170~65412690:- LIHC cis rs853679 1 rs11965538 ENSG00000204709.4 LINC01556 3.8 0.000174 0.0289 0.33 0.2 Depression; chr6:28272137 chr6:28943877~28944537:+ LIHC cis rs853679 0.882 rs2743555 ENSG00000204709.4 LINC01556 3.8 0.000174 0.0289 0.33 0.2 Depression; chr6:28273304 chr6:28943877~28944537:+ LIHC cis rs853679 1 rs1419183 ENSG00000204709.4 LINC01556 3.8 0.000174 0.0289 0.33 0.2 Depression; chr6:28275017 chr6:28943877~28944537:+ LIHC cis rs4713118 0.629 rs149899 ENSG00000219891.2 ZSCAN12P1 3.8 0.000174 0.0289 0.29 0.2 Parkinson's disease; chr6:28052201 chr6:28091154~28093664:+ LIHC cis rs4713118 0.629 rs172165 ENSG00000219891.2 ZSCAN12P1 3.8 0.000174 0.0289 0.29 0.2 Parkinson's disease; chr6:28053036 chr6:28091154~28093664:+ LIHC cis rs4713118 0.597 rs172166 ENSG00000219891.2 ZSCAN12P1 3.8 0.000174 0.0289 0.29 0.2 Parkinson's disease; chr6:28053042 chr6:28091154~28093664:+ LIHC cis rs4713118 0.629 rs203889 ENSG00000219891.2 ZSCAN12P1 3.8 0.000174 0.0289 0.29 0.2 Parkinson's disease; chr6:28053997 chr6:28091154~28093664:+ LIHC cis rs9467773 0.869 rs9295689 ENSG00000124549.13 BTN2A3P 3.8 0.000174 0.0289 0.18 0.2 Intelligence (multi-trait analysis); chr6:26455583 chr6:26421391~26432383:+ LIHC cis rs6001482 0.573 rs4990163 ENSG00000234630.1 LL22NC03-2H8.4 3.8 0.000174 0.0289 0.16 0.2 Diastolic blood pressure; chr22:22233778 chr22:22293733~22294794:+ LIHC cis rs7722022 0.961 rs6896636 ENSG00000253428.1 CTB-43E15.2 3.8 0.000174 0.0289 0.21 0.2 Adiponectin levels; chr5:173522438 chr5:173689459~173705849:+ LIHC cis rs950880 0.677 rs56224165 ENSG00000234389.1 AC007278.3 -3.8 0.000174 0.0289 -0.21 -0.2 Serum protein levels (sST2); chr2:102308763 chr2:102438713~102440475:+ LIHC cis rs12712135 0.706 rs6543114 ENSG00000234389.1 AC007278.3 -3.8 0.000174 0.0289 -0.21 -0.2 Blood protein levels; chr2:102309534 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs12470867 ENSG00000234389.1 AC007278.3 -3.8 0.000174 0.0289 -0.21 -0.2 Serum protein levels (sST2); chr2:102309906 chr2:102438713~102440475:+ LIHC cis rs2976388 0.556 rs4736321 ENSG00000253741.1 CTD-2292P10.4 3.8 0.000174 0.0289 0.26 0.2 Urinary tract infection frequency; chr8:142740776 chr8:142702252~142726973:- LIHC cis rs1405130 1 rs13031727 ENSG00000224287.2 MSL3P1 3.8 0.000174 0.0289 0.24 0.2 Coronary artery disease; chr2:234655402 chr2:233865437~233868444:- LIHC cis rs9952991 0.941 rs888270 ENSG00000260302.1 RP11-973H7.1 3.8 0.000174 0.0289 0.31 0.2 Inflammatory skin disease; chr18:12774895 chr18:12774651~12775923:- LIHC cis rs4891159 0.79 rs7241485 ENSG00000265778.2 RP11-17M16.2 -3.8 0.000174 0.029 -0.24 -0.2 Longevity; chr18:76410369 chr18:76491652~76493918:+ LIHC cis rs6832769 0.89 rs1522107 ENSG00000272969.1 RP11-528I4.2 3.8 0.000174 0.029 0.24 0.2 Personality dimensions; chr4:55514606 chr4:55547112~55547889:+ LIHC cis rs2762353 0.808 rs1165151 ENSG00000242387.1 HIST1H2APS2 3.8 0.000175 0.029 0.23 0.2 Blood metabolite levels; chr6:25821388 chr6:25882026~25882395:- LIHC cis rs2762353 0.808 rs1747522 ENSG00000242387.1 HIST1H2APS2 3.8 0.000175 0.029 0.23 0.2 Blood metabolite levels; chr6:25821579 chr6:25882026~25882395:- LIHC cis rs2762353 0.779 rs3799352 ENSG00000242387.1 HIST1H2APS2 3.8 0.000175 0.029 0.23 0.2 Blood metabolite levels; chr6:25822392 chr6:25882026~25882395:- LIHC cis rs3738443 0.868 rs2892054 ENSG00000259865.1 RP11-488L18.10 3.8 0.000175 0.029 0.18 0.2 Alcohol dependence; chr1:247203803 chr1:247187281~247188526:- LIHC cis rs8060598 0.716 rs11647841 ENSG00000275155.1 CTD-2595P9.4 -3.8 0.000175 0.029 -0.24 -0.2 Leprosy; chr16:50709420 chr16:49847018~49847632:- LIHC cis rs8060598 0.745 rs34133110 ENSG00000275155.1 CTD-2595P9.4 -3.8 0.000175 0.029 -0.24 -0.2 Leprosy; chr16:50710008 chr16:49847018~49847632:- LIHC cis rs948562 0.69 rs11229371 ENSG00000280010.1 AP001350.4 3.79 0.000175 0.029 0.34 0.2 Lymphoma; chr11:58344227 chr11:58627435~58628528:+ LIHC cis rs17736589 1 rs6728 ENSG00000267737.1 AC061992.2 -3.79 0.000175 0.029 -0.29 -0.2 Ulcerative colitis; chr17:78674151 chr17:78315729~78347798:+ LIHC cis rs7849270 1 rs7849270 ENSG00000268707.1 RP11-247A12.7 -3.79 0.000175 0.029 -0.21 -0.2 Blood metabolite ratios; chr9:129112362 chr9:129170434~129170940:+ LIHC cis rs1075265 0.563 rs2542588 ENSG00000265452.1 MIR3682 3.79 0.000175 0.029 0.25 0.2 Chronotype;Morning vs. evening chronotype; chr2:53791787 chr2:53849122~53849205:- LIHC cis rs10129255 1 rs11627342 ENSG00000211970.3 IGHV4-61 -3.79 0.000175 0.029 -0.16 -0.2 Kawasaki disease; chr14:106675823 chr14:106639119~106639657:- LIHC cis rs1577917 0.876 rs1582127 ENSG00000234155.1 RP11-30P6.6 3.79 0.000175 0.029 0.26 0.2 Response to antipsychotic treatment; chr6:85987486 chr6:85387219~85390186:- LIHC cis rs2271001 1 rs2271001 ENSG00000256464.1 YWHABP2 3.79 0.000175 0.029 0.21 0.2 Gut microbiome composition (winter); chr11:19146303 chr11:18490243~18490955:- LIHC cis rs673078 0.66 rs7970481 ENSG00000275759.1 RP11-131L12.3 -3.79 0.000175 0.029 -0.39 -0.2 Glucose homeostasis traits; chr12:118242112 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs7973455 ENSG00000275759.1 RP11-131L12.3 -3.79 0.000175 0.029 -0.39 -0.2 Glucose homeostasis traits; chr12:118247490 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs58113338 ENSG00000275759.1 RP11-131L12.3 -3.79 0.000175 0.029 -0.39 -0.2 Glucose homeostasis traits; chr12:118251335 chr12:118428281~118428870:+ LIHC cis rs673078 0.615 rs16948204 ENSG00000275759.1 RP11-131L12.3 -3.79 0.000175 0.029 -0.39 -0.2 Glucose homeostasis traits; chr12:118258252 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs7303417 ENSG00000275759.1 RP11-131L12.3 -3.79 0.000175 0.029 -0.39 -0.2 Glucose homeostasis traits; chr12:118258859 chr12:118428281~118428870:+ LIHC cis rs1440410 0.83 rs1470130 ENSG00000250326.1 RP11-284M14.1 -3.79 0.000175 0.029 -0.24 -0.2 Ischemic stroke; chr4:143257749 chr4:142933195~143184861:- LIHC cis rs5758659 0.692 rs5751251 ENSG00000227370.1 RP4-669P10.19 -3.79 0.000175 0.029 -0.22 -0.2 Cognitive function; chr22:42244600 chr22:42132543~42132998:+ LIHC cis rs6456156 0.586 rs7746628 ENSG00000227598.1 RP1-167A14.2 -3.79 0.000175 0.029 -0.21 -0.2 Primary biliary cholangitis; chr6:167069747 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs2345753 ENSG00000227598.1 RP1-167A14.2 -3.79 0.000175 0.029 -0.21 -0.2 Primary biliary cholangitis; chr6:167070856 chr6:166969626~166999065:- LIHC cis rs6456156 0.603 rs2345754 ENSG00000227598.1 RP1-167A14.2 -3.79 0.000175 0.029 -0.21 -0.2 Primary biliary cholangitis; chr6:167070873 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs7761977 ENSG00000227598.1 RP1-167A14.2 -3.79 0.000175 0.029 -0.21 -0.2 Primary biliary cholangitis; chr6:167072190 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs7742305 ENSG00000227598.1 RP1-167A14.2 -3.79 0.000175 0.029 -0.21 -0.2 Primary biliary cholangitis; chr6:167072235 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs7762156 ENSG00000227598.1 RP1-167A14.2 -3.79 0.000175 0.029 -0.21 -0.2 Primary biliary cholangitis; chr6:167072343 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs2001115 ENSG00000227598.1 RP1-167A14.2 -3.79 0.000175 0.029 -0.21 -0.2 Primary biliary cholangitis; chr6:167072730 chr6:166969626~166999065:- LIHC cis rs4595586 0.87 rs7962363 ENSG00000257718.1 RP11-396F22.1 -3.79 0.000175 0.029 -0.24 -0.2 Morning vs. evening chronotype; chr12:38905901 chr12:38906451~38909592:+ LIHC cis rs4792901 0.959 rs3826413 ENSG00000279602.1 CTD-3014M21.1 3.79 0.000175 0.029 0.24 0.2 Dupuytren's disease; chr17:43556277 chr17:43360041~43361361:- LIHC cis rs794185 0.537 rs304081 ENSG00000231249.1 ITPR1-AS1 -3.79 0.000175 0.029 -0.22 -0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4488191 chr3:4490891~4493163:- LIHC cis rs6832769 1 rs9684708 ENSG00000272969.1 RP11-528I4.2 -3.79 0.000175 0.029 -0.24 -0.2 Personality dimensions; chr4:55564214 chr4:55547112~55547889:+ LIHC cis rs899997 1 rs11633170 ENSG00000261143.1 ADAMTS7P3 -3.79 0.000175 0.029 -0.26 -0.2 Coronary artery disease or large artery stroke; chr15:78712300 chr15:77976042~77993057:+ LIHC cis rs304029 0.687 rs304091 ENSG00000231249.1 ITPR1-AS1 -3.79 0.000175 0.0291 -0.22 -0.2 Diabetic kidney disease; chr3:4477611 chr3:4490891~4493163:- LIHC cis rs9951150 0.557 rs34407950 ENSG00000267013.4 CTD-2171N6.1 3.79 0.000175 0.0291 0.27 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55138815 chr18:55105904~55124306:- LIHC cis rs4787491 0.679 rs12933575 ENSG00000250616.2 RP11-455F5.3 3.79 0.000175 0.0291 0.2 0.2 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30011243 chr16:30096430~30104116:+ LIHC cis rs4787491 0.729 rs7191849 ENSG00000250616.2 RP11-455F5.3 3.79 0.000175 0.0291 0.2 0.2 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30011836 chr16:30096430~30104116:+ LIHC cis rs4218 0.597 rs12438208 ENSG00000277144.1 RP11-59H7.4 -3.79 0.000175 0.0291 -0.22 -0.2 Social communication problems; chr15:59057715 chr15:59115547~59116089:- LIHC cis rs6600233 1 rs6600233 ENSG00000268836.1 LA16c-OS12.2 -3.79 0.000175 0.0291 -0.24 -0.2 High light scatter reticulocyte percentage of red cells; chr16:93505 chr16:185748~186294:- LIHC cis rs7712401 0.562 rs30046 ENSG00000263432.2 RN7SL689P 3.79 0.000176 0.0291 0.29 0.2 Mean platelet volume; chr5:122935538 chr5:123022487~123022783:- LIHC cis rs7712401 0.623 rs30044 ENSG00000263432.2 RN7SL689P 3.79 0.000176 0.0291 0.29 0.2 Mean platelet volume; chr5:122936385 chr5:123022487~123022783:- LIHC cis rs2933343 1 rs789213 ENSG00000261159.1 RP11-723O4.9 -3.79 0.000176 0.0291 -0.27 -0.2 IgG glycosylation; chr3:128897516 chr3:128859716~128860526:- LIHC cis rs673078 0.607 rs2784 ENSG00000275759.1 RP11-131L12.3 -3.79 0.000176 0.0291 -0.43 -0.2 Glucose homeostasis traits; chr12:118311745 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs7302387 ENSG00000275759.1 RP11-131L12.3 -3.79 0.000176 0.0291 -0.43 -0.2 Glucose homeostasis traits; chr12:118316546 chr12:118428281~118428870:+ LIHC cis rs17818399 0.815 rs17819022 ENSG00000239332.4 LINC01119 -3.79 0.000176 0.0291 -0.29 -0.2 Height; chr2:46623432 chr2:46816697~46859007:+ LIHC cis rs9450351 0.744 rs6937582 ENSG00000203875.9 SNHG5 -3.79 0.000176 0.0291 -0.44 -0.2 Interferon gamma-induced protein 10 levels; chr6:85855880 chr6:85660950~85678736:- LIHC cis rs9450351 0.744 rs9362250 ENSG00000203875.9 SNHG5 -3.79 0.000176 0.0291 -0.44 -0.2 Interferon gamma-induced protein 10 levels; chr6:85867970 chr6:85660950~85678736:- LIHC cis rs10851478 0.692 rs11632201 ENSG00000276593.1 RP11-295H24.5 3.79 0.000176 0.0292 0.22 0.2 Oral cavity cancer; chr15:49598897 chr15:49353485~49354034:+ LIHC cis rs703842 0.616 rs10877023 ENSG00000270039.1 RP11-571M6.17 -3.79 0.000176 0.0292 -0.29 -0.2 Multiple sclerosis; chr12:57830416 chr12:57803838~57804415:+ LIHC cis rs9527 0.615 rs10883800 ENSG00000236937.2 PTGES3P4 3.79 0.000176 0.0292 0.25 0.2 Arsenic metabolism; chr10:102911455 chr10:102845595~102845950:+ LIHC cis rs9527 0.615 rs7073295 ENSG00000236937.2 PTGES3P4 3.79 0.000176 0.0292 0.25 0.2 Arsenic metabolism; chr10:102912476 chr10:102845595~102845950:+ LIHC cis rs9527 0.569 rs10883801 ENSG00000236937.2 PTGES3P4 3.79 0.000176 0.0292 0.25 0.2 Arsenic metabolism; chr10:102918130 chr10:102845595~102845950:+ LIHC cis rs875971 0.545 rs1796217 ENSG00000224316.1 RP11-479O9.2 -3.79 0.000176 0.0292 -0.19 -0.2 Aortic root size; chr7:66620931 chr7:65773620~65802067:+ LIHC cis rs7119038 0.818 rs6589686 ENSG00000255422.1 AP002954.4 3.79 0.000176 0.0292 0.25 0.2 Sjögren's syndrome; chr11:118741856 chr11:118704607~118750263:+ LIHC cis rs13113518 0.812 rs4864996 ENSG00000223305.1 RN7SKP30 3.79 0.000176 0.0292 0.24 0.2 Height; chr4:55452921 chr4:55540502~55540835:- LIHC cis rs7192392 0.545 rs8052368 ENSG00000260816.2 RP11-319G9.3 3.79 0.000176 0.0292 0.19 0.2 Acute graft versus host disease in bone marrow transplantation (recipient effect); chr16:78899187 chr16:78895361~78899644:+ LIHC cis rs875971 1 rs778726 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66363744 chr7:66493706~66495474:+ LIHC cis rs875971 0.767 rs1695815 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66366357 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs778685 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66371189 chr7:66493706~66495474:+ LIHC cis rs875971 0.929 rs778682 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66372947 chr7:66493706~66495474:+ LIHC cis rs875971 0.964 rs11765965 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66377234 chr7:66493706~66495474:+ LIHC cis rs875971 0.964 rs1643388 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66379575 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs778722 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66379841 chr7:66493706~66495474:+ LIHC cis rs875971 0.964 rs778721 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66380410 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs778706 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66395437 chr7:66493706~66495474:+ LIHC cis rs875971 0.895 rs778700 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66401463 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs778699 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66403303 chr7:66493706~66495474:+ LIHC cis rs875971 0.929 rs778692 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66407462 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs4718343 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66409301 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs1968225 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66409786 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs6460295 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66417741 chr7:66493706~66495474:+ LIHC cis rs875971 0.964 rs6978721 ENSG00000237310.1 GS1-124K5.4 3.79 0.000176 0.0292 0.18 0.2 Aortic root size; chr7:66418217 chr7:66493706~66495474:+ LIHC cis rs8077577 0.562 rs8081042 ENSG00000260647.1 RP1-178F10.1 3.79 0.000176 0.0292 0.25 0.2 Obesity-related traits; chr17:18295753 chr17:18268080~18268828:+ LIHC cis rs7508 0.511 rs208026 ENSG00000253671.1 RP11-806O11.1 -3.79 0.000176 0.0292 -0.25 -0.2 Atrial fibrillation; chr8:18020646 chr8:17808941~17820868:+ LIHC cis rs8064024 0.62 rs8048709 ENSG00000267077.1 RP11-127I20.5 3.79 0.000176 0.0292 0.21 0.2 Cancer; chr16:4863760 chr16:4795265~4796532:- LIHC cis rs6061231 0.63 rs62196294 ENSG00000226332.2 RP11-157P1.4 3.79 0.000176 0.0292 0.21 0.2 Colorectal cancer; chr20:62398376 chr20:62305432~62306325:- LIHC cis rs694739 0.726 rs17857342 ENSG00000236935.1 AP003774.1 3.79 0.000176 0.0292 0.22 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64371433 chr11:64325050~64329504:- LIHC cis rs5743030 1 rs1030136 ENSG00000253559.1 OSGEPL1-AS1 -3.79 0.000176 0.0292 -0.35 -0.2 Subcutaneous adipose tissue; chr2:189870934 chr2:189762704~189765556:+ LIHC cis rs17772222 0.917 rs17188046 ENSG00000258789.1 RP11-507K2.3 -3.79 0.000176 0.0292 -0.24 -0.2 Coronary artery calcification; chr14:88624417 chr14:88551597~88552493:+ LIHC cis rs1115240 1 rs12433692 ENSG00000257842.4 NOVA1-AS1 -3.79 0.000176 0.0292 -0.19 -0.2 Educational attainment (years of education); chr14:26605164 chr14:26598412~26806467:+ LIHC cis rs11089937 0.512 rs13054756 ENSG00000211639.2 IGLV4-60 3.79 0.000177 0.0292 0.17 0.2 Periodontitis (PAL4Q3); chr22:22130948 chr22:22162199~22162681:+ LIHC cis rs11089937 0.597 rs4821768 ENSG00000211639.2 IGLV4-60 3.79 0.000177 0.0292 0.17 0.2 Periodontitis (PAL4Q3); chr22:22131047 chr22:22162199~22162681:+ LIHC cis rs2098713 0.599 rs12152831 ENSG00000250155.1 CTD-2353F22.1 3.79 0.000177 0.0292 0.19 0.2 Telomere length; chr5:37555215 chr5:36666214~36725195:- LIHC cis rs7560272 0.538 rs17434634 ENSG00000273245.1 RP11-434P11.2 -3.79 0.000177 0.0292 -0.25 -0.2 Schizophrenia; chr2:73695799 chr2:73750256~73750786:- LIHC cis rs643506 0.774 rs11214033 ENSG00000230911.1 PPIHP1 3.79 0.000177 0.0292 0.27 0.2 Breast cancer; chr11:111898978 chr11:112029858~112030367:- LIHC cis rs6547741 0.844 rs55826602 ENSG00000234072.1 AC074117.10 -3.79 0.000177 0.0292 -0.19 -0.2 Oral cavity cancer; chr2:27640585 chr2:27356246~27367622:+ LIHC cis rs7560272 0.538 rs4852972 ENSG00000273245.1 RP11-434P11.2 -3.79 0.000177 0.0292 -0.24 -0.2 Schizophrenia; chr2:73689545 chr2:73750256~73750786:- LIHC cis rs7560272 0.538 rs2421575 ENSG00000273245.1 RP11-434P11.2 -3.79 0.000177 0.0292 -0.24 -0.2 Schizophrenia; chr2:73692395 chr2:73750256~73750786:- LIHC cis rs7980687 0.657 rs10744151 ENSG00000256092.2 RP13-942N8.1 3.79 0.000177 0.0292 0.25 0.2 Head circumference (infant);Educational attainment;Height; chr12:123239188 chr12:123363868~123366113:+ LIHC cis rs8007846 0.523 rs12894902 ENSG00000276116.2 FUT8-AS1 3.79 0.000177 0.0293 0.26 0.2 Multiple sclerosis--Brain Glutamate Levels; chr14:65695081 chr14:65411170~65412690:- LIHC cis rs7200543 1 rs16966947 ENSG00000258354.1 MIR3180-1 -3.79 0.000177 0.0293 -0.23 -0.2 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15047188 chr16:14909887~14911345:- LIHC cis rs9303401 0.703 rs9909925 ENSG00000265415.1 CTD-2510F5.4 -3.79 0.000177 0.0293 -0.14 -0.2 Cognitive test performance; chr17:59132708 chr17:59202677~59203829:- LIHC cis rs73183643 0.689 rs2690944 ENSG00000239486.1 RP11-163E9.1 -3.79 0.000177 0.0293 -0.27 -0.2 Basal cell carcinoma; chr7:101759186 chr7:102380465~102382737:- LIHC cis rs73242632 1 rs17828496 ENSG00000269949.1 RP11-738E22.3 3.79 0.000177 0.0293 0.54 0.2 Congenital heart disease (maternal effect); chr4:56988847 chr4:56960927~56961373:- LIHC cis rs4792901 0.959 rs55955027 ENSG00000279602.1 CTD-3014M21.1 -3.79 0.000177 0.0293 -0.23 -0.2 Dupuytren's disease; chr17:43543788 chr17:43360041~43361361:- LIHC cis rs6430553 0.964 rs10496731 ENSG00000224043.6 CCNT2-AS1 -3.79 0.000177 0.0293 -0.23 -0.2 Blood metabolite levels; chr2:134840058 chr2:134735464~134918710:- LIHC cis rs617219 0.889 rs12659618 ENSG00000251675.1 CTC-458I2.2 -3.79 0.000177 0.0293 -0.22 -0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79169837 chr5:80128361~80143883:+ LIHC cis rs617219 0.889 rs10069036 ENSG00000251675.1 CTC-458I2.2 -3.79 0.000177 0.0293 -0.22 -0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79173400 chr5:80128361~80143883:+ LIHC cis rs617219 0.889 rs10044259 ENSG00000251675.1 CTC-458I2.2 -3.79 0.000177 0.0293 -0.22 -0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79176031 chr5:80128361~80143883:+ LIHC cis rs8177876 0.658 rs2911158 ENSG00000261061.1 RP11-303E16.2 3.79 0.000177 0.0293 0.27 0.2 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81057652 chr16:81030770~81031485:+ LIHC cis rs748404 0.697 rs513970 ENSG00000205771.5 CATSPER2P1 -3.79 0.000177 0.0293 -0.24 -0.2 Lung cancer; chr15:43287368 chr15:43726918~43747094:- LIHC cis rs1062753 0.771 rs932376 ENSG00000205702.9 CYP2D7 3.79 0.000177 0.0293 0.22 0.2 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42218356 chr22:42140203~42144577:- LIHC cis rs4792901 0.879 rs12600482 ENSG00000279602.1 CTD-3014M21.1 -3.79 0.000177 0.0293 -0.23 -0.2 Dupuytren's disease; chr17:43553229 chr17:43360041~43361361:- LIHC cis rs11098499 0.687 rs71610270 ENSG00000245958.5 RP11-33B1.1 -3.79 0.000177 0.0293 -0.2 -0.2 Corneal astigmatism; chr4:119366281 chr4:119454791~119552025:+ LIHC cis rs950169 0.58 rs11634322 ENSG00000259728.4 LINC00933 3.79 0.000177 0.0293 0.29 0.2 Schizophrenia; chr15:84628978 chr15:84570649~84580175:+ LIHC cis rs11613048 0.897 rs1485413 ENSG00000245614.3 DDX11-AS1 3.79 0.000177 0.0293 0.18 0.2 Major depressive disorder; chr12:30178767 chr12:31020763~31073847:- LIHC cis rs8177876 0.584 rs2602404 ENSG00000261061.1 RP11-303E16.2 3.79 0.000177 0.0293 0.27 0.2 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81056042 chr16:81030770~81031485:+ LIHC cis rs11089937 0.54 rs5756992 ENSG00000211639.2 IGLV4-60 3.79 0.000177 0.0293 0.18 0.2 Periodontitis (PAL4Q3); chr22:22132636 chr22:22162199~22162681:+ LIHC cis rs11089937 0.597 rs9622919 ENSG00000211639.2 IGLV4-60 3.79 0.000177 0.0293 0.18 0.2 Periodontitis (PAL4Q3); chr22:22132863 chr22:22162199~22162681:+ LIHC cis rs11089937 0.597 rs9619793 ENSG00000211639.2 IGLV4-60 3.79 0.000177 0.0293 0.18 0.2 Periodontitis (PAL4Q3); chr22:22132952 chr22:22162199~22162681:+ LIHC cis rs6580649 0.574 rs7964359 ENSG00000240399.1 RP1-228P16.1 -3.79 0.000177 0.0293 -0.19 -0.2 Lung cancer; chr12:48016783 chr12:48054813~48055591:- LIHC cis rs11098499 0.739 rs4833612 ENSG00000260091.1 RP11-33B1.4 3.79 0.000177 0.0293 0.13 0.2 Corneal astigmatism; chr4:119226441 chr4:119409333~119410233:+ LIHC cis rs11098499 0.739 rs10013032 ENSG00000260091.1 RP11-33B1.4 3.79 0.000177 0.0293 0.13 0.2 Corneal astigmatism; chr4:119228264 chr4:119409333~119410233:+ LIHC cis rs11098499 0.739 rs951570 ENSG00000260091.1 RP11-33B1.4 3.79 0.000177 0.0293 0.13 0.2 Corneal astigmatism; chr4:119229312 chr4:119409333~119410233:+ LIHC cis rs13113518 0.812 rs12505880 ENSG00000249700.7 SRD5A3-AS1 3.79 0.000177 0.0293 0.23 0.2 Height; chr4:55440988 chr4:55363971~55395847:- LIHC cis rs11123170 0.542 rs11123169 ENSG00000189223.12 PAX8-AS1 3.79 0.000177 0.0293 0.28 0.2 Renal function-related traits (BUN); chr2:113209498 chr2:113211522~113276581:+ LIHC cis rs4948102 0.727 rs4948097 ENSG00000226278.1 PSPHP1 -3.79 0.000177 0.0293 -0.24 -0.2 Plasma homocysteine levels (post-methionine load test); chr7:55988878 chr7:55764797~55773288:+ LIHC cis rs4948102 0.691 rs10435504 ENSG00000226278.1 PSPHP1 -3.79 0.000177 0.0293 -0.24 -0.2 Plasma homocysteine levels (post-methionine load test); chr7:55991898 chr7:55764797~55773288:+ LIHC cis rs4948102 0.653 rs6593294 ENSG00000226278.1 PSPHP1 -3.79 0.000177 0.0293 -0.24 -0.2 Plasma homocysteine levels (post-methionine load test); chr7:55995508 chr7:55764797~55773288:+ LIHC cis rs1799949 0.55 rs2343818 ENSG00000267681.1 CTD-3199J23.6 -3.79 0.000177 0.0293 -0.2 -0.2 Menopause (age at onset); chr17:43332406 chr17:43144956~43145255:+ LIHC cis rs1799949 0.526 rs4352088 ENSG00000267681.1 CTD-3199J23.6 -3.79 0.000177 0.0293 -0.2 -0.2 Menopause (age at onset); chr17:43337311 chr17:43144956~43145255:+ LIHC cis rs757081 0.648 rs214102 ENSG00000272034.1 SNORD14A -3.79 0.000177 0.0293 -0.21 -0.2 Systolic blood pressure; chr11:17266751 chr11:17074654~17074744:- LIHC cis rs3749237 0.537 rs4459909 ENSG00000270441.1 RP11-694I15.7 -3.79 0.000177 0.0293 -0.28 -0.2 Resting heart rate; chr3:49431784 chr3:49140086~49160851:- LIHC cis rs3749237 0.595 rs11130196 ENSG00000270441.1 RP11-694I15.7 -3.79 0.000177 0.0293 -0.28 -0.2 Resting heart rate; chr3:49452716 chr3:49140086~49160851:- LIHC cis rs7617773 0.78 rs13066044 ENSG00000228638.1 FCF1P2 -3.79 0.000178 0.0293 -0.23 -0.2 Coronary artery disease; chr3:48335786 chr3:48290793~48291375:- LIHC cis rs7617773 0.778 rs11715776 ENSG00000228638.1 FCF1P2 -3.79 0.000178 0.0293 -0.23 -0.2 Coronary artery disease; chr3:48336121 chr3:48290793~48291375:- LIHC cis rs7617773 0.778 rs11707997 ENSG00000228638.1 FCF1P2 -3.79 0.000178 0.0293 -0.23 -0.2 Coronary artery disease; chr3:48336385 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs11720026 ENSG00000228638.1 FCF1P2 -3.79 0.000178 0.0293 -0.23 -0.2 Coronary artery disease; chr3:48336431 chr3:48290793~48291375:- LIHC cis rs7617773 0.743 rs11715876 ENSG00000228638.1 FCF1P2 -3.79 0.000178 0.0293 -0.23 -0.2 Coronary artery disease; chr3:48336432 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs11716848 ENSG00000228638.1 FCF1P2 -3.79 0.000178 0.0293 -0.23 -0.2 Coronary artery disease; chr3:48337010 chr3:48290793~48291375:- LIHC cis rs8087799 0.83 rs72875061 ENSG00000273232.1 RP11-370A5.2 3.79 0.000178 0.0293 0.25 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22607843 chr18:22882825~22883357:- LIHC cis rs12554020 0.504 rs115096608 ENSG00000227603.1 RP11-165J3.6 3.79 0.000178 0.0293 0.31 0.2 Schizophrenia; chr9:93662119 chr9:93435332~93437121:- LIHC cis rs1223397 0.651 rs2496145 ENSG00000215022.6 RP1-257A7.4 3.79 0.000178 0.0293 0.21 0.2 Blood pressure; chr6:13312061 chr6:13264861~13295586:- LIHC cis rs7665090 0.87 rs228616 ENSG00000246560.2 RP11-10L12.4 -3.79 0.000178 0.0294 -0.24 -0.2 Primary biliary cholangitis; chr4:102658534 chr4:102828055~102844075:+ LIHC cis rs30380 0.69 rs2042381 ENSG00000272109.1 CTD-2260A17.3 -3.79 0.000178 0.0294 -0.25 -0.2 Cerebrospinal fluid biomarker levels; chr5:96852963 chr5:96804353~96806105:+ LIHC cis rs7607369 0.714 rs1344643 ENSG00000272555.1 RP11-459I19.1 -3.79 0.000178 0.0294 -0.23 -0.2 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218720252 chr2:218818690~218819144:+ LIHC cis rs2283792 0.715 rs56227348 ENSG00000224086.5 LL22NC03-86G7.1 -3.79 0.000178 0.0294 -0.21 -0.2 Multiple sclerosis; chr22:21791443 chr22:21938293~21977632:+ LIHC cis rs1598856 1 rs3774932 ENSG00000230069.3 LRRC37A15P -3.79 0.000178 0.0294 -0.18 -0.2 Primary biliary cholangitis; chr4:102503036 chr4:102727274~102730721:- LIHC cis rs9640161 0.742 rs2108854 ENSG00000261305.1 RP4-584D14.7 -3.79 0.000178 0.0294 -0.23 -0.2 Blood protein levels;Circulating chemerin levels; chr7:150320319 chr7:150341771~150342607:+ LIHC cis rs803903 0.57 rs13292335 ENSG00000230894.1 RP11-67K19.3 3.79 0.000178 0.0294 0.27 0.2 Breast cancer; chr9:116458926 chr9:116568449~116586328:+ LIHC cis rs35828350 1 rs35828350 ENSG00000259728.4 LINC00933 3.79 0.000178 0.0294 0.3 0.2 Autism spectrum disorder or schizophrenia; chr15:84812610 chr15:84570649~84580175:+ LIHC cis rs67601088 0.838 rs57587985 ENSG00000235669.1 AC004593.3 3.79 0.000178 0.0294 0.36 0.2 Pediatric bone mineral density (spine); chr7:29861367 chr7:29199540~29208970:- LIHC cis rs4948102 0.691 rs4470984 ENSG00000226278.1 PSPHP1 -3.79 0.000178 0.0294 -0.24 -0.2 Plasma homocysteine levels (post-methionine load test); chr7:55965865 chr7:55764797~55773288:+ LIHC cis rs2243480 1 rs2243480 ENSG00000232546.1 RP11-458F8.1 -3.79 0.000178 0.0294 -0.23 -0.2 Diabetic kidney disease; chr7:66134209 chr7:66848496~66858136:+ LIHC cis rs591584 0.874 rs10831243 ENSG00000255893.1 RP11-685N10.1 -3.79 0.000178 0.0294 -0.2 -0.2 Macrophage Migration Inhibitory Factor levels; chr11:94582124 chr11:94472908~94473570:- LIHC cis rs7726414 1 rs115808154 ENSG00000279469.1 RP11-215P8.2 3.79 0.000178 0.0294 0.53 0.2 Systemic lupus erythematosus; chr5:134128584 chr5:134394360~134395008:- LIHC cis rs7783857 1 rs7783857 ENSG00000273489.1 RP11-180C16.1 3.79 0.000178 0.0294 0.24 0.2 Coronary artery disease; chr7:130754299 chr7:131493964~131497694:- LIHC cis rs559928 0.606 rs55942618 ENSG00000236935.1 AP003774.1 3.79 0.000178 0.0294 0.29 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64168533 chr11:64325050~64329504:- LIHC cis rs367615 0.661 rs9326775 ENSG00000249476.1 CTD-2587M2.1 3.79 0.000178 0.0294 0.24 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109501224 chr5:109237120~109326369:- LIHC cis rs367615 0.66 rs10061221 ENSG00000249476.1 CTD-2587M2.1 3.79 0.000178 0.0294 0.24 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109503337 chr5:109237120~109326369:- LIHC cis rs755249 0.565 rs9729677 ENSG00000182109.6 RP11-69E11.4 -3.79 0.000178 0.0294 -0.25 -0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39587137 chr1:39522280~39546187:- LIHC cis rs6547741 0.935 rs6547738 ENSG00000234072.1 AC074117.10 3.79 0.000178 0.0294 0.19 0.2 Oral cavity cancer; chr2:27629770 chr2:27356246~27367622:+ LIHC cis rs4604234 0.518 rs73463537 ENSG00000272129.1 RP11-250B2.6 -3.79 0.000178 0.0294 -0.31 -0.2 Cancer; chr6:80275314 chr6:80355424~80356859:+ LIHC cis rs6732160 0.593 rs2288630 ENSG00000272702.1 RP11-44N22.3 3.79 0.000178 0.0294 0.23 0.2 Intelligence (multi-trait analysis); chr2:73230424 chr2:73113018~73115907:+ LIHC cis rs948562 0.69 rs12361133 ENSG00000280010.1 AP001350.4 3.79 0.000178 0.0294 0.35 0.2 Lymphoma; chr11:58357532 chr11:58627435~58628528:+ LIHC cis rs6860806 1 rs6860806 ENSG00000233006.5 AC034220.3 -3.79 0.000178 0.0294 -0.21 -0.2 Breast cancer; chr5:132304843 chr5:132311285~132369916:- LIHC cis rs17373728 0.71 rs12544686 ENSG00000249395.2 CASC9 3.79 0.000178 0.0294 0.21 0.2 Diabetic kidney disease; chr8:75305839 chr8:75223404~75324741:- LIHC cis rs2638953 0.672 rs10843203 ENSG00000247934.4 RP11-967K21.1 -3.79 0.000178 0.0294 -0.27 -0.2 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28563555 chr12:28163298~28190738:- LIHC cis rs3738443 0.868 rs35229190 ENSG00000259865.1 RP11-488L18.10 3.79 0.000178 0.0294 0.18 0.2 Alcohol dependence; chr1:247202339 chr1:247187281~247188526:- LIHC cis rs12908161 1 rs17600551 ENSG00000259728.4 LINC00933 3.79 0.000178 0.0295 0.29 0.2 Schizophrenia; chr15:84776027 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs62019469 ENSG00000259728.4 LINC00933 3.79 0.000178 0.0295 0.29 0.2 Schizophrenia; chr15:84777989 chr15:84570649~84580175:+ LIHC cis rs12908161 0.96 rs34452033 ENSG00000225151.9 GOLGA2P7 -3.79 0.000178 0.0295 -0.25 -0.2 Schizophrenia; chr15:84678762 chr15:84199311~84230136:- LIHC cis rs10981012 0.504 rs16916397 ENSG00000224644.1 RP11-16L21.7 -3.79 0.000178 0.0295 -0.23 -0.2 Coronary artery disease; chr9:111806336 chr9:111574192~111575427:+ LIHC cis rs783540 0.5 rs1313494 ENSG00000278603.1 RP13-608F4.5 -3.79 0.000179 0.0295 -0.25 -0.2 Schizophrenia; chr15:82605530 chr15:82472203~82472426:+ LIHC cis rs1023500 0.956 rs1894713 ENSG00000227370.1 RP4-669P10.19 3.79 0.000179 0.0295 0.27 0.2 Schizophrenia; chr22:41939617 chr22:42132543~42132998:+ LIHC cis rs11096990 0.892 rs6531696 ENSG00000249207.1 RP11-360F5.1 3.79 0.000179 0.0295 0.23 0.2 Cognitive function; chr4:39190134 chr4:39112677~39126818:- LIHC cis rs12908161 1 rs56864281 ENSG00000225151.9 GOLGA2P7 -3.79 0.000179 0.0295 -0.26 -0.2 Schizophrenia; chr15:84814418 chr15:84199311~84230136:- LIHC cis rs6723108 0.627 rs6430554 ENSG00000224043.6 CCNT2-AS1 -3.79 0.000179 0.0295 -0.28 -0.2 Type 2 diabetes; chr2:134880891 chr2:134735464~134918710:- LIHC cis rs875971 0.508 rs10258739 ENSG00000273024.4 INTS4P2 3.79 0.000179 0.0295 0.21 0.2 Aortic root size; chr7:66597948 chr7:65647864~65715661:+ LIHC cis rs11159086 0.793 rs10136668 ENSG00000270000.1 RP3-449M8.9 3.79 0.000179 0.0295 0.29 0.2 Advanced glycation end-product levels; chr14:74492183 chr14:74471930~74472360:- LIHC cis rs11159086 0.793 rs10139029 ENSG00000270000.1 RP3-449M8.9 3.79 0.000179 0.0295 0.29 0.2 Advanced glycation end-product levels; chr14:74492284 chr14:74471930~74472360:- LIHC cis rs11159086 0.793 rs10139122 ENSG00000270000.1 RP3-449M8.9 3.79 0.000179 0.0295 0.29 0.2 Advanced glycation end-product levels; chr14:74492353 chr14:74471930~74472360:- LIHC cis rs733175 0.855 rs10022499 ENSG00000250413.1 RP11-448G15.1 -3.79 0.000179 0.0295 -0.29 -0.2 Psychosis and Alzheimer's disease; chr4:10004913 chr4:10006482~10009725:+ LIHC cis rs733175 0.855 rs10016075 ENSG00000250413.1 RP11-448G15.1 -3.79 0.000179 0.0295 -0.29 -0.2 Psychosis and Alzheimer's disease; chr4:10005039 chr4:10006482~10009725:+ LIHC cis rs559928 0.606 rs76653616 ENSG00000236935.1 AP003774.1 3.79 0.000179 0.0295 0.29 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64168667 chr11:64325050~64329504:- LIHC cis rs673078 0.66 rs11068917 ENSG00000275409.1 RP11-131L12.4 -3.79 0.000179 0.0295 -0.25 -0.2 Glucose homeostasis traits; chr12:118353315 chr12:118430147~118430699:+ LIHC cis rs904251 0.802 rs2646933 ENSG00000204110.6 RP1-153P14.8 -3.79 0.000179 0.0295 -0.25 -0.2 Cognitive performance; chr6:37434294 chr6:37507348~37535616:+ LIHC cis rs481331 0.741 rs209377 ENSG00000185904.10 LINC00839 -3.79 0.000179 0.0295 -0.38 -0.2 Systemic juvenile idiopathic arthritis; chr10:42606258 chr10:42475543~42495336:+ LIHC cis rs2932538 0.922 rs12406906 ENSG00000225075.1 RP11-426L16.3 -3.79 0.000179 0.0295 -0.25 -0.2 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112575278 chr1:112693688~112696621:- LIHC cis rs6828577 0.819 rs1064034 ENSG00000269893.5 SNHG8 3.79 0.000179 0.0295 0.21 0.2 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118710837 chr4:118278709~118279823:+ LIHC cis rs7503807 1 rs4890056 ENSG00000262772.1 RP11-353N14.2 -3.79 0.000179 0.0295 -0.21 -0.2 Obesity; chr17:80617411 chr17:79823452~79827704:+ LIHC cis rs7829975 0.659 rs4382480 ENSG00000173295.6 FAM86B3P 3.79 0.000179 0.0296 0.25 0.2 Mood instability; chr8:8863963 chr8:8228595~8244865:+ LIHC cis rs17711722 0.701 rs781143 ENSG00000237310.1 GS1-124K5.4 3.79 0.000179 0.0296 0.2 0.2 Calcium levels; chr7:65974892 chr7:66493706~66495474:+ LIHC cis rs6832769 0.925 rs2412663 ENSG00000272969.1 RP11-528I4.2 -3.79 0.000179 0.0296 -0.23 -0.2 Personality dimensions; chr4:55589649 chr4:55547112~55547889:+ LIHC cis rs17508449 0.732 rs74533448 ENSG00000232450.1 RP4-730K3.3 -3.79 0.000179 0.0296 -0.28 -0.2 Leprosy; chr1:113750266 chr1:113698884~113699631:- LIHC cis rs1023500 0.551 rs2859438 ENSG00000205702.9 CYP2D7 3.79 0.000179 0.0296 0.23 0.2 Schizophrenia; chr22:42070976 chr22:42140203~42144577:- LIHC cis rs2554380 0.527 rs7164782 ENSG00000225151.9 GOLGA2P7 -3.79 0.000179 0.0296 -0.31 -0.2 Height; chr15:83833447 chr15:84199311~84230136:- LIHC cis rs9843304 0.528 rs1317213 ENSG00000244503.1 RP11-278L15.6 -3.79 0.000179 0.0296 -0.25 -0.2 Gallstone disease; chr3:149473363 chr3:149494660~149495995:+ LIHC cis rs2302464 1 rs10011868 ENSG00000214846.4 RP11-115L11.1 3.79 0.000179 0.0296 0.36 0.2 Cerebrospinal fluid biomarker levels; chr4:15659205 chr4:15730962~15731627:- LIHC cis rs9847710 0.838 rs2581795 ENSG00000242797.3 GLYCTK-AS1 3.79 0.000179 0.0296 0.2 0.2 Ulcerative colitis; chr3:53004770 chr3:52288580~52299067:- LIHC cis rs6142102 0.961 rs2056990 ENSG00000275784.1 RP5-1125A11.6 -3.79 0.000179 0.0296 -0.23 -0.2 Skin pigmentation; chr20:34035658 chr20:33989480~33991818:- LIHC cis rs7617773 0.78 rs13084616 ENSG00000228638.1 FCF1P2 3.79 0.000179 0.0296 0.23 0.2 Coronary artery disease; chr3:48298209 chr3:48290793~48291375:- LIHC cis rs7760535 1 rs7760535 ENSG00000255389.1 C6orf3 3.79 0.00018 0.0296 0.21 0.2 Metabolic traits; chr6:111425880 chr6:111599875~111602295:+ LIHC cis rs2301573 1 rs10934886 ENSG00000251474.5 RPL32P3 3.79 0.00018 0.0296 0.24 0.2 Hip circumference; chr3:129583786 chr3:129382922~129399655:- LIHC cis rs12145833 0.596 rs61833906 ENSG00000253326.2 RP11-261C10.7 -3.79 0.00018 0.0296 -0.44 -0.2 Obesity (early onset extreme); chr1:243256404 chr1:243054861~243056394:- LIHC cis rs12145833 0.665 rs78871868 ENSG00000253326.2 RP11-261C10.7 -3.79 0.00018 0.0296 -0.44 -0.2 Obesity (early onset extreme); chr1:243259020 chr1:243054861~243056394:- LIHC cis rs6545883 0.965 rs778752 ENSG00000271889.1 RP11-493E12.1 3.79 0.00018 0.0296 0.24 0.2 Tuberculosis; chr2:61549767 chr2:61151433~61162105:- LIHC cis rs7044246 0.924 rs9411424 ENSG00000224992.1 RP11-295G24.5 -3.79 0.00018 0.0296 -0.26 -0.2 Cognitive ability (multi-trait analysis);Cognitive ability; chr9:131988995 chr9:132769453~132770212:- LIHC cis rs9646944 0.836 rs10178214 ENSG00000234389.1 AC007278.3 3.79 0.00018 0.0296 0.24 0.2 Blood protein levels; chr2:102242461 chr2:102438713~102440475:+ LIHC cis rs6545883 0.831 rs9309336 ENSG00000271889.1 RP11-493E12.1 3.79 0.00018 0.0296 0.24 0.2 Tuberculosis; chr2:61536030 chr2:61151433~61162105:- LIHC cis rs539096 0.5 rs2367804 ENSG00000237950.1 RP11-7O11.3 3.79 0.00018 0.0296 0.21 0.2 Intelligence (multi-trait analysis); chr1:43848594 chr1:43944370~43946551:- LIHC cis rs6452524 0.618 rs1993948 ENSG00000271862.1 RP11-343L5.2 3.79 0.00018 0.0296 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83076461 chr5:83049376~83050964:- LIHC cis rs6452524 0.618 rs2075685 ENSG00000271862.1 RP11-343L5.2 3.79 0.00018 0.0296 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83076846 chr5:83049376~83050964:- LIHC cis rs9976767 0.637 rs9984108 ENSG00000225218.1 AP001628.6 -3.79 0.00018 0.0296 -0.19 -0.2 Type 1 diabetes; chr21:42405519 chr21:42831040~42836477:- LIHC cis rs17023223 0.537 rs10802075 ENSG00000231365.4 RP11-418J17.1 -3.79 0.00018 0.0296 -0.24 -0.2 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119084604 chr1:119140396~119275973:+ LIHC cis rs12543592 0.934 rs4431602 ENSG00000255325.2 RP11-96B2.1 3.79 0.00018 0.0297 0.22 0.2 Autism spectrum disorder; chr8:122504069 chr8:122485515~122489815:- LIHC cis rs4356975 0.563 rs12642938 ENSG00000250919.1 RP11-813N20.3 -3.79 0.00018 0.0297 -0.2 -0.2 Obesity-related traits; chr4:69110499 chr4:69027831~69044578:+ LIHC cis rs2904804 0.688 rs6601881 ENSG00000224251.5 RP11-499O7.7 3.79 0.00018 0.0297 0.25 0.2 Economic and political preferences (immigration/crime); chr10:4977409 chr10:4995488~4997380:+ LIHC cis rs7182621 0.639 rs35049216 ENSG00000182397.13 DNM1P46 3.79 0.00018 0.0297 0.27 0.2 Colonoscopy-negative controls vs population controls; chr15:99872562 chr15:99790156~99806927:- LIHC cis rs7182621 0.639 rs12906068 ENSG00000182397.13 DNM1P46 3.79 0.00018 0.0297 0.27 0.2 Colonoscopy-negative controls vs population controls; chr15:99873422 chr15:99790156~99806927:- LIHC cis rs755249 0.565 rs7539261 ENSG00000182109.6 RP11-69E11.4 -3.79 0.00018 0.0297 -0.25 -0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39584831 chr1:39522280~39546187:- LIHC cis rs745580 0.933 rs6964512 ENSG00000199085.2 MIR148A 3.79 0.00018 0.0297 0.2 0.2 Obesity-related traits; chr7:25986529 chr7:25949903~25950013:- LIHC cis rs6832769 1 rs1522111 ENSG00000272969.1 RP11-528I4.2 3.79 0.00018 0.0297 0.24 0.2 Personality dimensions; chr4:55463396 chr4:55547112~55547889:+ LIHC cis rs10256972 0.967 rs4723338 ENSG00000199023.2 MIR339 -3.79 0.00018 0.0297 -0.22 -0.2 Endometriosis;Longevity; chr7:996605 chr7:1022935~1023045:- LIHC cis rs7129556 0.702 rs650171 ENSG00000254459.1 RP11-91P24.7 3.79 0.00018 0.0297 0.33 0.2 Weight loss (gastric bypass surgery); chr11:77787440 chr11:77829654~77872262:- LIHC cis rs251925 0.734 rs2445803 ENSG00000280068.1 RP11-91H12.1 3.79 0.00018 0.0297 0.25 0.2 Obesity-related traits; chr5:175346986 chr5:175903874~175904371:- LIHC cis rs17711722 0.701 rs781145 ENSG00000237310.1 GS1-124K5.4 3.79 0.00018 0.0297 0.2 0.2 Calcium levels; chr7:65975383 chr7:66493706~66495474:+ LIHC cis rs2562754 0.527 rs1879894 ENSG00000278600.1 RP11-81A1.6 -3.79 0.00018 0.0297 -0.18 -0.2 Eosinophil percentage of granulocytes; chr15:79976477 chr15:79920195~79922455:- LIHC cis rs875971 0.638 rs6460305 ENSG00000224316.1 RP11-479O9.2 -3.79 0.00018 0.0297 -0.19 -0.2 Aortic root size; chr7:66595421 chr7:65773620~65802067:+ LIHC cis rs875971 0.66 rs10272357 ENSG00000224316.1 RP11-479O9.2 -3.79 0.00018 0.0297 -0.19 -0.2 Aortic root size; chr7:66598087 chr7:65773620~65802067:+ LIHC cis rs2599510 0.729 rs1135484 ENSG00000276334.1 AL133243.1 3.79 0.00018 0.0297 0.23 0.2 Interleukin-18 levels; chr2:32523993 chr2:32521927~32523547:+ LIHC cis rs2070488 0.965 rs2300668 ENSG00000229589.1 ACVR2B-AS1 -3.79 0.000181 0.0297 -0.23 -0.2 Electrocardiographic conduction measures; chr3:38499050 chr3:38451027~38454820:- LIHC cis rs9876781 1 rs7634377 ENSG00000229759.1 MRPS18AP1 3.79 0.000181 0.0298 0.21 0.2 Longevity; chr3:48379768 chr3:48256350~48256938:- LIHC cis rs1318937 0.764 rs11128738 ENSG00000224660.1 SH3BP5-AS1 3.79 0.000181 0.0298 0.18 0.2 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15200989 chr3:15254184~15264493:+ LIHC cis rs73183643 0.647 rs2690941 ENSG00000239486.1 RP11-163E9.1 -3.79 0.000181 0.0298 -0.27 -0.2 Basal cell carcinoma; chr7:101761278 chr7:102380465~102382737:- LIHC cis rs2976388 0.609 rs2244152 ENSG00000253196.1 RP11-706C16.7 3.79 0.000181 0.0298 0.19 0.2 Urinary tract infection frequency; chr8:142703467 chr8:142763116~142766427:+ LIHC cis rs193541 0.632 rs2910135 ENSG00000263432.2 RN7SL689P 3.79 0.000181 0.0298 0.32 0.2 Glucose homeostasis traits; chr5:122894095 chr5:123022487~123022783:- LIHC cis rs1023500 1 rs1023498 ENSG00000227370.1 RP4-669P10.19 3.79 0.000181 0.0298 0.27 0.2 Schizophrenia; chr22:41944565 chr22:42132543~42132998:+ LIHC cis rs151234 0.8 rs231974 ENSG00000259982.1 CDC37P1 -3.79 0.000181 0.0298 -0.47 -0.2 Platelet distribution width; chr16:28529001 chr16:28700294~28701540:- LIHC cis rs10829156 0.66 rs4338439 ENSG00000225527.1 RP11-383B4.4 -3.79 0.000181 0.0298 -0.34 -0.2 Sudden cardiac arrest; chr10:18594220 chr10:18531849~18533336:- LIHC cis rs6449502 0.92 rs2306350 ENSG00000272308.1 RP11-231G3.1 -3.79 0.000181 0.0298 -0.29 -0.2 Mean platelet volume; chr5:60890791 chr5:60866457~60866935:- LIHC cis rs6449502 0.92 rs2306351 ENSG00000272308.1 RP11-231G3.1 -3.79 0.000181 0.0298 -0.29 -0.2 Mean platelet volume; chr5:60891148 chr5:60866457~60866935:- LIHC cis rs3811273 1 rs17255612 ENSG00000275552.1 CH17-302M23.1 -3.79 0.000181 0.0298 -0.31 -0.2 Periodontal disease-related phenotypes; chr14:22255053 chr14:22595808~22598946:- LIHC cis rs4148883 0.898 rs4699726 ENSG00000214559.3 RP11-323J4.1 -3.79 0.000181 0.0298 -0.24 -0.2 Alcohol dependence; chr4:99178356 chr4:98251688~98261630:- LIHC cis rs9907295 0.636 rs4251724 ENSG00000267554.1 RP11-686D22.10 3.79 0.000181 0.0298 0.19 0.2 Fibroblast growth factor basic levels; chr17:35816641 chr17:35470069~35470628:- LIHC cis rs1115240 0.898 rs3794483 ENSG00000257842.4 NOVA1-AS1 3.79 0.000181 0.0298 0.19 0.2 Educational attainment (years of education); chr14:26524965 chr14:26598412~26806467:+ LIHC cis rs2383378 0.714 rs12897884 ENSG00000258474.1 RP11-187E13.1 3.79 0.000181 0.0298 0.25 0.2 Anorexia nervosa; chr14:32805240 chr14:31944853~31950382:+ LIHC cis rs9906944 0.545 rs1994969 ENSG00000251461.3 RP11-501C14.6 3.79 0.000181 0.0299 0.25 0.2 Intelligence (multi-trait analysis);Body fat percentage; chr17:49003069 chr17:49004731~49013725:- LIHC cis rs2439831 0.702 rs16977724 ENSG00000166763.7 STRCP1 3.79 0.000181 0.0299 0.31 0.2 Lung cancer in ever smokers; chr15:43859101 chr15:43699488~43718184:- LIHC cis rs6545883 0.826 rs1186697 ENSG00000271889.1 RP11-493E12.1 3.79 0.000181 0.0299 0.24 0.2 Tuberculosis; chr2:61434282 chr2:61151433~61162105:- LIHC cis rs11096990 0.656 rs6531709 ENSG00000249207.1 RP11-360F5.1 3.78 0.000182 0.0299 0.2 0.2 Cognitive function; chr4:39300629 chr4:39112677~39126818:- LIHC cis rs9675120 0.889 rs11868519 ENSG00000262006.1 RP11-700H6.4 -3.78 0.000182 0.0299 -0.22 -0.2 Cerebrospinal fluid biomarker levels; chr17:50842740 chr17:50909637~50910232:- LIHC cis rs643506 0.715 rs11214031 ENSG00000230911.1 PPIHP1 -3.78 0.000182 0.0299 -0.27 -0.2 Breast cancer; chr11:111895315 chr11:112029858~112030367:- LIHC cis rs12817211 0.502 rs7961065 ENSG00000272368.2 RP4-605O3.4 -3.78 0.000182 0.0299 -0.22 -0.2 Colorectal or endometrial cancer; chr12:50119904 chr12:50112197~50165618:+ LIHC cis rs4218 0.587 rs1446237 ENSG00000277144.1 RP11-59H7.4 -3.78 0.000182 0.0299 -0.22 -0.2 Social communication problems; chr15:59052603 chr15:59115547~59116089:- LIHC cis rs3015497 1 rs4075253 ENSG00000269906.1 RP11-248J18.2 3.78 0.000182 0.0299 0.25 0.2 Mean platelet volume; chr14:50641019 chr14:50662511~50663178:- LIHC cis rs1318937 0.764 rs60896928 ENSG00000224660.1 SH3BP5-AS1 3.78 0.000182 0.0299 0.18 0.2 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15201343 chr3:15254184~15264493:+ LIHC cis rs4578769 0.569 rs12605341 ENSG00000266850.1 RP11-370A5.1 -3.78 0.000182 0.0299 -0.21 -0.2 Eosinophil percentage of white cells; chr18:22803011 chr18:22723491~22907721:- LIHC cis rs2283792 0.765 rs9607241 ENSG00000224086.5 LL22NC03-86G7.1 -3.78 0.000182 0.0299 -0.21 -0.2 Multiple sclerosis; chr22:21750584 chr22:21938293~21977632:+ LIHC cis rs74181299 0.684 rs6741255 ENSG00000225889.6 AC074289.1 3.78 0.000182 0.0299 0.22 0.2 Pulse pressure; chr2:65079771 chr2:64143239~64252859:+ LIHC cis rs919433 0.963 rs12469546 ENSG00000231621.1 AC013264.2 3.78 0.000182 0.0299 0.18 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197314102 chr2:197197991~197199273:+ LIHC cis rs3845817 1 rs11126042 ENSG00000237979.1 AC007389.1 -3.78 0.000182 0.0299 -0.23 -0.2 Bipolar disorder; chr2:65536511 chr2:65500993~65502138:- LIHC cis rs875971 0.545 rs6460298 ENSG00000224316.1 RP11-479O9.2 3.78 0.000182 0.0299 0.19 0.2 Aortic root size; chr7:66442783 chr7:65773620~65802067:+ LIHC cis rs875971 0.545 rs35459055 ENSG00000224316.1 RP11-479O9.2 3.78 0.000182 0.0299 0.19 0.2 Aortic root size; chr7:66479399 chr7:65773620~65802067:+ LIHC cis rs875971 0.545 rs75577046 ENSG00000224316.1 RP11-479O9.2 3.78 0.000182 0.0299 0.19 0.2 Aortic root size; chr7:66493729 chr7:65773620~65802067:+ LIHC cis rs875971 0.545 rs3735147 ENSG00000224316.1 RP11-479O9.2 3.78 0.000182 0.0299 0.19 0.2 Aortic root size; chr7:66505541 chr7:65773620~65802067:+ LIHC cis rs4578769 0.797 rs1010800 ENSG00000265943.1 RP11-739L10.1 3.78 0.000182 0.03 0.26 0.2 Eosinophil percentage of white cells; chr18:23027857 chr18:22699481~22933764:- LIHC cis rs9457247 0.565 rs12178491 ENSG00000227598.1 RP1-167A14.2 -3.78 0.000182 0.03 -0.21 -0.2 Crohn's disease; chr6:167098986 chr6:166969626~166999065:- LIHC cis rs1795240 0.875 rs1795244 ENSG00000231424.2 RP1-45C12.1 3.78 0.000182 0.03 0.22 0.2 Lentiform nucleus volume; chr1:171149882 chr1:171247580~171251794:- LIHC cis rs950169 0.84 rs62019457 ENSG00000189136.7 UBE2Q2P1 3.78 0.000182 0.03 0.19 0.2 Schizophrenia; chr15:84558911 chr15:84526781~84571216:- LIHC cis rs2762353 0.902 rs3799344 ENSG00000242387.1 HIST1H2APS2 -3.78 0.000182 0.03 -0.22 -0.2 Blood metabolite levels; chr6:25786765 chr6:25882026~25882395:- LIHC cis rs7809950 0.773 rs2237668 ENSG00000238832.1 snoU109 -3.78 0.000182 0.03 -0.26 -0.2 Coronary artery disease; chr7:107409764 chr7:107603363~107603507:+ LIHC cis rs11651753 0.561 rs17616603 ENSG00000264920.1 RP11-6N17.4 -3.78 0.000182 0.03 -0.2 -0.2 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47882254 chr17:47891255~47895812:- LIHC cis rs1862618 0.671 rs2591964 ENSG00000271828.1 CTD-2310F14.1 -3.78 0.000182 0.03 -0.27 -0.2 Initial pursuit acceleration; chr5:56941073 chr5:56927874~56929573:+ LIHC cis rs1131351 0.644 rs4350703 ENSG00000234378.1 AC098828.2 3.78 0.000182 0.03 0.24 0.2 Seasonality; chr2:20200508 chr2:20063856~20106829:- LIHC cis rs6142102 0.961 rs4911411 ENSG00000275784.1 RP5-1125A11.6 -3.78 0.000182 0.03 -0.22 -0.2 Skin pigmentation; chr20:34128036 chr20:33989480~33991818:- LIHC cis rs4356975 0.563 rs6600896 ENSG00000250919.1 RP11-813N20.3 -3.78 0.000182 0.03 -0.2 -0.2 Obesity-related traits; chr4:69121000 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs6600897 ENSG00000250919.1 RP11-813N20.3 -3.78 0.000182 0.03 -0.2 -0.2 Obesity-related traits; chr4:69121531 chr4:69027831~69044578:+ LIHC cis rs9582259 0.581 rs9584921 ENSG00000203441.2 LINC00449 -3.78 0.000182 0.03 -0.4 -0.2 Immune reponse to smallpox (secreted IL-1beta); chr13:98731518 chr13:99499727~99501052:- LIHC cis rs3813567 0.759 rs12148319 ENSG00000261762.1 RP11-650L12.2 -3.78 0.000182 0.03 -0.27 -0.2 Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio; chr15:78663850 chr15:78589123~78591276:- LIHC cis rs783540 0.681 rs1259178 ENSG00000278603.1 RP13-608F4.5 -3.78 0.000183 0.03 -0.25 -0.2 Schizophrenia; chr15:82603127 chr15:82472203~82472426:+ LIHC cis rs6545883 0.895 rs796597 ENSG00000271889.1 RP11-493E12.1 3.78 0.000183 0.03 0.24 0.2 Tuberculosis; chr2:61453925 chr2:61151433~61162105:- LIHC cis rs67311347 1 rs7648952 ENSG00000223797.4 ENTPD3-AS1 -3.78 0.000183 0.03 -0.16 -0.2 Renal cell carcinoma; chr3:40415547 chr3:40313802~40453329:- LIHC cis rs11874381 0.54 rs1943982 ENSG00000267322.2 SNHG22 3.78 0.000183 0.03 0.24 0.2 C-reactive protein levels or HDL-cholesterol levels (pleiotropy); chr18:49692778 chr18:49814023~49851059:+ LIHC cis rs694739 1 rs646153 ENSG00000236935.1 AP003774.1 3.78 0.000183 0.03 0.22 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64322116 chr11:64325050~64329504:- LIHC cis rs11123170 0.542 rs11123169 ENSG00000274877.1 RP11-65I12.1 3.78 0.000183 0.03 0.26 0.2 Renal function-related traits (BUN); chr2:113209498 chr2:113237595~113240825:+ LIHC cis rs4948102 0.731 rs7800001 ENSG00000226278.1 PSPHP1 -3.78 0.000183 0.0301 -0.23 -0.2 Plasma homocysteine levels (post-methionine load test); chr7:56004317 chr7:55764797~55773288:+ LIHC cis rs12908161 1 rs12899981 ENSG00000259728.4 LINC00933 3.78 0.000183 0.0301 0.29 0.2 Schizophrenia; chr15:84759142 chr15:84570649~84580175:+ LIHC cis rs6569038 0.502 rs2051057 ENSG00000253194.1 RP11-351A11.1 3.78 0.000183 0.0301 0.27 0.2 Epstein-Barr virus copy number in lymphoblastoid cell lines; chr6:118978278 chr6:118934785~119031541:+ LIHC cis rs10883723 0.81 rs7092622 ENSG00000236937.2 PTGES3P4 -3.78 0.000183 0.0301 -0.27 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102490162 chr10:102845595~102845950:+ LIHC cis rs10883723 0.737 rs7074444 ENSG00000236937.2 PTGES3P4 -3.78 0.000183 0.0301 -0.27 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102490165 chr10:102845595~102845950:+ LIHC cis rs11651753 0.561 rs11654010 ENSG00000264920.1 RP11-6N17.4 3.78 0.000183 0.0301 0.2 0.2 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47883499 chr17:47891255~47895812:- LIHC cis rs10883723 0.773 rs7917402 ENSG00000236937.2 PTGES3P4 -3.78 0.000183 0.0301 -0.27 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102486933 chr10:102845595~102845950:+ LIHC cis rs8040855 0.658 rs4842864 ENSG00000259295.5 CSPG4P12 3.78 0.000183 0.0301 0.3 0.2 Bulimia nervosa; chr15:85101315 chr15:85191438~85213905:+ LIHC cis rs6700559 1 rs12076877 ENSG00000260088.1 RP11-92G12.3 -3.78 0.000183 0.0301 -0.26 -0.2 Coronary artery disease; chr1:200674277 chr1:200669507~200694250:+ LIHC cis rs1003719 0.715 rs2835657 ENSG00000272948.2 AP001412.1 -3.78 0.000183 0.0301 -0.22 -0.2 Eye color traits; chr21:37192763 chr21:37267784~37268497:+ LIHC cis rs10129255 0.5 rs6576231 ENSG00000211972.2 IGHV3-66 3.78 0.000183 0.0301 0.15 0.2 Kawasaki disease; chr14:106783693 chr14:106675017~106675544:- LIHC cis rs6700559 0.703 rs10919993 ENSG00000260088.1 RP11-92G12.3 3.78 0.000183 0.0301 0.28 0.2 Coronary artery disease; chr1:200658184 chr1:200669507~200694250:+ LIHC cis rs11613048 0.897 rs6487883 ENSG00000245614.3 DDX11-AS1 3.78 0.000183 0.0301 0.18 0.2 Major depressive disorder; chr12:30168656 chr12:31020763~31073847:- LIHC cis rs7760535 0.794 rs12529158 ENSG00000271789.1 RP5-1112D6.7 3.78 0.000183 0.0301 0.2 0.2 Metabolic traits; chr6:111501244 chr6:111297126~111298510:+ LIHC cis rs6048205 1 rs4815127 ENSG00000259974.2 LINC00261 -3.78 0.000183 0.0301 -0.31 -0.2 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22562396 chr20:22547671~22578642:- LIHC cis rs62025270 0.631 rs55968154 ENSG00000259295.5 CSPG4P12 -3.78 0.000183 0.0301 -0.36 -0.2 Idiopathic pulmonary fibrosis; chr15:85725399 chr15:85191438~85213905:+ LIHC cis rs62025270 0.688 rs55851385 ENSG00000259295.5 CSPG4P12 -3.78 0.000183 0.0301 -0.36 -0.2 Idiopathic pulmonary fibrosis; chr15:85725400 chr15:85191438~85213905:+ LIHC cis rs10461617 0.541 rs832575 ENSG00000271828.1 CTD-2310F14.1 3.78 0.000184 0.0302 0.33 0.2 Type 2 diabetes; chr5:56865960 chr5:56927874~56929573:+ LIHC cis rs1494950 1 rs1494950 ENSG00000214846.4 RP11-115L11.1 -3.78 0.000184 0.0302 -0.42 -0.2 Political ideology; chr4:14965545 chr4:15730962~15731627:- LIHC cis rs12908161 1 rs11637142 ENSG00000259728.4 LINC00933 3.78 0.000184 0.0302 0.29 0.2 Schizophrenia; chr15:84752696 chr15:84570649~84580175:+ LIHC cis rs801193 0.773 rs801207 ENSG00000273024.4 INTS4P2 3.78 0.000184 0.0302 0.22 0.2 Aortic root size; chr7:66555603 chr7:65647864~65715661:+ LIHC cis rs875971 0.543 rs801191 ENSG00000273024.4 INTS4P2 3.78 0.000184 0.0302 0.22 0.2 Aortic root size; chr7:66567968 chr7:65647864~65715661:+ LIHC cis rs7657257 1 rs7657257 ENSG00000214846.4 RP11-115L11.1 3.78 0.000184 0.0302 0.37 0.2 Blood protein levels; chr4:15645318 chr4:15730962~15731627:- LIHC cis rs4964805 0.865 rs35371470 ENSG00000257681.1 RP11-341G23.4 3.78 0.000184 0.0302 0.21 0.2 Attention deficit hyperactivity disorder; chr12:103809942 chr12:103746315~103768858:- LIHC cis rs919433 0.963 rs7582736 ENSG00000231621.1 AC013264.2 3.78 0.000184 0.0302 0.18 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197305618 chr2:197197991~197199273:+ LIHC cis rs919433 0.963 rs12618612 ENSG00000231621.1 AC013264.2 3.78 0.000184 0.0302 0.18 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197306334 chr2:197197991~197199273:+ LIHC cis rs919433 0.963 rs13033821 ENSG00000231621.1 AC013264.2 3.78 0.000184 0.0302 0.18 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197308812 chr2:197197991~197199273:+ LIHC cis rs67311347 0.544 rs7644643 ENSG00000223797.4 ENTPD3-AS1 -3.78 0.000184 0.0302 -0.17 -0.2 Renal cell carcinoma; chr3:40308718 chr3:40313802~40453329:- LIHC cis rs2933343 0.951 rs789220 ENSG00000261159.1 RP11-723O4.9 -3.78 0.000184 0.0302 -0.27 -0.2 IgG glycosylation; chr3:128873292 chr3:128859716~128860526:- LIHC cis rs4474465 0.833 rs6592792 ENSG00000246174.6 KCTD21-AS1 3.78 0.000184 0.0302 0.24 0.2 Alzheimer's disease (survival time); chr11:78560568 chr11:78139771~78175323:+ LIHC cis rs6545883 0.501 rs935860 ENSG00000212978.6 AC016747.3 -3.78 0.000184 0.0302 -0.22 -0.2 Tuberculosis; chr2:61179426 chr2:61141592~61144969:- LIHC cis rs9303401 0.646 rs9892425 ENSG00000265415.1 CTD-2510F5.4 3.78 0.000184 0.0302 0.13 0.2 Cognitive test performance; chr17:59164577 chr17:59202677~59203829:- LIHC cis rs875971 0.54 rs4717275 ENSG00000237310.1 GS1-124K5.4 -3.78 0.000184 0.0302 -0.2 -0.2 Aortic root size; chr7:65800193 chr7:66493706~66495474:+ LIHC cis rs17376456 0.825 rs10061377 ENSG00000251023.1 RP11-549J18.1 -3.78 0.000184 0.0302 -0.43 -0.2 Diabetic retinopathy; chr5:93838807 chr5:93860669~93863825:- LIHC cis rs244293 0.965 rs244334 ENSG00000275710.1 RP11-257O5.4 -3.78 0.000184 0.0302 -0.21 -0.2 Menarche (age at onset); chr17:55126694 chr17:54964474~54964679:+ LIHC cis rs6723108 0.603 rs3814355 ENSG00000224043.6 CCNT2-AS1 -3.78 0.000184 0.0303 -0.28 -0.2 Type 2 diabetes; chr2:134953946 chr2:134735464~134918710:- LIHC cis rs131777 0.577 rs131748 ENSG00000205559.3 CHKB-AS1 3.78 0.000184 0.0303 0.23 0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586408 chr22:50583026~50583877:+ LIHC cis rs7529073 0.683 rs340882 ENSG00000274895.1 RP11-478J18.2 3.78 0.000184 0.0303 0.21 0.2 Schizophrenia; chr1:213972388 chr1:213983793~213986419:- LIHC cis rs4792901 0.759 rs9915640 ENSG00000267747.1 RP11-392O1.4 -3.78 0.000184 0.0303 -0.24 -0.2 Dupuytren's disease; chr17:43526514 chr17:43544785~43610338:+ LIHC cis rs703842 1 rs10431505 ENSG00000270039.1 RP11-571M6.17 -3.78 0.000185 0.0303 -0.27 -0.2 Multiple sclerosis; chr12:57784806 chr12:57803838~57804415:+ LIHC cis rs703842 1 rs11172344 ENSG00000270039.1 RP11-571M6.17 -3.78 0.000185 0.0303 -0.27 -0.2 Multiple sclerosis; chr12:57799665 chr12:57803838~57804415:+ LIHC cis rs703842 1 rs10783847 ENSG00000270039.1 RP11-571M6.17 -3.78 0.000185 0.0303 -0.27 -0.2 Multiple sclerosis; chr12:57802664 chr12:57803838~57804415:+ LIHC cis rs703842 1 rs10783848 ENSG00000270039.1 RP11-571M6.17 -3.78 0.000185 0.0303 -0.27 -0.2 Multiple sclerosis; chr12:57802745 chr12:57803838~57804415:+ LIHC cis rs3015469 0.51 rs8009295 ENSG00000269906.1 RP11-248J18.2 3.78 0.000185 0.0303 0.26 0.2 Plasma amyloid beta peptide concentrations (ABx-40); chr14:50531065 chr14:50662511~50663178:- LIHC cis rs931127 0.747 rs11820062 ENSG00000265874.1 MIR4489 -3.78 0.000185 0.0303 -0.23 -0.2 Systemic lupus erythematosus; chr11:65662465 chr11:65649192~65649253:+ LIHC cis rs465969 1 rs9387010 ENSG00000255389.1 C6orf3 3.78 0.000185 0.0303 0.4 0.2 Psoriasis; chr6:111384741 chr6:111599875~111602295:+ LIHC cis rs337161 0.719 rs10863562 ENSG00000238078.1 LINC01352 3.78 0.000185 0.0303 0.23 0.2 Response to antipsychotic therapy (extrapyramidal side effects); chr1:220755813 chr1:220829255~220832429:+ LIHC cis rs2243480 0.522 rs73150635 ENSG00000232546.1 RP11-458F8.1 -3.78 0.000185 0.0303 -0.25 -0.2 Diabetic kidney disease; chr7:66507503 chr7:66848496~66858136:+ LIHC cis rs6547741 0.935 rs56001553 ENSG00000234072.1 AC074117.10 -3.78 0.000185 0.0303 -0.19 -0.2 Oral cavity cancer; chr2:27637059 chr2:27356246~27367622:+ LIHC cis rs600231 0.623 rs3015966 ENSG00000245532.5 NEAT1 3.78 0.000185 0.0304 0.2 0.2 Bone mineral density; chr11:65450118 chr11:65422774~65445540:+ LIHC cis rs12209785 0.806 rs7756094 ENSG00000231769.2 RP1-8B1.4 3.78 0.000185 0.0304 0.3 0.2 Survival in pancreatic cancer; chr6:45522975 chr6:46097093~46129706:- LIHC cis rs12209785 0.774 rs7760160 ENSG00000231769.2 RP1-8B1.4 3.78 0.000185 0.0304 0.3 0.2 Survival in pancreatic cancer; chr6:45523302 chr6:46097093~46129706:- LIHC cis rs12908161 0.92 rs35738019 ENSG00000259728.4 LINC00933 3.78 0.000185 0.0304 0.28 0.2 Schizophrenia; chr15:84736979 chr15:84570649~84580175:+ LIHC cis rs12908161 1 rs34570071 ENSG00000259728.4 LINC00933 3.78 0.000185 0.0304 0.28 0.2 Schizophrenia; chr15:84736981 chr15:84570649~84580175:+ LIHC cis rs6456156 0.586 rs6909180 ENSG00000227598.1 RP1-167A14.2 -3.78 0.000185 0.0304 -0.21 -0.2 Primary biliary cholangitis; chr6:167047049 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs12213683 ENSG00000227598.1 RP1-167A14.2 -3.78 0.000185 0.0304 -0.21 -0.2 Primary biliary cholangitis; chr6:167047230 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs12528323 ENSG00000227598.1 RP1-167A14.2 -3.78 0.000185 0.0304 -0.21 -0.2 Primary biliary cholangitis; chr6:167048157 chr6:166969626~166999065:- LIHC cis rs79349575 0.721 rs2291725 ENSG00000248278.1 SUMO2P17 3.78 0.000185 0.0304 0.25 0.2 Type 2 diabetes; chr17:48961770 chr17:48874860~48908983:- LIHC cis rs2243480 0.831 rs57294491 ENSG00000232546.1 RP11-458F8.1 3.78 0.000185 0.0304 0.22 0.2 Diabetic kidney disease; chr7:66219914 chr7:66848496~66858136:+ LIHC cis rs875971 0.522 rs781144 ENSG00000237310.1 GS1-124K5.4 3.78 0.000185 0.0304 0.2 0.2 Aortic root size; chr7:65975357 chr7:66493706~66495474:+ LIHC cis rs16958440 0.867 rs76558586 ENSG00000267724.1 RP11-49K24.8 3.78 0.000185 0.0304 0.38 0.2 Sitting height ratio; chr18:47211242 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs75228657 ENSG00000267724.1 RP11-49K24.8 3.78 0.000185 0.0304 0.38 0.2 Sitting height ratio; chr18:47214692 chr18:47105946~47108062:+ LIHC cis rs151234 0.676 rs508022 ENSG00000259982.1 CDC37P1 -3.78 0.000185 0.0304 -0.48 -0.2 Platelet distribution width; chr16:28562642 chr16:28700294~28701540:- LIHC cis rs151234 0.676 rs554206 ENSG00000259982.1 CDC37P1 -3.78 0.000185 0.0304 -0.48 -0.2 Platelet distribution width; chr16:28565048 chr16:28700294~28701540:- LIHC cis rs151234 0.741 rs151230 ENSG00000259982.1 CDC37P1 -3.78 0.000185 0.0304 -0.48 -0.2 Platelet distribution width; chr16:28571894 chr16:28700294~28701540:- LIHC cis rs921968 0.613 rs2710251 ENSG00000272555.1 RP11-459I19.1 -3.78 0.000185 0.0304 -0.22 -0.2 Mean corpuscular hemoglobin concentration; chr2:218678710 chr2:218818690~218819144:+ LIHC cis rs1405130 0.9 rs12997096 ENSG00000224287.2 MSL3P1 3.78 0.000185 0.0304 0.24 0.2 Coronary artery disease; chr2:234679344 chr2:233865437~233868444:- LIHC cis rs367615 0.704 rs60538082 ENSG00000249476.1 CTD-2587M2.1 3.78 0.000185 0.0304 0.24 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109493400 chr5:109237120~109326369:- LIHC cis rs13315871 0.929 rs35004361 ENSG00000272182.1 RP11-802O23.3 3.78 0.000185 0.0304 0.45 0.2 Cholesterol, total; chr3:58327667 chr3:58428255~58428815:+ LIHC cis rs3934487 0.547 rs4517390 ENSG00000223956.1 RP4-710M16.2 -3.78 0.000186 0.0304 -0.21 -0.2 Reticulocyte count; chr1:55861985 chr1:56414963~56415966:+ LIHC cis rs803923 0.585 rs803932 ENSG00000230894.1 RP11-67K19.3 -3.78 0.000186 0.0304 -0.25 -0.2 Lung function (FEV1/FVC); chr9:116695741 chr9:116568449~116586328:+ LIHC cis rs67311347 0.577 rs2371129 ENSG00000223797.4 ENTPD3-AS1 -3.78 0.000186 0.0305 -0.17 -0.2 Renal cell carcinoma; chr3:40206902 chr3:40313802~40453329:- LIHC cis rs10510102 0.516 rs12244921 ENSG00000226864.1 ATE1-AS1 3.78 0.000186 0.0305 0.33 0.2 Breast cancer; chr10:121990342 chr10:121928312~121951965:+ LIHC cis rs11212260 0.512 rs79797517 ENSG00000261098.1 RP11-819C21.1 3.78 0.000186 0.0305 0.35 0.2 IgG glycosylation; chr11:107303051 chr11:107312132~107316271:- LIHC cis rs3091242 0.933 rs909833 ENSG00000261349.1 RP3-465N24.5 -3.78 0.000186 0.0305 -0.2 -0.2 Erythrocyte sedimentation rate; chr1:25427649 chr1:25266102~25267136:- LIHC cis rs6723108 0.517 rs10928520 ENSG00000224043.6 CCNT2-AS1 -3.78 0.000186 0.0305 -0.23 -0.2 Type 2 diabetes; chr2:134846613 chr2:134735464~134918710:- LIHC cis rs16958440 0.867 rs79275306 ENSG00000267724.1 RP11-49K24.8 3.78 0.000186 0.0305 0.37 0.2 Sitting height ratio; chr18:47185249 chr18:47105946~47108062:+ LIHC cis rs16958440 0.609 rs75911383 ENSG00000267724.1 RP11-49K24.8 3.78 0.000186 0.0305 0.37 0.2 Sitting height ratio; chr18:47189640 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs75481537 ENSG00000267724.1 RP11-49K24.8 3.78 0.000186 0.0305 0.37 0.2 Sitting height ratio; chr18:47193575 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs9304342 ENSG00000267724.1 RP11-49K24.8 3.78 0.000186 0.0305 0.37 0.2 Sitting height ratio; chr18:47193828 chr18:47105946~47108062:+ LIHC cis rs6452524 0.618 rs10462394 ENSG00000271862.1 RP11-343L5.2 3.78 0.000186 0.0305 0.24 0.2 Hypertension (SNP x SNP interaction); chr5:83058735 chr5:83049376~83050964:- LIHC cis rs244293 0.7 rs12939352 ENSG00000275710.1 RP11-257O5.4 3.78 0.000186 0.0305 0.21 0.2 Menarche (age at onset); chr17:54930294 chr17:54964474~54964679:+ LIHC cis rs244293 0.76 rs4794547 ENSG00000275710.1 RP11-257O5.4 3.78 0.000186 0.0305 0.21 0.2 Menarche (age at onset); chr17:54933811 chr17:54964474~54964679:+ LIHC cis rs8060598 0.745 rs11642646 ENSG00000275155.1 CTD-2595P9.4 -3.78 0.000186 0.0305 -0.24 -0.2 Leprosy; chr16:50707275 chr16:49847018~49847632:- LIHC cis rs2842992 0.724 rs2273827 ENSG00000237927.1 RP3-393E18.2 -3.78 0.000186 0.0305 -0.24 -0.2 Age-related macular degeneration (geographic atrophy); chr6:159790307 chr6:159586955~159589169:- LIHC cis rs2842992 0.662 rs2273826 ENSG00000237927.1 RP3-393E18.2 -3.78 0.000186 0.0305 -0.24 -0.2 Age-related macular degeneration (geographic atrophy); chr6:159790389 chr6:159586955~159589169:- LIHC cis rs2842992 0.662 rs2273825 ENSG00000237927.1 RP3-393E18.2 -3.78 0.000186 0.0305 -0.24 -0.2 Age-related macular degeneration (geographic atrophy); chr6:159790392 chr6:159586955~159589169:- LIHC cis rs2842992 0.768 rs2273824 ENSG00000237927.1 RP3-393E18.2 -3.78 0.000186 0.0305 -0.24 -0.2 Age-related macular degeneration (geographic atrophy); chr6:159790413 chr6:159586955~159589169:- LIHC cis rs2842992 0.724 rs2273823 ENSG00000237927.1 RP3-393E18.2 -3.78 0.000186 0.0305 -0.24 -0.2 Age-related macular degeneration (geographic atrophy); chr6:159790453 chr6:159586955~159589169:- LIHC cis rs2842992 0.692 rs1128661 ENSG00000237927.1 RP3-393E18.2 -3.78 0.000186 0.0305 -0.24 -0.2 Age-related macular degeneration (geographic atrophy); chr6:159790522 chr6:159586955~159589169:- LIHC cis rs2842992 0.724 rs1128670 ENSG00000237927.1 RP3-393E18.2 -3.78 0.000186 0.0305 -0.24 -0.2 Age-related macular degeneration (geographic atrophy); chr6:159790604 chr6:159586955~159589169:- LIHC cis rs10256972 0.869 rs1007766 ENSG00000199023.2 MIR339 -3.78 0.000186 0.0305 -0.23 -0.2 Endometriosis;Longevity; chr7:995267 chr7:1022935~1023045:- LIHC cis rs12468226 0.938 rs3731700 ENSG00000272966.1 RP11-686O6.1 3.78 0.000186 0.0305 0.34 0.2 Urate levels; chr2:202291213 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs12464254 ENSG00000272966.1 RP11-686O6.1 3.78 0.000186 0.0305 0.34 0.2 Urate levels; chr2:202301641 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs12471060 ENSG00000272966.1 RP11-686O6.1 3.78 0.000186 0.0305 0.34 0.2 Urate levels; chr2:202309597 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs80315897 ENSG00000272966.1 RP11-686O6.1 3.78 0.000186 0.0305 0.34 0.2 Urate levels; chr2:202318044 chr2:202336739~202337200:+ LIHC cis rs1501911 0.509 rs34487 ENSG00000248489.1 CTD-2007H13.3 3.78 0.000186 0.0305 0.24 0.2 Lung function (FEV1/FVC); chr5:98872725 chr5:98929171~98995013:+ LIHC cis rs1501911 0.509 rs327786 ENSG00000248489.1 CTD-2007H13.3 3.78 0.000186 0.0305 0.24 0.2 Lung function (FEV1/FVC); chr5:98878301 chr5:98929171~98995013:+ LIHC cis rs1799949 1 rs2298862 ENSG00000267681.1 CTD-3199J23.6 -3.78 0.000186 0.0305 -0.2 -0.2 Menopause (age at onset); chr17:43024671 chr17:43144956~43145255:+ LIHC cis rs1799949 0.93 rs2298861 ENSG00000267681.1 CTD-3199J23.6 -3.78 0.000186 0.0305 -0.2 -0.2 Menopause (age at onset); chr17:43024814 chr17:43144956~43145255:+ LIHC cis rs1023500 1 rs1023499 ENSG00000227370.1 RP4-669P10.19 3.78 0.000186 0.0305 0.26 0.2 Schizophrenia; chr22:41944578 chr22:42132543~42132998:+ LIHC cis rs7617773 0.817 rs9819094 ENSG00000228638.1 FCF1P2 -3.78 0.000186 0.0305 -0.22 -0.2 Coronary artery disease; chr3:48278068 chr3:48290793~48291375:- LIHC cis rs2299116 0.889 rs1468446 ENSG00000225264.3 ZNRF2P2 -3.78 0.000186 0.0305 -0.24 -0.2 Serum thyroid-stimulating hormone levels; chr7:28757171 chr7:29598795~29685255:- LIHC cis rs12681287 0.517 rs34596274 ENSG00000254088.1 SLC2A3P4 3.78 0.000186 0.0305 0.24 0.2 Caudate activity during reward; chr8:86505450 chr8:86503591~86505061:+ LIHC cis rs8177253 1 rs8177272 ENSG00000244062.1 RP11-404G16.2 3.78 0.000186 0.0305 0.2 0.2 Iron status biomarkers; chr3:133764026 chr3:133760300~133762363:+ LIHC cis rs10833905 0.759 rs28526534 ENSG00000246225.5 RP11-17A1.3 -3.78 0.000186 0.0305 -0.25 -0.2 Sudden cardiac arrest; chr11:23033690 chr11:22829380~22945393:+ LIHC cis rs10833905 0.938 rs61889441 ENSG00000246225.5 RP11-17A1.3 -3.78 0.000186 0.0305 -0.25 -0.2 Sudden cardiac arrest; chr11:23034168 chr11:22829380~22945393:+ LIHC cis rs10833905 1 rs11026927 ENSG00000246225.5 RP11-17A1.3 -3.78 0.000186 0.0305 -0.25 -0.2 Sudden cardiac arrest; chr11:23035103 chr11:22829380~22945393:+ LIHC cis rs10833905 0.759 rs12224706 ENSG00000246225.5 RP11-17A1.3 -3.78 0.000186 0.0305 -0.25 -0.2 Sudden cardiac arrest; chr11:23035226 chr11:22829380~22945393:+ LIHC cis rs10833905 1 rs10833916 ENSG00000246225.5 RP11-17A1.3 -3.78 0.000186 0.0305 -0.25 -0.2 Sudden cardiac arrest; chr11:23036779 chr11:22829380~22945393:+ LIHC cis rs10833905 1 rs61889452 ENSG00000246225.5 RP11-17A1.3 -3.78 0.000186 0.0305 -0.25 -0.2 Sudden cardiac arrest; chr11:23037966 chr11:22829380~22945393:+ LIHC cis rs16958440 0.867 rs80106524 ENSG00000267724.1 RP11-49K24.8 3.78 0.000186 0.0305 0.37 0.2 Sitting height ratio; chr18:47150268 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs79712753 ENSG00000267724.1 RP11-49K24.8 3.78 0.000186 0.0305 0.37 0.2 Sitting height ratio; chr18:47150356 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs3809966 ENSG00000267724.1 RP11-49K24.8 3.78 0.000186 0.0305 0.37 0.2 Sitting height ratio; chr18:47151256 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs12326457 ENSG00000267724.1 RP11-49K24.8 3.78 0.000186 0.0305 0.37 0.2 Sitting height ratio; chr18:47152054 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs12326465 ENSG00000267724.1 RP11-49K24.8 3.78 0.000186 0.0305 0.37 0.2 Sitting height ratio; chr18:47152274 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs75934126 ENSG00000267724.1 RP11-49K24.8 3.78 0.000186 0.0305 0.37 0.2 Sitting height ratio; chr18:47153410 chr18:47105946~47108062:+ LIHC cis rs9907295 1 rs11080361 ENSG00000270871.1 AC015849.19 3.78 0.000186 0.0305 0.21 0.2 Fibroblast growth factor basic levels; chr17:35916184 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs11080362 ENSG00000270871.1 AC015849.19 3.78 0.000186 0.0305 0.21 0.2 Fibroblast growth factor basic levels; chr17:35916224 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs16971670 ENSG00000270871.1 AC015849.19 3.78 0.000186 0.0305 0.21 0.2 Fibroblast growth factor basic levels; chr17:35916548 chr17:35816717~35830293:- LIHC cis rs67311347 1 rs951560 ENSG00000223797.4 ENTPD3-AS1 3.78 0.000186 0.0305 0.16 0.2 Renal cell carcinoma; chr3:40421980 chr3:40313802~40453329:- LIHC cis rs10761256 0.778 rs3750358 ENSG00000227603.1 RP11-165J3.6 3.78 0.000186 0.0305 0.23 0.2 Itch intensity from mosquito bite adjusted by bite size; chr9:93662856 chr9:93435332~93437121:- LIHC cis rs2015599 0.514 rs10843376 ENSG00000275476.1 RP11-996F15.4 3.78 0.000186 0.0305 0.24 0.2 Platelet count;Mean platelet volume; chr12:29283651 chr12:29277397~29277882:- LIHC cis rs6456156 0.586 rs12203510 ENSG00000227598.1 RP1-167A14.2 -3.78 0.000186 0.0305 -0.21 -0.2 Primary biliary cholangitis; chr6:167059518 chr6:166969626~166999065:- LIHC cis rs673078 0.66 rs61945206 ENSG00000275759.1 RP11-131L12.3 -3.78 0.000186 0.0306 -0.37 -0.2 Glucose homeostasis traits; chr12:118238295 chr12:118428281~118428870:+ LIHC cis rs1003719 0.68 rs2154537 ENSG00000272948.2 AP001412.1 -3.78 0.000186 0.0306 -0.22 -0.2 Eye color traits; chr21:37129712 chr21:37267784~37268497:+ LIHC cis rs66887589 0.967 rs3775842 ENSG00000260091.1 RP11-33B1.4 -3.78 0.000186 0.0306 -0.13 -0.2 Diastolic blood pressure; chr4:119506577 chr4:119409333~119410233:+ LIHC cis rs1598856 1 rs93059 ENSG00000246560.2 RP11-10L12.4 3.78 0.000186 0.0306 0.22 0.2 Primary biliary cholangitis; chr4:102547361 chr4:102828055~102844075:+ LIHC cis rs12210905 1 rs6938397 ENSG00000216901.1 AL022393.7 3.78 0.000186 0.0306 0.34 0.2 Hip circumference adjusted for BMI; chr6:27263445 chr6:28176188~28176674:+ LIHC cis rs12210905 1 rs67310631 ENSG00000216901.1 AL022393.7 3.78 0.000186 0.0306 0.34 0.2 Hip circumference adjusted for BMI; chr6:27265464 chr6:28176188~28176674:+ LIHC cis rs12210905 1 rs9379967 ENSG00000216901.1 AL022393.7 3.78 0.000186 0.0306 0.34 0.2 Hip circumference adjusted for BMI; chr6:27265648 chr6:28176188~28176674:+ LIHC cis rs12210905 1 rs9368494 ENSG00000216901.1 AL022393.7 3.78 0.000186 0.0306 0.34 0.2 Hip circumference adjusted for BMI; chr6:27269522 chr6:28176188~28176674:+ LIHC cis rs794185 0.625 rs2819582 ENSG00000231249.1 ITPR1-AS1 -3.78 0.000187 0.0306 -0.22 -0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4470643 chr3:4490891~4493163:- LIHC cis rs712039 0.958 rs11868673 ENSG00000276054.1 RP11-378E13.3 3.78 0.000187 0.0306 0.24 0.2 Tuberculosis; chr17:37517559 chr17:37386886~37387926:+ LIHC cis rs244293 0.73 rs12165058 ENSG00000275710.1 RP11-257O5.4 3.78 0.000187 0.0306 0.23 0.2 Menarche (age at onset); chr17:54944688 chr17:54964474~54964679:+ LIHC cis rs244293 0.73 rs12945579 ENSG00000275710.1 RP11-257O5.4 3.78 0.000187 0.0306 0.23 0.2 Menarche (age at onset); chr17:54945353 chr17:54964474~54964679:+ LIHC cis rs244293 0.701 rs4793783 ENSG00000275710.1 RP11-257O5.4 3.78 0.000187 0.0306 0.23 0.2 Menarche (age at onset); chr17:54948119 chr17:54964474~54964679:+ LIHC cis rs12586317 0.508 rs10134914 ENSG00000258738.1 RP11-73E17.2 3.78 0.000187 0.0306 0.26 0.2 Psoriasis; chr14:34955806 chr14:34874343~34876459:+ LIHC cis rs12681366 0.839 rs3019280 ENSG00000253704.1 RP11-267M23.4 3.78 0.000187 0.0306 0.24 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94437804 chr8:94553722~94569745:+ LIHC cis rs12681366 0.839 rs3019281 ENSG00000253704.1 RP11-267M23.4 3.78 0.000187 0.0306 0.24 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94438061 chr8:94553722~94569745:+ LIHC cis rs3204270 0.81 rs62077191 ENSG00000281517.1 Metazoa_SRP -3.78 0.000187 0.0306 -0.4 -0.2 Dental caries; chr17:81711033 chr17:81718849~81719095:- LIHC cis rs673078 0.66 rs61943365 ENSG00000275409.1 RP11-131L12.4 -3.78 0.000187 0.0306 -0.25 -0.2 Glucose homeostasis traits; chr12:118339166 chr12:118430147~118430699:+ LIHC cis rs10761256 0.835 rs7019745 ENSG00000227603.1 RP11-165J3.6 3.78 0.000187 0.0306 0.23 0.2 Itch intensity from mosquito bite adjusted by bite size; chr9:93645204 chr9:93435332~93437121:- LIHC cis rs12468226 1 rs111542497 ENSG00000226261.1 AC064836.3 3.78 0.000187 0.0306 0.31 0.2 Urate levels; chr2:202330369 chr2:202336024~202336727:- LIHC cis rs11159086 0.793 rs11845370 ENSG00000270000.1 RP3-449M8.9 3.78 0.000187 0.0306 0.29 0.2 Advanced glycation end-product levels; chr14:74481587 chr14:74471930~74472360:- LIHC cis rs11159086 0.793 rs3784035 ENSG00000270000.1 RP3-449M8.9 3.78 0.000187 0.0306 0.29 0.2 Advanced glycation end-product levels; chr14:74482221 chr14:74471930~74472360:- LIHC cis rs11159086 0.793 rs12433382 ENSG00000270000.1 RP3-449M8.9 3.78 0.000187 0.0306 0.29 0.2 Advanced glycation end-product levels; chr14:74482940 chr14:74471930~74472360:- LIHC cis rs11159086 0.793 rs10148268 ENSG00000270000.1 RP3-449M8.9 3.78 0.000187 0.0306 0.29 0.2 Advanced glycation end-product levels; chr14:74484261 chr14:74471930~74472360:- LIHC cis rs11159086 0.793 rs11850070 ENSG00000270000.1 RP3-449M8.9 3.78 0.000187 0.0306 0.29 0.2 Advanced glycation end-product levels; chr14:74487575 chr14:74471930~74472360:- LIHC cis rs11159086 0.793 rs28378078 ENSG00000270000.1 RP3-449M8.9 3.78 0.000187 0.0306 0.29 0.2 Advanced glycation end-product levels; chr14:74487940 chr14:74471930~74472360:- LIHC cis rs11159086 0.793 rs4903229 ENSG00000270000.1 RP3-449M8.9 3.78 0.000187 0.0306 0.29 0.2 Advanced glycation end-product levels; chr14:74489865 chr14:74471930~74472360:- LIHC cis rs11159086 0.793 rs8016972 ENSG00000270000.1 RP3-449M8.9 3.78 0.000187 0.0306 0.29 0.2 Advanced glycation end-product levels; chr14:74491833 chr14:74471930~74472360:- LIHC cis rs11159086 0.793 rs8015894 ENSG00000270000.1 RP3-449M8.9 3.78 0.000187 0.0306 0.29 0.2 Advanced glycation end-product levels; chr14:74491917 chr14:74471930~74472360:- LIHC cis rs875971 1 rs6961717 ENSG00000237310.1 GS1-124K5.4 -3.78 0.000187 0.0306 -0.18 -0.2 Aortic root size; chr7:66122550 chr7:66493706~66495474:+ LIHC cis rs858239 0.863 rs466225 ENSG00000226816.2 AC005082.12 3.78 0.000187 0.0306 0.26 0.2 Cerebrospinal fluid biomarker levels; chr7:23292784 chr7:23206013~23208045:+ LIHC cis rs4964805 0.954 rs10861104 ENSG00000257681.1 RP11-341G23.4 3.78 0.000187 0.0306 0.21 0.2 Attention deficit hyperactivity disorder; chr12:103796145 chr12:103746315~103768858:- LIHC cis rs67981189 0.752 rs221902 ENSG00000274818.1 RP1-292L20.3 -3.78 0.000187 0.0306 -0.22 -0.2 Schizophrenia; chr14:71134362 chr14:70906657~70907111:- LIHC cis rs916888 0.61 rs199453 ENSG00000262881.1 RP11-669E14.4 -3.78 0.000187 0.0306 -0.21 -0.2 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:45907670~45910779:- LIHC cis rs591584 0.845 rs2155100 ENSG00000255893.1 RP11-685N10.1 -3.78 0.000187 0.0306 -0.2 -0.2 Macrophage Migration Inhibitory Factor levels; chr11:94588232 chr11:94472908~94473570:- LIHC cis rs591584 0.874 rs4354655 ENSG00000255893.1 RP11-685N10.1 -3.78 0.000187 0.0306 -0.2 -0.2 Macrophage Migration Inhibitory Factor levels; chr11:94588684 chr11:94472908~94473570:- LIHC cis rs591584 0.874 rs2155099 ENSG00000255893.1 RP11-685N10.1 -3.78 0.000187 0.0306 -0.2 -0.2 Macrophage Migration Inhibitory Factor levels; chr11:94588820 chr11:94472908~94473570:- LIHC cis rs2312236 0.673 rs12073480 ENSG00000225171.2 DUTP6 -3.78 0.000187 0.0306 -0.25 -0.2 Post-traumatic stress disorder; chr1:166742161 chr1:166868748~166869209:+ LIHC cis rs67311347 0.506 rs55962832 ENSG00000223797.4 ENTPD3-AS1 3.78 0.000187 0.0306 0.17 0.2 Renal cell carcinoma; chr3:40202960 chr3:40313802~40453329:- LIHC cis rs11096990 0.819 rs2711992 ENSG00000249685.1 RP11-360F5.3 -3.78 0.000187 0.0306 -0.27 -0.2 Cognitive function; chr4:39148651 chr4:39133913~39135608:+ LIHC cis rs987724 0.515 rs1320011 ENSG00000243926.1 TIPARP-AS1 3.78 0.000187 0.0306 0.22 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156899993 chr3:156671862~156674378:- LIHC cis rs6471393 0.929 rs4734251 ENSG00000253848.1 RP11-10N23.5 3.78 0.000187 0.0306 0.22 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93744195 chr8:93741193~93744534:+ LIHC cis rs6471393 0.929 rs4734252 ENSG00000253848.1 RP11-10N23.5 3.78 0.000187 0.0306 0.22 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93744286 chr8:93741193~93744534:+ LIHC cis rs10833905 1 rs61889442 ENSG00000246225.5 RP11-17A1.3 -3.78 0.000187 0.0306 -0.25 -0.2 Sudden cardiac arrest; chr11:23034201 chr11:22829380~22945393:+ LIHC cis rs6732160 0.631 rs7557285 ENSG00000272702.1 RP11-44N22.3 3.78 0.000187 0.0306 0.22 0.2 Intelligence (multi-trait analysis); chr2:73215684 chr2:73113018~73115907:+ LIHC cis rs854624 0.711 rs1608205 ENSG00000278690.1 RP11-104J23.2 3.78 0.000187 0.0306 0.43 0.2 Blood protein levels; chr17:36009727 chr17:36012504~36012891:+ LIHC cis rs7602568 1 rs7602568 ENSG00000223522.1 AC093690.1 3.78 0.000187 0.0307 0.22 0.2 Soluble interleukin-2 receptor subunit alpha; chr2:28361448 chr2:28307691~28310459:- LIHC cis rs703842 0.963 rs923829 ENSG00000270039.1 RP11-571M6.17 -3.78 0.000187 0.0307 -0.27 -0.2 Multiple sclerosis; chr12:57780523 chr12:57803838~57804415:+ LIHC cis rs4356203 0.875 rs527810 ENSG00000260196.1 RP1-239B22.5 -3.78 0.000187 0.0307 -0.24 -0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17179519 chr11:17380649~17383531:+ LIHC cis rs4356203 0.905 rs589319 ENSG00000260196.1 RP1-239B22.5 -3.78 0.000187 0.0307 -0.24 -0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17181050 chr11:17380649~17383531:+ LIHC cis rs694739 0.628 rs538147 ENSG00000236935.1 AP003774.1 3.78 0.000188 0.0307 0.22 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64362250 chr11:64325050~64329504:- LIHC cis rs1023500 1 rs9620001 ENSG00000227370.1 RP4-669P10.19 3.78 0.000188 0.0307 0.27 0.2 Schizophrenia; chr22:41934225 chr22:42132543~42132998:+ LIHC cis rs494562 0.892 rs640093 ENSG00000234155.1 RP11-30P6.6 -3.78 0.000188 0.0307 -0.41 -0.2 Metabolic traits;Blood metabolite levels; chr6:85406148 chr6:85387219~85390186:- LIHC cis rs9291683 0.645 rs11557743 ENSG00000250413.1 RP11-448G15.1 3.78 0.000188 0.0307 0.26 0.2 Bone mineral density; chr4:10116753 chr4:10006482~10009725:+ LIHC cis rs8087799 0.894 rs12709693 ENSG00000273232.1 RP11-370A5.2 3.78 0.000188 0.0307 0.23 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22676928 chr18:22882825~22883357:- LIHC cis rs5769707 0.967 rs763126 ENSG00000279345.1 RP3-522J7.7 3.78 0.000188 0.0307 0.18 0.2 Monocyte percentage of white cells;Monocyte count; chr22:49594926 chr22:49805452~49807208:+ LIHC cis rs9548988 0.967 rs9532469 ENSG00000176268.5 CYCSP34 -3.78 0.000188 0.0307 -0.2 -0.2 Ulcerative colitis; chr13:39934515 chr13:40863599~40863902:- LIHC cis rs2236231 0.55 rs12897715 ENSG00000259648.1 RP11-643G16.4 -3.78 0.000188 0.0307 -0.23 -0.2 Plasma kynurenine levels in major depressive disorder; chr14:67593117 chr14:67614929~67616626:+ LIHC cis rs2524005 1 rs2524005 ENSG00000237669.1 HCG4P3 -3.78 0.000188 0.0308 -0.25 -0.2 Bipolar disorder and schizophrenia; chr6:29931900 chr6:30006121~30007116:- LIHC cis rs4218 0.597 rs62002543 ENSG00000277144.1 RP11-59H7.4 -3.78 0.000188 0.0308 -0.22 -0.2 Social communication problems; chr15:59066646 chr15:59115547~59116089:- LIHC cis rs950169 0.922 rs4842939 ENSG00000189136.7 UBE2Q2P1 -3.78 0.000188 0.0308 -0.19 -0.2 Schizophrenia; chr15:84159214 chr15:84526781~84571216:- LIHC cis rs10905065 0.827 rs7089100 ENSG00000215267.7 AKR1C7P -3.78 0.000188 0.0308 -0.24 -0.2 Menopause (age at onset); chr10:5807914 chr10:5275173~5288470:- LIHC cis rs7674212 0.581 rs11946020 ENSG00000248971.2 KRT8P46 -3.78 0.000188 0.0308 -0.21 -0.2 Type 2 diabetes; chr4:103023585 chr4:102728746~102730171:- LIHC cis rs875971 1 rs2420820 ENSG00000237310.1 GS1-124K5.4 -3.78 0.000188 0.0308 -0.18 -0.2 Aortic root size; chr7:66626920 chr7:66493706~66495474:+ LIHC cis rs4218 0.635 rs10431792 ENSG00000277144.1 RP11-59H7.4 -3.78 0.000188 0.0308 -0.22 -0.2 Social communication problems; chr15:59066181 chr15:59115547~59116089:- LIHC cis rs4356975 0.563 rs12512526 ENSG00000250919.1 RP11-813N20.3 -3.78 0.000188 0.0308 -0.2 -0.2 Obesity-related traits; chr4:69100700 chr4:69027831~69044578:+ LIHC cis rs4356975 0.522 rs34386959 ENSG00000250919.1 RP11-813N20.3 -3.78 0.000188 0.0308 -0.2 -0.2 Obesity-related traits; chr4:69100837 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs55834557 ENSG00000250919.1 RP11-813N20.3 -3.78 0.000188 0.0308 -0.2 -0.2 Obesity-related traits; chr4:69100876 chr4:69027831~69044578:+ LIHC cis rs4356975 0.522 rs56388229 ENSG00000250919.1 RP11-813N20.3 -3.78 0.000188 0.0308 -0.2 -0.2 Obesity-related traits; chr4:69100940 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs34318523 ENSG00000250919.1 RP11-813N20.3 -3.78 0.000188 0.0308 -0.2 -0.2 Obesity-related traits; chr4:69101135 chr4:69027831~69044578:+ LIHC cis rs4356975 0.583 rs34630750 ENSG00000250919.1 RP11-813N20.3 -3.78 0.000188 0.0308 -0.2 -0.2 Obesity-related traits; chr4:69101208 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs12508257 ENSG00000250919.1 RP11-813N20.3 -3.78 0.000188 0.0308 -0.2 -0.2 Obesity-related traits; chr4:69101921 chr4:69027831~69044578:+ LIHC cis rs2839186 0.585 rs2839154 ENSG00000223901.2 AP001469.5 -3.78 0.000188 0.0308 -0.19 -0.2 Testicular germ cell tumor; chr21:46217846 chr21:46220269~46225364:+ LIHC cis rs2919917 1 rs1466526 ENSG00000254352.1 RP11-578O24.2 -3.78 0.000189 0.0308 -0.27 -0.2 Lymphocyte counts; chr8:78643239 chr8:78723796~78724136:- LIHC cis rs950169 0.58 rs11630887 ENSG00000259728.4 LINC00933 3.78 0.000189 0.0308 0.29 0.2 Schizophrenia; chr15:84649784 chr15:84570649~84580175:+ LIHC cis rs2179367 0.552 rs11155652 ENSG00000231760.4 RP11-350J20.5 3.77 0.000189 0.0308 0.33 0.2 Dupuytren's disease; chr6:149417849 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs12209364 ENSG00000231760.4 RP11-350J20.5 3.77 0.000189 0.0308 0.33 0.2 Dupuytren's disease; chr6:149418062 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs9498348 ENSG00000231760.4 RP11-350J20.5 3.77 0.000189 0.0308 0.33 0.2 Dupuytren's disease; chr6:149418352 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs9322179 ENSG00000231760.4 RP11-350J20.5 3.77 0.000189 0.0308 0.33 0.2 Dupuytren's disease; chr6:149418664 chr6:149796151~149826294:- LIHC cis rs11159086 1 rs4903233 ENSG00000270000.1 RP3-449M8.9 3.77 0.000189 0.0308 0.28 0.2 Advanced glycation end-product levels; chr14:74497291 chr14:74471930~74472360:- LIHC cis rs948562 0.947 rs73470773 ENSG00000280010.1 AP001350.4 3.77 0.000189 0.0309 0.35 0.2 Lymphoma; chr11:58648100 chr11:58627435~58628528:+ LIHC cis rs17767392 0.813 rs61989379 ENSG00000274818.1 RP1-292L20.3 3.77 0.000189 0.0309 0.31 0.2 Mitral valve prolapse; chr14:71497689 chr14:70906657~70907111:- LIHC cis rs2286503 0.78 rs1304431 ENSG00000228649.7 AC005682.5 3.77 0.000189 0.0309 0.23 0.2 Fibrinogen; chr7:22825793 chr7:22854178~22861579:+ LIHC cis rs17772222 0.793 rs7143853 ENSG00000258789.1 RP11-507K2.3 -3.77 0.000189 0.0309 -0.25 -0.2 Coronary artery calcification; chr14:88578477 chr14:88551597~88552493:+ LIHC cis rs308971 0.61 rs307553 ENSG00000225026.1 AC091492.2 3.77 0.000189 0.0309 0.51 0.2 Fasting blood insulin (BMI interaction); chr3:12105296 chr3:12328003~12328274:+ LIHC cis rs7804356 1 rs12534899 ENSG00000243766.6 HOTTIP -3.77 0.000189 0.0309 -0.32 -0.2 Type 1 diabetes; chr7:26837570 chr7:27198575~27207259:+ LIHC cis rs11159086 0.793 rs1029702 ENSG00000270000.1 RP3-449M8.9 3.77 0.000189 0.0309 0.29 0.2 Advanced glycation end-product levels; chr14:74473909 chr14:74471930~74472360:- LIHC cis rs6565180 0.632 rs8050812 ENSG00000183604.13 SMG1P5 -3.77 0.000189 0.0309 -0.22 -0.2 Tonsillectomy; chr16:30374516 chr16:30267553~30335374:- LIHC cis rs7809950 0.861 rs10264412 ENSG00000238832.1 snoU109 -3.77 0.000189 0.0309 -0.26 -0.2 Coronary artery disease; chr7:107543432 chr7:107603363~107603507:+ LIHC cis rs673078 0.607 rs7294498 ENSG00000275759.1 RP11-131L12.3 -3.77 0.000189 0.0309 -0.24 -0.2 Glucose homeostasis traits; chr12:118321680 chr12:118428281~118428870:+ LIHC cis rs2243480 1 rs387676 ENSG00000228409.4 CCT6P1 3.77 0.000189 0.0309 0.22 0.2 Diabetic kidney disease; chr7:66133233 chr7:65751142~65763354:+ LIHC cis rs9304742 1 rs9304742 ENSG00000213793.4 ZNF888 3.77 0.000189 0.0309 0.19 0.2 Psoriasis; chr19:52948038 chr19:52915196~52923470:- LIHC cis rs7607369 0.648 rs7582193 ENSG00000272555.1 RP11-459I19.1 -3.77 0.000189 0.0309 -0.23 -0.2 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218787809 chr2:218818690~218819144:+ LIHC cis rs12105510 0.626 rs1990145 ENSG00000231172.2 AC007099.1 -3.77 0.000189 0.0309 -0.23 -0.2 Response to platinum-based chemotherapy (cisplatin); chr2:75650524 chr2:75524068~75542706:+ LIHC cis rs7914558 0.646 rs10883795 ENSG00000236937.2 PTGES3P4 3.77 0.000189 0.0309 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102894820 chr10:102845595~102845950:+ LIHC cis rs7914558 0.646 rs10883796 ENSG00000236937.2 PTGES3P4 3.77 0.000189 0.0309 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102895558 chr10:102845595~102845950:+ LIHC cis rs7914558 0.646 rs4363528 ENSG00000236937.2 PTGES3P4 3.77 0.000189 0.0309 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102895758 chr10:102845595~102845950:+ LIHC cis rs7914558 0.621 rs7896290 ENSG00000236937.2 PTGES3P4 3.77 0.000189 0.0309 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102896258 chr10:102845595~102845950:+ LIHC cis rs7914558 0.621 rs12219346 ENSG00000236937.2 PTGES3P4 3.77 0.000189 0.0309 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102897543 chr10:102845595~102845950:+ LIHC cis rs6723108 0.559 rs1942051 ENSG00000224043.6 CCNT2-AS1 -3.77 0.000189 0.0309 -0.28 -0.2 Type 2 diabetes; chr2:134846120 chr2:134735464~134918710:- LIHC cis rs6723108 0.627 rs10928519 ENSG00000224043.6 CCNT2-AS1 -3.77 0.000189 0.0309 -0.28 -0.2 Type 2 diabetes; chr2:134846389 chr2:134735464~134918710:- LIHC cis rs6723108 0.627 rs4954189 ENSG00000224043.6 CCNT2-AS1 -3.77 0.000189 0.0309 -0.28 -0.2 Type 2 diabetes; chr2:134849763 chr2:134735464~134918710:- LIHC cis rs6723108 0.627 rs10432371 ENSG00000224043.6 CCNT2-AS1 -3.77 0.000189 0.0309 -0.28 -0.2 Type 2 diabetes; chr2:134852176 chr2:134735464~134918710:- LIHC cis rs6723108 0.627 rs2053726 ENSG00000224043.6 CCNT2-AS1 -3.77 0.000189 0.0309 -0.28 -0.2 Type 2 diabetes; chr2:134852584 chr2:134735464~134918710:- LIHC cis rs6545883 0.931 rs11125885 ENSG00000271889.1 RP11-493E12.1 3.77 0.000189 0.0309 0.24 0.2 Tuberculosis; chr2:61528593 chr2:61151433~61162105:- LIHC cis rs6545883 0.965 rs9989775 ENSG00000271889.1 RP11-493E12.1 3.77 0.000189 0.0309 0.24 0.2 Tuberculosis; chr2:61534639 chr2:61151433~61162105:- LIHC cis rs4561483 0.603 rs7202065 ENSG00000261560.1 RP11-166B2.3 3.77 0.000189 0.0309 0.24 0.2 Testicular germ cell tumor; chr16:11857188 chr16:11881075~11882569:- LIHC cis rs62025270 0.688 rs7179917 ENSG00000259295.5 CSPG4P12 -3.77 0.00019 0.0309 -0.36 -0.2 Idiopathic pulmonary fibrosis; chr15:85722413 chr15:85191438~85213905:+ LIHC cis rs919433 0.854 rs787994 ENSG00000231621.1 AC013264.2 -3.77 0.00019 0.0309 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197358397 chr2:197197991~197199273:+ LIHC cis rs7617773 0.817 rs3937 ENSG00000228638.1 FCF1P2 -3.77 0.00019 0.031 -0.22 -0.2 Coronary artery disease; chr3:48270912 chr3:48290793~48291375:- LIHC cis rs2283792 0.74 rs2283791 ENSG00000224086.5 LL22NC03-86G7.1 -3.77 0.00019 0.031 -0.21 -0.2 Multiple sclerosis; chr22:21776656 chr22:21938293~21977632:+ LIHC cis rs375092 0.543 rs7808331 ENSG00000230658.1 KLHL7-AS1 3.77 0.00019 0.031 0.34 0.2 Personality dimensions; chr7:23374070 chr7:23101228~23105703:- LIHC cis rs9457247 0.765 rs1322077 ENSG00000227598.1 RP1-167A14.2 -3.77 0.00019 0.031 -0.22 -0.2 Crohn's disease; chr6:167010805 chr6:166969626~166999065:- LIHC cis rs9457247 0.765 rs9457249 ENSG00000227598.1 RP1-167A14.2 -3.77 0.00019 0.031 -0.22 -0.2 Crohn's disease; chr6:167012950 chr6:166969626~166999065:- LIHC cis rs77204473 0.744 rs6589606 ENSG00000254851.1 RP11-109L13.1 3.77 0.00019 0.031 0.38 0.2 Sum eosinophil basophil counts;Eosinophil counts; chr11:117222170 chr11:117135528~117138582:+ LIHC cis rs6472235 0.656 rs57683289 ENSG00000272010.1 CTD-3025N20.3 -3.77 0.00019 0.031 -0.28 -0.2 Plateletcrit;Myopia (pathological); chr8:65973204 chr8:65591850~65592472:- LIHC cis rs2348418 0.515 rs17434556 ENSG00000247934.4 RP11-967K21.1 3.77 0.00019 0.031 0.23 0.2 Lung function (FEV1);Lung function (FVC); chr12:28442760 chr12:28163298~28190738:- LIHC cis rs2115630 0.645 rs2292463 ENSG00000225151.9 GOLGA2P7 3.77 0.00019 0.031 0.22 0.2 P wave terminal force; chr15:84632519 chr15:84199311~84230136:- LIHC cis rs2439831 0.867 rs496584 ENSG00000275601.1 AC011330.13 -3.77 0.00019 0.031 -0.27 -0.2 Lung cancer in ever smokers; chr15:43539725 chr15:43642389~43643023:- LIHC cis rs2070488 0.965 rs7372849 ENSG00000229589.1 ACVR2B-AS1 3.77 0.00019 0.031 0.23 0.2 Electrocardiographic conduction measures; chr3:38482837 chr3:38451027~38454820:- LIHC cis rs614226 0.688 rs75111771 ENSG00000278344.1 RP11-18C24.8 -3.77 0.00019 0.031 -0.35 -0.2 Type 1 diabetes nephropathy; chr12:120572140 chr12:120500735~120501090:- LIHC cis rs614226 0.748 rs78714658 ENSG00000278344.1 RP11-18C24.8 -3.77 0.00019 0.031 -0.35 -0.2 Type 1 diabetes nephropathy; chr12:120572141 chr12:120500735~120501090:- LIHC cis rs614226 0.935 rs77955762 ENSG00000278344.1 RP11-18C24.8 -3.77 0.00019 0.031 -0.35 -0.2 Type 1 diabetes nephropathy; chr12:120572145 chr12:120500735~120501090:- LIHC cis rs2243480 1 rs4718333 ENSG00000228409.4 CCT6P1 -3.77 0.00019 0.031 -0.21 -0.2 Diabetic kidney disease; chr7:66307771 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs7792391 ENSG00000228409.4 CCT6P1 -3.77 0.00019 0.031 -0.21 -0.2 Diabetic kidney disease; chr7:66308442 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs10247526 ENSG00000228409.4 CCT6P1 -3.77 0.00019 0.031 -0.21 -0.2 Diabetic kidney disease; chr7:66315709 chr7:65751142~65763354:+ LIHC cis rs2243480 0.908 rs1532573 ENSG00000228409.4 CCT6P1 -3.77 0.00019 0.031 -0.21 -0.2 Diabetic kidney disease; chr7:66333815 chr7:65751142~65763354:+ LIHC cis rs1348850 0.608 rs10176632 ENSG00000280374.1 RP11-337N6.3 3.77 0.00019 0.031 0.24 0.2 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr2:177361206 chr2:177317715~177318471:- LIHC cis rs1348850 0.539 rs1453371 ENSG00000280374.1 RP11-337N6.3 3.77 0.00019 0.031 0.24 0.2 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr2:177363134 chr2:177317715~177318471:- LIHC cis rs6424115 0.618 rs10917420 ENSG00000203589.2 RP5-886K2.1 3.77 0.00019 0.031 0.21 0.2 Immature fraction of reticulocytes; chr1:23736497 chr1:23705801~23706934:- LIHC cis rs4578769 0.765 rs10432158 ENSG00000265943.1 RP11-739L10.1 -3.77 0.00019 0.031 -0.26 -0.2 Eosinophil percentage of white cells; chr18:22826406 chr18:22699481~22933764:- LIHC cis rs4578769 0.765 rs10432159 ENSG00000265943.1 RP11-739L10.1 -3.77 0.00019 0.031 -0.26 -0.2 Eosinophil percentage of white cells; chr18:22826596 chr18:22699481~22933764:- LIHC cis rs4578769 0.765 rs16972382 ENSG00000265943.1 RP11-739L10.1 -3.77 0.00019 0.031 -0.26 -0.2 Eosinophil percentage of white cells; chr18:22831403 chr18:22699481~22933764:- LIHC cis rs7216064 0.684 rs7406031 ENSG00000265055.1 AC145343.2 -3.77 0.00019 0.0311 -0.21 -0.2 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68025637 chr17:68096046~68101474:- LIHC cis rs7809950 0.724 rs1858888 ENSG00000238832.1 snoU109 -3.77 0.00019 0.0311 -0.26 -0.2 Coronary artery disease; chr7:107405617 chr7:107603363~107603507:+ LIHC cis rs673078 0.66 rs16948193 ENSG00000275759.1 RP11-131L12.3 -3.77 0.00019 0.0311 -0.37 -0.2 Glucose homeostasis traits; chr12:118227115 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs61945187 ENSG00000275759.1 RP11-131L12.3 -3.77 0.00019 0.0311 -0.37 -0.2 Glucose homeostasis traits; chr12:118228989 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs73205512 ENSG00000275759.1 RP11-131L12.3 -3.77 0.00019 0.0311 -0.37 -0.2 Glucose homeostasis traits; chr12:118235770 chr12:118428281~118428870:+ LIHC cis rs74181299 0.684 rs6736728 ENSG00000225889.6 AC074289.1 -3.77 0.00019 0.0311 -0.23 -0.2 Pulse pressure; chr2:65078365 chr2:64143239~64252859:+ LIHC cis rs2599510 0.703 rs58852184 ENSG00000276334.1 AL133243.1 3.77 0.000191 0.0311 0.23 0.2 Interleukin-18 levels; chr2:32504696 chr2:32521927~32523547:+ LIHC cis rs2243480 0.708 rs13242216 ENSG00000275400.1 RP4-756H11.5 3.77 0.000191 0.0311 0.27 0.2 Diabetic kidney disease; chr7:66433290 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs67536397 ENSG00000275400.1 RP4-756H11.5 3.77 0.000191 0.0311 0.27 0.2 Diabetic kidney disease; chr7:66482930 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs58669269 ENSG00000275400.1 RP4-756H11.5 3.77 0.000191 0.0311 0.27 0.2 Diabetic kidney disease; chr7:66486966 chr7:66553805~66554199:- LIHC cis rs7760535 0.831 rs62420437 ENSG00000271789.1 RP5-1112D6.7 -3.77 0.000191 0.0311 -0.19 -0.2 Metabolic traits; chr6:111427577 chr6:111297126~111298510:+ LIHC cis rs803903 0.57 rs1475056 ENSG00000230894.1 RP11-67K19.3 3.77 0.000191 0.0311 0.27 0.2 Breast cancer; chr9:116480675 chr9:116568449~116586328:+ LIHC cis rs10129255 1 rs4612959 ENSG00000211972.2 IGHV3-66 3.77 0.000191 0.0311 0.16 0.2 Kawasaki disease; chr14:106767055 chr14:106675017~106675544:- LIHC cis rs27434 0.583 rs34761 ENSG00000272109.1 CTD-2260A17.3 -3.77 0.000191 0.0311 -0.24 -0.2 Ankylosing spondylitis; chr5:96817921 chr5:96804353~96806105:+ LIHC cis rs2439831 0.867 rs2412778 ENSG00000205771.5 CATSPER2P1 -3.77 0.000191 0.0311 -0.27 -0.2 Lung cancer in ever smokers; chr15:43368784 chr15:43726918~43747094:- LIHC cis rs6471393 0.83 rs57803852 ENSG00000253848.1 RP11-10N23.5 3.77 0.000191 0.0311 0.22 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93761156 chr8:93741193~93744534:+ LIHC cis rs7722022 0.961 rs2052508 ENSG00000253428.1 CTB-43E15.2 3.77 0.000191 0.0311 0.21 0.2 Adiponectin levels; chr5:173519245 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs1363604 ENSG00000253428.1 CTB-43E15.2 3.77 0.000191 0.0311 0.21 0.2 Adiponectin levels; chr5:173519732 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs4868281 ENSG00000253428.1 CTB-43E15.2 3.77 0.000191 0.0311 0.21 0.2 Adiponectin levels; chr5:173521733 chr5:173689459~173705849:+ LIHC cis rs34375054 0.525 rs7136220 ENSG00000279233.1 RP11-158L12.4 3.77 0.000191 0.0311 0.18 0.2 Post bronchodilator FEV1/FVC ratio; chr12:125118138 chr12:125138245~125141711:+ LIHC cis rs875971 0.662 rs448725 ENSG00000237310.1 GS1-124K5.4 3.77 0.000191 0.0311 0.18 0.2 Aortic root size; chr7:66049641 chr7:66493706~66495474:+ LIHC cis rs875971 0.658 rs432667 ENSG00000237310.1 GS1-124K5.4 3.77 0.000191 0.0311 0.18 0.2 Aortic root size; chr7:66049646 chr7:66493706~66495474:+ LIHC cis rs2976388 0.566 rs2585146 ENSG00000253741.1 CTD-2292P10.4 -3.77 0.000191 0.0311 -0.26 -0.2 Urinary tract infection frequency; chr8:142717223 chr8:142702252~142726973:- LIHC cis rs11098499 0.863 rs3775854 ENSG00000260091.1 RP11-33B1.4 -3.77 0.000191 0.0311 -0.14 -0.2 Corneal astigmatism; chr4:119550816 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs6853998 ENSG00000260091.1 RP11-33B1.4 -3.77 0.000191 0.0311 -0.14 -0.2 Corneal astigmatism; chr4:119554705 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs6858777 ENSG00000260091.1 RP11-33B1.4 -3.77 0.000191 0.0311 -0.14 -0.2 Corneal astigmatism; chr4:119554811 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs11731756 ENSG00000260091.1 RP11-33B1.4 -3.77 0.000191 0.0311 -0.14 -0.2 Corneal astigmatism; chr4:119557541 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs34308924 ENSG00000260091.1 RP11-33B1.4 -3.77 0.000191 0.0311 -0.14 -0.2 Corneal astigmatism; chr4:119560276 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs2170276 ENSG00000260091.1 RP11-33B1.4 -3.77 0.000191 0.0311 -0.14 -0.2 Corneal astigmatism; chr4:119564669 chr4:119409333~119410233:+ LIHC cis rs2243480 0.901 rs12530490 ENSG00000228409.4 CCT6P1 -3.77 0.000191 0.0311 -0.22 -0.2 Diabetic kidney disease; chr7:66226660 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs7778911 ENSG00000228409.4 CCT6P1 -3.77 0.000191 0.0311 -0.22 -0.2 Diabetic kidney disease; chr7:66229519 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1979823 ENSG00000228409.4 CCT6P1 -3.77 0.000191 0.0311 -0.22 -0.2 Diabetic kidney disease; chr7:66239626 chr7:65751142~65763354:+ LIHC cis rs4925386 0.819 rs2890083 ENSG00000226332.2 RP11-157P1.4 -3.77 0.000191 0.0312 -0.21 -0.2 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62336902 chr20:62305432~62306325:- LIHC cis rs17376456 1 rs12188453 ENSG00000251023.1 RP11-549J18.1 3.77 0.000191 0.0312 0.4 0.2 Diabetic retinopathy; chr5:94225102 chr5:93860669~93863825:- LIHC cis rs1023500 0.552 rs5758566 ENSG00000226450.2 CYP2D8P 3.77 0.000191 0.0312 0.25 0.2 Schizophrenia; chr22:42058350 chr22:42149886~42155001:- LIHC cis rs3764021 0.527 rs10844503 ENSG00000256673.1 RP11-599J14.2 -3.77 0.000191 0.0312 -0.2 -0.2 Type 1 diabetes; chr12:9701660 chr12:9398355~9414851:- LIHC cis rs3091242 0.933 rs932372 ENSG00000224183.1 SDHDP6 -3.77 0.000191 0.0312 -0.23 -0.2 Erythrocyte sedimentation rate; chr1:25428523 chr1:25294164~25294643:- LIHC cis rs7937890 0.874 rs6486191 ENSG00000251991.1 RNU7-49P 3.77 0.000191 0.0312 0.21 0.2 Mitochondrial DNA levels; chr11:14382193 chr11:14478892~14478953:+ LIHC cis rs6832769 0.922 rs28665088 ENSG00000272969.1 RP11-528I4.2 3.77 0.000191 0.0312 0.24 0.2 Personality dimensions; chr4:55384913 chr4:55547112~55547889:+ LIHC cis rs7674212 0.531 rs6816370 ENSG00000248971.2 KRT8P46 -3.77 0.000191 0.0312 -0.21 -0.2 Type 2 diabetes; chr4:103018276 chr4:102728746~102730171:- LIHC cis rs4964805 0.865 rs4964780 ENSG00000257681.1 RP11-341G23.4 3.77 0.000192 0.0312 0.21 0.2 Attention deficit hyperactivity disorder; chr12:103813081 chr12:103746315~103768858:- LIHC cis rs62246343 0.605 rs4328788 ENSG00000206573.7 THUMPD3-AS1 -3.77 0.000192 0.0312 -0.23 -0.2 Fibrinogen levels; chr3:9415577 chr3:9349689~9398579:- LIHC cis rs62246343 0.605 rs4308263 ENSG00000206573.7 THUMPD3-AS1 -3.77 0.000192 0.0312 -0.23 -0.2 Fibrinogen levels; chr3:9415674 chr3:9349689~9398579:- LIHC cis rs3934487 0.547 rs10789008 ENSG00000223956.1 RP4-710M16.2 -3.77 0.000192 0.0312 -0.21 -0.2 Reticulocyte count; chr1:55865275 chr1:56414963~56415966:+ LIHC cis rs1023500 0.596 rs133352 ENSG00000205702.9 CYP2D7 3.77 0.000192 0.0312 0.23 0.2 Schizophrenia; chr22:42038018 chr22:42140203~42144577:- LIHC cis rs8037137 0.915 rs2301825 ENSG00000258725.1 PRC1-AS1 -3.77 0.000192 0.0312 -0.25 -0.2 Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr15:90984840 chr15:90966345~90988624:+ LIHC cis rs1015362 0.504 rs6059552 ENSG00000228265.4 RALY-AS1 -3.77 0.000192 0.0312 -0.22 -0.2 Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling; chr20:33923820 chr20:33983052~33994357:- LIHC cis rs1344653 0.738 rs4666493 ENSG00000236204.4 LINC01376 -3.77 0.000192 0.0312 -0.24 -0.2 Pulse pressure; chr2:19565464 chr2:18986451~19346748:- LIHC cis rs7809950 0.817 rs10224503 ENSG00000238832.1 snoU109 -3.77 0.000192 0.0313 -0.26 -0.2 Coronary artery disease; chr7:107435124 chr7:107603363~107603507:+ LIHC cis rs919433 1 rs1560277 ENSG00000231621.1 AC013264.2 -3.77 0.000192 0.0313 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197323179 chr2:197197991~197199273:+ LIHC cis rs2638953 0.64 rs11049723 ENSG00000247934.4 RP11-967K21.1 3.77 0.000192 0.0313 0.27 0.2 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28575903 chr12:28163298~28190738:- LIHC cis rs227275 0.554 rs223334 ENSG00000248971.2 KRT8P46 3.77 0.000192 0.0313 0.2 0.2 Allergic disease (asthma, hay fever or eczema); chr4:102867054 chr4:102728746~102730171:- LIHC cis rs875971 0.545 rs67775320 ENSG00000224316.1 RP11-479O9.2 3.77 0.000192 0.0313 0.19 0.2 Aortic root size; chr7:66193792 chr7:65773620~65802067:+ LIHC cis rs1876905 0.539 rs240985 ENSG00000272356.1 RP5-1112D6.8 3.77 0.000192 0.0313 0.19 0.2 Mean corpuscular hemoglobin; chr6:111263428 chr6:111309203~111313517:+ LIHC cis rs74181299 0.62 rs6546123 ENSG00000225889.6 AC074289.1 3.77 0.000192 0.0313 0.22 0.2 Pulse pressure; chr2:65076448 chr2:64143239~64252859:+ LIHC cis rs4792901 0.802 rs28581728 ENSG00000267747.1 RP11-392O1.4 -3.77 0.000192 0.0313 -0.24 -0.2 Dupuytren's disease; chr17:43531968 chr17:43544785~43610338:+ LIHC cis rs4792901 0.802 rs28608935 ENSG00000267747.1 RP11-392O1.4 -3.77 0.000192 0.0313 -0.24 -0.2 Dupuytren's disease; chr17:43532102 chr17:43544785~43610338:+ LIHC cis rs4792901 0.729 rs72833142 ENSG00000267747.1 RP11-392O1.4 -3.77 0.000192 0.0313 -0.24 -0.2 Dupuytren's disease; chr17:43538188 chr17:43544785~43610338:+ LIHC cis rs1115240 0.574 rs6575031 ENSG00000257842.4 NOVA1-AS1 3.77 0.000192 0.0313 0.2 0.2 Educational attainment (years of education); chr14:26548981 chr14:26598412~26806467:+ LIHC cis rs1115240 0.574 rs61986530 ENSG00000257842.4 NOVA1-AS1 3.77 0.000192 0.0313 0.2 0.2 Educational attainment (years of education); chr14:26552508 chr14:26598412~26806467:+ LIHC cis rs1115240 0.853 rs7154811 ENSG00000257842.4 NOVA1-AS1 -3.77 0.000192 0.0313 -0.19 -0.2 Educational attainment (years of education); chr14:26527304 chr14:26598412~26806467:+ LIHC cis rs2462686 1 rs2453835 ENSG00000272556.1 RP11-638I8.1 3.77 0.000192 0.0313 0.31 0.2 Major depressive disorder; chr7:45927575 chr7:45814602~45815263:+ LIHC cis rs6860806 0.507 rs2631364 ENSG00000263597.1 MIR3936 -3.77 0.000192 0.0313 -0.21 -0.2 Breast cancer; chr5:132371222 chr5:132365490~132365599:- LIHC cis rs2283792 0.765 rs6518968 ENSG00000224086.5 LL22NC03-86G7.1 -3.77 0.000192 0.0313 -0.21 -0.2 Multiple sclerosis; chr22:21793327 chr22:21938293~21977632:+ LIHC cis rs6430553 0.964 rs56383182 ENSG00000224043.6 CCNT2-AS1 -3.77 0.000192 0.0313 -0.23 -0.2 Blood metabolite levels; chr2:134850641 chr2:134735464~134918710:- LIHC cis rs6723108 0.534 rs6430546 ENSG00000224043.6 CCNT2-AS1 -3.77 0.000192 0.0313 -0.23 -0.2 Type 2 diabetes; chr2:134851231 chr2:134735464~134918710:- LIHC cis rs6430553 0.964 rs60793693 ENSG00000224043.6 CCNT2-AS1 -3.77 0.000192 0.0313 -0.23 -0.2 Blood metabolite levels; chr2:134852125 chr2:134735464~134918710:- LIHC cis rs673078 0.607 rs2062519 ENSG00000275409.1 RP11-131L12.4 -3.77 0.000192 0.0313 -0.24 -0.2 Glucose homeostasis traits; chr12:118367577 chr12:118430147~118430699:+ LIHC cis rs193541 0.53 rs2125857 ENSG00000263432.2 RN7SL689P 3.77 0.000192 0.0313 0.3 0.2 Glucose homeostasis traits; chr5:122747461 chr5:123022487~123022783:- LIHC cis rs6545883 0.965 rs1562308 ENSG00000271889.1 RP11-493E12.1 3.77 0.000192 0.0313 0.24 0.2 Tuberculosis; chr2:61541286 chr2:61151433~61162105:- LIHC cis rs2243480 0.615 rs34363376 ENSG00000275400.1 RP4-756H11.5 3.77 0.000192 0.0313 0.27 0.2 Diabetic kidney disease; chr7:66474549 chr7:66553805~66554199:- LIHC cis rs4650994 0.571 rs11588907 ENSG00000273384.1 RP5-1098D14.1 -3.77 0.000192 0.0313 -0.25 -0.2 HDL cholesterol;HDL cholesterol levels; chr1:178540327 chr1:178651706~178652282:+ LIHC cis rs11212260 0.655 rs74862732 ENSG00000261098.1 RP11-819C21.1 3.77 0.000192 0.0313 0.35 0.2 IgG glycosylation; chr11:107302757 chr11:107312132~107316271:- LIHC cis rs11212260 0.512 rs7121072 ENSG00000261098.1 RP11-819C21.1 3.77 0.000192 0.0313 0.35 0.2 IgG glycosylation; chr11:107303713 chr11:107312132~107316271:- LIHC cis rs3096299 0.754 rs3102382 ENSG00000261118.1 RP11-104N10.1 3.77 0.000192 0.0313 0.19 0.2 Multiple myeloma (IgH translocation); chr16:89343334 chr16:89492017~89504460:- LIHC cis rs794185 0.532 rs1038639 ENSG00000231249.1 ITPR1-AS1 3.77 0.000192 0.0313 0.21 0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4520983 chr3:4490891~4493163:- LIHC cis rs17818399 0.708 rs1531133 ENSG00000239332.4 LINC01119 -3.77 0.000192 0.0313 -0.27 -0.2 Height; chr2:46616492 chr2:46816697~46859007:+ LIHC cis rs74233809 0.901 rs11191425 ENSG00000236937.2 PTGES3P4 3.77 0.000192 0.0313 0.32 0.2 Birth weight; chr10:102866213 chr10:102845595~102845950:+ LIHC cis rs5742933 0.857 rs1233282 ENSG00000253559.1 OSGEPL1-AS1 -3.77 0.000192 0.0313 -0.26 -0.2 Ferritin levels; chr2:189823518 chr2:189762704~189765556:+ LIHC cis rs57709857 0.915 rs12681196 ENSG00000272092.1 RP11-350N15.5 -3.77 0.000192 0.0313 -0.23 -0.2 Autism spectrum disorder or schizophrenia; chr8:38379076 chr8:38382364~38383461:+ LIHC cis rs6732160 0.691 rs13432787 ENSG00000272702.1 RP11-44N22.3 3.77 0.000193 0.0313 0.22 0.2 Intelligence (multi-trait analysis); chr2:73203106 chr2:73113018~73115907:+ LIHC cis rs11096990 0.964 rs11096986 ENSG00000249685.1 RP11-360F5.3 -3.77 0.000193 0.0314 -0.27 -0.2 Cognitive function; chr4:39257122 chr4:39133913~39135608:+ LIHC cis rs17711722 0.727 rs2658585 ENSG00000237310.1 GS1-124K5.4 3.77 0.000193 0.0314 0.2 0.2 Calcium levels; chr7:65996954 chr7:66493706~66495474:+ LIHC cis rs10883723 0.81 rs12265877 ENSG00000236937.2 PTGES3P4 -3.77 0.000193 0.0314 -0.26 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102487490 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs2296588 ENSG00000236937.2 PTGES3P4 -3.77 0.000193 0.0314 -0.26 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102488330 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs2296589 ENSG00000236937.2 PTGES3P4 -3.77 0.000193 0.0314 -0.26 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102488349 chr10:102845595~102845950:+ LIHC cis rs803903 0.57 rs34976241 ENSG00000230894.1 RP11-67K19.3 3.77 0.000193 0.0314 0.27 0.2 Breast cancer; chr9:116441007 chr9:116568449~116586328:+ LIHC cis rs803903 0.57 rs34430369 ENSG00000230894.1 RP11-67K19.3 3.77 0.000193 0.0314 0.27 0.2 Breast cancer; chr9:116444132 chr9:116568449~116586328:+ LIHC cis rs2072510 1 rs2540492 ENSG00000257878.1 RP11-256L6.3 -3.77 0.000193 0.0314 -0.18 -0.2 Metabolite levels (small molecules and protein measures); chr12:96023881 chr12:95996521~96011489:+ LIHC cis rs11096990 0.855 rs2167494 ENSG00000249207.1 RP11-360F5.1 3.77 0.000193 0.0314 0.24 0.2 Cognitive function; chr4:39214601 chr4:39112677~39126818:- LIHC cis rs6547741 0.935 rs4666005 ENSG00000234072.1 AC074117.10 3.77 0.000193 0.0314 0.18 0.2 Oral cavity cancer; chr2:27632372 chr2:27356246~27367622:+ LIHC cis rs4578769 0.765 rs9949825 ENSG00000265943.1 RP11-739L10.1 -3.77 0.000193 0.0314 -0.26 -0.2 Eosinophil percentage of white cells; chr18:22806055 chr18:22699481~22933764:- LIHC cis rs2836974 0.545 rs2776311 ENSG00000255568.3 BRWD1-AS2 3.77 0.000193 0.0314 0.19 0.2 Cognitive function; chr21:39344959 chr21:39313935~39314962:+ LIHC cis rs7617773 0.78 rs34523942 ENSG00000228638.1 FCF1P2 -3.77 0.000193 0.0314 -0.22 -0.2 Coronary artery disease; chr3:48301179 chr3:48290793~48291375:- LIHC cis rs2919917 0.628 rs10109359 ENSG00000254352.1 RP11-578O24.2 3.77 0.000193 0.0314 0.3 0.2 Lymphocyte counts; chr8:78694369 chr8:78723796~78724136:- LIHC cis rs1115240 0.685 rs4983181 ENSG00000257842.4 NOVA1-AS1 -3.77 0.000193 0.0314 -0.19 -0.2 Educational attainment (years of education); chr14:26690695 chr14:26598412~26806467:+ LIHC cis rs3772760 1 rs75601343 ENSG00000240622.1 RPL7P15 -3.77 0.000193 0.0314 -0.37 -0.2 Amyotrophic lateral sclerosis; chr3:124452192 chr3:124151960~124153063:- LIHC cis rs733175 0.951 rs6846692 ENSG00000250413.1 RP11-448G15.1 -3.77 0.000193 0.0314 -0.29 -0.2 Psychosis and Alzheimer's disease; chr4:10029509 chr4:10006482~10009725:+ LIHC cis rs2243480 1 rs313803 ENSG00000229886.1 RP5-1132H15.3 3.77 0.000193 0.0314 0.29 0.2 Diabetic kidney disease; chr7:66049744 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs313802 ENSG00000229886.1 RP5-1132H15.3 3.77 0.000193 0.0314 0.29 0.2 Diabetic kidney disease; chr7:66051386 chr7:66025126~66031544:- LIHC cis rs2243480 0.803 rs403089 ENSG00000229886.1 RP5-1132H15.3 3.77 0.000193 0.0314 0.29 0.2 Diabetic kidney disease; chr7:66052736 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs458291 ENSG00000229886.1 RP5-1132H15.3 3.77 0.000193 0.0314 0.29 0.2 Diabetic kidney disease; chr7:66055492 chr7:66025126~66031544:- LIHC cis rs1922291 0.546 rs3771185 ENSG00000281162.1 LINC01127 -3.77 0.000193 0.0314 -0.21 -0.2 Blood protein levels; chr2:102224047 chr2:101962056~101987167:+ LIHC cis rs8177253 1 rs8177271 ENSG00000244062.1 RP11-404G16.2 3.77 0.000193 0.0314 0.21 0.2 Iron status biomarkers; chr3:133763386 chr3:133760300~133762363:+ LIHC cis rs62184315 0.575 rs256546 ENSG00000273240.1 RP11-455J20.3 -3.77 0.000193 0.0314 -0.24 -0.2 Alcohol dependence (age at onset); chr2:189886437 chr2:189763859~189764456:- LIHC cis rs4144027 0.904 rs10438242 ENSG00000258914.1 CTD-2134A5.3 3.77 0.000193 0.0314 0.22 0.2 Blood metabolite levels; chr14:103878738 chr14:103875055~103877478:+ LIHC cis rs494562 0.73 rs313204 ENSG00000234155.1 RP11-30P6.6 -3.77 0.000193 0.0314 -0.42 -0.2 Metabolic traits;Blood metabolite levels; chr6:85404578 chr6:85387219~85390186:- LIHC cis rs2243480 1 rs13247184 ENSG00000226002.1 RP11-460N20.5 -3.77 0.000193 0.0314 -0.3 -0.2 Diabetic kidney disease; chr7:65893941 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs35283677 ENSG00000226002.1 RP11-460N20.5 -3.77 0.000193 0.0314 -0.3 -0.2 Diabetic kidney disease; chr7:65894246 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs35421653 ENSG00000226002.1 RP11-460N20.5 -3.77 0.000193 0.0314 -0.3 -0.2 Diabetic kidney disease; chr7:65898442 chr7:65084103~65100232:+ LIHC cis rs12681287 0.547 rs7465511 ENSG00000254088.1 SLC2A3P4 3.77 0.000193 0.0314 0.24 0.2 Caudate activity during reward; chr8:86509252 chr8:86503591~86505061:+ LIHC cis rs875971 0.522 rs1880556 ENSG00000237310.1 GS1-124K5.4 3.77 0.000193 0.0314 0.2 0.2 Aortic root size; chr7:65967557 chr7:66493706~66495474:+ LIHC cis rs6504622 0.537 rs1618989 ENSG00000263766.4 RP11-580I16.2 -3.77 0.000193 0.0314 -0.24 -0.2 Orofacial clefts; chr17:46916342 chr17:47603860~47649420:- LIHC cis rs13217239 0.572 rs9379958 ENSG00000241549.7 GUSBP2 -3.77 0.000193 0.0314 -0.2 -0.2 Schizophrenia; chr6:27098384 chr6:26871484~26956554:- LIHC cis rs13217239 0.646 rs9393789 ENSG00000241549.7 GUSBP2 -3.77 0.000193 0.0314 -0.2 -0.2 Schizophrenia; chr6:27099249 chr6:26871484~26956554:- LIHC cis rs13217239 0.646 rs6456767 ENSG00000241549.7 GUSBP2 -3.77 0.000193 0.0314 -0.2 -0.2 Schizophrenia; chr6:27102764 chr6:26871484~26956554:- LIHC cis rs17711722 0.727 rs781151 ENSG00000273024.4 INTS4P2 -3.77 0.000193 0.0314 -0.24 -0.2 Calcium levels; chr7:66014891 chr7:65647864~65715661:+ LIHC cis rs27434 0.607 rs26654 ENSG00000272109.1 CTD-2260A17.3 -3.77 0.000193 0.0314 -0.24 -0.2 Ankylosing spondylitis; chr5:96804664 chr5:96804353~96806105:+ LIHC cis rs2237234 0.542 rs7755997 ENSG00000124549.13 BTN2A3P 3.77 0.000193 0.0314 0.19 0.2 Autism spectrum disorder or schizophrenia; chr6:26482820 chr6:26421391~26432383:+ LIHC cis rs4834770 0.746 rs2389747 ENSG00000245958.5 RP11-33B1.1 -3.77 0.000193 0.0315 -0.19 -0.2 Blood protein levels; chr4:119314947 chr4:119454791~119552025:+ LIHC cis rs4834770 0.717 rs1022146 ENSG00000245958.5 RP11-33B1.1 -3.77 0.000193 0.0315 -0.19 -0.2 Blood protein levels; chr4:119314948 chr4:119454791~119552025:+ LIHC cis rs2303282 0.664 rs2432540 ENSG00000274031.1 RP11-413H22.3 3.77 0.000193 0.0315 0.24 0.2 Breast cancer; chr16:56385716 chr16:56465642~56466162:- LIHC cis rs9487094 0.744 rs12661287 ENSG00000260273.1 RP11-425D10.10 3.77 0.000193 0.0315 0.28 0.2 Height; chr6:109732047 chr6:109382795~109383666:+ LIHC cis rs9595908 0.709 rs3213532 ENSG00000212293.1 SNORA16 3.77 0.000193 0.0315 0.23 0.2 Body mass index; chr13:32773550 chr13:32420390~32420516:- LIHC cis rs853679 1 rs853679 ENSG00000204709.4 LINC01556 3.77 0.000194 0.0315 0.33 0.2 Depression; chr6:28329086 chr6:28943877~28944537:+ LIHC cis rs853679 1 rs6901575 ENSG00000219392.1 RP1-265C24.5 -3.77 0.000194 0.0315 -0.35 -0.2 Depression; chr6:28283207 chr6:28115628~28116551:+ LIHC cis rs10829156 0.786 rs7093907 ENSG00000225527.1 RP11-383B4.4 -3.77 0.000194 0.0315 -0.34 -0.2 Sudden cardiac arrest; chr10:18587225 chr10:18531849~18533336:- LIHC cis rs2439831 0.681 rs511673 ENSG00000166763.7 STRCP1 3.77 0.000194 0.0315 0.28 0.2 Lung cancer in ever smokers; chr15:43326665 chr15:43699488~43718184:- LIHC cis rs13113518 0.812 rs4865003 ENSG00000272969.1 RP11-528I4.2 3.77 0.000194 0.0315 0.22 0.2 Height; chr4:55514802 chr4:55547112~55547889:+ LIHC cis rs13113518 0.756 rs12510275 ENSG00000272969.1 RP11-528I4.2 3.77 0.000194 0.0315 0.22 0.2 Height; chr4:55516548 chr4:55547112~55547889:+ LIHC cis rs13113518 0.812 rs12510327 ENSG00000272969.1 RP11-528I4.2 3.77 0.000194 0.0315 0.22 0.2 Height; chr4:55516744 chr4:55547112~55547889:+ LIHC cis rs13113518 0.812 rs11939580 ENSG00000272969.1 RP11-528I4.2 3.77 0.000194 0.0315 0.22 0.2 Height; chr4:55517185 chr4:55547112~55547889:+ LIHC cis rs3749237 0.595 rs4855873 ENSG00000270441.1 RP11-694I15.7 -3.77 0.000194 0.0315 -0.28 -0.2 Resting heart rate; chr3:49421681 chr3:49140086~49160851:- LIHC cis rs3749237 0.595 rs1464566 ENSG00000270441.1 RP11-694I15.7 -3.77 0.000194 0.0315 -0.28 -0.2 Resting heart rate; chr3:49421943 chr3:49140086~49160851:- LIHC cis rs7560272 0.502 rs4513320 ENSG00000273245.1 RP11-434P11.2 -3.77 0.000194 0.0315 -0.24 -0.2 Schizophrenia; chr2:73693614 chr2:73750256~73750786:- LIHC cis rs6445975 0.715 rs4681836 ENSG00000272360.1 RP11-359I18.5 -3.77 0.000194 0.0315 -0.24 -0.2 Systemic lupus erythematosus; chr3:58281560 chr3:58490830~58491291:- LIHC cis rs12468226 0.938 rs13392645 ENSG00000226261.1 AC064836.3 3.77 0.000194 0.0315 0.31 0.2 Urate levels; chr2:202270116 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs7568159 ENSG00000226261.1 AC064836.3 3.77 0.000194 0.0315 0.31 0.2 Urate levels; chr2:202286226 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs7585867 ENSG00000226261.1 AC064836.3 3.77 0.000194 0.0315 0.31 0.2 Urate levels; chr2:202287040 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs58834901 ENSG00000226261.1 AC064836.3 3.77 0.000194 0.0315 0.31 0.2 Urate levels; chr2:202288169 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs1474002 ENSG00000226261.1 AC064836.3 3.77 0.000194 0.0315 0.31 0.2 Urate levels; chr2:202290195 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs6753044 ENSG00000226261.1 AC064836.3 3.77 0.000194 0.0315 0.31 0.2 Urate levels; chr2:202300710 chr2:202336024~202336727:- LIHC cis rs12468226 0.938 rs55681656 ENSG00000226261.1 AC064836.3 3.77 0.000194 0.0315 0.31 0.2 Urate levels; chr2:202319041 chr2:202336024~202336727:- LIHC cis rs4964805 1 rs73192052 ENSG00000257681.1 RP11-341G23.4 3.77 0.000194 0.0315 0.21 0.2 Attention deficit hyperactivity disorder; chr12:103797076 chr12:103746315~103768858:- LIHC cis rs4879656 0.593 rs10448231 ENSG00000225693.1 LAGE3P1 -3.77 0.000194 0.0315 -0.26 -0.2 Menopause (age at onset); chr9:33034053 chr9:33019682~33020165:- LIHC cis rs481331 1 rs481331 ENSG00000185904.10 LINC00839 -3.77 0.000194 0.0315 -0.38 -0.2 Systemic juvenile idiopathic arthritis; chr10:42507600 chr10:42475543~42495336:+ LIHC cis rs481331 0.867 rs671528 ENSG00000185904.10 LINC00839 -3.77 0.000194 0.0315 -0.38 -0.2 Systemic juvenile idiopathic arthritis; chr10:42507602 chr10:42475543~42495336:+ LIHC cis rs481331 0.866 rs210236 ENSG00000185904.10 LINC00839 -3.77 0.000194 0.0315 -0.38 -0.2 Systemic juvenile idiopathic arthritis; chr10:42517245 chr10:42475543~42495336:+ LIHC cis rs2658782 0.789 rs2605574 ENSG00000279684.1 RP11-755E23.2 -3.77 0.000194 0.0315 -0.32 -0.2 Pulmonary function decline; chr11:93403278 chr11:93286629~93288903:- LIHC cis rs2348418 0.832 rs1552760 ENSG00000247934.4 RP11-967K21.1 3.77 0.000194 0.0315 0.18 0.2 Lung function (FEV1);Lung function (FVC); chr12:28383884 chr12:28163298~28190738:- LIHC cis rs7915414 0.543 rs2093434 ENSG00000230338.1 MTND4P19 3.77 0.000194 0.0315 0.24 0.2 Clopidogrel active metabolite levels; chr10:94879100 chr10:94774156~94774633:- LIHC cis rs6471393 0.929 rs7016930 ENSG00000253848.1 RP11-10N23.5 3.77 0.000194 0.0315 0.22 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93743185 chr8:93741193~93744534:+ LIHC cis rs11159086 0.793 rs11621693 ENSG00000270000.1 RP3-449M8.9 3.77 0.000194 0.0315 0.29 0.2 Advanced glycation end-product levels; chr14:74472631 chr14:74471930~74472360:- LIHC cis rs2348418 0.798 rs7309905 ENSG00000247934.4 RP11-967K21.1 3.77 0.000194 0.0315 0.18 0.2 Lung function (FEV1);Lung function (FVC); chr12:28373473 chr12:28163298~28190738:- LIHC cis rs951005 0.564 rs2937382 ENSG00000281491.1 DNAJB5-AS1 -3.77 0.000194 0.0315 -0.37 -0.2 Rheumatoid arthritis; chr9:34726421 chr9:34985410~34989379:- LIHC cis rs951005 0.808 rs1810820 ENSG00000281491.1 DNAJB5-AS1 -3.77 0.000194 0.0315 -0.37 -0.2 Rheumatoid arthritis; chr9:34726527 chr9:34985410~34989379:- LIHC cis rs9303280 0.618 rs4065986 ENSG00000264968.1 RP11-387H17.4 -3.77 0.000194 0.0315 -0.2 -0.2 Self-reported allergy; chr17:39946388 chr17:39927742~39939601:+ LIHC cis rs4763879 0.593 rs7960328 ENSG00000256673.1 RP11-599J14.2 3.77 0.000194 0.0315 0.2 0.2 Type 1 diabetes; chr12:9699584 chr12:9398355~9414851:- LIHC cis rs803923 0.544 rs803930 ENSG00000230894.1 RP11-67K19.3 -3.77 0.000194 0.0315 -0.26 -0.2 Lung function (FEV1/FVC); chr9:116696652 chr9:116568449~116586328:+ LIHC cis rs6480314 1 rs3814184 ENSG00000233590.1 RP11-153K11.3 -3.77 0.000194 0.0315 -0.32 -0.2 Optic nerve measurement (disc area); chr10:68206494 chr10:68233251~68242379:- LIHC cis rs6745190 0.953 rs10930950 ENSG00000236153.1 AC104076.3 3.77 0.000194 0.0315 0.26 0.2 White blood cell count; chr2:181039677 chr2:180979427~180980090:- LIHC cis rs1005277 0.579 rs2474595 ENSG00000099251.13 HSD17B7P2 -3.77 0.000194 0.0315 -0.23 -0.2 Extrinsic epigenetic age acceleration; chr10:38137854 chr10:38356380~38378505:+ LIHC cis rs4144027 0.791 rs11160770 ENSG00000258534.1 CTD-2134A5.4 -3.77 0.000194 0.0315 -0.22 -0.2 Blood metabolite levels; chr14:103895954 chr14:103854366~103880111:- LIHC cis rs7734985 0.587 rs4355545 ENSG00000250551.1 RP11-254I22.1 -3.77 0.000194 0.0316 -0.23 -0.2 IgG glycosylation; chr5:96260990 chr5:96050115~96215519:+ LIHC cis rs453301 0.686 rs3989373 ENSG00000253893.2 FAM85B 3.77 0.000194 0.0316 0.27 0.2 Joint mobility (Beighton score); chr8:9053798 chr8:8167819~8226614:- LIHC cis rs17376456 0.825 rs6874766 ENSG00000251023.1 RP11-549J18.1 3.77 0.000194 0.0316 0.42 0.2 Diabetic retinopathy; chr5:93878101 chr5:93860669~93863825:- LIHC cis rs7849270 1 rs3124512 ENSG00000268707.1 RP11-247A12.7 3.77 0.000194 0.0316 0.21 0.2 Blood metabolite ratios; chr9:129141602 chr9:129170434~129170940:+ LIHC cis rs8031584 0.697 rs8036176 ENSG00000247728.2 RP11-932O9.7 -3.77 0.000194 0.0316 -0.29 -0.2 Huntington's disease progression; chr15:30883066 chr15:30616998~30625773:- LIHC cis rs2243480 1 rs160652 ENSG00000228409.4 CCT6P1 3.77 0.000194 0.0316 0.22 0.2 Diabetic kidney disease; chr7:66073444 chr7:65751142~65763354:+ LIHC cis rs1344653 0.738 rs12478491 ENSG00000236204.4 LINC01376 -3.77 0.000194 0.0316 -0.24 -0.2 Pulse pressure; chr2:19553563 chr2:18986451~19346748:- LIHC cis rs2299116 0.785 rs35010731 ENSG00000225264.3 ZNRF2P2 3.77 0.000194 0.0316 0.23 0.2 Serum thyroid-stimulating hormone levels; chr7:28753788 chr7:29598795~29685255:- LIHC cis rs10992797 0.509 rs10992796 ENSG00000227603.1 RP11-165J3.6 -3.77 0.000195 0.0316 -0.23 -0.2 Intelligence (multi-trait analysis); chr9:93598623 chr9:93435332~93437121:- LIHC cis rs673078 0.66 rs61943365 ENSG00000275759.1 RP11-131L12.3 -3.77 0.000195 0.0316 -0.25 -0.2 Glucose homeostasis traits; chr12:118339166 chr12:118428281~118428870:+ LIHC cis rs4730430 0.515 rs6943600 ENSG00000226965.1 AC003088.1 3.77 0.000195 0.0316 0.27 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr7:110492545 chr7:110432239~110534754:- LIHC cis rs751728 0.687 rs9357164 ENSG00000204188.6 GGNBP1 3.77 0.000195 0.0316 0.25 0.2 Crohn's disease; chr6:33793244 chr6:33540046~33589026:+ LIHC cis rs2808510 0.74 rs71633898 ENSG00000230623.2 RP11-469A15.2 -3.77 0.000195 0.0316 -0.23 -0.2 Myopia; chr1:200341770 chr1:200473920~200478293:+ LIHC cis rs5742933 0.948 rs7592066 ENSG00000253559.1 OSGEPL1-AS1 3.77 0.000195 0.0316 0.26 0.2 Ferritin levels; chr2:189778792 chr2:189762704~189765556:+ LIHC cis rs5742933 0.779 rs7595020 ENSG00000253559.1 OSGEPL1-AS1 3.77 0.000195 0.0316 0.26 0.2 Ferritin levels; chr2:189778950 chr2:189762704~189765556:+ LIHC cis rs3812762 0.783 rs34524863 ENSG00000254860.4 TMEM9B-AS1 3.77 0.000195 0.0316 0.23 0.2 Hypospadias; chr11:8755861 chr11:8964675~8977527:+ LIHC cis rs516805 0.748 rs12211993 ENSG00000279453.1 RP3-425C14.4 3.77 0.000195 0.0316 0.31 0.2 Lymphocyte counts; chr6:122570216 chr6:122436789~122439223:- LIHC cis rs6565180 0.926 rs12446288 ENSG00000273724.1 RP11-347C12.12 3.77 0.000195 0.0316 0.25 0.2 Tonsillectomy; chr16:30377388 chr16:30336400~30343336:+ LIHC cis rs2301573 1 rs11707404 ENSG00000251474.5 RPL32P3 3.77 0.000195 0.0317 0.23 0.2 Hip circumference; chr3:129587361 chr3:129382922~129399655:- LIHC cis rs1799949 1 rs8176273 ENSG00000267681.1 CTD-3199J23.6 -3.77 0.000195 0.0317 -0.19 -0.2 Menopause (age at onset); chr17:43059636 chr17:43144956~43145255:+ LIHC cis rs13217239 0.608 rs6930508 ENSG00000241549.7 GUSBP2 -3.77 0.000195 0.0317 -0.21 -0.2 Schizophrenia; chr6:27085363 chr6:26871484~26956554:- LIHC cis rs13217239 0.646 rs2142685 ENSG00000241549.7 GUSBP2 -3.77 0.000195 0.0317 -0.21 -0.2 Schizophrenia; chr6:27086718 chr6:26871484~26956554:- LIHC cis rs74181299 0.684 rs1228 ENSG00000225889.6 AC074289.1 3.77 0.000195 0.0317 0.22 0.2 Pulse pressure; chr2:65084421 chr2:64143239~64252859:+ LIHC cis rs7712401 0.601 rs1990890 ENSG00000263432.2 RN7SL689P 3.77 0.000195 0.0317 0.29 0.2 Mean platelet volume; chr5:122847275 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs154506 ENSG00000263432.2 RN7SL689P 3.77 0.000195 0.0317 0.29 0.2 Mean platelet volume; chr5:122867086 chr5:123022487~123022783:- LIHC cis rs10760123 1 rs10760123 ENSG00000226752.6 PSMD5-AS1 -3.77 0.000195 0.0317 -0.22 -0.2 Allergic disease (asthma, hay fever or eczema); chr9:120888256 chr9:120824828~120854385:+ LIHC cis rs2613514 1 rs74256103 ENSG00000204277.1 RP11-219G17.4 3.77 0.000195 0.0317 0.31 0.2 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78073692 chr17:78261349~78278492:- LIHC cis rs12908161 1 rs12911736 ENSG00000259728.4 LINC00933 3.77 0.000195 0.0317 0.29 0.2 Schizophrenia; chr15:84696777 chr15:84570649~84580175:+ LIHC cis rs11098499 0.863 rs7699064 ENSG00000250412.1 KLHL2P1 -3.77 0.000195 0.0317 -0.23 -0.2 Corneal astigmatism; chr4:119507154 chr4:119334329~119378233:+ LIHC cis rs6142102 0.886 rs6059583 ENSG00000275784.1 RP5-1125A11.6 -3.77 0.000195 0.0317 -0.23 -0.2 Skin pigmentation; chr20:33944308 chr20:33989480~33991818:- LIHC cis rs11089937 0.597 rs4821773 ENSG00000211639.2 IGLV4-60 3.77 0.000195 0.0317 0.17 0.2 Periodontitis (PAL4Q3); chr22:22131434 chr22:22162199~22162681:+ LIHC cis rs12586317 0.62 rs12437439 ENSG00000257307.1 RP11-317N8.4 -3.77 0.000195 0.0317 -0.24 -0.2 Psoriasis; chr14:35116463 chr14:35881001~35881709:+ LIHC cis rs17656349 0.664 rs6885505 ENSG00000269936.3 RP11-394O4.5 -3.77 0.000196 0.0318 -0.23 -0.2 Inflammatory bowel disease;Ulcerative colitis; chr5:150229216 chr5:149430286~149432834:+ LIHC cis rs2070488 0.896 rs11914389 ENSG00000229589.1 ACVR2B-AS1 3.77 0.000196 0.0318 0.22 0.2 Electrocardiographic conduction measures; chr3:38485724 chr3:38451027~38454820:- LIHC cis rs1799949 0.965 rs1842147 ENSG00000267681.1 CTD-3199J23.6 -3.77 0.000196 0.0318 -0.2 -0.2 Menopause (age at onset); chr17:43357824 chr17:43144956~43145255:+ LIHC cis rs875971 1 rs11971949 ENSG00000237310.1 GS1-124K5.4 -3.77 0.000196 0.0318 -0.18 -0.2 Aortic root size; chr7:66161027 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs11974264 ENSG00000237310.1 GS1-124K5.4 -3.77 0.000196 0.0318 -0.18 -0.2 Aortic root size; chr7:66182595 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs1540651 ENSG00000237310.1 GS1-124K5.4 -3.77 0.000196 0.0318 -0.18 -0.2 Aortic root size; chr7:66185134 chr7:66493706~66495474:+ LIHC cis rs875971 0.898 rs6977501 ENSG00000237310.1 GS1-124K5.4 -3.77 0.000196 0.0318 -0.18 -0.2 Aortic root size; chr7:66228355 chr7:66493706~66495474:+ LIHC cis rs875971 0.965 rs6971509 ENSG00000237310.1 GS1-124K5.4 -3.77 0.000196 0.0318 -0.18 -0.2 Aortic root size; chr7:66249983 chr7:66493706~66495474:+ LIHC cis rs1003719 0.715 rs7277820 ENSG00000272948.2 AP001412.1 -3.77 0.000196 0.0318 -0.22 -0.2 Eye color traits; chr21:37208008 chr21:37267784~37268497:+ LIHC cis rs1003719 0.715 rs2835675 ENSG00000272948.2 AP001412.1 -3.77 0.000196 0.0318 -0.22 -0.2 Eye color traits; chr21:37210514 chr21:37267784~37268497:+ LIHC cis rs2115630 1 rs11854313 ENSG00000189136.7 UBE2Q2P1 -3.77 0.000196 0.0318 -0.16 -0.2 P wave terminal force; chr15:84760817 chr15:84526781~84571216:- LIHC cis rs11064837 0.523 rs7967558 ENSG00000248636.5 RP11-768F21.1 3.77 0.000196 0.0318 0.34 0.2 Schizophrenia; chr12:119659201 chr12:119387987~119668079:- LIHC cis rs11064837 0.523 rs6490266 ENSG00000248636.5 RP11-768F21.1 3.77 0.000196 0.0318 0.34 0.2 Schizophrenia; chr12:119667935 chr12:119387987~119668079:- LIHC cis rs703842 0.616 rs871871 ENSG00000270039.1 RP11-571M6.17 -3.77 0.000196 0.0318 -0.29 -0.2 Multiple sclerosis; chr12:57825898 chr12:57803838~57804415:+ LIHC cis rs9595908 0.785 rs17515873 ENSG00000212293.1 SNORA16 3.77 0.000196 0.0318 0.22 0.2 Body mass index; chr13:32647711 chr13:32420390~32420516:- LIHC cis rs1494950 0.744 rs4367169 ENSG00000214846.4 RP11-115L11.1 3.76 0.000196 0.0318 0.41 0.2 Political ideology; chr4:15028179 chr4:15730962~15731627:- LIHC cis rs12692119 0.536 rs11694347 ENSG00000272789.1 RP11-286H15.1 -3.76 0.000196 0.0318 -0.48 -0.2 Pelvic organ prolapse (moderate/severe); chr2:126873033 chr2:127625997~127626848:- LIHC cis rs28829049 0.861 rs10492996 ENSG00000270728.1 RP4-657E11.10 -3.76 0.000196 0.0318 -0.17 -0.2 QRS duration in Tripanosoma cruzi seropositivity; chr1:19039058 chr1:19297080~19297903:+ LIHC cis rs55966801 0.732 rs117558678 ENSG00000279672.1 CMB9-55F22.1 3.76 0.000196 0.0318 0.34 0.2 Plateletcrit; chr11:270330 chr11:779617~780755:+ LIHC cis rs1939012 0.71 rs17099443 ENSG00000281655.1 RP11-817J15.3 -3.76 0.000196 0.0318 -0.27 -0.2 Epilepsy; chr11:102721859 chr11:102681310~102683913:+ LIHC cis rs11096990 0.855 rs75746161 ENSG00000249685.1 RP11-360F5.3 -3.76 0.000196 0.0318 -0.27 -0.2 Cognitive function; chr4:39167481 chr4:39133913~39135608:+ LIHC cis rs2159324 0.868 rs11672867 ENSG00000267348.2 CTB-179K24.3 3.76 0.000196 0.0318 0.22 0.2 Quantitative traits; chr19:45192860 chr19:45076510~45090391:- LIHC cis rs7474896 0.832 rs12570943 ENSG00000263064.2 RP11-291L22.7 3.76 0.000196 0.0318 0.28 0.2 Obesity (extreme); chr10:37733541 chr10:38448689~38448949:+ LIHC cis rs8087799 0.822 rs34470985 ENSG00000273232.1 RP11-370A5.2 3.76 0.000196 0.0318 0.24 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22680163 chr18:22882825~22883357:- LIHC cis rs10256972 0.63 rs10282584 ENSG00000199023.2 MIR339 -3.76 0.000196 0.0319 -0.23 -0.2 Endometriosis;Longevity; chr7:1041806 chr7:1022935~1023045:- LIHC cis rs6787172 0.811 rs7620927 ENSG00000272087.1 RP11-379F4.7 3.76 0.000196 0.0319 0.22 0.2 Subjective well-being; chr3:158528094 chr3:158693120~158693768:- LIHC cis rs2599510 0.693 rs2754514 ENSG00000276334.1 AL133243.1 3.76 0.000197 0.0319 0.23 0.2 Interleukin-18 levels; chr2:32563769 chr2:32521927~32523547:+ LIHC cis rs875971 0.54 rs1723268 ENSG00000237310.1 GS1-124K5.4 3.76 0.000197 0.0319 0.2 0.2 Aortic root size; chr7:66008093 chr7:66493706~66495474:+ LIHC cis rs1318937 0.764 rs2129947 ENSG00000224660.1 SH3BP5-AS1 3.76 0.000197 0.0319 0.18 0.2 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15180755 chr3:15254184~15264493:+ LIHC cis rs1115240 1 rs1950408 ENSG00000257842.4 NOVA1-AS1 -3.76 0.000197 0.0319 -0.18 -0.2 Educational attainment (years of education); chr14:26606208 chr14:26598412~26806467:+ LIHC cis rs1115240 0.947 rs2224039 ENSG00000257842.4 NOVA1-AS1 -3.76 0.000197 0.0319 -0.18 -0.2 Educational attainment (years of education); chr14:26606287 chr14:26598412~26806467:+ LIHC cis rs1115240 0.841 rs12589509 ENSG00000257842.4 NOVA1-AS1 -3.76 0.000197 0.0319 -0.18 -0.2 Educational attainment (years of education); chr14:26609965 chr14:26598412~26806467:+ LIHC cis rs1115240 1 rs2224038 ENSG00000257842.4 NOVA1-AS1 -3.76 0.000197 0.0319 -0.18 -0.2 Educational attainment (years of education); chr14:26610754 chr14:26598412~26806467:+ LIHC cis rs9487094 1 rs9480955 ENSG00000260273.1 RP11-425D10.10 3.76 0.000197 0.0319 0.24 0.2 Height; chr6:109423330 chr6:109382795~109383666:+ LIHC cis rs9487094 1 rs9320287 ENSG00000260273.1 RP11-425D10.10 3.76 0.000197 0.0319 0.24 0.2 Height; chr6:109423487 chr6:109382795~109383666:+ LIHC cis rs73186030 0.92 rs2001548 ENSG00000272758.4 RP11-299J3.8 3.76 0.000197 0.0319 0.37 0.2 Serum parathyroid hormone levels; chr3:122313942 chr3:122416207~122443180:+ LIHC cis rs11098499 0.604 rs2389887 ENSG00000260091.1 RP11-33B1.4 -3.76 0.000197 0.0319 -0.14 -0.2 Corneal astigmatism; chr4:119649489 chr4:119409333~119410233:+ LIHC cis rs1023500 1 rs1023497 ENSG00000227370.1 RP4-669P10.19 3.76 0.000197 0.0319 0.26 0.2 Schizophrenia; chr22:41944504 chr22:42132543~42132998:+ LIHC cis rs2658782 0.724 rs2605627 ENSG00000279684.1 RP11-755E23.2 -3.76 0.000197 0.0319 -0.29 -0.2 Pulmonary function decline; chr11:93526349 chr11:93286629~93288903:- LIHC cis rs1838105 0.51 rs740616 ENSG00000263766.4 RP11-580I16.2 3.76 0.000197 0.0319 0.23 0.2 Nonsyndromic cleft lip with cleft palate; chr17:46908399 chr17:47603860~47649420:- LIHC cis rs6471393 0.929 rs7017036 ENSG00000253848.1 RP11-10N23.5 3.76 0.000197 0.0319 0.22 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93743216 chr8:93741193~93744534:+ LIHC cis rs2243480 1 rs4718334 ENSG00000228409.4 CCT6P1 -3.76 0.000197 0.0319 -0.21 -0.2 Diabetic kidney disease; chr7:66324467 chr7:65751142~65763354:+ LIHC cis rs694739 0.628 rs617051 ENSG00000236935.1 AP003774.1 3.76 0.000197 0.0319 0.21 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64366166 chr11:64325050~64329504:- LIHC cis rs694739 0.628 rs508168 ENSG00000236935.1 AP003774.1 3.76 0.000197 0.0319 0.21 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64367963 chr11:64325050~64329504:- LIHC cis rs694739 0.595 rs11606015 ENSG00000236935.1 AP003774.1 3.76 0.000197 0.0319 0.21 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64369405 chr11:64325050~64329504:- LIHC cis rs694739 0.628 rs11606081 ENSG00000236935.1 AP003774.1 3.76 0.000197 0.0319 0.21 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64370403 chr11:64325050~64329504:- LIHC cis rs12681366 0.881 rs10464877 ENSG00000253704.1 RP11-267M23.4 3.76 0.000197 0.032 0.23 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94385615 chr8:94553722~94569745:+ LIHC cis rs2749097 1 rs11208268 ENSG00000244256.3 RN7SL130P -3.76 0.000197 0.032 -0.25 -0.2 Alcohol consumption (transferrin glycosylation); chr1:63672553 chr1:63655743~63656047:+ LIHC cis rs2072510 0.9 rs2110762 ENSG00000257878.1 RP11-256L6.3 -3.76 0.000197 0.032 -0.18 -0.2 Metabolite levels (small molecules and protein measures); chr12:96008756 chr12:95996521~96011489:+ LIHC cis rs7809950 0.817 rs2712195 ENSG00000238832.1 snoU109 -3.76 0.000197 0.032 -0.25 -0.2 Coronary artery disease; chr7:107487051 chr7:107603363~107603507:+ LIHC cis rs7809950 0.731 rs2712196 ENSG00000238832.1 snoU109 -3.76 0.000197 0.032 -0.25 -0.2 Coronary artery disease; chr7:107488352 chr7:107603363~107603507:+ LIHC cis rs943466 0.793 rs59137082 ENSG00000204188.6 GGNBP1 -3.76 0.000197 0.032 -0.29 -0.2 Body mass index (joint analysis main effects and physical activity interaction);Body mass index; chr6:33764588 chr6:33540046~33589026:+ LIHC cis rs4925386 1 rs2151512 ENSG00000273619.1 RP5-908M14.9 3.76 0.000197 0.032 0.16 0.2 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62338439 chr20:62386303~62386970:- LIHC cis rs11098499 0.954 rs6847248 ENSG00000260091.1 RP11-33B1.4 -3.76 0.000197 0.032 -0.15 -0.2 Corneal astigmatism; chr4:119304800 chr4:119409333~119410233:+ LIHC cis rs9450351 0.744 rs9353339 ENSG00000203875.9 SNHG5 3.76 0.000197 0.032 0.4 0.2 Interferon gamma-induced protein 10 levels; chr6:85794480 chr6:85660950~85678736:- LIHC cis rs67311347 1 rs2371186 ENSG00000223797.4 ENTPD3-AS1 3.76 0.000197 0.032 0.16 0.2 Renal cell carcinoma; chr3:40447222 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs9827461 ENSG00000223797.4 ENTPD3-AS1 3.76 0.000197 0.032 0.16 0.2 Renal cell carcinoma; chr3:40447860 chr3:40313802~40453329:- LIHC cis rs6142102 0.961 rs6088361 ENSG00000275784.1 RP5-1125A11.6 -3.76 0.000197 0.032 -0.23 -0.2 Skin pigmentation; chr20:33969520 chr20:33989480~33991818:- LIHC cis rs7665090 0.87 rs228614 ENSG00000246560.2 RP11-10L12.4 -3.76 0.000198 0.032 -0.24 -0.2 Primary biliary cholangitis; chr4:102657480 chr4:102828055~102844075:+ LIHC cis rs673078 0.66 rs61945190 ENSG00000275759.1 RP11-131L12.3 -3.76 0.000198 0.032 -0.37 -0.2 Glucose homeostasis traits; chr12:118231345 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs7977403 ENSG00000275759.1 RP11-131L12.3 -3.76 0.000198 0.032 -0.37 -0.2 Glucose homeostasis traits; chr12:118233446 chr12:118428281~118428870:+ LIHC cis rs1987511 1 rs11253092 ENSG00000231039.2 RP11-445P17.3 -3.76 0.000198 0.032 -0.25 -0.2 Intelligence; chr10:5307132 chr10:5234358~5263408:+ LIHC cis rs1987511 0.963 rs11253093 ENSG00000231039.2 RP11-445P17.3 -3.76 0.000198 0.032 -0.25 -0.2 Intelligence; chr10:5307134 chr10:5234358~5263408:+ LIHC cis rs875971 0.8 rs427557 ENSG00000237310.1 GS1-124K5.4 3.76 0.000198 0.032 0.18 0.2 Aortic root size; chr7:66054263 chr7:66493706~66495474:+ LIHC cis rs367615 0.506 rs1428932 ENSG00000249476.1 CTD-2587M2.1 -3.76 0.000198 0.032 -0.24 -0.2 Colorectal cancer (SNP x SNP interaction); chr5:109456778 chr5:109237120~109326369:- LIHC cis rs3764021 0.527 rs11052426 ENSG00000256673.1 RP11-599J14.2 -3.76 0.000198 0.032 -0.2 -0.2 Type 1 diabetes; chr12:9688330 chr12:9398355~9414851:- LIHC cis rs3764021 0.527 rs17806710 ENSG00000256673.1 RP11-599J14.2 -3.76 0.000198 0.032 -0.2 -0.2 Type 1 diabetes; chr12:9688368 chr12:9398355~9414851:- LIHC cis rs5743030 1 rs79444544 ENSG00000253559.1 OSGEPL1-AS1 -3.76 0.000198 0.032 -0.34 -0.2 Subcutaneous adipose tissue; chr2:189893806 chr2:189762704~189765556:+ LIHC cis rs5743030 1 rs16832158 ENSG00000253559.1 OSGEPL1-AS1 -3.76 0.000198 0.032 -0.34 -0.2 Subcutaneous adipose tissue; chr2:189893962 chr2:189762704~189765556:+ LIHC cis rs4658267 0.785 rs284188 ENSG00000203914.4 HSP90B3P 3.76 0.000198 0.032 0.29 0.2 Gestational age at birth (maternal effect); chr1:91768864 chr1:91642516~91644082:+ LIHC cis rs4879656 0.593 rs10971307 ENSG00000225693.1 LAGE3P1 3.76 0.000198 0.032 0.25 0.2 Menopause (age at onset); chr9:33009726 chr9:33019682~33020165:- LIHC cis rs4879656 0.569 rs10971308 ENSG00000225693.1 LAGE3P1 3.76 0.000198 0.032 0.25 0.2 Menopause (age at onset); chr9:33009727 chr9:33019682~33020165:- LIHC cis rs3204270 0.714 rs79243595 ENSG00000281517.1 Metazoa_SRP -3.76 0.000198 0.0321 -0.4 -0.2 Dental caries; chr17:81714190 chr17:81718849~81719095:- LIHC cis rs919433 0.963 rs4850787 ENSG00000231621.1 AC013264.2 3.76 0.000198 0.0321 0.18 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197317026 chr2:197197991~197199273:+ LIHC cis rs7867456 0.845 rs10964808 ENSG00000215221.2 UBA52P6 -3.76 0.000198 0.0321 -0.19 -0.2 Axial length; chr9:21033558 chr9:22012155~22012536:+ LIHC cis rs2658782 0.724 rs2658769 ENSG00000279684.1 RP11-755E23.2 -3.76 0.000198 0.0321 -0.29 -0.2 Pulmonary function decline; chr11:93518864 chr11:93286629~93288903:- LIHC cis rs854624 0.892 rs2702954 ENSG00000278690.1 RP11-104J23.2 3.76 0.000198 0.0321 0.43 0.2 Blood protein levels; chr17:36007697 chr17:36012504~36012891:+ LIHC cis rs854624 0.792 rs2687497 ENSG00000278690.1 RP11-104J23.2 3.76 0.000198 0.0321 0.43 0.2 Blood protein levels; chr17:36008126 chr17:36012504~36012891:+ LIHC cis rs10851478 0.692 rs7161744 ENSG00000276593.1 RP11-295H24.5 3.76 0.000198 0.0321 0.22 0.2 Oral cavity cancer; chr15:49580150 chr15:49353485~49354034:+ LIHC cis rs12681287 0.547 rs66808088 ENSG00000254088.1 SLC2A3P4 3.76 0.000198 0.0321 0.24 0.2 Caudate activity during reward; chr8:86508983 chr8:86503591~86505061:+ LIHC cis rs67601088 0.838 rs66713142 ENSG00000235669.1 AC004593.3 3.76 0.000198 0.0321 0.41 0.2 Pediatric bone mineral density (spine); chr7:29880333 chr7:29199540~29208970:- LIHC cis rs67601088 0.838 rs4496871 ENSG00000235669.1 AC004593.3 3.76 0.000198 0.0321 0.41 0.2 Pediatric bone mineral density (spine); chr7:29881228 chr7:29199540~29208970:- LIHC cis rs481331 0.866 rs11499093 ENSG00000185904.10 LINC00839 -3.76 0.000198 0.0321 -0.34 -0.2 Systemic juvenile idiopathic arthritis; chr10:42487342 chr10:42475543~42495336:+ LIHC cis rs8072100 0.576 rs12948299 ENSG00000228782.6 CTD-2026D20.3 3.76 0.000198 0.0321 0.25 0.2 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47325691 chr17:47450568~47492492:- LIHC cis rs151234 0.741 rs151229 ENSG00000259982.1 CDC37P1 -3.76 0.000198 0.0321 -0.47 -0.2 Platelet distribution width; chr16:28573616 chr16:28700294~28701540:- LIHC cis rs12817211 0.502 rs7294618 ENSG00000272368.2 RP4-605O3.4 -3.76 0.000198 0.0321 -0.22 -0.2 Colorectal or endometrial cancer; chr12:50119192 chr12:50112197~50165618:+ LIHC cis rs12817211 0.502 rs7961112 ENSG00000272368.2 RP4-605O3.4 -3.76 0.000198 0.0321 -0.22 -0.2 Colorectal or endometrial cancer; chr12:50119736 chr12:50112197~50165618:+ LIHC cis rs11018904 0.636 rs61903695 ENSG00000280385.1 AP000648.5 -3.76 0.000198 0.0321 -0.23 -0.2 Intelligence (multi-trait analysis); chr11:90189249 chr11:90193614~90198120:+ LIHC cis rs10129255 0.517 rs11625572 ENSG00000223648.3 IGHV3-64 3.76 0.000198 0.0321 0.15 0.2 Kawasaki disease; chr14:106656426 chr14:106643132~106658258:- LIHC cis rs2390582 0.524 rs34144413 ENSG00000231613.1 RP5-943J3.1 3.76 0.000198 0.0321 0.41 0.2 Coronary artery calcification; chr1:90234457 chr1:89788914~89790492:+ LIHC cis rs6456156 0.792 rs10946212 ENSG00000227598.1 RP1-167A14.2 -3.76 0.000198 0.0321 -0.2 -0.2 Primary biliary cholangitis; chr6:167102459 chr6:166969626~166999065:- LIHC cis rs6832769 0.961 rs11947623 ENSG00000272969.1 RP11-528I4.2 3.76 0.000198 0.0321 0.24 0.2 Personality dimensions; chr4:55483023 chr4:55547112~55547889:+ LIHC cis rs13434995 0.513 rs7698022 ENSG00000273257.1 RP11-177J6.1 3.76 0.000198 0.0321 0.32 0.2 Adiponectin levels; chr4:55541180 chr4:55387949~55388271:+ LIHC cis rs17772222 0.917 rs12431548 ENSG00000258789.1 RP11-507K2.3 -3.76 0.000199 0.0321 -0.24 -0.2 Coronary artery calcification; chr14:88635826 chr14:88551597~88552493:+ LIHC cis rs7809950 0.731 rs4730238 ENSG00000238832.1 snoU109 -3.76 0.000199 0.0321 -0.26 -0.2 Coronary artery disease; chr7:107414342 chr7:107603363~107603507:+ LIHC cis rs55966801 0.786 rs72865316 ENSG00000277290.1 RP11-326C3.16 -3.76 0.000199 0.0321 -0.26 -0.2 Plateletcrit; chr11:247028 chr11:243099~243483:- LIHC cis rs7945705 0.875 rs10769955 ENSG00000254860.4 TMEM9B-AS1 -3.76 0.000199 0.0321 -0.2 -0.2 Hemoglobin concentration; chr11:8763100 chr11:8964675~8977527:+ LIHC cis rs2301573 1 rs10934888 ENSG00000251474.5 RPL32P3 3.76 0.000199 0.0322 0.24 0.2 Hip circumference; chr3:129588348 chr3:129382922~129399655:- LIHC cis rs2301573 1 rs61319406 ENSG00000251474.5 RPL32P3 3.76 0.000199 0.0322 0.24 0.2 Hip circumference; chr3:129589114 chr3:129382922~129399655:- LIHC cis rs11098499 0.731 rs6846966 ENSG00000245958.5 RP11-33B1.1 -3.76 0.000199 0.0322 -0.2 -0.2 Corneal astigmatism; chr4:119372053 chr4:119454791~119552025:+ LIHC cis rs4879656 0.593 rs4879659 ENSG00000225693.1 LAGE3P1 3.76 0.000199 0.0322 0.25 0.2 Menopause (age at onset); chr9:33029470 chr9:33019682~33020165:- LIHC cis rs1115240 0.588 rs2877794 ENSG00000257842.4 NOVA1-AS1 3.76 0.000199 0.0322 0.2 0.2 Educational attainment (years of education); chr14:26605023 chr14:26598412~26806467:+ LIHC cis rs7976838 0.808 rs2711682 ENSG00000257443.1 RP11-150C16.1 -3.76 0.000199 0.0322 -0.52 -0.2 Response to zileuton treatment in asthma (FEV1 change interaction); chr12:59727151 chr12:58920639~59064238:+ LIHC cis rs2243480 1 rs6958420 ENSG00000228409.4 CCT6P1 -3.76 0.000199 0.0322 -0.21 -0.2 Diabetic kidney disease; chr7:66286184 chr7:65751142~65763354:+ LIHC cis rs875971 0.862 rs10274883 ENSG00000232559.3 GS1-124K5.12 -3.76 0.000199 0.0322 -0.15 -0.2 Aortic root size; chr7:66651104 chr7:66554588~66576923:- LIHC cis rs801193 0.569 rs881285 ENSG00000232559.3 GS1-124K5.12 -3.76 0.000199 0.0322 -0.15 -0.2 Aortic root size; chr7:66654433 chr7:66554588~66576923:- LIHC cis rs801193 0.569 rs3846973 ENSG00000232559.3 GS1-124K5.12 -3.76 0.000199 0.0322 -0.15 -0.2 Aortic root size; chr7:66655048 chr7:66554588~66576923:- LIHC cis rs801193 0.569 rs2013908 ENSG00000232559.3 GS1-124K5.12 -3.76 0.000199 0.0322 -0.15 -0.2 Aortic root size; chr7:66656082 chr7:66554588~66576923:- LIHC cis rs801193 0.548 rs2109297 ENSG00000232559.3 GS1-124K5.12 -3.76 0.000199 0.0322 -0.15 -0.2 Aortic root size; chr7:66657397 chr7:66554588~66576923:- LIHC cis rs801193 0.569 rs6978178 ENSG00000232559.3 GS1-124K5.12 -3.76 0.000199 0.0322 -0.15 -0.2 Aortic root size; chr7:66658097 chr7:66554588~66576923:- LIHC cis rs801193 0.591 rs721717 ENSG00000232559.3 GS1-124K5.12 -3.76 0.000199 0.0322 -0.15 -0.2 Aortic root size; chr7:66665305 chr7:66554588~66576923:- LIHC cis rs801193 0.569 rs6951302 ENSG00000232559.3 GS1-124K5.12 -3.76 0.000199 0.0322 -0.15 -0.2 Aortic root size; chr7:66667525 chr7:66554588~66576923:- LIHC cis rs240993 0.715 rs7776346 ENSG00000255389.1 C6orf3 3.76 0.000199 0.0322 0.23 0.2 Inflammatory skin disease;Psoriasis; chr6:111540162 chr6:111599875~111602295:+ LIHC cis rs10761256 0.806 rs10761252 ENSG00000227603.1 RP11-165J3.6 3.76 0.000199 0.0322 0.23 0.2 Itch intensity from mosquito bite adjusted by bite size; chr9:93662019 chr9:93435332~93437121:- LIHC cis rs10761256 0.778 rs7028306 ENSG00000227603.1 RP11-165J3.6 3.76 0.000199 0.0322 0.23 0.2 Itch intensity from mosquito bite adjusted by bite size; chr9:93663801 chr9:93435332~93437121:- LIHC cis rs10761256 0.806 rs10761254 ENSG00000227603.1 RP11-165J3.6 3.76 0.000199 0.0322 0.23 0.2 Itch intensity from mosquito bite adjusted by bite size; chr9:93664062 chr9:93435332~93437121:- LIHC cis rs875971 0.83 rs587360 ENSG00000237310.1 GS1-124K5.4 3.76 0.000199 0.0322 0.18 0.2 Aortic root size; chr7:66057711 chr7:66493706~66495474:+ LIHC cis rs17660992 0.716 rs8111426 ENSG00000273837.1 LLNLR-470E3.1 -3.76 0.000199 0.0322 -0.23 -0.2 Blood protein levels; chr19:51662110 chr19:51639478~51639931:- LIHC cis rs643506 0.845 rs7114594 ENSG00000230911.1 PPIHP1 -3.76 0.000199 0.0322 -0.27 -0.2 Breast cancer; chr11:111897389 chr11:112029858~112030367:- LIHC cis rs6787172 0.811 rs12637678 ENSG00000272087.1 RP11-379F4.7 3.76 0.000199 0.0323 0.22 0.2 Subjective well-being; chr3:158530833 chr3:158693120~158693768:- LIHC cis rs4356975 0.563 rs7439152 ENSG00000250919.1 RP11-813N20.3 -3.76 0.000199 0.0323 -0.2 -0.2 Obesity-related traits; chr4:69103288 chr4:69027831~69044578:+ LIHC cis rs3931020 0.772 rs1475396 ENSG00000272864.1 RP11-17E13.2 -3.76 0.000199 0.0323 -0.25 -0.2 Resistin levels; chr1:74776712 chr1:74698769~74699333:- LIHC cis rs2562456 0.917 rs9304987 ENSG00000268555.1 RP11-678G14.3 -3.76 0.000199 0.0323 -0.25 -0.2 Pain; chr19:21499472 chr19:21570822~21587322:- LIHC cis rs4934494 0.573 rs67157720 ENSG00000232936.4 RP11-80H5.2 3.76 0.000199 0.0323 0.23 0.2 Red blood cell count; chr10:89820415 chr10:89645282~89650667:+ LIHC cis rs10078 1 rs10078 ENSG00000221990.4 EXOC3-AS1 3.76 0.000199 0.0323 0.19 0.2 Fat distribution (HIV); chr5:437987 chr5:441498~443160:- LIHC cis rs739496 0.947 rs34368158 ENSG00000234608.6 MAPKAPK5-AS1 3.76 0.000199 0.0323 0.17 0.2 Platelet count; chr12:111408224 chr12:111839764~111842902:- LIHC cis rs1862618 0.671 rs2591958 ENSG00000271828.1 CTD-2310F14.1 -3.76 2e-04 0.0323 -0.26 -0.2 Initial pursuit acceleration; chr5:56943542 chr5:56927874~56929573:+ LIHC cis rs1862618 0.671 rs72644088 ENSG00000271828.1 CTD-2310F14.1 -3.76 2e-04 0.0323 -0.26 -0.2 Initial pursuit acceleration; chr5:56945192 chr5:56927874~56929573:+ LIHC cis rs4891159 0.79 rs72975925 ENSG00000265778.2 RP11-17M16.2 -3.76 2e-04 0.0323 -0.24 -0.2 Longevity; chr18:76431946 chr18:76491652~76493918:+ LIHC cis rs3934487 0.547 rs12034199 ENSG00000223956.1 RP4-710M16.2 -3.76 2e-04 0.0323 -0.21 -0.2 Reticulocyte count; chr1:55858869 chr1:56414963~56415966:+ LIHC cis rs757081 0.648 rs11024231 ENSG00000272034.1 SNORD14A -3.76 2e-04 0.0323 -0.21 -0.2 Systolic blood pressure; chr11:17265703 chr11:17074654~17074744:- LIHC cis rs950169 0.8 rs34302901 ENSG00000189136.7 UBE2Q2P1 3.76 2e-04 0.0323 0.19 0.2 Schizophrenia; chr15:84567712 chr15:84526781~84571216:- LIHC cis rs4938330 0.681 rs12271169 ENSG00000254851.1 RP11-109L13.1 3.76 2e-04 0.0323 0.26 0.2 Blood protein levels; chr11:117109305 chr11:117135528~117138582:+ LIHC cis rs12280210 0.655 rs76169968 ENSG00000254851.1 RP11-109L13.1 3.76 2e-04 0.0323 0.37 0.2 Lobe attachment (rater-scored or self-reported); chr11:117212250 chr11:117135528~117138582:+ LIHC cis rs6517329 0.538 rs4816521 ENSG00000231106.2 LINC01436 3.76 2e-04 0.0323 0.22 0.2 Schizophrenia; chr21:36138440 chr21:36005338~36007838:+ LIHC cis rs13028485 1 rs13028485 ENSG00000236449.1 AC018890.6 -3.76 2e-04 0.0323 -0.33 -0.2 Multiple myeloma (IgH translocation); chr2:173640196 chr2:174547141~174774827:+ LIHC cis rs12936587 0.536 rs8075153 ENSG00000223979.2 SMCR2 3.76 2e-04 0.0323 0.26 0.2 Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference; chr17:17719352 chr17:17674026~17677688:- LIHC cis rs1450985 0.864 rs17344417 ENSG00000280620.1 SCAANT1 -3.76 2e-04 0.0323 -0.28 -0.2 Breast cancer; chr3:64026861 chr3:63911518~63911772:- LIHC cis rs2976388 0.647 rs2585154 ENSG00000253741.1 CTD-2292P10.4 -3.76 2e-04 0.0323 -0.24 -0.2 Urinary tract infection frequency; chr8:142702067 chr8:142702252~142726973:- LIHC cis rs1665050 1 rs1665050 ENSG00000259250.1 RP11-50C13.1 -3.76 2e-04 0.0323 -0.2 -0.2 Atopic dermatitis; chr15:59001406 chr15:58587507~58591676:+ LIHC cis rs9901225 1 rs9901225 ENSG00000267185.1 PTP4A2P1 3.76 2e-04 0.0323 0.19 0.2 Colorectal or endometrial cancer; chr17:42603793 chr17:42533532~42534009:+ LIHC cis rs11089937 0.597 rs4821770 ENSG00000211639.2 IGLV4-60 3.76 2e-04 0.0323 0.17 0.2 Periodontitis (PAL4Q3); chr22:22131281 chr22:22162199~22162681:+ LIHC cis rs11089937 0.568 rs4821771 ENSG00000211639.2 IGLV4-60 3.76 2e-04 0.0323 0.17 0.2 Periodontitis (PAL4Q3); chr22:22131287 chr22:22162199~22162681:+ LIHC cis rs66887589 0.967 rs6844263 ENSG00000260091.1 RP11-33B1.4 -3.76 2e-04 0.0323 -0.13 -0.2 Diastolic blood pressure; chr4:119512652 chr4:119409333~119410233:+ LIHC cis rs4308124 0.679 rs7600458 ENSG00000227992.1 AC108463.2 -3.76 2e-04 0.0324 -0.26 -0.2 Vitiligo; chr2:111206013 chr2:111203964~111206215:- LIHC cis rs11096990 0.634 rs7564 ENSG00000249207.1 RP11-360F5.1 3.76 2e-04 0.0324 0.2 0.2 Cognitive function; chr4:39285702 chr4:39112677~39126818:- LIHC cis rs7129556 0.775 rs17752006 ENSG00000254459.1 RP11-91P24.7 3.76 2e-04 0.0324 0.34 0.2 Weight loss (gastric bypass surgery); chr11:77682948 chr11:77829654~77872262:- LIHC cis rs1062177 0.855 rs919262 ENSG00000253921.1 CTB-113P19.3 3.76 2e-04 0.0324 0.22 0.2 Preschool internalizing problems; chr5:151886523 chr5:151753992~151767247:+ LIHC cis rs1009647 0.656 rs10147254 ENSG00000258413.1 RP11-665C16.6 -3.76 2e-04 0.0324 -0.24 -0.2 Testicular germ cell tumor; chr14:55383597 chr14:55262767~55272075:- LIHC cis rs8100891 1 rs8100891 ENSG00000267213.4 AC007773.2 -3.76 2e-04 0.0324 -0.22 -0.2 Neuroticism; chr19:32338607 chr19:32390050~32405560:- LIHC cis rs524281 0.731 rs10791840 ENSG00000255320.1 RP11-755F10.1 3.76 2e-04 0.0324 0.33 0.2 Electroencephalogram traits; chr11:66035912 chr11:66244840~66246239:- LIHC cis rs2369473 1 rs2369473 ENSG00000224261.2 RP11-179G5.1 -3.76 2e-04 0.0324 -0.2 -0.2 Squamous cell lung carcinoma; chr1:160240937 chr1:160266340~160267225:- LIHC cis rs6569038 0.502 rs11967889 ENSG00000253194.1 RP11-351A11.1 -3.76 2e-04 0.0324 -0.26 -0.2 Epstein-Barr virus copy number in lymphoblastoid cell lines; chr6:118992468 chr6:118934785~119031541:+ LIHC cis rs10829156 0.741 rs9731044 ENSG00000225527.1 RP11-383B4.4 -3.76 0.000201 0.0324 -0.34 -0.2 Sudden cardiac arrest; chr10:18605356 chr10:18531849~18533336:- LIHC cis rs10829156 0.538 rs61840846 ENSG00000225527.1 RP11-383B4.4 -3.76 0.000201 0.0324 -0.34 -0.2 Sudden cardiac arrest; chr10:18606393 chr10:18531849~18533336:- LIHC cis rs1318878 1 rs983799 ENSG00000256751.4 PLBD1-AS1 3.76 0.000201 0.0324 0.31 0.2 Intelligence (multi-trait analysis); chr12:15391139 chr12:14567750~14619755:+ LIHC cis rs13287066 0.692 rs72743489 ENSG00000227603.1 RP11-165J3.6 3.76 0.000201 0.0324 0.23 0.2 Intelligence (multi-trait analysis); chr9:93406201 chr9:93435332~93437121:- LIHC cis rs643506 0.874 rs687152 ENSG00000230911.1 PPIHP1 -3.76 0.000201 0.0324 -0.26 -0.2 Breast cancer; chr11:111850950 chr11:112029858~112030367:- LIHC cis rs4237845 0.537 rs11172367 ENSG00000270039.1 RP11-571M6.17 -3.76 0.000201 0.0324 -0.28 -0.2 Intelligence (multi-trait analysis); chr12:57878703 chr12:57803838~57804415:+ LIHC cis rs7182621 0.639 rs34701806 ENSG00000182397.13 DNM1P46 3.76 0.000201 0.0324 0.27 0.2 Colonoscopy-negative controls vs population controls; chr15:99872953 chr15:99790156~99806927:- LIHC cis rs7182621 0.639 rs12906050 ENSG00000182397.13 DNM1P46 3.76 0.000201 0.0324 0.27 0.2 Colonoscopy-negative controls vs population controls; chr15:99873384 chr15:99790156~99806927:- LIHC cis rs7182621 0.639 rs35248328 ENSG00000182397.13 DNM1P46 3.76 0.000201 0.0324 0.27 0.2 Colonoscopy-negative controls vs population controls; chr15:99873399 chr15:99790156~99806927:- LIHC cis rs6969780 0.778 rs2465275 ENSG00000233429.8 HOTAIRM1 3.76 0.000201 0.0324 0.29 0.2 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27105481 chr7:27095647~27100265:+ LIHC cis rs12908161 1 rs35808647 ENSG00000259728.4 LINC00933 3.76 0.000201 0.0325 0.29 0.2 Schizophrenia; chr15:84834210 chr15:84570649~84580175:+ LIHC cis rs7219021 0.55 rs35929648 ENSG00000248278.1 SUMO2P17 3.76 0.000201 0.0325 0.27 0.2 Schizophrenia or bipolar disorder; chr17:48925181 chr17:48874860~48908983:- LIHC cis rs13113518 0.812 rs6830409 ENSG00000272969.1 RP11-528I4.2 3.76 0.000201 0.0325 0.22 0.2 Height; chr4:55522229 chr4:55547112~55547889:+ LIHC cis rs638893 0.636 rs583213 ENSG00000255422.1 AP002954.4 -3.76 0.000201 0.0325 -0.46 -0.2 Vitiligo; chr11:118798469 chr11:118704607~118750263:+ LIHC cis rs459482 1 rs459498 ENSG00000228318.3 AP001610.5 -3.76 0.000201 0.0325 -0.22 -0.2 IgG glycosylation; chr21:41423100 chr21:41441056~41445708:- LIHC cis rs17213965 0.925 rs3898632 ENSG00000207425.1 Y_RNA -3.76 0.000201 0.0325 -0.35 -0.2 Waist-hip ratio; chr16:15789384 chr16:14915457~14915556:- LIHC cis rs3749237 0.595 rs4855873 ENSG00000226913.1 BSN-AS2 -3.76 0.000201 0.0325 -0.26 -0.2 Resting heart rate; chr3:49421681 chr3:49549306~49554366:- LIHC cis rs3749237 0.595 rs1464566 ENSG00000226913.1 BSN-AS2 -3.76 0.000201 0.0325 -0.26 -0.2 Resting heart rate; chr3:49421943 chr3:49549306~49554366:- LIHC cis rs459482 1 rs461981 ENSG00000228318.3 AP001610.5 -3.76 0.000201 0.0325 -0.22 -0.2 IgG glycosylation; chr21:41422154 chr21:41441056~41445708:- LIHC cis rs367615 0.704 rs4286723 ENSG00000249476.1 CTD-2587M2.1 3.76 0.000201 0.0325 0.24 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109500258 chr5:109237120~109326369:- LIHC cis rs4144027 0.967 rs12879686 ENSG00000258914.1 CTD-2134A5.3 -3.76 0.000201 0.0325 -0.22 -0.2 Blood metabolite levels; chr14:103894404 chr14:103875055~103877478:+ LIHC cis rs11098499 0.73 rs12505735 ENSG00000260091.1 RP11-33B1.4 -3.76 0.000201 0.0325 -0.14 -0.2 Corneal astigmatism; chr4:119611801 chr4:119409333~119410233:+ LIHC cis rs2243480 1 rs1723267 ENSG00000275400.1 RP4-756H11.5 3.76 0.000201 0.0325 0.26 0.2 Diabetic kidney disease; chr7:66008327 chr7:66553805~66554199:- LIHC cis rs6142102 0.961 rs4911144 ENSG00000275784.1 RP5-1125A11.6 -3.76 0.000201 0.0325 -0.23 -0.2 Skin pigmentation; chr20:34026565 chr20:33989480~33991818:- LIHC cis rs875971 1 rs709595 ENSG00000237310.1 GS1-124K5.4 3.76 0.000201 0.0325 0.18 0.2 Aortic root size; chr7:66352346 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs811880 ENSG00000237310.1 GS1-124K5.4 3.76 0.000201 0.0325 0.18 0.2 Aortic root size; chr7:66353659 chr7:66493706~66495474:+ LIHC cis rs875971 0.964 rs778723 ENSG00000237310.1 GS1-124K5.4 3.76 0.000201 0.0325 0.18 0.2 Aortic root size; chr7:66364510 chr7:66493706~66495474:+ LIHC cis rs875971 0.929 rs778712 ENSG00000237310.1 GS1-124K5.4 3.76 0.000201 0.0325 0.18 0.2 Aortic root size; chr7:66384991 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs778710 ENSG00000237310.1 GS1-124K5.4 3.76 0.000201 0.0325 0.18 0.2 Aortic root size; chr7:66389847 chr7:66493706~66495474:+ LIHC cis rs875971 0.964 rs778708 ENSG00000237310.1 GS1-124K5.4 3.76 0.000201 0.0325 0.18 0.2 Aortic root size; chr7:66391332 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs778696 ENSG00000237310.1 GS1-124K5.4 3.76 0.000201 0.0325 0.18 0.2 Aortic root size; chr7:66405826 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs778694 ENSG00000237310.1 GS1-124K5.4 3.76 0.000201 0.0325 0.18 0.2 Aortic root size; chr7:66406571 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs4718344 ENSG00000237310.1 GS1-124K5.4 3.76 0.000201 0.0325 0.18 0.2 Aortic root size; chr7:66409394 chr7:66493706~66495474:+ LIHC cis rs875971 0.737 rs7803424 ENSG00000237310.1 GS1-124K5.4 3.76 0.000201 0.0325 0.18 0.2 Aortic root size; chr7:66415618 chr7:66493706~66495474:+ LIHC cis rs875971 0.83 rs7799834 ENSG00000237310.1 GS1-124K5.4 3.76 0.000201 0.0325 0.18 0.2 Aortic root size; chr7:66415707 chr7:66493706~66495474:+ LIHC cis rs1799949 0.827 rs74252763 ENSG00000267681.1 CTD-3199J23.6 -3.76 0.000201 0.0325 -0.2 -0.2 Menopause (age at onset); chr17:43324652 chr17:43144956~43145255:+ LIHC cis rs16958440 0.867 rs12326412 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47157223 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs77615793 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47158093 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs58061761 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47159794 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs75287977 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47160452 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs28578518 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47161177 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs28587821 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47161535 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs77599321 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47163271 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs75901436 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47163273 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs74845165 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47164481 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs114475395 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47164639 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs16949157 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47164953 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs75808931 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47166671 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs59217333 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47168473 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs10083937 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47169231 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs79395141 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47169309 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs80006910 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47170011 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs77149690 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47170772 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs79285649 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47172648 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs57744138 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47174111 chr18:47105946~47108062:+ LIHC cis rs16958440 0.867 rs16949275 ENSG00000267724.1 RP11-49K24.8 3.76 0.000201 0.0325 0.37 0.2 Sitting height ratio; chr18:47174332 chr18:47105946~47108062:+ LIHC cis rs1799949 1 rs8176269 ENSG00000267681.1 CTD-3199J23.6 -3.76 0.000201 0.0325 -0.19 -0.2 Menopause (age at onset); chr17:43061609 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs8176265 ENSG00000267681.1 CTD-3199J23.6 -3.76 0.000201 0.0325 -0.19 -0.2 Menopause (age at onset); chr17:43061979 chr17:43144956~43145255:+ LIHC cis rs4792901 0.802 rs2279191 ENSG00000267747.1 RP11-392O1.4 -3.76 0.000201 0.0325 -0.24 -0.2 Dupuytren's disease; chr17:43493059 chr17:43544785~43610338:+ LIHC cis rs1799949 0.965 rs34633610 ENSG00000267681.1 CTD-3199J23.6 -3.76 0.000201 0.0325 -0.19 -0.2 Menopause (age at onset); chr17:43342017 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs11654051 ENSG00000267681.1 CTD-3199J23.6 -3.76 0.000201 0.0325 -0.19 -0.2 Menopause (age at onset); chr17:43342288 chr17:43144956~43145255:+ LIHC cis rs1799949 0.93 rs56729776 ENSG00000267681.1 CTD-3199J23.6 -3.76 0.000201 0.0325 -0.19 -0.2 Menopause (age at onset); chr17:43344763 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs9646417 ENSG00000267681.1 CTD-3199J23.6 -3.76 0.000201 0.0325 -0.19 -0.2 Menopause (age at onset); chr17:43346885 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs1545764 ENSG00000267681.1 CTD-3199J23.6 -3.76 0.000201 0.0325 -0.19 -0.2 Menopause (age at onset); chr17:43347197 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs9646412 ENSG00000267681.1 CTD-3199J23.6 -3.76 0.000201 0.0325 -0.19 -0.2 Menopause (age at onset); chr17:43348525 chr17:43144956~43145255:+ LIHC cis rs1799949 1 rs4793231 ENSG00000267681.1 CTD-3199J23.6 -3.76 0.000201 0.0325 -0.19 -0.2 Menopause (age at onset); chr17:43350101 chr17:43144956~43145255:+ LIHC cis rs2838568 0.967 rs2838569 ENSG00000274225.1 KB-68A7.1 -3.76 0.000201 0.0325 -0.2 -0.2 Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals; chr21:44478340 chr21:44477850~44478493:+ LIHC cis rs1396626 0.855 rs11165438 ENSG00000230427.1 RP11-313A24.1 3.76 0.000201 0.0325 0.31 0.2 Diabetic kidney disease; chr1:95545748 chr1:95061596~95067545:+ LIHC cis rs6545883 0.929 rs3732170 ENSG00000271889.1 RP11-493E12.1 3.76 0.000201 0.0325 0.24 0.2 Tuberculosis; chr2:61522581 chr2:61151433~61162105:- LIHC cis rs6545883 0.965 rs12713439 ENSG00000271889.1 RP11-493E12.1 3.76 0.000201 0.0325 0.24 0.2 Tuberculosis; chr2:61525019 chr2:61151433~61162105:- LIHC cis rs733175 0.951 rs7669090 ENSG00000250413.1 RP11-448G15.1 -3.76 0.000201 0.0325 -0.29 -0.2 Psychosis and Alzheimer's disease; chr4:10026507 chr4:10006482~10009725:+ LIHC cis rs881375 0.967 rs2270231 ENSG00000226752.6 PSMD5-AS1 -3.76 0.000202 0.0325 -0.22 -0.2 Rheumatoid arthritis; chr9:120888704 chr9:120824828~120854385:+ LIHC cis rs881375 1 rs881375 ENSG00000226752.6 PSMD5-AS1 -3.76 0.000202 0.0325 -0.22 -0.2 Rheumatoid arthritis; chr9:120890620 chr9:120824828~120854385:+ LIHC cis rs960902 0.62 rs11693033 ENSG00000213553.4 RPLP0P6 -3.76 0.000202 0.0325 -0.16 -0.2 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37510063 chr2:38481851~38482804:+ LIHC cis rs6547741 0.816 rs7560847 ENSG00000234072.1 AC074117.10 -3.76 0.000202 0.0325 -0.19 -0.2 Oral cavity cancer; chr2:27659833 chr2:27356246~27367622:+ LIHC cis rs2439831 0.867 rs6493082 ENSG00000205771.5 CATSPER2P1 -3.76 0.000202 0.0325 -0.27 -0.2 Lung cancer in ever smokers; chr15:43342610 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs8041132 ENSG00000205771.5 CATSPER2P1 -3.76 0.000202 0.0325 -0.27 -0.2 Lung cancer in ever smokers; chr15:43342938 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs7170489 ENSG00000205771.5 CATSPER2P1 -3.76 0.000202 0.0325 -0.27 -0.2 Lung cancer in ever smokers; chr15:43344453 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs16957627 ENSG00000205771.5 CATSPER2P1 -3.76 0.000202 0.0325 -0.27 -0.2 Lung cancer in ever smokers; chr15:43350459 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs16957630 ENSG00000205771.5 CATSPER2P1 -3.76 0.000202 0.0325 -0.27 -0.2 Lung cancer in ever smokers; chr15:43350582 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs16957632 ENSG00000205771.5 CATSPER2P1 -3.76 0.000202 0.0325 -0.27 -0.2 Lung cancer in ever smokers; chr15:43350699 chr15:43726918~43747094:- LIHC cis rs2439831 0.717 rs7165471 ENSG00000205771.5 CATSPER2P1 -3.76 0.000202 0.0325 -0.27 -0.2 Lung cancer in ever smokers; chr15:43352590 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs6493085 ENSG00000205771.5 CATSPER2P1 -3.76 0.000202 0.0325 -0.27 -0.2 Lung cancer in ever smokers; chr15:43361984 chr15:43726918~43747094:- LIHC cis rs3213758 0.541 rs5005161 ENSG00000275191.1 RP11-36I17.2 -3.76 0.000202 0.0325 -0.25 -0.2 Vitiligo (non-segmental); chr16:53664764 chr16:53628256~53628816:- LIHC cis rs6430585 0.583 rs12472293 ENSG00000231890.6 DARS-AS1 -3.76 0.000202 0.0325 -0.3 -0.2 Corneal structure; chr2:135890507 chr2:135985176~136022593:+ LIHC cis rs2243480 1 rs313809 ENSG00000275400.1 RP4-756H11.5 3.76 0.000202 0.0325 0.27 0.2 Diabetic kidney disease; chr7:66034996 chr7:66553805~66554199:- LIHC cis rs4925386 0.802 rs6142735 ENSG00000226332.2 RP11-157P1.4 3.76 0.000202 0.0325 0.24 0.2 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62343031 chr20:62305432~62306325:- LIHC cis rs2281636 0.723 rs11190195 ENSG00000233690.1 EBAG9P1 -3.76 0.000202 0.0325 -0.21 -0.2 Obesity-related traits; chr10:99626710 chr10:99697407~99697949:- LIHC cis rs55794721 0.509 rs2982358 ENSG00000261349.1 RP3-465N24.5 -3.76 0.000202 0.0325 -0.19 -0.2 Mean corpuscular volume;Plateletcrit; chr1:25418713 chr1:25266102~25267136:- LIHC cis rs2658782 0.724 rs2658770 ENSG00000279684.1 RP11-755E23.2 -3.76 0.000202 0.0325 -0.29 -0.2 Pulmonary function decline; chr11:93528720 chr11:93286629~93288903:- LIHC cis rs13434995 0.513 rs6554285 ENSG00000273257.1 RP11-177J6.1 3.76 0.000202 0.0325 0.32 0.2 Adiponectin levels; chr4:55533953 chr4:55387949~55388271:+ LIHC cis rs2348418 0.832 rs11611406 ENSG00000247934.4 RP11-967K21.1 3.76 0.000202 0.0325 0.18 0.2 Lung function (FEV1);Lung function (FVC); chr12:28310910 chr12:28163298~28190738:- LIHC cis rs2348418 0.832 rs11611382 ENSG00000247934.4 RP11-967K21.1 3.76 0.000202 0.0325 0.18 0.2 Lung function (FEV1);Lung function (FVC); chr12:28310959 chr12:28163298~28190738:- LIHC cis rs6700559 0.967 rs12041320 ENSG00000260088.1 RP11-92G12.3 -3.76 0.000202 0.0326 -0.25 -0.2 Coronary artery disease; chr1:200652107 chr1:200669507~200694250:+ LIHC cis rs2658782 0.547 rs3020065 ENSG00000279684.1 RP11-755E23.2 -3.76 0.000202 0.0326 -0.29 -0.2 Pulmonary function decline; chr11:93326733 chr11:93286629~93288903:- LIHC cis rs2658782 0.526 rs3020062 ENSG00000279684.1 RP11-755E23.2 -3.76 0.000202 0.0326 -0.29 -0.2 Pulmonary function decline; chr11:93327993 chr11:93286629~93288903:- LIHC cis rs12681287 0.547 rs60982560 ENSG00000254088.1 SLC2A3P4 3.76 0.000202 0.0326 0.24 0.2 Caudate activity during reward; chr8:86502817 chr8:86503591~86505061:+ LIHC cis rs7560272 0.538 rs7370393 ENSG00000273245.1 RP11-434P11.2 -3.76 0.000202 0.0326 -0.24 -0.2 Schizophrenia; chr2:73698509 chr2:73750256~73750786:- LIHC cis rs1501138 0.642 rs10034095 ENSG00000249930.1 AC007016.3 3.76 0.000202 0.0326 0.27 0.2 Systemic juvenile idiopathic arthritis; chr4:16329244 chr4:15492729~15492972:- LIHC cis rs6952407 1 rs6952407 ENSG00000273024.4 INTS4P2 3.76 0.000202 0.0326 0.23 0.2 Cotinine glucuronidation; chr7:66580525 chr7:65647864~65715661:+ LIHC cis rs2952768 0.686 rs7569963 ENSG00000231908.1 IDH1-AS1 -3.76 0.000202 0.0326 -0.24 -0.2 Opioid sensitivity; chr2:207608460 chr2:208255247~208256181:+ LIHC cis rs6496667 0.51 rs16944405 ENSG00000213471.7 TTLL13P 3.76 0.000202 0.0326 0.26 0.2 Rheumatoid arthritis; chr15:90432285 chr15:90249530~90265482:+ LIHC cis rs950169 0.58 rs11634320 ENSG00000259728.4 LINC00933 -3.76 0.000202 0.0326 -0.28 -0.2 Schizophrenia; chr15:84628952 chr15:84570649~84580175:+ LIHC cis rs7829975 0.659 rs4382480 ENSG00000253981.4 ALG1L13P 3.76 0.000202 0.0326 0.23 0.2 Mood instability; chr8:8863963 chr8:8236003~8244667:- LIHC cis rs12468226 0.873 rs79071680 ENSG00000272966.1 RP11-686O6.1 3.76 0.000202 0.0326 0.34 0.2 Urate levels; chr2:202191520 chr2:202336739~202337200:+ LIHC cis rs12468226 0.873 rs79860867 ENSG00000272966.1 RP11-686O6.1 3.76 0.000202 0.0326 0.34 0.2 Urate levels; chr2:202192397 chr2:202336739~202337200:+ LIHC cis rs875971 0.522 rs4718285 ENSG00000237310.1 GS1-124K5.4 3.76 0.000202 0.0326 0.2 0.2 Aortic root size; chr7:65827018 chr7:66493706~66495474:+ LIHC cis rs17711722 0.64 rs13237956 ENSG00000237310.1 GS1-124K5.4 3.76 0.000202 0.0326 0.2 0.2 Calcium levels; chr7:65853042 chr7:66493706~66495474:+ LIHC cis rs875971 0.516 rs6945322 ENSG00000237310.1 GS1-124K5.4 3.76 0.000202 0.0326 0.2 0.2 Aortic root size; chr7:65871069 chr7:66493706~66495474:+ LIHC cis rs17711722 0.701 rs4467826 ENSG00000237310.1 GS1-124K5.4 3.76 0.000202 0.0326 0.2 0.2 Calcium levels; chr7:65903721 chr7:66493706~66495474:+ LIHC cis rs5742933 0.857 rs1233272 ENSG00000253559.1 OSGEPL1-AS1 -3.76 0.000202 0.0326 -0.25 -0.2 Ferritin levels; chr2:189814968 chr2:189762704~189765556:+ LIHC cis rs7044246 0.924 rs7025683 ENSG00000224992.1 RP11-295G24.5 -3.76 0.000202 0.0326 -0.24 -0.2 Cognitive ability (multi-trait analysis);Cognitive ability; chr9:131990428 chr9:132769453~132770212:- LIHC cis rs12157904 1 rs57066681 ENSG00000233360.4 Z83844.1 3.76 0.000202 0.0326 0.39 0.2 Response to anti-depressant treatment in major depressive disorder; chr22:37587560 chr22:37641832~37658377:- LIHC cis rs77683187 1 rs77683187 ENSG00000254851.1 RP11-109L13.1 3.76 0.000202 0.0326 0.38 0.2 Breast cancer; chr11:117214494 chr11:117135528~117138582:+ LIHC cis rs4561483 0.832 rs171656 ENSG00000261216.1 RP11-166B2.5 -3.76 0.000202 0.0326 -0.22 -0.2 Testicular germ cell tumor; chr16:11859310 chr16:11908208~11908916:+ LIHC cis rs7208859 0.673 rs57432042 ENSG00000266490.1 CTD-2349P21.9 3.76 0.000202 0.0326 0.26 0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30914020 chr17:30792372~30792833:+ LIHC cis rs7607369 0.648 rs55983650 ENSG00000272555.1 RP11-459I19.1 -3.76 0.000203 0.0326 -0.23 -0.2 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218790209 chr2:218818690~218819144:+ LIHC cis rs7914558 0.646 rs12768205 ENSG00000236937.2 PTGES3P4 3.76 0.000203 0.0326 0.25 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr10:102888092 chr10:102845595~102845950:+ LIHC cis rs1275468 1 rs1795379 ENSG00000257497.2 RP11-585P4.5 -3.76 0.000203 0.0326 -0.27 -0.2 Polycystic ovary syndrome; chr12:75547262 chr12:75483454~75489820:- LIHC cis rs2736345 0.755 rs2736340 ENSG00000255310.2 AF131215.2 3.76 0.000203 0.0326 0.18 0.2 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11486464 chr8:11107788~11109726:- LIHC cis rs17213965 0.925 rs62030569 ENSG00000207425.1 Y_RNA -3.76 0.000203 0.0327 -0.34 -0.2 Waist-hip ratio; chr16:15786892 chr16:14915457~14915556:- LIHC cis rs4682868 0.581 rs13068366 ENSG00000273328.4 RP11-141M3.6 3.76 0.000203 0.0327 0.2 0.2 Monocyte percentage of white cells; chr3:42880528 chr3:42809414~42908105:+ LIHC cis rs881375 1 rs10117059 ENSG00000226752.6 PSMD5-AS1 -3.76 0.000203 0.0327 -0.22 -0.2 Rheumatoid arthritis; chr9:120891199 chr9:120824828~120854385:+ LIHC cis rs8177253 1 rs3811647 ENSG00000244062.1 RP11-404G16.2 3.76 0.000203 0.0327 0.2 0.2 Iron status biomarkers; chr3:133765185 chr3:133760300~133762363:+ LIHC cis rs8177253 1 rs1358023 ENSG00000244062.1 RP11-404G16.2 3.76 0.000203 0.0327 0.2 0.2 Iron status biomarkers; chr3:133765549 chr3:133760300~133762363:+ LIHC cis rs2396442 1 rs2396442 ENSG00000231769.2 RP1-8B1.4 3.76 0.000203 0.0327 0.28 0.2 Left ventricle wall thickness; chr6:45489244 chr6:46097093~46129706:- LIHC cis rs1003719 0.715 rs4261789 ENSG00000272948.2 AP001412.1 -3.76 0.000203 0.0327 -0.22 -0.2 Eye color traits; chr21:37131462 chr21:37267784~37268497:+ LIHC cis rs2243480 0.803 rs160649 ENSG00000232546.1 RP11-458F8.1 -3.76 0.000203 0.0327 -0.22 -0.2 Diabetic kidney disease; chr7:66078212 chr7:66848496~66858136:+ LIHC cis rs2243480 1 rs160648 ENSG00000232546.1 RP11-458F8.1 -3.76 0.000203 0.0327 -0.22 -0.2 Diabetic kidney disease; chr7:66078397 chr7:66848496~66858136:+ LIHC cis rs1499614 1 rs2707832 ENSG00000232559.3 GS1-124K5.12 3.76 0.000203 0.0327 0.21 0.2 Gout; chr7:66671562 chr7:66554588~66576923:- LIHC cis rs10129255 0.957 rs2007467 ENSG00000211972.2 IGHV3-66 -3.76 0.000203 0.0327 -0.16 -0.2 Kawasaki disease; chr14:106771605 chr14:106675017~106675544:- LIHC cis rs881375 0.933 rs4837799 ENSG00000226752.6 PSMD5-AS1 -3.76 0.000203 0.0327 -0.22 -0.2 Rheumatoid arthritis; chr9:120906048 chr9:120824828~120854385:+ LIHC cis rs9595908 0.669 rs56291634 ENSG00000212293.1 SNORA16 3.76 0.000203 0.0327 0.23 0.2 Body mass index; chr13:32720404 chr13:32420390~32420516:- LIHC cis rs9595908 0.669 rs28637641 ENSG00000212293.1 SNORA16 3.76 0.000203 0.0327 0.23 0.2 Body mass index; chr13:32726997 chr13:32420390~32420516:- LIHC cis rs17767392 0.846 rs56180634 ENSG00000274818.1 RP1-292L20.3 3.76 0.000203 0.0327 0.31 0.2 Mitral valve prolapse; chr14:71523216 chr14:70906657~70907111:- LIHC cis rs757278 0.507 rs117863639 ENSG00000227199.1 ST7-AS1 -3.76 0.000203 0.0327 -0.34 -0.2 Response to methotrexate in juvenile idiopathic arthritis; chr7:117648024 chr7:116952446~116954334:- LIHC cis rs1106684 1 rs1477227 ENSG00000233559.1 AC016831.7 3.76 0.000203 0.0328 0.36 0.2 Body mass index; chr7:131770632 chr7:130853720~130928649:+ LIHC cis rs10857712 0.851 rs7913420 ENSG00000214279.11 SCART1 -3.76 0.000203 0.0328 -0.25 -0.2 Systemic lupus erythematosus; chr10:133400350 chr10:133453928~133523558:+ LIHC cis rs9910055 1 rs2071167 ENSG00000267080.4 ASB16-AS1 3.76 0.000203 0.0328 0.18 0.2 Total body bone mineral density; chr17:44210151 chr17:44175973~44186717:- LIHC cis rs1023500 0.551 rs133355 ENSG00000226450.2 CYP2D8P 3.76 0.000203 0.0328 0.24 0.2 Schizophrenia; chr22:42044281 chr22:42149886~42155001:- LIHC cis rs1530530 0.748 rs77066059 ENSG00000253771.4 TPTE2P1 -3.76 0.000203 0.0328 -0.43 -0.2 Obesity-related traits; chr13:24690737 chr13:24924677~24968487:- LIHC cis rs1530530 0.881 rs12872010 ENSG00000253771.4 TPTE2P1 -3.76 0.000203 0.0328 -0.43 -0.2 Obesity-related traits; chr13:24691133 chr13:24924677~24968487:- LIHC cis rs1530530 0.881 rs12871180 ENSG00000253771.4 TPTE2P1 -3.76 0.000203 0.0328 -0.43 -0.2 Obesity-related traits; chr13:24691357 chr13:24924677~24968487:- LIHC cis rs4356975 0.563 rs7442453 ENSG00000250919.1 RP11-813N20.3 -3.76 0.000204 0.0328 -0.2 -0.2 Obesity-related traits; chr4:69103462 chr4:69027831~69044578:+ LIHC cis rs4792901 0.959 rs2293015 ENSG00000279602.1 CTD-3014M21.1 -3.76 0.000204 0.0328 -0.23 -0.2 Dupuytren's disease; chr17:43544631 chr17:43360041~43361361:- LIHC cis rs4792901 0.918 rs79868029 ENSG00000279602.1 CTD-3014M21.1 -3.76 0.000204 0.0328 -0.23 -0.2 Dupuytren's disease; chr17:43545139 chr17:43360041~43361361:- LIHC cis rs4792901 0.918 rs2271959 ENSG00000279602.1 CTD-3014M21.1 -3.76 0.000204 0.0328 -0.23 -0.2 Dupuytren's disease; chr17:43545372 chr17:43360041~43361361:- LIHC cis rs4792901 0.797 rs118013810 ENSG00000279602.1 CTD-3014M21.1 -3.76 0.000204 0.0328 -0.23 -0.2 Dupuytren's disease; chr17:43548776 chr17:43360041~43361361:- LIHC cis rs4792901 0.797 rs117711821 ENSG00000279602.1 CTD-3014M21.1 -3.76 0.000204 0.0328 -0.23 -0.2 Dupuytren's disease; chr17:43548777 chr17:43360041~43361361:- LIHC cis rs4792901 0.959 rs72833147 ENSG00000279602.1 CTD-3014M21.1 -3.76 0.000204 0.0328 -0.23 -0.2 Dupuytren's disease; chr17:43549210 chr17:43360041~43361361:- LIHC cis rs8060598 0.745 rs17312836 ENSG00000275155.1 CTD-2595P9.4 -3.76 0.000204 0.0328 -0.23 -0.2 Leprosy; chr16:50707551 chr16:49847018~49847632:- LIHC cis rs1799949 0.602 rs8176257 ENSG00000267681.1 CTD-3199J23.6 -3.76 0.000204 0.0328 -0.2 -0.2 Menopause (age at onset); chr17:43064188 chr17:43144956~43145255:+ LIHC cis rs9646944 0.501 rs10202813 ENSG00000234389.1 AC007278.3 -3.76 0.000204 0.0328 -0.24 -0.2 Blood protein levels; chr2:102403280 chr2:102438713~102440475:+ LIHC cis rs875971 0.522 rs4718286 ENSG00000237310.1 GS1-124K5.4 3.76 0.000204 0.0328 0.2 0.2 Aortic root size; chr7:65827777 chr7:66493706~66495474:+ LIHC cis rs17711722 0.585 rs6942660 ENSG00000237310.1 GS1-124K5.4 3.76 0.000204 0.0328 0.2 0.2 Calcium levels; chr7:65837419 chr7:66493706~66495474:+ LIHC cis rs17711722 0.701 rs55773927 ENSG00000237310.1 GS1-124K5.4 3.76 0.000204 0.0328 0.2 0.2 Calcium levels; chr7:65872915 chr7:66493706~66495474:+ LIHC cis rs17711722 0.727 rs35850374 ENSG00000237310.1 GS1-124K5.4 3.76 0.000204 0.0328 0.2 0.2 Calcium levels; chr7:65892789 chr7:66493706~66495474:+ LIHC cis rs2832077 0.505 rs9305386 ENSG00000224649.1 AF124730.4 3.76 0.000204 0.0328 0.27 0.2 Cognitive test performance; chr21:29014430 chr21:29182027~29187795:- LIHC cis rs12468226 1 rs16839077 ENSG00000272966.1 RP11-686O6.1 3.76 0.000204 0.0328 0.33 0.2 Urate levels; chr2:202343970 chr2:202336739~202337200:+ LIHC cis rs12468226 1 rs58288071 ENSG00000272966.1 RP11-686O6.1 3.76 0.000204 0.0328 0.33 0.2 Urate levels; chr2:202350016 chr2:202336739~202337200:+ LIHC cis rs7208859 0.528 rs3764416 ENSG00000280069.1 CTD-2349P21.3 3.75 0.000204 0.0328 0.27 0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30573690 chr17:30738182~30740275:+ LIHC cis rs916888 0.773 rs538628 ENSG00000279685.2 MAPT-IT1 -3.75 0.000204 0.0328 -0.35 -0.2 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45895783~45898798:+ LIHC cis rs4578769 0.648 rs1902921 ENSG00000266850.1 RP11-370A5.1 -3.75 0.000204 0.0328 -0.23 -0.2 Eosinophil percentage of white cells; chr18:22964380 chr18:22723491~22907721:- LIHC cis rs1348850 0.651 rs1901826 ENSG00000280374.1 RP11-337N6.3 3.75 0.000204 0.0328 0.23 0.2 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr2:177360538 chr2:177317715~177318471:- LIHC cis rs2749097 1 rs61765315 ENSG00000244256.3 RN7SL130P -3.75 0.000204 0.0328 -0.25 -0.2 Alcohol consumption (transferrin glycosylation); chr1:63662638 chr1:63655743~63656047:+ LIHC cis rs340849 0.868 rs340851 ENSG00000274895.1 RP11-478J18.2 3.75 0.000204 0.0328 0.2 0.2 Alzheimer's disease; chr1:213939379 chr1:213983793~213986419:- LIHC cis rs875971 0.522 rs1701760 ENSG00000237310.1 GS1-124K5.4 3.75 0.000204 0.0328 0.2 0.2 Aortic root size; chr7:66008701 chr7:66493706~66495474:+ LIHC cis rs4713118 0.629 rs203888 ENSG00000219891.2 ZSCAN12P1 3.75 0.000204 0.0328 0.28 0.2 Parkinson's disease; chr6:28053811 chr6:28091154~28093664:+ LIHC cis rs11212260 0.655 rs11212172 ENSG00000261098.1 RP11-819C21.1 3.75 0.000204 0.0328 0.34 0.2 IgG glycosylation; chr11:107342003 chr11:107312132~107316271:- LIHC cis rs1275468 0.798 rs2366987 ENSG00000257497.2 RP11-585P4.5 -3.75 0.000204 0.0328 -0.27 -0.2 Polycystic ovary syndrome; chr12:75536346 chr12:75483454~75489820:- LIHC cis rs7968440 1 rs2731443 ENSG00000272368.2 RP4-605O3.4 3.75 0.000204 0.0329 0.3 0.2 Fibrinogen; chr12:50700355 chr12:50112197~50165618:+ LIHC cis rs4927850 0.752 rs7618864 ENSG00000207650.1 MIR570 3.75 0.000204 0.0329 0.21 0.2 Pancreatic cancer; chr3:196022690 chr3:195699401~195699497:+ LIHC cis rs812925 0.859 rs2593624 ENSG00000212978.6 AC016747.3 3.75 0.000204 0.0329 0.23 0.2 Immature fraction of reticulocytes; chr2:61325349 chr2:61141592~61144969:- LIHC cis rs6142102 0.602 rs6141435 ENSG00000275784.1 RP5-1125A11.6 -3.75 0.000204 0.0329 -0.21 -0.2 Skin pigmentation; chr20:33963473 chr20:33989480~33991818:- LIHC cis rs2243480 1 rs4718334 ENSG00000275400.1 RP4-756H11.5 -3.75 0.000204 0.0329 -0.26 -0.2 Diabetic kidney disease; chr7:66324467 chr7:66553805~66554199:- LIHC cis rs2275906 0.92 rs72843536 ENSG00000242387.1 HIST1H2APS2 3.75 0.000204 0.0329 0.34 0.2 Urate levels in lean individuals; chr6:25802210 chr6:25882026~25882395:- LIHC cis rs7647973 0.58 rs11716334 ENSG00000270441.1 RP11-694I15.7 -3.75 0.000204 0.0329 -0.28 -0.2 Menarche (age at onset); chr3:49192663 chr3:49140086~49160851:- LIHC cis rs853679 1 rs853678 ENSG00000204709.4 LINC01556 3.75 0.000205 0.0329 0.32 0.2 Depression; chr6:28329536 chr6:28943877~28944537:+ LIHC cis rs4356975 0.563 rs7685151 ENSG00000250919.1 RP11-813N20.3 -3.75 0.000205 0.0329 -0.2 -0.2 Obesity-related traits; chr4:69114055 chr4:69027831~69044578:+ LIHC cis rs2286503 1 rs2286503 ENSG00000226329.2 AC005682.6 3.75 0.000205 0.0329 0.25 0.2 Fibrinogen; chr7:22816987 chr7:22863874~22881350:- LIHC cis rs10504130 0.569 rs4626585 ENSG00000272024.1 RP11-546K22.3 3.75 0.000205 0.0329 0.32 0.2 Venous thromboembolism (SNP x SNP interaction); chr8:51767380 chr8:51950284~51950690:+ LIHC cis rs4218 0.638 rs8042516 ENSG00000277144.1 RP11-59H7.4 -3.75 0.000205 0.0329 -0.22 -0.2 Social communication problems; chr15:59067525 chr15:59115547~59116089:- LIHC cis rs12681287 0.517 rs7462883 ENSG00000254088.1 SLC2A3P4 3.75 0.000205 0.0329 0.24 0.2 Caudate activity during reward; chr8:86514562 chr8:86503591~86505061:+ LIHC cis rs494453 0.922 rs500184 ENSG00000227811.2 FAM212B-AS1 3.75 0.000205 0.0329 0.23 0.2 Osteoporosis-related phenotypes; chr1:111620924 chr1:111739841~111747798:+ LIHC cis rs7713065 0.531 rs2522051 ENSG00000233006.5 AC034220.3 3.75 0.000205 0.0329 0.21 0.2 Lung function (FEV1/FVC); chr5:132461886 chr5:132311285~132369916:- LIHC cis rs673078 0.66 rs61943525 ENSG00000275759.1 RP11-131L12.3 -3.75 0.000205 0.0329 -0.44 -0.2 Glucose homeostasis traits; chr12:118152927 chr12:118428281~118428870:+ LIHC cis rs2880765 0.506 rs719138 ENSG00000259295.5 CSPG4P12 3.75 0.000205 0.0329 0.28 0.2 Coronary artery disease; chr15:85511831 chr15:85191438~85213905:+ LIHC cis rs3934487 0.547 rs6660791 ENSG00000223956.1 RP4-710M16.2 -3.75 0.000205 0.033 -0.21 -0.2 Reticulocyte count; chr1:55863692 chr1:56414963~56415966:+ LIHC cis rs17373728 0.507 rs13248105 ENSG00000249395.2 CASC9 -3.75 0.000205 0.033 -0.21 -0.2 Diabetic kidney disease; chr8:75254634 chr8:75223404~75324741:- LIHC cis rs6449502 1 rs7712473 ENSG00000272308.1 RP11-231G3.1 3.75 0.000205 0.033 0.29 0.2 Mean platelet volume; chr5:60812643 chr5:60866457~60866935:- LIHC cis rs9747201 0.862 rs11651738 ENSG00000279692.1 RP11-1055B8.1 3.75 0.000205 0.033 0.34 0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82220815 chr17:81395609~81397144:- LIHC cis rs9747201 0.894 rs4503854 ENSG00000279692.1 RP11-1055B8.1 3.75 0.000205 0.033 0.34 0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82220820 chr17:81395609~81397144:- LIHC cis rs3749237 0.555 rs7637665 ENSG00000270441.1 RP11-694I15.7 -3.75 0.000205 0.033 -0.28 -0.2 Resting heart rate; chr3:49514862 chr3:49140086~49160851:- LIHC cis rs11096990 0.634 rs1057807 ENSG00000249207.1 RP11-360F5.1 3.75 0.000205 0.033 0.2 0.2 Cognitive function; chr4:39287853 chr4:39112677~39126818:- LIHC cis rs875971 0.522 rs2949690 ENSG00000237310.1 GS1-124K5.4 -3.75 0.000205 0.033 -0.2 -0.2 Aortic root size; chr7:66018255 chr7:66493706~66495474:+ LIHC cis rs11159086 0.793 rs17100414 ENSG00000270000.1 RP3-449M8.9 3.75 0.000205 0.033 0.29 0.2 Advanced glycation end-product levels; chr14:74467918 chr14:74471930~74472360:- LIHC cis rs2898681 0.519 rs73814886 ENSG00000248375.1 RP11-177B4.1 -3.75 0.000205 0.033 -0.32 -0.2 Optic nerve measurement (cup area); chr4:52867084 chr4:52720081~52720831:- LIHC cis rs2898681 0.561 rs58577680 ENSG00000248375.1 RP11-177B4.1 -3.75 0.000205 0.033 -0.32 -0.2 Optic nerve measurement (cup area); chr4:52868127 chr4:52720081~52720831:- LIHC cis rs5742933 0.681 rs4525728 ENSG00000253559.1 OSGEPL1-AS1 3.75 0.000205 0.033 0.26 0.2 Ferritin levels; chr2:189780324 chr2:189762704~189765556:+ LIHC cis rs7665090 1 rs10027437 ENSG00000230069.3 LRRC37A15P -3.75 0.000205 0.033 -0.19 -0.2 Primary biliary cholangitis; chr4:102636094 chr4:102727274~102730721:- LIHC cis rs6142102 0.961 rs4911405 ENSG00000275784.1 RP5-1125A11.6 -3.75 0.000205 0.033 -0.23 -0.2 Skin pigmentation; chr20:34087161 chr20:33989480~33991818:- LIHC cis rs13113518 0.729 rs12641881 ENSG00000223305.1 RN7SKP30 3.75 0.000205 0.033 0.24 0.2 Height; chr4:55401306 chr4:55540502~55540835:- LIHC cis rs4792901 0.802 rs12602059 ENSG00000279602.1 CTD-3014M21.1 -3.75 0.000205 0.033 -0.24 -0.2 Dupuytren's disease; chr17:43496362 chr17:43360041~43361361:- LIHC cis rs7671266 0.532 rs7349721 ENSG00000250413.1 RP11-448G15.1 -3.75 0.000205 0.033 -0.29 -0.2 Cardiovascular disease risk factors; chr4:10040938 chr4:10006482~10009725:+ LIHC cis rs2243480 0.831 rs57294491 ENSG00000228409.4 CCT6P1 -3.75 0.000206 0.033 -0.21 -0.2 Diabetic kidney disease; chr7:66219914 chr7:65751142~65763354:+ LIHC cis rs6445975 0.715 rs6809809 ENSG00000272360.1 RP11-359I18.5 -3.75 0.000206 0.033 -0.24 -0.2 Systemic lupus erythematosus; chr3:58282223 chr3:58490830~58491291:- LIHC cis rs9652601 0.959 rs7200940 ENSG00000274038.1 RP11-66H6.4 3.75 0.000206 0.033 0.24 0.2 Systemic lupus erythematosus; chr16:11070710 chr16:11056556~11057034:+ LIHC cis rs1318937 0.516 rs73023424 ENSG00000224660.1 SH3BP5-AS1 3.75 0.000206 0.033 0.18 0.2 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15201995 chr3:15254184~15264493:+ LIHC cis rs6456156 0.692 rs9457270 ENSG00000227598.1 RP1-167A14.2 -3.75 0.000206 0.0331 -0.21 -0.2 Primary biliary cholangitis; chr6:167099440 chr6:166969626~166999065:- LIHC cis rs950880 0.71 rs67723747 ENSG00000234389.1 AC007278.3 -3.75 0.000206 0.0331 -0.21 -0.2 Serum protein levels (sST2); chr2:102353347 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs56386507 ENSG00000234389.1 AC007278.3 -3.75 0.000206 0.0331 -0.21 -0.2 Serum protein levels (sST2); chr2:102354705 chr2:102438713~102440475:+ LIHC cis rs6545883 1 rs778758 ENSG00000271889.1 RP11-493E12.1 3.75 0.000206 0.0331 0.24 0.2 Tuberculosis; chr2:61555026 chr2:61151433~61162105:- LIHC cis rs9595908 0.758 rs2031354 ENSG00000212293.1 SNORA16 3.75 0.000206 0.0331 0.23 0.2 Body mass index; chr13:32641454 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs7332884 ENSG00000212293.1 SNORA16 3.75 0.000206 0.0331 0.23 0.2 Body mass index; chr13:32642412 chr13:32420390~32420516:- LIHC cis rs6991838 0.806 rs17302392 ENSG00000272010.1 CTD-3025N20.3 3.75 0.000206 0.0331 0.27 0.2 Intelligence (multi-trait analysis); chr8:65551073 chr8:65591850~65592472:- LIHC cis rs2070488 0.861 rs1858740 ENSG00000229589.1 ACVR2B-AS1 3.75 0.000206 0.0331 0.22 0.2 Electrocardiographic conduction measures; chr3:38396881 chr3:38451027~38454820:- LIHC cis rs6449502 0.92 rs12696976 ENSG00000272308.1 RP11-231G3.1 3.75 0.000206 0.0331 0.28 0.2 Mean platelet volume; chr5:60907079 chr5:60866457~60866935:- LIHC cis rs17123764 0.71 rs933738 ENSG00000257464.1 RP11-161H23.8 -3.75 0.000206 0.0331 -0.24 -0.2 Intelligence (multi-trait analysis); chr12:49549339 chr12:49442424~49442652:- LIHC cis rs8077577 0.747 rs62072511 ENSG00000260647.1 RP1-178F10.1 3.75 0.000206 0.0331 0.25 0.2 Obesity-related traits; chr17:18289843 chr17:18268080~18268828:+ LIHC cis rs8077577 0.747 rs3817992 ENSG00000260647.1 RP1-178F10.1 3.75 0.000206 0.0331 0.25 0.2 Obesity-related traits; chr17:18290697 chr17:18268080~18268828:+ LIHC cis rs10883723 0.668 rs12414407 ENSG00000236937.2 PTGES3P4 3.75 0.000206 0.0331 0.26 0.2 Allergic disease (asthma, hay fever or eczema); chr10:102627262 chr10:102845595~102845950:+ LIHC cis rs9747201 1 rs58472289 ENSG00000279692.1 RP11-1055B8.1 -3.75 0.000206 0.0331 -0.35 -0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82154019 chr17:81395609~81397144:- LIHC cis rs12480328 0.764 rs6096212 ENSG00000224397.4 LINC01272 -3.75 0.000206 0.0331 -0.39 -0.2 Prostate cancer; chr20:50969702 chr20:50267486~50279795:+ LIHC cis rs2919917 0.628 rs2625663 ENSG00000254352.1 RP11-578O24.2 3.75 0.000206 0.0331 0.3 0.2 Lymphocyte counts; chr8:78718106 chr8:78723796~78724136:- LIHC cis rs6465468 0.645 rs737902 ENSG00000233942.1 AC004012.1 -3.75 0.000206 0.0332 -0.39 -0.2 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);Body mass index; chr7:95509443 chr7:95471835~95473998:+ LIHC cis rs72793342 0.651 rs8050463 ENSG00000260082.1 RP11-2C24.5 -3.75 0.000207 0.0332 -0.28 -0.2 RANTES levels; chr16:30542838 chr16:30821068~30822110:- LIHC cis rs673078 0.66 rs11068908 ENSG00000275409.1 RP11-131L12.4 -3.75 0.000207 0.0332 -0.25 -0.2 Glucose homeostasis traits; chr12:118327265 chr12:118430147~118430699:+ LIHC cis rs481331 0.736 rs73253954 ENSG00000185904.10 LINC00839 3.75 0.000207 0.0332 0.39 0.2 Systemic juvenile idiopathic arthritis; chr10:42472273 chr10:42475543~42495336:+ LIHC cis rs6545883 0.899 rs1562309 ENSG00000271889.1 RP11-493E12.1 3.75 0.000207 0.0332 0.24 0.2 Tuberculosis; chr2:61542991 chr2:61151433~61162105:- LIHC cis rs6445975 1 rs4681681 ENSG00000272360.1 RP11-359I18.5 -3.75 0.000207 0.0332 -0.26 -0.2 Systemic lupus erythematosus; chr3:58347185 chr3:58490830~58491291:- LIHC cis rs10752881 1 rs10911185 ENSG00000224468.3 RP11-181K3.4 -3.75 0.000207 0.0332 -0.17 -0.2 Colorectal cancer; chr1:183002612 chr1:183138402~183141282:- LIHC cis rs10752881 1 rs10737235 ENSG00000224468.3 RP11-181K3.4 -3.75 0.000207 0.0332 -0.17 -0.2 Colorectal cancer; chr1:183002681 chr1:183138402~183141282:- LIHC cis rs5742933 0.75 rs10197331 ENSG00000253559.1 OSGEPL1-AS1 3.75 0.000207 0.0332 0.26 0.2 Ferritin levels; chr2:189768112 chr2:189762704~189765556:+ LIHC cis rs5742933 0.817 rs1055091 ENSG00000253559.1 OSGEPL1-AS1 3.75 0.000207 0.0332 0.26 0.2 Ferritin levels; chr2:189770417 chr2:189762704~189765556:+ LIHC cis rs5742933 0.817 rs6942 ENSG00000253559.1 OSGEPL1-AS1 3.75 0.000207 0.0332 0.26 0.2 Ferritin levels; chr2:189771685 chr2:189762704~189765556:+ LIHC cis rs1987511 1 rs61610073 ENSG00000231039.2 RP11-445P17.3 -3.75 0.000207 0.0332 -0.25 -0.2 Intelligence; chr10:5306635 chr10:5234358~5263408:+ LIHC cis rs2439831 0.867 rs933941 ENSG00000205771.5 CATSPER2P1 -3.75 0.000207 0.0332 -0.27 -0.2 Lung cancer in ever smokers; chr15:43340028 chr15:43726918~43747094:- LIHC cis rs4604234 0.614 rs59155686 ENSG00000272129.1 RP11-250B2.6 -3.75 0.000207 0.0332 -0.35 -0.2 Cancer; chr6:80141499 chr6:80355424~80356859:+ LIHC cis rs6545883 0.929 rs1186700 ENSG00000271889.1 RP11-493E12.1 3.75 0.000207 0.0332 0.24 0.2 Tuberculosis; chr2:61436237 chr2:61151433~61162105:- LIHC cis rs7208859 0.725 rs9910051 ENSG00000264538.5 SUZ12P1 -3.75 0.000207 0.0332 -0.2 -0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834184 chr17:30709299~30790908:+ LIHC cis rs17711722 1 rs17711722 ENSG00000237310.1 GS1-124K5.4 -3.75 0.000207 0.0333 -0.2 -0.2 Calcium levels; chr7:65806210 chr7:66493706~66495474:+ LIHC cis rs17711722 0.675 rs6947132 ENSG00000237310.1 GS1-124K5.4 -3.75 0.000207 0.0333 -0.2 -0.2 Calcium levels; chr7:65808508 chr7:66493706~66495474:+ LIHC cis rs2749097 1 rs2749096 ENSG00000244256.3 RN7SL130P -3.75 0.000207 0.0333 -0.26 -0.2 Alcohol consumption (transferrin glycosylation); chr1:63661991 chr1:63655743~63656047:+ LIHC cis rs5743030 0.793 rs5743116 ENSG00000253559.1 OSGEPL1-AS1 3.75 0.000207 0.0333 0.34 0.2 Subcutaneous adipose tissue; chr2:189849242 chr2:189762704~189765556:+ LIHC cis rs7412746 0.622 rs11552229 ENSG00000231073.1 RP11-316M1.3 3.75 0.000207 0.0333 0.2 0.2 Melanoma; chr1:150811509 chr1:150973123~150975534:+ LIHC cis rs9595908 0.869 rs9591185 ENSG00000212293.1 SNORA16 3.75 0.000208 0.0333 0.23 0.2 Body mass index; chr13:32627829 chr13:32420390~32420516:- LIHC cis rs1023500 0.573 rs4822088 ENSG00000226450.2 CYP2D8P 3.75 0.000208 0.0333 0.24 0.2 Schizophrenia; chr22:42074585 chr22:42149886~42155001:- LIHC cis rs7665090 1 rs2903283 ENSG00000230069.3 LRRC37A15P -3.75 0.000208 0.0333 -0.18 -0.2 Primary biliary cholangitis; chr4:102636596 chr4:102727274~102730721:- LIHC cis rs12468226 0.873 rs3181153 ENSG00000226261.1 AC064836.3 -3.75 0.000208 0.0333 -0.32 -0.2 Urate levels; chr2:202205155 chr2:202336024~202336727:- LIHC cis rs7829975 0.514 rs2979151 ENSG00000173295.6 FAM86B3P -3.75 0.000208 0.0333 -0.25 -0.2 Mood instability; chr8:8400509 chr8:8228595~8244865:+ LIHC cis rs1015362 0.503 rs1883708 ENSG00000228265.4 RALY-AS1 -3.75 0.000208 0.0333 -0.22 -0.2 Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling; chr20:33924107 chr20:33983052~33994357:- LIHC cis rs950169 0.544 rs62021193 ENSG00000259728.4 LINC00933 3.75 0.000208 0.0333 0.28 0.2 Schizophrenia; chr15:84627352 chr15:84570649~84580175:+ LIHC cis rs950169 0.58 rs17598114 ENSG00000259728.4 LINC00933 3.75 0.000208 0.0333 0.28 0.2 Schizophrenia; chr15:84628086 chr15:84570649~84580175:+ LIHC cis rs755249 0.565 rs7539279 ENSG00000182109.6 RP11-69E11.4 -3.75 0.000208 0.0333 -0.25 -0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39584896 chr1:39522280~39546187:- LIHC cis rs7508 0.509 rs441606 ENSG00000253671.1 RP11-806O11.1 3.75 0.000208 0.0333 0.24 0.2 Atrial fibrillation; chr8:18045537 chr8:17808941~17820868:+ LIHC cis rs763121 0.776 rs4820346 ENSG00000228274.3 RP3-508I15.9 3.75 0.000208 0.0333 0.22 0.2 Menopause (age at onset); chr22:38729069 chr22:38667585~38681820:- LIHC cis rs11096990 1 rs11096990 ENSG00000249207.1 RP11-360F5.1 -3.75 0.000208 0.0333 -0.23 -0.2 Cognitive function; chr4:39285329 chr4:39112677~39126818:- LIHC cis rs4792901 0.959 rs28659819 ENSG00000279602.1 CTD-3014M21.1 -3.75 0.000208 0.0333 -0.23 -0.2 Dupuytren's disease; chr17:43550162 chr17:43360041~43361361:- LIHC cis rs6831352 0.589 rs2602836 ENSG00000272777.1 RP11-571L19.8 3.75 0.000208 0.0334 0.27 0.2 Alcohol dependence; chr4:99093654 chr4:99067256~99068125:- LIHC cis rs151234 0.741 rs56236750 ENSG00000259982.1 CDC37P1 -3.75 0.000208 0.0334 -0.45 -0.2 Platelet distribution width; chr16:28583390 chr16:28700294~28701540:- LIHC cis rs6828577 0.779 rs419292 ENSG00000269893.5 SNHG8 3.75 0.000208 0.0334 0.2 0.2 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118712975 chr4:118278709~118279823:+ LIHC cis rs6828577 0.819 rs368669 ENSG00000269893.5 SNHG8 3.75 0.000208 0.0334 0.2 0.2 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118713120 chr4:118278709~118279823:+ LIHC cis rs11079159 0.959 rs4794562 ENSG00000263096.1 RP11-515O17.2 3.75 0.000208 0.0334 0.28 0.2 QRS duration; chr17:55302450 chr17:55271504~55273653:- LIHC cis rs755249 0.567 rs72661940 ENSG00000182109.6 RP11-69E11.4 3.75 0.000208 0.0334 0.26 0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39262975 chr1:39522280~39546187:- LIHC cis rs854624 0.892 rs1734959 ENSG00000278690.1 RP11-104J23.2 3.75 0.000208 0.0334 0.42 0.2 Blood protein levels; chr17:36009470 chr17:36012504~36012891:+ LIHC cis rs6545883 0.965 rs7421663 ENSG00000271889.1 RP11-493E12.1 3.75 0.000208 0.0334 0.24 0.2 Tuberculosis; chr2:61526651 chr2:61151433~61162105:- LIHC cis rs2658782 0.593 rs2243410 ENSG00000279684.1 RP11-755E23.2 -3.75 0.000208 0.0334 -0.29 -0.2 Pulmonary function decline; chr11:93522353 chr11:93286629~93288903:- LIHC cis rs4287000 0.585 rs4403473 ENSG00000227603.1 RP11-165J3.6 3.75 0.000208 0.0334 0.22 0.2 Itch intensity from mosquito bite adjusted by bite size; chr9:93636892 chr9:93435332~93437121:- LIHC cis rs591584 0.874 rs7110167 ENSG00000255893.1 RP11-685N10.1 -3.75 0.000208 0.0334 -0.2 -0.2 Macrophage Migration Inhibitory Factor levels; chr11:94587071 chr11:94472908~94473570:- LIHC cis rs591584 0.874 rs7111231 ENSG00000255893.1 RP11-685N10.1 -3.75 0.000208 0.0334 -0.2 -0.2 Macrophage Migration Inhibitory Factor levels; chr11:94588052 chr11:94472908~94473570:- LIHC cis rs4803480 0.572 rs17710743 ENSG00000270164.1 LINC01480 3.75 0.000208 0.0334 0.43 0.2 Schizophrenia; chr19:41569079 chr19:41535183~41536904:+ LIHC cis rs4453827 1 rs11709505 ENSG00000271916.1 RP11-884K10.6 3.75 0.000209 0.0334 0.39 0.2 Blood protein levels; chr3:53715471 chr3:53797764~53798019:- LIHC cis rs4453827 1 rs4453827 ENSG00000271916.1 RP11-884K10.6 3.75 0.000209 0.0334 0.39 0.2 Blood protein levels; chr3:53716057 chr3:53797764~53798019:- LIHC cis rs4453827 1 rs2125876 ENSG00000271916.1 RP11-884K10.6 3.75 0.000209 0.0334 0.39 0.2 Blood protein levels; chr3:53716239 chr3:53797764~53798019:- LIHC cis rs16958440 0.867 rs76922914 ENSG00000267724.1 RP11-49K24.8 3.75 0.000209 0.0334 0.37 0.2 Sitting height ratio; chr18:47162083 chr18:47105946~47108062:+ LIHC cis rs4148008 0.589 rs8079580 ENSG00000267250.1 RP11-118B18.2 -3.75 0.000209 0.0334 -0.26 -0.2 HDL cholesterol; chr17:68830090 chr17:68793549~68797822:- LIHC cis rs6832769 0.922 rs11133376 ENSG00000272969.1 RP11-528I4.2 3.75 0.000209 0.0334 0.23 0.2 Personality dimensions; chr4:55386866 chr4:55547112~55547889:+ LIHC cis rs803903 0.605 rs10983195 ENSG00000230894.1 RP11-67K19.3 3.75 0.000209 0.0334 0.27 0.2 Breast cancer; chr9:116492789 chr9:116568449~116586328:+ LIHC cis rs773506 0.692 rs10991835 ENSG00000273381.1 RP11-305L7.7 3.75 0.000209 0.0335 0.19 0.2 Type 2 diabetes nephropathy; chr9:91233309 chr9:91206175~91210299:- LIHC cis rs11733284 0.962 rs4695328 ENSG00000259959.1 RP11-121C2.2 3.75 0.000209 0.0335 0.18 0.2 Gout;Renal underexcretion gout; chr4:48028272 chr4:47840122~47844339:- LIHC cis rs9532669 0.889 rs7333447 ENSG00000168852.11 TPTE2P5 3.75 0.000209 0.0335 0.21 0.2 Cervical cancer; chr13:40917586 chr13:40822296~40921749:- LIHC cis rs10857712 0.851 rs56153177 ENSG00000214279.11 SCART1 -3.75 0.000209 0.0335 -0.25 -0.2 Systemic lupus erythematosus; chr10:133403471 chr10:133453928~133523558:+ LIHC cis rs7615952 0.641 rs2365019 ENSG00000171084.14 FAM86JP 3.75 0.000209 0.0335 0.32 0.2 Blood pressure (smoking interaction); chr3:126089292 chr3:125916620~125930024:+ LIHC cis rs6832769 1 rs28448438 ENSG00000272969.1 RP11-528I4.2 -3.75 0.000209 0.0335 -0.24 -0.2 Personality dimensions; chr4:55550498 chr4:55547112~55547889:+ LIHC cis rs6860806 0.531 rs270607 ENSG00000263597.1 MIR3936 3.75 0.000209 0.0335 0.22 0.2 Breast cancer; chr5:132313493 chr5:132365490~132365599:- LIHC cis rs4595586 0.87 rs7970097 ENSG00000257718.1 RP11-396F22.1 -3.75 0.000209 0.0335 -0.23 -0.2 Morning vs. evening chronotype; chr12:38908445 chr12:38906451~38909592:+ LIHC cis rs4578769 0.765 rs55762801 ENSG00000265943.1 RP11-739L10.1 -3.75 0.000209 0.0335 -0.26 -0.2 Eosinophil percentage of white cells; chr18:22807096 chr18:22699481~22933764:- LIHC cis rs5742933 0.857 rs1233284 ENSG00000253559.1 OSGEPL1-AS1 -3.75 0.000209 0.0335 -0.25 -0.2 Ferritin levels; chr2:189825045 chr2:189762704~189765556:+ LIHC cis rs5742933 0.817 rs1233288 ENSG00000253559.1 OSGEPL1-AS1 -3.75 0.000209 0.0335 -0.25 -0.2 Ferritin levels; chr2:189825999 chr2:189762704~189765556:+ LIHC cis rs1979679 0.842 rs4931727 ENSG00000278733.1 RP11-425D17.1 3.75 0.000209 0.0335 0.26 0.2 Ossification of the posterior longitudinal ligament of the spine; chr12:28146186 chr12:28185625~28186190:- LIHC cis rs10129255 0.833 rs7156689 ENSG00000223648.3 IGHV3-64 3.75 0.000209 0.0335 0.15 0.2 Kawasaki disease; chr14:106816039 chr14:106643132~106658258:- LIHC cis rs9532669 0.963 rs4942012 ENSG00000168852.11 TPTE2P5 3.75 0.000209 0.0335 0.22 0.2 Cervical cancer; chr13:40939112 chr13:40822296~40921749:- LIHC cis rs860295 0.65 rs12027412 ENSG00000203761.5 MSTO2P 3.75 0.000209 0.0335 0.17 0.2 Body mass index; chr1:155939139 chr1:155745829~155750137:+ LIHC cis rs80139154 0.658 rs76631336 ENSG00000224961.1 RP1-278O22.1 3.75 0.000209 0.0336 0.5 0.2 Diastolic blood pressure; chr20:10700575 chr20:10753090~10753966:+ LIHC cis rs9640161 0.783 rs35435439 ENSG00000261305.1 RP4-584D14.7 3.75 0.000209 0.0336 0.25 0.2 Blood protein levels;Circulating chemerin levels; chr7:150366445 chr7:150341771~150342607:+ LIHC cis rs6832769 1 rs11726609 ENSG00000272969.1 RP11-528I4.2 3.75 0.000209 0.0336 0.24 0.2 Personality dimensions; chr4:55534702 chr4:55547112~55547889:+ LIHC cis rs8002861 0.664 rs2325089 ENSG00000274001.1 RP11-5G9.5 -3.75 0.000209 0.0336 -0.21 -0.2 Leprosy; chr13:43876086 chr13:43877715~43878163:- LIHC cis rs6472827 0.953 rs35446151 ENSG00000253983.2 RP1-16A9.1 -3.75 0.000209 0.0336 -0.26 -0.2 Uterine fibroids; chr8:74209236 chr8:74199396~74208441:+ LIHC cis rs5742933 0.817 rs1233299 ENSG00000253559.1 OSGEPL1-AS1 -3.75 0.000209 0.0336 -0.26 -0.2 Ferritin levels; chr2:189799912 chr2:189762704~189765556:+ LIHC cis rs34734847 1 rs10431385 ENSG00000277423.1 RP11-173P15.9 3.75 0.00021 0.0336 0.21 0.2 Mean corpuscular volume; chr12:120691079 chr12:120703867~120704282:+ LIHC cis rs7607369 0.527 rs72966038 ENSG00000272555.1 RP11-459I19.1 -3.75 0.00021 0.0336 -0.23 -0.2 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218791467 chr2:218818690~218819144:+ LIHC cis rs9976767 0.714 rs35269816 ENSG00000225218.1 AP001628.6 -3.75 0.00021 0.0336 -0.2 -0.2 Type 1 diabetes; chr21:42414978 chr21:42831040~42836477:- LIHC cis rs9976767 0.714 rs35940194 ENSG00000225218.1 AP001628.6 -3.75 0.00021 0.0336 -0.2 -0.2 Type 1 diabetes; chr21:42414981 chr21:42831040~42836477:- LIHC cis rs745580 0.933 rs6461900 ENSG00000199085.2 MIR148A -3.75 0.00021 0.0336 -0.2 -0.2 Obesity-related traits; chr7:25985067 chr7:25949903~25950013:- LIHC cis rs1816213 0.744 rs12991012 ENSG00000273466.1 RP11-548H3.1 -3.75 0.00021 0.0336 -0.31 -0.2 Diastolic blood pressure; chr2:218585873 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs35588689 ENSG00000273466.1 RP11-548H3.1 -3.75 0.00021 0.0336 -0.31 -0.2 Diastolic blood pressure; chr2:218589806 chr2:218633256~218634014:- LIHC cis rs4578769 0.722 rs55758053 ENSG00000265943.1 RP11-739L10.1 -3.75 0.00021 0.0336 -0.26 -0.2 Eosinophil percentage of white cells; chr18:22958405 chr18:22699481~22933764:- LIHC cis rs11096990 0.964 rs35494908 ENSG00000249685.1 RP11-360F5.3 -3.75 0.00021 0.0336 -0.27 -0.2 Cognitive function; chr4:39252574 chr4:39133913~39135608:+ LIHC cis rs42490 0.576 rs425140 ENSG00000251136.7 RP11-37B2.1 -3.75 0.00021 0.0336 -0.17 -0.2 Leprosy; chr8:89852397 chr8:89609409~89757727:- LIHC cis rs4604234 0.522 rs73482011 ENSG00000272129.1 RP11-250B2.6 -3.75 0.00021 0.0336 -0.36 -0.2 Cancer; chr6:80210306 chr6:80355424~80356859:+ LIHC cis rs6471393 0.862 rs11994625 ENSG00000253848.1 RP11-10N23.5 3.75 0.00021 0.0336 0.22 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93760149 chr8:93741193~93744534:+ LIHC cis rs8077577 0.747 rs8081155 ENSG00000260647.1 RP1-178F10.1 3.75 0.00021 0.0336 0.25 0.2 Obesity-related traits; chr17:18288634 chr17:18268080~18268828:+ LIHC cis rs7231041 0.75 rs1625366 ENSG00000263846.1 CIAPIN1P 3.75 0.00021 0.0336 0.23 0.2 Obesity-related traits; chr18:25800596 chr18:26599408~26600338:+ LIHC cis rs11690935 0.632 rs6433323 ENSG00000228389.1 AC068039.4 3.75 0.00021 0.0336 0.25 0.2 Schizophrenia; chr2:172008155 chr2:171773482~171775844:+ LIHC cis rs875971 0.666 rs13242072 ENSG00000237310.1 GS1-124K5.4 -3.75 0.00021 0.0336 -0.19 -0.2 Aortic root size; chr7:66301001 chr7:66493706~66495474:+ LIHC cis rs4578769 0.722 rs1010801 ENSG00000266850.1 RP11-370A5.1 3.75 0.00021 0.0336 0.23 0.2 Eosinophil percentage of white cells; chr18:23027435 chr18:22723491~22907721:- LIHC cis rs7791362 1 rs7791362 ENSG00000227719.1 AC006042.6 -3.75 0.00021 0.0336 -0.36 -0.2 Cognitive function; chr7:8103297 chr7:8114025~8116561:+ LIHC cis rs4938303 0.587 rs10892017 ENSG00000254851.1 RP11-109L13.1 3.75 0.00021 0.0336 0.24 0.2 Triglycerides; chr11:116697165 chr11:117135528~117138582:+ LIHC cis rs6832769 0.961 rs2412647 ENSG00000272969.1 RP11-528I4.2 3.75 0.00021 0.0336 0.24 0.2 Personality dimensions; chr4:55452938 chr4:55547112~55547889:+ LIHC cis rs6456156 0.792 rs10946214 ENSG00000227598.1 RP1-167A14.2 -3.75 0.00021 0.0336 -0.2 -0.2 Primary biliary cholangitis; chr6:167102634 chr6:166969626~166999065:- LIHC cis rs7674212 0.507 rs6843738 ENSG00000248971.2 KRT8P46 -3.75 0.00021 0.0337 -0.21 -0.2 Type 2 diabetes; chr4:103014844 chr4:102728746~102730171:- LIHC cis rs12681287 0.547 rs9297921 ENSG00000254088.1 SLC2A3P4 -3.75 0.00021 0.0337 -0.24 -0.2 Caudate activity during reward; chr8:86530058 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs9297922 ENSG00000254088.1 SLC2A3P4 -3.75 0.00021 0.0337 -0.24 -0.2 Caudate activity during reward; chr8:86530089 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs35871312 ENSG00000254088.1 SLC2A3P4 -3.75 0.00021 0.0337 -0.24 -0.2 Caudate activity during reward; chr8:86530991 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs10087788 ENSG00000254088.1 SLC2A3P4 -3.75 0.00021 0.0337 -0.24 -0.2 Caudate activity during reward; chr8:86531946 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs10956873 ENSG00000254088.1 SLC2A3P4 -3.75 0.00021 0.0337 -0.24 -0.2 Caudate activity during reward; chr8:86534800 chr8:86503591~86505061:+ LIHC cis rs12681287 0.511 rs9297923 ENSG00000254088.1 SLC2A3P4 -3.75 0.00021 0.0337 -0.24 -0.2 Caudate activity during reward; chr8:86536761 chr8:86503591~86505061:+ LIHC cis rs9611519 1 rs3818003 ENSG00000231907.2 GAPDHP37 3.75 0.00021 0.0337 0.24 0.2 Neuroticism; chr22:41213686 chr22:40673484~40674451:- LIHC cis rs73198271 0.74 rs1039911 ENSG00000253893.2 FAM85B 3.75 0.00021 0.0337 0.31 0.2 Bone ultrasound measurement (broadband ultrasound attenuation); chr8:8790696 chr8:8167819~8226614:- LIHC cis rs494003 1 rs12287832 ENSG00000265874.1 MIR4489 3.75 0.00021 0.0337 0.33 0.2 Systemic lupus erythematosus; chr11:65786021 chr11:65649192~65649253:+ LIHC cis rs1061377 0.748 rs12649085 ENSG00000249685.1 RP11-360F5.3 3.75 0.00021 0.0337 0.23 0.2 Uric acid levels; chr4:39106459 chr4:39133913~39135608:+ LIHC cis rs61160187 0.582 rs7723901 ENSG00000272308.1 RP11-231G3.1 -3.75 0.00021 0.0337 -0.21 -0.2 Educational attainment (years of education);Educational attainment (college completion); chr5:60977163 chr5:60866457~60866935:- LIHC cis rs61160187 0.582 rs1471488 ENSG00000272308.1 RP11-231G3.1 -3.75 0.00021 0.0337 -0.21 -0.2 Educational attainment (years of education);Educational attainment (college completion); chr5:60990270 chr5:60866457~60866935:- LIHC cis rs9601248 0.711 rs9530937 ENSG00000227354.5 RBM26-AS1 -3.75 0.00021 0.0337 -0.23 -0.2 Major depressive disorder; chr13:79603701 chr13:79406309~79424328:+ LIHC cis rs718433 0.681 rs2097262 ENSG00000258441.1 LINC00641 -3.75 0.00021 0.0337 -0.2 -0.2 Intraocular pressure; chr14:21781015 chr14:21200079~21206900:- LIHC cis rs614226 1 rs614226 ENSG00000278344.1 RP11-18C24.8 -3.75 0.00021 0.0337 -0.32 -0.2 Type 1 diabetes nephropathy; chr12:120536707 chr12:120500735~120501090:- LIHC cis rs10752881 1 rs4233192 ENSG00000224468.3 RP11-181K3.4 3.75 0.000211 0.0337 0.17 0.2 Colorectal cancer; chr1:183001702 chr1:183138402~183141282:- LIHC cis rs2659703 0.933 rs2981024 ENSG00000261159.1 RP11-723O4.9 3.75 0.000211 0.0337 0.26 0.2 Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid); chr3:128455736 chr3:128859716~128860526:- LIHC cis rs13434995 0.589 rs62305201 ENSG00000273257.1 RP11-177J6.1 -3.75 0.000211 0.0337 -0.32 -0.2 Adiponectin levels; chr4:55386778 chr4:55387949~55388271:+ LIHC cis rs13434995 0.589 rs62305202 ENSG00000273257.1 RP11-177J6.1 -3.75 0.000211 0.0337 -0.32 -0.2 Adiponectin levels; chr4:55386861 chr4:55387949~55388271:+ LIHC cis rs9611519 0.964 rs2092563 ENSG00000231907.2 GAPDHP37 3.75 0.000211 0.0337 0.3 0.2 Neuroticism; chr22:41196673 chr22:40673484~40674451:- LIHC cis rs7121538 0.551 rs73424221 ENSG00000251991.1 RNU7-49P -3.75 0.000211 0.0337 -0.32 -0.2 HDL cholesterol; chr11:14565081 chr11:14478892~14478953:+ LIHC cis rs853679 0.882 rs4713140 ENSG00000219891.2 ZSCAN12P1 3.75 0.000211 0.0337 0.36 0.2 Depression; chr6:28129415 chr6:28091154~28093664:+ LIHC cis rs116139393 0.611 rs62439722 ENSG00000187953.9 PMS2CL -3.75 0.000211 0.0337 -0.21 -0.2 Alzheimer's disease (APOE e4 interaction); chr7:6725309 chr7:6710128~6753862:+ LIHC cis rs4453827 1 rs11719179 ENSG00000271916.1 RP11-884K10.6 3.75 0.000211 0.0337 0.39 0.2 Blood protein levels; chr3:53725694 chr3:53797764~53798019:- LIHC cis rs6471393 0.83 rs6981752 ENSG00000253848.1 RP11-10N23.5 3.75 0.000211 0.0337 0.22 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93761046 chr8:93741193~93744534:+ LIHC cis rs6445975 0.715 rs4681835 ENSG00000272360.1 RP11-359I18.5 -3.75 0.000211 0.0337 -0.23 -0.2 Systemic lupus erythematosus; chr3:58277624 chr3:58490830~58491291:- LIHC cis rs6500602 0.702 rs9929475 ENSG00000278700.1 Metazoa_SRP -3.75 0.000211 0.0337 -0.25 -0.2 Schizophrenia; chr16:4490884 chr16:4658851~4659151:+ LIHC cis rs2283792 0.765 rs2266969 ENSG00000224086.5 LL22NC03-86G7.1 -3.75 0.000211 0.0337 -0.21 -0.2 Multiple sclerosis; chr22:21819618 chr22:21938293~21977632:+ LIHC cis rs10943724 0.799 rs13199780 ENSG00000272129.1 RP11-250B2.6 3.75 0.000211 0.0338 0.22 0.2 Thiazide-induced adverse metabolic effects in hypertensive patients; chr6:80456461 chr6:80355424~80356859:+ LIHC cis rs2348418 0.832 rs1552761 ENSG00000247934.4 RP11-967K21.1 3.75 0.000211 0.0338 0.18 0.2 Lung function (FEV1);Lung function (FVC); chr12:28383406 chr12:28163298~28190738:- LIHC cis rs3091242 0.933 rs7541095 ENSG00000261349.1 RP3-465N24.5 -3.75 0.000211 0.0338 -0.19 -0.2 Erythrocyte sedimentation rate; chr1:25434800 chr1:25266102~25267136:- LIHC cis rs4561483 0.801 rs33623 ENSG00000261216.1 RP11-166B2.5 3.75 0.000211 0.0338 0.22 0.2 Testicular germ cell tumor; chr16:11913578 chr16:11908208~11908916:+ LIHC cis rs9674544 0.792 rs8076012 ENSG00000248278.1 SUMO2P17 -3.75 0.000211 0.0338 -0.27 -0.2 Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption); chr17:49024627 chr17:48874860~48908983:- LIHC cis rs3105593 0.583 rs7169154 ENSG00000273674.3 CTD-2378E12.1 3.75 0.000211 0.0338 0.24 0.2 QT interval; chr15:50521077 chr15:50839875~50908599:- LIHC cis rs3105593 0.583 rs3098191 ENSG00000273674.3 CTD-2378E12.1 3.75 0.000211 0.0338 0.24 0.2 QT interval; chr15:50521119 chr15:50839875~50908599:- LIHC cis rs2159324 0.868 rs11669018 ENSG00000267348.2 CTB-179K24.3 3.75 0.000212 0.0338 0.22 0.2 Quantitative traits; chr19:45192861 chr19:45076510~45090391:- LIHC cis rs2762353 0.808 rs1183201 ENSG00000242387.1 HIST1H2APS2 3.75 0.000212 0.0338 0.23 0.2 Blood metabolite levels; chr6:25823216 chr6:25882026~25882395:- LIHC cis rs2018683 0.649 rs221171 ENSG00000272568.4 CTB-113D17.1 -3.75 0.000212 0.0338 -0.26 -0.2 Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer; chr7:28966523 chr7:28979967~29013367:+ LIHC cis rs4873772 0.653 rs7014443 ENSG00000253608.1 RP11-770E5.1 3.75 0.000212 0.0338 0.22 0.2 Lobe attachment (rater-scored or self-reported); chr8:47684382 chr8:48551567~48698510:+ LIHC cis rs2281636 0.6 rs56901709 ENSG00000233690.1 EBAG9P1 3.74 0.000212 0.0338 0.2 0.2 Obesity-related traits; chr10:99639205 chr10:99697407~99697949:- LIHC cis rs35828350 1 rs35828350 ENSG00000225151.9 GOLGA2P7 -3.74 0.000212 0.0339 -0.26 -0.2 Autism spectrum disorder or schizophrenia; chr15:84812610 chr15:84199311~84230136:- LIHC cis rs6472827 1 rs6472827 ENSG00000253983.2 RP1-16A9.1 -3.74 0.000212 0.0339 -0.26 -0.2 Uterine fibroids; chr8:74207107 chr8:74199396~74208441:+ LIHC cis rs10916248 0.569 rs4654002 ENSG00000232628.4 RP11-365O16.3 3.74 0.000212 0.0339 0.24 0.2 QT interval (drug interaction); chr1:224075680 chr1:224208747~224213279:- LIHC cis rs2518049 0.519 rs4881402 ENSG00000225418.1 AKR1C5P 3.74 0.000212 0.0339 0.21 0.2 Metabolic traits; chr10:5126338 chr10:5122087~5135226:- LIHC cis rs4578769 0.569 rs8094359 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22907743 chr18:22723491~22907721:- LIHC cis rs4578769 0.55 rs8092358 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22911835 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs1379805 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22914589 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs1031652 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22916035 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs9967326 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22916787 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs9946660 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22917007 chr18:22723491~22907721:- LIHC cis rs12962334 0.568 rs2034932 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Breast cancer; chr18:22918727 chr18:22723491~22907721:- LIHC cis rs4578769 0.55 rs721578 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22922719 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs7229422 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22923157 chr18:22723491~22907721:- LIHC cis rs4578769 0.589 rs9964726 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22925516 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs9958831 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22926050 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs11659166 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22926143 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs12957183 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22927124 chr18:22723491~22907721:- LIHC cis rs4578769 0.531 rs12964304 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22928641 chr18:22723491~22907721:- LIHC cis rs4578769 0.531 rs12968784 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22928645 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs9948922 ENSG00000266850.1 RP11-370A5.1 3.74 0.000212 0.0339 0.22 0.2 Eosinophil percentage of white cells; chr18:22930198 chr18:22723491~22907721:- LIHC cis rs6723108 0.627 rs4954191 ENSG00000224043.6 CCNT2-AS1 -3.74 0.000212 0.0339 -0.28 -0.2 Type 2 diabetes; chr2:134854878 chr2:134735464~134918710:- LIHC cis rs7617773 0.78 rs3197223 ENSG00000228638.1 FCF1P2 -3.74 0.000212 0.0339 -0.23 -0.2 Coronary artery disease; chr3:48294367 chr3:48290793~48291375:- LIHC cis rs6545883 0.831 rs1186704 ENSG00000271889.1 RP11-493E12.1 3.74 0.000212 0.0339 0.24 0.2 Tuberculosis; chr2:61445856 chr2:61151433~61162105:- LIHC cis rs2439831 0.618 rs8023508 ENSG00000166763.7 STRCP1 -3.74 0.000212 0.0339 -0.3 -0.2 Lung cancer in ever smokers; chr15:43883905 chr15:43699488~43718184:- LIHC cis rs3749237 0.537 rs4459909 ENSG00000226913.1 BSN-AS2 -3.74 0.000212 0.0339 -0.26 -0.2 Resting heart rate; chr3:49431784 chr3:49549306~49554366:- LIHC cis rs3749237 0.595 rs11130196 ENSG00000226913.1 BSN-AS2 -3.74 0.000212 0.0339 -0.26 -0.2 Resting heart rate; chr3:49452716 chr3:49549306~49554366:- LIHC cis rs1816213 0.744 rs17601474 ENSG00000273466.1 RP11-548H3.1 -3.74 0.000212 0.0339 -0.31 -0.2 Diastolic blood pressure; chr2:218605352 chr2:218633256~218634014:- LIHC cis rs2117029 0.782 rs10459232 ENSG00000281789.1 Y_RNA 3.74 0.000212 0.0339 0.2 0.2 Intelligence (multi-trait analysis); chr12:49073293 chr12:48927939~48928033:- LIHC cis rs5743030 1 rs77934397 ENSG00000253559.1 OSGEPL1-AS1 -3.74 0.000212 0.034 -0.36 -0.2 Subcutaneous adipose tissue; chr2:189927529 chr2:189762704~189765556:+ LIHC cis rs2243480 1 rs1499614 ENSG00000232546.1 RP11-458F8.1 -3.74 0.000212 0.034 -0.22 -0.2 Diabetic kidney disease; chr7:66265811 chr7:66848496~66858136:+ LIHC cis rs1553477 0.64 rs10072767 ENSG00000272123.1 CTD-2366F13.2 3.74 0.000212 0.034 0.26 0.2 Monobrow; chr5:53822988 chr5:53089016~53089468:- LIHC cis rs10510102 0.935 rs12245528 ENSG00000273891.1 RP11-500G22.5 -3.74 0.000213 0.034 -0.26 -0.2 Breast cancer; chr10:121881006 chr10:121965764~121967700:+ LIHC cis rs794185 0.564 rs1825915 ENSG00000231249.1 ITPR1-AS1 -3.74 0.000213 0.034 -0.21 -0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4472186 chr3:4490891~4493163:- LIHC cis rs794185 0.565 rs1825916 ENSG00000231249.1 ITPR1-AS1 -3.74 0.000213 0.034 -0.21 -0.2 Multiple sclerosis--Brain Glutamate Levels; chr3:4472228 chr3:4490891~4493163:- LIHC cis rs2554380 0.55 rs11853949 ENSG00000225151.9 GOLGA2P7 -3.74 0.000213 0.034 -0.3 -0.2 Height; chr15:83848152 chr15:84199311~84230136:- LIHC cis rs6456156 0.586 rs13195158 ENSG00000227598.1 RP1-167A14.2 -3.74 0.000213 0.034 -0.21 -0.2 Primary biliary cholangitis; chr6:167067904 chr6:166969626~166999065:- LIHC cis rs3809912 0.546 rs4797730 ENSG00000266969.1 RP11-773H22.4 -3.74 0.000213 0.034 -0.28 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr18:13178097 chr18:12984694~12991173:- LIHC cis rs10129255 0.556 rs6576222 ENSG00000211972.2 IGHV3-66 3.74 0.000213 0.034 0.15 0.2 Kawasaki disease; chr14:106776442 chr14:106675017~106675544:- LIHC cis rs10129255 0.536 rs6576223 ENSG00000211972.2 IGHV3-66 3.74 0.000213 0.034 0.15 0.2 Kawasaki disease; chr14:106776448 chr14:106675017~106675544:- LIHC cis rs10129255 0.5 rs988134 ENSG00000211972.2 IGHV3-66 3.74 0.000213 0.034 0.15 0.2 Kawasaki disease; chr14:106776698 chr14:106675017~106675544:- LIHC cis rs10129255 0.5 rs988133 ENSG00000211972.2 IGHV3-66 3.74 0.000213 0.034 0.15 0.2 Kawasaki disease; chr14:106776724 chr14:106675017~106675544:- LIHC cis rs10129255 0.518 rs8009594 ENSG00000211972.2 IGHV3-66 3.74 0.000213 0.034 0.15 0.2 Kawasaki disease; chr14:106777494 chr14:106675017~106675544:- LIHC cis rs13113518 0.678 rs13149568 ENSG00000249700.7 SRD5A3-AS1 3.74 0.000213 0.034 0.22 0.2 Height; chr4:55370412 chr4:55363971~55395847:- LIHC cis rs1075265 0.933 rs7560947 ENSG00000233266.1 HMGB1P31 3.74 0.000213 0.034 0.24 0.2 Chronotype;Morning vs. evening chronotype; chr2:54087473 chr2:54051334~54051760:+ LIHC cis rs6545883 0.931 rs778765 ENSG00000271889.1 RP11-493E12.1 3.74 0.000213 0.034 0.24 0.2 Tuberculosis; chr2:61559250 chr2:61151433~61162105:- LIHC cis rs2658782 0.547 rs3020064 ENSG00000279684.1 RP11-755E23.2 -3.74 0.000213 0.0341 -0.29 -0.2 Pulmonary function decline; chr11:93327685 chr11:93286629~93288903:- LIHC cis rs2439831 0.867 rs935901 ENSG00000205771.5 CATSPER2P1 -3.74 0.000213 0.0341 -0.35 -0.2 Lung cancer in ever smokers; chr15:43359058 chr15:43726918~43747094:- LIHC cis rs12655019 0.92 rs6882657 ENSG00000271828.1 CTD-2310F14.1 3.74 0.000213 0.0341 0.4 0.2 Breast cancer (early onset); chr5:56926912 chr5:56927874~56929573:+ LIHC cis rs7617773 0.817 rs11130163 ENSG00000228638.1 FCF1P2 -3.74 0.000213 0.0341 -0.2 -0.2 Coronary artery disease; chr3:48271168 chr3:48290793~48291375:- LIHC cis rs12681287 0.577 rs10481197 ENSG00000254088.1 SLC2A3P4 -3.74 0.000213 0.0341 -0.24 -0.2 Caudate activity during reward; chr8:86534323 chr8:86503591~86505061:+ LIHC cis rs2439831 0.867 rs8039638 ENSG00000166763.7 STRCP1 3.74 0.000213 0.0341 0.28 0.2 Lung cancer in ever smokers; chr15:43342207 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs28415933 ENSG00000166763.7 STRCP1 3.74 0.000213 0.0341 0.28 0.2 Lung cancer in ever smokers; chr15:43343602 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs12324572 ENSG00000166763.7 STRCP1 3.74 0.000213 0.0341 0.28 0.2 Lung cancer in ever smokers; chr15:43344002 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs2412780 ENSG00000166763.7 STRCP1 3.74 0.000213 0.0341 0.28 0.2 Lung cancer in ever smokers; chr15:43363596 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs2412779 ENSG00000166763.7 STRCP1 3.74 0.000213 0.0341 0.28 0.2 Lung cancer in ever smokers; chr15:43363729 chr15:43699488~43718184:- LIHC cis rs2439831 0.867 rs2899082 ENSG00000166763.7 STRCP1 3.74 0.000213 0.0341 0.28 0.2 Lung cancer in ever smokers; chr15:43363845 chr15:43699488~43718184:- LIHC cis rs34375054 0.525 rs7133614 ENSG00000279233.1 RP11-158L12.4 3.74 0.000213 0.0341 0.17 0.2 Post bronchodilator FEV1/FVC ratio; chr12:125121411 chr12:125138245~125141711:+ LIHC cis rs6723108 0.627 rs6430549 ENSG00000224043.6 CCNT2-AS1 -3.74 0.000213 0.0341 -0.28 -0.2 Type 2 diabetes; chr2:134858776 chr2:134735464~134918710:- LIHC cis rs6723108 0.627 rs6430550 ENSG00000224043.6 CCNT2-AS1 -3.74 0.000213 0.0341 -0.28 -0.2 Type 2 diabetes; chr2:134858815 chr2:134735464~134918710:- LIHC cis rs6723108 0.627 rs1446523 ENSG00000224043.6 CCNT2-AS1 -3.74 0.000213 0.0341 -0.28 -0.2 Type 2 diabetes; chr2:134859051 chr2:134735464~134918710:- LIHC cis rs17818399 0.712 rs13008088 ENSG00000239332.4 LINC01119 -3.74 0.000214 0.0341 -0.28 -0.2 Height; chr2:46554441 chr2:46816697~46859007:+ LIHC cis rs763121 0.853 rs5750669 ENSG00000273076.1 RP3-508I15.22 3.74 0.000214 0.0341 0.24 0.2 Menopause (age at onset); chr22:38684633 chr22:38743495~38743910:+ LIHC cis rs9457247 0.765 rs6904946 ENSG00000227598.1 RP1-167A14.2 3.74 0.000214 0.0341 0.21 0.2 Crohn's disease; chr6:167020460 chr6:166969626~166999065:- LIHC cis rs12681287 0.604 rs7017716 ENSG00000254088.1 SLC2A3P4 3.74 0.000214 0.0341 0.23 0.2 Caudate activity during reward; chr8:86416772 chr8:86503591~86505061:+ LIHC cis rs694739 0.796 rs479777 ENSG00000236935.1 AP003774.1 3.74 0.000214 0.0341 0.21 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64340005 chr11:64325050~64329504:- LIHC cis rs733175 0.951 rs6826764 ENSG00000250413.1 RP11-448G15.1 3.74 0.000214 0.0341 0.29 0.2 Psychosis and Alzheimer's disease; chr4:10029170 chr4:10006482~10009725:+ LIHC cis rs7989336 0.625 rs1925108 ENSG00000247400.3 DNAJC3-AS1 3.74 0.000214 0.0341 0.21 0.2 Obesity; chr13:96354744 chr13:95648733~95676925:- LIHC cis rs12681366 0.801 rs2919668 ENSG00000253704.1 RP11-267M23.4 3.74 0.000214 0.0341 0.24 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94449193 chr8:94553722~94569745:+ LIHC cis rs9611519 0.754 rs4820435 ENSG00000231907.2 GAPDHP37 3.74 0.000214 0.0341 0.29 0.2 Neuroticism; chr22:41256842 chr22:40673484~40674451:- LIHC cis rs338389 0.542 rs28694418 ENSG00000260657.2 RP11-315D16.4 -3.74 0.000214 0.0341 -0.26 -0.2 Survival in rectal cancer; chr15:67949855 chr15:68267792~68277994:- LIHC cis rs338389 0.542 rs12914946 ENSG00000260657.2 RP11-315D16.4 -3.74 0.000214 0.0341 -0.26 -0.2 Survival in rectal cancer; chr15:67949990 chr15:68267792~68277994:- LIHC cis rs7121538 0.551 rs12420146 ENSG00000251991.1 RNU7-49P -3.74 0.000214 0.0341 -0.31 -0.2 HDL cholesterol; chr11:14622685 chr11:14478892~14478953:+ LIHC cis rs1023500 1 rs6002552 ENSG00000227370.1 RP4-669P10.19 3.74 0.000214 0.0341 0.26 0.2 Schizophrenia; chr22:41942347 chr22:42132543~42132998:+ LIHC cis rs494562 0.73 rs9450271 ENSG00000234155.1 RP11-30P6.6 -3.74 0.000214 0.0341 -0.41 -0.2 Metabolic traits;Blood metabolite levels; chr6:85405119 chr6:85387219~85390186:- LIHC cis rs3204270 0.5 rs62077175 ENSG00000281517.1 Metazoa_SRP -3.74 0.000214 0.0341 -0.38 -0.2 Dental caries; chr17:81682538 chr17:81718849~81719095:- LIHC cis rs7607369 0.714 rs4674332 ENSG00000272555.1 RP11-459I19.1 3.74 0.000214 0.0341 0.22 0.2 Amyotrophic lateral sclerosis;Red blood cell count; chr2:218739603 chr2:218818690~218819144:+ LIHC cis rs643506 0.874 rs609007 ENSG00000230911.1 PPIHP1 3.74 0.000214 0.0342 0.26 0.2 Breast cancer; chr11:111848870 chr11:112029858~112030367:- LIHC cis rs919433 1 rs919433 ENSG00000231621.1 AC013264.2 3.74 0.000214 0.0342 0.18 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197301841 chr2:197197991~197199273:+ LIHC cis rs13113518 0.783 rs1586555 ENSG00000249700.7 SRD5A3-AS1 3.74 0.000214 0.0342 0.23 0.2 Height; chr4:55587104 chr4:55363971~55395847:- LIHC cis rs287982 1 rs287975 ENSG00000269973.1 RP11-95D17.1 -3.74 0.000214 0.0342 -0.19 -0.2 Nonsyndromic cleft lip with cleft palate; chr2:9829346 chr2:9936360~9939590:+ LIHC cis rs10129255 0.912 rs67410411 ENSG00000211972.2 IGHV3-66 3.74 0.000214 0.0342 0.16 0.2 Kawasaki disease; chr14:106680324 chr14:106675017~106675544:- LIHC cis rs6545883 0.894 rs1186703 ENSG00000271889.1 RP11-493E12.1 3.74 0.000214 0.0342 0.24 0.2 Tuberculosis; chr2:61445830 chr2:61151433~61162105:- LIHC cis rs1816213 0.744 rs10498059 ENSG00000273466.1 RP11-548H3.1 -3.74 0.000214 0.0342 -0.32 -0.2 Diastolic blood pressure; chr2:218477182 chr2:218633256~218634014:- LIHC cis rs864537 0.618 rs1214595 ENSG00000273160.1 RP11-104L21.3 3.74 0.000214 0.0342 0.28 0.2 Celiac disease or Rheumatoid arthritis;Celiac disease; chr1:167458320 chr1:167457742~167459891:- LIHC cis rs919433 1 rs7422899 ENSG00000231621.1 AC013264.2 3.74 0.000214 0.0342 0.18 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197298803 chr2:197197991~197199273:+ LIHC cis rs4921799 0.662 rs7462063 ENSG00000249258.2 RP11-468H14.2 -3.74 0.000214 0.0342 -0.25 -0.2 Lung cancer;Adenocarcinoma; chr8:17678838 chr8:17131181~17149789:+ LIHC cis rs651907 0.535 rs13085776 ENSG00000244119.1 PDCL3P4 3.74 0.000214 0.0342 0.22 0.2 Colorectal cancer; chr3:101786663 chr3:101712472~101713191:+ LIHC cis rs2243480 0.908 rs4718273 ENSG00000229886.1 RP5-1132H15.3 -3.74 0.000214 0.0342 -0.29 -0.2 Diabetic kidney disease; chr7:65751112 chr7:66025126~66031544:- LIHC cis rs11098499 0.863 rs2306457 ENSG00000260091.1 RP11-33B1.4 -3.74 0.000214 0.0342 -0.14 -0.2 Corneal astigmatism; chr4:119551684 chr4:119409333~119410233:+ LIHC cis rs10760706 1 rs2416935 ENSG00000270412.1 RP11-92C4.6 3.74 0.000214 0.0342 0.23 0.2 Alopecia areata; chr9:99907275 chr9:98943337~98943775:- LIHC cis rs6442522 0.839 rs1107596 ENSG00000249786.6 EAF1-AS1 3.74 0.000214 0.0342 0.23 0.2 Uric acid levels; chr3:15366832 chr3:15436171~15455940:- LIHC cis rs1598856 1 rs93059 ENSG00000230069.3 LRRC37A15P -3.74 0.000214 0.0342 -0.18 -0.2 Primary biliary cholangitis; chr4:102547361 chr4:102727274~102730721:- LIHC cis rs7044106 0.734 rs12553070 ENSG00000238181.2 AHCYP2 -3.74 0.000214 0.0342 -0.23 -0.2 Hip circumference adjusted for BMI; chr9:120722988 chr9:120720673~120721972:+ LIHC cis rs8040855 0.658 rs12909111 ENSG00000259295.5 CSPG4P12 3.74 0.000215 0.0342 0.3 0.2 Bulimia nervosa; chr15:85061095 chr15:85191438~85213905:+ LIHC cis rs748404 0.65 rs518234 ENSG00000205771.5 CATSPER2P1 -3.74 0.000215 0.0342 -0.24 -0.2 Lung cancer; chr15:43281223 chr15:43726918~43747094:- LIHC cis rs748404 0.65 rs518261 ENSG00000205771.5 CATSPER2P1 -3.74 0.000215 0.0342 -0.24 -0.2 Lung cancer; chr15:43281231 chr15:43726918~43747094:- LIHC cis rs9649213 0.593 rs36017146 ENSG00000272950.1 RP11-307C18.1 3.74 0.000215 0.0343 0.23 0.2 Prostate cancer (SNP x SNP interaction); chr7:98345305 chr7:98322853~98323430:+ LIHC cis rs4555082 1 rs4555082 ENSG00000211892.3 IGHG4 -3.74 0.000215 0.0343 -0.19 -0.2 Platelet distribution width;Mean platelet volume; chr14:105292627 chr14:105624341~105626066:- LIHC cis rs4555082 1 rs4277291 ENSG00000211892.3 IGHG4 -3.74 0.000215 0.0343 -0.19 -0.2 Platelet distribution width;Mean platelet volume; chr14:105292672 chr14:105624341~105626066:- LIHC cis rs4555082 1 rs4334224 ENSG00000211892.3 IGHG4 -3.74 0.000215 0.0343 -0.19 -0.2 Platelet distribution width;Mean platelet volume; chr14:105292861 chr14:105624341~105626066:- LIHC cis rs1075265 0.756 rs698854 ENSG00000272156.1 RP11-477N3.1 -3.74 0.000215 0.0343 -0.23 -0.2 Chronotype;Morning vs. evening chronotype; chr2:53826784 chr2:54082554~54085066:+ LIHC cis rs875971 0.522 rs4502988 ENSG00000234338.1 RP11-797H7.1 -3.74 0.000215 0.0343 -0.19 -0.2 Aortic root size; chr7:65832759 chr7:64835280~64836882:- LIHC cis rs1115240 0.604 rs1950420 ENSG00000257842.4 NOVA1-AS1 3.74 0.000215 0.0343 0.19 0.2 Educational attainment (years of education); chr14:26671814 chr14:26598412~26806467:+ LIHC cis rs733175 0.855 rs10006397 ENSG00000250413.1 RP11-448G15.1 -3.74 0.000215 0.0343 -0.29 -0.2 Psychosis and Alzheimer's disease; chr4:10034516 chr4:10006482~10009725:+ LIHC cis rs2159324 0.903 rs11083765 ENSG00000267348.2 CTB-179K24.3 3.74 0.000215 0.0343 0.22 0.2 Quantitative traits; chr19:45193271 chr19:45076510~45090391:- LIHC cis rs2658782 0.789 rs1456238 ENSG00000279684.1 RP11-755E23.2 -3.74 0.000215 0.0343 -0.33 -0.2 Pulmonary function decline; chr11:93384204 chr11:93286629~93288903:- LIHC cis rs2348418 0.966 rs11049699 ENSG00000247934.4 RP11-967K21.1 3.74 0.000215 0.0343 0.18 0.2 Lung function (FEV1);Lung function (FVC); chr12:28535487 chr12:28163298~28190738:- LIHC cis rs6456156 0.586 rs9457266 ENSG00000227598.1 RP1-167A14.2 -3.74 0.000215 0.0343 -0.21 -0.2 Primary biliary cholangitis; chr6:167069067 chr6:166969626~166999065:- LIHC cis rs703842 1 rs6581155 ENSG00000270039.1 RP11-571M6.17 -3.74 0.000215 0.0343 -0.27 -0.2 Multiple sclerosis; chr12:57784379 chr12:57803838~57804415:+ LIHC cis rs17345786 1 rs3804775 ENSG00000244119.1 PDCL3P4 3.74 0.000215 0.0343 0.22 0.2 Colonoscopy-negative controls vs population controls; chr3:101587663 chr3:101712472~101713191:+ LIHC cis rs17772222 0.917 rs8006652 ENSG00000258789.1 RP11-507K2.3 -3.74 0.000215 0.0343 -0.24 -0.2 Coronary artery calcification; chr14:88631290 chr14:88551597~88552493:+ LIHC cis rs6142102 0.961 rs4911146 ENSG00000275784.1 RP5-1125A11.6 -3.74 0.000215 0.0343 -0.23 -0.2 Skin pigmentation; chr20:34052241 chr20:33989480~33991818:- LIHC cis rs4578769 0.513 rs2034933 ENSG00000266850.1 RP11-370A5.1 3.74 0.000216 0.0344 0.21 0.2 Eosinophil percentage of white cells; chr18:22918788 chr18:22723491~22907721:- LIHC cis rs7129556 0.737 rs623173 ENSG00000254459.1 RP11-91P24.7 -3.74 0.000216 0.0344 -0.33 -0.2 Weight loss (gastric bypass surgery); chr11:77818482 chr11:77829654~77872262:- LIHC cis rs600231 0.708 rs1784100 ENSG00000245532.5 NEAT1 3.74 0.000216 0.0344 0.19 0.2 Bone mineral density; chr11:65481756 chr11:65422774~65445540:+ LIHC cis rs6545883 0.894 rs778143 ENSG00000273302.1 RP11-493E12.2 3.74 0.000216 0.0344 0.22 0.2 Tuberculosis; chr2:61354755 chr2:61199979~61200769:+ LIHC cis rs4144027 0.869 rs55924227 ENSG00000258534.1 CTD-2134A5.4 -3.74 0.000216 0.0344 -0.23 -0.2 Blood metabolite levels; chr14:103895013 chr14:103854366~103880111:- LIHC cis rs11098499 0.604 rs34278750 ENSG00000260091.1 RP11-33B1.4 -3.74 0.000216 0.0344 -0.14 -0.2 Corneal astigmatism; chr4:119649981 chr4:119409333~119410233:+ LIHC cis rs751728 0.687 rs943479 ENSG00000204188.6 GGNBP1 3.74 0.000216 0.0344 0.25 0.2 Crohn's disease; chr6:33784236 chr6:33540046~33589026:+ LIHC cis rs751728 0.664 rs9394167 ENSG00000204188.6 GGNBP1 3.74 0.000216 0.0344 0.25 0.2 Crohn's disease; chr6:33786619 chr6:33540046~33589026:+ LIHC cis rs751728 0.626 rs6457741 ENSG00000204188.6 GGNBP1 3.74 0.000216 0.0344 0.25 0.2 Crohn's disease; chr6:33788249 chr6:33540046~33589026:+ LIHC cis rs7647973 0.58 rs11130184 ENSG00000270441.1 RP11-694I15.7 -3.74 0.000216 0.0344 -0.28 -0.2 Menarche (age at onset); chr3:49192497 chr3:49140086~49160851:- LIHC cis rs12468226 0.817 rs6722588 ENSG00000272966.1 RP11-686O6.1 -3.74 0.000216 0.0344 -0.33 -0.2 Urate levels; chr2:202187163 chr2:202336739~202337200:+ LIHC cis rs7809950 0.678 rs982447 ENSG00000238832.1 snoU109 -3.74 0.000216 0.0344 -0.25 -0.2 Coronary artery disease; chr7:107333089 chr7:107603363~107603507:+ LIHC cis rs2745572 0.557 rs2816299 ENSG00000272279.1 RP11-157J24.2 -3.74 0.000216 0.0344 -0.25 -0.2 Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure); chr6:1548451 chr6:1528364~1528911:- LIHC cis rs10129255 0.556 rs8010005 ENSG00000211972.2 IGHV3-66 3.74 0.000216 0.0344 0.15 0.2 Kawasaki disease; chr14:106777987 chr14:106675017~106675544:- LIHC cis rs10129255 0.556 rs6576224 ENSG00000211972.2 IGHV3-66 3.74 0.000216 0.0344 0.15 0.2 Kawasaki disease; chr14:106777997 chr14:106675017~106675544:- LIHC cis rs10129255 0.518 rs8010020 ENSG00000211972.2 IGHV3-66 3.74 0.000216 0.0344 0.15 0.2 Kawasaki disease; chr14:106778016 chr14:106675017~106675544:- LIHC cis rs3845817 0.868 rs702938 ENSG00000237979.1 AC007389.1 -3.74 0.000216 0.0344 -0.22 -0.2 Bipolar disorder; chr2:65520308 chr2:65500993~65502138:- LIHC cis rs3091242 0.933 rs28633797 ENSG00000261349.1 RP3-465N24.5 -3.74 0.000216 0.0344 -0.19 -0.2 Erythrocyte sedimentation rate; chr1:25415138 chr1:25266102~25267136:- LIHC cis rs683257 1 rs72988108 ENSG00000234147.1 RP3-460G2.2 -3.74 0.000216 0.0344 -0.36 -0.2 Facial emotion recognition (angry faces); chr6:140808121 chr6:140845958~140852924:- LIHC cis rs683257 0.85 rs72988116 ENSG00000234147.1 RP3-460G2.2 -3.74 0.000216 0.0344 -0.36 -0.2 Facial emotion recognition (angry faces); chr6:140813529 chr6:140845958~140852924:- LIHC cis rs7209700 0.614 rs7225927 ENSG00000228782.6 CTD-2026D20.3 -3.74 0.000216 0.0344 -0.23 -0.2 IgG glycosylation; chr17:47246568 chr17:47450568~47492492:- LIHC cis rs67311347 0.876 rs13068097 ENSG00000223797.4 ENTPD3-AS1 -3.74 0.000216 0.0344 -0.16 -0.2 Renal cell carcinoma; chr3:40462933 chr3:40313802~40453329:- LIHC cis rs2564921 0.73 rs60579898 ENSG00000242142.1 SERBP1P3 -3.74 0.000216 0.0344 -0.25 -0.2 Height; chr3:53069965 chr3:53064283~53065091:- LIHC cis rs6547741 0.874 rs28381983 ENSG00000234072.1 AC074117.10 3.74 0.000216 0.0344 0.18 0.2 Oral cavity cancer; chr2:27581565 chr2:27356246~27367622:+ LIHC cis rs1494950 1 rs2604582 ENSG00000214846.4 RP11-115L11.1 -3.74 0.000216 0.0344 -0.41 -0.2 Political ideology; chr4:15059518 chr4:15730962~15731627:- LIHC cis rs12468226 1 rs16824599 ENSG00000272966.1 RP11-686O6.1 3.74 0.000216 0.0345 0.34 0.2 Urate levels; chr2:202358243 chr2:202336739~202337200:+ LIHC cis rs2243480 1 rs4718269 ENSG00000229886.1 RP5-1132H15.3 -3.74 0.000216 0.0345 -0.29 -0.2 Diabetic kidney disease; chr7:65735810 chr7:66025126~66031544:- LIHC cis rs13028485 1 rs553135 ENSG00000236449.1 AC018890.6 -3.74 0.000217 0.0345 -0.32 -0.2 Multiple myeloma (IgH translocation); chr2:173644008 chr2:174547141~174774827:+ LIHC cis rs12681366 0.537 rs10095298 ENSG00000253704.1 RP11-267M23.4 3.74 0.000217 0.0345 0.23 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94472353 chr8:94553722~94569745:+ LIHC cis rs2243480 1 rs34970380 ENSG00000226002.1 RP11-460N20.5 -3.74 0.000217 0.0345 -0.29 -0.2 Diabetic kidney disease; chr7:65966506 chr7:65084103~65100232:+ LIHC cis rs2243480 0.901 rs73148097 ENSG00000226002.1 RP11-460N20.5 -3.74 0.000217 0.0345 -0.29 -0.2 Diabetic kidney disease; chr7:65966800 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs906134 ENSG00000226002.1 RP11-460N20.5 -3.74 0.000217 0.0345 -0.29 -0.2 Diabetic kidney disease; chr7:65979301 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs4718269 ENSG00000275400.1 RP4-756H11.5 -3.74 0.000217 0.0345 -0.27 -0.2 Diabetic kidney disease; chr7:65735810 chr7:66553805~66554199:- LIHC cis rs1494950 1 rs73797775 ENSG00000214846.4 RP11-115L11.1 -3.74 0.000217 0.0345 -0.41 -0.2 Political ideology; chr4:14975306 chr4:15730962~15731627:- LIHC cis rs1494950 1 rs57517602 ENSG00000214846.4 RP11-115L11.1 -3.74 0.000217 0.0345 -0.41 -0.2 Political ideology; chr4:14975818 chr4:15730962~15731627:- LIHC cis rs1494950 0.661 rs4698307 ENSG00000214846.4 RP11-115L11.1 -3.74 0.000217 0.0345 -0.41 -0.2 Political ideology; chr4:14976811 chr4:15730962~15731627:- LIHC cis rs1494950 1 rs28706742 ENSG00000214846.4 RP11-115L11.1 -3.74 0.000217 0.0345 -0.41 -0.2 Political ideology; chr4:14980027 chr4:15730962~15731627:- LIHC cis rs1494950 1 rs28611277 ENSG00000214846.4 RP11-115L11.1 -3.74 0.000217 0.0345 -0.41 -0.2 Political ideology; chr4:14980035 chr4:15730962~15731627:- LIHC cis rs8064029 0.803 rs11861487 ENSG00000267077.1 RP11-127I20.5 -3.74 0.000217 0.0345 -0.25 -0.2 Cancer; chr16:4822759 chr16:4795265~4796532:- LIHC cis rs7216064 0.532 rs8065296 ENSG00000278740.1 RP11-147L13.14 -3.74 0.000217 0.0345 -0.24 -0.2 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68022446 chr17:68188547~68189165:+ LIHC cis rs4650994 1 rs4076205 ENSG00000213057.5 C1orf220 3.74 0.000217 0.0345 0.17 0.2 HDL cholesterol;HDL cholesterol levels; chr1:178565022 chr1:178542752~178548889:+ LIHC cis rs2337406 0.641 rs10133227 ENSG00000274576.2 IGHV2-70 3.74 0.000217 0.0345 0.22 0.2 Alzheimer's disease (late onset); chr14:106814260 chr14:106770577~106771020:- LIHC cis rs643506 0.845 rs762550 ENSG00000230911.1 PPIHP1 -3.74 0.000217 0.0345 -0.27 -0.2 Breast cancer; chr11:111912376 chr11:112029858~112030367:- LIHC cis rs875971 0.522 rs6960048 ENSG00000237310.1 GS1-124K5.4 3.74 0.000217 0.0346 0.2 0.2 Aortic root size; chr7:65943052 chr7:66493706~66495474:+ LIHC cis rs6471393 0.964 rs3813853 ENSG00000253848.1 RP11-10N23.5 3.74 0.000217 0.0346 0.22 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93740526 chr8:93741193~93744534:+ LIHC cis rs448720 0.692 rs4777011 ENSG00000260657.2 RP11-315D16.4 -3.74 0.000217 0.0346 -0.22 -0.2 Cognitive performance; chr15:67928836 chr15:68267792~68277994:- LIHC cis rs2243480 1 rs313814 ENSG00000229886.1 RP5-1132H15.3 3.74 0.000217 0.0346 0.29 0.2 Diabetic kidney disease; chr7:66038306 chr7:66025126~66031544:- LIHC cis rs2932538 0.922 rs3790612 ENSG00000225075.1 RP11-426L16.3 3.74 0.000217 0.0346 0.25 0.2 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112541524 chr1:112693688~112696621:- LIHC cis rs987724 0.515 rs9876148 ENSG00000243926.1 TIPARP-AS1 3.74 0.000217 0.0346 0.21 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156894349 chr3:156671862~156674378:- LIHC cis rs6502050 0.761 rs11653003 ENSG00000279692.1 RP11-1055B8.1 -3.74 0.000217 0.0346 -0.3 -0.2 Life satisfaction; chr17:82100919 chr17:81395609~81397144:- LIHC cis rs703842 1 rs4646536 ENSG00000270039.1 RP11-571M6.17 -3.74 0.000217 0.0346 -0.27 -0.2 Multiple sclerosis; chr12:57764205 chr12:57803838~57804415:+ LIHC cis rs987724 0.501 rs9851913 ENSG00000243926.1 TIPARP-AS1 3.74 0.000217 0.0346 0.22 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156883165 chr3:156671862~156674378:- LIHC cis rs11951515 0.6 rs60207549 ENSG00000279557.1 CTD-2210P15.3 -3.74 0.000218 0.0346 -0.25 -0.2 Metabolite levels (X-11787); chr5:43272846 chr5:43586367~43587543:- LIHC cis rs6832769 1 rs59804446 ENSG00000272969.1 RP11-528I4.2 -3.74 0.000218 0.0346 -0.24 -0.2 Personality dimensions; chr4:55563374 chr4:55547112~55547889:+ LIHC cis rs4144027 0.904 rs10438242 ENSG00000258534.1 CTD-2134A5.4 3.74 0.000218 0.0346 0.22 0.2 Blood metabolite levels; chr14:103878738 chr14:103854366~103880111:- LIHC cis rs17428076 0.793 rs56275355 ENSG00000228389.1 AC068039.4 -3.74 0.000218 0.0346 -0.24 -0.2 Myopia; chr2:171853670 chr2:171773482~171775844:+ LIHC cis rs875971 0.66 rs7807944 ENSG00000224316.1 RP11-479O9.2 -3.74 0.000218 0.0346 -0.19 -0.2 Aortic root size; chr7:66622208 chr7:65773620~65802067:+ LIHC cis rs11676348 0.873 rs10210012 ENSG00000261338.2 RP11-378A13.1 -3.74 0.000218 0.0346 -0.22 -0.2 Ulcerative colitis; chr2:218148611 chr2:218255319~218257366:+ LIHC cis rs745580 0.933 rs6978844 ENSG00000199085.2 MIR148A -3.74 0.000218 0.0346 -0.2 -0.2 Obesity-related traits; chr7:25987156 chr7:25949903~25950013:- LIHC cis rs6142102 0.625 rs4911137 ENSG00000275784.1 RP5-1125A11.6 -3.74 0.000218 0.0346 -0.21 -0.2 Skin pigmentation; chr20:33947657 chr20:33989480~33991818:- LIHC cis rs2564921 0.704 rs62253603 ENSG00000242142.1 SERBP1P3 -3.74 0.000218 0.0346 -0.27 -0.2 Height; chr3:52938846 chr3:53064283~53065091:- LIHC cis rs881375 1 rs6478484 ENSG00000226752.6 PSMD5-AS1 -3.74 0.000218 0.0347 -0.22 -0.2 Rheumatoid arthritis; chr9:120890102 chr9:120824828~120854385:+ LIHC cis rs9646944 1 rs9646944 ENSG00000234389.1 AC007278.3 3.74 0.000218 0.0347 0.24 0.2 Blood protein levels; chr2:102249415 chr2:102438713~102440475:+ LIHC cis rs875971 0.522 rs34973832 ENSG00000237310.1 GS1-124K5.4 3.74 0.000218 0.0347 0.2 0.2 Aortic root size; chr7:65931217 chr7:66493706~66495474:+ LIHC cis rs4073416 0.712 rs7493004 ENSG00000276116.2 FUT8-AS1 3.74 0.000218 0.0347 0.25 0.2 N-glycan levels; chr14:65657386 chr14:65411170~65412690:- LIHC cis rs7208859 0.528 rs3764416 ENSG00000266490.1 CTD-2349P21.9 -3.74 0.000218 0.0347 -0.25 -0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30573690 chr17:30792372~30792833:+ LIHC cis rs2302464 1 rs75628417 ENSG00000214846.4 RP11-115L11.1 3.74 0.000218 0.0347 0.37 0.2 Cerebrospinal fluid biomarker levels; chr4:15672941 chr4:15730962~15731627:- LIHC cis rs875971 0.545 rs6460281 ENSG00000224316.1 RP11-479O9.2 3.74 0.000218 0.0347 0.19 0.2 Aortic root size; chr7:66216128 chr7:65773620~65802067:+ LIHC cis rs3758785 0.596 rs2096762 ENSG00000255893.1 RP11-685N10.1 3.74 0.000218 0.0347 0.2 0.2 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94381507 chr11:94472908~94473570:- LIHC cis rs3758785 0.619 rs2096763 ENSG00000255893.1 RP11-685N10.1 3.74 0.000218 0.0347 0.2 0.2 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94381528 chr11:94472908~94473570:- LIHC cis rs9487094 0.922 rs9487098 ENSG00000260273.1 RP11-425D10.10 3.74 0.000218 0.0347 0.23 0.2 Height; chr6:109422189 chr6:109382795~109383666:+ LIHC cis rs3749237 0.595 rs10865955 ENSG00000226913.1 BSN-AS2 -3.74 0.000218 0.0347 -0.26 -0.2 Resting heart rate; chr3:49462396 chr3:49549306~49554366:- LIHC cis rs3749237 0.576 rs3877784 ENSG00000226913.1 BSN-AS2 -3.74 0.000218 0.0347 -0.26 -0.2 Resting heart rate; chr3:49501984 chr3:49549306~49554366:- LIHC cis rs4144027 0.967 rs56126771 ENSG00000258914.1 CTD-2134A5.3 -3.74 0.000218 0.0347 -0.22 -0.2 Blood metabolite levels; chr14:103894806 chr14:103875055~103877478:+ LIHC cis rs673078 0.607 rs2036489 ENSG00000275759.1 RP11-131L12.3 -3.74 0.000218 0.0347 -0.24 -0.2 Glucose homeostasis traits; chr12:118364643 chr12:118428281~118428870:+ LIHC cis rs80226907 0.764 rs10132349 ENSG00000258413.1 RP11-665C16.6 -3.74 0.000218 0.0347 -0.31 -0.2 Mean platelet volume; chr14:55233240 chr14:55262767~55272075:- LIHC cis rs2762353 0.806 rs6909187 ENSG00000242387.1 HIST1H2APS2 -3.74 0.000219 0.0347 -0.22 -0.2 Blood metabolite levels; chr6:25785697 chr6:25882026~25882395:- LIHC cis rs17376456 0.825 rs1470150 ENSG00000251023.1 RP11-549J18.1 3.74 0.000219 0.0347 0.39 0.2 Diabetic retinopathy; chr5:93802948 chr5:93860669~93863825:- LIHC cis rs12468226 0.938 rs116601501 ENSG00000272966.1 RP11-686O6.1 3.74 0.000219 0.0348 0.33 0.2 Urate levels; chr2:202274567 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs76658848 ENSG00000272966.1 RP11-686O6.1 3.74 0.000219 0.0348 0.33 0.2 Urate levels; chr2:202275548 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs74454549 ENSG00000272966.1 RP11-686O6.1 3.74 0.000219 0.0348 0.33 0.2 Urate levels; chr2:202288044 chr2:202336739~202337200:+ LIHC cis rs9494145 0.68 rs9389269 ENSG00000232876.1 CTA-212D2.2 -3.74 0.000219 0.0348 -0.25 -0.2 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135106021 chr6:135055033~135060550:+ LIHC cis rs9494145 0.68 rs9402686 ENSG00000232876.1 CTA-212D2.2 -3.74 0.000219 0.0348 -0.25 -0.2 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135106679 chr6:135055033~135060550:+ LIHC cis rs6832769 1 rs726967 ENSG00000272969.1 RP11-528I4.2 -3.74 0.000219 0.0348 -0.24 -0.2 Personality dimensions; chr4:55555546 chr4:55547112~55547889:+ LIHC cis rs1023500 0.596 rs133369 ENSG00000205702.9 CYP2D7 3.74 0.000219 0.0348 0.22 0.2 Schizophrenia; chr22:42067810 chr22:42140203~42144577:- LIHC cis rs6565180 1 rs8049108 ENSG00000273724.1 RP11-347C12.12 -3.74 0.000219 0.0348 -0.24 -0.2 Tonsillectomy; chr16:30365165 chr16:30336400~30343336:+ LIHC cis rs9649213 0.531 rs35216698 ENSG00000272950.1 RP11-307C18.1 3.74 0.000219 0.0348 0.24 0.2 Prostate cancer (SNP x SNP interaction); chr7:98266863 chr7:98322853~98323430:+ LIHC cis rs11098499 0.739 rs9884728 ENSG00000260091.1 RP11-33B1.4 3.74 0.000219 0.0348 0.13 0.2 Corneal astigmatism; chr4:119205924 chr4:119409333~119410233:+ LIHC cis rs11098499 0.739 rs2203039 ENSG00000260091.1 RP11-33B1.4 3.74 0.000219 0.0348 0.13 0.2 Corneal astigmatism; chr4:119211192 chr4:119409333~119410233:+ LIHC cis rs11098499 0.739 rs7441137 ENSG00000260091.1 RP11-33B1.4 3.74 0.000219 0.0348 0.13 0.2 Corneal astigmatism; chr4:119212066 chr4:119409333~119410233:+ LIHC cis rs11098499 0.71 rs6851130 ENSG00000260091.1 RP11-33B1.4 3.74 0.000219 0.0348 0.13 0.2 Corneal astigmatism; chr4:119212557 chr4:119409333~119410233:+ LIHC cis rs7617773 0.78 rs13067450 ENSG00000228638.1 FCF1P2 -3.74 0.000219 0.0348 -0.23 -0.2 Coronary artery disease; chr3:48295716 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs4479622 ENSG00000228638.1 FCF1P2 -3.74 0.000219 0.0348 -0.23 -0.2 Coronary artery disease; chr3:48296683 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs34946886 ENSG00000228638.1 FCF1P2 -3.74 0.000219 0.0348 -0.23 -0.2 Coronary artery disease; chr3:48296997 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs34589064 ENSG00000228638.1 FCF1P2 -3.74 0.000219 0.0348 -0.23 -0.2 Coronary artery disease; chr3:48298059 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs2541 ENSG00000228638.1 FCF1P2 -3.74 0.000219 0.0348 -0.23 -0.2 Coronary artery disease; chr3:48298128 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs13085251 ENSG00000228638.1 FCF1P2 -3.74 0.000219 0.0348 -0.23 -0.2 Coronary artery disease; chr3:48298555 chr3:48290793~48291375:- LIHC cis rs1823874 0.584 rs1823872 ENSG00000182397.13 DNM1P46 -3.74 0.000219 0.0348 -0.24 -0.2 IgG glycosylation; chr15:99839246 chr15:99790156~99806927:- LIHC cis rs11096990 0.793 rs9997050 ENSG00000249685.1 RP11-360F5.3 -3.74 0.000219 0.0348 -0.28 -0.2 Cognitive function; chr4:39301045 chr4:39133913~39135608:+ LIHC cis rs2235573 0.673 rs5756894 ENSG00000230912.1 RP3-508I15.10 -3.74 0.000219 0.0348 -0.19 -0.2 Glioma;Glioblastoma; chr22:38054129 chr22:38666508~38668750:- LIHC cis rs2933343 0.951 rs789217 ENSG00000261159.1 RP11-723O4.9 3.74 0.000219 0.0348 0.27 0.2 IgG glycosylation; chr3:128874358 chr3:128859716~128860526:- LIHC cis rs7684187 0.96 rs13144509 ENSG00000251526.1 RP11-381N20.1 -3.74 0.000219 0.0348 -0.24 -0.2 Cancer; chr4:122552332 chr4:123505279~123527525:+ LIHC cis rs11096990 0.855 rs6855008 ENSG00000249685.1 RP11-360F5.3 -3.74 0.000219 0.0348 -0.27 -0.2 Cognitive function; chr4:39172006 chr4:39133913~39135608:+ LIHC cis rs617219 0.889 rs2121107 ENSG00000251675.1 CTC-458I2.2 -3.74 0.000219 0.0348 -0.22 -0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79172181 chr5:80128361~80143883:+ LIHC cis rs301901 0.662 rs7726960 ENSG00000250155.1 CTD-2353F22.1 3.74 0.000219 0.0348 0.19 0.2 Height; chr5:37490184 chr5:36666214~36725195:- LIHC cis rs10833905 0.68 rs2433479 ENSG00000246225.5 RP11-17A1.3 3.74 0.000219 0.0348 0.25 0.2 Sudden cardiac arrest; chr11:23013157 chr11:22829380~22945393:+ LIHC cis rs5743030 1 rs74703743 ENSG00000253559.1 OSGEPL1-AS1 -3.74 0.000219 0.0348 -0.34 -0.2 Subcutaneous adipose tissue; chr2:189927896 chr2:189762704~189765556:+ LIHC cis rs614226 1 rs541126 ENSG00000278344.1 RP11-18C24.8 -3.74 0.000219 0.0349 -0.32 -0.2 Type 1 diabetes nephropathy; chr12:120534593 chr12:120500735~120501090:- LIHC cis rs10761256 0.806 rs10992836 ENSG00000227603.1 RP11-165J3.6 3.74 0.000219 0.0349 0.23 0.2 Itch intensity from mosquito bite adjusted by bite size; chr9:93660138 chr9:93435332~93437121:- LIHC cis rs448720 1 rs430610 ENSG00000260657.2 RP11-315D16.4 3.74 0.000219 0.0349 0.24 0.2 Cognitive performance; chr15:67906284 chr15:68267792~68277994:- LIHC cis rs61160187 0.582 rs12652830 ENSG00000272308.1 RP11-231G3.1 -3.74 0.000219 0.0349 -0.21 -0.2 Educational attainment (years of education);Educational attainment (college completion); chr5:60956655 chr5:60866457~60866935:- LIHC cis rs61160187 0.582 rs4700402 ENSG00000272308.1 RP11-231G3.1 -3.74 0.000219 0.0349 -0.21 -0.2 Educational attainment (years of education);Educational attainment (college completion); chr5:60966220 chr5:60866457~60866935:- LIHC cis rs61160187 0.549 rs61017995 ENSG00000272308.1 RP11-231G3.1 -3.74 0.000219 0.0349 -0.21 -0.2 Educational attainment (years of education);Educational attainment (college completion); chr5:60968176 chr5:60866457~60866935:- LIHC cis rs875971 0.522 rs7784623 ENSG00000237310.1 GS1-124K5.4 3.74 0.00022 0.0349 0.2 0.2 Aortic root size; chr7:65930047 chr7:66493706~66495474:+ LIHC cis rs193541 0.593 rs154499 ENSG00000263432.2 RN7SL689P 3.74 0.00022 0.0349 0.32 0.2 Glucose homeostasis traits; chr5:122883971 chr5:123022487~123022783:- LIHC cis rs10256972 0.591 rs6968988 ENSG00000199023.2 MIR339 -3.74 0.00022 0.0349 -0.23 -0.2 Endometriosis;Longevity; chr7:1129983 chr7:1022935~1023045:- LIHC cis rs5751614 0.537 rs9608093 ENSG00000225282.1 AP000350.6 -3.74 0.00022 0.0349 -0.32 -0.2 Height; chr22:23271352 chr22:23926900~23929574:+ LIHC cis rs10829156 0.732 rs10741086 ENSG00000240291.1 RP11-499P20.2 3.74 0.00022 0.0349 0.35 0.2 Sudden cardiac arrest; chr10:18505027 chr10:18513115~18545651:- LIHC cis rs10256972 0.9 rs7812072 ENSG00000199023.2 MIR339 -3.74 0.00022 0.0349 -0.22 -0.2 Endometriosis;Longevity; chr7:1014226 chr7:1022935~1023045:- LIHC cis rs2243480 1 rs160646 ENSG00000232546.1 RP11-458F8.1 -3.74 0.00022 0.0349 -0.22 -0.2 Diabetic kidney disease; chr7:66091293 chr7:66848496~66858136:+ LIHC cis rs848490 0.651 rs12113119 ENSG00000214293.7 APTR 3.74 0.00022 0.0349 0.23 0.2 Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine); chr7:77685501 chr7:77657660~77696265:- LIHC cis rs6700559 0.692 rs2809342 ENSG00000260088.1 RP11-92G12.3 -3.74 0.00022 0.0349 -0.27 -0.2 Coronary artery disease; chr1:200628522 chr1:200669507~200694250:+ LIHC cis rs234043 1 rs234051 ENSG00000223387.5 RP11-408H1.3 -3.74 0.00022 0.0349 -0.22 -0.2 Renal cell carcinoma; chr3:172593922 chr3:172560888~172595607:- LIHC cis rs10851478 0.692 rs8027730 ENSG00000276593.1 RP11-295H24.5 3.73 0.00022 0.0349 0.22 0.2 Oral cavity cancer; chr15:49580388 chr15:49353485~49354034:+ LIHC cis rs9646944 0.501 rs11687768 ENSG00000234389.1 AC007278.3 3.73 0.00022 0.0349 0.25 0.2 Blood protein levels; chr2:102409278 chr2:102438713~102440475:+ LIHC cis rs6456156 0.586 rs12198816 ENSG00000227598.1 RP1-167A14.2 -3.73 0.00022 0.0349 -0.21 -0.2 Primary biliary cholangitis; chr6:167070058 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs2001114 ENSG00000227598.1 RP1-167A14.2 -3.73 0.00022 0.0349 -0.21 -0.2 Primary biliary cholangitis; chr6:167073090 chr6:166969626~166999065:- LIHC cis rs57221529 0.766 rs72703026 ENSG00000271781.1 CTD-2589H19.6 -3.73 0.00022 0.035 -0.31 -0.2 Lung disease severity in cystic fibrosis; chr5:572268 chr5:675826~676616:+ LIHC cis rs17818399 0.817 rs17767994 ENSG00000239332.4 LINC01119 3.73 0.00022 0.035 0.28 0.2 Height; chr2:46632940 chr2:46816697~46859007:+ LIHC cis rs4356975 0.563 rs7658752 ENSG00000250919.1 RP11-813N20.3 -3.73 0.00022 0.035 -0.2 -0.2 Obesity-related traits; chr4:69112350 chr4:69027831~69044578:+ LIHC cis rs6449502 0.92 rs7714071 ENSG00000272308.1 RP11-231G3.1 -3.73 0.00022 0.035 -0.28 -0.2 Mean platelet volume; chr5:60844627 chr5:60866457~60866935:- LIHC cis rs9929218 0.529 rs11640736 ENSG00000260459.2 FTLP14 3.73 0.000221 0.035 0.23 0.2 Colorectal cancer; chr16:68704421 chr16:68822587~68823070:+ LIHC cis rs853679 0.723 rs9366718 ENSG00000219392.1 RP1-265C24.5 -3.73 0.000221 0.035 -0.3 -0.2 Depression; chr6:28237724 chr6:28115628~28116551:+ LIHC cis rs6545883 0.929 rs2264100 ENSG00000271889.1 RP11-493E12.1 3.73 0.000221 0.035 0.24 0.2 Tuberculosis; chr2:61443694 chr2:61151433~61162105:- LIHC cis rs875971 0.66 rs79009421 ENSG00000224316.1 RP11-479O9.2 -3.73 0.000221 0.035 -0.19 -0.2 Aortic root size; chr7:66603522 chr7:65773620~65802067:+ LIHC cis rs875971 0.66 rs6460308 ENSG00000224316.1 RP11-479O9.2 -3.73 0.000221 0.035 -0.19 -0.2 Aortic root size; chr7:66619753 chr7:65773620~65802067:+ LIHC cis rs2410601 0.594 rs1814160 ENSG00000245281.5 CTD-2547L16.1 -3.73 0.000221 0.035 -0.23 -0.2 Urinary albumin excretion rate in type 1 diabetes; chr8:19051305 chr8:18084868~18096394:+ LIHC cis rs2015599 0.623 rs7313552 ENSG00000257176.2 RP11-996F15.2 3.73 0.000221 0.035 0.25 0.2 Platelet count;Mean platelet volume; chr12:29277302 chr12:29280418~29317848:- LIHC cis rs2015599 0.584 rs7299283 ENSG00000257176.2 RP11-996F15.2 3.73 0.000221 0.035 0.25 0.2 Platelet count;Mean platelet volume; chr12:29277442 chr12:29280418~29317848:- LIHC cis rs2015599 0.623 rs1006410 ENSG00000257176.2 RP11-996F15.2 3.73 0.000221 0.035 0.25 0.2 Platelet count;Mean platelet volume; chr12:29282682 chr12:29280418~29317848:- LIHC cis rs12936587 0.692 rs12943416 ENSG00000223979.2 SMCR2 3.73 0.000221 0.035 0.26 0.2 Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference; chr17:17632221 chr17:17674026~17677688:- LIHC cis rs3808502 0.527 rs2736374 ENSG00000269899.1 RP11-589N15.2 -3.73 0.000221 0.0351 -0.3 -0.2 Neuroticism; chr8:11256319 chr8:11846154~11846391:- LIHC cis rs12209785 0.774 rs6905847 ENSG00000231769.2 RP1-8B1.4 3.73 0.000221 0.0351 0.28 0.2 Survival in pancreatic cancer; chr6:45520207 chr6:46097093~46129706:- LIHC cis rs11096990 0.964 rs56284364 ENSG00000249207.1 RP11-360F5.1 3.73 0.000221 0.0351 0.23 0.2 Cognitive function; chr4:39255028 chr4:39112677~39126818:- LIHC cis rs1198872 0.563 rs2005011 ENSG00000272275.1 RP11-791G15.2 -3.73 0.000221 0.0351 -0.24 -0.2 Cardiac Troponin-T levels; chr2:10823799 chr2:10767875~10770058:- LIHC cis rs1198872 0.563 rs2008967 ENSG00000272275.1 RP11-791G15.2 -3.73 0.000221 0.0351 -0.24 -0.2 Cardiac Troponin-T levels; chr2:10824167 chr2:10767875~10770058:- LIHC cis rs4792901 0.877 rs9912927 ENSG00000279602.1 CTD-3014M21.1 -3.73 0.000221 0.0351 -0.23 -0.2 Dupuytren's disease; chr17:43542667 chr17:43360041~43361361:- LIHC cis rs7945705 0.875 rs10769957 ENSG00000254860.4 TMEM9B-AS1 3.73 0.000221 0.0351 0.2 0.2 Hemoglobin concentration; chr11:8787469 chr11:8964675~8977527:+ LIHC cis rs1318937 0.915 rs3773472 ENSG00000224660.1 SH3BP5-AS1 3.73 0.000221 0.0351 0.17 0.2 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15261246 chr3:15254184~15264493:+ LIHC cis rs6723108 0.581 rs10176573 ENSG00000224043.6 CCNT2-AS1 -3.73 0.000221 0.0351 -0.27 -0.2 Type 2 diabetes; chr2:134899901 chr2:134735464~134918710:- LIHC cis rs1223397 0.651 rs9349564 ENSG00000215022.6 RP1-257A7.4 -3.73 0.000221 0.0351 -0.21 -0.2 Blood pressure; chr6:13315792 chr6:13264861~13295586:- LIHC cis rs853679 1 rs853676 ENSG00000219392.1 RP1-265C24.5 -3.73 0.000221 0.0351 -0.35 -0.2 Depression; chr6:28331910 chr6:28115628~28116551:+ LIHC cis rs875971 0.66 rs10215132 ENSG00000237310.1 GS1-124K5.4 -3.73 0.000221 0.0351 -0.18 -0.2 Aortic root size; chr7:66589419 chr7:66493706~66495474:+ LIHC cis rs713477 1 rs4901562 ENSG00000258413.1 RP11-665C16.6 3.73 0.000221 0.0351 0.22 0.2 Pediatric bone mineral content (femoral neck); chr14:55434655 chr14:55262767~55272075:- LIHC cis rs7586604 0.638 rs1568786 ENSG00000230393.1 AC092667.2 3.73 0.000221 0.0351 0.26 0.2 Cannabis dependence symptom count; chr2:99805305 chr2:100104919~100107504:+ LIHC cis rs801193 0.904 rs4718405 ENSG00000273142.1 RP11-458F8.4 -3.73 0.000221 0.0351 -0.19 -0.2 Aortic root size; chr7:66789659 chr7:66902857~66906297:+ LIHC cis rs11096990 0.964 rs16995206 ENSG00000249685.1 RP11-360F5.3 -3.73 0.000221 0.0351 -0.27 -0.2 Cognitive function; chr4:39262887 chr4:39133913~39135608:+ LIHC cis rs7665090 0.967 rs6533022 ENSG00000248971.2 KRT8P46 -3.73 0.000221 0.0351 -0.21 -0.2 Primary biliary cholangitis; chr4:102637794 chr4:102728746~102730171:- LIHC cis rs6545883 0.929 rs7606167 ENSG00000271889.1 RP11-493E12.1 3.73 0.000221 0.0351 0.24 0.2 Tuberculosis; chr2:61515519 chr2:61151433~61162105:- LIHC cis rs7804356 0.556 rs10241404 ENSG00000214870.7 AC004540.5 3.73 0.000222 0.0351 0.27 0.2 Type 1 diabetes; chr7:26957565 chr7:26398593~26494256:+ LIHC cis rs1223397 0.651 rs2439534 ENSG00000215022.6 RP1-257A7.4 3.73 0.000222 0.0351 0.21 0.2 Blood pressure; chr6:13305525 chr6:13264861~13295586:- LIHC cis rs916888 0.61 rs199436 ENSG00000262881.1 RP11-669E14.4 3.73 0.000222 0.0351 0.21 0.2 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:45907670~45910779:- LIHC cis rs9457247 0.765 rs4710171 ENSG00000227598.1 RP1-167A14.2 -3.73 0.000222 0.0351 -0.21 -0.2 Crohn's disease; chr6:167016698 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs10946208 ENSG00000227598.1 RP1-167A14.2 -3.73 0.000222 0.0351 -0.21 -0.2 Primary biliary cholangitis; chr6:167046108 chr6:166969626~166999065:- LIHC cis rs67311347 1 rs13073003 ENSG00000223797.4 ENTPD3-AS1 -3.73 0.000222 0.0352 -0.16 -0.2 Renal cell carcinoma; chr3:40462835 chr3:40313802~40453329:- LIHC cis rs10851478 0.874 rs12910284 ENSG00000276593.1 RP11-295H24.5 3.73 0.000222 0.0352 0.23 0.2 Oral cavity cancer; chr15:49493719 chr15:49353485~49354034:+ LIHC cis rs7095607 1 rs10997982 ENSG00000233590.1 RP11-153K11.3 3.73 0.000222 0.0352 0.23 0.2 Lung function (FVC); chr10:68179791 chr10:68233251~68242379:- LIHC cis rs12681366 0.801 rs2921386 ENSG00000253704.1 RP11-267M23.4 3.73 0.000222 0.0352 0.24 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94446672 chr8:94553722~94569745:+ LIHC cis rs10129255 1 rs11627342 ENSG00000224373.3 IGHV4-59 3.73 0.000222 0.0352 0.16 0.2 Kawasaki disease; chr14:106675823 chr14:106627249~106627825:- LIHC cis rs67981189 0.896 rs2810098 ENSG00000274818.1 RP1-292L20.3 -3.73 0.000222 0.0352 -0.22 -0.2 Schizophrenia; chr14:70967194 chr14:70906657~70907111:- LIHC cis rs7722022 0.961 rs4868282 ENSG00000253428.1 CTB-43E15.2 3.73 0.000222 0.0352 0.21 0.2 Adiponectin levels; chr5:173521984 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs4868284 ENSG00000253428.1 CTB-43E15.2 3.73 0.000222 0.0352 0.21 0.2 Adiponectin levels; chr5:173522115 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs56683278 ENSG00000253428.1 CTB-43E15.2 3.73 0.000222 0.0352 0.21 0.2 Adiponectin levels; chr5:173522236 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs6897396 ENSG00000253428.1 CTB-43E15.2 3.73 0.000222 0.0352 0.21 0.2 Adiponectin levels; chr5:173522632 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs6878296 ENSG00000253428.1 CTB-43E15.2 3.73 0.000222 0.0352 0.21 0.2 Adiponectin levels; chr5:173522742 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs6878489 ENSG00000253428.1 CTB-43E15.2 3.73 0.000222 0.0352 0.21 0.2 Adiponectin levels; chr5:173522880 chr5:173689459~173705849:+ LIHC cis rs12550612 0.83 rs9918919 ENSG00000253616.4 RP11-875O11.3 3.73 0.000222 0.0352 0.24 0.2 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23109777 chr8:23071377~23074488:- LIHC cis rs11096990 0.656 rs6531710 ENSG00000249207.1 RP11-360F5.1 3.73 0.000222 0.0352 0.2 0.2 Cognitive function; chr4:39300658 chr4:39112677~39126818:- LIHC cis rs9487094 0.6 rs3799842 ENSG00000260273.1 RP11-425D10.10 3.73 0.000222 0.0353 0.23 0.2 Height; chr6:109471826 chr6:109382795~109383666:+ LIHC cis rs2613514 1 rs2311440 ENSG00000204277.1 RP11-219G17.4 3.73 0.000223 0.0353 0.31 0.2 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78071204 chr17:78261349~78278492:- LIHC cis rs7734985 0.598 rs10476663 ENSG00000250551.1 RP11-254I22.1 -3.73 0.000223 0.0353 -0.22 -0.2 IgG glycosylation; chr5:96204485 chr5:96050115~96215519:+ LIHC cis rs301901 0.796 rs62359002 ENSG00000250155.1 CTD-2353F22.1 3.73 0.000223 0.0353 0.19 0.2 Height; chr5:37499677 chr5:36666214~36725195:- LIHC cis rs673078 0.66 rs12229607 ENSG00000275409.1 RP11-131L12.4 -3.73 0.000223 0.0353 -0.25 -0.2 Glucose homeostasis traits; chr12:118338333 chr12:118430147~118430699:+ LIHC cis rs3764021 0.527 rs10844456 ENSG00000256673.1 RP11-599J14.2 -3.73 0.000223 0.0353 -0.2 -0.2 Type 1 diabetes; chr12:9689319 chr12:9398355~9414851:- LIHC cis rs16958440 0.708 rs57468764 ENSG00000267724.1 RP11-49K24.8 3.73 0.000223 0.0353 0.27 0.2 Sitting height ratio; chr18:47098485 chr18:47105946~47108062:+ LIHC cis rs16958440 0.708 rs62096462 ENSG00000267724.1 RP11-49K24.8 3.73 0.000223 0.0353 0.27 0.2 Sitting height ratio; chr18:47098808 chr18:47105946~47108062:+ LIHC cis rs16958440 0.708 rs62096465 ENSG00000267724.1 RP11-49K24.8 3.73 0.000223 0.0353 0.27 0.2 Sitting height ratio; chr18:47103253 chr18:47105946~47108062:+ LIHC cis rs16958440 0.708 rs1434528 ENSG00000267724.1 RP11-49K24.8 3.73 0.000223 0.0353 0.27 0.2 Sitting height ratio; chr18:47105952 chr18:47105946~47108062:+ LIHC cis rs7306456 0.623 rs10902513 ENSG00000256576.2 RP13-977J11.2 3.73 0.000223 0.0353 0.21 0.2 Anti-saccade response; chr12:132208942 chr12:132186735~132189695:- LIHC cis rs2274273 0.905 rs8007620 ENSG00000258413.1 RP11-665C16.6 -3.73 0.000223 0.0353 -0.23 -0.2 Protein biomarker; chr14:55119869 chr14:55262767~55272075:- LIHC cis rs1075265 0.836 rs1421622 ENSG00000272156.1 RP11-477N3.1 3.73 0.000223 0.0353 0.23 0.2 Chronotype;Morning vs. evening chronotype; chr2:54062644 chr2:54082554~54085066:+ LIHC cis rs301901 0.828 rs62361485 ENSG00000250155.1 CTD-2353F22.1 3.73 0.000223 0.0353 0.19 0.2 Height; chr5:37474739 chr5:36666214~36725195:- LIHC cis rs301901 0.828 rs56007618 ENSG00000250155.1 CTD-2353F22.1 3.73 0.000223 0.0353 0.19 0.2 Height; chr5:37475788 chr5:36666214~36725195:- LIHC cis rs301901 0.828 rs55731764 ENSG00000250155.1 CTD-2353F22.1 3.73 0.000223 0.0353 0.19 0.2 Height; chr5:37475789 chr5:36666214~36725195:- LIHC cis rs875971 0.66 rs10950044 ENSG00000237310.1 GS1-124K5.4 -3.73 0.000223 0.0353 -0.18 -0.2 Aortic root size; chr7:66577989 chr7:66493706~66495474:+ LIHC cis rs4144027 0.818 rs881057 ENSG00000258914.1 CTD-2134A5.3 3.73 0.000223 0.0353 0.22 0.2 Blood metabolite levels; chr14:103887921 chr14:103875055~103877478:+ LIHC cis rs853679 1 rs853685 ENSG00000204709.4 LINC01556 3.73 0.000223 0.0353 0.32 0.2 Depression; chr6:28321008 chr6:28943877~28944537:+ LIHC cis rs9595908 0.694 rs9596233 ENSG00000212293.1 SNORA16 3.73 0.000223 0.0353 0.22 0.2 Body mass index; chr13:32776878 chr13:32420390~32420516:- LIHC cis rs617219 0.853 rs72764970 ENSG00000251675.1 CTC-458I2.2 -3.73 0.000223 0.0353 -0.22 -0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79156454 chr5:80128361~80143883:+ LIHC cis rs4873772 0.743 rs4873529 ENSG00000253608.1 RP11-770E5.1 3.73 0.000223 0.0353 0.21 0.2 Lobe attachment (rater-scored or self-reported); chr8:47653224 chr8:48551567~48698510:+ LIHC cis rs6449502 0.92 rs35383830 ENSG00000272308.1 RP11-231G3.1 3.73 0.000223 0.0353 0.32 0.2 Mean platelet volume; chr5:60915109 chr5:60866457~60866935:- LIHC cis rs11971779 0.68 rs6965212 ENSG00000273391.1 RP11-634H22.1 3.73 0.000223 0.0353 0.17 0.2 Diisocyanate-induced asthma; chr7:139341719 chr7:139359032~139359566:- LIHC cis rs600231 0.708 rs2957269 ENSG00000245532.5 NEAT1 3.73 0.000223 0.0353 0.19 0.2 Bone mineral density; chr11:65475536 chr11:65422774~65445540:+ LIHC cis rs600231 0.708 rs2957268 ENSG00000245532.5 NEAT1 3.73 0.000223 0.0353 0.19 0.2 Bone mineral density; chr11:65478345 chr11:65422774~65445540:+ LIHC cis rs7809950 0.678 rs75617662 ENSG00000238832.1 snoU109 -3.73 0.000223 0.0354 -0.25 -0.2 Coronary artery disease; chr7:107389994 chr7:107603363~107603507:+ LIHC cis rs7809950 0.678 rs7790080 ENSG00000238832.1 snoU109 -3.73 0.000223 0.0354 -0.25 -0.2 Coronary artery disease; chr7:107390877 chr7:107603363~107603507:+ LIHC cis rs1005277 0.579 rs2472173 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38085710 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2472174 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38086454 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474563 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38087010 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs9418322 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38088368 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs9299760 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38088992 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2023351 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38089886 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474567 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38093564 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2472175 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38093973 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2472176 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38093993 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2983343 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38094404 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474569 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38094563 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2504143 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38094778 chr10:38356380~38378505:+ LIHC cis rs1005277 0.602 rs2504142 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38094865 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474571 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38095711 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2472181 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38097836 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474574 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38098367 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2504140 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38098651 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474575 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38098973 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2472182 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38099937 chr10:38356380~38378505:+ LIHC cis rs1005277 0.541 rs2263163 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38100959 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2021649 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38103194 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2505197 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38104382 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2505196 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38104635 chr10:38356380~38378505:+ LIHC cis rs1005277 0.541 rs2505193 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38105710 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474580 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38109785 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2504148 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38111860 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs176886 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38115046 chr10:38356380~38378505:+ LIHC cis rs1005277 0.557 rs176887 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38117166 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474594 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38137733 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs11011461 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38142499 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs1985707 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38145170 chr10:38356380~38378505:+ LIHC cis rs1005277 0.557 rs1854563 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38146033 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2505237 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38149970 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474599 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38150011 chr10:38356380~38378505:+ LIHC cis rs1005277 0.54 rs2224248 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38162958 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474608 ENSG00000099251.13 HSD17B7P2 3.73 0.000223 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38168181 chr10:38356380~38378505:+ LIHC cis rs9649213 0.574 rs17436977 ENSG00000272950.1 RP11-307C18.1 3.73 0.000223 0.0354 0.24 0.2 Prostate cancer (SNP x SNP interaction); chr7:98254147 chr7:98322853~98323430:+ LIHC cis rs8037137 0.915 rs8028409 ENSG00000258725.1 PRC1-AS1 -3.73 0.000223 0.0354 -0.25 -0.2 Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr15:90963192 chr15:90966345~90988624:+ LIHC cis rs7568498 1 rs10164593 ENSG00000227403.1 AC009299.3 3.73 0.000223 0.0354 0.3 0.2 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161125461 chr2:161244739~161249050:+ LIHC cis rs5742933 0.803 rs1233262 ENSG00000253559.1 OSGEPL1-AS1 -3.73 0.000223 0.0354 -0.25 -0.2 Ferritin levels; chr2:189793107 chr2:189762704~189765556:+ LIHC cis rs6732160 0.932 rs768851 ENSG00000272702.1 RP11-44N22.3 3.73 0.000223 0.0354 0.22 0.2 Intelligence (multi-trait analysis); chr2:73151113 chr2:73113018~73115907:+ LIHC cis rs6732160 0.934 rs2421390 ENSG00000272702.1 RP11-44N22.3 3.73 0.000223 0.0354 0.22 0.2 Intelligence (multi-trait analysis); chr2:73151975 chr2:73113018~73115907:+ LIHC cis rs6732160 0.932 rs6546802 ENSG00000272702.1 RP11-44N22.3 3.73 0.000223 0.0354 0.22 0.2 Intelligence (multi-trait analysis); chr2:73152436 chr2:73113018~73115907:+ LIHC cis rs6732160 0.932 rs13417029 ENSG00000272702.1 RP11-44N22.3 3.73 0.000223 0.0354 0.22 0.2 Intelligence (multi-trait analysis); chr2:73153295 chr2:73113018~73115907:+ LIHC cis rs6732160 0.932 rs6546803 ENSG00000272702.1 RP11-44N22.3 3.73 0.000223 0.0354 0.22 0.2 Intelligence (multi-trait analysis); chr2:73154187 chr2:73113018~73115907:+ LIHC cis rs67981189 0.896 rs7146591 ENSG00000274818.1 RP1-292L20.3 -3.73 0.000223 0.0354 -0.22 -0.2 Schizophrenia; chr14:70971511 chr14:70906657~70907111:- LIHC cis rs27434 0.607 rs695965 ENSG00000272109.1 CTD-2260A17.3 -3.73 0.000224 0.0354 -0.24 -0.2 Ankylosing spondylitis; chr5:96812663 chr5:96804353~96806105:+ LIHC cis rs1874124 0.577 rs2807880 ENSG00000257551.1 HLX-AS1 3.73 0.000224 0.0354 0.34 0.2 Cholesterol, total; chr1:220869661 chr1:220832763~220880140:- LIHC cis rs79349575 0.756 rs62078385 ENSG00000248278.1 SUMO2P17 3.73 0.000224 0.0354 0.25 0.2 Type 2 diabetes; chr17:48967647 chr17:48874860~48908983:- LIHC cis rs709400 0.77 rs7142883 ENSG00000258914.1 CTD-2134A5.3 3.73 0.000224 0.0354 0.29 0.2 Body mass index; chr14:103600308 chr14:103875055~103877478:+ LIHC cis rs1115240 1 rs1950406 ENSG00000257842.4 NOVA1-AS1 -3.73 0.000224 0.0354 -0.18 -0.2 Educational attainment (years of education); chr14:26610392 chr14:26598412~26806467:+ LIHC cis rs912057 1 rs1294407 ENSG00000261211.1 RP1-80N2.3 3.73 0.000224 0.0354 0.2 0.2 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index; chr6:6737870 chr6:6680309~6683633:- LIHC cis rs4604732 0.631 rs12038880 ENSG00000215795.2 RP11-488L18.3 3.73 0.000224 0.0354 0.23 0.2 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247461301 chr1:247183813~247185482:- LIHC cis rs6828577 0.862 rs298974 ENSG00000269893.5 SNHG8 3.73 0.000224 0.0354 0.2 0.2 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118714879 chr4:118278709~118279823:+ LIHC cis rs17376456 0.825 rs13161885 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000224 0.0354 -0.42 -0.2 Diabetic retinopathy; chr5:93735536 chr5:93860669~93863825:- LIHC cis rs17376456 0.778 rs72786662 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000224 0.0354 -0.42 -0.2 Diabetic retinopathy; chr5:93801924 chr5:93860669~93863825:- LIHC cis rs4891159 0.79 rs689885 ENSG00000265778.2 RP11-17M16.2 3.73 0.000224 0.0354 0.24 0.2 Longevity; chr18:76398607 chr18:76491652~76493918:+ LIHC cis rs8072100 0.576 rs7216112 ENSG00000228782.6 CTD-2026D20.3 -3.73 0.000224 0.0354 -0.24 -0.2 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47328979 chr17:47450568~47492492:- LIHC cis rs7247513 0.964 rs12979795 ENSG00000230310.1 CTD-2192J16.11 3.73 0.000224 0.0354 0.27 0.2 Bipolar disorder; chr19:12607033 chr19:12552597~12553644:+ LIHC cis rs2117029 0.782 rs6580698 ENSG00000281789.1 Y_RNA 3.73 0.000224 0.0354 0.2 0.2 Intelligence (multi-trait analysis); chr12:49084875 chr12:48927939~48928033:- LIHC cis rs1005277 0.579 rs2474584 ENSG00000099251.13 HSD17B7P2 3.73 0.000224 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38127461 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs1548255 ENSG00000099251.13 HSD17B7P2 3.73 0.000224 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38128265 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474586 ENSG00000099251.13 HSD17B7P2 3.73 0.000224 0.0354 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38129954 chr10:38356380~38378505:+ LIHC cis rs3733589 0.661 rs13114090 ENSG00000250413.1 RP11-448G15.1 3.73 0.000224 0.0354 0.35 0.2 Renal overload gout; chr4:9958275 chr4:10006482~10009725:+ LIHC cis rs6600671 0.934 rs12131379 ENSG00000227082.1 CH17-437K3.1 -3.73 0.000224 0.0354 -0.25 -0.2 Hip geometry; chr1:121551639 chr1:121396754~121463129:+ LIHC cis rs2834288 0.613 rs2040113 ENSG00000237945.6 LINC00649 3.73 0.000224 0.0354 0.25 0.2 Gut microbiota (bacterial taxa); chr21:33908879 chr21:33915534~33977691:+ LIHC cis rs2348418 0.767 rs7972954 ENSG00000247934.4 RP11-967K21.1 3.73 0.000224 0.0355 0.18 0.2 Lung function (FEV1);Lung function (FVC); chr12:28260273 chr12:28163298~28190738:- LIHC cis rs338389 0.609 rs338382 ENSG00000260657.2 RP11-315D16.4 -3.73 0.000224 0.0355 -0.3 -0.2 Survival in rectal cancer; chr15:67952045 chr15:68267792~68277994:- LIHC cis rs2554380 0.657 rs4530091 ENSG00000225151.9 GOLGA2P7 -3.73 0.000224 0.0355 -0.29 -0.2 Height; chr15:83814026 chr15:84199311~84230136:- LIHC cis rs11096990 0.892 rs28639548 ENSG00000249207.1 RP11-360F5.1 3.73 0.000224 0.0355 0.23 0.2 Cognitive function; chr4:39185530 chr4:39112677~39126818:- LIHC cis rs2613514 1 rs77832597 ENSG00000204277.1 RP11-219G17.4 3.73 0.000224 0.0355 0.31 0.2 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78087530 chr17:78261349~78278492:- LIHC cis rs11658311 0.85 rs11654482 ENSG00000197815.4 RP1-253P7.4 3.73 0.000224 0.0355 0.3 0.2 Obsessive-compulsive symptoms; chr17:17713773 chr17:17858227~17860041:+ LIHC cis rs2898681 0.561 rs7699960 ENSG00000248375.1 RP11-177B4.1 -3.73 0.000224 0.0355 -0.32 -0.2 Optic nerve measurement (cup area); chr4:52869494 chr4:52720081~52720831:- LIHC cis rs6547741 0.743 rs7564625 ENSG00000234072.1 AC074117.10 -3.73 0.000224 0.0355 -0.19 -0.2 Oral cavity cancer; chr2:27639530 chr2:27356246~27367622:+ LIHC cis rs2243480 1 rs2420170 ENSG00000228409.4 CCT6P1 -3.73 0.000224 0.0355 -0.21 -0.2 Diabetic kidney disease; chr7:66191066 chr7:65751142~65763354:+ LIHC cis rs1396626 0.89 rs876394 ENSG00000230427.1 RP11-313A24.1 3.73 0.000224 0.0355 0.31 0.2 Diabetic kidney disease; chr1:95516784 chr1:95061596~95067545:+ LIHC cis rs10883723 0.81 rs7094366 ENSG00000236937.2 PTGES3P4 -3.73 0.000225 0.0355 -0.26 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102514973 chr10:102845595~102845950:+ LIHC cis rs6545883 1 rs778763 ENSG00000271889.1 RP11-493E12.1 3.73 0.000225 0.0355 0.24 0.2 Tuberculosis; chr2:61558504 chr2:61151433~61162105:- LIHC cis rs13113518 0.812 rs2048564 ENSG00000223305.1 RN7SKP30 3.73 0.000225 0.0355 0.23 0.2 Height; chr4:55407965 chr4:55540502~55540835:- LIHC cis rs4671400 0.571 rs62152270 ENSG00000273302.1 RP11-493E12.2 -3.73 0.000225 0.0355 -0.23 -0.2 3-hydroxypropylmercapturic acid levels in smokers; chr2:61267125 chr2:61199979~61200769:+ LIHC cis rs4671400 0.571 rs12615222 ENSG00000273302.1 RP11-493E12.2 -3.73 0.000225 0.0355 -0.23 -0.2 3-hydroxypropylmercapturic acid levels in smokers; chr2:61267760 chr2:61199979~61200769:+ LIHC cis rs901683 1 rs34771643 ENSG00000230869.1 CTGLF10P -3.73 0.000225 0.0355 -0.49 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45475184 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34937315 ENSG00000230869.1 CTGLF10P -3.73 0.000225 0.0355 -0.49 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45475269 chr10:45678692~45700532:+ LIHC cis rs901683 0.85 rs34081552 ENSG00000230869.1 CTGLF10P -3.73 0.000225 0.0355 -0.49 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45475708 chr10:45678692~45700532:+ LIHC cis rs901683 0.557 rs34663276 ENSG00000230869.1 CTGLF10P -3.73 0.000225 0.0355 -0.49 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45475912 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34661476 ENSG00000230869.1 CTGLF10P -3.73 0.000225 0.0355 -0.49 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45475965 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71494787 ENSG00000230869.1 CTGLF10P -3.73 0.000225 0.0355 -0.49 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45476799 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71494789 ENSG00000230869.1 CTGLF10P -3.73 0.000225 0.0355 -0.49 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45477033 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs71494790 ENSG00000230869.1 CTGLF10P -3.73 0.000225 0.0355 -0.49 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45477163 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35464392 ENSG00000230869.1 CTGLF10P -3.73 0.000225 0.0355 -0.49 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45477432 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs34566829 ENSG00000230869.1 CTGLF10P -3.73 0.000225 0.0355 -0.49 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45478150 chr10:45678692~45700532:+ LIHC cis rs901683 1 rs35349326 ENSG00000230869.1 CTGLF10P -3.73 0.000225 0.0355 -0.49 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45478176 chr10:45678692~45700532:+ LIHC cis rs9929218 0.529 rs17715450 ENSG00000260459.2 FTLP14 3.73 0.000225 0.0355 0.22 0.2 Colorectal cancer; chr16:68695882 chr16:68822587~68823070:+ LIHC cis rs7563124 1 rs7563124 ENSG00000189223.12 PAX8-AS1 -3.73 0.000225 0.0356 -0.31 -0.2 Hematocrit; chr2:113207621 chr2:113211522~113276581:+ LIHC cis rs745580 0.933 rs4719845 ENSG00000199085.2 MIR148A -3.73 0.000225 0.0356 -0.2 -0.2 Obesity-related traits; chr7:25994588 chr7:25949903~25950013:- LIHC cis rs1922291 0.546 rs2310241 ENSG00000281162.1 LINC01127 3.73 0.000225 0.0356 0.21 0.2 Blood protein levels; chr2:102225489 chr2:101962056~101987167:+ LIHC cis rs703842 0.739 rs701008 ENSG00000270039.1 RP11-571M6.17 -3.73 0.000225 0.0356 -0.26 -0.2 Multiple sclerosis; chr12:57723862 chr12:57803838~57804415:+ LIHC cis rs7208859 0.623 rs9912440 ENSG00000264538.5 SUZ12P1 -3.73 0.000225 0.0356 -0.2 -0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30821754 chr17:30709299~30790908:+ LIHC cis rs881375 0.933 rs7859805 ENSG00000226752.6 PSMD5-AS1 -3.73 0.000225 0.0356 -0.22 -0.2 Rheumatoid arthritis; chr9:120901845 chr9:120824828~120854385:+ LIHC cis rs881375 0.933 rs10818485 ENSG00000226752.6 PSMD5-AS1 -3.73 0.000225 0.0356 -0.22 -0.2 Rheumatoid arthritis; chr9:120905538 chr9:120824828~120854385:+ LIHC cis rs881375 0.967 rs10435843 ENSG00000226752.6 PSMD5-AS1 -3.73 0.000225 0.0356 -0.22 -0.2 Rheumatoid arthritis; chr9:120905755 chr9:120824828~120854385:+ LIHC cis rs881375 0.967 rs10435844 ENSG00000226752.6 PSMD5-AS1 -3.73 0.000225 0.0356 -0.22 -0.2 Rheumatoid arthritis; chr9:120905921 chr9:120824828~120854385:+ LIHC cis rs881375 0.967 rs7848332 ENSG00000226752.6 PSMD5-AS1 -3.73 0.000225 0.0356 -0.22 -0.2 Rheumatoid arthritis; chr9:120907218 chr9:120824828~120854385:+ LIHC cis rs1816213 0.744 rs71415840 ENSG00000273466.1 RP11-548H3.1 -3.73 0.000225 0.0356 -0.31 -0.2 Diastolic blood pressure; chr2:218508341 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs35089758 ENSG00000273466.1 RP11-548H3.1 -3.73 0.000225 0.0356 -0.31 -0.2 Diastolic blood pressure; chr2:218512546 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs6729124 ENSG00000273466.1 RP11-548H3.1 -3.73 0.000225 0.0356 -0.31 -0.2 Diastolic blood pressure; chr2:218519768 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs35362395 ENSG00000273466.1 RP11-548H3.1 -3.73 0.000225 0.0356 -0.31 -0.2 Diastolic blood pressure; chr2:218523001 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs34887023 ENSG00000273466.1 RP11-548H3.1 -3.73 0.000225 0.0356 -0.31 -0.2 Diastolic blood pressure; chr2:218524345 chr2:218633256~218634014:- LIHC cis rs7797990 0.963 rs4717021 ENSG00000225224.1 RP4-814D15.2 3.73 0.000225 0.0356 0.27 0.2 Exploratory eye movement dysfunction in schizophrenia (cognitive search score); chr7:156219185 chr7:157192368~157192832:+ LIHC cis rs6142102 1 rs12480839 ENSG00000275784.1 RP5-1125A11.6 -3.73 0.000225 0.0356 -0.22 -0.2 Skin pigmentation; chr20:34139624 chr20:33989480~33991818:- LIHC cis rs6893782 0.887 rs274554 ENSG00000233006.5 AC034220.3 -3.73 0.000225 0.0356 -0.27 -0.2 Acylcarnitine levels; chr5:132389258 chr5:132311285~132369916:- LIHC cis rs2439831 0.85 rs694985 ENSG00000166763.7 STRCP1 3.73 0.000225 0.0356 0.27 0.2 Lung cancer in ever smokers; chr15:43521189 chr15:43699488~43718184:- LIHC cis rs7119 0.651 rs12902072 ENSG00000261143.1 ADAMTS7P3 3.73 0.000225 0.0356 0.28 0.2 Type 2 diabetes; chr15:77556390 chr15:77976042~77993057:+ LIHC cis rs8037137 0.915 rs112770790 ENSG00000258725.1 PRC1-AS1 -3.73 0.000225 0.0356 -0.25 -0.2 Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr15:90964265 chr15:90966345~90988624:+ LIHC cis rs950169 0.92 rs2135551 ENSG00000225151.9 GOLGA2P7 -3.73 0.000225 0.0356 -0.28 -0.2 Schizophrenia; chr15:84039099 chr15:84199311~84230136:- LIHC cis rs950169 1 rs12902672 ENSG00000225151.9 GOLGA2P7 -3.73 0.000225 0.0356 -0.28 -0.2 Schizophrenia; chr15:84048234 chr15:84199311~84230136:- LIHC cis rs950169 1 rs12903820 ENSG00000225151.9 GOLGA2P7 -3.73 0.000225 0.0356 -0.28 -0.2 Schizophrenia; chr15:84055068 chr15:84199311~84230136:- LIHC cis rs950169 0.919 rs12915589 ENSG00000225151.9 GOLGA2P7 -3.73 0.000225 0.0356 -0.28 -0.2 Schizophrenia; chr15:84065712 chr15:84199311~84230136:- LIHC cis rs950169 0.959 rs66801143 ENSG00000225151.9 GOLGA2P7 -3.73 0.000225 0.0356 -0.28 -0.2 Schizophrenia; chr15:84067905 chr15:84199311~84230136:- LIHC cis rs950169 1 rs35648189 ENSG00000225151.9 GOLGA2P7 -3.73 0.000225 0.0356 -0.28 -0.2 Schizophrenia; chr15:84071996 chr15:84199311~84230136:- LIHC cis rs950169 0.92 rs17300048 ENSG00000225151.9 GOLGA2P7 -3.73 0.000225 0.0356 -0.28 -0.2 Schizophrenia; chr15:84080725 chr15:84199311~84230136:- LIHC cis rs950169 1 rs1848093 ENSG00000225151.9 GOLGA2P7 -3.73 0.000225 0.0356 -0.28 -0.2 Schizophrenia; chr15:84086775 chr15:84199311~84230136:- LIHC cis rs950169 1 rs12915234 ENSG00000225151.9 GOLGA2P7 -3.73 0.000225 0.0356 -0.28 -0.2 Schizophrenia; chr15:84089549 chr15:84199311~84230136:- LIHC cis rs950169 1 rs34751999 ENSG00000225151.9 GOLGA2P7 -3.73 0.000225 0.0356 -0.28 -0.2 Schizophrenia; chr15:84089667 chr15:84199311~84230136:- LIHC cis rs950169 0.919 rs17300292 ENSG00000225151.9 GOLGA2P7 -3.73 0.000225 0.0356 -0.28 -0.2 Schizophrenia; chr15:84093816 chr15:84199311~84230136:- LIHC cis rs4356975 0.563 rs6851533 ENSG00000250919.1 RP11-813N20.3 -3.73 0.000225 0.0356 -0.2 -0.2 Obesity-related traits; chr4:69113032 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs7666195 ENSG00000250919.1 RP11-813N20.3 -3.73 0.000225 0.0356 -0.2 -0.2 Obesity-related traits; chr4:69113765 chr4:69027831~69044578:+ LIHC cis rs10851478 0.692 rs11854203 ENSG00000276593.1 RP11-295H24.5 3.73 0.000225 0.0356 0.22 0.2 Oral cavity cancer; chr15:49542549 chr15:49353485~49354034:+ LIHC cis rs10851478 0.692 rs12594670 ENSG00000276593.1 RP11-295H24.5 3.73 0.000225 0.0356 0.22 0.2 Oral cavity cancer; chr15:49569029 chr15:49353485~49354034:+ LIHC cis rs2658782 0.724 rs2248655 ENSG00000279684.1 RP11-755E23.2 -3.73 0.000225 0.0356 -0.29 -0.2 Pulmonary function decline; chr11:93521446 chr11:93286629~93288903:- LIHC cis rs3104707 0.858 rs3104705 ENSG00000279662.1 RP11-609N14.4 3.73 0.000225 0.0356 0.18 0.2 Subjective well-being; chr16:9975433 chr16:10445309~10449747:- LIHC cis rs853679 0.599 rs156743 ENSG00000204709.4 LINC01556 3.73 0.000226 0.0356 0.35 0.2 Depression; chr6:27999311 chr6:28943877~28944537:+ LIHC cis rs1115240 0.685 rs61988072 ENSG00000257842.4 NOVA1-AS1 3.73 0.000226 0.0356 0.19 0.2 Educational attainment (years of education); chr14:26615482 chr14:26598412~26806467:+ LIHC cis rs673078 0.66 rs6490175 ENSG00000275409.1 RP11-131L12.4 -3.73 0.000226 0.0356 -0.23 -0.2 Glucose homeostasis traits; chr12:118293559 chr12:118430147~118430699:+ LIHC cis rs3104707 0.557 rs3104702 ENSG00000279662.1 RP11-609N14.4 3.73 0.000226 0.0356 0.18 0.2 Subjective well-being; chr16:9970929 chr16:10445309~10449747:- LIHC cis rs4648045 0.647 rs17032705 ENSG00000230069.3 LRRC37A15P -3.73 0.000226 0.0357 -0.18 -0.2 Lymphocyte percentage of white cells; chr4:102511817 chr4:102727274~102730721:- LIHC cis rs7712401 0.601 rs418562 ENSG00000263432.2 RN7SL689P -3.73 0.000226 0.0357 -0.29 -0.2 Mean platelet volume; chr5:123004567 chr5:123022487~123022783:- LIHC cis rs4073416 0.712 rs11627084 ENSG00000276116.2 FUT8-AS1 3.73 0.000226 0.0357 0.25 0.2 N-glycan levels; chr14:65512118 chr14:65411170~65412690:- LIHC cis rs17213965 1 rs17213965 ENSG00000207425.1 Y_RNA -3.73 0.000226 0.0357 -0.34 -0.2 Waist-hip ratio; chr16:15788110 chr16:14915457~14915556:- LIHC cis rs10883723 0.703 rs7898410 ENSG00000236937.2 PTGES3P4 -3.73 0.000226 0.0357 -0.26 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102486101 chr10:102845595~102845950:+ LIHC cis rs10883723 0.775 rs7917158 ENSG00000236937.2 PTGES3P4 -3.73 0.000226 0.0357 -0.26 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102486714 chr10:102845595~102845950:+ LIHC cis rs10883723 0.81 rs7917525 ENSG00000236937.2 PTGES3P4 -3.73 0.000226 0.0357 -0.26 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102486998 chr10:102845595~102845950:+ LIHC cis rs853679 0.76 rs11967137 ENSG00000219392.1 RP1-265C24.5 -3.73 0.000226 0.0357 -0.3 -0.2 Depression; chr6:28231986 chr6:28115628~28116551:+ LIHC cis rs453301 0.506 rs686189 ENSG00000254340.1 RP11-10A14.3 -3.73 0.000226 0.0357 -0.2 -0.2 Joint mobility (Beighton score); chr8:8766127 chr8:9141424~9145435:+ LIHC cis rs67311347 0.955 rs11711994 ENSG00000223797.4 ENTPD3-AS1 3.73 0.000226 0.0357 0.16 0.2 Renal cell carcinoma; chr3:40349595 chr3:40313802~40453329:- LIHC cis rs748404 0.588 rs2255410 ENSG00000166763.7 STRCP1 3.73 0.000226 0.0357 0.24 0.2 Lung cancer; chr15:43538899 chr15:43699488~43718184:- LIHC cis rs13434995 0.513 rs62309729 ENSG00000273257.1 RP11-177J6.1 -3.73 0.000226 0.0357 -0.32 -0.2 Adiponectin levels; chr4:55536679 chr4:55387949~55388271:+ LIHC cis rs8177253 1 rs8177262 ENSG00000244062.1 RP11-404G16.2 -3.73 0.000226 0.0357 -0.2 -0.2 Iron status biomarkers; chr3:133761808 chr3:133760300~133762363:+ LIHC cis rs12449964 0.524 rs4925094 ENSG00000223979.2 SMCR2 3.73 0.000226 0.0357 0.25 0.2 Coronary artery disease or ischemic stroke; chr17:17665698 chr17:17674026~17677688:- LIHC cis rs1539019 0.641 rs4925546 ENSG00000202079.1 Y_RNA -3.73 0.000226 0.0357 -0.17 -0.2 Fibrinogen; chr1:247439666 chr1:247294835~247294941:+ LIHC cis rs12946454 0.521 rs66827053 ENSG00000267288.2 RP13-890H12.2 -3.73 0.000226 0.0357 -0.23 -0.2 Systolic blood pressure; chr17:45173286 chr17:45168800~45171584:- LIHC cis rs2745572 0.557 rs2745569 ENSG00000272279.1 RP11-157J24.2 -3.73 0.000226 0.0357 -0.25 -0.2 Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure); chr6:1547396 chr6:1528364~1528911:- LIHC cis rs9876781 1 rs4858793 ENSG00000229759.1 MRPS18AP1 -3.73 0.000226 0.0357 -0.21 -0.2 Longevity; chr3:48373517 chr3:48256350~48256938:- LIHC cis rs13242816 1 rs34678019 ENSG00000279086.1 RP11-667F14.1 3.73 0.000226 0.0357 0.35 0.2 P wave duration; chr7:116549436 chr7:116209234~116211511:- LIHC cis rs9309711 0.772 rs9309715 ENSG00000225234.1 TRAPPC12-AS1 3.73 0.000226 0.0357 0.19 0.2 Neurofibrillary tangles; chr2:3488547 chr2:3481242~3482409:- LIHC cis rs2564921 0.73 rs62253602 ENSG00000242142.1 SERBP1P3 -3.73 0.000226 0.0357 -0.27 -0.2 Height; chr3:52936861 chr3:53064283~53065091:- LIHC cis rs2564921 0.704 rs62253604 ENSG00000242142.1 SERBP1P3 -3.73 0.000226 0.0357 -0.27 -0.2 Height; chr3:52941053 chr3:53064283~53065091:- LIHC cis rs1816213 0.744 rs3806556 ENSG00000273466.1 RP11-548H3.1 -3.73 0.000227 0.0358 -0.3 -0.2 Diastolic blood pressure; chr2:218660284 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs34683377 ENSG00000273466.1 RP11-548H3.1 -3.73 0.000227 0.0358 -0.3 -0.2 Diastolic blood pressure; chr2:218665367 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs60520272 ENSG00000273466.1 RP11-548H3.1 -3.73 0.000227 0.0358 -0.3 -0.2 Diastolic blood pressure; chr2:218668506 chr2:218633256~218634014:- LIHC cis rs3105593 0.583 rs12900618 ENSG00000273674.3 CTD-2378E12.1 3.73 0.000227 0.0358 0.24 0.2 QT interval; chr15:50516340 chr15:50839875~50908599:- LIHC cis rs1005277 0.54 rs1987431 ENSG00000276805.1 RP11-291L22.6 3.73 0.000227 0.0358 0.24 0.2 Extrinsic epigenetic age acceleration; chr10:37699959 chr10:38451030~38451785:+ LIHC cis rs5743030 1 rs5743117 ENSG00000253559.1 OSGEPL1-AS1 -3.73 0.000227 0.0358 -0.34 -0.2 Subcutaneous adipose tissue; chr2:189849519 chr2:189762704~189765556:+ LIHC cis rs5743030 1 rs5743202 ENSG00000253559.1 OSGEPL1-AS1 -3.73 0.000227 0.0358 -0.35 -0.2 Subcutaneous adipose tissue; chr2:189877940 chr2:189762704~189765556:+ LIHC cis rs6517329 0.538 rs879893 ENSG00000231106.2 LINC01436 3.73 0.000227 0.0358 0.22 0.2 Schizophrenia; chr21:36136489 chr21:36005338~36007838:+ LIHC cis rs11098403 0.753 rs10006167 ENSG00000260404.2 RP11-384K6.6 3.73 0.000227 0.0358 0.13 0.2 Schizophrenia; chr4:117845960 chr4:118591773~118633729:+ LIHC cis rs11089937 0.597 rs4821774 ENSG00000211639.2 IGLV4-60 3.73 0.000227 0.0358 0.17 0.2 Periodontitis (PAL4Q3); chr22:22131536 chr22:22162199~22162681:+ LIHC cis rs853679 0.545 rs35949109 ENSG00000219392.1 RP1-265C24.5 -3.73 0.000227 0.0358 -0.36 -0.2 Depression; chr6:28058148 chr6:28115628~28116551:+ LIHC cis rs42490 0.716 rs43135 ENSG00000251136.7 RP11-37B2.1 -3.73 0.000227 0.0358 -0.17 -0.2 Leprosy; chr8:89823722 chr8:89609409~89757727:- LIHC cis rs2348418 0.832 rs10506031 ENSG00000247934.4 RP11-967K21.1 -3.73 0.000227 0.0358 -0.18 -0.2 Lung function (FEV1);Lung function (FVC); chr12:28379061 chr12:28163298~28190738:- LIHC cis rs875971 0.545 rs10261710 ENSG00000224316.1 RP11-479O9.2 3.73 0.000227 0.0358 0.19 0.2 Aortic root size; chr7:66249202 chr7:65773620~65802067:+ LIHC cis rs10761256 0.806 rs10761251 ENSG00000227603.1 RP11-165J3.6 3.73 0.000227 0.0358 0.23 0.2 Itch intensity from mosquito bite adjusted by bite size; chr9:93659264 chr9:93435332~93437121:- LIHC cis rs6504622 0.557 rs10853085 ENSG00000263766.4 RP11-580I16.2 3.73 0.000227 0.0358 0.23 0.2 Orofacial clefts; chr17:46917704 chr17:47603860~47649420:- LIHC cis rs7712401 0.623 rs30032 ENSG00000263432.2 RN7SL689P 3.73 0.000227 0.0358 0.3 0.2 Mean platelet volume; chr5:122902692 chr5:123022487~123022783:- LIHC cis rs4529888 0.761 rs2514890 ENSG00000255062.1 RP11-712L6.5 -3.73 0.000227 0.0358 -0.24 -0.2 Amyotrophic lateral sclerosis; chr11:127218497 chr11:126294298~126304318:- LIHC cis rs301901 0.828 rs10941337 ENSG00000250155.1 CTD-2353F22.1 3.73 0.000227 0.0358 0.19 0.2 Height; chr5:37474023 chr5:36666214~36725195:- LIHC cis rs875971 0.638 rs10249404 ENSG00000237310.1 GS1-124K5.4 -3.73 0.000227 0.0359 -0.18 -0.2 Aortic root size; chr7:66581737 chr7:66493706~66495474:+ LIHC cis rs867371 0.896 rs6495647 ENSG00000259429.4 UBE2Q2P2 -3.73 0.000227 0.0359 -0.19 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82244708 chr15:82355142~82420075:+ LIHC cis rs2348418 0.832 rs7136426 ENSG00000247934.4 RP11-967K21.1 3.73 0.000227 0.0359 0.18 0.2 Lung function (FEV1);Lung function (FVC); chr12:28400129 chr12:28163298~28190738:- LIHC cis rs694739 0.726 rs516124 ENSG00000236935.1 AP003774.1 3.73 0.000227 0.0359 0.21 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64360951 chr11:64325050~64329504:- LIHC cis rs7712401 0.623 rs26372 ENSG00000263432.2 RN7SL689P -3.73 0.000227 0.0359 -0.28 -0.2 Mean platelet volume; chr5:122870752 chr5:123022487~123022783:- LIHC cis rs2658782 0.688 rs2658768 ENSG00000279684.1 RP11-755E23.2 -3.73 0.000228 0.0359 -0.29 -0.2 Pulmonary function decline; chr11:93517661 chr11:93286629~93288903:- LIHC cis rs11089937 0.512 rs34963809 ENSG00000211639.2 IGLV4-60 3.73 0.000228 0.0359 0.17 0.2 Periodontitis (PAL4Q3); chr22:22130737 chr22:22162199~22162681:+ LIHC cis rs11089937 0.568 rs35626600 ENSG00000211639.2 IGLV4-60 3.73 0.000228 0.0359 0.17 0.2 Periodontitis (PAL4Q3); chr22:22130811 chr22:22162199~22162681:+ LIHC cis rs11089937 0.539 rs34228957 ENSG00000211639.2 IGLV4-60 3.73 0.000228 0.0359 0.17 0.2 Periodontitis (PAL4Q3); chr22:22130838 chr22:22162199~22162681:+ LIHC cis rs7617773 0.539 rs35460860 ENSG00000229759.1 MRPS18AP1 3.73 0.000228 0.0359 0.23 0.2 Coronary artery disease; chr3:48350595 chr3:48256350~48256938:- LIHC cis rs7617773 0.563 rs13082269 ENSG00000229759.1 MRPS18AP1 3.73 0.000228 0.0359 0.23 0.2 Coronary artery disease; chr3:48350784 chr3:48256350~48256938:- LIHC cis rs12908161 1 rs11638290 ENSG00000259728.4 LINC00933 3.73 0.000228 0.0359 0.28 0.2 Schizophrenia; chr15:84684405 chr15:84570649~84580175:+ LIHC cis rs6832769 0.89 rs564762 ENSG00000272969.1 RP11-528I4.2 3.73 0.000228 0.0359 0.23 0.2 Personality dimensions; chr4:55418464 chr4:55547112~55547889:+ LIHC cis rs160451 0.934 rs34036322 ENSG00000251136.7 RP11-37B2.1 3.73 0.000228 0.0359 0.17 0.2 Leprosy; chr8:89654670 chr8:89609409~89757727:- LIHC cis rs10067881 1 rs10067881 ENSG00000251000.1 AC008592.3 3.73 0.000228 0.0359 0.34 0.2 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells; chr5:95826771 chr5:95834424~95835046:- LIHC cis rs13113518 0.783 rs12504300 ENSG00000249700.7 SRD5A3-AS1 3.73 0.000228 0.0359 0.23 0.2 Height; chr4:55482360 chr4:55363971~55395847:- LIHC cis rs6723108 0.517 rs6430548 ENSG00000224043.6 CCNT2-AS1 -3.73 0.000228 0.0359 -0.23 -0.2 Type 2 diabetes; chr2:134854869 chr2:134735464~134918710:- LIHC cis rs673078 0.66 rs11068891 ENSG00000275409.1 RP11-131L12.4 3.73 0.000228 0.0359 0.25 0.2 Glucose homeostasis traits; chr12:118259814 chr12:118430147~118430699:+ LIHC cis rs2932538 0.885 rs3762335 ENSG00000225075.1 RP11-426L16.3 3.73 0.000228 0.036 0.25 0.2 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112557926 chr1:112693688~112696621:- LIHC cis rs2932538 0.922 rs17438324 ENSG00000225075.1 RP11-426L16.3 3.73 0.000228 0.036 0.25 0.2 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112557951 chr1:112693688~112696621:- LIHC cis rs12908161 1 rs35630683 ENSG00000259728.4 LINC00933 3.73 0.000228 0.036 0.29 0.2 Schizophrenia; chr15:84806000 chr15:84570649~84580175:+ LIHC cis rs4700393 0.52 rs6896680 ENSG00000250461.1 RP11-631M6.2 3.73 0.000228 0.036 0.3 0.2 Intelligence (multi-trait analysis); chr5:60695704 chr5:61375112~61375855:+ LIHC cis rs9868809 0.656 rs13324119 ENSG00000270441.1 RP11-694I15.7 3.73 0.000228 0.036 0.37 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr3:48673173 chr3:49140086~49160851:- LIHC cis rs7809950 0.678 rs6949634 ENSG00000238832.1 snoU109 -3.73 0.000228 0.036 -0.25 -0.2 Coronary artery disease; chr7:107344239 chr7:107603363~107603507:+ LIHC cis rs7809950 0.593 rs62482503 ENSG00000238832.1 snoU109 -3.73 0.000228 0.036 -0.25 -0.2 Coronary artery disease; chr7:107347543 chr7:107603363~107603507:+ LIHC cis rs1318937 0.915 rs3732728 ENSG00000224660.1 SH3BP5-AS1 -3.73 0.000228 0.036 -0.18 -0.2 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15256447 chr3:15254184~15264493:+ LIHC cis rs17376456 0.825 rs17314762 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93895494 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs34592268 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93897045 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs28645862 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93897422 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs28705226 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93897429 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs17314797 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93899139 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs17374166 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93902949 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs67328989 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93907427 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs10476590 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93909178 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs28610997 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93912669 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs28412976 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93912672 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs72786702 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93918951 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs74825443 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93919268 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs10079708 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93926091 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs10064368 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93930691 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs10052662 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93935680 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs12716453 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93935992 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs13361613 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93936471 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs12716454 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93936574 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs10054790 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93936815 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs55724660 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93940931 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs55947981 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93942399 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs10058331 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93943410 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs10054903 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93945786 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs10057130 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93946852 chr5:93860669~93863825:- LIHC cis rs17376456 0.825 rs35426871 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93955908 chr5:93860669~93863825:- LIHC cis rs17376456 1 rs67150649 ENSG00000251023.1 RP11-549J18.1 -3.73 0.000228 0.036 -0.41 -0.2 Diabetic retinopathy; chr5:93956672 chr5:93860669~93863825:- LIHC cis rs11098499 0.588 rs2389874 ENSG00000245958.5 RP11-33B1.1 3.73 0.000228 0.036 0.19 0.2 Corneal astigmatism; chr4:119633836 chr4:119454791~119552025:+ LIHC cis rs4453827 1 rs11708227 ENSG00000271916.1 RP11-884K10.6 3.73 0.000228 0.036 0.38 0.2 Blood protein levels; chr3:53714006 chr3:53797764~53798019:- LIHC cis rs6442522 0.64 rs6762964 ENSG00000249786.6 EAF1-AS1 3.72 0.000228 0.036 0.24 0.2 Uric acid levels; chr3:15485938 chr3:15436171~15455940:- LIHC cis rs12681287 0.547 rs56752411 ENSG00000254088.1 SLC2A3P4 3.72 0.000228 0.036 0.23 0.2 Caudate activity during reward; chr8:86502927 chr8:86503591~86505061:+ LIHC cis rs9309473 0.5 rs4852952 ENSG00000204872.3 NAT8B -3.72 0.000229 0.036 -0.26 -0.2 Metabolite levels; chr2:73642780 chr2:73700576~73701340:- LIHC cis rs780096 0.565 rs11681351 ENSG00000234072.1 AC074117.10 -3.72 0.000229 0.036 -0.19 -0.2 Total body bone mineral density; chr2:27520556 chr2:27356246~27367622:+ LIHC cis rs13315871 0.929 rs11130628 ENSG00000272182.1 RP11-802O23.3 3.72 0.000229 0.036 0.47 0.2 Cholesterol, total; chr3:58330108 chr3:58428255~58428815:+ LIHC cis rs16958440 0.581 rs11082564 ENSG00000267724.1 RP11-49K24.8 3.72 0.000229 0.036 0.27 0.2 Sitting height ratio; chr18:47132778 chr18:47105946~47108062:+ LIHC cis rs16958440 0.708 rs62096477 ENSG00000267724.1 RP11-49K24.8 3.72 0.000229 0.036 0.27 0.2 Sitting height ratio; chr18:47135939 chr18:47105946~47108062:+ LIHC cis rs7121538 0.756 rs1003077 ENSG00000251991.1 RNU7-49P -3.72 0.000229 0.036 -0.26 -0.2 HDL cholesterol; chr11:14386594 chr11:14478892~14478953:+ LIHC cis rs6452524 0.618 rs6452501 ENSG00000271862.1 RP11-343L5.2 3.72 0.000229 0.036 0.23 0.2 Hypertension (SNP x SNP interaction); chr5:83068681 chr5:83049376~83050964:- LIHC cis rs6142102 0.961 rs6059649 ENSG00000275784.1 RP5-1125A11.6 -3.72 0.000229 0.036 -0.23 -0.2 Skin pigmentation; chr20:34056071 chr20:33989480~33991818:- LIHC cis rs6142102 0.961 rs6059651 ENSG00000275784.1 RP5-1125A11.6 -3.72 0.000229 0.036 -0.23 -0.2 Skin pigmentation; chr20:34057246 chr20:33989480~33991818:- LIHC cis rs773506 0.565 rs4354431 ENSG00000273381.1 RP11-305L7.7 -3.72 0.000229 0.0361 -0.2 -0.2 Type 2 diabetes nephropathy; chr9:91347124 chr9:91206175~91210299:- LIHC cis rs6449502 0.623 rs7731760 ENSG00000272308.1 RP11-231G3.1 -3.72 0.000229 0.0361 -0.28 -0.2 Mean platelet volume; chr5:60841341 chr5:60866457~60866935:- LIHC cis rs12468226 0.938 rs10931993 ENSG00000272966.1 RP11-686O6.1 3.72 0.000229 0.0361 0.32 0.2 Urate levels; chr2:202243017 chr2:202336739~202337200:+ LIHC cis rs4938303 0.589 rs11216100 ENSG00000254851.1 RP11-109L13.1 3.72 0.000229 0.0361 0.23 0.2 Triglycerides; chr11:116701814 chr11:117135528~117138582:+ LIHC cis rs1023500 0.596 rs133350 ENSG00000205702.9 CYP2D7 3.72 0.000229 0.0361 0.23 0.2 Schizophrenia; chr22:42033045 chr22:42140203~42144577:- LIHC cis rs11098499 0.863 rs10018280 ENSG00000260091.1 RP11-33B1.4 -3.72 0.000229 0.0361 -0.14 -0.2 Corneal astigmatism; chr4:119556984 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs6534141 ENSG00000260091.1 RP11-33B1.4 -3.72 0.000229 0.0361 -0.14 -0.2 Corneal astigmatism; chr4:119564068 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs2127823 ENSG00000260091.1 RP11-33B1.4 -3.72 0.000229 0.0361 -0.14 -0.2 Corneal astigmatism; chr4:119564515 chr4:119409333~119410233:+ LIHC cis rs11098499 0.863 rs3775858 ENSG00000260091.1 RP11-33B1.4 -3.72 0.000229 0.0361 -0.14 -0.2 Corneal astigmatism; chr4:119564873 chr4:119409333~119410233:+ LIHC cis rs793571 0.744 rs4775097 ENSG00000259738.1 ZNF444P1 -3.72 0.000229 0.0361 -0.24 -0.2 Schizophrenia; chr15:58848602 chr15:58865006~58865303:+ LIHC cis rs2243480 1 rs316313 ENSG00000228409.4 CCT6P1 3.72 0.000229 0.0361 0.21 0.2 Diabetic kidney disease; chr7:66128561 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs316312 ENSG00000228409.4 CCT6P1 3.72 0.000229 0.0361 0.21 0.2 Diabetic kidney disease; chr7:66131504 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs419603 ENSG00000228409.4 CCT6P1 3.72 0.000229 0.0361 0.21 0.2 Diabetic kidney disease; chr7:66132354 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs431076 ENSG00000228409.4 CCT6P1 3.72 0.000229 0.0361 0.21 0.2 Diabetic kidney disease; chr7:66135333 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs2460422 ENSG00000228409.4 CCT6P1 3.72 0.000229 0.0361 0.21 0.2 Diabetic kidney disease; chr7:66136518 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs316334 ENSG00000228409.4 CCT6P1 3.72 0.000229 0.0361 0.21 0.2 Diabetic kidney disease; chr7:66137139 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs316330 ENSG00000228409.4 CCT6P1 3.72 0.000229 0.0361 0.21 0.2 Diabetic kidney disease; chr7:66140385 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs316326 ENSG00000228409.4 CCT6P1 3.72 0.000229 0.0361 0.21 0.2 Diabetic kidney disease; chr7:66144466 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs316325 ENSG00000228409.4 CCT6P1 3.72 0.000229 0.0361 0.21 0.2 Diabetic kidney disease; chr7:66144531 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs316321 ENSG00000228409.4 CCT6P1 3.72 0.000229 0.0361 0.21 0.2 Diabetic kidney disease; chr7:66146626 chr7:65751142~65763354:+ LIHC cis rs11098499 0.866 rs6847778 ENSG00000245958.5 RP11-33B1.1 -3.72 0.000229 0.0361 -0.2 -0.2 Corneal astigmatism; chr4:119372427 chr4:119454791~119552025:+ LIHC cis rs948562 0.69 rs734777 ENSG00000280010.1 AP001350.4 3.72 0.000229 0.0361 0.34 0.2 Lymphoma; chr11:58343636 chr11:58627435~58628528:+ LIHC cis rs673078 0.66 rs61945217 ENSG00000275759.1 RP11-131L12.3 -3.72 0.00023 0.0361 -0.43 -0.2 Glucose homeostasis traits; chr12:118261194 chr12:118428281~118428870:+ LIHC cis rs12468226 0.938 rs12463937 ENSG00000272966.1 RP11-686O6.1 3.72 0.00023 0.0361 0.33 0.2 Urate levels; chr2:202246543 chr2:202336739~202337200:+ LIHC cis rs6456156 0.565 rs7750209 ENSG00000227598.1 RP1-167A14.2 -3.72 0.00023 0.0361 -0.21 -0.2 Primary biliary cholangitis; chr6:167069407 chr6:166969626~166999065:- LIHC cis rs12370990 0.546 rs12372040 ENSG00000257261.4 RP11-96H19.1 3.72 0.00023 0.0361 0.33 0.2 Post bronchodilator FEV1 in COPD; chr12:46108112 chr12:46383679~46876159:+ LIHC cis rs713477 1 rs10782426 ENSG00000258413.1 RP11-665C16.6 3.72 0.00023 0.0362 0.22 0.2 Pediatric bone mineral content (femoral neck); chr14:55423984 chr14:55262767~55272075:- LIHC cis rs1799922 0.693 rs1688932 ENSG00000273270.1 RP11-212P7.2 3.72 0.00023 0.0362 0.25 0.2 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr7:128781081 chr7:128524016~128531069:- LIHC cis rs748404 0.723 rs11853991 ENSG00000166763.7 STRCP1 3.72 0.00023 0.0362 0.26 0.2 Lung cancer; chr15:43265351 chr15:43699488~43718184:- LIHC cis rs12379034 0.614 rs10984918 ENSG00000227355.1 RP11-162D16.2 -3.72 0.00023 0.0362 -0.49 -0.2 Rheumatoid arthritis; chr9:120452756 chr9:121375241~121452177:+ LIHC cis rs6547741 0.844 rs7382 ENSG00000234072.1 AC074117.10 -3.72 0.00023 0.0362 -0.19 -0.2 Oral cavity cancer; chr2:27650548 chr2:27356246~27367622:+ LIHC cis rs6547741 0.844 rs9678851 ENSG00000234072.1 AC074117.10 -3.72 0.00023 0.0362 -0.19 -0.2 Oral cavity cancer; chr2:27664167 chr2:27356246~27367622:+ LIHC cis rs950880 0.71 rs873022 ENSG00000234389.1 AC007278.3 -3.72 0.00023 0.0362 -0.2 -0.2 Serum protein levels (sST2); chr2:102339223 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs3771177 ENSG00000234389.1 AC007278.3 -3.72 0.00023 0.0362 -0.2 -0.2 Serum protein levels (sST2); chr2:102339400 chr2:102438713~102440475:+ LIHC cis rs950880 0.71 rs3732129 ENSG00000234389.1 AC007278.3 -3.72 0.00023 0.0362 -0.2 -0.2 Serum protein levels (sST2); chr2:102341072 chr2:102438713~102440475:+ LIHC cis rs9646944 0.501 rs34946515 ENSG00000234389.1 AC007278.3 3.72 0.00023 0.0362 0.25 0.2 Blood protein levels; chr2:102426860 chr2:102438713~102440475:+ LIHC cis rs9646944 0.501 rs10166330 ENSG00000234389.1 AC007278.3 3.72 0.00023 0.0362 0.25 0.2 Blood protein levels; chr2:102433930 chr2:102438713~102440475:+ LIHC cis rs9646944 0.501 rs2110736 ENSG00000234389.1 AC007278.3 3.72 0.00023 0.0362 0.25 0.2 Blood protein levels; chr2:102434395 chr2:102438713~102440475:+ LIHC cis rs9487094 1 rs36035949 ENSG00000260273.1 RP11-425D10.10 3.72 0.00023 0.0362 0.23 0.2 Height; chr6:109415411 chr6:109382795~109383666:+ LIHC cis rs308971 0.711 rs310750 ENSG00000225026.1 AC091492.2 3.72 0.00023 0.0362 0.56 0.2 Fasting blood insulin (BMI interaction); chr3:12232174 chr3:12328003~12328274:+ LIHC cis rs79040073 0.563 rs17478618 ENSG00000259531.2 RP11-295H24.3 -3.72 0.00023 0.0362 -0.38 -0.2 Lung cancer in ever smokers; chr15:49444621 chr15:49365124~49366685:- LIHC cis rs1005277 0.522 rs289647 ENSG00000099251.13 HSD17B7P2 3.72 0.00023 0.0362 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:37679350 chr10:38356380~38378505:+ LIHC cis rs4356975 0.563 rs6422324 ENSG00000250919.1 RP11-813N20.3 -3.72 0.00023 0.0362 -0.2 -0.2 Obesity-related traits; chr4:69087385 chr4:69027831~69044578:+ LIHC cis rs139824696 1 rs139824696 ENSG00000279204.1 RP11-175K6.2 3.72 0.00023 0.0362 0.28 0.2 Breast cancer; chr5:159141388 chr5:159106380~159108617:+ LIHC cis rs2243480 1 rs6460260 ENSG00000229886.1 RP5-1132H15.3 -3.72 0.00023 0.0362 -0.29 -0.2 Diabetic kidney disease; chr7:65750468 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs6460261 ENSG00000229886.1 RP5-1132H15.3 -3.72 0.00023 0.0362 -0.29 -0.2 Diabetic kidney disease; chr7:65750593 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs4718270 ENSG00000229886.1 RP5-1132H15.3 3.72 0.00023 0.0362 0.29 0.2 Diabetic kidney disease; chr7:65737415 chr7:66025126~66031544:- LIHC cis rs2243480 0.901 rs2900904 ENSG00000229886.1 RP5-1132H15.3 3.72 0.00023 0.0362 0.29 0.2 Diabetic kidney disease; chr7:65739282 chr7:66025126~66031544:- LIHC cis rs11098499 0.73 rs78971550 ENSG00000245958.5 RP11-33B1.1 -3.72 0.00023 0.0362 -0.21 -0.2 Corneal astigmatism; chr4:119359886 chr4:119454791~119552025:+ LIHC cis rs11098499 0.645 rs78422072 ENSG00000245958.5 RP11-33B1.1 -3.72 0.00023 0.0362 -0.21 -0.2 Corneal astigmatism; chr4:119359887 chr4:119454791~119552025:+ LIHC cis rs6142102 0.602 rs11696338 ENSG00000275784.1 RP5-1125A11.6 -3.72 0.000231 0.0362 -0.21 -0.2 Skin pigmentation; chr20:34099805 chr20:33989480~33991818:- LIHC cis rs6142102 0.58 rs6142101 ENSG00000275784.1 RP5-1125A11.6 -3.72 0.000231 0.0362 -0.21 -0.2 Skin pigmentation; chr20:34110039 chr20:33989480~33991818:- LIHC cis rs198389 0.589 rs198401 ENSG00000242349.4 NPPA-AS1 -3.72 0.000231 0.0363 -0.21 -0.2 B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome; chr1:11828327 chr1:11841017~11848079:+ LIHC cis rs9652601 0.92 rs12923098 ENSG00000274038.1 RP11-66H6.4 -3.72 0.000231 0.0363 -0.24 -0.2 Systemic lupus erythematosus; chr16:11083196 chr16:11056556~11057034:+ LIHC cis rs34734847 0.965 rs2005455 ENSG00000277423.1 RP11-173P15.9 3.72 0.000231 0.0363 0.21 0.2 Mean corpuscular volume; chr12:120690896 chr12:120703867~120704282:+ LIHC cis rs4073416 0.684 rs3783709 ENSG00000276116.2 FUT8-AS1 3.72 0.000231 0.0363 0.26 0.2 N-glycan levels; chr14:65591946 chr14:65411170~65412690:- LIHC cis rs2348418 0.83 rs7977418 ENSG00000247934.4 RP11-967K21.1 3.72 0.000231 0.0363 0.18 0.2 Lung function (FEV1);Lung function (FVC); chr12:28435309 chr12:28163298~28190738:- LIHC cis rs1799949 0.931 rs9912203 ENSG00000267681.1 CTD-3199J23.6 3.72 0.000231 0.0363 0.19 0.2 Menopause (age at onset); chr17:43367777 chr17:43144956~43145255:+ LIHC cis rs875971 1 rs1167612 ENSG00000237310.1 GS1-124K5.4 -3.72 0.000231 0.0363 -0.18 -0.2 Aortic root size; chr7:66102989 chr7:66493706~66495474:+ LIHC cis rs11096990 0.927 rs56009503 ENSG00000249207.1 RP11-360F5.1 3.72 0.000231 0.0363 0.23 0.2 Cognitive function; chr4:39242642 chr4:39112677~39126818:- LIHC cis rs11096990 0.964 rs7687651 ENSG00000249207.1 RP11-360F5.1 3.72 0.000231 0.0363 0.23 0.2 Cognitive function; chr4:39243072 chr4:39112677~39126818:- LIHC cis rs11096990 0.891 rs61691409 ENSG00000249207.1 RP11-360F5.1 3.72 0.000231 0.0363 0.23 0.2 Cognitive function; chr4:39243801 chr4:39112677~39126818:- LIHC cis rs6545883 0.868 rs2518933 ENSG00000271889.1 RP11-493E12.1 3.72 0.000231 0.0363 0.24 0.2 Tuberculosis; chr2:61569895 chr2:61151433~61162105:- LIHC cis rs228614 0.51 rs150893 ENSG00000248971.2 KRT8P46 3.72 0.000231 0.0363 0.2 0.2 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102817075 chr4:102728746~102730171:- LIHC cis rs2243480 1 rs466983 ENSG00000229886.1 RP5-1132H15.3 3.72 0.000231 0.0363 0.29 0.2 Diabetic kidney disease; chr7:66055509 chr7:66025126~66031544:- LIHC cis rs1665050 0.749 rs8037569 ENSG00000259250.1 RP11-50C13.1 3.72 0.000231 0.0363 0.2 0.2 Atopic dermatitis; chr15:59010263 chr15:58587507~58591676:+ LIHC cis rs10988802 0.683 rs12349375 ENSG00000236095.1 RP11-49O14.2 3.72 0.000231 0.0363 0.39 0.2 Chemerin levels; chr9:95629772 chr9:94900429~94904754:+ LIHC cis rs4915737 0.569 rs7553582 ENSG00000270742.1 RP4-802A10.1 3.72 0.000231 0.0363 0.3 0.2 Bipolar disorder; chr1:61358703 chr1:61124733~61125202:+ LIHC cis rs2439831 0.681 rs526450 ENSG00000166763.7 STRCP1 3.72 0.000231 0.0363 0.27 0.2 Lung cancer in ever smokers; chr15:43307127 chr15:43699488~43718184:- LIHC cis rs10500715 0.589 rs4910085 ENSG00000254860.4 TMEM9B-AS1 -3.72 0.000231 0.0363 -0.2 -0.2 Pancreatic cancer; chr11:9959750 chr11:8964675~8977527:+ LIHC cis rs2439831 0.867 rs3213990 ENSG00000205771.5 CATSPER2P1 -3.72 0.000231 0.0364 -0.27 -0.2 Lung cancer in ever smokers; chr15:43378028 chr15:43726918~43747094:- LIHC cis rs694739 1 rs694739 ENSG00000236935.1 AP003774.1 3.72 0.000231 0.0364 0.22 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64329761 chr11:64325050~64329504:- LIHC cis rs6142102 0.625 rs6142051 ENSG00000275784.1 RP5-1125A11.6 -3.72 0.000232 0.0364 -0.21 -0.2 Skin pigmentation; chr20:33945212 chr20:33989480~33991818:- LIHC cis rs1223397 0.651 rs2439548 ENSG00000215022.6 RP1-257A7.4 -3.72 0.000232 0.0364 -0.21 -0.2 Blood pressure; chr6:13314951 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs2496156 ENSG00000215022.6 RP1-257A7.4 -3.72 0.000232 0.0364 -0.21 -0.2 Blood pressure; chr6:13315146 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs2439549 ENSG00000215022.6 RP1-257A7.4 -3.72 0.000232 0.0364 -0.21 -0.2 Blood pressure; chr6:13315229 chr6:13264861~13295586:- LIHC cis rs683257 0.714 rs72991723 ENSG00000234147.1 RP3-460G2.2 -3.72 0.000232 0.0364 -0.37 -0.2 Facial emotion recognition (angry faces); chr6:140945138 chr6:140845958~140852924:- LIHC cis rs7722022 0.922 rs889016 ENSG00000253428.1 CTB-43E15.2 3.72 0.000232 0.0364 0.21 0.2 Adiponectin levels; chr5:173524851 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs6865384 ENSG00000253428.1 CTB-43E15.2 3.72 0.000232 0.0364 0.21 0.2 Adiponectin levels; chr5:173525866 chr5:173689459~173705849:+ LIHC cis rs7722022 0.848 rs116836682 ENSG00000253428.1 CTB-43E15.2 3.72 0.000232 0.0364 0.21 0.2 Adiponectin levels; chr5:173525949 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs6884593 ENSG00000253428.1 CTB-43E15.2 3.72 0.000232 0.0364 0.21 0.2 Adiponectin levels; chr5:173526092 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs6865880 ENSG00000253428.1 CTB-43E15.2 3.72 0.000232 0.0364 0.21 0.2 Adiponectin levels; chr5:173526177 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs1465414 ENSG00000253428.1 CTB-43E15.2 3.72 0.000232 0.0364 0.21 0.2 Adiponectin levels; chr5:173526535 chr5:173689459~173705849:+ LIHC cis rs7722022 0.922 rs1465412 ENSG00000253428.1 CTB-43E15.2 3.72 0.000232 0.0364 0.21 0.2 Adiponectin levels; chr5:173526677 chr5:173689459~173705849:+ LIHC cis rs7722022 0.922 rs60539383 ENSG00000253428.1 CTB-43E15.2 3.72 0.000232 0.0364 0.21 0.2 Adiponectin levels; chr5:173527166 chr5:173689459~173705849:+ LIHC cis rs6750795 0.502 rs11685196 ENSG00000181798.2 LINC00471 -3.72 0.000232 0.0364 -0.22 -0.2 Height; chr2:231516587 chr2:231508426~231514339:- LIHC cis rs4925386 0.808 rs1760073 ENSG00000226332.2 RP11-157P1.4 -3.72 0.000232 0.0364 -0.2 -0.2 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62351050 chr20:62305432~62306325:- LIHC cis rs13242816 1 rs3801993 ENSG00000279086.1 RP11-667F14.1 3.72 0.000232 0.0364 0.35 0.2 P wave duration; chr7:116550328 chr7:116209234~116211511:- LIHC cis rs4218 0.681 rs58335303 ENSG00000277144.1 RP11-59H7.4 -3.72 0.000232 0.0364 -0.21 -0.2 Social communication problems; chr15:59073206 chr15:59115547~59116089:- LIHC cis rs4891159 0.79 rs72975929 ENSG00000265778.2 RP11-17M16.2 -3.72 0.000232 0.0364 -0.24 -0.2 Longevity; chr18:76432674 chr18:76491652~76493918:+ LIHC cis rs2251260 0.945 rs2247196 ENSG00000232774.6 FLJ22447 -3.72 0.000232 0.0365 -0.27 -0.2 Yeast infection; chr14:61557599 chr14:61570540~61658696:+ LIHC cis rs2898681 0.519 rs6554057 ENSG00000248375.1 RP11-177B4.1 -3.72 0.000232 0.0365 -0.32 -0.2 Optic nerve measurement (cup area); chr4:52863980 chr4:52720081~52720831:- LIHC cis rs2898681 0.519 rs6848200 ENSG00000248375.1 RP11-177B4.1 -3.72 0.000232 0.0365 -0.32 -0.2 Optic nerve measurement (cup area); chr4:52864014 chr4:52720081~52720831:- LIHC cis rs2898681 0.519 rs7670068 ENSG00000248375.1 RP11-177B4.1 -3.72 0.000232 0.0365 -0.32 -0.2 Optic nerve measurement (cup area); chr4:52867817 chr4:52720081~52720831:- LIHC cis rs10129255 0.957 rs10132367 ENSG00000211970.3 IGHV4-61 -3.72 0.000232 0.0365 -0.16 -0.2 Kawasaki disease; chr14:106690981 chr14:106639119~106639657:- LIHC cis rs2880765 0.506 rs719138 ENSG00000259630.2 CTD-2262B20.1 -3.72 0.000232 0.0365 -0.28 -0.2 Coronary artery disease; chr15:85511831 chr15:85415228~85415633:+ LIHC cis rs4356975 0.527 rs62296943 ENSG00000250919.1 RP11-813N20.3 -3.72 0.000232 0.0365 -0.2 -0.2 Obesity-related traits; chr4:69093465 chr4:69027831~69044578:+ LIHC cis rs7095607 0.935 rs12774635 ENSG00000233590.1 RP11-153K11.3 3.72 0.000232 0.0365 0.24 0.2 Lung function (FVC); chr10:68190720 chr10:68233251~68242379:- LIHC cis rs7095607 1 rs7913582 ENSG00000233590.1 RP11-153K11.3 3.72 0.000232 0.0365 0.24 0.2 Lung function (FVC); chr10:68192824 chr10:68233251~68242379:- LIHC cis rs7095607 1 rs7094885 ENSG00000233590.1 RP11-153K11.3 3.72 0.000232 0.0365 0.24 0.2 Lung function (FVC); chr10:68194060 chr10:68233251~68242379:- LIHC cis rs17826219 0.706 rs57698184 ENSG00000264538.5 SUZ12P1 -3.72 0.000232 0.0365 -0.21 -0.2 Body mass index; chr17:30737900 chr17:30709299~30790908:+ LIHC cis rs17826219 0.706 rs9893922 ENSG00000264538.5 SUZ12P1 -3.72 0.000232 0.0365 -0.21 -0.2 Body mass index; chr17:30741407 chr17:30709299~30790908:+ LIHC cis rs17826219 0.5 rs9891256 ENSG00000264538.5 SUZ12P1 -3.72 0.000232 0.0365 -0.21 -0.2 Body mass index; chr17:30745674 chr17:30709299~30790908:+ LIHC cis rs7208859 0.623 rs7503335 ENSG00000264538.5 SUZ12P1 -3.72 0.000232 0.0365 -0.21 -0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746944 chr17:30709299~30790908:+ LIHC cis rs4650994 0.593 rs6676155 ENSG00000273384.1 RP5-1098D14.1 -3.72 0.000232 0.0365 -0.24 -0.2 HDL cholesterol;HDL cholesterol levels; chr1:178539225 chr1:178651706~178652282:+ LIHC cis rs9876781 1 rs9311423 ENSG00000229759.1 MRPS18AP1 3.72 0.000233 0.0365 0.2 0.2 Longevity; chr3:48378818 chr3:48256350~48256938:- LIHC cis rs709400 1 rs8018979 ENSG00000258534.1 CTD-2134A5.4 3.72 0.000233 0.0365 0.28 0.2 Body mass index; chr14:103642750 chr14:103854366~103880111:- LIHC cis rs988958 0.565 rs34465637 ENSG00000224875.2 AC083949.1 -3.72 0.000233 0.0365 -0.28 -0.2 Hypospadias; chr2:42002206 chr2:42143238~42170301:- LIHC cis rs745580 0.933 rs6461903 ENSG00000199085.2 MIR148A -3.72 0.000233 0.0365 -0.2 -0.2 Obesity-related traits; chr7:25994197 chr7:25949903~25950013:- LIHC cis rs2462686 1 rs28552707 ENSG00000272556.1 RP11-638I8.1 3.72 0.000233 0.0365 0.3 0.2 Major depressive disorder; chr7:45929117 chr7:45814602~45815263:+ LIHC cis rs13437751 0.649 rs73123050 ENSG00000236976.1 RP11-165H4.2 3.72 0.000233 0.0366 0.32 0.2 QT interval (drug interaction); chr7:63892883 chr7:64141538~64142401:- LIHC cis rs9487094 0.567 rs11964864 ENSG00000260273.1 RP11-425D10.10 3.72 0.000233 0.0366 0.25 0.2 Height; chr6:109773423 chr6:109382795~109383666:+ LIHC cis rs2179367 0.509 rs9485390 ENSG00000231760.4 RP11-350J20.5 3.72 0.000233 0.0366 0.31 0.2 Dupuytren's disease; chr6:149421004 chr6:149796151~149826294:- LIHC cis rs12935418 0.83 rs12928638 ENSG00000261061.1 RP11-303E16.2 -3.72 0.000233 0.0366 -0.27 -0.2 Mean corpuscular volume; chr16:81016195 chr16:81030770~81031485:+ LIHC cis rs7617773 0.815 rs9825637 ENSG00000228638.1 FCF1P2 -3.72 0.000233 0.0366 -0.22 -0.2 Coronary artery disease; chr3:48330792 chr3:48290793~48291375:- LIHC cis rs7945705 0.875 rs11042059 ENSG00000254860.4 TMEM9B-AS1 -3.72 0.000233 0.0366 -0.19 -0.2 Hemoglobin concentration; chr11:8773533 chr11:8964675~8977527:+ LIHC cis rs321358 0.731 rs555063 ENSG00000235286.1 AP000925.2 -3.72 0.000233 0.0366 -0.25 -0.2 Body mass index; chr11:111168621 chr11:111670956~111672404:- LIHC cis rs1598856 0.932 rs230530 ENSG00000230069.3 LRRC37A15P 3.72 0.000233 0.0366 0.18 0.2 Primary biliary cholangitis; chr4:102532823 chr4:102727274~102730721:- LIHC cis rs6997458 1 rs1532423 ENSG00000253549.4 RP11-317J10.2 3.72 0.000233 0.0366 0.22 0.2 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85356084 chr8:85441851~85464915:- LIHC cis rs6456156 0.792 rs2039321 ENSG00000227598.1 RP1-167A14.2 -3.72 0.000233 0.0366 -0.2 -0.2 Primary biliary cholangitis; chr6:167102811 chr6:166969626~166999065:- LIHC cis rs600231 0.708 rs661403 ENSG00000245532.5 NEAT1 3.72 0.000234 0.0366 0.19 0.2 Bone mineral density; chr11:65475007 chr11:65422774~65445540:+ LIHC cis rs853679 0.545 rs35949109 ENSG00000219891.2 ZSCAN12P1 3.72 0.000234 0.0366 0.35 0.2 Depression; chr6:28058148 chr6:28091154~28093664:+ LIHC cis rs2439831 0.681 rs28594657 ENSG00000205771.5 CATSPER2P1 -3.72 0.000234 0.0366 -0.34 -0.2 Lung cancer in ever smokers; chr15:43296690 chr15:43726918~43747094:- LIHC cis rs2665103 0.589 rs2134046 ENSG00000259429.4 UBE2Q2P2 -3.72 0.000234 0.0366 -0.21 -0.2 Intelligence (multi-trait analysis); chr15:82232203 chr15:82355142~82420075:+ LIHC cis rs2243480 1 rs316331 ENSG00000228409.4 CCT6P1 -3.72 0.000234 0.0366 -0.21 -0.2 Diabetic kidney disease; chr7:66139635 chr7:65751142~65763354:+ LIHC cis rs2253762 0.54 rs10159634 ENSG00000226864.1 ATE1-AS1 -3.72 0.000234 0.0366 -0.33 -0.2 Breast cancer; chr10:121994520 chr10:121928312~121951965:+ LIHC cis rs12936587 0.595 rs9911672 ENSG00000223979.2 SMCR2 -3.72 0.000234 0.0367 -0.24 -0.2 Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference; chr17:17625356 chr17:17674026~17677688:- LIHC cis rs1405130 0.9 rs12692151 ENSG00000224287.2 MSL3P1 3.72 0.000234 0.0367 0.23 0.2 Coronary artery disease; chr2:234678968 chr2:233865437~233868444:- LIHC cis rs17767392 0.781 rs14030 ENSG00000274818.1 RP1-292L20.3 3.72 0.000234 0.0367 0.3 0.2 Mitral valve prolapse; chr14:71489424 chr14:70906657~70907111:- LIHC cis rs17767392 0.846 rs12127 ENSG00000274818.1 RP1-292L20.3 3.72 0.000234 0.0367 0.3 0.2 Mitral valve prolapse; chr14:71489553 chr14:70906657~70907111:- LIHC cis rs6048205 0.881 rs5029909 ENSG00000259974.2 LINC00261 -3.72 0.000234 0.0367 -0.33 -0.2 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22543443 chr20:22547671~22578642:- LIHC cis rs4432842 1 rs4432842 ENSG00000249198.1 RP11-772C9.1 3.72 0.000234 0.0367 0.21 0.2 Birth weight; chr5:57876251 chr5:57751192~57751717:- LIHC cis rs5743030 0.793 rs4920654 ENSG00000253559.1 OSGEPL1-AS1 -3.72 0.000234 0.0367 -0.34 -0.2 Subcutaneous adipose tissue; chr2:189882046 chr2:189762704~189765556:+ LIHC cis rs5743030 1 rs76688555 ENSG00000253559.1 OSGEPL1-AS1 -3.72 0.000234 0.0367 -0.34 -0.2 Subcutaneous adipose tissue; chr2:189882689 chr2:189762704~189765556:+ LIHC cis rs5743030 1 rs6736360 ENSG00000253559.1 OSGEPL1-AS1 -3.72 0.000234 0.0367 -0.34 -0.2 Subcutaneous adipose tissue; chr2:189884023 chr2:189762704~189765556:+ LIHC cis rs7969148 0.71 rs412230 ENSG00000270130.1 RP11-214K3.23 -3.72 0.000234 0.0367 -0.31 -0.2 Clubfoot; chr12:124118882 chr12:123960717~123961244:- LIHC cis rs8035452 0.857 rs3131609 ENSG00000273674.3 CTD-2378E12.1 3.72 0.000234 0.0367 0.25 0.2 Alzheimer's disease (late onset); chr15:50510070 chr15:50839875~50908599:- LIHC cis rs2072510 0.966 rs2660896 ENSG00000257878.1 RP11-256L6.3 -3.72 0.000234 0.0367 -0.18 -0.2 Metabolite levels (small molecules and protein measures); chr12:96030004 chr12:95996521~96011489:+ LIHC cis rs6442522 0.615 rs13060973 ENSG00000249786.6 EAF1-AS1 -3.72 0.000234 0.0367 -0.22 -0.2 Uric acid levels; chr3:15459426 chr3:15436171~15455940:- LIHC cis rs1799949 1 rs35070007 ENSG00000267681.1 CTD-3199J23.6 3.72 0.000234 0.0367 0.19 0.2 Menopause (age at onset); chr17:43164730 chr17:43144956~43145255:+ LIHC cis rs3749237 0.595 rs1464568 ENSG00000270441.1 RP11-694I15.7 -3.72 0.000234 0.0367 -0.27 -0.2 Resting heart rate; chr3:49420833 chr3:49140086~49160851:- LIHC cis rs1075265 0.933 rs2287642 ENSG00000233266.1 HMGB1P31 3.72 0.000234 0.0367 0.24 0.2 Chronotype;Morning vs. evening chronotype; chr2:54108447 chr2:54051334~54051760:+ LIHC cis rs5850 0.602 rs1005786 ENSG00000226816.2 AC005082.12 3.72 0.000234 0.0367 0.24 0.2 Blood protein levels; chr7:23106218 chr7:23206013~23208045:+ LIHC cis rs2243480 1 rs34136756 ENSG00000226002.1 RP11-460N20.5 -3.72 0.000234 0.0367 -0.29 -0.2 Diabetic kidney disease; chr7:65916269 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs427044 ENSG00000229886.1 RP5-1132H15.3 3.72 0.000234 0.0368 0.29 0.2 Diabetic kidney disease; chr7:66043558 chr7:66025126~66031544:- LIHC cis rs10895987 1 rs12280510 ENSG00000254614.2 AP003068.23 3.72 0.000234 0.0368 0.35 0.2 Blood protein levels; chr11:65147076 chr11:65177606~65181834:- LIHC cis rs7474896 0.616 rs2474561 ENSG00000275858.1 RP11-291L22.8 3.72 0.000234 0.0368 0.25 0.2 Obesity (extreme); chr10:38084616 chr10:38450738~38451069:- LIHC cis rs12134133 1 rs10494890 ENSG00000274245.1 RP11-357P18.2 -3.72 0.000235 0.0368 -0.3 -0.2 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207251041 chr1:207372559~207373252:+ LIHC cis rs2312236 0.759 rs1102518 ENSG00000225171.2 DUTP6 3.72 0.000235 0.0368 0.26 0.2 Post-traumatic stress disorder; chr1:166774709 chr1:166868748~166869209:+ LIHC cis rs9532669 0.963 rs4941391 ENSG00000168852.11 TPTE2P5 3.72 0.000235 0.0368 0.23 0.2 Cervical cancer; chr13:40939787 chr13:40822296~40921749:- LIHC cis rs9380516 0.524 rs2273003 ENSG00000246982.5 RP1-179N16.6 -3.72 0.000235 0.0368 -0.23 -0.2 Hepatitis C induced liver fibrosis; chr6:35512099 chr6:36146698~36197205:- LIHC cis rs2243480 1 rs2243480 ENSG00000230295.1 RP11-458F8.2 -3.72 0.000235 0.0368 -0.21 -0.2 Diabetic kidney disease; chr7:66134209 chr7:66880708~66882981:+ LIHC cis rs1115240 0.574 rs3794485 ENSG00000257842.4 NOVA1-AS1 -3.72 0.000235 0.0368 -0.19 -0.2 Educational attainment (years of education); chr14:26590140 chr14:26598412~26806467:+ LIHC cis rs193541 0.632 rs7735618 ENSG00000263432.2 RN7SL689P 3.72 0.000235 0.0368 0.31 0.2 Glucose homeostasis traits; chr5:122840550 chr5:123022487~123022783:- LIHC cis rs7647973 0.58 rs12637576 ENSG00000270441.1 RP11-694I15.7 -3.72 0.000235 0.0368 -0.28 -0.2 Menarche (age at onset); chr3:49199901 chr3:49140086~49160851:- LIHC cis rs2439831 0.85 rs28590651 ENSG00000166763.7 STRCP1 3.72 0.000235 0.0368 0.3 0.2 Lung cancer in ever smokers; chr15:43820818 chr15:43699488~43718184:- LIHC cis rs2400997 0.967 rs8008153 ENSG00000272444.1 RP11-1017G21.6 -3.72 0.000235 0.0368 -0.22 -0.2 Prostate cancer (SNP x SNP interaction); chr14:101273343 chr14:101952416~101953063:+ LIHC cis rs8040855 0.627 rs11632899 ENSG00000259295.5 CSPG4P12 3.72 0.000235 0.0368 0.3 0.2 Bulimia nervosa; chr15:85057609 chr15:85191438~85213905:+ LIHC cis rs6822297 0.608 rs9654110 ENSG00000240005.4 RP11-293A21.1 -3.72 0.000235 0.0368 -0.22 -0.2 Obesity-related traits; chr4:26911472 chr4:26859806~26860599:- LIHC cis rs7945705 0.846 rs11042055 ENSG00000254860.4 TMEM9B-AS1 -3.72 0.000235 0.0368 -0.2 -0.2 Hemoglobin concentration; chr11:8735309 chr11:8964675~8977527:+ LIHC cis rs72634501 0.716 rs67062906 ENSG00000182109.6 RP11-69E11.4 3.72 0.000235 0.0368 0.25 0.2 HDL cholesterol; chr1:39151018 chr1:39522280~39546187:- LIHC cis rs11767191 0.565 rs12666311 ENSG00000146666.5 LINC00525 -3.72 0.000235 0.0368 -0.25 -0.2 Response to amphetamines; chr7:48670913 chr7:47761476~47766772:+ LIHC cis rs12091564 1 rs12091564 ENSG00000233396.6 RP11-458D21.1 3.72 0.000235 0.0368 0.28 0.2 Coronary heart disease (SNP X SNP interaction); chr1:146039391 chr1:146052566~146061948:+ LIHC cis rs4578769 0.765 rs1609463 ENSG00000265943.1 RP11-739L10.1 -3.72 0.000235 0.0368 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22824144 chr18:22699481~22933764:- LIHC cis rs6442522 0.673 rs1869855 ENSG00000249786.6 EAF1-AS1 3.72 0.000235 0.0368 0.23 0.2 Uric acid levels; chr3:15459635 chr3:15436171~15455940:- LIHC cis rs4237845 0.537 rs10877031 ENSG00000270039.1 RP11-571M6.17 -3.72 0.000235 0.0368 -0.28 -0.2 Intelligence (multi-trait analysis); chr12:57872912 chr12:57803838~57804415:+ LIHC cis rs957448 0.698 rs116348949 ENSG00000253704.1 RP11-267M23.4 3.72 0.000235 0.0368 0.22 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94557488 chr8:94553722~94569745:+ LIHC cis rs1115240 0.574 rs60064898 ENSG00000257842.4 NOVA1-AS1 3.72 0.000235 0.0368 0.2 0.2 Educational attainment (years of education); chr14:26586838 chr14:26598412~26806467:+ LIHC cis rs4848143 0.515 rs280199 ENSG00000280409.1 LINC01101 3.72 0.000235 0.0368 0.23 0.2 Capecitabine sensitivity; chr2:120975900 chr2:120464335~120466218:- LIHC cis rs12304921 0.54 rs7979705 ENSG00000277201.1 AC087884.1 3.72 0.000235 0.0369 0.21 0.2 Type 2 diabetes; chr12:51090863 chr12:51049921~51050025:+ LIHC cis rs13113518 0.812 rs6830409 ENSG00000223305.1 RN7SKP30 3.72 0.000235 0.0369 0.24 0.2 Height; chr4:55522229 chr4:55540502~55540835:- LIHC cis rs524281 0.731 rs3814744 ENSG00000255320.1 RP11-755F10.1 3.72 0.000235 0.0369 0.32 0.2 Electroencephalogram traits; chr11:66042292 chr11:66244840~66246239:- LIHC cis rs524281 0.648 rs4565902 ENSG00000255320.1 RP11-755F10.1 3.72 0.000235 0.0369 0.32 0.2 Electroencephalogram traits; chr11:66042574 chr11:66244840~66246239:- LIHC cis rs524281 0.731 rs78578425 ENSG00000255320.1 RP11-755F10.1 3.72 0.000235 0.0369 0.32 0.2 Electroencephalogram traits; chr11:66042768 chr11:66244840~66246239:- LIHC cis rs77204473 0.744 rs2046150 ENSG00000254851.1 RP11-109L13.1 3.72 0.000236 0.0369 0.37 0.2 Sum eosinophil basophil counts;Eosinophil counts; chr11:117182717 chr11:117135528~117138582:+ LIHC cis rs745580 0.933 rs2893234 ENSG00000199085.2 MIR148A -3.72 0.000236 0.0369 -0.2 -0.2 Obesity-related traits; chr7:25994979 chr7:25949903~25950013:- LIHC cis rs4237845 0.537 rs11172369 ENSG00000270039.1 RP11-571M6.17 -3.72 0.000236 0.0369 -0.28 -0.2 Intelligence (multi-trait analysis); chr12:57886809 chr12:57803838~57804415:+ LIHC cis rs1003719 0.591 rs13046303 ENSG00000272948.2 AP001412.1 -3.72 0.000236 0.0369 -0.21 -0.2 Eye color traits; chr21:37179674 chr21:37267784~37268497:+ LIHC cis rs6456156 0.586 rs10946209 ENSG00000227598.1 RP1-167A14.2 -3.72 0.000236 0.0369 -0.21 -0.2 Primary biliary cholangitis; chr6:167067503 chr6:166969626~166999065:- LIHC cis rs5769707 0.967 rs2187891 ENSG00000235111.1 RP1-29C18.8 -3.72 0.000236 0.0369 -0.23 -0.2 Monocyte percentage of white cells;Monocyte count; chr22:49600446 chr22:49612657~49615716:- LIHC cis rs4568518 0.74 rs12699927 ENSG00000279048.1 RP11-511H23.2 3.72 0.000236 0.0369 0.17 0.2 Measles; chr7:17972129 chr7:17940503~17942922:+ LIHC cis rs7129556 0.775 rs12286317 ENSG00000254459.1 RP11-91P24.7 3.72 0.000236 0.0369 0.33 0.2 Weight loss (gastric bypass surgery); chr11:77677975 chr11:77829654~77872262:- LIHC cis rs17767392 0.836 rs17178387 ENSG00000274818.1 RP1-292L20.3 3.72 0.000236 0.0369 0.3 0.2 Mitral valve prolapse; chr14:71531006 chr14:70906657~70907111:- LIHC cis rs494453 0.6 rs565612 ENSG00000227811.2 FAM212B-AS1 -3.72 0.000236 0.0369 -0.21 -0.2 Osteoporosis-related phenotypes; chr1:111677357 chr1:111739841~111747798:+ LIHC cis rs6545883 0.929 rs1186711 ENSG00000271889.1 RP11-493E12.1 3.72 0.000236 0.0369 0.24 0.2 Tuberculosis; chr2:61461370 chr2:61151433~61162105:- LIHC cis rs2403083 0.505 rs7829240 ENSG00000253549.4 RP11-317J10.2 3.72 0.000236 0.0369 0.22 0.2 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85231565 chr8:85441851~85464915:- LIHC cis rs11096990 0.855 rs3796524 ENSG00000249207.1 RP11-360F5.1 3.72 0.000236 0.037 0.23 0.2 Cognitive function; chr4:39194367 chr4:39112677~39126818:- LIHC cis rs11096990 0.892 rs4974924 ENSG00000249207.1 RP11-360F5.1 3.72 0.000236 0.037 0.23 0.2 Cognitive function; chr4:39196091 chr4:39112677~39126818:- LIHC cis rs7945705 0.776 rs2316865 ENSG00000254860.4 TMEM9B-AS1 -3.72 0.000236 0.037 -0.2 -0.2 Hemoglobin concentration; chr11:8793923 chr11:8964675~8977527:+ LIHC cis rs244293 0.695 rs9303360 ENSG00000275710.1 RP11-257O5.4 3.72 0.000236 0.037 0.21 0.2 Menarche (age at onset); chr17:54924095 chr17:54964474~54964679:+ LIHC cis rs6674176 0.597 rs9326136 ENSG00000237950.1 RP11-7O11.3 -3.72 0.000236 0.037 -0.21 -0.2 Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr1:43924720 chr1:43944370~43946551:- LIHC cis rs1023500 0.596 rs5758562 ENSG00000205702.9 CYP2D7 3.72 0.000236 0.037 0.23 0.2 Schizophrenia; chr22:42052234 chr22:42140203~42144577:- LIHC cis rs1023500 0.596 rs5751209 ENSG00000205702.9 CYP2D7 3.72 0.000236 0.037 0.23 0.2 Schizophrenia; chr22:42055599 chr22:42140203~42144577:- LIHC cis rs2933343 0.818 rs6764681 ENSG00000261159.1 RP11-723O4.9 -3.72 0.000236 0.037 -0.27 -0.2 IgG glycosylation; chr3:128849537 chr3:128859716~128860526:- LIHC cis rs1031261 0.512 rs4952282 ENSG00000229816.1 DDX50P1 3.72 0.000236 0.037 0.19 0.2 Hippocampal atrophy; chr2:32688540 chr2:32201600~32203999:+ LIHC cis rs3845817 0.703 rs702909 ENSG00000281920.1 RP11-418H16.1 3.72 0.000236 0.037 0.23 0.2 Bipolar disorder; chr2:65540113 chr2:65623272~65628424:+ LIHC cis rs9951150 0.537 rs4570961 ENSG00000267013.4 CTD-2171N6.1 3.72 0.000236 0.037 0.26 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55122208 chr18:55105904~55124306:- LIHC cis rs875971 0.54 rs35510581 ENSG00000237310.1 GS1-124K5.4 -3.72 0.000237 0.037 -0.19 -0.2 Aortic root size; chr7:66113790 chr7:66493706~66495474:+ LIHC cis rs7119038 0.818 rs10892293 ENSG00000255239.1 AP002954.6 -3.72 0.000237 0.037 -0.28 -0.2 Sjögren's syndrome; chr11:118794866 chr11:118688039~118690600:- LIHC cis rs77204473 0.744 rs2239678 ENSG00000254851.1 RP11-109L13.1 3.72 0.000237 0.037 0.37 0.2 Sum eosinophil basophil counts;Eosinophil counts; chr11:117199880 chr11:117135528~117138582:+ LIHC cis rs4578769 0.765 rs11662489 ENSG00000265943.1 RP11-739L10.1 -3.72 0.000237 0.037 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22816959 chr18:22699481~22933764:- LIHC cis rs17767392 0.767 rs61989382 ENSG00000274818.1 RP1-292L20.3 3.72 0.000237 0.037 0.3 0.2 Mitral valve prolapse; chr14:71516921 chr14:70906657~70907111:- LIHC cis rs17767392 0.881 rs35589413 ENSG00000274818.1 RP1-292L20.3 3.72 0.000237 0.037 0.3 0.2 Mitral valve prolapse; chr14:71524959 chr14:70906657~70907111:- LIHC cis rs4817642 0.549 rs2834423 ENSG00000272657.1 AP000320.7 3.72 0.000237 0.037 0.25 0.2 Cancer; chr21:34253429 chr21:34073592~34360033:+ LIHC cis rs10883723 0.962 rs10883726 ENSG00000236937.2 PTGES3P4 -3.72 0.000237 0.0371 -0.28 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102476519 chr10:102845595~102845950:+ LIHC cis rs10883723 0.962 rs1056738 ENSG00000236937.2 PTGES3P4 -3.72 0.000237 0.0371 -0.28 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102476724 chr10:102845595~102845950:+ LIHC cis rs10883723 0.962 rs1056739 ENSG00000236937.2 PTGES3P4 -3.72 0.000237 0.0371 -0.28 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102476785 chr10:102845595~102845950:+ LIHC cis rs763121 0.853 rs5757187 ENSG00000228274.3 RP3-508I15.9 3.72 0.000237 0.0371 0.22 0.2 Menopause (age at onset); chr22:38625517 chr22:38667585~38681820:- LIHC cis rs55966801 0.68 rs56093448 ENSG00000279672.1 CMB9-55F22.1 3.72 0.000237 0.0371 0.33 0.2 Plateletcrit; chr11:261209 chr11:779617~780755:+ LIHC cis rs3204270 0.639 rs79193599 ENSG00000281517.1 Metazoa_SRP -3.72 0.000237 0.0371 -0.38 -0.2 Dental caries; chr17:81684460 chr17:81718849~81719095:- LIHC cis rs9640161 0.742 rs2159235 ENSG00000261305.1 RP4-584D14.7 3.72 0.000237 0.0371 0.23 0.2 Blood protein levels;Circulating chemerin levels; chr7:150320139 chr7:150341771~150342607:+ LIHC cis rs6832769 1 rs473005 ENSG00000272969.1 RP11-528I4.2 3.72 0.000237 0.0371 0.23 0.2 Personality dimensions; chr4:55421958 chr4:55547112~55547889:+ LIHC cis rs1042026 0.813 rs10032099 ENSG00000214559.3 RP11-323J4.1 3.72 0.000237 0.0371 0.25 0.2 Esophageal cancer (alcohol interaction); chr4:99151868 chr4:98251688~98261630:- LIHC cis rs7712401 0.601 rs154501 ENSG00000263432.2 RN7SL689P 3.72 0.000237 0.0371 0.29 0.2 Mean platelet volume; chr5:122875899 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs154500 ENSG00000263432.2 RN7SL689P 3.72 0.000237 0.0371 0.29 0.2 Mean platelet volume; chr5:122876296 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs246271 ENSG00000263432.2 RN7SL689P 3.72 0.000237 0.0371 0.29 0.2 Mean platelet volume; chr5:122877127 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs257813 ENSG00000263432.2 RN7SL689P 3.72 0.000237 0.0371 0.29 0.2 Mean platelet volume; chr5:122881473 chr5:123022487~123022783:- LIHC cis rs202072 1 rs202073 ENSG00000215022.6 RP1-257A7.4 3.72 0.000237 0.0371 0.21 0.2 HIV-1 viral setpoint; chr6:13268373 chr6:13264861~13295586:- LIHC cis rs6828577 0.819 rs366656 ENSG00000269893.5 SNHG8 3.72 0.000237 0.0371 0.2 0.2 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118713539 chr4:118278709~118279823:+ LIHC cis rs875971 0.558 rs4433015 ENSG00000237310.1 GS1-124K5.4 -3.72 0.000237 0.0371 -0.2 -0.2 Aortic root size; chr7:66174736 chr7:66493706~66495474:+ LIHC cis rs5742933 0.817 rs7591929 ENSG00000253559.1 OSGEPL1-AS1 3.71 0.000237 0.0371 0.26 0.2 Ferritin levels; chr2:189778531 chr2:189762704~189765556:+ LIHC cis rs6547705 0.748 rs13010845 ENSG00000231259.4 AC125232.1 -3.71 0.000237 0.0371 -0.37 -0.2 Progressive supranuclear palsy; chr2:86662353 chr2:87031815~87053069:- LIHC cis rs2243480 0.764 rs2460423 ENSG00000228409.4 CCT6P1 3.71 0.000237 0.0371 0.21 0.2 Diabetic kidney disease; chr7:66136229 chr7:65751142~65763354:+ LIHC cis rs9646944 0.501 rs9807934 ENSG00000234389.1 AC007278.3 3.71 0.000238 0.0371 0.25 0.2 Blood protein levels; chr2:102423722 chr2:102438713~102440475:+ LIHC cis rs763121 0.853 rs2072795 ENSG00000228274.3 RP3-508I15.9 3.71 0.000238 0.0372 0.22 0.2 Menopause (age at onset); chr22:38668204 chr22:38667585~38681820:- LIHC cis rs9951150 0.517 rs34906855 ENSG00000267013.4 CTD-2171N6.1 3.71 0.000238 0.0372 0.26 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55125202 chr18:55105904~55124306:- LIHC cis rs131777 0.532 rs131747 ENSG00000273272.1 CTA-384D8.34 3.71 0.000238 0.0372 0.19 0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586645 chr22:50542650~50543011:+ LIHC cis rs4873772 0.8 rs4873478 ENSG00000253608.1 RP11-770E5.1 3.71 0.000238 0.0372 0.23 0.2 Lobe attachment (rater-scored or self-reported); chr8:47610734 chr8:48551567~48698510:+ LIHC cis rs9457247 0.73 rs9459841 ENSG00000227598.1 RP1-167A14.2 -3.71 0.000238 0.0372 -0.21 -0.2 Crohn's disease; chr6:167018461 chr6:166969626~166999065:- LIHC cis rs2976388 0.578 rs13254358 ENSG00000253741.1 CTD-2292P10.4 3.71 0.000238 0.0372 0.25 0.2 Urinary tract infection frequency; chr8:142742458 chr8:142702252~142726973:- LIHC cis rs757081 0.648 rs10832752 ENSG00000272034.1 SNORD14A -3.71 0.000238 0.0372 -0.21 -0.2 Systolic blood pressure; chr11:17263940 chr11:17074654~17074744:- LIHC cis rs710913 0.717 rs2068473 ENSG00000182109.6 RP11-69E11.4 -3.71 0.000238 0.0372 -0.2 -0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39572925 chr1:39522280~39546187:- LIHC cis rs688181 1 rs688167 ENSG00000271265.1 RP11-230C9.4 -3.71 0.000238 0.0373 -0.23 -0.2 Platelet distribution width; chr6:157671616 chr6:156774217~156774662:- LIHC cis rs2564921 0.704 rs35671032 ENSG00000242142.1 SERBP1P3 -3.71 0.000238 0.0373 -0.26 -0.2 Height; chr3:52972039 chr3:53064283~53065091:- LIHC cis rs7015263 0.572 rs11775728 ENSG00000250569.1 NTAN1P2 -3.71 0.000238 0.0373 -0.22 -0.2 Intelligence (multi-trait analysis); chr8:86375722 chr8:86481754~86483002:- LIHC cis rs17772222 0.917 rs12587200 ENSG00000258789.1 RP11-507K2.3 -3.71 0.000239 0.0373 -0.24 -0.2 Coronary artery calcification; chr14:88632060 chr14:88551597~88552493:+ LIHC cis rs703842 0.585 rs10877022 ENSG00000270039.1 RP11-571M6.17 -3.71 0.000239 0.0373 -0.28 -0.2 Multiple sclerosis; chr12:57830154 chr12:57803838~57804415:+ LIHC cis rs6496667 0.557 rs2526002 ENSG00000213471.7 TTLL13P 3.71 0.000239 0.0373 0.26 0.2 Rheumatoid arthritis; chr15:90422423 chr15:90249530~90265482:+ LIHC cis rs4578769 0.729 rs12456875 ENSG00000265943.1 RP11-739L10.1 -3.71 0.000239 0.0373 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22830208 chr18:22699481~22933764:- LIHC cis rs4578769 0.765 rs67551099 ENSG00000265943.1 RP11-739L10.1 -3.71 0.000239 0.0373 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22831167 chr18:22699481~22933764:- LIHC cis rs4578769 0.765 rs12455548 ENSG00000265943.1 RP11-739L10.1 -3.71 0.000239 0.0373 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22831514 chr18:22699481~22933764:- LIHC cis rs3772760 1 rs9878772 ENSG00000240622.1 RPL7P15 -3.71 0.000239 0.0373 -0.36 -0.2 Amyotrophic lateral sclerosis; chr3:124448082 chr3:124151960~124153063:- LIHC cis rs1115240 0.947 rs1950403 ENSG00000257842.4 NOVA1-AS1 -3.71 0.000239 0.0373 -0.18 -0.2 Educational attainment (years of education); chr14:26613781 chr14:26598412~26806467:+ LIHC cis rs1115240 0.947 rs1950402 ENSG00000257842.4 NOVA1-AS1 -3.71 0.000239 0.0373 -0.18 -0.2 Educational attainment (years of education); chr14:26616479 chr14:26598412~26806467:+ LIHC cis rs1115240 0.891 rs2207556 ENSG00000257842.4 NOVA1-AS1 -3.71 0.000239 0.0373 -0.18 -0.2 Educational attainment (years of education); chr14:26617064 chr14:26598412~26806467:+ LIHC cis rs6456156 0.586 rs12529876 ENSG00000227598.1 RP1-167A14.2 -3.71 0.000239 0.0373 -0.2 -0.2 Primary biliary cholangitis; chr6:167048013 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs12528689 ENSG00000227598.1 RP1-167A14.2 -3.71 0.000239 0.0373 -0.2 -0.2 Primary biliary cholangitis; chr6:167048258 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs13208636 ENSG00000227598.1 RP1-167A14.2 -3.71 0.000239 0.0373 -0.2 -0.2 Primary biliary cholangitis; chr6:167048477 chr6:166969626~166999065:- LIHC cis rs944990 0.597 rs61707921 ENSG00000227603.1 RP11-165J3.6 3.71 0.000239 0.0373 0.21 0.2 Body mass index; chr9:93475813 chr9:93435332~93437121:- LIHC cis rs17711722 0.727 rs1880555 ENSG00000237310.1 GS1-124K5.4 3.71 0.000239 0.0373 0.2 0.2 Calcium levels; chr7:65967580 chr7:66493706~66495474:+ LIHC cis rs1598856 0.873 rs230510 ENSG00000230069.3 LRRC37A15P 3.71 0.000239 0.0373 0.18 0.2 Primary biliary cholangitis; chr4:102555009 chr4:102727274~102730721:- LIHC cis rs6723108 0.604 rs1893396 ENSG00000224043.6 CCNT2-AS1 -3.71 0.000239 0.0373 -0.28 -0.2 Type 2 diabetes; chr2:134841439 chr2:134735464~134918710:- LIHC cis rs6723108 0.603 rs3739030 ENSG00000224043.6 CCNT2-AS1 -3.71 0.000239 0.0373 -0.28 -0.2 Type 2 diabetes; chr2:134841811 chr2:134735464~134918710:- LIHC cis rs2153977 1 rs11102658 ENSG00000229020.4 AKR7A2P1 3.71 0.000239 0.0373 0.2 0.2 Type 1 diabetes and autoimmune thyroid diseases; chr1:113577129 chr1:112923423~112924337:+ LIHC cis rs367615 0.679 rs4259216 ENSG00000249476.1 CTD-2587M2.1 3.71 0.000239 0.0373 0.24 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109506116 chr5:109237120~109326369:- LIHC cis rs7985 0.901 rs736690 ENSG00000244625.4 MIATNB 3.71 0.000239 0.0373 0.21 0.2 Electroencephalogram traits; chr22:26678805 chr22:26672767~26780207:+ LIHC cis rs4073416 0.651 rs1958561 ENSG00000276116.2 FUT8-AS1 3.71 0.000239 0.0373 0.25 0.2 N-glycan levels; chr14:65570043 chr14:65411170~65412690:- LIHC cis rs9467773 0.838 rs3734540 ENSG00000124549.13 BTN2A3P 3.71 0.000239 0.0374 0.18 0.2 Intelligence (multi-trait analysis); chr6:26463093 chr6:26421391~26432383:+ LIHC cis rs7606173 0.555 rs13024177 ENSG00000274769.1 RP11-493E12.3 3.71 0.000239 0.0374 0.32 0.2 F-cell distribution;Red cell distribution width; chr2:60489173 chr2:61115787~61164825:+ LIHC cis rs1075265 0.901 rs7591194 ENSG00000272156.1 RP11-477N3.1 3.71 0.000239 0.0374 0.23 0.2 Chronotype;Morning vs. evening chronotype; chr2:54086699 chr2:54082554~54085066:+ LIHC cis rs79349575 0.691 rs28528789 ENSG00000248278.1 SUMO2P17 -3.71 0.000239 0.0374 -0.24 -0.2 Type 2 diabetes; chr17:48909254 chr17:48874860~48908983:- LIHC cis rs79349575 0.715 rs999474 ENSG00000248278.1 SUMO2P17 -3.71 0.000239 0.0374 -0.24 -0.2 Type 2 diabetes; chr17:48910303 chr17:48874860~48908983:- LIHC cis rs79349575 0.679 rs9894239 ENSG00000248278.1 SUMO2P17 -3.71 0.000239 0.0374 -0.24 -0.2 Type 2 diabetes; chr17:48920597 chr17:48874860~48908983:- LIHC cis rs13242816 1 rs3801994 ENSG00000279086.1 RP11-667F14.1 3.71 0.000239 0.0374 0.35 0.2 P wave duration; chr7:116550415 chr7:116209234~116211511:- LIHC cis rs61160187 0.556 rs62367862 ENSG00000272308.1 RP11-231G3.1 -3.71 0.000239 0.0374 -0.2 -0.2 Educational attainment (years of education);Educational attainment (college completion); chr5:60973134 chr5:60866457~60866935:- LIHC cis rs12681287 0.64 rs13280468 ENSG00000254088.1 SLC2A3P4 3.71 0.000239 0.0374 0.23 0.2 Caudate activity during reward; chr8:86326223 chr8:86503591~86505061:+ LIHC cis rs3749237 0.595 rs4855839 ENSG00000226913.1 BSN-AS2 -3.71 0.000239 0.0374 -0.25 -0.2 Resting heart rate; chr3:49470414 chr3:49549306~49554366:- LIHC cis rs3749237 0.595 rs4855864 ENSG00000226913.1 BSN-AS2 -3.71 0.000239 0.0374 -0.25 -0.2 Resting heart rate; chr3:49484541 chr3:49549306~49554366:- LIHC cis rs3749237 0.595 rs11130199 ENSG00000226913.1 BSN-AS2 -3.71 0.000239 0.0374 -0.25 -0.2 Resting heart rate; chr3:49501366 chr3:49549306~49554366:- LIHC cis rs10246939 0.579 rs12703413 ENSG00000228775.6 WEE2-AS1 -3.71 0.000239 0.0374 -0.23 -0.2 Bitter taste perception; chr7:141847047 chr7:141704338~141738346:- LIHC cis rs848490 0.651 rs7810273 ENSG00000214293.7 APTR 3.71 0.000239 0.0374 0.23 0.2 Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine); chr7:77685327 chr7:77657660~77696265:- LIHC cis rs10975870 0.851 rs4439184 ENSG00000236924.1 RP11-390F4.6 -3.71 0.00024 0.0374 -0.31 -0.2 Body mass index; chr9:6866374 chr9:6645956~6670635:+ LIHC cis rs10800713 0.954 rs4623737 ENSG00000260088.1 RP11-92G12.3 -3.71 0.00024 0.0374 -0.24 -0.2 Tandem gait; chr1:200594578 chr1:200669507~200694250:+ LIHC cis rs7617773 0.851 rs13068288 ENSG00000228638.1 FCF1P2 -3.71 0.00024 0.0374 -0.22 -0.2 Coronary artery disease; chr3:48290261 chr3:48290793~48291375:- LIHC cis rs7474896 1 rs61858629 ENSG00000263064.2 RP11-291L22.7 3.71 0.00024 0.0374 0.27 0.2 Obesity (extreme); chr10:37725842 chr10:38448689~38448949:+ LIHC cis rs7474896 1 rs35258216 ENSG00000263064.2 RP11-291L22.7 3.71 0.00024 0.0374 0.27 0.2 Obesity (extreme); chr10:37729292 chr10:38448689~38448949:+ LIHC cis rs2243480 0.901 rs778730 ENSG00000275400.1 RP4-756H11.5 3.71 0.00024 0.0374 0.26 0.2 Diabetic kidney disease; chr7:66358338 chr7:66553805~66554199:- LIHC cis rs7945705 0.846 rs4929912 ENSG00000254860.4 TMEM9B-AS1 3.71 0.00024 0.0374 0.19 0.2 Hemoglobin concentration; chr11:8795148 chr11:8964675~8977527:+ LIHC cis rs1023500 1 rs7293091 ENSG00000227370.1 RP4-669P10.19 3.71 0.00024 0.0374 0.26 0.2 Schizophrenia; chr22:41945304 chr22:42132543~42132998:+ LIHC cis rs6517329 0.538 rs12483755 ENSG00000231106.2 LINC01436 3.71 0.00024 0.0374 0.22 0.2 Schizophrenia; chr21:36136140 chr21:36005338~36007838:+ LIHC cis rs1265120 0.691 rs1148516 ENSG00000271882.1 KB-1410C5.5 -3.71 0.00024 0.0374 -0.22 -0.2 Chronic obstructive pulmonary disease; chr8:102168999 chr8:101208148~101208558:+ LIHC cis rs2564921 0.704 rs11130333 ENSG00000242142.1 SERBP1P3 -3.71 0.00024 0.0374 -0.26 -0.2 Height; chr3:52977358 chr3:53064283~53065091:- LIHC cis rs7208859 0.573 rs8070182 ENSG00000264538.5 SUZ12P1 -3.71 0.00024 0.0374 -0.21 -0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30808576 chr17:30709299~30790908:+ LIHC cis rs875971 0.522 rs1968127 ENSG00000237310.1 GS1-124K5.4 -3.71 0.00024 0.0375 -0.18 -0.2 Aortic root size; chr7:66591816 chr7:66493706~66495474:+ LIHC cis rs6449502 1 rs6877849 ENSG00000272308.1 RP11-231G3.1 3.71 0.00024 0.0375 0.29 0.2 Mean platelet volume; chr5:60792792 chr5:60866457~60866935:- LIHC cis rs6449502 1 rs6876346 ENSG00000272308.1 RP11-231G3.1 -3.71 0.00024 0.0375 -0.29 -0.2 Mean platelet volume; chr5:60796009 chr5:60866457~60866935:- LIHC cis rs673078 0.66 rs61946063 ENSG00000275409.1 RP11-131L12.4 -3.71 0.00024 0.0375 -0.24 -0.2 Glucose homeostasis traits; chr12:118294448 chr12:118430147~118430699:+ LIHC cis rs933688 1 rs12656350 ENSG00000281357.1 ARRDC3-AS1 3.71 0.00024 0.0375 0.25 0.2 Smoking behavior; chr5:91455526 chr5:91380349~91439085:+ LIHC cis rs6456156 0.586 rs6456150 ENSG00000227598.1 RP1-167A14.2 -3.71 0.00024 0.0375 -0.21 -0.2 Primary biliary cholangitis; chr6:167055434 chr6:166969626~166999065:- LIHC cis rs2762353 0.808 rs1165183 ENSG00000242387.1 HIST1H2APS2 3.71 0.00024 0.0375 0.23 0.2 Blood metabolite levels; chr6:25836152 chr6:25882026~25882395:- LIHC cis rs7937890 0.668 rs12361851 ENSG00000251991.1 RNU7-49P -3.71 0.00024 0.0375 -0.22 -0.2 Mitochondrial DNA levels; chr11:14246122 chr11:14478892~14478953:+ LIHC cis rs3749237 0.555 rs7637665 ENSG00000226913.1 BSN-AS2 -3.71 0.00024 0.0375 -0.26 -0.2 Resting heart rate; chr3:49514862 chr3:49549306~49554366:- LIHC cis rs9341808 0.519 rs684251 ENSG00000272129.1 RP11-250B2.6 -3.71 0.00024 0.0375 -0.21 -0.2 Sitting height ratio; chr6:80257620 chr6:80355424~80356859:+ LIHC cis rs712039 0.958 rs1016679 ENSG00000276054.1 RP11-378E13.3 -3.71 0.000241 0.0375 -0.23 -0.2 Tuberculosis; chr17:37514228 chr17:37386886~37387926:+ LIHC cis rs2439831 0.867 rs12323999 ENSG00000205771.5 CATSPER2P1 -3.71 0.000241 0.0375 -0.27 -0.2 Lung cancer in ever smokers; chr15:43390917 chr15:43726918~43747094:- LIHC cis rs5760092 0.572 rs738806 ENSG00000225282.1 AP000350.6 3.71 0.000241 0.0375 0.27 0.2 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23926900~23929574:+ LIHC cis rs17508449 0.819 rs17359468 ENSG00000232450.1 RP4-730K3.3 -3.71 0.000241 0.0375 -0.29 -0.2 Leprosy; chr1:113700084 chr1:113698884~113699631:- LIHC cis rs10129255 0.872 rs1858683 ENSG00000211970.3 IGHV4-61 -3.71 0.000241 0.0376 -0.16 -0.2 Kawasaki disease; chr14:106670217 chr14:106639119~106639657:- LIHC cis rs17818399 0.926 rs13033177 ENSG00000239332.4 LINC01119 -3.71 0.000241 0.0376 -0.27 -0.2 Height; chr2:46603923 chr2:46816697~46859007:+ LIHC cis rs7809950 1 rs10273733 ENSG00000238832.1 snoU109 3.71 0.000241 0.0376 0.24 0.2 Coronary artery disease; chr7:107617676 chr7:107603363~107603507:+ LIHC cis rs801193 0.569 rs2659907 ENSG00000232559.3 GS1-124K5.12 3.71 0.000241 0.0376 0.15 0.2 Aortic root size; chr7:66699045 chr7:66554588~66576923:- LIHC cis rs713477 1 rs713477 ENSG00000258413.1 RP11-665C16.6 3.71 0.000241 0.0376 0.21 0.2 Pediatric bone mineral content (femoral neck); chr14:55437708 chr14:55262767~55272075:- LIHC cis rs11096990 0.855 rs11737290 ENSG00000249207.1 RP11-360F5.1 3.71 0.000241 0.0376 0.23 0.2 Cognitive function; chr4:39192318 chr4:39112677~39126818:- LIHC cis rs948562 0.69 rs60200286 ENSG00000280010.1 AP001350.4 3.71 0.000241 0.0376 0.34 0.2 Lymphoma; chr11:58347242 chr11:58627435~58628528:+ LIHC cis rs17264034 0.861 rs431288 ENSG00000250786.1 SNHG18 3.71 0.000241 0.0376 0.26 0.2 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9549347 chr5:9546200~9550609:+ LIHC cis rs9513627 0.748 rs61525545 ENSG00000280710.1 RP11-214F16.8 -3.71 0.000241 0.0376 -0.29 -0.2 Obesity-related traits; chr13:99466007 chr13:99498524~99501315:+ LIHC cis rs9513627 1 rs7317126 ENSG00000280710.1 RP11-214F16.8 -3.71 0.000241 0.0376 -0.29 -0.2 Obesity-related traits; chr13:99467485 chr13:99498524~99501315:+ LIHC cis rs9513627 0.92 rs16956607 ENSG00000280710.1 RP11-214F16.8 -3.71 0.000241 0.0376 -0.29 -0.2 Obesity-related traits; chr13:99467966 chr13:99498524~99501315:+ LIHC cis rs745580 0.933 rs766838 ENSG00000199085.2 MIR148A -3.71 0.000241 0.0376 -0.2 -0.2 Obesity-related traits; chr7:25990546 chr7:25949903~25950013:- LIHC cis rs13113518 0.812 rs4865003 ENSG00000223305.1 RN7SKP30 3.71 0.000241 0.0376 0.24 0.2 Height; chr4:55514802 chr4:55540502~55540835:- LIHC cis rs13113518 0.756 rs12510275 ENSG00000223305.1 RN7SKP30 3.71 0.000241 0.0376 0.24 0.2 Height; chr4:55516548 chr4:55540502~55540835:- LIHC cis rs13113518 0.812 rs12510327 ENSG00000223305.1 RN7SKP30 3.71 0.000241 0.0376 0.24 0.2 Height; chr4:55516744 chr4:55540502~55540835:- LIHC cis rs13113518 0.812 rs11939580 ENSG00000223305.1 RN7SKP30 3.71 0.000241 0.0376 0.24 0.2 Height; chr4:55517185 chr4:55540502~55540835:- LIHC cis rs4144027 0.869 rs55924227 ENSG00000258914.1 CTD-2134A5.3 -3.71 0.000241 0.0376 -0.21 -0.2 Blood metabolite levels; chr14:103895013 chr14:103875055~103877478:+ LIHC cis rs2439831 0.867 rs4075674 ENSG00000205771.5 CATSPER2P1 -3.71 0.000241 0.0376 -0.27 -0.2 Lung cancer in ever smokers; chr15:43358032 chr15:43726918~43747094:- LIHC cis rs11148252 0.967 rs11620062 ENSG00000278238.1 RP11-245D16.4 -3.71 0.000241 0.0376 -0.19 -0.2 Lewy body disease; chr13:52419891 chr13:52454775~52455331:- LIHC cis rs8177253 1 rs8177252 ENSG00000244062.1 RP11-404G16.2 3.71 0.000241 0.0376 0.2 0.2 Iron status biomarkers; chr3:133761330 chr3:133760300~133762363:+ LIHC cis rs8177253 0.931 rs8177256 ENSG00000244062.1 RP11-404G16.2 3.71 0.000241 0.0376 0.2 0.2 Iron status biomarkers; chr3:133761432 chr3:133760300~133762363:+ LIHC cis rs8177253 0.898 rs8177258 ENSG00000244062.1 RP11-404G16.2 3.71 0.000241 0.0376 0.2 0.2 Iron status biomarkers; chr3:133761543 chr3:133760300~133762363:+ LIHC cis rs8177253 0.828 rs8177259 ENSG00000244062.1 RP11-404G16.2 3.71 0.000241 0.0376 0.2 0.2 Iron status biomarkers; chr3:133761544 chr3:133760300~133762363:+ LIHC cis rs8177253 1 rs8177261 ENSG00000244062.1 RP11-404G16.2 3.71 0.000241 0.0376 0.2 0.2 Iron status biomarkers; chr3:133761744 chr3:133760300~133762363:+ LIHC cis rs8177253 1 rs6762719 ENSG00000244062.1 RP11-404G16.2 3.71 0.000241 0.0376 0.2 0.2 Iron status biomarkers; chr3:133761973 chr3:133760300~133762363:+ LIHC cis rs617219 0.613 rs6453436 ENSG00000251675.1 CTC-458I2.2 3.71 0.000242 0.0377 0.22 0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79330641 chr5:80128361~80143883:+ LIHC cis rs2243480 1 rs422164 ENSG00000228409.4 CCT6P1 3.71 0.000242 0.0377 0.21 0.2 Diabetic kidney disease; chr7:66121618 chr7:65751142~65763354:+ LIHC cis rs2880765 0.546 rs36098649 ENSG00000259630.2 CTD-2262B20.1 -3.71 0.000242 0.0377 -0.28 -0.2 Coronary artery disease; chr15:85513576 chr15:85415228~85415633:+ LIHC cis rs12586317 0.534 rs2273157 ENSG00000257307.1 RP11-317N8.4 -3.71 0.000242 0.0377 -0.22 -0.2 Psoriasis; chr14:34969630 chr14:35881001~35881709:+ LIHC cis rs79349575 0.715 rs11657238 ENSG00000248278.1 SUMO2P17 3.71 0.000242 0.0377 0.24 0.2 Type 2 diabetes; chr17:48908272 chr17:48874860~48908983:- LIHC cis rs8026198 0.929 rs1679009 ENSG00000260571.1 BNIP3P5 3.71 0.000242 0.0377 0.28 0.2 Fibrinogen levels; chr15:42175468 chr15:42313687~42314386:+ LIHC cis rs7129556 0.737 rs643388 ENSG00000254459.1 RP11-91P24.7 3.71 0.000242 0.0377 0.33 0.2 Weight loss (gastric bypass surgery); chr11:77759997 chr11:77829654~77872262:- LIHC cis rs7586604 0.608 rs11123796 ENSG00000230393.1 AC092667.2 3.71 0.000242 0.0377 0.25 0.2 Cannabis dependence symptom count; chr2:99773087 chr2:100104919~100107504:+ LIHC cis rs7665090 1 rs7665090 ENSG00000230069.3 LRRC37A15P 3.71 0.000242 0.0377 0.18 0.2 Primary biliary cholangitis; chr4:102630446 chr4:102727274~102730721:- LIHC cis rs2932538 0.883 rs7549547 ENSG00000225075.1 RP11-426L16.3 3.71 0.000242 0.0377 0.25 0.2 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112544095 chr1:112693688~112696621:- LIHC cis rs2932538 0.922 rs6659677 ENSG00000225075.1 RP11-426L16.3 3.71 0.000242 0.0377 0.25 0.2 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112544454 chr1:112693688~112696621:- LIHC cis rs2932538 0.922 rs12136781 ENSG00000225075.1 RP11-426L16.3 3.71 0.000242 0.0377 0.25 0.2 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112548033 chr1:112693688~112696621:- LIHC cis rs2836974 0.931 rs2776307 ENSG00000255568.3 BRWD1-AS2 -3.71 0.000242 0.0377 -0.22 -0.2 Cognitive function; chr21:39341907 chr21:39313935~39314962:+ LIHC cis rs875971 0.522 rs10807697 ENSG00000237310.1 GS1-124K5.4 3.71 0.000242 0.0377 0.2 0.2 Aortic root size; chr7:65951183 chr7:66493706~66495474:+ LIHC cis rs7809950 0.817 rs2237671 ENSG00000238832.1 snoU109 -3.71 0.000242 0.0377 -0.25 -0.2 Coronary artery disease; chr7:107491083 chr7:107603363~107603507:+ LIHC cis rs6545883 1 rs778762 ENSG00000271889.1 RP11-493E12.1 3.71 0.000242 0.0377 0.24 0.2 Tuberculosis; chr2:61555786 chr2:61151433~61162105:- LIHC cis rs6547705 0.858 rs12714202 ENSG00000231259.4 AC125232.1 3.71 0.000242 0.0377 0.35 0.2 Progressive supranuclear palsy; chr2:86672815 chr2:87031815~87053069:- LIHC cis rs9649213 0.613 rs7777415 ENSG00000272950.1 RP11-307C18.1 3.71 0.000242 0.0377 0.23 0.2 Prostate cancer (SNP x SNP interaction); chr7:98329902 chr7:98322853~98323430:+ LIHC cis rs11098499 0.739 rs6534130 ENSG00000260091.1 RP11-33B1.4 3.71 0.000242 0.0377 0.13 0.2 Corneal astigmatism; chr4:119210184 chr4:119409333~119410233:+ LIHC cis rs12935418 0.887 rs3743503 ENSG00000261061.1 RP11-303E16.2 -3.71 0.000242 0.0377 -0.31 -0.2 Mean corpuscular volume; chr16:81022836 chr16:81030770~81031485:+ LIHC cis rs4648045 0.647 rs1598857 ENSG00000230069.3 LRRC37A15P -3.71 0.000242 0.0377 -0.18 -0.2 Lymphocyte percentage of white cells; chr4:102518268 chr4:102727274~102730721:- LIHC cis rs7829975 0.508 rs4841006 ENSG00000253893.2 FAM85B 3.71 0.000242 0.0378 0.22 0.2 Mood instability; chr8:8643964 chr8:8167819~8226614:- LIHC cis rs1979679 0.842 rs11049373 ENSG00000278733.1 RP11-425D17.1 3.71 0.000242 0.0378 0.25 0.2 Ossification of the posterior longitudinal ligament of the spine; chr12:28148881 chr12:28185625~28186190:- LIHC cis rs6560517 0.581 rs2501933 ENSG00000219149.4 RP11-214N16.2 3.71 0.000242 0.0378 0.21 0.2 Dialysis-related mortality; chr9:76375259 chr9:76549282~76549771:- LIHC cis rs7529073 0.815 rs1431984 ENSG00000274895.1 RP11-478J18.2 -3.71 0.000242 0.0378 -0.21 -0.2 Schizophrenia; chr1:213975285 chr1:213983793~213986419:- LIHC cis rs7647973 0.58 rs2334958 ENSG00000270441.1 RP11-694I15.7 -3.71 0.000242 0.0378 -0.28 -0.2 Menarche (age at onset); chr3:49214931 chr3:49140086~49160851:- LIHC cis rs4819852 1 rs1034566 ENSG00000215493.3 XXbac-B562F10.11 -3.71 0.000243 0.0378 -0.18 -0.2 Pulse pressure; chr22:19996754 chr22:20450122~20451824:+ LIHC cis rs853679 1 rs1778508 ENSG00000219392.1 RP1-265C24.5 3.71 0.000243 0.0378 0.33 0.2 Depression; chr6:28262103 chr6:28115628~28116551:+ LIHC cis rs9400467 0.528 rs1989574 ENSG00000271789.1 RP5-1112D6.7 -3.71 0.000243 0.0378 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111407330 chr6:111297126~111298510:+ LIHC cis rs7712401 0.601 rs246275 ENSG00000263432.2 RN7SL689P 3.71 0.000243 0.0379 0.29 0.2 Mean platelet volume; chr5:122895718 chr5:123022487~123022783:- LIHC cis rs4578769 0.569 rs4800438 ENSG00000266850.1 RP11-370A5.1 3.71 0.000243 0.0379 0.21 0.2 Eosinophil percentage of white cells; chr18:22920482 chr18:22723491~22907721:- LIHC cis rs2152735 0.569 rs11162015 ENSG00000279778.1 RP11-60A14.1 3.71 0.000243 0.0379 0.19 0.2 Resting heart rate; chr1:87435181 chr1:87805286~87808372:- LIHC cis rs2658782 0.654 rs2605622 ENSG00000279684.1 RP11-755E23.2 -3.71 0.000243 0.0379 -0.29 -0.2 Pulmonary function decline; chr11:93515076 chr11:93286629~93288903:- LIHC cis rs17818399 0.815 rs17768132 ENSG00000239332.4 LINC01119 3.71 0.000243 0.0379 0.27 0.2 Height; chr2:46636110 chr2:46816697~46859007:+ LIHC cis rs4218 0.505 rs6494064 ENSG00000277144.1 RP11-59H7.4 3.71 0.000243 0.0379 0.21 0.2 Social communication problems; chr15:59053192 chr15:59115547~59116089:- LIHC cis rs3104707 0.925 rs3105687 ENSG00000279662.1 RP11-609N14.4 3.71 0.000243 0.0379 0.18 0.2 Subjective well-being; chr16:9970112 chr16:10445309~10449747:- LIHC cis rs875971 1 rs1544549 ENSG00000237310.1 GS1-124K5.4 -3.71 0.000243 0.0379 -0.17 -0.2 Aortic root size; chr7:66625676 chr7:66493706~66495474:+ LIHC cis rs7617773 0.539 rs11130165 ENSG00000229759.1 MRPS18AP1 3.71 0.000243 0.0379 0.23 0.2 Coronary artery disease; chr3:48343231 chr3:48256350~48256938:- LIHC cis rs7617773 0.539 rs1471217 ENSG00000229759.1 MRPS18AP1 3.71 0.000243 0.0379 0.23 0.2 Coronary artery disease; chr3:48343405 chr3:48256350~48256938:- LIHC cis rs853679 1 rs853694 ENSG00000204709.4 LINC01556 3.71 0.000243 0.0379 0.32 0.2 Depression; chr6:28311323 chr6:28943877~28944537:+ LIHC cis rs11722228 0.522 rs62286604 ENSG00000261490.1 RP11-448G15.3 3.71 0.000243 0.0379 0.25 0.2 Urate levels;Serum uric acid levels;Gout; chr4:10129537 chr4:10068089~10073019:- LIHC cis rs6669919 0.516 rs11577717 ENSG00000229832.1 RP11-384C4.2 3.71 0.000243 0.0379 0.21 0.2 Intelligence (multi-trait analysis); chr1:211495578 chr1:212357418~212358353:+ LIHC cis rs875971 1 rs875971 ENSG00000237310.1 GS1-124K5.4 -3.71 0.000244 0.0379 -0.18 -0.2 Aortic root size; chr7:66152608 chr7:66493706~66495474:+ LIHC cis rs7804356 0.556 rs17448611 ENSG00000214870.7 AC004540.5 3.71 0.000244 0.0379 0.27 0.2 Type 1 diabetes; chr7:26957541 chr7:26398593~26494256:+ LIHC cis rs4578769 0.685 rs6507432 ENSG00000266850.1 RP11-370A5.1 3.71 0.000244 0.0379 0.23 0.2 Eosinophil percentage of white cells; chr18:23010884 chr18:22723491~22907721:- LIHC cis rs875971 1 rs6979382 ENSG00000237310.1 GS1-124K5.4 3.71 0.000244 0.0379 0.17 0.2 Aortic root size; chr7:66421388 chr7:66493706~66495474:+ LIHC cis rs875971 1 rs6961990 ENSG00000237310.1 GS1-124K5.4 3.71 0.000244 0.0379 0.17 0.2 Aortic root size; chr7:66423583 chr7:66493706~66495474:+ LIHC cis rs8177253 1 rs6439439 ENSG00000244062.1 RP11-404G16.2 3.71 0.000244 0.0379 0.2 0.2 Iron status biomarkers; chr3:133762654 chr3:133760300~133762363:+ LIHC cis rs10256972 0.732 rs1574108 ENSG00000199023.2 MIR339 -3.71 0.000244 0.0379 -0.22 -0.2 Endometriosis;Longevity; chr7:1066169 chr7:1022935~1023045:- LIHC cis rs6500602 0.702 rs6500606 ENSG00000278700.1 Metazoa_SRP -3.71 0.000244 0.0379 -0.24 -0.2 Schizophrenia; chr16:4452513 chr16:4658851~4659151:+ LIHC cis rs4073416 0.691 rs11628765 ENSG00000276116.2 FUT8-AS1 3.71 0.000244 0.038 0.25 0.2 N-glycan levels; chr14:65701731 chr14:65411170~65412690:- LIHC cis rs6504622 0.537 rs197918 ENSG00000263766.4 RP11-580I16.2 -3.71 0.000244 0.038 -0.23 -0.2 Orofacial clefts; chr17:46925714 chr17:47603860~47649420:- LIHC cis rs2228479 0.867 rs62052185 ENSG00000261253.2 AC137932.6 3.71 0.000244 0.038 0.29 0.2 Skin colour saturation; chr16:89902846 chr16:89321133~89325110:+ LIHC cis rs4604234 0.614 rs73482029 ENSG00000272129.1 RP11-250B2.6 -3.71 0.000244 0.038 -0.36 -0.2 Cancer; chr6:80218143 chr6:80355424~80356859:+ LIHC cis rs13113518 0.812 rs12500686 ENSG00000223305.1 RN7SKP30 3.71 0.000244 0.038 0.24 0.2 Height; chr4:55457922 chr4:55540502~55540835:- LIHC cis rs16958440 0.867 rs117060920 ENSG00000267724.1 RP11-49K24.8 3.71 0.000244 0.038 0.37 0.2 Sitting height ratio; chr18:47182664 chr18:47105946~47108062:+ LIHC cis rs2554380 0.628 rs4473150 ENSG00000225151.9 GOLGA2P7 -3.71 0.000244 0.038 -0.29 -0.2 Height; chr15:83814079 chr15:84199311~84230136:- LIHC cis rs7586604 1 rs7566083 ENSG00000230393.1 AC092667.2 3.71 0.000244 0.038 0.28 0.2 Cannabis dependence symptom count; chr2:99790333 chr2:100104919~100107504:+ LIHC cis rs1032726 0.617 rs7432373 ENSG00000240776.1 RP11-435F17.1 3.71 0.000244 0.038 0.26 0.2 Sum eosinophil basophil counts;Eosinophil counts; chr3:112927852 chr3:113850237~113850731:- LIHC cis rs2115630 0.645 rs1107179 ENSG00000275120.1 RP11-182J1.17 3.71 0.000244 0.038 0.27 0.2 P wave terminal force; chr15:84655131 chr15:84599434~84606463:- LIHC cis rs683257 1 rs72986118 ENSG00000234147.1 RP3-460G2.2 -3.71 0.000244 0.038 -0.36 -0.2 Facial emotion recognition (angry faces); chr6:140745861 chr6:140845958~140852924:- LIHC cis rs4356203 0.933 rs12801545 ENSG00000260196.1 RP1-239B22.5 3.71 0.000244 0.038 0.26 0.2 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17244629 chr11:17380649~17383531:+ LIHC cis rs7247513 0.964 rs4804202 ENSG00000230310.1 CTD-2192J16.11 -3.71 0.000244 0.038 -0.27 -0.2 Bipolar disorder; chr19:12607805 chr19:12552597~12553644:+ LIHC cis rs673078 0.66 rs17440433 ENSG00000275759.1 RP11-131L12.3 -3.71 0.000244 0.038 -0.4 -0.2 Glucose homeostasis traits; chr12:118201507 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs17512219 ENSG00000275759.1 RP11-131L12.3 -3.71 0.000244 0.038 -0.4 -0.2 Glucose homeostasis traits; chr12:118211468 chr12:118428281~118428870:+ LIHC cis rs12468226 0.746 rs75987655 ENSG00000272966.1 RP11-686O6.1 3.71 0.000244 0.038 0.34 0.2 Urate levels; chr2:202581913 chr2:202336739~202337200:+ LIHC cis rs2243480 1 rs1723269 ENSG00000232559.3 GS1-124K5.12 3.71 0.000244 0.038 0.21 0.2 Diabetic kidney disease; chr7:66007799 chr7:66554588~66576923:- LIHC cis rs9303401 0.646 rs9303403 ENSG00000265415.1 CTD-2510F5.4 -3.71 0.000244 0.038 -0.13 -0.2 Cognitive test performance; chr17:59141939 chr17:59202677~59203829:- LIHC cis rs1223397 0.651 rs2496153 ENSG00000215022.6 RP1-257A7.4 -3.71 0.000245 0.038 -0.21 -0.2 Blood pressure; chr6:13314642 chr6:13264861~13295586:- LIHC cis rs9876781 1 rs28824259 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48384185 chr3:48256350~48256938:- LIHC cis rs9876781 1 rs12487542 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48384586 chr3:48256350~48256938:- LIHC cis rs9876781 1 rs73074358 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48385757 chr3:48256350~48256938:- LIHC cis rs9876781 0.967 rs34761139 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48386489 chr3:48256350~48256938:- LIHC cis rs9876781 0.868 rs9875280 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48387420 chr3:48256350~48256938:- LIHC cis rs9876781 1 rs6796491 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48388977 chr3:48256350~48256938:- LIHC cis rs9876781 1 rs6804774 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48389129 chr3:48256350~48256938:- LIHC cis rs9876781 1 rs9826195 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48392157 chr3:48256350~48256938:- LIHC cis rs9876781 0.967 rs9864815 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48392588 chr3:48256350~48256938:- LIHC cis rs9876781 1 rs9809843 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48392923 chr3:48256350~48256938:- LIHC cis rs9876781 1 rs1563736 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48395329 chr3:48256350~48256938:- LIHC cis rs9876781 1 rs13071337 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48396724 chr3:48256350~48256938:- LIHC cis rs9876781 1 rs6442118 ENSG00000229759.1 MRPS18AP1 3.71 0.000245 0.038 0.2 0.2 Longevity; chr3:48398582 chr3:48256350~48256938:- LIHC cis rs6700559 0.565 rs2809341 ENSG00000260088.1 RP11-92G12.3 -3.71 0.000245 0.038 -0.27 -0.2 Coronary artery disease; chr1:200628560 chr1:200669507~200694250:+ LIHC cis rs6456156 0.586 rs12525855 ENSG00000227598.1 RP1-167A14.2 -3.71 0.000245 0.0381 -0.21 -0.2 Primary biliary cholangitis; chr6:167066525 chr6:166969626~166999065:- LIHC cis rs10895987 0.83 rs12292693 ENSG00000255200.1 AP003068.18 -3.71 0.000245 0.0381 -0.34 -0.2 Blood protein levels; chr11:65169248 chr11:65174117~65176470:- LIHC cis rs9611519 0.62 rs9607782 ENSG00000231907.2 GAPDHP37 3.71 0.000245 0.0381 0.3 0.2 Neuroticism; chr22:41191552 chr22:40673484~40674451:- LIHC cis rs4308124 0.708 rs28766030 ENSG00000227992.1 AC108463.2 -3.71 0.000245 0.0381 -0.26 -0.2 Vitiligo; chr2:111204852 chr2:111203964~111206215:- LIHC cis rs4308124 0.708 rs28871990 ENSG00000227992.1 AC108463.2 -3.71 0.000245 0.0381 -0.26 -0.2 Vitiligo; chr2:111204864 chr2:111203964~111206215:- LIHC cis rs7615952 0.605 rs34865555 ENSG00000171084.14 FAM86JP 3.71 0.000245 0.0381 0.47 0.2 Blood pressure (smoking interaction); chr3:125585290 chr3:125916620~125930024:+ LIHC cis rs7193541 0.825 rs4411525 ENSG00000261079.1 RP11-252A24.3 3.71 0.000245 0.0381 0.22 0.2 Multiple myeloma; chr16:74561604 chr16:74367462~74369826:+ LIHC cis rs4555082 1 rs7146012 ENSG00000211892.3 IGHG4 -3.71 0.000245 0.0381 -0.19 -0.2 Platelet distribution width;Mean platelet volume; chr14:105291229 chr14:105624341~105626066:- LIHC cis rs2932538 0.922 rs2273369 ENSG00000225075.1 RP11-426L16.3 3.71 0.000245 0.0381 0.25 0.2 Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension; chr1:112529855 chr1:112693688~112696621:- LIHC cis rs3198697 0.617 rs11075253 ENSG00000263335.1 AF001548.5 -3.71 0.000245 0.0381 -0.33 -0.2 Triglycerides; chr16:15054789 chr16:15726674~15732993:+ LIHC cis rs9674544 0.792 rs8079167 ENSG00000248278.1 SUMO2P17 -3.71 0.000245 0.0381 -0.27 -0.2 Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption); chr17:49031593 chr17:48874860~48908983:- LIHC cis rs919433 0.927 rs7592748 ENSG00000231621.1 AC013264.2 3.71 0.000245 0.0381 0.18 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197305964 chr2:197197991~197199273:+ LIHC cis rs7568498 0.517 rs11678856 ENSG00000235724.7 AC009299.2 3.71 0.000245 0.0381 0.23 0.2 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161068932 chr2:161222785~161308303:- LIHC cis rs643506 0.874 rs4245045 ENSG00000230911.1 PPIHP1 -3.71 0.000245 0.0381 -0.26 -0.2 Breast cancer; chr11:111789200 chr11:112029858~112030367:- LIHC cis rs9847710 0.967 rs4687694 ENSG00000242797.3 GLYCTK-AS1 -3.71 0.000245 0.0381 -0.2 -0.2 Ulcerative colitis; chr3:53015031 chr3:52288580~52299067:- LIHC cis rs9847710 0.967 rs2581778 ENSG00000242797.3 GLYCTK-AS1 -3.71 0.000245 0.0381 -0.2 -0.2 Ulcerative colitis; chr3:53021295 chr3:52288580~52299067:- LIHC cis rs12681287 0.547 rs13249177 ENSG00000254088.1 SLC2A3P4 3.71 0.000245 0.0381 0.23 0.2 Caudate activity during reward; chr8:86500805 chr8:86503591~86505061:+ LIHC cis rs7560272 0.538 rs13014700 ENSG00000273245.1 RP11-434P11.2 -3.71 0.000245 0.0381 -0.24 -0.2 Schizophrenia; chr2:73692994 chr2:73750256~73750786:- LIHC cis rs9640161 0.742 rs2159236 ENSG00000261305.1 RP4-584D14.7 3.71 0.000245 0.0381 0.23 0.2 Blood protein levels;Circulating chemerin levels; chr7:150320125 chr7:150341771~150342607:+ LIHC cis rs12908161 0.959 rs3748376 ENSG00000259728.4 LINC00933 3.71 0.000245 0.0381 0.28 0.2 Schizophrenia; chr15:84785121 chr15:84570649~84580175:+ LIHC cis rs4803480 0.507 rs10420992 ENSG00000267107.5 PCAT19 3.71 0.000245 0.0381 0.24 0.2 Schizophrenia; chr19:41558092 chr19:41454169~41500649:- LIHC cis rs6048205 0.881 rs6048183 ENSG00000259974.2 LINC00261 -3.71 0.000245 0.0381 -0.31 -0.2 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22556674 chr20:22547671~22578642:- LIHC cis rs10761256 0.806 rs3763605 ENSG00000227603.1 RP11-165J3.6 3.71 0.000246 0.0381 0.23 0.2 Itch intensity from mosquito bite adjusted by bite size; chr9:93658108 chr9:93435332~93437121:- LIHC cis rs7568498 0.517 rs197261 ENSG00000235724.7 AC009299.2 3.71 0.000246 0.0382 0.23 0.2 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); chr2:161048312 chr2:161222785~161308303:- LIHC cis rs4604234 0.522 rs74614428 ENSG00000272129.1 RP11-250B2.6 -3.71 0.000246 0.0382 -0.36 -0.2 Cancer; chr6:80200459 chr6:80355424~80356859:+ LIHC cis rs4604234 0.614 rs3749896 ENSG00000272129.1 RP11-250B2.6 -3.71 0.000246 0.0382 -0.36 -0.2 Cancer; chr6:80203260 chr6:80355424~80356859:+ LIHC cis rs875971 0.83 rs427575 ENSG00000237310.1 GS1-124K5.4 3.71 0.000246 0.0382 0.18 0.2 Aortic root size; chr7:66054232 chr7:66493706~66495474:+ LIHC cis rs2658782 0.654 rs2605623 ENSG00000279684.1 RP11-755E23.2 -3.71 0.000246 0.0382 -0.29 -0.2 Pulmonary function decline; chr11:93516193 chr11:93286629~93288903:- LIHC cis rs11148252 0.774 rs9536066 ENSG00000278238.1 RP11-245D16.4 -3.71 0.000246 0.0382 -0.19 -0.2 Lewy body disease; chr13:52409846 chr13:52454775~52455331:- LIHC cis rs4891159 0.824 rs17059362 ENSG00000265778.2 RP11-17M16.2 -3.71 0.000246 0.0382 -0.24 -0.2 Longevity; chr18:76432351 chr18:76491652~76493918:+ LIHC cis rs4891159 0.79 rs72975930 ENSG00000265778.2 RP11-17M16.2 -3.71 0.000246 0.0382 -0.24 -0.2 Longevity; chr18:76432689 chr18:76491652~76493918:+ LIHC cis rs600231 0.571 rs10896000 ENSG00000245532.5 NEAT1 3.71 0.000246 0.0382 0.2 0.2 Bone mineral density; chr11:65450547 chr11:65422774~65445540:+ LIHC cis rs4891159 1 rs4891159 ENSG00000265778.2 RP11-17M16.2 3.71 0.000246 0.0382 0.23 0.2 Longevity; chr18:76389985 chr18:76491652~76493918:+ LIHC cis rs4595586 0.811 rs6580849 ENSG00000257718.1 RP11-396F22.1 -3.71 0.000246 0.0382 -0.23 -0.2 Morning vs. evening chronotype; chr12:38909837 chr12:38906451~38909592:+ LIHC cis rs801193 0.569 rs7800620 ENSG00000232559.3 GS1-124K5.12 3.71 0.000246 0.0382 0.15 0.2 Aortic root size; chr7:66758701 chr7:66554588~66576923:- LIHC cis rs6471393 0.929 rs56108220 ENSG00000253848.1 RP11-10N23.5 3.71 0.000246 0.0382 0.21 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93736965 chr8:93741193~93744534:+ LIHC cis rs9649213 0.593 rs1468341 ENSG00000272950.1 RP11-307C18.1 3.71 0.000246 0.0382 0.23 0.2 Prostate cancer (SNP x SNP interaction); chr7:98358384 chr7:98322853~98323430:+ LIHC cis rs875971 0.545 rs6979636 ENSG00000224316.1 RP11-479O9.2 3.71 0.000246 0.0382 0.19 0.2 Aortic root size; chr7:66276638 chr7:65773620~65802067:+ LIHC cis rs801193 0.569 rs11772819 ENSG00000232559.3 GS1-124K5.12 3.71 0.000246 0.0382 0.15 0.2 Aortic root size; chr7:66752983 chr7:66554588~66576923:- LIHC cis rs10256972 0.732 rs12701856 ENSG00000199023.2 MIR339 -3.71 0.000246 0.0382 -0.22 -0.2 Endometriosis;Longevity; chr7:1068071 chr7:1022935~1023045:- LIHC cis rs3798696 0.79 rs12199710 ENSG00000229950.1 TFAP2A-AS1 3.71 0.000246 0.0382 0.28 0.2 Amyotrophic lateral sclerosis (sporadic); chr6:10403947 chr6:10409340~10416446:+ LIHC cis rs5758511 0.68 rs5758692 ENSG00000273366.1 CTA-989H11.1 3.71 0.000246 0.0383 0.26 0.2 Birth weight; chr22:42273023 chr22:42278188~42278846:+ LIHC cis rs9646944 0.501 rs3771158 ENSG00000234389.1 AC007278.3 3.71 0.000246 0.0383 0.25 0.2 Blood protein levels; chr2:102393434 chr2:102438713~102440475:+ LIHC cis rs9646944 0.501 rs12991737 ENSG00000234389.1 AC007278.3 3.71 0.000246 0.0383 0.25 0.2 Blood protein levels; chr2:102401668 chr2:102438713~102440475:+ LIHC cis rs9646944 0.501 rs10181785 ENSG00000234389.1 AC007278.3 3.71 0.000246 0.0383 0.25 0.2 Blood protein levels; chr2:102408814 chr2:102438713~102440475:+ LIHC cis rs9646944 0.54 rs12712148 ENSG00000234389.1 AC007278.3 3.71 0.000246 0.0383 0.25 0.2 Blood protein levels; chr2:102409087 chr2:102438713~102440475:+ LIHC cis rs6951643 0.54 rs12706746 ENSG00000224138.1 AC000123.4 -3.71 0.000246 0.0383 -0.26 -0.2 Creutzfeldt-Jakob disease (sporadic); chr7:126802805 chr7:127350128~127351523:+ LIHC cis rs2439831 0.867 rs2245715 ENSG00000166763.7 STRCP1 3.71 0.000246 0.0383 0.28 0.2 Lung cancer in ever smokers; chr15:43525854 chr15:43699488~43718184:- LIHC cis rs14027 0.961 rs7017279 ENSG00000279347.1 RP11-85I17.2 3.71 0.000246 0.0383 0.19 0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119847580 chr8:119838736~119840385:- LIHC cis rs2976388 0.669 rs2976391 ENSG00000253741.1 CTD-2292P10.4 -3.7 0.000246 0.0383 -0.23 -0.2 Urinary tract infection frequency; chr8:142681306 chr8:142702252~142726973:- LIHC cis rs7617773 0.78 rs35297486 ENSG00000228638.1 FCF1P2 -3.7 0.000246 0.0383 -0.23 -0.2 Coronary artery disease; chr3:48336657 chr3:48290793~48291375:- LIHC cis rs340849 0.703 rs17762192 ENSG00000274895.1 RP11-478J18.2 -3.7 0.000246 0.0383 -0.21 -0.2 Alzheimer's disease; chr1:213951784 chr1:213983793~213986419:- LIHC cis rs6700559 0.81 rs7521550 ENSG00000260088.1 RP11-92G12.3 -3.7 0.000246 0.0383 -0.25 -0.2 Coronary artery disease; chr1:200623235 chr1:200669507~200694250:+ LIHC cis rs11096990 0.855 rs2566170 ENSG00000249685.1 RP11-360F5.3 -3.7 0.000247 0.0383 -0.27 -0.2 Cognitive function; chr4:39150757 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2566177 ENSG00000249685.1 RP11-360F5.3 -3.7 0.000247 0.0383 -0.27 -0.2 Cognitive function; chr4:39154558 chr4:39133913~39135608:+ LIHC cis rs11096990 0.855 rs2711934 ENSG00000249685.1 RP11-360F5.3 -3.7 0.000247 0.0383 -0.27 -0.2 Cognitive function; chr4:39156254 chr4:39133913~39135608:+ LIHC cis rs2749592 0.55 rs4934881 ENSG00000099251.13 HSD17B7P2 -3.7 0.000247 0.0383 -0.23 -0.2 Age-related hearing impairment (SNP x SNP interaction); chr10:37625418 chr10:38356380~38378505:+ LIHC cis rs957448 0.687 rs10104041 ENSG00000253704.1 RP11-267M23.4 3.7 0.000247 0.0383 0.22 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94559374 chr8:94553722~94569745:+ LIHC cis rs12586317 0.62 rs58320987 ENSG00000257307.1 RP11-317N8.4 -3.7 0.000247 0.0383 -0.23 -0.2 Psoriasis; chr14:35118520 chr14:35881001~35881709:+ LIHC cis rs3749237 0.576 rs4241406 ENSG00000270441.1 RP11-694I15.7 -3.7 0.000247 0.0383 -0.28 -0.2 Resting heart rate; chr3:49562993 chr3:49140086~49160851:- LIHC cis rs4578769 0.797 rs9304261 ENSG00000266850.1 RP11-370A5.1 -3.7 0.000247 0.0383 -0.23 -0.2 Eosinophil percentage of white cells; chr18:23026633 chr18:22723491~22907721:- LIHC cis rs7969148 1 rs7969148 ENSG00000270130.1 RP11-214K3.23 3.7 0.000247 0.0383 0.3 0.2 Clubfoot; chr12:124129992 chr12:123960717~123961244:- LIHC cis rs960902 0.62 rs11694646 ENSG00000213553.4 RPLP0P6 3.7 0.000247 0.0383 0.16 0.2 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37510924 chr2:38481851~38482804:+ LIHC cis rs4218 0.593 rs8040456 ENSG00000277144.1 RP11-59H7.4 -3.7 0.000247 0.0383 -0.21 -0.2 Social communication problems; chr15:59063904 chr15:59115547~59116089:- LIHC cis rs709400 0.859 rs942863 ENSG00000269958.1 RP11-73M18.8 3.7 0.000247 0.0383 0.27 0.2 Body mass index; chr14:103554931 chr14:103696353~103697163:+ LIHC cis rs9595908 0.869 rs9595946 ENSG00000212293.1 SNORA16 3.7 0.000247 0.0383 0.22 0.2 Body mass index; chr13:32628998 chr13:32420390~32420516:- LIHC cis rs11710567 0.734 rs17801943 ENSG00000272146.4 RP11-755B10.4 -3.7 0.000247 0.0383 -0.23 -0.2 Granulocyte percentage of myeloid white cells; chr3:57913639 chr3:57597715~57600927:+ LIHC cis rs2098713 0.599 rs12652658 ENSG00000250155.1 CTD-2353F22.1 3.7 0.000247 0.0383 0.19 0.2 Telomere length; chr5:37555461 chr5:36666214~36725195:- LIHC cis rs4650994 1 rs4650999 ENSG00000213057.5 C1orf220 -3.7 0.000247 0.0383 -0.17 -0.2 HDL cholesterol;HDL cholesterol levels; chr1:178563053 chr1:178542752~178548889:+ LIHC cis rs9400467 0.528 rs11153288 ENSG00000271789.1 RP5-1112D6.7 -3.7 0.000247 0.0383 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111394035 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs11153290 ENSG00000271789.1 RP5-1112D6.7 -3.7 0.000247 0.0383 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111396929 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs11153291 ENSG00000271789.1 RP5-1112D6.7 -3.7 0.000247 0.0383 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111398927 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs11153292 ENSG00000271789.1 RP5-1112D6.7 -3.7 0.000247 0.0383 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111401176 chr6:111297126~111298510:+ LIHC cis rs9400467 0.528 rs12190634 ENSG00000271789.1 RP5-1112D6.7 -3.7 0.000247 0.0383 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111403957 chr6:111297126~111298510:+ LIHC cis rs9400467 0.508 rs11153293 ENSG00000271789.1 RP5-1112D6.7 -3.7 0.000247 0.0383 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111404696 chr6:111297126~111298510:+ LIHC cis rs9400467 0.508 rs11756643 ENSG00000271789.1 RP5-1112D6.7 -3.7 0.000247 0.0383 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111404943 chr6:111297126~111298510:+ LIHC cis rs9400467 0.508 rs11153294 ENSG00000271789.1 RP5-1112D6.7 -3.7 0.000247 0.0383 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111409043 chr6:111297126~111298510:+ LIHC cis rs4891159 0.79 rs8087557 ENSG00000265778.2 RP11-17M16.2 -3.7 0.000247 0.0384 -0.23 -0.2 Longevity; chr18:76404892 chr18:76491652~76493918:+ LIHC cis rs4803480 0.529 rs4803481 ENSG00000267107.5 PCAT19 3.7 0.000247 0.0384 0.24 0.2 Schizophrenia; chr19:41560186 chr19:41454169~41500649:- LIHC cis rs7829975 0.593 rs2921061 ENSG00000253981.4 ALG1L13P 3.7 0.000247 0.0384 0.26 0.2 Mood instability; chr8:8460105 chr8:8236003~8244667:- LIHC cis rs2281636 0.691 rs6584306 ENSG00000233690.1 EBAG9P1 3.7 0.000247 0.0384 0.2 0.2 Obesity-related traits; chr10:99662739 chr10:99697407~99697949:- LIHC cis rs3845817 0.703 rs702887 ENSG00000281920.1 RP11-418H16.1 -3.7 0.000247 0.0384 -0.23 -0.2 Bipolar disorder; chr2:65527074 chr2:65623272~65628424:+ LIHC cis rs41313321 0.92 rs61646534 ENSG00000272696.1 RP11-339B21.13 3.7 0.000247 0.0384 0.27 0.2 Coenzyme Q10 levels; chr9:128301169 chr9:128316337~128316909:+ LIHC cis rs728616 0.558 rs55803802 ENSG00000225484.5 NUTM2B-AS1 -3.7 0.000247 0.0384 -0.4 -0.2 Chronic obstructive pulmonary disease-related biomarkers; chr10:79992908 chr10:79663088~79826594:- LIHC cis rs4873772 0.735 rs10958058 ENSG00000253608.1 RP11-770E5.1 3.7 0.000247 0.0384 0.21 0.2 Lobe attachment (rater-scored or self-reported); chr8:47592067 chr8:48551567~48698510:+ LIHC cis rs4604234 0.614 rs73479918 ENSG00000272129.1 RP11-250B2.6 -3.7 0.000248 0.0384 -0.34 -0.2 Cancer; chr6:80130255 chr6:80355424~80356859:+ LIHC cis rs17713451 0.542 rs73475440 ENSG00000204894.4 RP11-208G20.2 3.7 0.000248 0.0384 0.36 0.2 Interleukin-4 levels; chr7:151582299 chr7:152367171~152367260:+ LIHC cis rs2742417 0.624 rs2673029 ENSG00000244357.3 RN7SL145P 3.7 0.000248 0.0384 0.19 0.2 Response to anti-depressant treatment in major depressive disorder; chr3:45717375 chr3:45742675~45742970:+ LIHC cis rs10446497 0.513 rs13100811 ENSG00000226155.1 AC124944.3 3.7 0.000248 0.0384 0.24 0.2 Schizophrenia; chr3:196817453 chr3:195912049~195913986:+ LIHC cis rs10752881 1 rs4233193 ENSG00000224468.3 RP11-181K3.4 -3.7 0.000248 0.0384 -0.17 -0.2 Colorectal cancer; chr1:183001730 chr1:183138402~183141282:- LIHC cis rs643506 1 rs647080 ENSG00000230911.1 PPIHP1 -3.7 0.000248 0.0384 -0.27 -0.2 Breast cancer; chr11:111738450 chr11:112029858~112030367:- LIHC cis rs7176527 0.848 rs3748374 ENSG00000176700.18 SCAND2P 3.7 0.000248 0.0384 0.19 0.2 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84641012 chr15:84631451~84647478:+ LIHC cis rs748404 0.518 rs480108 ENSG00000166763.7 STRCP1 3.7 0.000248 0.0385 0.24 0.2 Lung cancer; chr15:43525208 chr15:43699488~43718184:- LIHC cis rs2462686 1 rs2471553 ENSG00000272556.1 RP11-638I8.1 -3.7 0.000248 0.0385 -0.3 -0.2 Major depressive disorder; chr7:45938524 chr7:45814602~45815263:+ LIHC cis rs3749237 0.595 rs3870338 ENSG00000270441.1 RP11-694I15.7 -3.7 0.000248 0.0385 -0.27 -0.2 Resting heart rate; chr3:49519618 chr3:49140086~49160851:- LIHC cis rs2742417 0.603 rs2673032 ENSG00000244357.3 RN7SL145P 3.7 0.000248 0.0385 0.19 0.2 Response to anti-depressant treatment in major depressive disorder; chr3:45715435 chr3:45742675~45742970:+ LIHC cis rs2742417 0.565 rs2673031 ENSG00000244357.3 RN7SL145P 3.7 0.000248 0.0385 0.19 0.2 Response to anti-depressant treatment in major depressive disorder; chr3:45715494 chr3:45742675~45742970:+ LIHC cis rs2742417 0.624 rs2742394 ENSG00000244357.3 RN7SL145P 3.7 0.000248 0.0385 0.19 0.2 Response to anti-depressant treatment in major depressive disorder; chr3:45716099 chr3:45742675~45742970:+ LIHC cis rs2742417 0.624 rs2673030 ENSG00000244357.3 RN7SL145P 3.7 0.000248 0.0385 0.19 0.2 Response to anti-depressant treatment in major depressive disorder; chr3:45716408 chr3:45742675~45742970:+ LIHC cis rs61542988 0.535 rs10807813 ENSG00000226816.2 AC005082.12 -3.7 0.000248 0.0385 -0.26 -0.2 Fibrinogen levels; chr7:22790342 chr7:23206013~23208045:+ LIHC cis rs763512 0.532 rs3110626 ENSG00000276054.1 RP11-378E13.3 -3.7 0.000248 0.0385 -0.25 -0.2 3-hydroxypropylmercapturic acid levels in smokers; chr17:37536300 chr17:37386886~37387926:+ LIHC cis rs9876781 1 rs9838618 ENSG00000229759.1 MRPS18AP1 3.7 0.000248 0.0385 0.21 0.2 Longevity; chr3:48445949 chr3:48256350~48256938:- LIHC cis rs7809950 0.817 rs62483725 ENSG00000238832.1 snoU109 -3.7 0.000248 0.0385 -0.25 -0.2 Coronary artery disease; chr7:107561130 chr7:107603363~107603507:+ LIHC cis rs1198872 0.563 rs1106185 ENSG00000272275.1 RP11-791G15.2 3.7 0.000248 0.0385 0.24 0.2 Cardiac Troponin-T levels; chr2:10823444 chr2:10767875~10770058:- LIHC cis rs10938353 0.68 rs1491313 ENSG00000273369.1 RP11-700J17.1 3.7 0.000248 0.0385 0.26 0.2 Body mass index; chr4:44783372 chr4:44693946~44694386:- LIHC cis rs6442522 0.64 rs13095087 ENSG00000249786.6 EAF1-AS1 -3.7 0.000248 0.0385 -0.23 -0.2 Uric acid levels; chr3:15477334 chr3:15436171~15455940:- LIHC cis rs3813567 0.702 rs7164665 ENSG00000261762.1 RP11-650L12.2 -3.7 0.000248 0.0385 -0.27 -0.2 Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio; chr15:78661577 chr15:78589123~78591276:- LIHC cis rs4356975 0.563 rs7676472 ENSG00000250919.1 RP11-813N20.3 -3.7 0.000248 0.0385 -0.2 -0.2 Obesity-related traits; chr4:69090226 chr4:69027831~69044578:+ LIHC cis rs7734985 0.587 rs7706771 ENSG00000250551.1 RP11-254I22.1 3.7 0.000248 0.0385 0.22 0.2 IgG glycosylation; chr5:96259661 chr5:96050115~96215519:+ LIHC cis rs11096990 0.964 rs6828598 ENSG00000249207.1 RP11-360F5.1 3.7 0.000248 0.0385 0.22 0.2 Cognitive function; chr4:39259850 chr4:39112677~39126818:- LIHC cis rs7224610 0.801 rs4793788 ENSG00000263096.1 RP11-515O17.2 -3.7 0.000248 0.0385 -0.27 -0.2 Urate levels; chr17:55304435 chr17:55271504~55273653:- LIHC cis rs6442522 0.526 rs3773448 ENSG00000249786.6 EAF1-AS1 3.7 0.000248 0.0385 0.23 0.2 Uric acid levels; chr3:15477755 chr3:15436171~15455940:- LIHC cis rs1005277 0.579 rs1740732 ENSG00000120555.12 SEPT7P9 3.7 0.000249 0.0385 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38202457 chr10:38383069~38402916:- LIHC cis rs34734847 0.871 rs2239760 ENSG00000277423.1 RP11-173P15.9 3.7 0.000249 0.0385 0.21 0.2 Mean corpuscular volume; chr12:120725715 chr12:120703867~120704282:+ LIHC cis rs1440410 0.835 rs34342939 ENSG00000250326.1 RP11-284M14.1 -3.7 0.000249 0.0385 -0.22 -0.2 Ischemic stroke; chr4:143240517 chr4:142933195~143184861:- LIHC cis rs4578769 0.569 rs12955131 ENSG00000265943.1 RP11-739L10.1 -3.7 0.000249 0.0385 -0.23 -0.2 Eosinophil percentage of white cells; chr18:22900424 chr18:22699481~22933764:- LIHC cis rs6449502 0.92 rs329618 ENSG00000272308.1 RP11-231G3.1 3.7 0.000249 0.0385 0.31 0.2 Mean platelet volume; chr5:60993696 chr5:60866457~60866935:- LIHC cis rs27434 0.607 rs34750 ENSG00000272109.1 CTD-2260A17.3 -3.7 0.000249 0.0386 -0.23 -0.2 Ankylosing spondylitis; chr5:96807103 chr5:96804353~96806105:+ LIHC cis rs10129255 0.957 rs2013423 ENSG00000211970.3 IGHV4-61 -3.7 0.000249 0.0386 -0.16 -0.2 Kawasaki disease; chr14:106690675 chr14:106639119~106639657:- LIHC cis rs10129255 0.957 rs56134540 ENSG00000211970.3 IGHV4-61 -3.7 0.000249 0.0386 -0.16 -0.2 Kawasaki disease; chr14:106691290 chr14:106639119~106639657:- LIHC cis rs4680 0.737 rs2239393 ENSG00000273311.1 DGCR11 3.7 0.000249 0.0386 0.24 0.2 Blood metabolite levels; chr22:19962905 chr22:19046162~19048375:- LIHC cis rs198389 0.589 rs198399 ENSG00000242349.4 NPPA-AS1 -3.7 0.000249 0.0386 -0.2 -0.2 B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome; chr1:11823572 chr1:11841017~11848079:+ LIHC cis rs9929218 0.508 rs1559366 ENSG00000260459.2 FTLP14 3.7 0.000249 0.0386 0.23 0.2 Colorectal cancer; chr16:68765708 chr16:68822587~68823070:+ LIHC cis rs9467773 1 rs9986382 ENSG00000261353.1 CTA-14H9.5 -3.7 0.000249 0.0386 -0.19 -0.2 Intelligence (multi-trait analysis); chr6:26550391 chr6:26527063~26527404:+ LIHC cis rs853679 1 rs9986596 ENSG00000204709.4 LINC01556 3.7 0.000249 0.0386 0.34 0.2 Depression; chr6:28251883 chr6:28943877~28944537:+ LIHC cis rs1115240 0.574 rs61988529 ENSG00000257842.4 NOVA1-AS1 3.7 0.000249 0.0386 0.2 0.2 Educational attainment (years of education); chr14:26461009 chr14:26598412~26806467:+ LIHC cis rs1115240 0.574 rs55928941 ENSG00000257842.4 NOVA1-AS1 3.7 0.000249 0.0386 0.2 0.2 Educational attainment (years of education); chr14:26463805 chr14:26598412~26806467:+ LIHC cis rs7208859 0.573 rs56031503 ENSG00000264538.5 SUZ12P1 -3.7 0.000249 0.0386 -0.21 -0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748647 chr17:30709299~30790908:+ LIHC cis rs712022 0.837 rs2159668 ENSG00000246225.5 RP11-17A1.3 3.7 0.000249 0.0386 0.25 0.2 Dialysis-related mortality; chr11:22817914 chr11:22829380~22945393:+ LIHC cis rs2115630 0.967 rs11073702 ENSG00000259295.5 CSPG4P12 -3.7 0.000249 0.0386 -0.23 -0.2 P wave terminal force; chr15:84766840 chr15:85191438~85213905:+ LIHC cis rs8005677 0.962 rs10130756 ENSG00000279656.1 RP11-298I3.6 3.7 0.000249 0.0386 0.22 0.2 Cognitive ability (multi-trait analysis); chr14:22927391 chr14:23023083~23024217:- LIHC cis rs7789940 0.809 rs12533836 ENSG00000205485.12 AC004980.7 -3.7 0.000249 0.0386 -0.2 -0.2 Multiple sclerosis; chr7:76306305 chr7:76549360~76627982:+ LIHC cis rs67311347 1 rs11707278 ENSG00000223797.4 ENTPD3-AS1 3.7 0.000249 0.0386 0.16 0.2 Renal cell carcinoma; chr3:40445584 chr3:40313802~40453329:- LIHC cis rs2243480 1 rs464895 ENSG00000232546.1 RP11-458F8.1 -3.7 0.000249 0.0386 -0.22 -0.2 Diabetic kidney disease; chr7:66062119 chr7:66848496~66858136:+ LIHC cis rs17373728 0.526 rs9298251 ENSG00000249395.2 CASC9 -3.7 0.000249 0.0386 -0.21 -0.2 Diabetic kidney disease; chr8:75243181 chr8:75223404~75324741:- LIHC cis rs1133906 0.522 rs4267 ENSG00000200769.1 Y_RNA -3.7 0.000249 0.0386 -0.25 -0.2 Systemic lupus erythematosus and Systemic sclerosis; chr7:93130149 chr7:92202243~92202334:- LIHC cis rs2098713 0.549 rs62359033 ENSG00000250155.1 CTD-2353F22.1 3.7 0.000249 0.0386 0.19 0.2 Telomere length; chr5:37549741 chr5:36666214~36725195:- LIHC cis rs875971 0.642 rs35526611 ENSG00000224316.1 RP11-479O9.2 -3.7 0.000249 0.0386 -0.19 -0.2 Aortic root size; chr7:66629021 chr7:65773620~65802067:+ LIHC cis rs11686241 0.872 rs16856226 ENSG00000232485.2 AC098820.3 3.7 0.000249 0.0386 0.19 0.2 Cancer; chr2:216484954 chr2:216479030~216498761:- LIHC cis rs2395128 0.834 rs4746237 ENSG00000237149.5 ZNF503-AS2 -3.7 0.000249 0.0386 -0.23 -0.2 Ulcerative colitis;Inflammatory bowel disease; chr10:74791744 chr10:75401519~75408982:+ LIHC cis rs74233809 0.901 rs7098825 ENSG00000236937.2 PTGES3P4 3.7 0.000249 0.0386 0.32 0.2 Birth weight; chr10:102868477 chr10:102845595~102845950:+ LIHC cis rs2439831 0.867 rs2584702 ENSG00000205771.5 CATSPER2P1 -3.7 0.000249 0.0386 -0.27 -0.2 Lung cancer in ever smokers; chr15:43392716 chr15:43726918~43747094:- LIHC cis rs2439831 0.867 rs2243434 ENSG00000205771.5 CATSPER2P1 -3.7 0.000249 0.0386 -0.27 -0.2 Lung cancer in ever smokers; chr15:43397669 chr15:43726918~43747094:- LIHC cis rs1987511 1 rs1987511 ENSG00000231039.2 RP11-445P17.3 -3.7 0.000249 0.0386 -0.25 -0.2 Intelligence; chr10:5306374 chr10:5234358~5263408:+ LIHC cis rs9400467 0.528 rs7451051 ENSG00000271789.1 RP5-1112D6.7 -3.7 0.000249 0.0386 -0.19 -0.2 Amino acid levels;Blood metabolite levels; chr6:111423615 chr6:111297126~111298510:+ LIHC cis rs11096990 0.855 rs2566183 ENSG00000249685.1 RP11-360F5.3 -3.7 0.00025 0.0386 -0.27 -0.2 Cognitive function; chr4:39162288 chr4:39133913~39135608:+ LIHC cis rs2072510 1 rs2072510 ENSG00000257878.1 RP11-256L6.3 3.7 0.00025 0.0386 0.17 0.2 Metabolite levels (small molecules and protein measures); chr12:96009421 chr12:95996521~96011489:+ LIHC cis rs11096990 0.927 rs56009503 ENSG00000249685.1 RP11-360F5.3 -3.7 0.00025 0.0387 -0.27 -0.2 Cognitive function; chr4:39242642 chr4:39133913~39135608:+ LIHC cis rs11096990 0.964 rs7687651 ENSG00000249685.1 RP11-360F5.3 -3.7 0.00025 0.0387 -0.27 -0.2 Cognitive function; chr4:39243072 chr4:39133913~39135608:+ LIHC cis rs11096990 0.891 rs61691409 ENSG00000249685.1 RP11-360F5.3 -3.7 0.00025 0.0387 -0.27 -0.2 Cognitive function; chr4:39243801 chr4:39133913~39135608:+ LIHC cis rs56080343 0.688 rs10083190 ENSG00000275759.1 RP11-131L12.3 -3.7 0.00025 0.0387 -0.24 -0.2 Neuroticism; chr12:118365385 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs10082823 ENSG00000275759.1 RP11-131L12.3 -3.7 0.00025 0.0387 -0.24 -0.2 Glucose homeostasis traits; chr12:118365386 chr12:118428281~118428870:+ LIHC cis rs4266144 1 rs4561781 ENSG00000243176.4 RP11-550I24.2 3.7 0.00025 0.0387 0.25 0.2 Coronary artery disease; chr3:157135154 chr3:157175223~157381265:+ LIHC cis rs793571 0.774 rs10851640 ENSG00000259738.1 ZNF444P1 -3.7 0.00025 0.0387 -0.24 -0.2 Schizophrenia; chr15:58845671 chr15:58865006~58865303:+ LIHC cis rs919433 0.889 rs788001 ENSG00000231621.1 AC013264.2 -3.7 0.00025 0.0387 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197348996 chr2:197197991~197199273:+ LIHC cis rs13242816 0.881 rs12672038 ENSG00000279086.1 RP11-667F14.1 3.7 0.00025 0.0387 0.35 0.2 P wave duration; chr7:116547052 chr7:116209234~116211511:- LIHC cis rs13242816 1 rs13243017 ENSG00000279086.1 RP11-667F14.1 3.7 0.00025 0.0387 0.35 0.2 P wave duration; chr7:116549317 chr7:116209234~116211511:- LIHC cis rs13242816 1 rs13242816 ENSG00000279086.1 RP11-667F14.1 3.7 0.00025 0.0387 0.35 0.2 P wave duration; chr7:116549322 chr7:116209234~116211511:- LIHC cis rs2745572 0.557 rs2745574 ENSG00000272279.1 RP11-157J24.2 -3.7 0.00025 0.0387 -0.24 -0.2 Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure); chr6:1548990 chr6:1528364~1528911:- LIHC cis rs4792901 0.802 rs55989313 ENSG00000267747.1 RP11-392O1.4 -3.7 0.00025 0.0387 -0.24 -0.2 Dupuytren's disease; chr17:43528880 chr17:43544785~43610338:+ LIHC cis rs13434995 0.513 rs62303732 ENSG00000273257.1 RP11-177J6.1 -3.7 0.00025 0.0387 -0.32 -0.2 Adiponectin levels; chr4:55499868 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs56196624 ENSG00000273257.1 RP11-177J6.1 -3.7 0.00025 0.0387 -0.32 -0.2 Adiponectin levels; chr4:55500340 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs62305264 ENSG00000273257.1 RP11-177J6.1 -3.7 0.00025 0.0387 -0.32 -0.2 Adiponectin levels; chr4:55502968 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs62305265 ENSG00000273257.1 RP11-177J6.1 -3.7 0.00025 0.0387 -0.32 -0.2 Adiponectin levels; chr4:55503474 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs62305268 ENSG00000273257.1 RP11-177J6.1 -3.7 0.00025 0.0387 -0.32 -0.2 Adiponectin levels; chr4:55506991 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs62305270 ENSG00000273257.1 RP11-177J6.1 -3.7 0.00025 0.0387 -0.32 -0.2 Adiponectin levels; chr4:55507842 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs7681414 ENSG00000273257.1 RP11-177J6.1 -3.7 0.00025 0.0387 -0.32 -0.2 Adiponectin levels; chr4:55508890 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs62305271 ENSG00000273257.1 RP11-177J6.1 -3.7 0.00025 0.0387 -0.32 -0.2 Adiponectin levels; chr4:55509715 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs10462033 ENSG00000273257.1 RP11-177J6.1 -3.7 0.00025 0.0387 -0.32 -0.2 Adiponectin levels; chr4:55511552 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs1915905 ENSG00000273257.1 RP11-177J6.1 -3.7 0.00025 0.0387 -0.32 -0.2 Adiponectin levels; chr4:55512381 chr4:55387949~55388271:+ LIHC cis rs287982 1 rs1119633 ENSG00000269973.1 RP11-95D17.1 -3.7 0.00025 0.0387 -0.18 -0.2 Nonsyndromic cleft lip with cleft palate; chr2:9827403 chr2:9936360~9939590:+ LIHC cis rs287982 0.935 rs1119632 ENSG00000269973.1 RP11-95D17.1 -3.7 0.00025 0.0387 -0.18 -0.2 Nonsyndromic cleft lip with cleft palate; chr2:9827535 chr2:9936360~9939590:+ LIHC cis rs916888 0.61 rs199438 ENSG00000262881.1 RP11-669E14.4 -3.7 0.00025 0.0387 -0.21 -0.2 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:45907670~45910779:- LIHC cis rs4819852 1 rs1034565 ENSG00000215493.3 XXbac-B562F10.11 3.7 0.00025 0.0387 0.17 0.2 Pulse pressure; chr22:19996688 chr22:20450122~20451824:+ LIHC cis rs3764021 0.506 rs11052372 ENSG00000256673.1 RP11-599J14.2 -3.7 0.00025 0.0387 -0.21 -0.2 Type 1 diabetes; chr12:9679363 chr12:9398355~9414851:- LIHC cis rs7893279 0.543 rs7086757 ENSG00000225527.1 RP11-383B4.4 3.7 0.00025 0.0387 0.28 0.2 Schizophrenia;Autism spectrum disorder or schizophrenia; chr10:18597832 chr10:18531849~18533336:- LIHC cis rs2976388 0.556 rs10956985 ENSG00000253741.1 CTD-2292P10.4 3.7 0.00025 0.0387 0.25 0.2 Urinary tract infection frequency; chr8:142737332 chr8:142702252~142726973:- LIHC cis rs13113518 0.776 rs13124436 ENSG00000272969.1 RP11-528I4.2 3.7 0.00025 0.0387 0.22 0.2 Height; chr4:55502504 chr4:55547112~55547889:+ LIHC cis rs13113518 0.783 rs6843997 ENSG00000272969.1 RP11-528I4.2 3.7 0.00025 0.0387 0.22 0.2 Height; chr4:55508982 chr4:55547112~55547889:+ LIHC cis rs13113518 0.783 rs12508367 ENSG00000272969.1 RP11-528I4.2 3.7 0.00025 0.0387 0.22 0.2 Height; chr4:55509442 chr4:55547112~55547889:+ LIHC cis rs13113518 0.812 rs2272073 ENSG00000272969.1 RP11-528I4.2 3.7 0.00025 0.0387 0.22 0.2 Height; chr4:55510177 chr4:55547112~55547889:+ LIHC cis rs10411161 0.938 rs17778649 ENSG00000269483.1 AC006272.1 3.7 0.00025 0.0387 0.26 0.2 Breast cancer; chr19:51878363 chr19:51839924~51843324:- LIHC cis rs643506 0.874 rs618031 ENSG00000230911.1 PPIHP1 -3.7 0.00025 0.0387 -0.26 -0.2 Breast cancer; chr11:111778139 chr11:112029858~112030367:- LIHC cis rs17818399 0.541 rs12712976 ENSG00000239332.4 LINC01119 -3.7 0.00025 0.0387 -0.27 -0.2 Height; chr2:46559352 chr2:46816697~46859007:+ LIHC cis rs7809950 0.723 rs2237662 ENSG00000238832.1 snoU109 -3.7 0.00025 0.0387 -0.26 -0.2 Coronary artery disease; chr7:107233620 chr7:107603363~107603507:+ LIHC cis rs4787491 0.729 rs11642399 ENSG00000250616.2 RP11-455F5.3 3.7 0.00025 0.0387 0.2 0.2 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30048272 chr16:30096430~30104116:+ LIHC cis rs67981189 0.896 rs17108822 ENSG00000274818.1 RP1-292L20.3 3.7 0.00025 0.0388 0.22 0.2 Schizophrenia; chr14:70979189 chr14:70906657~70907111:- LIHC cis rs10851478 0.692 rs12899680 ENSG00000276593.1 RP11-295H24.5 3.7 0.00025 0.0388 0.22 0.2 Oral cavity cancer; chr15:49579681 chr15:49353485~49354034:+ LIHC cis rs2638953 0.962 rs10771408 ENSG00000247934.4 RP11-967K21.1 -3.7 0.000251 0.0388 -0.26 -0.2 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28147679 chr12:28163298~28190738:- LIHC cis rs7712401 0.715 rs15577 ENSG00000263432.2 RN7SL689P -3.7 0.000251 0.0388 -0.28 -0.2 Mean platelet volume; chr5:123023495 chr5:123022487~123022783:- LIHC cis rs7712401 0.715 rs451195 ENSG00000263432.2 RN7SL689P -3.7 0.000251 0.0388 -0.28 -0.2 Mean platelet volume; chr5:123023945 chr5:123022487~123022783:- LIHC cis rs7712401 0.715 rs6862366 ENSG00000263432.2 RN7SL689P -3.7 0.000251 0.0388 -0.28 -0.2 Mean platelet volume; chr5:123024463 chr5:123022487~123022783:- LIHC cis rs2283792 0.765 rs7290469 ENSG00000224086.5 LL22NC03-86G7.1 -3.7 0.000251 0.0388 -0.2 -0.2 Multiple sclerosis; chr22:21796693 chr22:21938293~21977632:+ LIHC cis rs8012947 0.565 rs12891852 ENSG00000279636.2 LINC00216 -3.7 0.000251 0.0388 -0.17 -0.2 Alcohol consumption in current drinkers; chr14:58330922 chr14:58288033~58289158:+ LIHC cis rs950776 1 rs950776 ENSG00000261762.1 RP11-650L12.2 3.7 0.000251 0.0388 0.26 0.2 Sudden cardiac arrest; chr15:78633676 chr15:78589123~78591276:- LIHC cis rs1023500 0.573 rs2269524 ENSG00000226450.2 CYP2D8P -3.7 0.000251 0.0388 -0.24 -0.2 Schizophrenia; chr22:42079699 chr22:42149886~42155001:- LIHC cis rs9876781 0.56 rs2362451 ENSG00000229759.1 MRPS18AP1 -3.7 0.000251 0.0388 -0.2 -0.2 Longevity; chr3:48358338 chr3:48256350~48256938:- LIHC cis rs2243480 1 rs9769882 ENSG00000228409.4 CCT6P1 -3.7 0.000251 0.0388 -0.21 -0.2 Diabetic kidney disease; chr7:66177938 chr7:65751142~65763354:+ LIHC cis rs7044106 0.708 rs991121 ENSG00000238181.2 AHCYP2 -3.7 0.000251 0.0388 -0.22 -0.2 Hip circumference adjusted for BMI; chr9:120608067 chr9:120720673~120721972:+ LIHC cis rs6142102 0.961 rs909884 ENSG00000275784.1 RP5-1125A11.6 -3.7 0.000251 0.0388 -0.23 -0.2 Skin pigmentation; chr20:34058257 chr20:33989480~33991818:- LIHC cis rs11233413 0.874 rs17505158 ENSG00000246067.6 RAB30-AS1 3.7 0.000251 0.0388 0.27 0.2 Economic and political preferences (feminism/equality); chr11:83064699 chr11:83072066~83106719:+ LIHC cis rs17373728 0.526 rs13275074 ENSG00000249395.2 CASC9 -3.7 0.000251 0.0388 -0.21 -0.2 Diabetic kidney disease; chr8:75247125 chr8:75223404~75324741:- LIHC cis rs4713118 0.662 rs9380046 ENSG00000219891.2 ZSCAN12P1 3.7 0.000251 0.0388 0.28 0.2 Parkinson's disease; chr6:28062721 chr6:28091154~28093664:+ LIHC cis rs10991814 0.528 rs9792678 ENSG00000230537.1 RP11-305L7.1 -3.7 0.000251 0.0388 -0.23 -0.2 Neutrophil percentage of granulocytes; chr9:91206358 chr9:91104957~91107304:- LIHC cis rs12817211 0.524 rs10876000 ENSG00000272368.2 RP4-605O3.4 -3.7 0.000251 0.0388 -0.22 -0.2 Colorectal or endometrial cancer; chr12:50128431 chr12:50112197~50165618:+ LIHC cis rs10871290 0.801 rs3851726 ENSG00000262904.1 TMPOP2 3.7 0.000251 0.0388 0.18 0.2 Breast cancer; chr16:74437746 chr16:74667506~74668706:+ LIHC cis rs1115240 0.642 rs2207560 ENSG00000257842.4 NOVA1-AS1 -3.7 0.000251 0.0388 -0.19 -0.2 Educational attainment (years of education); chr14:26666402 chr14:26598412~26806467:+ LIHC cis rs433598 0.798 rs234280 ENSG00000260201.2 RP11-143N13.2 -3.7 0.000251 0.0388 -0.21 -0.2 Schizophrenia; chr16:20677618 chr16:20580999~20586640:+ LIHC cis rs11096990 0.964 rs35494908 ENSG00000249207.1 RP11-360F5.1 3.7 0.000251 0.0388 0.23 0.2 Cognitive function; chr4:39252574 chr4:39112677~39126818:- LIHC cis rs733175 0.953 rs4485819 ENSG00000250413.1 RP11-448G15.1 -3.7 0.000251 0.0388 -0.29 -0.2 Psychosis and Alzheimer's disease; chr4:10035769 chr4:10006482~10009725:+ LIHC cis rs9467773 1 rs12526680 ENSG00000261353.1 CTA-14H9.5 -3.7 0.000251 0.0389 -0.19 -0.2 Intelligence (multi-trait analysis); chr6:26550726 chr6:26527063~26527404:+ LIHC cis rs7989332 1 rs7320606 ENSG00000275964.1 RP11-61K9.3 -3.7 0.000251 0.0389 -0.26 -0.2 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20478382 chr13:19863858~19865048:+ LIHC cis rs944797 0.643 rs10757270 ENSG00000224854.3 CDKN2A-AS1 -3.7 0.000251 0.0389 -0.21 -0.2 Coronary heart disease; chr9:22072720 chr9:21966929~21967751:+ LIHC cis rs6430553 0.964 rs62168869 ENSG00000224043.6 CCNT2-AS1 -3.7 0.000251 0.0389 -0.23 -0.2 Blood metabolite levels; chr2:134889209 chr2:134735464~134918710:- LIHC cis rs12554020 0.591 rs2989754 ENSG00000227603.1 RP11-165J3.6 -3.7 0.000251 0.0389 -0.23 -0.2 Schizophrenia; chr9:93613875 chr9:93435332~93437121:- LIHC cis rs2998286 0.541 rs332180 ENSG00000254635.4 WAC-AS1 -3.7 0.000251 0.0389 -0.27 -0.2 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28621166 chr10:28522652~28532743:- LIHC cis rs2998286 0.678 rs332184 ENSG00000254635.4 WAC-AS1 -3.7 0.000251 0.0389 -0.27 -0.2 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28624042 chr10:28522652~28532743:- LIHC cis rs78487399 0.71 rs74382177 ENSG00000234936.1 AC010883.5 3.7 0.000252 0.0389 0.44 0.2 Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease; chr2:43300918 chr2:43229573~43233394:+ LIHC cis rs4845875 0.504 rs198396 ENSG00000242349.4 NPPA-AS1 -3.7 0.000252 0.0389 -0.24 -0.2 Midregional pro atrial natriuretic peptide levels; chr1:11821263 chr1:11841017~11848079:+ LIHC cis rs2976388 0.967 rs2976397 ENSG00000253741.1 CTD-2292P10.4 3.7 0.000252 0.0389 0.24 0.2 Urinary tract infection frequency; chr8:142683195 chr8:142702252~142726973:- LIHC cis rs2976388 0.967 rs2585183 ENSG00000253741.1 CTD-2292P10.4 3.7 0.000252 0.0389 0.24 0.2 Urinary tract infection frequency; chr8:142684641 chr8:142702252~142726973:- LIHC cis rs4604234 0.614 rs73479932 ENSG00000272129.1 RP11-250B2.6 -3.7 0.000252 0.0389 -0.34 -0.2 Cancer; chr6:80132154 chr6:80355424~80356859:+ LIHC cis rs1396626 0.926 rs12353949 ENSG00000230427.1 RP11-313A24.1 3.7 0.000252 0.0389 0.31 0.2 Diabetic kidney disease; chr1:95547422 chr1:95061596~95067545:+ LIHC cis rs3809912 0.546 rs12957584 ENSG00000266969.1 RP11-773H22.4 -3.7 0.000252 0.0389 -0.29 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr18:13178896 chr18:12984694~12991173:- LIHC cis rs858239 0.699 rs955187 ENSG00000226816.2 AC005082.12 -3.7 0.000252 0.0389 -0.23 -0.2 Cerebrospinal fluid biomarker levels; chr7:23154986 chr7:23206013~23208045:+ LIHC cis rs2115630 1 rs56074163 ENSG00000189136.7 UBE2Q2P1 -3.7 0.000252 0.0389 -0.16 -0.2 P wave terminal force; chr15:84808101 chr15:84526781~84571216:- LIHC cis rs17660992 0.603 rs8108345 ENSG00000273837.1 LLNLR-470E3.1 -3.7 0.000252 0.0389 -0.23 -0.2 Blood protein levels; chr19:51661033 chr19:51639478~51639931:- LIHC cis rs17660992 0.603 rs2167422 ENSG00000273837.1 LLNLR-470E3.1 -3.7 0.000252 0.0389 -0.23 -0.2 Blood protein levels; chr19:51661130 chr19:51639478~51639931:- LIHC cis rs11719291 0.915 rs9834996 ENSG00000270441.1 RP11-694I15.7 3.7 0.000252 0.039 0.41 0.2 Cognitive function; chr3:48717444 chr3:49140086~49160851:- LIHC cis rs2627282 0.577 rs921781 ENSG00000253696.2 KBTBD11-OT1 -3.7 0.000252 0.039 -0.22 -0.2 Blood pressure measurement (high sodium intervention); chr8:2914789 chr8:1971397~1976478:+ LIHC cis rs2274273 0.905 rs8007614 ENSG00000258413.1 RP11-665C16.6 -3.7 0.000252 0.039 -0.22 -0.2 Protein biomarker; chr14:55119857 chr14:55262767~55272075:- LIHC cis rs9907295 1 rs11080360 ENSG00000270871.1 AC015849.19 3.7 0.000252 0.039 0.21 0.2 Fibroblast growth factor basic levels; chr17:35916086 chr17:35816717~35830293:- LIHC cis rs9907295 1 rs11869976 ENSG00000270871.1 AC015849.19 3.7 0.000252 0.039 0.21 0.2 Fibroblast growth factor basic levels; chr17:35916492 chr17:35816717~35830293:- LIHC cis rs6445975 0.956 rs7631010 ENSG00000272360.1 RP11-359I18.5 3.7 0.000252 0.039 0.25 0.2 Systemic lupus erythematosus; chr3:58460283 chr3:58490830~58491291:- LIHC cis rs875971 0.545 rs73142265 ENSG00000273024.4 INTS4P2 -3.7 0.000252 0.039 -0.22 -0.2 Aortic root size; chr7:66234510 chr7:65647864~65715661:+ LIHC cis rs12379034 0.522 rs62577973 ENSG00000227355.1 RP11-162D16.2 -3.7 0.000252 0.039 -0.48 -0.2 Rheumatoid arthritis; chr9:120440719 chr9:121375241~121452177:+ LIHC cis rs12468226 1 rs3731696 ENSG00000272966.1 RP11-686O6.1 3.7 0.000252 0.039 0.34 0.2 Urate levels; chr2:202567081 chr2:202336739~202337200:+ LIHC cis rs12468226 0.81 rs115255999 ENSG00000272966.1 RP11-686O6.1 3.7 0.000252 0.039 0.34 0.2 Urate levels; chr2:202572326 chr2:202336739~202337200:+ LIHC cis rs11710088 0.74 rs73152634 ENSG00000244503.1 RP11-278L15.6 3.7 0.000252 0.039 0.25 0.2 QRS duration; chr3:149478717 chr3:149494660~149495995:+ LIHC cis rs4713118 0.662 rs149900 ENSG00000219891.2 ZSCAN12P1 3.7 0.000252 0.039 0.28 0.2 Parkinson's disease; chr6:28046819 chr6:28091154~28093664:+ LIHC cis rs11096990 0.964 rs6842390 ENSG00000249685.1 RP11-360F5.3 -3.7 0.000252 0.039 -0.26 -0.2 Cognitive function; chr4:39261862 chr4:39133913~39135608:+ LIHC cis rs67311347 1 rs6801185 ENSG00000223797.4 ENTPD3-AS1 -3.7 0.000252 0.039 -0.16 -0.2 Renal cell carcinoma; chr3:40463569 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs13095055 ENSG00000223797.4 ENTPD3-AS1 -3.7 0.000252 0.039 -0.16 -0.2 Renal cell carcinoma; chr3:40464175 chr3:40313802~40453329:- LIHC cis rs67311347 0.956 rs9822870 ENSG00000223797.4 ENTPD3-AS1 -3.7 0.000252 0.039 -0.16 -0.2 Renal cell carcinoma; chr3:40473399 chr3:40313802~40453329:- LIHC cis rs3749237 0.595 rs4855839 ENSG00000270441.1 RP11-694I15.7 -3.7 0.000252 0.039 -0.27 -0.2 Resting heart rate; chr3:49470414 chr3:49140086~49160851:- LIHC cis rs3749237 0.595 rs4855864 ENSG00000270441.1 RP11-694I15.7 -3.7 0.000252 0.039 -0.27 -0.2 Resting heart rate; chr3:49484541 chr3:49140086~49160851:- LIHC cis rs3749237 0.595 rs11130199 ENSG00000270441.1 RP11-694I15.7 -3.7 0.000252 0.039 -0.27 -0.2 Resting heart rate; chr3:49501366 chr3:49140086~49160851:- LIHC cis rs7809950 0.822 rs2712228 ENSG00000238832.1 snoU109 3.7 0.000252 0.039 0.22 0.2 Coronary artery disease; chr7:107659895 chr7:107603363~107603507:+ LIHC cis rs67981189 0.647 rs36555 ENSG00000274818.1 RP1-292L20.3 -3.7 0.000253 0.039 -0.22 -0.2 Schizophrenia; chr14:70897844 chr14:70906657~70907111:- LIHC cis rs35934224 0.771 rs34820460 ENSG00000232926.1 AC000078.5 3.7 0.000253 0.039 0.24 0.2 Glaucoma (primary open-angle); chr22:19881687 chr22:19887289~19887970:+ LIHC cis rs11159086 0.793 rs11625502 ENSG00000270000.1 RP3-449M8.9 3.7 0.000253 0.039 0.28 0.2 Advanced glycation end-product levels; chr14:74468309 chr14:74471930~74472360:- LIHC cis rs12370990 0.546 rs12371771 ENSG00000257261.4 RP11-96H19.1 3.7 0.000253 0.039 0.33 0.2 Post bronchodilator FEV1 in COPD; chr12:46117599 chr12:46383679~46876159:+ LIHC cis rs931127 0.719 rs7949980 ENSG00000265874.1 MIR4489 -3.7 0.000253 0.039 -0.23 -0.2 Systemic lupus erythematosus; chr11:65678479 chr11:65649192~65649253:+ LIHC cis rs9900497 0.504 rs2228100 ENSG00000262769.1 RP11-1113L8.1 3.7 0.000253 0.039 0.19 0.2 Response to paliperidone in schizophrenia (CGI-S score); chr17:19739639 chr17:19560111~19597922:- LIHC cis rs2933343 0.951 rs7648327 ENSG00000261159.1 RP11-723O4.9 3.7 0.000253 0.039 0.26 0.2 IgG glycosylation; chr3:128851865 chr3:128859716~128860526:- LIHC cis rs899997 0.862 rs11072787 ENSG00000261762.1 RP11-650L12.2 -3.7 0.000253 0.039 -0.24 -0.2 Coronary artery disease or large artery stroke; chr15:78680635 chr15:78589123~78591276:- LIHC cis rs11064837 0.523 rs7310266 ENSG00000248636.5 RP11-768F21.1 3.7 0.000253 0.039 0.34 0.2 Schizophrenia; chr12:119660604 chr12:119387987~119668079:- LIHC cis rs11064837 0.523 rs1978108 ENSG00000248636.5 RP11-768F21.1 3.7 0.000253 0.039 0.34 0.2 Schizophrenia; chr12:119664448 chr12:119387987~119668079:- LIHC cis rs11064837 0.523 rs11064873 ENSG00000248636.5 RP11-768F21.1 3.7 0.000253 0.039 0.34 0.2 Schizophrenia; chr12:119667187 chr12:119387987~119668079:- LIHC cis rs2745572 0.515 rs2250686 ENSG00000272279.1 RP11-157J24.2 -3.7 0.000253 0.0391 -0.24 -0.2 Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure); chr6:1548909 chr6:1528364~1528911:- LIHC cis rs4237845 0.514 rs4760339 ENSG00000270039.1 RP11-571M6.17 -3.7 0.000253 0.0391 -0.28 -0.2 Intelligence (multi-trait analysis); chr12:57874366 chr12:57803838~57804415:+ LIHC cis rs74233809 0.901 rs3824755 ENSG00000236937.2 PTGES3P4 3.7 0.000253 0.0391 0.29 0.2 Birth weight; chr10:102836092 chr10:102845595~102845950:+ LIHC cis rs803903 0.605 rs13296745 ENSG00000230894.1 RP11-67K19.3 3.7 0.000253 0.0391 0.27 0.2 Breast cancer; chr9:116492593 chr9:116568449~116586328:+ LIHC cis rs919433 0.75 rs788010 ENSG00000231621.1 AC013264.2 -3.7 0.000253 0.0391 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197366225 chr2:197197991~197199273:+ LIHC cis rs919433 0.783 rs2565165 ENSG00000231621.1 AC013264.2 -3.7 0.000253 0.0391 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197368851 chr2:197197991~197199273:+ LIHC cis rs919433 0.783 rs788007 ENSG00000231621.1 AC013264.2 -3.7 0.000253 0.0391 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197368952 chr2:197197991~197199273:+ LIHC cis rs919433 0.783 rs2565155 ENSG00000231621.1 AC013264.2 -3.7 0.000253 0.0391 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197371701 chr2:197197991~197199273:+ LIHC cis rs919433 0.783 rs3097383 ENSG00000231621.1 AC013264.2 -3.7 0.000253 0.0391 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197372163 chr2:197197991~197199273:+ LIHC cis rs919433 0.662 rs2043018 ENSG00000231621.1 AC013264.2 -3.7 0.000253 0.0391 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197372234 chr2:197197991~197199273:+ LIHC cis rs4578769 0.765 rs12456384 ENSG00000265943.1 RP11-739L10.1 -3.7 0.000253 0.0391 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22841032 chr18:22699481~22933764:- LIHC cis rs6048205 1 rs2277762 ENSG00000259974.2 LINC00261 -3.7 0.000253 0.0391 -0.3 -0.2 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22567645 chr20:22547671~22578642:- LIHC cis rs1440410 0.835 rs7684847 ENSG00000250326.1 RP11-284M14.1 -3.7 0.000253 0.0391 -0.22 -0.2 Ischemic stroke; chr4:143133414 chr4:142933195~143184861:- LIHC cis rs1405130 0.839 rs4663156 ENSG00000224287.2 MSL3P1 3.7 0.000253 0.0391 0.24 0.2 Coronary artery disease; chr2:234672717 chr2:233865437~233868444:- LIHC cis rs919433 0.75 rs788012 ENSG00000231621.1 AC013264.2 -3.7 0.000253 0.0391 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197365132 chr2:197197991~197199273:+ LIHC cis rs6142102 0.847 rs4911413 ENSG00000275784.1 RP5-1125A11.6 -3.7 0.000253 0.0391 -0.22 -0.2 Skin pigmentation; chr20:34133969 chr20:33989480~33991818:- LIHC cis rs6142102 1 rs2143230 ENSG00000275784.1 RP5-1125A11.6 -3.7 0.000253 0.0391 -0.22 -0.2 Skin pigmentation; chr20:34136539 chr20:33989480~33991818:- LIHC cis rs42490 0.635 rs42186 ENSG00000251136.7 RP11-37B2.1 -3.7 0.000253 0.0391 -0.17 -0.2 Leprosy; chr8:89827257 chr8:89609409~89757727:- LIHC cis rs17376456 0.877 rs2290937 ENSG00000251023.1 RP11-549J18.1 -3.7 0.000253 0.0391 -0.42 -0.2 Diabetic retinopathy; chr5:94020810 chr5:93860669~93863825:- LIHC cis rs2919917 0.628 rs1384803 ENSG00000254352.1 RP11-578O24.2 -3.7 0.000253 0.0391 -0.29 -0.2 Lymphocyte counts; chr8:78669393 chr8:78723796~78724136:- LIHC cis rs9573567 0.881 rs1570541 ENSG00000261553.4 RP11-29G8.3 3.7 0.000254 0.0391 0.29 0.2 Red blood cell count;Mean corpuscular volume; chr13:75500729 chr13:75549773~75807120:+ LIHC cis rs7712401 0.562 rs246267 ENSG00000263432.2 RN7SL689P 3.7 0.000254 0.0391 0.29 0.2 Mean platelet volume; chr5:122920409 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs246269 ENSG00000263432.2 RN7SL689P 3.7 0.000254 0.0391 0.29 0.2 Mean platelet volume; chr5:122921046 chr5:123022487~123022783:- LIHC cis rs673078 0.607 rs55929628 ENSG00000275759.1 RP11-131L12.3 -3.7 0.000254 0.0391 -0.42 -0.2 Glucose homeostasis traits; chr12:118371332 chr12:118428281~118428870:+ LIHC cis rs673078 0.517 rs73205578 ENSG00000275759.1 RP11-131L12.3 -3.7 0.000254 0.0391 -0.42 -0.2 Glucose homeostasis traits; chr12:118385113 chr12:118428281~118428870:+ LIHC cis rs673078 0.66 rs73205579 ENSG00000275759.1 RP11-131L12.3 -3.7 0.000254 0.0391 -0.42 -0.2 Glucose homeostasis traits; chr12:118385125 chr12:118428281~118428870:+ LIHC cis rs3096299 0.838 rs4785561 ENSG00000260259.1 RP11-368I7.4 3.7 0.000254 0.0391 0.22 0.2 Multiple myeloma (IgH translocation); chr16:89362644 chr16:89682620~89686569:- LIHC cis rs7617773 0.743 rs6804986 ENSG00000228638.1 FCF1P2 -3.7 0.000254 0.0391 -0.22 -0.2 Coronary artery disease; chr3:48322105 chr3:48290793~48291375:- LIHC cis rs6964833 0.935 rs13238996 ENSG00000277053.3 GTF2IP1 -3.7 0.000254 0.0391 -0.26 -0.2 Menarche (age at onset); chr7:74655318 chr7:75185385~75237696:- LIHC cis rs9309473 0.5 rs4852953 ENSG00000204872.3 NAT8B -3.7 0.000254 0.0391 -0.26 -0.2 Metabolite levels; chr2:73642781 chr2:73700576~73701340:- LIHC cis rs6723226 0.803 rs176415 ENSG00000276334.1 AL133243.1 -3.7 0.000254 0.0392 -0.22 -0.2 Intelligence (multi-trait analysis); chr2:32424710 chr2:32521927~32523547:+ LIHC cis rs2976388 0.609 rs2717550 ENSG00000253196.1 RP11-706C16.7 3.7 0.000254 0.0392 0.19 0.2 Urinary tract infection frequency; chr8:142706390 chr8:142763116~142766427:+ LIHC cis rs9652601 0.959 rs9888908 ENSG00000274038.1 RP11-66H6.4 -3.7 0.000254 0.0392 -0.24 -0.2 Systemic lupus erythematosus; chr16:11087387 chr16:11056556~11057034:+ LIHC cis rs2117029 1 rs11168839 ENSG00000258017.1 RP11-386G11.10 3.7 0.000254 0.0392 0.22 0.2 Intelligence (multi-trait analysis); chr12:49063852 chr12:49127782~49147869:+ LIHC cis rs9595908 0.785 rs969703 ENSG00000212293.1 SNORA16 3.7 0.000254 0.0392 0.22 0.2 Body mass index; chr13:32708264 chr13:32420390~32420516:- LIHC cis rs55794721 0.509 rs2375313 ENSG00000224183.1 SDHDP6 -3.7 0.000254 0.0392 -0.23 -0.2 Mean corpuscular volume;Plateletcrit; chr1:25421744 chr1:25294164~25294643:- LIHC cis rs7412746 0.611 rs10888395 ENSG00000231073.1 RP11-316M1.3 3.7 0.000254 0.0392 0.2 0.2 Melanoma; chr1:150789695 chr1:150973123~150975534:+ LIHC cis rs673078 0.607 rs4767671 ENSG00000275759.1 RP11-131L12.3 -3.7 0.000254 0.0392 -0.42 -0.2 Glucose homeostasis traits; chr12:118396038 chr12:118428281~118428870:+ LIHC cis rs11098403 0.753 rs4833553 ENSG00000260404.2 RP11-384K6.6 3.7 0.000254 0.0392 0.13 0.2 Schizophrenia; chr4:117844055 chr4:118591773~118633729:+ LIHC cis rs6832769 0.961 rs1011095 ENSG00000272969.1 RP11-528I4.2 3.7 0.000254 0.0392 0.23 0.2 Personality dimensions; chr4:55398774 chr4:55547112~55547889:+ LIHC cis rs1075265 0.656 rs2542574 ENSG00000272156.1 RP11-477N3.1 -3.7 0.000254 0.0393 -0.23 -0.2 Chronotype;Morning vs. evening chronotype; chr2:53820295 chr2:54082554~54085066:+ LIHC cis rs9307551 1 rs1371989 ENSG00000250334.4 LINC00989 3.7 0.000254 0.0393 0.26 0.2 Refractive error; chr4:79600692 chr4:79492416~79576460:+ LIHC cis rs6860806 0.507 rs200837 ENSG00000263597.1 MIR3936 3.7 0.000254 0.0393 0.21 0.2 Breast cancer; chr5:132364266 chr5:132365490~132365599:- LIHC cis rs6997458 0.776 rs1496531 ENSG00000253549.4 RP11-317J10.2 -3.7 0.000255 0.0393 -0.21 -0.2 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85341833 chr8:85441851~85464915:- LIHC cis rs886774 0.866 rs2108230 ENSG00000273055.1 CTB-13F3.1 3.7 0.000255 0.0393 0.21 0.2 Ulcerative colitis; chr7:107875079 chr7:107942116~107942740:+ LIHC cis rs919433 0.783 rs2565158 ENSG00000231621.1 AC013264.2 -3.7 0.000255 0.0393 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197371379 chr2:197197991~197199273:+ LIHC cis rs683257 0.714 rs9495866 ENSG00000234147.1 RP3-460G2.2 -3.7 0.000255 0.0393 -0.36 -0.2 Facial emotion recognition (angry faces); chr6:140933740 chr6:140845958~140852924:- LIHC cis rs6142102 0.961 rs6120519 ENSG00000275784.1 RP5-1125A11.6 -3.7 0.000255 0.0393 -0.22 -0.2 Skin pigmentation; chr20:34100307 chr20:33989480~33991818:- LIHC cis rs2776353 0.836 rs2849691 ENSG00000235772.1 AP001625.6 -3.7 0.000255 0.0393 -0.2 -0.2 Basal cell carcinoma; chr21:41665910 chr21:42560374~42561934:- LIHC cis rs34734847 1 rs2948149 ENSG00000277423.1 RP11-173P15.9 3.7 0.000255 0.0393 0.21 0.2 Mean corpuscular volume; chr12:120725051 chr12:120703867~120704282:+ LIHC cis rs12817211 0.524 rs2204683 ENSG00000272368.2 RP4-605O3.4 -3.7 0.000255 0.0393 -0.22 -0.2 Colorectal or endometrial cancer; chr12:50128593 chr12:50112197~50165618:+ LIHC cis rs34734847 0.703 rs3794215 ENSG00000241030.1 RPL29P24 3.7 0.000255 0.0393 0.19 0.2 Mean corpuscular volume; chr12:120730280 chr12:120522664~120523443:- LIHC cis rs4792901 0.918 rs79158595 ENSG00000279602.1 CTD-3014M21.1 -3.7 0.000255 0.0393 -0.23 -0.2 Dupuytren's disease; chr17:43545844 chr17:43360041~43361361:- LIHC cis rs4792901 0.959 rs3765174 ENSG00000279602.1 CTD-3014M21.1 -3.7 0.000255 0.0393 -0.23 -0.2 Dupuytren's disease; chr17:43546302 chr17:43360041~43361361:- LIHC cis rs7674212 0.531 rs4698876 ENSG00000248971.2 KRT8P46 -3.7 0.000255 0.0393 -0.2 -0.2 Type 2 diabetes; chr4:103012410 chr4:102728746~102730171:- LIHC cis rs7674212 0.531 rs7665026 ENSG00000248971.2 KRT8P46 -3.7 0.000255 0.0393 -0.2 -0.2 Type 2 diabetes; chr4:103015491 chr4:102728746~102730171:- LIHC cis rs9907295 0.901 rs4796119 ENSG00000270871.1 AC015849.19 -3.7 0.000255 0.0393 -0.21 -0.2 Fibroblast growth factor basic levels; chr17:35866084 chr17:35816717~35830293:- LIHC cis rs1200821 0.529 rs4934856 ENSG00000099251.13 HSD17B7P2 -3.7 0.000255 0.0393 -0.23 -0.2 Hemostatic factors and hematological phenotypes; chr10:37518919 chr10:38356380~38378505:+ LIHC cis rs2115630 0.691 rs2292462 ENSG00000275120.1 RP11-182J1.17 -3.7 0.000255 0.0393 -0.27 -0.2 P wave terminal force; chr15:84657523 chr15:84599434~84606463:- LIHC cis rs3934487 0.547 rs9326038 ENSG00000223956.1 RP4-710M16.2 3.7 0.000255 0.0393 0.21 0.2 Reticulocyte count; chr1:55860620 chr1:56414963~56415966:+ LIHC cis rs4650994 0.816 rs2811304 ENSG00000213057.5 C1orf220 -3.7 0.000255 0.0393 -0.16 -0.2 HDL cholesterol;HDL cholesterol levels; chr1:178627659 chr1:178542752~178548889:+ LIHC cis rs2976388 0.669 rs2585135 ENSG00000253741.1 CTD-2292P10.4 3.7 0.000255 0.0393 0.24 0.2 Urinary tract infection frequency; chr8:142732775 chr8:142702252~142726973:- LIHC cis rs9595908 0.869 rs9595962 ENSG00000212293.1 SNORA16 3.7 0.000255 0.0394 0.22 0.2 Body mass index; chr13:32634429 chr13:32420390~32420516:- LIHC cis rs9595908 0.869 rs2320301 ENSG00000212293.1 SNORA16 3.7 0.000255 0.0394 0.22 0.2 Body mass index; chr13:32635067 chr13:32420390~32420516:- LIHC cis rs7712401 0.546 rs10044921 ENSG00000263432.2 RN7SL689P 3.7 0.000255 0.0394 0.27 0.2 Mean platelet volume; chr5:122843662 chr5:123022487~123022783:- LIHC cis rs2439831 0.867 rs2278860 ENSG00000205771.5 CATSPER2P1 3.7 0.000255 0.0394 0.27 0.2 Lung cancer in ever smokers; chr15:43366848 chr15:43726918~43747094:- LIHC cis rs67981189 0.892 rs221899 ENSG00000274818.1 RP1-292L20.3 3.7 0.000255 0.0394 0.21 0.2 Schizophrenia; chr14:71138551 chr14:70906657~70907111:- LIHC cis rs7985 0.901 rs5761679 ENSG00000244625.4 MIATNB 3.7 0.000255 0.0394 0.21 0.2 Electroencephalogram traits; chr22:26681268 chr22:26672767~26780207:+ LIHC cis rs803903 0.57 rs6478237 ENSG00000230894.1 RP11-67K19.3 -3.7 0.000255 0.0394 -0.24 -0.2 Breast cancer; chr9:116430237 chr9:116568449~116586328:+ LIHC cis rs9907295 0.901 rs74622050 ENSG00000270871.1 AC015849.19 3.7 0.000255 0.0394 0.21 0.2 Fibroblast growth factor basic levels; chr17:35895939 chr17:35816717~35830293:- LIHC cis rs8060686 0.623 rs6499162 ENSG00000261469.1 RP11-96D1.6 -3.7 0.000255 0.0394 -0.22 -0.2 HDL cholesterol;Metabolic syndrome; chr16:68205557 chr16:68236845~68237667:- LIHC cis rs2243480 1 rs437889 ENSG00000229886.1 RP5-1132H15.3 3.7 0.000255 0.0394 0.29 0.2 Diabetic kidney disease; chr7:66044247 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs402418 ENSG00000229886.1 RP5-1132H15.3 3.7 0.000255 0.0394 0.29 0.2 Diabetic kidney disease; chr7:66044482 chr7:66025126~66031544:- LIHC cis rs2243480 0.803 rs423187 ENSG00000229886.1 RP5-1132H15.3 3.7 0.000255 0.0394 0.29 0.2 Diabetic kidney disease; chr7:66044512 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs431318 ENSG00000229886.1 RP5-1132H15.3 3.7 0.000255 0.0394 0.29 0.2 Diabetic kidney disease; chr7:66046610 chr7:66025126~66031544:- LIHC cis rs4388249 0.578 rs427691 ENSG00000271849.1 CTC-332L22.1 -3.7 0.000256 0.0394 -0.25 -0.2 Schizophrenia; chr5:109678809 chr5:109687802~109688329:- LIHC cis rs6471393 0.964 rs56282609 ENSG00000253848.1 RP11-10N23.5 3.7 0.000256 0.0394 0.21 0.2 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93737852 chr8:93741193~93744534:+ LIHC cis rs9747201 1 rs56051385 ENSG00000279692.1 RP11-1055B8.1 -3.7 0.000256 0.0394 -0.34 -0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82168836 chr17:81395609~81397144:- LIHC cis rs709400 0.93 rs10149249 ENSG00000258534.1 CTD-2134A5.4 3.7 0.000256 0.0394 0.28 0.2 Body mass index; chr14:103581420 chr14:103854366~103880111:- LIHC cis rs6449502 0.688 rs158920 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:60945441 chr5:60866457~60866935:- LIHC cis rs6449502 0.764 rs158925 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:60955977 chr5:60866457~60866935:- LIHC cis rs6449502 0.92 rs2928243 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:60966515 chr5:60866457~60866935:- LIHC cis rs6449502 0.92 rs182351 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:60968605 chr5:60866457~60866935:- LIHC cis rs6449502 0.92 rs2619891 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:60977972 chr5:60866457~60866935:- LIHC cis rs6449502 0.92 rs2619892 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:60978520 chr5:60866457~60866935:- LIHC cis rs6449502 0.92 rs167912 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:60989169 chr5:60866457~60866935:- LIHC cis rs6449502 0.92 rs329620 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:60992700 chr5:60866457~60866935:- LIHC cis rs6449502 0.92 rs329619 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:60992880 chr5:60866457~60866935:- LIHC cis rs6449502 0.92 rs290504 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:60999222 chr5:60866457~60866935:- LIHC cis rs6449502 0.92 rs162250 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:60999484 chr5:60866457~60866935:- LIHC cis rs6449502 0.844 rs2928246 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:61004082 chr5:60866457~60866935:- LIHC cis rs6449502 0.92 rs162239 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:61004808 chr5:60866457~60866935:- LIHC cis rs6449502 0.92 rs290508 ENSG00000272308.1 RP11-231G3.1 3.7 0.000256 0.0394 0.28 0.2 Mean platelet volume; chr5:61006972 chr5:60866457~60866935:- LIHC cis rs11123170 0.543 rs4849178 ENSG00000189223.12 PAX8-AS1 -3.7 0.000256 0.0394 -0.32 -0.2 Renal function-related traits (BUN); chr2:113225031 chr2:113211522~113276581:+ LIHC cis rs17345786 1 rs58907984 ENSG00000244119.1 PDCL3P4 3.7 0.000256 0.0394 0.22 0.2 Colonoscopy-negative controls vs population controls; chr3:101586326 chr3:101712472~101713191:+ LIHC cis rs79349575 0.655 rs62078384 ENSG00000248278.1 SUMO2P17 3.7 0.000256 0.0394 0.25 0.2 Type 2 diabetes; chr17:48967101 chr17:48874860~48908983:- LIHC cis rs7665090 1 rs4579121 ENSG00000230069.3 LRRC37A15P -3.69 0.000256 0.0395 -0.18 -0.2 Primary biliary cholangitis; chr4:102637012 chr4:102727274~102730721:- LIHC cis rs7665090 1 rs6810869 ENSG00000230069.3 LRRC37A15P -3.69 0.000256 0.0395 -0.18 -0.2 Primary biliary cholangitis; chr4:102637357 chr4:102727274~102730721:- LIHC cis rs7665090 0.934 rs6533020 ENSG00000230069.3 LRRC37A15P -3.69 0.000256 0.0395 -0.18 -0.2 Primary biliary cholangitis; chr4:102637648 chr4:102727274~102730721:- LIHC cis rs7665090 0.934 rs6533021 ENSG00000230069.3 LRRC37A15P -3.69 0.000256 0.0395 -0.18 -0.2 Primary biliary cholangitis; chr4:102637696 chr4:102727274~102730721:- LIHC cis rs2301573 1 rs75404673 ENSG00000251474.5 RPL32P3 3.69 0.000256 0.0395 0.24 0.2 Hip circumference; chr3:129577939 chr3:129382922~129399655:- LIHC cis rs929596 0.574 rs75444879 ENSG00000233445.1 RPL17P11 3.69 0.000256 0.0395 0.21 0.2 Total bilirubin levels in HIV-1 infection; chr2:233679202 chr2:233721522~233722065:- LIHC cis rs1193 1 rs1049457 ENSG00000266931.1 RP11-1252D15.1 3.69 0.000256 0.0395 0.26 0.2 High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count; chr2:86775905 chr2:87055658~87055800:- LIHC cis rs13434995 0.513 rs7660668 ENSG00000273257.1 RP11-177J6.1 3.69 0.000256 0.0395 0.32 0.2 Adiponectin levels; chr4:55535530 chr4:55387949~55388271:+ LIHC cis rs7809950 0.637 rs3801964 ENSG00000238832.1 snoU109 -3.69 0.000256 0.0395 -0.26 -0.2 Coronary artery disease; chr7:107195797 chr7:107603363~107603507:+ LIHC cis rs1075265 0.756 rs2542576 ENSG00000272156.1 RP11-477N3.1 -3.69 0.000256 0.0395 -0.23 -0.2 Chronotype;Morning vs. evening chronotype; chr2:53821659 chr2:54082554~54085066:+ LIHC cis rs494453 0.6 rs474860 ENSG00000227811.2 FAM212B-AS1 -3.69 0.000256 0.0395 -0.21 -0.2 Osteoporosis-related phenotypes; chr1:111672590 chr1:111739841~111747798:+ LIHC cis rs763121 0.853 rs1569492 ENSG00000273076.1 RP3-508I15.22 -3.69 0.000256 0.0395 -0.22 -0.2 Menopause (age at onset); chr22:38579506 chr22:38743495~38743910:+ LIHC cis rs17376456 0.877 rs10055741 ENSG00000251023.1 RP11-549J18.1 -3.69 0.000256 0.0395 -0.41 -0.2 Diabetic retinopathy; chr5:93961482 chr5:93860669~93863825:- LIHC cis rs4578769 0.759 rs1982565 ENSG00000266850.1 RP11-370A5.1 -3.69 0.000256 0.0395 -0.23 -0.2 Eosinophil percentage of white cells; chr18:22994861 chr18:22723491~22907721:- LIHC cis rs1005277 0.579 rs2505257 ENSG00000099251.13 HSD17B7P2 3.69 0.000256 0.0395 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38083736 chr10:38356380~38378505:+ LIHC cis rs11098403 0.753 rs4392571 ENSG00000260404.2 RP11-384K6.6 3.69 0.000256 0.0395 0.13 0.2 Schizophrenia; chr4:117846167 chr4:118591773~118633729:+ LIHC cis rs6832769 0.922 rs501679 ENSG00000272969.1 RP11-528I4.2 3.69 0.000256 0.0395 0.23 0.2 Personality dimensions; chr4:55371160 chr4:55547112~55547889:+ LIHC cis rs367615 0.704 rs11747622 ENSG00000249476.1 CTD-2587M2.1 3.69 0.000257 0.0395 0.23 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109509019 chr5:109237120~109326369:- LIHC cis rs367615 0.704 rs55956735 ENSG00000249476.1 CTD-2587M2.1 3.69 0.000257 0.0395 0.23 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109509341 chr5:109237120~109326369:- LIHC cis rs367615 0.704 rs7726991 ENSG00000249476.1 CTD-2587M2.1 3.69 0.000257 0.0395 0.23 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109511733 chr5:109237120~109326369:- LIHC cis rs367615 0.704 rs7705399 ENSG00000249476.1 CTD-2587M2.1 3.69 0.000257 0.0395 0.23 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109514650 chr5:109237120~109326369:- LIHC cis rs77204473 0.744 rs77661993 ENSG00000254851.1 RP11-109L13.1 3.69 0.000257 0.0395 0.39 0.2 Sum eosinophil basophil counts;Eosinophil counts; chr11:117139758 chr11:117135528~117138582:+ LIHC cis rs801193 0.569 rs2707824 ENSG00000232559.3 GS1-124K5.12 3.69 0.000257 0.0395 0.15 0.2 Aortic root size; chr7:66724256 chr7:66554588~66576923:- LIHC cis rs867371 1 rs1501372 ENSG00000259429.4 UBE2Q2P2 -3.69 0.000257 0.0395 -0.19 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82176114 chr15:82355142~82420075:+ LIHC cis rs3738443 0.904 rs61840000 ENSG00000259865.1 RP11-488L18.10 3.69 0.000257 0.0395 0.2 0.2 Alcohol dependence; chr1:247199027 chr1:247187281~247188526:- LIHC cis rs944990 0.576 rs3901421 ENSG00000227603.1 RP11-165J3.6 3.69 0.000257 0.0395 0.21 0.2 Body mass index; chr9:93442256 chr9:93435332~93437121:- LIHC cis rs57221529 0.766 rs4081846 ENSG00000271781.1 CTD-2589H19.6 -3.69 0.000257 0.0395 -0.3 -0.2 Lung disease severity in cystic fibrosis; chr5:573904 chr5:675826~676616:+ LIHC cis rs57221529 0.766 rs4081847 ENSG00000271781.1 CTD-2589H19.6 -3.69 0.000257 0.0395 -0.3 -0.2 Lung disease severity in cystic fibrosis; chr5:573957 chr5:675826~676616:+ LIHC cis rs3015469 0.542 rs1565838 ENSG00000269906.1 RP11-248J18.2 3.69 0.000257 0.0395 0.25 0.2 Plasma amyloid beta peptide concentrations (ABx-40); chr14:50539968 chr14:50662511~50663178:- LIHC cis rs755249 0.567 rs1537817 ENSG00000182109.6 RP11-69E11.4 -3.69 0.000257 0.0395 -0.24 -0.2 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39173981 chr1:39522280~39546187:- LIHC cis rs6456156 0.565 rs12525345 ENSG00000227598.1 RP1-167A14.2 -3.69 0.000257 0.0395 -0.2 -0.2 Primary biliary cholangitis; chr6:167065387 chr6:166969626~166999065:- LIHC cis rs4787491 0.729 rs4788212 ENSG00000250616.2 RP11-455F5.3 -3.69 0.000257 0.0396 -0.19 -0.2 Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction); chr16:30023148 chr16:30096430~30104116:+ LIHC cis rs2976388 0.578 rs3736010 ENSG00000253741.1 CTD-2292P10.4 3.69 0.000257 0.0396 0.25 0.2 Urinary tract infection frequency; chr8:142736085 chr8:142702252~142726973:- LIHC cis rs1005277 0.579 rs2474595 ENSG00000276805.1 RP11-291L22.6 -3.69 0.000257 0.0396 -0.24 -0.2 Extrinsic epigenetic age acceleration; chr10:38137854 chr10:38451030~38451785:+ LIHC cis rs7849270 1 rs3124511 ENSG00000268707.1 RP11-247A12.7 3.69 0.000257 0.0396 0.21 0.2 Blood metabolite ratios; chr9:129139179 chr9:129170434~129170940:+ LIHC cis rs34044649 0.84 rs1675570 ENSG00000214106.6 PAXIP1-AS2 3.69 0.000257 0.0396 0.15 0.2 Triptolide cytotoxicity; chr7:155857806 chr7:154928498~154949908:+ LIHC cis rs2195987 1 rs2916062 ENSG00000268442.1 CTD-2027I19.2 -3.69 0.000257 0.0396 -0.38 -0.2 Testicular germ cell tumor; chr19:24001459 chr19:24162370~24163425:- LIHC cis rs7182948 1 rs1605483 ENSG00000259531.2 RP11-295H24.3 -3.69 0.000257 0.0396 -0.29 -0.2 Lung adenocarcinoma; chr15:49533639 chr15:49365124~49366685:- LIHC cis rs11123170 0.543 rs12472361 ENSG00000189223.12 PAX8-AS1 -3.69 0.000257 0.0396 -0.33 -0.2 Renal function-related traits (BUN); chr2:113223068 chr2:113211522~113276581:+ LIHC cis rs2015599 0.623 rs7964831 ENSG00000275476.1 RP11-996F15.4 -3.69 0.000257 0.0396 -0.24 -0.2 Platelet count;Mean platelet volume; chr12:29286655 chr12:29277397~29277882:- LIHC cis rs3213758 0.541 rs1421092 ENSG00000275191.1 RP11-36I17.2 -3.69 0.000257 0.0396 -0.25 -0.2 Vitiligo (non-segmental); chr16:53700309 chr16:53628256~53628816:- LIHC cis rs709400 0.93 rs61996717 ENSG00000258914.1 CTD-2134A5.3 3.69 0.000257 0.0396 0.28 0.2 Body mass index; chr14:103582234 chr14:103875055~103877478:+ LIHC cis rs12468226 0.808 rs77251002 ENSG00000272966.1 RP11-686O6.1 3.69 0.000257 0.0396 0.35 0.2 Urate levels; chr2:202150236 chr2:202336739~202337200:+ LIHC cis rs11098499 0.618 rs28491261 ENSG00000260091.1 RP11-33B1.4 -3.69 0.000257 0.0396 -0.15 -0.2 Corneal astigmatism; chr4:119373745 chr4:119409333~119410233:+ LIHC cis rs948562 0.744 rs12363774 ENSG00000280010.1 AP001350.4 3.69 0.000257 0.0396 0.33 0.2 Lymphoma; chr11:58457562 chr11:58627435~58628528:+ LIHC cis rs733175 0.855 rs10023068 ENSG00000250413.1 RP11-448G15.1 3.69 0.000257 0.0396 0.28 0.2 Psychosis and Alzheimer's disease; chr4:10003208 chr4:10006482~10009725:+ LIHC cis rs6442522 0.671 rs2305615 ENSG00000249786.6 EAF1-AS1 3.69 0.000257 0.0396 0.23 0.2 Uric acid levels; chr3:15475518 chr3:15436171~15455940:- LIHC cis rs3738443 0.678 rs61636449 ENSG00000259865.1 RP11-488L18.10 3.69 0.000257 0.0396 0.17 0.2 Alcohol dependence; chr1:247213758 chr1:247187281~247188526:- LIHC cis rs7665090 0.528 rs3774968 ENSG00000230069.3 LRRC37A15P -3.69 0.000257 0.0396 -0.18 -0.2 Primary biliary cholangitis; chr4:102609955 chr4:102727274~102730721:- LIHC cis rs919433 0.783 rs788014 ENSG00000231621.1 AC013264.2 -3.69 0.000257 0.0396 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197364273 chr2:197197991~197199273:+ LIHC cis rs901683 1 rs35424022 ENSG00000230869.1 CTGLF10P -3.69 0.000257 0.0396 -0.49 -0.2 Mean corpuscular volume;Red blood cell traits; chr10:45481092 chr10:45678692~45700532:+ LIHC cis rs6001482 0.679 rs8142710 ENSG00000234630.1 LL22NC03-2H8.4 3.69 0.000257 0.0396 0.15 0.2 Diastolic blood pressure; chr22:22233044 chr22:22293733~22294794:+ LIHC cis rs481331 0.643 rs549167 ENSG00000185904.10 LINC00839 -3.69 0.000257 0.0396 -0.37 -0.2 Systemic juvenile idiopathic arthritis; chr10:42691373 chr10:42475543~42495336:+ LIHC cis rs9611519 0.78 rs9611527 ENSG00000231907.2 GAPDHP37 3.69 0.000258 0.0396 0.27 0.2 Neuroticism; chr22:41248424 chr22:40673484~40674451:- LIHC cis rs3087243 0.54 rs736611 ENSG00000213925.3 NPM1P33 -3.69 0.000258 0.0396 -0.2 -0.2 Rheumatoid arthritis;Type 1 diabetes;Hypothyroidism; chr2:203865742 chr2:203772631~203773502:- LIHC cis rs1816213 0.744 rs34313730 ENSG00000273466.1 RP11-548H3.1 -3.69 0.000258 0.0396 -0.3 -0.2 Diastolic blood pressure; chr2:218498262 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs35693258 ENSG00000273466.1 RP11-548H3.1 -3.69 0.000258 0.0396 -0.3 -0.2 Diastolic blood pressure; chr2:218508058 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs13014473 ENSG00000273466.1 RP11-548H3.1 -3.69 0.000258 0.0396 -0.3 -0.2 Diastolic blood pressure; chr2:218518968 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs13022976 ENSG00000273466.1 RP11-548H3.1 -3.69 0.000258 0.0396 -0.3 -0.2 Diastolic blood pressure; chr2:218520803 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs7572951 ENSG00000273466.1 RP11-548H3.1 -3.69 0.000258 0.0396 -0.3 -0.2 Diastolic blood pressure; chr2:218594982 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs13010106 ENSG00000273466.1 RP11-548H3.1 -3.69 0.000258 0.0396 -0.3 -0.2 Diastolic blood pressure; chr2:218601076 chr2:218633256~218634014:- LIHC cis rs67981189 0.896 rs2526877 ENSG00000274818.1 RP1-292L20.3 -3.69 0.000258 0.0396 -0.21 -0.2 Schizophrenia; chr14:70966605 chr14:70906657~70907111:- LIHC cis rs9330316 0.637 rs7572991 ENSG00000175772.10 LINC01106 3.69 0.000258 0.0396 0.27 0.2 Schizophrenia; chr2:109612679 chr2:110375138~110384442:- LIHC cis rs340849 0.788 rs443335 ENSG00000274895.1 RP11-478J18.2 3.69 0.000258 0.0396 0.2 0.2 Alzheimer's disease; chr1:213965816 chr1:213983793~213986419:- LIHC cis rs55794721 0.509 rs11249248 ENSG00000261349.1 RP3-465N24.5 -3.69 0.000258 0.0397 -0.19 -0.2 Mean corpuscular volume;Plateletcrit; chr1:25426560 chr1:25266102~25267136:- LIHC cis rs3091242 0.933 rs926438 ENSG00000261349.1 RP3-465N24.5 -3.69 0.000258 0.0397 -0.19 -0.2 Erythrocyte sedimentation rate; chr1:25427147 chr1:25266102~25267136:- LIHC cis rs4578769 0.765 rs8091950 ENSG00000265943.1 RP11-739L10.1 3.69 0.000258 0.0397 0.25 0.2 Eosinophil percentage of white cells; chr18:22859136 chr18:22699481~22933764:- LIHC cis rs2072510 0.593 rs2660900 ENSG00000257878.1 RP11-256L6.3 -3.69 0.000258 0.0397 -0.26 -0.2 Metabolite levels (small molecules and protein measures); chr12:96011299 chr12:95996521~96011489:+ LIHC cis rs2072510 0.593 rs2540493 ENSG00000257878.1 RP11-256L6.3 -3.69 0.000258 0.0397 -0.26 -0.2 Metabolite levels (small molecules and protein measures); chr12:96022064 chr12:95996521~96011489:+ LIHC cis rs2072510 0.593 rs2660838 ENSG00000257878.1 RP11-256L6.3 -3.69 0.000258 0.0397 -0.26 -0.2 Metabolite levels (small molecules and protein measures); chr12:96022605 chr12:95996521~96011489:+ LIHC cis rs2153977 0.959 rs12039224 ENSG00000229020.4 AKR7A2P1 3.69 0.000258 0.0397 0.2 0.2 Type 1 diabetes and autoimmune thyroid diseases; chr1:113574223 chr1:112923423~112924337:+ LIHC cis rs867371 1 rs8037224 ENSG00000259429.4 UBE2Q2P2 -3.69 0.000258 0.0397 -0.19 -0.2 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82172189 chr15:82355142~82420075:+ LIHC cis rs914615 0.508 rs7535292 ENSG00000203761.5 MSTO2P -3.69 0.000258 0.0397 -0.16 -0.2 Urinary albumin-to-creatinine ratio; chr1:155155273 chr1:155745829~155750137:+ LIHC cis rs4578769 0.722 rs4265922 ENSG00000265943.1 RP11-739L10.1 -3.69 0.000258 0.0397 -0.24 -0.2 Eosinophil percentage of white cells; chr18:22983169 chr18:22699481~22933764:- LIHC cis rs13434995 0.513 rs13134079 ENSG00000273257.1 RP11-177J6.1 3.69 0.000258 0.0397 0.32 0.2 Adiponectin levels; chr4:55542021 chr4:55387949~55388271:+ LIHC cis rs2613514 1 rs78731097 ENSG00000204277.1 RP11-219G17.4 3.69 0.000258 0.0397 0.3 0.2 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78087798 chr17:78261349~78278492:- LIHC cis rs2613514 1 rs78542065 ENSG00000204277.1 RP11-219G17.4 3.69 0.000258 0.0397 0.3 0.2 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78090264 chr17:78261349~78278492:- LIHC cis rs2613514 1 rs16970802 ENSG00000204277.1 RP11-219G17.4 3.69 0.000258 0.0397 0.3 0.2 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78090443 chr17:78261349~78278492:- LIHC cis rs2613514 1 rs3764377 ENSG00000204277.1 RP11-219G17.4 3.69 0.000258 0.0397 0.3 0.2 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78091673 chr17:78261349~78278492:- LIHC cis rs7246657 0.524 rs10411251 ENSG00000225975.5 LINC01534 3.69 0.000258 0.0397 0.31 0.2 Coronary artery calcification; chr19:36937853 chr19:36685440~36687449:- LIHC cis rs7182948 1 rs8040436 ENSG00000259531.2 RP11-295H24.3 -3.69 0.000258 0.0397 -0.29 -0.2 Lung adenocarcinoma; chr15:49522831 chr15:49365124~49366685:- LIHC cis rs11089937 0.568 rs12160318 ENSG00000211639.2 IGLV4-60 3.69 0.000258 0.0397 0.17 0.2 Periodontitis (PAL4Q3); chr22:22131627 chr22:22162199~22162681:+ LIHC cis rs4578769 0.765 rs57308197 ENSG00000265943.1 RP11-739L10.1 -3.69 0.000258 0.0397 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22874272 chr18:22699481~22933764:- LIHC cis rs4578769 0.765 rs61311054 ENSG00000265943.1 RP11-739L10.1 -3.69 0.000258 0.0397 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22906406 chr18:22699481~22933764:- LIHC cis rs4578769 0.765 rs10502430 ENSG00000265943.1 RP11-739L10.1 -3.69 0.000258 0.0397 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22916946 chr18:22699481~22933764:- LIHC cis rs4578769 0.681 rs72887615 ENSG00000265943.1 RP11-739L10.1 -3.69 0.000258 0.0397 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22928638 chr18:22699481~22933764:- LIHC cis rs4578769 0.765 rs898000 ENSG00000265943.1 RP11-739L10.1 -3.69 0.000258 0.0397 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22929109 chr18:22699481~22933764:- LIHC cis rs933688 1 rs1895448 ENSG00000281357.1 ARRDC3-AS1 3.69 0.000259 0.0397 0.24 0.2 Smoking behavior; chr5:91448037 chr5:91380349~91439085:+ LIHC cis rs763121 0.815 rs9306328 ENSG00000273076.1 RP3-508I15.22 3.69 0.000259 0.0397 0.21 0.2 Menopause (age at onset); chr22:38632908 chr22:38743495~38743910:+ LIHC cis rs10510102 0.935 rs12258426 ENSG00000273891.1 RP11-500G22.5 3.69 0.000259 0.0397 0.25 0.2 Breast cancer; chr10:121882189 chr10:121965764~121967700:+ LIHC cis rs10510102 0.935 rs12266380 ENSG00000273891.1 RP11-500G22.5 3.69 0.000259 0.0397 0.25 0.2 Breast cancer; chr10:121882559 chr10:121965764~121967700:+ LIHC cis rs10510102 0.935 rs11200212 ENSG00000273891.1 RP11-500G22.5 3.69 0.000259 0.0397 0.25 0.2 Breast cancer; chr10:121883145 chr10:121965764~121967700:+ LIHC cis rs10510102 0.935 rs11200213 ENSG00000273891.1 RP11-500G22.5 3.69 0.000259 0.0397 0.25 0.2 Breast cancer; chr10:121883228 chr10:121965764~121967700:+ LIHC cis rs10510102 0.935 rs12247749 ENSG00000273891.1 RP11-500G22.5 3.69 0.000259 0.0397 0.25 0.2 Breast cancer; chr10:121884196 chr10:121965764~121967700:+ LIHC cis rs12681287 0.752 rs10085920 ENSG00000254088.1 SLC2A3P4 3.69 0.000259 0.0398 0.24 0.2 Caudate activity during reward; chr8:86240437 chr8:86503591~86505061:+ LIHC cis rs7712401 0.645 rs246316 ENSG00000263432.2 RN7SL689P 3.69 0.000259 0.0398 0.29 0.2 Mean platelet volume; chr5:122930502 chr5:123022487~123022783:- LIHC cis rs1115240 0.574 rs55845836 ENSG00000257842.4 NOVA1-AS1 3.69 0.000259 0.0398 0.2 0.2 Educational attainment (years of education); chr14:26532558 chr14:26598412~26806467:+ LIHC cis rs13113518 0.934 rs3805155 ENSG00000223305.1 RN7SKP30 3.69 0.000259 0.0398 0.23 0.2 Height; chr4:55497842 chr4:55540502~55540835:- LIHC cis rs67311347 0.577 rs1317217 ENSG00000223797.4 ENTPD3-AS1 3.69 0.000259 0.0398 0.16 0.2 Renal cell carcinoma; chr3:40230206 chr3:40313802~40453329:- LIHC cis rs12210905 1 rs9368493 ENSG00000216901.1 AL022393.7 3.69 0.000259 0.0398 0.33 0.2 Hip circumference adjusted for BMI; chr6:27260521 chr6:28176188~28176674:+ LIHC cis rs2919917 0.628 rs7823970 ENSG00000254352.1 RP11-578O24.2 3.69 0.000259 0.0398 0.29 0.2 Lymphocyte counts; chr8:78681364 chr8:78723796~78724136:- LIHC cis rs2919917 0.616 rs7823723 ENSG00000254352.1 RP11-578O24.2 3.69 0.000259 0.0398 0.29 0.2 Lymphocyte counts; chr8:78681390 chr8:78723796~78724136:- LIHC cis rs10905065 0.965 rs2797488 ENSG00000215267.7 AKR1C7P -3.69 0.000259 0.0398 -0.23 -0.2 Menopause (age at onset); chr10:5742546 chr10:5275173~5288470:- LIHC cis rs7712401 0.601 rs2910136 ENSG00000263432.2 RN7SL689P -3.69 0.000259 0.0398 -0.29 -0.2 Mean platelet volume; chr5:122918322 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs173480 ENSG00000263432.2 RN7SL689P 3.69 0.000259 0.0398 0.29 0.2 Mean platelet volume; chr5:122918436 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs246265 ENSG00000263432.2 RN7SL689P 3.69 0.000259 0.0398 0.29 0.2 Mean platelet volume; chr5:122919255 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs193539 ENSG00000263432.2 RN7SL689P 3.69 0.000259 0.0398 0.29 0.2 Mean platelet volume; chr5:122921922 chr5:123022487~123022783:- LIHC cis rs7712401 0.607 rs246270 ENSG00000263432.2 RN7SL689P 3.69 0.000259 0.0398 0.29 0.2 Mean platelet volume; chr5:122922954 chr5:123022487~123022783:- LIHC cis rs7712401 0.562 rs377316 ENSG00000263432.2 RN7SL689P 3.69 0.000259 0.0398 0.29 0.2 Mean platelet volume; chr5:122924180 chr5:123022487~123022783:- LIHC cis rs77204473 0.744 rs12421425 ENSG00000254851.1 RP11-109L13.1 3.69 0.000259 0.0398 0.38 0.2 Sum eosinophil basophil counts;Eosinophil counts; chr11:117131244 chr11:117135528~117138582:+ LIHC cis rs853679 0.599 rs149990 ENSG00000204709.4 LINC01556 3.69 0.000259 0.0398 0.34 0.2 Depression; chr6:28030480 chr6:28943877~28944537:+ LIHC cis rs853679 0.599 rs149943 ENSG00000204709.4 LINC01556 3.69 0.000259 0.0398 0.34 0.2 Depression; chr6:28034610 chr6:28943877~28944537:+ LIHC cis rs67981189 0.806 rs2810107 ENSG00000274818.1 RP1-292L20.3 -3.69 0.000259 0.0398 -0.21 -0.2 Schizophrenia; chr14:70954340 chr14:70906657~70907111:- LIHC cis rs67981189 0.896 rs2526846 ENSG00000274818.1 RP1-292L20.3 -3.69 0.000259 0.0398 -0.21 -0.2 Schizophrenia; chr14:70957538 chr14:70906657~70907111:- LIHC cis rs67981189 0.896 rs2526890 ENSG00000274818.1 RP1-292L20.3 -3.69 0.000259 0.0398 -0.21 -0.2 Schizophrenia; chr14:70963410 chr14:70906657~70907111:- LIHC cis rs67981189 0.896 rs2810100 ENSG00000274818.1 RP1-292L20.3 -3.69 0.000259 0.0398 -0.21 -0.2 Schizophrenia; chr14:70965455 chr14:70906657~70907111:- LIHC cis rs67981189 0.896 rs34049963 ENSG00000274818.1 RP1-292L20.3 3.69 0.000259 0.0398 0.21 0.2 Schizophrenia; chr14:70974029 chr14:70906657~70907111:- LIHC cis rs67981189 0.896 rs3814871 ENSG00000274818.1 RP1-292L20.3 3.69 0.000259 0.0398 0.21 0.2 Schizophrenia; chr14:70978071 chr14:70906657~70907111:- LIHC cis rs67981189 0.896 rs8012728 ENSG00000274818.1 RP1-292L20.3 3.69 0.000259 0.0398 0.21 0.2 Schizophrenia; chr14:70981231 chr14:70906657~70907111:- LIHC cis rs67981189 0.896 rs34731365 ENSG00000274818.1 RP1-292L20.3 3.69 0.000259 0.0398 0.21 0.2 Schizophrenia; chr14:70982877 chr14:70906657~70907111:- LIHC cis rs9601248 0.627 rs9545151 ENSG00000227354.5 RBM26-AS1 -3.69 0.000259 0.0398 -0.25 -0.2 Major depressive disorder; chr13:79608400 chr13:79406309~79424328:+ LIHC cis rs950169 0.58 rs1061737 ENSG00000259728.4 LINC00933 3.69 0.000259 0.0398 0.29 0.2 Schizophrenia; chr15:84640559 chr15:84570649~84580175:+ LIHC cis rs919433 0.783 rs805497 ENSG00000231621.1 AC013264.2 -3.69 0.000259 0.0398 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197357824 chr2:197197991~197199273:+ LIHC cis rs3864261 0.515 rs12186995 ENSG00000272081.1 CTD-2376I4.2 3.69 0.000259 0.0398 0.22 0.2 Discordance in emotional problems in monozygotic twins; chr5:73039500 chr5:72955206~72955699:- LIHC cis rs9640161 0.83 rs17173682 ENSG00000261305.1 RP4-584D14.7 3.69 0.000259 0.0398 0.23 0.2 Blood protein levels;Circulating chemerin levels; chr7:150362513 chr7:150341771~150342607:+ LIHC cis rs3749237 0.555 rs2117939 ENSG00000226913.1 BSN-AS2 -3.69 0.000259 0.0398 -0.25 -0.2 Resting heart rate; chr3:49377746 chr3:49549306~49554366:- LIHC cis rs3749237 0.595 rs6797765 ENSG00000226913.1 BSN-AS2 -3.69 0.000259 0.0398 -0.25 -0.2 Resting heart rate; chr3:49386543 chr3:49549306~49554366:- LIHC cis rs67311347 0.524 rs11129869 ENSG00000223797.4 ENTPD3-AS1 3.69 0.000259 0.0399 0.16 0.2 Renal cell carcinoma; chr3:40218247 chr3:40313802~40453329:- LIHC cis rs67311347 0.577 rs11712626 ENSG00000223797.4 ENTPD3-AS1 3.69 0.000259 0.0399 0.16 0.2 Renal cell carcinoma; chr3:40218436 chr3:40313802~40453329:- LIHC cis rs67311347 0.577 rs11129870 ENSG00000223797.4 ENTPD3-AS1 3.69 0.000259 0.0399 0.16 0.2 Renal cell carcinoma; chr3:40218915 chr3:40313802~40453329:- LIHC cis rs9595908 0.655 rs2213377 ENSG00000212293.1 SNORA16 3.69 0.00026 0.0399 0.23 0.2 Body mass index; chr13:32743076 chr13:32420390~32420516:- LIHC cis rs2278034 0.516 rs9829709 ENSG00000229178.1 AC069513.4 -3.69 0.00026 0.0399 -0.2 -0.2 Bronchopulmonary dysplasia; chr3:195889802 chr3:195655565~195657927:- LIHC cis rs6442522 0.678 rs11128745 ENSG00000249786.6 EAF1-AS1 3.69 0.00026 0.0399 0.22 0.2 Uric acid levels; chr3:15456754 chr3:15436171~15455940:- LIHC cis rs1318937 0.764 rs735659 ENSG00000224660.1 SH3BP5-AS1 3.69 0.00026 0.0399 0.17 0.2 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15182487 chr3:15254184~15264493:+ LIHC cis rs4792901 0.802 rs9901586 ENSG00000279602.1 CTD-3014M21.1 -3.69 0.00026 0.0399 -0.23 -0.2 Dupuytren's disease; chr17:43503523 chr17:43360041~43361361:- LIHC cis rs919433 0.963 rs4850429 ENSG00000231621.1 AC013264.2 -3.69 0.00026 0.0399 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197313685 chr2:197197991~197199273:+ LIHC cis rs2976388 0.566 rs2585146 ENSG00000253196.1 RP11-706C16.7 3.69 0.00026 0.0399 0.21 0.2 Urinary tract infection frequency; chr8:142717223 chr8:142763116~142766427:+ LIHC cis rs943466 0.955 rs2281819 ENSG00000204188.6 GGNBP1 -3.69 0.00026 0.0399 -0.27 -0.2 Body mass index (joint analysis main effects and physical activity interaction);Body mass index; chr6:33803896 chr6:33540046~33589026:+ LIHC cis rs2976388 0.609 rs2263092 ENSG00000253196.1 RP11-706C16.7 3.69 0.00026 0.0399 0.19 0.2 Urinary tract infection frequency; chr8:142708548 chr8:142763116~142766427:+ LIHC cis rs2976388 0.609 rs1594999 ENSG00000253196.1 RP11-706C16.7 3.69 0.00026 0.0399 0.19 0.2 Urinary tract infection frequency; chr8:142709156 chr8:142763116~142766427:+ LIHC cis rs881375 0.967 rs7875829 ENSG00000226752.6 PSMD5-AS1 -3.69 0.00026 0.0399 -0.21 -0.2 Rheumatoid arthritis; chr9:120898120 chr9:120824828~120854385:+ LIHC cis rs881375 0.867 rs10818484 ENSG00000226752.6 PSMD5-AS1 -3.69 0.00026 0.0399 -0.21 -0.2 Rheumatoid arthritis; chr9:120898916 chr9:120824828~120854385:+ LIHC cis rs6061231 0.701 rs6061505 ENSG00000226332.2 RP11-157P1.4 3.69 0.00026 0.0399 0.21 0.2 Colorectal cancer; chr20:62385155 chr20:62305432~62306325:- LIHC cis rs2153535 0.869 rs11962457 ENSG00000230939.1 RP11-314C16.1 3.69 0.00026 0.0399 0.23 0.2 Motion sickness; chr6:8375622 chr6:8784178~8785445:+ LIHC cis rs6496044 0.963 rs6496050 ENSG00000259630.2 CTD-2262B20.1 -3.69 0.00026 0.0399 -0.2 -0.2 Interstitial lung disease; chr15:85526019 chr15:85415228~85415633:+ LIHC cis rs1005277 0.579 rs176838 ENSG00000099251.13 HSD17B7P2 -3.69 0.00026 0.0399 -0.23 -0.2 Extrinsic epigenetic age acceleration; chr10:38082971 chr10:38356380~38378505:+ LIHC cis rs4604234 0.708 rs11961412 ENSG00000272129.1 RP11-250B2.6 -3.69 0.00026 0.0399 -0.38 -0.2 Cancer; chr6:80342179 chr6:80355424~80356859:+ LIHC cis rs61160187 0.667 rs7722373 ENSG00000272308.1 RP11-231G3.1 -3.69 0.00026 0.0399 -0.2 -0.2 Educational attainment (years of education);Educational attainment (college completion); chr5:60951988 chr5:60866457~60866935:- LIHC cis rs2742417 0.587 rs2742375 ENSG00000244357.3 RN7SL145P 3.69 0.00026 0.04 0.19 0.2 Response to anti-depressant treatment in major depressive disorder; chr3:45743110 chr3:45742675~45742970:+ LIHC cis rs287982 0.932 rs9973654 ENSG00000269973.1 RP11-95D17.1 -3.69 0.00026 0.04 -0.19 -0.2 Nonsyndromic cleft lip with cleft palate; chr2:9822439 chr2:9936360~9939590:+ LIHC cis rs1494950 1 rs7667955 ENSG00000214846.4 RP11-115L11.1 -3.69 0.00026 0.04 -0.39 -0.2 Political ideology; chr4:15083298 chr4:15730962~15731627:- LIHC cis rs3813567 0.759 rs7163204 ENSG00000261762.1 RP11-650L12.2 -3.69 0.00026 0.04 -0.27 -0.2 Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio; chr15:78661398 chr15:78589123~78591276:- LIHC cis rs4648045 0.647 rs3774938 ENSG00000230069.3 LRRC37A15P -3.69 0.00026 0.04 -0.18 -0.2 Lymphocyte percentage of white cells; chr4:102517282 chr4:102727274~102730721:- LIHC cis rs4578769 0.531 rs4616385 ENSG00000266850.1 RP11-370A5.1 3.69 0.00026 0.04 0.21 0.2 Eosinophil percentage of white cells; chr18:22895327 chr18:22723491~22907721:- LIHC cis rs13434995 0.513 rs1021307 ENSG00000273257.1 RP11-177J6.1 3.69 0.00026 0.04 0.31 0.2 Adiponectin levels; chr4:55529547 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs1021306 ENSG00000273257.1 RP11-177J6.1 3.69 0.00026 0.04 0.31 0.2 Adiponectin levels; chr4:55529777 chr4:55387949~55388271:+ LIHC cis rs9595908 0.931 rs9595630 ENSG00000212293.1 SNORA16 -3.69 0.000261 0.04 -0.22 -0.2 Body mass index; chr13:32491306 chr13:32420390~32420516:- LIHC cis rs2333021 0.78 rs12887074 ENSG00000259015.1 RP11-109N23.6 3.69 0.000261 0.04 0.23 0.2 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72981132 chr14:72960595~72961993:+ LIHC cis rs6560517 0.581 rs2501934 ENSG00000219149.4 RP11-214N16.2 3.69 0.000261 0.04 0.21 0.2 Dialysis-related mortality; chr9:76375121 chr9:76549282~76549771:- LIHC cis rs13217239 0.646 rs7747454 ENSG00000241549.7 GUSBP2 -3.69 0.000261 0.04 -0.2 -0.2 Schizophrenia; chr6:27066474 chr6:26871484~26956554:- LIHC cis rs72634501 0.642 rs67452844 ENSG00000182109.6 RP11-69E11.4 3.69 0.000261 0.04 0.22 0.2 HDL cholesterol; chr1:39150610 chr1:39522280~39546187:- LIHC cis rs4144027 0.935 rs881056 ENSG00000258914.1 CTD-2134A5.3 3.69 0.000261 0.04 0.21 0.2 Blood metabolite levels; chr14:103887888 chr14:103875055~103877478:+ LIHC cis rs11096990 0.855 rs2566172 ENSG00000249685.1 RP11-360F5.3 -3.69 0.000261 0.04 -0.27 -0.2 Cognitive function; chr4:39150943 chr4:39133913~39135608:+ LIHC cis rs7674212 0.507 rs223413 ENSG00000248971.2 KRT8P46 3.69 0.000261 0.04 0.2 0.2 Type 2 diabetes; chr4:102811709 chr4:102728746~102730171:- LIHC cis rs919433 0.963 rs4850428 ENSG00000231621.1 AC013264.2 3.69 0.000261 0.04 0.18 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197305048 chr2:197197991~197199273:+ LIHC cis rs7712401 0.601 rs30029 ENSG00000263432.2 RN7SL689P -3.69 0.000261 0.04 -0.29 -0.2 Mean platelet volume; chr5:122947475 chr5:123022487~123022783:- LIHC cis rs61160187 0.576 rs10805374 ENSG00000272308.1 RP11-231G3.1 -3.69 0.000261 0.04 -0.2 -0.2 Educational attainment (years of education);Educational attainment (college completion); chr5:61004078 chr5:60866457~60866935:- LIHC cis rs703842 0.892 rs1021469 ENSG00000270039.1 RP11-571M6.17 -3.69 0.000261 0.04 -0.27 -0.2 Multiple sclerosis; chr12:57814381 chr12:57803838~57804415:+ LIHC cis rs4819052 0.704 rs2297283 ENSG00000184274.3 LINC00315 -3.69 0.000261 0.04 -0.25 -0.2 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45263675 chr21:45300245~45305257:- LIHC cis rs559928 0.597 rs2096706 ENSG00000236935.1 AP003774.1 3.69 0.000261 0.04 0.31 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64156974 chr11:64325050~64329504:- LIHC cis rs10129255 0.642 rs11624918 ENSG00000223648.3 IGHV3-64 3.69 0.000261 0.04 0.15 0.2 Kawasaki disease; chr14:106664672 chr14:106643132~106658258:- LIHC cis rs12682352 0.535 rs12677550 ENSG00000254340.1 RP11-10A14.3 -3.69 0.000261 0.04 -0.21 -0.2 Neuroticism; chr8:8786812 chr8:9141424~9145435:+ LIHC cis rs11710567 0.734 rs1053711 ENSG00000272146.4 RP11-755B10.4 -3.69 0.000261 0.04 -0.24 -0.2 Granulocyte percentage of myeloid white cells; chr3:57757519 chr3:57597715~57600927:+ LIHC cis rs2286503 1 rs2286501 ENSG00000226329.2 AC005682.6 3.69 0.000261 0.04 0.24 0.2 Fibrinogen; chr7:22817166 chr7:22863874~22881350:- LIHC cis rs1005277 0.579 rs2505194 ENSG00000099251.13 HSD17B7P2 3.69 0.000261 0.0401 0.23 0.2 Extrinsic epigenetic age acceleration; chr10:38104953 chr10:38356380~38378505:+ LIHC cis rs2898681 0.519 rs3811781 ENSG00000248375.1 RP11-177B4.1 -3.69 0.000261 0.0401 -0.32 -0.2 Optic nerve measurement (cup area); chr4:52862999 chr4:52720081~52720831:- LIHC cis rs12639258 0.961 rs6414427 ENSG00000273682.1 RP11-427P5.3 -3.69 0.000261 0.0401 -0.33 -0.2 Eotaxin levels; chr3:46471347 chr3:46918807~46918935:- LIHC cis rs3822625 0.541 rs12655019 ENSG00000271828.1 CTD-2310F14.1 3.69 0.000261 0.0401 0.41 0.2 Breast cancer (early onset); chr5:56899963 chr5:56927874~56929573:+ LIHC cis rs6723108 0.627 rs1446524 ENSG00000224043.6 CCNT2-AS1 -3.69 0.000261 0.0401 -0.27 -0.2 Type 2 diabetes; chr2:134873761 chr2:134735464~134918710:- LIHC cis rs6723108 0.627 rs10928522 ENSG00000224043.6 CCNT2-AS1 -3.69 0.000261 0.0401 -0.27 -0.2 Type 2 diabetes; chr2:134875292 chr2:134735464~134918710:- LIHC cis rs77204473 0.744 rs17120367 ENSG00000254851.1 RP11-109L13.1 3.69 0.000261 0.0401 0.38 0.2 Sum eosinophil basophil counts;Eosinophil counts; chr11:117132112 chr11:117135528~117138582:+ LIHC cis rs77204473 0.744 rs17120370 ENSG00000254851.1 RP11-109L13.1 3.69 0.000261 0.0401 0.38 0.2 Sum eosinophil basophil counts;Eosinophil counts; chr11:117132672 chr11:117135528~117138582:+ LIHC cis rs77204473 0.744 rs74735277 ENSG00000254851.1 RP11-109L13.1 3.69 0.000261 0.0401 0.38 0.2 Sum eosinophil basophil counts;Eosinophil counts; chr11:117132702 chr11:117135528~117138582:+ LIHC cis rs77204473 0.744 rs75208249 ENSG00000254851.1 RP11-109L13.1 3.69 0.000261 0.0401 0.38 0.2 Sum eosinophil basophil counts;Eosinophil counts; chr11:117132907 chr11:117135528~117138582:+ LIHC cis rs77204473 0.744 rs12417098 ENSG00000254851.1 RP11-109L13.1 3.69 0.000261 0.0401 0.38 0.2 Sum eosinophil basophil counts;Eosinophil counts; chr11:117134137 chr11:117135528~117138582:+ LIHC cis rs9494145 0.59 rs9376090 ENSG00000232876.1 CTA-212D2.2 -3.69 0.000262 0.0401 -0.26 -0.2 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135090090 chr6:135055033~135060550:+ LIHC cis rs2439831 0.867 rs2255042 ENSG00000275601.1 AC011330.13 3.69 0.000262 0.0401 0.26 0.2 Lung cancer in ever smokers; chr15:43542120 chr15:43642389~43643023:- LIHC cis rs17345786 1 rs11715368 ENSG00000244119.1 PDCL3P4 3.69 0.000262 0.0401 0.22 0.2 Colonoscopy-negative controls vs population controls; chr3:101617536 chr3:101712472~101713191:+ LIHC cis rs2286503 0.839 rs2240728 ENSG00000228649.7 AC005682.5 3.69 0.000262 0.0401 0.23 0.2 Fibrinogen; chr7:22812880 chr7:22854178~22861579:+ LIHC cis rs2286503 0.839 rs1054471 ENSG00000228649.7 AC005682.5 3.69 0.000262 0.0401 0.23 0.2 Fibrinogen; chr7:22813024 chr7:22854178~22861579:+ LIHC cis rs2286503 0.839 rs2240726 ENSG00000228649.7 AC005682.5 3.69 0.000262 0.0401 0.23 0.2 Fibrinogen; chr7:22813516 chr7:22854178~22861579:+ LIHC cis rs1075265 0.749 rs10203095 ENSG00000272156.1 RP11-477N3.1 -3.69 0.000262 0.0401 -0.23 -0.2 Chronotype;Morning vs. evening chronotype; chr2:53737150 chr2:54082554~54085066:+ LIHC cis rs9652601 0.649 rs7403919 ENSG00000274038.1 RP11-66H6.4 3.69 0.000262 0.0401 0.24 0.2 Systemic lupus erythematosus; chr16:10992111 chr16:11056556~11057034:+ LIHC cis rs4792901 0.802 rs72833136 ENSG00000267747.1 RP11-392O1.4 -3.69 0.000262 0.0401 -0.24 -0.2 Dupuytren's disease; chr17:43522322 chr17:43544785~43610338:+ LIHC cis rs999943 1 rs999943 ENSG00000196114.3 RP3-391O22.3 3.69 0.000262 0.0402 0.27 0.2 Obesity (extreme); chr6:33656956 chr6:34576258~34576656:- LIHC cis rs9640161 0.83 rs35840727 ENSG00000261305.1 RP4-584D14.7 3.69 0.000262 0.0402 0.24 0.2 Blood protein levels;Circulating chemerin levels; chr7:150366115 chr7:150341771~150342607:+ LIHC cis rs966423 0.55 rs4674176 ENSG00000232485.2 AC098820.3 -3.69 0.000262 0.0402 -0.17 -0.2 Thyroid cancer; chr2:217436396 chr2:216479030~216498761:- LIHC cis rs7671266 0.532 rs733175 ENSG00000250413.1 RP11-448G15.1 -3.69 0.000262 0.0402 -0.29 -0.2 Cardiovascular disease risk factors; chr4:10048517 chr4:10006482~10009725:+ LIHC cis rs7617773 0.78 rs6442111 ENSG00000228638.1 FCF1P2 -3.69 0.000262 0.0402 -0.22 -0.2 Coronary artery disease; chr3:48270570 chr3:48290793~48291375:- LIHC cis rs7617773 0.851 rs6775179 ENSG00000228638.1 FCF1P2 -3.69 0.000262 0.0402 -0.22 -0.2 Coronary artery disease; chr3:48271928 chr3:48290793~48291375:- LIHC cis rs67180937 0.621 rs2068814 ENSG00000225265.1 TAF1A-AS1 3.69 0.000262 0.0402 0.21 0.2 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222749659 chr1:222589825~222593032:+ LIHC cis rs7809950 0.635 rs62483629 ENSG00000238832.1 snoU109 -3.69 0.000262 0.0402 -0.26 -0.2 Coronary artery disease; chr7:107225733 chr7:107603363~107603507:+ LIHC cis rs1799949 0.965 rs2236762 ENSG00000267681.1 CTD-3199J23.6 -3.69 0.000262 0.0402 -0.19 -0.2 Menopause (age at onset); chr17:43074658 chr17:43144956~43145255:+ LIHC cis rs2286503 0.966 rs6949233 ENSG00000226329.2 AC005682.6 3.69 0.000262 0.0402 0.24 0.2 Fibrinogen; chr7:22818572 chr7:22863874~22881350:- LIHC cis rs683257 1 rs72990174 ENSG00000234147.1 RP3-460G2.2 -3.69 0.000262 0.0402 -0.36 -0.2 Facial emotion recognition (angry faces); chr6:140879827 chr6:140845958~140852924:- LIHC cis rs4578769 0.802 rs66816194 ENSG00000265943.1 RP11-739L10.1 -3.69 0.000263 0.0402 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22895554 chr18:22699481~22933764:- LIHC cis rs7211079 0.719 rs2289535 ENSG00000279259.1 RP11-334C17.3 3.69 0.000263 0.0402 0.18 0.2 Myocardial infarction; chr17:80137650 chr17:80147250~80148596:+ LIHC cis rs6547705 0.858 rs12714202 ENSG00000266931.1 RP11-1252D15.1 3.69 0.000263 0.0402 0.33 0.2 Progressive supranuclear palsy; chr2:86672815 chr2:87055658~87055800:- LIHC cis rs10760706 1 rs10123261 ENSG00000270412.1 RP11-92C4.6 3.69 0.000263 0.0403 0.22 0.2 Alopecia areata; chr9:99933160 chr9:98943337~98943775:- LIHC cis rs2032447 0.798 rs807212 ENSG00000242387.1 HIST1H2APS2 3.69 0.000263 0.0403 0.25 0.2 Intelligence (multi-trait analysis); chr6:26065393 chr6:25882026~25882395:- LIHC cis rs8054556 0.669 rs12931955 ENSG00000250616.2 RP11-455F5.3 3.69 0.000263 0.0403 0.19 0.2 Autism spectrum disorder or schizophrenia; chr16:30001745 chr16:30096430~30104116:+ LIHC cis rs17711722 1 rs17711722 ENSG00000234338.1 RP11-797H7.1 3.69 0.000263 0.0403 0.19 0.2 Calcium levels; chr7:65806210 chr7:64835280~64836882:- LIHC cis rs17711722 0.675 rs6947132 ENSG00000234338.1 RP11-797H7.1 3.69 0.000263 0.0403 0.19 0.2 Calcium levels; chr7:65808508 chr7:64835280~64836882:- LIHC cis rs1318937 0.831 rs9851648 ENSG00000224660.1 SH3BP5-AS1 3.69 0.000263 0.0403 0.18 0.2 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15259292 chr3:15254184~15264493:+ LIHC cis rs11613048 0.83 rs12810865 ENSG00000245614.3 DDX11-AS1 3.69 0.000263 0.0403 0.18 0.2 Major depressive disorder; chr12:30180307 chr12:31020763~31073847:- LIHC cis rs6732160 0.65 rs7560224 ENSG00000272702.1 RP11-44N22.3 3.69 0.000263 0.0403 0.22 0.2 Intelligence (multi-trait analysis); chr2:73179054 chr2:73113018~73115907:+ LIHC cis rs4925386 0.84 rs6143024 ENSG00000226332.2 RP11-157P1.4 3.69 0.000263 0.0403 0.23 0.2 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62339173 chr20:62305432~62306325:- LIHC cis rs9309473 0.5 rs13022837 ENSG00000273245.1 RP11-434P11.2 -3.69 0.000263 0.0403 -0.24 -0.2 Metabolite levels; chr2:73685440 chr2:73750256~73750786:- LIHC cis rs617219 0.889 rs1291041 ENSG00000251675.1 CTC-458I2.2 -3.69 0.000263 0.0403 -0.21 -0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79147912 chr5:80128361~80143883:+ LIHC cis rs365302 0.556 rs626959 ENSG00000216480.2 RP3-393E18.1 -3.69 0.000263 0.0403 -0.24 -0.2 Coronary heart disease; chr6:159210365 chr6:159526062~159526527:- LIHC cis rs1115240 0.853 rs1950404 ENSG00000257842.4 NOVA1-AS1 -3.69 0.000263 0.0403 -0.18 -0.2 Educational attainment (years of education); chr14:26613706 chr14:26598412~26806467:+ LIHC cis rs1115240 1 rs1955822 ENSG00000257842.4 NOVA1-AS1 -3.69 0.000263 0.0403 -0.18 -0.2 Educational attainment (years of education); chr14:26614033 chr14:26598412~26806467:+ LIHC cis rs763121 0.853 rs4821811 ENSG00000273076.1 RP3-508I15.22 3.69 0.000263 0.0403 0.23 0.2 Menopause (age at onset); chr22:38679140 chr22:38743495~38743910:+ LIHC cis rs1476670 0.71 rs2485993 ENSG00000230615.5 RP5-1198O20.4 3.69 0.000263 0.0403 0.27 0.2 Eotaxin levels; chr1:44037368 chr1:44030443~44115913:+ LIHC cis rs1198872 0.526 rs57282335 ENSG00000272275.1 RP11-791G15.2 -3.69 0.000263 0.0403 -0.25 -0.2 Cardiac Troponin-T levels; chr2:10788081 chr2:10767875~10770058:- LIHC cis rs875971 0.502 rs1796227 ENSG00000224316.1 RP11-479O9.2 -3.69 0.000263 0.0403 -0.19 -0.2 Aortic root size; chr7:66622032 chr7:65773620~65802067:+ LIHC cis rs4561483 0.801 rs4511557 ENSG00000261560.1 RP11-166B2.3 3.69 0.000264 0.0403 0.22 0.2 Testicular germ cell tumor; chr16:11855601 chr16:11881075~11882569:- LIHC cis rs6472827 0.953 rs4449781 ENSG00000253983.2 RP1-16A9.1 -3.69 0.000264 0.0403 -0.26 -0.2 Uterine fibroids; chr8:74209309 chr8:74199396~74208441:+ LIHC cis rs1318878 1 rs11056456 ENSG00000256751.4 PLBD1-AS1 -3.69 0.000264 0.0404 -0.3 -0.2 Intelligence (multi-trait analysis); chr12:15390824 chr12:14567750~14619755:+ LIHC cis rs17482078 0.879 rs10050860 ENSG00000248734.2 CTD-2260A17.1 -3.69 0.000264 0.0404 -0.27 -0.2 Behcet's disease;Blood protein levels; chr5:96786506 chr5:96784777~96785999:+ LIHC cis rs9309473 0.519 rs13022145 ENSG00000204872.3 NAT8B -3.69 0.000264 0.0404 -0.25 -0.2 Metabolite levels; chr2:73636346 chr2:73700576~73701340:- LIHC cis rs2919917 0.628 rs4739135 ENSG00000254352.1 RP11-578O24.2 3.69 0.000264 0.0404 0.28 0.2 Lymphocyte counts; chr8:78656057 chr8:78723796~78724136:- LIHC cis rs1223397 0.651 rs2496147 ENSG00000215022.6 RP1-257A7.4 -3.69 0.000264 0.0404 -0.21 -0.2 Blood pressure; chr6:13313001 chr6:13264861~13295586:- LIHC cis rs6545883 0.929 rs7561229 ENSG00000271889.1 RP11-493E12.1 3.69 0.000264 0.0404 0.23 0.2 Tuberculosis; chr2:61510855 chr2:61151433~61162105:- LIHC cis rs6545883 0.929 rs12617911 ENSG00000271889.1 RP11-493E12.1 3.69 0.000264 0.0404 0.23 0.2 Tuberculosis; chr2:61513690 chr2:61151433~61162105:- LIHC cis rs1494950 1 rs10084853 ENSG00000214846.4 RP11-115L11.1 -3.69 0.000264 0.0404 -0.4 -0.2 Political ideology; chr4:14971845 chr4:15730962~15731627:- LIHC cis rs240993 0.812 rs383022 ENSG00000230177.1 RP5-1112D6.4 -3.69 0.000264 0.0404 -0.21 -0.2 Inflammatory skin disease;Psoriasis; chr6:111382506 chr6:111277932~111278742:+ LIHC cis rs4964805 0.913 rs11111793 ENSG00000257681.1 RP11-341G23.4 3.69 0.000264 0.0404 0.2 0.2 Attention deficit hyperactivity disorder; chr12:103804340 chr12:103746315~103768858:- LIHC cis rs9330316 0.892 rs6752531 ENSG00000175772.10 LINC01106 3.69 0.000264 0.0404 0.26 0.2 Schizophrenia; chr2:109551955 chr2:110375138~110384442:- LIHC cis rs17264034 0.821 rs374218 ENSG00000250786.1 SNHG18 3.69 0.000264 0.0404 0.26 0.2 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9548331 chr5:9546200~9550609:+ LIHC cis rs12468226 0.808 rs73992849 ENSG00000273456.1 RP11-686O6.2 3.69 0.000264 0.0404 0.3 0.2 Urate levels; chr2:202152444 chr2:202374932~202375604:- LIHC cis rs17772222 0.876 rs56144430 ENSG00000258789.1 RP11-507K2.3 -3.69 0.000264 0.0404 -0.23 -0.2 Coronary artery calcification; chr14:88622013 chr14:88551597~88552493:+ LIHC cis rs916888 0.61 rs199454 ENSG00000262881.1 RP11-669E14.4 3.69 0.000264 0.0404 0.21 0.2 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:45907670~45910779:- LIHC cis rs7712401 0.686 rs154509 ENSG00000260686.1 CTB-36H16.2 -3.69 0.000264 0.0404 -0.21 -0.2 Mean platelet volume; chr5:122862645 chr5:122832356~122834533:+ LIHC cis rs1318878 1 rs983798 ENSG00000256751.4 PLBD1-AS1 3.69 0.000264 0.0404 0.3 0.2 Intelligence (multi-trait analysis); chr12:15390997 chr12:14567750~14619755:+ LIHC cis rs950169 0.959 rs12911210 ENSG00000225151.9 GOLGA2P7 -3.69 0.000264 0.0404 -0.27 -0.2 Schizophrenia; chr15:84123331 chr15:84199311~84230136:- LIHC cis rs2739330 0.789 rs5760109 ENSG00000228039.3 KB-1125A3.10 3.69 0.000264 0.0404 0.23 0.2 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23963780~23964374:+ LIHC cis rs9640161 0.742 rs11983355 ENSG00000261305.1 RP4-584D14.7 3.69 0.000264 0.0404 0.23 0.2 Blood protein levels;Circulating chemerin levels; chr7:150319608 chr7:150341771~150342607:+ LIHC cis rs11089937 0.54 rs2329931 ENSG00000211639.2 IGLV4-60 3.69 0.000264 0.0404 0.17 0.2 Periodontitis (PAL4Q3); chr22:22131994 chr22:22162199~22162681:+ LIHC cis rs11089937 0.568 rs2876996 ENSG00000211639.2 IGLV4-60 3.69 0.000264 0.0404 0.17 0.2 Periodontitis (PAL4Q3); chr22:22132006 chr22:22162199~22162681:+ LIHC cis rs9457247 0.765 rs9459838 ENSG00000227598.1 RP1-167A14.2 -3.69 0.000264 0.0404 -0.21 -0.2 Crohn's disease; chr6:167013111 chr6:166969626~166999065:- LIHC cis rs9457247 0.765 rs1060404 ENSG00000227598.1 RP1-167A14.2 -3.69 0.000264 0.0404 -0.21 -0.2 Crohn's disease; chr6:167015979 chr6:166969626~166999065:- LIHC cis rs7712401 0.525 rs246312 ENSG00000263432.2 RN7SL689P 3.69 0.000264 0.0405 0.29 0.2 Mean platelet volume; chr5:122933760 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs246308 ENSG00000263432.2 RN7SL689P 3.69 0.000264 0.0405 0.29 0.2 Mean platelet volume; chr5:122934395 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs30047 ENSG00000263432.2 RN7SL689P 3.69 0.000264 0.0405 0.29 0.2 Mean platelet volume; chr5:122934829 chr5:123022487~123022783:- LIHC cis rs12908161 0.959 rs34342559 ENSG00000259728.4 LINC00933 3.69 0.000265 0.0405 0.28 0.2 Schizophrenia; chr15:84788040 chr15:84570649~84580175:+ LIHC cis rs12908161 0.959 rs62019472 ENSG00000259728.4 LINC00933 3.69 0.000265 0.0405 0.28 0.2 Schizophrenia; chr15:84788262 chr15:84570649~84580175:+ LIHC cis rs12908161 0.959 rs35557864 ENSG00000259728.4 LINC00933 3.69 0.000265 0.0405 0.28 0.2 Schizophrenia; chr15:84788398 chr15:84570649~84580175:+ LIHC cis rs6442522 0.678 rs12634346 ENSG00000249786.6 EAF1-AS1 3.69 0.000265 0.0405 0.22 0.2 Uric acid levels; chr3:15458788 chr3:15436171~15455940:- LIHC cis rs10883723 0.81 rs1056857 ENSG00000236937.2 PTGES3P4 -3.69 0.000265 0.0405 -0.27 -0.2 Allergic disease (asthma, hay fever or eczema); chr10:102480246 chr10:102845595~102845950:+ LIHC cis rs3738443 0.678 rs57861883 ENSG00000259865.1 RP11-488L18.10 3.69 0.000265 0.0405 0.17 0.2 Alcohol dependence; chr1:247214089 chr1:247187281~247188526:- LIHC cis rs8060598 0.745 rs1861759 ENSG00000275155.1 CTD-2595P9.4 -3.69 0.000265 0.0405 -0.23 -0.2 Leprosy; chr16:50711672 chr16:49847018~49847632:- LIHC cis rs2243480 1 rs316322 ENSG00000228409.4 CCT6P1 3.69 0.000265 0.0405 0.21 0.2 Diabetic kidney disease; chr7:66146246 chr7:65751142~65763354:+ LIHC cis rs3934487 0.547 rs4927272 ENSG00000223956.1 RP4-710M16.2 -3.69 0.000265 0.0405 -0.21 -0.2 Reticulocyte count; chr1:55861362 chr1:56414963~56415966:+ LIHC cis rs4604234 0.522 rs3805918 ENSG00000272129.1 RP11-250B2.6 -3.69 0.000265 0.0405 -0.34 -0.2 Cancer; chr6:80197405 chr6:80355424~80356859:+ LIHC cis rs2613514 1 rs60105040 ENSG00000204277.1 RP11-219G17.4 3.69 0.000265 0.0405 0.3 0.2 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78102867 chr17:78261349~78278492:- LIHC cis rs933688 1 rs332529 ENSG00000281357.1 ARRDC3-AS1 3.69 0.000265 0.0405 0.25 0.2 Smoking behavior; chr5:91493653 chr5:91380349~91439085:+ LIHC cis rs8035452 0.857 rs3098183 ENSG00000273674.3 CTD-2378E12.1 3.69 0.000265 0.0405 0.24 0.2 Alzheimer's disease (late onset); chr15:50514272 chr15:50839875~50908599:- LIHC cis rs617219 0.889 rs12519500 ENSG00000251675.1 CTC-458I2.2 -3.69 0.000265 0.0405 -0.21 -0.2 Betaine levels in individuals undergoing cardiac evaluation; chr5:79141082 chr5:80128361~80143883:+ LIHC cis rs7915414 0.585 rs12570771 ENSG00000230338.1 MTND4P19 3.69 0.000265 0.0405 0.22 0.2 Clopidogrel active metabolite levels; chr10:94683342 chr10:94774156~94774633:- LIHC cis rs2243480 1 rs1638734 ENSG00000275400.1 RP4-756H11.5 3.69 0.000265 0.0405 0.26 0.2 Diabetic kidney disease; chr7:66632552 chr7:66553805~66554199:- LIHC cis rs4792901 0.802 rs56357945 ENSG00000267747.1 RP11-392O1.4 -3.69 0.000265 0.0405 -0.24 -0.2 Dupuytren's disease; chr17:43536323 chr17:43544785~43610338:+ LIHC cis rs4356975 0.563 rs35402056 ENSG00000250919.1 RP11-813N20.3 -3.69 0.000265 0.0405 -0.2 -0.2 Obesity-related traits; chr4:69108549 chr4:69027831~69044578:+ LIHC cis rs1443267 0.935 rs12938976 ENSG00000265542.4 RP11-60A24.3 3.69 0.000265 0.0405 0.29 0.2 Obstetric antiphospholipid syndrome; chr17:57825683 chr17:57771946~57834749:- LIHC cis rs2277425 0.755 rs2277424 ENSG00000255874.2 LINC00346 3.69 0.000265 0.0405 0.3 0.2 Sitting height ratio; chr13:110870073 chr13:110863987~110870251:- LIHC cis rs548181 1 rs548181 ENSG00000254671.2 STT3A-AS1 -3.69 0.000265 0.0405 -0.33 -0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr11:125591814 chr11:125570284~125592568:- LIHC cis rs1115240 0.898 rs28696921 ENSG00000257842.4 NOVA1-AS1 3.69 0.000265 0.0405 0.18 0.2 Educational attainment (years of education); chr14:26514564 chr14:26598412~26806467:+ LIHC cis rs6569038 0.502 rs794261 ENSG00000253194.1 RP11-351A11.1 3.69 0.000265 0.0406 0.27 0.2 Epstein-Barr virus copy number in lymphoblastoid cell lines; chr6:119007434 chr6:118934785~119031541:+ LIHC cis rs9425766 0.511 rs10912676 ENSG00000200674.1 RN7SKP160 3.69 0.000265 0.0406 0.23 0.2 Life satisfaction; chr1:173740477 chr1:173791548~173791887:+ LIHC cis rs11098499 0.697 rs35280960 ENSG00000250412.1 KLHL2P1 3.69 0.000265 0.0406 0.21 0.2 Corneal astigmatism; chr4:119335904 chr4:119334329~119378233:+ LIHC cis rs12807809 0.588 rs61910607 ENSG00000245498.5 RP11-677M14.7 3.69 0.000265 0.0406 0.25 0.2 Schizophrenia; chr11:124739473 chr11:124800450~124834487:+ LIHC cis rs7508 0.509 rs441764 ENSG00000253671.1 RP11-806O11.1 -3.69 0.000265 0.0406 -0.23 -0.2 Atrial fibrillation; chr8:18045648 chr8:17808941~17820868:+ LIHC cis rs7617773 0.78 rs13079728 ENSG00000228638.1 FCF1P2 -3.69 0.000265 0.0406 -0.23 -0.2 Coronary artery disease; chr3:48297870 chr3:48290793~48291375:- LIHC cis rs67311347 1 rs73078123 ENSG00000223797.4 ENTPD3-AS1 3.69 0.000266 0.0406 0.16 0.2 Renal cell carcinoma; chr3:40417472 chr3:40313802~40453329:- LIHC cis rs2179367 0.6 rs9498356 ENSG00000231760.4 RP11-350J20.5 3.69 0.000266 0.0406 0.36 0.2 Dupuytren's disease; chr6:149443337 chr6:149796151~149826294:- LIHC cis rs9951150 0.537 rs12969390 ENSG00000267013.4 CTD-2171N6.1 3.69 0.000266 0.0406 0.26 0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55121782 chr18:55105904~55124306:- LIHC cis rs13113518 0.678 rs7663650 ENSG00000249700.7 SRD5A3-AS1 -3.69 0.000266 0.0406 -0.21 -0.2 Height; chr4:55364952 chr4:55363971~55395847:- LIHC cis rs9303280 0.617 rs4795406 ENSG00000264968.1 RP11-387H17.4 -3.69 0.000266 0.0406 -0.19 -0.2 Self-reported allergy; chr17:39943881 chr17:39927742~39939601:+ LIHC cis rs12807809 0.588 rs3830078 ENSG00000245498.5 RP11-677M14.7 3.69 0.000266 0.0406 0.25 0.2 Schizophrenia; chr11:124737639 chr11:124800450~124834487:+ LIHC cis rs2348418 0.832 rs1405811 ENSG00000247934.4 RP11-967K21.1 3.68 0.000266 0.0406 0.18 0.2 Lung function (FEV1);Lung function (FVC); chr12:28428169 chr12:28163298~28190738:- LIHC cis rs4606360 1 rs4606360 ENSG00000200674.1 RN7SKP160 3.68 0.000266 0.0406 0.23 0.2 Subjective well-being; chr1:173729868 chr1:173791548~173791887:+ LIHC cis rs3812762 0.957 rs7120004 ENSG00000254860.4 TMEM9B-AS1 -3.68 0.000266 0.0406 -0.21 -0.2 Hypospadias; chr11:8747550 chr11:8964675~8977527:+ LIHC cis rs7119 0.717 rs8040702 ENSG00000261143.1 ADAMTS7P3 3.68 0.000266 0.0407 0.27 0.2 Type 2 diabetes; chr15:77511273 chr15:77976042~77993057:+ LIHC cis rs56322409 0.564 rs12359343 ENSG00000226688.5 ENTPD1-AS1 -3.68 0.000266 0.0407 -0.23 -0.2 Blood metabolite levels; chr10:95900815 chr10:95753206~96090238:- LIHC cis rs3749237 0.595 rs1050088 ENSG00000226913.1 BSN-AS2 3.68 0.000266 0.0407 0.26 0.2 Resting heart rate; chr3:49533449 chr3:49549306~49554366:- LIHC cis rs9500256 0.966 rs1322446 ENSG00000215190.7 LINC00680 -3.68 0.000266 0.0407 -0.2 -0.2 Eosinophilic esophagitis (pediatric); chr6:57985672 chr6:57946074~57961501:- LIHC cis rs1322639 0.614 rs6925201 ENSG00000229214.1 LINC00242 3.68 0.000266 0.0407 0.29 0.2 Pulse pressure; chr6:169163262 chr6:169788790~169798825:- LIHC cis rs11098499 0.69 rs34818745 ENSG00000260091.1 RP11-33B1.4 -3.68 0.000266 0.0407 -0.14 -0.2 Corneal astigmatism; chr4:119335900 chr4:119409333~119410233:+ LIHC cis rs6504622 0.537 rs7342957 ENSG00000263766.4 RP11-580I16.2 3.68 0.000267 0.0407 0.23 0.2 Orofacial clefts; chr17:46919990 chr17:47603860~47649420:- LIHC cis rs6504622 0.557 rs11654971 ENSG00000263766.4 RP11-580I16.2 3.68 0.000267 0.0407 0.23 0.2 Orofacial clefts; chr17:46921197 chr17:47603860~47649420:- LIHC cis rs308971 0.901 rs4684841 ENSG00000225026.1 AC091492.2 -3.68 0.000267 0.0407 -0.47 -0.2 Fasting blood insulin (BMI interaction); chr3:12150940 chr3:12328003~12328274:+ LIHC cis rs6430585 0.583 rs3754689 ENSG00000231890.6 DARS-AS1 -3.68 0.000267 0.0407 -0.27 -0.2 Corneal structure; chr2:135833176 chr2:135985176~136022593:+ LIHC cis rs9287719 0.649 rs12617968 ENSG00000243819.4 RN7SL832P -3.68 0.000267 0.0407 -0.44 -0.2 Prostate cancer; chr2:10581819 chr2:10690344~10692099:+ LIHC cis rs875971 0.545 rs4718348 ENSG00000273024.4 INTS4P2 -3.68 0.000267 0.0407 -0.23 -0.2 Aortic root size; chr7:66441589 chr7:65647864~65715661:+ LIHC cis rs600231 0.708 rs602838 ENSG00000245532.5 NEAT1 3.68 0.000267 0.0407 0.19 0.2 Bone mineral density; chr11:65485776 chr11:65422774~65445540:+ LIHC cis rs13113518 0.812 rs6849474 ENSG00000223305.1 RN7SKP30 3.68 0.000267 0.0407 0.23 0.2 Height; chr4:55452295 chr4:55540502~55540835:- LIHC cis rs11096990 0.964 rs6831700 ENSG00000249685.1 RP11-360F5.3 3.68 0.000267 0.0407 0.26 0.2 Cognitive function; chr4:39255344 chr4:39133913~39135608:+ LIHC cis rs4578769 0.765 rs60721147 ENSG00000265943.1 RP11-739L10.1 -3.68 0.000267 0.0407 -0.25 -0.2 Eosinophil percentage of white cells; chr18:22848569 chr18:22699481~22933764:- LIHC cis rs62025270 0.632 rs10520594 ENSG00000259295.5 CSPG4P12 3.68 0.000267 0.0407 0.33 0.2 Idiopathic pulmonary fibrosis; chr15:85585410 chr15:85191438~85213905:+ LIHC cis rs4713118 0.662 rs149961 ENSG00000219891.2 ZSCAN12P1 3.68 0.000267 0.0407 0.28 0.2 Parkinson's disease; chr6:28047791 chr6:28091154~28093664:+ LIHC cis rs4713118 0.662 rs9357060 ENSG00000219891.2 ZSCAN12P1 3.68 0.000267 0.0407 0.28 0.2 Parkinson's disease; chr6:28056708 chr6:28091154~28093664:+ LIHC cis rs4713118 0.662 rs9468271 ENSG00000219891.2 ZSCAN12P1 3.68 0.000267 0.0407 0.28 0.2 Parkinson's disease; chr6:28056792 chr6:28091154~28093664:+ LIHC cis rs4713118 0.662 rs9380045 ENSG00000219891.2 ZSCAN12P1 3.68 0.000267 0.0407 0.28 0.2 Parkinson's disease; chr6:28057501 chr6:28091154~28093664:+ LIHC cis rs4713118 0.616 rs9348789 ENSG00000219891.2 ZSCAN12P1 3.68 0.000267 0.0407 0.28 0.2 Parkinson's disease; chr6:28057708 chr6:28091154~28093664:+ LIHC cis rs4713118 0.662 rs9468274 ENSG00000219891.2 ZSCAN12P1 3.68 0.000267 0.0407 0.28 0.2 Parkinson's disease; chr6:28058299 chr6:28091154~28093664:+ LIHC cis rs4713118 0.662 rs9468275 ENSG00000219891.2 ZSCAN12P1 3.68 0.000267 0.0407 0.28 0.2 Parkinson's disease; chr6:28058358 chr6:28091154~28093664:+ LIHC cis rs4713118 0.662 rs9468276 ENSG00000219891.2 ZSCAN12P1 3.68 0.000267 0.0407 0.28 0.2 Parkinson's disease; chr6:28059910 chr6:28091154~28093664:+ LIHC cis rs4713118 0.662 rs9468277 ENSG00000219891.2 ZSCAN12P1 3.68 0.000267 0.0407 0.28 0.2 Parkinson's disease; chr6:28060612 chr6:28091154~28093664:+ LIHC cis rs4713118 0.662 rs9468278 ENSG00000219891.2 ZSCAN12P1 3.68 0.000267 0.0407 0.28 0.2 Parkinson's disease; chr6:28060704 chr6:28091154~28093664:+ LIHC cis rs4713118 0.662 rs13218430 ENSG00000219891.2 ZSCAN12P1 3.68 0.000267 0.0407 0.28 0.2 Parkinson's disease; chr6:28062059 chr6:28091154~28093664:+ LIHC cis rs12586317 0.553 rs3809448 ENSG00000257307.1 RP11-317N8.4 -3.68 0.000267 0.0407 -0.23 -0.2 Psoriasis; chr14:35045890 chr14:35881001~35881709:+ LIHC cis rs12586317 0.586 rs2295103 ENSG00000257307.1 RP11-317N8.4 -3.68 0.000267 0.0407 -0.23 -0.2 Psoriasis; chr14:35046714 chr14:35881001~35881709:+ LIHC cis rs301901 0.793 rs11750212 ENSG00000250155.1 CTD-2353F22.1 3.68 0.000267 0.0407 0.19 0.2 Height; chr5:37463644 chr5:36666214~36725195:- LIHC cis rs367615 0.704 rs17161885 ENSG00000249476.1 CTD-2587M2.1 3.68 0.000267 0.0407 0.23 0.2 Colorectal cancer (SNP x SNP interaction); chr5:109516941 chr5:109237120~109326369:- LIHC cis rs17774123 0.901 rs2254639 ENSG00000257808.1 RP11-1136G11.8 -3.68 0.000267 0.0408 -0.37 -0.2 Diastolic blood pressure; chr12:53871626 chr12:53159586~53161000:+ LIHC cis rs780096 0.546 rs2293572 ENSG00000234072.1 AC074117.10 3.68 0.000267 0.0408 0.18 0.2 Total body bone mineral density; chr2:27505910 chr2:27356246~27367622:+ LIHC cis rs4948102 0.731 rs6593292 ENSG00000226278.1 PSPHP1 -3.68 0.000267 0.0408 -0.23 -0.2 Plasma homocysteine levels (post-methionine load test); chr7:55975344 chr7:55764797~55773288:+ LIHC cis rs4948102 0.731 rs4535700 ENSG00000226278.1 PSPHP1 -3.68 0.000267 0.0408 -0.23 -0.2 Plasma homocysteine levels (post-methionine load test); chr7:55977755 chr7:55764797~55773288:+ LIHC cis rs7523455 1 rs28675749 ENSG00000270728.1 RP4-657E11.10 3.68 0.000267 0.0408 0.24 0.2 Methotrexate phramacokinetics (acute lymphoblastic leukemia); chr1:19006231 chr1:19297080~19297903:+ LIHC cis rs7529073 0.815 rs1431982 ENSG00000274895.1 RP11-478J18.2 -3.68 0.000267 0.0408 -0.21 -0.2 Schizophrenia; chr1:213975718 chr1:213983793~213986419:- LIHC cis rs10774547 0.965 rs7970534 ENSG00000278344.1 RP11-18C24.8 3.68 0.000267 0.0408 0.24 0.2 Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);Reading disability or specific language impairment (pleiotropy); chr12:120424392 chr12:120500735~120501090:- LIHC cis rs56080343 0.688 rs10083190 ENSG00000275409.1 RP11-131L12.4 -3.68 0.000267 0.0408 -0.23 -0.2 Neuroticism; chr12:118365385 chr12:118430147~118430699:+ LIHC cis rs673078 0.607 rs10082823 ENSG00000275409.1 RP11-131L12.4 -3.68 0.000267 0.0408 -0.23 -0.2 Glucose homeostasis traits; chr12:118365386 chr12:118430147~118430699:+ LIHC cis rs7119038 0.686 rs55894437 ENSG00000255422.1 AP002954.4 3.68 0.000267 0.0408 0.25 0.2 Sjögren's syndrome; chr11:118736708 chr11:118704607~118750263:+ LIHC cis rs9367716 0.868 rs9396267 ENSG00000215190.7 LINC00680 3.68 0.000267 0.0408 0.22 0.2 Coronary artery disease; chr6:57245613 chr6:57946074~57961501:- LIHC cis rs11105298 0.891 rs11105314 ENSG00000258302.2 RP11-981P6.1 3.68 0.000267 0.0408 0.26 0.2 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89530782 chr12:89561129~89594878:+ LIHC cis rs6723108 0.627 rs6430545 ENSG00000224043.6 CCNT2-AS1 3.68 0.000268 0.0408 0.27 0.2 Type 2 diabetes; chr2:134845031 chr2:134735464~134918710:- LIHC cis rs7989332 0.662 rs9552202 ENSG00000275964.1 RP11-61K9.3 3.68 0.000268 0.0408 0.24 0.2 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20487830 chr13:19863858~19865048:+ LIHC cis rs7989332 0.593 rs9315623 ENSG00000275964.1 RP11-61K9.3 3.68 0.000268 0.0408 0.24 0.2 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20488214 chr13:19863858~19865048:+ LIHC cis rs2858942 0.602 rs1211375 ENSG00000226942.2 IL9RP3 3.68 0.000268 0.0408 0.2 0.2 Mean corpuscular hemoglobin; chr16:190281 chr16:29336~38321:- LIHC cis rs42490 0.664 rs389848 ENSG00000251136.7 RP11-37B2.1 -3.68 0.000268 0.0408 -0.17 -0.2 Leprosy; chr8:89784739 chr8:89609409~89757727:- LIHC cis rs74181299 0.648 rs1050676 ENSG00000225889.6 AC074289.1 3.68 0.000268 0.0408 0.22 0.2 Pulse pressure; chr2:65083697 chr2:64143239~64252859:+ LIHC cis rs74181299 0.684 rs1420184 ENSG00000225889.6 AC074289.1 3.68 0.000268 0.0408 0.22 0.2 Pulse pressure; chr2:65088746 chr2:64143239~64252859:+ LIHC cis rs2834288 0.613 rs2834297 ENSG00000237945.6 LINC00649 -3.68 0.000268 0.0408 -0.25 -0.2 Gut microbiota (bacterial taxa); chr21:33910534 chr21:33915534~33977691:+ LIHC cis rs4891159 0.548 rs11150952 ENSG00000265778.2 RP11-17M16.2 3.68 0.000268 0.0408 0.23 0.2 Longevity; chr18:76416232 chr18:76491652~76493918:+ LIHC cis rs919433 0.783 rs788011 ENSG00000231621.1 AC013264.2 -3.68 0.000268 0.0408 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197366047 chr2:197197991~197199273:+ LIHC cis rs919433 0.783 rs55725278 ENSG00000231621.1 AC013264.2 -3.68 0.000268 0.0408 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197373499 chr2:197197991~197199273:+ LIHC cis rs919433 0.783 rs787980 ENSG00000231621.1 AC013264.2 -3.68 0.000268 0.0408 -0.18 -0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197374501 chr2:197197991~197199273:+ LIHC cis rs8046148 0.724 rs2041918 ENSG00000279356.1 RP11-429P3.8 3.68 0.000268 0.0408 0.19 0.2 Testicular germ cell tumor; chr16:50035401 chr16:50072862~50074986:+ LIHC cis rs10129255 0.785 rs10150044 ENSG00000224373.3 IGHV4-59 3.68 0.000268 0.0409 0.15 0.2 Kawasaki disease; chr14:106775695 chr14:106627249~106627825:- LIHC cis rs2439831 0.867 rs2245715 ENSG00000275601.1 AC011330.13 -3.68 0.000268 0.0409 -0.26 -0.2 Lung cancer in ever smokers; chr15:43525854 chr15:43642389~43643023:- LIHC cis rs3204270 0.759 rs62075725 ENSG00000281517.1 Metazoa_SRP -3.68 0.000268 0.0409 -0.38 -0.2 Dental caries; chr17:81644484 chr17:81718849~81719095:- LIHC cis rs709400 0.894 rs61996721 ENSG00000258914.1 CTD-2134A5.3 3.68 0.000268 0.0409 0.28 0.2 Body mass index; chr14:103595015 chr14:103875055~103877478:+ LIHC cis rs1023500 0.596 rs133352 ENSG00000226450.2 CYP2D8P 3.68 0.000268 0.0409 0.24 0.2 Schizophrenia; chr22:42038018 chr22:42149886~42155001:- LIHC cis rs673078 0.607 rs7304342 ENSG00000275759.1 RP11-131L12.3 -3.68 0.000268 0.0409 -0.37 -0.2 Glucose homeostasis traits; chr12:118390166 chr12:118428281~118428870:+ LIHC cis rs673078 0.615 rs61943397 ENSG00000275759.1 RP11-131L12.3 -3.68 0.000268 0.0409 -0.37 -0.2 Glucose homeostasis traits; chr12:118390996 chr12:118428281~118428870:+ LIHC cis rs673078 0.607 rs61943398 ENSG00000275759.1 RP11-131L12.3 -3.68 0.000268 0.0409 -0.37 -0.2 Glucose homeostasis traits; chr12:118393280 chr12:118428281~118428870:+ LIHC cis rs8077577 0.747 rs2294913 ENSG00000260647.1 RP1-178F10.1 3.68 0.000268 0.0409 0.25 0.2 Obesity-related traits; chr17:18299682 chr17:18268080~18268828:+ LIHC cis rs559928 0.597 rs2186572 ENSG00000236935.1 AP003774.1 3.68 0.000268 0.0409 0.31 0.2 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64128415 chr11:64325050~64329504:- LIHC cis rs7915414 0.543 rs34029985 ENSG00000230338.1 MTND4P19 3.68 0.000268 0.0409 0.23 0.2 Clopidogrel active metabolite levels; chr10:94889097 chr10:94774156~94774633:- LIHC cis rs7615952 0.576 rs6780025 ENSG00000171084.14 FAM86JP 3.68 0.000268 0.0409 0.32 0.2 Blood pressure (smoking interaction); chr3:126096781 chr3:125916620~125930024:+ LIHC cis rs7615952 0.576 rs6804482 ENSG00000171084.14 FAM86JP 3.68 0.000268 0.0409 0.32 0.2 Blood pressure (smoking interaction); chr3:126096919 chr3:125916620~125930024:+ LIHC cis rs3738443 0.951 rs61840056 ENSG00000259865.1 RP11-488L18.10 3.68 0.000268 0.0409 0.21 0.2 Alcohol dependence; chr1:247205930 chr1:247187281~247188526:- LIHC cis rs9409565 1 rs9409565 ENSG00000231806.2 PCAT7 -3.68 0.000268 0.0409 -0.24 -0.2 Colorectal cancer (alcohol consumption interaction); chr9:94488752 chr9:94555069~94568127:+ LIHC cis rs12681366 0.761 rs2197003 ENSG00000253704.1 RP11-267M23.4 3.68 0.000268 0.0409 0.23 0.2 Nonsyndromic cleft lip with cleft palate; chr8:94444758 chr8:94553722~94569745:+ LIHC cis rs9393777 0.546 rs9366673 ENSG00000241549.7 GUSBP2 3.68 0.000268 0.0409 0.28 0.2 Intelligence (multi-trait analysis); chr6:26925550 chr6:26871484~26956554:- LIHC cis rs987724 0.515 rs6762708 ENSG00000243926.1 TIPARP-AS1 -3.68 0.000268 0.0409 -0.21 -0.2 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156973815 chr3:156671862~156674378:- LIHC cis rs7937890 0.695 rs17557844 ENSG00000251991.1 RNU7-49P -3.68 0.000268 0.0409 -0.22 -0.2 Mitochondrial DNA levels; chr11:14241013 chr11:14478892~14478953:+ LIHC cis rs1115240 0.898 rs178203 ENSG00000257842.4 NOVA1-AS1 -3.68 0.000268 0.0409 -0.18 -0.2 Educational attainment (years of education); chr14:26490116 chr14:26598412~26806467:+ LIHC cis rs7121538 0.551 rs12417788 ENSG00000251991.1 RNU7-49P -3.68 0.000269 0.0409 -0.32 -0.2 HDL cholesterol; chr11:14676912 chr11:14478892~14478953:+ LIHC cis rs17660992 0.525 rs10421946 ENSG00000273837.1 LLNLR-470E3.1 -3.68 0.000269 0.0409 -0.23 -0.2 Blood protein levels; chr19:51661797 chr19:51639478~51639931:- LIHC cis rs340849 0.678 rs6696711 ENSG00000274895.1 RP11-478J18.2 -3.68 0.000269 0.0409 -0.21 -0.2 Alzheimer's disease; chr1:213931328 chr1:213983793~213986419:- LIHC cis rs6545883 0.931 rs778768 ENSG00000271889.1 RP11-493E12.1 3.68 0.000269 0.0409 0.24 0.2 Tuberculosis; chr2:61563154 chr2:61151433~61162105:- LIHC cis rs1045902 0.967 rs10207625 ENSG00000272702.1 RP11-44N22.3 3.68 0.000269 0.0409 0.22 0.2 Intelligence (multi-trait analysis); chr2:73237680 chr2:73113018~73115907:+ LIHC cis rs1045902 0.967 rs1469530 ENSG00000272702.1 RP11-44N22.3 3.68 0.000269 0.0409 0.22 0.2 Intelligence (multi-trait analysis); chr2:73237820 chr2:73113018~73115907:+ LIHC cis rs7208859 0.615 rs216462 ENSG00000266490.1 CTD-2349P21.9 -3.68 0.000269 0.0409 -0.25 -0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30568879 chr17:30792372~30792833:+ LIHC cis rs11123170 0.542 rs28522253 ENSG00000189223.12 PAX8-AS1 -3.68 0.000269 0.0409 -0.33 -0.2 Renal function-related traits (BUN); chr2:113209810 chr2:113211522~113276581:+ LIHC cis rs7617773 0.817 rs6800492 ENSG00000228638.1 FCF1P2 -3.68 0.000269 0.0409 -0.22 -0.2 Coronary artery disease; chr3:48282400 chr3:48290793~48291375:- LIHC cis rs938554 0.657 rs7660895 ENSG00000250413.1 RP11-448G15.1 -3.68 0.000269 0.0409 -0.27 -0.2 Blood metabolite levels; chr4:9983821 chr4:10006482~10009725:+ LIHC cis rs13333062 1 rs16944836 ENSG00000261241.4 RP11-883G14.1 -3.68 0.000269 0.041 -0.33 -0.2 Crohn's disease;Inflammatory bowel disease; chr16:50881903 chr16:50884209~50901061:+ LIHC cis rs710865 0.541 rs12567768 ENSG00000270728.1 RP4-657E11.10 -3.68 0.000269 0.041 -0.18 -0.2 Brain structure; chr1:19242109 chr1:19297080~19297903:+ LIHC cis rs11096990 0.964 rs6835064 ENSG00000249685.1 RP11-360F5.3 -3.68 0.000269 0.041 -0.26 -0.2 Cognitive function; chr4:39264346 chr4:39133913~39135608:+ LIHC cis rs3091242 0.967 rs665372 ENSG00000261349.1 RP3-465N24.5 -3.68 0.000269 0.041 -0.19 -0.2 Erythrocyte sedimentation rate; chr1:25392744 chr1:25266102~25267136:- LIHC cis rs875971 0.522 rs4502988 ENSG00000237310.1 GS1-124K5.4 3.68 0.000269 0.041 0.2 0.2 Aortic root size; chr7:65832759 chr7:66493706~66495474:+ LIHC cis rs875971 0.522 rs2008188 ENSG00000237310.1 GS1-124K5.4 3.68 0.000269 0.041 0.2 0.2 Aortic root size; chr7:65964026 chr7:66493706~66495474:+ LIHC cis rs752590 0.943 rs13407583 ENSG00000274877.1 RP11-65I12.1 -3.68 0.000269 0.041 -0.29 -0.2 Mucinous ovarian carcinoma; chr2:113210163 chr2:113237595~113240825:+ LIHC cis rs8087799 0.83 rs12967888 ENSG00000273232.1 RP11-370A5.2 3.68 0.000269 0.041 0.23 0.2 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22580490 chr18:22882825~22883357:- LIHC cis rs10838687 0.736 rs2279238 ENSG00000247675.5 LRP4-AS1 -3.68 0.000269 0.041 -0.25 -0.2 Proinsulin levels; chr11:47260473 chr11:46846412~46874396:+ LIHC cis rs7208859 0.673 rs75142521 ENSG00000280069.1 CTD-2349P21.3 -3.68 0.000269 0.041 -0.26 -0.2 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913519 chr17:30738182~30740275:+ LIHC cis rs72774916 0.636 rs4703529 ENSG00000251495.1 PPIAP11 -3.68 0.000269 0.041 -0.29 -0.2 Breast cancer; chr5:81834057 chr5:82009602~82010094:- LIHC cis rs703842 1 rs703842 ENSG00000270039.1 RP11-571M6.17 3.68 0.000269 0.041 0.27 0.2 Multiple sclerosis; chr12:57768956 chr12:57803838~57804415:+ LIHC cis rs673078 0.607 rs2036489 ENSG00000275409.1 RP11-131L12.4 -3.68 0.000269 0.041 -0.23 -0.2 Glucose homeostasis traits; chr12:118364643 chr12:118430147~118430699:+ LIHC cis rs1799949 1 rs915945 ENSG00000267681.1 CTD-3199J23.6 -3.68 0.000269 0.041 -0.19 -0.2 Menopause (age at onset); chr17:43027847 chr17:43144956~43145255:+ LIHC cis rs72634501 0.716 rs72660086 ENSG00000182109.6 RP11-69E11.4 3.68 0.000269 0.041 0.26 0.2 HDL cholesterol; chr1:39106320 chr1:39522280~39546187:- LIHC cis rs933688 1 rs11948075 ENSG00000281357.1 ARRDC3-AS1 3.68 0.000269 0.041 0.25 0.2 Smoking behavior; chr5:91384762 chr5:91380349~91439085:+ LIHC cis rs933688 0.938 rs7705465 ENSG00000281357.1 ARRDC3-AS1 3.68 0.000269 0.041 0.25 0.2 Smoking behavior; chr5:91385132 chr5:91380349~91439085:+ LIHC cis rs933688 1 rs889213 ENSG00000281357.1 ARRDC3-AS1 3.68 0.000269 0.041 0.25 0.2 Smoking behavior; chr5:91386334 chr5:91380349~91439085:+ LIHC cis rs933688 1 rs11950530 ENSG00000281357.1 ARRDC3-AS1 3.68 0.000269 0.041 0.25 0.2 Smoking behavior; chr5:91392923 chr5:91380349~91439085:+ LIHC cis rs933688 1 rs10058025 ENSG00000281357.1 ARRDC3-AS1 3.68 0.000269 0.041 0.25 0.2 Smoking behavior; chr5:91393235 chr5:91380349~91439085:+ LIHC cis rs950169 0.58 rs11633762 ENSG00000225151.9 GOLGA2P7 -3.68 0.00027 0.041 -0.25 -0.2 Schizophrenia; chr15:84643921 chr15:84199311~84230136:- LIHC cis rs11098499 0.562 rs13101722 ENSG00000245958.5 RP11-33B1.1 3.68 0.00027 0.041 0.19 0.2 Corneal astigmatism; chr4:119634820 chr4:119454791~119552025:+ LIHC cis rs4873772 0.837 rs2129618 ENSG00000253608.1 RP11-770E5.1 3.68 0.00027 0.041 0.21 0.2 Lobe attachment (rater-scored or self-reported); chr8:47643557 chr8:48551567~48698510:+ LIHC cis rs2243480 0.522 rs1638736 ENSG00000232546.1 RP11-458F8.1 -3.68 0.00027 0.0411 -0.24 -0.2 Diabetic kidney disease; chr7:66627321 chr7:66848496~66858136:+ LIHC cis rs875971 0.545 rs12670811 ENSG00000224316.1 RP11-479O9.2 3.68 0.00027 0.0411 0.19 0.2 Aortic root size; chr7:66358032 chr7:65773620~65802067:+ LIHC cis rs751728 0.648 rs6922275 ENSG00000204188.6 GGNBP1 3.68 0.00027 0.0411 0.24 0.2 Crohn's disease; chr6:33781962 chr6:33540046~33589026:+ LIHC cis rs751728 0.664 rs943474 ENSG00000204188.6 GGNBP1 3.68 0.00027 0.0411 0.24 0.2 Crohn's disease; chr6:33782057 chr6:33540046~33589026:+ LIHC cis rs751728 0.664 rs943478 ENSG00000204188.6 GGNBP1 3.68 0.00027 0.0411 0.24 0.2 Crohn's disease; chr6:33783163 chr6:33540046~33589026:+ LIHC cis rs2919917 0.628 rs6997255 ENSG00000254352.1 RP11-578O24.2 3.68 0.00027 0.0411 0.29 0.2 Lymphocyte counts; chr8:78694850 chr8:78723796~78724136:- LIHC cis rs2919917 0.628 rs7010299 ENSG00000254352.1 RP11-578O24.2 3.68 0.00027 0.0411 0.29 0.2 Lymphocyte counts; chr8:78707786 chr8:78723796~78724136:- LIHC cis rs3764021 0.506 rs10844468 ENSG00000256673.1 RP11-599J14.2 -3.68 0.00027 0.0411 -0.2 -0.2 Type 1 diabetes; chr12:9690799 chr12:9398355~9414851:- LIHC cis rs6754311 0.861 rs12475139 ENSG00000231890.6 DARS-AS1 -3.68 0.00027 0.0411 -0.23 -0.2 Mosquito bite size; chr2:136029081 chr2:135985176~136022593:+ LIHC cis rs2745572 0.538 rs4587210 ENSG00000272279.1 RP11-157J24.2 3.68 0.00027 0.0411 0.24 0.2 Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure); chr6:1542956 chr6:1528364~1528911:- LIHC cis rs2518049 0.528 rs76746365 ENSG00000224034.1 RP11-445P17.8 -3.68 0.00027 0.0411 -0.3 -0.2 Metabolic traits; chr10:5187025 chr10:5266033~5271236:- LIHC cis rs6456156 0.716 rs6905876 ENSG00000227598.1 RP1-167A14.2 -3.68 0.00027 0.0411 -0.2 -0.2 Primary biliary cholangitis; chr6:167108074 chr6:166969626~166999065:- LIHC cis rs960902 0.764 rs11124586 ENSG00000213553.4 RPLP0P6 -3.68 0.00027 0.0411 -0.16 -0.2 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37501324 chr2:38481851~38482804:+ LIHC cis rs752590 0.832 rs6542124 ENSG00000189223.12 PAX8-AS1 -3.68 0.00027 0.0411 -0.32 -0.2 Mucinous ovarian carcinoma; chr2:113194347 chr2:113211522~113276581:+ LIHC cis rs67981189 1 rs67981189 ENSG00000274818.1 RP1-292L20.3 3.68 0.00027 0.0411 0.22 0.2 Schizophrenia; chr14:71005509 chr14:70906657~70907111:- LIHC cis rs7560272 0.538 rs17434655 ENSG00000273245.1 RP11-434P11.2 3.68 0.00027 0.0411 0.23 0.2 Schizophrenia; chr2:73695962 chr2:73750256~73750786:- LIHC cis rs728616 0.51 rs12416084 ENSG00000225484.5 NUTM2B-AS1 -3.68 0.00027 0.0411 -0.4 -0.2 Chronic obstructive pulmonary disease-related biomarkers; chr10:79989459 chr10:79663088~79826594:- LIHC cis rs728616 0.51 rs34817075 ENSG00000225484.5 NUTM2B-AS1 -3.68 0.00027 0.0411 -0.4 -0.2 Chronic obstructive pulmonary disease-related biomarkers; chr10:79989984 chr10:79663088~79826594:- LIHC cis rs8005677 0.611 rs11624528 ENSG00000279656.1 RP11-298I3.6 3.68 0.000271 0.0412 0.22 0.2 Cognitive ability (multi-trait analysis); chr14:22989947 chr14:23023083~23024217:- LIHC cis rs6569038 0.533 rs12526935 ENSG00000253194.1 RP11-351A11.1 -3.68 0.000271 0.0412 -0.26 -0.2 Epstein-Barr virus copy number in lymphoblastoid cell lines; chr6:119052747 chr6:118934785~119031541:+ LIHC cis rs2120243 0.845 rs2316710 ENSG00000244515.1 KRT18P34 -3.68 0.000271 0.0412 -0.19 -0.2 Hepatocellular carcinoma in hepatitis B infection; chr3:157432391 chr3:157162663~157163932:- LIHC cis rs2120243 0.874 rs2316709 ENSG00000244515.1 KRT18P34 -3.68 0.000271 0.0412 -0.19 -0.2 Hepatocellular carcinoma in hepatitis B infection; chr3:157432458 chr3:157162663~157163932:- LIHC cis rs2120243 0.874 rs2316708 ENSG00000244515.1 KRT18P34 -3.68 0.000271 0.0412 -0.19 -0.2 Hepatocellular carcinoma in hepatitis B infection; chr3:157432510 chr3:157162663~157163932:- LIHC cis rs2120243 0.874 rs9868133 ENSG00000244515.1 KRT18P34 -3.68 0.000271 0.0412 -0.19 -0.2 Hepatocellular carcinoma in hepatitis B infection; chr3:157433672 chr3:157162663~157163932:- LIHC cis rs591584 0.659 rs638397 ENSG00000255893.1 RP11-685N10.1 -3.68 0.000271 0.0412 -0.2 -0.2 Macrophage Migration Inhibitory Factor levels; chr11:94600942 chr11:94472908~94473570:- LIHC cis rs67311347 1 rs4571217 ENSG00000223797.4 ENTPD3-AS1 3.68 0.000271 0.0412 0.16 0.2 Renal cell carcinoma; chr3:40480482 chr3:40313802~40453329:- LIHC cis rs548181 0.611 rs562599 ENSG00000254671.2 STT3A-AS1 -3.68 0.000271 0.0412 -0.36 -0.2 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr11:125590056 chr11:125570284~125592568:- LIHC cis rs4888671 1 rs17716830 ENSG00000261707.1 RP11-264M12.2 3.68 0.000271 0.0412 0.35 0.2 Obesity-related traits; chr16:77738102 chr16:77741468~77743000:- LIHC cis rs9357271 0.652 rs78054489 ENSG00000217165.1 ANKRD18EP -3.68 0.000271 0.0412 -0.14 -0.2 Restless legs syndrome; chr6:38434150 chr6:39110321~39112952:+ LIHC cis rs41313321 0.92 rs60514985 ENSG00000272696.1 RP11-339B21.13 3.68 0.000271 0.0412 0.27 0.2 Coenzyme Q10 levels; chr9:128301083 chr9:128316337~128316909:+ LIHC cis rs12468226 0.752 rs77319662 ENSG00000272966.1 RP11-686O6.1 3.68 0.000271 0.0412 0.34 0.2 Urate levels; chr2:202126928 chr2:202336739~202337200:+ LIHC cis rs11613048 0.897 rs1586279 ENSG00000245614.3 DDX11-AS1 3.68 0.000271 0.0412 0.17 0.2 Major depressive disorder; chr12:30172558 chr12:31020763~31073847:- LIHC cis rs10833905 0.68 rs11026907 ENSG00000246225.5 RP11-17A1.3 3.68 0.000271 0.0412 0.25 0.2 Sudden cardiac arrest; chr11:23017152 chr11:22829380~22945393:+ LIHC cis rs151234 0.676 rs231970 ENSG00000259982.1 CDC37P1 -3.68 0.000271 0.0412 -0.45 -0.2 Platelet distribution width; chr16:28555683 chr16:28700294~28701540:- LIHC cis rs2195987 0.914 rs10416636 ENSG00000268442.1 CTD-2027I19.2 3.68 0.000271 0.0412 0.36 0.2 Testicular germ cell tumor; chr19:23925645 chr19:24162370~24163425:- LIHC cis rs9450351 0.744 rs1447157 ENSG00000203875.9 SNHG5 -3.68 0.000271 0.0412 -0.43 -0.2 Interferon gamma-induced protein 10 levels; chr6:85879434 chr6:85660950~85678736:- LIHC cis rs1501138 0.688 rs1121630 ENSG00000263327.5 TAPT1-AS1 -3.68 0.000271 0.0412 -0.26 -0.2 Systemic juvenile idiopathic arthritis; chr4:16285117 chr4:16226685~16320140:+ LIHC cis rs7734985 0.55 rs7716096 ENSG00000250551.1 RP11-254I22.1 3.68 0.000271 0.0413 0.22 0.2 IgG glycosylation; chr5:96239212 chr5:96050115~96215519:+ LIHC cis rs7734985 0.587 rs10052354 ENSG00000250551.1 RP11-254I22.1 3.68 0.000271 0.0413 0.22 0.2 IgG glycosylation; chr5:96248385 chr5:96050115~96215519:+ LIHC cis rs7734985 0.55 rs10074626 ENSG00000250551.1 RP11-254I22.1 3.68 0.000271 0.0413 0.22 0.2 IgG glycosylation; chr5:96248690 chr5:96050115~96215519:+ LIHC cis rs704795 0.775 rs4665975 ENSG00000234072.1 AC074117.10 -3.68 0.000271 0.0413 -0.18 -0.2 Menopause (age at onset); chr2:27403150 chr2:27356246~27367622:+ LIHC cis rs10833905 0.938 rs10833918 ENSG00000246225.5 RP11-17A1.3 -3.68 0.000271 0.0413 -0.25 -0.2 Sudden cardiac arrest; chr11:23040402 chr11:22829380~22945393:+ LIHC cis rs2243480 1 rs160652 ENSG00000232546.1 RP11-458F8.1 -3.68 0.000272 0.0413 -0.22 -0.2 Diabetic kidney disease; chr7:66073444 chr7:66848496~66858136:+ LIHC cis rs1348850 0.526 rs78587445 ENSG00000213963.5 AC074286.1 3.68 0.000272 0.0413 0.35 0.2 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr2:177596611 chr2:177283508~177392691:- LIHC cis rs2564921 0.73 rs1811351 ENSG00000242142.1 SERBP1P3 -3.68 0.000272 0.0413 -0.27 -0.2 Height; chr3:53064759 chr3:53064283~53065091:- LIHC cis rs694739 0.93 rs574087 ENSG00000236935.1 AP003774.1 3.68 0.000272 0.0413 0.21 0.2 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64335476 chr11:64325050~64329504:- LIHC cis rs13113518 0.812 rs12500601 ENSG00000223305.1 RN7SKP30 3.68 0.000272 0.0413 0.23 0.2 Height; chr4:55451489 chr4:55540502~55540835:- LIHC cis rs9640161 0.83 rs35635199 ENSG00000261305.1 RP4-584D14.7 3.68 0.000272 0.0413 0.24 0.2 Blood protein levels;Circulating chemerin levels; chr7:150366253 chr7:150341771~150342607:+ LIHC cis rs3845817 0.843 rs6705904 ENSG00000237979.1 AC007389.1 -3.68 0.000272 0.0413 -0.21 -0.2 Bipolar disorder; chr2:65542897 chr2:65500993~65502138:- LIHC cis rs4218 0.681 rs1074701 ENSG00000277144.1 RP11-59H7.4 -3.68 0.000272 0.0413 -0.21 -0.2 Social communication problems; chr15:59073862 chr15:59115547~59116089:- LIHC cis rs4218 0.681 rs17302163 ENSG00000277144.1 RP11-59H7.4 -3.68 0.000272 0.0413 -0.21 -0.2 Social communication problems; chr15:59076773 chr15:59115547~59116089:- LIHC cis rs7095607 1 rs10823156 ENSG00000233590.1 RP11-153K11.3 3.68 0.000272 0.0413 0.23 0.2 Lung function (FVC); chr10:68192084 chr10:68233251~68242379:- LIHC cis rs7169304 0.559 rs117818498 ENSG00000259531.2 RP11-295H24.3 3.68 0.000272 0.0413 0.39 0.2 Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma; chr15:49436685 chr15:49365124~49366685:- LIHC cis rs12468226 0.938 rs57571703 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202281997 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs78928733 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202283787 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs116109808 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202287356 chr2:202336739~202337200:+ LIHC cis rs12468226 0.873 rs78175596 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202287993 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs56684065 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202289528 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs1474001 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202290230 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs76664732 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202296298 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs16841867 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202303512 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs79117531 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202307690 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs16839065 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202308774 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs115418918 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202315145 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs114922024 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202315958 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs77261109 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202316233 chr2:202336739~202337200:+ LIHC cis rs12468226 0.938 rs12466003 ENSG00000272966.1 RP11-686O6.1 3.68 0.000272 0.0413 0.32 0.2 Urate levels; chr2:202317317 chr2:202336739~202337200:+ LIHC cis rs7809950 0.678 rs17154040 ENSG00000238832.1 snoU109 3.68 0.000272 0.0413 0.25 0.2 Coronary artery disease; chr7:107364801 chr7:107603363~107603507:+ LIHC cis rs2237234 0.58 rs7763910 ENSG00000124549.13 BTN2A3P -3.68 0.000272 0.0413 -0.19 -0.2 Autism spectrum disorder or schizophrenia; chr6:26472427 chr6:26421391~26432383:+ LIHC cis rs4578769 0.524 rs9956919 ENSG00000266850.1 RP11-370A5.1 3.68 0.000272 0.0413 0.21 0.2 Eosinophil percentage of white cells; chr18:22896538 chr18:22723491~22907721:- LIHC cis rs4578769 0.569 rs12958551 ENSG00000266850.1 RP11-370A5.1 3.68 0.000272 0.0413 0.21 0.2 Eosinophil percentage of white cells; chr18:22897885 chr18:22723491~22907721:- LIHC cis rs5743030 1 rs77906836 ENSG00000253559.1 OSGEPL1-AS1 -3.68 0.000272 0.0413 -0.34 -0.2 Subcutaneous adipose tissue; chr2:189903383 chr2:189762704~189765556:+ LIHC cis rs5743030 1 rs4853634 ENSG00000253559.1 OSGEPL1-AS1 -3.68 0.000272 0.0413 -0.34 -0.2 Subcutaneous adipose tissue; chr2:189914505 chr2:189762704~189765556:+ LIHC cis rs7630852 1 rs7626440 ENSG00000226155.1 AC124944.3 -3.68 0.000272 0.0413 -0.23 -0.2 Eosinophil counts; chr3:196778019 chr3:195912049~195913986:+ LIHC cis rs4604234 0.803 rs3828750 ENSG00000272129.1 RP11-250B2.6 -3.68 0.000272 0.0413 -0.33 -0.2 Cancer; chr6:80253567 chr6:80355424~80356859:+ LIHC cis rs42490 0.536 rs379015 ENSG00000251136.7 RP11-37B2.1 -3.68 0.000272 0.0414 -0.17 -0.2 Leprosy; chr8:89856245 chr8:89609409~89757727:- LIHC cis rs7985 0.874 rs4822765 ENSG00000244625.4 MIATNB 3.68 0.000272 0.0414 0.21 0.2 Electroencephalogram traits; chr22:26667783 chr22:26672767~26780207:+ LIHC cis rs1665050 0.652 rs62002516 ENSG00000259250.1 RP11-50C13.1 3.68 0.000272 0.0414 0.19 0.2 Atopic dermatitis; chr15:59009703 chr15:58587507~58591676:+ LIHC cis rs481331 0.643 rs209387 ENSG00000185904.10 LINC00839 -3.68 0.000272 0.0414 -0.37 -0.2 Systemic juvenile idiopathic arthritis; chr10:42636784 chr10:42475543~42495336:+ LIHC cis rs17264034 0.861 rs1508798 ENSG00000250786.1 SNHG18 -3.68 0.000272 0.0414 -0.24 -0.2 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9556582 chr5:9546200~9550609:+ LIHC cis rs17345786 1 rs3804778 ENSG00000244119.1 PDCL3P4 3.68 0.000273 0.0414 0.22 0.2 Colonoscopy-negative controls vs population controls; chr3:101575728 chr3:101712472~101713191:+ LIHC cis rs2015599 0.623 rs7964831 ENSG00000257176.2 RP11-996F15.2 -3.68 0.000273 0.0414 -0.24 -0.2 Platelet count;Mean platelet volume; chr12:29286655 chr12:29280418~29317848:- LIHC cis rs875971 0.638 rs35986979 ENSG00000224316.1 RP11-479O9.2 -3.68 0.000273 0.0414 -0.19 -0.2 Aortic root size; chr7:66624003 chr7:65773620~65802067:+ LIHC cis rs244293 0.965 rs244350 ENSG00000275710.1 RP11-257O5.4 -3.68 0.000273 0.0414 -0.21 -0.2 Menarche (age at onset); chr17:55118771 chr17:54964474~54964679:+ LIHC cis rs4073416 0.684 rs78230848 ENSG00000276116.2 FUT8-AS1 3.68 0.000273 0.0414 0.25 0.2 N-glycan levels; chr14:65549666 chr14:65411170~65412690:- LIHC cis rs7809950 0.817 rs4727678 ENSG00000238832.1 snoU109 -3.68 0.000273 0.0414 -0.25 -0.2 Coronary artery disease; chr7:107443190 chr7:107603363~107603507:+ LIHC cis rs7809950 0.817 rs4727679 ENSG00000238832.1 snoU109 -3.68 0.000273 0.0414 -0.25 -0.2 Coronary artery disease; chr7:107444573 chr7:107603363~107603507:+ LIHC cis rs7712401 0.601 rs448505 ENSG00000263432.2 RN7SL689P -3.68 0.000273 0.0414 -0.29 -0.2 Mean platelet volume; chr5:123000995 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs2164773 ENSG00000263432.2 RN7SL689P -3.68 0.000273 0.0414 -0.29 -0.2 Mean platelet volume; chr5:123003222 chr5:123022487~123022783:- LIHC cis rs1115240 0.898 rs8004594 ENSG00000257842.4 NOVA1-AS1 3.68 0.000273 0.0414 0.18 0.2 Educational attainment (years of education); chr14:26516141 chr14:26598412~26806467:+ LIHC cis rs1115240 0.898 rs55816280 ENSG00000257842.4 NOVA1-AS1 3.68 0.000273 0.0414 0.18 0.2 Educational attainment (years of education); chr14:26516835 chr14:26598412~26806467:+ LIHC cis rs7534016 0.724 rs1353521 ENSG00000270457.1 RP11-467C18.1 3.68 0.000273 0.0414 0.22 0.2 Obesity-related traits; chr1:59282932 chr1:59289303~59289640:- LIHC cis rs9907295 0.591 rs2107538 ENSG00000267554.1 RP11-686D22.10 3.68 0.000273 0.0415 0.19 0.2 Fibroblast growth factor basic levels; chr17:35880776 chr17:35470069~35470628:- LIHC cis rs433598 1 rs396508 ENSG00000260201.2 RP11-143N13.2 3.68 0.000273 0.0415 0.2 0.2 Schizophrenia; chr16:20671032 chr16:20580999~20586640:+ LIHC cis rs61160187 0.582 rs2898309 ENSG00000272308.1 RP11-231G3.1 -3.68 0.000273 0.0415 -0.2 -0.2 Educational attainment (years of education);Educational attainment (college completion); chr5:60981546 chr5:60866457~60866935:- LIHC cis rs61160187 0.549 rs62367879 ENSG00000272308.1 RP11-231G3.1 -3.68 0.000273 0.0415 -0.2 -0.2 Educational attainment (years of education);Educational attainment (college completion); chr5:60996384 chr5:60866457~60866935:- LIHC cis rs17818399 0.926 rs13033177 ENSG00000279254.1 RP11-536C12.1 -3.68 0.000273 0.0415 -0.24 -0.2 Height; chr2:46603923 chr2:46668870~46670778:+ LIHC cis rs151234 0.741 rs10521145 ENSG00000259982.1 CDC37P1 3.68 0.000274 0.0415 0.43 0.2 Platelet distribution width; chr16:28585563 chr16:28700294~28701540:- LIHC cis rs9929218 0.551 rs9888942 ENSG00000260459.2 FTLP14 3.68 0.000274 0.0415 0.22 0.2 Colorectal cancer; chr16:68693669 chr16:68822587~68823070:+ LIHC cis rs481331 0.741 rs210282 ENSG00000185904.10 LINC00839 -3.68 0.000274 0.0415 -0.37 -0.2 Systemic juvenile idiopathic arthritis; chr10:42592201 chr10:42475543~42495336:+ LIHC cis rs481331 0.741 rs210281 ENSG00000185904.10 LINC00839 -3.68 0.000274 0.0415 -0.37 -0.2 Systemic juvenile idiopathic arthritis; chr10:42592315 chr10:42475543~42495336:+ LIHC cis rs4926298 0.926 rs8111617 ENSG00000228887.3 EEF1DP1 3.68 0.000274 0.0415 0.17 0.2 Bipolar disorder; chr19:13080647 chr19:14070342~14071237:+ LIHC cis rs3015497 1 rs3015495 ENSG00000269906.1 RP11-248J18.2 3.68 0.000274 0.0415 0.24 0.2 Mean platelet volume; chr14:50647985 chr14:50662511~50663178:- LIHC cis rs2115630 0.645 rs6496284 ENSG00000275120.1 RP11-182J1.17 -3.68 0.000274 0.0415 -0.27 -0.2 P wave terminal force; chr15:84635039 chr15:84599434~84606463:- LIHC cis rs9573567 1 rs9565170 ENSG00000261553.4 RP11-29G8.3 -3.68 0.000274 0.0416 -0.29 -0.2 Red blood cell count;Mean corpuscular volume; chr13:75490523 chr13:75549773~75807120:+ LIHC cis rs4356975 0.527 rs12643840 ENSG00000250919.1 RP11-813N20.3 -3.68 0.000274 0.0416 -0.2 -0.2 Obesity-related traits; chr4:69082245 chr4:69027831~69044578:+ LIHC cis rs7044106 0.791 rs10739572 ENSG00000238181.2 AHCYP2 -3.68 0.000274 0.0416 -0.23 -0.2 Hip circumference adjusted for BMI; chr9:120727537 chr9:120720673~120721972:+ LIHC cis rs12623288 0.51 rs4953363 ENSG00000239332.4 LINC01119 -3.68 0.000274 0.0416 -0.31 -0.2 Hair morphology; chr2:46409942 chr2:46816697~46859007:+ LIHC cis rs5751614 0.557 rs5759665 ENSG00000225282.1 AP000350.6 -3.68 0.000274 0.0416 -0.32 -0.2 Height; chr22:23260033 chr22:23926900~23929574:+ LIHC cis rs2348418 0.639 rs7969946 ENSG00000247934.4 RP11-967K21.1 -3.68 0.000274 0.0416 -0.18 -0.2 Lung function (FEV1);Lung function (FVC); chr12:28111814 chr12:28163298~28190738:- LIHC cis rs1005277 0.603 rs1998062 ENSG00000275858.1 RP11-291L22.8 3.68 0.000274 0.0416 0.22 0.2 Extrinsic epigenetic age acceleration; chr10:38168724 chr10:38450738~38451069:- LIHC cis rs2243480 1 rs34815098 ENSG00000226002.1 RP11-460N20.5 -3.68 0.000274 0.0416 -0.29 -0.2 Diabetic kidney disease; chr7:65827267 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs4548056 ENSG00000226002.1 RP11-460N20.5 -3.68 0.000274 0.0416 -0.29 -0.2 Diabetic kidney disease; chr7:65833886 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs7456042 ENSG00000226002.1 RP11-460N20.5 -3.68 0.000274 0.0416 -0.29 -0.2 Diabetic kidney disease; chr7:65834791 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs35735127 ENSG00000226002.1 RP11-460N20.5 -3.68 0.000274 0.0416 -0.29 -0.2 Diabetic kidney disease; chr7:65835436 chr7:65084103~65100232:+ LIHC cis rs2243480 0.901 rs35256305 ENSG00000226002.1 RP11-460N20.5 -3.68 0.000274 0.0416 -0.29 -0.2 Diabetic kidney disease; chr7:65841418 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs73142121 ENSG00000226002.1 RP11-460N20.5 -3.68 0.000274 0.0416 -0.29 -0.2 Diabetic kidney disease; chr7:65846219 chr7:65084103~65100232:+ LIHC cis rs2243480 0.803 rs34004500 ENSG00000226002.1 RP11-460N20.5 -3.68 0.000274 0.0416 -0.29 -0.2 Diabetic kidney disease; chr7:65847191 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs35825738 ENSG00000226002.1 RP11-460N20.5 -3.68 0.000274 0.0416 -0.29 -0.2 Diabetic kidney disease; chr7:65853040 chr7:65084103~65100232:+ LIHC cis rs801193 1 rs7782320 ENSG00000237310.1 GS1-124K5.4 3.68 0.000274 0.0416 0.18 0.19 Aortic root size; chr7:66712111 chr7:66493706~66495474:+ LIHC cis rs2613514 0.667 rs2311443 ENSG00000204277.1 RP11-219G17.4 3.68 0.000274 0.0416 0.28 0.19 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78058668 chr17:78261349~78278492:- LIHC cis rs2806356 0.713 rs2806372 ENSG00000203801.7 LINC00222 3.68 0.000274 0.0416 0.24 0.19 Chronic obstructive pulmonary disease; chr6:108900800 chr6:108751654~108769942:+ LIHC cis rs7647973 0.516 rs4536858 ENSG00000270441.1 RP11-694I15.7 -3.68 0.000274 0.0416 -0.28 -0.19 Menarche (age at onset); chr3:49155648 chr3:49140086~49160851:- LIHC cis rs17818399 0.926 rs13032670 ENSG00000279254.1 RP11-536C12.1 -3.68 0.000274 0.0416 -0.24 -0.19 Height; chr2:46603655 chr2:46668870~46670778:+ LIHC cis rs12586317 0.62 rs7147571 ENSG00000257307.1 RP11-317N8.4 -3.68 0.000275 0.0416 -0.23 -0.19 Psoriasis; chr14:35061030 chr14:35881001~35881709:+ LIHC cis rs17772222 0.917 rs4635267 ENSG00000258789.1 RP11-507K2.3 -3.68 0.000275 0.0417 -0.23 -0.19 Coronary artery calcification; chr14:88621922 chr14:88551597~88552493:+ LIHC cis rs4218 0.681 rs7178935 ENSG00000277144.1 RP11-59H7.4 -3.68 0.000275 0.0417 -0.21 -0.19 Social communication problems; chr15:59075968 chr15:59115547~59116089:- LIHC cis rs787274 0.543 rs10739377 ENSG00000271631.1 RP11-408O19.5 -3.68 0.000275 0.0417 -0.3 -0.19 Age-related hearing impairment (SNP x SNP interaction); chr9:112869318 chr9:112885158~112885767:+ LIHC cis rs67311347 0.955 rs1129200 ENSG00000223797.4 ENTPD3-AS1 3.68 0.000275 0.0417 0.16 0.19 Renal cell carcinoma; chr3:40490766 chr3:40313802~40453329:- LIHC cis rs17772222 0.917 rs17260415 ENSG00000258789.1 RP11-507K2.3 -3.68 0.000275 0.0417 -0.24 -0.19 Coronary artery calcification; chr14:88745629 chr14:88551597~88552493:+ LIHC cis rs6442522 0.56 rs2305614 ENSG00000249786.6 EAF1-AS1 3.68 0.000275 0.0417 0.23 0.19 Uric acid levels; chr3:15475811 chr3:15436171~15455940:- LIHC cis rs673078 0.607 rs884844 ENSG00000275759.1 RP11-131L12.3 -3.68 0.000275 0.0417 -0.37 -0.19 Glucose homeostasis traits; chr12:118377033 chr12:118428281~118428870:+ LIHC cis rs13113518 0.776 rs13124436 ENSG00000223305.1 RN7SKP30 3.68 0.000275 0.0417 0.23 0.19 Height; chr4:55502504 chr4:55540502~55540835:- LIHC cis rs13113518 0.783 rs6843997 ENSG00000223305.1 RN7SKP30 3.68 0.000275 0.0417 0.23 0.19 Height; chr4:55508982 chr4:55540502~55540835:- LIHC cis rs13113518 0.783 rs12508367 ENSG00000223305.1 RN7SKP30 3.68 0.000275 0.0417 0.23 0.19 Height; chr4:55509442 chr4:55540502~55540835:- LIHC cis rs13113518 0.812 rs2272073 ENSG00000223305.1 RN7SKP30 3.68 0.000275 0.0417 0.23 0.19 Height; chr4:55510177 chr4:55540502~55540835:- LIHC cis rs600231 0.598 rs2508712 ENSG00000245532.5 NEAT1 3.68 0.000275 0.0418 0.19 0.19 Bone mineral density; chr11:65464790 chr11:65422774~65445540:+ LIHC cis rs600231 0.708 rs3132767 ENSG00000245532.5 NEAT1 3.68 0.000275 0.0418 0.19 0.19 Bone mineral density; chr11:65467389 chr11:65422774~65445540:+ LIHC cis rs7394190 0.748 rs4082339 ENSG00000242338.5 BMS1P4 -3.68 0.000275 0.0418 -0.27 -0.19 Incident atrial fibrillation; chr10:73780054 chr10:73715843~73730469:- LIHC cis rs2348418 0.864 rs7299039 ENSG00000247934.4 RP11-967K21.1 3.68 0.000275 0.0418 0.18 0.19 Lung function (FEV1);Lung function (FVC); chr12:28454083 chr12:28163298~28190738:- LIHC cis rs9595908 0.686 rs7988353 ENSG00000212293.1 SNORA16 3.68 0.000276 0.0418 0.23 0.19 Body mass index; chr13:32760250 chr13:32420390~32420516:- LIHC cis rs2847297 1 rs2847297 ENSG00000260302.1 RP11-973H7.1 3.68 0.000276 0.0418 0.21 0.19 Rheumatoid arthritis; chr18:12797695 chr18:12774651~12775923:- LIHC cis rs340029 0.675 rs8033609 ENSG00000273958.1 RP11-219B17.3 -3.68 0.000276 0.0418 -0.2 -0.19 C-reactive protein levels; chr15:60646617 chr15:60593027~60593460:+ LIHC cis rs6142102 0.517 rs8119076 ENSG00000275784.1 RP5-1125A11.6 -3.68 0.000276 0.0418 -0.2 -0.19 Skin pigmentation; chr20:33937909 chr20:33989480~33991818:- LIHC cis rs7829975 0.572 rs7005000 ENSG00000254340.1 RP11-10A14.3 -3.68 0.000276 0.0418 -0.2 -0.19 Mood instability; chr8:8939092 chr8:9141424~9145435:+ LIHC cis rs2243480 1 rs781157 ENSG00000229886.1 RP5-1132H15.3 3.68 0.000276 0.0418 0.29 0.19 Diabetic kidney disease; chr7:66013324 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs781156 ENSG00000229886.1 RP5-1132H15.3 3.68 0.000276 0.0418 0.29 0.19 Diabetic kidney disease; chr7:66014154 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs781149 ENSG00000229886.1 RP5-1132H15.3 3.68 0.000276 0.0418 0.29 0.19 Diabetic kidney disease; chr7:66016297 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs451396 ENSG00000229886.1 RP5-1132H15.3 3.68 0.000276 0.0418 0.29 0.19 Diabetic kidney disease; chr7:66019087 chr7:66025126~66031544:- LIHC cis rs2243480 0.901 rs58207111 ENSG00000229886.1 RP5-1132H15.3 3.68 0.000276 0.0418 0.29 0.19 Diabetic kidney disease; chr7:66021736 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs1167613 ENSG00000229886.1 RP5-1132H15.3 3.68 0.000276 0.0418 0.29 0.19 Diabetic kidney disease; chr7:66022452 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs1715235 ENSG00000229886.1 RP5-1132H15.3 3.68 0.000276 0.0418 0.29 0.19 Diabetic kidney disease; chr7:66023407 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs313799 ENSG00000229886.1 RP5-1132H15.3 3.68 0.000276 0.0418 0.29 0.19 Diabetic kidney disease; chr7:66029343 chr7:66025126~66031544:- LIHC cis rs11009175 0.725 rs11009195 ENSG00000273038.2 RP11-479G22.8 -3.68 0.000276 0.0418 -0.24 -0.19 Depression (quantitative trait); chr10:33045345 chr10:32887255~32889311:- LIHC cis rs9929218 0.581 rs4783676 ENSG00000260459.2 FTLP14 3.68 0.000276 0.0418 0.23 0.19 Colorectal cancer; chr16:68767174 chr16:68822587~68823070:+ LIHC cis rs17221829 0.965 rs10830370 ENSG00000280367.1 RP11-121L10.2 3.68 0.000276 0.0418 0.22 0.19 Anxiety in major depressive disorder; chr11:89728367 chr11:90223153~90226538:+ LIHC cis rs17221829 0.931 rs10160803 ENSG00000280367.1 RP11-121L10.2 3.68 0.000276 0.0418 0.22 0.19 Anxiety in major depressive disorder; chr11:89728691 chr11:90223153~90226538:+ LIHC cis rs2742417 0.603 rs2064063 ENSG00000244357.3 RN7SL145P 3.68 0.000276 0.0418 0.19 0.19 Response to anti-depressant treatment in major depressive disorder; chr3:45718432 chr3:45742675~45742970:+ LIHC cis rs2742417 0.603 rs2064064 ENSG00000244357.3 RN7SL145P 3.68 0.000276 0.0418 0.19 0.19 Response to anti-depressant treatment in major depressive disorder; chr3:45718503 chr3:45742675~45742970:+ LIHC cis rs2742417 0.603 rs2064062 ENSG00000244357.3 RN7SL145P 3.68 0.000276 0.0418 0.19 0.19 Response to anti-depressant treatment in major depressive disorder; chr3:45719623 chr3:45742675~45742970:+ LIHC cis rs2742417 0.603 rs2673062 ENSG00000244357.3 RN7SL145P 3.68 0.000276 0.0418 0.19 0.19 Response to anti-depressant treatment in major depressive disorder; chr3:45722143 chr3:45742675~45742970:+ LIHC cis rs12681287 0.752 rs4427148 ENSG00000254088.1 SLC2A3P4 3.68 0.000276 0.0418 0.23 0.19 Caudate activity during reward; chr8:86238439 chr8:86503591~86505061:+ LIHC cis rs2333021 0.833 rs10141389 ENSG00000259015.1 RP11-109N23.6 3.68 0.000276 0.0418 0.23 0.19 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:73000413 chr14:72960595~72961993:+ LIHC cis rs7617773 0.563 rs62263035 ENSG00000229759.1 MRPS18AP1 3.67 0.000276 0.0418 0.22 0.19 Coronary artery disease; chr3:48350079 chr3:48256350~48256938:- LIHC cis rs4873772 0.837 rs12678110 ENSG00000253608.1 RP11-770E5.1 3.67 0.000276 0.0418 0.21 0.19 Lobe attachment (rater-scored or self-reported); chr8:47649528 chr8:48551567~48698510:+ LIHC cis rs41369048 0.858 rs10495155 ENSG00000272823.1 RP11-295M18.6 -3.67 0.000276 0.0418 -0.36 -0.19 Eosinophil counts;Sum eosinophil basophil counts; chr1:220902527 chr1:220828676~220829211:- LIHC cis rs1510272 0.921 rs2202965 ENSG00000243926.1 TIPARP-AS1 -3.67 0.000276 0.0419 -0.19 -0.19 Testicular germ cell tumor; chr3:156568927 chr3:156671862~156674378:- LIHC cis rs853679 1 rs2799079 ENSG00000219392.1 RP1-265C24.5 -3.67 0.000276 0.0419 -0.34 -0.19 Depression; chr6:28267398 chr6:28115628~28116551:+ LIHC cis rs17818399 0.926 rs35350086 ENSG00000279254.1 RP11-536C12.1 -3.67 0.000276 0.0419 -0.24 -0.19 Height; chr2:46606897 chr2:46668870~46670778:+ LIHC cis rs9907295 0.591 rs9908928 ENSG00000267554.1 RP11-686D22.10 3.67 0.000276 0.0419 0.19 0.19 Fibroblast growth factor basic levels; chr17:35862013 chr17:35470069~35470628:- LIHC cis rs2243480 1 rs78803505 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65917585 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs34933526 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65918212 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs34577383 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65920739 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs6949812 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65922114 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs6970243 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65923503 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs7794661 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65924743 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs7795242 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65925107 chr7:65084103~65100232:+ LIHC cis rs2243480 0.708 rs35310401 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65925372 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs35058610 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65925938 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs2177703 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65926730 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs35432774 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65928032 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs56985706 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65929575 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs60683927 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65929781 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs58062456 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65929865 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs34529418 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65938222 chr7:65084103~65100232:+ LIHC cis rs2243480 0.901 rs35087093 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65940221 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs35046236 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65943626 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs36068983 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65944004 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs68189316 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65944182 chr7:65084103~65100232:+ LIHC cis rs2243480 0.803 rs34804747 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65947955 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs11538349 ENSG00000226002.1 RP11-460N20.5 -3.67 0.000276 0.0419 -0.28 -0.19 Diabetic kidney disease; chr7:65956884 chr7:65084103~65100232:+ LIHC cis rs2243480 0.831 rs7806717 ENSG00000226002.1 RP11-460N20.5 3.67 0.000276 0.0419 0.28 0.19 Diabetic kidney disease; chr7:65928187 chr7:65084103~65100232:+ LIHC cis rs10471753 0.935 rs1363857 ENSG00000248359.1 CTC-537E7.2 -3.67 0.000276 0.0419 -0.24 -0.19 Hip minimal joint space width; chr5:68533669 chr5:68531690~68533530:- LIHC cis rs11096990 0.964 rs6828598 ENSG00000249685.1 RP11-360F5.3 -3.67 0.000277 0.0419 -0.26 -0.19 Cognitive function; chr4:39259850 chr4:39133913~39135608:+ LIHC cis rs2333021 0.78 rs28619241 ENSG00000259015.1 RP11-109N23.6 3.67 0.000277 0.0419 0.23 0.19 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72972902 chr14:72960595~72961993:+ LIHC cis rs2333021 0.78 rs12931 ENSG00000259015.1 RP11-109N23.6 3.67 0.000277 0.0419 0.23 0.19 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72974156 chr14:72960595~72961993:+ LIHC cis rs4891159 0.757 rs11665018 ENSG00000265778.2 RP11-17M16.2 -3.67 0.000277 0.0419 -0.24 -0.19 Longevity; chr18:76411633 chr18:76491652~76493918:+ LIHC cis rs6500395 1 rs7190106 ENSG00000261267.1 RP11-44I10.3 -3.67 0.000277 0.0419 -0.25 -0.19 Response to tocilizumab in rheumatoid arthritis; chr16:48671631 chr16:48559661~48587403:+ LIHC cis rs2228479 0.681 rs10153055 ENSG00000261253.2 AC137932.6 3.67 0.000277 0.0419 0.29 0.19 Skin colour saturation; chr16:89899434 chr16:89321133~89325110:+ LIHC cis rs875971 0.545 rs13311962 ENSG00000273024.4 INTS4P2 3.67 0.000277 0.0419 0.22 0.19 Aortic root size; chr7:66603142 chr7:65647864~65715661:+ LIHC cis rs6048205 0.649 rs4815126 ENSG00000259974.2 LINC00261 3.67 0.000277 0.042 0.31 0.19 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22540431 chr20:22547671~22578642:- LIHC cis rs7722022 0.922 rs4302609 ENSG00000253428.1 CTB-43E15.2 3.67 0.000277 0.042 0.21 0.19 Adiponectin levels; chr5:173528203 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs2339960 ENSG00000253428.1 CTB-43E15.2 3.67 0.000277 0.042 0.21 0.19 Adiponectin levels; chr5:173528211 chr5:173689459~173705849:+ LIHC cis rs4891159 0.79 rs7237974 ENSG00000265778.2 RP11-17M16.2 -3.67 0.000277 0.042 -0.24 -0.19 Longevity; chr18:76396904 chr18:76491652~76493918:+ LIHC cis rs4356975 0.509 rs6422323 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000277 0.042 -0.2 -0.19 Obesity-related traits; chr4:69087362 chr4:69027831~69044578:+ LIHC cis rs58873874 0.522 rs111370613 ENSG00000244331.1 CTB-47B8.1 3.67 0.000277 0.042 0.43 0.19 Bipolar disorder (body mass index interaction); chr5:157271128 chr5:157931258~157931563:- LIHC cis rs58873874 0.522 rs77458926 ENSG00000244331.1 CTB-47B8.1 3.67 0.000277 0.042 0.43 0.19 Bipolar disorder (body mass index interaction); chr5:157271198 chr5:157931258~157931563:- LIHC cis rs4356975 0.563 rs4538548 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000277 0.042 -0.19 -0.19 Obesity-related traits; chr4:69094951 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs6600883 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000277 0.042 -0.19 -0.19 Obesity-related traits; chr4:69094953 chr4:69027831~69044578:+ LIHC cis rs2286503 1 rs2286499 ENSG00000226329.2 AC005682.6 3.67 0.000277 0.042 0.24 0.19 Fibrinogen; chr7:22817858 chr7:22863874~22881350:- LIHC cis rs4919694 1 rs76255497 ENSG00000236937.2 PTGES3P4 3.67 0.000277 0.042 0.36 0.19 Arsenic metabolism; chr10:102892198 chr10:102845595~102845950:+ LIHC cis rs4919694 1 rs75691516 ENSG00000236937.2 PTGES3P4 3.67 0.000277 0.042 0.36 0.19 Arsenic metabolism; chr10:102892288 chr10:102845595~102845950:+ LIHC cis rs9487094 1 rs9487094 ENSG00000260273.1 RP11-425D10.10 3.67 0.000277 0.042 0.23 0.19 Height; chr6:109420812 chr6:109382795~109383666:+ LIHC cis rs7216064 1 rs7223930 ENSG00000279880.1 RP11-855A2.2 3.67 0.000278 0.042 0.22 0.19 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67846070 chr17:67973934~67976072:+ LIHC cis rs10895987 0.955 rs7114094 ENSG00000254614.2 AP003068.23 3.67 0.000278 0.042 0.35 0.19 Blood protein levels; chr11:65159740 chr11:65177606~65181834:- LIHC cis rs8064024 0.68 rs8056320 ENSG00000267077.1 RP11-127I20.5 3.67 0.000278 0.042 0.2 0.19 Cancer; chr16:4868016 chr16:4795265~4796532:- LIHC cis rs1816213 0.744 rs13006838 ENSG00000273466.1 RP11-548H3.1 -3.67 0.000278 0.042 -0.29 -0.19 Diastolic blood pressure; chr2:218461578 chr2:218633256~218634014:- LIHC cis rs734999 0.545 rs10910111 ENSG00000225931.3 RP3-395M20.7 3.67 0.000278 0.042 0.2 0.19 Ulcerative colitis; chr1:2611214 chr1:2566410~2569888:+ LIHC cis rs2115630 1 rs11073730 ENSG00000189136.7 UBE2Q2P1 -3.67 0.000278 0.042 -0.16 -0.19 P wave terminal force; chr15:84811365 chr15:84526781~84571216:- LIHC cis rs3934487 0.547 rs4244651 ENSG00000223956.1 RP4-710M16.2 -3.67 0.000278 0.042 -0.21 -0.19 Reticulocyte count; chr1:55861480 chr1:56414963~56415966:+ LIHC cis rs3934487 0.547 rs3922837 ENSG00000223956.1 RP4-710M16.2 -3.67 0.000278 0.042 -0.21 -0.19 Reticulocyte count; chr1:55861666 chr1:56414963~56415966:+ LIHC cis rs10774547 1 rs4767891 ENSG00000278344.1 RP11-18C24.8 3.67 0.000278 0.042 0.24 0.19 Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);Reading disability or specific language impairment (pleiotropy); chr12:120425619 chr12:120500735~120501090:- LIHC cis rs638893 0.636 rs61901410 ENSG00000278376.1 RP11-158I9.8 3.67 0.000278 0.042 0.37 0.19 Vitiligo; chr11:118790488 chr11:118791254~118793137:+ LIHC cis rs10510102 0.935 rs7921873 ENSG00000273891.1 RP11-500G22.5 3.67 0.000278 0.0421 0.25 0.19 Breast cancer; chr10:121881736 chr10:121965764~121967700:+ LIHC cis rs2933343 0.951 rs789251 ENSG00000261159.1 RP11-723O4.9 3.67 0.000278 0.0421 0.26 0.19 IgG glycosylation; chr3:128857927 chr3:128859716~128860526:- LIHC cis rs74781061 0.929 rs12441932 ENSG00000247240.6 UBL7-AS1 3.67 0.000278 0.0421 0.21 0.19 Endometriosis; chr15:74617658 chr15:74461265~74481302:+ LIHC cis rs12682352 0.602 rs4841044 ENSG00000173295.6 FAM86B3P -3.67 0.000278 0.0421 -0.26 -0.19 Neuroticism; chr8:8807430 chr8:8228595~8244865:+ LIHC cis rs5769707 0.935 rs1109320 ENSG00000279345.1 RP3-522J7.7 -3.67 0.000278 0.0421 -0.17 -0.19 Monocyte percentage of white cells;Monocyte count; chr22:49595458 chr22:49805452~49807208:+ LIHC cis rs5769707 0.839 rs73176988 ENSG00000279345.1 RP3-522J7.7 -3.67 0.000278 0.0421 -0.17 -0.19 Monocyte percentage of white cells;Monocyte count; chr22:49596001 chr22:49805452~49807208:+ LIHC cis rs4891159 0.79 rs72973773 ENSG00000265778.2 RP11-17M16.2 -3.67 0.000278 0.0421 -0.24 -0.19 Longevity; chr18:76403220 chr18:76491652~76493918:+ LIHC cis rs34734847 0.703 rs7978125 ENSG00000241030.1 RPL29P24 3.67 0.000278 0.0421 0.19 0.19 Mean corpuscular volume; chr12:120729236 chr12:120522664~120523443:- LIHC cis rs6732160 0.691 rs13402225 ENSG00000272702.1 RP11-44N22.3 3.67 0.000278 0.0421 0.22 0.19 Intelligence (multi-trait analysis); chr2:73189778 chr2:73113018~73115907:+ LIHC cis rs559928 0.606 rs56207008 ENSG00000236935.1 AP003774.1 3.67 0.000278 0.0421 0.28 0.19 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64115743 chr11:64325050~64329504:- LIHC cis rs875971 0.545 rs2279757 ENSG00000224316.1 RP11-479O9.2 3.67 0.000278 0.0421 0.19 0.19 Aortic root size; chr7:66363676 chr7:65773620~65802067:+ LIHC cis rs875971 0.545 rs11766183 ENSG00000224316.1 RP11-479O9.2 3.67 0.000278 0.0421 0.19 0.19 Aortic root size; chr7:66374173 chr7:65773620~65802067:+ LIHC cis rs875971 0.545 rs1065265 ENSG00000224316.1 RP11-479O9.2 3.67 0.000278 0.0421 0.19 0.19 Aortic root size; chr7:66376216 chr7:65773620~65802067:+ LIHC cis rs875971 0.545 rs7811204 ENSG00000224316.1 RP11-479O9.2 3.67 0.000278 0.0421 0.19 0.19 Aortic root size; chr7:66387213 chr7:65773620~65802067:+ LIHC cis rs7722022 0.961 rs60899884 ENSG00000253428.1 CTB-43E15.2 3.67 0.000278 0.0421 0.21 0.19 Adiponectin levels; chr5:173527208 chr5:173689459~173705849:+ LIHC cis rs7722022 0.848 rs62378559 ENSG00000253428.1 CTB-43E15.2 3.67 0.000278 0.0421 0.21 0.19 Adiponectin levels; chr5:173527228 chr5:173689459~173705849:+ LIHC cis rs481331 0.799 rs7919712 ENSG00000185904.10 LINC00839 3.67 0.000278 0.0421 0.37 0.19 Systemic juvenile idiopathic arthritis; chr10:42472862 chr10:42475543~42495336:+ LIHC cis rs1318937 0.764 rs9853971 ENSG00000224660.1 SH3BP5-AS1 3.67 0.000278 0.0421 0.18 0.19 Alcohol dependence;Alcohol and nicotine co-dependence; chr3:15183840 chr3:15254184~15264493:+ LIHC cis rs74233809 0.901 rs3824754 ENSG00000236937.2 PTGES3P4 3.67 0.000278 0.0421 0.3 0.19 Birth weight; chr10:102854593 chr10:102845595~102845950:+ LIHC cis rs4561483 0.603 rs11639888 ENSG00000261560.1 RP11-166B2.3 3.67 0.000278 0.0421 0.24 0.19 Testicular germ cell tumor; chr16:11840766 chr16:11881075~11882569:- LIHC cis rs7820838 0.543 rs4733343 ENSG00000272338.2 RP11-722E23.2 -3.67 0.000278 0.0421 -0.25 -0.19 Lung cancer;Post bronchodilator FEV1/FVC ratio in COPD; chr8:32502704 chr8:33360839~33361415:- LIHC cis rs12468226 0.702 rs114634431 ENSG00000272966.1 RP11-686O6.1 3.67 0.000279 0.0421 0.35 0.19 Urate levels; chr2:202142530 chr2:202336739~202337200:+ LIHC cis rs8035452 0.857 rs3098189 ENSG00000273674.3 CTD-2378E12.1 3.67 0.000279 0.0421 0.24 0.19 Alzheimer's disease (late onset); chr15:50520600 chr15:50839875~50908599:- LIHC cis rs17345786 0.628 rs11718446 ENSG00000244119.1 PDCL3P4 3.67 0.000279 0.0421 0.21 0.19 Colonoscopy-negative controls vs population controls; chr3:101833709 chr3:101712472~101713191:+ LIHC cis rs6832769 0.925 rs4865018 ENSG00000272969.1 RP11-528I4.2 -3.67 0.000279 0.0421 -0.23 -0.19 Personality dimensions; chr4:55591024 chr4:55547112~55547889:+ LIHC cis rs1106684 1 rs17792713 ENSG00000233559.1 AC016831.7 3.67 0.000279 0.0421 0.35 0.19 Body mass index; chr7:131778520 chr7:130853720~130928649:+ LIHC cis rs881375 1 rs4323544 ENSG00000226752.6 PSMD5-AS1 -3.67 0.000279 0.0421 -0.21 -0.19 Rheumatoid arthritis; chr9:120885099 chr9:120824828~120854385:+ LIHC cis rs41313321 0.541 rs2240956 ENSG00000272696.1 RP11-339B21.13 -3.67 0.000279 0.0422 -0.25 -0.19 Coenzyme Q10 levels; chr9:128286481 chr9:128316337~128316909:+ LIHC cis rs9450351 0.744 rs9353348 ENSG00000203875.9 SNHG5 -3.67 0.000279 0.0422 -0.4 -0.19 Interferon gamma-induced protein 10 levels; chr6:85981635 chr6:85660950~85678736:- LIHC cis rs12370990 0.546 rs10880915 ENSG00000257261.4 RP11-96H19.1 3.67 0.000279 0.0422 0.32 0.19 Post bronchodilator FEV1 in COPD; chr12:46102046 chr12:46383679~46876159:+ LIHC cis rs2348418 0.966 rs11049698 ENSG00000247934.4 RP11-967K21.1 3.67 0.000279 0.0422 0.18 0.19 Lung function (FEV1);Lung function (FVC); chr12:28535354 chr12:28163298~28190738:- LIHC cis rs694739 0.628 rs475032 ENSG00000236935.1 AP003774.1 -3.67 0.000279 0.0422 -0.21 -0.19 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373265 chr11:64325050~64329504:- LIHC cis rs832540 0.669 rs832539 ENSG00000271828.1 CTD-2310F14.1 3.67 0.000279 0.0422 0.25 0.19 Coronary artery disease; chr5:56903559 chr5:56927874~56929573:+ LIHC cis rs2976388 0.609 rs2572907 ENSG00000253741.1 CTD-2292P10.4 -3.67 0.000279 0.0422 -0.23 -0.19 Urinary tract infection frequency; chr8:142720520 chr8:142702252~142726973:- LIHC cis rs2976388 0.609 rs2572908 ENSG00000253741.1 CTD-2292P10.4 -3.67 0.000279 0.0422 -0.23 -0.19 Urinary tract infection frequency; chr8:142721218 chr8:142702252~142726973:- LIHC cis rs2976388 0.609 rs2717602 ENSG00000253741.1 CTD-2292P10.4 -3.67 0.000279 0.0422 -0.23 -0.19 Urinary tract infection frequency; chr8:142724265 chr8:142702252~142726973:- LIHC cis rs783540 0.521 rs1259176 ENSG00000278603.1 RP13-608F4.5 -3.67 0.000279 0.0422 -0.24 -0.19 Schizophrenia; chr15:82602149 chr15:82472203~82472426:+ LIHC cis rs1823874 0.72 rs1993296 ENSG00000182397.13 DNM1P46 -3.67 0.000279 0.0422 -0.23 -0.19 IgG glycosylation; chr15:99823383 chr15:99790156~99806927:- LIHC cis rs2115630 0.645 rs4842978 ENSG00000275120.1 RP11-182J1.17 -3.67 0.000279 0.0422 -0.27 -0.19 P wave terminal force; chr15:84654022 chr15:84599434~84606463:- LIHC cis rs950880 0.71 rs4851011 ENSG00000234389.1 AC007278.3 3.67 0.00028 0.0422 0.2 0.19 Serum protein levels (sST2); chr2:102473219 chr2:102438713~102440475:+ LIHC cis rs7819412 0.811 rs2409691 ENSG00000255394.4 C8orf49 -3.67 0.00028 0.0422 -0.26 -0.19 Triglycerides; chr8:11085766 chr8:11761256~11763223:+ LIHC cis rs7539624 0.577 rs1153950 ENSG00000188460.4 ACTBP11 3.67 0.00028 0.0422 0.22 0.19 Schizophrenia; chr1:223772094 chr1:223863726~223864851:- LIHC cis rs8177179 0.565 rs4355280 ENSG00000244062.1 RP11-404G16.2 3.67 0.00028 0.0423 0.2 0.19 Iron status biomarkers (transferrin levels); chr3:133749581 chr3:133760300~133762363:+ LIHC cis rs6449502 0.92 rs162240 ENSG00000272308.1 RP11-231G3.1 -3.67 0.00028 0.0423 -0.27 -0.19 Mean platelet volume; chr5:61003517 chr5:60866457~60866935:- LIHC cis rs12817211 0.502 rs34167640 ENSG00000272368.2 RP4-605O3.4 -3.67 0.00028 0.0423 -0.22 -0.19 Colorectal or endometrial cancer; chr12:50123208 chr12:50112197~50165618:+ LIHC cis rs12817211 0.524 rs1554845 ENSG00000272368.2 RP4-605O3.4 -3.67 0.00028 0.0423 -0.22 -0.19 Colorectal or endometrial cancer; chr12:50129721 chr12:50112197~50165618:+ LIHC cis rs3738443 0.951 rs61840467 ENSG00000259865.1 RP11-488L18.10 3.67 0.00028 0.0423 0.21 0.19 Alcohol dependence; chr1:247216936 chr1:247187281~247188526:- LIHC cis rs7364180 0.514 rs763263 ENSG00000237037.8 NDUFA6-AS1 -3.67 0.00028 0.0423 -0.27 -0.19 Alzheimer's disease biomarkers; chr22:41919786 chr22:42090931~42137742:+ LIHC cis rs12681287 0.511 rs7839601 ENSG00000254088.1 SLC2A3P4 3.67 0.00028 0.0423 0.23 0.19 Caudate activity during reward; chr8:86491610 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs7459877 ENSG00000254088.1 SLC2A3P4 3.67 0.00028 0.0423 0.23 0.19 Caudate activity during reward; chr8:86493431 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs7837569 ENSG00000254088.1 SLC2A3P4 3.67 0.00028 0.0423 0.23 0.19 Caudate activity during reward; chr8:86495137 chr8:86503591~86505061:+ LIHC cis rs12681287 0.517 rs34367154 ENSG00000254088.1 SLC2A3P4 3.67 0.00028 0.0423 0.23 0.19 Caudate activity during reward; chr8:86496520 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs9942792 ENSG00000254088.1 SLC2A3P4 3.67 0.00028 0.0423 0.23 0.19 Caudate activity during reward; chr8:86496817 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs9942793 ENSG00000254088.1 SLC2A3P4 3.67 0.00028 0.0423 0.23 0.19 Caudate activity during reward; chr8:86496862 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs9942823 ENSG00000254088.1 SLC2A3P4 3.67 0.00028 0.0423 0.23 0.19 Caudate activity during reward; chr8:86496948 chr8:86503591~86505061:+ LIHC cis rs673078 0.607 rs61943403 ENSG00000275759.1 RP11-131L12.3 -3.67 0.00028 0.0423 -0.37 -0.19 Glucose homeostasis traits; chr12:118399887 chr12:118428281~118428870:+ LIHC cis rs2518049 0.539 rs10795250 ENSG00000225418.1 AKR1C5P -3.67 0.00028 0.0423 -0.2 -0.19 Metabolic traits; chr10:5122644 chr10:5122087~5135226:- LIHC cis rs1106684 1 rs10954328 ENSG00000233559.1 AC016831.7 -3.67 0.00028 0.0423 -0.34 -0.19 Body mass index; chr7:131773266 chr7:130853720~130928649:+ LIHC cis rs2749592 0.588 rs2504144 ENSG00000099251.13 HSD17B7P2 3.67 0.00028 0.0423 0.24 0.19 Age-related hearing impairment (SNP x SNP interaction); chr10:38094597 chr10:38356380~38378505:+ LIHC cis rs2243480 1 rs6966322 ENSG00000228409.4 CCT6P1 -3.67 0.00028 0.0423 -0.21 -0.19 Diabetic kidney disease; chr7:66181767 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs4145008 ENSG00000228409.4 CCT6P1 -3.67 0.00028 0.0423 -0.21 -0.19 Diabetic kidney disease; chr7:66182524 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs4718315 ENSG00000228409.4 CCT6P1 -3.67 0.00028 0.0423 -0.21 -0.19 Diabetic kidney disease; chr7:66183554 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs4718316 ENSG00000228409.4 CCT6P1 -3.67 0.00028 0.0423 -0.21 -0.19 Diabetic kidney disease; chr7:66183744 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1873494 ENSG00000228409.4 CCT6P1 -3.67 0.00028 0.0423 -0.21 -0.19 Diabetic kidney disease; chr7:66184912 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs6959002 ENSG00000228409.4 CCT6P1 -3.67 0.00028 0.0423 -0.21 -0.19 Diabetic kidney disease; chr7:66185509 chr7:65751142~65763354:+ LIHC cis rs1405130 0.869 rs13010653 ENSG00000224287.2 MSL3P1 3.67 0.00028 0.0423 0.23 0.19 Coronary artery disease; chr2:234666629 chr2:233865437~233868444:- LIHC cis rs8005677 1 rs7145494 ENSG00000279656.1 RP11-298I3.6 3.67 0.00028 0.0423 0.22 0.19 Cognitive ability (multi-trait analysis); chr14:22930581 chr14:23023083~23024217:- LIHC cis rs8005677 1 rs7155857 ENSG00000279656.1 RP11-298I3.6 3.67 0.00028 0.0423 0.22 0.19 Cognitive ability (multi-trait analysis); chr14:22930850 chr14:23023083~23024217:- LIHC cis rs11089937 0.568 rs12159174 ENSG00000211639.2 IGLV4-60 3.67 0.00028 0.0424 0.17 0.19 Periodontitis (PAL4Q3); chr22:22131639 chr22:22162199~22162681:+ LIHC cis rs11089937 0.568 rs11089919 ENSG00000211639.2 IGLV4-60 3.67 0.00028 0.0424 0.17 0.19 Periodontitis (PAL4Q3); chr22:22131648 chr22:22162199~22162681:+ LIHC cis rs2070488 1 rs2070488 ENSG00000229589.1 ACVR2B-AS1 -3.67 0.000281 0.0424 -0.22 -0.19 Electrocardiographic conduction measures; chr3:38400999 chr3:38451027~38454820:- LIHC cis rs7044106 0.762 rs13291660 ENSG00000270917.1 RP11-27I1.6 -3.67 0.000281 0.0424 -0.25 -0.19 Hip circumference adjusted for BMI; chr9:120630470 chr9:120812475~120812845:- LIHC cis rs7586604 1 rs10198310 ENSG00000230393.1 AC092667.2 3.67 0.000281 0.0424 0.28 0.19 Cannabis dependence symptom count; chr2:99781586 chr2:100104919~100107504:+ LIHC cis rs9595908 0.709 rs7988089 ENSG00000212293.1 SNORA16 3.67 0.000281 0.0424 0.23 0.19 Body mass index; chr13:32759738 chr13:32420390~32420516:- LIHC cis rs2553218 0.746 rs8041282 ENSG00000277548.1 RP11-139H15.6 3.67 0.000281 0.0424 0.24 0.19 Immune response to smallpox vaccine (IL-6); chr15:54564987 chr15:55346347~55346752:- LIHC cis rs2439831 0.867 rs2255440 ENSG00000275601.1 AC011330.13 -3.67 0.000281 0.0424 -0.26 -0.19 Lung cancer in ever smokers; chr15:43538269 chr15:43642389~43643023:- LIHC cis rs4578769 0.569 rs12960915 ENSG00000266850.1 RP11-370A5.1 3.67 0.000281 0.0424 0.21 0.19 Eosinophil percentage of white cells; chr18:22924013 chr18:22723491~22907721:- LIHC cis rs524281 0.731 rs10791841 ENSG00000255320.1 RP11-755F10.1 3.67 0.000281 0.0424 0.31 0.19 Electroencephalogram traits; chr11:66041116 chr11:66244840~66246239:- LIHC cis rs12681287 0.547 rs6998303 ENSG00000254088.1 SLC2A3P4 3.67 0.000281 0.0424 0.23 0.19 Caudate activity during reward; chr8:86497956 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs13267858 ENSG00000254088.1 SLC2A3P4 3.67 0.000281 0.0424 0.23 0.19 Caudate activity during reward; chr8:86498642 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs7461366 ENSG00000254088.1 SLC2A3P4 3.67 0.000281 0.0424 0.23 0.19 Caudate activity during reward; chr8:86499456 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs4961197 ENSG00000254088.1 SLC2A3P4 3.67 0.000281 0.0424 0.23 0.19 Caudate activity during reward; chr8:86500207 chr8:86503591~86505061:+ LIHC cis rs4792901 0.765 rs35557239 ENSG00000267747.1 RP11-392O1.4 -3.67 0.000281 0.0424 -0.23 -0.19 Dupuytren's disease; chr17:43470907 chr17:43544785~43610338:+ LIHC cis rs7104764 0.917 rs3825075 ENSG00000250397.2 RP11-1391J7.1 -3.67 0.000281 0.0424 -0.22 -0.19 Menarche (age at onset); chr11:217140 chr11:856880~859795:- LIHC cis rs7584330 0.666 rs6760963 ENSG00000227107.1 AC096574.5 3.67 0.000281 0.0424 0.25 0.19 Prostate cancer; chr2:237489625 chr2:237612977~237626525:+ LIHC cis rs395892 0.793 rs61213408 ENSG00000267892.1 CTD-2540F13.2 -3.67 0.000281 0.0424 -0.28 -0.19 Eosinophil counts;Eosinophil percentage of white cells; chr19:39700146 chr19:38738284~38739863:+ LIHC cis rs42490 0.716 rs40547 ENSG00000251136.7 RP11-37B2.1 -3.67 0.000281 0.0424 -0.17 -0.19 Leprosy; chr8:89817685 chr8:89609409~89757727:- LIHC cis rs17373728 0.526 rs9886508 ENSG00000249395.2 CASC9 -3.67 0.000281 0.0424 -0.21 -0.19 Diabetic kidney disease; chr8:75240756 chr8:75223404~75324741:- LIHC cis rs948562 0.69 rs7342155 ENSG00000280010.1 AP001350.4 3.67 0.000281 0.0424 0.34 0.19 Lymphoma; chr11:58348171 chr11:58627435~58628528:+ LIHC cis rs948562 0.69 rs79894420 ENSG00000280010.1 AP001350.4 3.67 0.000281 0.0424 0.34 0.19 Lymphoma; chr11:58349359 chr11:58627435~58628528:+ LIHC cis rs7216064 1 rs7221651 ENSG00000279880.1 RP11-855A2.2 -3.67 0.000281 0.0424 -0.22 -0.19 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67836274 chr17:67973934~67976072:+ LIHC cis rs17376456 0.877 rs10052428 ENSG00000251023.1 RP11-549J18.1 -3.67 0.000281 0.0424 -0.41 -0.19 Diabetic retinopathy; chr5:94140825 chr5:93860669~93863825:- LIHC cis rs72675573 0.852 rs778125 ENSG00000235612.1 RP1-158P9.1 3.67 0.000281 0.0425 0.25 0.19 Monocyte count; chr1:56140074 chr1:56145721~56155224:+ LIHC cis rs4356975 0.522 rs12647681 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000281 0.0425 -0.19 -0.19 Obesity-related traits; chr4:69097442 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs12647682 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000281 0.0425 -0.19 -0.19 Obesity-related traits; chr4:69097450 chr4:69027831~69044578:+ LIHC cis rs710865 0.516 rs12062540 ENSG00000270728.1 RP4-657E11.10 -3.67 0.000281 0.0425 -0.17 -0.19 Brain structure; chr1:19202710 chr1:19297080~19297903:+ LIHC cis rs11686241 0.882 rs6736106 ENSG00000232485.2 AC098820.3 3.67 0.000281 0.0425 0.19 0.19 Cancer; chr2:216463723 chr2:216479030~216498761:- LIHC cis rs7129556 0.737 rs4344516 ENSG00000254459.1 RP11-91P24.7 3.67 0.000281 0.0425 0.32 0.19 Weight loss (gastric bypass surgery); chr11:77727014 chr11:77829654~77872262:- LIHC cis rs11105298 0.891 rs4842662 ENSG00000258302.2 RP11-981P6.1 3.67 0.000282 0.0425 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89539669 chr12:89561129~89594878:+ LIHC cis rs6442522 0.61 rs6808644 ENSG00000249786.6 EAF1-AS1 3.67 0.000282 0.0425 0.24 0.19 Uric acid levels; chr3:15485540 chr3:15436171~15455940:- LIHC cis rs4763879 0.594 rs12427310 ENSG00000256673.1 RP11-599J14.2 3.67 0.000282 0.0425 0.19 0.19 Type 1 diabetes; chr12:9707539 chr12:9398355~9414851:- LIHC cis rs10991814 0.513 rs7852888 ENSG00000230537.1 RP11-305L7.1 -3.67 0.000282 0.0425 -0.23 -0.19 Neutrophil percentage of granulocytes; chr9:91292564 chr9:91104957~91107304:- LIHC cis rs11971779 0.938 rs28477480 ENSG00000273391.1 RP11-634H22.1 -3.67 0.000282 0.0425 -0.2 -0.19 Diisocyanate-induced asthma; chr7:139351312 chr7:139359032~139359566:- LIHC cis rs853679 0.55 rs34477097 ENSG00000219392.1 RP1-265C24.5 -3.67 0.000282 0.0425 -0.28 -0.19 Depression; chr6:28229408 chr6:28115628~28116551:+ LIHC cis rs2242663 0.798 rs1945302 ENSG00000255517.5 CTD-3074O7.5 3.67 0.000282 0.0425 0.21 0.19 Bipolar disorder; chr11:66570027 chr11:66473490~66480233:- LIHC cis rs4819052 0.59 rs414743 ENSG00000276529.1 AP001505.10 -3.67 0.000282 0.0425 -0.21 -0.19 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45092160 chr21:44978832~44979274:+ LIHC cis rs7712401 0.686 rs185007 ENSG00000260686.1 CTB-36H16.2 -3.67 0.000282 0.0425 -0.21 -0.19 Mean platelet volume; chr5:122863623 chr5:122832356~122834533:+ LIHC cis rs7712401 0.686 rs246305 ENSG00000260686.1 CTB-36H16.2 -3.67 0.000282 0.0425 -0.21 -0.19 Mean platelet volume; chr5:122863911 chr5:122832356~122834533:+ LIHC cis rs2242663 0.798 rs1791679 ENSG00000255517.5 CTD-3074O7.5 3.67 0.000282 0.0425 0.21 0.19 Bipolar disorder; chr11:66570403 chr11:66473490~66480233:- LIHC cis rs79040073 1 rs79040073 ENSG00000259531.2 RP11-295H24.3 3.67 0.000282 0.0425 0.31 0.19 Lung cancer in ever smokers; chr15:49038657 chr15:49365124~49366685:- LIHC cis rs7722022 1 rs6876915 ENSG00000253428.1 CTB-43E15.2 3.67 0.000282 0.0425 0.2 0.19 Adiponectin levels; chr5:173527929 chr5:173689459~173705849:+ LIHC cis rs17213965 0.852 rs4781691 ENSG00000207425.1 Y_RNA -3.67 0.000282 0.0426 -0.34 -0.19 Waist-hip ratio; chr16:15783798 chr16:14915457~14915556:- LIHC cis rs8026198 0.929 rs1659217 ENSG00000260571.1 BNIP3P5 3.67 0.000282 0.0426 0.28 0.19 Fibrinogen levels; chr15:42324142 chr15:42313687~42314386:+ LIHC cis rs1922291 0.546 rs17637748 ENSG00000281162.1 LINC01127 3.67 0.000282 0.0426 0.2 0.19 Blood protein levels; chr2:102225255 chr2:101962056~101987167:+ LIHC cis rs11096990 0.634 rs2062229 ENSG00000249207.1 RP11-360F5.1 -3.67 0.000282 0.0426 -0.19 -0.19 Cognitive function; chr4:39285146 chr4:39112677~39126818:- LIHC cis rs10975870 0.847 rs7044390 ENSG00000236924.1 RP11-390F4.6 -3.67 0.000282 0.0426 -0.31 -0.19 Body mass index; chr9:6926907 chr9:6645956~6670635:+ LIHC cis rs2929278 0.638 rs2016840 ENSG00000275601.1 AC011330.13 3.67 0.000283 0.0426 0.24 0.19 Schizophrenia; chr15:43919670 chr15:43642389~43643023:- LIHC cis rs7617773 0.744 rs2125482 ENSG00000228638.1 FCF1P2 -3.67 0.000283 0.0426 -0.22 -0.19 Coronary artery disease; chr3:48281643 chr3:48290793~48291375:- LIHC cis rs6442522 0.678 rs2345106 ENSG00000249786.6 EAF1-AS1 3.67 0.000283 0.0426 0.22 0.19 Uric acid levels; chr3:15467521 chr3:15436171~15455940:- LIHC cis rs6442522 0.678 rs878946 ENSG00000249786.6 EAF1-AS1 3.67 0.000283 0.0426 0.22 0.19 Uric acid levels; chr3:15467705 chr3:15436171~15455940:- LIHC cis rs6442522 0.678 rs3773452 ENSG00000249786.6 EAF1-AS1 3.67 0.000283 0.0426 0.22 0.19 Uric acid levels; chr3:15468447 chr3:15436171~15455940:- LIHC cis rs7534016 0.724 rs835369 ENSG00000270457.1 RP11-467C18.1 -3.67 0.000283 0.0426 -0.22 -0.19 Obesity-related traits; chr1:59281308 chr1:59289303~59289640:- LIHC cis rs62229266 0.659 rs2835245 ENSG00000230212.5 AP000688.14 -3.67 0.000283 0.0426 -0.24 -0.19 Mitral valve prolapse; chr21:36044410 chr21:36069642~36126640:- LIHC cis rs9649213 0.593 rs12728 ENSG00000272950.1 RP11-307C18.1 3.67 0.000283 0.0426 0.23 0.19 Prostate cancer (SNP x SNP interaction); chr7:98293539 chr7:98322853~98323430:+ LIHC cis rs7589561 1 rs6704555 ENSG00000235319.1 AC012360.4 -3.67 0.000283 0.0426 -0.42 -0.19 Addiction; chr2:105861325 chr2:105324210~105330529:+ LIHC cis rs17376456 1 rs34756085 ENSG00000251023.1 RP11-549J18.1 -3.67 0.000283 0.0427 -0.41 -0.19 Diabetic retinopathy; chr5:94220589 chr5:93860669~93863825:- LIHC cis rs17376456 1 rs17376456 ENSG00000251023.1 RP11-549J18.1 3.67 0.000283 0.0427 0.41 0.19 Diabetic retinopathy; chr5:94221997 chr5:93860669~93863825:- LIHC cis rs6456156 0.586 rs6456149 ENSG00000227598.1 RP1-167A14.2 -3.67 0.000283 0.0427 -0.2 -0.19 Primary biliary cholangitis; chr6:167050414 chr6:166969626~166999065:- LIHC cis rs4865169 0.691 rs1056364 ENSG00000269949.1 RP11-738E22.3 -3.67 0.000283 0.0427 -0.25 -0.19 Breast cancer; chr4:57023511 chr4:56960927~56961373:- LIHC cis rs7394190 0.748 rs4746151 ENSG00000242338.5 BMS1P4 3.67 0.000283 0.0427 0.28 0.19 Incident atrial fibrillation; chr10:73818962 chr10:73715843~73730469:- LIHC cis rs7394190 0.748 rs3843939 ENSG00000242338.5 BMS1P4 3.67 0.000283 0.0427 0.28 0.19 Incident atrial fibrillation; chr10:73819190 chr10:73715843~73730469:- LIHC cis rs4650994 0.593 rs6694406 ENSG00000273384.1 RP5-1098D14.1 -3.67 0.000283 0.0427 -0.24 -0.19 HDL cholesterol;HDL cholesterol levels; chr1:178562875 chr1:178651706~178652282:+ LIHC cis rs7665090 0.51 rs223498 ENSG00000248971.2 KRT8P46 3.67 0.000283 0.0427 0.2 0.19 Primary biliary cholangitis; chr4:102730805 chr4:102728746~102730171:- LIHC cis rs11671005 0.737 rs11671033 ENSG00000269473.1 CTD-2619J13.19 3.67 0.000283 0.0427 0.34 0.19 Mean platelet volume; chr19:58452302 chr19:58440448~58445849:+ LIHC cis rs854624 0.901 rs1734960 ENSG00000278690.1 RP11-104J23.2 3.67 0.000283 0.0427 0.44 0.19 Blood protein levels; chr17:36009308 chr17:36012504~36012891:+ LIHC cis rs2658782 0.789 rs3019206 ENSG00000279684.1 RP11-755E23.2 -3.67 0.000283 0.0427 -0.32 -0.19 Pulmonary function decline; chr11:93377907 chr11:93286629~93288903:- LIHC cis rs6142102 0.961 rs2268088 ENSG00000275784.1 RP5-1125A11.6 -3.67 0.000283 0.0427 -0.22 -0.19 Skin pigmentation; chr20:34061258 chr20:33989480~33991818:- LIHC cis rs6142102 0.961 rs2284388 ENSG00000275784.1 RP5-1125A11.6 -3.67 0.000283 0.0427 -0.22 -0.19 Skin pigmentation; chr20:34067935 chr20:33989480~33991818:- LIHC cis rs4356203 0.525 rs111416579 ENSG00000260196.1 RP1-239B22.5 -3.67 0.000283 0.0427 -0.23 -0.19 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17227461 chr11:17380649~17383531:+ LIHC cis rs2275906 0.748 rs11964886 ENSG00000242387.1 HIST1H2APS2 3.67 0.000283 0.0427 0.28 0.19 Urate levels in lean individuals; chr6:25878151 chr6:25882026~25882395:- LIHC cis rs2275906 0.748 rs11969868 ENSG00000242387.1 HIST1H2APS2 3.67 0.000283 0.0427 0.28 0.19 Urate levels in lean individuals; chr6:25878278 chr6:25882026~25882395:- LIHC cis rs67311347 1 rs9833430 ENSG00000223797.4 ENTPD3-AS1 3.67 0.000283 0.0427 0.16 0.19 Renal cell carcinoma; chr3:40417552 chr3:40313802~40453329:- LIHC cis rs9929218 0.52 rs1078621 ENSG00000260459.2 FTLP14 3.67 0.000283 0.0427 0.23 0.19 Colorectal cancer; chr16:68745093 chr16:68822587~68823070:+ LIHC cis rs3845817 1 rs3845816 ENSG00000237979.1 AC007389.1 -3.67 0.000283 0.0427 -0.21 -0.19 Bipolar disorder; chr2:65531221 chr2:65500993~65502138:- LIHC cis rs2243480 0.708 rs35825036 ENSG00000228409.4 CCT6P1 3.67 0.000283 0.0427 0.21 0.19 Diabetic kidney disease; chr7:66521515 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs13237037 ENSG00000228409.4 CCT6P1 3.67 0.000283 0.0427 0.21 0.19 Diabetic kidney disease; chr7:66532895 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs13237344 ENSG00000228409.4 CCT6P1 3.67 0.000283 0.0427 0.21 0.19 Diabetic kidney disease; chr7:66557269 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1796228 ENSG00000228409.4 CCT6P1 3.67 0.000283 0.0427 0.21 0.19 Diabetic kidney disease; chr7:66568097 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1267820 ENSG00000228409.4 CCT6P1 3.67 0.000283 0.0427 0.21 0.19 Diabetic kidney disease; chr7:66585308 chr7:65751142~65763354:+ LIHC cis rs9907295 0.901 rs4796130 ENSG00000270871.1 AC015849.19 3.67 0.000283 0.0427 0.21 0.19 Fibroblast growth factor basic levels; chr17:35904264 chr17:35816717~35830293:- LIHC cis rs9907295 0.685 rs4796131 ENSG00000270871.1 AC015849.19 3.67 0.000283 0.0427 0.21 0.19 Fibroblast growth factor basic levels; chr17:35904812 chr17:35816717~35830293:- LIHC cis rs763014 0.932 rs2384974 ENSG00000261713.5 SSTR5-AS1 3.67 0.000284 0.0427 0.2 0.19 Height; chr16:601279 chr16:1064093~1078731:- LIHC cis rs6437061 0.745 rs3116222 ENSG00000237126.7 AC073254.1 -3.67 0.000284 0.0427 -0.21 -0.19 Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction); chr2:232008880 chr2:232580948~232611971:- LIHC cis rs2243480 0.901 rs778730 ENSG00000228409.4 CCT6P1 3.67 0.000284 0.0427 0.21 0.19 Diabetic kidney disease; chr7:66358338 chr7:65751142~65763354:+ LIHC cis rs9595908 0.709 rs55797910 ENSG00000212293.1 SNORA16 3.67 0.000284 0.0427 0.22 0.19 Body mass index; chr13:32787154 chr13:32420390~32420516:- LIHC cis rs9303401 0.703 rs8072182 ENSG00000265415.1 CTD-2510F5.4 3.67 0.000284 0.0427 0.14 0.19 Cognitive test performance; chr17:59133852 chr17:59202677~59203829:- LIHC cis rs7809950 0.598 rs2283038 ENSG00000238832.1 snoU109 -3.67 0.000284 0.0427 -0.26 -0.19 Coronary artery disease; chr7:107194965 chr7:107603363~107603507:+ LIHC cis rs875971 0.522 rs4718286 ENSG00000234338.1 RP11-797H7.1 -3.67 0.000284 0.0428 -0.18 -0.19 Aortic root size; chr7:65827777 chr7:64835280~64836882:- LIHC cis rs9951150 0.537 rs35325289 ENSG00000267013.4 CTD-2171N6.1 3.67 0.000284 0.0428 0.26 0.19 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55133120 chr18:55105904~55124306:- LIHC cis rs9951150 0.537 rs34778612 ENSG00000267013.4 CTD-2171N6.1 3.67 0.000284 0.0428 0.26 0.19 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55133421 chr18:55105904~55124306:- LIHC cis rs9595908 0.709 rs7327412 ENSG00000212293.1 SNORA16 -3.67 0.000284 0.0428 -0.22 -0.19 Body mass index; chr13:32774430 chr13:32420390~32420516:- LIHC cis rs481331 0.643 rs209390 ENSG00000185904.10 LINC00839 -3.67 0.000284 0.0428 -0.37 -0.19 Systemic juvenile idiopathic arthritis; chr10:42633432 chr10:42475543~42495336:+ LIHC cis rs916888 0.773 rs199457 ENSG00000279685.2 MAPT-IT1 -3.67 0.000284 0.0428 -0.35 -0.19 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45895783~45898798:+ LIHC cis rs916888 0.687 rs199456 ENSG00000279685.2 MAPT-IT1 -3.67 0.000284 0.0428 -0.35 -0.19 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45895783~45898798:+ LIHC cis rs950776 0.72 rs11633223 ENSG00000261762.1 RP11-650L12.2 3.67 0.000284 0.0428 0.28 0.19 Sudden cardiac arrest; chr15:78643134 chr15:78589123~78591276:- LIHC cis rs2098713 0.562 rs55794983 ENSG00000250155.1 CTD-2353F22.1 3.67 0.000284 0.0428 0.19 0.19 Telomere length; chr5:37549046 chr5:36666214~36725195:- LIHC cis rs875971 0.522 rs4718285 ENSG00000234338.1 RP11-797H7.1 -3.67 0.000284 0.0428 -0.18 -0.19 Aortic root size; chr7:65827018 chr7:64835280~64836882:- LIHC cis rs4694744 0.505 rs13108555 ENSG00000264696.1 AC108078.1 3.67 0.000284 0.0428 0.31 0.19 Bacteremia; chr4:69438891 chr4:69479331~69479434:+ LIHC cis rs988958 0.526 rs36036427 ENSG00000224875.2 AC083949.1 -3.67 0.000284 0.0428 -0.3 -0.19 Hypospadias; chr2:42025749 chr2:42143238~42170301:- LIHC cis rs988958 0.526 rs13024096 ENSG00000224875.2 AC083949.1 -3.67 0.000284 0.0428 -0.3 -0.19 Hypospadias; chr2:42025810 chr2:42143238~42170301:- LIHC cis rs988958 0.526 rs12712830 ENSG00000224875.2 AC083949.1 -3.67 0.000284 0.0428 -0.3 -0.19 Hypospadias; chr2:42025815 chr2:42143238~42170301:- LIHC cis rs988958 0.526 rs36109745 ENSG00000224875.2 AC083949.1 -3.67 0.000284 0.0428 -0.3 -0.19 Hypospadias; chr2:42025850 chr2:42143238~42170301:- LIHC cis rs6449502 0.92 rs3797562 ENSG00000272308.1 RP11-231G3.1 3.67 0.000284 0.0428 0.28 0.19 Mean platelet volume; chr5:60901273 chr5:60866457~60866935:- LIHC cis rs7208859 0.673 rs28588622 ENSG00000280069.1 CTD-2349P21.3 -3.67 0.000284 0.0428 -0.26 -0.19 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30918681 chr17:30738182~30740275:+ LIHC cis rs13178541 0.641 rs4499826 ENSG00000247627.2 MTND4P12 -3.67 0.000284 0.0428 -0.25 -0.19 IgG glycosylation; chr5:135792619 chr5:134926660~134928036:- LIHC cis rs12900463 0.813 rs186266 ENSG00000259295.5 CSPG4P12 3.67 0.000284 0.0428 0.26 0.19 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine); chr15:84859564 chr15:85191438~85213905:+ LIHC cis rs2098713 0.599 rs1812818 ENSG00000250155.1 CTD-2353F22.1 3.67 0.000284 0.0428 0.19 0.19 Telomere length; chr5:37546652 chr5:36666214~36725195:- LIHC cis rs8005677 1 rs1043209 ENSG00000279656.1 RP11-298I3.6 -3.67 0.000285 0.0428 -0.22 -0.19 Cognitive ability (multi-trait analysis); chr14:22904777 chr14:23023083~23024217:- LIHC cis rs3893377 1 rs28608142 ENSG00000214846.4 RP11-115L11.1 3.67 0.000285 0.0428 0.25 0.19 Current cigarettes per day in chronic obstructive pulmonary disease; chr4:15742366 chr4:15730962~15731627:- LIHC cis rs11098499 0.562 rs2389879 ENSG00000245958.5 RP11-33B1.1 3.67 0.000285 0.0428 0.19 0.19 Corneal astigmatism; chr4:119636529 chr4:119454791~119552025:+ LIHC cis rs7915414 0.585 rs2860838 ENSG00000230338.1 MTND4P19 3.67 0.000285 0.0428 0.23 0.19 Clopidogrel active metabolite levels; chr10:94693282 chr10:94774156~94774633:- LIHC cis rs919433 0.889 rs788004 ENSG00000231621.1 AC013264.2 -3.67 0.000285 0.0429 -0.18 -0.19 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197354308 chr2:197197991~197199273:+ LIHC cis rs4356975 0.583 rs4632729 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69080286 chr4:69027831~69044578:+ LIHC cis rs4356975 0.545 rs11249524 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69080653 chr4:69027831~69044578:+ LIHC cis rs4356975 0.545 rs11249526 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69080934 chr4:69027831~69044578:+ LIHC cis rs4356975 0.602 rs7674851 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69081113 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs7679550 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69081187 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs4478248 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69081498 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs7680709 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69081745 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs4540108 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69083614 chr4:69027831~69044578:+ LIHC cis rs4356975 0.545 rs4640729 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69083642 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs4522933 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69083780 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs11937683 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69084102 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs7659306 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69084560 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs4454000 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69084853 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs4273534 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69084927 chr4:69027831~69044578:+ LIHC cis rs4356975 0.522 rs4642304 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69085832 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs4446391 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69086364 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs7437174 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69086885 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs6600874 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69087695 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs6843382 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69087884 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs4694171 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000285 0.0429 -0.2 -0.19 Obesity-related traits; chr4:69088579 chr4:69027831~69044578:+ LIHC cis rs4356203 0.846 rs1685932 ENSG00000260196.1 RP1-239B22.5 -3.67 0.000285 0.0429 -0.23 -0.19 Schizophrenia;Schizophrenia or bipolar disorder; chr11:17202356 chr11:17380649~17383531:+ LIHC cis rs67981189 0.896 rs12883437 ENSG00000274818.1 RP1-292L20.3 3.67 0.000285 0.0429 0.21 0.19 Schizophrenia; chr14:70998064 chr14:70906657~70907111:- LIHC cis rs4073416 0.684 rs7161123 ENSG00000276116.2 FUT8-AS1 3.67 0.000285 0.0429 0.25 0.19 N-glycan levels; chr14:65586183 chr14:65411170~65412690:- LIHC cis rs4073416 0.684 rs4581615 ENSG00000276116.2 FUT8-AS1 3.67 0.000285 0.0429 0.25 0.19 N-glycan levels; chr14:65589225 chr14:65411170~65412690:- LIHC cis rs17826219 0.568 rs11658027 ENSG00000264538.5 SUZ12P1 3.67 0.000285 0.0429 0.21 0.19 Body mass index; chr17:30767864 chr17:30709299~30790908:+ LIHC cis rs1115240 0.574 rs17111258 ENSG00000257842.4 NOVA1-AS1 3.67 0.000285 0.0429 0.19 0.19 Educational attainment (years of education); chr14:26464654 chr14:26598412~26806467:+ LIHC cis rs3845817 1 rs3911863 ENSG00000237979.1 AC007389.1 -3.67 0.000285 0.0429 -0.22 -0.19 Bipolar disorder; chr2:65532630 chr2:65500993~65502138:- LIHC cis rs3845817 0.966 rs3845818 ENSG00000237979.1 AC007389.1 -3.67 0.000285 0.0429 -0.22 -0.19 Bipolar disorder; chr2:65533349 chr2:65500993~65502138:- LIHC cis rs1075265 0.669 rs805317 ENSG00000233266.1 HMGB1P31 3.67 0.000285 0.0429 0.24 0.19 Chronotype;Morning vs. evening chronotype; chr2:53907867 chr2:54051334~54051760:+ LIHC cis rs1075265 0.692 rs805318 ENSG00000233266.1 HMGB1P31 3.67 0.000285 0.0429 0.24 0.19 Chronotype;Morning vs. evening chronotype; chr2:53907915 chr2:54051334~54051760:+ LIHC cis rs11907546 1 rs11907546 ENSG00000275784.1 RP5-1125A11.6 -3.67 0.000285 0.0429 -0.22 -0.19 Cancer (pleiotropy);Cancer; chr20:34131991 chr20:33989480~33991818:- LIHC cis rs12681287 0.752 rs4288357 ENSG00000254088.1 SLC2A3P4 3.67 0.000285 0.0429 0.23 0.19 Caudate activity during reward; chr8:86239604 chr8:86503591~86505061:+ LIHC cis rs12681287 0.752 rs4472493 ENSG00000254088.1 SLC2A3P4 3.67 0.000285 0.0429 0.23 0.19 Caudate activity during reward; chr8:86239685 chr8:86503591~86505061:+ LIHC cis rs591584 0.834 rs4543942 ENSG00000255893.1 RP11-685N10.1 -3.67 0.000285 0.0429 -0.19 -0.19 Macrophage Migration Inhibitory Factor levels; chr11:94588727 chr11:94472908~94473570:- LIHC cis rs7219021 0.674 rs9904761 ENSG00000248278.1 SUMO2P17 -3.67 0.000285 0.0429 -0.27 -0.19 Schizophrenia or bipolar disorder; chr17:48879468 chr17:48874860~48908983:- LIHC cis rs9640161 0.83 rs11768108 ENSG00000261305.1 RP4-584D14.7 3.67 0.000285 0.0429 0.24 0.19 Blood protein levels;Circulating chemerin levels; chr7:150367061 chr7:150341771~150342607:+ LIHC cis rs7712401 0.601 rs30038 ENSG00000263432.2 RN7SL689P 3.67 0.000285 0.0429 0.28 0.19 Mean platelet volume; chr5:122941667 chr5:123022487~123022783:- LIHC cis rs8077577 0.747 rs62072507 ENSG00000260647.1 RP1-178F10.1 3.67 0.000285 0.0429 0.25 0.19 Obesity-related traits; chr17:18269021 chr17:18268080~18268828:+ LIHC cis rs8133974 0.887 rs73205303 ENSG00000234380.1 LINC01426 3.67 0.000285 0.0429 0.55 0.19 Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes; chr21:35095533 chr21:34745757~34784886:+ LIHC cis rs7308134 1 rs7957635 ENSG00000250132.5 RP11-359B12.2 3.67 0.000285 0.0429 0.3 0.19 QRS duration in Tripanosoma cruzi seropositivity; chr12:1875990 chr12:974133~991190:- LIHC cis rs2658782 0.547 rs3133454 ENSG00000279684.1 RP11-755E23.2 -3.67 0.000286 0.0429 -0.28 -0.19 Pulmonary function decline; chr11:93325853 chr11:93286629~93288903:- LIHC cis rs6471393 0.895 rs58103546 ENSG00000253848.1 RP11-10N23.5 3.67 0.000286 0.0429 0.21 0.19 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure); chr8:93749483 chr8:93741193~93744534:+ LIHC cis rs62025270 0.688 rs7164373 ENSG00000259295.5 CSPG4P12 -3.67 0.000286 0.0429 -0.34 -0.19 Idiopathic pulmonary fibrosis; chr15:85722432 chr15:85191438~85213905:+ LIHC cis rs4891159 0.79 rs1787448 ENSG00000265778.2 RP11-17M16.2 3.67 0.000286 0.0429 0.23 0.19 Longevity; chr18:76401223 chr18:76491652~76493918:+ LIHC cis rs4891159 0.79 rs9950025 ENSG00000265778.2 RP11-17M16.2 3.67 0.000286 0.0429 0.23 0.19 Longevity; chr18:76401640 chr18:76491652~76493918:+ LIHC cis rs227275 0.53 rs3960788 ENSG00000230069.3 LRRC37A15P -3.67 0.000286 0.043 -0.18 -0.19 Allergic disease (asthma, hay fever or eczema); chr4:102994461 chr4:102727274~102730721:- LIHC cis rs1411478 1 rs4652545 ENSG00000243155.1 RP11-46A10.5 -3.67 0.000286 0.043 -0.19 -0.19 Menopause (age at onset);Progressive supranuclear palsy; chr1:180978472 chr1:180944042~180976482:- LIHC cis rs516805 0.667 rs2816139 ENSG00000279453.1 RP3-425C14.4 -3.67 0.000286 0.043 -0.43 -0.19 Lymphocyte counts; chr6:122182267 chr6:122436789~122439223:- LIHC cis rs812925 0.537 rs10196146 ENSG00000271889.1 RP11-493E12.1 -3.67 0.000286 0.043 -0.23 -0.19 Immature fraction of reticulocytes; chr2:61378244 chr2:61151433~61162105:- LIHC cis rs4356975 0.563 rs11249527 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69089267 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs6846298 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69089278 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs11249528 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69089337 chr4:69027831~69044578:+ LIHC cis rs4356975 0.545 rs55757747 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69089919 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs56217918 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69089925 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs7663584 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69090392 chr4:69027831~69044578:+ LIHC cis rs5751614 0.537 rs5996508 ENSG00000225282.1 AP000350.6 -3.67 0.000286 0.043 -0.31 -0.19 Height; chr22:23270441 chr22:23926900~23929574:+ LIHC cis rs3738443 0.645 rs11811599 ENSG00000259865.1 RP11-488L18.10 3.67 0.000286 0.043 0.16 0.19 Alcohol dependence; chr1:247203133 chr1:247187281~247188526:- LIHC cis rs4356975 0.545 rs11249525 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.2 -0.19 Obesity-related traits; chr4:69080923 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs4443355 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.2 -0.19 Obesity-related traits; chr4:69083026 chr4:69027831~69044578:+ LIHC cis rs4700393 0.517 rs71592685 ENSG00000250148.1 KRT8P31 -3.67 0.000286 0.043 -0.34 -0.19 Intelligence (multi-trait analysis); chr5:60825411 chr5:60743563~60744970:- LIHC cis rs2243480 1 rs1638734 ENSG00000228409.4 CCT6P1 3.67 0.000286 0.043 0.21 0.19 Diabetic kidney disease; chr7:66632552 chr7:65751142~65763354:+ LIHC cis rs10508774 0.733 rs3758380 ENSG00000273038.2 RP11-479G22.8 3.67 0.000286 0.043 0.28 0.19 Peripheral arterial disease (traffic-related air pollution interaction); chr10:32899525 chr10:32887255~32889311:- LIHC cis rs10508774 0.81 rs10508776 ENSG00000273038.2 RP11-479G22.8 3.67 0.000286 0.043 0.28 0.19 Peripheral arterial disease (traffic-related air pollution interaction); chr10:32900099 chr10:32887255~32889311:- LIHC cis rs7915414 0.585 rs2860837 ENSG00000230338.1 MTND4P19 3.67 0.000286 0.043 0.22 0.19 Clopidogrel active metabolite levels; chr10:94689982 chr10:94774156~94774633:- LIHC cis rs6545883 0.965 rs766447 ENSG00000271889.1 RP11-493E12.1 3.67 0.000286 0.043 0.23 0.19 Tuberculosis; chr2:61508434 chr2:61151433~61162105:- LIHC cis rs4356975 0.563 rs4455491 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69095215 chr4:69027831~69044578:+ LIHC cis rs4356975 0.522 rs11940220 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69095222 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs11940316 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69095409 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs7668258 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69096360 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs58544196 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69097740 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs7439326 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69098462 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs7438244 ENSG00000250919.1 RP11-813N20.3 -3.67 0.000286 0.043 -0.19 -0.19 Obesity-related traits; chr4:69098491 chr4:69027831~69044578:+ LIHC cis rs875971 0.545 rs1796219 ENSG00000232546.1 RP11-458F8.1 -3.67 0.000286 0.043 -0.17 -0.19 Aortic root size; chr7:66645977 chr7:66848496~66858136:+ LIHC cis rs1405130 0.9 rs4663470 ENSG00000224287.2 MSL3P1 3.67 0.000286 0.043 0.22 0.19 Coronary artery disease; chr2:234678896 chr2:233865437~233868444:- LIHC cis rs913246 1 rs913246 ENSG00000277662.1 RP11-74J13.9 3.67 0.000286 0.043 0.29 0.19 Bipolar disorder and schizophrenia; chr13:40374014 chr13:41229180~41229676:- LIHC cis rs3738443 0.599 rs6693807 ENSG00000259865.1 RP11-488L18.10 -3.67 0.000286 0.043 -0.16 -0.19 Alcohol dependence; chr1:247230353 chr1:247187281~247188526:- LIHC cis rs933688 1 rs6869717 ENSG00000281357.1 ARRDC3-AS1 3.67 0.000286 0.043 0.24 0.19 Smoking behavior; chr5:91398980 chr5:91380349~91439085:+ LIHC cis rs9652601 1 rs9652601 ENSG00000274038.1 RP11-66H6.4 -3.67 0.000286 0.043 -0.24 -0.19 Systemic lupus erythematosus; chr16:11080508 chr16:11056556~11057034:+ LIHC cis rs11105298 0.891 rs11105318 ENSG00000258302.2 RP11-981P6.1 3.67 0.000286 0.043 0.25 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89532881 chr12:89561129~89594878:+ LIHC cis rs10833905 0.715 rs7117292 ENSG00000246225.5 RP11-17A1.3 3.67 0.000286 0.043 0.25 0.19 Sudden cardiac arrest; chr11:23017225 chr11:22829380~22945393:+ LIHC cis rs780096 0.527 rs11127044 ENSG00000234072.1 AC074117.10 -3.67 0.000286 0.0431 -0.19 -0.19 Total body bone mineral density; chr2:27517537 chr2:27356246~27367622:+ LIHC cis rs9400180 0.765 rs10484906 ENSG00000271734.1 RP1-111B22.3 3.66 0.000287 0.0431 0.23 0.19 Major depressive disorder; chr6:108020812 chr6:108030249~108030718:- LIHC cis rs853679 0.882 rs3757188 ENSG00000219891.2 ZSCAN12P1 3.66 0.000287 0.0431 0.36 0.19 Depression; chr6:28139579 chr6:28091154~28093664:+ LIHC cis rs67981189 0.896 rs4391999 ENSG00000274818.1 RP1-292L20.3 3.66 0.000287 0.0431 0.21 0.19 Schizophrenia; chr14:70978696 chr14:70906657~70907111:- LIHC cis rs10883723 0.962 rs1056740 ENSG00000236937.2 PTGES3P4 -3.66 0.000287 0.0431 -0.27 -0.19 Allergic disease (asthma, hay fever or eczema); chr10:102476795 chr10:102845595~102845950:+ LIHC cis rs4648045 0.687 rs4699030 ENSG00000246560.2 RP11-10L12.4 -3.66 0.000287 0.0431 -0.23 -0.19 Lymphocyte percentage of white cells; chr4:102582667 chr4:102828055~102844075:+ LIHC cis rs2243480 1 rs316331 ENSG00000229886.1 RP5-1132H15.3 -3.66 0.000287 0.0431 -0.29 -0.19 Diabetic kidney disease; chr7:66139635 chr7:66025126~66031544:- LIHC cis rs11009175 0.746 rs17230579 ENSG00000273038.2 RP11-479G22.8 3.66 0.000287 0.0431 0.22 0.19 Depression (quantitative trait); chr10:33059117 chr10:32887255~32889311:- LIHC cis rs2933343 0.729 rs1680780 ENSG00000261159.1 RP11-723O4.9 3.66 0.000287 0.0431 0.25 0.19 IgG glycosylation; chr3:128893816 chr3:128859716~128860526:- LIHC cis rs2933343 0.729 rs1680781 ENSG00000261159.1 RP11-723O4.9 3.66 0.000287 0.0431 0.25 0.19 IgG glycosylation; chr3:128893987 chr3:128859716~128860526:- LIHC cis rs4356975 0.563 rs7441750 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000287 0.0431 -0.19 -0.19 Obesity-related traits; chr4:69098803 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs7441774 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000287 0.0431 -0.19 -0.19 Obesity-related traits; chr4:69098836 chr4:69027831~69044578:+ LIHC cis rs4356975 0.522 rs7434332 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000287 0.0431 -0.19 -0.19 Obesity-related traits; chr4:69099141 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs4293848 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000287 0.0431 -0.19 -0.19 Obesity-related traits; chr4:69099784 chr4:69027831~69044578:+ LIHC cis rs673078 0.607 rs4766900 ENSG00000275759.1 RP11-131L12.3 -3.66 0.000287 0.0431 -0.37 -0.19 Glucose homeostasis traits; chr12:118375139 chr12:118428281~118428870:+ LIHC cis rs4073416 0.712 rs7142651 ENSG00000276116.2 FUT8-AS1 3.66 0.000287 0.0431 0.24 0.19 N-glycan levels; chr14:65666003 chr14:65411170~65412690:- LIHC cis rs1862618 0.671 rs2591965 ENSG00000271828.1 CTD-2310F14.1 -3.66 0.000287 0.0431 -0.26 -0.19 Initial pursuit acceleration; chr5:56940349 chr5:56927874~56929573:+ LIHC cis rs151234 0.741 rs11644791 ENSG00000259982.1 CDC37P1 -3.66 0.000287 0.0432 -0.44 -0.19 Platelet distribution width; chr16:28589865 chr16:28700294~28701540:- LIHC cis rs151234 0.741 rs3194168 ENSG00000259982.1 CDC37P1 -3.66 0.000287 0.0432 -0.44 -0.19 Platelet distribution width; chr16:28591691 chr16:28700294~28701540:- LIHC cis rs3942852 0.606 rs10734561 ENSG00000256897.1 RP11-17G12.2 3.66 0.000287 0.0432 0.23 0.19 Acute lymphoblastic leukemia (childhood); chr11:48075928 chr11:47220218~47221751:- LIHC cis rs6860806 0.531 rs274556 ENSG00000263597.1 MIR3936 -3.66 0.000287 0.0432 -0.21 -0.19 Breast cancer; chr5:132386383 chr5:132365490~132365599:- LIHC cis rs6547741 1 rs10205364 ENSG00000234072.1 AC074117.10 3.66 0.000287 0.0432 0.18 0.19 Oral cavity cancer; chr2:27571366 chr2:27356246~27367622:+ LIHC cis rs6547741 1 rs1919125 ENSG00000234072.1 AC074117.10 3.66 0.000287 0.0432 0.18 0.19 Oral cavity cancer; chr2:27578536 chr2:27356246~27367622:+ LIHC cis rs6547741 1 rs1919126 ENSG00000234072.1 AC074117.10 3.66 0.000287 0.0432 0.18 0.19 Oral cavity cancer; chr2:27578551 chr2:27356246~27367622:+ LIHC cis rs6547741 1 rs7604798 ENSG00000234072.1 AC074117.10 3.66 0.000287 0.0432 0.18 0.19 Oral cavity cancer; chr2:27602073 chr2:27356246~27367622:+ LIHC cis rs6496044 0.963 rs7165300 ENSG00000259630.2 CTD-2262B20.1 -3.66 0.000288 0.0432 -0.2 -0.19 Interstitial lung disease; chr15:85526838 chr15:85415228~85415633:+ LIHC cis rs1405130 0.9 rs12692152 ENSG00000224287.2 MSL3P1 3.66 0.000288 0.0432 0.22 0.19 Coronary artery disease; chr2:234679204 chr2:233865437~233868444:- LIHC cis rs2348418 0.831 rs10843173 ENSG00000247934.4 RP11-967K21.1 3.66 0.000288 0.0432 0.18 0.19 Lung function (FEV1);Lung function (FVC); chr12:28453092 chr12:28163298~28190738:- LIHC cis rs2348418 0.864 rs10843174 ENSG00000247934.4 RP11-967K21.1 3.66 0.000288 0.0432 0.18 0.19 Lung function (FEV1);Lung function (FVC); chr12:28453135 chr12:28163298~28190738:- LIHC cis rs1265120 0.691 rs1573309 ENSG00000271882.1 KB-1410C5.5 -3.66 0.000288 0.0432 -0.22 -0.19 Chronic obstructive pulmonary disease; chr8:102160658 chr8:101208148~101208558:+ LIHC cis rs3087243 0.56 rs231779 ENSG00000213925.3 NPM1P33 3.66 0.000288 0.0432 0.2 0.19 Rheumatoid arthritis;Type 1 diabetes;Hypothyroidism; chr2:203869764 chr2:203772631~203773502:- LIHC cis rs2055375 0.594 rs159542 ENSG00000272308.1 RP11-231G3.1 -3.66 0.000288 0.0432 -0.21 -0.19 Intelligence (multi-trait analysis); chr5:61189951 chr5:60866457~60866935:- LIHC cis rs748404 0.533 rs11632120 ENSG00000205771.5 CATSPER2P1 3.66 0.000288 0.0432 0.24 0.19 Lung cancer; chr15:43123175 chr15:43726918~43747094:- LIHC cis rs11733284 1 rs13146880 ENSG00000259959.1 RP11-121C2.2 3.66 0.000288 0.0432 0.18 0.19 Gout;Renal underexcretion gout; chr4:48029482 chr4:47840122~47844339:- LIHC cis rs4253772 0.872 rs11704508 ENSG00000260708.1 CTA-29F11.1 3.66 0.000288 0.0432 0.42 0.19 Cholesterol, total;LDL cholesterol; chr22:46242643 chr22:46761894~46762563:- LIHC cis rs4253772 0.938 rs14842 ENSG00000260708.1 CTA-29F11.1 3.66 0.000288 0.0432 0.42 0.19 Cholesterol, total;LDL cholesterol; chr22:46243560 chr22:46761894~46762563:- LIHC cis rs4253772 0.872 rs14843 ENSG00000260708.1 CTA-29F11.1 3.66 0.000288 0.0432 0.42 0.19 Cholesterol, total;LDL cholesterol; chr22:46243565 chr22:46761894~46762563:- LIHC cis rs4253772 0.938 rs75977757 ENSG00000260708.1 CTA-29F11.1 3.66 0.000288 0.0432 0.42 0.19 Cholesterol, total;LDL cholesterol; chr22:46245628 chr22:46761894~46762563:- LIHC cis rs4253772 0.938 rs78336060 ENSG00000260708.1 CTA-29F11.1 3.66 0.000288 0.0432 0.42 0.19 Cholesterol, total;LDL cholesterol; chr22:46245700 chr22:46761894~46762563:- LIHC cis rs943466 1 rs2395400 ENSG00000223837.2 BRD2-IT1 -3.66 0.000288 0.0433 -0.25 -0.19 Body mass index (joint analysis main effects and physical activity interaction);Body mass index; chr6:33802299 chr6:32970232~32970886:+ LIHC cis rs853679 0.882 rs9468300 ENSG00000219891.2 ZSCAN12P1 3.66 0.000288 0.0433 0.36 0.19 Depression; chr6:28159062 chr6:28091154~28093664:+ LIHC cis rs6496667 0.557 rs2601201 ENSG00000213471.7 TTLL13P 3.66 0.000288 0.0433 0.25 0.19 Rheumatoid arthritis; chr15:90414768 chr15:90249530~90265482:+ LIHC cis rs638893 0.578 rs582200 ENSG00000255422.1 AP002954.4 3.66 0.000288 0.0433 0.43 0.19 Vitiligo; chr11:118798199 chr11:118704607~118750263:+ LIHC cis rs853679 1 rs2799077 ENSG00000204709.4 LINC01556 3.66 0.000288 0.0433 0.32 0.19 Depression; chr6:28266819 chr6:28943877~28944537:+ LIHC cis rs875971 0.54 rs736270 ENSG00000237310.1 GS1-124K5.4 3.66 0.000289 0.0433 0.19 0.19 Aortic root size; chr7:65963835 chr7:66493706~66495474:+ LIHC cis rs6832769 1 rs4864998 ENSG00000272969.1 RP11-528I4.2 3.66 0.000289 0.0433 0.23 0.19 Personality dimensions; chr4:55466439 chr4:55547112~55547889:+ LIHC cis rs6832769 0.961 rs2140077 ENSG00000272969.1 RP11-528I4.2 3.66 0.000289 0.0433 0.23 0.19 Personality dimensions; chr4:55472786 chr4:55547112~55547889:+ LIHC cis rs10760706 1 rs10121601 ENSG00000270412.1 RP11-92C4.6 3.66 0.000289 0.0433 0.22 0.19 Alopecia areata; chr9:99925163 chr9:98943337~98943775:- LIHC cis rs10760706 0.962 rs10117828 ENSG00000270412.1 RP11-92C4.6 3.66 0.000289 0.0433 0.22 0.19 Alopecia areata; chr9:99926435 chr9:98943337~98943775:- LIHC cis rs10760706 1 rs6478987 ENSG00000270412.1 RP11-92C4.6 3.66 0.000289 0.0433 0.22 0.19 Alopecia areata; chr9:99928601 chr9:98943337~98943775:- LIHC cis rs10760706 1 rs9299335 ENSG00000270412.1 RP11-92C4.6 3.66 0.000289 0.0433 0.22 0.19 Alopecia areata; chr9:99929164 chr9:98943337~98943775:- LIHC cis rs10760706 0.962 rs2416940 ENSG00000270412.1 RP11-92C4.6 3.66 0.000289 0.0433 0.22 0.19 Alopecia areata; chr9:99931789 chr9:98943337~98943775:- LIHC cis rs1106684 0.929 rs73163156 ENSG00000233559.1 AC016831.7 3.66 0.000289 0.0433 0.35 0.19 Body mass index; chr7:131776735 chr7:130853720~130928649:+ LIHC cis rs10845170 1 rs10845170 ENSG00000256667.5 KLRAP1 -3.66 0.000289 0.0433 -0.18 -0.19 Itch intensity from mosquito bite adjusted by bite size; chr12:10571818 chr12:10588063~10599669:- LIHC cis rs2919917 0.628 rs6981103 ENSG00000254352.1 RP11-578O24.2 3.66 0.000289 0.0433 0.29 0.19 Lymphocyte counts; chr8:78691702 chr8:78723796~78724136:- LIHC cis rs2736340 0.539 rs9644687 ENSG00000269918.1 AF131215.9 -3.66 0.000289 0.0433 -0.18 -0.19 Systemic lupus erythematosus;Systemic lupus erythematosus or rheumatoid arthritis;Kawasaki disease;Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis; chr8:11465516 chr8:11104691~11106704:- LIHC cis rs1109916 0.506 rs1331051 ENSG00000236497.1 RP11-66A2.2 3.66 0.000289 0.0433 0.25 0.19 Facial morphology (factor 6, height of vermillion lower lip); chr1:232186554 chr1:232727254~232742715:- LIHC cis rs6997458 0.813 rs3758078 ENSG00000253549.4 RP11-317J10.2 3.66 0.000289 0.0433 0.22 0.19 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85462435 chr8:85441851~85464915:- LIHC cis rs9595908 0.869 rs9595949 ENSG00000212293.1 SNORA16 3.66 0.000289 0.0434 0.22 0.19 Body mass index; chr13:32629939 chr13:32420390~32420516:- LIHC cis rs42490 0.625 rs427854 ENSG00000251136.7 RP11-37B2.1 -3.66 0.000289 0.0434 -0.16 -0.19 Leprosy; chr8:89843518 chr8:89609409~89757727:- LIHC cis rs617219 0.889 rs4466139 ENSG00000251675.1 CTC-458I2.2 -3.66 0.000289 0.0434 -0.21 -0.19 Betaine levels in individuals undergoing cardiac evaluation; chr5:79134235 chr5:80128361~80143883:+ LIHC cis rs2658782 0.547 rs3020052 ENSG00000279684.1 RP11-755E23.2 -3.66 0.000289 0.0434 -0.27 -0.19 Pulmonary function decline; chr11:93322018 chr11:93286629~93288903:- LIHC cis rs797680 0.897 rs2295424 ENSG00000229567.1 RP4-717I23.2 -3.66 0.000289 0.0434 -0.24 -0.19 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93115322 chr1:93278961~93279129:- LIHC cis rs17711722 0.74 rs7809991 ENSG00000237310.1 GS1-124K5.4 3.66 0.000289 0.0434 0.19 0.19 Calcium levels; chr7:65941231 chr7:66493706~66495474:+ LIHC cis rs1874124 0.836 rs17596947 ENSG00000238078.1 LINC01352 3.66 0.00029 0.0434 0.33 0.19 Cholesterol, total; chr1:220820122 chr1:220829255~220832429:+ LIHC cis rs2613514 1 rs2273280 ENSG00000204277.1 RP11-219G17.4 3.66 0.00029 0.0434 0.3 0.19 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78107582 chr17:78261349~78278492:- LIHC cis rs3091242 0.809 rs660129 ENSG00000261349.1 RP3-465N24.5 -3.66 0.00029 0.0434 -0.19 -0.19 Erythrocyte sedimentation rate; chr1:25400947 chr1:25266102~25267136:- LIHC cis rs3091242 0.728 rs706845 ENSG00000261349.1 RP3-465N24.5 -3.66 0.00029 0.0434 -0.19 -0.19 Erythrocyte sedimentation rate; chr1:25404222 chr1:25266102~25267136:- LIHC cis rs7182948 1 rs1605480 ENSG00000259531.2 RP11-295H24.3 -3.66 0.00029 0.0434 -0.28 -0.19 Lung adenocarcinoma; chr15:49526646 chr15:49365124~49366685:- LIHC cis rs7182948 1 rs1546424 ENSG00000259531.2 RP11-295H24.3 -3.66 0.00029 0.0434 -0.28 -0.19 Lung adenocarcinoma; chr15:49531030 chr15:49365124~49366685:- LIHC cis rs7182948 1 rs1546425 ENSG00000259531.2 RP11-295H24.3 -3.66 0.00029 0.0434 -0.28 -0.19 Lung adenocarcinoma; chr15:49531152 chr15:49365124~49366685:- LIHC cis rs801193 1 rs17566701 ENSG00000273142.1 RP11-458F8.4 -3.66 0.00029 0.0434 -0.18 -0.19 Aortic root size; chr7:66728196 chr7:66902857~66906297:+ LIHC cis rs875971 0.638 rs6460305 ENSG00000237310.1 GS1-124K5.4 -3.66 0.00029 0.0434 -0.18 -0.19 Aortic root size; chr7:66595421 chr7:66493706~66495474:+ LIHC cis rs875971 0.66 rs10272357 ENSG00000237310.1 GS1-124K5.4 -3.66 0.00029 0.0434 -0.18 -0.19 Aortic root size; chr7:66598087 chr7:66493706~66495474:+ LIHC cis rs7208859 0.725 rs9891656 ENSG00000280069.1 CTD-2349P21.3 -3.66 0.00029 0.0434 -0.24 -0.19 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916337 chr17:30738182~30740275:+ LIHC cis rs9457247 1 rs416131 ENSG00000227598.1 RP1-167A14.2 3.66 0.00029 0.0434 0.2 0.19 Crohn's disease; chr6:166993056 chr6:166969626~166999065:- LIHC cis rs1799949 0.965 rs8176198 ENSG00000267681.1 CTD-3199J23.6 -3.66 0.00029 0.0434 -0.18 -0.19 Menopause (age at onset); chr17:43078520 chr17:43144956~43145255:+ LIHC cis rs17376456 1 rs34068652 ENSG00000251023.1 RP11-549J18.1 -3.66 0.00029 0.0434 -0.4 -0.19 Diabetic retinopathy; chr5:94227614 chr5:93860669~93863825:- LIHC cis rs1003719 0.591 rs2835618 ENSG00000272948.2 AP001412.1 -3.66 0.00029 0.0435 -0.22 -0.19 Eye color traits; chr21:37130826 chr21:37267784~37268497:+ LIHC cis rs301901 0.828 rs4308503 ENSG00000250155.1 CTD-2353F22.1 3.66 0.00029 0.0435 0.19 0.19 Height; chr5:37454091 chr5:36666214~36725195:- LIHC cis rs644148 0.5 rs2686773 ENSG00000186019.10 AC084219.4 -3.66 0.00029 0.0435 -0.19 -0.19 Personality dimensions; chr19:44495741 chr19:44105463~44113145:- LIHC cis rs4763879 0.634 rs7974396 ENSG00000256673.1 RP11-599J14.2 3.66 0.00029 0.0435 0.19 0.19 Type 1 diabetes; chr12:9708101 chr12:9398355~9414851:- LIHC cis rs9640161 0.617 rs56019796 ENSG00000261305.1 RP4-584D14.7 3.66 0.00029 0.0435 0.23 0.19 Blood protein levels;Circulating chemerin levels; chr7:150312137 chr7:150341771~150342607:+ LIHC cis rs4648045 0.621 rs980455 ENSG00000230069.3 LRRC37A15P -3.66 0.00029 0.0435 -0.18 -0.19 Lymphocyte percentage of white cells; chr4:102497800 chr4:102727274~102730721:- LIHC cis rs6472827 0.953 rs7827128 ENSG00000253983.2 RP1-16A9.1 3.66 0.00029 0.0435 0.25 0.19 Uterine fibroids; chr8:74209641 chr8:74199396~74208441:+ LIHC cis rs801193 0.569 rs13242290 ENSG00000232559.3 GS1-124K5.12 -3.66 0.00029 0.0435 -0.15 -0.19 Aortic root size; chr7:66656898 chr7:66554588~66576923:- LIHC cis rs2228479 0.717 rs62052210 ENSG00000261253.2 AC137932.6 3.66 0.00029 0.0435 0.28 0.19 Skin colour saturation; chr16:89913750 chr16:89321133~89325110:+ LIHC cis rs2072510 0.569 rs2540488 ENSG00000241556.1 RP11-490G8.1 3.66 0.00029 0.0435 0.26 0.19 Metabolite levels (small molecules and protein measures); chr12:96032967 chr12:95467397~95467861:- LIHC cis rs1501138 0.597 rs203442 ENSG00000263327.5 TAPT1-AS1 -3.66 0.00029 0.0435 -0.25 -0.19 Systemic juvenile idiopathic arthritis; chr4:16245045 chr4:16226685~16320140:+ LIHC cis rs7474896 1 rs11011344 ENSG00000263064.2 RP11-291L22.7 3.66 0.00029 0.0435 0.27 0.19 Obesity (extreme); chr10:37715918 chr10:38448689~38448949:+ LIHC cis rs9545047 0.604 rs2876740 ENSG00000227354.5 RBM26-AS1 -3.66 0.00029 0.0435 -0.23 -0.19 Schizophrenia; chr13:79409829 chr13:79406309~79424328:+ LIHC cis rs3091242 0.934 rs666686 ENSG00000261349.1 RP3-465N24.5 -3.66 0.00029 0.0435 -0.19 -0.19 Erythrocyte sedimentation rate; chr1:25393020 chr1:25266102~25267136:- LIHC cis rs4073416 0.771 rs11158596 ENSG00000276116.2 FUT8-AS1 3.66 0.00029 0.0435 0.24 0.19 N-glycan levels; chr14:65445257 chr14:65411170~65412690:- LIHC cis rs12210905 1 rs6917419 ENSG00000216901.1 AL022393.7 3.66 0.00029 0.0435 0.33 0.19 Hip circumference adjusted for BMI; chr6:27275701 chr6:28176188~28176674:+ LIHC cis rs453301 0.624 rs2288671 ENSG00000253893.2 FAM85B -3.66 0.00029 0.0435 -0.21 -0.19 Joint mobility (Beighton score); chr8:9003384 chr8:8167819~8226614:- LIHC cis rs4073416 0.746 rs12887673 ENSG00000276116.2 FUT8-AS1 3.66 0.00029 0.0435 0.24 0.19 N-glycan levels; chr14:65755053 chr14:65411170~65412690:- LIHC cis rs2288884 0.649 rs11667001 ENSG00000275055.1 CTC-471J1.11 -3.66 0.00029 0.0435 -0.25 -0.19 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52049416 chr19:52049007~52049754:+ LIHC cis rs4239252 0.929 rs4796116 ENSG00000267554.1 RP11-686D22.10 3.66 0.000291 0.0436 0.19 0.19 Blood protein levels; chr17:35841496 chr17:35470069~35470628:- LIHC cis rs4239252 0.929 rs4251791 ENSG00000267554.1 RP11-686D22.10 3.66 0.000291 0.0436 0.19 0.19 Blood protein levels; chr17:35845711 chr17:35470069~35470628:- LIHC cis rs12480328 1 rs76685994 ENSG00000224397.4 LINC01272 -3.66 0.000291 0.0436 -0.39 -0.19 Prostate cancer; chr20:50947674 chr20:50267486~50279795:+ LIHC cis rs875971 0.545 rs10950029 ENSG00000224316.1 RP11-479O9.2 3.66 0.000291 0.0436 0.18 0.19 Aortic root size; chr7:66169334 chr7:65773620~65802067:+ LIHC cis rs11686241 0.872 rs8179823 ENSG00000232485.2 AC098820.3 3.66 0.000291 0.0436 0.19 0.19 Cancer; chr2:216483403 chr2:216479030~216498761:- LIHC cis rs35797862 1 rs35797862 ENSG00000229567.1 RP4-717I23.2 3.66 0.000291 0.0436 0.23 0.19 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts; chr1:93272958 chr1:93278961~93279129:- LIHC cis rs548181 0.611 rs1293672 ENSG00000254671.2 STT3A-AS1 -3.66 0.000291 0.0436 -0.36 -0.19 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia; chr11:125591139 chr11:125570284~125592568:- LIHC cis rs6565180 0.926 rs4787643 ENSG00000273724.1 RP11-347C12.12 3.66 0.000291 0.0436 0.24 0.19 Tonsillectomy; chr16:30382339 chr16:30336400~30343336:+ LIHC cis rs6565180 0.926 rs4788409 ENSG00000273724.1 RP11-347C12.12 3.66 0.000291 0.0436 0.24 0.19 Tonsillectomy; chr16:30382450 chr16:30336400~30343336:+ LIHC cis rs1922291 0.546 rs3771187 ENSG00000281162.1 LINC01127 3.66 0.000291 0.0436 0.2 0.19 Blood protein levels; chr2:102223898 chr2:101962056~101987167:+ LIHC cis rs1922291 0.546 rs12472872 ENSG00000281162.1 LINC01127 3.66 0.000291 0.0436 0.2 0.19 Blood protein levels; chr2:102224384 chr2:101962056~101987167:+ LIHC cis rs2243480 1 rs160655 ENSG00000232546.1 RP11-458F8.1 -3.66 0.000291 0.0436 -0.22 -0.19 Diabetic kidney disease; chr7:66068227 chr7:66848496~66858136:+ LIHC cis rs34734847 0.766 rs3794214 ENSG00000241030.1 RPL29P24 -3.66 0.000291 0.0436 -0.19 -0.19 Mean corpuscular volume; chr12:120730442 chr12:120522664~120523443:- LIHC cis rs6832769 1 rs6811520 ENSG00000272969.1 RP11-528I4.2 3.66 0.000291 0.0436 0.23 0.19 Personality dimensions; chr4:55449011 chr4:55547112~55547889:+ LIHC cis rs848490 0.651 rs11489586 ENSG00000214293.7 APTR 3.66 0.000291 0.0436 0.23 0.19 Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine); chr7:77685900 chr7:77657660~77696265:- LIHC cis rs3015497 1 rs3015497 ENSG00000269906.1 RP11-248J18.2 3.66 0.000291 0.0436 0.24 0.19 Mean platelet volume; chr14:50646680 chr14:50662511~50663178:- LIHC cis rs875971 1 rs11971949 ENSG00000232559.3 GS1-124K5.12 -3.66 0.000291 0.0436 -0.16 -0.19 Aortic root size; chr7:66161027 chr7:66554588~66576923:- LIHC cis rs875971 1 rs11974264 ENSG00000232559.3 GS1-124K5.12 -3.66 0.000291 0.0436 -0.16 -0.19 Aortic root size; chr7:66182595 chr7:66554588~66576923:- LIHC cis rs875971 1 rs1540651 ENSG00000232559.3 GS1-124K5.12 -3.66 0.000291 0.0436 -0.16 -0.19 Aortic root size; chr7:66185134 chr7:66554588~66576923:- LIHC cis rs875971 0.898 rs6977501 ENSG00000232559.3 GS1-124K5.12 -3.66 0.000291 0.0436 -0.16 -0.19 Aortic root size; chr7:66228355 chr7:66554588~66576923:- LIHC cis rs875971 0.965 rs6971509 ENSG00000232559.3 GS1-124K5.12 -3.66 0.000291 0.0436 -0.16 -0.19 Aortic root size; chr7:66249983 chr7:66554588~66576923:- LIHC cis rs713477 1 rs8014621 ENSG00000258413.1 RP11-665C16.6 3.66 0.000292 0.0437 0.22 0.19 Pediatric bone mineral content (femoral neck); chr14:55440131 chr14:55262767~55272075:- LIHC cis rs709400 0.832 rs55864158 ENSG00000258914.1 CTD-2134A5.3 3.66 0.000292 0.0437 0.28 0.19 Body mass index; chr14:103602242 chr14:103875055~103877478:+ LIHC cis rs2243480 1 rs1404147 ENSG00000275400.1 RP4-756H11.5 3.66 0.000292 0.0437 0.26 0.19 Diabetic kidney disease; chr7:65799537 chr7:66553805~66554199:- LIHC cis rs9951150 0.537 rs12456943 ENSG00000267013.4 CTD-2171N6.1 3.66 0.000292 0.0437 0.26 0.19 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55134879 chr18:55105904~55124306:- LIHC cis rs14027 0.512 rs7012791 ENSG00000279347.1 RP11-85I17.2 3.66 0.000292 0.0437 0.18 0.19 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119707451 chr8:119838736~119840385:- LIHC cis rs2117029 0.782 rs11168850 ENSG00000281789.1 Y_RNA 3.66 0.000292 0.0437 0.2 0.19 Intelligence (multi-trait analysis); chr12:49079182 chr12:48927939~48928033:- LIHC cis rs17428076 0.793 rs3770449 ENSG00000228389.1 AC068039.4 -3.66 0.000292 0.0437 -0.24 -0.19 Myopia; chr2:171835538 chr2:171773482~171775844:+ LIHC cis rs7044106 0.664 rs7861679 ENSG00000238181.2 AHCYP2 3.66 0.000292 0.0437 0.22 0.19 Hip circumference adjusted for BMI; chr9:120613311 chr9:120720673~120721972:+ LIHC cis rs7727544 1 rs10076701 ENSG00000233006.5 AC034220.3 3.66 0.000292 0.0437 0.23 0.19 Blood metabolite levels; chr5:132260726 chr5:132311285~132369916:- LIHC cis rs7712401 0.541 rs6867714 ENSG00000263432.2 RN7SL689P 3.66 0.000292 0.0437 0.3 0.19 Mean platelet volume; chr5:123046364 chr5:123022487~123022783:- LIHC cis rs11105298 0.891 rs10777184 ENSG00000258302.2 RP11-981P6.1 3.66 0.000292 0.0437 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89525791 chr12:89561129~89594878:+ LIHC cis rs11105298 0.891 rs10858896 ENSG00000258302.2 RP11-981P6.1 3.66 0.000292 0.0437 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89526407 chr12:89561129~89594878:+ LIHC cis rs11105298 0.891 rs11105312 ENSG00000258302.2 RP11-981P6.1 3.66 0.000292 0.0437 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89526956 chr12:89561129~89594878:+ LIHC cis rs4561483 0.801 rs33620 ENSG00000261216.1 RP11-166B2.5 -3.66 0.000292 0.0437 -0.22 -0.19 Testicular germ cell tumor; chr16:11914689 chr16:11908208~11908916:+ LIHC cis rs2228479 1 rs117406136 ENSG00000261253.2 AC137932.6 3.66 0.000292 0.0437 0.29 0.19 Skin colour saturation; chr16:89908197 chr16:89321133~89325110:+ LIHC cis rs7211079 0.719 rs2289535 ENSG00000275479.1 RP11-334C17.6 3.66 0.000292 0.0437 0.19 0.19 Myocardial infarction; chr17:80137650 chr17:80149627~80149798:+ LIHC cis rs916888 0.773 rs199451 ENSG00000279685.2 MAPT-IT1 -3.66 0.000292 0.0437 -0.34 -0.19 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45895783~45898798:+ LIHC cis rs11671005 0.611 rs35138622 ENSG00000269473.1 CTD-2619J13.19 3.66 0.000292 0.0437 0.36 0.19 Mean platelet volume; chr19:58401421 chr19:58440448~58445849:+ LIHC cis rs854624 0.892 rs73990618 ENSG00000278690.1 RP11-104J23.2 -3.66 0.000292 0.0437 -0.45 -0.19 Blood protein levels; chr17:36004041 chr17:36012504~36012891:+ LIHC cis rs4680 0.737 rs3810595 ENSG00000273311.1 DGCR11 3.66 0.000292 0.0437 0.24 0.19 Blood metabolite levels; chr22:19962121 chr22:19046162~19048375:- LIHC cis rs4680 0.737 rs6269 ENSG00000273311.1 DGCR11 3.66 0.000292 0.0437 0.24 0.19 Blood metabolite levels; chr22:19962429 chr22:19046162~19048375:- LIHC cis rs7829975 0.606 rs891570 ENSG00000254340.1 RP11-10A14.3 -3.66 0.000292 0.0437 -0.2 -0.19 Mood instability; chr8:8936944 chr8:9141424~9145435:+ LIHC cis rs4356975 0.563 rs7662029 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000292 0.0438 -0.19 -0.19 Obesity-related traits; chr4:69096194 chr4:69027831~69044578:+ LIHC cis rs7119 0.717 rs12904254 ENSG00000261143.1 ADAMTS7P3 3.66 0.000292 0.0438 0.27 0.19 Type 2 diabetes; chr15:77510243 chr15:77976042~77993057:+ LIHC cis rs12682352 0.535 rs12677550 ENSG00000253981.4 ALG1L13P -3.66 0.000292 0.0438 -0.24 -0.19 Neuroticism; chr8:8786812 chr8:8236003~8244667:- LIHC cis rs10829156 0.898 rs10741120 ENSG00000225527.1 RP11-383B4.4 -3.66 0.000292 0.0438 -0.33 -0.19 Sudden cardiac arrest; chr10:18641063 chr10:18531849~18533336:- LIHC cis rs2242663 0.798 rs607736 ENSG00000255517.5 CTD-3074O7.5 3.66 0.000292 0.0438 0.21 0.19 Bipolar disorder; chr11:66561406 chr11:66473490~66480233:- LIHC cis rs7918405 1 rs7342028 ENSG00000234017.1 RP11-214N15.5 -3.66 0.000292 0.0438 -0.19 -0.19 QRS duration; chr10:112719503 chr10:112548632~112548872:- LIHC cis rs2253762 0.507 rs11200310 ENSG00000226864.1 ATE1-AS1 3.66 0.000293 0.0438 0.32 0.19 Breast cancer; chr10:121989944 chr10:121928312~121951965:+ LIHC cis rs367615 0.918 rs10055528 ENSG00000249476.1 CTD-2587M2.1 3.66 0.000293 0.0438 0.24 0.19 Colorectal cancer (SNP x SNP interaction); chr5:109525428 chr5:109237120~109326369:- LIHC cis rs9815925 1 rs9815925 ENSG00000171658.7 RP11-443P15.2 -3.66 0.000293 0.0438 -0.27 -0.19 Heschl's gyrus morphology; chr3:185000113 chr3:185959943~185980872:+ LIHC cis rs17376456 1 rs35184505 ENSG00000251023.1 RP11-549J18.1 -3.66 0.000293 0.0438 -0.4 -0.19 Diabetic retinopathy; chr5:94225830 chr5:93860669~93863825:- LIHC cis rs8026198 0.929 rs1678986 ENSG00000260571.1 BNIP3P5 -3.66 0.000293 0.0438 -0.27 -0.19 Fibrinogen levels; chr15:42228990 chr15:42313687~42314386:+ LIHC cis rs1530530 0.881 rs12869327 ENSG00000253771.4 TPTE2P1 -3.66 0.000293 0.0438 -0.44 -0.19 Obesity-related traits; chr13:24696088 chr13:24924677~24968487:- LIHC cis rs4763879 0.778 rs11052497 ENSG00000256673.1 RP11-599J14.2 3.66 0.000293 0.0438 0.19 0.19 Type 1 diabetes; chr12:9696679 chr12:9398355~9414851:- LIHC cis rs2243480 0.706 rs34466769 ENSG00000232546.1 RP11-458F8.1 -3.66 0.000293 0.0438 -0.2 -0.19 Diabetic kidney disease; chr7:65988305 chr7:66848496~66858136:+ LIHC cis rs11096990 0.927 rs6845858 ENSG00000249207.1 RP11-360F5.1 3.66 0.000293 0.0439 0.22 0.19 Cognitive function; chr4:39237099 chr4:39112677~39126818:- LIHC cis rs3002131 0.562 rs2173401 ENSG00000225265.1 TAF1A-AS1 -3.66 0.000293 0.0439 -0.29 -0.19 Interleukin-10 levels; chr1:222575992 chr1:222589825~222593032:+ LIHC cis rs2762353 0.603 rs4145221 ENSG00000242387.1 HIST1H2APS2 -3.66 0.000293 0.0439 -0.22 -0.19 Blood metabolite levels; chr6:25762964 chr6:25882026~25882395:- LIHC cis rs801193 1 rs2055682 ENSG00000273142.1 RP11-458F8.4 -3.66 0.000293 0.0439 -0.18 -0.19 Aortic root size; chr7:66795302 chr7:66902857~66906297:+ LIHC cis rs7193541 0.965 rs28616016 ENSG00000262904.1 TMPOP2 -3.66 0.000293 0.0439 -0.17 -0.19 Multiple myeloma; chr16:74643066 chr16:74667506~74668706:+ LIHC cis rs494453 0.736 rs548129 ENSG00000227811.2 FAM212B-AS1 -3.66 0.000294 0.0439 -0.22 -0.19 Osteoporosis-related phenotypes; chr1:111658548 chr1:111739841~111747798:+ LIHC cis rs74233809 0.901 rs17878846 ENSG00000236937.2 PTGES3P4 3.66 0.000294 0.0439 0.32 0.19 Birth weight; chr10:102870655 chr10:102845595~102845950:+ LIHC cis rs1318878 1 rs55851576 ENSG00000256751.4 PLBD1-AS1 -3.66 0.000294 0.0439 -0.29 -0.19 Intelligence (multi-trait analysis); chr12:15390972 chr12:14567750~14619755:+ LIHC cis rs4356975 0.583 rs6600877 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000294 0.0439 -0.19 -0.19 Obesity-related traits; chr4:69091505 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs6600878 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000294 0.0439 -0.19 -0.19 Obesity-related traits; chr4:69092618 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs57216626 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000294 0.0439 -0.19 -0.19 Obesity-related traits; chr4:69093105 chr4:69027831~69044578:+ LIHC cis rs4356975 0.522 rs59415892 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000294 0.0439 -0.19 -0.19 Obesity-related traits; chr4:69093191 chr4:69027831~69044578:+ LIHC cis rs4356975 0.522 rs62296942 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000294 0.0439 -0.19 -0.19 Obesity-related traits; chr4:69093401 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs7437039 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000294 0.0439 -0.19 -0.19 Obesity-related traits; chr4:69093758 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs7439792 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000294 0.0439 -0.19 -0.19 Obesity-related traits; chr4:69093881 chr4:69027831~69044578:+ LIHC cis rs4356975 0.545 rs62296944 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000294 0.0439 -0.19 -0.19 Obesity-related traits; chr4:69094492 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs6600879 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000294 0.0439 -0.19 -0.19 Obesity-related traits; chr4:69094669 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs6600880 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000294 0.0439 -0.19 -0.19 Obesity-related traits; chr4:69094762 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs4554144 ENSG00000250919.1 RP11-813N20.3 -3.66 0.000294 0.0439 -0.19 -0.19 Obesity-related traits; chr4:69094837 chr4:69027831~69044578:+ LIHC cis rs7044106 0.762 rs10739570 ENSG00000270917.1 RP11-27I1.6 -3.66 0.000294 0.0439 -0.24 -0.19 Hip circumference adjusted for BMI; chr9:120618944 chr9:120812475~120812845:- LIHC cis rs916888 0.773 rs199439 ENSG00000279685.2 MAPT-IT1 -3.66 0.000294 0.0439 -0.34 -0.19 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45895783~45898798:+ LIHC cis rs4578769 0.765 rs16972427 ENSG00000265943.1 RP11-739L10.1 -3.66 0.000294 0.0439 -0.25 -0.19 Eosinophil percentage of white cells; chr18:22833393 chr18:22699481~22933764:- LIHC cis rs2243480 1 rs4718333 ENSG00000275400.1 RP4-756H11.5 -3.66 0.000294 0.0439 -0.26 -0.19 Diabetic kidney disease; chr7:66307771 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs7792391 ENSG00000275400.1 RP4-756H11.5 -3.66 0.000294 0.0439 -0.26 -0.19 Diabetic kidney disease; chr7:66308442 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs10247526 ENSG00000275400.1 RP4-756H11.5 -3.66 0.000294 0.0439 -0.26 -0.19 Diabetic kidney disease; chr7:66315709 chr7:66553805~66554199:- LIHC cis rs2243480 0.908 rs1532573 ENSG00000275400.1 RP4-756H11.5 -3.66 0.000294 0.0439 -0.26 -0.19 Diabetic kidney disease; chr7:66333815 chr7:66553805~66554199:- LIHC cis rs34044649 0.84 rs1731840 ENSG00000214106.6 PAXIP1-AS2 3.66 0.000294 0.0439 0.15 0.19 Triptolide cytotoxicity; chr7:155858796 chr7:154928498~154949908:+ LIHC cis rs2195987 0.874 rs4932934 ENSG00000268442.1 CTD-2027I19.2 3.66 0.000294 0.0439 0.37 0.19 Testicular germ cell tumor; chr19:23924531 chr19:24162370~24163425:- LIHC cis rs7712401 0.645 rs154497 ENSG00000263432.2 RN7SL689P 3.66 0.000294 0.0439 0.29 0.19 Mean platelet volume; chr5:122885725 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs154496 ENSG00000263432.2 RN7SL689P 3.66 0.000294 0.0439 0.29 0.19 Mean platelet volume; chr5:122886036 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs144597 ENSG00000263432.2 RN7SL689P 3.66 0.000294 0.0439 0.29 0.19 Mean platelet volume; chr5:122887537 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs246282 ENSG00000263432.2 RN7SL689P 3.66 0.000294 0.0439 0.29 0.19 Mean platelet volume; chr5:122889910 chr5:123022487~123022783:- LIHC cis rs7712401 0.623 rs538424 ENSG00000263432.2 RN7SL689P 3.66 0.000294 0.0439 0.29 0.19 Mean platelet volume; chr5:122893068 chr5:123022487~123022783:- LIHC cis rs8087799 0.894 rs4592764 ENSG00000273232.1 RP11-370A5.2 3.66 0.000294 0.044 0.23 0.19 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22678519 chr18:22882825~22883357:- LIHC cis rs17818399 0.51 rs1451153 ENSG00000239332.4 LINC01119 -3.66 0.000294 0.044 -0.26 -0.19 Height; chr2:46572713 chr2:46816697~46859007:+ LIHC cis rs1862618 0.671 rs2255726 ENSG00000271828.1 CTD-2310F14.1 -3.66 0.000294 0.044 -0.26 -0.19 Initial pursuit acceleration; chr5:56947301 chr5:56927874~56929573:+ LIHC cis rs1862618 0.671 rs2591957 ENSG00000271828.1 CTD-2310F14.1 -3.66 0.000294 0.044 -0.26 -0.19 Initial pursuit acceleration; chr5:56947319 chr5:56927874~56929573:+ LIHC cis rs17818399 0.51 rs1451153 ENSG00000279254.1 RP11-536C12.1 -3.66 0.000294 0.044 -0.23 -0.19 Height; chr2:46572713 chr2:46668870~46670778:+ LIHC cis rs6445975 0.715 rs13320332 ENSG00000272360.1 RP11-359I18.5 -3.66 0.000294 0.044 -0.23 -0.19 Systemic lupus erythematosus; chr3:58282617 chr3:58490830~58491291:- LIHC cis rs9907295 0.579 rs9899866 ENSG00000270871.1 AC015849.19 -3.66 0.000294 0.044 -0.21 -0.19 Fibroblast growth factor basic levels; chr17:35908466 chr17:35816717~35830293:- LIHC cis rs4763879 0.778 rs1056151 ENSG00000256673.1 RP11-599J14.2 3.66 0.000294 0.044 0.19 0.19 Type 1 diabetes; chr12:9698427 chr12:9398355~9414851:- LIHC cis rs1598856 0.932 rs2168803 ENSG00000230069.3 LRRC37A15P -3.66 0.000295 0.044 -0.17 -0.19 Primary biliary cholangitis; chr4:102507458 chr4:102727274~102730721:- LIHC cis rs4578769 0.765 rs1584428 ENSG00000265943.1 RP11-739L10.1 3.66 0.000295 0.044 0.25 0.19 Eosinophil percentage of white cells; chr18:22807886 chr18:22699481~22933764:- LIHC cis rs4561483 0.801 rs8061189 ENSG00000261216.1 RP11-166B2.5 3.66 0.000295 0.044 0.21 0.19 Testicular germ cell tumor; chr16:11857892 chr16:11908208~11908916:+ LIHC cis rs17772222 0.597 rs17700521 ENSG00000258789.1 RP11-507K2.3 -3.66 0.000295 0.044 -0.24 -0.19 Coronary artery calcification; chr14:88849531 chr14:88551597~88552493:+ LIHC cis rs1799949 0.894 rs36062488 ENSG00000267681.1 CTD-3199J23.6 3.66 0.000295 0.044 0.19 0.19 Menopause (age at onset); chr17:43185455 chr17:43144956~43145255:+ LIHC cis rs2243480 0.901 rs778732 ENSG00000228409.4 CCT6P1 3.66 0.000295 0.044 0.21 0.19 Diabetic kidney disease; chr7:66357373 chr7:65751142~65763354:+ LIHC cis rs7412746 0.658 rs11589458 ENSG00000231073.1 RP11-316M1.3 3.66 0.000295 0.0441 0.2 0.19 Melanoma; chr1:150820140 chr1:150973123~150975534:+ LIHC cis rs3738443 1 rs74152976 ENSG00000259865.1 RP11-488L18.10 3.66 0.000295 0.0441 0.19 0.19 Alcohol dependence; chr1:247183504 chr1:247187281~247188526:- LIHC cis rs9532669 0.926 rs9525418 ENSG00000168852.11 TPTE2P5 -3.66 0.000295 0.0441 -0.22 -0.19 Cervical cancer; chr13:40879081 chr13:40822296~40921749:- LIHC cis rs904251 0.734 rs2797790 ENSG00000204110.6 RP1-153P14.8 3.66 0.000295 0.0441 0.23 0.19 Cognitive performance; chr6:37479299 chr6:37507348~37535616:+ LIHC cis rs8077577 0.747 rs1925 ENSG00000260647.1 RP1-178F10.1 3.66 0.000295 0.0441 0.25 0.19 Obesity-related traits; chr17:18274401 chr17:18268080~18268828:+ LIHC cis rs12817211 0.502 rs3741562 ENSG00000272368.2 RP4-605O3.4 -3.66 0.000295 0.0441 -0.22 -0.19 Colorectal or endometrial cancer; chr12:50135953 chr12:50112197~50165618:+ LIHC cis rs875971 0.628 rs6974355 ENSG00000273024.4 INTS4P2 -3.66 0.000295 0.0441 -0.23 -0.19 Aortic root size; chr7:66376994 chr7:65647864~65715661:+ LIHC cis rs4792901 0.959 rs72833148 ENSG00000279602.1 CTD-3014M21.1 -3.66 0.000295 0.0441 -0.22 -0.19 Dupuytren's disease; chr17:43551795 chr17:43360041~43361361:- LIHC cis rs2333021 0.866 rs10133784 ENSG00000259015.1 RP11-109N23.6 3.66 0.000295 0.0441 0.23 0.19 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:73003328 chr14:72960595~72961993:+ LIHC cis rs6545883 0.965 rs3771261 ENSG00000271889.1 RP11-493E12.1 3.66 0.000295 0.0441 0.23 0.19 Tuberculosis; chr2:61535026 chr2:61151433~61162105:- LIHC cis rs6545883 0.718 rs3771260 ENSG00000271889.1 RP11-493E12.1 3.66 0.000295 0.0441 0.23 0.19 Tuberculosis; chr2:61535249 chr2:61151433~61162105:- LIHC cis rs6545883 1 rs6742276 ENSG00000271889.1 RP11-493E12.1 3.66 0.000295 0.0441 0.23 0.19 Tuberculosis; chr2:61541610 chr2:61151433~61162105:- LIHC cis rs1005277 0.579 rs176880 ENSG00000099251.13 HSD17B7P2 -3.66 0.000295 0.0441 -0.22 -0.19 Extrinsic epigenetic age acceleration; chr10:38112489 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2505248 ENSG00000099251.13 HSD17B7P2 3.66 0.000295 0.0441 0.22 0.19 Extrinsic epigenetic age acceleration; chr10:38170169 chr10:38356380~38378505:+ LIHC cis rs6723226 0.721 rs10172510 ENSG00000276334.1 AL133243.1 3.66 0.000295 0.0441 0.2 0.19 Intelligence (multi-trait analysis); chr2:32395820 chr2:32521927~32523547:+ LIHC cis rs5743030 1 rs4920660 ENSG00000253559.1 OSGEPL1-AS1 -3.66 0.000295 0.0441 -0.33 -0.19 Subcutaneous adipose tissue; chr2:189879940 chr2:189762704~189765556:+ LIHC cis rs5743030 1 rs16832155 ENSG00000253559.1 OSGEPL1-AS1 -3.66 0.000295 0.0441 -0.33 -0.19 Subcutaneous adipose tissue; chr2:189885115 chr2:189762704~189765556:+ LIHC cis rs7044106 0.718 rs1981021 ENSG00000270917.1 RP11-27I1.6 -3.66 0.000296 0.0441 -0.24 -0.19 Hip circumference adjusted for BMI; chr9:120626115 chr9:120812475~120812845:- LIHC cis rs7044106 0.734 rs1981020 ENSG00000270917.1 RP11-27I1.6 -3.66 0.000296 0.0441 -0.24 -0.19 Hip circumference adjusted for BMI; chr9:120626186 chr9:120812475~120812845:- LIHC cis rs7044106 0.791 rs12554440 ENSG00000238181.2 AHCYP2 -3.66 0.000296 0.0441 -0.22 -0.19 Hip circumference adjusted for BMI; chr9:120723055 chr9:120720673~120721972:+ LIHC cis rs11696277 0.755 rs6044747 ENSG00000232333.1 RPS27AP2 3.66 0.000296 0.0441 0.3 0.19 Gut microbiome composition (summer); chr20:17342379 chr20:17516843~17517307:+ LIHC cis rs1396626 0.926 rs12354293 ENSG00000230427.1 RP11-313A24.1 -3.66 0.000296 0.0442 -0.29 -0.19 Diabetic kidney disease; chr1:95547517 chr1:95061596~95067545:+ LIHC cis rs13113518 0.812 rs12649507 ENSG00000272969.1 RP11-528I4.2 -3.66 0.000296 0.0442 -0.21 -0.19 Height; chr4:55514317 chr4:55547112~55547889:+ LIHC cis rs2348418 0.832 rs4244844 ENSG00000247934.4 RP11-967K21.1 3.66 0.000296 0.0442 0.18 0.19 Lung function (FEV1);Lung function (FVC); chr12:28434062 chr12:28163298~28190738:- LIHC cis rs1862618 0.671 rs28397234 ENSG00000271828.1 CTD-2310F14.1 -3.66 0.000296 0.0442 -0.26 -0.19 Initial pursuit acceleration; chr5:56952601 chr5:56927874~56929573:+ LIHC cis rs2120243 0.539 rs2047649 ENSG00000244515.1 KRT18P34 -3.66 0.000296 0.0442 -0.2 -0.19 Hepatocellular carcinoma in hepatitis B infection; chr3:157367816 chr3:157162663~157163932:- LIHC cis rs950881 0.932 rs3771175 ENSG00000234389.1 AC007278.3 -3.66 0.000296 0.0442 -0.26 -0.19 Allergy; chr2:102343750 chr2:102438713~102440475:+ LIHC cis rs2348418 0.715 rs1355471 ENSG00000247934.4 RP11-967K21.1 -3.66 0.000296 0.0442 -0.18 -0.19 Lung function (FEV1);Lung function (FVC); chr12:28568792 chr12:28163298~28190738:- LIHC cis rs9487094 1 rs9480953 ENSG00000260273.1 RP11-425D10.10 3.66 0.000296 0.0442 0.23 0.19 Height; chr6:109417941 chr6:109382795~109383666:+ LIHC cis rs763121 0.853 rs4821812 ENSG00000273076.1 RP3-508I15.22 3.66 0.000296 0.0442 0.23 0.19 Menopause (age at onset); chr22:38679230 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs9607566 ENSG00000273076.1 RP3-508I15.22 3.66 0.000296 0.0442 0.23 0.19 Menopause (age at onset); chr22:38679429 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs3827357 ENSG00000273076.1 RP3-508I15.22 3.66 0.000296 0.0442 0.23 0.19 Menopause (age at onset); chr22:38683408 chr22:38743495~38743910:+ LIHC cis rs6142102 0.961 rs2235597 ENSG00000275784.1 RP5-1125A11.6 -3.66 0.000296 0.0442 -0.22 -0.19 Skin pigmentation; chr20:34077808 chr20:33989480~33991818:- LIHC cis rs6142102 0.886 rs4911147 ENSG00000275784.1 RP5-1125A11.6 -3.66 0.000296 0.0442 -0.22 -0.19 Skin pigmentation; chr20:34079801 chr20:33989480~33991818:- LIHC cis rs6142102 0.961 rs8123521 ENSG00000275784.1 RP5-1125A11.6 -3.66 0.000296 0.0442 -0.22 -0.19 Skin pigmentation; chr20:34081079 chr20:33989480~33991818:- LIHC cis rs3805389 0.504 rs62308708 ENSG00000273257.1 RP11-177J6.1 -3.66 0.000296 0.0442 -0.33 -0.19 Waist-to-hip ratio adjusted for body mass index; chr4:55626177 chr4:55387949~55388271:+ LIHC cis rs5833486 1 rs5833486 ENSG00000189223.12 PAX8-AS1 -3.66 0.000296 0.0442 -0.3 -0.19 Red blood cell count; chr2:113199603 chr2:113211522~113276581:+ LIHC cis rs864537 0.676 rs1773561 ENSG00000273160.1 RP11-104L21.3 3.66 0.000296 0.0442 0.27 0.19 Celiac disease or Rheumatoid arthritis;Celiac disease; chr1:167452714 chr1:167457742~167459891:- LIHC cis rs193541 0.621 rs898391 ENSG00000263432.2 RN7SL689P 3.66 0.000296 0.0442 0.29 0.19 Glucose homeostasis traits; chr5:122746471 chr5:123022487~123022783:- LIHC cis rs2275906 0.557 rs62394317 ENSG00000216436.2 HIST1H2APS1 3.66 0.000296 0.0442 0.32 0.19 Urate levels in lean individuals; chr6:25882749 chr6:25732497~25732827:+ LIHC cis rs559928 0.606 rs11605856 ENSG00000236935.1 AP003774.1 3.66 0.000296 0.0442 0.28 0.19 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64158056 chr11:64325050~64329504:- LIHC cis rs559928 0.606 rs11231710 ENSG00000236935.1 AP003774.1 3.66 0.000296 0.0442 0.28 0.19 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64158271 chr11:64325050~64329504:- LIHC cis rs240993 0.812 rs9400476 ENSG00000230177.1 RP5-1112D6.4 3.66 0.000296 0.0442 0.21 0.19 Inflammatory skin disease;Psoriasis; chr6:111463172 chr6:111277932~111278742:+ LIHC cis rs340849 0.703 rs17762150 ENSG00000274895.1 RP11-478J18.2 -3.66 0.000297 0.0443 -0.22 -0.19 Alzheimer's disease; chr1:213951475 chr1:213983793~213986419:- LIHC cis rs3738443 0.569 rs6704060 ENSG00000227671.4 RP11-488L18.4 -3.66 0.000297 0.0443 -0.13 -0.19 Alcohol dependence; chr1:247218222 chr1:247189851~247210856:- LIHC cis rs938554 0.657 rs9994216 ENSG00000250413.1 RP11-448G15.1 -3.66 0.000297 0.0443 -0.27 -0.19 Blood metabolite levels; chr4:9982917 chr4:10006482~10009725:+ LIHC cis rs9907295 0.591 rs11650668 ENSG00000267554.1 RP11-686D22.10 3.66 0.000297 0.0443 0.19 0.19 Fibroblast growth factor basic levels; chr17:35822045 chr17:35470069~35470628:- LIHC cis rs9907295 0.591 rs4251749 ENSG00000267554.1 RP11-686D22.10 3.66 0.000297 0.0443 0.19 0.19 Fibroblast growth factor basic levels; chr17:35823421 chr17:35470069~35470628:- LIHC cis rs12908161 1 rs58416181 ENSG00000225151.9 GOLGA2P7 -3.66 0.000297 0.0443 -0.25 -0.19 Schizophrenia; chr15:84721230 chr15:84199311~84230136:- LIHC cis rs1109916 0.524 rs10864724 ENSG00000236497.1 RP11-66A2.2 3.66 0.000297 0.0443 0.24 0.19 Facial morphology (factor 6, height of vermillion lower lip); chr1:232183045 chr1:232727254~232742715:- LIHC cis rs8064024 0.68 rs2063101 ENSG00000267077.1 RP11-127I20.5 3.66 0.000297 0.0443 0.2 0.19 Cancer; chr16:4866347 chr16:4795265~4796532:- LIHC cis rs7111031 1 rs6589379 ENSG00000270179.1 RP11-159N11.4 3.66 0.000297 0.0443 0.27 0.19 Subjective well-being (multi-trait analysis);Neuroticism;Depressive symptoms (multi-trait analysis); chr11:113503845 chr11:113368478~113369117:+ LIHC cis rs7111031 0.729 rs61902812 ENSG00000270179.1 RP11-159N11.4 -3.66 0.000297 0.0443 -0.27 -0.19 Subjective well-being (multi-trait analysis);Neuroticism;Depressive symptoms (multi-trait analysis); chr11:113503698 chr11:113368478~113369117:+ LIHC cis rs4073416 0.684 rs12879805 ENSG00000276116.2 FUT8-AS1 3.66 0.000297 0.0443 0.25 0.19 N-glycan levels; chr14:65581077 chr14:65411170~65412690:- LIHC cis rs1799949 0.965 rs8067269 ENSG00000267002.1 RP11-242D8.1 3.66 0.000297 0.0443 0.18 0.19 Menopause (age at onset); chr17:43083782 chr17:43164183~43170403:- LIHC cis rs2613514 0.73 rs72894087 ENSG00000204277.1 RP11-219G17.4 3.66 0.000297 0.0443 0.29 0.19 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78068895 chr17:78261349~78278492:- LIHC cis rs2613514 0.73 rs56196034 ENSG00000204277.1 RP11-219G17.4 3.66 0.000297 0.0443 0.29 0.19 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78069700 chr17:78261349~78278492:- LIHC cis rs2613514 0.73 rs55825837 ENSG00000204277.1 RP11-219G17.4 3.66 0.000297 0.0443 0.29 0.19 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78069703 chr17:78261349~78278492:- LIHC cis rs2613514 0.73 rs56330517 ENSG00000204277.1 RP11-219G17.4 3.66 0.000297 0.0443 0.29 0.19 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78069766 chr17:78261349~78278492:- LIHC cis rs9595908 0.694 rs3752474 ENSG00000212293.1 SNORA16 3.66 0.000297 0.0443 0.23 0.19 Body mass index; chr13:32758510 chr13:32420390~32420516:- LIHC cis rs8087799 0.894 rs4800428 ENSG00000273232.1 RP11-370A5.2 3.66 0.000297 0.0443 0.24 0.19 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22689135 chr18:22882825~22883357:- LIHC cis rs301901 0.828 rs4304095 ENSG00000250155.1 CTD-2353F22.1 3.66 0.000297 0.0443 0.19 0.19 Height; chr5:37454360 chr5:36666214~36725195:- LIHC cis rs301901 0.796 rs62361483 ENSG00000250155.1 CTD-2353F22.1 3.66 0.000297 0.0443 0.19 0.19 Height; chr5:37468413 chr5:36666214~36725195:- LIHC cis rs1799949 0.683 rs55737636 ENSG00000267681.1 CTD-3199J23.6 -3.66 0.000297 0.0443 -0.19 -0.19 Menopause (age at onset); chr17:43112722 chr17:43144956~43145255:+ LIHC cis rs4964805 0.626 rs11111767 ENSG00000257681.1 RP11-341G23.4 -3.66 0.000297 0.0444 -0.2 -0.19 Attention deficit hyperactivity disorder; chr12:103782468 chr12:103746315~103768858:- LIHC cis rs1979679 0.842 rs4931729 ENSG00000278733.1 RP11-425D17.1 3.66 0.000297 0.0444 0.25 0.19 Ossification of the posterior longitudinal ligament of the spine; chr12:28146306 chr12:28185625~28186190:- LIHC cis rs7674212 0.531 rs10006474 ENSG00000248971.2 KRT8P46 -3.66 0.000297 0.0444 -0.2 -0.19 Type 2 diabetes; chr4:103006890 chr4:102728746~102730171:- LIHC cis rs10905065 0.931 rs6602240 ENSG00000215267.7 AKR1C7P 3.66 0.000297 0.0444 0.23 0.19 Menopause (age at onset); chr10:5774788 chr10:5275173~5288470:- LIHC cis rs755249 0.53 rs112205225 ENSG00000182109.6 RP11-69E11.4 3.66 0.000297 0.0444 0.25 0.19 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39121716 chr1:39522280~39546187:- LIHC cis rs7231041 0.751 rs1786731 ENSG00000263846.1 CIAPIN1P 3.66 0.000298 0.0444 0.22 0.19 Obesity-related traits; chr18:25799931 chr18:26599408~26600338:+ LIHC cis rs7734985 0.587 rs7443470 ENSG00000250551.1 RP11-254I22.1 3.65 0.000298 0.0444 0.22 0.19 IgG glycosylation; chr5:96255748 chr5:96050115~96215519:+ LIHC cis rs1440410 0.83 rs10519678 ENSG00000250326.1 RP11-284M14.1 -3.65 0.000298 0.0444 -0.22 -0.19 Ischemic stroke; chr4:143260920 chr4:142933195~143184861:- LIHC cis rs783540 0.632 rs17356528 ENSG00000278603.1 RP13-608F4.5 -3.65 0.000298 0.0444 -0.24 -0.19 Schizophrenia; chr15:82636799 chr15:82472203~82472426:+ LIHC cis rs12639258 0.961 rs13084167 ENSG00000273682.1 RP11-427P5.3 3.65 0.000298 0.0444 0.32 0.19 Eotaxin levels; chr3:46472390 chr3:46918807~46918935:- LIHC cis rs875971 0.66 rs801193 ENSG00000237310.1 GS1-124K5.4 -3.65 0.000298 0.0444 -0.18 -0.19 Aortic root size; chr7:66565625 chr7:66493706~66495474:+ LIHC cis rs1075265 0.933 rs7562055 ENSG00000233266.1 HMGB1P31 3.65 0.000298 0.0444 0.24 0.19 Chronotype;Morning vs. evening chronotype; chr2:54112694 chr2:54051334~54051760:+ LIHC cis rs2919917 0.628 rs7017898 ENSG00000254352.1 RP11-578O24.2 3.65 0.000298 0.0444 0.29 0.19 Lymphocyte counts; chr8:78697147 chr8:78723796~78724136:- LIHC cis rs734999 0.505 rs4445406 ENSG00000225931.3 RP3-395M20.7 3.65 0.000298 0.0445 0.2 0.19 Ulcerative colitis; chr1:2607961 chr1:2566410~2569888:+ LIHC cis rs7011507 0.617 rs10110839 ENSG00000253608.1 RP11-770E5.1 -3.65 0.000298 0.0445 -0.25 -0.19 Inflammatory bowel disease;Ulcerative colitis; chr8:48469716 chr8:48551567~48698510:+ LIHC cis rs853679 1 rs853676 ENSG00000204709.4 LINC01556 3.65 0.000298 0.0445 0.33 0.19 Depression; chr6:28331910 chr6:28943877~28944537:+ LIHC cis rs950881 0.867 rs10197862 ENSG00000234389.1 AC007278.3 3.65 0.000298 0.0445 0.26 0.19 Allergy; chr2:102350089 chr2:102438713~102440475:+ LIHC cis rs6669919 0.53 rs11587621 ENSG00000229832.1 RP11-384C4.2 -3.65 0.000298 0.0445 -0.19 -0.19 Intelligence (multi-trait analysis); chr1:211495058 chr1:212357418~212358353:+ LIHC cis rs12681287 0.511 rs4129535 ENSG00000254088.1 SLC2A3P4 3.65 0.000298 0.0445 0.23 0.19 Caudate activity during reward; chr8:86511865 chr8:86503591~86505061:+ LIHC cis rs12681287 0.547 rs6985066 ENSG00000254088.1 SLC2A3P4 3.65 0.000298 0.0445 0.23 0.19 Caudate activity during reward; chr8:86514210 chr8:86503591~86505061:+ LIHC cis rs3934487 0.547 rs10158252 ENSG00000223956.1 RP4-710M16.2 -3.65 0.000298 0.0445 -0.21 -0.19 Reticulocyte count; chr1:55859557 chr1:56414963~56415966:+ LIHC cis rs6456156 0.586 rs12527827 ENSG00000227598.1 RP1-167A14.2 -3.65 0.000298 0.0445 -0.2 -0.19 Primary biliary cholangitis; chr6:167055783 chr6:166969626~166999065:- LIHC cis rs6456156 0.565 rs12529959 ENSG00000227598.1 RP1-167A14.2 -3.65 0.000298 0.0445 -0.2 -0.19 Primary biliary cholangitis; chr6:167055804 chr6:166969626~166999065:- LIHC cis rs916888 0.773 rs9896243 ENSG00000279685.2 MAPT-IT1 -3.65 0.000298 0.0445 -0.33 -0.19 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45895783~45898798:+ LIHC cis rs11105298 0.891 rs10777185 ENSG00000258302.2 RP11-981P6.1 3.65 0.000299 0.0445 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89527498 chr12:89561129~89594878:+ LIHC cis rs11105298 0.786 rs10777186 ENSG00000258302.2 RP11-981P6.1 3.65 0.000299 0.0445 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89527500 chr12:89561129~89594878:+ LIHC cis rs11105298 0.786 rs10858897 ENSG00000258302.2 RP11-981P6.1 3.65 0.000299 0.0445 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89528255 chr12:89561129~89594878:+ LIHC cis rs11105298 0.891 rs10858898 ENSG00000258302.2 RP11-981P6.1 3.65 0.000299 0.0445 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89528334 chr12:89561129~89594878:+ LIHC cis rs11105298 0.891 rs10858899 ENSG00000258302.2 RP11-981P6.1 3.65 0.000299 0.0445 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89530034 chr12:89561129~89594878:+ LIHC cis rs780096 0.506 rs72819512 ENSG00000234072.1 AC074117.10 -3.65 0.000299 0.0445 -0.18 -0.19 Total body bone mineral density; chr2:27391582 chr2:27356246~27367622:+ LIHC cis rs42490 0.7 rs40459 ENSG00000251136.7 RP11-37B2.1 3.65 0.000299 0.0445 0.16 0.19 Leprosy; chr8:89833998 chr8:89609409~89757727:- LIHC cis rs17818399 0.781 rs34449783 ENSG00000239332.4 LINC01119 -3.65 0.000299 0.0445 -0.27 -0.19 Height; chr2:46636416 chr2:46816697~46859007:+ LIHC cis rs17818399 0.815 rs17768138 ENSG00000239332.4 LINC01119 -3.65 0.000299 0.0445 -0.27 -0.19 Height; chr2:46641078 chr2:46816697~46859007:+ LIHC cis rs13178541 0.671 rs9637923 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135791532 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs11242290 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135791660 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs12654633 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135791677 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs12656771 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135791696 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs10060930 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135791965 chr5:134926660~134928036:- LIHC cis rs13178541 0.606 rs10069058 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135792227 chr5:134926660~134928036:- LIHC cis rs13178541 0.574 rs9637925 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135792982 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs12153181 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135793126 chr5:134926660~134928036:- LIHC cis rs13178541 0.671 rs12153176 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135793155 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs12153182 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135793165 chr5:134926660~134928036:- LIHC cis rs13178541 0.574 rs11242292 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135793829 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs11954354 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135793998 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs11955110 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135794353 chr5:134926660~134928036:- LIHC cis rs13178541 0.606 rs11958506 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135794373 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs11948583 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135794589 chr5:134926660~134928036:- LIHC cis rs13178541 0.574 rs55798589 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135794616 chr5:134926660~134928036:- LIHC cis rs13178541 0.574 rs11748719 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135794979 chr5:134926660~134928036:- LIHC cis rs13178541 0.574 rs11745326 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135795200 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs10053928 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135795501 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs10069265 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135795700 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs10077045 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135795798 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs62364709 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135796257 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs11242294 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135797027 chr5:134926660~134928036:- LIHC cis rs13178541 0.606 rs11242295 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135797217 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs4976532 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135798385 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs4976534 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135798716 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs10900839 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135798845 chr5:134926660~134928036:- LIHC cis rs13178541 0.641 rs10900841 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135799020 chr5:134926660~134928036:- LIHC cis rs13178541 0.574 rs11738505 ENSG00000247627.2 MTND4P12 -3.65 0.000299 0.0445 -0.25 -0.19 IgG glycosylation; chr5:135800107 chr5:134926660~134928036:- LIHC cis rs34044649 0.84 rs1675567 ENSG00000214106.6 PAXIP1-AS2 3.65 0.000299 0.0445 0.15 0.19 Triptolide cytotoxicity; chr7:155858317 chr7:154928498~154949908:+ LIHC cis rs3782123 0.514 rs11246009 ENSG00000277290.1 RP11-326C3.16 -3.65 0.000299 0.0445 -0.25 -0.19 Red cell distribution width;Glycated hemoglobin levels; chr11:223733 chr11:243099~243483:- LIHC cis rs1115240 0.685 rs1955846 ENSG00000257842.4 NOVA1-AS1 -3.65 0.000299 0.0445 -0.18 -0.19 Educational attainment (years of education); chr14:26670929 chr14:26598412~26806467:+ LIHC cis rs524281 0.731 rs3829937 ENSG00000255320.1 RP11-755F10.1 3.65 0.000299 0.0445 0.32 0.19 Electroencephalogram traits; chr11:66020195 chr11:66244840~66246239:- LIHC cis rs524281 0.731 rs10791838 ENSG00000255320.1 RP11-755F10.1 3.65 0.000299 0.0445 0.32 0.19 Electroencephalogram traits; chr11:66022383 chr11:66244840~66246239:- LIHC cis rs4792901 0.802 rs76971300 ENSG00000279602.1 CTD-3014M21.1 -3.65 0.000299 0.0445 -0.23 -0.19 Dupuytren's disease; chr17:43503220 chr17:43360041~43361361:- LIHC cis rs1075265 0.901 rs7591194 ENSG00000233266.1 HMGB1P31 -3.65 0.000299 0.0445 -0.23 -0.19 Chronotype;Morning vs. evening chronotype; chr2:54086699 chr2:54051334~54051760:+ LIHC cis rs6684428 0.536 rs6695436 ENSG00000229871.1 RP4-710M16.1 -3.65 0.000299 0.0445 -0.3 -0.19 Airflow obstruction; chr1:55924483 chr1:56207567~56208456:- LIHC cis rs9649213 0.574 rs34817002 ENSG00000272950.1 RP11-307C18.1 3.65 0.000299 0.0446 0.24 0.19 Prostate cancer (SNP x SNP interaction); chr7:98257739 chr7:98322853~98323430:+ LIHC cis rs4253772 0.938 rs41371446 ENSG00000260708.1 CTA-29F11.1 3.65 0.000299 0.0446 0.42 0.19 Cholesterol, total;LDL cholesterol; chr22:46241375 chr22:46761894~46762563:- LIHC cis rs4253772 0.938 rs41355347 ENSG00000260708.1 CTA-29F11.1 3.65 0.000299 0.0446 0.42 0.19 Cholesterol, total;LDL cholesterol; chr22:46241614 chr22:46761894~46762563:- LIHC cis rs13113518 0.812 rs2412648 ENSG00000223305.1 RN7SKP30 3.65 0.000299 0.0446 0.23 0.19 Height; chr4:55454900 chr4:55540502~55540835:- LIHC cis rs13113518 0.812 rs12512737 ENSG00000223305.1 RN7SKP30 3.65 0.000299 0.0446 0.23 0.19 Height; chr4:55454938 chr4:55540502~55540835:- LIHC cis rs13113518 0.812 rs13125984 ENSG00000223305.1 RN7SKP30 3.65 0.000299 0.0446 0.23 0.19 Height; chr4:55455102 chr4:55540502~55540835:- LIHC cis rs794185 0.714 rs711636 ENSG00000231249.1 ITPR1-AS1 -3.65 0.000299 0.0446 -0.21 -0.19 Multiple sclerosis--Brain Glutamate Levels; chr3:4448093 chr3:4490891~4493163:- LIHC cis rs2531992 1 rs710893 ENSG00000262185.1 RP11-462G12.1 -3.65 0.000299 0.0446 -0.36 -0.19 Waist circumference; chr16:3964963 chr16:3947609~3950444:- LIHC cis rs10911232 0.524 rs4652773 ENSG00000224468.3 RP11-181K3.4 -3.65 0.000299 0.0446 -0.16 -0.19 Hypertriglyceridemia; chr1:183085692 chr1:183138402~183141282:- LIHC cis rs9906944 0.545 rs11079850 ENSG00000248278.1 SUMO2P17 -3.65 0.000299 0.0446 -0.27 -0.19 Intelligence (multi-trait analysis);Body fat percentage; chr17:49014890 chr17:48874860~48908983:- LIHC cis rs9906944 0.545 rs11079851 ENSG00000248278.1 SUMO2P17 -3.65 0.000299 0.0446 -0.27 -0.19 Intelligence (multi-trait analysis);Body fat percentage; chr17:49014948 chr17:48874860~48908983:- LIHC cis rs4356975 0.563 rs7438135 ENSG00000250919.1 RP11-813N20.3 -3.65 0.000299 0.0446 -0.19 -0.19 Obesity-related traits; chr4:69095621 chr4:69027831~69044578:+ LIHC cis rs1411478 1 rs7516739 ENSG00000243155.1 RP11-46A10.5 -3.65 0.000299 0.0446 -0.19 -0.19 Menopause (age at onset);Progressive supranuclear palsy; chr1:180979370 chr1:180944042~180976482:- LIHC cis rs1411478 1 rs7528526 ENSG00000243155.1 RP11-46A10.5 -3.65 0.000299 0.0446 -0.19 -0.19 Menopause (age at onset);Progressive supranuclear palsy; chr1:180979438 chr1:180944042~180976482:- LIHC cis rs7560272 0.538 rs13000788 ENSG00000273245.1 RP11-434P11.2 -3.65 0.000299 0.0446 -0.24 -0.19 Schizophrenia; chr2:73691185 chr2:73750256~73750786:- LIHC cis rs4239252 0.929 rs4251787 ENSG00000267554.1 RP11-686D22.10 3.65 0.000299 0.0446 0.19 0.19 Blood protein levels; chr17:35845577 chr17:35470069~35470628:- LIHC cis rs9595908 0.669 rs4057298 ENSG00000212293.1 SNORA16 3.65 0.000299 0.0446 0.23 0.19 Body mass index; chr13:32734227 chr13:32420390~32420516:- LIHC cis rs9595908 0.669 rs17516382 ENSG00000212293.1 SNORA16 3.65 0.000299 0.0446 0.23 0.19 Body mass index; chr13:32735426 chr13:32420390~32420516:- LIHC cis rs6142102 0.961 rs4911401 ENSG00000275784.1 RP5-1125A11.6 -3.65 3e-04 0.0446 -0.22 -0.19 Skin pigmentation; chr20:34066756 chr20:33989480~33991818:- LIHC cis rs10833905 0.938 rs12285669 ENSG00000246225.5 RP11-17A1.3 -3.65 3e-04 0.0446 -0.24 -0.19 Sudden cardiac arrest; chr11:23041871 chr11:22829380~22945393:+ LIHC cis rs950169 1 rs950169 ENSG00000225151.9 GOLGA2P7 -3.65 3e-04 0.0446 -0.27 -0.19 Schizophrenia; chr15:84037709 chr15:84199311~84230136:- LIHC cis rs10875746 0.669 rs10875770 ENSG00000276814.1 RP1-228P16.8 3.65 3e-04 0.0446 0.23 0.19 Longevity (90 years and older); chr12:48206737 chr12:48039784~48040761:- LIHC cis rs11159086 0.793 rs12432412 ENSG00000270000.1 RP3-449M8.9 3.65 3e-04 0.0446 0.28 0.19 Advanced glycation end-product levels; chr14:74474294 chr14:74471930~74472360:- LIHC cis rs11159086 0.793 rs1029700 ENSG00000270000.1 RP3-449M8.9 3.65 3e-04 0.0446 0.28 0.19 Advanced glycation end-product levels; chr14:74474309 chr14:74471930~74472360:- LIHC cis rs11159086 0.793 rs1029699 ENSG00000270000.1 RP3-449M8.9 3.65 3e-04 0.0446 0.28 0.19 Advanced glycation end-product levels; chr14:74474790 chr14:74471930~74472360:- LIHC cis rs193541 0.632 rs168913 ENSG00000263432.2 RN7SL689P 3.65 3e-04 0.0446 0.31 0.19 Glucose homeostasis traits; chr5:122890098 chr5:123022487~123022783:- LIHC cis rs2562456 0.917 rs2650804 ENSG00000268555.1 RP11-678G14.3 3.65 3e-04 0.0446 0.24 0.19 Pain; chr19:21497382 chr19:21570822~21587322:- LIHC cis rs1023500 0.551 rs2859438 ENSG00000226450.2 CYP2D8P 3.65 3e-04 0.0446 0.24 0.19 Schizophrenia; chr22:42070976 chr22:42149886~42155001:- LIHC cis rs365302 0.556 rs499865 ENSG00000216480.2 RP3-393E18.1 -3.65 3e-04 0.0446 -0.24 -0.19 Coronary heart disease; chr6:159217246 chr6:159526062~159526527:- LIHC cis rs17818399 0.612 rs4952834 ENSG00000236824.1 BCYRN1 -3.65 3e-04 0.0446 -0.23 -0.19 Height; chr2:46550323 chr2:47331060~47344517:+ LIHC cis rs7523455 0.929 rs16862451 ENSG00000270728.1 RP4-657E11.10 3.65 3e-04 0.0447 0.24 0.19 Methotrexate phramacokinetics (acute lymphoblastic leukemia); chr1:19006097 chr1:19297080~19297903:+ LIHC cis rs8028313 0.63 rs4776373 ENSG00000270964.1 RP11-502I4.3 -3.65 3e-04 0.0447 -0.21 -0.19 Obesity; chr15:67668185 chr15:67541072~67542604:- LIHC cis rs10129255 1 rs10134517 ENSG00000274576.2 IGHV2-70 3.65 3e-04 0.0447 0.16 0.19 Kawasaki disease; chr14:106718498 chr14:106770577~106771020:- LIHC cis rs1631486 0.739 rs1660241 ENSG00000267325.1 LINC01415 3.65 3e-04 0.0447 0.19 0.19 Obesity (early onset extreme); chr18:55368419 chr18:55776727~55781721:- LIHC cis rs2658782 0.547 rs3020054 ENSG00000279684.1 RP11-755E23.2 -3.65 3e-04 0.0447 -0.27 -0.19 Pulmonary function decline; chr11:93322390 chr11:93286629~93288903:- LIHC cis rs2998286 0.774 rs2790442 ENSG00000254635.4 WAC-AS1 -3.65 3e-04 0.0447 -0.27 -0.19 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28539597 chr10:28522652~28532743:- LIHC cis rs11096990 0.855 rs2566184 ENSG00000249685.1 RP11-360F5.3 -3.65 3e-04 0.0447 -0.27 -0.19 Cognitive function; chr4:39162700 chr4:39133913~39135608:+ LIHC cis rs763121 0.853 rs5757181 ENSG00000273076.1 RP3-508I15.22 3.65 3e-04 0.0447 0.23 0.19 Menopause (age at onset); chr22:38617517 chr22:38743495~38743910:+ LIHC cis rs7829975 0.606 rs6422352 ENSG00000254340.1 RP11-10A14.3 -3.65 3e-04 0.0447 -0.2 -0.19 Mood instability; chr8:8936683 chr8:9141424~9145435:+ LIHC cis rs950881 0.932 rs10189154 ENSG00000234389.1 AC007278.3 3.65 3e-04 0.0447 0.26 0.19 Allergy; chr2:102321084 chr2:102438713~102440475:+ LIHC cis rs950881 0.932 rs10189526 ENSG00000234389.1 AC007278.3 3.65 3e-04 0.0447 0.26 0.19 Allergy; chr2:102321423 chr2:102438713~102440475:+ LIHC cis rs10865050 1 rs10865050 ENSG00000234389.1 AC007278.3 3.65 3e-04 0.0447 0.26 0.19 Allergic disease (asthma, hay fever or eczema); chr2:102324851 chr2:102438713~102440475:+ LIHC cis rs2564921 0.73 rs12633064 ENSG00000242142.1 SERBP1P3 -3.65 3e-04 0.0447 -0.27 -0.19 Height; chr3:53027361 chr3:53064283~53065091:- LIHC cis rs7193541 0.965 rs8050262 ENSG00000261079.1 RP11-252A24.3 3.65 3e-04 0.0447 0.21 0.19 Multiple myeloma; chr16:74627261 chr16:74367462~74369826:+ LIHC cis rs6832769 0.961 rs28445925 ENSG00000272969.1 RP11-528I4.2 -3.65 3e-04 0.0447 -0.23 -0.19 Personality dimensions; chr4:55569682 chr4:55547112~55547889:+ LIHC cis rs7503807 1 rs12939613 ENSG00000262772.1 RP11-353N14.2 3.65 3e-04 0.0447 0.2 0.19 Obesity; chr17:80614402 chr17:79823452~79827704:+ LIHC cis rs950881 0.932 rs3771180 ENSG00000234389.1 AC007278.3 3.65 3e-04 0.0447 0.26 0.19 Allergy; chr2:102337157 chr2:102438713~102440475:+ LIHC cis rs950881 0.932 rs72823646 ENSG00000234389.1 AC007278.3 3.65 3e-04 0.0447 0.26 0.19 Allergy; chr2:102337753 chr2:102438713~102440475:+ LIHC cis rs950881 0.932 rs13431828 ENSG00000234389.1 AC007278.3 3.65 3e-04 0.0447 0.26 0.19 Allergy; chr2:102338193 chr2:102438713~102440475:+ LIHC cis rs950881 0.932 rs13408569 ENSG00000234389.1 AC007278.3 3.65 3e-04 0.0447 0.26 0.19 Allergy; chr2:102338596 chr2:102438713~102440475:+ LIHC cis rs950881 0.932 rs13408661 ENSG00000234389.1 AC007278.3 3.65 3e-04 0.0447 0.26 0.19 Allergy; chr2:102338622 chr2:102438713~102440475:+ LIHC cis rs950881 0.932 rs10173081 ENSG00000234389.1 AC007278.3 3.65 3e-04 0.0447 0.26 0.19 Allergy; chr2:102340888 chr2:102438713~102440475:+ LIHC cis rs7665090 1 rs7677509 ENSG00000230069.3 LRRC37A15P -3.65 3e-04 0.0447 -0.18 -0.19 Primary biliary cholangitis; chr4:102628849 chr4:102727274~102730721:- LIHC cis rs7665090 0.967 rs7699231 ENSG00000230069.3 LRRC37A15P -3.65 3e-04 0.0447 -0.18 -0.19 Primary biliary cholangitis; chr4:102628918 chr4:102727274~102730721:- LIHC cis rs7665090 1 rs7699678 ENSG00000230069.3 LRRC37A15P -3.65 3e-04 0.0447 -0.18 -0.19 Primary biliary cholangitis; chr4:102628939 chr4:102727274~102730721:- LIHC cis rs7665090 1 rs11724614 ENSG00000230069.3 LRRC37A15P -3.65 3e-04 0.0447 -0.18 -0.19 Primary biliary cholangitis; chr4:102629091 chr4:102727274~102730721:- LIHC cis rs7586604 0.608 rs4851231 ENSG00000230393.1 AC092667.2 3.65 0.000301 0.0447 0.25 0.19 Cannabis dependence symptom count; chr2:99769209 chr2:100104919~100107504:+ LIHC cis rs1023500 1 rs3752591 ENSG00000227370.1 RP4-669P10.19 3.65 0.000301 0.0447 0.26 0.19 Schizophrenia; chr22:41943512 chr22:42132543~42132998:+ LIHC cis rs2243480 1 rs781150 ENSG00000229886.1 RP5-1132H15.3 3.65 0.000301 0.0448 0.29 0.19 Diabetic kidney disease; chr7:66015986 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs313798 ENSG00000229886.1 RP5-1132H15.3 3.65 0.000301 0.0448 0.29 0.19 Diabetic kidney disease; chr7:66028044 chr7:66025126~66031544:- LIHC cis rs2243480 1 rs35396113 ENSG00000229886.1 RP5-1132H15.3 3.65 0.000301 0.0448 0.29 0.19 Diabetic kidney disease; chr7:66030474 chr7:66025126~66031544:- LIHC cis rs57221529 0.664 rs72704802 ENSG00000271781.1 CTD-2589H19.6 -3.65 0.000301 0.0448 -0.31 -0.19 Lung disease severity in cystic fibrosis; chr5:554096 chr5:675826~676616:+ LIHC cis rs11098499 0.865 rs10213221 ENSG00000250412.1 KLHL2P1 3.65 0.000301 0.0448 0.21 0.19 Corneal astigmatism; chr4:119334771 chr4:119334329~119378233:+ LIHC cis rs643506 0.874 rs582465 ENSG00000230911.1 PPIHP1 -3.65 0.000301 0.0448 -0.26 -0.19 Breast cancer; chr11:111797861 chr11:112029858~112030367:- LIHC cis rs643506 0.874 rs613292 ENSG00000230911.1 PPIHP1 -3.65 0.000301 0.0448 -0.26 -0.19 Breast cancer; chr11:111798081 chr11:112029858~112030367:- LIHC cis rs2980439 0.525 rs2980508 ENSG00000253426.4 RP11-10A14.4 3.65 0.000301 0.0448 0.26 0.19 Neuroticism; chr8:8314210 chr8:9151742~9168136:+ LIHC cis rs6449502 0.841 rs1609041 ENSG00000272308.1 RP11-231G3.1 3.65 0.000301 0.0448 0.28 0.19 Mean platelet volume; chr5:60966062 chr5:60866457~60866935:- LIHC cis rs797680 0.93 rs2295423 ENSG00000229567.1 RP4-717I23.2 -3.65 0.000301 0.0448 -0.24 -0.19 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93115467 chr1:93278961~93279129:- LIHC cis rs12370990 0.546 rs11183343 ENSG00000257261.4 RP11-96H19.1 -3.65 0.000301 0.0448 -0.31 -0.19 Post bronchodilator FEV1 in COPD; chr12:46104204 chr12:46383679~46876159:+ LIHC cis rs4945082 0.502 rs7119444 ENSG00000254810.1 RP11-672A2.4 3.65 0.000301 0.0448 0.28 0.19 Response to paliperidone in schizophrenia (PANSS score); chr11:76413389 chr11:76654169~76656712:- LIHC cis rs3091242 0.933 rs10903129 ENSG00000261349.1 RP3-465N24.5 -3.65 0.000301 0.0448 -0.19 -0.19 Erythrocyte sedimentation rate; chr1:25442446 chr1:25266102~25267136:- LIHC cis rs9565309 0.579 rs9635011 ENSG00000274898.1 AC001226.7 -3.65 0.000301 0.0448 -0.34 -0.19 Morning vs. evening chronotype; chr13:77022894 chr13:77027944~77028482:+ LIHC cis rs9565309 0.579 rs75413861 ENSG00000274898.1 AC001226.7 -3.65 0.000301 0.0448 -0.34 -0.19 Morning vs. evening chronotype; chr13:77022945 chr13:77027944~77028482:+ LIHC cis rs9565309 0.579 rs9573984 ENSG00000274898.1 AC001226.7 -3.65 0.000301 0.0448 -0.34 -0.19 Morning vs. evening chronotype; chr13:77024117 chr13:77027944~77028482:+ LIHC cis rs6456156 0.586 rs1407315 ENSG00000227598.1 RP1-167A14.2 -3.65 0.000301 0.0448 -0.2 -0.19 Primary biliary cholangitis; chr6:167055171 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs911632 ENSG00000227598.1 RP1-167A14.2 -3.65 0.000301 0.0448 -0.2 -0.19 Primary biliary cholangitis; chr6:167057973 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs2017338 ENSG00000227598.1 RP1-167A14.2 -3.65 0.000301 0.0448 -0.2 -0.19 Primary biliary cholangitis; chr6:167058226 chr6:166969626~166999065:- LIHC cis rs9457247 0.51 rs6456151 ENSG00000227598.1 RP1-167A14.2 -3.65 0.000301 0.0448 -0.2 -0.19 Crohn's disease; chr6:167058363 chr6:166969626~166999065:- LIHC cis rs6456156 0.565 rs6456153 ENSG00000227598.1 RP1-167A14.2 -3.65 0.000301 0.0448 -0.2 -0.19 Primary biliary cholangitis; chr6:167058679 chr6:166969626~166999065:- LIHC cis rs6456156 0.586 rs6456154 ENSG00000227598.1 RP1-167A14.2 -3.65 0.000301 0.0448 -0.2 -0.19 Primary biliary cholangitis; chr6:167058768 chr6:166969626~166999065:- LIHC cis rs17818399 0.926 rs13032670 ENSG00000239332.4 LINC01119 -3.65 0.000301 0.0448 -0.27 -0.19 Height; chr2:46603655 chr2:46816697~46859007:+ LIHC cis rs3758785 0.665 rs7933565 ENSG00000255893.1 RP11-685N10.1 3.65 0.000302 0.0448 0.2 0.19 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94378642 chr11:94472908~94473570:- LIHC cis rs2243480 1 rs1499614 ENSG00000232559.3 GS1-124K5.12 3.65 0.000302 0.0448 0.21 0.19 Diabetic kidney disease; chr7:66265811 chr7:66554588~66576923:- LIHC cis rs1987511 1 rs7071555 ENSG00000231039.2 RP11-445P17.3 -3.65 0.000302 0.0449 -0.24 -0.19 Intelligence; chr10:5303015 chr10:5234358~5263408:+ LIHC cis rs6025590 1 rs6025590 ENSG00000124097.7 HMGB1P1 -3.65 0.000302 0.0449 -0.26 -0.19 Obesity-related traits; chr20:57495449 chr20:57488392~57489027:- LIHC cis rs6840360 1 rs1877187 ENSG00000251603.1 RP11-164P12.4 -3.65 0.000302 0.0449 -0.18 -0.19 Intelligence (multi-trait analysis); chr4:151684469 chr4:151667224~151670502:+ LIHC cis rs3934487 0.547 rs4294458 ENSG00000223956.1 RP4-710M16.2 -3.65 0.000302 0.0449 -0.21 -0.19 Reticulocyte count; chr1:55859787 chr1:56414963~56415966:+ LIHC cis rs77204473 0.744 rs12420361 ENSG00000254851.1 RP11-109L13.1 3.65 0.000302 0.0449 0.39 0.19 Sum eosinophil basophil counts;Eosinophil counts; chr11:117123072 chr11:117135528~117138582:+ LIHC cis rs2933343 0.679 rs789254 ENSG00000261159.1 RP11-723O4.9 3.65 0.000302 0.0449 0.25 0.19 IgG glycosylation; chr3:128855750 chr3:128859716~128860526:- LIHC cis rs933688 0.877 rs1477349 ENSG00000281357.1 ARRDC3-AS1 3.65 0.000302 0.0449 0.24 0.19 Smoking behavior; chr5:91411956 chr5:91380349~91439085:+ LIHC cis rs933688 0.938 rs1477348 ENSG00000281357.1 ARRDC3-AS1 3.65 0.000302 0.0449 0.24 0.19 Smoking behavior; chr5:91412006 chr5:91380349~91439085:+ LIHC cis rs933688 1 rs12654787 ENSG00000281357.1 ARRDC3-AS1 3.65 0.000302 0.0449 0.24 0.19 Smoking behavior; chr5:91417442 chr5:91380349~91439085:+ LIHC cis rs933688 0.938 rs10063683 ENSG00000281357.1 ARRDC3-AS1 3.65 0.000302 0.0449 0.24 0.19 Smoking behavior; chr5:91418778 chr5:91380349~91439085:+ LIHC cis rs933688 1 rs6867219 ENSG00000281357.1 ARRDC3-AS1 3.65 0.000302 0.0449 0.24 0.19 Smoking behavior; chr5:91422191 chr5:91380349~91439085:+ LIHC cis rs933688 0.938 rs7708782 ENSG00000281357.1 ARRDC3-AS1 3.65 0.000302 0.0449 0.24 0.19 Smoking behavior; chr5:91422700 chr5:91380349~91439085:+ LIHC cis rs2243480 1 rs59794892 ENSG00000226002.1 RP11-460N20.5 -3.65 0.000302 0.0449 -0.28 -0.19 Diabetic kidney disease; chr7:65950886 chr7:65084103~65100232:+ LIHC cis rs2243480 0.803 rs36004293 ENSG00000226002.1 RP11-460N20.5 -3.65 0.000302 0.0449 -0.28 -0.19 Diabetic kidney disease; chr7:65951525 chr7:65084103~65100232:+ LIHC cis rs2243480 0.803 rs35268390 ENSG00000226002.1 RP11-460N20.5 -3.65 0.000302 0.0449 -0.28 -0.19 Diabetic kidney disease; chr7:65951549 chr7:65084103~65100232:+ LIHC cis rs3096299 0.582 rs12935119 ENSG00000261118.1 RP11-104N10.1 3.65 0.000302 0.0449 0.19 0.19 Multiple myeloma (IgH translocation); chr16:89476466 chr16:89492017~89504460:- LIHC cis rs3749237 0.595 rs35701831 ENSG00000270441.1 RP11-694I15.7 -3.65 0.000302 0.0449 -0.27 -0.19 Resting heart rate; chr3:49477567 chr3:49140086~49160851:- LIHC cis rs13113518 1 rs9312661 ENSG00000223305.1 RN7SKP30 3.65 0.000302 0.0449 0.23 0.19 Height; chr4:55476159 chr4:55540502~55540835:- LIHC cis rs933688 1 rs4382199 ENSG00000281357.1 ARRDC3-AS1 3.65 0.000302 0.0449 0.24 0.19 Smoking behavior; chr5:91448411 chr5:91380349~91439085:+ LIHC cis rs2797160 1 rs6569435 ENSG00000237742.5 RP11-624M8.1 -3.65 0.000303 0.0449 -0.19 -0.19 Endometrial cancer; chr6:125677040 chr6:125578558~125749190:- LIHC cis rs13113518 0.812 rs12648271 ENSG00000223305.1 RN7SKP30 3.65 0.000303 0.0449 0.24 0.19 Height; chr4:55501955 chr4:55540502~55540835:- LIHC cis rs7722022 0.922 rs2080971 ENSG00000253428.1 CTB-43E15.2 3.65 0.000303 0.045 0.21 0.19 Adiponectin levels; chr5:173512410 chr5:173689459~173705849:+ LIHC cis rs7829975 0.567 rs6601273 ENSG00000254340.1 RP11-10A14.3 -3.65 0.000303 0.045 -0.2 -0.19 Mood instability; chr8:8939009 chr8:9141424~9145435:+ LIHC cis rs2346177 0.806 rs56048837 ENSG00000279254.1 RP11-536C12.1 -3.65 0.000303 0.045 -0.24 -0.19 HDL cholesterol; chr2:46429508 chr2:46668870~46670778:+ LIHC cis rs11098499 0.754 rs1814813 ENSG00000245958.5 RP11-33B1.1 3.65 0.000303 0.045 0.2 0.19 Corneal astigmatism; chr4:119337052 chr4:119454791~119552025:+ LIHC cis rs2919917 0.628 rs10113703 ENSG00000254352.1 RP11-578O24.2 3.65 0.000303 0.045 0.29 0.19 Lymphocyte counts; chr8:78688404 chr8:78723796~78724136:- LIHC cis rs1106684 1 rs35480282 ENSG00000233559.1 AC016831.7 3.65 0.000303 0.045 0.34 0.19 Body mass index; chr7:131778332 chr7:130853720~130928649:+ LIHC cis rs643506 0.79 rs688095 ENSG00000230911.1 PPIHP1 -3.65 0.000303 0.045 -0.26 -0.19 Breast cancer; chr11:111808047 chr11:112029858~112030367:- LIHC cis rs643506 0.817 rs658373 ENSG00000230911.1 PPIHP1 -3.65 0.000303 0.045 -0.26 -0.19 Breast cancer; chr11:111812267 chr11:112029858~112030367:- LIHC cis rs752590 0.72 rs2305132 ENSG00000189223.12 PAX8-AS1 -3.65 0.000303 0.045 -0.3 -0.19 Mucinous ovarian carcinoma; chr2:113199364 chr2:113211522~113276581:+ LIHC cis rs1417770 0.899 rs1149649 ENSG00000235612.1 RP1-158P9.1 -3.65 0.000303 0.045 -0.25 -0.19 Lobe attachment (rater-scored or self-reported); chr1:56191825 chr1:56145721~56155224:+ LIHC cis rs2032447 0.765 rs6942072 ENSG00000242387.1 HIST1H2APS2 3.65 0.000303 0.045 0.24 0.19 Intelligence (multi-trait analysis); chr6:26014759 chr6:25882026~25882395:- LIHC cis rs12468226 0.752 rs116078354 ENSG00000272966.1 RP11-686O6.1 3.65 0.000303 0.045 0.34 0.19 Urate levels; chr2:202136356 chr2:202336739~202337200:+ LIHC cis rs10883723 1 rs10883723 ENSG00000236937.2 PTGES3P4 -3.65 0.000303 0.045 -0.28 -0.19 Allergic disease (asthma, hay fever or eczema); chr10:102466075 chr10:102845595~102845950:+ LIHC cis rs10883723 0.962 rs11191294 ENSG00000236937.2 PTGES3P4 -3.65 0.000303 0.045 -0.28 -0.19 Allergic disease (asthma, hay fever or eczema); chr10:102466080 chr10:102845595~102845950:+ LIHC cis rs9291683 0.679 rs2241483 ENSG00000250413.1 RP11-448G15.1 3.65 0.000303 0.045 0.25 0.19 Bone mineral density; chr4:10098207 chr4:10006482~10009725:+ LIHC cis rs2179367 0.586 rs9498341 ENSG00000231760.4 RP11-350J20.5 3.65 0.000303 0.045 0.31 0.19 Dupuytren's disease; chr6:149379737 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs9498342 ENSG00000231760.4 RP11-350J20.5 3.65 0.000303 0.045 0.31 0.19 Dupuytren's disease; chr6:149379806 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs12191079 ENSG00000231760.4 RP11-350J20.5 3.65 0.000303 0.045 0.31 0.19 Dupuytren's disease; chr6:149380333 chr6:149796151~149826294:- LIHC cis rs2179367 0.632 rs12204461 ENSG00000231760.4 RP11-350J20.5 3.65 0.000303 0.045 0.31 0.19 Dupuytren's disease; chr6:149380399 chr6:149796151~149826294:- LIHC cis rs960902 0.935 rs2373109 ENSG00000213553.4 RPLP0P6 -3.65 0.000303 0.045 -0.15 -0.19 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37490653 chr2:38481851~38482804:+ LIHC cis rs2237457 0.965 rs3819432 ENSG00000228897.1 CTD-2021A8.2 -3.65 0.000303 0.045 -0.22 -0.19 Schizophrenia (treatment resistant); chr7:50663373 chr7:51386363~51387101:- LIHC cis rs9907295 0.591 rs78655848 ENSG00000267554.1 RP11-686D22.10 3.65 0.000303 0.045 0.19 0.19 Fibroblast growth factor basic levels; chr17:35856952 chr17:35470069~35470628:- LIHC cis rs6732160 0.845 rs6546809 ENSG00000272702.1 RP11-44N22.3 3.65 0.000303 0.0451 0.21 0.19 Intelligence (multi-trait analysis); chr2:73162553 chr2:73113018~73115907:+ LIHC cis rs17767392 0.813 rs66645707 ENSG00000274818.1 RP1-292L20.3 3.65 0.000303 0.0451 0.3 0.19 Mitral valve prolapse; chr14:71519214 chr14:70906657~70907111:- LIHC cis rs17767392 0.813 rs61989386 ENSG00000274818.1 RP1-292L20.3 3.65 0.000303 0.0451 0.3 0.19 Mitral valve prolapse; chr14:71519828 chr14:70906657~70907111:- LIHC cis rs875971 0.545 rs17138156 ENSG00000273024.4 INTS4P2 -3.65 0.000303 0.0451 -0.22 -0.19 Aortic root size; chr7:66249708 chr7:65647864~65715661:+ LIHC cis rs763512 0.532 rs3094499 ENSG00000276054.1 RP11-378E13.3 3.65 0.000303 0.0451 0.25 0.19 3-hydroxypropylmercapturic acid levels in smokers; chr17:37531234 chr17:37386886~37387926:+ LIHC cis rs1494950 0.661 rs55952030 ENSG00000214846.4 RP11-115L11.1 -3.65 0.000304 0.0451 -0.41 -0.19 Political ideology; chr4:14985686 chr4:15730962~15731627:- LIHC cis rs1494950 1 rs10212717 ENSG00000214846.4 RP11-115L11.1 -3.65 0.000304 0.0451 -0.41 -0.19 Political ideology; chr4:14988936 chr4:15730962~15731627:- LIHC cis rs7915414 0.543 rs12778966 ENSG00000230338.1 MTND4P19 3.65 0.000304 0.0451 0.23 0.19 Clopidogrel active metabolite levels; chr10:94889643 chr10:94774156~94774633:- LIHC cis rs494562 1 rs1744122 ENSG00000234155.1 RP11-30P6.6 -3.65 0.000304 0.0451 -0.41 -0.19 Metabolic traits;Blood metabolite levels; chr6:85405500 chr6:85387219~85390186:- LIHC cis rs494562 0.542 rs554113 ENSG00000234155.1 RP11-30P6.6 -3.65 0.000304 0.0451 -0.41 -0.19 Metabolic traits;Blood metabolite levels; chr6:85405526 chr6:85387219~85390186:- LIHC cis rs494562 0.892 rs637346 ENSG00000234155.1 RP11-30P6.6 -3.65 0.000304 0.0451 -0.41 -0.19 Metabolic traits;Blood metabolite levels; chr6:85405564 chr6:85387219~85390186:- LIHC cis rs10946940 0.632 rs9366698 ENSG00000216901.1 AL022393.7 3.65 0.000304 0.0451 0.25 0.19 Systemic lupus erythematosus; chr6:27704256 chr6:28176188~28176674:+ LIHC cis rs17818399 0.612 rs4952834 ENSG00000279254.1 RP11-536C12.1 -3.65 0.000304 0.0451 -0.24 -0.19 Height; chr2:46550323 chr2:46668870~46670778:+ LIHC cis rs1635 0.655 rs9380024 ENSG00000216901.1 AL022393.7 3.65 0.000304 0.0451 0.35 0.19 Schizophrenia; chr6:27862576 chr6:28176188~28176674:+ LIHC cis rs295490 1 rs295490 ENSG00000272656.1 RP11-219D15.3 -3.65 0.000304 0.0451 -0.4 -0.19 PR interval in Tripanosoma cruzi seropositivity; chr3:139522529 chr3:139349024~139349371:- LIHC cis rs683257 1 rs683257 ENSG00000234147.1 RP3-460G2.2 3.65 0.000304 0.0451 0.35 0.19 Facial emotion recognition (angry faces); chr6:140771057 chr6:140845958~140852924:- LIHC cis rs1023500 1 rs6002554 ENSG00000227370.1 RP4-669P10.19 3.65 0.000304 0.0451 0.26 0.19 Schizophrenia; chr22:41943091 chr22:42132543~42132998:+ LIHC cis rs2243480 0.803 rs13224048 ENSG00000228409.4 CCT6P1 3.65 0.000304 0.0451 0.21 0.19 Diabetic kidney disease; chr7:66528779 chr7:65751142~65763354:+ LIHC cis rs55966801 0.624 rs741736 ENSG00000279672.1 CMB9-55F22.1 3.65 0.000304 0.0451 0.32 0.19 Plateletcrit; chr11:256978 chr11:779617~780755:+ LIHC cis rs8077577 0.747 rs3829956 ENSG00000260647.1 RP1-178F10.1 3.65 0.000304 0.0451 0.24 0.19 Obesity-related traits; chr17:18316521 chr17:18268080~18268828:+ LIHC cis rs919433 0.926 rs787996 ENSG00000231621.1 AC013264.2 -3.65 0.000304 0.0451 -0.18 -0.19 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197352081 chr2:197197991~197199273:+ LIHC cis rs4921799 0.662 rs11203898 ENSG00000249258.2 RP11-468H14.2 -3.65 0.000304 0.0451 -0.24 -0.19 Lung cancer;Adenocarcinoma; chr8:17679823 chr8:17131181~17149789:+ LIHC cis rs4921799 0.662 rs11987569 ENSG00000249258.2 RP11-468H14.2 -3.65 0.000304 0.0451 -0.24 -0.19 Lung cancer;Adenocarcinoma; chr8:17680140 chr8:17131181~17149789:+ LIHC cis rs151234 0.8 rs231972 ENSG00000259982.1 CDC37P1 -3.65 0.000304 0.0452 -0.46 -0.19 Platelet distribution width; chr16:28527015 chr16:28700294~28701540:- LIHC cis rs2253762 0.54 rs12249581 ENSG00000276742.1 RP11-500G22.4 3.65 0.000304 0.0452 0.31 0.19 Breast cancer; chr10:122013486 chr10:121956782~121957098:+ LIHC cis rs2253762 0.54 rs79586669 ENSG00000276742.1 RP11-500G22.4 3.65 0.000304 0.0452 0.31 0.19 Breast cancer; chr10:122015153 chr10:121956782~121957098:+ LIHC cis rs2441986 0.577 rs2867404 ENSG00000245571.5 AP001258.4 3.65 0.000304 0.0452 0.19 0.19 Systolic blood pressure; chr11:58189550 chr11:59130133~59143015:- LIHC cis rs5743030 0.702 rs256554 ENSG00000253559.1 OSGEPL1-AS1 -3.65 0.000304 0.0452 -0.28 -0.19 Subcutaneous adipose tissue; chr2:189874288 chr2:189762704~189765556:+ LIHC cis rs3738443 0.951 rs55914345 ENSG00000259865.1 RP11-488L18.10 3.65 0.000304 0.0452 0.21 0.19 Alcohol dependence; chr1:247216105 chr1:247187281~247188526:- LIHC cis rs643506 0.874 rs673679 ENSG00000230911.1 PPIHP1 -3.65 0.000304 0.0452 -0.26 -0.19 Breast cancer; chr11:111816076 chr11:112029858~112030367:- LIHC cis rs12639258 0.961 rs6441998 ENSG00000273682.1 RP11-427P5.3 -3.65 0.000305 0.0452 -0.33 -0.19 Eotaxin levels; chr3:46468443 chr3:46918807~46918935:- LIHC cis rs751728 0.664 rs2395402 ENSG00000204188.6 GGNBP1 3.65 0.000305 0.0452 0.24 0.19 Crohn's disease; chr6:33785896 chr6:33540046~33589026:+ LIHC cis rs13434995 0.513 rs6554282 ENSG00000273257.1 RP11-177J6.1 3.65 0.000305 0.0452 0.31 0.19 Adiponectin levels; chr4:55519812 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs6554283 ENSG00000273257.1 RP11-177J6.1 3.65 0.000305 0.0452 0.31 0.19 Adiponectin levels; chr4:55521053 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs1546004 ENSG00000273257.1 RP11-177J6.1 3.65 0.000305 0.0452 0.31 0.19 Adiponectin levels; chr4:55521612 chr4:55387949~55388271:+ LIHC cis rs13434995 0.513 rs4865006 ENSG00000273257.1 RP11-177J6.1 3.65 0.000305 0.0452 0.31 0.19 Adiponectin levels; chr4:55526112 chr4:55387949~55388271:+ LIHC cis rs10246939 0.579 rs9640205 ENSG00000228775.6 WEE2-AS1 3.65 0.000305 0.0452 0.22 0.19 Bitter taste perception; chr7:141844400 chr7:141704338~141738346:- LIHC cis rs10875746 0.669 rs10467101 ENSG00000276814.1 RP1-228P16.8 3.65 0.000305 0.0452 0.24 0.19 Longevity (90 years and older); chr12:48213954 chr12:48039784~48040761:- LIHC cis rs2243480 1 rs2533288 ENSG00000228409.4 CCT6P1 3.65 0.000305 0.0452 0.21 0.19 Diabetic kidney disease; chr7:66591724 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs2707844 ENSG00000228409.4 CCT6P1 3.65 0.000305 0.0452 0.21 0.19 Diabetic kidney disease; chr7:66594522 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs1796220 ENSG00000228409.4 CCT6P1 3.65 0.000305 0.0452 0.21 0.19 Diabetic kidney disease; chr7:66597113 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs2707831 ENSG00000228409.4 CCT6P1 3.65 0.000305 0.0452 0.21 0.19 Diabetic kidney disease; chr7:66597524 chr7:65751142~65763354:+ LIHC cis rs1106684 1 rs11764235 ENSG00000233559.1 AC016831.7 3.65 0.000305 0.0452 0.34 0.19 Body mass index; chr7:131778121 chr7:130853720~130928649:+ LIHC cis rs848490 0.674 rs4727461 ENSG00000214293.7 APTR 3.65 0.000305 0.0452 0.23 0.19 Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine); chr7:77691071 chr7:77657660~77696265:- LIHC cis rs2749592 0.725 rs9417245 ENSG00000263064.2 RP11-291L22.7 -3.65 0.000305 0.0452 -0.21 -0.19 Age-related hearing impairment (SNP x SNP interaction); chr10:37537394 chr10:38448689~38448949:+ LIHC cis rs9646944 0.636 rs72998585 ENSG00000234389.1 AC007278.3 3.65 0.000305 0.0452 0.25 0.19 Blood protein levels; chr2:102242030 chr2:102438713~102440475:+ LIHC cis rs600231 0.623 rs587080 ENSG00000245532.5 NEAT1 3.65 0.000305 0.0453 0.19 0.19 Bone mineral density; chr11:65486329 chr11:65422774~65445540:+ LIHC cis rs453301 0.653 rs1562211 ENSG00000253893.2 FAM85B 3.65 0.000305 0.0453 0.22 0.19 Joint mobility (Beighton score); chr8:9044914 chr8:8167819~8226614:- LIHC cis rs2243480 1 rs4718317 ENSG00000229886.1 RP5-1132H15.3 -3.65 0.000305 0.0453 -0.27 -0.19 Diabetic kidney disease; chr7:66183914 chr7:66025126~66031544:- LIHC cis rs6442522 0.64 rs28632773 ENSG00000249786.6 EAF1-AS1 3.65 0.000305 0.0453 0.23 0.19 Uric acid levels; chr3:15474411 chr3:15436171~15455940:- LIHC cis rs11671005 0.532 rs35983901 ENSG00000269473.1 CTD-2619J13.19 3.65 0.000305 0.0453 0.34 0.19 Mean platelet volume; chr19:58505423 chr19:58440448~58445849:+ LIHC cis rs7129556 0.737 rs2154972 ENSG00000254459.1 RP11-91P24.7 3.65 0.000305 0.0453 0.32 0.19 Weight loss (gastric bypass surgery); chr11:77777779 chr11:77829654~77872262:- LIHC cis rs7129556 0.775 rs623907 ENSG00000254459.1 RP11-91P24.7 3.65 0.000305 0.0453 0.32 0.19 Weight loss (gastric bypass surgery); chr11:77790402 chr11:77829654~77872262:- LIHC cis rs395892 0.793 rs4803286 ENSG00000267892.1 CTD-2540F13.2 3.65 0.000305 0.0453 0.27 0.19 Eosinophil counts;Eosinophil percentage of white cells; chr19:39686196 chr19:38738284~38739863:+ LIHC cis rs2333021 1 rs2333021 ENSG00000259015.1 RP11-109N23.6 3.65 0.000305 0.0453 0.23 0.19 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:73017676 chr14:72960595~72961993:+ LIHC cis rs62025270 0.632 rs62022924 ENSG00000259295.5 CSPG4P12 -3.65 0.000305 0.0453 -0.34 -0.19 Idiopathic pulmonary fibrosis; chr15:85692276 chr15:85191438~85213905:+ LIHC cis rs240993 0.812 rs2025269 ENSG00000271789.1 RP5-1112D6.7 -3.65 0.000305 0.0453 -0.22 -0.19 Inflammatory skin disease;Psoriasis; chr6:111489237 chr6:111297126~111298510:+ LIHC cis rs6599077 0.642 rs2257066 ENSG00000223797.4 ENTPD3-AS1 3.65 0.000306 0.0453 0.15 0.19 Sleep-related phenotypes; chr3:40046490 chr3:40313802~40453329:- LIHC cis rs2243480 1 rs1723267 ENSG00000229886.1 RP5-1132H15.3 3.65 0.000306 0.0453 0.28 0.19 Diabetic kidney disease; chr7:66008327 chr7:66025126~66031544:- LIHC cis rs9649213 0.574 rs7794187 ENSG00000272950.1 RP11-307C18.1 3.65 0.000306 0.0453 0.24 0.19 Prostate cancer (SNP x SNP interaction); chr7:98260446 chr7:98322853~98323430:+ LIHC cis rs8060686 0.516 rs8059575 ENSG00000261469.1 RP11-96D1.6 -3.65 0.000306 0.0453 -0.23 -0.19 HDL cholesterol;Metabolic syndrome; chr16:68238732 chr16:68236845~68237667:- LIHC cis rs8060686 0.516 rs7187202 ENSG00000261469.1 RP11-96D1.6 -3.65 0.000306 0.0453 -0.23 -0.19 HDL cholesterol;Metabolic syndrome; chr16:68239992 chr16:68236845~68237667:- LIHC cis rs8060686 0.516 rs7189794 ENSG00000261469.1 RP11-96D1.6 -3.65 0.000306 0.0453 -0.23 -0.19 HDL cholesterol;Metabolic syndrome; chr16:68243824 chr16:68236845~68237667:- LIHC cis rs7915414 0.543 rs2860903 ENSG00000230338.1 MTND4P19 -3.65 0.000306 0.0453 -0.21 -0.19 Clopidogrel active metabolite levels; chr10:94906328 chr10:94774156~94774633:- LIHC cis rs41369048 0.858 rs2784273 ENSG00000272823.1 RP11-295M18.6 -3.65 0.000306 0.0453 -0.35 -0.19 Eosinophil counts;Sum eosinophil basophil counts; chr1:220907744 chr1:220828676~220829211:- LIHC cis rs919433 0.963 rs12693815 ENSG00000231621.1 AC013264.2 3.65 0.000306 0.0454 0.18 0.19 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197303679 chr2:197197991~197199273:+ LIHC cis rs638893 0.528 rs521910 ENSG00000278376.1 RP11-158I9.8 3.65 0.000306 0.0454 0.32 0.19 Vitiligo; chr11:118739920 chr11:118791254~118793137:+ LIHC cis rs10471753 0.935 rs1363856 ENSG00000248359.1 CTC-537E7.2 -3.65 0.000306 0.0454 -0.24 -0.19 Hip minimal joint space width; chr5:68533671 chr5:68531690~68533530:- LIHC cis rs1987511 1 rs4448600 ENSG00000231039.2 RP11-445P17.3 -3.65 0.000306 0.0454 -0.24 -0.19 Intelligence; chr10:5303605 chr10:5234358~5263408:+ LIHC cis rs13113518 0.812 rs11932712 ENSG00000223305.1 RN7SKP30 3.65 0.000306 0.0454 0.23 0.19 Height; chr4:55436423 chr4:55540502~55540835:- LIHC cis rs13113518 0.812 rs12501746 ENSG00000223305.1 RN7SKP30 3.65 0.000306 0.0454 0.23 0.19 Height; chr4:55437438 chr4:55540502~55540835:- LIHC cis rs2243480 1 rs10807702 ENSG00000228409.4 CCT6P1 3.65 0.000306 0.0454 0.21 0.19 Diabetic kidney disease; chr7:66302856 chr7:65751142~65763354:+ LIHC cis rs886774 1 rs6949033 ENSG00000273055.1 CTB-13F3.1 3.65 0.000306 0.0454 0.21 0.19 Ulcerative colitis; chr7:107854772 chr7:107942116~107942740:+ LIHC cis rs75422866 0.867 rs7304743 ENSG00000276390.1 RP1-197B17.5 3.65 0.000306 0.0454 0.43 0.19 Pneumonia; chr12:47683658 chr12:47699401~47699917:- LIHC cis rs12468226 0.938 rs77062060 ENSG00000272966.1 RP11-686O6.1 3.65 0.000306 0.0454 0.32 0.19 Urate levels; chr2:202285639 chr2:202336739~202337200:+ LIHC cis rs9611519 0.78 rs2235852 ENSG00000231907.2 GAPDHP37 3.65 0.000306 0.0454 0.23 0.19 Neuroticism; chr22:41265150 chr22:40673484~40674451:- LIHC cis rs17818399 0.781 rs4952837 ENSG00000239332.4 LINC01119 -3.65 0.000306 0.0454 -0.27 -0.19 Height; chr2:46638595 chr2:46816697~46859007:+ LIHC cis rs17818399 0.781 rs6746598 ENSG00000239332.4 LINC01119 -3.65 0.000306 0.0454 -0.27 -0.19 Height; chr2:46638634 chr2:46816697~46859007:+ LIHC cis rs2613514 0.73 rs74255301 ENSG00000204277.1 RP11-219G17.4 3.65 0.000306 0.0454 0.28 0.19 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78053978 chr17:78261349~78278492:- LIHC cis rs4792901 0.765 rs9892162 ENSG00000267747.1 RP11-392O1.4 -3.65 0.000306 0.0454 -0.23 -0.19 Dupuytren's disease; chr17:43523432 chr17:43544785~43610338:+ LIHC cis rs4792901 0.694 rs9907819 ENSG00000267747.1 RP11-392O1.4 -3.65 0.000306 0.0454 -0.23 -0.19 Dupuytren's disease; chr17:43525497 chr17:43544785~43610338:+ LIHC cis rs4792901 0.802 rs9908559 ENSG00000267747.1 RP11-392O1.4 -3.65 0.000306 0.0454 -0.23 -0.19 Dupuytren's disease; chr17:43525793 chr17:43544785~43610338:+ LIHC cis rs11098499 0.615 rs59867181 ENSG00000245958.5 RP11-33B1.1 3.65 0.000306 0.0454 0.19 0.19 Corneal astigmatism; chr4:119635312 chr4:119454791~119552025:+ LIHC cis rs8077577 0.747 rs57490980 ENSG00000260647.1 RP1-178F10.1 3.65 0.000307 0.0454 0.24 0.19 Obesity-related traits; chr17:18257439 chr17:18268080~18268828:+ LIHC cis rs13178541 0.574 rs11958557 ENSG00000247627.2 MTND4P12 -3.65 0.000307 0.0454 -0.25 -0.19 IgG glycosylation; chr5:135794527 chr5:134926660~134928036:- LIHC cis rs6048205 0.881 rs6048184 ENSG00000259974.2 LINC00261 -3.65 0.000307 0.0454 -0.32 -0.19 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22557227 chr20:22547671~22578642:- LIHC cis rs703842 1 rs10877019 ENSG00000270039.1 RP11-571M6.17 3.65 0.000307 0.0454 0.27 0.19 Multiple sclerosis; chr12:57779146 chr12:57803838~57804415:+ LIHC cis rs13113518 0.729 rs13120134 ENSG00000223305.1 RN7SKP30 3.65 0.000307 0.0454 0.23 0.19 Height; chr4:55415153 chr4:55540502~55540835:- LIHC cis rs1494950 1 rs79999663 ENSG00000214846.4 RP11-115L11.1 -3.65 0.000307 0.0455 -0.4 -0.19 Political ideology; chr4:14972999 chr4:15730962~15731627:- LIHC cis rs2243480 1 rs316329 ENSG00000229886.1 RP5-1132H15.3 3.65 0.000307 0.0455 0.29 0.19 Diabetic kidney disease; chr7:66143429 chr7:66025126~66031544:- LIHC cis rs7824557 0.564 rs13260727 ENSG00000255495.1 AC145124.2 3.65 0.000307 0.0455 0.25 0.19 Retinal vascular caliber; chr8:11375351 chr8:12194467~12196280:+ LIHC cis rs7722022 0.961 rs2879652 ENSG00000253428.1 CTB-43E15.2 3.65 0.000307 0.0455 0.2 0.19 Adiponectin levels; chr5:173528333 chr5:173689459~173705849:+ LIHC cis rs61160187 0.582 rs12655209 ENSG00000272308.1 RP11-231G3.1 3.65 0.000307 0.0455 0.2 0.19 Educational attainment (years of education);Educational attainment (college completion); chr5:61010225 chr5:60866457~60866935:- LIHC cis rs17264034 0.861 rs1651285 ENSG00000250786.1 SNHG18 3.65 0.000307 0.0455 0.26 0.19 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9547829 chr5:9546200~9550609:+ LIHC cis rs17264034 0.808 rs1706987 ENSG00000250786.1 SNHG18 3.65 0.000307 0.0455 0.26 0.19 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9547853 chr5:9546200~9550609:+ LIHC cis rs17264034 0.861 rs1398337 ENSG00000250786.1 SNHG18 3.65 0.000307 0.0455 0.26 0.19 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9547986 chr5:9546200~9550609:+ LIHC cis rs7702057 0.53 rs56953556 ENSG00000272265.1 CTD-2287O16.4 3.65 0.000307 0.0455 0.31 0.19 Amyotrophic lateral sclerosis; chr5:116076903 chr5:116078110~116078570:- LIHC cis rs1405130 1 rs1405130 ENSG00000224287.2 MSL3P1 3.65 0.000307 0.0455 0.23 0.19 Coronary artery disease; chr2:234655048 chr2:233865437~233868444:- LIHC cis rs6545883 0.929 rs778154 ENSG00000271889.1 RP11-493E12.1 -3.65 0.000307 0.0455 -0.23 -0.19 Tuberculosis; chr2:61419496 chr2:61151433~61162105:- LIHC cis rs11720469 1 rs11720469 ENSG00000220343.5 RP11-440K22.1 -3.65 0.000307 0.0455 -0.22 -0.19 Fast beta electroencephalogram; chr3:166763420 chr3:167065831~167066320:+ LIHC cis rs2613514 1 rs3751962 ENSG00000204277.1 RP11-219G17.4 3.65 0.000307 0.0455 0.3 0.19 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78102638 chr17:78261349~78278492:- LIHC cis rs10510102 0.688 rs11812208 ENSG00000273891.1 RP11-500G22.5 3.65 0.000307 0.0455 0.25 0.19 Breast cancer; chr10:121924831 chr10:121965764~121967700:+ LIHC cis rs9906944 0.742 rs4073893 ENSG00000248278.1 SUMO2P17 -3.65 0.000307 0.0455 -0.32 -0.19 Intelligence (multi-trait analysis);Body fat percentage; chr17:49041161 chr17:48874860~48908983:- LIHC cis rs9906944 0.707 rs3816272 ENSG00000248278.1 SUMO2P17 -3.65 0.000307 0.0455 -0.32 -0.19 Intelligence (multi-trait analysis);Body fat percentage; chr17:49043105 chr17:48874860~48908983:- LIHC cis rs9906944 0.707 rs8068981 ENSG00000248278.1 SUMO2P17 -3.65 0.000307 0.0455 -0.32 -0.19 Intelligence (multi-trait analysis);Body fat percentage; chr17:49045163 chr17:48874860~48908983:- LIHC cis rs12681366 0.563 rs6999103 ENSG00000253704.1 RP11-267M23.4 3.65 0.000307 0.0455 0.23 0.19 Nonsyndromic cleft lip with cleft palate; chr8:94470309 chr8:94553722~94569745:+ LIHC cis rs6502050 0.736 rs11658040 ENSG00000279692.1 RP11-1055B8.1 -3.65 0.000307 0.0455 -0.29 -0.19 Life satisfaction; chr17:82102015 chr17:81395609~81397144:- LIHC cis rs12908161 0.96 rs11633450 ENSG00000275120.1 RP11-182J1.17 3.65 0.000307 0.0455 0.31 0.19 Schizophrenia; chr15:84764056 chr15:84599434~84606463:- LIHC cis rs2243480 1 rs4718269 ENSG00000226002.1 RP11-460N20.5 3.65 0.000307 0.0455 0.28 0.19 Diabetic kidney disease; chr7:65735810 chr7:65084103~65100232:+ LIHC cis rs3087243 0.56 rs231775 ENSG00000213925.3 NPM1P33 3.65 0.000307 0.0455 0.2 0.19 Rheumatoid arthritis;Type 1 diabetes;Hypothyroidism; chr2:203867991 chr2:203772631~203773502:- LIHC cis rs600231 0.708 rs1784860 ENSG00000245532.5 NEAT1 3.65 0.000307 0.0455 0.19 0.19 Bone mineral density; chr11:65473241 chr11:65422774~65445540:+ LIHC cis rs11096990 0.964 rs4974999 ENSG00000249685.1 RP11-360F5.3 3.65 0.000307 0.0455 0.26 0.19 Cognitive function; chr4:39262294 chr4:39133913~39135608:+ LIHC cis rs9640161 0.83 rs36069544 ENSG00000261305.1 RP4-584D14.7 3.65 0.000307 0.0455 0.24 0.19 Blood protein levels;Circulating chemerin levels; chr7:150364449 chr7:150341771~150342607:+ LIHC cis rs4671400 0.571 rs4672428 ENSG00000273302.1 RP11-493E12.2 -3.65 0.000307 0.0455 -0.22 -0.19 3-hydroxypropylmercapturic acid levels in smokers; chr2:61251362 chr2:61199979~61200769:+ LIHC cis rs2299116 0.962 rs4719953 ENSG00000225264.3 ZNRF2P2 -3.65 0.000307 0.0455 -0.2 -0.19 Serum thyroid-stimulating hormone levels; chr7:28774165 chr7:29598795~29685255:- LIHC cis rs62246343 0.719 rs1973243 ENSG00000254485.4 RP11-380O24.1 3.65 0.000307 0.0455 0.32 0.19 Fibrinogen levels; chr3:9450592 chr3:9292588~9363303:- LIHC cis rs4218 0.551 rs12906212 ENSG00000277144.1 RP11-59H7.4 -3.65 0.000307 0.0455 -0.22 -0.19 Social communication problems; chr15:59070556 chr15:59115547~59116089:- LIHC cis rs12681366 0.801 rs2011246 ENSG00000253704.1 RP11-267M23.4 3.65 0.000307 0.0455 0.23 0.19 Nonsyndromic cleft lip with cleft palate; chr8:94450846 chr8:94553722~94569745:+ LIHC cis rs2115630 0.645 rs4842978 ENSG00000259295.5 CSPG4P12 -3.65 0.000308 0.0456 -0.23 -0.19 P wave terminal force; chr15:84654022 chr15:85191438~85213905:+ LIHC cis rs9907295 0.901 rs11652536 ENSG00000270871.1 AC015849.19 3.65 0.000308 0.0456 0.21 0.19 Fibroblast growth factor basic levels; chr17:35891043 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs9789051 ENSG00000270871.1 AC015849.19 3.65 0.000308 0.0456 0.21 0.19 Fibroblast growth factor basic levels; chr17:35892000 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs3809769 ENSG00000270871.1 AC015849.19 3.65 0.000308 0.0456 0.21 0.19 Fibroblast growth factor basic levels; chr17:35892484 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs76016589 ENSG00000270871.1 AC015849.19 3.65 0.000308 0.0456 0.21 0.19 Fibroblast growth factor basic levels; chr17:35892923 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs4796124 ENSG00000270871.1 AC015849.19 3.65 0.000308 0.0456 0.21 0.19 Fibroblast growth factor basic levels; chr17:35893280 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs11656556 ENSG00000270871.1 AC015849.19 3.65 0.000308 0.0456 0.21 0.19 Fibroblast growth factor basic levels; chr17:35894090 chr17:35816717~35830293:- LIHC cis rs9907295 0.818 rs11653204 ENSG00000270871.1 AC015849.19 3.65 0.000308 0.0456 0.21 0.19 Fibroblast growth factor basic levels; chr17:35894538 chr17:35816717~35830293:- LIHC cis rs9907295 0.792 rs4796125 ENSG00000270871.1 AC015849.19 3.65 0.000308 0.0456 0.21 0.19 Fibroblast growth factor basic levels; chr17:35894847 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs79730543 ENSG00000270871.1 AC015849.19 3.65 0.000308 0.0456 0.21 0.19 Fibroblast growth factor basic levels; chr17:35896537 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs4796127 ENSG00000270871.1 AC015849.19 3.65 0.000308 0.0456 0.21 0.19 Fibroblast growth factor basic levels; chr17:35899127 chr17:35816717~35830293:- LIHC cis rs9907295 0.901 rs11868801 ENSG00000270871.1 AC015849.19 3.65 0.000308 0.0456 0.21 0.19 Fibroblast growth factor basic levels; chr17:35900047 chr17:35816717~35830293:- LIHC cis rs797680 0.964 rs2296558 ENSG00000229567.1 RP4-717I23.2 3.65 0.000308 0.0456 0.23 0.19 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93270998 chr1:93278961~93279129:- LIHC cis rs2243480 0.522 rs12698511 ENSG00000232546.1 RP11-458F8.1 -3.65 0.000308 0.0456 -0.23 -0.19 Diabetic kidney disease; chr7:66009932 chr7:66848496~66858136:+ LIHC cis rs11098499 0.69 rs34818745 ENSG00000250412.1 KLHL2P1 3.65 0.000308 0.0456 0.22 0.19 Corneal astigmatism; chr4:119335900 chr4:119334329~119378233:+ LIHC cis rs10923574 0.545 rs4659087 ENSG00000232650.4 RP5-834N19.1 3.65 0.000308 0.0456 0.24 0.19 Breast cancer;Folding of antihelix; chr1:118487464 chr1:119328176~119356182:+ LIHC cis rs10760706 1 rs4282626 ENSG00000270412.1 RP11-92C4.6 3.65 0.000308 0.0456 0.22 0.19 Alopecia areata; chr9:99927898 chr9:98943337~98943775:- LIHC cis rs950169 0.526 rs698620 ENSG00000275120.1 RP11-182J1.17 -3.65 0.000308 0.0456 -0.27 -0.19 Schizophrenia; chr15:84633977 chr15:84599434~84606463:- LIHC cis rs77204473 0.744 rs74955808 ENSG00000254851.1 RP11-109L13.1 3.65 0.000308 0.0456 0.38 0.19 Sum eosinophil basophil counts;Eosinophil counts; chr11:117121969 chr11:117135528~117138582:+ LIHC cis rs4578769 0.84 rs67940971 ENSG00000265943.1 RP11-739L10.1 -3.65 0.000308 0.0456 -0.24 -0.19 Eosinophil percentage of white cells; chr18:22902777 chr18:22699481~22933764:- LIHC cis rs72675573 0.748 rs2792796 ENSG00000235612.1 RP1-158P9.1 3.65 0.000308 0.0456 0.22 0.19 Monocyte count; chr1:56250236 chr1:56145721~56155224:+ LIHC cis rs854624 0.892 rs7209212 ENSG00000278690.1 RP11-104J23.2 -3.65 0.000308 0.0456 -0.45 -0.19 Blood protein levels; chr17:36002181 chr17:36012504~36012891:+ LIHC cis rs854624 0.892 rs7209448 ENSG00000278690.1 RP11-104J23.2 -3.65 0.000308 0.0456 -0.45 -0.19 Blood protein levels; chr17:36002365 chr17:36012504~36012891:+ LIHC cis rs854624 0.892 rs7213890 ENSG00000278690.1 RP11-104J23.2 -3.65 0.000308 0.0456 -0.45 -0.19 Blood protein levels; chr17:36002519 chr17:36012504~36012891:+ LIHC cis rs854624 0.892 rs7214040 ENSG00000278690.1 RP11-104J23.2 -3.65 0.000308 0.0456 -0.45 -0.19 Blood protein levels; chr17:36002615 chr17:36012504~36012891:+ LIHC cis rs854624 0.681 rs76144420 ENSG00000278690.1 RP11-104J23.2 -3.65 0.000308 0.0456 -0.45 -0.19 Blood protein levels; chr17:36003635 chr17:36012504~36012891:+ LIHC cis rs854624 0.892 rs73990617 ENSG00000278690.1 RP11-104J23.2 -3.65 0.000308 0.0456 -0.45 -0.19 Blood protein levels; chr17:36004002 chr17:36012504~36012891:+ LIHC cis rs854624 0.892 rs7221040 ENSG00000278690.1 RP11-104J23.2 -3.65 0.000308 0.0456 -0.45 -0.19 Blood protein levels; chr17:36004691 chr17:36012504~36012891:+ LIHC cis rs854624 0.892 rs77550805 ENSG00000278690.1 RP11-104J23.2 -3.65 0.000308 0.0456 -0.45 -0.19 Blood protein levels; chr17:36006617 chr17:36012504~36012891:+ LIHC cis rs854624 0.892 rs76910545 ENSG00000278690.1 RP11-104J23.2 -3.65 0.000308 0.0456 -0.45 -0.19 Blood protein levels; chr17:36006632 chr17:36012504~36012891:+ LIHC cis rs854624 0.892 rs9916758 ENSG00000278690.1 RP11-104J23.2 -3.65 0.000308 0.0456 -0.45 -0.19 Blood protein levels; chr17:36006835 chr17:36012504~36012891:+ LIHC cis rs854624 0.892 rs7217257 ENSG00000278690.1 RP11-104J23.2 -3.65 0.000308 0.0456 -0.45 -0.19 Blood protein levels; chr17:36007212 chr17:36012504~36012891:+ LIHC cis rs854624 0.892 rs7221769 ENSG00000278690.1 RP11-104J23.2 -3.65 0.000308 0.0456 -0.45 -0.19 Blood protein levels; chr17:36007407 chr17:36012504~36012891:+ LIHC cis rs7722022 0.961 rs1422770 ENSG00000253428.1 CTB-43E15.2 3.65 0.000308 0.0456 0.21 0.19 Adiponectin levels; chr5:173515594 chr5:173689459~173705849:+ LIHC cis rs7722022 0.961 rs4454066 ENSG00000253428.1 CTB-43E15.2 3.65 0.000308 0.0456 0.21 0.19 Adiponectin levels; chr5:173515633 chr5:173689459~173705849:+ LIHC cis rs812925 0.537 rs2593620 ENSG00000271889.1 RP11-493E12.1 -3.65 0.000308 0.0456 -0.23 -0.19 Immature fraction of reticulocytes; chr2:61386126 chr2:61151433~61162105:- LIHC cis rs7684187 0.96 rs4572894 ENSG00000251526.1 RP11-381N20.1 -3.65 0.000308 0.0456 -0.23 -0.19 Cancer; chr4:122551631 chr4:123505279~123527525:+ LIHC cis rs10833905 1 rs876092 ENSG00000246225.5 RP11-17A1.3 -3.65 0.000308 0.0456 -0.24 -0.19 Sudden cardiac arrest; chr11:23021075 chr11:22829380~22945393:+ LIHC cis rs6142102 0.517 rs6059577 ENSG00000275784.1 RP5-1125A11.6 -3.65 0.000308 0.0457 -0.2 -0.19 Skin pigmentation; chr20:33939880 chr20:33989480~33991818:- LIHC cis rs10129255 0.957 rs10137980 ENSG00000224373.3 IGHV4-59 3.65 0.000308 0.0457 0.15 0.19 Kawasaki disease; chr14:106775735 chr14:106627249~106627825:- LIHC cis rs17221829 0.965 rs12278734 ENSG00000280367.1 RP11-121L10.2 3.65 0.000309 0.0457 0.22 0.19 Anxiety in major depressive disorder; chr11:89728004 chr11:90223153~90226538:+ LIHC cis rs2451932 0.744 rs380747 ENSG00000251050.1 RP11-168A11.4 -3.65 0.000309 0.0457 -0.2 -0.19 LDL peak particle diameter (total fat intake interaction); chr5:80050744 chr5:80019609~80019920:+ LIHC cis rs891378 0.793 rs12021745 ENSG00000274245.1 RP11-357P18.2 3.65 0.000309 0.0457 0.24 0.19 Spherical equivalent (joint analysis main effects and education interaction); chr1:207293254 chr1:207372559~207373252:+ LIHC cis rs8067287 0.634 rs17793572 ENSG00000205312.7 KRT17P4 -3.65 0.000309 0.0457 -0.27 -0.19 Diabetic kidney disease; chr17:16940678 chr17:16847635~16852777:- LIHC cis rs11229555 0.874 rs11605297 ENSG00000280010.1 AP001350.4 -3.65 0.000309 0.0457 -0.31 -0.19 Crohn's disease;Ulcerative colitis;Inflammatory bowel disease; chr11:58529333 chr11:58627435~58628528:+ LIHC cis rs11229555 0.874 rs11229519 ENSG00000280010.1 AP001350.4 -3.65 0.000309 0.0457 -0.31 -0.19 Crohn's disease;Ulcerative colitis;Inflammatory bowel disease; chr11:58543114 chr11:58627435~58628528:+ LIHC cis rs11229555 0.874 rs12800710 ENSG00000280010.1 AP001350.4 -3.65 0.000309 0.0457 -0.31 -0.19 Crohn's disease;Ulcerative colitis;Inflammatory bowel disease; chr11:58547067 chr11:58627435~58628528:+ LIHC cis rs5742933 0.948 rs5743063 ENSG00000273240.1 RP11-455J20.3 3.65 0.000309 0.0457 0.25 0.19 Ferritin levels; chr2:189829723 chr2:189763859~189764456:- LIHC cis rs801193 0.773 rs801207 ENSG00000224316.1 RP11-479O9.2 -3.65 0.000309 0.0457 -0.18 -0.19 Aortic root size; chr7:66555603 chr7:65773620~65802067:+ LIHC cis rs875971 0.543 rs801191 ENSG00000224316.1 RP11-479O9.2 -3.65 0.000309 0.0457 -0.18 -0.19 Aortic root size; chr7:66567968 chr7:65773620~65802067:+ LIHC cis rs17818399 0.926 rs35350086 ENSG00000239332.4 LINC01119 -3.65 0.000309 0.0457 -0.27 -0.19 Height; chr2:46606897 chr2:46816697~46859007:+ LIHC cis rs3805389 0.504 rs10026315 ENSG00000273257.1 RP11-177J6.1 -3.65 0.000309 0.0457 -0.32 -0.19 Waist-to-hip ratio adjusted for body mass index; chr4:55612195 chr4:55387949~55388271:+ LIHC cis rs10471753 0.868 rs13356158 ENSG00000248359.1 CTC-537E7.2 -3.65 0.000309 0.0457 -0.24 -0.19 Hip minimal joint space width; chr5:68534020 chr5:68531690~68533530:- LIHC cis rs1816213 0.744 rs35021258 ENSG00000273466.1 RP11-548H3.1 -3.64 0.000309 0.0457 -0.29 -0.19 Diastolic blood pressure; chr2:218657724 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs35620463 ENSG00000273466.1 RP11-548H3.1 -3.64 0.000309 0.0457 -0.29 -0.19 Diastolic blood pressure; chr2:218658716 chr2:218633256~218634014:- LIHC cis rs1979679 0.842 rs10459091 ENSG00000278733.1 RP11-425D17.1 3.64 0.000309 0.0457 0.25 0.19 Ossification of the posterior longitudinal ligament of the spine; chr12:28188383 chr12:28185625~28186190:- LIHC cis rs4671400 0.571 rs6738482 ENSG00000273302.1 RP11-493E12.2 -3.64 0.000309 0.0457 -0.22 -0.19 3-hydroxypropylmercapturic acid levels in smokers; chr2:61267766 chr2:61199979~61200769:+ LIHC cis rs365302 0.556 rs552986 ENSG00000216480.2 RP3-393E18.1 -3.64 0.000309 0.0457 -0.24 -0.19 Coronary heart disease; chr6:159214063 chr6:159526062~159526527:- LIHC cis rs9976767 0.932 rs9784206 ENSG00000225218.1 AP001628.6 -3.64 0.000309 0.0458 -0.19 -0.19 Type 1 diabetes; chr21:42403271 chr21:42831040~42836477:- LIHC cis rs9649213 0.555 rs6948346 ENSG00000272950.1 RP11-307C18.1 3.64 0.000309 0.0458 0.23 0.19 Prostate cancer (SNP x SNP interaction); chr7:98330644 chr7:98322853~98323430:+ LIHC cis rs17508449 0.819 rs75290614 ENSG00000232450.1 RP4-730K3.3 -3.64 0.000309 0.0458 -0.26 -0.19 Leprosy; chr1:113700250 chr1:113698884~113699631:- LIHC cis rs1109916 0.506 rs10864725 ENSG00000236497.1 RP11-66A2.2 3.64 0.000309 0.0458 0.24 0.19 Facial morphology (factor 6, height of vermillion lower lip); chr1:232184366 chr1:232727254~232742715:- LIHC cis rs10752881 0.602 rs9425569 ENSG00000228918.3 LINC01344 -3.64 0.000309 0.0458 -0.21 -0.19 Colorectal cancer; chr1:182973067 chr1:182129310~182314061:- LIHC cis rs10883723 0.962 rs1056741 ENSG00000236937.2 PTGES3P4 -3.64 0.000309 0.0458 -0.27 -0.19 Allergic disease (asthma, hay fever or eczema); chr10:102476883 chr10:102845595~102845950:+ LIHC cis rs6969780 1 rs73071548 ENSG00000233429.8 HOTAIRM1 3.64 0.00031 0.0458 0.28 0.19 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27107811 chr7:27095647~27100265:+ LIHC cis rs754423 0.532 rs941625 ENSG00000273888.1 FRMD6-AS1 3.64 0.00031 0.0458 0.22 0.19 Craniofacial microsomia; chr14:52081017 chr14:51649516~51651744:- LIHC cis rs11105298 0.891 rs10858900 ENSG00000258302.2 RP11-981P6.1 3.64 0.00031 0.0458 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89531304 chr12:89561129~89594878:+ LIHC cis rs12468226 0.938 rs6435139 ENSG00000272966.1 RP11-686O6.1 -3.64 0.00031 0.0458 -0.31 -0.19 Urate levels; chr2:202255145 chr2:202336739~202337200:+ LIHC cis rs6832769 0.922 rs819271 ENSG00000272969.1 RP11-528I4.2 3.64 0.00031 0.0458 0.22 0.19 Personality dimensions; chr4:55372680 chr4:55547112~55547889:+ LIHC cis rs4218 0.531 rs10431791 ENSG00000277144.1 RP11-59H7.4 -3.64 0.00031 0.0458 -0.2 -0.19 Social communication problems; chr15:59055159 chr15:59115547~59116089:- LIHC cis rs57221529 0.766 rs4957053 ENSG00000271781.1 CTD-2589H19.6 -3.64 0.00031 0.0459 -0.3 -0.19 Lung disease severity in cystic fibrosis; chr5:575812 chr5:675826~676616:+ LIHC cis rs57221529 0.709 rs111352378 ENSG00000271781.1 CTD-2589H19.6 -3.64 0.00031 0.0459 -0.3 -0.19 Lung disease severity in cystic fibrosis; chr5:576964 chr5:675826~676616:+ LIHC cis rs57221529 0.709 rs72703034 ENSG00000271781.1 CTD-2589H19.6 -3.64 0.00031 0.0459 -0.3 -0.19 Lung disease severity in cystic fibrosis; chr5:576986 chr5:675826~676616:+ LIHC cis rs17345786 1 rs3762729 ENSG00000244119.1 PDCL3P4 3.64 0.00031 0.0459 0.21 0.19 Colonoscopy-negative controls vs population controls; chr3:101590030 chr3:101712472~101713191:+ LIHC cis rs17345786 1 rs73863360 ENSG00000244119.1 PDCL3P4 3.64 0.00031 0.0459 0.21 0.19 Colonoscopy-negative controls vs population controls; chr3:101597993 chr3:101712472~101713191:+ LIHC cis rs17345786 0.911 rs10936707 ENSG00000244119.1 PDCL3P4 3.64 0.00031 0.0459 0.21 0.19 Colonoscopy-negative controls vs population controls; chr3:101605219 chr3:101712472~101713191:+ LIHC cis rs10800713 0.56 rs10919965 ENSG00000260088.1 RP11-92G12.3 -3.64 0.00031 0.0459 -0.28 -0.19 Tandem gait; chr1:200532134 chr1:200669507~200694250:+ LIHC cis rs67311347 1 rs28707772 ENSG00000223797.4 ENTPD3-AS1 3.64 0.00031 0.0459 0.16 0.19 Renal cell carcinoma; chr3:40463175 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs73080126 ENSG00000223797.4 ENTPD3-AS1 3.64 0.00031 0.0459 0.16 0.19 Renal cell carcinoma; chr3:40467662 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs28871903 ENSG00000223797.4 ENTPD3-AS1 3.64 0.00031 0.0459 0.16 0.19 Renal cell carcinoma; chr3:40469603 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs56291770 ENSG00000223797.4 ENTPD3-AS1 3.64 0.00031 0.0459 0.16 0.19 Renal cell carcinoma; chr3:40473879 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs12630072 ENSG00000223797.4 ENTPD3-AS1 3.64 0.00031 0.0459 0.16 0.19 Renal cell carcinoma; chr3:40475699 chr3:40313802~40453329:- LIHC cis rs67311347 1 rs4128740 ENSG00000223797.4 ENTPD3-AS1 3.64 0.00031 0.0459 0.16 0.19 Renal cell carcinoma; chr3:40478041 chr3:40313802~40453329:- LIHC cis rs1816213 0.744 rs13383705 ENSG00000273466.1 RP11-548H3.1 -3.64 0.00031 0.0459 -0.29 -0.19 Diastolic blood pressure; chr2:218655878 chr2:218633256~218634014:- LIHC cis rs1816213 0.744 rs3731872 ENSG00000273466.1 RP11-548H3.1 -3.64 0.00031 0.0459 -0.29 -0.19 Diastolic blood pressure; chr2:218656172 chr2:218633256~218634014:- LIHC cis rs8060598 1 rs34552113 ENSG00000275155.1 CTD-2595P9.4 -3.64 0.00031 0.0459 -0.23 -0.19 Leprosy; chr16:50755339 chr16:49847018~49847632:- LIHC cis rs12908161 0.959 rs2175567 ENSG00000275120.1 RP11-182J1.17 3.64 0.00031 0.0459 0.31 0.19 Schizophrenia; chr15:84657715 chr15:84599434~84606463:- LIHC cis rs9425766 0.639 rs10798295 ENSG00000200674.1 RN7SKP160 3.64 0.000311 0.0459 0.23 0.19 Life satisfaction; chr1:173714815 chr1:173791548~173791887:+ LIHC cis rs4763879 0.778 rs1044771 ENSG00000256673.1 RP11-599J14.2 3.64 0.000311 0.0459 0.19 0.19 Type 1 diabetes; chr12:9699333 chr12:9398355~9414851:- LIHC cis rs3091242 0.933 rs9438905 ENSG00000261349.1 RP3-465N24.5 -3.64 0.000311 0.0459 -0.19 -0.19 Erythrocyte sedimentation rate; chr1:25437686 chr1:25266102~25267136:- LIHC cis rs7647973 0.6 rs35174559 ENSG00000270441.1 RP11-694I15.7 -3.64 0.000311 0.0459 -0.27 -0.19 Menarche (age at onset); chr3:49250326 chr3:49140086~49160851:- LIHC cis rs2070488 0.775 rs2051213 ENSG00000229589.1 ACVR2B-AS1 3.64 0.000311 0.0459 0.21 0.19 Electrocardiographic conduction measures; chr3:38518763 chr3:38451027~38454820:- LIHC cis rs11105298 0.891 rs10858879 ENSG00000258302.2 RP11-981P6.1 -3.64 0.000311 0.0459 -0.26 -0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89492801 chr12:89561129~89594878:+ LIHC cis rs4237845 0.537 rs7312623 ENSG00000270039.1 RP11-571M6.17 -3.64 0.000311 0.0459 -0.27 -0.19 Intelligence (multi-trait analysis); chr12:57868740 chr12:57803838~57804415:+ LIHC cis rs875971 0.628 rs6974355 ENSG00000237310.1 GS1-124K5.4 3.64 0.000311 0.046 0.19 0.19 Aortic root size; chr7:66376994 chr7:66493706~66495474:+ LIHC cis rs4730430 0.557 rs10953661 ENSG00000226965.1 AC003088.1 3.64 0.000311 0.046 0.26 0.19 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr7:110495422 chr7:110432239~110534754:- LIHC cis rs74233809 1 rs11191454 ENSG00000236937.2 PTGES3P4 3.64 0.000311 0.046 0.31 0.19 Birth weight; chr10:102900247 chr10:102845595~102845950:+ LIHC cis rs886774 0.74 rs10271497 ENSG00000273055.1 CTB-13F3.1 -3.64 0.000312 0.046 -0.2 -0.19 Ulcerative colitis; chr7:107939229 chr7:107942116~107942740:+ LIHC cis rs4578769 0.685 rs6507432 ENSG00000265943.1 RP11-739L10.1 3.64 0.000312 0.046 0.25 0.19 Eosinophil percentage of white cells; chr18:23010884 chr18:22699481~22933764:- LIHC cis rs864537 0.646 rs1723018 ENSG00000273160.1 RP11-104L21.3 3.64 0.000312 0.0461 0.25 0.19 Celiac disease or Rheumatoid arthritis;Celiac disease; chr1:167464183 chr1:167457742~167459891:- LIHC cis rs6028335 0.61 rs67487809 ENSG00000277581.1 RP4-616B8.6 -3.64 0.000312 0.0461 -0.32 -0.19 Alcohol and nicotine co-dependence; chr20:39059954 chr20:38962472~38962993:+ LIHC cis rs933688 1 rs10041402 ENSG00000281357.1 ARRDC3-AS1 3.64 0.000312 0.0461 0.24 0.19 Smoking behavior; chr5:91443131 chr5:91380349~91439085:+ LIHC cis rs933688 1 rs10073935 ENSG00000281357.1 ARRDC3-AS1 3.64 0.000312 0.0461 0.24 0.19 Smoking behavior; chr5:91446371 chr5:91380349~91439085:+ LIHC cis rs933688 1 rs10059163 ENSG00000281357.1 ARRDC3-AS1 3.64 0.000312 0.0461 0.24 0.19 Smoking behavior; chr5:91446627 chr5:91380349~91439085:+ LIHC cis rs1501138 0.562 rs203444 ENSG00000263327.5 TAPT1-AS1 -3.64 0.000312 0.0461 -0.25 -0.19 Systemic juvenile idiopathic arthritis; chr4:16247489 chr4:16226685~16320140:+ LIHC cis rs4460629 0.905 rs4971077 ENSG00000203761.5 MSTO2P -3.64 0.000312 0.0461 -0.16 -0.19 Serum magnesium levels; chr1:155156241 chr1:155745829~155750137:+ LIHC cis rs2348418 0.832 rs12303069 ENSG00000247934.4 RP11-967K21.1 3.64 0.000312 0.0461 0.18 0.19 Lung function (FEV1);Lung function (FVC); chr12:28294319 chr12:28163298~28190738:- LIHC cis rs6667605 0.527 rs6673993 ENSG00000225931.3 RP3-395M20.7 3.64 0.000312 0.0461 0.2 0.19 Ulcerative colitis;Inflammatory bowel disease; chr1:2620632 chr1:2566410~2569888:+ LIHC cis rs6969780 1 rs73071550 ENSG00000233429.8 HOTAIRM1 3.64 0.000312 0.0461 0.28 0.19 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27109480 chr7:27095647~27100265:+ LIHC cis rs4386084 1 rs12905434 ENSG00000244879.4 GABPB1-AS1 3.64 0.000312 0.0461 0.23 0.19 Basophil percentage of granulocytes;Basophil percentage of white cells; chr15:49939630 chr15:50354959~50372202:+ LIHC cis rs10761256 0.927 rs2398861 ENSG00000227603.1 RP11-165J3.6 -3.64 0.000312 0.0461 -0.24 -0.19 Itch intensity from mosquito bite adjusted by bite size; chr9:93668465 chr9:93435332~93437121:- LIHC cis rs8054556 0.647 rs4077410 ENSG00000250616.2 RP11-455F5.3 3.64 0.000312 0.0461 0.19 0.19 Autism spectrum disorder or schizophrenia; chr16:29986879 chr16:30096430~30104116:+ LIHC cis rs7539624 0.529 rs1153954 ENSG00000188460.4 ACTBP11 3.64 0.000312 0.0461 0.22 0.19 Schizophrenia; chr1:223769633 chr1:223863726~223864851:- LIHC cis rs9532669 0.89 rs4941999 ENSG00000168852.11 TPTE2P5 3.64 0.000312 0.0461 0.22 0.19 Cervical cancer; chr13:40859926 chr13:40822296~40921749:- LIHC cis rs6722750 0.716 rs6546057 ENSG00000229920.2 RPS4XP5 3.64 0.000312 0.0461 0.19 0.19 Neuroticism; chr2:64187031 chr2:63642455~63644038:- LIHC cis rs960902 0.805 rs12995330 ENSG00000213553.4 RPLP0P6 3.64 0.000312 0.0461 0.16 0.19 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37483426 chr2:38481851~38482804:+ LIHC cis rs17818399 0.633 rs2242033 ENSG00000236824.1 BCYRN1 -3.64 0.000312 0.0461 -0.22 -0.19 Height; chr2:46615271 chr2:47331060~47344517:+ LIHC cis rs72829446 0.53 rs8075009 ENSG00000263316.1 RP11-530N7.3 3.64 0.000313 0.0461 0.39 0.19 Androgen levels; chr17:7471189 chr17:6954098~6978960:- LIHC cis rs763121 0.815 rs4821799 ENSG00000273076.1 RP3-508I15.22 3.64 0.000313 0.0461 0.21 0.19 Menopause (age at onset); chr22:38625321 chr22:38743495~38743910:+ LIHC cis rs10774547 0.965 rs11065109 ENSG00000278344.1 RP11-18C24.8 3.64 0.000313 0.0461 0.23 0.19 Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);Reading disability or specific language impairment (pleiotropy); chr12:120426111 chr12:120500735~120501090:- LIHC cis rs2933343 0.7 rs1680779 ENSG00000261159.1 RP11-723O4.9 3.64 0.000313 0.0462 0.26 0.19 IgG glycosylation; chr3:128895927 chr3:128859716~128860526:- LIHC cis rs12681287 0.752 rs12677470 ENSG00000254088.1 SLC2A3P4 3.64 0.000313 0.0462 0.23 0.19 Caudate activity during reward; chr8:86248330 chr8:86503591~86505061:+ LIHC cis rs12681287 0.752 rs10435563 ENSG00000254088.1 SLC2A3P4 3.64 0.000313 0.0462 0.23 0.19 Caudate activity during reward; chr8:86253831 chr8:86503591~86505061:+ LIHC cis rs12681287 0.752 rs10435564 ENSG00000254088.1 SLC2A3P4 3.64 0.000313 0.0462 0.23 0.19 Caudate activity during reward; chr8:86254010 chr8:86503591~86505061:+ LIHC cis rs6840360 0.573 rs4696250 ENSG00000251603.1 RP11-164P12.4 -3.64 0.000313 0.0462 -0.18 -0.19 Intelligence (multi-trait analysis); chr4:151345169 chr4:151667224~151670502:+ LIHC cis rs9467773 0.596 rs3001369 ENSG00000124549.13 BTN2A3P 3.64 0.000313 0.0462 0.17 0.19 Intelligence (multi-trait analysis); chr6:26670741 chr6:26421391~26432383:+ LIHC cis rs783540 0.656 rs783524 ENSG00000278603.1 RP13-608F4.5 -3.64 0.000313 0.0462 -0.24 -0.19 Schizophrenia; chr15:82615393 chr15:82472203~82472426:+ LIHC cis rs6732160 0.809 rs13406142 ENSG00000272702.1 RP11-44N22.3 3.64 0.000313 0.0462 0.22 0.19 Intelligence (multi-trait analysis); chr2:73156970 chr2:73113018~73115907:+ LIHC cis rs1928295 1 rs9408902 ENSG00000233569.1 RP11-500B12.1 3.64 0.000313 0.0462 0.21 0.19 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117616686 chr9:117648606~117657027:+ LIHC cis rs6545883 0.929 rs6707830 ENSG00000271889.1 RP11-493E12.1 3.64 0.000313 0.0462 0.23 0.19 Tuberculosis; chr2:61522337 chr2:61151433~61162105:- LIHC cis rs10256972 0.528 rs7784607 ENSG00000199023.2 MIR339 -3.64 0.000313 0.0462 -0.22 -0.19 Endometriosis;Longevity; chr7:1139058 chr7:1022935~1023045:- LIHC cis rs7182948 0.918 rs2413947 ENSG00000259531.2 RP11-295H24.3 -3.64 0.000313 0.0462 -0.29 -0.19 Lung adenocarcinoma; chr15:49465188 chr15:49365124~49366685:- LIHC cis rs2274273 1 rs2274273 ENSG00000258413.1 RP11-665C16.6 3.64 0.000313 0.0462 0.24 0.19 Protein biomarker; chr14:55147918 chr14:55262767~55272075:- LIHC cis rs733175 0.904 rs3775944 ENSG00000250413.1 RP11-448G15.1 -3.64 0.000313 0.0462 -0.28 -0.19 Psychosis and Alzheimer's disease; chr4:10018350 chr4:10006482~10009725:+ LIHC cis rs4218 0.517 rs71480503 ENSG00000277144.1 RP11-59H7.4 -3.64 0.000314 0.0463 -0.22 -0.19 Social communication problems; chr15:59098246 chr15:59115547~59116089:- LIHC cis rs7022054 0.502 rs7020238 ENSG00000230581.2 ACTG1P14 -3.64 0.000314 0.0463 -0.19 -0.19 Schizophrenia; chr9:7209284 chr9:6834456~6835577:+ LIHC cis rs7044246 0.807 rs7026534 ENSG00000224992.1 RP11-295G24.5 3.64 0.000314 0.0463 0.24 0.19 Cognitive ability (multi-trait analysis);Cognitive ability; chr9:132031876 chr9:132769453~132770212:- LIHC cis rs6545883 0.929 rs2593626 ENSG00000271889.1 RP11-493E12.1 3.64 0.000314 0.0463 0.23 0.19 Tuberculosis; chr2:61438049 chr2:61151433~61162105:- LIHC cis rs6545883 0.929 rs2592352 ENSG00000271889.1 RP11-493E12.1 3.64 0.000314 0.0463 0.23 0.19 Tuberculosis; chr2:61438201 chr2:61151433~61162105:- LIHC cis rs6545883 0.929 rs2593625 ENSG00000271889.1 RP11-493E12.1 3.64 0.000314 0.0463 0.23 0.19 Tuberculosis; chr2:61441634 chr2:61151433~61162105:- LIHC cis rs3738443 0.52 rs6699577 ENSG00000227671.4 RP11-488L18.4 -3.64 0.000314 0.0463 -0.13 -0.19 Alcohol dependence; chr1:247224152 chr1:247189851~247210856:- LIHC cis rs2607426 0.579 rs2561531 ENSG00000276445.1 LLNLR-268E12.1 -3.64 0.000314 0.0463 -0.33 -0.19 Blood protein levels; chr19:40716014 chr19:39812972~39813555:- LIHC cis rs12468226 0.938 rs114177656 ENSG00000272966.1 RP11-686O6.1 3.64 0.000314 0.0463 0.32 0.19 Urate levels; chr2:202291596 chr2:202336739~202337200:+ LIHC cis rs7682481 0.92 rs17391154 ENSG00000251526.1 RP11-381N20.1 3.64 0.000314 0.0463 0.2 0.19 Alopecia areata; chr4:122635038 chr4:123505279~123527525:+ LIHC cis rs1075265 0.626 rs805412 ENSG00000233266.1 HMGB1P31 3.64 0.000314 0.0463 0.23 0.19 Chronotype;Morning vs. evening chronotype; chr2:53893683 chr2:54051334~54051760:+ LIHC cis rs6565681 0.76 rs9901680 ENSG00000280351.2 CTD-2561B21.8 -3.64 0.000314 0.0463 -0.22 -0.19 Moyamoya disease; chr17:80404288 chr17:81003335~81005132:+ LIHC cis rs1494950 1 rs2643079 ENSG00000214846.4 RP11-115L11.1 -3.64 0.000314 0.0463 -0.41 -0.19 Political ideology; chr4:14990872 chr4:15730962~15731627:- LIHC cis rs1494950 1 rs2643082 ENSG00000214846.4 RP11-115L11.1 -3.64 0.000314 0.0463 -0.41 -0.19 Political ideology; chr4:14993603 chr4:15730962~15731627:- LIHC cis rs1494950 1 rs2643083 ENSG00000214846.4 RP11-115L11.1 -3.64 0.000314 0.0463 -0.41 -0.19 Political ideology; chr4:14993965 chr4:15730962~15731627:- LIHC cis rs1494950 0.661 rs2643084 ENSG00000214846.4 RP11-115L11.1 -3.64 0.000314 0.0463 -0.41 -0.19 Political ideology; chr4:14996984 chr4:15730962~15731627:- LIHC cis rs1023500 0.551 rs133379 ENSG00000226450.2 CYP2D8P 3.64 0.000314 0.0463 0.24 0.19 Schizophrenia; chr22:42072531 chr22:42149886~42155001:- LIHC cis rs228614 0.536 rs223420 ENSG00000248971.2 KRT8P46 -3.64 0.000314 0.0463 -0.19 -0.19 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102806853 chr4:102728746~102730171:- LIHC cis rs2574985 0.52 rs10826126 ENSG00000231345.3 BEND3P1 -3.64 0.000314 0.0463 -0.22 -0.19 Subjective well-being; chr10:50507027 chr10:50655967~50660472:+ LIHC cis rs2179367 0.632 rs11155649 ENSG00000231760.4 RP11-350J20.5 3.64 0.000314 0.0463 0.31 0.19 Dupuytren's disease; chr6:149405830 chr6:149796151~149826294:- LIHC cis rs11089937 0.626 rs9619811 ENSG00000211639.2 IGLV4-60 3.64 0.000314 0.0463 0.18 0.19 Periodontitis (PAL4Q3); chr22:22159186 chr22:22162199~22162681:+ LIHC cis rs3738443 0.545 rs12566906 ENSG00000227671.4 RP11-488L18.4 -3.64 0.000314 0.0463 -0.13 -0.19 Alcohol dependence; chr1:247224904 chr1:247189851~247210856:- LIHC cis rs12543592 1 rs11784208 ENSG00000255325.2 RP11-96B2.1 -3.64 0.000314 0.0463 -0.21 -0.19 Autism spectrum disorder; chr8:122499008 chr8:122485515~122489815:- LIHC cis rs9500256 1 rs9500256 ENSG00000215190.7 LINC00680 -3.64 0.000314 0.0463 -0.2 -0.19 Eosinophilic esophagitis (pediatric); chr6:57982677 chr6:57946074~57961501:- LIHC cis rs17508449 0.819 rs78874053 ENSG00000232450.1 RP4-730K3.3 -3.64 0.000314 0.0463 -0.26 -0.19 Leprosy; chr1:113700251 chr1:113698884~113699631:- LIHC cis rs11096990 0.964 rs11096986 ENSG00000249207.1 RP11-360F5.1 3.64 0.000314 0.0463 0.22 0.19 Cognitive function; chr4:39257122 chr4:39112677~39126818:- LIHC cis rs643506 0.845 rs607327 ENSG00000230911.1 PPIHP1 -3.64 0.000315 0.0464 -0.26 -0.19 Breast cancer; chr11:111824985 chr11:112029858~112030367:- LIHC cis rs643506 0.874 rs663511 ENSG00000230911.1 PPIHP1 -3.64 0.000315 0.0464 -0.26 -0.19 Breast cancer; chr11:111839311 chr11:112029858~112030367:- LIHC cis rs7702057 0.53 rs1567330 ENSG00000272265.1 CTD-2287O16.4 3.64 0.000315 0.0464 0.31 0.19 Amyotrophic lateral sclerosis; chr5:116077348 chr5:116078110~116078570:- LIHC cis rs2243480 1 rs2462569 ENSG00000229886.1 RP5-1132H15.3 -3.64 0.000315 0.0464 -0.28 -0.19 Diabetic kidney disease; chr7:66009859 chr7:66025126~66031544:- LIHC cis rs5769707 0.967 rs763127 ENSG00000279345.1 RP3-522J7.7 -3.64 0.000315 0.0464 -0.17 -0.19 Monocyte percentage of white cells;Monocyte count; chr22:49612430 chr22:49805452~49807208:+ LIHC cis rs718433 0.648 rs10133882 ENSG00000258441.1 LINC00641 -3.64 0.000315 0.0464 -0.19 -0.19 Intraocular pressure; chr14:21746222 chr14:21200079~21206900:- LIHC cis rs9951150 0.537 rs11663684 ENSG00000267013.4 CTD-2171N6.1 3.64 0.000315 0.0464 0.25 0.19 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55120350 chr18:55105904~55124306:- LIHC cis rs1023500 0.596 rs5751204 ENSG00000226450.2 CYP2D8P 3.64 0.000315 0.0464 0.24 0.19 Schizophrenia; chr22:42037797 chr22:42149886~42155001:- LIHC cis rs11622475 1 rs11622475 ENSG00000258534.1 CTD-2134A5.4 3.64 0.000315 0.0464 0.24 0.19 Bipolar disorder; chr14:104042739 chr14:103854366~103880111:- LIHC cis rs6547741 1 rs6750943 ENSG00000234072.1 AC074117.10 3.64 0.000315 0.0464 0.18 0.19 Oral cavity cancer; chr2:27555037 chr2:27356246~27367622:+ LIHC cis rs7095607 1 rs7081213 ENSG00000233590.1 RP11-153K11.3 3.64 0.000315 0.0464 0.23 0.19 Lung function (FVC); chr10:68194533 chr10:68233251~68242379:- LIHC cis rs2243480 1 rs4718270 ENSG00000275400.1 RP4-756H11.5 3.64 0.000315 0.0464 0.26 0.19 Diabetic kidney disease; chr7:65737415 chr7:66553805~66554199:- LIHC cis rs2243480 0.901 rs2900904 ENSG00000275400.1 RP4-756H11.5 3.64 0.000315 0.0464 0.26 0.19 Diabetic kidney disease; chr7:65739282 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs6460260 ENSG00000275400.1 RP4-756H11.5 -3.64 0.000315 0.0464 -0.26 -0.19 Diabetic kidney disease; chr7:65750468 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs6460261 ENSG00000275400.1 RP4-756H11.5 -3.64 0.000315 0.0464 -0.26 -0.19 Diabetic kidney disease; chr7:65750593 chr7:66553805~66554199:- LIHC cis rs11098499 0.604 rs17051352 ENSG00000260091.1 RP11-33B1.4 -3.64 0.000315 0.0464 -0.14 -0.19 Corneal astigmatism; chr4:119660272 chr4:119409333~119410233:+ LIHC cis rs67981189 0.896 rs221922 ENSG00000274818.1 RP1-292L20.3 -3.64 0.000315 0.0464 -0.21 -0.19 Schizophrenia; chr14:71118396 chr14:70906657~70907111:- LIHC cis rs12468226 0.873 rs78798541 ENSG00000226261.1 AC064836.3 3.64 0.000315 0.0464 0.33 0.19 Urate levels; chr2:202194708 chr2:202336024~202336727:- LIHC cis rs516805 0.748 rs11968579 ENSG00000279453.1 RP3-425C14.4 3.64 0.000315 0.0465 0.3 0.19 Lymphocyte counts; chr6:122575950 chr6:122436789~122439223:- LIHC cis rs10129255 1 rs10129407 ENSG00000211970.3 IGHV4-61 -3.64 0.000316 0.0465 -0.15 -0.19 Kawasaki disease; chr14:106767956 chr14:106639119~106639657:- LIHC cis rs270601 0.909 rs2569265 ENSG00000263597.1 MIR3936 -3.64 0.000316 0.0465 -0.21 -0.19 Acylcarnitine levels; chr5:132368827 chr5:132365490~132365599:- LIHC cis rs17508449 0.732 rs74610368 ENSG00000232450.1 RP4-730K3.3 -3.64 0.000316 0.0465 -0.26 -0.19 Leprosy; chr1:113742681 chr1:113698884~113699631:- LIHC cis rs12468226 0.752 rs34829484 ENSG00000272966.1 RP11-686O6.1 -3.64 0.000316 0.0465 -0.31 -0.19 Urate levels; chr2:202137267 chr2:202336739~202337200:+ LIHC cis rs7200786 0.692 rs9935445 ENSG00000274038.1 RP11-66H6.4 -3.64 0.000316 0.0465 -0.22 -0.19 Systemic lupus erythematosus;Multiple sclerosis; chr16:10995532 chr16:11056556~11057034:+ LIHC cis rs2243480 1 rs313807 ENSG00000229886.1 RP5-1132H15.3 3.64 0.000316 0.0465 0.28 0.19 Diabetic kidney disease; chr7:66034494 chr7:66025126~66031544:- LIHC cis rs2243480 0.901 rs313808 ENSG00000229886.1 RP5-1132H15.3 3.64 0.000316 0.0465 0.28 0.19 Diabetic kidney disease; chr7:66034886 chr7:66025126~66031544:- LIHC cis rs7200543 0.848 rs62039480 ENSG00000188599.16 NPIPP1 -3.64 0.000316 0.0465 -0.17 -0.19 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15043593 chr16:15104312~15123498:- LIHC cis rs979976 0.765 rs7556997 ENSG00000227347.1 HNRNPKP2 3.64 0.000316 0.0465 0.25 0.19 Corneal astigmatism; chr2:137041036 chr2:136199114~136200503:- LIHC cis rs3091242 0.933 rs11249250 ENSG00000261349.1 RP3-465N24.5 -3.64 0.000316 0.0465 -0.19 -0.19 Erythrocyte sedimentation rate; chr1:25441118 chr1:25266102~25267136:- LIHC cis rs6061231 0.505 rs13037253 ENSG00000273619.1 RP5-908M14.9 -3.64 0.000316 0.0465 -0.18 -0.19 Colorectal cancer; chr20:62353668 chr20:62386303~62386970:- LIHC cis rs617219 0.671 rs2591388 ENSG00000251675.1 CTC-458I2.2 -3.64 0.000316 0.0465 -0.21 -0.19 Betaine levels in individuals undergoing cardiac evaluation; chr5:79261418 chr5:80128361~80143883:+ LIHC cis rs494003 1 rs10896043 ENSG00000265874.1 MIR4489 -3.64 0.000316 0.0465 -0.31 -0.19 Systemic lupus erythematosus; chr11:65776356 chr11:65649192~65649253:+ LIHC cis rs11861787 1 rs12934978 ENSG00000279357.1 RP11-475D10.4 -3.64 0.000316 0.0465 -0.22 -0.19 Epilepsy (remission after treatment); chr16:8470156 chr16:8666762~8667271:+ LIHC cis rs4578769 0.729 rs12456891 ENSG00000265943.1 RP11-739L10.1 -3.64 0.000316 0.0465 -0.25 -0.19 Eosinophil percentage of white cells; chr18:22830243 chr18:22699481~22933764:- LIHC cis rs9500256 0.934 rs1343391 ENSG00000272541.1 XXbac-BPGBPG55C20.1 -3.64 0.000316 0.0465 -0.21 -0.19 Eosinophilic esophagitis (pediatric); chr6:58017876 chr6:57855891~57856468:- LIHC cis rs2348418 0.798 rs7310297 ENSG00000247934.4 RP11-967K21.1 3.64 0.000316 0.0465 0.18 0.19 Lung function (FEV1);Lung function (FVC); chr12:28313638 chr12:28163298~28190738:- LIHC cis rs6545883 0.862 rs778141 ENSG00000271889.1 RP11-493E12.1 3.64 0.000316 0.0465 0.23 0.19 Tuberculosis; chr2:61455043 chr2:61151433~61162105:- LIHC cis rs6545883 0.929 rs778140 ENSG00000271889.1 RP11-493E12.1 3.64 0.000316 0.0465 0.23 0.19 Tuberculosis; chr2:61455841 chr2:61151433~61162105:- LIHC cis rs1348850 0.626 rs1901825 ENSG00000280374.1 RP11-337N6.3 3.64 0.000316 0.0465 0.23 0.19 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr2:177360603 chr2:177317715~177318471:- LIHC cis rs1348850 0.608 rs2364845 ENSG00000280374.1 RP11-337N6.3 3.64 0.000316 0.0465 0.23 0.19 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr2:177361512 chr2:177317715~177318471:- LIHC cis rs10129255 1 rs4612959 ENSG00000274576.2 IGHV2-70 3.64 0.000316 0.0466 0.16 0.19 Kawasaki disease; chr14:106767055 chr14:106770577~106771020:- LIHC cis rs2243480 0.901 rs34807232 ENSG00000275400.1 RP4-756H11.5 3.64 0.000316 0.0466 0.26 0.19 Diabetic kidney disease; chr7:66500146 chr7:66553805~66554199:- LIHC cis rs2243480 0.901 rs35823062 ENSG00000275400.1 RP4-756H11.5 3.64 0.000316 0.0466 0.26 0.19 Diabetic kidney disease; chr7:66500834 chr7:66553805~66554199:- LIHC cis rs7208859 0.573 rs8078182 ENSG00000264538.5 SUZ12P1 -3.64 0.000316 0.0466 -0.2 -0.19 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822646 chr17:30709299~30790908:+ LIHC cis rs10246939 0.579 rs10464444 ENSG00000228775.6 WEE2-AS1 -3.64 0.000317 0.0466 -0.22 -0.19 Bitter taste perception; chr7:141832387 chr7:141704338~141738346:- LIHC cis rs494562 0.892 rs638745 ENSG00000234155.1 RP11-30P6.6 -3.64 0.000317 0.0466 -0.41 -0.19 Metabolic traits;Blood metabolite levels; chr6:85405869 chr6:85387219~85390186:- LIHC cis rs494562 0.892 rs550499 ENSG00000234155.1 RP11-30P6.6 -3.64 0.000317 0.0466 -0.41 -0.19 Metabolic traits;Blood metabolite levels; chr6:85405884 chr6:85387219~85390186:- LIHC cis rs494562 1 rs527670 ENSG00000234155.1 RP11-30P6.6 -3.64 0.000317 0.0466 -0.41 -0.19 Metabolic traits;Blood metabolite levels; chr6:85406061 chr6:85387219~85390186:- LIHC cis rs12480328 1 rs7274624 ENSG00000224397.4 LINC01272 -3.64 0.000317 0.0466 -0.45 -0.19 Prostate cancer; chr20:50946563 chr20:50267486~50279795:+ LIHC cis rs919433 0.726 rs11904247 ENSG00000231621.1 AC013264.2 -3.64 0.000317 0.0466 -0.18 -0.19 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197373700 chr2:197197991~197199273:+ LIHC cis rs1075265 0.587 rs2949812 ENSG00000265452.1 MIR3682 -3.64 0.000317 0.0466 -0.24 -0.19 Chronotype;Morning vs. evening chronotype; chr2:53797190 chr2:53849122~53849205:- LIHC cis rs4218 0.689 rs12907187 ENSG00000277144.1 RP11-59H7.4 -3.64 0.000317 0.0466 -0.21 -0.19 Social communication problems; chr15:59100607 chr15:59115547~59116089:- LIHC cis rs11105298 0.891 rs3825330 ENSG00000258302.2 RP11-981P6.1 3.64 0.000317 0.0466 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89539933 chr12:89561129~89594878:+ LIHC cis rs4713118 0.662 rs9393881 ENSG00000219891.2 ZSCAN12P1 3.64 0.000317 0.0466 0.27 0.19 Parkinson's disease; chr6:28055973 chr6:28091154~28093664:+ LIHC cis rs1862618 0.641 rs170733 ENSG00000271828.1 CTD-2310F14.1 -3.64 0.000317 0.0466 -0.26 -0.19 Initial pursuit acceleration; chr5:56953424 chr5:56927874~56929573:+ LIHC cis rs2243480 1 rs55895244 ENSG00000226002.1 RP11-460N20.5 -3.64 0.000317 0.0466 -0.28 -0.19 Diabetic kidney disease; chr7:65922691 chr7:65084103~65100232:+ LIHC cis rs17376456 0.696 rs6860390 ENSG00000251023.1 RP11-549J18.1 3.64 0.000317 0.0466 0.29 0.19 Diabetic retinopathy; chr5:94159026 chr5:93860669~93863825:- LIHC cis rs9646944 0.501 rs7586983 ENSG00000234389.1 AC007278.3 3.64 0.000317 0.0466 0.25 0.19 Blood protein levels; chr2:102411606 chr2:102438713~102440475:+ LIHC cis rs875971 0.545 rs6969224 ENSG00000224316.1 RP11-479O9.2 3.64 0.000317 0.0466 0.19 0.19 Aortic root size; chr7:66370011 chr7:65773620~65802067:+ LIHC cis rs2742417 0.603 rs2742398 ENSG00000244357.3 RN7SL145P 3.64 0.000317 0.0466 0.18 0.19 Response to anti-depressant treatment in major depressive disorder; chr3:45717544 chr3:45742675~45742970:+ LIHC cis rs4873772 0.873 rs10109984 ENSG00000253608.1 RP11-770E5.1 -3.64 0.000317 0.0466 -0.21 -0.19 Lobe attachment (rater-scored or self-reported); chr8:47891114 chr8:48551567~48698510:+ LIHC cis rs1023500 0.551 rs2301521 ENSG00000205702.9 CYP2D7 3.64 0.000317 0.0466 0.23 0.19 Schizophrenia; chr22:42027106 chr22:42140203~42144577:- LIHC cis rs763121 0.853 rs5750668 ENSG00000273076.1 RP3-508I15.22 3.64 0.000317 0.0466 0.23 0.19 Menopause (age at onset); chr22:38683959 chr22:38743495~38743910:+ LIHC cis rs591584 0.874 rs10831245 ENSG00000255893.1 RP11-685N10.1 -3.64 0.000317 0.0466 -0.19 -0.19 Macrophage Migration Inhibitory Factor levels; chr11:94586722 chr11:94472908~94473570:- LIHC cis rs6787172 0.811 rs7648618 ENSG00000272087.1 RP11-379F4.7 3.64 0.000317 0.0467 0.21 0.19 Subjective well-being; chr3:158505049 chr3:158693120~158693768:- LIHC cis rs2348418 0.864 rs1949978 ENSG00000247934.4 RP11-967K21.1 3.64 0.000317 0.0467 0.17 0.19 Lung function (FEV1);Lung function (FVC); chr12:28443951 chr12:28163298~28190738:- LIHC cis rs1494950 1 rs9998291 ENSG00000214846.4 RP11-115L11.1 -3.64 0.000317 0.0467 -0.4 -0.19 Political ideology; chr4:15020653 chr4:15730962~15731627:- LIHC cis rs13113518 0.812 rs2035692 ENSG00000223305.1 RN7SKP30 3.64 0.000317 0.0467 0.23 0.19 Height; chr4:55528801 chr4:55540502~55540835:- LIHC cis rs13113518 0.812 rs4507426 ENSG00000223305.1 RN7SKP30 3.64 0.000317 0.0467 0.23 0.19 Height; chr4:55529387 chr4:55540502~55540835:- LIHC cis rs6433895 0.601 rs13033038 ENSG00000236153.1 AC104076.3 -3.64 0.000317 0.0467 -0.28 -0.19 Lymphocyte counts; chr2:181187828 chr2:180979427~180980090:- LIHC cis rs2396442 1 rs12197948 ENSG00000231769.2 RP1-8B1.4 -3.64 0.000317 0.0467 -0.27 -0.19 Left ventricle wall thickness; chr6:45487107 chr6:46097093~46129706:- LIHC cis rs9611519 1 rs5758264 ENSG00000231907.2 GAPDHP37 3.64 0.000317 0.0467 0.24 0.19 Neuroticism; chr22:41220280 chr22:40673484~40674451:- LIHC cis rs2599510 0.807 rs176416 ENSG00000276334.1 AL133243.1 -3.64 0.000317 0.0467 -0.22 -0.19 Interleukin-18 levels; chr2:32427155 chr2:32521927~32523547:+ LIHC cis rs6449502 0.614 rs13159372 ENSG00000272308.1 RP11-231G3.1 3.64 0.000317 0.0467 0.35 0.19 Mean platelet volume; chr5:60820706 chr5:60866457~60866935:- LIHC cis rs6684428 0.536 rs7538008 ENSG00000229871.1 RP4-710M16.1 -3.64 0.000318 0.0467 -0.31 -0.19 Airflow obstruction; chr1:55930411 chr1:56207567~56208456:- LIHC cis rs17221829 0.965 rs28614109 ENSG00000280367.1 RP11-121L10.2 3.64 0.000318 0.0467 0.22 0.19 Anxiety in major depressive disorder; chr11:89727775 chr11:90223153~90226538:+ LIHC cis rs17221829 0.965 rs12292340 ENSG00000280367.1 RP11-121L10.2 3.64 0.000318 0.0467 0.22 0.19 Anxiety in major depressive disorder; chr11:89728105 chr11:90223153~90226538:+ LIHC cis rs11148252 0.774 rs7334583 ENSG00000278238.1 RP11-245D16.4 3.64 0.000318 0.0467 0.18 0.19 Lewy body disease; chr13:52356217 chr13:52454775~52455331:- LIHC cis rs1553477 0.64 rs6866551 ENSG00000272123.1 CTD-2366F13.2 3.64 0.000318 0.0467 0.25 0.19 Monobrow; chr5:53824052 chr5:53089016~53089468:- LIHC cis rs10471753 0.868 rs10471339 ENSG00000248359.1 CTC-537E7.2 -3.64 0.000318 0.0467 -0.24 -0.19 Hip minimal joint space width; chr5:68527946 chr5:68531690~68533530:- LIHC cis rs12450239 0.514 rs35884841 ENSG00000262580.4 RP11-334C17.5 3.64 0.000318 0.0467 0.21 0.19 Body mass index; chr17:79463825 chr17:80200673~80205949:- LIHC cis rs228614 0.536 rs223419 ENSG00000248971.2 KRT8P46 -3.64 0.000318 0.0468 -0.19 -0.19 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102808586 chr4:102728746~102730171:- LIHC cis rs228614 0.536 rs223418 ENSG00000248971.2 KRT8P46 -3.64 0.000318 0.0468 -0.19 -0.19 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102809336 chr4:102728746~102730171:- LIHC cis rs2658782 0.756 rs3019223 ENSG00000279684.1 RP11-755E23.2 -3.64 0.000318 0.0468 -0.33 -0.19 Pulmonary function decline; chr11:93351016 chr11:93286629~93288903:- LIHC cis rs2658782 0.826 rs2925355 ENSG00000279684.1 RP11-755E23.2 -3.64 0.000318 0.0468 -0.33 -0.19 Pulmonary function decline; chr11:93357721 chr11:93286629~93288903:- LIHC cis rs7712401 0.562 rs2407403 ENSG00000263432.2 RN7SL689P 3.64 0.000318 0.0468 0.27 0.19 Mean platelet volume; chr5:122838336 chr5:123022487~123022783:- LIHC cis rs12145833 0.538 rs12026408 ENSG00000253326.2 RP11-261C10.7 -3.64 0.000318 0.0468 -0.4 -0.19 Obesity (early onset extreme); chr1:243203503 chr1:243054861~243056394:- LIHC cis rs694739 0.894 rs887314 ENSG00000236935.1 AP003774.1 3.64 0.000318 0.0468 0.21 0.19 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64285685 chr11:64325050~64329504:- LIHC cis rs720475 0.732 rs17195725 ENSG00000228960.5 OR2A9P 3.64 0.000318 0.0468 0.28 0.19 Breast cancer; chr7:144440044 chr7:144294480~144300934:+ LIHC cis rs2564921 0.666 rs11130335 ENSG00000242142.1 SERBP1P3 -3.64 0.000318 0.0468 -0.26 -0.19 Height; chr3:52989619 chr3:53064283~53065091:- LIHC cis rs4561483 0.801 rs33640 ENSG00000261216.1 RP11-166B2.5 -3.64 0.000318 0.0468 -0.22 -0.19 Testicular germ cell tumor; chr16:11893017 chr16:11908208~11908916:+ LIHC cis rs17376456 0.825 rs7715562 ENSG00000251023.1 RP11-549J18.1 3.64 0.000318 0.0468 0.4 0.19 Diabetic retinopathy; chr5:93886328 chr5:93860669~93863825:- LIHC cis rs2115630 0.875 rs8039472 ENSG00000259295.5 CSPG4P12 -3.64 0.000318 0.0468 -0.23 -0.19 P wave terminal force; chr15:84818413 chr15:85191438~85213905:+ LIHC cis rs875971 0.66 rs12698534 ENSG00000224316.1 RP11-479O9.2 3.64 0.000318 0.0468 0.18 0.19 Aortic root size; chr7:66521858 chr7:65773620~65802067:+ LIHC cis rs875971 0.66 rs62465434 ENSG00000224316.1 RP11-479O9.2 3.64 0.000318 0.0468 0.18 0.19 Aortic root size; chr7:66540165 chr7:65773620~65802067:+ LIHC cis rs875971 0.66 rs13224319 ENSG00000224316.1 RP11-479O9.2 3.64 0.000318 0.0468 0.18 0.19 Aortic root size; chr7:66542376 chr7:65773620~65802067:+ LIHC cis rs875971 0.66 rs801217 ENSG00000224316.1 RP11-479O9.2 -3.64 0.000318 0.0468 -0.18 -0.19 Aortic root size; chr7:66545590 chr7:65773620~65802067:+ LIHC cis rs875971 0.638 rs801216 ENSG00000224316.1 RP11-479O9.2 -3.64 0.000318 0.0468 -0.18 -0.19 Aortic root size; chr7:66546680 chr7:65773620~65802067:+ LIHC cis rs875971 0.66 rs801211 ENSG00000224316.1 RP11-479O9.2 -3.64 0.000318 0.0468 -0.18 -0.19 Aortic root size; chr7:66550702 chr7:65773620~65802067:+ LIHC cis rs875971 0.638 rs801205 ENSG00000224316.1 RP11-479O9.2 -3.64 0.000318 0.0468 -0.18 -0.19 Aortic root size; chr7:66557157 chr7:65773620~65802067:+ LIHC cis rs875971 0.617 rs810400 ENSG00000224316.1 RP11-479O9.2 -3.64 0.000318 0.0468 -0.18 -0.19 Aortic root size; chr7:66557902 chr7:65773620~65802067:+ LIHC cis rs875971 0.638 rs3898855 ENSG00000224316.1 RP11-479O9.2 -3.64 0.000318 0.0468 -0.18 -0.19 Aortic root size; chr7:66571411 chr7:65773620~65802067:+ LIHC cis rs875971 0.638 rs10278816 ENSG00000224316.1 RP11-479O9.2 -3.64 0.000318 0.0468 -0.18 -0.19 Aortic root size; chr7:66572000 chr7:65773620~65802067:+ LIHC cis rs875971 0.66 rs10281080 ENSG00000224316.1 RP11-479O9.2 -3.64 0.000318 0.0468 -0.18 -0.19 Aortic root size; chr7:66577454 chr7:65773620~65802067:+ LIHC cis rs5743030 1 rs733318 ENSG00000253559.1 OSGEPL1-AS1 -3.64 0.000318 0.0468 -0.34 -0.19 Subcutaneous adipose tissue; chr2:189859415 chr2:189762704~189765556:+ LIHC cis rs1979679 0.842 rs11049380 ENSG00000278733.1 RP11-425D17.1 3.64 0.000319 0.0468 0.25 0.19 Ossification of the posterior longitudinal ligament of the spine; chr12:28160904 chr12:28185625~28186190:- LIHC cis rs2243480 1 rs316327 ENSG00000229886.1 RP5-1132H15.3 -3.64 0.000319 0.0468 -0.29 -0.19 Diabetic kidney disease; chr7:66144214 chr7:66025126~66031544:- LIHC cis rs10991814 0.513 rs7852888 ENSG00000273381.1 RP11-305L7.7 3.64 0.000319 0.0468 0.21 0.19 Neutrophil percentage of granulocytes; chr9:91292564 chr9:91206175~91210299:- LIHC cis rs6545883 0.929 rs778155 ENSG00000271889.1 RP11-493E12.1 -3.64 0.000319 0.0468 -0.23 -0.19 Tuberculosis; chr2:61420766 chr2:61151433~61162105:- LIHC cis rs7980687 0.628 rs2851443 ENSG00000256092.2 RP13-942N8.1 3.64 0.000319 0.0468 0.24 0.19 Head circumference (infant);Educational attainment;Height; chr12:123209703 chr12:123363868~123366113:+ LIHC cis rs6545883 0.525 rs1729662 ENSG00000212978.6 AC016747.3 -3.64 0.000319 0.0468 -0.21 -0.19 Tuberculosis; chr2:61164170 chr2:61141592~61144969:- LIHC cis rs79349575 0.715 rs1058018 ENSG00000248278.1 SUMO2P17 3.64 0.000319 0.0468 0.23 0.19 Type 2 diabetes; chr17:48922889 chr17:48874860~48908983:- LIHC cis rs763121 0.853 rs3761454 ENSG00000228274.3 RP3-508I15.9 -3.64 0.000319 0.0468 -0.22 -0.19 Menopause (age at onset); chr22:38670815 chr22:38667585~38681820:- LIHC cis rs2212361 0.527 rs12282965 ENSG00000255893.1 RP11-685N10.1 -3.64 0.000319 0.0469 -0.21 -0.19 Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction); chr11:94528348 chr11:94472908~94473570:- LIHC cis rs12105510 0.638 rs2298944 ENSG00000231172.2 AC007099.1 3.64 0.000319 0.0469 0.24 0.19 Response to platinum-based chemotherapy (cisplatin); chr2:75704927 chr2:75524068~75542706:+ LIHC cis rs7338174 0.655 rs9316535 ENSG00000231856.2 RP11-327P2.5 3.64 0.000319 0.0469 0.35 0.19 Mitochondrial DNA levels; chr13:51329329 chr13:51803838~51813832:+ LIHC cis rs875971 1 rs1167612 ENSG00000232559.3 GS1-124K5.12 -3.64 0.000319 0.0469 -0.16 -0.19 Aortic root size; chr7:66102989 chr7:66554588~66576923:- LIHC cis rs10508774 0.866 rs72784062 ENSG00000273038.2 RP11-479G22.8 3.64 0.000319 0.0469 0.28 0.19 Peripheral arterial disease (traffic-related air pollution interaction); chr10:32905923 chr10:32887255~32889311:- LIHC cis rs6997458 0.785 rs2432083 ENSG00000253549.4 RP11-317J10.2 3.64 0.000319 0.0469 0.22 0.19 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count; chr8:85428379 chr8:85441851~85464915:- LIHC cis rs7674212 0.541 rs2045746 ENSG00000230069.3 LRRC37A15P 3.64 0.000319 0.0469 0.18 0.19 Type 2 diabetes; chr4:103162421 chr4:102727274~102730721:- LIHC cis rs4763879 0.729 rs10844472 ENSG00000256673.1 RP11-599J14.2 3.64 0.00032 0.0469 0.19 0.19 Type 1 diabetes; chr12:9691137 chr12:9398355~9414851:- LIHC cis rs7085142 0.71 rs3943077 ENSG00000227165.6 WDR11-AS1 3.64 0.00032 0.0469 0.25 0.19 Visceral fat; chr10:121185572 chr10:120761812~120851345:- LIHC cis rs7085142 0.71 rs7088428 ENSG00000227165.6 WDR11-AS1 3.64 0.00032 0.0469 0.25 0.19 Visceral fat; chr10:121185738 chr10:120761812~120851345:- LIHC cis rs28472312 0.667 rs9937676 ENSG00000259982.1 CDC37P1 -3.64 0.00032 0.047 -0.2 -0.19 Intelligence (multi-trait analysis); chr16:28958159 chr16:28700294~28701540:- LIHC cis rs6723108 0.627 rs2053727 ENSG00000224043.6 CCNT2-AS1 -3.64 0.00032 0.047 -0.27 -0.19 Type 2 diabetes; chr2:134885728 chr2:134735464~134918710:- LIHC cis rs4792901 0.592 rs57462570 ENSG00000279602.1 CTD-3014M21.1 -3.64 0.00032 0.047 -0.23 -0.19 Dupuytren's disease; chr17:43530611 chr17:43360041~43361361:- LIHC cis rs287982 1 rs2656329 ENSG00000269973.1 RP11-95D17.1 -3.64 0.00032 0.047 -0.18 -0.19 Nonsyndromic cleft lip with cleft palate; chr2:9828215 chr2:9936360~9939590:+ LIHC cis rs2271001 0.911 rs3802796 ENSG00000256464.1 YWHABP2 3.64 0.00032 0.047 0.2 0.19 Gut microbiome composition (winter); chr11:19149474 chr11:18490243~18490955:- LIHC cis rs13315871 0.615 rs13066167 ENSG00000272182.1 RP11-802O23.3 3.64 0.00032 0.047 0.37 0.19 Cholesterol, total; chr3:58354448 chr3:58428255~58428815:+ LIHC cis rs17826219 0.706 rs2322197 ENSG00000264538.5 SUZ12P1 -3.64 0.00032 0.047 -0.2 -0.19 Body mass index; chr17:30778787 chr17:30709299~30790908:+ LIHC cis rs5769707 0.967 rs9616327 ENSG00000279345.1 RP3-522J7.7 -3.64 0.00032 0.047 -0.17 -0.19 Monocyte percentage of white cells;Monocyte count; chr22:49617243 chr22:49805452~49807208:+ LIHC cis rs8064024 0.676 rs56919624 ENSG00000267077.1 RP11-127I20.5 3.64 0.00032 0.047 0.2 0.19 Cancer; chr16:4827592 chr16:4795265~4796532:- LIHC cis rs6545883 0.929 rs9679557 ENSG00000273302.1 RP11-493E12.2 3.64 0.00032 0.047 0.21 0.19 Tuberculosis; chr2:61482214 chr2:61199979~61200769:+ LIHC cis rs9876781 1 rs10470686 ENSG00000229759.1 MRPS18AP1 3.64 0.00032 0.047 0.2 0.19 Longevity; chr3:48408549 chr3:48256350~48256938:- LIHC cis rs2658782 1 rs2019814 ENSG00000279684.1 RP11-755E23.2 -3.64 0.00032 0.047 -0.35 -0.19 Pulmonary function decline; chr11:93435719 chr11:93286629~93288903:- LIHC cis rs7620503 0.613 rs11715814 ENSG00000228561.2 RP11-114M1.1 -3.64 0.00032 0.0471 -0.21 -0.19 Corneal structure; chr3:177562207 chr3:177683627~177691250:+ LIHC cis rs10400419 1 rs10400419 ENSG00000239335.4 LLPH-AS1 3.64 0.000321 0.0471 0.24 0.19 Axial length; chr12:65996188 chr12:66130751~66134449:+ LIHC cis rs875971 0.66 rs7807944 ENSG00000237310.1 GS1-124K5.4 -3.64 0.000321 0.0471 -0.18 -0.19 Aortic root size; chr7:66622208 chr7:66493706~66495474:+ LIHC cis rs643506 0.874 rs618421 ENSG00000230911.1 PPIHP1 -3.64 0.000321 0.0471 -0.26 -0.19 Breast cancer; chr11:111778085 chr11:112029858~112030367:- LIHC cis rs7712401 0.601 rs438196 ENSG00000263432.2 RN7SL689P 3.64 0.000321 0.0471 0.29 0.19 Mean platelet volume; chr5:122927368 chr5:123022487~123022783:- LIHC cis rs7712401 0.562 rs401729 ENSG00000263432.2 RN7SL689P 3.64 0.000321 0.0471 0.29 0.19 Mean platelet volume; chr5:122928590 chr5:123022487~123022783:- LIHC cis rs7712401 0.601 rs2910140 ENSG00000263432.2 RN7SL689P 3.64 0.000321 0.0471 0.29 0.19 Mean platelet volume; chr5:122928700 chr5:123022487~123022783:- LIHC cis rs11133665 0.683 rs7719875 ENSG00000249201.2 CTD-3080P12.3 -3.63 0.000321 0.0471 -0.21 -0.19 Urinary metabolites; chr5:1189973 chr5:1173141~1178605:- LIHC cis rs944990 0.538 rs10761234 ENSG00000227603.1 RP11-165J3.6 3.63 0.000321 0.0471 0.21 0.19 Body mass index; chr9:93545230 chr9:93435332~93437121:- LIHC cis rs7712401 0.642 rs17388251 ENSG00000263432.2 RN7SL689P 3.63 0.000321 0.0471 0.25 0.19 Mean platelet volume; chr5:123024708 chr5:123022487~123022783:- LIHC cis rs797680 0.964 rs4847398 ENSG00000229567.1 RP4-717I23.2 -3.63 0.000321 0.0471 -0.24 -0.19 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93112845 chr1:93278961~93279129:- LIHC cis rs367615 0.918 rs10067984 ENSG00000249476.1 CTD-2587M2.1 3.63 0.000321 0.0471 0.24 0.19 Colorectal cancer (SNP x SNP interaction); chr5:109536983 chr5:109237120~109326369:- LIHC cis rs3096299 0.606 rs2965960 ENSG00000274627.1 RP11-104N10.2 3.63 0.000321 0.0471 0.22 0.19 Multiple myeloma (IgH translocation); chr16:89475387 chr16:89516797~89522217:+ LIHC cis rs916888 0.531 rs183211 ENSG00000262881.1 RP11-669E14.4 -3.63 0.000321 0.0471 -0.2 -0.19 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:45907670~45910779:- LIHC cis rs35160687 0.712 rs2303359 ENSG00000231259.4 AC125232.1 -3.63 0.000321 0.0472 -0.2 -0.19 Night sleep phenotypes; chr2:86251547 chr2:87031815~87053069:- LIHC cis rs2998286 0.723 rs2807729 ENSG00000254635.4 WAC-AS1 3.63 0.000321 0.0472 0.27 0.19 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28526427 chr10:28522652~28532743:- LIHC cis rs2554380 0.55 rs12904106 ENSG00000225151.9 GOLGA2P7 -3.63 0.000321 0.0472 -0.3 -0.19 Height; chr15:83842571 chr15:84199311~84230136:- LIHC cis rs6048205 0.881 rs1203873 ENSG00000259974.2 LINC00261 -3.63 0.000322 0.0472 -0.28 -0.19 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22557295 chr20:22547671~22578642:- LIHC cis rs17376456 0.825 rs12188163 ENSG00000251023.1 RP11-549J18.1 3.63 0.000322 0.0472 0.4 0.19 Diabetic retinopathy; chr5:93914903 chr5:93860669~93863825:- LIHC cis rs9309473 0.5 rs12997018 ENSG00000273245.1 RP11-434P11.2 -3.63 0.000322 0.0472 -0.23 -0.19 Metabolite levels; chr2:73685772 chr2:73750256~73750786:- LIHC cis rs6723108 0.627 rs7593370 ENSG00000224043.6 CCNT2-AS1 3.63 0.000322 0.0472 0.26 0.19 Type 2 diabetes; chr2:134865947 chr2:134735464~134918710:- LIHC cis rs14027 0.512 rs6997976 ENSG00000279347.1 RP11-85I17.2 3.63 0.000322 0.0472 0.18 0.19 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr8:119722044 chr8:119838736~119840385:- LIHC cis rs853679 0.825 rs8180562 ENSG00000219891.2 ZSCAN12P1 3.63 0.000322 0.0472 0.36 0.19 Depression; chr6:28173682 chr6:28091154~28093664:+ LIHC cis rs853679 0.882 rs9380064 ENSG00000219891.2 ZSCAN12P1 3.63 0.000322 0.0472 0.36 0.19 Depression; chr6:28175340 chr6:28091154~28093664:+ LIHC cis rs2797160 1 rs1935772 ENSG00000237742.5 RP11-624M8.1 -3.63 0.000322 0.0472 -0.19 -0.19 Endometrial cancer; chr6:125673562 chr6:125578558~125749190:- LIHC cis rs6674176 0.597 rs4660262 ENSG00000237950.1 RP11-7O11.3 3.63 0.000322 0.0472 0.2 0.19 Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr1:43916852 chr1:43944370~43946551:- LIHC cis rs2762353 0.808 rs1165176 ENSG00000242387.1 HIST1H2APS2 3.63 0.000322 0.0472 0.22 0.19 Blood metabolite levels; chr6:25830070 chr6:25882026~25882395:- LIHC cis rs2762353 0.808 rs1185569 ENSG00000242387.1 HIST1H2APS2 3.63 0.000322 0.0472 0.22 0.19 Blood metabolite levels; chr6:25831375 chr6:25882026~25882395:- LIHC cis rs2762353 0.808 rs1185568 ENSG00000242387.1 HIST1H2APS2 3.63 0.000322 0.0472 0.22 0.19 Blood metabolite levels; chr6:25834200 chr6:25882026~25882395:- LIHC cis rs2762353 0.808 rs1185153 ENSG00000242387.1 HIST1H2APS2 3.63 0.000322 0.0472 0.22 0.19 Blood metabolite levels; chr6:25834320 chr6:25882026~25882395:- LIHC cis rs2762353 0.808 rs1184803 ENSG00000242387.1 HIST1H2APS2 3.63 0.000322 0.0472 0.22 0.19 Blood metabolite levels; chr6:25834430 chr6:25882026~25882395:- LIHC cis rs2762353 0.808 rs1185978 ENSG00000242387.1 HIST1H2APS2 3.63 0.000322 0.0472 0.22 0.19 Blood metabolite levels; chr6:25835667 chr6:25882026~25882395:- LIHC cis rs2762353 0.779 rs1165182 ENSG00000242387.1 HIST1H2APS2 3.63 0.000322 0.0472 0.22 0.19 Blood metabolite levels; chr6:25837601 chr6:25882026~25882395:- LIHC cis rs10895987 1 rs9971407 ENSG00000254614.2 AP003068.23 3.63 0.000322 0.0472 0.35 0.19 Blood protein levels; chr11:65130754 chr11:65177606~65181834:- LIHC cis rs10895987 1 rs11227126 ENSG00000254614.2 AP003068.23 3.63 0.000322 0.0472 0.35 0.19 Blood protein levels; chr11:65140591 chr11:65177606~65181834:- LIHC cis rs7219021 0.518 rs6504584 ENSG00000248278.1 SUMO2P17 -3.63 0.000322 0.0472 -0.25 -0.19 Schizophrenia or bipolar disorder; chr17:48864057 chr17:48874860~48908983:- LIHC cis rs2243480 1 rs35820085 ENSG00000226002.1 RP11-460N20.5 -3.63 0.000322 0.0472 -0.29 -0.19 Diabetic kidney disease; chr7:65977771 chr7:65084103~65100232:+ LIHC cis rs12145833 0.538 rs61833885 ENSG00000214837.7 LINC01347 -3.63 0.000322 0.0473 -0.27 -0.19 Obesity (early onset extreme); chr1:243233886 chr1:243056307~243101744:- LIHC cis rs9611519 1 rs5758268 ENSG00000232710.1 RP4-669P10.16 3.63 0.000322 0.0473 0.22 0.19 Neuroticism; chr22:41226415 chr22:42136433~42139927:- LIHC cis rs6504622 0.557 rs7225428 ENSG00000263766.4 RP11-580I16.2 3.63 0.000322 0.0473 0.22 0.19 Orofacial clefts; chr17:46923631 chr17:47603860~47649420:- LIHC cis rs6504622 0.577 rs35707546 ENSG00000263766.4 RP11-580I16.2 3.63 0.000322 0.0473 0.22 0.19 Orofacial clefts; chr17:46924175 chr17:47603860~47649420:- LIHC cis rs2098713 0.535 rs56044522 ENSG00000250155.1 CTD-2353F22.1 3.63 0.000322 0.0473 0.19 0.19 Telomere length; chr5:37582698 chr5:36666214~36725195:- LIHC cis rs2115630 0.905 rs1975277 ENSG00000189136.7 UBE2Q2P1 -3.63 0.000322 0.0473 -0.15 -0.19 P wave terminal force; chr15:84786327 chr15:84526781~84571216:- LIHC cis rs9649213 0.593 rs6973775 ENSG00000272950.1 RP11-307C18.1 3.63 0.000322 0.0473 0.23 0.19 Prostate cancer (SNP x SNP interaction); chr7:98375373 chr7:98322853~98323430:+ LIHC cis rs6142102 0.812 rs725478 ENSG00000275784.1 RP5-1125A11.6 3.63 0.000323 0.0473 0.22 0.19 Skin pigmentation; chr20:33930548 chr20:33989480~33991818:- LIHC cis rs9847710 0.933 rs1529544 ENSG00000242797.3 GLYCTK-AS1 3.63 0.000323 0.0473 0.2 0.19 Ulcerative colitis; chr3:53005439 chr3:52288580~52299067:- LIHC cis rs709400 0.93 rs10134399 ENSG00000269958.1 RP11-73M18.8 3.63 0.000323 0.0473 0.26 0.19 Body mass index; chr14:103617120 chr14:103696353~103697163:+ LIHC cis rs8046148 0.724 rs2058815 ENSG00000279356.1 RP11-429P3.8 3.63 0.000323 0.0473 0.19 0.19 Testicular germ cell tumor; chr16:50024308 chr16:50072862~50074986:+ LIHC cis rs7915414 0.543 rs1074145 ENSG00000230338.1 MTND4P19 3.63 0.000323 0.0473 0.23 0.19 Clopidogrel active metabolite levels; chr10:94922089 chr10:94774156~94774633:- LIHC cis rs2299116 0.695 rs7787400 ENSG00000225264.3 ZNRF2P2 -3.63 0.000323 0.0473 -0.21 -0.19 Serum thyroid-stimulating hormone levels; chr7:28792341 chr7:29598795~29685255:- LIHC cis rs17376456 0.825 rs10053405 ENSG00000251023.1 RP11-549J18.1 3.63 0.000323 0.0473 0.38 0.19 Diabetic retinopathy; chr5:93939698 chr5:93860669~93863825:- LIHC cis rs8177253 1 rs1525892 ENSG00000244062.1 RP11-404G16.2 3.63 0.000323 0.0474 0.2 0.19 Iron status biomarkers; chr3:133765868 chr3:133760300~133762363:+ LIHC cis rs4650994 1 rs4650999 ENSG00000273384.1 RP5-1098D14.1 -3.63 0.000323 0.0474 -0.23 -0.19 HDL cholesterol;HDL cholesterol levels; chr1:178563053 chr1:178651706~178652282:+ LIHC cis rs481331 0.689 rs644175 ENSG00000185904.10 LINC00839 -3.63 0.000323 0.0474 -0.36 -0.19 Systemic juvenile idiopathic arthritis; chr10:42703860 chr10:42475543~42495336:+ LIHC cis rs494562 0.892 rs617483 ENSG00000234155.1 RP11-30P6.6 -3.63 0.000323 0.0474 -0.41 -0.19 Metabolic traits;Blood metabolite levels; chr6:85414290 chr6:85387219~85390186:- LIHC cis rs6436017 0.589 rs1424918 ENSG00000237281.1 CATIP-AS2 3.63 0.000323 0.0474 0.23 0.19 Breast cancer; chr2:217876772 chr2:218326889~218357966:- LIHC cis rs4792901 0.802 rs56357945 ENSG00000279602.1 CTD-3014M21.1 -3.63 0.000323 0.0474 -0.23 -0.19 Dupuytren's disease; chr17:43536323 chr17:43360041~43361361:- LIHC cis rs10129255 1 rs10129255 ENSG00000211972.2 IGHV3-66 -3.63 0.000323 0.0474 -0.15 -0.19 Kawasaki disease; chr14:106767970 chr14:106675017~106675544:- LIHC cis rs4648045 0.647 rs3774933 ENSG00000230069.3 LRRC37A15P -3.63 0.000324 0.0474 -0.18 -0.19 Lymphocyte percentage of white cells; chr4:102505182 chr4:102727274~102730721:- LIHC cis rs8087799 0.83 rs9646515 ENSG00000273232.1 RP11-370A5.2 3.63 0.000324 0.0474 0.23 0.19 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22597909 chr18:22882825~22883357:- LIHC cis rs13113518 0.595 rs13120635 ENSG00000249700.7 SRD5A3-AS1 3.63 0.000324 0.0474 0.22 0.19 Height; chr4:55361200 chr4:55363971~55395847:- LIHC cis rs5743467 1 rs5743467 ENSG00000246089.3 RP11-115C21.2 3.63 0.000324 0.0474 0.29 0.19 Plasma kynurenine to tryptophan ratio in major depressive disorder;Plasma kynurenine levels in major depressive disorder; chr8:6874007 chr8:6403551~6407142:- LIHC cis rs172166 0.637 rs1225597 ENSG00000216901.1 AL022393.7 3.63 0.000324 0.0474 0.24 0.19 Cardiac Troponin-T levels; chr6:28194309 chr6:28176188~28176674:+ LIHC cis rs172166 0.637 rs1071893 ENSG00000216901.1 AL022393.7 3.63 0.000324 0.0474 0.24 0.19 Cardiac Troponin-T levels; chr6:28199857 chr6:28176188~28176674:+ LIHC cis rs9951150 0.537 rs34704187 ENSG00000267013.4 CTD-2171N6.1 3.63 0.000324 0.0475 0.26 0.19 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55133159 chr18:55105904~55124306:- LIHC cis rs763121 0.819 rs4560233 ENSG00000273076.1 RP3-508I15.22 3.63 0.000324 0.0475 0.23 0.19 Menopause (age at onset); chr22:38586437 chr22:38743495~38743910:+ LIHC cis rs16902947 0.617 rs72746429 ENSG00000245711.2 NADK2-AS1 3.63 0.000324 0.0475 0.17 0.19 Serum tamsulosin hydrochloride concentration; chr5:36351513 chr5:36221055~36221902:+ LIHC cis rs2243480 0.908 rs4718273 ENSG00000275400.1 RP4-756H11.5 -3.63 0.000324 0.0475 -0.26 -0.19 Diabetic kidney disease; chr7:65751112 chr7:66553805~66554199:- LIHC cis rs9595908 0.709 rs1924606 ENSG00000212293.1 SNORA16 3.63 0.000324 0.0475 0.22 0.19 Body mass index; chr13:32759230 chr13:32420390~32420516:- LIHC cis rs875971 0.66 rs79009421 ENSG00000237310.1 GS1-124K5.4 -3.63 0.000324 0.0475 -0.18 -0.19 Aortic root size; chr7:66603522 chr7:66493706~66495474:+ LIHC cis rs875971 0.66 rs6460308 ENSG00000237310.1 GS1-124K5.4 -3.63 0.000324 0.0475 -0.18 -0.19 Aortic root size; chr7:66619753 chr7:66493706~66495474:+ LIHC cis rs797680 0.964 rs1932314 ENSG00000229567.1 RP4-717I23.2 -3.63 0.000324 0.0475 -0.23 -0.19 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93172843 chr1:93278961~93279129:- LIHC cis rs11672691 0.792 rs7248215 ENSG00000270164.1 LINC01480 -3.63 0.000324 0.0475 -0.19 -0.19 Prostate cancer; chr19:41493212 chr19:41535183~41536904:+ LIHC cis rs801193 0.844 rs732465 ENSG00000224316.1 RP11-479O9.2 3.63 0.000324 0.0475 0.18 0.19 Aortic root size; chr7:66533463 chr7:65773620~65802067:+ LIHC cis rs4648045 0.582 rs2168805 ENSG00000230069.3 LRRC37A15P -3.63 0.000324 0.0475 -0.17 -0.19 Lymphocyte percentage of white cells; chr4:102489877 chr4:102727274~102730721:- LIHC cis rs4648045 0.598 rs6833745 ENSG00000230069.3 LRRC37A15P -3.63 0.000324 0.0475 -0.17 -0.19 Lymphocyte percentage of white cells; chr4:102494665 chr4:102727274~102730721:- LIHC cis rs10503709 0.896 rs7010418 ENSG00000251034.1 RP11-582J16.4 -3.63 0.000325 0.0475 -0.21 -0.19 Blood protein levels; chr8:21604069 chr8:22540845~22545405:- LIHC cis rs301901 0.796 rs6872681 ENSG00000250155.1 CTD-2353F22.1 3.63 0.000325 0.0475 0.19 0.19 Height; chr5:37535278 chr5:36666214~36725195:- LIHC cis rs301901 0.761 rs1533521 ENSG00000250155.1 CTD-2353F22.1 3.63 0.000325 0.0475 0.19 0.19 Height; chr5:37540355 chr5:36666214~36725195:- LIHC cis rs61824320 0.575 rs10910235 ENSG00000231768.1 LINC01354 3.63 0.000325 0.0476 0.22 0.19 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr1:233645588 chr1:234527891~234531779:- LIHC cis rs2348418 0.932 rs61922464 ENSG00000247934.4 RP11-967K21.1 3.63 0.000325 0.0476 0.17 0.19 Lung function (FEV1);Lung function (FVC); chr12:28485665 chr12:28163298~28190738:- LIHC cis rs2348418 0.932 rs11049661 ENSG00000247934.4 RP11-967K21.1 3.63 0.000325 0.0476 0.17 0.19 Lung function (FEV1);Lung function (FVC); chr12:28486215 chr12:28163298~28190738:- LIHC cis rs2348418 0.932 rs11049662 ENSG00000247934.4 RP11-967K21.1 3.63 0.000325 0.0476 0.17 0.19 Lung function (FEV1);Lung function (FVC); chr12:28487344 chr12:28163298~28190738:- LIHC cis rs2348418 0.932 rs7306581 ENSG00000247934.4 RP11-967K21.1 3.63 0.000325 0.0476 0.17 0.19 Lung function (FEV1);Lung function (FVC); chr12:28488641 chr12:28163298~28190738:- LIHC cis rs11089937 0.626 rs9619800 ENSG00000211639.2 IGLV4-60 3.63 0.000325 0.0476 0.18 0.19 Periodontitis (PAL4Q3); chr22:22141088 chr22:22162199~22162681:+ LIHC cis rs858239 0.669 rs1006709 ENSG00000226816.2 AC005082.12 3.63 0.000325 0.0476 0.23 0.19 Cerebrospinal fluid biomarker levels; chr7:23100480 chr7:23206013~23208045:+ LIHC cis rs6723226 0.598 rs2710629 ENSG00000276334.1 AL133243.1 3.63 0.000325 0.0476 0.21 0.19 Intelligence (multi-trait analysis); chr2:32540777 chr2:32521927~32523547:+ LIHC cis rs2348418 0.868 rs12302861 ENSG00000247934.4 RP11-967K21.1 3.63 0.000325 0.0476 0.18 0.19 Lung function (FEV1);Lung function (FVC); chr12:28516269 chr12:28163298~28190738:- LIHC cis rs9929218 0.551 rs2274240 ENSG00000260459.2 FTLP14 3.63 0.000325 0.0476 0.22 0.19 Colorectal cancer; chr16:68691583 chr16:68822587~68823070:+ LIHC cis rs6545883 0.801 rs778142 ENSG00000271889.1 RP11-493E12.1 3.63 0.000325 0.0476 0.23 0.19 Tuberculosis; chr2:61454293 chr2:61151433~61162105:- LIHC cis rs12586317 0.586 rs74243590 ENSG00000257307.1 RP11-317N8.4 -3.63 0.000325 0.0476 -0.23 -0.19 Psoriasis; chr14:35044040 chr14:35881001~35881709:+ LIHC cis rs5758511 0.68 rs739147 ENSG00000273366.1 CTA-989H11.1 3.63 0.000325 0.0476 0.25 0.19 Birth weight; chr22:42275060 chr22:42278188~42278846:+ LIHC cis rs74181299 0.75 rs13421845 ENSG00000225889.6 AC074289.1 3.63 0.000325 0.0476 0.21 0.19 Pulse pressure; chr2:65108899 chr2:64143239~64252859:+ LIHC cis rs9747201 1 rs9303020 ENSG00000279692.1 RP11-1055B8.1 3.63 0.000325 0.0476 0.33 0.19 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82205371 chr17:81395609~81397144:- LIHC cis rs10256972 0.527 rs28671326 ENSG00000199023.2 MIR339 -3.63 0.000326 0.0476 -0.22 -0.19 Endometriosis;Longevity; chr7:1135337 chr7:1022935~1023045:- LIHC cis rs6569038 0.502 rs4946383 ENSG00000253194.1 RP11-351A11.1 3.63 0.000326 0.0476 0.26 0.19 Epstein-Barr virus copy number in lymphoblastoid cell lines; chr6:118983460 chr6:118934785~119031541:+ LIHC cis rs6569038 0.502 rs2357020 ENSG00000253194.1 RP11-351A11.1 3.63 0.000326 0.0476 0.26 0.19 Epstein-Barr virus copy number in lymphoblastoid cell lines; chr6:118986644 chr6:118934785~119031541:+ LIHC cis rs950169 0.686 rs12906474 ENSG00000189136.7 UBE2Q2P1 3.63 0.000326 0.0477 0.18 0.19 Schizophrenia; chr15:84566006 chr15:84526781~84571216:- LIHC cis rs950169 0.81 rs2879976 ENSG00000189136.7 UBE2Q2P1 3.63 0.000326 0.0477 0.18 0.19 Schizophrenia; chr15:84566347 chr15:84526781~84571216:- LIHC cis rs12639258 0.961 rs6441999 ENSG00000273682.1 RP11-427P5.3 -3.63 0.000326 0.0477 -0.33 -0.19 Eotaxin levels; chr3:46475810 chr3:46918807~46918935:- LIHC cis rs2554380 0.55 rs6602997 ENSG00000225151.9 GOLGA2P7 -3.63 0.000326 0.0477 -0.29 -0.19 Height; chr15:83852646 chr15:84199311~84230136:- LIHC cis rs4356975 0.583 rs62296935 ENSG00000250919.1 RP11-813N20.3 -3.63 0.000326 0.0477 -0.2 -0.19 Obesity-related traits; chr4:69082878 chr4:69027831~69044578:+ LIHC cis rs4356975 0.563 rs62296936 ENSG00000250919.1 RP11-813N20.3 -3.63 0.000326 0.0477 -0.2 -0.19 Obesity-related traits; chr4:69082903 chr4:69027831~69044578:+ LIHC cis rs2439831 0.541 rs12440854 ENSG00000205771.5 CATSPER2P1 -3.63 0.000326 0.0477 -0.33 -0.19 Lung cancer in ever smokers; chr15:43318474 chr15:43726918~43747094:- LIHC cis rs6828577 0.862 rs298998 ENSG00000269893.5 SNHG8 -3.63 0.000326 0.0477 -0.19 -0.19 Perioperative myocardial infarction in coronary artery bypass surgery; chr4:118702312 chr4:118278709~118279823:+ LIHC cis rs2742417 0.603 rs2742456 ENSG00000244357.3 RN7SL145P 3.63 0.000326 0.0477 0.19 0.19 Response to anti-depressant treatment in major depressive disorder; chr3:45725684 chr3:45742675~45742970:+ LIHC cis rs67311347 1 rs4973998 ENSG00000223797.4 ENTPD3-AS1 3.63 0.000326 0.0477 0.16 0.19 Renal cell carcinoma; chr3:40418861 chr3:40313802~40453329:- LIHC cis rs8037137 0.822 rs2890156 ENSG00000258725.1 PRC1-AS1 -3.63 0.000326 0.0477 -0.24 -0.19 Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr15:90969927 chr15:90966345~90988624:+ LIHC cis rs10774547 1 rs10774547 ENSG00000278344.1 RP11-18C24.8 3.63 0.000326 0.0477 0.23 0.19 Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);Reading disability or specific language impairment (pleiotropy); chr12:120424913 chr12:120500735~120501090:- LIHC cis rs6496667 0.557 rs2589951 ENSG00000213471.7 TTLL13P 3.63 0.000326 0.0477 0.25 0.19 Rheumatoid arthritis; chr15:90415160 chr15:90249530~90265482:+ LIHC cis rs301901 0.796 rs11742177 ENSG00000250155.1 CTD-2353F22.1 3.63 0.000326 0.0477 0.19 0.19 Height; chr5:37504063 chr5:36666214~36725195:- LIHC cis rs301901 0.796 rs1829292 ENSG00000250155.1 CTD-2353F22.1 3.63 0.000326 0.0477 0.19 0.19 Height; chr5:37505544 chr5:36666214~36725195:- LIHC cis rs9595908 0.669 rs9285094 ENSG00000212293.1 SNORA16 3.63 0.000326 0.0477 0.22 0.19 Body mass index; chr13:32761453 chr13:32420390~32420516:- LIHC cis rs4891159 0.79 rs690619 ENSG00000265778.2 RP11-17M16.2 3.63 0.000326 0.0477 0.24 0.19 Longevity; chr18:76396788 chr18:76491652~76493918:+ LIHC cis rs2120243 0.874 rs7616177 ENSG00000244515.1 KRT18P34 -3.63 0.000326 0.0477 -0.18 -0.19 Hepatocellular carcinoma in hepatitis B infection; chr3:157435419 chr3:157162663~157163932:- LIHC cis rs9640161 0.659 rs7806429 ENSG00000261305.1 RP4-584D14.7 3.63 0.000326 0.0477 0.22 0.19 Blood protein levels;Circulating chemerin levels; chr7:150316304 chr7:150341771~150342607:+ LIHC cis rs12681287 0.517 rs13249753 ENSG00000254088.1 SLC2A3P4 3.63 0.000326 0.0477 0.23 0.19 Caudate activity during reward; chr8:86500987 chr8:86503591~86505061:+ LIHC cis rs875971 0.545 rs4718325 ENSG00000273024.4 INTS4P2 -3.63 0.000326 0.0477 -0.22 -0.19 Aortic root size; chr7:66215323 chr7:65647864~65715661:+ LIHC cis rs1023500 0.573 rs13057094 ENSG00000226450.2 CYP2D8P 3.63 0.000326 0.0478 0.24 0.19 Schizophrenia; chr22:42074313 chr22:42149886~42155001:- LIHC cis rs7674212 0.581 rs13150953 ENSG00000246560.2 RP11-10L12.4 3.63 0.000327 0.0478 0.23 0.19 Type 2 diabetes; chr4:103021341 chr4:102828055~102844075:+ LIHC cis rs7674212 0.556 rs13151569 ENSG00000246560.2 RP11-10L12.4 3.63 0.000327 0.0478 0.23 0.19 Type 2 diabetes; chr4:103021633 chr4:102828055~102844075:+ LIHC cis rs17767392 0.881 rs35625243 ENSG00000274818.1 RP1-292L20.3 3.63 0.000327 0.0478 0.29 0.19 Mitral valve prolapse; chr14:71478220 chr14:70906657~70907111:- LIHC cis rs1062177 0.855 rs1346489 ENSG00000253921.1 CTB-113P19.3 -3.63 0.000327 0.0478 -0.21 -0.19 Preschool internalizing problems; chr5:151886973 chr5:151753992~151767247:+ LIHC cis rs2243480 0.706 rs6460257 ENSG00000232559.3 GS1-124K5.12 3.63 0.000327 0.0478 0.19 0.19 Diabetic kidney disease; chr7:65731813 chr7:66554588~66576923:- LIHC cis rs812481 0.62 rs11706832 ENSG00000241884.2 RP11-85I21.1 3.63 0.000327 0.0478 0.23 0.19 Colorectal cancer; chr3:66452557 chr3:67296300~67306359:+ LIHC cis rs17818399 0.815 rs62136873 ENSG00000239332.4 LINC01119 -3.63 0.000327 0.0478 -0.27 -0.19 Height; chr2:46634098 chr2:46816697~46859007:+ LIHC cis rs3213758 0.541 rs7192060 ENSG00000275191.1 RP11-36I17.2 3.63 0.000327 0.0478 0.24 0.19 Vitiligo (non-segmental); chr16:53658287 chr16:53628256~53628816:- LIHC cis rs4578769 0.681 rs6507455 ENSG00000266850.1 RP11-370A5.1 3.63 0.000327 0.0478 0.23 0.19 Eosinophil percentage of white cells; chr18:23032669 chr18:22723491~22907721:- LIHC cis rs3733589 0.744 rs13101688 ENSG00000250413.1 RP11-448G15.1 3.63 0.000327 0.0478 0.33 0.19 Renal overload gout; chr4:9951387 chr4:10006482~10009725:+ LIHC cis rs9876781 1 rs9883759 ENSG00000229759.1 MRPS18AP1 3.63 0.000327 0.0478 0.2 0.19 Longevity; chr3:48422209 chr3:48256350~48256938:- LIHC cis rs9876781 1 rs6442120 ENSG00000229759.1 MRPS18AP1 3.63 0.000327 0.0478 0.2 0.19 Longevity; chr3:48423094 chr3:48256350~48256938:- LIHC cis rs9876781 0.9 rs1037773 ENSG00000229759.1 MRPS18AP1 3.63 0.000327 0.0478 0.2 0.19 Longevity; chr3:48426493 chr3:48256350~48256938:- LIHC cis rs9876781 1 rs2279077 ENSG00000229759.1 MRPS18AP1 3.63 0.000327 0.0478 0.2 0.19 Longevity; chr3:48432839 chr3:48256350~48256938:- LIHC cis rs4919694 1 rs77969925 ENSG00000236937.2 PTGES3P4 3.63 0.000327 0.0478 0.36 0.19 Arsenic metabolism; chr10:102889600 chr10:102845595~102845950:+ LIHC cis rs1005277 0.579 rs2474568 ENSG00000099251.13 HSD17B7P2 3.63 0.000327 0.0478 0.22 0.19 Extrinsic epigenetic age acceleration; chr10:38094219 chr10:38356380~38378505:+ LIHC cis rs11637445 1 rs11637445 ENSG00000260657.2 RP11-315D16.4 3.63 0.000327 0.0478 0.3 0.19 Posterior cortical atrophy and Alzheimer's disease; chr15:67699268 chr15:68267792~68277994:- LIHC cis rs11064837 0.511 rs278154 ENSG00000248636.5 RP11-768F21.1 3.63 0.000327 0.0478 0.33 0.19 Schizophrenia; chr12:119683245 chr12:119387987~119668079:- LIHC cis rs6545883 0.965 rs6734830 ENSG00000271889.1 RP11-493E12.1 3.63 0.000327 0.0479 0.23 0.19 Tuberculosis; chr2:61503977 chr2:61151433~61162105:- LIHC cis rs7095607 1 rs4745948 ENSG00000233590.1 RP11-153K11.3 3.63 0.000327 0.0479 0.23 0.19 Lung function (FVC); chr10:68178230 chr10:68233251~68242379:- LIHC cis rs7095607 1 rs4480432 ENSG00000233590.1 RP11-153K11.3 3.63 0.000327 0.0479 0.23 0.19 Lung function (FVC); chr10:68178908 chr10:68233251~68242379:- LIHC cis rs7095607 1 rs7096254 ENSG00000233590.1 RP11-153K11.3 3.63 0.000327 0.0479 0.23 0.19 Lung function (FVC); chr10:68180149 chr10:68233251~68242379:- LIHC cis rs7095607 1 rs7096686 ENSG00000233590.1 RP11-153K11.3 3.63 0.000327 0.0479 0.23 0.19 Lung function (FVC); chr10:68180481 chr10:68233251~68242379:- LIHC cis rs734999 0.545 rs12749591 ENSG00000225931.3 RP3-395M20.7 -3.63 0.000327 0.0479 -0.2 -0.19 Ulcerative colitis; chr1:2631811 chr1:2566410~2569888:+ LIHC cis rs1499614 1 rs1638731 ENSG00000232559.3 GS1-124K5.12 3.63 0.000328 0.0479 0.21 0.19 Gout; chr7:66679692 chr7:66554588~66576923:- LIHC cis rs1499614 1 rs1882655 ENSG00000232559.3 GS1-124K5.12 -3.63 0.000328 0.0479 -0.21 -0.19 Gout; chr7:66682070 chr7:66554588~66576923:- LIHC cis rs1499614 0.831 rs3800822 ENSG00000232559.3 GS1-124K5.12 -3.63 0.000328 0.0479 -0.21 -0.19 Gout; chr7:66682162 chr7:66554588~66576923:- LIHC cis rs1115240 1 rs12050159 ENSG00000257842.4 NOVA1-AS1 -3.63 0.000328 0.0479 -0.18 -0.19 Educational attainment (years of education); chr14:26604499 chr14:26598412~26806467:+ LIHC cis rs9595908 0.869 rs9591191 ENSG00000212293.1 SNORA16 3.63 0.000328 0.0479 0.22 0.19 Body mass index; chr13:32633397 chr13:32420390~32420516:- LIHC cis rs10129255 0.5 rs2027903 ENSG00000211972.2 IGHV3-66 3.63 0.000328 0.0479 0.15 0.19 Kawasaki disease; chr14:106807047 chr14:106675017~106675544:- LIHC cis rs4578769 0.765 rs11082147 ENSG00000265943.1 RP11-739L10.1 -3.63 0.000328 0.0479 -0.25 -0.19 Eosinophil percentage of white cells; chr18:22806559 chr18:22699481~22933764:- LIHC cis rs6732160 0.845 rs6546805 ENSG00000272702.1 RP11-44N22.3 3.63 0.000328 0.0479 0.21 0.19 Intelligence (multi-trait analysis); chr2:73158987 chr2:73113018~73115907:+ LIHC cis rs76648483 0.62 rs7177355 ENSG00000278600.1 RP11-81A1.6 -3.63 0.000328 0.0479 -0.19 -0.19 Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells; chr15:79975086 chr15:79920195~79922455:- LIHC cis rs8046148 0.694 rs2041920 ENSG00000279356.1 RP11-429P3.8 3.63 0.000328 0.0479 0.19 0.19 Testicular germ cell tumor; chr16:50034511 chr16:50072862~50074986:+ LIHC cis rs8046148 0.724 rs2160568 ENSG00000279356.1 RP11-429P3.8 3.63 0.000328 0.0479 0.19 0.19 Testicular germ cell tumor; chr16:50034534 chr16:50072862~50074986:+ LIHC cis rs2739330 0.828 rs2330635 ENSG00000228039.3 KB-1125A3.10 3.63 0.000328 0.0479 0.23 0.19 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23963780~23964374:+ LIHC cis rs7396835 0.537 rs10892035 ENSG00000280143.1 AP000892.6 3.63 0.000328 0.0479 0.23 0.19 Quantitative traits; chr11:116824222 chr11:117204967~117210292:+ LIHC cis rs5742933 0.803 rs1233302 ENSG00000253559.1 OSGEPL1-AS1 -3.63 0.000328 0.0479 -0.25 -0.19 Ferritin levels; chr2:189804154 chr2:189762704~189765556:+ LIHC cis rs67601088 1 rs67601088 ENSG00000235669.1 AC004593.3 3.63 0.000328 0.0479 0.4 0.19 Pediatric bone mineral density (spine); chr7:29879778 chr7:29199540~29208970:- LIHC cis rs4561483 0.801 rs33643 ENSG00000261216.1 RP11-166B2.5 -3.63 0.000328 0.0479 -0.22 -0.19 Testicular germ cell tumor; chr16:11892292 chr16:11908208~11908916:+ LIHC cis rs801193 1 rs2420824 ENSG00000273142.1 RP11-458F8.4 3.63 0.000328 0.048 0.18 0.19 Aortic root size; chr7:66666129 chr7:66902857~66906297:+ LIHC cis rs4561483 0.832 rs33645 ENSG00000261216.1 RP11-166B2.5 -3.63 0.000328 0.048 -0.22 -0.19 Testicular germ cell tumor; chr16:11891344 chr16:11908208~11908916:+ LIHC cis rs9309473 0.5 rs7608328 ENSG00000273245.1 RP11-434P11.2 -3.63 0.000328 0.048 -0.23 -0.19 Metabolite levels; chr2:73686892 chr2:73750256~73750786:- LIHC cis rs301901 0.796 rs4869527 ENSG00000250155.1 CTD-2353F22.1 3.63 0.000328 0.048 0.19 0.19 Height; chr5:37533964 chr5:36666214~36725195:- LIHC cis rs7980687 0.628 rs1727332 ENSG00000256092.2 RP13-942N8.1 3.63 0.000328 0.048 0.24 0.19 Head circumference (infant);Educational attainment;Height; chr12:123233754 chr12:123363868~123366113:+ LIHC cis rs8059260 0.524 rs1122185 ENSG00000274038.1 RP11-66H6.4 -3.63 0.000328 0.048 -0.25 -0.19 Alcohol consumption over the past year; chr16:11104119 chr16:11056556~11057034:+ LIHC cis rs858239 1 rs199347 ENSG00000226816.2 AC005082.12 3.63 0.000328 0.048 0.24 0.19 Cerebrospinal fluid biomarker levels; chr7:23254127 chr7:23206013~23208045:+ LIHC cis rs4578769 0.765 rs11082172 ENSG00000265943.1 RP11-739L10.1 -3.63 0.000328 0.048 -0.25 -0.19 Eosinophil percentage of white cells; chr18:22857866 chr18:22699481~22933764:- LIHC cis rs6545883 0.929 rs6705235 ENSG00000273302.1 RP11-493E12.2 3.63 0.000328 0.048 0.21 0.19 Tuberculosis; chr2:61486445 chr2:61199979~61200769:+ LIHC cis rs6942407 0.592 rs6966613 ENSG00000224046.1 AC005076.5 -3.63 0.000329 0.048 -0.18 -0.19 Food allergy; chr7:87164178 chr7:87151423~87152420:- LIHC cis rs11098499 0.954 rs2389803 ENSG00000249244.1 RP11-548H18.2 -3.63 0.000329 0.048 -0.21 -0.19 Corneal astigmatism; chr4:119472356 chr4:119391831~119395335:- LIHC cis rs6048205 1 rs6036146 ENSG00000259974.2 LINC00261 -3.63 0.000329 0.048 -0.31 -0.19 Fasting blood glucose;Fasting blood glucose (BMI interaction); chr20:22554983 chr20:22547671~22578642:- LIHC cis rs4218 0.689 rs12902628 ENSG00000277144.1 RP11-59H7.4 -3.63 0.000329 0.048 -0.21 -0.19 Social communication problems; chr15:59100193 chr15:59115547~59116089:- LIHC cis rs9818758 0.556 rs9835439 ENSG00000270441.1 RP11-694I15.7 3.63 0.000329 0.048 0.41 0.19 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels; chr3:49182897 chr3:49140086~49160851:- LIHC cis rs3764021 0.527 rs10844537 ENSG00000256673.1 RP11-599J14.2 -3.63 0.000329 0.048 -0.2 -0.19 Type 1 diabetes; chr12:9709528 chr12:9398355~9414851:- LIHC cis rs1874124 0.577 rs2807872 ENSG00000272823.1 RP11-295M18.6 -3.63 0.000329 0.048 -0.33 -0.19 Cholesterol, total; chr1:220866908 chr1:220828676~220829211:- LIHC cis rs1494950 1 rs77326179 ENSG00000214846.4 RP11-115L11.1 -3.63 0.000329 0.048 -0.4 -0.19 Political ideology; chr4:15023316 chr4:15730962~15731627:- LIHC cis rs67311347 0.521 rs2887963 ENSG00000223797.4 ENTPD3-AS1 -3.63 0.000329 0.048 -0.16 -0.19 Renal cell carcinoma; chr3:40201975 chr3:40313802~40453329:- LIHC cis rs4561483 0.583 rs1019813 ENSG00000261560.1 RP11-166B2.3 3.63 0.000329 0.048 0.22 0.19 Testicular germ cell tumor; chr16:11846972 chr16:11881075~11882569:- LIHC cis rs4604234 0.614 rs11961506 ENSG00000272129.1 RP11-250B2.6 -3.63 0.000329 0.048 -0.34 -0.19 Cancer; chr6:80224592 chr6:80355424~80356859:+ LIHC cis rs4038782 0.503 rs11862351 ENSG00000267077.1 RP11-127I20.5 3.63 0.000329 0.048 0.23 0.19 Cancer; chr16:4853582 chr16:4795265~4796532:- LIHC cis rs1223397 0.651 rs2439545 ENSG00000215022.6 RP1-257A7.4 3.63 0.000329 0.048 0.2 0.19 Blood pressure; chr6:13313612 chr6:13264861~13295586:- LIHC cis rs481331 0.866 rs522701 ENSG00000185904.10 LINC00839 3.63 0.000329 0.048 0.36 0.19 Systemic juvenile idiopathic arthritis; chr10:42674624 chr10:42475543~42495336:+ LIHC cis rs1440410 0.835 rs4690771 ENSG00000250326.1 RP11-284M14.1 -3.63 0.000329 0.048 -0.22 -0.19 Ischemic stroke; chr4:143129944 chr4:142933195~143184861:- LIHC cis rs794185 0.592 rs2633847 ENSG00000231249.1 ITPR1-AS1 -3.63 0.000329 0.048 -0.2 -0.19 Multiple sclerosis--Brain Glutamate Levels; chr3:4472589 chr3:4490891~4493163:- LIHC cis rs9674544 0.74 rs11870560 ENSG00000248278.1 SUMO2P17 -3.63 0.000329 0.048 -0.27 -0.19 Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption); chr17:49036671 chr17:48874860~48908983:- LIHC cis rs3845817 1 rs3845817 ENSG00000237979.1 AC007389.1 -3.63 0.000329 0.048 -0.21 -0.19 Bipolar disorder; chr2:65531391 chr2:65500993~65502138:- LIHC cis rs17376456 0.825 rs17372057 ENSG00000251023.1 RP11-549J18.1 -3.63 0.000329 0.048 -0.4 -0.19 Diabetic retinopathy; chr5:93736210 chr5:93860669~93863825:- LIHC cis rs55910451 0.732 rs2797496 ENSG00000224034.1 RP11-445P17.8 3.63 0.000329 0.0481 0.21 0.19 Breast cancer; chr10:5759269 chr10:5266033~5271236:- LIHC cis rs703842 1 rs11172349 ENSG00000270039.1 RP11-571M6.17 -3.63 0.000329 0.0481 -0.27 -0.19 Multiple sclerosis; chr12:57818745 chr12:57803838~57804415:+ LIHC cis rs4578769 0.685 rs11659242 ENSG00000266850.1 RP11-370A5.1 -3.63 0.000329 0.0481 -0.23 -0.19 Eosinophil percentage of white cells; chr18:23058085 chr18:22723491~22907721:- LIHC cis rs4948102 0.767 rs4948096 ENSG00000226278.1 PSPHP1 -3.63 0.00033 0.0481 -0.23 -0.19 Plasma homocysteine levels (post-methionine load test); chr7:55985425 chr7:55764797~55773288:+ LIHC cis rs10129255 0.957 rs4387509 ENSG00000211970.3 IGHV4-61 -3.63 0.00033 0.0481 -0.16 -0.19 Kawasaki disease; chr14:106704386 chr14:106639119~106639657:- LIHC cis rs5765524 0.604 rs8136296 ENSG00000226328.5 NUP50-AS1 -3.63 0.00033 0.0481 -0.24 -0.19 Red blood cell count; chr22:45587115 chr22:45133020~45163781:- LIHC cis rs5765524 0.604 rs11090644 ENSG00000226328.5 NUP50-AS1 -3.63 0.00033 0.0481 -0.24 -0.19 Red blood cell count; chr22:45587117 chr22:45133020~45163781:- LIHC cis rs67311347 1 rs6793596 ENSG00000223797.4 ENTPD3-AS1 3.63 0.00033 0.0481 0.16 0.19 Renal cell carcinoma; chr3:40416304 chr3:40313802~40453329:- LIHC cis rs2933343 1 rs1683811 ENSG00000261159.1 RP11-723O4.9 3.63 0.00033 0.0481 0.26 0.19 IgG glycosylation; chr3:128893270 chr3:128859716~128860526:- LIHC cis rs7665090 0.528 rs3774968 ENSG00000248971.2 KRT8P46 -3.63 0.00033 0.0481 -0.19 -0.19 Primary biliary cholangitis; chr4:102609955 chr4:102728746~102730171:- LIHC cis rs3845817 0.838 rs697150 ENSG00000237979.1 AC007389.1 3.63 0.00033 0.0481 0.22 0.19 Bipolar disorder; chr2:65522950 chr2:65500993~65502138:- LIHC cis rs8087799 0.894 rs878468 ENSG00000273232.1 RP11-370A5.2 -3.63 0.00033 0.0481 -0.22 -0.19 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22674101 chr18:22882825~22883357:- LIHC cis rs3096299 0.617 rs2353030 ENSG00000261118.1 RP11-104N10.1 -3.63 0.00033 0.0481 -0.19 -0.19 Multiple myeloma (IgH translocation); chr16:89339419 chr16:89492017~89504460:- LIHC cis rs6500395 1 rs12598514 ENSG00000261267.1 RP11-44I10.3 3.63 0.00033 0.0481 0.25 0.19 Response to tocilizumab in rheumatoid arthritis; chr16:48655408 chr16:48559661~48587403:+ LIHC cis rs931127 0.692 rs7934517 ENSG00000265874.1 MIR4489 -3.63 0.00033 0.0482 -0.22 -0.19 Systemic lupus erythematosus; chr11:65678202 chr11:65649192~65649253:+ LIHC cis rs4325129 0.705 rs11265216 ENSG00000231100.1 RP11-740C1.2 3.63 0.00033 0.0482 0.21 0.19 Obesity-related traits; chr1:159505857 chr1:159557368~159558200:+ LIHC cis rs6860806 0.507 rs274570 ENSG00000263597.1 MIR3936 -3.63 0.00033 0.0482 -0.21 -0.19 Breast cancer; chr5:132377534 chr5:132365490~132365599:- LIHC cis rs308971 0.808 rs308967 ENSG00000225026.1 AC091492.2 3.63 0.00033 0.0482 0.5 0.19 Fasting blood insulin (BMI interaction); chr3:12134689 chr3:12328003~12328274:+ LIHC cis rs2243480 1 rs34702770 ENSG00000226002.1 RP11-460N20.5 -3.63 0.00033 0.0482 -0.28 -0.19 Diabetic kidney disease; chr7:65879836 chr7:65084103~65100232:+ LIHC cis rs2243480 0.803 rs35480979 ENSG00000226002.1 RP11-460N20.5 -3.63 0.00033 0.0482 -0.28 -0.19 Diabetic kidney disease; chr7:65892097 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs34637256 ENSG00000226002.1 RP11-460N20.5 -3.63 0.00033 0.0482 -0.28 -0.19 Diabetic kidney disease; chr7:65895144 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs35391607 ENSG00000226002.1 RP11-460N20.5 -3.63 0.00033 0.0482 -0.28 -0.19 Diabetic kidney disease; chr7:65895842 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs13220979 ENSG00000226002.1 RP11-460N20.5 -3.63 0.00033 0.0482 -0.28 -0.19 Diabetic kidney disease; chr7:65898217 chr7:65084103~65100232:+ LIHC cis rs2243480 1 rs34974928 ENSG00000226002.1 RP11-460N20.5 -3.63 0.00033 0.0482 -0.28 -0.19 Diabetic kidney disease; chr7:65899019 chr7:65084103~65100232:+ LIHC cis rs2411984 0.603 rs1317701 ENSG00000262039.1 RP11-81K2.1 3.63 0.00033 0.0482 0.24 0.19 Sex hormone-binding globulin levels; chr17:49367432 chr17:49370740~49476988:+ LIHC cis rs2115630 0.967 rs8028490 ENSG00000259295.5 CSPG4P12 -3.63 0.00033 0.0482 -0.22 -0.19 P wave terminal force; chr15:84734657 chr15:85191438~85213905:+ LIHC cis rs3893377 1 rs11947310 ENSG00000214846.4 RP11-115L11.1 3.63 0.00033 0.0482 0.24 0.19 Current cigarettes per day in chronic obstructive pulmonary disease; chr4:15742953 chr4:15730962~15731627:- LIHC cis rs2839186 0.903 rs61182475 ENSG00000215447.6 BX322557.10 -3.63 0.000331 0.0482 -0.17 -0.19 Testicular germ cell tumor; chr21:46287136 chr21:45288052~45291738:+ LIHC cis rs11098499 0.562 rs58583086 ENSG00000245958.5 RP11-33B1.1 3.63 0.000331 0.0482 0.19 0.19 Corneal astigmatism; chr4:119635207 chr4:119454791~119552025:+ LIHC cis rs875971 0.66 rs12698534 ENSG00000237310.1 GS1-124K5.4 3.63 0.000331 0.0482 0.18 0.19 Aortic root size; chr7:66521858 chr7:66493706~66495474:+ LIHC cis rs875971 0.66 rs62465434 ENSG00000237310.1 GS1-124K5.4 3.63 0.000331 0.0482 0.18 0.19 Aortic root size; chr7:66540165 chr7:66493706~66495474:+ LIHC cis rs875971 0.66 rs13224319 ENSG00000237310.1 GS1-124K5.4 3.63 0.000331 0.0482 0.18 0.19 Aortic root size; chr7:66542376 chr7:66493706~66495474:+ LIHC cis rs875971 0.66 rs801217 ENSG00000237310.1 GS1-124K5.4 -3.63 0.000331 0.0482 -0.18 -0.19 Aortic root size; chr7:66545590 chr7:66493706~66495474:+ LIHC cis rs875971 0.638 rs801216 ENSG00000237310.1 GS1-124K5.4 -3.63 0.000331 0.0482 -0.18 -0.19 Aortic root size; chr7:66546680 chr7:66493706~66495474:+ LIHC cis rs875971 0.66 rs801211 ENSG00000237310.1 GS1-124K5.4 -3.63 0.000331 0.0482 -0.18 -0.19 Aortic root size; chr7:66550702 chr7:66493706~66495474:+ LIHC cis rs875971 0.638 rs801205 ENSG00000237310.1 GS1-124K5.4 -3.63 0.000331 0.0482 -0.18 -0.19 Aortic root size; chr7:66557157 chr7:66493706~66495474:+ LIHC cis rs875971 0.617 rs810400 ENSG00000237310.1 GS1-124K5.4 -3.63 0.000331 0.0482 -0.18 -0.19 Aortic root size; chr7:66557902 chr7:66493706~66495474:+ LIHC cis rs875971 0.638 rs3898855 ENSG00000237310.1 GS1-124K5.4 -3.63 0.000331 0.0482 -0.18 -0.19 Aortic root size; chr7:66571411 chr7:66493706~66495474:+ LIHC cis rs875971 0.638 rs10278816 ENSG00000237310.1 GS1-124K5.4 -3.63 0.000331 0.0482 -0.18 -0.19 Aortic root size; chr7:66572000 chr7:66493706~66495474:+ LIHC cis rs875971 0.66 rs10281080 ENSG00000237310.1 GS1-124K5.4 -3.63 0.000331 0.0482 -0.18 -0.19 Aortic root size; chr7:66577454 chr7:66493706~66495474:+ LIHC cis rs151234 0.612 rs11641853 ENSG00000259982.1 CDC37P1 -3.63 0.000331 0.0482 -0.46 -0.19 Platelet distribution width; chr16:28578398 chr16:28700294~28701540:- LIHC cis rs559928 0.557 rs7122408 ENSG00000236935.1 AP003774.1 3.63 0.000331 0.0482 0.3 0.19 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64131354 chr11:64325050~64329504:- LIHC cis rs12480328 1 rs73909848 ENSG00000224397.4 LINC01272 -3.63 0.000331 0.0482 -0.39 -0.19 Prostate cancer; chr20:50953866 chr20:50267486~50279795:+ LIHC cis rs9457247 0.765 rs9457251 ENSG00000227598.1 RP1-167A14.2 -3.63 0.000331 0.0482 -0.21 -0.19 Crohn's disease; chr6:167013219 chr6:166969626~166999065:- LIHC cis rs912057 0.965 rs1294409 ENSG00000261211.1 RP1-80N2.3 -3.63 0.000331 0.0482 -0.19 -0.19 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index; chr6:6738122 chr6:6680309~6683633:- LIHC cis rs2742417 0.603 rs2742395 ENSG00000244357.3 RN7SL145P 3.63 0.000331 0.0482 0.19 0.19 Response to anti-depressant treatment in major depressive disorder; chr3:45717103 chr3:45742675~45742970:+ LIHC cis rs7119 0.651 rs12917431 ENSG00000261143.1 ADAMTS7P3 3.63 0.000331 0.0483 0.27 0.19 Type 2 diabetes; chr15:77557842 chr15:77976042~77993057:+ LIHC cis rs4561483 0.583 rs1019814 ENSG00000261560.1 RP11-166B2.3 3.63 0.000331 0.0483 0.22 0.19 Testicular germ cell tumor; chr16:11846907 chr16:11881075~11882569:- LIHC cis rs2098713 0.599 rs62359042 ENSG00000250155.1 CTD-2353F22.1 3.63 0.000331 0.0483 0.19 0.19 Telomere length; chr5:37577604 chr5:36666214~36725195:- LIHC cis rs875971 0.895 rs4145009 ENSG00000232559.3 GS1-124K5.12 -3.63 0.000331 0.0483 -0.15 -0.19 Aortic root size; chr7:66261628 chr7:66554588~66576923:- LIHC cis rs2032447 0.966 rs7756117 ENSG00000242387.1 HIST1H2APS2 -3.63 0.000331 0.0483 -0.23 -0.19 Intelligence (multi-trait analysis); chr6:26046337 chr6:25882026~25882395:- LIHC cis rs6893782 0.83 rs274549 ENSG00000233006.5 AC034220.3 3.63 0.000331 0.0483 0.25 0.19 Acylcarnitine levels; chr5:132393426 chr5:132311285~132369916:- LIHC cis rs709400 0.93 rs10134399 ENSG00000258914.1 CTD-2134A5.3 3.63 0.000332 0.0483 0.28 0.19 Body mass index; chr14:103617120 chr14:103875055~103877478:+ LIHC cis rs2301573 1 rs58763722 ENSG00000251474.5 RPL32P3 3.63 0.000332 0.0483 0.23 0.19 Hip circumference; chr3:129584645 chr3:129382922~129399655:- LIHC cis rs2439831 0.717 rs9806227 ENSG00000205771.5 CATSPER2P1 -3.63 0.000332 0.0483 -0.26 -0.19 Lung cancer in ever smokers; chr15:43387917 chr15:43726918~43747094:- LIHC cis rs12478296 0.591 rs12468297 ENSG00000261186.2 RP11-341N2.1 -3.63 0.000332 0.0483 -0.24 -0.19 Obesity-related traits; chr2:242054323 chr2:242087351~242088457:- LIHC cis rs11710088 0.74 rs10935760 ENSG00000244503.1 RP11-278L15.6 3.63 0.000332 0.0483 0.24 0.19 QRS duration; chr3:149475636 chr3:149494660~149495995:+ LIHC cis rs2638953 0.853 rs11049679 ENSG00000247934.4 RP11-967K21.1 -3.63 0.000332 0.0483 -0.25 -0.19 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28508161 chr12:28163298~28190738:- LIHC cis rs9595908 0.709 rs1929937 ENSG00000212293.1 SNORA16 3.63 0.000332 0.0483 0.22 0.19 Body mass index; chr13:32722907 chr13:32420390~32420516:- LIHC cis rs9595908 0.709 rs7325016 ENSG00000212293.1 SNORA16 3.63 0.000332 0.0483 0.22 0.19 Body mass index; chr13:32728681 chr13:32420390~32420516:- LIHC cis rs2243480 1 rs313813 ENSG00000229886.1 RP5-1132H15.3 3.63 0.000332 0.0483 0.28 0.19 Diabetic kidney disease; chr7:66038513 chr7:66025126~66031544:- LIHC cis rs6545883 0.558 rs7587389 ENSG00000271889.1 RP11-493E12.1 -3.63 0.000332 0.0484 -0.23 -0.19 Tuberculosis; chr2:61422656 chr2:61151433~61162105:- LIHC cis rs559928 0.606 rs17773078 ENSG00000236935.1 AP003774.1 3.63 0.000332 0.0484 0.28 0.19 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64138752 chr11:64325050~64329504:- LIHC cis rs559928 0.556 rs734762 ENSG00000236935.1 AP003774.1 3.63 0.000332 0.0484 0.28 0.19 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64144717 chr11:64325050~64329504:- LIHC cis rs559928 0.606 rs12417635 ENSG00000236935.1 AP003774.1 3.63 0.000332 0.0484 0.28 0.19 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64145256 chr11:64325050~64329504:- LIHC cis rs6001482 0.702 rs5757581 ENSG00000234630.1 LL22NC03-2H8.4 -3.63 0.000332 0.0484 -0.15 -0.19 Diastolic blood pressure; chr22:22234220 chr22:22293733~22294794:+ LIHC cis rs9951150 0.537 rs61565273 ENSG00000267013.4 CTD-2171N6.1 3.63 0.000332 0.0484 0.25 0.19 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr18:55104281 chr18:55105904~55124306:- LIHC cis rs42490 0.664 rs372981 ENSG00000251136.7 RP11-37B2.1 -3.63 0.000332 0.0484 -0.17 -0.19 Leprosy; chr8:89784740 chr8:89609409~89757727:- LIHC cis rs17818399 0.708 rs1531133 ENSG00000236824.1 BCYRN1 -3.63 0.000332 0.0484 -0.22 -0.19 Height; chr2:46616492 chr2:47331060~47344517:+ LIHC cis rs3198697 0.663 rs12928099 ENSG00000263335.1 AF001548.5 -3.63 0.000332 0.0484 -0.33 -0.19 Triglycerides; chr16:15056648 chr16:15726674~15732993:+ LIHC cis rs9303401 0.646 rs7342863 ENSG00000267637.1 RP11-619I22.1 3.63 0.000332 0.0484 0.22 0.19 Cognitive test performance; chr17:59149649 chr17:59784813~59785035:+ LIHC cis rs2115630 0.967 rs10438428 ENSG00000189136.7 UBE2Q2P1 -3.63 0.000332 0.0484 -0.15 -0.19 P wave terminal force; chr15:84787514 chr15:84526781~84571216:- LIHC cis rs9747201 0.925 rs8072670 ENSG00000279692.1 RP11-1055B8.1 3.63 0.000332 0.0484 0.33 0.19 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82201690 chr17:81395609~81397144:- LIHC cis rs9747201 0.832 rs4072580 ENSG00000279692.1 RP11-1055B8.1 3.63 0.000332 0.0484 0.33 0.19 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82202461 chr17:81395609~81397144:- LIHC cis rs9747201 1 rs9747668 ENSG00000279692.1 RP11-1055B8.1 3.63 0.000332 0.0484 0.33 0.19 Peripheral arterial disease (traffic-related air pollution interaction); chr17:82203205 chr17:81395609~81397144:- LIHC cis rs4356975 0.503 rs11938761 ENSG00000250919.1 RP11-813N20.3 -3.63 0.000332 0.0484 -0.2 -0.19 Obesity-related traits; chr4:69083992 chr4:69027831~69044578:+ LIHC cis rs4356975 0.545 rs11935886 ENSG00000250919.1 RP11-813N20.3 -3.63 0.000332 0.0484 -0.2 -0.19 Obesity-related traits; chr4:69083994 chr4:69027831~69044578:+ LIHC cis rs8087799 0.928 rs4800423 ENSG00000273232.1 RP11-370A5.2 3.63 0.000333 0.0484 0.22 0.19 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr18:22643268 chr18:22882825~22883357:- LIHC cis rs10446497 0.61 rs12497046 ENSG00000226155.1 AC124944.3 3.63 0.000333 0.0484 0.23 0.19 Schizophrenia; chr3:196816775 chr3:195912049~195913986:+ LIHC cis rs734999 0.566 rs4648658 ENSG00000225931.3 RP3-395M20.7 -3.63 0.000333 0.0484 -0.2 -0.19 Ulcerative colitis; chr1:2629443 chr1:2566410~2569888:+ LIHC cis rs9907295 0.591 rs4325615 ENSG00000267554.1 RP11-686D22.10 3.63 0.000333 0.0484 0.19 0.19 Fibroblast growth factor basic levels; chr17:35826379 chr17:35470069~35470628:- LIHC cis rs9907295 0.551 rs28595279 ENSG00000267554.1 RP11-686D22.10 3.63 0.000333 0.0484 0.19 0.19 Fibroblast growth factor basic levels; chr17:35826416 chr17:35470069~35470628:- LIHC cis rs2396442 1 rs2677109 ENSG00000231769.2 RP1-8B1.4 -3.63 0.000333 0.0484 -0.25 -0.19 Left ventricle wall thickness; chr6:45439917 chr6:46097093~46129706:- LIHC cis rs12480328 0.681 rs60891371 ENSG00000224397.4 LINC01272 -3.63 0.000333 0.0485 -0.38 -0.19 Prostate cancer; chr20:50968399 chr20:50267486~50279795:+ LIHC cis rs638893 0.527 rs7933859 ENSG00000255422.1 AP002954.4 -3.63 0.000333 0.0485 -0.45 -0.19 Vitiligo; chr11:118791336 chr11:118704607~118750263:+ LIHC cis rs638893 0.578 rs4508234 ENSG00000255422.1 AP002954.4 -3.63 0.000333 0.0485 -0.45 -0.19 Vitiligo; chr11:118791494 chr11:118704607~118750263:+ LIHC cis rs638893 0.578 rs5006102 ENSG00000255422.1 AP002954.4 -3.63 0.000333 0.0485 -0.45 -0.19 Vitiligo; chr11:118791631 chr11:118704607~118750263:+ LIHC cis rs6061231 0.624 rs8668 ENSG00000228812.6 LAMA5-AS1 3.63 0.000333 0.0485 0.24 0.19 Colorectal cancer; chr20:62389008 chr20:62352995~62356480:+ LIHC cis rs4578769 0.722 rs4335860 ENSG00000266850.1 RP11-370A5.1 -3.62 0.000333 0.0485 -0.23 -0.19 Eosinophil percentage of white cells; chr18:22976664 chr18:22723491~22907721:- LIHC cis rs1405130 0.869 rs4663467 ENSG00000224287.2 MSL3P1 -3.62 0.000333 0.0485 -0.23 -0.19 Coronary artery disease; chr2:234666407 chr2:233865437~233868444:- LIHC cis rs6669919 0.553 rs12568639 ENSG00000229832.1 RP11-384C4.2 3.62 0.000333 0.0485 0.21 0.19 Intelligence (multi-trait analysis); chr1:211501958 chr1:212357418~212358353:+ LIHC cis rs2656620 0.647 rs12449222 ENSG00000260816.2 RP11-319G9.3 3.62 0.000333 0.0485 0.18 0.19 Cannabis use (initiation); chr16:78897123 chr16:78895361~78899644:+ LIHC cis rs4657482 0.962 rs4657487 ENSG00000203307.2 RP11-375H19.2 -3.62 0.000333 0.0485 -0.2 -0.19 Testicular germ cell tumor; chr1:165866127 chr1:166081183~166087483:+ LIHC cis rs2613514 0.73 rs9893684 ENSG00000204277.1 RP11-219G17.4 3.62 0.000333 0.0485 0.28 0.19 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78063701 chr17:78261349~78278492:- LIHC cis rs2613514 0.73 rs9893685 ENSG00000204277.1 RP11-219G17.4 3.62 0.000333 0.0485 0.28 0.19 Thiazide-induced adverse metabolic effects in hypertensive patients; chr17:78063703 chr17:78261349~78278492:- LIHC cis rs75422866 0.867 rs7303895 ENSG00000276390.1 RP1-197B17.5 -3.62 0.000333 0.0485 -0.43 -0.19 Pneumonia; chr12:47683290 chr12:47699401~47699917:- LIHC cis rs1268083 0.546 rs9398785 ENSG00000237742.5 RP11-624M8.1 -3.62 0.000333 0.0485 -0.18 -0.19 Migraine; chr6:125736602 chr6:125578558~125749190:- LIHC cis rs4561483 0.801 rs33619 ENSG00000261216.1 RP11-166B2.5 -3.62 0.000334 0.0485 -0.21 -0.19 Testicular germ cell tumor; chr16:11915084 chr16:11908208~11908916:+ LIHC cis rs948562 0.696 rs11229532 ENSG00000280010.1 AP001350.4 3.62 0.000334 0.0486 0.37 0.19 Lymphoma; chr11:58574877 chr11:58627435~58628528:+ LIHC cis rs10246939 0.579 rs35647444 ENSG00000228775.6 WEE2-AS1 3.62 0.000334 0.0486 0.22 0.19 Bitter taste perception; chr7:141833957 chr7:141704338~141738346:- LIHC cis rs2439831 0.867 rs2255042 ENSG00000166763.7 STRCP1 -3.62 0.000334 0.0486 -0.27 -0.19 Lung cancer in ever smokers; chr15:43542120 chr15:43699488~43718184:- LIHC cis rs7647973 0.58 rs35218722 ENSG00000270441.1 RP11-694I15.7 -3.62 0.000334 0.0486 -0.27 -0.19 Menarche (age at onset); chr3:49238372 chr3:49140086~49160851:- LIHC cis rs2439831 0.717 rs2470132 ENSG00000275601.1 AC011330.13 -3.62 0.000334 0.0486 -0.26 -0.19 Lung cancer in ever smokers; chr15:43543283 chr15:43642389~43643023:- LIHC cis rs2439831 0.867 rs2251844 ENSG00000275601.1 AC011330.13 -3.62 0.000334 0.0486 -0.26 -0.19 Lung cancer in ever smokers; chr15:43544280 chr15:43642389~43643023:- LIHC cis rs2439831 0.867 rs486301 ENSG00000275601.1 AC011330.13 -3.62 0.000334 0.0486 -0.26 -0.19 Lung cancer in ever smokers; chr15:43544751 chr15:43642389~43643023:- LIHC cis rs2439831 0.867 rs2255051 ENSG00000275601.1 AC011330.13 -3.62 0.000334 0.0486 -0.26 -0.19 Lung cancer in ever smokers; chr15:43553963 chr15:43642389~43643023:- LIHC cis rs7688540 0.771 rs7674560 ENSG00000275426.1 CH17-262A2.1 3.62 0.000334 0.0486 0.23 0.19 Facial morphology (factor 6, height of vermillion lower lip); chr4:269530 chr4:149738~150317:+ LIHC cis rs453301 0.658 rs9329175 ENSG00000253893.2 FAM85B 3.62 0.000334 0.0486 0.27 0.19 Joint mobility (Beighton score); chr8:9009151 chr8:8167819~8226614:- LIHC cis rs6700559 0.716 rs12140579 ENSG00000260088.1 RP11-92G12.3 3.62 0.000334 0.0486 0.26 0.19 Coronary artery disease; chr1:200655368 chr1:200669507~200694250:+ LIHC cis rs11089937 0.568 rs12160317 ENSG00000211639.2 IGLV4-60 3.62 0.000334 0.0486 0.17 0.19 Periodontitis (PAL4Q3); chr22:22131619 chr22:22162199~22162681:+ LIHC cis rs6969780 0.778 rs2428434 ENSG00000233429.8 HOTAIRM1 3.62 0.000334 0.0486 0.28 0.19 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27106116 chr7:27095647~27100265:+ LIHC cis rs6969780 0.778 rs79619106 ENSG00000233429.8 HOTAIRM1 3.62 0.000334 0.0486 0.28 0.19 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27106709 chr7:27095647~27100265:+ LIHC cis rs7617773 0.539 rs13087050 ENSG00000229759.1 MRPS18AP1 3.62 0.000335 0.0487 0.22 0.19 Coronary artery disease; chr3:48351310 chr3:48256350~48256938:- LIHC cis rs864537 0.676 rs2056625 ENSG00000273160.1 RP11-104L21.3 3.62 0.000335 0.0487 0.27 0.19 Celiac disease or Rheumatoid arthritis;Celiac disease; chr1:167451062 chr1:167457742~167459891:- LIHC cis rs2243480 1 rs1723269 ENSG00000229886.1 RP5-1132H15.3 3.62 0.000335 0.0487 0.28 0.19 Diabetic kidney disease; chr7:66007799 chr7:66025126~66031544:- LIHC cis rs7209700 0.547 rs884696 ENSG00000228782.6 CTD-2026D20.3 -3.62 0.000335 0.0487 -0.29 -0.19 IgG glycosylation; chr17:47263878 chr17:47450568~47492492:- LIHC cis rs6732160 0.845 rs6752507 ENSG00000272702.1 RP11-44N22.3 3.62 0.000335 0.0487 0.21 0.19 Intelligence (multi-trait analysis); chr2:73158030 chr2:73113018~73115907:+ LIHC cis rs4891159 0.548 rs2554830 ENSG00000265778.2 RP11-17M16.2 3.62 0.000335 0.0487 0.22 0.19 Longevity; chr18:76415746 chr18:76491652~76493918:+ LIHC cis rs9595908 0.709 rs4942897 ENSG00000212293.1 SNORA16 3.62 0.000335 0.0487 0.22 0.19 Body mass index; chr13:32757615 chr13:32420390~32420516:- LIHC cis rs6502050 0.761 rs13949 ENSG00000279692.1 RP11-1055B8.1 -3.62 0.000335 0.0487 -0.29 -0.19 Life satisfaction; chr17:82101720 chr17:81395609~81397144:- LIHC cis rs301901 0.796 rs3941788 ENSG00000250155.1 CTD-2353F22.1 3.62 0.000335 0.0487 0.19 0.19 Height; chr5:37498809 chr5:36666214~36725195:- LIHC cis rs494453 0.557 rs2473842 ENSG00000227811.2 FAM212B-AS1 -3.62 0.000335 0.0487 -0.21 -0.19 Osteoporosis-related phenotypes; chr1:111684778 chr1:111739841~111747798:+ LIHC cis rs5769707 0.967 rs5770585 ENSG00000279345.1 RP3-522J7.7 -3.62 0.000335 0.0487 -0.17 -0.19 Monocyte percentage of white cells;Monocyte count; chr22:49614226 chr22:49805452~49807208:+ LIHC cis rs9467773 0.869 rs1796521 ENSG00000124549.13 BTN2A3P -3.62 0.000335 0.0487 -0.18 -0.19 Intelligence (multi-trait analysis); chr6:26421164 chr6:26421391~26432383:+ LIHC cis rs17376456 1 rs13163610 ENSG00000251023.1 RP11-549J18.1 -3.62 0.000335 0.0487 -0.4 -0.19 Diabetic retinopathy; chr5:94213172 chr5:93860669~93863825:- LIHC cis rs17376456 1 rs13154249 ENSG00000251023.1 RP11-549J18.1 -3.62 0.000335 0.0487 -0.4 -0.19 Diabetic retinopathy; chr5:94214803 chr5:93860669~93863825:- LIHC cis rs17376456 1 rs17323433 ENSG00000251023.1 RP11-549J18.1 -3.62 0.000335 0.0487 -0.4 -0.19 Diabetic retinopathy; chr5:94215323 chr5:93860669~93863825:- LIHC cis rs17376456 1 rs66978370 ENSG00000251023.1 RP11-549J18.1 -3.62 0.000335 0.0487 -0.4 -0.19 Diabetic retinopathy; chr5:94217928 chr5:93860669~93863825:- LIHC cis rs17376456 1 rs13174700 ENSG00000251023.1 RP11-549J18.1 -3.62 0.000335 0.0487 -0.4 -0.19 Diabetic retinopathy; chr5:94218939 chr5:93860669~93863825:- LIHC cis rs1005277 0.579 rs2472183 ENSG00000099251.13 HSD17B7P2 3.62 0.000335 0.0487 0.22 0.19 Extrinsic epigenetic age acceleration; chr10:38103567 chr10:38356380~38378505:+ LIHC cis rs3749237 0.595 rs12489092 ENSG00000226913.1 BSN-AS2 -3.62 0.000335 0.0487 -0.25 -0.19 Resting heart rate; chr3:49513481 chr3:49549306~49554366:- LIHC cis rs3749237 0.595 rs3870337 ENSG00000226913.1 BSN-AS2 -3.62 0.000335 0.0487 -0.25 -0.19 Resting heart rate; chr3:49519662 chr3:49549306~49554366:- LIHC cis rs6452524 0.618 rs255561 ENSG00000271862.1 RP11-343L5.2 3.62 0.000335 0.0487 0.23 0.19 Hypertension (SNP x SNP interaction); chr5:83054991 chr5:83049376~83050964:- LIHC cis rs10752881 0.74 rs1889307 ENSG00000224468.3 RP11-181K3.4 -3.62 0.000335 0.0487 -0.16 -0.19 Colorectal cancer; chr1:183080254 chr1:183138402~183141282:- LIHC cis rs481331 0.741 rs209386 ENSG00000185904.10 LINC00839 -3.62 0.000335 0.0487 -0.36 -0.19 Systemic juvenile idiopathic arthritis; chr10:42638087 chr10:42475543~42495336:+ LIHC cis rs6732160 0.845 rs13413175 ENSG00000272702.1 RP11-44N22.3 3.62 0.000335 0.0487 0.21 0.19 Intelligence (multi-trait analysis); chr2:73162788 chr2:73113018~73115907:+ LIHC cis rs673078 0.66 rs17512142 ENSG00000275759.1 RP11-131L12.3 -3.62 0.000335 0.0487 -0.43 -0.19 Glucose homeostasis traits; chr12:118186186 chr12:118428281~118428870:+ LIHC cis rs9640161 0.658 rs60467296 ENSG00000261305.1 RP4-584D14.7 3.62 0.000335 0.0488 0.23 0.19 Blood protein levels;Circulating chemerin levels; chr7:150318382 chr7:150341771~150342607:+ LIHC cis rs10752881 0.967 rs10911186 ENSG00000224468.3 RP11-181K3.4 -3.62 0.000336 0.0488 -0.16 -0.19 Colorectal cancer; chr1:183003407 chr1:183138402~183141282:- LIHC cis rs6969780 0.915 rs3807597 ENSG00000233429.8 HOTAIRM1 -3.62 0.000336 0.0488 -0.27 -0.19 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27149576 chr7:27095647~27100265:+ LIHC cis rs6969780 0.915 rs12666926 ENSG00000233429.8 HOTAIRM1 -3.62 0.000336 0.0488 -0.27 -0.19 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27149942 chr7:27095647~27100265:+ LIHC cis rs6969780 0.915 rs886339 ENSG00000233429.8 HOTAIRM1 -3.62 0.000336 0.0488 -0.27 -0.19 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27151051 chr7:27095647~27100265:+ LIHC cis rs6832769 0.961 rs10009593 ENSG00000272969.1 RP11-528I4.2 -3.62 0.000336 0.0488 -0.23 -0.19 Personality dimensions; chr4:55570514 chr4:55547112~55547889:+ LIHC cis rs2115630 0.755 rs7169629 ENSG00000189136.7 UBE2Q2P1 3.62 0.000336 0.0488 0.15 0.19 P wave terminal force; chr15:84648043 chr15:84526781~84571216:- LIHC cis rs5758511 0.633 rs5758690 ENSG00000273366.1 CTA-989H11.1 3.62 0.000336 0.0488 0.25 0.19 Birth weight; chr22:42272289 chr22:42278188~42278846:+ LIHC cis rs5758511 0.68 rs1001586 ENSG00000273366.1 CTA-989H11.1 3.62 0.000336 0.0488 0.25 0.19 Birth weight; chr22:42274287 chr22:42278188~42278846:+ LIHC cis rs8005677 1 rs11157930 ENSG00000279656.1 RP11-298I3.6 3.62 0.000336 0.0488 0.21 0.19 Cognitive ability (multi-trait analysis); chr14:22933962 chr14:23023083~23024217:- LIHC cis rs7429990 0.931 rs62262084 ENSG00000229759.1 MRPS18AP1 3.62 0.000336 0.0488 0.26 0.19 Educational attainment (years of education); chr3:47612332 chr3:48256350~48256938:- LIHC cis rs12908161 1 rs12908161 ENSG00000259728.4 LINC00933 3.62 0.000336 0.0488 0.28 0.19 Schizophrenia; chr15:84664594 chr15:84570649~84580175:+ LIHC cis rs10774547 0.785 rs2076022 ENSG00000278344.1 RP11-18C24.8 -3.62 0.000336 0.0488 -0.23 -0.19 Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);Reading disability or specific language impairment (pleiotropy); chr12:120437987 chr12:120500735~120501090:- LIHC cis rs13113518 0.812 rs6825774 ENSG00000223305.1 RN7SKP30 3.62 0.000336 0.0488 0.23 0.19 Height; chr4:55491150 chr4:55540502~55540835:- LIHC cis rs4356975 0.563 rs6600876 ENSG00000250919.1 RP11-813N20.3 -3.62 0.000336 0.0488 -0.19 -0.19 Obesity-related traits; chr4:69091212 chr4:69027831~69044578:+ LIHC cis rs875971 0.545 rs1796219 ENSG00000224316.1 RP11-479O9.2 -3.62 0.000336 0.0488 -0.19 -0.19 Aortic root size; chr7:66645977 chr7:65773620~65802067:+ LIHC cis rs1115240 0.577 rs56256284 ENSG00000257842.4 NOVA1-AS1 3.62 0.000336 0.0488 0.19 0.19 Educational attainment (years of education); chr14:26548103 chr14:26598412~26806467:+ LIHC cis rs1115240 0.574 rs57064734 ENSG00000257842.4 NOVA1-AS1 3.62 0.000336 0.0488 0.19 0.19 Educational attainment (years of education); chr14:26548107 chr14:26598412~26806467:+ LIHC cis rs9649213 0.593 rs3823740 ENSG00000272950.1 RP11-307C18.1 3.62 0.000336 0.0488 0.23 0.19 Prostate cancer (SNP x SNP interaction); chr7:98327792 chr7:98322853~98323430:+ LIHC cis rs9649213 0.593 rs7807555 ENSG00000272950.1 RP11-307C18.1 3.62 0.000336 0.0488 0.23 0.19 Prostate cancer (SNP x SNP interaction); chr7:98328205 chr7:98322853~98323430:+ LIHC cis rs9649213 0.593 rs7807455 ENSG00000272950.1 RP11-307C18.1 3.62 0.000336 0.0488 0.23 0.19 Prostate cancer (SNP x SNP interaction); chr7:98328310 chr7:98322853~98323430:+ LIHC cis rs9649213 0.593 rs6465667 ENSG00000272950.1 RP11-307C18.1 3.62 0.000336 0.0488 0.23 0.19 Prostate cancer (SNP x SNP interaction); chr7:98328573 chr7:98322853~98323430:+ LIHC cis rs9649213 0.593 rs6949214 ENSG00000272950.1 RP11-307C18.1 3.62 0.000336 0.0488 0.23 0.19 Prostate cancer (SNP x SNP interaction); chr7:98330921 chr7:98322853~98323430:+ LIHC cis rs9649213 0.593 rs35535338 ENSG00000272950.1 RP11-307C18.1 3.62 0.000336 0.0488 0.23 0.19 Prostate cancer (SNP x SNP interaction); chr7:98333007 chr7:98322853~98323430:+ LIHC cis rs6832769 0.925 rs4371676 ENSG00000272969.1 RP11-528I4.2 3.62 0.000336 0.0488 0.23 0.19 Personality dimensions; chr4:55462841 chr4:55547112~55547889:+ LIHC cis rs367615 0.84 rs113540823 ENSG00000249476.1 CTD-2587M2.1 3.62 0.000336 0.0488 0.24 0.19 Colorectal cancer (SNP x SNP interaction); chr5:109543383 chr5:109237120~109326369:- LIHC cis rs4538475 0.79 rs11934811 ENSG00000214846.4 RP11-115L11.1 -3.62 0.000336 0.0488 -0.26 -0.19 Parkinson's disease; chr4:15736630 chr4:15730962~15731627:- LIHC cis rs1193 1 rs6711700 ENSG00000266931.1 RP11-1252D15.1 -3.62 0.000336 0.0488 -0.23 -0.19 High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count; chr2:86760864 chr2:87055658~87055800:- LIHC cis rs17376456 0.569 rs7732578 ENSG00000251023.1 RP11-549J18.1 3.62 0.000336 0.0488 0.29 0.19 Diabetic retinopathy; chr5:94074539 chr5:93860669~93863825:- LIHC cis rs7129556 0.701 rs72947668 ENSG00000254459.1 RP11-91P24.7 3.62 0.000336 0.0489 0.33 0.19 Weight loss (gastric bypass surgery); chr11:77717888 chr11:77829654~77872262:- LIHC cis rs7953249 0.935 rs7135337 ENSG00000241388.4 HNF1A-AS1 -3.62 0.000336 0.0489 -0.2 -0.19 N-glycan levels;Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr12:120966352 chr12:120941728~120980965:- LIHC cis rs4873772 0.834 rs6986054 ENSG00000253608.1 RP11-770E5.1 3.62 0.000337 0.0489 0.22 0.19 Lobe attachment (rater-scored or self-reported); chr8:47661576 chr8:48551567~48698510:+ LIHC cis rs13178541 0.641 rs10076272 ENSG00000247627.2 MTND4P12 -3.62 0.000337 0.0489 -0.25 -0.19 IgG glycosylation; chr5:135800540 chr5:134926660~134928036:- LIHC cis rs1799949 0.965 rs7212284 ENSG00000267681.1 CTD-3199J23.6 -3.62 0.000337 0.0489 -0.19 -0.19 Menopause (age at onset); chr17:43053924 chr17:43144956~43145255:+ LIHC cis rs12817211 0.502 rs7307230 ENSG00000272368.2 RP4-605O3.4 3.62 0.000337 0.0489 0.21 0.19 Colorectal or endometrial cancer; chr12:50118849 chr12:50112197~50165618:+ LIHC cis rs9876781 1 rs3214041 ENSG00000229759.1 MRPS18AP1 3.62 0.000337 0.0489 0.2 0.19 Longevity; chr3:48413059 chr3:48256350~48256938:- LIHC cis rs2243480 1 rs464895 ENSG00000229886.1 RP5-1132H15.3 3.62 0.000337 0.0489 0.28 0.19 Diabetic kidney disease; chr7:66062119 chr7:66025126~66031544:- LIHC cis rs6449502 1 rs6449502 ENSG00000272308.1 RP11-231G3.1 3.62 0.000337 0.0489 0.29 0.19 Mean platelet volume; chr5:60797268 chr5:60866457~60866935:- LIHC cis rs2243480 0.901 rs57126451 ENSG00000226002.1 RP11-460N20.5 -3.62 0.000337 0.0489 -0.28 -0.19 Diabetic kidney disease; chr7:65951319 chr7:65084103~65100232:+ LIHC cis rs3096299 0.566 rs4129126 ENSG00000274627.1 RP11-104N10.2 3.62 0.000337 0.0489 0.21 0.19 Multiple myeloma (IgH translocation); chr16:89495067 chr16:89516797~89522217:+ LIHC cis rs10883723 0.773 rs2296578 ENSG00000236937.2 PTGES3P4 -3.62 0.000337 0.049 -0.26 -0.19 Allergic disease (asthma, hay fever or eczema); chr10:102481217 chr10:102845595~102845950:+ LIHC cis rs10883723 0.775 rs2296579 ENSG00000236937.2 PTGES3P4 -3.62 0.000337 0.049 -0.26 -0.19 Allergic disease (asthma, hay fever or eczema); chr10:102481618 chr10:102845595~102845950:+ LIHC cis rs62025270 0.576 rs62022925 ENSG00000259295.5 CSPG4P12 -3.62 0.000337 0.049 -0.34 -0.19 Idiopathic pulmonary fibrosis; chr15:85692835 chr15:85191438~85213905:+ LIHC cis rs17376456 1 rs6867042 ENSG00000251023.1 RP11-549J18.1 -3.62 0.000337 0.049 -0.41 -0.19 Diabetic retinopathy; chr5:94220056 chr5:93860669~93863825:- LIHC cis rs11758351 0.66 rs75156165 ENSG00000261353.1 CTA-14H9.5 3.62 0.000338 0.049 0.28 0.19 Renal underexcretion gout;Gout; chr6:26235471 chr6:26527063~26527404:+ LIHC cis rs11758351 0.587 rs16891466 ENSG00000261353.1 CTA-14H9.5 3.62 0.000338 0.049 0.28 0.19 Renal underexcretion gout;Gout; chr6:26235509 chr6:26527063~26527404:+ LIHC cis rs2243480 0.901 rs778732 ENSG00000275400.1 RP4-756H11.5 3.62 0.000338 0.049 0.25 0.19 Diabetic kidney disease; chr7:66357373 chr7:66553805~66554199:- LIHC cis rs7129556 0.775 rs72945598 ENSG00000254459.1 RP11-91P24.7 3.62 0.000338 0.049 0.33 0.19 Weight loss (gastric bypass surgery); chr11:77656693 chr11:77829654~77872262:- LIHC cis rs7617773 0.78 rs35297395 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48301392 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs36075665 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48301597 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs34630841 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48301771 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs35190747 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48301800 chr3:48290793~48291375:- LIHC cis rs7617773 0.743 rs7621785 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48302218 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs4511915 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48302368 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs13066758 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48302387 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs4392440 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48302430 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs13082859 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48303185 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs35778847 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48305495 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs34749846 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48305678 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs7632297 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48306673 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs79089926 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48307074 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs4511916 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48308876 chr3:48290793~48291375:- LIHC cis rs7617773 0.815 rs7624450 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48308885 chr3:48290793~48291375:- LIHC cis rs7617773 0.815 rs6793150 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48310070 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs6793239 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48310128 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs6782166 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48310193 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs4130522 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48310823 chr3:48290793~48291375:- LIHC cis rs7617773 0.674 rs13069029 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48313534 chr3:48290793~48291375:- LIHC cis rs7617773 0.78 rs13081169 ENSG00000228638.1 FCF1P2 -3.62 0.000338 0.049 -0.22 -0.19 Coronary artery disease; chr3:48315307 chr3:48290793~48291375:- LIHC cis rs8059260 0.932 rs7186166 ENSG00000274038.1 RP11-66H6.4 -3.62 0.000338 0.049 -0.25 -0.19 Alcohol consumption over the past year; chr16:11011577 chr16:11056556~11057034:+ LIHC cis rs12681366 0.537 rs6999976 ENSG00000253704.1 RP11-267M23.4 3.62 0.000338 0.049 0.22 0.19 Nonsyndromic cleft lip with cleft palate; chr8:94470194 chr8:94553722~94569745:+ LIHC cis rs7129556 0.638 rs11604207 ENSG00000254459.1 RP11-91P24.7 3.62 0.000338 0.049 0.35 0.19 Weight loss (gastric bypass surgery); chr11:77656497 chr11:77829654~77872262:- LIHC cis rs72634501 0.716 rs2036465 ENSG00000182109.6 RP11-69E11.4 -3.62 0.000338 0.049 -0.25 -0.19 HDL cholesterol; chr1:39110310 chr1:39522280~39546187:- LIHC cis rs797680 0.856 rs1535701 ENSG00000229567.1 RP4-717I23.2 -3.62 0.000338 0.049 -0.24 -0.19 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93339644 chr1:93278961~93279129:- LIHC cis rs244293 0.965 rs244335 ENSG00000275710.1 RP11-257O5.4 -3.62 0.000338 0.0491 -0.21 -0.19 Menarche (age at onset); chr17:55124569 chr17:54964474~54964679:+ LIHC cis rs2658782 0.756 rs3019222 ENSG00000279684.1 RP11-755E23.2 -3.62 0.000338 0.0491 -0.33 -0.19 Pulmonary function decline; chr11:93346552 chr11:93286629~93288903:- LIHC cis rs875971 0.66 rs3764903 ENSG00000224316.1 RP11-479O9.2 -3.62 0.000338 0.0491 -0.18 -0.19 Aortic root size; chr7:66633495 chr7:65773620~65802067:+ LIHC cis rs17376456 0.542 rs17083380 ENSG00000251023.1 RP11-549J18.1 3.62 0.000338 0.0491 0.28 0.19 Diabetic retinopathy; chr5:93834770 chr5:93860669~93863825:- LIHC cis rs1862618 0.671 rs2591966 ENSG00000271828.1 CTD-2310F14.1 -3.62 0.000338 0.0491 -0.25 -0.19 Initial pursuit acceleration; chr5:56937861 chr5:56927874~56929573:+ LIHC cis rs61192259 0.54 rs4236060 ENSG00000217165.1 ANKRD18EP -3.62 0.000339 0.0491 -0.14 -0.19 Restless legs syndrome; chr6:38502311 chr6:39110321~39112952:+ LIHC cis rs7945705 0.806 rs12224436 ENSG00000254860.4 TMEM9B-AS1 -3.62 0.000339 0.0491 -0.19 -0.19 Hemoglobin concentration; chr11:8794278 chr11:8964675~8977527:+ LIHC cis rs7104764 0.833 rs12574034 ENSG00000250397.2 RP11-1391J7.1 -3.62 0.000339 0.0491 -0.22 -0.19 Menarche (age at onset); chr11:212262 chr11:856880~859795:- LIHC cis rs8077577 0.747 rs2071242 ENSG00000260647.1 RP1-178F10.1 3.62 0.000339 0.0491 0.24 0.19 Obesity-related traits; chr17:18251196 chr17:18268080~18268828:+ LIHC cis rs17376456 1 rs61132622 ENSG00000251023.1 RP11-549J18.1 -3.62 0.000339 0.0491 -0.4 -0.19 Diabetic retinopathy; chr5:94203979 chr5:93860669~93863825:- LIHC cis rs2243480 1 rs1546059 ENSG00000228409.4 CCT6P1 -3.62 0.000339 0.0491 -0.21 -0.19 Diabetic kidney disease; chr7:66189722 chr7:65751142~65763354:+ LIHC cis rs2243480 1 rs6958289 ENSG00000228409.4 CCT6P1 -3.62 0.000339 0.0491 -0.21 -0.19 Diabetic kidney disease; chr7:66192124 chr7:65751142~65763354:+ LIHC cis rs6558530 0.836 rs11136424 ENSG00000253982.1 CTD-2336O2.1 3.62 0.000339 0.0491 0.24 0.19 Systolic blood pressure; chr8:1768870 chr8:1761990~1764502:- LIHC cis rs8037137 0.571 rs3743445 ENSG00000258725.1 PRC1-AS1 -3.62 0.000339 0.0491 -0.24 -0.19 Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer; chr15:91017952 chr15:90966345~90988624:+ LIHC cis rs1440410 0.83 rs2165301 ENSG00000250326.1 RP11-284M14.1 -3.62 0.000339 0.0491 -0.22 -0.19 Ischemic stroke; chr4:143247497 chr4:142933195~143184861:- LIHC cis rs17345786 0.953 rs78645744 ENSG00000244119.1 PDCL3P4 3.62 0.000339 0.0491 0.21 0.19 Colonoscopy-negative controls vs population controls; chr3:101608945 chr3:101712472~101713191:+ LIHC cis rs17345786 0.817 rs11720560 ENSG00000244119.1 PDCL3P4 3.62 0.000339 0.0491 0.21 0.19 Colonoscopy-negative controls vs population controls; chr3:101609640 chr3:101712472~101713191:+ LIHC cis rs467650 0.509 rs152989 ENSG00000248489.1 CTD-2007H13.3 3.62 0.000339 0.0492 0.25 0.19 Venous thromboembolism (SNP x SNP interaction); chr5:98654131 chr5:98929171~98995013:+ LIHC cis rs1115240 1 rs1115240 ENSG00000257842.4 NOVA1-AS1 -3.62 0.000339 0.0492 -0.18 -0.19 Educational attainment (years of education); chr14:26621182 chr14:26598412~26806467:+ LIHC cis rs763121 0.853 rs6519119 ENSG00000273076.1 RP3-508I15.22 3.62 0.000339 0.0492 0.23 0.19 Menopause (age at onset); chr22:38593002 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs5757162 ENSG00000273076.1 RP3-508I15.22 3.62 0.000339 0.0492 0.23 0.19 Menopause (age at onset); chr22:38597365 chr22:38743495~38743910:+ LIHC cis rs763121 0.853 rs9622833 ENSG00000273076.1 RP3-508I15.22 3.62 0.000339 0.0492 0.23 0.19 Menopause (age at onset); chr22:38604392 chr22:38743495~38743910:+ LIHC cis rs7131987 0.834 rs12228468 ENSG00000275476.1 RP11-996F15.4 3.62 0.000339 0.0492 0.22 0.19 QT interval; chr12:29300677 chr12:29277397~29277882:- LIHC cis rs4578769 0.531 rs9957103 ENSG00000265943.1 RP11-739L10.1 3.62 0.000339 0.0492 0.23 0.19 Eosinophil percentage of white cells; chr18:22870172 chr18:22699481~22933764:- LIHC cis rs11105298 0.891 rs3741898 ENSG00000258302.2 RP11-981P6.1 3.62 0.000339 0.0492 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89539986 chr12:89561129~89594878:+ LIHC cis rs11105298 0.891 rs3741899 ENSG00000258302.2 RP11-981P6.1 3.62 0.000339 0.0492 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89540154 chr12:89561129~89594878:+ LIHC cis rs11105298 0.891 rs10858906 ENSG00000258302.2 RP11-981P6.1 3.62 0.000339 0.0492 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89540697 chr12:89561129~89594878:+ LIHC cis rs2243480 1 rs778729 ENSG00000275400.1 RP4-756H11.5 3.62 0.00034 0.0492 0.26 0.19 Diabetic kidney disease; chr7:66359432 chr7:66553805~66554199:- LIHC cis rs2243480 0.901 rs778687 ENSG00000275400.1 RP4-756H11.5 3.62 0.00034 0.0492 0.26 0.19 Diabetic kidney disease; chr7:66370832 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs778679 ENSG00000275400.1 RP4-756H11.5 3.62 0.00034 0.0492 0.26 0.19 Diabetic kidney disease; chr7:66375924 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs778704 ENSG00000275400.1 RP4-756H11.5 3.62 0.00034 0.0492 0.26 0.19 Diabetic kidney disease; chr7:66398480 chr7:66553805~66554199:- LIHC cis rs2243480 0.901 rs778693 ENSG00000275400.1 RP4-756H11.5 3.62 0.00034 0.0492 0.26 0.19 Diabetic kidney disease; chr7:66407358 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs778691 ENSG00000275400.1 RP4-756H11.5 3.62 0.00034 0.0492 0.26 0.19 Diabetic kidney disease; chr7:66408105 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs13235972 ENSG00000275400.1 RP4-756H11.5 3.62 0.00034 0.0492 0.26 0.19 Diabetic kidney disease; chr7:66418618 chr7:66553805~66554199:- LIHC cis rs2243480 1 rs34192067 ENSG00000275400.1 RP4-756H11.5 3.62 0.00034 0.0492 0.26 0.19 Diabetic kidney disease; chr7:66422670 chr7:66553805~66554199:- LIHC cis rs17214007 0.518 rs56374730 ENSG00000263335.1 AF001548.5 -3.62 0.00034 0.0492 -0.27 -0.19 Cognitive function; chr16:15773795 chr16:15726674~15732993:+ LIHC cis rs1005277 0.579 rs2474587 ENSG00000099251.13 HSD17B7P2 3.62 0.00034 0.0492 0.22 0.19 Extrinsic epigenetic age acceleration; chr10:38131738 chr10:38356380~38378505:+ LIHC cis rs1005277 0.579 rs2474588 ENSG00000099251.13 HSD17B7P2 3.62 0.00034 0.0492 0.22 0.19 Extrinsic epigenetic age acceleration; chr10:38131942 chr10:38356380~38378505:+ LIHC cis rs1115240 0.588 rs8008779 ENSG00000257842.4 NOVA1-AS1 3.62 0.00034 0.0492 0.19 0.19 Educational attainment (years of education); chr14:26620276 chr14:26598412~26806467:+ LIHC cis rs950169 0.58 rs1061737 ENSG00000275120.1 RP11-182J1.17 3.62 0.00034 0.0492 0.32 0.19 Schizophrenia; chr15:84640559 chr15:84599434~84606463:- LIHC cis rs10508774 0.852 rs28364830 ENSG00000273038.2 RP11-479G22.8 3.62 0.00034 0.0492 0.29 0.19 Peripheral arterial disease (traffic-related air pollution interaction); chr10:32902342 chr10:32887255~32889311:- LIHC cis rs948562 0.744 rs11229468 ENSG00000280010.1 AP001350.4 3.62 0.00034 0.0492 0.33 0.19 Lymphoma; chr11:58451300 chr11:58627435~58628528:+ LIHC cis rs948562 0.744 rs113392266 ENSG00000280010.1 AP001350.4 3.62 0.00034 0.0492 0.33 0.19 Lymphoma; chr11:58452278 chr11:58627435~58628528:+ LIHC cis rs948562 0.744 rs74406537 ENSG00000280010.1 AP001350.4 3.62 0.00034 0.0492 0.33 0.19 Lymphoma; chr11:58452887 chr11:58627435~58628528:+ LIHC cis rs2933343 1 rs2929859 ENSG00000261159.1 RP11-723O4.9 3.62 0.00034 0.0492 0.26 0.19 IgG glycosylation; chr3:128889498 chr3:128859716~128860526:- LIHC cis rs9380516 0.568 rs2894402 ENSG00000246982.5 RP1-179N16.6 3.62 0.00034 0.0492 0.2 0.19 Hepatitis C induced liver fibrosis; chr6:35516976 chr6:36146698~36197205:- LIHC cis rs780096 0.546 rs4425043 ENSG00000234072.1 AC074117.10 -3.62 0.00034 0.0493 -0.18 -0.19 Total body bone mineral density; chr2:27510585 chr2:27356246~27367622:+ LIHC cis rs7119 0.717 rs12898656 ENSG00000261143.1 ADAMTS7P3 -3.62 0.00034 0.0493 -0.29 -0.19 Type 2 diabetes; chr15:77515653 chr15:77976042~77993057:+ LIHC cis rs340849 0.874 rs340863 ENSG00000274895.1 RP11-478J18.2 3.62 0.00034 0.0493 0.2 0.19 Alzheimer's disease; chr1:213958947 chr1:213983793~213986419:- LIHC cis rs2581828 0.539 rs114317830 ENSG00000242142.1 SERBP1P3 -3.62 0.00034 0.0493 -0.26 -0.19 Crohn's disease; chr3:53126253 chr3:53064283~53065091:- LIHC cis rs2581828 0.539 rs114670283 ENSG00000242142.1 SERBP1P3 -3.62 0.00034 0.0493 -0.26 -0.19 Crohn's disease; chr3:53126254 chr3:53064283~53065091:- LIHC cis rs1411478 1 rs12744212 ENSG00000243155.1 RP11-46A10.5 -3.62 0.00034 0.0493 -0.19 -0.19 Menopause (age at onset);Progressive supranuclear palsy; chr1:180983380 chr1:180944042~180976482:- LIHC cis rs988958 0.565 rs6753173 ENSG00000224875.2 AC083949.1 -3.62 0.00034 0.0493 -0.28 -0.19 Hypospadias; chr2:42008835 chr2:42143238~42170301:- LIHC cis rs988958 0.565 rs6753186 ENSG00000224875.2 AC083949.1 -3.62 0.00034 0.0493 -0.28 -0.19 Hypospadias; chr2:42008858 chr2:42143238~42170301:- LIHC cis rs988958 0.53 rs6724482 ENSG00000224875.2 AC083949.1 -3.62 0.00034 0.0493 -0.28 -0.19 Hypospadias; chr2:42008870 chr2:42143238~42170301:- LIHC cis rs2098713 0.586 rs61435914 ENSG00000250155.1 CTD-2353F22.1 3.62 0.00034 0.0493 0.19 0.19 Telomere length; chr5:37607239 chr5:36666214~36725195:- LIHC cis rs7208859 0.524 rs77498725 ENSG00000264538.5 SUZ12P1 -3.62 0.000341 0.0493 -0.2 -0.19 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30736968 chr17:30709299~30790908:+ LIHC cis rs7208859 0.524 rs59923796 ENSG00000264538.5 SUZ12P1 -3.62 0.000341 0.0493 -0.2 -0.19 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737901 chr17:30709299~30790908:+ LIHC cis rs17826219 0.5 rs57005940 ENSG00000264538.5 SUZ12P1 -3.62 0.000341 0.0493 -0.2 -0.19 Body mass index; chr17:30739311 chr17:30709299~30790908:+ LIHC cis rs7208859 0.573 rs73267872 ENSG00000264538.5 SUZ12P1 -3.62 0.000341 0.0493 -0.2 -0.19 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30740189 chr17:30709299~30790908:+ LIHC cis rs7208859 0.623 rs56812022 ENSG00000264538.5 SUZ12P1 -3.62 0.000341 0.0493 -0.2 -0.19 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741715 chr17:30709299~30790908:+ LIHC cis rs7208859 0.524 rs57670615 ENSG00000264538.5 SUZ12P1 -3.62 0.000341 0.0493 -0.2 -0.19 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30742480 chr17:30709299~30790908:+ LIHC cis rs17826219 0.5 rs2874724 ENSG00000264538.5 SUZ12P1 -3.62 0.000341 0.0493 -0.2 -0.19 Body mass index; chr17:30745415 chr17:30709299~30790908:+ LIHC cis rs17826219 0.568 rs9898097 ENSG00000264538.5 SUZ12P1 -3.62 0.000341 0.0493 -0.2 -0.19 Body mass index; chr17:30745654 chr17:30709299~30790908:+ LIHC cis rs7208859 0.623 rs9911490 ENSG00000264538.5 SUZ12P1 -3.62 0.000341 0.0493 -0.2 -0.19 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30745995 chr17:30709299~30790908:+ LIHC cis rs7208859 0.623 rs7503542 ENSG00000264538.5 SUZ12P1 -3.62 0.000341 0.0493 -0.2 -0.19 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746812 chr17:30709299~30790908:+ LIHC cis rs7208859 0.573 rs11656278 ENSG00000264538.5 SUZ12P1 -3.62 0.000341 0.0493 -0.2 -0.19 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748170 chr17:30709299~30790908:+ LIHC cis rs7208859 0.623 rs6505207 ENSG00000264538.5 SUZ12P1 -3.62 0.000341 0.0493 -0.2 -0.19 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749553 chr17:30709299~30790908:+ LIHC cis rs1075265 0.933 rs7560947 ENSG00000272156.1 RP11-477N3.1 -3.62 0.000341 0.0493 -0.22 -0.19 Chronotype;Morning vs. evening chronotype; chr2:54087473 chr2:54082554~54085066:+ LIHC cis rs875971 0.66 rs801192 ENSG00000224316.1 RP11-479O9.2 -3.62 0.000341 0.0493 -0.18 -0.19 Aortic root size; chr7:66566965 chr7:65773620~65802067:+ LIHC cis rs875971 0.66 rs801190 ENSG00000224316.1 RP11-479O9.2 -3.62 0.000341 0.0493 -0.18 -0.19 Aortic root size; chr7:66568046 chr7:65773620~65802067:+ LIHC cis rs875971 0.66 rs3857686 ENSG00000224316.1 RP11-479O9.2 -3.62 0.000341 0.0493 -0.18 -0.19 Aortic root size; chr7:66571204 chr7:65773620~65802067:+ LIHC cis rs875971 0.619 rs12533585 ENSG00000224316.1 RP11-479O9.2 3.62 0.000341 0.0493 0.18 0.19 Aortic root size; chr7:66519618 chr7:65773620~65802067:+ LIHC cis rs875971 0.66 rs28698552 ENSG00000224316.1 RP11-479O9.2 3.62 0.000341 0.0493 0.18 0.19 Aortic root size; chr7:66540031 chr7:65773620~65802067:+ LIHC cis rs67981189 0.896 rs7157250 ENSG00000274818.1 RP1-292L20.3 3.62 0.000341 0.0493 0.21 0.19 Schizophrenia; chr14:70991112 chr14:70906657~70907111:- LIHC cis rs67981189 0.896 rs4132849 ENSG00000274818.1 RP1-292L20.3 3.62 0.000341 0.0493 0.21 0.19 Schizophrenia; chr14:70992806 chr14:70906657~70907111:- LIHC cis rs67981189 0.821 rs56021283 ENSG00000274818.1 RP1-292L20.3 3.62 0.000341 0.0493 0.21 0.19 Schizophrenia; chr14:70996042 chr14:70906657~70907111:- LIHC cis rs7734985 0.587 rs12054709 ENSG00000250551.1 RP11-254I22.1 3.62 0.000341 0.0493 0.21 0.19 IgG glycosylation; chr5:96255876 chr5:96050115~96215519:+ LIHC cis rs11105298 0.891 rs11105316 ENSG00000258302.2 RP11-981P6.1 3.62 0.000341 0.0493 0.26 0.19 B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio; chr12:89531423 chr12:89561129~89594878:+ LIHC cis rs950169 0.887 rs35986397 ENSG00000189136.7 UBE2Q2P1 3.62 0.000341 0.0493 0.18 0.19 Schizophrenia; chr15:84400409 chr15:84526781~84571216:- LIHC cis rs10508774 1 rs72784043 ENSG00000273038.2 RP11-479G22.8 3.62 0.000341 0.0494 0.28 0.19 Peripheral arterial disease (traffic-related air pollution interaction); chr10:32886644 chr10:32887255~32889311:- LIHC cis rs4873772 0.932 rs7827571 ENSG00000253608.1 RP11-770E5.1 -3.62 0.000341 0.0494 -0.23 -0.19 Lobe attachment (rater-scored or self-reported); chr8:47631195 chr8:48551567~48698510:+ LIHC cis rs2976388 0.573 rs1529865 ENSG00000253741.1 CTD-2292P10.4 -3.62 0.000341 0.0494 -0.22 -0.19 Urinary tract infection frequency; chr8:142707753 chr8:142702252~142726973:- LIHC cis rs2976388 0.609 rs1560986 ENSG00000253741.1 CTD-2292P10.4 -3.62 0.000341 0.0494 -0.22 -0.19 Urinary tract infection frequency; chr8:142708357 chr8:142702252~142726973:- LIHC cis rs2976388 0.609 rs2376491 ENSG00000253741.1 CTD-2292P10.4 -3.62 0.000341 0.0494 -0.22 -0.19 Urinary tract infection frequency; chr8:142709516 chr8:142702252~142726973:- LIHC cis rs4073416 0.712 rs12889002 ENSG00000276116.2 FUT8-AS1 3.62 0.000341 0.0494 0.25 0.19 N-glycan levels; chr14:65596864 chr14:65411170~65412690:- LIHC cis rs4073416 0.684 rs743085 ENSG00000276116.2 FUT8-AS1 3.62 0.000341 0.0494 0.25 0.19 N-glycan levels; chr14:65601415 chr14:65411170~65412690:- LIHC cis rs11098403 0.719 rs4429786 ENSG00000260404.2 RP11-384K6.6 3.62 0.000341 0.0494 0.13 0.19 Schizophrenia; chr4:117830918 chr4:118591773~118633729:+ LIHC cis rs13113518 0.812 rs13140173 ENSG00000272969.1 RP11-528I4.2 3.62 0.000341 0.0494 0.21 0.19 Height; chr4:55527164 chr4:55547112~55547889:+ LIHC cis rs6547705 0.702 rs4832049 ENSG00000231259.4 AC125232.1 3.62 0.000342 0.0494 0.32 0.19 Progressive supranuclear palsy; chr2:86826596 chr2:87031815~87053069:- LIHC cis rs9595908 0.785 rs3912038 ENSG00000212293.1 SNORA16 3.62 0.000342 0.0494 0.21 0.19 Body mass index; chr13:32682061 chr13:32420390~32420516:- LIHC cis rs9595908 0.785 rs3848085 ENSG00000212293.1 SNORA16 3.62 0.000342 0.0494 0.21 0.19 Body mass index; chr13:32687527 chr13:32420390~32420516:- LIHC cis rs559928 0.597 rs947939 ENSG00000236935.1 AP003774.1 3.62 0.000342 0.0494 0.3 0.19 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr11:64117815 chr11:64325050~64329504:- LIHC cis rs67133203 0.579 rs1038526 ENSG00000277201.1 AC087884.1 3.62 0.000342 0.0494 0.21 0.19 Urinary tract infection frequency; chr12:51090362 chr12:51049921~51050025:+ LIHC cis rs17376456 0.932 rs3940842 ENSG00000251023.1 RP11-549J18.1 -3.62 0.000342 0.0494 -0.41 -0.19 Diabetic retinopathy; chr5:94199153 chr5:93860669~93863825:- LIHC cis rs1799949 0.929 rs799906 ENSG00000267681.1 CTD-3199J23.6 -3.62 0.000342 0.0494 -0.19 -0.19 Menopause (age at onset); chr17:43126099 chr17:43144956~43145255:+ LIHC cis rs1799949 0.965 rs799908 ENSG00000267681.1 CTD-3199J23.6 -3.62 0.000342 0.0494 -0.19 -0.19 Menopause (age at onset); chr17:43126899 chr17:43144956~43145255:+ LIHC cis rs1799949 0.93 rs1554063 ENSG00000267681.1 CTD-3199J23.6 -3.62 0.000342 0.0494 -0.19 -0.19 Menopause (age at onset); chr17:43135128 chr17:43144956~43145255:+ LIHC cis rs62025270 0.688 rs12148571 ENSG00000259295.5 CSPG4P12 -3.62 0.000342 0.0494 -0.35 -0.19 Idiopathic pulmonary fibrosis; chr15:85724162 chr15:85191438~85213905:+ LIHC cis rs4866650 0.803 rs16869638 ENSG00000278350.1 AC091849.1 -3.62 0.000342 0.0494 -0.27 -0.19 Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction); chr5:2448424 chr5:1569421~1569533:- LIHC cis rs3738443 0.904 rs12569090 ENSG00000259865.1 RP11-488L18.10 3.62 0.000342 0.0494 0.21 0.19 Alcohol dependence; chr1:247234370 chr1:247187281~247188526:- LIHC cis rs17301853 1 rs75402546 ENSG00000227373.4 RP11-160H22.5 3.62 0.000342 0.0494 0.46 0.19 Migraine without aura;Migraine - clinic-based; chr1:174172092 chr1:174115300~174160004:- LIHC cis rs11159086 0.793 rs1029701 ENSG00000270000.1 RP3-449M8.9 3.62 0.000342 0.0494 0.27 0.19 Advanced glycation end-product levels; chr14:74474112 chr14:74471930~74472360:- LIHC cis rs643506 0.874 rs625477 ENSG00000230911.1 PPIHP1 -3.62 0.000342 0.0494 -0.26 -0.19 Breast cancer; chr11:111790962 chr11:112029858~112030367:- LIHC cis rs7172689 0.529 rs17875492 ENSG00000278029.1 CTD-2240J17.2 -3.62 0.000342 0.0494 -0.39 -0.19 Inattentive symptoms; chr15:81294745 chr15:81392759~81393384:+ LIHC cis rs728616 0.51 rs61860860 ENSG00000225484.5 NUTM2B-AS1 -3.62 0.000342 0.0494 -0.39 -0.19 Chronic obstructive pulmonary disease-related biomarkers; chr10:79998816 chr10:79663088~79826594:- LIHC cis rs801193 1 rs7782320 ENSG00000224316.1 RP11-479O9.2 3.62 0.000342 0.0494 0.18 0.19 Aortic root size; chr7:66712111 chr7:65773620~65802067:+ LIHC cis rs6832769 1 rs28514423 ENSG00000272969.1 RP11-528I4.2 -3.62 0.000342 0.0495 -0.23 -0.19 Personality dimensions; chr4:55563072 chr4:55547112~55547889:+ LIHC cis rs12908161 1 rs12905057 ENSG00000225151.9 GOLGA2P7 -3.62 0.000342 0.0495 -0.25 -0.19 Schizophrenia; chr15:84667534 chr15:84199311~84230136:- LIHC cis rs2243480 0.901 rs34807232 ENSG00000228409.4 CCT6P1 3.62 0.000342 0.0495 0.21 0.19 Diabetic kidney disease; chr7:66500146 chr7:65751142~65763354:+ LIHC cis rs2243480 0.901 rs35823062 ENSG00000228409.4 CCT6P1 3.62 0.000342 0.0495 0.21 0.19 Diabetic kidney disease; chr7:66500834 chr7:65751142~65763354:+ LIHC cis rs1115240 0.574 rs61986558 ENSG00000257842.4 NOVA1-AS1 3.62 0.000342 0.0495 0.19 0.19 Educational attainment (years of education); chr14:26577794 chr14:26598412~26806467:+ LIHC cis rs516805 0.748 rs72962455 ENSG00000279453.1 RP3-425C14.4 3.62 0.000342 0.0495 0.3 0.19 Lymphocyte counts; chr6:122563378 chr6:122436789~122439223:- LIHC cis rs1405130 0.967 rs13005472 ENSG00000224287.2 MSL3P1 3.62 0.000342 0.0495 0.23 0.19 Coronary artery disease; chr2:234665821 chr2:233865437~233868444:- LIHC cis rs1405130 0.933 rs12991619 ENSG00000224287.2 MSL3P1 3.62 0.000342 0.0495 0.23 0.19 Coronary artery disease; chr2:234665906 chr2:233865437~233868444:- LIHC cis rs7044106 0.664 rs7861679 ENSG00000270917.1 RP11-27I1.6 3.62 0.000342 0.0495 0.24 0.19 Hip circumference adjusted for BMI; chr9:120613311 chr9:120812475~120812845:- LIHC cis rs9733 0.519 rs11587444 ENSG00000231073.1 RP11-316M1.3 3.62 0.000342 0.0495 0.2 0.19 Tonsillectomy; chr1:150750368 chr1:150973123~150975534:+ LIHC cis rs1032726 0.663 rs61629858 ENSG00000240776.1 RP11-435F17.1 3.62 0.000342 0.0495 0.25 0.19 Sum eosinophil basophil counts;Eosinophil counts; chr3:112935600 chr3:113850237~113850731:- LIHC cis rs1115240 0.898 rs178195 ENSG00000257842.4 NOVA1-AS1 -3.62 0.000342 0.0495 -0.18 -0.19 Educational attainment (years of education); chr14:26500877 chr14:26598412~26806467:+ LIHC cis rs11096990 0.855 rs2711935 ENSG00000249685.1 RP11-360F5.3 -3.62 0.000342 0.0495 -0.27 -0.19 Cognitive function; chr4:39160837 chr4:39133913~39135608:+ LIHC cis rs9595908 0.709 rs4942892 ENSG00000212293.1 SNORA16 -3.62 0.000342 0.0495 -0.22 -0.19 Body mass index; chr13:32754269 chr13:32420390~32420516:- LIHC cis rs1223397 0.651 rs2496146 ENSG00000215022.6 RP1-257A7.4 -3.62 0.000343 0.0495 -0.2 -0.19 Blood pressure; chr6:13312242 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs2919686 ENSG00000215022.6 RP1-257A7.4 -3.62 0.000343 0.0495 -0.2 -0.19 Blood pressure; chr6:13312409 chr6:13264861~13295586:- LIHC cis rs1223397 0.651 rs3001966 ENSG00000215022.6 RP1-257A7.4 -3.62 0.000343 0.0495 -0.2 -0.19 Blood pressure; chr6:13312452 chr6:13264861~13295586:- LIHC cis rs643506 0.874 rs645411 ENSG00000230911.1 PPIHP1 -3.62 0.000343 0.0495 -0.25 -0.19 Breast cancer; chr11:111823766 chr11:112029858~112030367:- LIHC cis rs9976767 0.932 rs11910048 ENSG00000233056.2 ERVH48-1 -3.62 0.000343 0.0496 -0.22 -0.19 Type 1 diabetes; chr21:42402467 chr21:42916803~42925646:- LIHC cis rs445114 0.578 rs436238 ENSG00000246228.5 CASC8 3.62 0.000343 0.0496 0.19 0.19 Prostate cancer;Prostate cancer (SNP x SNP interaction); chr8:127332783 chr8:127289817~127482139:- LIHC cis rs17032980 0.744 rs13405122 ENSG00000232046.5 AC007392.3 -3.62 0.000343 0.0496 -0.32 -0.19 Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia; chr2:67075734 chr2:66574030~66730157:+ LIHC cis rs1510272 1 rs1510272 ENSG00000243926.1 TIPARP-AS1 -3.62 0.000343 0.0496 -0.18 -0.19 Testicular germ cell tumor; chr3:156582935 chr3:156671862~156674378:- LIHC cis rs4356975 0.563 rs4535394 ENSG00000250919.1 RP11-813N20.3 3.62 0.000343 0.0496 0.19 0.19 Obesity-related traits; chr4:69122735 chr4:69027831~69044578:+ LIHC cis rs12681366 0.801 rs55963151 ENSG00000253704.1 RP11-267M23.4 3.62 0.000343 0.0496 0.23 0.19 Nonsyndromic cleft lip with cleft palate; chr8:94466198 chr8:94553722~94569745:+ LIHC cis rs921968 0.613 rs6436066 ENSG00000272555.1 RP11-459I19.1 -3.62 0.000343 0.0496 -0.21 -0.19 Mean corpuscular hemoglobin concentration; chr2:218713638 chr2:218818690~218819144:+ LIHC cis rs943466 0.614 rs4711345 ENSG00000223837.2 BRD2-IT1 -3.62 0.000343 0.0496 -0.2 -0.19 Body mass index (joint analysis main effects and physical activity interaction);Body mass index; chr6:33763177 chr6:32970232~32970886:+ LIHC cis rs6674176 0.597 rs12127737 ENSG00000237950.1 RP11-7O11.3 3.62 0.000343 0.0496 0.2 0.19 Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr1:43936893 chr1:43944370~43946551:- LIHC cis rs10510102 0.507 rs12244092 ENSG00000276742.1 RP11-500G22.4 3.62 0.000343 0.0496 0.32 0.19 Breast cancer; chr10:122005769 chr10:121956782~121957098:+ LIHC cis rs4568518 0.535 rs4236293 ENSG00000237773.4 AC003075.4 3.62 0.000343 0.0496 0.24 0.19 Measles; chr7:18022819 chr7:17279834~17299357:- LIHC cis rs6832769 0.767 rs6850524 ENSG00000272969.1 RP11-528I4.2 3.62 0.000343 0.0496 0.23 0.19 Personality dimensions; chr4:55515830 chr4:55547112~55547889:+ LIHC cis rs6832769 0.767 rs11133394 ENSG00000272969.1 RP11-528I4.2 3.62 0.000343 0.0496 0.23 0.19 Personality dimensions; chr4:55517071 chr4:55547112~55547889:+ LIHC cis rs6832769 1 rs6851838 ENSG00000272969.1 RP11-528I4.2 -3.62 0.000344 0.0497 -0.23 -0.19 Personality dimensions; chr4:55554580 chr4:55547112~55547889:+ LIHC cis rs6832769 1 rs10034433 ENSG00000272969.1 RP11-528I4.2 -3.62 0.000344 0.0497 -0.23 -0.19 Personality dimensions; chr4:55555009 chr4:55547112~55547889:+ LIHC cis rs960902 0.764 rs7574012 ENSG00000213553.4 RPLP0P6 3.62 0.000344 0.0497 0.15 0.19 Response to TNF-alpha inhibitors in rheumatoid arthritis; chr2:37500087 chr2:38481851~38482804:+ LIHC cis rs481331 0.741 rs574720 ENSG00000185904.10 LINC00839 -3.62 0.000344 0.0497 -0.39 -0.19 Systemic juvenile idiopathic arthritis; chr10:42653951 chr10:42475543~42495336:+ LIHC cis rs27434 0.66 rs42398 ENSG00000272109.1 CTD-2260A17.3 -3.62 0.000344 0.0497 -0.26 -0.19 Ankylosing spondylitis; chr5:96784751 chr5:96804353~96806105:+ LIHC cis rs2227564 0.794 rs2633320 ENSG00000272791.1 RP11-464F9.22 3.62 0.000344 0.0497 0.19 0.19 Crohn's disease;Inflammatory bowel disease; chr10:73933548 chr10:73630556~73631490:+ LIHC cis rs7989332 1 rs7329823 ENSG00000275964.1 RP11-61K9.3 -3.62 0.000344 0.0497 -0.25 -0.19 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20475988 chr13:19863858~19865048:+ LIHC cis rs9976767 0.896 rs9975920 ENSG00000225218.1 AP001628.6 -3.62 0.000344 0.0497 -0.19 -0.19 Type 1 diabetes; chr21:42398547 chr21:42831040~42836477:- LIHC cis rs4356975 0.509 rs4587017 ENSG00000250919.1 RP11-813N20.3 -3.62 0.000344 0.0497 -0.2 -0.19 Obesity-related traits; chr4:69081680 chr4:69027831~69044578:+ LIHC cis rs4356975 0.509 rs4458521 ENSG00000250919.1 RP11-813N20.3 -3.62 0.000344 0.0497 -0.2 -0.19 Obesity-related traits; chr4:69086240 chr4:69027831~69044578:+ LIHC cis rs4356975 0.509 rs4694169 ENSG00000250919.1 RP11-813N20.3 -3.62 0.000344 0.0497 -0.2 -0.19 Obesity-related traits; chr4:69088433 chr4:69027831~69044578:+ LIHC cis rs12273350 0.89 rs1559800 ENSG00000254759.1 NAP1L1P1 3.62 0.000344 0.0497 0.23 0.19 Creutzfeldt-Jakob disease (variant); chr11:125363064 chr11:126067539~126068601:+ LIHC cis rs2243480 1 rs313809 ENSG00000229886.1 RP5-1132H15.3 3.62 0.000344 0.0497 0.28 0.19 Diabetic kidney disease; chr7:66034996 chr7:66025126~66031544:- LIHC cis rs9611519 1 rs2057070 ENSG00000231907.2 GAPDHP37 3.62 0.000344 0.0497 0.29 0.19 Neuroticism; chr22:41168283 chr22:40673484~40674451:- LIHC cis rs2838568 0.967 rs2838569 ENSG00000228709.1 AP001065.15 -3.62 0.000344 0.0497 -0.22 -0.19 Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals; chr21:44478340 chr21:44485577~44490288:+ LIHC cis rs8046148 0.724 rs1362633 ENSG00000279356.1 RP11-429P3.8 -3.62 0.000344 0.0497 -0.18 -0.19 Testicular germ cell tumor; chr16:50028661 chr16:50072862~50074986:+ LIHC cis rs4073416 0.679 rs7155541 ENSG00000276116.2 FUT8-AS1 3.62 0.000344 0.0497 0.25 0.19 N-glycan levels; chr14:65579524 chr14:65411170~65412690:- LIHC cis rs16958440 0.867 rs78585258 ENSG00000267724.1 RP11-49K24.8 3.62 0.000344 0.0497 0.36 0.19 Sitting height ratio; chr18:47151358 chr18:47105946~47108062:+ LIHC cis rs4925386 0.84 rs6143034 ENSG00000226332.2 RP11-157P1.4 3.62 0.000344 0.0498 0.22 0.19 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62345489 chr20:62305432~62306325:- LIHC cis rs7635879 0.693 rs4687496 ENSG00000230102.6 RP11-407B7.1 3.62 0.000345 0.0498 0.19 0.19 Breastfeeding duration; chr3:194011436 chr3:194005259~194070970:- LIHC cis rs1823874 0.653 rs12902823 ENSG00000182397.13 DNM1P46 -3.62 0.000345 0.0498 -0.23 -0.19 IgG glycosylation; chr15:99812013 chr15:99790156~99806927:- LIHC cis rs2658782 0.666 rs2925361 ENSG00000279684.1 RP11-755E23.2 -3.62 0.000345 0.0498 -0.32 -0.19 Pulmonary function decline; chr11:93365657 chr11:93286629~93288903:- LIHC cis rs2299116 1 rs55988723 ENSG00000225264.3 ZNRF2P2 -3.62 0.000345 0.0498 -0.22 -0.19 Serum thyroid-stimulating hormone levels; chr7:28770632 chr7:29598795~29685255:- LIHC cis rs2299116 1 rs56014181 ENSG00000225264.3 ZNRF2P2 -3.62 0.000345 0.0498 -0.22 -0.19 Serum thyroid-stimulating hormone levels; chr7:28770786 chr7:29598795~29685255:- LIHC cis rs875971 0.577 rs35072105 ENSG00000224316.1 RP11-479O9.2 -3.62 0.000345 0.0498 -0.19 -0.19 Aortic root size; chr7:66144830 chr7:65773620~65802067:+ LIHC cis rs3845817 0.703 rs702888 ENSG00000281920.1 RP11-418H16.1 -3.62 0.000345 0.0498 -0.23 -0.19 Bipolar disorder; chr2:65527905 chr2:65623272~65628424:+ LIHC cis rs7219021 0.743 rs575556 ENSG00000248278.1 SUMO2P17 3.62 0.000345 0.0498 0.25 0.19 Schizophrenia or bipolar disorder; chr17:48780125 chr17:48874860~48908983:- LIHC cis rs9649213 0.537 rs35997266 ENSG00000272950.1 RP11-307C18.1 3.62 0.000345 0.0498 0.23 0.19 Prostate cancer (SNP x SNP interaction); chr7:98336254 chr7:98322853~98323430:+ LIHC cis rs2119480 0.762 rs418935 ENSG00000277767.1 RP11-365P13.5 3.62 0.000345 0.0498 0.2 0.19 Diastolic blood pressure; chr13:110656920 chr13:110916004~110917827:+ LIHC cis rs287982 0.932 rs58521916 ENSG00000269973.1 RP11-95D17.1 -3.62 0.000345 0.0498 -0.18 -0.19 Nonsyndromic cleft lip with cleft palate; chr2:9826341 chr2:9936360~9939590:+ LIHC cis rs287982 0.932 rs11887231 ENSG00000269973.1 RP11-95D17.1 -3.62 0.000345 0.0498 -0.18 -0.19 Nonsyndromic cleft lip with cleft palate; chr2:9826987 chr2:9936360~9939590:+ LIHC cis rs287982 1 rs13404815 ENSG00000269973.1 RP11-95D17.1 -3.62 0.000345 0.0498 -0.18 -0.19 Nonsyndromic cleft lip with cleft palate; chr2:9827637 chr2:9936360~9939590:+ LIHC cis rs2933343 1 rs789227 ENSG00000261159.1 RP11-723O4.9 3.62 0.000345 0.0498 0.26 0.19 IgG glycosylation; chr3:128881742 chr3:128859716~128860526:- LIHC cis rs9847710 0.869 rs2564917 ENSG00000242797.3 GLYCTK-AS1 -3.62 0.000345 0.0498 -0.19 -0.19 Ulcerative colitis; chr3:53003679 chr3:52288580~52299067:- LIHC cis rs875971 0.66 rs1860470 ENSG00000224316.1 RP11-479O9.2 -3.62 0.000345 0.0498 -0.18 -0.19 Aortic root size; chr7:66638707 chr7:65773620~65802067:+ LIHC cis rs6445975 0.715 rs6790764 ENSG00000272360.1 RP11-359I18.5 -3.62 0.000345 0.0498 -0.22 -0.19 Systemic lupus erythematosus; chr3:58280223 chr3:58490830~58491291:- LIHC cis rs1267303 0.798 rs1267304 ENSG00000227857.2 RP4-533D7.5 3.62 0.000345 0.0498 0.26 0.19 Monobrow; chr1:46524754 chr1:46134531~46139081:+ LIHC cis rs4356975 0.563 rs12506962 ENSG00000250919.1 RP11-813N20.3 -3.62 0.000345 0.0498 -0.19 -0.19 Obesity-related traits; chr4:69100306 chr4:69027831~69044578:+ LIHC cis rs6832769 0.961 rs3805147 ENSG00000272969.1 RP11-528I4.2 3.62 0.000345 0.0498 0.23 0.19 Personality dimensions; chr4:55440563 chr4:55547112~55547889:+ LIHC cis rs2243480 1 rs1723267 ENSG00000232559.3 GS1-124K5.12 3.62 0.000345 0.0499 0.21 0.19 Diabetic kidney disease; chr7:66008327 chr7:66554588~66576923:- LIHC cis rs7722022 0.614 rs57729160 ENSG00000253428.1 CTB-43E15.2 3.62 0.000345 0.0499 0.2 0.19 Adiponectin levels; chr5:173522351 chr5:173689459~173705849:+ LIHC cis rs7722022 0.922 rs11746666 ENSG00000253428.1 CTB-43E15.2 3.62 0.000345 0.0499 0.2 0.19 Adiponectin levels; chr5:173523688 chr5:173689459~173705849:+ LIHC cis rs6982240 0.569 rs6992278 ENSG00000261655.1 CTD-3064M3.3 -3.62 0.000345 0.0499 -0.22 -0.19 Tonsillectomy; chr8:141269284 chr8:141353403~141355365:- LIHC cis rs11064837 0.523 rs7979627 ENSG00000248636.5 RP11-768F21.1 3.62 0.000345 0.0499 0.33 0.19 Schizophrenia; chr12:119662399 chr12:119387987~119668079:- LIHC cis rs9457247 0.765 rs12212247 ENSG00000227598.1 RP1-167A14.2 -3.62 0.000345 0.0499 -0.21 -0.19 Crohn's disease; chr6:167000051 chr6:166969626~166999065:- LIHC cis rs10256972 1 rs10256972 ENSG00000199023.2 MIR339 3.62 0.000345 0.0499 0.21 0.19 Endometriosis;Longevity; chr7:999367 chr7:1022935~1023045:- LIHC cis rs240993 0.812 rs9400476 ENSG00000271789.1 RP5-1112D6.7 3.62 0.000345 0.0499 0.21 0.19 Inflammatory skin disease;Psoriasis; chr6:111463172 chr6:111297126~111298510:+ LIHC cis rs10752881 1 rs4454510 ENSG00000224468.3 RP11-181K3.4 3.62 0.000345 0.0499 0.16 0.19 Colorectal cancer; chr1:183013168 chr1:183138402~183141282:- LIHC cis rs2251381 0.523 rs2832306 ENSG00000224649.1 AF124730.4 -3.61 0.000346 0.0499 -0.26 -0.19 Selective IgA deficiency; chr21:29382148 chr21:29182027~29187795:- LIHC cis rs4927850 0.723 rs7630825 ENSG00000242086.7 LINC00969 3.61 0.000346 0.0499 0.2 0.19 Pancreatic cancer; chr3:196026869 chr3:195658062~195739964:+ LIHC cis rs6732160 0.525 rs2303907 ENSG00000272702.1 RP11-44N22.3 3.61 0.000346 0.0499 0.22 0.19 Intelligence (multi-trait analysis); chr2:73243369 chr2:73113018~73115907:+ LIHC cis rs6732160 0.691 rs4536673 ENSG00000272702.1 RP11-44N22.3 3.61 0.000346 0.0499 0.21 0.19 Intelligence (multi-trait analysis); chr2:73186334 chr2:73113018~73115907:+ LIHC cis rs2117029 0.767 rs11168838 ENSG00000258017.1 RP11-386G11.10 -3.61 0.000346 0.0499 -0.22 -0.19 Intelligence (multi-trait analysis); chr12:49061223 chr12:49127782~49147869:+ LIHC cis rs367615 0.704 rs72802966 ENSG00000249476.1 CTD-2587M2.1 3.61 0.000346 0.0499 0.23 0.19 Colorectal cancer (SNP x SNP interaction); chr5:109511053 chr5:109237120~109326369:- LIHC cis rs367615 0.704 rs72804385 ENSG00000249476.1 CTD-2587M2.1 3.61 0.000346 0.0499 0.23 0.19 Colorectal cancer (SNP x SNP interaction); chr5:109512442 chr5:109237120~109326369:- LIHC cis rs8005677 0.962 rs11157931 ENSG00000279656.1 RP11-298I3.6 3.61 0.000346 0.0499 0.21 0.19 Cognitive ability (multi-trait analysis); chr14:22933984 chr14:23023083~23024217:- LIHC cis rs228614 0.51 rs223397 ENSG00000248971.2 KRT8P46 -3.61 0.000346 0.0499 -0.19 -0.19 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102821494 chr4:102728746~102730171:- LIHC cis rs1979679 0.842 rs35098487 ENSG00000278733.1 RP11-425D17.1 3.61 0.000346 0.0499 0.26 0.19 Ossification of the posterior longitudinal ligament of the spine; chr12:28191043 chr12:28185625~28186190:- LIHC cis rs2245008 0.95 rs824400 ENSG00000260932.1 RP11-483P21.6 3.61 0.000346 0.0499 0.29 0.19 Pursuit maintenance gain; chr16:83956331 chr16:83929796~83931223:- LIHC cis rs5758659 0.716 rs2143138 ENSG00000273366.1 CTA-989H11.1 -3.61 0.000346 0.0499 -0.23 -0.19 Cognitive function; chr22:42222334 chr22:42278188~42278846:+ LIHC cis rs1106684 1 rs11764453 ENSG00000233559.1 AC016831.7 3.61 0.000346 0.0499 0.34 0.19 Body mass index; chr7:131768225 chr7:130853720~130928649:+ LIHC cis rs7989332 0.662 rs9550655 ENSG00000275964.1 RP11-61K9.3 3.61 0.000346 0.0499 0.29 0.19 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin); chr13:20489835 chr13:19863858~19865048:+ LIHC cis rs1802575 0.675 rs11888023 ENSG00000272606.1 RP11-554J4.1 3.61 0.000346 0.0499 0.36 0.19 Childhood ear infection; chr2:55779850 chr2:55617909~55618373:+ LIHC cis rs875971 0.577 rs35072105 ENSG00000237310.1 GS1-124K5.4 -3.61 0.000346 0.05 -0.19 -0.19 Aortic root size; chr7:66144830 chr7:66493706~66495474:+ LIHC cis rs2301573 1 rs12635414 ENSG00000251474.5 RPL32P3 3.61 0.000346 0.05 0.26 0.19 Hip circumference; chr3:129594138 chr3:129382922~129399655:- LIHC cis rs7095607 1 rs1900014 ENSG00000233590.1 RP11-153K11.3 3.61 0.000346 0.05 0.22 0.19 Lung function (FVC); chr10:68184190 chr10:68233251~68242379:- LIHC cis rs2228479 1 rs62052186 ENSG00000261253.2 AC137932.6 3.61 0.000346 0.05 0.28 0.19 Skin colour saturation; chr16:89903159 chr16:89321133~89325110:+ LIHC cis rs11216126 0.778 rs17119975 ENSG00000254851.1 RP11-109L13.1 -3.61 0.000347 0.05 -0.28 -0.19 HDL cholesterol; chr11:116763841 chr11:117135528~117138582:+ LIHC trans rs13177918 0.677 rs3797622 ENSG00000213058.3 RP4-765C7.2 28.07 8.91e-91 2.12e-82 1.19 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs4841 ENSG00000213058.3 RP4-765C7.2 27.99 1.73e-90 4.08e-82 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446963 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs13183077 ENSG00000213058.3 RP4-765C7.2 27.99 1.73e-90 4.08e-82 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447009 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs13181401 ENSG00000213058.3 RP4-765C7.2 27.43 2.18e-88 4.74e-80 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs4541646 ENSG00000213058.3 RP4-765C7.2 27.43 2.18e-88 4.74e-80 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs3900644 ENSG00000213058.3 RP4-765C7.2 27.43 2.18e-88 4.74e-80 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs2070844 ENSG00000213058.3 RP4-765C7.2 27.43 2.18e-88 4.74e-80 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs2073472 ENSG00000213058.3 RP4-765C7.2 27.43 2.18e-88 4.74e-80 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr1:178411616~178411972:+ LIHC trans rs13177918 0.629 rs2070842 ENSG00000213058.3 RP4-765C7.2 27.43 2.18e-88 4.74e-80 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs13171800 ENSG00000213058.3 RP4-765C7.2 27.43 2.18e-88 4.74e-80 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs2070841 ENSG00000213058.3 RP4-765C7.2 27.43 2.18e-88 4.74e-80 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs13161417 ENSG00000213058.3 RP4-765C7.2 27.31 5.93e-88 1.27e-79 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs13161156 ENSG00000213058.3 RP4-765C7.2 27.31 5.93e-88 1.27e-79 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs13161099 ENSG00000213058.3 RP4-765C7.2 27.31 6.22e-88 1.32e-79 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr1:178411616~178411972:+ LIHC trans rs13177918 0.629 rs13161261 ENSG00000213058.3 RP4-765C7.2 27.31 6.22e-88 1.32e-79 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr1:178411616~178411972:+ LIHC trans rs13177918 0.75 rs58256223 ENSG00000213058.3 RP4-765C7.2 27.12 3.19e-87 6.69e-79 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442456 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs13177951 ENSG00000213058.3 RP4-765C7.2 27.04 6.47e-87 1.34e-78 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs13177970 ENSG00000213058.3 RP4-765C7.2 27.04 6.47e-87 1.34e-78 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs13164105 ENSG00000213058.3 RP4-765C7.2 27.04 6.47e-87 1.34e-78 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr1:178411616~178411972:+ LIHC trans rs941207 0.724 rs1979325 ENSG00000121089.4 NACA3P 27 8.41e-87 1.73e-78 1.03 0.83 Platelet count; chr12:56728152 chr4:164943290~164943937:+ LIHC trans rs13177918 0.75 rs59354956 ENSG00000213058.3 RP4-765C7.2 27 8.73e-87 1.78e-78 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442457 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs3857421 ENSG00000213058.3 RP4-765C7.2 -26.91 1.88e-86 3.83e-78 -1.15 -0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr1:178411616~178411972:+ LIHC trans rs13177918 0.686 rs12654827 ENSG00000213058.3 RP4-765C7.2 26.83 3.75e-86 7.48e-78 1.18 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs13160685 ENSG00000213058.3 RP4-765C7.2 26.83 3.75e-86 7.48e-78 1.18 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr1:178411616~178411972:+ LIHC trans rs941207 0.724 rs4788 ENSG00000121089.4 NACA3P 26.69 1.28e-85 2.53e-77 1.02 0.82 Platelet count; chr12:56712876 chr4:164943290~164943937:+ LIHC trans rs941207 0.756 rs2958149 ENSG00000121089.4 NACA3P 26.61 2.48e-85 4.87e-77 1.03 0.82 Platelet count; chr12:56716008 chr4:164943290~164943937:+ LIHC trans rs941207 0.756 rs7978685 ENSG00000121089.4 NACA3P 26.59 3.16e-85 6.18e-77 1.03 0.82 Platelet count; chr12:56709370 chr4:164943290~164943937:+ LIHC trans rs13177918 0.677 rs57890152 ENSG00000213058.3 RP4-765C7.2 26.23 7.06e-84 1.33e-75 1.18 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr1:178411616~178411972:+ LIHC trans rs13177918 0.557 rs12520101 ENSG00000213058.3 RP4-765C7.2 26.03 4.08e-83 7.64e-75 1.13 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr1:178411616~178411972:+ LIHC trans rs13177918 0.651 rs13184111 ENSG00000213058.3 RP4-765C7.2 25.96 7.45e-83 1.39e-74 1.18 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150434649 chr1:178411616~178411972:+ LIHC trans rs941207 0.756 rs2926743 ENSG00000121089.4 NACA3P 25.84 2.16e-82 3.97e-74 1.01 0.81 Platelet count; chr12:56720316 chr4:164943290~164943937:+ LIHC trans rs13177918 0.626 rs12186649 ENSG00000213058.3 RP4-765C7.2 25.73 5.41e-82 9.91e-74 1.17 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150438963 chr1:178411616~178411972:+ LIHC trans rs13177918 0.677 rs3797622 ENSG00000224114.1 RP11-343H5.4 25.71 6.33e-82 1.15e-73 1.17 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr1:206695837~206696269:- LIHC trans rs941207 0.756 rs7313074 ENSG00000121089.4 NACA3P -25.67 9.37e-82 1.68e-73 -1.03 -0.81 Platelet count; chr12:56760705 chr4:164943290~164943937:+ LIHC trans rs6477998 0.58 rs9299214 ENSG00000238072.1 RP11-305M3.2 25.66 1.04e-81 1.85e-73 1.04 0.81 Hematology traits; chr9:113273416 chr7:129410113~129410370:- LIHC trans rs6477998 0.603 rs10117451 ENSG00000238072.1 RP11-305M3.2 25.66 1.04e-81 1.85e-73 1.04 0.81 Hematology traits; chr9:113273610 chr7:129410113~129410370:- LIHC trans rs13177918 0.677 rs4841 ENSG00000224114.1 RP11-343H5.4 25.61 1.63e-81 2.86e-73 1.17 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446963 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs13183077 ENSG00000224114.1 RP11-343H5.4 25.61 1.63e-81 2.86e-73 1.17 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447009 chr1:206695837~206696269:- LIHC trans rs928391 0.681 rs12145743 ENSG00000227183.3 HDGFP1 25.51 3.94e-81 6.72e-73 1.05 0.81 Platelet count; chr1:156730859 chrX:131646639~131646890:+ LIHC trans rs13177918 0.677 rs3857421 ENSG00000224114.1 RP11-343H5.4 -25.06 2e-79 3.35e-71 -1.13 -0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs13181401 ENSG00000224114.1 RP11-343H5.4 25.03 2.61e-79 4.13e-71 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs4541646 ENSG00000224114.1 RP11-343H5.4 25.03 2.61e-79 4.13e-71 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs3900644 ENSG00000224114.1 RP11-343H5.4 25.03 2.61e-79 4.13e-71 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs2070844 ENSG00000224114.1 RP11-343H5.4 25.03 2.61e-79 4.13e-71 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs2073472 ENSG00000224114.1 RP11-343H5.4 25.03 2.61e-79 4.13e-71 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr1:206695837~206696269:- LIHC trans rs13177918 0.629 rs2070842 ENSG00000224114.1 RP11-343H5.4 25.03 2.61e-79 4.13e-71 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs13171800 ENSG00000224114.1 RP11-343H5.4 25.03 2.61e-79 4.13e-71 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs2070841 ENSG00000224114.1 RP11-343H5.4 25.03 2.61e-79 4.13e-71 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs13177951 ENSG00000224114.1 RP11-343H5.4 24.97 4.7e-79 7.36e-71 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs13177970 ENSG00000224114.1 RP11-343H5.4 24.97 4.7e-79 7.36e-71 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs13164105 ENSG00000224114.1 RP11-343H5.4 24.97 4.7e-79 7.36e-71 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr1:206695837~206696269:- LIHC trans rs13177918 0.75 rs58256223 ENSG00000224114.1 RP11-343H5.4 24.93 6.41e-79 9.97e-71 1.15 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442456 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs3797622 ENSG00000239528.1 RPS14P8 24.88 9.86e-79 1.52e-70 1.13 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs13161417 ENSG00000224114.1 RP11-343H5.4 24.85 1.31e-78 1.99e-70 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs13161156 ENSG00000224114.1 RP11-343H5.4 24.85 1.31e-78 1.99e-70 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs13161099 ENSG00000224114.1 RP11-343H5.4 24.83 1.62e-78 2.45e-70 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr1:206695837~206696269:- LIHC trans rs13177918 0.629 rs13161261 ENSG00000224114.1 RP11-343H5.4 24.83 1.62e-78 2.45e-70 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs4841 ENSG00000239528.1 RPS14P8 24.74 3.39e-78 5.09e-70 1.13 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446963 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs13183077 ENSG00000239528.1 RPS14P8 24.74 3.39e-78 5.09e-70 1.13 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447009 chr5:116562562~116562930:+ LIHC trans rs13177918 0.75 rs59354956 ENSG00000224114.1 RP11-343H5.4 24.73 3.86e-78 5.75e-70 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442457 chr1:206695837~206696269:- LIHC trans rs13177918 0.686 rs12654827 ENSG00000224114.1 RP11-343H5.4 24.44 5.12e-77 7.55e-69 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs13160685 ENSG00000224114.1 RP11-343H5.4 24.44 5.12e-77 7.55e-69 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr1:206695837~206696269:- LIHC trans rs13177918 0.75 rs58256223 ENSG00000239528.1 RPS14P8 24.32 1.53e-76 2.23e-68 1.12 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442456 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs13181401 ENSG00000239528.1 RPS14P8 24.3 1.8e-76 2.5e-68 1.12 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs4541646 ENSG00000239528.1 RPS14P8 24.3 1.8e-76 2.5e-68 1.12 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs3900644 ENSG00000239528.1 RPS14P8 24.3 1.8e-76 2.5e-68 1.12 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs2070844 ENSG00000239528.1 RPS14P8 24.3 1.8e-76 2.5e-68 1.12 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs2073472 ENSG00000239528.1 RPS14P8 24.3 1.8e-76 2.5e-68 1.12 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr5:116562562~116562930:+ LIHC trans rs13177918 0.629 rs2070842 ENSG00000239528.1 RPS14P8 24.3 1.8e-76 2.5e-68 1.12 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs13171800 ENSG00000239528.1 RPS14P8 24.3 1.8e-76 2.5e-68 1.12 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs2070841 ENSG00000239528.1 RPS14P8 24.3 1.8e-76 2.5e-68 1.12 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs13161417 ENSG00000239528.1 RPS14P8 24.08 1.2e-75 1.64e-67 1.12 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs13161156 ENSG00000239528.1 RPS14P8 24.08 1.2e-75 1.64e-67 1.12 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr5:116562562~116562930:+ LIHC trans rs13177918 0.75 rs59354956 ENSG00000239528.1 RPS14P8 24.05 1.59e-75 2.17e-67 1.12 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442457 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs13161099 ENSG00000239528.1 RPS14P8 24.03 1.9e-75 2.57e-67 1.13 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr5:116562562~116562930:+ LIHC trans rs13177918 0.629 rs13161261 ENSG00000239528.1 RPS14P8 24.03 1.9e-75 2.57e-67 1.13 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs57890152 ENSG00000224114.1 RP11-343H5.4 24.01 2.4e-75 3.23e-67 1.15 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr1:206695837~206696269:- LIHC trans rs13177918 0.677 rs3857421 ENSG00000239528.1 RPS14P8 -23.99 2.86e-75 3.83e-67 -1.09 -0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr5:116562562~116562930:+ LIHC trans rs7949030 0.626 rs1061093 ENSG00000186676.3 EEF1GP1 23.98 3.1e-75 4.15e-67 1.21 0.79 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62567436 chr7:125033453~125035301:+ LIHC trans rs13177918 0.677 rs13177951 ENSG00000239528.1 RPS14P8 23.96 3.75e-75 4.97e-67 1.12 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs13177970 ENSG00000239528.1 RPS14P8 23.96 3.75e-75 4.97e-67 1.12 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs13164105 ENSG00000239528.1 RPS14P8 23.96 3.75e-75 4.97e-67 1.12 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr5:116562562~116562930:+ LIHC trans rs6477998 0.58 rs10981715 ENSG00000238072.1 RP11-305M3.2 23.9 6.06e-75 8e-67 0.99 0.79 Hematology traits; chr9:113287218 chr7:129410113~129410370:- LIHC trans rs7949030 0.626 rs11231141 ENSG00000186676.3 EEF1GP1 23.75 2.47e-74 3.23e-66 1.2 0.79 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62558793 chr7:125033453~125035301:+ LIHC trans rs7949030 0.626 rs7943191 ENSG00000186676.3 EEF1GP1 23.75 2.47e-74 3.23e-66 1.2 0.79 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62561079 chr7:125033453~125035301:+ LIHC trans rs13177918 0.686 rs12654827 ENSG00000239528.1 RPS14P8 23.58 1.15e-73 1.48e-65 1.12 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr5:116562562~116562930:+ LIHC trans rs13177918 0.677 rs13160685 ENSG00000239528.1 RPS14P8 23.58 1.15e-73 1.48e-65 1.12 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr5:116562562~116562930:+ LIHC trans rs941207 0.756 rs1465081 ENSG00000121089.4 NACA3P -23.26 1.94e-72 2.45e-64 -0.98 -0.78 Platelet count; chr12:56656390 chr4:164943290~164943937:+ LIHC trans rs941207 0.789 rs2958145 ENSG00000121089.4 NACA3P -23.26 1.94e-72 2.45e-64 -0.98 -0.78 Platelet count; chr12:56662290 chr4:164943290~164943937:+ LIHC trans rs13177918 0.626 rs12186649 ENSG00000224114.1 RP11-343H5.4 23.25 2.21e-72 2.78e-64 1.15 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150438963 chr1:206695837~206696269:- LIHC trans rs13177918 0.651 rs13184111 ENSG00000224114.1 RP11-343H5.4 23.11 7.37e-72 9.25e-64 1.14 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150434649 chr1:206695837~206696269:- LIHC trans rs941207 0.756 rs2950394 ENSG00000121089.4 NACA3P -23.05 1.32e-71 1.64e-63 -0.98 -0.78 Platelet count; chr12:56644548 chr4:164943290~164943937:+ LIHC trans rs7949030 0.626 rs11231144 ENSG00000186676.3 EEF1GP1 23 2.04e-71 2.52e-63 1.18 0.78 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62560566 chr7:125033453~125035301:+ LIHC trans rs941207 0.756 rs10876915 ENSG00000121089.4 NACA3P -23 2.14e-71 2.64e-63 -0.98 -0.78 Platelet count; chr12:56655280 chr4:164943290~164943937:+ LIHC trans rs13177918 0.677 rs57890152 ENSG00000239528.1 RPS14P8 22.91 4.81e-71 5.89e-63 1.11 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr5:116562562~116562930:+ LIHC trans rs7949030 0.626 rs11231145 ENSG00000186676.3 EEF1GP1 22.9 5.02e-71 6e-63 1.19 0.78 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62561382 chr7:125033453~125035301:+ LIHC trans rs7949030 0.626 rs71490390 ENSG00000186676.3 EEF1GP1 22.9 5.02e-71 6e-63 1.19 0.78 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62561713 chr7:125033453~125035301:+ LIHC trans rs7949030 0.626 rs7124057 ENSG00000186676.3 EEF1GP1 22.9 5.02e-71 6e-63 1.19 0.78 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62566624 chr7:125033453~125035301:+ LIHC trans rs7949030 0.626 rs72927213 ENSG00000186676.3 EEF1GP1 22.9 5.02e-71 6e-63 1.19 0.78 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62583726 chr7:125033453~125035301:+ LIHC trans rs12291225 0.639 rs61883858 ENSG00000236360.2 RP11-334A14.2 22.87 6.76e-71 7.96e-63 0.98 0.78 Sense of smell; chr11:14273162 chr1:52993201~52993702:- LIHC trans rs12291225 0.679 rs11023170 ENSG00000236360.2 RP11-334A14.2 22.87 6.76e-71 7.96e-63 0.98 0.78 Sense of smell; chr11:14273363 chr1:52993201~52993702:- LIHC trans rs12291225 0.679 rs11023172 ENSG00000236360.2 RP11-334A14.2 22.87 6.76e-71 7.96e-63 0.98 0.78 Sense of smell; chr11:14273821 chr1:52993201~52993702:- LIHC trans rs12291225 0.679 rs4757245 ENSG00000236360.2 RP11-334A14.2 22.87 6.76e-71 7.96e-63 0.98 0.78 Sense of smell; chr11:14276326 chr1:52993201~52993702:- LIHC trans rs12291225 0.637 rs8570 ENSG00000236360.2 RP11-334A14.2 22.87 6.84e-71 8.03e-63 0.98 0.78 Sense of smell; chr11:14279213 chr1:52993201~52993702:- LIHC trans rs13177918 0.557 rs12520101 ENSG00000224114.1 RP11-343H5.4 22.8 1.24e-70 1.45e-62 1.09 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr1:206695837~206696269:- LIHC trans rs12291225 0.645 rs3763950 ENSG00000236360.2 RP11-334A14.2 22.79 1.35e-70 1.58e-62 0.98 0.78 Sense of smell; chr11:14256503 chr1:52993201~52993702:- LIHC trans rs1816752 0.905 rs9511264 ENSG00000237917.1 PARP4P1 -22.75 2.07e-70 2.39e-62 -0.88 -0.78 Obesity-related traits; chr13:24438079 chrY:26594851~26634652:- LIHC trans rs13177918 0.626 rs3819332 ENSG00000213058.3 RP4-765C7.2 22.74 2.28e-70 2.63e-62 1.05 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr1:178411616~178411972:+ LIHC trans rs13177918 0.626 rs13170300 ENSG00000213058.3 RP4-765C7.2 22.74 2.28e-70 2.63e-62 1.05 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr1:178411616~178411972:+ LIHC trans rs941207 0.756 rs9634246 ENSG00000121089.4 NACA3P -22.73 2.51e-70 2.87e-62 -0.98 -0.78 Platelet count; chr12:56640604 chr4:164943290~164943937:+ LIHC trans rs13177918 0.557 rs12520101 ENSG00000239528.1 RPS14P8 22.69 3.45e-70 3.93e-62 1.07 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr5:116562562~116562930:+ LIHC trans rs12291225 0.679 rs34238445 ENSG00000236360.2 RP11-334A14.2 22.67 4.01e-70 4.56e-62 0.97 0.77 Sense of smell; chr11:14294369 chr1:52993201~52993702:- LIHC trans rs12291225 0.679 rs10832240 ENSG00000236360.2 RP11-334A14.2 22.62 6.62e-70 7.51e-62 0.97 0.77 Sense of smell; chr11:14283198 chr1:52993201~52993702:- LIHC trans rs7949030 0.626 rs61296092 ENSG00000186676.3 EEF1GP1 22.62 6.74e-70 7.62e-62 1.18 0.77 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62553366 chr7:125033453~125035301:+ LIHC trans rs12291225 0.679 rs11605531 ENSG00000236360.2 RP11-334A14.2 22.61 7.02e-70 7.89e-62 0.97 0.77 Sense of smell; chr11:14270048 chr1:52993201~52993702:- LIHC trans rs12291225 0.753 rs1431374 ENSG00000236360.2 RP11-334A14.2 22.59 8.64e-70 9.64e-62 0.97 0.77 Sense of smell; chr11:14282429 chr1:52993201~52993702:- LIHC trans rs12291225 0.679 rs7934671 ENSG00000236360.2 RP11-334A14.2 22.59 8.64e-70 9.64e-62 0.97 0.77 Sense of smell; chr11:14283555 chr1:52993201~52993702:- LIHC trans rs12291225 0.679 rs11023178 ENSG00000236360.2 RP11-334A14.2 22.59 8.64e-70 9.64e-62 0.97 0.77 Sense of smell; chr11:14288736 chr1:52993201~52993702:- LIHC trans rs12291225 0.679 rs4756786 ENSG00000236360.2 RP11-334A14.2 22.58 9.71e-70 1.08e-61 0.97 0.77 Sense of smell; chr11:14264354 chr1:52993201~52993702:- LIHC trans rs941207 0.756 rs2958153 ENSG00000121089.4 NACA3P 22.57 1e-69 1.11e-61 0.96 0.77 Platelet count; chr12:56687733 chr4:164943290~164943937:+ LIHC trans rs1816752 0.875 rs1050110 ENSG00000237917.1 PARP4P1 22.57 1.04e-69 1.14e-61 0.89 0.77 Obesity-related traits; chr13:24435347 chrY:26594851~26634652:- LIHC trans rs941207 0.756 rs67046307 ENSG00000121089.4 NACA3P -22.53 1.51e-69 1.66e-61 -0.97 -0.77 Platelet count; chr12:56651152 chr4:164943290~164943937:+ LIHC trans rs941207 0.756 rs2950388 ENSG00000121089.4 NACA3P -22.52 1.65e-69 1.8e-61 -0.98 -0.77 Platelet count; chr12:56639569 chr4:164943290~164943937:+ LIHC trans rs13177918 0.651 rs13184111 ENSG00000239528.1 RPS14P8 22.46 2.68e-69 2.91e-61 1.11 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150434649 chr5:116562562~116562930:+ LIHC trans rs13177918 0.626 rs12186649 ENSG00000239528.1 RPS14P8 22.46 2.69e-69 2.92e-61 1.11 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150438963 chr5:116562562~116562930:+ LIHC trans rs1816752 0.905 rs13428 ENSG00000237917.1 PARP4P1 22.45 2.99e-69 3.2e-61 0.88 0.77 Obesity-related traits; chr13:24435303 chrY:26594851~26634652:- LIHC trans rs1816752 0.87 rs8000215 ENSG00000237917.1 PARP4P1 22.45 2.99e-69 3.2e-61 0.88 0.77 Obesity-related traits; chr13:24435648 chrY:26594851~26634652:- LIHC trans rs1816752 0.87 rs2033955 ENSG00000237917.1 PARP4P1 22.45 2.99e-69 3.2e-61 0.88 0.77 Obesity-related traits; chr13:24436406 chrY:26594851~26634652:- LIHC trans rs1816752 0.87 rs2033954 ENSG00000237917.1 PARP4P1 22.45 2.99e-69 3.2e-61 0.88 0.77 Obesity-related traits; chr13:24436429 chrY:26594851~26634652:- LIHC trans rs7949030 0.626 rs11231154 ENSG00000186676.3 EEF1GP1 22.41 4.5e-69 4.81e-61 1.18 0.77 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62594821 chr7:125033453~125035301:+ LIHC trans rs13177918 0.626 rs13175436 ENSG00000213058.3 RP4-765C7.2 22.37 6.31e-69 6.63e-61 1.04 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150450974 chr1:178411616~178411972:+ LIHC trans rs13177918 0.603 rs13175992 ENSG00000213058.3 RP4-765C7.2 22.37 6.31e-69 6.63e-61 1.04 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150451026 chr1:178411616~178411972:+ LIHC trans rs13177918 0.626 rs67026795 ENSG00000213058.3 RP4-765C7.2 22.37 6.31e-69 6.63e-61 1.04 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452097 chr1:178411616~178411972:+ LIHC trans rs13177918 0.578 rs35919198 ENSG00000213058.3 RP4-765C7.2 22.37 6.31e-69 6.63e-61 1.04 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452428 chr1:178411616~178411972:+ LIHC trans rs13177918 0.603 rs10447222 ENSG00000213058.3 RP4-765C7.2 22.37 6.31e-69 6.63e-61 1.04 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150453104 chr1:178411616~178411972:+ LIHC trans rs1816752 0.87 rs7320102 ENSG00000237917.1 PARP4P1 22.36 6.65e-69 6.9e-61 0.87 0.77 Obesity-related traits; chr13:24437435 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs7339140 ENSG00000237917.1 PARP4P1 22.36 6.65e-69 6.9e-61 0.87 0.77 Obesity-related traits; chr13:24437764 chrY:26594851~26634652:- LIHC trans rs1816752 0.87 rs9511261 ENSG00000237917.1 PARP4P1 22.36 6.65e-69 6.9e-61 0.87 0.77 Obesity-related traits; chr13:24437880 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs9511262 ENSG00000237917.1 PARP4P1 22.36 6.65e-69 6.9e-61 0.87 0.77 Obesity-related traits; chr13:24437885 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs9511260 ENSG00000237917.1 PARP4P1 22.36 7.22e-69 7.45e-61 0.88 0.77 Obesity-related traits; chr13:24437038 chrY:26594851~26634652:- LIHC trans rs6477998 0.58 rs10759638 ENSG00000238072.1 RP11-305M3.2 -22.35 7.59e-69 7.81e-61 -0.97 -0.77 Hematology traits; chr9:113280212 chr7:129410113~129410370:- LIHC trans rs13253073 0.723 rs1130474 ENSG00000260318.1 COX6CP1 22.35 7.83e-69 8.04e-61 1.24 0.77 Glucose homeostasis traits; chr8:99892049 chr16:11903923~11904137:- LIHC trans rs7949030 0.59 rs12225213 ENSG00000186676.3 EEF1GP1 22.34 8.07e-69 8.27e-61 1.17 0.77 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62582776 chr7:125033453~125035301:+ LIHC trans rs12291225 0.679 rs11238 ENSG00000236360.2 RP11-334A14.2 -22.32 9.99e-69 1.01e-60 -0.97 -0.77 Sense of smell; chr11:14266582 chr1:52993201~52993702:- LIHC trans rs12291225 0.679 rs11369 ENSG00000236360.2 RP11-334A14.2 22.32 9.99e-69 1.01e-60 0.97 0.77 Sense of smell; chr11:14266550 chr1:52993201~52993702:- LIHC trans rs941207 0.756 rs7315472 ENSG00000121089.4 NACA3P -22.29 1.31e-68 1.33e-60 -0.96 -0.77 Platelet count; chr12:56648276 chr4:164943290~164943937:+ LIHC trans rs1816752 0.817 rs7985394 ENSG00000237917.1 PARP4P1 22.2 2.88e-68 2.89e-60 0.87 0.77 Obesity-related traits; chr13:24438714 chrY:26594851~26634652:- LIHC trans rs1816752 0.789 rs7986037 ENSG00000237917.1 PARP4P1 22.2 2.88e-68 2.89e-60 0.87 0.77 Obesity-related traits; chr13:24438715 chrY:26594851~26634652:- LIHC trans rs6477998 0.58 rs11552582 ENSG00000238072.1 RP11-305M3.2 22.17 3.95e-68 3.94e-60 0.97 0.77 Hematology traits; chr9:113282718 chr7:129410113~129410370:- LIHC trans rs1816752 0.905 rs1050112 ENSG00000237917.1 PARP4P1 22.13 5.58e-68 5.55e-60 0.88 0.77 Obesity-related traits; chr13:24435159 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs11839006 ENSG00000237917.1 PARP4P1 22.12 6.11e-68 6.06e-60 0.88 0.77 Obesity-related traits; chr13:24435893 chrY:26594851~26634652:- LIHC trans rs6477998 0.557 rs11789755 ENSG00000238072.1 RP11-305M3.2 22.1 7.14e-68 7.01e-60 0.97 0.77 Hematology traits; chr9:113292796 chr7:129410113~129410370:- LIHC trans rs1816752 0.806 rs3816218 ENSG00000237917.1 PARP4P1 22.1 7.43e-68 7.23e-60 0.87 0.77 Obesity-related traits; chr13:24443033 chrY:26594851~26634652:- LIHC trans rs1816752 0.712 rs6490932 ENSG00000237917.1 PARP4P1 22.1 7.43e-68 7.23e-60 0.87 0.77 Obesity-related traits; chr13:24443313 chrY:26594851~26634652:- LIHC trans rs1816752 0.713 rs7336357 ENSG00000237917.1 PARP4P1 22.1 7.43e-68 7.23e-60 0.87 0.77 Obesity-related traits; chr13:24443452 chrY:26594851~26634652:- LIHC trans rs1816752 0.683 rs7330532 ENSG00000237917.1 PARP4P1 22.1 7.43e-68 7.23e-60 0.87 0.77 Obesity-related traits; chr13:24443453 chrY:26594851~26634652:- LIHC trans rs1816752 0.776 rs9511268 ENSG00000237917.1 PARP4P1 22.07 9.29e-68 8.93e-60 0.87 0.77 Obesity-related traits; chr13:24444182 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs7995909 ENSG00000237917.1 PARP4P1 22.07 9.52e-68 8.93e-60 0.86 0.77 Obesity-related traits; chr13:24439159 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs6490927 ENSG00000237917.1 PARP4P1 22.07 9.52e-68 8.93e-60 0.86 0.77 Obesity-related traits; chr13:24439802 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs6490928 ENSG00000237917.1 PARP4P1 22.07 9.52e-68 8.93e-60 0.86 0.77 Obesity-related traits; chr13:24439921 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs6490929 ENSG00000237917.1 PARP4P1 22.07 9.52e-68 8.93e-60 0.86 0.77 Obesity-related traits; chr13:24440114 chrY:26594851~26634652:- LIHC trans rs1816752 0.87 rs7998797 ENSG00000237917.1 PARP4P1 22.07 9.52e-68 8.93e-60 0.86 0.77 Obesity-related traits; chr13:24440850 chrY:26594851~26634652:- LIHC trans rs1816752 0.87 rs7981337 ENSG00000237917.1 PARP4P1 22.07 9.52e-68 8.93e-60 0.86 0.77 Obesity-related traits; chr13:24440915 chrY:26594851~26634652:- LIHC trans rs1816752 0.87 rs7981480 ENSG00000237917.1 PARP4P1 22.07 9.52e-68 8.93e-60 0.86 0.77 Obesity-related traits; chr13:24440966 chrY:26594851~26634652:- LIHC trans rs1816752 0.837 rs4769355 ENSG00000237917.1 PARP4P1 22.07 9.52e-68 8.93e-60 0.86 0.77 Obesity-related traits; chr13:24441059 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs4770680 ENSG00000237917.1 PARP4P1 22.07 9.52e-68 8.93e-60 0.86 0.77 Obesity-related traits; chr13:24441110 chrY:26594851~26634652:- LIHC trans rs1816752 0.666 rs7994022 ENSG00000237917.1 PARP4P1 22.06 1.03e-67 9.65e-60 0.87 0.77 Obesity-related traits; chr13:24443092 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs9511266 ENSG00000237917.1 PARP4P1 22.06 1.04e-67 9.69e-60 0.87 0.77 Obesity-related traits; chr13:24438366 chrY:26594851~26634652:- LIHC trans rs1816752 0.746 rs9511270 ENSG00000237917.1 PARP4P1 22.06 1.08e-67 1e-59 0.87 0.77 Obesity-related traits; chr13:24444542 chrY:26594851~26634652:- LIHC trans rs1816752 0.59 rs61947036 ENSG00000237917.1 PARP4P1 22.04 1.23e-67 1.14e-59 0.87 0.77 Obesity-related traits; chr13:24443544 chrY:26594851~26634652:- LIHC trans rs13253073 0.723 rs1130569 ENSG00000260318.1 COX6CP1 22.02 1.58e-67 1.46e-59 1.24 0.77 Glucose homeostasis traits; chr8:99887565 chr16:11903923~11904137:- LIHC trans rs1816752 0.87 rs3825449 ENSG00000237917.1 PARP4P1 22.01 1.62e-67 1.49e-59 0.86 0.77 Obesity-related traits; chr13:24440303 chrY:26594851~26634652:- LIHC trans rs1816752 0.776 rs7998843 ENSG00000237917.1 PARP4P1 21.94 3.08e-67 2.81e-59 0.86 0.76 Obesity-related traits; chr13:24443147 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs7317850 ENSG00000237917.1 PARP4P1 21.92 3.97e-67 3.61e-59 0.9 0.76 Obesity-related traits; chr13:24419899 chrY:26594851~26634652:- LIHC trans rs6477998 0.58 rs2296073 ENSG00000238072.1 RP11-305M3.2 21.9 4.53e-67 4.1e-59 0.95 0.76 Hematology traits; chr9:113299348 chr7:129410113~129410370:- LIHC trans rs1816752 0.905 rs7995492 ENSG00000237917.1 PARP4P1 21.9 4.74e-67 4.28e-59 0.85 0.76 Obesity-related traits; chr13:24438885 chrY:26594851~26634652:- LIHC trans rs13253073 0.723 rs7828241 ENSG00000260318.1 COX6CP1 21.81 1.04e-66 9.35e-59 1.25 0.76 Glucose homeostasis traits; chr8:99880417 chr16:11903923~11904137:- LIHC trans rs7949030 0.591 rs11231156 ENSG00000186676.3 EEF1GP1 21.71 2.57e-66 2.28e-58 1.17 0.76 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62598982 chr7:125033453~125035301:+ LIHC trans rs7949030 0.591 rs12049914 ENSG00000186676.3 EEF1GP1 21.71 2.57e-66 2.28e-58 1.17 0.76 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62601964 chr7:125033453~125035301:+ LIHC trans rs7949030 0.591 rs35156678 ENSG00000186676.3 EEF1GP1 21.71 2.57e-66 2.28e-58 1.17 0.76 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62602409 chr7:125033453~125035301:+ LIHC trans rs7949030 0.596 rs71490394 ENSG00000186676.3 EEF1GP1 21.71 2.57e-66 2.28e-58 1.17 0.76 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62602683 chr7:125033453~125035301:+ LIHC trans rs6477998 0.557 rs3750534 ENSG00000238072.1 RP11-305M3.2 21.71 2.68e-66 2.37e-58 0.96 0.76 Hematology traits; chr9:113297844 chr7:129410113~129410370:- LIHC trans rs1816752 0.805 rs61614647 ENSG00000237917.1 PARP4P1 21.7 2.76e-66 2.43e-58 0.85 0.76 Obesity-related traits; chr13:24441829 chrY:26594851~26634652:- LIHC trans rs1816752 0.774 rs55888616 ENSG00000237917.1 PARP4P1 21.7 2.76e-66 2.43e-58 0.85 0.76 Obesity-related traits; chr13:24441954 chrY:26594851~26634652:- LIHC trans rs13253073 0.723 rs35429753 ENSG00000260318.1 COX6CP1 21.69 3.11e-66 2.73e-58 1.25 0.76 Glucose homeostasis traits; chr8:99891015 chr16:11903923~11904137:- LIHC trans rs6477998 0.58 rs4979233 ENSG00000238072.1 RP11-305M3.2 21.67 3.69e-66 3.23e-58 0.97 0.76 Hematology traits; chr9:113295501 chr7:129410113~129410370:- LIHC trans rs6477998 0.535 rs3750535 ENSG00000238072.1 RP11-305M3.2 21.62 6.03e-66 5.25e-58 0.96 0.76 Hematology traits; chr9:113297453 chr7:129410113~129410370:- LIHC trans rs1816752 0.837 rs7139748 ENSG00000237917.1 PARP4P1 21.6 7.26e-66 6.25e-58 0.88 0.76 Obesity-related traits; chr13:24411531 chrY:26594851~26634652:- LIHC trans rs13253073 0.723 rs7844439 ENSG00000260318.1 COX6CP1 21.54 1.19e-65 1.02e-57 1.24 0.76 Glucose homeostasis traits; chr8:99878567 chr16:11903923~11904137:- LIHC trans rs6477998 0.58 rs3750532 ENSG00000238072.1 RP11-305M3.2 21.54 1.24e-65 1.05e-57 0.96 0.76 Hematology traits; chr9:113298207 chr7:129410113~129410370:- LIHC trans rs13253073 0.723 rs4626565 ENSG00000260318.1 COX6CP1 21.49 2.02e-65 1.69e-57 1.24 0.76 Glucose homeostasis traits; chr8:99878314 chr16:11903923~11904137:- LIHC trans rs13253073 0.723 rs4510829 ENSG00000260318.1 COX6CP1 21.49 2.02e-65 1.69e-57 1.24 0.76 Glucose homeostasis traits; chr8:99878982 chr16:11903923~11904137:- LIHC trans rs13253073 0.723 rs7812991 ENSG00000260318.1 COX6CP1 21.49 2.02e-65 1.69e-57 1.24 0.76 Glucose homeostasis traits; chr8:99884095 chr16:11903923~11904137:- LIHC trans rs13253073 0.723 rs12548840 ENSG00000260318.1 COX6CP1 21.49 2.02e-65 1.69e-57 1.24 0.76 Glucose homeostasis traits; chr8:99885580 chr16:11903923~11904137:- LIHC trans rs13253073 0.723 rs1135382 ENSG00000260318.1 COX6CP1 21.45 2.89e-65 2.41e-57 1.24 0.76 Glucose homeostasis traits; chr8:99879402 chr16:11903923~11904137:- LIHC trans rs6477998 0.58 rs12343629 ENSG00000238072.1 RP11-305M3.2 21.44 3.16e-65 2.63e-57 0.96 0.76 Hematology traits; chr9:113279301 chr7:129410113~129410370:- LIHC trans rs13253073 0.76 rs62534633 ENSG00000260318.1 COX6CP1 21.41 4.03e-65 3.34e-57 1.27 0.76 Glucose homeostasis traits; chr8:99884533 chr16:11903923~11904137:- LIHC trans rs6477998 0.58 rs7027833 ENSG00000238072.1 RP11-305M3.2 21.41 4.16e-65 3.44e-57 0.94 0.76 Hematology traits; chr9:113301377 chr7:129410113~129410370:- LIHC trans rs1816752 0.905 rs4770666 ENSG00000237917.1 PARP4P1 21.4 4.46e-65 3.67e-57 0.9 0.76 Obesity-related traits; chr13:24414891 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs7400631 ENSG00000237917.1 PARP4P1 21.4 4.46e-65 3.67e-57 0.9 0.76 Obesity-related traits; chr13:24415927 chrY:26594851~26634652:- LIHC trans rs13177918 0.559 rs10447224 ENSG00000213058.3 RP4-765C7.2 21.38 5.32e-65 4.36e-57 1 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454802 chr1:178411616~178411972:+ LIHC trans rs13177918 0.559 rs10447225 ENSG00000213058.3 RP4-765C7.2 21.38 5.32e-65 4.36e-57 1 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454891 chr1:178411616~178411972:+ LIHC trans rs13253073 0.657 rs35135010 ENSG00000260318.1 COX6CP1 21.37 5.77e-65 4.72e-57 1.24 0.76 Glucose homeostasis traits; chr8:99864209 chr16:11903923~11904137:- LIHC trans rs12291225 0.679 rs1043237 ENSG00000236360.2 RP11-334A14.2 21.37 6.08e-65 4.96e-57 0.95 0.76 Sense of smell; chr11:14267507 chr1:52993201~52993702:- LIHC trans rs1816752 0.905 rs7571 ENSG00000237917.1 PARP4P1 21.37 6.13e-65 4.99e-57 0.88 0.76 Obesity-related traits; chr13:24426479 chrY:26594851~26634652:- LIHC trans rs1816752 1 rs7999554 ENSG00000237917.1 PARP4P1 21.36 6.48e-65 5.26e-57 0.87 0.76 Obesity-related traits; chr13:24435631 chrY:26594851~26634652:- LIHC trans rs13253073 0.723 rs7813557 ENSG00000260318.1 COX6CP1 21.34 7.58e-65 6.13e-57 1.25 0.76 Glucose homeostasis traits; chr8:99878665 chr16:11903923~11904137:- LIHC trans rs1816752 0.905 rs8002215 ENSG00000237917.1 PARP4P1 21.31 1.05e-64 8.44e-57 0.9 0.76 Obesity-related traits; chr13:24416229 chrY:26594851~26634652:- LIHC trans rs2950393 0.509 rs10459247 ENSG00000121089.4 NACA3P -21.29 1.21e-64 9.67e-57 -0.96 -0.75 Platelet distribution width; chr12:56777732 chr4:164943290~164943937:+ LIHC trans rs6477998 0.58 rs3750533 ENSG00000238072.1 RP11-305M3.2 21.29 1.23e-64 9.84e-57 0.96 0.75 Hematology traits; chr9:113297941 chr7:129410113~129410370:- LIHC trans rs7949030 0.596 rs11231138 ENSG00000186676.3 EEF1GP1 21.27 1.49e-64 1.19e-56 1.17 0.75 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62548723 chr7:125033453~125035301:+ LIHC trans rs13177918 0.626 rs3819332 ENSG00000224114.1 RP11-343H5.4 21.25 1.75e-64 1.39e-56 1.03 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr1:206695837~206696269:- LIHC trans rs13177918 0.626 rs13170300 ENSG00000224114.1 RP11-343H5.4 21.25 1.75e-64 1.39e-56 1.03 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr1:206695837~206696269:- LIHC trans rs1816752 0.905 rs9511242 ENSG00000237917.1 PARP4P1 21.23 2.15e-64 1.7e-56 0.89 0.75 Obesity-related traits; chr13:24419261 chrY:26594851~26634652:- LIHC trans rs7949030 0.688 rs11231155 ENSG00000186676.3 EEF1GP1 21.17 3.6e-64 2.81e-56 1.15 0.75 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62598147 chr7:125033453~125035301:+ LIHC trans rs1816752 0.935 rs4770676 ENSG00000237917.1 PARP4P1 21.14 4.72e-64 3.65e-56 0.87 0.75 Obesity-related traits; chr13:24429745 chrY:26594851~26634652:- LIHC trans rs1816752 1 rs7326932 ENSG00000237917.1 PARP4P1 21.14 4.72e-64 3.65e-56 0.87 0.75 Obesity-related traits; chr13:24430355 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs9581026 ENSG00000237917.1 PARP4P1 21.14 4.73e-64 3.65e-56 0.87 0.75 Obesity-related traits; chr13:24423788 chrY:26594851~26634652:- LIHC trans rs1816752 0.719 rs11841989 ENSG00000237917.1 PARP4P1 21.12 6.03e-64 4.62e-56 0.87 0.75 Obesity-related traits; chr13:24423560 chrY:26594851~26634652:- LIHC trans rs13253073 0.723 rs12548542 ENSG00000260318.1 COX6CP1 21.04 1.2e-63 9.15e-56 1.27 0.75 Glucose homeostasis traits; chr8:99890167 chr16:11903923~11904137:- LIHC trans rs1816752 0.935 rs3816219 ENSG00000237917.1 PARP4P1 21.04 1.22e-63 9.31e-56 0.85 0.75 Obesity-related traits; chr13:24442995 chrY:26594851~26634652:- LIHC trans rs13253073 0.723 rs7157 ENSG00000260318.1 COX6CP1 21.03 1.36e-63 1.03e-55 1.25 0.75 Glucose homeostasis traits; chr8:99877449 chr16:11903923~11904137:- LIHC trans rs13177918 0.626 rs13175436 ENSG00000224114.1 RP11-343H5.4 21.01 1.58e-63 1.19e-55 1.03 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150450974 chr1:206695837~206696269:- LIHC trans rs13177918 0.603 rs13175992 ENSG00000224114.1 RP11-343H5.4 21.01 1.58e-63 1.19e-55 1.03 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150451026 chr1:206695837~206696269:- LIHC trans rs13177918 0.626 rs67026795 ENSG00000224114.1 RP11-343H5.4 21.01 1.58e-63 1.19e-55 1.03 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452097 chr1:206695837~206696269:- LIHC trans rs13177918 0.578 rs35919198 ENSG00000224114.1 RP11-343H5.4 21.01 1.58e-63 1.19e-55 1.03 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452428 chr1:206695837~206696269:- LIHC trans rs13177918 0.603 rs10447222 ENSG00000224114.1 RP11-343H5.4 21.01 1.58e-63 1.19e-55 1.03 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150453104 chr1:206695837~206696269:- LIHC trans rs13253073 0.723 rs12548344 ENSG00000260318.1 COX6CP1 21.01 1.64e-63 1.22e-55 1.28 0.75 Glucose homeostasis traits; chr8:99868676 chr16:11903923~11904137:- LIHC trans rs1816752 1 rs7988810 ENSG00000237917.1 PARP4P1 21 1.73e-63 1.29e-55 0.85 0.75 Obesity-related traits; chr13:24444958 chrY:26594851~26634652:- LIHC trans rs1816752 1 rs9511265 ENSG00000237917.1 PARP4P1 20.96 2.43e-63 1.79e-55 0.86 0.75 Obesity-related traits; chr13:24438221 chrY:26594851~26634652:- LIHC trans rs7949030 0.591 rs35880596 ENSG00000186676.3 EEF1GP1 20.85 7.06e-63 5.19e-55 1.17 0.75 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62602412 chr7:125033453~125035301:+ LIHC trans rs13253073 0.723 rs12546882 ENSG00000260318.1 COX6CP1 20.69 3.13e-62 2.27e-54 1.24 0.75 Glucose homeostasis traits; chr8:99869919 chr16:11903923~11904137:- LIHC trans rs7121616 0.562 rs7131452 ENSG00000234176.1 HSPA8P1 20.68 3.35e-62 2.42e-54 0.89 0.75 Breast cancer; chr11:123065314 chrX:121203182~121205014:- LIHC trans rs13177918 0.559 rs12109637 ENSG00000213058.3 RP4-765C7.2 20.65 4.33e-62 3.12e-54 0.95 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150455155 chr1:178411616~178411972:+ LIHC trans rs7121616 0.595 rs7949414 ENSG00000234176.1 HSPA8P1 20.61 6.64e-62 4.74e-54 0.88 0.74 Breast cancer; chr11:123072787 chrX:121203182~121205014:- LIHC trans rs1816752 0.719 rs11843470 ENSG00000237917.1 PARP4P1 20.55 1.1e-61 7.81e-54 0.86 0.74 Obesity-related traits; chr13:24423561 chrY:26594851~26634652:- LIHC trans rs7949030 0.626 rs7930896 ENSG00000186676.3 EEF1GP1 20.54 1.23e-61 8.78e-54 1.08 0.74 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62557800 chr7:125033453~125035301:+ LIHC trans rs1816752 0.837 rs7324645 ENSG00000237917.1 PARP4P1 20.53 1.38e-61 9.83e-54 0.84 0.74 Obesity-related traits; chr13:24426717 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs4769348 ENSG00000237917.1 PARP4P1 20.52 1.4e-61 9.95e-54 0.86 0.74 Obesity-related traits; chr13:24400975 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs4769352 ENSG00000237917.1 PARP4P1 20.49 1.91e-61 1.35e-53 0.84 0.74 Obesity-related traits; chr13:24426237 chrY:26594851~26634652:- LIHC trans rs1816752 0.805 rs4769353 ENSG00000237917.1 PARP4P1 20.49 1.91e-61 1.35e-53 0.84 0.74 Obesity-related traits; chr13:24426318 chrY:26594851~26634652:- LIHC trans rs1816752 0.87 rs9581029 ENSG00000237917.1 PARP4P1 20.42 3.76e-61 2.63e-53 0.85 0.74 Obesity-related traits; chr13:24425147 chrY:26594851~26634652:- LIHC trans rs1816752 0.774 rs7986162 ENSG00000237917.1 PARP4P1 20.42 3.8e-61 2.65e-53 0.84 0.74 Obesity-related traits; chr13:24425941 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs7991450 ENSG00000237917.1 PARP4P1 20.38 5.06e-61 3.5e-53 0.84 0.74 Obesity-related traits; chr13:24425898 chrY:26594851~26634652:- LIHC trans rs13253073 0.723 rs7009713 ENSG00000260318.1 COX6CP1 20.36 6.13e-61 4.22e-53 1.22 0.74 Glucose homeostasis traits; chr8:99869626 chr16:11903923~11904137:- LIHC trans rs7121616 0.576 rs11218967 ENSG00000234176.1 HSPA8P1 20.34 7.95e-61 5.47e-53 0.88 0.74 Breast cancer; chr11:123087551 chrX:121203182~121205014:- LIHC trans rs1816752 0.87 rs9581025 ENSG00000237917.1 PARP4P1 20.33 8.24e-61 5.63e-53 0.85 0.74 Obesity-related traits; chr13:24423687 chrY:26594851~26634652:- LIHC trans rs1816752 0.87 rs9581027 ENSG00000237917.1 PARP4P1 20.33 8.24e-61 5.63e-53 0.85 0.74 Obesity-related traits; chr13:24423790 chrY:26594851~26634652:- LIHC trans rs1816752 0.87 rs9318529 ENSG00000237917.1 PARP4P1 20.33 8.24e-61 5.63e-53 0.85 0.74 Obesity-related traits; chr13:24424190 chrY:26594851~26634652:- LIHC trans rs1816752 0.633 rs9578729 ENSG00000237917.1 PARP4P1 20.31 1.01e-60 6.91e-53 0.85 0.74 Obesity-related traits; chr13:24425106 chrY:26594851~26634652:- LIHC trans rs13177918 1 rs13161334 ENSG00000213058.3 RP4-765C7.2 20.27 1.52e-60 1.03e-52 1.12 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443110 chr1:178411616~178411972:+ LIHC trans rs13177918 1 rs35007082 ENSG00000213058.3 RP4-765C7.2 20.27 1.52e-60 1.03e-52 1.12 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150445015 chr1:178411616~178411972:+ LIHC trans rs6732160 0.574 rs12465780 ENSG00000236165.1 PRADC1P1 -20.26 1.65e-60 1.11e-52 -0.92 -0.74 Intelligence (multi-trait analysis); chr2:73244884 chr3:36976316~36976840:+ LIHC trans rs1816752 0.819 rs7400583 ENSG00000237917.1 PARP4P1 20.24 1.99e-60 1.34e-52 0.9 0.74 Obesity-related traits; chr13:24415916 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs9511249 ENSG00000237917.1 PARP4P1 20.18 3.51e-60 2.35e-52 0.84 0.74 Obesity-related traits; chr13:24425457 chrY:26594851~26634652:- LIHC trans rs13177918 1 rs13177918 ENSG00000213058.3 RP4-765C7.2 20.12 5.64e-60 3.75e-52 1.11 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446307 chr1:178411616~178411972:+ LIHC trans rs13177918 1 rs13161334 ENSG00000224114.1 RP11-343H5.4 20.12 5.76e-60 3.82e-52 1.13 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443110 chr1:206695837~206696269:- LIHC trans rs13177918 1 rs35007082 ENSG00000224114.1 RP11-343H5.4 20.12 5.76e-60 3.82e-52 1.13 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150445015 chr1:206695837~206696269:- LIHC trans rs13177918 1 rs13177918 ENSG00000224114.1 RP11-343H5.4 20.11 6.19e-60 4.1e-52 1.13 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446307 chr1:206695837~206696269:- LIHC trans rs13177918 0.906 rs12652032 ENSG00000213058.3 RP4-765C7.2 20.1 6.9e-60 4.56e-52 1.13 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442060 chr1:178411616~178411972:+ LIHC trans rs1816752 0.819 rs4770665 ENSG00000237917.1 PARP4P1 20.08 8.12e-60 5.34e-52 0.87 0.74 Obesity-related traits; chr13:24414810 chrY:26594851~26634652:- LIHC trans rs1816752 0.749 rs77832754 ENSG00000237917.1 PARP4P1 20.08 8.12e-60 5.34e-52 0.87 0.74 Obesity-related traits; chr13:24416016 chrY:26594851~26634652:- LIHC trans rs1816752 0.87 rs73469543 ENSG00000237917.1 PARP4P1 20.08 8.32e-60 5.46e-52 0.85 0.74 Obesity-related traits; chr13:24424832 chrY:26594851~26634652:- LIHC trans rs1816752 0.819 rs4770664 ENSG00000237917.1 PARP4P1 20.05 1.16e-59 7.58e-52 0.87 0.73 Obesity-related traits; chr13:24414695 chrY:26594851~26634652:- LIHC trans rs1816752 0.633 rs8002387 ENSG00000237917.1 PARP4P1 20.03 1.37e-59 8.93e-52 0.87 0.73 Obesity-related traits; chr13:24416306 chrY:26594851~26634652:- LIHC trans rs12291225 0.546 rs12795545 ENSG00000236360.2 RP11-334A14.2 19.95 2.76e-59 1.8e-51 0.91 0.73 Sense of smell; chr11:14334018 chr1:52993201~52993702:- LIHC trans rs7121616 0.563 rs4936770 ENSG00000234176.1 HSPA8P1 19.92 3.73e-59 2.42e-51 0.86 0.73 Breast cancer; chr11:123058167 chrX:121203182~121205014:- LIHC trans rs13177918 0.906 rs12652032 ENSG00000224114.1 RP11-343H5.4 19.9 4.31e-59 2.79e-51 1.14 0.73 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442060 chr1:206695837~206696269:- LIHC trans rs1816752 0.819 rs7985478 ENSG00000237917.1 PARP4P1 19.89 4.93e-59 3.18e-51 0.87 0.73 Obesity-related traits; chr13:24417135 chrY:26594851~26634652:- LIHC trans rs7121616 0.576 rs4802 ENSG00000234176.1 HSPA8P1 19.85 7.07e-59 4.54e-51 0.86 0.73 Breast cancer; chr11:123057914 chrX:121203182~121205014:- LIHC trans rs1816752 1 rs9507341 ENSG00000237917.1 PARP4P1 -19.83 8.17e-59 5.23e-51 -0.87 -0.73 Obesity-related traits; chr13:24432440 chrY:26594851~26634652:- LIHC trans rs12291225 0.546 rs12291662 ENSG00000236360.2 RP11-334A14.2 19.81 1.03e-58 6.55e-51 0.9 0.73 Sense of smell; chr11:14321403 chr1:52993201~52993702:- LIHC trans rs12291225 0.545 rs11023187 ENSG00000236360.2 RP11-334A14.2 19.81 1.03e-58 6.55e-51 0.9 0.73 Sense of smell; chr11:14324013 chr1:52993201~52993702:- LIHC trans rs12291225 0.585 rs11023194 ENSG00000236360.2 RP11-334A14.2 19.81 1.03e-58 6.55e-51 0.9 0.73 Sense of smell; chr11:14348223 chr1:52993201~52993702:- LIHC trans rs1816752 0.783 rs7317439 ENSG00000237917.1 PARP4P1 19.78 1.3e-58 8.09e-51 0.84 0.73 Obesity-related traits; chr13:24410939 chrY:26594851~26634652:- LIHC trans rs1816752 0.819 rs7317504 ENSG00000237917.1 PARP4P1 19.78 1.3e-58 8.09e-51 0.84 0.73 Obesity-related traits; chr13:24411287 chrY:26594851~26634652:- LIHC trans rs1816752 0.783 rs7317712 ENSG00000237917.1 PARP4P1 19.78 1.3e-58 8.09e-51 0.84 0.73 Obesity-related traits; chr13:24411365 chrY:26594851~26634652:- LIHC trans rs1816752 0.783 rs7139527 ENSG00000237917.1 PARP4P1 19.78 1.3e-58 8.09e-51 0.84 0.73 Obesity-related traits; chr13:24411374 chrY:26594851~26634652:- LIHC trans rs1816752 0.819 rs9511240 ENSG00000237917.1 PARP4P1 19.78 1.3e-58 8.09e-51 0.84 0.73 Obesity-related traits; chr13:24411768 chrY:26594851~26634652:- LIHC trans rs1816752 0.819 rs7988388 ENSG00000237917.1 PARP4P1 19.78 1.3e-58 8.09e-51 0.84 0.73 Obesity-related traits; chr13:24412675 chrY:26594851~26634652:- LIHC trans rs1816752 0.875 rs7993132 ENSG00000237917.1 PARP4P1 19.78 1.3e-58 8.09e-51 0.84 0.73 Obesity-related traits; chr13:24412903 chrY:26594851~26634652:- LIHC trans rs1816752 0.792 rs7330956 ENSG00000237917.1 PARP4P1 19.78 1.3e-58 8.09e-51 0.84 0.73 Obesity-related traits; chr13:24413174 chrY:26594851~26634652:- LIHC trans rs1816752 0.777 rs6490915 ENSG00000237917.1 PARP4P1 19.78 1.3e-58 8.09e-51 0.84 0.73 Obesity-related traits; chr13:24413724 chrY:26594851~26634652:- LIHC trans rs12291225 0.585 rs12270374 ENSG00000236360.2 RP11-334A14.2 19.73 2.12e-58 1.31e-50 0.9 0.73 Sense of smell; chr11:14353533 chr1:52993201~52993702:- LIHC trans rs12291225 0.585 rs4757250 ENSG00000236360.2 RP11-334A14.2 19.72 2.27e-58 1.4e-50 0.91 0.73 Sense of smell; chr11:14354137 chr1:52993201~52993702:- LIHC trans rs12291225 0.585 rs10832246 ENSG00000236360.2 RP11-334A14.2 19.72 2.41e-58 1.48e-50 0.9 0.73 Sense of smell; chr11:14359282 chr1:52993201~52993702:- LIHC trans rs12291225 0.585 rs11023197 ENSG00000236360.2 RP11-334A14.2 19.72 2.41e-58 1.48e-50 0.9 0.73 Sense of smell; chr11:14359452 chr1:52993201~52993702:- LIHC trans rs1816752 0.819 rs6490917 ENSG00000237917.1 PARP4P1 19.67 3.85e-58 2.35e-50 0.84 0.73 Obesity-related traits; chr13:24423119 chrY:26594851~26634652:- LIHC trans rs6732160 0.574 rs1991612 ENSG00000236165.1 PRADC1P1 19.66 4.07e-58 2.48e-50 0.91 0.73 Intelligence (multi-trait analysis); chr2:73253373 chr3:36976316~36976840:+ LIHC trans rs2950393 0.804 rs10783796 ENSG00000121089.4 NACA3P 19.54 1.22e-57 7.31e-50 0.85 0.73 Platelet distribution width; chr12:56733387 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs2958130 ENSG00000121089.4 NACA3P 19.51 1.67e-57 9.92e-50 0.86 0.73 Platelet distribution width; chr12:56746722 chr4:164943290~164943937:+ LIHC trans rs13253073 0.723 rs62534626 ENSG00000260318.1 COX6CP1 19.5 1.86e-57 1.1e-49 1.28 0.73 Glucose homeostasis traits; chr8:99866119 chr16:11903923~11904137:- LIHC trans rs941207 0.542 rs7315786 ENSG00000121089.4 NACA3P -19.48 2.1e-57 1.23e-49 -0.9 -0.73 Platelet count; chr12:56801595 chr4:164943290~164943937:+ LIHC trans rs6732160 0.525 rs2303907 ENSG00000236165.1 PRADC1P1 19.45 2.78e-57 1.62e-49 0.91 0.72 Intelligence (multi-trait analysis); chr2:73243369 chr3:36976316~36976840:+ LIHC trans rs12291225 0.585 rs4517475 ENSG00000236360.2 RP11-334A14.2 19.45 2.84e-57 1.66e-49 0.9 0.72 Sense of smell; chr11:14364599 chr1:52993201~52993702:- LIHC trans rs7121616 0.563 rs1461494 ENSG00000234176.1 HSPA8P1 19.44 3.11e-57 1.81e-49 0.85 0.72 Breast cancer; chr11:123055777 chrX:121203182~121205014:- LIHC trans rs6732160 0.574 rs7557055 ENSG00000236165.1 PRADC1P1 19.43 3.36e-57 1.94e-49 0.9 0.72 Intelligence (multi-trait analysis); chr2:73245542 chr3:36976316~36976840:+ LIHC trans rs2950393 0.777 rs7966391 ENSG00000121089.4 NACA3P 19.43 3.44e-57 1.99e-49 0.86 0.72 Platelet distribution width; chr12:56745272 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs1870674 ENSG00000121089.4 NACA3P -19.38 5.53e-57 3.14e-49 -0.89 -0.72 Platelet count; chr12:56805721 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs11171980 ENSG00000121089.4 NACA3P -19.37 5.78e-57 3.25e-49 -0.9 -0.72 Platelet count; chr12:56806397 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs12366897 ENSG00000121089.4 NACA3P -19.37 5.78e-57 3.25e-49 -0.9 -0.72 Platelet count; chr12:56808329 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs12367312 ENSG00000121089.4 NACA3P -19.37 5.78e-57 3.25e-49 -0.9 -0.72 Platelet count; chr12:56809369 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs12367339 ENSG00000121089.4 NACA3P -19.37 5.78e-57 3.25e-49 -0.9 -0.72 Platelet count; chr12:56809521 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs12367822 ENSG00000121089.4 NACA3P -19.37 5.78e-57 3.25e-49 -0.9 -0.72 Platelet count; chr12:56810376 chr4:164943290~164943937:+ LIHC trans rs12291225 0.585 rs34171876 ENSG00000236360.2 RP11-334A14.2 19.35 6.91e-57 3.88e-49 0.9 0.72 Sense of smell; chr11:14332411 chr1:52993201~52993702:- LIHC trans rs941207 0.542 rs6581107 ENSG00000121089.4 NACA3P -19.35 7.54e-57 4.23e-49 -0.89 -0.72 Platelet count; chr12:56801197 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs2126068 ENSG00000121089.4 NACA3P -19.35 7.56e-57 4.23e-49 -0.9 -0.72 Platelet count; chr12:56804716 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs67808059 ENSG00000121089.4 NACA3P -19.35 7.56e-57 4.23e-49 -0.9 -0.72 Platelet count; chr12:56805228 chr4:164943290~164943937:+ LIHC trans rs12291225 0.585 rs10832242 ENSG00000236360.2 RP11-334A14.2 -19.33 8.63e-57 4.81e-49 -0.89 -0.72 Sense of smell; chr11:14318958 chr1:52993201~52993702:- LIHC trans rs7949030 0.653 rs17773169 ENSG00000186676.3 EEF1GP1 19.32 9.22e-57 5.13e-49 1.09 0.72 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62551058 chr7:125033453~125035301:+ LIHC trans rs1816752 0.819 rs7316961 ENSG00000237917.1 PARP4P1 19.3 1.14e-56 6.33e-49 0.83 0.72 Obesity-related traits; chr13:24411039 chrY:26594851~26634652:- LIHC trans rs6732160 0.549 rs6744529 ENSG00000236165.1 PRADC1P1 19.27 1.56e-56 8.59e-49 0.9 0.72 Intelligence (multi-trait analysis); chr2:73253741 chr3:36976316~36976840:+ LIHC trans rs1816752 0.721 rs7399656 ENSG00000237917.1 PARP4P1 19.26 1.64e-56 9e-49 0.84 0.72 Obesity-related traits; chr13:24415708 chrY:26594851~26634652:- LIHC trans rs2950393 0.857 rs1563896 ENSG00000121089.4 NACA3P 19.22 2.31e-56 1.27e-48 0.87 0.72 Platelet distribution width; chr12:56699312 chr4:164943290~164943937:+ LIHC trans rs13177918 0.626 rs3819332 ENSG00000239528.1 RPS14P8 19.21 2.71e-56 1.48e-48 0.96 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr5:116562562~116562930:+ LIHC trans rs13177918 0.626 rs13170300 ENSG00000239528.1 RPS14P8 19.21 2.71e-56 1.48e-48 0.96 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr5:116562562~116562930:+ LIHC trans rs13177918 0.559 rs10447224 ENSG00000224114.1 RP11-343H5.4 19.2 2.78e-56 1.51e-48 0.96 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454802 chr1:206695837~206696269:- LIHC trans rs13177918 0.559 rs10447225 ENSG00000224114.1 RP11-343H5.4 19.2 2.78e-56 1.51e-48 0.96 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454891 chr1:206695837~206696269:- LIHC trans rs941207 0.542 rs1813109 ENSG00000121089.4 NACA3P -19.18 3.51e-56 1.9e-48 -0.9 -0.72 Platelet count; chr12:56798079 chr4:164943290~164943937:+ LIHC trans rs7949030 0.62 rs2428551 ENSG00000186676.3 EEF1GP1 19.17 3.91e-56 2.11e-48 1.09 0.72 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62562286 chr7:125033453~125035301:+ LIHC trans rs2950393 0.804 rs2958132 ENSG00000121089.4 NACA3P 19.16 4.21e-56 2.26e-48 0.86 0.72 Platelet distribution width; chr12:56750749 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs11171978 ENSG00000121089.4 NACA3P 19.16 4.28e-56 2.3e-48 0.89 0.72 Platelet count; chr12:56800015 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs7980317 ENSG00000121089.4 NACA3P 19.14 4.95e-56 2.64e-48 0.86 0.72 Platelet distribution width; chr12:56764399 chr4:164943290~164943937:+ LIHC trans rs941207 0.526 rs2950390 ENSG00000121089.4 NACA3P 19.12 6.1e-56 3.23e-48 0.86 0.72 Platelet count; chr12:56661507 chr4:164943290~164943937:+ LIHC trans rs6732160 0.691 rs7599223 ENSG00000236165.1 PRADC1P1 19.1 7.6e-56 4.02e-48 0.89 0.72 Intelligence (multi-trait analysis); chr2:73199975 chr3:36976316~36976840:+ LIHC trans rs6732160 0.657 rs10171459 ENSG00000236165.1 PRADC1P1 19.09 7.71e-56 4.07e-48 0.89 0.72 Intelligence (multi-trait analysis); chr2:73207600 chr3:36976316~36976840:+ LIHC trans rs13253073 0.723 rs7840626 ENSG00000260318.1 COX6CP1 19.09 7.74e-56 4.08e-48 1.24 0.72 Glucose homeostasis traits; chr8:99867598 chr16:11903923~11904137:- LIHC trans rs941207 0.542 rs4277148 ENSG00000121089.4 NACA3P -19.03 1.37e-55 6.95e-48 -0.89 -0.72 Platelet count; chr12:56787071 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs6581102 ENSG00000121089.4 NACA3P -19.03 1.37e-55 6.95e-48 -0.89 -0.72 Platelet count; chr12:56790632 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs6581103 ENSG00000121089.4 NACA3P -19.03 1.37e-55 6.95e-48 -0.89 -0.72 Platelet count; chr12:56790641 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs12370142 ENSG00000121089.4 NACA3P -19.03 1.37e-55 6.95e-48 -0.89 -0.72 Platelet count; chr12:56790801 chr4:164943290~164943937:+ LIHC trans rs12367822 0.956 rs9706160 ENSG00000121089.4 NACA3P -19.03 1.37e-55 6.95e-48 -0.89 -0.72 Platelet aggregation; chr12:56791119 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs2888095 ENSG00000121089.4 NACA3P -19.03 1.37e-55 6.95e-48 -0.89 -0.72 Platelet count; chr12:56793689 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs2888096 ENSG00000121089.4 NACA3P -19.03 1.37e-55 6.95e-48 -0.89 -0.72 Platelet count; chr12:56793851 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs6581106 ENSG00000121089.4 NACA3P -19.03 1.37e-55 6.95e-48 -0.89 -0.72 Platelet count; chr12:56796759 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs7311381 ENSG00000121089.4 NACA3P -19.03 1.37e-55 6.95e-48 -0.89 -0.72 Platelet count; chr12:56800286 chr4:164943290~164943937:+ LIHC trans rs1816752 0.905 rs3818938 ENSG00000237917.1 PARP4P1 19 1.78e-55 8.96e-48 0.79 0.72 Obesity-related traits; chr13:24454945 chrY:26594851~26634652:- LIHC trans rs6732160 0.631 rs7557285 ENSG00000236165.1 PRADC1P1 18.97 2.44e-55 1.22e-47 0.89 0.72 Intelligence (multi-trait analysis); chr2:73215684 chr3:36976316~36976840:+ LIHC trans rs1045902 0.967 rs10207625 ENSG00000236165.1 PRADC1P1 18.95 2.86e-55 1.42e-47 0.89 0.72 Intelligence (multi-trait analysis); chr2:73237680 chr3:36976316~36976840:+ LIHC trans rs1045902 0.967 rs1469530 ENSG00000236165.1 PRADC1P1 18.95 2.86e-55 1.42e-47 0.89 0.72 Intelligence (multi-trait analysis); chr2:73237820 chr3:36976316~36976840:+ LIHC trans rs2950393 0.895 rs2926740 ENSG00000121089.4 NACA3P 18.94 3.25e-55 1.6e-47 0.85 0.72 Platelet distribution width; chr12:56666751 chr4:164943290~164943937:+ LIHC trans rs13177918 0.626 rs13175436 ENSG00000239528.1 RPS14P8 18.94 3.25e-55 1.6e-47 0.96 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150450974 chr5:116562562~116562930:+ LIHC trans rs13177918 0.603 rs13175992 ENSG00000239528.1 RPS14P8 18.94 3.25e-55 1.6e-47 0.96 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150451026 chr5:116562562~116562930:+ LIHC trans rs13177918 0.626 rs67026795 ENSG00000239528.1 RPS14P8 18.94 3.25e-55 1.6e-47 0.96 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452097 chr5:116562562~116562930:+ LIHC trans rs13177918 0.578 rs35919198 ENSG00000239528.1 RPS14P8 18.94 3.25e-55 1.6e-47 0.96 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452428 chr5:116562562~116562930:+ LIHC trans rs13177918 0.603 rs10447222 ENSG00000239528.1 RPS14P8 18.94 3.25e-55 1.6e-47 0.96 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150453104 chr5:116562562~116562930:+ LIHC trans rs941207 0.526 rs11171916 ENSG00000121089.4 NACA3P -18.92 4.05e-55 1.98e-47 -0.85 -0.72 Platelet count; chr12:56653236 chr4:164943290~164943937:+ LIHC trans rs2950393 0.777 rs12828563 ENSG00000121089.4 NACA3P 18.91 4.11e-55 2.01e-47 0.84 0.72 Platelet distribution width; chr12:56709378 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs1131514 ENSG00000121089.4 NACA3P -18.91 4.15e-55 2.02e-47 -0.82 -0.71 Platelet distribution width; chr12:56739356 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs1903370 ENSG00000121089.4 NACA3P -18.91 4.32e-55 2.1e-47 -0.88 -0.71 Platelet count; chr12:56812900 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs898609 ENSG00000121089.4 NACA3P 18.91 4.41e-55 2.14e-47 0.83 0.71 Platelet distribution width; chr12:56713026 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs4902 ENSG00000121089.4 NACA3P 18.91 4.41e-55 2.14e-47 0.83 0.71 Platelet distribution width; chr12:56714419 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs2926748 ENSG00000121089.4 NACA3P 18.91 4.41e-55 2.14e-47 0.83 0.71 Platelet distribution width; chr12:56715628 chr4:164943290~164943937:+ LIHC trans rs13177918 1 rs13161334 ENSG00000239528.1 RPS14P8 18.87 5.96e-55 2.88e-47 1.07 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443110 chr5:116562562~116562930:+ LIHC trans rs13177918 1 rs35007082 ENSG00000239528.1 RPS14P8 18.87 5.96e-55 2.88e-47 1.07 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150445015 chr5:116562562~116562930:+ LIHC trans rs941207 0.542 rs11171983 ENSG00000121089.4 NACA3P -18.83 8.79e-55 4.19e-47 -0.88 -0.71 Platelet count; chr12:56814461 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs2958127 ENSG00000121089.4 NACA3P 18.83 8.95e-55 4.26e-47 0.84 0.71 Platelet distribution width; chr12:56720523 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs2035081 ENSG00000121089.4 NACA3P 18.83 9.29e-55 4.42e-47 0.83 0.71 Platelet distribution width; chr12:56732095 chr4:164943290~164943937:+ LIHC trans rs2950393 0.927 rs11171914 ENSG00000121089.4 NACA3P -18.77 1.58e-54 7.44e-47 -0.85 -0.71 Platelet distribution width; chr12:56649462 chr4:164943290~164943937:+ LIHC trans rs13177918 1 rs13177918 ENSG00000239528.1 RPS14P8 18.74 2.03e-54 9.54e-47 1.07 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446307 chr5:116562562~116562930:+ LIHC trans rs6732160 0.593 rs2288630 ENSG00000236165.1 PRADC1P1 18.74 2.06e-54 9.68e-47 0.89 0.71 Intelligence (multi-trait analysis); chr2:73230424 chr3:36976316~36976840:+ LIHC trans rs7121616 0.576 rs4936767 ENSG00000234176.1 HSPA8P1 18.74 2.11e-54 9.88e-47 0.84 0.71 Breast cancer; chr11:123047451 chrX:121203182~121205014:- LIHC trans rs2950393 0.804 rs2290894 ENSG00000121089.4 NACA3P 18.72 2.41e-54 1.12e-46 0.83 0.71 Platelet distribution width; chr12:56714911 chr4:164943290~164943937:+ LIHC trans rs6732160 0.691 rs13432787 ENSG00000236165.1 PRADC1P1 18.72 2.51e-54 1.17e-46 0.88 0.71 Intelligence (multi-trait analysis); chr2:73203106 chr3:36976316~36976840:+ LIHC trans rs928391 0.681 rs9427242 ENSG00000227183.3 HDGFP1 -18.69 3.19e-54 1.47e-46 -0.96 -0.71 Platelet count; chr1:156755209 chrX:131646639~131646890:+ LIHC trans rs6477998 0.58 rs4979231 ENSG00000238072.1 RP11-305M3.2 18.69 3.22e-54 1.48e-46 0.87 0.71 Hematology traits; chr9:113286475 chr7:129410113~129410370:- LIHC trans rs941207 0.526 rs7303216 ENSG00000121089.4 NACA3P 18.66 4.23e-54 1.92e-46 0.84 0.71 Platelet count; chr12:56680909 chr4:164943290~164943937:+ LIHC trans rs941207 0.507 rs7297289 ENSG00000121089.4 NACA3P 18.66 4.23e-54 1.92e-46 0.84 0.71 Platelet count; chr12:56682703 chr4:164943290~164943937:+ LIHC trans rs941207 0.526 rs4759028 ENSG00000121089.4 NACA3P 18.66 4.23e-54 1.92e-46 0.84 0.71 Platelet count; chr12:56686399 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs10876928 ENSG00000121089.4 NACA3P -18.66 4.3e-54 1.94e-46 -0.87 -0.71 Platelet count; chr12:56813646 chr4:164943290~164943937:+ LIHC trans rs941207 0.526 rs12229457 ENSG00000121089.4 NACA3P -18.66 4.46e-54 2.01e-46 -0.85 -0.71 Platelet count; chr12:56639896 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs3214051 ENSG00000121089.4 NACA3P 18.64 4.98e-54 2.24e-46 0.83 0.71 Platelet distribution width; chr12:56725452 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs1466382 ENSG00000121089.4 NACA3P -18.64 5.32e-54 2.39e-46 -0.82 -0.71 Platelet distribution width; chr12:56723050 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs2926752 ENSG00000121089.4 NACA3P 18.63 5.58e-54 2.51e-46 0.83 0.71 Platelet distribution width; chr12:56710144 chr4:164943290~164943937:+ LIHC trans rs2950393 0.777 rs2958148 ENSG00000121089.4 NACA3P 18.63 5.58e-54 2.51e-46 0.83 0.71 Platelet distribution width; chr12:56710153 chr4:164943290~164943937:+ LIHC trans rs10716881 1 rs10716881 ENSG00000121089.4 NACA3P -18.63 5.91e-54 2.65e-46 -0.84 -0.71 High light scatter reticulocyte count; chr12:56644387 chr4:164943290~164943937:+ LIHC trans rs13253073 0.723 rs13274441 ENSG00000260318.1 COX6CP1 18.61 6.58e-54 2.94e-46 1.26 0.71 Glucose homeostasis traits; chr8:99861038 chr16:11903923~11904137:- LIHC trans rs2950393 0.804 rs7967600 ENSG00000121089.4 NACA3P 18.61 6.81e-54 3.04e-46 0.84 0.71 Platelet distribution width; chr12:56768208 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs898611 ENSG00000121089.4 NACA3P -18.61 7.12e-54 3.18e-46 -0.84 -0.71 Platelet distribution width; chr12:56769532 chr4:164943290~164943937:+ LIHC trans rs6732160 0.691 rs6728147 ENSG00000236165.1 PRADC1P1 -18.56 1.1e-53 4.88e-46 -0.88 -0.71 Intelligence (multi-trait analysis); chr2:73196362 chr3:36976316~36976840:+ LIHC trans rs941207 0.526 rs2950393 ENSG00000121089.4 NACA3P -18.55 1.24e-53 5.45e-46 -0.85 -0.71 Platelet count; chr12:56642239 chr4:164943290~164943937:+ LIHC trans rs2950393 0.794 rs1563897 ENSG00000121089.4 NACA3P 18.54 1.36e-53 5.97e-46 0.84 0.71 Platelet distribution width; chr12:56699316 chr4:164943290~164943937:+ LIHC trans rs2950393 0.895 rs2958123 ENSG00000121089.4 NACA3P 18.53 1.45e-53 6.37e-46 0.84 0.71 Platelet distribution width; chr12:56668441 chr4:164943290~164943937:+ LIHC trans rs1816752 0.905 rs1348110 ENSG00000237917.1 PARP4P1 18.52 1.54e-53 6.74e-46 0.86 0.71 Obesity-related traits; chr13:24406537 chrY:26594851~26634652:- LIHC trans rs13177918 0.559 rs12109637 ENSG00000224114.1 RP11-343H5.4 18.5 1.84e-53 8.01e-46 0.92 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150455155 chr1:206695837~206696269:- LIHC trans rs2950393 0.726 rs10459246 ENSG00000121089.4 NACA3P -18.45 2.99e-53 1.29e-45 -0.85 -0.71 Platelet distribution width; chr12:56776034 chr4:164943290~164943937:+ LIHC trans rs13177918 0.906 rs12652032 ENSG00000239528.1 RPS14P8 18.44 3.39e-53 1.45e-45 1.07 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442060 chr5:116562562~116562930:+ LIHC trans rs2950393 0.777 rs2926747 ENSG00000121089.4 NACA3P 18.43 3.5e-53 1.5e-45 0.83 0.71 Platelet distribution width; chr12:56716147 chr4:164943290~164943937:+ LIHC trans rs941207 0.526 rs2255074 ENSG00000121089.4 NACA3P -18.34 8.68e-53 3.59e-45 -0.84 -0.7 Platelet count; chr12:56636242 chr4:164943290~164943937:+ LIHC trans rs2950393 0.929 rs2290893 ENSG00000121089.4 NACA3P 18.32 9.72e-53 4.01e-45 0.83 0.7 Platelet distribution width; chr12:56684836 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs11171979 ENSG00000121089.4 NACA3P -18.26 1.8e-52 7.24e-45 -0.85 -0.7 Platelet count; chr12:56802199 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs11171951 ENSG00000121089.4 NACA3P 18.25 1.9e-52 7.65e-45 0.83 0.7 Platelet distribution width; chr12:56718853 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs1026565 ENSG00000121089.4 NACA3P 18.22 2.58e-52 1.03e-44 0.82 0.7 Platelet distribution width; chr12:56744044 chr4:164943290~164943937:+ LIHC trans rs2950393 0.929 rs7973157 ENSG00000121089.4 NACA3P -18.22 2.62e-52 1.04e-44 -0.83 -0.7 Platelet distribution width; chr12:56655409 chr4:164943290~164943937:+ LIHC trans rs2950393 0.929 rs10876916 ENSG00000121089.4 NACA3P 18.22 2.67e-52 1.06e-44 0.83 0.7 Platelet distribution width; chr12:56692728 chr4:164943290~164943937:+ LIHC trans rs941207 0.805 rs2958139 ENSG00000121089.4 NACA3P -18.2 3.1e-52 1.23e-44 -0.92 -0.7 Platelet count; chr12:56610884 chr4:164943290~164943937:+ LIHC trans rs941207 0.547 rs56183434 ENSG00000121089.4 NACA3P 18.2 3.14e-52 1.25e-44 0.83 0.7 Platelet count; chr12:56676145 chr4:164943290~164943937:+ LIHC trans rs941207 0.507 rs1107479 ENSG00000121089.4 NACA3P -18.1 7.91e-52 3.08e-44 -0.83 -0.7 Platelet count; chr12:56636902 chr4:164943290~164943937:+ LIHC trans rs941207 0.542 rs11171986 ENSG00000121089.4 NACA3P -18.1 8.02e-52 3.13e-44 -0.88 -0.7 Platelet count; chr12:56819043 chr4:164943290~164943937:+ LIHC trans rs2950393 0.929 rs7980835 ENSG00000121089.4 NACA3P 18.08 9.01e-52 3.48e-44 0.82 0.7 Platelet distribution width; chr12:56676847 chr4:164943290~164943937:+ LIHC trans rs2950393 0.929 rs10747769 ENSG00000121089.4 NACA3P 18.08 9.01e-52 3.48e-44 0.82 0.7 Platelet distribution width; chr12:56677056 chr4:164943290~164943937:+ LIHC trans rs6732160 0.691 rs11886257 ENSG00000236165.1 PRADC1P1 18.08 9.19e-52 3.54e-44 0.87 0.7 Intelligence (multi-trait analysis); chr2:73189745 chr3:36976316~36976840:+ LIHC trans rs6732160 0.691 rs1960233 ENSG00000236165.1 PRADC1P1 18.08 9.19e-52 3.54e-44 0.87 0.7 Intelligence (multi-trait analysis); chr2:73194250 chr3:36976316~36976840:+ LIHC trans rs6732160 0.691 rs2007191 ENSG00000236165.1 PRADC1P1 18.08 9.19e-52 3.54e-44 0.87 0.7 Intelligence (multi-trait analysis); chr2:73194335 chr3:36976316~36976840:+ LIHC trans rs1816752 1 rs1816752 ENSG00000237917.1 PARP4P1 18.08 9.31e-52 3.58e-44 0.85 0.7 Obesity-related traits; chr13:24406811 chrY:26594851~26634652:- LIHC trans rs941207 0.855 rs2256341 ENSG00000121089.4 NACA3P -18.06 1.1e-51 4.2e-44 -0.91 -0.7 Platelet count; chr12:56599930 chr4:164943290~164943937:+ LIHC trans rs2950393 0.804 rs7295862 ENSG00000121089.4 NACA3P -18.04 1.3e-51 4.97e-44 -0.84 -0.7 Platelet distribution width; chr12:56775374 chr4:164943290~164943937:+ LIHC trans rs9899728 0.764 rs9660 ENSG00000234925.2 ATP5HP4 18.04 1.33e-51 5.06e-44 0.92 0.7 Alzheimer's disease or small vessel stroke; chr17:75042651 chr12:68642519~68642993:- LIHC trans rs2950393 0.857 rs9989034 ENSG00000121089.4 NACA3P 18.03 1.51e-51 5.73e-44 0.82 0.7 Platelet distribution width; chr12:56674508 chr4:164943290~164943937:+ LIHC trans rs13190036 1 rs13157667 ENSG00000217325.2 PRELID1P1 -18.02 1.67e-51 6.28e-44 -0.94 -0.7 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177186876 chr6:126643488~126644390:+ LIHC trans rs13190036 1 rs13167431 ENSG00000217325.2 PRELID1P1 -18.02 1.67e-51 6.28e-44 -0.94 -0.7 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177194074 chr6:126643488~126644390:+ LIHC trans rs13190036 1 rs35535623 ENSG00000217325.2 PRELID1P1 -18.02 1.67e-51 6.28e-44 -0.94 -0.7 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177202295 chr6:126643488~126644390:+ LIHC trans rs13190036 1 rs71601343 ENSG00000217325.2 PRELID1P1 -18.02 1.67e-51 6.28e-44 -0.94 -0.7 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177205106 chr6:126643488~126644390:+ LIHC trans rs13190036 1 rs71601344 ENSG00000217325.2 PRELID1P1 -18.02 1.67e-51 6.28e-44 -0.94 -0.7 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206492 chr6:126643488~126644390:+ LIHC trans rs13190036 1 rs3733875 ENSG00000217325.2 PRELID1P1 -18.02 1.67e-51 6.28e-44 -0.94 -0.7 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210239 chr6:126643488~126644390:+ LIHC trans rs12291225 0.546 rs11023199 ENSG00000236360.2 RP11-334A14.2 18.01 1.81e-51 6.81e-44 0.87 0.7 Sense of smell; chr11:14372712 chr1:52993201~52993702:- LIHC trans rs2950393 0.929 rs2958155 ENSG00000121089.4 NACA3P 17.99 2.11e-51 7.87e-44 0.82 0.7 Platelet distribution width; chr12:56670761 chr4:164943290~164943937:+ LIHC trans rs13190036 1 rs34446750 ENSG00000217325.2 PRELID1P1 -17.99 2.13e-51 7.95e-44 -0.94 -0.7 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177168079 chr6:126643488~126644390:+ LIHC trans rs941207 0.507 rs73337030 ENSG00000121089.4 NACA3P -17.97 2.52e-51 9.41e-44 -0.82 -0.7 Platelet count; chr12:56652410 chr4:164943290~164943937:+ LIHC trans rs941207 0.514 rs6581105 ENSG00000121089.4 NACA3P -17.96 2.83e-51 1.05e-43 -0.88 -0.7 Platelet count; chr12:56792184 chr4:164943290~164943937:+ LIHC trans rs1816752 0.837 rs9318530 ENSG00000237917.1 PARP4P1 -17.95 3.26e-51 1.21e-43 -0.78 -0.7 Obesity-related traits; chr13:24424419 chrY:26594851~26634652:- LIHC trans rs1816752 0.905 rs2000153 ENSG00000237917.1 PARP4P1 17.9 5.01e-51 1.85e-43 0.85 0.7 Obesity-related traits; chr13:24405752 chrY:26594851~26634652:- LIHC trans rs7943191 0.81 rs7942991 ENSG00000186676.3 EEF1GP1 -17.87 6.53e-51 2.41e-43 -1.07 -0.69 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62569731 chr7:125033453~125035301:+ LIHC trans rs13190036 0.892 rs71601339 ENSG00000217325.2 PRELID1P1 -17.78 1.45e-50 5.31e-43 -0.95 -0.69 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117495 chr6:126643488~126644390:+ LIHC trans rs13190036 1 rs13185316 ENSG00000217325.2 PRELID1P1 -17.77 1.64e-50 5.97e-43 -0.93 -0.69 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177213339 chr6:126643488~126644390:+ LIHC trans rs8010715 0.816 rs1134340 ENSG00000248988.1 RP11-815N9.2 17.75 1.99e-50 7.22e-43 0.87 0.69 IgG glycosylation; chr14:24125004 chr4:159007119~159007835:+ LIHC trans rs6732160 0.691 rs13402225 ENSG00000236165.1 PRADC1P1 17.74 2.18e-50 7.92e-43 0.86 0.69 Intelligence (multi-trait analysis); chr2:73189778 chr3:36976316~36976840:+ LIHC trans rs8010715 0.816 rs6573573 ENSG00000248988.1 RP11-815N9.2 17.71 2.93e-50 1.06e-42 0.88 0.69 IgG glycosylation; chr14:24130048 chr4:159007119~159007835:+ LIHC trans rs13253073 0.545 rs35769167 ENSG00000260318.1 COX6CP1 17.7 3.05e-50 1.11e-42 1.3 0.69 Glucose homeostasis traits; chr8:99872095 chr16:11903923~11904137:- LIHC trans rs13177918 0.871 rs11745133 ENSG00000213058.3 RP4-765C7.2 17.68 3.67e-50 1.33e-42 1.05 0.69 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150457826 chr1:178411616~178411972:+ LIHC trans rs6732160 0.691 rs4536673 ENSG00000236165.1 PRADC1P1 17.68 3.71e-50 1.34e-42 0.86 0.69 Intelligence (multi-trait analysis); chr2:73186334 chr3:36976316~36976840:+ LIHC trans rs13177918 0.559 rs10447224 ENSG00000239528.1 RPS14P8 17.66 4.52e-50 1.62e-42 0.9 0.69 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454802 chr5:116562562~116562930:+ LIHC trans rs13177918 0.559 rs10447225 ENSG00000239528.1 RPS14P8 17.66 4.52e-50 1.62e-42 0.9 0.69 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454891 chr5:116562562~116562930:+ LIHC trans rs13190036 0.901 rs55741473 ENSG00000217325.2 PRELID1P1 -17.65 5.06e-50 1.81e-42 -0.94 -0.69 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147218 chr6:126643488~126644390:+ LIHC trans rs8010715 0.816 rs762093 ENSG00000248988.1 RP11-815N9.2 17.64 5.54e-50 1.98e-42 0.87 0.69 IgG glycosylation; chr14:24122709 chr4:159007119~159007835:+ LIHC trans rs13253073 1 rs10955222 ENSG00000260318.1 COX6CP1 -17.63 6.09e-50 2.17e-42 -1.17 -0.69 Glucose homeostasis traits; chr8:99875122 chr16:11903923~11904137:- LIHC trans rs13190036 1 rs13177748 ENSG00000217325.2 PRELID1P1 -17.61 7.22e-50 2.57e-42 -0.92 -0.69 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177216953 chr6:126643488~126644390:+ LIHC trans rs13253073 0.55 rs6468697 ENSG00000260318.1 COX6CP1 17.59 8.77e-50 3.11e-42 1 0.69 Glucose homeostasis traits; chr8:99858154 chr16:11903923~11904137:- LIHC trans rs8010715 0.785 rs2877611 ENSG00000248988.1 RP11-815N9.2 17.57 1.07e-49 3.8e-42 0.87 0.69 IgG glycosylation; chr14:24126221 chr4:159007119~159007835:+ LIHC trans rs8010715 0.816 rs11574503 ENSG00000248988.1 RP11-815N9.2 -17.53 1.54e-49 5.41e-42 -0.88 -0.69 IgG glycosylation; chr14:24132109 chr4:159007119~159007835:+ LIHC trans rs13253073 1 rs4409375 ENSG00000260318.1 COX6CP1 17.53 1.57e-49 5.53e-42 1.22 0.69 Glucose homeostasis traits; chr8:99877759 chr16:11903923~11904137:- LIHC trans rs13177918 0.834 rs13163277 ENSG00000213058.3 RP4-765C7.2 17.53 1.58e-49 5.53e-42 1.05 0.69 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150459359 chr1:178411616~178411972:+ LIHC trans rs8010715 0.816 rs7153156 ENSG00000248988.1 RP11-815N9.2 17.52 1.63e-49 5.7e-42 0.88 0.69 IgG glycosylation; chr14:24129637 chr4:159007119~159007835:+ LIHC trans rs8010715 0.816 rs6573572 ENSG00000248988.1 RP11-815N9.2 17.52 1.63e-49 5.7e-42 0.88 0.69 IgG glycosylation; chr14:24130021 chr4:159007119~159007835:+ LIHC trans rs8010715 0.816 rs8015168 ENSG00000248988.1 RP11-815N9.2 17.52 1.63e-49 5.7e-42 0.88 0.69 IgG glycosylation; chr14:24130663 chr4:159007119~159007835:+ LIHC trans rs6732160 0.684 rs2043095 ENSG00000236165.1 PRADC1P1 17.51 1.85e-49 6.46e-42 0.85 0.69 Intelligence (multi-trait analysis); chr2:73180314 chr3:36976316~36976840:+ LIHC trans rs6732160 0.656 rs2043093 ENSG00000236165.1 PRADC1P1 17.47 2.64e-49 8.97e-42 0.86 0.69 Intelligence (multi-trait analysis); chr2:73180214 chr3:36976316~36976840:+ LIHC trans rs8010715 0.771 rs2277481 ENSG00000248988.1 RP11-815N9.2 17.44 3.4e-49 1.15e-41 0.88 0.69 IgG glycosylation; chr14:24118336 chr4:159007119~159007835:+ LIHC trans rs13253073 1 rs35935983 ENSG00000260318.1 COX6CP1 17.43 3.85e-49 1.3e-41 1.22 0.69 Glucose homeostasis traits; chr8:99888966 chr16:11903923~11904137:- LIHC trans rs6732160 0.691 rs10197935 ENSG00000236165.1 PRADC1P1 17.4 5.25e-49 1.73e-41 0.85 0.69 Intelligence (multi-trait analysis); chr2:73185234 chr3:36976316~36976840:+ LIHC trans rs13177918 0.798 rs12516161 ENSG00000213058.3 RP4-765C7.2 17.38 6.03e-49 1.98e-41 1.04 0.68 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150461098 chr1:178411616~178411972:+ LIHC trans rs6732160 0.65 rs7560224 ENSG00000236165.1 PRADC1P1 17.36 7.23e-49 2.35e-41 0.85 0.68 Intelligence (multi-trait analysis); chr2:73179054 chr3:36976316~36976840:+ LIHC trans rs2950393 0.895 rs2958154 ENSG00000121089.4 NACA3P -17.36 7.32e-49 2.37e-41 -0.8 -0.68 Platelet distribution width; chr12:56671929 chr4:164943290~164943937:+ LIHC trans rs941207 0.507 rs2958124 ENSG00000121089.4 NACA3P -17.34 9.02e-49 2.92e-41 -0.83 -0.68 Platelet count; chr12:56633837 chr4:164943290~164943937:+ LIHC trans rs7949030 0.626 rs35587183 ENSG00000186676.3 EEF1GP1 17.3 1.29e-48 4.14e-41 1.06 0.68 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62551184 chr7:125033453~125035301:+ LIHC trans rs13177918 0.559 rs12109637 ENSG00000239528.1 RPS14P8 17.23 2.37e-48 7.45e-41 0.87 0.68 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150455155 chr5:116562562~116562930:+ LIHC trans rs7943191 0.768 rs34065644 ENSG00000186676.3 EEF1GP1 17.19 3.45e-48 1.08e-40 1.06 0.68 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62604466 chr7:125033453~125035301:+ LIHC trans rs7949030 0.523 rs12223627 ENSG00000186676.3 EEF1GP1 17.19 3.47e-48 1.08e-40 1.06 0.68 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62601085 chr7:125033453~125035301:+ LIHC trans rs7943191 0.805 rs12226821 ENSG00000186676.3 EEF1GP1 17.19 3.47e-48 1.08e-40 1.06 0.68 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62601546 chr7:125033453~125035301:+ LIHC trans rs8081395 0.741 rs1292055 ENSG00000187870.7 RNFT1P3 17.19 3.64e-48 1.13e-40 0.72 0.68 White blood cell count; chr17:59881707 chr17:20743333~20754501:- LIHC trans rs13177918 0.834 rs13163277 ENSG00000224114.1 RP11-343H5.4 17.18 3.93e-48 1.22e-40 1.05 0.68 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150459359 chr1:206695837~206696269:- LIHC trans rs13177918 0.871 rs11745133 ENSG00000224114.1 RP11-343H5.4 17.18 3.97e-48 1.23e-40 1.04 0.68 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150457826 chr1:206695837~206696269:- LIHC trans rs8081395 0.741 rs2645462 ENSG00000187870.7 RNFT1P3 17.18 4e-48 1.24e-40 0.72 0.68 White blood cell count; chr17:59906198 chr17:20743333~20754501:- LIHC trans rs8081395 0.711 rs1292034 ENSG00000187870.7 RNFT1P3 17.18 4e-48 1.24e-40 0.72 0.68 White blood cell count; chr17:59912499 chr17:20743333~20754501:- LIHC trans rs8081395 0.775 rs2645482 ENSG00000187870.7 RNFT1P3 17.17 4.2e-48 1.3e-40 0.73 0.68 White blood cell count; chr17:59865754 chr17:20743333~20754501:- LIHC trans rs8081395 0.805 rs2645485 ENSG00000187870.7 RNFT1P3 17.17 4.2e-48 1.3e-40 0.73 0.68 White blood cell count; chr17:59866920 chr17:20743333~20754501:- LIHC trans rs1816752 0.748 rs6490912 ENSG00000237917.1 PARP4P1 17.16 4.59e-48 1.41e-40 0.82 0.68 Obesity-related traits; chr13:24408941 chrY:26594851~26634652:- LIHC trans rs1816752 0.819 rs1981276 ENSG00000237917.1 PARP4P1 17.16 4.59e-48 1.41e-40 0.82 0.68 Obesity-related traits; chr13:24409361 chrY:26594851~26634652:- LIHC trans rs1816752 0.837 rs57052031 ENSG00000237917.1 PARP4P1 17.16 4.59e-48 1.41e-40 0.82 0.68 Obesity-related traits; chr13:24409730 chrY:26594851~26634652:- LIHC trans rs7943191 0.81 rs7942154 ENSG00000186676.3 EEF1GP1 17.16 4.9e-48 1.5e-40 1.06 0.68 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62569691 chr7:125033453~125035301:+ LIHC trans rs13190036 1 rs4976682 ENSG00000217325.2 PRELID1P1 17.15 5.32e-48 1.63e-40 0.89 0.68 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177299001 chr6:126643488~126644390:+ LIHC trans rs8081395 0.741 rs1292051 ENSG00000187870.7 RNFT1P3 17.13 5.96e-48 1.82e-40 0.72 0.68 White blood cell count; chr17:59886562 chr17:20743333~20754501:- LIHC trans rs8081395 0.711 rs11368 ENSG00000187870.7 RNFT1P3 17.08 9.48e-48 2.85e-40 0.72 0.68 White blood cell count; chr17:59954051 chr17:20743333~20754501:- LIHC trans rs8081395 0.741 rs180532 ENSG00000187870.7 RNFT1P3 17.08 9.98e-48 3e-40 0.72 0.68 White blood cell count; chr17:59925936 chr17:20743333~20754501:- LIHC trans rs8081395 0.741 rs180530 ENSG00000187870.7 RNFT1P3 17.08 9.98e-48 3e-40 0.72 0.68 White blood cell count; chr17:59926233 chr17:20743333~20754501:- LIHC trans rs8010715 0.816 rs6573565 ENSG00000248988.1 RP11-815N9.2 -17.07 1.06e-47 3.17e-40 -0.85 -0.68 IgG glycosylation; chr14:24125524 chr4:159007119~159007835:+ LIHC trans rs8081395 0.737 rs4968401 ENSG00000187870.7 RNFT1P3 -17.07 1.1e-47 3.29e-40 -0.72 -0.68 White blood cell count; chr17:59963369 chr17:20743333~20754501:- LIHC trans rs8081395 0.741 rs180519 ENSG00000187870.7 RNFT1P3 17.06 1.21e-47 3.58e-40 0.72 0.68 White blood cell count; chr17:59938910 chr17:20743333~20754501:- LIHC trans rs6477998 0.966 rs10759637 ENSG00000238072.1 RP11-305M3.2 17.06 1.21e-47 3.59e-40 0.86 0.68 Hematology traits; chr9:113262744 chr7:129410113~129410370:- LIHC trans rs13190036 1 rs625882 ENSG00000217325.2 PRELID1P1 -17.06 1.24e-47 3.66e-40 -0.91 -0.68 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177108030 chr6:126643488~126644390:+ LIHC trans rs13253073 1 rs34029308 ENSG00000260318.1 COX6CP1 17.05 1.26e-47 3.72e-40 1.19 0.68 Glucose homeostasis traits; chr8:99892425 chr16:11903923~11904137:- LIHC trans rs928391 1 rs12129173 ENSG00000227183.3 HDGFP1 17.05 1.28e-47 3.77e-40 1.02 0.68 Platelet count; chr1:156803833 chrX:131646639~131646890:+ LIHC trans rs13177918 0.798 rs12516161 ENSG00000224114.1 RP11-343H5.4 16.99 2.2e-47 6.38e-40 1.04 0.68 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150461098 chr1:206695837~206696269:- LIHC trans rs8081395 0.707 rs1024637 ENSG00000187870.7 RNFT1P3 -16.96 3.04e-47 8.78e-40 -0.72 -0.68 White blood cell count; chr17:59961532 chr17:20743333~20754501:- LIHC trans rs6477998 0.535 rs10981712 ENSG00000238072.1 RP11-305M3.2 16.94 3.46e-47 9.84e-40 0.87 0.68 Hematology traits; chr9:113283846 chr7:129410113~129410370:- LIHC trans rs6477998 0.535 rs10817475 ENSG00000238072.1 RP11-305M3.2 16.94 3.59e-47 1.02e-39 0.89 0.68 Hematology traits; chr9:113296774 chr7:129410113~129410370:- LIHC trans rs928391 1 rs2777929 ENSG00000227183.3 HDGFP1 16.85 8.33e-47 2.33e-39 1.03 0.67 Platelet count; chr1:156797879 chrX:131646639~131646890:+ LIHC trans rs928391 1 rs2768767 ENSG00000227183.3 HDGFP1 16.85 8.33e-47 2.33e-39 1.03 0.67 Platelet count; chr1:156797933 chrX:131646639~131646890:+ LIHC trans rs13253073 1 rs13252579 ENSG00000260318.1 COX6CP1 16.84 9.08e-47 2.53e-39 1.2 0.67 Glucose homeostasis traits; chr8:99885073 chr16:11903923~11904137:- LIHC trans rs13253073 1 rs13253073 ENSG00000260318.1 COX6CP1 16.84 9.08e-47 2.53e-39 1.2 0.67 Glucose homeostasis traits; chr8:99885155 chr16:11903923~11904137:- LIHC trans rs928391 1 rs2644615 ENSG00000227183.3 HDGFP1 16.82 1.06e-46 2.93e-39 1.02 0.67 Platelet count; chr1:156791826 chrX:131646639~131646890:+ LIHC trans rs13253073 1 rs4480092 ENSG00000260318.1 COX6CP1 16.76 1.86e-46 5.13e-39 1.2 0.67 Glucose homeostasis traits; chr8:99873372 chr16:11903923~11904137:- LIHC trans rs13190036 0.748 rs28395268 ENSG00000217325.2 PRELID1P1 16.75 2.07e-46 5.7e-39 0.84 0.67 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177283546 chr6:126643488~126644390:+ LIHC trans rs13190036 0.551 rs28932178 ENSG00000217325.2 PRELID1P1 -16.73 2.41e-46 6.6e-39 -0.89 -0.67 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210575 chr6:126643488~126644390:+ LIHC trans rs7949030 0.588 rs2428549 ENSG00000186676.3 EEF1GP1 16.73 2.54e-46 6.94e-39 1.08 0.67 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62544922 chr7:125033453~125035301:+ LIHC trans rs1816752 0.74 rs6490924 ENSG00000237917.1 PARP4P1 -16.72 2.78e-46 7.57e-39 -0.75 -0.67 Obesity-related traits; chr13:24432914 chrY:26594851~26634652:- LIHC trans rs928391 1 rs2644606 ENSG00000227183.3 HDGFP1 16.7 3.42e-46 9.27e-39 1.02 0.67 Platelet count; chr1:156808053 chrX:131646639~131646890:+ LIHC trans rs928391 1 rs928391 ENSG00000227183.3 HDGFP1 16.68 3.98e-46 1.08e-38 1.02 0.67 Platelet count; chr1:156806925 chrX:131646639~131646890:+ LIHC trans rs6477998 1 rs10759636 ENSG00000238072.1 RP11-305M3.2 16.68 4.17e-46 1.13e-38 0.85 0.67 Hematology traits; chr9:113256497 chr7:129410113~129410370:- LIHC trans rs1045902 0.583 rs36106493 ENSG00000236165.1 PRADC1P1 16.62 7.07e-46 1.89e-38 0.83 0.67 Intelligence (multi-trait analysis); chr2:73215211 chr3:36976316~36976840:+ LIHC trans rs13253073 1 rs13259066 ENSG00000260318.1 COX6CP1 16.59 8.83e-46 2.34e-38 1.19 0.67 Glucose homeostasis traits; chr8:99889455 chr16:11903923~11904137:- LIHC trans rs1816752 0.755 rs1981277 ENSG00000237917.1 PARP4P1 16.56 1.15e-45 3.04e-38 0.8 0.67 Obesity-related traits; chr13:24409375 chrY:26594851~26634652:- LIHC trans rs1816752 0.811 rs9507337 ENSG00000237917.1 PARP4P1 16.56 1.15e-45 3.04e-38 0.8 0.67 Obesity-related traits; chr13:24410807 chrY:26594851~26634652:- LIHC trans rs1816752 0.712 rs9507335 ENSG00000237917.1 PARP4P1 16.56 1.21e-45 3.18e-38 0.8 0.67 Obesity-related traits; chr13:24409766 chrY:26594851~26634652:- LIHC trans rs6477998 0.535 rs4979232 ENSG00000238072.1 RP11-305M3.2 -16.55 1.37e-45 3.59e-38 -0.86 -0.67 Hematology traits; chr9:113286594 chr7:129410113~129410370:- LIHC trans rs1816752 0.774 rs2862895 ENSG00000237917.1 PARP4P1 16.52 1.7e-45 4.44e-38 0.8 0.67 Obesity-related traits; chr13:24410328 chrY:26594851~26634652:- LIHC trans rs6477998 0.903 rs7041615 ENSG00000238072.1 RP11-305M3.2 16.51 1.85e-45 4.84e-38 0.84 0.67 Hematology traits; chr9:113244747 chr7:129410113~129410370:- LIHC trans rs941207 0.762 rs10450 ENSG00000121089.4 NACA3P 16.49 2.22e-45 5.79e-38 0.84 0.67 Platelet count; chr12:56590822 chr4:164943290~164943937:+ LIHC trans rs1816752 0.875 rs59686377 ENSG00000237917.1 PARP4P1 16.43 4.17e-45 1.08e-37 0.74 0.66 Obesity-related traits; chr13:24475869 chrY:26594851~26634652:- LIHC trans rs1816752 0.583 rs6490918 ENSG00000237917.1 PARP4P1 -16.41 4.63e-45 1.2e-37 -0.75 -0.66 Obesity-related traits; chr13:24427977 chrY:26594851~26634652:- LIHC trans rs928391 1 rs2768766 ENSG00000227183.3 HDGFP1 16.37 6.77e-45 1.74e-37 1 0.66 Platelet count; chr1:156805842 chrX:131646639~131646890:+ LIHC trans rs13190036 0.591 rs78523677 ENSG00000217325.2 PRELID1P1 -16.34 8.92e-45 2.29e-37 -0.88 -0.66 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177124102 chr6:126643488~126644390:+ LIHC trans rs8081395 0.729 rs12453125 ENSG00000187870.7 RNFT1P3 -16.34 8.92e-45 2.29e-37 -0.72 -0.66 White blood cell count; chr17:59968715 chr17:20743333~20754501:- LIHC trans rs7121616 0.92 rs7109445 ENSG00000234176.1 HSPA8P1 16.32 1.07e-44 2.75e-37 0.78 0.66 Breast cancer; chr11:123094779 chrX:121203182~121205014:- LIHC trans rs6732160 0.845 rs13413175 ENSG00000236165.1 PRADC1P1 16.32 1.13e-44 2.88e-37 0.81 0.66 Intelligence (multi-trait analysis); chr2:73162788 chr3:36976316~36976840:+ LIHC trans rs928391 0.947 rs11264549 ENSG00000227183.3 HDGFP1 16.31 1.23e-44 3.12e-37 1.02 0.66 Platelet count; chr1:156781017 chrX:131646639~131646890:+ LIHC trans rs928391 1 rs12134991 ENSG00000227183.3 HDGFP1 16.31 1.23e-44 3.12e-37 1.02 0.66 Platelet count; chr1:156781285 chrX:131646639~131646890:+ LIHC trans rs928391 1 rs2274501 ENSG00000227183.3 HDGFP1 16.31 1.23e-44 3.12e-37 1.02 0.66 Platelet count; chr1:156782460 chrX:131646639~131646890:+ LIHC trans rs928391 1 rs12043405 ENSG00000227183.3 HDGFP1 16.31 1.23e-44 3.12e-37 1.02 0.66 Platelet count; chr1:156784508 chrX:131646639~131646890:+ LIHC trans rs6477998 1 rs7038769 ENSG00000238072.1 RP11-305M3.2 16.29 1.39e-44 3.52e-37 0.83 0.66 Hematology traits; chr9:113245303 chr7:129410113~129410370:- LIHC trans rs6477998 1 rs7022397 ENSG00000238072.1 RP11-305M3.2 16.29 1.39e-44 3.52e-37 0.83 0.66 Hematology traits; chr9:113245397 chr7:129410113~129410370:- LIHC trans rs928391 0.895 rs11264547 ENSG00000227183.3 HDGFP1 16.29 1.49e-44 3.77e-37 1.02 0.66 Platelet count; chr1:156776326 chrX:131646639~131646890:+ LIHC trans rs928391 1 rs61816272 ENSG00000227183.3 HDGFP1 16.29 1.49e-44 3.77e-37 1.02 0.66 Platelet count; chr1:156778073 chrX:131646639~131646890:+ LIHC trans rs1816752 0.819 rs4769349 ENSG00000237917.1 PARP4P1 -16.28 1.66e-44 4.18e-37 -0.78 -0.66 Obesity-related traits; chr13:24408694 chrY:26594851~26634652:- LIHC trans rs12291225 0.535 rs10832248 ENSG00000236360.2 RP11-334A14.2 16.25 2.05e-44 5.16e-37 0.83 0.66 Sense of smell; chr11:14391541 chr1:52993201~52993702:- LIHC trans rs6732160 0.845 rs72807999 ENSG00000236165.1 PRADC1P1 16.23 2.43e-44 6.1e-37 0.81 0.66 Intelligence (multi-trait analysis); chr2:73164567 chr3:36976316~36976840:+ LIHC trans rs1816752 0.669 rs7984513 ENSG00000237917.1 PARP4P1 -16.23 2.44e-44 6.12e-37 -0.73 -0.66 Obesity-related traits; chr13:24445117 chrY:26594851~26634652:- LIHC trans rs13190036 0.792 rs6874206 ENSG00000217325.2 PRELID1P1 -16.22 2.71e-44 6.77e-37 -0.86 -0.66 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177223970 chr6:126643488~126644390:+ LIHC trans rs13190036 0.901 rs10072499 ENSG00000217325.2 PRELID1P1 -16.22 2.71e-44 6.77e-37 -0.86 -0.66 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228236 chr6:126643488~126644390:+ LIHC trans rs55665837 0.559 rs11023210 ENSG00000236360.2 RP11-334A14.2 -16.2 3.38e-44 8.41e-37 -0.85 -0.66 Vitamin D levels; chr11:14401216 chr1:52993201~52993702:- LIHC trans rs55665837 0.559 rs11023209 ENSG00000236360.2 RP11-334A14.2 16.2 3.38e-44 8.41e-37 0.85 0.66 Vitamin D levels; chr11:14401054 chr1:52993201~52993702:- LIHC trans rs13190036 0.551 rs1052432 ENSG00000217325.2 PRELID1P1 -16.2 3.42e-44 8.5e-37 -0.88 -0.66 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177137188 chr6:126643488~126644390:+ LIHC trans rs55665837 0.583 rs78843135 ENSG00000236360.2 RP11-334A14.2 16.19 3.56e-44 8.85e-37 0.83 0.66 Vitamin D levels; chr11:14389708 chr1:52993201~52993702:- LIHC trans rs928391 0.895 rs12042999 ENSG00000227183.3 HDGFP1 16.19 3.67e-44 9.09e-37 1.01 0.66 Platelet count; chr1:156768636 chrX:131646639~131646890:+ LIHC trans rs6732160 0.845 rs6718690 ENSG00000236165.1 PRADC1P1 -16.16 4.76e-44 1.17e-36 -0.8 -0.66 Intelligence (multi-trait analysis); chr2:73160034 chr3:36976316~36976840:+ LIHC trans rs12291225 0.535 rs11023203 ENSG00000236360.2 RP11-334A14.2 16.15 5.26e-44 1.29e-36 0.83 0.66 Sense of smell; chr11:14388269 chr1:52993201~52993702:- LIHC trans rs12291225 0.535 rs12806025 ENSG00000236360.2 RP11-334A14.2 16.15 5.26e-44 1.29e-36 0.83 0.66 Sense of smell; chr11:14392271 chr1:52993201~52993702:- LIHC trans rs13253073 1 rs12541837 ENSG00000260318.1 COX6CP1 -16.15 5.37e-44 1.32e-36 -1.21 -0.66 Glucose homeostasis traits; chr8:99869645 chr16:11903923~11904137:- LIHC trans rs6732160 0.619 rs12105975 ENSG00000236165.1 PRADC1P1 16.13 6.06e-44 1.48e-36 0.81 0.66 Intelligence (multi-trait analysis); chr2:73178921 chr3:36976316~36976840:+ LIHC trans rs13190036 1 rs628506 ENSG00000217325.2 PRELID1P1 -16.12 6.75e-44 1.65e-36 -0.87 -0.66 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177107422 chr6:126643488~126644390:+ LIHC trans rs55665837 0.524 rs2882128 ENSG00000236360.2 RP11-334A14.2 16.11 7.78e-44 1.9e-36 0.82 0.66 Vitamin D levels; chr11:14393088 chr1:52993201~52993702:- LIHC trans rs6732160 0.845 rs11894833 ENSG00000236165.1 PRADC1P1 -16.1 8.42e-44 2.05e-36 -0.81 -0.66 Intelligence (multi-trait analysis); chr2:73161290 chr3:36976316~36976840:+ LIHC trans rs6732160 0.845 rs6546809 ENSG00000236165.1 PRADC1P1 16.09 9.27e-44 2.25e-36 0.8 0.66 Intelligence (multi-trait analysis); chr2:73162553 chr3:36976316~36976840:+ LIHC trans rs6477998 0.966 rs7851395 ENSG00000238072.1 RP11-305M3.2 16.08 9.77e-44 2.37e-36 0.83 0.66 Hematology traits; chr9:113240184 chr7:129410113~129410370:- LIHC trans rs6732160 0.809 rs13406142 ENSG00000236165.1 PRADC1P1 16.06 1.18e-43 2.85e-36 0.81 0.66 Intelligence (multi-trait analysis); chr2:73156970 chr3:36976316~36976840:+ LIHC trans rs13190036 1 rs59737888 ENSG00000217325.2 PRELID1P1 -16.06 1.19e-43 2.85e-36 -0.91 -0.66 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177160374 chr6:126643488~126644390:+ LIHC trans rs928391 1 rs10157555 ENSG00000227183.3 HDGFP1 -16.04 1.4e-43 3.35e-36 -0.96 -0.66 Platelet count; chr1:156802060 chrX:131646639~131646890:+ LIHC trans rs55665837 0.524 rs61884009 ENSG00000236360.2 RP11-334A14.2 16 2.17e-43 5.18e-36 0.85 0.65 Vitamin D levels; chr11:14404916 chr1:52993201~52993702:- LIHC trans rs6732160 0.741 rs6546806 ENSG00000236165.1 PRADC1P1 15.97 2.67e-43 6.35e-36 0.8 0.65 Intelligence (multi-trait analysis); chr2:73159032 chr3:36976316~36976840:+ LIHC trans rs8081395 0.741 rs1292053 ENSG00000187870.7 RNFT1P3 -15.96 2.96e-43 7.04e-36 -0.69 -0.65 White blood cell count; chr17:59886176 chr17:20743333~20754501:- LIHC trans rs1816752 0.875 rs17384871 ENSG00000237917.1 PARP4P1 15.96 2.96e-43 7.05e-36 0.73 0.65 Obesity-related traits; chr13:24484959 chrY:26594851~26634652:- LIHC trans rs6732160 0.809 rs6728959 ENSG00000236165.1 PRADC1P1 15.96 3.03e-43 7.2e-36 0.81 0.65 Intelligence (multi-trait analysis); chr2:73156199 chr3:36976316~36976840:+ LIHC trans rs8010715 0.52 rs12435994 ENSG00000248988.1 RP11-815N9.2 15.96 3.14e-43 7.45e-36 0.87 0.65 IgG glycosylation; chr14:24120252 chr4:159007119~159007835:+ LIHC trans rs8010715 0.596 rs12435995 ENSG00000248988.1 RP11-815N9.2 15.96 3.14e-43 7.45e-36 0.87 0.65 IgG glycosylation; chr14:24120255 chr4:159007119~159007835:+ LIHC trans rs6732160 0.838 rs13411380 ENSG00000236165.1 PRADC1P1 15.95 3.16e-43 7.5e-36 0.81 0.65 Intelligence (multi-trait analysis); chr2:73155718 chr3:36976316~36976840:+ LIHC trans rs6732160 0.845 rs6546805 ENSG00000236165.1 PRADC1P1 15.93 4.13e-43 9.75e-36 0.8 0.65 Intelligence (multi-trait analysis); chr2:73158987 chr3:36976316~36976840:+ LIHC trans rs6477998 0.874 rs10739390 ENSG00000238072.1 RP11-305M3.2 15.92 4.24e-43 9.99e-36 0.83 0.65 Hematology traits; chr9:113226209 chr7:129410113~129410370:- LIHC trans rs6477998 0.9 rs7850357 ENSG00000238072.1 RP11-305M3.2 15.91 4.63e-43 1.09e-35 0.83 0.65 Hematology traits; chr9:113222319 chr7:129410113~129410370:- LIHC trans rs6732160 0.845 rs6752507 ENSG00000236165.1 PRADC1P1 15.91 4.92e-43 1.16e-35 0.8 0.65 Intelligence (multi-trait analysis); chr2:73158030 chr3:36976316~36976840:+ LIHC trans rs6477998 0.868 rs10513189 ENSG00000238072.1 RP11-305M3.2 15.9 5.16e-43 1.21e-35 0.81 0.65 Hematology traits; chr9:113227941 chr7:129410113~129410370:- LIHC trans rs1816752 0.875 rs59531061 ENSG00000237917.1 PARP4P1 15.85 8.32e-43 1.92e-35 0.73 0.65 Obesity-related traits; chr13:24507297 chrY:26594851~26634652:- LIHC trans rs1292048 1 rs1292048 ENSG00000187870.7 RNFT1P3 15.85 8.49e-43 1.96e-35 0.69 0.65 Red cell distribution width; chr17:59877710 chr17:20743333~20754501:- LIHC trans rs8081395 0.775 rs2526355 ENSG00000187870.7 RNFT1P3 15.85 8.63e-43 1.99e-35 0.69 0.65 White blood cell count; chr17:59875872 chr17:20743333~20754501:- LIHC trans rs8081395 0.576 rs1292032 ENSG00000187870.7 RNFT1P3 15.84 8.68e-43 1.99e-35 0.69 0.65 White blood cell count; chr17:59914982 chr17:20743333~20754501:- LIHC trans rs55665837 0.559 rs9667144 ENSG00000236360.2 RP11-334A14.2 -15.8 1.34e-42 3.06e-35 -0.84 -0.65 Vitamin D levels; chr11:14399555 chr1:52993201~52993702:- LIHC trans rs8081395 0.741 rs1292056 ENSG00000187870.7 RNFT1P3 15.79 1.5e-42 3.43e-35 0.68 0.65 White blood cell count; chr17:59881686 chr17:20743333~20754501:- LIHC trans rs8010715 0.848 rs927494 ENSG00000248988.1 RP11-815N9.2 15.77 1.72e-42 3.92e-35 0.86 0.65 IgG glycosylation; chr14:24131181 chr4:159007119~159007835:+ LIHC trans rs12291225 0.535 rs16930126 ENSG00000236360.2 RP11-334A14.2 -15.72 2.62e-42 5.92e-35 -0.81 -0.65 Sense of smell; chr11:14383437 chr1:52993201~52993702:- LIHC trans rs6477998 0.903 rs4979226 ENSG00000238072.1 RP11-305M3.2 15.71 2.87e-42 6.47e-35 0.82 0.65 Hematology traits; chr9:113239516 chr7:129410113~129410370:- LIHC trans rs6732160 0.774 rs1367291 ENSG00000236165.1 PRADC1P1 15.71 2.98e-42 6.73e-35 0.8 0.65 Intelligence (multi-trait analysis); chr2:73147737 chr3:36976316~36976840:+ LIHC trans rs6732160 0.774 rs11890053 ENSG00000236165.1 PRADC1P1 15.71 3.09e-42 6.96e-35 0.8 0.65 Intelligence (multi-trait analysis); chr2:73146320 chr3:36976316~36976840:+ LIHC trans rs6477998 1 rs4560868 ENSG00000238072.1 RP11-305M3.2 -15.69 3.52e-42 7.9e-35 -0.82 -0.65 Hematology traits; chr9:113223219 chr7:129410113~129410370:- LIHC trans rs6732160 0.809 rs13387480 ENSG00000236165.1 PRADC1P1 15.68 3.81e-42 8.48e-35 0.8 0.65 Intelligence (multi-trait analysis); chr2:73143879 chr3:36976316~36976840:+ LIHC trans rs8081395 0.741 rs180520 ENSG00000187870.7 RNFT1P3 15.68 4.03e-42 8.97e-35 0.68 0.65 White blood cell count; chr17:59937788 chr17:20743333~20754501:- LIHC trans rs13190036 1 rs655623 ENSG00000217325.2 PRELID1P1 15.66 4.86e-42 1.08e-34 0.86 0.65 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177107515 chr6:126643488~126644390:+ LIHC trans rs13177918 0.871 rs11745133 ENSG00000239528.1 RPS14P8 15.63 6.44e-42 1.42e-34 0.97 0.65 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150457826 chr5:116562562~116562930:+ LIHC trans rs13177918 0.834 rs13163277 ENSG00000239528.1 RPS14P8 15.6 7.82e-42 1.71e-34 0.97 0.64 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150459359 chr5:116562562~116562930:+ LIHC trans rs13190036 0.551 rs4976639 ENSG00000217325.2 PRELID1P1 15.6 8.38e-42 1.83e-34 0.85 0.64 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177123300 chr6:126643488~126644390:+ LIHC trans rs928391 1 rs928392 ENSG00000227183.3 HDGFP1 15.57 1.03e-41 2.24e-34 0.96 0.64 Platelet count; chr1:156801024 chrX:131646639~131646890:+ LIHC trans rs13177918 0.798 rs12514700 ENSG00000213058.3 RP4-765C7.2 15.55 1.31e-41 2.83e-34 0.95 0.64 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150466096 chr1:178411616~178411972:+ LIHC trans rs7121616 0.595 rs7941144 ENSG00000234176.1 HSPA8P1 15.53 1.59e-41 3.4e-34 0.76 0.64 Breast cancer; chr11:123079805 chrX:121203182~121205014:- LIHC trans rs2950393 0.572 rs10783794 ENSG00000121089.4 NACA3P -15.53 1.62e-41 3.46e-34 -0.74 -0.64 Platelet distribution width; chr12:56593395 chr4:164943290~164943937:+ LIHC trans rs916888 0.773 rs199448 ENSG00000264070.1 DND1P1 15.52 1.63e-41 3.48e-34 1.13 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45585871~45586929:+ LIHC trans rs8010715 0.848 rs2277483 ENSG00000248988.1 RP11-815N9.2 15.52 1.65e-41 3.51e-34 0.83 0.64 IgG glycosylation; chr14:24122683 chr4:159007119~159007835:+ LIHC trans rs8010715 0.848 rs8009511 ENSG00000248988.1 RP11-815N9.2 15.52 1.65e-41 3.51e-34 0.83 0.64 IgG glycosylation; chr14:24124771 chr4:159007119~159007835:+ LIHC trans rs8010715 0.804 rs1134334 ENSG00000248988.1 RP11-815N9.2 15.52 1.65e-41 3.51e-34 0.83 0.64 IgG glycosylation; chr14:24124905 chr4:159007119~159007835:+ LIHC trans rs8010715 1 rs8010715 ENSG00000248988.1 RP11-815N9.2 15.5 1.99e-41 4.22e-34 0.85 0.64 IgG glycosylation; chr14:24139938 chr4:159007119~159007835:+ LIHC trans rs7973618 1 rs7973618 ENSG00000121089.4 NACA3P -15.48 2.55e-41 5.29e-34 -0.77 -0.64 Mean platelet volume; chr12:56625659 chr4:164943290~164943937:+ LIHC trans rs941207 0.526 rs2950387 ENSG00000121089.4 NACA3P -15.46 2.91e-41 6.02e-34 -0.77 -0.64 Platelet count; chr12:56627222 chr4:164943290~164943937:+ LIHC trans rs13253073 1 rs6468694 ENSG00000260318.1 COX6CP1 15.45 3.15e-41 6.5e-34 1.19 0.64 Glucose homeostasis traits; chr8:99853608 chr16:11903923~11904137:- LIHC trans rs916888 0.773 rs199451 ENSG00000264070.1 DND1P1 15.45 3.22e-41 6.65e-34 1.13 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45585871~45586929:+ LIHC trans rs928391 1 rs3765787 ENSG00000227183.3 HDGFP1 -15.43 3.93e-41 8.08e-34 -0.97 -0.64 Platelet count; chr1:156784673 chrX:131646639~131646890:+ LIHC trans rs1816752 0.716 rs9553289 ENSG00000237917.1 PARP4P1 -15.42 4.29e-41 8.8e-34 -0.72 -0.64 Obesity-related traits; chr13:24400640 chrY:26594851~26634652:- LIHC trans rs10037055 1 rs10037055 ENSG00000217325.2 PRELID1P1 -15.41 4.8e-41 9.83e-34 -0.79 -0.64 Migraine without aura; chr5:177264278 chr6:126643488~126644390:+ LIHC trans rs13190036 0.551 rs7710269 ENSG00000217325.2 PRELID1P1 -15.41 4.81e-41 9.84e-34 -0.82 -0.64 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177187528 chr6:126643488~126644390:+ LIHC trans rs13190036 0.515 rs2878686 ENSG00000217325.2 PRELID1P1 -15.41 4.81e-41 9.84e-34 -0.82 -0.64 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206748 chr6:126643488~126644390:+ LIHC trans rs916888 0.773 rs199439 ENSG00000264070.1 DND1P1 15.4 4.93e-41 1.01e-33 1.13 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45585871~45586929:+ LIHC trans rs916888 0.773 rs199445 ENSG00000264070.1 DND1P1 15.38 5.88e-41 1.2e-33 1.12 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45585871~45586929:+ LIHC trans rs916888 0.773 rs199443 ENSG00000264070.1 DND1P1 15.38 5.88e-41 1.2e-33 1.12 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45585871~45586929:+ LIHC trans rs13177918 0.798 rs12516161 ENSG00000239528.1 RPS14P8 15.38 6.22e-41 1.27e-33 0.96 0.64 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150461098 chr5:116562562~116562930:+ LIHC trans rs916888 0.773 rs199457 ENSG00000264070.1 DND1P1 15.38 6.24e-41 1.27e-33 1.13 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45585871~45586929:+ LIHC trans rs916888 0.687 rs199456 ENSG00000264070.1 DND1P1 15.38 6.24e-41 1.27e-33 1.13 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45585871~45586929:+ LIHC trans rs916888 0.821 rs70600 ENSG00000264070.1 DND1P1 15.36 7.62e-41 1.54e-33 1.14 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45585871~45586929:+ LIHC trans rs13177918 0.798 rs13182116 ENSG00000213058.3 RP4-765C7.2 -15.35 7.89e-41 1.6e-33 -0.95 -0.64 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150465963 chr1:178411616~178411972:+ LIHC trans rs9899728 0.572 rs4365317 ENSG00000234925.2 ATP5HP4 15.35 8.3e-41 1.68e-33 0.85 0.64 Alzheimer's disease or small vessel stroke; chr17:75063725 chr12:68642519~68642993:- LIHC trans rs6477998 0.932 rs4129395 ENSG00000238072.1 RP11-305M3.2 15.34 8.94e-41 1.81e-33 0.81 0.64 Hematology traits; chr9:113213109 chr7:129410113~129410370:- LIHC trans rs6477998 0.966 rs7859354 ENSG00000238072.1 RP11-305M3.2 15.34 8.94e-41 1.81e-33 0.81 0.64 Hematology traits; chr9:113214165 chr7:129410113~129410370:- LIHC trans rs8010715 1 rs3742500 ENSG00000248988.1 RP11-815N9.2 15.33 9.92e-41 2e-33 0.82 0.64 IgG glycosylation; chr14:24142769 chr4:159007119~159007835:+ LIHC trans rs10037055 1 rs6886255 ENSG00000217325.2 PRELID1P1 15.32 1.08e-40 2.17e-33 0.78 0.64 Migraine without aura; chr5:177291360 chr6:126643488~126644390:+ LIHC trans rs13177918 0.798 rs13182116 ENSG00000224114.1 RP11-343H5.4 -15.31 1.11e-40 2.21e-33 -0.96 -0.64 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150465963 chr1:206695837~206696269:- LIHC trans rs916888 0.779 rs199528 ENSG00000264070.1 DND1P1 15.3 1.22e-40 2.43e-33 1.15 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45585871~45586929:+ LIHC trans rs916888 0.821 rs199525 ENSG00000264070.1 DND1P1 15.3 1.22e-40 2.43e-33 1.15 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45585871~45586929:+ LIHC trans rs9899728 0.572 rs9915968 ENSG00000234925.2 ATP5HP4 15.28 1.49e-40 2.96e-33 0.85 0.64 Alzheimer's disease or small vessel stroke; chr17:75063521 chr12:68642519~68642993:- LIHC trans rs13177918 0.798 rs12514700 ENSG00000224114.1 RP11-343H5.4 15.28 1.58e-40 3.13e-33 0.95 0.64 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150466096 chr1:206695837~206696269:- LIHC trans rs10037055 0.853 rs4976680 ENSG00000217325.2 PRELID1P1 15.21 2.98e-40 5.83e-33 0.78 0.64 Migraine without aura; chr5:177275745 chr6:126643488~126644390:+ LIHC trans rs10037055 0.853 rs4976681 ENSG00000217325.2 PRELID1P1 15.21 2.98e-40 5.83e-33 0.78 0.64 Migraine without aura; chr5:177277662 chr6:126643488~126644390:+ LIHC trans rs10037055 0.812 rs11949435 ENSG00000217325.2 PRELID1P1 15.21 2.98e-40 5.83e-33 0.78 0.64 Migraine without aura; chr5:177287931 chr6:126643488~126644390:+ LIHC trans rs6732160 0.845 rs10203125 ENSG00000236165.1 PRADC1P1 15.2 3.18e-40 6.21e-33 0.8 0.63 Intelligence (multi-trait analysis); chr2:73134023 chr3:36976316~36976840:+ LIHC trans rs6732160 0.845 rs10203718 ENSG00000236165.1 PRADC1P1 15.2 3.18e-40 6.21e-33 0.8 0.63 Intelligence (multi-trait analysis); chr2:73134387 chr3:36976316~36976840:+ LIHC trans rs916888 0.773 rs199447 ENSG00000264070.1 DND1P1 15.2 3.2e-40 6.26e-33 1.12 0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45585871~45586929:+ LIHC trans rs6477998 1 rs10739388 ENSG00000238072.1 RP11-305M3.2 15.18 3.65e-40 7.11e-33 0.81 0.63 Hematology traits; chr9:113214895 chr7:129410113~129410370:- LIHC trans rs916888 0.773 rs199534 ENSG00000264070.1 DND1P1 15.18 3.72e-40 7.23e-33 1.12 0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45585871~45586929:+ LIHC trans rs916888 0.773 rs169201 ENSG00000264070.1 DND1P1 15.12 6.37e-40 1.23e-32 1.12 0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45585871~45586929:+ LIHC trans rs10037055 0.853 rs12660023 ENSG00000217325.2 PRELID1P1 15.11 7.12e-40 1.36e-32 0.78 0.63 Migraine without aura; chr5:177273884 chr6:126643488~126644390:+ LIHC trans rs916888 0.773 rs538628 ENSG00000264070.1 DND1P1 15.11 7.21e-40 1.38e-32 1.12 0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45585871~45586929:+ LIHC trans rs13190036 0.551 rs11957608 ENSG00000217325.2 PRELID1P1 -15.11 7.48e-40 1.43e-32 -0.81 -0.63 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228344 chr6:126643488~126644390:+ LIHC trans rs916888 0.773 rs199533 ENSG00000264070.1 DND1P1 15.08 9.05e-40 1.72e-32 1.12 0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45585871~45586929:+ LIHC trans rs916888 0.821 rs199504 ENSG00000264070.1 DND1P1 -15.08 9.69e-40 1.84e-32 -1.12 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:45585871~45586929:+ LIHC trans rs10037055 0.947 rs10063803 ENSG00000217325.2 PRELID1P1 15.08 9.83e-40 1.87e-32 0.78 0.63 Migraine without aura; chr5:177240326 chr6:126643488~126644390:+ LIHC trans rs6477998 0.934 rs4979223 ENSG00000238072.1 RP11-305M3.2 15.07 9.99e-40 1.89e-32 0.81 0.63 Hematology traits; chr9:113219836 chr7:129410113~129410370:- LIHC trans rs13190036 0.551 rs9313751 ENSG00000217325.2 PRELID1P1 -15.07 1.02e-39 1.93e-32 -0.81 -0.63 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177217174 chr6:126643488~126644390:+ LIHC trans rs916888 0.773 rs1378358 ENSG00000264070.1 DND1P1 15.07 1.05e-39 1.99e-32 1.12 0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45585871~45586929:+ LIHC trans rs10037055 0.853 rs9313749 ENSG00000217325.2 PRELID1P1 -15.07 1.07e-39 2.02e-32 -0.78 -0.63 Migraine without aura; chr5:177170693 chr6:126643488~126644390:+ LIHC trans rs116095464 0.558 rs10055354 ENSG00000185986.11 SDHAP3 15.05 1.22e-39 2.3e-32 1.13 0.63 Breast cancer; chr5:243679 chr5:1572222~1594620:- LIHC trans rs13190036 0.551 rs11955537 ENSG00000217325.2 PRELID1P1 -15.05 1.24e-39 2.34e-32 -0.82 -0.63 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147087 chr6:126643488~126644390:+ LIHC trans rs10037055 0.853 rs1546363 ENSG00000217325.2 PRELID1P1 -15.04 1.38e-39 2.6e-32 -0.78 -0.63 Migraine without aura; chr5:177174030 chr6:126643488~126644390:+ LIHC trans rs10037055 0.853 rs10056008 ENSG00000217325.2 PRELID1P1 -15.04 1.38e-39 2.6e-32 -0.78 -0.63 Migraine without aura; chr5:177194147 chr6:126643488~126644390:+ LIHC trans rs10037055 0.853 rs10476219 ENSG00000217325.2 PRELID1P1 -15.04 1.38e-39 2.6e-32 -0.78 -0.63 Migraine without aura; chr5:177201547 chr6:126643488~126644390:+ LIHC trans rs116095464 0.614 rs62344339 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:252880 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs9687898 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:253837 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs9688045 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:253920 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs112343653 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:257059 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs73024831 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:257077 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs62344345 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:257305 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs57335027 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:262792 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs6869925 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:263921 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs6875291 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:264077 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs6866776 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:264380 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs6874745 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:264412 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs7715108 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:264546 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs7730700 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:264598 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10057674 ENSG00000185986.11 SDHAP3 15.03 1.49e-39 2.76e-32 1.18 0.63 Breast cancer; chr5:266698 chr5:1572222~1594620:- LIHC trans rs10037055 0.741 rs4976640 ENSG00000217325.2 PRELID1P1 -15.03 1.5e-39 2.78e-32 -0.79 -0.63 Migraine without aura; chr5:177125006 chr6:126643488~126644390:+ LIHC trans rs916888 0.697 rs199516 ENSG00000264070.1 DND1P1 -15.02 1.62e-39 2.98e-32 -1.1 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45585871~45586929:+ LIHC trans rs916888 0.821 rs199514 ENSG00000264070.1 DND1P1 -15.02 1.62e-39 2.98e-32 -1.1 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45585871~45586929:+ LIHC trans rs916888 0.821 rs199512 ENSG00000264070.1 DND1P1 -15.02 1.62e-39 2.98e-32 -1.1 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45585871~45586929:+ LIHC trans rs916888 0.821 rs199509 ENSG00000264070.1 DND1P1 -15.02 1.62e-39 2.98e-32 -1.1 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45585871~45586929:+ LIHC trans rs916888 0.821 rs199507 ENSG00000264070.1 DND1P1 -15.02 1.62e-39 2.98e-32 -1.1 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45585871~45586929:+ LIHC trans rs916888 0.821 rs415430 ENSG00000264070.1 DND1P1 -15.02 1.62e-39 2.98e-32 -1.1 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45585871~45586929:+ LIHC trans rs916888 0.779 rs430685 ENSG00000264070.1 DND1P1 -15.02 1.62e-39 2.98e-32 -1.1 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45585871~45586929:+ LIHC trans rs916888 0.821 rs199505 ENSG00000264070.1 DND1P1 -15.02 1.62e-39 2.98e-32 -1.1 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45585871~45586929:+ LIHC trans rs916888 0.821 rs70602 ENSG00000264070.1 DND1P1 -15.02 1.62e-39 2.98e-32 -1.1 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45585871~45586929:+ LIHC trans rs116095464 0.558 rs1812843 ENSG00000185986.11 SDHAP3 15.01 1.8e-39 3.32e-32 1.18 0.63 Breast cancer; chr5:267543 chr5:1572222~1594620:- LIHC trans rs10037055 0.636 rs13166688 ENSG00000217325.2 PRELID1P1 -15 1.9e-39 3.48e-32 -0.81 -0.63 Migraine without aura; chr5:177156965 chr6:126643488~126644390:+ LIHC trans rs10037055 0.898 rs4976636 ENSG00000217325.2 PRELID1P1 -14.99 2.08e-39 3.81e-32 -0.8 -0.63 Migraine without aura; chr5:177118091 chr6:126643488~126644390:+ LIHC trans rs10037055 0.898 rs4976637 ENSG00000217325.2 PRELID1P1 -14.99 2.08e-39 3.81e-32 -0.8 -0.63 Migraine without aura; chr5:177118141 chr6:126643488~126644390:+ LIHC trans rs116095464 0.558 rs1971229 ENSG00000185986.11 SDHAP3 14.98 2.35e-39 4.28e-32 1.18 0.63 Breast cancer; chr5:268072 chr5:1572222~1594620:- LIHC trans rs116095464 0.614 rs4371799 ENSG00000185986.11 SDHAP3 14.98 2.35e-39 4.28e-32 1.18 0.63 Breast cancer; chr5:268077 chr5:1572222~1594620:- LIHC trans rs916888 0.821 rs199506 ENSG00000264070.1 DND1P1 -14.97 2.45e-39 4.47e-32 -1.1 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45585871~45586929:+ LIHC trans rs13190036 1 rs6880798 ENSG00000217325.2 PRELID1P1 14.97 2.59e-39 4.72e-32 0.8 0.63 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177277456 chr6:126643488~126644390:+ LIHC trans rs116095464 0.558 rs7708182 ENSG00000185986.11 SDHAP3 14.97 2.67e-39 4.79e-32 1.17 0.63 Breast cancer; chr5:234673 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10058428 ENSG00000185986.11 SDHAP3 14.97 2.67e-39 4.79e-32 1.17 0.63 Breast cancer; chr5:235493 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10036253 ENSG00000185986.11 SDHAP3 14.97 2.67e-39 4.79e-32 1.17 0.63 Breast cancer; chr5:238404 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10076655 ENSG00000185986.11 SDHAP3 14.97 2.67e-39 4.79e-32 1.17 0.63 Breast cancer; chr5:239349 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10057492 ENSG00000185986.11 SDHAP3 14.97 2.67e-39 4.79e-32 1.17 0.63 Breast cancer; chr5:239388 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs28418643 ENSG00000185986.11 SDHAP3 14.97 2.67e-39 4.79e-32 1.17 0.63 Breast cancer; chr5:240744 chr5:1572222~1594620:- LIHC trans rs116095464 0.681 rs10060016 ENSG00000185986.11 SDHAP3 14.97 2.67e-39 4.79e-32 1.17 0.63 Breast cancer; chr5:240985 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs7725227 ENSG00000185986.11 SDHAP3 14.96 2.78e-39 4.93e-32 1.17 0.63 Breast cancer; chr5:233402 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs7710005 ENSG00000185986.11 SDHAP3 14.96 2.78e-39 4.93e-32 1.17 0.63 Breast cancer; chr5:233457 chr5:1572222~1594620:- LIHC trans rs9467773 0.62 rs2451732 ENSG00000242375.1 RP11-498P14.3 -14.95 3.17e-39 5.62e-32 -0.73 -0.63 Intelligence (multi-trait analysis); chr6:26622676 chr9:97195351~97197687:- LIHC trans rs10037055 0.853 rs10036193 ENSG00000217325.2 PRELID1P1 -14.93 3.52e-39 6.22e-32 -0.79 -0.63 Migraine without aura; chr5:177141519 chr6:126643488~126644390:+ LIHC trans rs10037055 0.853 rs9885210 ENSG00000217325.2 PRELID1P1 -14.93 3.52e-39 6.22e-32 -0.79 -0.63 Migraine without aura; chr5:177142187 chr6:126643488~126644390:+ LIHC trans rs10037055 0.685 rs10039241 ENSG00000217325.2 PRELID1P1 -14.89 5.29e-39 9.24e-32 -0.81 -0.63 Migraine without aura; chr5:177151071 chr6:126643488~126644390:+ LIHC trans rs116095464 0.558 rs10057299 ENSG00000185986.11 SDHAP3 14.88 5.67e-39 9.83e-32 1.16 0.63 Breast cancer; chr5:242020 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs13357299 ENSG00000185986.11 SDHAP3 14.88 5.67e-39 9.83e-32 1.16 0.63 Breast cancer; chr5:242096 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs13356367 ENSG00000185986.11 SDHAP3 14.88 5.67e-39 9.83e-32 1.16 0.63 Breast cancer; chr5:242280 chr5:1572222~1594620:- LIHC trans rs116095464 0.85 rs10055295 ENSG00000185986.11 SDHAP3 14.88 5.67e-39 9.83e-32 1.16 0.63 Breast cancer; chr5:243634 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs60251075 ENSG00000185986.11 SDHAP3 14.88 5.67e-39 9.83e-32 1.16 0.63 Breast cancer; chr5:245177 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs62344300 ENSG00000185986.11 SDHAP3 14.88 5.67e-39 9.83e-32 1.16 0.63 Breast cancer; chr5:246221 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10462754 ENSG00000185986.11 SDHAP3 14.85 7.27e-39 1.25e-31 1.16 0.63 Breast cancer; chr5:246554 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10462755 ENSG00000185986.11 SDHAP3 14.85 7.27e-39 1.25e-31 1.16 0.63 Breast cancer; chr5:246633 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs13354585 ENSG00000185986.11 SDHAP3 14.85 7.5e-39 1.29e-31 1.17 0.63 Breast cancer; chr5:242148 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs2288458 ENSG00000185986.11 SDHAP3 14.85 7.54e-39 1.29e-31 1.16 0.63 Breast cancer; chr5:231145 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs2288457 ENSG00000185986.11 SDHAP3 14.85 7.54e-39 1.29e-31 1.16 0.63 Breast cancer; chr5:231155 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs7736600 ENSG00000185986.11 SDHAP3 14.85 7.54e-39 1.29e-31 1.16 0.63 Breast cancer; chr5:231222 chr5:1572222~1594620:- LIHC trans rs941207 0.526 rs2242497 ENSG00000121089.4 NACA3P -14.85 7.75e-39 1.33e-31 -0.76 -0.63 Platelet count; chr12:56598846 chr4:164943290~164943937:+ LIHC trans rs10037055 0.687 rs6556308 ENSG00000217325.2 PRELID1P1 -14.81 1.06e-38 1.8e-31 -0.77 -0.63 Migraine without aura; chr5:177219700 chr6:126643488~126644390:+ LIHC trans rs9467773 0.62 rs2504571 ENSG00000242375.1 RP11-498P14.3 14.8 1.21e-38 2.05e-31 0.73 0.62 Intelligence (multi-trait analysis); chr6:26643207 chr9:97195351~97197687:- LIHC trans rs9611565 0.694 rs5751107 ENSG00000268568.1 AC007228.9 14.78 1.42e-38 2.4e-31 1 0.62 Vitiligo; chr22:41461808 chr19:56672574~56673901:- LIHC trans rs9611565 0.649 rs5751108 ENSG00000268568.1 AC007228.9 14.78 1.42e-38 2.4e-31 1 0.62 Vitiligo; chr22:41462031 chr19:56672574~56673901:- LIHC trans rs8081395 0.805 rs1295927 ENSG00000187870.7 RNFT1P3 14.77 1.5e-38 2.54e-31 0.66 0.62 White blood cell count; chr17:59852174 chr17:20743333~20754501:- LIHC trans rs10037055 0.741 rs2336405 ENSG00000217325.2 PRELID1P1 -14.77 1.59e-38 2.69e-31 -0.77 -0.62 Migraine without aura; chr5:177230288 chr6:126643488~126644390:+ LIHC trans rs9611565 0.694 rs5758347 ENSG00000268568.1 AC007228.9 14.76 1.66e-38 2.79e-31 1.01 0.62 Vitiligo; chr22:41425015 chr19:56672574~56673901:- LIHC trans rs9611565 0.694 rs202613 ENSG00000268568.1 AC007228.9 14.76 1.66e-38 2.79e-31 1.01 0.62 Vitiligo; chr22:41425989 chr19:56672574~56673901:- LIHC trans rs9611565 0.649 rs202614 ENSG00000268568.1 AC007228.9 14.76 1.66e-38 2.79e-31 1.01 0.62 Vitiligo; chr22:41426146 chr19:56672574~56673901:- LIHC trans rs9611565 0.694 rs202616 ENSG00000268568.1 AC007228.9 14.76 1.66e-38 2.79e-31 1.01 0.62 Vitiligo; chr22:41426217 chr19:56672574~56673901:- LIHC trans rs9611565 0.569 rs188057 ENSG00000268568.1 AC007228.9 14.76 1.66e-38 2.79e-31 1.01 0.62 Vitiligo; chr22:41426301 chr19:56672574~56673901:- LIHC trans rs9611565 0.694 rs7285041 ENSG00000268568.1 AC007228.9 14.76 1.66e-38 2.79e-31 1.01 0.62 Vitiligo; chr22:41433145 chr19:56672574~56673901:- LIHC trans rs10037055 0.853 rs2336237 ENSG00000217325.2 PRELID1P1 14.76 1.74e-38 2.92e-31 0.77 0.62 Migraine without aura; chr5:177238878 chr6:126643488~126644390:+ LIHC trans rs9611565 0.649 rs202657 ENSG00000268568.1 AC007228.9 14.76 1.75e-38 2.94e-31 1 0.62 Vitiligo; chr22:41448782 chr19:56672574~56673901:- LIHC trans rs1045902 0.583 rs2303904 ENSG00000236165.1 PRADC1P1 -14.75 1.8e-38 3.02e-31 -0.76 -0.62 Intelligence (multi-trait analysis); chr2:73220647 chr3:36976316~36976840:+ LIHC trans rs9611565 0.694 rs202618 ENSG00000268568.1 AC007228.9 14.73 2.21e-38 3.7e-31 1.02 0.62 Vitiligo; chr22:41426852 chr19:56672574~56673901:- LIHC trans rs116095464 0.558 rs10075018 ENSG00000185986.11 SDHAP3 14.71 2.62e-38 4.35e-31 1.16 0.62 Breast cancer; chr5:239060 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs1541822 ENSG00000185986.11 SDHAP3 -14.71 2.68e-38 4.44e-31 -1.17 -0.62 Breast cancer; chr5:269119 chr5:1572222~1594620:- LIHC trans rs9611565 0.694 rs202622 ENSG00000268568.1 AC007228.9 14.71 2.79e-38 4.61e-31 1.01 0.62 Vitiligo; chr22:41429338 chr19:56672574~56673901:- LIHC trans rs9611565 0.649 rs202625 ENSG00000268568.1 AC007228.9 14.71 2.79e-38 4.61e-31 1.01 0.62 Vitiligo; chr22:41431078 chr19:56672574~56673901:- LIHC trans rs9611565 0.643 rs202634 ENSG00000268568.1 AC007228.9 14.69 3.24e-38 5.35e-31 0.98 0.62 Vitiligo; chr22:41413619 chr19:56672574~56673901:- LIHC trans rs916888 0.61 rs199529 ENSG00000264070.1 DND1P1 14.69 3.38e-38 5.57e-31 1.07 0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:45585871~45586929:+ LIHC trans rs10037055 0.853 rs1363405 ENSG00000217325.2 PRELID1P1 14.68 3.4e-38 5.6e-31 0.77 0.62 Migraine without aura; chr5:177209881 chr6:126643488~126644390:+ LIHC trans rs9611565 0.649 rs202645 ENSG00000268568.1 AC007228.9 14.63 5.49e-38 8.88e-31 0.99 0.62 Vitiligo; chr22:41402516 chr19:56672574~56673901:- LIHC trans rs116095464 0.558 rs12173244 ENSG00000185986.11 SDHAP3 14.62 5.85e-38 9.4e-31 1.17 0.62 Breast cancer; chr5:269409 chr5:1572222~1594620:- LIHC trans rs12709013 0.536 rs1646260 ENSG00000230849.2 GOT2P2 14.59 7.73e-38 1.22e-30 0.7 0.62 Blood metabolite ratios; chr16:58734951 chr1:173141100~173142350:- LIHC trans rs10037055 0.853 rs10035180 ENSG00000217325.2 PRELID1P1 -14.59 7.92e-38 1.25e-30 -0.77 -0.62 Migraine without aura; chr5:177171501 chr6:126643488~126644390:+ LIHC trans rs916888 0.773 rs199535 ENSG00000264070.1 DND1P1 14.59 8.08e-38 1.28e-30 1.1 0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45585871~45586929:+ LIHC trans rs116095464 0.558 rs10052012 ENSG00000185986.11 SDHAP3 14.59 8.1e-38 1.28e-30 1.16 0.62 Breast cancer; chr5:231793 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10077076 ENSG00000185986.11 SDHAP3 14.59 8.1e-38 1.28e-30 1.16 0.62 Breast cancer; chr5:231825 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10080225 ENSG00000185986.11 SDHAP3 14.59 8.1e-38 1.28e-30 1.16 0.62 Breast cancer; chr5:232060 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10475136 ENSG00000185986.11 SDHAP3 14.59 8.1e-38 1.28e-30 1.16 0.62 Breast cancer; chr5:232681 chr5:1572222~1594620:- LIHC trans rs12709013 0.613 rs4238801 ENSG00000230849.2 GOT2P2 14.58 8.61e-38 1.36e-30 0.69 0.62 Blood metabolite ratios; chr16:58738275 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs4575523 ENSG00000230849.2 GOT2P2 14.58 8.61e-38 1.36e-30 0.69 0.62 Blood metabolite ratios; chr16:58738559 chr1:173141100~173142350:- LIHC trans rs9467773 0.62 rs2504565 ENSG00000242375.1 RP11-498P14.3 14.57 9.46e-38 1.49e-30 0.73 0.62 Intelligence (multi-trait analysis); chr6:26656662 chr9:97195351~97197687:- LIHC trans rs1816752 0.875 rs3783076 ENSG00000237917.1 PARP4P1 14.56 1.02e-37 1.59e-30 0.7 0.62 Obesity-related traits; chr13:24490319 chrY:26594851~26634652:- LIHC trans rs9467773 0.62 rs2504567 ENSG00000242375.1 RP11-498P14.3 14.56 1.03e-37 1.61e-30 0.73 0.62 Intelligence (multi-trait analysis); chr6:26662692 chr9:97195351~97197687:- LIHC trans rs928391 0.948 rs2735657 ENSG00000227183.3 HDGFP1 14.54 1.29e-37 1.99e-30 0.87 0.62 Platelet count; chr1:156810514 chrX:131646639~131646890:+ LIHC trans rs9611565 0.765 rs132907 ENSG00000268568.1 AC007228.9 14.5 1.76e-37 2.71e-30 0.97 0.62 Vitiligo; chr22:41405264 chr19:56672574~56673901:- LIHC trans rs9611565 0.681 rs6002372 ENSG00000268568.1 AC007228.9 14.5 1.76e-37 2.71e-30 0.97 0.62 Vitiligo; chr22:41405295 chr19:56672574~56673901:- LIHC trans rs9611565 0.765 rs132908 ENSG00000268568.1 AC007228.9 14.5 1.76e-37 2.71e-30 0.97 0.62 Vitiligo; chr22:41405791 chr19:56672574~56673901:- LIHC trans rs116095464 0.51 rs7714944 ENSG00000185986.11 SDHAP3 14.5 1.82e-37 2.81e-30 1.16 0.62 Breast cancer; chr5:231650 chr5:1572222~1594620:- LIHC trans rs9611565 0.694 rs202656 ENSG00000268568.1 AC007228.9 14.49 1.98e-37 3.05e-30 1.01 0.62 Vitiligo; chr22:41446199 chr19:56672574~56673901:- LIHC trans rs116095464 0.614 rs78905930 ENSG00000185986.11 SDHAP3 14.48 2.25e-37 3.45e-30 1.16 0.62 Breast cancer; chr5:246445 chr5:1572222~1594620:- LIHC trans rs5758343 1 rs5758343 ENSG00000268568.1 AC007228.9 14.46 2.49e-37 3.78e-30 1.01 0.62 Allergic disease (asthma, hay fever or eczema); chr22:41420648 chr19:56672574~56673901:- LIHC trans rs9611565 0.649 rs5758344 ENSG00000268568.1 AC007228.9 14.46 2.49e-37 3.78e-30 1.01 0.62 Vitiligo; chr22:41421681 chr19:56672574~56673901:- LIHC trans rs9611565 0.694 rs2142505 ENSG00000268568.1 AC007228.9 14.46 2.49e-37 3.78e-30 1.01 0.62 Vitiligo; chr22:41424537 chr19:56672574~56673901:- LIHC trans rs116095464 0.51 rs60844864 ENSG00000185986.11 SDHAP3 14.46 2.51e-37 3.81e-30 1.16 0.62 Breast cancer; chr5:266885 chr5:1572222~1594620:- LIHC trans rs1816752 0.679 rs8181826 ENSG00000237917.1 PARP4P1 -14.46 2.63e-37 4e-30 -0.7 -0.62 Obesity-related traits; chr13:24396570 chrY:26594851~26634652:- LIHC trans rs9467773 0.62 rs2504540 ENSG00000242375.1 RP11-498P14.3 14.45 2.72e-37 4.11e-30 0.72 0.62 Intelligence (multi-trait analysis); chr6:26641398 chr9:97195351~97197687:- LIHC trans rs116095464 0.614 rs62344292 ENSG00000185986.11 SDHAP3 14.44 3.05e-37 4.61e-30 1.15 0.62 Breast cancer; chr5:244515 chr5:1572222~1594620:- LIHC trans rs9611565 0.694 rs202639 ENSG00000268568.1 AC007228.9 14.44 3.09e-37 4.66e-30 0.98 0.62 Vitiligo; chr22:41460133 chr19:56672574~56673901:- LIHC trans rs9611565 0.694 rs5758365 ENSG00000268568.1 AC007228.9 14.44 3.09e-37 4.66e-30 0.98 0.62 Vitiligo; chr22:41462653 chr19:56672574~56673901:- LIHC trans rs9611565 0.649 rs79009 ENSG00000268568.1 AC007228.9 14.44 3.09e-37 4.66e-30 0.98 0.62 Vitiligo; chr22:41464860 chr19:56672574~56673901:- LIHC trans rs61990749 0.544 rs7151211 ENSG00000235400.1 RP4-641G12.4 -14.43 3.44e-37 5.15e-30 -0.87 -0.62 Fibroblast growth factor basic levels; chr14:77685558 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs72685264 ENSG00000235400.1 RP4-641G12.4 -14.43 3.44e-37 5.15e-30 -0.87 -0.62 Fibroblast growth factor basic levels; chr14:77686655 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs7147516 ENSG00000235400.1 RP4-641G12.4 -14.43 3.44e-37 5.15e-30 -0.87 -0.62 Fibroblast growth factor basic levels; chr14:77687637 chr1:78749073~78750659:+ LIHC trans rs9467773 0.596 rs2451750 ENSG00000242375.1 RP11-498P14.3 14.43 3.48e-37 5.2e-30 0.72 0.62 Intelligence (multi-trait analysis); chr6:26646351 chr9:97195351~97197687:- LIHC trans rs9467773 0.596 rs2451751 ENSG00000242375.1 RP11-498P14.3 14.43 3.48e-37 5.2e-30 0.72 0.62 Intelligence (multi-trait analysis); chr6:26646486 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2504600 ENSG00000242375.1 RP11-498P14.3 14.43 3.48e-37 5.2e-30 0.72 0.62 Intelligence (multi-trait analysis); chr6:26648106 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2130657 ENSG00000242375.1 RP11-498P14.3 14.43 3.48e-37 5.2e-30 0.72 0.62 Intelligence (multi-trait analysis); chr6:26650598 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2498351 ENSG00000242375.1 RP11-498P14.3 14.43 3.48e-37 5.2e-30 0.72 0.62 Intelligence (multi-trait analysis); chr6:26659414 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2504566 ENSG00000242375.1 RP11-498P14.3 14.43 3.48e-37 5.2e-30 0.72 0.62 Intelligence (multi-trait analysis); chr6:26660260 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2494716 ENSG00000242375.1 RP11-498P14.3 14.43 3.48e-37 5.2e-30 0.72 0.62 Intelligence (multi-trait analysis); chr6:26662508 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2451711 ENSG00000242375.1 RP11-498P14.3 14.43 3.48e-37 5.2e-30 0.72 0.62 Intelligence (multi-trait analysis); chr6:26662882 chr9:97195351~97197687:- LIHC trans rs61990749 0.544 rs11628888 ENSG00000235400.1 RP4-641G12.4 -14.43 3.52e-37 5.25e-30 -0.87 -0.62 Fibroblast growth factor basic levels; chr14:77695163 chr1:78749073~78750659:+ LIHC trans rs9467773 0.62 rs2101581 ENSG00000242375.1 RP11-498P14.3 14.4 4.28e-37 6.36e-30 0.72 0.61 Intelligence (multi-trait analysis); chr6:26622541 chr9:97195351~97197687:- LIHC trans rs12709013 0.576 rs2432622 ENSG00000230849.2 GOT2P2 14.38 5.21e-37 7.73e-30 0.69 0.61 Blood metabolite ratios; chr16:58749681 chr1:173141100~173142350:- LIHC trans rs9467773 0.62 rs2504599 ENSG00000242375.1 RP11-498P14.3 14.38 5.45e-37 8.07e-30 0.72 0.61 Intelligence (multi-trait analysis); chr6:26640832 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2504592 ENSG00000242375.1 RP11-498P14.3 14.37 5.67e-37 8.36e-30 0.72 0.61 Intelligence (multi-trait analysis); chr6:26640723 chr9:97195351~97197687:- LIHC trans rs116095464 0.558 rs10043002 ENSG00000185986.11 SDHAP3 14.37 5.71e-37 8.36e-30 1.13 0.61 Breast cancer; chr5:226638 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs62347677 ENSG00000185986.11 SDHAP3 14.37 5.71e-37 8.36e-30 1.13 0.61 Breast cancer; chr5:227338 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs62347678 ENSG00000185986.11 SDHAP3 14.37 5.71e-37 8.36e-30 1.13 0.61 Breast cancer; chr5:227381 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs73031482 ENSG00000185986.11 SDHAP3 14.37 5.71e-37 8.36e-30 1.13 0.61 Breast cancer; chr5:227479 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs2162870 ENSG00000185986.11 SDHAP3 14.37 5.71e-37 8.36e-30 1.13 0.61 Breast cancer; chr5:228014 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs28729548 ENSG00000185986.11 SDHAP3 14.37 5.71e-37 8.36e-30 1.13 0.61 Breast cancer; chr5:228910 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs9688136 ENSG00000185986.11 SDHAP3 14.37 5.71e-37 8.36e-30 1.13 0.61 Breast cancer; chr5:229233 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs62347683 ENSG00000185986.11 SDHAP3 14.37 5.71e-37 8.36e-30 1.13 0.61 Breast cancer; chr5:230216 chr5:1572222~1594620:- LIHC trans rs116095464 0.51 rs55750776 ENSG00000185986.11 SDHAP3 14.37 5.71e-37 8.36e-30 1.13 0.61 Breast cancer; chr5:230352 chr5:1572222~1594620:- LIHC trans rs116095464 0.764 rs10069197 ENSG00000185986.11 SDHAP3 14.37 5.71e-37 8.36e-30 1.13 0.61 Breast cancer; chr5:230707 chr5:1572222~1594620:- LIHC trans rs116095464 0.867 rs10074958 ENSG00000185986.11 SDHAP3 14.37 5.71e-37 8.36e-30 1.13 0.61 Breast cancer; chr5:230713 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs2288459 ENSG00000185986.11 SDHAP3 14.37 5.71e-37 8.36e-30 1.13 0.61 Breast cancer; chr5:231028 chr5:1572222~1594620:- LIHC trans rs1045902 0.537 rs1018342 ENSG00000236165.1 PRADC1P1 14.37 5.8e-37 8.48e-30 0.8 0.61 Intelligence (multi-trait analysis); chr2:73244525 chr3:36976316~36976840:+ LIHC trans rs9467773 0.62 rs2494700 ENSG00000242375.1 RP11-498P14.3 14.37 5.81e-37 8.48e-30 0.72 0.61 Intelligence (multi-trait analysis); chr6:26631078 chr9:97195351~97197687:- LIHC trans rs9467773 0.584 rs1021372 ENSG00000242375.1 RP11-498P14.3 14.37 5.81e-37 8.48e-30 0.72 0.61 Intelligence (multi-trait analysis); chr6:26632216 chr9:97195351~97197687:- LIHC trans rs9467773 0.583 rs1021373 ENSG00000242375.1 RP11-498P14.3 14.37 5.81e-37 8.48e-30 0.72 0.61 Intelligence (multi-trait analysis); chr6:26632229 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2451744 ENSG00000242375.1 RP11-498P14.3 14.37 5.81e-37 8.48e-30 0.72 0.61 Intelligence (multi-trait analysis); chr6:26633235 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2494701 ENSG00000242375.1 RP11-498P14.3 14.37 5.81e-37 8.48e-30 0.72 0.61 Intelligence (multi-trait analysis); chr6:26634204 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs1027204 ENSG00000242375.1 RP11-498P14.3 14.37 5.81e-37 8.48e-30 0.72 0.61 Intelligence (multi-trait analysis); chr6:26639385 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2451731 ENSG00000242375.1 RP11-498P14.3 14.37 5.91e-37 8.61e-30 0.72 0.61 Intelligence (multi-trait analysis); chr6:26624594 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs9295701 ENSG00000242375.1 RP11-498P14.3 14.37 5.91e-37 8.61e-30 0.72 0.61 Intelligence (multi-trait analysis); chr6:26627280 chr9:97195351~97197687:- LIHC trans rs116095464 0.681 rs9687745 ENSG00000185986.11 SDHAP3 14.37 6e-37 8.73e-30 1.13 0.61 Breast cancer; chr5:229194 chr5:1572222~1594620:- LIHC trans rs9611565 0.694 rs202617 ENSG00000268568.1 AC007228.9 14.36 6.12e-37 8.9e-30 0.98 0.61 Vitiligo; chr22:41426789 chr19:56672574~56673901:- LIHC trans rs116095464 0.558 rs7708515 ENSG00000185986.11 SDHAP3 14.36 6.18e-37 8.99e-30 1.11 0.61 Breast cancer; chr5:234874 chr5:1572222~1594620:- LIHC trans rs7121616 0.531 rs10892958 ENSG00000234176.1 HSPA8P1 14.36 6.22e-37 9.04e-30 0.8 0.61 Breast cancer; chr11:123061415 chrX:121203182~121205014:- LIHC trans rs9467773 0.62 rs1490488 ENSG00000242375.1 RP11-498P14.3 14.34 7.3e-37 1.06e-29 0.72 0.61 Intelligence (multi-trait analysis); chr6:26614580 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2494692 ENSG00000242375.1 RP11-498P14.3 14.34 7.3e-37 1.06e-29 0.72 0.61 Intelligence (multi-trait analysis); chr6:26614995 chr9:97195351~97197687:- LIHC trans rs9611565 0.659 rs169361 ENSG00000268568.1 AC007228.9 14.34 7.37e-37 1.07e-29 0.99 0.61 Vitiligo; chr22:41481985 chr19:56672574~56673901:- LIHC trans rs116095464 0.558 rs55838121 ENSG00000185986.11 SDHAP3 14.34 7.41e-37 1.07e-29 1.16 0.61 Breast cancer; chr5:266775 chr5:1572222~1594620:- LIHC trans rs61990749 0.597 rs176946 ENSG00000235400.1 RP4-641G12.4 14.33 8.52e-37 1.22e-29 0.87 0.61 Fibroblast growth factor basic levels; chr14:77712096 chr1:78749073~78750659:+ LIHC trans rs116095464 0.51 rs73016876 ENSG00000185986.11 SDHAP3 14.33 8.61e-37 1.24e-29 1.15 0.61 Breast cancer; chr5:244360 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs6866632 ENSG00000185986.11 SDHAP3 14.31 9.68e-37 1.38e-29 1.17 0.61 Breast cancer; chr5:264314 chr5:1572222~1594620:- LIHC trans rs12709013 0.636 rs1646281 ENSG00000230849.2 GOT2P2 14.31 9.89e-37 1.41e-29 0.68 0.61 Blood metabolite ratios; chr16:58750512 chr1:173141100~173142350:- LIHC trans rs12709013 0.613 rs1618602 ENSG00000230849.2 GOT2P2 14.31 9.89e-37 1.41e-29 0.68 0.61 Blood metabolite ratios; chr16:58756080 chr1:173141100~173142350:- LIHC trans rs12709013 0.613 rs8049462 ENSG00000230849.2 GOT2P2 14.31 9.89e-37 1.41e-29 0.68 0.61 Blood metabolite ratios; chr16:58757654 chr1:173141100~173142350:- LIHC trans rs12709013 0.66 rs257629 ENSG00000230849.2 GOT2P2 14.31 9.89e-37 1.41e-29 0.68 0.61 Blood metabolite ratios; chr16:58758044 chr1:173141100~173142350:- LIHC trans rs9611565 0.527 rs73178638 ENSG00000268568.1 AC007228.9 -14.3 1.12e-36 1.6e-29 -0.99 -0.61 Vitiligo; chr22:41546900 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs4822037 ENSG00000268568.1 AC007228.9 -14.3 1.12e-36 1.6e-29 -0.99 -0.61 Vitiligo; chr22:41549109 chr19:56672574~56673901:- LIHC trans rs116095464 0.867 rs7726582 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:215234 chr5:1572222~1594620:- LIHC trans rs116095464 0.619 rs2303741 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:218241 chr5:1572222~1594620:- LIHC trans rs116095464 0.614 rs10067482 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:219213 chr5:1572222~1594620:- LIHC trans rs116095464 0.614 rs56299325 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:220479 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs62346526 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:220499 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs56043030 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:220802 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10067021 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:221375 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs9312977 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:221801 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs6881920 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:222296 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs6878061 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:222957 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs6882584 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:223296 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs3213838 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:223775 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs6555052 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:224153 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs61689490 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:224789 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs61492827 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:225659 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs56342538 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:225681 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs6555055 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:226045 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs6555056 ENSG00000185986.11 SDHAP3 14.29 1.15e-36 1.61e-29 1.16 0.61 Breast cancer; chr5:226107 chr5:1572222~1594620:- LIHC trans rs9467773 0.62 rs2451737 ENSG00000242375.1 RP11-498P14.3 14.29 1.22e-36 1.71e-29 0.71 0.61 Intelligence (multi-trait analysis); chr6:26618813 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2494694 ENSG00000242375.1 RP11-498P14.3 14.29 1.22e-36 1.71e-29 0.71 0.61 Intelligence (multi-trait analysis); chr6:26619100 chr9:97195351~97197687:- LIHC trans rs9467773 0.595 rs2451736 ENSG00000242375.1 RP11-498P14.3 14.29 1.22e-36 1.71e-29 0.71 0.61 Intelligence (multi-trait analysis); chr6:26620316 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2494696 ENSG00000242375.1 RP11-498P14.3 14.29 1.22e-36 1.71e-29 0.71 0.61 Intelligence (multi-trait analysis); chr6:26620666 chr9:97195351~97197687:- LIHC trans rs61990749 0.597 rs2364584 ENSG00000235400.1 RP4-641G12.4 -14.29 1.24e-36 1.73e-29 -0.86 -0.61 Fibroblast growth factor basic levels; chr14:77685943 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs10136053 ENSG00000235400.1 RP4-641G12.4 -14.29 1.24e-36 1.73e-29 -0.86 -0.61 Fibroblast growth factor basic levels; chr14:77688862 chr1:78749073~78750659:+ LIHC trans rs12709013 0.636 rs8045466 ENSG00000230849.2 GOT2P2 14.28 1.29e-36 1.81e-29 0.68 0.61 Blood metabolite ratios; chr16:58765113 chr1:173141100~173142350:- LIHC trans rs12709013 0.591 rs4784986 ENSG00000230849.2 GOT2P2 14.27 1.39e-36 1.94e-29 0.7 0.61 Blood metabolite ratios; chr16:58803007 chr1:173141100~173142350:- LIHC trans rs916888 0.821 rs199513 ENSG00000264070.1 DND1P1 -14.27 1.4e-36 1.94e-29 -1.03 -0.61 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:45585871~45586929:+ LIHC trans rs9611565 0.659 rs73178641 ENSG00000268568.1 AC007228.9 -14.27 1.4e-36 1.95e-29 -0.97 -0.61 Vitiligo; chr22:41556071 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs12483786 ENSG00000268568.1 AC007228.9 -14.27 1.41e-36 1.97e-29 -0.98 -0.61 Vitiligo; chr22:41542532 chr19:56672574~56673901:- LIHC trans rs7121616 0.531 rs11218941 ENSG00000234176.1 HSPA8P1 14.26 1.51e-36 2.1e-29 0.79 0.61 Breast cancer; chr11:123061701 chrX:121203182~121205014:- LIHC trans rs9467773 0.596 rs2494693 ENSG00000242375.1 RP11-498P14.3 14.26 1.56e-36 2.16e-29 0.71 0.61 Intelligence (multi-trait analysis); chr6:26618998 chr9:97195351~97197687:- LIHC trans rs7554547 0.667 rs2336377 ENSG00000261819.1 RP11-680G24.4 -14.26 1.6e-36 2.21e-29 -0.79 -0.61 Nonsyndromic cleft lip with cleft palate; chr1:11889913 chr16:14988259~14990160:- LIHC trans rs116095464 0.558 rs113796397 ENSG00000185986.11 SDHAP3 14.25 1.66e-36 2.3e-29 1.13 0.61 Breast cancer; chr5:246388 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs7714335 ENSG00000185986.11 SDHAP3 14.25 1.7e-36 2.35e-29 1.18 0.61 Breast cancer; chr5:263398 chr5:1572222~1594620:- LIHC trans rs11332131 1 rs11332131 ENSG00000187870.7 RNFT1P3 14.25 1.77e-36 2.44e-29 0.66 0.61 Platelet distribution width; chr17:59849031 chr17:20743333~20754501:- LIHC trans rs116095464 0.542 rs28650039 ENSG00000185986.11 SDHAP3 14.24 1.89e-36 2.6e-29 1.13 0.61 Breast cancer; chr5:273839 chr5:1572222~1594620:- LIHC trans rs9467773 0.62 rs2451741 ENSG00000242375.1 RP11-498P14.3 14.23 2.02e-36 2.78e-29 0.72 0.61 Intelligence (multi-trait analysis); chr6:26629176 chr9:97195351~97197687:- LIHC trans rs9611565 0.729 rs2413646 ENSG00000268568.1 AC007228.9 -14.22 2.28e-36 3.11e-29 -0.99 -0.61 Vitiligo; chr22:41510321 chr19:56672574~56673901:- LIHC trans rs12709013 0.591 rs30842 ENSG00000230849.2 GOT2P2 -14.22 2.3e-36 3.14e-29 -0.74 -0.61 Blood metabolite ratios; chr16:58709550 chr1:173141100~173142350:- LIHC trans rs116095464 0.558 rs56127718 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:270158 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs55664502 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:270370 chr5:1572222~1594620:- LIHC trans rs116095464 0.51 rs7723883 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:270683 chr5:1572222~1594620:- LIHC trans rs116095464 0.614 rs10061564 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:271214 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs55776650 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:273711 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs28635197 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:278956 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs59113266 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:279850 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs11959126 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:283765 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs7356696 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:284136 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs7356561 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:284266 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs59284383 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:284410 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs28558836 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:285633 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs7731089 ENSG00000185986.11 SDHAP3 14.21 2.45e-36 3.3e-29 1.12 0.61 Breast cancer; chr5:290307 chr5:1572222~1594620:- LIHC trans rs12709013 0.636 rs1646284 ENSG00000230849.2 GOT2P2 14.21 2.53e-36 3.39e-29 0.68 0.61 Blood metabolite ratios; chr16:58752093 chr1:173141100~173142350:- LIHC trans rs12709013 0.646 rs8046154 ENSG00000230849.2 GOT2P2 -14.21 2.55e-36 3.42e-29 -0.68 -0.61 Blood metabolite ratios; chr16:58773978 chr1:173141100~173142350:- LIHC trans rs61990749 0.597 rs176955 ENSG00000235400.1 RP4-641G12.4 14.2 2.8e-36 3.73e-29 0.87 0.61 Fibroblast growth factor basic levels; chr14:77714877 chr1:78749073~78750659:+ LIHC trans rs61990749 0.544 rs176962 ENSG00000235400.1 RP4-641G12.4 14.2 2.8e-36 3.73e-29 0.87 0.61 Fibroblast growth factor basic levels; chr14:77719167 chr1:78749073~78750659:+ LIHC trans rs616147 0.627 rs9871799 ENSG00000183298.5 RP11-556K13.1 14.16 3.72e-36 4.94e-29 0.82 0.61 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39442829 chr1:101786340~101787219:- LIHC trans rs12291225 0.877 rs11023160 ENSG00000236360.2 RP11-334A14.2 14.16 3.89e-36 5.17e-29 0.77 0.61 Sense of smell; chr11:14242679 chr1:52993201~52993702:- LIHC trans rs9611565 0.659 rs17367849 ENSG00000268568.1 AC007228.9 -14.09 6.88e-36 9.05e-29 -0.96 -0.61 Vitiligo; chr22:41527640 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs9607812 ENSG00000268568.1 AC007228.9 -14.09 7.03e-36 9.24e-29 -0.96 -0.61 Vitiligo; chr22:41545239 chr19:56672574~56673901:- LIHC trans rs9611565 0.694 rs106860 ENSG00000268568.1 AC007228.9 -14.08 7.77e-36 1.02e-28 -0.99 -0.61 Vitiligo; chr22:41444403 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs12484694 ENSG00000268568.1 AC007228.9 -14.07 8.47e-36 1.1e-28 -0.96 -0.61 Vitiligo; chr22:41523326 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs4822036 ENSG00000268568.1 AC007228.9 -14.07 8.76e-36 1.14e-28 -0.96 -0.61 Vitiligo; chr22:41540015 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs12484228 ENSG00000268568.1 AC007228.9 -14.07 8.76e-36 1.14e-28 -0.96 -0.61 Vitiligo; chr22:41543735 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs28623192 ENSG00000268568.1 AC007228.9 -14.07 8.76e-36 1.14e-28 -0.96 -0.61 Vitiligo; chr22:41544520 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs9607813 ENSG00000268568.1 AC007228.9 -14.07 8.79e-36 1.14e-28 -0.96 -0.61 Vitiligo; chr22:41545475 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs9611609 ENSG00000268568.1 AC007228.9 -14.07 8.79e-36 1.14e-28 -0.96 -0.61 Vitiligo; chr22:41549353 chr19:56672574~56673901:- LIHC trans rs61990749 0.544 rs8003979 ENSG00000235400.1 RP4-641G12.4 14.07 8.8e-36 1.14e-28 0.87 0.61 Fibroblast growth factor basic levels; chr14:77744947 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs8016416 ENSG00000235400.1 RP4-641G12.4 14.07 8.8e-36 1.14e-28 0.87 0.61 Fibroblast growth factor basic levels; chr14:77746757 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs2032781 ENSG00000235400.1 RP4-641G12.4 14.07 8.8e-36 1.14e-28 0.87 0.61 Fibroblast growth factor basic levels; chr14:77748532 chr1:78749073~78750659:+ LIHC trans rs61990749 0.686 rs11159288 ENSG00000235400.1 RP4-641G12.4 14.07 8.8e-36 1.14e-28 0.87 0.61 Fibroblast growth factor basic levels; chr14:77750629 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs3783980 ENSG00000235400.1 RP4-641G12.4 14.07 8.8e-36 1.14e-28 0.87 0.61 Fibroblast growth factor basic levels; chr14:77753464 chr1:78749073~78750659:+ LIHC trans rs8081395 0.801 rs2645479 ENSG00000187870.7 RNFT1P3 14.06 9.01e-36 1.17e-28 0.66 0.61 White blood cell count; chr17:59843171 chr17:20743333~20754501:- LIHC trans rs9611565 0.694 rs79011 ENSG00000268568.1 AC007228.9 14.06 9.13e-36 1.18e-28 0.95 0.61 Vitiligo; chr22:41470934 chr19:56672574~56673901:- LIHC trans rs61990749 0.597 rs176952 ENSG00000235400.1 RP4-641G12.4 14.06 9.64e-36 1.24e-28 0.86 0.61 Fibroblast growth factor basic levels; chr14:77714393 chr1:78749073~78750659:+ LIHC trans rs61990749 0.544 rs2544566 ENSG00000235400.1 RP4-641G12.4 14.06 9.64e-36 1.24e-28 0.86 0.61 Fibroblast growth factor basic levels; chr14:77715395 chr1:78749073~78750659:+ LIHC trans rs61990749 0.544 rs2544567 ENSG00000235400.1 RP4-641G12.4 14.06 9.64e-36 1.24e-28 0.86 0.61 Fibroblast growth factor basic levels; chr14:77715396 chr1:78749073~78750659:+ LIHC trans rs9611565 0.659 rs11090049 ENSG00000268568.1 AC007228.9 -14.05 9.93e-36 1.28e-28 -0.97 -0.61 Vitiligo; chr22:41519325 chr19:56672574~56673901:- LIHC trans rs61990749 0.597 rs6574391 ENSG00000235400.1 RP4-641G12.4 14.05 9.98e-36 1.28e-28 0.87 0.61 Fibroblast growth factor basic levels; chr14:77741778 chr1:78749073~78750659:+ LIHC trans rs116095464 0.558 rs7713524 ENSG00000185986.11 SDHAP3 -14.05 1.01e-35 1.3e-28 -1.04 -0.61 Breast cancer; chr5:276085 chr5:1572222~1594620:- LIHC trans rs9611565 0.659 rs9607815 ENSG00000268568.1 AC007228.9 -14.05 1.02e-35 1.31e-28 -0.95 -0.6 Vitiligo; chr22:41554667 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs12484175 ENSG00000268568.1 AC007228.9 -14.05 1.02e-35 1.31e-28 -0.95 -0.6 Vitiligo; chr22:41557735 chr19:56672574~56673901:- LIHC trans rs116095464 0.614 rs28736753 ENSG00000185986.11 SDHAP3 14.05 1.05e-35 1.34e-28 1.12 0.6 Breast cancer; chr5:273966 chr5:1572222~1594620:- LIHC trans rs10037055 0.853 rs6890580 ENSG00000217325.2 PRELID1P1 -14.03 1.19e-35 1.52e-28 -0.75 -0.6 Migraine without aura; chr5:177226519 chr6:126643488~126644390:+ LIHC trans rs116095464 0.558 rs7703803 ENSG00000185986.11 SDHAP3 14.03 1.22e-35 1.56e-28 1.12 0.6 Breast cancer; chr5:292196 chr5:1572222~1594620:- LIHC trans rs9611565 0.659 rs9611604 ENSG00000268568.1 AC007228.9 -14.03 1.23e-35 1.57e-28 -0.97 -0.6 Vitiligo; chr22:41519997 chr19:56672574~56673901:- LIHC trans rs9611565 0.579 rs73178621 ENSG00000268568.1 AC007228.9 -14.03 1.23e-35 1.57e-28 -0.97 -0.6 Vitiligo; chr22:41525661 chr19:56672574~56673901:- LIHC trans rs9611565 0.694 rs202637 ENSG00000268568.1 AC007228.9 14.02 1.32e-35 1.68e-28 0.98 0.6 Vitiligo; chr22:41457924 chr19:56672574~56673901:- LIHC trans rs61990749 0.597 rs176943 ENSG00000235400.1 RP4-641G12.4 -14.01 1.42e-35 1.81e-28 -0.87 -0.6 Fibroblast growth factor basic levels; chr14:77709454 chr1:78749073~78750659:+ LIHC trans rs116095464 0.558 rs9654452 ENSG00000185986.11 SDHAP3 14.01 1.46e-35 1.86e-28 1.12 0.6 Breast cancer; chr5:299446 chr5:1572222~1594620:- LIHC trans rs1045902 0.532 rs2288631 ENSG00000236165.1 PRADC1P1 14.01 1.51e-35 1.91e-28 0.79 0.6 Intelligence (multi-trait analysis); chr2:73228619 chr3:36976316~36976840:+ LIHC trans rs1045902 0.532 rs10185579 ENSG00000236165.1 PRADC1P1 14.01 1.51e-35 1.91e-28 0.79 0.6 Intelligence (multi-trait analysis); chr2:73229214 chr3:36976316~36976840:+ LIHC trans rs61990749 0.597 rs1477262 ENSG00000235400.1 RP4-641G12.4 14 1.59e-35 2.01e-28 0.87 0.6 Fibroblast growth factor basic levels; chr14:77760310 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs8016447 ENSG00000235400.1 RP4-641G12.4 14 1.61e-35 2.04e-28 0.87 0.6 Fibroblast growth factor basic levels; chr14:77755725 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs1008988 ENSG00000235400.1 RP4-641G12.4 13.99 1.83e-35 2.31e-28 0.87 0.6 Fibroblast growth factor basic levels; chr14:77794452 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs4903643 ENSG00000235400.1 RP4-641G12.4 13.98 1.87e-35 2.36e-28 0.87 0.6 Fibroblast growth factor basic levels; chr14:77788448 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs1477260 ENSG00000235400.1 RP4-641G12.4 13.98 1.87e-35 2.36e-28 0.87 0.6 Fibroblast growth factor basic levels; chr14:77790475 chr1:78749073~78750659:+ LIHC trans rs116095464 0.558 rs6872854 ENSG00000185986.11 SDHAP3 13.98 1.97e-35 2.48e-28 1.15 0.6 Breast cancer; chr5:208923 chr5:1572222~1594620:- LIHC trans rs9467773 0.595 rs7767847 ENSG00000242375.1 RP11-498P14.3 13.97 2.07e-35 2.6e-28 0.69 0.6 Intelligence (multi-trait analysis); chr6:26597665 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs3800303 ENSG00000242375.1 RP11-498P14.3 13.97 2.07e-35 2.6e-28 0.69 0.6 Intelligence (multi-trait analysis); chr6:26597960 chr9:97195351~97197687:- LIHC trans rs9611565 0.625 rs73178625 ENSG00000268568.1 AC007228.9 -13.96 2.3e-35 2.88e-28 -0.94 -0.6 Vitiligo; chr22:41532316 chr19:56672574~56673901:- LIHC trans rs61990749 0.597 rs2112136 ENSG00000235400.1 RP4-641G12.4 13.96 2.36e-35 2.95e-28 0.87 0.6 Fibroblast growth factor basic levels; chr14:77782609 chr1:78749073~78750659:+ LIHC trans rs13177918 0.798 rs12514700 ENSG00000239528.1 RPS14P8 13.94 2.86e-35 3.55e-28 0.88 0.6 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150466096 chr5:116562562~116562930:+ LIHC trans rs9611565 0.685 rs169363 ENSG00000268568.1 AC007228.9 13.93 2.92e-35 3.63e-28 0.96 0.6 Vitiligo; chr22:41457113 chr19:56672574~56673901:- LIHC trans rs9467773 0.549 rs9467805 ENSG00000242375.1 RP11-498P14.3 13.93 2.94e-35 3.65e-28 0.69 0.6 Intelligence (multi-trait analysis); chr6:26583138 chr9:97195351~97197687:- LIHC trans rs12709013 0.597 rs8051078 ENSG00000230849.2 GOT2P2 13.93 3.06e-35 3.79e-28 0.67 0.6 Blood metabolite ratios; chr16:58774200 chr1:173141100~173142350:- LIHC trans rs9611565 0.659 rs9611603 ENSG00000268568.1 AC007228.9 -13.93 3.08e-35 3.81e-28 -0.95 -0.6 Vitiligo; chr22:41516746 chr19:56672574~56673901:- LIHC trans rs9611565 0.729 rs2413647 ENSG00000268568.1 AC007228.9 -13.92 3.27e-35 4.04e-28 -0.97 -0.6 Vitiligo; chr22:41511144 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs1569516 ENSG00000268568.1 AC007228.9 -13.92 3.27e-35 4.04e-28 -0.97 -0.6 Vitiligo; chr22:41514240 chr19:56672574~56673901:- LIHC trans rs61990749 0.597 rs28534379 ENSG00000235400.1 RP4-641G12.4 -13.92 3.29e-35 4.06e-28 -0.86 -0.6 Fibroblast growth factor basic levels; chr14:77705797 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs176944 ENSG00000235400.1 RP4-641G12.4 -13.92 3.29e-35 4.06e-28 -0.86 -0.6 Fibroblast growth factor basic levels; chr14:77709868 chr1:78749073~78750659:+ LIHC trans rs7554547 0.667 rs4846072 ENSG00000261819.1 RP11-680G24.4 13.91 3.56e-35 4.38e-28 0.79 0.6 Nonsyndromic cleft lip with cleft palate; chr1:11890334 chr16:14988259~14990160:- LIHC trans rs12291225 0.877 rs2303974 ENSG00000236360.2 RP11-334A14.2 13.91 3.57e-35 4.39e-28 0.76 0.6 Sense of smell; chr11:14243433 chr1:52993201~52993702:- LIHC trans rs9611565 0.659 rs17367716 ENSG00000268568.1 AC007228.9 -13.91 3.76e-35 4.62e-28 -0.96 -0.6 Vitiligo; chr22:41517840 chr19:56672574~56673901:- LIHC trans rs61990749 0.597 rs6574402 ENSG00000235400.1 RP4-641G12.4 13.9 3.79e-35 4.66e-28 0.86 0.6 Fibroblast growth factor basic levels; chr14:77801607 chr1:78749073~78750659:+ LIHC trans rs61990749 0.5 rs8011337 ENSG00000235400.1 RP4-641G12.4 13.9 3.79e-35 4.66e-28 0.86 0.6 Fibroblast growth factor basic levels; chr14:77806283 chr1:78749073~78750659:+ LIHC trans rs1816752 0.669 rs9553309 ENSG00000237917.1 PARP4P1 -13.9 3.83e-35 4.7e-28 -0.66 -0.6 Obesity-related traits; chr13:24471476 chrY:26594851~26634652:- LIHC trans rs116095464 0.51 rs10057501 ENSG00000185986.11 SDHAP3 13.9 3.86e-35 4.74e-28 1.12 0.6 Breast cancer; chr5:239430 chr5:1572222~1594620:- LIHC trans rs9467773 0.549 rs9461273 ENSG00000242375.1 RP11-498P14.3 -13.9 3.89e-35 4.77e-28 -0.69 -0.6 Intelligence (multi-trait analysis); chr6:26584298 chr9:97195351~97197687:- LIHC trans rs61990749 0.597 rs8003691 ENSG00000235400.1 RP4-641G12.4 13.88 4.83e-35 5.88e-28 0.85 0.6 Fibroblast growth factor basic levels; chr14:77744882 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs2267768 ENSG00000235400.1 RP4-641G12.4 13.88 4.83e-35 5.88e-28 0.85 0.6 Fibroblast growth factor basic levels; chr14:77749671 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs1549119 ENSG00000235400.1 RP4-641G12.4 13.88 4.83e-35 5.88e-28 0.85 0.6 Fibroblast growth factor basic levels; chr14:77753469 chr1:78749073~78750659:+ LIHC trans rs9611565 0.659 rs1810461 ENSG00000268568.1 AC007228.9 -13.88 4.83e-35 5.88e-28 -0.95 -0.6 Vitiligo; chr22:41531816 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs4822034 ENSG00000268568.1 AC007228.9 -13.86 5.53e-35 6.7e-28 -0.95 -0.6 Vitiligo; chr22:41535006 chr19:56672574~56673901:- LIHC trans rs9611565 0.625 rs9611606 ENSG00000268568.1 AC007228.9 -13.86 5.53e-35 6.7e-28 -0.95 -0.6 Vitiligo; chr22:41535070 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs116959331 ENSG00000268568.1 AC007228.9 -13.86 5.53e-35 6.7e-28 -0.95 -0.6 Vitiligo; chr22:41536770 chr19:56672574~56673901:- LIHC trans rs61990749 0.597 rs12887282 ENSG00000235400.1 RP4-641G12.4 13.86 5.54e-35 6.72e-28 0.85 0.6 Fibroblast growth factor basic levels; chr14:77734242 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs12887606 ENSG00000235400.1 RP4-641G12.4 13.86 5.54e-35 6.72e-28 0.85 0.6 Fibroblast growth factor basic levels; chr14:77734277 chr1:78749073~78750659:+ LIHC trans rs1816752 0.692 rs6490944 ENSG00000237917.1 PARP4P1 -13.86 5.55e-35 6.72e-28 -0.65 -0.6 Obesity-related traits; chr13:24513866 chrY:26594851~26634652:- LIHC trans rs9611565 0.659 rs1810460 ENSG00000268568.1 AC007228.9 -13.86 5.58e-35 6.76e-28 -0.93 -0.6 Vitiligo; chr22:41531696 chr19:56672574~56673901:- LIHC trans rs61990749 0.597 rs2267761 ENSG00000235400.1 RP4-641G12.4 -13.86 5.58e-35 6.76e-28 -0.86 -0.6 Fibroblast growth factor basic levels; chr14:77681506 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs9323650 ENSG00000235400.1 RP4-641G12.4 13.86 5.73e-35 6.93e-28 0.84 0.6 Fibroblast growth factor basic levels; chr14:77683993 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs176980 ENSG00000235400.1 RP4-641G12.4 -13.85 6.4e-35 7.71e-28 -0.85 -0.6 Fibroblast growth factor basic levels; chr14:77732106 chr1:78749073~78750659:+ LIHC trans rs116095464 0.558 rs10079760 ENSG00000185986.11 SDHAP3 13.84 6.65e-35 7.99e-28 1.09 0.6 Breast cancer; chr5:230663 chr5:1572222~1594620:- LIHC trans rs12709013 0.514 rs8062639 ENSG00000230849.2 GOT2P2 13.84 6.66e-35 7.99e-28 0.69 0.6 Blood metabolite ratios; chr16:58800264 chr1:173141100~173142350:- LIHC trans rs12709013 0.591 rs4410065 ENSG00000230849.2 GOT2P2 13.84 6.66e-35 7.99e-28 0.69 0.6 Blood metabolite ratios; chr16:58800968 chr1:173141100~173142350:- LIHC trans rs12709013 0.591 rs2406234 ENSG00000230849.2 GOT2P2 13.84 6.66e-35 7.99e-28 0.69 0.6 Blood metabolite ratios; chr16:58801840 chr1:173141100~173142350:- LIHC trans rs12709013 0.591 rs2086206 ENSG00000230849.2 GOT2P2 13.84 6.66e-35 7.99e-28 0.69 0.6 Blood metabolite ratios; chr16:58802094 chr1:173141100~173142350:- LIHC trans rs61990749 0.597 rs759808 ENSG00000235400.1 RP4-641G12.4 13.84 6.72e-35 8.06e-28 0.85 0.6 Fibroblast growth factor basic levels; chr14:77784502 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs1048147 ENSG00000235400.1 RP4-641G12.4 -13.83 7.13e-35 8.55e-28 -0.86 -0.6 Fibroblast growth factor basic levels; chr14:77673645 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs2267758 ENSG00000235400.1 RP4-641G12.4 -13.83 7.13e-35 8.55e-28 -0.86 -0.6 Fibroblast growth factor basic levels; chr14:77681086 chr1:78749073~78750659:+ LIHC trans rs61990749 0.544 rs176979 ENSG00000235400.1 RP4-641G12.4 13.82 8.11e-35 9.69e-28 0.85 0.6 Fibroblast growth factor basic levels; chr14:77731729 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs1978416 ENSG00000235400.1 RP4-641G12.4 13.81 8.59e-35 1.02e-27 0.85 0.6 Fibroblast growth factor basic levels; chr14:77761558 chr1:78749073~78750659:+ LIHC trans rs61990749 0.544 rs3759728 ENSG00000235400.1 RP4-641G12.4 13.81 8.59e-35 1.02e-27 0.85 0.6 Fibroblast growth factor basic levels; chr14:77763816 chr1:78749073~78750659:+ LIHC trans rs9611565 0.659 rs73178626 ENSG00000268568.1 AC007228.9 -13.81 8.83e-35 1.05e-27 -0.96 -0.6 Vitiligo; chr22:41532367 chr19:56672574~56673901:- LIHC trans rs9467773 0.596 rs3001369 ENSG00000242375.1 RP11-498P14.3 13.8 1e-34 1.19e-27 0.7 0.6 Intelligence (multi-trait analysis); chr6:26670741 chr9:97195351~97197687:- LIHC trans rs9611565 0.659 rs56319767 ENSG00000268568.1 AC007228.9 -13.79 1.03e-34 1.22e-27 -0.96 -0.6 Vitiligo; chr22:41537833 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs73178632 ENSG00000268568.1 AC007228.9 -13.79 1.03e-34 1.22e-27 -0.96 -0.6 Vitiligo; chr22:41538569 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs28530678 ENSG00000268568.1 AC007228.9 -13.79 1.03e-34 1.22e-27 -0.96 -0.6 Vitiligo; chr22:41538957 chr19:56672574~56673901:- LIHC trans rs9467773 0.62 rs9461275 ENSG00000242375.1 RP11-498P14.3 13.79 1.09e-34 1.29e-27 0.69 0.6 Intelligence (multi-trait analysis); chr6:26590573 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs4368798 ENSG00000242375.1 RP11-498P14.3 13.79 1.09e-34 1.29e-27 0.69 0.6 Intelligence (multi-trait analysis); chr6:26593243 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs9461276 ENSG00000242375.1 RP11-498P14.3 13.79 1.09e-34 1.29e-27 0.69 0.6 Intelligence (multi-trait analysis); chr6:26594940 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs2101582 ENSG00000242375.1 RP11-498P14.3 13.78 1.11e-34 1.31e-27 0.69 0.6 Intelligence (multi-trait analysis); chr6:26622506 chr9:97195351~97197687:- LIHC trans rs9467773 0.62 rs6925087 ENSG00000242375.1 RP11-498P14.3 13.78 1.12e-34 1.32e-27 0.69 0.6 Intelligence (multi-trait analysis); chr6:26592625 chr9:97195351~97197687:- LIHC trans rs9611565 0.694 rs9607816 ENSG00000268568.1 AC007228.9 -13.78 1.17e-34 1.38e-27 -0.93 -0.6 Vitiligo; chr22:41554893 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs56364401 ENSG00000268568.1 AC007228.9 -13.78 1.17e-34 1.38e-27 -0.93 -0.6 Vitiligo; chr22:41555239 chr19:56672574~56673901:- LIHC trans rs1816752 0.646 rs2862905 ENSG00000237917.1 PARP4P1 -13.78 1.18e-34 1.39e-27 -0.64 -0.6 Obesity-related traits; chr13:24485142 chrY:26594851~26634652:- LIHC trans rs916888 0.773 rs9896243 ENSG00000264070.1 DND1P1 13.76 1.32e-34 1.55e-27 1.02 0.6 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45585871~45586929:+ LIHC trans rs12709013 0.536 rs9930758 ENSG00000230849.2 GOT2P2 13.76 1.37e-34 1.6e-27 0.69 0.6 Blood metabolite ratios; chr16:58803167 chr1:173141100~173142350:- LIHC trans rs61990749 0.597 rs2299930 ENSG00000235400.1 RP4-641G12.4 -13.75 1.45e-34 1.7e-27 -0.85 -0.6 Fibroblast growth factor basic levels; chr14:77697379 chr1:78749073~78750659:+ LIHC trans rs13177918 0.798 rs13182116 ENSG00000239528.1 RPS14P8 -13.75 1.46e-34 1.71e-27 -0.88 -0.6 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150465963 chr5:116562562~116562930:+ LIHC trans rs61990749 0.597 rs717683 ENSG00000235400.1 RP4-641G12.4 13.75 1.54e-34 1.8e-27 0.84 0.6 Fibroblast growth factor basic levels; chr14:77789110 chr1:78749073~78750659:+ LIHC trans rs61990749 0.544 rs1477259 ENSG00000235400.1 RP4-641G12.4 13.75 1.54e-34 1.8e-27 0.84 0.6 Fibroblast growth factor basic levels; chr14:77789795 chr1:78749073~78750659:+ LIHC trans rs12709013 0.574 rs9302706 ENSG00000230849.2 GOT2P2 13.75 1.56e-34 1.82e-27 0.7 0.6 Blood metabolite ratios; chr16:58812060 chr1:173141100~173142350:- LIHC trans rs1045902 0.574 rs1474298 ENSG00000236165.1 PRADC1P1 13.73 1.72e-34 2.01e-27 0.78 0.6 Intelligence (multi-trait analysis); chr2:73239464 chr3:36976316~36976840:+ LIHC trans rs9467773 0.62 rs9467810 ENSG00000242375.1 RP11-498P14.3 13.73 1.77e-34 2.07e-27 0.69 0.6 Intelligence (multi-trait analysis); chr6:26608033 chr9:97195351~97197687:- LIHC trans rs8081395 0.769 rs12449331 ENSG00000187870.7 RNFT1P3 -13.73 1.81e-34 2.11e-27 -0.64 -0.6 White blood cell count; chr17:59806285 chr17:20743333~20754501:- LIHC trans rs61990749 0.597 rs12896026 ENSG00000235400.1 RP4-641G12.4 13.72 1.87e-34 2.18e-27 0.84 0.6 Fibroblast growth factor basic levels; chr14:77778093 chr1:78749073~78750659:+ LIHC trans rs61990749 0.544 rs12435761 ENSG00000235400.1 RP4-641G12.4 13.72 1.87e-34 2.18e-27 0.84 0.6 Fibroblast growth factor basic levels; chr14:77779734 chr1:78749073~78750659:+ LIHC trans rs8081395 0.801 rs12938273 ENSG00000187870.7 RNFT1P3 -13.72 1.89e-34 2.2e-27 -0.64 -0.6 White blood cell count; chr17:59824291 chr17:20743333~20754501:- LIHC trans rs916888 0.738 rs199515 ENSG00000264070.1 DND1P1 -13.72 1.97e-34 2.29e-27 -1 -0.6 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:45585871~45586929:+ LIHC trans rs1816752 0.716 rs9553330 ENSG00000237917.1 PARP4P1 -13.72 1.99e-34 2.3e-27 -0.64 -0.6 Obesity-related traits; chr13:24516018 chrY:26594851~26634652:- LIHC trans rs8081395 0.836 rs1292061 ENSG00000187870.7 RNFT1P3 -13.72 2e-34 2.32e-27 -0.64 -0.6 White blood cell count; chr17:59833869 chr17:20743333~20754501:- LIHC trans rs1045902 0.516 rs7851 ENSG00000236165.1 PRADC1P1 13.71 2.16e-34 2.5e-27 0.78 0.6 Intelligence (multi-trait analysis); chr2:73251333 chr3:36976316~36976840:+ LIHC trans rs61990749 0.597 rs13379065 ENSG00000235400.1 RP4-641G12.4 -13.7 2.27e-34 2.62e-27 -0.85 -0.6 Fibroblast growth factor basic levels; chr14:77674952 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs17106157 ENSG00000235400.1 RP4-641G12.4 -13.7 2.27e-34 2.62e-27 -0.85 -0.6 Fibroblast growth factor basic levels; chr14:77680535 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs2267759 ENSG00000235400.1 RP4-641G12.4 -13.7 2.27e-34 2.62e-27 -0.85 -0.6 Fibroblast growth factor basic levels; chr14:77681272 chr1:78749073~78750659:+ LIHC trans rs13190036 0.551 rs7732930 ENSG00000217325.2 PRELID1P1 -13.69 2.66e-34 3.06e-27 -0.78 -0.59 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177121593 chr6:126643488~126644390:+ LIHC trans rs7949030 1 rs10897289 ENSG00000186676.3 EEF1GP1 13.68 2.88e-34 3.3e-27 0.9 0.59 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62632544 chr7:125033453~125035301:+ LIHC trans rs9611565 0.694 rs79008 ENSG00000268568.1 AC007228.9 -13.68 2.9e-34 3.33e-27 -0.94 -0.59 Vitiligo; chr22:41454496 chr19:56672574~56673901:- LIHC trans rs12709013 0.591 rs30841 ENSG00000230849.2 GOT2P2 13.66 3.27e-34 3.71e-27 0.73 0.59 Blood metabolite ratios; chr16:58709819 chr1:173141100~173142350:- LIHC trans rs9611565 0.694 rs202631 ENSG00000268568.1 AC007228.9 13.65 3.58e-34 4.05e-27 0.93 0.59 Vitiligo; chr22:41467419 chr19:56672574~56673901:- LIHC trans rs61990749 0.597 rs11624101 ENSG00000235400.1 RP4-641G12.4 -13.63 4.2e-34 4.73e-27 -0.86 -0.59 Fibroblast growth factor basic levels; chr14:77671716 chr1:78749073~78750659:+ LIHC trans rs1816752 0.646 rs9511309 ENSG00000237917.1 PARP4P1 -13.63 4.5e-34 5.05e-27 -0.65 -0.59 Obesity-related traits; chr13:24515435 chrY:26594851~26634652:- LIHC trans rs116095464 0.558 rs6879656 ENSG00000185986.11 SDHAP3 13.63 4.53e-34 5.09e-27 1.17 0.59 Breast cancer; chr5:264313 chr5:1572222~1594620:- LIHC trans rs2657294 0.603 rs11543 ENSG00000172974.11 AC007318.5 13.62 4.71e-34 5.28e-27 0.71 0.59 Pneumonia; chr10:75210855 chr2:65205108~65205988:+ LIHC trans rs9611565 0.659 rs9611602 ENSG00000268568.1 AC007228.9 -13.61 4.98e-34 5.58e-27 -0.96 -0.59 Vitiligo; chr22:41512401 chr19:56672574~56673901:- LIHC trans rs1816752 0.692 rs2282409 ENSG00000237917.1 PARP4P1 -13.61 4.99e-34 5.59e-27 -0.65 -0.59 Obesity-related traits; chr13:24512388 chrY:26594851~26634652:- LIHC trans rs12709013 0.613 rs6499984 ENSG00000230849.2 GOT2P2 13.61 5.39e-34 6.01e-27 0.69 0.59 Blood metabolite ratios; chr16:58810209 chr1:173141100~173142350:- LIHC trans rs9467773 0.583 rs2498380 ENSG00000242375.1 RP11-498P14.3 -13.57 7.11e-34 7.89e-27 -0.69 -0.59 Intelligence (multi-trait analysis); chr6:26643768 chr9:97195351~97197687:- LIHC trans rs9611565 0.649 rs202666 ENSG00000268568.1 AC007228.9 13.57 7.33e-34 8.13e-27 0.94 0.59 Vitiligo; chr22:41418715 chr19:56672574~56673901:- LIHC trans rs1816752 0.716 rs7995304 ENSG00000237917.1 PARP4P1 -13.57 7.41e-34 8.21e-27 -0.65 -0.59 Obesity-related traits; chr13:24514284 chrY:26594851~26634652:- LIHC trans rs8081395 0.801 rs2777895 ENSG00000187870.7 RNFT1P3 -13.57 7.63e-34 8.44e-27 -0.63 -0.59 White blood cell count; chr17:59802249 chr17:20743333~20754501:- LIHC trans rs1816752 0.608 rs7326664 ENSG00000237917.1 PARP4P1 -13.56 8.39e-34 9.24e-27 -0.65 -0.59 Obesity-related traits; chr13:24475868 chrY:26594851~26634652:- LIHC trans rs1816752 0.669 rs2862906 ENSG00000237917.1 PARP4P1 -13.55 8.64e-34 9.5e-27 -0.64 -0.59 Obesity-related traits; chr13:24494482 chrY:26594851~26634652:- LIHC trans rs12709013 0.591 rs9932967 ENSG00000230849.2 GOT2P2 13.55 9e-34 9.88e-27 0.68 0.59 Blood metabolite ratios; chr16:58805583 chr1:173141100~173142350:- LIHC trans rs9611565 0.694 rs19573 ENSG00000268568.1 AC007228.9 13.54 9.25e-34 1.01e-26 0.93 0.59 Vitiligo; chr22:41469805 chr19:56672574~56673901:- LIHC trans rs1816752 0.646 rs7995190 ENSG00000237917.1 PARP4P1 -13.54 9.73e-34 1.06e-26 -0.65 -0.59 Obesity-related traits; chr13:24475709 chrY:26594851~26634652:- LIHC trans rs61990749 0.597 rs7142390 ENSG00000235400.1 RP4-641G12.4 13.54 9.99e-34 1.09e-26 0.86 0.59 Fibroblast growth factor basic levels; chr14:77766537 chr1:78749073~78750659:+ LIHC trans rs61990749 0.597 rs176971 ENSG00000235400.1 RP4-641G12.4 13.53 1.02e-33 1.11e-26 0.86 0.59 Fibroblast growth factor basic levels; chr14:77725256 chr1:78749073~78750659:+ LIHC trans rs8081395 0.836 rs1295926 ENSG00000187870.7 RNFT1P3 -13.52 1.16e-33 1.25e-26 -0.64 -0.59 White blood cell count; chr17:59832012 chr17:20743333~20754501:- LIHC trans rs1816752 0.646 rs6490937 ENSG00000237917.1 PARP4P1 -13.52 1.17e-33 1.27e-26 -0.65 -0.59 Obesity-related traits; chr13:24475834 chrY:26594851~26634652:- LIHC trans rs12709013 0.636 rs967852 ENSG00000230849.2 GOT2P2 13.51 1.25e-33 1.35e-26 0.68 0.59 Blood metabolite ratios; chr16:58807313 chr1:173141100~173142350:- LIHC trans rs9611565 0.694 rs5758368 ENSG00000268568.1 AC007228.9 -13.51 1.28e-33 1.38e-26 -0.91 -0.59 Vitiligo; chr22:41466284 chr19:56672574~56673901:- LIHC trans rs1816752 0.716 rs1539096 ENSG00000237917.1 PARP4P1 -13.51 1.29e-33 1.4e-26 -0.64 -0.59 Obesity-related traits; chr13:24501721 chrY:26594851~26634652:- LIHC trans rs12709013 0.591 rs30838 ENSG00000230849.2 GOT2P2 13.5 1.32e-33 1.43e-26 0.67 0.59 Blood metabolite ratios; chr16:58711513 chr1:173141100~173142350:- LIHC trans rs1816752 0.524 rs7996445 ENSG00000237917.1 PARP4P1 -13.5 1.35e-33 1.46e-26 -0.65 -0.59 Obesity-related traits; chr13:24475329 chrY:26594851~26634652:- LIHC trans rs8081395 0.836 rs2063353 ENSG00000187870.7 RNFT1P3 -13.5 1.35e-33 1.46e-26 -0.64 -0.59 White blood cell count; chr17:59811831 chr17:20743333~20754501:- LIHC trans rs61990749 0.597 rs11623088 ENSG00000235400.1 RP4-641G12.4 -13.5 1.4e-33 1.51e-26 -0.85 -0.59 Fibroblast growth factor basic levels; chr14:77671392 chr1:78749073~78750659:+ LIHC trans rs9467773 0.62 rs2451738 ENSG00000242375.1 RP11-498P14.3 -13.5 1.42e-33 1.54e-26 -0.67 -0.59 Intelligence (multi-trait analysis); chr6:26618231 chr9:97195351~97197687:- LIHC trans rs12709013 0.591 rs30834 ENSG00000230849.2 GOT2P2 13.47 1.76e-33 1.89e-26 0.72 0.59 Blood metabolite ratios; chr16:58715394 chr1:173141100~173142350:- LIHC trans rs12709013 0.591 rs899375 ENSG00000230849.2 GOT2P2 13.47 1.77e-33 1.9e-26 0.68 0.59 Blood metabolite ratios; chr16:58792325 chr1:173141100~173142350:- LIHC trans rs61990749 0.597 rs4632066 ENSG00000235400.1 RP4-641G12.4 -13.47 1.83e-33 1.97e-26 -0.84 -0.59 Fibroblast growth factor basic levels; chr14:77780939 chr1:78749073~78750659:+ LIHC trans rs12709013 0.636 rs6499976 ENSG00000230849.2 GOT2P2 13.47 1.88e-33 2.01e-26 0.64 0.59 Blood metabolite ratios; chr16:58770330 chr1:173141100~173142350:- LIHC trans rs8081395 0.836 rs2150879 ENSG00000187870.7 RNFT1P3 -13.41 3e-33 3.18e-26 -0.63 -0.59 White blood cell count; chr17:59781849 chr17:20743333~20754501:- LIHC trans rs9611565 0.694 rs202664 ENSG00000268568.1 AC007228.9 13.4 3.49e-33 3.68e-26 0.93 0.59 Vitiligo; chr22:41417882 chr19:56672574~56673901:- LIHC trans rs9611565 0.694 rs202665 ENSG00000268568.1 AC007228.9 13.4 3.49e-33 3.68e-26 0.93 0.59 Vitiligo; chr22:41418397 chr19:56672574~56673901:- LIHC trans rs12709013 0.591 rs6499980 ENSG00000230849.2 GOT2P2 13.39 3.66e-33 3.86e-26 0.68 0.59 Blood metabolite ratios; chr16:58787972 chr1:173141100~173142350:- LIHC trans rs12709013 0.591 rs30840 ENSG00000230849.2 GOT2P2 13.39 3.68e-33 3.88e-26 0.73 0.59 Blood metabolite ratios; chr16:58710165 chr1:173141100~173142350:- LIHC trans rs727563 0.58 rs202626 ENSG00000268568.1 AC007228.9 13.39 3.69e-33 3.89e-26 0.91 0.59 Crohn's disease;Inflammatory bowel disease; chr22:41451186 chr19:56672574~56673901:- LIHC trans rs9611565 0.532 rs202627 ENSG00000268568.1 AC007228.9 13.39 3.69e-33 3.89e-26 0.91 0.59 Vitiligo; chr22:41451363 chr19:56672574~56673901:- LIHC trans rs6732160 1 rs6732160 ENSG00000236165.1 PRADC1P1 13.38 3.92e-33 4.12e-26 0.72 0.59 Intelligence (multi-trait analysis); chr2:73160100 chr3:36976316~36976840:+ LIHC trans rs9611565 0.592 rs4822038 ENSG00000268568.1 AC007228.9 -13.38 4.16e-33 4.37e-26 -0.96 -0.59 Vitiligo; chr22:41562491 chr19:56672574~56673901:- LIHC trans rs1816752 0.609 rs4770692 ENSG00000237917.1 PARP4P1 -13.37 4.19e-33 4.4e-26 -0.65 -0.59 Obesity-related traits; chr13:24468689 chrY:26594851~26634652:- LIHC trans rs1816752 0.609 rs4770694 ENSG00000237917.1 PARP4P1 -13.37 4.19e-33 4.4e-26 -0.65 -0.59 Obesity-related traits; chr13:24468891 chrY:26594851~26634652:- LIHC trans rs116095464 0.558 rs10055993 ENSG00000185986.11 SDHAP3 13.36 4.75e-33 4.98e-26 1.2 0.59 Breast cancer; chr5:264181 chr5:1572222~1594620:- LIHC trans rs1816752 0.624 rs9553312 ENSG00000237917.1 PARP4P1 -13.36 4.85e-33 5.08e-26 -0.65 -0.59 Obesity-related traits; chr13:24474055 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs2902359 ENSG00000237917.1 PARP4P1 -13.36 4.95e-33 5.19e-26 -0.65 -0.59 Obesity-related traits; chr13:24461783 chrY:26594851~26634652:- LIHC trans rs1045902 0.574 rs1053329 ENSG00000236165.1 PRADC1P1 13.35 5.39e-33 5.64e-26 0.78 0.59 Intelligence (multi-trait analysis); chr2:73234355 chr3:36976316~36976840:+ LIHC trans rs9611565 0.592 rs12484467 ENSG00000268568.1 AC007228.9 -13.35 5.4e-33 5.66e-26 -0.95 -0.59 Vitiligo; chr22:41561606 chr19:56672574~56673901:- LIHC trans rs1816752 0.646 rs9634403 ENSG00000237917.1 PARP4P1 -13.33 6.18e-33 6.44e-26 -0.65 -0.58 Obesity-related traits; chr13:24468211 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9581064 ENSG00000237917.1 PARP4P1 -13.33 6.18e-33 6.44e-26 -0.65 -0.58 Obesity-related traits; chr13:24468251 chrY:26594851~26634652:- LIHC trans rs1816752 0.609 rs4769361 ENSG00000237917.1 PARP4P1 -13.33 6.18e-33 6.44e-26 -0.65 -0.58 Obesity-related traits; chr13:24468834 chrY:26594851~26634652:- LIHC trans rs1816752 0.609 rs4770693 ENSG00000237917.1 PARP4P1 -13.33 6.18e-33 6.44e-26 -0.65 -0.58 Obesity-related traits; chr13:24468835 chrY:26594851~26634652:- LIHC trans rs1816752 0.609 rs4770695 ENSG00000237917.1 PARP4P1 -13.33 6.18e-33 6.44e-26 -0.65 -0.58 Obesity-related traits; chr13:24468895 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs7328391 ENSG00000237917.1 PARP4P1 -13.33 6.18e-33 6.44e-26 -0.65 -0.58 Obesity-related traits; chr13:24470325 chrY:26594851~26634652:- LIHC trans rs116095464 0.614 rs10059220 ENSG00000185986.11 SDHAP3 13.32 6.57e-33 6.83e-26 1.21 0.58 Breast cancer; chr5:242698 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs56081398 ENSG00000185986.11 SDHAP3 13.32 6.57e-33 6.83e-26 1.21 0.58 Breast cancer; chr5:247203 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10065584 ENSG00000185986.11 SDHAP3 13.32 6.57e-33 6.83e-26 1.21 0.58 Breast cancer; chr5:253882 chr5:1572222~1594620:- LIHC trans rs1816752 0.646 rs750389 ENSG00000237917.1 PARP4P1 -13.32 6.69e-33 6.95e-26 -0.65 -0.58 Obesity-related traits; chr13:24461677 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs750388 ENSG00000237917.1 PARP4P1 -13.32 6.69e-33 6.95e-26 -0.65 -0.58 Obesity-related traits; chr13:24461690 chrY:26594851~26634652:- LIHC trans rs7949030 0.754 rs36104523 ENSG00000186676.3 EEF1GP1 -13.32 6.74e-33 6.99e-26 -0.85 -0.58 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62628268 chr7:125033453~125035301:+ LIHC trans rs1816752 0.646 rs750390 ENSG00000237917.1 PARP4P1 -13.32 6.76e-33 7.02e-26 -0.65 -0.58 Obesity-related traits; chr13:24461603 chrY:26594851~26634652:- LIHC trans rs1816752 0.583 rs9553311 ENSG00000237917.1 PARP4P1 -13.32 6.86e-33 7.11e-26 -0.65 -0.58 Obesity-related traits; chr13:24474016 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs4480642 ENSG00000237917.1 PARP4P1 -13.3 7.8e-33 8.06e-26 -0.65 -0.58 Obesity-related traits; chr13:24471358 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9551108 ENSG00000237917.1 PARP4P1 -13.3 7.8e-33 8.06e-26 -0.65 -0.58 Obesity-related traits; chr13:24471434 chrY:26594851~26634652:- LIHC trans rs1816752 0.603 rs4238178 ENSG00000237917.1 PARP4P1 -13.3 7.8e-33 8.06e-26 -0.65 -0.58 Obesity-related traits; chr13:24472344 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs2862903 ENSG00000237917.1 PARP4P1 -13.3 7.8e-33 8.06e-26 -0.65 -0.58 Obesity-related traits; chr13:24473169 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs7319207 ENSG00000237917.1 PARP4P1 -13.3 7.8e-33 8.06e-26 -0.65 -0.58 Obesity-related traits; chr13:24473220 chrY:26594851~26634652:- LIHC trans rs1816752 0.624 rs9507354 ENSG00000237917.1 PARP4P1 -13.3 7.87e-33 8.13e-26 -0.65 -0.58 Obesity-related traits; chr13:24469227 chrY:26594851~26634652:- LIHC trans rs9611565 0.765 rs132905 ENSG00000268568.1 AC007228.9 13.29 8.45e-33 8.69e-26 0.91 0.58 Vitiligo; chr22:41403102 chr19:56672574~56673901:- LIHC trans rs9611565 0.765 rs132909 ENSG00000268568.1 AC007228.9 13.29 8.45e-33 8.69e-26 0.91 0.58 Vitiligo; chr22:41406027 chr19:56672574~56673901:- LIHC trans rs9611565 0.681 rs5751094 ENSG00000268568.1 AC007228.9 13.29 8.45e-33 8.69e-26 0.91 0.58 Vitiligo; chr22:41407275 chr19:56672574~56673901:- LIHC trans rs9611565 0.765 rs132914 ENSG00000268568.1 AC007228.9 13.29 8.45e-33 8.69e-26 0.91 0.58 Vitiligo; chr22:41409745 chr19:56672574~56673901:- LIHC trans rs9611565 0.765 rs132915 ENSG00000268568.1 AC007228.9 13.29 8.45e-33 8.69e-26 0.91 0.58 Vitiligo; chr22:41409778 chr19:56672574~56673901:- LIHC trans rs9611565 0.722 rs202635 ENSG00000268568.1 AC007228.9 13.29 8.45e-33 8.69e-26 0.91 0.58 Vitiligo; chr22:41413633 chr19:56672574~56673901:- LIHC trans rs9611565 0.765 rs132920 ENSG00000268568.1 AC007228.9 13.29 8.45e-33 8.69e-26 0.91 0.58 Vitiligo; chr22:41414166 chr19:56672574~56673901:- LIHC trans rs9611565 0.765 rs202659 ENSG00000268568.1 AC007228.9 13.29 8.45e-33 8.69e-26 0.91 0.58 Vitiligo; chr22:41415616 chr19:56672574~56673901:- LIHC trans rs9611565 0.765 rs202663 ENSG00000268568.1 AC007228.9 13.29 8.45e-33 8.69e-26 0.91 0.58 Vitiligo; chr22:41416815 chr19:56672574~56673901:- LIHC trans rs1816752 0.608 rs4770690 ENSG00000237917.1 PARP4P1 -13.27 1.02e-32 1.04e-25 -0.65 -0.58 Obesity-related traits; chr13:24467049 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs7337981 ENSG00000237917.1 PARP4P1 -13.26 1.17e-32 1.19e-25 -0.65 -0.58 Obesity-related traits; chr13:24469245 chrY:26594851~26634652:- LIHC trans rs12709013 0.636 rs1646268 ENSG00000230849.2 GOT2P2 13.25 1.31e-32 1.33e-25 0.62 0.58 Blood metabolite ratios; chr16:58743292 chr1:173141100~173142350:- LIHC trans rs1816752 0.624 rs2096093 ENSG00000237917.1 PARP4P1 -13.24 1.37e-32 1.4e-25 -0.65 -0.58 Obesity-related traits; chr13:24472753 chrY:26594851~26634652:- LIHC trans rs9611565 0.512 rs5758439 ENSG00000268568.1 AC007228.9 13.23 1.44e-32 1.46e-25 0.95 0.58 Vitiligo; chr22:41735758 chr19:56672574~56673901:- LIHC trans rs9611565 0.694 rs202641 ENSG00000268568.1 AC007228.9 13.23 1.49e-32 1.51e-25 0.91 0.58 Vitiligo; chr22:41437112 chr19:56672574~56673901:- LIHC trans rs9611565 0.649 rs79005 ENSG00000268568.1 AC007228.9 13.23 1.49e-32 1.51e-25 0.91 0.58 Vitiligo; chr22:41439540 chr19:56672574~56673901:- LIHC trans rs9611565 0.608 rs202652 ENSG00000268568.1 AC007228.9 13.23 1.49e-32 1.51e-25 0.91 0.58 Vitiligo; chr22:41442788 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs202653 ENSG00000268568.1 AC007228.9 13.23 1.49e-32 1.51e-25 0.91 0.58 Vitiligo; chr22:41444154 chr19:56672574~56673901:- LIHC trans rs1816752 0.646 rs9511295 ENSG00000237917.1 PARP4P1 -13.22 1.56e-32 1.58e-25 -0.64 -0.58 Obesity-related traits; chr13:24467794 chrY:26594851~26634652:- LIHC trans rs12709013 0.535 rs9924136 ENSG00000230849.2 GOT2P2 13.22 1.61e-32 1.63e-25 0.67 0.58 Blood metabolite ratios; chr16:58779573 chr1:173141100~173142350:- LIHC trans rs9611565 0.559 rs739136 ENSG00000268568.1 AC007228.9 -13.22 1.61e-32 1.63e-25 -0.95 -0.58 Vitiligo; chr22:41704271 chr19:56672574~56673901:- LIHC trans rs1816752 0.583 rs9511284 ENSG00000237917.1 PARP4P1 -13.22 1.64e-32 1.66e-25 -0.64 -0.58 Obesity-related traits; chr13:24463660 chrY:26594851~26634652:- LIHC trans rs12709013 0.591 rs7184377 ENSG00000230849.2 GOT2P2 13.22 1.65e-32 1.67e-25 0.68 0.58 Blood metabolite ratios; chr16:58808765 chr1:173141100~173142350:- LIHC trans rs1816752 0.646 rs7322323 ENSG00000237917.1 PARP4P1 -13.21 1.71e-32 1.73e-25 -0.63 -0.58 Obesity-related traits; chr13:24479189 chrY:26594851~26634652:- LIHC trans rs1816752 0.669 rs4770699 ENSG00000237917.1 PARP4P1 -13.21 1.78e-32 1.8e-25 -0.63 -0.58 Obesity-related traits; chr13:24488234 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9511296 ENSG00000237917.1 PARP4P1 -13.21 1.8e-32 1.82e-25 -0.64 -0.58 Obesity-related traits; chr13:24467962 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9634401 ENSG00000237917.1 PARP4P1 -13.21 1.8e-32 1.82e-25 -0.64 -0.58 Obesity-related traits; chr13:24468072 chrY:26594851~26634652:- LIHC trans rs1816752 0.624 rs9634402 ENSG00000237917.1 PARP4P1 -13.21 1.8e-32 1.82e-25 -0.64 -0.58 Obesity-related traits; chr13:24468119 chrY:26594851~26634652:- LIHC trans rs1816752 0.608 rs9511290 ENSG00000237917.1 PARP4P1 -13.18 2.29e-32 2.29e-25 -0.64 -0.58 Obesity-related traits; chr13:24467189 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9511291 ENSG00000237917.1 PARP4P1 -13.18 2.29e-32 2.29e-25 -0.64 -0.58 Obesity-related traits; chr13:24467609 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9511292 ENSG00000237917.1 PARP4P1 -13.18 2.29e-32 2.29e-25 -0.64 -0.58 Obesity-related traits; chr13:24467623 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9511293 ENSG00000237917.1 PARP4P1 -13.18 2.29e-32 2.29e-25 -0.64 -0.58 Obesity-related traits; chr13:24467747 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9511294 ENSG00000237917.1 PARP4P1 -13.18 2.29e-32 2.29e-25 -0.64 -0.58 Obesity-related traits; chr13:24467773 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs1361578 ENSG00000237917.1 PARP4P1 -13.18 2.34e-32 2.35e-25 -0.64 -0.58 Obesity-related traits; chr13:24491117 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9511301 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.63 -0.58 Obesity-related traits; chr13:24477034 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs7332220 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.63 -0.58 Obesity-related traits; chr13:24477081 chrY:26594851~26634652:- LIHC trans rs1816752 0.624 rs11149109 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.63 -0.58 Obesity-related traits; chr13:24477290 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9511302 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.63 -0.58 Obesity-related traits; chr13:24477580 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs8002599 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.63 -0.58 Obesity-related traits; chr13:24478486 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs7322329 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.63 -0.58 Obesity-related traits; chr13:24479193 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs2862902 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24461965 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs734715 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24462041 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs730030 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24462509 chrY:26594851~26634652:- LIHC trans rs1816752 0.609 rs7992667 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24462821 chrY:26594851~26634652:- LIHC trans rs1816752 0.609 rs7995958 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24462895 chrY:26594851~26634652:- LIHC trans rs1816752 0.609 rs8002741 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24462918 chrY:26594851~26634652:- LIHC trans rs1816752 0.609 rs7998198 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24462979 chrY:26594851~26634652:- LIHC trans rs1816752 0.609 rs7998203 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24462989 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs7998600 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24463222 chrY:26594851~26634652:- LIHC trans rs1816752 0.624 rs9511282 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24463597 chrY:26594851~26634652:- LIHC trans rs1816752 0.583 rs9511283 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24463656 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9507351 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24465118 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs12431171 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24466380 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs12854523 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24466460 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9578740 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24466692 chrY:26594851~26634652:- LIHC trans rs1816752 0.631 rs4769358 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24466940 chrY:26594851~26634652:- LIHC trans rs1816752 0.608 rs4769359 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24466966 chrY:26594851~26634652:- LIHC trans rs1816752 0.608 rs4769360 ENSG00000237917.1 PARP4P1 -13.18 2.4e-32 2.38e-25 -0.64 -0.58 Obesity-related traits; chr13:24467016 chrY:26594851~26634652:- LIHC trans rs1816752 0.716 rs1441058 ENSG00000237917.1 PARP4P1 -13.17 2.43e-32 2.41e-25 -0.64 -0.58 Obesity-related traits; chr13:24516275 chrY:26594851~26634652:- LIHC trans rs13177918 0.603 rs2748241 ENSG00000224114.1 RP11-343H5.4 13.17 2.56e-32 2.53e-25 0.74 0.58 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447931 chr1:206695837~206696269:- LIHC trans rs1816752 0.624 rs4770701 ENSG00000237917.1 PARP4P1 -13.17 2.62e-32 2.59e-25 -0.65 -0.58 Obesity-related traits; chr13:24508806 chrY:26594851~26634652:- LIHC trans rs8081395 0.801 rs2665405 ENSG00000187870.7 RNFT1P3 -13.16 2.66e-32 2.63e-25 -0.62 -0.58 White blood cell count; chr17:59797931 chr17:20743333~20754501:- LIHC trans rs5751150 1 rs5751150 ENSG00000268568.1 AC007228.9 13.16 2.82e-32 2.79e-25 0.96 0.58 Cannabis dependence symptom count; chr22:41757288 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs2050031 ENSG00000268568.1 AC007228.9 13.16 2.88e-32 2.85e-25 0.96 0.58 Vitiligo; chr22:41756262 chr19:56672574~56673901:- LIHC trans rs727563 0.562 rs5758458 ENSG00000268568.1 AC007228.9 13.16 2.88e-32 2.85e-25 0.96 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41758128 chr19:56672574~56673901:- LIHC trans rs13177918 0.626 rs2748240 ENSG00000224114.1 RP11-343H5.4 13.15 3.02e-32 2.98e-25 0.75 0.58 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449305 chr1:206695837~206696269:- LIHC trans rs9611565 0.512 rs5751147 ENSG00000268568.1 AC007228.9 13.15 3.07e-32 3.03e-25 0.95 0.58 Vitiligo; chr22:41743050 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs5758450 ENSG00000268568.1 AC007228.9 13.15 3.07e-32 3.03e-25 0.95 0.58 Vitiligo; chr22:41745636 chr19:56672574~56673901:- LIHC trans rs9611565 0.546 rs739129 ENSG00000268568.1 AC007228.9 13.14 3.34e-32 3.28e-25 0.95 0.58 Vitiligo; chr22:41722245 chr19:56672574~56673901:- LIHC trans rs9611565 0.546 rs739132 ENSG00000268568.1 AC007228.9 13.14 3.34e-32 3.28e-25 0.95 0.58 Vitiligo; chr22:41727095 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs5758436 ENSG00000268568.1 AC007228.9 13.14 3.34e-32 3.28e-25 0.95 0.58 Vitiligo; chr22:41728261 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs7291736 ENSG00000268568.1 AC007228.9 13.14 3.34e-32 3.28e-25 0.95 0.58 Vitiligo; chr22:41728870 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs2899347 ENSG00000268568.1 AC007228.9 13.13 3.46e-32 3.39e-25 0.96 0.58 Vitiligo; chr22:41762200 chr19:56672574~56673901:- LIHC trans rs727563 0.635 rs713988 ENSG00000268568.1 AC007228.9 13.13 3.46e-32 3.39e-25 0.96 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41763068 chr19:56672574~56673901:- LIHC trans rs12709013 0.569 rs30837 ENSG00000230849.2 GOT2P2 13.13 3.57e-32 3.49e-25 0.71 0.58 Blood metabolite ratios; chr16:58711942 chr1:173141100~173142350:- LIHC trans rs727563 0.636 rs2187795 ENSG00000268568.1 AC007228.9 13.13 3.57e-32 3.49e-25 0.95 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41696221 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs5751145 ENSG00000268568.1 AC007228.9 13.12 3.76e-32 3.66e-25 0.95 0.58 Vitiligo; chr22:41737548 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs768414 ENSG00000268568.1 AC007228.9 13.12 3.76e-32 3.66e-25 0.95 0.58 Vitiligo; chr22:41739747 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs8141103 ENSG00000268568.1 AC007228.9 13.12 3.76e-32 3.66e-25 0.95 0.58 Vitiligo; chr22:41740926 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs5751148 ENSG00000268568.1 AC007228.9 13.12 3.76e-32 3.66e-25 0.95 0.58 Vitiligo; chr22:41743074 chr19:56672574~56673901:- LIHC trans rs727563 0.635 rs5751149 ENSG00000268568.1 AC007228.9 13.12 3.76e-32 3.66e-25 0.95 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41743497 chr19:56672574~56673901:- LIHC trans rs727563 0.638 rs5996058 ENSG00000268568.1 AC007228.9 13.12 3.76e-32 3.66e-25 0.95 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41745448 chr19:56672574~56673901:- LIHC trans rs1816752 0.669 rs3783072 ENSG00000237917.1 PARP4P1 -13.11 4.11e-32 3.98e-25 -0.64 -0.58 Obesity-related traits; chr13:24493258 chrY:26594851~26634652:- LIHC trans rs9611565 0.545 rs5758432 ENSG00000268568.1 AC007228.9 13.11 4.15e-32 4.03e-25 0.95 0.58 Vitiligo; chr22:41715689 chr19:56672574~56673901:- LIHC trans rs6732160 0.967 rs6760964 ENSG00000236165.1 PRADC1P1 13.11 4.35e-32 4.22e-25 0.71 0.58 Intelligence (multi-trait analysis); chr2:73160258 chr3:36976316~36976840:+ LIHC trans rs6732160 0.932 rs768851 ENSG00000236165.1 PRADC1P1 13.1 4.63e-32 4.48e-25 0.72 0.58 Intelligence (multi-trait analysis); chr2:73151113 chr3:36976316~36976840:+ LIHC trans rs6732160 0.934 rs2421390 ENSG00000236165.1 PRADC1P1 13.1 4.63e-32 4.48e-25 0.72 0.58 Intelligence (multi-trait analysis); chr2:73151975 chr3:36976316~36976840:+ LIHC trans rs6732160 0.932 rs6546802 ENSG00000236165.1 PRADC1P1 13.1 4.63e-32 4.48e-25 0.72 0.58 Intelligence (multi-trait analysis); chr2:73152436 chr3:36976316~36976840:+ LIHC trans rs6732160 0.932 rs13417029 ENSG00000236165.1 PRADC1P1 13.1 4.63e-32 4.48e-25 0.72 0.58 Intelligence (multi-trait analysis); chr2:73153295 chr3:36976316~36976840:+ LIHC trans rs6732160 0.932 rs6546803 ENSG00000236165.1 PRADC1P1 13.1 4.63e-32 4.48e-25 0.72 0.58 Intelligence (multi-trait analysis); chr2:73154187 chr3:36976316~36976840:+ LIHC trans rs9611565 0.513 rs739135 ENSG00000268568.1 AC007228.9 13.1 4.66e-32 4.5e-25 0.95 0.58 Vitiligo; chr22:41694065 chr19:56672574~56673901:- LIHC trans rs4822044 0.68 rs8138780 ENSG00000268568.1 AC007228.9 13.1 4.66e-32 4.5e-25 0.95 0.58 Cannabis dependence symptom count; chr22:41701458 chr19:56672574~56673901:- LIHC trans rs9611565 0.592 rs5751139 ENSG00000268568.1 AC007228.9 13.1 4.66e-32 4.5e-25 0.95 0.58 Vitiligo; chr22:41703977 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs964899 ENSG00000268568.1 AC007228.9 13.1 4.74e-32 4.58e-25 0.95 0.58 Vitiligo; chr22:41746382 chr19:56672574~56673901:- LIHC trans rs1816752 0.716 rs9553331 ENSG00000237917.1 PARP4P1 -13.09 5e-32 4.81e-25 -0.64 -0.58 Obesity-related traits; chr13:24516030 chrY:26594851~26634652:- LIHC trans rs12709013 0.591 rs30838 ENSG00000233719.3 GOT2P3 13.09 5.28e-32 5.07e-25 0.61 0.58 Blood metabolite ratios; chr16:58711513 chr12:9641802~9643007:+ LIHC trans rs9611565 0.559 rs5758428 ENSG00000268568.1 AC007228.9 13.08 5.42e-32 5.2e-25 0.95 0.58 Vitiligo; chr22:41710212 chr19:56672574~56673901:- LIHC trans rs727563 0.636 rs2413653 ENSG00000268568.1 AC007228.9 13.08 5.42e-32 5.2e-25 0.95 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41710992 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs45500192 ENSG00000268568.1 AC007228.9 -13.08 5.48e-32 5.26e-25 -0.95 -0.58 Vitiligo; chr22:41781895 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs4822035 ENSG00000268568.1 AC007228.9 13.08 5.73e-32 5.48e-25 0.91 0.58 Vitiligo; chr22:41539908 chr19:56672574~56673901:- LIHC trans rs727563 0.593 rs132770 ENSG00000268568.1 AC007228.9 13.07 5.9e-32 5.63e-25 0.94 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41621260 chr19:56672574~56673901:- LIHC trans rs1816752 0.646 rs4770700 ENSG00000237917.1 PARP4P1 -13.07 5.9e-32 5.63e-25 -0.64 -0.58 Obesity-related traits; chr13:24494796 chrY:26594851~26634652:- LIHC trans rs1816752 0.624 rs7330766 ENSG00000237917.1 PARP4P1 -13.07 5.9e-32 5.63e-25 -0.64 -0.58 Obesity-related traits; chr13:24495579 chrY:26594851~26634652:- LIHC trans rs1816752 0.603 rs7984094 ENSG00000237917.1 PARP4P1 -13.07 5.9e-32 5.63e-25 -0.64 -0.58 Obesity-related traits; chr13:24496212 chrY:26594851~26634652:- LIHC trans rs116095464 0.558 rs34629844 ENSG00000185986.11 SDHAP3 13.07 5.92e-32 5.65e-25 1.25 0.58 Breast cancer; chr5:200714 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs62346506 ENSG00000185986.11 SDHAP3 13.07 5.92e-32 5.65e-25 1.25 0.58 Breast cancer; chr5:201479 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs9312957 ENSG00000185986.11 SDHAP3 13.07 5.92e-32 5.65e-25 1.25 0.58 Breast cancer; chr5:202079 chr5:1572222~1594620:- LIHC trans rs9611565 0.559 rs132761 ENSG00000268568.1 AC007228.9 13.06 6.86e-32 6.48e-25 0.94 0.58 Vitiligo; chr22:41608367 chr19:56672574~56673901:- LIHC trans rs9611565 0.559 rs132765 ENSG00000268568.1 AC007228.9 13.06 6.86e-32 6.48e-25 0.94 0.58 Vitiligo; chr22:41612064 chr19:56672574~56673901:- LIHC trans rs9611565 0.559 rs132768 ENSG00000268568.1 AC007228.9 13.06 6.86e-32 6.48e-25 0.94 0.58 Vitiligo; chr22:41617519 chr19:56672574~56673901:- LIHC trans rs9611565 0.559 rs5758397 ENSG00000268568.1 AC007228.9 13.06 6.86e-32 6.48e-25 0.94 0.58 Vitiligo; chr22:41623247 chr19:56672574~56673901:- LIHC trans rs9611565 0.559 rs132771 ENSG00000268568.1 AC007228.9 13.06 6.86e-32 6.48e-25 0.94 0.58 Vitiligo; chr22:41629346 chr19:56672574~56673901:- LIHC trans rs727563 0.52 rs132773 ENSG00000268568.1 AC007228.9 13.06 6.86e-32 6.48e-25 0.94 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41635764 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs1657161 ENSG00000230849.2 GOT2P2 13.05 7.13e-32 6.74e-25 0.62 0.58 Blood metabolite ratios; chr16:58743234 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs1646269 ENSG00000230849.2 GOT2P2 13.05 7.13e-32 6.74e-25 0.62 0.58 Blood metabolite ratios; chr16:58743412 chr1:173141100~173142350:- LIHC trans rs4822044 0.56 rs7284839 ENSG00000268568.1 AC007228.9 13.04 8.24e-32 7.75e-25 0.94 0.58 Cannabis dependence symptom count; chr22:41614898 chr19:56672574~56673901:- LIHC trans rs7949030 1 rs2956993 ENSG00000186676.3 EEF1GP1 -13.04 8.27e-32 7.78e-25 -0.85 -0.58 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62638690 chr7:125033453~125035301:+ LIHC trans rs1816752 0.646 rs9507355 ENSG00000237917.1 PARP4P1 13.03 8.73e-32 8.2e-25 0.62 0.58 Obesity-related traits; chr13:24476819 chrY:26594851~26634652:- LIHC trans rs9611565 0.512 rs1534932 ENSG00000268568.1 AC007228.9 13.02 9.25e-32 8.67e-25 0.94 0.58 Vitiligo; chr22:41754142 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs1646272 ENSG00000230849.2 GOT2P2 13.01 1.02e-31 9.55e-25 0.63 0.58 Blood metabolite ratios; chr16:58746508 chr1:173141100~173142350:- LIHC trans rs12709013 0.66 rs1657163 ENSG00000230849.2 GOT2P2 13.01 1.02e-31 9.55e-25 0.63 0.58 Blood metabolite ratios; chr16:58746688 chr1:173141100~173142350:- LIHC trans rs727563 0.635 rs2899348 ENSG00000268568.1 AC007228.9 13.01 1.03e-31 9.6e-25 0.96 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41768512 chr19:56672574~56673901:- LIHC trans rs202629 1 rs202629 ENSG00000268568.1 AC007228.9 13 1.09e-31 1.02e-24 0.9 0.58 Cannabis dependence symptom count; chr22:41453971 chr19:56672574~56673901:- LIHC trans rs9611565 0.649 rs202655 ENSG00000268568.1 AC007228.9 13 1.17e-31 1.09e-24 0.91 0.57 Vitiligo; chr22:41445560 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs1595180 ENSG00000230849.2 GOT2P2 13 1.17e-31 1.09e-24 0.62 0.57 Blood metabolite ratios; chr16:58770545 chr1:173141100~173142350:- LIHC trans rs9611565 0.729 rs73176686 ENSG00000268568.1 AC007228.9 -12.99 1.19e-31 1.11e-24 -0.94 -0.57 Vitiligo; chr22:41386115 chr19:56672574~56673901:- LIHC trans rs9611565 0.729 rs4822027 ENSG00000268568.1 AC007228.9 -12.99 1.19e-31 1.11e-24 -0.94 -0.57 Vitiligo; chr22:41390223 chr19:56672574~56673901:- LIHC trans rs727563 0.594 rs5758408 ENSG00000268568.1 AC007228.9 12.99 1.22e-31 1.14e-24 0.94 0.57 Crohn's disease;Inflammatory bowel disease; chr22:41681733 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs2050033 ENSG00000268568.1 AC007228.9 12.99 1.25e-31 1.15e-24 0.96 0.57 Vitiligo; chr22:41763225 chr19:56672574~56673901:- LIHC trans rs727563 0.593 rs5758461 ENSG00000268568.1 AC007228.9 12.99 1.25e-31 1.15e-24 0.96 0.57 Crohn's disease;Inflammatory bowel disease; chr22:41766185 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs2899349 ENSG00000268568.1 AC007228.9 12.99 1.25e-31 1.15e-24 0.96 0.57 Vitiligo; chr22:41768656 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs1983576 ENSG00000268568.1 AC007228.9 12.99 1.25e-31 1.15e-24 0.96 0.57 Vitiligo; chr22:41770482 chr19:56672574~56673901:- LIHC trans rs9611565 0.503 rs5996062 ENSG00000268568.1 AC007228.9 12.99 1.25e-31 1.15e-24 0.96 0.57 Vitiligo; chr22:41771460 chr19:56672574~56673901:- LIHC trans rs116095464 0.558 rs9312956 ENSG00000185986.11 SDHAP3 12.99 1.28e-31 1.18e-24 1.24 0.57 Breast cancer; chr5:201697 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs62346508 ENSG00000185986.11 SDHAP3 12.99 1.28e-31 1.18e-24 1.24 0.57 Breast cancer; chr5:203553 chr5:1572222~1594620:- LIHC trans rs12709013 0.585 rs7188608 ENSG00000230849.2 GOT2P2 12.98 1.3e-31 1.2e-24 0.62 0.57 Blood metabolite ratios; chr16:58736236 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs1657176 ENSG00000230849.2 GOT2P2 12.98 1.3e-31 1.2e-24 0.62 0.57 Blood metabolite ratios; chr16:58736833 chr1:173141100~173142350:- LIHC trans rs1816752 0.646 rs9511279 ENSG00000237917.1 PARP4P1 -12.98 1.31e-31 1.21e-24 -0.63 -0.57 Obesity-related traits; chr13:24463348 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9511280 ENSG00000237917.1 PARP4P1 -12.98 1.31e-31 1.21e-24 -0.63 -0.57 Obesity-related traits; chr13:24463364 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs9511281 ENSG00000237917.1 PARP4P1 -12.98 1.31e-31 1.21e-24 -0.63 -0.57 Obesity-related traits; chr13:24463441 chrY:26594851~26634652:- LIHC trans rs12709013 0.636 rs4538000 ENSG00000230849.2 GOT2P2 12.98 1.31e-31 1.21e-24 0.62 0.57 Blood metabolite ratios; chr16:58744506 chr1:173141100~173142350:- LIHC trans rs9611565 0.694 rs202628 ENSG00000268568.1 AC007228.9 -12.98 1.34e-31 1.24e-24 -0.88 -0.57 Vitiligo; chr22:41453509 chr19:56672574~56673901:- LIHC trans rs10865397 0.506 rs13414160 ENSG00000236165.1 PRADC1P1 12.98 1.36e-31 1.26e-24 0.75 0.57 Intelligence (multi-trait analysis); chr2:73156133 chr3:36976316~36976840:+ LIHC trans rs12709013 0.636 rs1646282 ENSG00000230849.2 GOT2P2 12.97 1.4e-31 1.29e-24 0.62 0.57 Blood metabolite ratios; chr16:58741296 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs4784977 ENSG00000230849.2 GOT2P2 12.97 1.4e-31 1.29e-24 0.62 0.57 Blood metabolite ratios; chr16:58742120 chr1:173141100~173142350:- LIHC trans rs13190036 1 rs4976682 ENSG00000226986.4 RP11-543B16.2 12.97 1.43e-31 1.32e-24 0.67 0.57 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177299001 chr1:211207239~211207897:+ LIHC trans rs8081395 0.801 rs2665404 ENSG00000187870.7 RNFT1P3 12.97 1.43e-31 1.32e-24 0.62 0.57 White blood cell count; chr17:59798035 chr17:20743333~20754501:- LIHC trans rs116095464 0.558 rs6962 ENSG00000185986.11 SDHAP3 12.97 1.44e-31 1.32e-24 1.15 0.57 Breast cancer; chr5:256394 chr5:1572222~1594620:- LIHC trans rs9611565 0.512 rs964898 ENSG00000268568.1 AC007228.9 -12.97 1.48e-31 1.36e-24 -0.91 -0.57 Vitiligo; chr22:41746302 chr19:56672574~56673901:- LIHC trans rs1816752 0.646 rs7997248 ENSG00000237917.1 PARP4P1 -12.97 1.49e-31 1.37e-24 -0.64 -0.57 Obesity-related traits; chr13:24507050 chrY:26594851~26634652:- LIHC trans rs13177918 0.603 rs2343806 ENSG00000224114.1 RP11-343H5.4 12.96 1.56e-31 1.43e-24 0.74 0.57 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452422 chr1:206695837~206696269:- LIHC trans rs727563 0.594 rs132807 ENSG00000268568.1 AC007228.9 12.96 1.59e-31 1.46e-24 0.94 0.57 Crohn's disease;Inflammatory bowel disease; chr22:41675580 chr19:56672574~56673901:- LIHC trans rs9611565 0.592 rs1811113 ENSG00000268568.1 AC007228.9 12.96 1.59e-31 1.46e-24 0.94 0.57 Vitiligo; chr22:41677130 chr19:56672574~56673901:- LIHC trans rs116095464 0.558 rs1968374 ENSG00000185986.11 SDHAP3 12.96 1.62e-31 1.48e-24 1.13 0.57 Breast cancer; chr5:248910 chr5:1572222~1594620:- LIHC trans rs9611565 0.681 rs132918 ENSG00000268568.1 AC007228.9 12.96 1.64e-31 1.51e-24 0.88 0.57 Vitiligo; chr22:41412346 chr19:56672574~56673901:- LIHC trans rs9611565 0.765 rs132921 ENSG00000268568.1 AC007228.9 12.96 1.64e-31 1.51e-24 0.88 0.57 Vitiligo; chr22:41416040 chr19:56672574~56673901:- LIHC trans rs9611565 0.592 rs8779 ENSG00000268568.1 AC007228.9 12.95 1.69e-31 1.54e-24 0.94 0.57 Vitiligo; chr22:41674272 chr19:56672574~56673901:- LIHC trans rs9611565 0.559 rs5758412 ENSG00000268568.1 AC007228.9 12.95 1.69e-31 1.54e-24 0.94 0.57 Vitiligo; chr22:41684799 chr19:56672574~56673901:- LIHC trans rs9611565 0.559 rs13056262 ENSG00000268568.1 AC007228.9 12.95 1.69e-31 1.54e-24 0.94 0.57 Vitiligo; chr22:41685917 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs4499224 ENSG00000230849.2 GOT2P2 12.94 1.89e-31 1.73e-24 0.62 0.57 Blood metabolite ratios; chr16:58770364 chr1:173141100~173142350:- LIHC trans rs6732160 0.51 rs57825971 ENSG00000236165.1 PRADC1P1 12.94 1.92e-31 1.75e-24 0.75 0.57 Intelligence (multi-trait analysis); chr2:73157668 chr3:36976316~36976840:+ LIHC trans rs10865397 0.506 rs60764301 ENSG00000236165.1 PRADC1P1 12.94 1.92e-31 1.75e-24 0.75 0.57 Intelligence (multi-trait analysis); chr2:73157722 chr3:36976316~36976840:+ LIHC trans rs1816752 0.646 rs4770688 ENSG00000237917.1 PARP4P1 -12.93 2.14e-31 1.94e-24 -0.64 -0.57 Obesity-related traits; chr13:24466007 chrY:26594851~26634652:- LIHC trans rs1816752 0.646 rs4770689 ENSG00000237917.1 PARP4P1 -12.93 2.14e-31 1.94e-24 -0.64 -0.57 Obesity-related traits; chr13:24466008 chrY:26594851~26634652:- LIHC trans rs10865397 0.506 rs6546807 ENSG00000236165.1 PRADC1P1 12.92 2.2e-31 2e-24 0.75 0.57 Intelligence (multi-trait analysis); chr2:73159084 chr3:36976316~36976840:+ LIHC trans rs9611565 0.765 rs9607800 ENSG00000268568.1 AC007228.9 -12.91 2.43e-31 2.21e-24 -0.92 -0.57 Vitiligo; chr22:41388558 chr19:56672574~56673901:- LIHC trans rs9611565 0.802 rs73176692 ENSG00000268568.1 AC007228.9 -12.91 2.43e-31 2.21e-24 -0.92 -0.57 Vitiligo; chr22:41389731 chr19:56672574~56673901:- LIHC trans rs9611565 0.802 rs73176694 ENSG00000268568.1 AC007228.9 -12.91 2.43e-31 2.21e-24 -0.92 -0.57 Vitiligo; chr22:41390784 chr19:56672574~56673901:- LIHC trans rs9467773 0.595 rs12525810 ENSG00000242375.1 RP11-498P14.3 12.88 3.08e-31 2.78e-24 0.68 0.57 Intelligence (multi-trait analysis); chr6:26623283 chr9:97195351~97197687:- LIHC trans rs13177918 0.626 rs2748240 ENSG00000213058.3 RP4-765C7.2 12.88 3.1e-31 2.8e-24 0.73 0.57 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449305 chr1:178411616~178411972:+ LIHC trans rs116095464 0.558 rs10059907 ENSG00000185986.11 SDHAP3 12.87 3.49e-31 3.15e-24 1.24 0.57 Breast cancer; chr5:205245 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10060089 ENSG00000185986.11 SDHAP3 12.87 3.49e-31 3.15e-24 1.24 0.57 Breast cancer; chr5:205450 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10068203 ENSG00000185986.11 SDHAP3 12.87 3.49e-31 3.15e-24 1.24 0.57 Breast cancer; chr5:206503 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs73029475 ENSG00000185986.11 SDHAP3 12.87 3.49e-31 3.15e-24 1.24 0.57 Breast cancer; chr5:206854 chr5:1572222~1594620:- LIHC trans rs12709013 0.613 rs1657178 ENSG00000230849.2 GOT2P2 12.87 3.5e-31 3.15e-24 0.61 0.57 Blood metabolite ratios; chr16:58735300 chr1:173141100~173142350:- LIHC trans rs10865397 0.539 rs13414338 ENSG00000236165.1 PRADC1P1 12.87 3.65e-31 3.28e-24 0.75 0.57 Intelligence (multi-trait analysis); chr2:73156247 chr3:36976316~36976840:+ LIHC trans rs12709013 0.636 rs1657164 ENSG00000230849.2 GOT2P2 12.86 3.8e-31 3.41e-24 0.62 0.57 Blood metabolite ratios; chr16:58747949 chr1:173141100~173142350:- LIHC trans rs9611565 0.512 rs6002474 ENSG00000268568.1 AC007228.9 12.86 3.83e-31 3.44e-24 0.95 0.57 Vitiligo; chr22:41772177 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs5996063 ENSG00000268568.1 AC007228.9 12.86 3.83e-31 3.44e-24 0.95 0.57 Vitiligo; chr22:41772763 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs72792430 ENSG00000230849.2 GOT2P2 -12.86 3.98e-31 3.56e-24 -0.62 -0.57 Blood metabolite ratios; chr16:58746990 chr1:173141100~173142350:- LIHC trans rs12709013 0.597 rs1616072 ENSG00000230849.2 GOT2P2 12.86 3.98e-31 3.56e-24 0.62 0.57 Blood metabolite ratios; chr16:58747194 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs2575374 ENSG00000230849.2 GOT2P2 12.86 3.98e-31 3.56e-24 0.62 0.57 Blood metabolite ratios; chr16:58747494 chr1:173141100~173142350:- LIHC trans rs12709013 0.537 rs1657167 ENSG00000230849.2 GOT2P2 12.86 3.98e-31 3.56e-24 0.62 0.57 Blood metabolite ratios; chr16:58748955 chr1:173141100~173142350:- LIHC trans rs8010715 0.636 rs2277482 ENSG00000248988.1 RP11-815N9.2 12.85 3.99e-31 3.58e-24 0.74 0.57 IgG glycosylation; chr14:24118586 chr4:159007119~159007835:+ LIHC trans rs9467773 0.62 rs1027203 ENSG00000242375.1 RP11-498P14.3 12.83 4.76e-31 4.25e-24 0.68 0.57 Intelligence (multi-trait analysis); chr6:26639104 chr9:97195351~97197687:- LIHC trans rs9467773 0.595 rs2172007 ENSG00000242375.1 RP11-498P14.3 12.83 4.76e-31 4.25e-24 0.68 0.57 Intelligence (multi-trait analysis); chr6:26639549 chr9:97195351~97197687:- LIHC trans rs61990749 0.597 rs9788540 ENSG00000235400.1 RP4-641G12.4 -12.83 4.82e-31 4.3e-24 -0.79 -0.57 Fibroblast growth factor basic levels; chr14:77665829 chr1:78749073~78750659:+ LIHC trans rs9611565 0.512 rs139571 ENSG00000268568.1 AC007228.9 -12.82 5.34e-31 4.76e-24 -0.94 -0.57 Vitiligo; chr22:41818234 chr19:56672574~56673901:- LIHC trans rs727563 0.569 rs73178647 ENSG00000268568.1 AC007228.9 -12.82 5.39e-31 4.8e-24 -0.96 -0.57 Crohn's disease;Inflammatory bowel disease; chr22:41568164 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs1646256 ENSG00000230849.2 GOT2P2 12.81 5.74e-31 5.11e-24 0.63 0.57 Blood metabolite ratios; chr16:58712114 chr1:173141100~173142350:- LIHC trans rs13177918 0.603 rs2748241 ENSG00000213058.3 RP4-765C7.2 12.81 5.8e-31 5.16e-24 0.72 0.57 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447931 chr1:178411616~178411972:+ LIHC trans rs9611565 0.512 rs139560 ENSG00000268568.1 AC007228.9 -12.81 5.87e-31 5.22e-24 -0.95 -0.57 Vitiligo; chr22:41798958 chr19:56672574~56673901:- LIHC trans rs9611565 0.765 rs28604950 ENSG00000268568.1 AC007228.9 -12.8 6.36e-31 5.64e-24 -0.92 -0.57 Vitiligo; chr22:41389808 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs6519289 ENSG00000268568.1 AC007228.9 12.8 6.68e-31 5.92e-24 0.95 0.57 Vitiligo; chr22:41774428 chr19:56672574~56673901:- LIHC trans rs8010715 0.636 rs2277480 ENSG00000248988.1 RP11-815N9.2 12.79 7.01e-31 6.2e-24 0.73 0.57 IgG glycosylation; chr14:24118306 chr4:159007119~159007835:+ LIHC trans rs9611565 0.503 rs5751156 ENSG00000268568.1 AC007228.9 12.79 7.04e-31 6.23e-24 0.95 0.57 Vitiligo; chr22:41774021 chr19:56672574~56673901:- LIHC trans rs9467773 0.596 rs62396201 ENSG00000242375.1 RP11-498P14.3 12.79 7.23e-31 6.39e-24 0.66 0.57 Intelligence (multi-trait analysis); chr6:26667988 chr9:97195351~97197687:- LIHC trans rs13177918 0.734 rs6579790 ENSG00000224114.1 RP11-343H5.4 12.79 7.28e-31 6.44e-24 0.8 0.57 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464379 chr1:206695837~206696269:- LIHC trans rs9611565 0.512 rs139573 ENSG00000268568.1 AC007228.9 -12.77 8.35e-31 7.37e-24 -0.94 -0.57 Vitiligo; chr22:41818781 chr19:56672574~56673901:- LIHC trans rs55665837 0.778 rs11023212 ENSG00000236360.2 RP11-334A14.2 12.77 8.5e-31 7.49e-24 0.72 0.57 Vitamin D levels; chr11:14410163 chr1:52993201~52993702:- LIHC trans rs9611565 0.512 rs715498 ENSG00000268568.1 AC007228.9 12.76 8.97e-31 7.9e-24 0.95 0.57 Vitiligo; chr22:41752463 chr19:56672574~56673901:- LIHC trans rs13190036 0.892 rs71601339 ENSG00000226986.4 RP11-543B16.2 -12.75 1.01e-30 8.9e-24 -0.69 -0.57 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117495 chr1:211207239~211207897:+ LIHC trans rs8081395 0.834 rs11650106 ENSG00000187870.7 RNFT1P3 -12.74 1.09e-30 9.59e-24 -0.62 -0.57 White blood cell count; chr17:59772890 chr17:20743333~20754501:- LIHC trans rs116095464 0.558 rs9687621 ENSG00000185986.11 SDHAP3 12.73 1.21e-30 1.06e-23 1.16 0.57 Breast cancer; chr5:229079 chr5:1572222~1594620:- LIHC trans rs12709013 0.601 rs2432621 ENSG00000230849.2 GOT2P2 12.73 1.23e-30 1.08e-23 0.62 0.57 Blood metabolite ratios; chr16:58749676 chr1:173141100~173142350:- LIHC trans rs8081395 0.899 rs2645477 ENSG00000187870.7 RNFT1P3 -12.71 1.37e-30 1.2e-23 -0.62 -0.57 White blood cell count; chr17:59768263 chr17:20743333~20754501:- LIHC trans rs9611565 0.765 rs767593 ENSG00000268568.1 AC007228.9 -12.7 1.49e-30 1.3e-23 -0.92 -0.57 Vitiligo; chr22:41383967 chr19:56672574~56673901:- LIHC trans rs727563 0.648 rs6002406 ENSG00000268568.1 AC007228.9 -12.7 1.54e-30 1.35e-23 -0.95 -0.57 Crohn's disease;Inflammatory bowel disease; chr22:41569233 chr19:56672574~56673901:- LIHC trans rs12709013 0.597 rs11076259 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58749860 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs1646278 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58750084 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs1646279 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58750235 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs1646280 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58750420 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs1624301 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58753491 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs1626006 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58753691 chr1:173141100~173142350:- LIHC trans rs12709013 0.684 rs1646287 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58753774 chr1:173141100~173142350:- LIHC trans rs12709013 0.671 rs1369933 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58753927 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs1369934 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58754124 chr1:173141100~173142350:- LIHC trans rs12709013 0.613 rs1646288 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58755576 chr1:173141100~173142350:- LIHC trans rs12709013 0.561 rs727484 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58756568 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs257627 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58758956 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs191783 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58759994 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs257624 ENSG00000230849.2 GOT2P2 12.7 1.56e-30 1.36e-23 0.62 0.57 Blood metabolite ratios; chr16:58760994 chr1:173141100~173142350:- LIHC trans rs116095464 0.558 rs28636067 ENSG00000185986.11 SDHAP3 12.7 1.57e-30 1.37e-23 1.24 0.57 Breast cancer; chr5:199300 chr5:1572222~1594620:- LIHC trans rs7121616 1 rs7121616 ENSG00000234176.1 HSPA8P1 12.7 1.57e-30 1.37e-23 0.66 0.57 Breast cancer; chr11:123095918 chrX:121203182~121205014:- LIHC trans rs116095464 1 rs28416084 ENSG00000185986.11 SDHAP3 12.68 1.77e-30 1.54e-23 1.2 0.57 Breast cancer; chr5:217525 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs9312978 ENSG00000185986.11 SDHAP3 12.68 1.77e-30 1.54e-23 1.2 0.57 Breast cancer; chr5:221815 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs9312979 ENSG00000185986.11 SDHAP3 12.68 1.77e-30 1.54e-23 1.2 0.57 Breast cancer; chr5:221942 chr5:1572222~1594620:- LIHC trans rs1816752 0.646 rs3783073 ENSG00000237917.1 PARP4P1 -12.68 1.9e-30 1.65e-23 -0.62 -0.57 Obesity-related traits; chr13:24493222 chrY:26594851~26634652:- LIHC trans rs12709013 0.636 rs8060717 ENSG00000230849.2 GOT2P2 12.67 1.92e-30 1.66e-23 0.62 0.57 Blood metabolite ratios; chr16:58765574 chr1:173141100~173142350:- LIHC trans rs12709013 0.559 rs8060721 ENSG00000230849.2 GOT2P2 12.67 1.92e-30 1.66e-23 0.62 0.57 Blood metabolite ratios; chr16:58765581 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs8044542 ENSG00000230849.2 GOT2P2 12.67 1.92e-30 1.66e-23 0.62 0.57 Blood metabolite ratios; chr16:58765620 chr1:173141100~173142350:- LIHC trans rs9611565 0.918 rs9611566 ENSG00000268568.1 AC007228.9 12.67 1.96e-30 1.7e-23 0.86 0.57 Vitiligo; chr22:41372621 chr19:56672574~56673901:- LIHC trans rs61990749 0.597 rs117131659 ENSG00000235400.1 RP4-641G12.4 -12.67 1.99e-30 1.72e-23 -0.79 -0.57 Fibroblast growth factor basic levels; chr14:77664783 chr1:78749073~78750659:+ LIHC trans rs6477998 0.513 rs10981720 ENSG00000238072.1 RP11-305M3.2 12.67 2e-30 1.74e-23 0.83 0.57 Hematology traits; chr9:113293831 chr7:129410113~129410370:- LIHC trans rs727563 0.635 rs5758444 ENSG00000268568.1 AC007228.9 12.67 2.02e-30 1.75e-23 0.92 0.57 Crohn's disease;Inflammatory bowel disease; chr22:41737917 chr19:56672574~56673901:- LIHC trans rs9611565 0.592 rs4822044 ENSG00000268568.1 AC007228.9 -12.67 2.02e-30 1.75e-23 -0.96 -0.57 Vitiligo; chr22:41583664 chr19:56672574~56673901:- LIHC trans rs727563 0.608 rs2076200 ENSG00000268568.1 AC007228.9 -12.67 2.02e-30 1.75e-23 -0.96 -0.57 Crohn's disease;Inflammatory bowel disease; chr22:41589952 chr19:56672574~56673901:- LIHC trans rs727563 0.552 rs4822045 ENSG00000268568.1 AC007228.9 -12.67 2.02e-30 1.75e-23 -0.96 -0.57 Crohn's disease;Inflammatory bowel disease; chr22:41589954 chr19:56672574~56673901:- LIHC trans rs9611565 0.559 rs9611619 ENSG00000268568.1 AC007228.9 -12.67 2.02e-30 1.75e-23 -0.96 -0.57 Vitiligo; chr22:41590710 chr19:56672574~56673901:- LIHC trans rs9611565 0.592 rs4822046 ENSG00000268568.1 AC007228.9 -12.67 2.02e-30 1.75e-23 -0.96 -0.57 Vitiligo; chr22:41591539 chr19:56672574~56673901:- LIHC trans rs9611565 0.559 rs4822048 ENSG00000268568.1 AC007228.9 -12.67 2.02e-30 1.75e-23 -0.96 -0.57 Vitiligo; chr22:41592221 chr19:56672574~56673901:- LIHC trans rs9611565 0.559 rs4822049 ENSG00000268568.1 AC007228.9 -12.67 2.02e-30 1.75e-23 -0.96 -0.57 Vitiligo; chr22:41597492 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs12325516 ENSG00000230849.2 GOT2P2 12.66 2.1e-30 1.81e-23 0.62 0.57 Blood metabolite ratios; chr16:58749899 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs11076260 ENSG00000230849.2 GOT2P2 12.66 2.14e-30 1.85e-23 0.62 0.56 Blood metabolite ratios; chr16:58749942 chr1:173141100~173142350:- LIHC trans rs9611565 0.512 rs9607841 ENSG00000268568.1 AC007228.9 -12.65 2.27e-30 1.96e-23 -0.94 -0.56 Vitiligo; chr22:41790834 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs9611667 ENSG00000268568.1 AC007228.9 -12.65 2.27e-30 1.96e-23 -0.94 -0.56 Vitiligo; chr22:41791011 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs9607842 ENSG00000268568.1 AC007228.9 -12.65 2.27e-30 1.96e-23 -0.94 -0.56 Vitiligo; chr22:41796718 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs132767 ENSG00000268568.1 AC007228.9 -12.64 2.67e-30 2.29e-23 -0.9 -0.56 Vitiligo; chr22:41613516 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs139561 ENSG00000268568.1 AC007228.9 12.62 2.97e-30 2.54e-23 0.91 0.56 Vitiligo; chr22:41799406 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs1646256 ENSG00000233719.3 GOT2P3 12.62 3.05e-30 2.61e-23 0.59 0.56 Blood metabolite ratios; chr16:58712114 chr12:9641802~9643007:+ LIHC trans rs9611565 0.918 rs9611561 ENSG00000268568.1 AC007228.9 -12.62 3.13e-30 2.68e-23 -0.87 -0.56 Vitiligo; chr22:41361230 chr19:56672574~56673901:- LIHC trans rs12709013 0.597 rs1657171 ENSG00000230849.2 GOT2P2 12.61 3.37e-30 2.88e-23 0.62 0.56 Blood metabolite ratios; chr16:58752083 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs1646285 ENSG00000230849.2 GOT2P2 12.61 3.37e-30 2.88e-23 0.62 0.56 Blood metabolite ratios; chr16:58752102 chr1:173141100~173142350:- LIHC trans rs9611565 0.918 rs9611562 ENSG00000268568.1 AC007228.9 -12.61 3.5e-30 2.99e-23 -0.87 -0.56 Vitiligo; chr22:41364168 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs1646268 ENSG00000233719.3 GOT2P3 12.6 3.58e-30 3.06e-23 0.57 0.56 Blood metabolite ratios; chr16:58743292 chr12:9641802~9643007:+ LIHC trans rs12709013 0.597 rs1646286 ENSG00000230849.2 GOT2P2 12.6 3.67e-30 3.13e-23 0.62 0.56 Blood metabolite ratios; chr16:58752651 chr1:173141100~173142350:- LIHC trans rs9611565 0.84 rs3788584 ENSG00000268568.1 AC007228.9 -12.58 4.25e-30 3.62e-23 -0.9 -0.56 Vitiligo; chr22:41383069 chr19:56672574~56673901:- LIHC trans rs61990749 0.597 rs10142722 ENSG00000235400.1 RP4-641G12.4 12.58 4.27e-30 3.63e-23 0.8 0.56 Fibroblast growth factor basic levels; chr14:77809206 chr1:78749073~78750659:+ LIHC trans rs9611565 0.527 rs2234053 ENSG00000268568.1 AC007228.9 -12.58 4.34e-30 3.69e-23 -0.9 -0.56 Vitiligo; chr22:41381311 chr19:56672574~56673901:- LIHC trans rs9611565 0.802 rs2234058 ENSG00000268568.1 AC007228.9 -12.58 4.34e-30 3.69e-23 -0.9 -0.56 Vitiligo; chr22:41381879 chr19:56672574~56673901:- LIHC trans rs9611565 0.84 rs2234059 ENSG00000268568.1 AC007228.9 -12.58 4.34e-30 3.69e-23 -0.9 -0.56 Vitiligo; chr22:41381909 chr19:56672574~56673901:- LIHC trans rs12709013 0.621 rs6499974 ENSG00000230849.2 GOT2P2 12.57 4.57e-30 3.88e-23 0.61 0.56 Blood metabolite ratios; chr16:58769642 chr1:173141100~173142350:- LIHC trans rs7121616 0.96 rs7122306 ENSG00000234176.1 HSPA8P1 12.57 4.68e-30 3.98e-23 0.66 0.56 Breast cancer; chr11:123096254 chrX:121203182~121205014:- LIHC trans rs116095464 0.558 rs6878087 ENSG00000185986.11 SDHAP3 -12.57 4.93e-30 4.19e-23 -1.04 -0.56 Breast cancer; chr5:223002 chr5:1572222~1594620:- LIHC trans rs12709013 0.561 rs1657174 ENSG00000230849.2 GOT2P2 12.56 5.11e-30 4.33e-23 0.61 0.56 Blood metabolite ratios; chr16:58755139 chr1:173141100~173142350:- LIHC trans rs9611565 0.802 rs9611577 ENSG00000268568.1 AC007228.9 -12.56 5.4e-30 4.57e-23 -0.9 -0.56 Vitiligo; chr22:41397086 chr19:56672574~56673901:- LIHC trans rs8081395 0.932 rs2777885 ENSG00000187870.7 RNFT1P3 -12.55 5.43e-30 4.6e-23 -0.62 -0.56 White blood cell count; chr17:59753112 chr17:20743333~20754501:- LIHC trans rs9611565 0.918 rs12484074 ENSG00000268568.1 AC007228.9 -12.55 5.44e-30 4.61e-23 -0.87 -0.56 Vitiligo; chr22:41356743 chr19:56672574~56673901:- LIHC trans rs13177918 0.603 rs2343806 ENSG00000213058.3 RP4-765C7.2 12.55 5.83e-30 4.93e-23 0.71 0.56 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452422 chr1:178411616~178411972:+ LIHC trans rs8081395 0.834 rs2665397 ENSG00000187870.7 RNFT1P3 -12.55 5.87e-30 4.96e-23 -0.62 -0.56 White blood cell count; chr17:59749370 chr17:20743333~20754501:- LIHC trans rs8081395 0.804 rs2777884 ENSG00000187870.7 RNFT1P3 -12.55 5.87e-30 4.96e-23 -0.62 -0.56 White blood cell count; chr17:59753065 chr17:20743333~20754501:- LIHC trans rs8081395 0.866 rs2777899 ENSG00000187870.7 RNFT1P3 -12.55 5.87e-30 4.96e-23 -0.62 -0.56 White blood cell count; chr17:59755030 chr17:20743333~20754501:- LIHC trans rs13177918 0.734 rs6579791 ENSG00000224114.1 RP11-343H5.4 12.54 5.96e-30 5.03e-23 0.79 0.56 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464440 chr1:206695837~206696269:- LIHC trans rs116095464 0.558 rs10065239 ENSG00000185986.11 SDHAP3 12.54 5.97e-30 5.03e-23 1.15 0.56 Breast cancer; chr5:275173 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs10056628 ENSG00000185986.11 SDHAP3 12.54 5.97e-30 5.03e-23 1.15 0.56 Breast cancer; chr5:279397 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs56298907 ENSG00000185986.11 SDHAP3 12.54 5.97e-30 5.03e-23 1.15 0.56 Breast cancer; chr5:283165 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs7356535 ENSG00000185986.11 SDHAP3 12.54 5.97e-30 5.03e-23 1.15 0.56 Breast cancer; chr5:284002 chr5:1572222~1594620:- LIHC trans rs116095464 0.558 rs55833259 ENSG00000185986.11 SDHAP3 12.54 5.97e-30 5.03e-23 1.15 0.56 Breast cancer; chr5:286613 chr5:1572222~1594620:- LIHC trans rs8081395 0.899 rs2777898 ENSG00000187870.7 RNFT1P3 -12.54 6.02e-30 5.08e-23 -0.62 -0.56 White blood cell count; chr17:59738247 chr17:20743333~20754501:- LIHC trans rs7121616 0.961 rs11218976 ENSG00000234176.1 HSPA8P1 12.54 6.19e-30 5.22e-23 0.64 0.56 Breast cancer; chr11:123090950 chrX:121203182~121205014:- LIHC trans rs12709013 0.636 rs1865836 ENSG00000230849.2 GOT2P2 12.54 6.3e-30 5.31e-23 0.61 0.56 Blood metabolite ratios; chr16:58768143 chr1:173141100~173142350:- LIHC trans rs12709013 0.636 rs10852565 ENSG00000230849.2 GOT2P2 12.52 7.09e-30 5.95e-23 0.62 0.56 Blood metabolite ratios; chr16:58771277 chr1:173141100~173142350:- LIHC trans rs616147 0.627 rs9871799 ENSG00000214263.2 RPSAP53 12.52 7.5e-30 6.29e-23 0.75 0.56 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39442829 chr13:67266845~67267706:- LIHC trans rs9611565 0.512 rs9611672 ENSG00000268568.1 AC007228.9 -12.51 7.82e-30 6.56e-23 -0.92 -0.56 Vitiligo; chr22:41813918 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs8054414 ENSG00000230849.2 GOT2P2 12.51 8.17e-30 6.85e-23 0.62 0.56 Blood metabolite ratios; chr16:58749772 chr1:173141100~173142350:- LIHC trans rs9611565 0.512 rs4512 ENSG00000268568.1 AC007228.9 -12.5 8.63e-30 7.22e-23 -0.91 -0.56 Vitiligo; chr22:41810080 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs1646272 ENSG00000233719.3 GOT2P3 12.5 8.79e-30 7.35e-23 0.57 0.56 Blood metabolite ratios; chr16:58746508 chr12:9641802~9643007:+ LIHC trans rs12709013 0.66 rs1657163 ENSG00000233719.3 GOT2P3 12.5 8.79e-30 7.35e-23 0.57 0.56 Blood metabolite ratios; chr16:58746688 chr12:9641802~9643007:+ LIHC trans rs10865397 0.506 rs6546810 ENSG00000236165.1 PRADC1P1 12.49 9.24e-30 7.72e-23 0.73 0.56 Intelligence (multi-trait analysis); chr2:73162588 chr3:36976316~36976840:+ LIHC trans rs12709013 0.636 rs257628 ENSG00000230849.2 GOT2P2 12.49 9.67e-30 8.08e-23 0.61 0.56 Blood metabolite ratios; chr16:58758924 chr1:173141100~173142350:- LIHC trans rs9611565 0.512 rs139562 ENSG00000268568.1 AC007228.9 -12.48 9.94e-30 8.29e-23 -0.92 -0.56 Vitiligo; chr22:41800680 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs139566 ENSG00000268568.1 AC007228.9 -12.48 9.94e-30 8.29e-23 -0.92 -0.56 Vitiligo; chr22:41803273 chr19:56672574~56673901:- LIHC trans rs61990749 0.597 rs59848135 ENSG00000235400.1 RP4-641G12.4 -12.46 1.19e-29 9.88e-23 -0.79 -0.56 Fibroblast growth factor basic levels; chr14:77662657 chr1:78749073~78750659:+ LIHC trans rs12709013 0.613 rs4238801 ENSG00000233719.3 GOT2P3 12.46 1.19e-29 9.89e-23 0.58 0.56 Blood metabolite ratios; chr16:58738275 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs4575523 ENSG00000233719.3 GOT2P3 12.46 1.19e-29 9.89e-23 0.58 0.56 Blood metabolite ratios; chr16:58738559 chr12:9641802~9643007:+ LIHC trans rs13177918 0.734 rs6579790 ENSG00000213058.3 RP4-765C7.2 12.46 1.22e-29 1.01e-22 0.78 0.56 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464379 chr1:178411616~178411972:+ LIHC trans rs13190036 1 rs13157667 ENSG00000226986.4 RP11-543B16.2 -12.45 1.34e-29 1.11e-22 -0.67 -0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177186876 chr1:211207239~211207897:+ LIHC trans rs13190036 1 rs13167431 ENSG00000226986.4 RP11-543B16.2 -12.45 1.34e-29 1.11e-22 -0.67 -0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177194074 chr1:211207239~211207897:+ LIHC trans rs13190036 1 rs35535623 ENSG00000226986.4 RP11-543B16.2 -12.45 1.34e-29 1.11e-22 -0.67 -0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177202295 chr1:211207239~211207897:+ LIHC trans rs13190036 1 rs71601343 ENSG00000226986.4 RP11-543B16.2 -12.45 1.34e-29 1.11e-22 -0.67 -0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177205106 chr1:211207239~211207897:+ LIHC trans rs13190036 1 rs71601344 ENSG00000226986.4 RP11-543B16.2 -12.45 1.34e-29 1.11e-22 -0.67 -0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206492 chr1:211207239~211207897:+ LIHC trans rs13190036 1 rs3733875 ENSG00000226986.4 RP11-543B16.2 -12.45 1.34e-29 1.11e-22 -0.67 -0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210239 chr1:211207239~211207897:+ LIHC trans rs13190036 1 rs34446750 ENSG00000226986.4 RP11-543B16.2 -12.45 1.35e-29 1.12e-22 -0.67 -0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177168079 chr1:211207239~211207897:+ LIHC trans rs12709013 0.636 rs9937713 ENSG00000230849.2 GOT2P2 12.45 1.38e-29 1.14e-22 0.61 0.56 Blood metabolite ratios; chr16:58771921 chr1:173141100~173142350:- LIHC trans rs13190036 1 rs13177748 ENSG00000226986.4 RP11-543B16.2 -12.44 1.42e-29 1.18e-22 -0.67 -0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177216953 chr1:211207239~211207897:+ LIHC trans rs727563 0.555 rs5751136 ENSG00000268568.1 AC007228.9 12.43 1.58e-29 1.31e-22 0.88 0.56 Crohn's disease;Inflammatory bowel disease; chr22:41679577 chr19:56672574~56673901:- LIHC trans rs13190036 1 rs13185316 ENSG00000226986.4 RP11-543B16.2 -12.43 1.65e-29 1.37e-22 -0.67 -0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177213339 chr1:211207239~211207897:+ LIHC trans rs12709013 0.536 rs1646260 ENSG00000233719.3 GOT2P3 12.42 1.69e-29 1.4e-22 0.59 0.56 Blood metabolite ratios; chr16:58734951 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs1657161 ENSG00000233719.3 GOT2P3 12.41 1.81e-29 1.5e-22 0.56 0.56 Blood metabolite ratios; chr16:58743234 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs1646269 ENSG00000233719.3 GOT2P3 12.41 1.81e-29 1.5e-22 0.56 0.56 Blood metabolite ratios; chr16:58743412 chr12:9641802~9643007:+ LIHC trans rs9611565 0.918 rs7290404 ENSG00000268568.1 AC007228.9 -12.41 1.86e-29 1.54e-22 -0.86 -0.56 Vitiligo; chr22:41353792 chr19:56672574~56673901:- LIHC trans rs8010715 0.636 rs3825584 ENSG00000248988.1 RP11-815N9.2 12.41 1.86e-29 1.54e-22 0.71 0.56 IgG glycosylation; chr14:24118430 chr4:159007119~159007835:+ LIHC trans rs916888 0.821 rs199499 ENSG00000264070.1 DND1P1 12.4 2.1e-29 1.73e-22 1.15 0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788132 chr17:45585871~45586929:+ LIHC trans rs9467773 0.595 rs13207371 ENSG00000242375.1 RP11-498P14.3 12.39 2.19e-29 1.8e-22 0.65 0.56 Intelligence (multi-trait analysis); chr6:26590846 chr9:97195351~97197687:- LIHC trans rs9611565 0.559 rs5751160 ENSG00000268568.1 AC007228.9 12.39 2.32e-29 1.9e-22 0.93 0.56 Vitiligo; chr22:41779691 chr19:56672574~56673901:- LIHC trans rs116095464 0.558 rs6555058 ENSG00000185986.11 SDHAP3 -12.38 2.52e-29 2.07e-22 -1.04 -0.56 Breast cancer; chr5:226261 chr5:1572222~1594620:- LIHC trans rs12291225 0.839 rs4757244 ENSG00000236360.2 RP11-334A14.2 -12.37 2.7e-29 2.21e-22 -0.7 -0.56 Sense of smell; chr11:14237109 chr1:52993201~52993702:- LIHC trans rs9611565 0.512 rs5758465 ENSG00000268568.1 AC007228.9 12.37 2.76e-29 2.26e-22 0.93 0.56 Vitiligo; chr22:41779310 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs4820444 ENSG00000268568.1 AC007228.9 12.36 2.85e-29 2.33e-22 0.91 0.56 Vitiligo; chr22:41806602 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs4538000 ENSG00000233719.3 GOT2P3 12.36 2.94e-29 2.4e-22 0.56 0.56 Blood metabolite ratios; chr16:58744506 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs1646282 ENSG00000233719.3 GOT2P3 12.34 3.32e-29 2.7e-22 0.56 0.56 Blood metabolite ratios; chr16:58741296 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs4784977 ENSG00000233719.3 GOT2P3 12.34 3.32e-29 2.7e-22 0.56 0.56 Blood metabolite ratios; chr16:58742120 chr12:9641802~9643007:+ LIHC trans rs61990749 0.597 rs1006039 ENSG00000235400.1 RP4-641G12.4 -12.34 3.56e-29 2.9e-22 -0.85 -0.55 Fibroblast growth factor basic levels; chr14:77796853 chr1:78749073~78750659:+ LIHC trans rs9611565 0.802 rs4822028 ENSG00000268568.1 AC007228.9 -12.33 3.75e-29 3.05e-22 -0.85 -0.55 Vitiligo; chr22:41393404 chr19:56672574~56673901:- LIHC trans rs12709013 0.585 rs7188608 ENSG00000233719.3 GOT2P3 12.33 3.81e-29 3.09e-22 0.56 0.55 Blood metabolite ratios; chr16:58736236 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs1657176 ENSG00000233719.3 GOT2P3 12.33 3.81e-29 3.09e-22 0.56 0.55 Blood metabolite ratios; chr16:58736833 chr12:9641802~9643007:+ LIHC trans rs13190036 0.901 rs55741473 ENSG00000226986.4 RP11-543B16.2 -12.32 3.97e-29 3.22e-22 -0.67 -0.55 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147218 chr1:211207239~211207897:+ LIHC trans rs9611565 0.729 rs73176689 ENSG00000268568.1 AC007228.9 -12.31 4.34e-29 3.52e-22 -0.91 -0.55 Vitiligo; chr22:41386629 chr19:56672574~56673901:- LIHC trans rs9611565 0.729 rs132902 ENSG00000268568.1 AC007228.9 -12.3 4.66e-29 3.77e-22 -0.85 -0.55 Vitiligo; chr22:41401754 chr19:56672574~56673901:- LIHC trans rs7949030 1 rs7949030 ENSG00000186676.3 EEF1GP1 12.3 4.83e-29 3.91e-22 0.82 0.55 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62627409 chr7:125033453~125035301:+ LIHC trans rs12709013 0.636 rs72792430 ENSG00000233719.3 GOT2P3 -12.28 5.67e-29 4.58e-22 -0.56 -0.55 Blood metabolite ratios; chr16:58746990 chr12:9641802~9643007:+ LIHC trans rs12709013 0.597 rs1616072 ENSG00000233719.3 GOT2P3 12.28 5.67e-29 4.58e-22 0.56 0.55 Blood metabolite ratios; chr16:58747194 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs2575374 ENSG00000233719.3 GOT2P3 12.28 5.67e-29 4.58e-22 0.56 0.55 Blood metabolite ratios; chr16:58747494 chr12:9641802~9643007:+ LIHC trans rs12709013 0.537 rs1657167 ENSG00000233719.3 GOT2P3 12.28 5.67e-29 4.58e-22 0.56 0.55 Blood metabolite ratios; chr16:58748955 chr12:9641802~9643007:+ LIHC trans rs6732160 0.834 rs57456443 ENSG00000236165.1 PRADC1P1 12.27 6.16e-29 4.96e-22 0.7 0.55 Intelligence (multi-trait analysis); chr2:73139313 chr3:36976316~36976840:+ LIHC trans rs12709013 0.591 rs30842 ENSG00000233719.3 GOT2P3 -12.26 7.12e-29 5.72e-22 -0.63 -0.55 Blood metabolite ratios; chr16:58709550 chr12:9641802~9643007:+ LIHC trans rs9611565 0.546 rs2092274 ENSG00000268568.1 AC007228.9 12.25 7.34e-29 5.89e-22 0.84 0.55 Vitiligo; chr22:41727733 chr19:56672574~56673901:- LIHC trans rs9611565 0.921 rs3927 ENSG00000268568.1 AC007228.9 -12.25 7.51e-29 6.02e-22 -0.83 -0.55 Vitiligo; chr22:41326860 chr19:56672574~56673901:- LIHC trans rs9611565 0.918 rs9538 ENSG00000268568.1 AC007228.9 -12.24 8.47e-29 6.78e-22 -0.86 -0.55 Vitiligo; chr22:41359853 chr19:56672574~56673901:- LIHC trans rs13177918 0.734 rs6579791 ENSG00000213058.3 RP4-765C7.2 12.22 9.3e-29 7.43e-22 0.77 0.55 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464440 chr1:178411616~178411972:+ LIHC trans rs9467773 1 rs9467791 ENSG00000242375.1 RP11-498P14.3 -12.22 9.35e-29 7.47e-22 -0.64 -0.55 Intelligence (multi-trait analysis); chr6:26562258 chr9:97195351~97197687:- LIHC trans rs9611565 0.546 rs5758430 ENSG00000268568.1 AC007228.9 12.22 9.42e-29 7.52e-22 0.84 0.55 Vitiligo; chr22:41713840 chr19:56672574~56673901:- LIHC trans rs9611565 0.546 rs5758431 ENSG00000268568.1 AC007228.9 12.22 9.42e-29 7.52e-22 0.84 0.55 Vitiligo; chr22:41713913 chr19:56672574~56673901:- LIHC trans rs2950393 0.611 rs7138821 ENSG00000121089.4 NACA3P -12.2 1.1e-28 8.75e-22 -0.62 -0.55 Platelet distribution width; chr12:56796206 chr4:164943290~164943937:+ LIHC trans rs9611565 0.592 rs5758427 ENSG00000268568.1 AC007228.9 12.2 1.16e-28 9.2e-22 0.84 0.55 Vitiligo; chr22:41703684 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs1657164 ENSG00000233719.3 GOT2P3 12.19 1.26e-28 1e-21 0.56 0.55 Blood metabolite ratios; chr16:58747949 chr12:9641802~9643007:+ LIHC trans rs9467773 1 rs6922824 ENSG00000242375.1 RP11-498P14.3 -12.18 1.34e-28 1.07e-21 -0.63 -0.55 Intelligence (multi-trait analysis); chr6:26553587 chr9:97195351~97197687:- LIHC trans rs12709013 0.613 rs1657178 ENSG00000233719.3 GOT2P3 12.18 1.37e-28 1.09e-21 0.55 0.55 Blood metabolite ratios; chr16:58735300 chr12:9641802~9643007:+ LIHC trans rs727563 0.638 rs4820443 ENSG00000268568.1 AC007228.9 -12.18 1.39e-28 1.1e-21 -0.89 -0.55 Crohn's disease;Inflammatory bowel disease; chr22:41797909 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs12325516 ENSG00000233719.3 GOT2P3 12.17 1.46e-28 1.16e-21 0.57 0.55 Blood metabolite ratios; chr16:58749899 chr12:9641802~9643007:+ LIHC trans rs9611565 0.84 rs4822025 ENSG00000268568.1 AC007228.9 -12.17 1.49e-28 1.18e-21 -0.88 -0.55 Vitiligo; chr22:41380642 chr19:56672574~56673901:- LIHC trans rs116095464 0.558 rs9654453 ENSG00000185986.11 SDHAP3 12.16 1.59e-28 1.26e-21 1.13 0.55 Breast cancer; chr5:299506 chr5:1572222~1594620:- LIHC trans rs12709013 0.601 rs2432621 ENSG00000233719.3 GOT2P3 12.16 1.61e-28 1.28e-21 0.56 0.55 Blood metabolite ratios; chr16:58749676 chr12:9641802~9643007:+ LIHC trans rs12367822 0.597 rs2371559 ENSG00000121089.4 NACA3P -12.15 1.8e-28 1.43e-21 -0.62 -0.55 Platelet aggregation; chr12:56805073 chr4:164943290~164943937:+ LIHC trans rs12709013 0.576 rs2432622 ENSG00000233719.3 GOT2P3 12.14 1.91e-28 1.51e-21 0.58 0.55 Blood metabolite ratios; chr16:58749681 chr12:9641802~9643007:+ LIHC trans rs7811142 0.775 rs1059129 ENSG00000228546.2 CTA-313A17.3 12.13 2.05e-28 1.62e-21 0.9 0.55 Platelet count; chr7:100328899 chr7:102337316~102339115:+ LIHC trans rs13177918 0.717 rs6874318 ENSG00000224114.1 RP11-343H5.4 -12.12 2.19e-28 1.72e-21 -0.74 -0.55 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150462836 chr1:206695837~206696269:- LIHC trans rs12709013 0.636 rs11076260 ENSG00000233719.3 GOT2P3 12.12 2.21e-28 1.73e-21 0.56 0.55 Blood metabolite ratios; chr16:58749942 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs8060717 ENSG00000233719.3 GOT2P3 12.12 2.26e-28 1.77e-21 0.56 0.55 Blood metabolite ratios; chr16:58765574 chr12:9641802~9643007:+ LIHC trans rs12709013 0.559 rs8060721 ENSG00000233719.3 GOT2P3 12.12 2.26e-28 1.77e-21 0.56 0.55 Blood metabolite ratios; chr16:58765581 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs8044542 ENSG00000233719.3 GOT2P3 12.12 2.26e-28 1.77e-21 0.56 0.55 Blood metabolite ratios; chr16:58765620 chr12:9641802~9643007:+ LIHC trans rs55665837 1 rs10832275 ENSG00000236360.2 RP11-334A14.2 12.11 2.51e-28 1.96e-21 0.68 0.55 Vitamin D levels; chr11:14456678 chr1:52993201~52993702:- LIHC trans rs7811142 0.667 rs3873746 ENSG00000228546.2 CTA-313A17.3 12.1 2.67e-28 2.09e-21 0.89 0.55 Platelet count; chr7:100337474 chr7:102337316~102339115:+ LIHC trans rs12709013 0.597 rs11076259 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58749860 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs1646278 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58750084 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs1646279 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58750235 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs1646280 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58750420 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs1624301 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58753491 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs1626006 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58753691 chr12:9641802~9643007:+ LIHC trans rs12709013 0.684 rs1646287 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58753774 chr12:9641802~9643007:+ LIHC trans rs12709013 0.671 rs1369933 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58753927 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs1369934 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58754124 chr12:9641802~9643007:+ LIHC trans rs12709013 0.613 rs1646288 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58755576 chr12:9641802~9643007:+ LIHC trans rs12709013 0.561 rs727484 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58756568 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs257627 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58758956 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs191783 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58759994 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs257624 ENSG00000233719.3 GOT2P3 12.09 2.84e-28 2.21e-21 0.56 0.55 Blood metabolite ratios; chr16:58760994 chr12:9641802~9643007:+ LIHC trans rs55665837 1 rs7121171 ENSG00000236360.2 RP11-334A14.2 12.09 2.92e-28 2.27e-21 0.67 0.55 Vitamin D levels; chr11:14424874 chr1:52993201~52993702:- LIHC trans rs12709013 0.636 rs8045466 ENSG00000233719.3 GOT2P3 12.08 3.11e-28 2.41e-21 0.57 0.55 Blood metabolite ratios; chr16:58765113 chr12:9641802~9643007:+ LIHC trans rs55665837 1 rs4412729 ENSG00000236360.2 RP11-334A14.2 12.08 3.18e-28 2.47e-21 0.67 0.55 Vitamin D levels; chr11:14417454 chr1:52993201~52993702:- LIHC trans rs12709013 0.597 rs1657171 ENSG00000233719.3 GOT2P3 12.08 3.19e-28 2.47e-21 0.56 0.55 Blood metabolite ratios; chr16:58752083 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs1646285 ENSG00000233719.3 GOT2P3 12.08 3.19e-28 2.47e-21 0.56 0.55 Blood metabolite ratios; chr16:58752102 chr12:9641802~9643007:+ LIHC trans rs55665837 1 rs2305305 ENSG00000236360.2 RP11-334A14.2 12.08 3.31e-28 2.57e-21 0.68 0.55 Vitamin D levels; chr11:14519396 chr1:52993201~52993702:- LIHC trans rs13190036 0.792 rs6874206 ENSG00000226986.4 RP11-543B16.2 -12.07 3.45e-28 2.67e-21 -0.64 -0.55 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177223970 chr1:211207239~211207897:+ LIHC trans rs13190036 0.901 rs10072499 ENSG00000226986.4 RP11-543B16.2 -12.07 3.45e-28 2.67e-21 -0.64 -0.55 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228236 chr1:211207239~211207897:+ LIHC trans rs9611565 0.921 rs6002333 ENSG00000268568.1 AC007228.9 -12.07 3.51e-28 2.71e-21 -0.82 -0.55 Vitiligo; chr22:41323465 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs1646281 ENSG00000233719.3 GOT2P3 12.06 3.65e-28 2.82e-21 0.57 0.55 Blood metabolite ratios; chr16:58750512 chr12:9641802~9643007:+ LIHC trans rs12709013 0.613 rs1618602 ENSG00000233719.3 GOT2P3 12.06 3.65e-28 2.82e-21 0.57 0.55 Blood metabolite ratios; chr16:58756080 chr12:9641802~9643007:+ LIHC trans rs12709013 0.613 rs8049462 ENSG00000233719.3 GOT2P3 12.06 3.65e-28 2.82e-21 0.57 0.55 Blood metabolite ratios; chr16:58757654 chr12:9641802~9643007:+ LIHC trans rs12709013 0.66 rs257629 ENSG00000233719.3 GOT2P3 12.06 3.65e-28 2.82e-21 0.57 0.55 Blood metabolite ratios; chr16:58758044 chr12:9641802~9643007:+ LIHC trans rs7811142 0.562 rs7786844 ENSG00000228546.2 CTA-313A17.3 12.06 3.66e-28 2.82e-21 0.89 0.55 Platelet count; chr7:100336385 chr7:102337316~102339115:+ LIHC trans rs55665837 0.922 rs12287212 ENSG00000236360.2 RP11-334A14.2 12.05 4.07e-28 3.13e-21 0.67 0.55 Vitamin D levels; chr11:14428315 chr1:52993201~52993702:- LIHC trans rs2657294 0.62 rs9783273 ENSG00000172974.11 AC007318.5 12.05 4.22e-28 3.25e-21 0.64 0.55 Pneumonia; chr10:75081982 chr2:65205108~65205988:+ LIHC trans rs55665837 1 rs12792120 ENSG00000236360.2 RP11-334A14.2 12.05 4.25e-28 3.26e-21 0.67 0.55 Vitamin D levels; chr11:14447897 chr1:52993201~52993702:- LIHC trans rs9611565 0.802 rs9611571 ENSG00000268568.1 AC007228.9 -12.04 4.36e-28 3.35e-21 -0.86 -0.55 Vitiligo; chr22:41388863 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs1646284 ENSG00000233719.3 GOT2P3 12.04 4.48e-28 3.44e-21 0.58 0.55 Blood metabolite ratios; chr16:58752093 chr12:9641802~9643007:+ LIHC trans rs55665837 1 rs10832268 ENSG00000236360.2 RP11-334A14.2 12.04 4.49e-28 3.44e-21 0.67 0.55 Vitamin D levels; chr11:14443522 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs10832269 ENSG00000236360.2 RP11-334A14.2 12.04 4.49e-28 3.44e-21 0.67 0.55 Vitamin D levels; chr11:14443523 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs10832271 ENSG00000236360.2 RP11-334A14.2 12.04 4.49e-28 3.44e-21 0.67 0.55 Vitamin D levels; chr11:14445373 chr1:52993201~52993702:- LIHC trans rs55665837 0.961 rs12576926 ENSG00000236360.2 RP11-334A14.2 12.04 4.49e-28 3.44e-21 0.67 0.55 Vitamin D levels; chr11:14458746 chr1:52993201~52993702:- LIHC trans rs13190036 1 rs625882 ENSG00000226986.4 RP11-543B16.2 -12.04 4.57e-28 3.5e-21 -0.65 -0.55 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177108030 chr1:211207239~211207897:+ LIHC trans rs12709013 0.636 rs1865836 ENSG00000233719.3 GOT2P3 12.04 4.63e-28 3.55e-21 0.56 0.55 Blood metabolite ratios; chr16:58768143 chr12:9641802~9643007:+ LIHC trans rs55665837 1 rs10832276 ENSG00000236360.2 RP11-334A14.2 12.02 5.18e-28 3.96e-21 0.68 0.55 Vitamin D levels; chr11:14461728 chr1:52993201~52993702:- LIHC trans rs2657294 0.62 rs4746259 ENSG00000172974.11 AC007318.5 12.02 5.53e-28 4.23e-21 0.64 0.54 Pneumonia; chr10:75082310 chr2:65205108~65205988:+ LIHC trans rs12709013 0.591 rs4784986 ENSG00000233719.3 GOT2P3 12.01 5.58e-28 4.27e-21 0.58 0.54 Blood metabolite ratios; chr16:58803007 chr12:9641802~9643007:+ LIHC trans rs12709013 0.597 rs1646286 ENSG00000233719.3 GOT2P3 12 6.13e-28 4.67e-21 0.56 0.54 Blood metabolite ratios; chr16:58752651 chr12:9641802~9643007:+ LIHC trans rs55665837 1 rs12804549 ENSG00000236360.2 RP11-334A14.2 12 6.16e-28 4.7e-21 0.66 0.54 Vitamin D levels; chr11:14416212 chr1:52993201~52993702:- LIHC trans rs12709013 0.621 rs6499974 ENSG00000233719.3 GOT2P3 11.99 6.6e-28 5.03e-21 0.56 0.54 Blood metabolite ratios; chr16:58769642 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs6499976 ENSG00000233719.3 GOT2P3 11.99 6.72e-28 5.11e-21 0.56 0.54 Blood metabolite ratios; chr16:58770330 chr12:9641802~9643007:+ LIHC trans rs55665837 1 rs10047429 ENSG00000236360.2 RP11-334A14.2 11.98 7.18e-28 5.45e-21 0.67 0.54 Vitamin D levels; chr11:14417486 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs10047457 ENSG00000236360.2 RP11-334A14.2 11.98 7.18e-28 5.45e-21 0.67 0.54 Vitamin D levels; chr11:14417913 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs3923294 ENSG00000236360.2 RP11-334A14.2 11.98 7.18e-28 5.45e-21 0.67 0.54 Vitamin D levels; chr11:14419856 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs12283797 ENSG00000236360.2 RP11-334A14.2 11.98 7.18e-28 5.45e-21 0.67 0.54 Vitamin D levels; chr11:14420716 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs10832256 ENSG00000236360.2 RP11-334A14.2 11.98 7.18e-28 5.45e-21 0.67 0.54 Vitamin D levels; chr11:14421329 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs10832257 ENSG00000236360.2 RP11-334A14.2 11.98 7.18e-28 5.45e-21 0.67 0.54 Vitamin D levels; chr11:14421770 chr1:52993201~52993702:- LIHC trans rs55665837 0.961 rs12795972 ENSG00000236360.2 RP11-334A14.2 11.98 7.18e-28 5.45e-21 0.67 0.54 Vitamin D levels; chr11:14422229 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs12287715 ENSG00000236360.2 RP11-334A14.2 11.98 7.18e-28 5.45e-21 0.67 0.54 Vitamin D levels; chr11:14423029 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs12295723 ENSG00000236360.2 RP11-334A14.2 11.98 7.18e-28 5.45e-21 0.67 0.54 Vitamin D levels; chr11:14428655 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs12288873 ENSG00000236360.2 RP11-334A14.2 11.98 7.18e-28 5.45e-21 0.67 0.54 Vitamin D levels; chr11:14428919 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs12295888 ENSG00000236360.2 RP11-334A14.2 11.98 7.18e-28 5.45e-21 0.67 0.54 Vitamin D levels; chr11:14428985 chr1:52993201~52993702:- LIHC trans rs12709013 0.636 rs1595180 ENSG00000233719.3 GOT2P3 11.98 7.58e-28 5.74e-21 0.55 0.54 Blood metabolite ratios; chr16:58770545 chr12:9641802~9643007:+ LIHC trans rs928391 0.592 rs7522395 ENSG00000227183.3 HDGFP1 -11.97 8.1e-28 6.12e-21 -0.84 -0.54 Platelet count; chr1:156826905 chrX:131646639~131646890:+ LIHC trans rs12709013 0.636 rs8054414 ENSG00000233719.3 GOT2P3 11.97 8.27e-28 6.25e-21 0.56 0.54 Blood metabolite ratios; chr16:58749772 chr12:9641802~9643007:+ LIHC trans rs12709013 0.792 rs1473206 ENSG00000230849.2 GOT2P2 11.97 8.3e-28 6.27e-21 0.56 0.54 Blood metabolite ratios; chr16:58737529 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs1473205 ENSG00000230849.2 GOT2P2 11.97 8.3e-28 6.27e-21 0.56 0.54 Blood metabolite ratios; chr16:58737547 chr1:173141100~173142350:- LIHC trans rs616147 0.627 rs816487 ENSG00000183298.5 RP11-556K13.1 -11.97 8.37e-28 6.32e-21 -0.73 -0.54 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39445999 chr1:101786340~101787219:- LIHC trans rs9611565 0.546 rs132793 ENSG00000268568.1 AC007228.9 11.96 8.67e-28 6.54e-21 0.9 0.54 Vitiligo; chr22:41667677 chr19:56672574~56673901:- LIHC trans rs12709013 0.561 rs1657174 ENSG00000233719.3 GOT2P3 11.95 9.24e-28 6.96e-21 0.56 0.54 Blood metabolite ratios; chr16:58755139 chr12:9641802~9643007:+ LIHC trans rs55665837 1 rs10832254 ENSG00000236360.2 RP11-334A14.2 11.95 9.43e-28 7.09e-21 0.67 0.54 Vitamin D levels; chr11:14413152 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs11023214 ENSG00000236360.2 RP11-334A14.2 11.95 9.43e-28 7.09e-21 0.67 0.54 Vitamin D levels; chr11:14414713 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs11023216 ENSG00000236360.2 RP11-334A14.2 11.95 9.46e-28 7.11e-21 0.67 0.54 Vitamin D levels; chr11:14415607 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs55665837 ENSG00000236360.2 RP11-334A14.2 11.95 9.74e-28 7.33e-21 0.67 0.54 Vitamin D levels; chr11:14473503 chr1:52993201~52993702:- LIHC trans rs2657294 0.62 rs7475340 ENSG00000172974.11 AC007318.5 11.95 1e-27 7.54e-21 0.64 0.54 Pneumonia; chr10:75079597 chr2:65205108~65205988:+ LIHC trans rs10037055 0.853 rs10077929 ENSG00000217325.2 PRELID1P1 11.94 1.08e-27 8.07e-21 0.63 0.54 Migraine without aura; chr5:177270843 chr6:126643488~126644390:+ LIHC trans rs4822044 0.561 rs132781 ENSG00000268568.1 AC007228.9 11.93 1.11e-27 8.31e-21 0.9 0.54 Cannabis dependence symptom count; chr22:41650118 chr19:56672574~56673901:- LIHC trans rs9611565 0.512 rs132784 ENSG00000268568.1 AC007228.9 11.93 1.11e-27 8.31e-21 0.9 0.54 Vitiligo; chr22:41656359 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs4499224 ENSG00000233719.3 GOT2P3 11.93 1.17e-27 8.72e-21 0.55 0.54 Blood metabolite ratios; chr16:58770364 chr12:9641802~9643007:+ LIHC trans rs9611565 0.918 rs4822024 ENSG00000268568.1 AC007228.9 -11.92 1.22e-27 9.13e-21 -0.82 -0.54 Vitiligo; chr22:41361643 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs257628 ENSG00000233719.3 GOT2P3 11.92 1.23e-27 9.22e-21 0.56 0.54 Blood metabolite ratios; chr16:58758924 chr12:9641802~9643007:+ LIHC trans rs10242455 0.702 rs73403290 ENSG00000228834.1 RP11-249L21.4 11.91 1.38e-27 1.03e-20 1.4 0.54 Blood metabolite levels; chr7:99560205 chr6:108907615~108907873:- LIHC trans rs9611565 0.838 rs4239894 ENSG00000268568.1 AC007228.9 -11.9 1.47e-27 1.1e-20 -0.84 -0.54 Vitiligo; chr22:41349544 chr19:56672574~56673901:- LIHC trans rs12709013 0.755 rs1424245 ENSG00000233719.3 GOT2P3 11.89 1.64e-27 1.22e-20 0.52 0.54 Blood metabolite ratios; chr16:58729926 chr12:9641802~9643007:+ LIHC trans rs7811142 0.83 rs11768967 ENSG00000228546.2 CTA-313A17.3 11.89 1.66e-27 1.23e-20 0.91 0.54 Platelet count; chr7:100370021 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs6975660 ENSG00000228546.2 CTA-313A17.3 11.89 1.66e-27 1.23e-20 0.91 0.54 Platelet count; chr7:100377643 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs73401443 ENSG00000228546.2 CTA-313A17.3 11.89 1.66e-27 1.23e-20 0.91 0.54 Platelet count; chr7:100379959 chr7:102337316~102339115:+ LIHC trans rs9467773 0.523 rs2498399 ENSG00000242375.1 RP11-498P14.3 11.88 1.68e-27 1.25e-20 0.63 0.54 Intelligence (multi-trait analysis); chr6:26795343 chr9:97195351~97197687:- LIHC trans rs9611565 0.5 rs10775759 ENSG00000268568.1 AC007228.9 11.88 1.72e-27 1.28e-20 0.82 0.54 Vitiligo; chr22:41692154 chr19:56672574~56673901:- LIHC trans rs12709013 0.694 rs1616798 ENSG00000230849.2 GOT2P2 11.88 1.76e-27 1.31e-20 0.55 0.54 Blood metabolite ratios; chr16:58739433 chr1:173141100~173142350:- LIHC trans rs12709013 0.574 rs35321124 ENSG00000230849.2 GOT2P2 11.87 1.87e-27 1.38e-20 0.62 0.54 Blood metabolite ratios; chr16:58786561 chr1:173141100~173142350:- LIHC trans rs9611565 0.592 rs5758405 ENSG00000268568.1 AC007228.9 11.87 1.9e-27 1.41e-20 0.81 0.54 Vitiligo; chr22:41680377 chr19:56672574~56673901:- LIHC trans rs9611565 0.918 rs28638318 ENSG00000268568.1 AC007228.9 -11.86 2.02e-27 1.49e-20 -0.91 -0.54 Vitiligo; chr22:41357055 chr19:56672574~56673901:- LIHC trans rs12709013 0.729 rs1657179 ENSG00000230849.2 GOT2P2 11.86 2.08e-27 1.54e-20 0.56 0.54 Blood metabolite ratios; chr16:58735115 chr1:173141100~173142350:- LIHC trans rs9611565 0.592 rs5751129 ENSG00000268568.1 AC007228.9 11.86 2.15e-27 1.59e-20 0.81 0.54 Vitiligo; chr22:41619761 chr19:56672574~56673901:- LIHC trans rs2657294 0.62 rs2395136 ENSG00000172974.11 AC007318.5 11.84 2.35e-27 1.73e-20 0.64 0.54 Pneumonia; chr10:75088213 chr2:65205108~65205988:+ LIHC trans rs9611565 0.592 rs5758406 ENSG00000268568.1 AC007228.9 11.84 2.38e-27 1.75e-20 0.81 0.54 Vitiligo; chr22:41680637 chr19:56672574~56673901:- LIHC trans rs7811142 0.83 rs10085549 ENSG00000228546.2 CTA-313A17.3 11.84 2.53e-27 1.86e-20 0.9 0.54 Platelet count; chr7:100385512 chr7:102337316~102339115:+ LIHC trans rs2657294 0.62 rs7903537 ENSG00000172974.11 AC007318.5 11.83 2.67e-27 1.96e-20 0.64 0.54 Pneumonia; chr10:75087732 chr2:65205108~65205988:+ LIHC trans rs7811142 0.83 rs7792959 ENSG00000228546.2 CTA-313A17.3 11.83 2.7e-27 1.98e-20 0.9 0.54 Platelet count; chr7:100374780 chr7:102337316~102339115:+ LIHC trans rs10037055 1 rs10037055 ENSG00000226986.4 RP11-543B16.2 -11.83 2.72e-27 2e-20 -0.6 -0.54 Migraine without aura; chr5:177264278 chr1:211207239~211207897:+ LIHC trans rs7811142 0.83 rs6979910 ENSG00000228546.2 CTA-313A17.3 11.82 2.96e-27 2.17e-20 0.88 0.54 Platelet count; chr7:100343007 chr7:102337316~102339115:+ LIHC trans rs9611565 0.559 rs1006407 ENSG00000268568.1 AC007228.9 -11.81 3.03e-27 2.21e-20 -0.95 -0.54 Vitiligo; chr22:41576028 chr19:56672574~56673901:- LIHC trans rs55665837 1 rs11023224 ENSG00000236360.2 RP11-334A14.2 11.8 3.54e-27 2.58e-20 0.67 0.54 Vitamin D levels; chr11:14436193 chr1:52993201~52993702:- LIHC trans rs55665837 0.961 rs11023226 ENSG00000236360.2 RP11-334A14.2 11.8 3.54e-27 2.58e-20 0.67 0.54 Vitamin D levels; chr11:14437271 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs11023227 ENSG00000236360.2 RP11-334A14.2 11.8 3.54e-27 2.58e-20 0.67 0.54 Vitamin D levels; chr11:14437541 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs10832264 ENSG00000236360.2 RP11-334A14.2 11.8 3.54e-27 2.58e-20 0.67 0.54 Vitamin D levels; chr11:14438436 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs11023229 ENSG00000236360.2 RP11-334A14.2 11.8 3.54e-27 2.58e-20 0.67 0.54 Vitamin D levels; chr11:14439455 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs12276938 ENSG00000236360.2 RP11-334A14.2 11.79 3.6e-27 2.62e-20 0.67 0.54 Vitamin D levels; chr11:14441942 chr1:52993201~52993702:- LIHC trans rs7811142 0.666 rs28401739 ENSG00000228546.2 CTA-313A17.3 11.79 3.7e-27 2.69e-20 0.89 0.54 Platelet count; chr7:100308061 chr7:102337316~102339115:+ LIHC trans rs9611565 0.512 rs4822052 ENSG00000268568.1 AC007228.9 -11.79 3.72e-27 2.7e-20 -0.83 -0.54 Vitiligo; chr22:41797737 chr19:56672574~56673901:- LIHC trans rs10242455 0.557 rs2404487 ENSG00000228834.1 RP11-249L21.4 11.79 3.81e-27 2.76e-20 1.37 0.54 Blood metabolite levels; chr7:99440434 chr6:108907615~108907873:- LIHC trans rs10242455 0.702 rs73711280 ENSG00000228834.1 RP11-249L21.4 11.79 3.81e-27 2.76e-20 1.37 0.54 Blood metabolite levels; chr7:99441981 chr6:108907615~108907873:- LIHC trans rs10242455 0.702 rs45448997 ENSG00000228834.1 RP11-249L21.4 11.79 3.81e-27 2.76e-20 1.37 0.54 Blood metabolite levels; chr7:99443975 chr6:108907615~108907873:- LIHC trans rs10242455 0.702 rs112475236 ENSG00000228834.1 RP11-249L21.4 11.79 3.81e-27 2.76e-20 1.37 0.54 Blood metabolite levels; chr7:99447056 chr6:108907615~108907873:- LIHC trans rs10242455 0.702 rs3528 ENSG00000228834.1 RP11-249L21.4 11.79 3.81e-27 2.76e-20 1.37 0.54 Blood metabolite levels; chr7:99458317 chr6:108907615~108907873:- LIHC trans rs9611565 0.546 rs739134 ENSG00000268568.1 AC007228.9 11.78 4.13e-27 2.99e-20 0.82 0.54 Vitiligo; chr22:41693619 chr19:56672574~56673901:- LIHC trans rs6477998 0.647 rs10981704 ENSG00000238072.1 RP11-305M3.2 -11.77 4.6e-27 3.33e-20 -0.7 -0.54 Hematology traits; chr9:113253989 chr7:129410113~129410370:- LIHC trans rs10242455 0.557 rs73401516 ENSG00000228834.1 RP11-249L21.4 11.76 4.69e-27 3.38e-20 1.36 0.54 Blood metabolite levels; chr7:99470728 chr6:108907615~108907873:- LIHC trans rs13190036 0.748 rs28395268 ENSG00000226986.4 RP11-543B16.2 11.76 4.81e-27 3.46e-20 0.6 0.54 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177283546 chr1:211207239~211207897:+ LIHC trans rs10242455 0.557 rs59672032 ENSG00000228834.1 RP11-249L21.4 11.76 4.83e-27 3.48e-20 1.36 0.54 Blood metabolite levels; chr7:99461074 chr6:108907615~108907873:- LIHC trans rs9467773 1 rs1078679 ENSG00000242375.1 RP11-498P14.3 11.76 4.84e-27 3.49e-20 0.63 0.54 Intelligence (multi-trait analysis); chr6:26568513 chr9:97195351~97197687:- LIHC trans rs12709013 0.646 rs8046154 ENSG00000233719.3 GOT2P3 -11.76 4.96e-27 3.57e-20 -0.56 -0.54 Blood metabolite ratios; chr16:58773978 chr12:9641802~9643007:+ LIHC trans rs9467773 1 rs6456734 ENSG00000242375.1 RP11-498P14.3 11.75 5.36e-27 3.84e-20 0.63 0.54 Intelligence (multi-trait analysis); chr6:26566737 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs1535277 ENSG00000242375.1 RP11-498P14.3 11.75 5.36e-27 3.84e-20 0.63 0.54 Intelligence (multi-trait analysis); chr6:26567574 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs1884948 ENSG00000242375.1 RP11-498P14.3 11.75 5.36e-27 3.84e-20 0.63 0.54 Intelligence (multi-trait analysis); chr6:26567760 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs1884949 ENSG00000242375.1 RP11-498P14.3 11.75 5.36e-27 3.84e-20 0.63 0.54 Intelligence (multi-trait analysis); chr6:26567839 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs9467796 ENSG00000242375.1 RP11-498P14.3 11.75 5.36e-27 3.84e-20 0.63 0.54 Intelligence (multi-trait analysis); chr6:26568183 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs9467797 ENSG00000242375.1 RP11-498P14.3 11.75 5.36e-27 3.84e-20 0.63 0.54 Intelligence (multi-trait analysis); chr6:26568245 chr9:97195351~97197687:- LIHC trans rs55665837 1 rs34382046 ENSG00000236360.2 RP11-334A14.2 11.74 5.6e-27 4e-20 0.66 0.54 Vitamin D levels; chr11:14429772 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs7945167 ENSG00000236360.2 RP11-334A14.2 11.74 5.6e-27 4e-20 0.66 0.54 Vitamin D levels; chr11:14430274 chr1:52993201~52993702:- LIHC trans rs55665837 0.961 rs60622588 ENSG00000236360.2 RP11-334A14.2 11.74 5.6e-27 4e-20 0.66 0.54 Vitamin D levels; chr11:14435452 chr1:52993201~52993702:- LIHC trans rs55665837 1 rs11023223 ENSG00000236360.2 RP11-334A14.2 11.74 5.6e-27 4e-20 0.66 0.54 Vitamin D levels; chr11:14435566 chr1:52993201~52993702:- LIHC trans rs13190036 0.551 rs28932178 ENSG00000226986.4 RP11-543B16.2 -11.74 5.68e-27 4.06e-20 -0.64 -0.54 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210575 chr1:211207239~211207897:+ LIHC trans rs13177918 0.717 rs6874318 ENSG00000213058.3 RP4-765C7.2 -11.72 6.49e-27 4.63e-20 -0.71 -0.54 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150462836 chr1:178411616~178411972:+ LIHC trans rs9611565 0.592 rs6519270 ENSG00000268568.1 AC007228.9 11.72 6.72e-27 4.79e-20 0.81 0.54 Vitiligo; chr22:41682662 chr19:56672574~56673901:- LIHC trans rs8081395 0.58 rs180515 ENSG00000187870.7 RNFT1P3 11.71 7.28e-27 5.18e-20 0.56 0.53 White blood cell count; chr17:59946914 chr17:20743333~20754501:- LIHC trans rs9467773 1 rs6932156 ENSG00000242375.1 RP11-498P14.3 11.71 7.58e-27 5.39e-20 0.63 0.53 Intelligence (multi-trait analysis); chr6:26571278 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs6924838 ENSG00000242375.1 RP11-498P14.3 11.71 7.58e-27 5.39e-20 0.63 0.53 Intelligence (multi-trait analysis); chr6:26571528 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs6925895 ENSG00000242375.1 RP11-498P14.3 11.71 7.58e-27 5.39e-20 0.63 0.53 Intelligence (multi-trait analysis); chr6:26571937 chr9:97195351~97197687:- LIHC trans rs12709013 0.574 rs35321124 ENSG00000233719.3 GOT2P3 11.7 8.13e-27 5.78e-20 0.57 0.53 Blood metabolite ratios; chr16:58786561 chr12:9641802~9643007:+ LIHC trans rs9467773 1 rs9461271 ENSG00000242375.1 RP11-498P14.3 11.69 8.52e-27 6.04e-20 0.62 0.53 Intelligence (multi-trait analysis); chr6:26554740 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs6930120 ENSG00000242375.1 RP11-498P14.3 11.69 8.52e-27 6.04e-20 0.62 0.53 Intelligence (multi-trait analysis); chr6:26555256 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs9467787 ENSG00000242375.1 RP11-498P14.3 11.69 8.52e-27 6.04e-20 0.62 0.53 Intelligence (multi-trait analysis); chr6:26556541 chr9:97195351~97197687:- LIHC trans rs9611565 0.546 rs5758426 ENSG00000268568.1 AC007228.9 11.69 8.75e-27 6.2e-20 0.81 0.53 Vitiligo; chr22:41702759 chr19:56672574~56673901:- LIHC trans rs616147 0.627 rs816510 ENSG00000183298.5 RP11-556K13.1 -11.68 9.66e-27 6.83e-20 -0.72 -0.53 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39430804 chr1:101786340~101787219:- LIHC trans rs55665837 1 rs10466412 ENSG00000236360.2 RP11-334A14.2 11.68 9.7e-27 6.86e-20 0.66 0.53 Vitamin D levels; chr11:14483643 chr1:52993201~52993702:- LIHC trans rs9467773 1 rs2224380 ENSG00000242375.1 RP11-498P14.3 11.67 1.02e-26 7.19e-20 0.62 0.53 Intelligence (multi-trait analysis); chr6:26553715 chr9:97195351~97197687:- LIHC trans rs55665837 1 rs12364959 ENSG00000236360.2 RP11-334A14.2 11.67 1.05e-26 7.4e-20 0.66 0.53 Vitamin D levels; chr11:14485889 chr1:52993201~52993702:- LIHC trans rs9467773 0.967 rs6941022 ENSG00000242375.1 RP11-498P14.3 11.66 1.07e-26 7.57e-20 0.62 0.53 Intelligence (multi-trait analysis); chr6:26553303 chr9:97195351~97197687:- LIHC trans rs12709013 0.591 rs30841 ENSG00000233719.3 GOT2P3 11.66 1.09e-26 7.66e-20 0.62 0.53 Blood metabolite ratios; chr16:58709819 chr12:9641802~9643007:+ LIHC trans rs55665837 1 rs34980103 ENSG00000236360.2 RP11-334A14.2 11.66 1.09e-26 7.68e-20 0.66 0.53 Vitamin D levels; chr11:14491339 chr1:52993201~52993702:- LIHC trans rs9467773 1 rs10484442 ENSG00000242375.1 RP11-498P14.3 11.65 1.19e-26 8.39e-20 0.62 0.53 Intelligence (multi-trait analysis); chr6:26555651 chr9:97195351~97197687:- LIHC trans rs2657294 0.62 rs2395132 ENSG00000172974.11 AC007318.5 11.65 1.2e-26 8.44e-20 0.62 0.53 Pneumonia; chr10:75080840 chr2:65205108~65205988:+ LIHC trans rs6732160 0.624 rs10865397 ENSG00000236165.1 PRADC1P1 11.65 1.22e-26 8.57e-20 0.66 0.53 Intelligence (multi-trait analysis); chr2:73131164 chr3:36976316~36976840:+ LIHC trans rs55665837 1 rs11023246 ENSG00000236360.2 RP11-334A14.2 11.65 1.23e-26 8.62e-20 0.66 0.53 Vitamin D levels; chr11:14515410 chr1:52993201~52993702:- LIHC trans rs13190036 1 rs6880798 ENSG00000226986.4 RP11-543B16.2 11.65 1.23e-26 8.64e-20 0.61 0.53 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177277456 chr1:211207239~211207897:+ LIHC trans rs616147 0.548 rs2370965 ENSG00000183298.5 RP11-556K13.1 -11.62 1.53e-26 1.06e-19 -0.71 -0.53 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39448996 chr1:101786340~101787219:- LIHC trans rs10242455 0.702 rs73397499 ENSG00000228834.1 RP11-249L21.4 11.62 1.57e-26 1.09e-19 1.36 0.53 Blood metabolite levels; chr7:99442004 chr6:108907615~108907873:- LIHC trans rs10242455 0.702 rs45461000 ENSG00000228834.1 RP11-249L21.4 11.62 1.57e-26 1.09e-19 1.36 0.53 Blood metabolite levels; chr7:99455087 chr6:108907615~108907873:- LIHC trans rs9467773 1 rs767471 ENSG00000242375.1 RP11-498P14.3 11.62 1.58e-26 1.1e-19 0.62 0.53 Intelligence (multi-trait analysis); chr6:26557626 chr9:97195351~97197687:- LIHC trans rs10242455 0.571 rs7805661 ENSG00000228834.1 RP11-249L21.4 11.61 1.68e-26 1.16e-19 1.32 0.53 Blood metabolite levels; chr7:99573899 chr6:108907615~108907873:- LIHC trans rs8081395 0.651 rs1292067 ENSG00000187870.7 RNFT1P3 -11.61 1.69e-26 1.16e-19 -0.55 -0.53 White blood cell count; chr17:59853285 chr17:20743333~20754501:- LIHC trans rs9611565 0.592 rs4481089 ENSG00000268568.1 AC007228.9 -11.6 1.85e-26 1.27e-19 -0.82 -0.53 Vitiligo; chr22:41584888 chr19:56672574~56673901:- LIHC trans rs9611565 0.592 rs5996039 ENSG00000268568.1 AC007228.9 -11.6 1.85e-26 1.27e-19 -0.82 -0.53 Vitiligo; chr22:41585953 chr19:56672574~56673901:- LIHC trans rs9611565 0.592 rs57102627 ENSG00000268568.1 AC007228.9 -11.6 1.85e-26 1.27e-19 -0.82 -0.53 Vitiligo; chr22:41591623 chr19:56672574~56673901:- LIHC trans rs9611565 0.592 rs28750375 ENSG00000268568.1 AC007228.9 -11.6 1.85e-26 1.27e-19 -0.82 -0.53 Vitiligo; chr22:41594640 chr19:56672574~56673901:- LIHC trans rs9611565 0.559 rs8139993 ENSG00000268568.1 AC007228.9 -11.6 1.85e-26 1.27e-19 -0.82 -0.53 Vitiligo; chr22:41599331 chr19:56672574~56673901:- LIHC trans rs7811142 0.83 rs6955367 ENSG00000228546.2 CTA-313A17.3 11.6 1.88e-26 1.29e-19 0.87 0.53 Platelet count; chr7:100363571 chr7:102337316~102339115:+ LIHC trans rs10242455 0.557 rs77997620 ENSG00000228834.1 RP11-249L21.4 11.6 1.92e-26 1.31e-19 1.36 0.53 Blood metabolite levels; chr7:99472792 chr6:108907615~108907873:- LIHC trans rs10242455 0.702 rs59240302 ENSG00000228834.1 RP11-249L21.4 11.6 1.92e-26 1.31e-19 1.36 0.53 Blood metabolite levels; chr7:99475368 chr6:108907615~108907873:- LIHC trans rs10242455 0.702 rs73403247 ENSG00000228834.1 RP11-249L21.4 11.6 1.92e-26 1.31e-19 1.36 0.53 Blood metabolite levels; chr7:99491107 chr6:108907615~108907873:- LIHC trans rs10242455 0.85 rs57367781 ENSG00000228834.1 RP11-249L21.4 11.6 1.92e-26 1.31e-19 1.36 0.53 Blood metabolite levels; chr7:99519196 chr6:108907615~108907873:- LIHC trans rs55665837 1 rs10832278 ENSG00000236360.2 RP11-334A14.2 11.59 1.97e-26 1.35e-19 0.66 0.53 Vitamin D levels; chr11:14475073 chr1:52993201~52993702:- LIHC trans rs55665837 0.961 rs11023237 ENSG00000236360.2 RP11-334A14.2 11.59 1.97e-26 1.35e-19 0.66 0.53 Vitamin D levels; chr11:14478788 chr1:52993201~52993702:- LIHC trans rs9611565 1 rs9611565 ENSG00000268568.1 AC007228.9 -11.59 2.01e-26 1.37e-19 -0.8 -0.53 Vitiligo; chr22:41371482 chr19:56672574~56673901:- LIHC trans rs13190036 0.591 rs78523677 ENSG00000226986.4 RP11-543B16.2 -11.58 2.1e-26 1.43e-19 -0.63 -0.53 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177124102 chr1:211207239~211207897:+ LIHC trans rs55665837 1 rs10766182 ENSG00000236360.2 RP11-334A14.2 11.58 2.13e-26 1.46e-19 0.66 0.53 Vitamin D levels; chr11:14477990 chr1:52993201~52993702:- LIHC trans rs12709013 0.574 rs9302706 ENSG00000233719.3 GOT2P3 11.58 2.26e-26 1.54e-19 0.58 0.53 Blood metabolite ratios; chr16:58812060 chr12:9641802~9643007:+ LIHC trans rs727563 0.635 rs5751141 ENSG00000268568.1 AC007228.9 11.58 2.27e-26 1.55e-19 0.86 0.53 Crohn's disease;Inflammatory bowel disease; chr22:41711741 chr19:56672574~56673901:- LIHC trans rs12709013 0.536 rs9930758 ENSG00000233719.3 GOT2P3 11.58 2.27e-26 1.55e-19 0.57 0.53 Blood metabolite ratios; chr16:58803167 chr12:9641802~9643007:+ LIHC trans rs12709013 0.636 rs10852565 ENSG00000233719.3 GOT2P3 11.57 2.28e-26 1.56e-19 0.55 0.53 Blood metabolite ratios; chr16:58771277 chr12:9641802~9643007:+ LIHC trans rs10242455 0.571 rs56167514 ENSG00000228834.1 RP11-249L21.4 11.57 2.42e-26 1.65e-19 1.32 0.53 Blood metabolite levels; chr7:99563724 chr6:108907615~108907873:- LIHC trans rs13177918 0.626 rs2748240 ENSG00000239528.1 RPS14P8 11.57 2.44e-26 1.67e-19 0.67 0.53 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449305 chr5:116562562~116562930:+ LIHC trans rs9611565 0.918 rs4820438 ENSG00000268568.1 AC007228.9 -11.57 2.46e-26 1.67e-19 -0.81 -0.53 Vitiligo; chr22:41371131 chr19:56672574~56673901:- LIHC trans rs6477998 1 rs6477998 ENSG00000238072.1 RP11-305M3.2 -11.56 2.68e-26 1.82e-19 -0.64 -0.53 Hematology traits; chr9:113234969 chr7:129410113~129410370:- LIHC trans rs9467773 0.967 rs7753565 ENSG00000242375.1 RP11-498P14.3 11.56 2.68e-26 1.82e-19 0.61 0.53 Intelligence (multi-trait analysis); chr6:26559784 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs6940188 ENSG00000242375.1 RP11-498P14.3 11.56 2.68e-26 1.82e-19 0.61 0.53 Intelligence (multi-trait analysis); chr6:26561801 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs6940053 ENSG00000242375.1 RP11-498P14.3 11.56 2.68e-26 1.82e-19 0.61 0.53 Intelligence (multi-trait analysis); chr6:26561894 chr9:97195351~97197687:- LIHC trans rs9611565 0.918 rs73176685 ENSG00000268568.1 AC007228.9 -11.55 2.73e-26 1.86e-19 -0.81 -0.53 Vitiligo; chr22:41385090 chr19:56672574~56673901:- LIHC trans rs12709013 0.514 rs8062639 ENSG00000233719.3 GOT2P3 11.55 2.82e-26 1.91e-19 0.57 0.53 Blood metabolite ratios; chr16:58800264 chr12:9641802~9643007:+ LIHC trans rs12709013 0.591 rs4410065 ENSG00000233719.3 GOT2P3 11.55 2.82e-26 1.91e-19 0.57 0.53 Blood metabolite ratios; chr16:58800968 chr12:9641802~9643007:+ LIHC trans rs12709013 0.591 rs2406234 ENSG00000233719.3 GOT2P3 11.55 2.82e-26 1.91e-19 0.57 0.53 Blood metabolite ratios; chr16:58801840 chr12:9641802~9643007:+ LIHC trans rs12709013 0.591 rs2086206 ENSG00000233719.3 GOT2P3 11.55 2.82e-26 1.91e-19 0.57 0.53 Blood metabolite ratios; chr16:58802094 chr12:9641802~9643007:+ LIHC trans rs9611565 0.5 rs2011053 ENSG00000268568.1 AC007228.9 11.54 3.04e-26 2.06e-19 0.81 0.53 Vitiligo; chr22:41725274 chr19:56672574~56673901:- LIHC trans rs9611565 0.649 rs738422 ENSG00000268568.1 AC007228.9 11.54 3.04e-26 2.06e-19 0.81 0.53 Vitiligo; chr22:41727395 chr19:56672574~56673901:- LIHC trans rs9611565 0.592 rs56021266 ENSG00000268568.1 AC007228.9 -11.53 3.19e-26 2.16e-19 -0.93 -0.53 Vitiligo; chr22:41360567 chr19:56672574~56673901:- LIHC trans rs12709013 0.636 rs9937713 ENSG00000233719.3 GOT2P3 11.53 3.24e-26 2.19e-19 0.55 0.53 Blood metabolite ratios; chr16:58771921 chr12:9641802~9643007:+ LIHC trans rs12709013 0.755 rs1424245 ENSG00000230849.2 GOT2P2 11.53 3.29e-26 2.22e-19 0.55 0.53 Blood metabolite ratios; chr16:58729926 chr1:173141100~173142350:- LIHC trans rs9611565 0.573 rs9306355 ENSG00000268568.1 AC007228.9 11.52 3.67e-26 2.48e-19 0.81 0.53 Vitiligo; chr22:41715892 chr19:56672574~56673901:- LIHC trans rs9611565 0.649 rs5758434 ENSG00000268568.1 AC007228.9 11.52 3.67e-26 2.48e-19 0.81 0.53 Vitiligo; chr22:41720159 chr19:56672574~56673901:- LIHC trans rs9467773 1 rs6456733 ENSG00000242375.1 RP11-498P14.3 11.51 3.8e-26 2.57e-19 0.62 0.53 Intelligence (multi-trait analysis); chr6:26566576 chr9:97195351~97197687:- LIHC trans rs9611565 0.608 rs2003816 ENSG00000268568.1 AC007228.9 11.51 3.87e-26 2.61e-19 0.8 0.53 Vitiligo; chr22:41699136 chr19:56672574~56673901:- LIHC trans rs9611565 0.694 rs11090056 ENSG00000268568.1 AC007228.9 11.51 3.87e-26 2.61e-19 0.8 0.53 Vitiligo; chr22:41699900 chr19:56672574~56673901:- LIHC trans rs9611565 0.644 rs2413652 ENSG00000268568.1 AC007228.9 11.51 3.87e-26 2.61e-19 0.8 0.53 Vitiligo; chr22:41701234 chr19:56672574~56673901:- LIHC trans rs9611565 0.659 rs9611610 ENSG00000268568.1 AC007228.9 -11.5 4.37e-26 2.94e-19 -0.9 -0.53 Vitiligo; chr22:41553255 chr19:56672574~56673901:- LIHC trans rs10242455 0.702 rs55927283 ENSG00000228834.1 RP11-249L21.4 11.5 4.41e-26 2.96e-19 1.35 0.53 Blood metabolite levels; chr7:99459568 chr6:108907615~108907873:- LIHC trans rs8081395 0.627 rs12952730 ENSG00000187870.7 RNFT1P3 11.49 4.64e-26 3.12e-19 0.55 0.53 White blood cell count; chr17:59901475 chr17:20743333~20754501:- LIHC trans rs9611565 0.84 rs2234052 ENSG00000268568.1 AC007228.9 -11.49 4.66e-26 3.13e-19 -0.84 -0.53 Vitiligo; chr22:41381237 chr19:56672574~56673901:- LIHC trans rs9611565 0.84 rs9607799 ENSG00000268568.1 AC007228.9 -11.49 4.66e-26 3.13e-19 -0.84 -0.53 Vitiligo; chr22:41381554 chr19:56672574~56673901:- LIHC trans rs928391 0.592 rs6427332 ENSG00000227183.3 HDGFP1 -11.48 5.01e-26 3.36e-19 -0.84 -0.53 Platelet count; chr1:156827052 chrX:131646639~131646890:+ LIHC trans rs55665837 1 rs2305306 ENSG00000236360.2 RP11-334A14.2 11.48 5.02e-26 3.36e-19 0.66 0.53 Vitamin D levels; chr11:14513453 chr1:52993201~52993702:- LIHC trans rs8081395 0.627 rs180536 ENSG00000187870.7 RNFT1P3 11.48 5.14e-26 3.44e-19 0.55 0.53 White blood cell count; chr17:59919445 chr17:20743333~20754501:- LIHC trans rs9467773 1 rs10214634 ENSG00000242375.1 RP11-498P14.3 11.47 5.32e-26 3.56e-19 0.61 0.53 Intelligence (multi-trait analysis); chr6:26564354 chr9:97195351~97197687:- LIHC trans rs9467773 0.873 rs9295698 ENSG00000242375.1 RP11-498P14.3 11.47 5.32e-26 3.56e-19 0.61 0.53 Intelligence (multi-trait analysis); chr6:26565871 chr9:97195351~97197687:- LIHC trans rs13177918 0.603 rs2748241 ENSG00000239528.1 RPS14P8 11.46 5.98e-26 4e-19 0.66 0.53 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447931 chr5:116562562~116562930:+ LIHC trans rs7811142 0.83 rs75636500 ENSG00000228546.2 CTA-313A17.3 11.45 6.72e-26 4.47e-19 0.93 0.53 Platelet count; chr7:100350034 chr7:102337316~102339115:+ LIHC trans rs616147 0.671 rs674192 ENSG00000183298.5 RP11-556K13.1 -11.44 6.93e-26 4.61e-19 -0.69 -0.53 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39458653 chr1:101786340~101787219:- LIHC trans rs616147 0.616 rs1768234 ENSG00000183298.5 RP11-556K13.1 -11.43 7.39e-26 4.91e-19 -0.7 -0.53 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39459821 chr1:101786340~101787219:- LIHC trans rs9611565 0.694 rs5758411 ENSG00000268568.1 AC007228.9 11.43 7.7e-26 5.11e-19 0.79 0.53 Vitiligo; chr22:41683730 chr19:56672574~56673901:- LIHC trans rs12709013 0.613 rs6499984 ENSG00000233719.3 GOT2P3 11.42 8.11e-26 5.38e-19 0.57 0.53 Blood metabolite ratios; chr16:58810209 chr12:9641802~9643007:+ LIHC trans rs9467773 1 rs9986382 ENSG00000242375.1 RP11-498P14.3 11.42 8.45e-26 5.6e-19 0.61 0.53 Intelligence (multi-trait analysis); chr6:26550391 chr9:97195351~97197687:- LIHC trans rs8081395 0.603 rs1292047 ENSG00000187870.7 RNFT1P3 11.42 8.5e-26 5.63e-19 0.55 0.53 White blood cell count; chr17:59877805 chr17:20743333~20754501:- LIHC trans rs616147 0.671 rs675595 ENSG00000183298.5 RP11-556K13.1 -11.41 8.72e-26 5.78e-19 -0.7 -0.53 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39458987 chr1:101786340~101787219:- LIHC trans rs9611565 0.592 rs80477 ENSG00000268568.1 AC007228.9 11.4 9.88e-26 6.54e-19 0.81 0.52 Vitiligo; chr22:41605179 chr19:56672574~56673901:- LIHC trans rs12709013 0.591 rs30840 ENSG00000233719.3 GOT2P3 11.4 9.92e-26 6.56e-19 0.61 0.52 Blood metabolite ratios; chr16:58710165 chr12:9641802~9643007:+ LIHC trans rs9611565 0.607 rs132792 ENSG00000268568.1 AC007228.9 11.4 9.99e-26 6.6e-19 0.79 0.52 Vitiligo; chr22:41666818 chr19:56672574~56673901:- LIHC trans rs12709013 0.591 rs9932967 ENSG00000233719.3 GOT2P3 11.39 1.06e-25 6.98e-19 0.57 0.52 Blood metabolite ratios; chr16:58805583 chr12:9641802~9643007:+ LIHC trans rs7811142 0.72 rs112622797 ENSG00000228546.2 CTA-313A17.3 11.39 1.09e-25 7.22e-19 0.93 0.52 Platelet count; chr7:100319793 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs1063945 ENSG00000228546.2 CTA-313A17.3 11.39 1.09e-25 7.22e-19 0.89 0.52 Platelet count; chr7:100332824 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs11761253 ENSG00000228546.2 CTA-313A17.3 11.39 1.09e-25 7.22e-19 0.89 0.52 Platelet count; chr7:100341698 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs6945952 ENSG00000228546.2 CTA-313A17.3 11.39 1.1e-25 7.26e-19 0.92 0.52 Platelet count; chr7:100384152 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs73401451 ENSG00000228546.2 CTA-313A17.3 11.39 1.1e-25 7.26e-19 0.92 0.52 Platelet count; chr7:100384272 chr7:102337316~102339115:+ LIHC trans rs13177918 0.603 rs2343806 ENSG00000239528.1 RPS14P8 11.38 1.19e-25 7.83e-19 0.66 0.52 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452422 chr5:116562562~116562930:+ LIHC trans rs12709013 0.636 rs967852 ENSG00000233719.3 GOT2P3 11.37 1.23e-25 8.11e-19 0.57 0.52 Blood metabolite ratios; chr16:58807313 chr12:9641802~9643007:+ LIHC trans rs9611565 0.921 rs761366 ENSG00000268568.1 AC007228.9 -11.37 1.24e-25 8.18e-19 -0.87 -0.52 Vitiligo; chr22:41348018 chr19:56672574~56673901:- LIHC trans rs616147 1 rs1768208 ENSG00000183298.5 RP11-556K13.1 -11.36 1.37e-25 8.99e-19 -0.7 -0.52 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39481512 chr1:101786340~101787219:- LIHC trans rs616147 0.655 rs1707981 ENSG00000183298.5 RP11-556K13.1 -11.35 1.51e-25 9.93e-19 -0.7 -0.52 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39461015 chr1:101786340~101787219:- LIHC trans rs616147 0.72 rs1768209 ENSG00000183298.5 RP11-556K13.1 -11.35 1.51e-25 9.93e-19 -0.7 -0.52 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39461184 chr1:101786340~101787219:- LIHC trans rs616147 0.72 rs2965067 ENSG00000183298.5 RP11-556K13.1 -11.35 1.51e-25 9.93e-19 -0.7 -0.52 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39461546 chr1:101786340~101787219:- LIHC trans rs9611565 0.571 rs2050032 ENSG00000268568.1 AC007228.9 11.34 1.68e-25 1.1e-18 0.84 0.52 Vitiligo; chr22:41756425 chr19:56672574~56673901:- LIHC trans rs13190036 0.551 rs1052432 ENSG00000226986.4 RP11-543B16.2 -11.34 1.68e-25 1.1e-18 -0.62 -0.52 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177137188 chr1:211207239~211207897:+ LIHC trans rs10242455 0.571 rs11734 ENSG00000228834.1 RP11-249L21.4 -11.33 1.77e-25 1.15e-18 -1.22 -0.52 Blood metabolite levels; chr7:99632145 chr6:108907615~108907873:- LIHC trans rs7811142 0.83 rs7792525 ENSG00000228546.2 CTA-313A17.3 11.32 1.88e-25 1.22e-18 0.93 0.52 Platelet count; chr7:100374499 chr7:102337316~102339115:+ LIHC trans rs9611565 0.649 rs5751144 ENSG00000268568.1 AC007228.9 -11.32 1.9e-25 1.24e-18 -0.79 -0.52 Vitiligo; chr22:41732093 chr19:56672574~56673901:- LIHC trans rs9611565 0.649 rs2064189 ENSG00000268568.1 AC007228.9 11.3 2.19e-25 1.43e-18 0.79 0.52 Vitiligo; chr22:41731995 chr19:56672574~56673901:- LIHC trans rs12291225 0.883 rs1864658 ENSG00000236360.2 RP11-334A14.2 -11.29 2.36e-25 1.54e-18 -0.65 -0.52 Sense of smell; chr11:14234898 chr1:52993201~52993702:- LIHC trans rs7811142 0.83 rs6948685 ENSG00000228546.2 CTA-313A17.3 11.29 2.47e-25 1.6e-18 0.91 0.52 Platelet count; chr7:100372565 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs73401450 ENSG00000228546.2 CTA-313A17.3 11.29 2.47e-25 1.6e-18 0.91 0.52 Platelet count; chr7:100384236 chr7:102337316~102339115:+ LIHC trans rs61990749 0.597 rs10148373 ENSG00000235400.1 RP4-641G12.4 11.27 2.86e-25 1.85e-18 0.8 0.52 Fibroblast growth factor basic levels; chr14:77813856 chr1:78749073~78750659:+ LIHC trans rs7811142 0.83 rs11765869 ENSG00000228546.2 CTA-313A17.3 11.27 2.87e-25 1.86e-18 0.93 0.52 Platelet count; chr7:100367166 chr7:102337316~102339115:+ LIHC trans rs13190036 0.551 rs7710269 ENSG00000226986.4 RP11-543B16.2 -11.26 3.02e-25 1.95e-18 -0.6 -0.52 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177187528 chr1:211207239~211207897:+ LIHC trans rs13190036 0.515 rs2878686 ENSG00000226986.4 RP11-543B16.2 -11.26 3.02e-25 1.95e-18 -0.6 -0.52 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206748 chr1:211207239~211207897:+ LIHC trans rs12709013 0.591 rs899375 ENSG00000233719.3 GOT2P3 11.26 3.07e-25 1.99e-18 0.56 0.52 Blood metabolite ratios; chr16:58792325 chr12:9641802~9643007:+ LIHC trans rs7811142 0.83 rs705866 ENSG00000228546.2 CTA-313A17.3 11.26 3.18e-25 2.05e-18 0.93 0.52 Platelet count; chr7:100367662 chr7:102337316~102339115:+ LIHC trans rs13190036 0.551 rs11957608 ENSG00000226986.4 RP11-543B16.2 -11.25 3.32e-25 2.14e-18 -0.6 -0.52 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228344 chr1:211207239~211207897:+ LIHC trans rs13190036 1 rs628506 ENSG00000226986.4 RP11-543B16.2 -11.25 3.42e-25 2.21e-18 -0.61 -0.52 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177107422 chr1:211207239~211207897:+ LIHC trans rs13190036 0.551 rs9313751 ENSG00000226986.4 RP11-543B16.2 -11.24 3.65e-25 2.34e-18 -0.59 -0.52 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177217174 chr1:211207239~211207897:+ LIHC trans rs13190036 0.551 rs4976639 ENSG00000226986.4 RP11-543B16.2 11.24 3.69e-25 2.37e-18 0.61 0.52 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177123300 chr1:211207239~211207897:+ LIHC trans rs6732160 0.613 rs62151837 ENSG00000236165.1 PRADC1P1 11.24 3.86e-25 2.48e-18 0.69 0.52 Intelligence (multi-trait analysis); chr2:73163268 chr3:36976316~36976840:+ LIHC trans rs12709013 0.591 rs30834 ENSG00000233719.3 GOT2P3 11.23 4.05e-25 2.6e-18 0.6 0.52 Blood metabolite ratios; chr16:58715394 chr12:9641802~9643007:+ LIHC trans rs7811142 0.72 rs7795656 ENSG00000228546.2 CTA-313A17.3 11.22 4.25e-25 2.72e-18 0.88 0.52 Platelet count; chr7:100352674 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs6965458 ENSG00000228546.2 CTA-313A17.3 11.22 4.42e-25 2.83e-18 0.93 0.52 Platelet count; chr7:100375779 chr7:102337316~102339115:+ LIHC trans rs7811142 0.779 rs28680963 ENSG00000228546.2 CTA-313A17.3 11.2 5.04e-25 3.22e-18 0.89 0.52 Platelet count; chr7:100307852 chr7:102337316~102339115:+ LIHC trans rs112721625 1 rs112721625 ENSG00000187870.7 RNFT1P3 11.2 5.11e-25 3.26e-18 0.55 0.52 Monocyte count; chr17:59850066 chr17:20743333~20754501:- LIHC trans rs12709013 0.597 rs8051078 ENSG00000233719.3 GOT2P3 11.2 5.33e-25 3.4e-18 0.54 0.52 Blood metabolite ratios; chr16:58774200 chr12:9641802~9643007:+ LIHC trans rs10037055 1 rs6886255 ENSG00000226986.4 RP11-543B16.2 11.18 5.98e-25 3.8e-18 0.57 0.52 Migraine without aura; chr5:177291360 chr1:211207239~211207897:+ LIHC trans rs616147 0.85 rs631312 ENSG00000183298.5 RP11-556K13.1 -11.18 6.17e-25 3.92e-18 -0.71 -0.52 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39467477 chr1:101786340~101787219:- LIHC trans rs7811142 0.83 rs11771936 ENSG00000228546.2 CTA-313A17.3 11.16 6.96e-25 4.41e-18 0.88 0.52 Platelet count; chr7:100345660 chr7:102337316~102339115:+ LIHC trans rs7811142 0.779 rs77370288 ENSG00000228546.2 CTA-313A17.3 11.16 6.96e-25 4.41e-18 0.88 0.52 Platelet count; chr7:100350274 chr7:102337316~102339115:+ LIHC trans rs10037055 0.947 rs10063803 ENSG00000226986.4 RP11-543B16.2 11.16 7.07e-25 4.48e-18 0.57 0.52 Migraine without aura; chr5:177240326 chr1:211207239~211207897:+ LIHC trans rs7811142 0.779 rs111312383 ENSG00000228546.2 CTA-313A17.3 11.16 7.27e-25 4.61e-18 0.89 0.52 Platelet count; chr7:100307702 chr7:102337316~102339115:+ LIHC trans rs10037055 0.685 rs10039241 ENSG00000226986.4 RP11-543B16.2 -11.15 7.94e-25 5.03e-18 -0.6 -0.52 Migraine without aura; chr5:177151071 chr1:211207239~211207897:+ LIHC trans rs12709013 0.591 rs6499980 ENSG00000233719.3 GOT2P3 11.15 7.99e-25 5.06e-18 0.56 0.52 Blood metabolite ratios; chr16:58787972 chr12:9641802~9643007:+ LIHC trans rs6732160 0.613 rs57208378 ENSG00000236165.1 PRADC1P1 11.15 8.05e-25 5.09e-18 0.69 0.52 Intelligence (multi-trait analysis); chr2:73162871 chr3:36976316~36976840:+ LIHC trans rs13190036 0.551 rs11955537 ENSG00000226986.4 RP11-543B16.2 -11.14 8.73e-25 5.51e-18 -0.6 -0.52 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147087 chr1:211207239~211207897:+ LIHC trans rs9611565 0.568 rs2413656 ENSG00000268568.1 AC007228.9 11.13 8.92e-25 5.63e-18 0.78 0.52 Vitiligo; chr22:41733353 chr19:56672574~56673901:- LIHC trans rs55665837 1 rs11023215 ENSG00000236360.2 RP11-334A14.2 11.12 9.97e-25 6.27e-18 0.63 0.52 Vitamin D levels; chr11:14415424 chr1:52993201~52993702:- LIHC trans rs4822044 0.617 rs13054514 ENSG00000268568.1 AC007228.9 11.12 1.02e-24 6.44e-18 0.78 0.52 Cannabis dependence symptom count; chr22:41734379 chr19:56672574~56673901:- LIHC trans rs12709013 0.591 rs7184377 ENSG00000233719.3 GOT2P3 11.11 1.05e-24 6.63e-18 0.57 0.52 Blood metabolite ratios; chr16:58808765 chr12:9641802~9643007:+ LIHC trans rs10037055 0.853 rs4976680 ENSG00000226986.4 RP11-543B16.2 11.1 1.13e-24 7.02e-18 0.57 0.51 Migraine without aura; chr5:177275745 chr1:211207239~211207897:+ LIHC trans rs10037055 0.853 rs4976681 ENSG00000226986.4 RP11-543B16.2 11.1 1.13e-24 7.02e-18 0.57 0.51 Migraine without aura; chr5:177277662 chr1:211207239~211207897:+ LIHC trans rs10037055 0.812 rs11949435 ENSG00000226986.4 RP11-543B16.2 11.1 1.13e-24 7.02e-18 0.57 0.51 Migraine without aura; chr5:177287931 chr1:211207239~211207897:+ LIHC trans rs9611565 0.512 rs4820446 ENSG00000268568.1 AC007228.9 -11.1 1.15e-24 7.14e-18 -0.89 -0.51 Vitiligo; chr22:41819680 chr19:56672574~56673901:- LIHC trans rs9611565 0.592 rs4822040 ENSG00000268568.1 AC007228.9 -11.1 1.22e-24 7.55e-18 -0.8 -0.51 Vitiligo; chr22:41567549 chr19:56672574~56673901:- LIHC trans rs9467773 0.572 rs13213953 ENSG00000242375.1 RP11-498P14.3 11.09 1.28e-24 7.95e-18 0.61 0.51 Intelligence (multi-trait analysis); chr6:26594306 chr9:97195351~97197687:- LIHC trans rs13190036 1 rs59737888 ENSG00000226986.4 RP11-543B16.2 -11.07 1.47e-24 9.13e-18 -0.63 -0.51 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177160374 chr1:211207239~211207897:+ LIHC trans rs9611565 0.58 rs5758449 ENSG00000268568.1 AC007228.9 11.07 1.56e-24 9.65e-18 0.77 0.51 Vitiligo; chr22:41744156 chr19:56672574~56673901:- LIHC trans rs10037055 0.636 rs13166688 ENSG00000226986.4 RP11-543B16.2 -11.06 1.64e-24 1.01e-17 -0.59 -0.51 Migraine without aura; chr5:177156965 chr1:211207239~211207897:+ LIHC trans rs12709013 0.569 rs30837 ENSG00000233719.3 GOT2P3 11.05 1.71e-24 1.06e-17 0.59 0.51 Blood metabolite ratios; chr16:58711942 chr12:9641802~9643007:+ LIHC trans rs9611565 0.568 rs5758441 ENSG00000268568.1 AC007228.9 11.05 1.81e-24 1.12e-17 0.78 0.51 Vitiligo; chr22:41736884 chr19:56672574~56673901:- LIHC trans rs9611565 0.649 rs5758442 ENSG00000268568.1 AC007228.9 11.05 1.81e-24 1.12e-17 0.78 0.51 Vitiligo; chr22:41737056 chr19:56672574~56673901:- LIHC trans rs7811142 0.83 rs7341507 ENSG00000228546.2 CTA-313A17.3 11.05 1.83e-24 1.13e-17 0.86 0.51 Platelet count; chr7:100353692 chr7:102337316~102339115:+ LIHC trans rs9611565 0.649 rs139540 ENSG00000268568.1 AC007228.9 -11.03 2.1e-24 1.29e-17 -0.77 -0.51 Vitiligo; chr22:41782036 chr19:56672574~56673901:- LIHC trans rs10037055 0.853 rs12660023 ENSG00000226986.4 RP11-543B16.2 11.03 2.1e-24 1.29e-17 0.57 0.51 Migraine without aura; chr5:177273884 chr1:211207239~211207897:+ LIHC trans rs7811142 0.775 rs1636980 ENSG00000228546.2 CTA-313A17.3 -11.02 2.27e-24 1.39e-17 -0.86 -0.51 Platelet count; chr7:100341241 chr7:102337316~102339115:+ LIHC trans rs6732160 0.613 rs10179063 ENSG00000236165.1 PRADC1P1 11.01 2.37e-24 1.45e-17 0.68 0.51 Intelligence (multi-trait analysis); chr2:73157983 chr3:36976316~36976840:+ LIHC trans rs6732160 0.613 rs6546804 ENSG00000236165.1 PRADC1P1 11.01 2.37e-24 1.45e-17 0.68 0.51 Intelligence (multi-trait analysis); chr2:73158791 chr3:36976316~36976840:+ LIHC trans rs7811142 0.83 rs28495773 ENSG00000228546.2 CTA-313A17.3 11.01 2.39e-24 1.46e-17 0.9 0.51 Platelet count; chr7:100345960 chr7:102337316~102339115:+ LIHC trans rs6732160 0.613 rs58317144 ENSG00000236165.1 PRADC1P1 11.01 2.55e-24 1.56e-17 0.69 0.51 Intelligence (multi-trait analysis); chr2:73161025 chr3:36976316~36976840:+ LIHC trans rs12709013 0.535 rs9924136 ENSG00000233719.3 GOT2P3 11 2.57e-24 1.57e-17 0.55 0.51 Blood metabolite ratios; chr16:58779573 chr12:9641802~9643007:+ LIHC trans rs3749237 0.595 rs3870338 ENSG00000197582.5 GPX1P1 11 2.65e-24 1.62e-17 0.76 0.51 Resting heart rate; chr3:49519618 chrX:13378735~13379340:- LIHC trans rs12709013 0.792 rs1473206 ENSG00000233719.3 GOT2P3 11 2.72e-24 1.66e-17 0.49 0.51 Blood metabolite ratios; chr16:58737529 chr12:9641802~9643007:+ LIHC trans rs12709013 0.792 rs1473205 ENSG00000233719.3 GOT2P3 11 2.72e-24 1.66e-17 0.49 0.51 Blood metabolite ratios; chr16:58737547 chr12:9641802~9643007:+ LIHC trans rs6732160 0.613 rs59979991 ENSG00000236165.1 PRADC1P1 10.99 2.8e-24 1.71e-17 0.68 0.51 Intelligence (multi-trait analysis); chr2:73157294 chr3:36976316~36976840:+ LIHC trans rs3779195 0.697 rs13232861 ENSG00000225169.1 BRI3P1 10.99 2.87e-24 1.74e-17 0.79 0.51 Sex hormone-binding globulin levels; chr7:98299769 chr1:100213293~100213670:+ LIHC trans rs7811142 0.83 rs76798830 ENSG00000228546.2 CTA-313A17.3 10.99 2.9e-24 1.76e-17 0.92 0.51 Platelet count; chr7:100355205 chr7:102337316~102339115:+ LIHC trans rs7811142 0.775 rs6946768 ENSG00000228546.2 CTA-313A17.3 10.99 2.9e-24 1.76e-17 0.92 0.51 Platelet count; chr7:100356770 chr7:102337316~102339115:+ LIHC trans rs9611565 0.921 rs4822021 ENSG00000268568.1 AC007228.9 -10.97 3.34e-24 2.03e-17 -0.75 -0.51 Vitiligo; chr22:41330049 chr19:56672574~56673901:- LIHC trans rs9467773 0.534 rs34453863 ENSG00000242375.1 RP11-498P14.3 10.97 3.38e-24 2.05e-17 0.6 0.51 Intelligence (multi-trait analysis); chr6:26627777 chr9:97195351~97197687:- LIHC trans rs7811142 0.83 rs77861211 ENSG00000228546.2 CTA-313A17.3 10.96 3.65e-24 2.21e-17 0.88 0.51 Platelet count; chr7:100364473 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs11769057 ENSG00000228546.2 CTA-313A17.3 10.96 3.65e-24 2.21e-17 0.88 0.51 Platelet count; chr7:100367038 chr7:102337316~102339115:+ LIHC trans rs9611565 0.532 rs4401299 ENSG00000268568.1 AC007228.9 10.96 3.65e-24 2.22e-17 0.78 0.51 Vitiligo; chr22:41760513 chr19:56672574~56673901:- LIHC trans rs3779195 0.627 rs6950023 ENSG00000225169.1 BRI3P1 10.96 3.71e-24 2.25e-17 0.81 0.51 Sex hormone-binding globulin levels; chr7:98286323 chr1:100213293~100213670:+ LIHC trans rs3779195 0.627 rs6967728 ENSG00000225169.1 BRI3P1 10.96 3.71e-24 2.25e-17 0.81 0.51 Sex hormone-binding globulin levels; chr7:98286325 chr1:100213293~100213670:+ LIHC trans rs9611565 0.649 rs6002480 ENSG00000268568.1 AC007228.9 -10.96 3.71e-24 2.25e-17 -0.8 -0.51 Vitiligo; chr22:41780913 chr19:56672574~56673901:- LIHC trans rs12200782 0.53 rs9379892 ENSG00000242375.1 RP11-498P14.3 10.96 3.77e-24 2.28e-17 0.74 0.51 Small cell lung carcinoma; chr6:26582186 chr9:97195351~97197687:- LIHC trans rs6732160 0.588 rs62151795 ENSG00000236165.1 PRADC1P1 10.95 3.87e-24 2.34e-17 0.68 0.51 Intelligence (multi-trait analysis); chr2:73149712 chr3:36976316~36976840:+ LIHC trans rs9611565 0.649 rs4822050 ENSG00000268568.1 AC007228.9 -10.95 4.1e-24 2.48e-17 -0.7 -0.51 Vitiligo; chr22:41781449 chr19:56672574~56673901:- LIHC trans rs13177918 0.734 rs6579790 ENSG00000239528.1 RPS14P8 10.94 4.23e-24 2.55e-17 0.7 0.51 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464379 chr5:116562562~116562930:+ LIHC trans rs9467773 0.572 rs62394558 ENSG00000242375.1 RP11-498P14.3 10.94 4.33e-24 2.61e-17 0.6 0.51 Intelligence (multi-trait analysis); chr6:26604422 chr9:97195351~97197687:- LIHC trans rs7554547 0.871 rs11588551 ENSG00000261819.1 RP11-680G24.4 -10.93 4.7e-24 2.83e-17 -0.66 -0.51 Nonsyndromic cleft lip with cleft palate; chr1:11881879 chr16:14988259~14990160:- LIHC trans rs9467773 1 rs9467779 ENSG00000242375.1 RP11-498P14.3 -10.93 4.75e-24 2.86e-17 -0.59 -0.51 Intelligence (multi-trait analysis); chr6:26536459 chr9:97195351~97197687:- LIHC trans rs9611565 0.592 rs12484254 ENSG00000268568.1 AC007228.9 -10.93 4.77e-24 2.87e-17 -0.79 -0.51 Vitiligo; chr22:41565999 chr19:56672574~56673901:- LIHC trans rs6732160 0.588 rs3891890 ENSG00000236165.1 PRADC1P1 10.93 4.8e-24 2.89e-17 0.69 0.51 Intelligence (multi-trait analysis); chr2:73150921 chr3:36976316~36976840:+ LIHC trans rs9611565 0.659 rs12483998 ENSG00000268568.1 AC007228.9 -10.93 4.91e-24 2.95e-17 -0.89 -0.51 Vitiligo; chr22:41539358 chr19:56672574~56673901:- LIHC trans rs928391 0.744 rs11264555 ENSG00000227183.3 HDGFP1 -10.9 5.93e-24 3.56e-17 -0.67 -0.51 Platelet count; chr1:156794246 chrX:131646639~131646890:+ LIHC trans rs10242455 0.702 rs7794068 ENSG00000228834.1 RP11-249L21.4 10.9 5.94e-24 3.56e-17 1.26 0.51 Blood metabolite levels; chr7:99549250 chr6:108907615~108907873:- LIHC trans rs9611565 0.649 rs139559 ENSG00000268568.1 AC007228.9 -10.89 6.68e-24 4e-17 -0.78 -0.51 Vitiligo; chr22:41795632 chr19:56672574~56673901:- LIHC trans rs6732160 0.588 rs28626211 ENSG00000236165.1 PRADC1P1 10.88 6.99e-24 4.19e-17 0.69 0.51 Intelligence (multi-trait analysis); chr2:73151394 chr3:36976316~36976840:+ LIHC trans rs9611565 0.57 rs12159188 ENSG00000268568.1 AC007228.9 10.88 7.34e-24 4.39e-17 0.75 0.51 Vitiligo; chr22:41725121 chr19:56672574~56673901:- LIHC trans rs9611565 0.649 rs2413659 ENSG00000268568.1 AC007228.9 10.87 7.79e-24 4.66e-17 0.78 0.51 Vitiligo; chr22:41768858 chr19:56672574~56673901:- LIHC trans rs6732160 0.564 rs60796597 ENSG00000236165.1 PRADC1P1 10.86 8.08e-24 4.83e-17 0.68 0.51 Intelligence (multi-trait analysis); chr2:73155786 chr3:36976316~36976840:+ LIHC trans rs12709013 0.729 rs1657179 ENSG00000233719.3 GOT2P3 10.86 8.33e-24 4.97e-17 0.49 0.51 Blood metabolite ratios; chr16:58735115 chr12:9641802~9643007:+ LIHC trans rs9611565 0.592 rs9611613 ENSG00000268568.1 AC007228.9 -10.84 9.6e-24 5.72e-17 -0.79 -0.51 Vitiligo; chr22:41565827 chr19:56672574~56673901:- LIHC trans rs6732160 0.588 rs13407363 ENSG00000236165.1 PRADC1P1 10.84 9.77e-24 5.82e-17 0.68 0.51 Intelligence (multi-trait analysis); chr2:73145430 chr3:36976316~36976840:+ LIHC trans rs6732160 0.588 rs1430344 ENSG00000236165.1 PRADC1P1 10.84 9.79e-24 5.82e-17 0.68 0.51 Intelligence (multi-trait analysis); chr2:73146216 chr3:36976316~36976840:+ LIHC trans rs6732160 0.588 rs2043100 ENSG00000236165.1 PRADC1P1 10.84 9.79e-24 5.82e-17 0.68 0.51 Intelligence (multi-trait analysis); chr2:73146968 chr3:36976316~36976840:+ LIHC trans rs6732160 0.588 rs2043099 ENSG00000236165.1 PRADC1P1 10.84 9.79e-24 5.82e-17 0.68 0.51 Intelligence (multi-trait analysis); chr2:73147028 chr3:36976316~36976840:+ LIHC trans rs6732160 0.588 rs11126392 ENSG00000236165.1 PRADC1P1 10.84 9.79e-24 5.82e-17 0.68 0.51 Intelligence (multi-trait analysis); chr2:73147326 chr3:36976316~36976840:+ LIHC trans rs6732160 0.588 rs7578991 ENSG00000236165.1 PRADC1P1 10.84 9.79e-24 5.82e-17 0.68 0.51 Intelligence (multi-trait analysis); chr2:73149043 chr3:36976316~36976840:+ LIHC trans rs6732160 0.564 rs7605716 ENSG00000236165.1 PRADC1P1 10.84 9.79e-24 5.82e-17 0.68 0.51 Intelligence (multi-trait analysis); chr2:73149122 chr3:36976316~36976840:+ LIHC trans rs12709013 0.694 rs1616798 ENSG00000233719.3 GOT2P3 10.83 1.04e-23 6.16e-17 0.49 0.51 Blood metabolite ratios; chr16:58739433 chr12:9641802~9643007:+ LIHC trans rs6732160 0.517 rs10189791 ENSG00000236165.1 PRADC1P1 10.83 1.06e-23 6.3e-17 0.7 0.51 Intelligence (multi-trait analysis); chr2:73170571 chr3:36976316~36976840:+ LIHC trans rs9611565 0.572 rs139569 ENSG00000268568.1 AC007228.9 -10.83 1.07e-23 6.33e-17 -0.76 -0.51 Vitiligo; chr22:41815137 chr19:56672574~56673901:- LIHC trans rs928391 0.744 rs3765783 ENSG00000227183.3 HDGFP1 -10.82 1.15e-23 6.8e-17 -0.67 -0.51 Platelet count; chr1:156796181 chrX:131646639~131646890:+ LIHC trans rs9611565 0.559 rs12483860 ENSG00000268568.1 AC007228.9 -10.81 1.27e-23 7.51e-17 -0.79 -0.5 Vitiligo; chr22:41565912 chr19:56672574~56673901:- LIHC trans rs9611565 0.559 rs7290990 ENSG00000268568.1 AC007228.9 -10.81 1.27e-23 7.51e-17 -0.79 -0.5 Vitiligo; chr22:41568353 chr19:56672574~56673901:- LIHC trans rs9611565 0.559 rs7290991 ENSG00000268568.1 AC007228.9 -10.81 1.27e-23 7.51e-17 -0.79 -0.5 Vitiligo; chr22:41568357 chr19:56672574~56673901:- LIHC trans rs9611565 0.592 rs5996037 ENSG00000268568.1 AC007228.9 -10.81 1.27e-23 7.51e-17 -0.79 -0.5 Vitiligo; chr22:41569288 chr19:56672574~56673901:- LIHC trans rs9611565 0.592 rs5996038 ENSG00000268568.1 AC007228.9 -10.81 1.27e-23 7.51e-17 -0.79 -0.5 Vitiligo; chr22:41569296 chr19:56672574~56673901:- LIHC trans rs6732160 0.588 rs2043101 ENSG00000236165.1 PRADC1P1 10.8 1.4e-23 8.3e-17 0.68 0.5 Intelligence (multi-trait analysis); chr2:73146922 chr3:36976316~36976840:+ LIHC trans rs10037055 0.853 rs1363405 ENSG00000226986.4 RP11-543B16.2 10.78 1.64e-23 9.68e-17 0.56 0.5 Migraine without aura; chr5:177209881 chr1:211207239~211207897:+ LIHC trans rs9611565 0.649 rs5758466 ENSG00000268568.1 AC007228.9 10.78 1.66e-23 9.8e-17 0.79 0.5 Vitiligo; chr22:41780055 chr19:56672574~56673901:- LIHC trans rs10037055 0.687 rs6556308 ENSG00000226986.4 RP11-543B16.2 -10.77 1.68e-23 9.91e-17 -0.56 -0.5 Migraine without aura; chr5:177219700 chr1:211207239~211207897:+ LIHC trans rs10037055 0.853 rs1546363 ENSG00000226986.4 RP11-543B16.2 -10.77 1.77e-23 1.04e-16 -0.56 -0.5 Migraine without aura; chr5:177174030 chr1:211207239~211207897:+ LIHC trans rs10037055 0.853 rs10056008 ENSG00000226986.4 RP11-543B16.2 -10.77 1.77e-23 1.04e-16 -0.56 -0.5 Migraine without aura; chr5:177194147 chr1:211207239~211207897:+ LIHC trans rs10037055 0.853 rs10476219 ENSG00000226986.4 RP11-543B16.2 -10.77 1.77e-23 1.04e-16 -0.56 -0.5 Migraine without aura; chr5:177201547 chr1:211207239~211207897:+ LIHC trans rs10037055 0.853 rs2336237 ENSG00000226986.4 RP11-543B16.2 10.75 2.1e-23 1.23e-16 0.56 0.5 Migraine without aura; chr5:177238878 chr1:211207239~211207897:+ LIHC trans rs10242455 0.557 rs73403272 ENSG00000228834.1 RP11-249L21.4 10.73 2.37e-23 1.39e-16 1.25 0.5 Blood metabolite levels; chr7:99536585 chr6:108907615~108907873:- LIHC trans rs13177918 0.734 rs6579791 ENSG00000239528.1 RPS14P8 10.73 2.37e-23 1.39e-16 0.69 0.5 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464440 chr5:116562562~116562930:+ LIHC trans rs7811142 0.83 rs78256546 ENSG00000228546.2 CTA-313A17.3 10.73 2.48e-23 1.45e-16 0.87 0.5 Platelet count; chr7:100355347 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs41280971 ENSG00000228546.2 CTA-313A17.3 10.73 2.48e-23 1.45e-16 0.87 0.5 Platelet count; chr7:100356834 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs3087502 ENSG00000228546.2 CTA-313A17.3 10.73 2.48e-23 1.45e-16 0.87 0.5 Platelet count; chr7:100357741 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs61735533 ENSG00000228546.2 CTA-313A17.3 10.73 2.48e-23 1.45e-16 0.87 0.5 Platelet count; chr7:100358243 chr7:102337316~102339115:+ LIHC trans rs7811142 0.83 rs11761426 ENSG00000228546.2 CTA-313A17.3 10.73 2.48e-23 1.45e-16 0.87 0.5 Platelet count; chr7:100359270 chr7:102337316~102339115:+ LIHC trans rs9467773 1 rs9467782 ENSG00000242375.1 RP11-498P14.3 10.72 2.52e-23 1.48e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26542545 chr9:97195351~97197687:- LIHC trans rs9467773 0.935 rs9461270 ENSG00000242375.1 RP11-498P14.3 10.72 2.52e-23 1.48e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26543882 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs4871 ENSG00000242375.1 RP11-498P14.3 10.72 2.52e-23 1.48e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26545404 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs1321480 ENSG00000242375.1 RP11-498P14.3 10.72 2.58e-23 1.51e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26532514 chr9:97195351~97197687:- LIHC trans rs10037055 0.853 rs9313749 ENSG00000226986.4 RP11-543B16.2 -10.72 2.58e-23 1.51e-16 -0.55 -0.5 Migraine without aura; chr5:177170693 chr1:211207239~211207897:+ LIHC trans rs10037055 0.853 rs10035180 ENSG00000226986.4 RP11-543B16.2 -10.72 2.58e-23 1.51e-16 -0.56 -0.5 Migraine without aura; chr5:177171501 chr1:211207239~211207897:+ LIHC trans rs616147 1 rs616147 ENSG00000183298.5 RP11-556K13.1 -10.71 2.75e-23 1.6e-16 -0.68 -0.5 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39492990 chr1:101786340~101787219:- LIHC trans rs9467773 1 rs9393731 ENSG00000242375.1 RP11-498P14.3 10.71 2.89e-23 1.68e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26529146 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs11756120 ENSG00000242375.1 RP11-498P14.3 10.71 2.89e-23 1.68e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26529580 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs9393732 ENSG00000242375.1 RP11-498P14.3 10.71 2.89e-23 1.68e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26530670 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs28558133 ENSG00000242375.1 RP11-498P14.3 10.71 2.89e-23 1.68e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26531205 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs10946835 ENSG00000242375.1 RP11-498P14.3 10.71 2.89e-23 1.68e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26533529 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs9467778 ENSG00000242375.1 RP11-498P14.3 10.71 2.89e-23 1.68e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26534515 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs2393670 ENSG00000242375.1 RP11-498P14.3 10.71 2.89e-23 1.68e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26535313 chr9:97195351~97197687:- LIHC trans rs9611565 0.504 rs5758452 ENSG00000268568.1 AC007228.9 10.71 2.92e-23 1.7e-16 0.77 0.5 Vitiligo; chr22:41748923 chr19:56672574~56673901:- LIHC trans rs7811142 0.943 rs111757992 ENSG00000228546.2 CTA-313A17.3 10.7 3.07e-23 1.78e-16 0.9 0.5 Platelet count; chr7:100418731 chr7:102337316~102339115:+ LIHC trans rs1816752 0.524 rs1965154 ENSG00000237917.1 PARP4P1 -10.7 3.1e-23 1.8e-16 -0.56 -0.5 Obesity-related traits; chr13:24498062 chrY:26594851~26634652:- LIHC trans rs727563 0.565 rs132774 ENSG00000268568.1 AC007228.9 -10.7 3.1e-23 1.8e-16 -0.74 -0.5 Crohn's disease;Inflammatory bowel disease; chr22:41635949 chr19:56672574~56673901:- LIHC trans rs9467773 1 rs10946834 ENSG00000242375.1 RP11-498P14.3 10.7 3.13e-23 1.82e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26533436 chr9:97195351~97197687:- LIHC trans rs928391 0.744 rs2274503 ENSG00000227183.3 HDGFP1 -10.69 3.21e-23 1.86e-16 -0.68 -0.5 Platelet count; chr1:156782256 chrX:131646639~131646890:+ LIHC trans rs13190036 1 rs655623 ENSG00000226986.4 RP11-543B16.2 10.69 3.23e-23 1.88e-16 0.59 0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177107515 chr1:211207239~211207897:+ LIHC trans rs9467773 1 rs1884946 ENSG00000242375.1 RP11-498P14.3 10.68 3.5e-23 2.03e-16 0.58 0.5 Intelligence (multi-trait analysis); chr6:26545080 chr9:97195351~97197687:- LIHC trans rs3749237 0.555 rs7637665 ENSG00000197582.5 GPX1P1 10.68 3.51e-23 2.03e-16 0.75 0.5 Resting heart rate; chr3:49514862 chrX:13378735~13379340:- LIHC trans rs10037055 0.741 rs2336405 ENSG00000226986.4 RP11-543B16.2 -10.68 3.53e-23 2.05e-16 -0.55 -0.5 Migraine without aura; chr5:177230288 chr1:211207239~211207897:+ LIHC trans rs9467773 1 rs1321481 ENSG00000242375.1 RP11-498P14.3 10.68 3.6e-23 2.08e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26537982 chr9:97195351~97197687:- LIHC trans rs9467773 0.967 rs6932865 ENSG00000242375.1 RP11-498P14.3 10.68 3.6e-23 2.08e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26539938 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs6933176 ENSG00000242375.1 RP11-498P14.3 10.68 3.6e-23 2.08e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26539950 chr9:97195351~97197687:- LIHC trans rs9467773 0.967 rs9358954 ENSG00000242375.1 RP11-498P14.3 10.68 3.6e-23 2.08e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26530950 chr9:97195351~97197687:- LIHC trans rs12200782 0.53 rs6929908 ENSG00000242375.1 RP11-498P14.3 10.68 3.72e-23 2.15e-16 0.73 0.5 Small cell lung carcinoma; chr6:26555061 chr9:97195351~97197687:- LIHC trans rs10242455 0.571 rs11972210 ENSG00000228834.1 RP11-249L21.4 10.67 3.9e-23 2.26e-16 1.24 0.5 Blood metabolite levels; chr7:99609320 chr6:108907615~108907873:- LIHC trans rs9611565 0.921 rs8137373 ENSG00000268568.1 AC007228.9 10.67 4.02e-23 2.32e-16 0.74 0.5 Vitiligo; chr22:41333212 chr19:56672574~56673901:- LIHC trans rs6732160 0.588 rs1430345 ENSG00000236165.1 PRADC1P1 10.66 4.39e-23 2.53e-16 0.67 0.5 Intelligence (multi-trait analysis); chr2:73143554 chr3:36976316~36976840:+ LIHC trans rs7554547 0.871 rs6661289 ENSG00000261819.1 RP11-680G24.4 10.65 4.75e-23 2.74e-16 0.65 0.5 Nonsyndromic cleft lip with cleft palate; chr1:11882724 chr16:14988259~14990160:- LIHC trans rs928391 0.572 rs11264548 ENSG00000227183.3 HDGFP1 -10.64 4.95e-23 2.85e-16 -0.67 -0.5 Platelet count; chr1:156779339 chrX:131646639~131646890:+ LIHC trans rs2657294 0.796 rs2804535 ENSG00000172974.11 AC007318.5 -10.64 5.05e-23 2.91e-16 -0.52 -0.5 Pneumonia; chr10:75212086 chr2:65205108~65205988:+ LIHC trans rs928391 0.744 rs6700964 ENSG00000227183.3 HDGFP1 -10.64 5.09e-23 2.93e-16 -0.66 -0.5 Platelet count; chr1:156790244 chrX:131646639~131646890:+ LIHC trans rs3749237 0.595 rs12489092 ENSG00000197582.5 GPX1P1 10.63 5.21e-23 3e-16 0.75 0.5 Resting heart rate; chr3:49513481 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs3870337 ENSG00000197582.5 GPX1P1 10.63 5.21e-23 3e-16 0.75 0.5 Resting heart rate; chr3:49519662 chrX:13378735~13379340:- LIHC trans rs61990749 0.511 rs10146144 ENSG00000235400.1 RP4-641G12.4 10.63 5.29e-23 3.04e-16 0.71 0.5 Fibroblast growth factor basic levels; chr14:77858957 chr1:78749073~78750659:+ LIHC trans rs9467773 1 rs12526680 ENSG00000242375.1 RP11-498P14.3 10.63 5.29e-23 3.04e-16 0.57 0.5 Intelligence (multi-trait analysis); chr6:26550726 chr9:97195351~97197687:- LIHC trans rs7811142 1 rs28490152 ENSG00000228546.2 CTA-313A17.3 10.63 5.36e-23 3.08e-16 0.89 0.5 Platelet count; chr7:100423359 chr7:102337316~102339115:+ LIHC trans rs7811142 0.943 rs28660238 ENSG00000228546.2 CTA-313A17.3 10.63 5.36e-23 3.08e-16 0.89 0.5 Platelet count; chr7:100425685 chr7:102337316~102339115:+ LIHC trans rs616147 0.627 rs816487 ENSG00000214263.2 RPSAP53 -10.63 5.6e-23 3.22e-16 -0.66 -0.5 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39445999 chr13:67266845~67267706:- LIHC trans rs9611565 0.559 rs6002408 ENSG00000268568.1 AC007228.9 -10.62 5.72e-23 3.29e-16 -0.78 -0.5 Vitiligo; chr22:41571866 chr19:56672574~56673901:- LIHC trans rs3779195 0.929 rs2906184 ENSG00000225169.1 BRI3P1 -10.62 5.78e-23 3.31e-16 -0.77 -0.5 Sex hormone-binding globulin levels; chr7:98310675 chr1:100213293~100213670:+ LIHC trans rs7930295 0.505 rs34303332 ENSG00000236257.1 EI24P2 10.6 6.71e-23 3.84e-16 0.67 0.5 Schizophrenia; chr11:125544288 chr1:158454198~158455273:+ LIHC trans rs6732160 0.588 rs10192654 ENSG00000236165.1 PRADC1P1 -10.6 6.71e-23 3.84e-16 -0.67 -0.5 Intelligence (multi-trait analysis); chr2:73143754 chr3:36976316~36976840:+ LIHC trans rs10037055 0.853 rs10036193 ENSG00000226986.4 RP11-543B16.2 -10.6 6.76e-23 3.87e-16 -0.56 -0.5 Migraine without aura; chr5:177141519 chr1:211207239~211207897:+ LIHC trans rs10037055 0.853 rs9885210 ENSG00000226986.4 RP11-543B16.2 -10.6 6.76e-23 3.87e-16 -0.56 -0.5 Migraine without aura; chr5:177142187 chr1:211207239~211207897:+ LIHC trans rs8067354 0.789 rs1292068 ENSG00000187870.7 RNFT1P3 10.6 6.9e-23 3.94e-16 0.57 0.5 Hemoglobin concentration; chr17:59851958 chr17:20743333~20754501:- LIHC trans rs10037055 0.898 rs4976636 ENSG00000226986.4 RP11-543B16.2 -10.59 7.19e-23 4.11e-16 -0.57 -0.5 Migraine without aura; chr5:177118091 chr1:211207239~211207897:+ LIHC trans rs10037055 0.898 rs4976637 ENSG00000226986.4 RP11-543B16.2 -10.59 7.19e-23 4.11e-16 -0.57 -0.5 Migraine without aura; chr5:177118141 chr1:211207239~211207897:+ LIHC trans rs9467773 1 rs4713008 ENSG00000242375.1 RP11-498P14.3 10.59 7.32e-23 4.18e-16 0.59 0.5 Intelligence (multi-trait analysis); chr6:26538040 chr9:97195351~97197687:- LIHC trans rs9611565 0.614 rs4822053 ENSG00000268568.1 AC007228.9 -10.59 7.73e-23 4.41e-16 -0.74 -0.5 Vitiligo; chr22:41816932 chr19:56672574~56673901:- LIHC trans rs9467773 1 rs9295695 ENSG00000242375.1 RP11-498P14.3 -10.58 8.13e-23 4.64e-16 -0.58 -0.5 Intelligence (multi-trait analysis); chr6:26528022 chr9:97195351~97197687:- LIHC trans rs9611565 0.649 rs139553 ENSG00000268568.1 AC007228.9 10.57 9.1e-23 5.18e-16 0.76 0.5 Vitiligo; chr22:41791195 chr19:56672574~56673901:- LIHC trans rs2657294 0.796 rs2657290 ENSG00000172974.11 AC007318.5 10.56 9.65e-23 5.49e-16 0.52 0.5 Pneumonia; chr10:75207404 chr2:65205108~65205988:+ LIHC trans rs3749237 0.555 rs2117939 ENSG00000197582.5 GPX1P1 10.55 1.01e-22 5.75e-16 0.74 0.5 Resting heart rate; chr3:49377746 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs6797765 ENSG00000197582.5 GPX1P1 10.55 1.01e-22 5.75e-16 0.74 0.5 Resting heart rate; chr3:49386543 chrX:13378735~13379340:- LIHC trans rs61990749 0.511 rs724263 ENSG00000235400.1 RP4-641G12.4 10.55 1.01e-22 5.76e-16 0.71 0.5 Fibroblast growth factor basic levels; chr14:77855531 chr1:78749073~78750659:+ LIHC trans rs2657294 0.726 rs4746275 ENSG00000172974.11 AC007318.5 10.55 1.06e-22 6e-16 0.52 0.5 Pneumonia; chr10:75214940 chr2:65205108~65205988:+ LIHC trans rs3749237 0.595 rs1464568 ENSG00000197582.5 GPX1P1 10.55 1.06e-22 6.01e-16 0.74 0.5 Resting heart rate; chr3:49420833 chrX:13378735~13379340:- LIHC trans rs61990749 0.511 rs10130790 ENSG00000235400.1 RP4-641G12.4 10.54 1.13e-22 6.38e-16 0.71 0.5 Fibroblast growth factor basic levels; chr14:77857849 chr1:78749073~78750659:+ LIHC trans rs6732160 0.564 rs1430346 ENSG00000236165.1 PRADC1P1 10.53 1.21e-22 6.86e-16 0.68 0.49 Intelligence (multi-trait analysis); chr2:73140117 chr3:36976316~36976840:+ LIHC trans rs3749237 0.537 rs4459909 ENSG00000197582.5 GPX1P1 10.53 1.22e-22 6.92e-16 0.74 0.49 Resting heart rate; chr3:49431784 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs11130196 ENSG00000197582.5 GPX1P1 10.53 1.22e-22 6.92e-16 0.74 0.49 Resting heart rate; chr3:49452716 chrX:13378735~13379340:- LIHC trans rs13177918 0.717 rs6874318 ENSG00000239528.1 RPS14P8 -10.53 1.24e-22 7.03e-16 -0.65 -0.49 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150462836 chr5:116562562~116562930:+ LIHC trans rs9611565 0.592 rs9611612 ENSG00000268568.1 AC007228.9 -10.53 1.25e-22 7.06e-16 -0.75 -0.49 Vitiligo; chr22:41565185 chr19:56672574~56673901:- LIHC trans rs3749237 0.595 rs17595772 ENSG00000197582.5 GPX1P1 10.52 1.27e-22 7.15e-16 0.74 0.49 Resting heart rate; chr3:49372271 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs7621003 ENSG00000197582.5 GPX1P1 10.52 1.27e-22 7.15e-16 0.74 0.49 Resting heart rate; chr3:49373971 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs4955412 ENSG00000197582.5 GPX1P1 10.52 1.27e-22 7.15e-16 0.74 0.49 Resting heart rate; chr3:49380735 chrX:13378735~13379340:- LIHC trans rs3749237 0.557 rs7631908 ENSG00000197582.5 GPX1P1 10.52 1.27e-22 7.15e-16 0.74 0.49 Resting heart rate; chr3:49388274 chrX:13378735~13379340:- LIHC trans rs3749237 0.615 rs55957735 ENSG00000197582.5 GPX1P1 10.52 1.27e-22 7.15e-16 0.74 0.49 Resting heart rate; chr3:49400725 chrX:13378735~13379340:- LIHC trans rs10242455 0.702 rs2293256 ENSG00000228834.1 RP11-249L21.4 -10.52 1.28e-22 7.21e-16 -1.05 -0.49 Blood metabolite levels; chr7:99460078 chr6:108907615~108907873:- LIHC trans rs3749237 0.595 rs4855873 ENSG00000197582.5 GPX1P1 10.52 1.35e-22 7.64e-16 0.74 0.49 Resting heart rate; chr3:49421681 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs1464566 ENSG00000197582.5 GPX1P1 10.52 1.35e-22 7.64e-16 0.74 0.49 Resting heart rate; chr3:49421943 chrX:13378735~13379340:- LIHC trans rs3779195 0.929 rs10953259 ENSG00000225169.1 BRI3P1 -10.51 1.42e-22 8.02e-16 -0.76 -0.49 Sex hormone-binding globulin levels; chr7:98383795 chr1:100213293~100213670:+ LIHC trans rs3749237 0.595 rs4855877 ENSG00000197582.5 GPX1P1 10.5 1.5e-22 8.46e-16 0.74 0.49 Resting heart rate; chr3:49411094 chrX:13378735~13379340:- LIHC trans rs616147 0.627 rs816510 ENSG00000214263.2 RPSAP53 -10.5 1.58e-22 8.9e-16 -0.66 -0.49 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39430804 chr13:67266845~67267706:- LIHC trans rs6732160 0.564 rs2043096 ENSG00000236165.1 PRADC1P1 10.48 1.84e-22 1.03e-15 0.66 0.49 Intelligence (multi-trait analysis); chr2:73148595 chr3:36976316~36976840:+ LIHC trans rs616147 0.962 rs1708104 ENSG00000183298.5 RP11-556K13.1 -10.47 1.9e-22 1.07e-15 -0.66 -0.49 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39493251 chr1:101786340~101787219:- LIHC trans rs7811142 0.83 rs118119933 ENSG00000228546.2 CTA-313A17.3 10.47 2e-22 1.12e-15 0.94 0.49 Platelet count; chr7:100341427 chr7:102337316~102339115:+ LIHC trans rs10037055 0.741 rs4976640 ENSG00000226986.4 RP11-543B16.2 -10.47 2.02e-22 1.13e-15 -0.55 -0.49 Migraine without aura; chr5:177125006 chr1:211207239~211207897:+ LIHC trans rs6732160 0.588 rs13403748 ENSG00000236165.1 PRADC1P1 10.46 2.05e-22 1.15e-15 0.66 0.49 Intelligence (multi-trait analysis); chr2:73144347 chr3:36976316~36976840:+ LIHC trans rs6732160 0.588 rs72841902 ENSG00000236165.1 PRADC1P1 10.46 2.05e-22 1.15e-15 0.66 0.49 Intelligence (multi-trait analysis); chr2:73145084 chr3:36976316~36976840:+ LIHC trans rs13190036 0.551 rs7732930 ENSG00000226986.4 RP11-543B16.2 -10.46 2.14e-22 1.2e-15 -0.58 -0.49 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177121593 chr1:211207239~211207897:+ LIHC trans rs3749237 0.595 rs35701831 ENSG00000197582.5 GPX1P1 10.45 2.3e-22 1.29e-15 0.73 0.49 Resting heart rate; chr3:49477567 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs2878298 ENSG00000197582.5 GPX1P1 10.44 2.5e-22 1.39e-15 0.74 0.49 Resting heart rate; chr3:49368647 chrX:13378735~13379340:- LIHC trans rs9467773 1 rs9467783 ENSG00000242375.1 RP11-498P14.3 10.44 2.51e-22 1.4e-15 0.58 0.49 Intelligence (multi-trait analysis); chr6:26542666 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs6910899 ENSG00000242375.1 RP11-498P14.3 10.44 2.57e-22 1.43e-15 0.58 0.49 Intelligence (multi-trait analysis); chr6:26524111 chr9:97195351~97197687:- LIHC trans rs9467773 0.967 rs9461267 ENSG00000242375.1 RP11-498P14.3 10.44 2.57e-22 1.43e-15 0.58 0.49 Intelligence (multi-trait analysis); chr6:26525227 chr9:97195351~97197687:- LIHC trans rs9467773 0.967 rs1056347 ENSG00000242375.1 RP11-498P14.3 10.44 2.57e-22 1.43e-15 0.58 0.49 Intelligence (multi-trait analysis); chr6:26527296 chr9:97195351~97197687:- LIHC trans rs616147 0.816 rs1768190 ENSG00000183298.5 RP11-556K13.1 10.44 2.58e-22 1.43e-15 0.67 0.49 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39467949 chr1:101786340~101787219:- LIHC trans rs7399018 0.739 rs6580811 ENSG00000223825.5 DAZAP2P1 10.42 2.81e-22 1.56e-15 0.62 0.49 Cisplatin-induced ototoxicity; chr12:51218717 chr2:202201384~202201886:- LIHC trans rs3749237 0.595 rs4855839 ENSG00000197582.5 GPX1P1 10.42 3e-22 1.66e-15 0.73 0.49 Resting heart rate; chr3:49470414 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs4855864 ENSG00000197582.5 GPX1P1 10.42 3e-22 1.66e-15 0.73 0.49 Resting heart rate; chr3:49484541 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs11130199 ENSG00000197582.5 GPX1P1 10.42 3e-22 1.66e-15 0.73 0.49 Resting heart rate; chr3:49501366 chrX:13378735~13379340:- LIHC trans rs12200782 0.505 rs9295696 ENSG00000242375.1 RP11-498P14.3 10.41 3.19e-22 1.77e-15 0.71 0.49 Small cell lung carcinoma; chr6:26550060 chr9:97195351~97197687:- LIHC trans rs6732160 0.588 rs13390460 ENSG00000236165.1 PRADC1P1 10.4 3.47e-22 1.92e-15 0.66 0.49 Intelligence (multi-trait analysis); chr2:73144348 chr3:36976316~36976840:+ LIHC trans rs9611565 0.649 rs9623450 ENSG00000268568.1 AC007228.9 10.35 5.24e-22 2.88e-15 0.76 0.49 Vitiligo; chr22:41779227 chr19:56672574~56673901:- LIHC trans rs9611565 0.568 rs5751159 ENSG00000268568.1 AC007228.9 10.35 5.24e-22 2.88e-15 0.76 0.49 Vitiligo; chr22:41779361 chr19:56672574~56673901:- LIHC trans rs61990749 0.511 rs2052444 ENSG00000235400.1 RP4-641G12.4 10.34 5.29e-22 2.91e-15 0.69 0.49 Fibroblast growth factor basic levels; chr14:77846575 chr1:78749073~78750659:+ LIHC trans rs3749237 0.595 rs6784820 ENSG00000197582.5 GPX1P1 -10.33 5.87e-22 3.22e-15 -0.74 -0.49 Resting heart rate; chr3:49413431 chrX:13378735~13379340:- LIHC trans rs10037055 0.853 rs6890580 ENSG00000226986.4 RP11-543B16.2 -10.31 7.16e-22 3.92e-15 -0.54 -0.49 Migraine without aura; chr5:177226519 chr1:211207239~211207897:+ LIHC trans rs2657294 0.765 rs2804533 ENSG00000172974.11 AC007318.5 10.3 7.31e-22 4e-15 0.51 0.49 Pneumonia; chr10:75207723 chr2:65205108~65205988:+ LIHC trans rs3749237 0.595 rs1568661 ENSG00000197582.5 GPX1P1 10.28 8.65e-22 4.71e-15 0.73 0.49 Resting heart rate; chr3:49483525 chrX:13378735~13379340:- LIHC trans rs3749237 0.576 rs4241406 ENSG00000197582.5 GPX1P1 10.28 8.83e-22 4.81e-15 0.74 0.49 Resting heart rate; chr3:49562993 chrX:13378735~13379340:- LIHC trans rs3779195 0.86 rs12704986 ENSG00000225169.1 BRI3P1 10.28 9.08e-22 4.94e-15 0.75 0.49 Sex hormone-binding globulin levels; chr7:98357118 chr1:100213293~100213670:+ LIHC trans rs3779195 0.858 rs3779196 ENSG00000225169.1 BRI3P1 10.28 9.08e-22 4.94e-15 0.75 0.49 Sex hormone-binding globulin levels; chr7:98360794 chr1:100213293~100213670:+ LIHC trans rs3779195 0.789 rs6965424 ENSG00000225169.1 BRI3P1 10.28 9.08e-22 4.94e-15 0.75 0.49 Sex hormone-binding globulin levels; chr7:98361813 chr1:100213293~100213670:+ LIHC trans rs9467773 1 rs9357010 ENSG00000242375.1 RP11-498P14.3 10.28 9.2e-22 5.01e-15 0.56 0.49 Intelligence (multi-trait analysis); chr6:26527717 chr9:97195351~97197687:- LIHC trans rs9467773 0.967 rs9295694 ENSG00000242375.1 RP11-498P14.3 10.28 9.21e-22 5.01e-15 0.57 0.49 Intelligence (multi-trait analysis); chr6:26512766 chr9:97195351~97197687:- LIHC trans rs9467773 0.967 rs9467775 ENSG00000242375.1 RP11-498P14.3 10.28 9.21e-22 5.01e-15 0.57 0.49 Intelligence (multi-trait analysis); chr6:26513207 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs9393729 ENSG00000242375.1 RP11-498P14.3 10.28 9.21e-22 5.01e-15 0.57 0.49 Intelligence (multi-trait analysis); chr6:26513938 chr9:97195351~97197687:- LIHC trans rs9467773 0.967 rs6456732 ENSG00000242375.1 RP11-498P14.3 10.28 9.21e-22 5.01e-15 0.57 0.49 Intelligence (multi-trait analysis); chr6:26514217 chr9:97195351~97197687:- LIHC trans rs6132905 0.52 rs2422823 ENSG00000235559.1 NOP56P1 -10.26 1.01e-21 5.49e-15 -0.55 -0.49 Mumps; chr20:2665687 chr6:28783633~28784004:- LIHC trans rs3749237 0.615 rs11130202 ENSG00000197582.5 GPX1P1 10.25 1.13e-21 6.11e-15 0.75 0.48 Resting heart rate; chr3:49529282 chrX:13378735~13379340:- LIHC trans rs616147 0.962 rs545397 ENSG00000183298.5 RP11-556K13.1 10.24 1.19e-21 6.43e-15 0.65 0.48 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39488592 chr1:101786340~101787219:- LIHC trans rs616147 0.962 rs1513219 ENSG00000183298.5 RP11-556K13.1 10.24 1.19e-21 6.43e-15 0.65 0.48 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39492268 chr1:101786340~101787219:- LIHC trans rs3779195 0.697 rs1688606 ENSG00000225169.1 BRI3P1 10.24 1.19e-21 6.43e-15 0.75 0.48 Sex hormone-binding globulin levels; chr7:98345539 chr1:100213293~100213670:+ LIHC trans rs9467773 1 rs4713006 ENSG00000242375.1 RP11-498P14.3 10.24 1.25e-21 6.74e-15 0.57 0.48 Intelligence (multi-trait analysis); chr6:26519644 chr9:97195351~97197687:- LIHC trans rs9467773 0.967 rs1535276 ENSG00000242375.1 RP11-498P14.3 10.24 1.25e-21 6.74e-15 0.57 0.48 Intelligence (multi-trait analysis); chr6:26520713 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs6925703 ENSG00000242375.1 RP11-498P14.3 10.24 1.25e-21 6.74e-15 0.57 0.48 Intelligence (multi-trait analysis); chr6:26521361 chr9:97195351~97197687:- LIHC trans rs616147 0.548 rs2370965 ENSG00000214263.2 RPSAP53 -10.23 1.33e-21 7.19e-15 -0.64 -0.48 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39448996 chr13:67266845~67267706:- LIHC trans rs7811142 0.943 rs28578163 ENSG00000228546.2 CTA-313A17.3 10.23 1.34e-21 7.25e-15 0.9 0.48 Platelet count; chr7:100447131 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs67239991 ENSG00000228546.2 CTA-313A17.3 10.23 1.34e-21 7.25e-15 0.9 0.48 Platelet count; chr7:100448881 chr7:102337316~102339115:+ LIHC trans rs5022636 0.594 rs12048670 ENSG00000180764.13 PIPSL 10.22 1.44e-21 7.76e-15 0.48 0.48 Gut microbiota (functional units); chr1:151272510 chr10:93958191~93961540:- LIHC trans rs9467773 0.525 rs1535274 ENSG00000242375.1 RP11-498P14.3 10.19 1.84e-21 9.85e-15 0.63 0.48 Intelligence (multi-trait analysis); chr6:26520519 chr9:97195351~97197687:- LIHC trans rs9467773 0.565 rs6925047 ENSG00000242375.1 RP11-498P14.3 10.19 1.84e-21 9.85e-15 0.63 0.48 Intelligence (multi-trait analysis); chr6:26521207 chr9:97195351~97197687:- LIHC trans rs9467773 0.565 rs4343916 ENSG00000242375.1 RP11-498P14.3 10.19 1.84e-21 9.85e-15 0.63 0.48 Intelligence (multi-trait analysis); chr6:26522447 chr9:97195351~97197687:- LIHC trans rs7121616 1 rs7123187 ENSG00000234176.1 HSPA8P1 10.18 1.93e-21 1.03e-14 0.59 0.48 Breast cancer; chr11:123090915 chrX:121203182~121205014:- LIHC trans rs7121616 0.774 rs74693612 ENSG00000234176.1 HSPA8P1 10.18 1.93e-21 1.03e-14 0.59 0.48 Breast cancer; chr11:123092310 chrX:121203182~121205014:- LIHC trans rs9611565 0.625 rs9607819 ENSG00000268568.1 AC007228.9 -10.18 1.96e-21 1.05e-14 -0.76 -0.48 Vitiligo; chr22:41562858 chr19:56672574~56673901:- LIHC trans rs10242455 0.571 rs45593341 ENSG00000228834.1 RP11-249L21.4 10.17 2.04e-21 1.09e-14 1.19 0.48 Blood metabolite levels; chr7:99707288 chr6:108907615~108907873:- LIHC trans rs3749237 0.595 rs11130192 ENSG00000197582.5 GPX1P1 10.16 2.22e-21 1.19e-14 0.74 0.48 Resting heart rate; chr3:49429773 chrX:13378735~13379340:- LIHC trans rs13096760 1 rs13096760 ENSG00000197582.5 GPX1P1 10.16 2.22e-21 1.19e-14 0.74 0.48 Intelligence (multi-trait analysis); chr3:49439373 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs885592 ENSG00000197582.5 GPX1P1 10.16 2.22e-21 1.19e-14 0.74 0.48 Resting heart rate; chr3:49460450 chrX:13378735~13379340:- LIHC trans rs6132905 0.52 rs2422824 ENSG00000235559.1 NOP56P1 10.16 2.3e-21 1.23e-14 0.54 0.48 Mumps; chr20:2666724 chr6:28783633~28784004:- LIHC trans rs10242455 0.571 rs45532337 ENSG00000228834.1 RP11-249L21.4 10.16 2.32e-21 1.24e-14 1.19 0.48 Blood metabolite levels; chr7:99712696 chr6:108907615~108907873:- LIHC trans rs7811142 0.943 rs67196635 ENSG00000228546.2 CTA-313A17.3 10.15 2.4e-21 1.28e-14 0.9 0.48 Platelet count; chr7:100427941 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs6962151 ENSG00000228546.2 CTA-313A17.3 10.15 2.4e-21 1.28e-14 0.9 0.48 Platelet count; chr7:100430861 chr7:102337316~102339115:+ LIHC trans rs7811142 0.943 rs67483801 ENSG00000228546.2 CTA-313A17.3 10.15 2.4e-21 1.28e-14 0.9 0.48 Platelet count; chr7:100434135 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs11761784 ENSG00000228546.2 CTA-313A17.3 10.15 2.4e-21 1.28e-14 0.9 0.48 Platelet count; chr7:100442347 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs112317829 ENSG00000228546.2 CTA-313A17.3 10.15 2.4e-21 1.28e-14 0.9 0.48 Platelet count; chr7:100445550 chr7:102337316~102339115:+ LIHC trans rs10242455 0.557 rs57830676 ENSG00000228834.1 RP11-249L21.4 10.14 2.7e-21 1.44e-14 1.18 0.48 Blood metabolite levels; chr7:99683740 chr6:108907615~108907873:- LIHC trans rs10242455 0.571 rs55830753 ENSG00000228834.1 RP11-249L21.4 10.14 2.7e-21 1.44e-14 1.18 0.48 Blood metabolite levels; chr7:99694599 chr6:108907615~108907873:- LIHC trans rs6732160 0.588 rs13394018 ENSG00000236165.1 PRADC1P1 10.13 2.85e-21 1.52e-14 0.64 0.48 Intelligence (multi-trait analysis); chr2:73145477 chr3:36976316~36976840:+ LIHC trans rs17711722 0.583 rs10085415 ENSG00000226824.5 RP4-756H11.3 10.12 3.05e-21 1.62e-14 0.65 0.48 Calcium levels; chr7:65628655 chr7:66654538~66669855:+ LIHC trans rs3749237 0.576 rs62259939 ENSG00000197582.5 GPX1P1 10.12 3.21e-21 1.7e-14 0.75 0.48 Resting heart rate; chr3:49348614 chrX:13378735~13379340:- LIHC trans rs7811142 1 rs66632384 ENSG00000228546.2 CTA-313A17.3 10.09 3.87e-21 2.05e-14 0.88 0.48 Platelet count; chr7:100421281 chr7:102337316~102339115:+ LIHC trans rs7811142 0.943 rs73403312 ENSG00000228546.2 CTA-313A17.3 10.09 3.87e-21 2.05e-14 0.88 0.48 Platelet count; chr7:100426530 chr7:102337316~102339115:+ LIHC trans rs7399018 0.643 rs6580810 ENSG00000223825.5 DAZAP2P1 10.09 4.06e-21 2.15e-14 0.6 0.48 Cisplatin-induced ototoxicity; chr12:51216694 chr2:202201384~202201886:- LIHC trans rs9467773 0.967 rs6924865 ENSG00000242375.1 RP11-498P14.3 10.09 4.1e-21 2.17e-14 0.56 0.48 Intelligence (multi-trait analysis); chr6:26521125 chr9:97195351~97197687:- LIHC trans rs77688320 0.517 rs10497868 ENSG00000235105.1 RP11-329A14.1 -10.08 4.27e-21 2.25e-14 -0.46 -0.48 Breast cancer; chr2:201439317 chr1:48435967~48437223:+ LIHC trans rs3749237 0.636 rs1568662 ENSG00000197582.5 GPX1P1 10.05 5.45e-21 2.86e-14 0.73 0.48 Resting heart rate; chr3:49483830 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs3924462 ENSG00000197582.5 GPX1P1 10.05 5.45e-21 2.86e-14 0.73 0.48 Resting heart rate; chr3:49486803 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs4855861 ENSG00000197582.5 GPX1P1 10.05 5.45e-21 2.86e-14 0.73 0.48 Resting heart rate; chr3:49488529 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs4855859 ENSG00000197582.5 GPX1P1 10.05 5.45e-21 2.86e-14 0.73 0.48 Resting heart rate; chr3:49488867 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs7643845 ENSG00000197582.5 GPX1P1 10.05 5.45e-21 2.86e-14 0.73 0.48 Resting heart rate; chr3:49493278 chrX:13378735~13379340:- LIHC trans rs3749237 0.595 rs7637999 ENSG00000197582.5 GPX1P1 10.05 5.45e-21 2.86e-14 0.73 0.48 Resting heart rate; chr3:49497682 chrX:13378735~13379340:- LIHC trans rs2657294 0.796 rs2804534 ENSG00000172974.11 AC007318.5 -10.05 5.53e-21 2.9e-14 -0.49 -0.48 Pneumonia; chr10:75208023 chr2:65205108~65205988:+ LIHC trans rs10242455 0.571 rs45527841 ENSG00000228834.1 RP11-249L21.4 10.04 5.65e-21 2.95e-14 1.18 0.48 Blood metabolite levels; chr7:99713342 chr6:108907615~108907873:- LIHC trans rs10242455 0.571 rs73713594 ENSG00000228834.1 RP11-249L21.4 10.04 5.7e-21 2.98e-14 1.18 0.48 Blood metabolite levels; chr7:99728875 chr6:108907615~108907873:- LIHC trans rs10242455 0.571 rs73713595 ENSG00000228834.1 RP11-249L21.4 10.04 5.7e-21 2.98e-14 1.18 0.48 Blood metabolite levels; chr7:99729036 chr6:108907615~108907873:- LIHC trans rs5022636 0.631 rs6587562 ENSG00000180764.13 PIPSL -10.04 6.04e-21 3.15e-14 -0.46 -0.48 Gut microbiota (functional units); chr1:151273765 chr10:93958191~93961540:- LIHC trans rs9611565 0.512 rs139572 ENSG00000268568.1 AC007228.9 -10.03 6.34e-21 3.31e-14 -0.78 -0.48 Vitiligo; chr22:41818528 chr19:56672574~56673901:- LIHC trans rs7930295 0.687 rs7117500 ENSG00000236257.1 EI24P2 10.02 6.89e-21 3.59e-14 0.64 0.48 Schizophrenia; chr11:125504232 chr1:158454198~158455273:+ LIHC trans rs7937890 0.9 rs7118682 ENSG00000236360.2 RP11-334A14.2 -10.01 7.6e-21 3.94e-14 -0.6 -0.48 Mitochondrial DNA levels; chr11:14253004 chr1:52993201~52993702:- LIHC trans rs5022636 0.594 rs7489 ENSG00000180764.13 PIPSL 10.01 7.64e-21 3.97e-14 0.47 0.48 Gut microbiota (functional units); chr1:151266575 chr10:93958191~93961540:- LIHC trans rs3749237 0.595 rs10865955 ENSG00000197582.5 GPX1P1 10 8.34e-21 4.32e-14 0.72 0.48 Resting heart rate; chr3:49462396 chrX:13378735~13379340:- LIHC trans rs3749237 0.576 rs3877784 ENSG00000197582.5 GPX1P1 10 8.34e-21 4.32e-14 0.72 0.48 Resting heart rate; chr3:49501984 chrX:13378735~13379340:- LIHC trans rs7811142 1 rs11763414 ENSG00000228546.2 CTA-313A17.3 9.99 8.67e-21 4.48e-14 0.88 0.48 Platelet count; chr7:100419221 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs67163493 ENSG00000228546.2 CTA-313A17.3 9.99 8.67e-21 4.48e-14 0.88 0.48 Platelet count; chr7:100426215 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs73161762 ENSG00000228546.2 CTA-313A17.3 9.98 9.42e-21 4.86e-14 0.9 0.47 Platelet count; chr7:100417223 chr7:102337316~102339115:+ LIHC trans rs61990749 0.571 rs4448861 ENSG00000235400.1 RP4-641G12.4 9.96 1.08e-20 5.56e-14 0.7 0.47 Fibroblast growth factor basic levels; chr14:77841392 chr1:78749073~78750659:+ LIHC trans rs3779195 1 rs3779195 ENSG00000225169.1 BRI3P1 -9.94 1.25e-20 6.39e-14 -0.73 -0.47 Sex hormone-binding globulin levels; chr7:98364050 chr1:100213293~100213670:+ LIHC trans rs7811142 0.943 rs111493473 ENSG00000228546.2 CTA-313A17.3 9.94 1.29e-20 6.63e-14 0.88 0.47 Platelet count; chr7:100452119 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs7809801 ENSG00000228546.2 CTA-313A17.3 9.94 1.29e-20 6.63e-14 0.88 0.47 Platelet count; chr7:100474408 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs11766752 ENSG00000228546.2 CTA-313A17.3 9.94 1.29e-20 6.63e-14 0.88 0.47 Platelet count; chr7:100475669 chr7:102337316~102339115:+ LIHC trans rs7121616 1 rs7113273 ENSG00000234176.1 HSPA8P1 -9.94 1.3e-20 6.67e-14 -0.58 -0.47 Breast cancer; chr11:123092192 chrX:121203182~121205014:- LIHC trans rs7811142 1 rs4472444 ENSG00000228546.2 CTA-313A17.3 9.93 1.37e-20 6.98e-14 0.88 0.47 Platelet count; chr7:100473135 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs68116612 ENSG00000228546.2 CTA-313A17.3 9.92 1.47e-20 7.5e-14 0.81 0.47 Platelet count; chr7:100408870 chr7:102337316~102339115:+ LIHC trans rs77688320 0.535 rs2540441 ENSG00000235105.1 RP11-329A14.1 -9.91 1.63e-20 8.3e-14 -0.48 -0.47 Breast cancer; chr2:201481946 chr1:48435967~48437223:+ LIHC trans rs3749237 0.595 rs11720264 ENSG00000197582.5 GPX1P1 9.9 1.74e-20 8.88e-14 0.73 0.47 Resting heart rate; chr3:49542914 chrX:13378735~13379340:- LIHC trans rs7811142 1 rs7783159 ENSG00000228546.2 CTA-313A17.3 9.89 1.86e-20 9.46e-14 0.83 0.47 Platelet count; chr7:100419831 chr7:102337316~102339115:+ LIHC trans rs7937890 0.904 rs11023169 ENSG00000236360.2 RP11-334A14.2 -9.89 1.89e-20 9.6e-14 -0.6 -0.47 Mitochondrial DNA levels; chr11:14269439 chr1:52993201~52993702:- LIHC trans rs77688320 0.535 rs6435084 ENSG00000235105.1 RP11-329A14.1 9.89 1.93e-20 9.8e-14 0.46 0.47 Breast cancer; chr2:201461274 chr1:48435967~48437223:+ LIHC trans rs7811142 0.943 rs10241492 ENSG00000228546.2 CTA-313A17.3 9.88 2.05e-20 1.04e-13 0.84 0.47 Platelet count; chr7:100397190 chr7:102337316~102339115:+ LIHC trans rs77688320 0.5 rs10931948 ENSG00000235105.1 RP11-329A14.1 9.88 2.09e-20 1.06e-13 0.46 0.47 Breast cancer; chr2:201459199 chr1:48435967~48437223:+ LIHC trans rs3749237 0.615 rs6792911 ENSG00000197582.5 GPX1P1 9.87 2.13e-20 1.08e-13 0.72 0.47 Resting heart rate; chr3:49392423 chrX:13378735~13379340:- LIHC trans rs7937890 0.904 rs67623158 ENSG00000236360.2 RP11-334A14.2 -9.87 2.26e-20 1.15e-13 -0.59 -0.47 Mitochondrial DNA levels; chr11:14273650 chr1:52993201~52993702:- LIHC trans rs616147 0.671 rs674192 ENSG00000214263.2 RPSAP53 -9.86 2.32e-20 1.17e-13 -0.62 -0.47 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39458653 chr13:67266845~67267706:- LIHC trans rs77688320 0.517 rs2270315 ENSG00000235105.1 RP11-329A14.1 9.85 2.49e-20 1.26e-13 0.46 0.47 Breast cancer; chr2:201452542 chr1:48435967~48437223:+ LIHC trans rs77688320 0.517 rs2287054 ENSG00000235105.1 RP11-329A14.1 9.85 2.49e-20 1.26e-13 0.46 0.47 Breast cancer; chr2:201454315 chr1:48435967~48437223:+ LIHC trans rs7121616 0.576 rs7123232 ENSG00000234176.1 HSPA8P1 9.84 2.71e-20 1.37e-13 0.74 0.47 Breast cancer; chr11:123056237 chrX:121203182~121205014:- LIHC trans rs10242455 0.571 rs41258334 ENSG00000228834.1 RP11-249L21.4 9.84 2.71e-20 1.37e-13 1.19 0.47 Blood metabolite levels; chr7:99674185 chr6:108907615~108907873:- LIHC trans rs10242455 0.571 rs28365067 ENSG00000228834.1 RP11-249L21.4 9.84 2.71e-20 1.37e-13 1.19 0.47 Blood metabolite levels; chr7:99674687 chr6:108907615~108907873:- LIHC trans rs7811142 1 rs1000215 ENSG00000228546.2 CTA-313A17.3 9.84 2.75e-20 1.39e-13 0.79 0.47 Platelet count; chr7:100406920 chr7:102337316~102339115:+ LIHC trans rs9467773 0.844 rs2393669 ENSG00000242375.1 RP11-498P14.3 9.84 2.8e-20 1.41e-13 0.55 0.47 Intelligence (multi-trait analysis); chr6:26503645 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs9461259 ENSG00000242375.1 RP11-498P14.3 9.84 2.8e-20 1.41e-13 0.55 0.47 Intelligence (multi-trait analysis); chr6:26504607 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs9467774 ENSG00000242375.1 RP11-498P14.3 9.84 2.8e-20 1.41e-13 0.55 0.47 Intelligence (multi-trait analysis); chr6:26504808 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs3736782 ENSG00000242375.1 RP11-498P14.3 9.84 2.8e-20 1.41e-13 0.55 0.47 Intelligence (multi-trait analysis); chr6:26505175 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs2208331 ENSG00000242375.1 RP11-498P14.3 9.84 2.8e-20 1.41e-13 0.55 0.47 Intelligence (multi-trait analysis); chr6:26507091 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs9393728 ENSG00000242375.1 RP11-498P14.3 9.84 2.8e-20 1.41e-13 0.55 0.47 Intelligence (multi-trait analysis); chr6:26509102 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs1056667 ENSG00000242375.1 RP11-498P14.3 9.84 2.8e-20 1.41e-13 0.55 0.47 Intelligence (multi-trait analysis); chr6:26510336 chr9:97195351~97197687:- LIHC trans rs10242455 0.571 rs41279866 ENSG00000228834.1 RP11-249L21.4 9.84 2.87e-20 1.45e-13 1.19 0.47 Blood metabolite levels; chr7:99717653 chr6:108907615~108907873:- LIHC trans rs616147 0.671 rs675595 ENSG00000214263.2 RPSAP53 -9.83 3.05e-20 1.54e-13 -0.62 -0.47 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39458987 chr13:67266845~67267706:- LIHC trans rs7554547 0.778 rs2008113 ENSG00000261819.1 RP11-680G24.4 -9.82 3.16e-20 1.59e-13 -0.58 -0.47 Nonsyndromic cleft lip with cleft palate; chr1:11878809 chr16:14988259~14990160:- LIHC trans rs10242455 0.571 rs80045298 ENSG00000228834.1 RP11-249L21.4 9.81 3.4e-20 1.71e-13 1.18 0.47 Blood metabolite levels; chr7:99709830 chr6:108907615~108907873:- LIHC trans rs9467773 1 rs3736781 ENSG00000242375.1 RP11-498P14.3 9.81 3.44e-20 1.73e-13 0.55 0.47 Intelligence (multi-trait analysis); chr6:26505134 chr9:97195351~97197687:- LIHC trans rs61990749 0.571 rs2364841 ENSG00000235400.1 RP4-641G12.4 9.81 3.54e-20 1.78e-13 0.8 0.47 Fibroblast growth factor basic levels; chr14:77817693 chr1:78749073~78750659:+ LIHC trans rs7937890 0.874 rs2303972 ENSG00000236360.2 RP11-334A14.2 -9.79 4.22e-20 2.11e-13 -0.6 -0.47 Mitochondrial DNA levels; chr11:14281736 chr1:52993201~52993702:- LIHC trans rs9467773 1 rs9467773 ENSG00000242375.1 RP11-498P14.3 9.78 4.47e-20 2.23e-13 0.55 0.47 Intelligence (multi-trait analysis); chr6:26498198 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs6926629 ENSG00000242375.1 RP11-498P14.3 9.78 4.47e-20 2.23e-13 0.55 0.47 Intelligence (multi-trait analysis); chr6:26499675 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs6903973 ENSG00000242375.1 RP11-498P14.3 9.78 4.47e-20 2.23e-13 0.55 0.47 Intelligence (multi-trait analysis); chr6:26499714 chr9:97195351~97197687:- LIHC trans rs9467773 1 rs2255070 ENSG00000242375.1 RP11-498P14.3 9.78 4.47e-20 2.23e-13 0.55 0.47 Intelligence (multi-trait analysis); chr6:26501549 chr9:97195351~97197687:- LIHC trans rs7811142 1 rs6979335 ENSG00000228546.2 CTA-313A17.3 9.76 5.1e-20 2.54e-13 0.91 0.47 Platelet count; chr7:100492237 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs73405353 ENSG00000228546.2 CTA-313A17.3 9.76 5.1e-20 2.54e-13 0.91 0.47 Platelet count; chr7:100493592 chr7:102337316~102339115:+ LIHC trans rs7937890 0.904 rs7484197 ENSG00000236360.2 RP11-334A14.2 9.75 5.78e-20 2.88e-13 0.6 0.47 Mitochondrial DNA levels; chr11:14262108 chr1:52993201~52993702:- LIHC trans rs9467773 1 rs1321479 ENSG00000242375.1 RP11-498P14.3 -9.75 5.79e-20 2.88e-13 -0.54 -0.47 Intelligence (multi-trait analysis); chr6:26501669 chr9:97195351~97197687:- LIHC trans rs9611565 0.512 rs5758464 ENSG00000268568.1 AC007228.9 9.69 8.59e-20 4.25e-13 0.81 0.46 Vitiligo; chr22:41775296 chr19:56672574~56673901:- LIHC trans rs7811142 1 rs11771419 ENSG00000228546.2 CTA-313A17.3 9.68 9.94e-20 4.91e-13 0.83 0.46 Platelet count; chr7:100390780 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs76913697 ENSG00000228546.2 CTA-313A17.3 9.68 9.94e-20 4.91e-13 0.83 0.46 Platelet count; chr7:100405149 chr7:102337316~102339115:+ LIHC trans rs9611565 0.649 rs126092 ENSG00000268568.1 AC007228.9 9.67 1.02e-19 5.05e-13 0.69 0.46 Vitiligo; chr22:41782437 chr19:56672574~56673901:- LIHC trans rs7930295 0.556 rs9704355 ENSG00000236257.1 EI24P2 9.67 1.05e-19 5.19e-13 0.61 0.46 Schizophrenia; chr11:125478435 chr1:158454198~158455273:+ LIHC trans rs616147 0.655 rs1707981 ENSG00000214263.2 RPSAP53 -9.64 1.27e-19 6.26e-13 -0.61 -0.46 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39461015 chr13:67266845~67267706:- LIHC trans rs616147 0.72 rs1768209 ENSG00000214263.2 RPSAP53 -9.64 1.27e-19 6.26e-13 -0.61 -0.46 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39461184 chr13:67266845~67267706:- LIHC trans rs616147 0.72 rs2965067 ENSG00000214263.2 RPSAP53 -9.64 1.27e-19 6.26e-13 -0.61 -0.46 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39461546 chr13:67266845~67267706:- LIHC trans rs3749237 0.595 rs1050088 ENSG00000197582.5 GPX1P1 -9.63 1.36e-19 6.68e-13 -0.7 -0.46 Resting heart rate; chr3:49533449 chrX:13378735~13379340:- LIHC trans rs7811142 1 rs67040465 ENSG00000228546.2 CTA-313A17.3 9.63 1.46e-19 7.15e-13 0.89 0.46 Platelet count; chr7:100485455 chr7:102337316~102339115:+ LIHC trans rs6132905 0.52 rs2422823 ENSG00000257956.1 NOP56P3 -9.62 1.54e-19 7.53e-13 -0.58 -0.46 Mumps; chr20:2665687 chr12:79558782~79559166:+ LIHC trans rs7258465 1 rs3810429 ENSG00000267533.1 RP11-815J4.7 9.62 1.55e-19 7.62e-13 0.61 0.46 Breast cancer; chr19:18432460 chr18:12067173~12068417:- LIHC trans rs7811142 1 rs74460138 ENSG00000228546.2 CTA-313A17.3 9.62 1.57e-19 7.68e-13 0.89 0.46 Platelet count; chr7:100429716 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs4989959 ENSG00000228546.2 CTA-313A17.3 9.62 1.57e-19 7.68e-13 0.89 0.46 Platelet count; chr7:100434665 chr7:102337316~102339115:+ LIHC trans rs616147 0.616 rs1768234 ENSG00000214263.2 RPSAP53 -9.61 1.58e-19 7.72e-13 -0.61 -0.46 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39459821 chr13:67266845~67267706:- LIHC trans rs7811142 0.943 rs3900792 ENSG00000228546.2 CTA-313A17.3 9.61 1.63e-19 7.96e-13 0.79 0.46 Platelet count; chr7:100406954 chr7:102337316~102339115:+ LIHC trans rs7258465 1 rs7258465 ENSG00000267533.1 RP11-815J4.7 9.61 1.64e-19 8.02e-13 0.59 0.46 Breast cancer; chr19:18422832 chr18:12067173~12068417:- LIHC trans rs7811142 1 rs11559117 ENSG00000228546.2 CTA-313A17.3 9.6 1.72e-19 8.41e-13 0.88 0.46 Platelet count; chr7:100478991 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs4463351 ENSG00000228546.2 CTA-313A17.3 9.6 1.72e-19 8.41e-13 0.88 0.46 Platelet count; chr7:100480603 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs60844404 ENSG00000228546.2 CTA-313A17.3 9.6 1.72e-19 8.41e-13 0.88 0.46 Platelet count; chr7:100482851 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs11763511 ENSG00000228546.2 CTA-313A17.3 9.6 1.72e-19 8.41e-13 0.88 0.46 Platelet count; chr7:100484321 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs60478351 ENSG00000228546.2 CTA-313A17.3 9.6 1.72e-19 8.41e-13 0.88 0.46 Platelet count; chr7:100491394 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs7787620 ENSG00000228546.2 CTA-313A17.3 9.6 1.72e-19 8.41e-13 0.88 0.46 Platelet count; chr7:100491611 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs11769700 ENSG00000228546.2 CTA-313A17.3 9.6 1.72e-19 8.41e-13 0.88 0.46 Platelet count; chr7:100492426 chr7:102337316~102339115:+ LIHC trans rs5022636 0.559 rs41302131 ENSG00000180764.13 PIPSL 9.59 1.86e-19 9.06e-13 0.45 0.46 Gut microbiota (functional units); chr1:151267532 chr10:93958191~93961540:- LIHC trans rs7568458 0.709 rs2043675 ENSG00000223886.3 RP11-251G23.2 -9.59 1.9e-19 9.29e-13 -0.57 -0.46 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85542852 chr7:105530209~105530671:+ LIHC trans rs2657294 0.965 rs7079694 ENSG00000172974.11 AC007318.5 9.59 1.97e-19 9.6e-13 0.5 0.46 Pneumonia; chr10:75136804 chr2:65205108~65205988:+ LIHC trans rs7121616 0.576 rs7111598 ENSG00000234176.1 HSPA8P1 9.58 2e-19 9.77e-13 0.74 0.46 Breast cancer; chr11:123055438 chrX:121203182~121205014:- LIHC trans rs7121616 0.531 rs1461497 ENSG00000234176.1 HSPA8P1 9.58 2.12e-19 1.03e-12 0.74 0.46 Breast cancer; chr11:123060505 chrX:121203182~121205014:- LIHC trans rs7121616 0.531 rs41361350 ENSG00000234176.1 HSPA8P1 9.58 2.12e-19 1.03e-12 0.74 0.46 Breast cancer; chr11:123060917 chrX:121203182~121205014:- LIHC trans rs3779195 0.524 rs76976120 ENSG00000225169.1 BRI3P1 -9.58 2.13e-19 1.04e-12 -0.79 -0.46 Sex hormone-binding globulin levels; chr7:98264860 chr1:100213293~100213670:+ LIHC trans rs3779195 0.585 rs73709460 ENSG00000225169.1 BRI3P1 -9.58 2.13e-19 1.04e-12 -0.79 -0.46 Sex hormone-binding globulin levels; chr7:98265942 chr1:100213293~100213670:+ LIHC trans rs3779195 0.585 rs56694862 ENSG00000225169.1 BRI3P1 -9.58 2.13e-19 1.04e-12 -0.79 -0.46 Sex hormone-binding globulin levels; chr7:98267808 chr1:100213293~100213670:+ LIHC trans rs7811142 1 rs11771241 ENSG00000228546.2 CTA-313A17.3 9.57 2.15e-19 1.05e-12 0.82 0.46 Platelet count; chr7:100397162 chr7:102337316~102339115:+ LIHC trans rs1816752 0.603 rs9511278 ENSG00000237917.1 PARP4P1 -9.57 2.2e-19 1.07e-12 -0.54 -0.46 Obesity-related traits; chr13:24455766 chrY:26594851~26634652:- LIHC trans rs7121616 0.576 rs11600486 ENSG00000234176.1 HSPA8P1 9.57 2.25e-19 1.09e-12 0.72 0.46 Breast cancer; chr11:123047060 chrX:121203182~121205014:- LIHC trans rs7811142 1 rs113738841 ENSG00000228546.2 CTA-313A17.3 9.56 2.32e-19 1.13e-12 0.87 0.46 Platelet count; chr7:100483683 chr7:102337316~102339115:+ LIHC trans rs2657294 0.965 rs10824286 ENSG00000172974.11 AC007318.5 9.56 2.39e-19 1.16e-12 0.5 0.46 Pneumonia; chr10:75172251 chr2:65205108~65205988:+ LIHC trans rs7258465 1 rs10442 ENSG00000267533.1 RP11-815J4.7 9.55 2.5e-19 1.22e-12 0.61 0.46 Breast cancer; chr19:18434531 chr18:12067173~12068417:- LIHC trans rs7258465 1 rs4595905 ENSG00000267533.1 RP11-815J4.7 9.55 2.5e-19 1.22e-12 0.61 0.46 Breast cancer; chr19:18436495 chr18:12067173~12068417:- LIHC trans rs7811142 1 rs7803454 ENSG00000228546.2 CTA-313A17.3 9.55 2.6e-19 1.26e-12 0.84 0.46 Platelet count; chr7:100393925 chr7:102337316~102339115:+ LIHC trans rs7811142 0.943 rs11769886 ENSG00000228546.2 CTA-313A17.3 9.55 2.6e-19 1.26e-12 0.84 0.46 Platelet count; chr7:100400984 chr7:102337316~102339115:+ LIHC trans rs7811142 0.887 rs35111986 ENSG00000228546.2 CTA-313A17.3 9.55 2.6e-19 1.26e-12 0.84 0.46 Platelet count; chr7:100402651 chr7:102337316~102339115:+ LIHC trans rs61990749 0.571 rs4903655 ENSG00000235400.1 RP4-641G12.4 9.55 2.6e-19 1.26e-12 0.69 0.46 Fibroblast growth factor basic levels; chr14:77839983 chr1:78749073~78750659:+ LIHC trans rs7258465 1 rs2303697 ENSG00000267533.1 RP11-815J4.7 9.54 2.76e-19 1.34e-12 0.61 0.46 Breast cancer; chr19:18435868 chr18:12067173~12068417:- LIHC trans rs7258465 1 rs10405636 ENSG00000267533.1 RP11-815J4.7 9.54 2.76e-19 1.34e-12 0.61 0.46 Breast cancer; chr19:18427932 chr18:12067173~12068417:- LIHC trans rs2657294 0.965 rs10762658 ENSG00000172974.11 AC007318.5 9.54 2.78e-19 1.35e-12 0.5 0.46 Pneumonia; chr10:75119804 chr2:65205108~65205988:+ LIHC trans rs7121616 0.545 rs11600517 ENSG00000234176.1 HSPA8P1 9.53 2.99e-19 1.45e-12 0.71 0.46 Breast cancer; chr11:123047247 chrX:121203182~121205014:- LIHC trans rs7811142 1 rs2406253 ENSG00000228546.2 CTA-313A17.3 9.52 3.14e-19 1.52e-12 0.87 0.46 Platelet count; chr7:100479650 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs2897358 ENSG00000228546.2 CTA-313A17.3 9.52 3.14e-19 1.52e-12 0.87 0.46 Platelet count; chr7:100491017 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs7794485 ENSG00000228546.2 CTA-313A17.3 9.52 3.2e-19 1.55e-12 0.91 0.46 Platelet count; chr7:100471313 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs7783550 ENSG00000228546.2 CTA-313A17.3 -9.52 3.37e-19 1.63e-12 -0.8 -0.46 Platelet count; chr7:100390182 chr7:102337316~102339115:+ LIHC trans rs7258465 1 rs10427083 ENSG00000267533.1 RP11-815J4.7 9.51 3.43e-19 1.66e-12 0.6 0.46 Breast cancer; chr19:18439466 chr18:12067173~12068417:- LIHC trans rs7811142 1 rs67471932 ENSG00000228546.2 CTA-313A17.3 9.51 3.52e-19 1.7e-12 0.82 0.46 Platelet count; chr7:100412362 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs73161759 ENSG00000228546.2 CTA-313A17.3 9.51 3.52e-19 1.7e-12 0.82 0.46 Platelet count; chr7:100412371 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs6975729 ENSG00000228546.2 CTA-313A17.3 9.51 3.54e-19 1.7e-12 0.88 0.46 Platelet count; chr7:100430564 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs1073 ENSG00000228546.2 CTA-313A17.3 9.51 3.54e-19 1.7e-12 0.88 0.46 Platelet count; chr7:100433989 chr7:102337316~102339115:+ LIHC trans rs7811142 0.887 rs4074838 ENSG00000228546.2 CTA-313A17.3 9.51 3.54e-19 1.7e-12 0.88 0.46 Platelet count; chr7:100435042 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs11764818 ENSG00000228546.2 CTA-313A17.3 9.51 3.54e-19 1.7e-12 0.88 0.46 Platelet count; chr7:100445432 chr7:102337316~102339115:+ LIHC trans rs7121616 0.545 rs7109348 ENSG00000234176.1 HSPA8P1 9.51 3.62e-19 1.74e-12 0.74 0.46 Breast cancer; chr11:123056555 chrX:121203182~121205014:- LIHC trans rs7811142 1 rs11761725 ENSG00000228546.2 CTA-313A17.3 9.48 4.28e-19 2.06e-12 0.91 0.46 Platelet count; chr7:100442192 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs2406255 ENSG00000228546.2 CTA-313A17.3 9.48 4.28e-19 2.06e-12 0.91 0.46 Platelet count; chr7:100456067 chr7:102337316~102339115:+ LIHC trans rs7258465 1 rs10413237 ENSG00000267533.1 RP11-815J4.7 9.48 4.37e-19 2.1e-12 0.61 0.46 Breast cancer; chr19:18437439 chr18:12067173~12068417:- LIHC trans rs7121616 0.545 rs7109336 ENSG00000234176.1 HSPA8P1 9.47 4.62e-19 2.22e-12 0.73 0.46 Breast cancer; chr11:123056530 chrX:121203182~121205014:- LIHC trans rs7811142 1 rs6972167 ENSG00000228546.2 CTA-313A17.3 9.47 4.65e-19 2.23e-12 0.86 0.46 Platelet count; chr7:100482390 chr7:102337316~102339115:+ LIHC trans rs7121616 0.576 rs1064585 ENSG00000234176.1 HSPA8P1 9.47 4.83e-19 2.32e-12 0.74 0.46 Breast cancer; chr11:123058699 chrX:121203182~121205014:- LIHC trans rs2657294 0.965 rs2657286 ENSG00000172974.11 AC007318.5 -9.47 4.88e-19 2.34e-12 -0.49 -0.46 Pneumonia; chr10:75145940 chr2:65205108~65205988:+ LIHC trans rs7121616 0.576 rs7949127 ENSG00000234176.1 HSPA8P1 9.47 4.92e-19 2.36e-12 0.73 0.46 Breast cancer; chr11:123057408 chrX:121203182~121205014:- LIHC trans rs7121616 0.576 rs7949220 ENSG00000234176.1 HSPA8P1 9.47 4.92e-19 2.36e-12 0.73 0.46 Breast cancer; chr11:123057418 chrX:121203182~121205014:- LIHC trans rs7121616 0.576 rs1461495 ENSG00000234176.1 HSPA8P1 -9.46 5.05e-19 2.42e-12 -0.72 -0.46 Breast cancer; chr11:123056136 chrX:121203182~121205014:- LIHC trans rs2657294 0.965 rs2395140 ENSG00000172974.11 AC007318.5 9.45 5.33e-19 2.54e-12 0.49 0.46 Pneumonia; chr10:75139253 chr2:65205108~65205988:+ LIHC trans rs2657294 0.965 rs2997754 ENSG00000172974.11 AC007318.5 9.45 5.33e-19 2.54e-12 0.49 0.46 Pneumonia; chr10:75144379 chr2:65205108~65205988:+ LIHC trans rs7121616 0.576 rs73610510 ENSG00000234176.1 HSPA8P1 9.45 5.61e-19 2.67e-12 0.71 0.45 Breast cancer; chr11:123049365 chrX:121203182~121205014:- LIHC trans rs7121616 0.576 rs7942164 ENSG00000234176.1 HSPA8P1 9.45 5.61e-19 2.67e-12 0.71 0.45 Breast cancer; chr11:123050459 chrX:121203182~121205014:- LIHC trans rs7121616 0.576 rs56131320 ENSG00000234176.1 HSPA8P1 9.45 5.61e-19 2.67e-12 0.71 0.45 Breast cancer; chr11:123053058 chrX:121203182~121205014:- LIHC trans rs7121616 0.576 rs7929869 ENSG00000234176.1 HSPA8P1 9.45 5.61e-19 2.67e-12 0.71 0.45 Breast cancer; chr11:123054435 chrX:121203182~121205014:- LIHC trans rs7121616 0.576 rs7111590 ENSG00000234176.1 HSPA8P1 9.45 5.61e-19 2.67e-12 0.71 0.45 Breast cancer; chr11:123055419 chrX:121203182~121205014:- LIHC trans rs7121616 0.576 rs1841580 ENSG00000234176.1 HSPA8P1 9.45 5.61e-19 2.67e-12 0.71 0.45 Breast cancer; chr11:123055956 chrX:121203182~121205014:- LIHC trans rs12200782 0.505 rs7765920 ENSG00000242375.1 RP11-498P14.3 9.44 5.99e-19 2.85e-12 0.69 0.45 Small cell lung carcinoma; chr6:26514543 chr9:97195351~97197687:- LIHC trans rs2657294 0.965 rs10824285 ENSG00000172974.11 AC007318.5 9.43 6.49e-19 3.09e-12 0.49 0.45 Pneumonia; chr10:75153271 chr2:65205108~65205988:+ LIHC trans rs2657294 0.965 rs4746264 ENSG00000172974.11 AC007318.5 9.43 6.52e-19 3.1e-12 0.49 0.45 Pneumonia; chr10:75114194 chr2:65205108~65205988:+ LIHC trans rs2657294 0.965 rs9299525 ENSG00000172974.11 AC007318.5 9.43 6.52e-19 3.1e-12 0.49 0.45 Pneumonia; chr10:75118267 chr2:65205108~65205988:+ LIHC trans rs9425766 0.679 rs7552939 ENSG00000213331.4 RP11-713C19.2 9.43 6.59e-19 3.13e-12 0.56 0.45 Life satisfaction; chr1:173798305 chr4:187970273~187971284:+ LIHC trans rs6132905 0.52 rs2422824 ENSG00000257956.1 NOP56P3 9.42 6.69e-19 3.18e-12 0.56 0.45 Mumps; chr20:2666724 chr12:79558782~79559166:+ LIHC trans rs7811142 1 rs67315960 ENSG00000228546.2 CTA-313A17.3 9.41 7.44e-19 3.53e-12 0.82 0.45 Platelet count; chr7:100417501 chr7:102337316~102339115:+ LIHC trans rs3779195 0.52 rs17169479 ENSG00000225169.1 BRI3P1 9.4 8.04e-19 3.8e-12 0.78 0.45 Sex hormone-binding globulin levels; chr7:98238721 chr1:100213293~100213670:+ LIHC trans rs7568458 0.684 rs7579147 ENSG00000223886.3 RP11-251G23.2 9.39 8.83e-19 4.17e-12 0.57 0.45 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85578531 chr7:105530209~105530671:+ LIHC trans rs7662987 0.793 rs7669660 ENSG00000228407.2 RP4-800M22.1 9.39 8.97e-19 4.24e-12 0.98 0.45 Smoking initiation; chr4:99071451 chr1:52160261~52160600:- LIHC trans rs616147 1 rs1768208 ENSG00000214263.2 RPSAP53 -9.38 9.53e-19 4.5e-12 -0.6 -0.45 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39481512 chr13:67266845~67267706:- LIHC trans rs3779195 0.591 rs77968419 ENSG00000225169.1 BRI3P1 -9.37 9.87e-19 4.66e-12 -0.78 -0.45 Sex hormone-binding globulin levels; chr7:98237168 chr1:100213293~100213670:+ LIHC trans rs7121616 0.576 rs73610509 ENSG00000234176.1 HSPA8P1 9.37 9.93e-19 4.69e-12 0.71 0.45 Breast cancer; chr11:123048564 chrX:121203182~121205014:- LIHC trans rs7568458 0.684 rs7593969 ENSG00000223886.3 RP11-251G23.2 -9.37 9.94e-19 4.69e-12 -0.57 -0.45 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85582547 chr7:105530209~105530671:+ LIHC trans rs7662987 0.793 rs12106 ENSG00000228407.2 RP4-800M22.1 9.37 1.02e-18 4.8e-12 0.98 0.45 Smoking initiation; chr4:99072199 chr1:52160261~52160600:- LIHC trans rs7662987 0.793 rs7684735 ENSG00000228407.2 RP4-800M22.1 9.37 1.03e-18 4.85e-12 0.98 0.45 Smoking initiation; chr4:99070355 chr1:52160261~52160600:- LIHC trans rs2657294 0.931 rs2804522 ENSG00000172974.11 AC007318.5 9.36 1.05e-18 4.95e-12 0.49 0.45 Pneumonia; chr10:75159132 chr2:65205108~65205988:+ LIHC trans rs7662987 0.793 rs28730632 ENSG00000228407.2 RP4-800M22.1 9.36 1.06e-18 5e-12 1 0.45 Smoking initiation; chr4:99074552 chr1:52160261~52160600:- LIHC trans rs7121616 0.576 rs60405069 ENSG00000234176.1 HSPA8P1 9.36 1.07e-18 5.04e-12 0.7 0.45 Breast cancer; chr11:123043616 chrX:121203182~121205014:- LIHC trans rs7568458 0.684 rs3731828 ENSG00000223886.3 RP11-251G23.2 9.35 1.14e-18 5.37e-12 0.57 0.45 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85579143 chr7:105530209~105530671:+ LIHC trans rs7258465 1 rs4808136 ENSG00000267533.1 RP11-815J4.7 -9.35 1.15e-18 5.39e-12 -0.58 -0.45 Breast cancer; chr19:18508057 chr18:12067173~12068417:- LIHC trans rs2657294 0.965 rs2047951 ENSG00000172974.11 AC007318.5 9.34 1.27e-18 5.94e-12 0.49 0.45 Pneumonia; chr10:75161310 chr2:65205108~65205988:+ LIHC trans rs2657294 0.965 rs2804523 ENSG00000172974.11 AC007318.5 9.34 1.27e-18 5.94e-12 0.49 0.45 Pneumonia; chr10:75161584 chr2:65205108~65205988:+ LIHC trans rs2657294 0.965 rs2657285 ENSG00000172974.11 AC007318.5 9.34 1.27e-18 5.94e-12 0.49 0.45 Pneumonia; chr10:75164166 chr2:65205108~65205988:+ LIHC trans rs2657294 0.965 rs7899946 ENSG00000172974.11 AC007318.5 9.34 1.27e-18 5.94e-12 0.49 0.45 Pneumonia; chr10:75166013 chr2:65205108~65205988:+ LIHC trans rs7121616 0.576 rs7102045 ENSG00000234176.1 HSPA8P1 9.33 1.35e-18 6.32e-12 0.72 0.45 Breast cancer; chr11:123052713 chrX:121203182~121205014:- LIHC trans rs9611565 0.571 rs7364123 ENSG00000268568.1 AC007228.9 -9.32 1.44e-18 6.75e-12 -0.69 -0.45 Vitiligo; chr22:41820322 chr19:56672574~56673901:- LIHC trans rs7662987 0.793 rs4699700 ENSG00000228407.2 RP4-800M22.1 9.32 1.51e-18 7.05e-12 1.01 0.45 Smoking initiation; chr4:99077184 chr1:52160261~52160600:- LIHC trans rs7258465 0.965 rs10409003 ENSG00000267533.1 RP11-815J4.7 9.31 1.54e-18 7.18e-12 0.6 0.45 Breast cancer; chr19:18432244 chr18:12067173~12068417:- LIHC trans rs7258465 0.965 rs2385088 ENSG00000267533.1 RP11-815J4.7 9.31 1.54e-18 7.18e-12 0.6 0.45 Breast cancer; chr19:18434730 chr18:12067173~12068417:- LIHC trans rs13190036 1 rs625882 ENSG00000228305.2 AC016734.2 -9.31 1.61e-18 7.53e-12 -0.54 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177108030 chr2:63622178~63622831:- LIHC trans rs7258465 0.965 rs10408290 ENSG00000267533.1 RP11-815J4.7 9.31 1.64e-18 7.65e-12 0.59 0.45 Breast cancer; chr19:18431891 chr18:12067173~12068417:- LIHC trans rs7930295 0.556 rs6590146 ENSG00000236257.1 EI24P2 9.3 1.75e-18 8.15e-12 0.59 0.45 Schizophrenia; chr11:125479933 chr1:158454198~158455273:+ LIHC trans rs7568458 0.684 rs7608074 ENSG00000223886.3 RP11-251G23.2 9.3 1.75e-18 8.19e-12 0.56 0.45 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85582580 chr7:105530209~105530671:+ LIHC trans rs7121616 0.576 rs73608699 ENSG00000234176.1 HSPA8P1 9.29 1.9e-18 8.85e-12 0.7 0.45 Breast cancer; chr11:123044718 chrX:121203182~121205014:- LIHC trans rs9611519 0.78 rs9611546 ENSG00000268568.1 AC007228.9 -9.28 1.94e-18 9.06e-12 -0.65 -0.45 Neuroticism; chr22:41302538 chr19:56672574~56673901:- LIHC trans rs7258465 1 rs28572537 ENSG00000267533.1 RP11-815J4.7 9.27 2.07e-18 9.62e-12 0.59 0.45 Breast cancer; chr19:18441398 chr18:12067173~12068417:- LIHC trans rs7811142 1 rs60257855 ENSG00000228546.2 CTA-313A17.3 9.27 2.13e-18 9.88e-12 0.86 0.45 Platelet count; chr7:100429157 chr7:102337316~102339115:+ LIHC trans rs2657294 0.929 rs6480771 ENSG00000172974.11 AC007318.5 9.27 2.14e-18 9.93e-12 0.48 0.45 Pneumonia; chr10:75101922 chr2:65205108~65205988:+ LIHC trans rs2731664 0.792 rs335467 ENSG00000215571.5 GRK6P1 9.27 2.17e-18 1.01e-11 0.58 0.45 Intelligence (multi-trait analysis); chr5:177463641 chr13:21319156~21320866:+ LIHC trans rs8067354 0.83 rs2453913 ENSG00000187870.7 RNFT1P3 9.26 2.23e-18 1.04e-11 0.51 0.45 Hemoglobin concentration; chr17:59782789 chr17:20743333~20754501:- LIHC trans rs13190036 1 rs4976682 ENSG00000228305.2 AC016734.2 9.26 2.28e-18 1.06e-11 0.53 0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177299001 chr2:63622178~63622831:- LIHC trans rs7121616 0.5 rs12574868 ENSG00000234176.1 HSPA8P1 9.26 2.39e-18 1.11e-11 0.7 0.45 Breast cancer; chr11:123040824 chrX:121203182~121205014:- LIHC trans rs7121616 0.531 rs12573932 ENSG00000234176.1 HSPA8P1 9.26 2.39e-18 1.11e-11 0.7 0.45 Breast cancer; chr11:123040995 chrX:121203182~121205014:- LIHC trans rs7121616 0.576 rs9665920 ENSG00000234176.1 HSPA8P1 9.26 2.39e-18 1.11e-11 0.7 0.45 Breast cancer; chr11:123041700 chrX:121203182~121205014:- LIHC trans rs13190036 1 rs13157667 ENSG00000228305.2 AC016734.2 -9.25 2.52e-18 1.17e-11 -0.54 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177186876 chr2:63622178~63622831:- LIHC trans rs13190036 1 rs13167431 ENSG00000228305.2 AC016734.2 -9.25 2.52e-18 1.17e-11 -0.54 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177194074 chr2:63622178~63622831:- LIHC trans rs13190036 1 rs35535623 ENSG00000228305.2 AC016734.2 -9.25 2.52e-18 1.17e-11 -0.54 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177202295 chr2:63622178~63622831:- LIHC trans rs13190036 1 rs71601343 ENSG00000228305.2 AC016734.2 -9.25 2.52e-18 1.17e-11 -0.54 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177205106 chr2:63622178~63622831:- LIHC trans rs13190036 1 rs71601344 ENSG00000228305.2 AC016734.2 -9.25 2.52e-18 1.17e-11 -0.54 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206492 chr2:63622178~63622831:- LIHC trans rs13190036 1 rs3733875 ENSG00000228305.2 AC016734.2 -9.25 2.52e-18 1.17e-11 -0.54 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210239 chr2:63622178~63622831:- LIHC trans rs2731664 0.792 rs335435 ENSG00000215571.5 GRK6P1 9.24 2.62e-18 1.21e-11 0.58 0.45 Intelligence (multi-trait analysis); chr5:177440942 chr13:21319156~21320866:+ LIHC trans rs3779195 0.585 rs58699591 ENSG00000225169.1 BRI3P1 -9.23 2.79e-18 1.29e-11 -0.76 -0.45 Sex hormone-binding globulin levels; chr7:98247392 chr1:100213293~100213670:+ LIHC trans rs5022636 0.594 rs10888408 ENSG00000180764.13 PIPSL 9.23 2.79e-18 1.29e-11 0.44 0.45 Gut microbiota (functional units); chr1:151267094 chr10:93958191~93961540:- LIHC trans rs61990749 0.511 rs7146020 ENSG00000235400.1 RP4-641G12.4 9.23 2.89e-18 1.33e-11 0.61 0.45 Fibroblast growth factor basic levels; chr14:77891976 chr1:78749073~78750659:+ LIHC trans rs7121616 0.531 rs11826861 ENSG00000234176.1 HSPA8P1 9.23 2.96e-18 1.36e-11 0.7 0.45 Breast cancer; chr11:123041207 chrX:121203182~121205014:- LIHC trans rs13190036 1 rs34446750 ENSG00000228305.2 AC016734.2 -9.22 3.17e-18 1.46e-11 -0.54 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177168079 chr2:63622178~63622831:- LIHC trans rs2731664 0.792 rs1130857 ENSG00000215571.5 GRK6P1 9.2 3.57e-18 1.64e-11 0.57 0.45 Intelligence (multi-trait analysis); chr5:177436518 chr13:21319156~21320866:+ LIHC trans rs7121616 0.576 rs7948948 ENSG00000234176.1 HSPA8P1 9.2 3.59e-18 1.65e-11 0.72 0.45 Breast cancer; chr11:123057467 chrX:121203182~121205014:- LIHC trans rs3779195 0.524 rs80195155 ENSG00000225169.1 BRI3P1 -9.2 3.65e-18 1.68e-11 -0.76 -0.45 Sex hormone-binding globulin levels; chr7:98248841 chr1:100213293~100213670:+ LIHC trans rs9425766 0.639 rs10798295 ENSG00000213331.4 RP11-713C19.2 9.2 3.65e-18 1.68e-11 0.54 0.45 Life satisfaction; chr1:173714815 chr4:187970273~187971284:+ LIHC trans rs2657294 0.62 rs4746261 ENSG00000172974.11 AC007318.5 -9.2 3.66e-18 1.68e-11 -0.51 -0.45 Pneumonia; chr10:75085874 chr2:65205108~65205988:+ LIHC trans rs12200782 0.505 rs1535275 ENSG00000242375.1 RP11-498P14.3 9.19 3.77e-18 1.73e-11 0.67 0.45 Small cell lung carcinoma; chr6:26520539 chr9:97195351~97197687:- LIHC trans rs9611565 0.729 rs137831 ENSG00000268568.1 AC007228.9 -9.19 3.9e-18 1.79e-11 -0.57 -0.45 Vitiligo; chr22:41507809 chr19:56672574~56673901:- LIHC trans rs13190036 1 rs13185316 ENSG00000228305.2 AC016734.2 -9.19 3.97e-18 1.82e-11 -0.54 -0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177213339 chr2:63622178~63622831:- LIHC trans rs4606360 1 rs4606360 ENSG00000213331.4 RP11-713C19.2 9.17 4.51e-18 2.06e-11 0.54 0.44 Subjective well-being; chr1:173729868 chr4:187970273~187971284:+ LIHC trans rs2731664 0.792 rs2731662 ENSG00000215571.5 GRK6P1 -9.17 4.62e-18 2.11e-11 -0.56 -0.44 Intelligence (multi-trait analysis); chr5:177445493 chr13:21319156~21320866:+ LIHC trans rs8067354 0.872 rs1292060 ENSG00000187870.7 RNFT1P3 9.16 4.77e-18 2.18e-11 0.52 0.44 Hemoglobin concentration; chr17:59836488 chr17:20743333~20754501:- LIHC trans rs9425766 0.511 rs10912676 ENSG00000213331.4 RP11-713C19.2 9.16 4.78e-18 2.19e-11 0.54 0.44 Life satisfaction; chr1:173740477 chr4:187970273~187971284:+ LIHC trans rs7258465 0.897 rs1043327 ENSG00000267533.1 RP11-815J4.7 9.16 4.9e-18 2.24e-11 0.58 0.44 Breast cancer; chr19:18444162 chr18:12067173~12068417:- LIHC trans rs7568458 0.684 rs67988001 ENSG00000223886.3 RP11-251G23.2 9.16 4.9e-18 2.24e-11 0.56 0.44 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85560000 chr7:105530209~105530671:+ LIHC trans rs13190036 1 rs13177748 ENSG00000228305.2 AC016734.2 -9.16 4.91e-18 2.25e-11 -0.54 -0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177216953 chr2:63622178~63622831:- LIHC trans rs8067354 0.789 rs4622571 ENSG00000187870.7 RNFT1P3 9.16 5.01e-18 2.29e-11 0.51 0.44 Hemoglobin concentration; chr17:59807036 chr17:20743333~20754501:- LIHC trans rs77688320 0.553 rs2080320 ENSG00000235105.1 RP11-329A14.1 9.15 5.21e-18 2.38e-11 0.46 0.44 Breast cancer; chr2:201514450 chr1:48435967~48437223:+ LIHC trans rs7258465 1 rs34746918 ENSG00000267533.1 RP11-815J4.7 9.15 5.3e-18 2.42e-11 0.59 0.44 Breast cancer; chr19:18428934 chr18:12067173~12068417:- LIHC trans rs13190036 0.901 rs55741473 ENSG00000228305.2 AC016734.2 -9.15 5.39e-18 2.46e-11 -0.54 -0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147218 chr2:63622178~63622831:- LIHC trans rs2731664 0.756 rs335433 ENSG00000215571.5 GRK6P1 9.14 5.49e-18 2.51e-11 0.56 0.44 Intelligence (multi-trait analysis); chr5:177440206 chr13:21319156~21320866:+ LIHC trans rs5022636 0.564 rs2275900 ENSG00000180764.13 PIPSL 9.14 5.52e-18 2.52e-11 0.43 0.44 Gut microbiota (functional units); chr1:151265746 chr10:93958191~93961540:- LIHC trans rs13190036 0.792 rs6874206 ENSG00000228305.2 AC016734.2 -9.14 5.76e-18 2.63e-11 -0.52 -0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177223970 chr2:63622178~63622831:- LIHC trans rs13190036 0.901 rs10072499 ENSG00000228305.2 AC016734.2 -9.14 5.76e-18 2.63e-11 -0.52 -0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228236 chr2:63622178~63622831:- LIHC trans rs7811142 0.945 rs6955362 ENSG00000228546.2 CTA-313A17.3 9.14 5.81e-18 2.65e-11 0.85 0.44 Platelet count; chr7:100458543 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs6975514 ENSG00000228546.2 CTA-313A17.3 9.14 5.81e-18 2.65e-11 0.85 0.44 Platelet count; chr7:100458597 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs7811142 ENSG00000228546.2 CTA-313A17.3 9.14 5.81e-18 2.65e-11 0.85 0.44 Platelet count; chr7:100467820 chr7:102337316~102339115:+ LIHC trans rs7811142 1 rs11773661 ENSG00000228546.2 CTA-313A17.3 9.14 5.81e-18 2.65e-11 0.85 0.44 Platelet count; chr7:100475446 chr7:102337316~102339115:+ LIHC trans rs7811142 0.943 rs66958101 ENSG00000228546.2 CTA-313A17.3 9.14 5.81e-18 2.65e-11 0.85 0.44 Platelet count; chr7:100476397 chr7:102337316~102339115:+ LIHC trans rs7930295 0.556 rs35904963 ENSG00000236257.1 EI24P2 9.12 6.45e-18 2.93e-11 0.58 0.44 Schizophrenia; chr11:125476956 chr1:158454198~158455273:+ LIHC trans rs2731664 0.756 rs2545796 ENSG00000215571.5 GRK6P1 9.12 6.54e-18 2.97e-11 0.56 0.44 Intelligence (multi-trait analysis); chr5:177437268 chr13:21319156~21320866:+ LIHC trans rs7258465 1 rs8109573 ENSG00000267533.1 RP11-815J4.7 9.12 6.72e-18 3.05e-11 0.56 0.44 Breast cancer; chr19:18506341 chr18:12067173~12068417:- LIHC trans rs8067354 0.872 rs2645488 ENSG00000187870.7 RNFT1P3 9.11 6.95e-18 3.16e-11 0.51 0.44 Hemoglobin concentration; chr17:59812044 chr17:20743333~20754501:- LIHC trans rs2731664 0.792 rs2630767 ENSG00000215571.5 GRK6P1 9.11 6.98e-18 3.17e-11 0.56 0.44 Intelligence (multi-trait analysis); chr5:177443699 chr13:21319156~21320866:+ LIHC trans rs9611565 0.765 rs132906 ENSG00000268568.1 AC007228.9 9.11 7.08e-18 3.21e-11 0.55 0.44 Vitiligo; chr22:41403763 chr19:56672574~56673901:- LIHC trans rs7568458 0.527 rs35416445 ENSG00000223886.3 RP11-251G23.2 9.11 7.28e-18 3.3e-11 0.55 0.44 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85546536 chr7:105530209~105530671:+ LIHC trans rs7568458 0.709 rs2028898 ENSG00000223886.3 RP11-251G23.2 9.11 7.28e-18 3.3e-11 0.55 0.44 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85550147 chr7:105530209~105530671:+ LIHC trans rs7568458 0.709 rs2592551 ENSG00000223886.3 RP11-251G23.2 9.11 7.28e-18 3.3e-11 0.55 0.44 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85553008 chr7:105530209~105530671:+ LIHC trans rs7568458 0.709 rs762684 ENSG00000223886.3 RP11-251G23.2 9.11 7.28e-18 3.3e-11 0.55 0.44 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85554900 chr7:105530209~105530671:+ LIHC trans rs13190036 1 rs655623 ENSG00000228305.2 AC016734.2 9.09 8.03e-18 3.63e-11 0.53 0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177107515 chr2:63622178~63622831:- LIHC trans rs9611565 0.506 rs2024566 ENSG00000268568.1 AC007228.9 -9.09 8.45e-18 3.82e-11 -0.63 -0.44 Vitiligo; chr22:41301334 chr19:56672574~56673901:- LIHC trans rs2731664 0.792 rs335466 ENSG00000215571.5 GRK6P1 9.08 8.9e-18 4.02e-11 0.57 0.44 Intelligence (multi-trait analysis); chr5:177462529 chr13:21319156~21320866:+ LIHC trans rs7258465 0.965 rs271628 ENSG00000267533.1 RP11-815J4.7 9.08 9.03e-18 4.08e-11 0.56 0.44 Breast cancer; chr19:18513523 chr18:12067173~12068417:- LIHC trans rs2731664 0.792 rs2630765 ENSG00000215571.5 GRK6P1 9.08 9.09e-18 4.1e-11 0.56 0.44 Intelligence (multi-trait analysis); chr5:177449824 chr13:21319156~21320866:+ LIHC trans rs2731664 0.792 rs2545795 ENSG00000215571.5 GRK6P1 9.08 9.09e-18 4.1e-11 0.56 0.44 Intelligence (multi-trait analysis); chr5:177460105 chr13:21319156~21320866:+ LIHC trans rs7662987 0.793 rs28730602 ENSG00000228407.2 RP4-800M22.1 9.08 9.11e-18 4.11e-11 1.03 0.44 Smoking initiation; chr4:99080531 chr1:52160261~52160600:- LIHC trans rs2731664 0.792 rs2544809 ENSG00000215571.5 GRK6P1 9.07 9.25e-18 4.17e-11 0.56 0.44 Intelligence (multi-trait analysis); chr5:177458498 chr13:21319156~21320866:+ LIHC trans rs7937890 0.967 rs963212 ENSG00000236360.2 RP11-334A14.2 -9.07 9.31e-18 4.19e-11 -0.56 -0.44 Mitochondrial DNA levels; chr11:14303186 chr1:52993201~52993702:- LIHC trans rs7937890 1 rs2970334 ENSG00000236360.2 RP11-334A14.2 -9.07 9.31e-18 4.19e-11 -0.56 -0.44 Mitochondrial DNA levels; chr11:14307809 chr1:52993201~52993702:- LIHC trans rs2731664 0.792 rs2630764 ENSG00000215571.5 GRK6P1 9.07 9.31e-18 4.2e-11 0.56 0.44 Intelligence (multi-trait analysis); chr5:177453084 chr13:21319156~21320866:+ LIHC trans rs13190036 0.748 rs28395268 ENSG00000228305.2 AC016734.2 9.06 1.01e-17 4.53e-11 0.5 0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177283546 chr2:63622178~63622831:- LIHC trans rs9611565 0.506 rs1984839 ENSG00000268568.1 AC007228.9 -9.06 1.01e-17 4.53e-11 -0.63 -0.44 Vitiligo; chr22:41289933 chr19:56672574~56673901:- LIHC trans rs7811142 0.887 rs111972532 ENSG00000228546.2 CTA-313A17.3 9.06 1.02e-17 4.6e-11 0.85 0.44 Platelet count; chr7:100471465 chr7:102337316~102339115:+ LIHC trans rs2731664 0.792 rs335432 ENSG00000215571.5 GRK6P1 9.06 1.03e-17 4.64e-11 0.56 0.44 Intelligence (multi-trait analysis); chr5:177439257 chr13:21319156~21320866:+ LIHC trans rs77688320 0.553 rs2243791 ENSG00000235105.1 RP11-329A14.1 -9.06 1.04e-17 4.65e-11 -0.45 -0.44 Breast cancer; chr2:201478079 chr1:48435967~48437223:+ LIHC trans rs5022636 0.525 rs6681163 ENSG00000180764.13 PIPSL 9.06 1.05e-17 4.69e-11 0.43 0.44 Gut microbiota (functional units); chr1:151259161 chr10:93958191~93961540:- LIHC trans rs7258465 1 rs271623 ENSG00000267533.1 RP11-815J4.7 9.05 1.08e-17 4.86e-11 0.57 0.44 Breast cancer; chr19:18518137 chr18:12067173~12068417:- LIHC trans rs7258465 0.965 rs271622 ENSG00000267533.1 RP11-815J4.7 9.05 1.08e-17 4.86e-11 0.57 0.44 Breast cancer; chr19:18518467 chr18:12067173~12068417:- LIHC trans rs2731664 0.765 rs2630766 ENSG00000215571.5 GRK6P1 9.05 1.11e-17 4.96e-11 0.57 0.44 Intelligence (multi-trait analysis); chr5:177447940 chr13:21319156~21320866:+ LIHC trans rs9611565 0.802 rs132916 ENSG00000268568.1 AC007228.9 9.05 1.12e-17 5.02e-11 0.54 0.44 Vitiligo; chr22:41410764 chr19:56672574~56673901:- LIHC trans rs616147 0.85 rs631312 ENSG00000214263.2 RPSAP53 -9.04 1.17e-17 5.25e-11 -0.59 -0.44 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39467477 chr13:67266845~67267706:- LIHC trans rs7258465 1 rs271621 ENSG00000267533.1 RP11-815J4.7 9.04 1.2e-17 5.36e-11 0.56 0.44 Breast cancer; chr19:18520522 chr18:12067173~12068417:- LIHC trans rs7258465 0.931 rs271629 ENSG00000267533.1 RP11-815J4.7 9.03 1.25e-17 5.59e-11 0.56 0.44 Breast cancer; chr19:18512388 chr18:12067173~12068417:- LIHC trans rs7258465 0.931 rs76195 ENSG00000267533.1 RP11-815J4.7 9.03 1.28e-17 5.72e-11 0.56 0.44 Breast cancer; chr19:18519020 chr18:12067173~12068417:- LIHC trans rs2731664 0.792 rs466256 ENSG00000215571.5 GRK6P1 9.02 1.36e-17 6.05e-11 0.57 0.44 Intelligence (multi-trait analysis); chr5:177448955 chr13:21319156~21320866:+ LIHC trans rs7258465 1 rs76194 ENSG00000267533.1 RP11-815J4.7 9.02 1.42e-17 6.34e-11 0.56 0.44 Breast cancer; chr19:18519770 chr18:12067173~12068417:- LIHC trans rs7258465 1 rs34171762 ENSG00000267533.1 RP11-815J4.7 9.01 1.43e-17 6.37e-11 0.57 0.44 Breast cancer; chr19:18448600 chr18:12067173~12068417:- LIHC trans rs7568458 0.66 rs2289972 ENSG00000223886.3 RP11-251G23.2 9.01 1.45e-17 6.48e-11 0.55 0.44 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85539422 chr7:105530209~105530671:+ LIHC trans rs58106596 0.66 rs62197212 ENSG00000259020.3 RP11-529H20.3 9.01 1.47e-17 6.54e-11 0.59 0.44 Lymphocyte counts;White blood cell count; chr2:231698017 chr14:92026566~92026887:+ LIHC trans rs9467773 0.935 rs1884947 ENSG00000242375.1 RP11-498P14.3 9.01 1.47e-17 6.55e-11 0.51 0.44 Intelligence (multi-trait analysis); chr6:26553045 chr9:97195351~97197687:- LIHC trans rs61990749 0.571 rs11628049 ENSG00000235400.1 RP4-641G12.4 -9 1.63e-17 7.23e-11 -0.64 -0.44 Fibroblast growth factor basic levels; chr14:77842108 chr1:78749073~78750659:+ LIHC trans rs7258465 0.965 rs2561043 ENSG00000267533.1 RP11-815J4.7 8.99 1.72e-17 7.66e-11 0.56 0.44 Breast cancer; chr19:18511873 chr18:12067173~12068417:- LIHC trans rs2657294 0.965 rs4746270 ENSG00000172974.11 AC007318.5 8.99 1.77e-17 7.85e-11 0.48 0.44 Pneumonia; chr10:75185189 chr2:65205108~65205988:+ LIHC trans rs9611565 0.506 rs2024567 ENSG00000268568.1 AC007228.9 -8.97 1.92e-17 8.5e-11 -0.62 -0.44 Vitiligo; chr22:41303202 chr19:56672574~56673901:- LIHC trans rs9611565 0.506 rs4822020 ENSG00000268568.1 AC007228.9 -8.97 1.92e-17 8.5e-11 -0.62 -0.44 Vitiligo; chr22:41304199 chr19:56672574~56673901:- LIHC trans rs9611519 0.732 rs1883826 ENSG00000268568.1 AC007228.9 -8.97 1.92e-17 8.5e-11 -0.62 -0.44 Neuroticism; chr22:41307424 chr19:56672574~56673901:- LIHC trans rs9611565 0.525 rs9611549 ENSG00000268568.1 AC007228.9 -8.97 1.92e-17 8.5e-11 -0.62 -0.44 Vitiligo; chr22:41309905 chr19:56672574~56673901:- LIHC trans rs9611565 0.729 rs203320 ENSG00000268568.1 AC007228.9 -8.97 1.94e-17 8.6e-11 -0.55 -0.44 Vitiligo; chr22:41517473 chr19:56672574~56673901:- LIHC trans rs3779195 0.929 rs4268041 ENSG00000225169.1 BRI3P1 -8.97 1.97e-17 8.71e-11 -0.63 -0.44 Sex hormone-binding globulin levels; chr7:98376226 chr1:100213293~100213670:+ LIHC trans rs13190036 1 rs628506 ENSG00000228305.2 AC016734.2 -8.97 1.99e-17 8.82e-11 -0.52 -0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177107422 chr2:63622178~63622831:- LIHC trans rs58106596 0.848 rs2241742 ENSG00000259020.3 RP11-529H20.3 8.96 2.07e-17 9.16e-11 0.58 0.44 Lymphocyte counts;White blood cell count; chr2:231710097 chr14:92026566~92026887:+ LIHC trans rs7258465 1 rs8106096 ENSG00000267533.1 RP11-815J4.7 8.96 2.12e-17 9.35e-11 0.59 0.44 Breast cancer; chr19:18425606 chr18:12067173~12068417:- LIHC trans rs7258465 0.931 rs8107347 ENSG00000267533.1 RP11-815J4.7 8.95 2.24e-17 9.89e-11 0.56 0.44 Breast cancer; chr19:18501938 chr18:12067173~12068417:- LIHC trans rs7258465 0.931 rs8107351 ENSG00000267533.1 RP11-815J4.7 8.95 2.24e-17 9.89e-11 0.56 0.44 Breast cancer; chr19:18501948 chr18:12067173~12068417:- LIHC trans rs77688320 0.535 rs60148247 ENSG00000235105.1 RP11-329A14.1 -8.95 2.29e-17 1.01e-10 -0.45 -0.44 Breast cancer; chr2:201513770 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs2080324 ENSG00000235105.1 RP11-329A14.1 -8.95 2.29e-17 1.01e-10 -0.45 -0.44 Breast cancer; chr2:201514089 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs2080323 ENSG00000235105.1 RP11-329A14.1 -8.95 2.29e-17 1.01e-10 -0.45 -0.44 Breast cancer; chr2:201514126 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs2080322 ENSG00000235105.1 RP11-329A14.1 -8.95 2.29e-17 1.01e-10 -0.45 -0.44 Breast cancer; chr2:201514317 chr1:48435967~48437223:+ LIHC trans rs5022636 0.896 rs4971032 ENSG00000180764.13 PIPSL 8.95 2.36e-17 1.04e-10 0.42 0.44 Gut microbiota (functional units); chr1:151317948 chr10:93958191~93961540:- LIHC trans rs9611565 0.605 rs202638 ENSG00000268568.1 AC007228.9 8.95 2.37e-17 1.04e-10 0.55 0.44 Vitiligo; chr22:41459454 chr19:56672574~56673901:- LIHC trans rs5022636 0.594 rs11204791 ENSG00000180764.13 PIPSL 8.94 2.44e-17 1.07e-10 0.42 0.44 Gut microbiota (functional units); chr1:151268066 chr10:93958191~93961540:- LIHC trans rs9611565 0.625 rs2076199 ENSG00000268568.1 AC007228.9 -8.94 2.44e-17 1.08e-10 -0.55 -0.44 Vitiligo; chr22:41507739 chr19:56672574~56673901:- LIHC trans rs9467773 0.933 rs35355150 ENSG00000242375.1 RP11-498P14.3 8.94 2.52e-17 1.11e-10 0.51 0.44 Intelligence (multi-trait analysis); chr6:26525811 chr9:97195351~97197687:- LIHC trans rs8067354 0.958 rs2777889 ENSG00000187870.7 RNFT1P3 8.94 2.55e-17 1.12e-10 0.5 0.44 Hemoglobin concentration; chr17:59770645 chr17:20743333~20754501:- LIHC trans rs9611565 0.525 rs9611548 ENSG00000268568.1 AC007228.9 -8.94 2.55e-17 1.12e-10 -0.66 -0.44 Vitiligo; chr22:41308139 chr19:56672574~56673901:- LIHC trans rs5022636 0.927 rs4971030 ENSG00000180764.13 PIPSL -8.93 2.6e-17 1.14e-10 -0.42 -0.43 Gut microbiota (functional units); chr1:151308519 chr10:93958191~93961540:- LIHC trans rs77688320 0.573 rs2714480 ENSG00000235105.1 RP11-329A14.1 -8.93 2.63e-17 1.16e-10 -0.45 -0.43 Breast cancer; chr2:201486286 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs2908763 ENSG00000235105.1 RP11-329A14.1 -8.93 2.63e-17 1.16e-10 -0.45 -0.43 Breast cancer; chr2:201503860 chr1:48435967~48437223:+ LIHC trans rs616147 0.816 rs1768190 ENSG00000214263.2 RPSAP53 8.93 2.65e-17 1.16e-10 0.59 0.43 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39467949 chr13:67266845~67267706:- LIHC trans rs5022636 0.525 rs7539584 ENSG00000180764.13 PIPSL 8.93 2.75e-17 1.2e-10 0.42 0.43 Gut microbiota (functional units); chr1:151210477 chr10:93958191~93961540:- LIHC trans rs58106596 0.95 rs11899963 ENSG00000259020.3 RP11-529H20.3 8.92 2.83e-17 1.24e-10 0.56 0.43 Lymphocyte counts;White blood cell count; chr2:231717190 chr14:92026566~92026887:+ LIHC trans rs7568458 0.684 rs1048740 ENSG00000223886.3 RP11-251G23.2 8.92 2.87e-17 1.26e-10 0.54 0.43 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85537843 chr7:105530209~105530671:+ LIHC trans rs7568458 0.684 rs1048739 ENSG00000223886.3 RP11-251G23.2 8.92 2.87e-17 1.26e-10 0.54 0.43 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85537845 chr7:105530209~105530671:+ LIHC trans rs9611565 0.694 rs4822032 ENSG00000268568.1 AC007228.9 -8.91 3.11e-17 1.36e-10 -0.54 -0.43 Vitiligo; chr22:41529531 chr19:56672574~56673901:- LIHC trans rs9611565 0.625 rs12483991 ENSG00000268568.1 AC007228.9 -8.91 3.16e-17 1.38e-10 -0.54 -0.43 Vitiligo; chr22:41539281 chr19:56672574~56673901:- LIHC trans rs58106596 0.8 rs11693819 ENSG00000259020.3 RP11-529H20.3 8.9 3.41e-17 1.49e-10 0.57 0.43 Lymphocyte counts;White blood cell count; chr2:231701496 chr14:92026566~92026887:+ LIHC trans rs7568458 0.636 rs11126995 ENSG00000223886.3 RP11-251G23.2 8.89 3.5e-17 1.53e-10 0.55 0.43 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85565285 chr7:105530209~105530671:+ LIHC trans rs2731664 0.819 rs449351 ENSG00000215571.5 GRK6P1 8.89 3.64e-17 1.59e-10 0.55 0.43 Intelligence (multi-trait analysis); chr5:177445590 chr13:21319156~21320866:+ LIHC trans rs916888 0.773 rs199457 ENSG00000214425.5 LRRC37A4P -8.89 3.7e-17 1.61e-10 -0.7 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45506741~45550335:- LIHC trans rs916888 0.687 rs199456 ENSG00000214425.5 LRRC37A4P -8.89 3.7e-17 1.61e-10 -0.7 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45506741~45550335:- LIHC trans rs916888 0.773 rs199451 ENSG00000214425.5 LRRC37A4P -8.88 3.82e-17 1.66e-10 -0.7 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45506741~45550335:- LIHC trans rs616147 0.962 rs545397 ENSG00000214263.2 RPSAP53 8.88 3.84e-17 1.67e-10 0.58 0.43 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39488592 chr13:67266845~67267706:- LIHC trans rs616147 0.962 rs1513219 ENSG00000214263.2 RPSAP53 8.88 3.84e-17 1.67e-10 0.58 0.43 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39492268 chr13:67266845~67267706:- LIHC trans rs916888 0.773 rs169201 ENSG00000214425.5 LRRC37A4P -8.88 3.92e-17 1.71e-10 -0.7 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45506741~45550335:- LIHC trans rs13190036 0.892 rs71601339 ENSG00000228305.2 AC016734.2 -8.87 4.18e-17 1.82e-10 -0.53 -0.43 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117495 chr2:63622178~63622831:- LIHC trans rs9611519 0.78 rs9611542 ENSG00000268568.1 AC007228.9 -8.86 4.29e-17 1.87e-10 -0.63 -0.43 Neuroticism; chr22:41281313 chr19:56672574~56673901:- LIHC trans rs916888 0.773 rs199439 ENSG00000214425.5 LRRC37A4P -8.86 4.37e-17 1.9e-10 -0.7 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45506741~45550335:- LIHC trans rs7399018 0.739 rs10747608 ENSG00000223825.5 DAZAP2P1 8.86 4.41e-17 1.92e-10 0.44 0.43 Cisplatin-induced ototoxicity; chr12:51222798 chr2:202201384~202201886:- LIHC trans rs10037055 0.853 rs9313749 ENSG00000228305.2 AC016734.2 -8.85 4.67e-17 2.03e-10 -0.48 -0.43 Migraine without aura; chr5:177170693 chr2:63622178~63622831:- LIHC trans rs7930295 1 rs34880099 ENSG00000236257.1 EI24P2 8.84 5.05e-17 2.19e-10 0.61 0.43 Schizophrenia; chr11:125442413 chr1:158454198~158455273:+ LIHC trans rs8067354 0.872 rs2645483 ENSG00000187870.7 RNFT1P3 8.84 5.16e-17 2.24e-10 0.5 0.43 Hemoglobin concentration; chr17:59770823 chr17:20743333~20754501:- LIHC trans rs616147 1 rs616147 ENSG00000214263.2 RPSAP53 -8.83 5.41e-17 2.34e-10 -0.58 -0.43 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39492990 chr13:67266845~67267706:- LIHC trans rs3779195 0.585 rs7777991 ENSG00000225169.1 BRI3P1 -8.83 5.43e-17 2.35e-10 -0.74 -0.43 Sex hormone-binding globulin levels; chr7:98236445 chr1:100213293~100213670:+ LIHC trans rs7930295 1 rs7930295 ENSG00000236257.1 EI24P2 8.83 5.47e-17 2.36e-10 0.6 0.43 Schizophrenia; chr11:125443703 chr1:158454198~158455273:+ LIHC trans rs58106596 0.95 rs55729107 ENSG00000259020.3 RP11-529H20.3 8.83 5.47e-17 2.37e-10 0.55 0.43 Lymphocyte counts;White blood cell count; chr2:231717375 chr14:92026566~92026887:+ LIHC trans rs7258465 1 rs271624 ENSG00000267533.1 RP11-815J4.7 8.83 5.55e-17 2.4e-10 0.56 0.43 Breast cancer; chr19:18517143 chr18:12067173~12068417:- LIHC trans rs7811142 1 rs6953107 ENSG00000228546.2 CTA-313A17.3 8.83 5.7e-17 2.46e-10 0.81 0.43 Platelet count; chr7:100498041 chr7:102337316~102339115:+ LIHC trans rs2657294 0.965 rs2657291 ENSG00000172974.11 AC007318.5 8.82 5.76e-17 2.49e-10 0.46 0.43 Pneumonia; chr10:75166945 chr2:65205108~65205988:+ LIHC trans rs916888 0.773 rs1378358 ENSG00000214425.5 LRRC37A4P -8.82 6.09e-17 2.63e-10 -0.7 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45506741~45550335:- LIHC trans rs2731664 0.792 rs465670 ENSG00000215571.5 GRK6P1 8.81 6.2e-17 2.67e-10 0.55 0.43 Intelligence (multi-trait analysis); chr5:177450623 chr13:21319156~21320866:+ LIHC trans rs2731664 0.792 rs335452 ENSG00000215571.5 GRK6P1 8.81 6.2e-17 2.67e-10 0.55 0.43 Intelligence (multi-trait analysis); chr5:177452670 chr13:21319156~21320866:+ LIHC trans rs2731664 0.792 rs385981 ENSG00000215571.5 GRK6P1 8.81 6.2e-17 2.67e-10 0.55 0.43 Intelligence (multi-trait analysis); chr5:177459538 chr13:21319156~21320866:+ LIHC trans rs13190036 1 rs6880798 ENSG00000228305.2 AC016734.2 8.81 6.22e-17 2.68e-10 0.49 0.43 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177277456 chr2:63622178~63622831:- LIHC trans rs916888 0.61 rs199529 ENSG00000214425.5 LRRC37A4P -8.81 6.27e-17 2.7e-10 -0.67 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:45506741~45550335:- LIHC trans rs7811142 0.945 rs6974282 ENSG00000228546.2 CTA-313A17.3 8.81 6.59e-17 2.84e-10 0.83 0.43 Platelet count; chr7:100500672 chr7:102337316~102339115:+ LIHC trans rs7811142 0.945 rs6978739 ENSG00000228546.2 CTA-313A17.3 8.81 6.59e-17 2.84e-10 0.83 0.43 Platelet count; chr7:100501057 chr7:102337316~102339115:+ LIHC trans rs916888 0.773 rs199447 ENSG00000214425.5 LRRC37A4P -8.8 6.65e-17 2.86e-10 -0.7 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45506741~45550335:- LIHC trans rs916888 0.773 rs199448 ENSG00000214425.5 LRRC37A4P -8.8 6.95e-17 2.99e-10 -0.69 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45506741~45550335:- LIHC trans rs2731664 0.792 rs652242 ENSG00000215571.5 GRK6P1 8.8 7.1e-17 3.05e-10 0.54 0.43 Intelligence (multi-trait analysis); chr5:177446009 chr13:21319156~21320866:+ LIHC trans rs77688320 0.529 rs2540438 ENSG00000235105.1 RP11-329A14.1 -8.79 7.26e-17 3.12e-10 -0.45 -0.43 Breast cancer; chr2:201485833 chr1:48435967~48437223:+ LIHC trans rs916888 0.773 rs538628 ENSG00000214425.5 LRRC37A4P -8.79 7.57e-17 3.25e-10 -0.7 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45506741~45550335:- LIHC trans rs9611565 0.694 rs5758389 ENSG00000268568.1 AC007228.9 -8.79 7.62e-17 3.27e-10 -0.53 -0.43 Vitiligo; chr22:41545745 chr19:56672574~56673901:- LIHC trans rs2657294 0.965 rs7088974 ENSG00000172974.11 AC007318.5 8.78 7.71e-17 3.31e-10 0.47 0.43 Pneumonia; chr10:75131338 chr2:65205108~65205988:+ LIHC trans rs7258465 1 rs2303695 ENSG00000267533.1 RP11-815J4.7 8.78 7.72e-17 3.31e-10 0.56 0.43 Breast cancer; chr19:18451814 chr18:12067173~12068417:- LIHC trans rs9467773 0.935 rs11752946 ENSG00000242375.1 RP11-498P14.3 8.78 7.92e-17 3.39e-10 0.5 0.43 Intelligence (multi-trait analysis); chr6:26560136 chr9:97195351~97197687:- LIHC trans rs2731664 0.792 rs335434 ENSG00000215571.5 GRK6P1 8.78 8.19e-17 3.5e-10 0.53 0.43 Intelligence (multi-trait analysis); chr5:177440275 chr13:21319156~21320866:+ LIHC trans rs7568458 0.684 rs6731700 ENSG00000223886.3 RP11-251G23.2 8.78 8.22e-17 3.52e-10 0.54 0.43 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85533868 chr7:105530209~105530671:+ LIHC trans rs8067354 0.872 rs2645466 ENSG00000187870.7 RNFT1P3 8.78 8.23e-17 3.52e-10 0.49 0.43 Hemoglobin concentration; chr17:59775853 chr17:20743333~20754501:- LIHC trans rs7662987 0.793 rs78790289 ENSG00000228407.2 RP4-800M22.1 8.76 9.48e-17 4.04e-10 0.93 0.43 Smoking initiation; chr4:99066736 chr1:52160261~52160600:- LIHC trans rs72615157 0.561 rs113401658 ENSG00000228546.2 CTA-313A17.3 8.75 9.7e-17 4.13e-10 0.73 0.43 Lung function (FEV1/FVC); chr7:100260882 chr7:102337316~102339115:+ LIHC trans rs5022636 0.927 rs943637 ENSG00000180764.13 PIPSL 8.74 1.06e-16 4.5e-10 0.41 0.43 Gut microbiota (functional units); chr1:151310543 chr10:93958191~93961540:- LIHC trans rs77688320 0.553 rs12473387 ENSG00000235105.1 RP11-329A14.1 8.74 1.07e-16 4.54e-10 0.43 0.43 Breast cancer; chr2:201415778 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs4507084 ENSG00000235105.1 RP11-329A14.1 8.74 1.07e-16 4.54e-10 0.43 0.43 Breast cancer; chr2:201420377 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs1558637 ENSG00000235105.1 RP11-329A14.1 -8.74 1.08e-16 4.61e-10 -0.43 -0.43 Breast cancer; chr2:201398651 chr1:48435967~48437223:+ LIHC trans rs7258465 0.896 rs8103660 ENSG00000267533.1 RP11-815J4.7 8.73 1.15e-16 4.9e-10 0.54 0.43 Breast cancer; chr19:18455585 chr18:12067173~12068417:- LIHC trans rs10037055 1 rs6886255 ENSG00000228305.2 AC016734.2 8.73 1.17e-16 4.97e-10 0.47 0.43 Migraine without aura; chr5:177291360 chr2:63622178~63622831:- LIHC trans rs616147 0.962 rs1708104 ENSG00000214263.2 RPSAP53 -8.72 1.21e-16 5.15e-10 -0.57 -0.43 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39493251 chr13:67266845~67267706:- LIHC trans rs7930295 1 rs34238592 ENSG00000236257.1 EI24P2 8.72 1.22e-16 5.18e-10 0.6 0.43 Schizophrenia; chr11:125445059 chr1:158454198~158455273:+ LIHC trans rs7930295 1 rs34504992 ENSG00000236257.1 EI24P2 8.72 1.22e-16 5.18e-10 0.6 0.43 Schizophrenia; chr11:125446177 chr1:158454198~158455273:+ LIHC trans rs12709013 0.716 rs6416775 ENSG00000230849.2 GOT2P2 8.72 1.24e-16 5.26e-10 0.47 0.43 Blood metabolite ratios; chr16:58830410 chr1:173141100~173142350:- LIHC trans rs916888 0.773 rs199534 ENSG00000214425.5 LRRC37A4P -8.72 1.27e-16 5.37e-10 -0.69 -0.43 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45506741~45550335:- LIHC trans rs8067354 0.958 rs8081468 ENSG00000187870.7 RNFT1P3 8.71 1.3e-16 5.52e-10 0.49 0.43 Hemoglobin concentration; chr17:59759563 chr17:20743333~20754501:- LIHC trans rs8067354 0.958 rs2333563 ENSG00000187870.7 RNFT1P3 8.71 1.3e-16 5.52e-10 0.49 0.43 Hemoglobin concentration; chr17:59762207 chr17:20743333~20754501:- LIHC trans rs77688320 0.553 rs2244438 ENSG00000235105.1 RP11-329A14.1 -8.71 1.31e-16 5.56e-10 -0.42 -0.43 Breast cancer; chr2:201387816 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs2540330 ENSG00000235105.1 RP11-329A14.1 -8.71 1.31e-16 5.56e-10 -0.42 -0.43 Breast cancer; chr2:201388133 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs2540331 ENSG00000235105.1 RP11-329A14.1 -8.71 1.31e-16 5.56e-10 -0.42 -0.43 Breast cancer; chr2:201388150 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs2540432 ENSG00000235105.1 RP11-329A14.1 -8.71 1.36e-16 5.76e-10 -0.44 -0.43 Breast cancer; chr2:201500171 chr1:48435967~48437223:+ LIHC trans rs7258465 0.965 rs748609 ENSG00000267533.1 RP11-815J4.7 8.7 1.43e-16 6.05e-10 0.55 0.43 Breast cancer; chr19:18449472 chr18:12067173~12068417:- LIHC trans rs7258465 0.931 rs34053595 ENSG00000267533.1 RP11-815J4.7 8.69 1.5e-16 6.35e-10 0.56 0.43 Breast cancer; chr19:18445939 chr18:12067173~12068417:- LIHC trans rs7258465 0.931 rs271626 ENSG00000267533.1 RP11-815J4.7 -8.69 1.57e-16 6.62e-10 -0.55 -0.43 Breast cancer; chr19:18516257 chr18:12067173~12068417:- LIHC trans rs9611565 0.506 rs1883825 ENSG00000268568.1 AC007228.9 -8.68 1.62e-16 6.84e-10 -0.62 -0.42 Vitiligo; chr22:41307404 chr19:56672574~56673901:- LIHC trans rs9611565 0.525 rs1883827 ENSG00000268568.1 AC007228.9 -8.68 1.62e-16 6.84e-10 -0.62 -0.42 Vitiligo; chr22:41307575 chr19:56672574~56673901:- LIHC trans rs7258465 1 rs7252707 ENSG00000267533.1 RP11-815J4.7 8.68 1.63e-16 6.88e-10 0.54 0.42 Breast cancer; chr19:18501447 chr18:12067173~12068417:- LIHC trans rs13014235 0.667 rs2540328 ENSG00000235105.1 RP11-329A14.1 -8.68 1.66e-16 6.97e-10 -0.42 -0.42 Basal cell carcinoma; chr2:201384337 chr1:48435967~48437223:+ LIHC trans rs77688320 0.509 rs2714487 ENSG00000235105.1 RP11-329A14.1 -8.68 1.66e-16 6.97e-10 -0.42 -0.42 Breast cancer; chr2:201384837 chr1:48435967~48437223:+ LIHC trans rs77688320 0.535 rs10186894 ENSG00000235105.1 RP11-329A14.1 8.68 1.68e-16 7.05e-10 0.42 0.42 Breast cancer; chr2:201440909 chr1:48435967~48437223:+ LIHC trans rs9611565 0.729 rs169362 ENSG00000268568.1 AC007228.9 8.68 1.7e-16 7.14e-10 0.53 0.42 Vitiligo; chr22:41431585 chr19:56672574~56673901:- LIHC trans rs916888 0.773 rs199533 ENSG00000214425.5 LRRC37A4P -8.67 1.71e-16 7.2e-10 -0.69 -0.42 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45506741~45550335:- LIHC trans rs77688320 0.573 rs2080327 ENSG00000235105.1 RP11-329A14.1 -8.67 1.73e-16 7.25e-10 -0.43 -0.42 Breast cancer; chr2:201461495 chr1:48435967~48437223:+ LIHC trans rs7930295 1 rs28593289 ENSG00000236257.1 EI24P2 8.67 1.73e-16 7.26e-10 0.59 0.42 Schizophrenia; chr11:125446628 chr1:158454198~158455273:+ LIHC trans rs538867 0.661 rs114772633 ENSG00000214263.2 RPSAP53 8.67 1.73e-16 7.29e-10 1.03 0.42 Alzheimer's disease (cognitive decline); chr3:39403407 chr13:67266845~67267706:- LIHC trans rs7930295 1 rs11220081 ENSG00000236257.1 EI24P2 8.67 1.78e-16 7.47e-10 0.6 0.42 Schizophrenia; chr11:125453646 chr1:158454198~158455273:+ LIHC trans rs538867 1 rs78956920 ENSG00000214263.2 RPSAP53 8.67 1.8e-16 7.57e-10 1.03 0.42 Alzheimer's disease (cognitive decline); chr3:39437633 chr13:67266845~67267706:- LIHC trans rs7258465 1 rs8107367 ENSG00000267533.1 RP11-815J4.7 8.65 2.01e-16 8.41e-10 0.55 0.42 Breast cancer; chr19:18453895 chr18:12067173~12068417:- LIHC trans rs77688320 0.553 rs2714488 ENSG00000235105.1 RP11-329A14.1 -8.65 2.06e-16 8.63e-10 -0.43 -0.42 Breast cancer; chr2:201405050 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs2249868 ENSG00000235105.1 RP11-329A14.1 -8.65 2.06e-16 8.63e-10 -0.43 -0.42 Breast cancer; chr2:201412503 chr1:48435967~48437223:+ LIHC trans rs5022636 1 rs4970948 ENSG00000180764.13 PIPSL 8.64 2.13e-16 8.91e-10 0.41 0.42 Gut microbiota (functional units); chr1:151318767 chr10:93958191~93961540:- LIHC trans rs916888 0.773 rs199445 ENSG00000214425.5 LRRC37A4P -8.64 2.14e-16 8.93e-10 -0.68 -0.42 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45506741~45550335:- LIHC trans rs916888 0.773 rs199443 ENSG00000214425.5 LRRC37A4P -8.64 2.14e-16 8.93e-10 -0.68 -0.42 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45506741~45550335:- LIHC trans rs9611519 0.78 rs1535048 ENSG00000268568.1 AC007228.9 -8.64 2.15e-16 8.97e-10 -0.6 -0.42 Neuroticism; chr22:41288089 chr19:56672574~56673901:- LIHC trans rs2731664 0.756 rs4976695 ENSG00000215571.5 GRK6P1 8.64 2.21e-16 9.22e-10 0.55 0.42 Intelligence (multi-trait analysis); chr5:177435962 chr13:21319156~21320866:+ LIHC trans rs7258465 1 rs10164323 ENSG00000267533.1 RP11-815J4.7 8.63 2.27e-16 9.46e-10 0.54 0.42 Breast cancer; chr19:18458682 chr18:12067173~12068417:- LIHC trans rs77688320 0.553 rs6722889 ENSG00000235105.1 RP11-329A14.1 -8.63 2.31e-16 9.61e-10 -0.42 -0.42 Breast cancer; chr2:201439359 chr1:48435967~48437223:+ LIHC trans rs9611565 0.729 rs505533 ENSG00000268568.1 AC007228.9 8.63 2.33e-16 9.71e-10 0.53 0.42 Vitiligo; chr22:41468212 chr19:56672574~56673901:- LIHC trans rs5022636 0.74 rs11204795 ENSG00000180764.13 PIPSL 8.63 2.34e-16 9.74e-10 0.42 0.42 Gut microbiota (functional units); chr1:151275522 chr10:93958191~93961540:- LIHC trans rs7258465 0.931 rs1560119 ENSG00000267533.1 RP11-815J4.7 8.63 2.34e-16 9.75e-10 0.54 0.42 Breast cancer; chr19:18462865 chr18:12067173~12068417:- LIHC trans rs7258465 1 rs10425982 ENSG00000267533.1 RP11-815J4.7 8.63 2.34e-16 9.75e-10 0.54 0.42 Breast cancer; chr19:18475709 chr18:12067173~12068417:- LIHC trans rs7258465 0.965 rs7256534 ENSG00000267533.1 RP11-815J4.7 8.63 2.34e-16 9.75e-10 0.54 0.42 Breast cancer; chr19:18475981 chr18:12067173~12068417:- LIHC trans rs77688320 0.553 rs2540449 ENSG00000235105.1 RP11-329A14.1 -8.63 2.37e-16 9.86e-10 -0.43 -0.42 Breast cancer; chr2:201451036 chr1:48435967~48437223:+ LIHC trans rs7811142 0.945 rs34989573 ENSG00000228546.2 CTA-313A17.3 8.62 2.61e-16 1.08e-09 0.8 0.42 Platelet count; chr7:100500272 chr7:102337316~102339115:+ LIHC trans rs9611519 0.754 rs4820435 ENSG00000268568.1 AC007228.9 -8.61 2.62e-16 1.09e-09 -0.62 -0.42 Neuroticism; chr22:41256842 chr19:56672574~56673901:- LIHC trans rs9611565 0.729 rs202654 ENSG00000268568.1 AC007228.9 8.61 2.74e-16 1.14e-09 0.53 0.42 Vitiligo; chr22:41445030 chr19:56672574~56673901:- LIHC trans rs10908521 0.611 rs7516736 ENSG00000227183.3 HDGFP1 -8.61 2.77e-16 1.15e-09 -0.53 -0.42 Uric acid clearance; chr1:156825994 chrX:131646639~131646890:+ LIHC trans rs7364180 0.582 rs139568 ENSG00000268568.1 AC007228.9 8.6 2.81e-16 1.17e-09 0.51 0.42 Alzheimer's disease biomarkers; chr22:41814981 chr19:56672574~56673901:- LIHC trans rs77688320 0.553 rs2540339 ENSG00000235105.1 RP11-329A14.1 -8.6 2.83e-16 1.17e-09 -0.42 -0.42 Breast cancer; chr2:201415725 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs2540340 ENSG00000235105.1 RP11-329A14.1 -8.6 2.83e-16 1.17e-09 -0.42 -0.42 Breast cancer; chr2:201416477 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs7582946 ENSG00000235105.1 RP11-329A14.1 8.6 2.83e-16 1.17e-09 0.42 0.42 Breast cancer; chr2:201423969 chr1:48435967~48437223:+ LIHC trans rs7258465 0.965 rs8100767 ENSG00000267533.1 RP11-815J4.7 8.6 2.89e-16 1.19e-09 0.54 0.42 Breast cancer; chr19:18478278 chr18:12067173~12068417:- LIHC trans rs7258465 1 rs10409483 ENSG00000267533.1 RP11-815J4.7 8.6 2.89e-16 1.19e-09 0.54 0.42 Breast cancer; chr19:18479413 chr18:12067173~12068417:- LIHC trans rs7258465 1 rs10409505 ENSG00000267533.1 RP11-815J4.7 8.6 2.89e-16 1.19e-09 0.54 0.42 Breast cancer; chr19:18479441 chr18:12067173~12068417:- LIHC trans rs7258465 0.965 rs7254249 ENSG00000267533.1 RP11-815J4.7 8.6 2.89e-16 1.19e-09 0.54 0.42 Breast cancer; chr19:18480935 chr18:12067173~12068417:- LIHC trans rs7258465 0.965 rs7253990 ENSG00000267533.1 RP11-815J4.7 8.6 2.89e-16 1.19e-09 0.54 0.42 Breast cancer; chr19:18493275 chr18:12067173~12068417:- LIHC trans rs7258465 1 rs10403249 ENSG00000267533.1 RP11-815J4.7 8.6 2.89e-16 1.19e-09 0.54 0.42 Breast cancer; chr19:18494132 chr18:12067173~12068417:- LIHC trans rs7258465 1 rs34256197 ENSG00000267533.1 RP11-815J4.7 8.6 2.89e-16 1.19e-09 0.54 0.42 Breast cancer; chr19:18495662 chr18:12067173~12068417:- LIHC trans rs7258465 0.931 rs7249020 ENSG00000267533.1 RP11-815J4.7 8.6 2.89e-16 1.19e-09 0.54 0.42 Breast cancer; chr19:18497337 chr18:12067173~12068417:- LIHC trans rs7258465 1 rs7251653 ENSG00000267533.1 RP11-815J4.7 8.58 3.25e-16 1.34e-09 0.54 0.42 Breast cancer; chr19:18497473 chr18:12067173~12068417:- LIHC trans rs7930295 1 rs6590145 ENSG00000236257.1 EI24P2 8.58 3.33e-16 1.37e-09 0.59 0.42 Schizophrenia; chr11:125448020 chr1:158454198~158455273:+ LIHC trans rs8067354 0.872 rs1295925 ENSG00000187870.7 RNFT1P3 -8.58 3.42e-16 1.41e-09 -0.49 -0.42 Hemoglobin concentration; chr17:59832902 chr17:20743333~20754501:- LIHC trans rs3740713 0.592 rs73434674 ENSG00000235847.2 LDHAP7 8.57 3.5e-16 1.44e-09 0.72 0.42 Amyotrophic lateral sclerosis (sporadic); chr11:18389950 chr2:84777259~84778223:- LIHC trans rs7930295 0.822 rs7112666 ENSG00000236257.1 EI24P2 8.57 3.58e-16 1.47e-09 0.59 0.42 Schizophrenia; chr11:125437980 chr1:158454198~158455273:+ LIHC trans rs7258465 1 rs4808801 ENSG00000267533.1 RP11-815J4.7 8.57 3.65e-16 1.5e-09 0.54 0.42 Breast cancer; chr19:18460331 chr18:12067173~12068417:- LIHC trans rs77688320 0.553 rs2540430 ENSG00000235105.1 RP11-329A14.1 -8.56 3.79e-16 1.56e-09 -0.43 -0.42 Breast cancer; chr2:201503791 chr1:48435967~48437223:+ LIHC trans rs2731664 0.792 rs337374 ENSG00000215571.5 GRK6P1 -8.56 3.87e-16 1.59e-09 -0.52 -0.42 Intelligence (multi-trait analysis); chr5:177463415 chr13:21319156~21320866:+ LIHC trans rs5022636 0.964 rs7518924 ENSG00000180764.13 PIPSL 8.56 3.87e-16 1.59e-09 0.4 0.42 Gut microbiota (functional units); chr1:151319225 chr10:93958191~93961540:- LIHC trans rs58106596 0.747 rs72994902 ENSG00000259020.3 RP11-529H20.3 8.56 3.9e-16 1.6e-09 0.55 0.42 Lymphocyte counts;White blood cell count; chr2:231720407 chr14:92026566~92026887:+ LIHC trans rs13190036 1 rs59737888 ENSG00000228305.2 AC016734.2 -8.55 4.16e-16 1.7e-09 -0.52 -0.42 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177160374 chr2:63622178~63622831:- LIHC trans rs7364180 0.515 rs6002503 ENSG00000268568.1 AC007228.9 -8.55 4.26e-16 1.75e-09 -0.51 -0.42 Alzheimer's disease biomarkers; chr22:41812668 chr19:56672574~56673901:- LIHC trans rs9611565 0.694 rs9611591 ENSG00000268568.1 AC007228.9 8.54 4.6e-16 1.88e-09 0.53 0.42 Vitiligo; chr22:41434208 chr19:56672574~56673901:- LIHC trans rs7258465 1 rs2278238 ENSG00000267533.1 RP11-815J4.7 8.53 4.69e-16 1.92e-09 0.54 0.42 Breast cancer; chr19:18465674 chr18:12067173~12068417:- LIHC trans rs10037055 1 rs10037055 ENSG00000228305.2 AC016734.2 -8.53 4.84e-16 1.98e-09 -0.47 -0.42 Migraine without aura; chr5:177264278 chr2:63622178~63622831:- LIHC trans rs7568458 0.709 rs56819945 ENSG00000223886.3 RP11-251G23.2 8.53 4.85e-16 1.98e-09 0.53 0.42 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85528016 chr7:105530209~105530671:+ LIHC trans rs7258465 1 rs10411009 ENSG00000267533.1 RP11-815J4.7 8.53 4.88e-16 2e-09 0.53 0.42 Breast cancer; chr19:18495456 chr18:12067173~12068417:- LIHC trans rs7937890 1 rs2970335 ENSG00000236360.2 RP11-334A14.2 8.52 5.13e-16 2.09e-09 0.53 0.42 Mitochondrial DNA levels; chr11:14303855 chr1:52993201~52993702:- LIHC trans rs8067354 0.831 rs2333617 ENSG00000187870.7 RNFT1P3 -8.52 5.17e-16 2.11e-09 -0.48 -0.42 Hemoglobin concentration; chr17:59818859 chr17:20743333~20754501:- LIHC trans rs8067354 0.872 rs7224006 ENSG00000187870.7 RNFT1P3 -8.52 5.17e-16 2.11e-09 -0.48 -0.42 Hemoglobin concentration; chr17:59818977 chr17:20743333~20754501:- LIHC trans rs916888 0.779 rs199528 ENSG00000214425.5 LRRC37A4P -8.52 5.27e-16 2.15e-09 -0.69 -0.42 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45506741~45550335:- LIHC trans rs916888 0.821 rs199525 ENSG00000214425.5 LRRC37A4P -8.52 5.27e-16 2.15e-09 -0.69 -0.42 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45506741~45550335:- LIHC trans rs9611565 0.729 rs203319 ENSG00000268568.1 AC007228.9 -8.51 5.53e-16 2.25e-09 -0.51 -0.42 Vitiligo; chr22:41518589 chr19:56672574~56673901:- LIHC trans rs2731664 0.74 rs2731670 ENSG00000215571.5 GRK6P1 -8.51 5.61e-16 2.28e-09 -0.51 -0.42 Intelligence (multi-trait analysis); chr5:177421018 chr13:21319156~21320866:+ LIHC trans rs4784054 0.803 rs11644269 ENSG00000230849.2 GOT2P2 8.51 5.63e-16 2.29e-09 0.55 0.42 Blood metabolite levels; chr16:58741398 chr1:173141100~173142350:- LIHC trans rs77688320 0.553 rs10804114 ENSG00000235105.1 RP11-329A14.1 8.49 6.19e-16 2.51e-09 0.42 0.42 Breast cancer; chr2:201402139 chr1:48435967~48437223:+ LIHC trans rs9611565 0.729 rs12165508 ENSG00000268568.1 AC007228.9 8.49 6.59e-16 2.67e-09 0.52 0.42 Vitiligo; chr22:41423956 chr19:56672574~56673901:- LIHC trans rs7258465 1 rs7252848 ENSG00000267533.1 RP11-815J4.7 8.48 6.73e-16 2.73e-09 0.52 0.42 Breast cancer; chr19:18501541 chr18:12067173~12068417:- LIHC trans rs13190036 0.551 rs28932178 ENSG00000228305.2 AC016734.2 -8.48 6.82e-16 2.76e-09 -0.5 -0.42 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210575 chr2:63622178~63622831:- LIHC trans rs4784054 1 rs4784054 ENSG00000230849.2 GOT2P2 -8.48 6.82e-16 2.76e-09 -0.55 -0.42 Blood metabolite levels; chr16:58742410 chr1:173141100~173142350:- LIHC trans rs7258465 0.931 rs875396 ENSG00000267533.1 RP11-815J4.7 8.48 6.95e-16 2.82e-09 0.53 0.42 Breast cancer; chr19:18500337 chr18:12067173~12068417:- LIHC trans rs916888 0.773 rs199535 ENSG00000280022.1 RP11-707O23.1 8.46 7.65e-16 3.08e-09 0.72 0.42 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45592621~45593369:+ LIHC trans rs7554547 0.905 rs4993564 ENSG00000261819.1 RP11-680G24.4 8.46 7.85e-16 3.16e-09 0.53 0.42 Nonsyndromic cleft lip with cleft palate; chr1:11909934 chr16:14988259~14990160:- LIHC trans rs9611565 0.765 rs727563 ENSG00000268568.1 AC007228.9 8.46 7.98e-16 3.21e-09 0.52 0.42 Vitiligo; chr22:41471373 chr19:56672574~56673901:- LIHC trans rs5022636 0.821 rs4246525 ENSG00000180764.13 PIPSL 8.45 8.71e-16 3.5e-09 0.41 0.42 Gut microbiota (functional units); chr1:151285263 chr10:93958191~93961540:- LIHC trans rs4784054 0.667 rs11864685 ENSG00000230849.2 GOT2P2 -8.45 8.79e-16 3.53e-09 -0.54 -0.42 Blood metabolite levels; chr16:58771226 chr1:173141100~173142350:- LIHC trans rs4784054 0.667 rs7206052 ENSG00000230849.2 GOT2P2 8.44 8.8e-16 3.53e-09 0.54 0.42 Blood metabolite levels; chr16:58769607 chr1:173141100~173142350:- LIHC trans rs3088050 1 rs12519145 ENSG00000217325.2 PRELID1P1 8.44 8.86e-16 3.56e-09 0.52 0.42 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr5:177128522 chr6:126643488~126644390:+ LIHC trans rs77688320 0.573 rs59674665 ENSG00000235105.1 RP11-329A14.1 -8.44 8.94e-16 3.59e-09 -0.44 -0.42 Breast cancer; chr2:201514881 chr1:48435967~48437223:+ LIHC trans rs8010715 0.816 rs7153156 ENSG00000238000.1 RP11-274E7.2 8.44 9.12e-16 3.66e-09 0.47 0.42 IgG glycosylation; chr14:24129637 chr5:98213402~98214121:+ LIHC trans rs8010715 0.816 rs6573572 ENSG00000238000.1 RP11-274E7.2 8.44 9.12e-16 3.66e-09 0.47 0.42 IgG glycosylation; chr14:24130021 chr5:98213402~98214121:+ LIHC trans rs8010715 0.816 rs8015168 ENSG00000238000.1 RP11-274E7.2 8.44 9.12e-16 3.66e-09 0.47 0.42 IgG glycosylation; chr14:24130663 chr5:98213402~98214121:+ LIHC trans rs8010715 0.816 rs11574503 ENSG00000238000.1 RP11-274E7.2 -8.44 9.32e-16 3.73e-09 -0.47 -0.42 IgG glycosylation; chr14:24132109 chr5:98213402~98214121:+ LIHC trans rs7554547 0.714 rs4845890 ENSG00000261819.1 RP11-680G24.4 8.43 9.54e-16 3.82e-09 0.52 0.41 Nonsyndromic cleft lip with cleft palate; chr1:11912612 chr16:14988259~14990160:- LIHC trans rs4784054 0.667 rs2013333 ENSG00000230849.2 GOT2P2 8.43 9.62e-16 3.85e-09 0.53 0.41 Blood metabolite levels; chr16:58750920 chr1:173141100~173142350:- LIHC trans rs4784054 0.803 rs11859128 ENSG00000230849.2 GOT2P2 8.43 9.62e-16 3.85e-09 0.53 0.41 Blood metabolite levels; chr16:58752257 chr1:173141100~173142350:- LIHC trans rs4784054 0.667 rs8052646 ENSG00000230849.2 GOT2P2 8.43 9.62e-16 3.85e-09 0.53 0.41 Blood metabolite levels; chr16:58754064 chr1:173141100~173142350:- LIHC trans rs4784054 0.667 rs11643711 ENSG00000230849.2 GOT2P2 8.43 9.62e-16 3.85e-09 0.53 0.41 Blood metabolite levels; chr16:58754648 chr1:173141100~173142350:- LIHC trans rs4784054 0.614 rs8054775 ENSG00000230849.2 GOT2P2 8.43 9.62e-16 3.85e-09 0.53 0.41 Blood metabolite levels; chr16:58759666 chr1:173141100~173142350:- LIHC trans rs5022636 0.927 rs10888410 ENSG00000180764.13 PIPSL 8.43 1e-15 4e-09 0.4 0.41 Gut microbiota (functional units); chr1:151299975 chr10:93958191~93961540:- LIHC trans rs7258465 1 rs4808133 ENSG00000267533.1 RP11-815J4.7 8.43 1.01e-15 4.03e-09 0.53 0.41 Breast cancer; chr19:18497708 chr18:12067173~12068417:- LIHC trans rs7258465 1 rs4808134 ENSG00000267533.1 RP11-815J4.7 8.43 1.01e-15 4.03e-09 0.53 0.41 Breast cancer; chr19:18497769 chr18:12067173~12068417:- LIHC trans rs3740713 0.669 rs2896526 ENSG00000235847.2 LDHAP7 8.42 1.04e-15 4.14e-09 0.71 0.41 Amyotrophic lateral sclerosis (sporadic); chr11:18398259 chr2:84777259~84778223:- LIHC trans rs7258465 1 rs8103622 ENSG00000267533.1 RP11-815J4.7 8.41 1.1e-15 4.37e-09 0.53 0.41 Breast cancer; chr19:18462024 chr18:12067173~12068417:- LIHC trans rs7258465 1 rs8111708 ENSG00000267533.1 RP11-815J4.7 8.41 1.13e-15 4.51e-09 0.54 0.41 Breast cancer; chr19:18448066 chr18:12067173~12068417:- LIHC trans rs7258465 1 rs34010330 ENSG00000267533.1 RP11-815J4.7 8.41 1.13e-15 4.51e-09 0.54 0.41 Breast cancer; chr19:18448847 chr18:12067173~12068417:- LIHC trans rs2731664 0.792 rs163199 ENSG00000215571.5 GRK6P1 8.4 1.18e-15 4.69e-09 0.53 0.41 Intelligence (multi-trait analysis); chr5:177463066 chr13:21319156~21320866:+ LIHC trans rs7258465 1 rs10164319 ENSG00000267533.1 RP11-815J4.7 8.4 1.24e-15 4.94e-09 0.53 0.41 Breast cancer; chr19:18459023 chr18:12067173~12068417:- LIHC trans rs7258465 0.965 rs1560118 ENSG00000267533.1 RP11-815J4.7 8.4 1.24e-15 4.94e-09 0.53 0.41 Breast cancer; chr19:18459225 chr18:12067173~12068417:- LIHC trans rs4784054 0.614 rs8046937 ENSG00000230849.2 GOT2P2 8.39 1.31e-15 5.19e-09 0.53 0.41 Blood metabolite levels; chr16:58762282 chr1:173141100~173142350:- LIHC trans rs4784054 0.803 rs4784980 ENSG00000230849.2 GOT2P2 8.39 1.31e-15 5.19e-09 0.53 0.41 Blood metabolite levels; chr16:58763722 chr1:173141100~173142350:- LIHC trans rs8010715 0.816 rs6573573 ENSG00000238000.1 RP11-274E7.2 8.39 1.32e-15 5.21e-09 0.47 0.41 IgG glycosylation; chr14:24130048 chr5:98213402~98214121:+ LIHC trans rs7930295 0.841 rs58929810 ENSG00000236257.1 EI24P2 8.38 1.39e-15 5.51e-09 0.58 0.41 Schizophrenia; chr11:125460892 chr1:158454198~158455273:+ LIHC trans rs10037055 0.947 rs10063803 ENSG00000228305.2 AC016734.2 8.38 1.39e-15 5.51e-09 0.46 0.41 Migraine without aura; chr5:177240326 chr2:63622178~63622831:- LIHC trans rs916888 0.821 rs70600 ENSG00000214425.5 LRRC37A4P -8.38 1.4e-15 5.53e-09 -0.67 -0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45506741~45550335:- LIHC trans rs916888 0.697 rs199516 ENSG00000214425.5 LRRC37A4P 8.38 1.44e-15 5.69e-09 0.66 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45506741~45550335:- LIHC trans rs916888 0.821 rs199514 ENSG00000214425.5 LRRC37A4P 8.38 1.44e-15 5.69e-09 0.66 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45506741~45550335:- LIHC trans rs916888 0.821 rs199512 ENSG00000214425.5 LRRC37A4P 8.38 1.44e-15 5.69e-09 0.66 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45506741~45550335:- LIHC trans rs916888 0.821 rs199509 ENSG00000214425.5 LRRC37A4P 8.38 1.44e-15 5.69e-09 0.66 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45506741~45550335:- LIHC trans rs916888 0.821 rs199507 ENSG00000214425.5 LRRC37A4P 8.38 1.44e-15 5.69e-09 0.66 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45506741~45550335:- LIHC trans rs916888 0.821 rs415430 ENSG00000214425.5 LRRC37A4P 8.38 1.44e-15 5.69e-09 0.66 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45506741~45550335:- LIHC trans rs916888 0.779 rs430685 ENSG00000214425.5 LRRC37A4P 8.38 1.44e-15 5.69e-09 0.66 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45506741~45550335:- LIHC trans rs916888 0.821 rs199505 ENSG00000214425.5 LRRC37A4P 8.38 1.44e-15 5.69e-09 0.66 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45506741~45550335:- LIHC trans rs916888 0.821 rs70602 ENSG00000214425.5 LRRC37A4P 8.38 1.44e-15 5.69e-09 0.66 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45506741~45550335:- LIHC trans rs2657294 0.796 rs6480770 ENSG00000172974.11 AC007318.5 8.37 1.45e-15 5.74e-09 0.43 0.41 Pneumonia; chr10:75098799 chr2:65205108~65205988:+ LIHC trans rs3740713 0.669 rs113003553 ENSG00000235847.2 LDHAP7 8.37 1.47e-15 5.79e-09 0.71 0.41 Amyotrophic lateral sclerosis (sporadic); chr11:18389314 chr2:84777259~84778223:- LIHC trans rs3088050 0.877 rs6872993 ENSG00000217325.2 PRELID1P1 8.37 1.47e-15 5.8e-09 0.51 0.41 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr5:177206392 chr6:126643488~126644390:+ LIHC trans rs8067354 0.957 rs9896742 ENSG00000187870.7 RNFT1P3 8.37 1.48e-15 5.84e-09 0.48 0.41 Hemoglobin concentration; chr17:59749169 chr17:20743333~20754501:- LIHC trans rs10037055 0.853 rs4976680 ENSG00000228305.2 AC016734.2 8.36 1.61e-15 6.33e-09 0.46 0.41 Migraine without aura; chr5:177275745 chr2:63622178~63622831:- LIHC trans rs10037055 0.853 rs4976681 ENSG00000228305.2 AC016734.2 8.36 1.61e-15 6.33e-09 0.46 0.41 Migraine without aura; chr5:177277662 chr2:63622178~63622831:- LIHC trans rs10037055 0.812 rs11949435 ENSG00000228305.2 AC016734.2 8.36 1.61e-15 6.33e-09 0.46 0.41 Migraine without aura; chr5:177287931 chr2:63622178~63622831:- LIHC trans rs4784054 0.667 rs8044439 ENSG00000230849.2 GOT2P2 8.36 1.61e-15 6.36e-09 0.53 0.41 Blood metabolite levels; chr16:58757121 chr1:173141100~173142350:- LIHC trans rs13190036 0.551 rs7710269 ENSG00000228305.2 AC016734.2 -8.36 1.65e-15 6.51e-09 -0.48 -0.41 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177187528 chr2:63622178~63622831:- LIHC trans rs13190036 0.515 rs2878686 ENSG00000228305.2 AC016734.2 -8.36 1.65e-15 6.51e-09 -0.48 -0.41 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206748 chr2:63622178~63622831:- LIHC trans rs7258465 1 rs2007981 ENSG00000267533.1 RP11-815J4.7 8.35 1.74e-15 6.83e-09 0.53 0.41 Breast cancer; chr19:18456745 chr18:12067173~12068417:- LIHC trans rs7662987 1 rs7683704 ENSG00000228407.2 RP4-800M22.1 8.35 1.75e-15 6.87e-09 1.14 0.41 Smoking initiation; chr4:99083075 chr1:52160261~52160600:- LIHC trans rs7554547 0.714 rs2878679 ENSG00000261819.1 RP11-680G24.4 8.35 1.77e-15 6.95e-09 0.52 0.41 Nonsyndromic cleft lip with cleft palate; chr1:11915586 chr16:14988259~14990160:- LIHC trans rs2657294 0.796 rs7082123 ENSG00000172974.11 AC007318.5 8.34 1.82e-15 7.14e-09 0.45 0.41 Pneumonia; chr10:75091101 chr2:65205108~65205988:+ LIHC trans rs2657294 0.895 rs4746262 ENSG00000172974.11 AC007318.5 8.34 1.82e-15 7.17e-09 0.45 0.41 Pneumonia; chr10:75093631 chr2:65205108~65205988:+ LIHC trans rs2657294 0.895 rs3088142 ENSG00000172974.11 AC007318.5 8.34 1.82e-15 7.17e-09 0.45 0.41 Pneumonia; chr10:75094806 chr2:65205108~65205988:+ LIHC trans rs4784054 0.667 rs12925537 ENSG00000230849.2 GOT2P2 8.34 1.85e-15 7.28e-09 0.53 0.41 Blood metabolite levels; chr16:58750094 chr1:173141100~173142350:- LIHC trans rs4784054 0.667 rs12931903 ENSG00000230849.2 GOT2P2 8.33 1.92e-15 7.56e-09 0.53 0.41 Blood metabolite levels; chr16:58755140 chr1:173141100~173142350:- LIHC trans rs10037055 0.687 rs6556308 ENSG00000228305.2 AC016734.2 -8.33 1.94e-15 7.62e-09 -0.46 -0.41 Migraine without aura; chr5:177219700 chr2:63622178~63622831:- LIHC trans rs10037055 0.853 rs1546363 ENSG00000228305.2 AC016734.2 -8.33 1.96e-15 7.69e-09 -0.46 -0.41 Migraine without aura; chr5:177174030 chr2:63622178~63622831:- LIHC trans rs10037055 0.853 rs10056008 ENSG00000228305.2 AC016734.2 -8.33 1.96e-15 7.69e-09 -0.46 -0.41 Migraine without aura; chr5:177194147 chr2:63622178~63622831:- LIHC trans rs10037055 0.853 rs10476219 ENSG00000228305.2 AC016734.2 -8.33 1.96e-15 7.69e-09 -0.46 -0.41 Migraine without aura; chr5:177201547 chr2:63622178~63622831:- LIHC trans rs959695 0.864 rs7844422 ENSG00000260318.1 COX6CP1 8.33 1.96e-15 7.71e-09 0.5 0.41 Hippocampal atrophy; chr8:99837782 chr16:11903923~11904137:- LIHC trans rs916888 0.821 rs199506 ENSG00000214425.5 LRRC37A4P 8.33 2.01e-15 7.87e-09 0.66 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45506741~45550335:- LIHC trans rs10908521 0.685 rs1998977 ENSG00000227183.3 HDGFP1 -8.32 2.09e-15 8.17e-09 -0.49 -0.41 Uric acid clearance; chr1:156834329 chrX:131646639~131646890:+ LIHC trans rs10037055 0.853 rs12660023 ENSG00000228305.2 AC016734.2 8.32 2.14e-15 8.38e-09 0.46 0.41 Migraine without aura; chr5:177273884 chr2:63622178~63622831:- LIHC trans rs4784054 0.803 rs73553527 ENSG00000230849.2 GOT2P2 8.31 2.2e-15 8.6e-09 0.53 0.41 Blood metabolite levels; chr16:58762002 chr1:173141100~173142350:- LIHC trans rs4784054 0.667 rs8052824 ENSG00000230849.2 GOT2P2 8.31 2.2e-15 8.6e-09 0.53 0.41 Blood metabolite levels; chr16:58762045 chr1:173141100~173142350:- LIHC trans rs916888 0.821 rs199504 ENSG00000214425.5 LRRC37A4P 8.31 2.22e-15 8.67e-09 0.66 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:45506741~45550335:- LIHC trans rs916888 0.773 rs199445 ENSG00000280022.1 RP11-707O23.1 8.31 2.25e-15 8.77e-09 0.7 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45592621~45593369:+ LIHC trans rs916888 0.773 rs199443 ENSG00000280022.1 RP11-707O23.1 8.31 2.25e-15 8.77e-09 0.7 0.41 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45592621~45593369:+ LIHC trans rs58106596 0.8 rs67402940 ENSG00000259020.3 RP11-529H20.3 8.31 2.32e-15 9.06e-09 0.52 0.41 Lymphocyte counts;White blood cell count; chr2:231701789 chr14:92026566~92026887:+ LIHC trans rs8010715 0.785 rs2877611 ENSG00000238000.1 RP11-274E7.2 8.3 2.5e-15 9.75e-09 0.46 0.41 IgG glycosylation; chr14:24126221 chr5:98213402~98214121:+ LIHC trans rs2731664 0.792 rs335468 ENSG00000215571.5 GRK6P1 -8.3 2.5e-15 9.77e-09 -0.51 -0.41 Intelligence (multi-trait analysis); chr5:177465348 chr13:21319156~21320866:+ LIHC trans rs5022636 0.927 rs10888409 ENSG00000180764.13 PIPSL 8.3 2.52e-15 9.82e-09 0.39 0.41 Gut microbiota (functional units); chr1:151299306 chr10:93958191~93961540:- LIHC trans rs5751901 1 rs5751901 ENSG00000280208.1 RP11-341D18.4 -8.29 2.6e-15 1.01e-08 -0.48 -0.41 Protein quantitative trait loci; chr22:24596299 chr13:18253526~18270822:- LIHC trans rs2657294 0.895 rs2395137 ENSG00000172974.11 AC007318.5 8.29 2.61e-15 1.01e-08 0.45 0.41 Pneumonia; chr10:75088235 chr2:65205108~65205988:+ LIHC trans rs4784054 0.803 rs73553511 ENSG00000230849.2 GOT2P2 8.29 2.65e-15 1.03e-08 0.54 0.41 Blood metabolite levels; chr16:58758077 chr1:173141100~173142350:- LIHC trans rs3088050 0.759 rs4343858 ENSG00000217325.2 PRELID1P1 8.29 2.69e-15 1.05e-08 0.51 0.41 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr5:177252406 chr6:126643488~126644390:+ LIHC trans rs3088050 0.938 rs4311433 ENSG00000217325.2 PRELID1P1 8.28 2.73e-15 1.06e-08 0.51 0.41 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr5:177186055 chr6:126643488~126644390:+ LIHC trans rs9611519 0.857 rs4820434 ENSG00000268568.1 AC007228.9 -8.27 2.96e-15 1.15e-08 -0.64 -0.41 Neuroticism; chr22:41241115 chr19:56672574~56673901:- LIHC trans rs9611565 0.569 rs6002328 ENSG00000268568.1 AC007228.9 -8.27 3.03e-15 1.18e-08 -0.59 -0.41 Vitiligo; chr22:41314030 chr19:56672574~56673901:- LIHC trans rs9611565 0.506 rs7364221 ENSG00000268568.1 AC007228.9 -8.27 3.04e-15 1.18e-08 -0.59 -0.41 Vitiligo; chr22:41254186 chr19:56672574~56673901:- LIHC trans rs7937890 1 rs7937890 ENSG00000236360.2 RP11-334A14.2 8.27 3.05e-15 1.18e-08 0.51 0.41 Mitochondrial DNA levels; chr11:14374939 chr1:52993201~52993702:- LIHC trans rs13190036 0.551 rs9313751 ENSG00000228305.2 AC016734.2 -8.27 3.09e-15 1.2e-08 -0.47 -0.41 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177217174 chr2:63622178~63622831:- LIHC trans rs4784054 0.667 rs12925419 ENSG00000230849.2 GOT2P2 8.27 3.1e-15 1.21e-08 0.53 0.41 Blood metabolite levels; chr16:58750078 chr1:173141100~173142350:- LIHC trans rs10037055 0.853 rs2336237 ENSG00000228305.2 AC016734.2 8.27 3.11e-15 1.21e-08 0.46 0.41 Migraine without aura; chr5:177238878 chr2:63622178~63622831:- LIHC trans rs10037055 0.741 rs2336405 ENSG00000228305.2 AC016734.2 -8.26 3.22e-15 1.25e-08 -0.46 -0.41 Migraine without aura; chr5:177230288 chr2:63622178~63622831:- LIHC trans rs3740713 0.669 rs34740438 ENSG00000235847.2 LDHAP7 8.25 3.47e-15 1.35e-08 0.71 0.41 Amyotrophic lateral sclerosis (sporadic); chr11:18393783 chr2:84777259~84778223:- LIHC trans rs77688320 0.535 rs10460403 ENSG00000235105.1 RP11-329A14.1 8.25 3.53e-15 1.37e-08 0.38 0.41 Breast cancer; chr2:201478014 chr1:48435967~48437223:+ LIHC trans rs13190036 0.551 rs11957608 ENSG00000228305.2 AC016734.2 -8.24 3.65e-15 1.41e-08 -0.47 -0.41 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228344 chr2:63622178~63622831:- LIHC trans rs7937890 1 rs6486190 ENSG00000236360.2 RP11-334A14.2 8.24 3.72e-15 1.44e-08 0.51 0.41 Mitochondrial DNA levels; chr11:14379670 chr1:52993201~52993702:- LIHC trans rs4784054 0.803 rs34295929 ENSG00000230849.2 GOT2P2 8.23 3.91e-15 1.51e-08 0.52 0.41 Blood metabolite levels; chr16:58748936 chr1:173141100~173142350:- LIHC trans rs7662987 0.793 rs12697 ENSG00000228407.2 RP4-800M22.1 -8.23 4.04e-15 1.56e-08 -0.86 -0.41 Smoking initiation; chr4:99072225 chr1:52160261~52160600:- LIHC trans rs10037055 0.853 rs10036193 ENSG00000228305.2 AC016734.2 -8.22 4.2e-15 1.62e-08 -0.46 -0.41 Migraine without aura; chr5:177141519 chr2:63622178~63622831:- LIHC trans rs10037055 0.853 rs9885210 ENSG00000228305.2 AC016734.2 -8.22 4.2e-15 1.62e-08 -0.46 -0.41 Migraine without aura; chr5:177142187 chr2:63622178~63622831:- LIHC trans rs538867 1 rs73068347 ENSG00000214263.2 RPSAP53 8.22 4.23e-15 1.63e-08 0.91 0.41 Alzheimer's disease (cognitive decline); chr3:39497669 chr13:67266845~67267706:- LIHC trans rs58106596 0.95 rs11695646 ENSG00000259020.3 RP11-529H20.3 -8.21 4.45e-15 1.71e-08 -0.49 -0.41 Lymphocyte counts;White blood cell count; chr2:231720097 chr14:92026566~92026887:+ LIHC trans rs2657294 0.895 rs2002023 ENSG00000172974.11 AC007318.5 8.2 5.02e-15 1.93e-08 0.44 0.41 Pneumonia; chr10:75088766 chr2:65205108~65205988:+ LIHC trans rs10037055 0.853 rs6890580 ENSG00000228305.2 AC016734.2 -8.19 5.27e-15 2.02e-08 -0.46 -0.4 Migraine without aura; chr5:177226519 chr2:63622178~63622831:- LIHC trans rs864643 0.947 rs704962 ENSG00000183298.5 RP11-556K13.1 -8.19 5.31e-15 2.04e-08 -0.59 -0.4 Attention deficit hyperactivity disorder; chr3:39515629 chr1:101786340~101787219:- LIHC trans rs77688320 0.5 rs7603584 ENSG00000235105.1 RP11-329A14.1 8.19 5.44e-15 2.09e-08 0.37 0.4 Breast cancer; chr2:201440422 chr1:48435967~48437223:+ LIHC trans rs77688320 0.5 rs6755428 ENSG00000235105.1 RP11-329A14.1 8.18 5.61e-15 2.15e-08 0.38 0.4 Breast cancer; chr2:201431043 chr1:48435967~48437223:+ LIHC trans rs8010715 0.816 rs762093 ENSG00000238000.1 RP11-274E7.2 8.18 5.69e-15 2.18e-08 0.46 0.4 IgG glycosylation; chr14:24122709 chr5:98213402~98214121:+ LIHC trans rs916888 0.773 rs199439 ENSG00000280022.1 RP11-707O23.1 8.17 5.91e-15 2.26e-08 0.7 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45592621~45593369:+ LIHC trans rs4240897 0.935 rs4846082 ENSG00000261819.1 RP11-680G24.4 8.17 6.08e-15 2.33e-08 0.51 0.4 Tuberculosis; chr1:11982386 chr16:14988259~14990160:- LIHC trans rs916888 0.821 rs199513 ENSG00000214425.5 LRRC37A4P 8.17 6.16e-15 2.35e-08 0.62 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:45506741~45550335:- LIHC trans rs9611519 0.78 rs3171692 ENSG00000268568.1 AC007228.9 -8.16 6.3e-15 2.41e-08 -0.58 -0.4 Neuroticism; chr22:41246208 chr19:56672574~56673901:- LIHC trans rs58106596 0.627 rs1058315 ENSG00000259020.3 RP11-529H20.3 8.16 6.35e-15 2.43e-08 0.51 0.4 Lymphocyte counts;White blood cell count; chr2:231709234 chr14:92026566~92026887:+ LIHC trans rs8010715 0.816 rs1134340 ENSG00000238000.1 RP11-274E7.2 8.16 6.5e-15 2.48e-08 0.45 0.4 IgG glycosylation; chr14:24125004 chr5:98213402~98214121:+ LIHC trans rs7568458 0.709 rs1446669 ENSG00000223886.3 RP11-251G23.2 8.16 6.61e-15 2.52e-08 0.49 0.4 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85535086 chr7:105530209~105530671:+ LIHC trans rs58106596 0.8 rs11686900 ENSG00000259020.3 RP11-529H20.3 8.15 6.71e-15 2.56e-08 0.52 0.4 Lymphocyte counts;White blood cell count; chr2:231703982 chr14:92026566~92026887:+ LIHC trans rs8010715 0.771 rs2277481 ENSG00000238000.1 RP11-274E7.2 8.15 6.93e-15 2.64e-08 0.46 0.4 IgG glycosylation; chr14:24118336 chr5:98213402~98214121:+ LIHC trans rs13190036 0.551 rs11955537 ENSG00000228305.2 AC016734.2 -8.13 7.77e-15 2.96e-08 -0.47 -0.4 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147087 chr2:63622178~63622831:- LIHC trans rs10037055 0.853 rs1363405 ENSG00000228305.2 AC016734.2 8.13 7.78e-15 2.96e-08 0.45 0.4 Migraine without aura; chr5:177209881 chr2:63622178~63622831:- LIHC trans rs959695 1 rs959695 ENSG00000260318.1 COX6CP1 8.13 7.78e-15 2.96e-08 0.5 0.4 Hippocampal atrophy; chr8:99822954 chr16:11903923~11904137:- LIHC trans rs916888 0.773 rs199457 ENSG00000280022.1 RP11-707O23.1 8.12 8.32e-15 3.16e-08 0.69 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45592621~45593369:+ LIHC trans rs916888 0.687 rs199456 ENSG00000280022.1 RP11-707O23.1 8.12 8.32e-15 3.16e-08 0.69 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45592621~45593369:+ LIHC trans rs7937890 0.732 rs7946902 ENSG00000236360.2 RP11-334A14.2 -8.12 8.81e-15 3.34e-08 -0.51 -0.4 Mitochondrial DNA levels; chr11:14251762 chr1:52993201~52993702:- LIHC trans rs916888 0.773 rs199535 ENSG00000214425.5 LRRC37A4P -8.12 8.81e-15 3.35e-08 -0.66 -0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45506741~45550335:- LIHC trans rs77688320 0.517 rs7573536 ENSG00000235105.1 RP11-329A14.1 8.11 8.96e-15 3.4e-08 0.37 0.4 Breast cancer; chr2:201469676 chr1:48435967~48437223:+ LIHC trans rs916888 0.773 rs199451 ENSG00000280022.1 RP11-707O23.1 8.11 9.24e-15 3.51e-08 0.69 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45592621~45593369:+ LIHC trans rs13190036 0.551 rs1052432 ENSG00000228305.2 AC016734.2 -8.11 9.39e-15 3.56e-08 -0.48 -0.4 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177137188 chr2:63622178~63622831:- LIHC trans rs7121616 0.515 rs11218966 ENSG00000234176.1 HSPA8P1 8.1 1.01e-14 3.81e-08 0.74 0.4 Breast cancer; chr11:123086510 chrX:121203182~121205014:- LIHC trans rs916888 0.61 rs199446 ENSG00000264070.1 DND1P1 -8.09 1.02e-14 3.86e-08 -0.47 -0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:45585871~45586929:+ LIHC trans rs916888 0.61 rs199536 ENSG00000264070.1 DND1P1 -8.09 1.02e-14 3.86e-08 -0.47 -0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:45585871~45586929:+ LIHC trans rs7568458 0.66 rs6722691 ENSG00000223886.3 RP11-251G23.2 8.09 1.05e-14 3.95e-08 0.49 0.4 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85531229 chr7:105530209~105530671:+ LIHC trans rs7554547 0.714 rs926269 ENSG00000261819.1 RP11-680G24.4 8.08 1.09e-14 4.13e-08 0.51 0.4 Nonsyndromic cleft lip with cleft palate; chr1:11909691 chr16:14988259~14990160:- LIHC trans rs538867 1 rs661422 ENSG00000214263.2 RPSAP53 8.08 1.1e-14 4.13e-08 0.9 0.4 Alzheimer's disease (cognitive decline); chr3:39519898 chr13:67266845~67267706:- LIHC trans rs3740713 0.748 rs35292478 ENSG00000235847.2 LDHAP7 8.08 1.1e-14 4.16e-08 0.7 0.4 Amyotrophic lateral sclerosis (sporadic); chr11:18408444 chr2:84777259~84778223:- LIHC trans rs7258465 1 rs4808804 ENSG00000267533.1 RP11-815J4.7 8.08 1.11e-14 4.18e-08 0.52 0.4 Breast cancer; chr19:18474515 chr18:12067173~12068417:- LIHC trans rs58106596 0.8 rs28883318 ENSG00000259020.3 RP11-529H20.3 8.08 1.12e-14 4.24e-08 0.51 0.4 Lymphocyte counts;White blood cell count; chr2:231698225 chr14:92026566~92026887:+ LIHC trans rs10037055 0.636 rs13166688 ENSG00000228305.2 AC016734.2 -8.07 1.19e-14 4.46e-08 -0.47 -0.4 Migraine without aura; chr5:177156965 chr2:63622178~63622831:- LIHC trans rs916888 0.773 rs538628 ENSG00000280022.1 RP11-707O23.1 8.07 1.23e-14 4.62e-08 0.69 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45592621~45593369:+ LIHC trans rs58106596 0.605 rs58212470 ENSG00000259020.3 RP11-529H20.3 8.06 1.31e-14 4.91e-08 0.51 0.4 Lymphocyte counts;White blood cell count; chr2:231696869 chr14:92026566~92026887:+ LIHC trans rs9611565 1 rs5751086 ENSG00000268568.1 AC007228.9 -8.06 1.32e-14 4.94e-08 -0.47 -0.4 Vitiligo; chr22:41372858 chr19:56672574~56673901:- LIHC trans rs2657294 0.861 rs6480769 ENSG00000172974.11 AC007318.5 8.05 1.39e-14 5.2e-08 0.44 0.4 Pneumonia; chr10:75091745 chr2:65205108~65205988:+ LIHC trans rs10037055 0.685 rs10039241 ENSG00000228305.2 AC016734.2 -8.05 1.43e-14 5.34e-08 -0.46 -0.4 Migraine without aura; chr5:177151071 chr2:63622178~63622831:- LIHC trans rs538867 1 rs1708099 ENSG00000214263.2 RPSAP53 8.03 1.61e-14 6.02e-08 0.9 0.4 Alzheimer's disease (cognitive decline); chr3:39476278 chr13:67266845~67267706:- LIHC trans rs9876781 1 rs1109227 ENSG00000235912.1 RP1-159A19.3 -8.02 1.67e-14 6.22e-08 -0.46 -0.4 Longevity; chr3:48437797 chr1:27649419~27649610:+ LIHC trans rs9876781 0.967 rs9876891 ENSG00000235912.1 RP1-159A19.3 -8.02 1.67e-14 6.22e-08 -0.46 -0.4 Longevity; chr3:48440024 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs3774808 ENSG00000235912.1 RP1-159A19.3 -8.02 1.67e-14 6.22e-08 -0.46 -0.4 Longevity; chr3:48440237 chr1:27649419~27649610:+ LIHC trans rs72615157 0.664 rs6953580 ENSG00000228546.2 CTA-313A17.3 8.02 1.72e-14 6.41e-08 0.6 0.4 Lung function (FEV1/FVC); chr7:100227652 chr7:102337316~102339115:+ LIHC trans rs916888 0.779 rs199528 ENSG00000280022.1 RP11-707O23.1 8.02 1.73e-14 6.46e-08 0.7 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45592621~45593369:+ LIHC trans rs916888 0.821 rs199525 ENSG00000280022.1 RP11-707O23.1 8.02 1.73e-14 6.46e-08 0.7 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45592621~45593369:+ LIHC trans rs538867 0.661 rs2016412 ENSG00000214263.2 RPSAP53 8.01 1.82e-14 6.76e-08 0.99 0.4 Alzheimer's disease (cognitive decline); chr3:39393561 chr13:67266845~67267706:- LIHC trans rs3740713 0.669 rs78098319 ENSG00000235847.2 LDHAP7 8.01 1.84e-14 6.85e-08 0.69 0.4 Amyotrophic lateral sclerosis (sporadic); chr11:18382752 chr2:84777259~84778223:- LIHC trans rs916888 0.773 rs1378358 ENSG00000280022.1 RP11-707O23.1 8 1.9e-14 7.05e-08 0.69 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45592621~45593369:+ LIHC trans rs58106596 0.8 rs11675826 ENSG00000259020.3 RP11-529H20.3 8 1.92e-14 7.12e-08 0.5 0.4 Lymphocyte counts;White blood cell count; chr2:231700797 chr14:92026566~92026887:+ LIHC trans rs9876781 1 rs9883759 ENSG00000235912.1 RP1-159A19.3 -8 1.95e-14 7.25e-08 -0.46 -0.4 Longevity; chr3:48422209 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs6442120 ENSG00000235912.1 RP1-159A19.3 -8 1.95e-14 7.25e-08 -0.46 -0.4 Longevity; chr3:48423094 chr1:27649419~27649610:+ LIHC trans rs9876781 0.9 rs1037773 ENSG00000235912.1 RP1-159A19.3 -8 1.95e-14 7.25e-08 -0.46 -0.4 Longevity; chr3:48426493 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs2279077 ENSG00000235912.1 RP1-159A19.3 -8 1.95e-14 7.25e-08 -0.46 -0.4 Longevity; chr3:48432839 chr1:27649419~27649610:+ LIHC trans rs916888 0.647 rs199524 ENSG00000264070.1 DND1P1 -8 1.99e-14 7.39e-08 -0.47 -0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:45585871~45586929:+ LIHC trans rs916888 0.773 rs169201 ENSG00000280022.1 RP11-707O23.1 7.99 2.02e-14 7.48e-08 0.69 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45592621~45593369:+ LIHC trans rs4784054 1 rs4784054 ENSG00000233719.3 GOT2P3 -7.99 2.04e-14 7.55e-08 -0.49 -0.4 Blood metabolite levels; chr16:58742410 chr12:9641802~9643007:+ LIHC trans rs7554547 0.667 rs11121839 ENSG00000261819.1 RP11-680G24.4 7.99 2.08e-14 7.69e-08 0.51 0.4 Nonsyndromic cleft lip with cleft palate; chr1:11908280 chr16:14988259~14990160:- LIHC trans rs7554547 0.667 rs12065911 ENSG00000261819.1 RP11-680G24.4 7.99 2.08e-14 7.69e-08 0.51 0.4 Nonsyndromic cleft lip with cleft palate; chr1:11908323 chr16:14988259~14990160:- LIHC trans rs13190036 0.551 rs4976639 ENSG00000228305.2 AC016734.2 7.99 2.09e-14 7.72e-08 0.47 0.4 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177123300 chr2:63622178~63622831:- LIHC trans rs72615157 0.613 rs56089143 ENSG00000228546.2 CTA-313A17.3 7.99 2.11e-14 7.79e-08 0.6 0.4 Lung function (FEV1/FVC); chr7:100222221 chr7:102337316~102339115:+ LIHC trans rs916888 0.61 rs199444 ENSG00000264070.1 DND1P1 7.99 2.11e-14 7.81e-08 0.46 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:45585871~45586929:+ LIHC trans rs916888 0.61 rs199442 ENSG00000264070.1 DND1P1 7.99 2.11e-14 7.81e-08 0.46 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:45585871~45586929:+ LIHC trans rs4240897 0.935 rs3766744 ENSG00000261819.1 RP11-680G24.4 7.99 2.12e-14 7.85e-08 0.5 0.4 Tuberculosis; chr1:11983660 chr16:14988259~14990160:- LIHC trans rs916888 0.821 rs70600 ENSG00000280022.1 RP11-707O23.1 7.99 2.15e-14 7.94e-08 0.69 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45592621~45593369:+ LIHC trans rs916888 0.647 rs199449 ENSG00000264070.1 DND1P1 7.98 2.25e-14 8.31e-08 0.46 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:45585871~45586929:+ LIHC trans rs916888 0.61 rs199529 ENSG00000280022.1 RP11-707O23.1 7.98 2.26e-14 8.35e-08 0.66 0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:45592621~45593369:+ LIHC trans rs916888 0.647 rs199523 ENSG00000264070.1 DND1P1 -7.98 2.29e-14 8.44e-08 -0.47 -0.4 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:45585871~45586929:+ LIHC trans rs7121616 0.515 rs76088419 ENSG00000234176.1 HSPA8P1 7.96 2.48e-14 9.11e-08 0.73 0.4 Breast cancer; chr11:123066813 chrX:121203182~121205014:- LIHC trans rs77688320 0.517 rs10931949 ENSG00000235105.1 RP11-329A14.1 7.96 2.51e-14 9.22e-08 0.37 0.4 Breast cancer; chr2:201459730 chr1:48435967~48437223:+ LIHC trans rs5022636 0.927 rs10788803 ENSG00000180764.13 PIPSL 7.96 2.57e-14 9.44e-08 0.38 0.4 Gut microbiota (functional units); chr1:151291306 chr10:93958191~93961540:- LIHC trans rs13190036 0.591 rs78523677 ENSG00000228305.2 AC016734.2 -7.96 2.63e-14 9.65e-08 -0.47 -0.4 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177124102 chr2:63622178~63622831:- LIHC trans rs864643 0.947 rs1708040 ENSG00000183298.5 RP11-556K13.1 7.96 2.64e-14 9.69e-08 0.57 0.4 Attention deficit hyperactivity disorder; chr3:39523258 chr1:101786340~101787219:- LIHC trans rs10037055 0.853 rs10035180 ENSG00000228305.2 AC016734.2 -7.95 2.7e-14 9.9e-08 -0.44 -0.4 Migraine without aura; chr5:177171501 chr2:63622178~63622831:- LIHC trans rs916888 0.773 rs199448 ENSG00000280022.1 RP11-707O23.1 7.95 2.77e-14 1.01e-07 0.68 0.39 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45592621~45593369:+ LIHC trans rs864643 0.945 rs1707972 ENSG00000183298.5 RP11-556K13.1 7.94 2.85e-14 1.04e-07 0.59 0.39 Attention deficit hyperactivity disorder; chr3:39507243 chr1:101786340~101787219:- LIHC trans rs7554547 0.765 rs34175640 ENSG00000261819.1 RP11-680G24.4 -7.94 2.9e-14 1.06e-07 -0.51 -0.39 Nonsyndromic cleft lip with cleft palate; chr1:11892155 chr16:14988259~14990160:- LIHC trans rs9876781 1 rs6776700 ENSG00000235912.1 RP1-159A19.3 -7.94 2.9e-14 1.06e-07 -0.46 -0.39 Longevity; chr3:48455358 chr1:27649419~27649610:+ LIHC trans rs538867 1 rs73064237 ENSG00000214263.2 RPSAP53 7.94 2.93e-14 1.07e-07 0.93 0.39 Alzheimer's disease (cognitive decline); chr3:39454410 chr13:67266845~67267706:- LIHC trans rs916888 0.531 rs183211 ENSG00000264070.1 DND1P1 7.93 3.07e-14 1.12e-07 0.46 0.39 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:45585871~45586929:+ LIHC trans rs9611519 0.78 rs1983631 ENSG00000268568.1 AC007228.9 -7.93 3.09e-14 1.13e-07 -0.56 -0.39 Neuroticism; chr22:41248070 chr19:56672574~56673901:- LIHC trans rs8010715 1 rs3742500 ENSG00000238000.1 RP11-274E7.2 7.93 3.14e-14 1.14e-07 0.45 0.39 IgG glycosylation; chr14:24142769 chr5:98213402~98214121:+ LIHC trans rs9876781 1 rs13091785 ENSG00000235912.1 RP1-159A19.3 -7.93 3.15e-14 1.15e-07 -0.46 -0.39 Longevity; chr3:48452692 chr1:27649419~27649610:+ LIHC trans rs77688320 0.517 rs12991600 ENSG00000235105.1 RP11-329A14.1 7.92 3.26e-14 1.19e-07 0.37 0.39 Breast cancer; chr2:201472513 chr1:48435967~48437223:+ LIHC trans rs916888 0.773 rs199534 ENSG00000280022.1 RP11-707O23.1 7.92 3.33e-14 1.21e-07 0.68 0.39 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45592621~45593369:+ LIHC trans rs77688320 0.5 rs4129010 ENSG00000235105.1 RP11-329A14.1 7.92 3.34e-14 1.21e-07 0.37 0.39 Breast cancer; chr2:201443602 chr1:48435967~48437223:+ LIHC trans rs77688320 0.5 rs4129011 ENSG00000235105.1 RP11-329A14.1 7.92 3.34e-14 1.21e-07 0.37 0.39 Breast cancer; chr2:201443863 chr1:48435967~48437223:+ LIHC trans rs4263408 0.935 rs62310129 ENSG00000237550.5 UBE2Q2P6 7.92 3.38e-14 1.23e-07 0.44 0.39 Plasma amyloid beta peptide concentrations (ABx-40); chr4:39772802 chr15:82372196~82372912:- LIHC trans rs7930295 0.822 rs7128228 ENSG00000236257.1 EI24P2 7.92 3.45e-14 1.25e-07 0.57 0.39 Schizophrenia; chr11:125437512 chr1:158454198~158455273:+ LIHC trans rs7568458 0.684 rs60012532 ENSG00000223886.3 RP11-251G23.2 7.92 3.45e-14 1.25e-07 0.48 0.39 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85525351 chr7:105530209~105530671:+ LIHC trans rs959695 1 rs2442756 ENSG00000260318.1 COX6CP1 7.92 3.47e-14 1.26e-07 0.48 0.39 Hippocampal atrophy; chr8:99816910 chr16:11903923~11904137:- LIHC trans rs7568458 0.66 rs6547623 ENSG00000223886.3 RP11-251G23.2 7.91 3.67e-14 1.33e-07 0.48 0.39 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85574841 chr7:105530209~105530671:+ LIHC trans rs77688320 0.517 rs6717641 ENSG00000235105.1 RP11-329A14.1 7.9 3.75e-14 1.36e-07 0.37 0.39 Breast cancer; chr2:201450484 chr1:48435967~48437223:+ LIHC trans rs916888 0.61 rs199453 ENSG00000264070.1 DND1P1 7.88 4.44e-14 1.6e-07 0.46 0.39 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:45585871~45586929:+ LIHC trans rs9876781 1 rs9881491 ENSG00000235912.1 RP1-159A19.3 -7.87 4.59e-14 1.65e-07 -0.45 -0.39 Longevity; chr3:48446507 chr1:27649419~27649610:+ LIHC trans rs10037055 0.741 rs4976640 ENSG00000228305.2 AC016734.2 -7.86 4.93e-14 1.77e-07 -0.44 -0.39 Migraine without aura; chr5:177125006 chr2:63622178~63622831:- LIHC trans rs916888 0.61 rs199454 ENSG00000264070.1 DND1P1 -7.86 5.16e-14 1.85e-07 -0.46 -0.39 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:45585871~45586929:+ LIHC trans rs916888 0.773 rs199533 ENSG00000280022.1 RP11-707O23.1 7.85 5.3e-14 1.9e-07 0.67 0.39 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45592621~45593369:+ LIHC trans rs7554547 0.69 rs4846064 ENSG00000261819.1 RP11-680G24.4 7.85 5.35e-14 1.91e-07 0.49 0.39 Nonsyndromic cleft lip with cleft palate; chr1:11874785 chr16:14988259~14990160:- LIHC trans rs916888 0.773 rs199447 ENSG00000280022.1 RP11-707O23.1 7.85 5.41e-14 1.94e-07 0.67 0.39 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45592621~45593369:+ LIHC trans rs7568458 0.709 rs11895399 ENSG00000223886.3 RP11-251G23.2 7.84 5.74e-14 2.05e-07 0.48 0.39 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85526683 chr7:105530209~105530671:+ LIHC trans rs7568458 0.709 rs11895401 ENSG00000223886.3 RP11-251G23.2 7.84 5.74e-14 2.05e-07 0.48 0.39 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85526724 chr7:105530209~105530671:+ LIHC trans rs8010715 0.816 rs6573565 ENSG00000238000.1 RP11-274E7.2 -7.83 6.35e-14 2.26e-07 -0.44 -0.39 IgG glycosylation; chr14:24125524 chr5:98213402~98214121:+ LIHC trans rs8067354 0.54 rs1051424 ENSG00000187870.7 RNFT1P3 7.82 6.45e-14 2.29e-07 0.48 0.39 Hemoglobin concentration; chr17:59946963 chr17:20743333~20754501:- LIHC trans rs916888 0.61 rs199436 ENSG00000264070.1 DND1P1 -7.81 6.92e-14 2.46e-07 -0.45 -0.39 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:45585871~45586929:+ LIHC trans rs7258465 1 rs8105994 ENSG00000267533.1 RP11-815J4.7 7.81 6.97e-14 2.48e-07 0.48 0.39 Breast cancer; chr19:18482743 chr18:12067173~12068417:- LIHC trans rs916888 0.61 rs199438 ENSG00000264070.1 DND1P1 7.8 7.35e-14 2.61e-07 0.46 0.39 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:45585871~45586929:+ LIHC trans rs4784054 0.803 rs11644269 ENSG00000233719.3 GOT2P3 7.8 7.64e-14 2.71e-07 0.48 0.39 Blood metabolite levels; chr16:58741398 chr12:9641802~9643007:+ LIHC trans rs864643 0.947 rs505176 ENSG00000183298.5 RP11-556K13.1 7.79 7.85e-14 2.78e-07 0.56 0.39 Attention deficit hyperactivity disorder; chr3:39524857 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs1708000 ENSG00000183298.5 RP11-556K13.1 7.79 7.85e-14 2.78e-07 0.56 0.39 Attention deficit hyperactivity disorder; chr3:39525645 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs1708001 ENSG00000183298.5 RP11-556K13.1 7.79 7.85e-14 2.78e-07 0.56 0.39 Attention deficit hyperactivity disorder; chr3:39525714 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs816519 ENSG00000183298.5 RP11-556K13.1 7.79 7.85e-14 2.78e-07 0.56 0.39 Attention deficit hyperactivity disorder; chr3:39527786 chr1:101786340~101787219:- LIHC trans rs864643 0.731 rs1417148 ENSG00000183298.5 RP11-556K13.1 7.79 7.85e-14 2.78e-07 0.56 0.39 Attention deficit hyperactivity disorder; chr3:39534217 chr1:101786340~101787219:- LIHC trans rs9876781 0.967 rs7618883 ENSG00000235912.1 RP1-159A19.3 -7.79 8.08e-14 2.86e-07 -0.45 -0.39 Longevity; chr3:48457056 chr1:27649419~27649610:+ LIHC trans rs8010715 0.848 rs927494 ENSG00000238000.1 RP11-274E7.2 7.78 8.39e-14 2.97e-07 0.46 0.39 IgG glycosylation; chr14:24131181 chr5:98213402~98214121:+ LIHC trans rs5022636 0.507 rs4579761 ENSG00000180764.13 PIPSL 7.78 8.43e-14 2.98e-07 0.4 0.39 Gut microbiota (functional units); chr1:151363433 chr10:93958191~93961540:- LIHC trans rs10037055 0.898 rs4976636 ENSG00000228305.2 AC016734.2 -7.78 8.57e-14 3.03e-07 -0.44 -0.39 Migraine without aura; chr5:177118091 chr2:63622178~63622831:- LIHC trans rs10037055 0.898 rs4976637 ENSG00000228305.2 AC016734.2 -7.78 8.57e-14 3.03e-07 -0.44 -0.39 Migraine without aura; chr5:177118141 chr2:63622178~63622831:- LIHC trans rs9467773 0.935 rs4573 ENSG00000242375.1 RP11-498P14.3 7.78 8.65e-14 3.06e-07 0.45 0.39 Intelligence (multi-trait analysis); chr6:26546580 chr9:97195351~97197687:- LIHC trans rs4263408 0.967 rs11947966 ENSG00000237550.5 UBE2Q2P6 7.77 9.01e-14 3.18e-07 0.44 0.39 Plasma amyloid beta peptide concentrations (ABx-40); chr4:39765721 chr15:82372196~82372912:- LIHC trans rs7554547 0.791 rs4846076 ENSG00000261819.1 RP11-680G24.4 7.77 9.01e-14 3.18e-07 0.51 0.39 Nonsyndromic cleft lip with cleft palate; chr1:11896708 chr16:14988259~14990160:- LIHC trans rs916888 0.773 rs9896243 ENSG00000214425.5 LRRC37A4P -7.77 9.21e-14 3.25e-07 -0.61 -0.39 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45506741~45550335:- LIHC trans rs72615157 0.612 rs7786505 ENSG00000228546.2 CTA-313A17.3 7.77 9.38e-14 3.31e-07 0.58 0.39 Lung function (FEV1/FVC); chr7:100219962 chr7:102337316~102339115:+ LIHC trans rs3088050 1 rs3088050 ENSG00000217325.2 PRELID1P1 -7.77 9.45e-14 3.33e-07 -0.49 -0.39 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr5:177299634 chr6:126643488~126644390:+ LIHC trans rs7930295 1 rs10893380 ENSG00000236257.1 EI24P2 -7.76 9.89e-14 3.48e-07 -0.54 -0.39 Schizophrenia; chr11:125441778 chr1:158454198~158455273:+ LIHC trans rs5751901 0.688 rs2017869 ENSG00000280208.1 RP11-341D18.4 7.76 1.01e-13 3.57e-07 0.43 0.39 Protein quantitative trait loci; chr22:24601342 chr13:18253526~18270822:- LIHC trans rs10870270 0.917 rs9971362 ENSG00000197358.9 BNIP3P1 7.75 1.09e-13 3.84e-07 0.46 0.39 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131976646 chr14:28264390~28265974:+ LIHC trans rs538867 1 rs1708044 ENSG00000214263.2 RPSAP53 7.74 1.12e-13 3.93e-07 0.85 0.39 Alzheimer's disease (cognitive decline); chr3:39545261 chr13:67266845~67267706:- LIHC trans rs538867 1 rs79077098 ENSG00000214263.2 RPSAP53 7.74 1.16e-13 4.07e-07 0.88 0.39 Alzheimer's disease (cognitive decline); chr3:39476816 chr13:67266845~67267706:- LIHC trans rs538867 1 rs1768204 ENSG00000214263.2 RPSAP53 7.74 1.16e-13 4.07e-07 0.88 0.39 Alzheimer's disease (cognitive decline); chr3:39478075 chr13:67266845~67267706:- LIHC trans rs6477998 0.676 rs10817470 ENSG00000238072.1 RP11-305M3.2 7.73 1.2e-13 4.18e-07 0.58 0.39 Hematology traits; chr9:113252129 chr7:129410113~129410370:- LIHC trans rs9425766 1 rs9425766 ENSG00000213331.4 RP11-713C19.2 7.73 1.24e-13 4.32e-07 0.47 0.39 Life satisfaction; chr1:173883989 chr4:187970273~187971284:+ LIHC trans rs916888 0.61 rs199452 ENSG00000264070.1 DND1P1 7.72 1.28e-13 4.46e-07 0.45 0.39 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:45585871~45586929:+ LIHC trans rs8010715 1 rs8010715 ENSG00000238000.1 RP11-274E7.2 7.72 1.28e-13 4.46e-07 0.46 0.39 IgG glycosylation; chr14:24139938 chr5:98213402~98214121:+ LIHC trans rs9876781 1 rs9838618 ENSG00000235912.1 RP1-159A19.3 -7.72 1.3e-13 4.53e-07 -0.44 -0.39 Longevity; chr3:48445949 chr1:27649419~27649610:+ LIHC trans rs4263408 1 rs4263408 ENSG00000237550.5 UBE2Q2P6 7.71 1.35e-13 4.69e-07 0.44 0.38 Plasma amyloid beta peptide concentrations (ABx-40); chr4:39783656 chr15:82372196~82372912:- LIHC trans rs864643 0.812 rs12490768 ENSG00000183298.5 RP11-556K13.1 -7.71 1.37e-13 4.77e-07 -0.51 -0.38 Attention deficit hyperactivity disorder; chr3:39521874 chr1:101786340~101787219:- LIHC trans rs864643 0.773 rs2280082 ENSG00000183298.5 RP11-556K13.1 -7.71 1.37e-13 4.77e-07 -0.51 -0.38 Attention deficit hyperactivity disorder; chr3:39528519 chr1:101786340~101787219:- LIHC trans rs864643 0.738 rs1398664 ENSG00000183298.5 RP11-556K13.1 -7.71 1.37e-13 4.77e-07 -0.51 -0.38 Attention deficit hyperactivity disorder; chr3:39534259 chr1:101786340~101787219:- LIHC trans rs864643 0.659 rs1398663 ENSG00000183298.5 RP11-556K13.1 -7.71 1.37e-13 4.78e-07 -0.51 -0.38 Attention deficit hyperactivity disorder; chr3:39534874 chr1:101786340~101787219:- LIHC trans rs9876781 1 rs2362450 ENSG00000235912.1 RP1-159A19.3 -7.71 1.4e-13 4.86e-07 -0.44 -0.38 Longevity; chr3:48419904 chr1:27649419~27649610:+ LIHC trans rs8067354 0.574 rs2250526 ENSG00000187870.7 RNFT1P3 7.7 1.46e-13 5.07e-07 0.47 0.38 Hemoglobin concentration; chr17:59874612 chr17:20743333~20754501:- LIHC trans rs9876781 0.967 rs1459249 ENSG00000235912.1 RP1-159A19.3 -7.7 1.48e-13 5.12e-07 -0.44 -0.38 Longevity; chr3:48438208 chr1:27649419~27649610:+ LIHC trans rs4784054 0.667 rs2013333 ENSG00000233719.3 GOT2P3 7.7 1.49e-13 5.18e-07 0.46 0.38 Blood metabolite levels; chr16:58750920 chr12:9641802~9643007:+ LIHC trans rs4784054 0.803 rs11859128 ENSG00000233719.3 GOT2P3 7.7 1.49e-13 5.18e-07 0.46 0.38 Blood metabolite levels; chr16:58752257 chr12:9641802~9643007:+ LIHC trans rs4784054 0.667 rs8052646 ENSG00000233719.3 GOT2P3 7.7 1.49e-13 5.18e-07 0.46 0.38 Blood metabolite levels; chr16:58754064 chr12:9641802~9643007:+ LIHC trans rs4784054 0.667 rs11643711 ENSG00000233719.3 GOT2P3 7.7 1.49e-13 5.18e-07 0.46 0.38 Blood metabolite levels; chr16:58754648 chr12:9641802~9643007:+ LIHC trans rs4784054 0.614 rs8054775 ENSG00000233719.3 GOT2P3 7.7 1.49e-13 5.18e-07 0.46 0.38 Blood metabolite levels; chr16:58759666 chr12:9641802~9643007:+ LIHC trans rs7554547 0.791 rs2064614 ENSG00000261819.1 RP11-680G24.4 7.7 1.51e-13 5.22e-07 0.5 0.38 Nonsyndromic cleft lip with cleft palate; chr1:11893883 chr16:14988259~14990160:- LIHC trans rs864643 0.812 rs1606473 ENSG00000183298.5 RP11-556K13.1 -7.7 1.52e-13 5.25e-07 -0.52 -0.38 Attention deficit hyperactivity disorder; chr3:39541433 chr1:101786340~101787219:- LIHC trans rs10870270 0.956 rs4131689 ENSG00000197358.9 BNIP3P1 -7.69 1.55e-13 5.37e-07 -0.44 -0.38 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131930824 chr14:28264390~28265974:+ LIHC trans rs8067354 0.574 rs7219089 ENSG00000187870.7 RNFT1P3 7.69 1.6e-13 5.53e-07 0.47 0.38 Hemoglobin concentration; chr17:59955504 chr17:20743333~20754501:- LIHC trans rs8067354 0.54 rs7221472 ENSG00000187870.7 RNFT1P3 7.69 1.6e-13 5.53e-07 0.47 0.38 Hemoglobin concentration; chr17:59959376 chr17:20743333~20754501:- LIHC trans rs8067354 0.54 rs12600680 ENSG00000187870.7 RNFT1P3 7.69 1.6e-13 5.53e-07 0.47 0.38 Hemoglobin concentration; chr17:59960013 chr17:20743333~20754501:- LIHC trans rs10870270 0.956 rs4880405 ENSG00000197358.9 BNIP3P1 7.69 1.63e-13 5.64e-07 0.46 0.38 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131973517 chr14:28264390~28265974:+ LIHC trans rs916888 0.738 rs199515 ENSG00000214425.5 LRRC37A4P 7.68 1.66e-13 5.74e-07 0.59 0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:45506741~45550335:- LIHC trans rs7554547 0.791 rs34117126 ENSG00000261819.1 RP11-680G24.4 7.68 1.68e-13 5.79e-07 0.5 0.38 Nonsyndromic cleft lip with cleft palate; chr1:11892138 chr16:14988259~14990160:- LIHC trans rs7554547 0.791 rs17037520 ENSG00000261819.1 RP11-680G24.4 7.68 1.68e-13 5.79e-07 0.5 0.38 Nonsyndromic cleft lip with cleft palate; chr1:11892349 chr16:14988259~14990160:- LIHC trans rs7554547 0.791 rs12749498 ENSG00000261819.1 RP11-680G24.4 7.68 1.68e-13 5.79e-07 0.5 0.38 Nonsyndromic cleft lip with cleft palate; chr1:11892570 chr16:14988259~14990160:- LIHC trans rs7554547 0.791 rs12036266 ENSG00000261819.1 RP11-680G24.4 7.68 1.68e-13 5.79e-07 0.5 0.38 Nonsyndromic cleft lip with cleft palate; chr1:11893257 chr16:14988259~14990160:- LIHC trans rs7554547 0.791 rs2065611 ENSG00000261819.1 RP11-680G24.4 7.68 1.68e-13 5.79e-07 0.5 0.38 Nonsyndromic cleft lip with cleft palate; chr1:11893469 chr16:14988259~14990160:- LIHC trans rs7554547 0.791 rs4492637 ENSG00000261819.1 RP11-680G24.4 7.68 1.68e-13 5.79e-07 0.5 0.38 Nonsyndromic cleft lip with cleft palate; chr1:11895787 chr16:14988259~14990160:- LIHC trans rs7554547 0.791 rs4846074 ENSG00000261819.1 RP11-680G24.4 7.68 1.68e-13 5.79e-07 0.5 0.38 Nonsyndromic cleft lip with cleft palate; chr1:11896172 chr16:14988259~14990160:- LIHC trans rs8067354 0.507 rs2645478 ENSG00000187870.7 RNFT1P3 7.67 1.75e-13 6.03e-07 0.46 0.38 Hemoglobin concentration; chr17:59937351 chr17:20743333~20754501:- LIHC trans rs8067354 0.54 rs72840315 ENSG00000187870.7 RNFT1P3 7.67 1.75e-13 6.03e-07 0.46 0.38 Hemoglobin concentration; chr17:59940781 chr17:20743333~20754501:- LIHC trans rs864643 1 rs704963 ENSG00000183298.5 RP11-556K13.1 -7.67 1.75e-13 6.03e-07 -0.59 -0.38 Attention deficit hyperactivity disorder; chr3:39515747 chr1:101786340~101787219:- LIHC trans rs55665837 0.519 rs1451677 ENSG00000236360.2 RP11-334A14.2 7.67 1.75e-13 6.03e-07 0.49 0.38 Vitamin D levels; chr11:14724466 chr1:52993201~52993702:- LIHC trans rs6477998 0.676 rs10759631 ENSG00000238072.1 RP11-305M3.2 7.67 1.77e-13 6.07e-07 0.57 0.38 Hematology traits; chr9:113233764 chr7:129410113~129410370:- LIHC trans rs6477998 0.676 rs10081797 ENSG00000238072.1 RP11-305M3.2 7.67 1.77e-13 6.07e-07 0.57 0.38 Hematology traits; chr9:113237973 chr7:129410113~129410370:- LIHC trans rs6477998 0.676 rs10759632 ENSG00000238072.1 RP11-305M3.2 7.67 1.77e-13 6.07e-07 0.57 0.38 Hematology traits; chr9:113238703 chr7:129410113~129410370:- LIHC trans rs9611565 1 rs1109151 ENSG00000268568.1 AC007228.9 -7.67 1.78e-13 6.11e-07 -0.49 -0.38 Vitiligo; chr22:41356940 chr19:56672574~56673901:- LIHC trans rs9611565 0.918 rs6002351 ENSG00000268568.1 AC007228.9 -7.67 1.79e-13 6.16e-07 -0.48 -0.38 Vitiligo; chr22:41361219 chr19:56672574~56673901:- LIHC trans rs9611565 0.879 rs5758311 ENSG00000268568.1 AC007228.9 -7.67 1.8e-13 6.19e-07 -0.49 -0.38 Vitiligo; chr22:41363371 chr19:56672574~56673901:- LIHC trans rs6477998 0.676 rs10981698 ENSG00000238072.1 RP11-305M3.2 7.67 1.81e-13 6.22e-07 0.57 0.38 Hematology traits; chr9:113233500 chr7:129410113~129410370:- LIHC trans rs538867 1 rs1708063 ENSG00000214263.2 RPSAP53 7.67 1.82e-13 6.24e-07 0.84 0.38 Alzheimer's disease (cognitive decline); chr3:39500602 chr13:67266845~67267706:- LIHC trans rs8067354 0.574 rs1292050 ENSG00000187870.7 RNFT1P3 7.67 1.86e-13 6.38e-07 0.47 0.38 Hemoglobin concentration; chr17:59887808 chr17:20743333~20754501:- LIHC trans rs77688320 0.517 rs7605375 ENSG00000235105.1 RP11-329A14.1 7.66 1.88e-13 6.43e-07 0.36 0.38 Breast cancer; chr2:201465907 chr1:48435967~48437223:+ LIHC trans rs864643 1 rs816492 ENSG00000183298.5 RP11-556K13.1 7.66 1.89e-13 6.47e-07 0.55 0.38 Attention deficit hyperactivity disorder; chr3:39514664 chr1:101786340~101787219:- LIHC trans rs4263408 1 rs7687557 ENSG00000237550.5 UBE2Q2P6 7.66 1.91e-13 6.54e-07 0.43 0.38 Plasma amyloid beta peptide concentrations (ABx-40); chr4:39767640 chr15:82372196~82372912:- LIHC trans rs58106596 0.747 rs6731997 ENSG00000259020.3 RP11-529H20.3 7.66 1.93e-13 6.61e-07 0.48 0.38 Lymphocyte counts;White blood cell count; chr2:231695701 chr14:92026566~92026887:+ LIHC trans rs916888 0.773 rs9896243 ENSG00000280022.1 RP11-707O23.1 7.66 1.95e-13 6.66e-07 0.64 0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45592621~45593369:+ LIHC trans rs9611519 0.78 rs9611527 ENSG00000268568.1 AC007228.9 -7.66 1.95e-13 6.66e-07 -0.54 -0.38 Neuroticism; chr22:41248424 chr19:56672574~56673901:- LIHC trans rs9425766 0.927 rs9425757 ENSG00000213331.4 RP11-713C19.2 7.66 1.95e-13 6.66e-07 0.47 0.38 Life satisfaction; chr1:173855675 chr4:187970273~187971284:+ LIHC trans rs9425766 0.85 rs1322770 ENSG00000213331.4 RP11-713C19.2 7.66 1.95e-13 6.66e-07 0.47 0.38 Life satisfaction; chr1:173863198 chr4:187970273~187971284:+ LIHC trans rs9425766 0.85 rs9425755 ENSG00000213331.4 RP11-713C19.2 7.66 1.98e-13 6.77e-07 0.47 0.38 Life satisfaction; chr1:173843501 chr4:187970273~187971284:+ LIHC trans rs864643 1 rs864643 ENSG00000183298.5 RP11-556K13.1 7.65 2.01e-13 6.88e-07 0.54 0.38 Attention deficit hyperactivity disorder; chr3:39514089 chr1:101786340~101787219:- LIHC trans rs8067354 0.574 rs2531898 ENSG00000187870.7 RNFT1P3 7.65 2.09e-13 7.13e-07 0.46 0.38 Hemoglobin concentration; chr17:59934990 chr17:20743333~20754501:- LIHC trans rs8067354 0.574 rs9789060 ENSG00000187870.7 RNFT1P3 7.65 2.09e-13 7.13e-07 0.46 0.38 Hemoglobin concentration; chr17:59941209 chr17:20743333~20754501:- LIHC trans rs4784054 0.667 rs12925537 ENSG00000233719.3 GOT2P3 7.65 2.12e-13 7.22e-07 0.46 0.38 Blood metabolite levels; chr16:58750094 chr12:9641802~9643007:+ LIHC trans rs4263408 0.934 rs2381428 ENSG00000237550.5 UBE2Q2P6 7.64 2.16e-13 7.34e-07 0.43 0.38 Plasma amyloid beta peptide concentrations (ABx-40); chr4:39761846 chr15:82372196~82372912:- LIHC trans rs2896526 0.736 rs78950598 ENSG00000235847.2 LDHAP7 7.64 2.23e-13 7.58e-07 0.7 0.38 Amyloid A serum levels; chr11:18375599 chr2:84777259~84778223:- LIHC trans rs916888 0.821 rs199504 ENSG00000280022.1 RP11-707O23.1 -7.64 2.23e-13 7.58e-07 -0.66 -0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:45592621~45593369:+ LIHC trans rs538867 1 rs1707987 ENSG00000214263.2 RPSAP53 7.64 2.23e-13 7.59e-07 0.84 0.38 Alzheimer's disease (cognitive decline); chr3:39510002 chr13:67266845~67267706:- LIHC trans rs72615157 0.634 rs74774557 ENSG00000228546.2 CTA-313A17.3 7.64 2.25e-13 7.66e-07 0.59 0.38 Lung function (FEV1/FVC); chr7:100212802 chr7:102337316~102339115:+ LIHC trans rs8067354 0.574 rs1295923 ENSG00000187870.7 RNFT1P3 7.63 2.29e-13 7.78e-07 0.47 0.38 Hemoglobin concentration; chr17:59883075 chr17:20743333~20754501:- LIHC trans rs8067354 0.574 rs1296279 ENSG00000187870.7 RNFT1P3 7.63 2.29e-13 7.78e-07 0.47 0.38 Hemoglobin concentration; chr17:59888370 chr17:20743333~20754501:- LIHC trans rs7568458 0.66 rs55692129 ENSG00000223886.3 RP11-251G23.2 7.63 2.32e-13 7.87e-07 0.49 0.38 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85565281 chr7:105530209~105530671:+ LIHC trans rs538867 1 rs1708070 ENSG00000214263.2 RPSAP53 7.63 2.36e-13 8e-07 0.84 0.38 Alzheimer's disease (cognitive decline); chr3:39501014 chr13:67266845~67267706:- LIHC trans rs9876781 0.967 rs1870444 ENSG00000235912.1 RP1-159A19.3 -7.63 2.37e-13 8.03e-07 -0.44 -0.38 Longevity; chr3:48445369 chr1:27649419~27649610:+ LIHC trans rs8067354 0.574 rs2531899 ENSG00000187870.7 RNFT1P3 -7.63 2.43e-13 8.23e-07 -0.46 -0.38 Hemoglobin concentration; chr17:59929832 chr17:20743333~20754501:- LIHC trans rs7121616 1 rs79401687 ENSG00000234176.1 HSPA8P1 7.62 2.51e-13 8.52e-07 0.58 0.38 Breast cancer; chr11:123096264 chrX:121203182~121205014:- LIHC trans rs9611565 0.879 rs5758307 ENSG00000268568.1 AC007228.9 -7.62 2.53e-13 8.58e-07 -0.48 -0.38 Vitiligo; chr22:41354215 chr19:56672574~56673901:- LIHC trans rs3740713 0.719 rs78515595 ENSG00000235847.2 LDHAP7 7.62 2.55e-13 8.63e-07 0.69 0.38 Amyotrophic lateral sclerosis (sporadic); chr11:18409830 chr2:84777259~84778223:- LIHC trans rs55665837 0.701 rs12286408 ENSG00000236360.2 RP11-334A14.2 7.61 2.62e-13 8.87e-07 0.49 0.38 Vitamin D levels; chr11:14557830 chr1:52993201~52993702:- LIHC trans rs538867 1 rs1398665 ENSG00000214263.2 RPSAP53 7.61 2.73e-13 9.22e-07 0.86 0.38 Alzheimer's disease (cognitive decline); chr3:39475520 chr13:67266845~67267706:- LIHC trans rs538867 1 rs73066233 ENSG00000214263.2 RPSAP53 7.61 2.73e-13 9.22e-07 0.86 0.38 Alzheimer's disease (cognitive decline); chr3:39475952 chr13:67266845~67267706:- LIHC trans rs7937890 0.874 rs6486191 ENSG00000236360.2 RP11-334A14.2 7.61 2.73e-13 9.22e-07 0.48 0.38 Mitochondrial DNA levels; chr11:14382193 chr1:52993201~52993702:- LIHC trans rs4784054 0.803 rs73553511 ENSG00000233719.3 GOT2P3 7.6 2.85e-13 9.59e-07 0.47 0.38 Blood metabolite levels; chr16:58758077 chr12:9641802~9643007:+ LIHC trans rs55665837 0.54 rs10832299 ENSG00000236360.2 RP11-334A14.2 7.6 2.86e-13 9.64e-07 0.48 0.38 Vitamin D levels; chr11:14747846 chr1:52993201~52993702:- LIHC trans rs55665837 0.523 rs10832301 ENSG00000236360.2 RP11-334A14.2 7.6 2.86e-13 9.64e-07 0.48 0.38 Vitamin D levels; chr11:14767418 chr1:52993201~52993702:- LIHC trans rs4784054 0.667 rs12931903 ENSG00000233719.3 GOT2P3 7.6 2.94e-13 9.88e-07 0.46 0.38 Blood metabolite levels; chr16:58755140 chr12:9641802~9643007:+ LIHC trans rs4784054 0.614 rs8046937 ENSG00000233719.3 GOT2P3 7.6 2.94e-13 9.89e-07 0.46 0.38 Blood metabolite levels; chr16:58762282 chr12:9641802~9643007:+ LIHC trans rs4784054 0.803 rs4784980 ENSG00000233719.3 GOT2P3 7.6 2.94e-13 9.89e-07 0.46 0.38 Blood metabolite levels; chr16:58763722 chr12:9641802~9643007:+ LIHC trans rs916888 0.697 rs199516 ENSG00000280022.1 RP11-707O23.1 -7.6 2.96e-13 9.93e-07 -0.64 -0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45592621~45593369:+ LIHC trans rs916888 0.821 rs199514 ENSG00000280022.1 RP11-707O23.1 -7.6 2.96e-13 9.93e-07 -0.64 -0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45592621~45593369:+ LIHC trans rs916888 0.821 rs199512 ENSG00000280022.1 RP11-707O23.1 -7.6 2.96e-13 9.93e-07 -0.64 -0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45592621~45593369:+ LIHC trans rs916888 0.821 rs199509 ENSG00000280022.1 RP11-707O23.1 -7.6 2.96e-13 9.93e-07 -0.64 -0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45592621~45593369:+ LIHC trans rs916888 0.821 rs199507 ENSG00000280022.1 RP11-707O23.1 -7.6 2.96e-13 9.93e-07 -0.64 -0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45592621~45593369:+ LIHC trans rs916888 0.821 rs415430 ENSG00000280022.1 RP11-707O23.1 -7.6 2.96e-13 9.93e-07 -0.64 -0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45592621~45593369:+ LIHC trans rs916888 0.779 rs430685 ENSG00000280022.1 RP11-707O23.1 -7.6 2.96e-13 9.93e-07 -0.64 -0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45592621~45593369:+ LIHC trans rs916888 0.821 rs199505 ENSG00000280022.1 RP11-707O23.1 -7.6 2.96e-13 9.93e-07 -0.64 -0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45592621~45593369:+ LIHC trans rs916888 0.821 rs70602 ENSG00000280022.1 RP11-707O23.1 -7.6 2.96e-13 9.93e-07 -0.64 -0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45592621~45593369:+ LIHC trans rs9876781 1 rs9883927 ENSG00000235912.1 RP1-159A19.3 -7.59 2.99e-13 1e-06 -0.43 -0.38 Longevity; chr3:48422302 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs2290822 ENSG00000235912.1 RP1-159A19.3 -7.59 2.99e-13 1e-06 -0.43 -0.38 Longevity; chr3:48431794 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs13076076 ENSG00000235912.1 RP1-159A19.3 -7.59 2.99e-13 1e-06 -0.43 -0.38 Longevity; chr3:48437629 chr1:27649419~27649610:+ LIHC trans rs55665837 0.54 rs10766192 ENSG00000236360.2 RP11-334A14.2 7.59 3.06e-13 1.03e-06 0.47 0.38 Vitamin D levels; chr11:14790140 chr1:52993201~52993702:- LIHC trans rs9876781 1 rs11130171 ENSG00000235912.1 RP1-159A19.3 -7.59 3.11e-13 1.04e-06 -0.43 -0.38 Longevity; chr3:48421052 chr1:27649419~27649610:+ LIHC trans rs9611565 1 rs5758314 ENSG00000268568.1 AC007228.9 -7.59 3.11e-13 1.04e-06 -0.47 -0.38 Vitiligo; chr22:41366519 chr19:56672574~56673901:- LIHC trans rs7121616 1 rs75228513 ENSG00000234176.1 HSPA8P1 7.59 3.11e-13 1.04e-06 0.59 0.38 Breast cancer; chr11:123096160 chrX:121203182~121205014:- LIHC trans rs3779195 0.584 rs1688605 ENSG00000225169.1 BRI3P1 -7.59 3.12e-13 1.05e-06 -0.63 -0.38 Sex hormone-binding globulin levels; chr7:98410534 chr1:100213293~100213670:+ LIHC trans rs10870270 0.83 rs10781571 ENSG00000197358.9 BNIP3P1 7.58 3.21e-13 1.07e-06 0.45 0.38 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131960812 chr14:28264390~28265974:+ LIHC trans rs55665837 0.54 rs10219313 ENSG00000236360.2 RP11-334A14.2 7.58 3.24e-13 1.09e-06 0.48 0.38 Vitamin D levels; chr11:14728303 chr1:52993201~52993702:- LIHC trans rs55665837 0.54 rs4144487 ENSG00000236360.2 RP11-334A14.2 7.58 3.24e-13 1.09e-06 0.48 0.38 Vitamin D levels; chr11:14728905 chr1:52993201~52993702:- LIHC trans rs55665837 0.519 rs10832297 ENSG00000236360.2 RP11-334A14.2 7.58 3.24e-13 1.09e-06 0.48 0.38 Vitamin D levels; chr11:14736191 chr1:52993201~52993702:- LIHC trans rs55665837 0.54 rs12788030 ENSG00000236360.2 RP11-334A14.2 7.58 3.24e-13 1.09e-06 0.48 0.38 Vitamin D levels; chr11:14743138 chr1:52993201~52993702:- LIHC trans rs9876781 1 rs9849509 ENSG00000235912.1 RP1-159A19.3 -7.58 3.25e-13 1.09e-06 -0.43 -0.38 Longevity; chr3:48442021 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs60512868 ENSG00000235912.1 RP1-159A19.3 -7.58 3.25e-13 1.09e-06 -0.43 -0.38 Longevity; chr3:48442035 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs7636044 ENSG00000235912.1 RP1-159A19.3 -7.58 3.25e-13 1.09e-06 -0.43 -0.38 Longevity; chr3:48443151 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs4490383 ENSG00000235912.1 RP1-159A19.3 -7.58 3.25e-13 1.09e-06 -0.43 -0.38 Longevity; chr3:48443275 chr1:27649419~27649610:+ LIHC trans rs9425766 0.962 rs2065171 ENSG00000213331.4 RP11-713C19.2 7.58 3.27e-13 1.09e-06 0.47 0.38 Life satisfaction; chr1:173876972 chr4:187970273~187971284:+ LIHC trans rs9425766 0.962 rs4652229 ENSG00000213331.4 RP11-713C19.2 7.58 3.27e-13 1.09e-06 0.47 0.38 Life satisfaction; chr1:173877452 chr4:187970273~187971284:+ LIHC trans rs9425766 0.927 rs9425765 ENSG00000213331.4 RP11-713C19.2 7.58 3.27e-13 1.09e-06 0.47 0.38 Life satisfaction; chr1:173878871 chr4:187970273~187971284:+ LIHC trans rs864643 1 rs1708002 ENSG00000183298.5 RP11-556K13.1 7.58 3.28e-13 1.1e-06 0.55 0.38 Attention deficit hyperactivity disorder; chr3:39511185 chr1:101786340~101787219:- LIHC trans rs8067354 0.609 rs1292066 ENSG00000187870.7 RNFT1P3 7.58 3.31e-13 1.11e-06 0.45 0.38 Hemoglobin concentration; chr17:59854953 chr17:20743333~20754501:- LIHC trans rs55665837 0.54 rs10832294 ENSG00000236360.2 RP11-334A14.2 7.58 3.33e-13 1.11e-06 0.48 0.38 Vitamin D levels; chr11:14725881 chr1:52993201~52993702:- LIHC trans rs538867 1 rs73066219 ENSG00000214263.2 RPSAP53 7.57 3.44e-13 1.15e-06 0.89 0.38 Alzheimer's disease (cognitive decline); chr3:39465016 chr13:67266845~67267706:- LIHC trans rs6477998 0.651 rs10121845 ENSG00000238072.1 RP11-305M3.2 7.57 3.44e-13 1.15e-06 0.56 0.38 Hematology traits; chr9:113227443 chr7:129410113~129410370:- LIHC trans rs55665837 0.54 rs1007392 ENSG00000236360.2 RP11-334A14.2 7.57 3.5e-13 1.17e-06 0.48 0.38 Vitamin D levels; chr11:14753045 chr1:52993201~52993702:- LIHC trans rs4784054 0.667 rs8044439 ENSG00000233719.3 GOT2P3 7.57 3.58e-13 1.19e-06 0.46 0.38 Blood metabolite levels; chr16:58757121 chr12:9641802~9643007:+ LIHC trans rs10870270 1 rs9971066 ENSG00000197358.9 BNIP3P1 7.57 3.6e-13 1.2e-06 0.45 0.38 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131974729 chr14:28264390~28265974:+ LIHC trans rs10870270 0.957 rs9971084 ENSG00000197358.9 BNIP3P1 7.56 3.73e-13 1.24e-06 0.45 0.38 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131975243 chr14:28264390~28265974:+ LIHC trans rs7399018 0.739 rs7399073 ENSG00000223825.5 DAZAP2P1 7.56 3.78e-13 1.26e-06 0.42 0.38 Cisplatin-induced ototoxicity; chr12:51220266 chr2:202201384~202201886:- LIHC trans rs4784054 0.803 rs34295929 ENSG00000233719.3 GOT2P3 7.55 3.89e-13 1.29e-06 0.46 0.38 Blood metabolite levels; chr16:58748936 chr12:9641802~9643007:+ LIHC trans rs58106596 0.747 rs10166046 ENSG00000259020.3 RP11-529H20.3 -7.55 3.9e-13 1.29e-06 -0.46 -0.38 Lymphocyte counts;White blood cell count; chr2:231696274 chr14:92026566~92026887:+ LIHC trans rs8067354 0.574 rs1292033 ENSG00000187870.7 RNFT1P3 7.55 3.9e-13 1.29e-06 0.46 0.38 Hemoglobin concentration; chr17:59913236 chr17:20743333~20754501:- LIHC trans rs72615157 0.634 rs2272343 ENSG00000228546.2 CTA-313A17.3 7.55 3.94e-13 1.31e-06 0.59 0.38 Lung function (FEV1/FVC); chr7:100180662 chr7:102337316~102339115:+ LIHC trans rs9467773 0.869 rs9295689 ENSG00000242375.1 RP11-498P14.3 7.55 3.94e-13 1.31e-06 0.44 0.38 Intelligence (multi-trait analysis); chr6:26455583 chr9:97195351~97197687:- LIHC trans rs916888 0.61 rs199530 ENSG00000264070.1 DND1P1 -7.55 3.95e-13 1.31e-06 -0.44 -0.38 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:45585871~45586929:+ LIHC trans rs8067354 0.527 rs1292039 ENSG00000187870.7 RNFT1P3 7.55 4.05e-13 1.34e-06 0.46 0.38 Hemoglobin concentration; chr17:59897552 chr17:20743333~20754501:- LIHC trans rs864643 1 rs816491 ENSG00000183298.5 RP11-556K13.1 -7.55 4.08e-13 1.35e-06 -0.53 -0.38 Attention deficit hyperactivity disorder; chr3:39514006 chr1:101786340~101787219:- LIHC trans rs9876781 1 rs9817615 ENSG00000235912.1 RP1-159A19.3 -7.54 4.14e-13 1.37e-06 -0.42 -0.38 Longevity; chr3:48429347 chr1:27649419~27649610:+ LIHC trans rs77954165 0.614 rs4742243 ENSG00000215210.3 RBMXP2 7.54 4.14e-13 1.37e-06 0.5 0.38 Stem cell growth factor beta levels; chr9:6717650 chr9:30689105~30690272:+ LIHC trans rs7121616 0.96 rs12361252 ENSG00000234176.1 HSPA8P1 7.54 4.18e-13 1.38e-06 0.58 0.38 Breast cancer; chr11:123091564 chrX:121203182~121205014:- LIHC trans rs4784054 0.667 rs7206052 ENSG00000233719.3 GOT2P3 7.54 4.19e-13 1.38e-06 0.46 0.38 Blood metabolite levels; chr16:58769607 chr12:9641802~9643007:+ LIHC trans rs10870270 1 rs4880263 ENSG00000197358.9 BNIP3P1 7.54 4.34e-13 1.43e-06 0.45 0.38 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131974125 chr14:28264390~28265974:+ LIHC trans rs801193 0.591 rs9986881 ENSG00000164669.11 INTS4P1 -7.53 4.45e-13 1.47e-06 -0.47 -0.38 Aortic root size; chr7:66708053 chr7:65141225~65234216:+ LIHC trans rs7568458 0.663 rs699664 ENSG00000223886.3 RP11-251G23.2 -7.53 4.48e-13 1.48e-06 -0.47 -0.38 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85553413 chr7:105530209~105530671:+ LIHC trans rs72615157 0.634 rs74742883 ENSG00000228546.2 CTA-313A17.3 7.53 4.62e-13 1.52e-06 0.59 0.38 Lung function (FEV1/FVC); chr7:100188142 chr7:102337316~102339115:+ LIHC trans rs816535 1 rs816535 ENSG00000279352.1 RP11-411B10.7 7.53 4.63e-13 1.52e-06 0.54 0.38 Parkinson disease and lewy body pathology; chr20:26275360 chr18:14010054~14010917:+ LIHC trans rs8067354 0.574 rs2526353 ENSG00000187870.7 RNFT1P3 7.53 4.7e-13 1.54e-06 0.46 0.38 Hemoglobin concentration; chr17:59911246 chr17:20743333~20754501:- LIHC trans rs8067354 0.574 rs1292035 ENSG00000187870.7 RNFT1P3 7.53 4.7e-13 1.54e-06 0.46 0.38 Hemoglobin concentration; chr17:59912196 chr17:20743333~20754501:- LIHC trans rs8067354 0.574 rs1291947 ENSG00000187870.7 RNFT1P3 7.52 4.78e-13 1.57e-06 0.46 0.38 Hemoglobin concentration; chr17:59918975 chr17:20743333~20754501:- LIHC trans rs7554547 0.791 rs6665662 ENSG00000261819.1 RP11-680G24.4 7.52 4.78e-13 1.57e-06 0.49 0.38 Nonsyndromic cleft lip with cleft palate; chr1:11891804 chr16:14988259~14990160:- LIHC trans rs9425766 0.886 rs1322775 ENSG00000213331.4 RP11-713C19.2 7.52 4.82e-13 1.58e-06 0.46 0.38 Life satisfaction; chr1:173886160 chr4:187970273~187971284:+ LIHC trans rs864643 0.678 rs1768206 ENSG00000183298.5 RP11-556K13.1 7.52 4.87e-13 1.6e-06 0.64 0.38 Attention deficit hyperactivity disorder; chr3:39480342 chr1:101786340~101787219:- LIHC trans rs2657294 0.704 rs10824266 ENSG00000172974.11 AC007318.5 7.52 4.9e-13 1.61e-06 0.4 0.38 Pneumonia; chr10:75083476 chr2:65205108~65205988:+ LIHC trans rs9611565 0.879 rs4820437 ENSG00000268568.1 AC007228.9 -7.52 4.97e-13 1.63e-06 -0.48 -0.38 Vitiligo; chr22:41365286 chr19:56672574~56673901:- LIHC trans rs4784054 0.667 rs12925419 ENSG00000233719.3 GOT2P3 7.51 5.04e-13 1.65e-06 0.46 0.38 Blood metabolite levels; chr16:58750078 chr12:9641802~9643007:+ LIHC trans rs538867 1 rs544505 ENSG00000214263.2 RPSAP53 7.51 5.17e-13 1.69e-06 0.86 0.38 Alzheimer's disease (cognitive decline); chr3:39488689 chr13:67266845~67267706:- LIHC trans rs877636 0.701 rs34415530 ENSG00000212994.5 RPS26P6 7.51 5.28e-13 1.73e-06 0.51 0.38 Cognitive function; chr12:56050848 chr8:100895771~100896118:+ LIHC trans rs8010715 0.52 rs12435994 ENSG00000238000.1 RP11-274E7.2 7.51 5.31e-13 1.74e-06 0.45 0.38 IgG glycosylation; chr14:24120252 chr5:98213402~98214121:+ LIHC trans rs8010715 0.596 rs12435995 ENSG00000238000.1 RP11-274E7.2 7.51 5.31e-13 1.74e-06 0.45 0.38 IgG glycosylation; chr14:24120255 chr5:98213402~98214121:+ LIHC trans rs11023332 1 rs11023332 ENSG00000236360.2 RP11-334A14.2 7.51 5.32e-13 1.74e-06 0.48 0.38 Vitamin D levels;Adiponectin levels; chr11:14762564 chr1:52993201~52993702:- LIHC trans rs55665837 0.502 rs4757269 ENSG00000236360.2 RP11-334A14.2 7.5 5.56e-13 1.82e-06 0.47 0.38 Vitamin D levels; chr11:14814646 chr1:52993201~52993702:- LIHC trans rs5022636 0.865 rs12069445 ENSG00000180764.13 PIPSL 7.5 5.62e-13 1.84e-06 0.35 0.38 Gut microbiota (functional units); chr1:151362964 chr10:93958191~93961540:- LIHC trans rs9425766 0.927 rs5878 ENSG00000213331.4 RP11-713C19.2 7.49 5.8e-13 1.89e-06 0.44 0.38 Life satisfaction; chr1:173909694 chr4:187970273~187971284:+ LIHC trans rs72615157 0.634 rs7789890 ENSG00000228546.2 CTA-313A17.3 7.49 5.94e-13 1.94e-06 0.58 0.38 Lung function (FEV1/FVC); chr7:100202936 chr7:102337316~102339115:+ LIHC trans rs55665837 0.54 rs4757261 ENSG00000236360.2 RP11-334A14.2 7.49 5.96e-13 1.94e-06 0.47 0.38 Vitamin D levels; chr11:14648256 chr1:52993201~52993702:- LIHC trans rs55665837 0.54 rs11023302 ENSG00000236360.2 RP11-334A14.2 7.49 5.96e-13 1.94e-06 0.47 0.38 Vitamin D levels; chr11:14672389 chr1:52993201~52993702:- LIHC trans rs55665837 0.54 rs10128681 ENSG00000236360.2 RP11-334A14.2 7.49 5.96e-13 1.94e-06 0.47 0.38 Vitamin D levels; chr11:14680030 chr1:52993201~52993702:- LIHC trans rs55665837 0.52 rs10766189 ENSG00000236360.2 RP11-334A14.2 7.49 5.96e-13 1.94e-06 0.47 0.38 Vitamin D levels; chr11:14712377 chr1:52993201~52993702:- LIHC trans rs877636 0.692 rs11171739 ENSG00000225071.1 GS1-184P14.2 7.49 5.96e-13 1.94e-06 0.45 0.38 Cognitive function; chr12:56076841 chrX:24429573~24429920:- LIHC trans rs538867 1 rs629170 ENSG00000214263.2 RPSAP53 7.49 6.06e-13 1.97e-06 0.85 0.38 Alzheimer's disease (cognitive decline); chr3:39472775 chr13:67266845~67267706:- LIHC trans rs351855 0.642 rs2546095 ENSG00000217325.2 PRELID1P1 7.48 6.22e-13 2.02e-06 0.45 0.38 Waist-to-hip ratio adjusted for body mass index; chr5:177082583 chr6:126643488~126644390:+ LIHC trans rs55665837 0.54 rs12416696 ENSG00000236360.2 RP11-334A14.2 7.47 6.59e-13 2.14e-06 0.47 0.37 Vitamin D levels; chr11:14769343 chr1:52993201~52993702:- LIHC trans rs9876781 1 rs6794875 ENSG00000235912.1 RP1-159A19.3 -7.47 6.62e-13 2.15e-06 -0.43 -0.37 Longevity; chr3:48414217 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs6442123 ENSG00000235912.1 RP1-159A19.3 -7.47 6.74e-13 2.19e-06 -0.42 -0.37 Longevity; chr3:48458887 chr1:27649419~27649610:+ LIHC trans rs7554547 0.791 rs1321073 ENSG00000261819.1 RP11-680G24.4 7.47 6.86e-13 2.22e-06 0.49 0.37 Nonsyndromic cleft lip with cleft palate; chr1:11891569 chr16:14988259~14990160:- LIHC trans rs10870270 1 rs7078692 ENSG00000197358.9 BNIP3P1 7.47 6.92e-13 2.24e-06 0.44 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131961866 chr14:28264390~28265974:+ LIHC trans rs10870270 1 rs7898755 ENSG00000197358.9 BNIP3P1 7.47 6.92e-13 2.24e-06 0.44 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131963618 chr14:28264390~28265974:+ LIHC trans rs72615157 0.634 rs79986079 ENSG00000228546.2 CTA-313A17.3 7.47 6.94e-13 2.25e-06 0.58 0.37 Lung function (FEV1/FVC); chr7:100204421 chr7:102337316~102339115:+ LIHC trans rs4784054 0.803 rs73553527 ENSG00000233719.3 GOT2P3 7.46 7.01e-13 2.27e-06 0.45 0.37 Blood metabolite levels; chr16:58762002 chr12:9641802~9643007:+ LIHC trans rs4784054 0.667 rs8052824 ENSG00000233719.3 GOT2P3 7.46 7.01e-13 2.27e-06 0.45 0.37 Blood metabolite levels; chr16:58762045 chr12:9641802~9643007:+ LIHC trans rs1292059 1 rs1292059 ENSG00000187870.7 RNFT1P3 7.46 7.35e-13 2.37e-06 0.45 0.37 Eosinophil percentage of granulocytes; chr17:59880527 chr17:20743333~20754501:- LIHC trans rs6477998 0.676 rs10981693 ENSG00000238072.1 RP11-305M3.2 -7.45 7.62e-13 2.46e-06 -0.55 -0.37 Hematology traits; chr9:113223137 chr7:129410113~129410370:- LIHC trans rs9425766 0.85 rs7349095 ENSG00000213331.4 RP11-713C19.2 7.45 7.78e-13 2.5e-06 0.46 0.37 Life satisfaction; chr1:173887899 chr4:187970273~187971284:+ LIHC trans rs10870270 1 rs6560695 ENSG00000197358.9 BNIP3P1 7.45 7.86e-13 2.53e-06 0.44 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131961482 chr14:28264390~28265974:+ LIHC trans rs10870270 1 rs7098014 ENSG00000197358.9 BNIP3P1 7.45 7.86e-13 2.53e-06 0.44 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131961525 chr14:28264390~28265974:+ LIHC trans rs9876781 0.933 rs6442124 ENSG00000235912.1 RP1-159A19.3 -7.44 8.04e-13 2.58e-06 -0.42 -0.37 Longevity; chr3:48463903 chr1:27649419~27649610:+ LIHC trans rs5022636 0.533 rs4971029 ENSG00000180764.13 PIPSL 7.44 8.12e-13 2.61e-06 0.38 0.37 Gut microbiota (functional units); chr1:151304783 chr10:93958191~93961540:- LIHC trans rs5022636 0.507 rs2031797 ENSG00000180764.13 PIPSL 7.44 8.12e-13 2.61e-06 0.38 0.37 Gut microbiota (functional units); chr1:151306029 chr10:93958191~93961540:- LIHC trans rs9611565 0.918 rs2281333 ENSG00000268568.1 AC007228.9 -7.44 8.44e-13 2.71e-06 -0.47 -0.37 Vitiligo; chr22:41353626 chr19:56672574~56673901:- LIHC trans rs9876781 1 rs9876781 ENSG00000235912.1 RP1-159A19.3 -7.43 8.68e-13 2.78e-06 -0.42 -0.37 Longevity; chr3:48445934 chr1:27649419~27649610:+ LIHC trans rs10870270 0.917 rs11146417 ENSG00000197358.9 BNIP3P1 7.43 8.73e-13 2.8e-06 0.45 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131977530 chr14:28264390~28265974:+ LIHC trans rs10870270 0.957 rs3753008 ENSG00000197358.9 BNIP3P1 7.43 8.76e-13 2.81e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131971625 chr14:28264390~28265974:+ LIHC trans rs55665837 0.54 rs3206554 ENSG00000236360.2 RP11-334A14.2 7.43 8.79e-13 2.81e-06 0.47 0.37 Vitamin D levels; chr11:14776399 chr1:52993201~52993702:- LIHC trans rs77954165 0.568 rs1133678 ENSG00000215210.3 RBMXP2 7.43 8.99e-13 2.87e-06 0.49 0.37 Stem cell growth factor beta levels; chr9:6717941 chr9:30689105~30690272:+ LIHC trans rs77954165 0.568 rs1133680 ENSG00000215210.3 RBMXP2 7.43 8.99e-13 2.87e-06 0.49 0.37 Stem cell growth factor beta levels; chr9:6718141 chr9:30689105~30690272:+ LIHC trans rs877636 0.702 rs773109 ENSG00000212994.5 RPS26P6 7.42 9.25e-13 2.94e-06 0.5 0.37 Cognitive function; chr12:55980911 chr8:100895771~100896118:+ LIHC trans rs2657294 0.734 rs10740449 ENSG00000172974.11 AC007318.5 7.42 9.36e-13 2.98e-06 0.39 0.37 Pneumonia; chr10:75086620 chr2:65205108~65205988:+ LIHC trans rs55665837 0.54 rs7938266 ENSG00000236360.2 RP11-334A14.2 7.42 9.43e-13 3e-06 0.47 0.37 Vitamin D levels; chr11:14687778 chr1:52993201~52993702:- LIHC trans rs6477998 0.702 rs7861707 ENSG00000238072.1 RP11-305M3.2 7.41 9.66e-13 3.07e-06 0.54 0.37 Hematology traits; chr9:113251428 chr7:129410113~129410370:- LIHC trans rs8010715 0.848 rs2277483 ENSG00000238000.1 RP11-274E7.2 7.41 9.72e-13 3.08e-06 0.43 0.37 IgG glycosylation; chr14:24122683 chr5:98213402~98214121:+ LIHC trans rs8010715 0.848 rs8009511 ENSG00000238000.1 RP11-274E7.2 7.41 9.72e-13 3.08e-06 0.43 0.37 IgG glycosylation; chr14:24124771 chr5:98213402~98214121:+ LIHC trans rs8010715 0.804 rs1134334 ENSG00000238000.1 RP11-274E7.2 7.41 9.72e-13 3.08e-06 0.43 0.37 IgG glycosylation; chr14:24124905 chr5:98213402~98214121:+ LIHC trans rs9425766 0.962 rs1322777 ENSG00000213331.4 RP11-713C19.2 7.41 9.78e-13 3.1e-06 0.46 0.37 Life satisfaction; chr1:173889962 chr4:187970273~187971284:+ LIHC trans rs7662987 1 rs6852848 ENSG00000228407.2 RP4-800M22.1 -7.41 9.8e-13 3.11e-06 -1.02 -0.37 Smoking initiation; chr4:99080781 chr1:52160261~52160600:- LIHC trans rs10870270 1 rs10870292 ENSG00000197358.9 BNIP3P1 7.4 1.03e-12 3.27e-06 0.44 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131957278 chr14:28264390~28265974:+ LIHC trans rs9425766 0.924 rs9286895 ENSG00000213331.4 RP11-713C19.2 7.4 1.04e-12 3.31e-06 0.45 0.37 Life satisfaction; chr1:173873329 chr4:187970273~187971284:+ LIHC trans rs77954165 0.568 rs12352193 ENSG00000215210.3 RBMXP2 7.4 1.07e-12 3.39e-06 0.49 0.37 Stem cell growth factor beta levels; chr9:6725319 chr9:30689105~30690272:+ LIHC trans rs9425766 0.886 rs9661233 ENSG00000213331.4 RP11-713C19.2 7.4 1.08e-12 3.41e-06 0.45 0.37 Life satisfaction; chr1:173874913 chr4:187970273~187971284:+ LIHC trans rs6477998 0.676 rs4979225 ENSG00000238072.1 RP11-305M3.2 7.4 1.09e-12 3.43e-06 0.55 0.37 Hematology traits; chr9:113225130 chr7:129410113~129410370:- LIHC trans rs5022636 0.964 rs1056847 ENSG00000180764.13 PIPSL 7.4 1.09e-12 3.44e-06 0.35 0.37 Gut microbiota (functional units); chr1:151315696 chr10:93958191~93961540:- LIHC trans rs7554547 0.69 rs12087996 ENSG00000261819.1 RP11-680G24.4 7.39 1.11e-12 3.5e-06 0.49 0.37 Nonsyndromic cleft lip with cleft palate; chr1:11897152 chr16:14988259~14990160:- LIHC trans rs864643 0.836 rs1708009 ENSG00000183298.5 RP11-556K13.1 7.39 1.14e-12 3.59e-06 0.52 0.37 Attention deficit hyperactivity disorder; chr3:39496851 chr1:101786340~101787219:- LIHC trans rs2657294 0.646 rs10762656 ENSG00000172974.11 AC007318.5 7.39 1.14e-12 3.6e-06 0.39 0.37 Pneumonia; chr10:75085706 chr2:65205108~65205988:+ LIHC trans rs916888 0.821 rs199513 ENSG00000280022.1 RP11-707O23.1 -7.39 1.16e-12 3.68e-06 -0.61 -0.37 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:45592621~45593369:+ LIHC trans rs77954165 0.568 rs7023651 ENSG00000215210.3 RBMXP2 7.38 1.2e-12 3.79e-06 0.49 0.37 Stem cell growth factor beta levels; chr9:6719060 chr9:30689105~30690272:+ LIHC trans rs77954165 0.568 rs4237167 ENSG00000215210.3 RBMXP2 7.38 1.2e-12 3.79e-06 0.49 0.37 Stem cell growth factor beta levels; chr9:6719456 chr9:30689105~30690272:+ LIHC trans rs864643 0.898 rs1473864 ENSG00000183298.5 RP11-556K13.1 7.38 1.21e-12 3.8e-06 0.51 0.37 Attention deficit hyperactivity disorder; chr3:39499703 chr1:101786340~101787219:- LIHC trans rs9467773 0.935 rs1056668 ENSG00000242375.1 RP11-498P14.3 7.38 1.21e-12 3.8e-06 0.43 0.37 Intelligence (multi-trait analysis); chr6:26510377 chr9:97195351~97197687:- LIHC trans rs7554547 0.667 rs12567187 ENSG00000261819.1 RP11-680G24.4 7.38 1.21e-12 3.81e-06 0.48 0.37 Nonsyndromic cleft lip with cleft palate; chr1:11896095 chr16:14988259~14990160:- LIHC trans rs877636 1 rs4759229 ENSG00000212994.5 RPS26P6 -7.38 1.21e-12 3.81e-06 -0.49 -0.37 Cognitive function; chr12:56080696 chr8:100895771~100896118:+ LIHC trans rs4646450 0.636 rs2003499 ENSG00000228834.1 RP11-249L21.4 7.38 1.23e-12 3.88e-06 0.72 0.37 Blood metabolite levels; chr7:99417361 chr6:108907615~108907873:- LIHC trans rs877636 0.702 rs773110 ENSG00000212994.5 RPS26P6 7.37 1.27e-12 4e-06 0.49 0.37 Cognitive function; chr12:55981353 chr8:100895771~100896118:+ LIHC trans rs3740713 1 rs73438690 ENSG00000235847.2 LDHAP7 7.37 1.29e-12 4.04e-06 0.66 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18439667 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73438695 ENSG00000235847.2 LDHAP7 7.37 1.29e-12 4.04e-06 0.66 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18440554 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73440606 ENSG00000235847.2 LDHAP7 7.37 1.29e-12 4.04e-06 0.66 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18442573 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73440615 ENSG00000235847.2 LDHAP7 7.37 1.29e-12 4.04e-06 0.66 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18445736 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs76062966 ENSG00000235847.2 LDHAP7 7.37 1.31e-12 4.11e-06 0.66 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18440857 chr2:84777259~84778223:- LIHC trans rs77954165 0.568 rs1052489 ENSG00000215210.3 RBMXP2 7.37 1.32e-12 4.13e-06 0.49 0.37 Stem cell growth factor beta levels; chr9:6723861 chr9:30689105~30690272:+ LIHC trans rs9425766 0.962 rs941989 ENSG00000213331.4 RP11-713C19.2 -7.37 1.33e-12 4.18e-06 -0.46 -0.37 Life satisfaction; chr1:173912733 chr4:187970273~187971284:+ LIHC trans rs10870270 1 rs11146354 ENSG00000197358.9 BNIP3P1 7.36 1.35e-12 4.23e-06 0.44 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131961253 chr14:28264390~28265974:+ LIHC trans rs877636 0.702 rs773111 ENSG00000212994.5 RPS26P6 7.36 1.36e-12 4.26e-06 0.49 0.37 Cognitive function; chr12:55981956 chr8:100895771~100896118:+ LIHC trans rs55665837 0.54 rs12290926 ENSG00000236360.2 RP11-334A14.2 7.36 1.38e-12 4.32e-06 0.47 0.37 Vitamin D levels; chr11:14673500 chr1:52993201~52993702:- LIHC trans rs538867 1 rs1707954 ENSG00000214263.2 RPSAP53 7.36 1.41e-12 4.39e-06 0.83 0.37 Alzheimer's disease (cognitive decline); chr3:39483681 chr13:67266845~67267706:- LIHC trans rs9876781 1 rs2242150 ENSG00000235912.1 RP1-159A19.3 7.35 1.43e-12 4.47e-06 0.42 0.37 Longevity; chr3:48464565 chr1:27649419~27649610:+ LIHC trans rs9467773 0.838 rs3734540 ENSG00000242375.1 RP11-498P14.3 7.35 1.44e-12 4.49e-06 0.43 0.37 Intelligence (multi-trait analysis); chr6:26463093 chr9:97195351~97197687:- LIHC trans rs10870270 0.83 rs11146269 ENSG00000197358.9 BNIP3P1 7.35 1.46e-12 4.54e-06 0.44 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131948316 chr14:28264390~28265974:+ LIHC trans rs877636 0.74 rs705702 ENSG00000212994.5 RPS26P6 -7.35 1.5e-12 4.67e-06 -0.49 -0.37 Cognitive function; chr12:55996852 chr8:100895771~100896118:+ LIHC trans rs4263408 0.967 rs4974948 ENSG00000237550.5 UBE2Q2P6 7.35 1.52e-12 4.72e-06 0.42 0.37 Plasma amyloid beta peptide concentrations (ABx-40); chr4:39751016 chr15:82372196~82372912:- LIHC trans rs916888 0.61 rs142167 ENSG00000264070.1 DND1P1 -7.34 1.53e-12 4.76e-06 -0.43 -0.37 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:45585871~45586929:+ LIHC trans rs10870270 1 rs4880250 ENSG00000197358.9 BNIP3P1 7.34 1.54e-12 4.8e-06 0.44 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131960415 chr14:28264390~28265974:+ LIHC trans rs2657294 0.674 rs10824268 ENSG00000172974.11 AC007318.5 7.34 1.54e-12 4.8e-06 0.39 0.37 Pneumonia; chr10:75085937 chr2:65205108~65205988:+ LIHC trans rs77954165 0.568 rs4740854 ENSG00000215210.3 RBMXP2 7.34 1.58e-12 4.9e-06 0.49 0.37 Stem cell growth factor beta levels; chr9:6717628 chr9:30689105~30690272:+ LIHC trans rs77954165 0.73 rs72697555 ENSG00000215210.3 RBMXP2 7.34 1.58e-12 4.91e-06 0.49 0.37 Stem cell growth factor beta levels; chr9:6720077 chr9:30689105~30690272:+ LIHC trans rs916888 0.821 rs199506 ENSG00000280022.1 RP11-707O23.1 -7.34 1.59e-12 4.94e-06 -0.63 -0.37 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45592621~45593369:+ LIHC trans rs9611565 0.921 rs2281332 ENSG00000268568.1 AC007228.9 -7.34 1.6e-12 4.95e-06 -0.46 -0.37 Vitiligo; chr22:41350208 chr19:56672574~56673901:- LIHC trans rs55665837 0.701 rs1522633 ENSG00000236360.2 RP11-334A14.2 7.34 1.61e-12 4.99e-06 0.47 0.37 Vitamin D levels; chr11:14623692 chr1:52993201~52993702:- LIHC trans rs58106596 0.66 rs13398149 ENSG00000259020.3 RP11-529H20.3 7.33 1.63e-12 5.07e-06 0.48 0.37 Lymphocyte counts;White blood cell count; chr2:231700171 chr14:92026566~92026887:+ LIHC trans rs9611565 0.921 rs2235846 ENSG00000268568.1 AC007228.9 -7.33 1.65e-12 5.11e-06 -0.46 -0.37 Vitiligo; chr22:41345038 chr19:56672574~56673901:- LIHC trans rs9611565 0.921 rs5751081 ENSG00000268568.1 AC007228.9 -7.33 1.65e-12 5.11e-06 -0.46 -0.37 Vitiligo; chr22:41346784 chr19:56672574~56673901:- LIHC trans rs877636 0.702 rs773112 ENSG00000212994.5 RPS26P6 7.33 1.66e-12 5.14e-06 0.49 0.37 Cognitive function; chr12:55982097 chr8:100895771~100896118:+ LIHC trans rs10870270 0.956 rs6557 ENSG00000197358.9 BNIP3P1 7.32 1.76e-12 5.44e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131967945 chr14:28264390~28265974:+ LIHC trans rs10870270 0.913 rs4550 ENSG00000197358.9 BNIP3P1 7.32 1.76e-12 5.44e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131968294 chr14:28264390~28265974:+ LIHC trans rs10870270 0.957 rs10870307 ENSG00000197358.9 BNIP3P1 7.32 1.78e-12 5.5e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131967106 chr14:28264390~28265974:+ LIHC trans rs864643 1 rs1768127 ENSG00000183298.5 RP11-556K13.1 7.32 1.78e-12 5.5e-06 0.53 0.37 Attention deficit hyperactivity disorder; chr3:39523790 chr1:101786340~101787219:- LIHC trans rs864643 1 rs2542 ENSG00000183298.5 RP11-556K13.1 7.32 1.78e-12 5.5e-06 0.53 0.37 Attention deficit hyperactivity disorder; chr3:39525858 chr1:101786340~101787219:- LIHC trans rs864643 0.891 rs816518 ENSG00000183298.5 RP11-556K13.1 7.32 1.78e-12 5.5e-06 0.53 0.37 Attention deficit hyperactivity disorder; chr3:39527559 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1615844 ENSG00000183298.5 RP11-556K13.1 7.32 1.78e-12 5.5e-06 0.53 0.37 Attention deficit hyperactivity disorder; chr3:39532375 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1513216 ENSG00000183298.5 RP11-556K13.1 7.32 1.78e-12 5.5e-06 0.53 0.37 Attention deficit hyperactivity disorder; chr3:39532651 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1768134 ENSG00000183298.5 RP11-556K13.1 7.32 1.78e-12 5.5e-06 0.53 0.37 Attention deficit hyperactivity disorder; chr3:39533080 chr1:101786340~101787219:- LIHC trans rs864643 0.891 rs1624647 ENSG00000183298.5 RP11-556K13.1 7.32 1.78e-12 5.5e-06 0.53 0.37 Attention deficit hyperactivity disorder; chr3:39533558 chr1:101786340~101787219:- LIHC trans rs877636 0.847 rs705704 ENSG00000212994.5 RPS26P6 7.32 1.83e-12 5.62e-06 0.5 0.37 Cognitive function; chr12:56041628 chr8:100895771~100896118:+ LIHC trans rs8067354 0.574 rs2526354 ENSG00000187870.7 RNFT1P3 7.31 1.87e-12 5.74e-06 0.45 0.37 Hemoglobin concentration; chr17:59899297 chr17:20743333~20754501:- LIHC trans rs4263408 1 rs13122400 ENSG00000237550.5 UBE2Q2P6 7.31 1.89e-12 5.81e-06 0.42 0.37 Plasma amyloid beta peptide concentrations (ABx-40); chr4:39712123 chr15:82372196~82372912:- LIHC trans rs55665837 0.701 rs2007361 ENSG00000236360.2 RP11-334A14.2 7.31 1.89e-12 5.82e-06 0.48 0.37 Vitamin D levels; chr11:14641176 chr1:52993201~52993702:- LIHC trans rs10870270 1 rs72636963 ENSG00000197358.9 BNIP3P1 7.31 1.91e-12 5.87e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131957767 chr14:28264390~28265974:+ LIHC trans rs877636 0.74 rs772920 ENSG00000212994.5 RPS26P6 7.31 1.91e-12 5.88e-06 0.49 0.37 Cognitive function; chr12:55996580 chr8:100895771~100896118:+ LIHC trans rs538867 1 rs946410 ENSG00000214263.2 RPSAP53 7.31 1.94e-12 5.94e-06 0.83 0.37 Alzheimer's disease (cognitive decline); chr3:39469884 chr13:67266845~67267706:- LIHC trans rs10870270 1 rs7199 ENSG00000197358.9 BNIP3P1 7.31 1.94e-12 5.94e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131956344 chr14:28264390~28265974:+ LIHC trans rs864643 0.891 rs1068953 ENSG00000183298.5 RP11-556K13.1 7.3 1.99e-12 6.09e-06 0.58 0.37 Attention deficit hyperactivity disorder; chr3:39515070 chr1:101786340~101787219:- LIHC trans rs10870270 1 rs4880246 ENSG00000197358.9 BNIP3P1 7.3 2.06e-12 6.32e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131950560 chr14:28264390~28265974:+ LIHC trans rs2731664 0.721 rs2450333 ENSG00000215571.5 GRK6P1 7.3 2.07e-12 6.34e-06 0.46 0.37 Intelligence (multi-trait analysis); chr5:177472545 chr13:21319156~21320866:+ LIHC trans rs10870270 0.956 rs10870293 ENSG00000197358.9 BNIP3P1 7.29 2.1e-12 6.43e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131957909 chr14:28264390~28265974:+ LIHC trans rs3740713 1 rs73438699 ENSG00000235847.2 LDHAP7 7.29 2.11e-12 6.44e-06 0.65 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18441137 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73440604 ENSG00000235847.2 LDHAP7 7.29 2.11e-12 6.44e-06 0.65 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18442124 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73440610 ENSG00000235847.2 LDHAP7 7.29 2.11e-12 6.44e-06 0.65 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18442922 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs75740864 ENSG00000235847.2 LDHAP7 7.29 2.11e-12 6.44e-06 0.65 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18449142 chr2:84777259~84778223:- LIHC trans rs9876781 1 rs7651407 ENSG00000235912.1 RP1-159A19.3 -7.29 2.12e-12 6.47e-06 -0.42 -0.37 Longevity; chr3:48402409 chr1:27649419~27649610:+ LIHC trans rs10870270 0.956 rs10870281 ENSG00000197358.9 BNIP3P1 7.29 2.12e-12 6.47e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131949138 chr14:28264390~28265974:+ LIHC trans rs10870270 1 rs11146324 ENSG00000197358.9 BNIP3P1 7.29 2.12e-12 6.47e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131953941 chr14:28264390~28265974:+ LIHC trans rs10870270 0.956 rs11146325 ENSG00000197358.9 BNIP3P1 7.29 2.12e-12 6.47e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131954025 chr14:28264390~28265974:+ LIHC trans rs10870270 1 rs7077744 ENSG00000197358.9 BNIP3P1 7.29 2.12e-12 6.47e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131956697 chr14:28264390~28265974:+ LIHC trans rs10870270 1 rs11146338 ENSG00000197358.9 BNIP3P1 7.29 2.12e-12 6.47e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131956787 chr14:28264390~28265974:+ LIHC trans rs3740713 1 rs73438697 ENSG00000235847.2 LDHAP7 7.29 2.13e-12 6.52e-06 0.65 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18440830 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs114330751 ENSG00000235847.2 LDHAP7 7.29 2.13e-12 6.52e-06 0.65 0.37 Amyotrophic lateral sclerosis (sporadic); chr11:18440928 chr2:84777259~84778223:- LIHC trans rs3002142 0.658 rs3008634 ENSG00000219201.4 RP11-181C21.4 7.29 2.17e-12 6.63e-06 0.4 0.37 LDL peak particle diameter (total fat intake interaction); chr1:222672069 chr1:77810861~77811781:- LIHC trans rs4263408 1 rs7656037 ENSG00000237550.5 UBE2Q2P6 7.29 2.18e-12 6.65e-06 0.42 0.37 Plasma amyloid beta peptide concentrations (ABx-40); chr4:39716345 chr15:82372196~82372912:- LIHC trans rs9876781 1 rs922075 ENSG00000235912.1 RP1-159A19.3 7.29 2.21e-12 6.75e-06 0.42 0.37 Longevity; chr3:48447994 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs2045554 ENSG00000235912.1 RP1-159A19.3 7.29 2.21e-12 6.75e-06 0.42 0.37 Longevity; chr3:48453142 chr1:27649419~27649610:+ LIHC trans rs77954165 0.568 rs6477104 ENSG00000215210.3 RBMXP2 7.28 2.25e-12 6.84e-06 0.48 0.37 Stem cell growth factor beta levels; chr9:6722393 chr9:30689105~30690272:+ LIHC trans rs4784054 0.667 rs11864685 ENSG00000233719.3 GOT2P3 -7.28 2.25e-12 6.86e-06 -0.45 -0.37 Blood metabolite levels; chr16:58771226 chr12:9641802~9643007:+ LIHC trans rs10870270 0.956 rs7894 ENSG00000197358.9 BNIP3P1 7.28 2.3e-12 6.99e-06 0.43 0.37 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131955978 chr14:28264390~28265974:+ LIHC trans rs3849046 0.79 rs188731 ENSG00000226666.1 HSPA9P1 7.28 2.37e-12 7.2e-06 0.43 0.37 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138545415 chr2:221961737~221963765:+ LIHC trans rs3849046 0.619 rs181919 ENSG00000226666.1 HSPA9P1 7.28 2.37e-12 7.2e-06 0.43 0.37 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138546923 chr2:221961737~221963765:+ LIHC trans rs3849046 0.875 rs255999 ENSG00000226666.1 HSPA9P1 7.28 2.37e-12 7.2e-06 0.43 0.37 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138554110 chr2:221961737~221963765:+ LIHC trans rs3849046 0.846 rs10117 ENSG00000226666.1 HSPA9P1 7.28 2.37e-12 7.2e-06 0.43 0.37 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138556481 chr2:221961737~221963765:+ LIHC trans rs55665837 0.701 rs10766188 ENSG00000236360.2 RP11-334A14.2 7.27 2.4e-12 7.27e-06 0.47 0.37 Vitamin D levels; chr11:14639280 chr1:52993201~52993702:- LIHC trans rs7568458 0.905 rs10198569 ENSG00000223886.3 RP11-251G23.2 -7.27 2.4e-12 7.29e-06 -0.41 -0.37 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85567292 chr7:105530209~105530671:+ LIHC trans rs2731664 0.792 rs2630763 ENSG00000215571.5 GRK6P1 7.27 2.45e-12 7.42e-06 0.46 0.37 Intelligence (multi-trait analysis); chr5:177474004 chr13:21319156~21320866:+ LIHC trans rs77954165 0.614 rs7028933 ENSG00000215210.3 RBMXP2 7.27 2.45e-12 7.43e-06 0.48 0.37 Stem cell growth factor beta levels; chr9:6722942 chr9:30689105~30690272:+ LIHC trans rs77954165 0.667 rs7036678 ENSG00000215210.3 RBMXP2 7.26 2.55e-12 7.69e-06 0.48 0.37 Stem cell growth factor beta levels; chr9:6720682 chr9:30689105~30690272:+ LIHC trans rs77954165 0.568 rs7019696 ENSG00000215210.3 RBMXP2 7.26 2.59e-12 7.8e-06 0.48 0.37 Stem cell growth factor beta levels; chr9:6720584 chr9:30689105~30690272:+ LIHC trans rs77954165 0.614 rs7039865 ENSG00000215210.3 RBMXP2 7.26 2.59e-12 7.8e-06 0.48 0.37 Stem cell growth factor beta levels; chr9:6720677 chr9:30689105~30690272:+ LIHC trans rs7312770 0.637 rs705699 ENSG00000234513.1 AC073072.7 7.26 2.7e-12 8.11e-06 0.46 0.37 Polycystic ovary syndrome;Hypothyroidism; chr12:55991020 chr7:22773646~22773993:- LIHC trans rs72615157 0.634 rs11762932 ENSG00000228546.2 CTA-313A17.3 -7.26 2.71e-12 8.14e-06 -0.56 -0.37 Lung function (FEV1/FVC); chr7:100195043 chr7:102337316~102339115:+ LIHC trans rs9876781 1 rs11130170 ENSG00000235912.1 RP1-159A19.3 -7.25 2.72e-12 8.17e-06 -0.42 -0.37 Longevity; chr3:48408490 chr1:27649419~27649610:+ LIHC trans rs864643 1 rs1708055 ENSG00000183298.5 RP11-556K13.1 7.25 2.87e-12 8.61e-06 0.58 0.36 Attention deficit hyperactivity disorder; chr3:39531672 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1615046 ENSG00000183298.5 RP11-556K13.1 7.25 2.87e-12 8.61e-06 0.58 0.36 Attention deficit hyperactivity disorder; chr3:39532309 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1615994 ENSG00000183298.5 RP11-556K13.1 7.25 2.87e-12 8.61e-06 0.58 0.36 Attention deficit hyperactivity disorder; chr3:39532428 chr1:101786340~101787219:- LIHC trans rs4263408 0.935 rs62310123 ENSG00000237550.5 UBE2Q2P6 7.24 2.9e-12 8.69e-06 0.41 0.36 Plasma amyloid beta peptide concentrations (ABx-40); chr4:39744462 chr15:82372196~82372912:- LIHC trans rs7554547 0.791 rs1321072 ENSG00000261819.1 RP11-680G24.4 7.24 2.91e-12 8.72e-06 0.48 0.36 Nonsyndromic cleft lip with cleft palate; chr1:11891261 chr16:14988259~14990160:- LIHC trans rs10917477 0.594 rs2792043 ENSG00000224237.1 MINOS1P3 7.24 2.94e-12 8.81e-06 0.45 0.36 Thyroid function; chr1:19598168 chr3:27214816~27215018:- LIHC trans rs864643 1 rs816494 ENSG00000183298.5 RP11-556K13.1 7.24 2.95e-12 8.83e-06 0.57 0.36 Attention deficit hyperactivity disorder; chr3:39515354 chr1:101786340~101787219:- LIHC trans rs10037055 0.853 rs10077929 ENSG00000226986.4 RP11-543B16.2 7.24 3.03e-12 9.04e-06 0.38 0.36 Migraine without aura; chr5:177270843 chr1:211207239~211207897:+ LIHC trans rs538867 1 rs1768141 ENSG00000214263.2 RPSAP53 7.23 3.08e-12 9.2e-06 0.76 0.36 Alzheimer's disease (cognitive decline); chr3:39548800 chr13:67266845~67267706:- LIHC trans rs4240897 0.835 rs4845891 ENSG00000261819.1 RP11-680G24.4 7.23 3.13e-12 9.31e-06 0.47 0.36 Tuberculosis; chr1:11982449 chr16:14988259~14990160:- LIHC trans rs916888 0.738 rs199515 ENSG00000280022.1 RP11-707O23.1 -7.23 3.18e-12 9.45e-06 -0.59 -0.36 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:45592621~45593369:+ LIHC trans rs4263408 0.934 rs4975036 ENSG00000237550.5 UBE2Q2P6 7.23 3.24e-12 9.64e-06 0.42 0.36 Plasma amyloid beta peptide concentrations (ABx-40); chr4:39713470 chr15:82372196~82372912:- LIHC trans rs9876781 0.872 rs11797 ENSG00000235912.1 RP1-159A19.3 -7.23 3.24e-12 9.65e-06 -0.43 -0.36 Longevity; chr3:48467186 chr1:27649419~27649610:+ LIHC trans rs877636 0.884 rs705705 ENSG00000212994.5 RPS26P6 7.23 3.25e-12 9.66e-06 0.49 0.36 Cognitive function; chr12:56041720 chr8:100895771~100896118:+ LIHC trans rs9611565 0.921 rs5751080 ENSG00000268568.1 AC007228.9 -7.23 3.28e-12 9.76e-06 -0.45 -0.36 Vitiligo; chr22:41340263 chr19:56672574~56673901:- LIHC trans rs864643 1 rs1340225 ENSG00000183298.5 RP11-556K13.1 7.22 3.35e-12 9.96e-06 0.53 0.36 Attention deficit hyperactivity disorder; chr3:39533951 chr1:101786340~101787219:- LIHC trans rs877636 0.859 rs3741499 ENSG00000212994.5 RPS26P6 -7.21 3.5e-12 1.04e-05 -0.48 -0.36 Cognitive function; chr12:56080595 chr8:100895771~100896118:+ LIHC trans rs55665837 0.701 rs11023272 ENSG00000236360.2 RP11-334A14.2 7.21 3.53e-12 1.05e-05 0.47 0.36 Vitamin D levels; chr11:14608824 chr1:52993201~52993702:- LIHC trans rs7312770 0.637 rs705700 ENSG00000234513.1 AC073072.7 7.21 3.59e-12 1.06e-05 0.45 0.36 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr7:22773646~22773993:- LIHC trans rs55665837 0.665 rs11023273 ENSG00000236360.2 RP11-334A14.2 7.21 3.59e-12 1.06e-05 0.47 0.36 Vitamin D levels; chr11:14609273 chr1:52993201~52993702:- LIHC trans rs77954165 0.568 rs7040131 ENSG00000215210.3 RBMXP2 -7.21 3.64e-12 1.08e-05 -0.47 -0.36 Stem cell growth factor beta levels; chr9:6720831 chr9:30689105~30690272:+ LIHC trans rs864643 1 rs559349 ENSG00000183298.5 RP11-556K13.1 7.21 3.7e-12 1.1e-05 0.57 0.36 Attention deficit hyperactivity disorder; chr3:39505562 chr1:101786340~101787219:- LIHC trans rs9611565 0.877 rs3817999 ENSG00000268568.1 AC007228.9 7.2 3.74e-12 1.1e-05 0.45 0.36 Vitiligo; chr22:41351713 chr19:56672574~56673901:- LIHC trans rs7568458 0.837 rs12714145 ENSG00000223886.3 RP11-251G23.2 7.2 3.75e-12 1.11e-05 0.41 0.36 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85560218 chr7:105530209~105530671:+ LIHC trans rs877636 0.692 rs11171739 ENSG00000234513.1 AC073072.7 7.2 3.85e-12 1.14e-05 0.44 0.36 Cognitive function; chr12:56076841 chr7:22773646~22773993:- LIHC trans rs3849046 0.817 rs4835687 ENSG00000226666.1 HSPA9P1 -7.2 3.88e-12 1.15e-05 -0.43 -0.36 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138536367 chr2:221961737~221963765:+ LIHC trans rs3849046 0.846 rs154076 ENSG00000226666.1 HSPA9P1 -7.2 3.94e-12 1.16e-05 -0.43 -0.36 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138527445 chr2:221961737~221963765:+ LIHC trans rs7554547 0.69 rs7516708 ENSG00000261819.1 RP11-680G24.4 7.19 4.03e-12 1.19e-05 0.47 0.36 Nonsyndromic cleft lip with cleft palate; chr1:11890148 chr16:14988259~14990160:- LIHC trans rs7554547 0.739 rs4846073 ENSG00000261819.1 RP11-680G24.4 7.19 4.03e-12 1.19e-05 0.47 0.36 Nonsyndromic cleft lip with cleft palate; chr1:11890521 chr16:14988259~14990160:- LIHC trans rs7554547 0.765 rs57176983 ENSG00000261819.1 RP11-680G24.4 7.19 4.05e-12 1.19e-05 0.47 0.36 Nonsyndromic cleft lip with cleft palate; chr1:11891041 chr16:14988259~14990160:- LIHC trans rs877636 0.702 rs61937249 ENSG00000212994.5 RPS26P6 7.19 4.1e-12 1.21e-05 0.49 0.36 Cognitive function; chr12:55988132 chr8:100895771~100896118:+ LIHC trans rs877636 0.702 rs773108 ENSG00000212994.5 RPS26P6 7.19 4.2e-12 1.23e-05 0.49 0.36 Cognitive function; chr12:55976127 chr8:100895771~100896118:+ LIHC trans rs9425766 0.962 rs9425430 ENSG00000213331.4 RP11-713C19.2 7.19 4.21e-12 1.24e-05 0.45 0.36 Life satisfaction; chr1:173888145 chr4:187970273~187971284:+ LIHC trans rs4784054 0.568 rs7193640 ENSG00000230849.2 GOT2P2 7.19 4.21e-12 1.24e-05 0.45 0.36 Blood metabolite levels; chr16:58785816 chr1:173141100~173142350:- LIHC trans rs4784054 0.568 rs35512562 ENSG00000230849.2 GOT2P2 7.19 4.22e-12 1.24e-05 0.45 0.36 Blood metabolite levels; chr16:58805641 chr1:173141100~173142350:- LIHC trans rs7662987 1 rs6852848 ENSG00000233859.2 ADH5P4 -7.18 4.28e-12 1.26e-05 -0.83 -0.36 Smoking initiation; chr4:99080781 chr6:65836930~65838039:- LIHC trans rs875971 0.545 rs10261710 ENSG00000164669.11 INTS4P1 -7.18 4.38e-12 1.29e-05 -0.49 -0.36 Aortic root size; chr7:66249202 chr7:65141225~65234216:+ LIHC trans rs10870270 0.913 rs115236491 ENSG00000197358.9 BNIP3P1 7.18 4.39e-12 1.29e-05 0.43 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131953351 chr14:28264390~28265974:+ LIHC trans rs4263408 1 rs7661070 ENSG00000237550.5 UBE2Q2P6 7.18 4.42e-12 1.3e-05 0.41 0.36 Plasma amyloid beta peptide concentrations (ABx-40); chr4:39722745 chr15:82372196~82372912:- LIHC trans rs3740713 1 rs35593189 ENSG00000235847.2 LDHAP7 7.18 4.48e-12 1.31e-05 0.66 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18446831 chr2:84777259~84778223:- LIHC trans rs55665837 0.701 rs11023265 ENSG00000236360.2 RP11-334A14.2 7.17 4.61e-12 1.35e-05 0.47 0.36 Vitamin D levels; chr11:14594492 chr1:52993201~52993702:- LIHC trans rs55665837 0.701 rs10160597 ENSG00000236360.2 RP11-334A14.2 7.17 4.62e-12 1.35e-05 0.47 0.36 Vitamin D levels; chr11:14582446 chr1:52993201~52993702:- LIHC trans rs864643 0.678 rs1768244 ENSG00000183298.5 RP11-556K13.1 7.17 4.69e-12 1.37e-05 0.5 0.36 Attention deficit hyperactivity disorder; chr3:39500688 chr1:101786340~101787219:- LIHC trans rs7554547 0.791 rs57678332 ENSG00000261819.1 RP11-680G24.4 7.17 4.74e-12 1.38e-05 0.47 0.36 Nonsyndromic cleft lip with cleft palate; chr1:11890834 chr16:14988259~14990160:- LIHC trans rs9425766 0.962 rs6663875 ENSG00000213331.4 RP11-713C19.2 7.17 4.81e-12 1.4e-05 0.43 0.36 Life satisfaction; chr1:173894071 chr4:187970273~187971284:+ LIHC trans rs864643 1 rs634338 ENSG00000183298.5 RP11-556K13.1 7.16 4.88e-12 1.42e-05 0.51 0.36 Attention deficit hyperactivity disorder; chr3:39522752 chr1:101786340~101787219:- LIHC trans rs55665837 0.701 rs11023278 ENSG00000236360.2 RP11-334A14.2 7.16 4.95e-12 1.44e-05 0.47 0.36 Vitamin D levels; chr11:14619638 chr1:52993201~52993702:- LIHC trans rs7554547 0.765 rs4845886 ENSG00000261819.1 RP11-680G24.4 7.16 4.95e-12 1.44e-05 0.47 0.36 Nonsyndromic cleft lip with cleft palate; chr1:11888603 chr16:14988259~14990160:- LIHC trans rs7554547 0.791 rs4846069 ENSG00000261819.1 RP11-680G24.4 7.16 4.95e-12 1.44e-05 0.47 0.36 Nonsyndromic cleft lip with cleft palate; chr1:11888974 chr16:14988259~14990160:- LIHC trans rs7554547 0.791 rs11121837 ENSG00000261819.1 RP11-680G24.4 7.16 4.95e-12 1.44e-05 0.47 0.36 Nonsyndromic cleft lip with cleft palate; chr1:11889414 chr16:14988259~14990160:- LIHC trans rs7554547 0.765 rs4846070 ENSG00000261819.1 RP11-680G24.4 7.16 4.95e-12 1.44e-05 0.47 0.36 Nonsyndromic cleft lip with cleft palate; chr1:11889464 chr16:14988259~14990160:- LIHC trans rs7554547 0.739 rs61527718 ENSG00000261819.1 RP11-680G24.4 7.16 4.95e-12 1.44e-05 0.47 0.36 Nonsyndromic cleft lip with cleft palate; chr1:11889583 chr16:14988259~14990160:- LIHC trans rs7554547 0.714 rs4846071 ENSG00000261819.1 RP11-680G24.4 7.16 4.95e-12 1.44e-05 0.47 0.36 Nonsyndromic cleft lip with cleft palate; chr1:11889612 chr16:14988259~14990160:- LIHC trans rs864643 0.945 rs1768254 ENSG00000183298.5 RP11-556K13.1 7.16 4.97e-12 1.45e-05 0.57 0.36 Attention deficit hyperactivity disorder; chr3:39506929 chr1:101786340~101787219:- LIHC trans rs4240897 0.935 rs2236055 ENSG00000261819.1 RP11-680G24.4 7.16 5.07e-12 1.47e-05 0.46 0.36 Tuberculosis; chr1:11982204 chr16:14988259~14990160:- LIHC trans rs864643 1 rs1707973 ENSG00000183298.5 RP11-556K13.1 7.15 5.21e-12 1.51e-05 0.57 0.36 Attention deficit hyperactivity disorder; chr3:39507275 chr1:101786340~101787219:- LIHC trans rs864643 1 rs816490 ENSG00000183298.5 RP11-556K13.1 7.15 5.21e-12 1.51e-05 0.57 0.36 Attention deficit hyperactivity disorder; chr3:39512993 chr1:101786340~101787219:- LIHC trans rs9898641 1 rs9898641 ENSG00000187870.7 RNFT1P3 7.15 5.26e-12 1.53e-05 0.41 0.36 Interleukin-1-beta levels; chr17:59493672 chr17:20743333~20754501:- LIHC trans rs8067354 0.645 rs28516945 ENSG00000187870.7 RNFT1P3 7.15 5.4e-12 1.57e-05 0.43 0.36 Hemoglobin concentration; chr17:59739217 chr17:20743333~20754501:- LIHC trans rs5022636 0.533 rs1752387 ENSG00000180764.13 PIPSL -7.15 5.4e-12 1.57e-05 -0.38 -0.36 Gut microbiota (functional units); chr1:151341903 chr10:93958191~93961540:- LIHC trans rs864643 1 rs1768252 ENSG00000183298.5 RP11-556K13.1 7.15 5.4e-12 1.57e-05 0.57 0.36 Attention deficit hyperactivity disorder; chr3:39506768 chr1:101786340~101787219:- LIHC trans rs3849046 0.846 rs462783 ENSG00000226666.1 HSPA9P1 -7.14 5.5e-12 1.59e-05 -0.43 -0.36 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138536427 chr2:221961737~221963765:+ LIHC trans rs12709013 0.716 rs6416775 ENSG00000233719.3 GOT2P3 7.14 5.54e-12 1.61e-05 0.37 0.36 Blood metabolite ratios; chr16:58830410 chr12:9641802~9643007:+ LIHC trans rs3740713 1 rs76586692 ENSG00000235847.2 LDHAP7 7.14 5.7e-12 1.65e-05 0.65 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18432179 chr2:84777259~84778223:- LIHC trans rs7568458 0.905 rs10172544 ENSG00000223886.3 RP11-251G23.2 7.13 5.83e-12 1.69e-05 0.41 0.36 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85561147 chr7:105530209~105530671:+ LIHC trans rs3740713 1 rs73436638 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18418758 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73436642 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18419088 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73436666 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18421383 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73438611 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18426129 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs2643872 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18428897 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs75381502 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18430339 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs57311859 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18432863 chr2:84777259~84778223:- LIHC trans rs3740713 0.92 rs112973292 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18434341 chr2:84777259~84778223:- LIHC trans rs3740713 0.92 rs73438656 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18434388 chr2:84777259~84778223:- LIHC trans rs3740713 0.92 rs73438659 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18434406 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73438666 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18434964 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs16935424 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18435190 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73438674 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18435342 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs78549183 ENSG00000235847.2 LDHAP7 7.13 6.1e-12 1.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18438168 chr2:84777259~84778223:- LIHC trans rs2657294 0.734 rs2894244 ENSG00000172974.11 AC007318.5 7.12 6.21e-12 1.79e-05 0.38 0.36 Pneumonia; chr10:75087112 chr2:65205108~65205988:+ LIHC trans rs76228276 0.737 rs4735642 ENSG00000260318.1 COX6CP1 7.12 6.38e-12 1.84e-05 0.96 0.36 Childhood ear infection; chr8:99746260 chr16:11903923~11904137:- LIHC trans rs12497850 0.627 rs4974078 ENSG00000197582.5 GPX1P1 7.12 6.48e-12 1.86e-05 0.55 0.36 Parkinson's disease; chr3:48971953 chrX:13378735~13379340:- LIHC trans rs10870270 1 rs10781564 ENSG00000197358.9 BNIP3P1 7.12 6.53e-12 1.88e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131944418 chr14:28264390~28265974:+ LIHC trans rs10870270 0.913 rs4880326 ENSG00000197358.9 BNIP3P1 7.12 6.53e-12 1.88e-05 0.43 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131932043 chr14:28264390~28265974:+ LIHC trans rs55665837 0.701 rs12787709 ENSG00000236360.2 RP11-334A14.2 7.11 6.66e-12 1.91e-05 0.48 0.36 Vitamin D levels; chr11:14617711 chr1:52993201~52993702:- LIHC trans rs5751901 0.614 rs5760489 ENSG00000280208.1 RP11-341D18.4 7.11 6.78e-12 1.94e-05 0.45 0.36 Protein quantitative trait loci; chr22:24594679 chr13:18253526~18270822:- LIHC trans rs7312770 0.612 rs773114 ENSG00000234513.1 AC073072.7 7.11 6.8e-12 1.95e-05 0.45 0.36 Polycystic ovary syndrome;Hypothyroidism; chr12:55985276 chr7:22773646~22773993:- LIHC trans rs11023332 0.832 rs10832289 ENSG00000236360.2 RP11-334A14.2 -7.11 6.95e-12 1.99e-05 -0.46 -0.36 Vitamin D levels;Adiponectin levels; chr11:14647950 chr1:52993201~52993702:- LIHC trans rs877636 0.692 rs10876870 ENSG00000225071.1 GS1-184P14.2 -7.1 7.05e-12 2.02e-05 -0.44 -0.36 Cognitive function; chr12:56084218 chrX:24429573~24429920:- LIHC trans rs877636 0.692 rs7971751 ENSG00000225071.1 GS1-184P14.2 -7.1 7.05e-12 2.02e-05 -0.44 -0.36 Cognitive function; chr12:56084874 chrX:24429573~24429920:- LIHC trans rs5022636 0.507 rs2800953 ENSG00000180764.13 PIPSL -7.1 7.06e-12 2.02e-05 -0.37 -0.36 Gut microbiota (functional units); chr1:151366094 chr10:93958191~93961540:- LIHC trans rs4240897 0.935 rs1474868 ENSG00000261819.1 RP11-680G24.4 -7.1 7.07e-12 2.02e-05 -0.45 -0.36 Tuberculosis; chr1:11984107 chr16:14988259~14990160:- LIHC trans rs12210905 1 rs9348752 ENSG00000242375.1 RP11-498P14.3 -7.1 7.13e-12 2.04e-05 -0.66 -0.36 Hip circumference adjusted for BMI; chr6:27107704 chr9:97195351~97197687:- LIHC trans rs9876781 1 rs10470686 ENSG00000235912.1 RP1-159A19.3 -7.1 7.15e-12 2.05e-05 -0.41 -0.36 Longevity; chr3:48408549 chr1:27649419~27649610:+ LIHC trans rs10870270 0.956 rs11146425 ENSG00000197358.9 BNIP3P1 7.1 7.23e-12 2.07e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131920757 chr14:28264390~28265974:+ LIHC trans rs10870270 0.956 rs7904594 ENSG00000197358.9 BNIP3P1 7.1 7.23e-12 2.07e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131921167 chr14:28264390~28265974:+ LIHC trans rs10870270 0.956 rs7915388 ENSG00000197358.9 BNIP3P1 7.1 7.23e-12 2.07e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131921468 chr14:28264390~28265974:+ LIHC trans rs10870270 0.912 rs7079991 ENSG00000197358.9 BNIP3P1 7.1 7.23e-12 2.07e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131922626 chr14:28264390~28265974:+ LIHC trans rs2731664 0.792 rs335420 ENSG00000215571.5 GRK6P1 -7.1 7.27e-12 2.08e-05 -0.44 -0.36 Intelligence (multi-trait analysis); chr5:177471618 chr13:21319156~21320866:+ LIHC trans rs9876781 1 rs9864371 ENSG00000235912.1 RP1-159A19.3 -7.1 7.47e-12 2.13e-05 -0.41 -0.36 Longevity; chr3:48385276 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs11712561 ENSG00000235912.1 RP1-159A19.3 -7.1 7.47e-12 2.13e-05 -0.41 -0.36 Longevity; chr3:48393807 chr1:27649419~27649610:+ LIHC trans rs10917477 0.624 rs2745217 ENSG00000224237.1 MINOS1P3 -7.09 7.63e-12 2.18e-05 -0.44 -0.36 Thyroid function; chr1:19595253 chr3:27214816~27215018:- LIHC trans rs10870270 0.957 rs3829156 ENSG00000197358.9 BNIP3P1 7.09 7.64e-12 2.18e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131975882 chr14:28264390~28265974:+ LIHC trans rs3740713 1 rs75487138 ENSG00000235847.2 LDHAP7 7.09 7.67e-12 2.19e-05 0.65 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18440331 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73440614 ENSG00000235847.2 LDHAP7 7.09 7.67e-12 2.19e-05 0.65 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18445153 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs1848048 ENSG00000235847.2 LDHAP7 7.09 7.67e-12 2.19e-05 0.65 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18447449 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs16935432 ENSG00000235847.2 LDHAP7 7.09 7.67e-12 2.19e-05 0.65 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18448940 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73440625 ENSG00000235847.2 LDHAP7 7.09 7.67e-12 2.19e-05 0.65 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18449253 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs76599129 ENSG00000235847.2 LDHAP7 7.09 7.67e-12 2.19e-05 0.65 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18450080 chr2:84777259~84778223:- LIHC trans rs9467773 0.869 rs1796521 ENSG00000242375.1 RP11-498P14.3 -7.09 7.72e-12 2.2e-05 -0.43 -0.36 Intelligence (multi-trait analysis); chr6:26421164 chr9:97195351~97197687:- LIHC trans rs9876781 1 rs3214041 ENSG00000235912.1 RP1-159A19.3 -7.09 7.72e-12 2.2e-05 -0.41 -0.36 Longevity; chr3:48413059 chr1:27649419~27649610:+ LIHC trans rs11220082 0.666 rs12789687 ENSG00000236257.1 EI24P2 -7.09 7.75e-12 2.21e-05 -0.43 -0.36 Schizophrenia; chr11:125461254 chr1:158454198~158455273:+ LIHC trans rs11220082 0.666 rs12223186 ENSG00000236257.1 EI24P2 -7.09 7.75e-12 2.21e-05 -0.43 -0.36 Schizophrenia; chr11:125461743 chr1:158454198~158455273:+ LIHC trans rs864643 0.891 rs816493 ENSG00000183298.5 RP11-556K13.1 7.08 7.99e-12 2.28e-05 0.57 0.36 Attention deficit hyperactivity disorder; chr3:39514702 chr1:101786340~101787219:- LIHC trans rs10870270 1 rs10870270 ENSG00000197358.9 BNIP3P1 7.08 8.23e-12 2.34e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131940830 chr14:28264390~28265974:+ LIHC trans rs7312770 0.612 rs1873914 ENSG00000234513.1 AC073072.7 7.08 8.25e-12 2.35e-05 0.46 0.36 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr7:22773646~22773993:- LIHC trans rs4784054 0.568 rs13333259 ENSG00000230849.2 GOT2P2 7.08 8.36e-12 2.38e-05 0.44 0.36 Blood metabolite levels; chr16:58789172 chr1:173141100~173142350:- LIHC trans rs10870270 1 rs10870232 ENSG00000197358.9 BNIP3P1 7.08 8.44e-12 2.4e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131925033 chr14:28264390~28265974:+ LIHC trans rs3740713 1 rs73438686 ENSG00000235847.2 LDHAP7 7.07 8.8e-12 2.5e-05 0.67 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18438238 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs113497813 ENSG00000235847.2 LDHAP7 7.06 9.09e-12 2.58e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18432127 chr2:84777259~84778223:- LIHC trans rs10870270 1 rs6560694 ENSG00000197358.9 BNIP3P1 7.06 9.32e-12 2.64e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131959944 chr14:28264390~28265974:+ LIHC trans rs7930295 0.558 rs11220069 ENSG00000236257.1 EI24P2 7.06 9.46e-12 2.68e-05 0.55 0.36 Schizophrenia; chr11:125428235 chr1:158454198~158455273:+ LIHC trans rs7930295 0.558 rs34141026 ENSG00000236257.1 EI24P2 7.06 9.46e-12 2.68e-05 0.55 0.36 Schizophrenia; chr11:125433911 chr1:158454198~158455273:+ LIHC trans rs877636 1 rs705696 ENSG00000212994.5 RPS26P6 7.06 9.5e-12 2.69e-05 0.48 0.36 Cognitive function; chr12:56086864 chr8:100895771~100896118:+ LIHC trans rs9611565 0.921 rs5758297 ENSG00000268568.1 AC007228.9 -7.06 9.51e-12 2.69e-05 -0.44 -0.36 Vitiligo; chr22:41324693 chr19:56672574~56673901:- LIHC trans rs9611565 0.921 rs5751077 ENSG00000268568.1 AC007228.9 -7.06 9.51e-12 2.69e-05 -0.44 -0.36 Vitiligo; chr22:41324724 chr19:56672574~56673901:- LIHC trans rs10870270 0.957 rs7074604 ENSG00000197358.9 BNIP3P1 7.05 9.66e-12 2.73e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131926869 chr14:28264390~28265974:+ LIHC trans rs3740713 1 rs73436645 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18419236 chr2:84777259~84778223:- LIHC trans rs3740713 0.925 rs73436650 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18419751 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73436655 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18420420 chr2:84777259~84778223:- LIHC trans rs3740713 0.92 rs80254575 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18420919 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73436662 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18421076 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs113725670 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18421753 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73436682 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18422142 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73436685 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18422229 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs2056781 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18423442 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73436701 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18425116 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73438604 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18425556 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73438607 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18425974 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs75010364 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18427419 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73438627 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18430369 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73438634 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18430809 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs113036885 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18431185 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs112410494 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18431208 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs74741949 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18431501 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs61081934 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18432770 chr2:84777259~84778223:- LIHC trans rs3740713 0.92 rs112818034 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18433633 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73438668 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18434989 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs75647856 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18438259 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs73438687 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18438312 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs74663287 ENSG00000235847.2 LDHAP7 7.05 9.8e-12 2.76e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18438753 chr2:84777259~84778223:- LIHC trans rs7937890 0.81 rs10734224 ENSG00000236360.2 RP11-334A14.2 7.05 9.96e-12 2.81e-05 0.46 0.36 Mitochondrial DNA levels; chr11:14402578 chr1:52993201~52993702:- LIHC trans rs10870270 1 rs3935905 ENSG00000197358.9 BNIP3P1 7.05 1.01e-11 2.83e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131944758 chr14:28264390~28265974:+ LIHC trans rs9876781 1 rs725310 ENSG00000235912.1 RP1-159A19.3 7.04 1.03e-11 2.9e-05 0.4 0.36 Longevity; chr3:48377081 chr1:27649419~27649610:+ LIHC trans rs10870270 0.956 rs67378218 ENSG00000197358.9 BNIP3P1 7.04 1.04e-11 2.92e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131938916 chr14:28264390~28265974:+ LIHC trans rs3740713 0.925 rs55727925 ENSG00000235847.2 LDHAP7 7.03 1.1e-11 3.09e-05 0.64 0.36 Amyotrophic lateral sclerosis (sporadic); chr11:18432146 chr2:84777259~84778223:- LIHC trans rs10870270 1 rs10159746 ENSG00000197358.9 BNIP3P1 7.03 1.14e-11 3.19e-05 0.42 0.36 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131929173 chr14:28264390~28265974:+ LIHC trans rs7568458 0.87 rs1010 ENSG00000223886.3 RP11-251G23.2 -7.02 1.18e-11 3.31e-05 -0.4 -0.36 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85581859 chr7:105530209~105530671:+ LIHC trans rs12210905 1 rs115268625 ENSG00000242375.1 RP11-498P14.3 -7.02 1.19e-11 3.33e-05 -0.86 -0.35 Hip circumference adjusted for BMI; chr6:26980450 chr9:97195351~97197687:- LIHC trans rs9876781 1 rs13069724 ENSG00000235912.1 RP1-159A19.3 -7.02 1.22e-11 3.43e-05 -0.42 -0.35 Longevity; chr3:48436629 chr1:27649419~27649610:+ LIHC trans rs877636 0.669 rs7297175 ENSG00000225071.1 GS1-184P14.2 -7.01 1.24e-11 3.48e-05 -0.43 -0.35 Cognitive function; chr12:56080024 chrX:24429573~24429920:- LIHC trans rs4263408 0.654 rs305827 ENSG00000237550.5 UBE2Q2P6 7.01 1.3e-11 3.64e-05 0.42 0.35 Plasma amyloid beta peptide concentrations (ABx-40); chr4:39758369 chr15:82372196~82372912:- LIHC trans rs11220082 0.666 rs12224788 ENSG00000236257.1 EI24P2 -7.01 1.3e-11 3.64e-05 -0.41 -0.35 Schizophrenia; chr11:125459165 chr1:158454198~158455273:+ LIHC trans rs10917477 0.653 rs1770480 ENSG00000224237.1 MINOS1P3 7 1.32e-11 3.69e-05 0.43 0.35 Thyroid function; chr1:19590290 chr3:27214816~27215018:- LIHC trans rs77688320 0.535 rs12468504 ENSG00000235105.1 RP11-329A14.1 -7 1.33e-11 3.71e-05 -0.34 -0.35 Breast cancer; chr2:201393746 chr1:48435967~48437223:+ LIHC trans rs3740713 1 rs73438631 ENSG00000235847.2 LDHAP7 7 1.33e-11 3.72e-05 0.64 0.35 Amyotrophic lateral sclerosis (sporadic); chr11:18430571 chr2:84777259~84778223:- LIHC trans rs3740713 1 rs76708296 ENSG00000235847.2 LDHAP7 7 1.33e-11 3.72e-05 0.63 0.35 Amyotrophic lateral sclerosis (sporadic); chr11:18434586 chr2:84777259~84778223:- LIHC trans rs864643 0.947 rs563767 ENSG00000183298.5 RP11-556K13.1 7 1.36e-11 3.79e-05 0.49 0.35 Attention deficit hyperactivity disorder; chr3:39498075 chr1:101786340~101787219:- LIHC trans rs12138950 0.681 rs9783019 ENSG00000224237.1 MINOS1P3 7 1.37e-11 3.82e-05 0.44 0.35 Hypothyroidism;Thyroid volume; chr1:19523162 chr3:27214816~27215018:- LIHC trans rs864643 0.891 rs1708032 ENSG00000183298.5 RP11-556K13.1 7 1.37e-11 3.84e-05 0.51 0.35 Attention deficit hyperactivity disorder; chr3:39497642 chr1:101786340~101787219:- LIHC trans rs10870270 1 rs10430617 ENSG00000197358.9 BNIP3P1 7 1.39e-11 3.88e-05 0.42 0.35 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131935385 chr14:28264390~28265974:+ LIHC trans rs10870270 0.956 rs10430618 ENSG00000197358.9 BNIP3P1 7 1.39e-11 3.88e-05 0.42 0.35 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131935492 chr14:28264390~28265974:+ LIHC trans rs12210905 1 rs12192446 ENSG00000242375.1 RP11-498P14.3 -6.99 1.45e-11 4.04e-05 -0.9 -0.35 Hip circumference adjusted for BMI; chr6:27027859 chr9:97195351~97197687:- LIHC trans rs2250402 0.51 rs8031319 ENSG00000234106.3 RP11-288E14.2 6.99 1.47e-11 4.09e-05 0.56 0.35 Corneal curvature; chr15:40031491 chr11:93535468~93535816:+ LIHC trans rs7930295 0.632 rs12271647 ENSG00000236257.1 EI24P2 6.99 1.47e-11 4.09e-05 0.49 0.35 Schizophrenia; chr11:125754161 chr1:158454198~158455273:+ LIHC trans rs864643 1 rs1707968 ENSG00000183298.5 RP11-556K13.1 6.99 1.49e-11 4.14e-05 0.56 0.35 Attention deficit hyperactivity disorder; chr3:39506914 chr1:101786340~101787219:- LIHC trans rs875971 0.545 rs316328 ENSG00000164669.11 INTS4P1 6.98 1.5e-11 4.17e-05 0.45 0.35 Aortic root size; chr7:66143851 chr7:65141225~65234216:+ LIHC trans rs8067354 0.645 rs9910518 ENSG00000187870.7 RNFT1P3 6.98 1.53e-11 4.27e-05 0.42 0.35 Hemoglobin concentration; chr17:59734706 chr17:20743333~20754501:- LIHC trans rs9467773 0.869 rs742090 ENSG00000242375.1 RP11-498P14.3 -6.98 1.55e-11 4.3e-05 -0.42 -0.35 Intelligence (multi-trait analysis); chr6:26415409 chr9:97195351~97197687:- LIHC trans rs9611565 0.879 rs2235845 ENSG00000268568.1 AC007228.9 -6.98 1.56e-11 4.33e-05 -0.43 -0.35 Vitiligo; chr22:41333290 chr19:56672574~56673901:- LIHC trans rs3740713 1 rs3740713 ENSG00000235847.2 LDHAP7 6.98 1.57e-11 4.37e-05 0.63 0.35 Amyotrophic lateral sclerosis (sporadic); chr11:18429549 chr2:84777259~84778223:- LIHC trans rs5751901 0.614 rs6519520 ENSG00000280208.1 RP11-341D18.4 6.97 1.62e-11 4.5e-05 0.44 0.35 Protein quantitative trait loci; chr22:24595928 chr13:18253526~18270822:- LIHC trans rs8067354 0.645 rs56236317 ENSG00000187870.7 RNFT1P3 6.97 1.64e-11 4.56e-05 0.42 0.35 Hemoglobin concentration; chr17:59744764 chr17:20743333~20754501:- LIHC trans rs8067354 0.645 rs7215180 ENSG00000187870.7 RNFT1P3 6.97 1.64e-11 4.56e-05 0.42 0.35 Hemoglobin concentration; chr17:59744993 chr17:20743333~20754501:- LIHC trans rs8067354 0.681 rs9907923 ENSG00000187870.7 RNFT1P3 6.97 1.64e-11 4.56e-05 0.42 0.35 Hemoglobin concentration; chr17:59747566 chr17:20743333~20754501:- LIHC trans rs8067354 0.645 rs72840522 ENSG00000187870.7 RNFT1P3 6.97 1.64e-11 4.56e-05 0.42 0.35 Hemoglobin concentration; chr17:59752631 chr17:20743333~20754501:- LIHC trans rs6477998 0.676 rs4979224 ENSG00000238072.1 RP11-305M3.2 6.97 1.65e-11 4.58e-05 0.51 0.35 Hematology traits; chr9:113219998 chr7:129410113~129410370:- LIHC trans rs538867 0.661 rs114772633 ENSG00000183298.5 RP11-556K13.1 6.97 1.67e-11 4.62e-05 0.86 0.35 Alzheimer's disease (cognitive decline); chr3:39403407 chr1:101786340~101787219:- LIHC trans rs12138950 0.596 rs10917471 ENSG00000224237.1 MINOS1P3 6.97 1.67e-11 4.62e-05 0.44 0.35 Hypothyroidism;Thyroid volume; chr1:19521118 chr3:27214816~27215018:- LIHC trans rs10908521 1 rs10908521 ENSG00000227183.3 HDGFP1 6.97 1.68e-11 4.64e-05 0.44 0.35 Uric acid clearance; chr1:156843858 chrX:131646639~131646890:+ LIHC trans rs864643 1 rs552724 ENSG00000183298.5 RP11-556K13.1 -6.97 1.68e-11 4.65e-05 -0.56 -0.35 Attention deficit hyperactivity disorder; chr3:39513455 chr1:101786340~101787219:- LIHC trans rs7662987 1 rs7683704 ENSG00000233859.2 ADH5P4 6.97 1.68e-11 4.65e-05 0.81 0.35 Smoking initiation; chr4:99083075 chr6:65836930~65838039:- LIHC trans rs714543 0.61 rs4724320 ENSG00000219797.2 PPIAP9 -6.96 1.74e-11 4.8e-05 -0.4 -0.35 Plateletcrit; chr7:44775735 chr6:31519480~31520291:- LIHC trans rs8067354 0.645 rs2645489 ENSG00000187870.7 RNFT1P3 6.96 1.75e-11 4.83e-05 0.41 0.35 Hemoglobin concentration; chr17:59806010 chr17:20743333~20754501:- LIHC trans rs3849046 0.817 rs154069 ENSG00000226666.1 HSPA9P1 6.96 1.75e-11 4.84e-05 0.42 0.35 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138541231 chr2:221961737~221963765:+ LIHC trans rs864643 0.513 rs1707956 ENSG00000183298.5 RP11-556K13.1 -6.96 1.76e-11 4.85e-05 -0.5 -0.35 Attention deficit hyperactivity disorder; chr3:39482025 chr1:101786340~101787219:- LIHC trans rs864643 0.588 rs604869 ENSG00000183298.5 RP11-556K13.1 6.96 1.76e-11 4.85e-05 0.5 0.35 Attention deficit hyperactivity disorder; chr3:39486307 chr1:101786340~101787219:- LIHC trans rs72615157 0.697 rs2056726 ENSG00000228546.2 CTA-313A17.3 6.96 1.76e-11 4.86e-05 0.56 0.35 Lung function (FEV1/FVC); chr7:100182660 chr7:102337316~102339115:+ LIHC trans rs8067354 0.645 rs2665400 ENSG00000187870.7 RNFT1P3 6.96 1.77e-11 4.89e-05 0.41 0.35 Hemoglobin concentration; chr17:59802840 chr17:20743333~20754501:- LIHC trans rs538867 1 rs78956920 ENSG00000183298.5 RP11-556K13.1 6.95 1.82e-11 5.03e-05 0.86 0.35 Alzheimer's disease (cognitive decline); chr3:39437633 chr1:101786340~101787219:- LIHC trans rs875971 0.545 rs73142233 ENSG00000164669.11 INTS4P1 -6.95 1.83e-11 5.05e-05 -0.47 -0.35 Aortic root size; chr7:66221293 chr7:65141225~65234216:+ LIHC trans rs9467773 0.869 rs1796520 ENSG00000242375.1 RP11-498P14.3 -6.95 1.84e-11 5.06e-05 -0.42 -0.35 Intelligence (multi-trait analysis); chr6:26410572 chr9:97195351~97197687:- LIHC trans rs7554547 0.69 rs7524721 ENSG00000261819.1 RP11-680G24.4 6.95 1.84e-11 5.08e-05 0.46 0.35 Nonsyndromic cleft lip with cleft palate; chr1:11890119 chr16:14988259~14990160:- LIHC trans rs77688320 0.517 rs12623282 ENSG00000235105.1 RP11-329A14.1 6.95 1.87e-11 5.14e-05 0.33 0.35 Breast cancer; chr2:201382734 chr1:48435967~48437223:+ LIHC trans rs8067354 0.645 rs9901606 ENSG00000187870.7 RNFT1P3 6.95 1.88e-11 5.17e-05 0.41 0.35 Hemoglobin concentration; chr17:59734046 chr17:20743333~20754501:- LIHC trans rs7568458 0.87 rs2366639 ENSG00000223886.3 RP11-251G23.2 6.95 1.89e-11 5.2e-05 0.4 0.35 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85582832 chr7:105530209~105530671:+ LIHC trans rs7121616 0.733 rs10790554 ENSG00000234176.1 HSPA8P1 6.95 1.9e-11 5.22e-05 0.44 0.35 Breast cancer; chr11:123130376 chrX:121203182~121205014:- LIHC trans rs9876781 1 rs28824259 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48384185 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs12487542 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48384586 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs73074358 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48385757 chr1:27649419~27649610:+ LIHC trans rs9876781 0.967 rs34761139 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48386489 chr1:27649419~27649610:+ LIHC trans rs9876781 0.868 rs9875280 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48387420 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs6796491 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48388977 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs6804774 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48389129 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs9826195 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48392157 chr1:27649419~27649610:+ LIHC trans rs9876781 0.967 rs9864815 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48392588 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs9809843 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48392923 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs1563736 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48395329 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs13071337 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48396724 chr1:27649419~27649610:+ LIHC trans rs9876781 1 rs6442118 ENSG00000235912.1 RP1-159A19.3 -6.95 1.91e-11 5.25e-05 -0.4 -0.35 Longevity; chr3:48398582 chr1:27649419~27649610:+ LIHC trans rs8067354 0.645 rs9899611 ENSG00000187870.7 RNFT1P3 6.94 1.97e-11 5.4e-05 0.41 0.35 Hemoglobin concentration; chr17:59754829 chr17:20743333~20754501:- LIHC trans rs77688320 0.535 rs11680694 ENSG00000235105.1 RP11-329A14.1 6.94 1.97e-11 5.41e-05 0.33 0.35 Breast cancer; chr2:201393498 chr1:48435967~48437223:+ LIHC trans rs13014235 0.592 rs55860809 ENSG00000235105.1 RP11-329A14.1 6.94 1.97e-11 5.41e-05 0.33 0.35 Basal cell carcinoma; chr2:201394347 chr1:48435967~48437223:+ LIHC trans rs9581094 0.505 rs6490945 ENSG00000237917.1 PARP4P1 6.94 1.97e-11 5.41e-05 0.44 0.35 Sudden cardiac arrest; chr13:24514056 chrY:26594851~26634652:- LIHC trans rs10870270 1 rs10159943 ENSG00000197358.9 BNIP3P1 6.94 2e-11 5.49e-05 0.41 0.35 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131931240 chr14:28264390~28265974:+ LIHC trans rs10870270 0.956 rs10781555 ENSG00000197358.9 BNIP3P1 6.94 2e-11 5.49e-05 0.41 0.35 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131932216 chr14:28264390~28265974:+ LIHC trans rs875971 0.545 rs4718325 ENSG00000164669.11 INTS4P1 -6.94 2.03e-11 5.58e-05 -0.47 -0.35 Aortic root size; chr7:66215323 chr7:65141225~65234216:+ LIHC trans rs11220082 0.627 rs34912904 ENSG00000236257.1 EI24P2 -6.93 2.04e-11 5.6e-05 -0.42 -0.35 Schizophrenia; chr11:125475460 chr1:158454198~158455273:+ LIHC trans rs864643 0.812 rs2039843 ENSG00000183298.5 RP11-556K13.1 -6.93 2.07e-11 5.66e-05 -0.47 -0.35 Attention deficit hyperactivity disorder; chr3:39515347 chr1:101786340~101787219:- LIHC trans rs864643 0.812 rs6809442 ENSG00000183298.5 RP11-556K13.1 -6.93 2.07e-11 5.66e-05 -0.47 -0.35 Attention deficit hyperactivity disorder; chr3:39517666 chr1:101786340~101787219:- LIHC trans rs875971 0.502 rs2465121 ENSG00000164669.11 INTS4P1 6.93 2.07e-11 5.67e-05 0.47 0.35 Aortic root size; chr7:66156017 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs73142245 ENSG00000164669.11 INTS4P1 -6.93 2.08e-11 5.7e-05 -0.47 -0.35 Aortic root size; chr7:66226662 chr7:65141225~65234216:+ LIHC trans rs7937890 0.684 rs12799007 ENSG00000236360.2 RP11-334A14.2 6.93 2.09e-11 5.72e-05 0.45 0.35 Mitochondrial DNA levels; chr11:14404938 chr1:52993201~52993702:- LIHC trans rs538867 1 rs73068347 ENSG00000183298.5 RP11-556K13.1 6.93 2.12e-11 5.79e-05 0.79 0.35 Alzheimer's disease (cognitive decline); chr3:39497669 chr1:101786340~101787219:- LIHC trans rs877636 0.74 rs705698 ENSG00000212994.5 RPS26P6 6.93 2.13e-11 5.84e-05 0.47 0.35 Cognitive function; chr12:55990903 chr8:100895771~100896118:+ LIHC trans rs9467773 0.933 rs2024970 ENSG00000242375.1 RP11-498P14.3 6.92 2.17e-11 5.93e-05 0.41 0.35 Intelligence (multi-trait analysis); chr6:26497292 chr9:97195351~97197687:- LIHC trans rs864643 0.513 rs6599028 ENSG00000183298.5 RP11-556K13.1 6.92 2.19e-11 5.99e-05 0.5 0.35 Attention deficit hyperactivity disorder; chr3:39492344 chr1:101786340~101787219:- LIHC trans rs864643 0.513 rs1707944 ENSG00000183298.5 RP11-556K13.1 6.92 2.19e-11 6e-05 0.5 0.35 Attention deficit hyperactivity disorder; chr3:39487141 chr1:101786340~101787219:- LIHC trans rs3740713 1 rs79199586 ENSG00000235847.2 LDHAP7 6.92 2.23e-11 6.08e-05 0.67 0.35 Amyotrophic lateral sclerosis (sporadic); chr11:18430599 chr2:84777259~84778223:- LIHC trans rs11220082 0.602 rs10893383 ENSG00000236257.1 EI24P2 -6.92 2.25e-11 6.15e-05 -0.42 -0.35 Schizophrenia; chr11:125466237 chr1:158454198~158455273:+ LIHC trans rs864643 1 rs1707969 ENSG00000183298.5 RP11-556K13.1 6.92 2.26e-11 6.17e-05 0.55 0.35 Attention deficit hyperactivity disorder; chr3:39506998 chr1:101786340~101787219:- LIHC trans rs875971 0.545 rs73376401 ENSG00000164669.11 INTS4P1 -6.92 2.27e-11 6.19e-05 -0.47 -0.35 Aortic root size; chr7:66174841 chr7:65141225~65234216:+ LIHC trans rs5022636 0.896 rs744536 ENSG00000180764.13 PIPSL 6.92 2.29e-11 6.24e-05 0.33 0.35 Gut microbiota (functional units); chr1:151356318 chr10:93958191~93961540:- LIHC trans rs864643 0.513 rs614823 ENSG00000183298.5 RP11-556K13.1 6.92 2.3e-11 6.28e-05 0.5 0.35 Attention deficit hyperactivity disorder; chr3:39493267 chr1:101786340~101787219:- LIHC trans rs12210905 1 rs76889265 ENSG00000242375.1 RP11-498P14.3 -6.91 2.37e-11 6.45e-05 -0.9 -0.35 Hip circumference adjusted for BMI; chr6:27041056 chr9:97195351~97197687:- LIHC trans rs864643 0.513 rs1768202 ENSG00000183298.5 RP11-556K13.1 6.91 2.4e-11 6.54e-05 0.5 0.35 Attention deficit hyperactivity disorder; chr3:39476053 chr1:101786340~101787219:- LIHC trans rs864643 0.513 rs481523 ENSG00000183298.5 RP11-556K13.1 6.91 2.4e-11 6.54e-05 0.5 0.35 Attention deficit hyperactivity disorder; chr3:39477849 chr1:101786340~101787219:- LIHC trans rs4784054 0.568 rs13333259 ENSG00000233719.3 GOT2P3 6.91 2.42e-11 6.59e-05 0.4 0.35 Blood metabolite levels; chr16:58789172 chr12:9641802~9643007:+ LIHC trans rs77688320 0.535 rs7575721 ENSG00000235105.1 RP11-329A14.1 6.9 2.49e-11 6.77e-05 0.33 0.35 Breast cancer; chr2:201392055 chr1:48435967~48437223:+ LIHC trans rs77688320 0.535 rs3815515 ENSG00000235105.1 RP11-329A14.1 6.9 2.49e-11 6.77e-05 0.33 0.35 Breast cancer; chr2:201393207 chr1:48435967~48437223:+ LIHC trans rs77688320 0.535 rs13001194 ENSG00000235105.1 RP11-329A14.1 6.9 2.49e-11 6.77e-05 0.33 0.35 Breast cancer; chr2:201396452 chr1:48435967~48437223:+ LIHC trans rs77688320 0.535 rs7597850 ENSG00000235105.1 RP11-329A14.1 6.9 2.49e-11 6.77e-05 0.33 0.35 Breast cancer; chr2:201396679 chr1:48435967~48437223:+ LIHC trans rs77688320 0.535 rs7571761 ENSG00000235105.1 RP11-329A14.1 6.9 2.49e-11 6.77e-05 0.33 0.35 Breast cancer; chr2:201396837 chr1:48435967~48437223:+ LIHC trans rs77688320 0.535 rs10931944 ENSG00000235105.1 RP11-329A14.1 6.9 2.49e-11 6.77e-05 0.33 0.35 Breast cancer; chr2:201398875 chr1:48435967~48437223:+ LIHC trans rs77688320 0.553 rs11681526 ENSG00000235105.1 RP11-329A14.1 6.9 2.49e-11 6.77e-05 0.33 0.35 Breast cancer; chr2:201399037 chr1:48435967~48437223:+ LIHC trans rs77688320 0.535 rs13022344 ENSG00000235105.1 RP11-329A14.1 6.9 2.49e-11 6.77e-05 0.33 0.35 Breast cancer; chr2:201399433 chr1:48435967~48437223:+ LIHC trans rs77688320 0.535 rs6732993 ENSG00000235105.1 RP11-329A14.1 6.9 2.49e-11 6.77e-05 0.33 0.35 Breast cancer; chr2:201399593 chr1:48435967~48437223:+ LIHC trans rs9858542 0.953 rs9814873 ENSG00000197582.5 GPX1P1 -6.9 2.51e-11 6.83e-05 -0.56 -0.35 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49416679 chrX:13378735~13379340:- LIHC trans rs864643 1 rs1513214 ENSG00000183298.5 RP11-556K13.1 6.9 2.58e-11 7e-05 0.53 0.35 Attention deficit hyperactivity disorder; chr3:39518774 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1768267 ENSG00000183298.5 RP11-556K13.1 6.9 2.58e-11 7e-05 0.53 0.35 Attention deficit hyperactivity disorder; chr3:39518945 chr1:101786340~101787219:- LIHC trans rs864643 0.891 rs661366 ENSG00000183298.5 RP11-556K13.1 6.9 2.58e-11 7e-05 0.53 0.35 Attention deficit hyperactivity disorder; chr3:39519857 chr1:101786340~101787219:- LIHC trans rs864643 1 rs572971 ENSG00000183298.5 RP11-556K13.1 6.9 2.58e-11 7e-05 0.53 0.35 Attention deficit hyperactivity disorder; chr3:39519936 chr1:101786340~101787219:- LIHC trans rs864643 0.945 rs1355733 ENSG00000183298.5 RP11-556K13.1 6.9 2.58e-11 7e-05 0.53 0.35 Attention deficit hyperactivity disorder; chr3:39521165 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs587054 ENSG00000183298.5 RP11-556K13.1 6.9 2.58e-11 7e-05 0.53 0.35 Attention deficit hyperactivity disorder; chr3:39524496 chr1:101786340~101787219:- LIHC trans rs864643 1 rs602527 ENSG00000183298.5 RP11-556K13.1 6.9 2.58e-11 7e-05 0.53 0.35 Attention deficit hyperactivity disorder; chr3:39527293 chr1:101786340~101787219:- LIHC trans rs864643 1 rs816520 ENSG00000183298.5 RP11-556K13.1 6.9 2.58e-11 7e-05 0.53 0.35 Attention deficit hyperactivity disorder; chr3:39528222 chr1:101786340~101787219:- LIHC trans rs864643 1 rs866537 ENSG00000183298.5 RP11-556K13.1 6.9 2.58e-11 7e-05 0.53 0.35 Attention deficit hyperactivity disorder; chr3:39530125 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1708056 ENSG00000183298.5 RP11-556K13.1 6.9 2.58e-11 7e-05 0.53 0.35 Attention deficit hyperactivity disorder; chr3:39531662 chr1:101786340~101787219:- LIHC trans rs5751901 0.614 rs874852 ENSG00000280208.1 RP11-341D18.4 6.9 2.58e-11 7e-05 0.44 0.35 Protein quantitative trait loci; chr22:24591997 chr13:18253526~18270822:- LIHC trans rs916888 0.779 rs199498 ENSG00000264070.1 DND1P1 6.9 2.59e-11 7.01e-05 0.4 0.35 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:45585871~45586929:+ LIHC trans rs77688320 0.553 rs6761777 ENSG00000235105.1 RP11-329A14.1 6.89 2.63e-11 7.11e-05 0.33 0.35 Breast cancer; chr2:201399879 chr1:48435967~48437223:+ LIHC trans rs12709013 0.635 rs6993 ENSG00000230849.2 GOT2P2 6.89 2.63e-11 7.12e-05 0.44 0.35 Blood metabolite ratios; chr16:58707463 chr1:173141100~173142350:- LIHC trans rs7937890 0.631 rs7118886 ENSG00000236360.2 RP11-334A14.2 6.89 2.64e-11 7.16e-05 0.46 0.35 Mitochondrial DNA levels; chr11:14405971 chr1:52993201~52993702:- LIHC trans rs9876781 1 rs6442117 ENSG00000235912.1 RP1-159A19.3 6.89 2.65e-11 7.18e-05 0.39 0.35 Longevity; chr3:48378407 chr1:27649419~27649610:+ LIHC trans rs877636 0.692 rs11171739 ENSG00000212994.5 RPS26P6 6.89 2.67e-11 7.23e-05 0.42 0.35 Cognitive function; chr12:56076841 chr8:100895771~100896118:+ LIHC trans rs864643 0.891 rs1626197 ENSG00000183298.5 RP11-556K13.1 6.88 2.86e-11 7.74e-05 0.59 0.35 Attention deficit hyperactivity disorder; chr3:39539974 chr1:101786340~101787219:- LIHC trans rs864643 0.513 rs1398666 ENSG00000183298.5 RP11-556K13.1 6.88 2.88e-11 7.78e-05 0.5 0.35 Attention deficit hyperactivity disorder; chr3:39475540 chr1:101786340~101787219:- LIHC trans rs877636 0.669 rs7297175 ENSG00000234513.1 AC073072.7 -6.87 3e-11 8.1e-05 -0.43 -0.35 Cognitive function; chr12:56080024 chr7:22773646~22773993:- LIHC trans rs7032940 0.533 rs7868072 ENSG00000262519.1 TXNP4 6.87 3.03e-11 8.17e-05 0.44 0.35 Height; chr9:110205824 chr17:4572206~4572515:+ LIHC trans rs3849046 0.68 rs11746692 ENSG00000226666.1 HSPA9P1 -6.87 3.07e-11 8.27e-05 -0.43 -0.35 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138610666 chr2:221961737~221963765:+ LIHC trans rs4784054 0.568 rs35512562 ENSG00000233719.3 GOT2P3 6.87 3.1e-11 8.35e-05 0.41 0.35 Blood metabolite levels; chr16:58805641 chr12:9641802~9643007:+ LIHC trans rs875971 0.545 rs17138156 ENSG00000164669.11 INTS4P1 -6.86 3.17e-11 8.54e-05 -0.46 -0.35 Aortic root size; chr7:66249708 chr7:65141225~65234216:+ LIHC trans rs7568458 0.87 rs1009 ENSG00000223886.3 RP11-251G23.2 6.86 3.2e-11 8.61e-05 0.39 0.35 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85581614 chr7:105530209~105530671:+ LIHC trans rs875971 0.545 rs73142265 ENSG00000164669.11 INTS4P1 -6.86 3.23e-11 8.7e-05 -0.46 -0.35 Aortic root size; chr7:66234510 chr7:65141225~65234216:+ LIHC trans rs864643 0.773 rs3821373 ENSG00000183298.5 RP11-556K13.1 -6.86 3.26e-11 8.78e-05 -0.46 -0.35 Attention deficit hyperactivity disorder; chr3:39512285 chr1:101786340~101787219:- LIHC trans rs6477998 0.627 rs10114381 ENSG00000238072.1 RP11-305M3.2 6.86 3.34e-11 8.97e-05 0.51 0.35 Hematology traits; chr9:113213692 chr7:129410113~129410370:- LIHC trans rs6477998 0.651 rs10114423 ENSG00000238072.1 RP11-305M3.2 6.86 3.34e-11 8.97e-05 0.51 0.35 Hematology traits; chr9:113213751 chr7:129410113~129410370:- LIHC trans rs6477998 0.676 rs10817460 ENSG00000238072.1 RP11-305M3.2 6.86 3.34e-11 8.97e-05 0.51 0.35 Hematology traits; chr9:113214118 chr7:129410113~129410370:- LIHC trans rs6477998 0.603 rs7859189 ENSG00000238072.1 RP11-305M3.2 6.86 3.34e-11 8.97e-05 0.51 0.35 Hematology traits; chr9:113217389 chr7:129410113~129410370:- LIHC trans rs6477998 0.676 rs6477997 ENSG00000238072.1 RP11-305M3.2 6.86 3.34e-11 8.97e-05 0.51 0.35 Hematology traits; chr9:113218833 chr7:129410113~129410370:- LIHC trans rs6477998 0.627 rs3810914 ENSG00000238072.1 RP11-305M3.2 6.86 3.34e-11 8.97e-05 0.51 0.35 Hematology traits; chr9:113219441 chr7:129410113~129410370:- LIHC trans rs6477998 0.676 rs4978536 ENSG00000238072.1 RP11-305M3.2 6.86 3.34e-11 8.97e-05 0.51 0.35 Hematology traits; chr9:113220123 chr7:129410113~129410370:- LIHC trans rs9858542 0.953 rs6997 ENSG00000197582.5 GPX1P1 -6.85 3.35e-11 9e-05 -0.58 -0.35 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49416401 chrX:13378735~13379340:- LIHC trans rs1051424 0.651 rs1292063 ENSG00000187870.7 RNFT1P3 -6.85 3.36e-11 9.04e-05 -0.41 -0.35 Obesity-related traits; chr17:59830407 chr17:20743333~20754501:- LIHC trans rs864643 1 rs1340224 ENSG00000183298.5 RP11-556K13.1 6.85 3.4e-11 9.12e-05 0.52 0.35 Attention deficit hyperactivity disorder; chr3:39508072 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1340223 ENSG00000183298.5 RP11-556K13.1 6.85 3.4e-11 9.12e-05 0.52 0.35 Attention deficit hyperactivity disorder; chr3:39508208 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1340222 ENSG00000183298.5 RP11-556K13.1 6.85 3.4e-11 9.12e-05 0.52 0.35 Attention deficit hyperactivity disorder; chr3:39508312 chr1:101786340~101787219:- LIHC trans rs864643 1 rs536454 ENSG00000183298.5 RP11-556K13.1 6.85 3.4e-11 9.12e-05 0.52 0.35 Attention deficit hyperactivity disorder; chr3:39508827 chr1:101786340~101787219:- LIHC trans rs864643 0.945 rs583083 ENSG00000183298.5 RP11-556K13.1 6.85 3.4e-11 9.12e-05 0.52 0.35 Attention deficit hyperactivity disorder; chr3:39508954 chr1:101786340~101787219:- LIHC trans rs864643 1 rs581691 ENSG00000183298.5 RP11-556K13.1 6.85 3.4e-11 9.12e-05 0.52 0.35 Attention deficit hyperactivity disorder; chr3:39509244 chr1:101786340~101787219:- LIHC trans rs864643 1 rs689352 ENSG00000183298.5 RP11-556K13.1 6.85 3.4e-11 9.12e-05 0.52 0.35 Attention deficit hyperactivity disorder; chr3:39509275 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1513213 ENSG00000183298.5 RP11-556K13.1 6.85 3.4e-11 9.12e-05 0.52 0.35 Attention deficit hyperactivity disorder; chr3:39509406 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1768261 ENSG00000183298.5 RP11-556K13.1 6.85 3.4e-11 9.12e-05 0.52 0.35 Attention deficit hyperactivity disorder; chr3:39510494 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1768262 ENSG00000183298.5 RP11-556K13.1 6.85 3.4e-11 9.12e-05 0.52 0.35 Attention deficit hyperactivity disorder; chr3:39511785 chr1:101786340~101787219:- LIHC trans rs864643 1 rs1612165 ENSG00000183298.5 RP11-556K13.1 6.85 3.42e-11 9.18e-05 0.57 0.35 Attention deficit hyperactivity disorder; chr3:39501996 chr1:101786340~101787219:- LIHC trans rs9858542 0.953 rs10640 ENSG00000197582.5 GPX1P1 -6.85 3.44e-11 9.23e-05 -0.58 -0.35 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49416844 chrX:13378735~13379340:- LIHC trans rs9876781 1 rs13314659 ENSG00000235912.1 RP1-159A19.3 6.85 3.46e-11 9.26e-05 0.39 0.35 Longevity; chr3:48407742 chr1:27649419~27649610:+ LIHC trans rs877636 0.692 rs2271194 ENSG00000225071.1 GS1-184P14.2 -6.85 3.49e-11 9.34e-05 -0.43 -0.35 Cognitive function; chr12:56083910 chrX:24429573~24429920:- LIHC trans rs9858542 0.953 rs7648841 ENSG00000197582.5 GPX1P1 -6.85 3.5e-11 9.36e-05 -0.58 -0.35 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49379392 chrX:13378735~13379340:- LIHC trans rs3002142 0.57 rs3008633 ENSG00000219201.4 RP11-181C21.4 -6.85 3.51e-11 9.39e-05 -0.4 -0.35 LDL peak particle diameter (total fat intake interaction); chr1:222671498 chr1:77810861~77811781:- LIHC trans rs864643 0.513 rs1768149 ENSG00000183298.5 RP11-556K13.1 6.85 3.55e-11 9.5e-05 0.5 0.35 Attention deficit hyperactivity disorder; chr3:39466089 chr1:101786340~101787219:- LIHC trans rs3740713 1 rs73436668 ENSG00000235847.2 LDHAP7 6.84 3.57e-11 9.54e-05 0.63 0.35 Amyotrophic lateral sclerosis (sporadic); chr11:18421546 chr2:84777259~84778223:- LIHC trans rs12200782 1 rs4292511 ENSG00000242375.1 RP11-498P14.3 -6.84 3.57e-11 9.54e-05 -0.81 -0.35 Small cell lung carcinoma; chr6:26622062 chr9:97195351~97197687:- LIHC trans rs3849046 0.846 rs2043273 ENSG00000226666.1 HSPA9P1 -6.84 3.57e-11 9.55e-05 -0.42 -0.35 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138595402 chr2:221961737~221963765:+ LIHC trans rs3849046 0.846 rs256006 ENSG00000226666.1 HSPA9P1 6.84 3.59e-11 9.6e-05 0.42 0.35 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138561405 chr2:221961737~221963765:+ LIHC trans rs875971 0.545 rs2460427 ENSG00000164669.11 INTS4P1 6.84 3.59e-11 9.6e-05 0.47 0.35 Aortic root size; chr7:66154218 chr7:65141225~65234216:+ LIHC trans rs3740713 1 rs60376560 ENSG00000235847.2 LDHAP7 6.84 3.59e-11 9.61e-05 0.63 0.35 Amyotrophic lateral sclerosis (sporadic); chr11:18432195 chr2:84777259~84778223:- LIHC trans rs13190036 0.551 rs7732930 ENSG00000228305.2 AC016734.2 -6.84 3.6e-11 9.62e-05 -0.41 -0.35 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177121593 chr2:63622178~63622831:- LIHC trans rs875971 0.545 rs67397473 ENSG00000164669.11 INTS4P1 -6.84 3.64e-11 9.71e-05 -0.47 -0.35 Aortic root size; chr7:66168318 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs10950027 ENSG00000164669.11 INTS4P1 -6.84 3.64e-11 9.71e-05 -0.47 -0.35 Aortic root size; chr7:66169164 chr7:65141225~65234216:+ LIHC trans rs10870270 0.784 rs10430614 ENSG00000197358.9 BNIP3P1 -6.84 3.65e-11 9.75e-05 -0.4 -0.35 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131935136 chr14:28264390~28265974:+ LIHC trans rs7568458 0.87 rs1972297 ENSG00000223886.3 RP11-251G23.2 6.84 3.66e-11 9.77e-05 0.39 0.35 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85581450 chr7:105530209~105530671:+ LIHC trans rs3740713 1 rs73440637 ENSG00000235847.2 LDHAP7 6.84 3.68e-11 9.82e-05 0.66 0.35 Amyotrophic lateral sclerosis (sporadic); chr11:18452581 chr2:84777259~84778223:- LIHC trans rs9876781 1 rs9311423 ENSG00000235912.1 RP1-159A19.3 -6.84 3.76e-11 1e-04 -0.39 -0.35 Longevity; chr3:48378818 chr1:27649419~27649610:+ LIHC trans rs7937890 0.599 rs2597204 ENSG00000236360.2 RP11-334A14.2 6.83 3.85e-11 0.000103 0.46 0.35 Mitochondrial DNA levels; chr11:14459471 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2034480 ENSG00000236360.2 RP11-334A14.2 6.83 3.91e-11 0.000104 0.44 0.35 Mitochondrial DNA levels; chr11:14445377 chr1:52993201~52993702:- LIHC trans rs11023332 0.641 rs4281505 ENSG00000236360.2 RP11-334A14.2 6.83 3.93e-11 0.000105 0.43 0.35 Vitamin D levels;Adiponectin levels; chr11:14779114 chr1:52993201~52993702:- LIHC trans rs11023332 0.65 rs2122942 ENSG00000236360.2 RP11-334A14.2 6.83 3.93e-11 0.000105 0.43 0.35 Vitamin D levels;Adiponectin levels; chr11:14785829 chr1:52993201~52993702:- LIHC trans rs9876781 1 rs7630741 ENSG00000235912.1 RP1-159A19.3 -6.83 3.95e-11 0.000105 -0.4 -0.35 Longevity; chr3:48378233 chr1:27649419~27649610:+ LIHC trans rs7568458 0.87 rs1058588 ENSG00000223886.3 RP11-251G23.2 -6.83 3.95e-11 0.000105 -0.39 -0.35 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85581748 chr7:105530209~105530671:+ LIHC trans rs11023332 0.617 rs1451678 ENSG00000236360.2 RP11-334A14.2 6.83 3.97e-11 0.000105 0.43 0.35 Vitamin D levels;Adiponectin levels; chr11:14760075 chr1:52993201~52993702:- LIHC trans rs8067354 0.645 rs2645486 ENSG00000187870.7 RNFT1P3 6.83 3.99e-11 0.000106 0.41 0.35 Hemoglobin concentration; chr17:59808540 chr17:20743333~20754501:- LIHC trans rs8067354 0.645 rs2645487 ENSG00000187870.7 RNFT1P3 6.83 3.99e-11 0.000106 0.41 0.35 Hemoglobin concentration; chr17:59808764 chr17:20743333~20754501:- LIHC trans rs1051424 0.642 rs115869798 ENSG00000187870.7 RNFT1P3 6.83 3.99e-11 0.000106 0.41 0.35 Obesity-related traits; chr17:59815468 chr17:20743333~20754501:- LIHC trans rs7032940 0.626 rs4314718 ENSG00000228236.2 TXNP5 6.82 4.02e-11 0.000107 0.4 0.35 Height; chr9:110211368 chr2:149068596~149068910:- LIHC trans rs77688320 0.553 rs3795966 ENSG00000235105.1 RP11-329A14.1 6.82 4.04e-11 0.000107 0.32 0.35 Breast cancer; chr2:201380521 chr1:48435967~48437223:+ LIHC trans rs77688320 0.535 rs7579853 ENSG00000235105.1 RP11-329A14.1 6.82 4.04e-11 0.000107 0.32 0.35 Breast cancer; chr2:201384256 chr1:48435967~48437223:+ LIHC trans rs11220082 0.644 rs34435097 ENSG00000236257.1 EI24P2 -6.82 4.05e-11 0.000107 -0.41 -0.35 Schizophrenia; chr11:125469075 chr1:158454198~158455273:+ LIHC trans rs877636 0.669 rs7297175 ENSG00000212994.5 RPS26P6 -6.82 4.09e-11 0.000108 -0.43 -0.35 Cognitive function; chr12:56080024 chr8:100895771~100896118:+ LIHC trans rs875971 0.545 rs6460281 ENSG00000164669.11 INTS4P1 -6.82 4.12e-11 0.000109 -0.46 -0.35 Aortic root size; chr7:66216128 chr7:65141225~65234216:+ LIHC trans rs3849046 0.81 rs11957778 ENSG00000226666.1 HSPA9P1 -6.82 4.19e-11 0.000111 -0.41 -0.35 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138582137 chr2:221961737~221963765:+ LIHC trans rs77688320 0.535 rs7561048 ENSG00000235105.1 RP11-329A14.1 6.81 4.27e-11 0.000113 0.32 0.35 Breast cancer; chr2:201388316 chr1:48435967~48437223:+ LIHC trans rs3849046 0.846 rs256014 ENSG00000226666.1 HSPA9P1 6.81 4.3e-11 0.000114 0.41 0.35 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138567395 chr2:221961737~221963765:+ LIHC trans rs5022636 0.896 rs10788804 ENSG00000180764.13 PIPSL 6.81 4.34e-11 0.000115 0.33 0.35 Gut microbiota (functional units); chr1:151365312 chr10:93958191~93961540:- LIHC trans rs9858542 0.953 rs1801143 ENSG00000197582.5 GPX1P1 -6.81 4.35e-11 0.000115 -0.57 -0.35 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49532767 chrX:13378735~13379340:- LIHC trans rs7554547 0.69 rs1474576 ENSG00000261819.1 RP11-680G24.4 6.81 4.44e-11 0.000117 0.45 0.35 Nonsyndromic cleft lip with cleft palate; chr1:11887572 chr16:14988259~14990160:- LIHC trans rs9876781 1 rs9812647 ENSG00000235912.1 RP1-159A19.3 6.81 4.51e-11 0.000119 0.38 0.35 Longevity; chr3:48407507 chr1:27649419~27649610:+ LIHC trans rs9611519 1 rs9611519 ENSG00000268568.1 AC007228.9 -6.8 4.56e-11 0.00012 -0.52 -0.35 Neuroticism; chr22:41217184 chr19:56672574~56673901:- LIHC trans rs9611519 1 rs9611520 ENSG00000268568.1 AC007228.9 -6.8 4.56e-11 0.00012 -0.52 -0.35 Neuroticism; chr22:41217299 chr19:56672574~56673901:- LIHC trans rs5751901 0.614 rs6519519 ENSG00000280208.1 RP11-341D18.4 6.8 4.56e-11 0.00012 0.44 0.35 Protein quantitative trait loci; chr22:24595896 chr13:18253526~18270822:- LIHC trans rs77688320 0.535 rs11691118 ENSG00000235105.1 RP11-329A14.1 6.8 4.59e-11 0.000121 0.32 0.35 Breast cancer; chr2:201405121 chr1:48435967~48437223:+ LIHC trans rs714543 0.811 rs13238404 ENSG00000219797.2 PPIAP9 6.8 4.6e-11 0.000121 0.41 0.35 Plateletcrit; chr7:44811812 chr6:31519480~31520291:- LIHC trans rs11220082 0.666 rs7103665 ENSG00000236257.1 EI24P2 -6.8 4.6e-11 0.000121 -0.41 -0.35 Schizophrenia; chr11:125472998 chr1:158454198~158455273:+ LIHC trans rs11220082 0.644 rs61917855 ENSG00000236257.1 EI24P2 -6.8 4.6e-11 0.000121 -0.41 -0.35 Schizophrenia; chr11:125473652 chr1:158454198~158455273:+ LIHC trans rs864643 0.947 rs1417147 ENSG00000183298.5 RP11-556K13.1 6.8 4.6e-11 0.000121 0.48 0.35 Attention deficit hyperactivity disorder; chr3:39499236 chr1:101786340~101787219:- LIHC trans rs7662987 1 rs28730640 ENSG00000228407.2 RP4-800M22.1 6.8 4.6e-11 0.000121 0.96 0.35 Smoking initiation; chr4:99072902 chr1:52160261~52160600:- LIHC trans rs7662987 1 rs7658118 ENSG00000228407.2 RP4-800M22.1 6.8 4.6e-11 0.000121 0.96 0.35 Smoking initiation; chr4:99073457 chr1:52160261~52160600:- LIHC trans rs9876781 0.967 rs2885509 ENSG00000235912.1 RP1-159A19.3 6.8 4.67e-11 0.000123 0.4 0.35 Longevity; chr3:48376729 chr1:27649419~27649610:+ LIHC trans rs875971 0.545 rs67775320 ENSG00000164669.11 INTS4P1 -6.8 4.74e-11 0.000125 -0.46 -0.35 Aortic root size; chr7:66193792 chr7:65141225~65234216:+ LIHC trans rs453301 0.571 rs2929453 ENSG00000253893.2 FAM85B 6.8 4.78e-11 0.000126 0.47 0.34 Joint mobility (Beighton score); chr8:9226831 chr8:8167819~8226614:- LIHC trans rs875971 0.545 rs73376394 ENSG00000164669.11 INTS4P1 -6.8 4.81e-11 0.000127 -0.46 -0.34 Aortic root size; chr7:66172694 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs316305 ENSG00000164669.11 INTS4P1 6.79 4.86e-11 0.000128 0.46 0.34 Aortic root size; chr7:66152984 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs316306 ENSG00000164669.11 INTS4P1 6.79 4.86e-11 0.000128 0.46 0.34 Aortic root size; chr7:66153687 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs10950025 ENSG00000164669.11 INTS4P1 -6.79 4.86e-11 0.000128 -0.46 -0.34 Aortic root size; chr7:66158946 chr7:65141225~65234216:+ LIHC trans rs875971 0.52 rs12666485 ENSG00000164669.11 INTS4P1 -6.79 4.86e-11 0.000128 -0.46 -0.34 Aortic root size; chr7:66160135 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs67688847 ENSG00000164669.11 INTS4P1 -6.79 4.86e-11 0.000128 -0.46 -0.34 Aortic root size; chr7:66161064 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs12673308 ENSG00000164669.11 INTS4P1 -6.79 4.86e-11 0.000128 -0.46 -0.34 Aortic root size; chr7:66166374 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs6460276 ENSG00000164669.11 INTS4P1 -6.79 4.91e-11 0.000129 -0.46 -0.34 Aortic root size; chr7:66182290 chr7:65141225~65234216:+ LIHC trans rs7937890 0.504 rs2575847 ENSG00000236360.2 RP11-334A14.2 6.79 4.96e-11 0.00013 0.44 0.34 Mitochondrial DNA levels; chr11:14449626 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2575825 ENSG00000236360.2 RP11-334A14.2 6.79 4.96e-11 0.00013 0.44 0.34 Mitochondrial DNA levels; chr11:14450550 chr1:52993201~52993702:- LIHC trans rs7937890 0.532 rs2575827 ENSG00000236360.2 RP11-334A14.2 6.79 4.96e-11 0.00013 0.44 0.34 Mitochondrial DNA levels; chr11:14453969 chr1:52993201~52993702:- LIHC trans rs7937890 0.532 rs2256884 ENSG00000236360.2 RP11-334A14.2 6.79 4.96e-11 0.00013 0.44 0.34 Mitochondrial DNA levels; chr11:14454856 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2597206 ENSG00000236360.2 RP11-334A14.2 6.79 4.96e-11 0.00013 0.44 0.34 Mitochondrial DNA levels; chr11:14455992 chr1:52993201~52993702:- LIHC trans rs5751901 0.614 rs4820599 ENSG00000280208.1 RP11-341D18.4 6.79 4.99e-11 0.000131 0.43 0.34 Protein quantitative trait loci; chr22:24594246 chr13:18253526~18270822:- LIHC trans rs7662987 1 rs11547772 ENSG00000228407.2 RP4-800M22.1 6.79 5.02e-11 0.000132 0.92 0.34 Smoking initiation; chr4:99071642 chr1:52160261~52160600:- LIHC trans rs77688320 0.535 rs10804115 ENSG00000235105.1 RP11-329A14.1 6.79 5.03e-11 0.000132 0.33 0.34 Breast cancer; chr2:201415510 chr1:48435967~48437223:+ LIHC trans rs875971 0.545 rs7787063 ENSG00000164669.11 INTS4P1 -6.79 5.04e-11 0.000132 -0.46 -0.34 Aortic root size; chr7:66164012 chr7:65141225~65234216:+ LIHC trans rs3849046 0.817 rs13160755 ENSG00000226666.1 HSPA9P1 6.79 5.07e-11 0.000133 0.41 0.34 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138549942 chr2:221961737~221963765:+ LIHC trans rs9876781 1 rs7634377 ENSG00000235912.1 RP1-159A19.3 -6.79 5.09e-11 0.000134 -0.39 -0.34 Longevity; chr3:48379768 chr1:27649419~27649610:+ LIHC trans rs864643 0.812 rs3821372 ENSG00000183298.5 RP11-556K13.1 -6.79 5.1e-11 0.000134 -0.46 -0.34 Attention deficit hyperactivity disorder; chr3:39506880 chr1:101786340~101787219:- LIHC trans rs9876781 1 rs9815103 ENSG00000235912.1 RP1-159A19.3 -6.79 5.12e-11 0.000134 -0.39 -0.34 Longevity; chr3:48372725 chr1:27649419~27649610:+ LIHC trans rs77688320 0.535 rs7579617 ENSG00000235105.1 RP11-329A14.1 6.78 5.15e-11 0.000135 0.33 0.34 Breast cancer; chr2:201384065 chr1:48435967~48437223:+ LIHC trans rs9425766 0.64 rs2295366 ENSG00000213331.4 RP11-713C19.2 6.78 5.16e-11 0.000135 0.43 0.34 Life satisfaction; chr1:173856554 chr4:187970273~187971284:+ LIHC trans rs5751901 0.614 rs5760485 ENSG00000280208.1 RP11-341D18.4 6.78 5.2e-11 0.000136 0.44 0.34 Protein quantitative trait loci; chr22:24590505 chr13:18253526~18270822:- LIHC trans rs7937890 0.587 rs11023204 ENSG00000236360.2 RP11-334A14.2 6.78 5.28e-11 0.000138 0.44 0.34 Mitochondrial DNA levels; chr11:14389677 chr1:52993201~52993702:- LIHC trans rs12210905 0.748 rs6901225 ENSG00000242375.1 RP11-498P14.3 -6.78 5.31e-11 0.000139 -0.69 -0.34 Hip circumference adjusted for BMI; chr6:26670263 chr9:97195351~97197687:- LIHC trans rs864643 0.812 rs1398669 ENSG00000183298.5 RP11-556K13.1 -6.78 5.32e-11 0.000139 -0.46 -0.34 Attention deficit hyperactivity disorder; chr3:39504500 chr1:101786340~101787219:- LIHC trans rs77688320 0.535 rs2241118 ENSG00000235105.1 RP11-329A14.1 6.78 5.43e-11 0.000142 0.33 0.34 Breast cancer; chr2:201388993 chr1:48435967~48437223:+ LIHC trans rs3749237 1 rs11130214 ENSG00000197582.5 GPX1P1 -6.77 5.47e-11 0.000143 -0.48 -0.34 Resting heart rate; chr3:49698313 chrX:13378735~13379340:- LIHC trans rs12200782 1 rs3800304 ENSG00000242375.1 RP11-498P14.3 -6.77 5.59e-11 0.000146 -0.8 -0.34 Small cell lung carcinoma; chr6:26598570 chr9:97195351~97197687:- LIHC trans rs12200782 1 rs72844495 ENSG00000242375.1 RP11-498P14.3 -6.77 5.59e-11 0.000146 -0.8 -0.34 Small cell lung carcinoma; chr6:26610412 chr9:97195351~97197687:- LIHC trans rs12200782 1 rs72844496 ENSG00000242375.1 RP11-498P14.3 -6.77 5.59e-11 0.000146 -0.8 -0.34 Small cell lung carcinoma; chr6:26611380 chr9:97195351~97197687:- LIHC trans rs12200782 1 rs6456741 ENSG00000242375.1 RP11-498P14.3 -6.77 5.59e-11 0.000146 -0.8 -0.34 Small cell lung carcinoma; chr6:26616830 chr9:97195351~97197687:- LIHC trans rs12200782 1 rs6456742 ENSG00000242375.1 RP11-498P14.3 -6.77 5.59e-11 0.000146 -0.8 -0.34 Small cell lung carcinoma; chr6:26616847 chr9:97195351~97197687:- LIHC trans rs12200782 1 rs4515370 ENSG00000242375.1 RP11-498P14.3 -6.77 5.59e-11 0.000146 -0.8 -0.34 Small cell lung carcinoma; chr6:26625091 chr9:97195351~97197687:- LIHC trans rs12200782 1 rs12205909 ENSG00000242375.1 RP11-498P14.3 -6.77 5.59e-11 0.000146 -0.8 -0.34 Small cell lung carcinoma; chr6:26630771 chr9:97195351~97197687:- LIHC trans rs12200782 1 rs72845509 ENSG00000242375.1 RP11-498P14.3 -6.77 5.59e-11 0.000146 -0.8 -0.34 Small cell lung carcinoma; chr6:26639637 chr9:97195351~97197687:- LIHC trans rs12200782 0.932 rs12212145 ENSG00000242375.1 RP11-498P14.3 -6.77 5.59e-11 0.000146 -0.8 -0.34 Small cell lung carcinoma; chr6:26646190 chr9:97195351~97197687:- LIHC trans rs12200782 0.799 rs72845515 ENSG00000242375.1 RP11-498P14.3 -6.77 5.59e-11 0.000146 -0.8 -0.34 Small cell lung carcinoma; chr6:26646643 chr9:97195351~97197687:- LIHC trans rs12210905 0.8 rs12209651 ENSG00000242375.1 RP11-498P14.3 -6.77 5.59e-11 0.000146 -0.8 -0.34 Hip circumference adjusted for BMI; chr6:26660697 chr9:97195351~97197687:- LIHC trans rs12210905 0.8 rs12201890 ENSG00000242375.1 RP11-498P14.3 -6.77 5.59e-11 0.000146 -0.8 -0.34 Hip circumference adjusted for BMI; chr6:26662398 chr9:97195351~97197687:- LIHC trans rs9425766 0.962 rs1322780 ENSG00000213331.4 RP11-713C19.2 6.77 5.6e-11 0.000146 0.41 0.34 Life satisfaction; chr1:173896448 chr4:187970273~187971284:+ LIHC trans rs9425766 0.962 rs9425435 ENSG00000213331.4 RP11-713C19.2 6.77 5.7e-11 0.000148 0.41 0.34 Life satisfaction; chr1:173896936 chr4:187970273~187971284:+ LIHC trans rs13014235 0.562 rs2080325 ENSG00000235105.1 RP11-329A14.1 -6.76 5.84e-11 0.000152 -0.33 -0.34 Basal cell carcinoma; chr2:201513640 chr1:48435967~48437223:+ LIHC trans rs6424115 0.83 rs3003333 ENSG00000228217.1 AL390877.1 6.76 5.86e-11 0.000153 0.39 0.34 Immature fraction of reticulocytes; chr1:23867524 chr1:117778087~117778506:- LIHC trans rs76228276 0.737 rs2067529 ENSG00000260318.1 COX6CP1 6.76 5.9e-11 0.000154 0.92 0.34 Childhood ear infection; chr8:99618731 chr16:11903923~11904137:- LIHC trans rs7554547 0.69 rs1474577 ENSG00000261819.1 RP11-680G24.4 6.76 5.92e-11 0.000154 0.45 0.34 Nonsyndromic cleft lip with cleft palate; chr1:11887712 chr16:14988259~14990160:- LIHC trans rs77688320 0.535 rs6751543 ENSG00000235105.1 RP11-329A14.1 6.76 5.99e-11 0.000156 0.33 0.34 Breast cancer; chr2:201400210 chr1:48435967~48437223:+ LIHC trans rs77688320 0.535 rs34625194 ENSG00000235105.1 RP11-329A14.1 6.76 5.99e-11 0.000156 0.33 0.34 Breast cancer; chr2:201406815 chr1:48435967~48437223:+ LIHC trans rs77688320 0.535 rs11691859 ENSG00000235105.1 RP11-329A14.1 6.76 5.99e-11 0.000156 0.33 0.34 Breast cancer; chr2:201407268 chr1:48435967~48437223:+ LIHC trans rs77688320 0.517 rs11691865 ENSG00000235105.1 RP11-329A14.1 6.76 5.99e-11 0.000156 0.33 0.34 Breast cancer; chr2:201407309 chr1:48435967~48437223:+ LIHC trans rs9858542 0.951 rs1800668 ENSG00000197582.5 GPX1P1 -6.76 6.09e-11 0.000158 -0.58 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49358324 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs1987628 ENSG00000197582.5 GPX1P1 -6.76 6.09e-11 0.000158 -0.58 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49361826 chrX:13378735~13379340:- LIHC trans rs148734725 1 rs148734725 ENSG00000197582.5 GPX1P1 -6.76 6.09e-11 0.000158 -0.58 -0.34 Educational attainment (college completion); chr3:49369275 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs34588335 ENSG00000197582.5 GPX1P1 -6.76 6.09e-11 0.000158 -0.58 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49370227 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs6809216 ENSG00000197582.5 GPX1P1 -6.76 6.09e-11 0.000158 -0.58 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49375126 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs7623659 ENSG00000197582.5 GPX1P1 -6.76 6.09e-11 0.000158 -0.58 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49377358 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs6446264 ENSG00000197582.5 GPX1P1 -6.76 6.09e-11 0.000158 -0.58 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49379810 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs35169793 ENSG00000197582.5 GPX1P1 -6.76 6.09e-11 0.000158 -0.58 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49385841 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs9878943 ENSG00000197582.5 GPX1P1 -6.76 6.09e-11 0.000158 -0.58 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49397221 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs11706370 ENSG00000197582.5 GPX1P1 -6.76 6.09e-11 0.000158 -0.58 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49403658 chrX:13378735~13379340:- LIHC trans rs1023500 1 rs9620001 ENSG00000268568.1 AC007228.9 -6.75 6.16e-11 0.00016 -0.48 -0.34 Schizophrenia; chr22:41934225 chr19:56672574~56673901:- LIHC trans rs72615157 0.716 rs75779608 ENSG00000228546.2 CTA-313A17.3 6.75 6.19e-11 0.000161 0.58 0.34 Lung function (FEV1/FVC); chr7:100171334 chr7:102337316~102339115:+ LIHC trans rs9467773 0.836 rs1624440 ENSG00000242375.1 RP11-498P14.3 -6.75 6.23e-11 0.000162 -0.41 -0.34 Intelligence (multi-trait analysis); chr6:26433101 chr9:97195351~97197687:- LIHC trans rs1023500 1 rs10154646 ENSG00000268568.1 AC007228.9 -6.75 6.25e-11 0.000162 -0.48 -0.34 Schizophrenia; chr22:41935405 chr19:56672574~56673901:- LIHC trans rs877636 0.692 rs10876870 ENSG00000234513.1 AC073072.7 -6.75 6.36e-11 0.000165 -0.43 -0.34 Cognitive function; chr12:56084218 chr7:22773646~22773993:- LIHC trans rs877636 0.692 rs7971751 ENSG00000234513.1 AC073072.7 -6.75 6.36e-11 0.000165 -0.43 -0.34 Cognitive function; chr12:56084874 chr7:22773646~22773993:- LIHC trans rs7312770 0.612 rs773114 ENSG00000212994.5 RPS26P6 6.75 6.39e-11 0.000166 0.43 0.34 Polycystic ovary syndrome;Hypothyroidism; chr12:55985276 chr8:100895771~100896118:+ LIHC trans rs864643 0.891 rs4129648 ENSG00000183298.5 RP11-556K13.1 6.75 6.42e-11 0.000166 0.57 0.34 Attention deficit hyperactivity disorder; chr3:39519319 chr1:101786340~101787219:- LIHC trans rs864643 1 rs574074 ENSG00000183298.5 RP11-556K13.1 6.75 6.42e-11 0.000166 0.57 0.34 Attention deficit hyperactivity disorder; chr3:39520090 chr1:101786340~101787219:- LIHC trans rs864643 1 rs673426 ENSG00000183298.5 RP11-556K13.1 6.75 6.42e-11 0.000166 0.57 0.34 Attention deficit hyperactivity disorder; chr3:39520286 chr1:101786340~101787219:- LIHC trans rs864643 0.945 rs529839 ENSG00000183298.5 RP11-556K13.1 6.75 6.42e-11 0.000166 0.57 0.34 Attention deficit hyperactivity disorder; chr3:39525267 chr1:101786340~101787219:- LIHC trans rs864643 1 rs546031 ENSG00000183298.5 RP11-556K13.1 6.75 6.42e-11 0.000166 0.57 0.34 Attention deficit hyperactivity disorder; chr3:39529886 chr1:101786340~101787219:- LIHC trans rs864643 1 rs569888 ENSG00000183298.5 RP11-556K13.1 6.75 6.42e-11 0.000166 0.57 0.34 Attention deficit hyperactivity disorder; chr3:39530165 chr1:101786340~101787219:- LIHC trans rs864643 1 rs946409 ENSG00000183298.5 RP11-556K13.1 6.75 6.42e-11 0.000166 0.57 0.34 Attention deficit hyperactivity disorder; chr3:39531549 chr1:101786340~101787219:- LIHC trans rs7937890 0.572 rs2597202 ENSG00000236360.2 RP11-334A14.2 6.75 6.46e-11 0.000167 0.45 0.34 Mitochondrial DNA levels; chr11:14463099 chr1:52993201~52993702:- LIHC trans rs7312770 0.637 rs705700 ENSG00000212994.5 RPS26P6 6.75 6.49e-11 0.000168 0.43 0.34 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr8:100895771~100896118:+ LIHC trans rs9876781 1 rs6784322 ENSG00000235912.1 RP1-159A19.3 -6.75 6.52e-11 0.000169 -0.39 -0.34 Longevity; chr3:48380745 chr1:27649419~27649610:+ LIHC trans rs7444 0.941 rs12158299 ENSG00000274602.3 PI4KAP1 -6.75 6.53e-11 0.000169 -0.44 -0.34 Systemic lupus erythematosus; chr22:21625295 chr22:18533646~18577968:- LIHC trans rs3849046 0.79 rs17207604 ENSG00000226666.1 HSPA9P1 -6.74 6.7e-11 0.000173 -0.42 -0.34 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138595901 chr2:221961737~221963765:+ LIHC trans rs72615157 0.606 rs941288 ENSG00000228546.2 CTA-313A17.3 6.74 6.89e-11 0.000178 0.52 0.34 Lung function (FEV1/FVC); chr7:100179185 chr7:102337316~102339115:+ LIHC trans rs12138950 0.681 rs28630511 ENSG00000224237.1 MINOS1P3 6.73 6.96e-11 0.00018 0.42 0.34 Hypothyroidism;Thyroid volume; chr1:19516538 chr3:27214816~27215018:- LIHC trans rs875971 0.545 rs316316 ENSG00000164669.11 INTS4P1 6.73 6.99e-11 0.00018 0.46 0.34 Aortic root size; chr7:66149270 chr7:65141225~65234216:+ LIHC trans rs8067354 0.645 rs2645467 ENSG00000187870.7 RNFT1P3 6.73 7e-11 0.000181 0.4 0.34 Hemoglobin concentration; chr17:59777422 chr17:20743333~20754501:- LIHC trans rs8067354 0.645 rs2645491 ENSG00000187870.7 RNFT1P3 6.73 7e-11 0.000181 0.4 0.34 Hemoglobin concentration; chr17:59799688 chr17:20743333~20754501:- LIHC trans rs864643 0.812 rs1513218 ENSG00000183298.5 RP11-556K13.1 6.73 7.15e-11 0.000184 0.45 0.34 Attention deficit hyperactivity disorder; chr3:39504097 chr1:101786340~101787219:- LIHC trans rs3849046 0.817 rs68128065 ENSG00000226666.1 HSPA9P1 -6.73 7.28e-11 0.000188 -0.41 -0.34 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138590778 chr2:221961737~221963765:+ LIHC trans rs3849046 0.846 rs11738995 ENSG00000226666.1 HSPA9P1 -6.73 7.28e-11 0.000188 -0.41 -0.34 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138591930 chr2:221961737~221963765:+ LIHC trans rs12210905 1 rs12198077 ENSG00000242375.1 RP11-498P14.3 -6.73 7.29e-11 0.000188 -0.9 -0.34 Hip circumference adjusted for BMI; chr6:27201528 chr9:97195351~97197687:- LIHC trans rs864643 0.947 rs1473863 ENSG00000183298.5 RP11-556K13.1 6.72 7.47e-11 0.000192 0.47 0.34 Attention deficit hyperactivity disorder; chr3:39499544 chr1:101786340~101787219:- LIHC trans rs7937890 0.531 rs2575828 ENSG00000236360.2 RP11-334A14.2 6.72 7.51e-11 0.000193 0.44 0.34 Mitochondrial DNA levels; chr11:14462646 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2575829 ENSG00000236360.2 RP11-334A14.2 6.72 7.51e-11 0.000193 0.44 0.34 Mitochondrial DNA levels; chr11:14463475 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2597201 ENSG00000236360.2 RP11-334A14.2 6.72 7.51e-11 0.000193 0.44 0.34 Mitochondrial DNA levels; chr11:14463858 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2597200 ENSG00000236360.2 RP11-334A14.2 6.72 7.51e-11 0.000193 0.44 0.34 Mitochondrial DNA levels; chr11:14464054 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2575830 ENSG00000236360.2 RP11-334A14.2 6.72 7.51e-11 0.000193 0.44 0.34 Mitochondrial DNA levels; chr11:14464056 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2575831 ENSG00000236360.2 RP11-334A14.2 6.72 7.51e-11 0.000193 0.44 0.34 Mitochondrial DNA levels; chr11:14464648 chr1:52993201~52993702:- LIHC trans rs7937890 0.532 rs2575832 ENSG00000236360.2 RP11-334A14.2 6.72 7.51e-11 0.000193 0.44 0.34 Mitochondrial DNA levels; chr11:14467264 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2597197 ENSG00000236360.2 RP11-334A14.2 6.72 7.51e-11 0.000193 0.44 0.34 Mitochondrial DNA levels; chr11:14468286 chr1:52993201~52993702:- LIHC trans rs3849046 0.68 rs13165665 ENSG00000226666.1 HSPA9P1 -6.72 7.63e-11 0.000196 -0.43 -0.34 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138610811 chr2:221961737~221963765:+ LIHC trans rs9858542 0.903 rs17080528 ENSG00000197582.5 GPX1P1 -6.72 7.7e-11 0.000198 -0.58 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49352409 chrX:13378735~13379340:- LIHC trans rs13090388 1 rs13090388 ENSG00000197582.5 GPX1P1 -6.72 7.7e-11 0.000198 -0.58 -0.34 Educational attainment (years of education);Intelligence (multi-trait analysis); chr3:49353649 chrX:13378735~13379340:- LIHC trans rs538867 1 rs1708063 ENSG00000183298.5 RP11-556K13.1 6.72 7.71e-11 0.000198 0.76 0.34 Alzheimer's disease (cognitive decline); chr3:39500602 chr1:101786340~101787219:- LIHC trans rs538867 1 rs73064237 ENSG00000183298.5 RP11-556K13.1 6.72 7.73e-11 0.000199 0.81 0.34 Alzheimer's disease (cognitive decline); chr3:39454410 chr1:101786340~101787219:- LIHC trans rs3849046 0.846 rs256002 ENSG00000226666.1 HSPA9P1 6.71 7.86e-11 0.000202 0.41 0.34 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138559529 chr2:221961737~221963765:+ LIHC trans rs2250402 0.51 rs6492926 ENSG00000234106.3 RP11-288E14.2 6.71 7.88e-11 0.000202 0.54 0.34 Corneal curvature; chr15:40033628 chr11:93535468~93535816:+ LIHC trans rs9858542 0.953 rs9858280 ENSG00000197582.5 GPX1P1 -6.71 7.88e-11 0.000202 -0.58 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49560304 chrX:13378735~13379340:- LIHC trans rs13202860 0.584 rs598958 ENSG00000249855.1 EEF1A1P19 6.71 8.01e-11 0.000205 0.46 0.34 Sexual dysfunction (female); chr6:86678312 chr5:43495073~43496454:- LIHC trans rs8067354 0.645 rs2102507 ENSG00000187870.7 RNFT1P3 6.71 8.11e-11 0.000208 0.4 0.34 Hemoglobin concentration; chr17:59798546 chr17:20743333~20754501:- LIHC trans rs864643 0.945 rs614453 ENSG00000183298.5 RP11-556K13.1 6.7 8.59e-11 0.00022 0.57 0.34 Attention deficit hyperactivity disorder; chr3:39541076 chr1:101786340~101787219:- LIHC trans rs538867 1 rs538867 ENSG00000214263.2 RPSAP53 6.7 8.68e-11 0.000222 0.77 0.34 Alzheimer's disease (cognitive decline); chr3:39471787 chr13:67266845~67267706:- LIHC trans rs4240897 1 rs4240897 ENSG00000261819.1 RP11-680G24.4 -6.7 8.81e-11 0.000225 -0.42 -0.34 Tuberculosis; chr1:11982698 chr16:14988259~14990160:- LIHC trans rs9858542 0.953 rs6779524 ENSG00000197582.5 GPX1P1 -6.7 8.82e-11 0.000225 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49413016 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs4625 ENSG00000197582.5 GPX1P1 -6.7 8.82e-11 0.000226 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49534707 chrX:13378735~13379340:- LIHC trans rs11023332 0.617 rs1879888 ENSG00000236360.2 RP11-334A14.2 6.69 8.98e-11 0.00023 0.42 0.34 Vitamin D levels;Adiponectin levels; chr11:14657701 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2597208 ENSG00000236360.2 RP11-334A14.2 6.69 9e-11 0.00023 0.44 0.34 Mitochondrial DNA levels; chr11:14450783 chr1:52993201~52993702:- LIHC trans rs538867 1 rs1708070 ENSG00000183298.5 RP11-556K13.1 6.69 9.02e-11 0.000231 0.76 0.34 Alzheimer's disease (cognitive decline); chr3:39501014 chr1:101786340~101787219:- LIHC trans rs6921919 0.848 rs9468350 ENSG00000204625.9 HCG9 6.69 9.15e-11 0.000234 0.47 0.34 Autism spectrum disorder or schizophrenia; chr6:28351330 chr6:29975112~29978410:+ LIHC trans rs7937890 0.532 rs2575833 ENSG00000236360.2 RP11-334A14.2 6.69 9.2e-11 0.000235 0.43 0.34 Mitochondrial DNA levels; chr11:14470959 chr1:52993201~52993702:- LIHC trans rs12210905 1 rs12213361 ENSG00000242375.1 RP11-498P14.3 -6.69 9.25e-11 0.000236 -0.9 -0.34 Hip circumference adjusted for BMI; chr6:27170608 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs72843613 ENSG00000242375.1 RP11-498P14.3 -6.69 9.25e-11 0.000236 -0.9 -0.34 Hip circumference adjusted for BMI; chr6:27170688 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs6931711 ENSG00000242375.1 RP11-498P14.3 -6.69 9.25e-11 0.000236 -0.9 -0.34 Hip circumference adjusted for BMI; chr6:27177807 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs1102557 ENSG00000242375.1 RP11-498P14.3 6.69 9.25e-11 0.000236 0.9 0.34 Hip circumference adjusted for BMI; chr6:27182015 chr9:97195351~97197687:- LIHC trans rs875971 0.545 rs316324 ENSG00000164669.11 INTS4P1 6.69 9.32e-11 0.000238 0.46 0.34 Aortic root size; chr7:66145627 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs316323 ENSG00000164669.11 INTS4P1 6.69 9.32e-11 0.000238 0.46 0.34 Aortic root size; chr7:66146002 chr7:65141225~65234216:+ LIHC trans rs12210905 1 rs72838266 ENSG00000242375.1 RP11-498P14.3 -6.69 9.36e-11 0.000239 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27047273 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs72843615 ENSG00000242375.1 RP11-498P14.3 -6.68 9.49e-11 0.000242 -0.9 -0.34 Hip circumference adjusted for BMI; chr6:27182790 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs12210905 ENSG00000242375.1 RP11-498P14.3 -6.68 9.49e-11 0.000242 -0.9 -0.34 Hip circumference adjusted for BMI; chr6:27183530 chr9:97195351~97197687:- LIHC trans rs9876781 1 rs7653691 ENSG00000235912.1 RP1-159A19.3 6.68 9.63e-11 0.000245 0.39 0.34 Longevity; chr3:48378199 chr1:27649419~27649610:+ LIHC trans rs877636 1 rs2292239 ENSG00000212994.5 RPS26P6 6.68 9.66e-11 0.000246 0.43 0.34 Cognitive function; chr12:56088396 chr8:100895771~100896118:+ LIHC trans rs12709013 0.766 rs11648511 ENSG00000230849.2 GOT2P2 6.68 9.71e-11 0.000247 0.4 0.34 Blood metabolite ratios; chr16:58798171 chr1:173141100~173142350:- LIHC trans rs875971 0.545 rs10950029 ENSG00000164669.11 INTS4P1 -6.68 9.84e-11 0.00025 -0.45 -0.34 Aortic root size; chr7:66169334 chr7:65141225~65234216:+ LIHC trans rs7312770 0.612 rs1873914 ENSG00000212994.5 RPS26P6 6.68 9.96e-11 0.000253 0.44 0.34 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr8:100895771~100896118:+ LIHC trans rs9876781 1 rs725309 ENSG00000235912.1 RP1-159A19.3 6.67 1e-10 0.000254 0.39 0.34 Longevity; chr3:48377218 chr1:27649419~27649610:+ LIHC trans rs7312770 1 rs7312770 ENSG00000234513.1 AC073072.7 -6.67 1.01e-10 0.000257 -0.41 -0.34 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr7:22773646~22773993:- LIHC trans rs7121616 0.531 rs10892958 ENSG00000229091.2 HSPA8P8 6.67 1.05e-10 0.000267 0.41 0.34 Breast cancer; chr11:123061415 chr7:10451311~10452526:+ LIHC trans rs7937890 0.869 rs2915404 ENSG00000236360.2 RP11-334A14.2 6.67 1.05e-10 0.000268 0.44 0.34 Mitochondrial DNA levels; chr11:14383279 chr1:52993201~52993702:- LIHC trans rs2074193 0.585 rs11183915 ENSG00000249193.1 HSPD1P5 -6.67 1.06e-10 0.000268 -0.4 -0.34 Migraine with aura; chr12:47377201 chr4:144845625~144847344:+ LIHC trans rs12210905 1 rs12201498 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27062305 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs12203728 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27083971 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs12209429 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27087088 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs12192049 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27088960 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs12201774 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27090533 chr9:97195351~97197687:- LIHC trans rs12210905 0.841 rs12206996 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27098636 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs12208534 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27098980 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs72842200 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27100257 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs12209393 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27117294 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs12209456 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27117446 chr9:97195351~97197687:- LIHC trans rs12210905 0.92 rs6911234 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27119080 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs12192320 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27122526 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs12214930 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27125936 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs3531 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27127534 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs4636015 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27129537 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs41269245 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27132317 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs72843607 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27142936 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs7756481 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27147290 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs72843608 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27154971 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs72843609 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27158098 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs72843611 ENSG00000242375.1 RP11-498P14.3 -6.66 1.07e-10 0.000271 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27163603 chr9:97195351~97197687:- LIHC trans rs7937890 0.559 rs2597196 ENSG00000236360.2 RP11-334A14.2 -6.66 1.07e-10 0.000272 -0.44 -0.34 Mitochondrial DNA levels; chr11:14470055 chr1:52993201~52993702:- LIHC trans rs1023500 1 rs1047997 ENSG00000268568.1 AC007228.9 -6.66 1.07e-10 0.000272 -0.48 -0.34 Schizophrenia; chr22:41938949 chr19:56672574~56673901:- LIHC trans rs9611519 1 rs9611510 ENSG00000268568.1 AC007228.9 -6.66 1.08e-10 0.000273 -0.51 -0.34 Neuroticism; chr22:41173120 chr19:56672574~56673901:- LIHC trans rs12709013 0.716 rs11647582 ENSG00000230849.2 GOT2P2 6.66 1.08e-10 0.000274 0.4 0.34 Blood metabolite ratios; chr16:58801474 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs35684307 ENSG00000230849.2 GOT2P2 6.66 1.08e-10 0.000274 0.4 0.34 Blood metabolite ratios; chr16:58801651 chr1:173141100~173142350:- LIHC trans rs12210905 1 rs72843619 ENSG00000242375.1 RP11-498P14.3 -6.66 1.09e-10 0.000276 -0.87 -0.34 Hip circumference adjusted for BMI; chr6:27187051 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs116005859 ENSG00000242375.1 RP11-498P14.3 -6.66 1.09e-10 0.000276 -0.87 -0.34 Hip circumference adjusted for BMI; chr6:27187706 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs12196889 ENSG00000242375.1 RP11-498P14.3 -6.66 1.09e-10 0.000276 -0.87 -0.34 Hip circumference adjusted for BMI; chr6:27188316 chr9:97195351~97197687:- LIHC trans rs12210905 0.687 rs72843622 ENSG00000242375.1 RP11-498P14.3 -6.66 1.09e-10 0.000276 -0.87 -0.34 Hip circumference adjusted for BMI; chr6:27193373 chr9:97195351~97197687:- LIHC trans rs8067354 0.645 rs2271304 ENSG00000187870.7 RNFT1P3 6.66 1.1e-10 0.000277 0.4 0.34 Hemoglobin concentration; chr17:59737280 chr17:20743333~20754501:- LIHC trans rs3088050 0.775 rs2011077 ENSG00000217325.2 PRELID1P1 -6.66 1.1e-10 0.000279 -0.42 -0.34 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr5:177094455 chr6:126643488~126644390:+ LIHC trans rs3740713 1 rs12289603 ENSG00000235847.2 LDHAP7 6.66 1.1e-10 0.000279 0.59 0.34 Amyotrophic lateral sclerosis (sporadic); chr11:18449823 chr2:84777259~84778223:- LIHC trans rs9858542 0.953 rs9859556 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49418553 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs11922013 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49420922 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs6446272 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49425854 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs7646366 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49433235 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs35115732 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49437722 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs9841110 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49455048 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs67216675 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49455718 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs9853683 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49475155 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs12330269 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49476477 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs9827021 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49477331 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs9818590 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49487663 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs11719996 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49488525 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs34363169 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49500279 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs35261698 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49500406 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs6766131 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49501499 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs6766581 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49501968 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs9821311 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49506223 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs7622302 ENSG00000197582.5 GPX1P1 -6.66 1.12e-10 0.000282 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49510128 chrX:13378735~13379340:- LIHC trans rs714543 0.585 rs9655458 ENSG00000219797.2 PPIAP9 6.66 1.13e-10 0.000284 0.39 0.34 Plateletcrit; chr7:44771386 chr6:31519480~31520291:- LIHC trans rs12210905 0.925 rs12193820 ENSG00000242375.1 RP11-498P14.3 -6.65 1.14e-10 0.000286 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27146032 chr9:97195351~97197687:- LIHC trans rs7568458 0.837 rs3770098 ENSG00000223886.3 RP11-251G23.2 6.65 1.16e-10 0.000292 0.38 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85578244 chr7:105530209~105530671:+ LIHC trans rs7568458 0.837 rs3731827 ENSG00000223886.3 RP11-251G23.2 6.65 1.16e-10 0.000292 0.38 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85578945 chr7:105530209~105530671:+ LIHC trans rs9858542 0.953 rs9837027 ENSG00000197582.5 GPX1P1 -6.65 1.17e-10 0.000294 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49559580 chrX:13378735~13379340:- LIHC trans rs9858542 0.903 rs35999162 ENSG00000197582.5 GPX1P1 -6.65 1.17e-10 0.000294 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49559797 chrX:13378735~13379340:- LIHC trans rs714543 0.811 rs13238404 ENSG00000226038.5 PPIAP21 6.65 1.17e-10 0.000296 0.39 0.34 Plateletcrit; chr7:44811812 chr20:43230760~43231260:+ LIHC trans rs8067354 0.645 rs72838857 ENSG00000187870.7 RNFT1P3 6.65 1.17e-10 0.000296 0.4 0.34 Hemoglobin concentration; chr17:59759406 chr17:20743333~20754501:- LIHC trans rs8067354 0.645 rs16943838 ENSG00000187870.7 RNFT1P3 6.65 1.17e-10 0.000296 0.4 0.34 Hemoglobin concentration; chr17:59762243 chr17:20743333~20754501:- LIHC trans rs8067354 0.645 rs1874548 ENSG00000187870.7 RNFT1P3 6.65 1.17e-10 0.000296 0.4 0.34 Hemoglobin concentration; chr17:59763996 chr17:20743333~20754501:- LIHC trans rs7568458 0.905 rs17026396 ENSG00000223886.3 RP11-251G23.2 -6.65 1.18e-10 0.000297 -0.38 -0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85532004 chr7:105530209~105530671:+ LIHC trans rs7568458 0.875 rs2044474 ENSG00000223886.3 RP11-251G23.2 6.65 1.18e-10 0.000297 0.38 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85531667 chr7:105530209~105530671:+ LIHC trans rs2250402 0.51 rs2291621 ENSG00000234106.3 RP11-288E14.2 6.64 1.2e-10 0.000302 0.53 0.34 Corneal curvature; chr15:40032636 chr11:93535468~93535816:+ LIHC trans rs9467773 0.649 rs2145318 ENSG00000242375.1 RP11-498P14.3 6.64 1.22e-10 0.000308 0.39 0.34 Intelligence (multi-trait analysis); chr6:26496375 chr9:97195351~97197687:- LIHC trans rs9858542 0.953 rs3811699 ENSG00000197582.5 GPX1P1 -6.64 1.23e-10 0.000309 -0.57 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49358927 chrX:13378735~13379340:- LIHC trans rs7568458 0.87 rs1562323 ENSG00000223886.3 RP11-251G23.2 6.64 1.23e-10 0.000309 0.38 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85582588 chr7:105530209~105530671:+ LIHC trans rs9876781 1 rs2885510 ENSG00000235912.1 RP1-159A19.3 6.64 1.23e-10 0.000309 0.39 0.34 Longevity; chr3:48376736 chr1:27649419~27649610:+ LIHC trans rs7121616 0.531 rs11218941 ENSG00000229091.2 HSPA8P8 6.64 1.24e-10 0.000311 0.41 0.34 Breast cancer; chr11:123061701 chr7:10451311~10452526:+ LIHC trans rs9876781 1 rs6442119 ENSG00000235912.1 RP1-159A19.3 -6.64 1.24e-10 0.000312 -0.38 -0.34 Longevity; chr3:48398713 chr1:27649419~27649610:+ LIHC trans rs12210905 1 rs12205921 ENSG00000242375.1 RP11-498P14.3 -6.64 1.25e-10 0.000313 -0.88 -0.34 Hip circumference adjusted for BMI; chr6:27145761 chr9:97195351~97197687:- LIHC trans rs877636 1 rs877636 ENSG00000212994.5 RPS26P6 -6.64 1.25e-10 0.000315 -0.44 -0.34 Cognitive function; chr12:56086799 chr8:100895771~100896118:+ LIHC trans rs7444 0.66 rs11089637 ENSG00000274602.3 PI4KAP1 -6.64 1.26e-10 0.000315 -0.44 -0.34 Systemic lupus erythematosus; chr22:21624807 chr22:18533646~18577968:- LIHC trans rs9876781 1 rs1459242 ENSG00000235912.1 RP1-159A19.3 6.64 1.27e-10 0.000318 0.39 0.34 Longevity; chr3:48372047 chr1:27649419~27649610:+ LIHC trans rs2250402 0.51 rs2898984 ENSG00000234106.3 RP11-288E14.2 6.63 1.28e-10 0.000322 0.52 0.34 Corneal curvature; chr15:40031874 chr11:93535468~93535816:+ LIHC trans rs12210905 1 rs72843629 ENSG00000242375.1 RP11-498P14.3 -6.63 1.29e-10 0.000324 -0.87 -0.34 Hip circumference adjusted for BMI; chr6:27207436 chr9:97195351~97197687:- LIHC trans rs7662987 0.793 rs28730602 ENSG00000233859.2 ADH5P4 6.63 1.32e-10 0.00033 0.66 0.34 Smoking initiation; chr4:99080531 chr6:65836930~65838039:- LIHC trans rs7554547 0.667 rs6666533 ENSG00000261819.1 RP11-680G24.4 6.63 1.33e-10 0.000332 0.44 0.34 Nonsyndromic cleft lip with cleft palate; chr1:11889068 chr16:14988259~14990160:- LIHC trans rs9876781 1 rs6810060 ENSG00000235912.1 RP1-159A19.3 -6.62 1.36e-10 0.000339 -0.38 -0.34 Longevity; chr3:48393284 chr1:27649419~27649610:+ LIHC trans rs1023500 0.956 rs1894713 ENSG00000268568.1 AC007228.9 -6.62 1.41e-10 0.000352 -0.47 -0.34 Schizophrenia; chr22:41939617 chr19:56672574~56673901:- LIHC trans rs9858542 0.953 rs11711485 ENSG00000197582.5 GPX1P1 -6.62 1.42e-10 0.000355 -0.56 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49454550 chrX:13378735~13379340:- LIHC trans rs7809615 0.551 rs952319 ENSG00000228834.1 RP11-249L21.4 6.62 1.43e-10 0.000356 0.62 0.34 Blood metabolite ratios; chr7:99573826 chr6:108907615~108907873:- LIHC trans rs7444 0.941 rs5754426 ENSG00000274602.3 PI4KAP1 -6.62 1.43e-10 0.000356 -0.43 -0.34 Systemic lupus erythematosus; chr22:21626349 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs4821130 ENSG00000274602.3 PI4KAP1 -6.62 1.43e-10 0.000356 -0.43 -0.34 Systemic lupus erythematosus; chr22:21626605 chr22:18533646~18577968:- LIHC trans rs714543 0.875 rs35585318 ENSG00000226038.5 PPIAP21 -6.62 1.43e-10 0.000357 -0.4 -0.34 Plateletcrit; chr7:44852220 chr20:43230760~43231260:+ LIHC trans rs7568458 0.905 rs6547620 ENSG00000223886.3 RP11-251G23.2 6.62 1.43e-10 0.000357 0.38 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85528805 chr7:105530209~105530671:+ LIHC trans rs7568458 0.87 rs6719046 ENSG00000223886.3 RP11-251G23.2 6.62 1.43e-10 0.000357 0.38 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85530248 chr7:105530209~105530671:+ LIHC trans rs7568458 0.87 rs6733913 ENSG00000223886.3 RP11-251G23.2 6.62 1.43e-10 0.000357 0.38 0.34 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85530256 chr7:105530209~105530671:+ LIHC trans rs7444 0.941 rs181360 ENSG00000274602.3 PI4KAP1 -6.62 1.43e-10 0.000358 -0.43 -0.34 Systemic lupus erythematosus; chr22:21574627 chr22:18533646~18577968:- LIHC trans rs7554547 0.69 rs6669571 ENSG00000261819.1 RP11-680G24.4 6.61 1.49e-10 0.00037 0.44 0.34 Nonsyndromic cleft lip with cleft palate; chr1:11887253 chr16:14988259~14990160:- LIHC trans rs76228276 0.737 rs1349244 ENSG00000260318.1 COX6CP1 6.61 1.49e-10 0.000371 0.88 0.34 Childhood ear infection; chr8:99745774 chr16:11903923~11904137:- LIHC trans rs77688320 0.535 rs13027669 ENSG00000235105.1 RP11-329A14.1 6.61 1.5e-10 0.000374 0.32 0.34 Breast cancer; chr2:201382596 chr1:48435967~48437223:+ LIHC trans rs8010715 0.636 rs2277482 ENSG00000238000.1 RP11-274E7.2 6.61 1.51e-10 0.000376 0.39 0.34 IgG glycosylation; chr14:24118586 chr5:98213402~98214121:+ LIHC trans rs9876781 1 rs6770470 ENSG00000235912.1 RP1-159A19.3 -6.61 1.51e-10 0.000376 -0.38 -0.34 Longevity; chr3:48393659 chr1:27649419~27649610:+ LIHC trans rs7444 0.941 rs5754422 ENSG00000274602.3 PI4KAP1 -6.6 1.53e-10 0.000381 -0.43 -0.34 Systemic lupus erythematosus; chr22:21625968 chr22:18533646~18577968:- LIHC trans rs916888 0.821 rs199499 ENSG00000280022.1 RP11-707O23.1 6.6 1.55e-10 0.000386 0.67 0.34 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788132 chr17:45592621~45593369:+ LIHC trans rs6424115 0.83 rs3123554 ENSG00000228217.1 AL390877.1 6.6 1.57e-10 0.000389 0.39 0.34 Immature fraction of reticulocytes; chr1:23869911 chr1:117778087~117778506:- LIHC trans rs7662987 0.793 rs12106 ENSG00000233859.2 ADH5P4 6.6 1.57e-10 0.00039 0.61 0.34 Smoking initiation; chr4:99072199 chr6:65836930~65838039:- LIHC trans rs714543 0.585 rs1065646 ENSG00000219797.2 PPIAP9 6.6 1.57e-10 0.00039 0.4 0.34 Plateletcrit; chr7:44769674 chr6:31519480~31520291:- LIHC trans rs9611565 0.921 rs2143695 ENSG00000268568.1 AC007228.9 -6.6 1.57e-10 0.00039 -0.42 -0.34 Vitiligo; chr22:41332616 chr19:56672574~56673901:- LIHC trans rs864643 0.773 rs13077475 ENSG00000183298.5 RP11-556K13.1 -6.6 1.58e-10 0.000393 -0.46 -0.34 Attention deficit hyperactivity disorder; chr3:39546814 chr1:101786340~101787219:- LIHC trans rs7312770 1 rs7312770 ENSG00000212994.5 RPS26P6 -6.6 1.59e-10 0.000395 -0.41 -0.34 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr8:100895771~100896118:+ LIHC trans rs3849046 0.817 rs409273 ENSG00000226666.1 HSPA9P1 -6.59 1.62e-10 0.000401 -0.4 -0.34 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138578193 chr2:221961737~221963765:+ LIHC trans rs7937890 0.559 rs1116739 ENSG00000236360.2 RP11-334A14.2 6.59 1.63e-10 0.000405 0.43 0.34 Mitochondrial DNA levels; chr11:14467636 chr1:52993201~52993702:- LIHC trans rs13086611 1 rs13086611 ENSG00000197582.5 GPX1P1 -6.59 1.64e-10 0.000406 -0.57 -0.34 Educational attainment; chr3:49347984 chrX:13378735~13379340:- LIHC trans rs12210905 1 rs12214848 ENSG00000242375.1 RP11-498P14.3 -6.59 1.64e-10 0.000406 -0.89 -0.34 Hip circumference adjusted for BMI; chr6:27095569 chr9:97195351~97197687:- LIHC trans rs3849046 0.846 rs256007 ENSG00000226666.1 HSPA9P1 6.59 1.65e-10 0.000409 0.4 0.34 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138561900 chr2:221961737~221963765:+ LIHC trans rs9858542 0.953 rs7633271 ENSG00000197582.5 GPX1P1 -6.59 1.65e-10 0.00041 -0.56 -0.34 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49518530 chrX:13378735~13379340:- LIHC trans rs9467773 0.901 rs1407045 ENSG00000242375.1 RP11-498P14.3 6.59 1.67e-10 0.000413 0.4 0.34 Intelligence (multi-trait analysis); chr6:26475927 chr9:97195351~97197687:- LIHC trans rs6424115 0.867 rs34902309 ENSG00000228217.1 AL390877.1 6.59 1.7e-10 0.00042 0.39 0.34 Immature fraction of reticulocytes; chr1:23865710 chr1:117778087~117778506:- LIHC trans rs9611519 0.964 rs5995992 ENSG00000268568.1 AC007228.9 -6.58 1.72e-10 0.000425 -0.52 -0.34 Neuroticism; chr22:41091214 chr19:56672574~56673901:- LIHC trans rs3002142 0.658 rs2291833 ENSG00000219201.4 RP11-181C21.4 -6.58 1.74e-10 0.000431 -0.41 -0.34 LDL peak particle diameter (total fat intake interaction); chr1:222653505 chr1:77810861~77811781:- LIHC trans rs3740713 1 rs73440636 ENSG00000235847.2 LDHAP7 6.58 1.8e-10 0.000443 0.59 0.34 Amyotrophic lateral sclerosis (sporadic); chr11:18452009 chr2:84777259~84778223:- LIHC trans rs7662987 0.793 rs7684735 ENSG00000233859.2 ADH5P4 6.57 1.87e-10 0.00046 0.6 0.33 Smoking initiation; chr4:99070355 chr6:65836930~65838039:- LIHC trans rs538867 1 rs661422 ENSG00000183298.5 RP11-556K13.1 6.57 1.88e-10 0.000462 0.76 0.33 Alzheimer's disease (cognitive decline); chr3:39519898 chr1:101786340~101787219:- LIHC trans rs6743068 0.541 rs6761514 ENSG00000235105.1 RP11-329A14.1 6.57 1.92e-10 0.000473 0.33 0.33 Lymphocyte percentage of white cells; chr2:201362826 chr1:48435967~48437223:+ LIHC trans rs8067354 0.645 rs11079389 ENSG00000187870.7 RNFT1P3 6.57 1.93e-10 0.000475 0.4 0.33 Hemoglobin concentration; chr17:59810591 chr17:20743333~20754501:- LIHC trans rs8067354 0.645 rs2665403 ENSG00000187870.7 RNFT1P3 6.57 1.93e-10 0.000475 0.4 0.33 Hemoglobin concentration; chr17:59812624 chr17:20743333~20754501:- LIHC trans rs8067354 0.645 rs2173120 ENSG00000187870.7 RNFT1P3 6.57 1.93e-10 0.000475 0.4 0.33 Hemoglobin concentration; chr17:59815279 chr17:20743333~20754501:- LIHC trans rs3749237 0.964 rs11717463 ENSG00000197582.5 GPX1P1 6.56 1.97e-10 0.000485 0.49 0.33 Resting heart rate; chr3:49771548 chrX:13378735~13379340:- LIHC trans rs7032940 0.533 rs7868072 ENSG00000228236.2 TXNP5 6.56 1.98e-10 0.000488 0.39 0.33 Height; chr9:110205824 chr2:149068596~149068910:- LIHC trans rs1023500 1 rs7293091 ENSG00000268568.1 AC007228.9 -6.56 2.02e-10 0.000497 -0.46 -0.33 Schizophrenia; chr22:41945304 chr19:56672574~56673901:- LIHC trans rs7662987 0.793 rs7669660 ENSG00000233859.2 ADH5P4 6.56 2.03e-10 5e-04 0.6 0.33 Smoking initiation; chr4:99071451 chr6:65836930~65838039:- LIHC trans rs714543 0.61 rs4724320 ENSG00000226038.5 PPIAP21 -6.55 2.05e-10 0.000504 -0.37 -0.33 Plateletcrit; chr7:44775735 chr20:43230760~43231260:+ LIHC trans rs12210905 0.841 rs28410967 ENSG00000242375.1 RP11-498P14.3 -6.55 2.06e-10 0.000505 -0.84 -0.33 Hip circumference adjusted for BMI; chr6:27297456 chr9:97195351~97197687:- LIHC trans rs12210905 0.92 rs72839451 ENSG00000242375.1 RP11-498P14.3 -6.55 2.06e-10 0.000505 -0.84 -0.33 Hip circumference adjusted for BMI; chr6:27297658 chr9:97195351~97197687:- LIHC trans rs12210905 0.92 rs72839453 ENSG00000242375.1 RP11-498P14.3 -6.55 2.06e-10 0.000505 -0.84 -0.33 Hip circumference adjusted for BMI; chr6:27297982 chr9:97195351~97197687:- LIHC trans rs12210905 0.92 rs9348759 ENSG00000242375.1 RP11-498P14.3 -6.55 2.06e-10 0.000505 -0.84 -0.33 Hip circumference adjusted for BMI; chr6:27323109 chr9:97195351~97197687:- LIHC trans rs12210905 0.92 rs9368500 ENSG00000242375.1 RP11-498P14.3 -6.55 2.06e-10 0.000505 -0.84 -0.33 Hip circumference adjusted for BMI; chr6:27323202 chr9:97195351~97197687:- LIHC trans rs12210905 0.92 rs9366690 ENSG00000242375.1 RP11-498P14.3 -6.55 2.06e-10 0.000505 -0.84 -0.33 Hip circumference adjusted for BMI; chr6:27323300 chr9:97195351~97197687:- LIHC trans rs9899728 0.614 rs12949451 ENSG00000234925.2 ATP5HP4 -6.55 2.07e-10 0.000508 -0.79 -0.33 Alzheimer's disease or small vessel stroke; chr17:75036224 chr12:68642519~68642993:- LIHC trans rs9425766 0.888 rs1799876 ENSG00000213331.4 RP11-713C19.2 6.55 2.11e-10 0.000517 0.41 0.33 Life satisfaction; chr1:173909333 chr4:187970273~187971284:+ LIHC trans rs7312770 0.637 rs705699 ENSG00000212994.5 RPS26P6 6.55 2.12e-10 0.00052 0.42 0.33 Polycystic ovary syndrome;Hypothyroidism; chr12:55991020 chr8:100895771~100896118:+ LIHC trans rs864643 0.853 rs4676643 ENSG00000183298.5 RP11-556K13.1 -6.55 2.14e-10 0.000524 -0.47 -0.33 Attention deficit hyperactivity disorder; chr3:39537413 chr1:101786340~101787219:- LIHC trans rs7662987 0.793 rs28730632 ENSG00000233859.2 ADH5P4 6.55 2.16e-10 0.000528 0.62 0.33 Smoking initiation; chr4:99074552 chr6:65836930~65838039:- LIHC trans rs12210905 0.764 rs72835248 ENSG00000242375.1 RP11-498P14.3 -6.55 2.17e-10 0.00053 -0.83 -0.33 Hip circumference adjusted for BMI; chr6:26964038 chr9:97195351~97197687:- LIHC trans rs9611519 0.964 rs2092563 ENSG00000268568.1 AC007228.9 -6.54 2.18e-10 0.000534 -0.51 -0.33 Neuroticism; chr22:41196673 chr19:56672574~56673901:- LIHC trans rs4535700 0.501 rs10245725 ENSG00000204894.4 RP11-208G20.2 -6.54 2.2e-10 0.000538 -0.36 -0.33 Macular telangiectasia type 2; chr7:55908855 chr7:152367171~152367260:+ LIHC trans rs714543 0.61 rs4724320 ENSG00000214975.4 PPIAP29 -6.54 2.23e-10 0.000544 -0.37 -0.33 Plateletcrit; chr7:44775735 chr6:24976419~24976982:+ LIHC trans rs7937890 0.507 rs4463820 ENSG00000236360.2 RP11-334A14.2 6.54 2.29e-10 0.00056 0.43 0.33 Mitochondrial DNA levels; chr11:14534796 chr1:52993201~52993702:- LIHC trans rs7568458 0.87 rs6757263 ENSG00000223886.3 RP11-251G23.2 6.53 2.31e-10 0.000565 0.38 0.33 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85576419 chr7:105530209~105530671:+ LIHC trans rs9611519 0.894 rs4821990 ENSG00000268568.1 AC007228.9 -6.53 2.36e-10 0.000577 -0.5 -0.33 Neuroticism; chr22:41042706 chr19:56672574~56673901:- LIHC trans rs864643 0.947 rs1473865 ENSG00000183298.5 RP11-556K13.1 6.53 2.38e-10 0.000581 0.47 0.33 Attention deficit hyperactivity disorder; chr3:39501313 chr1:101786340~101787219:- LIHC trans rs864643 0.773 rs13064980 ENSG00000183298.5 RP11-556K13.1 -6.53 2.39e-10 0.000582 -0.44 -0.33 Attention deficit hyperactivity disorder; chr3:39503973 chr1:101786340~101787219:- LIHC trans rs877636 0.692 rs11171739 ENSG00000243403.1 RP11-330L19.1 6.53 2.42e-10 0.000591 0.39 0.33 Cognitive function; chr12:56076841 chr15:64592979~64593326:+ LIHC trans rs12210905 1 rs72843643 ENSG00000242375.1 RP11-498P14.3 -6.52 2.45e-10 0.000598 -0.88 -0.33 Hip circumference adjusted for BMI; chr6:27243468 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs72843644 ENSG00000242375.1 RP11-498P14.3 -6.52 2.45e-10 0.000598 -0.88 -0.33 Hip circumference adjusted for BMI; chr6:27243822 chr9:97195351~97197687:- LIHC trans rs1499614 0.803 rs1796229 ENSG00000164669.11 INTS4P1 6.52 2.46e-10 0.000599 0.58 0.33 Gout; chr7:66654674 chr7:65141225~65234216:+ LIHC trans rs1499614 0.901 rs3936 ENSG00000164669.11 INTS4P1 6.52 2.46e-10 0.000599 0.58 0.33 Gout; chr7:66661502 chr7:65141225~65234216:+ LIHC trans rs9876781 0.77 rs4858795 ENSG00000235912.1 RP1-159A19.3 6.52 2.48e-10 0.000605 0.38 0.33 Longevity; chr3:48473670 chr1:27649419~27649610:+ LIHC trans rs7937890 0.572 rs2597218 ENSG00000236360.2 RP11-334A14.2 6.52 2.49e-10 0.000606 0.44 0.33 Mitochondrial DNA levels; chr11:14510792 chr1:52993201~52993702:- LIHC trans rs7937890 0.598 rs10734225 ENSG00000236360.2 RP11-334A14.2 6.52 2.51e-10 0.00061 0.44 0.33 Mitochondrial DNA levels; chr11:14421448 chr1:52993201~52993702:- LIHC trans rs12200782 0.932 rs72844476 ENSG00000242375.1 RP11-498P14.3 -6.52 2.6e-10 0.000631 -0.8 -0.33 Small cell lung carcinoma; chr6:26573922 chr9:97195351~97197687:- LIHC trans rs1023500 1 rs6002554 ENSG00000268568.1 AC007228.9 -6.51 2.65e-10 0.000644 -0.46 -0.33 Schizophrenia; chr22:41943091 chr19:56672574~56673901:- LIHC trans rs8010715 0.636 rs2277480 ENSG00000238000.1 RP11-274E7.2 6.51 2.65e-10 0.000645 0.38 0.33 IgG glycosylation; chr14:24118306 chr5:98213402~98214121:+ LIHC trans rs2980436 1 rs2980436 ENSG00000253982.1 CTD-2336O2.1 -6.51 2.67e-10 0.000648 -0.47 -0.33 Schizophrenia; chr8:8234503 chr8:1761990~1764502:- LIHC trans rs916888 0.647 rs199524 ENSG00000214425.5 LRRC37A4P 6.51 2.68e-10 0.000652 0.36 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:45506741~45550335:- LIHC trans rs11220082 0.666 rs35203305 ENSG00000236257.1 EI24P2 -6.5 2.76e-10 0.00067 -0.4 -0.33 Schizophrenia; chr11:125468987 chr1:158454198~158455273:+ LIHC trans rs1499614 0.901 rs2178742 ENSG00000164669.11 INTS4P1 6.5 2.77e-10 0.000673 0.58 0.33 Gout; chr7:66732812 chr7:65141225~65234216:+ LIHC trans rs6921919 0.789 rs6456814 ENSG00000204625.9 HCG9 6.5 2.78e-10 0.000676 0.46 0.33 Autism spectrum disorder or schizophrenia; chr6:28338035 chr6:29975112~29978410:+ LIHC trans rs2243480 0.803 rs13224048 ENSG00000164669.11 INTS4P1 6.5 2.79e-10 0.000676 0.58 0.33 Diabetic kidney disease; chr7:66528779 chr7:65141225~65234216:+ LIHC trans rs3088050 1 rs12519145 ENSG00000226986.4 RP11-543B16.2 6.5 2.81e-10 0.00068 0.37 0.33 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr5:177128522 chr1:211207239~211207897:+ LIHC trans rs9876781 1 rs7635522 ENSG00000235912.1 RP1-159A19.3 -6.5 2.82e-10 0.000684 -0.37 -0.33 Longevity; chr3:48382166 chr1:27649419~27649610:+ LIHC trans rs2243480 0.708 rs13242216 ENSG00000164669.11 INTS4P1 6.5 2.88e-10 0.000697 0.58 0.33 Diabetic kidney disease; chr7:66433290 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs67536397 ENSG00000164669.11 INTS4P1 6.5 2.88e-10 0.000697 0.58 0.33 Diabetic kidney disease; chr7:66482930 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs58669269 ENSG00000164669.11 INTS4P1 6.5 2.88e-10 0.000697 0.58 0.33 Diabetic kidney disease; chr7:66486966 chr7:65141225~65234216:+ LIHC trans rs9425766 0.64 rs9425756 ENSG00000213331.4 RP11-713C19.2 6.5 2.88e-10 0.000698 0.42 0.33 Life satisfaction; chr1:173847448 chr4:187970273~187971284:+ LIHC trans rs9425766 0.546 rs6691001 ENSG00000213331.4 RP11-713C19.2 6.5 2.88e-10 0.000698 0.42 0.33 Life satisfaction; chr1:173849938 chr4:187970273~187971284:+ LIHC trans rs12210905 1 rs9368498 ENSG00000242375.1 RP11-498P14.3 -6.5 2.9e-10 0.000701 -0.87 -0.33 Hip circumference adjusted for BMI; chr6:27286227 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs9368499 ENSG00000242375.1 RP11-498P14.3 -6.5 2.9e-10 0.000701 -0.87 -0.33 Hip circumference adjusted for BMI; chr6:27286553 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs114337870 ENSG00000242375.1 RP11-498P14.3 -6.5 2.9e-10 0.000701 -0.87 -0.33 Hip circumference adjusted for BMI; chr6:27287158 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs9379970 ENSG00000242375.1 RP11-498P14.3 -6.5 2.9e-10 0.000701 -0.87 -0.33 Hip circumference adjusted for BMI; chr6:27287452 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs9348758 ENSG00000242375.1 RP11-498P14.3 -6.5 2.9e-10 0.000701 -0.87 -0.33 Hip circumference adjusted for BMI; chr6:27287459 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs9393803 ENSG00000242375.1 RP11-498P14.3 -6.5 2.9e-10 0.000701 -0.87 -0.33 Hip circumference adjusted for BMI; chr6:27289935 chr9:97195351~97197687:- LIHC trans rs9876781 1 rs7636782 ENSG00000235912.1 RP1-159A19.3 -6.5 2.91e-10 0.000704 -0.37 -0.33 Longevity; chr3:48379897 chr1:27649419~27649610:+ LIHC trans rs8067354 0.507 rs72840511 ENSG00000187870.7 RNFT1P3 6.49 2.95e-10 0.000714 0.4 0.33 Hemoglobin concentration; chr17:59728650 chr17:20743333~20754501:- LIHC trans rs7568458 0.837 rs35215812 ENSG00000223886.3 RP11-251G23.2 6.49 2.98e-10 0.000719 0.37 0.33 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85565261 chr7:105530209~105530671:+ LIHC trans rs7568458 0.905 rs10187424 ENSG00000223886.3 RP11-251G23.2 6.49 2.98e-10 0.000719 0.37 0.33 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85567174 chr7:105530209~105530671:+ LIHC trans rs9611519 0.894 rs9623320 ENSG00000268568.1 AC007228.9 -6.49 3.01e-10 0.000726 -0.5 -0.33 Neuroticism; chr22:41082478 chr19:56672574~56673901:- LIHC trans rs8067354 0.681 rs76856339 ENSG00000187870.7 RNFT1P3 6.49 3.02e-10 0.000729 0.4 0.33 Hemoglobin concentration; chr17:59723605 chr17:20743333~20754501:- LIHC trans rs7662987 0.793 rs4699700 ENSG00000233859.2 ADH5P4 6.49 3.06e-10 0.000738 0.62 0.33 Smoking initiation; chr4:99077184 chr6:65836930~65838039:- LIHC trans rs7444 0.941 rs9619386 ENSG00000274602.3 PI4KAP1 -6.49 3.06e-10 0.000738 -0.43 -0.33 Systemic lupus erythematosus; chr22:21625649 chr22:18533646~18577968:- LIHC trans rs5877 0.568 rs1951627 ENSG00000213331.4 RP11-713C19.2 6.49 3.08e-10 0.000741 0.4 0.33 Subjective well-being (multi-trait analysis); chr1:173922679 chr4:187970273~187971284:+ LIHC trans rs75870422 0.609 rs6491563 ENSG00000271654.1 RP11-685B14.3 -6.48 3.16e-10 0.00076 -0.78 -0.33 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100464986 chr8:18387108~18387777:- LIHC trans rs2243480 0.708 rs35825036 ENSG00000164669.11 INTS4P1 6.48 3.23e-10 0.000776 0.57 0.33 Diabetic kidney disease; chr7:66521515 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs13237037 ENSG00000164669.11 INTS4P1 6.48 3.23e-10 0.000776 0.57 0.33 Diabetic kidney disease; chr7:66532895 chr7:65141225~65234216:+ LIHC trans rs2243480 0.901 rs13237344 ENSG00000164669.11 INTS4P1 6.48 3.23e-10 0.000776 0.57 0.33 Diabetic kidney disease; chr7:66557269 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs1796228 ENSG00000164669.11 INTS4P1 6.48 3.23e-10 0.000776 0.57 0.33 Diabetic kidney disease; chr7:66568097 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs1267820 ENSG00000164669.11 INTS4P1 6.48 3.23e-10 0.000776 0.57 0.33 Diabetic kidney disease; chr7:66585308 chr7:65141225~65234216:+ LIHC trans rs12210905 1 rs10946906 ENSG00000242375.1 RP11-498P14.3 -6.48 3.25e-10 0.000782 -0.87 -0.33 Hip circumference adjusted for BMI; chr6:27285001 chr9:97195351~97197687:- LIHC trans rs6424115 0.83 rs2503002 ENSG00000228217.1 AL390877.1 -6.48 3.28e-10 0.000788 -0.37 -0.33 Immature fraction of reticulocytes; chr1:23870467 chr1:117778087~117778506:- LIHC trans rs916888 0.647 rs199523 ENSG00000214425.5 LRRC37A4P 6.47 3.3e-10 0.000793 0.36 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:45506741~45550335:- LIHC trans rs9876781 1 rs9876781 ENSG00000225528.1 RP3-370M22.8 -6.47 3.31e-10 0.000796 -0.37 -0.33 Longevity; chr3:48445934 chr22:39960397~39964683:+ LIHC trans rs3740713 1 rs73440634 ENSG00000235847.2 LDHAP7 6.47 3.34e-10 0.000803 0.58 0.33 Amyotrophic lateral sclerosis (sporadic); chr11:18451999 chr2:84777259~84778223:- LIHC trans rs77688320 1 rs2540334 ENSG00000235105.1 RP11-329A14.1 -6.47 3.38e-10 0.000811 -0.38 -0.33 Breast cancer; chr2:201406624 chr1:48435967~48437223:+ LIHC trans rs9876781 1 rs898225 ENSG00000235912.1 RP1-159A19.3 6.47 3.4e-10 0.000817 0.38 0.33 Longevity; chr3:48371689 chr1:27649419~27649610:+ LIHC trans rs12210905 0.925 rs12214640 ENSG00000242375.1 RP11-498P14.3 -6.47 3.43e-10 0.000824 -0.76 -0.33 Hip circumference adjusted for BMI; chr6:26739806 chr9:97195351~97197687:- LIHC trans rs12600277 1 rs12600277 ENSG00000233719.3 GOT2P3 -6.47 3.43e-10 0.000824 -0.47 -0.33 Aortic root size; chr16:58725428 chr12:9641802~9643007:+ LIHC trans rs12210905 1 rs12189835 ENSG00000242375.1 RP11-498P14.3 -6.47 3.46e-10 0.00083 -0.84 -0.33 Hip circumference adjusted for BMI; chr6:27230492 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs72843640 ENSG00000242375.1 RP11-498P14.3 -6.47 3.46e-10 0.00083 -0.84 -0.33 Hip circumference adjusted for BMI; chr6:27234314 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs72843641 ENSG00000242375.1 RP11-498P14.3 -6.47 3.46e-10 0.00083 -0.84 -0.33 Hip circumference adjusted for BMI; chr6:27235556 chr9:97195351~97197687:- LIHC trans rs6921919 0.789 rs13210258 ENSG00000204625.9 HCG9 6.46 3.6e-10 0.000862 0.45 0.33 Autism spectrum disorder or schizophrenia; chr6:28340894 chr6:29975112~29978410:+ LIHC trans rs7937890 0.504 rs2575822 ENSG00000236360.2 RP11-334A14.2 6.46 3.6e-10 0.000862 0.42 0.33 Mitochondrial DNA levels; chr11:14498305 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2575823 ENSG00000236360.2 RP11-334A14.2 6.46 3.6e-10 0.000862 0.42 0.33 Mitochondrial DNA levels; chr11:14499808 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2597221 ENSG00000236360.2 RP11-334A14.2 6.46 3.6e-10 0.000862 0.42 0.33 Mitochondrial DNA levels; chr11:14505529 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs6486197 ENSG00000236360.2 RP11-334A14.2 6.46 3.6e-10 0.000862 0.42 0.33 Mitochondrial DNA levels; chr11:14508328 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2597219 ENSG00000236360.2 RP11-334A14.2 6.46 3.6e-10 0.000862 0.42 0.33 Mitochondrial DNA levels; chr11:14509320 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2597217 ENSG00000236360.2 RP11-334A14.2 6.46 3.6e-10 0.000862 0.42 0.33 Mitochondrial DNA levels; chr11:14511337 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2575852 ENSG00000236360.2 RP11-334A14.2 6.46 3.6e-10 0.000862 0.42 0.33 Mitochondrial DNA levels; chr11:14511822 chr1:52993201~52993702:- LIHC trans rs7937890 0.531 rs2597216 ENSG00000236360.2 RP11-334A14.2 6.46 3.6e-10 0.000862 0.42 0.33 Mitochondrial DNA levels; chr11:14512370 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2575853 ENSG00000236360.2 RP11-334A14.2 6.46 3.6e-10 0.000862 0.42 0.33 Mitochondrial DNA levels; chr11:14512417 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs1548074 ENSG00000236360.2 RP11-334A14.2 6.46 3.6e-10 0.000862 0.42 0.33 Mitochondrial DNA levels; chr11:14513279 chr1:52993201~52993702:- LIHC trans rs6424115 0.8 rs4649123 ENSG00000228217.1 AL390877.1 -6.46 3.66e-10 0.000876 -0.37 -0.33 Immature fraction of reticulocytes; chr1:23871206 chr1:117778087~117778506:- LIHC trans rs6424115 0.83 rs2503000 ENSG00000228217.1 AL390877.1 -6.46 3.66e-10 0.000876 -0.37 -0.33 Immature fraction of reticulocytes; chr1:23871408 chr1:117778087~117778506:- LIHC trans rs6424115 0.83 rs2502999 ENSG00000228217.1 AL390877.1 -6.46 3.66e-10 0.000876 -0.37 -0.33 Immature fraction of reticulocytes; chr1:23871831 chr1:117778087~117778506:- LIHC trans rs6424115 0.793 rs2502998 ENSG00000228217.1 AL390877.1 -6.46 3.66e-10 0.000876 -0.37 -0.33 Immature fraction of reticulocytes; chr1:23871837 chr1:117778087~117778506:- LIHC trans rs1023500 1 rs3752591 ENSG00000268568.1 AC007228.9 -6.46 3.69e-10 0.000882 -0.46 -0.33 Schizophrenia; chr22:41943512 chr19:56672574~56673901:- LIHC trans rs538867 0.661 rs2016412 ENSG00000183298.5 RP11-556K13.1 6.45 3.73e-10 0.00089 0.83 0.33 Alzheimer's disease (cognitive decline); chr3:39393561 chr1:101786340~101787219:- LIHC trans rs12709013 0.792 rs11649387 ENSG00000230849.2 GOT2P2 6.45 3.74e-10 0.000892 0.38 0.33 Blood metabolite ratios; chr16:58803176 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs11649133 ENSG00000230849.2 GOT2P2 6.45 3.74e-10 0.000892 0.38 0.33 Blood metabolite ratios; chr16:58803275 chr1:173141100~173142350:- LIHC trans rs3088050 0.759 rs4343858 ENSG00000226986.4 RP11-543B16.2 6.45 3.77e-10 9e-04 0.37 0.33 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr5:177252406 chr1:211207239~211207897:+ LIHC trans rs7937890 0.505 rs4403769 ENSG00000236360.2 RP11-334A14.2 6.45 3.78e-10 0.000901 0.42 0.33 Mitochondrial DNA levels; chr11:14428630 chr1:52993201~52993702:- LIHC trans rs8067354 0.645 rs2132715 ENSG00000187870.7 RNFT1P3 6.45 3.78e-10 0.000901 0.39 0.33 Hemoglobin concentration; chr17:59781013 chr17:20743333~20754501:- LIHC trans rs8067354 0.645 rs2173119 ENSG00000187870.7 RNFT1P3 6.45 3.78e-10 0.000901 0.39 0.33 Hemoglobin concentration; chr17:59782344 chr17:20743333~20754501:- LIHC trans rs2250402 0.51 rs2291619 ENSG00000234106.3 RP11-288E14.2 -6.45 3.81e-10 0.000909 -0.53 -0.33 Corneal curvature; chr15:40036832 chr11:93535468~93535816:+ LIHC trans rs7554547 0.6 rs2180180 ENSG00000261819.1 RP11-680G24.4 -6.45 3.85e-10 0.000916 -0.4 -0.33 Nonsyndromic cleft lip with cleft palate; chr1:11959312 chr16:14988259~14990160:- LIHC trans rs877636 0.669 rs7297175 ENSG00000243403.1 RP11-330L19.1 -6.45 3.86e-10 0.00092 -0.39 -0.33 Cognitive function; chr12:56080024 chr15:64592979~64593326:+ LIHC trans rs4784054 0.568 rs7193640 ENSG00000233719.3 GOT2P3 6.45 3.89e-10 0.000925 0.39 0.33 Blood metabolite levels; chr16:58785816 chr12:9641802~9643007:+ LIHC trans rs7444 0.941 rs878825 ENSG00000274602.3 PI4KAP1 -6.45 3.89e-10 0.000926 -0.4 -0.33 Systemic lupus erythematosus; chr22:21627960 chr22:18533646~18577968:- LIHC trans rs7937890 0.561 rs2575849 ENSG00000236360.2 RP11-334A14.2 6.44 3.98e-10 0.000947 0.42 0.33 Mitochondrial DNA levels; chr11:14518093 chr1:52993201~52993702:- LIHC trans rs12210905 1 rs12209800 ENSG00000242375.1 RP11-498P14.3 6.44 4.04e-10 0.000961 0.8 0.33 Hip circumference adjusted for BMI; chr6:27221738 chr9:97195351~97197687:- LIHC trans rs7937890 0.56 rs2597194 ENSG00000236360.2 RP11-334A14.2 6.44 4.05e-10 0.000961 0.44 0.33 Mitochondrial DNA levels; chr11:14475723 chr1:52993201~52993702:- LIHC trans rs7937890 0.593 rs2597189 ENSG00000236360.2 RP11-334A14.2 6.44 4.05e-10 0.000963 0.43 0.33 Mitochondrial DNA levels; chr11:14490514 chr1:52993201~52993702:- LIHC trans rs12210905 1 rs7759955 ENSG00000242375.1 RP11-498P14.3 -6.44 4.06e-10 0.000964 -0.75 -0.33 Hip circumference adjusted for BMI; chr6:26792463 chr9:97195351~97197687:- LIHC trans rs1499614 1 rs1267818 ENSG00000164669.11 INTS4P1 6.44 4.06e-10 0.000965 0.58 0.33 Gout; chr7:66642037 chr7:65141225~65234216:+ LIHC trans rs6921919 0.789 rs1119211 ENSG00000204625.9 HCG9 -6.44 4.1e-10 0.000974 -0.45 -0.33 Autism spectrum disorder or schizophrenia; chr6:28341359 chr6:29975112~29978410:+ LIHC trans rs77688320 1 rs2714486 ENSG00000235105.1 RP11-329A14.1 -6.43 4.18e-10 0.000992 -0.38 -0.33 Breast cancer; chr2:201384985 chr1:48435967~48437223:+ LIHC trans rs7937890 0.559 rs2597188 ENSG00000236360.2 RP11-334A14.2 6.43 4.3e-10 0.00102 0.42 0.33 Mitochondrial DNA levels; chr11:14495360 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2597187 ENSG00000236360.2 RP11-334A14.2 6.43 4.3e-10 0.00102 0.42 0.33 Mitochondrial DNA levels; chr11:14495473 chr1:52993201~52993702:- LIHC trans rs55665837 0.539 rs10500804 ENSG00000236360.2 RP11-334A14.2 6.43 4.31e-10 0.00102 0.42 0.33 Vitamin D levels; chr11:14888727 chr1:52993201~52993702:- LIHC trans rs13014235 0.846 rs10454127 ENSG00000235105.1 RP11-329A14.1 6.43 4.37e-10 0.00103 0.34 0.33 Basal cell carcinoma; chr2:201347651 chr1:48435967~48437223:+ LIHC trans rs7568458 0.905 rs6739015 ENSG00000223886.3 RP11-251G23.2 6.43 4.37e-10 0.00103 0.37 0.33 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85528234 chr7:105530209~105530671:+ LIHC trans rs2243480 1 rs2533288 ENSG00000164669.11 INTS4P1 6.42 4.43e-10 0.00105 0.57 0.33 Diabetic kidney disease; chr7:66591724 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs2707844 ENSG00000164669.11 INTS4P1 6.42 4.43e-10 0.00105 0.57 0.33 Diabetic kidney disease; chr7:66594522 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs1796220 ENSG00000164669.11 INTS4P1 6.42 4.43e-10 0.00105 0.57 0.33 Diabetic kidney disease; chr7:66597113 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs2707831 ENSG00000164669.11 INTS4P1 6.42 4.43e-10 0.00105 0.57 0.33 Diabetic kidney disease; chr7:66597524 chr7:65141225~65234216:+ LIHC trans rs1499614 1 rs1882655 ENSG00000164669.11 INTS4P1 -6.42 4.44e-10 0.00105 -0.57 -0.33 Gout; chr7:66682070 chr7:65141225~65234216:+ LIHC trans rs1499614 0.831 rs3800822 ENSG00000164669.11 INTS4P1 -6.42 4.44e-10 0.00105 -0.57 -0.33 Gout; chr7:66682162 chr7:65141225~65234216:+ LIHC trans rs1499614 1 rs1638731 ENSG00000164669.11 INTS4P1 6.42 4.44e-10 0.00105 0.57 0.33 Gout; chr7:66679692 chr7:65141225~65234216:+ LIHC trans rs7568458 0.837 rs35565292 ENSG00000223886.3 RP11-251G23.2 6.42 4.46e-10 0.00105 0.38 0.33 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85563193 chr7:105530209~105530671:+ LIHC trans rs12200782 0.932 rs12202419 ENSG00000242375.1 RP11-498P14.3 6.42 4.56e-10 0.00108 0.91 0.33 Small cell lung carcinoma; chr6:26465156 chr9:97195351~97197687:- LIHC trans rs1023500 1 rs1023499 ENSG00000268568.1 AC007228.9 -6.42 4.57e-10 0.00108 -0.46 -0.33 Schizophrenia; chr22:41944578 chr19:56672574~56673901:- LIHC trans rs2250402 0.51 rs7535 ENSG00000234106.3 RP11-288E14.2 6.42 4.58e-10 0.00108 0.52 0.33 Corneal curvature; chr15:40036374 chr11:93535468~93535816:+ LIHC trans rs3096299 0.719 rs2911262 ENSG00000215030.5 RPL13P12 -6.42 4.62e-10 0.00109 -0.33 -0.33 Multiple myeloma (IgH translocation); chr16:89448633 chr17:17383377~17384012:- LIHC trans rs7312770 1 rs7312770 ENSG00000243403.1 RP11-330L19.1 -6.42 4.64e-10 0.00109 -0.38 -0.33 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr15:64592979~64593326:+ LIHC trans rs3849046 0.817 rs11959184 ENSG00000226666.1 HSPA9P1 6.42 4.66e-10 0.0011 0.4 0.33 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138596189 chr2:221961737~221963765:+ LIHC trans rs12210905 1 rs9357034 ENSG00000242375.1 RP11-498P14.3 -6.42 4.68e-10 0.0011 -0.86 -0.33 Hip circumference adjusted for BMI; chr6:27275646 chr9:97195351~97197687:- LIHC trans rs875971 0.545 rs17138149 ENSG00000164669.11 INTS4P1 -6.41 4.7e-10 0.00111 -0.43 -0.33 Aortic root size; chr7:66228193 chr7:65141225~65234216:+ LIHC trans rs6424115 0.83 rs2501423 ENSG00000228217.1 AL390877.1 -6.41 4.82e-10 0.00114 -0.38 -0.33 Immature fraction of reticulocytes; chr1:23872536 chr1:117778087~117778506:- LIHC trans rs6424115 0.733 rs2502996 ENSG00000228217.1 AL390877.1 -6.41 4.82e-10 0.00114 -0.38 -0.33 Immature fraction of reticulocytes; chr1:23872551 chr1:117778087~117778506:- LIHC trans rs7568458 0.837 rs6547624 ENSG00000223886.3 RP11-251G23.2 6.41 4.86e-10 0.00114 0.37 0.33 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85575011 chr7:105530209~105530671:+ LIHC trans rs1499614 1 rs2659913 ENSG00000164669.11 INTS4P1 6.41 4.91e-10 0.00115 0.56 0.33 Gout; chr7:66692349 chr7:65141225~65234216:+ LIHC trans rs1499614 1 rs2707840 ENSG00000164669.11 INTS4P1 6.41 4.91e-10 0.00115 0.56 0.33 Gout; chr7:66693028 chr7:65141225~65234216:+ LIHC trans rs1499614 1 rs2659911 ENSG00000164669.11 INTS4P1 6.41 4.91e-10 0.00115 0.56 0.33 Gout; chr7:66693433 chr7:65141225~65234216:+ LIHC trans rs1499614 1 rs2707838 ENSG00000164669.11 INTS4P1 6.41 4.91e-10 0.00115 0.56 0.33 Gout; chr7:66694214 chr7:65141225~65234216:+ LIHC trans rs1499614 1 rs60326618 ENSG00000164669.11 INTS4P1 6.41 4.91e-10 0.00115 0.56 0.33 Gout; chr7:66701371 chr7:65141225~65234216:+ LIHC trans rs1499614 1 rs2707830 ENSG00000164669.11 INTS4P1 6.41 4.91e-10 0.00115 0.56 0.33 Gout; chr7:66702658 chr7:65141225~65234216:+ LIHC trans rs1499614 1 rs2707828 ENSG00000164669.11 INTS4P1 6.41 4.91e-10 0.00115 0.56 0.33 Gout; chr7:66706390 chr7:65141225~65234216:+ LIHC trans rs1499614 0.803 rs1922723 ENSG00000164669.11 INTS4P1 6.41 4.91e-10 0.00115 0.56 0.33 Gout; chr7:66710076 chr7:65141225~65234216:+ LIHC trans rs1499614 1 rs2659903 ENSG00000164669.11 INTS4P1 6.41 4.91e-10 0.00115 0.56 0.33 Gout; chr7:66715944 chr7:65141225~65234216:+ LIHC trans rs1499614 1 rs2141924 ENSG00000164669.11 INTS4P1 6.41 4.91e-10 0.00115 0.56 0.33 Gout; chr7:66721259 chr7:65141225~65234216:+ LIHC trans rs7937890 0.559 rs2575836 ENSG00000236360.2 RP11-334A14.2 6.41 4.92e-10 0.00116 0.42 0.33 Mitochondrial DNA levels; chr11:14476318 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2575837 ENSG00000236360.2 RP11-334A14.2 6.41 4.92e-10 0.00116 0.42 0.33 Mitochondrial DNA levels; chr11:14476455 chr1:52993201~52993702:- LIHC trans rs7937890 0.559 rs2575838 ENSG00000236360.2 RP11-334A14.2 6.41 4.92e-10 0.00116 0.42 0.33 Mitochondrial DNA levels; chr11:14476675 chr1:52993201~52993702:- LIHC trans rs7937890 0.535 rs2575857 ENSG00000236360.2 RP11-334A14.2 6.41 4.92e-10 0.00116 0.42 0.33 Mitochondrial DNA levels; chr11:14479750 chr1:52993201~52993702:- LIHC trans rs9876781 1 rs9817615 ENSG00000225528.1 RP3-370M22.8 -6.41 4.92e-10 0.00116 -0.37 -0.33 Longevity; chr3:48429347 chr22:39960397~39964683:+ LIHC trans rs12210905 1 rs9348756 ENSG00000242375.1 RP11-498P14.3 -6.4 5e-10 0.00117 -0.87 -0.33 Hip circumference adjusted for BMI; chr6:27260480 chr9:97195351~97197687:- LIHC trans rs2243480 0.615 rs34363376 ENSG00000164669.11 INTS4P1 6.4 5.08e-10 0.00119 0.58 0.33 Diabetic kidney disease; chr7:66474549 chr7:65141225~65234216:+ LIHC trans rs9876781 1 rs9883927 ENSG00000225528.1 RP3-370M22.8 -6.4 5.09e-10 0.0012 -0.36 -0.33 Longevity; chr3:48422302 chr22:39960397~39964683:+ LIHC trans rs9876781 1 rs2290822 ENSG00000225528.1 RP3-370M22.8 -6.4 5.09e-10 0.0012 -0.36 -0.33 Longevity; chr3:48431794 chr22:39960397~39964683:+ LIHC trans rs9876781 1 rs13076076 ENSG00000225528.1 RP3-370M22.8 -6.4 5.09e-10 0.0012 -0.36 -0.33 Longevity; chr3:48437629 chr22:39960397~39964683:+ LIHC trans rs9876781 1 rs11130171 ENSG00000225528.1 RP3-370M22.8 -6.4 5.1e-10 0.0012 -0.36 -0.33 Longevity; chr3:48421052 chr22:39960397~39964683:+ LIHC trans rs7647973 0.506 rs11920251 ENSG00000197582.5 GPX1P1 6.4 5.2e-10 0.00122 0.48 0.33 Menarche (age at onset); chr3:49319238 chrX:13378735~13379340:- LIHC trans rs6424115 0.83 rs6680132 ENSG00000228217.1 AL390877.1 -6.39 5.3e-10 0.00124 -0.38 -0.33 Immature fraction of reticulocytes; chr1:23872314 chr1:117778087~117778506:- LIHC trans rs6424115 0.83 rs6672157 ENSG00000228217.1 AL390877.1 -6.39 5.3e-10 0.00124 -0.38 -0.33 Immature fraction of reticulocytes; chr1:23872350 chr1:117778087~117778506:- LIHC trans rs12210905 1 rs1062834 ENSG00000242375.1 RP11-498P14.3 -6.39 5.36e-10 0.00125 -0.86 -0.33 Hip circumference adjusted for BMI; chr6:27254760 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs12205628 ENSG00000242375.1 RP11-498P14.3 -6.39 5.36e-10 0.00125 -0.86 -0.33 Hip circumference adjusted for BMI; chr6:27258180 chr9:97195351~97197687:- LIHC trans rs12200782 1 rs12204145 ENSG00000242375.1 RP11-498P14.3 -6.39 5.36e-10 0.00126 -0.77 -0.33 Small cell lung carcinoma; chr6:26599928 chr9:97195351~97197687:- LIHC trans rs877636 0.74 rs705702 ENSG00000234513.1 AC073072.7 -6.39 5.43e-10 0.00127 -0.43 -0.33 Cognitive function; chr12:55996852 chr7:22773646~22773993:- LIHC trans rs875971 0.502 rs1796227 ENSG00000164669.11 INTS4P1 6.39 5.49e-10 0.00128 0.44 0.33 Aortic root size; chr7:66622032 chr7:65141225~65234216:+ LIHC trans rs9876781 1 rs2242150 ENSG00000225528.1 RP3-370M22.8 6.39 5.5e-10 0.00129 0.37 0.33 Longevity; chr3:48464565 chr22:39960397~39964683:+ LIHC trans rs11098499 0.779 rs7699346 ENSG00000275858.1 RP11-291L22.8 6.39 5.54e-10 0.0013 0.38 0.33 Corneal astigmatism; chr4:119389387 chr10:38450738~38451069:- LIHC trans rs11220082 0.644 rs36143594 ENSG00000236257.1 EI24P2 -6.39 5.57e-10 0.0013 -0.4 -0.33 Schizophrenia; chr11:125457076 chr1:158454198~158455273:+ LIHC trans rs9876781 1 rs4858817 ENSG00000235912.1 RP1-159A19.3 6.39 5.57e-10 0.0013 0.37 0.33 Longevity; chr3:48375266 chr1:27649419~27649610:+ LIHC trans rs9876781 0.933 rs6442124 ENSG00000225528.1 RP3-370M22.8 -6.38 5.71e-10 0.00133 -0.37 -0.33 Longevity; chr3:48463903 chr22:39960397~39964683:+ LIHC trans rs714543 0.811 rs13238404 ENSG00000214975.4 PPIAP29 6.38 5.83e-10 0.00136 0.37 0.33 Plateletcrit; chr7:44811812 chr6:24976419~24976982:+ LIHC trans rs7873102 0.521 rs776021 ENSG00000229007.1 EXOSC3P1 6.38 5.88e-10 0.00137 0.41 0.33 Brain structure; chr9:37936467 chr21:32496812~32497311:+ LIHC trans rs11098499 0.909 rs11723839 ENSG00000275858.1 RP11-291L22.8 6.37 6.04e-10 0.00141 0.38 0.33 Corneal astigmatism; chr4:119378518 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs12506546 ENSG00000275858.1 RP11-291L22.8 6.37 6.04e-10 0.00141 0.38 0.33 Corneal astigmatism; chr4:119380463 chr10:38450738~38451069:- LIHC trans rs7937890 0.559 rs2167160 ENSG00000236360.2 RP11-334A14.2 6.37 6.04e-10 0.00141 0.42 0.33 Mitochondrial DNA levels; chr11:14485903 chr1:52993201~52993702:- LIHC trans rs7937890 0.531 rs2575859 ENSG00000236360.2 RP11-334A14.2 6.37 6.04e-10 0.00141 0.42 0.33 Mitochondrial DNA levels; chr11:14489190 chr1:52993201~52993702:- LIHC trans rs1563304 1 rs1563304 ENSG00000264070.1 DND1P1 6.37 6.09e-10 0.00142 0.61 0.33 Neuroticism; chr17:46797087 chr17:45585871~45586929:+ LIHC trans rs9876781 1 rs6442123 ENSG00000225528.1 RP3-370M22.8 -6.37 6.26e-10 0.00145 -0.36 -0.33 Longevity; chr3:48458887 chr22:39960397~39964683:+ LIHC trans rs7568458 0.846 rs2028900 ENSG00000223886.3 RP11-251G23.2 -6.36 6.52e-10 0.00151 -0.38 -0.33 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85540612 chr7:105530209~105530671:+ LIHC trans rs12709013 0.792 rs12600201 ENSG00000230849.2 GOT2P2 6.36 6.56e-10 0.00152 0.37 0.33 Blood metabolite ratios; chr16:58773132 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs12600206 ENSG00000230849.2 GOT2P2 6.36 6.56e-10 0.00152 0.37 0.33 Blood metabolite ratios; chr16:58773169 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs11076263 ENSG00000230849.2 GOT2P2 6.36 6.56e-10 0.00152 0.37 0.33 Blood metabolite ratios; chr16:58773295 chr1:173141100~173142350:- LIHC trans rs75870422 0.609 rs9585442 ENSG00000271654.1 RP11-685B14.3 6.36 6.59e-10 0.00153 0.78 0.33 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100468696 chr8:18387108~18387777:- LIHC trans rs877636 0.692 rs10876870 ENSG00000212994.5 RPS26P6 -6.36 6.62e-10 0.00153 -0.4 -0.33 Cognitive function; chr12:56084218 chr8:100895771~100896118:+ LIHC trans rs877636 0.692 rs7971751 ENSG00000212994.5 RPS26P6 -6.36 6.62e-10 0.00153 -0.4 -0.33 Cognitive function; chr12:56084874 chr8:100895771~100896118:+ LIHC trans rs3749237 1 rs2291542 ENSG00000197582.5 GPX1P1 6.35 6.7e-10 0.00155 0.46 0.32 Resting heart rate; chr3:49714152 chrX:13378735~13379340:- LIHC trans rs3749237 1 rs11130216 ENSG00000197582.5 GPX1P1 6.35 6.8e-10 0.00157 0.47 0.32 Resting heart rate; chr3:49698739 chrX:13378735~13379340:- LIHC trans rs3749237 1 rs6804655 ENSG00000197582.5 GPX1P1 6.35 6.8e-10 0.00157 0.47 0.32 Resting heart rate; chr3:49701512 chrX:13378735~13379340:- LIHC trans rs714543 1 rs714543 ENSG00000226038.5 PPIAP21 -6.35 6.86e-10 0.00159 -0.38 -0.32 Plateletcrit; chr7:44847477 chr20:43230760~43231260:+ LIHC trans rs714543 1 rs757693 ENSG00000226038.5 PPIAP21 -6.35 6.86e-10 0.00159 -0.38 -0.32 Plateletcrit; chr7:44848430 chr20:43230760~43231260:+ LIHC trans rs12709013 0.792 rs12325510 ENSG00000230849.2 GOT2P2 6.35 6.87e-10 0.00159 0.39 0.32 Blood metabolite ratios; chr16:58749707 chr1:173141100~173142350:- LIHC trans rs9876781 1 rs9849509 ENSG00000225528.1 RP3-370M22.8 -6.34 7.08e-10 0.00164 -0.36 -0.32 Longevity; chr3:48442021 chr22:39960397~39964683:+ LIHC trans rs9876781 1 rs60512868 ENSG00000225528.1 RP3-370M22.8 -6.34 7.08e-10 0.00164 -0.36 -0.32 Longevity; chr3:48442035 chr22:39960397~39964683:+ LIHC trans rs9876781 1 rs7636044 ENSG00000225528.1 RP3-370M22.8 -6.34 7.08e-10 0.00164 -0.36 -0.32 Longevity; chr3:48443151 chr22:39960397~39964683:+ LIHC trans rs9876781 1 rs4490383 ENSG00000225528.1 RP3-370M22.8 -6.34 7.08e-10 0.00164 -0.36 -0.32 Longevity; chr3:48443275 chr22:39960397~39964683:+ LIHC trans rs7662987 0.793 rs78790289 ENSG00000233859.2 ADH5P4 6.34 7.12e-10 0.00164 0.59 0.32 Smoking initiation; chr4:99066736 chr6:65836930~65838039:- LIHC trans rs714543 1 rs10278679 ENSG00000219797.2 PPIAP9 -6.34 7.17e-10 0.00166 -0.4 -0.32 Plateletcrit; chr7:44825465 chr6:31519480~31520291:- LIHC trans rs1336472 0.509 rs4916032 ENSG00000233381.3 AK4P3 -6.34 7.21e-10 0.00166 -0.36 -0.32 Venous thromboembolism (SNP x SNP interaction); chr1:65215939 chr12:31615771~31616439:- LIHC trans rs6951245 0.515 rs73257955 ENSG00000278202.1 RP11-152F13.8 6.34 7.3e-10 0.00168 0.75 0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:967378 chr15:82418651~82434235:+ LIHC trans rs877636 0.692 rs2271194 ENSG00000234513.1 AC073072.7 -6.34 7.34e-10 0.00169 -0.41 -0.32 Cognitive function; chr12:56083910 chr7:22773646~22773993:- LIHC trans rs11098499 0.863 rs13134665 ENSG00000275858.1 RP11-291L22.8 6.34 7.36e-10 0.0017 0.38 0.32 Corneal astigmatism; chr4:119505275 chr10:38450738~38451069:- LIHC trans rs538867 1 rs1707987 ENSG00000183298.5 RP11-556K13.1 6.34 7.39e-10 0.0017 0.72 0.32 Alzheimer's disease (cognitive decline); chr3:39510002 chr1:101786340~101787219:- LIHC trans rs3749237 1 rs11710675 ENSG00000197582.5 GPX1P1 6.34 7.41e-10 0.00171 0.46 0.32 Resting heart rate; chr3:49714467 chrX:13378735~13379340:- LIHC trans rs6743068 0.541 rs7578456 ENSG00000235105.1 RP11-329A14.1 6.34 7.46e-10 0.00172 0.33 0.32 Lymphocyte percentage of white cells; chr2:201370625 chr1:48435967~48437223:+ LIHC trans rs141670911 1 rs141670911 ENSG00000242375.1 RP11-498P14.3 -6.34 7.48e-10 0.00172 -0.88 -0.32 Small cell lung carcinoma; chr6:26581030 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs3800310 ENSG00000242375.1 RP11-498P14.3 -6.33 7.58e-10 0.00174 -0.83 -0.32 Hip circumference adjusted for BMI; chr6:27239064 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs5030955 ENSG00000242375.1 RP11-498P14.3 -6.33 7.58e-10 0.00174 -0.83 -0.32 Hip circumference adjusted for BMI; chr6:27246088 chr9:97195351~97197687:- LIHC trans rs12210905 1 rs5030958 ENSG00000242375.1 RP11-498P14.3 -6.33 7.58e-10 0.00174 -0.83 -0.32 Hip circumference adjusted for BMI; chr6:27246478 chr9:97195351~97197687:- LIHC trans rs11220082 0.666 rs2241514 ENSG00000236257.1 EI24P2 -6.33 7.84e-10 0.0018 -0.39 -0.32 Schizophrenia; chr11:125456130 chr1:158454198~158455273:+ LIHC trans rs1499614 1 rs1267817 ENSG00000164669.11 INTS4P1 6.33 7.86e-10 0.00181 0.56 0.32 Gout; chr7:66645053 chr7:65141225~65234216:+ LIHC trans rs12709013 0.792 rs1657165 ENSG00000230849.2 GOT2P2 6.33 7.88e-10 0.00181 0.38 0.32 Blood metabolite ratios; chr16:58747980 chr1:173141100~173142350:- LIHC trans rs11220082 0.627 rs35102191 ENSG00000236257.1 EI24P2 -6.33 7.88e-10 0.00181 -0.4 -0.32 Schizophrenia; chr11:125455250 chr1:158454198~158455273:+ LIHC trans rs9876781 1 rs9883759 ENSG00000225528.1 RP3-370M22.8 -6.33 7.92e-10 0.00182 -0.37 -0.32 Longevity; chr3:48422209 chr22:39960397~39964683:+ LIHC trans rs9876781 1 rs6442120 ENSG00000225528.1 RP3-370M22.8 -6.33 7.92e-10 0.00182 -0.37 -0.32 Longevity; chr3:48423094 chr22:39960397~39964683:+ LIHC trans rs9876781 0.9 rs1037773 ENSG00000225528.1 RP3-370M22.8 -6.33 7.92e-10 0.00182 -0.37 -0.32 Longevity; chr3:48426493 chr22:39960397~39964683:+ LIHC trans rs9876781 1 rs2279077 ENSG00000225528.1 RP3-370M22.8 -6.33 7.92e-10 0.00182 -0.37 -0.32 Longevity; chr3:48432839 chr22:39960397~39964683:+ LIHC trans rs714543 0.967 rs10951776 ENSG00000226038.5 PPIAP21 -6.32 7.94e-10 0.00182 -0.38 -0.32 Plateletcrit; chr7:44858152 chr20:43230760~43231260:+ LIHC trans rs9858542 0.953 rs11926781 ENSG00000197582.5 GPX1P1 -6.32 8e-10 0.00184 -0.56 -0.32 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49565856 chrX:13378735~13379340:- LIHC trans rs11098499 0.865 rs11098513 ENSG00000275858.1 RP11-291L22.8 6.32 8.18e-10 0.00188 0.38 0.32 Corneal astigmatism; chr4:119394920 chr10:38450738~38451069:- LIHC trans rs12709013 0.818 rs1646273 ENSG00000230849.2 GOT2P2 6.32 8.32e-10 0.00191 0.38 0.32 Blood metabolite ratios; chr16:58748318 chr1:173141100~173142350:- LIHC trans rs73108077 0.607 rs6057566 ENSG00000279352.1 RP11-411B10.7 6.32 8.37e-10 0.00192 0.82 0.32 Red blood cell density in sickle cell anemia; chr20:31227621 chr18:14010054~14010917:+ LIHC trans rs7937890 0.559 rs4369365 ENSG00000236360.2 RP11-334A14.2 6.31 8.42e-10 0.00193 0.42 0.32 Mitochondrial DNA levels; chr11:14422969 chr1:52993201~52993702:- LIHC trans rs11098499 0.954 rs10017371 ENSG00000275858.1 RP11-291L22.8 6.31 8.51e-10 0.00195 0.38 0.32 Corneal astigmatism; chr4:119372621 chr10:38450738~38451069:- LIHC trans rs4073221 0.52 rs66659472 ENSG00000279926.1 RP3-406P24.5 -6.31 8.7e-10 0.00199 -0.51 -0.32 Parkinson's disease; chr3:18155035 chr6:3982673~3984130:+ LIHC trans rs12200782 0.932 rs12189841 ENSG00000242375.1 RP11-498P14.3 -6.31 8.71e-10 0.00199 -0.76 -0.32 Small cell lung carcinoma; chr6:26544570 chr9:97195351~97197687:- LIHC trans rs9876781 1 rs6776700 ENSG00000225528.1 RP3-370M22.8 -6.31 8.81e-10 0.00201 -0.37 -0.32 Longevity; chr3:48455358 chr22:39960397~39964683:+ LIHC trans rs12709013 0.792 rs1646270 ENSG00000230849.2 GOT2P2 6.3 9.14e-10 0.00209 0.38 0.32 Blood metabolite ratios; chr16:58745823 chr1:173141100~173142350:- LIHC trans rs877636 0.692 rs10876870 ENSG00000243403.1 RP11-330L19.1 -6.3 9.19e-10 0.0021 -0.38 -0.32 Cognitive function; chr12:56084218 chr15:64592979~64593326:+ LIHC trans rs877636 0.692 rs7971751 ENSG00000243403.1 RP11-330L19.1 -6.3 9.19e-10 0.0021 -0.38 -0.32 Cognitive function; chr12:56084874 chr15:64592979~64593326:+ LIHC trans rs2243480 0.522 rs73150635 ENSG00000164669.11 INTS4P1 6.3 9.32e-10 0.00212 0.61 0.32 Diabetic kidney disease; chr7:66507503 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs1796217 ENSG00000164669.11 INTS4P1 6.3 9.37e-10 0.00213 0.43 0.32 Aortic root size; chr7:66620931 chr7:65141225~65234216:+ LIHC trans rs9876781 1 rs13091785 ENSG00000225528.1 RP3-370M22.8 -6.3 9.4e-10 0.00214 -0.37 -0.32 Longevity; chr3:48452692 chr22:39960397~39964683:+ LIHC trans rs714543 1 rs13245012 ENSG00000226038.5 PPIAP21 -6.3 9.4e-10 0.00214 -0.39 -0.32 Plateletcrit; chr7:44826120 chr20:43230760~43231260:+ LIHC trans rs11098499 0.954 rs28572238 ENSG00000275858.1 RP11-291L22.8 6.29 9.49e-10 0.00216 0.38 0.32 Corneal astigmatism; chr4:119395531 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs28714195 ENSG00000275858.1 RP11-291L22.8 6.29 9.49e-10 0.00216 0.38 0.32 Corneal astigmatism; chr4:119395795 chr10:38450738~38451069:- LIHC trans rs9876781 1 rs2362452 ENSG00000235912.1 RP1-159A19.3 6.29 9.49e-10 0.00216 0.37 0.32 Longevity; chr3:48376724 chr1:27649419~27649610:+ LIHC trans rs6743068 0.541 rs10178982 ENSG00000235105.1 RP11-329A14.1 6.29 9.51e-10 0.00216 0.32 0.32 Lymphocyte percentage of white cells; chr2:201362917 chr1:48435967~48437223:+ LIHC trans rs9876781 1 rs1109227 ENSG00000225528.1 RP3-370M22.8 -6.29 9.65e-10 0.00219 -0.37 -0.32 Longevity; chr3:48437797 chr22:39960397~39964683:+ LIHC trans rs9876781 0.967 rs9876891 ENSG00000225528.1 RP3-370M22.8 -6.29 9.65e-10 0.00219 -0.37 -0.32 Longevity; chr3:48440024 chr22:39960397~39964683:+ LIHC trans rs9876781 1 rs3774808 ENSG00000225528.1 RP3-370M22.8 -6.29 9.65e-10 0.00219 -0.37 -0.32 Longevity; chr3:48440237 chr22:39960397~39964683:+ LIHC trans rs1023500 1 rs1023498 ENSG00000268568.1 AC007228.9 -6.29 9.76e-10 0.00222 -0.45 -0.32 Schizophrenia; chr22:41944565 chr19:56672574~56673901:- LIHC trans rs7568458 0.905 rs59877521 ENSG00000223886.3 RP11-251G23.2 6.29 9.77e-10 0.00222 0.37 0.32 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85532371 chr7:105530209~105530671:+ LIHC trans rs12709013 0.766 rs12599331 ENSG00000230849.2 GOT2P2 6.29 9.86e-10 0.00224 0.37 0.32 Blood metabolite ratios; chr16:58805307 chr1:173141100~173142350:- LIHC trans rs1023500 1 rs6002548 ENSG00000268568.1 AC007228.9 -6.29 9.92e-10 0.00225 -0.45 -0.32 Schizophrenia; chr22:41941036 chr19:56672574~56673901:- LIHC trans rs9858542 0.953 rs11713474 ENSG00000197582.5 GPX1P1 -6.29 9.93e-10 0.00225 -0.56 -0.32 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49574024 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs71324979 ENSG00000197582.5 GPX1P1 -6.29 9.93e-10 0.00225 -0.56 -0.32 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49582218 chrX:13378735~13379340:- LIHC trans rs9858542 0.953 rs9811982 ENSG00000197582.5 GPX1P1 -6.29 9.93e-10 0.00225 -0.56 -0.32 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49586944 chrX:13378735~13379340:- LIHC trans rs875971 0.545 rs73378304 ENSG00000164669.11 INTS4P1 -6.28 1.01e-09 0.00229 -0.43 -0.32 Aortic root size; chr7:66175760 chr7:65141225~65234216:+ LIHC trans rs11951515 0.509 rs12521249 ENSG00000174977.8 AC026271.5 6.28 1.03e-09 0.00233 0.38 0.32 Metabolite levels (X-11787); chr5:43558527 chr17:18650195~18651542:+ LIHC trans rs7312770 0.637 rs705700 ENSG00000243403.1 RP11-330L19.1 6.28 1.03e-09 0.00234 0.38 0.32 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr15:64592979~64593326:+ LIHC trans rs714543 0.967 rs11762008 ENSG00000226038.5 PPIAP21 -6.28 1.04e-09 0.00234 -0.38 -0.32 Plateletcrit; chr7:44864065 chr20:43230760~43231260:+ LIHC trans rs7568458 0.846 rs6705971 ENSG00000223886.3 RP11-251G23.2 -6.28 1.04e-09 0.00235 -0.38 -0.32 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85534294 chr7:105530209~105530671:+ LIHC trans rs3749237 1 rs4768 ENSG00000197582.5 GPX1P1 6.27 1.08e-09 0.00243 0.46 0.32 Resting heart rate; chr3:49721331 chrX:13378735~13379340:- LIHC trans rs3749237 0.964 rs11714957 ENSG00000197582.5 GPX1P1 6.27 1.08e-09 0.00243 0.46 0.32 Resting heart rate; chr3:49738745 chrX:13378735~13379340:- LIHC trans rs864643 0.678 rs521139 ENSG00000183298.5 RP11-556K13.1 6.27 1.08e-09 0.00245 0.5 0.32 Attention deficit hyperactivity disorder; chr3:39486128 chr1:101786340~101787219:- LIHC trans rs12200782 1 rs12195971 ENSG00000242375.1 RP11-498P14.3 -6.27 1.09e-09 0.00246 -0.78 -0.32 Small cell lung carcinoma; chr6:26460196 chr9:97195351~97197687:- LIHC trans rs12200782 1 rs12211201 ENSG00000242375.1 RP11-498P14.3 -6.27 1.09e-09 0.00246 -0.78 -0.32 Small cell lung carcinoma; chr6:26461233 chr9:97195351~97197687:- LIHC trans rs916888 0.61 rs199454 ENSG00000214425.5 LRRC37A4P 6.27 1.09e-09 0.00246 0.35 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:45506741~45550335:- LIHC trans rs3849046 0.79 rs13187637 ENSG00000226666.1 HSPA9P1 6.27 1.1e-09 0.00249 0.38 0.32 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138540962 chr2:221961737~221963765:+ LIHC trans rs6491750 1 rs9586200 ENSG00000270804.1 CTD-2583A14.11 -6.27 1.11e-09 0.0025 -0.5 -0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr13:103479838 chr19:57867885~57868834:+ LIHC trans rs2243480 1 rs1638734 ENSG00000164669.11 INTS4P1 6.26 1.14e-09 0.00257 0.56 0.32 Diabetic kidney disease; chr7:66632552 chr7:65141225~65234216:+ LIHC trans rs714543 1 rs1990053 ENSG00000226038.5 PPIAP21 -6.26 1.15e-09 0.00258 -0.38 -0.32 Plateletcrit; chr7:44886297 chr20:43230760~43231260:+ LIHC trans rs714543 0.935 rs2331174 ENSG00000226038.5 PPIAP21 -6.26 1.15e-09 0.00258 -0.38 -0.32 Plateletcrit; chr7:44887228 chr20:43230760~43231260:+ LIHC trans rs3849046 0.817 rs9327813 ENSG00000226666.1 HSPA9P1 6.26 1.15e-09 0.00258 0.38 0.32 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138528732 chr2:221961737~221963765:+ LIHC trans rs3849046 0.817 rs34629616 ENSG00000226666.1 HSPA9P1 6.26 1.15e-09 0.00258 0.38 0.32 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138532917 chr2:221961737~221963765:+ LIHC trans rs3849046 0.934 rs7714751 ENSG00000226666.1 HSPA9P1 -6.26 1.15e-09 0.00259 -0.38 -0.32 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138513377 chr2:221961737~221963765:+ LIHC trans rs3749237 0.964 rs62260719 ENSG00000197582.5 GPX1P1 6.26 1.16e-09 0.00262 0.48 0.32 Resting heart rate; chr3:49814986 chrX:13378735~13379340:- LIHC trans rs3088050 0.877 rs6872993 ENSG00000226986.4 RP11-543B16.2 6.26 1.17e-09 0.00263 0.36 0.32 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr5:177206392 chr1:211207239~211207897:+ LIHC trans rs3749237 1 rs2307021 ENSG00000197582.5 GPX1P1 6.26 1.17e-09 0.00264 0.46 0.32 Resting heart rate; chr3:49728050 chrX:13378735~13379340:- LIHC trans rs11951515 0.508 rs11958046 ENSG00000174977.8 AC026271.5 -6.26 1.18e-09 0.00265 -0.38 -0.32 Metabolite levels (X-11787); chr5:43583287 chr17:18650195~18651542:+ LIHC trans rs3849046 1 rs13155345 ENSG00000226666.1 HSPA9P1 -6.26 1.18e-09 0.00265 -0.38 -0.32 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138519235 chr2:221961737~221963765:+ LIHC trans rs8067354 0.645 rs2645492 ENSG00000187870.7 RNFT1P3 -6.25 1.19e-09 0.00268 -0.38 -0.32 Hemoglobin concentration; chr17:59798193 chr17:20743333~20754501:- LIHC trans rs714543 1 rs8840 ENSG00000226038.5 PPIAP21 6.25 1.21e-09 0.00271 0.38 0.32 Plateletcrit; chr7:44877441 chr20:43230760~43231260:+ LIHC trans rs538867 1 rs73066219 ENSG00000183298.5 RP11-556K13.1 6.25 1.22e-09 0.00273 0.76 0.32 Alzheimer's disease (cognitive decline); chr3:39465016 chr1:101786340~101787219:- LIHC trans rs7568458 0.905 rs6714709 ENSG00000223886.3 RP11-251G23.2 6.25 1.22e-09 0.00274 0.36 0.32 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85529252 chr7:105530209~105530671:+ LIHC trans rs916888 0.61 rs199446 ENSG00000214425.5 LRRC37A4P 6.25 1.24e-09 0.00277 0.34 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:45506741~45550335:- LIHC trans rs916888 0.61 rs199536 ENSG00000214425.5 LRRC37A4P 6.25 1.24e-09 0.00277 0.34 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:45506741~45550335:- LIHC trans rs9876781 1 rs9881491 ENSG00000225528.1 RP3-370M22.8 -6.25 1.24e-09 0.00279 -0.37 -0.32 Longevity; chr3:48446507 chr22:39960397~39964683:+ LIHC trans rs12210905 1 rs12196084 ENSG00000242375.1 RP11-498P14.3 -6.24 1.28e-09 0.00285 -0.84 -0.32 Hip circumference adjusted for BMI; chr6:27230425 chr9:97195351~97197687:- LIHC trans rs12709013 0.792 rs62066381 ENSG00000230849.2 GOT2P2 6.24 1.28e-09 0.00286 0.37 0.32 Blood metabolite ratios; chr16:58807981 chr1:173141100~173142350:- LIHC trans rs3849046 0.817 rs6596438 ENSG00000226666.1 HSPA9P1 6.24 1.29e-09 0.0029 0.38 0.32 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138569759 chr2:221961737~221963765:+ LIHC trans rs3849046 0.817 rs6874487 ENSG00000226666.1 HSPA9P1 6.24 1.29e-09 0.0029 0.38 0.32 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138571317 chr2:221961737~221963765:+ LIHC trans rs75870422 0.609 rs6491564 ENSG00000271654.1 RP11-685B14.3 6.24 1.31e-09 0.00292 0.76 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100465063 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs9585440 ENSG00000271654.1 RP11-685B14.3 6.24 1.31e-09 0.00292 0.76 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100466611 chr8:18387108~18387777:- LIHC trans rs75870422 0.702 rs9300605 ENSG00000271654.1 RP11-685B14.3 6.24 1.31e-09 0.00292 0.76 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100467713 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs9585441 ENSG00000271654.1 RP11-685B14.3 6.24 1.31e-09 0.00292 0.76 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100468024 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs9582395 ENSG00000271654.1 RP11-685B14.3 6.24 1.31e-09 0.00292 0.76 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100468228 chr8:18387108~18387777:- LIHC trans rs11098499 0.863 rs12508173 ENSG00000275858.1 RP11-291L22.8 6.24 1.31e-09 0.00292 0.37 0.32 Corneal astigmatism; chr4:119397371 chr10:38450738~38451069:- LIHC trans rs11098499 0.908 rs12504149 ENSG00000275858.1 RP11-291L22.8 6.24 1.31e-09 0.00292 0.37 0.32 Corneal astigmatism; chr4:119397422 chr10:38450738~38451069:- LIHC trans rs9876781 1 rs6794875 ENSG00000225528.1 RP3-370M22.8 -6.24 1.31e-09 0.00292 -0.36 -0.32 Longevity; chr3:48414217 chr22:39960397~39964683:+ LIHC trans rs11098499 0.779 rs7674500 ENSG00000275858.1 RP11-291L22.8 6.24 1.32e-09 0.00293 0.37 0.32 Corneal astigmatism; chr4:119382438 chr10:38450738~38451069:- LIHC trans rs11098499 0.865 rs4507344 ENSG00000275858.1 RP11-291L22.8 6.24 1.32e-09 0.00293 0.37 0.32 Corneal astigmatism; chr4:119386330 chr10:38450738~38451069:- LIHC trans rs11098499 0.697 rs4373140 ENSG00000275858.1 RP11-291L22.8 6.24 1.32e-09 0.00293 0.37 0.32 Corneal astigmatism; chr4:119386543 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs13113483 ENSG00000275858.1 RP11-291L22.8 6.24 1.32e-09 0.00293 0.37 0.32 Corneal astigmatism; chr4:119387884 chr10:38450738~38451069:- LIHC trans rs11098499 0.542 rs10440343 ENSG00000275858.1 RP11-291L22.8 6.24 1.32e-09 0.00293 0.37 0.32 Corneal astigmatism; chr4:119388632 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs28668716 ENSG00000275858.1 RP11-291L22.8 6.24 1.32e-09 0.00293 0.37 0.32 Corneal astigmatism; chr4:119388720 chr10:38450738~38451069:- LIHC trans rs11098499 0.542 rs7677836 ENSG00000275858.1 RP11-291L22.8 6.24 1.32e-09 0.00293 0.37 0.32 Corneal astigmatism; chr4:119389483 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs10002083 ENSG00000275858.1 RP11-291L22.8 6.24 1.32e-09 0.00293 0.37 0.32 Corneal astigmatism; chr4:119389997 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs10024844 ENSG00000275858.1 RP11-291L22.8 6.24 1.32e-09 0.00293 0.37 0.32 Corneal astigmatism; chr4:119390373 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs4345162 ENSG00000275858.1 RP11-291L22.8 6.24 1.32e-09 0.00293 0.37 0.32 Corneal astigmatism; chr4:119391804 chr10:38450738~38451069:- LIHC trans rs11098499 0.657 rs4463052 ENSG00000275858.1 RP11-291L22.8 6.24 1.32e-09 0.00293 0.37 0.32 Corneal astigmatism; chr4:119392103 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs13151285 ENSG00000275858.1 RP11-291L22.8 6.24 1.32e-09 0.00293 0.37 0.32 Corneal astigmatism; chr4:119393586 chr10:38450738~38451069:- LIHC trans rs75870422 0.609 rs7995634 ENSG00000271654.1 RP11-685B14.3 6.24 1.32e-09 0.00294 0.75 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100471971 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs78678769 ENSG00000271654.1 RP11-685B14.3 6.24 1.32e-09 0.00294 0.75 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100472686 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs74438629 ENSG00000271654.1 RP11-685B14.3 6.24 1.32e-09 0.00294 0.75 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100473054 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs7997932 ENSG00000271654.1 RP11-685B14.3 6.24 1.32e-09 0.00294 0.75 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100475159 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs7997468 ENSG00000271654.1 RP11-685B14.3 6.24 1.32e-09 0.00294 0.75 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100475424 chr8:18387108~18387777:- LIHC trans rs875971 0.545 rs1796222 ENSG00000164669.11 INTS4P1 6.24 1.33e-09 0.00296 0.43 0.32 Aortic root size; chr7:66592167 chr7:65141225~65234216:+ LIHC trans rs9858542 0.903 rs9875617 ENSG00000197582.5 GPX1P1 -6.23 1.33e-09 0.00297 -0.55 -0.32 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49597263 chrX:13378735~13379340:- LIHC trans rs9425766 0.64 rs2281486 ENSG00000213331.4 RP11-713C19.2 6.23 1.33e-09 0.00297 0.41 0.32 Life satisfaction; chr1:173853083 chr4:187970273~187971284:+ LIHC trans rs9425766 0.64 rs16846439 ENSG00000213331.4 RP11-713C19.2 6.23 1.33e-09 0.00297 0.41 0.32 Life satisfaction; chr1:173854900 chr4:187970273~187971284:+ LIHC trans rs9876781 1 rs2362450 ENSG00000225528.1 RP3-370M22.8 -6.23 1.34e-09 0.00298 -0.36 -0.32 Longevity; chr3:48419904 chr22:39960397~39964683:+ LIHC trans rs12709013 0.59 rs982848 ENSG00000230849.2 GOT2P2 6.23 1.36e-09 0.00303 0.37 0.32 Blood metabolite ratios; chr16:58704294 chr1:173141100~173142350:- LIHC trans rs9858542 0.953 rs3811697 ENSG00000197582.5 GPX1P1 -6.23 1.39e-09 0.00309 -0.55 -0.32 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49553337 chrX:13378735~13379340:- LIHC trans rs11098499 0.954 rs12508504 ENSG00000275858.1 RP11-291L22.8 6.23 1.4e-09 0.0031 0.37 0.32 Corneal astigmatism; chr4:119489452 chr10:38450738~38451069:- LIHC trans rs3088050 0.938 rs4311433 ENSG00000226986.4 RP11-543B16.2 6.23 1.4e-09 0.0031 0.36 0.32 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr5:177186055 chr1:211207239~211207897:+ LIHC trans rs13177918 0.677 rs13177951 ENSG00000226396.1 RP5-1056L3.3 6.22 1.41e-09 0.00313 0.3 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr1:19608114~19608568:+ LIHC trans rs13177918 0.677 rs13177970 ENSG00000226396.1 RP5-1056L3.3 6.22 1.41e-09 0.00313 0.3 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr1:19608114~19608568:+ LIHC trans rs13177918 0.677 rs13164105 ENSG00000226396.1 RP5-1056L3.3 6.22 1.41e-09 0.00313 0.3 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr1:19608114~19608568:+ LIHC trans rs11098499 0.618 rs6858383 ENSG00000275858.1 RP11-291L22.8 6.22 1.43e-09 0.00316 0.37 0.32 Corneal astigmatism; chr4:119375617 chr10:38450738~38451069:- LIHC trans rs11098499 0.697 rs6832410 ENSG00000275858.1 RP11-291L22.8 6.22 1.43e-09 0.00316 0.37 0.32 Corneal astigmatism; chr4:119375645 chr10:38450738~38451069:- LIHC trans rs11098499 0.865 rs1112817 ENSG00000275858.1 RP11-291L22.8 6.22 1.43e-09 0.00316 0.37 0.32 Corneal astigmatism; chr4:119376645 chr10:38450738~38451069:- LIHC trans rs11098499 0.779 rs10016060 ENSG00000275858.1 RP11-291L22.8 6.22 1.43e-09 0.00316 0.37 0.32 Corneal astigmatism; chr4:119377257 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs10005644 ENSG00000275858.1 RP11-291L22.8 6.22 1.43e-09 0.00316 0.37 0.32 Corneal astigmatism; chr4:119377322 chr10:38450738~38451069:- LIHC trans rs11098499 0.697 rs10016448 ENSG00000275858.1 RP11-291L22.8 6.22 1.43e-09 0.00316 0.37 0.32 Corneal astigmatism; chr4:119377690 chr10:38450738~38451069:- LIHC trans rs11098499 0.657 rs9996569 ENSG00000275858.1 RP11-291L22.8 6.22 1.43e-09 0.00316 0.37 0.32 Corneal astigmatism; chr4:119377849 chr10:38450738~38451069:- LIHC trans rs11098499 0.908 rs11729050 ENSG00000275858.1 RP11-291L22.8 6.22 1.43e-09 0.00316 0.37 0.32 Corneal astigmatism; chr4:119378911 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs28429722 ENSG00000275858.1 RP11-291L22.8 6.22 1.43e-09 0.00316 0.37 0.32 Corneal astigmatism; chr4:119378938 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs10014845 ENSG00000275858.1 RP11-291L22.8 6.22 1.43e-09 0.00316 0.37 0.32 Corneal astigmatism; chr4:119379922 chr10:38450738~38451069:- LIHC trans rs916888 0.61 rs199530 ENSG00000214425.5 LRRC37A4P 6.22 1.43e-09 0.00316 0.34 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:45506741~45550335:- LIHC trans rs3088050 1 rs3088050 ENSG00000226986.4 RP11-543B16.2 -6.22 1.45e-09 0.0032 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index; chr5:177299634 chr1:211207239~211207897:+ LIHC trans rs11098499 0.909 rs10020034 ENSG00000275858.1 RP11-291L22.8 6.22 1.45e-09 0.00321 0.38 0.32 Corneal astigmatism; chr4:119373176 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs59394118 ENSG00000275858.1 RP11-291L22.8 6.22 1.45e-09 0.00321 0.38 0.32 Corneal astigmatism; chr4:119374396 chr10:38450738~38451069:- LIHC trans rs11098499 0.865 rs9996417 ENSG00000275858.1 RP11-291L22.8 6.22 1.45e-09 0.00321 0.38 0.32 Corneal astigmatism; chr4:119374707 chr10:38450738~38451069:- LIHC trans rs714543 1 rs10278679 ENSG00000226038.5 PPIAP21 -6.22 1.45e-09 0.00321 -0.38 -0.32 Plateletcrit; chr7:44825465 chr20:43230760~43231260:+ LIHC trans rs11098499 0.954 rs59866101 ENSG00000275858.1 RP11-291L22.8 6.22 1.46e-09 0.00322 0.37 0.32 Corneal astigmatism; chr4:119375436 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs7437420 ENSG00000275858.1 RP11-291L22.8 6.22 1.46e-09 0.00322 0.37 0.32 Corneal astigmatism; chr4:119391748 chr10:38450738~38451069:- LIHC trans rs75870422 0.609 rs6491565 ENSG00000271654.1 RP11-685B14.3 6.22 1.49e-09 0.00328 0.75 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100470579 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs77492719 ENSG00000271654.1 RP11-685B14.3 6.22 1.49e-09 0.00328 0.75 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100471411 chr8:18387108~18387777:- LIHC trans rs17060993 0.618 rs17056484 ENSG00000246089.3 RP11-115C21.2 -6.21 1.5e-09 0.00332 -0.57 -0.32 Musician's dystonia; chr8:26990811 chr8:6403551~6407142:- LIHC trans rs6743068 0.541 rs6737085 ENSG00000235105.1 RP11-329A14.1 6.21 1.5e-09 0.00332 0.32 0.32 Lymphocyte percentage of white cells; chr2:201356718 chr1:48435967~48437223:+ LIHC trans rs11098499 0.954 rs10008392 ENSG00000275858.1 RP11-291L22.8 6.21 1.53e-09 0.00337 0.37 0.32 Corneal astigmatism; chr4:119397684 chr10:38450738~38451069:- LIHC trans rs9611519 0.929 rs926914 ENSG00000268568.1 AC007228.9 -6.21 1.53e-09 0.00338 -0.48 -0.32 Neuroticism; chr22:41022150 chr19:56672574~56673901:- LIHC trans rs3749237 0.964 rs7431078 ENSG00000197582.5 GPX1P1 6.21 1.53e-09 0.00338 0.46 0.32 Resting heart rate; chr3:49770757 chrX:13378735~13379340:- LIHC trans rs11098499 0.779 rs10011097 ENSG00000275858.1 RP11-291L22.8 6.21 1.54e-09 0.00339 0.37 0.32 Corneal astigmatism; chr4:119389204 chr10:38450738~38451069:- LIHC trans rs875971 0.545 rs1267814 ENSG00000164669.11 INTS4P1 6.21 1.54e-09 0.0034 0.42 0.32 Aortic root size; chr7:66579422 chr7:65141225~65234216:+ LIHC trans rs12709013 0.792 rs1646276 ENSG00000230849.2 GOT2P2 6.21 1.55e-09 0.00341 0.38 0.32 Blood metabolite ratios; chr16:58749654 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs1646277 ENSG00000230849.2 GOT2P2 6.21 1.55e-09 0.00341 0.38 0.32 Blood metabolite ratios; chr16:58750037 chr1:173141100~173142350:- LIHC trans rs9876781 1 rs9838618 ENSG00000225528.1 RP3-370M22.8 -6.21 1.56e-09 0.00345 -0.36 -0.32 Longevity; chr3:48445949 chr22:39960397~39964683:+ LIHC trans rs11098499 0.909 rs7681978 ENSG00000275858.1 RP11-291L22.8 6.21 1.57e-09 0.00346 0.37 0.32 Corneal astigmatism; chr4:119462620 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs10006525 ENSG00000275858.1 RP11-291L22.8 6.21 1.58e-09 0.00348 0.36 0.32 Corneal astigmatism; chr4:119487776 chr10:38450738~38451069:- LIHC trans rs9649213 0.574 rs7794187 ENSG00000225169.1 BRI3P1 6.2 1.59e-09 0.0035 0.43 0.32 Prostate cancer (SNP x SNP interaction); chr7:98260446 chr1:100213293~100213670:+ LIHC trans rs11098499 0.908 rs7696649 ENSG00000275858.1 RP11-291L22.8 6.2 1.59e-09 0.00351 0.37 0.32 Corneal astigmatism; chr4:119401022 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs1383533 ENSG00000275858.1 RP11-291L22.8 6.2 1.61e-09 0.00355 0.37 0.32 Corneal astigmatism; chr4:119513421 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs2291185 ENSG00000275858.1 RP11-291L22.8 6.2 1.61e-09 0.00355 0.37 0.32 Corneal astigmatism; chr4:119513678 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs28884220 ENSG00000275858.1 RP11-291L22.8 6.2 1.63e-09 0.00358 0.37 0.32 Corneal astigmatism; chr4:119386056 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs28793658 ENSG00000275858.1 RP11-291L22.8 6.2 1.63e-09 0.00358 0.37 0.32 Corneal astigmatism; chr4:119386059 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs79026312 ENSG00000275858.1 RP11-291L22.8 6.2 1.65e-09 0.00362 0.37 0.32 Corneal astigmatism; chr4:119519522 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs35111518 ENSG00000275858.1 RP11-291L22.8 6.2 1.65e-09 0.00362 0.37 0.32 Corneal astigmatism; chr4:119519527 chr10:38450738~38451069:- LIHC trans rs12709013 0.766 rs1657175 ENSG00000230849.2 GOT2P2 6.2 1.65e-09 0.00362 0.38 0.32 Blood metabolite ratios; chr16:58755527 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs1646289 ENSG00000230849.2 GOT2P2 6.2 1.65e-09 0.00362 0.38 0.32 Blood metabolite ratios; chr16:58755689 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs1646290 ENSG00000230849.2 GOT2P2 6.2 1.65e-09 0.00362 0.38 0.32 Blood metabolite ratios; chr16:58755807 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs1364346 ENSG00000230849.2 GOT2P2 6.2 1.65e-09 0.00362 0.38 0.32 Blood metabolite ratios; chr16:58756420 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs257626 ENSG00000230849.2 GOT2P2 6.2 1.65e-09 0.00362 0.38 0.32 Blood metabolite ratios; chr16:58759574 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs257625 ENSG00000230849.2 GOT2P2 6.2 1.65e-09 0.00362 0.38 0.32 Blood metabolite ratios; chr16:58759978 chr1:173141100~173142350:- LIHC trans rs4073221 0.52 rs66569729 ENSG00000279926.1 RP3-406P24.5 -6.2 1.65e-09 0.00363 -0.5 -0.32 Parkinson's disease; chr3:18148131 chr6:3982673~3984130:+ LIHC trans rs11098499 0.863 rs3775843 ENSG00000275858.1 RP11-291L22.8 6.2 1.66e-09 0.00364 0.37 0.32 Corneal astigmatism; chr4:119506689 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs3775844 ENSG00000275858.1 RP11-291L22.8 6.2 1.66e-09 0.00364 0.37 0.32 Corneal astigmatism; chr4:119506878 chr10:38450738~38451069:- LIHC trans rs875971 0.545 rs1796226 ENSG00000164669.11 INTS4P1 -6.2 1.67e-09 0.00365 -0.42 -0.32 Aortic root size; chr7:66622723 chr7:65141225~65234216:+ LIHC trans rs11098499 0.909 rs11723757 ENSG00000275858.1 RP11-291L22.8 6.2 1.67e-09 0.00366 0.37 0.32 Corneal astigmatism; chr4:119378514 chr10:38450738~38451069:- LIHC trans rs1593 0.531 rs4241821 ENSG00000269378.1 ITGB1P1 -6.2 1.67e-09 0.00367 -0.34 -0.32 Activated partial thromboplastin time; chr4:186255680 chr19:14621634~14622242:- LIHC trans rs7554547 0.6 rs2273290 ENSG00000261819.1 RP11-680G24.4 6.19 1.68e-09 0.00368 0.4 0.32 Nonsyndromic cleft lip with cleft palate; chr1:11958321 chr16:14988259~14990160:- LIHC trans rs875971 0.545 rs2707851 ENSG00000164669.11 INTS4P1 6.19 1.68e-09 0.00369 0.43 0.32 Aortic root size; chr7:66624178 chr7:65141225~65234216:+ LIHC trans rs11098499 0.863 rs3822192 ENSG00000275858.1 RP11-291L22.8 6.19 1.7e-09 0.00372 0.38 0.32 Corneal astigmatism; chr4:119524565 chr10:38450738~38451069:- LIHC trans rs7312770 0.637 rs705700 ENSG00000225071.1 GS1-184P14.2 6.19 1.7e-09 0.00373 0.39 0.32 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chrX:24429573~24429920:- LIHC trans rs11098499 0.697 rs11941899 ENSG00000275858.1 RP11-291L22.8 6.19 1.71e-09 0.00373 0.37 0.32 Corneal astigmatism; chr4:119461603 chr10:38450738~38451069:- LIHC trans rs11098499 0.821 rs28665282 ENSG00000275858.1 RP11-291L22.8 6.19 1.71e-09 0.00373 0.37 0.32 Corneal astigmatism; chr4:119463031 chr10:38450738~38451069:- LIHC trans rs11098499 0.738 rs10026493 ENSG00000275858.1 RP11-291L22.8 6.19 1.71e-09 0.00373 0.37 0.32 Corneal astigmatism; chr4:119463039 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs7681214 ENSG00000275858.1 RP11-291L22.8 6.19 1.71e-09 0.00373 0.37 0.32 Corneal astigmatism; chr4:119464165 chr10:38450738~38451069:- LIHC trans rs11098499 0.908 rs71614449 ENSG00000275858.1 RP11-291L22.8 6.19 1.71e-09 0.00373 0.37 0.32 Corneal astigmatism; chr4:119465900 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs35063680 ENSG00000275858.1 RP11-291L22.8 6.19 1.71e-09 0.00373 0.37 0.32 Corneal astigmatism; chr4:119465947 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs34858317 ENSG00000275858.1 RP11-291L22.8 6.19 1.71e-09 0.00373 0.37 0.32 Corneal astigmatism; chr4:119465955 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs17046116 ENSG00000275858.1 RP11-291L22.8 6.19 1.71e-09 0.00373 0.37 0.32 Corneal astigmatism; chr4:119466104 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs17046118 ENSG00000275858.1 RP11-291L22.8 6.19 1.71e-09 0.00373 0.37 0.32 Corneal astigmatism; chr4:119466341 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs7654587 ENSG00000275858.1 RP11-291L22.8 6.19 1.71e-09 0.00373 0.37 0.32 Corneal astigmatism; chr4:119467251 chr10:38450738~38451069:- LIHC trans rs714543 1 rs13245012 ENSG00000219797.2 PPIAP9 -6.19 1.71e-09 0.00374 -0.39 -0.32 Plateletcrit; chr7:44826120 chr6:31519480~31520291:- LIHC trans rs13177918 0.651 rs13184111 ENSG00000226396.1 RP5-1056L3.3 6.19 1.72e-09 0.00376 0.3 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150434649 chr1:19608114~19608568:+ LIHC trans rs11098499 0.58 rs12509234 ENSG00000275858.1 RP11-291L22.8 6.19 1.72e-09 0.00376 0.37 0.32 Corneal astigmatism; chr4:119398279 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs10014719 ENSG00000275858.1 RP11-291L22.8 6.19 1.72e-09 0.00376 0.37 0.32 Corneal astigmatism; chr4:119399560 chr10:38450738~38451069:- LIHC trans rs12709013 0.635 rs6993 ENSG00000233719.3 GOT2P3 6.19 1.74e-09 0.00379 0.37 0.32 Blood metabolite ratios; chr16:58707463 chr12:9641802~9643007:+ LIHC trans rs13177918 0.626 rs12186649 ENSG00000226396.1 RP5-1056L3.3 6.19 1.74e-09 0.0038 0.3 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150438963 chr1:19608114~19608568:+ LIHC trans rs9876781 0.967 rs7618883 ENSG00000225528.1 RP3-370M22.8 -6.19 1.74e-09 0.0038 -0.36 -0.32 Longevity; chr3:48457056 chr22:39960397~39964683:+ LIHC trans rs11098499 0.697 rs4560394 ENSG00000275858.1 RP11-291L22.8 6.19 1.74e-09 0.00381 0.37 0.32 Corneal astigmatism; chr4:119392280 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs7664986 ENSG00000275858.1 RP11-291L22.8 6.19 1.74e-09 0.00381 0.37 0.32 Corneal astigmatism; chr4:119508797 chr10:38450738~38451069:- LIHC trans rs11098499 0.818 rs10008791 ENSG00000275858.1 RP11-291L22.8 6.19 1.74e-09 0.00381 0.37 0.32 Corneal astigmatism; chr4:119510314 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs11736416 ENSG00000275858.1 RP11-291L22.8 6.19 1.74e-09 0.00381 0.37 0.32 Corneal astigmatism; chr4:119510506 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs3775845 ENSG00000275858.1 RP11-291L22.8 6.19 1.74e-09 0.00381 0.37 0.32 Corneal astigmatism; chr4:119511292 chr10:38450738~38451069:- LIHC trans rs12709013 0.792 rs12928733 ENSG00000230849.2 GOT2P2 6.19 1.76e-09 0.00383 0.37 0.32 Blood metabolite ratios; chr16:58807216 chr1:173141100~173142350:- LIHC trans rs7364180 0.514 rs763263 ENSG00000268568.1 AC007228.9 -6.18 1.77e-09 0.00387 -0.45 -0.32 Alzheimer's disease biomarkers; chr22:41919786 chr19:56672574~56673901:- LIHC trans rs11098499 0.863 rs1383532 ENSG00000275858.1 RP11-291L22.8 -6.18 1.78e-09 0.00388 -0.36 -0.32 Corneal astigmatism; chr4:119513249 chr10:38450738~38451069:- LIHC trans rs740160 0.558 rs17161669 ENSG00000228834.1 RP11-249L21.4 6.18 1.78e-09 0.00389 0.69 0.32 Dehydroepiandrosterone sulphate levels; chr7:99311040 chr6:108907615~108907873:- LIHC trans rs12709013 0.792 rs36098613 ENSG00000230849.2 GOT2P2 6.18 1.81e-09 0.00394 0.37 0.32 Blood metabolite ratios; chr16:58810562 chr1:173141100~173142350:- LIHC trans rs6477998 0.603 rs12338803 ENSG00000238072.1 RP11-305M3.2 6.18 1.81e-09 0.00395 0.54 0.32 Hematology traits; chr9:113263148 chr7:129410113~129410370:- LIHC trans rs7873102 0.521 rs1082865 ENSG00000229007.1 EXOSC3P1 6.18 1.84e-09 0.00399 0.39 0.32 Brain structure; chr9:37932317 chr21:32496812~32497311:+ LIHC trans rs2243480 1 rs6964245 ENSG00000164669.11 INTS4P1 -6.18 1.85e-09 0.00402 -0.55 -0.32 Diabetic kidney disease; chr7:66253730 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs6964530 ENSG00000164669.11 INTS4P1 -6.18 1.85e-09 0.00402 -0.55 -0.32 Diabetic kidney disease; chr7:66253864 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs10807701 ENSG00000164669.11 INTS4P1 -6.18 1.85e-09 0.00402 -0.55 -0.32 Diabetic kidney disease; chr7:66259699 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs1499613 ENSG00000164669.11 INTS4P1 -6.18 1.85e-09 0.00402 -0.55 -0.32 Diabetic kidney disease; chr7:66265873 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs1553174 ENSG00000164669.11 INTS4P1 -6.18 1.85e-09 0.00402 -0.55 -0.32 Diabetic kidney disease; chr7:66266207 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs10950032 ENSG00000164669.11 INTS4P1 -6.18 1.85e-09 0.00402 -0.55 -0.32 Diabetic kidney disease; chr7:66273604 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs1392104 ENSG00000164669.11 INTS4P1 -6.18 1.85e-09 0.00402 -0.55 -0.32 Diabetic kidney disease; chr7:66294120 chr7:65141225~65234216:+ LIHC trans rs538867 1 rs1708099 ENSG00000183298.5 RP11-556K13.1 6.18 1.85e-09 0.00403 0.72 0.32 Alzheimer's disease (cognitive decline); chr3:39476278 chr1:101786340~101787219:- LIHC trans rs7873102 0.521 rs776018 ENSG00000229007.1 EXOSC3P1 6.18 1.86e-09 0.00403 0.39 0.32 Brain structure; chr9:37940442 chr21:32496812~32497311:+ LIHC trans rs877636 0.669 rs7297175 ENSG00000227887.1 RPS26P13 -6.18 1.86e-09 0.00404 -0.37 -0.32 Cognitive function; chr12:56080024 chr1:208697369~208697698:- LIHC trans rs864643 0.738 rs13063581 ENSG00000183298.5 RP11-556K13.1 -6.18 1.87e-09 0.00406 -0.43 -0.32 Attention deficit hyperactivity disorder; chr3:39551168 chr1:101786340~101787219:- LIHC trans rs9899728 0.706 rs7224300 ENSG00000234925.2 ATP5HP4 6.17 1.88e-09 0.00409 0.85 0.32 Alzheimer's disease or small vessel stroke; chr17:75033161 chr12:68642519~68642993:- LIHC trans rs740160 0.558 rs73395508 ENSG00000228834.1 RP11-249L21.4 6.17 1.89e-09 0.0041 0.69 0.32 Dehydroepiandrosterone sulphate levels; chr7:99304271 chr6:108907615~108907873:- LIHC trans rs740160 0.558 rs68164591 ENSG00000228834.1 RP11-249L21.4 6.17 1.89e-09 0.0041 0.69 0.32 Dehydroepiandrosterone sulphate levels; chr7:99306817 chr6:108907615~108907873:- LIHC trans rs12709013 0.792 rs1646262 ENSG00000230849.2 GOT2P2 6.17 1.91e-09 0.00415 0.38 0.32 Blood metabolite ratios; chr16:58760593 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs257623 ENSG00000230849.2 GOT2P2 6.17 1.91e-09 0.00415 0.38 0.32 Blood metabolite ratios; chr16:58761247 chr1:173141100~173142350:- LIHC trans rs10815468 0.585 rs4742264 ENSG00000215210.3 RBMXP2 6.17 1.92e-09 0.00416 0.38 0.32 Bipolar disorder and schizophrenia; chr9:6783414 chr9:30689105~30690272:+ LIHC trans rs714543 1 rs714543 ENSG00000219797.2 PPIAP9 -6.17 1.92e-09 0.00416 -0.38 -0.32 Plateletcrit; chr7:44847477 chr6:31519480~31520291:- LIHC trans rs714543 1 rs757693 ENSG00000219797.2 PPIAP9 -6.17 1.92e-09 0.00416 -0.38 -0.32 Plateletcrit; chr7:44848430 chr6:31519480~31520291:- LIHC trans rs11098499 0.954 rs17005535 ENSG00000275858.1 RP11-291L22.8 6.17 1.92e-09 0.00418 0.36 0.32 Corneal astigmatism; chr4:119490407 chr10:38450738~38451069:- LIHC trans rs6424115 1 rs7521961 ENSG00000228217.1 AL390877.1 6.17 1.93e-09 0.00419 0.37 0.32 Immature fraction of reticulocytes; chr1:23831144 chr1:117778087~117778506:- LIHC trans rs6424115 1 rs7515969 ENSG00000228217.1 AL390877.1 6.17 1.93e-09 0.00419 0.37 0.32 Immature fraction of reticulocytes; chr1:23831908 chr1:117778087~117778506:- LIHC trans rs13177918 0.677 rs13181401 ENSG00000226396.1 RP5-1056L3.3 6.17 1.93e-09 0.00419 0.29 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr1:19608114~19608568:+ LIHC trans rs13177918 0.677 rs4541646 ENSG00000226396.1 RP5-1056L3.3 6.17 1.93e-09 0.00419 0.29 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr1:19608114~19608568:+ LIHC trans rs13177918 0.677 rs3900644 ENSG00000226396.1 RP5-1056L3.3 6.17 1.93e-09 0.00419 0.29 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr1:19608114~19608568:+ LIHC trans rs13177918 0.677 rs2070844 ENSG00000226396.1 RP5-1056L3.3 6.17 1.93e-09 0.00419 0.29 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr1:19608114~19608568:+ LIHC trans rs13177918 0.677 rs2073472 ENSG00000226396.1 RP5-1056L3.3 6.17 1.93e-09 0.00419 0.29 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr1:19608114~19608568:+ LIHC trans rs13177918 0.629 rs2070842 ENSG00000226396.1 RP5-1056L3.3 6.17 1.93e-09 0.00419 0.29 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr1:19608114~19608568:+ LIHC trans rs13177918 0.677 rs13171800 ENSG00000226396.1 RP5-1056L3.3 6.17 1.93e-09 0.00419 0.29 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr1:19608114~19608568:+ LIHC trans rs13177918 0.677 rs2070841 ENSG00000226396.1 RP5-1056L3.3 6.17 1.93e-09 0.00419 0.29 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr1:19608114~19608568:+ LIHC trans rs714543 1 rs2898 ENSG00000226038.5 PPIAP21 -6.17 1.94e-09 0.00421 -0.37 -0.32 Plateletcrit; chr7:44827034 chr20:43230760~43231260:+ LIHC trans rs714543 1 rs10267576 ENSG00000226038.5 PPIAP21 -6.17 1.94e-09 0.00421 -0.37 -0.32 Plateletcrit; chr7:44831334 chr20:43230760~43231260:+ LIHC trans rs714543 0.967 rs12536807 ENSG00000226038.5 PPIAP21 -6.17 1.94e-09 0.00421 -0.37 -0.32 Plateletcrit; chr7:44838675 chr20:43230760~43231260:+ LIHC trans rs1499614 1 rs2707832 ENSG00000164669.11 INTS4P1 6.17 1.95e-09 0.00422 0.52 0.32 Gout; chr7:66671562 chr7:65141225~65234216:+ LIHC trans rs9649213 0.593 rs6969731 ENSG00000225169.1 BRI3P1 6.17 1.97e-09 0.00426 0.4 0.32 Prostate cancer (SNP x SNP interaction); chr7:98295259 chr1:100213293~100213670:+ LIHC trans rs11098499 0.954 rs10017543 ENSG00000275858.1 RP11-291L22.8 6.16 2.01e-09 0.00435 0.37 0.32 Corneal astigmatism; chr4:119400265 chr10:38450738~38451069:- LIHC trans rs11098499 0.908 rs7695996 ENSG00000275858.1 RP11-291L22.8 6.16 2.01e-09 0.00435 0.37 0.32 Corneal astigmatism; chr4:119400878 chr10:38450738~38451069:- LIHC trans rs2243480 1 rs316329 ENSG00000164669.11 INTS4P1 6.16 2.02e-09 0.00436 0.55 0.32 Diabetic kidney disease; chr7:66143429 chr7:65141225~65234216:+ LIHC trans rs714543 0.967 rs10951776 ENSG00000219797.2 PPIAP9 -6.16 2.03e-09 0.00438 -0.38 -0.32 Plateletcrit; chr7:44858152 chr6:31519480~31520291:- LIHC trans rs11098499 0.954 rs10518331 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119402440 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs13133522 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119403269 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs35091806 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119404374 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs35165976 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119404475 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs2389802 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119404577 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs6846442 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119405168 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs71614422 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119438185 chr10:38450738~38451069:- LIHC trans rs11098499 0.738 rs34566984 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119440115 chr10:38450738~38451069:- LIHC trans rs11098499 0.738 rs34965784 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119440431 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs17009122 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119441248 chr10:38450738~38451069:- LIHC trans rs11098499 0.505 rs75122014 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119441271 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs9685777 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119444810 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs71614438 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119450097 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs66506550 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119450290 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs7659501 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119450397 chr10:38450738~38451069:- LIHC trans rs11098499 0.657 rs71614442 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119458191 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs2892848 ENSG00000275858.1 RP11-291L22.8 6.16 2.04e-09 0.0044 0.36 0.32 Corneal astigmatism; chr4:119460186 chr10:38450738~38451069:- LIHC trans rs13014235 0.905 rs6435082 ENSG00000235105.1 RP11-329A14.1 6.16 2.06e-09 0.00444 0.32 0.32 Basal cell carcinoma; chr2:201372558 chr1:48435967~48437223:+ LIHC trans rs13014235 0.905 rs6730666 ENSG00000235105.1 RP11-329A14.1 6.16 2.06e-09 0.00444 0.32 0.32 Basal cell carcinoma; chr2:201374076 chr1:48435967~48437223:+ LIHC trans rs875971 0.502 rs6460311 ENSG00000164669.11 INTS4P1 6.16 2.07e-09 0.00445 0.43 0.32 Aortic root size; chr7:66646886 chr7:65141225~65234216:+ LIHC trans rs8010715 0.636 rs3825584 ENSG00000238000.1 RP11-274E7.2 6.16 2.09e-09 0.00449 0.36 0.32 IgG glycosylation; chr14:24118430 chr5:98213402~98214121:+ LIHC trans rs13177918 0.677 rs13161099 ENSG00000226396.1 RP5-1056L3.3 6.15 2.11e-09 0.00453 0.3 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr1:19608114~19608568:+ LIHC trans rs13177918 0.629 rs13161261 ENSG00000226396.1 RP5-1056L3.3 6.15 2.11e-09 0.00453 0.3 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr1:19608114~19608568:+ LIHC trans rs75870422 0.609 rs7998326 ENSG00000271654.1 RP11-685B14.3 6.15 2.12e-09 0.00456 0.64 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100476024 chr8:18387108~18387777:- LIHC trans rs6477998 0.58 rs10817467 ENSG00000238072.1 RP11-305M3.2 6.15 2.13e-09 0.00457 0.54 0.32 Hematology traits; chr9:113246803 chr7:129410113~129410370:- LIHC trans rs12709013 0.792 rs62066815 ENSG00000230849.2 GOT2P2 6.15 2.14e-09 0.00459 0.38 0.32 Blood metabolite ratios; chr16:58751577 chr1:173141100~173142350:- LIHC trans rs2243480 1 rs2420171 ENSG00000164669.11 INTS4P1 -6.15 2.14e-09 0.00459 -0.55 -0.32 Diabetic kidney disease; chr7:66172773 chr7:65141225~65234216:+ LIHC trans rs11098499 0.908 rs9995234 ENSG00000275858.1 RP11-291L22.8 6.15 2.15e-09 0.00461 0.37 0.32 Corneal astigmatism; chr4:119400672 chr10:38450738~38451069:- LIHC trans rs13177918 0.677 rs13161417 ENSG00000226396.1 RP5-1056L3.3 6.15 2.15e-09 0.00462 0.29 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr1:19608114~19608568:+ LIHC trans rs13177918 0.677 rs13161156 ENSG00000226396.1 RP5-1056L3.3 6.15 2.15e-09 0.00462 0.29 0.32 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr1:19608114~19608568:+ LIHC trans rs9611519 0.78 rs9611528 ENSG00000268568.1 AC007228.9 -6.15 2.16e-09 0.00463 -0.38 -0.32 Neuroticism; chr22:41252498 chr19:56672574~56673901:- LIHC trans rs75870422 0.609 rs7318874 ENSG00000271654.1 RP11-685B14.3 6.15 2.16e-09 0.00463 0.74 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100476506 chr8:18387108~18387777:- LIHC trans rs864643 0.947 rs6762416 ENSG00000183298.5 RP11-556K13.1 6.15 2.16e-09 0.00464 0.49 0.32 Attention deficit hyperactivity disorder; chr3:39496111 chr1:101786340~101787219:- LIHC trans rs12709013 0.755 rs1628029 ENSG00000230849.2 GOT2P2 6.15 2.17e-09 0.00466 0.38 0.32 Blood metabolite ratios; chr16:58763846 chr1:173141100~173142350:- LIHC trans rs916888 0.61 rs199444 ENSG00000214425.5 LRRC37A4P -6.15 2.18e-09 0.00467 -0.34 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:45506741~45550335:- LIHC trans rs916888 0.61 rs199442 ENSG00000214425.5 LRRC37A4P -6.15 2.18e-09 0.00467 -0.34 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:45506741~45550335:- LIHC trans rs75870422 0.609 rs7983459 ENSG00000271654.1 RP11-685B14.3 6.15 2.18e-09 0.00467 0.75 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100478736 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs7989467 ENSG00000271654.1 RP11-685B14.3 6.15 2.18e-09 0.00467 0.75 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100479492 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs2057446 ENSG00000271654.1 RP11-685B14.3 6.15 2.18e-09 0.00467 0.75 0.32 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100480448 chr8:18387108~18387777:- LIHC trans rs877636 0.692 rs2271194 ENSG00000212994.5 RPS26P6 -6.15 2.18e-09 0.00468 -0.4 -0.32 Cognitive function; chr12:56083910 chr8:100895771~100896118:+ LIHC trans rs2243480 1 rs6958420 ENSG00000164669.11 INTS4P1 -6.15 2.19e-09 0.00469 -0.54 -0.32 Diabetic kidney disease; chr7:66286184 chr7:65141225~65234216:+ LIHC trans rs916888 0.647 rs199449 ENSG00000214425.5 LRRC37A4P -6.15 2.19e-09 0.00469 -0.34 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:45506741~45550335:- LIHC trans rs74781061 0.929 rs10459648 ENSG00000227288.3 RP5-837I24.1 -6.15 2.19e-09 0.00469 -0.36 -0.32 Endometriosis; chr15:74573099 chr1:81501794~81503468:+ LIHC trans rs12709013 0.792 rs1657170 ENSG00000230849.2 GOT2P2 6.15 2.2e-09 0.00471 0.38 0.32 Blood metabolite ratios; chr16:58752082 chr1:173141100~173142350:- LIHC trans rs877636 0.884 rs705705 ENSG00000243403.1 RP11-330L19.1 6.15 2.21e-09 0.00473 0.41 0.32 Cognitive function; chr12:56041720 chr15:64592979~64593326:+ LIHC trans rs2243480 0.901 rs12530490 ENSG00000164669.11 INTS4P1 -6.14 2.24e-09 0.00479 -0.54 -0.32 Diabetic kidney disease; chr7:66226660 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs7778911 ENSG00000164669.11 INTS4P1 -6.14 2.24e-09 0.00479 -0.54 -0.32 Diabetic kidney disease; chr7:66229519 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs1979823 ENSG00000164669.11 INTS4P1 -6.14 2.24e-09 0.00479 -0.54 -0.32 Diabetic kidney disease; chr7:66239626 chr7:65141225~65234216:+ LIHC trans rs2243480 0.831 rs57294491 ENSG00000164669.11 INTS4P1 -6.14 2.25e-09 0.00482 -0.55 -0.32 Diabetic kidney disease; chr7:66219914 chr7:65141225~65234216:+ LIHC trans rs1023500 1 rs6002552 ENSG00000268568.1 AC007228.9 -6.14 2.26e-09 0.00484 -0.44 -0.32 Schizophrenia; chr22:41942347 chr19:56672574~56673901:- LIHC trans rs11098499 0.908 rs28559989 ENSG00000275858.1 RP11-291L22.8 6.14 2.28e-09 0.00488 0.36 0.32 Corneal astigmatism; chr4:119465472 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs28632018 ENSG00000275858.1 RP11-291L22.8 6.14 2.28e-09 0.00488 0.36 0.32 Corneal astigmatism; chr4:119465575 chr10:38450738~38451069:- LIHC trans rs2243480 1 rs1499614 ENSG00000164669.11 INTS4P1 6.14 2.29e-09 0.0049 0.54 0.32 Diabetic kidney disease; chr7:66265811 chr7:65141225~65234216:+ LIHC trans rs3849046 0.817 rs2268439 ENSG00000226666.1 HSPA9P1 6.14 2.29e-09 0.0049 0.37 0.32 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138545103 chr2:221961737~221963765:+ LIHC trans rs116095464 1 rs6555160 ENSG00000185986.11 SDHAP3 -6.14 2.29e-09 0.0049 -0.8 -0.32 Breast cancer; chr5:311554 chr5:1572222~1594620:- LIHC trans rs4073221 0.52 rs13067391 ENSG00000279926.1 RP3-406P24.5 -6.14 2.3e-09 0.00491 -0.5 -0.32 Parkinson's disease; chr3:18150437 chr6:3982673~3984130:+ LIHC trans rs1023500 1 rs1023497 ENSG00000268568.1 AC007228.9 -6.14 2.31e-09 0.00493 -0.43 -0.32 Schizophrenia; chr22:41944504 chr19:56672574~56673901:- LIHC trans rs11220237 0.92 rs10893426 ENSG00000236257.1 EI24P2 6.14 2.31e-09 0.00493 0.39 0.32 Itch intensity from mosquito bite adjusted by bite size; chr11:125778426 chr1:158454198~158455273:+ LIHC trans rs740160 0.558 rs12538893 ENSG00000228834.1 RP11-249L21.4 6.14 2.33e-09 0.00498 0.68 0.31 Dehydroepiandrosterone sulphate levels; chr7:99310874 chr6:108907615~108907873:- LIHC trans rs864643 0.947 rs4113192 ENSG00000183298.5 RP11-556K13.1 6.14 2.35e-09 0.00502 0.49 0.31 Attention deficit hyperactivity disorder; chr3:39495699 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs4113193 ENSG00000183298.5 RP11-556K13.1 6.14 2.35e-09 0.00502 0.49 0.31 Attention deficit hyperactivity disorder; chr3:39495779 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs6762335 ENSG00000183298.5 RP11-556K13.1 6.14 2.35e-09 0.00502 0.49 0.31 Attention deficit hyperactivity disorder; chr3:39496043 chr1:101786340~101787219:- LIHC trans rs13177918 0.677 rs3797622 ENSG00000226396.1 RP5-1056L3.3 6.13 2.36e-09 0.00503 0.29 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr1:19608114~19608568:+ LIHC trans rs877636 0.847 rs705704 ENSG00000243403.1 RP11-330L19.1 6.13 2.37e-09 0.00505 0.41 0.31 Cognitive function; chr12:56041628 chr15:64592979~64593326:+ LIHC trans rs13177918 0.677 rs4841 ENSG00000226396.1 RP5-1056L3.3 6.13 2.37e-09 0.00505 0.29 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446963 chr1:19608114~19608568:+ LIHC trans rs13177918 0.677 rs13183077 ENSG00000226396.1 RP5-1056L3.3 6.13 2.37e-09 0.00505 0.29 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447009 chr1:19608114~19608568:+ LIHC trans rs7364180 0.502 rs7290134 ENSG00000268568.1 AC007228.9 -6.13 2.37e-09 0.00506 -0.45 -0.31 Alzheimer's disease biomarkers; chr22:41925247 chr19:56672574~56673901:- LIHC trans rs7873102 0.521 rs2890783 ENSG00000229007.1 EXOSC3P1 -6.13 2.39e-09 0.00509 -0.4 -0.31 Brain structure; chr9:38024461 chr21:32496812~32497311:+ LIHC trans rs12709013 0.693 rs1627257 ENSG00000230849.2 GOT2P2 6.13 2.4e-09 0.00512 0.38 0.31 Blood metabolite ratios; chr16:58763764 chr1:173141100~173142350:- LIHC trans rs875971 0.545 rs6950988 ENSG00000164669.11 INTS4P1 -6.13 2.42e-09 0.00515 -0.42 -0.31 Aortic root size; chr7:66511428 chr7:65141225~65234216:+ LIHC trans rs11220237 1 rs11518432 ENSG00000236257.1 EI24P2 6.13 2.43e-09 0.00517 0.4 0.31 Itch intensity from mosquito bite adjusted by bite size; chr11:125814838 chr1:158454198~158455273:+ LIHC trans rs11220237 0.92 rs12272767 ENSG00000236257.1 EI24P2 6.13 2.43e-09 0.00517 0.4 0.31 Itch intensity from mosquito bite adjusted by bite size; chr11:125824748 chr1:158454198~158455273:+ LIHC trans rs9649213 0.593 rs6970801 ENSG00000225169.1 BRI3P1 6.13 2.47e-09 0.00525 0.4 0.31 Prostate cancer (SNP x SNP interaction); chr7:98295928 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs12704982 ENSG00000225169.1 BRI3P1 6.13 2.47e-09 0.00525 0.4 0.31 Prostate cancer (SNP x SNP interaction); chr7:98296741 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs34129434 ENSG00000225169.1 BRI3P1 6.13 2.47e-09 0.00525 0.4 0.31 Prostate cancer (SNP x SNP interaction); chr7:98297152 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs12704983 ENSG00000225169.1 BRI3P1 6.13 2.47e-09 0.00525 0.4 0.31 Prostate cancer (SNP x SNP interaction); chr7:98297733 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs7781916 ENSG00000225169.1 BRI3P1 6.13 2.47e-09 0.00525 0.4 0.31 Prostate cancer (SNP x SNP interaction); chr7:98300426 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs736753 ENSG00000225169.1 BRI3P1 6.13 2.47e-09 0.00525 0.4 0.31 Prostate cancer (SNP x SNP interaction); chr7:98302177 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs736754 ENSG00000225169.1 BRI3P1 6.13 2.47e-09 0.00525 0.4 0.31 Prostate cancer (SNP x SNP interaction); chr7:98302247 chr1:100213293~100213670:+ LIHC trans rs75870422 0.609 rs1074602 ENSG00000271654.1 RP11-685B14.3 6.13 2.48e-09 0.00528 0.75 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100481421 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs9585446 ENSG00000271654.1 RP11-685B14.3 6.13 2.48e-09 0.00528 0.75 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100482743 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs77344977 ENSG00000271654.1 RP11-685B14.3 6.13 2.48e-09 0.00528 0.75 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100482916 chr8:18387108~18387777:- LIHC trans rs2243480 1 rs1546059 ENSG00000164669.11 INTS4P1 -6.13 2.49e-09 0.00528 -0.54 -0.31 Diabetic kidney disease; chr7:66189722 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs6958289 ENSG00000164669.11 INTS4P1 -6.13 2.49e-09 0.00528 -0.54 -0.31 Diabetic kidney disease; chr7:66192124 chr7:65141225~65234216:+ LIHC trans rs9876781 1 rs922075 ENSG00000225528.1 RP3-370M22.8 6.13 2.49e-09 0.00529 0.36 0.31 Longevity; chr3:48447994 chr22:39960397~39964683:+ LIHC trans rs9876781 1 rs2045554 ENSG00000225528.1 RP3-370M22.8 6.13 2.49e-09 0.00529 0.36 0.31 Longevity; chr3:48453142 chr22:39960397~39964683:+ LIHC trans rs881952 0.585 rs934797 ENSG00000250564.1 RP11-215P8.4 6.12 2.5e-09 0.0053 0.39 0.31 Glucose homeostasis traits; chr2:60675030 chr5:134429051~134460615:- LIHC trans rs2243480 1 rs2420170 ENSG00000164669.11 INTS4P1 -6.12 2.51e-09 0.00532 -0.54 -0.31 Diabetic kidney disease; chr7:66191066 chr7:65141225~65234216:+ LIHC trans rs11098499 0.697 rs28655325 ENSG00000275858.1 RP11-291L22.8 6.12 2.51e-09 0.00533 0.37 0.31 Corneal astigmatism; chr4:119451844 chr10:38450738~38451069:- LIHC trans rs9876781 0.967 rs1459249 ENSG00000225528.1 RP3-370M22.8 -6.12 2.52e-09 0.00534 -0.36 -0.31 Longevity; chr3:48438208 chr22:39960397~39964683:+ LIHC trans rs13177918 0.686 rs12654827 ENSG00000226396.1 RP5-1056L3.3 6.12 2.54e-09 0.00538 0.3 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr1:19608114~19608568:+ LIHC trans rs13177918 0.677 rs13160685 ENSG00000226396.1 RP5-1056L3.3 6.12 2.54e-09 0.00538 0.3 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr1:19608114~19608568:+ LIHC trans rs12709013 0.686 rs151817 ENSG00000230849.2 GOT2P2 -6.12 2.54e-09 0.00538 -0.36 -0.31 Blood metabolite ratios; chr16:58704014 chr1:173141100~173142350:- LIHC trans rs12709013 0.686 rs244919 ENSG00000230849.2 GOT2P2 -6.12 2.54e-09 0.00538 -0.36 -0.31 Blood metabolite ratios; chr16:58704146 chr1:173141100~173142350:- LIHC trans rs6743068 0.541 rs6435081 ENSG00000235105.1 RP11-329A14.1 6.12 2.54e-09 0.00538 0.32 0.31 Lymphocyte percentage of white cells; chr2:201355900 chr1:48435967~48437223:+ LIHC trans rs7937890 0.559 rs10766184 ENSG00000236360.2 RP11-334A14.2 6.12 2.55e-09 0.00541 0.4 0.31 Mitochondrial DNA levels; chr11:14521031 chr1:52993201~52993702:- LIHC trans rs11098499 0.863 rs10004484 ENSG00000275858.1 RP11-291L22.8 6.12 2.57e-09 0.00544 0.37 0.31 Corneal astigmatism; chr4:119521273 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs1155576 ENSG00000275858.1 RP11-291L22.8 6.12 2.57e-09 0.00544 0.37 0.31 Corneal astigmatism; chr4:119529004 chr10:38450738~38451069:- LIHC trans rs7568458 0.84 rs2886722 ENSG00000223886.3 RP11-251G23.2 -6.12 2.58e-09 0.00546 -0.36 -0.31 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85515174 chr7:105530209~105530671:+ LIHC trans rs2243480 0.901 rs778730 ENSG00000164669.11 INTS4P1 6.12 2.6e-09 0.00551 0.54 0.31 Diabetic kidney disease; chr7:66358338 chr7:65141225~65234216:+ LIHC trans rs11098499 0.863 rs34868248 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119521275 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs3733525 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119525893 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs3775847 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119526487 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs3775848 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119526569 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs10013305 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119529269 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs3775849 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119529753 chr10:38450738~38451069:- LIHC trans rs11098499 0.818 rs7688802 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119530513 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs7695620 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119531621 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs12502389 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119533036 chr10:38450738~38451069:- LIHC trans rs11098499 0.821 rs3775852 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119533401 chr10:38450738~38451069:- LIHC trans rs11098499 0.82 rs6534140 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119534156 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs7657849 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119534339 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs10034450 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119534494 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs1480939 ENSG00000275858.1 RP11-291L22.8 6.12 2.61e-09 0.00551 0.37 0.31 Corneal astigmatism; chr4:119535772 chr10:38450738~38451069:- LIHC trans rs7032940 0.626 rs4314718 ENSG00000262519.1 TXNP4 6.12 2.63e-09 0.00556 0.4 0.31 Height; chr9:110211368 chr17:4572206~4572515:+ LIHC trans rs875971 0.545 rs801199 ENSG00000164669.11 INTS4P1 6.11 2.65e-09 0.00559 0.42 0.31 Aortic root size; chr7:66560286 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs1638724 ENSG00000164669.11 INTS4P1 6.11 2.65e-09 0.00559 0.42 0.31 Aortic root size; chr7:66575494 chr7:65141225~65234216:+ LIHC trans rs12709013 0.792 rs1615326 ENSG00000230849.2 GOT2P2 6.11 2.66e-09 0.00562 0.38 0.31 Blood metabolite ratios; chr16:58747148 chr1:173141100~173142350:- LIHC trans rs875971 0.502 rs11769702 ENSG00000164669.11 INTS4P1 -6.11 2.67e-09 0.00564 -0.42 -0.31 Aortic root size; chr7:66255529 chr7:65141225~65234216:+ LIHC trans rs11098499 0.865 rs11722183 ENSG00000275858.1 RP11-291L22.8 6.11 2.7e-09 0.00569 0.37 0.31 Corneal astigmatism; chr4:119359442 chr10:38450738~38451069:- LIHC trans rs7312770 1 rs7312770 ENSG00000225071.1 GS1-184P14.2 -6.11 2.71e-09 0.00572 -0.37 -0.31 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chrX:24429573~24429920:- LIHC trans rs877636 0.692 rs11171739 ENSG00000196656.7 AC004057.1 6.11 2.75e-09 0.0058 0.38 0.31 Cognitive function; chr12:56076841 chr4:113214046~113217170:- LIHC trans rs3849046 0.718 rs28587037 ENSG00000226666.1 HSPA9P1 6.11 2.79e-09 0.00587 0.38 0.31 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138599355 chr2:221961737~221963765:+ LIHC trans rs6743068 0.541 rs10206231 ENSG00000235105.1 RP11-329A14.1 6.1 2.8e-09 0.00588 0.32 0.31 Lymphocyte percentage of white cells; chr2:201364502 chr1:48435967~48437223:+ LIHC trans rs2243480 1 rs6966322 ENSG00000164669.11 INTS4P1 -6.1 2.8e-09 0.00589 -0.54 -0.31 Diabetic kidney disease; chr7:66181767 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs4145008 ENSG00000164669.11 INTS4P1 -6.1 2.8e-09 0.00589 -0.54 -0.31 Diabetic kidney disease; chr7:66182524 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs4718315 ENSG00000164669.11 INTS4P1 -6.1 2.8e-09 0.00589 -0.54 -0.31 Diabetic kidney disease; chr7:66183554 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs4718316 ENSG00000164669.11 INTS4P1 -6.1 2.8e-09 0.00589 -0.54 -0.31 Diabetic kidney disease; chr7:66183744 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs1873494 ENSG00000164669.11 INTS4P1 -6.1 2.8e-09 0.00589 -0.54 -0.31 Diabetic kidney disease; chr7:66184912 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs6959002 ENSG00000164669.11 INTS4P1 -6.1 2.8e-09 0.00589 -0.54 -0.31 Diabetic kidney disease; chr7:66185509 chr7:65141225~65234216:+ LIHC trans rs864643 0.738 rs34922979 ENSG00000183298.5 RP11-556K13.1 -6.1 2.83e-09 0.00594 -0.42 -0.31 Attention deficit hyperactivity disorder; chr3:39550934 chr1:101786340~101787219:- LIHC trans rs916888 0.61 rs199438 ENSG00000214425.5 LRRC37A4P -6.1 2.84e-09 0.00597 -0.34 -0.31 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:45506741~45550335:- LIHC trans rs7554547 0.69 rs6667637 ENSG00000261819.1 RP11-680G24.4 6.1 2.86e-09 0.00602 0.4 0.31 Nonsyndromic cleft lip with cleft palate; chr1:11887900 chr16:14988259~14990160:- LIHC trans rs2243480 1 rs9769882 ENSG00000164669.11 INTS4P1 -6.1 2.88e-09 0.00604 -0.54 -0.31 Diabetic kidney disease; chr7:66177938 chr7:65141225~65234216:+ LIHC trans rs2243480 0.711 rs2420172 ENSG00000164669.11 INTS4P1 -6.1 2.9e-09 0.00609 -0.54 -0.31 Diabetic kidney disease; chr7:66170354 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs6974723 ENSG00000164669.11 INTS4P1 -6.1 2.9e-09 0.00609 -0.54 -0.31 Diabetic kidney disease; chr7:66172952 chr7:65141225~65234216:+ LIHC trans rs13217239 0.646 rs10946888 ENSG00000242375.1 RP11-498P14.3 6.09 2.96e-09 0.00621 0.37 0.31 Schizophrenia; chr6:26983899 chr9:97195351~97197687:- LIHC trans rs714543 0.875 rs35585318 ENSG00000219797.2 PPIAP9 -6.09 2.96e-09 0.00621 -0.38 -0.31 Plateletcrit; chr7:44852220 chr6:31519480~31520291:- LIHC trans rs916888 0.61 rs199453 ENSG00000214425.5 LRRC37A4P -6.09 2.98e-09 0.00624 -0.34 -0.31 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:45506741~45550335:- LIHC trans rs4535700 0.501 rs6943341 ENSG00000204894.4 RP11-208G20.2 6.09 2.99e-09 0.00625 0.36 0.31 Macular telangiectasia type 2; chr7:55907489 chr7:152367171~152367260:+ LIHC trans rs12709013 0.792 rs12598527 ENSG00000230849.2 GOT2P2 6.09 2.99e-09 0.00626 0.36 0.31 Blood metabolite ratios; chr16:58772987 chr1:173141100~173142350:- LIHC trans rs875971 0.545 rs2420612 ENSG00000164669.11 INTS4P1 -6.09 3e-09 0.00628 -0.42 -0.31 Aortic root size; chr7:66536825 chr7:65141225~65234216:+ LIHC trans rs10815468 0.585 rs4742263 ENSG00000215210.3 RBMXP2 6.09 3.1e-09 0.00647 0.38 0.31 Bipolar disorder and schizophrenia; chr9:6782225 chr9:30689105~30690272:+ LIHC trans rs11098499 0.863 rs1480940 ENSG00000275858.1 RP11-291L22.8 6.09 3.12e-09 0.00651 0.37 0.31 Corneal astigmatism; chr4:119536527 chr10:38450738~38451069:- LIHC trans rs2243480 1 rs778729 ENSG00000164669.11 INTS4P1 6.08 3.14e-09 0.00655 0.54 0.31 Diabetic kidney disease; chr7:66359432 chr7:65141225~65234216:+ LIHC trans rs2243480 0.901 rs778687 ENSG00000164669.11 INTS4P1 6.08 3.14e-09 0.00655 0.54 0.31 Diabetic kidney disease; chr7:66370832 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs778679 ENSG00000164669.11 INTS4P1 6.08 3.14e-09 0.00655 0.54 0.31 Diabetic kidney disease; chr7:66375924 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs778704 ENSG00000164669.11 INTS4P1 6.08 3.14e-09 0.00655 0.54 0.31 Diabetic kidney disease; chr7:66398480 chr7:65141225~65234216:+ LIHC trans rs2243480 0.901 rs778693 ENSG00000164669.11 INTS4P1 6.08 3.14e-09 0.00655 0.54 0.31 Diabetic kidney disease; chr7:66407358 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs778691 ENSG00000164669.11 INTS4P1 6.08 3.14e-09 0.00655 0.54 0.31 Diabetic kidney disease; chr7:66408105 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs13235972 ENSG00000164669.11 INTS4P1 6.08 3.14e-09 0.00655 0.54 0.31 Diabetic kidney disease; chr7:66418618 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs34192067 ENSG00000164669.11 INTS4P1 6.08 3.14e-09 0.00655 0.54 0.31 Diabetic kidney disease; chr7:66422670 chr7:65141225~65234216:+ LIHC trans rs538867 1 rs544505 ENSG00000183298.5 RP11-556K13.1 6.08 3.14e-09 0.00655 0.72 0.31 Alzheimer's disease (cognitive decline); chr3:39488689 chr1:101786340~101787219:- LIHC trans rs12138950 0.681 rs10917468 ENSG00000224237.1 MINOS1P3 -6.08 3.18e-09 0.00664 -0.39 -0.31 Hypothyroidism;Thyroid volume; chr1:19516860 chr3:27214816~27215018:- LIHC trans rs3749237 0.964 rs13084243 ENSG00000197582.5 GPX1P1 6.08 3.19e-09 0.00665 0.46 0.31 Resting heart rate; chr3:49784445 chrX:13378735~13379340:- LIHC trans rs3749237 1 rs11920900 ENSG00000197582.5 GPX1P1 6.08 3.19e-09 0.00665 0.46 0.31 Resting heart rate; chr3:49785591 chrX:13378735~13379340:- LIHC trans rs13177918 0.75 rs58256223 ENSG00000226396.1 RP5-1056L3.3 6.08 3.21e-09 0.00669 0.29 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442456 chr1:19608114~19608568:+ LIHC trans rs6743068 0.541 rs6714736 ENSG00000235105.1 RP11-329A14.1 -6.08 3.22e-09 0.00671 -0.31 -0.31 Lymphocyte percentage of white cells; chr2:201349425 chr1:48435967~48437223:+ LIHC trans rs12210905 0.925 rs858985 ENSG00000242375.1 RP11-498P14.3 6.08 3.23e-09 0.00672 0.79 0.31 Hip circumference adjusted for BMI; chr6:27210249 chr9:97195351~97197687:- LIHC trans rs1336472 0.509 rs4916031 ENSG00000233381.3 AK4P3 -6.08 3.25e-09 0.00677 -0.35 -0.31 Venous thromboembolism (SNP x SNP interaction); chr1:65215860 chr12:31615771~31616439:- LIHC trans rs864643 0.704 rs4441592 ENSG00000183298.5 RP11-556K13.1 -6.08 3.27e-09 0.0068 -0.42 -0.31 Attention deficit hyperactivity disorder; chr3:39550772 chr1:101786340~101787219:- LIHC trans rs7444 0.941 rs181366 ENSG00000274602.3 PI4KAP1 -6.08 3.28e-09 0.00682 -0.4 -0.31 Systemic lupus erythematosus; chr22:21579491 chr22:18533646~18577968:- LIHC trans rs6477998 0.58 rs7851623 ENSG00000238072.1 RP11-305M3.2 6.08 3.28e-09 0.00682 0.54 0.31 Hematology traits; chr9:113240285 chr7:129410113~129410370:- LIHC trans rs916888 0.61 rs199452 ENSG00000214425.5 LRRC37A4P -6.08 3.29e-09 0.00685 -0.33 -0.31 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:45506741~45550335:- LIHC trans rs2243480 0.901 rs778732 ENSG00000164669.11 INTS4P1 6.08 3.3e-09 0.00686 0.53 0.31 Diabetic kidney disease; chr7:66357373 chr7:65141225~65234216:+ LIHC trans rs6743068 0.541 rs2349075 ENSG00000235105.1 RP11-329A14.1 6.08 3.3e-09 0.00686 0.32 0.31 Lymphocyte percentage of white cells; chr2:201358843 chr1:48435967~48437223:+ LIHC trans rs2243480 1 rs34703416 ENSG00000273142.1 RP11-458F8.4 -6.07 3.31e-09 0.00688 -0.39 -0.31 Diabetic kidney disease; chr7:65835655 chr7:66902857~66906297:+ LIHC trans rs11098499 0.779 rs28495013 ENSG00000275858.1 RP11-291L22.8 6.07 3.31e-09 0.00688 0.36 0.31 Corneal astigmatism; chr4:119454676 chr10:38450738~38451069:- LIHC trans rs6915893 0.669 rs10456213 ENSG00000267156.1 TPMTP1 6.07 3.31e-09 0.00688 0.35 0.31 Intrinsic epigenetic age acceleration; chr6:18118881 chr18:47630112~47630848:+ LIHC trans rs2243480 1 rs4149468 ENSG00000164669.11 INTS4P1 6.07 3.35e-09 0.00696 0.53 0.31 Diabetic kidney disease; chr7:66360703 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs3885839 ENSG00000273142.1 RP11-458F8.4 -6.07 3.39e-09 0.00703 -0.39 -0.31 Diabetic kidney disease; chr7:65825416 chr7:66902857~66906297:+ LIHC trans rs2243480 0.901 rs3813708 ENSG00000273142.1 RP11-458F8.4 -6.07 3.39e-09 0.00703 -0.39 -0.31 Diabetic kidney disease; chr7:65840645 chr7:66902857~66906297:+ LIHC trans rs2243480 1 rs73142122 ENSG00000273142.1 RP11-458F8.4 -6.07 3.39e-09 0.00703 -0.39 -0.31 Diabetic kidney disease; chr7:65846311 chr7:66902857~66906297:+ LIHC trans rs2243480 0.901 rs73142137 ENSG00000273142.1 RP11-458F8.4 -6.07 3.39e-09 0.00703 -0.39 -0.31 Diabetic kidney disease; chr7:65878455 chr7:66902857~66906297:+ LIHC trans rs2243480 0.901 rs34807232 ENSG00000164669.11 INTS4P1 6.07 3.4e-09 0.00704 0.54 0.31 Diabetic kidney disease; chr7:66500146 chr7:65141225~65234216:+ LIHC trans rs2243480 0.901 rs35823062 ENSG00000164669.11 INTS4P1 6.07 3.4e-09 0.00704 0.54 0.31 Diabetic kidney disease; chr7:66500834 chr7:65141225~65234216:+ LIHC trans rs12200782 1 rs12213722 ENSG00000242375.1 RP11-498P14.3 -6.07 3.4e-09 0.00706 -0.73 -0.31 Small cell lung carcinoma; chr6:26472855 chr9:97195351~97197687:- LIHC trans rs12200782 1 rs72843802 ENSG00000242375.1 RP11-498P14.3 -6.07 3.4e-09 0.00706 -0.73 -0.31 Small cell lung carcinoma; chr6:26517287 chr9:97195351~97197687:- LIHC trans rs12200782 0.674 rs12207224 ENSG00000242375.1 RP11-498P14.3 -6.07 3.4e-09 0.00706 -0.73 -0.31 Small cell lung carcinoma; chr6:26519052 chr9:97195351~97197687:- LIHC trans rs10037055 0.853 rs10077929 ENSG00000228305.2 AC016734.2 6.07 3.41e-09 0.00707 0.33 0.31 Migraine without aura; chr5:177270843 chr2:63622178~63622831:- LIHC trans rs6743068 0.521 rs2349078 ENSG00000235105.1 RP11-329A14.1 6.07 3.42e-09 0.00709 0.31 0.31 Lymphocyte percentage of white cells; chr2:201369342 chr1:48435967~48437223:+ LIHC trans rs11098499 0.954 rs10518328 ENSG00000275858.1 RP11-291L22.8 6.07 3.43e-09 0.0071 0.36 0.31 Corneal astigmatism; chr4:119480624 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs6822679 ENSG00000275858.1 RP11-291L22.8 6.07 3.43e-09 0.0071 0.36 0.31 Corneal astigmatism; chr4:119481547 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs4577559 ENSG00000275858.1 RP11-291L22.8 6.07 3.43e-09 0.0071 0.36 0.31 Corneal astigmatism; chr4:119482888 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs7656252 ENSG00000275858.1 RP11-291L22.8 6.07 3.43e-09 0.0071 0.36 0.31 Corneal astigmatism; chr4:119483113 chr10:38450738~38451069:- LIHC trans rs11098499 0.865 rs28845498 ENSG00000275858.1 RP11-291L22.8 6.07 3.43e-09 0.0071 0.36 0.31 Corneal astigmatism; chr4:119484031 chr10:38450738~38451069:- LIHC trans rs11098499 0.865 rs28753180 ENSG00000275858.1 RP11-291L22.8 6.07 3.43e-09 0.0071 0.36 0.31 Corneal astigmatism; chr4:119484212 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs56270433 ENSG00000275858.1 RP11-291L22.8 6.07 3.43e-09 0.0071 0.36 0.31 Corneal astigmatism; chr4:119484875 chr10:38450738~38451069:- LIHC trans rs3749237 0.964 rs35210174 ENSG00000197582.5 GPX1P1 6.07 3.44e-09 0.00713 0.45 0.31 Resting heart rate; chr3:49775173 chrX:13378735~13379340:- LIHC trans rs2243480 1 rs7804223 ENSG00000164669.11 INTS4P1 -6.07 3.45e-09 0.00715 -0.54 -0.31 Diabetic kidney disease; chr7:66199572 chr7:65141225~65234216:+ LIHC trans rs11098499 0.863 rs10030660 ENSG00000275858.1 RP11-291L22.8 6.07 3.46e-09 0.00716 0.37 0.31 Corneal astigmatism; chr4:119515549 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs13149407 ENSG00000275858.1 RP11-291L22.8 6.07 3.46e-09 0.00716 0.37 0.31 Corneal astigmatism; chr4:119516670 chr10:38450738~38451069:- LIHC trans rs4535700 0.501 rs9642405 ENSG00000204894.4 RP11-208G20.2 6.07 3.46e-09 0.00716 0.36 0.31 Macular telangiectasia type 2; chr7:55910473 chr7:152367171~152367260:+ LIHC trans rs916888 0.61 rs142167 ENSG00000214425.5 LRRC37A4P 6.07 3.46e-09 0.00716 0.33 0.31 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:45506741~45550335:- LIHC trans rs13177918 0.75 rs59354956 ENSG00000226396.1 RP5-1056L3.3 6.07 3.48e-09 0.0072 0.29 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442457 chr1:19608114~19608568:+ LIHC trans rs2243480 1 rs4718317 ENSG00000164669.11 INTS4P1 -6.06 3.53e-09 0.0073 -0.52 -0.31 Diabetic kidney disease; chr7:66183914 chr7:65141225~65234216:+ LIHC trans rs3002142 0.658 rs1053316 ENSG00000219201.4 RP11-181C21.4 6.06 3.54e-09 0.00731 0.37 0.31 LDL peak particle diameter (total fat intake interaction); chr1:222666496 chr1:77810861~77811781:- LIHC trans rs875971 0.545 rs6969224 ENSG00000164669.11 INTS4P1 -6.06 3.54e-09 0.00732 -0.42 -0.31 Aortic root size; chr7:66370011 chr7:65141225~65234216:+ LIHC trans rs12155039 1 rs12155039 ENSG00000226038.5 PPIAP21 -6.06 3.57e-09 0.00737 -0.37 -0.31 Mean platelet volume; chr7:44833526 chr20:43230760~43231260:+ LIHC trans rs13177918 0.557 rs12520101 ENSG00000226396.1 RP5-1056L3.3 6.06 3.58e-09 0.0074 0.28 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr1:19608114~19608568:+ LIHC trans rs875971 0.545 rs73146609 ENSG00000164669.11 INTS4P1 -6.06 3.6e-09 0.00743 -0.42 -0.31 Aortic root size; chr7:66302477 chr7:65141225~65234216:+ LIHC trans rs3096299 0.719 rs2353581 ENSG00000215030.5 RPL13P12 -6.06 3.6e-09 0.00744 -0.31 -0.31 Multiple myeloma (IgH translocation); chr16:89452500 chr17:17383377~17384012:- LIHC trans rs4535700 0.501 rs2135116 ENSG00000204894.4 RP11-208G20.2 6.06 3.64e-09 0.00752 0.36 0.31 Macular telangiectasia type 2; chr7:55923451 chr7:152367171~152367260:+ LIHC trans rs11098499 0.863 rs3822190 ENSG00000275858.1 RP11-291L22.8 6.06 3.69e-09 0.0076 0.37 0.31 Corneal astigmatism; chr4:119506943 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs3822191 ENSG00000275858.1 RP11-291L22.8 6.06 3.69e-09 0.0076 0.37 0.31 Corneal astigmatism; chr4:119506946 chr10:38450738~38451069:- LIHC trans rs714543 0.967 rs11762008 ENSG00000219797.2 PPIAP9 -6.05 3.72e-09 0.00767 -0.38 -0.31 Plateletcrit; chr7:44864065 chr6:31519480~31520291:- LIHC trans rs9876781 0.967 rs1870444 ENSG00000225528.1 RP3-370M22.8 -6.05 3.81e-09 0.00785 -0.35 -0.31 Longevity; chr3:48445369 chr22:39960397~39964683:+ LIHC trans rs4535700 0.501 rs57251705 ENSG00000204894.4 RP11-208G20.2 6.05 3.82e-09 0.00786 0.36 0.31 Macular telangiectasia type 2; chr7:55913390 chr7:152367171~152367260:+ LIHC trans rs3849046 0.901 rs11956240 ENSG00000226666.1 HSPA9P1 6.05 3.82e-09 0.00787 0.36 0.31 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138504604 chr2:221961737~221963765:+ LIHC trans rs7582180 1 rs7582180 ENSG00000131401.10 NAPSB -6.05 3.84e-09 0.0079 -0.35 -0.31 Intelligence (multi-trait analysis); chr2:100296001 chr19:50333796~50344767:- LIHC trans rs877636 0.702 rs773109 ENSG00000234513.1 AC073072.7 6.05 3.85e-09 0.00792 0.41 0.31 Cognitive function; chr12:55980911 chr7:22773646~22773993:- LIHC trans rs12210905 0.925 rs858989 ENSG00000242375.1 RP11-498P14.3 6.05 3.87e-09 0.00796 0.78 0.31 Hip circumference adjusted for BMI; chr6:27211594 chr9:97195351~97197687:- LIHC trans rs3749237 0.964 rs34522271 ENSG00000197582.5 GPX1P1 6.04 3.92e-09 0.00807 0.46 0.31 Resting heart rate; chr3:49771084 chrX:13378735~13379340:- LIHC trans rs875971 0.545 rs6970498 ENSG00000164669.11 INTS4P1 -6.04 3.94e-09 0.00809 -0.42 -0.31 Aortic root size; chr7:66275908 chr7:65141225~65234216:+ LIHC trans rs13177918 0.559 rs10447224 ENSG00000226396.1 RP5-1056L3.3 6.04 3.99e-09 0.0082 0.27 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454802 chr1:19608114~19608568:+ LIHC trans rs13177918 0.559 rs10447225 ENSG00000226396.1 RP5-1056L3.3 6.04 3.99e-09 0.0082 0.27 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454891 chr1:19608114~19608568:+ LIHC trans rs11098499 0.863 rs6858592 ENSG00000275858.1 RP11-291L22.8 6.04 4e-09 0.00821 0.37 0.31 Corneal astigmatism; chr4:119537537 chr10:38450738~38451069:- LIHC trans rs12709013 0.792 rs12926512 ENSG00000230849.2 GOT2P2 6.04 4e-09 0.00822 0.37 0.31 Blood metabolite ratios; chr16:58768317 chr1:173141100~173142350:- LIHC trans rs12210905 0.858 rs858988 ENSG00000242375.1 RP11-498P14.3 6.04 4.03e-09 0.00827 0.78 0.31 Hip circumference adjusted for BMI; chr6:27211416 chr9:97195351~97197687:- LIHC trans rs6424115 0.931 rs2982390 ENSG00000228217.1 AL390877.1 -6.04 4.06e-09 0.00832 -0.36 -0.31 Immature fraction of reticulocytes; chr1:23821340 chr1:117778087~117778506:- LIHC trans rs11098499 0.954 rs7681544 ENSG00000275858.1 RP11-291L22.8 6.04 4.06e-09 0.00834 0.35 0.31 Corneal astigmatism; chr4:119490100 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs11940028 ENSG00000275858.1 RP11-291L22.8 6.04 4.06e-09 0.00834 0.35 0.31 Corneal astigmatism; chr4:119490752 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs11935596 ENSG00000275858.1 RP11-291L22.8 6.04 4.06e-09 0.00834 0.35 0.31 Corneal astigmatism; chr4:119491302 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs12507964 ENSG00000275858.1 RP11-291L22.8 6.04 4.06e-09 0.00834 0.35 0.31 Corneal astigmatism; chr4:119491906 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs11098530 ENSG00000275858.1 RP11-291L22.8 6.04 4.06e-09 0.00834 0.35 0.31 Corneal astigmatism; chr4:119491999 chr10:38450738~38451069:- LIHC trans rs12709013 0.792 rs12596434 ENSG00000230849.2 GOT2P2 6.04 4.07e-09 0.00834 0.37 0.31 Blood metabolite ratios; chr16:58792309 chr1:173141100~173142350:- LIHC trans rs2243480 1 rs4718333 ENSG00000164669.11 INTS4P1 -6.04 4.07e-09 0.00835 -0.53 -0.31 Diabetic kidney disease; chr7:66307771 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs7792391 ENSG00000164669.11 INTS4P1 -6.04 4.07e-09 0.00835 -0.53 -0.31 Diabetic kidney disease; chr7:66308442 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs10247526 ENSG00000164669.11 INTS4P1 -6.04 4.07e-09 0.00835 -0.53 -0.31 Diabetic kidney disease; chr7:66315709 chr7:65141225~65234216:+ LIHC trans rs2243480 0.908 rs1532573 ENSG00000164669.11 INTS4P1 -6.04 4.07e-09 0.00835 -0.53 -0.31 Diabetic kidney disease; chr7:66333815 chr7:65141225~65234216:+ LIHC trans rs6743068 0.541 rs12052257 ENSG00000235105.1 RP11-329A14.1 -6.04 4.09e-09 0.00839 -0.3 -0.31 Lymphocyte percentage of white cells; chr2:201376871 chr1:48435967~48437223:+ LIHC trans rs12709013 0.792 rs12935488 ENSG00000230849.2 GOT2P2 6.04 4.1e-09 0.0084 0.37 0.31 Blood metabolite ratios; chr16:58766320 chr1:173141100~173142350:- LIHC trans rs10511779 0.719 rs73642985 ENSG00000280107.1 AL022393.9 -6.04 4.11e-09 0.00842 -0.71 -0.31 Attention function in attention deficit hyperactive disorder; chr9:26727441 chr6:28170845~28172521:+ LIHC trans rs11098499 0.863 rs6534139 ENSG00000275858.1 RP11-291L22.8 -6.04 4.13e-09 0.00846 -0.37 -0.31 Corneal astigmatism; chr4:119528301 chr10:38450738~38451069:- LIHC trans rs4535700 0.543 rs2174459 ENSG00000204894.4 RP11-208G20.2 6.03 4.14e-09 0.00848 0.36 0.31 Macular telangiectasia type 2; chr7:55923600 chr7:152367171~152367260:+ LIHC trans rs13080594 0.638 rs13091584 ENSG00000251015.1 SLC25A30-AS1 -6.03 4.17e-09 0.00854 -0.35 -0.31 Personality traits in bipolar disorder; chr3:7363357 chr13:45418162~45420371:+ LIHC trans rs13080594 0.638 rs11719710 ENSG00000251015.1 SLC25A30-AS1 -6.03 4.17e-09 0.00854 -0.35 -0.31 Personality traits in bipolar disorder; chr3:7363847 chr13:45418162~45420371:+ LIHC trans rs875971 0.545 rs6979636 ENSG00000164669.11 INTS4P1 -6.03 4.17e-09 0.00854 -0.42 -0.31 Aortic root size; chr7:66276638 chr7:65141225~65234216:+ LIHC trans rs714543 1 rs2898 ENSG00000219797.2 PPIAP9 -6.03 4.17e-09 0.00854 -0.37 -0.31 Plateletcrit; chr7:44827034 chr6:31519480~31520291:- LIHC trans rs714543 1 rs10267576 ENSG00000219797.2 PPIAP9 -6.03 4.17e-09 0.00854 -0.37 -0.31 Plateletcrit; chr7:44831334 chr6:31519480~31520291:- LIHC trans rs714543 0.967 rs12536807 ENSG00000219797.2 PPIAP9 -6.03 4.17e-09 0.00854 -0.37 -0.31 Plateletcrit; chr7:44838675 chr6:31519480~31520291:- LIHC trans rs875971 0.545 rs2279757 ENSG00000164669.11 INTS4P1 -6.03 4.2e-09 0.00859 -0.42 -0.31 Aortic root size; chr7:66363676 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs11766183 ENSG00000164669.11 INTS4P1 -6.03 4.2e-09 0.00859 -0.42 -0.31 Aortic root size; chr7:66374173 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs1065265 ENSG00000164669.11 INTS4P1 -6.03 4.2e-09 0.00859 -0.42 -0.31 Aortic root size; chr7:66376216 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs7811204 ENSG00000164669.11 INTS4P1 -6.03 4.2e-09 0.00859 -0.42 -0.31 Aortic root size; chr7:66387213 chr7:65141225~65234216:+ LIHC trans rs9611519 1 rs2057070 ENSG00000268568.1 AC007228.9 -6.03 4.21e-09 0.00861 -0.48 -0.31 Neuroticism; chr22:41168283 chr19:56672574~56673901:- LIHC trans rs2069408 1 rs2069408 ENSG00000212994.5 RPS26P6 -6.03 4.21e-09 0.00861 -0.4 -0.31 Asthma; chr12:55970537 chr8:100895771~100896118:+ LIHC trans rs13016963 0.546 rs11691602 ENSG00000235105.1 RP11-329A14.1 6.03 4.22e-09 0.00862 0.31 0.31 Esophageal squamous cell carcinoma;Melanoma; chr2:201362976 chr1:48435967~48437223:+ LIHC trans rs11098499 0.954 rs6849171 ENSG00000275858.1 RP11-291L22.8 6.03 4.23e-09 0.00865 0.35 0.31 Corneal astigmatism; chr4:119488394 chr10:38450738~38451069:- LIHC trans rs9611519 0.964 rs4820428 ENSG00000268568.1 AC007228.9 6.03 4.23e-09 0.00865 0.48 0.31 Neuroticism; chr22:41141585 chr19:56672574~56673901:- LIHC trans rs12210905 0.925 rs858984 ENSG00000242375.1 RP11-498P14.3 6.03 4.24e-09 0.00866 0.72 0.31 Hip circumference adjusted for BMI; chr6:27209582 chr9:97195351~97197687:- LIHC trans rs12709013 0.792 rs62064901 ENSG00000230849.2 GOT2P2 6.03 4.26e-09 0.00869 0.37 0.31 Blood metabolite ratios; chr16:58776758 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs12325054 ENSG00000230849.2 GOT2P2 6.03 4.26e-09 0.00871 0.37 0.31 Blood metabolite ratios; chr16:58749804 chr1:173141100~173142350:- LIHC trans rs2243480 1 rs316326 ENSG00000164669.11 INTS4P1 6.03 4.27e-09 0.00872 0.54 0.31 Diabetic kidney disease; chr7:66144466 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs316325 ENSG00000164669.11 INTS4P1 6.03 4.27e-09 0.00872 0.54 0.31 Diabetic kidney disease; chr7:66144531 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs316321 ENSG00000164669.11 INTS4P1 6.03 4.27e-09 0.00872 0.54 0.31 Diabetic kidney disease; chr7:66146626 chr7:65141225~65234216:+ LIHC trans rs13177918 0.677 rs57890152 ENSG00000226396.1 RP5-1056L3.3 6.03 4.29e-09 0.00876 0.29 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr1:19608114~19608568:+ LIHC trans rs1840440 0.934 rs1840441 ENSG00000269967.1 RP11-84A19.4 6.03 4.29e-09 0.00876 0.32 0.31 Weight; chr18:25677062 chr1:31851913~31921841:- LIHC trans rs7444 1 rs7444 ENSG00000274602.3 PI4KAP1 -6.03 4.29e-09 0.00877 -0.39 -0.31 Systemic lupus erythematosus; chr22:21622645 chr22:18533646~18577968:- LIHC trans rs7444 0.825 rs131664 ENSG00000274602.3 PI4KAP1 -6.03 4.3e-09 0.00877 -0.39 -0.31 Systemic lupus erythematosus; chr22:21566114 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs131665 ENSG00000274602.3 PI4KAP1 -6.03 4.3e-09 0.00877 -0.39 -0.31 Systemic lupus erythematosus; chr22:21566614 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs140491 ENSG00000274602.3 PI4KAP1 -6.03 4.3e-09 0.00877 -0.39 -0.31 Systemic lupus erythematosus; chr22:21568075 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs140498 ENSG00000274602.3 PI4KAP1 -6.03 4.3e-09 0.00877 -0.39 -0.31 Systemic lupus erythematosus; chr22:21572775 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs140499 ENSG00000274602.3 PI4KAP1 -6.03 4.3e-09 0.00877 -0.39 -0.31 Systemic lupus erythematosus; chr22:21572942 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs73166622 ENSG00000274602.3 PI4KAP1 -6.03 4.3e-09 0.00877 -0.39 -0.31 Systemic lupus erythematosus; chr22:21584574 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs1034329 ENSG00000274602.3 PI4KAP1 -6.03 4.3e-09 0.00877 -0.39 -0.31 Systemic lupus erythematosus; chr22:21589649 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs2283789 ENSG00000274602.3 PI4KAP1 -6.03 4.3e-09 0.00877 -0.39 -0.31 Systemic lupus erythematosus; chr22:21590189 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs5998619 ENSG00000274602.3 PI4KAP1 -6.03 4.3e-09 0.00877 -0.39 -0.31 Systemic lupus erythematosus; chr22:21591562 chr22:18533646~18577968:- LIHC trans rs11098499 0.863 rs7678400 ENSG00000275858.1 RP11-291L22.8 6.03 4.3e-09 0.00877 0.36 0.31 Corneal astigmatism; chr4:119540802 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs1480936 ENSG00000275858.1 RP11-291L22.8 6.03 4.3e-09 0.00877 0.36 0.31 Corneal astigmatism; chr4:119541706 chr10:38450738~38451069:- LIHC trans rs131656 1 rs131656 ENSG00000274602.3 PI4KAP1 -6.03 4.32e-09 0.00881 -0.39 -0.31 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells; chr22:21563161 chr22:18533646~18577968:- LIHC trans rs13177918 0.677 rs3857421 ENSG00000226396.1 RP5-1056L3.3 -6.03 4.33e-09 0.00882 -0.28 -0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr1:19608114~19608568:+ LIHC trans rs73193808 0.639 rs2832242 ENSG00000204685.6 STARD7-AS1 -6.03 4.34e-09 0.00885 -0.32 -0.31 Coronary artery disease; chr21:29179864 chr2:96208416~96242621:+ LIHC trans rs2243480 1 rs34815098 ENSG00000273142.1 RP11-458F8.4 -6.03 4.35e-09 0.00887 -0.38 -0.31 Diabetic kidney disease; chr7:65827267 chr7:66902857~66906297:+ LIHC trans rs2243480 1 rs4548056 ENSG00000273142.1 RP11-458F8.4 -6.03 4.35e-09 0.00887 -0.38 -0.31 Diabetic kidney disease; chr7:65833886 chr7:66902857~66906297:+ LIHC trans rs2243480 1 rs7456042 ENSG00000273142.1 RP11-458F8.4 -6.03 4.35e-09 0.00887 -0.38 -0.31 Diabetic kidney disease; chr7:65834791 chr7:66902857~66906297:+ LIHC trans rs2243480 1 rs35735127 ENSG00000273142.1 RP11-458F8.4 -6.03 4.35e-09 0.00887 -0.38 -0.31 Diabetic kidney disease; chr7:65835436 chr7:66902857~66906297:+ LIHC trans rs2243480 0.901 rs35256305 ENSG00000273142.1 RP11-458F8.4 -6.03 4.35e-09 0.00887 -0.38 -0.31 Diabetic kidney disease; chr7:65841418 chr7:66902857~66906297:+ LIHC trans rs2243480 1 rs73142121 ENSG00000273142.1 RP11-458F8.4 -6.03 4.35e-09 0.00887 -0.38 -0.31 Diabetic kidney disease; chr7:65846219 chr7:66902857~66906297:+ LIHC trans rs2243480 0.803 rs34004500 ENSG00000273142.1 RP11-458F8.4 -6.03 4.35e-09 0.00887 -0.38 -0.31 Diabetic kidney disease; chr7:65847191 chr7:66902857~66906297:+ LIHC trans rs2243480 1 rs35825738 ENSG00000273142.1 RP11-458F8.4 -6.03 4.35e-09 0.00887 -0.38 -0.31 Diabetic kidney disease; chr7:65853040 chr7:66902857~66906297:+ LIHC trans rs11098499 0.954 rs3890049 ENSG00000275858.1 RP11-291L22.8 6.02 4.39e-09 0.00893 0.36 0.31 Corneal astigmatism; chr4:119405128 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs67265404 ENSG00000275858.1 RP11-291L22.8 6.02 4.39e-09 0.00893 0.36 0.31 Corneal astigmatism; chr4:119438115 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs71629403 ENSG00000275858.1 RP11-291L22.8 6.02 4.39e-09 0.00893 0.36 0.31 Corneal astigmatism; chr4:119451412 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs28571712 ENSG00000275858.1 RP11-291L22.8 6.02 4.39e-09 0.00893 0.36 0.31 Corneal astigmatism; chr4:119454825 chr10:38450738~38451069:- LIHC trans rs11098499 0.865 rs9994730 ENSG00000275858.1 RP11-291L22.8 6.02 4.39e-09 0.00893 0.36 0.31 Corneal astigmatism; chr4:119460409 chr10:38450738~38451069:- LIHC trans rs12709013 0.792 rs12595974 ENSG00000230849.2 GOT2P2 6.02 4.4e-09 0.00894 0.37 0.31 Blood metabolite ratios; chr16:58769132 chr1:173141100~173142350:- LIHC trans rs12709013 0.792 rs1836877 ENSG00000230849.2 GOT2P2 6.02 4.4e-09 0.00894 0.37 0.31 Blood metabolite ratios; chr16:58769821 chr1:173141100~173142350:- LIHC trans rs714543 1 rs1990053 ENSG00000219797.2 PPIAP9 -6.02 4.4e-09 0.00896 -0.38 -0.31 Plateletcrit; chr7:44886297 chr6:31519480~31520291:- LIHC trans rs714543 0.935 rs2331174 ENSG00000219797.2 PPIAP9 -6.02 4.4e-09 0.00896 -0.38 -0.31 Plateletcrit; chr7:44887228 chr6:31519480~31520291:- LIHC trans rs1079467 0.73 rs72846600 ENSG00000233426.3 EIF3FP3 -6.02 4.41e-09 0.00896 -0.47 -0.31 Response to anti-TNF therapy in rheumatoid arthritis; chr11:7952994 chr2:58251440~58252525:+ LIHC trans rs4535700 0.504 rs66528253 ENSG00000204894.4 RP11-208G20.2 6.02 4.41e-09 0.00897 0.36 0.31 Macular telangiectasia type 2; chr7:55929070 chr7:152367171~152367260:+ LIHC trans rs11098499 0.618 rs28491261 ENSG00000275858.1 RP11-291L22.8 6.02 4.41e-09 0.00897 0.37 0.31 Corneal astigmatism; chr4:119373745 chr10:38450738~38451069:- LIHC trans rs11220237 1 rs11220218 ENSG00000236257.1 EI24P2 6.02 4.43e-09 0.009 0.39 0.31 Itch intensity from mosquito bite adjusted by bite size; chr11:125793961 chr1:158454198~158455273:+ LIHC trans rs11220237 0.925 rs9651705 ENSG00000236257.1 EI24P2 6.02 4.43e-09 0.009 0.39 0.31 Itch intensity from mosquito bite adjusted by bite size; chr11:125798921 chr1:158454198~158455273:+ LIHC trans rs11220237 1 rs7938074 ENSG00000236257.1 EI24P2 6.02 4.43e-09 0.009 0.39 0.31 Itch intensity from mosquito bite adjusted by bite size; chr11:125804743 chr1:158454198~158455273:+ LIHC trans rs7930295 0.632 rs11220215 ENSG00000236257.1 EI24P2 6.02 4.45e-09 0.00904 0.4 0.31 Schizophrenia; chr11:125771766 chr1:158454198~158455273:+ LIHC trans rs7930295 0.632 rs12287044 ENSG00000236257.1 EI24P2 6.02 4.45e-09 0.00904 0.4 0.31 Schizophrenia; chr11:125772649 chr1:158454198~158455273:+ LIHC trans rs7930295 0.632 rs2081502 ENSG00000236257.1 EI24P2 6.02 4.45e-09 0.00904 0.4 0.31 Schizophrenia; chr11:125773374 chr1:158454198~158455273:+ LIHC trans rs11098499 0.738 rs28408407 ENSG00000275858.1 RP11-291L22.8 6.02 4.47e-09 0.00907 0.36 0.31 Corneal astigmatism; chr4:119454875 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs1809406 ENSG00000275858.1 RP11-291L22.8 6.02 4.47e-09 0.00907 0.36 0.31 Corneal astigmatism; chr4:119455967 chr10:38450738~38451069:- LIHC trans rs11098499 0.865 rs2389809 ENSG00000275858.1 RP11-291L22.8 6.02 4.47e-09 0.00907 0.36 0.31 Corneal astigmatism; chr4:119456244 chr10:38450738~38451069:- LIHC trans rs11098499 0.697 rs10020027 ENSG00000275858.1 RP11-291L22.8 6.02 4.47e-09 0.00907 0.36 0.31 Corneal astigmatism; chr4:119460724 chr10:38450738~38451069:- LIHC trans rs11098499 0.779 rs7356491 ENSG00000275858.1 RP11-291L22.8 6.02 4.47e-09 0.00907 0.36 0.31 Corneal astigmatism; chr4:119460819 chr10:38450738~38451069:- LIHC trans rs6424115 1 rs4649115 ENSG00000228217.1 AL390877.1 6.02 4.5e-09 0.00913 0.36 0.31 Immature fraction of reticulocytes; chr1:23829241 chr1:117778087~117778506:- LIHC trans rs2726453 0.562 rs2713834 ENSG00000259641.4 PCAT29 -6.02 4.5e-09 0.00914 -0.37 -0.31 Intelligence (multi-trait analysis); chr4:105389363 chr15:69592129~69695750:+ LIHC trans rs877636 0.74 rs772920 ENSG00000234513.1 AC073072.7 6.02 4.53e-09 0.00919 0.41 0.31 Cognitive function; chr12:55996580 chr7:22773646~22773993:- LIHC trans rs875971 0.545 rs73152714 ENSG00000164669.11 INTS4P1 -6.02 4.55e-09 0.00922 -0.41 -0.31 Aortic root size; chr7:66534641 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs4718364 ENSG00000164669.11 INTS4P1 -6.02 4.55e-09 0.00922 -0.41 -0.31 Aortic root size; chr7:66536353 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs6961853 ENSG00000164669.11 INTS4P1 -6.02 4.55e-09 0.00922 -0.41 -0.31 Aortic root size; chr7:66537035 chr7:65141225~65234216:+ LIHC trans rs875971 0.528 rs801213 ENSG00000164669.11 INTS4P1 6.02 4.55e-09 0.00922 0.41 0.31 Aortic root size; chr7:66549931 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs801212 ENSG00000164669.11 INTS4P1 6.02 4.55e-09 0.00922 0.41 0.31 Aortic root size; chr7:66550643 chr7:65141225~65234216:+ LIHC trans rs702485 1 rs702485 ENSG00000249936.3 RAC1P2 6.02 4.56e-09 0.00925 0.33 0.31 HDL cholesterol levels;HDL cholesterol; chr7:6409641 chr4:46723830~46724408:- LIHC trans rs9611519 0.929 rs9611509 ENSG00000268568.1 AC007228.9 -6.02 4.57e-09 0.00926 -0.48 -0.31 Neuroticism; chr22:41169823 chr19:56672574~56673901:- LIHC trans rs875971 0.545 rs2173571 ENSG00000164669.11 INTS4P1 -6.02 4.61e-09 0.00935 -0.42 -0.31 Aortic root size; chr7:66305392 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs11770063 ENSG00000164669.11 INTS4P1 -6.02 4.61e-09 0.00935 -0.42 -0.31 Aortic root size; chr7:66318029 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs3936065 ENSG00000164669.11 INTS4P1 -6.02 4.61e-09 0.00935 -0.42 -0.31 Aortic root size; chr7:66325577 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs4718335 ENSG00000164669.11 INTS4P1 -6.02 4.61e-09 0.00935 -0.42 -0.31 Aortic root size; chr7:66339619 chr7:65141225~65234216:+ LIHC trans rs877636 0.702 rs773111 ENSG00000234513.1 AC073072.7 6.01 4.62e-09 0.00937 0.41 0.31 Cognitive function; chr12:55981956 chr7:22773646~22773993:- LIHC trans rs12709013 0.792 rs62064940 ENSG00000230849.2 GOT2P2 6.01 4.65e-09 0.00941 0.37 0.31 Blood metabolite ratios; chr16:58796560 chr1:173141100~173142350:- LIHC trans rs3096299 0.692 rs4785565 ENSG00000215030.5 RPL13P12 -6.01 4.66e-09 0.00943 -0.31 -0.31 Multiple myeloma (IgH translocation); chr16:89449351 chr17:17383377~17384012:- LIHC trans rs11098499 0.866 rs72676074 ENSG00000275858.1 RP11-291L22.8 6.01 4.66e-09 0.00943 0.36 0.31 Corneal astigmatism; chr4:119438686 chr10:38450738~38451069:- LIHC trans rs9876781 0.624 rs12491849 ENSG00000235912.1 RP1-159A19.3 -6.01 4.66e-09 0.00944 -0.38 -0.31 Longevity; chr3:48489975 chr1:27649419~27649610:+ LIHC trans rs538867 1 rs629170 ENSG00000183298.5 RP11-556K13.1 6.01 4.67e-09 0.00946 0.71 0.31 Alzheimer's disease (cognitive decline); chr3:39472775 chr1:101786340~101787219:- LIHC trans rs538867 1 rs1707954 ENSG00000183298.5 RP11-556K13.1 6.01 4.69e-09 0.0095 0.7 0.31 Alzheimer's disease (cognitive decline); chr3:39483681 chr1:101786340~101787219:- LIHC trans rs9425766 0.64 rs3791020 ENSG00000213331.4 RP11-713C19.2 -6.01 4.71e-09 0.00953 -0.4 -0.31 Life satisfaction; chr1:173844059 chr4:187970273~187971284:+ LIHC trans rs9649213 0.593 rs6970990 ENSG00000225169.1 BRI3P1 6.01 4.74e-09 0.00957 0.4 0.31 Prostate cancer (SNP x SNP interaction); chr7:98296070 chr1:100213293~100213670:+ LIHC trans rs9649213 0.555 rs34695842 ENSG00000225169.1 BRI3P1 6.01 4.74e-09 0.00957 0.4 0.31 Prostate cancer (SNP x SNP interaction); chr7:98301750 chr1:100213293~100213670:+ LIHC trans rs875971 0.545 rs2420456 ENSG00000164669.11 INTS4P1 -6.01 4.77e-09 0.00963 -0.42 -0.31 Aortic root size; chr7:66280619 chr7:65141225~65234216:+ LIHC trans rs4535700 0.501 rs28828764 ENSG00000204894.4 RP11-208G20.2 6.01 4.8e-09 0.00969 0.36 0.31 Macular telangiectasia type 2; chr7:55920986 chr7:152367171~152367260:+ LIHC trans rs9513593 0.579 rs12859788 ENSG00000211482.1 AC092574.1 -6.01 4.82e-09 0.00973 -0.6 -0.31 Psoriasis; chr13:99303183 chr4:409809~409915:+ LIHC trans rs1023500 0.753 rs12158335 ENSG00000268568.1 AC007228.9 -6.01 4.82e-09 0.00973 -0.42 -0.31 Schizophrenia; chr22:41928618 chr19:56672574~56673901:- LIHC trans rs877636 0.702 rs773112 ENSG00000234513.1 AC073072.7 6 4.93e-09 0.00994 0.41 0.31 Cognitive function; chr12:55982097 chr7:22773646~22773993:- LIHC trans rs732577 1 rs56037662 ENSG00000270964.1 RP11-502I4.3 -6 4.93e-09 0.00995 -0.31 -0.31 Sudden cardiac arrest; chr7:12889685 chr15:67541072~67542604:- LIHC trans rs2243480 1 rs316322 ENSG00000164669.11 INTS4P1 6 4.97e-09 0.01 0.54 0.31 Diabetic kidney disease; chr7:66146246 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs10807702 ENSG00000164669.11 INTS4P1 6 4.97e-09 0.01 0.53 0.31 Diabetic kidney disease; chr7:66302856 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs316317 ENSG00000164669.11 INTS4P1 6 4.98e-09 0.01 0.54 0.31 Diabetic kidney disease; chr7:66148650 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs316304 ENSG00000164669.11 INTS4P1 6 4.98e-09 0.01 0.54 0.31 Diabetic kidney disease; chr7:66151907 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs2465120 ENSG00000164669.11 INTS4P1 6 4.98e-09 0.01 0.54 0.31 Diabetic kidney disease; chr7:66155987 chr7:65141225~65234216:+ LIHC trans rs2243480 0.908 rs2460431 ENSG00000164669.11 INTS4P1 -6 4.98e-09 0.01 -0.54 -0.31 Diabetic kidney disease; chr7:66157859 chr7:65141225~65234216:+ LIHC trans rs2243480 0.711 rs2460426 ENSG00000164669.11 INTS4P1 -6 4.98e-09 0.01 -0.54 -0.31 Diabetic kidney disease; chr7:66158142 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs4718309 ENSG00000164669.11 INTS4P1 -6 4.98e-09 0.01 -0.54 -0.31 Diabetic kidney disease; chr7:66162777 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs6460274 ENSG00000164669.11 INTS4P1 -6 4.98e-09 0.01 -0.54 -0.31 Diabetic kidney disease; chr7:66163497 chr7:65141225~65234216:+ LIHC trans rs2243480 1 rs7787230 ENSG00000164669.11 INTS4P1 -6 4.98e-09 0.01 -0.54 -0.31 Diabetic kidney disease; chr7:66164112 chr7:65141225~65234216:+ LIHC trans rs11098499 0.908 rs28499576 ENSG00000275858.1 RP11-291L22.8 6 4.98e-09 0.01 0.36 0.31 Corneal astigmatism; chr4:119465522 chr10:38450738~38451069:- LIHC trans rs11098499 0.908 rs11098527 ENSG00000275858.1 RP11-291L22.8 6 5.01e-09 0.0101 0.35 0.31 Corneal astigmatism; chr4:119478751 chr10:38450738~38451069:- LIHC trans rs9611519 0.929 rs73174660 ENSG00000268568.1 AC007228.9 -6 5.01e-09 0.0101 -0.47 -0.31 Neuroticism; chr22:41041300 chr19:56672574~56673901:- LIHC trans rs9611519 0.929 rs12484971 ENSG00000268568.1 AC007228.9 -6 5.01e-09 0.0101 -0.47 -0.31 Neuroticism; chr22:41043300 chr19:56672574~56673901:- LIHC trans rs9611519 0.929 rs13055800 ENSG00000268568.1 AC007228.9 -6 5.01e-09 0.0101 -0.47 -0.31 Neuroticism; chr22:41044420 chr19:56672574~56673901:- LIHC trans rs9611519 0.929 rs4821991 ENSG00000268568.1 AC007228.9 -6 5.01e-09 0.0101 -0.47 -0.31 Neuroticism; chr22:41044679 chr19:56672574~56673901:- LIHC trans rs4073221 0.52 rs13065273 ENSG00000279926.1 RP3-406P24.5 -6 5.02e-09 0.0101 -0.48 -0.31 Parkinson's disease; chr3:18153360 chr6:3982673~3984130:+ LIHC trans rs877636 0.702 rs773110 ENSG00000234513.1 AC073072.7 6 5.04e-09 0.0102 0.41 0.31 Cognitive function; chr12:55981353 chr7:22773646~22773993:- LIHC trans rs7312770 0.612 rs1873914 ENSG00000225071.1 GS1-184P14.2 6 5.04e-09 0.0102 0.39 0.31 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chrX:24429573~24429920:- LIHC trans rs13177918 0.626 rs3819332 ENSG00000226396.1 RP5-1056L3.3 6 5.13e-09 0.0103 0.27 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr1:19608114~19608568:+ LIHC trans rs13177918 0.626 rs13170300 ENSG00000226396.1 RP5-1056L3.3 6 5.13e-09 0.0103 0.27 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr1:19608114~19608568:+ LIHC trans rs916888 0.61 rs199436 ENSG00000214425.5 LRRC37A4P 6 5.15e-09 0.0103 0.33 0.31 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:45506741~45550335:- LIHC trans rs3849046 0.817 rs2304057 ENSG00000226666.1 HSPA9P1 5.99 5.2e-09 0.0104 0.37 0.31 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138561485 chr2:221961737~221963765:+ LIHC trans rs538867 1 rs946410 ENSG00000183298.5 RP11-556K13.1 5.99 5.22e-09 0.0105 0.7 0.31 Alzheimer's disease (cognitive decline); chr3:39469884 chr1:101786340~101787219:- LIHC trans rs1079467 0.735 rs75941265 ENSG00000233426.3 EIF3FP3 -5.99 5.22e-09 0.0105 -0.47 -0.31 Response to anti-TNF therapy in rheumatoid arthritis; chr11:7949542 chr2:58251440~58252525:+ LIHC trans rs875971 0.545 rs13311962 ENSG00000164669.11 INTS4P1 5.99 5.23e-09 0.0105 0.41 0.31 Aortic root size; chr7:66603142 chr7:65141225~65234216:+ LIHC trans rs6424115 1 rs2179395 ENSG00000228217.1 AL390877.1 -5.99 5.24e-09 0.0105 -0.36 -0.31 Immature fraction of reticulocytes; chr1:23821875 chr1:117778087~117778506:- LIHC trans rs6424115 1 rs6424115 ENSG00000228217.1 AL390877.1 5.99 5.24e-09 0.0105 0.36 0.31 Immature fraction of reticulocytes; chr1:23826741 chr1:117778087~117778506:- LIHC trans rs7312770 0.612 rs773114 ENSG00000243403.1 RP11-330L19.1 5.99 5.26e-09 0.0106 0.37 0.31 Polycystic ovary syndrome;Hypothyroidism; chr12:55985276 chr15:64592979~64593326:+ LIHC trans rs3749237 1 rs3749237 ENSG00000197582.5 GPX1P1 5.99 5.27e-09 0.0106 0.44 0.31 Resting heart rate; chr3:49732599 chrX:13378735~13379340:- LIHC trans rs11098499 0.779 rs80242894 ENSG00000275858.1 RP11-291L22.8 5.99 5.3e-09 0.0106 0.36 0.31 Corneal astigmatism; chr4:119454597 chr10:38450738~38451069:- LIHC trans rs7662987 1 rs28730640 ENSG00000233859.2 ADH5P4 5.99 5.32e-09 0.0107 0.71 0.31 Smoking initiation; chr4:99072902 chr6:65836930~65838039:- LIHC trans rs7662987 1 rs7658118 ENSG00000233859.2 ADH5P4 5.99 5.32e-09 0.0107 0.71 0.31 Smoking initiation; chr4:99073457 chr6:65836930~65838039:- LIHC trans rs9611519 0.929 rs73174657 ENSG00000268568.1 AC007228.9 -5.99 5.33e-09 0.0107 -0.46 -0.31 Neuroticism; chr22:41038154 chr19:56672574~56673901:- LIHC trans rs9611519 0.929 rs9611474 ENSG00000268568.1 AC007228.9 -5.99 5.33e-09 0.0107 -0.46 -0.31 Neuroticism; chr22:41038854 chr19:56672574~56673901:- LIHC trans rs12210905 0.92 rs9379975 ENSG00000242375.1 RP11-498P14.3 -5.99 5.41e-09 0.0108 -0.77 -0.31 Hip circumference adjusted for BMI; chr6:27328029 chr9:97195351~97197687:- LIHC trans rs75870422 0.609 rs77392999 ENSG00000271654.1 RP11-685B14.3 5.99 5.42e-09 0.0109 0.73 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100485354 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs9582393 ENSG00000271654.1 RP11-685B14.3 5.99 5.43e-09 0.0109 0.75 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100462129 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs9582394 ENSG00000271654.1 RP11-685B14.3 5.99 5.43e-09 0.0109 0.75 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100462263 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs28565916 ENSG00000271654.1 RP11-685B14.3 5.99 5.43e-09 0.0109 0.75 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100463792 chr8:18387108~18387777:- LIHC trans rs875971 0.545 rs7783889 ENSG00000164669.11 INTS4P1 -5.99 5.45e-09 0.0109 -0.41 -0.31 Aortic root size; chr7:66283366 chr7:65141225~65234216:+ LIHC trans rs538867 1 rs79077098 ENSG00000183298.5 RP11-556K13.1 5.99 5.46e-09 0.0109 0.71 0.31 Alzheimer's disease (cognitive decline); chr3:39476816 chr1:101786340~101787219:- LIHC trans rs538867 1 rs1768204 ENSG00000183298.5 RP11-556K13.1 5.99 5.46e-09 0.0109 0.71 0.31 Alzheimer's disease (cognitive decline); chr3:39478075 chr1:101786340~101787219:- LIHC trans rs3849046 1 rs13164092 ENSG00000226666.1 HSPA9P1 -5.99 5.46e-09 0.0109 -0.36 -0.31 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138505171 chr2:221961737~221963765:+ LIHC trans rs3849046 0.967 rs55985421 ENSG00000226666.1 HSPA9P1 -5.99 5.46e-09 0.0109 -0.36 -0.31 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138505574 chr2:221961737~221963765:+ LIHC trans rs35306767 0.855 rs11253459 ENSG00000279296.1 RP11-609D21.3 5.98 5.47e-09 0.0109 0.47 0.31 Eosinophil percentage of granulocytes; chr10:840462 chr17:6772831~6776116:- LIHC trans rs35306767 0.903 rs1341741 ENSG00000279296.1 RP11-609D21.3 5.98 5.47e-09 0.0109 0.47 0.31 Eosinophil percentage of granulocytes; chr10:842133 chr17:6772831~6776116:- LIHC trans rs35306767 0.903 rs11253462 ENSG00000279296.1 RP11-609D21.3 5.98 5.47e-09 0.0109 0.47 0.31 Eosinophil percentage of granulocytes; chr10:843383 chr17:6772831~6776116:- LIHC trans rs11098499 0.865 rs4001305 ENSG00000275858.1 RP11-291L22.8 5.98 5.5e-09 0.011 0.35 0.31 Corneal astigmatism; chr4:119438081 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs4309825 ENSG00000275858.1 RP11-291L22.8 -5.98 5.51e-09 0.011 -0.36 -0.31 Corneal astigmatism; chr4:119393726 chr10:38450738~38451069:- LIHC trans rs73108077 0.736 rs56047717 ENSG00000279352.1 RP11-411B10.7 5.98 5.56e-09 0.0111 0.74 0.31 Red blood cell density in sickle cell anemia; chr20:31279756 chr18:14010054~14010917:+ LIHC trans rs9649213 0.593 rs6947208 ENSG00000225169.1 BRI3P1 5.98 5.56e-09 0.0111 0.4 0.31 Prostate cancer (SNP x SNP interaction); chr7:98282892 chr1:100213293~100213670:+ LIHC trans rs9649213 0.574 rs7790229 ENSG00000225169.1 BRI3P1 5.98 5.57e-09 0.0111 0.39 0.31 Prostate cancer (SNP x SNP interaction); chr7:98290026 chr1:100213293~100213670:+ LIHC trans rs916888 0.531 rs183211 ENSG00000214425.5 LRRC37A4P -5.98 5.58e-09 0.0112 -0.33 -0.31 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:45506741~45550335:- LIHC trans rs9876781 0.874 rs56298324 ENSG00000235912.1 RP1-159A19.3 5.98 5.63e-09 0.0112 0.35 0.31 Longevity; chr3:48393626 chr1:27649419~27649610:+ LIHC trans rs9649213 0.593 rs13246725 ENSG00000225169.1 BRI3P1 5.98 5.64e-09 0.0113 0.39 0.31 Prostate cancer (SNP x SNP interaction); chr7:98285586 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs11766808 ENSG00000225169.1 BRI3P1 5.98 5.64e-09 0.0113 0.39 0.31 Prostate cancer (SNP x SNP interaction); chr7:98286064 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs11760930 ENSG00000225169.1 BRI3P1 5.98 5.64e-09 0.0113 0.39 0.31 Prostate cancer (SNP x SNP interaction); chr7:98286477 chr1:100213293~100213670:+ LIHC trans rs9649213 0.555 rs6968193 ENSG00000225169.1 BRI3P1 5.98 5.64e-09 0.0113 0.39 0.31 Prostate cancer (SNP x SNP interaction); chr7:98286590 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs35941058 ENSG00000225169.1 BRI3P1 5.98 5.64e-09 0.0113 0.39 0.31 Prostate cancer (SNP x SNP interaction); chr7:98288847 chr1:100213293~100213670:+ LIHC trans rs7662987 1 rs11547772 ENSG00000233859.2 ADH5P4 5.98 5.68e-09 0.0113 0.69 0.31 Smoking initiation; chr4:99071642 chr6:65836930~65838039:- LIHC trans rs11098499 0.909 rs9759478 ENSG00000275858.1 RP11-291L22.8 5.98 5.71e-09 0.0114 0.36 0.31 Corneal astigmatism; chr4:119446843 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs11098525 ENSG00000275858.1 RP11-291L22.8 5.98 5.71e-09 0.0114 0.35 0.31 Corneal astigmatism; chr4:119468997 chr10:38450738~38451069:- LIHC trans rs12155039 1 rs12155039 ENSG00000219797.2 PPIAP9 -5.98 5.73e-09 0.0114 -0.37 -0.31 Mean platelet volume; chr7:44833526 chr6:31519480~31520291:- LIHC trans rs73108077 0.736 rs6060993 ENSG00000279352.1 RP11-411B10.7 5.98 5.75e-09 0.0115 0.75 0.31 Red blood cell density in sickle cell anemia; chr20:31278917 chr18:14010054~14010917:+ LIHC trans rs4535700 0.501 rs11765577 ENSG00000204894.4 RP11-208G20.2 5.98 5.76e-09 0.0115 0.36 0.31 Macular telangiectasia type 2; chr7:55930245 chr7:152367171~152367260:+ LIHC trans rs75870422 0.609 rs9585450 ENSG00000271654.1 RP11-685B14.3 5.98 5.77e-09 0.0115 0.74 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100489925 chr8:18387108~18387777:- LIHC trans rs11098499 0.909 rs10026736 ENSG00000275858.1 RP11-291L22.8 5.98 5.77e-09 0.0115 0.36 0.31 Corneal astigmatism; chr4:119463167 chr10:38450738~38451069:- LIHC trans rs11098499 0.82 rs13128602 ENSG00000275858.1 RP11-291L22.8 -5.97 5.84e-09 0.0116 -0.36 -0.31 Corneal astigmatism; chr4:119538211 chr10:38450738~38451069:- LIHC trans rs7568458 0.846 rs6705839 ENSG00000223886.3 RP11-251G23.2 5.97 5.85e-09 0.0116 0.36 0.31 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85534156 chr7:105530209~105530671:+ LIHC trans rs9611519 0.828 rs28814423 ENSG00000268568.1 AC007228.9 -5.97 5.96e-09 0.0119 -0.47 -0.31 Neuroticism; chr22:41056297 chr19:56672574~56673901:- LIHC trans rs7444 0.941 rs181359 ENSG00000274602.3 PI4KAP1 -5.97 5.96e-09 0.0119 -0.39 -0.31 Systemic lupus erythematosus; chr22:21574352 chr22:18533646~18577968:- LIHC trans rs877636 0.692 rs11171739 ENSG00000227887.1 RPS26P13 5.97 5.96e-09 0.0119 0.35 0.31 Cognitive function; chr12:56076841 chr1:208697369~208697698:- LIHC trans rs2243480 1 rs316318 ENSG00000164669.11 INTS4P1 5.97 5.97e-09 0.0119 0.53 0.31 Diabetic kidney disease; chr7:66147917 chr7:65141225~65234216:+ LIHC trans rs11098499 0.954 rs12502423 ENSG00000275858.1 RP11-291L22.8 5.97 6e-09 0.0119 0.35 0.31 Corneal astigmatism; chr4:119503017 chr10:38450738~38451069:- LIHC trans rs12210905 1 rs72843633 ENSG00000242375.1 RP11-498P14.3 -5.97 6.03e-09 0.012 -0.76 -0.31 Hip circumference adjusted for BMI; chr6:27215170 chr9:97195351~97197687:- LIHC trans rs7444 0.941 rs181363 ENSG00000274602.3 PI4KAP1 -5.97 6.04e-09 0.012 -0.39 -0.31 Systemic lupus erythematosus; chr22:21577975 chr22:18533646~18577968:- LIHC trans rs6424115 1 rs34477640 ENSG00000228217.1 AL390877.1 5.97 6.04e-09 0.012 0.36 0.31 Immature fraction of reticulocytes; chr1:23827577 chr1:117778087~117778506:- LIHC trans rs6424115 1 rs7519554 ENSG00000228217.1 AL390877.1 5.97 6.04e-09 0.012 0.36 0.31 Immature fraction of reticulocytes; chr1:23828076 chr1:117778087~117778506:- LIHC trans rs1079467 0.73 rs74933956 ENSG00000233426.3 EIF3FP3 -5.97 6.05e-09 0.012 -0.46 -0.31 Response to anti-TNF therapy in rheumatoid arthritis; chr11:7950507 chr2:58251440~58252525:+ LIHC trans rs1079467 0.73 rs77880011 ENSG00000233426.3 EIF3FP3 -5.97 6.05e-09 0.012 -0.46 -0.31 Response to anti-TNF therapy in rheumatoid arthritis; chr11:7950656 chr2:58251440~58252525:+ LIHC trans rs7200543 1 rs2740 ENSG00000250569.1 NTAN1P2 5.97 6.05e-09 0.012 0.38 0.31 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15038251 chr8:86481754~86483002:- LIHC trans rs7312770 0.612 rs1873914 ENSG00000243403.1 RP11-330L19.1 5.97 6.09e-09 0.0121 0.38 0.31 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr15:64592979~64593326:+ LIHC trans rs2657294 0.632 rs2657289 ENSG00000172974.11 AC007318.5 5.96 6.13e-09 0.0122 0.29 0.31 Pneumonia; chr10:75206705 chr2:65205108~65205988:+ LIHC trans rs11662763 0.938 rs76857496 ENSG00000266563.1 EIF1P5 -5.96 6.13e-09 0.0122 -0.7 -0.31 Immunoglobulin A; chr18:5871801 chr17:21259968~21260501:- LIHC trans rs12600277 1 rs12600277 ENSG00000230849.2 GOT2P2 -5.96 6.14e-09 0.0122 -0.46 -0.31 Aortic root size; chr16:58725428 chr1:173141100~173142350:- LIHC trans rs7444 0.941 rs140489 ENSG00000274602.3 PI4KAP1 -5.96 6.18e-09 0.0123 -0.38 -0.31 Systemic lupus erythematosus; chr22:21567005 chr22:18533646~18577968:- LIHC trans rs7444 0.882 rs140492 ENSG00000274602.3 PI4KAP1 -5.96 6.18e-09 0.0123 -0.38 -0.31 Systemic lupus erythematosus; chr22:21568855 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs181362 ENSG00000274602.3 PI4KAP1 -5.96 6.18e-09 0.0123 -0.38 -0.31 Systemic lupus erythematosus; chr22:21577779 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs5749485 ENSG00000274602.3 PI4KAP1 -5.96 6.18e-09 0.0123 -0.38 -0.31 Systemic lupus erythematosus; chr22:21583935 chr22:18533646~18577968:- LIHC trans rs7444 0.882 rs5754217 ENSG00000274602.3 PI4KAP1 -5.96 6.18e-09 0.0123 -0.38 -0.31 Systemic lupus erythematosus; chr22:21585386 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs5749493 ENSG00000274602.3 PI4KAP1 -5.96 6.18e-09 0.0123 -0.38 -0.31 Systemic lupus erythematosus; chr22:21585398 chr22:18533646~18577968:- LIHC trans rs3096299 0.642 rs12934829 ENSG00000215030.5 RPL13P12 -5.96 6.18e-09 0.0123 -0.31 -0.31 Multiple myeloma (IgH translocation); chr16:89456941 chr17:17383377~17384012:- LIHC trans rs11098499 0.865 rs28634456 ENSG00000275858.1 RP11-291L22.8 5.96 6.19e-09 0.0123 0.36 0.31 Corneal astigmatism; chr4:119454623 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs78332141 ENSG00000275858.1 RP11-291L22.8 5.96 6.19e-09 0.0123 0.36 0.31 Corneal astigmatism; chr4:119454627 chr10:38450738~38451069:- LIHC trans rs4535700 0.501 rs57153841 ENSG00000204894.4 RP11-208G20.2 5.96 6.2e-09 0.0123 0.37 0.31 Macular telangiectasia type 2; chr7:55927400 chr7:152367171~152367260:+ LIHC trans rs2243480 1 rs13247184 ENSG00000273142.1 RP11-458F8.4 -5.96 6.23e-09 0.0123 -0.39 -0.31 Diabetic kidney disease; chr7:65893941 chr7:66902857~66906297:+ LIHC trans rs2243480 1 rs35283677 ENSG00000273142.1 RP11-458F8.4 -5.96 6.23e-09 0.0123 -0.39 -0.31 Diabetic kidney disease; chr7:65894246 chr7:66902857~66906297:+ LIHC trans rs2243480 1 rs35421653 ENSG00000273142.1 RP11-458F8.4 -5.96 6.23e-09 0.0123 -0.39 -0.31 Diabetic kidney disease; chr7:65898442 chr7:66902857~66906297:+ LIHC trans rs2657294 0.606 rs10824290 ENSG00000172974.11 AC007318.5 5.96 6.23e-09 0.0123 0.29 0.31 Pneumonia; chr10:75204210 chr2:65205108~65205988:+ LIHC trans rs11098499 0.909 rs9994810 ENSG00000275858.1 RP11-291L22.8 5.96 6.25e-09 0.0124 0.35 0.31 Corneal astigmatism; chr4:119460435 chr10:38450738~38451069:- LIHC trans rs6424115 0.965 rs2502979 ENSG00000228217.1 AL390877.1 -5.96 6.27e-09 0.0124 -0.36 -0.31 Immature fraction of reticulocytes; chr1:23822825 chr1:117778087~117778506:- LIHC trans rs494562 0.73 rs9450270 ENSG00000136149.6 RPL13AP25 -5.96 6.34e-09 0.0125 -0.38 -0.31 Metabolic traits;Blood metabolite levels; chr6:85405048 chr13:54440704~54441315:- LIHC trans rs877636 0.74 rs705702 ENSG00000243403.1 RP11-330L19.1 -5.96 6.34e-09 0.0126 -0.39 -0.31 Cognitive function; chr12:55996852 chr15:64592979~64593326:+ LIHC trans rs3749237 0.964 rs2352967 ENSG00000197582.5 GPX1P1 5.96 6.37e-09 0.0126 0.44 0.31 Resting heart rate; chr3:49834208 chrX:13378735~13379340:- LIHC trans rs12709013 0.792 rs11644344 ENSG00000230849.2 GOT2P2 5.96 6.42e-09 0.0127 0.36 0.31 Blood metabolite ratios; chr16:58803080 chr1:173141100~173142350:- LIHC trans rs2243480 0.522 rs1638736 ENSG00000164669.11 INTS4P1 5.96 6.42e-09 0.0127 0.57 0.31 Diabetic kidney disease; chr7:66627321 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs11767262 ENSG00000164669.11 INTS4P1 -5.96 6.42e-09 0.0127 -0.41 -0.31 Aortic root size; chr7:66302237 chr7:65141225~65234216:+ LIHC trans rs11220237 1 rs11220238 ENSG00000236257.1 EI24P2 5.96 6.43e-09 0.0127 0.38 0.31 Itch intensity from mosquito bite adjusted by bite size; chr11:125839807 chr1:158454198~158455273:+ LIHC trans rs11220237 1 rs11220239 ENSG00000236257.1 EI24P2 5.96 6.43e-09 0.0127 0.38 0.31 Itch intensity from mosquito bite adjusted by bite size; chr11:125840630 chr1:158454198~158455273:+ LIHC trans rs875971 0.545 rs75840613 ENSG00000164669.11 INTS4P1 -5.96 6.44e-09 0.0127 -0.41 -0.31 Aortic root size; chr7:66376399 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs73148639 ENSG00000164669.11 INTS4P1 -5.96 6.44e-09 0.0127 -0.41 -0.31 Aortic root size; chr7:66390342 chr7:65141225~65234216:+ LIHC trans rs3849046 1 rs3849046 ENSG00000226666.1 HSPA9P1 5.96 6.44e-09 0.0127 0.36 0.31 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138515503 chr2:221961737~221963765:+ LIHC trans rs73108077 0.736 rs6060596 ENSG00000279352.1 RP11-411B10.7 5.96 6.44e-09 0.0127 0.75 0.31 Red blood cell density in sickle cell anemia; chr20:31261457 chr18:14010054~14010917:+ LIHC trans rs73108077 0.736 rs6060617 ENSG00000279352.1 RP11-411B10.7 5.96 6.44e-09 0.0127 0.75 0.31 Red blood cell density in sickle cell anemia; chr20:31261849 chr18:14010054~14010917:+ LIHC trans rs73108077 0.736 rs77855283 ENSG00000279352.1 RP11-411B10.7 5.96 6.44e-09 0.0127 0.75 0.31 Red blood cell density in sickle cell anemia; chr20:31262576 chr18:14010054~14010917:+ LIHC trans rs11098499 0.821 rs10032151 ENSG00000275858.1 RP11-291L22.8 5.95 6.48e-09 0.0128 0.35 0.31 Corneal astigmatism; chr4:119470473 chr10:38450738~38451069:- LIHC trans rs11098499 0.865 rs10032158 ENSG00000275858.1 RP11-291L22.8 5.95 6.48e-09 0.0128 0.35 0.31 Corneal astigmatism; chr4:119470477 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs6838814 ENSG00000275858.1 RP11-291L22.8 5.95 6.48e-09 0.0128 0.35 0.31 Corneal astigmatism; chr4:119471288 chr10:38450738~38451069:- LIHC trans rs3749237 0.964 rs2234385 ENSG00000197582.5 GPX1P1 5.95 6.5e-09 0.0128 0.44 0.31 Resting heart rate; chr3:49808608 chrX:13378735~13379340:- LIHC trans rs3749237 0.964 rs1799843 ENSG00000197582.5 GPX1P1 5.95 6.5e-09 0.0128 0.44 0.31 Resting heart rate; chr3:49812290 chrX:13378735~13379340:- LIHC trans rs3749237 1 rs11717256 ENSG00000197582.5 GPX1P1 5.95 6.5e-09 0.0128 0.44 0.31 Resting heart rate; chr3:49831087 chrX:13378735~13379340:- LIHC trans rs7444 0.883 rs7445 ENSG00000274602.3 PI4KAP1 -5.95 6.5e-09 0.0128 -0.39 -0.31 Systemic lupus erythematosus; chr22:21622758 chr22:18533646~18577968:- LIHC trans rs10220309 0.513 rs2371149 ENSG00000243974.1 VTI1BP1 5.95 6.56e-09 0.0129 0.46 0.31 Lung function (FEV1); chr14:80121279 chr3:100225374~100226073:+ LIHC trans rs877636 1 rs2292239 ENSG00000243403.1 RP11-330L19.1 5.95 6.57e-09 0.013 0.37 0.31 Cognitive function; chr12:56088396 chr15:64592979~64593326:+ LIHC trans rs830383 0.584 rs31769 ENSG00000205312.7 KRT17P4 -5.95 6.61e-09 0.0131 -0.47 -0.31 Intelligence (multi-trait analysis); chr5:166069482 chr17:16847635~16852777:- LIHC trans rs6945071 0.59 rs6945001 ENSG00000276259.1 RP11-481J2.4 5.95 6.63e-09 0.0131 0.41 0.31 Superior frontal gyrus grey matter volume; chr7:26088762 chr16:58522970~58523842:+ LIHC trans rs9649213 0.593 rs6975156 ENSG00000225169.1 BRI3P1 5.95 6.63e-09 0.0131 0.39 0.31 Prostate cancer (SNP x SNP interaction); chr7:98296222 chr1:100213293~100213670:+ LIHC trans rs714543 1 rs8840 ENSG00000219797.2 PPIAP9 5.95 6.67e-09 0.0132 0.37 0.31 Plateletcrit; chr7:44877441 chr6:31519480~31520291:- LIHC trans rs9649213 0.531 rs35216698 ENSG00000225169.1 BRI3P1 5.95 6.68e-09 0.0132 0.41 0.31 Prostate cancer (SNP x SNP interaction); chr7:98266863 chr1:100213293~100213670:+ LIHC trans rs9611519 0.828 rs4822008 ENSG00000268568.1 AC007228.9 -5.95 6.69e-09 0.0132 -0.47 -0.31 Neuroticism; chr22:41143202 chr19:56672574~56673901:- LIHC trans rs9611519 1 rs9611505 ENSG00000268568.1 AC007228.9 -5.95 6.69e-09 0.0132 -0.47 -0.31 Neuroticism; chr22:41144275 chr19:56672574~56673901:- LIHC trans rs2243480 0.522 rs778717 ENSG00000164669.11 INTS4P1 5.95 6.8e-09 0.0134 0.58 0.31 Diabetic kidney disease; chr7:66383164 chr7:65141225~65234216:+ LIHC trans rs12210905 1 rs12153912 ENSG00000242375.1 RP11-498P14.3 5.94 6.84e-09 0.0135 0.73 0.31 Hip circumference adjusted for BMI; chr6:27212050 chr9:97195351~97197687:- LIHC trans rs1023500 1 rs1023500 ENSG00000268568.1 AC007228.9 5.94 6.84e-09 0.0135 0.41 0.31 Schizophrenia; chr22:41944840 chr19:56672574~56673901:- LIHC trans rs11220237 0.92 rs1365081 ENSG00000236257.1 EI24P2 -5.94 6.85e-09 0.0135 -0.38 -0.31 Itch intensity from mosquito bite adjusted by bite size; chr11:125778087 chr1:158454198~158455273:+ LIHC trans rs864643 0.678 rs1768158 ENSG00000183298.5 RP11-556K13.1 -5.94 6.88e-09 0.0135 -0.48 -0.31 Attention deficit hyperactivity disorder; chr3:39465870 chr1:101786340~101787219:- LIHC trans rs9425766 0.64 rs1322774 ENSG00000213331.4 RP11-713C19.2 5.94 6.91e-09 0.0136 0.4 0.31 Life satisfaction; chr1:173870102 chr4:187970273~187971284:+ LIHC trans rs3849046 0.817 rs4835690 ENSG00000226666.1 HSPA9P1 5.94 6.95e-09 0.0137 0.37 0.31 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138594081 chr2:221961737~221963765:+ LIHC trans rs74781061 0.929 rs12441932 ENSG00000227288.3 RP5-837I24.1 5.94 6.96e-09 0.0137 0.36 0.31 Endometriosis; chr15:74617658 chr1:81501794~81503468:+ LIHC trans rs12709013 0.792 rs7185513 ENSG00000230849.2 GOT2P2 5.94 6.97e-09 0.0137 0.37 0.31 Blood metabolite ratios; chr16:58794889 chr1:173141100~173142350:- LIHC trans rs2657294 0.632 rs1259503 ENSG00000172974.11 AC007318.5 5.94 6.98e-09 0.0137 0.28 0.31 Pneumonia; chr10:75232686 chr2:65205108~65205988:+ LIHC trans rs9649213 0.593 rs6465665 ENSG00000225169.1 BRI3P1 5.94 7e-09 0.0138 0.39 0.31 Prostate cancer (SNP x SNP interaction); chr7:98304838 chr1:100213293~100213670:+ LIHC trans rs864643 0.678 rs617068 ENSG00000183298.5 RP11-556K13.1 -5.94 7.02e-09 0.0138 -0.47 -0.31 Attention deficit hyperactivity disorder; chr3:39492781 chr1:101786340~101787219:- LIHC trans rs11098499 0.954 rs3733524 ENSG00000275858.1 RP11-291L22.8 5.94 7.03e-09 0.0138 0.35 0.31 Corneal astigmatism; chr4:119502574 chr10:38450738~38451069:- LIHC trans rs9649213 0.593 rs7778015 ENSG00000225169.1 BRI3P1 5.94 7.08e-09 0.0139 0.39 0.31 Prostate cancer (SNP x SNP interaction); chr7:98290958 chr1:100213293~100213670:+ LIHC trans rs11220082 0.542 rs11220079 ENSG00000236257.1 EI24P2 -5.94 7.09e-09 0.0139 -0.38 -0.31 Schizophrenia; chr11:125450033 chr1:158454198~158455273:+ LIHC trans rs1840440 0.966 rs965178 ENSG00000269967.1 RP11-84A19.4 5.94 7.1e-09 0.0139 0.32 0.31 Weight; chr18:25681256 chr1:31851913~31921841:- LIHC trans rs875971 0.545 rs66594357 ENSG00000164669.11 INTS4P1 -5.94 7.17e-09 0.0141 -0.41 -0.31 Aortic root size; chr7:66327797 chr7:65141225~65234216:+ LIHC trans rs7444 0.941 rs73166632 ENSG00000274602.3 PI4KAP1 -5.94 7.2e-09 0.0141 -0.39 -0.31 Systemic lupus erythematosus; chr22:21591884 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs4821108 ENSG00000274602.3 PI4KAP1 -5.94 7.2e-09 0.0141 -0.39 -0.31 Systemic lupus erythematosus; chr22:21604749 chr22:18533646~18577968:- LIHC trans rs9649213 0.593 rs1132971 ENSG00000225169.1 BRI3P1 5.93 7.26e-09 0.0142 0.39 0.31 Prostate cancer (SNP x SNP interaction); chr7:98292221 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs6465664 ENSG00000225169.1 BRI3P1 5.93 7.26e-09 0.0142 0.39 0.31 Prostate cancer (SNP x SNP interaction); chr7:98292522 chr1:100213293~100213670:+ LIHC trans rs13177918 0.626 rs13175436 ENSG00000226396.1 RP5-1056L3.3 5.93 7.28e-09 0.0142 0.27 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150450974 chr1:19608114~19608568:+ LIHC trans rs13177918 0.603 rs13175992 ENSG00000226396.1 RP5-1056L3.3 5.93 7.28e-09 0.0142 0.27 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150451026 chr1:19608114~19608568:+ LIHC trans rs13177918 0.626 rs67026795 ENSG00000226396.1 RP5-1056L3.3 5.93 7.28e-09 0.0142 0.27 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452097 chr1:19608114~19608568:+ LIHC trans rs13177918 0.578 rs35919198 ENSG00000226396.1 RP5-1056L3.3 5.93 7.28e-09 0.0142 0.27 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452428 chr1:19608114~19608568:+ LIHC trans rs13177918 0.603 rs10447222 ENSG00000226396.1 RP5-1056L3.3 5.93 7.28e-09 0.0142 0.27 0.31 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150453104 chr1:19608114~19608568:+ LIHC trans rs11220082 0.644 rs12577961 ENSG00000236257.1 EI24P2 -5.93 7.38e-09 0.0144 -0.38 -0.31 Schizophrenia; chr11:125438943 chr1:158454198~158455273:+ LIHC trans rs75870422 0.609 rs6491561 ENSG00000271654.1 RP11-685B14.3 5.93 7.4e-09 0.0145 0.75 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100457544 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs6491562 ENSG00000271654.1 RP11-685B14.3 5.93 7.4e-09 0.0145 0.75 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100457581 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs78736115 ENSG00000271654.1 RP11-685B14.3 5.93 7.4e-09 0.0145 0.75 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100458856 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs74558387 ENSG00000271654.1 RP11-685B14.3 5.93 7.4e-09 0.0145 0.75 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100459625 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs7997368 ENSG00000271654.1 RP11-685B14.3 5.93 7.4e-09 0.0145 0.75 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100459965 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs60279792 ENSG00000271654.1 RP11-685B14.3 5.93 7.4e-09 0.0145 0.75 0.31 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100460579 chr8:18387108~18387777:- LIHC trans rs3749237 0.964 rs1799845 ENSG00000197582.5 GPX1P1 5.93 7.42e-09 0.0145 0.44 0.31 Resting heart rate; chr3:49810190 chrX:13378735~13379340:- LIHC trans rs11098499 0.954 rs9993199 ENSG00000275858.1 RP11-291L22.8 -5.93 7.42e-09 0.0145 -0.34 -0.31 Corneal astigmatism; chr4:119471718 chr10:38450738~38451069:- LIHC trans rs6074578 0.587 rs6110460 ENSG00000199836.1 RNU1-47P -5.93 7.48e-09 0.0146 -0.32 -0.31 Hirschsprung disease; chr20:227527 chr14:99945315~99945477:+ LIHC trans rs9649213 0.555 rs6955259 ENSG00000225169.1 BRI3P1 5.93 7.48e-09 0.0146 0.4 0.31 Prostate cancer (SNP x SNP interaction); chr7:98263044 chr1:100213293~100213670:+ LIHC trans rs9649213 0.574 rs7802560 ENSG00000225169.1 BRI3P1 -5.93 7.55e-09 0.0147 -0.39 -0.31 Prostate cancer (SNP x SNP interaction); chr7:98274494 chr1:100213293~100213670:+ LIHC trans rs11098499 0.954 rs13107475 ENSG00000275858.1 RP11-291L22.8 5.93 7.55e-09 0.0147 0.35 0.31 Corneal astigmatism; chr4:119471856 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs73842633 ENSG00000275858.1 RP11-291L22.8 5.93 7.58e-09 0.0148 0.35 0.31 Corneal astigmatism; chr4:119454309 chr10:38450738~38451069:- LIHC trans rs1840440 0.966 rs12955389 ENSG00000269967.1 RP11-84A19.4 5.93 7.6e-09 0.0148 0.32 0.31 Weight; chr18:25691322 chr1:31851913~31921841:- LIHC trans rs73193808 0.614 rs2245023 ENSG00000204685.6 STARD7-AS1 -5.93 7.61e-09 0.0148 -0.32 -0.31 Coronary artery disease; chr21:29174539 chr2:96208416~96242621:+ LIHC trans rs2657294 0.659 rs1259500 ENSG00000172974.11 AC007318.5 5.93 7.62e-09 0.0148 0.28 0.31 Pneumonia; chr10:75230355 chr2:65205108~65205988:+ LIHC trans rs766622 0.964 rs6130508 ENSG00000236318.1 AC019117.1 5.92 7.64e-09 0.0149 0.4 0.31 Red blood cell count; chr20:44048175 chr7:17374867~17466664:+ LIHC trans rs11098499 0.954 rs7436506 ENSG00000275858.1 RP11-291L22.8 5.92 7.69e-09 0.015 0.35 0.31 Corneal astigmatism; chr4:119472614 chr10:38450738~38451069:- LIHC trans rs877636 1 rs2292239 ENSG00000227887.1 RPS26P13 5.92 7.71e-09 0.015 0.36 0.31 Cognitive function; chr12:56088396 chr1:208697369~208697698:- LIHC trans rs9611519 0.894 rs9611486 ENSG00000268568.1 AC007228.9 -5.92 7.75e-09 0.0151 -0.46 -0.3 Neuroticism; chr22:41062780 chr19:56672574~56673901:- LIHC trans rs9611519 0.894 rs13053242 ENSG00000268568.1 AC007228.9 -5.92 7.75e-09 0.0151 -0.46 -0.3 Neuroticism; chr22:41063482 chr19:56672574~56673901:- LIHC trans rs864643 0.678 rs625898 ENSG00000183298.5 RP11-556K13.1 -5.92 7.76e-09 0.0151 -0.47 -0.3 Attention deficit hyperactivity disorder; chr3:39471624 chr1:101786340~101787219:- LIHC trans rs6984305 0.541 rs17716118 ENSG00000237032.1 RP11-398C13.2 -5.92 7.76e-09 0.0151 -0.51 -0.3 Liver enzyme levels (alkaline phosphatase); chr8:9322624 chr10:14723171~14724055:- LIHC trans rs11098499 0.954 rs6834796 ENSG00000275858.1 RP11-291L22.8 5.92 7.78e-09 0.0151 0.35 0.3 Corneal astigmatism; chr4:119493538 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs11729521 ENSG00000275858.1 RP11-291L22.8 5.92 7.78e-09 0.0151 0.35 0.3 Corneal astigmatism; chr4:119495633 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs11734241 ENSG00000275858.1 RP11-291L22.8 5.92 7.78e-09 0.0151 0.35 0.3 Corneal astigmatism; chr4:119495717 chr10:38450738~38451069:- LIHC trans rs11220237 1 rs59868022 ENSG00000236257.1 EI24P2 5.92 7.81e-09 0.0152 0.38 0.3 Itch intensity from mosquito bite adjusted by bite size; chr11:125850985 chr1:158454198~158455273:+ LIHC trans rs12155039 1 rs12155039 ENSG00000214975.4 PPIAP29 -5.92 7.86e-09 0.0153 -0.36 -0.3 Mean platelet volume; chr7:44833526 chr6:24976419~24976982:+ LIHC trans rs9649213 0.593 rs6465673 ENSG00000225169.1 BRI3P1 5.92 7.9e-09 0.0153 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98339575 chr1:100213293~100213670:+ LIHC trans rs2243480 1 rs34702770 ENSG00000273142.1 RP11-458F8.4 -5.92 7.9e-09 0.0153 -0.38 -0.3 Diabetic kidney disease; chr7:65879836 chr7:66902857~66906297:+ LIHC trans rs2243480 0.803 rs35480979 ENSG00000273142.1 RP11-458F8.4 -5.92 7.9e-09 0.0153 -0.38 -0.3 Diabetic kidney disease; chr7:65892097 chr7:66902857~66906297:+ LIHC trans rs2243480 1 rs34637256 ENSG00000273142.1 RP11-458F8.4 -5.92 7.9e-09 0.0153 -0.38 -0.3 Diabetic kidney disease; chr7:65895144 chr7:66902857~66906297:+ LIHC trans rs2243480 1 rs35391607 ENSG00000273142.1 RP11-458F8.4 -5.92 7.9e-09 0.0153 -0.38 -0.3 Diabetic kidney disease; chr7:65895842 chr7:66902857~66906297:+ LIHC trans rs2243480 1 rs13220979 ENSG00000273142.1 RP11-458F8.4 -5.92 7.9e-09 0.0153 -0.38 -0.3 Diabetic kidney disease; chr7:65898217 chr7:66902857~66906297:+ LIHC trans rs2243480 1 rs34974928 ENSG00000273142.1 RP11-458F8.4 -5.92 7.9e-09 0.0153 -0.38 -0.3 Diabetic kidney disease; chr7:65899019 chr7:66902857~66906297:+ LIHC trans rs11098499 0.954 rs17006190 ENSG00000275858.1 RP11-291L22.8 5.92 7.91e-09 0.0153 0.35 0.3 Corneal astigmatism; chr4:119497683 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs28685688 ENSG00000275858.1 RP11-291L22.8 5.92 7.91e-09 0.0153 0.35 0.3 Corneal astigmatism; chr4:119499179 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs7687843 ENSG00000275858.1 RP11-291L22.8 5.92 7.91e-09 0.0153 0.35 0.3 Corneal astigmatism; chr4:119500056 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs2306455 ENSG00000275858.1 RP11-291L22.8 5.92 7.91e-09 0.0153 0.35 0.3 Corneal astigmatism; chr4:119500814 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs10031483 ENSG00000275858.1 RP11-291L22.8 5.92 7.91e-09 0.0153 0.35 0.3 Corneal astigmatism; chr4:119501481 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs10031665 ENSG00000275858.1 RP11-291L22.8 5.92 7.91e-09 0.0153 0.35 0.3 Corneal astigmatism; chr4:119501697 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs3733519 ENSG00000275858.1 RP11-291L22.8 5.92 7.91e-09 0.0153 0.35 0.3 Corneal astigmatism; chr4:119502293 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs3733523 ENSG00000275858.1 RP11-291L22.8 5.92 7.91e-09 0.0153 0.35 0.3 Corneal astigmatism; chr4:119502564 chr10:38450738~38451069:- LIHC trans rs875971 0.545 rs1547529 ENSG00000164669.11 INTS4P1 -5.92 7.92e-09 0.0154 -0.41 -0.3 Aortic root size; chr7:66258859 chr7:65141225~65234216:+ LIHC trans rs11220237 1 rs7121477 ENSG00000236257.1 EI24P2 5.92 7.93e-09 0.0154 0.38 0.3 Itch intensity from mosquito bite adjusted by bite size; chr11:125853528 chr1:158454198~158455273:+ LIHC trans rs11220237 0.925 rs6590178 ENSG00000236257.1 EI24P2 5.92 7.93e-09 0.0154 0.38 0.3 Itch intensity from mosquito bite adjusted by bite size; chr11:125853735 chr1:158454198~158455273:+ LIHC trans rs7568458 1 rs7568458 ENSG00000223886.3 RP11-251G23.2 5.92 7.93e-09 0.0154 0.36 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85561052 chr7:105530209~105530671:+ LIHC trans rs2243480 1 rs1618893 ENSG00000164669.11 INTS4P1 5.92 7.96e-09 0.0154 0.49 0.3 Diabetic kidney disease; chr7:66631132 chr7:65141225~65234216:+ LIHC trans rs11098499 0.738 rs72918577 ENSG00000275858.1 RP11-291L22.8 5.92 7.97e-09 0.0155 0.35 0.3 Corneal astigmatism; chr4:119405546 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs3733520 ENSG00000275858.1 RP11-291L22.8 5.92 7.97e-09 0.0155 0.35 0.3 Corneal astigmatism; chr4:119502325 chr10:38450738~38451069:- LIHC trans rs7444 0.941 rs2283790 ENSG00000274602.3 PI4KAP1 5.92 8.04e-09 0.0156 0.39 0.3 Systemic lupus erythematosus; chr22:21602364 chr22:18533646~18577968:- LIHC trans rs2243480 1 rs4718334 ENSG00000164669.11 INTS4P1 -5.91 8.09e-09 0.0157 -0.51 -0.3 Diabetic kidney disease; chr7:66324467 chr7:65141225~65234216:+ LIHC trans rs7312770 0.637 rs705699 ENSG00000243403.1 RP11-330L19.1 5.91 8.1e-09 0.0157 0.37 0.3 Polycystic ovary syndrome;Hypothyroidism; chr12:55991020 chr15:64592979~64593326:+ LIHC trans rs1155865 0.945 rs6552046 ENSG00000237973.1 RP5-857K21.6 5.91 8.11e-09 0.0157 0.45 0.3 Cognitive test performance; chr4:66927186 chr1:631074~632616:+ LIHC trans rs1155865 0.945 rs6552047 ENSG00000237973.1 RP5-857K21.6 5.91 8.11e-09 0.0157 0.45 0.3 Cognitive test performance; chr4:66927279 chr1:631074~632616:+ LIHC trans rs9649213 0.574 rs7791321 ENSG00000225169.1 BRI3P1 5.91 8.17e-09 0.0158 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98314813 chr1:100213293~100213670:+ LIHC trans rs1336472 0.615 rs11208611 ENSG00000233381.3 AK4P3 5.91 8.19e-09 0.0159 0.36 0.3 Venous thromboembolism (SNP x SNP interaction); chr1:65218742 chr12:31615771~31616439:- LIHC trans rs7444 0.941 rs5754295 ENSG00000274602.3 PI4KAP1 -5.91 8.21e-09 0.0159 -0.39 -0.3 Systemic lupus erythematosus; chr22:21597451 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs4821112 ENSG00000274602.3 PI4KAP1 -5.91 8.21e-09 0.0159 -0.39 -0.3 Systemic lupus erythematosus; chr22:21610472 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs5754352 ENSG00000274602.3 PI4KAP1 -5.91 8.21e-09 0.0159 -0.39 -0.3 Systemic lupus erythematosus; chr22:21610662 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs738127 ENSG00000274602.3 PI4KAP1 -5.91 8.21e-09 0.0159 -0.39 -0.3 Systemic lupus erythematosus; chr22:21613932 chr22:18533646~18577968:- LIHC trans rs9611519 0.929 rs9611469 ENSG00000268568.1 AC007228.9 -5.91 8.24e-09 0.0159 -0.45 -0.3 Neuroticism; chr22:41037315 chr19:56672574~56673901:- LIHC trans rs875971 0.571 rs78668714 ENSG00000164669.11 INTS4P1 -5.91 8.25e-09 0.016 -0.41 -0.3 Aortic root size; chr7:66474464 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs73150604 ENSG00000164669.11 INTS4P1 -5.91 8.25e-09 0.016 -0.41 -0.3 Aortic root size; chr7:66480545 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs7810213 ENSG00000164669.11 INTS4P1 -5.91 8.25e-09 0.016 -0.41 -0.3 Aortic root size; chr7:66481592 chr7:65141225~65234216:+ LIHC trans rs11220237 1 rs12273204 ENSG00000236257.1 EI24P2 5.91 8.25e-09 0.016 0.38 0.3 Itch intensity from mosquito bite adjusted by bite size; chr11:125784704 chr1:158454198~158455273:+ LIHC trans rs11098499 0.863 rs7699064 ENSG00000275858.1 RP11-291L22.8 -5.91 8.28e-09 0.016 -0.37 -0.3 Corneal astigmatism; chr4:119507154 chr10:38450738~38451069:- LIHC trans rs9425766 0.64 rs2208850 ENSG00000213331.4 RP11-713C19.2 5.91 8.29e-09 0.016 0.4 0.3 Life satisfaction; chr1:173862569 chr4:187970273~187971284:+ LIHC trans rs11220237 0.544 rs12361784 ENSG00000236257.1 EI24P2 -5.91 8.32e-09 0.0161 -0.43 -0.3 Itch intensity from mosquito bite adjusted by bite size; chr11:125685531 chr1:158454198~158455273:+ LIHC trans rs11098499 0.863 rs1010740 ENSG00000275858.1 RP11-291L22.8 -5.91 8.34e-09 0.0161 -0.36 -0.3 Corneal astigmatism; chr4:119542254 chr10:38450738~38451069:- LIHC trans rs3096299 0.685 rs2911244 ENSG00000215030.5 RPL13P12 -5.91 8.41e-09 0.0162 -0.3 -0.3 Multiple myeloma (IgH translocation); chr16:89455452 chr17:17383377~17384012:- LIHC trans rs538867 1 rs1398665 ENSG00000183298.5 RP11-556K13.1 5.91 8.43e-09 0.0163 0.69 0.3 Alzheimer's disease (cognitive decline); chr3:39475520 chr1:101786340~101787219:- LIHC trans rs538867 1 rs73066233 ENSG00000183298.5 RP11-556K13.1 5.91 8.43e-09 0.0163 0.69 0.3 Alzheimer's disease (cognitive decline); chr3:39475952 chr1:101786340~101787219:- LIHC trans rs4535700 0.501 rs28678267 ENSG00000204894.4 RP11-208G20.2 5.91 8.46e-09 0.0163 0.35 0.3 Macular telangiectasia type 2; chr7:55941797 chr7:152367171~152367260:+ LIHC trans rs4535700 0.501 rs11765531 ENSG00000204894.4 RP11-208G20.2 5.91 8.46e-09 0.0163 0.35 0.3 Macular telangiectasia type 2; chr7:55942594 chr7:152367171~152367260:+ LIHC trans rs4535700 0.501 rs10227764 ENSG00000204894.4 RP11-208G20.2 5.91 8.46e-09 0.0163 0.35 0.3 Macular telangiectasia type 2; chr7:55944729 chr7:152367171~152367260:+ LIHC trans rs4535700 0.501 rs60517461 ENSG00000204894.4 RP11-208G20.2 5.91 8.46e-09 0.0163 0.35 0.3 Macular telangiectasia type 2; chr7:55949952 chr7:152367171~152367260:+ LIHC trans rs3096299 0.667 rs2965947 ENSG00000215030.5 RPL13P12 -5.91 8.5e-09 0.0164 -0.3 -0.3 Multiple myeloma (IgH translocation); chr16:89452262 chr17:17383377~17384012:- LIHC trans rs9649213 0.593 rs6947340 ENSG00000225169.1 BRI3P1 -5.9 8.57e-09 0.0165 -0.39 -0.3 Prostate cancer (SNP x SNP interaction); chr7:98282929 chr1:100213293~100213670:+ LIHC trans rs152439 0.831 rs152438 ENSG00000272711.1 RP11-259N19.1 -5.9 8.59e-09 0.0166 -0.37 -0.3 PR interval in Tripanosoma cruzi seropositivity; chr5:142544567 chr2:74832655~74833987:- LIHC trans rs9649213 0.593 rs10953255 ENSG00000225169.1 BRI3P1 5.9 8.59e-09 0.0166 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98293886 chr1:100213293~100213670:+ LIHC trans rs12709013 0.818 rs1646273 ENSG00000233719.3 GOT2P3 5.9 8.63e-09 0.0166 0.34 0.3 Blood metabolite ratios; chr16:58748318 chr12:9641802~9643007:+ LIHC trans rs11098499 0.954 rs10008459 ENSG00000275858.1 RP11-291L22.8 5.9 8.66e-09 0.0167 0.35 0.3 Corneal astigmatism; chr4:119473076 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs2127821 ENSG00000275858.1 RP11-291L22.8 5.9 8.66e-09 0.0167 0.35 0.3 Corneal astigmatism; chr4:119473380 chr10:38450738~38451069:- LIHC trans rs72615157 0.629 rs55839153 ENSG00000228546.2 CTA-313A17.3 5.9 8.67e-09 0.0167 0.53 0.3 Lung function (FEV1/FVC); chr7:100154943 chr7:102337316~102339115:+ LIHC trans rs11662763 0.938 rs7506228 ENSG00000266563.1 EIF1P5 -5.9 8.69e-09 0.0167 -0.71 -0.3 Immunoglobulin A; chr18:5861336 chr17:21259968~21260501:- LIHC trans rs864643 0.678 rs1707953 ENSG00000183298.5 RP11-556K13.1 5.9 8.7e-09 0.0168 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39483918 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs683089 ENSG00000183298.5 RP11-556K13.1 5.9 8.7e-09 0.0168 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39484334 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs590805 ENSG00000183298.5 RP11-556K13.1 5.9 8.7e-09 0.0168 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39485463 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs606973 ENSG00000183298.5 RP11-556K13.1 5.9 8.7e-09 0.0168 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39485876 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs521226 ENSG00000183298.5 RP11-556K13.1 5.9 8.7e-09 0.0168 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39486099 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs519385 ENSG00000183298.5 RP11-556K13.1 5.9 8.7e-09 0.0168 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39486304 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs604831 ENSG00000183298.5 RP11-556K13.1 5.9 8.7e-09 0.0168 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39486327 chr1:101786340~101787219:- LIHC trans rs864643 0.625 rs517376 ENSG00000183298.5 RP11-556K13.1 5.9 8.7e-09 0.0168 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39486571 chr1:101786340~101787219:- LIHC trans rs35306767 0.859 rs11817793 ENSG00000279296.1 RP11-609D21.3 5.9 8.7e-09 0.0168 0.46 0.3 Eosinophil percentage of granulocytes; chr10:832955 chr17:6772831~6776116:- LIHC trans rs9858542 0.953 rs11715915 ENSG00000197582.5 GPX1P1 5.9 8.72e-09 0.0168 0.49 0.3 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49417897 chrX:13378735~13379340:- LIHC trans rs864643 0.898 rs530080 ENSG00000183298.5 RP11-556K13.1 5.9 8.74e-09 0.0168 0.51 0.3 Attention deficit hyperactivity disorder; chr3:39547507 chr1:101786340~101787219:- LIHC trans rs1155865 0.945 rs1383718 ENSG00000237973.1 RP5-857K21.6 5.9 8.76e-09 0.0168 0.45 0.3 Cognitive test performance; chr4:66925319 chr1:631074~632616:+ LIHC trans rs864643 0.678 rs1707957 ENSG00000183298.5 RP11-556K13.1 5.9 8.77e-09 0.0169 0.48 0.3 Attention deficit hyperactivity disorder; chr3:39482000 chr1:101786340~101787219:- LIHC trans rs875971 0.545 rs12670811 ENSG00000164669.11 INTS4P1 -5.9 8.78e-09 0.0169 -0.41 -0.3 Aortic root size; chr7:66358032 chr7:65141225~65234216:+ LIHC trans rs6424115 0.931 rs2473377 ENSG00000228217.1 AL390877.1 -5.9 8.84e-09 0.017 -0.36 -0.3 Immature fraction of reticulocytes; chr1:23821770 chr1:117778087~117778506:- LIHC trans rs7399018 1 rs7399018 ENSG00000223825.5 DAZAP2P1 -5.9 8.87e-09 0.0171 -0.33 -0.3 Cisplatin-induced ototoxicity; chr12:51216581 chr2:202201384~202201886:- LIHC trans rs9611519 0.894 rs9611488 ENSG00000268568.1 AC007228.9 -5.9 8.94e-09 0.0172 -0.46 -0.3 Neuroticism; chr22:41066588 chr19:56672574~56673901:- LIHC trans rs9611519 0.894 rs4821998 ENSG00000268568.1 AC007228.9 -5.9 8.94e-09 0.0172 -0.46 -0.3 Neuroticism; chr22:41072269 chr19:56672574~56673901:- LIHC trans rs9611519 0.894 rs8136923 ENSG00000268568.1 AC007228.9 -5.9 8.94e-09 0.0172 -0.46 -0.3 Neuroticism; chr22:41074518 chr19:56672574~56673901:- LIHC trans rs1840440 1 rs1840440 ENSG00000269967.1 RP11-84A19.4 -5.89 9.02e-09 0.0173 -0.31 -0.3 Weight; chr18:25677222 chr1:31851913~31921841:- LIHC trans rs1961649 0.75 rs11614294 ENSG00000214900.7 LINC01588 -5.89 9.04e-09 0.0173 -0.5 -0.3 Metabolite levels (HVA/5-HIAA ratio); chr12:99519776 chr14:49981712~50007520:- LIHC trans rs12709013 0.729 rs34324769 ENSG00000230849.2 GOT2P2 5.89 9.12e-09 0.0175 0.36 0.3 Blood metabolite ratios; chr16:58778131 chr1:173141100~173142350:- LIHC trans rs864643 0.947 rs482495 ENSG00000183298.5 RP11-556K13.1 5.89 9.15e-09 0.0175 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39498924 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs645403 ENSG00000183298.5 RP11-556K13.1 5.89 9.15e-09 0.0175 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39498968 chr1:101786340~101787219:- LIHC trans rs714543 1 rs1990053 ENSG00000214975.4 PPIAP29 -5.89 9.21e-09 0.0177 -0.36 -0.3 Plateletcrit; chr7:44886297 chr6:24976419~24976982:+ LIHC trans rs714543 0.935 rs2331174 ENSG00000214975.4 PPIAP29 -5.89 9.21e-09 0.0177 -0.36 -0.3 Plateletcrit; chr7:44887228 chr6:24976419~24976982:+ LIHC trans rs7444 0.941 rs738128 ENSG00000274602.3 PI4KAP1 -5.89 9.21e-09 0.0177 -0.38 -0.3 Systemic lupus erythematosus; chr22:21616721 chr22:18533646~18577968:- LIHC trans rs7444 0.825 rs738129 ENSG00000274602.3 PI4KAP1 -5.89 9.21e-09 0.0177 -0.38 -0.3 Systemic lupus erythematosus; chr22:21616752 chr22:18533646~18577968:- LIHC trans rs10493485 1 rs1855647 ENSG00000234741.6 GAS5 5.89 9.23e-09 0.0177 0.21 0.3 Hemostatic factors and hematological phenotypes; chr1:71596133 chr1:173863900~173868882:- LIHC trans rs9611519 0.964 rs20551 ENSG00000268568.1 AC007228.9 -5.89 9.28e-09 0.0178 -0.47 -0.3 Neuroticism; chr22:41152004 chr19:56672574~56673901:- LIHC trans rs12200782 1 rs12200782 ENSG00000242375.1 RP11-498P14.3 -5.89 9.31e-09 0.0178 -0.74 -0.3 Small cell lung carcinoma; chr6:26402808 chr9:97195351~97197687:- LIHC trans rs714543 1 rs8840 ENSG00000214975.4 PPIAP29 5.89 9.38e-09 0.018 0.35 0.3 Plateletcrit; chr7:44877441 chr6:24976419~24976982:+ LIHC trans rs3849046 0.79 rs10793825 ENSG00000226666.1 HSPA9P1 5.89 9.39e-09 0.018 0.37 0.3 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138598882 chr2:221961737~221963765:+ LIHC trans rs7444 0.941 rs2266964 ENSG00000274602.3 PI4KAP1 -5.89 9.43e-09 0.018 -0.38 -0.3 Systemic lupus erythematosus; chr22:21604015 chr22:18533646~18577968:- LIHC trans rs11098499 0.863 rs58452170 ENSG00000275858.1 RP11-291L22.8 5.89 9.44e-09 0.0181 0.36 0.3 Corneal astigmatism; chr4:119538519 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs10006706 ENSG00000275858.1 RP11-291L22.8 5.89 9.44e-09 0.0181 0.35 0.3 Corneal astigmatism; chr4:119487997 chr10:38450738~38451069:- LIHC trans rs864643 0.678 rs1609646 ENSG00000183298.5 RP11-556K13.1 5.89 9.46e-09 0.0181 0.48 0.3 Attention deficit hyperactivity disorder; chr3:39491415 chr1:101786340~101787219:- LIHC trans rs875971 0.545 rs10950036 ENSG00000164669.11 INTS4P1 -5.88 9.53e-09 0.0182 -0.41 -0.3 Aortic root size; chr7:66353241 chr7:65141225~65234216:+ LIHC trans rs9425766 0.678 rs1951625 ENSG00000213331.4 RP11-713C19.2 5.88 9.55e-09 0.0182 0.4 0.3 Life satisfaction; chr1:173867464 chr4:187970273~187971284:+ LIHC trans rs9649213 0.574 rs12873 ENSG00000225169.1 BRI3P1 5.88 9.55e-09 0.0182 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98293461 chr1:100213293~100213670:+ LIHC trans rs2243480 0.706 rs6460257 ENSG00000273142.1 RP11-458F8.4 -5.88 9.64e-09 0.0184 -0.33 -0.3 Diabetic kidney disease; chr7:65731813 chr7:66902857~66906297:+ LIHC trans rs12709013 0.792 rs11646756 ENSG00000230849.2 GOT2P2 5.88 9.68e-09 0.0185 0.35 0.3 Blood metabolite ratios; chr16:58773598 chr1:173141100~173142350:- LIHC trans rs7444 0.941 rs5998599 ENSG00000274602.3 PI4KAP1 -5.88 9.73e-09 0.0186 -0.38 -0.3 Systemic lupus erythematosus; chr22:21587692 chr22:18533646~18577968:- LIHC trans rs7444 0.941 rs2070512 ENSG00000274602.3 PI4KAP1 -5.88 9.8e-09 0.0187 -0.38 -0.3 Systemic lupus erythematosus; chr22:21595122 chr22:18533646~18577968:- LIHC trans rs7568458 0.811 rs10175792 ENSG00000223886.3 RP11-251G23.2 5.88 9.84e-09 0.0188 0.35 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85534531 chr7:105530209~105530671:+ LIHC trans rs7568458 0.846 rs10179195 ENSG00000223886.3 RP11-251G23.2 5.88 9.84e-09 0.0188 0.35 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85535638 chr7:105530209~105530671:+ LIHC trans rs7568458 0.846 rs6743030 ENSG00000223886.3 RP11-251G23.2 5.88 9.84e-09 0.0188 0.35 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85536397 chr7:105530209~105530671:+ LIHC trans rs9649213 0.593 rs13232181 ENSG00000225169.1 BRI3P1 5.88 9.88e-09 0.0188 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98306359 chr1:100213293~100213670:+ LIHC trans rs7444 0.941 rs11089629 ENSG00000274602.3 PI4KAP1 -5.88 9.9e-09 0.0189 -0.38 -0.3 Systemic lupus erythematosus; chr22:21604583 chr22:18533646~18577968:- LIHC trans rs11098499 0.908 rs1002152 ENSG00000275858.1 RP11-291L22.8 5.88 9.95e-09 0.0189 0.35 0.3 Corneal astigmatism; chr4:119352232 chr10:38450738~38451069:- LIHC trans rs877636 0.701 rs34415530 ENSG00000243403.1 RP11-330L19.1 5.88 9.97e-09 0.019 0.39 0.3 Cognitive function; chr12:56050848 chr15:64592979~64593326:+ LIHC trans rs9649213 0.593 rs3823740 ENSG00000225169.1 BRI3P1 5.88 9.99e-09 0.019 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98327792 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs7807555 ENSG00000225169.1 BRI3P1 5.88 9.99e-09 0.019 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98328205 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs7807455 ENSG00000225169.1 BRI3P1 5.88 9.99e-09 0.019 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98328310 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs6465667 ENSG00000225169.1 BRI3P1 5.88 9.99e-09 0.019 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98328573 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs6949214 ENSG00000225169.1 BRI3P1 5.88 9.99e-09 0.019 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98330921 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs35535338 ENSG00000225169.1 BRI3P1 5.88 9.99e-09 0.019 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98333007 chr1:100213293~100213670:+ LIHC trans rs9581094 0.591 rs9553318 ENSG00000237917.1 PARP4P1 -5.88 1e-08 0.0191 -0.42 -0.3 Sudden cardiac arrest; chr13:24477107 chrY:26594851~26634652:- LIHC trans rs714543 1 rs714543 ENSG00000214975.4 PPIAP29 -5.87 1.01e-08 0.0191 -0.36 -0.3 Plateletcrit; chr7:44847477 chr6:24976419~24976982:+ LIHC trans rs714543 1 rs757693 ENSG00000214975.4 PPIAP29 -5.87 1.01e-08 0.0191 -0.36 -0.3 Plateletcrit; chr7:44848430 chr6:24976419~24976982:+ LIHC trans rs11098499 0.909 rs1546504 ENSG00000275858.1 RP11-291L22.8 5.87 1.01e-08 0.0191 0.36 0.3 Corneal astigmatism; chr4:119320024 chr10:38450738~38451069:- LIHC trans rs9649213 0.593 rs6949718 ENSG00000225169.1 BRI3P1 5.87 1.01e-08 0.0191 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98295171 chr1:100213293~100213670:+ LIHC trans rs864643 0.678 rs1707959 ENSG00000183298.5 RP11-556K13.1 5.87 1.01e-08 0.0191 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39481807 chr1:101786340~101787219:- LIHC trans rs7200543 1 rs7200543 ENSG00000250569.1 NTAN1P2 -5.87 1.01e-08 0.0192 -0.38 -0.3 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15036113 chr8:86481754~86483002:- LIHC trans rs1593 0.531 rs4253251 ENSG00000269378.1 ITGB1P1 5.87 1.01e-08 0.0192 0.33 0.3 Activated partial thromboplastin time; chr4:186235319 chr19:14621634~14622242:- LIHC trans rs11098499 0.863 rs3775841 ENSG00000275858.1 RP11-291L22.8 5.87 1.01e-08 0.0192 0.36 0.3 Corneal astigmatism; chr4:119504622 chr10:38450738~38451069:- LIHC trans rs1961649 0.75 rs17386299 ENSG00000214900.7 LINC01588 -5.87 1.01e-08 0.0193 -0.49 -0.3 Metabolite levels (HVA/5-HIAA ratio); chr12:99496998 chr14:49981712~50007520:- LIHC trans rs9611519 0.78 rs5751071 ENSG00000268568.1 AC007228.9 -5.87 1.02e-08 0.0193 -0.35 -0.3 Neuroticism; chr22:41260328 chr19:56672574~56673901:- LIHC trans rs796364 0.625 rs4673837 ENSG00000270060.1 RP11-390K5.6 5.87 1.02e-08 0.0194 0.24 0.3 Schizophrenia; chr2:200266436 chr11:47168281~47169563:- LIHC trans rs12709013 0.792 rs1657165 ENSG00000233719.3 GOT2P3 5.87 1.02e-08 0.0194 0.34 0.3 Blood metabolite ratios; chr16:58747980 chr12:9641802~9643007:+ LIHC trans rs17589516 0.881 rs78354187 ENSG00000255355.1 AP000640.2 5.87 1.03e-08 0.0195 0.72 0.3 Insulin resistance/response; chr6:37798027 chr11:59669312~59676041:+ LIHC trans rs6938574 0.672 rs6569520 ENSG00000231842.1 RP11-527F13.1 5.87 1.03e-08 0.0195 0.5 0.3 Menarche (age at onset); chr6:128043889 chr6:126177193~126202239:+ LIHC trans rs9431487 0.544 rs11118154 ENSG00000279469.1 RP11-215P8.2 -5.87 1.03e-08 0.0195 -0.38 -0.3 Gut microbiome composition (summer); chr1:218793534 chr5:134394360~134395008:- LIHC trans rs1039766 0.929 rs55843720 ENSG00000224334.1 AP000357.4 5.87 1.04e-08 0.0197 0.45 0.3 Lung adenocarcinoma;Lung cancer; chr2:65268436 chr22:24686923~24688087:+ LIHC trans rs864643 0.678 rs1768224 ENSG00000183298.5 RP11-556K13.1 5.87 1.04e-08 0.0197 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39491843 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs7627794 ENSG00000183298.5 RP11-556K13.1 5.87 1.04e-08 0.0197 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39492039 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs7639473 ENSG00000183298.5 RP11-556K13.1 5.87 1.04e-08 0.0197 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39492324 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs10510702 ENSG00000183298.5 RP11-556K13.1 5.87 1.04e-08 0.0197 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39492461 chr1:101786340~101787219:- LIHC trans rs864643 0.625 rs602408 ENSG00000183298.5 RP11-556K13.1 5.87 1.04e-08 0.0197 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39493754 chr1:101786340~101787219:- LIHC trans rs864643 0.625 rs601925 ENSG00000183298.5 RP11-556K13.1 5.87 1.04e-08 0.0197 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39493871 chr1:101786340~101787219:- LIHC trans rs351855 0.642 rs2546095 ENSG00000226986.4 RP11-543B16.2 5.87 1.04e-08 0.0198 0.32 0.3 Waist-to-hip ratio adjusted for body mass index; chr5:177082583 chr1:211207239~211207897:+ LIHC trans rs7568458 0.783 rs1561198 ENSG00000223886.3 RP11-251G23.2 5.87 1.05e-08 0.0198 0.35 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85582866 chr7:105530209~105530671:+ LIHC trans rs7444 0.941 rs2298429 ENSG00000274602.3 PI4KAP1 -5.87 1.05e-08 0.0199 -0.38 -0.3 Systemic lupus erythematosus; chr22:21628971 chr22:18533646~18577968:- LIHC trans rs17206232 0.534 rs114695114 ENSG00000279789.1 CTD-2574D22.3 5.87 1.05e-08 0.0199 0.54 0.3 Schizophrenia; chr5:65388144 chr16:29913144~29915337:- LIHC trans rs13080594 0.638 rs1039263 ENSG00000251015.1 SLC25A30-AS1 -5.87 1.06e-08 0.02 -0.34 -0.3 Personality traits in bipolar disorder; chr3:7368283 chr13:45418162~45420371:+ LIHC trans rs864643 0.678 rs1609647 ENSG00000183298.5 RP11-556K13.1 5.86 1.07e-08 0.0201 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39491580 chr1:101786340~101787219:- LIHC trans rs538867 1 rs1708011 ENSG00000214263.2 RPSAP53 5.86 1.07e-08 0.0202 0.74 0.3 Alzheimer's disease (cognitive decline); chr3:39551743 chr13:67266845~67267706:- LIHC trans rs6901152 0.525 rs4896651 ENSG00000226084.5 RP4-706A16.3 5.86 1.08e-08 0.0203 0.32 0.3 Acute lymphoblastic leukemia (childhood); chr6:143370256 chr1:77129114~77129668:+ LIHC trans rs73193808 0.614 rs2832251 ENSG00000204685.6 STARD7-AS1 -5.86 1.08e-08 0.0204 -0.31 -0.3 Coronary artery disease; chr21:29187231 chr2:96208416~96242621:+ LIHC trans rs6491750 0.744 rs9519054 ENSG00000270804.1 CTD-2583A14.11 5.86 1.09e-08 0.0205 0.49 0.3 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr13:103478218 chr19:57867885~57868834:+ LIHC trans rs864643 0.678 rs656071 ENSG00000183298.5 RP11-556K13.1 5.86 1.1e-08 0.0207 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39488646 chr1:101786340~101787219:- LIHC trans rs864643 0.625 rs656454 ENSG00000183298.5 RP11-556K13.1 5.86 1.1e-08 0.0207 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39488711 chr1:101786340~101787219:- LIHC trans rs864643 0.625 rs1708112 ENSG00000183298.5 RP11-556K13.1 5.86 1.1e-08 0.0207 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39489034 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs1708111 ENSG00000183298.5 RP11-556K13.1 5.86 1.1e-08 0.0207 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39489098 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs1768219 ENSG00000183298.5 RP11-556K13.1 5.86 1.1e-08 0.0207 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39489162 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs1398675 ENSG00000183298.5 RP11-556K13.1 5.86 1.1e-08 0.0207 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39489772 chr1:101786340~101787219:- LIHC trans rs864643 0.625 rs1768220 ENSG00000183298.5 RP11-556K13.1 5.86 1.1e-08 0.0207 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39490545 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs1768221 ENSG00000183298.5 RP11-556K13.1 5.86 1.1e-08 0.0207 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39490789 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs1768222 ENSG00000183298.5 RP11-556K13.1 5.86 1.1e-08 0.0207 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39490852 chr1:101786340~101787219:- LIHC trans rs10815468 0.624 rs7037259 ENSG00000215210.3 RBMXP2 -5.86 1.1e-08 0.0208 -0.36 -0.3 Bipolar disorder and schizophrenia; chr9:6784144 chr9:30689105~30690272:+ LIHC trans rs34977459 1 rs34977459 ENSG00000274602.3 PI4KAP1 -5.86 1.11e-08 0.0209 -0.38 -0.3 Mean corpuscular hemoglobin; chr22:21578365 chr22:18533646~18577968:- LIHC trans rs6424115 1 rs6697805 ENSG00000228217.1 AL390877.1 5.86 1.11e-08 0.0209 0.35 0.3 Immature fraction of reticulocytes; chr1:23825506 chr1:117778087~117778506:- LIHC trans rs8177876 0.822 rs804902 ENSG00000226040.3 AC005740.3 5.86 1.11e-08 0.021 0.5 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81071360 chr5:141896168~141896689:- LIHC trans rs11098499 0.863 rs1552095 ENSG00000275858.1 RP11-291L22.8 5.85 1.13e-08 0.0212 0.36 0.3 Corneal astigmatism; chr4:119539151 chr10:38450738~38451069:- LIHC trans rs7200543 1 rs14347 ENSG00000250569.1 NTAN1P2 5.85 1.13e-08 0.0212 0.37 0.3 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15040032 chr8:86481754~86483002:- LIHC trans rs7444 0.941 rs5998672 ENSG00000274602.3 PI4KAP1 -5.85 1.13e-08 0.0213 -0.38 -0.3 Systemic lupus erythematosus; chr22:21612153 chr22:18533646~18577968:- LIHC trans rs3735485 0.738 rs11552377 ENSG00000265095.1 FTLP12 -5.85 1.13e-08 0.0213 -0.46 -0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:45064532 chr17:16391434~16391882:+ LIHC trans rs9611519 0.929 rs9611465 ENSG00000268568.1 AC007228.9 -5.85 1.13e-08 0.0213 -0.45 -0.3 Neuroticism; chr22:41030135 chr19:56672574~56673901:- LIHC trans rs9611519 0.929 rs9611466 ENSG00000268568.1 AC007228.9 -5.85 1.13e-08 0.0213 -0.45 -0.3 Neuroticism; chr22:41030295 chr19:56672574~56673901:- LIHC trans rs864643 0.678 rs1707960 ENSG00000183298.5 RP11-556K13.1 -5.85 1.14e-08 0.0214 -0.47 -0.3 Attention deficit hyperactivity disorder; chr3:39481761 chr1:101786340~101787219:- LIHC trans rs11098499 0.954 rs10006877 ENSG00000275858.1 RP11-291L22.8 5.85 1.14e-08 0.0214 0.35 0.3 Corneal astigmatism; chr4:119321638 chr10:38450738~38451069:- LIHC trans rs9649213 0.593 rs6963210 ENSG00000225169.1 BRI3P1 5.85 1.14e-08 0.0214 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98315674 chr1:100213293~100213670:+ LIHC trans rs9649213 0.574 rs9648908 ENSG00000225169.1 BRI3P1 5.85 1.14e-08 0.0214 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98315924 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs7797943 ENSG00000225169.1 BRI3P1 5.85 1.14e-08 0.0214 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98317590 chr1:100213293~100213670:+ LIHC trans rs6743068 0.541 rs13014235 ENSG00000235105.1 RP11-329A14.1 5.85 1.15e-08 0.0215 0.3 0.3 Lymphocyte percentage of white cells; chr2:201350769 chr1:48435967~48437223:+ LIHC trans rs9649213 0.537 rs35997266 ENSG00000225169.1 BRI3P1 5.85 1.15e-08 0.0216 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98336254 chr1:100213293~100213670:+ LIHC trans rs881952 0.585 rs934796 ENSG00000250564.1 RP11-215P8.4 -5.85 1.16e-08 0.0218 -0.38 -0.3 Glucose homeostasis traits; chr2:60675295 chr5:134429051~134460615:- LIHC trans rs9649213 0.613 rs7777415 ENSG00000225169.1 BRI3P1 5.85 1.17e-08 0.0219 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98329902 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs6967457 ENSG00000225169.1 BRI3P1 5.85 1.17e-08 0.0219 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98282909 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs35983874 ENSG00000225169.1 BRI3P1 5.85 1.17e-08 0.022 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98287149 chr1:100213293~100213670:+ LIHC trans rs877636 0.701 rs34415530 ENSG00000225071.1 GS1-184P14.2 5.85 1.18e-08 0.0221 0.4 0.3 Cognitive function; chr12:56050848 chrX:24429573~24429920:- LIHC trans rs3849046 0.817 rs4835689 ENSG00000226666.1 HSPA9P1 5.85 1.18e-08 0.0221 0.36 0.3 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138580078 chr2:221961737~221963765:+ LIHC trans rs7200543 1 rs4985154 ENSG00000250569.1 NTAN1P2 5.85 1.18e-08 0.0221 0.37 0.3 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15037785 chr8:86481754~86483002:- LIHC trans rs7200543 1 rs1135999 ENSG00000250569.1 NTAN1P2 5.85 1.18e-08 0.0221 0.37 0.3 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15038105 chr8:86481754~86483002:- LIHC trans rs7200543 1 rs1136001 ENSG00000250569.1 NTAN1P2 5.85 1.18e-08 0.0221 0.37 0.3 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15038117 chr8:86481754~86483002:- LIHC trans rs7200543 1 rs34614532 ENSG00000250569.1 NTAN1P2 5.85 1.18e-08 0.0221 0.37 0.3 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15039051 chr8:86481754~86483002:- LIHC trans rs35306767 0.903 rs7074642 ENSG00000279296.1 RP11-609D21.3 5.84 1.19e-08 0.0222 0.46 0.3 Eosinophil percentage of granulocytes; chr10:832419 chr17:6772831~6776116:- LIHC trans rs11098499 0.863 rs6835635 ENSG00000275858.1 RP11-291L22.8 5.84 1.19e-08 0.0223 0.35 0.3 Corneal astigmatism; chr4:119537712 chr10:38450738~38451069:- LIHC trans rs9649213 0.593 rs2107716 ENSG00000225169.1 BRI3P1 5.84 1.19e-08 0.0223 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98315432 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs13246942 ENSG00000225169.1 BRI3P1 5.84 1.19e-08 0.0223 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98285709 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs6968144 ENSG00000225169.1 BRI3P1 5.84 1.19e-08 0.0223 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98286385 chr1:100213293~100213670:+ LIHC trans rs9649213 0.574 rs62479853 ENSG00000225169.1 BRI3P1 5.84 1.19e-08 0.0223 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98287846 chr1:100213293~100213670:+ LIHC trans rs11098499 0.618 rs35265692 ENSG00000275858.1 RP11-291L22.8 5.84 1.2e-08 0.0224 0.35 0.3 Corneal astigmatism; chr4:119403980 chr10:38450738~38451069:- LIHC trans rs7568458 0.811 rs1446668 ENSG00000223886.3 RP11-251G23.2 5.84 1.21e-08 0.0226 0.35 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85537837 chr7:105530209~105530671:+ LIHC trans rs9611519 0.78 rs5751072 ENSG00000268568.1 AC007228.9 -5.84 1.21e-08 0.0227 -0.35 -0.3 Neuroticism; chr22:41260505 chr19:56672574~56673901:- LIHC trans rs9649213 0.511 rs6950994 ENSG00000225169.1 BRI3P1 5.84 1.21e-08 0.0227 0.41 0.3 Prostate cancer (SNP x SNP interaction); chr7:98258560 chr1:100213293~100213670:+ LIHC trans rs35306767 0.903 rs12254002 ENSG00000279296.1 RP11-609D21.3 -5.84 1.21e-08 0.0227 -0.46 -0.3 Eosinophil percentage of granulocytes; chr10:883193 chr17:6772831~6776116:- LIHC trans rs9649213 0.593 rs7789380 ENSG00000225169.1 BRI3P1 5.84 1.21e-08 0.0227 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98326868 chr1:100213293~100213670:+ LIHC trans rs3849046 0.738 rs57958956 ENSG00000226666.1 HSPA9P1 5.84 1.22e-08 0.0227 0.36 0.3 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138590952 chr2:221961737~221963765:+ LIHC trans rs877636 0.692 rs10876870 ENSG00000227887.1 RPS26P13 -5.84 1.22e-08 0.0228 -0.35 -0.3 Cognitive function; chr12:56084218 chr1:208697369~208697698:- LIHC trans rs877636 0.692 rs7971751 ENSG00000227887.1 RPS26P13 -5.84 1.22e-08 0.0228 -0.35 -0.3 Cognitive function; chr12:56084874 chr1:208697369~208697698:- LIHC trans rs17589516 0.881 rs115494201 ENSG00000255355.1 AP000640.2 5.84 1.22e-08 0.0228 0.7 0.3 Insulin resistance/response; chr6:37806821 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs74914986 ENSG00000255355.1 AP000640.2 5.84 1.22e-08 0.0228 0.7 0.3 Insulin resistance/response; chr6:37807950 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs76842427 ENSG00000255355.1 AP000640.2 5.84 1.22e-08 0.0228 0.7 0.3 Insulin resistance/response; chr6:37808488 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs41273098 ENSG00000255355.1 AP000640.2 5.84 1.22e-08 0.0228 0.7 0.3 Insulin resistance/response; chr6:37816068 chr11:59669312~59676041:+ LIHC trans rs9649213 0.537 rs6465663 ENSG00000225169.1 BRI3P1 5.84 1.22e-08 0.0228 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98289571 chr1:100213293~100213670:+ LIHC trans rs6743068 0.541 rs6435079 ENSG00000235105.1 RP11-329A14.1 5.84 1.23e-08 0.0229 0.29 0.3 Lymphocyte percentage of white cells; chr2:201335608 chr1:48435967~48437223:+ LIHC trans rs17589516 0.764 rs114645217 ENSG00000255355.1 AP000640.2 5.84 1.23e-08 0.0229 0.69 0.3 Insulin resistance/response; chr6:37963116 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs17648055 ENSG00000255355.1 AP000640.2 5.84 1.23e-08 0.0229 0.69 0.3 Insulin resistance/response; chr6:37964587 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs17581755 ENSG00000255355.1 AP000640.2 5.84 1.23e-08 0.0229 0.69 0.3 Insulin resistance/response; chr6:37970436 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs76829897 ENSG00000255355.1 AP000640.2 5.84 1.23e-08 0.0229 0.69 0.3 Insulin resistance/response; chr6:37981515 chr11:59669312~59676041:+ LIHC trans rs864643 0.891 rs55780606 ENSG00000183298.5 RP11-556K13.1 5.84 1.23e-08 0.023 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39496599 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs1708015 ENSG00000183298.5 RP11-556K13.1 5.84 1.23e-08 0.023 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39496891 chr1:101786340~101787219:- LIHC trans rs3808502 0.527 rs2736374 ENSG00000246089.3 RP11-115C21.2 -5.84 1.24e-08 0.023 -0.4 -0.3 Neuroticism; chr8:11256319 chr8:6403551~6407142:- LIHC trans rs11098499 0.954 rs12505469 ENSG00000275858.1 RP11-291L22.8 5.84 1.24e-08 0.0231 0.35 0.3 Corneal astigmatism; chr4:119328430 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs3822195 ENSG00000275858.1 RP11-291L22.8 5.84 1.25e-08 0.0232 0.35 0.3 Corneal astigmatism; chr4:119550505 chr10:38450738~38451069:- LIHC trans rs875971 0.545 rs6460298 ENSG00000164669.11 INTS4P1 -5.83 1.25e-08 0.0233 -0.41 -0.3 Aortic root size; chr7:66442783 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs35459055 ENSG00000164669.11 INTS4P1 -5.83 1.25e-08 0.0233 -0.41 -0.3 Aortic root size; chr7:66479399 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs75577046 ENSG00000164669.11 INTS4P1 -5.83 1.25e-08 0.0233 -0.41 -0.3 Aortic root size; chr7:66493729 chr7:65141225~65234216:+ LIHC trans rs875971 0.545 rs3735147 ENSG00000164669.11 INTS4P1 -5.83 1.25e-08 0.0233 -0.41 -0.3 Aortic root size; chr7:66505541 chr7:65141225~65234216:+ LIHC trans rs864643 0.678 rs610006 ENSG00000183298.5 RP11-556K13.1 5.83 1.26e-08 0.0235 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39481104 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs1768201 ENSG00000183298.5 RP11-556K13.1 5.83 1.27e-08 0.0235 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39476050 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs568085 ENSG00000183298.5 RP11-556K13.1 5.83 1.27e-08 0.0236 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39472661 chr1:101786340~101787219:- LIHC trans rs864643 0.625 rs628725 ENSG00000183298.5 RP11-556K13.1 5.83 1.27e-08 0.0236 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39472887 chr1:101786340~101787219:- LIHC trans rs864643 0.625 rs570136 ENSG00000183298.5 RP11-556K13.1 5.83 1.27e-08 0.0236 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39472922 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs7615732 ENSG00000183298.5 RP11-556K13.1 5.83 1.27e-08 0.0236 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39473732 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs512923 ENSG00000183298.5 RP11-556K13.1 5.83 1.27e-08 0.0236 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39480472 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs621842 ENSG00000183298.5 RP11-556K13.1 5.83 1.27e-08 0.0236 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39480785 chr1:101786340~101787219:- LIHC trans rs3849046 0.817 rs9968657 ENSG00000226666.1 HSPA9P1 5.83 1.27e-08 0.0236 0.36 0.3 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138584741 chr2:221961737~221963765:+ LIHC trans rs11220237 0.764 rs11220207 ENSG00000236257.1 EI24P2 5.83 1.27e-08 0.0236 0.45 0.3 Itch intensity from mosquito bite adjusted by bite size; chr11:125747298 chr1:158454198~158455273:+ LIHC trans rs11098499 0.863 rs3822194 ENSG00000275858.1 RP11-291L22.8 5.83 1.28e-08 0.0237 0.35 0.3 Corneal astigmatism; chr4:119550493 chr10:38450738~38451069:- LIHC trans rs17589516 0.881 rs79339238 ENSG00000255355.1 AP000640.2 5.83 1.28e-08 0.0237 0.7 0.3 Insulin resistance/response; chr6:37822562 chr11:59669312~59676041:+ LIHC trans rs2992756 0.519 rs2992740 ENSG00000234740.1 RP11-272P10.2 -5.83 1.28e-08 0.0237 -0.37 -0.3 Breast cancer; chr1:18483850 chr9:13274510~13279187:- LIHC trans rs3849046 0.817 rs7711958 ENSG00000226666.1 HSPA9P1 5.83 1.28e-08 0.0238 0.36 0.3 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138565812 chr2:221961737~221963765:+ LIHC trans rs3849046 0.781 rs10070909 ENSG00000226666.1 HSPA9P1 5.83 1.28e-08 0.0238 0.36 0.3 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138581104 chr2:221961737~221963765:+ LIHC trans rs3735485 0.698 rs10248390 ENSG00000265095.1 FTLP12 -5.83 1.28e-08 0.0238 -0.48 -0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:45071352 chr17:16391434~16391882:+ LIHC trans rs3735485 0.738 rs2289370 ENSG00000265095.1 FTLP12 -5.83 1.28e-08 0.0238 -0.48 -0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:45074490 chr17:16391434~16391882:+ LIHC trans rs3735485 0.738 rs2289372 ENSG00000265095.1 FTLP12 -5.83 1.28e-08 0.0238 -0.48 -0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:45074627 chr17:16391434~16391882:+ LIHC trans rs864643 0.574 rs1768213 ENSG00000183298.5 RP11-556K13.1 5.83 1.29e-08 0.0239 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39486790 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs493794 ENSG00000183298.5 RP11-556K13.1 5.83 1.29e-08 0.0239 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39486804 chr1:101786340~101787219:- LIHC trans rs7568458 0.591 rs55971080 ENSG00000223886.3 RP11-251G23.2 5.83 1.29e-08 0.0239 0.36 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85585623 chr7:105530209~105530671:+ LIHC trans rs1961649 0.75 rs2860043 ENSG00000214900.7 LINC01588 -5.83 1.29e-08 0.0239 -0.47 -0.3 Metabolite levels (HVA/5-HIAA ratio); chr12:99500282 chr14:49981712~50007520:- LIHC trans rs12709013 0.792 rs1615326 ENSG00000233719.3 GOT2P3 5.83 1.3e-08 0.024 0.34 0.3 Blood metabolite ratios; chr16:58747148 chr12:9641802~9643007:+ LIHC trans rs1336472 1 rs1336472 ENSG00000233381.3 AK4P3 -5.83 1.3e-08 0.024 -0.34 -0.3 Venous thromboembolism (SNP x SNP interaction); chr1:65230247 chr12:31615771~31616439:- LIHC trans rs6424115 0.964 rs2473375 ENSG00000228217.1 AL390877.1 -5.83 1.3e-08 0.0241 -0.35 -0.3 Immature fraction of reticulocytes; chr1:23810055 chr1:117778087~117778506:- LIHC trans rs9649213 0.574 rs34830366 ENSG00000225169.1 BRI3P1 5.83 1.31e-08 0.0243 0.4 0.3 Prostate cancer (SNP x SNP interaction); chr7:98270223 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs34776142 ENSG00000225169.1 BRI3P1 5.83 1.31e-08 0.0243 0.4 0.3 Prostate cancer (SNP x SNP interaction); chr7:98270561 chr1:100213293~100213670:+ LIHC trans rs864643 0.678 rs1629282 ENSG00000183298.5 RP11-556K13.1 -5.83 1.31e-08 0.0243 -0.46 -0.3 Attention deficit hyperactivity disorder; chr3:39491770 chr1:101786340~101787219:- LIHC trans rs7226229 1 rs4985953 ENSG00000211513.4 MIR320E -5.83 1.32e-08 0.0243 -0.35 -0.3 Blood trace element (Se levels); chr17:20994271 chr19:46709271~46709382:- LIHC trans rs7226229 1 rs4985954 ENSG00000211513.4 MIR320E -5.83 1.32e-08 0.0243 -0.35 -0.3 Blood trace element (Se levels); chr17:20994639 chr19:46709271~46709382:- LIHC trans rs9649213 0.555 rs6948346 ENSG00000225169.1 BRI3P1 5.83 1.32e-08 0.0243 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98330644 chr1:100213293~100213670:+ LIHC trans rs11220237 1 rs7934485 ENSG00000236257.1 EI24P2 5.83 1.32e-08 0.0243 0.38 0.3 Itch intensity from mosquito bite adjusted by bite size; chr11:125804339 chr1:158454198~158455273:+ LIHC trans rs6491750 1 rs76198387 ENSG00000270804.1 CTD-2583A14.11 -5.83 1.32e-08 0.0244 -0.49 -0.3 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr13:103484275 chr19:57867885~57868834:+ LIHC trans rs73108077 0.736 rs6058479 ENSG00000279352.1 RP11-411B10.7 5.82 1.32e-08 0.0245 0.72 0.3 Red blood cell density in sickle cell anemia; chr20:31282419 chr18:14010054~14010917:+ LIHC trans rs6915893 0.967 rs9477631 ENSG00000267156.1 TPMTP1 5.82 1.33e-08 0.0245 0.33 0.3 Intrinsic epigenetic age acceleration; chr6:18123541 chr18:47630112~47630848:+ LIHC trans rs12193281 0.626 rs35651100 ENSG00000258608.1 DNAJC19P9 5.82 1.33e-08 0.0247 0.36 0.3 Electrodermal activity; chr6:83596999 chr14:45290036~45290386:+ LIHC trans rs11098499 0.954 rs6848389 ENSG00000275858.1 RP11-291L22.8 5.82 1.35e-08 0.025 0.34 0.3 Corneal astigmatism; chr4:119481467 chr10:38450738~38451069:- LIHC trans rs7444 0.825 rs5994638 ENSG00000274602.3 PI4KAP1 -5.82 1.35e-08 0.025 -0.38 -0.3 Systemic lupus erythematosus; chr22:21598987 chr22:18533646~18577968:- LIHC trans rs7444 0.882 rs5998644 ENSG00000274602.3 PI4KAP1 -5.82 1.35e-08 0.025 -0.38 -0.3 Systemic lupus erythematosus; chr22:21598999 chr22:18533646~18577968:- LIHC trans rs1593 0.531 rs4253326 ENSG00000269378.1 ITGB1P1 5.82 1.36e-08 0.0251 0.33 0.3 Activated partial thromboplastin time; chr4:186257445 chr19:14621634~14622242:- LIHC trans rs714543 1 rs13245012 ENSG00000214975.4 PPIAP29 -5.82 1.36e-08 0.0251 -0.36 -0.3 Plateletcrit; chr7:44826120 chr6:24976419~24976982:+ LIHC trans rs11098499 0.954 rs11098526 ENSG00000275858.1 RP11-291L22.8 5.82 1.36e-08 0.0252 0.34 0.3 Corneal astigmatism; chr4:119469204 chr10:38450738~38451069:- LIHC trans rs864643 0.678 rs7631217 ENSG00000183298.5 RP11-556K13.1 -5.82 1.36e-08 0.0252 -0.47 -0.3 Attention deficit hyperactivity disorder; chr3:39478568 chr1:101786340~101787219:- LIHC trans rs9649213 0.593 rs7796611 ENSG00000225169.1 BRI3P1 5.82 1.37e-08 0.0253 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98278911 chr1:100213293~100213670:+ LIHC trans rs9649213 0.574 rs13238610 ENSG00000225169.1 BRI3P1 5.82 1.37e-08 0.0253 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98279965 chr1:100213293~100213670:+ LIHC trans rs877636 0.859 rs3741499 ENSG00000225071.1 GS1-184P14.2 -5.82 1.38e-08 0.0254 -0.39 -0.3 Cognitive function; chr12:56080595 chrX:24429573~24429920:- LIHC trans rs7312770 0.637 rs705700 ENSG00000242970.2 AC068522.4 5.82 1.39e-08 0.0256 0.36 0.3 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr8:58588420~58588764:- LIHC trans rs9649213 0.593 rs3801264 ENSG00000225169.1 BRI3P1 5.81 1.39e-08 0.0257 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98321308 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs1468338 ENSG00000225169.1 BRI3P1 5.81 1.39e-08 0.0257 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98321806 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs2158553 ENSG00000225169.1 BRI3P1 5.81 1.39e-08 0.0257 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98321819 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs10808107 ENSG00000225169.1 BRI3P1 5.81 1.39e-08 0.0257 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98322359 chr1:100213293~100213670:+ LIHC trans rs9649213 0.613 rs10953256 ENSG00000225169.1 BRI3P1 5.81 1.39e-08 0.0257 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98322574 chr1:100213293~100213670:+ LIHC trans rs9649213 0.613 rs2286074 ENSG00000225169.1 BRI3P1 5.81 1.39e-08 0.0257 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98322699 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs7458551 ENSG00000225169.1 BRI3P1 5.81 1.39e-08 0.0257 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98322855 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs6948540 ENSG00000225169.1 BRI3P1 5.81 1.39e-08 0.0257 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98330754 chr1:100213293~100213670:+ LIHC trans rs9649213 0.574 rs6979373 ENSG00000225169.1 BRI3P1 5.81 1.39e-08 0.0257 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98332532 chr1:100213293~100213670:+ LIHC trans rs9649213 0.574 rs34717219 ENSG00000225169.1 BRI3P1 5.81 1.39e-08 0.0257 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98332959 chr1:100213293~100213670:+ LIHC trans rs9649213 0.593 rs62478177 ENSG00000225169.1 BRI3P1 5.81 1.39e-08 0.0257 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98335299 chr1:100213293~100213670:+ LIHC trans rs11098499 0.863 rs11098531 ENSG00000275858.1 RP11-291L22.8 5.81 1.4e-08 0.0257 0.35 0.3 Corneal astigmatism; chr4:119543846 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs28718422 ENSG00000275858.1 RP11-291L22.8 5.81 1.4e-08 0.0257 0.35 0.3 Corneal astigmatism; chr4:119545149 chr10:38450738~38451069:- LIHC trans rs11098499 0.818 rs12498599 ENSG00000275858.1 RP11-291L22.8 5.81 1.4e-08 0.0257 0.35 0.3 Corneal astigmatism; chr4:119547348 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs10009626 ENSG00000275858.1 RP11-291L22.8 5.81 1.4e-08 0.0257 0.35 0.3 Corneal astigmatism; chr4:119548850 chr10:38450738~38451069:- LIHC trans rs77954165 0.614 rs4742243 ENSG00000217835.3 RP6-159A1.2 5.81 1.4e-08 0.0257 0.4 0.3 Stem cell growth factor beta levels; chr9:6717650 chrX:65956289~65957196:- LIHC trans rs7200543 0.961 rs3803573 ENSG00000250569.1 NTAN1P2 5.81 1.4e-08 0.0257 0.37 0.3 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15044556 chr8:86481754~86483002:- LIHC trans rs73108077 0.736 rs6061028 ENSG00000279352.1 RP11-411B10.7 5.81 1.4e-08 0.0257 0.73 0.3 Red blood cell density in sickle cell anemia; chr20:31285774 chr18:14010054~14010917:+ LIHC trans rs73108077 0.736 rs6058492 ENSG00000279352.1 RP11-411B10.7 5.81 1.4e-08 0.0257 0.73 0.3 Red blood cell density in sickle cell anemia; chr20:31286965 chr18:14010054~14010917:+ LIHC trans rs11098499 0.863 rs9997631 ENSG00000275858.1 RP11-291L22.8 5.81 1.4e-08 0.0257 0.35 0.3 Corneal astigmatism; chr4:119548840 chr10:38450738~38451069:- LIHC trans rs714543 0.967 rs10951776 ENSG00000214975.4 PPIAP29 -5.81 1.4e-08 0.0258 -0.35 -0.3 Plateletcrit; chr7:44858152 chr6:24976419~24976982:+ LIHC trans rs12210905 1 rs6902012 ENSG00000242375.1 RP11-498P14.3 5.81 1.41e-08 0.0259 0.74 0.3 Hip circumference adjusted for BMI; chr6:27275988 chr9:97195351~97197687:- LIHC trans rs11098499 0.908 rs2017057 ENSG00000275858.1 RP11-291L22.8 5.81 1.41e-08 0.0259 0.35 0.3 Corneal astigmatism; chr4:119336556 chr10:38450738~38451069:- LIHC trans rs11098499 0.566 rs7664440 ENSG00000275858.1 RP11-291L22.8 5.81 1.41e-08 0.0259 0.35 0.3 Corneal astigmatism; chr4:119657385 chr10:38450738~38451069:- LIHC trans rs7200543 1 rs1121 ENSG00000250569.1 NTAN1P2 5.81 1.41e-08 0.0259 0.37 0.3 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15037219 chr8:86481754~86483002:- LIHC trans rs877636 0.859 rs3741499 ENSG00000234513.1 AC073072.7 -5.81 1.41e-08 0.026 -0.39 -0.3 Cognitive function; chr12:56080595 chr7:22773646~22773993:- LIHC trans rs13217239 0.646 rs10946897 ENSG00000242375.1 RP11-498P14.3 5.81 1.43e-08 0.0262 0.35 0.3 Schizophrenia; chr6:27027472 chr9:97195351~97197687:- LIHC trans rs13217239 0.646 rs6937880 ENSG00000242375.1 RP11-498P14.3 5.81 1.44e-08 0.0264 0.35 0.3 Schizophrenia; chr6:27032457 chr9:97195351~97197687:- LIHC trans rs13217239 0.621 rs12527231 ENSG00000242375.1 RP11-498P14.3 5.81 1.44e-08 0.0264 0.35 0.3 Schizophrenia; chr6:27033509 chr9:97195351~97197687:- LIHC trans rs13217239 0.646 rs12523820 ENSG00000242375.1 RP11-498P14.3 5.81 1.44e-08 0.0264 0.35 0.3 Schizophrenia; chr6:27033723 chr9:97195351~97197687:- LIHC trans rs864643 0.574 rs1768192 ENSG00000183298.5 RP11-556K13.1 5.81 1.44e-08 0.0264 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39470669 chr1:101786340~101787219:- LIHC trans rs3096299 0.504 rs4785574 ENSG00000215030.5 RPL13P12 -5.81 1.44e-08 0.0265 -0.3 -0.3 Multiple myeloma (IgH translocation); chr16:89502467 chr17:17383377~17384012:- LIHC trans rs6915893 0.967 rs12199316 ENSG00000267156.1 TPMTP1 5.81 1.45e-08 0.0266 0.33 0.3 Intrinsic epigenetic age acceleration; chr6:18123271 chr18:47630112~47630848:+ LIHC trans rs9649213 0.593 rs12728 ENSG00000225169.1 BRI3P1 5.81 1.46e-08 0.0267 0.39 0.3 Prostate cancer (SNP x SNP interaction); chr7:98293539 chr1:100213293~100213670:+ LIHC trans rs17589516 0.881 rs75618461 ENSG00000255355.1 AP000640.2 5.81 1.46e-08 0.0268 0.69 0.3 Insulin resistance/response; chr6:37869163 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs78448512 ENSG00000255355.1 AP000640.2 5.81 1.46e-08 0.0268 0.69 0.3 Insulin resistance/response; chr6:37871527 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs114415721 ENSG00000255355.1 AP000640.2 5.81 1.46e-08 0.0268 0.69 0.3 Insulin resistance/response; chr6:37872167 chr11:59669312~59676041:+ LIHC trans rs73108077 0.736 rs6119276 ENSG00000279352.1 RP11-411B10.7 5.81 1.47e-08 0.0269 0.74 0.3 Red blood cell density in sickle cell anemia; chr20:31363733 chr18:14010054~14010917:+ LIHC trans rs9858542 0.953 rs9827708 ENSG00000197582.5 GPX1P1 -5.8 1.47e-08 0.0269 -0.53 -0.3 Blood protein levels;Ulcerative colitis;Crohn's disease; chr3:49612556 chrX:13378735~13379340:- LIHC trans rs864643 0.625 rs1707958 ENSG00000183298.5 RP11-556K13.1 5.8 1.47e-08 0.027 0.47 0.3 Attention deficit hyperactivity disorder; chr3:39481931 chr1:101786340~101787219:- LIHC trans rs6491750 0.744 rs9558091 ENSG00000270804.1 CTD-2583A14.11 5.8 1.49e-08 0.0273 0.5 0.3 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr13:103479056 chr19:57867885~57868834:+ LIHC trans rs9649213 0.593 rs6465662 ENSG00000225169.1 BRI3P1 5.8 1.5e-08 0.0274 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98288489 chr1:100213293~100213670:+ LIHC trans rs1961649 0.75 rs1858380 ENSG00000214900.7 LINC01588 -5.8 1.51e-08 0.0276 -0.48 -0.3 Metabolite levels (HVA/5-HIAA ratio); chr12:99521733 chr14:49981712~50007520:- LIHC trans rs17589516 0.764 rs79593757 ENSG00000255355.1 AP000640.2 5.8 1.52e-08 0.0277 0.69 0.3 Insulin resistance/response; chr6:37828249 chr11:59669312~59676041:+ LIHC trans rs17589516 0.764 rs76767526 ENSG00000255355.1 AP000640.2 5.8 1.52e-08 0.0277 0.69 0.3 Insulin resistance/response; chr6:37842734 chr11:59669312~59676041:+ LIHC trans rs17589516 0.536 rs75083804 ENSG00000255355.1 AP000640.2 5.8 1.52e-08 0.0277 0.69 0.3 Insulin resistance/response; chr6:37852566 chr11:59669312~59676041:+ LIHC trans rs17589516 0.649 rs79071360 ENSG00000255355.1 AP000640.2 5.8 1.52e-08 0.0277 0.69 0.3 Insulin resistance/response; chr6:37868830 chr11:59669312~59676041:+ LIHC trans rs13177918 0.559 rs12109637 ENSG00000226396.1 RP5-1056L3.3 5.8 1.52e-08 0.0278 0.25 0.3 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150455155 chr1:19608114~19608568:+ LIHC trans rs1336472 1 rs1855982 ENSG00000233381.3 AK4P3 5.8 1.53e-08 0.0279 0.34 0.3 Venous thromboembolism (SNP x SNP interaction); chr1:65230170 chr12:31615771~31616439:- LIHC trans rs877636 0.884 rs705705 ENSG00000234513.1 AC073072.7 5.8 1.53e-08 0.0279 0.41 0.3 Cognitive function; chr12:56041720 chr7:22773646~22773993:- LIHC trans rs11098499 0.954 rs9998585 ENSG00000275858.1 RP11-291L22.8 5.8 1.53e-08 0.0279 0.34 0.3 Corneal astigmatism; chr4:119475647 chr10:38450738~38451069:- LIHC trans rs11098499 0.909 rs6842762 ENSG00000275858.1 RP11-291L22.8 5.8 1.53e-08 0.0279 0.34 0.3 Corneal astigmatism; chr4:119477081 chr10:38450738~38451069:- LIHC trans rs12478296 0.591 rs12468297 ENSG00000260923.4 AC137934.1 -5.8 1.53e-08 0.028 -0.38 -0.3 Obesity-related traits; chr2:242054323 chr16:90185997~90222678:+ LIHC trans rs2336384 1 rs873457 ENSG00000261819.1 RP11-680G24.4 5.8 1.55e-08 0.0282 0.39 0.3 Platelet count; chr1:11986277 chr16:14988259~14990160:- LIHC trans rs17589516 0.881 rs115903608 ENSG00000255355.1 AP000640.2 5.8 1.55e-08 0.0282 0.69 0.3 Insulin resistance/response; chr6:37915768 chr11:59669312~59676041:+ LIHC trans rs17589516 0.764 rs80191465 ENSG00000255355.1 AP000640.2 5.8 1.55e-08 0.0282 0.69 0.3 Insulin resistance/response; chr6:37921741 chr11:59669312~59676041:+ LIHC trans rs17589516 0.764 rs77522971 ENSG00000255355.1 AP000640.2 5.8 1.55e-08 0.0282 0.69 0.3 Insulin resistance/response; chr6:37924421 chr11:59669312~59676041:+ LIHC trans rs17589516 0.649 rs116134681 ENSG00000255355.1 AP000640.2 5.8 1.55e-08 0.0282 0.69 0.3 Insulin resistance/response; chr6:37931399 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs77728194 ENSG00000255355.1 AP000640.2 5.8 1.55e-08 0.0282 0.69 0.3 Insulin resistance/response; chr6:37935021 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs79523900 ENSG00000255355.1 AP000640.2 5.8 1.55e-08 0.0282 0.69 0.3 Insulin resistance/response; chr6:37942728 chr11:59669312~59676041:+ LIHC trans rs7873102 0.521 rs4878741 ENSG00000229007.1 EXOSC3P1 5.79 1.56e-08 0.0284 0.38 0.3 Brain structure; chr9:38023200 chr21:32496812~32497311:+ LIHC trans rs864643 0.678 rs3856566 ENSG00000183298.5 RP11-556K13.1 5.79 1.57e-08 0.0285 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39491097 chr1:101786340~101787219:- LIHC trans rs3735485 0.698 rs62458154 ENSG00000265095.1 FTLP12 -5.79 1.58e-08 0.0287 -0.48 -0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:45078349 chr17:16391434~16391882:+ LIHC trans rs3735485 0.738 rs62458155 ENSG00000265095.1 FTLP12 -5.79 1.58e-08 0.0287 -0.48 -0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:45078599 chr17:16391434~16391882:+ LIHC trans rs12709013 0.792 rs8049572 ENSG00000230849.2 GOT2P2 5.79 1.58e-08 0.0287 0.36 0.3 Blood metabolite ratios; chr16:58809672 chr1:173141100~173142350:- LIHC trans rs12709013 0.766 rs34438483 ENSG00000230849.2 GOT2P2 5.79 1.58e-08 0.0287 0.36 0.3 Blood metabolite ratios; chr16:58810530 chr1:173141100~173142350:- LIHC trans rs9611519 0.929 rs12484477 ENSG00000268568.1 AC007228.9 -5.79 1.58e-08 0.0287 -0.45 -0.3 Neuroticism; chr22:41033080 chr19:56672574~56673901:- LIHC trans rs9611519 0.929 rs4820423 ENSG00000268568.1 AC007228.9 -5.79 1.58e-08 0.0287 -0.45 -0.3 Neuroticism; chr22:41034334 chr19:56672574~56673901:- LIHC trans rs9649213 0.593 rs3801263 ENSG00000225169.1 BRI3P1 5.79 1.58e-08 0.0288 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98335704 chr1:100213293~100213670:+ LIHC trans rs9649213 0.555 rs12667634 ENSG00000225169.1 BRI3P1 5.79 1.58e-08 0.0288 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98336130 chr1:100213293~100213670:+ LIHC trans rs7568458 0.777 rs12473819 ENSG00000223886.3 RP11-251G23.2 5.79 1.59e-08 0.0288 0.35 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85545938 chr7:105530209~105530671:+ LIHC trans rs714543 1 rs2898 ENSG00000214975.4 PPIAP29 -5.79 1.59e-08 0.0289 -0.35 -0.3 Plateletcrit; chr7:44827034 chr6:24976419~24976982:+ LIHC trans rs714543 1 rs10267576 ENSG00000214975.4 PPIAP29 -5.79 1.59e-08 0.0289 -0.35 -0.3 Plateletcrit; chr7:44831334 chr6:24976419~24976982:+ LIHC trans rs714543 0.967 rs12536807 ENSG00000214975.4 PPIAP29 -5.79 1.59e-08 0.0289 -0.35 -0.3 Plateletcrit; chr7:44838675 chr6:24976419~24976982:+ LIHC trans rs9611519 0.78 rs2235850 ENSG00000268568.1 AC007228.9 -5.79 1.6e-08 0.0291 -0.35 -0.3 Neuroticism; chr22:41261622 chr19:56672574~56673901:- LIHC trans rs11098499 0.863 rs11947234 ENSG00000275858.1 RP11-291L22.8 5.79 1.61e-08 0.0292 0.35 0.3 Corneal astigmatism; chr4:119553704 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs11933966 ENSG00000275858.1 RP11-291L22.8 5.79 1.61e-08 0.0292 0.35 0.3 Corneal astigmatism; chr4:119555560 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs36040693 ENSG00000275858.1 RP11-291L22.8 5.79 1.61e-08 0.0292 0.35 0.3 Corneal astigmatism; chr4:119556461 chr10:38450738~38451069:- LIHC trans rs11098499 0.954 rs12499324 ENSG00000275858.1 RP11-291L22.8 5.79 1.61e-08 0.0293 0.34 0.3 Corneal astigmatism; chr4:119472631 chr10:38450738~38451069:- LIHC trans rs11951515 0.508 rs7705166 ENSG00000174977.8 AC026271.5 -5.79 1.61e-08 0.0293 -0.36 -0.3 Metabolite levels (X-11787); chr5:43587346 chr17:18650195~18651542:+ LIHC trans rs34626435 0.85 rs17322942 ENSG00000259687.1 LINC01220 -5.79 1.62e-08 0.0293 -0.74 -0.3 Schizophrenia; chr3:173797092 chr14:75294404~75296638:+ LIHC trans rs11098499 0.863 rs10018280 ENSG00000275858.1 RP11-291L22.8 5.79 1.62e-08 0.0295 0.35 0.3 Corneal astigmatism; chr4:119556984 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs6534141 ENSG00000275858.1 RP11-291L22.8 5.79 1.62e-08 0.0295 0.35 0.3 Corneal astigmatism; chr4:119564068 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs2127823 ENSG00000275858.1 RP11-291L22.8 5.79 1.62e-08 0.0295 0.35 0.3 Corneal astigmatism; chr4:119564515 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs3775858 ENSG00000275858.1 RP11-291L22.8 5.79 1.62e-08 0.0295 0.35 0.3 Corneal astigmatism; chr4:119564873 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs2306456 ENSG00000275858.1 RP11-291L22.8 5.79 1.63e-08 0.0295 0.35 0.3 Corneal astigmatism; chr4:119551267 chr10:38450738~38451069:- LIHC trans rs7312770 0.612 rs773114 ENSG00000242970.2 AC068522.4 5.79 1.63e-08 0.0295 0.36 0.3 Polycystic ovary syndrome;Hypothyroidism; chr12:55985276 chr8:58588420~58588764:- LIHC trans rs7649818 0.813 rs978659 ENSG00000230734.1 RPL10P3 5.79 1.63e-08 0.0296 0.32 0.3 Daytime sleep phenotypes; chr3:6724579 chr9:117180628~117181095:- LIHC trans rs17589516 0.881 rs75423996 ENSG00000255355.1 AP000640.2 5.79 1.64e-08 0.0296 0.69 0.3 Insulin resistance/response; chr6:37892634 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs114905311 ENSG00000255355.1 AP000640.2 5.79 1.64e-08 0.0296 0.69 0.3 Insulin resistance/response; chr6:37949437 chr11:59669312~59676041:+ LIHC trans rs864643 0.898 rs614494 ENSG00000183298.5 RP11-556K13.1 5.78 1.64e-08 0.0297 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39547136 chr1:101786340~101787219:- LIHC trans rs1593 0.531 rs4253299 ENSG00000269378.1 ITGB1P1 5.78 1.65e-08 0.0298 0.33 0.3 Activated partial thromboplastin time; chr4:186250201 chr19:14621634~14622242:- LIHC trans rs10870270 1 rs10870271 ENSG00000197358.9 BNIP3P1 -5.78 1.65e-08 0.0298 -0.35 -0.3 Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals; chr10:131941303 chr14:28264390~28265974:+ LIHC trans rs9611519 0.929 rs2064560 ENSG00000268568.1 AC007228.9 -5.78 1.66e-08 0.03 -0.46 -0.3 Neuroticism; chr22:41134036 chr19:56672574~56673901:- LIHC trans rs877636 1 rs2292239 ENSG00000225071.1 GS1-184P14.2 5.78 1.68e-08 0.0303 0.37 0.3 Cognitive function; chr12:56088396 chrX:24429573~24429920:- LIHC trans rs1961649 0.73 rs17471508 ENSG00000214900.7 LINC01588 -5.78 1.68e-08 0.0303 -0.48 -0.3 Metabolite levels (HVA/5-HIAA ratio); chr12:99514790 chr14:49981712~50007520:- LIHC trans rs73108077 0.736 rs6060436 ENSG00000279352.1 RP11-411B10.7 5.78 1.68e-08 0.0304 0.69 0.3 Red blood cell density in sickle cell anemia; chr20:31258500 chr18:14010054~14010917:+ LIHC trans rs11220237 0.62 rs60531419 ENSG00000236257.1 EI24P2 5.78 1.69e-08 0.0306 0.44 0.3 Itch intensity from mosquito bite adjusted by bite size; chr11:125692958 chr1:158454198~158455273:+ LIHC trans rs2069408 1 rs2069408 ENSG00000242970.2 AC068522.4 -5.78 1.7e-08 0.0306 -0.37 -0.3 Asthma; chr12:55970537 chr8:58588420~58588764:- LIHC trans rs877636 1 rs4759229 ENSG00000225071.1 GS1-184P14.2 -5.78 1.7e-08 0.0307 -0.39 -0.3 Cognitive function; chr12:56080696 chrX:24429573~24429920:- LIHC trans rs877636 1 rs4759229 ENSG00000234513.1 AC073072.7 -5.78 1.7e-08 0.0307 -0.39 -0.3 Cognitive function; chr12:56080696 chr7:22773646~22773993:- LIHC trans rs12709013 0.792 rs1646270 ENSG00000233719.3 GOT2P3 5.78 1.7e-08 0.0308 0.33 0.3 Blood metabolite ratios; chr16:58745823 chr12:9641802~9643007:+ LIHC trans rs864643 0.678 rs1768203 ENSG00000183298.5 RP11-556K13.1 5.78 1.71e-08 0.0308 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39476377 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs1708100 ENSG00000183298.5 RP11-556K13.1 5.78 1.71e-08 0.0308 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39476400 chr1:101786340~101787219:- LIHC trans rs864643 0.625 rs7613883 ENSG00000183298.5 RP11-556K13.1 5.78 1.71e-08 0.0308 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39476825 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs6779639 ENSG00000183298.5 RP11-556K13.1 5.78 1.71e-08 0.0308 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39477191 chr1:101786340~101787219:- LIHC trans rs864643 0.678 rs6782255 ENSG00000183298.5 RP11-556K13.1 5.78 1.71e-08 0.0308 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39477236 chr1:101786340~101787219:- LIHC trans rs73108077 0.736 rs2376545 ENSG00000279352.1 RP11-411B10.7 5.78 1.71e-08 0.0308 0.72 0.3 Red blood cell density in sickle cell anemia; chr20:31293314 chr18:14010054~14010917:+ LIHC trans rs73108077 0.736 rs13433373 ENSG00000279352.1 RP11-411B10.7 5.78 1.71e-08 0.0308 0.72 0.3 Red blood cell density in sickle cell anemia; chr20:31296736 chr18:14010054~14010917:+ LIHC trans rs73108077 0.688 rs6061150 ENSG00000279352.1 RP11-411B10.7 5.78 1.71e-08 0.0308 0.72 0.3 Red blood cell density in sickle cell anemia; chr20:31301527 chr18:14010054~14010917:+ LIHC trans rs3735485 0.579 rs10269518 ENSG00000265095.1 FTLP12 -5.78 1.71e-08 0.0308 -0.48 -0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:45076670 chr17:16391434~16391882:+ LIHC trans rs7312770 0.637 rs705699 ENSG00000225071.1 GS1-184P14.2 5.78 1.71e-08 0.0309 0.37 0.3 Polycystic ovary syndrome;Hypothyroidism; chr12:55991020 chrX:24429573~24429920:- LIHC trans rs864643 0.947 rs645488 ENSG00000183298.5 RP11-556K13.1 5.78 1.71e-08 0.0309 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39499028 chr1:101786340~101787219:- LIHC trans rs912969 1 rs927798 ENSG00000234818.1 AC092687.5 5.78 1.72e-08 0.0309 0.45 0.3 Smoking behavior; chr13:103215654 chr2:10589166~10604830:+ LIHC trans rs864643 0.678 rs500507 ENSG00000183298.5 RP11-556K13.1 5.78 1.73e-08 0.0311 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39492886 chr1:101786340~101787219:- LIHC trans rs17589516 0.764 rs17581538 ENSG00000255355.1 AP000640.2 5.77 1.74e-08 0.0313 0.69 0.3 Insulin resistance/response; chr6:37958066 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs76831879 ENSG00000255355.1 AP000640.2 5.77 1.74e-08 0.0313 0.69 0.3 Insulin resistance/response; chr6:37966376 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs116569901 ENSG00000255355.1 AP000640.2 5.77 1.74e-08 0.0313 0.69 0.3 Insulin resistance/response; chr6:37970140 chr11:59669312~59676041:+ LIHC trans rs17589516 0.536 rs75660916 ENSG00000255355.1 AP000640.2 5.77 1.74e-08 0.0313 0.69 0.3 Insulin resistance/response; chr6:37976135 chr11:59669312~59676041:+ LIHC trans rs1039766 1 rs10116 ENSG00000224334.1 AP000357.4 5.77 1.75e-08 0.0314 0.44 0.3 Lung adenocarcinoma;Lung cancer; chr2:65269595 chr22:24686923~24688087:+ LIHC trans rs1039766 0.929 rs268881 ENSG00000224334.1 AP000357.4 5.77 1.75e-08 0.0314 0.44 0.3 Lung adenocarcinoma;Lung cancer; chr2:65274249 chr22:24686923~24688087:+ LIHC trans rs35306767 0.903 rs10508208 ENSG00000279296.1 RP11-609D21.3 5.77 1.76e-08 0.0317 0.45 0.3 Eosinophil percentage of granulocytes; chr10:865043 chr17:6772831~6776116:- LIHC trans rs3735485 0.738 rs28636402 ENSG00000265095.1 FTLP12 -5.77 1.78e-08 0.032 -0.48 -0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:45067278 chr17:16391434~16391882:+ LIHC trans rs1039766 1 rs268878 ENSG00000224334.1 AP000357.4 5.77 1.78e-08 0.032 0.44 0.3 Lung adenocarcinoma;Lung cancer; chr2:65270437 chr22:24686923~24688087:+ LIHC trans rs73193808 0.639 rs7277858 ENSG00000204685.6 STARD7-AS1 -5.77 1.78e-08 0.032 -0.31 -0.3 Coronary artery disease; chr21:29180556 chr2:96208416~96242621:+ LIHC trans rs17589516 0.881 rs115605543 ENSG00000255355.1 AP000640.2 5.77 1.79e-08 0.0321 0.68 0.3 Insulin resistance/response; chr6:38011036 chr11:59669312~59676041:+ LIHC trans rs17589516 0.881 rs76056010 ENSG00000255355.1 AP000640.2 5.77 1.79e-08 0.0321 0.68 0.3 Insulin resistance/response; chr6:38011214 chr11:59669312~59676041:+ LIHC trans rs1840440 1 rs11083145 ENSG00000269967.1 RP11-84A19.4 -5.77 1.79e-08 0.0321 -0.3 -0.3 Weight; chr18:25668147 chr1:31851913~31921841:- LIHC trans rs12709013 0.792 rs12325510 ENSG00000233719.3 GOT2P3 5.77 1.79e-08 0.0322 0.34 0.3 Blood metabolite ratios; chr16:58749707 chr12:9641802~9643007:+ LIHC trans rs75870422 0.609 rs28750247 ENSG00000271654.1 RP11-685B14.3 5.77 1.8e-08 0.0322 0.74 0.3 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100455520 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs28661086 ENSG00000271654.1 RP11-685B14.3 5.77 1.8e-08 0.0322 0.74 0.3 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100455664 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs79654047 ENSG00000271654.1 RP11-685B14.3 5.77 1.8e-08 0.0322 0.74 0.3 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100456124 chr8:18387108~18387777:- LIHC trans rs75870422 0.609 rs7335300 ENSG00000271654.1 RP11-685B14.3 5.77 1.8e-08 0.0322 0.74 0.3 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100456746 chr8:18387108~18387777:- LIHC trans rs11098499 0.954 rs878373 ENSG00000275858.1 RP11-291L22.8 5.77 1.81e-08 0.0324 0.35 0.3 Corneal astigmatism; chr4:119316329 chr10:38450738~38451069:- LIHC trans rs732577 0.818 rs57481768 ENSG00000270964.1 RP11-502I4.3 -5.77 1.81e-08 0.0325 -0.3 -0.3 Sudden cardiac arrest; chr7:12888829 chr15:67541072~67542604:- LIHC trans rs11098499 0.863 rs1552092 ENSG00000275858.1 RP11-291L22.8 5.77 1.82e-08 0.0326 0.35 0.3 Corneal astigmatism; chr4:119567341 chr10:38450738~38451069:- LIHC trans rs77954165 0.568 rs1052489 ENSG00000217835.3 RP6-159A1.2 5.76 1.83e-08 0.0328 0.39 0.3 Stem cell growth factor beta levels; chr9:6723861 chrX:65956289~65957196:- LIHC trans rs12210905 0.92 rs858995 ENSG00000242375.1 RP11-498P14.3 5.76 1.83e-08 0.0328 0.72 0.3 Hip circumference adjusted for BMI; chr6:27213922 chr9:97195351~97197687:- LIHC trans rs714543 0.967 rs11762008 ENSG00000214975.4 PPIAP29 -5.76 1.84e-08 0.033 -0.35 -0.3 Plateletcrit; chr7:44864065 chr6:24976419~24976982:+ LIHC trans rs11098499 0.818 rs55825515 ENSG00000275858.1 RP11-291L22.8 5.76 1.84e-08 0.033 0.35 0.3 Corneal astigmatism; chr4:119565247 chr10:38450738~38451069:- LIHC trans rs830233 0.654 rs26442 ENSG00000205312.7 KRT17P4 -5.76 1.85e-08 0.0331 -0.42 -0.3 QT interval (sulfonylurea treatment interaction); chr5:165946205 chr17:16847635~16852777:- LIHC trans rs10511779 1 rs10511779 ENSG00000280107.1 AL022393.9 -5.76 1.85e-08 0.0332 -0.68 -0.3 Attention function in attention deficit hyperactive disorder; chr9:26725704 chr6:28170845~28172521:+ LIHC trans rs1961649 0.784 rs73147353 ENSG00000214900.7 LINC01588 -5.76 1.86e-08 0.0333 -0.47 -0.3 Metabolite levels (HVA/5-HIAA ratio); chr12:99511196 chr14:49981712~50007520:- LIHC trans rs877636 0.702 rs61937249 ENSG00000234513.1 AC073072.7 5.76 1.87e-08 0.0334 0.4 0.3 Cognitive function; chr12:55988132 chr7:22773646~22773993:- LIHC trans rs4073221 0.789 rs13078687 ENSG00000279926.1 RP3-406P24.5 -5.76 1.87e-08 0.0334 -0.44 -0.3 Parkinson's disease; chr3:18181950 chr6:3982673~3984130:+ LIHC trans rs12709013 0.59 rs982848 ENSG00000233719.3 GOT2P3 5.76 1.87e-08 0.0334 0.32 0.3 Blood metabolite ratios; chr16:58704294 chr12:9641802~9643007:+ LIHC trans rs9649213 0.593 rs34534766 ENSG00000225169.1 BRI3P1 5.76 1.87e-08 0.0335 0.38 0.3 Prostate cancer (SNP x SNP interaction); chr7:98291559 chr1:100213293~100213670:+ LIHC trans rs7930295 0.632 rs35245130 ENSG00000236257.1 EI24P2 5.76 1.88e-08 0.0335 0.38 0.3 Schizophrenia; chr11:125771018 chr1:158454198~158455273:+ LIHC trans rs7671900 0.516 rs6531968 ENSG00000271095.1 BNIP3P28 5.76 1.89e-08 0.0337 0.29 0.3 Intelligence (multi-trait analysis); chr4:87278332 chr19:21997648~21998840:+ LIHC trans rs959695 0.834 rs6468693 ENSG00000260318.1 COX6CP1 -5.76 1.89e-08 0.0337 -0.36 -0.3 Hippocampal atrophy; chr8:99839040 chr16:11903923~11904137:- LIHC trans rs877636 0.74 rs705698 ENSG00000243403.1 RP11-330L19.1 5.76 1.89e-08 0.0338 0.38 0.3 Cognitive function; chr12:55990903 chr15:64592979~64593326:+ LIHC trans rs11951515 0.508 rs1366410 ENSG00000174977.8 AC026271.5 -5.76 1.9e-08 0.0339 -0.36 -0.3 Metabolite levels (X-11787); chr5:43601508 chr17:18650195~18651542:+ LIHC trans rs864643 0.678 rs1768191 ENSG00000183298.5 RP11-556K13.1 5.76 1.91e-08 0.034 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39469772 chr1:101786340~101787219:- LIHC trans rs7312770 0.612 rs773114 ENSG00000225071.1 GS1-184P14.2 5.76 1.92e-08 0.0342 0.36 0.3 Polycystic ovary syndrome;Hypothyroidism; chr12:55985276 chrX:24429573~24429920:- LIHC trans rs12709013 0.792 rs12595974 ENSG00000233719.3 GOT2P3 5.76 1.92e-08 0.0342 0.33 0.3 Blood metabolite ratios; chr16:58769132 chr12:9641802~9643007:+ LIHC trans rs12709013 0.792 rs1836877 ENSG00000233719.3 GOT2P3 5.76 1.92e-08 0.0342 0.33 0.3 Blood metabolite ratios; chr16:58769821 chr12:9641802~9643007:+ LIHC trans rs7568458 0.846 rs7605975 ENSG00000223886.3 RP11-251G23.2 5.76 1.92e-08 0.0342 0.35 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85545425 chr7:105530209~105530671:+ LIHC trans rs7568458 0.846 rs6547621 ENSG00000223886.3 RP11-251G23.2 5.76 1.92e-08 0.0342 0.35 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85547553 chr7:105530209~105530671:+ LIHC trans rs7568458 0.846 rs6738645 ENSG00000223886.3 RP11-251G23.2 5.76 1.92e-08 0.0342 0.35 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85556005 chr7:105530209~105530671:+ LIHC trans rs75870422 0.609 rs7981326 ENSG00000271654.1 RP11-685B14.3 -5.76 1.92e-08 0.0343 -0.65 -0.3 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100467252 chr8:18387108~18387777:- LIHC trans rs864643 0.677 rs1708087 ENSG00000183298.5 RP11-556K13.1 5.76 1.92e-08 0.0343 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39468197 chr1:101786340~101787219:- LIHC trans rs11098499 0.863 rs12498539 ENSG00000275858.1 RP11-291L22.8 5.75 1.93e-08 0.0344 0.35 0.3 Corneal astigmatism; chr4:119547215 chr10:38450738~38451069:- LIHC trans rs864643 0.678 rs1398668 ENSG00000183298.5 RP11-556K13.1 5.75 1.93e-08 0.0344 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39475753 chr1:101786340~101787219:- LIHC trans rs9611519 0.78 rs2284079 ENSG00000268568.1 AC007228.9 -5.75 1.94e-08 0.0346 -0.35 -0.3 Neuroticism; chr22:41262628 chr19:56672574~56673901:- LIHC trans rs12138950 0.711 rs10799821 ENSG00000224237.1 MINOS1P3 5.75 1.95e-08 0.0347 0.36 0.3 Hypothyroidism;Thyroid volume; chr1:19511475 chr3:27214816~27215018:- LIHC trans rs7568458 0.846 rs1078004 ENSG00000223886.3 RP11-251G23.2 5.75 1.95e-08 0.0347 0.35 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr2:85542588 chr7:105530209~105530671:+ LIHC trans rs877636 0.74 rs705702 ENSG00000225071.1 GS1-184P14.2 -5.75 1.96e-08 0.0348 -0.39 -0.3 Cognitive function; chr12:55996852 chrX:24429573~24429920:- LIHC trans rs13217239 0.646 rs11756275 ENSG00000242375.1 RP11-498P14.3 -5.75 1.97e-08 0.0351 -0.35 -0.3 Schizophrenia; chr6:27039334 chr9:97195351~97197687:- LIHC trans rs714543 0.875 rs35585318 ENSG00000214975.4 PPIAP29 -5.75 1.97e-08 0.0351 -0.35 -0.3 Plateletcrit; chr7:44852220 chr6:24976419~24976982:+ LIHC trans rs9611519 0.929 rs4820425 ENSG00000268568.1 AC007228.9 -5.75 1.99e-08 0.0354 -0.45 -0.3 Neuroticism; chr22:41035338 chr19:56672574~56673901:- LIHC trans rs28714278 0.762 rs12050884 ENSG00000261888.1 AC144831.1 -5.75 2e-08 0.0355 -0.32 -0.3 Mean corpuscular hemoglobin; chr15:40014133 chr17:83104255~83106910:+ LIHC trans rs73193808 0.614 rs9976839 ENSG00000204685.6 STARD7-AS1 -5.75 2.01e-08 0.0356 -0.3 -0.3 Coronary artery disease; chr21:29190389 chr2:96208416~96242621:+ LIHC trans rs9488343 0.647 rs7751951 ENSG00000235605.1 RP5-827C21.1 5.75 2.02e-08 0.0357 0.27 0.3 Gray matter volume (schizophrenia interaction); chr6:114169392 chr1:234356704~234357141:- LIHC trans rs74781061 0.929 rs6495108 ENSG00000227288.3 RP5-837I24.1 5.75 2.03e-08 0.036 0.34 0.3 Endometriosis; chr15:74502186 chr1:81501794~81503468:+ LIHC trans rs11098499 0.604 rs2389886 ENSG00000275858.1 RP11-291L22.8 5.75 2.03e-08 0.036 0.34 0.3 Corneal astigmatism; chr4:119649267 chr10:38450738~38451069:- LIHC trans rs3849046 0.817 rs11953219 ENSG00000226666.1 HSPA9P1 5.75 2.03e-08 0.036 0.36 0.3 Autism spectrum disorder or schizophrenia;Schizophrenia; chr5:138592481 chr2:221961737~221963765:+ LIHC trans rs877636 1 rs877636 ENSG00000225071.1 GS1-184P14.2 -5.74 2.04e-08 0.0361 -0.38 -0.3 Cognitive function; chr12:56086799 chrX:24429573~24429920:- LIHC trans rs714543 0.934 rs10275962 ENSG00000219797.2 PPIAP9 -5.74 2.05e-08 0.0362 -0.36 -0.3 Plateletcrit; chr7:44809141 chr6:31519480~31520291:- LIHC trans rs864643 0.898 rs66860744 ENSG00000183298.5 RP11-556K13.1 5.74 2.05e-08 0.0362 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39548245 chr1:101786340~101787219:- LIHC trans rs3735485 0.678 rs1132130 ENSG00000265095.1 FTLP12 -5.74 2.05e-08 0.0363 -0.48 -0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:45080649 chr17:16391434~16391882:+ LIHC trans rs1961649 0.784 rs73147344 ENSG00000214900.7 LINC01588 -5.74 2.05e-08 0.0363 -0.47 -0.3 Metabolite levels (HVA/5-HIAA ratio); chr12:99502921 chr14:49981712~50007520:- LIHC trans rs714543 0.783 rs7806283 ENSG00000219797.2 PPIAP9 -5.74 2.06e-08 0.0364 -0.36 -0.3 Plateletcrit; chr7:44779104 chr6:31519480~31520291:- LIHC trans rs73193808 0.666 rs7276548 ENSG00000204685.6 STARD7-AS1 -5.74 2.06e-08 0.0365 -0.3 -0.3 Coronary artery disease; chr21:29180518 chr2:96208416~96242621:+ LIHC trans rs7200543 1 rs6498540 ENSG00000250569.1 NTAN1P2 5.74 2.06e-08 0.0365 0.37 0.3 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15036737 chr8:86481754~86483002:- LIHC trans rs17834760 1 rs56229006 ENSG00000215190.7 LINC00680 -5.74 2.07e-08 0.0365 -0.47 -0.3 Antipsychotic drug-induced QTc interval change in schizophrenia; chr6:61842625 chr6:57946074~57961501:- LIHC trans rs9488343 0.647 rs7751951 ENSG00000244538.1 RP11-10G12.1 5.74 2.09e-08 0.0369 0.29 0.3 Gray matter volume (schizophrenia interaction); chr6:114169392 chr4:22594196~22594450:+ LIHC trans rs3735485 0.843 rs6463256 ENSG00000265095.1 FTLP12 5.74 2.09e-08 0.037 0.48 0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:44985277 chr17:16391434~16391882:+ LIHC trans rs3735485 0.843 rs3213658 ENSG00000265095.1 FTLP12 5.74 2.09e-08 0.037 0.48 0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:44986121 chr17:16391434~16391882:+ LIHC trans rs3735485 0.76 rs10232306 ENSG00000265095.1 FTLP12 5.74 2.09e-08 0.037 0.48 0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:44987137 chr17:16391434~16391882:+ LIHC trans rs7121616 0.733 rs10892967 ENSG00000234176.1 HSPA8P1 5.74 2.11e-08 0.0372 0.39 0.3 Breast cancer; chr11:123130350 chrX:121203182~121205014:- LIHC trans rs4073221 0.52 rs1108439 ENSG00000279926.1 RP3-406P24.5 -5.74 2.12e-08 0.0373 -0.47 -0.3 Parkinson's disease; chr3:18159827 chr6:3982673~3984130:+ LIHC trans rs11098499 0.604 rs2389882 ENSG00000275858.1 RP11-291L22.8 5.74 2.12e-08 0.0373 0.34 0.3 Corneal astigmatism; chr4:119645578 chr10:38450738~38451069:- LIHC trans rs5763662 1 rs5763681 ENSG00000227855.3 DPY19L2P3 5.74 2.12e-08 0.0374 0.64 0.3 LDL cholesterol levels;LDL cholesterol; chr22:29993857 chr7:29650227~29742594:+ LIHC trans rs877636 0.702 rs773110 ENSG00000243403.1 RP11-330L19.1 5.74 2.13e-08 0.0375 0.38 0.3 Cognitive function; chr12:55981353 chr15:64592979~64593326:+ LIHC trans rs3749237 0.964 rs10865959 ENSG00000197582.5 GPX1P1 5.73 2.15e-08 0.0379 0.43 0.3 Resting heart rate; chr3:49853569 chrX:13378735~13379340:- LIHC trans rs7312770 0.637 rs705699 ENSG00000196656.7 AC004057.1 5.73 2.17e-08 0.0382 0.37 0.3 Polycystic ovary syndrome;Hypothyroidism; chr12:55991020 chr4:113214046~113217170:- LIHC trans rs77954165 0.568 rs1133678 ENSG00000217835.3 RP6-159A1.2 5.73 2.17e-08 0.0382 0.39 0.3 Stem cell growth factor beta levels; chr9:6717941 chrX:65956289~65957196:- LIHC trans rs77954165 0.568 rs1133680 ENSG00000217835.3 RP6-159A1.2 5.73 2.17e-08 0.0382 0.39 0.3 Stem cell growth factor beta levels; chr9:6718141 chrX:65956289~65957196:- LIHC trans rs1593 0.531 rs2221843 ENSG00000269378.1 ITGB1P1 5.73 2.18e-08 0.0383 0.32 0.3 Activated partial thromboplastin time; chr4:186223046 chr19:14621634~14622242:- LIHC trans rs538867 1 rs538867 ENSG00000183298.5 RP11-556K13.1 5.73 2.18e-08 0.0383 0.67 0.3 Alzheimer's disease (cognitive decline); chr3:39471787 chr1:101786340~101787219:- LIHC trans rs877636 0.847 rs705704 ENSG00000234513.1 AC073072.7 5.73 2.19e-08 0.0384 0.4 0.3 Cognitive function; chr12:56041628 chr7:22773646~22773993:- LIHC trans rs7032940 0.651 rs7873398 ENSG00000228236.2 TXNP5 5.73 2.19e-08 0.0385 0.35 0.3 Height; chr9:110194413 chr2:149068596~149068910:- LIHC trans rs7312770 0.612 rs1873914 ENSG00000242970.2 AC068522.4 5.73 2.2e-08 0.0386 0.37 0.3 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr8:58588420~58588764:- LIHC trans rs7200543 1 rs4985124 ENSG00000250569.1 NTAN1P2 5.73 2.2e-08 0.0387 0.36 0.3 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15031584 chr8:86481754~86483002:- LIHC trans rs877636 0.701 rs34415530 ENSG00000234513.1 AC073072.7 5.73 2.2e-08 0.0387 0.4 0.3 Cognitive function; chr12:56050848 chr7:22773646~22773993:- LIHC trans rs2292368 0.687 rs55829876 ENSG00000258741.3 RP11-386M24.4 5.73 2.21e-08 0.0388 0.38 0.3 Fibroblast growth factor basic levels; chr10:14035624 chr15:92715710~92734195:- LIHC trans rs2030746 0.521 rs2311598 ENSG00000272990.1 RP11-305K5.1 -5.73 2.21e-08 0.0388 -0.33 -0.3 LDL cholesterol;Total cholesterol levels;LDL cholesterol levels; chr2:120573526 chr3:156523740~156524247:- LIHC trans rs877636 0.702 rs773108 ENSG00000234513.1 AC073072.7 5.73 2.22e-08 0.039 0.4 0.3 Cognitive function; chr12:55976127 chr7:22773646~22773993:- LIHC trans rs11098499 0.863 rs3775854 ENSG00000275858.1 RP11-291L22.8 5.73 2.23e-08 0.039 0.35 0.3 Corneal astigmatism; chr4:119550816 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs6853998 ENSG00000275858.1 RP11-291L22.8 5.73 2.23e-08 0.039 0.35 0.3 Corneal astigmatism; chr4:119554705 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs6858777 ENSG00000275858.1 RP11-291L22.8 5.73 2.23e-08 0.039 0.35 0.3 Corneal astigmatism; chr4:119554811 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs11731756 ENSG00000275858.1 RP11-291L22.8 5.73 2.23e-08 0.039 0.35 0.3 Corneal astigmatism; chr4:119557541 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs34308924 ENSG00000275858.1 RP11-291L22.8 5.73 2.23e-08 0.039 0.35 0.3 Corneal astigmatism; chr4:119560276 chr10:38450738~38451069:- LIHC trans rs11098499 0.863 rs2170276 ENSG00000275858.1 RP11-291L22.8 5.73 2.23e-08 0.039 0.35 0.3 Corneal astigmatism; chr4:119564669 chr10:38450738~38451069:- LIHC trans rs766622 0.857 rs1555118 ENSG00000236318.1 AC019117.1 5.73 2.24e-08 0.0393 0.37 0.3 Red blood cell count; chr20:44041123 chr7:17374867~17466664:+ LIHC trans rs9649213 0.593 rs6465672 ENSG00000225169.1 BRI3P1 -5.73 2.24e-08 0.0393 -0.38 -0.3 Prostate cancer (SNP x SNP interaction); chr7:98334405 chr1:100213293~100213670:+ LIHC trans rs877636 0.74 rs772920 ENSG00000243403.1 RP11-330L19.1 5.73 2.26e-08 0.0396 0.38 0.3 Cognitive function; chr12:55996580 chr15:64592979~64593326:+ LIHC trans rs3735485 0.8 rs4724348 ENSG00000265095.1 FTLP12 5.72 2.28e-08 0.0399 0.46 0.3 White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts; chr7:45019640 chr17:16391434~16391882:+ LIHC trans rs1961649 0.75 rs73147361 ENSG00000214900.7 LINC01588 -5.72 2.3e-08 0.0401 -0.48 -0.3 Metabolite levels (HVA/5-HIAA ratio); chr12:99524308 chr14:49981712~50007520:- LIHC trans rs11220237 1 rs7124578 ENSG00000236257.1 EI24P2 5.72 2.3e-08 0.0401 0.37 0.3 Itch intensity from mosquito bite adjusted by bite size; chr11:125850600 chr1:158454198~158455273:+ LIHC trans rs17834760 1 rs1547073 ENSG00000215190.7 LINC00680 -5.72 2.3e-08 0.0401 -0.47 -0.3 Antipsychotic drug-induced QTc interval change in schizophrenia; chr6:61835688 chr6:57946074~57961501:- LIHC trans rs17834760 1 rs17176557 ENSG00000215190.7 LINC00680 -5.72 2.3e-08 0.0401 -0.47 -0.3 Antipsychotic drug-induced QTc interval change in schizophrenia; chr6:61836548 chr6:57946074~57961501:- LIHC trans rs7580717 0.893 rs6714129 ENSG00000241155.1 ARHGAP31-AS1 5.72 2.3e-08 0.0402 0.29 0.3 Multiple myeloma; chr2:231314944 chr3:119314293~119322760:- LIHC trans rs9611519 0.761 rs35445172 ENSG00000268568.1 AC007228.9 -5.72 2.31e-08 0.0402 -0.35 -0.3 Neuroticism; chr22:41264297 chr19:56672574~56673901:- LIHC trans rs10991814 0.92 rs7874056 ENSG00000211820.1 TRAV41 -5.72 2.31e-08 0.0402 -0.56 -0.3 Neutrophil percentage of granulocytes; chr9:91325340 chr14:22320188~22320691:+ LIHC trans rs877636 0.702 rs773112 ENSG00000243403.1 RP11-330L19.1 5.72 2.31e-08 0.0402 0.37 0.3 Cognitive function; chr12:55982097 chr15:64592979~64593326:+ LIHC trans rs7200543 0.961 rs1741 ENSG00000250569.1 NTAN1P2 5.72 2.31e-08 0.0403 0.36 0.3 Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels; chr16:15036494 chr8:86481754~86483002:- LIHC trans rs1961649 0.784 rs1961512 ENSG00000214900.7 LINC01588 -5.72 2.33e-08 0.0406 -0.48 -0.3 Metabolite levels (HVA/5-HIAA ratio); chr12:99517650 chr14:49981712~50007520:- LIHC trans rs864643 0.678 rs1708109 ENSG00000183298.5 RP11-556K13.1 5.72 2.34e-08 0.0407 0.46 0.3 Attention deficit hyperactivity disorder; chr3:39490085 chr1:101786340~101787219:- LIHC trans rs864643 0.891 rs1708018 ENSG00000183298.5 RP11-556K13.1 5.72 2.34e-08 0.0407 0.45 0.3 Attention deficit hyperactivity disorder; chr3:39496978 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs535220 ENSG00000183298.5 RP11-556K13.1 5.72 2.34e-08 0.0407 0.45 0.3 Attention deficit hyperactivity disorder; chr3:39497234 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs538214 ENSG00000183298.5 RP11-556K13.1 5.72 2.34e-08 0.0407 0.45 0.3 Attention deficit hyperactivity disorder; chr3:39497603 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs538972 ENSG00000183298.5 RP11-556K13.1 5.72 2.34e-08 0.0407 0.45 0.3 Attention deficit hyperactivity disorder; chr3:39497652 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs614359 ENSG00000183298.5 RP11-556K13.1 5.72 2.34e-08 0.0407 0.45 0.3 Attention deficit hyperactivity disorder; chr3:39498035 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs1768237 ENSG00000183298.5 RP11-556K13.1 5.72 2.34e-08 0.0407 0.45 0.3 Attention deficit hyperactivity disorder; chr3:39498712 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs645457 ENSG00000183298.5 RP11-556K13.1 5.72 2.34e-08 0.0407 0.45 0.3 Attention deficit hyperactivity disorder; chr3:39499006 chr1:101786340~101787219:- LIHC trans rs2030746 0.521 rs13415147 ENSG00000272990.1 RP11-305K5.1 -5.72 2.34e-08 0.0407 -0.33 -0.3 LDL cholesterol;Total cholesterol levels;LDL cholesterol levels; chr2:120572192 chr3:156523740~156524247:- LIHC trans rs6493858 1 rs6493858 ENSG00000260733.1 RP11-264L1.4 5.72 2.36e-08 0.041 0.33 0.3 Relative hand skill in reading disability; chr15:56444280 chr16:78495926~78506568:- LIHC trans rs1961649 0.75 rs11610344 ENSG00000214900.7 LINC01588 -5.72 2.37e-08 0.0412 -0.46 -0.3 Metabolite levels (HVA/5-HIAA ratio); chr12:99493352 chr14:49981712~50007520:- LIHC trans rs13080594 1 rs13080594 ENSG00000251015.1 SLC25A30-AS1 -5.72 2.38e-08 0.0414 -0.33 -0.3 Personality traits in bipolar disorder; chr3:7361959 chr13:45418162~45420371:+ LIHC trans rs11220237 0.764 rs34125226 ENSG00000236257.1 EI24P2 5.72 2.39e-08 0.0414 0.43 0.3 Itch intensity from mosquito bite adjusted by bite size; chr11:125738705 chr1:158454198~158455273:+ LIHC trans rs7662987 1 rs17595424 ENSG00000228407.2 RP4-800M22.1 5.71 2.39e-08 0.0416 0.7 0.3 Smoking initiation; chr4:99072718 chr1:52160261~52160600:- LIHC trans rs1041530 0.933 rs10829580 ENSG00000237828.1 PA2G4P1 5.71 2.4e-08 0.0416 0.32 0.3 Gut microbiota (functional units); chr10:129143620 chrX:120868611~120869807:- LIHC trans rs11615274 0.645 rs77813936 ENSG00000274929.1 RP11-165D7.5 5.71 2.41e-08 0.0419 0.48 0.3 Body mass index and cholesterol (psychopharmacological treatment); chr12:73214025 chr13:48532013~48532599:- LIHC trans rs11615274 0.583 rs11608821 ENSG00000274929.1 RP11-165D7.5 5.71 2.41e-08 0.0419 0.48 0.3 Body mass index and cholesterol (psychopharmacological treatment); chr12:73215464 chr13:48532013~48532599:- LIHC trans rs13217239 0.646 rs7451149 ENSG00000242375.1 RP11-498P14.3 -5.71 2.42e-08 0.042 -0.35 -0.3 Schizophrenia; chr6:27089739 chr9:97195351~97197687:- LIHC trans rs1039766 1 rs268882 ENSG00000224334.1 AP000357.4 -5.71 2.43e-08 0.0421 -0.43 -0.3 Lung adenocarcinoma;Lung cancer; chr2:65275668 chr22:24686923~24688087:+ LIHC trans rs35006 0.93 rs26610 ENSG00000273450.1 RP11-76P2.4 5.71 2.43e-08 0.0421 0.39 0.3 Coronary artery disease; chr5:54134814 chr10:94314907~94315327:- LIHC trans rs35006 1 rs35006 ENSG00000273450.1 RP11-76P2.4 5.71 2.43e-08 0.0421 0.39 0.3 Coronary artery disease; chr5:54146895 chr10:94314907~94315327:- LIHC trans rs6424115 1 rs4237 ENSG00000228217.1 AL390877.1 -5.71 2.46e-08 0.0425 -0.34 -0.3 Immature fraction of reticulocytes; chr1:23787639 chr1:117778087~117778506:- LIHC trans rs11098499 0.604 rs34278750 ENSG00000275858.1 RP11-291L22.8 5.71 2.46e-08 0.0426 0.34 0.29 Corneal astigmatism; chr4:119649981 chr10:38450738~38451069:- LIHC trans rs2073820 1 rs2073820 ENSG00000236054.1 LL22NC03-104C7.1 -5.71 2.47e-08 0.0427 -0.32 -0.29 Mean corpuscular volume; chr9:132988790 chr22:32583300~32584204:+ LIHC trans rs10988802 0.516 rs10819953 ENSG00000277829.1 RP5-1054A22.4 -5.71 2.47e-08 0.0427 -0.4 -0.29 Chemerin levels; chr9:95636674 chr20:38233251~38233799:- LIHC trans rs11098499 0.954 rs10034623 ENSG00000275858.1 RP11-291L22.8 5.71 2.47e-08 0.0428 0.34 0.29 Corneal astigmatism; chr4:119476674 chr10:38450738~38451069:- LIHC trans rs11098499 0.604 rs2389887 ENSG00000275858.1 RP11-291L22.8 5.71 2.49e-08 0.0431 0.34 0.29 Corneal astigmatism; chr4:119649489 chr10:38450738~38451069:- LIHC trans rs864643 0.841 rs1708042 ENSG00000183298.5 RP11-556K13.1 5.71 2.5e-08 0.0431 0.45 0.29 Attention deficit hyperactivity disorder; chr3:39546246 chr1:101786340~101787219:- LIHC trans rs9425766 0.678 rs55829688 ENSG00000213331.4 RP11-713C19.2 5.71 2.5e-08 0.0432 0.39 0.29 Life satisfaction; chr1:173868168 chr4:187970273~187971284:+ LIHC trans rs77954165 0.568 rs7023651 ENSG00000217835.3 RP6-159A1.2 5.71 2.52e-08 0.0435 0.39 0.29 Stem cell growth factor beta levels; chr9:6719060 chrX:65956289~65957196:- LIHC trans rs77954165 0.568 rs4237167 ENSG00000217835.3 RP6-159A1.2 5.71 2.52e-08 0.0435 0.39 0.29 Stem cell growth factor beta levels; chr9:6719456 chrX:65956289~65957196:- LIHC trans rs766622 0.929 rs6065690 ENSG00000236318.1 AC019117.1 5.7 2.55e-08 0.044 0.38 0.29 Red blood cell count; chr20:44042530 chr7:17374867~17466664:+ LIHC trans rs3096299 0.503 rs9925045 ENSG00000215030.5 RPL13P12 -5.7 2.55e-08 0.044 -0.29 -0.29 Multiple myeloma (IgH translocation); chr16:89490068 chr17:17383377~17384012:- LIHC trans rs13217239 0.646 rs10456352 ENSG00000242375.1 RP11-498P14.3 5.7 2.55e-08 0.044 0.35 0.29 Schizophrenia; chr6:27022579 chr9:97195351~97197687:- LIHC trans rs13217239 0.646 rs4583981 ENSG00000242375.1 RP11-498P14.3 5.7 2.55e-08 0.044 0.35 0.29 Schizophrenia; chr6:27024244 chr9:97195351~97197687:- LIHC trans rs6741148 0.881 rs12053002 ENSG00000241907.1 RPS20P4 5.7 2.55e-08 0.044 0.66 0.29 Erectile dysfunction and prostate cancer treatment; chr2:38002426 chr5:150021567~150021921:- LIHC trans rs11220237 0.841 rs7118459 ENSG00000236257.1 EI24P2 5.7 2.55e-08 0.044 0.37 0.29 Itch intensity from mosquito bite adjusted by bite size; chr11:125867837 chr1:158454198~158455273:+ LIHC trans rs11220237 1 rs12288151 ENSG00000236257.1 EI24P2 5.7 2.55e-08 0.044 0.37 0.29 Itch intensity from mosquito bite adjusted by bite size; chr11:125873344 chr1:158454198~158455273:+ LIHC trans rs12709013 0.693 rs1627257 ENSG00000233719.3 GOT2P3 5.7 2.56e-08 0.0441 0.33 0.29 Blood metabolite ratios; chr16:58763764 chr12:9641802~9643007:+ LIHC trans rs73193808 0.639 rs2832241 ENSG00000204685.6 STARD7-AS1 -5.7 2.58e-08 0.0445 -0.3 -0.29 Coronary artery disease; chr21:29179715 chr2:96208416~96242621:+ LIHC trans rs17589516 0.764 rs77778796 ENSG00000255355.1 AP000640.2 5.7 2.58e-08 0.0445 0.68 0.29 Insulin resistance/response; chr6:38015693 chr11:59669312~59676041:+ LIHC trans rs3096299 0.685 rs4785675 ENSG00000215030.5 RPL13P12 -5.7 2.59e-08 0.0445 -0.3 -0.29 Multiple myeloma (IgH translocation); chr16:89473566 chr17:17383377~17384012:- LIHC trans rs3096299 0.685 rs4238830 ENSG00000215030.5 RPL13P12 -5.7 2.59e-08 0.0445 -0.3 -0.29 Multiple myeloma (IgH translocation); chr16:89473833 chr17:17383377~17384012:- LIHC trans rs1155865 0.945 rs2201478 ENSG00000237973.1 RP5-857K21.6 -5.7 2.6e-08 0.0447 -0.42 -0.29 Cognitive test performance; chr4:66926139 chr1:631074~632616:+ LIHC trans rs9425766 0.64 rs2067079 ENSG00000213331.4 RP11-713C19.2 5.7 2.6e-08 0.0447 0.39 0.29 Life satisfaction; chr1:173866073 chr4:187970273~187971284:+ LIHC trans rs13217239 0.646 rs35691005 ENSG00000242375.1 RP11-498P14.3 5.7 2.6e-08 0.0448 0.35 0.29 Schizophrenia; chr6:27004291 chr9:97195351~97197687:- LIHC trans rs13217239 0.646 rs10946891 ENSG00000242375.1 RP11-498P14.3 5.7 2.6e-08 0.0448 0.35 0.29 Schizophrenia; chr6:27005436 chr9:97195351~97197687:- LIHC trans rs13217239 0.646 rs12201393 ENSG00000242375.1 RP11-498P14.3 5.7 2.6e-08 0.0448 0.35 0.29 Schizophrenia; chr6:27007911 chr9:97195351~97197687:- LIHC trans rs13217239 0.646 rs12209886 ENSG00000242375.1 RP11-498P14.3 5.7 2.6e-08 0.0448 0.35 0.29 Schizophrenia; chr6:27016978 chr9:97195351~97197687:- LIHC trans rs6940638 0.531 rs12211984 ENSG00000242375.1 RP11-498P14.3 5.7 2.6e-08 0.0448 0.35 0.29 Intelligence (multi-trait analysis); chr6:27018275 chr9:97195351~97197687:- LIHC trans rs13217239 0.646 rs10456351 ENSG00000242375.1 RP11-498P14.3 5.7 2.6e-08 0.0448 0.35 0.29 Schizophrenia; chr6:27019013 chr9:97195351~97197687:- LIHC trans rs3096299 0.658 rs12443705 ENSG00000215030.5 RPL13P12 -5.7 2.61e-08 0.0448 -0.3 -0.29 Multiple myeloma (IgH translocation); chr16:89480646 chr17:17383377~17384012:- LIHC trans rs11220237 1 rs11220221 ENSG00000236257.1 EI24P2 5.7 2.61e-08 0.0449 0.37 0.29 Itch intensity from mosquito bite adjusted by bite size; chr11:125796232 chr1:158454198~158455273:+ LIHC trans rs1041530 0.933 rs7909469 ENSG00000237828.1 PA2G4P1 5.7 2.61e-08 0.0449 0.32 0.29 Gut microbiota (functional units); chr10:129143526 chrX:120868611~120869807:- LIHC trans rs17834760 0.909 rs977381 ENSG00000215190.7 LINC00680 -5.7 2.63e-08 0.0451 -0.47 -0.29 Antipsychotic drug-induced QTc interval change in schizophrenia; chr6:61177479 chr6:57946074~57961501:- LIHC trans rs17834760 0.955 rs62426168 ENSG00000215190.7 LINC00680 -5.7 2.63e-08 0.0451 -0.47 -0.29 Antipsychotic drug-induced QTc interval change in schizophrenia; chr6:61178055 chr6:57946074~57961501:- LIHC trans rs17834760 0.863 rs62426166 ENSG00000215190.7 LINC00680 -5.7 2.63e-08 0.0451 -0.47 -0.29 Antipsychotic drug-induced QTc interval change in schizophrenia; chr6:61178561 chr6:57946074~57961501:- LIHC trans rs17834760 0.955 rs61328155 ENSG00000215190.7 LINC00680 -5.7 2.63e-08 0.0451 -0.47 -0.29 Antipsychotic drug-induced QTc interval change in schizophrenia; chr6:61179880 chr6:57946074~57961501:- LIHC trans rs17834760 0.909 rs62426165 ENSG00000215190.7 LINC00680 -5.7 2.63e-08 0.0451 -0.47 -0.29 Antipsychotic drug-induced QTc interval change in schizophrenia; chr6:61180684 chr6:57946074~57961501:- LIHC trans rs17834760 0.955 rs62423559 ENSG00000215190.7 LINC00680 -5.7 2.63e-08 0.0451 -0.47 -0.29 Antipsychotic drug-induced QTc interval change in schizophrenia; chr6:61190696 chr6:57946074~57961501:- LIHC trans rs17834760 0.955 rs1832209 ENSG00000215190.7 LINC00680 -5.7 2.63e-08 0.0451 -0.47 -0.29 Antipsychotic drug-induced QTc interval change in schizophrenia; chr6:61195812 chr6:57946074~57961501:- LIHC trans rs2980436 1 rs2980436 ENSG00000255495.1 AC145124.2 -5.7 2.63e-08 0.0452 -0.35 -0.29 Schizophrenia; chr8:8234503 chr8:12194467~12196280:+ LIHC trans rs714543 1 rs10278679 ENSG00000214975.4 PPIAP29 -5.69 2.69e-08 0.0461 -0.35 -0.29 Plateletcrit; chr7:44825465 chr6:24976419~24976982:+ LIHC trans rs6424115 1 rs35385477 ENSG00000228217.1 AL390877.1 -5.69 2.7e-08 0.0463 -0.34 -0.29 Immature fraction of reticulocytes; chr1:23829434 chr1:117778087~117778506:- LIHC trans rs12210905 0.925 rs72838228 ENSG00000242375.1 RP11-498P14.3 -5.69 2.73e-08 0.0467 -0.64 -0.29 Hip circumference adjusted for BMI; chr6:26978141 chr9:97195351~97197687:- LIHC trans rs1375785 1 rs6473411 ENSG00000247950.5 SEC24B-AS1 5.69 2.73e-08 0.0467 0.38 0.29 Information processing speed; chr8:83080544 chr4:109347475~109433817:- LIHC trans rs17834760 0.955 rs62424082 ENSG00000215190.7 LINC00680 -5.69 2.75e-08 0.0469 -0.47 -0.29 Antipsychotic drug-induced QTc interval change in schizophrenia; chr6:61144916 chr6:57946074~57961501:- LIHC trans rs17834760 0.909 rs1414789 ENSG00000215190.7 LINC00680 -5.69 2.75e-08 0.0469 -0.47 -0.29 Antipsychotic drug-induced QTc interval change in schizophrenia; chr6:61151921 chr6:57946074~57961501:- LIHC trans rs864643 0.947 rs1708053 ENSG00000183298.5 RP11-556K13.1 5.69 2.75e-08 0.047 0.44 0.29 Attention deficit hyperactivity disorder; chr3:39499706 chr1:101786340~101787219:- LIHC trans rs864643 0.891 rs1708057 ENSG00000183298.5 RP11-556K13.1 5.69 2.75e-08 0.047 0.44 0.29 Attention deficit hyperactivity disorder; chr3:39499895 chr1:101786340~101787219:- LIHC trans rs864643 0.947 rs1768241 ENSG00000183298.5 RP11-556K13.1 5.69 2.75e-08 0.047 0.44 0.29 Attention deficit hyperactivity disorder; chr3:39499987 chr1:101786340~101787219:- LIHC trans rs864643 0.891 rs1708059 ENSG00000183298.5 RP11-556K13.1 5.69 2.75e-08 0.047 0.44 0.29 Attention deficit hyperactivity disorder; chr3:39500059 chr1:101786340~101787219:- LIHC trans rs7364180 0.92 rs2269657 ENSG00000268568.1 AC007228.9 -5.69 2.76e-08 0.0471 -0.37 -0.29 Alzheimer's disease biomarkers; chr22:41868265 chr19:56672574~56673901:- LIHC trans rs9876781 0.563 rs4858821 ENSG00000235912.1 RP1-159A19.3 5.69 2.76e-08 0.0471 0.38 0.29 Longevity; chr3:48512515 chr1:27649419~27649610:+ LIHC trans rs864643 0.579 rs694365 ENSG00000183298.5 RP11-556K13.1 5.69 2.77e-08 0.0472 0.46 0.29 Attention deficit hyperactivity disorder; chr3:39494422 chr1:101786340~101787219:- LIHC trans rs11951515 0.508 rs7706431 ENSG00000174977.8 AC026271.5 -5.69 2.78e-08 0.0474 -0.35 -0.29 Metabolite levels (X-11787); chr5:43582321 chr17:18650195~18651542:+ LIHC trans rs11951515 0.508 rs6898866 ENSG00000174977.8 AC026271.5 -5.69 2.78e-08 0.0474 -0.35 -0.29 Metabolite levels (X-11787); chr5:43586273 chr17:18650195~18651542:+ LIHC trans rs75870422 0.609 rs77344656 ENSG00000271654.1 RP11-685B14.3 5.69 2.78e-08 0.0475 0.71 0.29 Facial morphology (factor 5, width of mouth relative to central midface); chr13:100496743 chr8:18387108~18387777:- LIHC trans rs9425766 0.64 rs9660881 ENSG00000213331.4 RP11-713C19.2 5.69 2.8e-08 0.0477 0.39 0.29 Life satisfaction; chr1:173867378 chr4:187970273~187971284:+ LIHC trans rs877636 0.692 rs2271194 ENSG00000196656.7 AC004057.1 -5.68 2.81e-08 0.0479 -0.37 -0.29 Cognitive function; chr12:56083910 chr4:113214046~113217170:- LIHC trans rs877636 0.702 rs773111 ENSG00000243403.1 RP11-330L19.1 5.68 2.83e-08 0.0483 0.37 0.29 Cognitive function; chr12:55981956 chr15:64592979~64593326:+ LIHC trans rs12200782 1 rs12201802 ENSG00000242375.1 RP11-498P14.3 -5.68 2.84e-08 0.0484 -0.73 -0.29 Small cell lung carcinoma; chr6:26398436 chr9:97195351~97197687:- LIHC trans rs864643 0.773 rs11129838 ENSG00000183298.5 RP11-556K13.1 5.68 2.89e-08 0.0491 0.4 0.29 Attention deficit hyperactivity disorder; chr3:39557696 chr1:101786340~101787219:- LIHC trans rs877636 0.692 rs2271194 ENSG00000227887.1 RPS26P13 -5.68 2.91e-08 0.0495 -0.35 -0.29 Cognitive function; chr12:56083910 chr1:208697369~208697698:- LIHC trans rs77954165 0.568 rs12352193 ENSG00000217835.3 RP6-159A1.2 5.68 2.92e-08 0.0496 0.39 0.29 Stem cell growth factor beta levels; chr9:6725319 chrX:65956289~65957196:- LIHC trans rs17589516 0.881 rs79958946 ENSG00000255355.1 AP000640.2 5.68 2.92e-08 0.0497 0.68 0.29 Insulin resistance/response; chr6:37853946 chr11:59669312~59676041:+ LIHC trans rs6424115 0.965 rs2502986 ENSG00000228217.1 AL390877.1 -5.68 2.93e-08 0.0497 -0.34 -0.29 Immature fraction of reticulocytes; chr1:23808802 chr1:117778087~117778506:- LIHC trans rs12138950 0.681 rs60066365 ENSG00000224237.1 MINOS1P3 5.68 2.93e-08 0.0498 0.36 0.29 Hypothyroidism;Thyroid volume; chr1:19512191 chr3:27214816~27215018:- LIHC trans rs12339966 0.514 rs10738223 ENSG00000261114.1 RP11-325K4.2 5.68 2.93e-08 0.0498 0.32 0.29 Systolic blood pressure; chr9:11283067 chr16:56941028~56941726:+ LIHC trans rs864643 0.625 rs694380 ENSG00000183298.5 RP11-556K13.1 5.68 2.93e-08 0.0498 0.46 0.29 Attention deficit hyperactivity disorder; chr3:39494399 chr1:101786340~101787219:- LIHC trans rs12709013 0.792 rs1646262 ENSG00000233719.3 GOT2P3 5.68 2.94e-08 0.0498 0.33 0.29 Blood metabolite ratios; chr16:58760593 chr12:9641802~9643007:+ LIHC trans rs12709013 0.792 rs257623 ENSG00000233719.3 GOT2P3 5.68 2.94e-08 0.0498 0.33 0.29 Blood metabolite ratios; chr16:58761247 chr12:9641802~9643007:+ LIHC trans rs7258465 0.511 rs11668719 ENSG00000267533.1 RP11-815J4.7 5.68 2.94e-08 0.0498 0.38 0.29 Breast cancer; chr19:18404931 chr18:12067173~12068417:- LIHC trans rs35306767 0.855 rs12770190 ENSG00000279296.1 RP11-609D21.3 5.68 2.94e-08 0.0499 0.47 0.29 Eosinophil percentage of granulocytes; chr10:905322 chr17:6772831~6776116:-